PMID- 42954786 OWN - NLM STAT- MEDLINE DCOM- 20261029 LR - 20261029 IS - 2638-6135 (Electronic) IS - 2638-6135 (Linking) VI - 8 IP - 5 DP - 2026 Oct TI - Pulmonary Hypertension: Clinical Classification Updates, Pathology, and Multimodality Imaging Evaluation. PG - e260101 LID - 10.1148/ryct.260101 [doi] AB - Pulmonary hypertension (PH) is a progressive disease associated with high morbidity and mortality. PH is classified into five groups based on underlying pathophysiology and etiology: pulmonary arterial hypertension (group 1); PH due to left heart disease (group 2); PH secondary to lung disease (group 3); pulmonary artery obstruction, including chronic thromboembolic pulmonary hypertension (CTEPH) (group 4); and PH due to unclear or multifactorial mechanisms (group 5). Radiologists play a major role in the multidisciplinary evaluation of patients with PH alongside specialists in pathology, pulmonary medicine, and cardiology. Given the widespread use of CT, imaging may be the first modality to suggest PH and plays a central role in the diagnosis and management of CTEPH. This review describes the pathophysiology of the five PH groups and emphasizes imaging findings that raise suspicion for PH. Discussion includes the roles of CT and MRI in PH evaluation, risk stratification, and assessment of treatment response, as well as the current applications of multienergy CT, echocardiography, and cardiac MRI in PH management. Keywords: CT Angiography, CT-Dual Energy, CT, MR Imaging, Pulmonary Arteries, Pulmonary, Echocardiography, Thorax, Vascular, Pathology, Pulmonary Hypertension, Chronic Thromboembolic Disease, Chronic Thromboembolic Pulmonary Hypertension, Pulmonary Embolism, Pulmonary Arterial Hypertension, Pulmonary Venoocclusive Disease, Pulmonary Capillary Hemangiomatosis, Pulmonary Hypertension Groups, Dual-Energy CT, Photon-counting CT, Spectral CT (c) RSNA, 2026. FAU - Tamizuddin, Farah AU - Tamizuddin F AUID- ORCID: 0000-0001-6832-5803 AD - Department of Radiology, NYU Grossman School of Medicine, NYU Langone Health, 660 First Ave, New York, NY 10016. FAU - Fujikura, Kana AU - Fujikura K AUID- ORCID: 0000-0001-7610-850X AD - Department of Radiology, NYU Grossman School of Medicine, NYU Langone Health, 660 First Ave, New York, NY 10016. FAU - Narula, Navneet AU - Narula N AUID- ORCID: 0009-0001-2133-5884 AD - Department of Pathology, NYU Grossman School of Medicine, NYU Langone Health, New York, NY. AD - Department of Pathology, McGovern Medical School, University of Texas Health, Houston, Tex. FAU - Stojanovska, Jadranka AU - Stojanovska J AUID- ORCID: 0000-0003-2742-6274 AD - Department of Radiology, NYU Grossman School of Medicine, NYU Langone Health, 660 First Ave, New York, NY 10016. FAU - Sulica, Roxana AU - Sulica R AD - Department of Medicine, NYU Grossman School of Medicine, NYU Langone Health, New York, NY. FAU - Zhou, Fang AU - Zhou F AUID- ORCID: 0000-0002-5542-2994 AD - Department of Pathology, NYU Grossman School of Medicine, NYU Langone Health, New York, NY. FAU - Moore, William H AU - Moore WH AUID- ORCID: 0009-0008-5860-3804 AD - Department of Radiology, NYU Grossman School of Medicine, NYU Langone Health, 660 First Ave, New York, NY 10016. FAU - Azour, Lea AU - Azour L AUID- ORCID: 0000-0002-3658-8956 AD - Department of Radiology, NYU Grossman School of Medicine, NYU Langone Health, 660 First Ave, New York, NY 10016. AD - Department of Radiology, UCLA Health, Los Angeles, Calif. FAU - Moreira, Andre L AU - Moreira AL AUID- ORCID: 0000-0003-1857-3774 AD - Department of Pathology, NYU Grossman School of Medicine, NYU Langone Health, New York, NY. FAU - Ko, Jane P AU - Ko JP AUID- ORCID: 0000-0001-9355-7200 AD - Department of Radiology, NYU Grossman School of Medicine, NYU Langone Health, 660 First Ave, New York, NY 10016. LA - eng PT - Journal Article PT - Review PL - United States TA - Radiol Cardiothorac Imaging JT - Radiology. Cardiothoracic imaging JID - 101748663 SB - IM MH - Humans MH - *Hypertension, Pulmonary/diagnostic imaging/classification/pathology/physiopathology MH - *Multimodal Imaging/methods MH - Tomography, X-Ray Computed/methods OTO - NOTNLM OT - CT OT - CT Angiography OT - CT-Dual Energy OT - Chronic Thromboembolic Disease OT - Chronic Thromboembolic Pulmonary Hypertension OT - Dual-Energy CT OT - Echocardiography OT - MR Imaging OT - Pathology OT - Photon-counting CT OT - Pulmonary OT - Pulmonary Arterial Hypertension OT - Pulmonary Arteries OT - Pulmonary Capillary Hemangiomatosis OT - Pulmonary Embolism OT - Pulmonary Hypertension OT - Pulmonary Hypertension Groups OT - Pulmonary Venoocclusive Disease OT - Spectral CT OT - Thorax OT - Vascular EDAT- 2026/10/29 15:20 MHDA- 2026/10/29 15:21 CRDT- 2026/10/29 09:53 PHST- 2026/10/29 15:21 [medline] PHST- 2026/10/29 15:20 [pubmed] PHST- 2026/10/29 09:53 [entrez] AID - 10.1148/ryct.260101 [doi] PST - ppublish SO - Radiol Cardiothorac Imaging. 2026 Oct;8(5):e260101. doi: 10.1148/ryct.260101. PMID- 42954783 OWN - NLM STAT- Publisher LR - 20261029 IS - 1879-3479 (Electronic) IS - 0020-7292 (Linking) DP - 2026 Oct 29 TI - Pregnancy considerations in women with uncorrected tetralogy of Fallot. LID - 10.1002/ijgo.71435 [doi] AB - Tetralogy of Fallot (TOF) is the most common cyanotic congenital heart disease, accounting for approximately 7-10% of all congenital cardiac malformations. Although early surgical repair has transformed its natural history in high-income settings, with contemporary long-term survival exceeding 90%, uncorrected TOF continues to be encountered in pregnancy, particularly in women from resource-limited regions or those with previously undiagnosed disease. The physiological adaptations of pregnancy, including reduction in systemic vascular resistance, plasma volume expansion, and a 30-50% rise in cardiac output, are poorly tolerated in the presence of a non-restrictive ventricular septal defect and fixed right ventricular outflow tract obstruction, leading to progressive cyanosis, right ventricular strain, and uteroplacental hypoperfusion. Current European Society of Cardiology (ESC) guidance classifies unrepaired cyanotic heart disease without Eisenmenger syndrome as mWHO 2.0 class III, while Eisenmenger syndrome is classified as mWHO 2.0 class IV. Contemporary data from the ESC EORP Registry of Pregnancy and Cardiac Disease (ROPAC) report maternal mortality of 0.7% and heart failure in 8.7% of pregnancies with uncorrected congenital heart disease, with markedly worse outcomes in cyanotic subsets. This narrative review synthesizes the pathophysiology, risk stratification, obstetric management, intrapartum anesthetic considerations, comparative outcomes of uncorrected versus corrected disease, and key evidence gaps that continue to constrain care for this population, providing a physiology-driven framework for the pregnancy heart team. CI - (c) 2026 International Federation of Gynecology and Obstetrics. FAU - Bhardwaj, Akinchan AU - Bhardwaj A AD - Department of Internal Medicine, Icahn School of Medicine at Mount Sinai Morningside West, New York, New York, USA. FAU - Balachandran, Divya Mecheril AU - Balachandran DM AUID- ORCID: 0000-0002-9037-3024 AD - Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, Deoghar, Jharkhand, India. FAU - Vasudev, Ishita AU - Vasudev I AD - Department of Internal Medicine, BronxCare Health System, Icahn School of Medicine at Mount Sinai, New York, New York, USA. LA - eng PT - Journal Article PT - Review DEP - 20261029 PL - United States TA - Int J Gynaecol Obstet JT - International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics JID - 0210174 SB - IM OTO - NOTNLM OT - cyanotic congenital heart disease OT - fetal outcomes OT - maternal outcomes OT - modified World Health Organization classification OT - pregnancy OT - resource-limited settings OT - right ventricular outflow tract obstruction OT - uncorrected tetralogy of Fallot EDAT- 2026/10/29 15:20 MHDA- 2026/10/29 15:20 CRDT- 2026/10/29 09:53 PHST- 2026/09/21 00:00 [revised] PHST- 2026/07/02 00:00 [received] PHST- 2026/09/27 00:00 [accepted] PHST- 2026/10/29 15:20 [medline] PHST- 2026/10/29 15:20 [pubmed] PHST- 2026/10/29 09:53 [entrez] AID - 10.1002/ijgo.71435 [doi] PST - aheadofprint SO - Int J Gynaecol Obstet. 2026 Oct 29. doi: 10.1002/ijgo.71435. PMID- 42954298 OWN - NLM STAT- Publisher LR - 20261029 IS - 1537-6591 (Electronic) IS - 1058-4838 (Linking) DP - 2026 Oct 29 TI - Performance of the recent Duke criteria versions in patients with suspected infective endocarditis and sufficient cardiac imaging: The more things change, the more they remain the same. LID - ciag688 [pii] LID - 10.1093/cid/ciag688 [doi] AB - BACKGROUND: Even after the major revisions incorporated into the International Society for Cardiovascular Infectious Diseases (ISCVID) and 2023 European Society of Cardiology (ESC) Duke criteria, approximately one third of cases remain categorized as "possible" IE. We evaluated the diagnostic performance of the Duke criteria in a cohort of patients who underwent guideline-concordant multimodality cardiac imaging. METHODS: This retrospective study at two Swiss university hospitals (2014-2025), included adult patients with suspected IE who underwent guideline-concordant cardiac imaging. The reference standard was the final diagnosis established by the Endocarditis Team. Each episode was classified according to 2015 Duke-ESC, 2023 Duke-ISCVID, and 2023 Duke-ESC clinical criteria as definite, possible, and rejected IE. Diagnostic performance was assessed using two approaches: (1) definite IE versus possible/rejected IE, and (2) definite/possible IE versus rejected IE. RESULTS: Among 3,448 of suspected IE, 1,302 (38%) were adjudicated as IE. The proportion of episodes classified as possible IE remained high: 2015 Duke-ESC: 29%; 2023 Duke-ISCVID: 33%; and 2023 Duke-ESC: 29%. Sensitivity (definite IE vs possible/rejected IE) increased from 63% (95% CI 60-66%) with the 2015 Duke-ESC criteria to 74% (71-76%) with the 2023 Duke-ISCVID criteria and 71% (68-73%) with the 2023 Duke-ESC criteria. Specificity (definite/possible IE versus rejected IE) declined from 72% (70-74%) to 59% (57-61%) and 66% (64-68%), respectively. CONCLUSIONS: In this large cohort of patients who underwent guideline-concordant imaging, both 2023 Duke criteria increased sensitivity but failed to reduce the persistent diagnostic gray-zone of "possible" IE, highlighting an ongoing limitation with direct clinical and research implications. CI - (c) The Author(s) 2026. Published by Oxford University Press on behalf of Infectious Diseases Society of America. FAU - Stavropoulou, Elisavet AU - Stavropoulou E AUID- ORCID: 0000-0002-8299-9035 AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. AD - Department of Basic and Clinical Sciences, Medical School, University of Nicosia, UNIC Athens, 16777, Athens, Greece. FAU - Padrutt, Maria AU - Padrutt M AD - Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich and University of Zurich, Zurich, Switzerland. FAU - Siedentop, Berit AU - Siedentop B AUID- ORCID: 0000-0003-0802-7681 AD - Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich and University of Zurich, Zurich, Switzerland. FAU - Monney, Pierre AU - Monney P AUID- ORCID: 0000-0002-3083-7333 AD - Department of Cardiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Frank, Michelle AU - Frank M AD - Department of Cardiology, University Hospital Zurich and University of Zurich, Zurich, Switzerland. FAU - Tzimas, Georgios AU - Tzimas G AUID- ORCID: 0000-0002-2810-8887 AD - Department of Cardiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Fourre, Nicolas AU - Fourre N AUID- ORCID: 0009-0006-1660-9365 AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Zimmermann, Virgile AU - Zimmermann V AUID- ORCID: 0009-0005-1812-0216 AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Ianculescu, Nicoleta AU - Ianculescu N AD - Department of Cardiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Senn, Laurence AU - Senn L AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Niclauss, Lars AU - Niclauss L AUID- ORCID: 0000-0003-4453-5202 AD - Department of Cardiac Surgery, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Kirsch, Matthias AU - Kirsch M AUID- ORCID: 0000-0002-9213-7578 AD - Department of Cardiac Surgery, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Van Hemelrijck, Mathias AU - Van Hemelrijck M AUID- ORCID: 0000-0002-0191-757X AD - Department of Cardiac Surgery, University Hospital Zurich and University of Zurich, Zurich, Switzerland. FAU - Dzemali, Omer AU - Dzemali O AUID- ORCID: 0000-0001-7910-5152 AD - Department of Cardiac Surgery, University Hospital Zurich and University of Zurich, Zurich, Switzerland. AD - Department of Cardiac Surgery, City Hospital of Zurich - Triemli, Zurich, Switzerland. AD - Center for Experimental and Translational Cardiology, University of Zurich, Zurich, Switzerland. FAU - Guery, Benoit AU - Guery B AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Hasse, Barbara AU - Hasse B AUID- ORCID: 0000-0001-7196-3734 AD - Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich and University of Zurich, Zurich, Switzerland. FAU - Papadimitriou-Olivgeris, Matthaios AU - Papadimitriou-Olivgeris M AUID- ORCID: 0000-0003-0565-5105 AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. AD - Infectious Diseases Service, Hospital of Valais and Institut Central des Hopitaux, Sion, Switzerland. CN - on befalf of the ESCMID Study Group for Bloodstream Infections, Endocarditis, and Sepsis (ESGBIES) LA - eng PT - Journal Article DEP - 20261029 PL - United States TA - Clin Infect Dis JT - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America JID - 9203213 SB - IM OTO - NOTNLM OT - Duke criteria OT - Endocarditis Team OT - International Society for Cardiovascular Infectious Diseases (ISCVID) OT - infective endocarditis OT - transesophageal echocardiography EDAT- 2026/10/29 15:20 MHDA- 2026/10/29 15:20 CRDT- 2026/10/29 07:23 PHST- 2026/05/30 00:00 [received] PHST- 2026/10/12 00:00 [revised] PHST- 2026/10/19 00:00 [accepted] PHST- 2026/10/29 15:20 [medline] PHST- 2026/10/29 15:20 [pubmed] PHST- 2026/10/29 07:23 [entrez] AID - 9004404 [pii] AID - 10.1093/cid/ciag688 [doi] PST - aheadofprint SO - Clin Infect Dis. 2026 Oct 29:ciag688. doi: 10.1093/cid/ciag688. PMID- 42953593 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20261029 LR - 20261029 IS - 2472-0054 (Electronic) IS - 2472-0054 (Linking) VI - 11 IP - 6 DP - 2026 Nov-Dec TI - Reducing Serious Hospital-acquired Pressure Injuries in Pediatric Intensive Care Units through Proactive Interdisciplinary Rounding. PG - e943 LID - 10.1097/pq9.0000000000000943 [doi] LID - e943 AB - INTRODUCTION: Hospital-acquired pressure injuries (HAPIs) contribute to significant morbidity, prolonged hospitalization, and increased healthcare costs in pediatric intensive care units (PICUs). Critically ill children are at increased risk due to immobility, complex comorbidities, and frequent use of medical devices. Despite stable rates of adherence to prevention bundles, an increase in serious HAPIs (sHAPIs)-defined as stage 3, stage 4, or unstageable injuries-was observed at our institution. This quality improvement initiative aimed to reduce the rate of sHAPIs by 10% through the implementation of proactive interdisciplinary rounding. METHODS: Weekly interdisciplinary pressure injury rounds were implemented across the cardiac intensive care unit, neonatal intensive care unit, and PICU at a freestanding 364-bed children's hospital. Rounding teams included physicians, nurses, certified wound ostomy nurses, clinical quality coordinator nurses, and rehabilitation therapists. High-risk patients were identified using the Braden QD Scale and unit-specific criteria. During rounds, teams discussed prevention strategies and implemented targeted interventions, including device optimization, mobility promotion, nutrition assessment, skin protection measures, and bedside education. Outcome, process, and balancing metrics were tracked. RESULTS: Within 1 year of implementation, the ICU sHAPI rate was reduced by 39% from 0.564 to 0.343 per 1,000 patient-days. The time between events increased in the PICU and cardiac intensive care unit. More than 1,400 proactive interventions were implemented. Rates of non-sHAPI hospital-acquired conditions decreased from 4.8 to 2.8 events per month. CONCLUSIONS: Proactive interdisciplinary rounding was feasible, reproducible across ICUs, and associated with fewer sHAPIs. CI - Copyright (c) 2026 the Author(s). Published by Wolters Kluwer Health, LLC. FAU - Gahagen, Rachel E AU - Gahagen RE AD - From the Division of Pediatric Critical Care, Ann and Robert H. Lurie Children's Hospital, Chicago, Ill. AD - Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Ill. FAU - Lucey, Kate AU - Lucey K AD - Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Ill. AD - Division of Hospital Based Medicine, Ann and Robert H. Lurie Children's Hospital, Chicago, Ill. FAU - Kronforst, Kenny AU - Kronforst K AD - Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Ill. AD - Division of Neonatology, Ann and Robert H. Lurie Children's Hospital, Chicago, Ill. AD - Center for Quality and Safety, Ann and Robert H. Lurie Children's Hospital, Chicago, Ill. FAU - Knell, Jacqueline M AU - Knell JM AD - Lefkofsky Family Pediatric Intensive Care Unit, Ann and Robert H. Lurie Children's Hospital, Chicago, Ill. FAU - Chapman, Kate AU - Chapman K AD - Center for Quality and Safety, Ann and Robert H. Lurie Children's Hospital, Chicago, Ill. FAU - Mindel, Monica AU - Mindel M AD - Center for Quality and Safety, Ann and Robert H. Lurie Children's Hospital, Chicago, Ill. FAU - Sarmiento, John AU - Sarmiento J AD - Lefkofsky Family Pediatric Intensive Care Unit, Ann and Robert H. Lurie Children's Hospital, Chicago, Ill. FAU - Weisert, Lauren M AU - Weisert LM AD - Center for Quality and Safety, Ann and Robert H. Lurie Children's Hospital, Chicago, Ill. FAU - Vogel, Casey AU - Vogel C AD - Division of Rehabilitation, Ann and Robert H. Lurie Children's Hospital, Chicago, Ill. FAU - Collins, Catherine A AU - Collins CA AD - Division of Cardiology, Ann and Robert H. Lurie Children's Hospital, Chicago, Ill. LA - eng PT - Journal Article DEP - 20261028 PL - United States TA - Pediatr Qual Saf JT - Pediatric quality & safety JID - 101702480 PMC - PMC13716412 EDAT- 2026/10/29 15:20 MHDA- 2026/10/29 15:21 PMCR- 2026/10/28 CRDT- 2026/10/29 06:05 PHST- 2026/05/30 00:00 [received] PHST- 2026/09/25 00:00 [revised] PHST- 2026/09/28 00:00 [accepted] PHST- 2026/10/29 15:21 [medline] PHST- 2026/10/29 15:20 [pubmed] PHST- 2026/10/29 06:05 [entrez] PHST- 2026/10/28 00:00 [pmc-release] AID - PQS-D-26-00078 [pii] AID - 10.1097/pq9.0000000000000943 [doi] PST - epublish SO - Pediatr Qual Saf. 2026 Oct 28;11(6):e943. doi: 10.1097/pq9.0000000000000943. eCollection 2026 Nov-Dec. PMID- 42953362 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20261029 LR - 20261029 IS - 0970-9134 (Print) IS - 0973-7723 (Electronic) IS - 0970-9134 (Linking) VI - 42 IP - 11 DP - 2026 Nov TI - Developing proficiency in a transcatheter aortic valve replacement program: lessons from a single academic center's learning curve. PG - 1194-1203 LID - 10.1007/s12055-026-02249-x [doi] AB - PURPOSE: Aortic stenosis (AS) is a prevalent and high-mortality valve disease. Transcatheter aortic valve replacement (TAVR) is a minimally invasive treatment with outcomes often better than surgery, requiring a multidisciplinary team. This study analyzes outcomes and trends from a high-volume TAVR program in an urban, low-income setting since 2017 to guide future practices. METHODS: Medical records of patients that underwent TAVR were analyzed retrospectively from 2018 to 2023, dividing them into two cohorts to analyze trends in operative details, complications, length of stay (LOS), and readmission/mortality rates. The learning curve (LC) was assessed by operative time. RESULTS: Risk-adjusted cumulative sum (RA-CUSUM) analysis identified the transition point at case 76, dividing the cohort into early LC phase group (n = 76) and post-LC phase group (n = 190). Median operative time decreased from 106 to 80 minutes. After adjustment, operative time was 14% shorter in the post-learning-curve cohort (GMR 0.86, 95% CI 0.77-0.96; p = 0.005). CONCLUSION: Operative time serves as a useful benchmark for institutional maturation. In our program, reaching 76 cases represented a key transition point toward optimized workflows, enhanced efficiency, and improved resource utilization. CI - (c) Indian Association of Cardiovascular-Thoracic Surgeons 2026. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. FAU - Manueli Laos, Emiliano Gabriel AU - Manueli Laos EG AUID- ORCID: 0009-0008-5289-6546 AD - Division of General, Minimally Invasive and Robotic Surgery, Department of Surgery, University of Illinois Chicago, Chicago, IL 60612 USA. ROR: https://ror.org/02mpq6x41. GRID: grid.185648.6. ISNI: 0000 0001 2175 0319 AD - Digestive Disease Institute, Cleveland Clinic, Cleveland, OH 44195 USA. ROR: https://ror.org/03xjacd83. GRID: grid.239578.2. ISNI: 0000 0001 0675 4725 FAU - Fontaine-Nicola, Andres AU - Fontaine-Nicola A AD - Division of Cardiothoracic Surgery, Department of Surgery, University of Illinois Chicago, Chicago, IL 60612 USA. ROR: https://ror.org/02mpq6x41. GRID: grid.185648.6. ISNI: 0000 0001 2175 0319 AD - Department of Surgery, North Shore University Hospital, Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY 11030 USA. ROR: https://ror.org/05m8d2x46. GRID: grid.240382.f. ISNI: 0000 0001 0490 6107 FAU - Zhang, Lily AU - Zhang L AD - Division of General, Minimally Invasive and Robotic Surgery, Department of Surgery, University of Illinois Chicago, Chicago, IL 60612 USA. ROR: https://ror.org/02mpq6x41. GRID: grid.185648.6. ISNI: 0000 0001 2175 0319 FAU - Carlson, Andrew AU - Carlson A AD - Department of Medicine, University of Illinois Chicago, Chicago, IL 60612 USA. ROR: https://ror.org/02mpq6x41. GRID: grid.185648.6. ISNI: 0000 0001 2175 0319 FAU - Masrur, Mario A AU - Masrur MA AD - Division of General, Minimally Invasive and Robotic Surgery, Department of Surgery, University of Illinois Chicago, Chicago, IL 60612 USA. ROR: https://ror.org/02mpq6x41. GRID: grid.185648.6. ISNI: 0000 0001 2175 0319 FAU - Ardati, Amer K AU - Ardati AK AD - Department of Medicine, Division of Cardiology, University of Illinois College of Medicine, Chicago, IL 60612 USA. ROR: https://ror.org/047426m28. GRID: grid.35403.31. ISNI: 0000 0004 1936 9991 FAU - Ibrahim, Khalil AU - Ibrahim K AD - Department of Medicine, Division of Cardiology, University of Illinois College of Medicine, Chicago, IL 60612 USA. ROR: https://ror.org/047426m28. GRID: grid.35403.31. ISNI: 0000 0004 1936 9991 FAU - Shroff, Adhir AU - Shroff A AD - Department of Medicine, Division of Cardiology, University of Illinois College of Medicine, Chicago, IL 60612 USA. ROR: https://ror.org/047426m28. GRID: grid.35403.31. ISNI: 0000 0004 1936 9991 FAU - Abdelhady, Khaled AU - Abdelhady K AD - Division of Cardiothoracic Surgery, Department of Surgery, University of Illinois Chicago, Chicago, IL 60612 USA. ROR: https://ror.org/02mpq6x41. GRID: grid.185648.6. ISNI: 0000 0001 2175 0319 LA - eng PT - Journal Article DEP - 20260804 PL - India TA - Indian J Thorac Cardiovasc Surg JT - Indian journal of thoracic and cardiovascular surgery JID - 8700105 PMC - PMC13714239 OTO - NOTNLM OT - Minimally invasive surgery OT - Single-center experience OT - Transcatheter aortic valve replacement COIS- Conflict of interestThe authors declare no existing conflicts of interest to disclose. EDAT- 2026/10/29 15:20 MHDA- 2026/10/29 15:21 PMCR- 2027/11/01 CRDT- 2026/10/29 05:51 PHST- 2025/11/04 00:00 [received] PHST- 2026/07/03 00:00 [revised] PHST- 2026/07/08 00:00 [accepted] PHST- 2026/10/29 15:21 [medline] PHST- 2026/10/29 15:20 [pubmed] PHST- 2026/10/29 05:51 [entrez] PHST- 2027/11/01 00:00 [pmc-release] AID - 2249 [pii] AID - 10.1007/s12055-026-02249-x [doi] PST - ppublish SO - Indian J Thorac Cardiovasc Surg. 2026 Nov;42(11):1194-1203. doi: 10.1007/s12055-026-02249-x. Epub 2026 Aug 4. PMID- 42952268 OWN - NLM STAT- MEDLINE DCOM- 20261029 LR - 20261029 IS - 1478-5153 (Electronic) IS - 1362-1017 (Print) IS - 1362-1017 (Linking) VI - 31 IP - 6 DP - 2026 Nov TI - Rapid Response System Escalation During Recovery of Hospital Bed Occupancy: An Observational Longitudinal Study. LID - e70761 [pii] LID - 10.1111/nicc.70761 [doi] AB - BACKGROUND: Early warning scores (EWS) identify patient deterioration, but their impact depends on how they are integrated into workflows and escalation culture, particularly as hospitals recover from pandemic-related bed pressures. AIMS: To evaluate changes in rapid response system (RRS) escalation processes and rare safety outcomes after embedding an EWS within proactive Critical Care Outreach Team (CCOT) rounds as hospital bed occupancy recovered. STUDY DESIGN: Observational longitudinal study at a single tertiary hospital in Japan comparing one pre-intervention year (2021) with three post-intervention years (2022-2024). In January 2022, a standardised EWS was embedded into proactive CCOT rounds and used as a prompt for shared clinical reasoning rather than a strict numeric trigger. Monthly aggregated ward-level data were analysed using Poisson regression, adjusting for seasonality, patient characteristics and bed occupancy. RESULTS: Across 71 985 admissions and 692 942 general-ward patient-days, rates of nurse-initiated escalations, RRS activations and resuscitation-status updates per 1000 patient-days increased in post-intervention analyses, but these differences were attenuated after full adjustment. In fully adjusted models, post-intervention incidence rate ratios (IRRs) were close to 1.0 for all process outcomes. For nurse-initiated escalations, IRRs ranged from 0.94 to 1.14, and all 95% confidence intervals included 1.0. Rates of unexpected in-hospital cardiac arrest and unplanned ICU admission remained low and stable. Bed occupancy increased over the study period, but within-year associations with outcomes were weak. CONCLUSIONS: After adjustment for patient characteristics and hospital bed occupancy, embedding an EWS within proactive CCOT rounds was associated with broadly stable escalation process indicators and no clear evidence of deterioration in rare safety outcomes. RELEVANCE TO CLINICAL PRACTICE: These findings suggest that approaches to the RRS afferent limb that embed EWS use within structured dialogue between ward nurses and outreach teams may provide one plausible mechanism for sustaining escalation behaviours under operational pressure. CI - (c) 2026 The Author(s). Nursing in Critical Care published by John Wiley & Sons Ltd on behalf of British Association of Critical Care Nurses. FAU - Noguchi, Ayako AU - Noguchi A AUID- ORCID: 0000-0002-1055-9794 AD - Intensive Care Unit, Institute of Science Tokyo Hospital, Tokyo, Japan. AD - Department of Disaster and Critical Care Nursing, Track of Nursing Innovation Science, Graduate School of Health Care Sciences Institute of Science Tokyo, Tokyo, Japan. FAU - Yamada, Tomoaki AU - Yamada T AUID- ORCID: 0009-0007-3044-578X AD - Division of Clinical Management, Medical Informatics, Institute of Science Tokyo Hospital, Tokyo, Japan. FAU - Anzai, Tatsuhiko AU - Anzai T AUID- ORCID: 0000-0003-1073-2996 AD - Department of Biostatistics, M&D Data Science Center, Institute of Science Tokyo, Tokyo, Japan. FAU - Oka, Kouji AU - Oka K AD - Department of Nursing, Institute of Science Tokyo Hospital, Tokyo, Japan. FAU - Ai, Masumi AU - Ai M AD - Department of Insured Medical Care Management, Institute of Science Tokyo Hospital, Tokyo, Japan. FAU - Uchimura, Yuji AU - Uchimura Y AUID- ORCID: 0000-0002-1645-466X AD - Division of Clinical Management, Medical Informatics, Institute of Science Tokyo Hospital, Tokyo, Japan. FAU - Toba, Mikayo AU - Toba M AUID- ORCID: 0000-0002-7765-3988 AD - Quality Management Centre, Institute of Science Tokyo, Tokyo, Japan. FAU - Takahashi, Kunihiko AU - Takahashi K AUID- ORCID: 0000-0003-2387-7772 AD - Department of Biostatistics, M&D Data Science Center, Institute of Science Tokyo, Tokyo, Japan. FAU - Moriwaki, Mutsuko AU - Moriwaki M AUID- ORCID: 0000-0002-4222-0891 AD - Quality Management Centre, Institute of Science Tokyo, Tokyo, Japan. FAU - Wakabayashi, Kenji AU - Wakabayashi K AUID- ORCID: 0000-0001-5332-6192 AD - Intensive Care Unit, Institute of Science Tokyo Hospital, Tokyo, Japan. AD - Department of Intensive Care Medicine, Graduate School of Medical and Dental Sciences Institute of Science Tokyo, Tokyo, Japan. LA - eng GR - 22K17469ZA/Japan Society for the Promotion of Science (JSPS) KAKENHI/ PT - Journal Article PT - Observational Study PL - England TA - Nurs Crit Care JT - Nursing in critical care JID - 9808649 SB - IM MH - Humans MH - Longitudinal Studies MH - *Bed Occupancy/statistics & numerical data MH - Japan MH - *Hospital Rapid Response Team/organization & administration MH - *Early Warning Score MH - *Intensive Care Units MH - Male MH - Female PMC - PMC13717281 OTO - NOTNLM OT - critical care outreach OT - early warning scores OT - escalation of care OT - longitudinal study OT - rapid response systems COIS- The authors declare no conflicts of interest. EDAT- 2026/10/29 05:30 MHDA- 2026/10/29 05:31 PMCR- 2026/10/29 CRDT- 2026/10/29 02:52 PHST- 2026/10/06 00:00 [revised] PHST- 2026/06/05 00:00 [received] PHST- 2026/10/08 00:00 [accepted] PHST- 2026/10/29 05:31 [medline] PHST- 2026/10/29 05:30 [pubmed] PHST- 2026/10/29 02:52 [entrez] PHST- 2026/10/29 00:00 [pmc-release] AID - e70761 [pii] AID - NICC70761 [pii] AID - 10.1111/nicc.70761 [doi] PST - ppublish SO - Nurs Crit Care. 2026 Nov;31(6):e70761. doi: 10.1111/nicc.70761. PMID- 42951945 OWN - NLM STAT- Publisher LR - 20261029 IS - 1538-4683 (Electronic) IS - 1061-5377 (Linking) DP - 2026 Oct 29 TI - Beyond Blood Cultures and Echocardiography: Emerging Diagnostics for Infective Endocarditis. LID - 10.1097/CRD.0000000000001514 [doi] AB - Management of infective endocarditis (IE) is often confounded by the presence of prosthetic valves, transcatheter prostheses, and cardiovascular implantable electronic devices, as well as by changing epidemiologic risks and antimicrobial resistance patterns. For the diagnosis of IE, blood cultures and echocardiography remain foundational, but important gaps persist, particularly in culture-negative and prosthetic/device-associated infections. Contemporary diagnostic criteria and guidelines now support a multimodality approach incorporating molecular microbiology and advanced imaging. This review summarizes emerging technologies including broad-range 16S/18S/28S rRNA polymerase chain reaction and sequencing, fluorescence in situ hybridization coupled with sequencing, targeted and shotgun metagenomic next-generation sequencing (mNGS), plasma microbial cell-free DNA, cardiac computed tomography, and 18F-fluorodeoxyglucose positron-emission tomography/computed tomography. We also examine the potential role of artificial intelligence in echocardiographic interpretation and of large language models in multimodal data integration. Current evidence suggests that tissue-based molecular testing generally provides greater microbiologic yield than valve culture in culture-negative IE, while blood-based mNGS and microbial cell-free DNA may extend pathogen detection after antibiotic exposure and reduce reliance on tissue-based diagnosis. However, heterogeneity in specimen handling, sequencing pipelines, contamination control, reporting thresholds, and clinical interpretation remains a major barrier to implementation. Future progress should move beyond pathogen detection toward rapid, reproducible, clinically actionable diagnosis that integrates organism identification, anatomic localization, disseminated disease, and personalized treatment. Prospective outcome trials, standardized workflows, cost-effectiveness studies, and multidisciplinary Endocarditis Team integration can help determine whether these technologies translate into better antimicrobial stewardship, procedural decision-making, and patient outcomes. CI - Copyright (c) 2026 Wolters Kluwer Health, LLC. All rights reserved. FAU - Park, Hongshik AU - Park H AD - From the Department of Medicine, New York Medical College, Valhalla, NY. FAU - Dhand, Abhay AU - Dhand A AD - From the Department of Medicine, New York Medical College, Valhalla, NY. AD - Department of Surgery, Westchester Medical Center/New York Medical College, Valhalla, NY. LA - eng PT - Journal Article DEP - 20261029 PL - United States TA - Cardiol Rev JT - Cardiology in review JID - 9304686 SB - IM OTO - NOTNLM OT - 16S rRNA PCR OT - FDG PET/CT OT - FISHseq OT - artificial intelligence OT - cardiac computed tomography OT - culture-negative endocarditis OT - infective endocarditis OT - metagenomic next-generation sequencing OT - microbial cell-free DNA COIS- Disclosure: The authors declare no conflicts of interest. EDAT- 2026/10/29 05:30 MHDA- 2026/10/29 05:30 CRDT- 2026/10/29 00:07 PHST- 2026/10/29 05:30 [medline] PHST- 2026/10/29 05:30 [pubmed] PHST- 2026/10/29 00:07 [entrez] AID - 00045415-990000000-01057 [pii] AID - 10.1097/CRD.0000000000001514 [doi] PST - aheadofprint SO - Cardiol Rev. 2026 Oct 29. doi: 10.1097/CRD.0000000000001514. PMID- 42951446 OWN - NLM STAT- MEDLINE DCOM- 20261028 LR - 20261028 IS - 1558-0474 (Electronic) IS - 0889-8545 (Linking) VI - 53 IP - 4 DP - 2026 Dec TI - Postpartum Follow-Up for Cardiovascular Disease Provoked by Pregnancy. PG - 815-834 LID - S0889-8545(26)00068-9 [pii] LID - 10.1016/j.ogc.2026.07.006 [doi] AB - Pregnancy and the postpartum period are times of significant hemodynamic change and can cause new cardiac disease, highlight previously unknown cardiovascular disease (CVD) or exacerbate known underlying CVD. While cardiovascular events frequently occur during pregnancy, half of maternal deaths occur in the postpartum period. Postpartum monitoring needs to be individualized based on the underlying disease process and must include inpatient and outpatient management plans. Care by a multidisciplinary team, including a mindful transition from obstetrics (OB) to primary care and/or cardiology, is necessary to optimize future pregnancy and long-term health. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Reiger, Sarah AU - Reiger S AD - Department of General Internal Medicine, University of Washington Medical Center, Seattle, WA, USA. FAU - Buber, Jonathan AU - Buber J AD - Division of Cardiology, Department of Medicine, University of Washington Medical Center, Seattle, WA, USA. FAU - Albright, Catherine AU - Albright C AD - Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, University of Washington Medical Center, Seattle, WA, USA. Electronic address: cmalbrig@uw.edu. LA - eng PT - Journal Article PT - Review DEP - 20260811 PL - United States TA - Obstet Gynecol Clin North Am JT - Obstetrics and gynecology clinics of North America JID - 8709551 SB - IM MH - Humans MH - Female MH - Pregnancy MH - *Pregnancy Complications, Cardiovascular/therapy/diagnosis/physiopathology MH - *Cardiovascular Diseases/therapy/diagnosis/physiopathology MH - Postpartum Period MH - *Postnatal Care/methods OTO - NOTNLM OT - Cardiovascular disease OT - Heart disease OT - Postpartum OT - Pregnancy COIS- Disclosure The authors have no financial disclosures or conflicts of interest to disclose. EDAT- 2026/10/28 23:27 MHDA- 2026/10/29 05:30 CRDT- 2026/10/28 21:55 PHST- 2026/10/29 05:30 [medline] PHST- 2026/10/28 23:27 [pubmed] PHST- 2026/10/28 21:55 [entrez] AID - S0889-8545(26)00068-9 [pii] AID - 10.1016/j.ogc.2026.07.006 [doi] PST - ppublish SO - Obstet Gynecol Clin North Am. 2026 Dec;53(4):815-834. doi: 10.1016/j.ogc.2026.07.006. Epub 2026 Aug 11. PMID- 42951444 OWN - NLM STAT- MEDLINE DCOM- 20261028 LR - 20261028 IS - 1558-0474 (Electronic) IS - 0889-8545 (Linking) VI - 53 IP - 4 DP - 2026 Dec TI - Anesthetic Considerations for Delivery of Patients with Cardiovascular Disease. PG - 781-801 LID - S0889-8545(26)00061-6 [pii] LID - 10.1016/j.ogc.2026.06.004 [doi] AB - Pregnant patients with cardiovascular disease benefit from early evaluation by a pregnancy heart team and formal risk stratification to guide delivery planning and determine the need for care at a tertiary center. Carefully titrated neuraxial anesthesia is preferred to reduce maternal catecholamines, decrease cardiac workload, and enable controlled hemodynamic management. From a cardiovascular standpoint, vaginal delivery is generally favored over cesarean delivery due to its more gradual hemodynamic changes and lower physiologic stress. Intrapartum management should be guided by lesion-specific physiology, with contingencies in place for obstetric and cardiac emergencies. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Thomas, A Taylor AU - Thomas AT AD - Department of Anesthesiology, Massachusetts General Hospital, 55 Fruit Street, GRB 444, Boston, MA 02114, USA. Electronic address: athomas@mgh.harvard.edu. FAU - Naoum, Emily E AU - Naoum EE AD - Department of Anesthesiology, Massachusetts General Hospital, 55 Fruit Street, GRB 444, Boston, MA 02114, USA. LA - eng PT - Journal Article PT - Review DEP - 20260811 PL - United States TA - Obstet Gynecol Clin North Am JT - Obstetrics and gynecology clinics of North America JID - 8709551 SB - IM MH - Humans MH - Female MH - Pregnancy MH - *Pregnancy Complications, Cardiovascular/physiopathology/therapy MH - *Anesthesia, Obstetrical/methods MH - *Delivery, Obstetric/methods MH - *Cardiovascular Diseases/physiopathology/complications MH - Cesarean Section/methods OTO - NOTNLM OT - Antenatal anesthesia consult OT - Cardio-obstetrics OT - Cardiovascular disease in pregnancy OT - Maternal anesthetic management OT - Maternal levels of care OT - Neuraxial anesthesia OT - Pregnancy heart team COIS- Disclosure The authors declare no relevant conflicts of interest. EDAT- 2026/10/28 23:27 MHDA- 2026/10/29 05:30 CRDT- 2026/10/28 21:55 PHST- 2026/10/29 05:30 [medline] PHST- 2026/10/28 23:27 [pubmed] PHST- 2026/10/28 21:55 [entrez] AID - S0889-8545(26)00061-6 [pii] AID - 10.1016/j.ogc.2026.06.004 [doi] PST - ppublish SO - Obstet Gynecol Clin North Am. 2026 Dec;53(4):781-801. doi: 10.1016/j.ogc.2026.06.004. Epub 2026 Aug 11. PMID- 42951210 OWN - NLM STAT- Publisher LR - 20261028 IS - 2352-5568 (Electronic) IS - 2352-5568 (Linking) DP - 2026 Oct 28 TI - Procedure-specific bleeding risk assessment: a multidisciplinary expert consensus companion to the 2026 periprocedural anticoagulant management guidelines. PG - 101962 LID - S2352-5568(26)00220-1 [pii] LID - 10.1016/j.accpm.2026.101962 [doi] AB - BACKGROUND: Periprocedural anticoagulant management requires balancing thrombotic risk against procedure-specific bleeding risk. Existing procedure bleeding risk classifications are fragmented across specialties, inconsistent in methodology, and rarely extend beyond a few procedural domains, limiting their clinical applicability. OBJECTIVE: To develop a comprehensive, standardized, procedure-specific bleeding risk classification to accompany the 2026 GIHP-SFAR periprocedural anticoagulant management guidelines. METHODS: A formal multidisciplinary consensus was conducted under the auspices of GIHP and SFAR, in collaboration with 24 surgical and interventional specialty societies. For each procedural domain, a working group performed a systematic literature review. Procedures were classified into four tiers: no bleeding risk, low bleeding risk, high bleeding risk, and very high bleeding risk. A specific category was created for procedures carrying particular contextual risk (e.g., anatomical site, patient factors, or need for reversible anticoagulation). Consensus was reached by the full expert panel. RESULTS: Twenty-four procedural domains were classified, ranging from regional anaesthesia and digestive endoscopy to cardiac surgery, neurosurgery, and ophthalmology. Each domain provides a procedure-specific bleeding risk table, with narrative supporting evidence. Procedures warranting delayed resumption of anticoagulation (>/=72 hours) or use of short-acting/reversible anticoagulants are identified. The classification covers common and complex surgical scenarios, including those with limited published evidence where structured expert opinion was applied. CONCLUSION: This companion document provides clinicians with a standardized, evidence-based, procedure-specific bleeding risk framework across 24 domains to support individualized periprocedural anticoagulant decisions in daily practice. CI - Copyright (c) 2026. Published by Elsevier Masson SAS. FAU - Godier, Anne AU - Godier A AD - Universite Paris Cite, service d'anesthesie-reanimation, AP-HP, Hopital Georges Pompidou, UMRS_1140, F-75006 Paris, France. Electronic address: Anne.godier@aphp.fr. FAU - Roullet, Stephanie AU - Roullet S AD - Assistance Publique - Hopitaux de Paris (AP-HP), Hopital Paul Brousse, Departement d'Anesthesie Reanimation, Villejuif, France and Universite Paris-Saclay, INSERM, Hemostase inflammation thrombose HITH U1176, Le Kremlin-Bicetre, France. FAU - Lanoiselee, Julien AU - Lanoiselee J AD - National Institute of Health and Medical Research, U1059, Vascular Dysfunction and Hemostasis, Saint-Etienne, France, Department of Anesthesia and Intensive Care, University Hospital of Saint-Etienne, Saint-Etienne, France. FAU - Aim, Florence AU - Aim F AD - Chirurgie Orthopedique, GH Diaconesses Croix Saint Simon, Paris. FAU - Alantar, Alp AU - Alantar A AD - UF de Chirurgie orale, Hopital de Nanterre, 92000, France. FAU - Assouline, Jessica AU - Assouline J AD - Service de radiologie, AP-HP. FAU - Atallah, Sarah AU - Atallah S AD - Sorbonne Universite, Service ORL et chirurgie cervico-faciale, Hopital Tenon, AP-HP, Paris, France. FAU - Badet, Roger AU - Badet R AD - Clinique St Charles, Lyon et Clinique Saint Vincent de Paul, Bourgoin-Jallieu, France. FAU - Baroncini, Marc AU - Baroncini M AD - Neurochirurgie, CHU de Lille. FAU - Berdah, Stephane AU - Berdah S AD - Departement de Chirurgie Viscerale et Digestive, Hopital Nord, AP-HM, Aix-Marseille Universite. FAU - Beyer, Laura AU - Beyer L AD - Departement de Chirurgie Viscerale et Digestive, Hopital Nord, AP-HM, Aix-Marseille Universite. FAU - Blanchet, Marie-Cecile AU - Blanchet MC AD - Centre Lyonnais de Chirurgie Digestive, Centre Specialise Obesite Lyon Sauvegarde. FAU - Bouchard, Dominique AU - Bouchard D AD - Service de Proctologie, Hopital Bagatelle, Bordeaux, membre du CA de la SNFCP. FAU - Brenet, Esteban AU - Brenet E AD - MCU-PH Chirurgie carcinologique et reconstructrice ORL, Service ORL, CHU Reims, Universite Reims Champagne Ardenne. FAU - Buffenoir, Kevin AU - Buffenoir K AD - Service de Neurochirurgie, CHU de la Reunion - site de Saint Pierre. FAU - Carsuzaa, Florent AU - Carsuzaa F AD - Service ORL et chirurgie cervico-faciale, CHU de Poitiers, Poitiers, France. FAU - Alegria, Guillermo Carvajal AU - Alegria GC AD - Center for Molecular Biophysics, UPR CNRS 4301, Orleans-Tours, Nanomedicines and Nanoprobes Department, University of Tours, Department of Rheumatology, University Hospital Center of Tours, Tours, France. FAU - Chauleur, Celine AU - Chauleur C AD - Service de Gynecologie-obstetrique, CHU de Saint-Etienne, INSERM, SAINBIOSE, U1059, Dysfonction Vasculaire et Hemostase, Universite Jean-Monnet, CIC1408, Saint-Etienne, France. FAU - Cazato, Luigi AU - Cazato L AD - Service de radiologie, Hopitaux Universitaires de Strasbourg. FAU - de Parades, Vincent AU - de Parades V AD - Service de proctologie, Hopital Saint Joseph, Paris, President de la SNFCP. FAU - Delambre, Jerome AU - Delambre J AD - Chirurgie Orthopedique, Institut du Rachis, Paris, France. FAU - Destrieux, Laurence AU - Destrieux L AD - Departement de Chirurgie Vasculaire, Clinique Generale, Groupe Vivalto, Annecy, France. FAU - Drissi, Farouk AU - Drissi F AD - Clinique Jules Verne, Nantes, France. FAU - Ejeil, Anne-Laure AU - Ejeil AL AD - Universite Paris Cite, Faculte de chirurgie dentaire, service de medecine bucco-dentaire, Hopital Bretonneau, Paris, AP-HP. FAU - Fautrel, Bruno AU - Fautrel B AD - Sorbonne Universite-Assistance Publique Hopitaux de Paris, Service de Rhumatologie, Hopital Pitie-Salpetriere, AP-HP, 75013 Paris, France; INSERM UMRS 1136, Institut Pierre-Louis d'Epidemiologie et Sante Publique, 75013 Paris, France. FAU - Fauchier, Laurent AU - Fauchier L AD - Service de Cardiologie, Centre Hospitalier Universitaire Trousseau et Faculte de Medecine, Universite Francois Rabelais, Tours, France. FAU - Favier, Valentin AU - Favier V AD - Service ORL et chirurgie cervico-faciale, Hopital Gui de Cauliacs, CHU Montpellier, Montpellier, France. FAU - Fiard, Gaelle AU - Fiard G AD - CHU Grenoble Alpes, service d'urologie et de la transplantation renale. FAU - Fieux, Maxime AU - Fieux M AD - Hospices Civils de Lyon, Hopital Lyon Sud, Service d'ORL, d'otoneurochirurgie et de chirurgie cervico-faciale, F-69310 Pierre Benite; Universite de Lyon, Universite Lyon 1, F-69003 Lyon; UMR 5305, LBTI, Institut de Biologie et Chimie des Proteines, CNRS/UCBL, Lyon, France. FAU - Gouin, Francois AU - Gouin F AD - Departement de Chirurgie oncologique, Centre Leon Berard, Lyon, France. FAU - Guyot, Michel AU - Guyot M AD - Chirurgien-dentiste a Fontenay-le-Comte. FAU - Hermann, Ruben AU - Hermann R AD - Service d'ORL, de chirurgie cervico-faciale et d'audiophonologie, Hopital Edouard Herriot, Hospices Civils de Lyon, Lyon, France. FAU - Hersant, Barbara AU - Hersant B AD - Cabinet Foch, 65 avenue Foch, 75116 Paris, France. FAU - Herrero, Astrid AU - Herrero A AD - Service de chirurgie viscerale et digestive, oncologique et transplantation, CHU de Montpellier, Universite de Montpellier. FAU - Higuero, Thierry AU - Higuero T AD - Cabinet de Proctologie, Beausoleil. FAU - Hulet, Christophe AU - Hulet C AD - Chirurgie Orthopedique, Unite INSERM COMETE 1075, CHU de Caen. FAU - Iung, Bernard AU - Iung B AD - Hopital Bichat, AP-HP, INSERM LVTS 1148, Universite Paris Cite, Paris, France. FAU - Juguet, Frederic AU - Juguet F AD - Clinique Tivoli Duclos, Bordeaux, France. FAU - Karsenti, David AU - Karsenti D AD - Clinique Paris-Bercy, Pole digestif Paris-Bercy, Charenton-le-Pont, France. FAU - Kobeiter, Hicham AU - Kobeiter H AD - Service de radiologie, CHU Mondor, Creteil, France. FAU - Lafon, Arnaud AU - Lafon A AD - Universite Lyon, Laboratoire des Multimateriaux et Interfaces UMR CNRS 5615, Faculte d'Odontologie, Lyon 69008, France; Hospices Civils de Lyon, Pole d'Odontologie, Lyon, France. FAU - Lahlou, Ghizlene AU - Lahlou G AD - Service ORL et Implants Auditifs, Hopital Pitie Salpetriere, AP-HP, Sorbonne Universite, Paris, France. FAU - Langbour, Camille AU - Langbour C AD - Service de rhumatologie, CHU d'Orleans, 14, avenue de l'Hopital, CS 86709, 45067 Orleans cedex 2, France. FAU - Lefevre, Jeremie AU - Lefevre J AD - Sorbonne Universite, Department of Digestive Surgery, AP-HP, Hopital Saint Antoine, Paris, France. FAU - Lescaille, Geraldine AU - Lescaille G AD - Universite Paris Cite, Faculte de chirurgie dentaire, AP-HP Hopital Pitie Salpetriere, service de medecine bucco-dentaire. FAU - Lustig, Sebastien AU - Lustig S AD - Service de chirurgie orthopedique, Hospices Civils de Lyon. FAU - Mabrut, Jean-Yves AU - Mabrut JY AD - Service de chirurgie generale, digestive et transplantations hepatiques et intestinales, Hospices Civils de Lyon. FAU - Maggiori, Leon AU - Maggiori L AD - Service de Chirurgie Viscerale, Cancerologique et Endocrinienne, Hopital Saint-Louis, AP-HP, Universite de Paris Cite. FAU - Mege, Diane AU - Mege D AD - MCU-PH, Service de chirurgie colorectale, La Timone, AP-HM, Marseille; membre du CA de la SNFCP. FAU - Meneveau, Nicolas AU - Meneveau N AD - Service de Cardiologie, Centre Hospitalier Universitaire Besancon, Universite Marie et Louis Pasteur. FAU - Merlot, Isabelle AU - Merlot I AD - Neurochirurgie, Hopital Central, CHRU de Nancy. FAU - Moreddu, Eric AU - Moreddu E AD - Service d'ORL et chirurgie cervico-faciale pediatrique, Hopital d'enfants de la Timone, AP-HM, Aix-Marseille Universite, Marseille, France. FAU - Moszkowicz, David AU - Moszkowicz D AD - Service de Chirurgie Viscerale, Hopital Louis Mourier, AP-HP, Universite de Paris Cite. FAU - Deballon, Pablo Ortega AU - Deballon PO AD - Service de Chirurgie Viscerale, CHU de Dijon. FAU - Phulpin, Berengere AU - Phulpin B AD - Universite de Lorraine, CHRU-Nancy, Service d'Odontologie, Departement de chirurgie orale, Universite de Lorraine, Faculte d'Odontologie, F-54500 Nancy, France. FAU - Pigot, Francois AU - Pigot F AD - Service de Proctologie, Hopital Bagatelle, Bordeaux, France. FAU - Poghosyan, Tigran AU - Poghosyan T AD - Service de chirurgie digestive, Hopital Bichat, AP-HP, Universite de Paris. FAU - Rabarin, Fabrice AU - Rabarin F AD - Centre de la Main, Angers Assistance Main, Trelaze, France. FAU - Radoi, Loredana AU - Radoi L AD - Universite Paris Cite, Faculte de chirurgie dentaire, AP-HP Nord, Hopital Louis Mourier, service de medecine bucco-dentaire. FAU - Rouillon, Jean-Michel AU - Rouillon JM AD - Polyclinique Montreal, Carcassonne, France. FAU - Sapoval, Marc AU - Sapoval M AD - Service de radiologie, AP-HP, HEGP. FAU - Soudan, Damien AU - Soudan D AD - Cabinet de Proctologie de Nantes, Clinique Jules Verne; membre du CA de la SNFCP. FAU - Teissier, Natacha AU - Teissier N AD - Service d'ORL pediatrique, NeuroDiderot, Inserm U1141, Hopital Robert Debre, F-75019, Paris, France. FAU - Vidal, Vincent AU - Vidal V AD - Service de radiologie, Hopitaux Universitaires de Marseille. FAU - Vincentelli, Andre AU - Vincentelli A AD - Department of Cardiac Surgery, University of Lille, CHU Lille, Lille, France. FAU - Motte, Serge AU - Motte S AD - Universite Libre de Bruxelles, Hopital Universitaire de Bruxelles, Bruxelles, Belgium. FAU - Blais, Normand AU - Blais N AD - Service d'hematologie et d'oncologie medicale, Centre Hospitalier de l'Universite de Montreal, Canada. FAU - Bonhomme, Fanny AU - Bonhomme F AD - Service d'Anesthesiologie, Departement de Medecine Aigue, Hopitaux Universitaires de Geneve. FAU - Bourguignon, Alex AU - Bourguignon A AD - Service d'hemato-oncologie, Centre Hospitalier Universitaire de Montreal, Montreal, Canada. FAU - Cohen, Ariel AU - Cohen A AD - Service de cardiologie, hopital Saint-Antoine, hopital Tenon, Assistance publique-Hopitaux de Paris, Sorbonne universite, Paris, France. FAU - de Maistre, Emmanuel AU - de Maistre E AD - Service d'Hematologie Biologique, Hopital Le Bocage, CHRU de Dijon, 21000 Dijon, France. FAU - Douillet, Delphine AU - Douillet D AD - Emergency Department, Health Faculty, Angers University Hospital, Angers, France; UMR MitoVasc CNRS 6015 - INSERM 1083, Equipe CARME, UNIV Angers, Angers, France; F-CRIN INNOVTE Network, Saint-Etienne, France. FAU - Fontana, Pierre AU - Fontana P AD - Division of Angiology and Haemostasis, University Hospitals of Geneva, Geneva, Switzerland. FAU - Huet, Delphine Garrigue AU - Huet DG AD - Department of anesthesiology and surgical care, CHU Lille, F-59000 Lille, France. FAU - Godon, Alexandre AU - Godon A AD - Univ. Grenoble Alpes, Anesthesiology and Critical Care, CHU Grenoble Alpes, Grenoble, France. FAU - Gouin-Thibault, Isabelle AU - Gouin-Thibault I AD - Department of Laboratory Hematology, Pontchaillou University Hospital; IRSET-INSERM-1085, Univ Rennes, Rennes, France. FAU - Gruel, Yves AU - Gruel Y AD - Universite Francois Rabelais, Inserm UMR1327 ISCHEMIA, Faculte de Medecine, Tours, France. FAU - Jebara, Samia AU - Jebara S AD - St Joseph University, Department of anesthesia and critical care, Hotel Dieu de France hospital, Beirut, Lebanon. FAU - Lasne, Dominique AU - Lasne D AD - Laboratoire d'hematologie generale, AP-HP, Hopital Necker-Enfants Malades, INSERM UMRS_1176, Paris, France. FAU - Laporte, Silvy AU - Laporte S AD - Universite Jean Monnet Saint-Etienne, CHU Saint-Etienne, Service de Pharmacologie Clinique, INSERM, SAINBIOSE U1059, F-42023 Saint-Etienne, France. FAU - Lecompte, Thomas AU - Lecompte T AD - Universite de Lorraine, medecine; CHRU de Nancy, medecine vasculaire, France. FAU - Le Gal, Gregoire AU - Le Gal G AD - Department of Medicine, University of Ottawa, Ottawa, ON, Canada. FAU - Martin, Anne-Celine AU - Martin AC AD - Unite Medico-chirurgicale d'Insuffisance Cardiaque Severe, Chirurgie Cardiaque, AP-HP, Hopital Europeen Georges-Pompidou, and Universite Paris Cite, INSERM UMRS_1140, F-75006 Paris, France. FAU - Mazighi, Mikael AU - Mazighi M AD - Neurology Department, Hopital Lariboisiere, and Interventional Neuroradiology Department, Hopital Fondation A. de Rothschild, FHU Neurovasc, INSERM 1144, Universite Paris-Cite, Paris, France. FAU - Mismetti, Patrick AU - Mismetti P AD - Universite Jean Monnet Saint-Etienne, CHU Saint-Etienne, Service de Medecine Vasculaire et Therapeutique, INSERM, SAINBIOSE U1059, F-42023 Saint-Etienne, France. FAU - Morange, Pierre AU - Morange P AD - Aix Marseille Univ, INSERM 1263, INRAE 1260, C2VN, Marseille, France; Hematology Laboratory, La Timone University Hospital of Marseille, Marseille, France. FAU - Mullier, Francois AU - Mullier F AD - Universite catholique de Louvain, CHU UCL Namur, Namur Thrombosis & Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), Namur, and Institute of Experimental and Clinical Research, UCLouvain, Belgium. FAU - Nguyen, Philippe AU - Nguyen P AD - Universite de Reims Champagne Ardenne, Reims, France. FAU - Pernod, Gilles AU - Pernod G AD - Service de Medecine Vasculaire, Universite Grenoble-Alpes, Grenoble, France; F-CRIN INNOVTE network, Saint-Etienne, France. FAU - Rosencher, Nadia AU - Rosencher N AD - Paris, France. FAU - Roy, Pierre-Marie AU - Roy PM AD - F-CRIN INNOVTE, 42055 Saint-Etienne cedex 2, France; Departement de medecine d'urgence et service de medecine vasculaire, CHU d'Angers, 49000 Angers, France; Institut Mitovasc, UMR 1083, UFR sante, universite d'Angers, 49000 Angers, France. FAU - Schved, Jean-Francois AU - Schved JF AD - Universite Montpellier. FAU - Sie, Pierre AU - Sie P AD - Toulouse University Hospital, 31300 Toulouse, France. FAU - Susen, Sophie AU - Susen S AD - University Lille, Inserm, Institut Pasteur de Lille, U1011-EGID, F-59000 Lille, France. FAU - Tacquard, Charles AU - Tacquard C AD - Department of anesthesia and intensive care, Strasbourg University Hospital, Strasbourg; UMR_S1255 EFS-INSERM, Strasbourg, France. FAU - Vardon, Fanny AU - Vardon F AD - University Hospital of Toulouse, Anaesthesia, Critical Care and Perioperative Medicine, Toulouse, France; University of Toulouse III INSERM U1297, Institute of Cardiovascular and Metabolic Diseases, Toulouse, France. FAU - Zufferey, Paul AU - Zufferey P AD - CHU Saint-Etienne, Service d'Anesthesie Reanimation, INSERM, SAINBIOSE U1059, F-42023 Saint-Etienne, France. FAU - Mariat, Christophe AU - Mariat C AD - Universite Jean Monnet Saint-Etienne, CHU Saint-Etienne, Service de Nephrologie, Dialyse et Transplantation Renale, Hopital Nord, CIRI INSERM U1111/UMR5108, F-42023 Saint-Etienne, France. FAU - Mansour, Alexandre AU - Mansour A AD - Department of Anesthesia and Critical Care, Pontchaillou, University Hospital of Rennes, France; Univ Rennes, CHU Rennes, Inserm, IRSET, UMR_S 1085, F-35000 Rennes, France. FAU - Albaladejo, Pierre AU - Albaladejo P AD - Department of Anaesthesia and Critical Care, Grenoble Alpes University Hospital, Grenoble, France. LA - eng PT - Journal Article DEP - 20261028 PL - France TA - Anaesth Crit Care Pain Med JT - Anaesthesia, critical care & pain medicine JID - 101652401 SB - IM EDAT- 2026/10/28 23:27 MHDA- 2026/10/28 23:27 CRDT- 2026/10/28 20:36 PHST- 2026/09/21 00:00 [received] PHST- 2026/10/11 00:00 [revised] PHST- 2026/10/12 00:00 [accepted] PHST- 2026/10/28 23:27 [medline] PHST- 2026/10/28 23:27 [pubmed] PHST- 2026/10/28 20:36 [entrez] AID - S2352-5568(26)00220-1 [pii] AID - 10.1016/j.accpm.2026.101962 [doi] PST - aheadofprint SO - Anaesth Crit Care Pain Med. 2026 Oct 28:101962. doi: 10.1016/j.accpm.2026.101962. PMID- 42948648 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20261028 LR - 20261029 IS - 2755-9637 (Electronic) IS - 2755-9637 (Linking) VI - 4 IP - 4 DP - 2026 Oct TI - Multimodality imaging for surgical decision-making in tricuspid regurgitation: from referral to intraoperative assessment. PG - qyag168 LID - 10.1093/ehjimp/qyag168 [doi] LID - qyag168 AB - Tricuspid regurgitation (TR) is a clinical syndrome in which integrated multimodality imaging is central to diagnosis, timely referral, procedural selection, and assessment of treatment success. This narrative state-of-the-art review focuses on the imaging information that changes decisions along the surgical pathway while positioning surgery within contemporary transcatheter practice. Transthoracic echocardiography remains the gateway examination; three-dimensional transoesophageal echocardiography refines leaflet and annular anatomy; cardiac magnetic resonance provides the most reproducible assessment of right ventricular volumes and function; and cardiac computed tomography defines annular geometry, adjacent structures, device leads, and access. We distinguish guideline-endorsed thresholds from observational or consensus-derived decision aids and link mechanism, annular dilatation, leaflet tethering, right ventricular reserve, pulmonary haemodynamics, and end-organ risk to the choice of repair, replacement, transcatheter therapy, or surveillance. Particular emphasis is placed on perioperative imaging: the effects of anaesthesia and loading conditions, accurate septolateral annular measurement, the definition of an acceptable post-bypass result, and the significance of central vs. eccentric residual jets. A dedicated section compares imaging requirements for transcatheter edge-to-edge repair and transcatheter tricuspid valve replacement and summarizes post-procedural surveillance. The central message is that imaging does not replace clinical judgement; it provides the shared language through which the Heart Team selects the right intervention before irreversible right-heart and end-organ damage develops. CI - (c) The Author(s) 2026. Published by Oxford University Press on behalf of the European Society of Cardiology. FAU - Ghazy, Ahmed AU - Ghazy A AUID- ORCID: 0000-0001-8263-926X AD - Department of Cardiovascular Surgery, University Medical Center Mainz, Johannes Gutenberg University Mainz, Langenbeckstrasse 1, Mainz 55131, Germany. FAU - Humbert, Till AU - Humbert T AUID- ORCID: 0009-0003-1183-6372 AD - Department of Cardiovascular Surgery, University Medical Center Mainz, Johannes Gutenberg University Mainz, Langenbeckstrasse 1, Mainz 55131, Germany. FAU - Albitar, Mohamad AU - Albitar M AD - Department of Cardiovascular Surgery, University Medical Center Mainz, Johannes Gutenberg University Mainz, Langenbeckstrasse 1, Mainz 55131, Germany. FAU - Elzomor, Hesham AU - Elzomor H AUID- ORCID: 0000-0002-5919-1660 AD - CURAM, SFI Research Centre for Medical Devices, University of Galway, Galway, Ireland. FAU - Danesi, Tommaso Hinna AU - Danesi TH AUID- ORCID: 0000-0003-3500-897X AD - Division of Cardiac Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. FAU - Refaey, Ashraf AU - Refaey A AD - Faculty of Veterinary Medicine, Kafrelsheikh University, Kafrelsheikh, Egypt. FAU - Duerr, Georg Daniel AU - Duerr GD AUID- ORCID: 0000-0002-0310-6236 AD - Department of Cardiovascular Surgery, University Medical Center Mainz, Johannes Gutenberg University Mainz, Langenbeckstrasse 1, Mainz 55131, Germany. FAU - Treede, Hendrik AU - Treede H AUID- ORCID: 0000-0002-8458-7667 AD - Department of Cardiovascular Surgery, University Medical Center Mainz, Johannes Gutenberg University Mainz, Langenbeckstrasse 1, Mainz 55131, Germany. FAU - Zancanaro, Edoardo AU - Zancanaro E AUID- ORCID: 0000-0003-0259-0844 AD - Division of Cardiac Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. LA - eng PT - Journal Article PT - Review DEP - 20260929 PL - England TA - Eur Heart J Imaging Methods Pract JT - European heart journal. Imaging methods and practice JID - 9918697088006676 PMC - PMC13711681 OTO - NOTNLM OT - multimodality imaging OT - right ventricular function OT - transcatheter intervention OT - transoesophageal echocardiography OT - tricuspid regurgitation OT - tricuspid valve surgery COIS- Conflict of interest: The authors declare no conflict of interest related to this manuscript. EDAT- 2026/10/28 11:36 MHDA- 2026/10/28 11:37 PMCR- 2026/09/29 CRDT- 2026/10/28 05:43 PHST- 2026/07/10 00:00 [received] PHST- 2026/09/18 00:00 [accepted] PHST- 2026/10/28 11:37 [medline] PHST- 2026/10/28 11:36 [pubmed] PHST- 2026/10/28 05:43 [entrez] PHST- 2026/09/29 00:00 [pmc-release] AID - qyag168 [pii] AID - 10.1093/ehjimp/qyag168 [doi] PST - epublish SO - Eur Heart J Imaging Methods Pract. 2026 Sep 29;4(4):qyag168. doi: 10.1093/ehjimp/qyag168. eCollection 2026 Oct. PMID- 42948425 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20261028 LR - 20261029 IS - 2666-2736 (Electronic) IS - 2666-2736 (Linking) VI - 33 DP - 2026 Oct TI - Evaluating preoperative imaging in patients with chronic thromboembolic pulmonary hypertension: Is computed tomography pulmonary angiography a reliable alternative to pulmonary angiography? PG - 101960 LID - 10.1016/j.xjon.2026.101960 [doi] LID - 101960 AB - OBJECTIVES: Chronic thromboembolic pulmonary hypertension is a potentially curable form of pulmonary hypertension, with pulmonary endarterectomy serving as a key surgical treatment option. Accurate preoperative imaging is critical for determining surgical candidacy and optimizing operative outcomes. Although digital subtraction pulmonary angiography remains the gold standard, computed tomography pulmonary angiography has emerged as a noninvasive alternative. This study compares the concordance of computed tomography pulmonary angiography and digital subtraction pulmonary angiography with intraoperative specimen findings to determine their diagnostic accuracy. METHODS: We conducted a retrospective cohort study of patients who underwent pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension at a single Canadian center between 2014 and 2017. All patients underwent preoperative computed tomography pulmonary angiography and digital subtraction pulmonary angiography as part of their routine evaluation. Imaging findings were compared with operative findings using a territory-based anatomic assessment across major pulmonary artery segments. Functional and hemodynamic outcomes were also assessed before and after surgery. RESULTS: Seventeen patients (mean age 52.8 years [+/-3.7]; 53% female) were included. Computed tomography pulmonary angiography demonstrated greater agreement with operative findings in the right main pulmonary artery, left upper lobe, and lingula. Digital subtraction pulmonary angiography demonstrated greater agreement in the right upper lobe, whereas both modalities showed similar agreement in the left main pulmonary artery and left lower lobe. Patients experienced postoperative improvements in New York Heart Association functional class, pulmonary artery pressures, and cardiac index. Despite overall agreement between imaging and operative findings, discrepancies persisted across several vascular territories. CONCLUSIONS: Computed tomography pulmonary angiography demonstrated substantial agreement with operative findings in central and lobar pulmonary arterial territories, supporting its role as an important frontline imaging modality in the evaluation of chronic thromboembolic pulmonary hypertension. However, persistent discrepancies between imaging and operative assessment, particularly in more distal territories, support the continued use of a multimodal approach integrating computed tomography pulmonary angiography, digital subtraction pulmonary angiography, hemodynamic assessment, and multidisciplinary evaluation when determining operability and treatment strategy. CI - (c) 2026 The Author(s). FAU - Alamri, Rawan AU - Alamri R AD - Division of Cardiac Surgery, Jewish General Hospital, McGill University, Montreal, Quebec, Canada. FAU - Majeed, Hamnah AU - Majeed H AD - Division of Cardiac Surgery, University of Toronto, Toronto, Ontario, Canada. FAU - Ahmad, Fayeza AU - Ahmad F AD - Division of Cardiac Surgery, Jewish General Hospital, McGill University, Montreal, Quebec, Canada. FAU - Sarfaraz, Ziyab AU - Sarfaraz Z AD - Division of Cardiac Surgery, Houston Methodist, Houston, Tex. FAU - Hirsch, Andrew AU - Hirsch A AD - Division of Pulmonary Diseases, Department of Medicine, Jewish General Hospital, McGill University, Montreal, Quebec, Canada. AD - Center of Excellence in Thrombosis and Anticoagulation Care, Jewish General Hospital, McGill University, Montreal, Quebec, Canada. FAU - Morin, Jean-Francois AU - Morin JF AD - Division of Cardiac Surgery, Jewish General Hospital, McGill University, Montreal, Quebec, Canada. LA - eng PT - Journal Article DEP - 20260710 PL - Netherlands TA - JTCVS Open JT - JTCVS open JID - 101768541 PMC - PMC13711198 OTO - NOTNLM OT - chronic thromboembolic pulmonary hypertension OT - computed tomography pulmonary angiography OT - digital subtraction pulmonary angiography OT - pulmonary endarterectomy COIS- The authors reported no conflicts of interest. The Journal policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest. EDAT- 2026/10/28 11:36 MHDA- 2026/10/28 11:37 PMCR- 2026/07/10 CRDT- 2026/10/28 05:32 PHST- 2026/01/22 00:00 [received] PHST- 2026/06/12 00:00 [revised] PHST- 2026/06/26 00:00 [accepted] PHST- 2026/10/28 11:37 [medline] PHST- 2026/10/28 11:36 [pubmed] PHST- 2026/10/28 05:32 [entrez] PHST- 2026/07/10 00:00 [pmc-release] AID - S2666-2736(26)00383-9 [pii] AID - 101960 [pii] AID - 10.1016/j.xjon.2026.101960 [doi] PST - epublish SO - JTCVS Open. 2026 Jul 10;33:101960. doi: 10.1016/j.xjon.2026.101960. eCollection 2026 Oct. PMID- 42946504 OWN - NLM STAT- MEDLINE DCOM- 20261027 LR - 20261027 IS - 1532-6497 (Electronic) IS - 1067-991X (Linking) VI - 45 IP - 6 DP - 2026 Nov-Dec TI - Feasibility of Prehospital Central Venous Cannulation During Cardiac Arrest in an Ambulance. PG - 524-526 LID - S1067-991X(26)00250-6 [pii] LID - 10.1016/j.amj.2026.08.003 [doi] AB - Central venous cannulation is routinely performed in hospital settings but is rarely considered in the prehospital environment, where confined workspaces and concurrent resuscitative demands may limit procedural feasibility. We conducted a simulation-based feasibility study to evaluate whether central venous cannulation could be performed during ongoing cardiac arrest resuscitation within a standard ambulance. A multidisciplinary team consisting of emergency medical services clinicians and a physician participated in repeated simulations using a resuscitation manikin. A refractory shockable cardiac arrest scenario requiring ongoing advanced cardiac life support was simulated, while airway management, medication administration, cardiac monitoring, and chest compressions continued uninterrupted. Central venous cannulation was successfully completed in all simulations using standard sterile technique. The technical aspects of cannulation were largely unchanged from hospital-based practice, and left femoral venous access was identified as the most practical site. The primary challenges were limited workspace and unfavorable ergonomics related to the fixed stretcher height, which required the operator performing cannulation to work in an awkward position. Despite these constraints, all major advanced cardiac life support interventions were maintained throughout the procedure. These findings suggest that central venous cannulation during ongoing cardiac arrest resuscitation is technically feasible within a standard ambulance environment and support further investigation into advanced vascular access procedures in prehospital critical care. CI - Copyright (c) 2026 Air Medical Journal Associates. Published by Elsevier Inc. All rights reserved. FAU - Shekhar, Aditya C AU - Shekhar AC AD - Center for Resuscitation Science and Innovation, Icahn School of Medicine at Mount Sinai, New York City, NY. Electronic address: shekhar.aditya.c@gmail.com. FAU - Altman-Ezzard, Michael AU - Altman-Ezzard M AD - Simulation Teaching and Research Center, Icahn School of Medicine at Mount Sinai, New York City, NY. FAU - Ashley, Evan AU - Ashley E AD - Department of Emergency Medicine, Icahn School of Medicine at Mount Sinai, New York City, NY. FAU - Shedlovskiy, Daniel AU - Shedlovskiy D AD - Department of Emergency Medicine, Icahn School of Medicine at Mount Sinai, New York City, NY. FAU - Herring, W Campbell AU - Herring WC AD - Center for Resuscitation Science and Innovation, Icahn School of Medicine at Mount Sinai, New York City, NY. FAU - Lederer, Thomas AU - Lederer T AD - Center for Resuscitation Science and Innovation, Icahn School of Medicine at Mount Sinai, New York City, NY. FAU - Ammar, Lama A AU - Ammar LA AD - Center for Resuscitation Science and Innovation, Icahn School of Medicine at Mount Sinai, New York City, NY. FAU - Nazari, Sean AU - Nazari S AD - Department of Emergency Medicine, Icahn School of Medicine at Mount Sinai, New York City, NY. FAU - Delaney, Jess AU - Delaney J AD - Department of Emergency Medicine, Icahn School of Medicine at Mount Sinai, New York City, NY. FAU - Abella, Benjamin S AU - Abella BS AD - Center for Resuscitation Science and Innovation, Icahn School of Medicine at Mount Sinai, New York City, NY; Department of Emergency Medicine, Icahn School of Medicine at Mount Sinai, New York City, NY. FAU - Chason, Kevin AU - Chason K AD - Department of Emergency Medicine, Icahn School of Medicine at Mount Sinai, New York City, NY. FAU - Kutzin, Jared AU - Kutzin J AD - Simulation Teaching and Research Center, Icahn School of Medicine at Mount Sinai, New York City, NY. LA - eng PT - Journal Article DEP - 20260911 PL - United States TA - Air Med J JT - Air medical journal JID - 9312325 SB - IM MH - Humans MH - Feasibility Studies MH - *Catheterization, Central Venous/methods MH - *Emergency Medical Services/methods MH - Manikins MH - *Out-of-Hospital Cardiac Arrest/therapy MH - Cardiopulmonary Resuscitation/methods MH - *Heart Arrest/therapy MH - Advanced Cardiac Life Support MH - *Ambulances COIS- Declaration of competing interest The authors have no relevant disclosures. There was no grant funding or financial support for this manuscript. EDAT- 2026/10/27 23:28 MHDA- 2026/10/27 23:29 CRDT- 2026/10/27 21:53 PHST- 2026/02/02 00:00 [received] PHST- 2026/07/17 00:00 [revised] PHST- 2026/08/06 00:00 [accepted] PHST- 2026/10/27 23:29 [medline] PHST- 2026/10/27 23:28 [pubmed] PHST- 2026/10/27 21:53 [entrez] AID - S1067-991X(26)00250-6 [pii] AID - 10.1016/j.amj.2026.08.003 [doi] PST - ppublish SO - Air Med J. 2026 Nov-Dec;45(6):524-526. doi: 10.1016/j.amj.2026.08.003. Epub 2026 Sep 11. PMID- 42946209 OWN - NLM STAT- Publisher LR - 20261027 IS - 1898-4002 (Electronic) IS - 1896-1126 (Linking) DP - 2026 Oct 27 TI - Shock Teams May Improve Outcomes of Patients with Cardiogenic Shock (STOP-CS): a systematic review and meta-analysis. LID - S1896-1126(26)00047-7 [pii] LID - 10.1016/j.advms.2026.10.007 [doi] AB - PURPOSE: A multidisciplinary team-based approach became one of the main paradigms in health care. Current evidence regarding the efficacy of Shock Teams and related advanced shock care models in cardiogenic shock (CS) comes from observational studies, with limited synthetic data available. We aimed to assess the association between advanced shock care models and short- and mid-term outcomes of CS patients. MATERIALS AND METHODS: This systematic review and meta-analysis (PROSPERO registration: CRD42024581904) were conducted according to the PRISMA 2020 Statement. We included observational studies of at least 25 adult CS patients managed with or without a Shock Team or related advanced shock care models. We searched Embase, Medline Ultimate, PubMed, Scopus, and Web of Science from 01.01.2016 to 13.08.2024. Risk of bias was assessed with the Newcastle-Ottawa Scale. Meta-analyses were performed with a random-effects model. The primary outcome was in-hospital mortality. RESULTS: Nine studies with a total of 658,708 patients met the inclusion criteria. For medium-term mortality, follow-up ranged from 60 to 365 days. Treatment of patients within the included models was associated with lower in-hospital mortality (OR: 0.81, 95%CI: [0.74, 0.90], p<0.0001, I(2)=58%), lower intensive care unit mortality (OR: 0.58, 95%CI: [0.43, 0.78], p=0.0004, I(2)=45%), and lower medium-term mortality (HR: 0.59, 95%CI: [0.48, 0.72], p<0.00001, I(2)=0%). These associations remained significant in sensitivity analyses, although clinical and methodological heterogeneity persisted. CONCLUSIONS: Advanced shock care models may be associated with improved short- and mid-term outcomes in CS patients including lower in-hospital and medium-term mortality. Prospective studies are needed to confirm these results. CI - Copyright (c) 2026. Published by Elsevier B.V. FAU - Procyk, Grzegorz AU - Procyk G AD - First Department of Cardiology, Medical University of Warsaw, Warsaw, Poland; Doctoral School, Medical University of Warsaw, Warsaw, Poland. Electronic address: grzegorz.procyk@wum.edu.pl. FAU - Bertaina, Maurizio AU - Bertaina M AD - Division of Cardiology, San Giovanni Bosco Hospital, ASL Citta di Torino, Turin, Italy. FAU - Gasecka, Aleksandra AU - Gasecka A AD - First Department of Cardiology, Medical University of Warsaw, Warsaw, Poland. FAU - Pietrasik, Arkadiusz AU - Pietrasik A AD - First Department of Cardiology, Medical University of Warsaw, Warsaw, Poland. FAU - Savi, Lucia AU - Savi L AD - Division of Cardiology, San Giovanni Bosco Hospital, ASL Citta di Torino, Turin, Italy. FAU - Boccuzzi, Giacomo Giovanni AU - Boccuzzi GG AD - Division of Cardiology, San Giovanni Bosco Hospital, ASL Citta di Torino, Turin, Italy. FAU - Chieffo, Alaide AU - Chieffo A AD - Division of Metabolic and Cardiovascular Sciences, San Raffaele Scientific Institute, Milan, Italy. FAU - Iannaccone, Mario AU - Iannaccone M AD - Division of Cardiology, San Giovanni Bosco Hospital, ASL Citta di Torino, Turin, Italy. LA - eng PT - Journal Article PT - Review DEP - 20261027 PL - Netherlands TA - Adv Med Sci JT - Advances in medical sciences JID - 101276222 SB - IM OTO - NOTNLM OT - cardiogenic shock OT - hospital mortality OT - meta-analysis OT - patient care team EDAT- 2026/10/27 23:28 MHDA- 2026/10/27 23:28 CRDT- 2026/10/27 20:36 PHST- 2026/01/04 00:00 [received] PHST- 2026/05/25 00:00 [revised] PHST- 2026/10/22 00:00 [accepted] PHST- 2026/10/27 23:28 [medline] PHST- 2026/10/27 23:28 [pubmed] PHST- 2026/10/27 20:36 [entrez] AID - S1896-1126(26)00047-7 [pii] AID - 10.1016/j.advms.2026.10.007 [doi] PST - aheadofprint SO - Adv Med Sci. 2026 Oct 27:S1896-1126(26)00047-7. doi: 10.1016/j.advms.2026.10.007. PMID- 42937287 OWN - NLM STAT- Publisher LR - 20261027 IS - 2564-6850 (Print) IS - 2564-6850 (Linking) DP - 2026 Oct 27 TI - Quality of life in elderly patients undergoing coronary artery bypass graft surgery: The role of inflammation, nutrition and functional status. LID - 10.47717/turkjsurg.2026.2025-11-18 [doi] AB - OBJECTIVE: This prospective descriptive correlational study aimed to examine inflammation, changes in functional status, nutritional status, and quality of life in older adults undergoing coronary artery bypass graft (CABG) surgery. MATERIAL AND METHODS: The study sample consisted of 120 conscious and voluntary patients aged 65 years and older who underwent on-pump CABG surgery between February 2017 and January 2018 at the Department of Cardiovascular Surgery of a Ege University Medical Faculty Hospital. Data were collected at hospital admission and at the eighth postoperative week through face-to-face interviews. Data collection included sociodemographic and clinical characteristics, inflammatory markers, functional status, nutritional status, and quality of life. Data were analyzed using SPSS for Windows, version 23.0. RESULTS: At the eighth postoperative week, significant declines were observed in functional status, nutritional status, and physical quality of life compared with the preoperative period (p<0.05). Significant differences were also found in mental status scores, inflammatory markers, five times sit-to-stand test results, timed up and go test scores, handgrip strength, Katz index of activities of daily living scores, Lawton-Brody instrumental activities of daily living scores, anthropometric measurements, and mini nutritional assessment scores (p<0.05). Age was not significantly associated with functional status, nutritional status, or quality of life. Exploratory, unadjusted correlation analyses identified several low associations among inflammatory markers, functional status, nutritional status, and the physical and mental components of quality of life; none met the relevant Bonferroni-adjusted thresholds. CONCLUSION: During the first eight weeks after CABG, older individuals in this cohort showed multidimensional postoperative changes, particularly in functional capacity, nutritional status, inflammatory profile, and quality of life. Because the study did not include a comparator group, these temporal changes should not be interpreted as effects attributable specifically to CABG. The findings indicate a need for multidisciplinary assessment and support for functional recovery, nutritional status, and overall well-being. FAU - Yoltay, Hatice Eda AU - Yoltay HE AUID- ORCID: 0000-0002-6493-3374 AD - Department of Surgical Diseases Nursing, Ege University Faculty of Nursing, Izmir, Turkiye. FAU - Demir Korkmaz, Fatma AU - Demir Korkmaz F AUID- ORCID: 0000-0003-3810-297X AD - Department of Surgical Diseases Nursing, Ege University Faculty of Nursing, Izmir, Turkiye. FAU - Engin, Cagatay AU - Engin C AUID- ORCID: 0000-0003-4025-7874 AD - Department of Cardiovascular Surgery, Ege University Hospital Health Practice and Research Centre, Izmir, Turkiye. LA - eng PT - Journal Article DEP - 20261027 PL - Turkey TA - Turk J Surg JT - Turkish journal of surgery JID - 101704837 OTO - NOTNLM OT - Cardiac surgery OT - functional status OT - inflammation OT - nutrition OT - older adults OT - quality of life COIS- No conflict of interest was declared by the authors. EDAT- 2026/10/27 11:31 MHDA- 2026/10/27 11:31 CRDT- 2026/10/27 08:35 PHST- 2026/10/27 11:31 [medline] PHST- 2026/10/27 11:31 [pubmed] PHST- 2026/10/27 08:35 [entrez] AID - 10.47717/turkjsurg.2026.2025-11-18 [doi] PST - aheadofprint SO - Turk J Surg. 2026 Oct 27. doi: 10.47717/turkjsurg.2026.2025-11-18. PMID- 42934615 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20261027 LR - 20261029 IS - 1472-6955 (Print) IS - 1472-6955 (Electronic) IS - 1472-6955 (Linking) VI - 25 IP - 1 DP - 2026 Jul 29 TI - Design and protocol of a randomized assessor-blinded controlled trial evaluating an educational escape room for individual and team cardiopulmonary resuscitation skills among nursing students. LID - 10.1186/s12912-026-05151-4 [doi] LID - 1021 AB - BACKGROUND: High-quality cardiopulmonary resuscitation (CPR) depends not only on technical competence but also on effective communication, role clarity, leadership, and coordinated team performance under pressure. However, conventional CPR instruction may not adequately reproduce the collaborative and time-sensitive demands of real resuscitation. Educational escape rooms (EERs), as simulation-based gamified learning strategies, may provide a more immersive and learner-centered approach to strengthening both cognitive and teamwork-related aspects of CPR training. This study protocol was developed to evaluate the effect of a team-based CPR educational escape room (CPR-EER) integrated into advanced life support (ALS) training for undergraduate nursing students. METHODS: This study was designed as a two-arm, parallel-group, assessor-blinded randomized controlled trial with a 1:1 allocation ratio. Participants were seventh-semester undergraduate nursing students at Shahid Sadoughi University of Medical Sciences, Yazd, Iran. All participants first received a standardized 8-hour CPR refresher workshop to establish a common educational baseline. The intervention group then participated in a structured CPR-EER delivered in fixed six-member teams in a simulated in-hospital cardiac arrest environment, whereas the control group continued with the routine curriculum during the primary comparison phase and received the intervention after post-test assessment. The primary outcome was team coordination during CPR, assessed using a Team Objective Structured Clinical Examination (TOSCE). Secondary outcomes included role-specific performance, CPR knowledge, and learner satisfaction. Outcomes were assessed at baseline and one month after the intervention. Data analysis was prespecified using a per-protocol framework and distribution-appropriate statistical tests. DISCUSSION: This protocol provides a methodologically explicit and pedagogically grounded model for evaluating a gamified, team-based CPR-EER training strategy in undergraduate nursing education. By aligning intervention design, educational objectives, and outcome assessment, it may contribute to the development of more immersive, competency-oriented, and reproducible approaches to resuscitation training. TRIAL REGISTRATION: Iranian Registry of Clinical Trials (IRCT), registered on 16 October 2024, IRCT20240815062770N1. Available at: https://irct.behdasht.gov.ir/ . CI - (c) 2026. The Author(s). FAU - Bakhshi, Fatemeh AU - Bakhshi F AUID- ORCID: 0000-0002-9238-0340 AD - Research Center for Nursing and Midwifery Care, Comprehensive Research Institute for Maternal and Child Health, School of Nursing and Midwifery, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. FAU - Ashkezari, Amir Dehghani AU - Ashkezari AD AUID- ORCID: 0009-0007-8821-5469 AD - Department of Nursing, School of Nursing and Midwifery, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. FAU - Heydari, Sara AU - Heydari S AUID- ORCID: 0000-0003-0033-7028 AD - Department of Medical Education, Medical Education and Development Center, Shahid Sadoughi University of Medical Sciences, Bouali Ave., Safaeyeh, Yazd, 8916877443, Iran. S.heydari.287@gmail.com. LA - eng GR - 18765/Shahid Sadoughi University of Medical Sciences/ PT - Journal Article DEP - 20260729 PL - England TA - BMC Nurs JT - BMC nursing JID - 101088683 PMC - PMC13711775 OTO - NOTNLM OT - Advanced life support OT - Cardiopulmonary resuscitation OT - Educational escape room OT - Gamified learning OT - Nursing students OT - Team coordination COIS- Declarations. Ethics approval and consent to participate: The study protocol is designed and conducted in compliance with the Declaration of Helsinki. Written informed consent is obtained from all participants after they receive a detailed explanation of the study objectives. Participation is voluntary, and students retain the right to withdraw at any stage. To ensure ethical safety in an educational setting, students are assured that their involvement, performance, and scores in the study activities, including the workshops, CPR-ERG, and TOSCE assessments, will have no bearing on their official academic evaluations or course grades. Ethical approval for this study was granted by the Research Ethics Committee of Shahid Sadoughi University of Medical Sciences (Ethics Code: IR.SSU.RSI.REC.1403.068). Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2026/10/27 05:29 MHDA- 2026/10/27 05:30 PMCR- 2026/07/29 CRDT- 2026/10/27 00:39 PHST- 2024/12/05 00:00 [received] PHST- 2026/07/27 00:00 [accepted] PHST- 2026/10/27 05:30 [medline] PHST- 2026/10/27 05:29 [pubmed] PHST- 2026/10/27 00:39 [entrez] PHST- 2026/07/29 00:00 [pmc-release] AID - 10.1186/s12912-026-05151-4 [pii] AID - 5151 [pii] AID - 10.1186/s12912-026-05151-4 [doi] PST - epublish SO - BMC Nurs. 2026 Jul 29;25(1):1021. doi: 10.1186/s12912-026-05151-4. PMID- 42934199 OWN - NLM STAT- Publisher LR - 20261027 IS - 2048-8734 (Electronic) IS - 2048-8726 (Linking) DP - 2026 Oct 27 TI - Urgent, Emergency, and Salvage Transcatheter Aortic Valve Implantation for Acute Decompensated Severe Aortic Stenosis: A Prospective Cohort Study. LID - zuag130 [pii] LID - 10.1093/ehjacc/zuag130 [doi] AB - BACKGROUND: Acute decompensated severe aortic stenosis may preclude waiting for elective treatment, and evidence for non-elective transcatheter aortic valve implantation (TAVI) is limited. We assessed 12-month mortality, 30-day safety, and recovery after urgent, emergency, or salvage TAVI. METHODS: We prospectively enrolled patients undergoing urgent, emergency, or salvage TAVI at one centre in 2022-2025. The primary endpoint was 12-month all-cause mortality; secondary endpoints included device success, 30-day safety, and functional and echocardiographic recovery. RESULTS: Among 53 patients, 36 underwent urgent, 14 emergency, and 3 salvage TAVI. Device success was 52/53 (98.1%). Thirty-day mortality was 1/36, 0/14, and 0/3; 12-month mortality was 2/36, 1/14, and 0/3 (3/53). Kaplan-Meier 12-month survival was 94.3% (95% confidence interval 83.5-98.1%). New atrioventricular block was detected in 2/53 on postoperative day 2; by 30 days, haemofiltration or renal replacement therapy occurred in 1/53 and permanent pacemaker implantation in 0/53. At 12 months, cardiovascular mortality was 2/53, heart-failure readmission 4/53, stroke 1/53, a separate Valve Academic Research Consortium-3 type 2 bleeding event 1/53, and permanent pacemaker implantation 0/53. Paired analyses showed improved New York Heart Association class, Kansas City Cardiomyopathy Questionnaire-12, left ventricular ejection fraction, and transvalvular gradients at 30 days and 12 months (all P<0.001). CONCLUSIONS: Selected patients had high device success and low early event rates after non-elective TAVI; paired data showed sustained functional and haemodynamic improvement. These findings support timely Heart Team assessment and consideration of non-elective TAVI, when appropriate, at experienced centres; comparative benefit over alternative strategies warrants prospective study. CI - (c) The Author(s) 2026. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com. FAU - Zhao, Menglin AU - Zhao M AD - Department of Emergency Medicine, Qilu Hospital of Shandong University, Jinan, China. AD - Shandong Provincial Clinical Research Center for Emergency and Critical Care Medicine, Institute of Emergency and Critical Care Medicine of Shandong University, Chest Pain Center, Qilu Hospital of Shandong University, Jinan, China. AD - Key Laboratory of Emergency and Critical Care Medicine of Shandong Province, Key Laboratory of Cardiopulmonary-Cerebral Resuscitation Research of Shandong Province, Shandong Provincial Engineering Laboratory for Emergency and Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, China. AD - Shandong Key Laboratory: Magnetic Field-free Medicine & Functional Imaging (MF), Qilu Hospital of Shandong University, Jinan, China. AD - NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug, Qilu Hospital of Shandong University, Jinan, China. FAU - Wang, Jiahao AU - Wang J AD - Department of Emergency Medicine, Qilu Hospital of Shandong University, Jinan, China. AD - Shandong Provincial Clinical Research Center for Emergency and Critical Care Medicine, Institute of Emergency and Critical Care Medicine of Shandong University, Chest Pain Center, Qilu Hospital of Shandong University, Jinan, China. AD - Key Laboratory of Emergency and Critical Care Medicine of Shandong Province, Key Laboratory of Cardiopulmonary-Cerebral Resuscitation Research of Shandong Province, Shandong Provincial Engineering Laboratory for Emergency and Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, China. AD - Shandong Key Laboratory: Magnetic Field-free Medicine & Functional Imaging (MF), Qilu Hospital of Shandong University, Jinan, China. AD - NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug, Qilu Hospital of Shandong University, Jinan, China. FAU - Gao, Luyao AU - Gao L AD - Department of Emergency Medicine, Qilu Hospital of Shandong University, Jinan, China. AD - Shandong Provincial Clinical Research Center for Emergency and Critical Care Medicine, Institute of Emergency and Critical Care Medicine of Shandong University, Chest Pain Center, Qilu Hospital of Shandong University, Jinan, China. AD - Key Laboratory of Emergency and Critical Care Medicine of Shandong Province, Key Laboratory of Cardiopulmonary-Cerebral Resuscitation Research of Shandong Province, Shandong Provincial Engineering Laboratory for Emergency and Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, China. AD - Shandong Key Laboratory: Magnetic Field-free Medicine & Functional Imaging (MF), Qilu Hospital of Shandong University, Jinan, China. AD - NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug, Qilu Hospital of Shandong University, Jinan, China. FAU - Wu, Tianshu AU - Wu T AUID- ORCID: 0009-0008-4889-3510 AD - Department of Emergency Medicine, Qilu Hospital of Shandong University, Jinan, China. AD - Shandong Provincial Clinical Research Center for Emergency and Critical Care Medicine, Institute of Emergency and Critical Care Medicine of Shandong University, Chest Pain Center, Qilu Hospital of Shandong University, Jinan, China. AD - Key Laboratory of Emergency and Critical Care Medicine of Shandong Province, Key Laboratory of Cardiopulmonary-Cerebral Resuscitation Research of Shandong Province, Shandong Provincial Engineering Laboratory for Emergency and Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, China. AD - Shandong Key Laboratory: Magnetic Field-free Medicine & Functional Imaging (MF), Qilu Hospital of Shandong University, Jinan, China. AD - NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug, Qilu Hospital of Shandong University, Jinan, China. FAU - Wang, Zerui AU - Wang Z AD - Department of Emergency Medicine, Qilu Hospital of Shandong University, Jinan, China. AD - Shandong Provincial Clinical Research Center for Emergency and Critical Care Medicine, Institute of Emergency and Critical Care Medicine of Shandong University, Chest Pain Center, Qilu Hospital of Shandong University, Jinan, China. AD - Key Laboratory of Emergency and Critical Care Medicine of Shandong Province, Key Laboratory of Cardiopulmonary-Cerebral Resuscitation Research of Shandong Province, Shandong Provincial Engineering Laboratory for Emergency and Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, China. AD - Shandong Key Laboratory: Magnetic Field-free Medicine & Functional Imaging (MF), Qilu Hospital of Shandong University, Jinan, China. AD - NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug, Qilu Hospital of Shandong University, Jinan, China. FAU - Luo, Shuang AU - Luo S AD - Department of Emergency Medicine, Qilu Hospital of Shandong University, Jinan, China. AD - Shandong Provincial Clinical Research Center for Emergency and Critical Care Medicine, Institute of Emergency and Critical Care Medicine of Shandong University, Chest Pain Center, Qilu Hospital of Shandong University, Jinan, China. AD - Key Laboratory of Emergency and Critical Care Medicine of Shandong Province, Key Laboratory of Cardiopulmonary-Cerebral Resuscitation Research of Shandong Province, Shandong Provincial Engineering Laboratory for Emergency and Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, China. AD - Shandong Key Laboratory: Magnetic Field-free Medicine & Functional Imaging (MF), Qilu Hospital of Shandong University, Jinan, China. AD - NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug, Qilu Hospital of Shandong University, Jinan, China. FAU - Li, Yong AU - Li Y AD - Department of Emergency Medicine, Qilu Hospital of Shandong University, Jinan, China. AD - Shandong Provincial Clinical Research Center for Emergency and Critical Care Medicine, Institute of Emergency and Critical Care Medicine of Shandong University, Chest Pain Center, Qilu Hospital of Shandong University, Jinan, China. AD - Key Laboratory of Emergency and Critical Care Medicine of Shandong Province, Key Laboratory of Cardiopulmonary-Cerebral Resuscitation Research of Shandong Province, Shandong Provincial Engineering Laboratory for Emergency and Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, China. AD - Shandong Key Laboratory: Magnetic Field-free Medicine & Functional Imaging (MF), Qilu Hospital of Shandong University, Jinan, China. AD - NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug, Qilu Hospital of Shandong University, Jinan, China. FAU - Liu, Rugang AU - Liu R AD - Department of Emergency Medicine, Qilu Hospital of Shandong University, Jinan, China. AD - Shandong Provincial Clinical Research Center for Emergency and Critical Care Medicine, Institute of Emergency and Critical Care Medicine of Shandong University, Chest Pain Center, Qilu Hospital of Shandong University, Jinan, China. AD - Key Laboratory of Emergency and Critical Care Medicine of Shandong Province, Key Laboratory of Cardiopulmonary-Cerebral Resuscitation Research of Shandong Province, Shandong Provincial Engineering Laboratory for Emergency and Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, China. AD - Shandong Key Laboratory: Magnetic Field-free Medicine & Functional Imaging (MF), Qilu Hospital of Shandong University, Jinan, China. AD - NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug, Qilu Hospital of Shandong University, Jinan, China. FAU - Tang, Zhenyu AU - Tang Z AD - Department of Emergency Medicine, Qilu Hospital of Shandong University, Jinan, China. AD - Shandong Provincial Clinical Research Center for Emergency and Critical Care Medicine, Institute of Emergency and Critical Care Medicine of Shandong University, Chest Pain Center, Qilu Hospital of Shandong University, Jinan, China. AD - Key Laboratory of Emergency and Critical Care Medicine of Shandong Province, Key Laboratory of Cardiopulmonary-Cerebral Resuscitation Research of Shandong Province, Shandong Provincial Engineering Laboratory for Emergency and Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, China. AD - Shandong Key Laboratory: Magnetic Field-free Medicine & Functional Imaging (MF), Qilu Hospital of Shandong University, Jinan, China. AD - NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug, Qilu Hospital of Shandong University, Jinan, China. FAU - Feng, Meng AU - Feng M AD - Department of Emergency Medicine, Qilu Hospital of Shandong University, Jinan, China. AD - Shandong Provincial Clinical Research Center for Emergency and Critical Care Medicine, Institute of Emergency and Critical Care Medicine of Shandong University, Chest Pain Center, Qilu Hospital of Shandong University, Jinan, China. AD - Key Laboratory of Emergency and Critical Care Medicine of Shandong Province, Key Laboratory of Cardiopulmonary-Cerebral Resuscitation Research of Shandong Province, Shandong Provincial Engineering Laboratory for Emergency and Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, China. AD - Shandong Key Laboratory: Magnetic Field-free Medicine & Functional Imaging (MF), Qilu Hospital of Shandong University, Jinan, China. AD - NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug, Qilu Hospital of Shandong University, Jinan, China. FAU - Hua, Mingqiang AU - Hua M AD - Department of Emergency Medicine, Qilu Hospital of Shandong University, Jinan, China. AD - Shandong Provincial Clinical Research Center for Emergency and Critical Care Medicine, Institute of Emergency and Critical Care Medicine of Shandong University, Chest Pain Center, Qilu Hospital of Shandong University, Jinan, China. AD - Key Laboratory of Emergency and Critical Care Medicine of Shandong Province, Key Laboratory of Cardiopulmonary-Cerebral Resuscitation Research of Shandong Province, Shandong Provincial Engineering Laboratory for Emergency and Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, China. AD - Shandong Key Laboratory: Magnetic Field-free Medicine & Functional Imaging (MF), Qilu Hospital of Shandong University, Jinan, China. AD - NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug, Qilu Hospital of Shandong University, Jinan, China. FAU - Yuan, Jiaquan AU - Yuan J AD - Department of Emergency Medicine, Qilu Hospital of Shandong University, Jinan, China. AD - Shandong Provincial Clinical Research Center for Emergency and Critical Care Medicine, Institute of Emergency and Critical Care Medicine of Shandong University, Chest Pain Center, Qilu Hospital of Shandong University, Jinan, China. AD - Key Laboratory of Emergency and Critical Care Medicine of Shandong Province, Key Laboratory of Cardiopulmonary-Cerebral Resuscitation Research of Shandong Province, Shandong Provincial Engineering Laboratory for Emergency and Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, China. AD - Shandong Key Laboratory: Magnetic Field-free Medicine & Functional Imaging (MF), Qilu Hospital of Shandong University, Jinan, China. AD - NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug, Qilu Hospital of Shandong University, Jinan, China. FAU - Zhang, Yiwen AU - Zhang Y AD - Department of Emergency Medicine, Qilu Hospital of Shandong University, Jinan, China. AD - Shandong Provincial Clinical Research Center for Emergency and Critical Care Medicine, Institute of Emergency and Critical Care Medicine of Shandong University, Chest Pain Center, Qilu Hospital of Shandong University, Jinan, China. AD - Key Laboratory of Emergency and Critical Care Medicine of Shandong Province, Key Laboratory of Cardiopulmonary-Cerebral Resuscitation Research of Shandong Province, Shandong Provincial Engineering Laboratory for Emergency and Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, China. AD - Shandong Key Laboratory: Magnetic Field-free Medicine & Functional Imaging (MF), Qilu Hospital of Shandong University, Jinan, China. AD - NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug, Qilu Hospital of Shandong University, Jinan, China. FAU - Bian, Yuan AU - Bian Y AD - Department of Emergency Medicine, Qilu Hospital of Shandong University, Jinan, China. AD - Shandong Provincial Clinical Research Center for Emergency and Critical Care Medicine, Institute of Emergency and Critical Care Medicine of Shandong University, Chest Pain Center, Qilu Hospital of Shandong University, Jinan, China. AD - Key Laboratory of Emergency and Critical Care Medicine of Shandong Province, Key Laboratory of Cardiopulmonary-Cerebral Resuscitation Research of Shandong Province, Shandong Provincial Engineering Laboratory for Emergency and Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, China. AD - Shandong Key Laboratory: Magnetic Field-free Medicine & Functional Imaging (MF), Qilu Hospital of Shandong University, Jinan, China. AD - NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug, Qilu Hospital of Shandong University, Jinan, China. FAU - Chen, Yuguo AU - Chen Y AUID- ORCID: 0000-0001-9501-2546 AD - Department of Emergency Medicine, Qilu Hospital of Shandong University, Jinan, China. AD - Shandong Provincial Clinical Research Center for Emergency and Critical Care Medicine, Institute of Emergency and Critical Care Medicine of Shandong University, Chest Pain Center, Qilu Hospital of Shandong University, Jinan, China. AD - Key Laboratory of Emergency and Critical Care Medicine of Shandong Province, Key Laboratory of Cardiopulmonary-Cerebral Resuscitation Research of Shandong Province, Shandong Provincial Engineering Laboratory for Emergency and Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, China. AD - Shandong Key Laboratory: Magnetic Field-free Medicine & Functional Imaging (MF), Qilu Hospital of Shandong University, Jinan, China. AD - NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug, Qilu Hospital of Shandong University, Jinan, China. FAU - Li, Chuanbao AU - Li C AUID- ORCID: 0000-0002-1224-0509 AD - Department of Emergency Medicine, Qilu Hospital of Shandong University, Jinan, China. AD - Shandong Provincial Clinical Research Center for Emergency and Critical Care Medicine, Institute of Emergency and Critical Care Medicine of Shandong University, Chest Pain Center, Qilu Hospital of Shandong University, Jinan, China. AD - Key Laboratory of Emergency and Critical Care Medicine of Shandong Province, Key Laboratory of Cardiopulmonary-Cerebral Resuscitation Research of Shandong Province, Shandong Provincial Engineering Laboratory for Emergency and Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, China. AD - Shandong Key Laboratory: Magnetic Field-free Medicine & Functional Imaging (MF), Qilu Hospital of Shandong University, Jinan, China. AD - NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug, Qilu Hospital of Shandong University, Jinan, China. LA - eng PT - Journal Article DEP - 20261027 PL - England TA - Eur Heart J Acute Cardiovasc Care JT - European heart journal. Acute cardiovascular care JID - 101591369 SB - IM OTO - NOTNLM OT - acute decompensated severe aortic stenosis OT - cardiogenic shock OT - emergency procedure OT - salvage procedure OT - transcatheter aortic valve implantation OT - urgent procedure EDAT- 2026/10/27 05:29 MHDA- 2026/10/27 05:29 CRDT- 2026/10/27 00:04 PHST- 2026/07/11 00:00 [received] PHST- 2026/10/05 00:00 [revised] PHST- 2026/10/27 05:29 [medline] PHST- 2026/10/27 05:29 [pubmed] PHST- 2026/10/27 00:04 [entrez] AID - 9002532 [pii] AID - 10.1093/ehjacc/zuag130 [doi] PST - aheadofprint SO - Eur Heart J Acute Cardiovasc Care. 2026 Oct 27:zuag130. doi: 10.1093/ehjacc/zuag130. PMID- 42933995 OWN - NLM STAT- MEDLINE DCOM- 20261026 LR - 20261028 IS - 1468-2834 (Electronic) IS - 0002-0729 (Linking) VI - 55 IP - 10 DP - 2026 Aug 3 TI - Systematic review and meta-analysis of impact of 'Vascular Geriatrics' interventions on short-term outcomes for vascular surgery inpatients. LID - afag311 [pii] LID - 10.1093/ageing/afag311 [doi] AB - INTRODUCTION: Vascular surgeons are treating more older, frail and multimorbid patients. Integrated care models including both surgeons and geriatricians have improved peri-operative outcomes in orthopaedics. This meta-analysis investigated the impact of 'Vascular Geriatrics' services on short-term outcomes for vascular surgery inpatients. METHODS: PubMed, Scopus, Embase and recent conference abstracts were searched for studies of all methodologies comparing outcomes before and after the introduction of 'Vascular Geriatrics' service. Risk of bias was assessed using Methodological Index for Non-Randomised Studies criteria for non-randomised studies and Risk of Bias Tool (Version Two) tool for randomised. Certainty of evidence was assessed using Grading of Recommendations, Assessment, Development, and Evaluations analysis. Meta-analyses compared the relative risks of inpatient mortality, complications, discharge to home and 30-day readmission using a random-effects model. Length of stay (LOS) in days was compared using mean difference. RESULTS: Eight studies with 2441 patients were included. Models included outpatient pre-operative comprehensive geriatric assessment, inpatient geriatric liaison service and geriatrician-surgeon co-management. 'Vascular Geriatrics' was associated with a lower risk of inpatient mortality (RR 0.65, 95% CI 0.46-0.9, P = .010), cardiac complications (RR 0.35, 95% CI 0.19-0.62, P < .001) and infective complications (RR 0.48, 95% CI 0.38-0.63, P < .001). Delirium risk was reduced but not significantly (RR 0.58, 95% CI 0.25-1.34, P = .20). There was no association in LOS (P = .37), discharge to home (P = .55) or 30-day readmission risk (P = .64). CONCLUSIONS: Though study quality was poor, formalised geriatric involvement was associated with a decreased risk of adverse peri-operative outcomes in vascular patients compared to traditional care models. Further studies are needed to investigate the most effective design of geriatrician-surgeon partnership. CI - (c) The Author(s) 2026. Published by Oxford University Press on behalf of the British Geriatrics Society. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com. FAU - Power Foley, Megan AU - Power Foley M AUID- ORCID: 0000-0002-7731-3182 AD - Vascular Surgery, University Hospital Galway, Galway, Ireland. AD - Royal College of Surgeons in Ireland, Dublin, Leinster, Ireland. FAU - Young, Conor AU - Young C AD - Mercer's Institute for Successful Ageing, St James Hospital, Dublin 8, Ireland. FAU - Canavan, Michelle AU - Canavan M AD - Department of Geriatric Medicine, Galway University Hospitals, Galway, County Galway, Ireland. FAU - Walsh, Stewart R AU - Walsh SR AD - Lambe Institute for Translational Research, University of Galway, Galway, County Galway, Ireland. AD - National Surgical Research Support Centre, Royal College of Surgeons in Ireland, Dublin, Leinster, Ireland. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review PL - England TA - Age Ageing JT - Age and ageing JID - 0375655 SB - IM MH - Humans MH - *Vascular Surgical Procedures/adverse effects/mortality MH - Treatment Outcome MH - Aged MH - Risk Factors MH - Length of Stay MH - Time Factors MH - Patient Readmission MH - Geriatric Assessment MH - *Geriatrics MH - *Inpatients MH - Postoperative Complications/mortality/etiology MH - Age Factors MH - Hospital Mortality MH - Aged, 80 and over MH - *Delivery of Health Care, Integrated/organization & administration MH - *Health Services for the Aged MH - Patient Care Team/organization & administration MH - Female MH - Patient Discharge OTO - NOTNLM OT - older people OT - perioperative care OT - surgical geriatrics OT - systematic review OT - vascular surgery EDAT- 2026/10/26 23:27 MHDA- 2026/10/26 23:28 CRDT- 2026/10/26 22:33 PHST- 2026/03/12 00:00 [received] PHST- 2026/09/14 00:00 [revised] PHST- 2026/09/21 00:00 [accepted] PHST- 2026/10/26 23:28 [medline] PHST- 2026/10/26 23:27 [pubmed] PHST- 2026/10/26 22:33 [entrez] AID - 9002253 [pii] AID - 10.1093/ageing/afag311 [doi] PST - ppublish SO - Age Ageing. 2026 Aug 3;55(10):afag311. doi: 10.1093/ageing/afag311. PMID- 42933676 OWN - NLM STAT- Publisher LR - 20261029 IS - 1873-2615 (Electronic) IS - 1050-1738 (Linking) DP - 2026 Oct 26 TI - The myocardial footprint and the coronary culprit: What cardiac magnetic resonance can and cannot establish in MINOCA. LID - S1050-1738(26)00127-1 [pii] LID - 10.1016/j.tcm.2026.10.006 [doi] AB - Myocardial infarction with nonobstructive coronary arteries (MINOCA) is a working diagnosis in which cardiac magnetic resonance (CMR) defines the myocardial phenotype, separates ischemic injury from nonischemic mimics, and quantifies the burden of injury, yet usually cannot establish the coronary mechanism that produced it. Paired studies of CMR and intracoronary imaging show that the myocardial footprint and the coronary culprit often fail to correspond, because each test observes a different biological target within its own window of visibility, and a negative result cannot exclude transient or functional mechanisms such as spasm, embolism, or microvascular dysfunction. We synthesize evidence on imaging timing, quantitative tissue characterization, stress perfusion, multimodality reclassification, prognosis, and mechanism-guided treatment, and indicate the type of evidence supporting key claims. On this basis, we propose a conceptual framework, not an evidence-based guideline, that expresses mechanistic confidence in graded terms, places that judgment within an integrated heart-team report, and reserves further testing for questions likely to change diagnosis, treatment, or follow-up. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Abdu, Fuad A AU - Abdu FA AD - School of Medical Sciences, Shandong Xiehe University, 6277 Jiqing Road, Jinan, 250109, China. Electronic address: drfuadabdua@gmail.com. FAU - Mohammed, Abdul-Quddus AU - Mohammed AQ AD - Department of Cardiology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, 301 Yanchang Road, Shanghai, 200072, China. LA - eng PT - Journal Article PT - Review DEP - 20261026 PL - United States TA - Trends Cardiovasc Med JT - Trends in cardiovascular medicine JID - 9108337 SB - IM OTO - NOTNLM OT - Cardiac magnetic resonance OT - Diagnostic discordance OT - MINOCA OT - Multimodality imaging OT - Myocardial tissue characterization OT - Optical coherence tomography COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/10/26 23:27 MHDA- 2026/10/26 23:27 CRDT- 2026/10/26 20:34 PHST- 2026/08/26 00:00 [received] PHST- 2026/10/24 00:00 [revised] PHST- 2026/10/24 00:00 [accepted] PHST- 2026/10/26 23:27 [pubmed] PHST- 2026/10/26 23:27 [medline] PHST- 2026/10/26 20:34 [entrez] AID - S1050-1738(26)00127-1 [pii] AID - 10.1016/j.tcm.2026.10.006 [doi] PST - aheadofprint SO - Trends Cardiovasc Med. 2026 Oct 26:S1050-1738(26)00127-1. doi: 10.1016/j.tcm.2026.10.006. PMID- 42933524 OWN - NLM STAT- Publisher LR - 20261026 IS - 1552-6259 (Electronic) IS - 0003-4975 (Linking) DP - 2026 Oct 26 TI - Lifetime Management of Aortic Stenosis: Expert Review of Evidence and Consensus Guidelines. LID - S0003-4975(26)01052-0 [pii] LID - 10.1016/j.athoracsur.2026.09.062 [doi] AB - BACKGROUND: The 2025 European Society of Cardiology/European Association for Cardio-Thoracic Surgery Guidelines introduced a Class I recommendation for transfemoral transcatheter aortic valve implantation (TAVI) in selected patients aged 70 years or older with tricuspid aortic stenosis and suitable anatomy, while surgical aortic valve replacement (SAVR) remains recommended in younger low-risk patients. In patients with long expected survival, this framework requires careful consideration of valve durability, future reintervention, and patient preferences. This expert review, developed by the Italian Cardiac Surgery Working Group, examines contemporary evidence and consensus recommendations from a lifetime-management perspective. METHODS: We performed a narrative, evidence-based synthesis of randomized trials, trial-based meta-analyses, and propensity-matched real-world registries comparing transfemoral TAVI and SAVR, with primary emphasis on low-risk patients. Lower-intermediate-risk evidence was included only when directly relevant to lifetime management, durability, or reintervention. RESULTS: Evidence suggests that treatment effects are time-dependent: early non-inferiority of TAVI may attenuate with longer follow-up, particularly in patients with substantial life expectancy. Randomized durability data remain limited, whereas propensity-matched real-world registries have suggested possible higher late mortality after TAVI in younger, lower-risk populations. Reintervention after a transcatheter-first strategy may be associated with increasing technical complexity and procedural risk over time. CONCLUSIONS: This review supports appropriate application of current guidelines through a pragmatic framework for individualized, Heart Team-based decision-making. Transfemoral TAVI is often appropriate in patients with limited life expectancy or recognized high surgical risk when anatomically feasible. In patients with long expected survival, SAVR should retain a central role as an important reference strategy. CI - Copyright (c) 2026. Published by Elsevier Inc. FAU - Centofanti, Paolo AU - Centofanti P AD - Cardiac Surgery Unit, AO Ordine Mauriziano Hospital, Turin, Italy. Electronic address: pcentofanti@mauriziano.it. FAU - Rinaldi, Mauro AU - Rinaldi M AD - Cardiac Surgery Unit, AOU Citta della Salute e della Scienza University Hospital, Turin, Italy. FAU - Di Eusanio, Marco AU - Di Eusanio M AD - Cardiac Surgery Unit, Ospedali Riuniti University Hospital, Ancona, Italy. FAU - D'Onofrio, Augusto AU - D'Onofrio A AD - Cardiac Surgery Unit, Policlinico Tor Vergata University Hospital, Rome, Italy. FAU - Gerosa, Gino AU - Gerosa G AD - Cardiac Surgery Unit, University Hospital of Padua, Padua, Italy. FAU - Lodo, Vittoria AU - Lodo V AD - Cardiac Surgery Unit, AO Ordine Mauriziano Hospital, Turin, Italy. FAU - Pacini, Davide AU - Pacini D AD - Cardiac Surgery Unit, Policlinico Sant'Orsola-Malpighi University Hospital, Bologna, Italy. FAU - Salizzoni, Stefano AU - Salizzoni S AD - Cardiac Surgery Unit, AOU Citta della Salute e della Scienza University Hospital, Turin, Italy. FAU - Stefano, Pierluigi AU - Stefano P AD - Cardiac Surgery Unit, Careggi University Hospital, Florence, Italy. FAU - Pilato, Michele AU - Pilato M AD - Cardiac Surgery Unit, IRCCS ISMETT - UPMC, Palermo, Italy. CN - Italian Cardiac Surgery Working Group LA - eng PT - Journal Article PT - Review DEP - 20261026 PL - Netherlands TA - Ann Thorac Surg JT - The Annals of thoracic surgery JID - 15030100R SB - IM FIR - Agnino, Alfonso IR - Agnino A FIR - Albertini, Alberto IR - Albertini A FIR - Attisani, Matteo IR - Attisani M FIR - Audo, Andrea IR - Audo A FIR - Benedetto, Umberto IR - Benedetto U FIR - Benussi, Stefano IR - Benussi S FIR - Bergonzini, Marcello IR - Bergonzini M FIR - Biancari, Fausto IR - Biancari F FIR - Bonalumi, Giorgia IR - Bonalumi G FIR - Borghetti, Valentino IR - Borghetti V FIR - Bottio, Tomaso IR - Bottio T FIR - Casali, Giovanni IR - Casali G FIR - Cassese, Mauro IR - Cassese M FIR - Chello, Massimo IR - Chello M FIR - Cirio, Emiliano IR - Cirio E FIR - Colli, Andrea IR - Colli A FIR - Coscioni, Enrico IR - Coscioni E FIR - Di Credico, Germano IR - Di Credico G FIR - Fabbrocini, Mario IR - Fabbrocini M FIR - Fanelli, Vitantonio IR - Fanelli V FIR - Fattouch, Khalil IR - Fattouch K FIR - De Feo, Marisa IR - De Feo M FIR - Fiorani, Brenno IR - Fiorani B FIR - Fiorani, Vinicio IR - Fiorani V FIR - Formica, Francesco IR - Formica F FIR - Fratto, Pasquale Antonio IR - Fratto PA FIR - Fuga, Raffaele IR - Fuga R FIR - Garatti, Andrea IR - Garatti A FIR - Gelpi, Guido IR - Gelpi G FIR - Del Giglio, Mauro IR - Del Giglio M FIR - Glauber, Mattia IR - Glauber M FIR - Iesu, Severino IR - Iesu S FIR - Lentini, Salvatore IR - Lentini S FIR - Luciani, Giovanni Battista IR - Luciani GB FIR - Luzi, Giampaolo IR - Luzi G FIR - Maisano, Francesco IR - Maisano F FIR - Mangino, Domenico IR - Mangino D FIR - Marchetto, Giovanni IR - Marchetto G FIR - Martinelli, Luigi IR - Martinelli L FIR - Maselli, Daniele IR - Maselli D FIR - Massetti, Massimo IR - Massetti M FIR - Mastroroberto, Pasquale IR - Mastroroberto P FIR - Di Mauro, Michele IR - Di Mauro M FIR - Mazzaro, Enzo IR - Mazzaro E FIR - Melina, Giovanni IR - Melina G FIR - Merlo, Maurizio IR - Merlo M FIR - Messina, Antonio IR - Messina A FIR - Minniti, Giuseppe IR - Minniti G FIR - Miraldi, Fabio IR - Miraldi F FIR - Montalto, Andrea IR - Montalto A FIR - Montesi, Gianfranco IR - Montesi G FIR - Muneretto, Claudio IR - Muneretto C FIR - Musazzi, Andrea IR - Musazzi A FIR - Musumeci, Francesco IR - Musumeci F FIR - Navarra, Emiliano IR - Navarra E FIR - Nicolini, Francesco IR - Nicolini F FIR - Onorati, Francesco IR - Onorati F FIR - Paparella, Domenico IR - Paparella D FIR - Parolari, Alessandro IR - Parolari A FIR - Patane, Francesco IR - Patane F FIR - Pelenghi, Stefano IR - Pelenghi S FIR - Pilato, Emanuele IR - Pilato E FIR - Pisano, Calogera IR - Pisano C FIR - Pollari, Francesco IR - Pollari F FIR - Polvani, Gianluca IR - Polvani G FIR - Portoghese, Michele IR - Portoghese M FIR - Rambaldini, Manfredo IR - Rambaldini M FIR - Ricci, Davide IR - Ricci D FIR - Roberto, Maurizio IR - Roberto M FIR - Russo, Claudio IR - Russo C FIR - Salvador, Loris IR - Salvador L FIR - Santarelli, Filippo IR - Santarelli F FIR - Santarpino, Giuseppe IR - Santarpino G FIR - Santini, Francesco IR - Santini F FIR - Savini, Carlo IR - Savini C FIR - Solinas, Marco IR - Solinas M FIR - Speziale, Giuseppe IR - Speziale G FIR - Torracca, Lucia IR - Torracca L FIR - Triggiani, Michele IR - Triggiani M FIR - Troise, Giovanni IR - Troise G FIR - Vendramin, Igor IR - Vendramin I FIR - De Vincentiis, Carlo IR - De Vincentiis C FIR - Zebele, Carlo IR - Zebele C EDAT- 2026/10/26 23:27 MHDA- 2026/10/26 23:27 CRDT- 2026/10/26 20:31 PHST- 2026/03/28 00:00 [received] PHST- 2026/08/10 00:00 [revised] PHST- 2026/09/22 00:00 [accepted] PHST- 2026/10/26 23:27 [medline] PHST- 2026/10/26 23:27 [pubmed] PHST- 2026/10/26 20:31 [entrez] AID - S0003-4975(26)01052-0 [pii] AID - 10.1016/j.athoracsur.2026.09.062 [doi] PST - aheadofprint SO - Ann Thorac Surg. 2026 Oct 26:S0003-4975(26)01052-0. doi: 10.1016/j.athoracsur.2026.09.062. PMID- 42928327 OWN - NLM STAT- MEDLINE DCOM- 20261026 LR - 20261027 IS - 1534-3170 (Electronic) IS - 1523-3782 (Linking) VI - 28 IP - 1 DP - 2026 Oct 26 TI - Pharmacist-Led Medication Titration for Cardiometabolic Disease: Evidence, Equity, and Scale. LID - 117 [pii] LID - 10.1007/s11886-026-02432-x [doi] AB - PURPOSE OF REVIEW: To review community-based pharmacist-led medication titration across cardiometabolic conditions and the infrastructure needed to deliver this model at scale. RECENT FINDINGS: This review reframes cardiometabolic medication optimization as a continuum from passive gap identification to active longitudinal medication management. Registries, dashboards, audit and feedback, electronic health record alerts, and inpatient initiation can identify undertreatment or prompt prescribing, but they do not provide infrastructure for dose adjustment, monitoring, adherence support, and medication-access navigation. Pharmacist-led, team-based models occupy the active end of this continuum. The strongest evidence is in hypertension, with meaningful blood pressure reductions; in heart failure, interdisciplinary titration programs more directly address target-dose achievement than alerts or decision-support tools. Emerging data extend this framework to diabetes, lipidology, and obesity. Value-based care provides a reimbursement framework to support these services. Pharmacist-led titration can close gaps between therapies and delivery, but scaling requires equity-focused implementation, flexible staffing, population health infrastructure that connects artificial intelligence-enabled patient identification to action, and sustainable reimbursement. CI - (c) 2026. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Yarlagadda, Siddharth AU - Yarlagadda S AUID- ORCID: 0000-0001-8148-9167 AD - Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA. AD - Harvard Medical School, Boston, MA, USA. FAU - Blood, Alexander J AU - Blood AJ AUID- ORCID: 0000-0002-8391-2536 AD - Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA. ablood3@mgb.org. AD - Harvard Medical School, Boston, MA, USA. ablood3@mgb.org. LA - eng PT - Journal Article PT - Review DEP - 20261026 PL - United States TA - Curr Cardiol Rep JT - Current cardiology reports JID - 100888969 SB - IM MH - Humans MH - *Pharmacists MH - Value-Based Health Care MH - *Cardiovascular Diseases/drug therapy MH - Hypertension/drug therapy MH - Diabetes Mellitus/drug therapy MH - Professional Role MH - Heart Failure/drug therapy OTO - NOTNLM OT - Artificial Intelligence-Enabled Patient Identification OT - Cardiometabolic Disease OT - Medication Titration OT - Pharmacist-Led Care OT - Population Health OT - Value-Based Care COIS- Declarations. Human and Animal Rights and Informed Consent: No animal or human subjects by the authors were used in this study. Competing interests: S.Y. declares no competing interests. A.J.B. discloses Grants: AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Eli Lilly, General Electric Health, Merck; Consulting: AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Corcept Therapeutics, Milestone Therapeutics, NODE Health, Alnylam Pharma, Color Health, Medscape, Nference Inc., Walgreens Health, Withings, HelloHeart; Equity: AIwithCare, Knownwell Health, Porter Health, Nference; Payment or Honoraria: McMaster University, Geisinger Health, Medscape; Support for attending meetings and/or travel: American Heart Association; Patents: Retrieval-augmented generation for medical data (pending). Use of Artificial Intelligence: AI tools were used to assist with language and grammar editing, organization of source notes, and management of source-derived information during manuscript preparation. The authors independently determined the article structure, selected all cited sources, and chose the information extracted from each source. AI was not used to independently analyze or interpret data, create figures or tables, or draw scientific conclusions. All content was reviewed, edited, and approved by the authors, who take full responsibility for the final manuscript. EDAT- 2026/10/26 05:30 MHDA- 2026/10/26 05:31 CRDT- 2026/10/26 00:27 PHST- 2026/07/16 00:00 [received] PHST- 2026/10/02 00:00 [accepted] PHST- 2026/10/26 05:31 [medline] PHST- 2026/10/26 05:30 [pubmed] PHST- 2026/10/26 00:27 [entrez] AID - 10.1007/s11886-026-02432-x [pii] AID - 10.1007/s11886-026-02432-x [doi] PST - epublish SO - Curr Cardiol Rep. 2026 Oct 26;28(1):117. doi: 10.1007/s11886-026-02432-x. PMID- 42925019 OWN - NLM STAT- Publisher LR - 20261024 IS - 1559-0879 (Electronic) IS - 1556-9845 (Linking) DP - 2026 Oct 23 TI - Optimizing Saphenous Vein Grafts: From Workhorse to an Evidence-Based Conduit Strategy. PG - 15569845261489230 LID - 10.1177/15569845261489230 [doi] AB - OBJECTIVE: The saphenous vein graft (SVG) remains the most common conduit in coronary artery bypass grafting (CABG) but suffers from inferior long-term patency compared with arterial grafts. This review evaluates the concept of viewing the SVG not as an inherently flawed conduit but as one that can be systematically optimized through evidence-based strategies. METHODS: A narrative review was conducted to address the following clinical question: "In patients undergoing CABG, how do contemporary surgical harvesting techniques, intraoperative preservation methods, and postoperative pharmacologic strategies interact to optimize the long-term patency of saphenous vein grafts?" We synthesized evidence from recent landmark randomized controlled trials and meta-analyses to define a comprehensive optimization strategy. RESULTS: SVG failure is a cascade initiated by surgical trauma and propagated by hemodynamic stress. The "no-touch" harvesting technique, which preserves protective perivascular tissue, has demonstrated superior long-term patency in classic trials, although recent evidence has sparked debate regarding its universal reproducibility. Intraoperative preservation with endothelial-sparing solutions and aggressive postoperative pharmacotherapy-including high-intensity statins and tailored antiplatelet strategies-provide crucial secondary protection. Notably, when graft failure occurs, recent randomized evidence challenges the dogma of a strict "native vessel first" approach, supporting instead an individualized, anatomy-driven strategy that balances early procedural hazard against long-term durability. CONCLUSIONS: The SVG is an optimizable conduit. A modern, integrated approach-combining meticulous harvesting, biological preservation, and aggressive secondary prevention-can substantially improve graft durability. By shifting focus from simple conduit selection to comprehensive conduit optimization and appropriate patient-specific target selection, the Heart Team can significantly improve long-term cardiovascular outcomes. FAU - Zhou, Ziqiang AU - Zhou Z AUID- ORCID: 0009-0002-2717-410X AD - Cardiovascular Center, Beijing Tongren Hospital, Capital Medical University, China. FAU - Zhao, Jiangang AU - Zhao J AD - Cardiovascular Center, Beijing Tongren Hospital, Capital Medical University, China. FAU - Wang, Yanjun AU - Wang Y AD - Cardiovascular Center, Beijing Tongren Hospital, Capital Medical University, China. FAU - Wu, Wenbo AU - Wu W AD - Cardiovascular Center, Beijing Tongren Hospital, Capital Medical University, China. LA - eng PT - Journal Article PT - Review DEP - 20261023 PL - United States TA - Innovations (Phila) JT - Innovations (Philadelphia, Pa.) JID - 101257528 SB - IM OTO - NOTNLM OT - conduit optimization OT - coronary artery bypass grafting OT - no-touch technique OT - saphenous vein OT - vein graft failure EDAT- 2026/10/25 03:36 MHDA- 2026/10/25 03:36 CRDT- 2026/10/24 12:17 PHST- 2026/10/25 03:36 [medline] PHST- 2026/10/25 03:36 [pubmed] PHST- 2026/10/24 12:17 [entrez] AID - 10.1177/15569845261489230 [doi] PST - aheadofprint SO - Innovations (Phila). 2026 Oct 23:15569845261489230. doi: 10.1177/15569845261489230. PMID- 42922950 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20261024 LR - 20261025 IS - 2297-055X (Print) IS - 2297-055X (Electronic) IS - 2297-055X (Linking) VI - 13 DP - 2026 TI - Long-term survival after transcatheter aortic valve implantation in nonagenarian patients: a multicenter real-world study. PG - 1945453 LID - 10.3389/fcvm.2026.1945453 [doi] LID - 1945453 AB - BACKGROUND: The growing number of nonagenarian patients with severe aortic stenosis has increased interest in transcatheter aortic valve implantation (TAVI) in this population. However, data on long-term outcomes remain limited. This study aimed to evaluate long-term survival and procedural outcomes of TAVI in nonagenarians and to explore clinical factors associated with long-term mortality. METHODS: We conducted an ambispective multicenter observational cohort study including patients aged >/=90 years who underwent TAVI for severe aortic stenosis between 2013 and 2021 at six centers in the Emilia-Romagna region, Italy. Baseline and procedural data were collected retrospectively, while outcome ascertainment combined prospective follow-up contacts with retrospective verification of dates of death or last confirmed vital status. Survival was estimated using the Kaplan-Meier method, and associations with mortality were examined using an exploratory Cox regression analysis. RESULTS: A total of 60 nonagenarian patients (mean age 91 +/- 1.5 years; 67% female) were included. Procedural success was achieved in 97% of cases. In-hospital mortality was 5%, and 30-day mortality was 8.3%. Over a mean observation period of 5.7 years from TAVI to death or the last confirmed vital-status assessment, the Kaplan-Meier estimated 5-year survival was 35%. In the exploratory multivariable analysis, male sex and chronic obstructive pulmonary disease (COPD) were associated with higher long-term mortality. CONCLUSIONS: In patients aged >/=90 years selected by the Heart Team for TAVI, the Kaplan-Meier estimated 5-year survival was 35%. The procedure demonstrated a high success rate and an acceptable safety profile. Male sex and COPD showed an exploratory association with worse prognosis. These findings suggest that TAVI may be a feasible option in carefully selected nonagenarians when guided by comprehensive clinical assessment and individualized decision-making. CI - (c) 2026 Pagnoni, Loffi, Caleffi, Darroudi, Masaracchia, Frassoni, Marangi, di Michele, Gabbieri, Losi, Monello, Sgura, Arrotti, Rossi, Iaccarino, Ruozzi, Guiducci, Gurgoglione, Benatti, Vignali, Niccoli, Boriani, Aschieri and Coppi. FAU - Pagnoni, Gianluca AU - Pagnoni G AD - Cardiology Unit, Specialistic Medicine Department, Guglielmo da Saliceto Hospital, Piacenza, Italy. AD - National Institute for Cardiovascular Research (INRC), Bologna, Italy. FAU - Loffi, Marco AU - Loffi M AD - Division of Cardiology, Azienda Socio-Sanitaria Territoriale di Cremona, Cremona, Italy. FAU - Caleffi, Dalia AU - Caleffi D AD - Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy. FAU - Darroudi, Susan AU - Darroudi S AD - Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, Modena, Italy. FAU - Masaracchia, Giuseppe AU - Masaracchia G AD - Cardiology Division, Department of Biomedical Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy. FAU - Frassoni, Benedetta AU - Frassoni B AD - Cardiology Department, Azienda Ospedaliero-Universitaria of Parma, Parma, Italy. FAU - Marangi, Francesco AU - Marangi F AD - Cardiology Division, Department of Biomedical Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy. FAU - di Michele, Sophia AU - di Michele S AD - Cardiology Division, Department of Biomedical Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy. FAU - Gabbieri, Davide AU - Gabbieri D AD - Cardiac Surgery Division, Hesperia Hospital, Modena, Italy. FAU - Losi, Luciano AU - Losi L AD - Cardiology Unit, Specialistic Medicine Department, Guglielmo da Saliceto Hospital, Piacenza, Italy. FAU - Monello, Alberto AU - Monello A AD - Cardiology Unit, Specialistic Medicine Department, Guglielmo da Saliceto Hospital, Piacenza, Italy. FAU - Sgura, Fabio Alfredo AU - Sgura FA AD - Cardiology Division, Department of Biomedical Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy. FAU - Arrotti, Salvatore AU - Arrotti S AD - Cardiology Division, Department of Biomedical Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy. FAU - Rossi, Rosario AU - Rossi R AD - Cardiology Division, Department of Biomedical Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy. FAU - Iaccarino, Daniele AU - Iaccarino D AD - Cardiology Department, Nuovo Ospedale S. Agostino Estense, Modena, Italy. FAU - Ruozzi, Marco AU - Ruozzi M AD - Cardiology Department, Nuovo Ospedale S. Agostino Estense, Modena, Italy. FAU - Guiducci, Vincenzo AU - Guiducci V AD - Cardiology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy. FAU - Gurgoglione, Filippo Luca AU - Gurgoglione FL AD - Cardiology Department, Azienda Ospedaliero-Universitaria of Parma, Parma, Italy. FAU - Benatti, Giorgio AU - Benatti G AD - Cardiology Department, Azienda Ospedaliero-Universitaria of Parma, Parma, Italy. FAU - Vignali, Luigi AU - Vignali L AD - Cardiology Department, Azienda Ospedaliero-Universitaria of Parma, Parma, Italy. FAU - Niccoli, Giampaolo AU - Niccoli G AD - Cardiology Department, Azienda Ospedaliero-Universitaria of Parma, Parma, Italy. FAU - Boriani, Giuseppe AU - Boriani G AD - Cardiac Surgery Division, Hesperia Hospital, Modena, Italy. FAU - Aschieri, Daniela AU - Aschieri D AD - Cardiology Unit, Specialistic Medicine Department, Guglielmo da Saliceto Hospital, Piacenza, Italy. FAU - Coppi, Francesca AU - Coppi F AD - National Institute for Cardiovascular Research (INRC), Bologna, Italy. AD - Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, Modena, Italy. LA - eng PT - Journal Article DEP - 20261008 PL - Switzerland TA - Front Cardiovasc Med JT - Frontiers in cardiovascular medicine JID - 101653388 PMC - PMC13687073 OTO - NOTNLM OT - long-term survival OT - mortality OT - nonagenarians OT - procedural outcomestranscatheter aortic valve implantation (TAVI) OT - severe aortic stenosis OT - survival OT - transcatheter aortic valve implantation COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor EZ declared a past co-authorship with the author DG. EDAT- 2026/10/25 03:36 MHDA- 2026/10/25 03:37 PMCR- 2026/10/08 CRDT- 2026/10/24 10:34 PHST- 2026/07/22 00:00 [received] PHST- 2026/09/18 00:00 [revised] PHST- 2026/09/29 00:00 [accepted] PHST- 2026/10/25 03:37 [medline] PHST- 2026/10/25 03:36 [pubmed] PHST- 2026/10/24 10:34 [entrez] PHST- 2026/10/08 00:00 [pmc-release] AID - 10.3389/fcvm.2026.1945453 [doi] PST - epublish SO - Front Cardiovasc Med. 2026 Oct 8;13:1945453. doi: 10.3389/fcvm.2026.1945453. eCollection 2026. PMID- 42912522 OWN - NLM STAT- Publisher LR - 20261026 IS - 2168-2208 (Electronic) IS - 2168-2194 (Linking) VI - PP DP - 2026 Oct 23 TI - Q-AortaECG: A Quantum-Inspired Multi-Agent 12-Lead ECG System for Early Triage of Acute Aortic Syndrome. LID - 10.1109/JBHI.2026.3746586 [doi] AB - Acute aortic syndrome (AAS) is a time-critical vascular emergency in which delayed recognition may occur because the presenting symptoms and electrocardiographic phenotypes often overlap with acute coronary syndrome, pulmonary embolism, pericarditis, and other emergency diagnoses. Computed tomographic angiography (CTA) remains the confirmatory standard, but the 12-lead electrocardiogram (ECG) is usually obtained earlier, is universally available at triage, and may carry distributed signatures of malperfusion, ischemia mimicry, autonomic stress, conduction delay, and hemodynamic compromise. We developed Q-AortaECG, a classically implemented quantum-inspired multi-agent ECG system that integrates multiscale waveform representations, specialist ECG agents, density-state uncertainty fusion, a variational-circuit style consensus layer, and a safety-gated multidisciplinary team-style report for early AAS triage. The system was evaluated in three suspected-AAS/CTA-evaluable cohorts comprising 1,251 patients, including 467 with CTA-, surgery-, or autopsy-confirmed AAS. Across 700 locked-test patients, Q-AortaECG achieved an area under the receiver operating characteristic curve (AUROC) of 0.881 (95% confidence interval (CI), 0.852-0.908), area under the precision-recall curve (AUPRC) of 0.743 (95% CI, 0.695-0.790), sensitivity of 0.955 (231/242; 95% CI, 0.920-0.977), specificity of 0.721 (330/458; 95% CI, 0.677-0.761), positive predictive value (PPV) of 0.643, and negative predictive value (NPV) of 0.968 at the prespecified high-sensitivity threshold. Performance remained consistent in external retrospective validation and prospective silent-run evaluation, although AUPRC decreased in the lower-prevalence prospective cohort. Ablation experiments supported the contributions of self-supervised ECG pretraining, agent specialization, density-matrix uncertainty fusion, and differential diagnosis modeling. In a counterbalanced paired reader study, Q-AortaECG assistance improved overall clinician sensitivity from 0.696 to 0.870 while preserving specificity (0.851 ver sus 0.846). In prospective silent-run analysis, counterfactual alerts would have advanced the median time to the correct diagnostic pathway from 187 to 61 minutes among initially unsuspected AAS presentations. These findings support ECG first, calibrated, safety-gated decision support as an early warning scaffold for AAS triage, while preserving CTA and expert imaging interpretation as the diagnostic standard. FAU - Yu, Lu AU - Yu L FAU - Qiao, Guanyu AU - Qiao G FAU - Jiang, Xiaolang AU - Jiang X FAU - Liu, Yifan AU - Liu Y FAU - Wang, Penghui AU - Wang P FAU - Xi, Wen AU - Xi W FAU - Fu, Weiguo AU - Fu W FAU - Fang, Gang AU - Fang G FAU - Dong, Zhihui AU - Dong Z LA - eng PT - Journal Article DEP - 20261023 PL - United States TA - IEEE J Biomed Health Inform JT - IEEE journal of biomedical and health informatics JID - 101604520 SB - IM EDAT- 2026/10/23 18:31 MHDA- 2026/10/23 18:31 CRDT- 2026/10/23 13:36 PHST- 2026/10/23 18:31 [pubmed] PHST- 2026/10/23 18:31 [medline] PHST- 2026/10/23 13:36 [entrez] AID - 10.1109/JBHI.2026.3746586 [doi] PST - aheadofprint SO - IEEE J Biomed Health Inform. 2026 Oct 23;PP. doi: 10.1109/JBHI.2026.3746586. PMID- 42910416 OWN - NLM STAT- Publisher LR - 20261023 IS - 1524-4539 (Electronic) IS - 0009-7322 (Linking) DP - 2026 Oct 22 TI - Multidisciplinary Collaboration in the Performance of Aortic Surgery: A Scientific Statement From the American Heart Association. LID - 10.1161/CIR.0000000000001490 [doi] AB - Intraoperative management of a patient undergoing cardiac surgery requires continuous and independent interventions by multiple healthcare professionals, including surgeons, anesthesiologists, and perfusionists, among others. Although each clinician performs tasks based on their training and accepted techniques, guidelines, and protocols, an action by one member of the team can have immediate consequences for other team members. Aortic surgery adds a level of complexity, with the need for interventions such as single-lung ventilation, systemic cooling (and subsequent rewarming), and myocardial, cerebral, and visceral protection. Much has been made of the utility of the multidisciplinary team. This scientific statement is intended to approach the patient undergoing aortic surgery from 3 different viewpoints: that of the surgeon, the anesthesiologist, and the perfusionist. This scientific statement is not intended to provide an exhaustive summary of approaches to aortic surgery but rather to illustrate the specific concerns that each member of the team may have. FAU - DeAnda, Abe Jr AU - DeAnda A Jr FAU - Steppan, Jochen AU - Steppan J FAU - Boskovski, Marko T AU - Boskovski MT FAU - Cherry, Anne D AU - Cherry AD FAU - Dickey, Renee A AU - Dickey RA FAU - Gray DeAngelis, Kathryn AU - Gray DeAngelis K FAU - Ibekwe, Stephanie O AU - Ibekwe SO FAU - Tseng, Elaine E AU - Tseng EE CN - American Heart Association Council on Cardiovascular Surgery and Anesthesia, Education and Publication Committee; Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Peripheral Vascular Disease; Council on Lifelong Congenital Heart Disease and Heart Health in the Young; and Council on Cardiovascular Radiology and Intervention LA - eng PT - Journal Article PT - Review DEP - 20261022 PL - United States TA - Circulation JT - Circulation JID - 0147763 SB - IM OTO - NOTNLM OT - AHA Scientific Statements OT - anesthesiologists OT - aortic aneurysm OT - one-lung ventilation OT - patient care team OT - surgeons EDAT- 2026/10/23 18:31 MHDA- 2026/10/23 18:31 CRDT- 2026/10/23 12:07 PHST- 2026/10/23 18:31 [medline] PHST- 2026/10/23 18:31 [pubmed] PHST- 2026/10/23 12:07 [entrez] AID - 10.1161/CIR.0000000000001490 [doi] PST - aheadofprint SO - Circulation. 2026 Oct 22. doi: 10.1161/CIR.0000000000001490. PMID- 42908338 OWN - NLM STAT- Publisher LR - 20261022 IS - 1724-6032 (Electronic) IS - 1129-7298 (Linking) DP - 2026 Oct 22 TI - Vascular access management after kidney transplantation position paper on behalf of the Vascular Access Society and the European Kidney Transplant Association. PG - 11297298261468406 LID - 10.1177/11297298261468406 [doi] AB - There is no consensus on whether to ligate or preserve uncomplicated vascular access (VA) after kidney transplantation (KT), as International Guidelines do not address this issue. Enhanced survival rates of kidney grafts may elevate the risk of cardiac morbidity and mortality due to prolonged exposure to the hemodynamic effects of arterio-venous fistulas (AVF). Although VA ligation reduces left ventricle (LV) mass, its impact on cardiovascular (CV) morbidity or mortality is unclear. High-flow VAs can complicate KT patients, and immunosuppressive medication may increase these complications. Despite preserving VA for future hemodialysis (HD) use, central catheters are used in nearly two-thirds of patients. Detecting transplant patients who can undergo AVF ligation and reconstruction when returning to HD allows for flexible decision-making with a multidisciplinary approach, personally tailored to patients at their discretion. Therefore, an algorithm involving Doppler ultrasound and cardiac evaluation is advisable. FAU - Akin, Baris AU - Akin B AD - Department of Surgery, Florence Nightingale Hospital, Demiroglu Bilim University, Istanbul, Turkey. AD - European Kidney Transplant Association, Section of European Society of Transplantation, Amsterdam, Netherlands. FAU - Jemcov, Tamara K AU - Jemcov TK AD - Department of Nephrology, Clinical Hospital Center Zemun, Belgrade, Serbia. AD - Faculty of Medicine, University of Belgrade, Belgrade, Serbia. AD - Vascular Access Society, Maastricht, Netherlands. FAU - Cucchiari, David AU - Cucchiari D AD - European Kidney Transplant Association, Section of European Society of Transplantation, Amsterdam, Netherlands. AD - Department of Nephrology and Kidney Transplantation, Hospital Clinic of Barcelona, Barcelona, Spain. FAU - Malik, Jan AU - Malik J AD - Vascular Access Society, Maastricht, Netherlands. AD - First Medical Faculty, Complex Cardiovascular Center, General University Hospital, Charles University, Prague, Czechia. FAU - Pettigrew, Gavin J AU - Pettigrew GJ AD - Department of Surgery, University of Cambridge, London, UK. FAU - Hahn Lundstrom, Ulrika AU - Hahn Lundstrom U AD - Vascular Access Society, Maastricht, Netherlands. AD - Division of Renal Medicine, Department of CLINTEC, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden. FAU - Zaza, Gianluigi AU - Zaza G AD - European Kidney Transplant Association, Section of European Society of Transplantation, Amsterdam, Netherlands. AD - Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy. FAU - Rotmans, Joris I AU - Rotmans JI AD - Vascular Access Society, Maastricht, Netherlands. AD - Department of Internal Medicine, Leiden University Medical Center, Leiden, Netherlands. LA - eng PT - Journal Article DEP - 20261022 PL - United States TA - J Vasc Access JT - The journal of vascular access JID - 100940729 SB - IM OTO - NOTNLM OT - AVF flow reduction OT - Ligation of arteriovenous fistula OT - hemodialysis OT - kidney failure OT - kidney transplantation EDAT- 2026/10/23 05:32 MHDA- 2026/10/23 05:32 CRDT- 2026/10/22 23:18 PHST- 2026/10/23 05:32 [medline] PHST- 2026/10/23 05:32 [pubmed] PHST- 2026/10/22 23:18 [entrez] AID - 10.1177/11297298261468406 [doi] PST - aheadofprint SO - J Vasc Access. 2026 Oct 22:11297298261468406. doi: 10.1177/11297298261468406. PMID- 42908056 OWN - NLM STAT- Publisher LR - 20261022 IS - 1533-404X (Electronic) IS - 0195-7910 (Linking) DP - 2026 Oct 22 TI - Unexpected Death in a Preschool Child: Forensic Assessment of Acute Myocarditis on Left Ventricular Hypertrophy. LID - 10.1097/PAF.0000000000001186 [doi] AB - Myocarditis is an inflammatory disease of the myocardium with a highly variable clinical spectrum, ranging from mild or subclinical forms to severe manifestations, including heart failure, arrhythmias, and sudden cardiac death. In this article, we report a case of sudden death in a 4-year-old child in whom autopsy and histopathologic investigations identified myocarditis developing on a substrate of left ventricular hypertrophy. Given the lack of pathognomonic symptoms in myocarditis, maintaining a high index of clinical suspicion is paramount for ensuring timely admission. Early diagnosis is crucial to initiating treatment before clinical deterioration occurs. Furthermore, implementing standardized and systematic autopsy analysis is essential to maximizing the diagnostic yield in cases of unexpected death in childhood. In the absence of a unified investigative framework and multidisciplinary approach, postmortem examinations risk remaining incomplete, potentially leaving critical pathologic findings undetected. CI - Copyright (c) 2026 Wolters Kluwer Health, LLC. All rights reserved. FAU - Incarnato, Sofia AU - Incarnato S AD - Department of Legal and Forensic Medicine, University of Genova, Genova. FAU - Luta, Robert AU - Luta R AD - Department of Legal and Forensic Medicine, University of Genova, Genova. FAU - Fraternali Orcioni, Giulio AU - Fraternali Orcioni G AD - Department of Clinical Pathology, S. Croce e Carle Hospital, Cuneo. FAU - Barranco, Rosario AU - Barranco R AD - Department of Legal and Forensic Medicine, University of Genova, Genova. AD - Legal Medicine Unit, Policlinico San Martino Hospital, Largo Rosanna Benzi 10, Genova, Italy. FAU - Ventura, Francesco AU - Ventura F AD - Department of Legal and Forensic Medicine, University of Genova, Genova. AD - Legal Medicine Unit, Policlinico San Martino Hospital, Largo Rosanna Benzi 10, Genova, Italy. LA - eng PT - Journal Article DEP - 20261022 PL - United States TA - Am J Forensic Med Pathol JT - The American journal of forensic medicine and pathology JID - 8108948 SB - IM OTO - NOTNLM OT - autopsy OT - forensic pathology OT - pediatric myocarditis OT - sudden unexpected death in children COIS- The authors report no conflict of interest. EDAT- 2026/10/22 23:29 MHDA- 2026/10/22 23:29 CRDT- 2026/10/22 22:47 PHST- 2026/06/04 00:00 [received] PHST- 2026/09/20 00:00 [accepted] PHST- 2026/10/22 23:29 [medline] PHST- 2026/10/22 23:29 [pubmed] PHST- 2026/10/22 22:47 [entrez] AID - 00000433-990000000-00415 [pii] AID - 10.1097/PAF.0000000000001186 [doi] PST - aheadofprint SO - Am J Forensic Med Pathol. 2026 Oct 22. doi: 10.1097/PAF.0000000000001186. PMID- 42905170 OWN - NLM STAT- MEDLINE DCOM- 20261022 LR - 20261027 IS - 1433-7339 (Electronic) IS - 0941-4355 (Linking) VI - 34 IP - 11 DP - 2026 Oct 21 TI - Effectiveness of cardiac resynchronization therapy in cancer therapy-related cardiac dysfunction: a systematic review and meta-analysis. LID - 1133 [pii] LID - 10.1007/s00520-026-11364-9 [doi] AB - INTRODUCTION: Advances in cancer treatment have increased the number of survivors, making cancer therapy-related cardiac dysfunction (CTRCD) an important concern. While cardiac resynchronization therapy (CRT) is established for heart failure with reduced ejection fraction and conduction disorders, its role in CTRCD remains unclear. We conducted a meta-analysis to assess the benefit of CRT in patients with CTRCD. METHODS: We performed a literature search of studies showing CRT outcomes in the specific group of CTRCD patients. The outcomes of interest were left ventricular ejection fraction (LVEF) and LV volume improvement. A random effects meta-analysis was done to estimate 95% confidence intervals (CI). RESULTS: This analysis included four studies (one prospective and three retrospective) comprising 110 patients with CTRCD, the majority (91%, n = 100) being survivors of breast cancer or lymphoma/leukemia. Baseline LVEF ranged from 18.6% +/- 7.6% to 28.5% +/- 3.8% (mean 24% +/- 7%). After a mean follow-up of 9 +/- 5 months, LVEF increased by 9.95% (95% CI 7.79-12.11) and end-systolic volume decreased by 39.17 mL (95% CI 24.99-53.35). Three studies included a control group of patients with other forms of non-ischemic cardiomyopathy who underwent CRT implantation, showing no significant difference in LVEF improvement between the two groups. CONCLUSION: This meta-analysis suggests that CRT improves LVEF and LV volumes in selected patients with CTRCD, with a magnitude of reverse remodeling that appears similar to that observed in other etiologies of non-ischemic cardiomyopathy. However, the evidence is limited to small observational studies, so conclusions about clinical outcomes remain uncertain. Thus, CRT may be considered in cancer patients who meet standard criteria for CRT implantation, but the decision should be individualized and guided by multidisciplinary assessment, cancer prognosis, and competing clinical risks. CI - (c) 2026. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Magalhaes, Andreia AU - Magalhaes A AD - Servico de Cardiologia, Departamento de Coracao E Vasos, Centro Hospital Universitario Lisboa Norte (CHULN), ULS Santa Maria, CAML, Lisbon, Portugal. AD - Centro Cardiovascular da Universidade de Lisboa (CCUL@RISE), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal. FAU - Araujo, Ines AU - Araujo I AUID- ORCID: 0009-0001-4521-7284 AD - Servico de Cardiologia, Departamento de Coracao E Vasos, Centro Hospital Universitario Lisboa Norte (CHULN), ULS Santa Maria, CAML, Lisbon, Portugal. inesaraujo96@gmail.com. AD - Centro Cardiovascular da Universidade de Lisboa (CCUL@RISE), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal. inesaraujo96@gmail.com. FAU - Brabec, Martin AU - Brabec M AD - Faculty of Medicine, Pilsen - Charles University, Pilsen, Czech Republic. FAU - Menezes, Miguel Nobre AU - Menezes MN AD - Servico de Cardiologia, Departamento de Coracao E Vasos, Centro Hospital Universitario Lisboa Norte (CHULN), ULS Santa Maria, CAML, Lisbon, Portugal. AD - Centro Cardiovascular da Universidade de Lisboa (CCUL@RISE), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal. FAU - Fiuza, Manuela AU - Fiuza M AD - Servico de Cardiologia, Departamento de Coracao E Vasos, Centro Hospital Universitario Lisboa Norte (CHULN), ULS Santa Maria, CAML, Lisbon, Portugal. AD - Centro Cardiovascular da Universidade de Lisboa (CCUL@RISE), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal. FAU - Caldeira, Daniel AU - Caldeira D AD - Servico de Cardiologia, Departamento de Coracao E Vasos, Centro Hospital Universitario Lisboa Norte (CHULN), ULS Santa Maria, CAML, Lisbon, Portugal. AD - Centro Cardiovascular da Universidade de Lisboa (CCUL@RISE), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal. AD - Centro de Estudos de Medicina Baseada Na Evidencia (CEMBE), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal. AD - Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal. LA - eng PT - Journal Article PT - Meta-Analysis PT - Review PT - Systematic Review DEP - 20261021 PL - Germany TA - Support Care Cancer JT - Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer JID - 9302957 SB - IM MH - Humans MH - *Cardiac Resynchronization Therapy/methods MH - *Neoplasms/therapy MH - Stroke Volume MH - *Heart Diseases/therapy/etiology MH - Treatment Outcome MH - Ventricular Function, Left OTO - NOTNLM OT - Cardiac resynchronization therapy OT - Cardiotoxicity OT - Heart failure OT - Left ventricular dysfunction OT - Meta-analysis COIS- Declarations. Ethical approval: Not applicable. Consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2026/10/22 23:29 MHDA- 2026/10/22 23:30 CRDT- 2026/10/22 17:20 PHST- 2026/04/12 00:00 [received] PHST- 2026/10/12 00:00 [accepted] PHST- 2026/10/22 23:30 [medline] PHST- 2026/10/22 23:29 [pubmed] PHST- 2026/10/22 17:20 [entrez] AID - 10.1007/s00520-026-11364-9 [pii] AID - 10.1007/s00520-026-11364-9 [doi] PST - epublish SO - Support Care Cancer. 2026 Oct 21;34(11):1133. doi: 10.1007/s00520-026-11364-9. PMID- 42902785 OWN - NLM STAT- MEDLINE DCOM- 20261022 LR - 20261024 IS - 1365-2060 (Electronic) IS - 0785-3890 (Print) IS - 0785-3890 (Linking) VI - 58 IP - 1 DP - 2026 Dec TI - Temporal trends in incidence, clinical characteristics and outcomes of pyogenic vertebral osteomyelitis in Southern Denmark from 2009 to 2022: a retrospective population-based cohort study. PG - 2738249 LID - 10.1080/07853890.2026.2738249 [doi] LID - 2738249 AB - OBJECTIVES: Pyogenic vertebral osteomyelitis (PVO) is a severe infection with increasing incidence. We aimed to describe long-term population-based temporal trends in incidence, clinical presentation, diagnostic approaches, microbiology, and outcomes. MATERIALS AND METHODS: We conducted a retrospective population-based cohort study including 1,017 adults with multidisciplinary team-verified PVO diagnosed at a tertiary infectious diseases referral centre in the Region of Southern Denmark between 2009 and 2022. Incidence rates (IRs) per 100,000 person-years (PY) were calculated using regional population data and compared across three calendar periods (2009-2013, 2014-2018, 2019-2022). Temporal changes in clinical characteristics, microbiology, diagnostic strategies, and outcomes were assessed. RESULTS: In total, 1,017 patients were included. The crude IR increased from 4.7 per 100,000 PY in 2009-2013 to 11.0 in 2019-2022, with the largest increase among patients aged >/=70 years. Mean age and comorbidity burden rose over time. Pain was common, fever was often absent, and neurological deficits occurred in 33.5% (n = 341). Postsurgical infection was the most frequent primary focus, and concomitant endocarditis occurred in 8.3% (n = 84). A microbiological diagnosis was established in 64.8% (n = 635) of cases, most commonly Staphylococcus aureus. Use of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography ([(18)F]FDG-PET/CT) increased over time. Median hospital stay remained 33 days. One-year mortality increased from 9.5% to 18.2%, while relapse declined, resulting in a stable composite risk of death or relapse (20.7%). CONCLUSIONS: The incidence of PVO increased markedly from 2009 to 2022, predominantly in older patients with comorbidities. Despite improved diagnostics, microbiologically-negative cases remain frequent. Mortality remained high and increased over time. FAU - Lindvig, Susan Olaf AU - Lindvig SO AUID- ORCID: 0000-0002-7488-2830 AD - Department of Infectious Diseases, Odense University Hospital, Odense, Denmark. AD - Department of Clinical Research, University of Southern Denmark, Odense, Denmark. FAU - Kehrer, Michala AU - Kehrer M AUID- ORCID: 0000-0002-8671-3188 AD - Department of Infectious Diseases, Odense University Hospital, Odense, Denmark. AD - Department of Clinical Research, University of Southern Denmark, Odense, Denmark. FAU - Petersen, Inge AU - Petersen I AUID- ORCID: 0000-0001-8057-8336 AD - Department of Infectious Diseases, Odense University Hospital, Odense, Denmark. AD - Department of Clinical Research, University of Southern Denmark, Odense, Denmark. FAU - Hess, Soren AU - Hess S AUID- ORCID: 0000-0003-1249-133X AD - Department of Clinical Research, University of Southern Denmark, Odense, Denmark. AD - Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark. FAU - Theilgaard, Zahra Persson AU - Theilgaard ZP AUID- ORCID: 0009-0001-9217-3632 AD - Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. AD - Department of Internal Medicine, Infectious Diseases Unit, Zealand University Hospital, Roskilde, Denmark. FAU - Rosenvinge, Flemming Schonning AU - Rosenvinge FS AUID- ORCID: 0000-0003-2129-328X AD - Department of Clinical Microbiology, Odense University Hospital, Odense, Denmark. AD - Research Unit of Clinical Microbiology, University of Southern Denmark, Odense, Denmark. FAU - Johansen, Isik Somuncu AU - Johansen IS AUID- ORCID: 0000-0002-2189-9823 AD - Department of Infectious Diseases, Odense University Hospital, Odense, Denmark. AD - Department of Clinical Research, University of Southern Denmark, Odense, Denmark. LA - eng PT - Journal Article DEP - 20261021 PL - England TA - Ann Med JT - Annals of medicine JID - 8906388 SB - IM MH - Humans MH - Denmark/epidemiology MH - Female MH - *Osteomyelitis/epidemiology/microbiology/diagnosis MH - Retrospective Studies MH - Incidence MH - Aged MH - Male MH - Middle Aged MH - Adult MH - Aged, 80 and over MH - *Spinal Diseases/epidemiology/microbiology PMC - PMC13689801 OAB - The incidence of pyogenic vertebral osteomyelitis increased substantially over the 14-year study period, particularly in an ageing and increasingly comorbid population. Patients presented with signs of more advanced disease despite shorter symptom duration, while the persistently high proportion of microbiologically negative cases underscored ongoing diagnostic challenges. Sustained mortality and long-term pain highlight the considerable burden of PVO and the need for improved diagnostic pathways, risk stratification, and treatment strategies. OABL- eng OTO - NOTNLM OT - Pyogenic vertebral osteomyelitis OT - cohort OT - epidemiology OT - incidence OT - mortality OT - temporal trends COIS- No potential conflict of interest was reported by the author(s). EDAT- 2026/10/22 13:25 MHDA- 2026/10/22 13:26 PMCR- 2026/10/21 CRDT- 2026/10/22 08:38 PHST- 2026/10/22 13:26 [medline] PHST- 2026/10/22 13:25 [pubmed] PHST- 2026/10/22 08:38 [entrez] PHST- 2026/10/21 00:00 [pmc-release] AID - 2738249 [pii] AID - 10.1080/07853890.2026.2738249 [doi] PST - ppublish SO - Ann Med. 2026 Dec;58(1):2738249. doi: 10.1080/07853890.2026.2738249. Epub 2026 Oct 21. PMID- 42899333 OWN - NLM STAT- MEDLINE DCOM- 20261020 LR - 20261020 IS - 1938-2715 (Electronic) IS - 1049-9091 (Linking) VI - 43 IP - 12 DP - 2026 Dec TI - Enhancing Palliative Care Integration in the Cardiac Surgical Intensive Care Unit: A Multidisciplinary Quality Improvement Project. PG - 1297-1304 LID - 10.1177/10499091251387260 [doi] AB - ObjectiveThe rate of unmet palliative care (PC) needs is high in critical care areas, especially in the surgical patient population, where PC involvement is notoriously late in the patient's clinical progression. This quality improvement project aimed to evaluate the ability of education, workflow delineation, and an evidence-based assessment tool to improve the integration of PC in a cardiac surgical intensive care unit (TICU).MethodsThis 12-week project utilized a pre-post intervention design to improve PC integration in a 16-bed TICU that serves cardiac, vascular and thoracic surgical, critical care patients. The intervention included education, workflow delineation, and an evidence-based frailty assessment (FA) implementation. PC consultation rate, advance care planning (ACP) note completion rate, and FA completion rate were measured to assess the feasibility and impact of this intervention on PC integration.ResultsA total of 313 patients were enrolled in this project. There was a 53.5% increase in palliative care consultation (P = 0.16), however the ACP note completion rate remained unchanged. The rate of FA completion rose from 0% to 30.4% (P < 0.0001).ConclusionFA is important in the setting of critical care, surgical patients. The outcomes of this project were similar to those of the existing literature, further revealing that ICUs are challenging care settings in which to connect patients with PC for the first time. Future studies on the effects of FA in the cardiac surgical patient population are warranted to find the most appropriate settings for assessment and associated interventions based on identifying a patient's frailty. FAU - Schiano, Crystal Hope Bennett AU - Schiano CHB AUID- ORCID: 0000-0003-2238-4263 AD - UNC Health, Chapel Hill, NC, USA. LA - eng PT - Journal Article DEP - 20251014 PL - United States TA - Am J Hosp Palliat Care JT - The American journal of hospice & palliative care JID - 9008229 SB - IM MH - Humans MH - *Palliative Care/organization & administration MH - *Quality Improvement/organization & administration MH - Female MH - Aged MH - Male MH - *Intensive Care Units/organization & administration MH - Advance Care Planning/organization & administration MH - Middle Aged MH - Aged, 80 and over MH - *Cardiac Surgical Procedures MH - *Critical Care/organization & administration MH - Frailty/diagnosis OTO - NOTNLM OT - cardiac surgery OT - critical care OT - frailty assessment OT - palliative care COIS- Declaration of Conflicting InterestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2026/10/20 17:34 MHDA- 2026/10/20 17:35 CRDT- 2026/10/20 13:28 PHST- 2026/10/20 17:35 [medline] PHST- 2026/10/20 17:34 [pubmed] PHST- 2026/10/20 13:28 [entrez] AID - 10.1177/10499091251387260 [doi] PST - ppublish SO - Am J Hosp Palliat Care. 2026 Dec;43(12):1297-1304. doi: 10.1177/10499091251387260. Epub 2025 Oct 14. PMID- 42897918 OWN - NLM STAT- Publisher LR - 20261020 IS - 1308-4488 (Electronic) IS - 1016-5169 (Linking) DP - 2026 Oct 19 TI - Effects of ChatGPT Use on Self-care Cardiac Rehabilitation Adherence in Patients with Coronary Artery Disease. LID - 10.5543/tkda.2026.31777 [doi] AB - OBJECTIVE: To clarify the possible effects of ChatGPT use on self-care cardiac rehabilitation (CR) adherence in patients with coronary artery disease (CAD). METHOD: Patients in the ChatGPT group participated in a standard cardiac rehabilitation program supplemented with personalized digital support via ChatGPT (n=48). The control group participated in conventional cardiac rehabilitation only, without AI-based support (n=48). Both groups completed a 6-month structured rehabilitation program supervised by a multidisciplinary team. Baseline demographic and clinical data, patient satisfaction assessed using a Likert scale, physical activity levels assessed using the International Physical Activity Questionnaire (IPAQ), and metabolic equivalent of task (MET) values were recorded. RESULTS: The postrehabilitation MET score was 1537 in the ChatGPT group and 1413 in the control group (P = 0.001). Similarly, the change in MET score after rehabilitation was greater in the ChatGPT group than in the control group (1029 vs. 875, P = 0.001). SF-36 parameters, including physical functioning, role-physical, mental health, bodily pain, and general health, were significantly higher in the ChatGPT group than in the control group (P < 0.05 for all). Program compliance was higher in the ChatGPT group than in the control group (91.7% vs. 75.0%, P = 0.028). Patient satisfaction was also higher in the ChatGPT group (4.5 vs. 3.8, P = 0.001). CONCLUSION: ChatGPT use during CR was associated with higher patient compliance rates. Moreover, ChatGPT-supported CR was associated with higher physical activity levels, greater patient satisfaction, and better selected quality-of-life scores. FAU - Ift I, Hac AU - Ift I H AD - Department of Cardiology, Beykent University, Istanbul, T��rkiye. FAU - Yet T, Do An AU - Yet T DA AD - Department of Cardiovascular Surgery, Beykent University, Istanbul, T��rkiye. LA - eng PT - Journal Article TT - Koroner Arter Hastalar��nda ��z Bak��m Temelli Kardiyak Rehabilitasyon Uyumunda ChatGPT Kullan��m��n��n Etkileri. DEP - 20261019 PL - Turkey TA - Turk Kardiyol Dern Ars JT - Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir JID - 9426239 SB - IM EDAT- 2026/10/20 05:30 MHDA- 2026/10/20 05:30 CRDT- 2026/10/20 02:53 PHST- 2026/10/20 05:30 [medline] PHST- 2026/10/20 05:30 [pubmed] PHST- 2026/10/20 02:53 [entrez] AID - 10.5543/tkda.2026.31777 [doi] PST - aheadofprint SO - Turk Kardiyol Dern Ars. 2026 Oct 19. doi: 10.5543/tkda.2026.31777. PMID- 42896218 OWN - NLM STAT- Publisher LR - 20261019 IS - 1477-111X (Electronic) IS - 0267-6591 (Linking) DP - 2026 Oct 19 TI - Optimal timing of surgical intervention for post-myocardial infarction ventricular septal rupture: A comprehensive evidence review. PG - 2676591261499955 LID - 10.1177/02676591261499955 [doi] AB - BackgroundVentricular septal rupture (VSR) is a rare but devastating complication of acute myocardial infarction, historically associated with extremely high mortality rates. The optimal timing of surgical repair-balancing the risks of operating on friable, acute necrosis against the dangers of progressive cardiogenic shock during a waiting period-remains a central clinical dilemma.MethodsA systematic narrative review was conducted following PRISMA guidelines. PubMed/MEDLINE, Embase, and Cochrane Library databases were searched from 2000 to 2024 for studies comparing early (7 days) surgical repair of post-MI VSR. Data were extracted on patient characteristics, mechanical circulatory support (MCS) use, surgical techniques, and clinical outcomes, including operative mortality, reoperation rates, and long-term survival.ResultsEvidence from contemporary observational studies confirms that delayed surgical repair is associated with significantly lower operative mortality compared to early repair, primarily due to superior tissue integrity and lower rates of residual shunt. However, this mortality gap has substantially narrowed in the contemporary era with routine use of advanced MCS, particularly veno-arterial extracorporeal membrane oxygenation (VA-ECMO) and Impella devices. These technologies enable hemodynamic stabilization, transforming early repair from a salvage procedure to a more controlled intervention. Modern management has evolved from a rigid temporal dichotomy to a patient-tailored strategy emphasizing immediate stabilization, risk stratification, and selective MCS bridging to the optimal surgical window.ConclusionWhile delayed repair remains preferred for hemodynamically stable patients, early repair supported by advanced MCS represents a viable and often necessary strategy for patients with refractory shock. The decision paradigm has shifted toward "stabilize, support, then repair," requiring multidisciplinary heart team collaboration. Future directions include standardized MCS protocols, validated risk scores, and exploration of hybrid percutaneous-surgical approaches to further improve outcomes for this high-risk population. FAU - Rasheed, Irfan AU - Rasheed I AUID- ORCID: 0009-0001-7266-1786 AD - Cardiothoracic Surgery Department, St.Bartholomew's Hospital, London, UK. RINGGOLD: 112003 FAU - Arif, Muhammad AU - Arif M AD - Cardiothoracic Surgery Department, St.Bartholomew's Hospital, London, UK. RINGGOLD: 112003 FAU - Kolvekar, Shyam Sunder AU - Kolvekar SS AD - Cardiothoracic Surgery Department, St.Bartholomew's Hospital, London, UK. RINGGOLD: 112003 LA - eng PT - Journal Article PT - Review DEP - 20261019 PL - England TA - Perfusion JT - Perfusion JID - 8700166 SB - IM OTO - NOTNLM OT - cardiogenic shock OT - mechanical circulatory support OT - myocardial infarction OT - operative timing OT - surgical repair OT - ventricular septal rupture EDAT- 2026/10/19 23:30 MHDA- 2026/10/19 23:30 CRDT- 2026/10/19 17:33 PHST- 2026/10/19 23:30 [medline] PHST- 2026/10/19 23:30 [pubmed] PHST- 2026/10/19 17:33 [entrez] AID - 10.1177/02676591261499955 [doi] PST - aheadofprint SO - Perfusion. 2026 Oct 19:2676591261499955. doi: 10.1177/02676591261499955. PMID- 42892972 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20261018 LR - 20261019 IS - 2590-0889 (Electronic) IS - 2590-0889 (Linking) VI - 8 IP - 4 DP - 2026 Dec TI - Reducing surgical site infections among paediatric patients undergoing cardiac surgery: a multi-disciplinary quality improvement initiative. PG - 100581 LID - 10.1016/j.infpip.2026.100581 [doi] LID - 100581 AB - INTRODUCTION: Sternal wound surgical site infections (SSIs) in paediatric cardiac surgery are associated with significant morbidity, prolonged hospitalization, and elevated healthcare burden. In response to baseline surveillance at our cardiac centre, between July and December 2024 13 SSIs were identified among 128 open-heart paediatric cardiac surgeries (10.2%), exceeding national and international benchmarks; a structured quality-improvement initiative was implemented to reduce SSI rates and enhance SSI prevention practices. METHODS: An evidence-based SSI-prevention bundle that included preoperative chlorhexidine gluconate (CHG) preparation, optimal antibiotic selection, dosing, timing, and redosing, standard wound care, sterile delayed sternal closure protocols, and improved environmental cleaning was implemented from January to December 2025 a by a multi-disciplinary team. Plan-Do-Study-Act (PDSA) cycles, statistical process control charts, compliance audits, and mixed qualitative feedback were used to measure impacts. The measures were the SSI rate and bundle adherence reliability. Essential elements include strengthening adherence to perioperative bundle components across all phases; a sterile delayed sternal closure setup; and intensified environmental cleaning consistent with national guidelines, supported by staff education, real-time process and outcome monitoring with feedback, electronic health record prompts, daily audits, and ongoing staff and leadership engagement. RESULTS: During the baseline period (July-December 2024), 13 SSIs occurred among 128 paediatric cardiac surgeries (10.2%). After bundle implementation (January-December 2025), eight SSIs were identified among 357 procedures (2.2%); representing a relative reduction of more than 75% in the overall SSI rate with considerable improvements seen in superficial, deep, and delayed-sternal-closure-related infections. Bundle adherence increased from a baseline mean of 37% to 77%, with sustained compliance above 80% from June 2025 onwards. CONCLUSION: A comprehensive, multi-disciplinary SSI-prevention care bundle was associated with reduced paediatric cardiac SSIs and improved care reliability. The approach is sustainable, adaptable to other contexts with appropriate modifications, and provides a practical model for enhancing surgical safety in high-risk paediatric groups. CI - (c) 2026 The Authors. FAU - Alnahdi, Faizah Amer AU - Alnahdi FA AD - Prince Sultan Cardiac Centre, Riyadh, Saudi Arabia. FAU - Alamro, Sahar Abdullah AU - Alamro SA AD - Prince Sultan Cardiac Centre, Riyadh, Saudi Arabia. FAU - Alanezi, Tareq Jamal AU - Alanezi TJ AD - Prince Sultan Cardiac Centre, Riyadh, Saudi Arabia. FAU - Alaklabi, Mohammed AU - Alaklabi M AD - Prince Sultan Cardiac Centre, Riyadh, Saudi Arabia. FAU - Elshaib, Lubna Abdulrahman AU - Elshaib LA AD - Prince Sultan Cardiac Centre, Riyadh, Saudi Arabia. FAU - Alabuod, Eman Abdullah AU - Alabuod EA AD - Prince Sultan Cardiac Centre, Riyadh, Saudi Arabia. FAU - Albishi, Najla Najim AU - Albishi NN AD - Prince Sultan Cardiac Centre, Riyadh, Saudi Arabia. FAU - Althomairi, Abdulmohsen Ali AU - Althomairi AA AD - Prince Sultan Cardiac Centre, Riyadh, Saudi Arabia. FAU - Alkhuraisi, Fadwa Fahad AU - Alkhuraisi FF AD - Prince Sultan Cardiac Centre, Riyadh, Saudi Arabia. LA - eng PT - Journal Article DEP - 20260826 PL - England TA - Infect Prev Pract JT - Infection prevention in practice JID - 101777928 PMC - PMC13675731 OTO - NOTNLM OT - Paediatric cardiac surgery OT - Quality improvement OT - Surgical site infection COIS- The authors declare no conflicts of interest related to this work. EDAT- 2026/10/18 05:38 MHDA- 2026/10/18 05:39 PMCR- 2026/08/26 CRDT- 2026/10/18 04:52 PHST- 2026/01/27 00:00 [received] PHST- 2026/08/04 00:00 [accepted] PHST- 2026/10/18 05:39 [medline] PHST- 2026/10/18 05:38 [pubmed] PHST- 2026/10/18 04:52 [entrez] PHST- 2026/08/26 00:00 [pmc-release] AID - S2590-0889(26)00075-2 [pii] AID - 100581 [pii] AID - 10.1016/j.infpip.2026.100581 [doi] PST - epublish SO - Infect Prev Pract. 2026 Aug 26;8(4):100581. doi: 10.1016/j.infpip.2026.100581. eCollection 2026 Dec. PMID- 42888459 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20261017 LR - 20261020 IS - 2731-6203 (Electronic) IS - 2731-6203 (Linking) VI - 5 IP - 1 DP - 2026 Oct 16 TI - Revascularize first, resect second: off-pump excision of giant SVG pseudoaneurysm. LID - 10.1186/s44215-026-00273-2 [doi] LID - 46 AB - BACKGROUND: Saphenous vein graft pseudoaneurysm is a rare late complication of coronary artery bypass grafting. Management is particularly challenging when the pseudoaneurysm-bearing graft remains an active source of myocardial perfusion. A 67-year-old man presented 33 years after coronary artery bypass grafting with progressive exertional dyspnea. Echocardiography demonstrated a large mass abutting the right atrium. Computed tomography angiography showed a 10 x 7 x 6 cm partially thrombosed pseudoaneurysm arising from the saphenous vein graft to the right posterior descending artery, with right atrial compression. Coronary angiography demonstrated pseudoaneurysm filling from the graft, chronic native right coronary artery occlusion, patent mammary grafts, and severe proximal graft stenosis. The heart team considered transcatheter exclusion unsuitable because of the distal entry site, calcific graft disease, and ongoing distal right coronary dependence. Redo off-pump saphenous vein grafting to the right posterior descending artery was performed before old-graft ligation. After transit-time flow measurement confirmed new-graft function, the pseudoaneurysm-bearing graft was ligated proximally and distally and excised en bloc. The patient was discharged on postoperative day 5. Three-month computed tomography angiography demonstrated a patent new graft without residual pseudoaneurysm. DISCUSSION: This case highlights that graft patency and myocardial dependence should be defined before exclusion of a saphenous vein graft pseudoaneurysm. In selected patients, revascularization before graft sacrifice can be performed off pump, avoiding cardiopulmonary bypass while preserving myocardial perfusion. CI - (c) 2026. The Author(s). FAU - Rakesh, Aadhya AU - Rakesh A AD - Department of Cardiovascular Surgery, Mayo Clinic, 200 First St SW, Rochester, MN, USA. FAU - Saran, Nishant AU - Saran N AUID- ORCID: 0000-0002-2204-9775 AD - Department of Cardiovascular Surgery, Mayo Clinic, 200 First St SW, Rochester, MN, USA. Saran.nishant@mayo.edu. LA - eng PT - Journal Article DEP - 20261016 PL - England TA - Gen Thorac Cardiovasc Surg Cases JT - General thoracic and cardiovascular surgery cases JID - 9918900337406676 PMC - PMC13673732 OTO - NOTNLM OT - Off-pump CABG OT - Redo sternotomy OT - Saphenous vein graft pseudoaneurysm COIS- Declarations. Ethics approval and consent to participate: At Mayo Clinic, this single-patient case report does not constitute human subjects research and therefore did not require Institutional Review Board approval. Written patient consent for publication was obtained. EDAT- 2026/10/17 05:34 MHDA- 2026/10/17 05:35 PMCR- 2026/10/16 CRDT- 2026/10/17 00:06 PHST- 2026/06/21 00:00 [received] PHST- 2026/08/08 00:00 [accepted] PHST- 2026/10/17 05:35 [medline] PHST- 2026/10/17 05:34 [pubmed] PHST- 2026/10/17 00:06 [entrez] PHST- 2026/10/16 00:00 [pmc-release] AID - 10.1186/s44215-026-00273-2 [pii] AID - 273 [pii] AID - 10.1186/s44215-026-00273-2 [doi] PST - epublish SO - Gen Thorac Cardiovasc Surg Cases. 2026 Oct 16;5(1):46. doi: 10.1186/s44215-026-00273-2. PMID- 42886116 OWN - NLM STAT- Publisher LR - 20261016 IS - 2666-0849 (Electronic) IS - 2666-0849 (Linking) DP - 2026 Oct 16 TI - Cardiac CT Planning of Surgical Treatment of Multiple Coronary-Pulmonary Fistulas With Chronic Coronary Occlusion. PG - 110768 LID - S2666-0849(26)03928-8 [pii] LID - 10.1016/j.jaccas.2026.110768 [doi] AB - ANATOMY: Coronary fistulas are rare congenital anomalies that may lead to myocardial ischemia through a coronary steal phenomenon, particularly when associated with coronary artery disease. PATHOLOGY: We describe a case of cardiac computed tomography angiography (CCTA) diagnosis of multiple coronary-pulmonary artery fistulas associated with chronic occlusion of the right coronary artery, in a 66-year-old man presenting with unstable angina. IMAGING CORRELATION: CCTA and echocardiography were used for evaluation of procedural planning in an acute setting. TREATMENT: The fistulas were effectively treated with surgical exclusion combined with coronary artery bypass grafting, yielding an optimal result on the postoperative computed tomography scan. TAKE-HOME MESSAGES: Coronary fistulas are rare but important causes of myocardial ischemia. This case highlights the importance of CCTA definition of anatomical complexity and multidisciplinary decision-making in the management of complex coronary fistulas. Surgical repair remains the preferred approach in complex anatomy cases or associated coronary artery disease requiring revascularization. CI - Copyright (c) 2026 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Nicoli, Flavia AU - Nicoli F AD - Cardiology Unit, Cardiovascular Department, Humanitas Gavazzeni, Bergamo, Italy. Electronic address: flavia_nicoli@yahoo.it. FAU - Giroletti, Laura AU - Giroletti L AD - Department of Cardiovascular Surgery and Division of Robotic and Mini-Invasive Cardiac Surgery, Bergamo, Italy. FAU - Spira, Giuseppe AU - Spira G AD - Department of Cardiovascular Surgery and Division of Robotic and Mini-Invasive Cardiac Surgery, Bergamo, Italy. FAU - Collaku, Elona AU - Collaku E AD - Radiology Unit, Cardiovascular Department, Bergamo, Italy. FAU - Mollace, Rocco AU - Mollace R AD - Cardiology Unit, Cardiovascular Department, Humanitas Gavazzeni, Bergamo, Italy. FAU - Agati, Giorgio AU - Agati G AD - Radiology Unit, Cardiovascular Department, Bergamo, Italy. FAU - Zanello, Alessandro AU - Zanello A AD - Radiology Unit, Cardiovascular Department, Bergamo, Italy. FAU - Agnino, Alfonso AU - Agnino A AD - Department of Cardiovascular Surgery and Division of Robotic and Mini-Invasive Cardiac Surgery, Bergamo, Italy. FAU - Panisi, Paolo Giulio Giovanni AU - Panisi PGG AD - Department of Cardiovascular Surgery and Division of Robotic and Mini-Invasive Cardiac Surgery, Bergamo, Italy. FAU - Bertella, Erika AU - Bertella E AD - Cardiology Unit, Cardiovascular Department, Humanitas Gavazzeni, Bergamo, Italy. LA - eng PT - Journal Article DEP - 20261016 PL - Netherlands TA - JACC Case Rep JT - JACC. Case reports JID - 101757292 OTO - NOTNLM OT - computed tomography OT - imaging OT - myocardial ischemia OT - myocardial revascularization COIS- Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2026/10/16 11:38 MHDA- 2026/10/16 11:38 CRDT- 2026/10/16 10:32 PHST- 2026/06/08 00:00 [received] PHST- 2026/08/20 00:00 [revised] PHST- 2026/09/16 00:00 [accepted] PHST- 2026/10/16 11:38 [medline] PHST- 2026/10/16 11:38 [pubmed] PHST- 2026/10/16 10:32 [entrez] AID - S2666-0849(26)03928-8 [pii] AID - 10.1016/j.jaccas.2026.110768 [doi] PST - aheadofprint SO - JACC Case Rep. 2026 Oct 16:110768. doi: 10.1016/j.jaccas.2026.110768. PMID- 42884458 OWN - NLM STAT- MEDLINE DCOM- 20261016 LR - 20261020 IS - 1424-8220 (Electronic) IS - 1424-8220 (Linking) VI - 26 IP - 19 DP - 2026 Oct 2 TI - MDT-HMTL: A Multidimensional Temporal Hierarchical Multi-Task Learning Framework for Myocardial Infarction Detection and State Classification Using PPG Signals. LID - 10.3390/s26196259 [doi] LID - 6259 AB - Continuous assessment of myocardial infarction (MI) using photoplethysmography (PPG) signals has potential for out-of-hospital cardiovascular monitoring, yet conventional single-channel and short-window approaches have limitations in capturing complex hemodynamic variations and dynamic disease-state transitions. To address these limitations, we propose MDT-HMTL, a Multidimensional Temporal Hierarchical Multi-Task Learning framework tailored for simultaneous MI detection and disease-state classification. By integrating multi-channel physiological representations with hierarchical temporal modeling, MDT-HMTL captures local morphological characteristics and longer-range temporal dependencies within a unified multi-task architecture. Evaluation on the MIMIC-III clinical database achieved an average area under the ROC curve (AUC) of 0.908 and an overall accuracy of 86.4%. Furthermore, ablation studies demonstrated the contributions of multi-dimensional representation learning and hierarchical temporal modeling to the overall performance. The proposed framework demonstrates the feasibility of PPG-based MI detection and longitudinal disease-state assessment, highlighting its potential for future non-invasive and wearable-compatible cardiovascular monitoring. FAU - Hui, Hui AU - Hui H AD - College of Bioengineering, Chongqing University, Chongqing 400030, China. FAU - Wang, Jun AU - Wang J AD - College of Bioengineering, Chongqing University, Chongqing 400030, China. FAU - Cheng, Jinxiu AU - Cheng J AD - College of Bioengineering, Chongqing University, Chongqing 400030, China. FAU - Zhao, Huimeng AU - Zhao H AD - College of Bioengineering, Chongqing University, Chongqing 400030, China. FAU - Ji, Zhong AU - Ji Z AD - College of Bioengineering, Chongqing University, Chongqing 400030, China. AD - Key Laboratory of Biorheological Science and Technology, Chongqing University, Ministry of Education, Chongqing 400044, China. LA - eng GR - 81971700/National Natural Science Foundation of China/ GR - CYB823073/Graduate Research and Innovation Foundation of Chongqing/ PT - Journal Article DEP - 20261002 PL - Switzerland TA - Sensors (Basel) JT - Sensors (Basel, Switzerland) JID - 101204366 SB - IM MH - *Myocardial Infarction/diagnosis/physiopathology MH - Humans MH - *Photoplethysmography/methods MH - *Machine Learning MH - Signal Processing, Computer-Assisted MH - Algorithms MH - Monitoring, Physiologic/methods MH - ROC Curve PMC - PMC13667647 OTO - NOTNLM OT - adaptive feature extraction OT - derivative signals OT - machine learning OT - myocardial infarction OT - photoplethysmography (PPG) OT - wearable health monitoring COIS- The authors declare no conflicts of interest. EDAT- 2026/10/16 05:33 MHDA- 2026/10/16 05:34 PMCR- 2026/10/02 CRDT- 2026/10/16 01:09 PHST- 2026/08/22 00:00 [received] PHST- 2026/09/28 00:00 [revised] PHST- 2026/09/30 00:00 [accepted] PHST- 2026/10/16 05:34 [medline] PHST- 2026/10/16 05:33 [pubmed] PHST- 2026/10/16 01:09 [entrez] PHST- 2026/10/02 00:00 [pmc-release] AID - s26196259 [pii] AID - sensors-26-06259 [pii] AID - 10.3390/s26196259 [doi] PST - epublish SO - Sensors (Basel). 2026 Oct 2;26(19):6259. doi: 10.3390/s26196259. PMID- 42882403 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20261016 LR - 20261020 IS - 2075-4418 (Print) IS - 2075-4418 (Electronic) IS - 2075-4418 (Linking) VI - 16 IP - 19 DP - 2026 Oct 8 TI - Percutaneous Removal of a Tricuspid Valve Vegetation Using the AngioVac System in a Young Woman Who Injects Drugs. LID - 10.3390/diagnostics16193248 [doi] LID - 3248 AB - Right-sided infective endocarditis (RSIE) is a difficult clinical problem, particularly among people who inject drugs (PWID), in whom large tricuspid vegetations may be complicated by severe regurgitation and septic pulmonary embolization. We describe a woman in her twenties with tricuspid valve infective endocarditis and bilateral cavitary pulmonary lesions consistent with septic emboli, in whom the vegetation enlarged from 18 x 11 mm to 18 x 20 mm and tricuspid regurgitation (TR) progressed from moderate to severe (vena contracta 12 mm, effective regurgitant orifice area 1.5 cm(2), regurgitant volume 110 mL) over ten days of empirical anti-staphylococcal therapy. Surgery was considered by an individualized Heart Team assessment of the complete clinical course, but the patient declined open-heart surgery. After multidisciplinary Heart Team discussion, transesophageal echocardiography (TEE)-guided percutaneous aspiration with the AngioVac system was undertaken as an individualized debulking and source-control strategy, not as an equivalent alternative to surgery. Under general anesthesia, bilateral femoral venous access was obtained and seven aspiration passes retrieved four large vegetation fragments, with no residual intracardiac mass on completion TEE. Culture of the aspirated material yielded Serratia marcescens and Escherichia coli, neither of which was covered by the empirical regimen, which was replaced by susceptibility-guided ciprofloxacin and co-trimoxazole; ceftazidime was added when Pseudomonas aeruginosa was later isolated from blood. Residual regurgitation arose from a flail, prolapsing posterior leaflet rather than from mass effect-a finding that may reflect pre-existing infective leaflet destruction, leaflet injury during aspiration, or both-and was quantitatively reduced three to four weeks after the procedure (vena contracta 6 mm, effective regurgitant orifice area 0.55 cm(2), regurgitant volume 36 mL); at six months it was moderate-to-severe and stable, with preserved right ventricular function (TAPSE 30 mm) and no recurrent vegetation. This case supports a potential diagnostic and therapeutic role for AngioVac-assisted debulking as an individualized adjunct in highly selected patients with RSIE who refuse surgery, with the caveat that aspiration reduces vegetation and embolic burden without correcting the underlying valvular lesion. FAU - Skowerski, Tomasz AU - Skowerski T AUID- ORCID: 0000-0003-1149-7457 AD - Department of Cardiology, School of Health Sciences, Medical University of Silesia, 40-6340-6355 Katowice, Poland. FAU - Kulach, Andrzej AU - Kulach A AUID- ORCID: 0000-0002-3140-1806 AD - Department of Cardiology, School of Health Sciences, Medical University of Silesia, 40-6340-6355 Katowice, Poland. FAU - Grabka, Marek AU - Grabka M AD - First Department of Cardiology, School of Medicine in Katowice, Medical University of Silesia, 40-6340-6355 Katowice, Poland. FAU - Pysz, Piotr AU - Pysz P AD - Division of Cardiology and Structural Heart Diseases, School of Medicine in Katowice, Medical University of Silesia, 40-6340-6355 Katowice, Poland. FAU - Kudzia, Paulina AU - Kudzia P AD - Department of Cardiology, School of Health Sciences, Medical University of Silesia, 40-6340-6355 Katowice, Poland. FAU - Adamczyk-Filipek, Eliza AU - Adamczyk-Filipek E AD - Department of Cardiology, School of Health Sciences, Medical University of Silesia, 40-6340-6355 Katowice, Poland. FAU - Gocol, Radoslaw AU - Gocol R AD - Department of Cardiac Surgery, School of Medicine in Katowice, Medical University of Silesia, 40-6340-6355 Katowice, Poland. FAU - Smolka, Grzegorz AU - Smolka G AD - Department of Cardiology, School of Health Sciences, Medical University of Silesia, 40-6340-6355 Katowice, Poland. LA - eng PT - Journal Article DEP - 20261008 PL - Switzerland TA - Diagnostics (Basel) JT - Diagnostics (Basel, Switzerland) JID - 101658402 PMC - PMC13664219 OTO - NOTNLM OT - AngioVac OT - infective endocarditis OT - people who inject drugs OT - percutaneous mechanical aspiration OT - septic pulmonary embolism OT - transesophageal echocardiography OT - tricuspid regurgitation OT - tricuspid valve COIS- The authors declare no conflicts of interest. EDAT- 2026/10/16 05:33 MHDA- 2026/10/16 05:34 PMCR- 2026/10/08 CRDT- 2026/10/16 01:03 PHST- 2026/07/23 00:00 [received] PHST- 2026/09/29 00:00 [revised] PHST- 2026/09/30 00:00 [accepted] PHST- 2026/10/16 05:34 [medline] PHST- 2026/10/16 05:33 [pubmed] PHST- 2026/10/16 01:03 [entrez] PHST- 2026/10/08 00:00 [pmc-release] AID - diagnostics16193248 [pii] AID - diagnostics-16-03248 [pii] AID - 10.3390/diagnostics16193248 [doi] PST - epublish SO - Diagnostics (Basel). 2026 Oct 8;16(19):3248. doi: 10.3390/diagnostics16193248. PMID- 42882311 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20261016 LR - 20261020 IS - 2075-4418 (Print) IS - 2075-4418 (Electronic) IS - 2075-4418 (Linking) VI - 16 IP - 19 DP - 2026 Sep 28 TI - Curriculum-Based Deep Learning for Automated Segmental Left Ventricular Hypertrophy Classification Using Short-Axis Echocardiography. LID - 10.3390/diagnostics16193157 [doi] LID - 3157 AB - Background: Accurate detection and classification of segmental left ventricular hypertrophy (LVH) are challenging due to rib and reverberation artifacts in two-dimensional short-axis (2D-SAX) echocardiography view. These artifacts lead to ambiguity in the boundaries of the myocardial region. Existing artificial intelligence techniques focus on global LVH detection compared to segmental LVH classification. Methodology: To solve the abovementioned problem, a curriculum-based left ventricular hypertrophy deep learning (LVH-DL) framework is proposed for segmental LVH classification. The proposed framework was tested with 2000 images of segmental LVH, which consists of (a) apical-423, (b) basal-382, (c) mid-ventricular-349, (d) diffuse-453, and (e) normal-393. The curriculum-based deep learning model consists of proposed algorithms such as (i) preprocessing of Mountaineering-Team-Based Optimization Deep Denoised Convolutional Neural Network (MTBO-DnCNN) for removing artifacts and enhancing the boundaries, (ii) segmentation of modified active contour segmentation (MACS) algorithm accurately extracting the myocardium region from the background, and (iii) classification of curriculum-based ConvNeXt-V2 model classifying segmental LVH using inter-channel features such as valvular structures and chamber size from the segmented myocardial region. Results: The proposed LVH-DL framework achieves a classification accuracy of about (a) 96.5% for apical, (b) 95% for basal, (c) 95.8% for mid-ventricular, (d) 97.2% for diffuse, and (e) 95% for normal. Conclusions: Thus, Thus, the proposed LVH-DL framework acts as a decision support tool for early identification of segmental LVH. FAU - Periyasamy, Rajeswari AU - Periyasamy R AD - Department of Computer Science and Engineering, R.M.D Engineering College, RSM Nagar, Kavaraipettai 601206, India. FAU - Selvaraj, Srinivasan AU - Selvaraj S AD - Department of Computer Science and Engineering, R.M.D Engineering College, RSM Nagar, Kavaraipettai 601206, India. FAU - Pitchaimuthu, Francis Antony Selvi AU - Pitchaimuthu FAS AD - Department of Electrical and Electronics Engineering, R.V.S. College of Engineering, Dindigul 624005, India. FAU - Lucas, Aneesh Euprazia AU - Lucas AE AD - Department of Artificial Intelligence and Data Science, Vel Tech Rangarajan Dr. Sagunthala R&D Institute of Science and Technology, Chennai 600062, India. LA - eng PT - Journal Article DEP - 20260928 PL - Switzerland TA - Diagnostics (Basel) JT - Diagnostics (Basel, Switzerland) JID - 101658402 PMC - PMC13664295 OTO - NOTNLM OT - ConvNeXt-V2 OT - curriculum learning OT - deep learning OT - echocardiography OT - left ventricular hypertrophy OT - myocardial segmentation COIS- The authors declare no conflicts of interest. EDAT- 2026/10/16 05:33 MHDA- 2026/10/16 05:34 PMCR- 2026/09/28 CRDT- 2026/10/16 01:02 PHST- 2026/07/22 00:00 [received] PHST- 2026/09/08 00:00 [revised] PHST- 2026/09/09 00:00 [accepted] PHST- 2026/10/16 05:34 [medline] PHST- 2026/10/16 05:33 [pubmed] PHST- 2026/10/16 01:02 [entrez] PHST- 2026/09/28 00:00 [pmc-release] AID - diagnostics16193157 [pii] AID - diagnostics-16-03157 [pii] AID - 10.3390/diagnostics16193157 [doi] PST - epublish SO - Diagnostics (Basel). 2026 Sep 28;16(19):3157. doi: 10.3390/diagnostics16193157. PMID- 42882018 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20261016 LR - 20261020 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 15 IP - 19 DP - 2026 Sep 29 TI - Clinical Outcomes of Combined TAVR-PCI Versus SAVR-CABG in Patients with Aortic Stenosis and Coronary Artery Disease: A Systematic Review and Meta-Analysis. LID - 10.3390/jcm15197556 [doi] LID - 7556 AB - Background/Objectives: Coronary artery disease coexists with severe aortic stenosis in about half of patients. Surgical aortic valve replacement with coronary artery bypass grafting (SAVR+CABG) is guideline-recommended, but transcatheter aortic valve replacement with percutaneous coronary intervention (TAVR+PCI) is increasingly used. Prior meta-analyses double-counted overlapping populations and did not report randomized evidence separately; we re-examined the comparison after correcting both. Methods: PubMed, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science and ClinicalTrials.gov were searched up to July 2026 for randomized and comparative observational studies, excluding reports with overlapping populations. Outcomes were pooled with random-effects models, stratified by study design, and re-analysed without administrative databases. Certainty was rated with the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Results: Fourteen studies were included (two randomized trials, nine cohorts, three administrative databases), comprising 154,892 patients (28,569 TAVR+PCI; 126,323 SAVR+CABG). TAVR+PCI was associated with lower early mortality (odds ratio (OR) 0.60, 95% confidence interval (CI) 0.44-0.84) and less acute kidney injury (OR 0.34, 0.20-0.57), but greater pacemaker implantation (OR 2.18, 1.93-2.46) and major vascular complications (OR 3.38, 1.65-6.89). Stroke, myocardial infarction and one-year mortality (OR 0.80, 0.58-1.10) did not differ; bleeding results were inconsistent (I(2) = 95%). Over 12-72 months, mortality was higher with TAVR+PCI (hazard ratio (HR) 1.38, 1.28-1.49; nine observational studies), unchanged without the largest cohort. Administrative databases drove heterogeneity but not the direction of any early outcome. Certainty was moderate for pacemaker implantation and low or very low otherwise; randomized data were too limited to confirm these findings. Conclusions: In predominantly observational evidence, TAVR+PCI was associated with lower early risk but higher mortality over longer follow-up. This trade-off supports individualized Heart Team decisions rather than the superiority of either strategy. Adequately powered randomized trials with long-term follow-up are needed. FAU - Rodriguez Mejia, Ricardo Antonio AU - Rodriguez Mejia RA AD - https://ror.org/045czjy48Cape Fear Valley Medical Center, Methodist University Cape Fear Valley Health School of Medicine, Fayetteville, NC 28304, USA. FAU - Aldaoud, Mathhar AU - Aldaoud M AD - Department of Cardiology, Faculty of Medicine, https://ror.org/05k89ew48University of Jordan, Amman 11942, Jordan. FAU - Momodu, Ifeanyi AU - Momodu I AD - https://ror.org/045czjy48Cape Fear Valley Medical Center, Methodist University Cape Fear Valley Health School of Medicine, Fayetteville, NC 28304, USA. FAU - Dongol, Merina AU - Dongol M AD - https://ror.org/045czjy48Cape Fear Valley Medical Center, Methodist University Cape Fear Valley Health School of Medicine, Fayetteville, NC 28304, USA. FAU - Feyissa, Girum AU - Feyissa G AD - https://ror.org/045czjy48Cape Fear Valley Medical Center, Methodist University Cape Fear Valley Health School of Medicine, Fayetteville, NC 28304, USA. FAU - Aruogu, Kelechi AU - Aruogu K AD - https://ror.org/045czjy48Cape Fear Valley Medical Center, Methodist University Cape Fear Valley Health School of Medicine, Fayetteville, NC 28304, USA. FAU - Bhatti, Zamaraq M AU - Bhatti ZM AD - https://ror.org/045czjy48Cape Fear Valley Medical Center, Methodist University Cape Fear Valley Health School of Medicine, Fayetteville, NC 28304, USA. FAU - Riaz, Abdul Haseeb AU - Riaz AH AD - https://ror.org/045czjy48Cape Fear Valley Medical Center, Methodist University Cape Fear Valley Health School of Medicine, Fayetteville, NC 28304, USA. FAU - Saleem, Nafisa AU - Saleem N AD - https://ror.org/045czjy48Cape Fear Valley Medical Center, Methodist University Cape Fear Valley Health School of Medicine, Fayetteville, NC 28304, USA. LA - eng PT - Journal Article PT - Review DEP - 20260929 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC13665907 OTO - NOTNLM OT - aortic stenosis OT - coronary artery bypass grafting OT - coronary artery disease OT - meta-analysis OT - percutaneous coronary intervention OT - surgical aortic valve replacement OT - systematic review OT - transcatheter aortic valve replacement COIS- The authors declare no conflicts of interest. EDAT- 2026/10/16 05:33 MHDA- 2026/10/16 05:34 PMCR- 2026/09/29 CRDT- 2026/10/16 01:01 PHST- 2026/08/22 00:00 [received] PHST- 2026/09/21 00:00 [revised] PHST- 2026/09/23 00:00 [accepted] PHST- 2026/10/16 05:34 [medline] PHST- 2026/10/16 05:33 [pubmed] PHST- 2026/10/16 01:01 [entrez] PHST- 2026/09/29 00:00 [pmc-release] AID - jcm15197556 [pii] AID - jcm-15-07556 [pii] AID - 10.3390/jcm15197556 [doi] PST - epublish SO - J Clin Med. 2026 Sep 29;15(19):7556. doi: 10.3390/jcm15197556. PMID- 42881914 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20261016 LR - 20261020 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 15 IP - 19 DP - 2026 Sep 24 TI - Transcatheter Aortic Valve Implantation in Complex Anatomy: An Anatomy-Driven Framework for Bicuspid Stenosis, Pure Aortic Regurgitation, and the Small Annulus in the Era of Lifetime Management. LID - 10.3390/jcm15197452 [doi] LID - 7452 AB - Background: Transcatheter aortic valve implantation is established for severe calcific tricuspid aortic stenosis, but its application in bicuspid aortic valve (BAV) stenosis, pure native aortic regurgitation (AR), and small aortic annulus anatomy remains limited by heterogeneous morphology, device-specific constraints, and uncertain long-term outcomes. These settings require decisions that extend beyond immediate procedural success to encompass coronary access, reintervention, valve durability, and associated aortopathy. This review synthesizes current evidence and proposes an anatomy-driven framework integrating imaging, device selection, procedural planning, and lifetime management. Methods: A structured narrative review was conducted in accordance with the Scale for the Assessment of Narrative Review Articles (SANRA) criteria. PubMed/MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials were searched from 1 January 2010 to 31 March 2026 for studies addressing TAVI in BAV stenosis, pure native AR, and small aortic annulus anatomy. Randomized trials, meta-analyses, multicenter registries, pivotal device studies, and guideline or consensus documents were prioritized. After screening 2663 records and assessing 330 full-text reports, 101 records were retained for qualitative synthesis. Evidence was appraised by anatomical substrate, imaging phenotype, device strategy, procedural hazards, and implications for lifetime management. Results: In BAV stenosis, contemporary registry and prospective cohort data support high device success and acceptable early and mid-term outcomes in carefully selected patients; however, calcified raphe, bulky asymmetric leaflet or left ventricular outflow tract calcification, annular eccentricity, and concomitant aortopathy identify higher-risk phenotypes that often favor surgery. Randomized evidence in younger low-risk BAV patients remains limited and exploratory, with the NOTION-2 trial showing a numerically higher 3-year composite event rate after TAVI than surgical aortic valve replacement (20.4% vs. 7.8%; hazard ratio 2.9, 95% confidence interval 0.9-9.0) in the small bicuspid subgroup. In pure native AR, lack of annular calcification and frequent root dilatation impair anchoring of conventional transcatheter heart valves, increasing risks of migration, embolization, residual AR, and second-valve implantation. Dedicated leaflet-anchoring devices have improved outcomes: in ALIGN-AR, the JenaValve Trilogy system achieved procedural success above 95% in high-surgical-risk patients, although evidence remains single-arm and nonrandomized. In small annuli, the strongest comparative evidence comes from the SMART trial, in which supra-annular self-expanding valves were non-inferior to balloon-expandable valves for the 12-month clinical composite and reduced moderate/severe prosthesis-patient mismatch at 30 days (11.2% vs. 35.3%). Across all three phenotypes, electrocardiography-gated computed tomography is fundamental for defining anchoring, sizing, calcium distribution, root and coronary anatomy, anticipated coronary re-access, and the feasibility of redo-TAVI. Surgery remains particularly relevant when aortic repair, annular/root enlargement, or a more durable lifetime strategy is required. Conclusions: TAVI is feasible in selected patients with BAV stenosis, pure native AR, and small aortic annuli, but the evidentiary strength and optimal procedural strategy differ substantially across these anatomies. Treatment should be guided by an anatomy-driven, computed-tomography-based Heart Team assessment that integrates immediate procedural feasibility with age, surgical candidacy, aortopathy, prosthesis-patient mismatch risk, coronary access, durability, and future reintervention options. Surgery remains the more established strategy for many younger, operable patients with unfavorable BAV morphology or aortopathy, AR with root dilatation, or very small annuli amenable to enlargement. Dedicated randomized trials, standardized imaging criteria, and long-term durability data are needed to refine lifetime management in complex aortic valve anatomy. FAU - Brie, Daniel Miron AU - Brie DM AUID- ORCID: 0000-0001-9003-456X AD - Cardiovascular Disease Institute Timisoara, Gheorghe Adam Street, No. 13A, 300310 Timisoara, Romania. AD - Research Center, Institute of Cardiovascular Diseases, Gheorghe Adam Street, No. 13A, 300310 Timisoara, Romania. FAU - Mornos, Cristian AU - Mornos C AUID- ORCID: 0000-0002-6096-9601 AD - Cardiovascular Disease Institute Timisoara, Gheorghe Adam Street, No. 13A, 300310 Timisoara, Romania. AD - Research Center, Institute of Cardiovascular Diseases, Gheorghe Adam Street, No. 13A, 300310 Timisoara, Romania. AD - Department of Cardiology, "Victor Babes" University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square, No. 2, 300041 Timisoara, Romania. FAU - Popescu, Roxana AU - Popescu R AUID- ORCID: 0000-0002-9387-1141 AD - Department of Cell and Molecular Biology, "Victor Babes" University of Medicine and Pharmacy, Tudor Vladimirescu Street, No. 14, 300174 Timisoara, Romania. AD - ANAPATMOL Research Center, "Victor Babes" University of Medicine and Pharmacy, Tudor Vladimirescu Street, No. 14, 300174 Timisoara, Romania. FAU - Brie, Alina Diduta AU - Brie AD AUID- ORCID: 0009-0002-4078-1537 AD - Department of Cell and Molecular Biology, "Victor Babes" University of Medicine and Pharmacy, Tudor Vladimirescu Street, No. 14, 300174 Timisoara, Romania. AD - ANAPATMOL Research Center, "Victor Babes" University of Medicine and Pharmacy, Tudor Vladimirescu Street, No. 14, 300174 Timisoara, Romania. AD - "Louis Turcanu" Emergency Children Hospital, Doctor Iosif Nemoianu Street, No. 2, 300011 Timisoara, Romania. LA - eng GR - Victor Babes University of Medicine and Pharmacy Timisoara/ PT - Journal Article PT - Review DEP - 20260924 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC13665837 OTO - NOTNLM OT - Heart Team OT - aortic stenosis OT - bicuspid aortic valve OT - computed tomography OT - lifetime management OT - prosthesis-patient mismatch OT - pure native aortic regurgitation OT - small aortic annulus OT - transcatheter aortic valve implantation OT - transcatheter aortic valve replacement COIS- The authors declare no conflicts of interest. EDAT- 2026/10/16 05:32 MHDA- 2026/10/16 05:33 PMCR- 2026/09/24 CRDT- 2026/10/16 01:01 PHST- 2026/08/07 00:00 [received] PHST- 2026/09/06 00:00 [revised] PHST- 2026/09/22 00:00 [accepted] PHST- 2026/10/16 05:33 [medline] PHST- 2026/10/16 05:32 [pubmed] PHST- 2026/10/16 01:01 [entrez] PHST- 2026/09/24 00:00 [pmc-release] AID - jcm15197452 [pii] AID - jcm-15-07452 [pii] AID - 10.3390/jcm15197452 [doi] PST - epublish SO - J Clin Med. 2026 Sep 24;15(19):7452. doi: 10.3390/jcm15197452. PMID- 42881885 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20261016 LR - 20261020 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 15 IP - 19 DP - 2026 Sep 24 TI - Perioperative Outcomes of Multivessel Minimally Invasive Coronary Revascularization at a Specialized Center: A Retrospective Cohort of Complete Surgical and Planned Hybrid Strategies. LID - 10.3390/jcm15197424 [doi] LID - 7424 AB - Background: Multivessel minimally invasive coronary revascularization combines surgical myocardial revascularization through a left mini-thoracotomy with, in selected patients, a planned hybrid percutaneous component. Evidence from contemporary single-center cohorts remains limited. Methods: We retrospectively analyzed 180 Heart Team-selected patients treated with a multivessel minimally invasive strategy at the Department of Cardiac Surgery, University Hospital Bonn, between December 2021 and February 2025. The cohort comprised complete surgical revascularization and planned hybrid strategies. Results: Complete surgical revascularization was documented in 121/180 patients (67.2%), while 59/180 (32.8%) underwent planned hybrid revascularization. No in-hospital deaths occurred (0.0%; exact 95% CI, 0.0-2.0%). Stroke occurred in 2/180 (1.1%), re-thoracotomy for bleeding in 3/180 (1.7%), wound infection in 3/180 (1.7%), and AKI in 8/180 (4.4%). Three patients received postoperative dialysis; two were dialysis-dependent before surgery and one required new postoperative renal replacement therapy (0.6%). Postoperative atrial fibrillation was documented in 7 patients (3.9%). Post-discharge follow-up information was available for 140/180 patients (77.8%), with three recorded deaths. Conclusions: This cohort demonstrates that a Heart Team-driven multivessel minimally invasive coronary revascularization program incorporating both complete surgical and planned hybrid strategies can be implemented with favorable observed perioperative outcomes in carefully selected patients. At the same time, the results should not be interpreted as evidence that MV-MIDCAB or hybrid coronary revascularization is superior to conventional CABG. FAU - Ciobanu, Veaceslav AU - Ciobanu V AD - Department of Cardiac Surgery, University Hospital Bonn, 53127 Bonn, Germany. FAU - Krasivskyi, Ihor AU - Krasivskyi I AUID- ORCID: 0000-0003-0573-8218 AD - Department of Cardiac Surgery, University Hospital Bonn, 53127 Bonn, Germany. FAU - Pizzulli, Luca AU - Pizzulli L AD - Department of Cardiac Surgery, University Hospital Bonn, 53127 Bonn, Germany. FAU - Alaj, Eissa AU - Alaj E AD - Department of Cardiac Surgery, University Hospital Bonn, 53127 Bonn, Germany. FAU - Hamiko, Marwan AU - Hamiko M AUID- ORCID: 0009-0000-9763-7304 AD - Department of Cardiac Surgery, University Hospital Bonn, 53127 Bonn, Germany. FAU - Monsefi, Nadejda AU - Monsefi N AD - Department of Cardiac Surgery, University Hospital Bonn, 53127 Bonn, Germany. FAU - Bakhtiary, Farhad AU - Bakhtiary F AD - Department of Cardiac Surgery, University Hospital Bonn, 53127 Bonn, Germany. FAU - Eghbalzadeh, Kaveh AU - Eghbalzadeh K AD - Department of Cardiac Surgery, University Hospital Bonn, 53127 Bonn, Germany. LA - eng PT - Journal Article DEP - 20260924 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC13666338 OTO - NOTNLM OT - MIDCAB OT - coronary artery disease OT - hybrid coronary revascularization OT - minimally invasive coronary surgery OT - multivessel coronary disease OT - off-pump coronary artery bypass COIS- The authors declare no conflicts of interest. EDAT- 2026/10/16 05:32 MHDA- 2026/10/16 05:33 PMCR- 2026/09/24 CRDT- 2026/10/16 01:01 PHST- 2026/08/01 00:00 [received] PHST- 2026/09/17 00:00 [revised] PHST- 2026/09/23 00:00 [accepted] PHST- 2026/10/16 05:33 [medline] PHST- 2026/10/16 05:32 [pubmed] PHST- 2026/10/16 01:01 [entrez] PHST- 2026/09/24 00:00 [pmc-release] AID - jcm15197424 [pii] AID - jcm-15-07424 [pii] AID - 10.3390/jcm15197424 [doi] PST - epublish SO - J Clin Med. 2026 Sep 24;15(19):7424. doi: 10.3390/jcm15197424. PMID- 42881085 OWN - NLM STAT- Publisher LR - 20261015 IS - 1938-131X (Electronic) IS - 1553-7250 (Linking) DP - 2026 Sep 24 TI - Collaborative Multidisciplinary Assessment of Performance: A Development Guide for Pediatric Heart Centers. LID - S1553-7250(26)00247-3 [pii] LID - 10.1016/j.jcjq.2026.09.004 [doi] AB - In July 2023 the Criss Heart Center at Children's Nebraska launched weekly Collaborative Multidisciplinary Assessment of Performance Rounds (CMAP) as part of a structured, prospective Safety Management System framework. CMAP are designed to facilitate transparent, timely, and multidisciplinary evaluation of patient outcomes following pediatric heart surgery. This initiative uses real-time data from the Society of Thoracic Surgeons Congenital Heart Surgery Database to create plots of each surgical patient's journey of risk-versus-time, from surgery through discharge, which are presented at weekly one-hour rounds. The ultimate goal of CMAP is to improve team performance and enhance patient outcomes. CI - Copyright (c) 2026 Joint Commission. Published by Elsevier Inc. All rights reserved. FAU - L'Heureux, Timothe E AU - L'Heureux TE FAU - McGlinchey, Amanda M AU - McGlinchey AM FAU - Torres, Sasha M AU - Torres SM FAU - Hancock Friesen, Camille L AU - Hancock Friesen CL LA - eng PT - Journal Article DEP - 20260924 PL - Netherlands TA - Jt Comm J Qual Patient Saf JT - Joint Commission journal on quality and patient safety JID - 101238023 SB - IM EDAT- 2026/10/15 23:31 MHDA- 2026/10/15 23:31 CRDT- 2026/10/15 22:07 PHST- 2026/06/08 00:00 [received] PHST- 2026/09/10 00:00 [revised] PHST- 2026/09/21 00:00 [accepted] PHST- 2026/10/15 23:31 [medline] PHST- 2026/10/15 23:31 [pubmed] PHST- 2026/10/15 22:07 [entrez] AID - S1553-7250(26)00247-3 [pii] AID - 10.1016/j.jcjq.2026.09.004 [doi] PST - aheadofprint SO - Jt Comm J Qual Patient Saf. 2026 Sep 24:S1553-7250(26)00247-3. doi: 10.1016/j.jcjq.2026.09.004. PMID- 42878989 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20261023 LR - 20261026 IS - 1568-5888 (Print) IS - 1876-6250 (Electronic) IS - 1568-5888 (Linking) VI - 34 IP - 11 DP - 2026 Nov TI - 2025 European Society of Cardiology guidelines for the management of cardiovascular disease and pregnancy : Statement of endorsement by the NVVC. PG - 388-398 LID - 10.1007/s12471-026-02085-z [doi] AB - This article contextualises the 2025 European Society of Cardiology (ESC) guidelines for managing cardiovascular disease (CVD) and pregnancy in the Netherlands. The guideline addendum provides additional recommendations for situations where the ESC guidelines may not fully align with Dutch clinical practice. By endorsing the ESC guidelines through this addendum, the Netherlands Society of Cardiology (Nederlandse Vereniging Voor Cardiologie) supports its members in adhering to evidence-based management strategies for CVD and pregnancy. CI - (c) 2026. The Author(s). FAU - van der Zwaan, Heleen B AU - van der Zwaan HB AD - Department of Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands. h.b.vanderzwaan-3@umcutrecht.nl. FAU - Kalkman, Deborah N AU - Kalkman DN AD - Department of Cardiology, Amsterdam University Medical Center, Amsterdam, The Netherlands. FAU - Broekman, Marjolijn J AU - Broekman MJ AD - Department of Obstetrics and Gynaecology, University Medical Center Utrecht, Utrecht, The Netherlands. FAU - Evers, Annemiek C C AU - Evers ACC AD - Department of Obstetrics and Gynaecology, University Medical Center Utrecht, Utrecht, The Netherlands. FAU - Stegeman, Bernardine H AU - Stegeman BH AD - Knowledge Institute of the Federation of Medical Specialists, Utrecht, The Netherlands. FAU - Kies, Philippine AU - Kies P AD - Department of Cardiology, Heart Lung Center, Leiden University Medical Center Leiden, Leiden, The Netherlands. FAU - van der Marel, Caroline M AU - van der Marel CM AD - Department of Anesthesia, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. FAU - van der Vloed, Judith AU - van der Vloed J AD - Dutch Heart Foundation, Den Haag, The Netherlands. FAU - Westendorp, Iris C D AU - Westendorp ICD AD - Department of Cardiology, Red Cross Hospital, Beverwijk, The Netherlands. FAU - Cornette, Jerome M J AU - Cornette JMJ AD - Department of Obstetrics and Fetal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. LA - eng PT - Journal Article PT - Review DEP - 20261015 PL - Netherlands TA - Neth Heart J JT - Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation JID - 101095458 PMC - PMC13694674 OTO - NOTNLM OT - Aortopathies OT - Cardiovascular disease OT - Congenital heart disease OT - Peripartum OT - Pregnancy OT - Pregnancy heart team COIS- Declarations. Conflict of interest: H.B. van der Zwaan, D.N. Kalkman, M.J. Broekman, A.C.C. Evers, B.H. Stegeman, P. Kies, C.M. van der Marel, J. van der Vloed, I.C.D. Westendorp and J.M.J. Cornette declare that they have no competing interests. EDAT- 2026/10/15 23:30 MHDA- 2026/10/15 23:31 PMCR- 2026/10/15 CRDT- 2026/10/15 18:29 PHST- 2026/04/08 00:00 [received] PHST- 2026/09/14 00:00 [accepted] PHST- 2026/10/15 23:31 [medline] PHST- 2026/10/15 23:30 [pubmed] PHST- 2026/10/15 18:29 [entrez] PHST- 2026/10/15 00:00 [pmc-release] AID - 10.1007/s12471-026-02085-z [pii] AID - 2085 [pii] AID - 10.1007/s12471-026-02085-z [doi] PST - ppublish SO - Neth Heart J. 2026 Nov;34(11):388-398. doi: 10.1007/s12471-026-02085-z. Epub 2026 Oct 15. PMID- 42878521 OWN - NLM STAT- Publisher LR - 20261015 IS - 1937-1578 (Electronic) IS - 1935-1089 (Linking) DP - 2026 Oct 14 TI - Paracentral Acute Middle Maculopathy Prompting Diagnosis of Severe Aortic Regurgitation and Ascending Aortic Aneurysm. LID - 10.1097/ICB.0000000000002002 [doi] AB - PURPOSE: To report a case of paracentral acute middle maculopathy (PAMM) in which persistent paracentral dysfunction prompted cardiovascular investigation and diagnosis of severe aortic regurgitation, reduced ejection fraction, and ascending aortic aneurysm. METHODS: Longitudinal ophthalmic assessment, multimodal retinal imaging, Humphrey SITA Central 10-2 testing, cardiovascular evaluation, surgical findings, histopathology, and targeted aortopathy genetic testing were reviewed. RESULTS: A 44-year-old man presented with intermittent right-eye visual disturbance and persistent paracentral scotoma after non-explanatory neuroimaging. Unaided visual acuity remained 20/25 (6/7.5; approximately 0.10 logMAR) in each eye, intraocular pressure was 16-19 mmHg, and anterior-segment examination was unremarkable. Multimodal imaging supported PAMM, with structural OCT inner retinal/inner nuclear layer involvement and qualitative OCT-A/fluorescein angiographic parafoveal perfusion compromise. The affected inner retinal/inner nuclear layer region decreased from 45 micrometres to 32 micrometres. Right-eye Humphrey SITA Central 10-2 mean deviation worsened from -3.67 dB on 03 March 2020 to -5.19 dB in February 2026 despite unchanged central acuity. Cardiovascular assessment revealed a 5.5-cm ascending aortic aneurysm, severe aortic regurgitation, and left-ventricular ejection fraction of 49%. The patient underwent elective Bentall procedure, with postoperative ejection-fraction improvement to 55%. No postoperative quantitative OCT-A reperfusion claim is made. CONCLUSION: PAMM may warrant systemic cardiovascular assessment when ocular findings do not fully explain persistent paracentral dysfunction. This case supports cautious multidisciplinary evaluation while avoiding unsupported claims of causality, quantitative OCT-A perfusion deficit, or postoperative retinal reperfusion. CI - Copyright (c) 2026 The Author(s). Published by Wolters Kluwer Health, LLC. on behalf of the Opthalmic Communications Society, Inc. FAU - Palexas, George N AU - Palexas GN AUID- ORCID: 0009-0004-8095-7925 AD - Department of Ophthalmology, North Middlesex University Hospital NHS Trust, Sterling Way, Edmonton, London, United Kingdom. LA - eng PT - Journal Article DEP - 20261014 PL - United States TA - Retin Cases Brief Rep JT - Retinal cases & brief reports JID - 101298744 SB - IM OTO - NOTNLM OT - Bentall procedure OT - Humphrey SITA 10-2 OT - OCT angiography OT - Paracentral acute middle maculopathy OT - aortic regurgitation OT - ascending aortic aneurysm OT - case report OT - retinal ischemia EDAT- 2026/10/15 23:30 MHDA- 2026/10/15 23:30 CRDT- 2026/10/15 17:20 PHST- 2026/10/15 23:30 [medline] PHST- 2026/10/15 23:30 [pubmed] PHST- 2026/10/15 17:20 [entrez] AID - 01271216-990000000-00731 [pii] AID - 10.1097/ICB.0000000000002002 [doi] PST - aheadofprint SO - Retin Cases Brief Rep. 2026 Oct 14. doi: 10.1097/ICB.0000000000002002. PMID- 42876391 OWN - NLM STAT- Publisher LR - 20261015 IS - 1522-726X (Electronic) IS - 1522-1946 (Linking) DP - 2026 Oct 15 TI - Mitral Transcatheter Edge-to-Edge Repair at Centers With and Without On-Site Cardiac Surgery: A Comparative Registry With a Shared Interventional Team. LID - 10.1002/ccd.70874 [doi] AB - BACKGROUND: Comparative evidence for M-TEER performed at centers with versus without on-site cardiac surgery is lacking. We compared early outcomes at two centers that shared the same interventional operator team but differed in the availability of on-site cardiac surgery. METHODS: We retrospectively analyzed prospectively collected registry data from 64 consecutive patients with severe (4+) MR treated at a center without on-site cardiac surgery (no-CCH, n = 21) and a center with on-site cardiac surgery (CCH, n = 43). The same interventional operator team performed every procedure. At the no-CCH center, surgical expertise was provided through a shared Heart Team and a formal emergency transfer pathway. The cohorts were treated in sequential calendar periods. Principal comparative endpoints were MVARC device and procedural success at 30 days. Exploratory non-inferiority analyses used margins of -12.5% and -10%. RESULTS: MVARC technical success was 100% versus 97.7%. Device and procedural success were each 81.0% versus 72.1% (risk difference [RD] +8.9%, 95% CI -14.9 to +27.5; p = 0.547). Freedom from major MVARC serious adverse events was 95.2% versus 95.3%. Twelve of 16 device-success failures involved a mean transmitral gradient >/= 5 mmHg. Surgical conversion and in-hospital death were 0% in both centers. CONCLUSIONS: In this preliminary same-team comparison, 30-day MVARC device and procedural success rates were 81.0% at the no-CCH center and 72.1% at the CCH center. Confidence intervals were wide and non-inferiority was not established. These findings support prospective evaluation of network-based M-TEER programs with shared interventional expertise and formal surgical backup. CI - (c) 2026 Wiley Periodicals LLC. FAU - Marchisio, Giulia AU - Marchisio G AD - Division of Cardiology, Umberto Parini Regional Hospital, Azienda USL della Valle d'Aosta, Aosta, Italy. FAU - Pelloni, Elisa AU - Pelloni E AD - Division of Cardiology, Umberto Parini Regional Hospital, Azienda USL della Valle d'Aosta, Aosta, Italy. FAU - Pisano, Francesco AU - Pisano F AUID- ORCID: 0000-0001-5432-7226 AD - Division of Cardiology, Umberto Parini Regional Hospital, Azienda USL della Valle d'Aosta, Aosta, Italy. FAU - Zaccaro, Lorenzo AU - Zaccaro L AD - Division of Cardiology, Umberto Parini Regional Hospital, Azienda USL della Valle d'Aosta, Aosta, Italy. FAU - Contu, Laura AU - Contu L AD - Division of Cardiology, Umberto Parini Regional Hospital, Azienda USL della Valle d'Aosta, Aosta, Italy. FAU - Tusa, Maurizio AU - Tusa M AD - Clinical and Interventional Cardiology Department, IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy. FAU - Brambilla, Nedy AU - Brambilla N AD - Clinical and Interventional Cardiology Department, IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy. FAU - Guerrini, Marco AU - Guerrini M AD - Clinical and Interventional Cardiology Department, IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy. FAU - Bedogni, Francesco AU - Bedogni F AUID- ORCID: 0000-0002-4975-6605 AD - Clinical and Interventional Cardiology Department, IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy. FAU - Scacciatella, Paolo AU - Scacciatella P AD - Division of Cardiology, Umberto Parini Regional Hospital, Azienda USL della Valle d'Aosta, Aosta, Italy. LA - eng PT - Journal Article DEP - 20261015 PL - United States TA - Catheter Cardiovasc Interv JT - Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions JID - 100884139 SB - IM OTO - NOTNLM OT - Heart Team OT - MitraClip OT - mitral regurgitation OT - multicenter registry OT - on-site cardiac surgery OT - transcatheter edge-to-edge repair EDAT- 2026/10/15 07:18 MHDA- 2026/10/15 07:18 CRDT- 2026/10/15 04:30 PHST- 2026/08/28 00:00 [revised] PHST- 2026/08/28 00:00 [received] PHST- 2026/09/02 00:00 [accepted] PHST- 2026/10/15 07:18 [medline] PHST- 2026/10/15 07:18 [pubmed] PHST- 2026/10/15 04:30 [entrez] AID - 10.1002/ccd.70874 [doi] PST - aheadofprint SO - Catheter Cardiovasc Interv. 2026 Oct 15. doi: 10.1002/ccd.70874. PMID- 42873662 OWN - NLM STAT- Publisher LR - 20261014 IS - 2150-136X (Electronic) IS - 2150-1351 (Linking) DP - 2026 Oct 14 TI - The Fontan Procedure in Patients with Single-Lung Physiology: Insights from a Case Report and Scoping Review. PG - 21501351261491199 LID - 10.1177/21501351261491199 [doi] AB - The Fontan operation represents the third stage of single-ventricle palliation and requires optimal cardiovascular and pulmonary conditions to achieve success. We report a 6-year-old boy with tricuspid atresia, pulmonary atresia, and functional single-lung circulation secondary to severe left pulmonary artery (LPA) hypoplasia and disconnection after previous palliation. Following comprehensive clinical, hemodynamic, and anatomic evaluation, including unsuccessful attempts at LPA recruitment, the patient underwent an extracardiac fenestrated single-lung Fontan procedure. At 2 years of follow-up, he remained in good functional status without Fontan-related complications or the need for reintervention. Additionally, we present a scoping review of published case reports and case series of children with single-lung physiology undergoing the Fontan procedure, focusing on early and follow-up survival. This case, together with the available literature, suggests that single-lung Fontan completion may be feasible in carefully selected patients following meticulous multidisciplinary evaluation, although long-term outcomes remain uncertain. FAU - Guerrero-Becerra, Albert Franz AU - Guerrero-Becerra AF AUID- ORCID: 0000-0003-2964-788X AD - Congenital and Pediatric Heart Diseases Center, Cardiovascular Institute, Hospital Internacional de Colombia HIC-Fundacion Cardiovascular de Colombia FCV-Fundacion Universitaria FCV, Santander, Colombia. FAU - Rubio-Duarte, Andres Felipe AU - Rubio-Duarte AF AUID- ORCID: 0000-0001-9091-5367 AD - Congenital and Pediatric Heart Diseases Center, Cardiovascular Institute, Hospital Internacional de Colombia HIC-Fundacion Cardiovascular de Colombia FCV-Fundacion Universitaria FCV, Santander, Colombia. AD - Epidemiology and Data Analysis Unit, Hospital Internacional de Colombia HIC-Fundacion Cardiovascular de Colombia FCV-Fundacion Universitaria FCV, Santander, Colombia. FAU - Fontecha-Vargas, Estefania Alejandra AU - Fontecha-Vargas EA AUID- ORCID: 0009-0004-4742-3112 AD - Faculty of Health Sciences, Universidad Industrial de Santander, Bucaramanga, Colombia. RINGGOLD: 28014 FAU - Marquez-Bohorquez, Diego AU - Marquez-Bohorquez D AUID- ORCID: 0000-0001-8610-5644 AD - Congenital and Pediatric Heart Diseases Center, Cardiovascular Institute, Hospital Internacional de Colombia HIC-Fundacion Cardiovascular de Colombia FCV-Fundacion Universitaria FCV, Santander, Colombia. LA - eng PT - Journal Article DEP - 20261014 PL - United States TA - World J Pediatr Congenit Heart Surg JT - World journal for pediatric & congenital heart surgery JID - 101518415 SB - IM EDAT- 2026/10/14 18:14 MHDA- 2026/10/14 18:14 CRDT- 2026/10/14 15:46 PHST- 2026/10/14 18:14 [medline] PHST- 2026/10/14 18:14 [pubmed] PHST- 2026/10/14 15:46 [entrez] AID - 10.1177/21501351261491199 [doi] PST - aheadofprint SO - World J Pediatr Congenit Heart Surg. 2026 Oct 14:21501351261491199. doi: 10.1177/21501351261491199. PMID- 42873147 OWN - NLM STAT- Publisher LR - 20261014 IS - 2515-7949 (Electronic) IS - 1750-4589 (Linking) DP - 2026 Oct 14 TI - Preoperative anaesthetic and cardiology MDT: Enhancing perioperative efficiency in elective non-cardiac surgery. PG - 17504589261489023 LID - 10.1177/17504589261489023 [doi] AB - BACKGROUND: Delays in obtaining specialist cardiology input for elective non-cardiac surgery can postpone definitive perioperative decision-making, increase short-notice cancellations and reduce theatre efficiency. In January 2021, our NHS trust introduced a weekly virtual Preoperative Anaesthetic and Cardiology Multidisciplinary Team meeting as a pathway redesign to improve access to specialist perioperative cardiovascular assessment. METHODS: We conducted a retrospective service evaluation of consecutive Preoperative Anaesthetic and Cardiology Multidisciplinary Team referrals between 1 January 2021 and 31 December 2024. Registry data were reviewed for referral indication, specialty, time from referral to first multidisciplinary team review and initial multidisciplinary team outcome. The impact on cardiology outpatient activity was estimated by comparing the Preoperative Anaesthetic and Cardiology Multidisciplinary Team pathway with the previous practice whereby non-emergency pre-assessment referrals were directed to a routine cardiology clinic. RESULTS: A total of 869 patients were reviewed; four were excluded because of incomplete records, leaving 865 analysable cases. Mean time from referral to first multidisciplinary team review was under 14 days. In a typical 1-h meeting, six to ten cases were discussed (mean 8), with a mean discussion time of approximately 8 min per patient. At first review, 64% of patients received a definitive advisory outcome: 62% were considered fit to proceed and 2% unfit for surgery. The remaining 36% required further action; 24% were triaged to cardiology clinic and 12% were managed through expedited investigation or treatment adjustment pathways. Compared with the pre-existing pathway, this represented a 76% reduction in pre-assessment referrals to a general cardiology clinic, equivalent to 657 outpatient appointments avoided over 4 years. CONCLUSIONS: A virtual anaesthetic-cardiology multidisciplinary team can provide timely specialist perioperative cardiovascular decision-making, reduce reliance on outpatient cardiology review and support elective pathway efficiency. This model is pragmatic, reproducible and may be valuable for NHS organisations seeking to streamline preoperative assessment while preserving access to specialist input for patients who need it most - a promising strategy for addressing elective surgery backlogs. FAU - Sivakumaran, Prasanthi AU - Sivakumaran P AUID- ORCID: 0000-0002-8047-5000 AD - Barking, Havering and Redbridge University Hospitals NHS Trust, Romford, UK. FAU - Gopinathan, Chitra AU - Gopinathan C AD - Barking, Havering and Redbridge University Hospitals NHS Trust, Romford, UK. FAU - Serrano-Gomez, Alcira AU - Serrano-Gomez A AD - Barking, Havering and Redbridge University Hospitals NHS Trust, Romford, UK. FAU - Saheecha, Saad AU - Saheecha S AD - Barking, Havering and Redbridge University Hospitals NHS Trust, Romford, UK. FAU - Farooqi, Fahad AU - Farooqi F AD - Barking, Havering and Redbridge University Hospitals NHS Trust, Romford, UK. LA - eng PT - Journal Article DEP - 20261014 PL - England TA - J Perioper Pract JT - Journal of perioperative practice JID - 101271023 SB - IM OTO - NOTNLM OT - Anaesthetics - management and care OT - Cardiology OT - Pre-assessment OT - Service improvement EDAT- 2026/10/14 18:14 MHDA- 2026/10/14 18:14 CRDT- 2026/10/14 14:40 PHST- 2026/10/14 18:14 [medline] PHST- 2026/10/14 18:14 [pubmed] PHST- 2026/10/14 14:40 [entrez] AID - 10.1177/17504589261489023 [doi] PST - aheadofprint SO - J Perioper Pract. 2026 Oct 14:17504589261489023. doi: 10.1177/17504589261489023. PMID- 42871861 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20261014 LR - 20261015 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 18 IP - 9 DP - 2026 Sep TI - Integrated Clinical, Biological, and Echocardiographic Factors Independently Associated With In-Hospital Mortality in Infective Endocarditis: A Single-Centre Cohort Study From Morocco. PG - e116161 LID - 10.7759/cureus.116161 [doi] LID - e116161 AB - Background Infective endocarditis (IE) remains associated with substantial in-hospital mortality worldwide, with a disproportionate burden in low- and middle-income countries (LMICs). Identifying clinical, biological, microbiological, and echocardiographic factors associated with adverse outcomes may help characterize patients at increased risk of death. Objectives To identify clinical, biological, microbiological, and echocardiographic factors independently associated with in-hospital mortality among patients hospitalized with IE in a North African tertiary referral centre. Methods We conducted a retrospective observational cohort study including 260 consecutive patients admitted with definite IE according to the 2023 Duke-International Society for Cardiovascular Infectious Diseases (Duke-ISCVID) criteria, between January 2020 and April 2026. Patients were classified as survivors (n = 188) or non-survivors (n = 72). Demographic characteristics, clinical presentation, biological parameters, microbiological data, and echocardiographic findings were systematically collected. Univariable and multivariable binary logistic regression analyses were performed. Multivariable analysis used backward Wald elimination. Model discrimination was assessed using the area under the receiver operating characteristic curve, and calibration was evaluated using the Hosmer-Lemeshow test. Results Among 260 patients with definite IE, 188 (72.3%) survived to hospital discharge, and 72 (27.7%) died during hospitalization. The mean age was 47 +/- 16 years, with a male predominance. Rheumatic heart disease was the most frequent underlying valvular condition. In multivariable analysis, septic shock was associated with increased in-hospital mortality (adjusted odds ratio (aOR), 28.45; 95% CI, 3.42-106.80; p < 0.001), as were local cardiac complications (aOR, 3.52; 95% CI, 1.42-8.72; p = 0.007), age >/=60 years (aOR, 3.84; 95% CI, 1.48-9.96; p = 0.010), vegetation diameter >15 mm (aOR, 2.50; 95% CI, 1.00-6.20; p = 0.049), male sex (aOR, 2.68; 95% CI, 1.12-6.42; p = 0.027), haemoglobin <10 g/dL (aOR, 2.80; 95% CI, 1.10-7.22; p = 0.031), and estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m(2) (aOR, 2.70; 95% CI, 1.03-7.01; p = 0.042). The final model showed good discrimination, with a C-statistic of 0.84 (95% CI, 0.78-0.90), and no evidence of poor calibration according to the Hosmer-Lemeshow test (chi(2) = 6.42, df = 8, p = 0.60). Given the sparse distribution of septic shock among survivors (n = 2), a Firth-penalized sensitivity analysis yielded an OR of 9.80 (95% CI, 2.85-33.70), supporting the robustness of the direction of this association despite sparse-data concerns. Conclusions In this contemporary Moroccan cohort, septic shock, local cardiac complications, older age, vegetation diameter >15 mm, male sex, anaemia, and severe renal dysfunction were independently associated with in-hospital mortality. These findings may support early recognition of high-risk clinical features and multidisciplinary assessment, but should not be interpreted as a validated mortality prediction model. Prospective multicentre studies with internal and external validation are warranted to assess the generalizability of these findings. CI - Copyright (c) 2026, El Karimy et al. FAU - El Karimy, Tariq AU - El Karimy T AD - Department of Cardiology, Mohammed VI University Hospital, Marrakech, MAR. FAU - Rizkou, Hiba AU - Rizkou H AD - Department of Cardiology, Mohammed VI University Hospital, Marrakech, MAR. FAU - Elmasrioui, Joumana AU - Elmasrioui J AD - Department of Cardiology, Mohammed VI University Hospital, Marrakech, MAR. FAU - Elhattaoui, Mustapha AU - Elhattaoui M AD - Department of Cardiology, Mohammed VI University Hospital, Marrakech, MAR. LA - eng PT - Journal Article DEP - 20260913 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC13659316 OTO - NOTNLM OT - echocardiography OT - in-hospital mortality OT - infective endocarditis OT - low- and middle-income countries OT - morocco OT - renal dysfunction OT - risk stratification OT - septic shock COIS- Human subjects: Informed consent for treatment and open access publication was obtained or waived by all participants in this study. Biomedical Research Ethics Committee of the Faculty of Medicine and Pharmacy of Marrakech, Cadi Ayyad University issued approval CE-FMPM/2020 - 17/2020. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. EDAT- 2026/10/14 18:14 MHDA- 2026/10/14 18:15 PMCR- 2026/09/13 CRDT- 2026/10/14 11:53 PHST- 2026/09/12 00:00 [accepted] PHST- 2026/10/14 18:15 [medline] PHST- 2026/10/14 18:14 [pubmed] PHST- 2026/10/14 11:53 [entrez] PHST- 2026/09/13 00:00 [pmc-release] AID - 10.7759/cureus.116161 [doi] PST - epublish SO - Cureus. 2026 Sep 13;18(9):e116161. doi: 10.7759/cureus.116161. eCollection 2026 Sep. PMID- 42870861 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20261014 LR - 20261015 IS - 2218-6751 (Print) IS - 2226-4477 (Electronic) IS - 2218-6751 (Linking) VI - 15 IP - 9 DP - 2026 Sep 30 TI - Vietnamese expert consensus on the diagnosis and multidisciplinary management of resectable non-small cell lung cancer. PG - 289 LID - 10.21037/tlcr-2026-0852 [doi] LID - 289 AB - BACKGROUND: The management of resectable non-small cell lung cancer (NSCLC) has evolved rapidly from a surgery-centered approach toward biomarker-informed, multimodality care integrating staging, pathology, surgery, perioperative systemic treatment, and postoperative surveillance. In Vietnam, implementation remains heterogeneous across institutions, particularly in access to fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT), invasive mediastinal staging, molecular testing, perioperative therapy, pathology standardization, and multidisciplinary review. This project aimed to develop a Vietnamese multidisciplinary expert consensus to contextualize contemporary international evidence for clinical practice in Vietnam. METHODS: A structured, modified Delphi-informed consensus process was conducted in Vietnam between August 2025 and January 2026. The workflow comprised seven stages: scoping; a baseline practice survey; initial draft development; expert review of parts 1 and 2; post-meeting written feedback, revision, electronic recirculation, and formal voting for these sections; a multidisciplinary consensus meeting and formal voting for parts 3 and 4; and editorial harmonization and consolidation. The panel included specialists in thoracic surgery, medical oncology, respiratory medicine, pathology, nuclear medicine, radiation oncology, and related disciplines. Classes of recommendation were adapted from the European Society of Cardiology framework. All statements submitted to formal consensus voting were formally rated, with consensus predefined as at least 75% agreement. RESULTS: The final document comprised 35 consensus statements across four domains: preoperative diagnosis and staging (n=7), surgery and postoperative surveillance (n=8), neoadjuvant and perioperative treatment (n=12), and adjuvant treatment (n=8). Across the meeting rosters, 32 unique experts were identified, with strong representation from thoracic surgery and medical oncology. The baseline survey and expert discussions highlighted implementation gaps in FDG-PET/CT, invasive mediastinal staging, biomarker testing, perioperative therapy, pathology standardization, and multidisciplinary review. All 35 consensus statements met the predefined threshold, with agreement ranging from 82% to 100%. CONCLUSIONS: These consensus statements provide a multidisciplinary, evidence-informed framework for the diagnosis and management of resectable NSCLC across the perioperative pathway. By contextualizing international evidence within Vietnamese clinical practice, the document may help improve consistency of care, support biomarker-guided and multimodality treatment, and strengthen multidisciplinary decision-making across institutions. CI - (c) AME Publishing Company. FAU - Do, Que Kim AU - Do QK AD - Thoracic and Cardiovascular Surgery Department, Thong Nhat Hospital, Ho Chi Minh City, Vietnam. AD - Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Vietnam. FAU - Pham, Dung Xuan AU - Pham DX AD - Ho Chi Minh City Cancer Society, Ho Chi Minh City, Vietnam. FAU - Nguyen, Hoa Thi Thai AU - Nguyen HTT AD - Department of Medical Oncology, National Cancer Hospital, Hanoi, Vietnam. FAU - Binh, Nguyen Hoang AU - Binh NH AD - Department of Thoracic Surgery, Cho Ray Hospital, Ho Chi Minh City, Vietnam. FAU - Nguyen, Khoi Tuan AU - Nguyen KT AD - Thoracic and Gynecologic Medical Oncology Department, Ho Chi Minh City Oncology Hospital, Ho Chi Minh City, Vietnam. FAU - Lam, Trung Quoc AU - Lam TQ AD - Department of Chemotherapy, University Medical Center Ho Chi Minh City, Ho Chi Minh City, Vietnam. FAU - Truong, Thiet Thanh AU - Truong TT AD - Department of Thoracic Surgery, Pham Ngoc Thach Hospital, Ho Chi Minh City, Vietnam. FAU - Trinh, Dung Tuan AU - Trinh DT AD - Department of Pathology and Cytology, Tam Anh General Hospital, Hanoi, Vietnam. AD - Vietnam Society of Pathology and Cytology, Hanoi, Vietnam. FAU - Le, Dung Thanh AU - Le DT AD - Department of Radiology, Viet Duc University Hospital, Hanoi, Vietnam. FAU - Le, Anh Tuan AU - Le AT AD - Cancer Center, Cho Ray Hospital, Ho Chi Minh City, Vietnam. FAU - Le, Ha Thu AU - Le HT AD - Department of Lung-Breast Medical Oncology, Hanoi Oncology Hospital, Hanoi, Vietnam. FAU - Nguyen, Dung Thi Ngoc AU - Nguyen DTN AD - Ho Chi Minh City Medical Association, Ho Chi Minh City, Vietnam. LA - eng PT - Journal Article PT - Review DEP - 20260922 PL - China TA - Transl Lung Cancer Res JT - Translational lung cancer research JID - 101646875 PMC - PMC13657883 OTO - NOTNLM OT - Resectable non-small cell lung cancer (resectable NSCLC) OT - Vietnam OT - expert consensus OT - multidisciplinary management OT - perioperative treatment COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-2026-0852/coif). All authors report the present project was supported by an educational grant from AstraZeneca Vietnam, which also provided medical writing support. The authors have no other conflicts of interest to declare. EDAT- 2026/10/14 11:34 MHDA- 2026/10/14 11:35 PMCR- 2026/09/30 CRDT- 2026/10/14 05:23 PHST- 2026/06/30 00:00 [received] PHST- 2026/08/26 00:00 [accepted] PHST- 2026/10/14 11:35 [medline] PHST- 2026/10/14 11:34 [pubmed] PHST- 2026/10/14 05:23 [entrez] PHST- 2026/09/30 00:00 [pmc-release] AID - tlcr-15-9-289 [pii] AID - 10.21037/tlcr-2026-0852 [doi] PST - ppublish SO - Transl Lung Cancer Res. 2026 Sep 30;15(9):289. doi: 10.21037/tlcr-2026-0852. Epub 2026 Sep 22. PMID- 42869269 OWN - NLM STAT- Publisher LR - 20261028 IS - 1873-1740 (Electronic) IS - 0033-0620 (Linking) DP - 2026 Oct 13 TI - Lifetime management of valvular heart disease in younger and low risk patients. LID - S0033-0620(26)00115-5 [pii] LID - 10.1016/j.pcad.2026.10.006 [doi] AB - Valvular heart disease in younger and low-risk patients presents unique therapeutic challenges because treatment decisions must account not only for immediate procedural success but also for the durability of the index intervention, the feasibility of future reinterventions, and the preservation of subsequent treatment options. Consequently, lifetime management has emerged as a longitudinal treatment paradigm in which every intervention influences the sequence, complexity, and outcomes of future procedures. Over the past decade, transcatheter valve therapies have expanded rapidly from a treatment reserved for elderly and high-surgical-risk patients to an increasingly adopted option in younger and lower-risk populations. Although contemporary evidence has demonstrated excellent procedural safety and mid-term outcomes, important uncertainties remain regarding long-term durability and the optimal management of structural valve deterioration and repeat interventions. These considerations highlight the importance of approaching each intervention not as an isolated procedure, but as a step within a predefined lifetime therapeutic strategy. In this context, structured Heart Team discussion and shared decision-making are fundamental to develop an individualized treatment plan that optimizes outcomes while preserving future surgical and transcatheter options across decades of patient care. This review aims to provide a practical framework for the lifetime management of aortic, mitral, and tricuspid valve disease in younger and low-risk patients. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Novelli, Laura AU - Novelli L AD - Servicio de Cardiologia, Hospital Universitari i Politecnic La Fe, Valencia, Spain. FAU - Fernandez Ortiz, Nerea AU - Fernandez Ortiz N AD - Servicio de Cardiologia, Hospital Universitari i Politecnic La Fe, Valencia, Spain. FAU - Murillo Varona, Guillem AU - Murillo Varona G AD - Servicio de Cardiologia, Hospital Universitari i Politecnic La Fe, Valencia, Spain. FAU - Diez Gil, Jose Luis AU - Diez Gil JL AD - Servicio de Cardiologia, Hospital Universitari i Politecnic La Fe, Valencia, Spain; CIBER-CV: Biomedical Research Networking Center in Cardiovascular Diseases, Institute of Health Carlos III, Madrid, Spain. FAU - Sanz Sanchez, Jorge AU - Sanz Sanchez J AD - Servicio de Cardiologia, Hospital Universitari i Politecnic La Fe, Valencia, Spain; CIBER-CV: Biomedical Research Networking Center in Cardiovascular Diseases, Institute of Health Carlos III, Madrid, Spain. Electronic address: sjorge4@gmx.com. LA - eng PT - Journal Article PT - Review DEP - 20261013 PL - United States TA - Prog Cardiovasc Dis JT - Progress in cardiovascular diseases JID - 0376442 SB - IM OTO - NOTNLM OT - Lifetime management OT - Low risk OT - Valvular heart disease COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/10/13 23:36 MHDA- 2026/10/13 23:36 CRDT- 2026/10/13 19:37 PHST- 2026/07/14 00:00 [received] PHST- 2026/10/06 00:00 [revised] PHST- 2026/10/10 00:00 [accepted] PHST- 2026/10/13 23:36 [pubmed] PHST- 2026/10/13 23:36 [medline] PHST- 2026/10/13 19:37 [entrez] AID - S0033-0620(26)00115-5 [pii] AID - 10.1016/j.pcad.2026.10.006 [doi] PST - aheadofprint SO - Prog Cardiovasc Dis. 2026 Oct 13:S0033-0620(26)00115-5. doi: 10.1016/j.pcad.2026.10.006. PMID- 42866888 OWN - NLM STAT- Publisher LR - 20261013 IS - 1524-4539 (Electronic) IS - 0009-7322 (Linking) DP - 2026 Oct 13 TI - Multidisciplinary Approach to Antiplatelet Management in Coronary Syndromes: A Scientific Statement From the American Heart Association. LID - 10.1161/CIR.0000000000001478 [doi] AB - Antiplatelet therapy is a cornerstone of care for patients with acute coronary syndrome and chronic coronary disease, yet its optimal use requires careful balancing of thrombotic risk reduction with bleeding complications. Since the mid-2000s, advances in stent technology, antiplatelet pharmacotherapy, procedural technique, and risk stratification tools have led to increasingly individualized approaches to antiplatelet management. Current guidelines and evidence emphasize tailoring agent selection, intensity, and duration of therapy according to patient-, procedure-, and disease-specific factors rather than a uniform strategy. However, the growing complexity of evidence, frequent care transitions, social determinants of health, and variability in patient characteristics have increased the risk of inappropriate prescribing, nonadherence, and adverse outcomes. This scientific statement reviews contemporary evidence informing antiplatelet strategies and highlights the critical role of the multidisciplinary cardiovascular team (interventional cardiology, general cardiology, pharmacists, advanced practice nurses) and the importance of their collective expertise in ensuring antithrombotic stewardship in patients with acute coronary syndrome and chronic coronary disease. FAU - Beavers, Craig J AU - Beavers CJ FAU - Dobesh, Paul P AU - Dobesh PP FAU - Cushman, Mary AU - Cushman M FAU - DiDomenico, Robert J AU - DiDomenico RJ FAU - Ijioma, Nkechinyere AU - Ijioma N FAU - Joshi, Ravi V AU - Joshi RV FAU - Medina-Beckwith, Jonathan AU - Medina-Beckwith J FAU - Pereira, Naveen AU - Pereira N FAU - Ruel, Marc AU - Ruel M FAU - Tabak, Rachel G AU - Tabak RG CN - American Heart Association Clinical Pharmacology Committee of the Council of Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Surgery and Anesthesia; and Council on Genomic and Precision Medicine LA - eng PT - Journal Article PT - Review DEP - 20261013 PL - United States TA - Circulation JT - Circulation JID - 0147763 SB - IM OTO - NOTNLM OT - AHA Scientific Statements OT - acute coronary syndrome OT - coronary disease OT - duration of therapy OT - inappropriate prescribing OT - risk assessment OT - thrombosis EDAT- 2026/10/13 17:37 MHDA- 2026/10/13 17:37 CRDT- 2026/10/13 15:02 PHST- 2026/10/13 17:37 [medline] PHST- 2026/10/13 17:37 [pubmed] PHST- 2026/10/13 15:02 [entrez] AID - 10.1161/CIR.0000000000001478 [doi] PST - aheadofprint SO - Circulation. 2026 Oct 13. doi: 10.1161/CIR.0000000000001478. PMID- 42866104 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20261013 LR - 20261014 IS - 1758-3896 (Electronic) IS - 1758-3896 (Print) IS - 1758-3896 (Linking) VI - 20 DP - 2026 TI - Cardiogenic Shock Systems of Care Best Practices. Part 1: Prehospital and Emergency Department Evaluation and Management. PG - e21 LID - 10.15420/usc.2025.16 [doi] LID - e21 AB - This paper explores best practices for the prehospital and emergency department evaluation and management of cardiogenic shock, a critical condition marked by high mortality rates, within a contemporary cardiogenic shock system of care. It highlights the significance of early identification and immediate intervention to prevent irreversible cardiac and non-cardiac organ damage. Emphasizing multidisciplinary team-based care and data-driven insights, the paper details optimal strategies for managing cardiogenic shock from initial contact, noting challenges in prehospital identification and treatment due to patient and disease heterogeneity and the variability in response capabilities of prehospital teams. CI - Copyright (c) The Author(s), 2026. Published by Radcliffe Group Ltd. FAU - Lauria, Michael J AU - Lauria MJ AUID- ORCID: 0000-0002-5157-2610 AD - Section of Critical Care, Department of Emergency Medicine, University of Washington Seattle, WA. AD - Section of EMS, Department of Emergency Medicine, University of Washington Seattle, WA. AD - Resuscitation Engineering Sciences Unit (RESCU) Research Center, University of Washington Seattle, WA. AD - Airlift Northwest Seattle, WA. FAU - Gottula, Adam L AU - Gottula AL AUID- ORCID: 0000-0001-8250-5149 AD - Center for Resuscitation Medicine, University of Minnesota Minneapolis, MN. AD - Division of Critical Care, Department of Anesthesiology, University of Minnesota Minneapolis, MN. AD - Department of Emergency Medicine, University of Minnesota Minneapolis, MN. FAU - Hallinan, William AU - Hallinan W AUID- ORCID: 0009-0003-8353-5077 AD - Heart Recovery, Johnson and Johnson Danvers, MA. FAU - Thomas, Eric AU - Thomas E AUID- ORCID: 0009-0001-1037-7878 AD - University of Rochester Rochester, NY. FAU - Wood, Katherine L AU - Wood KL AUID- ORCID: 0000-0003-4628-6852 AD - Department of Cardiothoracic Surgery, Cooperman Barnabas Medical Center Livingston, NJ. FAU - Basir, Mir B AU - Basir MB AUID- ORCID: 0000-0003-3486-6753 AD - Department of Cardiology, Henry Ford Health Detroit, MI. FAU - Truesdell, Alexander G AU - Truesdell AG AUID- ORCID: 0000-0001-5656-4401 AD - Virginia Heart, Inova Heart and Vascular Institute Falls Church, VA. FAU - Gorder, Kari L AU - Gorder KL AUID- ORCID: 0000-0003-3539-7696 AD - Critical Care Medicine, Ohio Health, Riverside Methodist Hospital Columbus, OH. LA - eng PT - Journal Article PT - Review DEP - 20260922 PL - England TA - US Cardiol JT - US cardiology JID - 101574791 PMC - PMC13655749 OTO - NOTNLM OT - Cardiogenic shock OT - emergency medicine OT - prehospital medicine OT - system of care COIS- Disclosure: WH is an employee of JNJ MedTech Abiomed. KLW has received consulting fees and honoraria from Abbott Laboratories and travel support from CVRx and Abbott Laboratories. MBB has received consulting fees and honoraria from Abiomed, Boston Scientific, Chiesi, and Zoll. AGT has received consulting fees and honoraria from Abiomed, Getinge, and Zoll. All other authors have no conflicts of interest to declare. EDAT- 2026/10/13 17:37 MHDA- 2026/10/13 17:38 PMCR- 2026/09/22 CRDT- 2026/10/13 13:14 PHST- 2025/10/07 00:00 [received] PHST- 2026/01/09 00:00 [accepted] PHST- 2026/10/13 17:38 [medline] PHST- 2026/10/13 17:37 [pubmed] PHST- 2026/10/13 13:14 [entrez] PHST- 2026/09/22 00:00 [pmc-release] AID - 10.15420/usc.2025.16 [doi] PST - epublish SO - US Cardiol. 2026 Sep 22;20:e21. doi: 10.15420/usc.2025.16. eCollection 2026. PMID- 42866100 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20261013 LR - 20261014 IS - 1758-3896 (Electronic) IS - 1758-3896 (Print) IS - 1758-3896 (Linking) VI - 20 DP - 2026 TI - Cardiogenic Shock Systems of Care Best Practices. Part 2: The Shock Team and Inpatient Management. PG - e22 LID - 10.15420/usc.2025.17 [doi] LID - e22 AB - This paper describes the contemporary inpatient management of cardiogenic shock, including critical care management and the use of mechanical circulatory support as part of a cardiogenic shock system of care. It highlights the importance of multidisciplinary shock teams for improving patient outcomes through advanced mechanical circulatory support systems and critical care management strategies. Drawing on successful models in trauma care, the paper discusses the evolution of specialized teams, the reduction of care variability, and the enhancement of survival rates through standardized best practices. A case study illustrates the effective implementation of these principles, resulting in improved short-term survival and long-term recovery for patients. CI - Copyright (c) The Author(s), 2026. Published by Radcliffe Group Ltd. FAU - Gorder, Kari L AU - Gorder KL AUID- ORCID: 0000-0003-3539-7696 AD - Critical Care Medicine, Ohio Health, Riverside Methodist Hospital Columbus, OH. FAU - Lauria, Michael J AU - Lauria MJ AUID- ORCID: 0000-0002-5157-2610 AD - Section of Critical Care, Department of Emergency Medicine, University of Washington Seattle, WA. AD - Section of EMS, Department of Emergency Medicine, University of Washington Seattle, WA. AD - Resuscitation Engineering Sciences Unit (RESCU) Research Center, University of Washington Seattle, WA. AD - Airlift Northwest Seattle, WA. FAU - Hallinan, William AU - Hallinan W AUID- ORCID: 0009-0003-8353-5077 AD - Heart Recovery, Johnson and Johnson Danvers, MA. FAU - Thomas, Eric AU - Thomas E AUID- ORCID: 0009-0001-1037-7878 AD - University of Rochester Rochester, NY. FAU - Wood, Katherine L AU - Wood KL AUID- ORCID: 0000-0003-4628-6852 AD - Department of Cardiothoracic Surgery, Cooperman Barnabas Medical Center Livingston, NJ. FAU - Basir, Mir B AU - Basir MB AUID- ORCID: 0000-0003-3486-6753 AD - Department of Cardiology, Henry Ford Health Detroit, MI. FAU - Truesdell, Alexander G AU - Truesdell AG AUID- ORCID: 0000-0001-5656-4401 AD - Virginia Heart, Inova Heart and Vascular Institute Falls Church, VA. FAU - Gottula, Adam L AU - Gottula AL AUID- ORCID: 0000-0001-8250-5149 AD - Center for Resuscitation Medicine, University of Minnesota Minneapolis, MN. AD - Division of Critical Care, Department of Anesthesiology, University of Minnesota Minneapolis, MN. AD - Department of Emergency Medicine, University of Minnesota Minneapolis, MN. LA - eng PT - Journal Article PT - Review DEP - 20260922 PL - England TA - US Cardiol JT - US cardiology JID - 101574791 PMC - PMC13655750 OTO - NOTNLM OT - Cardiogenic shock OT - critical care medicine OT - mechanical circulatory support OT - system of care COIS- Disclosure: WH is an employee of JNJ MedTech Abiomed. KLW has received consulting fees and honoraria from Abbott Laboratories and travel support from CVRx and Abbott Laboratories. MBB has received consulting fees and honoraria from Abiomed, Boston Scientific, Chiesi, and Zoll. AGT has received consulting fees and honoraria from Abiomed, Getinge, and Zoll. All other authors have no conflicts of interest to declare. EDAT- 2026/10/13 17:37 MHDA- 2026/10/13 17:38 PMCR- 2026/09/22 CRDT- 2026/10/13 13:14 PHST- 2025/10/07 00:00 [received] PHST- 2026/01/14 00:00 [accepted] PHST- 2026/10/13 17:38 [medline] PHST- 2026/10/13 17:37 [pubmed] PHST- 2026/10/13 13:14 [entrez] PHST- 2026/09/22 00:00 [pmc-release] AID - 10.15420/usc.2025.17 [doi] PST - epublish SO - US Cardiol. 2026 Sep 22;20:e22. doi: 10.15420/usc.2025.17. eCollection 2026. PMID- 42864679 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20261013 LR - 20261014 IS - 2057-4967 (Electronic) IS - 2095-9370 (Print) IS - 2057-4967 (Linking) VI - 12 IP - 1 DP - 2026 Oct 12 TI - Early experience of a dedicated heart-brain integrated ward at Peking Union Medical College Hospital: a retrospective descriptive study. LID - 10.1186/s41016-026-00451-9 [doi] LID - 32 AB - BACKGROUND: Heart-brain comorbidities present unique diagnostic and therapeutic challenges because neurological and cardiac conditions often share pathophysiological mechanisms yet create conflicting treatment demands. Multidisciplinary wards integrating neurosurgery, cardiac surgery, cardiology, and neurology have been proposed, but real-world experience remains limited. We report the initial experience of a dedicated heart-brain integrated ward at a Chinese tertiary referral center. METHODS: We conducted a retrospective descriptive study of all consecutive patients admitted to the Heart-Brain Integrated Ward at Peking Union Medical College Hospital between July 1 and August 21, 2026. Clinical data were entered prospectively into the electronic medical record during routine care and analyzed retrospectively. Variables included demographics, neurological and cardiac diagnoses, a six-category comorbidity classification, MDT decisions, treatment strategies, and discharge outcomes. Treatment categories were predefined as: (i) diagnostic procedures, (ii) therapeutic single-system interventions, (iii) staged dual-system treatment within the same admission, and (iv) synchronous dual-system treatment in a single session. RESULTS: Fifty-six patients (42 males, 75.0%; mean age 62.4 +/- 12.2 years, range 19-80) were enrolled. The most common category was I.1 (shared atherosclerotic vascular disease; 29/56, 51.8%), predominantly ischemic cerebrovascular disease with coronary artery disease (18/56, 32.1%). Category IV (psychocardiological disorders) accounted for 12 patients (21.4%), and Category V (therapeutically interactive) for 3 (5.4%). All patients underwent at least one MDT discussion (100%), and 55 (98.2%) required a second. Of 56 patients, 41 (73.2%) underwent surgical or endovascular intervention and 15 (26.8%) received medical management or remained under evaluation. Among treated patients, 4 (7.1%) received synchronous dual-system procedures, 13 (23.2%) completed staged procedures within the same admission, and 24 (42.9%) underwent single-system intervention. Fourteen patients (25.0%) required intervention for both organ systems. No in-hospital mortality or major procedure-related complications were observed among 38 discharged patients (67.9%); 18 patients (32.1%) remained hospitalized at data cutoff. CONCLUSIONS: Establishing a dedicated heart-brain integrated ward at a tertiary referral center appears operationally feasible and enables structured MDT-based care for complex neuro-cardiac patients. The early disease spectrum is dominated by atherosclerotic pan-vascular disease. Synchronous dual-system procedures were performed in a small selected subset without observed major early events among discharged patients, but this cannot establish safety or generalizability. Larger prospective studies with controlled comparisons and longer follow-up are needed. CI - (c) 2026. The Author(s). FAU - Liu, Qi AU - Liu Q AD - Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Zhao, Yang AU - Zhao Y AD - Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Zhao, Yanxue AU - Zhao Y AD - Department of Cardiac Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Yang, Sheng AU - Yang S AD - Department of Cardiac Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Zheng, Jun AU - Zheng J AD - Department of Cardiac Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. zhengjun@pumch.cn. FAU - Zhao, Yuanli AU - Zhao Y AD - Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. zhaoyuanli@126.com. LA - eng GR - 2026-PUMCH-A-083/Peking Union Medical College Hospital Central High-Level Hospital Clinical Research Special Projec/ PT - Journal Article DEP - 20261012 PL - England TA - Chin Neurosurg J JT - Chinese neurosurgical journal JID - 101672561 PMC - PMC13656498 OTO - NOTNLM OT - Coronary artery disease OT - Heart-brain comorbidity OT - Hybrid operating room OT - Integrated care OT - Multidisciplinary team OT - Pan-vascular disease OT - Stroke COIS- Declarations. Ethics approval and consent to participate: This was a retrospective descriptive study conducted at the Heart-Brain Integrated Ward of PUMCH, Beijing, China. The study period covered July 1 through August 21, 2026. In consultation with the Institutional Review Board of PUMCH (1-26YJ0951), the study was deemed exempt from full ethical review due to its retrospective, de-identified nature; the requirement for individual informed consent was waived. Clinical data were entered prospectively into the electronic medical record during routine care and were analyzed retrospectively. Consent for publication: Not applicable. No individual patient data or images are presented. Competing interests: The authors declare no competing interests. EDAT- 2026/10/13 05:31 MHDA- 2026/10/13 05:32 PMCR- 2026/10/12 CRDT- 2026/10/13 00:45 PHST- 2026/08/24 00:00 [received] PHST- 2026/09/30 00:00 [accepted] PHST- 2026/10/13 05:32 [medline] PHST- 2026/10/13 05:31 [pubmed] PHST- 2026/10/13 00:45 [entrez] PHST- 2026/10/12 00:00 [pmc-release] AID - 10.1186/s41016-026-00451-9 [pii] AID - 451 [pii] AID - 10.1186/s41016-026-00451-9 [doi] PST - epublish SO - Chin Neurosurg J. 2026 Oct 12;12(1):32. doi: 10.1186/s41016-026-00451-9. PMID- 42864253 OWN - NLM STAT- Publisher LR - 20261012 IS - 1444-2892 (Electronic) IS - 1443-9506 (Linking) DP - 2026 Oct 12 TI - Coronary Revascularisation Strategies for Patients with Obstructive Coronary Artery Disease Requiring Lung Transplantation: A Narrative Review and Single-Centre Experience. LID - S1443-9506(26)00423-3 [pii] LID - 10.1016/j.hlc.2026.05.014 [doi] AB - BACKGROUND: Lung transplant (LTx) candidates often have multiple risk factors for coronary artery disease (CAD), which was previously considered a contraindication to transplantation. Improvements in revascularisation techniques have broadened transplant eligibility; however, because available evidence is based on small and heterogeneous cohorts, the optimal revascularisation strategy remains unclear. METHOD: We conducted a literature review and describe our centre's experience with current approaches to revascularisation in LTx candidates with obstructive CAD. RESULTS: The literature review identified 174 studies in the initial search, of which 29 studies were considered relevant. However, only six retrospective studies directly compared percutaneous coronary intervention (PCI) and coronary artery bypass graft surgery (CABG), comprising 376 revascularised patients. In some cohorts, CABG was associated with longer ventilation time and longer intensive care unit (ICU) stay and overall hospital stay, although this finding was not consistent across all studies. At our centre, 20 patients underwent concomitant CABG, and 11 underwent PCI within 12 months before transplant listing, after obstructive CAD was diagnosed during transplant assessment. Procedure time in patients undergoing concomitant CABG was significantly longer (1.2 hours; p<0.05); however, all patients in this group underwent bilateral transplantation. Three patients in the PCI group experienced postoperative coronary events, and overall mortality was higher in this group. There were no differences in other outcomes, including ICU and overall length of stay. CONCLUSIONS: These findings highlight the heterogeneity and complexity of this patient cohort. Although no patients who underwent CABG experienced postoperative coronary events, the limited published evidence does not support a single preferred revascularisation strategy for patients being considered for lung transplantation. Case-by-case management guided by a multidisciplinary team is therefore warranted. CI - Copyright (c) 2026 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights reserved. FAU - Adonopulos, Aaron AU - Adonopulos A AD - Department of Cardiothoracic Surgery, St Vincent's Hospital, Sydney, NSW, Australia; University of New South Wales, Sydney, NSW, Australia. Electronic address: aaron.adonopulos@svha.org.au. FAU - Kempton, Hannah AU - Kempton H AD - University of New South Wales, Sydney, NSW, Australia; Department of Cardiology, St Vincent's Hospital, Sydney, NSW, Australia. FAU - Meredith, Thomas AU - Meredith T AD - University of New South Wales, Sydney, NSW, Australia; Department of Cardiology, St Vincent's Hospital, Sydney, NSW, Australia; Victor Chang Cardiac Research Institute, Sydney, NSW, Australia. FAU - Mullin, Alexander AU - Mullin A AD - Department of Heart Lung Transplant, St Vincent's Hospital, Sydney, NSW, Australia. FAU - Havryk, Adrian AU - Havryk A AD - Department of Heart Lung Transplant, St Vincent's Hospital, Sydney, NSW, Australia. FAU - Jansz, Paul AU - Jansz P AD - Department of Cardiothoracic Surgery, St Vincent's Hospital, Sydney, NSW, Australia; Department of Heart Lung Transplant, St Vincent's Hospital, Sydney, NSW, Australia. FAU - Macdonald, Peter AU - Macdonald P AD - Department of Cardiology, St Vincent's Hospital, Sydney, NSW, Australia; Victor Chang Cardiac Research Institute, Sydney, NSW, Australia; Department of Heart Lung Transplant, St Vincent's Hospital, Sydney, NSW, Australia. LA - eng PT - Journal Article DEP - 20261012 PL - Australia TA - Heart Lung Circ JT - Heart, lung & circulation JID - 100963739 SB - IM OTO - NOTNLM OT - Coronary artery disease OT - Ischaemic heart disease OT - Revascularisation OT - Transplantation COIS- Declaration of Competing Interests There are no conflicts of interest to disclose. EDAT- 2026/10/13 00:16 MHDA- 2026/10/13 00:16 CRDT- 2026/10/12 22:03 PHST- 2026/02/17 00:00 [received] PHST- 2026/05/06 00:00 [revised] PHST- 2026/05/07 00:00 [accepted] PHST- 2026/10/13 00:16 [medline] PHST- 2026/10/13 00:16 [pubmed] PHST- 2026/10/12 22:03 [entrez] AID - S1443-9506(26)00423-3 [pii] AID - 10.1016/j.hlc.2026.05.014 [doi] PST - aheadofprint SO - Heart Lung Circ. 2026 Oct 12:S1443-9506(26)00423-3. doi: 10.1016/j.hlc.2026.05.014. PMID- 42862133 OWN - NLM STAT- Publisher LR - 20261012 IS - 1916-7075 (Electronic) IS - 0828-282X (Linking) DP - 2026 Oct 12 TI - Canadian Cardiovascular Society/Canadian Society of Cardiovascular Surgery/Canadian Association of Interventional Cardiology Clinical Practice Update on Transcatheter Mitral and Tricuspid Valve Intervention: Patient Evaluation and Management. LID - S0828-282X(26)01054-8 [pii] LID - 10.1016/j.cjca.2026.07.372 [doi] AB - The management of mitral valve (MV) and tricuspid valve (TV) regurgitation has undergone significant transformation during the past decade. This change has been driven by a growing understanding of the adverse clinical consequences of these conditions, particularly their strong association with heart failure progression, reduced quality of life, and increased mortality-and by the emergence of effective transcatheter options for valve intervention. Among these, transcatheter MV edge-to-edge repair and replacement and transcatheter tricuspid edge-to-edge repair and replacement have become important therapeutic tools that provide a less invasive alternative to surgery in appropriately selected patients. In this clinical practice update we aim to provide contemporary, evidence-based guidance for clinicians in the evaluation and management of patients with severe, symptomatic MV or TV regurgitation who might benefit from transcatheter intervention. Key topics include the clinical presentation of these valve lesions, the diagnostic evaluation with emphasis on multimodality imaging and hemodynamics, criteria for patient selection, and current data on procedural and long-term clinical outcomes. A central theme is the role of timely referral and structured assessment to avoid missed opportunities for intervention. Optimal outcomes require active engagement from referring physicians and close collaboration within a multidisciplinary heart team, including cardiologists, cardiac surgeons, imaging specialists, heart failure specialists, and nursing partners-to ensure careful patient selection, procedural planning, and comprehensive post-intervention follow-up. By integrating clinical judgement with guideline-based recommendations and procedural expertise, transcatheter edge-to-edge repair or transcatheter valve replacement can offer substantial symptomatic relief and improved quality of life for selected patients, while minimizing procedural risk and enhancing overall cardiovascular outcomes. CI - Copyright (c) 2026 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved. FAU - Asgar, Anita W AU - Asgar AW AD - Bluhm Cardiovascular Institute, Northwestern Medicine, Northwestern University, Chicago, Illinois, USA. FAU - Cohen, Gideon AU - Cohen G AD - Division of Cardiac Surgery, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada. FAU - Adams, Corey AU - Adams C AD - Cumming School of Medicine, Department of Cardiac Sciences, Foothills Medical Centre, University of Calgary, Calgary, Alberta, Canada. FAU - Boone, Robert H AU - Boone RH AD - Division of Cardiology, St Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Hayami, Doug AU - Hayami D AD - Division of Cardiology, QEII Health Sciences Center, Dalhousie University, Halifax, Nova Scotia, Canada. FAU - Lauck, Sandra B AU - Lauck SB AD - St Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Messika-Zeitoun, David AU - Messika-Zeitoun D AD - Division of Cardiology, University of Ottawa Heart Institute, University of Ottawa, Ottawa, Ontario, Canada. FAU - Ong, Geraldine AU - Ong G AD - Division of Cardiology, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada. FAU - Walker, Mathieu AU - Walker M AD - Division of Cardiology, St Mary's Center Hospital, McGill University, Montreal, Quebec, Canada. FAU - Fam, Neil P AU - Fam NP AD - Division of Cardiology, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada. Electronic address: Neil.Fam@unityhealth.to. LA - eng PT - Journal Article PT - Practice Guideline DEP - 20261012 PL - England TA - Can J Cardiol JT - The Canadian journal of cardiology JID - 8510280 SB - IM OTO - NOTNLM OT - mitral regurgitation OT - transcatheter edge-to-edge repair OT - transcatheter valve replacement OT - tricuspid regurgitation EDAT- 2026/10/12 11:41 MHDA- 2026/10/12 11:41 CRDT- 2026/10/12 10:29 PHST- 2026/06/12 00:00 [received] PHST- 2026/07/26 00:00 [revised] PHST- 2026/07/27 00:00 [accepted] PHST- 2026/10/12 11:41 [medline] PHST- 2026/10/12 11:41 [pubmed] PHST- 2026/10/12 10:29 [entrez] AID - S0828-282X(26)01054-8 [pii] AID - 10.1016/j.cjca.2026.07.372 [doi] PST - aheadofprint SO - Can J Cardiol. 2026 Oct 12:S0828-282X(26)01054-8. doi: 10.1016/j.cjca.2026.07.372. PMID- 42861142 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20261012 LR - 20261013 IS - 2223-4292 (Print) IS - 2223-4306 (Electronic) IS - 2223-4306 (Linking) VI - 16 IP - 10 DP - 2026 Oct 1 TI - Echocardiographic characteristics and clinical features of cardiac involvement in Behcet's disease: a retrospective single-center case series. PG - 793 LID - 10.21037/qims-2026-1122 [doi] LID - 793 AB - BACKGROUND: Cardiac involvement in Behcet's disease (BD) is uncommon but potentially life-threatening and may mimic other cardiovascular disorders, complicating early diagnosis. This study aimed to characterize the clinical and echocardiographic features, treatment, pathological findings, and clinical outcomes of patients with cardiac BD, with particular emphasis on the utility of echocardiography in raising diagnostic suspicion. METHODS: We retrospectively screened 186 patients with diagnosed or suspected BD at The Second Affiliated Hospital of Jiangxi Medical College, Nanchang University between October 2020 and January 2026. Of the 112 patients who underwent transthoracic echocardiography, 23 met the International Criteria for BD and were determined by multidisciplinary evaluation to have cardiac lesions attributable to BD after exclusion of alternative etiologies. Clinical, laboratory, electrocardiographic, echocardiographic, pathological, treatment, and follow-up data were descriptively analyzed. RESULTS: The cohort was predominantly male (82.6%), with a mean age of 43.5+/-13.1 years. The most frequent systemic manifestations were oral ulcers (95.7%), cutaneous lesions (73.9%), and genital ulcers (60.9%). Elevated inflammatory markers, including erythrocyte sedimentation rate (87.0%) and C-reactive protein (82.6%), were frequently observed. B-type natriuretic peptide levels were elevated in 91.3% of patients. Among the 19 patients without a history of cardiac surgery, severe aortic regurgitation was the predominant echocardiographic finding (94.7%) and was most often associated with aortic valve prolapse (78.9%). Other echocardiographic findings included aortic cusp aneurysm with perforation (15.8%), echo-free spaces around the aortic root (21.1%), aortic root and/or ascending aortic dilatation (63.2%), pulmonary artery dilatation (52.6%), left-sided chamber enlargement (84.2%), four-chamber enlargement (10.5%), and reduced left ventricular ejection fraction (21.1%). Among the four patients with a history of cardiac or great-vessel surgery, all three who had undergone aortic valve replacement developed prosthetic valve dehiscence with severe paravalvular leakage within 2-6 months of surgery. Pathological examination of 14 surgical specimens revealed inflammatory-destructive changes involving the aortic wall and valve, characterized by fibrosis, hyalinization, myxoid degeneration, and chronic inflammatory cell infiltration. All patients received glucocorticoid-based immunosuppressive therapy, and 17 also underwent surgical treatment. At the last follow-up, 16 of 23 patients were alive and clinically stable, four were lost to follow-up, and three had died. CONCLUSIONS: In this case series, cardiac BD was mainly characterized by destructive valvulo-aortic lesions, particularly severe aortic regurgitation associated with cusp prolapse and periannular or aortic root abnormalities. Echocardiography plays an important role in defining lesion morphology and severity, detecting postoperative prosthetic valve complications, and identifying structural abnormalities that may raise suspicion for cardiac BD in the appropriate clinical context. CI - (c) AME Publishing Company. FAU - Wang, Wei AU - Wang W AUID- ORCID: 0009-0002-0422-432X AD - Department of ultrasound, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China. FAU - Wu, Shan AU - Wu S AUID- ORCID: 0009-0003-6437-4052 AD - Department of ultrasound, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China. FAU - Yang, Liling AU - Yang L AUID- ORCID: 0009-0003-3650-0621 AD - Department of ultrasound, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China. FAU - Liao, Jie AU - Liao J AUID- ORCID: 0009-0004-9701-2530 AD - Jiangxi Medical College, Nanchang University, Nanchang, China. FAU - Wang, Mengying AU - Wang M AUID- ORCID: 0009-0006-2176-5506 AD - Department of ultrasound, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China. FAU - Wang, Jiwei AU - Wang J AUID- ORCID: 0000-0002-6202-4652 AD - Department of ultrasound, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China. LA - eng PT - Journal Article DEP - 20260919 PL - China TA - Quant Imaging Med Surg JT - Quantitative imaging in medicine and surgery JID - 101577942 PMC - PMC13654100 OTO - NOTNLM OT - Behcet's disease (BD) OT - aortic regurgitation OT - cardiac involvement OT - echocardiography OT - prosthetic valve dehiscence COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://qims.amegroups.com/article/view/10.21037/qims-2026-1122/coif). The authors have no conflicts of interest to declare. EDAT- 2026/10/12 05:32 MHDA- 2026/10/12 05:33 PMCR- 2026/10/01 CRDT- 2026/10/12 04:17 PHST- 2026/05/08 00:00 [received] PHST- 2026/08/18 00:00 [accepted] PHST- 2026/10/12 05:33 [medline] PHST- 2026/10/12 05:32 [pubmed] PHST- 2026/10/12 04:17 [entrez] PHST- 2026/10/01 00:00 [pmc-release] AID - qims-16-10-793 [pii] AID - 10.21037/qims-2026-1122 [doi] PST - ppublish SO - Quant Imaging Med Surg. 2026 Oct 1;16(10):793. doi: 10.21037/qims-2026-1122. Epub 2026 Sep 19. PMID- 42860941 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20261012 LR - 20261013 IS - 2221-2965 (Electronic) IS - 2221-2965 (Linking) VI - 12 DP - 2026 TI - Transitioning from direct vision to totally endoscopic minimally invasive cardiac surgery. PG - 44 LID - 10.21037/jovs-2025-1-55 [doi] LID - 44 AB - Minimally invasive cardiac surgery (MICS) has evolved significantly over the past two decades, shifting from conventional median sternotomy toward sternal-sparing approaches that offer reduced surgical trauma, lower complication rates, and faster patient recovery. As incision size has progressively decreased, the field has advanced toward totally endoscopic cardiac surgery (TECS), in which the entire intracardiac procedure is performed exclusively under thoracoscopic visualization. Despite growing adoption, the transition from direct-vision MICS to TECS remains technically demanding and operationally complex. Drawing on our institutional experience at Brigham and Women's Hospital, Harvard Medical School, and a review of the current literature, we provide a comprehensive overview of the key elements required to successfully build and sustain a TECS program. These include a working definition of totally endoscopic surgery, a proposed four-phase surgeon training pathway, simulation-based learning strategies, robotic credentialing, team-based training, technical instrumentation, scope management, patient selection criteria, procedural challenges, and postoperative outcomes. Both non-robotic and robotic-assisted endoscopic platforms are discussed. Large-scale evidence confirms that MICS and TECS achieve outcomes equivalent or superior to sternotomy, with low mortality and stroke rates, and significantly improved health-related quality of life. Notably, non-robotic TECS offers a scalable and cost-effective pathway that does not require an expert bedside assistant, can address multiple pathologies simultaneously, and is feasible across diverse healthcare settings. Emerging technologies-including articulated robotic instruments, artificial intelligence-enhanced imaging, and next-generation robotic platforms-are expected to further expand the reach and safety of fully endoscopic cardiac procedures. CI - (c) AME Publishing Company. FAU - Danesi, Tommaso Hinna AU - Danesi TH AD - Division of Cardiac Surgery, Mass General Brigham, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. FAU - Zancanaro, Edoardo AU - Zancanaro E AUID- ORCID: 0000-0003-0259-0844 AD - Division of Cardiac Surgery, Mass General Brigham, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. LA - eng PT - Journal Article PT - Review DEP - 20260921 PL - China TA - J Vis Surg JT - Journal of visualized surgery JID - 101677561 PMC - PMC13653785 OTO - NOTNLM OT - Totally endoscopic cardiac surgery (TECS) OT - minimally invasive cardiac surgery (MICS) OT - mitral valve OT - robotic cardiac surgery OT - surgeon training COIS- Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://jovs.amegroups.com/article/view/10.21037/jovs-2025-1-55/coif). The series "Endoscopic Cardiac Surgery" was commissioned by the editorial office without any funding or sponsorship. T.H.D. served as the unpaid Guest Editor of the series and serves as an unpaid editorial board member in Journal of Visualized Surgery from September 2024 to December 2028. The authors have no other conflicts of interest to declare. EDAT- 2026/10/12 05:32 MHDA- 2026/10/12 05:33 PMCR- 2026/09/21 CRDT- 2026/10/12 03:59 PHST- 2025/11/26 00:00 [received] PHST- 2026/07/08 00:00 [accepted] PHST- 2026/10/12 05:33 [medline] PHST- 2026/10/12 05:32 [pubmed] PHST- 2026/10/12 03:59 [entrez] PHST- 2026/09/21 00:00 [pmc-release] AID - jovs-12-44 [pii] AID - 10.21037/jovs-2025-1-55 [doi] PST - epublish SO - J Vis Surg. 2026 Sep 21;12:44. doi: 10.21037/jovs-2025-1-55. eCollection 2026. PMID- 42860806 OWN - NLM STAT- MEDLINE DCOM- 20261012 LR - 20261027 IS - 1099-0496 (Electronic) IS - 8755-6863 (Print) IS - 1099-0496 (Linking) VI - 61 IP - 10 DP - 2026 Oct TI - Making the Diagnosis of Primary Ciliary Dyskinesia in Australia. PG - e71863 LID - e71863 [pii] LID - 10.1002/ppul.71863 [doi] AB - BACKGROUND AND OBJECTIVE: Primary Ciliary Dyskinesia (PCD) is a genetic disorder associated with recurrent infections and irreversible airway damage. No single diagnostic test exists, necessitating use of a diagnostic algorithm that varies internationally. This retrospective study aimed to describe the clinical characteristics of patients, and algorithm used to diagnose PCD in New South Wales between 2014 and 2024. METHODS: A retrospective review of patients diagnosed with PCD at Concord Repatriation General Hospital (CRGH) from 2014 to 2024 was performed. RESULTS: This study included 52 patients with median age of diagnosis 7.0 years. The diagnostic algorithm consists of nasal nitric oxide (nNO) in patients > 5 years, and nasal brushings for high-speed video microscopy (HSVMA), immunofluorescence (IF) and electron microscopy (EM). Whole exome sequencing is not routine and was performed in 33% of the cohort. The diagnosis was confirmed by a multidisciplinary team that considered the test results and clinical phenotype. Non-diagnostic results occurred in 14% (nNO), 15% (HSVMA), 41% (IF) and 30% (EM) of patients eventually diagnosed with PCD or PCD "highly likely". Cumulatively, 56% of patients had at least one non-diagnostic result. Of the 17 patients who underwent whole exome sequencing with a PCD panel, 41% had diagnostic genetic results. CONCLUSION: Ciliary studies continue to be the mainstay of PCD diagnosis at CRGH. Although genetic testing is not part of the CRGH diagnostic algorithm, the CRGH algorithm has similar diagnostic performance to the ERS and ATS guidelines. CI - (c) 2026 The Author(s). Pediatric Pulmonology published by Wiley Periodicals LLC. FAU - Cai, Michelle AU - Cai M AUID- ORCID: 0009-0004-0404-661X AD - Discipline of Paediatrics and Child Health, School of Clinical Medicine, Faculty of Medicine and Health, Sydney, NSW, Australia. FAU - Frohlich, Megan AU - Frohlich M AD - Discipline of Paediatrics and Child Health, School of Clinical Medicine, Faculty of Medicine and Health, Sydney, NSW, Australia. AD - Department of Respiratory Medicine, Sydney Children's Hospital, Sydney, NSW, Australia. FAU - Owens, Louisa AU - Owens L AD - Discipline of Paediatrics and Child Health, School of Clinical Medicine, Faculty of Medicine and Health, Sydney, NSW, Australia. AD - Department of Respiratory Medicine, Children's Health Ireland, Crumlin, Ireland. FAU - Hardaker, Kate AU - Hardaker K AUID- ORCID: 0009-0006-9792-6636 AD - Department of Thoracic Medicine, Concord Repatriation General Hospital, Sydney, NSW, Australia. FAU - Fitzgerald, Dominic A AU - Fitzgerald DA AUID- ORCID: 0000-0001-8181-9648 AD - Department of Respiratory Medicine, The Children's Hospital at Westmead, Sydney, NSW, Australia. AD - Discipline of Paediatrics and Child Health, Faculty of Medicine, University of Sydney, Sydney, NSW, Australia. FAU - Campbell, Raewyn AU - Campbell R AUID- ORCID: 0000-0002-6512-3613 AD - Macquarie University Hospital, Sydney, NSW, Australia. AD - Faculty of Medicine, University of Sydney, Sydney, NSW, Australia. FAU - Prentice, Bernadette AU - Prentice B AUID- ORCID: 0000-0002-8600-1009 AD - Discipline of Paediatrics and Child Health, School of Clinical Medicine, Faculty of Medicine and Health, Sydney, NSW, Australia. AD - Department of Respiratory Medicine, Sydney Children's Hospital, Sydney, NSW, Australia. FAU - Morgan, Lucy AU - Morgan L AD - Department of Thoracic Medicine, Concord Repatriation General Hospital, Sydney, NSW, Australia. AD - Faculty of Medicine, University of Sydney, Sydney, NSW, Australia. LA - eng GR - Sydney Children's Hospitals Foundation/ GR - Sydney Children's Hospitals Network Kids Research Clinician Researcher fellowship/ PT - Journal Article PL - United States TA - Pediatr Pulmonol JT - Pediatric pulmonology JID - 8510590 RN - 31C4KY9ESH (Nitric Oxide) SB - IM MH - Humans MH - Female MH - *Kartagener Syndrome/diagnosis/genetics MH - Retrospective Studies MH - Child, Preschool MH - Child MH - Male MH - Algorithms MH - New South Wales MH - Adolescent MH - Nitric Oxide/analysis MH - Microscopy, Electron MH - Microscopy, Video MH - Infant PMC - PMC13655486 OTO - NOTNLM OT - Australia OT - cilia OT - diagnosis OT - primary ciliary dyskinesia COIS- M.F. served as a board member for PCD Australia from 2022 to 2025. DF serves as the Editor-in-Chief of Paediatric Respiratory Reviews. L.M. has received consulting fees from GSK, Pfizer, reCODE Therapeutics, Sanofi, and Chiesi. L.M. has also received payment from Boehringer Ingelheim for education events and serves as the Chair of Lung Foundation Australia. All other authors have no conflicts of interest to report. EDAT- 2026/10/12 05:32 MHDA- 2026/10/12 05:33 PMCR- 2026/10/12 CRDT- 2026/10/12 02:34 PHST- 2026/08/08 00:00 [revised] PHST- 2025/10/09 00:00 [received] PHST- 2026/09/26 00:00 [accepted] PHST- 2026/10/12 05:33 [medline] PHST- 2026/10/12 05:32 [pubmed] PHST- 2026/10/12 02:34 [entrez] PHST- 2026/10/12 00:00 [pmc-release] AID - e71863 [pii] AID - PPUL71863 [pii] AID - 10.1002/ppul.71863 [doi] PST - ppublish SO - Pediatr Pulmonol. 2026 Oct;61(10):e71863. doi: 10.1002/ppul.71863. PMID- 42859523 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20261011 LR - 20261012 IS - 2153-8174 (Electronic) IS - 1530-6550 (Print) IS - 1530-6550 (Linking) VI - 27 IP - 9 DP - 2026 Sep TI - Single-Stage Computed Tomography Angiography, Percutaneous Coronary Intervention, and Transcatheter Aortic Valve Replacement in an Octogenarian With Femoral Neck Fracture, Non-ST-Elevation Myocardial Infarction, and Severe Aortic Stenosis: A Case Report and Literature Review of Multidisciplinary Approaches. PG - 50145 LID - 10.31083/RCM50145 [doi] LID - 50145 AB - Geriatric femoral neck fractures are associated with high mortality. Early surgery within 48 hours improves survival, whereas delayed arthroplasty is associated with a 41% increase in mortality. Multimorbidity in this population often prolongs preoperative optimization, thereby exacerbating perioperative risk. Current evidence indicates that 5%-10% of patients with hip fractures have concomitant severe aortic stenosis (AS), which independently increases the risk of anesthesia-related complications. Perioperative acute myocardial infarction further increases mortality risk, making cardiac management a critical challenge. The advent of transcatheter aortic valve replacement (TAVR) has revolutionized care paradigms. Nonetheless, this situation requires multidisciplinary consensus on optimizing the fracture-to-surgery interval, antithrombotic bridging strategies, and concomitant coronary revascularization. Here, we present a case of single-stage aorta-coronary computed tomography angiography (CTA), percutaneous coronary intervention (PCI), and TAVR in an octogenarian with femoral neck fracture, severe AS, and non-ST-elevation myocardial infarction (NSTEMI). This pioneering case is accompanied by a systematic review of contemporary management strategies. CI - Copyright: (c) 2026 The Author(s). Published by IMR Press. FAU - Zhang, Ming AU - Zhang M AUID- ORCID: 0000-0003-2871-5115 AD - Senior Department of Cardiology, The First Medical Center of PLA General Hospital, 100853 Beijing, China. FAU - Pan, Xietian AU - Pan X AUID- ORCID: 0000-0002-7471-890X AD - Senior Department of Cardiology, The Sixth Medical Center of PLA General Hospital, 100853 Beijing, China. FAU - Yang, Lina AU - Yang L AD - Senior Department of Cardiology, The First Medical Center of PLA General Hospital, 100853 Beijing, China. FAU - Mu, Yang AU - Mu Y AUID- ORCID: 0000-0003-1375-4760 AD - Senior Department of Cardiology, The Sixth Medical Center of PLA General Hospital, 100853 Beijing, China. FAU - Jiang, Bo AU - Jiang B AD - Senior Department of Cardiology, The Sixth Medical Center of PLA General Hospital, 100853 Beijing, China. FAU - Chen, Tao AU - Chen T AD - Senior Department of Cardiology, The Sixth Medical Center of PLA General Hospital, 100853 Beijing, China. FAU - Wang, Jing AU - Wang J AUID- ORCID: 0009-0007-0915-5681 AD - Senior Department of Cardiology, The Sixth Medical Center of PLA General Hospital, 100853 Beijing, China. FAU - Wang, Lin AU - Wang L AUID- ORCID: 0000-0002-2610-695X AD - Senior Department of Cardiology, The Sixth Medical Center of PLA General Hospital, 100853 Beijing, China. FAU - Li, Jiayue AU - Li J AUID- ORCID: 0000-0002-8052-9099 AD - Senior Department of Cardiology, The Sixth Medical Center of PLA General Hospital, 100853 Beijing, China. FAU - Liu, Jing AU - Liu J AUID- ORCID: 0000-0003-0007-845X AD - Senior Department of Anesthesiology, The First Medical Center of PLA General Hospital, 100853 Beijing, China. FAU - Zhang, Zhuo AU - Zhang Z AUID- ORCID: 0000-0003-2503-4445 AD - Senior Department of Orthopedics, The First Medical Center of PLA General Hospital, 100853 Beijing, China. FAU - Liu, Changfu AU - Liu C AUID- ORCID: 0009-0005-1054-1198 AD - Senior Department of Cardiology, The Sixth Medical Center of PLA General Hospital, 100853 Beijing, China. LA - eng PT - Journal Article PT - Review DEP - 20260917 PL - Singapore TA - Rev Cardiovasc Med JT - Reviews in cardiovascular medicine JID - 100960007 PMC - PMC13653188 OTO - NOTNLM OT - aortic valve stenosis OT - femoral neck fracture OT - non-ST-elevated myocardial infarction COIS- The authors declare no conflicts of interest. EDAT- 2026/10/11 05:38 MHDA- 2026/10/11 05:39 PMCR- 2026/09/17 CRDT- 2026/10/11 04:10 PHST- 2026/01/19 00:00 [received] PHST- 2026/05/06 00:00 [revised] PHST- 2026/05/12 00:00 [accepted] PHST- 2026/10/11 05:39 [medline] PHST- 2026/10/11 05:38 [pubmed] PHST- 2026/10/11 04:10 [entrez] PHST- 2026/09/17 00:00 [pmc-release] AID - S2153-8174(26)04655-0 [pii] AID - 10.31083/RCM50145 [doi] PST - epublish SO - Rev Cardiovasc Med. 2026 Sep 17;27(9):50145. doi: 10.31083/RCM50145. eCollection 2026 Sep. PMID- 42859403 OWN - NLM STAT- MEDLINE DCOM- 20261027 LR - 20261027 IS - 1744-8344 (Electronic) IS - 1477-9072 (Linking) VI - 24 IP - 10 DP - 2026 Oct TI - Complications associated with thoracic endovascular aortic repair: highlighting the role of peri- and post-operative cardiac monitoring. PG - 943-958 LID - 10.1080/14779072.2026.2748716 [doi] AB - INTRODUCTION: Thoracic endovascular aortic repair (TEVAR) is first-line therapy for most descending thoracic aortic pathologies, yet it is performed in patients with a heavy burden of coronary disease, hypertension and limited cardiac reserve, and its cardiac complications remain underemphasized relative to neurological and device-related events. AREAS COVERED: We summarize the complication profile of TEVAR briefly and then concentrate on its cardiac dimension: myocardial injury after non-cardiac surgery, arrhythmia, acute heart failure, and the chronic ventricular consequences of stent-graft-induced aortic stiffening. We review the mechanisms linking endograft deployment to ventricular-arterial uncoupling, the echocardiographic markers of interest, blood pressure management, and a phase-based framework for peri- and post-operative cardiac monitoring, distinguishing guideline-supported recommendations from expert opinion and from evidence extrapolated from general vascular surgery. PubMed/MEDLINE were searched from database inception to August 2026. EXPERT OPINION: Cardiac surveillance around TEVAR is inconsistent and largely informal. We argue for baseline echocardiography in all elective patients, protocolized high-sensitivity troponin and natriuretic peptide measurement, defined-duration rhythm monitoring, structured blood pressure control, and longitudinal assessment of ventricular-arterial coupling within a heart-team pathway. TEVAR-specific outcome data and Windkessel-preserving graft design are the priorities for the next phase of endovascular aortic care. FAU - Xanthopoulos, Andrew AU - Xanthopoulos A AD - Department of Cardiology, Faculty of Medicine, University of Thessaly, Larissa, Greece. FAU - Androutsopoulou, Vasiliki AU - Androutsopoulou V AD - Department of Cardiothoracic Surgery, Faculty of Medicine, University of Thessaly, Larissa, Greece. FAU - Zotos, Prokopis-Andreas AU - Zotos PA AD - Department of Cardiothoracic Surgery, Faculty of Medicine, University of Thessaly, Larissa, Greece. FAU - Giamouzis, Grigorios AU - Giamouzis G AD - Department of Cardiology, Faculty of Medicine, University of Thessaly, Larissa, Greece. FAU - Skoularigis, John AU - Skoularigis J AD - Department of Cardiology, Faculty of Medicine, University of Thessaly, Larissa, Greece. FAU - Magouliotis, Dimitrios E AU - Magouliotis DE AD - Department of Cardiac Surgery Research, Lankenau Institute for Medical Research, Wynnewood, PA, USA. LA - eng PT - Journal Article PT - Review DEP - 20261012 PL - England TA - Expert Rev Cardiovasc Ther JT - Expert review of cardiovascular therapy JID - 101182328 SB - IM MH - Humans MH - *Endovascular Aneurysm Repair/adverse effects/methods MH - *Postoperative Complications/etiology/diagnosis MH - *Aorta, Thoracic/surgery MH - *Endovascular Procedures/adverse effects/methods MH - Monitoring, Physiologic/methods OTO - NOTNLM OT - TEVAR OT - Thoracic endovascular aortic repair OT - aortic stiffness OT - blood pressure OT - cardiac complications OT - myocardial injury after non-cardiac surgery OT - perioperative monitoring OT - ventricular-arterial coupling EDAT- 2026/10/11 05:38 MHDA- 2026/10/27 05:29 CRDT- 2026/10/11 02:02 PHST- 2026/10/27 05:29 [medline] PHST- 2026/10/11 05:38 [pubmed] PHST- 2026/10/11 02:02 [entrez] AID - 10.1080/14779072.2026.2748716 [doi] PST - ppublish SO - Expert Rev Cardiovasc Ther. 2026 Oct;24(10):943-958. doi: 10.1080/14779072.2026.2748716. Epub 2026 Oct 12. PMID- 42858955 OWN - NLM STAT- Publisher LR - 20261010 IS - 2047-4881 (Electronic) IS - 2047-4873 (Linking) DP - 2026 Oct 11 TI - Cardiovascular health in transgender and gender diverse individuals: an expert opinion on gender-affirming hormone therapy, risk assessment and clinical management. LID - zwag528 [pii] LID - 10.1093/eurjpc/zwag528 [doi] AB - Transgender and gender diverse (TGD) individuals represent a growing population with specific cardiovascular health needs. Current cardiovascular prevention strategies are largely derived from cisgender populations and may not adequately account for the combined effects of gender-affirming hormone therapy (GAHT) and other determinants. This expert opinion summarizes current evidence regarding cardiovascular health in TGD individuals, focusing on the cardiovascular effects of GAHT, population-specific cardiovascular risk factors, practical approaches to cardiovascular risk assessment, and future research priorities. Available evidence indicates that GAHT is associated with changes in cardiometabolic risk factors, haemostasis, vascular function, and cardiac physiology. Feminizing GAHT is associated with an increased risk of venous thromboembolism, whereas masculinizing GAHT is associated with adverse lipid changes, erythrocytosis, and a potentially increased risk of major cardiovascular events. However, causal inference is limited by the predominance of observational studies, relatively young study populations, heterogeneous GAHT regimens, short follow-up, and the absence of randomized study evidence. Population-level cardiovascular disparities in TGD should not be attributed to GAHT alone and smoking, obesity, physical inactivity, minority stress, socioeconomic disadvantage, and unequal access to healthcare may independently or interactively influence cardiovascular risk. Current cardiovascular risk prediction tools have not been validated or calibrated in TGD populations and do not account for GAHT exposure or TGD-specific psychosocial and structural determinants. Cardiovascular risk assessment in TGD individuals should integrate conventional risk factors, transgender-related cardiovascular risk factors, and patient involvement regarding individual goals. A coordinated multidisciplinary approach may facilitate personalized cardiovascular prevention while supporting access to gender-affirming care. Future research should prioritize long-term prospective studies and development of risk prediction models tailored to TGD populations. CI - (c) The Author(s) 2026. Published by Oxford University Press on behalf of the European Society of Cardiology. FAU - Vecchiato, Marco AU - Vecchiato M AUID- ORCID: 0000-0003-2395-4977 AD - Department of Medicine, University of Padova, Via Giustiniani 2, 35128 Padova, Italy. AD - Department of Theoretical and Applied Sciences, eCampus University, Novedrate, 22060 Como, Italy. AD - Sports Medicine and Cardiovascular Rehabilitation Unit, ULSS3 Serenissima, Noale, 30033 Venice, Italy. FAU - van Zijverden, Lieve Mees AU - van Zijverden LM AUID- ORCID: 0000-0003-3757-0261 AD - Center of Expertise on Gender Dysphoria, Department of Endocrinology, Amsterdam UMC location Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081HV, Amsterdam, The Netherlands. FAU - van Heesewijk, Jason AU - van Heesewijk J AUID- ORCID: 0000-0002-6941-1815 AD - Center of Expertise on Gender Dysphoria, Department of Endocrinology, Amsterdam UMC location Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081HV, Amsterdam, The Netherlands. FAU - Scala, Alberto AU - Scala A AUID- ORCID: 0009-0009-1960-537X AD - Department of Medicine, University of Padova, Via Giustiniani 2, 35128 Padova, Italy. AD - Department of Systems Medicine, Unit of Andrology and Reproductive Medicine, University Hospital of Padova, Padova, Italy. AD - Regional Reference Center for Gender Incongruence of the Veneto Region, University Hospital of Padova, Padova, Italy. FAU - Biffi, Alessandro AU - Biffi A AD - Medical Partner Scuderia Ferrari, Med-Ex, Medicine & Exercise, Roma-Maranello (MO), 00187 Rome, Italy. FAU - Campello, Elena AU - Campello E AUID- ORCID: 0000-0002-0377-3741 AD - Department of Medicine, University of Padova, Via Giustiniani 2, 35128 Padova, Italy. AD - First Chair of Internal Medicine and Thrombotic and Hemorrhagic Diseases Unit, University Hospital of Padova, 35128 Padova, Italy. FAU - Connelly, Paul AU - Connelly P AUID- ORCID: 0000-0002-1744-9977 AD - Department of Endocrinology & Diabetes, Queen Elizabeth University Hospital, Glasgow, UK. FAU - Garolla, Andrea AU - Garolla A AUID- ORCID: 0000-0003-4736-9051 AD - Department of Medicine, University of Padova, Via Giustiniani 2, 35128 Padova, Italy. AD - Department of Systems Medicine, Unit of Andrology and Reproductive Medicine, University Hospital of Padova, Padova, Italy. AD - Regional Reference Center for Gender Incongruence of the Veneto Region, University Hospital of Padova, Padova, Italy. FAU - Iwamoto, Sean J AU - Iwamoto SJ AUID- ORCID: 0000-0002-7316-8256 AD - Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado School of Medicine, University of Colorado Anschutz, 12801 E. 17 th Ave, Room 7103, Research 1 South, Aurora, Colorado, 80045, United States. FAU - Jones, Bethany A AU - Jones BA AUID- ORCID: 0000-0001-8872-5847 AD - Institute of Psychology, Nottingham Trent University, Nottingham, NG1 4FQ, England. FAU - Korzh, Oleksii AU - Korzh O AUID- ORCID: 0000-0001-6838-4360 AD - Department of General Practice - Family Medicine, Kharkiv National Medical University, Kharkiv, Ukraine. FAU - Kurpas, Donata AU - Kurpas D AUID- ORCID: 0000-0002-6996-8920 AD - Division of Research Methodology, Department of Nursing, Faculty of Nursing and Midwifery, Wroclaw Medical University, ul. Kazimierza Bartla 5, 51-618 Wroclaw, Poland. FAU - Papakonstantinou, Panteleimon AU - Papakonstantinou P AUID- ORCID: 0000-0003-4691-7183 AD - Atrial Fibrillation Institute, Heart and Vascular Centre and Cardiovascular Research Institute Dublin, Royal College of Surgeons of Ireland, Mater Private Hospital, 71 Eccles St, Dublin 7, D07 WKW8, Ireland. FAU - Palermi, Stefano AU - Palermi S AUID- ORCID: 0000-0003-1558-4857 AD - Departmental Faculty of Medicine and Surgery - Unicamillus-Saint Camillus International University of Health Sciences, Rome, Italy. FAU - Peters, Sanne A E AU - Peters SAE AUID- ORCID: 0000-0003-0346-5412 AD - Julius Center for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands. AD - The George Institute for Global Health, School of Public Health, Imperial College London, London, UK. FAU - Venturini, Elio AU - Venturini E AUID- ORCID: 0000-0001-7223-7574 AD - Department of Cardiac Rehabilitation, Cecina Civil Hospital, Cecina (Livorno), Italy. FAU - Marketou, Maria AU - Marketou M AUID- ORCID: 0000-0003-1888-3430 AD - School of Medicine, University of Crete, 71500 Giofirakia, Heraklion, Crete, Greece. FAU - Defreyne, Justine AU - Defreyne J AUID- ORCID: 0000-0002-6570-2340 AD - Department of Endocrinology, Ghent University Hospital, 9000 Ghent, Belgium. FAU - Glintborg, Dorte AU - Glintborg D AUID- ORCID: 0000-0002-8338-8025 AD - Department of Endocrinology, Klovervaenget 6, 5th floor, University of Southern Denmark, DK-5000 Odense C, Denmark. LA - eng PT - Journal Article DEP - 20261011 PL - England TA - Eur J Prev Cardiol JT - European journal of preventive cardiology JID - 101564430 SB - IM OTO - NOTNLM OT - GAHT OT - TGD OT - cardiovascular prevention OT - cardiovascular risk OT - gender incongruence OT - minority stress OT - primary prevention OT - sex differences OT - thrombosis EDAT- 2026/10/11 04:08 MHDA- 2026/10/11 04:08 CRDT- 2026/10/10 20:03 PHST- 2026/06/14 00:00 [received] PHST- 2026/08/23 00:00 [revised] PHST- 2026/10/11 04:08 [medline] PHST- 2026/10/11 04:08 [pubmed] PHST- 2026/10/10 20:03 [entrez] AID - 8907365 [pii] AID - 10.1093/eurjpc/zwag528 [doi] PST - aheadofprint SO - Eur J Prev Cardiol. 2026 Oct 11:zwag528. doi: 10.1093/eurjpc/zwag528. PMID- 42858771 OWN - NLM STAT- Publisher LR - 20261029 IS - 1557-3117 (Electronic) IS - 1053-2498 (Linking) DP - 2026 Oct 10 TI - Interstitial lung disease with associated severe pulmonary hypertension is rarely idiopathic by clinical or pathologic measures. LID - S1053-2498(26)02135-2 [pii] LID - 10.1016/j.healun.2026.10.002 [doi] AB - BACKGROUND: Interstitial lung disease (ILD) patients who develop severe pulmonary hypertension (PH) have rapidly progressive disease and increased mortality, but their clinical and pathologic phenotypes are poorly defined. Improved understanding and identification of these patients will expedite beneficial PH-targeted therapeutics and referral for lung transplantation. METHODS: We conducted a comprehensive retrospective study of a large cohort of ILD patients who underwent lung transplant at University of California, Los Angeles. Multidisciplinary Discussion (MDD) was used to establish ILD etiologies incorporating all available clinical, radiographic, and pathologic data. Severe pre-capillary PH was defined as pulmonary vascular resistance >5 Wood units on cardiac catheterization. Quantitative histopathologic analysis of explanted idiopathic pulmonary fibrosis (IPF) lungs was performed using blinded whole-slide annotation by two pulmonary pathologists, comparing the pathologic features of IPF with severe PH to IPF without PH. RESULTS: Among 347 ILD patients, 13% had severe PH. In the large majority of cases (86%), the correct ILD diagnosis/etiology was established clinically with MDD alone. Only 20% of severe PH cases were classified as IPF, with the most common subtype identified as autoimmune-associated ILD. On histopathology, IPF patients with severe PH demonstrated a similar extent of usual interstitial pneumonia but markedly less normal lung and a greater burden of atypical pathology, particularly nonspecific interstitial pneumonia, compared to IPF patients without PH. CONCLUSIONS: Our study illustrates the low prevalence of IPF in severe PH-ILD, describes a novel finding of distinct histopathologic features of IPF patients with severe PH versus no PH, and demonstrates the diagnostic utility of MDD without explant pathology. CI - Published by Elsevier Inc. FAU - Brownstein, Adam J AU - Brownstein AJ AD - Division of Pulmonary and Critical Care Medicine, University of California, Los Angeles, Los Angeles, California. Electronic address: abrownstein@mednet.ucla.edu. FAU - Shaikh, Faisal AU - Shaikh F AD - Division of Pulmonary, Allergy, and Critical Care Medicine, Columbia University Irving Medical Center, New York, New York. FAU - Xiao, Guang-Qian AU - Xiao GQ AD - Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, California. FAU - Wilhalme, Holly AU - Wilhalme H AD - Department of Medicine Statistics Core, David Geffen School of Medicine, University of California, Los Angeles, California. FAU - Abtin, Fereidoun AU - Abtin F AD - Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California. FAU - Stefanko, Daniel P AU - Stefanko DP AD - Department of Pathology David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California. FAU - Liang, Lloyd L AU - Liang LL AD - Division of Pulmonary and Critical Care Medicine, University of California, Los Angeles, Los Angeles, California. FAU - Hong, Jason AU - Hong J AD - Division of Pulmonary and Critical Care Medicine, University of California, Los Angeles, Los Angeles, California. FAU - Rahaghi, Farbod AU - Rahaghi F AD - Division of Pulmonary and Critical Care Medicine, University of California, Los Angeles, Los Angeles, California. FAU - Shino, Michael AU - Shino M AD - Division of Pulmonary and Critical Care Medicine, University of California, Los Angeles, Los Angeles, California. FAU - Samuel Weigt, S AU - Samuel Weigt S AD - Division of Pulmonary and Critical Care Medicine, University of California, Los Angeles, Los Angeles, California. FAU - Sayah, David AU - Sayah D AD - Division of Pulmonary and Critical Care Medicine, University of California, Los Angeles, Los Angeles, California. FAU - Channick, Richard AU - Channick R AD - Division of Pulmonary and Critical Care Medicine, University of California, Los Angeles, Los Angeles, California. FAU - Wallace, Dean AU - Wallace D AD - Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, California. FAU - Kim, Airie AU - Kim A AD - Division of Pulmonary and Critical Care Medicine, University of California, Los Angeles, Los Angeles, California. FAU - Saggar, Rajan AU - Saggar R AD - Division of Pulmonary and Critical Care Medicine, University of California, Los Angeles, Los Angeles, California. Electronic address: RSaggar@mednet.ucla.edu. LA - eng PT - Journal Article DEP - 20261010 PL - United States TA - J Heart Lung Transplant JT - The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation JID - 9102703 SB - IM OTO - NOTNLM OT - Idiopathic pulmonary fibrosis OT - Interstitial lung disease OT - Lung explant histopathology OT - Multidisciplinary discussion OT - Pulmonary hypertension EDAT- 2026/10/11 04:08 MHDA- 2026/10/11 04:08 CRDT- 2026/10/10 19:31 PHST- 2026/06/03 00:00 [received] PHST- 2026/10/01 00:00 [revised] PHST- 2026/10/02 00:00 [accepted] PHST- 2026/10/11 04:08 [pubmed] PHST- 2026/10/11 04:08 [medline] PHST- 2026/10/10 19:31 [entrez] AID - S1053-2498(26)02135-2 [pii] AID - 10.1016/j.healun.2026.10.002 [doi] PST - aheadofprint SO - J Heart Lung Transplant. 2026 Oct 10:S1053-2498(26)02135-2. doi: 10.1016/j.healun.2026.10.002. PMID- 42857632 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20261010 LR - 20261012 IS - 2950-6050 (Electronic) IS - 2950-6050 (Linking) VI - 12 DP - 2026 Dec TI - Enhanced recovery after surgery turnkey order set for periprocedural care of the patient undergoing transcatheter aortic valve replacement. PG - 100146 LID - 10.1016/j.xjse.2026.100146 [doi] LID - 100146 AB - OBJECTIVE: Transcatheter aortic valve replacement is now a leading treatment for severe symptomatic aortic stenosis across the risk spectrum. The choice between transcatheter and surgical aortic valve replacement remains a shared decision, particularly for patients aged 65 to 80 years. Despite extensive device-level randomized evidence and procedural standardization, periprocedural care pathways remain variable across programs. This turnkey order set integrates contemporary guidelines and consensus documents into a practical order set for the periprocedural care of patients undergoing transcatheter aortic valve replacement. METHODS: Subject matter experts translated existing peer-reviewed society guidelines, expert consensus documents, and randomized trial evidence, identified through a structured PICO-framed (population, intervention, comparator, outcome) literature review, into a sample turnkey order set. Orders derived from consistent Class I or IIa (or equivalent) recommendations across referenced documents appear in the order set in bold type. Orders that were inconsistently Class I or IIa, Class IIb, or supported by peer-reviewed evidence appear in italic type. RESULTS: Preprocedural care centers on interdisciplinary Heart Team evaluation, frailty and cognition assessment, baseline conduction risk stratification, anemia and iron deficiency screening, structured antithrombotic and endocrine medication management, and weight-based antibiotic prophylaxis. Intraprocedural care prioritizes ultrasound-guided femoral access, procedural sedation when feasible, normothermia, contrast minimization, and balanced procedural anticoagulation. Postprocedural care emphasizes telemetry-guided conduction monitoring, single antiplatelet therapy in patients without an indication for oral anticoagulation, oral anticoagulation alone in those with an existing indication, and early mobilization. Standardized discharge criteria target next-day discharge in appropriately selected transfemoral patients. CONCLUSIONS: Comprehensive periprocedural pathways for transcatheter aortic valve replacement have been demonstrated to shorten length of stay without compromising safety. This turnkey order set translates contemporary guideline recommendations into actionable orders to facilitate standardized adoption of best practices across programs. The composite pathway has not been prospectively validated. CI - (c) 2026 The Author(s). FAU - Engelman, Daniel T AU - Engelman DT AD - Heart and Vascular Program, Baystate Health, University of Massachusetts Chan Medical School-Baystate, Springfield, Mass. FAU - Ailawadi, Gorav AU - Ailawadi G AD - Department of Cardiac Surgery, University of Michigan, Ann Arbor, Mich. FAU - Russo, Mark J AU - Russo MJ AD - Division of Cardiac Surgery, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ. FAU - Allen, Keith B AU - Allen KB AD - Department of Cardiovascular and Thoracic Surgery, Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City, Kansas City, Mo. FAU - Shah, Pinak B AU - Shah PB AD - Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass. FAU - Szerlip, Molly AU - Szerlip M AD - Baylor Scott & White, The Heart Hospital, Plano, Tex. FAU - Chhatriwalla, Adnan K AU - Chhatriwalla AK AD - Department of Cardiology, Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City, Kansas City, Mo. FAU - Wieruszewski, Patrick M AU - Wieruszewski PM AD - Department of Pharmacy and Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minn. FAU - Chatterjee, Subhasis AU - Chatterjee S AD - Department of Surgery, Baylor College of Medicine and Texas Heart Institute, Houston, Tex. CN - ERAS Cardiac Working Group * CN - ERAS Cardiac Working Group LA - eng PT - Journal Article DEP - 20260831 PL - United States TA - JTCVS Struct Endovasc JT - JTCVS structural and endovascular JID - 9918991787106676 PMC - PMC13651565 OTO - NOTNLM OT - aortic stenosis OT - enhanced recovery after surgery OT - next-day discharge OT - periprocedural care OT - transcatheter aortic valve replacement OT - turnkey order set COIS- D.T.E. reports membership on a Data and Safety Monitoring Board for Edwards Lifesciences; membership on Steering Committees for Alexion and Chugai; and membership on Advisory Boards for Medela, Arthrex, AtriCure, Pharmacosmos, and Roivios. G.A. reports serving as a consultant for Abbott, Arthrex, Anteris, Edwards, Medtronic, JenaValve, EnableCV, Cultiv8, and Philips. M.J.R. reports serving as a consultant for Edwards Lifesciences, Abbott, and JenaValve. K.B.A. reports research grants, proctoring, and consulting from Edwards, Medtronic, and Abbott, with all payments made to the institution and none personally; research grants from Boston Scientific paid to the institution; and consulting for PiCardia. P.B.S. reports educational grants from Edwards Lifesciences, Abbott, and Medtronic. M.S. reports serving as a speaker and consultant for Edwards Lifesciences; membership on a Steering Committee for Medtronic; membership on a Steering Committee and an Advisory Board and serving as a proctor for Abbott; and membership on an Advisory Board and serving as a speaker for Boston Scientific. A.K.C. reports a research grant from Boston Scientific; serving on the Speakers Bureau and as a consultant for Abbott Vascular, Edwards Lifesciences, and Medtronic; and membership on Clinical Events Committees for Abiomed and Medtronic. P.M.W. reports consulting for Wolters Kluwer UpToDate and research funding from ZOLL Foundation. S.C. reported no conflicts of interest. The Journal policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest. FIR - Gregory, Alexander J IR - Gregory AJ FIR - Arora, Rakesh C IR - Arora RC FIR - Salenger, Rawn IR - Salenger R FIR - Grant, Michael C IR - Grant MC FIR - Rea, Amanda IR - Rea A FIR - Morton-Bailey, Vicki IR - Morton-Bailey V FIR - Crisafi, Cheryl IR - Crisafi C FIR - Lobdell, Kevin W IR - Lobdell KW FIR - Reddy, V Seenu IR - Reddy VS FIR - Gunaydin, Serdar IR - Gunaydin S FIR - Stoppe, Christian IR - Stoppe C EDAT- 2026/10/11 05:07 MHDA- 2026/10/11 05:08 PMCR- 2026/08/31 CRDT- 2026/10/10 16:44 PHST- 2026/06/24 00:00 [received] PHST- 2026/08/05 00:00 [revised] PHST- 2026/08/22 00:00 [accepted] PHST- 2026/10/11 05:08 [medline] PHST- 2026/10/11 05:07 [pubmed] PHST- 2026/10/10 16:44 [entrez] PHST- 2026/08/31 00:00 [pmc-release] AID - S2950-6050(26)00051-3 [pii] AID - 100146 [pii] AID - 10.1016/j.xjse.2026.100146 [doi] PST - epublish SO - JTCVS Struct Endovasc. 2026 Aug 31;12:100146. doi: 10.1016/j.xjse.2026.100146. eCollection 2026 Dec. PMID- 42857486 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20261010 LR - 20261012 IS - 1995-705X (Print) IS - 0976-5123 (Electronic) IS - 1995-705X (Linking) VI - 27 DP - 2026 TI - Management of Tricuspid Valve Regurgitation Consensus Recommendations. PG - 6 LID - 10.4103/heartviews.heartviews_94_26 [doi] LID - 6 AB - Tricuspid regurgitation (TR) is a prevalent condition historically associated with high mortality and underrecognition. While medical therapy remains common, standalone surgical interventions involve significant perioperative risks. This has led to the emergence of transcatheter tricuspid valve interventions (TTVI) as a vital alternative for high-risk patients. Initiated and led by the Gulf Interventional Society, a multidisciplinary panel of experts was brought together to develop the current evidence and formulate a regional consensus and evidence-based recommendations for the management of tricuspid valve regurgitation in the Gulf region. TR is classified into primary (10%) and secondary (90%) types, with secondary TR further divided into atrial and ventricular subtypes. Evaluation relies on multimodality imaging, with echocardiography as the cornerstone and cardiac magnetic resonance for right ventricular assessment. While medical therapy focuses on decongestion, it does not modify TR progression. Surgical repair remains the gold standard for low-to-intermediate risk patients, but early referral is critical to avoid futile procedures in advanced disease. TTVI options, including edge-to-edge repair and replacement, are expanding in the Gulf, though regional adoption is hampered by fragmented healthcare systems and late presentations. Effective TR management in the Gulf requires a transition toward patient-centered care, early identification by primary care physicians, and a multidisciplinary "Heart Team" approach. Integrating digital health tools and establishing regional registries are essential to improving clinical outcomes and survival. CI - Copyright: (c) 2026 Heart Views. FAU - Samargandy, Sondos AU - Samargandy S AD - Department of Adult Cardiology, Prince Sultan Cardiac Center, Riyadh, Saudi Arabia. FAU - Alshuhri, Bander AU - Alshuhri B AD - Department of Adult Cardiology, Prince Sultan Cardiac Center, Riyadh, Saudi Arabia. FAU - Mackensen, Burkhard AU - Mackensen B AD - Anesthesiology Clinical Services, UW Medical Center, Montlake, Washington, USA. FAU - Almutairi, Fawaz AU - Almutairi F AD - King Abdulaziz Cardiac Center, National Guard Hospital, Riyadh, Saudi Arabia. FAU - Tang, Gilbert H L AU - Tang GHL AD - Department of Cardiovascular Surgery, Mount Sinai Health System, New York, NY, USA. FAU - Alshengheti, Lamia AU - Alshengheti L AD - Department of Adult Cardiology, Prince Sultan Cardiac Center, Riyadh, Saudi Arabia. FAU - Alreshidan, Mohammad AU - Alreshidan M AD - King Salman Heart Center, Executive Director of Shared Services, King Fahad Medical City, Riyadh Second Cluster, Ministry of Health, Riyadh, Saudi Arabia. FAU - Al-Hijji, Mohammed AU - Al-Hijji M AD - Department of Cardiology, Hamad Medical Corporation, Doha, Qatar. FAU - Albinmousa, Zakariya AU - Albinmousa Z AD - Department of Adult Cardiology, Prince Sultan Cardiac Center, Riyadh, Saudi Arabia. LA - eng PT - Journal Article PT - Review DEP - 20260915 PL - India TA - Heart Views JT - Heart views : the official journal of the Gulf Heart Association JID - 101316474 PMC - PMC13652574 OTO - NOTNLM OT - Clinical consensus OT - Gulf region OT - coronary artery disease OT - intravascular imaging OT - intravascular ultrasound OT - optical coherence tomography OT - percutaneous coronary intervention COIS- There are no conflicts of interest. EDAT- 2026/10/11 05:07 MHDA- 2026/10/11 05:08 PMCR- 2026/09/15 CRDT- 2026/10/10 15:47 PHST- 2026/04/29 00:00 [received] PHST- 2026/05/27 00:00 [accepted] PHST- 2026/10/11 05:08 [medline] PHST- 2026/10/11 05:07 [pubmed] PHST- 2026/10/10 15:47 [entrez] PHST- 2026/09/15 00:00 [pmc-release] AID - HV-27-6 [pii] AID - 10.4103/heartviews.heartviews_94_26 [doi] PST - epublish SO - Heart Views. 2026 Sep 15;27:6. doi: 10.4103/heartviews.heartviews_94_26. eCollection 2026. PMID- 42854320 OWN - NLM STAT- MEDLINE DCOM- 20261009 LR - 20261009 IS - 1526-2359 (Electronic) IS - 1073-2748 (Linking) VI - 33 DP - 2026 Jan-Dec TI - Association Between Multidisciplinary Team Meetings and Short-Term Postoperative Outcomes in Gastrointestinal Malignancies: A Retrospective Cohort Study. PG - 10732748261495563 LID - 10.1177/10732748261495563 [doi] AB - IntroductionMultidisciplinary team meetings (MTMs) integrate expertise from different specialties to support individualized treatment planning. However, their association with short-term postoperative outcomes in high-risk patients with gastrointestinal malignancies remains unclear. This study evaluated the implementation of preoperative MTM discussion and its association with postoperative outcomes in patients with gastric cancer (GC) or colorectal cancer (CRC) complicated by diabetes mellitus and/or coronary heart disease.MethodsThis single-center retrospective cohort study included consecutive patients with histologically confirmed gastric or colorectal adenocarcinoma and concomitant diabetes mellitus and/or coronary heart disease who underwent radical resection between January 2020 and January 2024. Patients were divided into MTM and no-MTM groups according to whether they received preoperative MTM discussion. The primary outcome was the severity of postoperative complications during the hospitalization, categorized as no complication, Clavien-Dindo grade I-II, or grade III or higher. Multivariable ordinal logistic regression was used to estimate the association between the absence of preoperative MTM discussion and increasing complication severity. The secondary outcome was the occurrence of any postoperative complication and was analyzed using binary logistic regression. Firth penalized logistic regression for major postoperative complications was performed as a sensitivity analysis.ResultsA total of 477 patients were included, with 191 in the MTM group and 286 in the no-MTM group. The no-MTM group had a higher overall postoperative complication rate than the MTM group (19.2% vs. 12.0%, p=0.039), whereas ICU admission and hospitalization costs were higher in the MTM group. Multivariable ordinal logistic regression showed that absence of preoperative MTM discussion, longer operative time per 30-minute increase, and preoperative hypoalbuminemia were independently associated with increasing postoperative complication severity. Secondary analyses yielded generally consistent findings.ConclusionsPreoperative MTM discussion was associated with a lower occurrence and lower severity of postoperative complications during the hospitalization among high-risk patients with GC or CRC. FAU - Zhao, Hengbin AU - Zhao H AD - Department of General Surgery, Tianjin Medical University General Hospital, Tianjin, China. RINGGOLD: 117865 FAU - Liu, Bang AU - Liu B AD - Department of General Surgery, Tianjin Medical University General Hospital, Tianjin, China. RINGGOLD: 117865 FAU - Wu, Mingze AU - Wu M AD - Department of General Surgery, Tianjin Medical University General Hospital, Tianjin, China. RINGGOLD: 117865 FAU - Ding, Guozheng AU - Ding G AD - Department of General Surgery, Tianjin Medical University General Hospital, Tianjin, China. RINGGOLD: 117865 FAU - Yan, Yongjia AU - Yan Y AD - Department of General Surgery, Tianjin Medical University General Hospital, Tianjin, China. RINGGOLD: 117865 FAU - Fu, Weihua AU - Fu W AUID- ORCID: 0000-0003-2576-865X AD - Department of General Surgery, Tianjin Medical University General Hospital, Tianjin, China. RINGGOLD: 117865 LA - eng PT - Journal Article DEP - 20261009 PL - United States TA - Cancer Control JT - Cancer control : journal of the Moffitt Cancer Center JID - 9438457 SB - IM MH - Humans MH - Retrospective Studies MH - Female MH - Male MH - *Postoperative Complications/epidemiology MH - Middle Aged MH - Aged MH - *Patient Care Team/organization & administration MH - *Gastrointestinal Neoplasms/surgery MH - *Interdisciplinary Communication OTO - NOTNLM OT - Colorectal cancer OT - Gastric cancer OT - Multidisciplinary team meetings OT - Postoperative complications OT - Short-term outcomes COIS- Declaration of Conflicting InterestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2026/10/09 23:31 MHDA- 2026/10/09 23:32 CRDT- 2026/10/09 18:03 PHST- 2026/10/09 23:32 [medline] PHST- 2026/10/09 23:31 [pubmed] PHST- 2026/10/09 18:03 [entrez] AID - 10.1177/10732748261495563 [doi] PST - ppublish SO - Cancer Control. 2026 Jan-Dec;33:10732748261495563. doi: 10.1177/10732748261495563. Epub 2026 Oct 9. PMID- 42853292 OWN - NLM STAT- Publisher LR - 20261009 IS - 1436-2813 (Electronic) IS - 0941-1291 (Linking) DP - 2026 Oct 9 TI - Long-term survival after multiple arterial coronary artery bypass grafting compared with percutaneous coronary intervention: a systematic review and meta-analysis. LID - 10.1007/s00595-026-03502-x [doi] AB - BACKGROUND: Multiple arterial coronary artery bypass grafting (CABG) has been associated with superior long-term outcomes compared with single arterial CABG. However, randomized trials comparing percutaneous coronary intervention (PCI) with CABG have largely evaluated single arterial grafting strategies, leaving evidence comparing multiple arterial CABG with PCI limited. METHODS: This systematic review and meta-analysis was registered prospectively in PROSPERO (CRD42025106759). MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials were searched for studies published from inception through September 30, 2025, that compared outcomes between multiple arterial CABG and PCI in patients with multivessel coronary artery disease. Study-level meta-analyses and reconstructed individual patient data (IPD) meta-analyses were performed. The primary outcome was all-cause mortality, and the secondary outcome was major adverse cardiovascular and cerebrovascular events (MACCE). RESULTS: Ten observational studies were included. Study-level meta-analysis showed higher all-cause mortality with PCI (hazard ratio [HR] 1.78, 95% confidence interval [CI] 1.51-2.09), consistent with reconstructed IPD analysis (HR 2.05, 95% CI 1.86-2.27). PCI was also associated with increased MACCE (study-level HR 2.48, 95% CI 1.91-3.21; IPD HR 2.94, 95% CI 2.56-3.39). CONCLUSION: In multivessel coronary artery disease, multiple arterial CABG was associated with significantly lower long-term mortality and MACCE than PCI, supporting its consideration in heart team decision-making. CI - (c) 2026. The Author(s) under exclusive licence to Springer Nature Singapore Pte Ltd. FAU - Nishida, Hidefumi AU - Nishida H AUID- ORCID: 0009-0005-5532-5974 AD - Graduate School of Public Health, St. Luke's International University, Tokyo, Japan. hidefumi226@gmail.com. AD - Department of Cardiovascular Surgery, St. Luke's International Hospital, 9-1 Akashi-cho, Chuo-ku, Tokyo, 104-0044, Japan. hidefumi226@gmail.com. FAU - Nakamura, Ryota AU - Nakamura R AD - Department of Cardiovascular Surgery, St. Luke's International Hospital, 9-1 Akashi-cho, Chuo-ku, Tokyo, 104-0044, Japan. FAU - Tamaki, Rihito AU - Tamaki R AD - Department of Cardiovascular Surgery, St. Luke's International Hospital, 9-1 Akashi-cho, Chuo-ku, Tokyo, 104-0044, Japan. FAU - Abe, Kohei AU - Abe K AD - Department of Cardiovascular Surgery, St. Luke's International Hospital, 9-1 Akashi-cho, Chuo-ku, Tokyo, 104-0044, Japan. FAU - Rahman, Mahbubur AU - Rahman M AD - Graduate School of Public Health, St. Luke's International University, Tokyo, Japan. LA - eng PT - Journal Article PT - Review DEP - 20261009 PL - Japan TA - Surg Today JT - Surgery today JID - 9204360 SB - IM OTO - NOTNLM OT - Coronary artery bypass grafting OT - Multiple arterial graft OT - Percutaneous coronary intervention COIS- Declarations. Conflict of interest: None. EDAT- 2026/10/09 17:34 MHDA- 2026/10/09 17:34 CRDT- 2026/10/09 11:05 PHST- 2026/04/09 00:00 [received] PHST- 2026/09/24 00:00 [accepted] PHST- 2026/10/09 17:34 [medline] PHST- 2026/10/09 17:34 [pubmed] PHST- 2026/10/09 11:05 [entrez] AID - 10.1007/s00595-026-03502-x [pii] AID - 10.1007/s00595-026-03502-x [doi] PST - aheadofprint SO - Surg Today. 2026 Oct 9. doi: 10.1007/s00595-026-03502-x. PMID- 42846436 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20261008 LR - 20261010 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 18 IP - 9 DP - 2026 Sep TI - Outcomes of Pediatric Tracheostomy at Sultan Qaboos University Hospital, Oman: A Multidisciplinary Approach. PG - e115888 LID - 10.7759/cureus.115888 [doi] LID - e115888 AB - Objectives and rationale Tracheostomy is a surgical procedure associated with a high morbidity rate among neonates and children. Moreover, the decision to perform it is stressful to both parents and physicians, as it is associated with early and late complications and death. However, there are insufficient studies in Oman concerning the outcomes of tracheostomy among children. Therefore, this study aimed to assess the indications, efficacy, outcomes, and complications of tracheostomy performed in children presenting in Sultan Qaboos University Hospital (SQUH), Muscat, Oman, with different indications. Patients and methods A retrospective cohort study was conducted among children (< 14 years old) who had undergone tracheostomy in the department of surgery at SQUH between January 1, 2011, and January 1, 2021. Data were collected from electronic patient records from the hospital information system, and descriptive analysis was used to show the results. Results A total of 71 children were included in the study. The number of teams involved ranged from two to nine per patient. There were 53 (74.6%) patients who required two to five teams, where 83 (63.8%) complications occurred, while 18 (25.4%) required six to nine teams, where 47 (36.2%) complications developed. The most common early complication was accidental decannulation in 12 (17%) patients, and the most common late complication was colonization by a pathogen occurring in 21 (29.6%) patients. The mortality rate was 26.8% (n=19). The most common cause of death was heart attack/cardiac arrest, where 14 (19.7%) died, followed by 10 (14.1%) deaths due to respiratory failure. The mean duration of hospital stay was 50.18 days (standard deviation (SD) 73.191). Conclusion This study shows a reduction in both early and late complications when more teams are involved in the patient's care. Some of our findings are in line with those mentioned in the literature. This study provided the basis for future retrospective and prospective cohort studies assessing the indications and outcomes of pediatric tracheostomy. We recommend that telemedicine be implemented in the multidisciplinary approach due to its benefits. CI - Copyright (c) 2026, Al Lawati et al. FAU - Al Lawati, Meetham AU - Al Lawati M AD - College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, OMN. FAU - Al-Hadhrami, Wijdan AU - Al-Hadhrami W AD - College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, OMN. FAU - Al Washahi, Mohammed AU - Al Washahi M AD - Department of Otolaryngology-Head and Neck Surgery, Sultan Qaboos University Hospital, Muscat, OMN. LA - eng PT - Journal Article DEP - 20260907 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC13644299 OTO - NOTNLM OT - multi-disciplinary teams OT - pediatric tracheostomy OT - tracheostomy complications OT - tracheostomy outcomes OT - tracheostomy procedure COIS- Human subjects: Informed consent for treatment and open access publication was obtained or waived by all participants in this study. Medical Research Ethics Committee at the College of Medicine and Health Sciences issued approval (MREC #2619). Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. EDAT- 2026/10/08 17:35 MHDA- 2026/10/08 17:36 PMCR- 2026/09/07 CRDT- 2026/10/08 12:55 PHST- 2026/09/07 00:00 [accepted] PHST- 2026/10/08 17:36 [medline] PHST- 2026/10/08 17:35 [pubmed] PHST- 2026/10/08 12:55 [entrez] PHST- 2026/09/07 00:00 [pmc-release] AID - 10.7759/cureus.115888 [doi] PST - epublish SO - Cureus. 2026 Sep 7;18(9):e115888. doi: 10.7759/cureus.115888. eCollection 2026 Sep. PMID- 42845080 OWN - NLM STAT- MEDLINE DCOM- 20261008 LR - 20261008 IS - 2338-2732 (Electronic) IS - 0125-9326 (Linking) VI - 58 IP - 3 DP - 2026 Jul TI - Cost-Effectiveness Analysis of Multidisciplinary Care in Chronic Heart Failure: Insights from an Indonesian Tertiary Hospital. PG - 402-414 AB - BACKGROUND: Chronic heart failure (CHF) is the leading cause of morbidity and healthcare expenditure in Indonesia, largely due to recurrent hospitalizations. Multidisciplinary Programs (MDSs) have been introduced to provide clinical and economic advantages by reducing hospitalizations. This study aimed to compare direct medical cost trajectories between patients managed under MDP and standard care (SC) at a tertiary referral hospital. METHODS: The retrospective cohort study was conducted at Dr. Cipto Mangunkusumo National Hospital and included 189 patients with CHF who completed at least eight consecutive outpatient visits. Patient demographics, clinical data, and direct medical costs were obtained from medical records and hospital billing data. RESULTS: Patients in the MDP group were younger (median age 55 vs 60 years) and had a more frequent ischemic etiology compared with SC. Outpatient costs were higher in MDP, mainly due to medications and consultation fees, while inpatient costs were substantially lower, particularly for procedures, consumables, and ward charges. The total direct medical cost per patient was significantly lower in MDP compared with SC (Rp 19.4 million vs Rp 31.3 million), reflecting a 38% reduction. CONCLUSION: Implementation of an MDP reduced overall direct medical costs by shifting expenditures toward outpatient management and lowering costly inpatient utilization. These findings support MDP as a feasible and cost-efficient strategy in resource-limited health systems. CI - Articles published in this journal are licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). FAU - Lusiani, Lusiani AU - Lusiani L AD - 1. Department of Epidemiology, Faculty of Public Health, Universitas Indonesia, Depok, Indonesia. 2. Cardiology Division, Internal Medicine Department, Faculty of Medicine, Universitas Indonesia. 3. Adult Cardiovascular Division, Cardiovascular Department, Cipto Mangunkusumo Hospital, Jakarta, Indonesia. 4. Integrated Cardiocerebrovascular Services of Cipto Mangunkusumo Hospital, Jakarta, Indonesia. lusianirusdi@gmail.com. FAU - Prihartono, Nurhayati Adnan AU - Prihartono NA AD - Department of Epidemiology, Faculty of Public Health, Universitas Indonesia, Depok, Indonesia. doclus78@gmail.com. FAU - Nadjib, Mardiati AU - Nadjib M AD - Department of Health Policy and Administration, Faculty of Public Health, Universitas Indonesia, Depok, Indonesia. doclus78@gmail.com. FAU - Alwi, Idrus AU - Alwi I AD - 1. Cardiology Division, Internal Medicine Department, Faculty of Medicine, Universitas Indonesia. 2. Adult Cardiovascular Division, Cardiovascular Department, Cipto Mangunkusumo Hospital, Jakarta, Indonesia. 3. Integrated Cardiocerebrovascular Services of Cipto Mangunkusumo Hospital, Jakarta, Indonesia.. idrusalwich@gmail.com. LA - eng PT - Journal Article PL - Indonesia TA - Acta Med Indones JT - Acta medica Indonesiana JID - 7901042 SB - IM MH - Humans MH - *Heart Failure/economics/therapy MH - Indonesia MH - Female MH - Retrospective Studies MH - Tertiary Care Centers/economics MH - Cost-Benefit Analysis MH - Male MH - Middle Aged MH - Cost-Effectiveness Analysis MH - Chronic Disease MH - Aged MH - Hospitalization/economics MH - Ambulatory Care/economics MH - *Health Care Costs MH - *Patient Care Team/economics MH - Health Expenditures MH - Adult OTO - NOTNLM OT - Cost-benefit analysis OT - Heart failure OT - Indonesia OT - Patient care team OT - Tertiary care centers OT - quality-adjusted life years COIS- The author declared no conflict of interest EDAT- 2026/10/08 05:31 MHDA- 2026/10/08 05:32 CRDT- 2026/10/08 03:43 PHST- 2026/10/08 05:32 [medline] PHST- 2026/10/08 05:31 [pubmed] PHST- 2026/10/08 03:43 [entrez] PST - ppublish SO - Acta Med Indones. 2026 Jul;58(3):402-414. PMID- 42844232 OWN - NLM STAT- Publisher LR - 20261007 IS - 1557-7740 (Electronic) IS - 1557-7740 (Linking) DP - 2026 Oct 7 TI - Top Ten Tips Palliative Care Clinicians Should Know About Caring for People Receiving Critical Care for Cardiovascular Disease. PG - 10966218261496677 LID - 10.1177/10966218261496677 [doi] AB - Cardiovascular disease (CVD) remains the leading cause of death worldwide and is a major driver of critical illness, resulting in admission to cardiac intensive care units (CICUs). Patients with acute, life-threatening CVD often experience episodes of acute decompensation characterized by high symptom burden that may portend progressive loss of function, significantly impair quality of life (QOL), and involve high-intensity, technologically advanced therapies to sustain life. Despite these advances, up to 30% of patients die during CICU hospitalizations, and those who survive may subsequently face persistent functional impairment and psychosocial distress. During critical CVD (CCVD), patients often endure prognostic uncertainty and face complex decisions regarding life-sustaining therapies alongside refractory symptoms. Thus, care that focuses exclusively on disease-directed or life-prolonging therapies is often insufficient to address the full spectrum of patient and caregiver needs. When integrated alongside intensive cardiovascular care, palliative care (PC) offers a complementary and essential approach to the management of CCVD to inform therapeutic decisions, improve QOL, and address psychosocial and spiritual well-being. In this article, a multidisciplinary team featuring PC clinicians (physicians, nurse practitioners, social worker, psychologist, and chaplain), cardiologists, cardiac surgeons, cardiothoracic anesthesiologists, and intensivists present evidence-based guidance in a "Top Ten Tips" format to support PC clinicians caring for CICU patients and their caregivers. FAU - Song, Anne AU - Song A AUID- ORCID: 0000-0003-4717-3374 AD - Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA. AD - Palliative and Advanced Illness Research (PAIR) Center at the University of Pennsylvania, Philadelphia, Pennsylvania, USA. AD - Leonard Davis Institute of Health Economics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA. FAU - Feder, Shelli L AU - Feder SL AD - Yale School of Nursing, West Haven, Connecticut, USA. AD - Veterans Affairs Connecticut Healthcare System, West Haven, Connecticut, USA. FAU - Elmadhoun, Omar AU - Elmadhoun O AD - Division of Critical Care Medicine, Mayo Clinic, Rochester, Minnesota, USA. FAU - Mehta, Ankita AU - Mehta A AUID- ORCID: 0000-0002-7049-0151 AD - Department of Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA. FAU - Wladkowski, Stephanie P AU - Wladkowski SP AD - College of Health and Human Services, Bowling Green State University, Bowling Green, Ohio, USA. FAU - Sullivan, Donald R AU - Sullivan DR AD - Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, Oregon Health & Science University, Portland, Oregon, USA. FAU - Creel-Bulos, Christina AU - Creel-Bulos C AD - Department of Anesthesiology, Emory University School of Medicine, Atlanta, Georgia, USA. AD - Department of Emergency Medicine, Emory University School of Medicine, Atlanta, Georgia, USA. FAU - Applebaum, Allison J AU - Applebaum AJ AD - Brookdale Department of Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA. FAU - Byrne-Martelli, Sarah E AU - Byrne-Martelli SE AUID- ORCID: 0000-0001-8864-1328 AD - Department of Supportive Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. AD - Center for Palliative Care, Harvard Medical School, Boston, Massachusetts, USA. FAU - Swol, Justyna AU - Swol J AUID- ORCID: 0000-0002-2903-092X AD - Department of Respiratory Medicine, Paracelsus Medical University, Nuremberg, Germany. FAU - Lorusso, Roberto AU - Lorusso R AD - Cardio-Thoracic Surgery Department, Maastricht University Medical Centre, Maastricht, The Netherlands. AD - Cardiovascular Research Institute Maastricht (CARIM), Maastricht, The Netherlands. FAU - Thiele, Holger AU - Thiele H AD - Department of Internal Medicine/Cardiology and Leipzig Heart Institute, Heart Center Leipzig at University of Leipzig, Leipzig, Germany. FAU - Vandenbriele, Christophe AU - Vandenbriele C AD - Heart Center Aalst, Azorg Hospital, Aalst, Belgium. AD - Cardiac Intensive Care, Harefield Hospital, Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom. AD - Department of Surgery and Cancer, Faculty of Medicine, Imperial College, London, United Kingdom. FAU - Godfrey, Sarah J AU - Godfrey SJ AD - Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA. AD - Department of Internal Medicine/Community Internal Medicine, Geriatrics, and Palliative Care, Mayo Clinic, Rochester, Minnesota, USA. FAU - Batten, Jason N AU - Batten JN AD - Department of Anesthesiology and Perioperative Medicine, University of California, Los Angeles, Los Angeles, California, USA. FAU - Rosa, William E AU - Rosa WE AD - Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York, USA. FAU - Wieruszewski, Patrick M AU - Wieruszewski PM AD - Department of Anesthesiology, Mayo Clinic, Rochester, Minnesota, USA. AD - Department of Pharmacy, Mayo Clinic, Rochester, Minnesota, USA. FAU - Robbins-Welty, Gregg A AU - Robbins-Welty GA AUID- ORCID: 0000-0003-4516-7368 AD - Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA. AD - Division of Palliative and Supportive Medicine, Department of Family and Preventive Medicine, Emory University School of Medicine, Atlanta, Georgia, USA. AD - Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia, USA. AD - Grady Memorial Hospital, Emory University School of Medicine, Atlanta, Georgia, USA. FAU - D'Andria Ursoleo, Jacopo AU - D'Andria Ursoleo J AD - Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy. LA - eng PT - Journal Article DEP - 20261007 PL - United States TA - J Palliat Med JT - Journal of palliative medicine JID - 9808462 SB - IM OTO - NOTNLM OT - cardiovascular disease OT - goal-concordant care OT - intensive therapies OT - palliative care OT - severe exacerbations OT - symptom management EDAT- 2026/10/07 23:30 MHDA- 2026/10/07 23:30 CRDT- 2026/10/07 22:53 PHST- 2026/10/07 23:30 [medline] PHST- 2026/10/07 23:30 [pubmed] PHST- 2026/10/07 22:53 [entrez] AID - 10.1177/10966218261496677 [doi] PST - aheadofprint SO - J Palliat Med. 2026 Oct 7:10966218261496677. doi: 10.1177/10966218261496677. PMID- 42842208 OWN - NLM STAT- MEDLINE DCOM- 20261007 LR - 20261007 IS - 1936-2692 (Electronic) IS - 1088-0224 (Linking) VI - 32 IP - Spec. No. 9 DP - 2026 Sep 1 TI - The Right Care Initiative: Promoting Accountable Care to Prevent Cardiovascular Death. PG - eSP544-eSP547 LID - 10.37765/ajmc.2026.90015 [doi] AB - OBJECTIVE: We describe the rationale for and implementation of the Right Care Initiative and its University of Best Practices (UBP), a model designed to close the implementation gap between clinical evidence and the real-world management of cardiovascular risk factors. The model aims to move beyond institutional silos toward an accountable care model that emphasizes interorganizational partnerships and the systematic sharing of best practices to eliminate preventable mortality. METHODS: We summarize lessons from a 17-year learning collaborative involving clinicians, pharmacists, health plans, and public health officials. The collaborative focuses on sharing best practices, peer accountability, and the dissemination of team-based care. The article synthesizes evidence from regional pilot projects, performance variation, and federal policy shifts to support a transition to precision prevention. RESULTS: Effective strategies identified include integrating clinical pharmacists into primary care to manage complex biometrics and utilizing coronary artery calcium imaging for early disease staging. Collaborative learning models address clinical inertia by identifying drug therapy problems and scaling proven interventions, including support for healthy nutrition, weight reduction, and physical activity, across health systems. Aligning value-based payment models with measurable reductions in cardiovascular disease risk holds promise to improve population health. CONCLUSION: Making progress toward 0 preventable cardiovascular deaths requires developing organizational infrastructure rather than just generating new science. By fostering radical collaboration and adopting advanced diagnostic and team-based tools, health care leaders can ensure that lifesaving evidence reaches patients effectively. FAU - Rodriguez, Hector P AU - Rodriguez HP AD - Division of Health Policy and Management, School of Public Health, University of California, Berkeley, 2121 Berkeley Way #5427, Berkeley, CA 94720. Email: hrod@berkeley.edu. FAU - Hanley, Hattie R AU - Hanley HR AD - Division of Health Policy and Management, School of Public Health, University of California, Berkeley, Berkeley, CA. FAU - Shortell, Stephen M AU - Shortell SM AD - Division of Health Policy and Management, School of Public Health, University of California, Berkeley, Berkeley, CA. LA - eng PT - Journal Article DEP - 20260901 PL - United States TA - Am J Manag Care JT - The American journal of managed care JID - 9613960 SB - IM MH - Humans MH - *Cardiovascular Diseases/prevention & control/mortality MH - *Accountable Care Organizations/organization & administration MH - United States MH - Value-Based Health Care MH - Primary Health Care/organization & administration EDAT- 2026/10/07 17:33 MHDA- 2026/10/07 17:34 CRDT- 2026/10/07 12:30 PHST- 2026/10/07 17:34 [medline] PHST- 2026/10/07 17:33 [pubmed] PHST- 2026/10/07 12:30 [entrez] AID - 90015 [pii] AID - 10.37765/ajmc.2026.90015 [doi] PST - epublish SO - Am J Manag Care. 2026 Sep 1;32(Spec. No. 9):eSP544-eSP547. doi: 10.37765/ajmc.2026.90015. PMID- 42839658 OWN - NLM STAT- MEDLINE DCOM- 20261007 LR - 20261008 IS - 1873-734X (Electronic) IS - 1010-7940 (Linking) VI - 68 IP - 10 DP - 2026 Oct 7 TI - EACTS Expert Consensus Document on aortic valve repair and valve-sparing aortic root replacement procedures. LID - ezag182 [pii] LID - 10.1093/ejcts/ezag182 [doi] AB - Aortic valve repair is a complex and evolving field that requires multidisciplinary teamwork among heart specialists to diagnose and treat various causes and mechanisms of aortic regurgitation and proximal thoracic aortic aneurysms across all age groups. From a surgical standpoint, aortic valve repair includes all procedures aimed at restoring or maintaining native valve function. This European Association for Cardio-Thoracic Surgery (EACTS) Expert Consensus Document critically evaluates the current evidence on the common causes and mechanisms of aortic regurgitation, the use of echocardiographic parameters in patient selection, intraoperative assessment, and prognostic evaluation as well as the surgical techniques in practice. It outlines fundamental surgical principles shared across different repair methods and provides consensus statements to guide clinical practice. These statements are intended for a broad audience, including paediatric and adult cardiologists, echocardiographers, cardiovascular imaging specialists, and cardiac surgeons. Where high-quality evidence is unavailable, the guidance relies on the collective experience and expert judgement of the multidisciplinary author team. This document presents the official stance of the EACTS and aims to promote standardized, evidence-based decision-making in the management of patients undergoing aortic valve repair. CI - (c) European Association for Cardio-Thoracic Surgery 2026. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com. FAU - De Paulis, Ruggero AU - De Paulis R AUID- ORCID: 0000-0002-3603-2202 AD - Department of Cardiac Surgery, European Hospital, Unicamillus University, Rome, Italy. FAU - Folino, Giulio AU - Folino G AUID- ORCID: 0000-0002-6708-6617 AD - Department of Cardiac Surgery, European Hospital, Unicamillus University, Rome, Italy. FAU - Berrebi, Alain AU - Berrebi A AD - Department of Cardiac Surgery European Georges Pompidou Hospital, Universite Paris Cite, France and Institut Medico-chirurgical Montsouris, Paris, France. FAU - Casselman, Filip P A AU - Casselman FPA AD - Cluster of Cardiovascular Surgery, Heart Center AZORG, Aalst, Belgium. FAU - Cerqueira, Rui J AU - Cerqueira RJ AUID- ORCID: 0000-0002-4471-4019 AD - Department of Surgery and Physiology, Faculty of Medicine, University of Porto, Porto, Portugal. AD - Department of Cardiothoracic Surgery, Hospital Universitario de Sao Joao, Porto, Portugal. FAU - Della Corte, Alessandro AU - Della Corte A AUID- ORCID: 0000-0002-4636-3339 AD - Department of Translational Medical Sciences, Cardiac Surgery Unit, University of Campania 'L. Vanvitelli', Naples, Italy. FAU - De Kerchove, Laurent AU - De Kerchove L AUID- ORCID: 0000-0002-2967-8099 AD - Pole de Recherche Cardiovasculaire (CARD), Institut de Recherche Experimentale et Clinique (IREC), Universite Catholique de Louvain (UCLouvain), Brussels, Belgium. AD - Division of Cardiothoracic and Vascular Surgery, Cliniques Universitaires Saint-Luc, Brussels, Belgium. FAU - d'Udekem, Yves AU - d'Udekem Y AUID- ORCID: 0000-0003-1851-7836 AD - Division of Cardiac Surgery, Children's National Hospital, Washington, DC, USA. FAU - Forteza, Alberto AU - Forteza A AD - Department of Cardiac Surgery, University Hospital Quironsalud Madrid/La Luz, Madrid, Spain. FAU - Irimie, Vadim P AU - Irimie VP AD - Department of Cardiac Surgery, Rhon Clinic - Campus Bad Neustadt, Bad Neustadt an der Saale, Bavaria, Germany. FAU - Jahangiri, Marjan AU - Jahangiri M AUID- ORCID: 0000-0002-4142-2889 AD - Department of Cardiac Surgery, St. George's Hospital, London, UK. FAU - Jasinski, Marek AU - Jasinski M AUID- ORCID: 0000-0002-9989-7748 AD - Department of Cardiac Surgery, Institute Heart Diseases, Wroclaw Medical University, Wroclaw, Poland. AD - Department of Pediatric Cardiothoracic Surgery, Children Memorial Pediatric Health Institute, Warsaw, Poland. FAU - Lansac, Emmanuel AU - Lansac E AD - Department of Cardiac and Thoracic Surgery, Pitie-Salpetriere University Hospital, Sorbonne University, APHP, Paris, France. FAU - Michelena, Hector I AU - Michelena HI AD - Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA. FAU - Milojevic, Milan AU - Milojevic M AUID- ORCID: 0000-0003-0984-9011 AD - Department of Cardiac Surgery and Cardiovascular Research, National Institute for Heart and Blood Vessels "Dedinje", Belgrade, Serbia. AD - Department of Cardiac Surgery, University Hospital Zurich, University of Zurich, Zurich, Switzerland. FAU - Schafers, Hans-Joachim AU - Schafers HJ AD - Department of Cardiac Surgery, University Hospital Quironsalud Madrid/La Luz, Madrid, Spain. FAU - Vancraeynest, David AU - Vancraeynest D AD - Cardiology department, Cliniques universitaires Saint-Luc and institut de recherche experimentale et clinique (IREC), Pole CARD, UClouvain, Brussels, Belgium. FAU - Villa Hincapie, Carlos A AU - Villa Hincapie CA AD - Cardiovascular Surgery Department, Fundacion Cardioinfantil-LaCardio, Bogota, Colombia. FAU - Vojacek, Jan AU - Vojacek J AUID- ORCID: 0000-0001-7724-9734 AD - Department of Cardiac Surgery, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic. AD - Faculty of Medicine Hradec Kralove, Charles University, Hradec Kralove, Czech Republic. CN - EACTS Scientific Document Group LA - eng GR - EACTS/ PT - Consensus Statement PT - Journal Article PT - Systematic Review PL - Germany TA - Eur J Cardiothorac Surg JT - European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery JID - 8804069 SB - IM MH - Humans MH - Aortic Aneurysm, Thoracic/surgery MH - Aortic Root Aneurysm MH - *Aortic Valve/surgery MH - *Aortic Valve Insufficiency/surgery MH - *Heart Valve Prosthesis Implantation/methods OTO - NOTNLM OT - aortic regurgitation OT - aortic root aneurysm OT - aortic valve OT - aortic valve repair OT - aortic valve-sparing root replacement OT - bicuspid aortic valve OT - thoracic aortic aneurysm FIR - Sadaba, J Rafael IR - Sadaba JR FIR - Siepe, Matthias IR - Siepe M FIR - Boodhwani, Munir IR - Boodhwani M FIR - Dumfarth, Julia IR - Dumfarth J FIR - Girdauskas, Evaldas IR - Girdauskas E FIR - Holubec, Tomas IR - Holubec T FIR - Jassar, Arminder Singh IR - Jassar AS FIR - Kolowca, Maciej K IR - Kolowca MK FIR - Kreibich, Maximilian IR - Kreibich M FIR - Micovic, Slobodan IR - Micovic S EDAT- 2026/10/07 05:31 MHDA- 2026/10/07 05:32 CRDT- 2026/10/07 02:03 PHST- 2025/07/29 00:00 [received] PHST- 2025/12/19 00:00 [revised] PHST- 2026/03/05 00:00 [accepted] PHST- 2026/10/07 05:32 [medline] PHST- 2026/10/07 05:31 [pubmed] PHST- 2026/10/07 02:03 [entrez] AID - 8868904 [pii] AID - 10.1093/ejcts/ezag182 [doi] PST - ppublish SO - Eur J Cardiothorac Surg. 2026 Oct 7;68(10):ezag182. doi: 10.1093/ejcts/ezag182. PMID- 42839657 OWN - NLM STAT- MEDLINE DCOM- 20261007 LR - 20261029 IS - 1873-734X (Electronic) IS - 1010-7940 (Linking) VI - 68 IP - 10 DP - 2026 Oct 7 TI - EACTS Expert Consensus Document on Robotic Cardiac Surgery Minimum Standards for Programme Implementation, Training and Quality Assurance, developed in collaboration with EACTAIC and EBCP. LID - ezag187 [pii] LID - 10.1093/ejcts/ezag187 [doi] AB - Robotic cardiac surgery is entering a renewed phase of adoption, supported by growing clinical experience, evolving robotic platforms, and rising demand for less invasive procedures and faster recovery. However, implementation remains technically demanding and resource-intensive and can expose patients to avoidable harm when initiated without a structured training programme, clear technical standards, and rigorous outcome monitoring. This expert consensus document summarizes the current state of robotic cardiac surgery and defines requirements for the safe, effective, and sustainable development of robotic cardiac programmes. It addresses the current regulatory environment for surgical robots and accessories and proposes minimum requirements for hardware, software, and instruments for reconstructive intracardiac and coronary cardiac procedures. Furthermore, it outlines prerequisites for starting and developing training centres, including surgeon experience, multidisciplinary team composition, patient selection, and institutional infrastructure and volume considerations. A stepwise, competency-based training pathway is presented that integrates video and live case observation, virtual and simulation-based skills acquisition, wet/dry laboratory training, and proctored clinical implementation, ideally supported by dual-console systems. The document emphasises the need for transparent documentation and outcome benchmarking via a society-driven database to support quality assurance, learning-curve oversight, and continuous improvement. Finally, it highlights priorities for further research, including harmonized reporting standards, long-term and procedure-specific outcome evaluation, and prospective studies assessing training models, cost-effectiveness, and the incremental value of emerging technologies. CI - (c) European Association for Cardio-Thoracic Surgery 2026. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com. FAU - Oosterlinck, Wouter AU - Oosterlinck W AUID- ORCID: 0000-0002-8313-3559 AD - Department of Cardiovascular Sciences, Research Unit of Cardiac Surgery, KULeuven, Leuven, Belgium. FAU - Palmen, Meindert AU - Palmen M AUID- ORCID: 0000-0002-7213-5452 AD - Department of Cardiothoracic Surgery, Leiden University Medical Center, Leiden, The Netherlands. FAU - Gianoli, Monica AU - Gianoli M AUID- ORCID: 0000-0002-8835-2339 AD - Department of Cardiothoracic Surgery, Heart and Lungs Division, UMC Utrecht, Utrecht, The Netherlands. FAU - Milojevic, Milan AU - Milojevic M AUID- ORCID: 0000-0003-0984-9011 AD - Department of Cardiac Surgery and Center of Excellence, National Institute for Heart and Blood Vessels Dedinje, Belgrade, Serbia. AD - Department of Cardiac Surgery, University Hospital Zurich, University of Zurich, Zurich, Switzerland. FAU - Bekaert, Jan AU - Bekaert J AD - Department of Cardiovascular Sciences, Research Unit of Cardiac Surgery, KULeuven, Leuven, Belgium. FAU - Beyersdorf, Friedhelm AU - Beyersdorf F AUID- ORCID: 0000-0003-2975-2751 AD - Department of Cardiovascular Surgery, University Heart Centre Freiburg, University Hospital Freiburg, Freiburg, Germany. AD - Faculty of Medicine, University of Freiburg, Freiburg, Germany. FAU - Casselman, Filip P A AU - Casselman FPA AD - Department of Cardiac Surgery, Heart Center Azorg, Aalst, Belgium. FAU - Degezelle, Karlien AU - Degezelle K AD - Department of Cardiac Surgery, University Hospitals Leuven, Leuven, Belgium. FAU - Falk, Volkmar AU - Falk V AUID- ORCID: 0000-0002-7911-8620 AD - Deutsches Herzzentrum der Charite, Charite University Medicine Berlin, Berlin, Germany. AD - DZHK (German Center for Cardiovascular Research) partner site, Berlin, Germany. AD - Swiss Federal Institute of Technology, Department of Health Science and Technology, Zurich, Switzerland. FAU - Folliguet, Thierry AU - Folliguet T AUID- ORCID: 0000-0003-0009-6543 AD - Department of Cardiac Surgery, Hopitaux Universitaires Henri Mondor, Assistance Publique-Hopitaux de Paris, Creteil, France. FAU - Franke, Ulrich AU - Franke U AUID- ORCID: 0000-0003-2289-8715 AD - Department of Cardiovascular Surgery, University Heart Centre Freiburg, University Hospital Freiburg, Freiburg, Germany. FAU - Hedvicak, Pavel AU - Hedvicak P AD - Department of Cardiovascular Surgery, Motol and Homolka University Hospital - Campus Motol, Prague, Czech Republic. FAU - Hoogma, Danny F AU - Hoogma DF AD - Department of Cardiovascular Sciences, KU Leuven, Leuven, Belgium. AD - Department of Anaesthesiology, University Hospitals of Leuven, Leuven, Belgium. FAU - Kempfert, Jorg AU - Kempfert J AD - Deutsches Herzzentrum der Charite, Charite University Medicine Berlin, Berlin, Germany. AD - DZHK (German Center for Cardiovascular Research) partner site, Berlin, Germany. FAU - Kyle, Bonnie AU - Kyle B AD - Department of Perioperative Medicine, Barts Heart Centre, London, UK. FAU - Melvin, Tom AU - Melvin T AD - Institute for Clinical Trials, University of Galway, Galway, Ireland. FAU - Pereda, Daniel AU - Pereda D AUID- ORCID: 0000-0002-0526-8722 AD - Department of Cardiovascular Surgery, Hospital Clinic, Barcelona, Spain. AD - Center for Congenital Heart Disease, Hospital Sant Joan de Deu, Barcelona, Spain. AD - Centro de Investigacion Biomedica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain. FAU - Quattroni, Paola AU - Quattroni P AUID- ORCID: 0000-0001-7620-8981 AD - European Association for Cardio-Thoracic Surgery (EACTS), Windsor, UK. FAU - Navarro-Ripoll, Ricard AU - Navarro-Ripoll R AD - Institut d'Investigacions Biomediques August Pi I Sunyer (IDIBAPS), Barcelona, Spain. AD - Anesthesia Department, Hospital Clinic, Barcelona, Spain. FAU - Vander Poorten, Emmanuel AU - Vander Poorten E AD - Robot-Assisted Surgery Group, Department of Mechanical Engineering, KU Leuven, Leuven, Belgium. FAU - Bonatti, Johannes O AU - Bonatti JO AD - Department of Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, PA, USA. FAU - Cerny, Stepan AU - Cerny S AUID- ORCID: 0000-0002-7770-6402 AD - Department of Cardiovascular Surgery, Motol and Homolka University Hospital - Campus Motol, Prague, Czech Republic. CN - EACTS Scientific Document Group LA - eng GR - EACTS/ PT - Consensus Statement PT - Journal Article PL - Germany TA - Eur J Cardiothorac Surg JT - European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery JID - 8804069 SB - IM MH - Humans MH - *Robotic Surgical Procedures/education/standards MH - *Cardiac Surgical Procedures/education/standards/methods MH - *Quality Assurance, Health Care/standards MH - Clinical Competence/standards OTO - NOTNLM OT - RA-MIDCAB OT - RA-TECAB OT - Robotic cardiac surgery OT - cardiac anaesthesia OT - heart team OT - medical device regulation OT - minimally invasive cardiac surgery OT - mitral valve repair OT - proctoring OT - quality assurance registry OT - robotic-assisted surgery OT - simulation training FIR - Suwalski, Piotr IR - Suwalski P FIR - Gaudino, Mario IR - Gaudino M FIR - Agnino, Alfonso IR - Agnino A FIR - Aktuerk, Dincer IR - Aktuerk D FIR - Balkhy, Husam H IR - Balkhy HH FIR - Philipsen, Tine E IR - Philipsen TE FIR - Rex, Steffen IR - Rex S FIR - Rosati, Fabrizio IR - Rosati F FIR - Singh, Sandeep IR - Singh S EDAT- 2026/10/07 05:31 MHDA- 2026/10/07 05:32 CRDT- 2026/10/07 02:03 PHST- 2026/04/01 00:00 [received] PHST- 2026/05/09 00:00 [revised] PHST- 2026/06/01 00:00 [accepted] PHST- 2026/10/07 05:32 [medline] PHST- 2026/10/07 05:31 [pubmed] PHST- 2026/10/07 02:03 [entrez] AID - 8868903 [pii] AID - 10.1093/ejcts/ezag187 [doi] PST - ppublish SO - Eur J Cardiothorac Surg. 2026 Oct 7;68(10):ezag187. doi: 10.1093/ejcts/ezag187. PMID- 42838762 OWN - NLM STAT- Publisher LR - 20261006 IS - 1879-0828 (Electronic) IS - 0953-6205 (Linking) DP - 2026 Oct 6 TI - External validation of the SHARPEN score for predicting in-hospital mortality in infective endocarditis. PG - 107227 LID - S0953-6205(26)00532-7 [pii] LID - 10.1016/j.ejim.2026.107227 [doi] AB - BACKGROUND: Risk stratification of infective endocarditis (IE) using IE-specific variables remains limited. In this study, we evaluated SHARPEN in an Italian cohort and performed an exploratory paired comparison with baseline Sequential Organ Failure Assessment (SOFA) score. METHODS: We performed a retrospective study of consecutive adults with definite IE hospitalized at a tertiary center from 2000 to 2021.Primary endpoint was all-cause in-hospital mortality. Discrimination was assessed by ROC curves, calibration by Brier score, calibration intercept and slope, Hosmer-Lemeshow test, and decile-based plots. The optimal threshold was identified using the Youden index. A prespecified multivariable model including SHARPEN, hemoglobin, INR, and pre-existing heart failure was evaluated. Baseline SOFA was compared with SHARPEN in paired complete-case subset. RESULTS: 245 patients were included. In-hospital mortality occurred in 44 (18%). Non-survivors had higher SHARPEN scores (median 11 vs. 9,p < 0.001). The score showed good discrimination (AUC 0.748;95%CI0.660-0.834) and acceptable calibration (Brier 0.1269; Hosmer-Lemeshow p = 0.458), with an optimal threshold of 11, yielding sensitivity 0.703, specificity 0.737, and NPV 0.918. A simple multivariable model combining SHARPEN with hemoglobin, INR, and chronic heart failure significantly improved discrimination (AUC 0.859; 95%CI0.796-0.921). Baseline SOFA was available in 75 patients (20 deaths); in this selected paired subset, AUCs were 0.759 (95%CI0.625-0.893) for SHARPEN and 0.878 (95%CI0.788-0.968) for SOFA. CONCLUSIONS: The SHARPEN score demonstrated reproducible discrimination for predicting in-hospital mortality in IE in our cohort. The exploratory SOFA comparison did not establish superiority. SHARPEN could serve as an adjunct to multidisciplinary assessment rather than a stand-alone decision tool. CI - Copyright (c) 2026 The Author(s). Published by Elsevier B.V. All rights reserved. FAU - Ramadan, Mohammad Said AU - Ramadan MS AD - Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy; Department of Medicine, UConn University School of Medicine, Farmington, CT, USA. FAU - Bertolino, Lorenzo AU - Bertolino L AD - Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy. FAU - Peluso, Anna Maria Carolina AU - Peluso AMC AD - Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy. FAU - Infante, Oriana AU - Infante O AD - Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy. FAU - Scarpulla, Nathalie AU - Scarpulla N AD - Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy. FAU - Cafarella, Iolanda AU - Cafarella I AD - Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy. FAU - Patauner, Fabian AU - Patauner F AD - Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy. FAU - Durante-Mangoni, Emanuele AU - Durante-Mangoni E AD - Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy; Internal Medicine Unit, AORN Ospedali dei Colli-Monaldi Hospital, Naples, Italy. Electronic address: emanuele.durante@unicampania.it. LA - eng PT - Journal Article DEP - 20261006 PL - Netherlands TA - Eur J Intern Med JT - European journal of internal medicine JID - 9003220 SB - IM OTO - NOTNLM OT - Infective endocarditis OT - Mortality prediction OT - Risk stratification OT - SHARPEN score COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/10/06 23:29 MHDA- 2026/10/06 23:29 CRDT- 2026/10/06 21:58 PHST- 2026/06/09 00:00 [received] PHST- 2026/09/27 00:00 [revised] PHST- 2026/09/29 00:00 [accepted] PHST- 2026/10/06 23:29 [medline] PHST- 2026/10/06 23:29 [pubmed] PHST- 2026/10/06 21:58 [entrez] AID - S0953-6205(26)00532-7 [pii] AID - 10.1016/j.ejim.2026.107227 [doi] PST - aheadofprint SO - Eur J Intern Med. 2026 Oct 6:107227. doi: 10.1016/j.ejim.2026.107227. PMID- 42833986 OWN - NLM STAT- Publisher LR - 20261005 IS - 1879-0828 (Electronic) IS - 0953-6205 (Linking) DP - 2026 Oct 5 TI - Implementation of guideline-directed cardioprotective therapy in patients living with type 2 diabetes in outpatient cardiology ambulatory setting: the Italian CardioMET registry. PG - 107183 LID - S0953-6205(26)00488-7 [pii] LID - 10.1016/j.ejim.2026.107183 [doi] AB - BACKGROUND: To assess the implementation of guideline-directed glucose-lowering therapies with proven cardiovascular (CV) benefit in individuals with type 2 diabetes mellitus (T2DM) attending Italian outpatient cardiology clinics. METHODS: CardioMET is a multicenter, real-world registry including 2527 consecutive patients with T2DM enrolled between January 2022 and December 2025. Clinical characteristics, CV risk profile, and prescription rates of sodium-glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) were assessed. Multivariable logistic regression was performed to identify predictors of non-prescription. RESULTS: Overall, 70.7% of patients had established atherosclerotic CV disease (ASCVD), while 86.1% of those without ASCVD were classified at high or very high CV risk. Heart failure (HF) was present in 48.9% of patients with available data. SGLT2i were prescribed in 42.2% and GLP-1 RA in 27.7% of patients, whereas 14.8% received combination therapy. SGLT2i use was higher in patients with ASCVD than in high/very high CV risk no ASCVD patients (45.0%vs. 34.9%; p < 0.001) and in patients with HF, whereas no differences between groups in prescription rates of GLP-1 RA were observed. Prescription of both drug classes significantly increased after publication of 2023 ESC Guidelines (SGLT2i: 54.7% vs. 35.0%; GLP-1 RA: 48.4% vs. 15.8%; both p < 0.001). Older age, female sex (for SGLT2i), and absence of established ASCVD independently predicted non-prescription. CONCLUSIONS: Implementation of cardioprotective glucose-lowering therapies remains suboptimal in Italian outpatient cardiology practice, underscoring the need for a multidisciplinary approach integrating recommendations from CV, T2DM, and kidney guidelines to optimize implementation of therapy in patients with T2DM. CI - Copyright (c) 2026 The Authors. Published by Elsevier B.V. All rights reserved. FAU - Gargiulo, Paola AU - Gargiulo P AD - Department of Advanced Biomedical Sciences, Federico II University of Naples, Naples, Italy. FAU - Marzano, Federica AU - Marzano F AD - Department of Advanced Biomedical Sciences, Federico II University of Naples, Naples, Italy. FAU - Liccardi, Laura AU - Liccardi L AD - Department of Advanced Biomedical Sciences, Federico II University of Naples, Naples, Italy. FAU - Nodari, Savina AU - Nodari S AD - Cardiology, Department of Medical and Surgical Specialities, Radiological Sciences and Public Health, University of Brescia, Cardiothoracic Department, Civil Hospitals, Brescia, Italy. FAU - Cameli, Matteo AU - Cameli M AD - Department of Medical Biotechnologies, Division of Cardiology, University of Siena, Siena, Italy. FAU - Giallauria, Francesco AU - Giallauria F AD - Department of Translational Medical Sciences, Federico II University of Naples, Naples, Italy. FAU - Guerra, Federico AU - Guerra F AD - Cardiology and Arrhythmology Clinic, Department of Biomedical Sciences and Public Health, Marche Polytechnic University, Ancona, Italy; University Hospital Ospedali Riuniti, Ancona, Italy. FAU - Imbalzano, Egidio AU - Imbalzano E AD - Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy. FAU - Sinagra, Gianfranco AU - Sinagra G AD - Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste, Center for Diagnosis and Treatment of Cardiomyopathies, Trieste, Italy; European Reference Network for Rare, Low-Prevalence and Complex Diseases of the Heart (ERN GUARD-Heart), Trieste, Italy. FAU - Carugo, Stefano AU - Carugo S AD - Department Cardio-Thoracic-Vascular Diseases, Foundation IRCCS Ca Granda Ospedale Maggiore Policlinico, Milan, Italy. FAU - Pizzi, Carmine AU - Pizzi C AD - Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum, University of Bologna, Bologna, Italy; Cardiovascular Division, Morgagni-Pierantoni University Hospital, Forli, Italy. FAU - Cipollone, Francesco AU - Cipollone F AD - Department of Medicine and Science of Aging, G. D'Annunzio University, Chieti, Italy. FAU - Grigioni, Francesco AU - Grigioni F AD - Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy; Research Unit of Cardiovascular Science, Department of Medicine and Surgery, Universita Campus Bio-Medico di Roma, Rome, Italy. FAU - Muscoli, Saverio AU - Muscoli S AD - Division of Cardiology, Fondazione Policlinico Tor Vergata, Rome, Italy. FAU - Polimeni, Alberto AU - Polimeni A AD - Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende, Italy; Division of Interventional Cardiology, Annunziata Hospital, Cosenza, Italy. FAU - Perrone Filardi, Pasquale AU - Perrone Filardi P AD - Department of Advanced Biomedical Sciences, Federico II University of Naples, Naples, Italy. Electronic address: fpperron@unina.it. CN - CardioMET investigators LA - eng PT - Journal Article DEP - 20261005 PL - Netherlands TA - Eur J Intern Med JT - European journal of internal medicine JID - 9003220 SB - IM OTO - NOTNLM OT - Cardiovascular diseases OT - Glucagon-like peptide 1 receptor agonists OT - Sodium-glucose transporter 2 inhibitors OT - Type 2 diabetes mellitus COIS- Declaration of competing interest The authors have no competing interests to declare. FIR - Indolfi, Ciro IR - Indolfi C IRAD- Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende, Italy. FIR - Calabro, Paolo IR - Calabro P IRAD- Division of Clinical Cardiology - A.O.R.N. Sant'Anna e San Sebastiano, Caserta, Italy.; Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy. FIR - Crisci, Mario IR - Crisci M IRAD- Unit of Interventional Cardiology, AORN dei Colli, Monaldi Hospital, Naples, Italy. FIR - Ferri, Claudio IR - Ferri C IRAD- Department MeSVA, University of L'Aquila, U.O.C. of Internal Medicine and Nephrology, San Salvatore Hospital, L'Aquila, Italy. FIR - Carerj, Scipione IR - Carerj S IRAD- University Hospital Ospedali Riuniti, Ancona, Italy.; Interdisciplinar Center for Health Sciences, Scuola Superiore Sant'Anna, Pisa, Italy. FIR - Varbella, Ferdinando IR - Varbella F IRAD- Division of Cardiology, Interventional Unit, Infermi Rivoli Hospital, Rivoli, Turin, Italy.; Interventional Cardiology Unit, San Luigi Gonzaga University Hospital, Orbassano, Italy. FIR - Porto, Italo IR - Porto I IRAD- Department of Internal Medicine and Medical Specialties, Universita di Genova, Genoa, Italy.; Cardiothoracic and Vascular Department, IRCCS Ospedale Policlinico San Martino, Genoa, Italy. FIR - Galasso, Gennaro IR - Galasso G IRAD- Department of Medicine, Surgery and Dentistry, University of Salerno, Salerno, Italy. FIR - Agostoni, Piergiuseppe IR - Agostoni P IRAD- Centro Cardiologico Monzino, IRCCS, Milan, Italy. FIR - Patti, Giuseppe IR - Patti G IRAD- Division of Cardiology, Maggiore della Carita Hospital, University of Eastern Piedmont, Novara, Italy. FIR - Brunetti, Natale Daniele IR - Brunetti ND IRAD- Department of Medical & Surgical Sciences, University of Foggia, Foggia, Italy. FIR - Barbati, Giovanni IR - Barbati G IRAD- Department of Cardiology, San Bortolo Hospital, Vicenza, Italy. FIR - Galassi, Alfredo Ruggero IR - Galassi AR IRAD- Division of Cardiology, Department of Excellence of Sciences for Health Promotion and Maternal-Child Care, Internal Medicine and Specialties (ProMISE) "G. D'Alessandro", Paolo Giaccone Hospital, University of Palermo, Palermo, Italy. FIR - Marazia, Stefania IR - Marazia S IRAD- Department of Cardiology, 'Vito Fazzi' Hospital, Lecce, Italy. FIR - Cittadini, Antonio IR - Cittadini A IRAD- Department of Translational Medical Sciences, Federico II University of Naples, Naples, Italy. FIR - Esposito, Giovanni IR - Esposito G IRAD- Department of Advanced Biomedical Sciences, Federico II University of Naples, Naples, Italy. FIR - Paolillo, Stefania IR - Paolillo S IRAD- Department of Advanced Biomedical Sciences, Federico II University of Naples, Naples, Italy. FIR - Amarante, Mattia IR - Amarante M IRAD- Cardiology, Department of Medical and Surgical Specialities, Radiological Sciences and Public Health, University of Brescia, Cardiothoracic Department, Civil Hospitals, Brescia, Italy. FIR - Assoni, Luca IR - Assoni L IRAD- Cardiology, Department of Medical and Surgical Specialities, Radiological Sciences and Public Health, University of Brescia, Cardiothoracic Department, Civil Hospitals, Brescia, Italy. FIR - Lombardi, Matilde IR - Lombardi M IRAD- Department of Medical Biotechnologies, Division of Cardiology, University of Siena, Siena, Italy. FIR - Cuomo, Gianluigi IR - Cuomo G IRAD- Department of Translational Medical Sciences, Federico II University of Naples, Naples, Italy. FIR - Stronati, Giulia IR - Stronati G IRAD- Cardiology and Arrhythmology Clinic, Department of Biomedical Sciences and Public Health, Marche Polytechnic University, Ancona, Italy.; University Hospital Ospedali Riuniti, Ancona, Italy. FIR - Gigliotti De Fazio, Marianna IR - Gigliotti De Fazio M IRAD- Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy. FIR - Rossi, Maddalena IR - Rossi M IRAD- Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste, Center for Diagnosis and Treatment of Cardiomyopathies, Trieste, Italy.; European Reference Network for Rare, Low-Prevalence and Complex Diseases of the Heart (ERN GUARD-Heart), Trieste, Italy. FIR - Faggiano, Andrea IR - Faggiano A IRAD- Department Cardio-Thoracic-Vascular Diseases, Foundation IRCCS Ca Granda Ospedale Maggiore Policlinico, Milan, Italy. FIR - Fedele, Damiano IR - Fedele D IRAD- Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum, University of Bologna, Bologna, Italy.; Cardiovascular Division, Morgagni-Pierantoni University Hospital, Forli, Italy. FIR - D'Ardes, Damiano IR - D'Ardes D IRAD- Department of Medicine and Science of Aging, G. D'Annunzio University, Chieti, Italy. FIR - Cavallari, Ilaria IR - Cavallari I IRAD- Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.; Research Unit of Cardiovascular Science, Department of Medicine and Surgery, Universita Campus Bio-Medico di Roma, Rome, Italy. FIR - Sangiorgi, Giuseppe Massimo IR - Sangiorgi GM IRAD- Division of Cardiology, Fondazione Policlinico Tor Vergata, Rome, Italy.; Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy. FIR - Quarta, Rossella IR - Quarta R IRAD- Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende, Italy.; Division of Interventional Cardiology, Annunziata Hospital, Cosenza, Italy. FIR - Cesaro, Arturo IR - Cesaro A IRAD- Division of Clinical Cardiology - A.O.R.N. Sant'Anna e San Sebastiano, Caserta, Italy.; Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy. FIR - di Lorenzo, Emilio IR - di Lorenzo E IRAD- Unit of Interventional Cardiology, AORN dei Colli, Monaldi Hospital, Naples, Italy. FIR - Baldini, Gianluca IR - Baldini G IRAD- Department MeSVA, University of L'Aquila, U.O.C. of Internal Medicine and Nephrology, San Salvatore Hospital, L'Aquila, Italy. FIR - Trimarchi, Giancarlo IR - Trimarchi G IRAD- University Hospital Ospedali Riuniti, Ancona, Italy.; Interdisciplinar Center for Health Sciences, Scuola Superiore Sant'Anna, Pisa, Italy. FIR - Corleto, Antonella IR - Corleto A IRAD- Division of Cardiology, Interventional Unit, Infermi Rivoli Hospital, Rivoli, Turin, Italy.; Interventional Cardiology Unit, San Luigi Gonzaga University Hospital, Orbassano, Italy. FIR - Tanda, Silvia IR - Tanda S IRAD- Cardiology and UTIC, Hospital San Paolo, Savona, Italy. FIR - Bellino, Michele IR - Bellino M IRAD- Department of Medicine, Surgery and Dentistry, University of Salerno, Salerno, Italy. FIR - Salvioni, Elisabetta IR - Salvioni E IRAD- Centro Cardiologico Monzino, IRCCS, Milan, Italy. FIR - Marengo, Alessandra IR - Marengo A IRAD- Division of Cardiology, Maggiore della Carita Hospital, University of Eastern Piedmont, Novara, Italy. FIR - Santagata, Federica IR - Santagata F IRAD- Department of Medical & Surgical Sciences, University of Foggia, Foggia, Italy. FIR - Madaudo, Cristina IR - Madaudo C IRAD- Division of Cardiology, Department of Excellence of Sciences for Health Promotion and Maternal-Child Care, Internal Medicine and Specialties (ProMISE) "G. D'Alessandro", Paolo Giaccone Hospital, University of Palermo, Palermo, Italy. FIR - Marra, Alberto Maria IR - Marra AM IRAD- Department of Translational Medical Sciences, Federico II University of Naples, Naples, Italy. FIR - Mancusi, Costantino IR - Mancusi C IRAD- Department of Advanced Biomedical Sciences, Federico II University of Naples, Naples, Italy. FIR - Fucile, Ilaria IR - Fucile I IRAD- Department of Advanced Biomedical Sciences, Federico II University of Naples, Naples, Italy. FIR - Cotticelli, Ciro IR - Cotticelli C IRAD- Department of Advanced Biomedical Sciences, Federico II University of Naples, Naples, Italy. FIR - Abbellito, Giuseppe Maria IR - Abbellito GM IRAD- Department of Advanced Biomedical Sciences, Federico II University of Naples, Naples, Italy. FIR - Criscuolo, Marco IR - Criscuolo M IRAD- Department of Advanced Biomedical Sciences, Federico II University of Naples, Naples, Italy. FIR - Parlati, Antonio Luca Maria IR - Parlati ALM IRAD- Department of Advanced Biomedical Sciences, Federico II University of Naples, Naples, Italy. FIR - Martone, Isabel IR - Martone I IRAD- Department of Advanced Biomedical Sciences, Federico II University of Naples, Naples, Italy. FIR - Perrone Filardi, Fabrizio IR - Perrone Filardi F IRAD- Department of Translational Medical Sciences, Federico II University of Naples, Naples, Italy. EDAT- 2026/10/05 23:30 MHDA- 2026/10/05 23:30 CRDT- 2026/10/05 22:02 PHST- 2026/07/26 00:00 [received] PHST- 2026/08/21 00:00 [revised] PHST- 2026/09/02 00:00 [accepted] PHST- 2026/10/05 23:30 [medline] PHST- 2026/10/05 23:30 [pubmed] PHST- 2026/10/05 22:02 [entrez] AID - S0953-6205(26)00488-7 [pii] AID - 10.1016/j.ejim.2026.107183 [doi] PST - aheadofprint SO - Eur J Intern Med. 2026 Oct 5:107183. doi: 10.1016/j.ejim.2026.107183. PMID- 42831591 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20261005 LR - 20261016 IS - 2052-0573 (Print) IS - 2052-0573 (Electronic) IS - 2052-0573 (Linking) VI - 2026 IP - 4 DP - 2026 Oct 1 TI - Mitral valve regurgitation and emotional dysregulation secondary to long-standing Graves' thyrotoxicosis. LID - 10.1530/EDM-26-0023 [doi] LID - EDM260023 AB - SUMMARY: Graves' disease is common, with an estimated prevalence of 0.2-2% and multiple associated complications. We present a case of severe mitral regurgitation secondary to poorly controlled Graves' disease for 11 years, highlighting the need for definitive treatment. A 30-year-old female attended hospital with palpitations, agitation and generalised pain. Her past medical history included Graves' disease diagnosed in 2014, with poor compliance and engagement with secondary care and medical treatment. Biochemical investigations and clinical examination confirmed thyrotoxicosis (TSH < 0.05 mIU/L, free T3 > 30.72 pmol/L and free T4 34.7 pmol/L). Carbimazole 40 mg once daily and propranolol 40 mg three times daily were restarted. She later developed worsening dyspnoea, attributed to decompensated heart failure. An echocardiogram showed severe mitral regurgitation secondary to anterior mitral valve prolapse. She also displayed psychiatric abnormalities, including anxiety and anger outbursts. Multiple conversations were thus needed with the patient, her family and the multidisciplinary team regarding treatment options, and an inpatient thyroidectomy was agreed upon. She recovered well postoperatively and is awaiting mitral valve repair. Our case highlights two crucial complications occurring secondary to long-standing uncontrolled Graves' thyrotoxicosis: mitral valve regurgitation with heart failure and neuropsychiatric complications with an impact on capacity for treatment decisions. We emphasise the complex support needed for these vulnerable patients to prevent end-stage complications of Graves' disease. CI - (c) the author(s). FAU - Chaudhury, Nadia AU - Chaudhury N AUID- ORCID: 0009-0000-8235-5494 FAU - Puttergill, Brooke AU - Puttergill B FAU - Ashraf, Masood AU - Ashraf M LA - eng PT - Journal Article PL - England TA - Endocrinol Diabetes Metab Case Rep JT - Endocrinology, diabetes & metabolism case reports JID - 101618943 PMC - PMC13663592 OTO - NOTNLM OT - Graves' OT - anxiety OT - hyperthyroidism OT - mitral valve regurgitation OT - psychiatry OT - thyrotoxicosis COIS- The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the work reported. EDAT- 2026/10/05 11:31 MHDA- 2026/10/05 11:32 PMCR- 2026/10/03 CRDT- 2026/10/05 08:33 PHST- 2026/04/22 00:00 [received] PHST- 2026/07/16 00:00 [revised] PHST- 2026/09/16 00:00 [accepted] PHST- 2026/10/05 11:32 [medline] PHST- 2026/10/05 11:31 [pubmed] PHST- 2026/10/05 08:33 [entrez] PHST- 2026/10/03 00:00 [pmc-release] AID - 78318 [pii] AID - EDM-26-0023 [pii] AID - 10.1530/EDM-26-0023 [doi] PST - ppublish SO - Endocrinol Diabetes Metab Case Rep. 2026 Oct 1;2026(4):EDM260023. doi: 10.1530/EDM-26-0023. PMID- 42831482 OWN - NLM STAT- MEDLINE DCOM- 20261027 LR - 20261027 IS - 1744-8344 (Electronic) IS - 1477-9072 (Linking) VI - 24 IP - 10 DP - 2026 Oct TI - Pregnancy-associated cardiac remodeling: from physiological adaptation to long-term cardiovascular risk. PG - 907-927 LID - 10.1080/14779072.2026.2743947 [doi] AB - INTRODUCTION: Pregnancy imposes a sustained hemodynamic load that can unmask latent cardiovascular vulnerability, yet distinguishing physiological adaptation from early maladaptive remodeling remains difficult with conventional echocardiography. AREAS COVERED: This special report reviews trimester-specific cardiac adaptation, myocardial deformation imaging, right ventricular-pulmonary arterial coupling, postpartum reverse remodeling, and the maladaptive phenotypes of preeclampsia, gestational diabetes, and peripartum cardiomyopathy. It also covers circulating biomarkers and the risk framework of the 2025 European Society of Cardiology guidelines, including the modified World Health Organization 2.0 classification and the Pregnancy Heart Team. PubMed/MEDLINE, Scopus, and Web of Science were searched for articles published between January 2000 and March 2026. EXPERT OPINION: Strain imaging and biomarkers can detect subclinical dysfunction that ejection fraction misses, but pregnancy- and ethnicity-specific reference values and outcome data are lacking. Until these are available, such tools should be used selectively, serially, and in combination within Pregnancy Heart Team pathways that extend well beyond delivery. FAU - Tanyeri Uzel, Seda AU - Tanyeri Uzel S AUID- ORCID: 0000-0002-0933-9233 AD - Cardiology Department, Kartal Kosuyolu High Specialization Education and Research Hospital, Kartal, Turkey. FAU - Kultursay, Barkin AU - Kultursay B AUID- ORCID: 0000-0002-1424-2209 AD - Cardiology Department, Tunceli State Hospital, Tunceli, Turkey. FAU - Karacam, Murat AU - Karacam M AUID- ORCID: 0000-0001-7323-8843 AD - Cardiology Department, Bitlis State Hospital, Bitlis, Turkey. FAU - Ceneli, Dogancan AU - Ceneli D AUID- ORCID: 0000-0002-2849-2276 AD - Cardiology Department, Kartal Kosuyolu High Specialization Education and Research Hospital, Kartal, Turkey. FAU - Yucel, Enver AU - Yucel E AUID- ORCID: 0000-0002-3654-2448 AD - Cardiology Department, Kartal Kosuyolu High Specialization Education and Research Hospital, Kartal, Turkey. FAU - Karagoz, Ali AU - Karagoz A AUID- ORCID: 0000-0002-0438-2021 AD - Cardiology Department, Kartal Kosuyolu High Specialization Education and Research Hospital, Kartal, Turkey. LA - eng PT - Journal Article PT - Review DEP - 20261006 PL - England TA - Expert Rev Cardiovasc Ther JT - Expert review of cardiovascular therapy JID - 101182328 RN - 0 (Biomarkers) SB - IM MH - Humans MH - Female MH - Pregnancy MH - Adaptation, Physiological/physiology MH - *Pregnancy Complications, Cardiovascular/physiopathology/diagnostic imaging MH - *Ventricular Remodeling/physiology MH - Echocardiography/methods MH - Biomarkers/metabolism MH - Heart Disease Risk Factors MH - Peripartum Cardiomyopathy MH - Diabetes, Gestational/physiopathology MH - *Cardiovascular Diseases/physiopathology/diagnostic imaging MH - Animals OTO - NOTNLM OT - Pregnancy OT - cardiac adaptation OT - gestational diabetes mellitus OT - global longitudinal strain OT - myocardial remodeling OT - peripartum cardiomyopathy OT - preeclampsia OT - speckle-tracking echocardiography EDAT- 2026/10/05 11:31 MHDA- 2026/10/27 05:29 CRDT- 2026/10/05 07:13 PHST- 2026/10/27 05:29 [medline] PHST- 2026/10/05 11:31 [pubmed] PHST- 2026/10/05 07:13 [entrez] AID - 10.1080/14779072.2026.2743947 [doi] PST - ppublish SO - Expert Rev Cardiovasc Ther. 2026 Oct;24(10):907-927. doi: 10.1080/14779072.2026.2743947. Epub 2026 Oct 6. PMID- 42829509 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20261004 LR - 20261005 IS - 2090-6404 (Print) IS - 2090-6412 (Electronic) IS - 2090-6404 (Linking) VI - 2026 DP - 2026 TI - Unexpected Cardiogenic Shock in a Young Woman: A Case Report. PG - 7627691 LID - 10.1155/cric/7627691 [doi] LID - 7627691 AB - Recent cardiogenic shock (CS) literature emphasizes early recognition, staging, and treatment to improve survival, highlighting the need for system-wide detection pathways and prompt shock team activation to enable timely intervention. We present a 26-year-old woman initially diagnosed with septic shock who deteriorated despite therapy. Ongoing reassessment led to reclassification as CS, prompting shock team activation and initiation of mechanical circulatory support, ultimately resulting in full recovery. CS is uncommon in young adults and may be misdiagnosed as distributive shock. Repeated evaluations with focused examinations, laboratory testing, and echocardiography are critical for early detection and proper diagnosis and management. CI - Copyright (c) 2026 Benjamin A. Johnson et al. Case Reports in Cardiology published by John Wiley & Sons Ltd. FAU - Johnson, Benjamin A AU - Johnson BA AUID- ORCID: 0000-0002-2323-1958 AD - Department of Internal Medicine University of South Florida Tampa Florida USA usf.edu. FAU - Ortiz, Luis A AU - Ortiz LA AD - Department of Internal Medicine University of South Florida Tampa Florida USA usf.edu. FAU - Prida, Xavier E AU - Prida XE AUID- ORCID: 0000-0003-3583-8842 AD - Department of Internal Medicine Division of Cardiovascular Sciences University of South Florida Tampa Florida USA usf.edu. LA - eng PT - Journal Article DEP - 20261002 PL - United States TA - Case Rep Cardiol JT - Case reports in cardiology JID - 101576452 PMC - PMC13633448 COIS- The authors declare no conflicts of interest. EDAT- 2026/10/04 05:36 MHDA- 2026/10/04 05:37 PMCR- 2026/10/02 CRDT- 2026/10/04 03:50 PHST- 2026/04/02 00:00 [received] PHST- 2026/09/18 00:00 [revised] PHST- 2026/09/23 00:00 [accepted] PHST- 2026/10/04 05:37 [medline] PHST- 2026/10/04 05:36 [pubmed] PHST- 2026/10/04 03:50 [entrez] PHST- 2026/10/02 00:00 [pmc-release] AID - CRIC7627691 [pii] AID - 10.1155/cric/7627691 [doi] PST - epublish SO - Case Rep Cardiol. 2026 Oct 2;2026:7627691. doi: 10.1155/cric/7627691. eCollection 2026. PMID- 42828808 OWN - NLM STAT- Publisher LR - 20261015 IS - 2772-963X (Electronic) IS - 2772-963X (Linking) VI - 5 IP - 11 Pt 2 DP - 2026 Oct 3 TI - Association of Predicted Surgical Risk With 3-Year Outcomes After Isolated Tricuspid Valve Surgery: An Analysis of Medicare Beneficiaries. PG - 103297 LID - S2772-963X(26)00719-2 [pii] LID - 10.1016/j.jacadv.2026.103297 [doi] LID - 103297 AB - BACKGROUND: With recent approval of transcatheter tricuspid valve (TV) interventions for high/prohibitive surgical risk patients, understanding the long-term outcomes of isolated TV surgery has become increasingly relevant. OBJECTIVES: The objective of the study was to evaluate longitudinal outcomes and health care costs of isolated surgical TV surgery to provide a potential benchmark for emerging transcatheter therapies. METHODS: Using the U.S. fee-for-service Medicare database, we evaluated longitudinal outcomes of all beneficiaries undergoing isolated TV repair or replacement (TVR) from 2018 to 2022. Patients with endocarditis were excluded. A claims-based, frailty-inclusive multivariable logistic regression model of predicted in-hospital mortality was developed (optimism-corrected area under the receiver-operating characteristic curve = 0.870). Patients were stratified by low (<4%), intermediate (4% to 8%), or high (>8%) predicated risk of surgical mortality. Kaplan-Meier and Fine Gray methods were used for time to event analysis. RESULTS: A total of 3,437 patients underwent isolated TVR (n = 1,285) or TV repair (n = 2,152). In-hospital mortality was higher for TVR (8.1% vs 5.3%; P = 0.001). Most patients (71.0%) were low risk, 9.0% intermediate, and 20.0% high risk. Three-year survival was significantly higher in the low (84.9%) and intermediate (66.5%) risk groups compared to high risk (49.6%), P < 0.001. Heart failure readmission-free survival correlated with predicted risk whereas valve reintervention was low in all groups (2.5% at 3 years). Index hospitalization costs increased with predicted risk. CONCLUSIONS: In Medicare beneficiaries undergoing isolated TV surgery, predicted operative mortality was associated with 3-year survival, heart failure readmission, and health care costs. These contemporary real-world data may inform heart team discussions and future trial designs for emerging transcatheter therapies. CI - Copyright (c) 2026 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Mehaffey, J Hunter AU - Mehaffey JH AD - Department of Cardiovascular and Thoracic Surgery, West Virginia University, Morgantown, West Virginia, USA. Electronic address: james.mehaffey@wvumedicine.org. FAU - Cohen, David J AU - Cohen DJ AD - Cardiovascular Research Foundation, New York, New York, USA; Division of Cardiology, St. Francis Hospital and Heart Center, Roslyn, New York, USA. FAU - Davidson, Charles AU - Davidson C AD - Division of Cardiology, Bluhm Cardiovascular Institute, Northwestern University, Chicago, Illinois, USA. FAU - Hahn, Rebecca AU - Hahn R AD - Division of Cardiology, Columbia University Irving Medical Center, New York, New York, USA. FAU - Daggubati, Ramesh AU - Daggubati R AD - Department of Cardiology, West Virginia University, Morgantown, West Virginia, USA. FAU - Hayanga, J W AU - Hayanga JW AD - Department of Cardiovascular and Thoracic Surgery, West Virginia University, Morgantown, West Virginia, USA. FAU - Badhwar, Vinay AU - Badhwar V AD - Department of Cardiovascular and Thoracic Surgery, West Virginia University, Morgantown, West Virginia, USA. LA - eng GR - UM1 HL088925/HL/NHLBI NIH HHS/United States PT - Journal Article DEP - 20261003 PL - United States TA - JACC Adv JT - JACC. Advances JID - 9918419284106676 PMC - PMC13660539 OTO - NOTNLM OT - Health care Cost OT - TVR OT - TVr OT - longitudinal outcomes OT - tricuspid valve surgery COIS- Funding support and author disclosures The study was supported by NIH NHLBI#2UM1HL088925 12 (Dr Mehaffey, Dr Hayanga, and Dr Badhwar). Dr Cohen has received research grant support from Edwards Lifesciences, Boston Scientific, Abbott, and Philips; and consulting income from Edwards Lifesciences, Boston Scientific, Abbott, and Medtronic. Dr Davidson has received research grant support from Edwards Lifesciences and Abbott Vascular; and served as an uncompensated advisor for Edwards Lifesciences. Dr Hahn has received speaker fees from Abbott Vascular, Baylis Medical, and Edwards Lifescience; institutional consulting agreements for which she receives no direct compensation with Abbott Vascular, Boston Scientific, Edwards Lifescience, Medtronic, and Novartis; equity with Navigate; and is the Chief Scientific Officer for the Echocardiography Core Laboratory at the Cardiovascular Research Foundation. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2026/10/04 00:33 MHDA- 2026/10/04 00:33 PMCR- 2026/10/03 CRDT- 2026/10/03 18:01 PHST- 2026/03/19 00:00 [received] PHST- 2026/07/22 00:00 [revised] PHST- 2026/08/28 00:00 [accepted] PHST- 2026/10/04 00:33 [medline] PHST- 2026/10/04 00:33 [pubmed] PHST- 2026/10/03 18:01 [entrez] PHST- 2026/10/03 00:00 [pmc-release] AID - S2772-963X(26)00719-2 [pii] AID - 103297 [pii] AID - 10.1016/j.jacadv.2026.103297 [doi] PST - aheadofprint SO - JACC Adv. 2026 Oct 3;5(11 Pt 2):103297. doi: 10.1016/j.jacadv.2026.103297. PMID- 42828012 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20261003 LR - 20261005 IS - 2051-3380 (Print) IS - 2051-3380 (Electronic) IS - 2051-3380 (Linking) VI - 14 IP - 10 DP - 2026 Oct TI - Giant Intrapulmonary Solitary Fibrous Tumour With a Possible Liver Metastasis: A Rare Case. PG - e70754 LID - 10.1002/rcr2.70754 [doi] LID - e70754 AB - Intrapulmonary solitary fibrous tumours (SFTs) are exceptionally rare mesenchymal neoplasms, particularly when presenting as giant thoracic masses. We report a case of a 57-year-old woman with progressive chest pain and dyspnoea who initially presented with pleural effusion and hypoglycaemia and received empirical anti-tuberculosis therapy without improvement. Contrast-enhanced CT revealed a left lower lobe mass enlarging to 11 x 16.5 x 15.2 cm on repeat imaging, with rightward cardiac displacement, pericardial effusion and a hepatic nodule suspicious for metastasis to the liver. Core needle biopsy revealed a low-grade spindle cell neoplasm. Immunohistochemistry revealed diffuse STAT6 positivity, partial CD34 positivity, Ki-67 < 5%, and negativity for CK7, desmin, SMA and S100, supporting the diagnosis of SFT. Following a multidisciplinary evaluation, six cycles of systemic chemotherapy were administered, and the patient remained clinically stable. This case highlights the diagnostic challenges of giant intrapulmonary SFT and the pivotal role of STAT6 immunohistochemistry in establishing the diagnosis. CI - (c) 2026 The Author(s). Respirology Case Reports published by John Wiley & Sons Australia, Ltd on behalf of The Asian Pacific Society of Respirology. FAU - Desdiani, Desdiani AU - Desdiani D AUID- ORCID: 0000-0002-5907-9476 AD - Faculty of Medicine and Nutrition IPB University Bogor Indonesia. FAU - Siregar, Nurjati Chairani AU - Siregar NC AD - Department of Anatomical Pathology, Faculty of Medicine Universitas Indonesia-Cipto Mangunkusumo Hospital Jakarta Indonesia. FAU - Prawiro, Asysyukriati AU - Prawiro A AD - Faculty of Medicine UPN Veteran Jakarta Jakarta Indonesia. FAU - Syahbunan, Khansa Kiasati Chandra AU - Syahbunan KKC AD - Faculty of Medicine Universitas Airlangga Surabaya Indonesia. LA - eng PT - Journal Article DEP - 20261001 PL - United States TA - Respirol Case Rep JT - Respirology case reports JID - 101631052 PMC - PMC13631407 OTO - NOTNLM OT - hypoglycaemia OT - intrapulmonary solitary fibrous tumour OT - neoplasm metastasis OT - pericardial effusion OT - pleural effusion COIS- The authors declare no conflicts of interest. EDAT- 2026/10/04 00:33 MHDA- 2026/10/04 00:34 PMCR- 2026/10/01 CRDT- 2026/10/03 06:23 PHST- 2026/06/17 00:00 [received] PHST- 2026/08/19 00:00 [revised] PHST- 2026/08/24 00:00 [accepted] PHST- 2026/10/04 00:34 [medline] PHST- 2026/10/04 00:33 [pubmed] PHST- 2026/10/03 06:23 [entrez] PHST- 2026/10/01 00:00 [pmc-release] AID - RCR270754 [pii] AID - 10.1002/rcr2.70754 [doi] PST - epublish SO - Respirol Case Rep. 2026 Oct 1;14(10):e70754. doi: 10.1002/rcr2.70754. eCollection 2026 Oct. PMID- 42827012 OWN - NLM STAT- MEDLINE DCOM- 20261002 LR - 20261005 IS - 1556-1380 (Electronic) IS - 1556-0864 (Linking) VI - 21 IP - 10 DP - 2026 Oct TI - Advances in Pathology: Journal of Thoracic Oncology 20th Anniversary Series. PG - 104116 LID - S1556-0864(26)00569-1 [pii] LID - 10.1016/j.jtho.2026.104116 [doi] AB - In its 20-year history, the Journal of Thoracic Oncology (JTO) has published many major articles that have had a profound impact on the pathology of thoracic malignancies. One reason JTO has had such a great influence on thoracic oncology is the visionary leadership of the International Association for the Study of Lung Cancer (IASLC), which emphasizes an international, multidisciplinary approach across all its endeavors. JTO is one of the most important initiatives of the IASLC, and its global scope, encompassing all specialties, has enabled many pathologists to play a important role in the journal. This is reflected in the participation of multiple pathologists on the editorial board and in the prioritization of publishing impactful articles led by pathologists. This has been a good investment for JTO and IASLC, because eight of the top 20 most cited articles in the journal in the past 20 years were led by pathologists. This article reviews the many advances published in JTO, most of which concern lung cancer, mesothelioma, thymic tumors, and cardiac tumors. During this period, many breakthroughs occurred in surgical pathology, small biopsy and cytology, management of lung cancer after neoadjuvant therapy, molecular genetics, and biomarker testing. Many of these advances have had a direct impact on patient care, providing new ways to stratify patients for therapeutic management decisions. CI - Copyright (c) 2026. Published by Elsevier Inc. FAU - Travis, William D AU - Travis WD AD - Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: travisw@mskcc.org. FAU - Baine, Marina K AU - Baine MK AD - Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Beasley, Mary Beth AU - Beasley MB AD - Department of Pathology, Mount Sinai Medical Center, New York, New York. FAU - Brambilla, Elizabeth AU - Brambilla E AD - Department of Pathology, Grenoble Alpes University, Grenoble, France. FAU - Bubendorf, Lukas AU - Bubendorf L AD - Institute of Medical Genetics and Pathology, University of Basel, Basel, Switzerland. FAU - Burke, Allen AU - Burke A AD - Joint Pathology Center, Bethesda, Maryland. FAU - Churg, Andrew AU - Churg A AD - Department of Pathology, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Cooper, Wendy AU - Cooper W AD - Department of Pathology, University of Sydney, Sydney, Australia. FAU - Dacic, Sanja AU - Dacic S AD - Department of Pathology, Yale, New Haven Hospital, New Haven, Connecticut. FAU - Galeteau-Salle, Francoise AU - Galeteau-Salle F AD - College MESOPATH, Paris, France; University of Caen Normandie, Caen, France. FAU - Hirsch, Fred R AU - Hirsch FR AD - Mount Sinai Tisch Cancer Center, Icahn School of Medicine, Mount Sinai, New York, New York. FAU - Kerr, Keith AU - Kerr K AD - Department of Pathology, University of Aberdeen, Aberdeen, Scotland, United Kingdom. FAU - Maleszewski, Joseph AU - Maleszewski J AD - Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota. FAU - Marx, Alexander AU - Marx A AD - Department of Pathology, University Medical Center, Gottingen, Germany. FAU - Nicholson, Andrew G AU - Nicholson AG AD - Department of Histopathology, Royal Brompton Hospital, Guy's and St Thomas' NHS Foundation Trust and National Heart and Lung Institute, Imperial College, London, United Kingdom. FAU - Noguchi, Masayuki AU - Noguchi M AD - Department of Pathology, Shonan Kamakura General Hospital, Kamakura City, Japan. FAU - Pavlisko, Elizabeth AU - Pavlisko E AD - Department of Pathology, Duke University Medical Center, Durham, North Carolina. FAU - Rekhtman, Natasha AU - Rekhtman N AD - Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Roggli, Victor AU - Roggli V AD - Department of Pathology, Duke University Medical Center, Durham, North Carolina. FAU - Sauter, Jennifer L AU - Sauter JL AD - Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Stroebel, Phillipp AU - Stroebel P AD - Department of Pathology, University Medical Center, Gottingen, Germany. FAU - Tsao, Ming Sound AU - Tsao MS AD - Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada. FAU - Wistuba, Ignacio AU - Wistuba I AD - Department of Translational Pathology, Moffitt Cancer Center, Tampa, Florida. FAU - Yatabe, Yasushi AU - Yatabe Y AD - Department of Pathology, National Cancer Center, Tokyo, Japan. LA - eng PT - Historical Article PT - Journal Article PL - United States TA - J Thorac Oncol JT - Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer JID - 101274235 SB - IM MH - Humans MH - Anniversaries and Special Events MH - History, 20th Century MH - History, 21st Century MH - *Lung Neoplasms/pathology MH - *Medical Oncology MH - *Periodicals as Topic MH - *Thoracic Neoplasms/pathology OTO - NOTNLM OT - Cardiac tumors OT - Lung cancer OT - Mesothelioma OT - Molecular OT - Pathology OT - Thymoma COIS- Disclosure Dr. Burke consults with plaintiff and defense attorneys in asbestos litigation. Dr. Bubendorf reports grants or contracts from Roche, Novartis, Boehringer Ingelheim, Thermo Fisher, Systems Oncology, and AstraZeneca, and consulting fees from Systems Oncology, Janssen, Merck Sharp & Dohme, Takeda, Amgen, Bayer, Eli Lilly, and Bristol Myers Squibb. Dr. Fred Hirsch reports consulting fees from AstraZeneca-Daiichi, Regeneron, Pfizer, Amgen, Leica, OncoHost, Henlius/Fosun, Ntera, and Novocure and a patent through the University of Colorado for EGFR protein and gene copy number as a predictive biomarker for EGFR-directed therapies. He is also on the Advisory Board for Henlius/Fosun and on the Board of Directors for CHOSA Oncology AB. Dr. Beasley is on an RO1 CA254104 NIH grant investigating macrophage molecular and functional diversity in tumor immunity. She also receives consulting fees from AbbVie, Sanofi, and AstraZeneca and receives payment for lectures from AbbVie, Medscape, and Haymarket Media. In addition, she receives payment for asbestos litigation. Also, she has received support from IASLC to attend WCLC meetings. Dr. Nicholson receives consulting fees from Glaxo Smith Klein Ltd., AstraZeneca Ltd., Eli Lilly Ltd., Pfizer, Boehringer Ingelheim, Novartis, Merck, Roche, Novartis, Takeda UK, Fidia, Bioclinica, AbbVie, and Oncimmune Ltd. Dr. Pavlisko consults with defense attorneys in asbestos litigation. Dr. Phillipp Stroebel is co-editor of the upcoming Sixth Edition of the WHO Classification (thymic section). Dr. Ming Tsao has grants to his institution with AstraZeneca and Sanofi and receives consulting fees from AstraZeneca, Daiichi Sankyo, AbbVie, Boehringer Ingelheim, Pfizer, DH Diagnostics, and Diaceutics. He has also served on the IASLC Board of Directors from 2021 to 2025. Dr. Yasushi Yatabe has contracts through his department with Merck Biopharma, Chugai Pharma, Konica-Minolta REALM, Optieum Biotechnologies, Eizai, DNA chip laboratory, and Pfizer. In addition, he has received payments from Merck Sharp & Dohme, Chugai Pharma, AstraZeneca, Merck Biopharma, Amgen, Daiichi Sankyo, and Thermo Fisher Scientific. Dr. Alexander Marx is an unpaid volunteer member of the medical advisory board of the Deutsche Myasthenie Gesellschaft (German Myasthenia Gravis Association). Dr. Marina Baine received an honorarium for a lecture for ASCO Advantage. Dr. Keith Kerr received fees from AbbVie, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Janssen, Merck Serono, Merck Sharp & Dohme, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda, and Ventana and he received payment or honoraria for lectures or educational events from AbbVie, AstraZeneca, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Merck Serono, Merck Sharp & Dohme, Mirati, Novartis, Pfizer, Roche, Sanofi, Ventana, Medscape, Mirati, Prime Oncology, PeerVoice, and Physician Education Resource. Dr. Natasha Rekhtman received payment for honoraria for serving as an Associated Editor for Modern Pathology and serving as a Grand Rounds Speaker and Support for travel to speak at the USCAP Interactive Microscopy conference. Dr. William Travis is supported by the MSKCC NCI Core Grant: P30 CA008748. Dr. Ignacio Wistuba reports grants or contracts through his institution from Genentech, Merck, Bristol Myers Squibb, Medimmune, Adaptive, Adaptimmune, EMD Serono, Pfizer, Takeda, Amgen, Karus, Johnson & Johnson, Bayer, Iovance, 4D, and Novartis and consulting fees from Genentech/Roche, AstraZeneca, Merck, Daiichi Sankyo, Amgen, AbbVie, and Boehringer-Ingelheim and payment for honoraria or educational activities from Medscape, Genentech/Roche, Platform Health, and Physician Education Resource. The remaining authors declare no conflict of interest. EDAT- 2026/10/02 23:30 MHDA- 2026/10/02 23:31 CRDT- 2026/10/02 20:52 PHST- 2026/04/20 00:00 [received] PHST- 2026/07/22 00:00 [revised] PHST- 2026/07/23 00:00 [accepted] PHST- 2026/10/02 23:31 [medline] PHST- 2026/10/02 23:30 [pubmed] PHST- 2026/10/02 20:52 [entrez] AID - S1556-0864(26)00569-1 [pii] AID - 10.1016/j.jtho.2026.104116 [doi] PST - ppublish SO - J Thorac Oncol. 2026 Oct;21(10):104116. doi: 10.1016/j.jtho.2026.104116. PMID- 42825049 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20261002 LR - 20261003 IS - 2772-4875 (Electronic) IS - 2772-4875 (Linking) VI - 31 DP - 2026 Dec TI - Five-year implementation and longitudinal performance of a multidisciplinary acute myocardial infarction program in a middle-income country. PG - 200711 LID - 10.1016/j.ijcrp.2026.200711 [doi] LID - 200711 AB - BACKGROUND: Acute myocardial infarction (AMI) remains a leading cause of mortality in low- and middle-income countries, where delayed reperfusion worsens outcomes. Evidence on the long-term operation of multidisciplinary AMI programs in these settings is limited. We aimed to describe the five-year performance of a multidisciplinary AMI program in quality-of-care indicators and clinical outcomes. METHODS: Prospective cohort of adults with type 1 AMI treated between 2021 and 2025 in an internationally multidisciplinary AMI Center of Excellence, integrating standardized reperfusion pathways, multidisciplinary inpatient care, cardiac rehabilitation, and structured post-discharge follow-up. Indicators were compared across years; multivariable logistic regression identified factors associated with in-hospital mortality. RESULTS: Of 3581 patients, 131 (3.7%) died in hospital. Non-survivors more often had STEMI (54.2% vs 42.2%; P = 0.007), Killip class III-IV (52.2% vs 7.9%), and higher TIMI and GRACE scores (all P < 0.001). Killip class was independently associated with mortality, rising stepwise from class II (aOR 3.81; 95%CI 2.00-7.25) to class IV (aOR 35.81; 95%CI 19.54-65.65); AUC 0.789. Compared with 2021, adjusted odds of in-hospital mortality were lower in 2025 (aOR 0.34; 95%CI 0.14-0.84; P = 0.019). Nursing education adherence (92.0% to 98.9%) and timely phase I cardiac rehabilitation (74.6% to 96.7%) were higher in later years, and ECG acquisition time was shorter (all P < 0.001). Unadjusted in-hospital mortality did not differ significantly across years (P = 0.287), and door-to-balloon time remained stable (P = 0.118). CONCLUSION: The program sustained high adherence to quality indicators and stable reperfusion metrics, whereas post-discharge follow-up completion declined. These findings do not establish causal effects. CI - (c) 2026 The Authors. Published by Elsevier B.V. FAU - Perez, Beatriz Mantilla AU - Perez BM AD - Hospital Internacional de Colombia HIC - Fundacion Cardiovascular de Colombia FCV - Fundacion Universitaria FCV, Santander, Colombia. FAU - Hurtado-Ortiz, Alexandra AU - Hurtado-Ortiz A AD - Hospital Internacional de Colombia HIC - Fundacion Cardiovascular de Colombia FCV - Fundacion Universitaria FCV, Santander, Colombia. FAU - Gualteros Cely, Paula Andrea AU - Gualteros Cely PA AD - Hospital Internacional de Colombia HIC - Fundacion Cardiovascular de Colombia FCV - Fundacion Universitaria FCV, Santander, Colombia. FAU - Serrano, Juliet Lopez AU - Serrano JL AD - Hospital Internacional de Colombia HIC - Fundacion Cardiovascular de Colombia FCV - Fundacion Universitaria FCV, Santander, Colombia. FAU - Angarita, Anderson Bermon AU - Angarita AB AD - Hospital Internacional de Colombia HIC - Fundacion Cardiovascular de Colombia FCV - Fundacion Universitaria FCV, Santander, Colombia. FAU - Manrique-Hernandez, Edgar Fabian AU - Manrique-Hernandez EF AD - Hospital Internacional de Colombia HIC - Fundacion Cardiovascular de Colombia FCV - Fundacion Universitaria FCV, Santander, Colombia. FAU - Licht-Ardila, Maricel AU - Licht-Ardila M AD - Hospital Internacional de Colombia HIC - Fundacion Cardiovascular de Colombia FCV - Fundacion Universitaria FCV, Santander, Colombia. FAU - Saiibi, Jose Federico AU - Saiibi JF AD - Hospital Internacional de Colombia HIC - Fundacion Cardiovascular de Colombia FCV - Fundacion Universitaria FCV, Santander, Colombia. LA - eng PT - Journal Article DEP - 20260916 PL - Netherlands TA - Int J Cardiol Cardiovasc Risk Prev JT - International journal of cardiology. Cardiovascular risk and prevention JID - 9918282077306676 PMC - PMC13628670 OTO - NOTNLM OT - Continuity of patient care OT - Myocardial infarction OT - Non-ST elevated myocardial infarction OT - Percutaneous coronary intervention OT - ST elevation myocardial infarction COIS- The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/10/02 13:37 MHDA- 2026/10/02 13:38 PMCR- 2026/09/16 CRDT- 2026/10/02 07:08 PHST- 2026/06/30 00:00 [received] PHST- 2026/08/31 00:00 [revised] PHST- 2026/09/15 00:00 [accepted] PHST- 2026/10/02 13:38 [medline] PHST- 2026/10/02 13:37 [pubmed] PHST- 2026/10/02 07:08 [entrez] PHST- 2026/09/16 00:00 [pmc-release] AID - S2772-4875(26)00141-8 [pii] AID - 200711 [pii] AID - 10.1016/j.ijcrp.2026.200711 [doi] PST - epublish SO - Int J Cardiol Cardiovasc Risk Prev. 2026 Sep 16;31:200711. doi: 10.1016/j.ijcrp.2026.200711. eCollection 2026 Dec. PMID- 42820788 OWN - NLM STAT- MEDLINE DCOM- 20261001 LR - 20261003 IS - 2639-8028 (Electronic) IS - 2639-8028 (Linking) VI - 8 IP - 10 DP - 2026 Oct 1 TI - Palliative Care Involvement in Relation to Rapid Response Events: A Focus on Care Intensity at the End of Life. PG - e1489 LID - 10.1097/CCE.0000000000001489 [doi] LID - e1489 AB - OBJECTIVES: To examine current practice patterns of palliative care involvement in relation to rapid response (RR) events and to evaluate its association with ICU utilization and intensity of care received before death. DESIGN: Retrospective cohort study of patients who underwent a RR event. SETTING: General medical, cardiology, oncology, and observation patients admitted to a tertiary care academic medical center in the United States. PATIENTS: Adults (>/= 18 yr) with an RR event. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: A total of 903 RR events occurred in 616 unique patients. The palliative care team was involved in 110 of 616 (17.9%) patients. Palliative care (PC) involvement was not associated with differences in repeat RR events or ICU transfer rates following an event. In-hospital mortality or hospice discharge occurred in 32.0% (197/616). Palliative care was involved in 36.5% (72/197) of these patients. PC involvement was associated with lower intensity of care within 24 hours before death after adjustment for age, sex, Charlson Comorbidity Index, pre-RR code status, and RR trigger (adjusted odds ratio [aOR], 0.26; 95% CI, 0.14-0.47; p < 0.001; Brant test, p = 0.44). This finding remained across sensitivity analyses for oncology status, primary service line, ICU transfer, and advanced directive documentation. PC consultation occurred only before RR in 16 of 110 (14.5%), only after RR in 63 of 110 (57.3%), and both before and after in 31 of 110 (28.2%). In timing-stratified ordinal regression, PC consultation only after RR (aOR, 0.19; 95% CI, 0.10-0.38; p < 0.001) or both before and after RR (aOR, 0.22; 95% CI, 0.09-0.56; p = 0.002) was associated with less-intense care, while pre-RR PC alone was not (aOR, 1.06; 95% CI, 0.33-3.35; p = 0.93). CONCLUSIONS: Palliative services may be underutilized in the RR patient population, a group with a high in-hospital mortality rate; when palliative care is consulted, it may be associated with a reduction in the intensity of interventions at the end of life. CI - Copyright (c) 2026 The Authors. Published by Wolters Kluwer Health, LLC. on behalf of the Society of Critical Care Medicine. FAU - Arnold, Jason M AU - Arnold JM AUID- ORCID: 0000-0001-8687-0063 AD - Division of Pulmonary & Critical Care Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL. FAU - Ni, Chuanfen AU - Ni C AD - Center for Education in Health Sciences, Feinberg School of Medicine, Northwestern University, Chicago, IL. FAU - Thompson, Kayla AU - Thompson K AD - Division of Internal Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL. FAU - Lipa, Mary Clare AU - Lipa MC AD - Division of Internal Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL. FAU - Daryani, Deepa AU - Daryani D AD - Division of Internal Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL. FAU - Christenson, Megan AU - Christenson M AD - Division of Critical Care, Division of Palliative Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL. FAU - Nadig, Nandita R AU - Nadig NR AD - Division of Pulmonary & Critical Care Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL. FAU - Russell, Susan R AU - Russell SR AD - Division of Pulmonary & Critical Care Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL. LA - eng PT - Journal Article DEP - 20261001 PL - United States TA - Crit Care Explor JT - Critical care explorations JID - 101746347 SB - IM MH - Humans MH - *Palliative Care/statistics & numerical data/organization & administration MH - Female MH - Retrospective Studies MH - Male MH - *Terminal Care/statistics & numerical data/organization & administration MH - Hospital Mortality MH - Aged MH - *Hospital Rapid Response Team/statistics & numerical data MH - Middle Aged MH - Intensive Care Units/statistics & numerical data MH - United States PMC - PMC13629844 OTO - NOTNLM OT - delivery of healthcare OT - hospital mortality OT - hospital rapid response teams OT - palliative care OT - patient care planning COIS- The authors have disclosed that they do not have any potential conflicts of interest. EDAT- 2026/10/02 03:09 MHDA- 2026/10/02 03:10 PMCR- 2026/10/01 CRDT- 2026/10/01 18:34 PHST- 2026/10/02 03:10 [medline] PHST- 2026/10/02 03:09 [pubmed] PHST- 2026/10/01 18:34 [entrez] PHST- 2026/10/01 00:00 [pmc-release] AID - 02107256-202610000-00007 [pii] AID - CCE-D-26-00229 [pii] AID - 10.1097/CCE.0000000000001489 [doi] PST - epublish SO - Crit Care Explor. 2026 Oct 1;8(10):e1489. doi: 10.1097/CCE.0000000000001489. eCollection 2026 Oct 1. PMID- 42822608 OWN - NLM STAT- Publisher LR - 20261029 IS - 1097-6809 (Electronic) IS - 0741-5214 (Linking) DP - 2026 Oct 2 TI - Selective endovascular aortic repair in connective tissue disease patients within a multidisciplinary program achieves comparable outcomes in high-risk patients. LID - S0741-5214(26)01690-3 [pii] LID - 10.1016/j.jvs.2026.08.044 [doi] AB - INTRODUCTION: Endovascular aortic repair (ENDO) in patients with connective tissue disease (CTD) has historically been discouraged in society guidelines because of durability concerns. However, high-volume aortic centers increasingly employ ENDO strategies in carefully selected high-risk patients across scenarios such as rupture, dissection-related pathology, or hostile anatomy. Herein, we describe temporal ENDO adoption at our multidisciplinary CTD aortic program. METHODS: In this study, 92 patients with CTD undergoing aortic intervention at a single high-volume aortic center between 2005 and 2023 were analyzed. Patients were stratified by ENDO (n = 50) vs open repair (OPEN; n = 42). The primary outcome was freedom from aortic-related mortality (ARM). The secondary outcomes included technical success, complications, secondary aortic intervention (SAI), and overall survival. A prespecified contemporary analysis (2018-2023) was conducted to evaluate the outcomes following the establishment of a multidisciplinary CTD aortic program. The Kaplan-Meier method was used to estimate survival and freedom from SAI. RESULTS: The mean age was 48 +/- 16 years, and 34% (n = 31) were female. Diagnoses included Marfan syndrome (69%), Loeys-Dietz syndrome (15%), familial aortopathy (11%), and vascular Ehlers-Danlos syndrome (5%). Patients who underwent ENDO more frequently had prior sternotomy/open cardiac surgery (68% vs 19%; P < .0001), prior aortic surgery (70% vs 33%; P = .0007), and urgent presentation (50% vs 14%; P = .0004). Overall, 60% of these patients were deemed unfit for open repair by the multidisciplinary aortic team because of physiologic risk, anatomic complexity, or urgent presentation. The technical success rate was lower after ENDO (82% vs 98%; P = .02), and the 30-day reintervention rate was higher (16% vs 0%; P = .01). The median follow-up period was 2.3 years [interquartile range, 1.1-4.7]. SAIs occurred more frequently following ENDO (56% vs 12%; P = .0001), including planned staged procedures (ENDO: 28.6% vs OPEN: 20%; P = 1) and unplanned reinterventions (ENDO: 71.4% vs OPEN: 80%; P = 1). In the full cohort, patients undergoing ENDO had lower 3-year survival rates (71% +/- 7% vs 92% +/- 4%; log-rank P = .03). In the contemporary cohort, survival at 2 years following ENDO (n = 17) was poorer than that after OPEN (n = 42), although the difference did not reach significance (71% +/- 14% vs 92% +/- 4%; log-rank P = .1). Similarly, the rate of freedom from ARM was lower, but not significantly different (88% +/- 12% vs 98% +/- 2%; log-rank P = .4). CONCLUSIONS: Open repair remains the gold standard for connective tissue disease-associated aortic disease. In carefully selected high-risk patients, ENDO serves as a complementary strategy with acceptable contemporary survival and comparable freedom from ARM. Higher secondary intervention rates reflect both planned staged repair and unplanned surveillance-detected failure modes, underscoring the need for lifelong follow-up within multidisciplinary programs. CI - Copyright (c) 2026. Published by Elsevier Inc. FAU - Ueland, Walker R AU - Ueland WR AD - Division of Vascular Surgery and Endovascular Therapy, Gainesville, FL. FAU - Mazirka, Pavel AU - Mazirka P AD - Division of Vascular Surgery and Endovascular Therapy, Gainesville, FL. FAU - Fassler, Michael J AU - Fassler MJ AD - Division of Vascular Surgery and Endovascular Therapy, Gainesville, FL. FAU - Neal, Dan AU - Neal D AD - Division of Vascular Surgery and Endovascular Therapy, Gainesville, FL. FAU - Shahid, Zain AU - Shahid Z AD - Division of Vascular Surgery and Endovascular Therapy, Gainesville, FL. FAU - Cooper, Michol A AU - Cooper MA AD - Division of Vascular Surgery and Endovascular Therapy, Gainesville, FL. FAU - Upchurch, Gilbert R Jr AU - Upchurch GR Jr AD - Division of Vascular Surgery and Endovascular Therapy, Gainesville, FL. FAU - Spratt, John AU - Spratt J AD - Division of Vascular Surgery and Endovascular Therapy, Gainesville, FL. FAU - Jeng, Eric AU - Jeng E AD - Division of Vascular Surgery and Endovascular Therapy, Gainesville, FL. FAU - Beaver, Thomas AU - Beaver T AD - Division of Cardiovascular Surgery, Gainesville, FL. FAU - Martin, Tomas AU - Martin T AD - Division of Cardiovascular Surgery, Gainesville, FL. FAU - Scali, Salvatore T AU - Scali ST AD - Division of Vascular Surgery and Endovascular Therapy, Gainesville, FL. FAU - Back, Martin R AU - Back MR AD - Division of Vascular Surgery and Endovascular Therapy, Gainesville, FL. Electronic address: Martin.Back@surgery.ufl.edu. LA - eng PT - Journal Article DEP - 20261002 PL - United States TA - J Vasc Surg JT - Journal of vascular surgery JID - 8407742 SB - IM OTO - NOTNLM OT - Connective tissue disease OT - Endovascular aortic repair OT - Heritable aortopathy OT - Multidisciplinary aortic program OT - Open aortic repair OT - Secondary aortic intervention COIS- Disclosures None. EDAT- 2026/10/01 23:30 MHDA- 2026/10/01 23:30 CRDT- 2026/10/01 20:06 PHST- 2026/06/04 00:00 [received] PHST- 2026/07/29 00:00 [revised] PHST- 2026/08/01 00:00 [accepted] PHST- 2026/10/01 23:30 [pubmed] PHST- 2026/10/01 23:30 [medline] PHST- 2026/10/01 20:06 [entrez] AID - S0741-5214(26)01690-3 [pii] AID - 10.1016/j.jvs.2026.08.044 [doi] PST - aheadofprint SO - J Vasc Surg. 2026 Oct 2:S0741-5214(26)01690-3. doi: 10.1016/j.jvs.2026.08.044. PMID- 42821859 OWN - NLM STAT- MEDLINE DCOM- 20261001 LR - 20261001 IS - 1538-8646 (Electronic) IS - 0730-4625 (Linking) VI - 45 IP - 6 DP - 2026 Nov-Dec 01 TI - Hospital-acquired Pressure Injury Prevention Assisted by a Leadership-supported Dedicated Turn-team. PG - 335-341 LID - 10.1097/DCC.0000000000000801 [doi] AB - BACKGROUND: Critically ill patients are at high risk for hospital-acquired pressure injury development due to immobility and hemodynamic instability. In the 24-bed Cardiac Intensive Care Unit within an academic medical center, registered nurses have multiple competing responsibilities and priorities that reduced consistency and quality of patient repositioning, including movement from bed to chair. An inconsistent repositioning/out-of-bed schedule can prompt hospital-acquired pressure injuries to bony prominences. OBJECTIVES: To examine surface hospital-acquired pressure injury rates pre-post intervention implementation and assess perceived usefulness and added value of the turn-team in a high-acuity coronary intensive care unit that routinely utilized advanced life support technologies. METHODS: This project was a single unit, continuous improvement initiative. A nonclinical turn-team provided consistent repositioning/up-to-chair of patients to reduce hospital-acquired pressure injury incidence. Inferential statistics were used to assess pre-post surface hospital-acquired pressure injury rates and clinicians' surveys were analyzed descriptively. RESULTS: In the postimplementation period, repositioning consistency increased, and the hospital-acquired pressure injury rate was reduced by 42% (P=.043). After adjusting for daily patient census, daily risk of surface hospital-acquired pressure injury changed from 6.74% to 4.03%, adjusted odds ratio 0.581 (95% confidence interval: 0.33, 1.02), P=.059. At 30 days, survey results reflected strong team collaboration and turn-team members support that enhanced clinical nurse productivity. CONCLUSION: A dedicated turn-team was a valuable adjunct to patient positioning when busy nursing caregivers were unable to complete this important role at regular intervals. Clinical nurses and turn-team members worked well together to achieve patient care outcomes. CI - Copyright (c) 2026 Wolters Kluwer Health, LLC. All rights reserved. FAU - Tapper, Gissel M AU - Tapper GM AUID- ORCID: 0009-0007-8526-8987 AD - Program Manager Policies and Evidence-Based Practice, Quality Patient Safety Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates. FAU - Hornby, Steve AU - Hornby S AD - Nurse Manager, Cardiac Intensive Care Unit, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates. FAU - Kanwar, Oshin AU - Kanwar O AUID- ORCID: 0009-0007-1873-3287 AD - Research Scholar-Academics, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates. FAU - Petre, Marc AU - Petre M AD - Chief Operation Officer, Operations, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates. FAU - Albert, Nancy M AU - Albert NM AUID- ORCID: 0000-0002-3619-966 AD - Executive Director/Associate Chief Nursing Officer, Research and Innovation-Nursing Institute, Cleveland Clinic, Cleveland, OH. LA - eng PT - Journal Article DEP - 20260930 PL - United States TA - Dimens Crit Care Nurs JT - Dimensions of critical care nursing : DCCN JID - 8211489 SB - IM MH - Humans MH - *Pressure Ulcer/prevention & control MH - *Leadership MH - *Patient Positioning MH - *Iatrogenic Disease/prevention & control MH - *Patient Care Team MH - Female MH - Coronary Care Units MH - Intensive Care Units MH - Moving and Lifting Patients OTO - NOTNLM OT - continuous improvement OT - intensive care units OT - patient repositioning OT - pressure injury OT - scope of practice EDAT- 2026/10/01 23:30 MHDA- 2026/10/01 23:31 CRDT- 2026/10/01 19:36 PHST- 2025/11/04 00:00 [received] PHST- 2026/08/18 00:00 [accepted] PHST- 2026/10/01 23:31 [medline] PHST- 2026/10/01 23:30 [pubmed] PHST- 2026/10/01 19:36 [entrez] AID - 00003465-202611000-00010 [pii] AID - 10.1097/DCC.0000000000000801 [doi] PST - ppublish SO - Dimens Crit Care Nurs. 2026 Nov-Dec 01;45(6):335-341. doi: 10.1097/DCC.0000000000000801. Epub 2026 Sep 30. PMID- 42821180 OWN - NLM STAT- Publisher LR - 20261001 IS - 1878-7649 (Print) IS - 1878-7649 (Linking) DP - 2026 Oct 1 TI - Perioperative care in older adults: a narrative review. LID - 10.1007/s41999-026-01617-5 [doi] AB - PURPOSE: The perioperative care of older patients is challenging due to clinical complexity. In this narrative review, we summarized the most important aspects of perioperative care of very old adults. METHODS: We performed a non-systematic narrative review of available studies to summarize evidence to support best clinical practice in perioperative care of very old patients. When appropriate, evidence was supplemented with data from broader population of older adults. RESULTS: The preoperative assessment should take into consideration comorbidities and cardiac risk as well as geriatric syndromes, including cognitive decline, sarcopenia, frailty, and malnutrition. Identification of geriatric syndromes should prompt intervention or involvement of an interdisciplinary team. In the perioperative period, caution regarding medication is advised due to frequent polypharmacy and altered pharmacodynamics of drugs. Perioperative delirium should be prevented and adequately managed. Due to a significant risk of postoperative functional decline, rehabilitation and coordinated post-discharge care play a pivotal role in the postoperative period. CONCLUSION: Our review briefly summarizes the most important clinical problems in the perioperative care of very old adults, drawing where necessary on evidence from broader older populations. Despite increase of high-quality evidence in the field, an individualized approach and involvement of an interdisciplinary team are frequently required in this group of patients. CI - (c) 2026. The Author(s). FAU - Szczeklik, W AU - Szczeklik W AUID- ORCID: 0000-0002-1349-1123 AD - Centre for Intensive Care and Perioperative Medicine, Jagiellonian University Medical College, ul. Wroclawska 1-3, 30 - 901, Krakow, Poland. wojciech.szczeklik@uj.edu.pl. AD - Department of Anaesthesiology and Intensive Care, 5th Military Hospital, Krakow, Poland. wojciech.szczeklik@uj.edu.pl. FAU - Pasieka, P AU - Pasieka P AD - Centre for Intensive Care and Perioperative Medicine, Jagiellonian University Medical College, ul. Wroclawska 1-3, 30 - 901, Krakow, Poland. FAU - Piotrowicz, K AU - Piotrowicz K AD - Department of Internal Medicine and Gerontology, Jagiellonian University Medical College, Krakow, Poland. FAU - Wludarczyk, A AU - Wludarczyk A AD - Centre for Intensive Care and Perioperative Medicine, Jagiellonian University Medical College, ul. Wroclawska 1-3, 30 - 901, Krakow, Poland. AD - Department of Anaesthesiology and Intensive Care, 5th Military Hospital, Krakow, Poland. LA - eng PT - Journal Article PT - Review DEP - 20261001 PL - Switzerland TA - Eur Geriatr Med JT - European geriatric medicine JID - 101533694 SB - IM OTO - NOTNLM OT - Anesthesiology OT - Frailty OT - Interdisciplinary care OT - Perioperative care OT - Surgery OT - Very old adults COIS- Declarations. Conflict of interest: The authors declare no conflict of interest. Ethical approval: This article does not contain any studies with human participants or animals performed by any of the authors. Informed consent: For this type of study informed consent is not required. EDAT- 2026/10/01 23:30 MHDA- 2026/10/01 23:30 CRDT- 2026/10/01 19:00 PHST- 2026/07/15 00:00 [received] PHST- 2026/09/16 00:00 [accepted] PHST- 2026/09/11 00:00 [revised] PHST- 2026/10/01 23:30 [medline] PHST- 2026/10/01 23:30 [pubmed] PHST- 2026/10/01 19:00 [entrez] AID - 10.1007/s41999-026-01617-5 [pii] AID - 10.1007/s41999-026-01617-5 [doi] PST - aheadofprint SO - Eur Geriatr Med. 2026 Oct 1. doi: 10.1007/s41999-026-01617-5. PMID- 42819666 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20261001 LR - 20261001 IS - 1687-6962 (Print) IS - 1687-6970 (Electronic) IS - 1687-6962 (Linking) VI - 2026 DP - 2026 TI - Pheochromocytoma Across the Perioperative Course: Current Concepts and Clinical Management. PG - 4406992 LID - 10.1155/anrp/4406992 [doi] LID - 4406992 AB - Pheochromocytoma is an uncommon neuroendocrine tumor with myriad nonspecific clinical presentations. If not recognized and treated, it is associated with the development of target organ damage and complications such as myocarditis, cardiomyopathy, cerebrovascular accidents, and diabetes mellitus, among numerous others. The pheochromocytoma diagnosis is based on biochemical proof of catecholamine excess followed by imaging localization of the tumor. Patients with newly diagnosed pheochromocytoma should be seen by a multidisciplinary perioperative team, including the anesthesiologist, operating surgeon, endocrinologist, and cardiologist. Perioperative antihypertensive therapy should be instituted prior to adrenal resection to allow for cardiovascular recovery and to hopefully mitigate the hypertensive response to laryngoscopy and tumor manipulation. The anesthesiologist must be prepared to manage both intraoperative hypertension, hypotension, and glycemic disturbances, among other possible complications. Patients with previously undiagnosed pheochromocytoma who present for unrelated surgery represent a high-risk group. Once intraoperatively suspected, priority should be given to immediate stabilization, cessation of surgery when feasible, and close communication with the surgical team regarding whether the procedure should be aborted, limited, or continued based on the urgency of the operation and the patient's clinical status. In most cases, nonessential surgery should be aborted. The postoperative level of care should be based on intraoperative patient courses and institutional protocols and guidelines to monitor and manage postresection hypoglycemia and vasoplegia, when they occur. This narrative review aims to provide practicing anesthesiologists with an updated, practical framework for the perioperative recognition and management of pheochromocytoma. We integrate contemporary evidence with anesthesia-specific decision-making, including the management of catecholamine-induced cardiovascular dysfunction, perioperative fluid and vasoactive therapy, medication-triggered crises, and a dedicated approach to previously undiagnosed pheochromocytoma presenting during unrelated surgery. CI - Copyright (c) 2026 Aibek E. Mirrakhimov and Nicole Bashall. Anesthesiology Research and Practice published by John Wiley & Sons Ltd. FAU - Mirrakhimov, Aibek E AU - Mirrakhimov AE AUID- ORCID: 0000-0003-1604-1053 AD - Department of Anesthesiology, Perioperative, Critical Care, and Pain Medicine, Division of Adult Cardiothoracic Anesthesiology, University of Kentucky, Lexington, Kentucky, USA, uky.edu. FAU - Bashall, Nicole AU - Bashall N AD - Division of Adult Cardiothoracic Anesthesia and Intensive Care and Resuscitation, Cleveland Clinic Foundation, Cleveland, Ohio, USA, clevelandclinic.org. LA - eng PT - Journal Article PT - Review DEP - 20260929 PL - United States TA - Anesthesiol Res Pract JT - Anesthesiology research and practice JID - 101532982 PMC - PMC13624540 COIS- The authors declare no conflicts of interest. EDAT- 2026/10/01 17:29 MHDA- 2026/10/01 17:30 PMCR- 2026/09/29 CRDT- 2026/10/01 16:55 PHST- 2025/10/05 00:00 [received] PHST- 2026/09/08 00:00 [revised] PHST- 2026/09/09 00:00 [accepted] PHST- 2026/10/01 17:30 [medline] PHST- 2026/10/01 17:29 [pubmed] PHST- 2026/10/01 16:55 [entrez] PHST- 2026/09/29 00:00 [pmc-release] AID - ANRP4406992 [pii] AID - 10.1155/anrp/4406992 [doi] PST - epublish SO - Anesthesiol Res Pract. 2026 Sep 29;2026:4406992. doi: 10.1155/anrp/4406992. eCollection 2026. PMID- 42815938 OWN - NLM STAT- MEDLINE DCOM- 20260930 LR - 20260930 IS - 1526-3347 (Electronic) IS - 0191-9601 (Linking) VI - 47 IP - 10 DP - 2026 Oct 1 TI - 22q11.2 Deletion Syndrome: A Comprehensive Review for Pediatricians From Diagnosis to Adult Care Transition. PG - 581-591 LID - 10.1542/pir.2025-006952 [doi] AB - Affecting ~1 in 4000 to 6000 live births, 22q11.2 deletion syndrome (22q11.2DS) is the most common chromosomal microdeletion syndrome. It results from a 1.5 to 3 Mb heterozygous deletion at chromosome 22q11.2 and is associated with a broad spectrum of clinical manifestations, including cardiac defects, palatal abnormalities, thymic hypoplasia, developmental delays, and neuropsychiatric symptoms. Multiple techniques such as chromosomal microarray and sequencing techniques such as fluorescence in situ hybridization help in the diagnosis of 22q11.2DS. A multidisciplinary approach to management is required, involving cardiology, immunology, endocrinology, speech therapy, psychiatry, and genetics. Surveillance should include monitoring for immunodeficiency, hypocalcemia, thyroid dysfunction, hematologic complications, and psychiatric illness. Genetic counselling and prenatal testing are crucial components in guiding families and informing reproductive decision-making. Additionally, structured transition of care programs should be employed to ensure continued care into adulthood. Although 22q11.2DS has gained significant recognition in the past decades, educational gaps still persist for pediatricians, especially regarding when to suspect, genetic testing, and coordination of care. This review aims to provide insights into the epidemiology, pathogenesis, system-based clinical features, diagnosis, management, and surveillance of 22q11.2DS, highlighting practical strategies that can be employed by pediatricians to improve early detection and optimize long-term outcomes. CI - (c) American Academy of Pediatrics, 2026. All rights reserved. FAU - Ali, Suzain AU - Ali S AD - Rollins School of Public Health, Emory University, Atlanta, Georgia. FAU - Gupta, Pranav AU - Gupta P AD - Children's Healthcare of Atlanta, Atlanta, Georgia. AD - Emory University School of Medicine, Atlanta, Georgia. LA - eng PT - Journal Article PT - Review PL - United States TA - Pediatr Rev JT - Pediatrics in review JID - 8103046 SB - IM MH - Humans MH - *DiGeorge Syndrome/diagnosis/therapy/genetics/epidemiology MH - *Transition to Adult Care MH - Adult MH - Pediatricians MH - Genetic Counseling EDAT- 2026/09/30 23:30 MHDA- 2026/09/30 23:31 CRDT- 2026/09/30 20:13 PHST- 2025/09/04 00:00 [received] PHST- 2026/01/15 00:00 [accepted] PHST- 2026/09/30 23:31 [medline] PHST- 2026/09/30 23:30 [pubmed] PHST- 2026/09/30 20:13 [entrez] AID - 210708 [pii] AID - 10.1542/pir.2025-006952 [doi] PST - ppublish SO - Pediatr Rev. 2026 Oct 1;47(10):581-591. doi: 10.1542/pir.2025-006952. PMID- 42814850 OWN - NLM STAT- Publisher LR - 20260930 IS - 1538-4683 (Electronic) IS - 1061-5377 (Linking) DP - 2026 Sep 29 TI - Optimal Surgical Timing After Postinfarction Ventricular Septal Rupture: A Narrative Review With a Proposed Heart Team Decision Algorithm. LID - 10.1097/CRD.0000000000001481 [doi] AB - Postinfarction ventricular septal rupture is a rare, frequently lethal mechanical complication of acute myocardial infarction, and the optimal timing of repair remains controversial. Early surgery is often unavoidable in refractory shock but is technically hazardous because necrotic, friable myocardium provides poor suture support. Delayed repair after tissue maturation is associated with lower operative mortality, although this apparent benefit is substantially inflated by survivorship and immortal time bias. Mechanical circulatory support, including intra-aortic balloon counterpulsation, venoarterial extracorporeal membrane oxygenation, and microaxial flow pumps, may stabilize selected patients, permit end-organ recovery, and bridge them to later repair. However, available evidence is almost entirely observational, and the certainty supporting major timing and device selection recommendations is low or very low. This narrative review synthesizes the biological basis of timing, diagnostic and anatomic considerations, surgical and transcatheter options, mechanical support strategies, and transplantation. We propose a practical Heart Team framework based on hemodynamic status, tissue maturation, rupture anatomy, and daily reassessment, with explicit clinical triggers for abandoning delay. Surgical timing should therefore be individualized according to physiology rather than dictated by a fixed chronological threshold, pending prospective multicenter validation. CI - Copyright (c) 2026 Wolters Kluwer Health, LLC. All rights reserved. FAU - Khalil, Essam Ahmed AU - Khalil EA AD - From the Cardiology Department, Faculty of Medicine, Al-Azhar University, Cairo, Egypt. FAU - Elshamy, Mahmoud Ibrahim Ali AU - Elshamy MIA AD - Radiology Department, Faculty of Medicine, Al-Azhar University, Cairo, Egypt. FAU - Rehan, Mohamed Kamal AU - Rehan MK AD - Internal Medicine Department, Faculty of Medicine, Beni Suef University, Beni Suef, Egypt. FAU - Eldaly, Ahmed Mohamed Aboul Fotouh AU - Eldaly AMAF AD - Radiology Department, Faculty of Medicine, Al-Azhar University, Cairo, Egypt. FAU - Ezzat, Mohammed Ahmed AU - Ezzat MA AD - From the Cardiology Department, Faculty of Medicine, Al-Azhar University, Cairo, Egypt. FAU - Elhadary, Abdelrahman AU - Elhadary A AD - From the Cardiology Department, Faculty of Medicine, Al-Azhar University, Cairo, Egypt. FAU - Ramadan, Yasser Abdelgaleel AU - Ramadan YA AD - From the Cardiology Department, Faculty of Medicine, Al-Azhar University, Cairo, Egypt. FAU - Mohammed, Wasiem Atteya AU - Mohammed WA AD - Cardiothoracic Surgery Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt. FAU - Mohamed, Marwa Ramadan AU - Mohamed MR AD - Cardiothoracic Surgery Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt. FAU - Elkasaby, Mohamed Hamouda AU - Elkasaby MH AD - Department of Medicine, Faculty of Medicine, Al-Azhar University, Cairo, Egypt. FAU - Frishman, William H AU - Frishman WH AD - Departments of Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY. FAU - Aronow, Wilbert S AU - Aronow WS AD - Departments of Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY. LA - eng PT - Journal Article DEP - 20260929 PL - United States TA - Cardiol Rev JT - Cardiology in review JID - 9304686 SB - IM OTO - NOTNLM OT - Heart Team decision-making OT - acute myocardial infarction OT - cardiogenic shock OT - infarct exclusion repair OT - mechanical circulatory support OT - surgical timing OT - ventricular septal rupture COIS- Disclosures: The authors have no conflicts of interest to report. EDAT- 2026/09/30 17:32 MHDA- 2026/09/30 17:32 CRDT- 2026/09/30 14:13 PHST- 2026/09/30 17:32 [medline] PHST- 2026/09/30 17:32 [pubmed] PHST- 2026/09/30 14:13 [entrez] AID - 00045415-990000000-01031 [pii] AID - 10.1097/CRD.0000000000001481 [doi] PST - aheadofprint SO - Cardiol Rev. 2026 Sep 29. doi: 10.1097/CRD.0000000000001481. PMID- 42813689 OWN - NLM STAT- MEDLINE DCOM- 20260930 LR - 20261002 IS - 1478-5153 (Electronic) IS - 1362-1017 (Print) IS - 1362-1017 (Linking) VI - 31 IP - 6 DP - 2026 Nov TI - End-Of-Life Care in a Cardiac Intensive Care Unit: A Retrospective Analysis of Interventions During the Last 48 Hours. PG - e70717 LID - 10.1111/nicc.70717 [doi] LID - e70717 AB - BACKGROUND: Palliative care in intensive care units should be planned jointly with patients and their families and documented in medical records. Proximity to death should prompt reassessment of the therapeutic strategy. AIM: To analyse the interventions performed during the last 48 h in patients who died in the cardiac intensive care unit. STUDY DESIGN: A retrospective cohort study was conducted in the cardiac intensive care unit of a large university hospital in Southeastern Brazil between March and April 2025. The deaths that occurred in 2022, 2023 and 2024 were evaluated. RESULTS: A total of 83 deaths with more than 5 days of hospital admission were analysed. There were few records documenting patients' and families' wishes. Only 12 (14.5%) records of limitations of life-sustaining treatments and 11 (13.3%) records of do-not-resuscitate orders directed to the healthcare team were identified. CONCLUSION: Interventions intended to modify the course of the disease exceeded those aimed at palliative care in our cohort. RELEVANCE TO CLINICAL PRACTICE: These findings may support the implementation of trigger-based protocols for palliative care assessment in cardiac ICUs, the development of training strategies focused on communication and documentation of patient preferences for ICU teams, the strengthening of the role of the multidisciplinary team, and standardized comfort-focused interventions during the last 48 h of life. CI - (c) 2026 The Author(s). Nursing in Critical Care published by John Wiley & Sons Ltd on behalf of British Association of Critical Care Nurses. FAU - Gomes, Eduardo Tavares AU - Gomes ET AUID- ORCID: 0000-0002-9506-5303 AD - Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil. FAU - Celes, Larissa Braga AU - Celes LB AUID- ORCID: 0009-0007-9402-0828 AD - Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil. FAU - Dos Reis Cirino, Geovana Aparecida AU - Dos Reis Cirino GA AUID- ORCID: 0000-0001-9182-5371 AD - Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil. LA - eng PT - Journal Article PL - England TA - Nurs Crit Care JT - Nursing in critical care JID - 9808649 SB - IM MH - Humans MH - Retrospective Studies MH - *Terminal Care MH - Female MH - *Palliative Care MH - Male MH - *Intensive Care Units MH - Brazil MH - Aged MH - Middle Aged PMC - PMC13625662 OTO - NOTNLM OT - cardiology OT - critical care OT - critical care nurses OT - intensive care units OT - palliative care COIS- The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/09/30 11:35 MHDA- 2026/09/30 11:36 PMCR- 2026/09/30 CRDT- 2026/09/30 08:23 PHST- 2026/08/21 00:00 [revised] PHST- 2026/06/07 00:00 [received] PHST- 2026/09/08 00:00 [accepted] PHST- 2026/09/30 11:36 [medline] PHST- 2026/09/30 11:35 [pubmed] PHST- 2026/09/30 08:23 [entrez] PHST- 2026/09/30 00:00 [pmc-release] AID - NICC70717 [pii] AID - 10.1111/nicc.70717 [doi] PST - ppublish SO - Nurs Crit Care. 2026 Nov;31(6):e70717. doi: 10.1111/nicc.70717. PMID- 42811858 OWN - NLM STAT- MEDLINE DCOM- 20260930 LR - 20261006 IS - 2408-8757 (Electronic) IS - 1022-4742 (Linking) VI - 35 IP - 4 DP - 2026 Oct TI - Medical Personnel Understanding Regarding Cardiac Rehabilitation Among Cardiac Patients in Bangladesh Medical University. PG - 1241-1248 AB - In Bangladesh, Cardiovascular diseases (CVDs) impose a significant healthcare and socioeconomic burden. Cardiac rehabilitation, a proven multidisciplinary approach, enhances the well-being of Cardiovascular disease (CVD) patients. However, there may be gaps in medical personnel's understanding of this vital intervention. This study, conducted at Bangladesh Medical University (BMU), Dhaka, Bangladesh a renowned cardiac care institution in Bangladesh, seeks to evaluate and improve medical professionals' knowledge, perceptions and attitudes regarding cardiac rehabilitation to enhance patient care and outcomes. The aim of this study was to identify the key factors influencing medical personnel's understanding of cardiac rehabilitation, including their training, experience and exposure to current guidelines. This cross-sectional observational study was conducted in the Department of Cardiology of Bangladesh Medical University (BMU), Dhaka, Bangladesh during the period from August 2022 to July 2023. In total 100 medical personnel included in the study. We found that the Mean+/-SD of age was 33.16+/-7.06 and the majority (80.0%) were female, followed by 20.0% who were male and 5.0% who were physicians. We also found that the majority of medical personnel have a positive understanding of cardiac rehabilitation. Cardiac rehabilitation (CR) is underutilized in Bangladesh, including among healthcare professionals. This study aims to enhance CR awareness and integration for better patient outcomes at Bangladesh Medical University, ultimately improving cardiovascular care in Bangladesh. FAU - Shoma, F K AU - Shoma FK AD - Dr Farzana Khan Shoma, Associate Professor, Department of Physical Medicine and Rehabilitation, Bangladesh Medical University (BMU), Dhaka, Bangladesh; E-mail: farzanadmck53@gmail.com. FAU - Khaled, M F I AU - Khaled MFI FAU - Shakoor, M A AU - Shakoor MA FAU - Azad, M A K AU - Azad MAK FAU - Chowdhury, Z R AU - Chowdhury ZR FAU - Hoque, M H AU - Hoque MH LA - eng PT - Journal Article PT - Observational Study PL - Bangladesh TA - Mymensingh Med J JT - Mymensingh medical journal : MMJ JID - 9601799 SB - IM MH - Adult MH - Female MH - Humans MH - Male MH - Bangladesh MH - *Cardiac Rehabilitation MH - Cross-Sectional Studies MH - *Health Knowledge, Attitudes, Practice MH - Academic Medical Centers MH - *Health Personnel/statistics & numerical data EDAT- 2026/09/30 05:30 MHDA- 2026/09/30 05:31 CRDT- 2026/09/30 03:13 PHST- 2026/09/30 05:31 [medline] PHST- 2026/09/30 05:30 [pubmed] PHST- 2026/09/30 03:13 [entrez] PST - ppublish SO - Mymensingh Med J. 2026 Oct;35(4):1241-1248. PMID- 42809786 OWN - NLM STAT- MEDLINE DCOM- 20260929 LR - 20260930 IS - 0717-6163 (Electronic) IS - 0034-9887 (Linking) VI - 154 IP - 7 DP - 2026 Jul TI - Chilean Multidisciplinary Consensus on the Use of GLP-1 Receptor Agonists: Recommendations Based on the GRADE Methodology. PG - 1070-1082 LID - S0034-98872026000701070 [pii] LID - 10.4067/s0034-98872026000701070 [doi] AB - Type 2 diabetes (T2DM), obesity, chronic kidney disease (CKD), and heart failure (HF) pose a major public health burden in Chile and Latin America. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) provide glycemic, cardiovascular, renal, and weight-loss benefits, extending their therapeutic role beyond glycemic control. AIM: To develop a national consensus, based on GRADE methodology, that synthesizes the best available evidence and adapts it to the Chilean healthcare context, providing practical recommendations for the rational use of GLP-1 RA (GLP-1 receptor agonists). METHODS: A multidisciplinary panel convened by six Chilean scientific societies developed this consensus, using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) framework. A systematic review of randomized trials and meta-analyses was conducted. Evidence tables were prepared and critically appraised to support transparent recommendations adapted to the Chilean healthcare context. RESULTS: The panel formulated seven key recommendations: (1) a strong recommendation for GLP-1 RAs in patients with T2DM and CKD; (2) a weak recommendation in CKD without diabetes; (3) a strong recommendation in T2DM with high cardiovascular risk; (4) a weak recommendation over sulfonylureas as add-on to metformin; (5) a strong recommendation in HF with preserved ejection fraction (HFpEF) and BMI >/=27; (6) a strong recommendation in obesity with T2DM; and (7) a weak recommendation in obesity without T2DM. CONCLUSIONS: This consensus synthesizes international evidence and contextualizes it to Chile, supporting rational, equitable, and transparent implementation of GLP-1 RAs. These agents are positioned as central tools in the management of the cardiorenal-metabolic syndrome, complementing current cost-effective therapies and lifestyle interventions. FAU - Cabrera, Sebastian AU - Cabrera S AD - Sociedad Chilena de Nefrologia, Santiago, Chile. FAU - Walbaum, Magdalena AU - Walbaum M AD - Care Policy and Evaluation Centre, London School of Economics and Political Science, London, UK. FAU - Borquez, Tamara AU - Borquez T AD - Sociedad Chilena de Nefrologia, Santiago, Chile. FAU - Fuentes, Catalina AU - Fuentes C AD - Asociacion Chilena de Nutricion Clinica, Obesidad y Metabolismo, Santiago, Chile. FAU - Acevedo, Monica AU - Acevedo M AD - Sociedad Chilena de Cardiologia y Cirugia Cardiovascular, Santiago, Chile. FAU - Varleta, Paola AU - Varleta P AD - Sociedad Chilena de Cardiologia y Cirugia Cardiovascular, Santiago, Chile. FAU - Belmar, Pamela AU - Belmar P AD - Sociedad Chilena de Diabetologia, Santiago, Chile. FAU - Gomez, Patricia AU - Gomez P AD - Sociedad Chilena de Diabetologia, Santiago, Chile. FAU - Sanzana, Maria Gabriela AU - Sanzana MG AD - Sociedad Chilena de Endocrinologia y Diabetes, Santiago, Chile. FAU - Vega, Javier AU - Vega J AD - Sociedad Chilena de Endocrinologia y Diabetes, Santiago, Chile. FAU - Navarro, Gustavo AU - Navarro G AD - Universidad Austral de Chile, Chile. FAU - Saavedra, Carla AU - Saavedra C AD - Sociedad Chilena de Obesidad, Santiago, Chile. FAU - Hernandez, Mario AU - Hernandez M AD - Sociedad Chilena de Nefrologia, Santiago, Chile. FAU - Gomez, Sabrina AU - Gomez S AD - Hospital Clinico, Universidad de Chile, Chile. FAU - Lorca, Eduardo AU - Lorca E AD - Sociedad Chilena de Nefrologia, Santiago, Chile. LA - eng LA - spa PT - Consensus Statement PT - Journal Article TT - Consenso multidisciplinario chileno sobre el uso de agonistas de GLP-1: Recomendaciones basadas en metodologia GRADE. PL - Chile TA - Rev Med Chil JT - Revista medica de Chile JID - 0404312 RN - 0 (Glucagon-Like Peptide-1 Receptor Agonists) RN - 0 (Hypoglycemic Agents) SB - IM MH - Humans MH - Chile MH - *Diabetes Mellitus, Type 2/drug therapy MH - *Glucagon-Like Peptide-1 Receptor Agonists MH - Heart Failure/drug therapy MH - *Hypoglycemic Agents/therapeutic use MH - Obesity/drug therapy MH - Renal Insufficiency, Chronic/drug therapy EDAT- 2026/09/29 19:04 MHDA- 2026/09/29 19:05 CRDT- 2026/09/29 15:59 PHST- 2025/09/02 00:00 [received] PHST- 2025/12/09 00:00 [accepted] PHST- 2026/09/29 19:05 [medline] PHST- 2026/09/29 19:04 [pubmed] PHST- 2026/09/29 15:59 [entrez] AID - S0034-98872026000701070 [pii] AID - 10.4067/s0034-98872026000701070 [doi] PST - ppublish SO - Rev Med Chil. 2026 Jul;154(7):1070-1082. doi: 10.4067/s0034-98872026000701070. PMID- 42803737 OWN - NLM STAT- Publisher LR - 20260928 IS - 1527-2966 (Electronic) IS - 0099-1767 (Linking) DP - 2026 Sep 28 TI - Emergency Nursing Recognition of Clinically Suspected Transfusion-Related Acute Lung Injury Type II After Transfusion: The Adjunctive Role of Bedside Point-of-Care Ultrasound. LID - S0099-1767(26)00256-4 [pii] LID - 10.1016/j.jen.2026.07.018 [doi] AB - Transfusion-related acute lung injury is a rare but potentially fatal transfusion reaction that can be difficult to recognize in critically ill emergency department patients. We report a 69-year-old man with suspected sepsis, gastrointestinal bleeding, severe thrombocytopenia, acute kidney injury, and vasopressor-dependent hypotension. He received 1 unit of leukocyte-reduced apheresis platelets followed by 2 units of packed red blood cells. Approximately 2.5 hours after transfusion completion, he developed a fever and acute hypoxemic respiratory deterioration, with oxygen saturation decreasing to 70% despite oxygen delivery by mask at 15 L/min. Because deterioration occurred within 6 hours after transfusion, transfusion-related acute lung injury and transfusion-associated circulatory overload were considered. Bedside point-of-care ultrasound showed bilateral B-lines, grossly preserved cardiac function, no obvious left ventricular systolic dysfunction, and no pleural effusion. N-terminal pro-B-type natriuretic peptide was 345 pg/mL. Formal echocardiography performed approximately 6 hours later showed a left ventricular ejection fraction of 57%, no significant valvular disease or pulmonary hypertension, and no reported volume overload. These findings did not strongly support isolated transfusion-associated circulatory overload or cardiogenic pulmonary edema. Based on the 2019 international consensus redefinition, the case was most consistent with clinically suspected transfusion-related acute lung injury Type II, although complete documentation confirming respiratory stability throughout the 12 hours before transfusion was not available. This case highlights the emergency nurse's role in recognizing posttransfusion respiratory deterioration, escalating care, and communicating with the interprofessional team. Point-of-care ultrasound should be used as an adjunctive bedside assessment rather than a confirmatory test. CI - Copyright (c) 2026 Emergency Nurses Association. Published by Elsevier Inc. All rights reserved. FAU - Lin, Lu-Chun AU - Lin LC FAU - Chen, Ho-Hsiang AU - Chen HH LA - eng PT - Journal Article DEP - 20260928 PL - United States TA - J Emerg Nurs JT - Journal of emergency nursing JID - 7605913 SB - IM OTO - NOTNLM OT - Emergency nursing OT - Point-of-care systems OT - Transfusion-associated circulatory overload OT - Transfusion-related acute lung injury OT - Ultrasonography EDAT- 2026/09/28 11:40 MHDA- 2026/09/28 11:40 CRDT- 2026/09/28 10:28 PHST- 2026/06/06 00:00 [received] PHST- 2026/07/23 00:00 [revised] PHST- 2026/07/23 00:00 [accepted] PHST- 2026/09/28 11:40 [medline] PHST- 2026/09/28 11:40 [pubmed] PHST- 2026/09/28 10:28 [entrez] AID - S0099-1767(26)00256-4 [pii] AID - 10.1016/j.jen.2026.07.018 [doi] PST - aheadofprint SO - J Emerg Nurs. 2026 Sep 28:S0099-1767(26)00256-4. doi: 10.1016/j.jen.2026.07.018. PMID- 42803602 OWN - NLM STAT- Publisher LR - 20260928 IS - 1221-9118 (Print) IS - 1221-9118 (Linking) VI - 121 IP - Ahead of print DP - 2026 Sep 1 TI - Anastomotic Fistula After Upper Gastric Resection for Incarcerated Hiatal Hernia, Successfully Managed via Endoscopic Approach: A Case Report. PG - 1-7 LID - 3 [pii] LID - 10.21614/chirurgia.3417 [doi] AB - INTRODUCTION: Acute incarcerated hiatal hernia with gastric perforation is rare and life-threatening condition. The clinical presentation is often atypical, which can delay diagnosis and contribute to high mortality from secondary mediastinitis and peritonitis. CASE REPORT: We present the case of a 71-year-old woman initially admitted with suspected acute coronary syndrome. The onset of melena, together with findings on gastroscopy and computed tomography, revealed an incarcerated hiatal hernia with gangrene and perforation of the proximal stomach. Emergency proximal gastrectomy was performed, together with extensive lavage of the abdominal and mediastinal cavities. The postoperative course was complicated by a development of a gastrocutaneous fistula on postoperative day 20, which was successfully managed with endoscopic clip placement. The patient required 31 days of intensive care before being discharged in good general condition. CONCLUSION: This case underscores the value of a multidisciplinary approach, demonstrating that endoscopic management can provide a feasible alternative to high-risk reoperation for postoperative fistula in a septic patient. Five-year follow-up showed a favorable long-term outcome. CI - Celsius. FAU - Spasovski, Zharko AU - Spasovski Z FAU - Avramovska, Maja AU - Avramovska M FAU - Krstevski, Stefan AU - Krstevski S FAU - Avramovski, Petar AU - Avramovski P FAU - Sotiroski, Kosta AU - Sotiroski K FAU - Talev, Stefan AU - Talev S FAU - Blazevski, Bozidar AU - Blazevski B FAU - Stojkovski, Vladimir AU - Stojkovski V FAU - Todorovska, Liljana AU - Todorovska L FAU - Stefanovska, Svetlana AU - Stefanovska S FAU - Aleksoska, Elena AU - Aleksoska E FAU - Ginovska, Elena AU - Ginovska E LA - eng PT - Journal Article DEP - 20260901 PL - Romania TA - Chirurgia (Bucur) JT - Chirurgia (Bucharest, Romania : 1990) JID - 9213031 SB - IM OTO - NOTNLM OT - gastricperforation OT - gastrocutaneousfistula OT - incarceratedhiatalhernia OT - mediastinitis EDAT- 2026/09/28 11:40 MHDA- 2026/09/28 11:40 CRDT- 2026/09/28 09:13 PHST- 2026/09/01 00:00 [accepted] PHST- 2026/09/28 11:40 [medline] PHST- 2026/09/28 11:40 [pubmed] PHST- 2026/09/28 09:13 [entrez] AID - 3 [pii] AID - 10.21614/chirurgia.3417 [doi] PST - aheadofprint SO - Chirurgia (Bucur). 2026 Sep 1;121(Ahead of print):1-7. doi: 10.21614/chirurgia.3417. PMID- 42799440 OWN - NLM STAT- MEDLINE DCOM- 20260926 LR - 20261001 IS - 2211-8179 (Electronic) IS - 2211-8160 (Print) IS - 2211-8160 (Linking) VI - 21 IP - 1 DP - 2026 TI - Menopause Hormone Therapy in Women With Cardiovascular Risk Factors or Established Ischemic Heart Disease: A Joint FIGO and WHF Position Paper. PG - 67 LID - 10.5334/gh.1576 [doi] LID - 67 AB - Extending women's health-span is a key challenge for the medical community. Although women live longer than men, they face a higher burden of chronic diseases, such as cardiovascular diseases (CVDs) and disabilities. Endogenous estrogens appear to benefit cardiovascular health, and their marked decline at menopause is associated with increased cardiovascular risk; conversely, poor cardiovascular health may hasten menopause onset. Systemic menopause hormone therapy (MHT) begun early-ideally soon after symptom onset and at most within 10 years of the final menstrual period-alleviates climacteric symptoms and is associated with long-term benefits. This joint position paper between the International Federation of Gynecology and Obstetrics (FIGO) and the World Heart Federation (WHF) aims at supporting both gynecologists and cardiologists in providing a tailored and evidence-based counseling on systemic MHT use to women with increased CVD risk or established ischemic heart disease (IHD). Women with CVD risk factors require thorough risk stratification to tailor MHT type, dose, and route. For those at high thromboembolic risk, transdermal estrogen, with micronized progesterone or dydrogesterone when needed, is considered the safest regimen. Women with established IHD may receive systemic MHT for symptom relief, provided risks and benefits are carefully reviewed. Transdermal low-dose estrogen, alone or with micronized progesterone or dydrogesterone, is the best choice. All primary and secondary prevention measures, including statins, should be continued. Managing the most complex cases warrants the adoption of a multidisciplinary approach between cardiologists, gynecologists, internists and primary care providers to offer the best possible care. CI - Copyright: (c) 2026 International Federation of Gynecology and Obstetrics and World Heart Federation. FAU - Benedetto, Chiara AU - Benedetto C AUID- ORCID: 0000-0003-1514-4771 AD - Department of Obstetrics and Gynecology, Sant'Anna University Hospital, Torino, Italy. AD - Department of Surgical Sciences, University of Torino, Torino, Italy. AD - FIGO Committee on Women at Menopausal Age, UK. FAU - Gulati, Martha AU - Gulati M AUID- ORCID: 0000-0003-0735-9756 AD - The Davis Women's Heart Center, Department of Cardiology, Houston Methodist Debakey Heart and Vascular Center, Houston, Texas, USA. FAU - Khadilkar, Suvarna S AU - Khadilkar SS AUID- ORCID: 0009-0005-6316-6352 AD - FIGO Committee on Women at Menopausal Age, UK. AD - Department of Obstetrics and Gynecology, Bombay Hospital, Mumbai, India. FAU - Maas, Angela H E M AU - Maas AHEM AUID- ORCID: 0000-0001-5782-9926 AD - Cardiology for Women, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Frezet, Federica AU - Frezet F AUID- ORCID: 0009-0002-6881-621X AD - Department of Obstetrics and Gynecology, Sant'Anna University Hospital, Torino, Italy. FAU - de Oliveira, Glaucia Maria Moraes AU - de Oliveira GMM AUID- ORCID: 0000-0002-0737-6188 AD - Department of Women's Cardiology of the Brazilian Society of Cardiology, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil. FAU - Genazzani, Andrea R AU - Genazzani AR AUID- ORCID: 0000-0003-4260-3929 AD - FIGO Committee on Women at Menopausal Age, UK. AD - Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. FAU - Divakar, Hema AU - Divakar H AUID- ORCID: 0000-0002-5418-9596 AD - Obstetrics and Gynecology, Divakars Speciality Hospital, Bengaluru, India. AD - FIGO Division on Well Woman Health Care, UK. FAU - Poppas, Athena AU - Poppas A AUID- ORCID: 0000-0001-9238-1784 AD - Division of Cardiology, Brown University Health Cardiovascular Institute, Providence, Rhode Island, USA. CN - International Federation of Gynecology and Obstetrics (FIGO) and World Heart Federation (WHF) LA - eng PT - Consensus Statement PT - Journal Article PT - Review DEP - 20260922 PL - England TA - Glob Heart JT - Global heart JID - 101584391 RN - 0 (Estrogens) SB - IM MH - Humans MH - Female MH - *Myocardial Ischemia/epidemiology/prevention & control/drug therapy MH - *Menopause MH - Heart Disease Risk Factors MH - *Estrogen Replacement Therapy/methods MH - *Cardiovascular Diseases/prevention & control/epidemiology MH - Women's Health MH - *Hormone Replacement Therapy/methods MH - Risk Factors MH - Risk Assessment MH - Estrogens PMC - PMC13614246 OTO - NOTNLM OT - CVD Sex-Specific Risk Factors OT - CVD Traditional Risk Factors OT - Cardiovascular Disease Risk OT - Coronary Heart Disease OT - Ischemic Heart Disease OT - MHT Benefits OT - MHT Risks OT - Menopause OT - Menopause Hormone Therapy COIS- Chiara Benedetto has acted in an advisory capacity for Gedeon Richter. Martha Gulati serves on a data monitoring committee for Merck on a lipid lowering agent. MG Serves on advisory boards/consulting for Amgen, Bayer, Boerhinger Ingelheim, Regeneron and Pfizer. Funding: She is supported by the Davis Endowment for women's cardiovascular health. Suvarna S. Khadilkar has no competing interests to declare. Angela H.E.M. Maas has no competing interests to declare. Federica Frezet has no competing interests to declare. Glaucia Maria Moraes de Oliveira has no competing interests to declare. Andrea R. Genazzani is immediate Past President of the International Society of Gynecological Endocrinology (ISGE) and European Society of Gynecology (ESG), President of the International Academy of Human Reproduction (IAHR), and Executive Director of ISGE. He has lectured and acted in an advisory capacity for Abbott, Astellas, Bayer, Besins, Bionorica, Elea, Gedeon Richter, Secure Pharma, Serelis, and Theramex. Hema Divakar has no competing interests to declare. Athena Poppas is a member of WHF board. EDAT- 2026/09/27 02:27 MHDA- 2026/09/27 02:28 PMCR- 2026/09/22 CRDT- 2026/09/26 07:31 PHST- 2026/07/15 00:00 [received] PHST- 2026/07/17 00:00 [accepted] PHST- 2026/09/27 02:28 [medline] PHST- 2026/09/27 02:27 [pubmed] PHST- 2026/09/26 07:31 [entrez] PHST- 2026/09/22 00:00 [pmc-release] AID - 10.5334/gh.1576 [doi] PST - epublish SO - Glob Heart. 2026 Sep 22;21(1):67. doi: 10.5334/gh.1576. eCollection 2026. PMID- 42799284 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260928 IS - 2572-9292 (Electronic) IS - 2572-9292 (Linking) VI - 10 IP - 5 DP - 2026 Oct TI - Rapid Treatment of Acute Decompensated Heart Failure with Cardiogenic Shock in the Emergency Setting. PG - 263-273 LID - 10.26502/fccm.92920505 [doi] AB - Acute decompensated heart failure accounts for more than a million United States hospitalizations each year, and its most severe expression, cardiogenic shock, carries an in-hospital mortality approaching fifty percent. Most randomized evidence in heart failure concerns the chronic outpatient population, which leaves the emergency department phase, during which a large share of the eventual trajectory is determined, supported by comparatively few dedicated trials. This review draws together what is currently known about the recognition and early stabilization of acute decompensated heart failure complicated by cardiogenic shock in the emergency setting. It describes the shock spiral, in which falling cardiac output lowers coronary perfusion pressure and further impairs contractility, together with the inflammatory component that explains why a subset of patients present with an inappropriately low systemic vascular resistance. It reviews bedside phenotyping along the axes of perfusion and congestion, severity staging with the SCAI SHOCK classification, and the diagnostic tools available at the bedside, including point-of-care ultrasound of the lungs, heart, and inferior vena cava, the electrocardiogram as a means of identifying the precipitating arrhythmia, and the laboratory markers of perfusion and end-organ stress. The management section argues that sequence is itself a therapeutic decision: perfusion pressure is restored first, contractility second, and congestion third, because each intervention is actively harmful when performed out of order. Non-invasive ventilation, rate and rhythm management, and correction of anemia are addressed as parallel contributors to oxygen delivery. The review closes with criteria for escalation to mechanical circulatory support and multidisciplinary shock team care, and states plainly the unequal quality of the evidence supporting each recommendation. FAU - Chaudhary, Fihr AU - Chaudhary F AD - Department of Translational Research, College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, California 91766 USA. FAU - Afzal, Sahil AU - Afzal S AD - University of California, Merced, CA 95343, USA. FAU - Chaudhary, Nasr AU - Chaudhary N AD - The San Joaquin Valley PRIME+ BS-MD Program, University of California, Merced, CA 95343, USA. FAU - Agrawal, Devendra K AU - Agrawal DK AD - Department of Translational Research, College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, California 91766 USA. LA - eng GR - R25 AI179582/AI/NIAID NIH HHS/United States PT - Journal Article DEP - 20260907 PL - United States TA - Cardiol Cardiovasc Med JT - Cardiology and cardiovascular medicine JID - 101721428 PMC - PMC13614691 MID - NIHMS2209182 OTO - NOTNLM OT - Acute decompensated heart failure OT - Cardiogenic shock OT - Emergency department OT - Hemodynamic phenotyping OT - Mechanical circulatory support OT - Non-invasive ventilation OT - Norepinephrine OT - Point-of-care ultrasound OT - SCAI SHOCK classification OT - Shock team COIS- Competing interests: All authors have read the manuscript and declare no relevant financial or non-financial interests. No writing assistance was utilized in the production of this manuscript. EDAT- 2026/09/27 02:27 MHDA- 2026/09/27 02:28 PMCR- 2026/09/27 CRDT- 2026/09/26 07:10 PHST- 2026/09/27 02:28 [medline] PHST- 2026/09/27 02:27 [pubmed] PHST- 2026/09/26 07:10 [entrez] PHST- 2026/09/27 00:00 [pmc-release] AID - 10.26502/fccm.92920505 [doi] PST - ppublish SO - Cardiol Cardiovasc Med. 2026 Oct;10(5):263-273. doi: 10.26502/fccm.92920505. Epub 2026 Sep 7. PMID- 42798208 OWN - NLM STAT- Publisher LR - 20260926 IS - 2327-6924 (Electronic) IS - 2327-6886 (Linking) DP - 2026 Sep 25 TI - Nurse practitioner impact across the cardiovascular care continuum: Insights from the American College of Cardiology Advanced Practice Nursing Workgroup. LID - 10.1097/JXX.0000000000001369 [doi] AB - Nurse Practitioners (NPs) are essential contributors to the contemporary cardiology workforce. The increasing prevalence of cardiovascular disease, coupled with persistent clinician shortages, has accelerated the integration of NPs across ambulatory and acute settings. This article explores the contributions of NPs to cardiology care across a continuum from longitudinal patient care and prevention to leadership and translational science. Investment in NP education, training, and role utilization will be pivotal to shaping an efficient, patient-centered cardiology workforce for the future. CI - Copyright (c) 2026 American Association of Nurse Practitioners. FAU - Dimsdale, Carolina R AU - Dimsdale CR AUID- ORCID: 0000-0001-7464-5010 AD - Duke University School of Nursing, Durham, North Carolina. FAU - Okwueze, Tochi AU - Okwueze T AD - Ascension Alexian Heart and Vascular Care Elk Grove, Elk Grove Village, Illinois. FAU - Alland, Michelle AU - Alland M AD - Mayo Clinic, Phoenix, Arizona. FAU - Slone, Sarah E AU - Slone SE AD - School of Nursing, University of South Carolina, Columbia, South Carolina. FAU - Bates, Katie AU - Bates K AD - Kittitas Valley Healthcare, Ellensburg, Washington. FAU - Enstrom, Cate AU - Enstrom C AD - HCA Tristar Centennial Medical Center, Nashville, Tennessee. FAU - Thornsberry, Joshua D AU - Thornsberry JD AD - Wellstar Center for Cardiovascular Care, Atlanta, Georgia. FAU - Bowers, Margaret AU - Bowers M AD - Duke University School of Nursing, Durham, North Carolina. LA - eng PT - Journal Article DEP - 20260925 PL - United States TA - J Am Assoc Nurse Pract JT - Journal of the American Association of Nurse Practitioners JID - 101600770 SB - IM OTO - NOTNLM OT - Advanced practice nursing OT - cardiology OT - nurse practitioner OT - prevention OT - team-based care EDAT- 2026/09/26 05:35 MHDA- 2026/09/26 05:35 CRDT- 2026/09/26 02:32 PHST- 2026/03/09 00:00 [received] PHST- 2026/08/18 00:00 [accepted] PHST- 2026/09/26 05:35 [medline] PHST- 2026/09/26 05:35 [pubmed] PHST- 2026/09/26 02:32 [entrez] AID - 01741002-990000000-00463 [pii] AID - 10.1097/JXX.0000000000001369 [doi] PST - aheadofprint SO - J Am Assoc Nurse Pract. 2026 Sep 25. doi: 10.1097/JXX.0000000000001369. PMID- 42795933 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260926 LR - 20260929 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 15 IP - 18 DP - 2026 Sep 15 TI - Temporary Mechanical Circulatory Support in Patients in Cardiogenic Shock Requiring Cardiac Surgery: Protected Cardiac Surgery Concept. LID - 10.3390/jcm15187158 [doi] LID - 7158 AB - Temporary mechanical circulatory support (tMCS) has evolved as a first-line treatment of cardiogenic shock refractory to medical therapy. In recent years, tMCS has been applied to bridge and precondition end-stage heart failure patients with structural heart disease for surgery or intervention. This review describes three clinical scenarios: preoperative stabilization and bridge-to-surgery (Type 1), planned intraoperative support in patients at high risk of perioperative low cardiac output (Type 2), and rescue support for failure to wean from cardiopulmonary bypass or postoperative heart failure (Type 3). PubMed/MEDLINE was searched for publications from January 2017 onward. It discusses microaxial flow pumps (mAFP), intra-aortic balloon pumps (IABP), veno-arterial extracorporeal life support (VA-ECLS), and combined strategies, including left ventricular unloading during VA-ECLS. Clinical applications include acute myocardial infarction-related cardiogenic shock, acute mitral regurgitation, post-infarction ventricular septal defect and advanced heart failure therapy. Current European and American recommendations support early, individualized and Heart Team-guided use in selected patients. In this review, we aim to summarize the important aspects of protected tMCS implementation in cardiac surgery and highlight some recent evidence in this field. FAU - Nagel, Anika AU - Nagel A AUID- ORCID: 0009-0001-0458-6841 AD - Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charite, Augustenburger Platz 1, 13353 Berlin, Germany. AD - Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Chariteplatz 1, 10117 Berlin, Germany. FAU - Geiger, Dominik AU - Geiger D AD - Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charite, Augustenburger Platz 1, 13353 Berlin, Germany. AD - Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Chariteplatz 1, 10117 Berlin, Germany. FAU - Nersesian, Gaik AU - Nersesian G AUID- ORCID: 0000-0002-9524-7705 AD - Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charite, Augustenburger Platz 1, 13353 Berlin, Germany. AD - Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Chariteplatz 1, 10117 Berlin, Germany. AD - DZHK (German Center for Cardiovascular Research), Partner Site Berlin, 10785 Berlin, Germany. FAU - Lewin, Daniel AU - Lewin D AUID- ORCID: 0000-0001-9831-6289 AD - Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charite, Augustenburger Platz 1, 13353 Berlin, Germany. AD - Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Chariteplatz 1, 10117 Berlin, Germany. FAU - Hrytsyna, Yuriy AU - Hrytsyna Y AD - Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charite, Augustenburger Platz 1, 13353 Berlin, Germany. AD - Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Chariteplatz 1, 10117 Berlin, Germany. AD - DZHK (German Center for Cardiovascular Research), Partner Site Berlin, 10785 Berlin, Germany. FAU - Stegmann, Anna AU - Stegmann A AUID- ORCID: 0000-0003-0115-9315 AD - Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charite, Augustenburger Platz 1, 13353 Berlin, Germany. AD - Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Chariteplatz 1, 10117 Berlin, Germany. AD - DZHK (German Center for Cardiovascular Research), Partner Site Berlin, 10785 Berlin, Germany. FAU - Pitts, Leonard AU - Pitts L AUID- ORCID: 0009-0006-0339-5791 AD - Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charite, Augustenburger Platz 1, 13353 Berlin, Germany. AD - Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Chariteplatz 1, 10117 Berlin, Germany. AD - DZHK (German Center for Cardiovascular Research), Partner Site Berlin, 10785 Berlin, Germany. FAU - Kaemmel, Julius AU - Kaemmel J AUID- ORCID: 0000-0002-5640-0543 AD - Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charite, Augustenburger Platz 1, 13353 Berlin, Germany. AD - Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Chariteplatz 1, 10117 Berlin, Germany. AD - DZHK (German Center for Cardiovascular Research), Partner Site Berlin, 10785 Berlin, Germany. FAU - Lanmueller, Pia AU - Lanmueller P AD - Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charite, Augustenburger Platz 1, 13353 Berlin, Germany. AD - Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Chariteplatz 1, 10117 Berlin, Germany. AD - DZHK (German Center for Cardiovascular Research), Partner Site Berlin, 10785 Berlin, Germany. FAU - Falk, Volkmar AU - Falk V AUID- ORCID: 0000-0002-7911-8620 AD - Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charite, Augustenburger Platz 1, 13353 Berlin, Germany. AD - Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Chariteplatz 1, 10117 Berlin, Germany. AD - DZHK (German Center for Cardiovascular Research), Partner Site Berlin, 10785 Berlin, Germany. FAU - Potapov, Evgenij AU - Potapov E AUID- ORCID: 0000-0002-9720-3175 AD - Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charite, Augustenburger Platz 1, 13353 Berlin, Germany. AD - Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Chariteplatz 1, 10117 Berlin, Germany. AD - DZHK (German Center for Cardiovascular Research), Partner Site Berlin, 10785 Berlin, Germany. LA - eng PT - Journal Article PT - Review DEP - 20260915 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC13607504 OTO - NOTNLM OT - ECLS OT - cardiogenic shock OT - microaxial flow pump OT - protected cardiac surgery OT - temporary mechanical circulatory support COIS- V.F. reports financial relationships outside the submitted work with Medtronic, Biotronik, Abbott, Boston Scientific, Edwards Lifesciences, Berlin Heart, Novartis, JOTEC, and Zurich Heart (educational grants, travel, lectures, consultancy, research funds). E.P. received payments for proctoring, consulting, speaking, and institutional grants from Abbott, Abiomed, Medtronic, Recovery Therapeutics, and Cor Medical outside of the submitted work. P.L. received study/educational grants and speaker fees from Abiomed outside the submitted work. A.N., D.G., G.N., D.L., Y.H., A.S., L.P. and J.K. declare no conflicts of interest. EDAT- 2026/09/26 05:35 MHDA- 2026/09/26 05:36 PMCR- 2026/09/15 CRDT- 2026/09/26 01:11 PHST- 2026/07/20 00:00 [received] PHST- 2026/09/07 00:00 [revised] PHST- 2026/09/09 00:00 [accepted] PHST- 2026/09/26 05:36 [medline] PHST- 2026/09/26 05:35 [pubmed] PHST- 2026/09/26 01:11 [entrez] PHST- 2026/09/15 00:00 [pmc-release] AID - jcm15187158 [pii] AID - jcm-15-07158 [pii] AID - 10.3390/jcm15187158 [doi] PST - epublish SO - J Clin Med. 2026 Sep 15;15(18):7158. doi: 10.3390/jcm15187158. PMID- 42793759 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260926 LR - 20260929 IS - 2075-4418 (Print) IS - 2075-4418 (Electronic) IS - 2075-4418 (Linking) VI - 16 IP - 18 DP - 2026 Sep 14 TI - Fatal Choking in Patients with Psychiatric Disorders: A Systematic Review of Forensic Evidence. LID - 10.3390/diagnostics16182974 [doi] LID - 2974 AB - Background: Fatal choking is a preventable cause of mechanical asphyxia that occurs more frequently among individuals with psychiatric disorders due to behavioural abnormalities, neurological comorbidities, and medication-related swallowing impairment. This review aims to highlight the clinical and forensic factors contributing to fatal choking and the importance of a multidisciplinary approach to its investigation. Methods: A systematic review was conducted according to PRISMA guidelines by searching PubMed, Scopus, and Web of Science. In total, 25 studies describing fatal choking in adults with psychiatric disorders and including medico-legal investigations were selected and analyzed. Results: Schizophrenia was the most frequently reported psychiatric condition, followed by bipolar disorder, depression, and dementia. Antipsychotics, antidepressants, anxiolytics, and other psychotropic drugs were recurrently associated with dysphagia and reduced airway protective reflexes. Food boluses represented the predominant obstructive material, although several unusual foreign bodies were documented. Virtopsy, autopsy, histological, and toxicological investigations consistently proved essential for confirming airway obstruction, reconstructing the mechanism of death, and identifying contributing clinical and pharmacological factors. Conclusions: Fatal choking in psychiatric patients is a multifactorial event requiring early risk assessment, preventive strategies, and comprehensive forensic evaluation to improve patient safety and ensure accurate determination of the cause of death. FAU - Candela, Lucia AU - Candela L AD - Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Via Consolare Valeria, 1, 98125 Messina, Italy. FAU - Rigano, Giorgia AU - Rigano G AUID- ORCID: 0009-0005-7510-3367 AD - Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Via Consolare Valeria, 1, 98125 Messina, Italy. FAU - Spatola, Salvatore Ruben AU - Spatola SR AD - Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Via Consolare Valeria, 1, 98125 Messina, Italy. FAU - Caplinskiene, Marija AU - Caplinskiene M AUID- ORCID: 0000-0002-5432-0224 AD - State Forensic Science, Mykolas Romeris University, 08303 Vilnius, Lithuania. FAU - Ventura Spagnolo, Elvira AU - Ventura Spagnolo E AD - Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Via Consolare Valeria, 1, 98125 Messina, Italy. FAU - Baldino, Gennaro AU - Baldino G AUID- ORCID: 0000-0002-7973-9259 AD - Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Via Consolare Valeria, 1, 98125 Messina, Italy. LA - eng PT - Journal Article PT - Review DEP - 20260914 PL - Switzerland TA - Diagnostics (Basel) JT - Diagnostics (Basel, Switzerland) JID - 101658402 PMC - PMC13605668 OTO - NOTNLM OT - cafe coronary OT - choking OT - drugs OT - forensic pathology OT - psychiatric disorders COIS- The authors declare no conflicts of interest. EDAT- 2026/09/26 05:35 MHDA- 2026/09/26 05:36 PMCR- 2026/09/14 CRDT- 2026/09/26 01:05 PHST- 2026/08/13 00:00 [received] PHST- 2026/09/03 00:00 [revised] PHST- 2026/09/05 00:00 [accepted] PHST- 2026/09/26 05:36 [medline] PHST- 2026/09/26 05:35 [pubmed] PHST- 2026/09/26 01:05 [entrez] PHST- 2026/09/14 00:00 [pmc-release] AID - diagnostics16182974 [pii] AID - diagnostics-16-02974 [pii] AID - 10.3390/diagnostics16182974 [doi] PST - epublish SO - Diagnostics (Basel). 2026 Sep 14;16(18):2974. doi: 10.3390/diagnostics16182974. PMID- 42792031 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260926 LR - 20260929 IS - 2079-6382 (Print) IS - 2079-6382 (Electronic) IS - 2079-6382 (Linking) VI - 15 IP - 9 DP - 2026 Sep 9 TI - Optimizing Treatment of Infective Endocarditis in Patients Who Inject Drugs. LID - 10.3390/antibiotics15090881 [doi] LID - 881 AB - The treatment of infective endocarditis (IE) in patients who inject drugs (PWID) is complex and challenging. These patients face stigma in the healthcare system, as well as higher mortality, longer length of hospital stay, higher rates of recurrent infections, and lower likelihood of antibiotic completion. Standard treatment for IE involves several weeks of antibiotics. For PWID, these prolonged courses often mean intravenous antibiotics administered in the inpatient setting for at least 4 to 6 weeks, which increases both healthcare costs and the risk of patient-directed discharge against medical advice. Effective treatment of IE in PWID involves a combination of addiction management and appropriate antibiotic therapy. To promote rational use of healthcare resources and optimize antibiotic stewardship, novel approaches to antibiotic therapy must be utilized. This review discusses evidence supporting treatment strategies outside of the inpatient hospital setting, including outpatient parenteral antibiotic therapy (OPAT), long-acting lipoglycopeptides, and oral antibiotic therapy for the treatment of endocarditis. Optimal treatment of IE in PWID involves support from a multidisciplinary healthcare team, management of substance use disorder, and effective antibiotic therapy. FAU - Worden, Jarett AU - Worden J AUID- ORCID: 0009-0006-5205-693X AD - College of Pharmacy & Health Sciences, Belmont University, Nashville, TN 37212, USA. FAU - Baumeister, Tyler AU - Baumeister T AD - Pharmacy, Williamson Medical Center, Franklin, TN 37067, USA. FAU - Eaton, Ellen AU - Eaton E AD - Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, Birmingham, AL 35233, USA. LA - eng PT - Journal Article PT - Review DEP - 20260909 PL - Switzerland TA - Antibiotics (Basel) JT - Antibiotics (Basel, Switzerland) JID - 101637404 PMC - PMC13603579 OTO - NOTNLM OT - OPAT OT - PWID OT - Staphylococcus aureus OT - endocarditis OT - intravenous drug use OT - long-acting lipoglycopeptides OT - oral antibiotics OT - outpatient parenteral antibiotic therapy OT - persons who inject drugs OT - substance use disorder COIS- The authors declare no conflicts of interest. EDAT- 2026/09/26 05:34 MHDA- 2026/09/26 05:35 PMCR- 2026/09/09 CRDT- 2026/09/26 01:01 PHST- 2026/08/11 00:00 [received] PHST- 2026/09/04 00:00 [revised] PHST- 2026/09/06 00:00 [accepted] PHST- 2026/09/26 05:35 [medline] PHST- 2026/09/26 05:34 [pubmed] PHST- 2026/09/26 01:01 [entrez] PHST- 2026/09/09 00:00 [pmc-release] AID - antibiotics15090881 [pii] AID - antibiotics-15-00881 [pii] AID - 10.3390/antibiotics15090881 [doi] PST - epublish SO - Antibiotics (Basel). 2026 Sep 9;15(9):881. doi: 10.3390/antibiotics15090881. PMID- 42791829 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260926 LR - 20260929 IS - 2306-5354 (Print) IS - 2306-5354 (Electronic) IS - 2306-5354 (Linking) VI - 13 IP - 9 DP - 2026 Aug 22 TI - Myval Beyond the Aortic Valve: Device-Anatomy Interaction, Procedural Strategy, and Clinical Evidence in Mitral, Tricuspid, and Pulmonary Positions. LID - 10.3390/bioengineering13090957 [doi] LID - 957 AB - The Myval balloon-expandable transcatheter heart valve was developed for transcatheter aortic valve implantation, but its broad 20-32 mm size matrix and controlled deployment have prompted use in non-aortic landing zones. This narrative review critically synthesizes Myval-specific case reports, case series, and observational cohorts, together with relevant platform-level evidence, addressing device design, anatomical selection, imaging, procedural strategy, clinical outcomes, and evidence gaps. Reported applications include mitral valve-in-valve, valve-in-ring, and valve-in-mitral annular calcification; tricuspid valve-in-valve and valve-in-ring; and pulmonary implantation in conduits, surgical bioprostheses, and selected native or patched right ventricular outflow tracts. Outcomes appear most predictable within circular stented surgical bioprostheses, whereas non-circular rings, severe mitral annular calcification, and compliant or aneurysmal outflow tracts present greater risks of inadequate anchoring, paravalvular regurgitation, embolization, frame deformation, left ventricular outflow tract obstruction, and coronary compression. Intermediate and extra-large diameters increase the available nominal sizing options; however, no clinical evidence demonstrates that this reduces embolization, paravalvular regurgitation, residual gradients, or reintervention. The available data document procedural feasibility in anatomically selected patients but are predominantly observational, with limited independent adjudication and follow-up. These procedures are generally off-label and should remain individualized Heart Team decisions; prospective multicenter studies are required to define comparative safety, antithrombotic management, durability, and lifetime reintervention strategies. FAU - Papadopoulos, Georgios E AU - Papadopoulos GE AUID- ORCID: 0000-0002-7155-9907 AD - 2nd Cardiology Department, Interbalkan Medical Center, 57001 Thessaloniki, Greece. FAU - Ninios, Ilias AU - Ninios I AUID- ORCID: 0000-0002-4444-3781 AD - 2nd Cardiology Department, Interbalkan Medical Center, 57001 Thessaloniki, Greece. FAU - Evangelou, Sotirios AU - Evangelou S AUID- ORCID: 0000-0002-3080-5729 AD - 2nd Cardiology Department, Interbalkan Medical Center, 57001 Thessaloniki, Greece. FAU - Marvaki, Apostolia AU - Marvaki A AD - 2nd Cardiology Department, Interbalkan Medical Center, 57001 Thessaloniki, Greece. FAU - Kalaitzoglou, Maria AU - Kalaitzoglou M AUID- ORCID: 0009-0007-5600-7454 AD - 2nd Cardiology Department, Interbalkan Medical Center, 57001 Thessaloniki, Greece. FAU - Ioannides, Andreas AU - Ioannides A AD - 2nd Cardiology Department, Interbalkan Medical Center, 57001 Thessaloniki, Greece. FAU - Giamouzis, Grigorios AU - Giamouzis G AUID- ORCID: 0000-0002-7406-5427 AD - School of Medicine, University of Thessaly, 41110 Larissa, Greece. FAU - Ninios, Vlasis AU - Ninios V AUID- ORCID: 0000-0002-0390-7172 AD - 2nd Cardiology Department, Interbalkan Medical Center, 57001 Thessaloniki, Greece. LA - eng PT - Journal Article PT - Review DEP - 20260822 PL - Switzerland TA - Bioengineering (Basel) JT - Bioengineering (Basel, Switzerland) JID - 101676056 PMC - PMC13603376 OTO - NOTNLM OT - Myval OT - balloon-expandable transcatheter heart valve OT - mitral valve-in-ring OT - mitral valve-in-valve OT - right ventricular outflow tract OT - transcatheter pulmonary valve implantation OT - tricuspid valve-in-valve OT - valve-in-mitral annular calcification COIS- The authors declare no conflicts of interest. EDAT- 2026/09/26 05:35 MHDA- 2026/09/26 05:36 PMCR- 2026/08/22 CRDT- 2026/09/26 01:00 PHST- 2026/07/26 00:00 [received] PHST- 2026/08/13 00:00 [revised] PHST- 2026/08/17 00:00 [accepted] PHST- 2026/09/26 05:36 [medline] PHST- 2026/09/26 05:35 [pubmed] PHST- 2026/09/26 01:00 [entrez] PHST- 2026/08/22 00:00 [pmc-release] AID - bioengineering13090957 [pii] AID - bioengineering-13-00957 [pii] AID - 10.3390/bioengineering13090957 [doi] PST - epublish SO - Bioengineering (Basel). 2026 Aug 22;13(9):957. doi: 10.3390/bioengineering13090957. PMID- 42788838 OWN - NLM STAT- Publisher LR - 20261009 IS - 1545-0066 (Electronic) IS - 1090-3127 (Linking) DP - 2026 Oct 9 TI - A Robust Educational Initiative for EMS Clinicians Focusing on Pit-Crew CPR Improves Neurologically Intact Survival. PG - 1-7 LID - 10.1080/10903127.2026.2739421 [doi] AB - OBJECTIVES: To evaluate whether the implementation of a region-wide pit-crew cardiopulmonary resuscitation (CPR) initiative was associated with improved survival to hospital discharge with good neurological function among adults with non-traumatic out-of-hospital cardiac arrest (OHCA) in a heterogenous, multi-agency emergency medical services (EMS) system in south-central Connecticut. METHODS: We conducted a retrospective, before-and-after observational study using the Cardiac Arrest Registry to Enhance Survival (CARES). The pit-crew CPR intervention, comprising structured didactic and hands-on simulation-based training was delivered across 27 EMS agencies from September 28, 2021 through August 2, 2022. The primary outcome was survival to hospital discharge with good neurological function (Cerebral Performance Category 1-2). Secondary outcomes included survival to hospital discharge and sustained return of spontaneous circulation (ROSC). We performed an interrupted time series analysis using the beginning of our intervention (September 28, 2021) as the interruption to model. Multivariable logistic regression models were adjusted for age, sex, race, shockable initial rhythm, witnessed arrest, arrest location, and bystander CPR. RESULTS: A total of 1917 adult non-traumatic OHCA patients (922 pre-intervention; 995 post-intervention) were resuscitated by EMS clinicians in the study period. In progression since intervention, there was a significant increase in neurologically intact survival per 4-month interval (adjusted odds ratio [OR] 1.20; 95% confidence interval [CI], 1.01-1.44), suggesting a gradual improvement in outcomes over time after protocol implementation. At intervention start, there was a significant increase in ROSC (aOR 1.41; 95% CI, 1.1-1.81). There was no change in survival to hospital discharge prior to the intervention, at the time of the intervention, or following the intervention. CONCLUSIONS: Implementation of a pit-crew CPR model across a heterogenous, multi-agency EMS system was associated with a significant gradual increase in neurologically intact survival in the post-intervention period, as well as a significant immediate improvement in ROSC at the time of protocol implementation. These findings support structured, team-based resuscitation as a feasible and effective strategy to improve cardiac arrest outcomes within existing EMS systems. FAU - Yang, David H AU - Yang DH AUID- ORCID: 0000-0002-1252-9820 AD - Department of Emergency Medicine, Yale University School of Medicine, New Haven, Connecticut. AD - Yale University School of Medicine, New Haven, Connecticut. FAU - Yen, Yi-Hsuan AU - Yen YH AD - Department of Emergency Medicine, Yale University School of Medicine, New Haven, Connecticut. AD - Yale University School of Medicine, New Haven, Connecticut. FAU - Logan, Ross AU - Logan R AD - Department of Emergency Medicine, Yale University School of Medicine, New Haven, Connecticut. AD - Yale University School of Medicine, New Haven, Connecticut. FAU - DeAngelis, Joseph AU - DeAngelis J AD - Center for Emergency Medical Services, Yale New Haven Hospital, New Haven, Connecticut. FAU - Lardaro, Thomas AU - Lardaro T AUID- ORCID: 0000-0002-4668-3842 AD - Department of Emergency Medicine, Yale University School of Medicine, New Haven, Connecticut. AD - Yale University School of Medicine, New Haven, Connecticut. FAU - Couturier, Katherine AU - Couturier K AUID- ORCID: 0000-0001-9744-3956 AD - Department of Emergency Medicine, Yale University School of Medicine, New Haven, Connecticut. AD - Yale University School of Medicine, New Haven, Connecticut. FAU - Joseph, Daniel AU - Joseph D AD - Department of Emergency Medicine, University of British Columbia, Vancouver, BC, Canada. FAU - Perman, Sarah AU - Perman S AUID- ORCID: 0000-0002-0849-0847 AD - Department of Emergency Medicine, Yale University School of Medicine, New Haven, Connecticut. AD - Yale University School of Medicine, New Haven, Connecticut. FAU - Nelson, Alexander R AU - Nelson AR AD - Department of Emergency Medicine, Yale University School of Medicine, New Haven, Connecticut. AD - Yale University School of Medicine, New Haven, Connecticut. LA - eng PT - Journal Article DEP - 20261009 PL - England TA - Prehosp Emerg Care JT - Prehospital emergency care JID - 9703530 SB - IM EDAT- 2026/09/25 11:45 MHDA- 2026/09/25 11:45 CRDT- 2026/09/25 10:48 PHST- 2026/09/25 11:45 [pubmed] PHST- 2026/09/25 11:45 [medline] PHST- 2026/09/25 10:48 [entrez] AID - 10.1080/10903127.2026.2739421 [doi] PST - aheadofprint SO - Prehosp Emerg Care. 2026 Oct 9:1-7. doi: 10.1080/10903127.2026.2739421. PMID- 42788628 OWN - NLM STAT- MEDLINE DCOM- 20260925 LR - 20261027 IS - 1099-0496 (Electronic) IS - 8755-6863 (Print) IS - 1099-0496 (Linking) VI - 61 IP - 10 DP - 2026 Oct TI - A Multidisciplinary Approach to the Anesthetic Management of Patients With Duchenne Muscular Dystrophy. PG - e71833 LID - e71833 [pii] LID - 10.1002/ppul.71833 [doi] AB - Duchenne muscular dystrophy (DMD) is an inherited neuromuscular disorder with multisystem involvement that causes progressive muscular weakness and cardiorespiratory dysfunction. The first comprehensive recommendations regarding anesthetic management are now almost 20 years old and, in the interval, DMD care has evolved. Patients with DMD are experiencing prolongation of survival and, with widespread use of assisted ventilation, cardiac function has become the main determinant of their survival. Newer procedures, such as advanced cardiac interventions, are now performed, in a population of older, medically fragile individuals. Regional anesthetic techniques have advanced, allowing more patients to avoid the risks of inhalational anesthesia, and newer techniques for reversing neuromuscular blockade and minimizing cardiorespiratory depression have become available. Additionally, new medications are being used that have anesthetic implications, including newer guideline-directed heart failure medications. Overall, it has become increasingly important for perioperative management to be addressed in a multidisciplinary way, with coordination between medical, surgical, and anesthetic clinicians. In this narrative review, we provide information on how DMD's multi-system involvement impacts perioperative assessment and management, and we advocate for a multidisciplinary approach to perioperative care. CI - (c) 2026 The Author(s). Pediatric Pulmonology published by Wiley Periodicals LLC. FAU - Racca, Fabrizio AU - Racca F AD - Division of Anesthesia and Intensive Care, AO Ordine Mauriziano, Torino, Italy. FAU - Conti, Elena AU - Conti E AD - Division of Anesthesia and Intensive Care, AO Ordine Mauriziano, Torino, Italy. FAU - Racca, Giulia AU - Racca G AUID- ORCID: 0000-0002-4870-0116 AD - Department of Surgical Sciences, University of Turin, Torino, Italy. FAU - Barberis, Luigi AU - Barberis L AD - Division of Anesthesia and Intensive Care, AO Ordine Mauriziano, Torino, Italy. FAU - Birnkrant, David J AU - Birnkrant DJ AUID- ORCID: 0000-0001-6327-5616 AD - Department of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA. LA - eng PT - Journal Article PT - Review PL - United States TA - Pediatr Pulmonol JT - Pediatric pulmonology JID - 8510590 SB - IM MH - Humans MH - *Muscular Dystrophy, Duchenne/complications/physiopathology/surgery MH - *Perioperative Care/methods MH - *Anesthesia/methods MH - Patient Care Team MH - Pediatric Anesthesia PMC - PMC13614003 OTO - NOTNLM OT - Duchenne muscular dystrophy OT - adrenal insufficiency OT - anesthesia OT - cardiomyopathy OT - hypoventilation OT - neuromuscular blocking agents OT - noninvasive ventilation OT - respiratory insufficiency OT - rhabdomyolysis OT - volatile anesthetic agents COIS- Dr. Birnkrant has a financial interest in patents he developed for respiratory devices. These patents are not currently licensed to a commercial entity. EDAT- 2026/09/25 11:45 MHDA- 2026/09/25 11:46 PMCR- 2026/09/25 CRDT- 2026/09/25 10:38 PHST- 2026/08/13 00:00 [revised] PHST- 2026/03/27 00:00 [received] PHST- 2026/09/07 00:00 [accepted] PHST- 2026/09/25 11:46 [medline] PHST- 2026/09/25 11:45 [pubmed] PHST- 2026/09/25 10:38 [entrez] PHST- 2026/09/25 00:00 [pmc-release] AID - e71833 [pii] AID - PPUL71833 [pii] AID - 10.1002/ppul.71833 [doi] PST - ppublish SO - Pediatr Pulmonol. 2026 Oct;61(10):e71833. doi: 10.1002/ppul.71833. PMID- 42788373 OWN - NLM STAT- Publisher LR - 20260925 IS - 1531-7013 (Electronic) IS - 1087-2418 (Linking) DP - 2026 Sep 28 TI - Management of patients with cardiopulmonary comorbidities awaiting liver transplantation. LID - 10.1097/MOT.0000000000001312 [doi] AB - PURPOSE OF REVIEW: The need for liver transplant continues to rise especially among those with metabolic dysfunction associated steatotic liver disease. Consequently, more transplant candidates have concurrent cardiopulmonary comorbidities. This review summarizes contemporary developments in cardiopulmonary care in liver transplant candidates. RECENT FINDINGS: Recent guidelines recommend noninvasive anatomic cardiovascular assessment before invasive coronary angiography for evaluation of coronary artery disease. Post-PCI DAPT can be used for as short as 1 month before waitlist activation. Practice-based guidance recommends echocardiographic surveillance on the waitlist especially with the evolving data on the impact of Cirrhotic Cardiomyopathy. Emerging evidence suggests that guideline directed medical therapy for heart disease is safe in patients with advanced liver disease. Updated portopulmonary hypertension guidelines emphasize revised screening and diagnostic thresholds, early initiation of medical therapy, and timely liver transplant evaluation. SUMMARY: Management of cardiopulmonary comorbidities in liver transplant candidates continues to advance yet remains nuanced requiring a multidisciplinary approach for optimal care. CI - Copyright (c) 2026 The Author(s). Published by Wolters Kluwer Health, LLC. FAU - Liu, Alex AU - Liu A AD - Vanderbilt University Medical Center, Department of Medicine, Division of Gastroenterology, Hepatology, and Nutrition, Nashville, Tennessee, USA. FAU - Izzy, Manhal AU - Izzy M LA - eng PT - Journal Article DEP - 20260928 PL - United States TA - Curr Opin Organ Transplant JT - Current opinion in organ transplantation JID - 9717388 SB - IM OTO - NOTNLM OT - cardiopulmonary disease OT - liver cirrhosis OT - perioperative management EDAT- 2026/09/25 11:45 MHDA- 2026/09/25 11:45 CRDT- 2026/09/25 10:24 PHST- 2026/09/25 11:45 [medline] PHST- 2026/09/25 11:45 [pubmed] PHST- 2026/09/25 10:24 [entrez] AID - 00075200-990000000-00245 [pii] AID - 10.1097/MOT.0000000000001312 [doi] PST - aheadofprint SO - Curr Opin Organ Transplant. 2026 Sep 28. doi: 10.1097/MOT.0000000000001312. PMID- 42786661 OWN - NLM STAT- MEDLINE DCOM- 20261008 LR - 20261008 IS - 2047-9980 (Electronic) IS - 2047-9980 (Linking) VI - 15 IP - 19 DP - 2026 Oct 6 TI - Scope of Practice Laws Affecting Team-Based Heart Disease Care in Rural America: Policy Challenges and Opportunities. PG - e049493 LID - 10.1161/JAHA.126.049493 [doi] AB - BACKGROUND: Heart disease is the leading cause of death in the United States with a disproportionate impact in rural America, and health worker shortages contribute to these disparities. Team-based heart disease care models can help mitigate health worker shortages, but lack of role clarity and restrictive scope of practice laws can be a barrier to their implementation. METHODS: To better understand the intersection of licensed scope of practice laws with rural heart disease care, we performed a legal epidemiology analysis to identify and describe licensed scope of practice laws for 9 health worker cadres in 13 state and federal jurisdictions for 8 heart disease services. RESULTS: We found substantial ambiguity, variation, and some important gaps, which may undermine the predictability of regulatory and reimbursement environments and hinder implementation of innovative team-based care models. CONCLUSIONS: Three policy opportunities to address the identified gaps include: (1) linking licensed scope of practice definitions to the scope of accredited training curricula, (2) shifting away from collaborative practice agreements to define licensed scope of practice, and (3) prohibiting insurance plans from conditioning reimbursement based solely on provider cadre. FAU - Lane, Jeff AU - Lane J AUID- ORCID: 0000-0001-7001-1010 AD - Department of Global Health University of Washington Seattle WA USA. FAU - Burchim, Signe AU - Burchim S AUID- ORCID: 0009-0004-4803-0847 AD - Department of Global Health University of Washington Seattle WA USA. FAU - Li, Amanda AU - Li A AUID- ORCID: 0009-0004-8005-1672 AD - Department of Global Health University of Washington Seattle WA USA. FAU - Graves, Janessa M AU - Graves JM AUID- ORCID: 0000-0002-7659-2634 AD - Department of Family Medicine University of Washington Seattle WA USA. FAU - Longenecker, Chris AU - Longenecker C AUID- ORCID: 0000-0002-9468-0179 AD - Department of Global Health University of Washington Seattle WA USA. FAU - Masyuko, Sarah AU - Masyuko S AUID- ORCID: 0000-0002-9836-4616 AD - Department of Global Health University of Washington Seattle WA USA. FAU - Bacci, Jennifer AU - Bacci J AUID- ORCID: 0000-0001-9944-6050 AD - School of Pharmacy, University of Washington Seattle WA USA. FAU - Gimbel, Sarah AU - Gimbel S AUID- ORCID: 0000-0003-3330-1208 AD - School of Nursing, University of Washington Seattle WA USA. FAU - Webel, Allison AU - Webel A AD - School of Nursing, University of Washington Seattle WA USA. FAU - Hammersla, Margaret AU - Hammersla M AUID- ORCID: 0000-0002-5665-0438 AD - Mark & Robyn Jones College of Nursing, Montana State University Bozeman MT USA. FAU - Leonard, Cassandra AU - Leonard C AUID- ORCID: 0000-0002-0584-5585 AD - Idaho Office of Underserved and Rural Medical Research, Idaho WWAMI Medical Education Program University of Idaho Moscow ID USA. FAU - Shalen, Evan Foster AU - Shalen EF AUID- ORCID: 0000-0002-1164-873X AD - Division of Cardiovascular Medicine Knight Cardiovascular Institute, Oregon Health and Science University Portland OR USA. FAU - O'Connell, Bridget AU - O'Connell B AUID- ORCID: 0009-0008-9407-249X AD - Palo Alto Veterans Institute for Research (PAVIR) Palo Alto CA USA. FAU - Thoroughman, Rose AU - Thoroughman R AUID- ORCID: 0009-0003-9409-7236 AD - Heart Institute, Cincinnati Children's Hospital Medical Center Cincinnati OH USA. FAU - Ornato, Joseph P AU - Ornato JP AUID- ORCID: 0000-0002-0333-4853 AD - Department of Emergency Medicine Virginia Commonwealth University Richmond VA USA. FAU - Frogner, Bianca K AU - Frogner BK AUID- ORCID: 0000-0002-5120-1828 AD - Department of Family Medicine University of Washington Seattle WA USA. LA - eng PT - Journal Article DEP - 20260924 PL - England TA - J Am Heart Assoc JT - Journal of the American Heart Association JID - 101580524 SB - IM MH - Humans MH - United States MH - *Rural Health Services/legislation & jurisprudence/organization & administration MH - *Heart Diseases/therapy/epidemiology/diagnosis MH - *Patient Care Team/legislation & jurisprudence MH - *Scope of Practice/legislation & jurisprudence MH - *Health Policy/legislation & jurisprudence OTO - NOTNLM OT - cardiovascular disease OT - health policy OT - rural health OT - scope of practice OT - team-based care EDAT- 2026/09/25 05:31 MHDA- 2026/10/08 05:31 CRDT- 2026/09/25 00:56 PHST- 2026/10/08 05:31 [medline] PHST- 2026/09/25 05:31 [pubmed] PHST- 2026/09/25 00:56 [entrez] AID - 10.1161/JAHA.126.049493 [doi] PST - ppublish SO - J Am Heart Assoc. 2026 Oct 6;15(19):e049493. doi: 10.1161/JAHA.126.049493. Epub 2026 Sep 24. PMID- 42783459 OWN - NLM STAT- MEDLINE DCOM- 20260924 LR - 20260928 IS - 2076-3271 (Electronic) IS - 2076-3271 (Linking) VI - 14 IP - 5 DP - 2026 Sep 18 TI - Artificial Intelligence and the Ethical Foundations of Cardiothoracic Surgery: Evidence, Accountability, and the Limits of Delegated Judgment. LID - 10.3390/medsci14050586 [doi] LID - 586 AB - Artificial intelligence (AI) is moving rapidly from retrospective prediction and image analysis into treatment selection, operative planning, intraoperative guidance, and postoperative prognostication in cardiothoracic surgery. This transition raises an ethical problem that cannot be resolved by model accuracy alone: when an algorithm begins to shape a high-stakes clinical decision, the distribution of knowledge, authority, and responsibility also changes. This review synthesizes cardiothoracic and closely related medical evidence available through August 2026, with emphasis on quantitative performance, human-AI interaction, bias, patient autonomy, and liability. The available evidence is simultaneously encouraging and cautionary. Machine-learning approaches can improve predictive performance and AI-assisted thoracic planning can reduce errors and increase procedural consistency; however, these gains have not consistently translated into superior patient outcomes. Human-AI studies similarly demonstrate that improved accuracy may coexist with automation bias and overacceptance of algorithmic recommendations. Evidence of demographic performance disparities and limitations in the representativeness of training and validation datasets further raises concerns regarding fairness and equitable access to care. On this basis, we argue that cardiothoracic AI should be governed according to the level of decision influence rather than by technology type alone. We distinguish non-delegable professional duties, distributed system responsibilities, and non-transferable patient authority, and propose an Ethical Heart Team Framework for converting algorithmic output into ethically defensible clinical action. FAU - Leivaditis, Vasileios AU - Leivaditis V AUID- ORCID: 0000-0001-8692-0059 AD - Department of Cardiothoracic and Vascular Surgery, Westpfalz Klinikum, 67655 Kaiserslautern, Germany. FAU - Mulita, Francesk AU - Mulita F AUID- ORCID: 0000-0001-7198-2628 AD - Department of General Surgery, General University Hospital of Alexandroupolis, Medical School, Democritus University of Thrace, 68100 Alexandroupolis, Greece. FAU - Androutsopoulou, Vasiliki AU - Androutsopoulou V AUID- ORCID: 0009-0005-2445-0879 AD - Department of Cardiothoracic Surgery, University Hospital of Larissa, 41110 Larissa, Greece. FAU - Mitsos, Sofoklis AU - Mitsos S AUID- ORCID: 0000-0002-0606-7287 AD - Department of Thoracic Surgery, Attikon General Hospital, National and Kapodistrian University of Athens, 12462 Athens, Greece. FAU - Tomos, Periklis AU - Tomos P AD - Department of Thoracic Surgery, Attikon General Hospital, National and Kapodistrian University of Athens, 12462 Athens, Greece. FAU - Panagiotopoulos, Ioannis AU - Panagiotopoulos I AUID- ORCID: 0000-0002-2779-5398 AD - Department of Cardiac Surgery, Ippokrateio General Hospital of Athens, 11527 Athens, Greece. FAU - Nikolakopoulos, Konstantinos AU - Nikolakopoulos K AD - Department of Vascular Surgery, General University Hospital of Patras, 26504 Patras, Greece. FAU - Liolis, Elias AU - Liolis E AD - Department of Oncology, General University Hospital of Patras, 26504 Patras, Greece. FAU - Skoura, Theodora AU - Skoura T AUID- ORCID: 0000-0002-3137-5361 AD - Medical School, National and Kapodistrian University of Athens (NKUA), Aretaeion Hospital, 11528 Athens, Greece. FAU - Koletsis, Efstratios AU - Koletsis E AUID- ORCID: 0000-0003-1660-4047 AD - Department of Cardiothoracic Surgery, General University Hospital of Patras, 26504 Patras, Greece. LA - eng PT - Journal Article PT - Review DEP - 20260918 PL - Switzerland TA - Med Sci (Basel) JT - Medical sciences (Basel, Switzerland) JID - 101629322 SB - IM MH - Humans MH - *Artificial Intelligence/ethics MH - *Thoracic Surgical Procedures/ethics MH - *Thoracic Surgery/ethics MH - Algorithms MH - Judgment MH - *Cardiac Surgical Procedures/ethics PMC - PMC13609802 OTO - NOTNLM OT - accountability OT - algorithmic bias OT - artificial intelligence OT - cardiac surgery OT - cardiothoracic surgery OT - human oversight OT - informed consent OT - surgical judgment OT - thoracic surgery COIS- The authors declare no conflicts of interest. EDAT- 2026/09/24 23:52 MHDA- 2026/09/24 23:53 PMCR- 2026/09/18 CRDT- 2026/09/24 18:14 PHST- 2026/08/23 00:00 [received] PHST- 2026/09/06 00:00 [revised] PHST- 2026/09/15 00:00 [accepted] PHST- 2026/09/24 23:53 [medline] PHST- 2026/09/24 23:52 [pubmed] PHST- 2026/09/24 18:14 [entrez] PHST- 2026/09/18 00:00 [pmc-release] AID - medsci14050586 [pii] AID - medsci-14-00586 [pii] AID - 10.3390/medsci14050586 [doi] PST - epublish SO - Med Sci (Basel). 2026 Sep 18;14(5):586. doi: 10.3390/medsci14050586. PMID- 42780492 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260924 LR - 20260926 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 18 IP - 8 DP - 2026 Aug TI - Evolution of Emergency Airway Management From Anatomical Prediction to a Systems-Based Resuscitative Approach in the Emergency Department: A Narrative Review. PG - e115046 LID - 10.7759/cureus.115046 [doi] LID - e115046 AB - Airway management in the emergency department (ED) is one of the most critical and time-pressured procedures in acute care medicine. Patients frequently present with severe physiological compromise, including severe hypoxia, hemodynamic instability, shock, altered mental status, trauma, or cardiac arrest, leaving clinicians with minimal preparation time and incomplete clinical information. While anatomical predictors of laryngoscopic difficulty have traditionally guided pre-intubation assessment, growing evidence suggests that the greatest threats during emergency airway management are often physiological rather than anatomical. Conditions such as profound hypoxemia, hemodynamic instability, metabolic acidosis, and severe respiratory failure significantly increase the risk of peri-intubation complications, including cardiovascular collapse and cardiac arrest, regardless of airway anatomy. PubMed, Google Scholar, and Scopus were searched from January 2000 through December 2025 using structured Boolean search terms, supplemented by hand-searching reference lists and relevant society guidelines. Relevant studies were selected according to predefined eligibility criteria and synthesized narratively. Among the included studies, physiological instability, particularly hypoxemia, metabolic acidosis, and circulatory shock, was consistently associated with an increased risk of peri-intubation cardiac arrest and appeared to be at least as important as bedside anatomical findings in emergency airway risk assessment. Current evidence supports a structured approach to emergency airway management that includes physiological optimization before laryngoscopy, use of the HEAVEN criteria for airway risk stratification, individualized drug selection based on the patient's hemodynamic status, structured airway bundles, video laryngoscopy as the preferred primary intubation device in appropriate emergency airway settings, and team-based cognitive tools such as the Vortex Approach. The DEVICE randomized trial demonstrated a 14.3-percentage-point improvement in first-pass success with video laryngoscopy versus direct laryngoscopy in critically ill adults. Prospective validation of these approaches in lower-resource settings, with neurological recovery rather than intubation success alone as the primary outcome, remains an important research priority. CI - Copyright (c) 2026, Hrushikesh et al. FAU - Hrushikesh, Anagani AU - Hrushikesh A AD - Emergency Medicine, Amrita Institute of Medical Sciences, Kochi, IND. FAU - Vishnupriya, Chinnam AU - Vishnupriya C AD - Emergency Medicine, Amrita Institute of Medical Sciences, Kochi, IND. FAU - Rakesh, Chetla AU - Rakesh C AD - Emergency Medicine, Amrita Institute of Medical Sciences, Kochi, IND. FAU - K, Anusree AU - K A AD - Biostatistician, Amrita Institute of Medical Sciences, Kochi, IND. FAU - B S, Dhanasekaran AU - B S D AD - Emergency Medicine, Amrita Institute of Medical Sciences, Kochi, IND. FAU - Kumar, Gireesh AU - Kumar G AD - Emergency Medicine, Amrita Institute of Medical Sciences, Kochi, IND. LA - eng PT - Journal Article PT - Review DEP - 20260823 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC13598311 OTO - NOTNLM OT - airway management OT - emergency department OT - first-pass success OT - heaven criteria OT - human factors OT - narrative review OT - peri-intubation cardiac arrest OT - physiologically difficult airway OT - point-of-care ultrasound OT - video laryngoscopy COIS- Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. EDAT- 2026/09/24 17:31 MHDA- 2026/09/24 17:32 PMCR- 2026/08/23 CRDT- 2026/09/24 12:27 PHST- 2026/06/10 00:00 [received] PHST- 2026/08/23 00:00 [accepted] PHST- 2026/09/24 17:32 [medline] PHST- 2026/09/24 17:31 [pubmed] PHST- 2026/09/24 12:27 [entrez] PHST- 2026/08/23 00:00 [pmc-release] AID - 10.7759/cureus.115046 [doi] PST - epublish SO - Cureus. 2026 Aug 23;18(8):e115046. doi: 10.7759/cureus.115046. eCollection 2026 Aug. PMID- 42775646 OWN - NLM STAT- Publisher LR - 20260923 IS - 1522-726X (Electronic) IS - 1522-1946 (Linking) DP - 2026 Sep 23 TI - Planned Versus Standby V-A ECMO Strategy During High-Risk PCI: A Retrospective Cohort Study. LID - 10.1002/ccd.70916 [doi] AB - BACKGROUND: The role of mechanical circulatory support (MCS) in high-risk percutaneous coronary intervention (HR-PCI) remains controversial, and the optimal timing of its initiation is not well defined. Veno-arterial extracorporeal membrane oxygenation (V-A ECMO) provides full hemodynamic support; however, comparative data on planned versus standby strategies are limited. AIM: To compare clinical outcomes of planned versus standby V-A ECMO support in patients undergoing elective HR-PCI, with a focus on the impact of timing of ECMO initiation. METHODS: This single-center retrospective observational study included 74 consecutive patients who underwent high-risk PCI between 2019 and 2025 and were managed according to a preprocedurally determined V-A ECMO strategy. Before PCI, the multidisciplinary Heart Team selected either a planned strategy (n = 43), in which V-A ECMO was initiated before PCI, or a standby strategy (n = 31), in which ECMO equipment and vascular access were prepared in advance, but ECMO was initiated only in response to predefined intraprocedural hemodynamic deterioration. The primary endpoint was in-hospital major adverse cardiac and cerebrovascular events (MACCE), defined as a composite of death, myocardial infarction, stroke, and repeat revascularization. RESULTS: No statistically significant differences were observed in the measured baseline variables. ECMO support during PCI was required in 19/32 (61.3%) of patients in the standby-strategy group. The incidence of in-hospital MACCE was significantly higher in the standby-strategy group compared with the planned-strategy group (48.4% vs. 14.0%, p = 0.002). The standby-strategy group also had longer ICU stay (8 [5-12] vs. 6 [4-9] days, p = 0.03) and hospital stay (15 [11-20] vs. 12 [9-16] days, p = 0.02), as well as higher vasoactive-inotropic scores (p = 0.033). In multivariable analysis, the standby strategy was associated with higher odds of in-hospital MACCE after adjustment (adjusted OR, 4.20; 95% CI, 1.35-13.10; p = 0.013). CONCLUSIONS: In this single-center retrospective cohort of patients undergoing elective HR-PCI, a planned V-A ECMO strategy was associated with a lower incidence of in-hospital MACCE than a standby strategy. Given the nonrandomized treatment allocation, inclusion of standby patients who did not ultimately require ECMO, and limited number of events, these findings are hypothesis-generating and do not establish a causal benefit of planned ECMO or harm from rescue initiation. CI - (c) 2026 Wiley Periodicals LLC. FAU - Todurov, Mykhailo AU - Todurov M AUID- ORCID: 0009-0008-6299-8319 AD - Department of Cardiosurgery, X-ray and Extracorporeal Technologies, PL Shupyk National Healthcare University of Ukraine, Kyiv, Ukraine. FAU - Todurov, Borys AU - Todurov B AUID- ORCID: 0009-0000-2047-4447 AD - Department of Cardiosurgery, X-ray and Extracorporeal Technologies, PL Shupyk National Healthcare University of Ukraine, Kyiv, Ukraine. AD - Department of Acute Coronary Syndrome, Heart Institute Ministry of Health of Ukraine, Kyiv, Ukraine. FAU - Zybaha, Yulia AU - Zybaha Y AUID- ORCID: 0009-0003-1520-7581 AD - Department of Acute Coronary Syndrome, Heart Institute Ministry of Health of Ukraine, Kyiv, Ukraine. FAU - Kipot, Artem AU - Kipot A AUID- ORCID: 0009-0003-4792-2133 AD - Department of Acute Coronary Syndrome, Heart Institute Ministry of Health of Ukraine, Kyiv, Ukraine. FAU - Maruniak, Stepan AU - Maruniak S AUID- ORCID: 0000-0001-7538-2443 AD - Department of Cardiosurgery, X-ray and Extracorporeal Technologies, PL Shupyk National Healthcare University of Ukraine, Kyiv, Ukraine. AD - Department of Extracorporeal Methods of Treatment, Heart Institute Ministry of Health of Ukraine, Kyiv, Ukraine. LA - eng PT - Journal Article DEP - 20260923 PL - United States TA - Catheter Cardiovasc Interv JT - Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions JID - 100884139 SB - IM OTO - NOTNLM OT - MACCE OT - V-A ECMO OT - high-risk PCI OT - mechanical circulatory support OT - revascularization EDAT- 2026/09/23 11:50 MHDA- 2026/09/23 11:50 CRDT- 2026/09/23 08:01 PHST- 2026/09/08 00:00 [revised] PHST- 2026/05/13 00:00 [received] PHST- 2026/09/16 00:00 [accepted] PHST- 2026/09/23 11:50 [medline] PHST- 2026/09/23 11:50 [pubmed] PHST- 2026/09/23 08:01 [entrez] AID - 10.1002/ccd.70916 [doi] PST - aheadofprint SO - Catheter Cardiovasc Interv. 2026 Sep 23. doi: 10.1002/ccd.70916. PMID- 42775163 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260923 LR - 20260924 IS - 2328-8957 (Print) IS - 2328-8957 (Electronic) IS - 2328-8957 (Linking) VI - 13 IP - 9 DP - 2026 Sep TI - Diagnosis and Management of Patients With Suspected Left-Sided Prosthetic Valve Endocarditis According to Cardiac FDG-PET CT Results. PG - ofag580 LID - 10.1093/ofid/ofag580 [doi] LID - ofag580 AB - BACKGROUND: Despite advances in echocardiography, the definitive diagnosis of prosthetic valve endocarditis (PVE) remains difficult. (18)F-fluorodeoxyglucose (chemical name 2-deoxy-2-[(18)F]fluro-D-glucose) positron emission tomography (PET) shows promise with improved sensitivity. Our study explored the effects of PET findings on the diagnosis of PVE and patient management decisions. METHOD: Between 2016 and 2022, 140 patients underwent PET to evaluate suspected left-sided PVE, resulting in 93 patients with positive PET (+PET) and 47 patients with negative PET. Patients were classified as definite, possible, or rejected PVE according to the 2023 Duke-International Society for Cardiovascular Infectious Diseases guidelines, initially excluding and then including PET results. We evaluated the association between PET results and clinical outcomes such as duration of antibiotics, performance of cardiac surgery within 3 months, and long-term mortality. A qualitative analysis of medical decision-making was performed. RESULTS: Demographics were similar between groups. patients with +PET had higher C-reactive protein levels (9.8 vs 3.1 mg/L, P = .001) and were more likely to have positive blood culture and echocardiographic findings. The addition of PET significantly increased the diagnosis of definite endocarditis (46%-63%, P < .001). A +PET was positively associated with ongoing use of antibiotics after 3 months (odds ratio [OR] 3.93, P = .002) and surgical management (OR 5.99, P = .008). Based on qualitative review of medical decision-making, PET influenced management in 88 patients (63%), supporting longer duration of antibiotics in 22%, surgical management in 8.6%, and shorter duration of antibiotics in 11% of patients. CONCLUSIONS: Positron emission tomography results, when incorporated into multidisciplinary discussion, aided in a more definitive diagnosis of PVE and influenced management in the majority of patients. CI - (c) The Author(s) 2026. Published by Oxford University Press on behalf of Infectious Diseases Society of America. FAU - Caceres, Juan AU - Caceres J AUID- ORCID: 0000-0002-9647-8994 AD - Department of Internal Medicine, Division of Cardiovascular Medicine, Michigan Medicine, Ann Arbor, Michigan, USA. FAU - Edwards, Mark AU - Edwards M AD - Department of Internal Medicine, Michigan Medicine, Ann Arbor, Michigan, USA. FAU - Kurz, Sarah AU - Kurz S AD - Department of Internal Medicine, Division of Infectious Diseases, Michigan Medicine, Ann Arbor, Michigan, USA. FAU - Hamilton, Barbara C S AU - Hamilton BCS AD - Department of Cardiac Surgery, Michigan Medicine, Ann Arbor, Michigan, USA. FAU - Madamanchi, Chaitanya AU - Madamanchi C AUID- ORCID: 0000-0003-4971-0110 AD - Department of Internal Medicine, Michigan Medicine, Ann Arbor, Michigan, USA. FAU - Murthy, Venkatesh AU - Murthy V AUID- ORCID: 0000-0002-7901-1321 AD - Department of Internal Medicine, Michigan Medicine, Ann Arbor, Michigan, USA. FAU - Deeb, G Michael AU - Deeb GM AD - Department of Cardiac Surgery, Michigan Medicine, Ann Arbor, Michigan, USA. FAU - Harris, Andrew W AU - Harris AW AUID- ORCID: 0000-0003-0026-4519 AD - Department of Internal Medicine, Division of Cardiovascular Medicine, Michigan Medicine, Ann Arbor, Michigan, USA. LA - eng PT - Journal Article DEP - 20260915 PL - United States TA - Open Forum Infect Dis JT - Open forum infectious diseases JID - 101637045 PMC - PMC13595288 OTO - NOTNLM OT - cardiovascular imaging OT - positron emission tomography (PET) OT - prosthetic valve endocarditis COIS- Potential conflicts of interest. All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. Ethics statement. The authors vouch that the research conducted for this manuscript was conducted in a manner consistent with the ethical standards of the Helsinki Declaration. Patient consent statement. The University of Michigan Institution Review Board approved a waiver of consent due to the minimal risk associated with this retrospective, observational study. EDAT- 2026/09/23 11:50 MHDA- 2026/09/23 11:51 PMCR- 2026/09/15 CRDT- 2026/09/23 07:23 PHST- 2026/04/28 00:00 [received] PHST- 2026/09/01 00:00 [accepted] PHST- 2026/09/23 11:51 [medline] PHST- 2026/09/23 11:50 [pubmed] PHST- 2026/09/23 07:23 [entrez] PHST- 2026/09/15 00:00 [pmc-release] AID - ofag580 [pii] AID - 10.1093/ofid/ofag580 [doi] PST - epublish SO - Open Forum Infect Dis. 2026 Sep 15;13(9):ofag580. doi: 10.1093/ofid/ofag580. eCollection 2026 Sep. PMID- 42774765 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260923 LR - 20260924 IS - 1756-1485 (Electronic) IS - 1756-1477 (Print) IS - 1756-1485 (Linking) VI - 21 DP - 2026 TI - Five Practical Considerations for the Management of Out-of-hospital Cardiac Arrest: Reflections from the British Cardiovascular Intervention Society Out-of-hospital Cardiac Arrest Focus Group. PG - e21 LID - 10.15420/icr.2026.18 [doi] LID - e21 AB - Out-of-hospital cardiac arrest (OHCA) remains associated with poor survival and marked variation in post-resuscitation care. Drawing on discussion from the British Cardiovascular Intervention Society (BCIS) OHCA focus group, this article summarises five practical considerations for management following return of spontaneous circulation. First, selective conveyance to specialist cardiac arrest centres may be most effective when aligned with the BCIS algorithm, particularly for patients with features suggesting a reversible cardiac cause. Second, early risk stratification with MIRACLE(2) may support decision-making when interpreted alongside specialist clinical judgement. Third, early multidisciplinary team review may improve coherence in a complex condition that often spans cardiology, intensive care, neurology and emergency medicine. Fourth, neuroprognostication is likely to be most robust when delayed appropriately, guided by European Resuscitation Council recommendations and delivered through a structured multimodal multidisciplinary team process. Finally, post-survival rehabilitation and family support should be regarded as core components of the OHCA pathway rather than optional afterthoughts. CI - Copyright (c) The Author(s), 2026. Published by Radcliffe Group Ltd. FAU - Movio, Guilherme AU - Movio G AUID- ORCID: 0000-0001-8117-0818 AD - Essex Cardiothoracic Centre, Mid and South Essex NHS Foundation Trust Essex, UK. AD - Circulatory Health, Anglia Ruskin University Chelmsford, UK. FAU - Sajjad, Uzma AU - Sajjad U AUID- ORCID: 0009-0005-0360-5122 AD - Essex Cardiothoracic Centre, Mid and South Essex NHS Foundation Trust Essex, UK. AD - Circulatory Health, Anglia Ruskin University Chelmsford, UK. FAU - Ansell, Evan AU - Ansell E AUID- ORCID: 0009-0001-4066-0551 AD - Department of Cardiology, King's College Hospital NHS Foundation Trust London, UK. FAU - Simpson, Rupert AU - Simpson R AUID- ORCID: 0000-0002-0897-792X AD - Essex Cardiothoracic Centre, Mid and South Essex NHS Foundation Trust Essex, UK. AD - Circulatory Health, Anglia Ruskin University Chelmsford, UK. FAU - Mion, Marco AU - Mion M AUID- ORCID: 0000-0002-3656-5965 AD - Essex Cardiothoracic Centre, Mid and South Essex NHS Foundation Trust Essex, UK. AD - Circulatory Health, Anglia Ruskin University Chelmsford, UK. FAU - Rees, Paul AU - Rees P AUID- ORCID: 0000-0002-6560-6332 AD - Barts Heart Centre, St Bartholomew's Hospital London, UK. AD - Center for Resuscitation Medicine, Department of Cardiology, University of Minnesota Minneapolis, MN, US. FAU - Johnson, Thomas AU - Johnson T AUID- ORCID: 0000-0003-4638-601X AD - Bristol Heart Institute, University Hospitals Bristol UK. FAU - Curzen, Nick AU - Curzen N AUID- ORCID: 0000-0001-9651-7829 AD - Department of Cardiology, University Hospital Southampton NHS Foundation Trust Southampton, UK. AD - Clinical Cardiology Research, Faculty of Medicine, University of Southampton Southampton, UK. FAU - Maccaroni, Maria Rita AU - Maccaroni MR AD - Essex Cardiothoracic Centre, Mid and South Essex NHS Foundation Trust Essex, UK. AD - Circulatory Health, Anglia Ruskin University Chelmsford, UK. FAU - Davies, John R AU - Davies JR AUID- ORCID: 0000-0003-2693-5114 AD - Essex Cardiothoracic Centre, Mid and South Essex NHS Foundation Trust Essex, UK. AD - Circulatory Health, Anglia Ruskin University Chelmsford, UK. FAU - Pareek, Nilesh AU - Pareek N AUID- ORCID: 0000-0002-2720-2134 AD - Department of Cardiology, King's College Hospital NHS Foundation Trust London, UK. FAU - Keeble, Thomas R AU - Keeble TR AUID- ORCID: 0000-0001-8695-7994 AD - Essex Cardiothoracic Centre, Mid and South Essex NHS Foundation Trust Essex, UK. AD - Circulatory Health, Anglia Ruskin University Chelmsford, UK. LA - eng PT - Journal Article PT - Review DEP - 20260909 PL - England TA - Interv Cardiol JT - Interventional cardiology (London, England) JID - 101559687 PMC - PMC13595269 OTO - NOTNLM OT - Cardiac arrest centre OT - MIRACLE2 score OT - cardiac intensive care OT - conveyance algorithm OT - neuroprognostication OT - out-of-hospital cardiac arrest OT - survivorship COIS- Disclosure: TJ has received grants from Abbott Vascular, consulting fees from Abbott Vascular, Boston Scientific, Cordis and Terumo and honoraria from Abbott Vascular, Boston Scientific and Terumo, and has served on a Clinical Endpoint Committee for SELUTION Small Vessel US. NC has received grants from Boston Scientific, Haemonetics, Heartflow and Beckman Coulter, consulting fees from Heartflow and Abbott, and honoraria and travel support from Heartflow, Abbott and Shockwave; and is on the Interventional Cardiology editorial board; this did not influence peer review. JRD has received educational grants from Abbott Vascular and Terumo, consulting fees from Vascular Perspectives and speaker fees from Shockwave and AstraZeneca. NP has received grants from Abbott Vascular, British Heart Foundation Centre of Research Excellence and Heart Research UK and honoraria from NIPRO, and has served on advisory boards for Boston Scientific and Johnson & Johnson. TK has received grants from NHS East of England Cardiac Network. All other authors have no conflicts of interest to declare. EDAT- 2026/09/23 11:50 MHDA- 2026/09/23 11:51 PMCR- 2026/09/09 CRDT- 2026/09/23 06:46 PHST- 2026/04/13 00:00 [received] PHST- 2026/06/03 00:00 [accepted] PHST- 2026/09/23 11:51 [medline] PHST- 2026/09/23 11:50 [pubmed] PHST- 2026/09/23 06:46 [entrez] PHST- 2026/09/09 00:00 [pmc-release] AID - 10.15420/icr.2026.18 [doi] PST - epublish SO - Interv Cardiol. 2026 Sep 9;21:e21. doi: 10.15420/icr.2026.18. eCollection 2026. PMID- 42774009 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260923 LR - 20260924 IS - 2772-9303 (Electronic) IS - 2772-9303 (Linking) VI - 5 IP - 9 DP - 2026 Sep TI - A Multicenter, Mixed Methods Study of United States Heart Teams and Health Policy: The EVOLVE Study Design and Protocol. PG - 105512 LID - 10.1016/j.jscai.2026.105512 [doi] LID - 105512 AB - BACKGROUND: The management of patients with aortic stenosis is rapidly evolving, along with the "heart team," a multidisciplinary group collaborating in program management. There is scant research providing rigorous data on the variability in heart teams' approach to optimal patient care delivery. This investigation aimed to describe the current health care delivery strategies and attitudes of contemporary heart teams at diverse hospitals across the United States and provide key insight into future health policy and guideline directions. METHODS: We will conduct a convergent parallel design mixed methods study integrating quantitative (survey) and qualitative (semistructured interviews, coded using qualitative research software) data to develop a deeper understanding of heart valve team roles, functions, health care delivery strategies, and clinician perceptions of the impacts of health policy mandates on team and patient experience. Guided by a grounded theory approach, we will generate themes inductively from perspectives expressed by the participants. Heart valve teams will be recruited until saturation of themes and to maximize variation in practice settings (academic status, geographical location, transcatheter aortic valve replacement program volume, program tenure). We anticipate 8 to 20 programs and 40 to 100 participants. This study is approved by the Western Copernicus Group Institutional Review Board and adheres to Good Reporting of a Mixed Methods Study guidelines for mixed methods research. CONCLUSIONS: This study is designed to be the largest investigation to date of United States heart teams focused on aortic stenosis, aimed to inform health policy and guideline efforts to streamline care, address continued inequities and undertreatment, and optimize patient outcomes. CI - (c) 2026 The Author(s). FAU - Coylewright, Megan AU - Coylewright M AD - Heart and Vascular Center, Essentia Health, Duluth, Minnesota. FAU - Kolte, Dhaval AU - Kolte D AD - Cardiology Division, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. FAU - Kruse, Gina AU - Kruse G AD - Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado. FAU - Suri, Rakesh M AU - Suri RM AD - Corewell Health, William Beaumont University Hospital, Royal Oak, Michigan. FAU - Elmariah, Sammy AU - Elmariah S AD - Division of Cardiology, University of California San Francisco, San Francisco, California. FAU - Strong, Susan R AU - Strong SR AD - Empath Health Services, Seattle, Washington. FAU - Perpetua, Elizabeth M AU - Perpetua EM AD - Empath Health Services, Seattle, Washington. AD - Department of Biobehavioral Health and Informatics, University of Washington School of Nursing, Seattle, Washington. LA - eng PT - Journal Article DEP - 20260716 PL - United States TA - J Soc Cardiovasc Angiogr Interv JT - Journal of the Society for Cardiovascular Angiography & Interventions JID - 9918419271306676 PMC - PMC13593401 OTO - NOTNLM OT - aortic stenosis OT - health policy OT - heart team OT - heart valve team OT - multidisciplinary valvular heart disease OT - transcatheter aortic valve replacement EDAT- 2026/09/23 05:35 MHDA- 2026/09/23 05:36 PMCR- 2026/07/16 CRDT- 2026/09/23 04:37 PHST- 2026/04/10 00:00 [received] PHST- 2026/05/27 00:00 [revised] PHST- 2026/06/09 00:00 [accepted] PHST- 2026/09/23 05:36 [medline] PHST- 2026/09/23 05:35 [pubmed] PHST- 2026/09/23 04:37 [entrez] PHST- 2026/07/16 00:00 [pmc-release] AID - S2772-9303(26)01259-7 [pii] AID - 105512 [pii] AID - 10.1016/j.jscai.2026.105512 [doi] PST - epublish SO - J Soc Cardiovasc Angiogr Interv. 2026 Jul 16;5(9):105512. doi: 10.1016/j.jscai.2026.105512. eCollection 2026 Sep. PMID- 42769961 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260922 LR - 20260923 IS - 2772-9303 (Electronic) IS - 2772-9303 (Linking) VI - 5 IP - 9 DP - 2026 Sep TI - Building a Multidisciplinary Cardiogenic Shock Program in Latin America: Outcomes From the TecSalud Program. PG - 105508 LID - 10.1016/j.jscai.2026.105508 [doi] LID - 105508 AB - BACKGROUND: Cardiogenic shock (CS) remains associated with high mortality despite modern reperfusion and mechanical circulatory support. Multidisciplinary "CS teams" have demonstrated improved outcomes; however, data from low- and middle-income countries are scarce. This study describes the experience and outcomes following the implementation of a dedicated CS team at a tertiary hospital in Mexico. METHODS: We conducted a retrospective, single-center cohort study including consecutive adults with CS admitted to TecSalud between January 2021 and August 2025. The multidisciplinary CS team was established in August 2022. Patients were divided into 2 cohorts: pre-team (January 2021 to July 2022) and post-team (August 2022 to August 2025). The primary end point was 30-day all-cause mortality. Mortality rates were compared using the Fisher exact test. RESULTS: A total of 67 patients were included (27 preteam, 40 postteam). Among the postteam cohort, the mean age was 63 +/- 15.2 years, and 73% were male. The leading etiology was acute myocardial infarction-related CS (67.5%), followed by decompensated heart failure (20%). The median hospital stay was 11.5 days (0-122), and the average ICU stay was 7 days (1-105). Most patients presented in the Society for Cardiovascular Angiography & Interventions (SCAI) SHOCK stage E (33%), 80% required mechanical circulatory support, and 18% underwent extracorporeal cardiopulmonary resuscitation. Implementation of the CS team was associated with a reduction in 30-day mortality from 63% to 25%. CONCLUSIONS: The implementation of a multidisciplinary CS team at a tertiary center in Mexico was associated with a substantial reduction in 30-day mortality and improved care coordination. These findings support the feasibility and effectiveness of structured CS programs in complex health care environments. CI - (c) 2026 The Author(s). FAU - Jimenez-Franco, Vicente AU - Jimenez-Franco V AD - Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Nuevo Leon, Mexico. AD - Instituto de Cardiologia y Medicina Vascular, TecSalud, Escuela de Medicina y Ciencias de la Salud, Tecnologico de Monterrey, San Pedro Garza Garcia, Nuevo Leon, Mexico. FAU - Rodriguez-Rivera, Jahir AU - Rodriguez-Rivera J AD - Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Nuevo Leon, Mexico. AD - Instituto de Cardiologia y Medicina Vascular, TecSalud, Escuela de Medicina y Ciencias de la Salud, Tecnologico de Monterrey, San Pedro Garza Garcia, Nuevo Leon, Mexico. FAU - Quevedo-Salazar, Renata AU - Quevedo-Salazar R AD - Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Nuevo Leon, Mexico. FAU - Salinas-Casanova, Jose A AU - Salinas-Casanova JA AD - Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Nuevo Leon, Mexico. AD - Instituto de Cardiologia y Medicina Vascular, TecSalud, Escuela de Medicina y Ciencias de la Salud, Tecnologico de Monterrey, San Pedro Garza Garcia, Nuevo Leon, Mexico. FAU - Flores-Zertuche, Monica AU - Flores-Zertuche M AD - Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Nuevo Leon, Mexico. AD - Instituto de Cardiologia y Medicina Vascular, TecSalud, Escuela de Medicina y Ciencias de la Salud, Tecnologico de Monterrey, San Pedro Garza Garcia, Nuevo Leon, Mexico. FAU - Gocher-Janet, Cecilia AU - Gocher-Janet C AD - Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Nuevo Leon, Mexico. FAU - Ibarrola-Pena, Juan Carlos AU - Ibarrola-Pena JC AD - Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Nuevo Leon, Mexico. AD - Instituto de Cardiologia y Medicina Vascular, TecSalud, Escuela de Medicina y Ciencias de la Salud, Tecnologico de Monterrey, San Pedro Garza Garcia, Nuevo Leon, Mexico. FAU - Jerjes-Sanchez, Carlos AU - Jerjes-Sanchez C AD - Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Nuevo Leon, Mexico. AD - Instituto de Cardiologia y Medicina Vascular, TecSalud, Escuela de Medicina y Ciencias de la Salud, Tecnologico de Monterrey, San Pedro Garza Garcia, Nuevo Leon, Mexico. FAU - Gomez-Gutierrez, Rene D AU - Gomez-Gutierrez RD AD - Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Nuevo Leon, Mexico. AD - Instituto de Cardiologia y Medicina Vascular, TecSalud, Escuela de Medicina y Ciencias de la Salud, Tecnologico de Monterrey, San Pedro Garza Garcia, Nuevo Leon, Mexico. FAU - Quezada-Valenzuela, Guillermo AU - Quezada-Valenzuela G AD - Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Nuevo Leon, Mexico. AD - Instituto de Cardiologia y Medicina Vascular, TecSalud, Escuela de Medicina y Ciencias de la Salud, Tecnologico de Monterrey, San Pedro Garza Garcia, Nuevo Leon, Mexico. FAU - Pena, Erasmo de la AU - Pena E AD - Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Nuevo Leon, Mexico. AD - Instituto de Cardiologia y Medicina Vascular, TecSalud, Escuela de Medicina y Ciencias de la Salud, Tecnologico de Monterrey, San Pedro Garza Garcia, Nuevo Leon, Mexico. AD - Instituto de Cardiologia y Medicina Vascular, TecSalud, Escuela de Medicina y Ciencias de la Salud, Tecnologico de Monterrey, San Pedro Garza Garcia, Nuevo Leon, Mexico. FAU - Torre-Amione, Guillermo AU - Torre-Amione G AD - Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Nuevo Leon, Mexico. AD - Instituto de Cardiologia y Medicina Vascular, TecSalud, Escuela de Medicina y Ciencias de la Salud, Tecnologico de Monterrey, San Pedro Garza Garcia, Nuevo Leon, Mexico. AD - Instituto de Cardiologia y Medicina Vascular, TecSalud, Escuela de Medicina y Ciencias de la Salud, Tecnologico de Monterrey, San Pedro Garza Garcia, Nuevo Leon, Mexico. LA - eng PT - Journal Article DEP - 20260707 PL - United States TA - J Soc Cardiovasc Angiogr Interv JT - Journal of the Society for Cardiovascular Angiography & Interventions JID - 9918419271306676 PMC - PMC13591530 OTO - NOTNLM OT - cardiogenic shock OT - low- and middle-income countries OT - mechanical circulatory support OT - multidisciplinary team OT - program development COIS- The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2026/09/22 12:42 MHDA- 2026/09/22 12:43 PMCR- 2026/07/07 CRDT- 2026/09/22 06:40 PHST- 2026/02/06 00:00 [received] PHST- 2026/05/11 00:00 [revised] PHST- 2026/06/03 00:00 [accepted] PHST- 2026/09/22 12:43 [medline] PHST- 2026/09/22 12:42 [pubmed] PHST- 2026/09/22 06:40 [entrez] PHST- 2026/07/07 00:00 [pmc-release] AID - S2772-9303(26)01255-X [pii] AID - 105508 [pii] AID - 10.1016/j.jscai.2026.105508 [doi] PST - epublish SO - J Soc Cardiovasc Angiogr Interv. 2026 Jul 7;5(9):105508. doi: 10.1016/j.jscai.2026.105508. eCollection 2026 Sep. PMID- 42769046 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260922 LR - 20260923 IS - 2297-055X (Print) IS - 2297-055X (Electronic) IS - 2297-055X (Linking) VI - 13 DP - 2026 TI - Clinicopathological analysis of 124 cardiac tumors: a single-center retrospective study. PG - 1903934 LID - 10.3389/fcvm.2026.1903934 [doi] LID - 1903934 AB - OBJECTIVE: To characterize the clinicopathological features, pathological spectrum, and anatomical distribution of cardiac tumors and to evaluate the diagnostic challenges associated with these rare lesions. METHODS: A retrospective analysis was performed on 124 surgically resected cardiac tumors diagnosed at the Affiliated Hospital of Zunyi Medical University between January 2012 and June 2026. Histological examination, immunohistochemistry, and fluorescence in situ hybridization (FISH), when indicated, were reviewed. All tumors were reclassified according to the 2021 WHO Classification of Thoracic Tumours. Clinicopathological characteristics and exploratory statistical analyses were performed. RESULTS: Among the 124 cardiac tumors, myxoma constituted the predominant entity (104/124, 83.9%). A marked predilection for the left atrium was noted, with 78.8% of myxomas located there (82/104), significantly surpassing the frequency in the right atrium (P < 0.001). Although malignant tumors were uncommon (12 cases), they exhibited considerable histopathological diversity. Exploratory analysis revealed a higher proportion of malignant tumors in patients aged 2 mg/dL, vegetations >10 mm, severe regurgitation, abscess, negative blood cultures, Staphylococcus aureus infection, absence of surgical indication and surgical indication without intention to operate. The model showed good discrimination and calibration (area under the receiver operating characteristic (AUROC) 0.763; Hosmer-Lemeshow p=0.825; Brier score 0.09). In the external validation cohort, 48/377 patients (12.7%) died; discrimination remained excellent (AUROC 0.799; 95% CI 0.730 to 0.868) with good calibration (slope 1.017; expected-to-observed ratio 1.124). CONCLUSIONS: The EURO-ENDO risk score, incorporating 11 variables available during the initial diagnostic evaluation, accurately predicts individualised 30-day mortality in patients with LSIE and showed consistent performance in both internal and external validation cohorts. This tool may support early risk stratification, multidisciplinary endocarditis team discussions and clinical decision-making (https://scoreei.web.app/score). CI - (c) Author(s) (or their employer(s)) 2026. No commercial re-use. See rights and permissions. Published by BMJ Group. FAU - Sambola, Antonia AU - Sambola A AD - Department of Cardiology, Hospital Universitari Vall d'Hebron, Barcelona, Spain antonia.sambolaayala@gmail.com. FAU - Lozano-Torres, Jordi AU - Lozano-Torres J AUID- ORCID: 0000-0003-0308-8186 AD - Department of Cardiology, Hospital Universitari Vall d'Hebron, Barcelona, Spain. FAU - Boersma, Eric AU - Boersma E AUID- ORCID: 0000-0003-1159-7802 AD - Department of Cardiology, Erasmus MC Cardiovascular Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands. FAU - Escabias, Claudia AU - Escabias C AD - Department of Cardiology, Hospital Universitari Germans Trias I Pujol, Universitat Autonoma, CIBER-CV, Badalona, Spain. FAU - Admella, Lluis AU - Admella L AD - Department of Cardiology, Hospital Universitari Vall d'Hebron, Barcelona, Spain. FAU - Pidone, Chiara AU - Pidone C AD - Department of Cardiology, Hospital Universitari Germans Trias I Pujol, Universitat Autonoma, CIBER-CV, Badalona, Spain. FAU - Mehmood-Wahid, Arwa AU - Mehmood-Wahid A AUID- ORCID: 0009-0002-5893-8416 AD - Department of Cardiology, Hospital Universitari Vall d'Hebron, Barcelona, Spain. FAU - Delgado, Victoria AU - Delgado V AUID- ORCID: 0000-0002-9841-2737 AD - Department of Cardiology, Hospital Universitari Germans Trias I Pujol, Universitat Autonoma, CIBER-CV, Badalona, Spain. FAU - Rello, Pau AU - Rello P AD - Department of Cardiology, Hospital Universitari Vall d'Hebron, Barcelona, Spain. FAU - Rodenas-Alsina, Eduard AU - Rodenas-Alsina E AUID- ORCID: 0000-0003-1638-7820 AD - Department of Cardiology, Hospital Universitari Vall d'Hebron, Barcelona, Spain. AD - Universitat de Barcelona, CIBER-CV, Hospital Vall d'Hebron, Barcelona, Spain. FAU - Olmos, Carmen AU - Olmos C AUID- ORCID: 0000-0001-9544-0508 AD - Instituto Cardiovascular, Hospital Clinico San Carlos, Instituto de Investigacion Sanitaria del Hospital Clinico San Carlos (IdISSC), Madrid, Spain. FAU - Ternacle, Julien AU - Ternacle J AUID- ORCID: 0000-0002-9629-5864 AD - Department of cardiology, SOS Endocardites, Henri Mondor Hospital, Creteil, France. FAU - Tribouilloy, Christophe AU - Tribouilloy C AUID- ORCID: 0000-0001-7867-3668 AD - Department of Cardiology, Amiens University Hospital, Amiens, France. FAU - Reskovic Luksic, Vlatka AU - Reskovic Luksic V AUID- ORCID: 0000-0002-4721-3236 AD - Department of Cardiovascular Diseases, University of Zagreb School of Medicine and University Hospital Centre, Zagreb, Croatia. FAU - Separovic-Hanzevacki, Jadranka AU - Separovic-Hanzevacki J AD - Department of Cardiovascular Diseases, University of Zagreb School of Medicine and University Hospital Centre, Zagreb, Croatia. FAU - Park, Seung-Woo AU - Park SW AD - Division of Cardiology, Samsung Medical Center, Seoul, Korea. FAU - Bekkers, Sebastiaan C A M AU - Bekkers SCAM AD - Department of Cardiology, Maastricht University Medical Center, Maastricht, The Netherlands. FAU - Chan, Kwan-Leung AU - Chan KL AUID- ORCID: 0000-0002-4273-1093 AD - University of Ottawa Heart Institute, Ottawa, Ontario, Canada. FAU - Almaghraby, Abdallah AU - Almaghraby A AD - Department of Cardiology, Faculty of Medicine, Alexandria University, Alexandria, Egypt. FAU - Iung, Bernard AU - Iung B AUID- ORCID: 0000-0002-9127-348X AD - Hopital Bichat, Paris, France. FAU - Lancellotti, Patrizio AU - Lancellotti P AD - University of Liege Hospital, GIGA Institute, Departments of Cardiology, Heart Valve Clinic, CHU Sart Tilman, Liege, Belgium. AD - Gruppo Villa Maria Care and Research, Anthea Hospital, Bari, Italy. FAU - Habib, Gilbert AU - Habib G AUID- ORCID: 0000-0003-3899-9983 AD - Cardiology Department, APHM, La Timone Hospital, Boulevard Jean Moulin, Marseille, France. AD - Aix Marseille Univ, IRD, APHM, MEPHI, IHU-Mediterranee Infection, Marseille, France. CN - ESC-EORP EURO-ENDO Investigators LA - eng PT - Journal Article DEP - 20260918 PL - England TA - Heart JT - Heart (British Cardiac Society) JID - 9602087 SB - IM OTO - NOTNLM OT - Cardiac Surgical Procedures OT - Endocarditis COIS- Competing interests: None declared. EDAT- 2026/09/18 23:36 MHDA- 2026/09/18 23:36 CRDT- 2026/09/18 21:32 PHST- 2026/02/21 00:00 [received] PHST- 2026/08/06 00:00 [accepted] PHST- 2026/09/18 23:36 [medline] PHST- 2026/09/18 23:36 [pubmed] PHST- 2026/09/18 21:32 [entrez] AID - heartjnl-2026-328064 [pii] AID - 10.1136/heartjnl-2026-328064 [doi] PST - aheadofprint SO - Heart. 2026 Sep 18:heartjnl-2026-328064. doi: 10.1136/heartjnl-2026-328064. PMID- 42759504 OWN - NLM STAT- Publisher LR - 20260918 IS - 2666-6340 (Electronic) IS - 2666-6340 (Linking) DP - 2026 Sep 18 TI - Pregnancy-associated cardiac complications. PG - 101301 LID - S2666-6340(26)00304-1 [pii] LID - 10.1016/j.medj.2026.101301 [doi] AB - Cardiovascular disease has become the most common cause of maternal mortality in the United States and non-obstetric cause of maternal mortality worldwide. Pregnancy profoundly alters maternal physiology and creates multiple maternal vulnerabilities, especially but not uniquely in women with preexisting cardiac disease. Common cardiac conditions represented in this patient population include arrhythmias, cardiomyopathies, and valvular heart disease, putting women at risk for numerous adverse events of pregnancy, including pre-eclampsia, heart failure, preterm delivery, and small-for-gestational-age babies. These complications often foretell long-term maternal cardiovascular risks and are also highly influenced by socioeconomic circumstances. To address these issues, cardio-obstetrics has emerged as a diverse and growing field spanning multiple medical specialties. Due to the breadth of pathology, a multidisciplinary Cardio-Obstetrics management team strategy is crucial. We review here common cardiac pathologies and their management throughout the peripartum period. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Thordsen, Sarah AU - Thordsen S AD - Division of Cardiovascular Medicine, Department of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA. FAU - Arany, Zoltan AU - Arany Z AD - Department of Physiology and of Medicine, and Cardiovascular Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: zarany@pennmedicine.upenn.edu. LA - eng PT - Journal Article PT - Review DEP - 20260918 PL - United States TA - Med JT - Med (New York, N.Y.) JID - 101769215 SB - IM OTO - NOTNLM OT - cardiac problems in pregnancy OT - cardio-obstetrics OT - cardio-obstetrics team OT - cardiovascular disease in pregnancy OT - maternal cardiovascular disease OT - maternal mortality OT - maternal outcomes OT - pregnancy heart team COIS- Declaration of interests The authors declare no competing interests. EDAT- 2026/09/18 23:36 MHDA- 2026/09/18 23:36 CRDT- 2026/09/18 18:41 PHST- 2026/05/11 00:00 [received] PHST- 2026/07/31 00:00 [revised] PHST- 2026/08/26 00:00 [accepted] PHST- 2026/09/18 23:36 [medline] PHST- 2026/09/18 23:36 [pubmed] PHST- 2026/09/18 18:41 [entrez] AID - S2666-6340(26)00304-1 [pii] AID - 10.1016/j.medj.2026.101301 [doi] PST - aheadofprint SO - Med. 2026 Sep 18:101301. doi: 10.1016/j.medj.2026.101301. PMID- 42757935 OWN - NLM STAT- MEDLINE DCOM- 20261008 LR - 20261008 IS - 2047-9980 (Electronic) IS - 2047-9980 (Linking) VI - 15 IP - 19 DP - 2026 Oct 6 TI - Cerebral Injury and Impaired Brain Metabolism in Patients With Left Ventricular Assist Device and Chronic Heart Failure -An Interdisciplinary Cognition, Blood-Based Biomarker and Brain Metabolism Assessment. PG - e043727 LID - 10.1161/JAHA.125.043727 [doi] AB - BACKGROUND: Chronic heart failure is linked to cognitive dysfunction. Left ventricular assist devices (LVAD) potentially ameliorate cognition, but continuous flow profiles might result in long-term progression. In this cross-sectional pilot study, we aimed to investigate the association between LVAD therapy and neuronal impairment measured by cognitive performance, blood-based biomarkers of neuronal injury and (18)F-fluorodeoxyglucose-positron emission tomography/computed tomography-derived brain metabolism. METHODS: We prospectively enrolled 19 patients with LVAD and 13 patients with advanced chronic heart failure receiving best medical treatment. Cognitive performance was assessed using the Montreal Cognitive Assessment and Frontal Assessment Battery. Serum levels of NfL (neurofilament light chain), pTau181 (phosphorylated Tau protein at threonine 181), and GFAP (glial fibrillary acidic protein) were measured by immunoassay. Brain metabolism was assessed using (18)F-fluorodeoxyglucose-positron emission tomography/computed tomography by statistical parametric mapping analyses compared with 16 healthy controls (P<0.001 uncorrected). RESULTS: Of all patients, 69% showed cognitive dysfunction, 5 patients had evidence for frontotemporal impairment. Median neurochemical biomarker concentrations were elevated in the whole cohort (NfL 45.7 pg/mL [26.9-80.2]; pTau181 23.1 pg/mL [18.1-40.1]; GFAP 191.3 pg/mL [126.3-251.7]). Both groups did not differ regarding cognitive performance and biomarker levels. The uncorrected statistical parametric mapping analyses indicated frontotemporally accentuated hypometabolism in both groups compared with healthy controls. Patients with LVAD revealed more hypometabolic volumes in single-subject analyses (LVAD 1.03 mL (0-7.34); chronic heart failure 0 mL (0-0.01), P<0.003). CONCLUSIONS: In this exploratory study, patients with chronic heart failure and patients with LVAD exhibited impaired cognitive performance and elevated biomarker levels of neuronal injury. (18)F-fluorodeoxyglucose-positron emission tomography/computed tomography results of uncorrected thresholds suggested subtle frontal hypometabolism. Neurochemical biomarkers and (18)F-fluorodeoxyglucose-positron emission tomographyappear promising for further investigation of cerebral health in patients with heart failure. FAU - Jungclaus, Martin S AU - Jungclaus MS AUID- ORCID: 0009-0006-0595-7137 AD - Department of Neurology Hannover Medical School Hannover Germany. FAU - Barba, Lorenzo AU - Barba L AUID- ORCID: 0000-0003-1328-3620 AD - Department of Neurology Martin-Luther-University Halle-Wittenberg Halle (Saale) Germany. FAU - Otto, Markus AU - Otto M AUID- ORCID: 0000-0003-4273-4267 AD - Department of Neurology Martin-Luther-University Halle-Wittenberg Halle (Saale) Germany. FAU - Wilke, Florian AU - Wilke F AD - Department of Nuclear Medicine Hannover Medical School Hannover Germany. FAU - Ruhparwar, Arjang AU - Ruhparwar A AD - Department of Cardiac, Thoracic, Transplantation and Vascular Surgery Hannover Medical School Hannover Germany. FAU - Hanke, Jasmin S AU - Hanke JS AUID- ORCID: 0000-0002-1434-6905 AD - Department of Cardiac, Thoracic, Transplantation and Vascular Surgery Hannover Medical School Hannover Germany. FAU - Schmitto, Jan D AU - Schmitto JD AD - Department of Cardiac, Thoracic, Transplantation and Vascular Surgery Hannover Medical School Hannover Germany. FAU - Berliner, Dominik AU - Berliner D AUID- ORCID: 0000-0002-5710-3540 AD - Department of Cardiology and Angiology Hannover Medical School Hannover Germany. FAU - Derlin, Thorsten AU - Derlin T AUID- ORCID: 0000-0002-8786-4105 AD - Department of Nuclear Medicine Hannover Medical School Hannover Germany. AD - Institute of Radiology, Nuclear Medicine, and Molecular Imaging, Heart and Diabetes Center North Rhine-Westphalia, Ruhr University Bochum and Medical Faculty OWL (University Bielefeld) Bad Oeynhausen Germany. FAU - Werner, Rudolf A AU - Werner RA AUID- ORCID: 0000-0003-3372-6046 AD - Department of Nuclear Medicine Hannover Medical School Hannover Germany. AD - Department of Nuclear Medicine Ludwig-Maximilians-University of Munich Munich Germany. FAU - Bengel, Frank M AU - Bengel FM AUID- ORCID: 0000-0003-4529-7963 AD - Department of Nuclear Medicine Hannover Medical School Hannover Germany. FAU - Weissenborn, Karin AU - Weissenborn K AUID- ORCID: 0000-0002-1157-8938 AD - Department of Neurology Hannover Medical School Hannover Germany. FAU - Kahl, Kai G AU - Kahl KG AUID- ORCID: 0000-0002-8530-0605 AD - Department of Psychiatry, Social Psychiatry and Psychotherapy Hannover Medical School Hannover Germany. FAU - Hoffmeister, Julia AU - Hoffmeister J AD - Department of Psychiatry, Social Psychiatry and Psychotherapy Hannover Medical School Hannover Germany. FAU - Berding, Georg AU - Berding G AUID- ORCID: 0000-0001-5592-8373 AD - Department of Nuclear Medicine Hannover Medical School Hannover Germany. FAU - Worthmann, Hans AU - Worthmann H AD - Department of Neurology Hannover Medical School Hannover Germany. FAU - Weiberg, Desiree AU - Weiberg D AUID- ORCID: 0000-0002-0512-7954 AD - Department of Nuclear Medicine Hannover Medical School Hannover Germany. FAU - Gabriel, Maria M AU - Gabriel MM AUID- ORCID: 0000-0002-6862-5168 AD - Department of Neurology Hannover Medical School Hannover Germany. LA - eng PT - Journal Article DEP - 20260918 PL - England TA - J Am Heart Assoc JT - Journal of the American Heart Association JID - 101580524 RN - 0 (Biomarkers) RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18) RN - 0 (Glial Fibrillary Acidic Protein) RN - 0 (tau Proteins) RN - 0 (neurofilament protein L) RN - 0 (Neurofilament Proteins) RN - 0 (GFAP protein, human) RN - 0 (MAPT protein, human) RN - 0 (Radiopharmaceuticals) SB - IM MH - Humans MH - *Heart Failure/therapy/psychology/physiopathology/complications/blood MH - Female MH - Male MH - *Heart-Assist Devices/adverse effects MH - Biomarkers/blood MH - Middle Aged MH - Positron Emission Tomography Computed Tomography MH - Pilot Projects MH - *Brain/metabolism/diagnostic imaging MH - Prospective Studies MH - Cross-Sectional Studies MH - *Cognition MH - Chronic Disease MH - Fluorodeoxyglucose F18/administration & dosage MH - Glial Fibrillary Acidic Protein/blood MH - tau Proteins/blood MH - Aged MH - Neurofilament Proteins/blood MH - *Cognitive Dysfunction/etiology/psychology/diagnosis/blood MH - *Ventricular Function, Left MH - Radiopharmaceuticals/administration & dosage MH - Adult MH - *Brain Injuries/etiology/psychology OTO - NOTNLM OT - FDG-PET OT - brain metabolism OT - cognitive impairment OT - fluid biomarkers OT - left ventricular assist device EDAT- 2026/09/18 12:26 MHDA- 2026/10/08 05:31 CRDT- 2026/09/18 09:43 PHST- 2026/10/08 05:31 [medline] PHST- 2026/09/18 12:26 [pubmed] PHST- 2026/09/18 09:43 [entrez] AID - 10.1161/JAHA.125.043727 [doi] PST - ppublish SO - J Am Heart Assoc. 2026 Oct 6;15(19):e043727. doi: 10.1161/JAHA.125.043727. Epub 2026 Sep 18. PMID- 42756877 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260918 LR - 20260919 IS - 1680-5348 (Electronic) IS - 1020-4989 (Print) IS - 1020-4989 (Linking) VI - 50 DP - 2026 TI - 2025 AHA/ACC blood pressure guideline and HEARTS 2.0: implications for the future evolution of integrated cardiovascular-kidney-metabolic care in the Americas. PG - e85 LID - 10.26633/RPSP.2026.85 [doi] LID - e85 AB - Hypertension is the leading modifiable risk factor for cardiovascular disease. In 2025, two major evidence-based frameworks evolved in parallel: HEARTS 2.0, an implementation-oriented clinical pathway for integrated cardiovascular-kidney-metabolic (CKM) care through primary health care, and the updated American Heart Association/American College of Cardiology Blood Pressure Guideline, one of the world's leading hypertension guidelines. Although developed for different intended applications, both drew on a common and rapidly expanding evidence base, making it timely to examine their areas of convergence and divergence. Using the four operational domains of the HEARTS 2.0 Clinical Pathway, this article compares both approaches and examines their implications for the future evolution of integrated CKM care in the Americas. The analysis demonstrates substantial concordance across all domains, including accurate blood pressure measurement, risk-based care, simplified treatment protocols with early use of single-pill combinations, rapid treatment intensification, team-based care, and comprehensive CKM risk reduction. The few remaining differences should not be viewed as contradictions but as opportunities for future refinement. They primarily concern the diagnostic threshold for hypertension, the application of blood pressure targets below 130/80 mmHg, and emerging cardiometabolic therapies. These areas reflect ongoing debates and evolving evidence that may inform future updates of HEARTS 2.0, with adoption varying across countries according to context, feasibility, affordability, and implementation capacity. Overall, this comparison reinforces the scientific foundations of both frameworks and supports their interpretation as complementary and mutually reinforcing approaches for advancing the implementation of scalable, integrated CKM care in the Americas. FAU - DiPette, Donald J AU - DiPette DJ AUID- ORCID: 0000-0002-5762-9104 AD - University of South Carolina Floyd School of Medicine Prisma Health System-Midlands ColumbiaSouth Carolina United States of America University of South Carolina, Floyd School of Medicine, Prisma Health System-Midlands, Columbia, South Carolina, United States of America. FAU - Battle, Sean J AU - Battle SJ AUID- ORCID: 0009-0002-3056-2584 AD - University of South Carolina Floyd School of Medicine Prisma Health System-Midlands ColumbiaSouth Carolina United States of America University of South Carolina, Floyd School of Medicine, Prisma Health System-Midlands, Columbia, South Carolina, United States of America. FAU - Rosende, Andres AU - Rosende A AUID- ORCID: 0000-0001-8173-0686 AD - Department of Noncommunicable Diseases and Mental Health Pan American Health Organization Washington, DC United States of America Department of Noncommunicable Diseases and Mental Health, Pan American Health Organization, Washington, DC, United States of America. FAU - Brettler, Jeffrey AU - Brettler J AUID- ORCID: 0000-0002-2069-9643 AD - Department of Clinical Science Kaiser Permanente Bernard J. Tyson School of Medicine PasadenaCalifornia United States of America Department of Clinical Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California, United States of America. FAU - Jaffe, Marc G AU - Jaffe MG AUID- ORCID: 0000-0002-5049-7815 AD - Department of Endocrinology The Permanente Medical Group, Kaiser San Francisco Medical Center San FranciscoCalifornia United States of America Department of Endocrinology, The Permanente Medical Group, Kaiser San Francisco Medical Center, San Francisco, California, United States of America. FAU - Whelton, Paul K AU - Whelton PK AUID- ORCID: 0000-0002-2225-383X AD - Department of Epidemiology Tulane University Celia Scott Weatherhood School of Public Health and Tropical Medicine New OrleansLouisiana United States of America Department of Epidemiology, Tulane University Celia Scott Weatherhood School of Public Health and Tropical Medicine, New Orleans, Louisiana, United States of America. FAU - Ordunez, Pedro AU - Ordunez P AUID- ORCID: 0000-0002-9871-6845 AD - Department of Noncommunicable Diseases and Mental Health Pan American Health Organization Washington, DC United States of America Department of Noncommunicable Diseases and Mental Health, Pan American Health Organization, Washington, DC, United States of America. LA - eng PT - Journal Article DEP - 20260917 PL - United States TA - Rev Panam Salud Publica JT - Revista panamericana de salud publica = Pan American journal of public health JID - 9705400 PMC - PMC13584972 OTO - NOTNLM OT - Hypertension OT - cardiovascular diseases OT - health policy COIS- Conflicts of interest: None declared. EDAT- 2026/09/18 12:26 MHDA- 2026/09/18 12:27 PMCR- 2026/09/17 CRDT- 2026/09/18 08:04 PHST- 2026/07/02 00:00 [received] PHST- 2026/07/28 00:00 [accepted] PHST- 2026/09/18 12:27 [medline] PHST- 2026/09/18 12:26 [pubmed] PHST- 2026/09/18 08:04 [entrez] PHST- 2026/09/17 00:00 [pmc-release] AID - RPSP.2026.85 [pii] AID - 10.26633/RPSP.2026.85 [doi] PST - epublish SO - Rev Panam Salud Publica. 2026 Sep 17;50:e85. doi: 10.26633/RPSP.2026.85. eCollection 2026. PMID- 42756287 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260918 LR - 20260919 IS - 2050-0904 (Print) IS - 2050-0904 (Electronic) IS - 2050-0904 (Linking) VI - 14 IP - 9 DP - 2026 Sep TI - Metastatic Soft Tissue Sarcoma With Cardiac Involvement: A Case Study on the Role of Multimodal Imaging in Diagnosis and Management. PG - e72112 LID - 10.1002/ccr3.72112 [doi] LID - e72112 AB - This case highlights the critical role of multimodal imaging in diagnosing and managing rare cardiac metastasis from soft-tissue sarcoma, emphasizing the importance of early detection and a multidisciplinary approach to improve outcomes. CI - (c) 2026 The Author(s). Clinical Case Reports published by John Wiley & Sons Ltd. FAU - Alizadehasl, Azin AU - Alizadehasl A AD - Cardio-Oncology Research Center, Rajaie Cardiovascular, Medical, and Research Center, School of Medicine Iran University of Medical Sciences Tehran Iran. FAU - Akhavan, Sina AU - Akhavan S AD - Cardio-Oncology Research Center, Rajaie Cardiovascular, Medical, and Research Center, School of Medicine Iran University of Medical Sciences Tehran Iran. FAU - Jebelli, Seyedeh Fatemeh Hosseini AU - Jebelli SFH AD - Cardio-Oncology Research Center, Rajaie Cardiovascular, Medical, and Research Center, School of Medicine Iran University of Medical Sciences Tehran Iran. FAU - Najmabadi, Amirafraz Fallah AU - Najmabadi AF AD - Cardiovascular Research Center, Rajaie Cardiovascular, Medical and Research Center Iran University of Medical Sciences Tehran Iran. FAU - Marzbali, Nargeuss Abbaszade AU - Marzbali NA AD - Cardio-Oncology Research Center, Rajaie Cardiovascular, Medical, and Research Center, School of Medicine Iran University of Medical Sciences Tehran Iran. FAU - Yousefimoghaddam, Fateme AU - Yousefimoghaddam F AUID- ORCID: 0000-0002-6069-8151 AD - School of Medicine Shahid Beheshti University of Medical Sciences Tehran Iran. FAU - Haghazali, Mehrdad AU - Haghazali M AD - Cardiovascular Research Center, Rajaie Cardiovascular, Medical and Research Center Iran University of Medical Sciences Tehran Iran. FAU - Rafiei, Sajjad AU - Rafiei S AD - School of Medicine Birjand University of Medical Sciences Birjand Iran. LA - eng PT - Journal Article DEP - 20260916 PL - England TA - Clin Case Rep JT - Clinical case reports JID - 101620385 PMC - PMC13583055 COIS- The authors declare no conflicts of interest. EDAT- 2026/09/18 12:25 MHDA- 2026/09/18 12:26 PMCR- 2026/09/16 CRDT- 2026/09/18 07:08 PHST- 2025/01/22 00:00 [received] PHST- 2025/06/30 00:00 [revised] PHST- 2025/09/20 00:00 [accepted] PHST- 2026/09/18 12:26 [medline] PHST- 2026/09/18 12:25 [pubmed] PHST- 2026/09/18 07:08 [entrez] PHST- 2026/09/16 00:00 [pmc-release] AID - CCR372112 [pii] AID - 10.1002/ccr3.72112 [doi] PST - epublish SO - Clin Case Rep. 2026 Sep 16;14(9):e72112. doi: 10.1002/ccr3.72112. eCollection 2026 Sep. PMID- 42754842 OWN - NLM STAT- MEDLINE DCOM- 20260918 LR - 20260920 IS - 1471-227X (Electronic) IS - 1471-227X (Linking) VI - 26 IP - 1 DP - 2026 Sep 11 TI - ECPR readiness without perfusionist support: a cross-sectional national survey on circuit preparation, team structure, and training. LID - 10.1186/s12873-026-01766-7 [doi] LID - 253 AB - BACKGROUND: Extracorporeal cardiopulmonary resuscitation (ECPR) is a time-critical intervention for selected patients with refractory cardiac arrest. Survival depends on minimizing low-flow duration before ECPR initiation. Timely deployment requires organizational preparedness, trained personnel, and rapid extracorporeal membrane oxygenation (ECMO) circuit readiness. However, data on ECPR organization in centers operating without dedicated perfusionist support are limited. METHODS: A nationwide cross-sectional online survey was conducted among German ECMO centers operating without perfusionist support. The questionnaire assessed circuit readiness, responsible personnel, training frequency, and the availability of standard operating procedures (SOPs). RESULTS: Responses from 42 centers were evaluated, of which 64% reported performing ECPR (n = 27). Most centers (90%, n = 38) had low annual ECMO volumes (< 50 cases). ECMO use was largely limited to the Cardiohelp and iLA activve/Xenios Console systems. Setup times were significantly shorter for ECPR than for non-ECPR ECMO: median 15 min (IQR 12-18; range 5-30) versus 30 min (IQR 20-40; range 15-105) (Mann-Whitney U = 46, p < 0.0001; Cliff's delta = 0.77; 95% CI 0.54-0.94). Nurses were more frequently involved in ECMO deployment in ECPR than in non-ECPR settings (59% (16/27 centers) vs. 20% (3/15 centers)). Within ECPR programs, regular training was reported more frequently for nurses than for physicians (87.5% (14/16 centers) vs. 60% (6/10 centers)). Overall, 76% (n = 32) of centers reported regular training (at least annually) for responsible personnel, 86% (n = 36) had internal SOPs in place, and 69% (n = 29) expressed the need for a universally applicable evidence-based SOP. All centers that reported a pre-defined maximum storage duration (n = 28) adhered to the Extracorporeal Life Support Organization guidelines regarding maximum storage duration of pre-assembled ECMO systems (30 days). CONCLUSIONS: German ECMO centers without perfusionist support reported substantial heterogeneity in ECPR readiness and operational workflows. ECPR-performing centers were associated with shorter setup times and more frequently reported interdisciplinary team structures and recurrent team training. These findings describe current organizational practices and perceived needs and support the value of interdisciplinary teamwork, structured training, and standardized protocols as organizational components that may facilitate timely, standardized ECPR deployment. CI - (c) 2026. The Author(s). FAU - Mishuris, Eva AU - Mishuris E AD - Department of Anaesthesiology, Medical Faculty, University Hospital RWTH Aachen, Pauwelsstrasse 30, 52074, Aachen, Germany. FAU - Wallraff, Alexander AU - Wallraff A AUID- ORCID: 0009-0007-4779-1443 AD - Department of Heart Surgery, Medical Faculty, University Hospital RWTH Aachen, Pauwelsstrasse 30, 52074, Aachen, Germany. FAU - Kopp, Rudger AU - Kopp R AD - Department of Intensive Care, Medical Faculty, University Hospital RWTH Aachen, Pauwelsstrasse 30, 52074, Aachen, Germany. FAU - Larmann, Jan AU - Larmann J AUID- ORCID: 0000-0003-3365-4572 AD - Department of Anaesthesiology, Medical Faculty, University Hospital RWTH Aachen, Pauwelsstrasse 30, 52074, Aachen, Germany. FAU - Strudthoff, Lasse J AU - Strudthoff LJ AUID- ORCID: 0000-0002-6810-6317 AD - Biorheology Research Laboratory, Griffith University, 1 Parklands Dr, Southport, Gold Coast, QLD, 4215, Australia. FAU - Bleilevens, Christian AU - Bleilevens C AUID- ORCID: 0000-0002-2104-1843 AD - Department of Anaesthesiology, Medical Faculty, University Hospital RWTH Aachen, Pauwelsstrasse 30, 52074, Aachen, Germany. FAU - Winnersbach, Patrick AU - Winnersbach P AUID- ORCID: 0000-0001-6979-6818 AD - Department of Anaesthesiology, Medical Faculty, University Hospital RWTH Aachen, Pauwelsstrasse 30, 52074, Aachen, Germany. pwinnersbach@ukaachen.de. LA - eng PT - Journal Article DEP - 20260911 PL - England TA - BMC Emerg Med JT - BMC emergency medicine JID - 100968543 SB - IM MH - *Extracorporeal Membrane Oxygenation/methods/statistics & numerical data/standards/education MH - Cross-Sectional Studies MH - Humans MH - *Cardiopulmonary Resuscitation/methods/education MH - Germany MH - Surveys and Questionnaires MH - *Heart Arrest/therapy MH - *Patient Care Team/organization & administration PMC - PMC13587460 OTO - NOTNLM OT - Extracorporeal cardiopulmonary resuscitation (ECPR) OT - Extracorporeal membrane oxygenation (ECMO) OT - Pre-assembly OT - Pre-priming OT - Standard operating procedures (SOPs) OT - Team structure OT - Training COIS- Declarations. Ethics approval and consent to participate: This study was conducted in accordance with the principles of the Declaration of Helsinki. The study protocol was reviewed by the Ethics Committee of the Medical Faculty of RWTH Aachen University (reference number EK 24-118). The Ethics Committee concluded that, due to the anonymous design of the online survey as a quality assurance measure, formal ethics approval was not required and that there were no ethical or professional concerns regarding the conduct of the study. Participation in the anonymous survey was voluntary. Completion and submission of the questionnaire were considered to indicate consent to participate. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2026/09/18 05:36 MHDA- 2026/09/18 05:37 PMCR- 2026/09/11 CRDT- 2026/09/17 23:59 PHST- 2026/05/27 00:00 [received] PHST- 2026/08/31 00:00 [accepted] PHST- 2026/09/18 05:37 [medline] PHST- 2026/09/18 05:36 [pubmed] PHST- 2026/09/17 23:59 [entrez] PHST- 2026/09/11 00:00 [pmc-release] AID - 10.1186/s12873-026-01766-7 [pii] AID - 1766 [pii] AID - 10.1186/s12873-026-01766-7 [doi] PST - epublish SO - BMC Emerg Med. 2026 Sep 11;26(1):253. doi: 10.1186/s12873-026-01766-7. PMID- 42752378 OWN - NLM STAT- MEDLINE DCOM- 20261029 LR - 20261029 IS - 0392-856X (Print) IS - 0392-856X (Linking) VI - 44 IP - 10 DP - 2026 Oct TI - Cardiac involvement in Behcet's disease: a comprehensive state-of-the-art review. PG - 2140-2152 LID - 10.55563/clinexprheumatol/6h353p [doi] AB - Behcet's disease (BD) is a chronic multisystemic inflammatory vasculitis which can cause cardiac involvement in less than 6%. It can affect all cardiac wall giving rise to pericarditis, myocarditis, endocardial lesions with valvular involvement (especially aortic insufficiency), intracardiac thrombosis, coronary arteritis, myocardial infarcts, arrythmia, and aortitis. Clinical presentation can be confusing, silent, or overshadowed, so diagnosis is frequently delayed. Early diagnosis is mandatory and different imaging techniques play a pivotal role to screen the heart. Biological agents, including tumour necrosis factor inhibitors, show promising results. Cardiac surgery must be accompanied by immunosuppressive therapy to prevent iatrogenic or trauma-triggered pseudo aneurysm secondary to arterial hypersensitivity. A multidisciplinary approach and tailored monitoring are essential to improve patient outcome. Strong data are still lacking to define evidence-based diagnostic algorithms, risk-stratification tools, and standardised management strategies for this severe cardiac manifestation. Besides, further studies are needed to determine specific biomarkers to refine early diagnosis, assess therapeutic efficiency, and prognosis. Through a comprehensive literature review, we aim to synthesise current data on the epidemiology, clinical presentation, contemporary imaging modalities, prognosis, and evidence‑based management strategies of cardiac involvement in BD, and to highlight emerging perspectives. FAU - Belfeki, Nabil AU - Belfeki N AD - Department of Internal Medicine and Clinical Immunology, Groupe Hospitalier Sud Ile de France, Melun, France. nabil.belfeki@ghsif.fr. FAU - Ghriss, Nouha AU - Ghriss N AD - Department of Internal Medicine and Clinical Immunology, Groupe Hospitalier Sud Ile de France, Melun, France. FAU - Jebri, Faten AU - Jebri F AD - Department of Cardiology, Polyclinique de l'Europe, Saint Nazaire, France. FAU - Hamrouni, Houssem AU - Hamrouni H AD - Department of Imaging, Groupe Hospitalier Sud Ile de France, Melun, France. FAU - Hatemi, Gulen AU - Hatemi G AD - Department of Internal Medicine, Division of Rheumatology, Istanbul University-Cerrahpasa Hospital, Istanbul, Turkey. FAU - Mekinian, Arsene AU - Mekinian A AD - Department of Internal Medicine and Inflammation-Immunopathology-Biotherapy (DHUi2B), Hopital Saint Antoine, Assistance Publique des Hopitaux de Paris, Sorbonne Universites, UPMC University, Paris, France. LA - eng PT - Journal Article PT - Review DEP - 20260904 PL - Italy TA - Clin Exp Rheumatol JT - Clinical and experimental rheumatology JID - 8308521 RN - 0 (Immunosuppressive Agents) SB - IM MH - Humans MH - *Behcet Syndrome/epidemiology/therapy/complications/diagnosis MH - *Heart Diseases/therapy/epidemiology/diagnosis/etiology MH - Immunosuppressive Agents/therapeutic use MH - Predictive Value of Tests MH - Risk Factors MH - Prognosis MH - Early Diagnosis MH - Treatment Outcome EDAT- 2026/09/17 18:32 MHDA- 2026/10/29 15:19 CRDT- 2026/09/17 15:39 PHST- 2026/02/07 00:00 [received] PHST- 2026/04/10 00:00 [accepted] PHST- 2026/10/29 15:19 [medline] PHST- 2026/09/17 18:32 [pubmed] PHST- 2026/09/17 15:39 [entrez] AID - 23641 [pii] AID - 10.55563/clinexprheumatol/6h353p [doi] PST - ppublish SO - Clin Exp Rheumatol. 2026 Oct;44(10):2140-2152. doi: 10.55563/clinexprheumatol/6h353p. Epub 2026 Sep 4. PMID- 42746691 OWN - NLM STAT- MEDLINE DCOM- 20260916 LR - 20260918 IS - 2054-1058 (Electronic) IS - 2054-1058 (Linking) VI - 13 IP - 9 DP - 2026 Sep TI - Effectiveness of an Information Platform-Based Multidisciplinary Enhanced Recovery After Surgery Program on Recovery After Transcatheter Aortic Valve Implantation: A Non-Concurrent Controlled Study. PG - e70838 LID - 10.1002/nop2.70838 [doi] LID - e70838 AB - AIM: To evaluate the implementation effectiveness of a multicomponent multidisciplinary Enhanced Recovery After Surgery pathway integrated with an information platform for patients undergoing transcatheter aortic valve implantation. DESIGN: A single-center quasi-experimental study with a non-concurrent historical control group. METHODS: A single-center quasi-experimental study with a non-concurrent historical control group included 154 patients. Outcomes were assessed using a study-specific transcatheter aortic valve implantation knowledge questionnaire, the Fried frailty phenotype, Barthel Index, 12-Item Short Form Health Survey, 6-min walk test, left ventricular ejection fraction and hospital length of stay. Between-group comparisons used independent-samples t-tests, Mann-Whitney U tests and chi(2) tests, as appropriate. Post hoc gamma regression and generalized estimating equations were used in sensitivity analyses addressing measurable temporal differences between treatment periods. RESULTS: Patients treated after pathway implementation showed greater procedural knowledge, less postoperative frailty, greater functional independence, shorter hospitalization and more favourable functional and health-status outcomes. The association with shorter hospitalization persisted after adjustment for measured patient and procedural characteristics, whereas the longitudinal difference in left ventricular systolic function was attenuated after adjustment. CONCLUSION: Implementation of the multicomponent pathway was associated with better functional recovery and shorter hospitalization after transcatheter aortic valve implantation. Component-specific effects and residual temporal confounding cannot be excluded. IMPLICATIONS FOR THE PROFESSION AND/OR PATIENT CARE: Extending structured education and rehabilitation support from hospital to home may help nurses coordinate recovery and continuity of care after transcatheter aortic valve implantation. IMPACT: This study provides implementation evidence for a digitally supported multidisciplinary recovery pathway after transcatheter aortic valve implantation. REPORTING METHOD: The study was reported in accordance with the Transparent Reporting of Evaluations with Nonrandomized Designs statement. PATIENT OR PUBLIC CONTRIBUTION: There was no patient or public contribution to the design, analysis, interpretation, or preparation of this study. CI - (c) 2026 The Author(s). Nursing Open published by John Wiley & Sons Ltd. FAU - Lin, Shaoping AU - Lin S AD - Department of Nursing, Jinshazhou Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China. FAU - Feng, Cuicui AU - Feng C AD - Department of Nursing, Jinshazhou Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China. FAU - Lin, Lian AU - Lin L AD - Department of Nursing, Jinshazhou Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China. FAU - Liu, Jiezhen AU - Liu J AD - Department of Nursing, Jinshazhou Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China. FAU - Guan, Meizhen AU - Guan M AD - Department of Nursing, Jinshazhou Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China. FAU - Li, Jiaxin AU - Li J AD - Department of Nursing, Jinshazhou Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China. FAU - Lin, Fangfang AU - Lin F AUID- ORCID: 0009-0009-7251-4709 AD - Department of Nursing, Jinshazhou Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China. LA - eng PT - Journal Article PL - United States TA - Nurs Open JT - Nursing open JID - 101675107 SB - IM MH - Humans MH - *Transcatheter Aortic Valve Replacement/rehabilitation/methods MH - Female MH - Male MH - Aged, 80 and over MH - Aged MH - Length of Stay/statistics & numerical data MH - Surveys and Questionnaires MH - Recovery of Function PMC - PMC13579374 OTO - NOTNLM OT - aortic stenosis OT - digital health platform OT - enhanced recovery after surgery (ERAS) OT - multidisciplinary team OT - patient recovery OT - transcatheter aortic valve implantation (TAVI) COIS- No generative artificial intelligence (AI) tools were used in the preparation, writing, editing, analysis, or revision of this manuscript. Statistical Declaration: The authors have checked to ensure that this submission conforms, as applicable, to the statistical guidelines of Nursing Open. The statistical analyses were reviewed prior to submission by an expert statistician, Fangfang Lin (18928803701@163.com). The review included the descriptive and comparative analyses and the post hoc sensitivity analyses using gamma regression and generalized estimating equations. The authors affirm that the statistical methods were appropriately selected and applied within the context of the non-concurrent study design and that the statistical findings were implemented and interpreted correctly. The authors accept responsibility for the appropriateness, conduct and interpretation of all statistical analyses reported in this manuscript. The authors declare no conflicts of interest. EDAT- 2026/09/16 11:41 MHDA- 2026/09/16 11:42 PMCR- 2026/09/16 CRDT- 2026/09/16 06:25 PHST- 2026/08/07 00:00 [revised] PHST- 2026/05/12 00:00 [received] PHST- 2026/09/03 00:00 [accepted] PHST- 2026/09/16 11:42 [medline] PHST- 2026/09/16 11:41 [pubmed] PHST- 2026/09/16 06:25 [entrez] PHST- 2026/09/16 00:00 [pmc-release] AID - NOP270838 [pii] AID - 10.1002/nop2.70838 [doi] PST - ppublish SO - Nurs Open. 2026 Sep;13(9):e70838. doi: 10.1002/nop2.70838. PMID- 42740616 OWN - NLM STAT- MEDLINE DCOM- 20260915 LR - 20260917 IS - 1365-2834 (Electronic) IS - 0966-0429 (Print) IS - 0966-0429 (Linking) VI - 2026 IP - 1 DP - 2026 TI - Development of Job Standards for Nurse-Led Rapid Response Teams in the Republic of Korea. PG - e8558376 LID - 10.1155/jonm/8558376 [doi] LID - 8558376 AB - BACKGROUND: Nurse-led rapid response teams (RRTs) significantly improve patient safety. However, the absence of specific job standards can precipitate role ambiguity and compromise care quality. Therefore, establishing tailored job standards that reflect the distinct healthcare context of the Republic of Korea is imperative to optimize RRT performance and clinical outcomes. AIM: To identify nurses' activities in nurse-led RRTs and to develop job standards that define the desired performance levels of RRT nurses and enable task evaluation within the Korean healthcare context. METHODS: This study used a two-step methodological approach, guided by a conceptual framework integrating Hamric's advanced practice nursing model with nine Korean advanced practice nursing core competency domains: (1) identifying the nursing activities of nurse-led RRTs through an integrative evidence review, benchmarking of domestic and international institutions, and in-depth interviews with domestic nurses; and (2) developing draft standards and validating them through a two-round Delphi survey and field verification of practical suitability. RESULTS: A total of 210 potential activities were initially identified and refined into 55 nursing activities across nine core competency domains: advanced nursing practice, education, counseling, consultation, ethical decision-making, research, collaboration, evidence-based practice, and leadership. Draft job standards comprising 9 standards, 16 criteria, and 53 indicators were developed and validated through a two-round Delphi survey with eight experts; after Round 1 revisions and two added indicators, all items met the retention criteria in Round 2 (I-CVI >/= 0.88, mean I-CVI = 0.96, S-CVI/Ave = 0.94). In field verification with 62 RRT nurses across 19 hospitals nationwide, all items showed practical suitability above 90%, and 9 standards, 16 criteria, and 55 indicators were ultimately confirmed. These standards integrate internationally accepted competency frameworks while reflecting the distinctive Korean context, such as EMR-based screening and the absence of independent nurse prescriptive authority. CONCLUSION: This study identified nurse-led RRT work activities and developed job standards for desired performance levels of RRT nurses. This provides a foundational framework for performance evaluation and continuous quality improvement. As a methodological study, it did not empirically test clinical outcomes; rather, the developed standards may support future outcome evaluations using metrics, such as cardiac arrest rates, unplanned ICU admissions, and failure-to-rescue, and may thereby provide a basis for advancing nursing care quality and professionalism in managing ward patient deterioration. IMPLICATIONS FOR NURSING MANAGEMENT: The job standards provide practical guidance for new and experienced RRT nurses and offer a foundation for defining job skills, structuring task instructions, workforce planning, and conducting performance evaluations across diverse hospital environments, while also informing qualification criteria. They may also serve as a useful framework to inform future empirical research evaluating the impact of nurse-led RRTs on patient outcomes. To support consistent adoption, a phased implementation strategy involving nursing associations, professional bodies, and the Ministry of Health and Welfare is proposed. CI - Copyright (c) 2026 Ju-Ry Lee et al. Journal of Nursing Management published by John Wiley & Sons Ltd. FAU - Lee, Ju-Ry AU - Lee JR AUID- ORCID: 0000-0002-2376-9141 AD - Department of Nursing, Geoje University, Geoje 53325, Gyeongsangnam-do, South Korea. FAU - Lee, Ju Hee AU - Lee JH AUID- ORCID: 0000-0002-2805-1622 AD - Yonsei University Mo-Im Kim Nursing Research Institute, 50 Yonsei-ro Seodaemun-gu, Seoul 03722, South Korea. FAU - Jang, Yeon Soo AU - Jang YS AUID- ORCID: 0000-0002-1898-025X AD - Yonsei University Mo-Im Kim Nursing Research Institute, 50 Yonsei-ro Seodaemun-gu, Seoul 03722, South Korea. FAU - Kim, Yeon Hee AU - Kim YH AUID- ORCID: 0000-0002-9409-7354 AD - University of Ulsan Department of Clinical Nursing, 88 Olympic-ro 43-gil, Seoul 05505, South Korea. FAU - Oh, Eui Geum AU - Oh EG AUID- ORCID: 0000-0002-6941-0708 AD - Yonsei University Mo-Im Kim Nursing Research Institute, 50 Yonsei-ro Seodaemun-gu, Seoul 03722, South Korea. LA - eng PT - Journal Article PL - England TA - J Nurs Manag JT - Journal of nursing management JID - 9306050 SB - IM MH - Humans MH - Republic of Korea MH - *Hospital Rapid Response Team/standards/organization & administration MH - Surveys and Questionnaires MH - Delphi Technique MH - Clinical Competence/standards PMC - PMC13575639 OTO - NOTNLM OT - clinical competence OT - hospital rapid response team OT - nurse specialists OT - patient outcomes OT - standards COIS- The authors declare no conflicts of interest. EDAT- 2026/09/15 05:36 MHDA- 2026/09/15 11:37 PMCR- 2026/09/15 CRDT- 2026/09/15 03:44 PHST- 2026/08/05 00:00 [revised] PHST- 2025/03/05 00:00 [received] PHST- 2026/08/06 00:00 [accepted] PHST- 2026/09/15 11:37 [medline] PHST- 2026/09/15 05:36 [pubmed] PHST- 2026/09/15 03:44 [entrez] PHST- 2026/09/15 00:00 [pmc-release] AID - JONM8558376 [pii] AID - 10.1155/jonm/8558376 [doi] PST - ppublish SO - J Nurs Manag. 2026;2026(1):e8558376. doi: 10.1155/jonm/8558376. PMID- 42739824 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260915 LR - 20260916 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 15 IP - 17 DP - 2026 Sep 3 TI - Sex Disparities in Outcomes After Minimally Invasive Direct CABG for Single-Vessel Disease: A Propensity Score-Matched Analysis. LID - 10.3390/jcm15176821 [doi] LID - 6821 AB - Background: Female sex is widely regarded as an independent risk factor for adverse outcomes after conventional coronary artery bypass grafting (CABG) and is incorporated as a risk variable in EuroSCORE II. Whether this disadvantage persists in the setting of minimally invasive direct coronary artery bypass (MIDCAB), in which sternotomy and cardiopulmonary bypass are avoided, remains insufficiently characterised. We assessed sex-specific short- and long-term outcomes after MIDCAB in a single-centre cohort with extended follow-up. Methods: We retrospectively analysed 350 consecutive patients who underwent MIDCAB at Hannover Medical School between July 1999 and April 2025 (follow-up to April 2025). Eligibility criteria and heart team-applied exclusion criteria (prior left thoracotomy, unfavourable LAD anatomy, prohibitive respiratory reserve, hostile chest wall, active endocarditis, or haemodynamic instability requiring on-pump revascularization) are detailed in the Methods. Females (n = 102) and males (n = 248) were compared before and after 1:1 propensity score matching using greedy nearest-neighbour matching with a caliper of 0.2 x SD of the logit propensity score. The primary endpoint was all-cause long-term mortality; secondary endpoints included perioperative complications and in-hospital outcomes. Long-term survival was assessed by Kaplan-Meier analysis and multivariable Cox proportional hazards regression performed in the full unmatched cohort. A pre-specified subgroup analysis of long-term survival by coronary disease pattern (single-vessel vs. multivessel disease) was also performed. Results: Matching produced 100 female-male pairs with excellent covariate balance (all standardized mean differences < 0.20). MIDCAB was completed without intraoperative conversion in all patients. Thirty-day mortality was 0% in both sexes; no postoperative stroke or new requirement for dialysis occurred. New-onset atrial fibrillation (3.0% vs. 1.0%, p = 0.621), length of intensive care unit stay (median 1 day in both groups), and hospital length of stay (median 8 days in both groups) were comparable between females and males. Re-exploration for bleeding was numerically more frequent in women (5.0% vs. 0.0%; Newcombe 95% CI for the risk difference +0.3 to +11.2%; Fisher's exact p = 0.059). At a median follow-up of 19.0 years (IQR 11.8-23.9), all-cause mortality was identical (12.0% vs. 12.0%, p = 1.000; log-rank p = 0.703). In multivariable Cox regression in the full unmatched cohort, female sex was not associated with long-term mortality (adjusted HR 0.80, 95% CI 0.38-1.70, p = 0.560); only advancing age emerged as a strong independent predictor (HR 1.10 per year, 95% CI 1.05-1.15, p < 0.001), with EuroSCORE II approaching significance (HR 1.67 per unit, 95% CI 1.00-2.82, p = 0.052). Long-term survival in patients with multivessel disease (20-year Kaplan-Meier 90.9%) was equivalent to that in single-vessel disease (92.3%; log-rank p = 0.94). Conclusions: In this propensity-matched analysis with two decades of follow-up, MIDCAB conferred equivalent perioperative safety and long-term survival in women and men. Female sex was not an independent predictor of adverse outcome. These findings support MIDCAB as a sex-neutral revascularization strategy for single-vessel and LAD-predominant coronary artery disease in the very low-risk, appropriately selected population studied, and are consistent with the most recent published MIDCAB literature. FAU - Amanov, Lukman AU - Amanov L AD - Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany. FAU - Arjomandi Rad, Arian AU - Arjomandi Rad A AUID- ORCID: 0000-0002-4931-4049 AD - Department of Cardiothoracic Surgery, Oxford Heart Centre, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 9DU, UK. FAU - Ali-Hasan-Al-Saegh, Sadeq AU - Ali-Hasan-Al-Saegh S AD - Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany. FAU - Salman, Jawad AU - Salman J AD - Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany. FAU - Ius, Fabio AU - Ius F AD - Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany. FAU - Tahir, Abdullah AU - Tahir A AD - Department of Trauma and Orthopedics, University Hospitals of North Midlands NHS Trust, Stoke-on-Trent ST4 6QG, UK. FAU - Athanasiou, Thanos AU - Athanasiou T AD - Department of Surgery and Cancer, Imperial College London, London SW7 2AZ, UK. FAU - Torabi, Saeed AU - Torabi S AUID- ORCID: 0000-0003-0646-0465 AD - Department of Anesthesiology and Intensive Care Medicine, Medical Faculty of Cologne University, University Hospital of Cologne, 50937 Cologne, Germany. FAU - Rumke, Stefan AU - Rumke S AD - Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany. FAU - Schmack, Bastian AU - Schmack B AD - Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany. FAU - Ruhparwar, Arjang AU - Ruhparwar A AUID- ORCID: 0000-0003-2725-9912 AD - Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany. FAU - Zubarevich, Alina AU - Zubarevich A AD - Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany. FAU - Weymann, Alexander AU - Weymann A AD - Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany. LA - eng PT - Journal Article DEP - 20260903 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC13566088 OTO - NOTNLM OT - MIDCAB OT - coronary revascularization OT - gender OT - left anterior descending artery OT - long-term survival OT - minimally invasive direct coronary artery bypass OT - propensity score matching OT - sex COIS- The authors declare no conflicts of interest. EDAT- 2026/09/15 05:36 MHDA- 2026/09/15 05:37 PMCR- 2026/09/03 CRDT- 2026/09/15 03:25 PHST- 2026/07/07 00:00 [received] PHST- 2026/08/22 00:00 [revised] PHST- 2026/08/26 00:00 [accepted] PHST- 2026/09/15 05:37 [medline] PHST- 2026/09/15 05:36 [pubmed] PHST- 2026/09/15 03:25 [entrez] PHST- 2026/09/03 00:00 [pmc-release] AID - jcm15176821 [pii] AID - jcm-15-06821 [pii] AID - 10.3390/jcm15176821 [doi] PST - epublish SO - J Clin Med. 2026 Sep 3;15(17):6821. doi: 10.3390/jcm15176821. PMID- 42736572 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260915 LR - 20260916 IS - 2586-7296 (Electronic) IS - 2586-7210 (Print) VI - 34 IP - 1 DP - 2026 Sep 14 TI - Pulmonary hypertension in pregnancy: hemodynamic challenges, maternal risk, and multidisciplinary management. LID - 10.1186/s44348-026-00096-3 [doi] LID - 33 AB - Pulmonary hypertension (PH) during pregnancy remains a high-risk clinical condition because normal gestational cardiovascular adaptation may exceed the reserve of the right ventricular (RV)-pulmonary circulation unit. Pregnancy is characterized by progressive increases in plasma volume, heart rate, stroke volume, and cardiac output, together with a reduction in systemic vascular resistance. These changes become particularly hazardous during labor, delivery, and the early postpartum period, when abrupt shifts in preload, venous return, and filling pressures may precipitate RV failure, hypoxemia, arrhythmia, or circulatory collapse. However, pregnancy-related risk in PH is heterogeneous and depends on the underlying PH phenotype, pulmonary vascular disease severity, RV function, oxygenation, and access to expert multidisciplinary care. This review summarizes the hemodynamic challenges of pregnancy in women with PH, phenotype-specific maternal and fetal risks, contemporary outcome data, treatment considerations, delivery planning, and postpartum management. Particular emphasis is placed on the first 24 to 72 h postpartum as a vulnerable period of hemodynamic stress and on the role of imaging, particularly echocardiographic surveillance, in identifying maladaptive RV responses and guiding timely escalation of care. CI - (c) 2026. The Author(s). FAU - Chang, Sung-A AU - Chang SA AUID- ORCID: 0000-0001-5124-605X AD - Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. elisabet.chang@gmail.com. AD - Pulmonary Hypertension Center, Heart Vascular Stroke Institute, Samsung Medical Center, Seoul, Republic of Korea. elisabet.chang@gmail.com. LA - eng PT - Journal Article PT - Review DEP - 20260914 PL - England TA - J Cardiovasc Imaging JT - Journal of cardiovascular imaging JID - 101728106 PMC - PMC13573449 OTO - NOTNLM OT - Diagnostic Imaging OT - Echocardiography OT - Patient Care Team OT - Postpartum Period OT - Pregnancy OT - Pulmonary Hypertension OT - Ventricular Function, Right COIS- Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: The authors declare that they have no competing interests. EDAT- 2026/09/15 05:36 MHDA- 2026/09/15 05:37 PMCR- 2026/09/14 CRDT- 2026/09/15 03:08 PHST- 2026/06/28 00:00 [received] PHST- 2026/08/12 00:00 [accepted] PHST- 2026/09/15 05:37 [medline] PHST- 2026/09/15 05:36 [pubmed] PHST- 2026/09/15 03:08 [entrez] PHST- 2026/09/14 00:00 [pmc-release] AID - 10.1186/s44348-026-00096-3 [pii] AID - 96 [pii] AID - 10.1186/s44348-026-00096-3 [doi] PST - epublish SO - J Cardiovasc Imaging. 2026 Sep 14;34(1):33. doi: 10.1186/s44348-026-00096-3. PMID- 37983343 STAT- Publisher CTDT- 20260913 PB - StatPearls Publishing DP - 2026 Jan TI - Evinacumab. BTI - StatPearls AB - Homozygous familial hypercholesterolemia is a rare hereditary lipid disorder characterized by markedly elevated low-density lipoprotein cholesterol levels and early risk of atherosclerotic cardiovascular disease, myocardial infarction, stroke, and aortic valve disease. Evinacumab is an angiopoietin-like protein 3 inhibitor approved as adjunctive therapy for patients aged 1 year and older with homozygous familial hypercholesterolemia. Many clinicians remain unfamiliar with its low-density lipoprotein receptor-independent mechanism, appropriate patient selection, administration requirements, safety considerations, monitoring needs, and role within combination lipid-lowering therapy. This activity addresses that gap by reviewing diagnostic criteria, therapeutic indications, dosing, pharmacokinetics, adverse effects, contraindications, toxicity considerations, and team-based care. Participants are expected to gain practical skills in identifying eligible patients, applying evidence-based treatment strategies, monitoring response and safety, preventing complications, counseling patients, and coordinating care among clinicians, nurses, pharmacists, and specialists. CI - Copyright (c) 2026, StatPearls Publishing LLC. FAU - Patel, Neal T AU - Patel NT AD - Broward Health Medical Center FAU - Parmar, Mayur AU - Parmar M AD - Nova Southeastern University FAU - Patel, Preeti AU - Patel P LA - eng PT - Study Guide PT - Book Chapter PL - Treasure Island (FL) COIS- Disclosure: Neal T Patel declares no relevant financial relationships with ineligible companies. Disclosure: Mayur Parmar declares no relevant financial relationships with ineligible companies. Disclosure: Preeti Patel declares no relevant financial relationships with ineligible companies. EDAT- 2026/09/13 00:00 CRDT- 2026/09/13 00:00 AID - NBK597342 [bookaccession] PMID- 42726829 OWN - NLM STAT- MEDLINE DCOM- 20260911 LR - 20260911 IS - 1426-9686 (Print) IS - 1426-9686 (Linking) VI - 54 IP - 4 DP - 2026 TI - Factors assosmall es, Cyrilliciated with ocular structural changes inherent to pseudoexfoliation syndrome among Ukrainian patients. PG - 472-477 LID - 10.36740/Merkur202604114 [doi] AB - OBJECTIVE: Aim: To identify factors associated with ocular structural changes inherent to PEX among Ukrainian patients. PATIENTS AND METHODS: Materials and capital EM, Cyrillicethods: The study was based on a clinical examination of 56 patients (112 eyes) aged 14 to 88 years. The main group included 39 patients (78 eyes) with ocular structural changes confirming the diagnosis of PEX: 14 patients (28 eyes) and 25 patients (50 eyes) with uni- and bilateral lateral involvement, respectively. The control group consisted of 17 patients (34 eyes) without any signs of PEX. The follow-up period was 5 years. RESULTS: Results: The findings of the study support the concept of PEX as a systemic fibrillopathy, accompanied by a significant association with chronic coronary syndrome (64%), joint pathology (72%), diabetes mellitus (40%), and central nervous system (56%) disorders compared with the control group. Environmental factors, particularly urbanization (52%) and increased radiation background (64%), are likely additional contributors to disease development. The study demonstrated that bilateral PEX is accompanied by changes in eye structures: pronounced trabecular pigmentation (48%), a critical decrease in corneal endothelial cell density (80%), progression of age-related macular degeneration (40-44%), and the development of posterior subcapsular cataract (96%). In contrast, patients with unilateral PEX demonstrated a significantly higher long-term risk of nuclear cataract progression. CONCLUSION: Conclusions: Managing patients with PEX necessitates a comprehensive multidisciplinary approach in view of the associated comorbidities and contributing factors. The clinical course of unilateral PEX is strongly linked to exposure to exogenous triggers (urbanization, increased background radiation, and tobacco smoking). The absolute majority of eyes with bilateral PEX showed biomechanical weakness of the sclera and cornea. FAU - Kolot, Nataliia M AU - Kolot NM AD - BOGOMOLETS NATIONAL MEDICAL UNIVERSITY, KYIV, UKRAINE. FAU - Shargorodska, Iryna V AU - Shargorodska IV AD - BOGOMOLETS NATIONAL MEDICAL UNIVERSITY, KYIV, UKRAINE. FAU - Ivaniuta, Pavla P AU - Ivaniuta PP AD - BOGOMOLETS NATIONAL MEDICAL UNIVERSITY, KYIV, UKRAINE. FAU - Kovalov, Ivan A AU - Kovalov IA AD - BOGOMOLETS NATIONAL MEDICAL UNIVERSITY, KYIV, UKRAINE. FAU - Averyanova, Oksana S AU - Averyanova OS AD - AILAS MEDICAL CENTER, KYIV, UKRAINE. LA - eng PT - Journal Article PL - Poland TA - Pol Merkur Lekarski JT - Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego JID - 9705469 SB - IM MH - Humans MH - *Exfoliation Syndrome/pathology/complications/epidemiology MH - Aged, 80 and over MH - Female MH - Male MH - Middle Aged MH - Aged MH - Ukraine/epidemiology MH - Adult MH - Adolescent MH - Young Adult MH - Risk Factors OTO - NOTNLM OT - cataract OT - disease laterality OT - pseudoexfoliation syndrome EDAT- 2026/09/11 17:36 MHDA- 2026/09/11 17:37 CRDT- 2026/09/11 14:03 PHST- 2026/09/11 17:37 [medline] PHST- 2026/09/11 17:36 [pubmed] PHST- 2026/09/11 14:03 [entrez] AID - 10.36740/Merkur202604114 [doi] PST - ppublish SO - Pol Merkur Lekarski. 2026;54(4):472-477. doi: 10.36740/Merkur202604114. PMID- 42724769 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260911 LR - 20260912 IS - 2284-2594 (Electronic) IS - 2284-2594 (Linking) VI - 13 IP - 9 DP - 2026 TI - Vaginal Agenesis (Mayer-Rokitansky-Kuster-Hauser Syndrome) Presenting with Exertional Dyspnoea, Fatigue and Intermittent Palpitations. PG - 007349 LID - 10.12890/2026_007349 [doi] LID - 007349 AB - INTRODUCTION: Mayer-Rokitansky-Kuster-Hauser (MRKH) syndrome represents a spectrum of Mullerian duct anomalies. MRKH type I involves isolated agenesis of the uterus and vagina, while MRKH type II involves extra-genital defects most commonly affecting the skeletal, renal, cardiovascular and auditory systems with functional ovaries along with agenesis of the uterus and vagina. CASE DESCRIPTION: A 19-year-old female presented with exertional dyspnoea, fatigue and intermittent palpitations for the last 2 years. Clinical evaluation revealed a classic machinery murmur at the left second intercostal space, suspecting the diagnosis of patent ductus arteriosus (PDA), which was confirmed by two-dimensional echocardiography. She also presented with primary amenorrhea, for which an ultrasound of the abdomen and pelvis was done, which showed a rudimentary uterus and absence of the upper third of the vagina with normal ovaries. Hence, a diagnosis of MRKH syndrome type II was made. A cardiac computed tomography scan revealed a persistent left superior vena cava (PLSVC), which is a rare association in an MRKH patient. There was also the presence of an extrarenal pelvis seen on a kidney, ureter, bladder (KUB) X-ray. CONCLUSION: This case highlights the rare association of MRKH syndrome type II with PDA, PLSVC, and the extrarenal pelvis, emphasising the need for comprehensive multisystem evaluation. These patients need effective counselling regarding sexual well-being and appropriate management of extra genital manifestations. LEARNING POINTS: Mayer-Rokitansky-Kuster-Hauser (MRKH) Type II is a multisystem congenital syndrome that requires comprehensive evaluation. A multidisciplinary approach is essential, involving gynaecology, cardiology, nephrology and radiology.Rare cardiovascular anomalies can coexist with MRKH type II, like patent ductus arteriosus and persistent left superior vena cava (PLSVC). PLSVC may be asymptomatic in a patient, but it is important to know because it can make certain procedures more challenging, like pacemaker insertion, intra-cardiac device implantation, left-sided central line placement and cardiac surgeries. A card should be given to these patients in case they need such procedures.An extra-renal pelvis is a benign congenital condition which does not need treatment. Generally, it is asymptomatic, but sometimes it increases the risk of urinary tract infection (UTI) due to slowed urine flow, so such patients should be monitored for UTI and have renal function tests regularly. CI - (c) EFIM 2026. FAU - Dave, Priti AU - Dave P AD - Department of Medicine, Symbiosis Medical College for Women (SMCW), Symbiosis International (Deemed) University (SIU), Pune, India. FAU - Sharma, Sakshi AU - Sharma S AD - Department of Medicine, Symbiosis Medical College for Women (SMCW), Symbiosis International (Deemed) University (SIU), Pune, India. FAU - Nagarkar, Manasi AU - Nagarkar M AD - Department of Medicine, Symbiosis Medical College for Women (SMCW), Symbiosis International (Deemed) University (SIU), Pune, India. FAU - Saklecha, Abhishek AU - Saklecha A AD - Department of Medicine, Symbiosis Medical College for Women (SMCW), Symbiosis International (Deemed) University (SIU), Pune, India. FAU - Jagtap, Atharva AU - Jagtap A AD - Department of Medicine, Symbiosis Medical College for Women (SMCW), Symbiosis International (Deemed) University (SIU), Pune, India. LA - eng PT - Journal Article DEP - 20260821 PL - Italy TA - Eur J Case Rep Intern Med JT - European journal of case reports in internal medicine JID - 101648453 PMC - PMC13561142 OTO - NOTNLM OT - MRKH type II OT - Mullerian agenesis OT - extrarenal pelvis OT - patent ductus arteriosus OT - persistent left superior vena cava COIS- Conflicts of Interests: The Authors declare that there are no competing interests. EDAT- 2026/09/11 11:38 MHDA- 2026/09/11 11:39 PMCR- 2026/08/21 CRDT- 2026/09/11 10:33 PHST- 2026/07/15 00:00 [received] PHST- 2026/07/27 00:00 [accepted] PHST- 2026/09/11 11:39 [medline] PHST- 2026/09/11 11:38 [pubmed] PHST- 2026/09/11 10:33 [entrez] PHST- 2026/08/21 00:00 [pmc-release] AID - 7349 [pii] AID - 10.12890/2026_007349 [doi] PST - epublish SO - Eur J Case Rep Intern Med. 2026 Aug 21;13(9):007349. doi: 10.12890/2026_007349. eCollection 2026. PMID- 42723617 OWN - NLM STAT- Publisher LR - 20260911 IS - 2753-670X (Electronic) IS - 2753-670X (Linking) DP - 2026 Sep 10 TI - Development of the first quality assessment framework for the endocarditis multi-disciplinary team meeting. LID - ivag219 [pii] LID - 10.1093/icvts/ivag219 [doi] AB - OBJECTIVE: Endocarditis is increasing in incidence with substantial morbidity and mortality. The endocarditis multi-disciplinary team (MDT) is a core guideline recommendation with clear patient outcome benefits by expediting diagnosis, coordinating investigations and management. There is significant variability in content and specialist input, with no validated metric available to assess decision-making or demonstrate improvement over time. MDT-MODe (Metric-for-the-Observation-of-Decision-making) is a validated quality assessment tool extensively utilised for cancer MDTs. This paper describes adaptation of the psychometrically tested MDT-MODe to an endocarditis setting, resulting in the development of MDT-MODIE (Metric-for-the-Observation-of-Decision-making for Infective-Endocarditis). METHODS: An expert interview panel was engaged at a single high-volume London centre. Domains were assessed and analysed using a content validity index, through which final MDT-MODIE was defined. Feasibility testing was conducted during MDTs between September 2024 - April 2025. Inter-rater reliability was assessed using intraclass correlation coefficients (ICC), while internal validation was evaluated through point-biserial correlation coefficients. Statistical analyses performed using IBM SPSS Statistics (version29.0). RESULTS: Domains scored as excellent or good were included in MDT-MODIE. Feasibility and reliability testing was performed with 152 patient discussions assessed, and scores matched to decision outcomes for each patient. Inter-rater reliability confirmed across all domains (p < 0.001). Internal Validation demonstrated a positive correlation between overall MODIE scores and MDT decision-making outcomes (rpb(96)=.216, p=0.033). CONCLUSIONS: MDT-MODIE provides a reliable framework for evaluating endocarditis MDT decision-making, which has undergone preliminary validation. It addresses a key gap in the literature, supporting cardiac centres in assessing quality of guideline-recommended MDTs and monitoring improvement over time. CI - (c) The Author(s) 2026. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. FAU - Rizzo, Victoria AU - Rizzo V AD - Cardiothoracic Surgery, St Bartholomew's Hospital, Barts-Health NHS Trust. FAU - Raevsky, Evgeny AU - Raevsky E AD - Cardiothoracic Surgery, St Bartholomew's Hospital, Barts-Health NHS Trust. FAU - Primus, Christopher AU - Primus C AD - Cardiology, St Bartholomew's Hospital, Barts-Health NHS Trust. FAU - Davies, Ceri AU - Davies C AD - Cardiology, St Bartholomew's Hospital, Barts-Health NHS Trust. FAU - Das, Satya AU - Das S AD - Microbiology and Infectious Disease, St Bartholomew's Hospital, Barts-Health NHS Trust. FAU - Suarez, Cristina AU - Suarez C AD - Microbiology and Infectious Disease, St Bartholomew's Hospital, Barts-Health NHS Trust. FAU - Ambekar, Shirish AU - Ambekar S AD - Cardiothoracic Surgery, St Bartholomew's Hospital, Barts-Health NHS Trust. FAU - Roberts, Neil AU - Roberts N AD - Cardiothoracic Surgery, St Bartholomew's Hospital, Barts-Health NHS Trust. FAU - Marczin, Nandor AU - Marczin N AD - Department of Surgery and Cancer, Imperial College London. FAU - Uppal, Rakesh AU - Uppal R AD - Cardiothoracic Surgery, St Bartholomew's Hospital, Barts-Health NHS Trust. FAU - Lall, Kulvinder AU - Lall K AD - Cardiothoracic Surgery, St Bartholomew's Hospital, Barts-Health NHS Trust. FAU - Woldman, Simon AU - Woldman S AD - Cardiology, St Bartholomew's Hospital, Barts-Health NHS Trust. FAU - Athanasiou, Thanos AU - Athanasiou T AD - Department of Surgery and Cancer, Imperial College London. FAU - Soukup, Tayana AU - Soukup T AD - Department of Surgery and Cancer, Imperial College London. LA - eng PT - Journal Article DEP - 20260910 PL - England TA - Interdiscip Cardiovasc Thorac Surg JT - Interdisciplinary cardiovascular and thoracic surgery JID - 9918540787006676 SB - IM OTO - NOTNLM OT - Endocarditis OT - Multi-Disciplinary-Team OT - Quality assessment framework EDAT- 2026/09/11 11:38 MHDA- 2026/09/11 11:38 CRDT- 2026/09/11 05:03 PHST- 2026/03/15 00:00 [received] PHST- 2026/05/28 00:00 [revised] PHST- 2026/07/13 00:00 [accepted] PHST- 2026/09/11 11:38 [medline] PHST- 2026/09/11 11:38 [pubmed] PHST- 2026/09/11 05:03 [entrez] AID - 8790339 [pii] AID - 10.1093/icvts/ivag219 [doi] PST - aheadofprint SO - Interdiscip Cardiovasc Thorac Surg. 2026 Sep 10:ivag219. doi: 10.1093/icvts/ivag219. PMID- 42719501 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260910 LR - 20260911 IS - 2090-6404 (Print) IS - 2090-6412 (Electronic) IS - 2090-6404 (Linking) VI - 2026 DP - 2026 TI - Tricuspid Valve Infective Endocarditis With Biventricular Thrombi: An Unusual Presentation. PG - 2016181 LID - 10.1155/cric/2016181 [doi] LID - 2016181 AB - BACKGROUND: Biventricular thrombi (BVT) is a rare presentation associated with high morbidity and mortality due to the potential sequela of life-threatening complications including embolic events and cardiac failure. As an uncommon entity, there is limited research on best practice for the management of BVT. PRESENTATION: We present a case of BVT with Streptococcus anginosus and Staphylococcus hominis concomitant bloodstream infection, tricuspid valve infective endocarditis (TVIE), septic emboli and decompensated dilated cardiomyopathy (LVEF 20%-25%). Guideline directed heart failure management, antimicrobials and anticoagulation were initiated with a remarkable recovery within 2 months. DISCUSSION: Given the rarity of this presentation, a multidisciplinary approach was taken to guide management. Follow-up echocardiography after completion of antimicrobial therapy demonstrated an LVEF of 53%, no detectable thrombus and resolution of congestive symptoms. Although there is minimal population-based evidence, this case supports a conservative approach for the treatment of TVIE, BVT and its potential sequelae in select patients. CI - Copyright (c) 2026 Genevieve Phipps et al. Case Reports in Cardiology published by John Wiley & Sons Ltd. FAU - Phipps, Genevieve AU - Phipps G AUID- ORCID: 0000-0002-4087-5608 AD - Department of Cardiology, Cairns Hospital, Cairns, Queensland, Australia, health.qld.gov.au. FAU - Singh, Sarteg AU - Singh S AD - Department of Respiratory Medicine, Gold Coast University Hospital, Gold Coast, Queensland, Australia, qld.gov.au. FAU - Preston, Shane AU - Preston S AD - Department of Cardiology, Cairns Hospital, Cairns, Queensland, Australia, health.qld.gov.au. LA - eng PT - Journal Article DEP - 20260908 PL - United States TA - Case Rep Cardiol JT - Case reports in cardiology JID - 101576452 PMC - PMC13554727 COIS- The authors declare no conflicts of interest. EDAT- 2026/09/10 11:53 MHDA- 2026/09/10 11:54 PMCR- 2026/09/08 CRDT- 2026/09/10 08:16 PHST- 2026/02/05 00:00 [received] PHST- 2026/08/07 00:00 [revised] PHST- 2026/08/28 00:00 [accepted] PHST- 2026/09/10 11:54 [medline] PHST- 2026/09/10 11:53 [pubmed] PHST- 2026/09/10 08:16 [entrez] PHST- 2026/09/08 00:00 [pmc-release] AID - CRIC2016181 [pii] AID - 10.1155/cric/2016181 [doi] PST - epublish SO - Case Rep Cardiol. 2026 Sep 8;2026:2016181. doi: 10.1155/cric/2016181. eCollection 2026. PMID- 42717057 OWN - NLM STAT- Publisher LR - 20260910 IS - 1759-5053 (Electronic) IS - 1759-5045 (Linking) DP - 2026 Sep 9 TI - Heart-liver co-management in MASLD: expert perspectives and recommendations from a multidisciplinary cardiometabolic framework. LID - 10.1038/s41575-026-01255-z [doi] AB - Metabolic dysfunction-associated steatotic liver disease (MASLD) is recognized as a systemic metabolic disorder with marked cardiovascular implications, as cardiovascular disease is a leading cause of death. Despite non-invasive diagnostic tests, such as the fibrosis-4 index and vibration-controlled transient elastography, and the availability of resmetirom and emerging pharmacotherapies with dual liver and cardiovascular benefits (for example, glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors), substantial gaps in coordinated clinical management remain. MASLD is often under-recognized in cardiology, and the cardiovascular risk associated with MASLD is similarly under-appreciated in hepatology practice, resulting in fragmented care and a lack of integrated management pathways. This discrepancy leads to missed opportunities for early intervention and suboptimal outcomes in the progression of both hepatic and cardiovascular diseases. To address these gaps, a more collaborative, multidisciplinary approach is needed, integrating early screening, risk stratification and coordinated management across specialities. In this Expert Recommendation, we outline key considerations for heart-liver co-management in MASLD, propose practical strategies for screening and risk stratification, and discuss pathways to implement coordinated multidisciplinary care in clinical practice within a structured metabolic care framework. CI - (c) 2026. Springer Nature Limited. FAU - Zhou, Xiao-Dong AU - Zhou XD AUID- ORCID: 0000-0002-8534-0818 AD - MAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. AD - Key Laboratory of Diagnosis and Treatment for the Development of Chronic Liver Disease in Zhejiang Province, Wenzhou, Zhejiang, China. FAU - Jeong, Seogsong AU - Jeong S AUID- ORCID: 0000-0003-4646-8998 AD - Department of Biomedical Informatics, Korea University College of Medicine, Seoul, Korea. AD - Biomedical Research Center, Korea University Guro Hospital, Seoul, Korea. FAU - Chen, Qin-Fen AU - Chen QF AUID- ORCID: 0000-0001-6596-5004 AD - Medical Care Center, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China. AD - Institute of Aging, The Center for Geriatric Medicine, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China. FAU - Targher, Giovanni AU - Targher G AUID- ORCID: 0000-0002-4325-3900 AD - Department of Medicine, University of Verona, Verona, Italy. AD - Metabolic Diseases Research Unit, IRCCS Sacro Cuore - Don Calabria Hospital, Negrar di Valpolicella, Italy. FAU - Byrne, Christopher D AU - Byrne CD AUID- ORCID: 0000-0001-6322-7753 AD - Southampton National Institute for Health and Care Research Biomedical Research Centre, University Hospital Southampton, and University of Southampton, Southampton General Hospital, Southampton, UK. FAU - Chew, Nicholas W S AU - Chew NWS AD - Department of Cardiology, National University Heart Centre, National University Health System, Singapore, Singapore. AD - Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. FAU - Younossi, Zobair M AU - Younossi ZM AD - The Global NASH/MASH Council, Center for Outcomes Research in Liver Diseases, Washington, DC, USA. FAU - Lip, Gregory Y H AU - Lip GYH AUID- ORCID: 0000-0002-7566-1626 AD - Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, UK. AD - Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. AD - Medical University of Bialystok, Bialystok, Poland. FAU - Tilg, Herbert AU - Tilg H AUID- ORCID: 0000-0002-4235-2579 AD - Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology and Metabolism, Medical University Innsbruck, Innsbruck, Austria. FAU - George, Jacob AU - George J AUID- ORCID: 0000-0002-8421-5476 AD - Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Sydney, New South Wales, Australia. FAU - Stefan, Norbert AU - Stefan N AUID- ORCID: 0000-0002-2186-9595 AD - Department of Internal Medicine IV, University Hospital Tubingen, Tubingen, Germany. AD - Institute of Diabetes Research and Metabolic Diseases, Helmholtz Centre Munich, Tubingen, Germany. AD - German Center for Diabetes Research, Neuherberg, Germany. FAU - Sperling, Laurence S AU - Sperling LS AD - Division of Cardiology, Department of Medicine, Emory Clinical Cardiovascular Research Institute; and Emory University School of Medicine, Atlanta, GA, USA. FAU - Luu, Hung N AU - Luu HN AD - Dr. Mary and Ron Neal Cancer Center, Houston Methodist Research Institute, Houston, TX, USA. AD - Weill Cornell Medicine, Cornell University, New York, NY, USA. FAU - Fudim, Marat AU - Fudim M AUID- ORCID: 0000-0002-8671-7007 AD - Duke University Medical Center; and Duke Clinical Research Institute, Durham, NC, USA. FAU - Loomba, Rohit AU - Loomba R AD - MASLD Research Center, Division of Gastroenterology and Hepatology, Department of Medicine, University of California at San Diego, La Jolla, CA, USA. FAU - Zheng, Ming-Hua AU - Zheng MH AUID- ORCID: 0000-0003-4984-2631 AD - MAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. zhengmh@wmu.edu.cn. AD - Key Laboratory of Diagnosis and Treatment for the Development of Chronic Liver Disease in Zhejiang Province, Wenzhou, Zhejiang, China. zhengmh@wmu.edu.cn. LA - eng PT - Journal Article PT - Review DEP - 20260909 PL - England TA - Nat Rev Gastroenterol Hepatol JT - Nature reviews. Gastroenterology & hepatology JID - 101500079 SB - IM COIS- Competing interests: M.-H.Z. serves as a speaker for AstraZeneca, Hisky Medical Technologies and Novo Nordisk; serves as a consultant for Boehringer Ingelheim and Eieling Technology; and has received consulting fees from Boehringer Ingelheim. C.D.B. has received research funding from Echosens. Z.M.Y. has received research funding and/or serves as a consultant or adviser to Intercept, Cymabay, Boehringer Ingelheim, Ipsen, BMS, GSK, Novo Nordisk, Siemens, Madridgal, Merck, Aligos, Akero, Sanofi and Abbott. N.S. received fees for consultancy and giving scientific talks from Allergan, AstraZeneca, Boehringer Ingelheim, Gilead, Genkyotex, GSK, Intercept Pharma, Lilly, Merck Sharpe & Dohme, Novartis, Novo Nordisk, Pfizer and Sanofi; and received research support from AstraZeneca, Sanofi, DSM Nutritional Products and Roche Diagnostics. J.G. has served on advisory boards and receives honoraria for talks from Novo Nordisk, AstraZeneca, Roche, BMS, Pfizer, Cincera, Pharmaxis, Boehringer Mannheim, CSL, Norgine, Gilead and Eisai. R.L. serves as a consultant to Aardvark Therapeutics, Altimmune, Arrowhead Pharmaceuticals, AstraZeneca, Cascade Pharmaceuticals, Eli Lilly, Gilead, Glympse bio, Inipharma, Intercept, Inventiva, Ionis, Janssen Inc., Lipidio, Madrigal, Neurobo, Novo Nordisk, Merck, Pfizer, Sagimet, 89bio, Takeda, Terns Pharmaceuticals and Viking Therapeutics; and has stock options in Sagimet Biosciences; in addition, his institution received research grants from Arrowhead Pharmaceuticals, Astrazeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Galectin Therapeutics, Gilead, Intercept, Hanmi, Intercept, Inventiva, Ionis, Janssen, Madrigal Pharmaceuticals, Merck, Novo Nordisk, Pfizer, Sonic Incytes and Terns Pharmaceuticals. G.Y.H.L. is a National Institute for Health and Care Research (NIHR) Senior Investigator; and has been a consultant and speaker for Bristol-Myers Squibb-Pfizer, Boehringer Ingelheim, Daiichi and Anthos. M.F. was supported by the NIH, Alleviant, Gradient, Reprieve, Sardocor, Tenax and the Doris Duke Foundation; serves as a consultant for and/or has ownership interests in Abbott, Acorai, Ajax, Alio Health, Alleviant, Artha, Astellas, Audicor, Axon Therapies, Bodyguide, Bodyport, Boston Scientific, Broadview, Cadence, Cardiosense, Cardioflow, Clinical Accelerator, CVRx, Daxor, Edwards LifeSciences, Echosens, Endotronix, Feldschuh Foundation, Fire1, FlowMod, FutureCardia, Gradient, Hatteras, HemodynamiQ, Impulse Dynamics, ISHI, Lumia Health, Medtronic, Novo Nordisk, NucleusRx, Omega, Orchestra, Parasym, Pharmacosmos, Presidio, Procyreon, Proton Intelligence, Puzzle, ReCor, Scirent, SCPharma, Shifamed, Splendo, Summacor, SyMap, Terumo, Vifor Pharma, Vironix, Viscardia and Zol. The other authors declare no conflicts of interests. EDAT- 2026/09/10 05:36 MHDA- 2026/09/10 05:36 CRDT- 2026/09/10 01:27 PHST- 2026/08/18 00:00 [accepted] PHST- 2026/09/10 05:36 [medline] PHST- 2026/09/10 05:36 [pubmed] PHST- 2026/09/10 01:27 [entrez] AID - 10.1038/s41575-026-01255-z [pii] AID - 10.1038/s41575-026-01255-z [doi] PST - aheadofprint SO - Nat Rev Gastroenterol Hepatol. 2026 Sep 9. doi: 10.1038/s41575-026-01255-z. PMID- 42716272 OWN - NLM STAT- Publisher LR - 20260909 IS - 1552-6259 (Electronic) IS - 0003-4975 (Linking) DP - 2026 Sep 9 TI - Emerging Longer-Term Evidence on Transcatheter Aortic Valve Implantation for Severe Aortic Stenosis in Low-Risk Patients: A Call for Caution. LID - S0003-4975(26)00894-5 [pii] LID - 10.1016/j.athoracsur.2026.08.016 [doi] AB - The expanding use of transcatheter aortic valve implantation (TAVI) in low-risk patients with severe aortic stenosis, including populations underrepresented in pivotal trials and often beyond established guideline recommendations, makes extended follow-up from TAVI versus surgical aortic valve replacement (SAVR) trials central to assessing valve durability and late adverse events and to informing lifetime management strategy. Although Evolut Low Risk 6- to 7-year follow-up showed no statistically significant difference in the primary composite of death or disabling stroke, the signals of later mortality accrual, more myocardial infarction events, and higher aortic valve reintervention rates with TAVI raise concerns about durability and stability of the early treatment effect. In PARTNER 3, 7-year outcomes appeared broadly similar when comparing the reported composite endpoints, but their interpretation is limited by heterogeneous endpoint construction, non-prespecified hierarchical analysis, incomplete follow-up, and the influence of post hoc vital-status ascertainment on late mortality estimates. In an intermediate-risk population, PARTNER 2A showed lower 10-year survival and higher aortic valve reintervention rates with TAVI than with SAVR. Together with the presented UK-TAVI, meta-analyses, and large observational studies, these findings underscore uncertainty about durability and reintervention burden of TAVI and future treatment strategies. By integrating extended follow-up from pivotal trials with other new data, this review calls for a more rigorous and transparent long-term evidence framework before further expanding TAVI, particularly in younger, low-risk patients. Treatment decisions should remain individualized within a structured Heart Team framework, with explicit discussion of expected survival, anatomical suitability, valve durability, reintervention options, and lifetime-management implications. CI - Copyright (c) 2026. Published by Elsevier Inc. FAU - Sousa Uva, Miguel AU - Sousa Uva M AD - Department of Cardio-thoracic Surgery, Hospital de Santa Cruz, Carnaxide, Portugal; RISE-Health, Porto Medical School, University of Porto, Portugal. Electronic address: migueluva@gmail.com. FAU - Milojevic, Milan AU - Milojevic M AD - Department of Cardiac Surgery and Cardiovascular Research, Dedinje Cardiovascular Institute, Belgrade, Serbia; Department of Cardiac Surgery, University Hospital Zurich, University of Zurich, Zurich, Switzerland. FAU - Marin-Cuartas, Mateo AU - Marin-Cuartas M AD - University Department of Cardiac Surgery, Leipzig Heart Center, Leipzig, Germany. FAU - Kaul, Sanjay AU - Kaul S AD - Department of Cardiology, Cedars-Sinai Medical Centre, Los Angeles, CA, USA. FAU - De Caterina, Raffaele AU - De Caterina R AD - Division of Cardiology, Pisa University Hospital and University of Pisa, Pisa, Italy. FAU - Redberg, Rita AU - Redberg R AD - Division of Cardiology, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA. FAU - Heuts, Samuel AU - Heuts S AD - Department of Cardiothoracic Surgery, Maastricht University Medical Center, Maastricht, the Netherlands; Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, the Netherlands. FAU - Doenst, Torsten AU - Doenst T AD - Department of Cardiothoracic Surgery, Jena University Hospital, Friedrich-Schiller-University of Jena, Jena, Germany. FAU - Dayan, Victor AU - Dayan V AD - Hospital de Clinicas, Universidad de la Republica, Montevideo, Uruguay. FAU - Siepe, Matthias AU - Siepe M AD - Department of Cardiac Surgery, University Hospital Bern, Inselspital, University of Bern, Bern, Switzerland. FAU - Badhwar, Vinay AU - Badhwar V AD - Department of Cardiovascular and Thoracic Surgery, West Virginia University, Morgantown, WV, USA. FAU - Falk, Volkmar AU - Falk V AD - Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charite, Charite University Medicine Berlin, Germany; DZHK (German Center for Cardiovascular Research) partner site, Berlin, Germany. FAU - Borger, Michael A AU - Borger MA AD - University Department of Cardiac Surgery, Leipzig Heart Center, Leipzig, Germany. FAU - Myers, Patrick O AU - Myers PO AD - Department of Cardiac Surgery, University Hospital Zurich, University of Zurich, Zurich, Switzerland. FAU - Sadaba, Rafael AU - Sadaba R AD - Department of Cardiac Surgery, Navarra University Hospital, Pamplona, Spain; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain. LA - eng PT - Journal Article PT - Review DEP - 20260909 PL - Netherlands TA - Ann Thorac Surg JT - The Annals of thoracic surgery JID - 15030100R SB - IM EDAT- 2026/09/09 23:36 MHDA- 2026/09/09 23:36 CRDT- 2026/09/09 19:12 PHST- 2026/04/27 00:00 [received] PHST- 2026/07/16 00:00 [revised] PHST- 2026/08/19 00:00 [accepted] PHST- 2026/09/09 23:36 [medline] PHST- 2026/09/09 23:36 [pubmed] PHST- 2026/09/09 19:12 [entrez] AID - S0003-4975(26)00894-5 [pii] AID - 10.1016/j.athoracsur.2026.08.016 [doi] PST - aheadofprint SO - Ann Thorac Surg. 2026 Sep 9:S0003-4975(26)00894-5. doi: 10.1016/j.athoracsur.2026.08.016. PMID- 42713201 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260909 LR - 20260910 IS - 2045-8932 (Print) IS - 2045-8940 (Electronic) IS - 2045-8932 (Linking) VI - 16 IP - 3 DP - 2026 Jul TI - Invasive Management for Acute-on-Chronic Thromboembolic Pulmonary Hypertension: Feasibility and Clinical Outcomes in a Single-Center Cohort. PG - e70407 LID - 10.1002/pul2.70407 [doi] LID - e70407 AB - Acute-on-chronic thromboembolic pulmonary hypertension (acute-on-CTEPH) is associated with rapid clinical deterioration, yet the role of invasive intervention in the acute phase remains poorly defined. We retrospectively analyzed consecutive patients with acute-on-CTEPH presenting with severe hypoxemia and/or cardiogenic shock at a single center between 2023 and 2026. Acute-on-CTEPH was defined as acute clinical deterioration requiring ventilatory or circulatory support, including ECMO, with imaging evidence of chronic thromboembolic disease and superimposed acute thrombi. Invasive strategies included pulmonary endarterectomy (PEA) and/or balloon pulmonary angioplasty (BPA), selected based on multidisciplinary assessment. The primary outcome was change in pulmonary hemodynamics; secondary outcomes included acute-phase mortality and clinical recovery after stabilization. A total of 15 patients (median age 69 years; 53% male), all in World Health Organization functional class IV, were included. Mechanical ventilation and ECMO were required in 53% and 47% of patients, respectively. Initial treatment consisted of PEA (40%) or BPA (60%), with combined approaches in selected cases. Acute-phase mortality was 20%. Among survivors, mean pulmonary artery pressure decreased from 42 to 17 mmHg, pulmonary vascular resistance from 11.6 to 2.4 WU, and cardiac index increased from 1.7 to 2.7 L/min/m(2). Among patients requiring ECMO, 5 were successfully weaned and 4 survived to discharge. At follow-up, 11 of the 12 survivors were in WHO functional class I or II, and 8 (67%) had discontinued home oxygen therapy. Despite substantial acute-phase mortality, invasive strategies were associated with marked hemodynamic improvement and may represent a potential therapeutic option in this life-threatening clinical setting. CI - (c) 2026 The Author(s). Pulmonary Circulation published by John Wiley & Sons Ltd on behalf of Pulmonary Vascular Research Institute. FAU - Yamashita, Jun AU - Yamashita J AUID- ORCID: 0000-0002-0620-1685 AD - Department of Cardiology Tokyo Medical University Tokyo Japan. FAU - Ito, Ryosuke AU - Ito R AUID- ORCID: 0000-0001-6546-3696 AD - Department of Cardiology Tokyo Medical University Tokyo Japan. FAU - Ikeda, Sayo AU - Ikeda S AUID- ORCID: 0009-0000-5799-0445 AD - Department of Cardiology Tokyo Medical University Tokyo Japan. FAU - Hasegawa, Koki AU - Hasegawa K AD - Department of Cardiology Tokyo Medical University Tokyo Japan. FAU - Takeuchi, Yoshikazu AU - Takeuchi Y AUID- ORCID: 0009-0007-5523-5375 AD - Department of Cardiology Tokyo Medical University Tokyo Japan. FAU - Kasahara, Tomohiro AU - Kasahara T AUID- ORCID: 0009-0000-4077-7197 AD - Department of Cardiology Tokyo Medical University Tokyo Japan. FAU - Murata, Naotaka AU - Murata N AD - Department of Cardiology Tokyo Medical University Tokyo Japan. FAU - Suzuki, Shun AU - Suzuki S AD - Department of Cardiovascular Surgery Tokyo Medical University Tokyo Japan. FAU - Kanazawa, Hideaki AU - Kanazawa H AUID- ORCID: 0000-0002-0934-3910 AD - Department of Cardiology Tokyo Medical University Tokyo Japan. FAU - Shimahara, Yusuke AU - Shimahara Y AD - Department of Cardiovascular Surgery Tokyo Medical University Tokyo Japan. FAU - Satomi, Kazuhiro AU - Satomi K AUID- ORCID: 0000-0001-6858-8523 AD - Department of Cardiology Tokyo Medical University Tokyo Japan. LA - eng PT - Journal Article DEP - 20260908 PL - United States TA - Pulm Circ JT - Pulmonary circulation JID - 101557243 PMC - PMC13551590 OTO - NOTNLM OT - acute-on-chronic thromboembolic pulmonary hypertension OT - balloon pulmonary angioplasty OT - extracorporeal membrane oxygenation OT - pulmonary endarterectomy COIS- Jun Yamashita reports grants from Abbott Medical Japan and WIN International and personal fees from Kaneka Medix, Boston Scientific Japan, Nihon Kohden, Nippon Shinyaku, Mallinckrodt Pharma, AstraZeneca, and Kowa Company outside the submitted work. Ryosuke Ito, Sayo Ikeda, Hideaki Kanazawa, Naotaka Murata, Tomohiro Kasahara, Koki Hasegawa, and Yoshikazu Takeuchi are affiliated with an endowed department supported by funding from Abbott Medical Japan and WIN International. Shun Suzuki, Yusuke Shimahara, and Kazuhiro Satomi have no conflicts of interest to declare. EDAT- 2026/09/09 11:38 MHDA- 2026/09/09 11:39 PMCR- 2026/09/08 CRDT- 2026/09/09 07:23 PHST- 2026/06/01 00:00 [received] PHST- 2026/07/29 00:00 [revised] PHST- 2026/09/01 00:00 [accepted] PHST- 2026/09/09 11:39 [medline] PHST- 2026/09/09 11:38 [pubmed] PHST- 2026/09/09 07:23 [entrez] PHST- 2026/09/08 00:00 [pmc-release] AID - PUL270407 [pii] AID - 10.1002/pul2.70407 [doi] PST - epublish SO - Pulm Circ. 2026 Sep 8;16(3):e70407. doi: 10.1002/pul2.70407. eCollection 2026 Jul. PMID- 42709333 OWN - NLM STAT- MEDLINE DCOM- 20260908 LR - 20261008 IS - 1534-3170 (Electronic) IS - 1523-3782 (Linking) VI - 28 IP - 1 DP - 2026 Sep 8 TI - TAVR Explant in the Era of Lifetime Valve Management: Indications, Operative Challenges, and Contemporary Outcomes. LID - 91 [pii] LID - 10.1007/s11886-026-02412-1 [doi] AB - PURPOSE OF REVIEW: This review summarizes contemporary evidence on transcatheter aortic valve replacement (TAVR) explantation, emphasizing epidemiology, indications, operative challenges, outcomes, risk prediction, and implications for lifetime valve management. RECENT FINDINGS: As TAVR expands to younger and lower-risk patients, explantation is becoming an increasingly relevant component of lifetime valve care. Recent systematic reviews, registries, national databases, and center experiences show that TAVR explant is technically complex, frequently requires concomitant procedures, and carries early mortality that exceeds conventional risk predictions. TAVR-in-TAVR is feasible in selected patients with structural valve degeneration but may be limited by infection, small annulus, coronary obstruction risk, or impaired future coronary access. TAVR explant should be considered during index valve selection. Heart Team planning should incorporate durability, coronary access, annular size, redo-TAVR feasibility, and surgical explant complexity, particularly in younger patients. CI - (c) 2026. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Lopez-Trevino, Maria G AU - Lopez-Trevino MG AD - Department of Cardiovascular Surgery, Houston Methodist DeBakey Heart & Vascular Center, Houston Methodist Hospital, 6565 Fannin Street, Houston, TX, 77030, USA. mglopeztrevino@houstonmethodist.org. FAU - Szekely, Marcell AU - Szekely M AD - Department of Cardiovascular Surgery, Houston Methodist DeBakey Heart & Vascular Center, Houston Methodist Hospital, 6565 Fannin Street, Houston, TX, 77030, USA. FAU - Ramirez-Del Val, Fernando AU - Ramirez-Del Val F AD - Department of Cardiovascular Surgery, Houston Methodist DeBakey Heart & Vascular Center, Houston Methodist Hospital, 6565 Fannin Street, Houston, TX, 77030, USA. FAU - Reardon, Michael J AU - Reardon MJ AD - Department of Cardiovascular Surgery, Houston Methodist DeBakey Heart & Vascular Center, Houston Methodist Hospital, 6565 Fannin Street, Houston, TX, 77030, USA. LA - eng PT - Journal Article PT - Review DEP - 20260908 PL - United States TA - Curr Cardiol Rep JT - Current cardiology reports JID - 100888969 SB - IM MH - Humans MH - *Transcatheter Aortic Valve Replacement/methods MH - *Aortic Valve Stenosis/surgery MH - *Aortic Valve/surgery MH - *Device Removal/methods MH - Heart Valve Prosthesis MH - Treatment Outcome MH - Risk Factors MH - Reoperation OTO - NOTNLM OT - Lifetime valve management OT - Redo-TAVR OT - Structural valve deterioration OT - Surgical explantation OT - TAVR explant OT - Transcatheter aortic valve replacement COIS- Declarations. Competing interests: Michael J. Reardon reports personal fees from Medtronic, Boston Scientific, Abbott Medical, and Edwards Lifesciences, outside the submitted work. The other authors declare that they have no conflict of interest. Use of artificial intelligence: Artificial intelligence (AI) tools were used solely for language and grammar editing. AI was not used to generate scientific content, analyze or interpret data, create figures or tables, or draw conclusions. All content was reviewed and approved by the authors, who take full responsibility for the final manuscript. Human and animal rights and informed consent: This article does not contain any studies with human, or animal subjects performed by any of the authors. EDAT- 2026/09/08 17:36 MHDA- 2026/09/08 17:37 CRDT- 2026/09/08 11:37 PHST- 2026/08/12 00:00 [received] PHST- 2026/09/01 00:00 [accepted] PHST- 2026/09/08 17:37 [medline] PHST- 2026/09/08 17:36 [pubmed] PHST- 2026/09/08 11:37 [entrez] AID - 10.1007/s11886-026-02412-1 [pii] AID - 10.1007/s11886-026-02412-1 [doi] PST - epublish SO - Curr Cardiol Rep. 2026 Sep 8;28(1):91. doi: 10.1007/s11886-026-02412-1. PMID- 42708190 OWN - NLM STAT- MEDLINE DCOM- 20261012 LR - 20261012 IS - 1524-4539 (Electronic) IS - 0009-7322 (Linking) VI - 154 IP - 15 DP - 2026 Oct 13 TI - Infective Endocarditis: Diagnosis, Antibiotic Therapy, and Management: A Scientific Statement From the American Heart Association. PG - e593-e619 LID - 10.1161/CIR.0000000000001466 [doi] AB - Since the publication of the 2015 American Heart Association scientific statement on infective endocarditis, its incidence has increased, its epidemiology has changed, and novel diagnostic and treatment options have become available. Updated case definitions, non-culture-based pathogen identification methods, and advanced multimodality imaging techniques have emerged. A randomized controlled trial of partial oral therapy published in 2019 may change the treatment landscape for the foreseeable future. Percutaneous mechanical aspiration of right-sided vegetations is being used in select patients with uncontrolled infection despite appropriate antimicrobial therapy. The importance of an endocarditis team has become increasingly recognized in the management of this life-threatening syndrome. Therefore, multidisciplinary experts in cardiovascular infections were commissioned to develop this updated scientific statement on the diagnosis and management of infective endocarditis. FAU - DeSimone, Daniel C AU - DeSimone DC FAU - Marks, Laura AU - Marks L FAU - Dayer, Mark J AU - Dayer MJ FAU - Esquer Garrigos, Zerelda AU - Esquer Garrigos Z FAU - Messika-Zeitoun, David AU - Messika-Zeitoun D FAU - O'Gara, Patrick T AU - O'Gara PT FAU - Pettersson, Gosta B AU - Pettersson GB FAU - Bucholz, Emily M AU - Bucholz EM FAU - Andrews, Lindsey S AU - Andrews LS FAU - Fowler, Vance G Jr AU - Fowler VG Jr FAU - Miro, Jose M AU - Miro JM FAU - Baddour, Larry M AU - Baddour LM CN - American Heart Association Council on Lifelong Congenital Heart Disease and Heart Health in the Young CN - Council on Clinical Cardiology CN - Council on Cardiovascular and Stroke Nursing CN - Council on Cardiovascular Radiology and Intervention LA - eng PT - Journal Article PT - Review DEP - 20260908 PL - United States TA - Circulation JT - Circulation JID - 0147763 RN - 0 (Anti-Bacterial Agents) SB - IM EIN - Circulation. 2026 Oct 13;154(15):e620. doi: 10.1161/CIR.0000000000001485. PMID: 42862916 MH - Humans MH - United States/epidemiology MH - American Heart Association MH - *Anti-Bacterial Agents/therapeutic use MH - *Endocarditis/diagnosis/drug therapy/epidemiology/therapy MH - *Endocarditis, Bacterial/diagnosis/drug therapy OTO - NOTNLM OT - AHA Scientific Statements OT - cardiovascular infections OT - echocardiography OT - embolism OT - endocarditis OT - heart valves OT - treatment outcome EDAT- 2026/09/08 12:33 MHDA- 2026/10/12 17:30 CRDT- 2026/09/08 06:56 PHST- 2026/10/12 17:30 [medline] PHST- 2026/09/08 12:33 [pubmed] PHST- 2026/09/08 06:56 [entrez] AID - 10.1161/CIR.0000000000001466 [doi] PST - ppublish SO - Circulation. 2026 Oct 13;154(15):e593-e619. doi: 10.1161/CIR.0000000000001466. Epub 2026 Sep 8. PMID- 42707926 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260908 LR - 20260909 IS - 2090-6420 (Print) IS - 2090-6439 (Electronic) IS - 2090-6420 (Linking) VI - 2026 DP - 2026 TI - Beyond the Diagnosis: A Comprehensive Case Report on Duchenne Muscular Dystrophy. PG - 9969987 LID - 10.1155/crcc/9969987 [doi] LID - 9969987 AB - BACKGROUND: Duchenne muscular dystrophy (DMD) is an X-linked recessive genetic disorder characterized by the absence of dystrophin, leading to progressive muscle degeneration and generalized weakness. It primarily affects males in early childhood and progresses to loss of ambulation and cardiac and respiratory complications. CASE REPORT: This case report describes a 26-year-old male with terminal-stage DMD who was admitted to the surgical intensive care unit (SICU) in a critically ill state with multiple-organ failure. He was ventilator-dependent via tracheostomy, hypotensive, anemic, and required cardiovascular support. He also had multiple pressure ulcers, including a Stage IV ulcer with associated edema, acute renal failure managed with continuous renal replacement therapy (CRRT), and sepsis due to mixed bacterial and fungal infections. Broad-spectrum antimicrobial therapy and intensive wound care were provided. This case highlights that advanced-stage DMD is a severe multisystem condition requiring intensive, specialized, and multidisciplinary care. CONCLUSION: This case underscores the critical importance of a multidisciplinary approach in managing complex patient conditions, emphasizing the prevention of secondary complications such as pressure ulcers and pulmonary infections. Adherence to evidence-based guidelines, coupled with psychosocial and ethical considerations related to quality of life, remains essential. Establishing standardized care protocols, enhancing healthcare team training on the specific needs of these patients, and promoting home-based and palliative care services are strongly recommended to ensure comprehensive, coordinated, and patient-centered management. CI - Copyright (c) 2026 Mahmoud Abdel Hameed Shahin et al. Case Reports in Critical Care published by John Wiley & Sons Ltd. FAU - Shahin, Mahmoud Abdel Hameed AU - Shahin MAH AUID- ORCID: 0000-0001-5145-3702 AD - Nursing Department, Prince Sultan Military College of Health Sciences, Dhahran, Eastern Region, Saudi Arabia. FAU - Asiri, Atheer Ali AU - Asiri AA AUID- ORCID: 0009-0005-0705-5711 AD - Nursing Department, Prince Sultan Military College of Health Sciences, Dhahran, Eastern Region, Saudi Arabia. FAU - Alotaibi, Areej Salah AU - Alotaibi AS AUID- ORCID: 0009-0008-9452-6607 AD - Nursing Department, Prince Sultan Military College of Health Sciences, Dhahran, Eastern Region, Saudi Arabia. FAU - Majrashi, Huda AU - Majrashi H AUID- ORCID: 0009-0000-2885-898X AD - Nursing Department, Prince Sultan Military College of Health Sciences, Dhahran, Eastern Region, Saudi Arabia. FAU - Khubrani, Saeedah AU - Khubrani S AUID- ORCID: 0009-0009-0789-7918 AD - Nursing Department, Prince Sultan Military College of Health Sciences, Dhahran, Eastern Region, Saudi Arabia. FAU - AlQarni, Shorouq Hashel AU - AlQarni SH AUID- ORCID: 0009-0009-8269-7289 AD - Nursing Department, Prince Sultan Military College of Health Sciences, Dhahran, Eastern Region, Saudi Arabia. FAU - Alqurashi, Shomokh Saad AU - Alqurashi SS AUID- ORCID: 0009-0004-5953-5429 AD - Nursing Department, Prince Sultan Military College of Health Sciences, Dhahran, Eastern Region, Saudi Arabia. FAU - Samti, Manal Essa AU - Samti ME AUID- ORCID: 0009-0000-9074-9370 AD - Nursing Department, Prince Sultan Military College of Health Sciences, Dhahran, Eastern Region, Saudi Arabia. FAU - AlQarni, Zahra Hashel AU - AlQarni ZH AUID- ORCID: 0009-0002-2372-3431 AD - Preventive Medicine Program Department, Armed Forces Hospital Southern Region, Abha City, Saudi Arabia, afhsr.med.sa. LA - eng PT - Journal Article DEP - 20260907 PL - United States TA - Case Rep Crit Care JT - Case reports in critical care JID - 101598416 PMC - PMC13548414 OTO - NOTNLM OT - Duchenne muscular dystrophy OT - X-linked muscular dystrophy OT - calf hypertrophy OT - muscle wasting OT - proximal muscle weakness COIS- The authors declare no conflicts of interest. EDAT- 2026/09/08 12:33 MHDA- 2026/09/08 12:34 PMCR- 2026/09/07 CRDT- 2026/09/08 06:35 PHST- 2026/03/06 00:00 [received] PHST- 2026/06/26 00:00 [revised] PHST- 2026/07/18 00:00 [accepted] PHST- 2026/09/08 12:34 [medline] PHST- 2026/09/08 12:33 [pubmed] PHST- 2026/09/08 06:35 [entrez] PHST- 2026/09/07 00:00 [pmc-release] AID - CRCC9969987 [pii] AID - 10.1155/crcc/9969987 [doi] PST - epublish SO - Case Rep Crit Care. 2026 Sep 7;2026:9969987. doi: 10.1155/crcc/9969987. eCollection 2026. PMID- 42706683 OWN - NLM STAT- Publisher LR - 20260908 IS - 1749-4486 (Electronic) IS - 1749-4478 (Linking) DP - 2026 Sep 7 TI - Paediatric Voice Disorders in a Multidisciplinary Voice Clinic: A Retrospective Observational Study. LID - 10.1111/coa.70167 [doi] AB - BACKGROUND: Paediatric voice disorders encompass a broad diagnostic spectrum, but contemporary descriptions of multidisciplinary voice clinic case-mix, assessment and management remain limited. METHODS: We performed a retrospective observational study of routinely collected clinical data from a quaternary multidisciplinary paediatric voice clinic in the United Kingdom. Children and adolescents aged 4-17 years who were seen between January 2024 and December 2025 were included. Patient-level variables included demographics, symptom duration, referral-to-first clinic waiting time, and primary diagnosis. Appointment-level variables included documentation of patient-reported outcome measures, endoscopic findings reported in clinic letters, management outcomes, and procedure follow-through. RESULTS: Of 111 listed appointments, 96 were attended (74 new and 22 follow-up) and 15 were non-attendances. These attended appointments represented 87 patients; median age at first appointment was 12 years (range 4-17 years), and 51/87 (58.6%) were male. Dysphonia was the main presenting symptom in 83/87 (95.4%). Median symptom duration at referral was 6.3 years (range 0.12-17.0 years), and median referral-to-first clinic waiting time was 154 days (range 16-1032 days). The most common diagnoses were vocal cord palsy (19/87, 21.8%), vocal cord nodules (11/87, 12.6%), and muscle tension dysphonia (9/87, 10.3%). In the vocal cord palsy/paresis subgroup (n = 20), 15/20 were left-sided and 13/20 were secondary to post-cardiac surgery/patent ductus arteriosus ligation. CONCLUSIONS: Children commonly experienced prolonged symptoms before specialist review, with a heterogeneous diagnostic spectrum and frequent vocal fold immobility. Standardised outcome capture and longer follow-up are needed to evaluate interventions and inform referral guidance. CI - (c) 2026 John Wiley & Sons Ltd. FAU - Yip, Hao Meng AU - Yip HM AUID- ORCID: 0000-0002-3089-3933 AD - Department of ENT, Great Ormond Street Hospital NHS Trust, London, UK. FAU - Cochrane, Lesley-Ann AU - Cochrane LA AD - Department of ENT, Great Ormond Street Hospital NHS Trust, London, UK. FAU - Cavalli, Lesley AU - Cavalli L AD - Department of SLT, Great Ormond Street Hospital NHS Trust, London, UK. AD - Division of Psychology and Language Sciences, Faculty of Brain Sciences, University College London, London, UK. FAU - Gallagher, Emily AU - Gallagher E AD - Department of SLT, Great Ormond Street Hospital NHS Trust, London, UK. FAU - Gorb, Nicola AU - Gorb N AD - Department of SLT, Great Ormond Street Hospital NHS Trust, London, UK. FAU - Jephson, Christopher G AU - Jephson CG AD - Department of ENT, Great Ormond Street Hospital NHS Trust, London, UK. LA - eng PT - Journal Article DEP - 20260907 PL - England TA - Clin Otolaryngol JT - Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery JID - 101247023 SB - IM OTO - NOTNLM OT - dysphonia OT - multidisciplinary voice clinic OT - paediatric voice disorders OT - speech and language therapy OT - stroboscopy OT - vocal cord palsy EDAT- 2026/09/08 05:36 MHDA- 2026/09/08 05:36 CRDT- 2026/09/08 01:04 PHST- 2026/07/14 00:00 [revised] PHST- 2026/04/20 00:00 [received] PHST- 2026/08/27 00:00 [accepted] PHST- 2026/09/08 05:36 [medline] PHST- 2026/09/08 05:36 [pubmed] PHST- 2026/09/08 01:04 [entrez] AID - 10.1111/coa.70167 [doi] PST - aheadofprint SO - Clin Otolaryngol. 2026 Sep 7. doi: 10.1111/coa.70167. PMID- 42702733 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260907 LR - 20260909 IS - 2055-0464 (Print) IS - 2055-0464 (Electronic) IS - 2055-0464 (Linking) VI - 13 IP - 1 DP - 2026 Sep 7 TI - Artificial intelligence-based prediction of procedural success in transcatheter mitral valve edge-to-edge repair. LID - 10.1186/s44156-026-00134-2 [doi] LID - 33 AB - BACKGROUND: Patient selection for transcatheter mitral valve edge-to-edge repair (MTEER) remains challenging, particularly in individuals with complex mitral valve anatomy. Conventional risk scores incorporate limited clinical variables and do not adequately account for detailed echocardiographic features, resulting in suboptimal prediction of procedural success. OBJECTIVES: To develop and evaluate machine learning (ML) and deep learning (DL) models integrating clinical and echocardiographic data to predict procedural success following MTEER. METHODS: Consecutive patients undergoing MTEER at a single tertiary center between 2014 and 2022 were retrospectively analyzed. Procedural success was defined as residual mitral regurgitation /=65 years to guide future service provision. METHODS: Through the Irish Surgical Research Collaborative, approval was granted for prospective snapshot audit in eight Irish hospitals. For fourteen consecutive days, all emergency general surgery admissions >/=65 years were screened for frailty using the Clinical Frailty Score. Demographics, comorbidities and inpatient course at 30 days were compared between frail and non-frail patients using SPSS. RESULTS: In 112 cal l sessions, 244 patients >/=65 years were admitted and 55.5% were frail (n = 134/241). Frail patients were significantly older (p < 0.001), with higher rates of multimorbidity (p < 0.001), polypharmacy (p < 0.001), and both physical (p < 0.001) and cognitive impairment (p < 0.001). Similar numbers of frail and non-frail patients underwent surgery under general anaesthesia, though proportionally more frail patients required ICU care post-op. Frailty was associated with significantly higher rates of all inpatient complications (p < 0.001), including nosocomial infection (p = 0.034), cardiac events (p = 0.026), delirium (p = 0.025) and death (p = 0.016). Frail patients required significantly more medical consults (p = 0.034), MDT input (p < 0.001) and increased home-care packages (p = 0.024). Frail patients had longer hospital stays (p = 0.033) and fewer discharges to home (p < 0.001). CONCLUSIONS: High levels of frailty and frailty-associated morbidity were noted amongst emergency surgical admissions. Collaborative pathways between surgeons and geriatricians may optimise outcomes in this high-risk cohort. CI - Copyright (c) 2026 Royal College of Surgeons of Edinburgh (Scottish charity number SC005317) and Royal College of Surgeons in Ireland. Published by Elsevier Ltd. All rights reserved. FAU - Foley, Megan Power AU - Foley MP AD - Department of Surgery, Beaumont Hospital, Beaumont Road, Dublin, 9, D09 V2N0, Ireland. Electronic address: meganpfoley@rcsi.com. FAU - Cullinane, Carolyn AU - Cullinane C AD - University Hospital Limerick, St Nessan's Road, Dooradoyle, Limerick, V94F858, Ireland. FAU - Ismaiel, Mohamed AU - Ismaiel M AD - University Hospital Limerick, St Nessan's Road, Dooradoyle, Limerick, V94F858, Ireland. FAU - Devine, Michael AU - Devine M AD - Mayo University Hospital, Westport Road, Knockaphunta, Castlebar, Co. Mayo, F23 H529, Ireland. FAU - Kennedy, Czara AU - Kennedy C AD - St Vincent's University Hospital, Elm Park, Merrion Road, Donnybrook, Dublin, 4, D04 T6F4, Ireland. FAU - O'Neill, Aine AU - O'Neill A AD - Our Lady of Lourdes Hospital, Windmill Road, Moneymore, Drogheda, Louth, A92 VW28, Ireland. FAU - Al Azzawi, Mohammed AU - Al Azzawi M AD - Department of Surgery, Beaumont Hospital, Beaumont Road, Dublin, 9, D09 V2N0, Ireland. FAU - Ryan, Eanna AU - Ryan E AD - Mater Misericordiae University Hospital, Eccles Street, Dublin, 7, D07 R2WY, Ireland. FAU - Raftery, Nicola AU - Raftery N AD - St James' Hospital, James's Street, Dublin, 8, D08 NHY1, Ireland. FAU - Toale, Conor AU - Toale C AD - Tallaght University Hospital, Cookstown Way, Tallaght, Dublin, 24, D24 NR0A, Ireland. CN - Irish Surgical Research Collaborative LA - eng PT - Journal Article DEP - 20260831 PL - Scotland TA - Surgeon JT - The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland JID - 101168329 SB - IM OTO - NOTNLM OT - Complications OT - Emergency general surgery OT - Frailty OT - Patient outcomes OT - Surgical geriatrics COIS- Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: The authors have no conflicts of interest to declare If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. FIR - Abaker, Sugood IR - Abaker S FIR - Barry, Michael Kevin IR - Barry MK FIR - Beattie, Eibhlin Burns IR - Beattie EB FIR - Campbell, Sally IR - Campbell S FIR - Conway, Orla IR - Conway O FIR - Costello, Liam IR - Costello L FIR - Cvetkova, Jelizaveta IR - Cvetkova J FIR - de Sousa, Emma IR - de Sousa E FIR - Elliot, Jessie IR - Elliot J FIR - Ensar, Dilara IR - Ensar D FIR - Flemming, Christina A IR - Flemming CA FIR - Gillis, Amy IR - Gillis A FIR - Henehan, Helen IR - Henehan H FIR - Hill, Arnold IR - Hill A FIR - Khan, Iqbal IR - Khan I FIR - Kazi, Ahmed IR - Kazi A FIR - Linehan, Eimear IR - Linehan E FIR - Muslow, Jurgen IR - Muslow J FIR - O'Mahony, Aaron IR - O'Mahony A FIR - Ryan, Odhran IR - Ryan O FIR - Salama, Mahmoud IR - Salama M FIR - Shahbaz, Chaudhri Muhammad IR - Shahbaz CM FIR - Suliman, Hussein IR - Suliman H FIR - Toriola, Olutayo IR - Toriola O EDAT- 2026/08/31 23:43 MHDA- 2026/08/31 23:43 CRDT- 2026/08/31 21:52 PHST- 2026/03/23 00:00 [received] PHST- 2026/08/08 00:00 [revised] PHST- 2026/08/10 00:00 [accepted] PHST- 2026/08/31 23:43 [medline] PHST- 2026/08/31 23:43 [pubmed] PHST- 2026/08/31 21:52 [entrez] AID - S1479-666X(26)00055-7 [pii] AID - 10.1016/j.surge.2026.08.006 [doi] PST - aheadofprint SO - Surgeon. 2026 Aug 31:S1479-666X(26)00055-7. doi: 10.1016/j.surge.2026.08.006. PMID- 42668745 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260830 LR - 20260831 IS - 2050-0904 (Print) IS - 2050-0904 (Electronic) IS - 2050-0904 (Linking) VI - 14 IP - 9 DP - 2026 Sep TI - Management of Infective Endocarditis Complicated by Ruptured Cerebral Mycotic Aneurysm: A Case Report. PG - e73429 LID - 10.1002/ccr3.73429 [doi] LID - e73429 AB - This case highlights multidisciplinary decision-making and the timing of staged surgical intervention in infective endocarditis complicated by intracranial hemorrhage. Early cardiac surgery following neurosurgical treatment may be considered in carefully selected patients. CI - (c) 2026 The Author(s). Clinical Case Reports published by John Wiley & Sons Ltd. FAU - Oyama, Shogo AU - Oyama S AUID- ORCID: 0000-0002-2024-8666 AD - Department of Cardiac Surgery The Jikei University Hospital Tokyo Japan. FAU - Yamauchi, Junpei AU - Yamauchi J AUID- ORCID: 0009-0001-2362-1665 AD - Department of Cardiac Surgery The Jikei University Hospital Tokyo Japan. FAU - Arimura, Satoshi AU - Arimura S AUID- ORCID: 0000-0002-7659-5632 AD - Department of Cardiac Surgery The Jikei University Hospital Tokyo Japan. FAU - Saku, Kosuke AU - Saku K AUID- ORCID: 0000-0002-2940-5728 AD - Department of Cardiac Surgery The Jikei University Hospital Tokyo Japan. FAU - Takagi, Tomomitsu AU - Takagi T AD - Department of Cardiac Surgery The Jikei University Hospital Tokyo Japan. FAU - Hoshino, Satoshi AU - Hoshino S AD - Department of Cardiac Surgery The Jikei University Hospital Tokyo Japan. FAU - Abe, Takayuki AU - Abe T AD - Department of Cardiac Surgery The Jikei University Hospital Tokyo Japan. FAU - Matsumura, Yoko AU - Matsumura Y AD - Department of Cardiac Surgery The Jikei University Hospital Tokyo Japan. FAU - Yoshitake, Michio AU - Yoshitake M AD - Department of Cardiac Surgery The Jikei University Hospital Tokyo Japan. FAU - Nagahori, Ryuichi AU - Nagahori R AD - Department of Cardiac Surgery The Jikei University Hospital Tokyo Japan. FAU - Bando, Ko AU - Bando K AD - Department of Cardiac Surgery The Jikei University Hospital Tokyo Japan. FAU - Kunihara, Takashi AU - Kunihara T AUID- ORCID: 0000-0001-6903-6501 AD - Department of Cardiac Surgery The Jikei University Hospital Tokyo Japan. FAU - Nagayama, Gota AU - Nagayama G AD - Department of Neurosurgery The Jikei University Hospital Tokyo Japan. FAU - Murayama, Yuichi AU - Murayama Y AD - Department of Neurosurgery The Jikei University Hospital Tokyo Japan. LA - eng PT - Journal Article DEP - 20260828 PL - England TA - Clin Case Rep JT - Clinical case reports JID - 101620385 PMC - PMC13525342 OTO - NOTNLM OT - cerebral mycotic aneurysm OT - infective endocarditis OT - mitral valve replacement OT - multidisciplinary team OT - subarachnoid hemorrhage COIS- The authors declare no conflicts of interest. EDAT- 2026/08/30 05:37 MHDA- 2026/08/30 05:38 PMCR- 2026/08/28 CRDT- 2026/08/30 04:06 PHST- 2026/04/08 00:00 [received] PHST- 2026/06/26 00:00 [revised] PHST- 2026/08/20 00:00 [accepted] PHST- 2026/08/30 05:38 [medline] PHST- 2026/08/30 05:37 [pubmed] PHST- 2026/08/30 04:06 [entrez] PHST- 2026/08/28 00:00 [pmc-release] AID - CCR373429 [pii] AID - 10.1002/ccr3.73429 [doi] PST - epublish SO - Clin Case Rep. 2026 Aug 28;14(9):e73429. doi: 10.1002/ccr3.73429. eCollection 2026 Sep. PMID- 42667236 OWN - NLM STAT- MEDLINE DCOM- 20260829 LR - 20260908 IS - 1940-087X (Electronic) IS - 1940-087X (Linking) IP - 234 DP - 2026 Aug 28 TI - Diagnosis and Treatment of Patent Foramen Ovale-associated Cryptogenic Stroke. LID - 10.3791/72345 [doi] AB - Patent foramen ovale (PFO) is an important cause of cryptogenic stroke (CS), and its pathogenic mechanisms involve paradoxical embolism, in situ thrombus, hemodynamic changes caused by atrial remodeling, and high-risk anatomical features such as atrial septal aneurysm. Clinical assessment requires multidisciplinary evaluation of anatomical high-risk features, stroke imaging characteristics, and Risk of Paradoxical Embolism (RoPE) score to determine treatment plans. Currently, interventional closure and oral antithrombotic therapy are recommended, but the determination of interventional indications and the choice between anticoagulants and antiplatelet drugs remain controversial. From the perspective of pathological mechanisms, patients with PFO-related CS may have venous emboli caused by right-to-left shunting, and anticoagulant therapy can more precisely intervene in the chain reaction of embolism by inhibiting venous thrombus formation and promoting the dissolution of in situ thrombi. Based on the PICO principle, this review summarizes currently published studies on PFO, including clinical trials, guideline statements, and position papers. It summarizes the diagnosis and treatment of PFO and proposes mechanism-based hypotheses for validation in future large-scale clinical studies. FAU - Liang, Liju AU - Liang L AD - Department of Pharmacy, The Fifth Affiliated Hospital of Dali University. FAU - Guo, Yun AU - Guo Y AD - Department of Pharmacy, The Fifth Affiliated Hospital of Dali University. FAU - Dong, Shoutang AU - Dong S AD - School of Basic Medical, Baoshan College of Traditional Chinese Medicine. FAU - Shao, Weili AU - Shao W AD - Department of Pharmacy, The Fifth Affiliated Hospital of Dali University. FAU - Zhao, Guoli AU - Zhao G AD - Department of Pharmacy, The Fifth Affiliated Hospital of Dali University. FAU - Yang, Zixuan AU - Yang Z AD - Department of Pharmacy, The Fifth Affiliated Hospital of Dali University; yangzixuan@dali.edu.cn. FAU - Wang, Huaibin AU - Wang H AD - School of Basic Medical, Baoshan College of Traditional Chinese Medicine; ynwhb1988@126.com. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review PT - Video-Audio Media DEP - 20260828 PL - United States TA - J Vis Exp JT - Journal of visualized experiments : JoVE JID - 101313252 SB - IM MH - *Foramen Ovale, Patent/complications/diagnosis/therapy/surgery MH - Humans MH - *Stroke/etiology/diagnosis/therapy EDAT- 2026/08/29 12:02 MHDA- 2026/08/29 12:03 CRDT- 2026/08/29 08:42 PHST- 2026/08/29 12:03 [medline] PHST- 2026/08/29 12:02 [pubmed] PHST- 2026/08/29 08:42 [entrez] AID - 10.3791/72345 [doi] PST - epublish SO - J Vis Exp. 2026 Aug 28;(234). doi: 10.3791/72345. PMID- 42665304 OWN - NLM STAT- MEDLINE DCOM- 20260828 LR - 20260904 IS - 2052-4439 (Electronic) IS - 2052-4439 (Linking) VI - 13 IP - 1 DP - 2026 Aug 28 TI - Therapeutic options for patients with obstructive sleep apnoea: a retrospective review of difficult-to-treat cases in a multidisciplinary approach. LID - 10.1136/bmjresp-2026-004233 [doi] LID - e004233 AB - INTRODUCTION: Continuous positive airway pressure (CPAP) is the first-line treatment for obstructive sleep apnoea (OSA) but long-term adherence is limited. This study evaluates the implementation and outcomes of a multidisciplinary team approach to managing CPAP-intolerant patients using alternative therapies. METHODS: A retrospective review was conducted on 'difficult-to-treat' OSA cases discussed at multidisciplinary team meetings at the Guy's and St Thomas' NHS Foundation Trust Sleep Disorders Centre (project number 17 160). Patient demographics, comorbidities, OSA severity (Apnoea-Hypopnoea Index (AHI), Epworth Sleepiness Scale (ESS), 3% Oxygen Desaturation Index (ODI)), management plans and outcomes were extracted from meeting minutes and clinical records. Statistical analysis included analysis of variance (ANOVA) to compare baseline characteristics (AHI, age, body mass index (BMI)) across treatment groups and paired t-tests to assess pre-treatment and post-treatment changes in OSA indices (p<0.05). RESULTS: We reviewed a cohort of 138 patients (103/138 male, age 51 (17) years, BMI 29.5 (5.1) kg/m(2)) with severe OSA (AHI 37.7 (21.4)/hour). Common comorbidities included hypertension (29.0%), anxiety/depression (25.4%), history of previous Otorhinolaryngology (ENT) intervention (17.4%) and cardiac diseases (16.7%). Treatment selection was guided by predefined criteria, including OSA severity, BMI, patient preferences, anatomical abnormalities and comorbidities. Treatment recommendations included mandibular advancement devices (27.5%), hypoglossal nerve stimulation pathway (24.6%), weight management (23.9%), CPAP retrial (13.8%), other ENT surgery (10.9%) and BiPAP/ASV (10.1%). Follow-up data from patients with postintervention data demonstrated significant reductions in AHI (-44.1%, n=29), ESS (-32.9%, n=13) and ODI (-67.2%, n=12) post-treatment (p<0.05). CONCLUSION: A multidisciplinary approach enables structured delivery of evidence-based treatment selection for patients with OSA who failed first-line therapy. Observed improvements in a subset of patients suggest potential benefit of tailored non-CPAP strategies and super-regional accessibility. CI - (c) Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. FAU - Ho, Oscar Sing Him AU - Ho OSH AUID- ORCID: 0009-0005-8130-4077 AD - King's College London GKT School of Medical Education, London, UK singhim.ho@kcl.ac.uk. FAU - Brown, Richard AU - Brown R AD - Sleep Disorders Centre, Guy's and St Thomas' NHS Foundation Trust, London, UK. FAU - Karagama, Yakubu AU - Karagama Y AD - ENT Department, Guy's and St Thomas' NHS Foundation Trust, London, UK. FAU - Desai, Aditi AU - Desai A AD - British Society of Dental Sleep Medicine, London, UK. FAU - Hare, Alanna AU - Hare A AD - Royal Brompton & Harefield NHS Foundation Trust, London, UK. FAU - Bavisha, Kalpesh AU - Bavisha K AD - Restorative Dentistry, Guy's and St Thomas' NHS Foundation Trust, London, UK. FAU - Fan, Kathy AU - Fan K AD - Oral & Maxillofacial Surgery, King's College Hospital NHS Foundation Trust, London, UK. FAU - Meurling, Johan AU - Meurling J AD - Sleep Disorders Centre, Guy's and St Thomas' NHS Foundation Trust, London, UK. FAU - Steier, Joerg Sebastian AU - Steier JS AD - Lane Fox Unit/Sleep Disorders Centre, Guy's and St Thomas' NHS Foundation Trust, London, UK. LA - eng PT - Journal Article DEP - 20260828 PL - England TA - BMJ Open Respir Res JT - BMJ open respiratory research JID - 101638061 SB - IM MH - Humans MH - *Sleep Apnea, Obstructive/therapy MH - Retrospective Studies MH - Female MH - Male MH - *Continuous Positive Airway Pressure/methods MH - Middle Aged MH - *Patient Care Team MH - Treatment Outcome MH - Adult MH - Severity of Illness Index MH - Aged MH - Mandibular Advancement MH - Polysomnography MH - Patient Compliance PMC - PMC13536113 OTO - NOTNLM OT - Sleep apnoea COIS- Competing interests: None declared. EDAT- 2026/08/28 23:34 MHDA- 2026/08/28 23:35 PMCR- 2026/08/28 CRDT- 2026/08/28 20:43 PHST- 2026/03/05 00:00 [received] PHST- 2026/07/25 00:00 [accepted] PHST- 2026/08/28 23:35 [medline] PHST- 2026/08/28 23:34 [pubmed] PHST- 2026/08/28 20:43 [entrez] PHST- 2026/08/28 00:00 [pmc-release] AID - 13/1/e004233 [pii] AID - bmjresp-2026-004233 [pii] AID - 10.1136/bmjresp-2026-004233 [doi] PST - epublish SO - BMJ Open Respir Res. 2026 Aug 28;13(1):e004233. doi: 10.1136/bmjresp-2026-004233. PMID- 33232009 STAT- Publisher CTDT- 20260828 PB - StatPearls Publishing DP - 2026 Jan TI - Mechanical Aortic Valve Replacement. BTI - StatPearls AB - Mechanical aortic valve replacement (MAVR) is a critical intervention for patients with severe aortic valve disease that compromises valvular function, including aortic stenosis and regurgitation. The procedure involves surgically implanting a mechanical prosthetic valve designed to replicate the native valve's function while offering durability that often surpasses that of bioprosthetic valves; mechanical valves can last about 20 years. Since the first successful aortic valve replacement in the 1960s, valve design, surgical techniques, and perioperative care have advanced significantly, improving patient outcomes. Mechanical valves are favored in certain patient populations due to their long-term durability. They often outlast biological valves, which tend to degrade over time. Patients, especially younger individuals or those without contraindications to lifelong anticoagulation therapy, may benefit from the durability of a mechanical valve, reducing the likelihood of reoperation. However, the requirement for lifelong anticoagulation presents unique challenges, as it increases the risk of bleeding complications. This activity for healthcare professionals reviews the indications, patient selection, surgical techniques, anticoagulation management, and long-term outcomes of MAVR and highlights the interprofessional team's role in improving outcomes for patients undergoing this procedure. CI - Copyright (c) 2026, StatPearls Publishing LLC. FAU - Gopal, Shwetha AU - Gopal S AD - Bayhealth Medical Center FAU - Alahmadi, Mohamed H AU - Alahmadi MH AD - Shalamar Hospital and Avicenna Medical & Dental College and Hospital, Lahore FAU - Mahboobi, Sohail K AU - Mahboobi SK LA - eng PT - Study Guide PT - Book Chapter PL - Treasure Island (FL) COIS- Disclosure: Shwetha Gopal declares no relevant financial relationships with ineligible companies. Disclosure: Mohamed H Alahmadi declares no relevant financial relationships with ineligible companies. Disclosure: Sohail K Mahboobi declares no relevant financial relationships with ineligible companies. EDAT- 2026/08/28 00:00 CRDT- 2026/08/28 00:00 AID - NBK564339 [bookaccession] PMID- 42657750 OWN - NLM STAT- MEDLINE DCOM- 20260902 LR - 20260902 IS - 2047-9980 (Electronic) IS - 2047-9980 (Linking) VI - 15 IP - 17 DP - 2026 Sep TI - Multidisciplinary Heart Team Model to Deliver Advanced Cardiovascular Care in a Public Safety-Net Hospital. PG - e051826 LID - 10.1161/JAHA.126.051826 [doi] AB - BACKGROUND: Implementation of guideline-supported Multidisciplinary Heart Teams (MHT) for the management of complex cardiovascular disease has not been described in a public safety-net hospital setting. In May 2023, an MHT was established at Los Angeles General Medical Center to deliver comprehensive cardiovascular care to an underserved population in a resource-constrained setting. METHODS: We conducted a retrospective review of all cases discussed by a comprehensive MHT at Los Angeles General Medical Center from May 24, 2023 through January 21, 2026. The MHT convenes weekly in a hybrid format, using a privacy-compliant centralized platform for longitudinal care coordination. Referral pathways extend to affiliated safety-net clinics and hospitals. RESULTS: During the study period, the MHT discussed 494 patients, including 369 (74.7%) with any valvular disease, 78 (15.8%) with complex coronary disease, 29 (5.9%) with congenital heart disease, and 33 (6.7%) with endocarditis. The patient cohort reflected a high prevalence of health care disparities, with 93.9% reporting a race or ethnicity other than non-Hispanic White, a high proportion with publicly funded (69.0% Medicaid) or uninsured (3.6%) status, and frequent substance use disorders (28.1%). The MHT generated consensus recommendations including cardiac surgery (99 [20.0%]), transcatheter intervention (122 [24.7%]), complex percutaneous coronary intervention (30 [6.1%]), and medical management (149 [30.2%]). In-hospital mortality was low among patients who underwent surgical or percutaneous procedure (9 [3.6%]). Programmatic growth included development of a transcatheter valve repair program and increased complexity of cardiac surgical case volume. CONCLUSIONS: Establishment of an MHT in a resource-constrained public safety-net hospital was feasible and sustainable. Our model may serve as a blueprint to deliver guideline-concordant cardiovascular therapies to underserved populations. FAU - Zern, Emily K AU - Zern EK AUID- ORCID: 0000-0001-8334-4199 AD - Los Angeles General Medical Center Los Angeles CA USA. AD - Keck School of Medicine of the University of Southern California Los Angeles CA USA. FAU - Rege, Soham AU - Rege S AD - Keck School of Medicine of the University of Southern California Los Angeles CA USA. FAU - Gorgy, Isaac AU - Gorgy I AD - Keck School of Medicine of the University of Southern California Los Angeles CA USA. FAU - Tang, Wilson AU - Tang W AD - Keck School of Medicine of the University of Southern California Los Angeles CA USA. FAU - Patel, Parth P AU - Patel PP AUID- ORCID: 0009-0006-2772-0165 AD - Keck School of Medicine of the University of Southern California Los Angeles CA USA. FAU - Benck, Kelley AU - Benck K AUID- ORCID: 0000-0002-8496-9008 AD - Keck School of Medicine of the University of Southern California Los Angeles CA USA. FAU - Lucas, Eric D AU - Lucas ED AD - Keck School of Medicine of the University of Southern California Los Angeles CA USA. FAU - Shen, Adriana AU - Shen A AD - Keck School of Medicine of the University of Southern California Los Angeles CA USA. FAU - Steyer, Henry AU - Steyer H AD - Keck School of Medicine of the University of Southern California Los Angeles CA USA. FAU - Sanousi, Imam AU - Sanousi I AD - Keck School of Medicine of the University of Southern California Los Angeles CA USA. FAU - Ge, Brandon B AU - Ge BB AD - Keck School of Medicine of the University of Southern California Los Angeles CA USA. FAU - Lin, Ben A AU - Lin BA AD - Los Angeles General Medical Center Los Angeles CA USA. AD - Keck School of Medicine of the University of Southern California Los Angeles CA USA. FAU - Gordon, Samuel S AU - Gordon SS AD - Los Angeles General Medical Center Los Angeles CA USA. AD - Keck School of Medicine of the University of Southern California Los Angeles CA USA. FAU - Justino, Christopher AU - Justino C AD - Los Angeles General Medical Center Los Angeles CA USA. FAU - Do, Diane AU - Do D AD - Los Angeles General Medical Center Los Angeles CA USA. FAU - Zamora, Nicole C AU - Zamora NC AD - Los Angeles General Medical Center Los Angeles CA USA. FAU - Stachel, Maxine AU - Stachel M AD - Keck School of Medicine of the University of Southern California Los Angeles CA USA. FAU - Patel, Sanjeet AU - Patel S AUID- ORCID: 0000-0002-3303-4253 AD - Keck School of Medicine of the University of Southern California Los Angeles CA USA. FAU - Nikolic, Ivana AU - Nikolic I AD - Los Angeles General Medical Center Los Angeles CA USA. FAU - Govea, Alayn AU - Govea A AD - Los Angeles General Medical Center Los Angeles CA USA. FAU - Van Herle, Helga AU - Van Herle H AD - Los Angeles General Medical Center Los Angeles CA USA. AD - Keck School of Medicine of the University of Southern California Los Angeles CA USA. FAU - Kobsa, Serge AU - Kobsa S AD - Los Angeles General Medical Center Los Angeles CA USA. AD - Keck School of Medicine of the University of Southern California Los Angeles CA USA. FAU - Baden, Rachel AU - Baden R AUID- ORCID: 0009-0004-5620-7286 AD - Los Angeles General Medical Center Los Angeles CA USA. AD - Keck School of Medicine of the University of Southern California Los Angeles CA USA. FAU - Spellberg, Brad AU - Spellberg B AD - Los Angeles General Medical Center Los Angeles CA USA. AD - Keck School of Medicine of the University of Southern California Los Angeles CA USA. FAU - Mehra, Anilkumar AU - Mehra A AD - Los Angeles General Medical Center Los Angeles CA USA. AD - Keck School of Medicine of the University of Southern California Los Angeles CA USA. FAU - Wiley, Brandon M AU - Wiley BM AUID- ORCID: 0000-0003-3651-7231 AD - Los Angeles General Medical Center Los Angeles CA USA. AD - Keck School of Medicine of the University of Southern California Los Angeles CA USA. LA - eng PT - Journal Article DEP - 20260827 PL - England TA - J Am Heart Assoc JT - Journal of the American Heart Association JID - 101580524 SB - IM MH - Humans MH - *Safety-net Providers/organization & administration MH - *Patient Care Team/organization & administration MH - Retrospective Studies MH - Female MH - Male MH - Middle Aged MH - Los Angeles MH - Healthcare Disparities MH - Aged MH - *Cardiovascular Diseases/therapy MH - Resource-Limited Settings MH - Adult MH - *Hospitals, Public OTO - NOTNLM OT - health disparities OT - health equity OT - heart team OT - multidisciplinary care OT - safety-net hospital OT - structural heart disease EDAT- 2026/08/27 12:36 MHDA- 2026/09/02 05:36 CRDT- 2026/08/27 07:23 PHST- 2026/09/02 05:36 [medline] PHST- 2026/08/27 12:36 [pubmed] PHST- 2026/08/27 07:23 [entrez] AID - 10.1161/JAHA.126.051826 [doi] PST - ppublish SO - J Am Heart Assoc. 2026 Sep;15(17):e051826. doi: 10.1161/JAHA.126.051826. Epub 2026 Aug 27. PMID- 42652839 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260827 LR - 20260829 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 15 IP - 16 DP - 2026 Aug 20 TI - Single Coronary Artery in the Context of Vascular Disease: Anatomy, Development, Multimodality Imaging, and Clinical Interpretation. LID - 10.3390/jcm15166435 [doi] LID - 6435 AB - Background: Single coronary artery (SCA) is a rare and anatomically heterogeneous congenital coronary anomaly in which the entire coronary circulation arises from a single aortic ostium. Its clinical significance depends on the ostial and proximal morphology, coronary course, associated coronary disease, symptoms and, where indicated, functional findings. Methods: PubMed/MEDLINE was searched with free-text terms from 24 December 2025 to 12 July 2026 and rerun on 9 August 2026; relevant reference lists were screened manually. Results: SCA-specific evidence consisted mainly of case reports, small series, and descriptive imaging studies. A single ostium or Lipton code does not fully describe the relevant anatomy. Reports should state whether a true common trunk is present, map the course and supplied territory of each major branch, and document proximal morphology and acquired coronary disease. Coronary computed tomography angiography (CCTA) is central to anatomical assessment in many adults. Functional testing is most informative when the method addresses the suspected mechanism. Conclusions: SCA should be interpreted by integrating detailed anatomy, symptoms, coexisting coronary disease and, when appropriate, mechanism-matched functional findings. The three-domain structure used here supports reporting and multidisciplinary discussion, but it is not a validated risk model or treatment algorithm. Prospective evidence on SCA-specific outcomes and management remains limited. FAU - Muhtaroglu, Musa AU - Muhtaroglu M AUID- ORCID: 0000-0002-5173-4528 AD - Department of Anatomy, Faculty of Medicine, European University of Lefke, Lefke 99728, Northern Cyprus, TR-10 Mersin, Turkiye. FAU - Birtan, Hasan AU - Birtan H AUID- ORCID: 0000-0002-4952-9402 AD - Department of Cardiovascular Surgery, Dr. Burhan Nalbantoglu State Hospital, Nicosia 99010, Cyprus. LA - eng PT - Journal Article PT - Review DEP - 20260820 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC13513484 OTO - NOTNLM OT - anomalous coronary artery OT - clinical interpretation OT - coronary artery anomalies OT - coronary computed tomography angiography OT - multimodality imaging OT - single coronary artery OT - vascular disease COIS- The authors declare no conflicts of interest. EDAT- 2026/08/27 05:35 MHDA- 2026/08/27 05:36 PMCR- 2026/08/20 CRDT- 2026/08/27 01:07 PHST- 2026/07/22 00:00 [received] PHST- 2026/08/14 00:00 [revised] PHST- 2026/08/18 00:00 [accepted] PHST- 2026/08/27 05:36 [medline] PHST- 2026/08/27 05:35 [pubmed] PHST- 2026/08/27 01:07 [entrez] PHST- 2026/08/20 00:00 [pmc-release] AID - jcm15166435 [pii] AID - jcm-15-06435 [pii] AID - 10.3390/jcm15166435 [doi] PST - epublish SO - J Clin Med. 2026 Aug 20;15(16):6435. doi: 10.3390/jcm15166435. PMID- 42652676 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260827 LR - 20260829 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 15 IP - 16 DP - 2026 Aug 13 TI - Fetal Hepatosplenomegaly: Stepwise Diagnostic Framework, Diagnostic Approach to Fetal Hepatosplenomegaly. LID - 10.3390/jcm15166274 [doi] LID - 6274 AB - Background/Objectives: Fetal hepatosplenomegaly is an uncommon but clinically significant prenatal finding associated with a wide range of heterogeneous conditions, including congenital infections, fetal anemia, genetic syndromes, metabolic disorders, and other, less common abnormalities. Because of its nonspecific presentation and diverse etiologies, it represents a diagnostic challenge that requires a structured, multidisciplinary approach. This review aims to present a practical, clinically oriented, stepwise approach to the prenatal evaluation of fetal hepatosplenomegaly, integrating current evidence to facilitate differential diagnosis and guide prenatal management. Methods: A comprehensive literature review was performed, focusing on ultrasound diagnosis, differential diagnosis, genetic evaluation, and prenatal management strategies in fetuses with hepatosplenomegaly. Results: The prenatal detection of hepatosplenomegaly should prompt a detailed ultrasound assessment, including the confirmation of organ enlargement, evaluation of associated structural abnormalities, Doppler studies, and screening for signs of fetal anemia, infection, hydrops fetalis, or cardiac dysfunction. The diagnostic workup should begin with targeted maternal and fetal investigations directed toward the most common causes. In unresolved cases, genetic testing-including chromosomal microarray analysis and next-generation sequencing-may help establish the diagnosis. The preservation of biological material obtained during invasive procedures should be considered to allow future molecular analyses if new clinical findings emerge. The management depends on the underlying etiology and may include fetal therapy, maternal treatment, or specific interventions in selected genetic and metabolic conditions. Conclusions: Fetal hepatosplenomegaly requires a systematic diagnostic strategy that integrates ultrasound, laboratory, and genetic assessment. A structured approach may improve diagnostic accuracy, optimize prenatal counseling, and facilitate the timely management of potentially treatable conditions. FAU - Mazek, Maria AU - Mazek M AD - Department of Obstetrics, Perinatology, Gynecology and Reproductive Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland. FAU - Ciebiera, Michal AU - Ciebiera M AUID- ORCID: 0000-0001-5780-5983 AD - Warsaw Institute of Women's Health, 00-189 Warsaw, Poland. AD - Department of Gynecology, Obstetrics and Gynecological Endocrinology, Centre of Postgraduate Medical Education, 01-813 Warsaw, Poland. FAU - Massalska, Diana AU - Massalska D AUID- ORCID: 0000-0002-0547-6388 AD - Warsaw Institute of Women's Health, 00-189 Warsaw, Poland. AD - Department of Gynecology, Obstetrics and Gynecological Endocrinology, Centre of Postgraduate Medical Education, 01-813 Warsaw, Poland. LA - eng GR - 501-1-022-26-26/Centre of Postgraduate Medical Education/ PT - Journal Article PT - Review DEP - 20260813 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC13513750 OTO - NOTNLM OT - congenital infection OT - fetal hepatomegaly OT - fetal hepatosplenomegaly OT - fetal splenomegaly OT - non-immunological fetal hydrops OT - prenatal diagnosis OT - prenatal ultrasound COIS- The authors declare no conflicts of interest. EDAT- 2026/08/27 05:35 MHDA- 2026/08/27 05:36 PMCR- 2026/08/13 CRDT- 2026/08/27 01:06 PHST- 2026/06/29 00:00 [received] PHST- 2026/08/04 00:00 [revised] PHST- 2026/08/06 00:00 [accepted] PHST- 2026/08/27 05:36 [medline] PHST- 2026/08/27 05:35 [pubmed] PHST- 2026/08/27 01:06 [entrez] PHST- 2026/08/13 00:00 [pmc-release] AID - jcm15166274 [pii] AID - jcm-15-06274 [pii] AID - 10.3390/jcm15166274 [doi] PST - epublish SO - J Clin Med. 2026 Aug 13;15(16):6274. doi: 10.3390/jcm15166274. PMID- 42651025 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260827 LR - 20260829 IS - 2075-4418 (Print) IS - 2075-4418 (Electronic) IS - 2075-4418 (Linking) VI - 16 IP - 16 DP - 2026 Aug 19 TI - Parental Decision-Making Process in Termination of Pregnancy for Congenital Heart Disease: From the Multidisciplinary Perinatal Council of a Turkish Tertiary Center. LID - 10.3390/diagnostics16162624 [doi] LID - 2624 AB - Background/Objectives: Termination of pregnancy (TOP) following a prenatal diagnosis of congenital heart disease (CHD) is a complex decision shaped by clinical, ethical, and psychosocial factors. This study evaluated the clinical factors associated with parental acceptance of TOP after prenatal diagnosis of CHD in a multidisciplinary counselling setting. Methods: This retrospective cohort study was conducted at a tertiary referral center where fetal CHD cases are evaluated in a multidisciplinary perinatology council. Pregnancies with a prenatal CHD diagnosis for which TOP was medically recommended between December 2023 and February 2026 were included. Maternal, fetal, and genetic data were analyzed. Cardiac severity was classified using the fetal cardiovascular disease severity scale. Because the cohort included only 62 pregnancies, a simplified multivariable logistic regression model with three clinically prespecified variables (four parameters: gestational age, cardiac severity, and genetic-evaluation status) was used to identify variables associated with termination acceptance. Results: Sixty-two pregnancies were included; 41 (66.1%) accepted termination and 21 (33.9%) continued the pregnancy. Maternal characteristics and gestational age at diagnosis were similar between groups. In the multivariable model, genetic-evaluation status was the only variable independently associated with termination acceptance. Compared with cases without genetic testing, both major chromosomal/pathogenic anomalies (aOR 4.97; 95% CI 1.29-19.11; p = 0.020) and a normal genetic-evaluation status (aOR 4.71; 95% CI 1.07-20.77; p = 0.041) were associated with higher termination acceptance. Cardiac severity and gestational age were not independently associated with parental decision. Conclusions: Genetic-evaluation status was associated with parental acceptance of termination after prenatal CHD diagnosis in a multidisciplinary counselling setting; given the small sample size and the selected, council-recommended cohort studied, this association should be interpreted as hypothesis-generating rather than as evidence of a causal or independent predictive effect. FAU - Oktem, Abdulmecit AU - Oktem A AD - Department of Perinatology, Izmir City Hospital, Izmir 35540, Turkey. FAU - Ceylan, Mukremin AU - Ceylan M AUID- ORCID: 0009-0002-3662-8740 AD - Department of Perinatology, Izmir City Hospital, Izmir 35540, Turkey. FAU - Golbasi, Hakan AU - Golbasi H AUID- ORCID: 0000-0001-8682-5537 AD - Department of Perinatology, Izmir City Hospital, Izmir 35540, Turkey. LA - eng PT - Journal Article DEP - 20260819 PL - Switzerland TA - Diagnostics (Basel) JT - Diagnostics (Basel, Switzerland) JID - 101658402 PMC - PMC13512715 OTO - NOTNLM OT - abortion OT - congenital heart defects OT - decision making OT - genetic testing OT - prenatal diagnosis COIS- The authors declare no conflicts of interest. EDAT- 2026/08/27 05:35 MHDA- 2026/08/27 05:36 PMCR- 2026/08/19 CRDT- 2026/08/27 01:03 PHST- 2026/07/01 00:00 [received] PHST- 2026/08/04 00:00 [revised] PHST- 2026/08/16 00:00 [accepted] PHST- 2026/08/27 05:36 [medline] PHST- 2026/08/27 05:35 [pubmed] PHST- 2026/08/27 01:03 [entrez] PHST- 2026/08/19 00:00 [pmc-release] AID - diagnostics16162624 [pii] AID - diagnostics-16-02624 [pii] AID - 10.3390/diagnostics16162624 [doi] PST - epublish SO - Diagnostics (Basel). 2026 Aug 19;16(16):2624. doi: 10.3390/diagnostics16162624. PMID- 42648003 OWN - NLM STAT- MEDLINE DCOM- 20260915 LR - 20260915 IS - 1872-8464 (Electronic) IS - 0165-5876 (Linking) VI - 209 DP - 2026 Oct TI - The value of multidisciplinary aerodigestive evaluation in pediatric vascular ring and sling management: A retrospective cohort study. PG - 112990 LID - S0165-5876(26)00286-7 [pii] LID - 10.1016/j.ijporl.2026.112990 [doi] AB - OBJECTIVES: Respiratory and feeding symptoms in children with vascular rings and slings are nonspecific and may not be solely attributable to the vascular anomaly. We evaluated the impact of Aerodigestive Clinic (ADC) assessment on long-term postoperative outcomes and characterized its diagnostic yield. METHODS: We retrospectively studied children with vascular rings or slings at a tertiary pediatric center (2011-2024), comparing those who underwent primary ADC evaluation with those who did not. The primary outcome was residual respiratory or feeding symptoms >/=1-year after repair. Multivariable regression assessed factors associated with symptom persistence. RESULTS: Among 219 patients, 91 (41.6%) underwent primary ADC evaluation and 8 (3.7%) were evaluated post-repair. ADC assessment identified additional aerodigestive pathology prompting treatment modifications in 56.6% (56/99). Surgical repair was deferred in 57.1% (52/91) of patients undergoing primary ADC evaluation; 40.4% (21/52) had treatment modifications based on ADC findings. Overall, 118 patients (53.9%) underwent repair at a median age of 372 days (IQR 133-1030). Among 108 patients with >/=1-year follow-up, residual symptoms occurred in 30 (27.8%), including 21.9% of ADC patients and 30.3% of non-ADC patients. ADC involvement was not associated with reduced residual symptoms (adjusted OR 0.71; 95%CI 0.18-2.41; P = .6), whereas preoperative respiratory medication use predicted symptom persistence (adjusted OR 3.28; 95%CI 1.25-8.98; P = .02). CONCLUSIONS: Despite the lack of statistically significant reduction in residual symptoms, ADC involvement identifies alternative causes of respiratory or feeding symptoms, informs surgical decision-making, guides pre- and postoperative management, and may, in some cases, defer the need for major cardiovascular surgery. CI - Copyright (c) 2026 Elsevier B.V. All rights reserved. FAU - Risbud, Adwight AU - Risbud A AD - Division of Otolaryngology, Head and Neck Surgery, Cedars Sinai, Los Angeles, CA, USA. FAU - Frank, Ethan D AU - Frank ED AD - Department of Otolaryngology, Head and Neck Surgery, University of California San Diego, Rady Children's Hospital, San Diego, CA, USA. FAU - Sun, Heather Y AU - Sun HY AD - Division of Pediatric Cardiology, Rady Children's Hospital, University of California, San Diego, CA, USA. FAU - Rao, Aparna AU - Rao A AD - Division of Respiratory Medicine, Rady Children's Hospital, University of California, San Diego, CA, USA. FAU - Qian, Z Jason AU - Qian ZJ AD - Department of Otolaryngology, Head and Neck Surgery, University of California San Diego, Rady Children's Hospital, San Diego, CA, USA. FAU - Brigger, Matthew T AU - Brigger MT AD - Department of Otolaryngology, Head and Neck Surgery, University of California San Diego, Rady Children's Hospital, San Diego, CA, USA. FAU - Kumar, Soma AU - Kumar S AD - Division of Gastroenterology, Rady Children's Hospital, University of California, San Diego, CA, USA. FAU - Floco, Virginia AU - Floco V AD - Department of Otolaryngology, Head and Neck Surgery, University of California San Diego, Rady Children's Hospital, San Diego, CA, USA. FAU - LaSalle, Elizabeth E AU - LaSalle EE AD - Division of Pediatric Cardiology, Rady Children's Hospital, University of California, San Diego, CA, USA. FAU - Morris, Kimberly AU - Morris K AD - Speech Language Pathology, Rady Children's Hospital San Diego, San Diego, CA, USA. FAU - Horvay, Lisa AU - Horvay L AD - Occupational Therapy, Rady Children's Hospital San Diego, San Diego, CA, USA. FAU - Friesen, Tzyynong L AU - Friesen TL AD - Department of Otolaryngology, Head and Neck Surgery, University of California San Diego, Rady Children's Hospital, San Diego, CA, USA. Electronic address: tfriesen@health.ucsd.edu. LA - eng PT - Journal Article DEP - 20260824 PL - Ireland TA - Int J Pediatr Otorhinolaryngol JT - International journal of pediatric otorhinolaryngology JID - 8003603 SB - IM MH - Humans MH - Retrospective Studies MH - Female MH - Male MH - *Vascular Ring/surgery/complications/diagnosis MH - Infant MH - Child, Preschool MH - Treatment Outcome MH - Child OTO - NOTNLM OT - Aerodigestive evaluation OT - Dysphagia OT - Multidisciplinary care OT - Pediatric airway OT - Tracheomalacia OT - Vascular rings COIS- Declaration of competing interests The authors declare no conflict of interest in submission of this article. EDAT- 2026/08/26 23:35 MHDA- 2026/09/15 23:35 CRDT- 2026/08/26 18:02 PHST- 2026/07/16 00:00 [received] PHST- 2026/08/18 00:00 [revised] PHST- 2026/08/23 00:00 [accepted] PHST- 2026/09/15 23:35 [medline] PHST- 2026/08/26 23:35 [pubmed] PHST- 2026/08/26 18:02 [entrez] AID - S0165-5876(26)00286-7 [pii] AID - 10.1016/j.ijporl.2026.112990 [doi] PST - ppublish SO - Int J Pediatr Otorhinolaryngol. 2026 Oct;209:112990. doi: 10.1016/j.ijporl.2026.112990. Epub 2026 Aug 24. PMID- 42645924 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260826 LR - 20260828 IS - 2075-4426 (Print) IS - 2075-4426 (Electronic) IS - 2075-4426 (Linking) VI - 16 IP - 8 DP - 2026 Aug 14 TI - Aortitis as a High-Risk Vascular Syndrome: Integrating Phenotype-Driven Diagnosis, Multidisciplinary Assessment, and Personalised Management. LID - 10.3390/jpm16080430 [doi] LID - 430 AB - Aortitis-inflammation of the aortic wall-presents at the interface of vasculitis, infection, structural aortic disease, and cardiovascular risk. It may occur in giant cell arteritis (GCA), Takayasu arteritis, immunoglobulin G4 (IgG4)-related disease, drug-induced injury, infection, or as an isolated finding after aortic surgery. Modern imaging detects aortic inflammation more frequently, but the main challenge is classification rather than detection: determining whether disease is infectious or immune-mediated, active or dominated by fixed structural damage, systemic or isolated, and whether the dominant threat is aneurysm, dissection, undertreated infection, or avoidable immunosuppression. This review considers aortitis as a high-risk vascular syndrome requiring aetiology-first classification rather than descriptive labelling. Before escalating immunosuppression, infection must be actively excluded and inflammatory activity distinguished from fixed vascular damage. Treatment should be individualised according to phenotype, age, vascular territory, comorbidity, and toxicity risk, with surveillance continuing even after symptoms and inflammatory markers improve. Optimal care depends on multidisciplinary assessment integrating rheumatology, infectious diseases, vascular surgery, radiology, and cardiology expertise. Progress will require standardised imaging definitions, registries linking inflammatory control with structural vascular outcomes, and validation of artificial intelligence (AI) tools before clinical adoption. FAU - Georghiou, Georgios P AU - Georghiou GP AUID- ORCID: 0009-0006-1667-3172 AD - Department of Surgery, Gray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv 6997801, Israel. AD - School of Medicine, European University Cyprus, Egkomi, Nicosia 2404, Cyprus. FAU - Socratous, Klitia AU - Socratous K AD - School of Medicine, European University Cyprus, Egkomi, Nicosia 2404, Cyprus. FAU - Kyriakou, Sotiris AU - Kyriakou S AUID- ORCID: 0000-0002-2259-5004 AD - Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AD, UK. FAU - Lampropoulos, Konstantinos AU - Lampropoulos K AD - School of Medicine, European University Cyprus, Egkomi, Nicosia 2404, Cyprus. FAU - Georghiou, Panos AU - Georghiou P AUID- ORCID: 0000-0001-7523-9786 AD - Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AD, UK. FAU - Georgiou, Amalia AU - Georgiou A AD - Department of Cardiology, Krankenhaus Maria-Hilf, 47805 Krefeld, Germany. FAU - Neokleous, Marilina AU - Neokleous M AD - School of Medicine, University of Cyprus, Aglanztia, Nicosia 2029, Cyprus. FAU - Ttofi, Iakovos AU - Ttofi I AD - School of Medicine, European University Cyprus, Egkomi, Nicosia 2404, Cyprus. FAU - Iosif, Nikolas AU - Iosif N AUID- ORCID: 0009-0006-5114-7020 AD - Klinik fur Gastroenterologie, Hepatologie, Endokrinologie, Diabetologie, Helios Universitatsklinikum, 42283 Wuppertal, Germany. FAU - Triposkiadis, Filippos AU - Triposkiadis F AD - School of Medicine, European University Cyprus, Egkomi, Nicosia 2404, Cyprus. LA - eng PT - Journal Article PT - Review DEP - 20260814 PL - Switzerland TA - J Pers Med JT - Journal of personalized medicine JID - 101602269 PMC - PMC13514586 OTO - NOTNLM OT - IgG4-related disease OT - Takayasu arteritis OT - aortic aneurysm OT - aortitis OT - giant cell arteritis OT - infectious aortitis OT - large-vessel vasculitis OT - multidisciplinary care OT - multimodality imaging OT - personalised medicine COIS- The authors declare no conflicts of interest. EDAT- 2026/08/26 17:37 MHDA- 2026/08/26 17:38 PMCR- 2026/08/14 CRDT- 2026/08/26 11:28 PHST- 2026/06/18 00:00 [received] PHST- 2026/07/31 00:00 [revised] PHST- 2026/08/13 00:00 [accepted] PHST- 2026/08/26 17:38 [medline] PHST- 2026/08/26 17:37 [pubmed] PHST- 2026/08/26 11:28 [entrez] PHST- 2026/08/14 00:00 [pmc-release] AID - jpm16080430 [pii] AID - jpm-16-00430 [pii] AID - 10.3390/jpm16080430 [doi] PST - epublish SO - J Pers Med. 2026 Aug 14;16(8):430. doi: 10.3390/jpm16080430. PMID- 42645868 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260826 LR - 20260828 IS - 2308-3425 (Electronic) IS - 2308-3425 (Linking) VI - 13 IP - 8 DP - 2026 Aug 19 TI - Forward Dynamics: Modern Insights into Mitral Systolic Anterior Motion. LID - 10.3390/jcdd13080397 [doi] LID - 397 AB - Systolic anterior motion (SAM) of the mitral valve can occur either in association with or in the absence of hypertrophic obstructive cardiomyopathy (HOCM). SAM induces dynamic left ventricular outflow tract obstruction (LVOTO) and, in the majority of cases, is associated with a substantial degree of mitral regurgitation (MR) that significantly impacts patient morbidity and mortality. This narrative review explores the contemporary understanding of the pathophysiology, diagnosis, and management of SAM, focusing particularly on surgical strategies and the novel therapeutic class of cardiac myosin inhibitors. Extended septal myectomy remains the gold-standard treatment for HOCM-related SAM, yielding superior long-term outcomes compared to alcohol septal ablation (ASA). Advanced imaging modalities, including three-dimensional transesophageal echocardiography (3D-TEE), enable precise pre-operative characterization of the mitral valve apparatus. Some patients may benefit from septal reduction strategies while concomitant mitral valve interventions are generally reserved for highly selected cases with intrinsic valve pathology or persistent residual SAM, thereby avoiding unnecessary valvular manipulation and its potential hemodynamic risks. Mavacamten, a selective cardiac myosin inhibitor, represents an important advance in pharmacological management, achieving a mean LVOT gradient reduction of 37.2 mmHg in symptomatic patients. Furthermore, data from the MARVEL registry confirm the real-world clinical efficacy of mavacamten in obstructive hypertrophic cardiomyopathy, with 86% of patients successfully down-staged to NYHA functional class I-II. Although ASA serves as a viable alternative to surgery, it entails a higher risk of conduction abnormalities requiring permanent pacemaker implantation and subsequent re-intervention. Beyond classical hypertrophic SAM, this review addresses the diagnosis and management of post-mitral repair complications and non-hypertrophic variants. Optimal management and risk stratification remain an evolving field requiring a multidisciplinary Heart Team approach, leverage of advanced imaging, and adoption of novel medical therapies. Interventional strategies must be carefully tailored to maximize the efficacy-to-safety profile on an individualized patient basis. FAU - Samet Bouhaik, Fatima Zahra AU - Samet Bouhaik FZ AD - Department of Cardiology, Centre Hospitalier General Victor Jousselin de Dreux, 28100 Dreux, France. FAU - Monaco, Ilenia AU - Monaco I AD - Department of Cardiology, Centre Hospitalier General Victor Jousselin de Dreux, 28100 Dreux, France. FAU - Sedrati, Mounia AU - Sedrati M AD - Department of Cardiology, Centre Hospitalier General Victor Jousselin de Dreux, 28100 Dreux, France. FAU - Bouvet, Alix AU - Bouvet A AD - Emergency Department, Centre Hospitalier Regional et Universitaire de Tours, 37170 Tours, France. FAU - Gervais, Benedicte AU - Gervais B AD - Emergency Department, Centre Hospitalier Regional et Universitaire de Tours, 37170 Tours, France. FAU - Trivelloni, Valeria AU - Trivelloni V AD - Department of Cardiology, Centre Hospitalier General Victor Jousselin de Dreux, 28100 Dreux, France. FAU - Bencharef, Yassine AU - Bencharef Y AD - Department of Cardiology, Centre Hospitalier General Victor Jousselin de Dreux, 28100 Dreux, France. FAU - Sekkal, Fouad Mohammed AU - Sekkal FM AD - Department of Cardiology, Centre Hospitalier General Victor Jousselin de Dreux, 28100 Dreux, France. FAU - Bottigliero, Dario AU - Bottigliero D AUID- ORCID: 0009-0007-1646-2196 AD - Department of Cardiology, Centre Hospitalier General Victor Jousselin de Dreux, 28100 Dreux, France. LA - eng PT - Journal Article PT - Review DEP - 20260819 PL - Switzerland TA - J Cardiovasc Dev Dis JT - Journal of cardiovascular development and disease JID - 101651414 PMC - PMC13513795 OTO - NOTNLM OT - alcohol septal ablation OT - echocardiography OT - hypertrophic cardiomyopathy OT - left ventricular outflow tract obstruction OT - mavacamten OT - mitral regurgitation OT - mitral valve OT - septal myectomy OT - surgical management OT - systolic anterior motion COIS- The authors declare no conflicts of interest. EDAT- 2026/08/26 17:36 MHDA- 2026/08/26 17:37 PMCR- 2026/08/19 CRDT- 2026/08/26 11:28 PHST- 2026/07/11 00:00 [received] PHST- 2026/08/09 00:00 [revised] PHST- 2026/08/18 00:00 [accepted] PHST- 2026/08/26 17:37 [medline] PHST- 2026/08/26 17:36 [pubmed] PHST- 2026/08/26 11:28 [entrez] PHST- 2026/08/19 00:00 [pmc-release] AID - jcdd13080397 [pii] AID - jcdd-13-00397 [pii] AID - 10.3390/jcdd13080397 [doi] PST - epublish SO - J Cardiovasc Dev Dis. 2026 Aug 19;13(8):397. doi: 10.3390/jcdd13080397. PMID- 42645861 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260826 LR - 20260828 IS - 2308-3425 (Electronic) IS - 2308-3425 (Linking) VI - 13 IP - 8 DP - 2026 Aug 14 TI - The Limits of Comorbidity Indices in TAVI: How Aggregation Dilutes the Prognostic Power of Individual Biomarkers. LID - 10.3390/jcdd13080390 [doi] LID - 390 AB - OBJECTIVE: Heart-team decisions in transcatheter aortic valve implantation (TAVI) lean on EuroSCORE II, yet the comorbidity burden that often drives the final choice is rarely scored. We tested a specific two-part hypothesis: whether formally quantifying comorbidity burden (via the Charlson Comorbidity Index [CCI] and a modified CCI [mCCI]) recovers prognostic value beyond EuroSCORE II for Valve Academic Research Consortium-3 (VARC-3) outcomes, and whether aggregating comorbidities preserves or dilutes the prognostic signal of individually informative predictors. METHODS: In 234 consecutive patients (mean age 76.6 +/- 6.1 years) undergoing TAVI for severe aortic stenosis, EuroSCORE II, CCI, and mCCI were computed before the procedure. The primary endpoint was the 30-day VARC-3 composite; secondary endpoints were individual VARC-3 outcomes and one-year mortality. We compared discrimination (AUC, DeLong test) and incremental value with bootstrapping, and analyzed survival by Kaplan-Meier/Cox regression. RESULTS: All three scores discriminated the 30-day composite (63 patients, 26.9%) poorly (AUCs 0.50-0.54), collapsing to chance after correction; neither comorbidity index improved on EuroSCORE II (all p > 0.40). EuroSCORE II's only meaningful signal was stage 3 acute kidney injury (AKI; AUC 0.676), where it significantly exceeded mCCI (p = 0.048). Serum albumin and chronic kidney disease (HR 2.97 for one-year mortality) were informative individually but not within an aggregate score. CONCLUSIONS: In elderly TAVI, the actionable prognostic information resided in individual markers of organ reserve-serum albumin and chronic kidney disease-that count-based comorbidity aggregation dissipated rather than concentrated. EuroSCORE II retained a focused, mechanistically coherent association with stage 3 AKI, reflecting its renal components. These findings support a shift from disease-counting toward direct measurement of organ reserve and frailty in TAVI risk assessment, and the development of TAVI-specific tools that preserve dominant individual predictors rather than averaging them into a single score. FAU - Bilgin Dogan, Nazile AU - Bilgin Dogan N AUID- ORCID: 0000-0001-5863-8822 AD - Department of Cardiology, Turkish Ministry of Health Izmir Bayrakli City Hospital, Izmir 35540, Turkey. FAU - Kuzucu, Ozdemir AU - Kuzucu O AUID- ORCID: 0000-0003-0163-9351 AD - Department of Cardiology, Turkish Ministry of Health Izmir Bayrakli City Hospital, Izmir 35540, Turkey. LA - eng PT - Journal Article DEP - 20260814 PL - Switzerland TA - J Cardiovasc Dev Dis JT - Journal of cardiovascular development and disease JID - 101651414 PMC - PMC13513905 OTO - NOTNLM OT - acute kidney injury OT - aged OT - aortic valve stenosis OT - comorbidity OT - risk assessment OT - transcatheter aortic valve replacement COIS- The authors declare no conflicts of interest. EDAT- 2026/08/26 17:36 MHDA- 2026/08/26 17:37 PMCR- 2026/08/14 CRDT- 2026/08/26 11:28 PHST- 2026/07/04 00:00 [received] PHST- 2026/07/20 00:00 [revised] PHST- 2026/08/12 00:00 [accepted] PHST- 2026/08/26 17:37 [medline] PHST- 2026/08/26 17:36 [pubmed] PHST- 2026/08/26 11:28 [entrez] PHST- 2026/08/14 00:00 [pmc-release] AID - jcdd13080390 [pii] AID - jcdd-13-00390 [pii] AID - 10.3390/jcdd13080390 [doi] PST - epublish SO - J Cardiovasc Dev Dis. 2026 Aug 14;13(8):390. doi: 10.3390/jcdd13080390. PMID- 42641533 OWN - NLM STAT- MEDLINE DCOM- 20260926 LR - 20260926 IS - 1876-035X (Electronic) IS - 1876-0341 (Linking) VI - 19 IP - 10 DP - 2026 Oct TI - Brucella endocarditis presenting as culture-negative infective endocarditis in a tertiary cardiac center in Saudi Arabia: A 15-year case series. PG - 103338 LID - S1876-0341(26)00210-8 [pii] LID - 10.1016/j.jiph.2026.103338 [doi] AB - BACKGROUND: Brucella endocarditis is a life-threatening complication of brucellosis that frequently presents as culture-negative endocarditis in endemic regions, posing significant diagnostic and therapeutic challenges. METHODS: We conducted a retrospective case series of 22 patients (median age 52.5 years, 90.9% male) with confirmed Brucella endocarditis managed at a tertiary center in a brucellosis-endemic area between 2009 and 2024. RESULTS: Initial blood cultures were negative in 59% of patients, while Brucella spp. were ultimately isolated from blood or valve tissue cultures in 10 patients. Serology was positive in 20/22 (90.9%), with a median standard agglutination test (SAT) titer of 1:2560 (range 1:320-1:10240). Underlying valvular disease was universal: rheumatic (31.8%), congenital (36.4%) predominantly tetralogy of Fallot and prosthetic valves (31.8%). Echocardiography showed large, mobile vegetations (mean diameter 12 mm), abscess formation in 22.7%, and frequent multivalvular involvement. All patients received combination antimicrobial therapy (median duration 4.5 months), most commonly doxycycline, rifampicin, and an aminoglycoside. Surgical intervention was required in 72.7% (16/22), primarily valve replacement; one patient died (4.5%). Relapse occurred in 18.2% (4/22), all successfully retreated. At follow-up, serological titers declined significantly. CONCLUSIONS: Brucella endocarditis should be actively considered in patients with culture-negative endocarditis in endemic regions, particularly in those with structural or prosthetic heart disease. This case series emphasizes the importance of early recognition, multidisciplinary evaluation and individualized medical and surgical management in this complex infection. CI - Copyright (c) 2026 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Alawad, Eman AU - Alawad E AD - Department of Medicine, Division of Infectious Diseases, Prince Sultan Military Medical City, Riyadh, Saudi Arabia; Infection Prevention and Control Department, Division of Infectious Diseases, Prince Sultan Cardiac Center, Riyadh, Saudi Arabia. Electronic address: ebinawad@pscc.med.sa. FAU - Mirza, Kiran Athar AU - Mirza KA AD - Department of Medicine, Division of Infectious Diseases, Prince Sultan Military Medical City, Riyadh, Saudi Arabia. FAU - Hillaru, Mohammed Haris AU - Hillaru MH AD - Department of Medicine, Division of Infectious Diseases, Prince Sultan Military Medical City, Riyadh, Saudi Arabia. FAU - Akhter, Yasin AU - Akhter Y AD - Department of Medicine, Division of Infectious Diseases, Prince Sultan Military Medical City, Riyadh, Saudi Arabia; Infection Prevention and Control Department, Division of Infectious Diseases, Prince Sultan Cardiac Center, Riyadh, Saudi Arabia. FAU - Alraddadi, Mohammed A AU - Alraddadi MA AD - Department of Medicine, Division of Infectious Diseases, Prince Sultan Military Medical City, Riyadh, Saudi Arabia. FAU - Alsufyani, Eid AU - Alsufyani E AD - Department of Medicine, Division of Infectious Diseases, Prince Sultan Military Medical City, Riyadh, Saudi Arabia. FAU - Alnomani, Mohammed AU - Alnomani M AD - Department of Medicine, Internal Medicine Residency Training Program, Prince Sultan Military Medical City, Riyadh, Saudi Arabia. FAU - Eltaib, Nazik AU - Eltaib N AD - Department of Medicine, Division of Infectious Diseases, Prince Sultan Military Medical City, Riyadh, Saudi Arabia. FAU - Alsaeed, Mohammed AU - Alsaeed M AD - Department of Medicine, Division of Infectious Diseases, Prince Sultan Military Medical City, Riyadh, Saudi Arabia. FAU - Alsherebeeni, Nissrin AU - Alsherebeeni N AD - Department of Medicine, Division of Infectious Diseases, Prince Sultan Military Medical City, Riyadh, Saudi Arabia. FAU - Elzain, Fatehi AU - Elzain F AD - Department of Medicine, Division of Infectious Diseases, Prince Sultan Military Medical City, Riyadh, Saudi Arabia. FAU - Naji, Khalid AU - Naji K AD - Department of Adult Cardiology, Advanced Cardiac Imaging and Nuclear Cardiology Laboratory, Prince Sultan Cardiac Center, Riyadh, Saudi Arabia. FAU - Alnajashi, Khalid AU - Alnajashi K AD - Adult Congenital Heart Disease Department, Interventional Congenital Adult and Pediatric Cardiology, Prince Sultan Cardiac Center, Riyadh, Saudi Arabia. FAU - Ismail, Huda AU - Ismail H AD - Adult Cardiac Surgery Department, Prince Sultan Cardiac Center, Riyadh, Saudi Arabia. FAU - Musa, Zakaryia Albin AU - Musa ZA AD - Adult Cardiology Department, Echocardiography Division, Prince Sultan Cardiac Center, Riyadh, Saudi Arabia. LA - eng PT - Journal Article DEP - 20260816 PL - England TA - J Infect Public Health JT - Journal of infection and public health JID - 101487384 RN - 0 (Anti-Bacterial Agents) SB - IM MH - Humans MH - *Brucellosis/diagnosis/drug therapy/epidemiology MH - Male MH - Retrospective Studies MH - Female MH - Saudi Arabia/epidemiology MH - Middle Aged MH - Tertiary Care Centers MH - *Endocarditis, Bacterial/diagnosis/microbiology/drug therapy/epidemiology MH - *Brucella/isolation & purification MH - Adult MH - Anti-Bacterial Agents/therapeutic use MH - Aged MH - Echocardiography MH - Young Adult OTO - NOTNLM OT - Brucella endocarditis OT - Culture-negative endocarditis OT - Endemic region OT - Serology OT - Valve surgery COIS- Declaration of Competing Interest On behalf of all authors, I confirm that the authors have no known competing financial interests, personal relationships, affiliations, or other conflicts of interest that could have influenced the work reported in the manuscript entitled: "Brucella Endocarditis as a Cause of Culture-Negative Endocarditis in a Tertiary Cardiac Center in Saudi Arabia: A 15-Year Experience." All authors have reviewed and approved this declaration and confirm that there are no competing interests to disclose related to this work. EDAT- 2026/08/25 23:33 MHDA- 2026/09/27 02:29 CRDT- 2026/08/25 18:10 PHST- 2026/05/18 00:00 [received] PHST- 2026/08/11 00:00 [revised] PHST- 2026/08/12 00:00 [accepted] PHST- 2026/09/27 02:29 [medline] PHST- 2026/08/25 23:33 [pubmed] PHST- 2026/08/25 18:10 [entrez] AID - S1876-0341(26)00210-8 [pii] AID - 10.1016/j.jiph.2026.103338 [doi] PST - ppublish SO - J Infect Public Health. 2026 Oct;19(10):103338. doi: 10.1016/j.jiph.2026.103338. Epub 2026 Aug 16. PMID- 42638839 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260825 LR - 20260826 IS - 2050-0904 (Print) IS - 2050-0904 (Electronic) IS - 2050-0904 (Linking) VI - 14 IP - 9 DP - 2026 Sep TI - Angiography-Negative Subarachnoid Hemorrhage Detected After Emergent Percutaneous Coronary Intervention for Non-ST-Segment Elevation Myocardial Infarction: A Case Report. PG - e73363 LID - 10.1002/ccr3.73363 [doi] LID - e73363 AB - Neurological deterioration, headache, vomiting, bradycardia, or hypertension after emergent percutaneous coronary intervention should prompt immediate brain imaging. When subarachnoid hemorrhage is detected shortly after coronary stenting, the hemorrhage onset may remain uncertain, and antiplatelet decisions require individualized multidisciplinary assessment. CI - (c) 2026 The Author(s). Clinical Case Reports published by John Wiley & Sons Ltd. FAU - Lee, Chul Hee AU - Lee CH AUID- ORCID: 0000-0001-8024-4192 AD - Department of Neurosurgery, College of Medicine Gyeongsang National University Hospital Jinju Republic of Korea. LA - eng PT - Journal Article DEP - 20260823 PL - England TA - Clin Case Rep JT - Clinical case reports JID - 101620385 PMC - PMC13500905 OTO - NOTNLM OT - acute coronary syndrome OT - angiography-negative subarachnoid hemorrhage OT - antiplatelet therapy OT - hydrocephalus OT - percutaneous coronary intervention COIS- The author declares no conflicts of interest. EDAT- 2026/08/25 11:38 MHDA- 2026/08/25 11:39 PMCR- 2026/08/23 CRDT- 2026/08/25 05:38 PHST- 2026/07/18 00:00 [received] PHST- 2026/08/06 00:00 [revised] PHST- 2026/08/13 00:00 [accepted] PHST- 2026/08/25 11:39 [medline] PHST- 2026/08/25 11:38 [pubmed] PHST- 2026/08/25 05:38 [entrez] PHST- 2026/08/23 00:00 [pmc-release] AID - CCR373363 [pii] AID - 10.1002/ccr3.73363 [doi] PST - epublish SO - Clin Case Rep. 2026 Aug 23;14(9):e73363. doi: 10.1002/ccr3.73363. eCollection 2026 Sep. PMID- 42638668 OWN - NLM STAT- MEDLINE DCOM- 20260825 LR - 20260826 IS - 1664-2295 (Electronic) IS - 1664-2295 (Linking) VI - 17 DP - 2026 TI - Pathophysiological frameworks and emerging preventative strategies in SUDEP. PG - 1916085 LID - 10.3389/fneur.2026.1916085 [doi] LID - 1916085 AB - Sudden Unexpected Death in Epilepsy (SUDEP) represents a leading cause of epilepsy-related mortality, reflecting a severe disruption of systemic physiology that remains challenging to address using standard clinical protocols. Although generalized tonic-clonic seizures (GTCS) and pharmacoresistance are established risk indicators, current clinical risk stratification frequently lacks the predictive granularity required to anticipate individual cardiorespiratory collapse. This review provides a comprehensive synthesis of the SUDEP pathophysiological framework, aiming to bridge the gap between retrospective clinical observation and proactive precision medicine. We delineate a translational framework focused on the intrinsic biological susceptibility of the neuro-cardiac axis, particularly the genetic "dual pathology" of channelopathies and structural cardiac remodeling. Furthermore, we evaluate the transition from reactive risk identification toward multimodal "digital phenotyping" leveraging artificial intelligence. Finally, we assess the developmental trajectory of "secondary prevention" strategies, such as automated neurostimulation, designed to interrupt the terminal cascade. By integrating genomic vulnerability with emerging preventative technologies, this review outlines a multidisciplinary approach to transforming SUDEP into a more predictable and preventable clinical entity. CI - Copyright (c) 2026 Xu, Wang, Nie, Gao and Guan. FAU - Xu, Chenxi AU - Xu C AD - First Clinical Medical College of Henan University of Chinese Medicine, Zhengzhou, Henan, China. AD - Department of Encephalopathy, The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou, Henan, China. FAU - Wang, Yiyuan AU - Wang Y AD - First Clinical Medical College of Henan University of Chinese Medicine, Zhengzhou, Henan, China. AD - Department of Encephalopathy, The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou, Henan, China. FAU - Nie, Suping AU - Nie S AD - First Clinical Medical College of Henan University of Chinese Medicine, Zhengzhou, Henan, China. AD - Department of Encephalopathy, The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou, Henan, China. FAU - Gao, Jia AU - Gao J AD - First Clinical Medical College of Henan University of Chinese Medicine, Zhengzhou, Henan, China. AD - Department of Encephalopathy, The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou, Henan, China. FAU - Guan, Yunxiang AU - Guan Y AD - Department of Encephalopathy, The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou, Henan, China. LA - eng PT - Journal Article PT - Review DEP - 20260810 PL - Switzerland TA - Front Neurol JT - Frontiers in neurology JID - 101546899 SB - IM MH - Humans MH - *Sudden Unexpected Death in Epilepsy/prevention & control/etiology MH - Animals MH - *Epilepsy/physiopathology/complications PMC - PMC13500304 OTO - NOTNLM OT - SUDEP OT - biomarkers OT - central autonomic network OT - neurostimulation OT - pathophysiology OT - prevention COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/08/25 11:38 MHDA- 2026/08/25 11:39 PMCR- 2026/08/10 CRDT- 2026/08/25 05:12 PHST- 2026/06/22 00:00 [received] PHST- 2026/07/15 00:00 [revised] PHST- 2026/07/22 00:00 [accepted] PHST- 2026/08/25 11:39 [medline] PHST- 2026/08/25 11:38 [pubmed] PHST- 2026/08/25 05:12 [entrez] PHST- 2026/08/10 00:00 [pmc-release] AID - 10.3389/fneur.2026.1916085 [doi] PST - epublish SO - Front Neurol. 2026 Aug 10;17:1916085. doi: 10.3389/fneur.2026.1916085. eCollection 2026. PMID- 42633108 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260823 LR - 20260824 IS - 2474-8714 (Electronic) IS - 2474-8706 (Print) IS - 2474-8706 (Linking) VI - 10 IP - 9 DP - 2026 Sep TI - Balloon Aortic Valvuloplasty as a Bridge Therapy in Acute Valve Syndrome: A Narrative Review of Evidence Gaps and Future Directions. PG - 101059 LID - 10.1016/j.shj.2026.101059 [doi] LID - 101059 AB - Acute valve syndrome represents a high-acuity, decompensated presentation of severe aortic stenosis (AS), often manifesting as acute heart failure, cardiogenic shock, or cardiac arrest. Transcatheter aortic valve replacement (TAVR) remains the only durable therapy for severe AS in patients with prohibitive surgical risk, yet acute valve syndrome patients may be too unstable for standard preprocedural planning. Balloon aortic valvuloplasty (BAV) has re-emerged as a bridge strategy that can provide rapid hemodynamic stabilization and permit subsequent valve replacement. Registry analyses report lower mortality in emergent TAVR compared with BAV, but these comparisons are confounded by procedural indication and unmatched AS severity. Smaller hemodynamically characterized cohorts suggest that selected patients who stabilize after BAV and proceed to TAVR may achieve outcomes comparable to direct TAVR, although these studies remain underpowered for definitive inference. In this narrative review, we evaluate evidence comparing BAV-bridged strategies with emergent TAVR, identify key evidence gaps, and discuss how acute hemodynamic status may inform Heart Team decision-making. CI - (c) 2026 The Author(s). FAU - Saleh, Omar AU - Saleh O AD - Macon and Joan Brock Virginia Health Sciences at Old Dominion University, Eastern Virginia Medical School, Norfolk, Virginia, USA. FAU - Jafar, Omar AU - Jafar O AD - Macon and Joan Brock Virginia Health Sciences at Old Dominion University, Department of Internal Medicine, Eastern Virginia Medical School, Norfolk, Virginia, USA. FAU - Valle, Nicholas AU - Valle N AD - Macon and Joan Brock Virginia Health Sciences at Old Dominion University, Department of Internal Medicine, Eastern Virginia Medical School, Norfolk, Virginia, USA. FAU - Yasa, Shirish AU - Yasa S AD - Macon and Joan Brock Virginia Health Sciences at Old Dominion University, Eastern Virginia Medical School, Norfolk, Virginia, USA. FAU - Mostafa, Saleh AU - Mostafa S AD - Macon and Joan Brock Virginia Health Sciences at Old Dominion University, Eastern Virginia Medical School, Norfolk, Virginia, USA. FAU - Benza, Raymond L AU - Benza RL AD - Department of Cardiology, Macon and Joan Brock Virginia Health Sciences at Old Dominion University, Eastern Virginia Medical School, Norfolk, Virginia, USA. FAU - Talreja, Deepak R AU - Talreja DR AD - Department of Structural Cardiology, Sentara Medical Group, Sentara Health, Virginia Beach, Virginia, USA. FAU - Peterson, Benjamin D AU - Peterson BD AD - Intermountain Medical Center Heart Institute, Intermountain Medical Center, Salt Lake City, Utah, USA. FAU - Summers, Matthew R AU - Summers MR AD - Department of Structural Cardiology, Sentara Medical Group, Sentara Health, Virginia Beach, Virginia, USA. LA - eng PT - Journal Article PT - Review DEP - 20260623 PL - United States TA - Struct Heart JT - Structural heart : the journal of the Heart Team JID - 101743256 PMC - PMC13499043 OTO - NOTNLM OT - Acute valve syndrome OT - Aortic stenosis OT - Balloon aortic valvuloplasty OT - Cardiogenic shock OT - Mechanical circulatory support OT - Transcatheter aortic valve replacement COIS- Raymond L. Benza receives speaking, consulting, and proctoring income from Abbott. Deepak R. Talreja receives speaking, consulting, and proctoring income from Medtronic, Abbott, Abiomed, Bristol Myers Squibb, Novartis, and Amgen. Matthew R. Summers receives speaking, consulting, and proctoring income from Abbott Pharmaceuticals and Medtronic and serves on the advisory board for Abbott Pharmaceuticals, Medtronic, Picardia, Shockwave, DASI, and Abiomed. The other authors had no conflicts to declare. EDAT- 2026/08/23 05:41 MHDA- 2026/08/23 05:42 PMCR- 2026/06/23 CRDT- 2026/08/23 04:03 PHST- 2026/03/01 00:00 [received] PHST- 2026/05/07 00:00 [revised] PHST- 2026/05/16 00:00 [accepted] PHST- 2026/08/23 05:42 [medline] PHST- 2026/08/23 05:41 [pubmed] PHST- 2026/08/23 04:03 [entrez] PHST- 2026/06/23 00:00 [pmc-release] AID - S2474-8706(26)00268-X [pii] AID - 101059 [pii] AID - 10.1016/j.shj.2026.101059 [doi] PST - epublish SO - Struct Heart. 2026 Jun 23;10(9):101059. doi: 10.1016/j.shj.2026.101059. eCollection 2026 Sep. PMID- 42628644 OWN - NLM STAT- Publisher LR - 20261001 IS - 2352-3840 (Electronic) IS - 1499-2671 (Linking) DP - 2026 Aug 21 TI - Feasibility of a Progressive High-Intensity Interval Training Model of Exercise for Patients With Type 2 Diabetes Mellitus Enrolled in Cardiac Rehabilitation. LID - S1499-2671(26)00166-8 [pii] LID - 10.1016/j.jcjd.2026.08.004 [doi] AB - OBJECTIVE: A link exists between type 2 diabetes mellitus (T2DM) and developing cardiovascular disease. Lifestyle interventions targeting T2DM and cardiovascular disease are required. Cardiac rehabilitation offers a multidisciplinary approach for management. High-intensity interval training (HIIT) may provide equivalent benefits compared to moderate-intensity continuous exercise in improving cardiorespiratory fitness and glycemic control. HIIT should be considered when prescribing exercise for patients living with T2DM; however, further feasibility research is required. The objective of this study was to determine the feasibility of progressive HIIT in patients living with T2DM. METHODS: Patients in a 24-week cardiac rehabilitation program provided research consent at 12 weeks. Feasibility was assessed using intervention adherence, dropout rate and reason, patient satisfaction, and safety. Patients completed the HIIT protocol 3 times per week, at 80% to 95% heart rate reserve. Patients started at Stage 1 (10x30-s high intensity:30-s recovery) and progressed to Stages 2 to 4 every 3 weeks according to patient desire and achievement of target work rate without adverse events. Possible progressions included Stage 2 (10x1-min high intensity:1-min recovery), Stage 3 (6x2-min high intensity:2-min recovery), and Stage 4 (4x4-min high intensity:3-min recovery). RESULTS: Twenty-two participants consented to participation, and 17 (60.2+/-12.4 years) completed the program (23% dropout rate). Adherence to on-site HIIT sessions was 79%, and to at-home unsupervised sessions was 70%. Five patients (4 females) remained at Stage 1; 4 (2 females) progressed to Stage 2; 7 (2 females) progressed to Stage 3; and 1 (male) progressed to Stage 4. Satisfaction surveys revealed that patients enjoyed HIIT as much as moderate-intensity continuous exercise (p=0.29). No HIIT-related adverse events were reported. CONCLUSIONS: Progressive HIIT is feasible, enjoyable, and safe among patients living with T2DM. CI - Copyright (c) 2026 Diabetes Canada. Published by Elsevier Inc. All rights reserved. FAU - Cotie, Lisa M AU - Cotie LM AD - Knowledge, Innovation, Talent, Everywhere (KITE) Research Institute, Toronto Rehabilitation Institute, University Health Network Cardiovascular Prevention and Rehabilitation Program, Toronto, Ontario, Canada; Faculty of Health Sciences, Ontario Tech University, Oshawa, Ontario, Canada. FAU - Banks, Laura AU - Banks L AD - Knowledge, Innovation, Talent, Everywhere (KITE) Research Institute, Toronto Rehabilitation Institute, University Health Network Cardiovascular Prevention and Rehabilitation Program, Toronto, Ontario, Canada; Faculty of Health Sciences, Ontario Tech University, Oshawa, Ontario, Canada. FAU - Pinto da Silva, Lillian AU - Pinto da Silva L AD - Faculty of Physical Therapy, Federal University of Juiz de Fora, Juiz de Fora, Brazil; Graduate Program in Physical Education, Faculty of Physical Education and Sports, Federal University of Juiz de Fora, Juiz de Fora, Brazil. FAU - Carvalho, Carolina G AU - Carvalho CG AD - Knowledge, Innovation, Talent, Everywhere (KITE) Research Institute, Toronto Rehabilitation Institute, University Health Network Cardiovascular Prevention and Rehabilitation Program, Toronto, Ontario, Canada; Department of Medicine, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. FAU - Oh, Paul AU - Oh P AD - Knowledge, Innovation, Talent, Everywhere (KITE) Research Institute, Toronto Rehabilitation Institute, University Health Network Cardiovascular Prevention and Rehabilitation Program, Toronto, Ontario, Canada; Department of Medicine, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. FAU - Colella, Tracey J F AU - Colella TJF AD - Knowledge, Innovation, Talent, Everywhere (KITE) Research Institute, Toronto Rehabilitation Institute, University Health Network Cardiovascular Prevention and Rehabilitation Program, Toronto, Ontario, Canada; Lawrence S. Bloomberg Faculty of Nursing, Rehabilitation Sciences Institute, University of Toronto, Toronto, Ontario, Canada. Electronic address: tracey.colella@uhn.ca. LA - eng PT - Journal Article DEP - 20260821 PL - Canada TA - Can J Diabetes JT - Canadian journal of diabetes JID - 101148810 SB - IM OTO - NOTNLM OT - cardiac rehabilitation OT - diabete de type 2 OT - entrainement par intervalles a haute intensite OT - feasibility OT - high-intensity interval training OT - readaptation cardiaque OT - type 2 diabetes mellitus EDAT- 2026/08/21 23:37 MHDA- 2026/08/21 23:37 CRDT- 2026/08/21 19:12 PHST- 2025/09/30 00:00 [received] PHST- 2026/07/28 00:00 [revised] PHST- 2026/08/10 00:00 [accepted] PHST- 2026/08/21 23:37 [pubmed] PHST- 2026/08/21 23:37 [medline] PHST- 2026/08/21 19:12 [entrez] AID - S1499-2671(26)00166-8 [pii] AID - 10.1016/j.jcjd.2026.08.004 [doi] PST - aheadofprint SO - Can J Diabetes. 2026 Aug 21:S1499-2671(26)00166-8. doi: 10.1016/j.jcjd.2026.08.004. PMID- 42627053 OWN - NLM STAT- Publisher LR - 20260821 IS - 1532-5520 (Electronic) IS - 0009-9201 (Linking) DP - 2026 Aug 21 TI - Anesthetic and Analgesic Considerations in Pregnant Patients With Cardiac Disease. LID - 10.1097/GRF.0000000000001055 [doi] AB - Successful anesthetic management of pregnant patients with cardiac disease requires an understanding of both maternal physiology and alterations induced by labor analgesia and anesthesia for cesarean delivery. This review provides an overview of physiological changes of pregnancy pertinent to obstetric anesthesiology in regard to patients with cardiac disease, including modifications to labor analgesic techniques, indications for additional monitoring, and both regional anesthetic and general anesthetic management of complex cardiac patients for cesarean delivery. The importance of a comprehensive pregnancy heart team cannot be overstated, especially when managing patients with very high-risk cardiac comorbidities. CI - Copyright (c) 2026 Wolters Kluwer Health, LLC. All rights reserved. FAU - Kraitem, Afif AU - Kraitem A AUID- ORCID: 0000-0002-8523-4695 AD - Departments of Anesthesiology, Division of Obstetric Anesthesiology. FAU - Brennan, Kaitlyn A AU - Brennan KA AD - Anesthesiology, Divisions of Critical Care Medicine and Obstetric Anesthesiology, Vanderbilt University Medical Center, Nashville, Tennessee. LA - eng PT - Journal Article DEP - 20260821 PL - United States TA - Clin Obstet Gynecol JT - Clinical obstetrics and gynecology JID - 0070014 SB - IM OTO - NOTNLM OT - Maternal Physiology OT - Obstetric Anesthesia OT - Peripartum Management OT - Regional Anesthesia EDAT- 2026/08/21 11:39 MHDA- 2026/08/21 11:39 CRDT- 2026/08/21 08:03 PHST- 2026/06/08 00:00 [received] PHST- 2026/08/03 00:00 [accepted] PHST- 2026/08/21 11:39 [medline] PHST- 2026/08/21 11:39 [pubmed] PHST- 2026/08/21 08:03 [entrez] AID - 00003081-990000000-00323 [pii] AID - 10.1097/GRF.0000000000001055 [doi] PST - aheadofprint SO - Clin Obstet Gynecol. 2026 Aug 21. doi: 10.1097/GRF.0000000000001055. PMID- 42626630 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260821 LR - 20260822 IS - 2634-3916 (Electronic) IS - 2634-3916 (Linking) VI - 7 IP - 7 DP - 2026 Aug TI - Development of an LLM pipeline exceeding physician-documented cardiovascular risk scores under routine clinical conditions. PG - ztag124 LID - 10.1093/ehjdh/ztag124 [doi] LID - ztag124 AB - AIMS: Risk scores are essential to evidence-based cardiovascular care, but manual calculation is labour intensive and error prone. Large language models (LLMs) could automate this process, yet LLMs are limited by their propensity for calculation errors and factual hallucinations. Pipelines separating LLM-based data extraction from deterministic score computation may improve reliability and transparency. METHODS AND RESULTS: We conducted a retrospective diagnostic study at a quaternary heart centre in Germany (January 2020 to July 2023). Patients with atrial fibrillation (n = 179) from an ablation registry and patients with severe aortic stenosis (n = 76) evaluated by a heart team were included. Six LLMs (GPT-5.2, Gemini 3.1 Pro, DeepSeek-R1, Qwen3, GPT-OSS 120B, and Kimi K2.5) were tested in standalone, retrieval-augmented generation (RAG), and pipeline configurations to compute HAS-BLED, CHA(2)DS(2)-VASc, and EuroSCORE II scores from routine clinical reports. Accuracy was assessed against expert-adjudicated ground truth using root mean squared error (RMSE) and Krippendorff's alpha to evaluate numerical deviation and categorical agreement, respectively. Pipeline-generated scores showed substantially higher agreement with expert adjudication than standalone LLMs, LLMs with RAG, and treating physicians (mean Krippendorff's alpha: 0.78 vs. 0.32 vs. 0.39 vs. 0.31) and lower deviation from ground truth (mean RMSE: 0.89 vs. 5.81 vs. 1.85 vs. 1.34). CONCLUSION: Pipelines combining expert-curated knowledge injection, LLM-based clinical data extraction, and deterministic score calculation enable accurate and scalable cardiovascular risk score computation from unstructured real-world clinical data, outperforming physician-documented scores. Such pipelines could form the basis for clinical decision-support systems that automate routine risk assessment, reduce clinician workload, and promote more consistent evidence-based care. CI - (c) The Author(s) 2026. Published by Oxford University Press on behalf of the European Society of Cardiology. FAU - Roeschl, Tobias AU - Roeschl T AUID- ORCID: 0000-0002-8376-3366 AD - Deutsches Herzzentrum der Charite, Department of Cardiology, Angiology and Intensive Care Medicine, Chariteplatz 1, Berlin 10117, Germany. AD - Charite - Universitatsmedizin Berlin, corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Chariteplatz 1, Berlin 10117, Germany. AD - Charite - Universitatsmedizin Berlin, Institute for Artificial Intelligence in Medicine, Invalidenstrasse 120, Berlin 10115, Germany. AD - Berlin Institute of Health at Charite - Universitatsmedizin Berlin, Chariteplatz 1, Berlin 10117, Germany. AD - DZHK (German Centre for Cardiovascular Research), partner Site Berlin, Potsdamer Str. 58, 10785 Berlin, Germany. AD - Deutsches Herzzentrum der Charite, Department of Cardiothoracic and Vascular Surgery, Augustenburger Platz 1, Berlin 13353, Germany. FAU - Hoffmann, Marie AU - Hoffmann M AD - Charite - Universitatsmedizin Berlin, corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Chariteplatz 1, Berlin 10117, Germany. AD - Charite - Universitatsmedizin Berlin, Institute for Artificial Intelligence in Medicine, Invalidenstrasse 120, Berlin 10115, Germany. AD - DZHK (German Centre for Cardiovascular Research), partner Site Berlin, Potsdamer Str. 58, 10785 Berlin, Germany. AD - Deutsches Herzzentrum der Charite, Department of Cardiothoracic and Vascular Surgery, Augustenburger Platz 1, Berlin 13353, Germany. FAU - Unbehaun, Axel AU - Unbehaun A AD - Charite - Universitatsmedizin Berlin, corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Chariteplatz 1, Berlin 10117, Germany. AD - Deutsches Herzzentrum der Charite, Department of Cardiothoracic and Vascular Surgery, Augustenburger Platz 1, Berlin 13353, Germany. FAU - Dreger, Henryk AU - Dreger H AD - Charite - Universitatsmedizin Berlin, corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Chariteplatz 1, Berlin 10117, Germany. AD - Deutsches Herzzentrum der Charite, Department of Cardiology, Angiology and Intensive Care Medicine, Augustenburger Platz 1, Berlin 13353, Germany. FAU - Hindricks, Gerhard AU - Hindricks G AUID- ORCID: 0000-0002-0132-0773 AD - Deutsches Herzzentrum der Charite, Department of Cardiology, Angiology and Intensive Care Medicine, Chariteplatz 1, Berlin 10117, Germany. AD - Charite - Universitatsmedizin Berlin, corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Chariteplatz 1, Berlin 10117, Germany. FAU - Falk, Volkmar AU - Falk V AUID- ORCID: 0000-0002-7911-8620 AD - Charite - Universitatsmedizin Berlin, corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Chariteplatz 1, Berlin 10117, Germany. AD - DZHK (German Centre for Cardiovascular Research), partner Site Berlin, Potsdamer Str. 58, 10785 Berlin, Germany. AD - Deutsches Herzzentrum der Charite, Department of Cardiothoracic and Vascular Surgery, Augustenburger Platz 1, Berlin 13353, Germany. AD - Translational Cardiovascular Technologies, Institute of Translational Medicine, Department of Health Sciences and Technology, Swiss Federal Institute of Technology, Zurich 8092, Switzerland. FAU - Balicer, Ran AU - Balicer R AUID- ORCID: 0000-0002-7783-6362 AD - Charite - Universitatsmedizin Berlin, corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Chariteplatz 1, Berlin 10117, Germany. AD - Innovation Division, Clalit Health Services, Clalit Research Institute, Tel Aviv, Israel. FAU - Tanacli, Radu AU - Tanacli R AUID- ORCID: 0000-0002-2193-9813 AD - Charite - Universitatsmedizin Berlin, corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Chariteplatz 1, Berlin 10117, Germany. AD - Deutsches Herzzentrum der Charite, Department of Cardiology, Angiology and Intensive Care Medicine, Augustenburger Platz 1, Berlin 13353, Germany. FAU - Hohendanner, Felix AU - Hohendanner F AD - Deutsches Herzzentrum der Charite, Department of Cardiology, Angiology and Intensive Care Medicine, Chariteplatz 1, Berlin 10117, Germany. AD - Charite - Universitatsmedizin Berlin, corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Chariteplatz 1, Berlin 10117, Germany. AD - Deutsches Herzzentrum der Charite, Department of Cardiology, Angiology and Intensive Care Medicine, Augustenburger Platz 1, Berlin 13353, Germany. FAU - Meyer, Alexander AU - Meyer A AUID- ORCID: 0000-0002-6944-2478 AD - Charite - Universitatsmedizin Berlin, corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Chariteplatz 1, Berlin 10117, Germany. AD - Charite - Universitatsmedizin Berlin, Institute for Artificial Intelligence in Medicine, Invalidenstrasse 120, Berlin 10115, Germany. AD - Berlin Institute of Health at Charite - Universitatsmedizin Berlin, Chariteplatz 1, Berlin 10117, Germany. AD - DZHK (German Centre for Cardiovascular Research), partner Site Berlin, Potsdamer Str. 58, 10785 Berlin, Germany. AD - Berlin Institute for the Foundations of Learning and Data - TU Berlin, Berlin, Germany. LA - eng PT - Journal Article DEP - 20260728 PL - England TA - Eur Heart J Digit Health JT - European heart journal. Digital health JID - 101778323 PMC - PMC13492338 OTO - NOTNLM OT - Cardiovascular risk scores OT - Clinical information extraction OT - Clinical workflow automation OT - Digital health OT - Knowledge retrieval OT - Large language models COIS- Conflict of interest: A.U. serves as physician proctor to Boston Scientific, Edwards Lifesciences, and Medtronic. V.F. declares relevant financial activities outside the submitted work with the following commercial entities: Medtronic GmbH; Biotronik SE & Co.; Abbott GmbH & Co. KG; Boston Scientific; Edwards Lifesciences; Berlin Heart; Novartis Pharma GmbH; JOTEC GmbH; Zurich Heart. In relation to: Educational Grants (including travel support); Fees for lectures and speeches; Fees for professional consultation; Research and study funds. A.M. declares the receipt of consulting and lecturing fees from Medtronic, lecturing fees from Bayer, and consulting fees from Pfizer. A.M. is the founder and managing director of x-cardiac GmbH. The remaining authors have no conflicts of interest to disclose. EDAT- 2026/08/21 11:39 MHDA- 2026/08/21 11:40 PMCR- 2026/07/28 CRDT- 2026/08/21 06:25 PHST- 2025/12/04 00:00 [received] PHST- 2026/05/11 00:00 [revised] PHST- 2026/06/23 00:00 [accepted] PHST- 2026/08/21 11:40 [medline] PHST- 2026/08/21 11:39 [pubmed] PHST- 2026/08/21 06:25 [entrez] PHST- 2026/07/28 00:00 [pmc-release] AID - ztag124 [pii] AID - 10.1093/ehjdh/ztag124 [doi] PST - epublish SO - Eur Heart J Digit Health. 2026 Jul 28;7(7):ztag124. doi: 10.1093/ehjdh/ztag124. eCollection 2026 Aug. PMID- 42625855 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260821 LR - 20260822 IS - 2050-0904 (Print) IS - 2050-0904 (Electronic) IS - 2050-0904 (Linking) VI - 14 IP - 8 DP - 2026 Aug TI - Case Report: Successful Management of a Ruptured Abdominal Aortic Aneurysm With Concurrent Acute Myocardial Infarction in an 84-Year-Old Male. PG - e73127 LID - 10.1002/ccr3.73127 [doi] LID - e73127 AB - Rupture of an abdominal aortic aneurysm (AAA) is a catastrophic event with mortality rates historically approaching 80%, often compounded by significant coronary artery disease. We present the challenging case of an 84-year-old man who presented with a contained AAA rupture and a synchronous acute myocardial infarction. Given his hemodynamically stable but precarious state, our team prioritized immediate percutaneous coronary intervention with drug-eluting stents, which mandated dual antiplatelet therapy (DAPT). An ensuing attempt at endovascular repair (EVAR) failed because of extensive iliac calcification and a femoral artery injury that occurred during access. Consequently, open surgical repair was undertaken on hospital Day 5 despite ongoing DAPT-a high-risk maneuver that proceeded without major bleeding complications. This exceptional outcome underscores that, in select patients with a contained rupture, a strategy of prioritized coronary revascularization followed by open repair while on DAPT can be successful, highlighting the vital importance of adaptable, multidisciplinary decision-making. At 2.5 years, the patient remains alive and functionally independent, confirming the durability of this approach. CI - (c) 2026 The Author(s). Clinical Case Reports published by John Wiley & Sons Ltd. FAU - Ghatfan, Ali AU - Ghatfan A AD - School of Medicine Aja University of Medical Sciences Tehran Iran. FAU - Taherian, Maisam AU - Taherian M AD - Interventional Cardiologist, Madaen Hospital Tehran Iran. FAU - Zafar Asoodeh, AliAsghar AU - Zafar Asoodeh A AD - Anesthesiologist, Madaen Hospital Tehran Iran. FAU - Farzaei, AliReza AU - Farzaei A AUID- ORCID: 0000-0002-4909-0778 AD - School of Medicine Aja University of Medical Sciences Tehran Iran. AD - School of Medicine Shahid Beheshti University of Medical Sciences Tehran Iran. LA - eng PT - Journal Article DEP - 20260819 PL - England TA - Clin Case Rep JT - Clinical case reports JID - 101620385 PMC - PMC13490710 OTO - NOTNLM OT - EVAR OT - coronary artery disease OT - multidisciplinary management OT - open surgical repair OT - ruptured AAA COIS- The authors declare no conflicts of interest. EDAT- 2026/08/21 11:39 MHDA- 2026/08/21 11:40 PMCR- 2026/08/19 CRDT- 2026/08/21 05:30 PHST- 2025/12/18 00:00 [received] PHST- 2026/05/21 00:00 [revised] PHST- 2026/06/19 00:00 [accepted] PHST- 2026/08/21 11:40 [medline] PHST- 2026/08/21 11:39 [pubmed] PHST- 2026/08/21 05:30 [entrez] PHST- 2026/08/19 00:00 [pmc-release] AID - CCR373127 [pii] AID - 10.1002/ccr3.73127 [doi] PST - epublish SO - Clin Case Rep. 2026 Aug 19;14(8):e73127. doi: 10.1002/ccr3.73127. eCollection 2026 Aug. PMID- 42623956 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260924 LR - 20260924 IS - 2772-963X (Electronic) IS - 2772-963X (Linking) VI - 5 IP - 9 DP - 2026 Sep TI - A National Survey of VA to Assess Availability of Care for Patients With Cardiac Amyloidosis. PG - 103169 LID - S2772-963X(26)00590-9 [pii] LID - 10.1016/j.jacadv.2026.103169 [doi] LID - 103169 AB - BACKGROUND: Despite heightened awareness of cardiac amyloidosis (CA), the care of patients with CA remains challenging, particularly at the Veterans Affairs (VA), where populations are predominantly older and male. OBJECTIVES: This study aimed to characterize the current landscape of CA care across the VA. METHODS: As a quality improvement study, a survey instrument was developed and disseminated to all 127 VA cardiology programs from March to May 2025. The survey captured data on diagnostic modality availability, therapeutic resources, multidisciplinary care team composition, and self-designated amyloidosis center designation. RESULTS: Complete responses were received from 54 cardiology programs (42.5%). There was substantial variability in program-level experience, clinician comfort, access to diagnostics, and therapeutics regardless of clinical complexity index designation. Thirty-one survey respondents (57.4%) reported feeling "very comfortable" treating CA, although 7 (13.0%) reported being "hesitant" to provide care for Veterans with CA. Twelve programs (22.2%) reported having only one cardiologist managing CA patients, and 7 (13.0%) indicated that no cardiologists at their center treated Veterans with CA. Only 4 programs (7.4%) reported having a formalized multidisciplinary CA team. Lastly, facility complexity did not have an obvious relationship to size, scope, or readiness to care for Veterans with CA. CONCLUSIONS: The VA appears strongest at the initial diagnostic stages, with high availability to initiate a workup for transthyretin CA, with considerable latent capacity to support comprehensive CA care including a high-risk patient population, widespread diagnostic capabilities, national access to therapies, and robust telehealth infrastructure. Targeted implementation to standardize CA care delivery, while leveraging existing strengths, could meaningfully improve care for Veterans with CA. CI - Published by Elsevier Inc. FAU - Yoo, Sang Gune K AU - Yoo SGK AD - Departments of Cardiology and Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. FAU - Zelleke, Amen B AU - Zelleke AB AD - Division of Cardiology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA. FAU - Khaira, Kavita B AU - Khaira KB AD - VA Puget Sound Healthcare, Seattle, Washington, USA. FAU - Dev, Sandesh AU - Dev S AD - Southern Arizona VA Health Care System, Tucson, Arizona, USA. FAU - Shah, Nishant R AU - Shah NR AD - Providence VA Medical Center, Providence, Rhode Island, USA. FAU - Mitchell, Joshua D AU - Mitchell JD AD - Division of Cardiology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA. FAU - Warner, Alberta AU - Warner A AD - Los Angelas VA Medical Center, Los Angelas, California, USA. FAU - Javaheri, Ali AU - Javaheri A AD - Division of Cardiology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA; John Cochran St. Louis VA Medical Center, St. Louis, Missouri, USA. FAU - Moreno, Jonathan D AU - Moreno JD AD - Division of Cardiology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA; John Cochran St. Louis VA Medical Center, St. Louis, Missouri, USA. Electronic address: jonathan.moreno@va.gov. LA - eng PT - Journal Article DEP - 20260820 PL - United States TA - JACC Adv JT - JACC. Advances JID - 9918419284106676 PMC - PMC13524572 OTO - NOTNLM OT - VA health care OT - amyloidosis OT - quality improvement COIS- Funding support and author disclosures Dr Dev has received grants from Pfizer, Alnylam, and BridgeBio; and has served on the advisory board for Pfizer and Alnylam. Dr Shah has received grants from Pfizer. Dr Mitchell has served as a consultant for Pfizer, Alnylam, AstraZeneca, and BridgeBio. Dr Moreno has served as a consultant for BridgeBio. The contents do not represent the views of the U.S. Department of Veterans Affairs. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2026/08/20 23:35 MHDA- 2026/08/20 23:36 PMCR- 2026/08/20 CRDT- 2026/08/20 18:07 PHST- 2026/03/24 00:00 [received] PHST- 2026/07/10 00:00 [revised] PHST- 2026/07/20 00:00 [accepted] PHST- 2026/08/20 23:36 [medline] PHST- 2026/08/20 23:35 [pubmed] PHST- 2026/08/20 18:07 [entrez] PHST- 2026/08/20 00:00 [pmc-release] AID - S2772-963X(26)00590-9 [pii] AID - 103169 [pii] AID - 10.1016/j.jacadv.2026.103169 [doi] PST - ppublish SO - JACC Adv. 2026 Sep;5(9):103169. doi: 10.1016/j.jacadv.2026.103169. Epub 2026 Aug 20. PMID- 42623266 OWN - NLM STAT- MEDLINE DCOM- 20260820 LR - 20261028 IS - 1527-1323 (Electronic) IS - 0271-5333 (Linking) VI - 46 IP - 9 DP - 2026 Sep TI - Challenging Anatomic and Pathologic Features for Transcatheter Aortic Valve Replacement Planning. PG - e250099 LID - 10.1148/rg.250099 [doi] AB - Segmentation and processing of CT datasets for transcatheter aortic valve replacement (TAVR) planning is now an essential part of the transcatheter heart valve team process. Output for TAVR planning includes geometric and pathologic findings of the aortic valve, root, and left ventricular outflow tract. In addition, access route selection requires assessment of the size and course of the access vessel and identification of any associated variant anatomic or pathologic conditions that could affect the procedure. Spurious or erroneous output from three-dimensional processing software can occur, especially with gradient-based segmentation algorithms. Identification and correction of these processing errors is imperative for accurate TAVR planning output. The authors review specific considerations for each anatomic region in which TAVR planning is needed and outline processing tips for providing high-quality planning output. ((c))RSNA, 2026 Supplemental material is available for this article. FAU - Hallett, Richard L AU - Hallett RL AUID- ORCID: 0000-0001-9442-6173 AD - 3D Visualization Laboratory, Department of Radiology, Banner University Medical Center-Phoenix, 1111 E McDowell Rd, Phoenix, AZ 85006. AD - Department of Radiology, University of Arizona College of Medicine-Phoenix, Phoenix, Ariz. FAU - Hatch, Kimberly A AU - Hatch KA AD - 3D Visualization Laboratory, Department of Radiology, Banner University Medical Center-Phoenix, 1111 E McDowell Rd, Phoenix, AZ 85006. FAU - Bratcher, Jodi A AU - Bratcher JA AD - 3D Visualization Laboratory, Department of Radiology, Banner University Medical Center-Phoenix, 1111 E McDowell Rd, Phoenix, AZ 85006. FAU - Grooters, Lindsey R AU - Grooters LR AD - 3D Visualization Laboratory, Department of Radiology, Banner University Medical Center-Phoenix, 1111 E McDowell Rd, Phoenix, AZ 85006. FAU - DeBellevue, Rayna L AU - DeBellevue RL AD - 3D Visualization Laboratory, Department of Radiology, Banner University Medical Center-Phoenix, 1111 E McDowell Rd, Phoenix, AZ 85006. FAU - Miner Denzine, Linda AU - Miner Denzine L AD - 3D Visualization Laboratory, Department of Radiology, Banner University Medical Center-Phoenix, 1111 E McDowell Rd, Phoenix, AZ 85006. FAU - Fedewa, Jason L AU - Fedewa JL AD - 3D Visualization Laboratory, Department of Radiology, Banner University Medical Center-Phoenix, 1111 E McDowell Rd, Phoenix, AZ 85006. FAU - Walsh, Mark F AU - Walsh MF AD - 3D Visualization Laboratory, Department of Radiology, Banner University Medical Center-Phoenix, 1111 E McDowell Rd, Phoenix, AZ 85006. FAU - Rybicki, Frank J AU - Rybicki FJ AUID- ORCID: 0000-0002-4669-5886 AD - 3D Visualization Laboratory, Department of Radiology, Banner University Medical Center-Phoenix, 1111 E McDowell Rd, Phoenix, AZ 85006. AD - Department of Radiology, University of Arizona College of Medicine-Phoenix, Phoenix, Ariz. FAU - Morris, Michael F AU - Morris MF AUID- ORCID: 0000-0001-8076-0488 AD - 3D Visualization Laboratory, Department of Radiology, Banner University Medical Center-Phoenix, 1111 E McDowell Rd, Phoenix, AZ 85006. AD - Department of Radiology, University of Arizona College of Medicine-Phoenix, Phoenix, Ariz. LA - eng PT - Journal Article PT - Review PL - United States TA - Radiographics JT - Radiographics : a review publication of the Radiological Society of North America, Inc JID - 8302501 SB - IM MH - *Transcatheter Aortic Valve Replacement/methods MH - Humans MH - *Tomography, X-Ray Computed/methods MH - *Aortic Valve/diagnostic imaging/surgery/anatomy & histology/pathology MH - Imaging, Three-Dimensional MH - *Aortic Valve Stenosis/surgery/diagnostic imaging/pathology MH - *Patient Care Planning EDAT- 2026/08/20 17:35 MHDA- 2026/08/20 17:36 CRDT- 2026/08/20 12:53 PHST- 2026/08/20 17:36 [medline] PHST- 2026/08/20 17:35 [pubmed] PHST- 2026/08/20 12:53 [entrez] AID - 10.1148/rg.250099 [doi] PST - ppublish SO - Radiographics. 2026 Sep;46(9):e250099. doi: 10.1148/rg.250099. PMID- 42619605 OWN - NLM STAT- MEDLINE DCOM- 20260923 LR - 20260924 IS - 1524-4636 (Electronic) IS - 1079-5642 (Linking) VI - 46 IP - 10 DP - 2026 Oct TI - Lipoprotein(a), Oxidized Phospholipids and Tensile Clot Strength Measured by Thromboelastography in Patients Undergoing Percutaneous Intervention. PG - e324402 LID - 10.1161/ATVBAHA.126.324402 [doi] AB - BACKGROUND: Lp(a) (lipoprotein[a]) and tensile clot strength (TCS) are distinct and independent risk factors for incident cardiovascular disease and recurrent ischemic events. Lp(a) is a carrier of oxidized phospholipids (OxPL) that contribute to its atherothrombotic properties. The current objective is to study the relationship of Lp(a) and OxPL biomarkers with TCS in patients with high-risk vascular diseases. METHODS: In a subanalysis of the ongoing MBRACE trial (Multidisciplinary Approach to Reduce Cardiovascular Health Disparities in the Baltimore Racial Minority Communities), we studied Lp(a), OxPL biomarkers, and TCS in healthy subjects (n=17) and in patients with cardiovascular disease undergoing percutaneous intervention (multivessel coronary artery disease [n=60], myocardial infarction [n=86], and ischemic stroke [n=28]). Lp(a), OxPL-apoB, OxPL-apo(a), OxPL-plasminogen (OxPL-PLG), and total plasminogen were measured using enzyme-linked immunoassays. High Lp(a) was defined as >/=125 nmol/L. TCS was measured by thromboelastography, and hypercoagulability was defined by values >/=66.5 mm. RESULTS: Compared with healthy subjects, patients had higher Lp(a), OxPL-apoB, OxPL-apo(a), and TCS (P<0.05 for all). Black patients, compared with White patients, had higher Lp(a), OxPL biomarkers, and TCS (P/=65 years with end-stage renal disease (ESRD) requiring chronic dialysis, and is a leading cause of mortality. Improved survival among patients on dialysis has led to an increasing number requiring treatment for multivessel CAD. Current guidelines on myocardial revascularization favour coronary artery bypass grafting (CABG) in patients with a life expectancy exceeding 1 year; however, clear recommendations regarding the optimal revascularization strategy are lacking. No prospective randomized trials have compared CABG with percutaneous coronary intervention (PCI), and observational studies have yielded conflicting results. We therefore conducted this nationwide retrospective cohort study to assess short- and long-term all-cause mortality in dialysis patients with ESRD and three-vessel CAD who had undergone CABG or PCI. METHODS: All dialysis patients >/=18 years old with three-vessel disease who underwent a first-time PCI (n=412) or CABG (n=199) in Sweden during 2006-2020 were identified in the SWEDEHEART registry. Individual patient data were merged from three nationwide mandatory registers. The Swedish Cardiac Surgery Registry, which is a part of the SWEDEHEART registry, was used along with the National Patient Register (NPR) to collect data on patients' characteristics, including ESRD requiring dialysis. The Swedish Cause of Death Register was used to obtain mortality. Short- and long-term mortality were assessed using multivariable Cox regression models adjusted for age, sex, and comorbidities, with a sensitivity analysis using a propensity score-matched model. Median follow-up was 1.7 (range, 0.7-3.7) years in the PCI group and 2.5 (range, 1.1-5.0) years in the CABG group. RESULTS: Patients undergoing PCI were older, had longer dialysis duration, and more often had a history of cancer, whereas prior myocardial infarction, hyperlipidaemia, and atrial fibrillation were more common in the CABG group. The crude 30-day mortality was 6.8% and 4.5%, respectively, in the PCI and CABG groups, and the crude mortality at the end of follow-up was 63.8% and 54.8%, respectively. At the end of follow-up, the mortality risk was lower after CABG than after PCI [multi-adjusted hazard ratio (HR): 0.70; 95% confidence interval (CI): 0.55-0.89]. These results were confirmed in the propensity score analysis for both 30-day mortality (multi-adjusted HR: 0.72; 95% CI: 0.29-1.80) and long-term mortality (multi-adjusted HR: 0.68; 95% CI: 0.51-0.91). CONCLUSIONS: Patients who underwent CABG or PCI with three-vessel CAD and ESRD requiring chronic dialysis had a high risk of mortality. The long-term mortality risk was lower after CABG. Treatment should be individualized for each patient through a multidisciplinary discussion that considers potential benefits and risks as well as patient preferences. CI - (c) AME Publishing Company. FAU - Nielsen, Susanne J AU - Nielsen SJ AD - Department of Molecular and Clinical Medicine, Sahlgrenska Academy, Gothenburg University, Sweden. AD - Department of Cardiothoracic Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden. FAU - Bjorklund, Erik AU - Bjorklund E AD - Department of Internal Medicine, Southern Alvsborg Hospital, Boras, Sweden. FAU - Perrotta, Sossio AU - Perrotta S AUID- ORCID: 0000-0002-6947-4576 AD - Department of Cardiothoracic Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden. LA - eng PT - Journal Article DEP - 20260623 PL - China TA - J Thorac Dis JT - Journal of thoracic disease JID - 101533916 PMC - PMC13460234 OTO - NOTNLM OT - Coronary artery disease (CAD) OT - coronary artery bypass grafting (CABG) OT - dialysis OT - kidney failure OT - percutaneous coronary intervention (PCI) COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-1-0332/coif). S.J.N. reports support from the Swedish state under the agreement between the Swedish government and the county councils for research and education of doctors. E.B. reports travel and accommodation support from Medtronic (bifurcation stenting course, Copenhagen, March 2026) and Philips (intravascular ultrasound course, Stockholm, November 2025), all unrelated to the present work. The other author has no conflicts of interest to declare. EDAT- 2026/08/12 11:38 MHDA- 2026/08/12 11:39 PMCR- 2026/07/31 CRDT- 2026/08/12 07:10 PHST- 2026/02/04 00:00 [received] PHST- 2026/05/27 00:00 [accepted] PHST- 2026/08/12 11:39 [medline] PHST- 2026/08/12 11:38 [pubmed] PHST- 2026/08/12 07:10 [entrez] PHST- 2026/07/31 00:00 [pmc-release] AID - jtd-18-07-754 [pii] AID - 10.21037/jtd-2026-1-0332 [doi] PST - ppublish SO - J Thorac Dis. 2026 Jul 31;18(7):754. doi: 10.21037/jtd-2026-1-0332. Epub 2026 Jun 23. PMID- 42582279 OWN - NLM STAT- MEDLINE DCOM- 20260812 LR - 20260826 IS - 1664-2392 (Print) IS - 1664-2392 (Electronic) IS - 1664-2392 (Linking) VI - 17 DP - 2026 TI - From conceptual emergence to multidisciplinary expansion: a bibliometric and knowledge mapping analysis of cardiovascular-kidney-metabolic syndrome research. PG - 1895884 LID - 10.3389/fendo.2026.1895884 [doi] LID - 1895884 AB - BACKGROUND: The concept of cardiovascular-kidney-metabolic (CKM) syndrome has recently been introduced as an integrated framework linking heart, kidney, and metabolic disorders. However, a global overview of the research landscape in this emerging field is still lacking. METHODS: Publications related to CKM published between 2023 and 2025 were retrieved from the Web of Science Core Collection and Scopus. The search strategy incorporated the following terms: TS = ("cardiovascular-kidney-metabolic" OR "cardiovascular kidney metabolic" OR "cardiovascular-kidney-metabolic syndrome" OR "cardiovascular kidney metabolic syndrome" OR "CKM syndrome" OR "CKM health" OR "CKM framework" OR "cardiovascular-kidney-metabolic health"). Bibliometric indicators, including publication volume, authorship patterns, institutional and country contributions, journal distribution, co-citation networks, and keyword burst analysis, were systematically assessed. RESULTS: A total of 1, 854 articles from 665 journals were identified. Annual output surged from 8 in 2023 to 1, 544 in 2025. A total of 8, 359 authors contributed, with an average of 7.95 co-authors per paper, reflecting strong collaborative activity. China and the United States were the most productive countries, with the latter acting as a central node in international collaboration networks. Keyword and citation analyses showed a clear shift from individual risk factors toward integrated cardiometabolic-renal interactions, clinical outcomes, and mortality. Highly cited works mainly addressed the definition, epidemiology, and clinical relevance of CKM. CONCLUSION: Since its introduction in 2023, CKM research has grown rapidly into a collaborative and multidisciplinary field. Future efforts should focus on strengthening international partnerships, advancing mechanistic research, and improving the clinical translation of the CKM framework for risk stratification and prevention. CI - Copyright (c) 2026 Lv, Xiong and Zhu. FAU - Lv, Tian AU - Lv T AD - Department of Neurology, Zhuji Affiliated Hospital of Wenzhou Medical University, Zhuji, China. FAU - Xiong, Yu-Jun AU - Xiong YJ AD - Department of Gastroenterology, Beijing Hospital, National Center for Gerontology, Beijing, China. AD - National Clinical Research Center for Gerontology, Beijing, China. AD - The Key Laboratory of Geriatrics of NHC, Beijing, China. AD - Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. FAU - Zhu, Qian-Yuan AU - Zhu QY AD - Department of Neurology, Fenghua Hospital of Traditional Chinese Medicine, Ningbo, China. LA - eng PT - Journal Article PT - Systematic Review DEP - 20260728 PL - Switzerland TA - Front Endocrinol (Lausanne) JT - Frontiers in endocrinology JID - 101555782 SB - IM MH - *Bibliometrics MH - Humans MH - *Metabolic Syndrome/epidemiology MH - *Biomedical Research/trends MH - *Cardio-Renal Syndrome/epidemiology MH - *Cardiovascular Diseases PMC - PMC13457382 OTO - NOTNLM OT - CKM OT - CiteSpace OT - VOSviewer OT - bibliometric analysis OT - biblioshiny COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/08/12 11:38 MHDA- 2026/08/12 11:39 PMCR- 2026/07/28 CRDT- 2026/08/12 05:52 PHST- 2026/05/31 00:00 [received] PHST- 2026/07/15 00:00 [revised] PHST- 2026/07/15 00:00 [accepted] PHST- 2026/08/12 11:39 [medline] PHST- 2026/08/12 11:38 [pubmed] PHST- 2026/08/12 05:52 [entrez] PHST- 2026/07/28 00:00 [pmc-release] AID - 10.3389/fendo.2026.1895884 [doi] PST - epublish SO - Front Endocrinol (Lausanne). 2026 Jul 28;17:1895884. doi: 10.3389/fendo.2026.1895884. eCollection 2026. PMID- 42581350 OWN - NLM STAT- MEDLINE DCOM- 20260812 LR - 20260814 IS - 1471-2415 (Electronic) IS - 1471-2415 (Linking) VI - 26 IP - 1 DP - 2026 Aug 10 TI - Ocular findings in pediatric candidates for cochlear implantation with bilateral sensorineural hearing loss: a brief report from northwestern Iran. LID - 10.1186/s12886-026-05205-w [doi] LID - 479 AB - BACKGROUND: The presence of ocular abnormalities in patients with sensorineural hearing loss (SNHL) may affect children's developmental milestones due to impairment of primary sensory inputs. This study aimed to evaluate the prevalence of different ophthalmologic abnormalities in pediatric patients with bilateral SNHL who were candidates for cochlear implantation (CI). METHODS: We performed a retrospective medical chart review of 261 pediatric patients under 13 years of age with bilateral SNHL who were candidates for CI and were evaluated at a tertiary cochlear implantation referral center in northwestern Iran between March 21, 2017, and June 20, 2025. Ophthalmologic findings were assessed as the main outcome measures. RESULTS: The overall prevalence of ocular findings was 19.5%. Cardiac abnormalities were observed in 17.6% of patients, and refractive errors were identified in 8.4%. Jaundice was the most common prenatal complication, and 36.8% of patients had a history of neurologic complications. Ocular, cardiologic, and neurologic manifestations occurred independently of one another, with no significant pairwise co-occurrence among the three systems. CONCLUSIONS: Our findings highlight the need for a multidisciplinary approach in candidates for CI with bilateral SNHL. Comprehensive ophthalmologic evaluation is essential in this population, with particular attention to refractive errors, ocular alignment, and fundus assessment. Because ocular, cardiologic, and neurologic findings occurred independently in the exploratory analysis, screening for each system should be pursued comprehensively and in parallel rather than selectively guided by findings in another system. TRIAL REGISTRATION: Not applicable. CI - (c) 2026. The Author(s). FAU - Sobhi, Navid AU - Sobhi N AUID- ORCID: 0000-0003-0663-850X AD - Translational Ophthalmology Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran. FAU - Vahedi, Hadi AU - Vahedi H AUID- ORCID: 0009-0008-4769-451X AD - Nikookari Eye Center, Tabriz University of Medical Sciences, Tabriz, Iran. FAU - Ashayeri, Hamidreza AU - Ashayeri H AUID- ORCID: 0000-0002-2593-9810 AD - Research Center for Evidence-Based Medicine, Iranian EBM Centre: A JBI Centre of Excellence, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. FAU - Razmjooei, Fatemeh AU - Razmjooei F AUID- ORCID: 0009-0000-3757-5172 AD - Poostchi Ophthalmology Research Center, Department of Ophthalmology, Medical School, Shiraz University of Medical Sciences, Shiraz, Iran. FAU - Jafarizadeh, Ali AU - Jafarizadeh A AUID- ORCID: 0000-0003-4922-1923 AD - Nikookari Eye Center, Tabriz University of Medical Sciences, Tabriz, Iran. FAU - Nouri, Ali AU - Nouri A AD - Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. FAU - Ariafar, Aida AU - Ariafar A AUID- ORCID: 0009-0000-3807-4230 AD - Department of Otolaryngology, Head and Neck Surgery, Tabriz University of Medical Sciences, Tabriz, Iran. FAU - Jabbari Moghaddam, Yalda AU - Jabbari Moghaddam Y AUID- ORCID: 0000-0003-3217-8391 AD - Department of Otolaryngology, Head and Neck Surgery, Tabriz University of Medical Sciences, Tabriz, Iran. yj_moghaddam@yahoo.com. FAU - Naderpour, Masoud AU - Naderpour M AUID- ORCID: 0000-0001-6552-2166 AD - Department of Otolaryngology, Head and Neck Surgery, Tabriz University of Medical Sciences, Tabriz, Iran. naderpourmasoud6@gmail.com. LA - eng PT - Journal Article DEP - 20260810 PL - England TA - BMC Ophthalmol JT - BMC ophthalmology JID - 100967802 SB - IM MH - Humans MH - Retrospective Studies MH - Iran/epidemiology MH - Female MH - *Hearing Loss, Sensorineural/surgery/epidemiology/complications MH - *Cochlear Implantation MH - Child, Preschool MH - Child MH - Male MH - Infant MH - *Hearing Loss, Bilateral/surgery/complications/epidemiology MH - Adolescent MH - Prevalence MH - *Eye Abnormalities/epidemiology PMC - PMC13459247 OTO - NOTNLM OT - Bilateral SNHL OT - Cochlear implantation OT - Fundus abnormalities OT - Multidisciplinary care OT - Ocular abnormalities OT - Pediatric ophthalmology OT - Refractive errors OT - Sensorineural hearing loss OT - Strabismus OT - Visual screening COIS- Declarations. Ethics approval and consent to participate: The authors declare that the research presented in this manuscript adheres to the ethical principles outlined by the Ethics Committee of Tabriz University of Medical Sciences and complies with approved ethical standards (IR.TBZMED.FMD.REC.1404.034). All procedures involving human participants were conducted in accordance with the ethical standards of the Ethics Committee of Tabriz University of Medical Sciences and the Declaration of Helsinki (1964), as revised in 2024. Written informed consent to participate was obtained from the parents or legal guardians of all participants, as all enrolled patients were minors under the age of 16 years. Consent for publication: N/A. Competing interests: The authors declare no competing interests. EDAT- 2026/08/12 06:05 MHDA- 2026/08/12 06:06 PMCR- 2026/08/10 CRDT- 2026/08/12 00:17 PHST- 2026/04/11 00:00 [received] PHST- 2026/08/03 00:00 [accepted] PHST- 2026/08/12 06:06 [medline] PHST- 2026/08/12 06:05 [pubmed] PHST- 2026/08/12 00:17 [entrez] PHST- 2026/08/10 00:00 [pmc-release] AID - 10.1186/s12886-026-05205-w [pii] AID - 5205 [pii] AID - 10.1186/s12886-026-05205-w [doi] PST - epublish SO - BMC Ophthalmol. 2026 Aug 10;26(1):479. doi: 10.1186/s12886-026-05205-w. PMID- 42579793 OWN - NLM STAT- Publisher LR - 20260817 IS - 1557-2501 (Electronic) IS - 1042-3931 (Linking) DP - 2026 Aug 5 TI - Large language models in interventional cardiology: current evidence and future directions. LID - 10.25270/jic/26.00176 [doi] AB - Large language models (LLMs) have rapidly emerged as a transformative class of artificial intelligence systems capable of understanding and generating human-like text from vast corpora of clinical and scientific literature. While their use in general cardiology has been extensively reviewed, their specific role in interventional cardiology and within the catheterization laboratory (cath lab) environment remains less well characterized. This narrative review synthesizes the current evidence on LLM applications across the interventional cardiology workflow, including coronary revascularization decision-making, multidisciplinary Heart Team support, structural heart intervention planning, periprocedural communication, and acute cath lab decision support. Recent studies suggest that contemporary LLMs such as ChatGPT-4 (OpenAI), Claude (Anthropic), and Gemini (Alphabet, Inc.) can achieve clinically meaningful concordance with expert Heart Team recommendations for percutaneous coronary intervention vs coronary artery bypass grafting, and that their outputs may approach or even match those of early-career interventional cardiologists in simulated emergency scenarios. However, important limitations persist, including variable accuracy across prompt formats, susceptibility to hallucinations, lack of multimodal integration with angiographic and intravascular imaging, opacity of training sources, and unresolved medicolegal issues. The authors discuss the current evidence base, highlight promising avenues such as multimodal LLMs and retrieval-augmented generation tools that leverage current guidelines, and outline regulatory and ethical considerations that must accompany clinical adoption. LLMs are unlikely to replace interventional cardiologists in the foreseeable future, but they may meaningfully support decision-making, education, and patient communication in a domain where speed, complexity, and risk converge. FAU - Skalidis, Ioannis AU - Skalidis I AD - Department of Cardiology, HFR - Fribourg Cantonal Hospital and University, Fribourg, Switzerland. Email: Skalidis7@gmail.com. FAU - Simioni, Lisa AU - Simioni L AD - Department of Cardiology, HFR - Fribourg Cantonal Hospital and University, Fribourg, Switzerland. FAU - Beretta, Giulia S AU - Beretta GS AD - Department of Cardiology, HFR - Fribourg Cantonal Hospital and University, Fribourg, Switzerland. FAU - Cioffi, Giacomo Maria AU - Cioffi GM AD - Department of Cardiology, HFR - Fribourg Cantonal Hospital and University, Fribourg, Switzerland. FAU - Jelisejevas, Julius AU - Jelisejevas J AD - Department of Cardiology, HFR - Fribourg Cantonal Hospital and University, Fribourg, Switzerland. FAU - Wenaweser, Peter AU - Wenaweser P AD - Department of Cardiology, HFR - Fribourg Cantonal Hospital and University, Fribourg, Switzerland. FAU - Meier, Pascal AU - Meier P AD - Department of Cardiology, HFR - Fribourg Cantonal Hospital and University, Fribourg, Switzerland. FAU - Garot, Philippe AU - Garot P AD - Institut Cardiovasculaire Paris-Sud, Hopital Jacques Cartier, Massy, France. FAU - Hovasse, Thomas AU - Hovasse T AD - Institut Cardiovasculaire Paris-Sud, Hopital Jacques Cartier, Massy, France. FAU - Akodad, Mariama AU - Akodad M AD - Institut Cardiovasculaire Paris-Sud, Hopital Jacques Cartier, Massy, France. FAU - Puricel, Serban AU - Puricel S AD - Department of Cardiology, HFR - Fribourg Cantonal Hospital and University, Fribourg, Switzerland. FAU - Cook, Stephane AU - Cook S AD - Department of Cardiology, HFR - Fribourg Cantonal Hospital and University, Fribourg, Switzerland. FAU - Togni, Mario AU - Togni M AD - Department of Cardiology, HFR - Fribourg Cantonal Hospital and University, Fribourg, Switzerland. LA - eng PT - Journal Article DEP - 20260805 PL - United States TA - J Invasive Cardiol JT - The Journal of invasive cardiology JID - 8917477 SB - IM OTO - NOTNLM OT - artificial intelligence OT - heart team OT - large language models EDAT- 2026/08/11 17:36 MHDA- 2026/08/11 17:36 CRDT- 2026/08/11 15:23 PHST- 2026/08/11 17:36 [medline] PHST- 2026/08/11 17:36 [pubmed] PHST- 2026/08/11 15:23 [entrez] AID - 10.25270/jic/26.00176 [doi] PST - aheadofprint SO - J Invasive Cardiol. 2026 Aug 5. doi: 10.25270/jic/26.00176. PMID- 42573550 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20261001 LR - 20261009 IS - 2666-0849 (Electronic) IS - 2666-0849 (Linking) VI - 31 IP - 39 DP - 2026 Sep 30 TI - Mitral Valve Malignant Glomus Tumor Presenting With Multiple Embolic Events. PG - 109562 LID - S2666-0849(26)02723-3 [pii] LID - 10.1016/j.jaccas.2026.109562 [doi] LID - 109562 AB - CASE SUMMARY: We report a case of a malignant glomus tumor involving the mitral valve, resulting in repeat presentations with arterial embolic events including non-ST-segment elevation myocardial infarction and stroke. This is the third existing case report of an intracardiac malignant glomus tumor and highlights the need for a multidisciplinary approach to the diagnosis and management of cardiac tumors. TAKE-HOME MESSAGES: Glomus tumors are extremely rare, and even less commonly malignant. They can involve cardiac structures and pose risk for embolic events. Patients with cardiac glomus tumors should be evaluated rapidly by a multidisciplinary cardio-oncology team and receive prompt referral for consideration of surgical resection. CI - Copyright (c) 2026 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Franquiz, Miguel J AU - Franquiz MJ AD - Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA; Stanford Cardio-oncology Center, Cardiovascular Medicine, Stanford Hospitals and Clinics, Stanford, California, USA. Electronic address: franquiz@stanford.edu. FAU - Krishnan, Aravind AU - Krishnan A AD - Department of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, California, USA. FAU - Lopez, Jesus R AU - Lopez JR AD - Department of Pathology, Stanford University School of Medicine, Stanford, California, USA. FAU - Sanchez, Andrew C AU - Sanchez AC AD - Department of Pathology, Stanford University School of Medicine, Stanford, California, USA. FAU - Myall, Nathaniel J AU - Myall NJ AD - Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA. FAU - Zhou, Maggie Yuxi AU - Zhou MY AD - Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA. FAU - Charville, Gregory W AU - Charville GW AD - Department of Pathology, Stanford University School of Medicine, Stanford, California, USA. FAU - MacArthur, John W AU - MacArthur JW AD - Department of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, California, USA; Stanford Cardiovascular Institute, Stanford, California, USA. FAU - Berry, Gerald AU - Berry G AD - Department of Pathology, Stanford University School of Medicine, Stanford, California, USA; Stanford Cardiovascular Institute, Stanford, California, USA. FAU - Zhu, Han AU - Zhu H AD - Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA; Stanford Cardio-oncology Center, Cardiovascular Medicine, Stanford Hospitals and Clinics, Stanford, California, USA; Stanford Cardiovascular Institute, Stanford, California, USA. FAU - Rockson, Stanley G AU - Rockson SG AD - Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA; Stanford Cardiovascular Institute, Stanford, California, USA. Electronic address: rockson@stanford.edu. LA - eng PT - Journal Article DEP - 20260810 PL - Netherlands TA - JACC Case Rep JT - JACC. Case reports JID - 101757292 PMC - PMC13643460 OTO - NOTNLM OT - MR sequences OT - echocardiography OT - hybrid imaging OT - left-sided catheterization OT - myocardial ischemia COIS- Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2026/08/10 12:36 MHDA- 2026/08/10 12:37 PMCR- 2026/08/10 CRDT- 2026/08/10 10:29 PHST- 2026/06/08 00:00 [received] PHST- 2026/06/23 00:00 [accepted] PHST- 2026/08/10 12:37 [medline] PHST- 2026/08/10 12:36 [pubmed] PHST- 2026/08/10 10:29 [entrez] PHST- 2026/08/10 00:00 [pmc-release] AID - S2666-0849(26)02723-3 [pii] AID - 109562 [pii] AID - 10.1016/j.jaccas.2026.109562 [doi] PST - ppublish SO - JACC Case Rep. 2026 Sep 30;31(39):109562. doi: 10.1016/j.jaccas.2026.109562. Epub 2026 Aug 10. PMID- 42572828 OWN - NLM STAT- MEDLINE DCOM- 20260930 LR - 20260930 IS - 2047-9018 (Electronic) IS - 0029-6570 (Linking) VI - 41 IP - 10 DP - 2026 Sep 30 TI - Understanding, assessing and managing shock in adults. PG - 43-51 LID - 10.7748/ns.2026.e12685 [doi] AB - Shock is a potentially life-threatening condition characterised by impaired perfusion of tissues and organs and inadequate cellular oxygenation. If left untreated, shock can lead to organ dysfunction, organ failure and death. This article explores the pathophysiology of shock and its underlying causes, including key physiological concepts such as blood pressure, cardiac output, preload, contractility and afterload. It examines the different types of shock and their relationship to these physiological concepts, alongside strategies for assessment and management. The authors also discuss the crucial role of nurses in assessing and managing patients with shock as part of the multidisciplinary team. CI - (c) Royal College of Nursing of the United Kingdom (The) 2026. All rights reserved. Not to be copied, transmitted or recorded in any way, in whole or part, without prior permission of the publishers. FAU - Birch, Rachel AU - Birch R AD - School of Nursing and Public Health, Manchester Metropolitan University, Manchester, England. FAU - Turner, Sam AU - Turner S AD - School of Nursing and Public Health, Manchester Metropolitan University, Manchester, England. LA - eng PT - Journal Article DEP - 20260810 PL - England TA - Nurs Stand JT - Nursing standard (Royal College of Nursing (Great Britain) : 1987) JID - 9012906 SB - IM MH - Humans MH - *Shock/physiopathology/therapy/nursing/diagnosis MH - United Kingdom MH - Cardiac Output OTO - NOTNLM OT - cardiology OT - cardiorespiratory OT - critical care OT - intensive care OT - nursing care OT - observations OT - patient assessment OT - patients OT - signs and symptoms COIS- None declared EDAT- 2026/08/10 06:36 MHDA- 2026/09/30 05:30 CRDT- 2026/08/10 04:13 PHST- 2026/06/15 00:00 [accepted] PHST- 2026/09/30 05:30 [medline] PHST- 2026/08/10 06:36 [pubmed] PHST- 2026/08/10 04:13 [entrez] AID - e12685 [pii] AID - 10.7748/ns.2026.e12685 [doi] PST - ppublish SO - Nurs Stand. 2026 Sep 30;41(10):43-51. doi: 10.7748/ns.2026.e12685. Epub 2026 Aug 10. PMID- 42567797 OWN - NLM STAT- Publisher LR - 20260807 IS - 1873-5126 (Electronic) IS - 1353-8020 (Linking) DP - 2026 Jul 29 TI - A framework for multidisciplinary management of autonomic dysfunction in Parkinson disease. PG - 108905 LID - S1353-8020(26)00732-7 [pii] LID - 10.1016/j.parkreldis.2026.108905 [doi] AB - Autonomic dysfunction (AD) is present in nearly all people with Parkinson disease (PD), contributing to tremendous morbidity and mortality. Highly variable presentations including cardiovascular, gastrointestinal, urogenital, and thermoregulatory dysfunction can substantially affect daily function, safety, medication tolerance, and quality of life. Although autonomic symptoms are frequently encountered in neurologic practice, their management frequently extends beyond the traditional scope of neurologic care and may require input from multiple disciplines. Despite the increasing complexity of PD care and the need for coordinated multidisciplinary involvement, there are currently limited practical frameworks to guide specialist collaboration. Consequently, people with PD and their caregivers are often left to navigate fragmented care systems, conflicting recommendations, and uncertainty regarding which clinician should guide management. To help address these gaps, we provide a framework for the possible indications for specialist referrals and the potential roles of different healthcare practitioners in evaluating and treating AD. The manuscript also discusses the intersection between autonomic and neuropsychiatric manifestations in PD and offers practical clinical guidance for addressing this overlap. By providing a framework informed by coauthors in movement disorders, autonomic disorders, cardiology, nephrology, gastroenterology, urogynecology, physical therapy, and psychiatry, we hope to encourage neurologists - who often serve as the central point of contact - to collaborate closely and actively engage multidisciplinary team members in the management of these complex patients. CI - Copyright (c) 2026 Elsevier Ltd. All rights reserved. FAU - Miller-Patterson, Cameron AU - Miller-Patterson C AD - Virginia Commonwealth University, Department of Neurology, Richmond, VA, USA. Electronic address: cameron.millerpatterson@vcuhealth.org. FAU - Safarpour, Delaram AU - Safarpour D AD - Oregon Health and Science University, Department of Neurology, Portland, OR, USA. FAU - Longardner, Katherine AU - Longardner K AD - University of California San Diego, Department of Neurosciences, La Jolla, CA, USA. FAU - Lamotte, Guillaume AU - Lamotte G AD - University of Utah, Department of Neurology, Salt Lake City, UT, USA; George E Wahlen VA Medical Center, Veterans Affairs, Salt Lake City, UT, USA. FAU - Lenka, Abhishek AU - Lenka A AD - Virginia Commonwealth University, Department of Neurology, Richmond, VA, USA. FAU - Mahajan, Abhimanyu AU - Mahajan A AD - University of Cincinnati, Department of Neurology and Rehabilitation Medicine, James J and Joan A Gardner Family Center for Parkinson's Disease and Movement Disorders, Cincinnati, OH, USA. FAU - Diamond, Sarah AU - Diamond S AD - Oregon Health and Science University, Department of Medicine, Division of Gastroenterology and Hepatology, Portland, OR, USA. FAU - Gupta, Ankita AU - Gupta A AD - University of Louisville, Division of Urogynecology and Reconstructive Pelvic Surgery, Louisville, KY, USA. FAU - Hershberg, Julie AU - Hershberg J AD - University of Southern California, Division of Biokinesiology and Physical Therapy, Los Angeles, CA, USA. FAU - Khalsa, Sahib AU - Khalsa S AD - University of California Los Angeles, Department of Psychiatry and Biobehavioral Sciences, Los Angeles, CA, USA. FAU - Olshansky, Brian AU - Olshansky B AD - The University of Iowa, Department of Medicine, Division of Cardiology, Iowa City, IA, USA. FAU - Pontone, Gregory M AU - Pontone GM AD - University of Florida, Norman Fixel Institute for Brain Disorders, Department of Neurology, Gainesville, FL, USA. FAU - Rope, Robert AU - Rope R AD - Oregon Health and Science University, Department of Medicine, Division of Nephrology and Hypertension, Portland, OR, USA. FAU - Pfeiffer, Ronald F AU - Pfeiffer RF AD - Oregon Health and Science University, Department of Neurology, Portland, OR, USA. FAU - Subramanian, Indu AU - Subramanian I AD - PADRECC, West Los Angeles VA Medical Center, Veterans Administration, Los Angeles, CA, USA; University of California Los Angeles, Department of Neurology, Los Angeles, CA, USA. LA - eng PT - Journal Article PT - Review DEP - 20260729 PL - England TA - Parkinsonism Relat Disord JT - Parkinsonism & related disorders JID - 9513583 SB - IM OTO - NOTNLM OT - Collaborative OT - Multidisciplinary OT - Parkinson OT - autonomic COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/08/08 00:37 MHDA- 2026/08/08 00:37 CRDT- 2026/08/07 21:56 PHST- 2026/06/10 00:00 [received] PHST- 2026/07/23 00:00 [revised] PHST- 2026/07/25 00:00 [accepted] PHST- 2026/08/08 00:37 [medline] PHST- 2026/08/08 00:37 [pubmed] PHST- 2026/08/07 21:56 [entrez] AID - S1353-8020(26)00732-7 [pii] AID - 10.1016/j.parkreldis.2026.108905 [doi] PST - aheadofprint SO - Parkinsonism Relat Disord. 2026 Jul 29:108905. doi: 10.1016/j.parkreldis.2026.108905. PMID- 42564814 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260807 LR - 20260926 IS - 2090-6404 (Print) IS - 2090-6412 (Electronic) IS - 2090-6404 (Linking) VI - 2026 DP - 2026 TI - The Dyspnea Dilemma: Immune Checkpoint Inhibitor-Associated Myocarditis Mimicking Overlapping Cardiac Pathologies-A Case Report. PG - 9654777 LID - 10.1155/cric/9654777 [doi] LID - 9654777 AB - BACKGROUND: Immune checkpoint inhibitors (ICIs) such as durvalumab improve survival in solid tumors but can rarely cause fulminant myocarditis (reported in 1% of cases, with 25%-40% mortality). Clinical overlap with coronary artery disease (CAD), chemotherapy-related cardiomyopathy, or malignancy-associated complications makes diagnosis challenging. CASE PRESENTATION: A 62-year-old woman with gallbladder adenocarcinoma on gemcitabine, cisplatin, and durvalumab presented with 1 week of progressive dyspnea, leg edema, and chest pain. She had a history of portal vein thrombosis on apixaban. On exam, she was tachycardic and hypoxic with signs of volume overload. Labs showed elevated BNP and troponin. EKG revealed lateral T-wave inversions and chest x-ray demonstrated pulmonary edema. Echocardiography showed a large fibrinous pericardial effusion without tamponade and reduced LVEF (41%) with apical wall motion abnormalities. Differentials included ischemia, chemotherapy toxicity, ICI myocarditis, or malignant/hemorrhagic effusion. After a multidisciplinary discussion, anticoagulation was held, and the patient was transfused. Serial echocardiography showed a stable effusion but persistent ST-T changes. Coronary angiography excluded obstructive CAD. Cardiac MRI demonstrated diffuse myocardial edema, most pronounced in apical segments, consistent with myocarditis. Given the temporal relationship to ICI therapy, durvalumab-associated myocarditis was diagnosed. High-dose corticosteroids were initiated with symptomatic improvement. She was discharged on gemcitabine-cisplatin, with durvalumab omitted. Anticoagulation was resumed. Discharge echocardiography showed persistent apical wall motion abnormalities with a small effusion. CONCLUSION: This case highlights the diagnostic complexity of dyspnea in oncology patients, where multiple cardiac pathologies may coexist. A systematic, multidisciplinary approach-progressing from pericardial evaluation to ischemic work-up to advanced imaging-was crucial for diagnosis. Clinicians should maintain suspicion for ICI myocarditis when new heart failure or wall motion abnormalities occur without obstructive CAD, as early immunosuppressive therapy is critical. CI - Copyright (c) 2026 Nismat Javed et al. Case Reports in Cardiology published by John Wiley & Sons Ltd. FAU - Javed, Nismat AU - Javed N AUID- ORCID: 0000-0002-8756-927X AD - Department of Cardiology, Mount Sinai Morningside, New York, New York, USA. AD - Division of Cardiology, Department of Internal Medicine, BronxCare Health System, Bronx, New York, USA, bronxcare.org. FAU - Itare, Vikram AU - Itare V AUID- ORCID: 0009-0003-0943-696X AD - Department of Cardiology, Mount Sinai Morningside, New York, New York, USA. AD - Division of Cardiology, Department of Internal Medicine, BronxCare Health System, Bronx, New York, USA, bronxcare.org. FAU - Ashraf, Shoaib AU - Ashraf S AD - Department of Cardiology, Mount Sinai Morningside, New York, New York, USA. AD - Division of Cardiology, Department of Internal Medicine, BronxCare Health System, Bronx, New York, USA, bronxcare.org. FAU - Allu, Sai Vishnu Vardhan AU - Allu SVV AD - Department of Cardiology, Mount Sinai Morningside, New York, New York, USA. AD - Division of Cardiology, Department of Internal Medicine, BronxCare Health System, Bronx, New York, USA, bronxcare.org. FAU - Jadhav, Preeti AU - Jadhav P AD - Department of Cardiology, Mount Sinai Morningside, New York, New York, USA. AD - Division of Cardiology, Department of Internal Medicine, BronxCare Health System, Bronx, New York, USA, bronxcare.org. AD - Division of Cardiology, Department of Medicine at NYU Grossman School of Medicine, New York, New York, USA. LA - eng PT - Journal Article DEP - 20260806 PL - United States TA - Case Rep Cardiol JT - Case reports in cardiology JID - 101576452 PMC - PMC13444721 OTO - NOTNLM OT - ICI OT - acute coronary syndrome OT - multimodality imaging OT - myocarditis COIS- The authors declare no conflicts of interest. EDAT- 2026/08/07 12:39 MHDA- 2026/08/07 12:40 PMCR- 2026/08/06 CRDT- 2026/08/07 06:07 PHST- 2026/01/13 00:00 [received] PHST- 2026/07/27 00:00 [revised] PHST- 2026/07/29 00:00 [accepted] PHST- 2026/08/07 12:40 [medline] PHST- 2026/08/07 12:39 [pubmed] PHST- 2026/08/07 06:07 [entrez] PHST- 2026/08/06 00:00 [pmc-release] AID - CRIC9654777 [pii] AID - 10.1155/cric/9654777 [doi] PST - epublish SO - Case Rep Cardiol. 2026 Aug 6;2026:9654777. doi: 10.1155/cric/9654777. eCollection 2026. PMID- 42562222 OWN - NLM STAT- Publisher LR - 20260827 IS - 1615-5947 (Electronic) IS - 0890-5096 (Linking) VI - 133 DP - 2026 Aug 6 TI - N-Terminal Pro-B-type Natriuretic Peptide Predicts Mortality after Major Lower-Limb Amputation for Peripheral Arterial Disease. PG - 324-333 LID - S0890-5096(26)00582-0 [pii] LID - 10.1016/j.avsg.2026.07.066 [doi] AB - AIMS: N-terminal pro-B-type natriuretic peptide (NT-proBNP) is known to predict adverse cardiac outcomes in non-cardiac surgery. However, its prognostic role in patients undergoing major limb amputation (MLA) remains under-explored. This study aimed to evaluate the relationship between NT-proBNP levels and mortality following MLA. METHODS: A retrospective cohort study of all patients undergoing MLA at a single tertiary vascular center between 01/01/2019-31/12/2023 was performed. Demographic data, comorbidities, American Society of Anaesthesiologists (ASA) grade, frailty status, amputation level, and NT-proBNP measurements were collected. NT-proBNP-specific analyses were restricted to the 203 patients with at least one pre- or post-operative measurement (122 pre-operative, 81 post-operative). Univariable associations with 1- and 2-year mortality were assessed, followed by multivariable binary logistic regression incorporating clinically relevant covariates. RESULTS: There were 433 Amputations in 409 patients analyzed (317 [73.20%] male; median age 72 [62.40-80.30] years). There were 261 (60.30%) Below-knee amputations (BKA), 170 (39.70%) above-knee amputations (AKA). The cohort demonstrated substantial comorbidity 263 (60.70%) diabetes, 234 (54%) hypertension, 133 (30.70%) ischaemic heart disease) with ASA grade III-IV in 425 (98%) and frailty present in 407 (94%). Overall mortality was high at 8 (1.96%) at 30 days, 116 (26.80%) at 1 year and 145 (33.50%) at 2 years. A total of 209 NT-proBNP measurements were collected, of which 203 were used in the analysis (122 pre-operative, 81 post-operative). Median pre-operative NT-proBNP was 1,162 (274-3,721)ng/L, and post-operative NT-proBNP was 1,194 (496-5,966) ng/L. Pre-operative and post-operative NT-proBNP was significantly higher in non-survivors at 1 and 2 years (All P 2000 ng/L remained an independent predictor of mortality at one and 2 years after multivariable adjustment: OR: 3.90, 95% CI (1.44-10.59), P = 0.008, and OR 2.57, 95% CI (1.05-6.32), P = 0.04 respectively. CONCLUSION: Patients undergoing MLA experience very high early and medium-term mortality. Both pre-operative and post-operative NT-proBNP independently predict mortality beyond age, frailty, and amputation level, supporting its role as a powerful biomarker for peri-operative risk stratification and multidisciplinary decision-making in this high-risk population. CI - Crown Copyright (c) 2026. Published by Elsevier Inc. All rights reserved. FAU - Mills, Henry Lewis AU - Mills HL AD - Norfolk and Norwich Vascular Unit, Norfolk & Norwich University Hospital, Norwich, UK. FAU - Shaikh, Ateeqahamed AU - Shaikh A AD - Norfolk and Norwich Vascular Unit, Norfolk & Norwich University Hospital, Norwich, UK. FAU - Bennett, Philip C AU - Bennett PC AD - Norfolk and Norwich Vascular Unit, Norfolk & Norwich University Hospital, Norwich, UK. Electronic address: philip.bennett@nnuh.nhs.uk. LA - eng PT - Journal Article DEP - 20260806 PL - Netherlands TA - Ann Vasc Surg JT - Annals of vascular surgery JID - 8703941 SB - IM EDAT- 2026/08/07 00:35 MHDA- 2026/08/07 00:35 CRDT- 2026/08/06 19:19 PHST- 2026/02/21 00:00 [received] PHST- 2026/07/27 00:00 [revised] PHST- 2026/07/28 00:00 [accepted] PHST- 2026/08/07 00:35 [pubmed] PHST- 2026/08/07 00:35 [medline] PHST- 2026/08/06 19:19 [entrez] AID - S0890-5096(26)00582-0 [pii] AID - 10.1016/j.avsg.2026.07.066 [doi] PST - aheadofprint SO - Ann Vasc Surg. 2026 Aug 6;133:324-333. doi: 10.1016/j.avsg.2026.07.066. PMID- 42561722 OWN - NLM STAT- Publisher LR - 20260806 IS - 1532-8171 (Electronic) IS - 0735-6757 (Linking) VI - 110 DP - 2026 Aug 1 TI - Concurrent cardiocerebral infarction in the emergency department: A case series from a tertiary care centre in South India. PG - 8-14 LID - S0735-6757(26)00374-8 [pii] LID - 10.1016/j.ajem.2026.07.052 [doi] AB - BACKGROUND: Concurrent cardiocerebral infarction (CCI), defined as the near-simultaneous occurrence of acute ischemic stroke (AIS) and acute myocardial infarction (AMI), is a rare but life-threatening emergency with complex and often conflicting management priorities. Evidence guiding optimal treatment strategies remains limited. METHODS: We conducted a retrospective observational study of adult patients presenting with CCI to the emergency department of a tertiary care centre in South India over a 2-year period. Patients with AIS and AMI occurring within 24 h were included. Demographic, clinical, imaging, treatment, and outcome data were extracted. Descriptive comparisons were performed to summarize differences between survivors and non-survivors. The primary outcome was in-hospital mortality. RESULTS: A total of 11 patients were included. The median age was 55 years (IQR, 38-65), with a male predominance (73%). Most patients presented beyond established therapeutic windows (chest pain >12 h: 73%; neurological symptoms >4.5 h: 91%). Anterior circulation strokes predominated (91%), with moderate-to-severe neurological deficits (median NIHSS 11; IQR, 7-18). Regarding treatment eligibility, three patients were within the treatment window for both AIS and AMI, three were eligible for AMI treatment only, one for AIS treatment only, and four were outside the treatment window for both conditions. Reperfusion therapy consisted of intravenous thrombolysis alone in 18% and combined intravenous thrombolysis with percutaneous coronary intervention (PCI) in 18%, while 64% received medical management alone. In-hospital mortality was 73%. Descriptive comparisons showed that survivors had lower NIHSS scores and higher ASPECTS and GCS scores at presentation. CONCLUSION: CCI is associated with high in-hospital mortality. These findings suggest that delayed presentation and limited eligibility for timely reperfusion may contribute to poor outcomes, particularly in patients with severe neurological involvement. In emergency settings, early recognition, rapid risk stratification, and coordinated multidisciplinary decision-making are critical for optimizing outcomes in this complex dual vascular emergency. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Jayajothi, Thenemukil AU - Jayajothi T AD - Department of Emergency Medicine and Trauma, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India. FAU - Amrithanand, V T AU - Amrithanand VT AD - Department of Emergency Medicine and Trauma, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India. Electronic address: amrithanandvt@gmail.com. FAU - Anukarthika, Somasundaram AU - Anukarthika S AD - Department of Emergency Medicine and Trauma, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India. LA - eng PT - Journal Article DEP - 20260801 PL - United States TA - Am J Emerg Med JT - The American journal of emergency medicine JID - 8309942 SB - IM OTO - NOTNLM OT - Acute ischemic stroke OT - Acute myocardial infarction OT - Cardiocerebral infarction OT - In-hospital mortality OT - Medical management OT - Percutaneous intervention OT - Thrombolysis COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/08/07 00:35 MHDA- 2026/08/07 00:35 CRDT- 2026/08/06 18:08 PHST- 2026/04/28 00:00 [received] PHST- 2026/07/24 00:00 [revised] PHST- 2026/07/25 00:00 [accepted] PHST- 2026/08/07 00:35 [medline] PHST- 2026/08/07 00:35 [pubmed] PHST- 2026/08/06 18:08 [entrez] AID - S0735-6757(26)00374-8 [pii] AID - 10.1016/j.ajem.2026.07.052 [doi] PST - aheadofprint SO - Am J Emerg Med. 2026 Aug 1;110:8-14. doi: 10.1016/j.ajem.2026.07.052. PMID- 42560223 OWN - NLM STAT- MEDLINE DCOM- 20260806 LR - 20260806 IS - 1930-613X (Electronic) IS - 0026-4075 (Linking) VI - 191 IP - Supplement_1 DP - 2026 Aug 1 TI - Evaluation of Interprofessional Collaboration, Communication, Teamwork, and Prehospital Clinical Competencies Among Military Healthcare Providers During a Medical Trauma Simulation Exercise: A Cross-sectional Study. PG - 354-361 LID - 10.1093/milmed/usag097 [doi] AB - INTRODUCTION: Medical Trauma-related injuries necessitate timely and systematic management to minimize long-term complications and mortality. Simulation-based training has become integral in military medicine, providing opportunities for healthcare providers to practice time sensitive and high-stakes skills in a controlled environment.This study aimed to evaluate the impact of an interprofessional medical trauma clinical simulation exercise on the collaboration, communication, teamwork, and prehospital clinical competencies of Canadian Forces Health Services (CFHS) reserve force healthcare personnel. MATERIALS AND METHODS: A cross-sectional, pre-post-test pilot design was employed. Participants engaged in four trauma scenarios, including opioid toxicity, cardiac arrest, airway trauma, and massive hemorrhage. Data were collected using subjective and objective validated tools, focusing on interprofessional education, collaboration, teamwork, satisfaction, and medical trauma prehospital clinical competencies. RESULTS: The study comprised of 21 military healthcare providers from medical reserve units. The study found statistically significant improvements in participants' perceptions and attitudes toward interprofessional education and teamwork. Participants also reported high levels of satisfaction and self-confidence in learning. However, competency levels varied across scenarios, with weaker performance in trauma airway management. CONCLUSION: This study demonstrates the multifaceted benefits of interprofessional, simulation-based medical trauma training for military healthcare providers. Although improvements in attitudes and satisfaction were evident, variations in prehospital clinical competency highlight the need for ongoing evaluation and targeted training. This research advances simulation pedagogy within the CFHS and informs future studies to enhance military medical training and operational readiness. CI - (c) The Association of Military Surgeons of the United States 2026. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com. FAU - Lok, Jana AU - Lok J AD - Canadian Forces Health Services Headquarters, Gloucester, Ottawa, ON, Canada. FAU - McDougall, Garrett AU - McDougall G AD - 23 Field Ambulance, Hamilton, ON L8L 4V7, Canada. FAU - Qureshi, Imran AU - Qureshi I AD - 25 (Toronto) Field Ambulance, Toronto, ON M5A 1R9, Canada. FAU - Jackson, Ted AU - Jackson T AD - 25 (Toronto) Field Ambulance, Toronto, ON M5A 1R9, Canada. FAU - Marshall, Luke AU - Marshall L AD - 33 Field Ambulance, Halifax, NS, Canada. FAU - Dhillon, Paul AU - Dhillon P AD - 11/12 Field Ambulance, Vancouver, BC, Canada. FAU - Wickett, Megan AU - Wickett M AD - Canadian Forces Health Services Headquarters, Gloucester, Ottawa, ON, Canada. FAU - Jain, Trevor AU - Jain T AD - Canadian Forces Health Services Headquarters, Gloucester, Ottawa, ON, Canada. FAU - Ibrahim, Sarah AU - Ibrahim S AD - 25 (Toronto) Field Ambulance, Toronto, ON M5A 1R9, Canada. LA - eng PT - Journal Article PL - England TA - Mil Med JT - Military medicine JID - 2984771R SB - IM MH - Humans MH - Cross-Sectional Studies MH - *Clinical Competence/standards/statistics & numerical data MH - Male MH - Patient Care Team/standards MH - Female MH - Adult MH - *Simulation Training/methods/standards MH - *Military Medicine/education/methods MH - Communication MH - *Military Personnel/education/statistics & numerical data MH - *Interprofessional Relations MH - *Cooperative Behavior MH - Canada MH - Wounds and Injuries/therapy MH - Pilot Projects MH - *Health Personnel/education/statistics & numerical data MH - Emergency Medical Services/methods/standards EDAT- 2026/08/06 12:37 MHDA- 2026/08/06 12:38 CRDT- 2026/08/06 10:03 PHST- 2026/08/06 12:38 [medline] PHST- 2026/08/06 12:37 [pubmed] PHST- 2026/08/06 10:03 [entrez] AID - 8751835 [pii] AID - 10.1093/milmed/usag097 [doi] PST - ppublish SO - Mil Med. 2026 Aug 1;191(Supplement_1):354-361. doi: 10.1093/milmed/usag097. PMID- 42558703 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260806 LR - 20260813 IS - 2297-055X (Print) IS - 2297-055X (Electronic) IS - 2297-055X (Linking) VI - 13 DP - 2026 TI - Percutaneous closure of a giant left ventricular pseudoaneurysm using an Amplatzer muscular VSD occluder in a high-risk patient with recurrent heart failure following multiple myocardial infarctions. PG - 1879721 LID - 10.3389/fcvm.2026.1879721 [doi] LID - 1879721 AB - BACKGROUND: Left ventricular pseudoaneurysm (LVPA) is a rare and potentially fatal complication of myocardial infarction (MI), with mortality reaching 48% in untreated patients. While surgical repair has been the conventional therapy, perioperative mortality of 10%-36% renders it prohibitive in patients with multiple comorbidities. Percutaneous transcatheter closure has emerged as a life-saving alternative for high-risk surgical candidates. CASE REPORT: A 75-year-old male with prior coronary artery bypass grafting (2010) and two subsequent myocardial infarctions (2019 and 2020) treated with percutaneous coronary intervention presented with refractory decompensated heart failure, massive left pleural effusion, and markedly elevated NT-proBNP (7,172 pg/mL). Cardiac magnetic resonance imaging revealed a giant LVPA (61 mm x 28 mm; end-diastolic volume 55 mL) arising from the lateral-to-posterolateral wall, with transmural late gadolinium enhancement confirming a post-infarction etiology. After multidisciplinary heart-team consensus, percutaneous transcatheter closure was performed via a transfemoral retrograde approach under transesophageal echocardiographic guidance using a 16 mm Amplatzer Muscular VSD Occluder. The procedure was uncomplicated, with no significant residual flow. The patient was discharged on postoperative day 2. At 3-month follow-up, he was in NYHA class I-II with marked symptomatic improvement, NT-proBNP reduction to approximately 500 pg/mL, and no residual flow. CONCLUSIONS: Percutaneous transcatheter closure with an Amplatzer Muscular VSD Occluder is a feasible, safe, and life-saving therapeutic option in selected high-risk patients with post-infarction LVPA presenting with refractory heart failure. CI - (c) 2026 Coskun, Sag, Ozdabakoglu and Kilic. FAU - Coskun, Senol AU - Coskun S AD - Faculty of Health Sciences, Kocaeli Health and Technology University, Kocaeli, Turkiye. FAU - Sag, Saim AU - Sag S AD - Department of Cardiology, Acibadem Bursa Hospital, Bursa, Turkiye. FAU - Ozdabakoglu, Osman AU - Ozdabakoglu O AD - Department of Cardiology, Acibadem Bursa Hospital, Bursa, Turkiye. FAU - Kilic, Teoman AU - Kilic T AD - Structural Heart Interventions Unit, Department of Cardiology, Kocaeli University School of Medicine, Kocaeli, Turkiye. LA - eng PT - Journal Article DEP - 20260722 PL - Switzerland TA - Front Cardiovasc Med JT - Frontiers in cardiovascular medicine JID - 101653388 PMC - PMC13438288 OTO - NOTNLM OT - VSD occluder device OT - aneurysm OT - false OT - heart failure OT - heart ventricles OT - post myocardial infarction COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/08/06 12:37 MHDA- 2026/08/06 12:38 PMCR- 2026/07/22 CRDT- 2026/08/06 06:19 PHST- 2026/05/12 00:00 [received] PHST- 2026/06/10 00:00 [revised] PHST- 2026/06/30 00:00 [accepted] PHST- 2026/08/06 12:38 [medline] PHST- 2026/08/06 12:37 [pubmed] PHST- 2026/08/06 06:19 [entrez] PHST- 2026/07/22 00:00 [pmc-release] AID - 10.3389/fcvm.2026.1879721 [doi] PST - epublish SO - Front Cardiovasc Med. 2026 Jul 22;13:1879721. doi: 10.3389/fcvm.2026.1879721. eCollection 2026. PMID- 42558062 OWN - NLM STAT- MEDLINE DCOM- 20260908 LR - 20260908 IS - 1524-4539 (Electronic) IS - 0009-7322 (Linking) VI - 154 IP - 10 DP - 2026 Sep 8 TI - Surviving Pediatric Cardiogenic Shock: Clinical Approach, Improving Outcomes, and Future Directions: A Scientific Statement From the American Heart Association. PG - e374-e392 LID - 10.1161/CIR.0000000000001461 [doi] AB - Pediatric heart failure-related cardiogenic shock carries high morbidity and mortality but is understudied. Improving outcomes in pediatric cardiogenic shock hinges on timely diagnosis and appropriate triage, medical management tailored to the cause and phenotype of cardiogenic shock, and optimal timing of escalation to appropriate mechanical circulatory support. This scientific statement provides a diagnostic framework for the bedside clinician, in addition to proposing a pediatric cardiogenic shock definition and severity staging aligned with systems previously validated in other studies. It outlines the initial approach to diagnosis and stabilization of a child with suspected cardiogenic shock and offers guidance on optimal noninvasive and invasive monitoring strategies to determine clinical trajectory because a significant proportion of children with cardiogenic shock will continue to deteriorate in the first 24 hours. Last, it identifies future directions for the field, including educational interventions for the frontline clinicians seeing these patients, studying the role of a multidisciplinary shock team, evaluating the prognostic and clinical relevance of known and novel biomarkers, and leveraging all these to develop clinical decision tools or algorithms to guide nuanced management of these patients. FAU - Puri, Kriti AU - Puri K FAU - Allen, Kiona AU - Allen K FAU - Jentzer, Jacob AU - Jentzer J FAU - Soderstrom, Rhynn AU - Soderstrom R FAU - Lorts, Angela AU - Lorts A FAU - Schumacher, Kurt AU - Schumacher K FAU - Barnes, Sean AU - Barnes S FAU - Greene, Christina L AU - Greene CL FAU - Jeewa, Aamir AU - Jeewa A CN - American Heart Association's Young Hearts Pediatric and Congenital Critical Care Cardiology Committee of the Council on Lifelong Congenital Heart Disease and Heart Health in the Young LA - eng PT - Journal Article PT - Review DEP - 20260806 PL - United States TA - Circulation JT - Circulation JID - 0147763 SB - IM MH - Humans MH - *Shock, Cardiogenic/therapy/diagnosis/mortality/physiopathology MH - American Heart Association MH - United States MH - Child MH - Treatment Outcome MH - Heart Failure/therapy OTO - NOTNLM OT - AHA Scientific Statements OT - cardiomyopathies OT - heart defects, congenital OT - heart failure OT - pediatrics OT - shock, cardiogenic EDAT- 2026/08/06 11:36 MHDA- 2026/09/08 17:36 CRDT- 2026/08/06 05:03 PHST- 2026/09/08 17:36 [medline] PHST- 2026/08/06 11:36 [pubmed] PHST- 2026/08/06 05:03 [entrez] AID - 10.1161/CIR.0000000000001461 [doi] PST - ppublish SO - Circulation. 2026 Sep 8;154(10):e374-e392. doi: 10.1161/CIR.0000000000001461. Epub 2026 Aug 6. PMID- 42558030 OWN - NLM STAT- MEDLINE DCOM- 20260806 LR - 20260916 IS - 1478-5153 (Electronic) IS - 1362-1017 (Print) IS - 1362-1017 (Linking) VI - 31 IP - 5 DP - 2026 Sep TI - From Paper to Proactive Safety: Digitalising Shift Checklists in a Paediatric Cardiac ICU. PG - e70622 LID - 10.1111/nicc.70622 [doi] LID - e70622 AB - BACKGROUND: In paediatric cardiac intensive care units (PCICUs), shift-based safety checks are critical to ensuring equipment readiness during time-sensitive emergencies. Reliance on paper-based checklists resulted in variable compliance and limited accountability. A critical incident involving a non-functional defibrillator during a paediatric cardiac arrest was identified as a system-level failure rather than individual staff error, exposing the risk of unpreparedness. AIM: To improve and sustain compliance with shift safety checks through a QR code-based digital checklist system with automated reminders and escalation, enhancing patient safety and staff readiness. STUDY DESIGN: Following root cause analysis and guided by a Just Culture approach, this quality improvement project, conducted in a tertiary PCICU in the United Arab Emirates, used Kotter's eight-step change model and Plan-Do-Check-Act (PDCA) cycles. A multidisciplinary team developed a mobile-accessible digital checklist. QR codes were placed on critical equipment and clinical areas. Staff scanned the QR code at the item location and completed checks in real time. Microsoft Power Automate sent reminders to the team leader after 2 h, with escalation to the unit manager after 3 h if checks remained incomplete. The intervention was piloted over 1 month and expanded unit wide. RESULTS: Compliance with shift safety checks improved from a baseline of 82% to 90% at 3 months. After resolution of technical issues and reinforcement of staff education, compliance reached and was sustained at 100% by 6 months. Staff satisfaction increased from 68% at baseline to 91% at 3 months and 96.3% at 6 months. Documentation became fully auditable, equipment readiness at the start of each shift markedly improved, and no further critical equipment failures were reported during emergency events. CONCLUSIONS: Sustained improvement was achieved by combining accessible digital technology with structured change management, iterative PDCA cycles and a Just Culture approach, supporting durable transformation of shift safety checks in a high-acuity PCICU. RELEVANCE TO CLINICAL PRACTICE: QR code-based digital checklists with automated reminders and escalation offer a low-cost, scalable approach for critical care units to strengthen equipment readiness, enable real-time documentation at the point of checking, improve auditability and reduce reliance on paper and time away from patients. CI - (c) 2026 British Association of Critical Care Nurses. FAU - Gamal, Mohamed AU - Gamal M AUID- ORCID: 0009-0009-3593-2194 AD - Al Jalila Children's Hospital, Dubai, UAE. FAU - Elsahy, Reda AU - Elsahy R AUID- ORCID: 0009-0007-9565-3563 AD - Al Jalila Children's Hospital, Dubai, UAE. FAU - Farina, Martin AU - Farina M AD - Al Jalila Children's Hospital, Dubai, UAE. FAU - Almaazmi, Munira AU - Almaazmi M AD - Al Jalila Children's Hospital, Dubai, UAE. FAU - Abdulla, Hisham AU - Abdulla H AUID- ORCID: 0000-0002-5170-9904 AD - Al Jalila Children's Hospital, Dubai, UAE. FAU - Hamad, Yuser AU - Hamad Y AD - Al Jalila Children's Hospital, Dubai, UAE. FAU - Osman, Shabaan AU - Osman S AUID- ORCID: 0009-0009-7915-9594 AD - Al Jalila Children's Hospital, Dubai, UAE. LA - eng PT - Journal Article PL - England TA - Nurs Crit Care JT - Nursing in critical care JID - 9808649 SB - IM MH - Humans MH - *Checklist MH - *Intensive Care Units, Pediatric/organization & administration/standards MH - *Patient Safety/standards MH - Quality Improvement MH - United Arab Emirates MH - Medical Errors/prevention & control MH - Heart Arrest/therapy PMC - PMC13445135 OTO - NOTNLM OT - QR code OT - automated reminders OT - digital checklists OT - just culture OT - paediatric cardiac ICU OT - patient safety OT - quality improvement COIS- The authors declare no conflicts of interest. EDAT- 2026/08/06 11:36 MHDA- 2026/08/06 11:37 PMCR- 2026/08/06 CRDT- 2026/08/06 04:53 PHST- 2026/07/08 00:00 [revised] PHST- 2026/04/17 00:00 [received] PHST- 2026/07/20 00:00 [accepted] PHST- 2026/08/06 11:37 [medline] PHST- 2026/08/06 11:36 [pubmed] PHST- 2026/08/06 04:53 [entrez] PHST- 2026/08/06 00:00 [pmc-release] AID - NICC70622 [pii] AID - 10.1111/nicc.70622 [doi] PST - ppublish SO - Nurs Crit Care. 2026 Sep;31(5):e70622. doi: 10.1111/nicc.70622. PMID- 42556452 OWN - NLM STAT- MEDLINE DCOM- 20261027 LR - 20261027 IS - 1552-6259 (Electronic) IS - 0003-4975 (Linking) VI - 122 IP - 5 DP - 2026 Nov TI - Reducing sternal Wound Infections After Cardiac Surgery Through Targeted, Interdisciplinary Efforts: A Large, Single-Center Experience. PG - 1368-1376 LID - S0003-4975(26)00810-6 [pii] LID - 10.1016/j.athoracsur.2026.07.036 [doi] AB - BACKGROUND: Sternal wound infections (SWIs) are associated with significant morbidity, mortality, and health care costs. After root-cause analysis, the study center implemented an evidence-based SWI prevention bundle and evaluated its effect on the SWI burden. METHODS: Adult patients who underwent coronary artery bypass grafting or valve surgery, or both, through median sternotomy between 2021 and 2024 were reviewed (N = 2185). Patients were stratified by era (prebundle era vs postbundle era). Propensity score matching yielded 2 groups of 802 patients each. The primary outcome was deep SWI as defined by the National Healthcare Safety Network. RESULTS: Matched groups were similar across key baseline variables. The SWI rate decreased from 2.7% in the prebundle era to 1.1% in the postbundle era (P = .03), driven by a 3-fold reduction in deep SWIs (2.1% vs 0.7%; P = .04). Superficial SWIs were unchanged (0.6% vs 0.3%; P = .87). Thirty-day readmissions also decreased (1.3% vs 0.4%; P = .01). Multivariable analysis identified diabetes, higher body mass index, and the prebundle era as predictors of SWI. A greater number and proportion of culture isolates were fungal in the postbundle era (33% vs 9.1%; P = .047). CONCLUSIONS: Implementation of an SWI prevention bundle significantly reduced deep SWIs and associated readmissions. The relative increase in fungal infections highlights the need for targeted strategies against Candida species. CI - Copyright (c) 2026 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved. FAU - Vinogradsky, Alice V AU - Vinogradsky AV AD - Division of Cardiac, Thoracic, and Vascular Surgery, Department of Surgery, Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, New York, New York. FAU - Soliman, Fady K AU - Soliman FK AD - Division of Cardiac, Thoracic, and Vascular Surgery, Department of Surgery, Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, New York, New York. FAU - Kurlansky, Paul AU - Kurlansky P AD - Division of Cardiac, Thoracic, and Vascular Surgery, Department of Surgery, Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, New York, New York; Center for Innovation and Outcomes Research, Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, New York, New York. FAU - Ali, Faridi AU - Ali F AD - Division of Cardiac, Thoracic, and Vascular Surgery, Department of Surgery, Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, New York, New York. FAU - Cohen, Jill B AU - Cohen JB AD - Division of Cardiac, Thoracic, and Vascular Surgery, Department of Surgery, Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, New York, New York. FAU - Berger, Alexandra Taylor AU - Berger AT AD - Division of Cardiac, Thoracic, and Vascular Surgery, Department of Surgery, Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, New York, New York. FAU - Chacko, Tilu AU - Chacko T AD - Division of Cardiac, Thoracic, and Vascular Surgery, Department of Surgery, Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, New York, New York. FAU - Dunn, Kayla AU - Dunn K AD - Division of Cardiac, Thoracic, and Vascular Surgery, Department of Surgery, Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, New York, New York. FAU - Spicer, Michael AU - Spicer M AD - Division of Cardiac, Thoracic, and Vascular Surgery, Department of Surgery, Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, New York, New York. FAU - Raza, Syed Tasnim AU - Raza ST AD - Division of Cardiac, Thoracic, and Vascular Surgery, Department of Surgery, Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, New York, New York. FAU - Takayama, Hiroo AU - Takayama H AD - Division of Cardiac, Thoracic, and Vascular Surgery, Department of Surgery, Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, New York, New York. FAU - Kaku, Yuji AU - Kaku Y AD - Division of Cardiac, Thoracic, and Vascular Surgery, Department of Surgery, Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, New York, New York. FAU - Elmously, Adham AU - Elmously A AD - Division of Cardiac, Thoracic, and Vascular Surgery, Department of Surgery, Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, New York, New York. Electronic address: ae2740@cumc.columbia.edu. LA - eng PT - Journal Article DEP - 20260805 PL - Netherlands TA - Ann Thorac Surg JT - The Annals of thoracic surgery JID - 15030100R SB - IM MH - Humans MH - *Surgical Wound Infection/prevention & control/epidemiology MH - Female MH - *Sternotomy/adverse effects MH - Aged MH - Male MH - *Cardiac Surgical Procedures/adverse effects MH - Middle Aged MH - Retrospective Studies MH - *Coronary Artery Bypass/adverse effects MH - *Patient Care Bundles MH - Propensity Score COIS- Disclosures The authors have no conflicts of interest to disclose. EDAT- 2026/08/06 11:36 MHDA- 2026/10/27 23:27 CRDT- 2026/08/05 19:16 PHST- 2026/02/03 00:00 [received] PHST- 2026/07/10 00:00 [revised] PHST- 2026/07/28 00:00 [accepted] PHST- 2026/10/27 23:27 [medline] PHST- 2026/08/06 11:36 [pubmed] PHST- 2026/08/05 19:16 [entrez] AID - S0003-4975(26)00810-6 [pii] AID - 10.1016/j.athoracsur.2026.07.036 [doi] PST - ppublish SO - Ann Thorac Surg. 2026 Nov;122(5):1368-1376. doi: 10.1016/j.athoracsur.2026.07.036. Epub 2026 Aug 5. PMID- 42552576 OWN - NLM STAT- Publisher LR - 20260805 IS - 1538-943X (Electronic) IS - 1058-2916 (Linking) DP - 2026 Aug 5 TI - Novel Explantation Protocol for Cardiac Recovery and Device Weaning Post-Left Ventricular Assist Device Therapy: A Single-Center Experience. LID - 10.1097/MAT.0000000000002689 [doi] AB - Although some patients may exhibit significant myocardial improvement after the placement of a durable left ventricular assist device (LVAD), there are no established guidelines on determining patients who may be eligible for explantation. In this single-center case series, three patients were evaluated for LVAD explantation 8-24 months after implantation using a rigorous multimodality protocol along with multidisciplinary team discussions to assess appropriateness for explantation. Although two of the patients have remained successful device-free, the third patient ultimately underwent heart transplantation 2 months post-explantation. We propose evaluating this protocol more broadly in patients with durable LVADs who demonstrate improved left ventricular function with the goal of ultimately developing standardized guidelines to assess appropriateness for LVAD explantation. CI - Copyright (c) ASAIO 2026. FAU - Kumar, Aarti AU - Kumar A AD - From the Department of Internal Medicine, University of California, Los Angeles, California. FAU - Mitchell, Ashley J AU - Mitchell AJ AD - Department of Medicine, Cedars-Sinai Kidney Transplant Program, Los Angeles, California. FAU - Shahandeh, Negeen AU - Shahandeh N AD - Division of Cardiology, University of California, Los Angeles, California. FAU - Vucicevic, Darko AU - Vucicevic D AD - Division of Cardiology, University of California, Los Angeles, California. FAU - Kwon, Murray H AU - Kwon MH AD - Division of Cardiac Surgery, University of California, Los Angeles, California. FAU - Srivastava, Pratyaksh K AU - Srivastava PK AD - Division of Cardiology, University of California, Los Angeles, California. FAU - Nsair, Ali AU - Nsair A AD - Division of Cardiology, University of California, Los Angeles, California. FAU - Kamath, Megan Y AU - Kamath MY AUID- ORCID: 0000-0002-6585-7561 AD - Division of Cardiology, University of California, Los Angeles, California. LA - eng PT - Journal Article DEP - 20260805 PL - United States TA - ASAIO J JT - ASAIO journal (American Society for Artificial Internal Organs : 1992) JID - 9204109 SB - IM OTO - NOTNLM OT - cardiac recovery OT - durable left ventricular assist device OT - heart failure OT - mechanical circulatory support COIS- Disclosure: The authors have no conflicts of interest to report. EDAT- 2026/08/05 06:42 MHDA- 2026/08/05 06:42 CRDT- 2026/08/05 00:31 PHST- 2026/08/05 06:42 [medline] PHST- 2026/08/05 06:42 [pubmed] PHST- 2026/08/05 00:31 [entrez] AID - 00002480-990000000-01034 [pii] AID - 10.1097/MAT.0000000000002689 [doi] PST - aheadofprint SO - ASAIO J. 2026 Aug 5. doi: 10.1097/MAT.0000000000002689. PMID- 42546303 OWN - NLM STAT- MEDLINE DCOM- 20260817 LR - 20260817 IS - 1539-3704 (Electronic) IS - 0003-4819 (Linking) VI - 179 IP - 8 DP - 2026 Aug TI - In adults with uncontrolled hypertension, a multifaceted team-based intervention vs. enhanced usual care improved BP control at 18 mo. PG - JC92 LID - 10.7326/ANNALS-26-02797-JC [doi] AB - GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text]. FAU - Aung, KoKo AU - Aung K AD - Paul L. Foster School of Medicine, El Paso, Texas, USA (K.A., T.H.). FAU - Htay, Thwe AU - Htay T AD - Paul L. Foster School of Medicine, El Paso, Texas, USA (K.A., T.H.). CN - ACP Journal Club Editorial Team at McMaster University LA - eng PT - Journal Article DEP - 20260804 PL - United States TA - Ann Intern Med JT - Annals of internal medicine JID - 0372351 RN - 0 (Antihypertensive Agents) SB - IM MH - Humans MH - *Hypertension/drug therapy/therapy MH - *Antihypertensive Agents/therapeutic use MH - *Patient Care Team MH - Blood Pressure COIS- Disclosures: Disclosure forms are available with the article online. EDAT- 2026/08/03 18:37 MHDA- 2026/08/17 23:39 CRDT- 2026/08/03 17:02 PHST- 2026/08/17 23:39 [medline] PHST- 2026/08/03 18:37 [pubmed] PHST- 2026/08/03 17:02 [entrez] AID - 10.7326/ANNALS-26-02797-JC [doi] PST - ppublish SO - Ann Intern Med. 2026 Aug;179(8):JC92. doi: 10.7326/ANNALS-26-02797-JC. Epub 2026 Aug 4. PMID- 42543248 OWN - NLM STAT- MEDLINE DCOM- 20261015 LR - 20261015 IS - 1744-8344 (Electronic) IS - 1477-9072 (Linking) VI - 24 IP - 9 DP - 2026 Sep TI - Identifying patients at risk of Takotsubo syndrome during cancer treatment: a sex-based cardio-oncology review. PG - 793-804 LID - 10.1080/14779072.2026.2714263 [doi] AB - INTRODUCTION: Takotsubo syndrome is an acute, transient ventricular dysfunction that frequently mimics acute coronary syndrome. Patients with cancer may be particularly vulnerable because malignancy-related stress and cancer therapies converge with cardiovascular susceptibility. AREAS COVERED: This narrative review examines sex-related susceptibility and acuity, cancer-related stressors, implicated therapy classes, diagnostic differentiation, management, and treatment rechallenge. PubMed/MEDLINE was searched from January 2000 through June 2026 using combinations of terms for Takotsubo syndrome, cancer, cardio-oncology, sex, specific antineoplastic agents, imaging, outcomes, and rechallenge; reference lists of relevant consensus statements and reviews were also screened. Evidence is predominantly derived from registries, retrospective cohorts, case series, and case reports. EXPERT OPINION: Sex should be treated as a risk modifier rather than a stand-alone determinant. A cumulative vulnerability framework integrating patient susceptibility, cancer-related stress burden, and treatment exposure may support earlier recognition and multidisciplinary decisions, but prospective validation and standardized sex-stratified reporting are required. FAU - Tesoro, Nicole AU - Tesoro N AD - Department of Internal Medicine, NYC Health and Hospitals/South Brooklyn Health, Brooklyn, NY, USA. FAU - Marsidi, Jennifer AU - Marsidi J AD - Division of Cardiology, Rush University Medical Center, Chicago, IL, USA. FAU - Spaan, Jonathan AU - Spaan J AD - Rush College of Medicine, Chicago, IL, USA. FAU - Okoroike, Henry AU - Okoroike H AD - Department of Pharmacy, Rush University Medical Center, Chicago, IL, USA. FAU - Sutter, Joanne AU - Sutter J AD - Division of Cardiology, Rush University Medical Center, Chicago, IL, USA. FAU - Jonas, Rebecca AU - Jonas R AD - Division of Cardiology, Rush University Medical Center, Chicago, IL, USA. FAU - Altenburg, Marie AU - Altenburg M AD - Division of Cardiology, Rush University Medical Center, Chicago, IL, USA. FAU - Okwuosa, Tochi AU - Okwuosa T AD - Division of Cardiology, Rush University Medical Center, Chicago, IL, USA. FAU - Volgman, Annabelle Santos AU - Volgman AS AD - Division of Cardiology, Rush University Medical Center, Chicago, IL, USA. LA - eng PT - Journal Article PT - Review DEP - 20260805 PL - England TA - Expert Rev Cardiovasc Ther JT - Expert review of cardiovascular therapy JID - 101182328 RN - 0 (Antineoplastic Agents) SB - IM MH - Humans MH - *Takotsubo Cardiomyopathy/diagnosis/etiology/physiopathology MH - *Neoplasms/therapy/drug therapy/complications MH - *Antineoplastic Agents/adverse effects/administration & dosage MH - Sex Factors MH - Male MH - Risk Factors MH - Acute Coronary Syndrome/diagnosis MH - Cardio-Oncology MH - Female MH - Diagnosis, Differential OTO - NOTNLM OT - Takotsubo syndrome OT - cancer therapy OT - cardio-oncology OT - cardiovascular toxicity OT - sex differences OT - stress cardiomyopathy EDAT- 2026/08/03 00:35 MHDA- 2026/10/15 07:17 CRDT- 2026/08/02 22:33 PHST- 2026/10/15 07:17 [medline] PHST- 2026/08/03 00:35 [pubmed] PHST- 2026/08/02 22:33 [entrez] AID - 10.1080/14779072.2026.2714263 [doi] PST - ppublish SO - Expert Rev Cardiovasc Ther. 2026 Sep;24(9):793-804. doi: 10.1080/14779072.2026.2714263. Epub 2026 Aug 5. PMID- 42539755 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260801 LR - 20260927 IS - 2090-6889 (Print) IS - 2090-6897 (Electronic) IS - 2090-6897 (Linking) VI - 2026 DP - 2026 TI - Myopericarditis in Systemic Lupus Erythematosus Unmasking a Concomitant Diagnosis of Marfan Syndrome: A Case Report. PG - 1055310 LID - 10.1155/crrh/1055310 [doi] LID - 1055310 AB - INTRODUCTION: Cardiovascular complications represent a major source of morbidity and mortality in systemic lupus erythematosus (SLE). While pericarditis is common, acute myopericarditis leading to significant systolic dysfunction is a less frequent but potentially life-threatening manifestation. The diagnostic evaluation can be complicated by overlapping clinical features and the presence of underlying, undiagnosed comorbidities. Hereditary connective tissue disorders, such as Marfan syndrome, present their own spectrum of cardiovascular risks, and their coexistence with autoimmune diseases like SLE is rare and poses significant diagnostic and therapeutic challenges. CASE PRESENTATION: We present the case of a 32-year-old woman with a long-standing diagnosis of SLE who was admitted with new-onset heart failure. Her symptoms included progressive dyspnea and pleuritic chest pain. The initial workup revealed active systemic inflammation, a newly reduced left ventricular ejection fraction of 44%, and a significant fusiform aneurysm of the ascending aorta (4.4 cm) associated with a bicuspid aortic valve. Cardiac magnetic resonance imaging was highly suggestive of active myopericarditis. While the initial findings were attributed to her lupus, the significant aortopathy in a young patient, combined with high myopia and a slender build, prompted further investigation. A formal clinical evaluation confirmed a diagnosis of Marfan syndrome based on the revised Ghent nosology. The patient responded favorably to intensified immunosuppression for her myopericarditis and was concurrently started on guideline-directed medical therapy for her aortopathy. CONCLUSION: This case underscores the importance of maintaining a broad differential diagnosis in complex clinical presentations. The diagnosis of lupus myopericarditis was complicated and ultimately overshadowed by the unmasking of Marfan syndrome, a finding that fundamentally altered the patient's long-term prognosis and management strategy. This report highlights the critical need for a multidisciplinary approach and illustrates how a seemingly straightforward complication of a known disease can be the gateway to identifying a second, life-altering diagnosis. CI - Copyright (c) 2026 Guilherme Cabrera et al. Case Reports in Rheumatology published by John Wiley & Sons Ltd. FAU - Cabrera, Guilherme AU - Cabrera G AUID- ORCID: 0000-0002-2114-1369 AD - Departamento de Medicina, Disciplina de Clinica Medica e Medicina Laboratorial, Escola Paulista de Medicina (EPM), Universidade Federal de Sao Paulo (UNIFESP), Sao Paulo, State of Sao Paulo, Brazil, unifesp.br. FAU - Neves, Gabriella AU - Neves G AD - Departamento de Medicina, Disciplina de Clinica Medica e Medicina Laboratorial, Escola Paulista de Medicina (EPM), Universidade Federal de Sao Paulo (UNIFESP), Sao Paulo, State of Sao Paulo, Brazil, unifesp.br. FAU - Dias, Wellinghton AU - Dias W AUID- ORCID: 0000-0002-8162-8494 AD - Departamento de Medicina, Disciplina de Clinica Medica e Medicina Laboratorial, Escola Paulista de Medicina (EPM), Universidade Federal de Sao Paulo (UNIFESP), Sao Paulo, State of Sao Paulo, Brazil, unifesp.br. FAU - Duarte, Edson AU - Duarte E AD - Departamento de Medicina, Disciplina de Clinica Medica e Medicina Laboratorial, Escola Paulista de Medicina (EPM), Universidade Federal de Sao Paulo (UNIFESP), Sao Paulo, State of Sao Paulo, Brazil, unifesp.br. FAU - Faico-Filho, Klinger Soares AU - Faico-Filho KS AUID- ORCID: 0000-0003-2071-0061 AD - Departamento de Medicina, Disciplina de Clinica Medica e Medicina Laboratorial, Escola Paulista de Medicina (EPM), Universidade Federal de Sao Paulo (UNIFESP), Sao Paulo, State of Sao Paulo, Brazil, unifesp.br. LA - eng PT - Journal Article DEP - 20260730 PL - United States TA - Case Rep Rheumatol JT - Case reports in rheumatology JID - 101585353 PMC - PMC13424611 OTO - NOTNLM OT - Marfan syndrome OT - aortic aneurysm OT - case report OT - connective tissue disease OT - myopericarditis OT - systemic lupus erythematosus COIS- The authors declare no conflicts of interest. EDAT- 2026/08/02 00:30 MHDA- 2026/08/02 00:31 PMCR- 2026/07/30 CRDT- 2026/08/01 06:15 PHST- 2026/03/24 00:00 [received] PHST- 2026/06/23 00:00 [revised] PHST- 2026/07/14 00:00 [accepted] PHST- 2026/08/02 00:31 [medline] PHST- 2026/08/02 00:30 [pubmed] PHST- 2026/08/01 06:15 [entrez] PHST- 2026/07/30 00:00 [pmc-release] AID - CRRH1055310 [pii] AID - 10.1155/crrh/1055310 [doi] PST - epublish SO - Case Rep Rheumatol. 2026 Jul 30;2026:1055310. doi: 10.1155/crrh/1055310. eCollection 2026. PMID- 42533537 OWN - NLM STAT- MEDLINE DCOM- 20261014 LR - 20261016 IS - 1522-726X (Electronic) IS - 1522-1946 (Linking) VI - 108 IP - 4 DP - 2026 Oct TI - Impact of Failure Mode and Effects Analysis-Oriented Multidisciplinary Collaborative Nursing Model on Bleeding Prevention and Prognosis in Patients Undergoing Transradial Artery Coronary Angiography: A Randomized Controlled Trial. PG - 1354-1365 LID - 10.1002/ccd.70789 [doi] AB - BACKGROUND: Transradial artery coronary angiography (TRA) is widely used for coronary disease diagnosis, but postoperative puncture site bleeding (incidence: 3.1%-16.7%) remains a major clinical challenge. Fragmented care and poor multidisciplinary collaboration (MDC) contribute to this issue, while Failure Mode and Effects Analysis (FMEA)-a proactive risk tool-has not been integrated into MDC for TRA bleeding prevention. AIMS: To evaluate the efficacy of an FMEA-oriented MDC nursing model on TRA postoperative bleeding, nursing efficiency, and patient outcomes. METHODS: A single-center randomized controlled trial (RCT) enrolled 280 TRA patients (March 2024 to March 2025), randomized 1:1 to the experimental group (FMEA-oriented MDC care: joint assessment, standardized intraoperative collaboration, graded monitoring) or control group (conventional care). PRIMARY OUTCOME: 24-h bleeding incidence (EAPCI criteria). SECONDARY OUTCOMES: hemostasis time, length of hospital stay (LOS), healthcare provider-patient satisfaction, and psychological status (SAS/SDS). RESULTS: The experimental group had lower 24-h bleeding incidence (4.3% vs. 13.6%, chi(2) = 7.832, p = 0.005), shorter hemostasis time (38.2 +/- 8.5 vs. 54.6 +/- 10.2 min, t = 13.264, p < 0.001) and LOS (3.1 +/- 0.8 vs. 4.5 +/- 1.2 days, t = 10.587, p < 0.001). Higher satisfaction scores (healthcare provider: 93.5 +/- 4.2 vs. 77.8 +/- 6.5; patient: 92.1 +/- 3.8 vs. 80.5 +/- 5.3; both p < 0.001) and lower postoperative SAS/SDS scores (both p < 0.001) were observed in the experimental group. CONCLUSION: The FMEA-oriented MDC model reduces TRA postoperative bleeding, improves nursing efficiency and satisfaction, and alleviates patient anxiety/depression, providing a standardized clinical solution. CI - (c) 2026 Wiley Periodicals LLC. FAU - Fan, Lingxia AU - Fan L AD - 980th Hospital of the Joint Logistics Support Force of the Chinese People 's Liberation Army, Shijiazhuang, China. FAU - Guo, Xiaoping AU - Guo X AD - 980th Hospital of the Joint Logistics Support Force of the Chinese People 's Liberation Army, Shijiazhuang, China. FAU - Ma, Yanzhuo AU - Ma Y AD - 980th Hospital of the Joint Logistics Support Force of the Chinese People 's Liberation Army, Shijiazhuang, China. FAU - Li, Wei AU - Li W AUID- ORCID: 0009-0001-5413-1351 AD - 980th Hospital of the Joint Logistics Support Force of the Chinese People 's Liberation Army, Shijiazhuang, China. LA - eng GR - 20261440/Study on the construction and verification of FMEA hierarchical management model for bleeding risk at puncture site after radial artery approach coronary angiography/ PT - Journal Article PT - Randomized Controlled Trial DEP - 20260730 PL - United States TA - Catheter Cardiovasc Interv JT - Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions JID - 100884139 SB - IM MH - Humans MH - *Radial Artery MH - Female MH - Male MH - *Coronary Angiography/adverse effects/nursing MH - Aged MH - Middle Aged MH - Time Factors MH - Treatment Outcome MH - Risk Factors MH - Punctures MH - *Catheterization, Peripheral/adverse effects/nursing MH - Risk Assessment MH - *Postoperative Hemorrhage/prevention & control/nursing/etiology/epidemiology MH - *Patient Care Team MH - *Hemostatic Techniques/nursing MH - Patient Satisfaction MH - Length of Stay MH - Cooperative Behavior MH - Interdisciplinary Communication MH - Intersectoral Collaboration OTO - NOTNLM OT - failure mode and effects analysis (FMEA) OT - multidisciplinary collaboration OT - postoperative bleeding OT - randomized controlled trial OT - transradial artery coronary angiography (TRA) EDAT- 2026/07/31 06:37 MHDA- 2026/10/14 18:14 CRDT- 2026/07/31 02:23 PHST- 2026/06/30 00:00 [revised] PHST- 2026/03/06 00:00 [received] PHST- 2026/07/25 00:00 [accepted] PHST- 2026/10/14 18:14 [medline] PHST- 2026/07/31 06:37 [pubmed] PHST- 2026/07/31 02:23 [entrez] AID - 10.1002/ccd.70789 [doi] PST - ppublish SO - Catheter Cardiovasc Interv. 2026 Oct;108(4):1354-1365. doi: 10.1002/ccd.70789. Epub 2026 Jul 30. PMID- 42533336 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260731 LR - 20260813 IS - 3059-4057 (Electronic) IS - 3059-4057 (Linking) VI - 12 IP - 1 DP - 2026 Jul 31 TI - Metabolic disorder-MASLD-cardiovascular disease-kidney disease (MMCK) syndrome: an expansion of the Cardiovascular-Kidney-Metabolic (CKM) framework. LID - 10.1186/s40842-026-00317-0 [doi] LID - 48 AB - BACKGROUND: The Cardiovascular-Kidney-Metabolic (CKM) syndrome framework acknowledges metabolic dysfunction-associated steatotic liver disease (MASLD) as a major manifestation, yet hepatic involvement remains insufficiently incorporated into risk stratification. This review proposes the metabolic disorder-MASLD-cardiovascular disease-kidney disease (MMCK) syndrome as an operational extension that integrates hepatic fibrosis assessment into cardiometabolic-renal care. METHODS: We conducted a comprehensive narrative review across PubMed/MEDLINE, Embase, Web of Science, Cochrane Library, and Scopus through March 2026. We synthesized evidence on pathophysiological crosstalk, proposed the Multi-Organ Risk Score (MORS)-enabled MMCK staging criteria (Stages 0-4), and developed stage-specific management algorithms. RESULTS: The MMCK framework introduces four key operational advances: (i) quantitative multi-organ risk stratification through the MORS (L + C + B + K, range 0-12) with mandatory FIB-4/VCTE-based hepatic fibrosis assessment as the L-Score; (ii) stage-specific therapeutic thresholds linked to objective clinical cutoffs; (iii) a structured multidisciplinary team governance model with MORS-based electronic health record triggers; and (iv) a three-tiered endpoint framework for quality improvement and prospective validation. Observational evidence indicates that incorporating MASLD fibrosis into cardiometabolic staging improves coronary artery disease risk prediction. The MMCK framework positions MASLD as a cardiovascular risk-modifying axis within established cardiometabolic-renal care. CONCLUSIONS: The MMCK syndrome operationalizes hepatic integration within established cardiometabolic-renal care by providing a quantitative, stage-specific framework for multi-organ risk assessment and management. Future research should prospectively validate MORS-based staging in diverse cohorts and evaluate whether MMCK-guided management improves clinical outcomes compared with CKM-guided care alone. CI - (c) 2026. The Author(s). FAU - Guo, Yan AU - Guo Y AD - Department of Endocrinology and Metabolism, Changhai Hospital, Naval Medical University, Shanghai, China. FAU - Zhang, Ying AU - Zhang Y AD - Department of Endocrinology and Metabolism, Changhai Hospital, Naval Medical University, Shanghai, China. FAU - Liu, Suxuan AU - Liu S AD - Department of Geriatric Medicine, Changhai Hospital, Navy Medical University, Shanghai, China. FAU - Zou, Dajin AU - Zou D AD - Department of Endocrinology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. zoudajin@hotmail.com. LA - eng PT - Journal Article PT - Review DEP - 20260731 PL - England TA - Cardiovasc Diabetol Endocrinol Rep JT - Cardiovascular diabetology. Endocrinology reports JID - 9918994893106676 PMC - PMC13425926 COIS- Declarations. Ethical approval: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2026/07/31 06:36 MHDA- 2026/07/31 06:37 PMCR- 2026/07/31 CRDT- 2026/07/31 00:15 PHST- 2026/03/21 00:00 [received] PHST- 2026/05/19 00:00 [accepted] PHST- 2026/07/31 06:37 [medline] PHST- 2026/07/31 06:36 [pubmed] PHST- 2026/07/31 00:15 [entrez] PHST- 2026/07/31 00:00 [pmc-release] AID - 10.1186/s40842-026-00317-0 [pii] AID - 317 [pii] AID - 10.1186/s40842-026-00317-0 [doi] PST - epublish SO - Cardiovasc Diabetol Endocrinol Rep. 2026 Jul 31;12(1):48. doi: 10.1186/s40842-026-00317-0. PMID- 42528826 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260730 LR - 20260813 IS - 2297-055X (Print) IS - 2297-055X (Electronic) IS - 2297-055X (Linking) VI - 13 DP - 2026 TI - Strategies to improve adherence to exercise-based phase II cardiac rehabilitation after percutaneous coronary intervention: a best evidence summary. PG - 1868542 LID - 10.3389/fcvm.2026.1868542 [doi] LID - 1868542 AB - OBJECTIVE: To identify, appraise, and synthesize the best available evidence on strategies to improve adherence to exercise-based phase II cardiac rehabilitation in patients after percutaneous coronary intervention, and to provide evidence-informed guidance for clinical practice. METHODS: Guided by the 6S evidence pyramid, a systematic search was conducted across evidence-based resources, guideline repositories, professional association websites, and primary literature databases for studies addressing strategies to improve adherence to exercise-based phase II cardiac rehabilitation after percutaneous coronary intervention. The search covered the period from database inception to November 30, 2025. Two reviewers independently screened the literature, appraised methodological quality using design-specific tools, and synthesized the evidence according to the Joanna Briggs Institute evidence grading and recommendation system. RESULTS: A total of 24 studies were included, comprising 1 clinical decision support resource, 6 guidelines, 6 systematic reviews and meta-analyses, 6 expert consensus statements, 4 randomized controlled trials, and 1 quasi-experimental study. Thirty-two evidence statements were synthesized across seven dimensions: program referral and initiation, multidisciplinary cardiac rehabilitation team, individualized exercise prescription, adherence-enhancing interventions, population-specific strategies, social support, and quality management and outcome evaluation. CONCLUSION: This study synthesized the best available evidence on strategies to improve adherence to exercise-based phase II cardiac rehabilitation in patients after percutaneous coronary intervention. The findings provide an evidence-informed basis for clinical practice and may support healthcare professionals in developing context-sensitive rehabilitation strategies to enhance patient participation and sustained engagement in phase II cardiac rehabilitation. SYSTEMATIC REVIEW REGISTRATION: Evidence-Based Nursing Center of Fudan University. Registration number ES20257186. CI - (c) 2026 Guo, Xia, Du, Ji, Yang and Liu. FAU - Guo, Hao AU - Guo H AD - Department of Cardiology, The Second Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China. FAU - Xia, Chengyu AU - Xia C AD - Department of Cardiology, The Second Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China. FAU - Du, Yuheng AU - Du Y AD - Department of Cardiology, The Second Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China. FAU - Ji, Liuxia AU - Ji L AD - Department of Cardiology, The Second Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China. FAU - Yang, Xuehui AU - Yang X AD - Department of Cardiology, The Second Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China. FAU - Liu, Hui AU - Liu H AD - Department of Cardiology, The Second Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China. LA - eng PT - Journal Article PT - Systematic Review DEP - 20260715 PL - Switzerland TA - Front Cardiovasc Med JT - Frontiers in cardiovascular medicine JID - 101653388 PMC - PMC13415501 OTO - NOTNLM OT - cardiac rehabilitation OT - exercise adherence OT - percutaneous coronary intervention OT - phase II cardiac rehabilitation OT - summary of the evidence COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/07/30 06:41 MHDA- 2026/07/30 06:42 PMCR- 2026/07/15 CRDT- 2026/07/30 04:46 PHST- 2026/04/29 00:00 [received] PHST- 2026/06/14 00:00 [revised] PHST- 2026/06/23 00:00 [accepted] PHST- 2026/07/30 06:42 [medline] PHST- 2026/07/30 06:41 [pubmed] PHST- 2026/07/30 04:46 [entrez] PHST- 2026/07/15 00:00 [pmc-release] AID - 10.3389/fcvm.2026.1868542 [doi] PST - epublish SO - Front Cardiovasc Med. 2026 Jul 15;13:1868542. doi: 10.3389/fcvm.2026.1868542. eCollection 2026. PMID- 42527206 OWN - NLM STAT- MEDLINE DCOM- 20261001 LR - 20261001 IS - 1444-2892 (Electronic) IS - 1443-9506 (Linking) VI - 35 IP - 10 DP - 2026 Oct TI - Feasibility and Safety of Rotational Atherectomy in a Rural Centre Without On-Site Cardiac Surgery. PG - 1455-1460 LID - S1443-9506(26)00203-9 [pii] LID - 10.1016/j.hlc.2026.01.023 [doi] AB - BACKGROUND: Rotational atherectomy has become increasingly common in centres without on-site cardiac surgery to treat heavily calcified coronary artery disease. However, there is limited evidence on its safety in rural centres with significant travel distances from tertiary centres with cardiac surgery. METHOD: This is a retrospective cohort study of all consecutive patients treated with rotational atherectomy in Mackay Base Hospital (MBH), Australia between March 2021 and September 2023. MBH is located 385 km away from the nearest tertiary centre with on-site cardiac surgery. The primary outcomes were procedural success, major peri-procedural complications, and all-cause mortality during hospitalisation. Secondary outcomes were major adverse cardiovascular events and complications at 30-day follow-up RESULTS: Of 20 patients treated with rotational atherectomy, the mean age was 72.3 years (standard deviation [SD]=9.9) and one-quarter were female. Their mean SYNTAX score was 20 (SD=9), while their mean EuroSCORE was 1.60 (SD=1.22). Target vessels included the right coronary artery (n=12; 60%), left anterior descending artery (n=7; 35%), and left circumflex artery (n=1; 5%). The mean rotablation burr diameter was 1.5 mm (SD=0.1), and all patients received at least one drug-eluting stent following atherectomy. The procedural success rate was 100%. Two major peri-procedural complications were observed; one may be attributable to rotational atherectomy, while the other was not specific: one intra-procedural cardiac arrest related to coronary slow-flow, and one upper mediastinal haematoma most likely related to accidental injury to a small arterial branch during the negotiation of a tortuous right brachiocephalic artery with a hydrophilic guidewire. No patient required emergency coronary artery bypass surgery. There was no all-cause mortality during hospitalisation and no major adverse cardiovascular event at 30-day follow-up. CONCLUSIONS: Rotational atherectomy is feasible and safe in rural centres without on-site cardiac surgery. Careful case selection and a team-based approach with two operators are advised. Factors contributing to atherectomy safety, including operator volumes, adequate catheterisation laboratory team training, and strong partnership with the tertiary cardiac surgical centre, should be considered before establishing high-risk procedures in these centres. CI - Copyright (c) 2026 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights reserved. FAU - Ananda, Roshan A AU - Ananda RA AD - Department of Cardiology, Mackay Base Hospital, Mackay, Qld, Australia. Electronic address: roshan.ananda21@alumni.imperial.ac.uk. FAU - Wong, Lin Ling AU - Wong LL AD - Department of Cardiology, Mackay Base Hospital, Mackay, Qld, Australia. FAU - Musameh, Muntaser AU - Musameh M AD - Department of Cardiology, Mackay Base Hospital, Mackay, Qld, Australia. FAU - Zhang, Zhihua AU - Zhang Z AD - Department of Cardiology, Mackay Base Hospital, Mackay, Qld, Australia. LA - eng PT - Journal Article DEP - 20260729 PL - Australia TA - Heart Lung Circ JT - Heart, lung & circulation JID - 100963739 SB - IM MH - Humans MH - Female MH - *Atherectomy, Coronary/methods MH - Male MH - Aged MH - Retrospective Studies MH - *Coronary Artery Disease/surgery/diagnosis MH - Feasibility Studies MH - Follow-Up Studies MH - *Rural Population MH - *Coronary Vessels/surgery/diagnostic imaging MH - Australia/epidemiology MH - *Cardiac Surgical Procedures OTO - NOTNLM OT - Coronary artery calcification OT - Non-surgical centres OT - Outcomes OT - Rotational atherectomy COIS- Declaration of Competing Interests There are no conflicts of interest to disclose. EDAT- 2026/07/30 00:38 MHDA- 2026/10/01 23:30 CRDT- 2026/07/29 21:57 PHST- 2025/01/23 00:00 [received] PHST- 2025/11/25 00:00 [revised] PHST- 2026/01/28 00:00 [accepted] PHST- 2026/10/01 23:30 [medline] PHST- 2026/07/30 00:38 [pubmed] PHST- 2026/07/29 21:57 [entrez] AID - S1443-9506(26)00203-9 [pii] AID - 10.1016/j.hlc.2026.01.023 [doi] PST - ppublish SO - Heart Lung Circ. 2026 Oct;35(10):1455-1460. doi: 10.1016/j.hlc.2026.01.023. Epub 2026 Jul 29. PMID- 42524805 OWN - NLM STAT- MEDLINE DCOM- 20261022 LR - 20261022 IS - 1558-3597 (Electronic) IS - 0735-1097 (Linking) VI - 88 IP - 16 DP - 2026 Oct 20 TI - Clinical Considerations in Management of Hypertrophic Cardiomyopathy in Pregnancy: JACC State-of-the-Art Review. PG - 1914-1938 LID - S0735-1097(26)06770-7 [pii] LID - 10.1016/j.jacc.2026.06.004 [doi] AB - Hypertrophic cardiomyopathy (HCM) in pregnancy presents unique hemodynamic and arrhythmic challenges despite generally low maternal mortality. This JACC State-of-the-Art Review synthesizes current evidence on preconception risk stratification, genetic counseling, antepartum surveillance, arrhythmia management, and delivery and postpartum care. Key considerations include assessing left ventricular outflow tract obstruction, systolic function, and arrhythmia burden and applying CARPREG II (Cardiac Disease in Pregnancy Study II)/modified World Health Organization classifications to guide monitoring intensity. Pregnancy is typically well tolerated in low-risk women, whereas severe obstruction or systolic dysfunction confers high maternal-fetal risk. Multidisciplinary pregnancy heart team management remains essential to optimize outcomes and support informed decision making across the reproductive continuum. CI - Copyright (c) 2026 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. FAU - Abdelfattah, Omar M AU - Abdelfattah OM AD - Division of Cardiovascular Medicine, Dell Medical School, University of Texas at Austin, Austin, Texas, USA; Ascension Texas Cardiovascular, Ascension Seton, Austin, Texas, USA. FAU - Abdeldayem, Jasmin AU - Abdeldayem J AD - Division of Maternal Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, Texas, USA. FAU - Hassan, Ahmed A AU - Hassan AA AD - Department of Cardiology and Cardiothoracic Surgery, Children's Health of Ireland at Crumlin, Dublin, Ireland. FAU - Gulati, Martha AU - Gulati M AD - The Davis Women's Heart Center at the DeBakey Heart & Vascular Institute, Houston Methodist Medical Center, Houston, Texas, USA. FAU - Phillips, Sabrina AU - Phillips S AD - Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, Florida, USA. FAU - Owens, Anjali T AU - Owens AT AD - Center for Inherited Cardiovascular Disease, Division of Cardiovascular Medicine, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA. FAU - Sharma, Garima AU - Sharma G AD - Inova Schar Heart and Vascular Institute, Inova Health System, Falls Church, Virginia, USA. FAU - Wood, Malissa J AU - Wood MJ AD - Lee Health Heart Institute, Fort Myers, Florida, USA. FAU - Pirwitz, Mark J AU - Pirwitz MJ AD - Division of Cardiovascular Medicine, Dell Medical School, University of Texas at Austin, Austin, Texas, USA; Ascension Texas Cardiovascular, Ascension Seton, Austin, Texas, USA. FAU - Shepherd, Meghan C AU - Shepherd MC AD - Division of Maternal Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, Texas, USA. FAU - Sibai, Baha AU - Sibai B AD - Division of Maternal Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, Texas, USA. FAU - Link, Mark S AU - Link MS AD - University of Texas Southwestern Medical Center, Dallas, Texas, USA. FAU - Nagueh, Sherif F AU - Nagueh SF AD - Department of Cardiovascular Medicine, Houston Methodist DeBakey Heart and Vascular Center, Houston, Texas, USA. FAU - Martinez, Matthew W AU - Martinez MW AD - Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, Florida, USA. Electronic address: martinez.matthew@mayo.edu. LA - eng PT - Journal Article PT - Review DEP - 20260729 PL - United States TA - J Am Coll Cardiol JT - Journal of the American College of Cardiology JID - 8301365 SB - IM MH - Humans MH - Female MH - Pregnancy MH - *Cardiomyopathy, Hypertrophic/therapy/diagnosis MH - *Pregnancy Complications, Cardiovascular/therapy/diagnosis/physiopathology MH - *Disease Management OTO - NOTNLM OT - cardio-obstetrics OT - hypertrophic cardiomyopathy OT - management OT - outcomes OT - pregnancy COIS- Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2026/07/29 13:54 MHDA- 2026/10/22 17:33 CRDT- 2026/07/29 10:46 PHST- 2025/12/17 00:00 [received] PHST- 2026/05/28 00:00 [revised] PHST- 2026/06/04 00:00 [accepted] PHST- 2026/10/22 17:33 [medline] PHST- 2026/07/29 13:54 [pubmed] PHST- 2026/07/29 10:46 [entrez] AID - S0735-1097(26)06770-7 [pii] AID - 10.1016/j.jacc.2026.06.004 [doi] PST - ppublish SO - J Am Coll Cardiol. 2026 Oct 20;88(16):1914-1938. doi: 10.1016/j.jacc.2026.06.004. Epub 2026 Jul 29. PMID- 42524418 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260729 LR - 20260813 IS - 1753-4313 (Electronic) IS - 0969-6113 (Print) IS - 0969-6113 (Linking) VI - 33 IP - 1 DP - 2026 TI - Mapping the patient pathway for ICI cardiac toxicities: a single-centre case series with clinical practice insights. PG - 011 LID - 10.5837/bjc.2026.011 [doi] LID - 011 AB - Immune checkpoint inhibitors (ICIs) have revolutionised cancer care, but can cause serious cardiac immune-related adverse events (irAEs), particularly myocarditis, which carries up to 50% mortality. This study explores patient pathways to improve early recognition and management of ICI myocarditis in acute settings. This was a retrospective, single-centre case series from a UK tertiary hospital with a specialist cardio-oncology multi-disciplinary team (MDT). Ten patients referred to the cardio-oncology MDT between March and August 2024 were included if diagnosed with myocarditis, pericarditis, or arrhythmias linked to ICI treatment. Clinical pathways were described using structured vignettes. Seven patients had myocarditis, two pericarditis, and one bradyarrhythmia. Fatigue (57%) was the most common presenting symptom in myocarditis. Echocardiography was unremarkable in 86% of cases, while cardiac magnetic resonance imaging (MRI) confirmed myocarditis in 57%. N-terminal pro-B-type natriuretic protein (NT-proBNP) rose 17-fold from baseline compared with a four-fold rise in troponin T. Early MDT referral facilitated prompt diagnosis and treatment, while delayed recognition was associated with worse outcomes. This case series highlights the importance of early MDT involvement, and the utility of additional cardiac biomarkers, such as NT-proBNP. It provides practical guidance to improve the acute care pathway for patients developing ICI-associated cardiac toxicities. CI - Copyright (c) 2026 Medinews (Cardiology) Limited. FAU - Yang, Yu-Hsuen AU - Yang YH AD - Clinical Research Fellow in Medical Oncology, Oak Cancer Centre, The Royal Marsden Hospital, London. FAU - Datta, Shayan AU - Datta S AD - Clinical Education Fellow in Medicine, Royal Sussex County Hospital, University Hospitals Sussex NHS Foundation Trust, Brighton. FAU - Thomas-Orogan, Oluwabukola AU - Thomas-Orogan O AD - Foundation Year 2 Doctor, Eastbourne District General Hospital, East Sussex Healthcare Trust. FAU - Ellery, Susan AU - Ellery S AD - Consultant Cardiologist, Sussex Cardiac Centre, Royal Sussex County Hospital, University Hospitals Sussex NHS Foundation Trust, Brighton. FAU - Olsson-Brown, Anna AU - Olsson-Brown A AD - Consultant Medical Oncologist, Sussex Cancer Centre, Royal Sussex County Hospital, University Hospitals Sussex NHS Foundation Trust, Brighton; Department of Pharmacology and Therapeutics, The University of Liverpool, Liverpool. LA - eng PT - Journal Article DEP - 20260303 PL - England TA - Br J Cardiol JT - The British journal of cardiology JID - 9503762 PMC - PMC13410972 OTO - NOTNLM OT - cardiac immune-related adverse events OT - cardio-oncology OT - case series OT - immune checkpoint OT - inhibitors OT - myocarditis COIS- Conflicts of interest None declared. EDAT- 2026/07/29 13:54 MHDA- 2026/07/29 13:55 PMCR- 2026/03/03 CRDT- 2026/07/29 10:34 PHST- 2026/07/29 13:55 [medline] PHST- 2026/07/29 13:54 [pubmed] PHST- 2026/07/29 10:34 [entrez] PHST- 2026/03/03 00:00 [pmc-release] AID - bjc.2026.011 [pii] AID - 10.5837/bjc.2026.011 [doi] PST - epublish SO - Br J Cardiol. 2026 Mar 3;33(1):011. doi: 10.5837/bjc.2026.011. eCollection 2026. PMID- 42524239 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260729 LR - 20260813 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 18 IP - 6 DP - 2026 Jun TI - Development and Clinical Deployment of the Systematic Urgent Team Response in the Operating Room (SUTO) Protocol for Intraoperative Massive Hemorrhage: A Technical Report. PG - e111648 LID - 10.7759/cureus.111648 [doi] LID - e111648 AB - Massive intraoperative hemorrhage is a time-critical event requiring simultaneous hemodynamic resuscitation, bleeding source control, transfusion support, equipment preparation, and escalation to multidisciplinary support. This technical report provides, to our knowledge, the first English-language description of the Systematic Urgent Team Response in the Operating Room (SUTO) protocol for intraoperative massive hemorrhage. The protocol was previously developed and reported in Japanese as an institution-specific response system. This English-language report was prepared with permission from the original journal and describes the protocol for an international readership, with additional emphasis on simulation-based preparation and clinical deployment during an actual episode of intraoperative massive hemorrhage. The SUTO protocol was designed to convert the general principles of hemorrhage management into a locally executable, role-based workflow, with predefined procedures for emergency activation, command assignment, task allocation, transfusion support, equipment mobilization, and escalation to cardiovascular surgery and interventional radiology support. The protocol was posted at the entrance of each operating room as an environmental cognitive aid and linked to a dedicated massive hemorrhage cart. Multidisciplinary in situ simulation was conducted using actual operating room equipment to rehearse emergency activation, parallel task execution, transfusion preparation, and escalation pathways. Clinical deployment is illustrated by an unexpected massive hemorrhage caused by splenic artery injury during surgery for esophagogastric junction cancer. Emergency activation, commander declaration, transfusion preparation, equipment mobilization, and consultation with cardiovascular, hepatopancreatobiliary, and interventional radiology teams proceeded in parallel. Definitive hemostasis was achieved by proximal and distal ligation of the injured splenic artery, and the patient was discharged on postoperative day 17. Although causality cannot be inferred from a single clinical deployment, this report suggests that the SUTO protocol may provide a shared operational framework for rapid multidisciplinary coordination during high-acuity operating room crises. Regular simulation and feedback-driven revision are required to maintain organizational readiness as staff and workflows change. CI - Copyright (c) 2026, Suto et al. FAU - Suto, Misako AU - Suto M AD - Division of Operating Room, Tottori University Hospital, Yonago, JPN. FAU - Hanaki, Takehiko AU - Hanaki T AD - Division of Medical Education, Tottori University, Faculty of Medicine, Yonago, JPN. AD - Division of Gastrointestinal and Pediatric Surgery, Tottori University, Faculty of Medicine, Yonago, JPN. FAU - Moriyama, Naoki AU - Moriyama N AD - Division of Anesthesiology and Critical Care Medicine, Tottori University, Faculty of Medicine, Yonago, JPN. FAU - Otsuki, Akihiro AU - Otsuki A AD - Division of Anesthesiology and Critical Care Medicine, Tottori University, Faculty of Medicine, Yonago, JPN. FAU - Fujiwara, Yoshiyuki AU - Fujiwara Y AD - Division of Gastrointestinal and Pediatric Surgery, Tottori University, Faculty of Medicine, Yonago, JPN. AD - Division of Operating Room, Tottori University Hospital, Yonago, JPN. LA - eng PT - Journal Article DEP - 20260628 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC13410606 OTO - NOTNLM OT - crisis resource management OT - emergency response algorithm OT - intraoperative bleeding OT - massive hemorrhage OT - multidisciplinary team OT - operating room crisis OT - patient safety OT - simulation-based training OT - suto protocol COIS- Human subjects: Informed consent for treatment and open access publication was obtained or waived by all participants in this study. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. EDAT- 2026/07/29 13:54 MHDA- 2026/07/29 13:55 PMCR- 2026/06/28 CRDT- 2026/07/29 10:30 PHST- 2026/06/28 00:00 [accepted] PHST- 2026/07/29 13:55 [medline] PHST- 2026/07/29 13:54 [pubmed] PHST- 2026/07/29 10:30 [entrez] PHST- 2026/06/28 00:00 [pmc-release] AID - 10.7759/cureus.111648 [doi] PST - epublish SO - Cureus. 2026 Jun 28;18(6):e111648. doi: 10.7759/cureus.111648. eCollection 2026 Jun. PMID- 42524153 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260729 LR - 20260813 IS - 1011-6842 (Print) IS - 1011-6842 (Linking) VI - 42 IP - 4 DP - 2026 Jul TI - Surgical Treatment of Hypertrophic Obstructive Cardiomyopathy: Results of Extended Septal Myectomy in 24 Patients. PG - 544-550 LID - 10.6515/ACS.202607_42(4).20251124D [doi] AB - BACKGROUND: Hypertrophic obstructive cardiomyopathy generally responds well to medical therapy. However, about 5% of patients require invasive procedures. There is no clear consensus on the invasive treatment for these patients. Therefore, we aimed to analyze and present the results of our experience with surgical treatment between 2014 and 2024. METHODS: A total of 24 patients who underwent extended septal myectomy were retrospectively analyzed. Preoperative demographic and comorbid factors were assessed. The patients underwent echocardiography 12 months after surgery. Preoperative and postoperative functional capacity in the first year and the results of the echocardiographic examinations were analyzed. RESULTS: Nineteen (79.1%) patients were in New York Heart Association (NYHA) class III-IV before surgery, while none were in NYHA class III-IV after surgery (p < 0.001). The septal thickness (mm) was 19.7 +/- 2.34 before surgery compared to 10.9 +/- 1.38 after surgery; the left ventricular outflow tract gradient (mmHg) was 90.6 +/- 15.4 before surgery compared to 21.3 +/- 4.48 after surgery, and the decrease was statistically significant (p < 0.001). No statistically significant differences were found between left ventricular ejection fraction (%), left ventricular end-diastolic diameter (mm), left ventricular end-systolic diameter (mm) and mean pulmonary artery pressure (mmHg) values before and after surgery. CONCLUSIONS: Extended septal myectomy performed after evaluation by the heart team for the treatment of hypertrophic obstructive cardiomyopathy led to satisfactory results in suitable patients. A surgical treatment option could be considered in symptomatic patients despite optimal medical therapy. FAU - Karaagac, Erturk AU - Karaagac E AD - Department of Cardiovascular Surgery, Izmir Katip Celebi University, Ataturk Training and Research Hospital. FAU - Iner, Hasan AU - Iner H AD - Department of Cardiovascular Surgery, Izmir Katip Celebi University, Ataturk Training and Research Hospital. FAU - Ozdal, Suat AU - Ozdal S AD - Department of Cardiovascular Surgery, Izmir Katip Celebi University, Ataturk Training and Research Hospital. FAU - Selcuk, Hidayet Onur AU - Selcuk HO AD - Department of Cardiovascular Surgery, Izmir Katip Celebi University, Ataturk Training and Research Hospital. FAU - Gurbuz, Seray Deniz AU - Gurbuz SD AD - Faculty of Economics and Administrative Sciences, Department of International Trade and Business, Izmir Katip Celebi University, Izmir, Turkey. FAU - Besir, Yuksel AU - Besir Y AD - Department of Cardiovascular Surgery, Izmir Katip Celebi University, Ataturk Training and Research Hospital. FAU - Gokalp, Orhan AU - Gokalp O AD - Department of Cardiovascular Surgery, Izmir Katip Celebi University, Ataturk Training and Research Hospital. FAU - Yilik, Levent AU - Yilik L AD - Department of Cardiovascular Surgery, Izmir Katip Celebi University, Ataturk Training and Research Hospital. LA - eng PT - Journal Article PL - China (Republic : 1949- ) TA - Acta Cardiol Sin JT - Acta Cardiologica Sinica JID - 101687085 PMC - PMC13409160 OTO - NOTNLM OT - Hypertrophic obstructive cardiomyopathy OT - Mitral valve regurgitation OT - SAM OT - Septal myectomy COIS- The authors state that there is no conflict of interest and there is no funding to report for this study. The data that support the findings of this study are available from the corresponding author, upon reasonable request. EDAT- 2026/07/29 13:54 MHDA- 2026/07/29 13:55 PMCR- 2026/07/01 CRDT- 2026/07/29 10:27 PHST- 2025/04/11 00:00 [received] PHST- 2025/11/24 00:00 [accepted] PHST- 2026/07/29 13:55 [medline] PHST- 2026/07/29 13:54 [pubmed] PHST- 2026/07/29 10:27 [entrez] PHST- 2026/07/01 00:00 [pmc-release] AID - 10.6515/ACS.202607_42(4).20251124D [doi] PST - ppublish SO - Acta Cardiol Sin. 2026 Jul;42(4):544-550. doi: 10.6515/ACS.202607_42(4).20251124D. PMID- 42524111 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260729 LR - 20260813 IS - 1011-6842 (Print) IS - 1011-6842 (Linking) VI - 42 IP - 4 DP - 2026 Jul TI - TAMIS Consensus on Multidisciplinary Team Care in Post-Acute Stage of Acute Coronary Syndrome: Nutrition, Pharmacotherapy, and Cardiac Rehabilitation. PG - 534-543 LID - 10.6515/ACS.202607_42(4).20260309B [doi] AB - BACKGROUND: Post-acute care (PAC) following acute coronary syndrome (ACS) aims to reduce recurrent cardiovascular events, improve cardiac function, enhance quality of life, and lower mortality. Effective PAC requires a multidisciplinary team including cardiologists, nurses, dietitians, rehabilitation specialists, and psychologists to deliver individualized strategies. OBJECTIVES: To summarize current evidence and provide consensus recommendations across three key domains of PAC: nutritional management, pharmacotherapy, and cardiac rehabilitation. METHODS: This consensus was developed from 2024-2025 through expert discussions hosted by the Taiwan Myocardial Infarction Society (TAMIS) Expert Committee, based on a review of current scientific and clinical evidence. RESULTS: Nutritional management emphasizes Mediterranean and DASH dietary patterns, restriction of saturated and trans fats, and weight control; evidence for most nutraceuticals remains limited. Pharmacotherapy focuses on guideline-directed medical therapy and adherence management, with pharmacist-provided education and follow-up shown to improve clinical outcomes. For cardiac rehabilitation, center-based programs have been shown to reduce rehospitalization, recurrent events, and mortality. Home-based models improve quality of life and accessibility with comparable functional benefits and no significant difference in short-term mortality compared to center-based care. Telerehabilitation also enhances functional recovery, though its specific effects on mortality and rehospitalization remain inconclusive. CONCLUSIONS: Current evidence underscores that nutrition planning, pharmacist involvement, and structured rehabilitation are central to integrated PAC for ACS. Multidisciplinary collaboration is essential to optimize long-term outcomes and support patient recovery. FAU - Chao, Ching-Ping AU - Chao CP AD - Division of Cardiology, Cardiovascular Medical Center, Far Eastern Memorial Hospital. FAU - Chiu, Chun-Chih AU - Chiu CC AD - Division of Cardiology, Department of Internal Medicine. AD - Department of Medical Quality, Shuang Ho Hospital, Taipei Medical University, New Taipei City. AD - Taipei Heart Institute, Taipei Medical University, Taipei. FAU - Lin, Wei-Cheng AU - Lin WC AD - Division of Cardiology, Department of Internal Medicine, Kaohsiung Yuan's General Hospital. AD - Department of Nursing, Fooyin University. FAU - Chuang, Hsin-Chiao AU - Chuang HC AD - Division of Cardiology, Cardiovascular Medical Center, Far Eastern Memorial Hospital. FAU - Hu, Jia-Ying AU - Hu JY AD - Department of Nurse Practitioner, Kaohsiung Yuan's General Hospital, Kaohsiung. AD - Institute of Clinical Nursing, National Yang Ming Chiao Tung University, Taipei. FAU - Liu, Li-Wei AU - Liu LW AD - Division of Cardiology, Department of Internal Medicine, Tainan Municipal Hospital, Tainan. FAU - Huang, Chun-Yao AU - Huang CY AD - Taipei Heart Institute, Taipei Medical University, Taipei. AD - Division of Cardiology and Cardiovascular Research Center, Department of Internal Medicine, Taipei Medical University Hospital. AD - Division of Cardiology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei. FAU - Wang, Yu-Chen AU - Wang YC AD - Division of Cardiology, Department of Internal Medicine, Asia University Hospital. AD - Department of Medical Laboratory Science and Biotechnology, Asia University, Taichung. FAU - Huang, Wei-Chun AU - Huang WC AD - Department of Cardiology, Pingtung Christian Hospital, Pingtung County. FAU - Lin, Kolong AU - Lin K AD - Department of Physical Medicine and Rehabilitation, Kaohsiung Medical University Hospital. AD - Division of Rehabilitation, Kaohsiung Medical University College of Medicine, Kaohsiung, Taiwan. FAU - Su, Hsiu-Yueh AU - Su HY AD - Nutrition Department, Taipei Medical University Hospital, Taipei. FAU - Wu, Yen-Wen AU - Wu YW AD - Division of Cardiology, Cardiovascular Center, and Department of Nuclear Medicine, Far Eastern Memorial Hospital, New Taipei City. AD - School of Medicine, National Yang Ming Chiao Tung University, Taipei. AD - Graduate Institute of Medicine, Yuan Ze University, Taoyuan, Taiwan. LA - eng PT - Journal Article PL - China (Republic : 1949- ) TA - Acta Cardiol Sin JT - Acta Cardiologica Sinica JID - 101687085 PMC - PMC13409461 OTO - NOTNLM OT - Acute coronary syndrome OT - Cardiac rehabilitation OT - Multidisciplinary OT - Nutrition OT - Pharmacotherapy OT - Post-acute care COIS- All authors declare no conflicts of interest. EDAT- 2026/07/29 13:54 MHDA- 2026/07/29 13:55 PMCR- 2026/07/01 CRDT- 2026/07/29 10:26 PHST- 2025/12/02 00:00 [received] PHST- 2026/03/09 00:00 [accepted] PHST- 2026/07/29 13:55 [medline] PHST- 2026/07/29 13:54 [pubmed] PHST- 2026/07/29 10:26 [entrez] PHST- 2026/07/01 00:00 [pmc-release] AID - 10.6515/ACS.202607_42(4).20260309B [doi] PST - ppublish SO - Acta Cardiol Sin. 2026 Jul;42(4):534-543. doi: 10.6515/ACS.202607_42(4).20260309B. PMID- 42523174 OWN - NLM STAT- Publisher LR - 20260729 IS - 1879-6400 (Electronic) IS - 1879-6397 (Linking) DP - 2026 Jul 29 TI - Psychosis in Huntington's disease: A case supporting multidisciplinary and early palliative care. PG - 18796397261472525 LID - 10.1177/18796397261472525 [doi] AB - Following an abrupt medication switch from olanzapine to aripiprazole, a 61-year-old female with Huntington's disease developed psychosis that persisted despite olanzapine reinstitution. Subsequent hospitalization led to significant complications, including medication adverse effects, infections (parotitis, endocarditis, cystitis), trauma in the setting of restraints, and malnutrition. This case illustrates the risk of medical and pharmacologic complications during prolonged hospitalization, diagnostic challenges in advanced HD, and the importance of multidisciplinary care with early palliative involvement. FAU - Le, Vy AU - Le V AUID- ORCID: 0009-0000-7995-9967 AD - Department of Psychiatry, UNC School of Medicine, Chapel Hill, NC, USA. RINGGOLD: 2331 FAU - Sigler, Edith AU - Sigler E AD - Department of Internal Medicine, KU School of Medicine - Wichita, KS, USA. RINGGOLD: 21638 FAU - Liu, Jonathan AU - Liu J AD - Department of Internal Medicine, KU School of Medicine - Wichita, KS, USA. RINGGOLD: 21638 FAU - Abualama, Hiba AU - Abualama H AD - Department of Psychiatry & Behavioral Sciences, KU School of Medicine - Wichita, KS, USA. RINGGOLD: 21638 FAU - Surineni, Kamalakar AU - Surineni K AD - Department of Psychiatry & Behavioral Sciences, KU School of Medicine - Wichita, KS, USA. RINGGOLD: 21638 LA - eng PT - Journal Article DEP - 20260729 PL - United States TA - J Huntingtons Dis JT - Journal of Huntington's disease JID - 101589965 SB - IM OTO - NOTNLM OT - cognition OT - movement disorders OT - neurophysiology OT - neuropsychiatry OT - psychiatry EDAT- 2026/07/29 13:54 MHDA- 2026/07/29 13:54 CRDT- 2026/07/29 09:43 PHST- 2026/07/29 13:54 [medline] PHST- 2026/07/29 13:54 [pubmed] PHST- 2026/07/29 09:43 [entrez] AID - 10.1177/18796397261472525 [doi] PST - aheadofprint SO - J Huntingtons Dis. 2026 Jul 29:18796397261472525. doi: 10.1177/18796397261472525. PMID- 42522390 OWN - NLM STAT- MEDLINE DCOM- 20260729 LR - 20260824 IS - 2386-5857 (Electronic) IS - 1137-6821 (Linking) VI - 38 IP - 4 DP - 2026 Aug TI - Implementation of shock teams and impact on the therapeutic approach and prognosis of cardiogenic shock in Spain. PG - 261-268 LID - 10.55633/s3me/052.2026 [doi] AB - OBJECTIVE: There are no data on the implementation of shock teams (ST) or their impact on cardiogenic shock (CS) in Spain. METHODS: We conducted a retrospective observational study including episodes of CS (2016-2022) from hospitals within the Spanish National Health System with availability of an Interventional Cardiology Unit. The population was divided into a) patients hospitalized in centers with ST (CS-ST) and b) patients hospitalized in centers without ST (CSNST). Furthermore, the availability of a cardiac intensive care unit (CICU), cardiac surgery, heart transplant program, and volume of CS cases at each center were recorded. The outcome variable was the in-hospital mortality rate. RESULTS: A total of 15,879 episodes were analyzed, 32% (5,095) of which corresponded to the CS-ST group. The proportion of enters with ST availability increased progressively from 7% in 2016 to 39% in 2022. Patients from the CS-ST group were younger (68 vs 71 years, P < .001) and more frequently underwent mechanical ventilation, renal replacement therapy, and circulatory support (P < .001), showing a higher rate of acute kidney failure and stroke and longer lengths of stay (12 days vs 9 days, P < .001). Care in centers with ST (OR, 0.86; 95% CI, 0.77-0.96; P = .005) and CICU (OR, 0.82; 95% CI, 0.69-0.98; P < .033) was significantly associated with a lower mortality rate. CONCLUSIONS: The availability of ST has expanded in our setting. Patients admitted to centers with ST are managed more invasively, with a lower in-hospital mortality rate despite a higher rate of complications. FAU - Marcos-Mangas, Marta AU - Marcos-Mangas M AD - Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Espana. FAU - Jorge-Perez, Pablo AU - Jorge-Perez P AD - Hospital Universitario de Canarias, Tenerife, Espana. FAU - Comin-Colet, Josep AU - Comin-Colet J AD - Servicio de Cardiologia, Hospital Universitari de Bellvitge; IDIBELL. L'Hospitalet de Llobregat, Barcelona, Espana. Universitat de Barcelona (UB), Barcelona, Espana. Centro de Investigacion Biomedica en Red, Enfermedades Cardiovasculares, CIBER-CV, Espana. FAU - Del Prado, Nayade AU - Del Prado N AD - Fundacion Instituto para la Mejora de la Asistencia Sanitaria, Madrid, Espana. FAU - Fernandez, Cristina AU - Fernandez C AD - Fundacion Instituto para la Mejora de la Asistencia Sanitaria, Madrid, Espana. Servicio de Medicina Preventiva, Area Sanitaria de Santiago de Compostela y Barbanza, Instituto de Investigaciones Sanitarias de Santiago (IDIS), Santiago de Compostela, Espana. FAU - Viana Tejedor, Ana AU - Viana Tejedor A AD - Servicio de Cardiologia, Hospital Universitario Clinico San Carlos, Madrid, Espana. Instituto de Investigacion Sanitaria Hospital Clinico San Carlos (IdISSC), Madrid, Espana. FAU - Bernal, Jose Luis AU - Bernal JL AD - Fundacion Instituto para la Mejora de la Asistencia Sanitaria, Madrid, Espana. Catedra IMAS - Universidad Rey Juan Carlos, Madrid, Espana. FAU - Andrea, Rut AU - Andrea R AD - Universitat de Barcelona (UB), Barcelona, Espana. Seccion de Cuidados Cardiacos Agudos, Servicio de Cardiologia, Institut Clinic Cardiovascular, Hospital Clinic de Barcelona, Barcelona, Espana. FAU - Sionis, Alessandro AU - Sionis A AD - Unidad de Cuidados Agudos Cardiologicos, Servicio de Cardiologia, Hospital de la Santa Creu i Sant Pau, Institut de Recerca II-B Sant Pau, Universidad Autonoma de Barcelona, Barcelona, Espana. FAU - Segovia-Cubero, Javier AU - Segovia-Cubero J AD - Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Espana. FAU - Baneras, Jordi AU - Baneras J AD - Hospital de la Vall d'Hebron, Barcelona, Espana. FAU - Barrionuevo Sanchez, M Isabel AU - Barrionuevo Sanchez MI AD - Servicio de Cardiologia, Hospital Universitari de Bellvitge; IDIBELL. L'Hospitalet de Llobregat, Barcelona, Espana. FAU - Sanchez-Salado, Jose C AU - Sanchez-Salado JC AD - Servicio de Cardiologia, Hospital Universitari de Bellvitge; IDIBELL. L'Hospitalet de Llobregat, Barcelona, Espana. FAU - Gonzalez-Costello, Jose AU - Gonzalez-Costello J AD - Servicio de Cardiologia, Hospital Universitari de Bellvitge; IDIBELL. L'Hospitalet de Llobregat, Barcelona, Espana. Universitat de Barcelona (UB), Barcelona, Espana. Centro de Investigacion Biomedica en Red, Enfermedades Cardiovasculares, CIBER-CV, Espana. FAU - Alegre, Oriol AU - Alegre O AD - Servicio de Cardiologia, Hospital Universitari de Bellvitge; IDIBELL. L'Hospitalet de Llobregat, Barcelona, Espana. FAU - Martinez-Selles, Manuel AU - Martinez-Selles M AD - Servicio de Cardiologia, Hospital General Universitario Gregorio Maranon, Instituto de Investigacion Sanitaria Gregorio Maranon, CIBERCV, Instituto de Salud Carlos III, Facultad de Ciencias Biomedicas y de la Salud, Universidad Europea. Facultad de Medicina, Universidad Complutense, Madrid, Espana. FAU - Martin-Asenjo, Roberto AU - Martin-Asenjo R AD - Hospital Universitario 12 de Octubre, Madrid. Instituto de Investigacion Sanitaria Hospital 12 de Octubre (IMAS12), Madrid, Espana. FAU - Crespo-Leiro, Maria Generosa AU - Crespo-Leiro MG AD - Centro de Investigacion Biomedica en Red, Enfermedades Cardiovasculares, CIBER-CV, Espana. Complexo Hospitalario Universitario de A Coruna. INIBIC. UDC. CIBERCV, Espana. FAU - Gomez-Hospital, Joan Antoni AU - Gomez-Hospital JA AD - Servicio de Cardiologia, Hospital Universitari de Bellvitge; IDIBELL. L'Hospitalet de Llobregat, Barcelona, Espana. Universitat de Barcelona (UB), Barcelona, Espana. Centro de Investigacion Biomedica en Red, Enfermedades Cardiovasculares, CIBER-CV, Espana. FAU - Elola, Javier AU - Elola J AD - Fundacion Instituto para la Mejora de la Asistencia Sanitaria, Madrid, Espana. Catedra IMAS - Universidad Rey Juan Carlos, Madrid, Espana. FAU - Ariza-Sole, Albert AU - Ariza-Sole A AD - Servicio de Cardiologia, Hospital Universitari de Bellvitge; IDIBELL. L'Hospitalet de Llobregat, Barcelona, Espana. Universitat de Barcelona (UB), Barcelona, Espana. Centro de Investigacion Biomedica en Red, Enfermedades Cardiovasculares, CIBER-CV, Espana. LA - spa LA - eng PT - Journal Article PT - Observational Study TT - Implementacion de equipos de shock (shock teams) e impacto en el abordaje terapeutico y el pronostico del shock cardiogenico en Espana. PL - Spain TA - Emergencias JT - Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias JID - 9805751 SB - IM MH - Humans MH - *Shock, Cardiogenic/therapy/mortality MH - Spain/epidemiology MH - Retrospective Studies MH - Female MH - Male MH - Hospital Mortality MH - Aged MH - Prognosis MH - *Patient Care Team/organization & administration MH - Middle Aged MH - Length of Stay/statistics & numerical data MH - Coronary Care Units/statistics & numerical data OTO - NOTNLM OT - Cardiac intensive care unit OT - Cardiogenic shock OT - Mortalidad OT - Mortality OT - Shock cardiogenico OT - Shock team OT - Unidad de Cuidados Intensivos Cardiologicos EDAT- 2026/07/29 06:35 MHDA- 2026/07/29 18:39 CRDT- 2026/07/29 03:42 PHST- 2026/07/29 18:39 [medline] PHST- 2026/07/29 06:35 [pubmed] PHST- 2026/07/29 03:42 [entrez] AID - 10.55633/s3me/052.2026 [doi] PST - ppublish SO - Emergencias. 2026 Aug;38(4):261-268. doi: 10.55633/s3me/052.2026. PMID- 42522231 OWN - NLM STAT- Publisher LR - 20260729 IS - 1553-5606 (Electronic) IS - 1553-5592 (Linking) DP - 2026 Jul 28 TI - Impact of a multidisciplinary endocarditis evaluation team for opioid use associated infective endocarditis. LID - 10.1002/jhm.70412 [doi] AB - BACKGROUND: Infective endocarditis (IE) related to opioid use disorder (OUD) and injection substance use is on the rise. Multidisciplinary care is recommended for individuals with substance-related IE, but little is known about the impact of this care. OBJECTIVES: A retrospective cohort study to evaluate the impact of a multidisciplinary endocarditis evaluation team (MEET) on outcomes for patients with IE and specifically OUD-related IE. The MEET is a clinical team from multiple specialities that collaboratively facilitates optimal hospital-based treatment, including addiction-related treatment. METHODS: The study compares a historical control group of hospitalized adults with OUD and OUD-related IE who did not receive the MEET intervention (treatment as usual [TAU] group) with a group of hospitalized adults with OUD and OUD-related IE who received the MEET intervention. The primary outcome is receipt of medication for OUD (MOUD) at hospital discharge. Secondary outcomes are receipt of OUD treatment referral, 30-day ED visits, 30-day hospital re-admission, all-cause mortality, recurrence of IE, and repeat IE-related surgery. RESULTS: Nearly all patients in the MEET group (n = 68) were discharged on MOUD compared with the TAU group (n = 58) (98.5% vs. 56.9%) and received a referral for OUD treatment (97.1% vs. 74.1%). We were unable to detect a difference in 30-day ED visits and hospital readmissions, all-cause mortality, recurrent IE, and repeat IE-related surgery. CONCLUSIONS: A multidisciplinary intervention was associated with improved OUD-related outcomes. No change was observed in health care utilization, all-cause mortality, or other IE-related outcomes. CI - (c) 2026 Society of Hospital Medicine. FAU - Weimer, Melissa B AU - Weimer MB AUID- ORCID: 0000-0002-5624-2434 AD - Department of Medicine, Yale School of Medicine, Program in Addiction Medicine, Section of General Internal Medicine, New Haven, Connecticut, USA. AD - Department of Chronic Disease Epidemiology, School of Public Health, New Haven, Connecticut, USA. FAU - Wang, Kaicheng AU - Wang K AD - Yale Center for Analytical Sciences, Yale School of Public Health, New Haven, Connecticut, USA. FAU - Degife, Ellelan AU - Degife E AD - Division of Cardiac Surgery, Yale School of Medicine, New Haven, Connecticut, USA. FAU - Wells, Nicholas AU - Wells N AD - Division of Cardiac Surgery, Yale School of Medicine, New Haven, Connecticut, USA. FAU - Golden, Marjorie AU - Golden M AD - Department of Medicine, Yale School of Medicine, Section of Infectious Diseases, New Haven, Connecticut, USA. FAU - Hull, Sarah C AU - Hull SC AD - Department of Medicine, Yale School of Medicine, Section of Cardiovascular Medicine, New Haven, Connecticut, USA. FAU - Vallabhajosyula, Prashanth AU - Vallabhajosyula P AD - Division of Cardiac Surgery, Yale School of Medicine, New Haven, Connecticut, USA. FAU - Geirsson, Arnar AU - Geirsson A AD - Division of Cardiac Surgery, Columbia University Medical Center, New York, New York, USA. LA - eng PT - Journal Article DEP - 20260728 PL - United States TA - J Hosp Med JT - Journal of hospital medicine JID - 101271025 SB - IM EDAT- 2026/07/29 06:35 MHDA- 2026/07/29 06:35 CRDT- 2026/07/29 02:03 PHST- 2026/05/25 00:00 [revised] PHST- 2026/01/26 00:00 [received] PHST- 2026/06/29 00:00 [accepted] PHST- 2026/07/29 06:35 [medline] PHST- 2026/07/29 06:35 [pubmed] PHST- 2026/07/29 02:03 [entrez] AID - 10.1002/jhm.70412 [doi] PST - aheadofprint SO - J Hosp Med. 2026 Jul 28. doi: 10.1002/jhm.70412. PMID- 42521741 OWN - NLM STAT- Publisher LR - 20260728 IS - 1476-5543 (Electronic) IS - 0743-8346 (Linking) DP - 2026 Jul 28 TI - Team-based care with early recognition and treatment of cardiac dysfunction for infants with CDH. LID - 10.1038/s41372-026-02841-4 [doi] AB - OBJECTIVE: Identify how a core congenital diaphragmatic hernia (CDH) team coupled with early recognition and treatment of cardiac dysfunction changed outcomes for infants with CDH. METHODS: A retrospective chart review compared a historical cohort from 2015-2019 (n = 51) with a post-guideline cohort from 2020-2025 (n = 53). Statistical analysis was performed with Fisher's exact, unpaired t-test, and Mann Whitney U-test. RESULTS: Survival improved from 68.6% to 88.7% (p = 0.016) and ECMO utilization decreased, 51.0% to 26.4% (p = 0.015). Infants with cardiac dysfunction had increased survival (47.3% vs. 81.8%, p = 0.014) and less ECMO utilization (68.4% vs. 36.3%, p = 0.043). Vasoactive choices evolved with dopamine replaced by norepinephrine, low-dose epinephrine, or calcium gluconate. Inhaled nitric oxide (iNO) use in the first 48 h decreased significantly while prostaglandin E1 (PGE1) use increased. DISCUSSION: We implemented a core CDH team focused on a generalizable, physiology-driven approach to identify and treat cardiac dysfunction using standard neonatal echocardiography to improve outcomes. CI - (c) 2026. The Author(s). FAU - Sloan, Patrick E AU - Sloan PE AUID- ORCID: 0000-0001-6546-5069 AD - Division of Newborn Medicine, Department of Pediatrics, Washington University in St. Louis, St. Louis, MO, USA. sloan.patrick@wustl.edu. FAU - Sanning, Lila S AU - Sanning LS AUID- ORCID: 0000-0002-4185-2686 AD - Division of Newborn Medicine, Department of Pediatrics, Washington University in St. Louis, St. Louis, MO, USA. FAU - Liviskie, Caren AU - Liviskie C AUID- ORCID: 0000-0002-2007-6577 AD - Department of Pharmacy, St. Louis Children's Hospital, St. Louis, MO, USA. FAU - Clark, Kristen AU - Clark K AD - Saint Louis Children's Hospital NICU, St. Louis, MO, USA. FAU - Bushroe, Kylie AU - Bushroe K AUID- ORCID: 0000-0003-0652-8220 AD - Division of Newborn Medicine, Department of Pediatrics, Washington University in St. Louis, St. Louis, MO, USA. FAU - Riley, Melissa AU - Riley M AUID- ORCID: 0000-0002-3339-8639 AD - Division of Newborn Medicine, Department of Pediatrics, Washington University in St. Louis, St. Louis, MO, USA. FAU - Lijowska, Anna AU - Lijowska A AD - Division of Newborn Medicine, Department of Pediatrics, Washington University in St. Louis, St. Louis, MO, USA. FAU - Vrecenak, Jesse AU - Vrecenak J AD - Division of Pediatric Surgery, Department of Surgery, Washington University in St. Louis, St. Louis, MO, USA. FAU - Najaf, Tasnim AU - Najaf T AD - Division of Newborn Medicine, Department of Pediatrics, Washington University in St. Louis, St. Louis, MO, USA. LA - eng PT - Journal Article DEP - 20260728 PL - United States TA - J Perinatol JT - Journal of perinatology : official journal of the California Perinatal Association JID - 8501884 SB - IM COIS- Competing interests: The authors declare no competing interests. Ethics and consent to participate: This study was approved by the Washington University in St. Louis Institutional Review Board (#202510238). All methods were performed in accordance with the relevant guidelines and regulations outlined by the IRB. The requirement for informed consent was waived by the IRB due to the retrospective design of the study. EDAT- 2026/07/29 00:35 MHDA- 2026/07/29 00:35 CRDT- 2026/07/28 23:19 PHST- 2026/03/24 00:00 [received] PHST- 2026/07/20 00:00 [accepted] PHST- 2026/07/01 00:00 [revised] PHST- 2026/07/29 00:35 [medline] PHST- 2026/07/29 00:35 [pubmed] PHST- 2026/07/28 23:19 [entrez] AID - 10.1038/s41372-026-02841-4 [pii] AID - 10.1038/s41372-026-02841-4 [doi] PST - aheadofprint SO - J Perinatol. 2026 Jul 28. doi: 10.1038/s41372-026-02841-4. PMID- 42521616 OWN - NLM STAT- MEDLINE DCOM- 20260903 LR - 20260909 IS - 1463-1326 (Electronic) IS - 1462-8902 (Print) IS - 1462-8902 (Linking) VI - 28 IP - 10 DP - 2026 Oct TI - Economic Impact of Multidisciplinary Pre-operative Diabetes Care Versus Usual Care in Adults Undergoing Elective Non-cardiac Surgery in Australia: A Trial-Based Analysis. PG - 9367-9376 LID - 10.1111/dom.71139 [doi] AB - AIMS: The detrimental impact of perioperative hyperglycaemia on surgical outcomes is well documented. However, economic evaluations on interventions to improve perioperative blood glucose management are lacking. This study aimed to assess the cost-effectiveness of a multidisciplinary pre-operative diabetes service compared with usual care in adults with diabetes undergoing elective non-cardiac surgery. MATERIALS AND METHODS: An economic evaluation was conducted using data from a 3-year prospective interventional study involving adults with sub-optimally managed diabetes who were scheduled for elective non-cardiac surgery. Analysis was from a healthcare institution perspective. A decision analytic model was used to compare healthcare costs and outcomes between an intervention arm receiving multidisciplinary pre-operative diabetes input and a simulated usual care arm. Model inputs were derived from the interventional study, National Surgical Quality Improvement Program (NSQIP) data and published literature. Univariate and probabilistic sensitivity analyses were performed to assess the robustness of the model outcome. RESULTS: The intervention arm had a lower modelled incidence of 30-day post-operative infection-related readmissions and lower total costs per patient compared with the usual care arm. The intervention avoided 7 readmissions per 100 patients treated and generated cost savings of A$3967 per patient (total cost intervention: A$8335 vs. total cost usual care: $12 302). Probabilistic sensitivity analysis revealed an 89.5% probability that the intervention would remain dominant, with lower costs and fewer post-operative infection-related readmissions than usual care. CONCLUSIONS: In adults awaiting elective non-cardiac surgery, a multidisciplinary pre-operative diabetes service represents a cost-effective strategy compared with usual care from a healthcare institution perspective. CI - (c) 2026 The Author(s). Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. FAU - Yu, Abby AU - Yu A AUID- ORCID: 0000-0002-0705-6459 AD - School of Pharmacy and Pharmaceutical Sciences, The University of Queensland, Woolloongabba, Queensland, Australia. AD - Department of Pharmacy, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia. FAU - Whitfield, Karen AU - Whitfield K AD - School of Pharmacy and Pharmaceutical Sciences, The University of Queensland, Woolloongabba, Queensland, Australia. FAU - Hale, Andrew AU - Hale A AD - Discipline of Pharmacy, School of Clinical Sciences, Queensland University of Technology, Brisbane, Queensland, Australia. FAU - D'Emden, Michael AU - D'Emden M AD - Department of Endocrinology and Diabetes, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia. FAU - Donovan, Peter AU - Donovan P AD - Department of Endocrinology and Diabetes, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia. FAU - Snoswell, Centaine AU - Snoswell C AD - School of Pharmacy and Pharmaceutical Sciences, The University of Queensland, Woolloongabba, Queensland, Australia. LA - eng PT - Comparative Study PT - Journal Article DEP - 20260728 PL - England TA - Diabetes Obes Metab JT - Diabetes, obesity & metabolism JID - 100883645 SB - IM MH - Humans MH - *Elective Surgical Procedures/economics/adverse effects MH - Cost-Benefit Analysis MH - Female MH - *Preoperative Care/economics/methods MH - Male MH - Middle Aged MH - Cost-Effectiveness Analysis MH - Australia/epidemiology MH - Prospective Studies MH - Aged MH - Health Care Costs MH - *Postoperative Complications/economics/prevention & control/epidemiology MH - Adult MH - *Diabetes Mellitus/economics/therapy MH - Patient Care Team/economics MH - Patient Readmission/economics/statistics & numerical data MH - *Hyperglycemia/prevention & control/economics PMC - PMC13538755 OTO - NOTNLM OT - cost-effectiveness OT - glycaemic control OT - health economics OT - real-world evidence COIS- The authors declare no conflicts of interest. EDAT- 2026/07/29 00:35 MHDA- 2026/09/03 05:36 PMCR- 2026/09/03 CRDT- 2026/07/28 22:03 PHST- 2026/07/05 00:00 [revised] PHST- 2026/02/19 00:00 [received] PHST- 2026/07/13 00:00 [accepted] PHST- 2026/09/03 05:36 [medline] PHST- 2026/07/29 00:35 [pubmed] PHST- 2026/07/28 22:03 [entrez] PHST- 2026/09/03 00:00 [pmc-release] AID - DOM71139 [pii] AID - 10.1111/dom.71139 [doi] PST - ppublish SO - Diabetes Obes Metab. 2026 Oct;28(10):9367-9376. doi: 10.1111/dom.71139. Epub 2026 Jul 28. PMID- 42521141 OWN - NLM STAT- Publisher LR - 20260822 IS - 1532-8414 (Electronic) IS - 1071-9164 (Linking) DP - 2026 Jul 28 TI - Stepping it Up on Temporary Mechanical Circulatory Support: Mobilization and Prehabilitation of Patients in ICUs. LID - S1071-9164(26)00440-9 [pii] LID - 10.1016/j.cardfail.2026.07.017 [doi] AB - Early mobilization and prehabilitation in patients supported with temporary mechanical circulatory support (tMCS) have emerged as promising strategies to mitigate the deconditioning and sarcopenia associated with critical illness and immobility. While small studies have demonstrated that ambulation with tMCS is both safe and feasible in selected patients, significant variability exists in practice patterns across centers. Implementation of early mobility protocols requires a multidisciplinary team, including cardiology, surgery, critical care, physical therapy, respiratory therapy, nursing, and nutrition supported by dedicated personnel, familiar with the unique considerations of tMCS devices. Despite increasing adoption, there remains a paucity of high-quality data evaluating the impact of early ambulation on clinical outcomes, functional recovery, and candidacy for advanced therapies. This review outlines current practices, key challenges, and emerging strategies in tMCS rehabilitation and calls for standardized protocols and prospective studies to guide optimal implementation across institutions. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Bhardwaj, Anju AU - Bhardwaj A AD - Division of Cardiology, University of Texas/McGovern Medical School, Houston, TX. Electronic address: bhardwajan@gmail.com. FAU - Randhawa, Varinder AU - Randhawa V AD - University of Toronto, Department of Medicine, Toronto, ON. FAU - Abramov, Dmitry AU - Abramov D AD - Division of Cardiology, Loma Linda University Medical Center, Loma Linda, CA. FAU - Radfar, Jason AU - Radfar J AD - Division of Physical therapy, Memorial Hermann Hospital, Houston, Tx. FAU - Wald, Joyce AU - Wald J AD - Division of Cardiology, Hospital of the University of Pennsylvania, Philadelphia, PA. FAU - Vest, Amanda R AU - Vest AR AD - Cleveland Clinic, Department of Cardiovascular Medicine, Cleveland, OH. FAU - Munagala, Mrudula AU - Munagala M AD - University of Miami, Miller School of Medicine, Miami, FL. FAU - Sridharan, Lakshmi AU - Sridharan L AD - Emory University, Atlanta, GA. FAU - Contreras, Johanna AU - Contreras J AD - Mount Sinai School of Medicine, New York, NY. FAU - Hackmann, Amy E AU - Hackmann AE AD - Heart and Vascular Institute, Mass General Brigham, Boston, MA. LA - eng PT - Journal Article PT - Review DEP - 20260728 PL - United States TA - J Card Fail JT - Journal of cardiac failure JID - 9442138 SB - IM OTO - NOTNLM OT - Temporary mechanical circulatory support OT - nutrition OT - physical therapy OT - rehabilitation COIS- Declaration of competing interest Dr. Anju Bhardwaj has served on an advisory board for Johnson & Johnson. The remaining authors report no relevant disclosures. EDAT- 2026/07/29 00:35 MHDA- 2026/07/29 00:35 CRDT- 2026/07/28 19:21 PHST- 2026/03/25 00:00 [received] PHST- 2026/07/19 00:00 [revised] PHST- 2026/07/20 00:00 [accepted] PHST- 2026/07/29 00:35 [pubmed] PHST- 2026/07/29 00:35 [medline] PHST- 2026/07/28 19:21 [entrez] AID - S1071-9164(26)00440-9 [pii] AID - 10.1016/j.cardfail.2026.07.017 [doi] PST - aheadofprint SO - J Card Fail. 2026 Jul 28:S1071-9164(26)00440-9. doi: 10.1016/j.cardfail.2026.07.017. PMID- 42516891 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260729 LR - 20260927 IS - 2090-6404 (Print) IS - 2090-6412 (Electronic) IS - 2090-6404 (Linking) VI - 2026 DP - 2026 TI - Successful Vaginal Delivery in a Young Female With Eisenmenger Syndrome and Double Outlet Right Ventricle: A Challenging Case Report. PG - 3877926 LID - 10.1155/cric/3877926 [doi] LID - 3877926 AB - BACKGROUND: Eisenmenger syndrome (ES), a severe complication of uncorrected congenital heart defects, is characterized by pulmonary hypertension and right-to-left intracardiac shunting resulting in systemic hypoxemia. Double outlet right ventricle (DORV), a rare congenital anomaly where both great arteries arise predominantly from the right ventricle, further exacerbates hemodynamic instability. Pregnancy in women with ES and DORV is associated with extremely high maternal and fetal mortality rates, requiring meticulous, multidisciplinary management. CASE PRESENTATION: A 20-year-old Gravida 1 Para 0 woman at 34 weeks gestation presented with progressive dyspnea, cyanosis, and generalized edema. She had a single antenatal visit with no cardiovascular evaluation. Examination revealed finger clubbing, elevated jugular venous pressure, pitting edema, bibasilar lung crackles, and a systolic murmur. Vital signs were notable for heart rate 130 bpm, BP 110/70 mmHg, RR 25/min, and SpO(2) 80% on supplemental oxygen. Laboratory tests showed anemia and elevated CRP without fever. Imaging and echocardiography revealed a large ventricular and atrial septal defect with bidirectional shunt, severe tricuspid regurgitation, and estimated pulmonary artery pressure of 85 mmHg. DORV was suggested with the aorta arising from the right ventricle. A multidisciplinary team opted for vaginal delivery. Labor was induced with misoprostol (Bishop score 5) under continuous maternal monitoring. The patient delivered vaginally after 4 h. The newborn weighed 2.7 kg, with Apgar scores of 5 and 7 at 1 and 5 min, respectively. Postpartum, the mother received diuretics, blood transfusions, and antibiotics for elevated CRP. She stabilized by day seven and was transferred to cardiology for ongoing management. DISCUSSION: This case highlights the challenges of managing pregnancy in women with ES and complex congenital heart defects like DORV. The successful vaginal delivery emphasizes the importance of a multidisciplinary approach, individualized treatment plans, and comprehensive monitoring to minimize risks. This case also demonstrates that vaginal delivery can be a viable option in selected patients when meticulously managed. CONCLUSION: Careful planning and multidisciplinary care can lead to favorable outcomes in pregnancies complicated by ES and DORV, despite their significant risks. CI - Copyright (c) 2026 Osman Farah Dahir et al. Case Reports in Cardiology published by John Wiley & Sons Ltd. FAU - Dahir, Osman Farah AU - Dahir OF AUID- ORCID: 0009-0009-9531-5876 AD - Cardiology Department, Mogadishu Somali Turkiye Training and Research Hospital, Mogadishu, Somalia. AD - Faculty of Medicine and Surgery, Salaam University, Mogadishu, Somalia. FAU - Ahmed, Said Abdirahman AU - Ahmed SA AUID- ORCID: 0000-0002-3647-4449 AD - Cardiology Department, Mogadishu Somali Turkiye Training and Research Hospital, Mogadishu, Somalia. FAU - Abdi, Ahmed Elmi AU - Abdi AE AD - Cardiology Department, Mogadishu Somali Turkiye Training and Research Hospital, Mogadishu, Somalia. FAU - Abdi, Ishak Ahmed AU - Abdi IA AUID- ORCID: 0000-0003-1492-9251 AD - Cardiology Department, Mogadishu Somali Turkiye Training and Research Hospital, Mogadishu, Somalia. FAU - Aden, Ahmed Shafie AU - Aden AS AD - Cardiology Department, Mogadishu Somali Turkiye Training and Research Hospital, Mogadishu, Somalia. FAU - Mohamed, Mohamed Mukhtar AU - Mohamed MM AD - Emergency Department, Mogadishu Somali Turkiye Training and Research Hospital, Mogadishu, Somalia. FAU - Waberi, Mohamud Mire AU - Waberi MM AD - Cardiology Department, Mogadishu Somali Turkiye Training and Research Hospital, Mogadishu, Somalia. FAU - Hassan, Mohamed Omar AU - Hassan MO AD - Cardiology Department, Mogadishu Somali Turkiye Training and Research Hospital, Mogadishu, Somalia. LA - eng PT - Journal Article DEP - 20260726 PL - United States TA - Case Rep Cardiol JT - Case reports in cardiology JID - 101576452 PMC - PMC13402882 OTO - NOTNLM OT - Eisenmenger syndrome OT - congenital heart defect OT - double outlet right ventricle OT - fetal outcomes OT - high-risk pregnancy OT - maternal outcomes OT - pulmonary hypertension COIS- The authors declare no conflicts of interest. EDAT- 2026/07/28 06:37 MHDA- 2026/07/28 06:38 PMCR- 2026/07/26 CRDT- 2026/07/28 04:41 PHST- 2026/01/16 00:00 [received] PHST- 2026/07/02 00:00 [revised] PHST- 2026/07/06 00:00 [accepted] PHST- 2026/07/28 06:38 [medline] PHST- 2026/07/28 06:37 [pubmed] PHST- 2026/07/28 04:41 [entrez] PHST- 2026/07/26 00:00 [pmc-release] AID - CRIC3877926 [pii] AID - 10.1155/cric/3877926 [doi] PST - epublish SO - Case Rep Cardiol. 2026 Jul 26;2026:3877926. doi: 10.1155/cric/3877926. eCollection 2026. PMID- 42516487 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260729 LR - 20260813 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 18 IP - 6 DP - 2026 Jun TI - The Oral Cavity as a Window to Systemic Disease: Diagnostic Clues and Pre-treatment Dental Management for Interdisciplinary Trainees. PG - e111615 LID - 10.7759/cureus.111615 [doi] LID - e111615 AB - The oral cavity frequently harbors the earliest clinical manifestations of systemic diseases, yet a persistent knowledge gap exists between dental and medical training programs regarding oral-systemic correlations. Simultaneously, pre-treatment dental evaluation before oncologic therapy and cardiac surgery remains an underutilized step that, when omitted, can lead to osteoradionecrosis, infective endocarditis, treatment delays, and increased morbidity. This narrative review aimed to catalog oral diagnostic clues, organized by organ system, and to synthesize current pre-treatment dental protocols for oncologic and cardiac surgical patients, targeting interdisciplinary trainees in dentistry and internal medicine. A literature search was conducted across PubMed/MEDLINE, Scopus, Web of Science, and the Cochrane Library. Clinical studies, systematic reviews, guidelines, and consensus statements published between 2000 and 2025 were included. Oral lesions may precede systemic symptoms in conditions including pemphigus vulgaris, Crohn's disease, leukemia, and Addison's disease. The bidirectional relationship between periodontitis and diabetes mellitus is supported by evidence demonstrating increased rates of type 2 diabetes among affected individuals. Current pre-treatment dental protocols endorsed by major professional organizations recommend comprehensive oral evaluation, elimination of active infection, and defined healing intervals before radiation therapy. Integrating oral examination into systemic disease screening and embedding standardized dental evaluation into oncologic and cardiac surgical pathways may improve early diagnosis, reduce complications, and enhance patient outcomes. Interdisciplinary education and standardized medical-dental consultation templates remain important priorities. CI - Copyright (c) 2026, Sarbeland et al. FAU - Sarbeland, Lina AU - Sarbeland L AD - Medicine, Aria University, Mazar-i-Sharif, AFG. FAU - Sultani, Mohammad Yousuf AU - Sultani MY AD - Dentistry, Stomatology National and Teaching Hospital, Kabul, AFG. FAU - Afzalzada, Nilab AU - Afzalzada N AD - Medicine, Khatam Al-Nabieen University, Kabul, AFG. FAU - Latifi, Fraidoon AU - Latifi F AD - Psychiatry, Balkh University, Mazar-i-Sharif, AFG. FAU - Ali, Samira AU - Ali S AD - Obstetrics and Gynecology, Isteqlal Hospital, Kabul, AFG. FAU - Muradi, Maryam AU - Muradi M AD - Medicine, Aria University, Mazar-i-Sharif, AFG. FAU - Elmyar, Abdul Hamid AU - Elmyar AH AD - Public Health, Kabul University of Medical Sciences "Abu Ali Ibn Sina", Kabul, AFG. FAU - Sultani, Mohammad Ibrahim AU - Sultani MI AD - Medicine, Ankara Yildirim Beyazit University, Ankara, TUR. FAU - Yousofi, Tamanna AU - Yousofi T AD - Medicine, Herat University, Herat, AFG. FAU - Sharify, Mursal AU - Sharify M AD - Medicine, Cheragh Medical University, Kabul, AFG. FAU - Kamran Qadiri, Rateba AU - Kamran Qadiri R AD - Medicine, Balkh University, Mazar-i-Sharif, AFG. FAU - Naziri Sarir, Nella AU - Naziri Sarir N AD - Obstetrics and Gynecology, Khair Khana 102-Bed Hospital, Kabul, AFG. FAU - Sadat Sultany, Humaira AU - Sadat Sultany H AD - Medicine, Kabul University of Medical Sciences "Abu Ali Ibn Sina", Kabul, AFG. LA - eng PT - Journal Article PT - Review DEP - 20260627 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC13404506 OTO - NOTNLM OT - dental clearance OT - infective endocarditis OT - interdisciplinary education OT - mronj OT - narrative review OT - oral manifestations OT - osteoradionecrosis OT - systemic disease COIS- Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. EDAT- 2026/07/28 06:36 MHDA- 2026/07/28 06:37 PMCR- 2026/06/27 CRDT- 2026/07/28 04:37 PHST- 2026/06/27 00:00 [accepted] PHST- 2026/07/28 06:37 [medline] PHST- 2026/07/28 06:36 [pubmed] PHST- 2026/07/28 04:37 [entrez] PHST- 2026/06/27 00:00 [pmc-release] AID - 10.7759/cureus.111615 [doi] PST - epublish SO - Cureus. 2026 Jun 27;18(6):e111615. doi: 10.7759/cureus.111615. eCollection 2026 Jun. PMID- 42516101 OWN - NLM STAT- Publisher LR - 20260728 IS - 1477-111X (Electronic) IS - 0267-6591 (Linking) DP - 2026 Jul 28 TI - A national evaluation of perioperative temporary mechanical circulatory support infrastructure and governance in the UK: A survey of adult cardiac surgical centres. PG - 2676591261473450 LID - 10.1177/02676591261473450 [doi] AB - IntroductionTemporary mechanical circulatory support (tMCS) for refractory post-cardiac surgery cardiogenic shock (PCCS) is required in 1-2% of cardiac surgical patients. As a prelude to a year-long national service evaluation of tMCS provision in this context, we undertook the first national system-level evaluation of the infrastructure and governance of tMCS for adult cardiac surgery in the UK.MethodsA survey was distributed to the Association for Cardiothoracic Anaesthesia & Critical Care Linkperson Network, including all 35 UK adult cardiac surgical centres. The twenty-question survey inquired about local tMCS availability and use, management of PCCS, reporting frameworks and other local resources.ResultsComplete results were obtained from 26 centres (74%), including two-thirds of the UK's adult heart transplant centres. Centres reported preoperative tMCS use in 1.4%, and up to 4% postoperatively. All centres could provide intra-aortic balloon pump support, which was the most common therapy nationally. Transvalvular microaxial flow pump (39% of centres), venoarterial extracorporeal membrane oxygenation (54%) and ventricular assist devices (19%) were less widely available and less frequently used. Most centres (89%) reported no protocol for the management of PCCS and no local shock team (85%).ConclusionsThe UK currently lacks a co-ordinated perioperative tMCS pathway, and there is marked heterogeneity in the organisation, availability and delivery of perioperative tMCS services across the UK. There is a need to address key system-level gaps, with nationally coordinated pathways, multidisciplinary shock models, standardised reporting structures and network-based referral systems. FAU - Milne, Benjamin AU - Milne B AUID- ORCID: 0000-0002-1804-6125 AD - Department of Critical Care, Guy's & St Thomas' Hospital NHS Foundation Trust, London, UK. AD - Department of Anaesthesia, Guy's & St Thomas' Hospital NHS Foundation Trust, London, UK. FAU - Charlton, Matthew AU - Charlton M AD - Department of Cardiothoracic Critical Care Medicine and ECMO Unit, Glenfield Hospital, University Hospitals of Leicester NHS Trust, Leicester, UK. RINGGOLD: 156757 AD - Department of Cardiovascular Sciences, University of Leicester, Leicester, UK. FAU - Yusuff, Hakeem AU - Yusuff H AD - Department of Cardiothoracic Critical Care Medicine and ECMO Unit, Glenfield Hospital, University Hospitals of Leicester NHS Trust, Leicester, UK. RINGGOLD: 156757 AD - Department of Respiratory Sciences, University of Leicester, Leicester, UK. AD - National Institute for Health and Care Research (NIHR) Leicester Biomedical Research Centre, Leicester, UK. FAU - Zochios, Vasileios AU - Zochios V AD - Department of Cardiothoracic Critical Care Medicine and ECMO Unit, Glenfield Hospital, University Hospitals of Leicester NHS Trust, Leicester, UK. RINGGOLD: 156757 AD - Department of Cardiovascular Sciences, University of Leicester, Leicester, UK. FAU - Kunst, Gudrun AU - Kunst G AUID- ORCID: 0000-0002-9789-1334 AD - Department of Anaesthesia, King's College Hospital NHS Foundation Trust, London, UK. RINGGOLD: 8948 AD - School of Cardiovascular and Metabolic Medicine & Sciences, King's College London, London, UK. RINGGOLD: 4616 LA - eng PT - Journal Article DEP - 20260728 PL - England TA - Perfusion JT - Perfusion JID - 8700166 SB - IM OTO - NOTNLM OT - ECMO OT - cardiac surgery OT - cardiogenic shock OT - mechanical circulatory support OT - ventricular assist device EDAT- 2026/07/28 06:37 MHDA- 2026/07/28 06:37 CRDT- 2026/07/28 04:23 PHST- 2026/07/28 06:37 [medline] PHST- 2026/07/28 06:37 [pubmed] PHST- 2026/07/28 04:23 [entrez] AID - 10.1177/02676591261473450 [doi] PST - aheadofprint SO - Perfusion. 2026 Jul 28:2676591261473450. doi: 10.1177/02676591261473450. PMID- 42513638 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260729 LR - 20260813 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 15 IP - 14 DP - 2026 Jul 21 TI - The Shifting Boundary Between Invasive and Non-Invasive Angiographic Investigation in Contemporary Cardiology and Cardiac Surgery: An Up-to-Date Narrative Review. LID - 10.3390/jcm15145723 [doi] LID - 5723 AB - Background: Invasive coronary angiography has historically been the reference standard for coronary, valvular, and structural heart disease. Over the past decade, coronary computed tomography angiography (CCTA), CT-derived fractional flow reserve (CT-FFR), photon-counting detector computed tomography (PCCT), and cardiac magnetic resonance (CMR) have expanded the range of clinical questions answerable without an intra-arterial catheter, but this shift has been uneven across clinical domains. Methods: We performed a narrative review and synthesis of randomized trials, registries, society guidelines, and consensus documents (2009-2026) identified through PubMed and major cardiovascular guideline databases, written from a joint cardiology and cardiac-surgical standpoint. Results: The boundary has shifted asymmetrically, by which we mean a domain-dependent rather than uniform displacement of invasive angiography. Non-invasive imaging is now established as the first-line approach for stable chest pain at low-to-moderate pretest probability, for pre-transcatheter aortic valve replacement (TAVR) and structural procedural planning, and for aortic disease. It remains contested for stable multivessel disease and pre-coronary artery bypass grafting (CABG) planning, where CCTA- or CT-FFR-only planning is still investigational. Invasive angiography stays first-line for ST-elevation myocardial infarction (STEMI), cardiogenic shock, and complex percutaneous coronary intervention (PCI), where diagnosis and therapy are inseparable. Conclusions: Invasive and non-invasive modalities are complementary rather than competing. The appropriate first-line investigation depends on the disease domain, pretest probability, anatomical complexity, imaging quality, and whether diagnosis and treatment can be separated. We propose a complexity-stratified, heart-team framework and identify the surgical research gaps that remain. FAU - Ren, Justin AU - Ren J AUID- ORCID: 0000-0001-9855-4850 AD - Department of Surgery, The University of Melbourne, Melbourne, VIC 3010, Australia. AD - Department of Cardiothoracic Surgery, Royal Melbourne Hospital, Melbourne, VIC 3052, Australia. AD - Medical School, The University of Western Australia, Perth, WA 6009, Australia. FAU - Royse, Colin AU - Royse C AUID- ORCID: 0000-0002-2250-8927 AD - Department of Surgery, The University of Melbourne, Melbourne, VIC 3010, Australia. AD - Department of Anaesthesia and Pain Management, Royal Melbourne Hospital, Melbourne, VIC 3052, Australia. AD - Outcomes Research, University of Texas Health, Houston, TX 77030, USA. FAU - Chan, William AU - Chan W AUID- ORCID: 0000-0001-9684-888X AD - Department of Cardiology, Royal Melbourne Hospital, Melbourne, VIC 3052, Australia. AD - Baker Heart and Diabetes Institute, Melbourne, VIC 3004, Australia. AD - Department of Cardiology, Western Health, Melbourne, VIC 3011, Australia. FAU - Stub, Dion AU - Stub D AD - School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC 3004, Australia. AD - Department of Cardiology, The Alfred Hospital, Melbourne, VIC 3004, Australia. FAU - Hamilton, Garry W AU - Hamilton GW AD - Department of Cardiology, Austin Health, Melbourne, VIC 3084, Australia. AD - Department of Medicine, University of Melbourne, Melbourne, VIC 3010, Australia. FAU - Bloom, Jason E AU - Bloom JE AD - Baker Heart and Diabetes Institute, Melbourne, VIC 3004, Australia. AD - Department of Cardiology, The Alfred Hospital, Melbourne, VIC 3004, Australia. FAU - Fruehwald, Tobias AU - Fruehwald T AUID- ORCID: 0000-0002-1319-1390 AD - Department of Surgery, The University of Melbourne, Melbourne, VIC 3010, Australia. FAU - Srivastav, Nilesh AU - Srivastav N AD - Department of Surgery, The University of Melbourne, Melbourne, VIC 3010, Australia. AD - Heart Vascular and Thoracic Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi P.O. Box 112412, United Arab Emirates. FAU - Royse, Alistair AU - Royse A AUID- ORCID: 0000-0002-4449-663X AD - Department of Surgery, The University of Melbourne, Melbourne, VIC 3010, Australia. AD - Department of Cardiothoracic Surgery, Royal Melbourne Hospital, Melbourne, VIC 3052, Australia. AD - Department of Surgery, Universiti Kebangsaan Malaysia, Kuala Lumpur 56000, Malaysia. LA - eng PT - Journal Article PT - Review DEP - 20260721 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC13412774 OTO - NOTNLM OT - CT-FFR OT - cardiac magnetic resonance OT - clinical decision-making OT - coronary artery bypass grafting OT - coronary computed tomography angiography OT - heart team OT - photon-counting CT OT - transcatheter aortic valve replacement COIS- The authors declare no conflicts of interest. EDAT- 2026/07/28 06:37 MHDA- 2026/07/28 06:38 PMCR- 2026/07/21 CRDT- 2026/07/28 01:15 PHST- 2026/06/17 00:00 [received] PHST- 2026/07/16 00:00 [revised] PHST- 2026/07/20 00:00 [accepted] PHST- 2026/07/28 06:38 [medline] PHST- 2026/07/28 06:37 [pubmed] PHST- 2026/07/28 01:15 [entrez] PHST- 2026/07/21 00:00 [pmc-release] AID - jcm15145723 [pii] AID - jcm-15-05723 [pii] AID - 10.3390/jcm15145723 [doi] PST - epublish SO - J Clin Med. 2026 Jul 21;15(14):5723. doi: 10.3390/jcm15145723. PMID- 42513505 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260729 LR - 20260813 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 15 IP - 14 DP - 2026 Jul 16 TI - Minimally Invasive Standalone Left Atrial Appendage Occlusion for Atrial Fibrillation: Procedural Approaches and Complications. LID - 10.3390/jcm15145587 [doi] LID - 5587 AB - The left atrial appendage is well recognized as the site of thrombus formation in patients with atrial fibrillation. However, in patients who are either unsuitable for long-term oral anticoagulation or in whom this therapy is inefficient, left atrial occlusion has emerged as a mechanical strategy option to diminish stroke risk. Minimally invasive percutaneous and standalone surgical thoracoscopic techniques are appearing as viable options for left atrial appendage exclusion, each with distinct procedural risk profiles and characteristics, as well as evidence from trials or registers. We suggest that the choice between percutaneous and thoracoscopic left atrial appendage occlusion should be individualized, ideally within the multidisciplinary heart team, considering left atrial appendage anatomy, patient bleeding and thromboembolic risk profile, comorbidities, prior cardiac interventions, and institutional expertise and resources. We aim to present in this review the value of multimodality imaging in patient selection for minimally invasive left atrial appendage occlusion to minimize the possibility of complications, and to compare technical advancements and indications for percutaneous and standalone thoracoscopic left atrial appendage occlusion. FAU - Jaksic Jurinjak, Sandra AU - Jaksic Jurinjak S AD - Department of Cardiovascular Diseases, University Hospital Centre Zagreb, Kispaticeva 12, 10000 Zagreb, Croatia. AD - School of Medicine, University of Zagreb, Salata 3, 10000 Zagreb, Croatia. FAU - Reskovic Luksic, Vlatka AU - Reskovic Luksic V AUID- ORCID: 0000-0002-4721-3236 AD - Department of Cardiovascular Diseases, University Hospital Centre Zagreb, Kispaticeva 12, 10000 Zagreb, Croatia. AD - Algebra Bernays University, Gradiscanska 24, 10000 Zagreb, Croatia. FAU - Kopjar, Tomislav AU - Kopjar T AUID- ORCID: 0000-0002-4745-999X AD - School of Medicine, University of Zagreb, Salata 3, 10000 Zagreb, Croatia. AD - Department of Cardiac Surgery, University Hospital Centre Zagreb, Kispaticeva 12, 10000 Zagreb, Croatia. FAU - Velagic, Vedran AU - Velagic V AUID- ORCID: 0000-0001-5425-5840 AD - Department of Cardiovascular Diseases, University Hospital Centre Zagreb, Kispaticeva 12, 10000 Zagreb, Croatia. AD - School of Medicine, University of Zagreb, Salata 3, 10000 Zagreb, Croatia. LA - eng PT - Journal Article PT - Review DEP - 20260716 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC13413060 OTO - NOTNLM OT - left atrial appendage OT - minimally invasive procedure OT - occlusion COIS- The authors declare no conflicts of interest. EDAT- 2026/07/28 06:37 MHDA- 2026/07/28 06:38 PMCR- 2026/07/16 CRDT- 2026/07/28 01:15 PHST- 2026/06/01 00:00 [received] PHST- 2026/07/01 00:00 [revised] PHST- 2026/07/03 00:00 [accepted] PHST- 2026/07/28 06:38 [medline] PHST- 2026/07/28 06:37 [pubmed] PHST- 2026/07/28 01:15 [entrez] PHST- 2026/07/16 00:00 [pmc-release] AID - jcm15145587 [pii] AID - jcm-15-05587 [pii] AID - 10.3390/jcm15145587 [doi] PST - epublish SO - J Clin Med. 2026 Jul 16;15(14):5587. doi: 10.3390/jcm15145587. PMID- 42512571 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260728 LR - 20260813 IS - 2227-9032 (Print) IS - 2227-9032 (Electronic) IS - 2227-9032 (Linking) VI - 14 IP - 14 DP - 2026 Jul 9 TI - Wear-Smile: A Multidisciplinary Telemedicine-Based Smoking Cessation Program Assisted by Wearable Monitoring Devices for Persons Who Smoke-Protocol for a Randomized Controlled Trial. LID - 10.3390/healthcare14142055 [doi] LID - 2055 AB - BACKGROUND: Tobacco smoking remains one of the leading preventable causes of morbidity and mortality worldwide and is associated with cardiovascular, respiratory, oral, and psychological disorders. Although conventional smoking cessation interventions are effective, barriers related to accessibility, adherence, healthcare costs, and continuity of care frequently limit long-term success. Recent advances in technology may offer innovative opportunities to improve multidisciplinary smoking cessation pathways. METHODOLOGY: The Wear-Smile project is a non-profit, monocentric, randomized controlled trial registered in the Clinical Trial Protocol Registry and Results System (code No.: NCT07593742), designed to evaluate the effectiveness of a multidisciplinary telemedicine-based smoking cessation program assisted by wearable remote-monitoring devices. Adults who smoke combustible or heated tobacco or electronic nicotine delivery systems will be randomly allocated in a 1:1 ratio to either an experimental group receiving telemedicine-assisted rehabilitation integrated with wearable monitoring devices or a control group receiving standard in-person smoking cessation care. The intervention will include a multidisciplinary behavioral smoking cessation intervention involving cardiology, respiratory, dental, and psychology specialists. Primary outcomes will include Continuous Abstinence Rates and Point Prevalence Abstinence assessed at 6 and 12 months. Secondary outcomes will include cardiopulmonary and oral health parameters, smoking-related variables, health- and oral health-related quality of life (QoL), as well as adherence, usability, acceptability, and satisfaction with the rehabilitation program. CONCLUSIONS: The project may provide preliminary evidence regarding the potential feasibility, acceptability, and effectiveness of a multidisciplinary smoking cessation program integrating telemedicine and wearable monitoring technologies in improving abstinence outcomes, patient engagement, continuity of care, and QoL. FAU - Di Palo, Maria Pia AU - Di Palo MP AUID- ORCID: 0000-0002-5443-8185 AD - Department of Medicine, Surgery and Dentistry, University of Salerno, 84081 Baronissi, Italy. FAU - Amato, Massimo AU - Amato M AD - Department of Medicine, Surgery and Dentistry, University of Salerno, 84081 Baronissi, Italy. FAU - Vecchione, Carmine AU - Vecchione C AD - Department of Medicine, Surgery and Dentistry, University of Salerno, 84081 Baronissi, Italy. FAU - Ciccarelli, Michele AU - Ciccarelli M AUID- ORCID: 0000-0003-2379-1960 AD - Department of Medicine, Surgery and Dentistry, University of Salerno, 84081 Baronissi, Italy. FAU - Garofano, Marina AU - Garofano M AUID- ORCID: 0000-0003-1600-4682 AD - Department of Medicine, Surgery and Dentistry, University of Salerno, 84081 Baronissi, Italy. FAU - Di Spirito, Federica AU - Di Spirito F AUID- ORCID: 0000-0002-5458-6559 AD - Department of Innovative Technologies in Medicine & Dentistry, University "G. d'Annunzio" Chieti-Pescara, 66100 Chieti, Italy. FAU - Mignogna, Michele Davide AU - Mignogna MD AD - Department of Neuroscience, Reproductive Science and Dentistry, University of Naples Federico II, 80131 Naples, Italy. FAU - Corallo, Francesco AU - Corallo F AUID- ORCID: 0000-0003-4862-3832 AD - IRCCS Centro Neurolesi Bonino-Pulejo, Via Palermo, S.S. 113, C.da Casazza, 98124 Messina, Italy. FAU - Pagano, Maria AU - Pagano M AUID- ORCID: 0000-0002-0978-605X AD - IRCCS Centro Neurolesi Bonino-Pulejo, Via Palermo, S.S. 113, C.da Casazza, 98124 Messina, Italy. FAU - Cappadona, Irene AU - Cappadona I AUID- ORCID: 0000-0002-3984-2331 AD - IRCCS Centro Neurolesi Bonino-Pulejo, Via Palermo, S.S. 113, C.da Casazza, 98124 Messina, Italy. FAU - Pessolano, Colomba AU - Pessolano C AD - Department of Medicine, Surgery and Dentistry, University of Salerno, 84081 Baronissi, Italy. FAU - Nunziante, Alessia AU - Nunziante A AD - Department of Medicine, Surgery and Dentistry, University of Salerno, 84081 Baronissi, Italy. FAU - Bramanti, Alessia AU - Bramanti A AUID- ORCID: 0000-0002-5247-9901 AD - Department of Medicine, Surgery and Dentistry, University of Salerno, 84081 Baronissi, Italy. LA - eng PT - Journal Article DEP - 20260709 PL - Switzerland TA - Healthcare (Basel) JT - Healthcare (Basel, Switzerland) JID - 101666525 PMC - PMC13410000 OTO - NOTNLM OT - cardiopulmonary health OT - oral health OT - quality of life OT - smoker OT - smoking cessation OT - telehealth OT - telemedicine OT - telemonitoring OT - tobacco OT - wearable devices COIS- The authors declare no conflicts of interest. EDAT- 2026/07/28 06:37 MHDA- 2026/07/28 06:38 PMCR- 2026/07/09 CRDT- 2026/07/28 01:12 PHST- 2026/06/05 00:00 [received] PHST- 2026/06/30 00:00 [revised] PHST- 2026/07/06 00:00 [accepted] PHST- 2026/07/28 06:38 [medline] PHST- 2026/07/28 06:37 [pubmed] PHST- 2026/07/28 01:12 [entrez] PHST- 2026/07/09 00:00 [pmc-release] AID - healthcare14142055 [pii] AID - healthcare-14-02055 [pii] AID - 10.3390/healthcare14142055 [doi] PST - epublish SO - Healthcare (Basel). 2026 Jul 9;14(14):2055. doi: 10.3390/healthcare14142055. PMID- 42512012 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260729 LR - 20260813 IS - 2227-9059 (Print) IS - 2227-9059 (Electronic) IS - 2227-9059 (Linking) VI - 14 IP - 7 DP - 2026 Jul 9 TI - The Expanding Therapeutic Armamentarium for Mitral Regurgitation: Surgical and Transcatheter Interventions. LID - 10.3390/biomedicines14071539 [doi] LID - 1539 AB - Background: Mitral regurgitation (MR) is one of the most prevalent valvular heart diseases, with a rising global incidence. The 2025 European Society of Cardiology (ESC) guidelines introduced updated pathophysiological and morphological concepts for secondary MR, distinguishing ventricular and atrial mechanisms. Concurrent advances in cardiovascular imaging and therapeutic technologies have transformed the diagnostic and management landscape of MR. Methods: This review summarizes current evidence on the diagnosis and treatment of MR, with a focus on the updated ESC classification, multimodality cardiovascular imaging, minimally invasive surgical techniques, and contemporary transcatheter repair strategies. Recent literature was evaluated to highlight advances in anatomical assessment and individualized therapeutic approaches. Results: Multimodality imaging provides comprehensive evaluation of mitral valve anatomy, ventricular remodeling, and disease mechanisms, enabling accurate patient selection and procedural planning. Surgical management has evolved from conventional repair or replacement to minimally invasive approaches, including video-assisted right thoracotomy and robotic-assisted surgery, which have demonstrated favorable perioperative and clinical outcomes. In parallel, transcatheter interventions have expanded the therapeutic armamentarium for patients at high surgical risk or with complex anatomy. These include direct and indirect annuloplasty, transcatheter edge-to-edge repair, and emerging catheter-based repair technologies targeting specific structural abnormalities of the mitral valve apparatus. Conclusions: Contemporary management of MR requires an integrated understanding of disease pathophysiology, advanced imaging, and patient-specific anatomical characteristics. The combination of minimally invasive surgical techniques and rapidly evolving transcatheter interventions has broadened treatment options and supports a tailored, multidisciplinary approach to improve clinical outcomes and expand access to effective therapy for patients with severe MR. FAU - Kalompatsou, Argyro AU - Kalompatsou A AUID- ORCID: 0009-0005-7714-0516 AD - First Cardiology Department, Hippokration General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece. FAU - Tousoulis, Dimitris AU - Tousoulis D AD - First Cardiology Department, Hippokration General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece. FAU - Ververeli, Charilila-Loukia AU - Ververeli CL AD - First Cardiology Department, Hippokration General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece. FAU - Kachrimanidis, Ioannis AU - Kachrimanidis I AUID- ORCID: 0009-0006-8964-329X AD - First Cardiology Department, Hippokration General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece. FAU - Dimitroglou, Yannis AU - Dimitroglou Y AUID- ORCID: 0000-0001-7340-5242 AD - First Cardiology Department, Hippokration General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece. FAU - Tsalamandris, Sotirios AU - Tsalamandris S AUID- ORCID: 0000-0002-9945-930X AD - First Cardiology Department, Hippokration General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece. FAU - Drakopoulou, Maria AU - Drakopoulou M AD - First Cardiology Department, Hippokration General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece. FAU - Aznaouridis, Konstantinos AU - Aznaouridis K AUID- ORCID: 0000-0002-0706-4424 AD - First Cardiology Department, Hippokration General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece. FAU - Dimitriadis, Kyriakos AU - Dimitriadis K AD - First Cardiology Department, Hippokration General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece. FAU - Koukos, Markos AU - Koukos M AUID- ORCID: 0009-0003-7228-1083 AD - First Cardiology Department, Hippokration General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece. FAU - Papanikolaou, Aggelos AU - Papanikolaou A AUID- ORCID: 0000-0003-2726-9520 AD - First Cardiology Department, Hippokration General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece. FAU - Lozos, Vasilis AU - Lozos V AD - Department of Cardiothoracic Surgery, Hippokration Hospital, 11527 Athens, Greece. FAU - Toutouzas, Konstantinos AU - Toutouzas K AD - First Cardiology Department, Hippokration General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece. FAU - Tsioufis, Konstantinos AU - Tsioufis K AUID- ORCID: 0000-0002-7636-6725 AD - First Cardiology Department, Hippokration General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece. FAU - Aggeli, Constantina AU - Aggeli C AD - First Cardiology Department, Hippokration General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece. LA - eng GR - none/ PT - Journal Article PT - Review DEP - 20260709 PL - Switzerland TA - Biomedicines JT - Biomedicines JID - 101691304 PMC - PMC13406090 OTO - NOTNLM OT - mitral regurgitation OT - mitral therapies COIS- The authors declare no conflict of interest. EDAT- 2026/07/28 06:37 MHDA- 2026/07/28 06:38 PMCR- 2026/07/09 CRDT- 2026/07/28 01:10 PHST- 2026/06/07 00:00 [received] PHST- 2026/06/27 00:00 [revised] PHST- 2026/06/29 00:00 [accepted] PHST- 2026/07/28 06:38 [medline] PHST- 2026/07/28 06:37 [pubmed] PHST- 2026/07/28 01:10 [entrez] PHST- 2026/07/09 00:00 [pmc-release] AID - biomedicines14071539 [pii] AID - biomedicines-14-01539 [pii] AID - 10.3390/biomedicines14071539 [doi] PST - epublish SO - Biomedicines. 2026 Jul 9;14(7):1539. doi: 10.3390/biomedicines14071539. PMID- 42510137 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260729 LR - 20260813 IS - 2075-4418 (Print) IS - 2075-4418 (Electronic) IS - 2075-4418 (Linking) VI - 16 IP - 14 DP - 2026 Jul 21 TI - Hybrid Operating Room Applications in Otolaryngology: A Seven-Year Single-Center Experience with Image-Guided and Multidisciplinary Procedures. LID - 10.3390/diagnostics16142273 [doi] LID - 2273 AB - Background/Objectives: Hybrid operating rooms combine advanced intraoperative imaging, endovascular capabilities, and multidisciplinary resources within a single procedural environment. However, their use in otolaryngology remains insufficiently characterized. This study evaluated institutional patterns of hybrid operating room use, principal clinical indications, multidisciplinary involvement, and perioperative resource utilization in otolaryngology. Methods: We conducted a retrospective single-center study of eligible otolaryngologic procedures performed between 1 October 2018 and 31 December 2025. Patient characteristics, operative sites, hybrid operating room applications, multidisciplinary involvement, intraoperative blood loss, postoperative intensive care unit admission, and length of hospital stay were analyzed. Results: A total of 55 unique procedures were included. The median age was 46.0 years (interquartile range, 33.0-58.5 years; range, 5-76 years), and 33 patients (60.0%) were male. Computed tomography-based localization and navigation represented the predominant application, accounting for nearly three-quarters of procedures. The sinonasal cavity, nasopharynx, and skull base were the most frequently treated anatomical regions, comprising approximately 60% of operative sites. Angiography and endovascular intervention constituted the second most common application. Multidisciplinary collaboration, most frequently involving cardiovascular surgery and interventional radiology, was required in nearly one-quarter of procedures. Procedures relying primarily on intraoperative imaging were associated with a median estimated blood loss of 20 mL and a median hospital stay of 3 days. Cases requiring vascular, cardiopulmonary, or other advanced hybrid capabilities showed greater postoperative resource utilization, including more frequent intensive care admission and longer hospitalization. Conclusions: The hybrid operating room served as a versatile platform for image-guided, vascular, and multidisciplinary procedures in otolaryngology. Its capabilities were used during the management of anatomically complex and high-acuity cases, while differences in postoperative resource utilization appeared to reflect procedural complexity and baseline clinical risk. FAU - Huang, Tzu-Chen AU - Huang TC AD - Department of Otolaryngology, Tungs' Taichung MetroHarbor Hospital, Taichung 435403, Taiwan. FAU - Hung, Hao-Chun AU - Hung HC AD - Department of Medical Imaging, Tungs' Taichung MetroHarbor Hospital, Taichung 435403, Taiwan. FAU - Yeh, Shu-Wei AU - Yeh SW AD - Department of Medical Education, Tungs' Taichung MetroHarbor Hospital, Taichung 435403, Taiwan. FAU - Pan, Chang-Yo AU - Pan CY AD - Department of Medical Education, Tungs' Taichung MetroHarbor Hospital, Taichung 435403, Taiwan. FAU - Nian, Mei-Wen AU - Nian MW AUID- ORCID: 0000-0003-0665-9538 AD - Department of Otolaryngology, Tungs' Taichung MetroHarbor Hospital, Taichung 435403, Taiwan. AD - Department of Medical Research, Tungs' Taichung MetroHarbor Hospital, Taichung 435403, Taiwan. FAU - Lin, Iva AU - Lin I AD - Teachers College, Columbia University, New York, NY 10027, USA. FAU - Chen, Chung-Hsiung AU - Chen CH AD - Department of Otolaryngology, Tungs' Taichung MetroHarbor Hospital, Taichung 435403, Taiwan. FAU - Tsai, Stella Chin-Shaw AU - Tsai SC AUID- ORCID: 0000-0003-2694-1207 AD - Department of Otolaryngology, Tungs' Taichung MetroHarbor Hospital, Taichung 435403, Taiwan. AD - Department of Post-Baccalaureate Medicine, National Chung Hsing University, Taichung 402202, Taiwan. LA - eng GR - TTMHH-R1150070/Tungs' Taichung MetroHarbor Hospital/ PT - Journal Article DEP - 20260721 PL - Switzerland TA - Diagnostics (Basel) JT - Diagnostics (Basel, Switzerland) JID - 101658402 PMC - PMC13408605 OTO - NOTNLM OT - endovascular intervention OT - hybrid operating room OT - image-guided surgery OT - intraoperative imaging OT - multidisciplinary care OT - otolaryngology COIS- The authors declare no conflicts of interest. EDAT- 2026/07/28 06:37 MHDA- 2026/07/28 06:38 PMCR- 2026/07/21 CRDT- 2026/07/28 01:02 PHST- 2026/06/17 00:00 [received] PHST- 2026/07/15 00:00 [revised] PHST- 2026/07/19 00:00 [accepted] PHST- 2026/07/28 06:38 [medline] PHST- 2026/07/28 06:37 [pubmed] PHST- 2026/07/28 01:02 [entrez] PHST- 2026/07/21 00:00 [pmc-release] AID - diagnostics16142273 [pii] AID - diagnostics-16-02273 [pii] AID - 10.3390/diagnostics16142273 [doi] PST - epublish SO - Diagnostics (Basel). 2026 Jul 21;16(14):2273. doi: 10.3390/diagnostics16142273. PMID- 42508842 OWN - NLM STAT- MEDLINE DCOM- 20260728 LR - 20260731 IS - 1876-7605 (Electronic) IS - 1936-8798 (Linking) VI - 19 IP - 14 DP - 2026 Jul 27 TI - A Multidomain Lifestyle Intervention for Invasively Confirmed ANOCA: The SAMCRO Randomized Trial. PG - 1864-1875 LID - S1936-8798(26)01821-2 [pii] LID - 10.1016/j.jcin.2026.05.021 [doi] AB - BACKGROUND: Angina with no obstructive coronary artery disease (ANOCA) is associated with persistent symptoms and impaired quality of life. Although guidelines advocate a patient-centered, multidisciplinary approach, randomized evidence is lacking. OBJECTIVES: The aim of this study was to determine whether a multidomain lifestyle intervention improves patient-reported health status and quality of life in patients with ANOCA. METHODS: SAMCRO was a prospective, multicenter, randomized trial with blinded endpoint assessment. Patients with angina and invasive evidence of coronary microvascular dysfunction and/or coronary vasomotor disorder were randomized 1:1 to endotype-guided therapy plus a structured multidomain lifestyle intervention (intervention group) or endotype-guided therapy alone (control group). The intervention integrated exercise training, Mediterranean dietary counseling, and psychological support. The primary endpoint was the change in Seattle Angina Questionnaire summary score. RESULTS: A total of 123 patients were randomized (62 to intervention and 61 to control), with follow-up completed at 12 months for the primary endpoint. The mean age was 65.8 +/- 9 years, and 46% were women. The adjusted mean improvement in Seattle Angina Questionnaire summary score was significantly greater in the intervention group (between-group difference: 13.12 points; 95% CI: 9.68-16.56; P < 0.001). A clinically meaningful improvement (>/=10-point increase) was achieved in 48 (77%) versus 23 (38%) of patients, respectively (adjusted risk ratio: 1.98; 95% CI: 1.20-3.26; P < 0.001). Significant improvements were also observed in the EuroQol 5-Dimension 5-Level index and Beck Depression Inventory scores. CONCLUSIONS: In patients with invasively confirmed ANOCA, a structured multidomain lifestyle intervention provided clinically meaningful improvements in patient-reported health status on top of endotype-guided medical therapy. REGISTRATION: (Standardizing the Management of Patients With Coronary Microvascular Dysfunction [SAMCRO]; NCT06025994). CI - Copyright (c) 2026 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. FAU - Caglioni, Serena AU - Caglioni S AD - Cardiology Unit, Azienda Ospedaliero Universitaria di Ferrara, Ferrara, Italy. FAU - Raisi, Andrea AU - Raisi A AD - Center for Exercise Science and Sport, University of Ferrara, Ferrara, Italy. FAU - Erriquez, Andrea AU - Erriquez A AD - Cardiology Unit, Azienda Ospedaliero Universitaria di Ferrara, Ferrara, Italy. FAU - Piva, Tommaso AU - Piva T AD - Center for Exercise Science and Sport, University of Ferrara, Ferrara, Italy. FAU - Cocco, Marta AU - Cocco M AD - Cardiology Unit, Azienda Ospedaliero Universitaria di Ferrara, Ferrara, Italy. FAU - Zerbini, Valentina AU - Zerbini V AD - Center for Exercise Science and Sport, University of Ferrara, Ferrara, Italy. FAU - Farina, Jacopo AU - Farina J AD - Cardiology Unit, Azienda Ospedaliero Universitaria di Ferrara, Ferrara, Italy. FAU - Menegatti, Erica AU - Menegatti E AD - Center for Exercise Science and Sport, University of Ferrara, Ferrara, Italy. FAU - Sarti, Alberto AU - Sarti A AD - Cardiology Unit, Azienda Ospedaliero Universitaria di Ferrara, Ferrara, Italy. FAU - Mandini, Simona AU - Mandini S AD - Center for Exercise Science and Sport, University of Ferrara, Ferrara, Italy. FAU - Cantone, Anna AU - Cantone A AD - Cardiology Unit, Azienda Ospedaliero Universitaria di Ferrara, Ferrara, Italy. FAU - Grazzi, Nicola AU - Grazzi N AD - ABCardio Health and Fitness, Bologna, Italy; Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy. FAU - Pavasini, Rita AU - Pavasini R AD - Cardiology Unit, Azienda Ospedaliero Universitaria di Ferrara, Ferrara, Italy. FAU - Mazzoni, Gianni AU - Mazzoni G AD - Center for Exercise Science and Sport, University of Ferrara, Ferrara, Italy. FAU - Biscaglia, Simone AU - Biscaglia S AD - Cardiology Unit, Azienda Ospedaliero Universitaria di Ferrara, Ferrara, Italy. FAU - Gurgoglione, Filippo Luca AU - Gurgoglione FL AD - Division of Cardiology, University of Parma, Parma University Hospital, Parma, Italy. FAU - Lazzeroni, Davide AU - Lazzeroni D AD - IRCCS Fondazione Don Carlo Gnocchi, Milan, Italy. FAU - Martella, Donato AU - Martella D AD - We4 Clinical Research, Milan, Italy. FAU - Leone, Antonio Maria AU - Leone AM AD - Center of Excellence in Cardiovascular Sciences Ospedale Isola Tiberina, Gemelli Isola Universita Cattolica del Sacro Cuore, Roma, Italy. FAU - Grazzi, Giovanni AU - Grazzi G AD - Center for Exercise Science and Sport, University of Ferrara, Ferrara, Italy. FAU - Niccoli, Giampaolo AU - Niccoli G AD - Division of Cardiology, University of Parma, Parma University Hospital, Parma, Italy. FAU - Campo, Gianluca AU - Campo G AD - Cardiology Unit, Azienda Ospedaliero Universitaria di Ferrara, Ferrara, Italy. Electronic address: cmpglc@unife.it. LA - eng SI - ClinicalTrials.gov/NCT06025994 PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't PL - United States TA - JACC Cardiovasc Interv JT - JACC. Cardiovascular interventions JID - 101467004 SB - IM MH - Humans MH - Female MH - Treatment Outcome MH - Male MH - Aged MH - *Risk Reduction Behavior MH - Time Factors MH - Middle Aged MH - Prospective Studies MH - Quality of Life MH - *Angina Pectoris/therapy/physiopathology/diagnosis/psychology MH - Health Status MH - *Counseling MH - *Healthy Lifestyle MH - *Exercise Therapy/adverse effects MH - *Coronary Artery Disease/therapy/physiopathology/diagnosis MH - Patient Reported Outcome Measures MH - Diet, Healthy OTO - NOTNLM OT - Vasospasm OT - angina with no obstructive coronary artery disease OT - coronary microvascular dysfunction OT - multidomain lifestyle intervention OT - patient reported outcome measures COIS- Funding Support and Author Disclosures Abbott Vascular provided unrestricted funding to the study sponsor for the conduction of the trial. The company had no involvement in the trial design, data collection, analysis, interpretation, or writing of the manuscript. Dr Biscaglia has received personal fees from Abbott Vascular and Siemens Healthcare, outside the submitted work. Dr Campo has received research grants and personal fees from Abbott Vascular, GADA, Menarini, Amgen, Daiichi-Sankyo, and Sanofi, outside the submitted work. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2026/07/28 00:36 MHDA- 2026/07/28 06:37 CRDT- 2026/07/27 20:53 PHST- 2026/03/23 00:00 [received] PHST- 2026/04/21 00:00 [revised] PHST- 2026/05/18 00:00 [accepted] PHST- 2026/07/28 06:37 [medline] PHST- 2026/07/28 00:36 [pubmed] PHST- 2026/07/27 20:53 [entrez] AID - S1936-8798(26)01821-2 [pii] AID - 10.1016/j.jcin.2026.05.021 [doi] PST - ppublish SO - JACC Cardiovasc Interv. 2026 Jul 27;19(14):1864-1875. doi: 10.1016/j.jcin.2026.05.021. PMID- 42508381 OWN - NLM STAT- MEDLINE DCOM- 20260903 LR - 20260903 IS - 1879-0372 (Electronic) IS - 0952-7915 (Linking) VI - 102 DP - 2026 Oct TI - Cardiac sarcoidosis: from early recognition to management. PG - 102831 LID - S0952-7915(26)00108-1 [pii] LID - 10.1016/j.coi.2026.102831 [doi] AB - Cardiac sarcoidosis is a potentially fatal inflammatory disorder with the tendency to mostly affect the myocardial tissues. It is commonly associated with extra-cardiac structures such as the lungs and the thoracic lymph nodes; however, when it manifests as an isolated disease, it can be insidious. The clinical presentation is variable depending on the location and extent of the cardiac tissues involved, including asymptomatic cases, conduction abnormalities, arrhythmia, heart failure and sudden cardiac death (SCD). It is an enigmatic disease to diagnose owing to the variable clinical presentation; as a result, most centres are adopting a multidisciplinary approach to diagnosis, risk stratification and management. The mainstay of treatment in CS is immunosuppression, guideline-directed medical therapy for patients with heart failure in addition to device therapy for individuals at high risk of SCD, and heart transplantation for patients with advanced heart failure. We synthesise the existing evidence in the diagnosis and management of cardiac sarcoidosis in our review. CI - Copyright (c) 2026 Elsevier Ltd. All rights reserved. FAU - Umeojiako, Wilfred Ifeanyi AU - Umeojiako WI AD - Royal Brompton and Harefield Hospitals, part of Guy's and St Thomas' NHS Foundation Trust, UK. FAU - Kouranos, Vasileios AU - Kouranos V AD - Royal Brompton and Harefield Hospitals, part of Guy's and St Thomas' NHS Foundation Trust, UK; King's College London School of Cardiovascular Medicine and Sciences, UK; National Heart and Lung Institute, Imperial College London, London, UK. FAU - Sharma, Rakesh AU - Sharma R AD - Royal Brompton and Harefield Hospitals, part of Guy's and St Thomas' NHS Foundation Trust, UK; King's College London School of Cardiovascular Medicine and Sciences, UK; National Heart and Lung Institute, Imperial College London, London, UK. Electronic address: Rakesh.sharma4@nhs.net. LA - eng PT - Journal Article PT - Review DEP - 20260727 PL - England TA - Curr Opin Immunol JT - Current opinion in immunology JID - 8900118 SB - IM MH - Humans MH - *Sarcoidosis/diagnosis/therapy MH - *Cardiomyopathies/diagnosis/therapy/etiology MH - Animals MH - Disease Management MH - Early Diagnosis MH - Heart Transplantation MH - Death, Sudden, Cardiac COIS- Declaration of Competing Interest All authors have nothing to declare in relation to this work. EDAT- 2026/07/28 00:36 MHDA- 2026/09/03 23:36 CRDT- 2026/07/27 18:09 PHST- 2026/05/10 00:00 [received] PHST- 2026/07/10 00:00 [revised] PHST- 2026/07/13 00:00 [accepted] PHST- 2026/09/03 23:36 [medline] PHST- 2026/07/28 00:36 [pubmed] PHST- 2026/07/27 18:09 [entrez] AID - S0952-7915(26)00108-1 [pii] AID - 10.1016/j.coi.2026.102831 [doi] PST - ppublish SO - Curr Opin Immunol. 2026 Oct;102:102831. doi: 10.1016/j.coi.2026.102831. Epub 2026 Jul 27. PMID- 42503629 OWN - NLM STAT- Publisher LR - 20260727 IS - 0310-057X (Print) IS - 0310-057X (Linking) DP - 2026 Jul 26 TI - Carotid blowout with 'can't intubate, can't oxygenate' crisis: Supraglottic surgical airway rescue. PG - 310057X261462196 LID - 10.1177/0310057X261462196 [doi] AB - We describe an out-of-theatre hypoxic cardiac arrest precipitated by spontaneous carotid blowout syndrome, resulting in massive haemorrhage with airway contamination and a 'can't intubate, can't oxygenate' crisis. Emergency front-of-neck access (eFONA) using a scalpel-bougie technique unintentionally traversed the thyrohyoid membrane; however, this fortuitously enabled effective oxygenation and return of spontaneous circulation. Ongoing oropharyngeal haemorrhage was stabilised with packing and haemostatic resuscitation prior to definitive endovascular repair of an internal carotid pseudoaneurysm. This case demonstrates that an unintended thyrohyoidotomy, although not recommended, may function as a viable eFONA route in extremis, and highlights that temporary packing should be considered as part of a multidisciplinary approach to the management of major airway bleeding. FAU - Birkett, William T AU - Birkett WT AUID- ORCID: 0000-0001-7668-6537 AD - Department of Anaesthesia and Perioperative Medicine, Monash Health, Melbourne, Australia. AD - Department of Surgery, School of Clinical Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia. FAU - Martis, Walston R AU - Martis WR AUID- ORCID: 0009-0003-3720-914X AD - Department of Anaesthesia and Perioperative Medicine, Monash Health, Melbourne, Australia. AD - Department of Surgery, School of Clinical Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia. AD - Department of Anaesthesia, Perioperative and Pain Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia. AD - Department of Critical Care, University of Melbourne, Melbourne, Australia. FAU - O'Halloran, Luke AU - O'Halloran L AD - Department of Anaesthesia and Perioperative Medicine, Monash Health, Melbourne, Australia. LA - eng PT - Journal Article DEP - 20260726 PL - United States TA - Anaesth Intensive Care JT - Anaesthesia and intensive care JID - 0342017 SB - IM OTO - NOTNLM OT - Difficult airway OT - airway emergency OT - emergency front-of-neck access OT - remote anaesthesia OT - tracheostomy EDAT- 2026/07/27 06:34 MHDA- 2026/07/27 06:34 CRDT- 2026/07/27 00:44 PHST- 2026/07/27 06:34 [medline] PHST- 2026/07/27 06:34 [pubmed] PHST- 2026/07/27 00:44 [entrez] AID - 10.1177/0310057X261462196 [doi] PST - aheadofprint SO - Anaesth Intensive Care. 2026 Jul 26:310057X261462196. doi: 10.1177/0310057X261462196. PMID- 42503540 OWN - NLM STAT- MEDLINE DCOM- 20260726 LR - 20261010 IS - 1863-2491 (Electronic) IS - 1863-2483 (Linking) VI - 20 IP - 1 DP - 2026 Jul 27 TI - Evolution of coronary artery bypass grafting: conventional, minimally invasive, robotic, and hybrid revascularisation techniques. LID - 761 [pii] LID - 10.1007/s11701-026-03737-3 [doi] AB - Coronary artery bypass grafting (CABG) remains one of the most durable treatments for obstructive coronary artery disease (CAD), particularly in anatomically complex multivessel disease, diabetes, left main disease and ischaemic cardiomyopathy. During the last three decades, the conventional operation performed through median sternotomy with cardiopulmonary bypass has been complemented by off-pump, minimally invasive direct coronary artery bypass (MIDCAB), multivessel minimally invasive coronary surgery, robotic-assisted CABG, totally endoscopic CABG (TECAB) and hybrid coronary revascularisation (HCR). This narrative review summarises the evolution of CABG, compares conventional and minimally invasive approaches, and discusses current evidence, indications, limitations, implementation challenges, future directions and a practical decision algorithm for patient selection. A narrative literature review was conducted using PubMed/MEDLINE, Google Scholar, major cardiology and cardiothoracic guideline documents, and recent open-access reviews and meta-analyses published up to June 2026. Priority was given to contemporary guidelines, landmark trials, systematic reviews, meta-analyses and large observational series. Because this is a narrative review, no formal pooled analysis or risk-of-bias grading was performed. Conventional CABG provides reliable complete revascularisation and remains the preferred strategy for many patients with complex multivessel CAD. The survival value of the left internal mammary artery to left anterior descending artery graft underpins both conventional and minimally invasive strategies. MIDCAB is most established for isolated LAD disease and as the surgical component of HCR. Robotic-assisted CABG and TECAB reduce access trauma and may improve recovery, transfusion requirements and wound morbidity, but they require dedicated training, a specialised team and a high-volume programme to overcome the learning curve. HCR offers a biologically attractive compromise by combining durable LIMA-LAD bypass with PCI to non-LAD vessels, yet randomised evidence remains limited. The proposed algorithm translates these data into a clinically practical Heart Team pathway rather than a purely technique-centred comparison. The future of CABG is not a replacement of conventional surgery by a single minimally invasive method, but a personalised revascularisation strategy selected by a Heart Team. The most clinically relevant question is not whether one technique is universally superior, but which patient, coronary anatomy and institutional environment are best suited to conventional CABG, MIDCAB, robotic/TECAB or HCR. CI - (c) 2026. The Author(s), under exclusive licence to Springer-Verlag London Ltd., part of Springer Nature. FAU - Muafa, Hussein Mussa AU - Muafa HM AUID- ORCID: 0000-0002-5290-025X AD - Department of Surgery, 21 September University for Medical and Applied Sciences, Sana'a, Yemen. h.m.muafa@gmail.com. LA - eng PT - Journal Article PT - Review DEP - 20260727 PL - England TA - J Robot Surg JT - Journal of robotic surgery JID - 101300401 SB - IM MH - Humans MH - *Robotic Surgical Procedures/methods/trends MH - *Coronary Artery Bypass/methods/trends MH - *Minimally Invasive Surgical Procedures/methods/trends MH - *Coronary Artery Disease/surgery OTO - NOTNLM OT - CABG OT - Coronary artery bypass grafting OT - Coronary artery disease OT - Hybrid coronary revascularisation OT - Left anterior descending artery OT - Left internal mammary artery OT - MIDCAB OT - Minimally invasive cardiac surgery OT - Robotic CABG OT - TECAB COIS- Declarations. Competing interests: The authors declare no competing interests. Ethics approval and consent to participate: Not applicable. This is a narrative review of previously published literature. Consent for publication: Not applicable. EDAT- 2026/07/27 00:34 MHDA- 2026/07/27 00:35 CRDT- 2026/07/26 23:25 PHST- 2026/06/24 00:00 [received] PHST- 2026/07/15 00:00 [accepted] PHST- 2026/07/27 00:35 [medline] PHST- 2026/07/27 00:34 [pubmed] PHST- 2026/07/26 23:25 [entrez] AID - 10.1007/s11701-026-03737-3 [pii] AID - 10.1007/s11701-026-03737-3 [doi] PST - epublish SO - J Robot Surg. 2026 Jul 27;20(1):761. doi: 10.1007/s11701-026-03737-3. PMID- 42503500 OWN - NLM STAT- MEDLINE DCOM- 20260730 LR - 20260828 IS - 2055-5822 (Electronic) IS - 2055-5822 (Linking) VI - 13 IP - 4 DP - 2026 Jul 4 TI - Study design of the EDGEFIRM trial: transcatheter edge-to-edge repair versus guideline-directed medical therapy in atrial functional mitral regurgitation and HFpEF. LID - 10.1093/eschf/xvag203 [doi] LID - xvag203 AB - INTRODUCTION: Over the past decade, mitral valve transcatheter edge-to-edge repair (M-TEER) has become an established interventional treatment option for functional mitral regurgitation. One subtype that has recently gained increasing scientific attention is atrial functional mitral regurgitation (aFMR) occurring in patients with heart failure (HF) with preserved ejection fraction (HFpEF). Randomized trials to date have largely excluded patients with HFpEF, leading to limited data in this cohort. STUDY DESIGN: The randomized evaluation of transcatheter edge-to-edge repair in patients with atrial functional mitral regurgitation and HF with preserved ejection fraction compared with GDMT (EDGEFIRM) is a prospective, open-label, randomized, multicentre trial evaluating the additive effect of M-TEER in patients with aFMR and HFpEF compared to guideline-directed medical therapy (GDMT) only. Eligible patients must be symptomatic under stable GDMT with significant aFMR (>grade II or grade II with hemodynamic relevance) and HFpEF and considered high risk for surgical therapy by Heart Team evaluation. Randomization will be conducted in a 2:1 manner M-TEER + GDMT vs GDMT only. The primary combined endpoint consists of cardiovascular mortality, HF hospitalization/worsening HF, improvement <10 points in KCCQ-Score after 1 year. Secondary endpoints include reduction of mitral regurgitation, device safety, functional capacity as well as the individual components of the combined endpoint. DISCUSSION: The EDGEFIRM trial aims to evaluate the additive effect of M-TEER compared with GDMT only in patients with symptomatic aFMR and HFpEF. CI - (c) The Author(s) 2026. Published by Oxford University Press on behalf of the European Society of Cardiology. FAU - Ozturk, Can AU - Ozturk C AUID- ORCID: 0000-0002-5419-2488 AD - Department of Cardiology, Heart Centre, University Hospital Bonn, Bonn, Germany. FAU - Bohm, Lukas AU - Bohm L AD - Department of Cardiology, Heart Centre, University Hospital Bonn, Bonn, Germany. FAU - Altintac, Enes AU - Altintac E AD - Department of Cardiology, Heart Centre, University Hospital Bonn, Bonn, Germany. FAU - Vogelhuber, Johanna AU - Vogelhuber J AUID- ORCID: 0000-0002-2568-8812 AD - Department of Cardiology, Heart Centre, University Hospital Bonn, Bonn, Germany. FAU - Weber, Marcel AU - Weber M AD - Department of Cardiology, Heart Centre, University Hospital Bonn, Bonn, Germany. FAU - Zimmer, Sebastian AU - Zimmer S AUID- ORCID: 0000-0002-1531-2088 AD - Department of Cardiology, Heart Centre, University Hospital Bonn, Bonn, Germany. FAU - Nickenig, Georg AU - Nickenig G AD - Department of Cardiology, Heart Centre, University Hospital Bonn, Bonn, Germany. LA - eng GR - Abbott/ PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial PL - England TA - ESC Heart Fail JT - ESC heart failure JID - 101669191 SB - IM MH - Humans MH - *Mitral Valve Insufficiency/surgery/physiopathology/complications/diagnosis MH - *Stroke Volume/physiology MH - *Heart Failure/complications/physiopathology MH - Prospective Studies MH - *Cardiac Catheterization/methods MH - Treatment Outcome MH - *Heart Atria/physiopathology MH - *Practice Guidelines as Topic MH - Follow-Up Studies PMC - PMC13412382 OTO - NOTNLM OT - Atrial functional mitral regurgitation OT - Heart failure OT - Preserved ejection fraction OT - Transcatheter edge-to-edge repair EDAT- 2026/07/27 00:34 MHDA- 2026/07/30 18:36 PMCR- 2026/07/18 CRDT- 2026/07/26 23:02 PHST- 2026/07/06 00:00 [received] PHST- 2026/07/15 00:00 [accepted] PHST- 2026/07/30 18:36 [medline] PHST- 2026/07/27 00:34 [pubmed] PHST- 2026/07/26 23:02 [entrez] PHST- 2026/07/18 00:00 [pmc-release] AID - 8742131 [pii] AID - xvag203 [pii] AID - 10.1093/eschf/xvag203 [doi] PST - ppublish SO - ESC Heart Fail. 2026 Jul 4;13(4):xvag203. doi: 10.1093/eschf/xvag203. PMID- 42499650 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260725 LR - 20260813 IS - 2950-1334 (Electronic) IS - 2950-1334 (Linking) VI - 13 DP - 2026 Aug TI - Cardiogenic shock in pregnancy: Prolonged axillary Impella 5.5 support during pregnancy and postpartum as bridge to heart transplantation. PG - 100620 LID - 10.1016/j.jhlto.2026.100620 [doi] LID - 100620 AB - BACKGROUND: Cardiogenic shock during pregnancy carries substantial maternal and fetal morbidity and mortality, and guidance on temporary mechanical circulatory support (tMCS) in this setting remains limited. CASE SUMMARY: A 36-year-old woman at 21 weeks' gestation presented with severe dilated cardiomyopathy (ejection fraction 20%, LVIDd 8.0 cm), cardiogenic shock (cardiac index 1.7 L/min/m(2)), and recurrent ventricular arrhythmias. She declined termination of pregnancy. An axillary Impella 5.5 was placed for hemodynamic stabilization with rapid improvement in cardiac output and filling pressures. Progressive ventricular arrhythmias at 23 weeks and 3 days necessitated urgent cesarean delivery; the neonate did not survive. The patient was supported with the Impella 5.5 for 66 days and underwent successful orthotopic heart transplantation. DISCUSSION: To our knowledge, this is one of the longest reported durations of Impella 5.5 support initiated during pregnancy and continued into the postpartum period. This case highlights important considerations that may inform individualized multidisciplinary decision-making on temporary mechanical circulatory support selection in pregnancy-associated cardiogenic shock. CI - (c) 2026 The Author(s). FAU - Laks, Shahar AU - Laks S AD - Department of Maternal-Fetal Medicine, Atrium Health, Charlotte, North Carolina. FAU - Pierce-Williams, Rebecca AU - Pierce-Williams R AD - Department of Maternal-Fetal Medicine, Atrium Health, Charlotte, North Carolina. FAU - Connors, Ngina AU - Connors N AD - Department of Maternal-Fetal Medicine, Atrium Health, Charlotte, North Carolina. FAU - Brown, Kelecia AU - Brown K AD - Department of Maternal-Fetal Medicine, Atrium Health, Charlotte, North Carolina. FAU - Philips, Jennifer AU - Philips J AD - Department of Maternal-Fetal Medicine, Atrium Health, Charlotte, North Carolina. FAU - Holmes, Diane AU - Holmes D AD - Department of Cardiovascular Medicine, Atrium Health Sanger Heart & Vascular Institute, Charlotte, North Carolina. FAU - Canha, Catarina AU - Canha C AD - Department of Cardiovascular Medicine, Atrium Health Sanger Heart & Vascular Institute, Charlotte, North Carolina. FAU - Cyrille-Superville, Nicole AU - Cyrille-Superville N AD - Department of Cardiovascular Medicine, Atrium Health Sanger Heart & Vascular Institute, Charlotte, North Carolina. FAU - Kim, Esther AU - Kim E AD - Department of Cardiovascular Medicine, Atrium Health Sanger Heart & Vascular Institute, Charlotte, North Carolina. FAU - Oye, Monique AU - Oye M AD - Department of Cardiovascular Medicine, Atrium Health Sanger Heart & Vascular Institute, Charlotte, North Carolina. LA - eng PT - Journal Article DEP - 20260630 PL - United States TA - JHLT Open JT - JHLT open JID - 9918716187806676 PMC - PMC13396756 OTO - NOTNLM OT - advanced heart failure OT - cardio-obstetrics OT - impella OT - mechanical circulatory support OT - permpartum cardiomyopathy OT - pregnancy OT - transplant COIS- The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/07/25 06:36 MHDA- 2026/07/25 06:37 PMCR- 2026/06/30 CRDT- 2026/07/25 04:57 PHST- 2026/07/25 06:37 [medline] PHST- 2026/07/25 06:36 [pubmed] PHST- 2026/07/25 04:57 [entrez] PHST- 2026/06/30 00:00 [pmc-release] AID - S2950-1334(26)00141-2 [pii] AID - 100620 [pii] AID - 10.1016/j.jhlto.2026.100620 [doi] PST - epublish SO - JHLT Open. 2026 Jun 30;13:100620. doi: 10.1016/j.jhlto.2026.100620. eCollection 2026 Aug. PMID- 42499544 OWN - NLM STAT- MEDLINE DCOM- 20260725 LR - 20260813 IS - 2235-2988 (Electronic) IS - 2235-2988 (Linking) VI - 16 DP - 2026 TI - Emerging insights into infective endocarditis in the era of transcatheter aortic valve implantation. PG - 1822120 LID - 10.3389/fcimb.2026.1822120 [doi] LID - 1822120 AB - With the rapid expansion of transcatheter aortic valve implantation (TAVI), infective endocarditis (IE) involving transcatheter prostheses has emerged as a major clinical challenge associated with high morbidity and mortality. Although the overall incidence of TAVI-associated IE remains relatively low, outcomes are poor, particularly in elderly and frail patients with multiple comorbidities. Importantly, TAVI-associated IE differs from surgical prosthetic valve endocarditis in several aspects, including patient profile, microbiological characteristics, imaging findings, and therapeutic management. This contemporary review summarizes recent evidence regarding the epidemiology, microbiology, multimodality imaging, management strategies, and prognosis of IE following TAVI. Particular emphasis is placed on the prominent role of enterococci, the limitations of conventional echocardiography, and the growing importance of multimodality imaging techniques such as cardiac CT and [(1)(8)F]-FDG PET/CT for diagnosis and detection of perivalvular complications. Current evidence regarding surgical versus conservative management remains limited and strongly influenced by patient selection and operative risk, making individualized Heart Team decision-making essential. Despite advances in transcatheter therapies and imaging modalities, TAVI-associated IE continues to carry very high short- and long-term mortality. Improved preventive strategies, earlier diagnosis, optimized multimodality imaging algorithms, and better selection of patients for surgical intervention are needed to improve outcomes in this high-risk population. CI - Copyright (c) 2026 Dadarlat-Pop, Serban, Molnar, Oprea, Tomoaia, Mot, Mot and Rosianu. FAU - Dadarlat-Pop, Alexandra AU - Dadarlat-Pop A AD - Cardiology Department, Heart Institute Niculae Stancioiu, Cluj-Napoca, Romania. AD - Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania. FAU - Serban, Adela AU - Serban A AD - Cardiology Department, Heart Institute Niculae Stancioiu, Cluj-Napoca, Romania. AD - Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania. FAU - Molnar, Adrian AU - Molnar A AD - Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania. AD - Cardiovascular Surgery Department, Heart Institute Niculae Stancioiu, Cluj-Napoca, Romania. FAU - Oprea, Alexandru AU - Oprea A AD - Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania. AD - Cardiovascular Surgery Department, Heart Institute Niculae Stancioiu, Cluj-Napoca, Romania. FAU - Tomoaia, Raluca AU - Tomoaia R AD - Cardiology Department, Heart Institute Niculae Stancioiu, Cluj-Napoca, Romania. AD - Cardiology Department, Rehabilitation Hospital, Cluj-Napoca, Romania. FAU - Mot, Stefan-Dan AU - Mot SD AD - Cardiology Department, Heart Institute Niculae Stancioiu, Cluj-Napoca, Romania. AD - Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania. FAU - Mot, Iulia Dorli Demetra AU - Mot IDD AD - Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania. FAU - Rosianu, Horia AU - Rosianu H AD - Cardiology Department, Heart Institute Niculae Stancioiu, Cluj-Napoca, Romania. AD - Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania. LA - eng PT - Journal Article PT - Review DEP - 20260710 PL - Switzerland TA - Front Cell Infect Microbiol JT - Frontiers in cellular and infection microbiology JID - 101585359 SB - IM MH - Humans MH - *Transcatheter Aortic Valve Replacement/adverse effects MH - *Endocarditis/epidemiology/therapy/diagnosis/microbiology MH - *Prosthesis-Related Infections/epidemiology/microbiology/diagnosis/therapy MH - *Endocarditis, Bacterial/epidemiology/diagnosis/therapy/microbiology MH - Prognosis MH - Heart Valve Prosthesis/microbiology/adverse effects MH - Echocardiography MH - Risk Factors MH - Multimodal Imaging PMC - PMC13397106 OTO - NOTNLM OT - controversial management OT - high surgical risk OT - infective endocarditis OT - particularities OT - percutaneous aortic valve implantation COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/07/25 06:36 MHDA- 2026/07/25 06:37 PMCR- 2026/07/10 CRDT- 2026/07/25 04:56 PHST- 2026/03/03 00:00 [received] PHST- 2026/05/18 00:00 [revised] PHST- 2026/06/09 00:00 [accepted] PHST- 2026/07/25 06:37 [medline] PHST- 2026/07/25 06:36 [pubmed] PHST- 2026/07/25 04:56 [entrez] PHST- 2026/07/10 00:00 [pmc-release] AID - 10.3389/fcimb.2026.1822120 [doi] PST - epublish SO - Front Cell Infect Microbiol. 2026 Jul 10;16:1822120. doi: 10.3389/fcimb.2026.1822120. eCollection 2026. PMID- 42498673 OWN - NLM STAT- Publisher LR - 20260724 IS - 1555-9823 (Electronic) IS - 0003-1348 (Linking) DP - 2026 Jul 24 TI - Blunt Splenic Injury in Hemophilia A: Embolic Agent Selection When Hemostasis Cannot be Assumed. PG - 31348261471468 LID - 10.1177/00031348261471468 [doi] AB - Blunt splenic injury in a patient with hemophilia A presents a dilemma that has traditionally been settled by splenectomy. Removing the spleen leaves a patient already prone to bleeding without its immune function, and the factor VIII (FVIII) exposure that open surgery requires is itself a recognized trigger for inhibitor formation. In the general trauma population, nonoperative management is now the standard for hemodynamically stable patients: observation suffices in most, and splenic artery embolization is reserved for higher-risk injuries. Patients with inherited coagulopathy, however, sit outside the trials and guidelines that built this paradigm. We present a 66-year-old man with mild hemophilia A (FVIII activity 13%), cardiac comorbidity, and a plasma allergy who sustained a blunt splenic laceration graded as American Association for the Surgery of Trauma (AAST) Grade II. No interim computed tomography was obtained; by hospital day 3, selective angiography showed an arteriovenous fistula that had been absent at presentation, a delayed vascular complication of the original injury. Coils and particulate agents failed to achieve occlusion, whereas a 1:3 N-butyl cyanoacrylate (NBCA)-lipiodol mixture produced immediate and complete vessel sealing via coagulation-independent polymerization. Using this case as an anchor, we review nonoperative management of splenic injury across inherited and acquired coagulopathy, compare coagulation-dependent and coagulation-independent embolic agents, and propose a multidisciplinary approach spanning factor replacement, agent selection, and immunoprophylaxis for this underserved population. FAU - Akalin, Cagri AU - Akalin C AD - Department of General Surgery, Ordu University Training and Research Hospital, Ordu, Turkey. RINGGOLD: 187474 FAU - Akkaya, Huseyin AU - Akkaya H AD - Department of Interventional Radiology, Ondokuz Mayis University, Samsun, Turkey. RINGGOLD: 63991 LA - eng PT - Journal Article PT - Review DEP - 20260724 PL - United States TA - Am Surg JT - The American surgeon JID - 0370522 SB - IM OTO - NOTNLM OT - arteriovenous fistula OT - blunt splenic injury OT - hemophilia A OT - nonoperative management OT - splenic artery embolization EDAT- 2026/07/25 00:36 MHDA- 2026/07/25 00:36 CRDT- 2026/07/24 22:02 PHST- 2026/07/25 00:36 [medline] PHST- 2026/07/25 00:36 [pubmed] PHST- 2026/07/24 22:02 [entrez] AID - 10.1177/00031348261471468 [doi] PST - aheadofprint SO - Am Surg. 2026 Jul 24:31348261471468. doi: 10.1177/00031348261471468. PMID- 42496618 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260902 LR - 20260914 IS - 2772-3747 (Electronic) IS - 2772-3747 (Linking) VI - 6 IP - 9 DP - 2026 Sep TI - Transcatheter Edge-to-Edge Repair for Tricuspid Regurgitation: Design and Rationale of the TEER-CHINA Trial. PG - 1959-1968 LID - S2772-3747(26)00441-2 [pii] LID - 10.1016/j.jacasi.2026.06.012 [doi] AB - BACKGROUND: Tricuspid regurgitation (TR) is common, and severe TR independently predicts mortality and heart failure hospitalization, leading to functional impairment and poor quality of life. Optimal medical therapy (OMT), mainly using diuretic agents, provides symptomatic relief but does not correct valvular dysfunction and is often limited by the resistance of diuretic agents. Isolated tricuspid valve surgery remains high risk. Transcatheter options have therefore emerged, with transcatheter edge-to-edge repair (TEER) widely adopted. OBJECTIVES: The Transcatheter Edge-to-Edge Repair for Tricuspid Regurgitation in China (TEER-CHINA) study is designed to evaluate the safety and efficacy of the DragonFly-T System compared with OMT in patients with severe TR. METHODS: The TEER-CHINA trial is a prospective, multicenter, randomized controlled trial (NCT05556460) in which a total of 236 participants will be enrolled across 35 centers in China and randomized 1:1 to the device group or OMT alone. Key inclusion criteria include patients with severe or greater TR (>/=3+) who remain clinically symptomatic despite OMT for at least 30 days, are at intermediate or higher surgical risk for tricuspid valve surgery by the local Heart Team, and are anatomically suitable for use of the investigational device. Participants will be followed up at 30 days, 6 months, 12 months, and annually thereafter for up to 5 years. RESULTS: The primary endpoint is a hierarchical composite assessed at 12 months, including all-cause mortality or tricuspid valve intervention, annualized heart failure hospitalization rates, and improvement in health status measured by the Kansas City Cardiomyopathy Questionnaire. CONCLUSIONS: The TEER-CHINA trial is designed to assess the efficacy and safety of the DragonFly-T System and to inform future treatment strategies for severe TR. CI - Copyright (c) 2026 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Ren, Kaida AU - Ren K AD - Department of Cardiology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China; State Key Laboratory of Transvascular Implantation Devices, Hangzhou, Zhejiang, China; Heart Regeneration and Repair Key Laboratory of Zhejiang province, Hangzhou, Zhejiang, China. FAU - Tan, Boren AU - Tan B AD - Department of Cardiology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China; State Key Laboratory of Transvascular Implantation Devices, Hangzhou, Zhejiang, China; Heart Regeneration and Repair Key Laboratory of Zhejiang province, Hangzhou, Zhejiang, China. FAU - Lin, Xinping AU - Lin X AD - Department of Cardiology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China; State Key Laboratory of Transvascular Implantation Devices, Hangzhou, Zhejiang, China; Heart Regeneration and Repair Key Laboratory of Zhejiang province, Hangzhou, Zhejiang, China. FAU - Pu, Zhaoxia AU - Pu Z AD - Department of Cardiology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China; State Key Laboratory of Transvascular Implantation Devices, Hangzhou, Zhejiang, China; Heart Regeneration and Repair Key Laboratory of Zhejiang province, Hangzhou, Zhejiang, China. FAU - Wang, Lihan AU - Wang L AD - Department of Cardiology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China; State Key Laboratory of Transvascular Implantation Devices, Hangzhou, Zhejiang, China; Heart Regeneration and Repair Key Laboratory of Zhejiang province, Hangzhou, Zhejiang, China. FAU - Hu, Po AU - Hu P AD - Department of Cardiology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China; State Key Laboratory of Transvascular Implantation Devices, Hangzhou, Zhejiang, China; Heart Regeneration and Repair Key Laboratory of Zhejiang province, Hangzhou, Zhejiang, China. FAU - Jiang, Jubo AU - Jiang J AD - Department of Cardiology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China; State Key Laboratory of Transvascular Implantation Devices, Hangzhou, Zhejiang, China; Heart Regeneration and Repair Key Laboratory of Zhejiang province, Hangzhou, Zhejiang, China. FAU - Zhu, QiFeng AU - Zhu Q AD - Department of Cardiology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China; State Key Laboratory of Transvascular Implantation Devices, Hangzhou, Zhejiang, China; Heart Regeneration and Repair Key Laboratory of Zhejiang province, Hangzhou, Zhejiang, China. FAU - Fan, Jiaqi AU - Fan J AD - Department of Cardiology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China; State Key Laboratory of Transvascular Implantation Devices, Hangzhou, Zhejiang, China; Heart Regeneration and Repair Key Laboratory of Zhejiang province, Hangzhou, Zhejiang, China. FAU - He, Yuxin AU - He Y AD - Department of Cardiology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China; State Key Laboratory of Transvascular Implantation Devices, Hangzhou, Zhejiang, China; Heart Regeneration and Repair Key Laboratory of Zhejiang province, Hangzhou, Zhejiang, China. FAU - Guo, Yuchao AU - Guo Y AD - Department of Cardiology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China; State Key Laboratory of Transvascular Implantation Devices, Hangzhou, Zhejiang, China; Heart Regeneration and Repair Key Laboratory of Zhejiang province, Hangzhou, Zhejiang, China. FAU - Liu, Qiong AU - Liu Q AD - Department of Cardiology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China; State Key Laboratory of Transvascular Implantation Devices, Hangzhou, Zhejiang, China; Heart Regeneration and Repair Key Laboratory of Zhejiang province, Hangzhou, Zhejiang, China. FAU - Liang, Jie AU - Liang J AD - Department of Cardiology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China; State Key Laboratory of Transvascular Implantation Devices, Hangzhou, Zhejiang, China; Heart Regeneration and Repair Key Laboratory of Zhejiang province, Hangzhou, Zhejiang, China. FAU - Li, Huajun AU - Li H AD - Department of Cardiology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China; State Key Laboratory of Transvascular Implantation Devices, Hangzhou, Zhejiang, China; Heart Regeneration and Repair Key Laboratory of Zhejiang province, Hangzhou, Zhejiang, China. FAU - Yan, Huixiang AU - Yan H AD - Department of Cardiology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China; State Key Laboratory of Transvascular Implantation Devices, Hangzhou, Zhejiang, China; Heart Regeneration and Repair Key Laboratory of Zhejiang province, Hangzhou, Zhejiang, China. FAU - Hu, Haochang AU - Hu H AD - Department of Cardiology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China; State Key Laboratory of Transvascular Implantation Devices, Hangzhou, Zhejiang, China; Heart Regeneration and Repair Key Laboratory of Zhejiang province, Hangzhou, Zhejiang, China. FAU - Liu, Xianbao AU - Liu X AD - Department of Cardiology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China; State Key Laboratory of Transvascular Implantation Devices, Hangzhou, Zhejiang, China; Heart Regeneration and Repair Key Laboratory of Zhejiang province, Hangzhou, Zhejiang, China; Transvascular Implant Instrument Research Institute, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China; Binjiang Institute of Zhejiang University, Hangzhou, China. Electronic address: liuxb@zju.edu.cn. FAU - Wang, Jian'an AU - Wang J AD - Department of Cardiology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China; State Key Laboratory of Transvascular Implantation Devices, Hangzhou, Zhejiang, China; Heart Regeneration and Repair Key Laboratory of Zhejiang province, Hangzhou, Zhejiang, China; Transvascular Implant Instrument Research Institute, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China; Binjiang Institute of Zhejiang University, Hangzhou, China. Electronic address: wangjianan111@zju.edu.cn. LA - eng PT - Journal Article DEP - 20260723 PL - United States TA - JACC Asia JT - JACC. Asia JID - 9918452380106676 PMC - PMC13554751 OTO - NOTNLM OT - DragonFly-T OT - randomized controlled trial OT - transcatheter edge-to-edge repair OT - tricuspid regurgitation COIS- Funding Support and Author Disclosures This work was supported by the Noncommunicable Chronic Diseases-National Science and Technology Major Project (no. 2024ZD0527100 for XBL); the Healthy Zhejiang One Million People Cohort (K-20230085); the State Key Laboratory of Transvascular Implantation Devices; the National Natural Science Foundation of China (no. 82271606 for XBL and no. 82425007 for XBL); the National Science Fund for Distinguished Young Scholars of China (no. 82425007 for XBL); the Zhejiang Province Science and Technology Department Key R&D Program (no. 2022C03063 for XBL and no. 2024C03024 for JW); and the Zhejiang Province Science and Technology Innovation Leading Talents Project (no. 2023R5236 for XBL). The authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2026/07/24 12:37 MHDA- 2026/07/24 12:38 PMCR- 2026/07/23 CRDT- 2026/07/24 10:28 PHST- 2026/01/20 00:00 [received] PHST- 2026/05/12 00:00 [revised] PHST- 2026/06/11 00:00 [accepted] PHST- 2026/07/24 12:38 [medline] PHST- 2026/07/24 12:37 [pubmed] PHST- 2026/07/24 10:28 [entrez] PHST- 2026/07/23 00:00 [pmc-release] AID - S2772-3747(26)00441-2 [pii] AID - 10.1016/j.jacasi.2026.06.012 [doi] PST - ppublish SO - JACC Asia. 2026 Sep;6(9):1959-1968. doi: 10.1016/j.jacasi.2026.06.012. Epub 2026 Jul 23. PMID- 42496134 OWN - NLM STAT- Publisher LR - 20260724 IS - 1879-0844 (Electronic) IS - 1388-9842 (Linking) DP - 2026 Jul 24 TI - Revascularization of coronary artery disease in heart failure. A European Journal of Heart Failure Expert Consensus Statement. LID - xuag230 [pii] LID - 10.1093/ejhf/xuag230 [doi] AB - The role of myocardial revascularization in HF patients with coronary artery disease by either percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery (CABG) is controversial. For patients with HFrEF, prior to the advances in pharmacological heart failure therapy over the last 10 years, evidence suggests a modest, long-term benefit of CABG over guideline-recommended medical therapy. In the era of modern medical therapy, revascularization had no benefit in HFrEF. Whether a patient with HF and CAD should be advised to have revascularization and, if so, which procedure remains unclear and should be discussed by the heart team given the limited and conflicting evidence. Evidence for viability or ischaemia-guided selection strategies is controversial. In all cases with HF, establishing and optimizing GDMT and device therapy is required. When HF symptoms dominate despite GDMT, additional invasive procedures are not indicated. When angina persists despite GDMT and device therapy, revascularization should be considered. The choice of revascularization procedure should be discussed in the heart team, considering symptoms and ischemic burden, surgical risk, coronary complexity and the applicable HF treatment. CI - (c) The Author(s) 2026. Published by Oxford University Press on behalf of the European Society of Cardiology. FAU - Haring, Bernhard AU - Haring B AUID- ORCID: 0000-0001-6109-431X AD - Department of Medicine IV, Clinic Hietzing, Vienna, Austria. AD - HOMICAREM (Homburg Institute of CardioRenalMetabolic Medicine), Saarland University, Germany. AD - Department of Epidemiology & Population Health, Albert Einstein College of Medicine, NYC, USA. FAU - Iaconelli, Antonio AU - Iaconelli A AD - Department of Cardiovascular Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. AD - School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK. FAU - Perera, Divaka AU - Perera D AUID- ORCID: 0000-0001-6362-1291 AD - School of Cardiovascular and Metabolic Medicine and Sciences, King's College London, UK. AD - Guy's and St Thomas' Hospital, London, UK. FAU - Velazquez, Eric J AU - Velazquez EJ AD - Department of Internal Medicine, Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, CT, USA. FAU - Murphy, Gavin J AU - Murphy GJ AD - Department of Cardiovascular Sciences, University of Leicester, Leicester, UK. FAU - Barbato, Emanuele AU - Barbato E AUID- ORCID: 0000-0002-0050-5178 AD - Department of Clinical and Molecular Medicine, Sapienza University, Rome, Italy. AD - Cardiology Unit, Sant'Andrea University Hospital, Rome, Italy. FAU - Maron, David J AU - Maron DJ AUID- ORCID: 0000-0002-4867-8588 AD - Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA. FAU - Metra, Marco AU - Metra M AD - Cardiology, University and Civil Hospitals of Brescia, Brescia, Italy. FAU - Adamopoulos, Stamatis AU - Adamopoulos S AUID- ORCID: 0000-0001-5223-5782 AD - Department of Cardiology, Onassis Cardiac Surgery Center Athens, Greece. FAU - Petrie, Mark C AU - Petrie MC AUID- ORCID: 0000-0002-6333-9496 AD - School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK. FAU - Farmakis, Dimitrios AU - Farmakis D AUID- ORCID: 0000-0001-8364-3447 AD - Department of Cardiology, Attikon University Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece. FAU - Bayes-Genis, Antoni AU - Bayes-Genis A AUID- ORCID: 0000-0002-3044-197X AD - Department of Medicine, Universitat Autonoma de Barcelona, Barcelona, Spain and Institut del Cor, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain. FAU - Bohm, Michael AU - Bohm M AUID- ORCID: 0000-0002-2976-2514 AD - Department of Medicine IV, Clinic Hietzing, Vienna, Austria. AD - HOMICAREM (Homburg Institute of CardioRenalMetabolic Medicine), Saarland University, Germany. LA - eng PT - Journal Article DEP - 20260724 PL - England TA - Eur J Heart Fail JT - European journal of heart failure JID - 100887595 SB - IM OTO - NOTNLM OT - Coronary Artery Bypass Graft OT - Heart Failure OT - Percutaneous Coronary Intervention OT - Revascularization EDAT- 2026/07/24 12:37 MHDA- 2026/07/24 12:37 CRDT- 2026/07/24 09:12 PHST- 2026/01/25 00:00 [received] PHST- 2026/05/26 00:00 [revised] PHST- 2026/07/07 00:00 [accepted] PHST- 2026/07/24 12:37 [medline] PHST- 2026/07/24 12:37 [pubmed] PHST- 2026/07/24 09:12 [entrez] AID - 8741289 [pii] AID - 10.1093/ejhf/xuag230 [doi] PST - aheadofprint SO - Eur J Heart Fail. 2026 Jul 24:xuag230. doi: 10.1093/ejhf/xuag230. PMID- 42496055 OWN - NLM STAT- MEDLINE DCOM- 20260724 LR - 20260927 IS - 2314-6753 (Electronic) IS - 2314-6745 (Print) VI - 2026 IP - 1 DP - 2026 TI - Healing Outcomes in Diabetic Foot Ulcers Managed Within a Structured Multidisciplinary Care Model: A Retrospective Study. PG - e1730605 LID - 10.1155/jdr/1730605 [doi] LID - 1730605 AB - BACKGROUND: Diabetic foot ulcers (DFU) impose a healthcare burden due to prolonged hospitalization, high amputation rates, and increased mortality. This study evaluated healing outcomes and explored factors associated with adverse outcomes among patients managed within a structured multidisciplinary DFU care setting at a specialized diabetes care center in Kerala. METHODS: A retrospective analysis was conducted among 1057 patients with DFUs managed between January and November 2022. Care included wound culture-directed antibiotics, glycemic optimization, offloading, daily debridement and dressing, and vascular assessment when indicated. Healing outcomes were assessed, and factors associated with poor outcomes and delayed healing were evaluated using multivariable logistic regression. RESULTS: In the full cohort, 74.7% of patients achieved complete healing, whereas the major amputation rate was 2.6%. After excluding referrals, deaths, and loss to follow-up, 887 patients comprised the complete follow-up cohort, of whom 790 (89.1%) achieved favorable outcomes, and 97 (10.9%) experienced poor outcomes (nonhealing ulcer or major amputation). Coronary artery disease (OR 2.08, 95% CI 1.23-3.51; p = 0.006) and prior ulcer history (OR 2.41, 95% CI 1.55-3.74; p < 0.001) were independently associated with poor outcomes. Among patients with healing-time data (n = 766), chronic kidney disease was independently associated with delayed healing (> 5 months) (OR 1.96, 95% CI 1.26-3.06; p = 0.003). CONCLUSION: High rates of favorable outcomes and low rates of major amputation were observed in this cohort managed within a multidisciplinary DFU care model. These findings support the need for prospective multicenter evaluations of multidisciplinary DFU care models. CI - Copyright (c) 2026 Gadadharan Vijayakumar et al. Journal of Diabetes Research published by John Wiley & Sons Ltd. FAU - Vijayakumar, Gadadharan AU - Vijayakumar G AUID- ORCID: 0000-0002-4017-7893 AD - Medical Trust Hospital and Diabetes Care Centre, Pathanamthitta, Kerala, India. FAU - Rahim, Jazeela Abdul AU - Rahim JA AUID- ORCID: 0009-0007-1688-7426 AD - Medical Trust Hospital and Diabetes Care Centre, Pathanamthitta, Kerala, India. FAU - Satheesh, Gopika AU - Satheesh G AUID- ORCID: 0000-0002-5541-6404 AD - Cardiovascular Diseases and Diabetes Biology, BRIC-Rajiv Gandhi Centre for Biotechnology (BRIC-RGCB), Thiruvananthapuram, Kerala, India. AD - Manipal Academy of Higher Education, Manipal, Karnataka, India, manipal.edu. FAU - Sreehari, G K AU - Sreehari GK AUID- ORCID: 0009-0001-3391-9975 AD - Medical Trust Hospital and Diabetes Care Centre, Pathanamthitta, Kerala, India. FAU - Aswathi, V AU - Aswathi V AUID- ORCID: 0009-0003-0003-5836 AD - Medical Trust Hospital and Diabetes Care Centre, Pathanamthitta, Kerala, India. FAU - Sreekanth, K AU - Sreekanth K AUID- ORCID: 0009-0007-3836-620X AD - Medical Trust Hospital and Diabetes Care Centre, Pathanamthitta, Kerala, India. FAU - Revathi, V AU - Revathi V AUID- ORCID: 0009-0009-1878-6973 AD - Medical Trust Hospital and Diabetes Care Centre, Pathanamthitta, Kerala, India. FAU - Vishnu Narayanan, C S AU - Vishnu Narayanan CS AUID- ORCID: 0009-0003-9514-3329 AD - Medical Trust Hospital and Diabetes Care Centre, Pathanamthitta, Kerala, India. FAU - Gopan, Aswathy AU - Gopan A AUID- ORCID: 0009-0005-2083-9385 AD - Medical Trust Hospital and Diabetes Care Centre, Pathanamthitta, Kerala, India. FAU - Jaleel, Abdul AU - Jaleel A AUID- ORCID: 0000-0003-2536-9093 AD - Medical Trust Hospital and Diabetes Care Centre, Pathanamthitta, Kerala, India. AD - Cardiovascular Diseases and Diabetes Biology, BRIC-Rajiv Gandhi Centre for Biotechnology (BRIC-RGCB), Thiruvananthapuram, Kerala, India. LA - eng PT - Journal Article PL - United States TA - J Diabetes Res JT - Journal of diabetes research JID - 101605237 SB - IM MH - Humans MH - *Diabetic Foot/therapy MH - Retrospective Studies MH - *Wound Healing/physiology MH - Male MH - Female MH - Amputation, Surgical/statistics & numerical data MH - Middle Aged MH - Treatment Outcome MH - Aged MH - Debridement MH - *Patient Care Team PMC - PMC13398153 OTO - NOTNLM OT - comorbidity OT - debridement OT - diabetes mellitus OT - podiatry OT - revascularization OT - treatment outcome COIS- The authors declare no conflicts of interest. EDAT- 2026/07/24 12:37 MHDA- 2026/07/24 12:38 PMCR- 2026/07/24 CRDT- 2026/07/24 08:33 PHST- 2026/07/06 00:00 [revised] PHST- 2025/06/26 00:00 [received] PHST- 2026/07/09 00:00 [accepted] PHST- 2026/07/24 12:38 [medline] PHST- 2026/07/24 12:37 [pubmed] PHST- 2026/07/24 08:33 [entrez] PHST- 2026/07/24 00:00 [pmc-release] AID - JDR1730605 [pii] AID - 10.1155/jdr/1730605 [doi] PST - ppublish SO - J Diabetes Res. 2026;2026(1):e1730605. doi: 10.1155/jdr/1730605. PMID- 42495727 OWN - NLM STAT- MEDLINE DCOM- 20260915 LR - 20260915 IS - 1942-0080 (Electronic) IS - 1941-9651 (Linking) VI - 19 IP - 9 DP - 2026 Sep TI - How to Use Cardiovascular Imaging in Pregnancy. PG - e018658 LID - 10.1161/CIRCIMAGING.125.018658 [doi] AB - Cardiovascular imaging plays a central role in the diagnosis, risk stratification, and longitudinal management of cardiovascular disease during pregnancy. Physiological adaptations-including increased blood volume, cardiac output, and chamber remodeling-pose important challenges for image acquisition and interpretation, necessitating a nuanced understanding of normal versus pathological findings. This review provides a practical, cardiology-focused framework for the use of imaging in pregnant patients with suspected or established cardiovascular disease. We emphasize key aspects relevant to cardiac imagers, including appropriate modality selection, pregnancy-adapted imaging protocols, and interpretation of findings in the context of dynamic physiological changes. Transthoracic echocardiography remains the first-line modality, while cardiovascular magnetic resonance offers complementary, radiation-free evaluation in selected cases. Imaging techniques involving ionizing radiation, such as computed tomography and invasive angiography, should be reserved for acute or high-risk scenarios and carefully optimized to minimize fetal exposure. We further discuss common diagnostic pitfalls, limitations of each modality, and areas of uncertainty, including the use of contrast agents and thresholds for advanced imaging. The importance of integrating imaging findings into multidisciplinary decision-making within Pregnancy Heart Teams is highlighted. By providing a structured, clinically oriented approach, this review aims to support cardiac imagers in delivering safe, accurate, and evidence-informed care to this complex patient population. FAU - Van Berendoncks, An AU - Van Berendoncks A AD - Department of Cardiology, Antwerp University Hospital, Edegem, Belgium (A.V.B.). AD - Research Group Cardiovascular Diseases, GENCOR, University of Antwerp, Belgium (A.V.B.). FAU - Rodriguez-Palomares, Jose AU - Rodriguez-Palomares J AD - Department of Cardiology, Hospital Universitari Vall d'Hebron, Barcelona, Spain (J.R.P.). AD - Cardiovascular Diseases, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain (J.R.P.). AD - Department of Medicine, Universitat Autonoma de Barcelona, Bellaterra, Spain (J.R.P.). AD - CIBER de Enfermedades Cardiovasculares, Instituto de Salud Carlos III, Madrid, Spain (J.R.P.). FAU - De Backer, Julie AU - De Backer J AUID- ORCID: 0000-0001-8878-1507 AD - Department of Cardiology and Center for Medical Genetics, Ghent University Hospital, Belgium (J.D.B.). LA - eng PT - Journal Article PT - Review DEP - 20260724 PL - United States TA - Circ Cardiovasc Imaging JT - Circulation. Cardiovascular imaging JID - 101479935 SB - IM MH - Humans MH - Female MH - Pregnancy MH - *Pregnancy Complications, Cardiovascular/diagnostic imaging/physiopathology/therapy MH - Predictive Value of Tests MH - Risk Assessment MH - *Cardiac Imaging Techniques MH - Prognosis MH - *Cardiovascular Diseases/diagnostic imaging/physiopathology MH - Risk Factors OTO - NOTNLM OT - blood volume OT - cardiovascular diseases OT - diagnostic imaging OT - pregnancy OT - risk assessment COIS- None. EDAT- 2026/07/24 06:35 MHDA- 2026/09/15 18:07 CRDT- 2026/07/24 05:08 PHST- 2026/09/15 18:07 [medline] PHST- 2026/07/24 06:35 [pubmed] PHST- 2026/07/24 05:08 [entrez] AID - 10.1161/CIRCIMAGING.125.018658 [doi] PST - ppublish SO - Circ Cardiovasc Imaging. 2026 Sep;19(9):e018658. doi: 10.1161/CIRCIMAGING.125.018658. Epub 2026 Jul 24. PMID- 42495065 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260724 LR - 20260813 IS - 1758-3764 (Electronic) IS - 1758-3756 (Print) IS - 1758-3756 (Linking) VI - 21 DP - 2026 TI - Redo Transcatheter Aortic Valve Replacement: Device Selection and Risks. PG - e41 LID - 10.15420/ecr.2025.05 [doi] LID - e41 AB - Transcatheter aortic valve replacement (TAVR) has become the preferred treatment for patients with severe aortic valve stenosis or regurgitation, especially those at intermediate-to-high surgical risk. As TAVR indications expand, the patient population is progressively younger, increasing the likelihood of bioprosthetic valve failure (BVF) over time. This shift highlights the need for effective long-term management strategies. This review focuses on the evolving role of redo-TAVR, specifically the TAV-in-TAV approach, for managing BVF. Key challenges include coronary obstruction, valve migration and device selection. Preprocedural planning, particularly through advanced imaging techniques, such as CT, is critical if complications are to be minimised. This review discusses important technical considerations for TAV-in-TAV procedures, including valve sizing, implantation depth and the impact of valve design on coronary access. A multidisciplinary heart team is essential for assessing patient anatomy and appropriate device selection. Although outcomes appear promising, further research is required to refine procedural techniques and optimise long-term results for patients undergoing redo-TAVR. CI - Copyright (c) The Author(s) 2026. Published by Radcliffe Group Ltd. FAU - Fabris, Tommaso AU - Fabris T AD - Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova Padova, Italy. FAU - Putorti, Francesco AU - Putorti F AUID- ORCID: 0009-0006-4830-0354 AD - Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova Padova, Italy. FAU - Tarantini, Giuseppe AU - Tarantini G AUID- ORCID: 0000-0002-8177-2269 AD - Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova Padova, Italy. LA - eng PT - Journal Article PT - Review DEP - 20260710 PL - England TA - Eur Cardiol JT - European cardiology JID - 101574780 PMC - PMC13392300 OTO - NOTNLM OT - Redo transcatheter aortic valve replacement OT - TAV-in-TAV OT - transcatheter aortic valve replacement COIS- Disclosure: GT has received lecture fees from Medtronic, Edwards Lifesciences, Abbott and Boston Scientific. All other authors have no conflicts of interest to declare. EDAT- 2026/07/24 06:35 MHDA- 2026/07/24 06:36 PMCR- 2026/07/10 CRDT- 2026/07/24 05:02 PHST- 2025/01/30 00:00 [received] PHST- 2026/01/19 00:00 [accepted] PHST- 2026/07/24 06:36 [medline] PHST- 2026/07/24 06:35 [pubmed] PHST- 2026/07/24 05:02 [entrez] PHST- 2026/07/10 00:00 [pmc-release] AID - 10.15420/ecr.2025.05 [doi] PST - epublish SO - Eur Cardiol. 2026 Jul 10;21:e41. doi: 10.15420/ecr.2025.05. eCollection 2026. PMID- 42489902 OWN - NLM STAT- Publisher LR - 20260723 IS - 1432-1971 (Electronic) IS - 0172-0643 (Linking) DP - 2026 Jul 23 TI - Mixed Reality as a Tool for Congenital Heart Disease Case Management Discussions. LID - 10.1007/s00246-026-04395-w [doi] AB - Understanding congenital heart disease requires a 3D mental framework, yet clinicians typically rely on 2D imaging. Multi-disciplinary case management conference (CMC) discussions often involve review of complex anatomy utilizing cross-sectional imaging. Mixed reality (MR) offers immersive 3D visualization that may enhance these discussions. Our objectives were to demonstrate the feasibility of integrating MR-guided discussions into CMC and assess Heart Center perceptions of its use. This prospective, single-center study was conducted during multi-disciplinary CMCs. Baseline and post-presentation Likert-scale questionnaires were administered. EchoPixel True3D (Santa Clara, CA) was used to present 3D MR models from cardiac CT datasets. Participants used electronic glasses wirelessly linked to a 3D projector to view the MR models in conference, which were manipulated in real-time. On the baseline survey (n = 46), 67% agreed that complex cardiac anatomy is difficult to interpret with 2D imaging. Twelve MR cases were presented. On the post-survey (n = 100), 93% rated the MR model quality as good/excellent, 75% felt that MR improved their understanding of the cardiac anatomy, and 89% supported regular use of MR in CMC. Among surgeons and interventionalists, 82% reported improved procedural planning and 57% altered their procedural approach. Mixed reality imaging can be successfully incorporated into CMC presentations and discussions, with positive participant responses. MR provides a virtual 3D framework that closely replicates patient anatomy and supports pre-procedural planning and execution. CI - (c) 2026. The Author(s). FAU - Gunsaulus, Megan AU - Gunsaulus M AUID- ORCID: 0000-0002-6057-1644 AD - Division of Pediatric Cardiology, The Heart Center, Nationwide Children's Hospital, Columbus, OH, USA. megan.gunsaulus@nationwidechildrens.org. FAU - Parthasarathy, Jayanthi AU - Parthasarathy J AUID- ORCID: 0000-0001-5161-852X AD - Department of Radiology, Nationwide Children's Hospital, Columbus, OH, USA. FAU - Richardson, Carson AU - Richardson C AUID- ORCID: 0009-0004-8710-1097 AD - Biostatistics Resource, Nationwide Children's Hospital, Columbus, OH, USA. AD - Center for Biostatistics, The Ohio State University College of Medicine, Columbus, OH, USA. FAU - Schmitt, Christopher AU - Schmitt C AUID- ORCID: 0009-0006-4826-1068 AD - Department of Pediatric Cardiology, Seattle Children's Hospital, Seattle, WA, USA. FAU - Carrillo, Sergio A AU - Carrillo SA AD - Department of Cardiothoracic Surgery, The Heart Center, Nationwide Children's Hospital, Columbus, OH, USA. FAU - Dutro, Marc AU - Dutro M AUID- ORCID: 0000-0002-8989-7242 AD - Division of Pediatric Cardiology, The Heart Center, Nationwide Children's Hospital, Columbus, OH, USA. FAU - Salavitabar, Arash AU - Salavitabar A AUID- ORCID: 0000-0002-9632-4725 AD - Division of Pediatric Cardiology, The Heart Center, Nationwide Children's Hospital, Columbus, OH, USA. arash.salavitabar@nationwidechildrens.org. LA - eng PT - Journal Article DEP - 20260723 PL - United States TA - Pediatr Cardiol JT - Pediatric cardiology JID - 8003849 SB - IM OTO - NOTNLM OT - Cardiac imaging OT - Congenital heart disease OT - Mixed reality OT - Multidisciplinary case conference OT - Pre-procedural planning OT - Three-dimensional visualization COIS- Declarations. Conflict of interest: The authors declare no competing interests. Ethical Approval: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the Nationwide Children's Hospital Institutional Review Board. Consent to Participate: Informed consent was obtained from all individual participants included in the study. EDAT- 2026/07/23 12:37 MHDA- 2026/07/23 12:37 CRDT- 2026/07/23 11:13 PHST- 2026/04/01 00:00 [received] PHST- 2026/07/15 00:00 [accepted] PHST- 2026/07/23 12:37 [medline] PHST- 2026/07/23 12:37 [pubmed] PHST- 2026/07/23 11:13 [entrez] AID - 10.1007/s00246-026-04395-w [pii] AID - 10.1007/s00246-026-04395-w [doi] PST - aheadofprint SO - Pediatr Cardiol. 2026 Jul 23. doi: 10.1007/s00246-026-04395-w. PMID- 42489383 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260723 LR - 20260813 IS - 2772-963X (Electronic) IS - 2772-963X (Linking) VI - 5 IP - 7 DP - 2026 Jul TI - Infective Endocarditis of Transcatheter Aortic Valve Replacement and Transcatheter Edge-to-Edge Repair Devices. PG - 102944 LID - S2772-963X(26)00365-0 [pii] LID - 10.1016/j.jacadv.2026.102944 [doi] LID - 102944 AB - Infective endocarditis following transcatheter aortic valve replacement and mitral valve transcatheter edge-to-edge repair poses a significant clinical challenge, necessitating a multidisciplinary approach for timely diagnosis and appropriate management that may include surgical intervention for patients of less than prohibitive risk. Although advances in imaging modalities, including (18)F-fluorodeoxyglucose positron emission tomography/computed tomography, show promise in enhancing diagnostic accuracy, standardized guidelines for management are lacking, especially regarding the appropriateness of antimicrobial suppression therapy. Future research should focus on refining diagnostic criteria, optimizing therapeutic strategies, and improving patient outcomes in these populations. CI - Copyright (c) 2026 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Aoun, Joe AU - Aoun J AD - Cardiology Department, Houston Methodist DeBakey Heart & Vascular Center, Houston, Texas, USA. FAU - Kharsa, Chloe AU - Kharsa C AD - Cardiology Department, Houston Methodist DeBakey Heart & Vascular Center, Houston, Texas, USA. FAU - Desai, Parth AU - Desai P AD - Cardiology Department, Houston Methodist DeBakey Heart & Vascular Center, Houston, Texas, USA. FAU - Zeid, Karl Abou AU - Zeid KA AD - Cardiology Department, Houston Methodist DeBakey Heart & Vascular Center, Houston, Texas, USA. FAU - Goel, Sachin S AU - Goel SS AD - Cardiology Department, Houston Methodist DeBakey Heart & Vascular Center, Houston, Texas, USA. FAU - Kleiman, Neal S AU - Kleiman NS AD - Cardiology Department, Houston Methodist DeBakey Heart & Vascular Center, Houston, Texas, USA. FAU - Little, Stephen H AU - Little SH AD - Cardiology Department, Houston Methodist DeBakey Heart & Vascular Center, Houston, Texas, USA. FAU - Faza, Nadeen N AU - Faza NN AD - Cardiology Department, Houston Methodist DeBakey Heart & Vascular Center, Houston, Texas, USA. FAU - Sorajja, Paul AU - Sorajja P AD - Cardiology Department, Allina Health Minneapolis Heart Institute, Minneapolis, USA. FAU - Tang, Gilbert Hl AU - Tang GH AD - Department of Cardiovascular Surgery, Mount Sinai Health System, New York, USA. FAU - Baddour, Larry M AU - Baddour LM AD - Division of Public Health, Infectious Diseases and Occupational Health, Departments of Medicine and Cardiovascular Medicine, Mayo Clinic, Minnesota, USA. FAU - Bavry, Anthony A AU - Bavry AA AD - Department of Internal Medicine, UT Southwestern Medical Center, Dallas, USA. FAU - Harrington, Katherine AU - Harrington K AD - Cardiovascular Surgery Department, Baylor Scott & White, Dallas, Texas, USA. FAU - Badhwar, Vinay AU - Badhwar V AD - Department of Cardiovascular and Thoracic Surgery, West Virginia University, Morgantown, West Virginia, USA. FAU - Fowler, Vance G Jr AU - Fowler VG Jr AD - Infectious Disease Department, Duke, North Carolina, USA. FAU - Quarti, Andrea Giulio AU - Quarti AG AD - Cardiovascular Surgery Department, Houston Methodist DeBakey Heart & Vascular Center, Houston, Texas, USA. FAU - Reardon, Michael J AU - Reardon MJ AD - Cardiovascular Surgery Department, Houston Methodist DeBakey Heart & Vascular Center, Houston, Texas, USA. Electronic address: MReardon@houstonmethodist.org. LA - eng PT - Journal Article PT - Review PL - United States TA - JACC Adv JT - JACC. Advances JID - 9918419284106676 PMC - PMC13400124 OTO - NOTNLM OT - TAVR OT - TEER OT - antibiotic prophylaxis OT - device OT - imaging OT - infective endocarditis COIS- Funding support and author disclosures Dr Aoun has a research grant from Abbott Laboratories. Dr Goel is a consultant for Medtronic, W L Gore & Associates, and on the Speakers Bureau for Abbott Structural Heart. Dr Kleiman is a local principal investigator for trials sponsored by Boston Scientific, Medtronic, Abbott, and Edwards Lifesciences. Dr Baddour has received royalty payments from UpToDate, Inc. Dr Bavry reports receiving research support from Edwards Lifesciences and Abbott and proctors for Edwards Lifesciences. Dr Fowler reports receiving grants and research support from AstraZeneca, MedImmune, Merck, ContraFect, Karius, Genentech, Regeneron, and Basilea; he is a consultant for AstraZeneca, GSK, Armata, Debiopharm, Genentech, Basilea, Affinergy, Janssen, ContraFect, and Destiny; he earns royalties from UpToDate and holds stock options in ArcBio and ValanBio; and additionally, he has a patent pending for sepsis diagnostics. Dr Tang has received speaker honoraria and served as a physician proctor, consultant, advisory board member, TAVR publications committee member, RESTORE study steering committee member, APOLLO trial screening committee member, and IMPACT MR steering committee member for Medtronic; has received speaker honoraria and served as a physician proctor, consultant, advisory board member, and TRILUMINATE trial anatomic eligibility and publications committee member for Abbott Structural Heart; has served as an advisory board member for Boston Scientific and JenaValve; has served as a consultant and physician screening committee member for Shockwave Medical; has served as a consultant for Philips, Edwards Lifesciences, Anteris, Peija Medical, and Shenqi Medical Technology; and has received speaker's honoraria from Siemens Healthineers. Dr Sorajja is co-principal investigator for the TRILUMINATE Pivotal trial; serves on the advisory boards for Abbott Structural, Adona, Boston Scientific, Medtronic, Valcare, and VDyne; and has received consulting fees from Abbott Structural, Boston Scientific, ConKay, Coramaze, CroiValve, Cultiv8, Edwards Lifesciences, Egg Medical, Evolution Medical, Fodax, GE Medical, Haemonetics, InQ8, LAZA, Medtronic, Mirus, Philips, Polares, Tricares, Unorthodox Ventures, Valcare, and xDot. Dr Adams is co-principal investigator for the TRILUMINATE Pivotal trial and receives royalties from Edward Lifesciences and Medtronic. Dr Reardon is a consultant for Medtronic, Boston Scientific, Abbott, and W L Gore & Associates. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2026/07/23 12:37 MHDA- 2026/07/23 12:38 PMCR- 2026/07/22 CRDT- 2026/07/23 08:28 PHST- 2026/04/14 00:00 [received] PHST- 2026/05/19 00:00 [revised] PHST- 2026/05/20 00:00 [accepted] PHST- 2026/07/23 12:38 [medline] PHST- 2026/07/23 12:37 [pubmed] PHST- 2026/07/23 08:28 [entrez] PHST- 2026/07/22 00:00 [pmc-release] AID - S2772-963X(26)00365-0 [pii] AID - 102944 [pii] AID - 10.1016/j.jacadv.2026.102944 [doi] PST - ppublish SO - JACC Adv. 2026 Jul;5(7):102944. doi: 10.1016/j.jacadv.2026.102944. PMID- 42488537 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260723 LR - 20260813 IS - 2297-055X (Print) IS - 2297-055X (Electronic) IS - 2297-055X (Linking) VI - 13 DP - 2026 TI - Chest pain unit implementation in a multidisciplinary hospital: a retrospective observational study. PG - 1762236 LID - 10.3389/fcvm.2026.1762236 [doi] LID - 1762236 AB - BACKGROUND: Acute chest pain is a common reason for emergency department visits and requires rapid differentiation between life-threatening and non-life-threatening conditions. Chest Pain Units (CPUs) were developed to improve diagnostic efficiency and optimize management of patients with suspected acute coronary syndrome (ACS). This study evaluated clinical and healthcare utilization patterns before and after CPU implementation in a multidisciplinary hospital in Kazakhstan. METHODS: A retrospective case-control study was conducted at a 250-bed tertiary hospital. Two consecutive periods were analyzed: pre-implementation (2015-2017) and post-implementation (2018-2020) of CPU. Patients presenting before CPU implementation received standard emergency department care (non-CPU group, n = 1,595), whereas those presenting after implementation were managed in the CPU (n = 2,121). All consecutive patients with suspected ACS (ICD-10 I20-I22) were included (total n = 3,716). Final diagnoses were based on discharge ICD-10 coding. The CPU protocol included standardized assessment, electrocardiography, serial cardiac troponin measurements, and HEART pathway risk stratification. Outcomes included invasive procedures, mortality, hospital length of stay, and direct treatment costs. RESULTS: Baseline characteristics showed a higher proportion of men in both groups (p = 0.015), with no significant age difference (p = 0.066). The CPU group had a higher PCI rate (OR 1.43, 95% CI 1.26-1.64, p < 0.001), whereas diagnostic angiography was more frequent in the non-CPU group (OR 0.76, 95% CI 0.67-0.87, p = 0.02). No significant difference was observed for CABG (p = 0.07). AMI diagnoses were more frequent in the CPU group (37.6% vs. 25.1%; OR 1.80, 95% CI 1.57-2.09, p < 0.001), while unstable angina was more common in the non-CPU group (OR 0.50, 95% CI 0.48-0.64, p < 0.001). Mortality did not differ significantly between groups (2.4% vs. 2.2%, p = 0.543). Direct treatment costs were significantly higher following CPU implementation (p < 0.001). CONCLUSION: CPU implementation was associated with higher rates of AMI identification and increased PCI use compared with the traditional emergency department approach. CPU-based pathways may improve diagnostic accuracy and management patterns in patients with suspected ACS. CI - (c) 2026 Umbetzhanova, Derbissalina, Vakpayev, Bekbergenova and Koikov. FAU - Umbetzhanova, Ayagyoz AU - Umbetzhanova A AD - Department of Family Medicine with Course of Evidence-Based Medicine, Astana Medical University, Astana, Kazakhstan. FAU - Derbissalina, Gulmira AU - Derbissalina G AD - Department of Family Medicine with Course of Evidence-Based Medicine, Astana Medical University, Astana, Kazakhstan. FAU - Vakpayev, Dias AU - Vakpayev D AD - Department of Family Medicine with Course of Evidence-Based Medicine, Astana Medical University, Astana, Kazakhstan. FAU - Bekbergenova, Zhanagul AU - Bekbergenova Z AD - Department of Family Medicine with Course of Evidence-Based Medicine, Astana Medical University, Astana, Kazakhstan. FAU - Koikov, Vitaliy AU - Koikov V AD - Department of Family Medicine with Course of Evidence-Based Medicine, Astana Medical University, Astana, Kazakhstan. LA - eng PT - Journal Article DEP - 20260708 PL - Switzerland TA - Front Cardiovasc Med JT - Frontiers in cardiovascular medicine JID - 101653388 PMC - PMC13388264 OTO - NOTNLM OT - acute coronary syndrome OT - chest pain OT - emergency service OT - hospital OT - myocardial infarction OT - outcome assessment (Health care) COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/07/23 06:39 MHDA- 2026/07/23 06:40 PMCR- 2026/07/08 CRDT- 2026/07/23 04:52 PHST- 2025/12/06 00:00 [received] PHST- 2026/05/27 00:00 [revised] PHST- 2026/06/10 00:00 [accepted] PHST- 2026/07/23 06:40 [medline] PHST- 2026/07/23 06:39 [pubmed] PHST- 2026/07/23 04:52 [entrez] PHST- 2026/07/08 00:00 [pmc-release] AID - 10.3389/fcvm.2026.1762236 [doi] PST - epublish SO - Front Cardiovasc Med. 2026 Jul 8;13:1762236. doi: 10.3389/fcvm.2026.1762236. eCollection 2026. PMID- 42482846 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260722 LR - 20260813 IS - 2514-1775 (Electronic) IS - 2514-1775 (Linking) VI - 10 IP - 3 DP - 2026 TI - Towards an integrated and proactive management of pulmonary hypertension in systemic sclerosis: a practical approach for early diagnosis and optimal patient management. PG - rkag077 LID - 10.1093/rap/rkag077 [doi] LID - rkag077 AB - Pulmonary arterial hypertension (PAH) is a severe vascular complication of SSc and a leading cause of disease-related mortality. Despite the availability of validated screening tools and treatment recommendations, diagnosis delay and suboptimal therapeutic implementation remain frequent in real-world practice. The 2022 European Society of Cardiology/European Respiratory Society guidelines and 2025 EULAR recommendations advocate systematic annual screening and initial combination therapy with an endothelin receptor antagonist and a phosphodiesterase type 5 inhibitor at PAH diagnosis. In SSc patients already receiving a dual combination, escalation to triple therapy including selexipag, or in selected cases switching to riociguat, should be promptly considered. Given the rapid progression and poorer prognosis of SSc-PAH, follow-up within 3 months of diagnosis is critical. Structured referral networks, implementation of the DETECT algorithm and involvement of a dedicated case manager and/or nurse can further improve timely diagnosis and continuity of care. Optimizing SSc-PAH management requires a proactive, integrated approach that bridges rheumatology and cardiology expertise. CI - (c) The Author(s) 2026. Published by Oxford University Press on behalf of the British Society for Rheumatology. FAU - Giuggioli, Dilia AU - Giuggioli D AUID- ORCID: 0000-0002-0041-3695 AD - Rheumatology Unit, University Hospital of Modena, Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, Modena, Italy. FAU - Del Galdo, Francesco AU - Del Galdo F AUID- ORCID: 0000-0002-8528-2283 AD - Leeds Institute of Rheumatic and Musculoskeletal Medicine, LIRMM, Leeds, UK. AD - NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK. FAU - D'Alto, Michele AU - D'Alto M AUID- ORCID: 0000-0001-5729-1038 AD - Cardiology, Ospedali dei Colli-C.T.O. Hospital, Naples, Italy. FAU - Matucci-Cerinic, Marco AU - Matucci-Cerinic M AUID- ORCID: 0000-0002-9324-3161 AD - Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UniRAR), IRCCS San Raffaele Scientific Institute, Milan, Italy. AD - Universita Vita Salute San Raffaele, Milan, Italy. AD - Inflammation Fibrosis and Ageing Initiative (INFLAGE), Division of Genetics and Cell Biology, IRCCS San Raffaele Scientific Institute, Milan, Italy. LA - eng PT - Journal Article PT - Review DEP - 20260709 PL - England TA - Rheumatol Adv Pract JT - Rheumatology advances in practice JID - 101736676 PMC - PMC13387162 OTO - NOTNLM OT - care pathways OT - diagnosis OT - multidisciplinary team OT - pulmonary arterial hypertension (PAH) OT - systemic sclerosis (SSc) EDAT- 2026/07/22 12:37 MHDA- 2026/07/22 12:38 PMCR- 2026/07/09 CRDT- 2026/07/22 04:25 PHST- 2026/04/14 00:00 [received] PHST- 2026/06/19 00:00 [accepted] PHST- 2026/07/22 12:38 [medline] PHST- 2026/07/22 12:37 [pubmed] PHST- 2026/07/22 04:25 [entrez] PHST- 2026/07/09 00:00 [pmc-release] AID - rkag077 [pii] AID - 10.1093/rap/rkag077 [doi] PST - epublish SO - Rheumatol Adv Pract. 2026 Jul 9;10(3):rkag077. doi: 10.1093/rap/rkag077. eCollection 2026. PMID- 42481905 OWN - NLM STAT- MEDLINE DCOM- 20260822 LR - 20260825 IS - 1179-2000 (Electronic) IS - 1177-1062 (Print) IS - 1177-1062 (Linking) VI - 30 IP - 5 DP - 2026 Sep TI - Multidisciplinary and Personalized Molecular Diagnosis to Solving Sudden Death During Sport. PG - 759-770 LID - 10.1007/s40291-026-00867-0 [doi] AB - Sudden cardiac death is the leading cause of death among athletes during exercise. These events are devastating for both the family and society, especially when they occur in children and young adults. Some of these unexpected deceases occur in athletes who carry genetic alterations that predispose them to malignant arrhythmias, and exercise is the main trigger for these lethal episodes. These genetic alterations are the origin of inherited arrhythmogenic syndromes, often latent, and the first clinical manifestation can be sudden death itself. It is also important to take into account the toxicology data, since high doses of certain substances, as well as mixtures of them, can also be significant triggers of malignant arrhythmias, especially in genetically predisposed hearts. Genetic studies that can provide a diagnosis can be performed on deceased individuals (molecular autopsy) or on their relatives, who may be carriers of the genetic defect and at risk of malignant arrhythmogenic events. Early identification of individuals at risk allows adoption of preventive measures helping to reduce risk of life-threatening arrhythmogenic episodes. Our study examines the main arrhythmogenic causes of sudden cardiac death in athletes during exercise, highlighting a multidisciplinary interpretation of forensic, clinical, genetic and molecular data to obtain a definite cause for the lethal episode. CI - (c) 2026. The Author(s). FAU - Costantino, Andrea AU - Costantino A AD - Forensic Medical Sciences, Department of Health Science, University of Florence, 50121, Florence, Italy. FAU - Campuzano, Oscar AU - Campuzano O AUID- ORCID: 0000-0001-5298-5276 AD - Medical Science Department, School of Medicine, University of Girona, 17003, Girona, Catalonia, Spain. oscar@brugada.org. AD - Centro de Investigacion Biomedica en Red, Enfermedades Cardiovasculares, Madrid, Spain. oscar@brugada.org. FAU - Vaiano, Fabio AU - Vaiano F AD - FT-LAB Forensic Toxicology Laboratory, Department of Health Science, University of Florence, 50121, Florence, Italy. FAU - Nardi, Eleonora AU - Nardi E AD - Area of Pathology, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Istituto di Anatomia Patologica, Rome, Italy. FAU - Dimitrova, Alexandra AU - Dimitrova A AD - Area of Pathology, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Istituto di Anatomia Patologica, Rome, Italy. FAU - Greco, Andrea AU - Greco A AD - Pediatric Arrhythmias, Inherited Cardiac Diseases and Sudden Death Unit, Cardiology Department, Sant Joan de Deu Hospital de Barcelona, Barcelona, Spain. AD - Malalties Cardiovasculars en el Desenvolupament, Institut de Recerca Sant Joan de Deu, Arritmies Pediatriques, Cardiologia Genetica I Mort Sobtada, Esplugues de Llobregat, Barcelona, Spain. AD - Low Prevalence and Complex Diseases of the Heart (ERN GUARD-Heart), European Reference Network for Rare, Amsterdam, the Netherlands. FAU - Martinez-Barrios, Estefania AU - Martinez-Barrios E AD - Pediatric Arrhythmias, Inherited Cardiac Diseases and Sudden Death Unit, Cardiology Department, Sant Joan de Deu Hospital de Barcelona, Barcelona, Spain. AD - Malalties Cardiovasculars en el Desenvolupament, Institut de Recerca Sant Joan de Deu, Arritmies Pediatriques, Cardiologia Genetica I Mort Sobtada, Esplugues de Llobregat, Barcelona, Spain. AD - Low Prevalence and Complex Diseases of the Heart (ERN GUARD-Heart), European Reference Network for Rare, Amsterdam, the Netherlands. FAU - Arena, Vincenzo AU - Arena V AD - Area of Pathology, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Istituto di Anatomia Patologica, Rome, Italy. FAU - Jarvis, Hannah AU - Jarvis H AD - Harris County Institute of Forensic Sciences, 1861 Old Spanish Trail, Houston, TX, 77054, USA. FAU - Sarquella-Brugada, Georgia AU - Sarquella-Brugada G AD - Medical Science Department, School of Medicine, University of Girona, 17003, Girona, Catalonia, Spain. AD - Pediatric Arrhythmias, Inherited Cardiac Diseases and Sudden Death Unit, Cardiology Department, Sant Joan de Deu Hospital de Barcelona, Barcelona, Spain. AD - Malalties Cardiovasculars en el Desenvolupament, Institut de Recerca Sant Joan de Deu, Arritmies Pediatriques, Cardiologia Genetica I Mort Sobtada, Esplugues de Llobregat, Barcelona, Spain. AD - Low Prevalence and Complex Diseases of the Heart (ERN GUARD-Heart), European Reference Network for Rare, Amsterdam, the Netherlands. AD - Pediatrics Department, School of Medicine, Universitat de Barcelona, Barcelona, Spain. FAU - Brugada, Ramon AU - Brugada R AD - Medical Science Department, School of Medicine, University of Girona, 17003, Girona, Catalonia, Spain. AD - Centro de Investigacion Biomedica en Red, Enfermedades Cardiovasculares, Madrid, Spain. AD - Cardiology Department, Hospital Josep Trueta, Girona, Spain. AD - Institut Investigacions Biomediques de Girona, IDIBGI, Girona, Spain. FAU - Oliva, Antonio AU - Oliva A AD - Section of Legal Medicine, Department of Health Surveillance and Bioethics, Fondazione Policlinico A. Gemelli IRCCS, Universita Cattolica del Sacro Cuore, Rome, Italy. FAU - Grassi, Simone AU - Grassi S AD - Forensic Medical Sciences, Department of Health Science, University of Florence, 50121, Florence, Italy. simone.grassi@unifi.it. AD - FT-LAB Forensic Toxicology Laboratory, Department of Health Science, University of Florence, 50121, Florence, Italy. simone.grassi@unifi.it. LA - eng GR - FBA_2025/Fundacio Bosch i Aymerich/ GR - FDB_2024/Fundacio Privada Daniel Bravo Andreu/ GR - PERIS: SLT042/25/000012/Departament de Salut, Generalitat de Catalunya/ PT - Journal Article PT - Review DEP - 20260721 PL - New Zealand TA - Mol Diagn Ther JT - Molecular diagnosis & therapy JID - 101264260 SB - IM MH - Humans MH - *Death, Sudden, Cardiac/etiology/prevention & control MH - Arrhythmias, Cardiac/genetics/diagnosis MH - Athletes MH - *Sports MH - Genetic Predisposition to Disease MH - *Precision Medicine/methods MH - *Molecular Diagnostic Techniques/methods MH - Exercise PMC - PMC13499825 COIS- Declarations. Author Contributions: Conceptualization: AC, OC, AO, and SG; Data curation and Formal analysis: AC, OC, FV, EN, AD, AG, EMB, VA, HJ, GSB, RB, AO, and GSB; Writing-original draft: AC, OC, and SG. All authors critically revised the manuscript and approved the published manuscript. Funding: This work would not have been possible without the support of Fundacio Bosch I Aymerich, and Fundacio Daniel Bravo Andreu. GSB is supported with protected research time granted under the PERIS intensification call SLT042/25/000012 of the Pla Estrategic de Recerca i Innovacio en Salut (PERIS), Department de Salut de la Generalitat de Catalunya. All these institutions played no role in the study design, data collection, data analysis, interpretation, or writing of the report. Institutional Review Board Statement: Not applicable. Informed Consent Statement: Not applicable. Data Availability Statement: All the data that support the findings of this study are in the manuscript. Code Availability: Not applicable. Conflicts of Interest: All authors have reported that they have no relationships relevant to the contents of this paper to disclose. Disclosure: Equity, Diversity and Inclusion Statement: all relevant articles were included regardless of country, sex, age, participant level, ethnicity, socioeconomic status, or marginalized group representation. EDAT- 2026/07/22 12:37 MHDA- 2026/08/22 22:40 PMCR- 2026/07/21 CRDT- 2026/07/21 23:35 PHST- 2026/04/23 00:00 [received] PHST- 2026/07/07 00:00 [accepted] PHST- 2026/08/22 22:40 [medline] PHST- 2026/07/22 12:37 [pubmed] PHST- 2026/07/21 23:35 [entrez] PHST- 2026/07/21 00:00 [pmc-release] AID - 10.1007/s40291-026-00867-0 [pii] AID - 867 [pii] AID - 10.1007/s40291-026-00867-0 [doi] PST - ppublish SO - Mol Diagn Ther. 2026 Sep;30(5):759-770. doi: 10.1007/s40291-026-00867-0. Epub 2026 Jul 21. PMID- 42480644 OWN - NLM STAT- MEDLINE DCOM- 20261015 LR - 20261015 IS - 2213-3348 (Electronic) IS - 2213-333X (Print) IS - 2213-333X (Linking) VI - 14 IP - 6 DP - 2026 Nov TI - Standardizing leave of absence and round-trip protocols for surgical management of pulmonary embolism. PG - 102580 LID - S2213-333X(26)00140-X [pii] LID - 10.1016/j.jvsv.2026.102580 [doi] LID - 102580 AB - BACKGROUND: Pulmonary embolism (PE) remains a significant public health challenge, causing 100,000 to 200,000 deaths annually in the United States. Despite advances in medical technology, mortality rates for high-risk patients with PE remain substantial, highlighting the critical need for standardized interhospital transfer protocols for surgical management. In addition, as hospitals struggle with capacity challenges, other access mechanisms to advanced care for time-sensitive conditions should be explored. OBJECTIVE: This framework aims to develop detailed, evidence-based recommendations for leave of absence and round trip protocols specific to surgical PE management, addressing current gaps in patient transfer and intervention processes. METHODS: Through a detailed analysis of the large academic medical center's workflow, this paper examines current interhospital transfer practices for patients with PE. The methodology involves evaluating patient selection criteria, pretransfer medical optimization, transport logistics, and postprocedure care coordination, using validated risk assessment tools such as the simplified Pulmonary Embolism Severity Index score, Bleeding, Age, Cancer, Syncope, echocardiographic evaluations, and the 2026 American Heart Association/American College of Cardiology acute PE clinical categories (A-E). This work represents a quality improvement and protocol development analysis; as no primary patient data were collected, Institutional Review Board review was not required. This framework paper does not involve primary patient data collection; sex-disaggregated analysis is therefore not applicable. CONCLUSIONS: The framework offers a systematic approach to improving surgical management of PE through standardized leave of absence and round trip protocols, potentially reducing mortality and improving patient care. The proposed framework includes rigorous patient selection criteria, specialized transfer team composition, thorough pretransfer optimization protocols, and standardized communication and documentation processes. Critical components include careful patient risk stratification, specialized critical care transport teams, and structured postprocedure monitoring and transfer protocols. By establishing a standardized approach to PE patient transfers, this paper aims to provide a construct for timely access to higher-level care to improve clinical outcomes, enhance patient safety, and optimize resource utilization across health care institutions. CI - Published by Elsevier Inc. FAU - Fitzpatrick, Suzanna AU - Fitzpatrick S AD - University of Maryland Medical Center, Baltimore, MD. Electronic address: Suzanna.fitzpatrick@umm.edu. FAU - Nagarsheth, Khanjan AU - Nagarsheth K AD - University of Maryland Medical Center, Baltimore, MD. FAU - Dunlap, Eleanor AU - Dunlap E AD - University of Maryland Medical Center, Baltimore, MD. FAU - Madabhushi, Vashisht AU - Madabhushi V AD - Indiana University, Indianapolis, IN. FAU - Marcozzi, David AU - Marcozzi D AD - University of Maryland Medical Center, Baltimore, MD. LA - eng PT - Journal Article DEP - 20260721 PL - United States TA - J Vasc Surg Venous Lymphat Disord JT - Journal of vascular surgery. Venous and lymphatic disorders JID - 101607771 SB - IM MH - Humans MH - *Pulmonary Embolism/surgery/mortality/diagnosis MH - *Patient Transfer/standards/organization & administration MH - Clinical Protocols/standards MH - Risk Assessment MH - Treatment Outcome MH - Risk Factors MH - Time Factors MH - Academic Medical Centers/standards MH - Workflow MH - Patient Selection MH - *Embolectomy/standards/adverse effects MH - Patient Care Team/standards/organization & administration PMC - PMC13524666 OTO - NOTNLM OT - Interhospital transfer OT - Pulmonary embolism OT - Surgical management EDAT- 2026/07/22 12:37 MHDA- 2026/10/15 23:30 PMCR- 2026/07/21 CRDT- 2026/07/21 19:10 PHST- 2026/04/01 00:00 [received] PHST- 2026/07/07 00:00 [revised] PHST- 2026/07/12 00:00 [accepted] PHST- 2026/10/15 23:30 [medline] PHST- 2026/07/22 12:37 [pubmed] PHST- 2026/07/21 19:10 [entrez] PHST- 2026/07/21 00:00 [pmc-release] AID - S2213-333X(26)00140-X [pii] AID - 102580 [pii] AID - 10.1016/j.jvsv.2026.102580 [doi] PST - ppublish SO - J Vasc Surg Venous Lymphat Disord. 2026 Nov;14(6):102580. doi: 10.1016/j.jvsv.2026.102580. Epub 2026 Jul 21. PMID- 42479608 OWN - NLM STAT- In-Process LR - 20261012 IS - 2047-4881 (Electronic) IS - 2047-4873 (Linking) VI - 33 IP - 14 DP - 2026 Oct 13 TI - Multidisciplinary cardiac rehabilitation-an indispensable therapeutic intervention when starting a GLP-1 receptor agonist therapy? PG - 2675-2677 LID - 10.1093/eurjpc/zwag351 [doi] FAU - Rauch, Bernhard AU - Rauch B AUID- ORCID: 0000-0003-2391-8466 AD - Stiftung IHF, Institut fur Herzinfarktforschung Ludwigshafen, Bremserstrasse 79, D-67063 Ludwighafen am Rhein, Germany. FAU - Tessitore, Elena AU - Tessitore E AUID- ORCID: 0000-0003-1680-0152 AD - Cardiology Division, Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 4, Geneva 1205, Switzerland. LA - eng PT - Journal Article PL - England TA - Eur J Prev Cardiol JT - European journal of preventive cardiology JID - 101564430 SB - IM COIS- Conflict of interest: There are no conflicts of interest to be declared . EDAT- 2026/07/21 18:34 MHDA- 2026/07/21 18:34 CRDT- 2026/07/21 13:03 PHST- 2026/07/21 18:34 [pubmed] PHST- 2026/07/21 18:34 [medline] PHST- 2026/07/21 13:03 [entrez] AID - 8739285 [pii] AID - 10.1093/eurjpc/zwag351 [doi] PST - ppublish SO - Eur J Prev Cardiol. 2026 Oct 13;33(14):2675-2677. doi: 10.1093/eurjpc/zwag351. PMID- 42478986 OWN - NLM STAT- MEDLINE DCOM- 20260721 LR - 20260820 IS - 1221-9118 (Print) IS - 1221-9118 (Linking) VI - 121 IP - 3 DP - 2026 Jun TI - Cardiotoxicity Associated with Antineoplastic Therapy: A Multidisciplinary Approach to Personalized Monitoring Using Radionuclide Imaging and Molecular Biomarkers. PG - 328-336 LID - 10 [pii] LID - 10.21614/chirurgia.3310 [doi] AB - Background: Cardiotoxicity associated with antineoplastic therapy may compromise both cardiovascular outcomes and continuity of cancer treatment. We evaluated a multimodal strategy based on radionuclide imaging and molecular biomarkers for early detection of subclinical cardiac dysfunction and for personalized monitoring applicable in multidisciplinary oncologic care. Methodology: In this prospective, observational, single-center study, 90 adults with breast cancer, lymphoma, or lung cancer receiving potentially cardiotoxic regimens were evaluated at baseline (T0), after 3-4 cycles (T1), at treatment completion (T2), and at 6-month follow-up (T3). Antineoplastic exposure was classified according to dominant cardiotoxic profile, including anthracycline-containing regimens, anti-HER2 therapy, platinum/taxane-based chemotherapy, immunotherapy, and targeted agents when used. Monitoring included clinical assessment, ECG, MUGA/gated SPECT, echocardiography with LVEF and GLS, and serial hs-Tn, NT-proBNP, and sST2. Results: Median age was 56 years, and 62% of patients were women. Mean baseline LVEF was 60A+-5% and mean GLS A cent? '19.5A+-2.1%. During treatment, hs-Tn, NT-proBNP, and sST2 increased progressively, while LVEF declined to 57A+-6% and GLS to A cent? '16.6A+-2.5% at treatment completion. Imaging-defined cardiac dysfunction occurred in 30% of patients, including overt cardiotoxicity in 10%. Changes in hs-Tn correlated most strongly with GLS (r=A cent? '0.42, p=0.002). The integrated model showed the best predictive performance (AUC 0.91). Conclusions: Beyond diagnostic value, this multimodal model may support multidisciplinary decision-making in surgical oncology by identifying patients who require intensified surveillance, early cardioprotection, preoperative optimization, or adjustment of treatment sequencing. The findings should be interpreted as clinically promising and hypothesis-generating, requiring multicenter validation before routine implementation. CI - Celsius. FAU - Kajanto, Lidia Anca AU - Kajanto LA FAU - Stanculeanu, Dana Lucia AU - Stanculeanu DL FAU - Ionescu, Anita-Cristina AU - Ionescu AC FAU - Sa Rbu, Ioan AU - Sa Rbu I FAU - Popovici, Ion Alexandru AU - Popovici IA FAU - Bulbuc, Ionut AU - Bulbuc I FAU - Pundiche, Mihaela AU - Pundiche M FAU - Manea-Sabau, Ileana-Delia AU - Manea-Sabau ID FAU - Kajanto, Andreea Diana AU - Kajanto AD FAU - Caraban, Bogdan AU - Caraban B LA - eng PT - Journal Article PT - Observational Study PL - Romania TA - Chirurgia (Bucur) JT - Chirurgia (Bucharest, Romania : 1990) JID - 9213031 RN - 0 (Biomarkers) RN - 0 (Antineoplastic Agents) RN - 114471-18-0 (Natriuretic Peptide, Brain) RN - 0 (pro-brain natriuretic peptide (1-76)) RN - 0 (Peptide Fragments) RN - 0 (Troponin) SB - IM MH - Humans MH - Female MH - Middle Aged MH - Prospective Studies MH - Biomarkers/blood MH - Male MH - *Cardiotoxicity/etiology/blood/diagnosis MH - *Antineoplastic Agents/adverse effects MH - Natriuretic Peptide, Brain/blood MH - Aged MH - Predictive Value of Tests MH - Adult MH - Peptide Fragments/blood MH - Treatment Outcome MH - Tomography, Emission-Computed, Single-Photon MH - Breast Neoplasms/drug therapy MH - Lung Neoplasms/drug therapy MH - Precision Medicine/methods MH - Echocardiography MH - Troponin/blood MH - Follow-Up Studies OTO - NOTNLM OT - antineoplastictherapy OT - biomarkers OT - cardiotoxicity OT - globallongitudinalstrain OT - multidisciplinarycare OT - radionuclideimaging EDAT- 2026/07/21 12:35 MHDA- 2026/07/21 12:36 CRDT- 2026/07/21 10:13 PHST- 2026/06/01 00:00 [accepted] PHST- 2026/07/21 12:36 [medline] PHST- 2026/07/21 12:35 [pubmed] PHST- 2026/07/21 10:13 [entrez] AID - 10 [pii] AID - 10.21614/chirurgia.3310 [doi] PST - ppublish SO - Chirurgia (Bucur). 2026 Jun;121(3):328-336. doi: 10.21614/chirurgia.3310. PMID- 42478356 OWN - NLM STAT- MEDLINE DCOM- 20260814 LR - 20260816 IS - 2055-5822 (Electronic) IS - 2055-5822 (Linking) VI - 13 IP - 4 DP - 2026 Jul 4 TI - Indication for durable mechanical circulatory support: an expert opinion review. LID - 10.1093/eschf/xvag201 [doi] LID - xvag201 AB - Advanced heart failure represents a significant and expanding clinical challenge, establishing durable mechanical circulatory support as the critical therapeutic pillar, whether utilized as a bridge to transplantation or as a standalone therapy. This expert review provides a contemporary clinical decision framework that supplements existing guidelines by shifting the primary focus towards the pre-operative phase and the essential multidisciplinary processes required for clinical success. This review emphasizes precise patient selection and pre-operative optimization strategies designed to mitigate medical harm. This is particularly important in complex scenarios with relevant cardiac and non-cardiac comorbidities and in early stages of advanced heart failure to adequately address specific high-risk populations and conditions. By codifying the necessity of interdisciplinary team dynamics, targeted ambulatory as well as in-hospital workups, and shared decision-making, this review provides a structured approach to ensure equitable access and optimal long-term survival within the evolving landscape of advanced heart failure care. CI - (c) The Author(s) 2026. Published by Oxford University Press on behalf of the European Society of Cardiology. FAU - Schoenrath, Felix AU - Schoenrath F AUID- ORCID: 0000-0002-8221-1295 AD - Deutsches Herzzentrum der Charite, Department of Cardiothoracic and Vascular Surgery, Augustenburger Platz 1, Berlin 13353, Germany. AD - Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Chariteplatz 1, Berlin 10117, Germany. AD - DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Berlin, Germany. FAU - Bonios, Michael AU - Bonios M AUID- ORCID: 0000-0003-0425-6532 AD - Heart Failure and Transplant Unit, Onassis Cardiac Surgery Centre, Athens, Greece. FAU - Iacovoni, Attilio AU - Iacovoni A AUID- ORCID: 0000-0003-0347-6672 AD - Cardiovascular Department, ASST Papa Giovanni XXIII Hospital, Bergamo, Italy. FAU - Just, Isabell Anna AU - Just IA AUID- ORCID: 0000-0003-1141-9387 AD - Deutsches Herzzentrum der Charite, Department of Cardiothoracic and Vascular Surgery, Augustenburger Platz 1, Berlin 13353, Germany. AD - Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Chariteplatz 1, Berlin 10117, Germany. AD - DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Berlin, Germany. FAU - Roehrich, Luise AU - Roehrich L AUID- ORCID: 0000-0002-8826-075X AD - Deutsches Herzzentrum der Charite, Department of Cardiothoracic and Vascular Surgery, Augustenburger Platz 1, Berlin 13353, Germany. AD - Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Chariteplatz 1, Berlin 10117, Germany. AD - DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Berlin, Germany. FAU - Miera, Oliver AU - Miera O AUID- ORCID: 0000-0002-7643-1611 AD - Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Chariteplatz 1, Berlin 10117, Germany. AD - Department of Congenital Heart Disease-Pediatric Cardiology, Deutsches Herzzentrum der Charite (DHZC), Berlin, Germany. FAU - Baudry, Guillaume AU - Baudry G AUID- ORCID: 0000-0002-9200-2729 AD - Universite de Lorraine, INSERM, Centre D'Investigation Clinique 1433, CHRU de Nancy, Inserm U1116 and INI-CRCT (Cardiovascular and Renal Clinical Trialists F-CRIN Network), Nancy, France. AD - REICATRA, Recherche et Enseignement en IC Avancee, Transplantation, Assistance, Universite de Lorraine, Vandoeuvre-les-Nancy, France. FAU - Ben Gal, Tuvia AU - Ben Gal T AUID- ORCID: 0000-0001-6941-1738 AD - Heart Failure Unit, Cardiology Department, Rabin Medical Center, Grey School of Medicine, Tel-Aviv University, Tel Aviv, Israel. FAU - Crespo-Leiro, Maria Generosa AU - Crespo-Leiro MG AUID- ORCID: 0000-0002-3085-167X AD - Hospital Universitario A Coruna (CHUAC), Instituto Investigacion Biomedica A Coruna (INIBIC), A Coruna, Spain. AD - Centro Investigacion Biomedica en Red Cardiovascular (CIBERCV), Madrid, Spain. FAU - Joyce, Emer AU - Joyce E AUID- ORCID: 0000-0002-1241-0870 AD - Department of Cardiology, Mater University Hospital, Dublin, Ireland. AD - School of Medcine, University College Dublin, Dublin, Ireland. FAU - Kapelios, Chris J AU - Kapelios CJ AUID- ORCID: 0000-0003-1616-6307 AD - Heart Failure Unit, 2nd Department of Cardiology, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece. FAU - Lim, Hoong Sern AU - Lim HS AUID- ORCID: 0000-0002-6569-1805 AD - Department of Cardiology, University Hospitals Birmingham NHS Foundation Trust, Edgbaston, Birmingham, UK. FAU - Skouri, Hadi AU - Skouri H AUID- ORCID: 0000-0003-0541-4926 AD - Cardiology Department, School of Medicine, Balamand University, Beirut, Lebanon. AD - Cardiology Division, Sheikh Shakhbout Medical City, Abu Dhabi, UAE. FAU - Damman, Kevin AU - Damman K AUID- ORCID: 0000-0003-0190-2228 AD - Department of Cardiology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, Location AB31, 9713 GZ Groningen, The Netherlands. LA - eng PT - Journal Article PT - Review PL - England TA - ESC Heart Fail JT - ESC heart failure JID - 101669191 SB - IM MH - Humans MH - *Heart Failure/therapy/surgery/physiopathology MH - *Heart-Assist Devices MH - *Patient Selection PMC - PMC13475127 OTO - NOTNLM OT - Advanced heart failure OT - Cardiogenic shock OT - Durable mechanical circulatory support OT - European Society of Cardiology OT - Heart Failure Association OT - Ventricular assist device EDAT- 2026/07/21 06:34 MHDA- 2026/08/14 17:39 PMCR- 2026/07/21 CRDT- 2026/07/21 04:53 PHST- 2026/04/08 00:00 [received] PHST- 2026/06/12 00:00 [revised] PHST- 2026/07/14 00:00 [accepted] PHST- 2026/08/14 17:39 [medline] PHST- 2026/07/21 06:34 [pubmed] PHST- 2026/07/21 04:53 [entrez] PHST- 2026/07/21 00:00 [pmc-release] AID - 8738995 [pii] AID - xvag201 [pii] AID - 10.1093/eschf/xvag201 [doi] PST - ppublish SO - ESC Heart Fail. 2026 Jul 4;13(4):xvag201. doi: 10.1093/eschf/xvag201. PMID- 42477111 OWN - NLM STAT- Publisher LR - 20260720 IS - 1476-5543 (Electronic) IS - 0743-8346 (Linking) DP - 2026 Jul 20 TI - Targeted neonatal echocardiography-guided management of high flow cerebral vascular malformations: Impact of a multidisciplinary neurohemodynamics team. LID - 10.1038/s41372-026-02787-7 [doi] AB - BACKGROUND AND OBJECTIVE: High-flow cerebral vascular malformations (HFCVM) are rare, life-threatening anomalies causing severe neonatal cardiorespiratory compromise. Targeted neonatal echocardiography (TNE) enables detailed hemodynamic assessment to guide stabilization and embolization timing. We evaluated a multidisciplinary, TNE-guided protocol to optimize individualized care and shorten shunting duration. METHODS: Single-center case series of five neonates with HFCVM admitted to a Level IV NICU (June 2022-June 2025). The protocol incorporated serial TNE for prenatal diagnosis, pre-/post-embolization care, and intra-procedural monitoring. TNE categorized cardiovascular phenotypes, guided embolization timing, and monitored cardiac function. RESULTS: Five neonates with HFCVM were managed using this protocol. Median number of embolizations per neonate were 2 (2.0-2.5). Four patients exhibited flow-mediated physiology with high cardiac output and ductal-dependent systemic perfusion. Four patients survived to discharge. One patient experienced a fatal intracranial hemorrhage. CONCLUSION: A physiology-driven, TNE-guided approach for neonatal HFCVM is feasible and supports tailored hemodynamic management and staged embolization. Prospective multicenter validation is warranted. CI - (c) 2026. The Author(s). FAU - Aleem, N A AU - Aleem NA AD - Division of Neonatology, Department of Pediatrics, University of Iowa Healthcare, Iowa City, IA, USA. FAU - Stanford, A H AU - Stanford AH AUID- ORCID: 0000-0003-0015-466X AD - Division of Neonatology, Department of Pediatrics, University of Iowa Healthcare, Iowa City, IA, USA. FAU - Lee, S S AU - Lee SS AUID- ORCID: 0000-0003-1253-6366 AD - Division of Neonatology, Department of Pediatrics, University of Iowa Healthcare, Iowa City, IA, USA. FAU - Ortega-Gutierrez, S AU - Ortega-Gutierrez S AD - Department of Neurology, Neurosurgery and Radiology, University of Iowa Healthcare, Iowa City, IA, USA. FAU - McNamara, P J AU - McNamara PJ AUID- ORCID: 0000-0001-7648-8872 AD - Division of Neonatology, Department of Pediatrics, University of Iowa Healthcare, Iowa City, IA, USA. patrick-mcnamara@uiowa.edu. LA - eng PT - Journal Article DEP - 20260720 PL - United States TA - J Perinatol JT - Journal of perinatology : official journal of the California Perinatal Association JID - 8501884 SB - IM COIS- Competing interests: The authors have no conflicts of interest to declare. SOG receive grant from NIH-NINDS (RO1NS127114, RO1NS138765, RO3NS126804), PCORI, Stryker, Medtronic, Methinks. He is a consultant for Medtronic and Stryker Neurovascular. He is National PI or CO-PI for US tandem Registry, DONE SYMPLE, DIRECT, VOTER registry, ATHENA, SMAR-LVO and Institutional PI/ Steering Committee for SEGA, TESLA, and SELECT 2, SPLENDID, SUMMIT, MYSTIQUE. Holds Shares/Stock options on BrainFlow, Motif, Gravity and EUREKA. ethics: This study protocol was reviewed and approved by the Institutional Review Board at the University of Iowa. Written consent was not obtained from the included human participants as an exemption was granted by the Institutional Review Board given that all data collected was retrospective. EDAT- 2026/07/21 00:35 MHDA- 2026/07/21 00:35 CRDT- 2026/07/20 23:23 PHST- 2025/12/11 00:00 [received] PHST- 2026/06/17 00:00 [accepted] PHST- 2026/04/28 00:00 [revised] PHST- 2026/07/21 00:35 [medline] PHST- 2026/07/21 00:35 [pubmed] PHST- 2026/07/20 23:23 [entrez] AID - 10.1038/s41372-026-02787-7 [pii] AID - 10.1038/s41372-026-02787-7 [doi] PST - aheadofprint SO - J Perinatol. 2026 Jul 20. doi: 10.1038/s41372-026-02787-7. PMID- 42475150 OWN - NLM STAT- MEDLINE DCOM- 20260720 LR - 20260720 IS - 0038-3317 (Print) IS - 0038-3317 (Linking) VI - 78 IP - 11 DP - 2025 Nov TI - Heart Failure With Reduced Ejection Fraction Update: A Review Of Clinical Trials and New Therapeutic Considerations. PG - 519-522 AB - Heart failure with reduced ejection fraction (HFrEF) is a prevalent and complex condition characterized by the heart's inability to pump sufficient blood, leading to significant morbidity and mortality. It is primarily caused by ischemic heart disease, hypertension, and dilated cardiomyopathy. The pathophysiology of HFrEF involves myocardial remodeling, neurohormonal activation, and resultant systolic dysfunction, contributing to symptoms like dyspnea and fatigue. Comorbidities such as diabetes, obesity, and chronic kidney disease exacerbate its progression. Diagnosis relies on clinical symptoms, biomarkers, and imaging, including echocardiography and chest radiography. Key therapies for HFrEF include Renin-Angiotensin-Aldosterone System (RAAS) inhibitors [Angiotensin-converting enzyme (ACE) inhibitors, Angiotensin II Receptor Blockers (ARBs), Angiotensin receptor-neprilysin inhibitor (ARNIs)], beta-blockers, and mineralocorticoid receptor antagonists, which improve survival and reduce hospitalizations. The use of sodium-glucose cotransporter-2 (SGLT2) inhibitors and intravenous iron therapy has also become integral to treatment, showing benefits in reducing mortality and improving symptoms. Device therapies, such as implantable cardioverter-defibrillators (ICDs), cardiac resynchronization therapy (CRT), and left ventricular assist devices (LVADs), are critical for advanced cases. Despite therapeutic advancements, challenges remain in optimal dosing, patient adherence, and the integration of newer therapies. Ongoing trials, including those investigating the AccuCinch Ventricular Restoration System and novel antibodies, promise to expand treatment options. Ultimately, a multidisciplinary approach, personalized care, and continuous research are essential to improving outcomes in HFrEF, a condition that remains a major global health burden. CI - Copyright(c) South Dakota State Medical Association. FAU - Wasef, Natale AU - Wasef N AD - Cardiology Fellowship Program, University of South Dakota Sanford School of Medicine. AD - Sanford USD Medical Center, Sioux Falls, South Dakota. FAU - Stys, Adam AU - Stys A AD - Cardiology Fellowship Program, University of South Dakota Sanford School of Medicine. AD - Sanford USD Medical Center, Sioux Falls, South Dakota. LA - eng PT - Journal Article PT - Review PL - United States TA - S D Med JT - South Dakota medicine : the journal of the South Dakota State Medical Association JID - 101265265 RN - 0 (Angiotensin-Converting Enzyme Inhibitors) RN - 0 (Angiotensin Receptor Antagonists) SB - IM MH - Humans MH - *Heart Failure/therapy/physiopathology/diagnosis MH - *Stroke Volume MH - Clinical Trials as Topic MH - Angiotensin-Converting Enzyme Inhibitors/therapeutic use MH - Angiotensin Receptor Antagonists/therapeutic use EDAT- 2026/07/20 12:40 MHDA- 2026/07/20 18:35 CRDT- 2026/07/20 11:53 PHST- 2026/07/20 18:35 [medline] PHST- 2026/07/20 12:40 [pubmed] PHST- 2026/07/20 11:53 [entrez] PST - ppublish SO - S D Med. 2025 Nov;78(11):519-522. PMID- 42470860 OWN - NLM STAT- MEDLINE DCOM- 20260906 LR - 20260914 IS - 1879-1360 (Electronic) IS - 0022-3999 (Linking) VI - 210 DP - 2026 Nov TI - Cardiovascular risks in psychiatric disorders and psychiatric risks in cardiovascular disorders: implications for prevention and clinical management - a large-scale umbrella review encompassing 76 meta-analyses. PG - 112930 LID - S0022-3999(26)00414-9 [pii] LID - 10.1016/j.jpsychores.2026.112930 [doi] AB - OBJECTIVE: Psychiatric and cardiovascular disorders often co-occur, complicating their assessment and management. No umbrella review(UR) has summarized the meta-analytic evidence on the co-occurrence of psychiatric and cardiovascular disorders and assessed its credibility. METHODS: Meta-analytic systematic reviews of observational studies documenting the prevalence, risk factors, and outcomes associated with the co-occurrence of cardiovascular and psychiatric disorders, indexed from inception through March.16.2026, and meeting established diagnostic criteria, were included. Meta-analytic association and prevalence estimates were recalculated and graded based on established or adapted criteria. The AMSTAR-2 assessed the quality of the meta-analyses, while several subgroup analyses and meta-regressions aimed to explain the heterogeneity. RESULTS: We included 76 meta-analyses yielding 131 meta-analytic estimates. Based on pre-existing meta-analytic evidence, 22/24 prevalence estimates (91.7%) met moderate/strong credibility criteria. Strong credibility emerged for: orthostatic hypotension in Lewy body(58%;95%C.I. = 50-66%) and Alzheimer's dementias(28.0% = 95%C.I. = 17.0-40.0%); pericardial effusion in anorexia nervosa(25.0%;95%C.I. = 17.0-34.0%); in heart failure(HF): major depressive disorder(MDD)(41.9%;95%C.I. = 36.7-47.1%), mild cognitive impairment(MCI)(41.4%;95%C.I. = 38.3-45.6%), anxiety(32.0%;95%C.I. = 26.5-37.6%), MDD + anxiety(24.7%;95%C.I. = 17.9-34.3%), and dementia(19.8%;95%C.I. = 12.9-27.8%); in atrial fibrillation(AF): MCI(26.0%;95%C.I. = 21.0-30.0%), anxiety in patients undergoing pulmonary vein isolation(PVI)(25.0%;95%C.I. = 12.0-46.0%), MDD in PVI patients (20.0%;95%C.I. = 13.0-29.0%); in coronary artery disease: MDD + anxiety(19.8%;95%C.I. = 16.0-24.6%): in schizophrenia spectrum disorders: clozapine-associated-cardiomyopathy(0.6%;95%C.I. = 0.2-2.3%); clozapine-associated-cardiomyopathy absolute death rates (0.0003;95%C.I. = 0.0001-0.0012); clozapine-associated-cardiomyopathy case fatality rate (0.078;95%C.I. = 0.018-0.285). Several additional disorders were multimorbid in>5% of people, yet with a lower credibility rating. No re-pooled risk factors/outcomes reached strong credibility criteria. CONCLUSIONS: The present study provides an atlas of cardiovascular and psychiatric multimorbidity across varying levels of credibility, reinforcing the need for an integrated, multidisciplinary approach to patient care and for more research on actionable risk/protective factors and outcomes. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Fornaro, Michele AU - Fornaro M AD - Department of Psychiatry, Federico II University of Naples, Italy. Electronic address: dott.fornaro@gmail.com. FAU - Di Lorenzo, Chiara AU - Di Lorenzo C AD - Federico II University of Naples, Italy. FAU - Esposito, Augusto AU - Esposito A AD - University Cardiology, Luigi Vanvitelli University of Campania, AORN Sant'Anna e San Sebastiano of Caserta, Italy. FAU - Perona, Davide AU - Perona D AD - Division of Cardiology, Medical Center San Giuseppe - Voghera (Pavia), Italy. LA - eng PT - Journal Article PT - Systematic Review DEP - 20260717 PL - England TA - J Psychosom Res JT - Journal of psychosomatic research JID - 0376333 SB - IM MH - Humans MH - *Cardiovascular Diseases/epidemiology/prevention & control MH - *Comorbidity MH - *Mental Disorders/epidemiology MH - Meta-Analysis as Topic MH - Risk Factors MH - Systematic Reviews as Topic OTO - NOTNLM OT - Cardiology OT - Multi-morbidity OT - Psychiatry OT - Risk factor OT - Umbrella review OT - meta-analysis COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/07/19 04:00 MHDA- 2026/09/06 23:34 CRDT- 2026/07/18 18:04 PHST- 2026/04/29 00:00 [received] PHST- 2026/07/07 00:00 [revised] PHST- 2026/07/16 00:00 [accepted] PHST- 2026/09/06 23:34 [medline] PHST- 2026/07/19 04:00 [pubmed] PHST- 2026/07/18 18:04 [entrez] AID - S0022-3999(26)00414-9 [pii] AID - 10.1016/j.jpsychores.2026.112930 [doi] PST - ppublish SO - J Psychosom Res. 2026 Nov;210:112930. doi: 10.1016/j.jpsychores.2026.112930. Epub 2026 Jul 17. PMID- 42469616 OWN - NLM STAT- MEDLINE DCOM- 20261016 LR - 20261022 IS - 1471-2261 (Electronic) IS - 1471-2261 (Linking) VI - 26 IP - 1 DP - 2026 Jul 18 TI - Stakeholder experiences and expectations of transition of care services to reduce medication-related hospital readmission for cardiology patients. LID - 10.1186/s12872-026-06294-7 [doi] LID - 930 AB - BACKGROUND: Transition of care (ToC) for patients with cardiovascular diseases is a complex, high-risk period often leading to medication-related harm (MRH) and hospital readmissions. While specialised programs exist, a gap in individualised medication management services exist for specific cardiology patient populations. Pharmacist-led, interdisciplinary ToC services have demonstrated a positive impact on patient outcomes. The REducing hospital re-admission for high-risk CARDiology patients (RECARD) program aims to address this by co-designing, implementing, and evaluating a new pharmacist-led ToC service in post-acute myocardial infarction (AMI) or cardiac surgery patients. The current study focuses on understanding the experiences and expectations of patients and clinicians to inform the development of this service. METHODS: This qualitative study utilised semi-structured interviews and focus groups to gather data from patients and hospital and community clinicians aligned with three Queensland hospitals and surrounding primary and community care settings. Patients who had experienced an AMI or cardiac surgery in the past three months were interviewed via telephone or Microsoft TEAMS. Clinicians participated in focus groups or individual interviews. Data were audio-recorded, transcribed, and analysed using the six-phase thematic analysis method by Braun and Clarke, guided by Bradshaw's model of need to understand stakeholders' expressed and comparative needs. RESULTS: Data were obtained from 13 patient interviews and 40 clinicians, through seven focus groups and one interview. Three main themes, with associated subthemes, emerged from the data; Patient-level issues, System and process issues and Interprofessional collaboration. Patients described information overload, medication uncertainty, and anxiety at discharge, while clinicians identified delayed discharge summaries, fragmented communication with primary care, and service gaps - particularly impacting rural patients- as key risks for medication‑related harm. CONCLUSIONS: The study's findings highlight the critical need for a patient-centred, pharmacist-led interdisciplinary ToC service that addresses patient knowledge deficits, psychosocial barriers, and the communication gaps between hospital and community care settings. The results from this study will inform the development of the RECARD program's "Adaptive ToC Pathway," ensuring it is tailored to meet the specific needs and expectations of both patients and clinicians, ultimately aiming to reduce MRH and hospital readmissions. CI - (c) 2026. The Author(s). FAU - Wilkinson, Shelley A AU - Wilkinson SA AUID- ORCID: 0000-0003-3365-3473 AD - School of Pharmacy and Pharmaceutical Sciences, Pharmacy Australia Centre of Excellence, The University of Queensland, Cornwall St, Dutton Park , 4102, Australia. s.wilkinson@uq.edu.au. AD - Department of Obstetric Medicine, Mater Mothers' Hospitals, South Brisbane, 4101, Australia. s.wilkinson@uq.edu.au. FAU - Snoswell, Centaine AU - Snoswell C AD - School of Pharmacy and Pharmaceutical Sciences, Pharmacy Australia Centre of Excellence, The University of Queensland, Cornwall St, Dutton Park , 4102, Australia. FAU - Raggatt, Liza AU - Raggatt L AD - School of Pharmacy and Pharmaceutical Sciences, Pharmacy Australia Centre of Excellence, The University of Queensland, Cornwall St, Dutton Park , 4102, Australia. AD - Pharmacy Department, Royal Brisbane and Women's Hospital, Herston, Brisbane, 4029, Australia. FAU - Coombes, Ian AU - Coombes I AD - School of Pharmacy and Pharmaceutical Sciences, Pharmacy Australia Centre of Excellence, The University of Queensland, Cornwall St, Dutton Park , 4102, Australia. AD - Pharmacy Department, Royal Brisbane and Women's Hospital, Herston, Brisbane, 4029, Australia. FAU - Robertson, Kelvin AU - Robertson K AD - Pharmacy Department, Townsville University Hospital, Douglas, Townsville, 4814, Australia. FAU - Miles, Jared AU - Miles J AD - School of Pharmacy and Pharmaceutical Sciences, Pharmacy Australia Centre of Excellence, The University of Queensland, Cornwall St, Dutton Park , 4102, Australia. AD - Poche Centre for Indigenous Health, The University of Queensland, St Lucia, Brisbane, 4067, Australia. FAU - Wang, William Y S AU - Wang WYS AD - Princess Alexandra Southside Clinical Unit, The University of Queensland, Woolloongabba, Brisbane, 4102, Australia. AD - Cardiology Department, Princess Alexandra Hospital, Woolloongabba, Brisbane, 4102, Australia. FAU - Atherton, John J AU - Atherton JJ AD - Faculty of Health, Medicine and Behavioural Sciences, Cardiology Department, Royal Brisbane and Women's Hospital, University of Queensland, Herston, Brisbane, 4029, Australia. FAU - Paradissis, Chariclia AU - Paradissis C AD - School of Pharmacy and Pharmaceutical Sciences, Pharmacy Australia Centre of Excellence, The University of Queensland, Cornwall St, Dutton Park , 4102, Australia. FAU - Carson, Sue AU - Carson S AD - Faculty of Health, School of Clinical Sciences, Pharmacy, Queensland University of Technology, Brisbane, 4000, Australia. FAU - Jones, Andrew AU - Jones A AD - Data Science Collaborative Research Platform, The University of Queensland, St Lucia, Brisbane, 4067, Australia. FAU - Jensen, Estelle AU - Jensen E AD - School of Pharmacy and Pharmaceutical Sciences, Pharmacy Australia Centre of Excellence, The University of Queensland, Cornwall St, Dutton Park , 4102, Australia. AD - Pharmacy Department, The Princess Alexandra Hospital, Woolloongabba, Brisbane, 4102, Australia. FAU - Barras, Michael AU - Barras M AD - School of Pharmacy and Pharmaceutical Sciences, Pharmacy Australia Centre of Excellence, The University of Queensland, Cornwall St, Dutton Park , 4102, Australia. AD - Pharmacy Department, The Princess Alexandra Hospital, Woolloongabba, Brisbane, 4102, Australia. FAU - Falconer, Nazanin AU - Falconer N AD - School of Pharmacy and Pharmaceutical Sciences, Pharmacy Australia Centre of Excellence, The University of Queensland, Cornwall St, Dutton Park , 4102, Australia. AD - Pharmacy Department, The Princess Alexandra Hospital, Woolloongabba, Brisbane, 4102, Australia. LA - eng GR - MRFF 2022 Quality, Safety and Effectiveness of Medicine Use by Pharmacists Grant (no. MRFMMIP0000440)/Australian Government/ GR - (no. MRFMMIP0000440)/Australian Government, MRFF 2022 Quality, Safety and Effectiveness of Medicine Use by Pharmacists Grant/ PT - Journal Article PT - Multicenter Study DEP - 20260718 PL - England TA - BMC Cardiovasc Disord JT - BMC cardiovascular disorders JID - 100968539 RN - 0 (Cardiovascular Agents) SB - IM MH - Humans MH - *Patient Readmission MH - Male MH - Female MH - *Attitude of Health Personnel MH - Health Knowledge, Attitudes, Practice MH - *Cardiovascular Agents/adverse effects MH - Aged MH - Qualitative Research MH - *Pharmacists/organization & administration MH - *Stakeholder Participation MH - Middle Aged MH - Time Factors MH - *Cardiac Surgical Procedures/adverse effects MH - Focus Groups MH - Risk Factors MH - Patient Care Team/organization & administration MH - Interviews as Topic MH - Delivery of Health Care, Integrated/organization & administration MH - Interdisciplinary Communication MH - Myocardial Infarction MH - Professional Role MH - Treatment Outcome MH - *Cardiologists/psychology MH - *Patient Transfer PMC - PMC13673588 OTO - NOTNLM OT - Acute myocardial infarction OT - Cardiac surgery OT - Medication related harm OT - Transition of care COIS- Declarations. Ethics approval and consent to participate: Ethics approval was obtained from Metro North Health Human Research Ethics Committee (HREC) B (Patients: HREC/2024/MNHB/103581; Clinicians: HREC/2023/MNHB/104151), both were ratified by the University of Queensland HREC (Patients: 2024/HE000970; Clinicians: 2024/HE000962). Site specific approval was granted by each site (Metro North, Metro South, Townsville University Hospital Research Governance Offices). Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2026/07/18 00:38 MHDA- 2026/10/16 05:32 PMCR- 2026/07/18 CRDT- 2026/07/17 23:53 PHST- 2025/11/20 00:00 [received] PHST- 2026/07/10 00:00 [accepted] PHST- 2026/10/16 05:32 [medline] PHST- 2026/07/18 00:38 [pubmed] PHST- 2026/07/17 23:53 [entrez] PHST- 2026/07/18 00:00 [pmc-release] AID - 10.1186/s12872-026-06294-7 [pii] AID - 6294 [pii] AID - 10.1186/s12872-026-06294-7 [doi] PST - epublish SO - BMC Cardiovasc Disord. 2026 Jul 18;26(1):930. doi: 10.1186/s12872-026-06294-7. PMID- 42469071 OWN - NLM STAT- MEDLINE DCOM- 20260916 LR - 20261004 IS - 1532-8422 (Electronic) IS - 1053-0770 (Linking) VI - 40 IP - 10 DP - 2026 Oct TI - The Pediatric Cardiac Extubation Readiness Framework: An Evidence-Derived Translational Framework for Structured Extubation Assessment Following Pediatric Cardiac Surgery. PG - 3085-3100 LID - S1053-0770(26)00501-X [pii] LID - 10.1053/j.jvca.2026.06.024 [doi] AB - This Special Article aimed to develop an evidence-derived translational framework for structured assessment of readiness for early extubation following pediatric cardiac surgery, informed by a previously published systematic review and meta-analysis. Framework development was based on secondary synthesis of aggregated study-level data from pediatric cardiac surgical populations across multiple institutions; no clinical intervention was performed. Extracted study-level data, subgroup findings, sensitivity analyses, and predefined clinical interpretability criteria were used. Candidate variables associated with extubation timing and postoperative outcomes were mapped into clinically coherent domains according to recurrent representation within the evidence base, biological plausibility, and applicability to routine multidisciplinary assessment. The Pediatric Cardiac Extubation Readiness Framework (PCERF) was revised into a 2-layer translational framework. Layer 1 comprises age, weight, procedural complexity, cardiopulmonary stability, and peri-extubation pathway factors. Layer 2 comprises mandatory non-scored clinical safety modifiers intended to identify physiological states that may independently preclude consideration of early extubation. The numerical score structure, weight categories, equal weighting, and readiness bands are illustrative prototype framework components rather than statistically optimized or outcome-derived thresholds. PCERF is a hypothesis-generating translational framework intended to support structured multidisciplinary assessment of extubation readiness following pediatric cardiac surgery. It is not a validated prediction model and requires prospective multicenter evaluation before clinical implementation. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Alkhatip, Ahmed A A M M AU - Alkhatip AAAMM AD - Department of Anaesthesia, Birmingham Children's Hospital, Birmingham, United Kingdom; Department of Anesthesia, Pain Management and Surgical Intensive Care, Beni-Suef University Hospital and Faculty of Medicine, Beni Suef University, Beni Suef, Egypt. Electronic address: ahmed.alkhatip@nhs.net. FAU - Mills, Kerry E AU - Mills KE AD - Department of Science and Technology, University of Canberra, Canberra, Australia. Electronic address: kerry.mills@canberra.edu.au. FAU - Akram, Abdullah AU - Akram A AD - Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan. Electronic address: abdullahakram097@gmail.com. FAU - Farag, Ehab AU - Farag E AD - Department of Anesthesia, Pain Management and Surgical Intensive Care, Beni-Suef University Hospital and Faculty of Medicine, Beni Suef University, Beni Suef, Egypt. Electronic address: ehab.yaseeen@med.bsu.edu.eg. FAU - Hamza, Mohamed Khaled AU - Hamza MK AD - Department of Anesthesia, Kasr Al Ainy Faculty of Medicine and Cairo University Hospitals, Cairo University, Cairo, Egypt. Electronic address: mkhamza@kasralainy.edu.eg. FAU - Abdelkader, Mohamed AU - Abdelkader M AD - Department of Anesthesia, Pain Management and Surgical Intensive Care, Beni-Suef University Hospital and Faculty of Medicine, Beni Suef University, Beni Suef, Egypt. Electronic address: mohamed_abdelkader@med.bsu.edu.eg. FAU - Bahr, Mahmoud AU - Bahr M AD - Department of Anesthesia, Pain Management and Surgical Intensive Care, Beni-Suef University Hospital and Faculty of Medicine, Beni Suef University, Beni Suef, Egypt. Electronic address: mahmoud.mohamed1@med.bsu.edu.eg. FAU - ELEmady, Mohamed Farid Mohamed AU - ELEmady MFM AD - Department of Anesthesia, Kasr Al Ainy Faculty of Medicine and Cairo University Hospitals, Cairo University, Cairo, Egypt. Electronic address: mohamed.farid@hotmail.com. FAU - Hosny, Hisham AU - Hosny H AD - Department of Anesthesia, Kasr Al Ainy Faculty of Medicine and Cairo University Hospitals, Cairo University, Cairo, Egypt; Department of Cardiothoracic Anaesthesia and Intensive Care Medicine, Freeman Hospital, Newcastle upon Tyne Foundation Trust, Newcastle upon Tyne, United Kingdom. Electronic address: hisham.hosny@nhs.net. FAU - Sallam, Amr AU - Sallam A AD - Department of Anaesthesia, St. Vincent's University Hospital, Dublin, Ireland. Electronic address: dr.amrsallam@hotmail.com. FAU - Farag, Ahmed M G AU - Farag AMG AD - Department of Cardiac Anaesthesia, King Abdullah Medical City, Makkah al-Mukarramah, Saudi Arabia. Electronic address: galalfarag.a@kamc.med.sa. FAU - Wagih, Mohamed AU - Wagih M AD - Department of Anesthesia, Kasr Al Ainy Faculty of Medicine and Cairo University Hospitals, Cairo University, Cairo, Egypt. Electronic address: mohamedwagih@kasralainy.edu.eg. FAU - Naguib, Amr AU - Naguib A AD - Department of Anesthesia, Kasr Al Ainy Faculty of Medicine and Cairo University Hospitals, Cairo University, Cairo, Egypt. Electronic address: kazamora1979@hotmail.com. LA - eng PT - Journal Article DEP - 20260623 PL - United States TA - J Cardiothorac Vasc Anesth JT - Journal of cardiothoracic and vascular anesthesia JID - 9110208 SB - IM MH - Child MH - Humans MH - *Airway Extubation/methods/standards MH - *Cardiac Surgical Procedures/methods MH - *Translational Research, Biomedical/methods/standards OTO - NOTNLM OT - early extubation OT - extubation readiness OT - mechanical ventilation OT - pediatric cardiac surgery OT - perioperative care OT - translational framework COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/07/18 04:01 MHDA- 2026/09/16 23:34 CRDT- 2026/07/17 21:52 PHST- 2026/04/15 00:00 [received] PHST- 2026/06/13 00:00 [revised] PHST- 2026/06/17 00:00 [accepted] PHST- 2026/09/16 23:34 [medline] PHST- 2026/07/18 04:01 [pubmed] PHST- 2026/07/17 21:52 [entrez] AID - S1053-0770(26)00501-X [pii] AID - 10.1053/j.jvca.2026.06.024 [doi] PST - ppublish SO - J Cardiothorac Vasc Anesth. 2026 Oct;40(10):3085-3100. doi: 10.1053/j.jvca.2026.06.024. Epub 2026 Jun 23. PMID- 42466555 OWN - NLM STAT- MEDLINE DCOM- 20260729 LR - 20260826 IS - 2047-9980 (Electronic) IS - 2047-9980 (Linking) VI - 15 IP - 14 DP - 2026 Jul 21 TI - Nontechnical Skills and Leadership Are Associated With More Efficient Mechanical Cardiopulmonary Resuscitation Deployment in Real-World Cardiac Arrest. PG - e049012 LID - 10.1161/JAHA.125.049012 [doi] LID - e049012 AB - BACKGROUND: Mechanical cardiopulmonary resuscitation (MCPR) devices provide consistent compressions, yet guidelines discourage routine use partly because deployment can increase no-flow time. Although nontechnical skills improve manual CPR performance, their association with deployment safety during MCPR remains unclear. This study examined the association between nontechnical skills and cumulative no-flow time during MCPR deployment in real-world resuscitations. METHODS: We conducted a prospective observational study of video-recorded cardiac arrest events in a tertiary emergency department. NTS were assessed by trained raters using the Team Emergency Assessment Measure (TEAM). The primary outcome was the association between TEAM scores and cumulative no-flow time during deployment, analyzed with multivariable linear mixed-effects models adjusted for patient characteristics and team leader clustering. Secondary outcomes included MCPR deployment duration and other technical intervals. RESULTS: Eighty-five eligible MCPR cases were analyzed. For each 1-point increase in TEAM global rating, cumulative no-flow time was 6 seconds shorter (95% CI, -10 to -1; P=0.009). Higher TEAM global rating was also associated with shorter MCPR deployment duration (-20 seconds; P=0.003) and earlier intravenous line placement (-43 seconds; P=0.011). Leadership was the only TEAM subdimension significantly associated with cumulative no-flow time (P=0.010). CONCLUSIONS: Higher nontechnical skills ratings, particularly leadership, were associated with shorter cumulative no-flow time and greater operational efficiency during MCPR deployment. These findings support an association between team nontechnical performance and deployment efficiency in real-world mechanical resuscitation. FAU - Lien, Chun-Ju AU - Lien CJ AUID- ORCID: 0009-0001-6417-876X AD - Department of Emergency Medicine National Taiwan University Hospital Hsin-Chu Branch Hsinchu Taiwan. FAU - Huang, Shuo-Kuen AU - Huang SK AUID- ORCID: 0000-0002-8524-6389 AD - Department of Emergency Medicine National Taiwan University Hospital Hsin-Chu Branch Hsinchu Taiwan. FAU - Chang, Jia-How AU - Chang JH AUID- ORCID: 0000-0003-3545-4507 AD - Department of Emergency Medicine National Taiwan University Hospital Hsin-Chu Branch Hsinchu Taiwan. FAU - Huang, Edward Pei-Chuan AU - Huang EP AUID- ORCID: 0000-0002-4800-2561 AD - Department of Emergency Medicine National Taiwan University Hospital Hsin-Chu Branch Hsinchu Taiwan. AD - Department of Emergency Medicine, College of Medicine National Taiwan University Taipei Taiwan. AD - Department of Emergency Medicine National Taiwan University Hospital Taipei Taiwan. LA - eng PT - Journal Article PT - Observational Study PT - Research Support, Non-U.S. Gov't DEP - 20260717 PL - England TA - J Am Heart Assoc JT - Journal of the American Heart Association JID - 101580524 SB - IM MH - Humans MH - *Heart Arrest/therapy/diagnosis MH - *Cardiopulmonary Resuscitation/instrumentation/methods MH - *Leadership MH - Prospective Studies MH - Male MH - Video Recording MH - Time Factors MH - Female MH - *Clinical Competence MH - Middle Aged MH - Aged MH - Emergency Service, Hospital MH - Patient Care Team PMC - PMC13477304 OTO - NOTNLM OT - Team Emergency Assessment Measure OT - leadership OT - mechanical CPR OT - nontechnical skills OT - resuscitation COIS- None. EDAT- 2026/07/17 12:41 MHDA- 2026/07/29 18:38 PMCR- 2026/07/17 CRDT- 2026/07/17 07:23 PHST- 2026/07/29 18:38 [medline] PHST- 2026/07/17 12:41 [pubmed] PHST- 2026/07/17 07:23 [entrez] PHST- 2026/07/17 00:00 [pmc-release] AID - JAH370911 [pii] AID - 10.1161/JAHA.125.049012 [doi] PST - ppublish SO - J Am Heart Assoc. 2026 Jul 21;15(14):e049012. doi: 10.1161/JAHA.125.049012. Epub 2026 Jul 17. PMID- 42464602 OWN - NLM STAT- Publisher LR - 20260717 IS - 1308-4488 (Electronic) IS - 1016-5169 (Linking) DP - 2026 Jul 17 TI - Suspected Tick-Borne Viral Infection-Associated Myocarditis Presenting with ST-Segment Elevation in V1-V3. LID - 10.5543/tkda.2026.03220 [doi] AB - A 59-year-old male presented to the emergency department with acute-onset chest pain described as precordial tightness radiating to the left upper extremity, persisting for approximately 24 hours. His symptoms were accompanied by several days of fever and generalized body aches. Laboratory evaluation revealed a marked inflammatory response and significantly elevated cardiac injury biomarkers. Electrocardiography (ECG) demonstrated ST-segment elevation with pathological Q waves in V1-V3, while angiography excluded obstructive coronary disease. The patient was treated with methylprednisolone, antiviral therapy (ganciclovir), empirical antibiotic therapy (ampicillin), and cardioprotective treatment including cyclic adenosine monophosphate meglumine for eight days. This regimen resulted in substantial improvement in clinical symptoms and laboratory parameters. This case highlights the diagnostic complexity of viral myocarditis presenting as myocardial infarction with non-obstructive coronary arteries, particularly in geographic regions endemic for tick-borne infections. A multidisciplinary approach involving cardiology, infectious disease expertise, and laboratory diagnostics is essential for timely intervention and optimal outcomes in patients with myocarditis presenting as myocardial infarction. FAU - Piao, Meina AU - Piao M AD - Department of Cardiology and Hypertension, The Affiliated Hospital of Yanbian University (Yanbian Hospital), Yanji, China. FAU - Kumar, Vipi AU - Kumar V AD - Jilin Provincial Key Laboratory of Stress and Cardiovascular Disease, Yanbian University, Yanji, China. FAU - Narisawa, Megumi AU - Narisawa M AD - Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan. FAU - Yang, Guang AU - Yang G AD - Department of Cardiology and Hypertension, The Affiliated Hospital of Yanbian University (Yanbian Hospital), Yanji, China. FAU - Xu, Chongjun AU - Xu C AD - Department of Medical Ultrasound, The Affiliated Hospital of Yanbian University (Yanbian Hospital), Yanji, China. FAU - Jin, Enhao AU - Jin E AD - Department of Imaging, The Affiliated Hospital of Yanbian University (Yanbian Hospital), Yanji, China. FAU - Wei, Chaoyi AU - Wei C AD - Jilin Provincial Key Laboratory of Stress and Cardiovascular Disease, Yanbian University, Yanji, China. FAU - Xu, Wenhu AU - Xu W AD - Department of Cardiology and Hypertension, The Affiliated Hospital of Yanbian University (Yanbian Hospital), Yanji, China. FAU - Cheng, Xian Wu AU - Cheng XW AD - Department of Cardiology and Hypertension, The Affiliated Hospital of Yanbian University (Yanbian Hospital), Yanji, China, Jilin Provincial Key Laboratory of Stress and Cardiovascular Disease, Yanbian University, Yanji, China. LA - eng PT - Journal Article TT - V1-V3'te ST-Segment Elevasyonu ile Prezente Olan Supheli Kene Kaynakli Viral Enfeksiyon Iliskili Miyokardit. DEP - 20260717 PL - Turkey TA - Turk Kardiyol Dern Ars JT - Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir JID - 9426239 SB - IM EDAT- 2026/07/17 06:44 MHDA- 2026/07/17 06:44 CRDT- 2026/07/17 02:54 PHST- 2026/07/17 06:44 [medline] PHST- 2026/07/17 06:44 [pubmed] PHST- 2026/07/17 02:54 [entrez] AID - 10.5543/tkda.2026.03220 [doi] PST - aheadofprint SO - Turk Kardiyol Dern Ars. 2026 Jul 17. doi: 10.5543/tkda.2026.03220. PMID- 42464485 OWN - NLM STAT- Publisher LR - 20260717 IS - 1940-5596 (Electronic) IS - 1089-2532 (Linking) DP - 2026 Jul 16 TI - Survival Beyond 72 hours After Penetrating Arrow Injury to the Heart Managed Without Cardiopulmonary Bypass: A Case of Delayed Physiologic Stabilization and Off-Pump Repair. PG - 10892532261469240 LID - 10.1177/10892532261469240 [doi] AB - Penetrating chest injuries are associated with high mortality because visceral and vascular structures are situated close together, and injury to these can be devastating due to the limited time for resuscitation. Such injuries often cause massive hemorrhage, tension pneumothorax, hemothorax, cardiac tamponade, or direct penetration of the heart and great vessels. Survival in penetrating chest injuries involving the heart, especially with delayed hospital presentation, is very uncommon. The mechanism of penetration significantly influences the diagnostic approach and necessary interventions. Bedside POCUS protocols, such as eFAST, RUSH, and BLUE, enable immediate resuscitation before further investigations. High-velocity injuries like gunshots and crossbow bolts are linked to high mortality due to rapid tissue destruction caused by kinetic energy transfer. Certain pathological conditions, such as cardiac tamponade or effusion, may sometimes be beneficial in these injuries. We present a case of an accidental penetrating arrow injury to the chest, piercing the heart, yet the patient survived after more than three days of delayed transfer to higher care with hemopneumothorax and mediastinal involvement. Survival after a penetrating chest injury through the heart is very rare. Prompt, rapid resuscitation with a multidisciplinary approach can improve outcomes. However, the prognosis depends on factors such as the type and location of the injury, the speed of medical response, the presence of cardiac tamponade, and the patient's pre-existing clinical condition. FAU - Maremanda, Krishna Rao AU - Maremanda KR AUID- ORCID: 0000-0001-5873-0485 AD - Department of Anesthesiology, Nizam's Institute of Medical Sciences, Hyderabad, India. RINGGOLD: 28605 FAU - Bora, Hemalatha AU - Bora H AD - Department of Anesthesiology, Nizam's Institute of Medical Sciences, Hyderabad, India. RINGGOLD: 28605 FAU - Kaluvala, Prasad Rao AU - Kaluvala PR AD - Department of Anesthesiology, Nizam's Institute of Medical Sciences, Hyderabad, India. RINGGOLD: 28605 FAU - Dilli, Prasadh AU - Dilli P AD - Department of Anesthesiology, Nizam's Institute of Medical Sciences, Hyderabad, India. RINGGOLD: 28605 FAU - Naqiya, Noorain AU - Naqiya N AD - Department of Anesthesiology, Nizam's Institute of Medical Sciences, Hyderabad, India. RINGGOLD: 28605 FAU - Emani, Roja AU - Emani R AD - Department of Anesthesiology, Nizam's Institute of Medical Sciences, Hyderabad, India. RINGGOLD: 28605 FAU - Bhaskarapanthula, Sumana AU - Bhaskarapanthula S AD - Department of Anesthesiology, Nizam's Institute of Medical Sciences, Hyderabad, India. RINGGOLD: 28605 LA - eng PT - Journal Article DEP - 20260716 PL - United States TA - Semin Cardiothorac Vasc Anesth JT - Seminars in cardiothoracic and vascular anesthesia JID - 9807630 SB - IM OTO - NOTNLM OT - cardiac tamponade OT - hemothorax OT - mediastinal emphysema OT - one-lung ventilation OT - penetrating chest injury EDAT- 2026/07/17 10:03 MHDA- 2026/07/17 10:03 CRDT- 2026/07/17 01:33 PHST- 2026/07/17 10:03 [medline] PHST- 2026/07/17 10:03 [pubmed] PHST- 2026/07/17 01:33 [entrez] AID - 10.1177/10892532261469240 [doi] PST - aheadofprint SO - Semin Cardiothorac Vasc Anesth. 2026 Jul 16:10892532261469240. doi: 10.1177/10892532261469240. PMID- 42462847 OWN - NLM STAT- Publisher LR - 20260813 IS - 1916-7075 (Electronic) IS - 0828-282X (Linking) DP - 2026 Jul 16 TI - The SALZBURG Score: A Simple Clinical Tool for Long-term Risk Stratification After Self-Expanding Transcatheter Aortic Valve Implantation. LID - S0828-282X(26)00689-6 [pii] LID - 10.1016/j.cjca.2026.07.008 [doi] AB - BACKGROUND: Long-term survival after transcatheter aortic valve implantation (TAVI) remains difficult to estimate, and established risk scores perform suboptimally in this setting. We aimed to develop and externally validate a simple bedside score for prediction of long-term mortality after transfemoral TAVI. METHODS: In this multicentre study, 585 consecutive patients who underwent transfemoral TAVI with self-expanding valve systems comprised the derivation cohort, whereas 117 patients formed an independent external validation cohort. Predictors of 3-year all-cause mortality were identified using least absolute shrinkage and selection operator-Cox regression and multivariable Cox modelling. Model performance was assessed using discrimination, calibration, decision curve analysis, and net reclassification improvement. RESULTS: Six routinely available variables-age > 80 years, male sex, estimated glomerular filtration rate < 60 mL/min, atrial fibrillation, anemia, and diabetes mellitus-were incorporated into the SALZBURG Score (0-11 points). In the derivation cohort, the score predicted 3-year mortality with an area under the curve of 0.66 (95% confidence interval, 0.61-0.71), which outperformed the European System for Cardiac Operative Risk Evaluation (EuroSCORE) II (0.56; P = 0.002), the Society of Thoracic Surgeons (STS) Score; 0.57; P = 0.005), and the Transcatheter Aortic Valve Replacement (TAVR)-Risk Score (0.62; P = 0.035), and showed discrimination similar to the TAVI(2)-SCORe (0.63; P = 0.166). Calibration was good across predefined risk groups, and risk reclassification improved compared with established surgical and TAVI-specific risk models. In the external validation cohort, discrimination remained stable (C-index, 0.62; 95% confidence interval, 0.54-0.69). CONCLUSIONS: The SALZBURG Score is a simple and externally validated bedside tool for estimating long-term mortality risk after transfemoral TAVI using routinely available clinical variables. Pending validation in larger contemporary TAVI cohorts, it might serve as a complementary tool to support individualized long-term risk assessment and multidisciplinary heart team discussions. CI - Copyright (c) 2026 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Boxhammer, Elke AU - Boxhammer E AD - Department of Internal Medicine II, Division of Cardiology, Paracelsus Medical University of Salzburg, Salzburg, Austria. Electronic address: e.boxhammer@salk.at. FAU - Clodi, Nikolaus AU - Clodi N AD - Department of Internal Medicine II, Division of Cardiology, Paracelsus Medical University of Salzburg, Salzburg, Austria. FAU - Rezar, Richard AU - Rezar R AD - Department of Internal Medicine II, Division of Cardiology, Paracelsus Medical University of Salzburg, Salzburg, Austria. FAU - Dinges, Christian AU - Dinges C AD - Department of Cardiovascular and Endovascular Surgery, Paracelsus Medical University of Salzburg, Salzburg, Austria. FAU - Lichtenauer, Michael AU - Lichtenauer M AD - Department of Internal Medicine II, Division of Cardiology, Paracelsus Medical University of Salzburg, Salzburg, Austria. FAU - Lamm, Gudrun AU - Lamm G AD - Department of Cardiology, University Hospital Sankt Poelten, Karl Landsteiner University of Health Sciences, Krems, Austria. FAU - Reiter, Christian AU - Reiter C AD - Department of Cardiology, Kepler University Hospital, Medical Faculty of the Johannes Kepler University Linz, Linz, Austria. FAU - Kammler, Jurgen AU - Kammler J AD - Department of Cardiology, Kepler University Hospital, Medical Faculty of the Johannes Kepler University Linz, Linz, Austria. FAU - Kellermair, Jorg AU - Kellermair J AD - Department of Cardiology, Kepler University Hospital, Medical Faculty of the Johannes Kepler University Linz, Linz, Austria. FAU - Steinwender, Clemens AU - Steinwender C AD - Department of Cardiology, Kepler University Hospital, Medical Faculty of the Johannes Kepler University Linz, Linz, Austria. FAU - Kirnbauer, Michael AU - Kirnbauer M AD - Department of Anesthesiology, Perioperative Medicine and Critical Care Medicine, Paracelsus Medical University of Salzburg, Salzburg, Austria. FAU - Neuner, Matthias AU - Neuner M AD - Department of Anesthesiology, Perioperative Medicine and Critical Care Medicine, Paracelsus Medical University of Salzburg, Salzburg, Austria. FAU - Hammerer, Matthias AU - Hammerer M AD - Department of Internal Medicine II, Division of Cardiology, Paracelsus Medical University of Salzburg, Salzburg, Austria. FAU - Hoppe, Uta C AU - Hoppe UC AD - Department of Internal Medicine II, Division of Cardiology, Paracelsus Medical University of Salzburg, Salzburg, Austria. LA - eng PT - Journal Article DEP - 20260716 PL - England TA - Can J Cardiol JT - The Canadian journal of cardiology JID - 8510280 SB - IM OTO - NOTNLM OT - Transcatheter aortic valve implantation OT - clinical prediction model OT - comorbidity burden OT - external validation OT - long-term mortality OT - risk stratification EDAT- 2026/07/17 00:42 MHDA- 2026/07/17 00:42 CRDT- 2026/07/16 19:11 PHST- 2026/04/27 00:00 [received] PHST- 2026/07/01 00:00 [revised] PHST- 2026/07/03 00:00 [accepted] PHST- 2026/07/17 00:42 [pubmed] PHST- 2026/07/17 00:42 [medline] PHST- 2026/07/16 19:11 [entrez] AID - S0828-282X(26)00689-6 [pii] AID - 10.1016/j.cjca.2026.07.008 [doi] PST - aheadofprint SO - Can J Cardiol. 2026 Jul 16:S0828-282X(26)00689-6. doi: 10.1016/j.cjca.2026.07.008. PMID- 42462158 OWN - NLM STAT- MEDLINE DCOM- 20260720 LR - 20260820 IS - 2055-5822 (Electronic) IS - 2055-5822 (Linking) VI - 13 IP - 4 DP - 2026 Jul 4 TI - Severe tricuspid regurgitation: aetiology, patient characteristics, and treatment: a multicentre, prospective registry. LID - 10.1093/eschf/xvag190 [doi] LID - xvag190 AB - BACKGROUND AND AIMS: Severe tricuspid regurgitation (TR) is associated with increased mortality and hospitalizations for heart failure (HF). Aetiologies of TR include: secondary (atrial or ventricular), primary and cardiac implantable electronic device (CIED)-related. The aim of the study was to assess the prevalence of different TR aetiologies, as well as characteristics and treatment of patients with severe TR in a real-life setting. METHODS: This was a prospective, observational study of patients with severe TR, conducted in 18 cardiology centres. Consecutive adult patients with severe TR were included, regardless of the presence of TR symptoms and the cause of hospital admission. RESULTS: A total of 1295 patients with severe TR were enrolled (median age 76 years, 53% women). The most common reason for admission was HF decompensation (40%). Single TR aetiology was identified in 79% patients. The most frequent overlap between aetiologies included secondary ventricular and atrial TR, and was found in 11% of patients. The most common TR aetiology was secondary atrial (37%), followed by secondary ventricular (25%). Primary and CIED-related TR accounted for 10% and 15%, respectively. In 2.4% TR aetiology was not determined. Patients with secondary atrial and CIED-related TR were the oldest (79 and 78 years, respectively), and those with primary TR the youngest (68 years). Patients with CIED-related and secondary ventricular TR were more often hospitalized for HF decompensation, had more advanced HF symptoms, worse left- and right-ventricular function, worse kidney and liver function, and higher in-hospital mortality. Only 40% of patients underwent evaluation by the Heart Team and 21% were qualified for TR interventions. CONCLUSIONS: In real life, unequivocal identification of TR aetiology remains challenging. Secondary atrial TR is the most common aetiology. There are significant differences in characteristics and outcomes depending on TR aetiology. Too few patients with severe TR undergo evaluation by the Heart Team. CI - (c) The Author(s) 2026. Published by Oxford University Press on behalf of the European Society of Cardiology. FAU - Kaplon-Cieslicka, Agnieszka AU - Kaplon-Cieslicka A AD - 1st Chair and Department of Cardiology, Medical University of Warsaw, Banacha 1A, Warsaw 02-097, Poland. FAU - Piasecki, Adam AU - Piasecki A AUID- ORCID: 0009-0002-5614-6415 AD - 1st Chair and Department of Cardiology, Medical University of Warsaw, Banacha 1A, Warsaw 02-097, Poland. FAU - Semczuk-Kaczmarek, Karolina AU - Semczuk-Kaczmarek K AD - 1st Chair and Department of Cardiology, Medical University of Warsaw, Banacha 1A, Warsaw 02-097, Poland. FAU - Holcman, Katarzyna AU - Holcman K AUID- ORCID: 0000-0002-6895-4076 AD - Department of Cardiac and Vascular Diseases, Jagiellonian University Medical College, Institute of Cardiology, St. John Paul II Hospital, Krakow, Poland. AD - Department of Nuclear Medicine, St. John Paul II Hospital, Krakow, Poland. FAU - Szczepara, Sylwia AU - Szczepara S AD - Department of Cardiac and Vascular Diseases, Jagiellonian University Medical College, Institute of Cardiology, St. John Paul II Hospital, Krakow, Poland. FAU - Kopec, Grzegorz AU - Kopec G AD - Department of Cardiac and Vascular Diseases, Jagiellonian University Medical College, Institute of Cardiology, St. John Paul II Hospital, Krakow, Poland. AD - Pulmonary Circulation Centre Department of Cardiac and Vascular Diseases, Jagiellonian University Medical College, Krakow, Poland. FAU - Krawczyk-Ozog, Agata AU - Krawczyk-Ozog A AD - Department of Cardiology and Cardiovascular Interventions, University Hospital, Krakow, Poland. AD - Department of Anatomy, Jagiellonian University Medical College, Krakow, Poland. FAU - Rajtar-Salwa, Renata AU - Rajtar-Salwa R AD - Department of Cardiology and Cardiovascular Interventions, University Hospital, Krakow, Poland. AD - 2nd Department of Cardiology, Jagiellonian University Medical College, Krakow, Poland. FAU - Sorysz, Danuta AU - Sorysz D AD - Department of Cardiology and Cardiovascular Interventions, University Hospital, Krakow, Poland. AD - 2nd Department of Cardiology, Jagiellonian University Medical College, Krakow, Poland. FAU - Kaminski, Karol AU - Kaminski K AD - Department of Cardiology and Internal Medicine with Cardiac Intensive Care Unit, Medical University of Bialystok, Bialystok, Poland. AD - Department of Population Medicine and Prevention of Lifestyle Diseases, Medical University of Bialystok, Bialystok, Poland. FAU - Knapp, Malgorzata AU - Knapp M AD - Department of Cardiology and Internal Medicine with Cardiac Intensive Care Unit, Medical University of Bialystok, Bialystok, Poland. FAU - Stelmaszek, Sebastian AU - Stelmaszek S AD - Department of Cardiology and Internal Medicine with Cardiac Intensive Care Unit, Medical University of Bialystok, Bialystok, Poland. FAU - Krolikowska, Maria AU - Krolikowska M AD - Department of Coronary Disease and Heart Failure, Jagiellonian University, Medical College, St. John Paul II Hospital, Krakow, Poland. FAU - Furman-Niedziejko, Anna AU - Furman-Niedziejko A AD - Department of Coronary Disease and Heart Failure, Jagiellonian University, Medical College, St. John Paul II Hospital, Krakow, Poland. AD - Department of Emergency Medicine, Faculty of Health Sciences, Jagiellonian University Medical College, Krakow, Poland. FAU - Gackowski, Andrzej AU - Gackowski A AUID- ORCID: 0000-0003-4545-6514 AD - Department of Coronary Disease and Heart Failure, Jagiellonian University, Medical College, St. John Paul II Hospital, Krakow, Poland. FAU - Polanska-Szczap, Agata AU - Polanska-Szczap A AD - Department of Cardiology, Kociewie Health Center, Starograd Gdanski, Poland. FAU - Tuskowska, Grazyna AU - Tuskowska G AD - Department of Cardiology, Kociewie Health Center, Starograd Gdanski, Poland. FAU - Kozinski, Marek AU - Kozinski M AD - Department of Cardiology, Kociewie Health Center, Starograd Gdanski, Poland. AD - 1st Department of Cardiology, Medical University of Gdansk, Gdansk, Poland. FAU - Tomaszuk-Kazberuk, Anna AU - Tomaszuk-Kazberuk A AD - Department of Cardiology, Lipidology and Internal Medicine with Intensive Cardiac Care Unit, Medical University of Bialystok, Bialystok, Poland. FAU - Dudzinska, Kinga AU - Dudzinska K AD - Department of Cardiology, Lipidology and Internal Medicine with Intensive Cardiac Care Unit, Medical University of Bialystok, Bialystok, Poland. FAU - Muszynski, Pawel AU - Muszynski P AD - Department of Cardiology, Lipidology and Internal Medicine with Intensive Cardiac Care Unit, Medical University of Bialystok, Bialystok, Poland. FAU - Danilowicz-Szymanowicz, Ludmila AU - Danilowicz-Szymanowicz L AD - Department of Cardiology and Electrotherapy, Faculty of Medicine, Medical University of Gdansk, Gdansk, Poland. FAU - Kaufmann, Damian AU - Kaufmann D AD - Department of Cardiology and Electrotherapy, Faculty of Medicine, Medical University of Gdansk, Gdansk, Poland. FAU - Szwoch, Malgorzata AU - Szwoch M AD - Department of Cardiology and Electrotherapy, Faculty of Medicine, Medical University of Gdansk, Gdansk, Poland. FAU - Uzieblo-Zyczkowska, Beata AU - Uzieblo-Zyczkowska B AD - Department of Cardiology and Internal Diseases, Military Institute of Medicine-National Research Institute, Warsaw, Poland. FAU - Maciorowska, Malgorzata AU - Maciorowska M AD - Department of Cardiology and Internal Diseases, Military Institute of Medicine-National Research Institute, Warsaw, Poland. FAU - Krzesinski, Pawel AU - Krzesinski P AD - Department of Cardiology and Internal Diseases, Military Institute of Medicine-National Research Institute, Warsaw, Poland. FAU - Markiewicz, Agata AU - Markiewicz A AD - 1st Department of Cardiology, Poznan University of Medical Sciences, Poznan, Poland. FAU - Bartczak-Rutkowska, Agnieszka AU - Bartczak-Rutkowska A AD - 1st Department of Cardiology, Poznan University of Medical Sciences, Poznan, Poland. FAU - Grygier, Marek AU - Grygier M AD - 1st Department of Cardiology, Poznan University of Medical Sciences, Poznan, Poland. FAU - Kijewski, Bartosz AU - Kijewski B AD - Department of Cardiology, Medical University of Lublin, University Centre of Cardiology and Cardiac Surgery, Lublin, Poland. FAU - Blaszczyk, Robert AU - Blaszczyk R AD - Department of Cardiology, Medical University of Lublin, University Centre of Cardiology and Cardiac Surgery, Lublin, Poland. FAU - Kondracki, Bartosz AU - Kondracki B AD - Department of Cardiology, Medical University of Lublin, University Centre of Cardiology and Cardiac Surgery, Lublin, Poland. FAU - Rudzinski, Piotr Nikodem AU - Rudzinski PN AD - Department of Coronary and Structural Heart Diseases, The Cardinal Stefan Wyszynski National Institute of Cardiology, Warsaw, Poland. FAU - Demkow, Marcin AU - Demkow M AD - Department of Coronary and Structural Heart Diseases, The Cardinal Stefan Wyszynski National Institute of Cardiology, Warsaw, Poland. FAU - Debski, Mariusz AU - Debski M AD - Department of Coronary and Structural Heart Diseases, The Cardinal Stefan Wyszynski National Institute of Cardiology, Warsaw, Poland. FAU - Tokarek, Tomasz AU - Tokarek T AD - 2nd Clinical Department of Cardiology, Faculty of Medicine and Health Science, University of Applied Science in Nowy Sacz, Nowy Sacz, Poland. AD - Center for Innovative Medical Education, Jagiellonian University Medical College, Krakow, Poland. FAU - Dykla, Dominika AU - Dykla D AD - 2nd Clinical Department of Cardiology, Faculty of Medicine and Health Science, University of Applied Science in Nowy Sacz, Nowy Sacz, Poland. AD - The Faculty of Medicine and Health Sciences, University of Applied Sciences in Nowy Sacz, Nowy Sacz, Poland. FAU - Zelias, Aleksander AU - Zelias A AD - 2nd Clinical Department of Cardiology, Faculty of Medicine and Health Science, University of Applied Science in Nowy Sacz, Nowy Sacz, Poland. AD - The Faculty of Medicine and Health Sciences, University of Applied Sciences in Nowy Sacz, Nowy Sacz, Poland. FAU - Galaska, Rafal AU - Galaska R AD - 1st Department of Cardiology, Medical University of Gdansk, Gdansk, Poland. FAU - Fijalkowski, Marcin AU - Fijalkowski M AD - 1st Department of Cardiology, Medical University of Gdansk, Gdansk, Poland. FAU - Niemiec, Malgorzata AU - Niemiec M AD - First Department of Cardiology, Chair of Cardiology, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland. AD - Centre of the European Reference Network for Rare, Low Prevalence or Complex Diseases of the Heart (ERN GUARD Heart), Katowice, Poland. FAU - Mizia-Stec, Katarzyna AU - Mizia-Stec K AUID- ORCID: 0000-0001-6907-2799 AD - First Department of Cardiology, Chair of Cardiology, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland. AD - Centre of the European Reference Network for Rare, Low Prevalence or Complex Diseases of the Heart (ERN GUARD Heart), Katowice, Poland. FAU - Kurnicka, Katarzyna AU - Kurnicka K AD - Independent Scientific Echocardiography Laboratory, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland. FAU - Pruszczyk, Piotr AU - Pruszczyk P AUID- ORCID: 0000-0002-9768-0000 AD - Department of Internal Medicine and Cardiology, Medical University of Warsaw, Warsaw, Poland. FAU - Pregowski, Jerzy AU - Pregowski J AD - Department of Interventional Cardiology and Angiology, National Institute of Cardiology, Warsaw, Poland. FAU - Skowronski, Jaroslaw AU - Skowronski J AD - Department of Interventional Cardiology and Angiology, National Institute of Cardiology, Warsaw, Poland. FAU - Bielecka-Dabrowa, Agata AU - Bielecka-Dabrowa A AD - Department of Preventive Cardiology and Lipidology, Medical University of Lodz, Lodz, Poland. AD - Department of Cardiology and Congenital Heart Diseases of Adults, Polish Mother's Memorial Hospital Research Institute (PMMHRI), Lodz, Poland. FAU - Kupczynska, Karolina AU - Kupczynska K AD - Department of Cardiology and Congenital Heart Diseases of Adults, Polish Mother's Memorial Hospital Research Institute (PMMHRI), Lodz, Poland. FAU - Pedzich, Ewa AU - Pedzich E AD - 1st Chair and Department of Cardiology, Medical University of Warsaw, Banacha 1A, Warsaw 02-097, Poland. FAU - Ostrowska, Ewa AU - Ostrowska E AD - 1st Chair and Department of Cardiology, Medical University of Warsaw, Banacha 1A, Warsaw 02-097, Poland. FAU - Tomaniak, Mariusz AU - Tomaniak M AD - 1st Chair and Department of Cardiology, Medical University of Warsaw, Banacha 1A, Warsaw 02-097, Poland. FAU - Grabowski, Marcin AU - Grabowski M AD - 1st Chair and Department of Cardiology, Medical University of Warsaw, Banacha 1A, Warsaw 02-097, Poland. FAU - Scislo, Piotr AU - Scislo P AD - 1st Chair and Department of Cardiology, Medical University of Warsaw, Banacha 1A, Warsaw 02-097, Poland. FAU - Rdzanek, Adam AU - Rdzanek A AUID- ORCID: 0000-0002-0235-9696 AD - 1st Chair and Department of Cardiology, Medical University of Warsaw, Banacha 1A, Warsaw 02-097, Poland. LA - eng GR - Polish Cardiac Society/ GR - PCS Scientific Platform/ PT - Journal Article PT - Multicenter Study PT - Observational Study PL - England TA - ESC Heart Fail JT - ESC heart failure JID - 101669191 SB - IM MH - Humans MH - Female MH - *Tricuspid Valve Insufficiency/etiology/diagnosis/epidemiology/therapy MH - Prospective Studies MH - *Registries MH - Aged MH - Male MH - Severity of Illness Index MH - Prevalence MH - Echocardiography MH - Heart Failure MH - Follow-Up Studies MH - Aged, 80 and over PMC - PMC13381786 OTO - NOTNLM OT - Lead extraction OT - Right-sided heart failure OT - Surgery OT - Transcatheter edge-to-edge repair OT - Tricuspid valve EDAT- 2026/07/16 18:46 MHDA- 2026/07/20 06:38 PMCR- 2026/07/16 CRDT- 2026/07/16 15:52 PHST- 2026/03/15 00:00 [received] PHST- 2026/05/21 00:00 [revised] PHST- 2026/07/01 00:00 [accepted] PHST- 2026/07/20 06:38 [medline] PHST- 2026/07/16 18:46 [pubmed] PHST- 2026/07/16 15:52 [entrez] PHST- 2026/07/16 00:00 [pmc-release] AID - 8736027 [pii] AID - xvag190 [pii] AID - 10.1093/eschf/xvag190 [doi] PST - ppublish SO - ESC Heart Fail. 2026 Jul 4;13(4):xvag190. doi: 10.1093/eschf/xvag190. PMID- 42460896 OWN - NLM STAT- MEDLINE DCOM- 20260716 LR - 20260716 IS - 2052-286X (Electronic) IS - 1357-6321 (Linking) VI - 32 IP - 7 DP - 2026 Jul 2 TI - Factors associated with the implementation of advance care planning among nurses caring for patients with heart failure: A cross-sectional survey in Japan. PG - 334-344 LID - 10.12968/ijpn.2025.0082 [doi] AB - BACKGROUND: Multiple barriers and facilitators affect nurses' implementation of advance care planning for patients with heart failure. However, differences in nurses' perceptions according to their experience with advance care planning remain unclear. AIMS: This study examined factors associated with advance care planning implementation among Japanese nurses. METHODS: In this cross-sectional study, 1250 cardiology hospitals were selected using prefecture-based stratified sampling. Nurses were classified into three groups according to their experience with advance care planning, and factors associated with the implementation of advance care planning were analysed. FINDINGS: A total of 238 nurses responded. Participation in workshops and training sessions had the strongest influence on advance care planning implementation. With greater experience of advance care planning, items related to anxiety were more prevalent than those related to reduction. CONCLUSIONS: Establishing an educational framework that reflects the characteristics of Japanese nurses is essential for promoting its implementation. In addition, a multidisciplinary approach is recommended to address nurses' anxiety. IMPLICATIONS FOR PRACTICE: Providing structured education and training on advance care planning may enhance nurses' confidence and implementation of advance care planning in patients with heart failure. Multidisciplinary support should also be incorporated to address nurses' anxiety and facilitate the integration of advance care planning into routine clinical practice. FAU - Tamaki, Yuya AU - Tamaki Y AD - Gerontological Nursing, School of Health Sciences, Faculty of Medicine, University of the Ryukyus, Japan. AD - Division of Biostatistics, School of Health Sciences, Faculty of Medicine, University of the Ryukyus, Japan. FAU - Nagata, Haruno AU - Nagata H AD - Department of Rehabilitation Medicine, University of the Ryukyus Hospital, Japan. AD - Department of Cardiovascular Medicine, Nephrology and Neurology, Graduate School of Medicine, University of the Ryukyus, Japan. FAU - Hirata, Terumi AU - Hirata T AD - Department of Rehabilitation Medicine, University of the Ryukyus Hospital, Japan. FAU - Ikemiya, Shuichiro AU - Ikemiya S AD - Department of Rehabilitation Medicine, University of the Ryukyus Hospital, Japan. FAU - Kusunose, Kenya AU - Kusunose K AD - Department of Cardiovascular Medicine, Nephrology and Neurology, Graduate School of Medicine, University of the Ryukyus, Japan. FAU - Ohya, Yusuke AU - Ohya Y AD - Department of Rehabilitation Medicine, University of the Ryukyus Hospital, Japan. AD - Department of Medicine, University of the Ryukyus Hospital, Japan. FAU - Yonemoto, Koji AU - Yonemoto K AD - Division of Biostatistics, School of Health Sciences, Faculty of Medicine, University of the Ryukyus, Japan. LA - eng PT - Journal Article DEP - 20260716 PL - England TA - Int J Palliat Nurs JT - International journal of palliative nursing JID - 9506762 SB - IM MH - Humans MH - *Advance Care Planning MH - Japan MH - Cross-Sectional Studies MH - *Heart Failure/nursing MH - Female MH - Surveys and Questionnaires MH - Male MH - Adult MH - Middle Aged MH - Attitude of Health Personnel MH - *Nursing Staff, Hospital/psychology OTO - NOTNLM OT - Japan OT - advance care planning OT - education OT - heart failure OT - implementation COIS- Statement of interest: None EDAT- 2026/07/16 16:06 MHDA- 2026/07/16 16:07 CRDT- 2026/07/16 08:13 PHST- 2026/07/16 16:07 [medline] PHST- 2026/07/16 16:06 [pubmed] PHST- 2026/07/16 08:13 [entrez] AID - 10.12968/ijpn.2025.0082 [doi] PST - ppublish SO - Int J Palliat Nurs. 2026 Jul 2;32(7):334-344. doi: 10.12968/ijpn.2025.0082. Epub 2026 Jul 16. PMID- 42458196 OWN - NLM STAT- Publisher LR - 20260715 IS - 1179-1985 (Electronic) IS - 1120-9879 (Linking) DP - 2026 Jul 15 TI - Pregnancy as a Window for Hypertension and Cardiovascular Prevention in Women: A Life-Course Perspective Based on the 2025 ESC Guidelines. LID - 10.1007/s40292-026-00815-3 [doi] AB - The 2025 European Society of Cardiology (ESC) Guidelines on cardiovascular disease in pregnancy introduce a life-course approach to cardiovascular prevention, extending risk assessment and management from preconception through the postpartum period. Beyond the management of established cardiovascular disease, the guidelines emphasize the importance of identifying modifiable risk factors and pregnancy-related complications as early markers of future cardiovascular risk. This narrative mini-review provides a prevention-oriented interpretation of the 2025 ESC Guidelines, focusing on their implications for hypertension prevention and long-term cardiovascular health in women. Pregnancy is increasingly recognized as a biological stress test capable of unmasking latent cardiometabolic and vascular vulnerability, while adverse pregnancy outcomes, including preeclampsia, gestational hypertension, gestational diabetes, fetal growth restriction, and preterm delivery, represent important predictors of future hypertension and cardiovascular disease. Particular emphasis is placed on preconception cardiovascular assessment, lifestyle optimization, obesity management, and the cardiovascular implications of assisted reproductive technologies. The Pregnancy Heart Team is discussed as a multidisciplinary model for integrating cardiovascular and obstetric care across the reproductive continuum. In addition, we propose a practical life-course prevention framework incorporating structured postpartum surveillance, blood pressure monitoring, cardiometabolic screening, and long-term follow-up after adverse pregnancy outcomes. By translating contemporary ESC recommendations into a clinically applicable prevention strategy, this review highlights pregnancy as a unique opportunity for early cardiovascular risk identification and implementation of sex-specific preventive interventions aimed at reducing the future burden of hypertension and cardiovascular disease in women. CI - (c) 2026. The Author(s). FAU - Mattioli, Anna Vittoria AU - Mattioli AV AUID- ORCID: 0000-0003-1487-9530 AD - Department for Quality of Life Sciences, University of Bologna-Alma Mater Studiorum, Via Irnerio, 48, Bologna, Italy. annavittoria.mattioli@unibo.it. FAU - Renda, Giulia AU - Renda G AUID- ORCID: 0000-0002-4770-8386 AD - Department of Neuroscience, Imaging and Clinical Sciences, "G. d'Annunzio" University of Chieti-Pescara, Chieti, Italy. FAU - Ferri, Claudio AU - Ferri C AUID- ORCID: 0000-0002-3594-2503 AD - Department of Life, Health and Environmental Sciences - L'Aquila University, L'Aquila, Italy. FAU - Gallina, Sabina AU - Gallina S AUID- ORCID: 0000-0003-0263-4851 AD - Department of Neuroscience, Imaging and Clinical Sciences, "G. d'Annunzio" University of Chieti-Pescara, Chieti, Italy. FAU - Borghi, Claudio AU - Borghi C AD - University of Bologna-Alma Mater Studiorum, Bologna, Italy. LA - eng PT - Journal Article PT - Review DEP - 20260715 PL - New Zealand TA - High Blood Press Cardiovasc Prev JT - High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension JID - 9421087 SB - IM OTO - NOTNLM OT - Adverse pregnancy outcomes OT - Assisted reproduction OT - Cardiovascular prevention OT - Life-course approach OT - Obesity OT - Preeclampsia OT - Pregnancy OT - Pregnancy Heart Team COIS- Declarations. Conflict of interest: The authors declare that they have no conflict of interest. EDAT- 2026/07/16 00:35 MHDA- 2026/07/16 00:35 CRDT- 2026/07/15 23:30 PHST- 2026/04/11 00:00 [received] PHST- 2026/07/01 00:00 [accepted] PHST- 2026/07/16 00:35 [medline] PHST- 2026/07/16 00:35 [pubmed] PHST- 2026/07/15 23:30 [entrez] AID - 10.1007/s40292-026-00815-3 [pii] AID - 10.1007/s40292-026-00815-3 [doi] PST - aheadofprint SO - High Blood Press Cardiovasc Prev. 2026 Jul 15. doi: 10.1007/s40292-026-00815-3. PMID- 27786435 STAT- Publisher DRDT- 20260716 CTDT- 20161027 PB - University of Washington, Seattle DP - 1993 TI - MBD5 Haploinsufficiency. BTI - GeneReviews((R)) AB - CLINICAL CHARACTERISTICS: MBD5 haploinsufficiency is a neurodevelopmental disorder characterized by developmental delay, intellectual disability, severe speech impairment, seizures, sleep disturbances, and abnormal behaviors. Most children lack speech entirely or have single words, short phrases, or short sentences. Seizures are present in more than 80% of children; onset is usually around age two years. Sleep disturbances, present in about 90%, can result in excessive daytime drowsiness. Abnormal behaviors can include autistic-like behaviors (80%) and self-injury and aggression (>60%). DIAGNOSIS/TESTING: The diagnosis of MBD5 haploinsufficiency is established in a proband by identification on molecular genetic testing of a heterozygous deletion of 2q23.1 encompassing all or part of MBD5, or of an intragenic MBD5 pathogenic variant. MANAGEMENT: Treatment of manifestations: A multidisciplinary approach that typically includes specialists in clinical genetics, neurology, child development, behavioral therapy, nutrition/feeding, speech and language therapy, and occupational and physical therapy is recommended. Infants benefit from enrollment in an early-intervention program, and school-age children benefit from an individualized educational program. Speech therapy (including nonverbal methods of communication) should be introduced early. Seizures, behavior problems, sleep disturbances, and constipation are treated in a routine manner. Feeding therapy with gastrostomy tube feeding as needed; treatment of hip dysplasia and scoliosis per orthopedist; treatment of cardiovascular anomalies per cardiologist; family support including social work involvement and care coordination. Surveillance: Periodic neurodevelopmental and behavioral evaluations to assist in the management of cognitive issues, behavior issues, and sleep disturbance. Assess for seizures, feeding issues, constipation, and family support needs at each visit. Clinical assessment for scoliosis annually. GENETIC COUNSELING: MBD5 haploinsufficiency is an autosomal dominant disorder typically caused by a de novo genetic alteration. To date, parent-to-child transmission of a 2q23.1 deletion that encompasses all or part of MBD5 has not been reported. Parent-to-child transmissions of MBD5 intragenic deletions and pathogenic sequence variants have been reported. Rarely, parent-to-child transmission of an unbalanced derivative chromosome involving the 2q23.1 region occurs. Once the genetic alteration resulting in MBD5 haploinsufficiency has been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic testing are possible. CI - Copyright (c) 1993-2026, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved. FED - Adam, Margaret P ED - Adam MP FED - Bick, Sarah ED - Bick S FED - Mirzaa, Ghayda M ED - Mirzaa GM FED - Wallace, Stephanie E ED - Wallace SE FED - Amemiya, Anne ED - Amemiya A FAU - Mullegama, Sureni V AU - Mullegama SV AD - GeneDx, Inc, Gaithersburg, Maryland FAU - Mendoza-Londono, Roberto AU - Mendoza-Londono R AD - Associate Professor of Paediatrics and Molecular Genetics, University of Toronto;, The Hospital for Sick Children, Division of Clinical and Metabolic Genetics, Toronto, Ontario, Canada FAU - Elsea, Sarah H AU - Elsea SH AD - Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas LA - eng PT - Review PT - Book Chapter PL - Seattle (WA) OTO - NLM OT - 2q23.1 Microdeletion Syndrome OT - Pseudo-Angelman Syndrome OT - 2q23.1 Microdeletion Syndrome OT - Methyl-CpG-binding domain protein 5 OT - MBD5 OT - MBD5 Haploinsufficiency EDAT- 2026/07/16 00:00 CRDT- 2026/07/16 00:00 AID - NBK390803 [bookaccession] PMID- 42453544 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260715 LR - 20260813 IS - 1178-2390 (Print) IS - 1178-2390 (Electronic) IS - 1178-2390 (Linking) VI - 19 DP - 2026 TI - Enhancing Creativity and Innovation in Medical Sciences Students Through Multidisciplinary Problem-Based Learning (MPBL): A Pre-Post Intervention Study. PG - 601318 LID - 10.2147/JMDH.S601318 [doi] LID - 601318 AB - INTRODUCTION: The growing complexity of healthcare systems requires the development of creativity and innovation among health professionals. These competencies are essential for professional growth and entrepreneurial thinking. Problem-Based Learning (PBL) and Multidisciplinary approaches have been recognized as effective strategies to foster such skills. This study aimed to evaluate the effectiveness of Multidisciplinary Problem-Based Learning (MPBL) in promoting creativity and innovation among medical sciences students. MATERIALS AND METHODS: This pre-post interventional study was conducted in 2024 with 70 students from various medical disciplines at Hamadan University of Medical Sciences. Participants engaged in three 4-hour MPBL workshops (12 hours total) featuring clinical scenarios on sepsis, cardiac arrest, and multiple trauma. The intervention incorporated higher-order thinking activities, structured group discussions, and debriefing sessions. Creativity was assessed using the abbreviated figural version of the Torrance Tests of Creative Thinking (TTCT), and innovation was measured using an adapted version of the Research and Innovation Competency Measure Questionnaire (RIC-MQ). Satisfaction was also evaluated. Data were analyzed using SPSS version 24. RESULTS: Participants had a mean age of 21.83 years, with 66.2% female. Overall, creativity and innovation scores increased significantly post-intervention (p < 0.05), except for innovation in the medical group and creativity in the midwifery group. High satisfaction was reported by 58.6% of participants. Although some changes reached statistical significance, the short intervention period limits the ability to infer sustained or educationally meaningful learning; thus, findings are presented as proof-of-concept. CONCLUSION: MPBL may be associated with short-term improvements in creativity and innovation among medical sciences students. However, the pre-post design precludes causal attribution, and results should be interpreted as preliminary. Observed variations across disciplines underscore the need for further research with larger, more diverse samples and controlled designs to assess broader applicability. CI - (c) 2026 Sarhadi et al. FAU - Sarhadi, Maryam AU - Sarhadi M AUID- ORCID: 0009-0002-6840-1241 AD - Hamadan University of Medical Sciences, Hamadan, Iran. FAU - Aliabadi, Faezeh AU - Aliabadi F AUID- ORCID: 0009-0009-2126-9248 AD - Hamadan University of Medical Sciences, Hamadan, Iran. FAU - Jiryaee, Nasrin AU - Jiryaee N AUID- ORCID: 0000-0001-9828-9989 AD - Department of Social Medicine, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran. FAU - Seidi, Masoumeh AU - Seidi M AUID- ORCID: 0000-0001-8473-9571 AD - Educational Development Center (EDC), Hamadan University of Medical Sciences, Hamadan, Iran. LA - eng PT - Journal Article DEP - 20260710 PL - New Zealand TA - J Multidiscip Healthc JT - Journal of multidisciplinary healthcare JID - 101512691 PMC - PMC13367265 OTO - NOTNLM OT - creativity OT - education OT - multidisciplinary OT - problem-based learning OT - students OT - undergraduate COIS- The authors declare that they have no competing interests in this work. EDAT- 2026/07/15 10:10 MHDA- 2026/07/15 10:11 PMCR- 2026/07/10 CRDT- 2026/07/15 04:48 PHST- 2026/02/04 00:00 [received] PHST- 2026/07/02 00:00 [accepted] PHST- 2026/07/15 10:11 [medline] PHST- 2026/07/15 10:10 [pubmed] PHST- 2026/07/15 04:48 [entrez] PHST- 2026/07/10 00:00 [pmc-release] AID - 601318 [pii] AID - 10.2147/JMDH.S601318 [doi] PST - epublish SO - J Multidiscip Healthc. 2026 Jul 10;19:601318. doi: 10.2147/JMDH.S601318. eCollection 2026. PMID- 42452712 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260715 LR - 20260813 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 15 IP - 13 DP - 2026 Jul 5 TI - Outcomes and Decision-Making Following Out-of-Hospital Cardiac Arrest Within a Multidisciplinary Neuroprognostication Pathway in a Tertiary Cardiac Intensive Care Unit. LID - 10.3390/jcm15135252 [doi] LID - 5252 AB - Background/Objectives: Neuroprognostication after out-of-hospital cardiac arrest (OHCA) remains clinically challenging, particularly when withdrawal of life-sustaining treatment (WLST) is considered. International guidelines recommend delayed, multimodal assessment, but real-world descriptions of how this is operationalised within multidisciplinary pathways remain limited. Methods: We conducted a single-centre retrospective observational cohort study of adults admitted to a tertiary cardiac arrest centre intensive care unit following OHCA between June 2022 and December 2025. Patients were conveyed according to the British Cardiovascular Intervention Society OHCA pathway; therefore, this was a selected cardiac arrest centre cohort enriched for shockable rhythms and suspected reversible cardiac causes, rather than an unselected OHCA population. Patients who remained unconscious at >/=72 h following a sedation hold entered a structured multidisciplinary team (MDT) neuroprognostication pathway. Outcomes included survival to hospital discharge, Cerebral Performance Category (CPC) at discharge, neuroprognostication investigation use, and timing of WLST. Results: Of 406 patients admitted following OHCA, 310 were admitted to ICU and included in the analysis. The cohort was predominantly male (82.3%), with a mean age of 63.8 years; 82.9% had ventricular fibrillation as the initial rhythm. Overall, 182 patients (58.7%) survived to hospital discharge, of whom 160 (87.9%) had a favourable neurological outcome (CPC 1-2). A total of 119 patients entered the neuroprognostication pathway. Of these, 72 underwent WLST after completed MDT review, 10 died before MDT decision-making, and 37 survived to hospital discharge. Among patients undergoing WLST, investigation use was high: CT brain 100%, NSE 91.7%, EEG 90.3%, SSEP 88.9%, and MRI brain 27.8%. Median time to WLST was 5.5 days. Conclusions: In this selected tertiary CAC cohort, enriched for shockable rhythms through BCIS pathway-based conveyance, survival to hospital discharge was high and neurological outcomes among survivors were predominantly favourable. Within this setting, delayed, multimodal neuroprognostication and WLST decision-making were operationalised through a structured MDT pathway aligned with contemporary guideline recommendations. These findings provide contemporary real-world benchmark data on pathway implementation for comparable centres seeking to evaluate or develop structured neuroprognostication services. FAU - Movio, Guilherme AU - Movio G AD - Essex Cardiothoracic Centre, Mid and South Essex NHS Foundation Trust, Basildon SS16 5NL, UK. AD - Anglia Ruskin School of Medicine & MTRC, Chelmsford CM1 1SQ, UK. FAU - Sajjad, Uzma AU - Sajjad U AUID- ORCID: 0009-0005-0360-5122 AD - Essex Cardiothoracic Centre, Mid and South Essex NHS Foundation Trust, Basildon SS16 5NL, UK. AD - Anglia Ruskin School of Medicine & MTRC, Chelmsford CM1 1SQ, UK. FAU - Prisenznakova, Dana AU - Prisenznakova D AUID- ORCID: 0009-0003-1073-2918 AD - Essex Cardiothoracic Centre, Mid and South Essex NHS Foundation Trust, Basildon SS16 5NL, UK. FAU - Beadle, Emma AU - Beadle E AD - Essex Cardiothoracic Centre, Mid and South Essex NHS Foundation Trust, Basildon SS16 5NL, UK. FAU - Perilla, Daryl AU - Perilla D AD - Essex Cardiothoracic Centre, Mid and South Essex NHS Foundation Trust, Basildon SS16 5NL, UK. FAU - Choi, Soyun AU - Choi S AD - Essex Cardiothoracic Centre, Mid and South Essex NHS Foundation Trust, Basildon SS16 5NL, UK. AD - Anglia Ruskin School of Medicine & MTRC, Chelmsford CM1 1SQ, UK. FAU - Woolford, Lauren AU - Woolford L AD - Essex Cardiothoracic Centre, Mid and South Essex NHS Foundation Trust, Basildon SS16 5NL, UK. FAU - Mion, Marco AU - Mion M AUID- ORCID: 0000-0002-3656-5965 AD - Essex Cardiothoracic Centre, Mid and South Essex NHS Foundation Trust, Basildon SS16 5NL, UK. AD - Anglia Ruskin School of Medicine & MTRC, Chelmsford CM1 1SQ, UK. FAU - Mohan, Ayush AU - Mohan A AD - Essex Cardiothoracic Centre, Mid and South Essex NHS Foundation Trust, Basildon SS16 5NL, UK. FAU - Damian, Maxwell AU - Damian M AD - Essex Cardiothoracic Centre, Mid and South Essex NHS Foundation Trust, Basildon SS16 5NL, UK. FAU - Nevajda, Branimir AU - Nevajda B AD - Essex Cardiothoracic Centre, Mid and South Essex NHS Foundation Trust, Basildon SS16 5NL, UK. FAU - Suresh, Saneesh AU - Suresh S AD - Essex Cardiothoracic Centre, Mid and South Essex NHS Foundation Trust, Basildon SS16 5NL, UK. FAU - Davies, John R AU - Davies JR AD - Essex Cardiothoracic Centre, Mid and South Essex NHS Foundation Trust, Basildon SS16 5NL, UK. AD - Anglia Ruskin School of Medicine & MTRC, Chelmsford CM1 1SQ, UK. FAU - Maccaroni, Maria Rita AU - Maccaroni MR AD - Essex Cardiothoracic Centre, Mid and South Essex NHS Foundation Trust, Basildon SS16 5NL, UK. AD - Anglia Ruskin School of Medicine & MTRC, Chelmsford CM1 1SQ, UK. FAU - Keeble, Thomas R AU - Keeble TR AUID- ORCID: 0000-0001-8695-7994 AD - Essex Cardiothoracic Centre, Mid and South Essex NHS Foundation Trust, Basildon SS16 5NL, UK. AD - Anglia Ruskin School of Medicine & MTRC, Chelmsford CM1 1SQ, UK. LA - eng PT - Journal Article DEP - 20260705 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC13363386 OTO - NOTNLM OT - Cerebral Performance Category OT - intensive care OT - multidisciplinary team OT - neuroprognostication OT - out-of-hospital cardiac arrest OT - post-cardiac arrest care OT - withdrawal of life-sustaining treatment COIS- The authors declare no conflicts of interest. EDAT- 2026/07/15 06:37 MHDA- 2026/07/15 06:38 PMCR- 2026/07/05 CRDT- 2026/07/15 01:10 PHST- 2026/05/29 00:00 [received] PHST- 2026/06/24 00:00 [revised] PHST- 2026/07/03 00:00 [accepted] PHST- 2026/07/15 06:38 [medline] PHST- 2026/07/15 06:37 [pubmed] PHST- 2026/07/15 01:10 [entrez] PHST- 2026/07/05 00:00 [pmc-release] AID - jcm15135252 [pii] AID - jcm-15-05252 [pii] AID - 10.3390/jcm15135252 [doi] PST - epublish SO - J Clin Med. 2026 Jul 5;15(13):5252. doi: 10.3390/jcm15135252. PMID- 42452549 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260715 LR - 20260813 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 15 IP - 13 DP - 2026 Jun 30 TI - Diagnostic Challenges in Takotsubo Syndrome: Bridging Mimics, Mechanisms, and Management. LID - 10.3390/jcm15135088 [doi] LID - 5088 AB - Takotsubo syndrome (TTS), also known as stress-induced cardiomyopathy, is a form of transient left ventricular systolic dysfunction that typically mimics acute coronary syndrome (ACS). Although increasingly recognized, its diagnosis remains challenging due to heterogeneous clinical presentations, evolving pathophysiological concepts, and significant overlap with other acute cardiac conditions. Contemporary criteria, including the InterTAK diagnostic framework, aim to refine case identification, yet distinctions from myocardial infarction, myocarditis, and other cardiomyopathies often remain blurred. Advances in multimodal imaging, biomarkers, and artificial intelligence hold promise for improving diagnostic precision. This review explores current diagnostic challenges in TTS, integrating clinical presentation, mechanistic understanding, and management implications. By bridging mimics, mechanisms, and management, we highlight the need for a nuanced, multidisciplinary approach that balances clinical vigilance with emerging diagnostic tools to optimize patients' outcomes. FAU - Mitsis, Andreas AU - Mitsis A AUID- ORCID: 0000-0002-0286-7762 AD - Cardiology Department, Nicosia General Hospital, State Health Services Organization, Nicosia 2029, Cyprus. FAU - Khattab, Elina AU - Khattab E AUID- ORCID: 0009-0002-8634-6805 AD - Cardiology Department, Nicosia General Hospital, State Health Services Organization, Nicosia 2029, Cyprus. FAU - Christodoulou, Evi AU - Christodoulou E AD - Cardiology Department, Limassol General Hospital, State Health Services Organization, Limassol 4131, Cyprus. FAU - Sakellaropoulos, Stefanos AU - Sakellaropoulos S AD - Department of Internal Medicine, Cardiology Clinic, Kantonsspital Baden, 5404 Baden, Switzerland. FAU - Kadoglou, Nikolaos P E AU - Kadoglou NPE AUID- ORCID: 0000-0002-7830-3488 AD - Medical School, University of Cyprus, Nicosia 2115, Cyprus. LA - eng PT - Journal Article PT - Review DEP - 20260630 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC13362829 OTO - NOTNLM OT - InterTAK Diagnostic Score OT - acute coronary syndrome mimics OT - cardiac imaging OT - diagnostic criteria OT - differential diagnosis OT - stress-induced cardiomyopathy OT - takotsubo syndrome COIS- The authors declare no conflict of interest. EDAT- 2026/07/15 10:10 MHDA- 2026/07/15 10:11 PMCR- 2026/06/30 CRDT- 2026/07/15 01:09 PHST- 2026/05/24 00:00 [received] PHST- 2026/06/15 00:00 [revised] PHST- 2026/06/22 00:00 [accepted] PHST- 2026/07/15 10:11 [medline] PHST- 2026/07/15 10:10 [pubmed] PHST- 2026/07/15 01:09 [entrez] PHST- 2026/06/30 00:00 [pmc-release] AID - jcm15135088 [pii] AID - jcm-15-05088 [pii] AID - 10.3390/jcm15135088 [doi] PST - epublish SO - J Clin Med. 2026 Jun 30;15(13):5088. doi: 10.3390/jcm15135088. PMID- 42451025 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260715 LR - 20260813 IS - 2227-9032 (Print) IS - 2227-9032 (Electronic) IS - 2227-9032 (Linking) VI - 14 IP - 13 DP - 2026 Jul 6 TI - Multidisciplinary Management of Women Suffering from Migraine: Rationale, Design and Results of a National Delphi Consensus. LID - 10.3390/healthcare14132014 [doi] LID - 2014 AB - Background/Objectives: Migraine is a common, disabling neurological disorder disproportionately affecting women during hormonally sensitive phases like menarche, pregnancy, and menopause. Despite awareness of sex-specific risk factors, management remains fragmented and predominantly neurologist-led, with limited coordination. To address these gaps, this project aimed to develop a national expert consensus, endorsed by scientific societies, on multidisciplinary migraine management in women across the lifespan, integrating perspectives from neurology, gynecology, endocrinology, cardiology, and general medicine. Methods: A two-round Delphi survey was conducted among 145 Italian clinicians representing the five specialties. The Scientific Board formulated 50 questions, each consisting of a variable number of statements, covering diagnostic approaches, hormonal therapies, comorbidities, and organizational care pathways. Statements were rated on a nine-point Likert scale, and consensus was defined using pre-specified criteria based on median scores and agreement. Results: Overall, 79 of 145 statements (54%) achieved consensus. High-level agreement emerged on sex-informed diagnostic strategies, including systematic gynecological and endocrinological evaluation and hormonal profiling in women with migraine. Round 2 facilitated consensus on contentious issues, such as avoiding estrogen-containing contraceptives in migraine with aura, individualized thrombotic risk assessment during menopause, and structured interdisciplinary coordination-particularly among neurologists, gynecologists, and general practitioners-during fertility planning and assisted reproduction. Qualitative feedback emphasized the need to update clinical pathways, implement standardized referral models, and strengthen interprofessional communication. However, persistent divergence remained on selected topics, particularly the role of hormonal contraceptives as a first-line approach to migraine management in women of reproductive age, reflecting different priorities between gynecologists and neurologists. Conclusions: This Delphi initiative provides the first national multidisciplinary consensus on migraine management in women in Italy. The findings support the development of sex- and life-stage-specific clinical guidance and integrated care models tailored to the complex needs of women with migraine. FAU - Barbanti, Piero AU - Barbanti P AUID- ORCID: 0000-0002-5670-3755 AD - Headache and Pain Unit, IRCCS San Raffaele, 00163 Rome, Italy. AD - Department of Neuroscience and Neurorehabilitation, San Raffaele University, 00166 Rome, Italy. FAU - Nappi, Rossella E AU - Nappi RE AUID- ORCID: 0000-0002-5216-9882 AD - Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, 27100 Pavia, Italy. AD - Research Center for Reproductive Medicine, Gynecological Endocrinology and Menopause, IRCCS S. Matteo Foundation, 27100 Pavia, Italy. FAU - Cevoli, Sabina AU - Cevoli S AUID- ORCID: 0000-0003-4668-4295 AD - IRCCS Istituto Delle Scienze Neurologiche di Bologna, 40139 Bologna, Italy. FAU - Pasqualetti, Patrizio AU - Pasqualetti P AUID- ORCID: 0000-0001-5560-1979 AD - Department of Wellbeing, Health & Environmental Sustainability, Sapienza University of Rome, 00185 Rome, Italy. FAU - Perrone Filardi, Pasquale AU - Perrone Filardi P AD - Department of Advanced Biomedical Sciences, University of Naples Federico II, 80131 Naples, Italy. FAU - Rainero, Innocenzo AU - Rainero I AUID- ORCID: 0000-0001-6074-9628 AD - Center for Alzheimer's Disease and Related Dementias, Department of Neuroscience and Mental Health, A.O.U. Citta Della Salute e Della Scienza di Torino, 10126 Turin, Italy. AD - Department of Neuroscience "Rita Levi Montalcini", University of Torino, 10126 Turin, Italy. FAU - Rossi, Alessandro AU - Rossi A AD - Italian College of General Practitioners and Primary Care (SIMG), 50142 Florence, Italy. FAU - Trojano, Vito AU - Trojano V AD - Italian Society of Gynecology and Obstetrics (SIGO), 00187 Rome, Italy. FAU - Colao, Annamaria AU - Colao A AUID- ORCID: 0000-0001-6986-266X AD - Endocrinology, Diabetology and Andrology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Naples, Italy. AD - UNESCO, Education for Health and Sustainable Development, University of Naples Federico II, 80131 Naples, Italy. LA - eng GR - Non Applicable/Organon Italia/ PT - Journal Article DEP - 20260706 PL - Switzerland TA - Healthcare (Basel) JT - Healthcare (Basel, Switzerland) JID - 101666525 PMC - PMC13361374 OTO - NOTNLM OT - Delphi consensus OT - menstrual migraine OT - migraine in women OT - multidisciplinary care OT - sex-specific medicine COIS- P.B. reports personal compensation for consulting, serving on a scientific advisory board and for speaker panels, travel grants, research support, collaboration for clinical trials, or other activities with AbbVie, Angelini, Assosalute, Biohaven, DOC generici, Eli-Lilly, Fondazione Ricerca e Salute, GSK, Lundbeck, Noema Pharma, Pfizer, Teva, and Viatris Visufarma and serves as President of the Italian Association of Headache Sufferers (AIC). R.E.N. has on-going relationship with Abbott, Astellas, Bayer HealthCare AG, Besins Healthcare, Biocodex, Exeltis, Fidia, Gedeon Richter, Ibsa, Merck & Co, Novo Nordisk, Organon & Co, Shionogi Limited, Theramex, Viatris. R.E.N. is the current President of the International Menopause Society (IMS). S.C. received honoraria for speaker panels from Teva, AbbVie and Organon. PPF is the current President of the Italian Society of Cardiology (SIC). I.R. received honoraria from Pfizer, Eli Lilly Italy, Teva, AbbVie, and is the current President of Italian Society for the Study of Headaches (SISC). A.R. received honoraria from Sanofi Pasteur and GSK, and is the current President of the Italian Society of General Medicine and Primary Care (SIMG). V.T. is the National President of the Italian Society of Gynecology and Obstetrics (SIGO). A.C. has been principal investigator of Research Studies for Novartis, Ipsen, Pfizer, Lilly, Merck, and Novo Nordisk, a consultant for Novartis, Ipsen, and Pfizer, and has received honoraria from Novartis, Ipsen, and Pfizer, and is Chairholder of the UNESCO Chair in Education for Health and Sustainable Development, Federico II University of Naples. P.P. declares no conflict of interests. EDAT- 2026/07/15 06:38 MHDA- 2026/07/15 06:39 PMCR- 2026/07/06 CRDT- 2026/07/15 01:05 PHST- 2026/05/05 00:00 [received] PHST- 2026/06/12 00:00 [revised] PHST- 2026/07/02 00:00 [accepted] PHST- 2026/07/15 06:39 [medline] PHST- 2026/07/15 06:38 [pubmed] PHST- 2026/07/15 01:05 [entrez] PHST- 2026/07/06 00:00 [pmc-release] AID - healthcare14132014 [pii] AID - healthcare-14-02014 [pii] AID - 10.3390/healthcare14132014 [doi] PST - epublish SO - Healthcare (Basel). 2026 Jul 6;14(13):2014. doi: 10.3390/healthcare14132014. PMID- 42450909 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260715 LR - 20260813 IS - 2227-9032 (Print) IS - 2227-9032 (Electronic) IS - 2227-9032 (Linking) VI - 14 IP - 13 DP - 2026 Jun 30 TI - Preoperative Risk Assessment and Shared Decision-Making in Older Patients Eligible for Cardiac Surgery: Protocol for a Non-Randomized Prospective Study. LID - 10.3390/healthcare14131900 [doi] LID - 1900 AB - Background: The number of older patients undergoing cardiac surgery is increasing, and a substantial proportion of these patients are frail. Frailty is associated with increased mortality, psychological complications, functional decline, and reduced health-related quality of life, complicating treatment decision-making. Currently, treatment recommendations are formulated by the multidisciplinary Heart Team and are mainly based on disease-related parameters. To better integrate patient preferences, geriatric assessment, and shared decision-making into routine cardiothoracic practice, a nurse-led preoperative outpatient pathway was developed: the Preoperative RIsk assessment and shared decision-Making in patients Eligible for cardiac surgery (PRIME) clinic. This study aims to evaluate whether the implementation of PRIME consultation influences Heart Team treatment recommendations and to assess its cost-effectiveness. Methods: This single-center, non-randomized prospective study is conducted in the Netherlands. Patients aged >/=70 years who are eligible for cardiac surgery and have two or more risk factors for adverse postoperative outcomes are included. All patients are initially discussed in the Heart Team, resulting in a treatment recommendation. Patients in the intervention group subsequently visit the PRIME clinic, where a comprehensive geriatric assessment and a shared decision-making consultation are performed. Following this visit, patients are re-evaluated by the Heart Team. The primary outcome is the comparison between the initial and subsequent Heart Team treatment recommendations. Secondary outcomes include health-related quality of life and cost-effectiveness. Discussion: This prospective exploratory study evaluates the implementation of a novel, patient-centered preoperative care model integrating geriatric assessment and shared decision-making into routine cardiac surgical practice. By focusing on outcomes meaningful to older patients and their relatives, the study contributes to the development of value-based, individualized surgical care. Trial registration: The PRIME study was registered in ClinicalTrials.gov (trial registration number: NCT06616129). FAU - Dieen, Milou S H van AU - Dieen MSHV AUID- ORCID: 0000-0002-4973-7658 AD - Research Group Nursing Diagnostics, School of Nursing, Hanze University of Applied Sciences, Petrus Driessenstraat 3, 9714 CA Groningen, The Netherlands. AD - Department of Critical Care, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands. FAU - Blokzijl, Fredrike AU - Blokzijl F AUID- ORCID: 0000-0002-4120-761X AD - Department of Critical Care, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands. AD - Department of Cardiothoracic Surgery, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands. FAU - Kuijpers, Michiel AU - Kuijpers M AUID- ORCID: 0000-0001-9238-8556 AD - Department of Cardiothoracic Surgery, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands. FAU - Paans, Wolter AU - Paans W AD - Research Group Nursing Diagnostics, School of Nursing, Hanze University of Applied Sciences, Petrus Driessenstraat 3, 9714 CA Groningen, The Netherlands. AD - Department of Critical Care, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands. FAU - Bayon, Maria Agustina AU - Bayon MA AD - Department of Cardiothoracic Surgery, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands. FAU - Festen, Suzanne AU - Festen S AD - Department of Geriatric Medicine, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands. FAU - Dieperink, Willem AU - Dieperink W AUID- ORCID: 0000-0003-2738-7471 AD - Research Group Nursing Diagnostics, School of Nursing, Hanze University of Applied Sciences, Petrus Driessenstraat 3, 9714 CA Groningen, The Netherlands. AD - Department of Critical Care, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands. FAU - Bouma, Wobbe AU - Bouma W AD - Department of Cardiothoracic Surgery, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands. FAU - Rienstra, Michiel AU - Rienstra M AUID- ORCID: 0000-0002-2581-070X AD - Department of Cardiology, University Medical Center Groningen, University of Groningen, Hanzepein 1, 9713 GZ Groningen, The Netherlands. FAU - Mariani, Massimo A AU - Mariani MA AD - Department of Cardiothoracic Surgery, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. LA - eng SI - ClinicalTrials.gov/NCT06616129 PT - Journal Article DEP - 20260630 PL - Switzerland TA - Healthcare (Basel) JT - Healthcare (Basel, Switzerland) JID - 101666525 PMC - PMC13362024 OTO - NOTNLM OT - cardiac surgical procedures OT - clinical trial protocol OT - decision-making OT - frail elderly OT - nursing OT - quality of life OT - shared COIS- Professor Mariani has received grants from AtriCure, Edwards Lifesciences, Abbott, and has provided training for Corcym and Artivion. Professor Rienstra has received consultancy fees from Bayer (OCEANIC-AF national PI) and InCarda Therapeutics (RESTORE-SR national PI). Dr. Festen has received funding from the Maarten van der Weijden Foundation and is involved in grants from KWF and ZonMW. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. All other authors declare that they have no competing interests. EDAT- 2026/07/15 06:37 MHDA- 2026/07/15 06:38 PMCR- 2026/06/30 CRDT- 2026/07/15 01:04 PHST- 2026/04/17 00:00 [received] PHST- 2026/05/29 00:00 [revised] PHST- 2026/06/25 00:00 [accepted] PHST- 2026/07/15 06:38 [medline] PHST- 2026/07/15 06:37 [pubmed] PHST- 2026/07/15 01:04 [entrez] PHST- 2026/06/30 00:00 [pmc-release] AID - healthcare14131900 [pii] AID - healthcare-14-01900 [pii] AID - 10.3390/healthcare14131900 [doi] PST - epublish SO - Healthcare (Basel). 2026 Jun 30;14(13):1900. doi: 10.3390/healthcare14131900. PMID- 42448258 OWN - NLM STAT- MEDLINE DCOM- 20260926 LR - 20260926 IS - 1879-1913 (Electronic) IS - 0002-9149 (Linking) VI - 277 DP - 2026 Oct 15 TI - Anticoagulant Regimen for Nonvalvular Atrial Fibrillation in the Elderly and Frail Population. PG - 73-84 LID - S0002-9149(26)00445-5 [pii] LID - 10.1016/j.amjcard.2026.07.006 [doi] AB - Anticoagulant therapy is the cornerstone of stroke prevention in atrial fibrillation (AF), yet its management in elderly and frail patients remains particularly challenging. This review aims to summarize current evidence, guideline recommendations, and future perspectives regarding the optimal anticoagulant strategy in this vulnerable population. A narrative review of pivotal randomized clinical trials and major real-world registries was conducted, focusing on outcomes of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) in patients aged >/=75 years or meeting frailty criteria. Across studies, DOACs consistently demonstrated similar or superior efficacy compared with VKAs for the prevention of stroke and systemic embolism, with a substantially lower risk of intracranial hemorrhage. Apixaban and edoxaban, particularly at adjusted doses, showed the most favorable balance between thromboembolic protection and bleeding risk. Conversely, switching stable elderly patients from long-term VKAs to DOACs, as in the FRAIL-AF trial, was associated with an early excess of clinically relevant nonmajor bleeding. Frailty, multimorbidity, renal impairment, and polypharmacy remain critical modifiers of both efficacy and safety, underlining the need for individualized dosing and regular renal function monitoring. Recent European Society of Cardiology/European Association for Cardio-Thoracic Surgery (ESC/EACTS) and the American Heart Association/American College of Cardiology/Heart Rhythm Society (AHA/ACC/HRS) guidelines recommend DOACs as the preferred treatment for nonvalvular AF, emphasizing comprehensive risk assessment and shared decision-making. Emerging agents, such as factor XI inhibitors, offer a promising approach to minimizing bleeding risk in the elderly, though confirmation of their efficacy against ischemic events remains to be fully established. In elderly and frail patients with AF, DOACs represent the first-line anticoagulant therapy when appropriately dosed and monitored. A personalized, multidisciplinary approach incorporating frailty assessment, renal evaluation, and patient preference is essential to optimize outcomes. Future trials specifically enrolling very old and severely frail patients are urgently needed to close existing evidence gaps. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Scalia, Lorenzo AU - Scalia L AD - Department of Cardiology, Umberto I Hospital, Enna, Italy. Electronic address: lorenzoscalia1993@gmail.com. FAU - Gatto, Laura AU - Gatto L AD - Cardiovascular Department, San Giovanni Addolorata Hospital, Rome, Italy; Department of Cardiovascular Sciences, UniCamillus-Saint Camillus International University of Health Sciences, Rome, Italy. FAU - Agnello, Federica AU - Agnello F AD - Department of Cardiology, Umberto I Hospital, Enna, Italy; Faculty of Medicine and Surgery, University of Enna "Kore", Enna, Italy. FAU - Calderone, Dario AU - Calderone D AD - Invasive Cardiology, Department of Cardiology, San Luca Hospital, IRCCS Istituto Auxologico Italiano, Milan, Italy. FAU - Celeski, Mihail AU - Celeski M AD - Department of Cardiology, Fabrizio Spaziani Hospital, Frosinone, Italy. FAU - Popolo Rubbio, Antonio AU - Popolo Rubbio A AD - Department of Cardiology, IRCCS Policlinico San Donato, Milan, Italy. FAU - Prati, Francesco AU - Prati F AD - Cardiovascular Department, San Giovanni Addolorata Hospital, Rome, Italy; Department of Cardiovascular Sciences, UniCamillus-Saint Camillus International University of Health Sciences, Rome, Italy. FAU - Testa, Luca AU - Testa L AD - Department of Cardiology, IRCCS Policlinico San Donato, Milan, Italy. FAU - Capodanno, Davide AU - Capodanno D AD - Division of Cardiology, Azienda Ospedaliero Universitaria Policlinico "G. Rodolico-San Marco" University of Catania, Catania, Italy. FAU - Barbanti, Marco AU - Barbanti M AD - Department of Cardiology, Umberto I Hospital, Enna, Italy; Faculty of Medicine and Surgery, University of Enna "Kore", Enna, Italy. LA - eng PT - Journal Article PT - Review DEP - 20260714 PL - United States TA - Am J Cardiol JT - The American journal of cardiology JID - 0207277 RN - 0 (Anticoagulants) RN - 12001-79-5 (Vitamin K) SB - IM MH - Humans MH - *Atrial Fibrillation/complications/drug therapy MH - *Anticoagulants/therapeutic use MH - *Frail Elderly MH - Aged MH - *Stroke/prevention & control/etiology MH - Hemorrhage/chemically induced MH - Vitamin K/antagonists & inhibitors OTO - NOTNLM OT - DOACs OT - anticoagulation OT - atrial fibrillation OT - bleeding risk OT - elderly OT - frailty COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/07/15 00:34 MHDA- 2026/09/27 02:29 CRDT- 2026/07/14 19:14 PHST- 2026/05/26 00:00 [received] PHST- 2026/06/14 00:00 [revised] PHST- 2026/07/03 00:00 [accepted] PHST- 2026/09/27 02:29 [medline] PHST- 2026/07/15 00:34 [pubmed] PHST- 2026/07/14 19:14 [entrez] AID - S0002-9149(26)00445-5 [pii] AID - 10.1016/j.amjcard.2026.07.006 [doi] PST - ppublish SO - Am J Cardiol. 2026 Oct 15;277:73-84. doi: 10.1016/j.amjcard.2026.07.006. Epub 2026 Jul 14. PMID- 42447381 OWN - NLM STAT- Publisher LR - 20260714 IS - 1550-5154 (Electronic) IS - 1063-8628 (Linking) DP - 2026 Jul 14 TI - Interdisciplinary Collaborative Strategies to Improve Delirium Screening Documentation in the Pediatric CICU. LID - 10.1097/QMH.0000000000000568 [doi] AB - BACKGROUND AND OBJECTIVES: A lack of consistent delirium screening and documentation has been a recurring problem across intensive care units. We aim to improve the rate of delirium screening and documentation among patients admitted to cardiac intensive care units (CICU) in a 34-bed tertiary pediatric cardiac intensive care unit from 10% to 85% over 12 months. METHODS: We first reviewed our existing practice of delirium screening and documentation in the electronic Epic patient database system. Once key barriers in our unit practice were identified, the intervention included Epic admission order-sets and Flowsheet updates for standardized delirium screening ordering and documentation. We also provided unit-wide nursing education on delirium screening and documentation using the Cornell Assessment of Pediatric Delirium tool. Delirium documentation compliance was assessed before and after the implementation of the new strategy for those with age <18 years and CICU admission > 48 hours. RESULTS: Our initial review showed inconsistent and sporadic screening and documentation of delirium where only 10% of eligible admitted patients had documented delirium scores in the chart. After implementing Epic changes and education, 97% of admitted patients had screening and documentation of delirium over a 1-year period following the change. CONCLUSIONS: Newly implemented multi-disciplinary strategy targeting a standardized delirium screening order and efficient Flowsheet organization along with nurse-focused education on delirium led to significant improvement in delirium screening and documentation in our pediatric cardiac intensive care unit. CI - Copyright (c) 2026 Wolters Kluwer Health, LLC. All rights reserved. FAU - Palmere, Samantha AU - Palmere S AD - Author Affiliations: Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio (Mrs Palmere, Mrs Thielen, Mrs Roesel, Dr Homanick, Dr Koh); Heart Center, INOVA Children's Hospital, Falls Church, Virginia (Dr Iliopoulos); and Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio (Dr Koh). FAU - Thielen, Jessica AU - Thielen J FAU - Roesel, Ashley AU - Roesel A FAU - Homanick, Brendan AU - Homanick B FAU - Iliopoulos, Ilias AU - Iliopoulos I FAU - Koh, Wonshill AU - Koh W LA - eng PT - Journal Article DEP - 20260714 PL - United States TA - Qual Manag Health Care JT - Quality management in health care JID - 9306156 SB - IM OTO - NOTNLM OT - cardiac intensive care unit OT - delirium OT - delirium screening OT - pediatrics EDAT- 2026/07/14 18:39 MHDA- 2026/07/14 18:39 CRDT- 2026/07/14 15:52 PHST- 2026/07/14 18:39 [medline] PHST- 2026/07/14 18:39 [pubmed] PHST- 2026/07/14 15:52 [entrez] AID - 00019514-990000000-00174 [pii] AID - 10.1097/QMH.0000000000000568 [doi] PST - aheadofprint SO - Qual Manag Health Care. 2026 Jul 14. doi: 10.1097/QMH.0000000000000568. PMID- 42445530 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260714 LR - 20260813 IS - 2297-055X (Print) IS - 2297-055X (Electronic) IS - 2297-055X (Linking) VI - 13 DP - 2026 TI - Female sex is not associated with worse surgical outcomes in infective endocarditis: a prospective study disproving a common assumption. PG - 1883895 LID - 10.3389/fcvm.2026.1883895 [doi] LID - 1883895 AB - BACKGROUND: Sex-based disparities in infective endocarditis (IE) have been increasingly recognized, yet their impact on surgical access and outcomes remains controversial. In particular, whether biological sex influences the likelihood of undergoing surgical treatment and the subsequent prognosis of surgical patients remains a subject of debate. METHODS: This is a single-center, observational, prospective cohort study including 264 consecutive patients diagnosed and treated for IE at a tertiary referral center between January 2023 and December 2025. Among these 264 patients, 194 had an indication for cardiac surgery and 117 finally underwent the operation. Our study included only the group of surgically treated patients. The primary objective was to evaluate the impact of sex on in-hospital mortality following surgery for IE. The secondary objective was to assess the association between sex and mid-term outcomes, defined as a composite endpoint including all-cause mortality, repeat cardiac surgery, hospital readmission for heart failure, or relapse/reinfection of IE within one year from diagnosis. Finally, we investigated whether female sex was associated with reduced surgical access in patients with a formal indication. RESULTS: A total of 117 patients undergoing cardiac surgery for IE were included: 22 (18.8%) were female. Comorbidities, microbiological etiology and clinical presentation were largely comparable between sexes. The proportion of patients with a formal surgical indication was similar in women and men (67.2% vs. 75.6%, p = 0.175). However, women tended to undergo cardiac surgery less frequently than men (48.9% vs. 63.8%). At univariable analysis female sex emerged as a suggestive factor for reduced access to surgery (OR 0.544, p = 0.076). Overall in-hospital mortality was 12.8% with no significant sex-related differences (9.1% vs. 13.7% in males, p = 0.561). At multivariable analysis, female sex did not emerge as an independent predictor of in-hospital mortality (OR 0.387, p = 0.409) nor mid-term outcomes. DISCUSSION AND CONCLUSIONS: This study indicates a potential sex-based disparity in surgical access despite similar clinical indications and survival rates. Our findings challenge the assumption that female sex is associated with worse surgical outcomes, highlighting the need for careful individualized clinical judgment and multidisciplinary discussion to prevent potential treatment disparities. CI - (c) 2026 Pavone, d'Acierno, Mazzenga, Cammertoni, Calabrese, Giovannenze, Testa, Scoppettuolo, Pasquini, Grandinetti, Romagnoli, Chiariello, Bruno and Massetti. FAU - Pavone, N AU - Pavone N AD - Department of Cardiovascular Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy. FAU - d'Acierno, E M AU - d'Acierno EM AD - Department of Cardiovascular Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy. AD - Universita Cattolica del Sacro Cuore, Rome, Italy. FAU - Mazzenga, G AU - Mazzenga G AD - Universita Cattolica del Sacro Cuore, Rome, Italy. FAU - Cammertoni, F AU - Cammertoni F AD - Department of Cardiovascular Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy. FAU - Calabrese, M AU - Calabrese M AD - Department of Cardiovascular Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy. FAU - Giovannenze, F AU - Giovannenze F AD - UOC Malattie Infettive-Dipartimento Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. FAU - Testa, N AU - Testa N AD - Department of Cardiovascular Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy. FAU - Scoppettuolo, G AU - Scoppettuolo G AD - Universita Cattolica del Sacro Cuore, Rome, Italy. AD - UOC Malattie Infettive-Dipartimento Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. FAU - Pasquini, A AU - Pasquini A AD - Department of Cardiovascular Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy. FAU - Grandinetti, M AU - Grandinetti M AD - Department of Cardiovascular Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy. FAU - Romagnoli, E AU - Romagnoli E AD - Department of Cardiovascular Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy. AD - Universita Cattolica del Sacro Cuore, Rome, Italy. FAU - Chiariello, G A AU - Chiariello GA AD - Department of Cardiovascular Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy. FAU - Bruno, P AU - Bruno P AD - Department of Cardiovascular Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy. AD - Universita Cattolica del Sacro Cuore, Rome, Italy. FAU - Massetti, M AU - Massetti M AD - Department of Cardiovascular Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy. AD - Universita Cattolica del Sacro Cuore, Rome, Italy. LA - eng PT - Journal Article DEP - 20260629 PL - Switzerland TA - Front Cardiovasc Med JT - Frontiers in cardiovascular medicine JID - 101653388 PMC - PMC13357413 OTO - NOTNLM OT - Endocarditis Team OT - cardiac surgery OT - gender gap OT - infective endocarditis OT - sex disparities OT - surgical outcomes COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/07/14 18:26 MHDA- 2026/07/14 18:27 PMCR- 2026/06/29 CRDT- 2026/07/14 06:52 PHST- 2026/05/17 00:00 [received] PHST- 2026/06/08 00:00 [revised] PHST- 2026/06/09 00:00 [accepted] PHST- 2026/07/14 18:27 [medline] PHST- 2026/07/14 18:26 [pubmed] PHST- 2026/07/14 06:52 [entrez] PHST- 2026/06/29 00:00 [pmc-release] AID - 10.3389/fcvm.2026.1883895 [doi] PST - epublish SO - Front Cardiovasc Med. 2026 Jun 29;13:1883895. doi: 10.3389/fcvm.2026.1883895. eCollection 2026. PMID- 42442717 OWN - NLM STAT- MEDLINE DCOM- 20260813 LR - 20260825 IS - 1439-1651 (Electronic) IS - 0948-2393 (Linking) VI - 230 IP - 4 DP - 2026 Aug TI - Resuscitation in pregnant women - the current international guidelines under close scrutiny. PG - 291-299 LID - 10.1055/a-2892-2999 [doi] AB - The management of cardiac arrest in pregnant women requires adjustments to account for the physiology of pregnancy, the specific causes of cardiac arrest, and the potential need for a resuscitative delivery if a return of spontaneous circulation cannot be achieved. Successful resuscitation hinges upon the prompt availability and stringent coordination of a multidisciplinary specialized team. Resuscitation measures are often compromised by delays in initiating interventions (uterine lateralization; high-quality, minimally interrupted cardiopulmonary resus-citation; dealing with potentially difficult airways; resuscitative cesarean delivery). Resuscitative cesarean delivery is one of the rarest, yet physically and emotionally demanding procedures in dealing with obstetric emergencies potentially leading to the birth of a viable newborn infant in need of resuscitation itself. Timely access to the resources and personnel capable of coordinating this multidisciplinary endeavor varies based on the local environment. Therefore, unequivocal treatment recommendations are of paramount clinical importance. Despite broad consensus, differences between the current recommendations released October 2025 by the American Heart Association (AHA) and the European Resuscitation Council Guidelines (ERC) may cause confusion. Clinical implementation therefore remains a challenge, particularly when resuscitation takes place outside a hospital and/or in the absence of a trained team. The complexity of this clinical scenario underscores the need for teams to prepare and train for these rare emergency situations. CI - Thieme. All rights reserved. FAU - Strauss, Alexander AU - Strauss A AUID- ORCID: 0000-0001-6943-2862 AD - Christian-Albrechts-University Kiel, Germany. FAU - Haupt, Oliver AU - Haupt O AD - Institute for Emergency Medicine, University Hospital Schleswig-Holstein Campus Kiel and Lubeck, Germany. FAU - Grasner, Jan-Thorsten AU - Grasner JT AD - Institute for Emergency Medicine, University Hospital Schleswig-Holstein Campus Kiel and Lubeck, Germany. AD - University Hospital Schleswig-Holstein Campus Kiel, Department for Anaesthesiology and Intensive Care Medicine, Germany. FAU - Jacobsen, Nils AU - Jacobsen N AD - Institute for Emergency Medicine, University Hospital Schleswig-Holstein Campus Kiel and Lubeck, Germany. LA - eng PT - Journal Article PT - Review DEP - 20260713 PL - Germany TA - Z Geburtshilfe Neonatol JT - Zeitschrift fur Geburtshilfe und Neonatologie JID - 9508901 SB - IM MH - Female MH - Humans MH - Pregnancy MH - *Practice Guidelines as Topic MH - *Pregnancy Complications, Cardiovascular/therapy MH - *Heart Arrest/therapy MH - *Resuscitation/standards MH - *Cardiopulmonary Resuscitation/standards MH - Cesarean Section MH - Infant, Newborn COIS- The authors declare that they have no conflict of interest. EDAT- 2026/07/14 00:35 MHDA- 2026/08/13 23:36 CRDT- 2026/07/13 19:23 PHST- 2026/08/13 23:36 [medline] PHST- 2026/07/14 00:35 [pubmed] PHST- 2026/07/13 19:23 [entrez] AID - 10.1055/a-2892-2999 [doi] PST - ppublish SO - Z Geburtshilfe Neonatol. 2026 Aug;230(4):291-299. doi: 10.1055/a-2892-2999. Epub 2026 Jul 13. PMID- 42440260 OWN - NLM STAT- Publisher LR - 20260713 IS - 1930-613X (Electronic) IS - 0026-4075 (Linking) DP - 2026 Jul 13 TI - Incidental Cardiac Fibroma in a Young Soldier: Exercise Authorization and Graded Fitness-for-Duty Determination. LID - usag320 [pii] LID - 10.1093/milmed/usag320 [doi] AB - Cardiac fibroma is the second most common primary cardiac tumor in children but is uncommonly diagnosed in adulthood, where it is usually discovered incidentally. Neither the 2020 ESC guidelines nor the 2025 AHA/ACC scientific statement on sports cardiology specifically address exercise recommendations for this entity, and data on fitness-for-duty determination in military personnel with incidental cardiac tumors are nonexistent. We report the case of a 25-year-old active-duty soldier in whom routine electrocardiographic screening prompted transthoracic echocardiography that unexpectedly identified a well-circumscribed intramyocardial mass (20 x 20 mm) in the basal interventricular septum. Cardiac MRI demonstrated features highly consistent with a fibroma. Comprehensive assessment including repeated exercise stress testing, exercise echocardiography with hemodynamic evaluation, and Holter monitoring was unremarkable. After multidisciplinary evaluation, a conservative strategy was adopted. Recreational sports participation was authorized based on a structured, stepwise risk assessment. Full operational fitness was restricted, but a graded approach to military duties was implemented, acknowledging that fitness-for-duty in military populations is not a binary determination. Three-year follow-up confirmed clinical and imaging stability. This case adds to the limited evidence guiding exercise and fitness-for-duty decisions in adults with cardiac fibroma. CI - (c) The Association of Military Surgeons of the United States 2026. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com. FAU - Demoulin, Raphael AU - Demoulin R AUID- ORCID: 0000-0002-5055-4234 AD - Department of Cardiology, Sainte Anne Military Hospital, 83000 Toulon, France. FAU - Parsai, Chirine AU - Parsai C AD - Department of Cardiology, Polyclinique Les Fleurs, 83190 Ollioules, France. FAU - Bone, Adele Chane Kaye AU - Bone ACK AD - French Armed Forces Health Service, French Navy, France. FAU - Schmitt, Paul AU - Schmitt P AD - Department of Cardiology, Sainte Anne Military Hospital, 83000 Toulon, France. FAU - Adet, Alisson AU - Adet A AD - Department of Cardiology, Sainte Anne Military Hospital, 83000 Toulon, France. FAU - Prevautel, Thibaut AU - Prevautel T AUID- ORCID: 0000-0002-4709-373X AD - Department of Cardiology, Sainte Anne Military Hospital, 83000 Toulon, France. FAU - Cellarier, Gilles Rolland AU - Cellarier GR AD - Department of Cardiology, Sainte Anne Military Hospital, 83000 Toulon, France. LA - eng PT - Journal Article DEP - 20260713 PL - England TA - Mil Med JT - Military medicine JID - 2984771R SB - IM EDAT- 2026/07/13 12:35 MHDA- 2026/07/13 12:35 CRDT- 2026/07/13 11:22 PHST- 2026/07/13 12:35 [medline] PHST- 2026/07/13 12:35 [pubmed] PHST- 2026/07/13 11:22 [entrez] AID - 8733389 [pii] AID - 10.1093/milmed/usag320 [doi] PST - aheadofprint SO - Mil Med. 2026 Jul 13:usag320. doi: 10.1093/milmed/usag320. PMID- 42440200 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20261009 LR - 20261011 IS - 2365-6271 (Electronic) IS - 2365-6271 (Linking) VI - 12 IP - 1 DP - 2026 Jul 13 TI - Precision planning in congenital heart disease: the impact of 3D printing and virtual simulation. LID - 10.1186/s41205-026-00336-8 [doi] LID - 30 AB - BACKGROUND: Surgical planning in complex congenital heart disease (CHD) often involves challenging decisions between univentricular and biventricular repair. Traditional imaging modalities such as echocardiography, CT, MRI, and angiography provide detailed data but lack intuitive three-dimensional spatial visualization. This study aimed to establish a low-cost, scalable 3D modeling and surgical simulation approach for broader access to this technology in mid-sized or resource-limited pediatric cardiology centers. METHODS: We retrospectively studied 25 patients with complex CHD who underwent 3D modeling to assess suitability for biventricular repair. Patient-specific cardiac models were generated using open-source segmentation and post-processing software and fabricated using a desktop stereolithography (SLA) Formlabs 3D printer. Surgical baffles were simulated digitally and incorporated into the models to assess the feasibility of biventricular repair. Models were reviewed in multidisciplinary team meetings and shared online via a 3D viewing platform (Sketchfab) to allow remote consultation. RESULTS: Of the 25 patients evaluated, 14 (56%) underwent a change in surgical strategy from univentricular to biventricular repair after review of the 3D models and simulated baffles. All patients who underwent revised biventricular repair had favorable short-term outcomes. The cost of model production ranged from USD 350 to 480 per patient, significantly lower than traditional outsourced workflows. The approach enabled improved spatial understanding of cardiac anatomy and facilitated collaborative decision-making across institutions. CONCLUSIONS: Low-cost 3D printed models can significantly impact surgical planning in complex CHD, increasing the feasibility of biventricular repair and reducing reliance on univentricular pathways. CI - (c) 2026. The Author(s). FAU - Maghrabi, Khadijah AU - Maghrabi K AD - Pediatric Department, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia. kamaghrabi@kau.edu.sa. AD - Pediatric Cardiac Center of Excellence, King Abdulaziz University, Jeddah, Saudi Arabia. kamaghrabi@kau.edu.sa. AD - Department of Pediatrics, Pediatric Cardiac Center of Excellence, King Abdulaziz University, PO Box 80215, Jeddah, 21589, Saudi Arabia. kamaghrabi@kau.edu.sa. FAU - Al-Radi, Osman AU - Al-Radi O AD - Cardiac Surgery Division, Department of Surgery, King Abdulaziz University, Jeddah, Saudi Arabia. LA - eng PT - Journal Article DEP - 20260713 PL - England TA - 3D Print Med JT - 3D printing in medicine JID - 101721758 PMC - PMC13651262 OTO - NOTNLM OT - 3D printing OT - Cardiac surgery OT - Congenital heart disease COIS- Declarations. Ethics approval and consent to participate: The study received ethical approval from the KAUH Institutional Review Board (reference number 420-25). The requirement for informed consent was waived because of the retrospective nature of the study. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2026/07/13 12:34 MHDA- 2026/07/13 12:35 PMCR- 2026/07/13 CRDT- 2026/07/13 11:16 PHST- 2025/12/14 00:00 [received] PHST- 2026/07/06 00:00 [accepted] PHST- 2026/07/13 12:35 [medline] PHST- 2026/07/13 12:34 [pubmed] PHST- 2026/07/13 11:16 [entrez] PHST- 2026/07/13 00:00 [pmc-release] AID - 10.1186/s41205-026-00336-8 [pii] AID - 336 [pii] AID - 10.1186/s41205-026-00336-8 [doi] PST - epublish SO - 3D Print Med. 2026 Jul 13;12(1):30. doi: 10.1186/s41205-026-00336-8. PMID- 42438450 OWN - NLM STAT- MEDLINE DCOM- 20260930 LR - 20260930 IS - 1467-1107 (Electronic) IS - 1047-9511 (Linking) VI - 36 IP - 7 DP - 2026 Jul TI - Anxiety in parents of children with CHD. PG - 1352-1355 LID - 10.1017/S1047951126111986 [doi] AB - OBJECTIVES: The diagnosis of CHD not only affects the patient but also their entire environment, including parents, causing significant alterations in their mental health. This study was to assess the levels of anxiety and depression in parents of children with CHD at different stages of the disease. METHODS: The PMNCC and PMNCR questionnaires were administered to parents of children with CHD to measure levels of state anxiety (STAI-E) and trait anxiety (STAI-R). RESULTS: A total of 459 questionnaires were administered. For the state anxiety questionnaire (STAI-E), the mean score was 36, with high anxiety levels observed in 81.3% of participants and above-average levels in 18.7%. Regarding the severity of state anxiety, 82.6% presented severe anxiety, followed by moderate anxiety in 17.2%. For the trait anxiety questionnaire (STAI-R), the mean score was 43, with high levels observed in 91.5% of participants and above-average levels in 7.2%. Severe anxiety predominated in 96.7% of cases. CONCLUSIONS: The mental health of parents of children with CHD is often neither diagnosed nor adequately addressed in a timely manner by paediatric cardiology teams. Assessment and support from a multidisciplinary team are required for the early identification of these conditions. FAU - Masini Aguilera, Italo AU - Masini Aguilera I AD - Cirugia de Torax y Cardiovascular, Hospital Civil de Guadalajara Unidad Hospitalaria Fray Antonio Alcalde, Mexico. FAU - Lopez Taylor, Jaime Gilberto AU - Lopez Taylor JG AD - Servicio de Torax y Cardiovascular, Hospital Civil de Guadalajara Unidad Hospitalaria Fray Antonio Alcalde, Mexico. FAU - Ramirez Cedillo, David AU - Ramirez Cedillo D AD - Servicio de Torax y Cardiovascular, Hospital Civil de Guadalajara Unidad Hospitalaria Fray Antonio Alcalde, Mexico. FAU - Jimenez Fernandez, Carlos Alberto AU - Jimenez Fernandez CA AD - Servicio de Torax y Cardiovascular, Hospital Civil de Guadalajara Unidad Hospitalaria Fray Antonio Alcalde, Mexico. FAU - Olmos Sanchez, Halina AU - Olmos Sanchez H AD - Servicio de Torax y Cardiovascular, Hospital Civil de Guadalajara Unidad Hospitalaria Fray Antonio Alcalde, Mexico. FAU - Ramirez Frias, Cynthia AU - Ramirez Frias C AD - Servicio de Torax y Cardiovascular, Hospital Civil de Guadalajara Unidad Hospitalaria Fray Antonio Alcalde, Mexico. FAU - Contreras Godinez, Alondra AU - Contreras Godinez A AD - Servicio de Torax y Cardiovascular, Hospital Civil de Guadalajara Unidad Hospitalaria Fray Antonio Alcalde, Mexico. FAU - Flores Flores, Oscar Alonso AU - Flores Flores OA AD - Servicio de Torax y Cardiovascular, Hospital Civil de Guadalajara Unidad Hospitalaria Fray Antonio Alcalde, Mexico. FAU - Pena, Rocio A AU - Pena RA AUID- ORCID: 0000-0001-7179-7262 AD - Cardiologia Pediatrica, Instituto Nacional de Pediatria, Mexico. ROR: https://ror.org/02epdjj68 AD - Cardiologia Pediatrica, Hospital General de Occidente, Mexico. ROR: https://ror.org/0070wyz29 LA - eng PT - Journal Article DEP - 20260713 PL - England TA - Cardiol Young JT - Cardiology in the young JID - 9200019 SB - IM MH - Humans MH - *Parents/psychology MH - *Heart Defects, Congenital/psychology MH - Male MH - Female MH - Surveys and Questionnaires MH - Child MH - *Anxiety/epidemiology/etiology MH - Adult MH - Adolescent MH - Child, Preschool MH - *Depression/epidemiology OTO - NOTNLM OT - Anxiety OT - CHD OT - mental health OT - parents EDAT- 2026/07/13 06:32 MHDA- 2026/09/30 23:29 CRDT- 2026/07/13 03:43 PHST- 2026/09/30 23:29 [medline] PHST- 2026/07/13 06:32 [pubmed] PHST- 2026/07/13 03:43 [entrez] AID - S1047951126111986 [pii] AID - 10.1017/S1047951126111986 [doi] PST - ppublish SO - Cardiol Young. 2026 Jul;36(7):1352-1355. doi: 10.1017/S1047951126111986. Epub 2026 Jul 13. PMID- 42437779 OWN - NLM STAT- Publisher LR - 20260712 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) DP - 2026 Jul 12 TI - Team-based versus individual learning for out-of-hospital cardiac arrest rhythm recognition in newly hired emergency medical service providers: cluster-randomized equivalence trial. LID - 10.1038/s41598-026-61027-2 [doi] AB - Early recognition of shockable and non-shockable rhythms is critical for survival in out-of-hospital cardiac arrest (OHCA). Team-based learning (TBL) occurs in emergency care, yet its impact on rhythm recognition remains unclear. We tested whether team-based and individual formats yielded equivalent short-term improvements in OHCA rhythm recognition. A single-center, session-level cluster-randomized parallel-group equivalence trial was conducted within an induction course for newly hired EMS personnel in South Korea. Eight training sessions (four per arm) were the unit of randomization, allocated in permuted blocks of size two in TBL-->Individual (AB) or Individual-->TBL (BA) sequences. The 90-min curriculum included lectures, interactive defibrillator rhythm cases, and feedback. Outcome was OHCA rhythm recognition (0-9). Secondary outcomes included confidence (1-5 Likert scale) and 1-month online follow-ups. Paired t-tests, analysis of covariance, and equivalence testing within a 1.0-point margin were used. Participants (n = 387) completed both assessments (individual 188, team 199). Knowledge improved by + 1.32 points (95% confidence interval [CI], 1.12-1.52). Between-format difference in gain (team-individual = - 0.13; 90% CI - 0.47 to 0.21) met the equivalence margin. At one month, knowledge gains were maintained among completers, but follow-up completion was differential between arms. Paramedic job category was independently associated with higher post-training scores, whereas career duration was not. When content and feedback were held constant, team-based and individual formats yielded equivalent short-term gains in arrest-rhythm recognition. The 1-month retention findings should be interpreted cautiously because of differential follow-up completion. Future work should test behavioral and patient-level outcomes.Clinical trial registration This trial was retrospectively registered at the Clinical Research Information Service (CRIS, KCT0011562) on February 2, 2026. CI - (c) 2026. The Author(s). FAU - Cho, Young Shin AU - Cho YS AD - Department of Emergency Medicine, Soonchunhyang University Seoul Hospital, Seoul, Republic of Korea. FAU - Lee, Choung Ah AU - Lee CA AUID- ORCID: 0000-0003-2487-8988 AD - Department of Emergency Medicine, Hallym University Dongtan Sacred Heart Hospital, Hwaseong si, Gyeonggi do, Republic of Korea. cuccum@hanmail.net. LA - eng PT - Journal Article DEP - 20260712 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 SB - IM OTO - NOTNLM OT - Defibrillation OT - Emergency medical services OT - Out-of-hospital cardiac arrest OT - Rhythm recognition OT - Team-based learning COIS- Declarations. Competing interests: The authors declare no competing interests. Ethical approval and consent to participate: This study was conducted in accordance with the ethical standards of the institutional research committee and with the principles of the Declaration of Helsinki. Ethical approval was obtained from the Institutional Review Board of Hallym University Dongtan Sacred Heart Hospital (IRB No. HDT 2022-11-010). Written informed consent was obtained from all participants prior to participation. EDAT- 2026/07/13 00:32 MHDA- 2026/07/13 00:32 CRDT- 2026/07/12 23:21 PHST- 2026/01/28 00:00 [received] PHST- 2026/07/01 00:00 [accepted] PHST- 2026/07/13 00:32 [medline] PHST- 2026/07/13 00:32 [pubmed] PHST- 2026/07/12 23:21 [entrez] AID - 10.1038/s41598-026-61027-2 [pii] AID - 10.1038/s41598-026-61027-2 [doi] PST - aheadofprint SO - Sci Rep. 2026 Jul 12. doi: 10.1038/s41598-026-61027-2. PMID- 42435793 OWN - NLM STAT- MEDLINE DCOM- 20260821 LR - 20260909 IS - 1873-1570 (Electronic) IS - 0300-9572 (Linking) VI - 226 DP - 2026 Sep TI - Perceived cognitive load among emergency department code blue teams: distribution, correlates and relationship with team performance. PG - 111206 LID - S0300-9572(26)00253-4 [pii] LID - 10.1016/j.resuscitation.2026.111206 [doi] AB - BACKGROUND: Advanced life support algorithms standardise core actions during cardiac arrest, yet clinical resuscitation also requires coordination, adaptation and decision-making under time pressure. This study examined perceived cognitive load across team roles and its association with team performance in authentic clinical emergency department teams. METHODS: In this multicentre cross-sectional study with prospective data collection, perceived cognitive load was measured using the Paas 9-point mental effort scale. Team performance was assessed using the Team Emergency Assessment Measure (TEAM), completed by participating team members and aggregated at event level. RESULTS: A total of 58 resuscitations with 228 healthcare professional observations were included. Perceived cognitive load varied across roles and was highest among team leaders (mean 5.5, SD 1.7). In multilevel analysis, the team leader role was associated with higher perceived cognitive load (beta = 1.12, 95% CI 0.27-1.98, p = 0.025), whereas increasing age and more than ten years of clinical experience were associated with lower load. Team leaders' perceived cognitive load was positively associated with cognitive load among team members (beta = 0.53, 95% CI 0.38-0.67, p < 0.001) and negatively associated with TEAM-assessed team performance (beta = -0.80, 95% CI -1.38 to -0.23, p = 0.007). CONCLUSIONS: Perceived cognitive load was unevenly distributed within resuscitation teams, with highest levels among team leaders. Higher team leader cognitive load was associated with higher load among other team members and lower TEAM-assessed performance, highlighting team leader cognitive load as a relevant target for future research and interventions to support resuscitation team performance. CI - Copyright (c) 2026 The Author(s). Published by Elsevier B.V. All rights reserved. FAU - Mommers, Lars AU - Mommers L AD - Department of Simulation in Healthcare, Maastricht University Medical Centre, Maastricht, the Netherlands; Department of Anaesthesiology and Pain Medicine, Maastricht University Medical Centre, Maastricht, the Netherlands; School of Health Professions Education, Maastricht University, the Netherlands. Electronic address: l.mommers@mumc.nl. FAU - Franssen, Myriam AU - Franssen M AD - Department of Emergency Medicine, Zuyderland Medical Centre, the Netherlands. FAU - Hensgens, Kirsten AU - Hensgens K AD - Department of Emergency Medicine, Zuyderland Medical Centre, the Netherlands. FAU - Morsink, Marlies E B AU - Morsink MEB AD - Department of Emergency Medicine, Radboud University Medical Centre, Nijmegen, the Netherlands. FAU - Slagt, Cornelis AU - Slagt C AD - Department of Anaesthesiology and Pain Medicine, Radboud University Medical Centre, Nijmegen, the Netherlands. FAU - van Kuijk, Sander M J AU - van Kuijk SMJ AD - Department of Clinical Epidemiology and Medical Technology Assessment (KEMTA), Maastricht University Medical Centre, Maastricht, the Netherlands. FAU - Verstegen, Danielle AU - Verstegen D AD - School of Health Professions Education, Maastricht University, the Netherlands; Department of Educational Development and Research, Faculty of Health, Medicine and Life Sciences, Maastricht University, the Netherlands. FAU - Dolmans, Diana AU - Dolmans D AD - School of Health Professions Education, Maastricht University, the Netherlands; Department of Educational Development and Research, Faculty of Health, Medicine and Life Sciences, Maastricht University, the Netherlands. FAU - van Mook, Walther N K A AU - van Mook WNKA AD - School of Health Professions Education, Maastricht University, the Netherlands; Department of Postgraduate Medical Training, Maastricht University Medical Centre, Maastricht, the Netherlands; Department of Intensive Care Medicine, Maastricht University Medical Centre, Maastricht, the Netherlands. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20260711 PL - Ireland TA - Resuscitation JT - Resuscitation JID - 0332173 SB - IM MH - Humans MH - Cross-Sectional Studies MH - *Emergency Service, Hospital/organization & administration MH - Female MH - *Heart Arrest/therapy MH - *Patient Care Team/organization & administration/standards MH - Male MH - Prospective Studies MH - *Cognition MH - *Cardiopulmonary Resuscitation MH - Adult MH - Leadership MH - *Hospital Rapid Response Team MH - Middle Aged OTO - NOTNLM OT - Cognitive load OT - Interprofessional collaboration OT - Non-technical skills OT - Resuscitation OT - Team performance COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/07/12 00:54 MHDA- 2026/08/21 23:37 CRDT- 2026/07/11 19:10 PHST- 2026/05/27 00:00 [received] PHST- 2026/06/29 00:00 [revised] PHST- 2026/07/05 00:00 [accepted] PHST- 2026/08/21 23:37 [medline] PHST- 2026/07/12 00:54 [pubmed] PHST- 2026/07/11 19:10 [entrez] AID - S0300-9572(26)00253-4 [pii] AID - 10.1016/j.resuscitation.2026.111206 [doi] PST - ppublish SO - Resuscitation. 2026 Sep;226:111206. doi: 10.1016/j.resuscitation.2026.111206. Epub 2026 Jul 11. PMID- 42430197 OWN - NLM STAT- MEDLINE DCOM- 20261028 LR - 20261028 IS - 1879-0844 (Electronic) IS - 1388-9842 (Linking) VI - 28 IP - 4 DP - 2026 Oct 28 TI - European Society of Cardiology updated curriculum for heart failure nurses: developed by the Heart Failure Association, in collaboration with the Association of Cardiovascular Nurses and Allied Professions of the European Society of Cardiology. PG - 592-620 LID - 10.1093/ejhf/xuag077 [doi] AB - The role of the nurse in the heart failure (HF) multi-disciplinary team (MDT) has become well-established, with clear evidence of improved patient outcomes and recommended by professional guidelines. Recognizing the change in the HF landscape since the publication of the first Heart Failure Association (HFA) of the European Society of Cardiology (ESC) HF nurse curriculum in 2016, and the expanding role of HF nurses of in the HF MDT, the HFA in collaboration with the Association of Cardiovascular Nursing and Allied Professions (ACNAP) of the ESC prioritized this update to the curriculum. Standardized training programmes for HF nurses improve the quality of care provided to patients with HF and their caregivers. Recognizing the variability of education background and clinical autonomy across Europe and beyond, this curriculum is designed in a flexible way to be able to be adapted and adjusted based on individual country regulations and forms. Endorsement of this curriculum from national professional bodies or Nursing Councils would ensure uniformity and enhance the profession's contribution to HF care. The updated specialist HF nurse curriculum provides the basis for the advanced level of knowledge, skills and attitudes required for the appropriate expansion of the role of the HF nurse that can be adapted across Europe and beyond, while complying with professional legislation of different healthcare systems and supporting nurses who move between countries. CI - (c) The Author(s) 2026. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com. FAU - Lambrinou, Ekaterini AU - Lambrinou E AUID- ORCID: 0000-0002-2601-8861 AD - Department of Nursing, School of Health Sciences, Cyprus University of Technology, 30, Archbishop Kyprianou Str., Limassol 3036, Cyprus. FAU - Simpson, Maggie AU - Simpson M AUID- ORCID: 0000-0003-1781-4978 AD - Edinburgh Medical School, University of Edinburgh, Edinburgh, UK. FAU - Barisone, Michela AU - Barisone M AUID- ORCID: 0000-0003-4224-8779 AD - Clinical Epidemiology and Research Center, Humanitas Research Hospital, Milan, Italy. FAU - Hill, Loreena AU - Hill L AUID- ORCID: 0000-0001-5232-0936 AD - Faculty of Life and Health Sciences, Ulster University, Derry-Londonderry, Northern Ireland. FAU - Hage, Camilla AU - Hage C AUID- ORCID: 0000-0002-4142-2416 AD - Karolinska University Hospital, Department of Medicine, Stockholm, Sweden. FAU - Denfeld, Quin AU - Denfeld Q AUID- ORCID: 0000-0001-7568-9568 AD - School of Nursing and Division of Cardiovascular Medicine, Oregon Health & Science University, Portland, OR, USA. FAU - Pike, Rodolfo AU - Pike R AD - Heart Function Clinic, Newfoundland and Labrador Health Services, St John's, Canada. FAU - Mullens, Wilfried AU - Mullens W AUID- ORCID: 0000-0001-9995-8590 AD - Department of Cardiology, Ziekenhuis Oost-Limburg A.V., Genk, Belgium. AD - Faculty of Medicine and Life Sciences, Hasselt University, Diepenbeek, Belgium. FAU - Adamo, Marianna AU - Adamo M AUID- ORCID: 0000-0002-3855-1815 AD - ASST Spedali Civili di Brescia and Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Institute of Cardiology, University of Brescia, Brescia, Italy. FAU - Filippatos, Gerasimos AU - Filippatos G AUID- ORCID: 0000-0002-5640-0332 AD - Department of Cardiology, Attikon University Hospital, School of Medicine, National and Kapodistrian Universiy of Athens, Athens, Greece. FAU - Rosano, Giuseppe AU - Rosano G AUID- ORCID: 0000-0003-4023-2263 AD - Department of Human Sciences and Promotion of Quality of Life, San Raffaele Open University of Rome, Rome, Italy. AD - Cardiology, San Raffaele Cassino Hospital, Cassino, Italy. AD - Cardiology Clinical Academic Group, Molecular and Clinical Sciences Research Institute, City St George's, University of London, London, UK. FAU - Metra, Marco AU - Metra M AD - ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Institute of Cardiology, University of Brescia, Brescia, Italy. FAU - Uchmanowicz, Izabella AU - Uchmanowicz I AUID- ORCID: 0000-0001-5452-0210 AD - Faculty of Nursing and Midwifery, Department of Nursing, Wroclaw Medical University, Wroclaw, Poland. LA - eng GR - Heart Failure Association of the European Society of Cardiology/ PT - Journal Article PL - England TA - Eur J Heart Fail JT - European journal of heart failure JID - 100887595 SB - IM MH - *Heart Failure/nursing MH - Humans MH - Europe MH - *Curriculum MH - *Cardiology/education MH - *Cardiovascular Nursing/education MH - *Societies, Medical MH - Clinical Competence OTO - NOTNLM OT - Competence OT - Education OT - Heart failure nurse OT - Knowledge OT - Multidisciplinary team EDAT- 2026/07/10 12:46 MHDA- 2026/10/28 17:31 CRDT- 2026/07/10 11:53 PHST- 2025/08/22 00:00 [received] PHST- 2025/11/16 00:00 [revised] PHST- 2026/02/23 00:00 [accepted] PHST- 2026/10/28 17:31 [medline] PHST- 2026/07/10 12:46 [pubmed] PHST- 2026/07/10 11:53 [entrez] AID - 8732026 [pii] AID - 10.1093/ejhf/xuag077 [doi] PST - ppublish SO - Eur J Heart Fail. 2026 Oct 28;28(4):592-620. doi: 10.1093/ejhf/xuag077. PMID- 42428621 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260710 LR - 20260813 IS - 2434-0790 (Electronic) IS - 2434-0790 (Linking) VI - 8 IP - 7 DP - 2026 Jul 10 TI - Antepartum Transcatheter Patent Foramen Ovale Closure During Pregnancy: A Risk-Based Clinical Perspective. PG - 1188-1193 LID - 10.1253/circrep.CR-26-0009 [doi] AB - BACKGROUND: Transcatheter closure of a patent foramen ovale (PFO) during pregnancy is generally not recommended, because of concerns regarding fetal safety, procedural radiation exposure, and a lack of robust evidence. Postpartum intervention therefore is usually preferred. Pregnancy itself is a hypercoagulable state, and a subset of pregnant patients with PFO may face an unacceptably high risk of recurrent embolic events after pregnancy recognition, despite optimized medical therapy. How such exceptional situations should be evaluated remains insufficiently defined. METHODS AND RESULTS: This Statement/Opinion (SO) synthesizes current recommendations from the 2025 European Society of Cardiology guidelines on cardiovascular disease in pregnancy and the relevant literature, to propose a structured framework for decision-making regarding antepartum PFO closure. We focus on (1) rigorous maternal risk stratification, (2) multidisciplinary evaluation by a pregnancy heart team, and (3) procedural strategies to minimize fetal risk, including adherence to the "as low as reasonably achievable" (ALARA) principle. A representative clinical case illustrates application of this framework. CONCLUSIONS: Antepartum transcatheter PFO closure should not be considered a routine therapeutic option during pregnancy. However, it should also not be considered an absolute contraindication when the anticipated maternal risk of recurrent embolic events clearly outweighs the fetal procedural risk under carefully controlled conditions. This SO provides a conceptual framework to guide clinical judgment in rare, highly selected cases, without advocating indications. CI - Copyright (c) 2026, THE JAPANESE CIRCULATION SOCIETY. FAU - Waga, Sari AU - Waga S AD - Division of Cardiovascular Medicine, Toho University Ohashi Medical Center Tokyo Japan. FAU - Hashimoto, Go AU - Hashimoto G AD - Division of Cardiovascular Medicine, Toho University Ohashi Medical Center Tokyo Japan. FAU - Tsukagoshi, Yutsuki AU - Tsukagoshi Y AD - Division of Cardiovascular Medicine, Toho University Ohashi Medical Center Tokyo Japan. FAU - Saito, Atsuhiro AU - Saito A AD - Division of Cardiovascular Medicine, Toho University Ohashi Medical Center Tokyo Japan. FAU - Ide, Shiho AU - Ide S AD - Division of Cardiovascular Medicine, Toho University Ohashi Medical Center Tokyo Japan. FAU - Makino, Kenji AU - Makino K AD - Division of Cardiovascular Medicine, Toho University Ohashi Medical Center Tokyo Japan. FAU - Niikura, Hiroki AU - Niikura H AD - Division of Cardiovascular Medicine, Toho University Ohashi Medical Center Tokyo Japan. FAU - Hara, Hidehiko AU - Hara H AD - Division of Cardiovascular Medicine, Toho University Ohashi Medical Center Tokyo Japan. LA - eng PT - Journal Article DEP - 20260526 PL - Japan TA - Circ Rep JT - Circulation reports JID - 101746642 PMC - PMC13349507 OTO - NOTNLM OT - Multidisciplinary decision-making OT - Paradoxical embolism OT - Patent foramen ovale OT - Pregnancy OT - Radiation exposure COIS- The authors declare no conflicts of interest related to this work. EDAT- 2026/07/10 06:35 MHDA- 2026/07/10 06:36 PMCR- 2026/05/26 CRDT- 2026/07/10 05:18 PHST- 2026/01/12 00:00 [received] PHST- 2026/02/16 00:00 [revised] PHST- 2026/03/07 00:00 [accepted] PHST- 2026/07/10 06:36 [medline] PHST- 2026/07/10 06:35 [pubmed] PHST- 2026/07/10 05:18 [entrez] PHST- 2026/05/26 00:00 [pmc-release] AID - 10.1253/circrep.CR-26-0009 [doi] PST - epublish SO - Circ Rep. 2026 May 26;8(7):1188-1193. doi: 10.1253/circrep.CR-26-0009. eCollection 2026 Jul 10. PMID- 42427949 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260710 LR - 20260813 IS - 2296-2360 (Print) IS - 2296-2360 (Electronic) IS - 2296-2360 (Linking) VI - 14 DP - 2026 TI - Phenotypic profile and predictors of adverse outcomes during paediatric cardiac catheterisation at an academic hospital, South Africa. PG - 1843252 LID - 10.3389/fped.2026.1843252 [doi] LID - 1843252 AB - BACKGROUND: Paediatric cardiac catheterization is pivotal in the diagnosis and management of patients with congenital heart disease. Although cardiac referral centres exist, access to cardiac surgery remains limited in low-income countries. The study aimed to describe the demographic and clinical profile, determine adverse outcomes, and identify predictors of complications among children undergoing cardiac catheterization at a state hospital in Johannesburg, Gauteng. METHODS: A retrospective cohort study was performed on children aged 0-18 years with congenital heart disease who presented for cardiac catheterisation between January 2018 and December 2022. Patient data was obtained from the cardiac catheterisation laboratory, anaesthetic records and the paediatric cardiac database. Descriptive and multivariate regression data analysis were performed. RESULTS: A total of 597 paediatric cardiac catheterization procedures were analysed. The median (IQR) age was 1.8 (0.8-4.0) years with 52% males. Two-thirds, 397 (66%), were on anti-failure treatment and 236 (40%) had pulmonary hypertension. The Catheterisation RISk score for Paediatrics (CRISP) score was significantly associated with complications AOR 1.21 (95% CI 1.10-1.33; p < 0.001). Age <1 year was predictive of complications AOR 1.83 (95% CI 1.11-3.01; p = 0.018). The presence of a congenital syndrome was also associated with increased odds of complications AOR 1.72 (95% CI 1.10-2.67; p = 0.016). Peri-operative administration of inotropes AOR 18.3 (95% CI 6.05-70.0; p < 0.001), beta blockers AOR 2.43 (95% CI 1.28-4.54; p = 0.006), and prostin AOR 0.25 (95% CI 0.07-0.80; p = 0.025) were associated with complications. Mortality in this cohort was 5 (0.8%). Pulmonary hypertension was not associated with increased perioperative complications. CONCLUSION: The current study demonstrates that paediatric cardiac catheterisation procedures in a high-burden, resource-limited South African setting are associated with a diverse patient population, including a significant proportion with pulmonary hypertension and those receiving anti-failure therapy. Despite these challenges, the overall incidence of severe adverse outcomes including mortality remained low, supporting the feasibility and safety of these interventions when managed by an experienced multidisciplinary team. CI - (c) 2026 Chalwe, Cilliers, Motshabi Chakane and Mogane. FAU - Chalwe, Crystal AU - Chalwe C AD - Department of Anesthesiology, School of Clinical Medicine, University of the Witwatersrand, Johannesburg, South Africa. FAU - Cilliers, Antoinette AU - Cilliers A AD - Division of Cardiology, School of Clinical Medicine, University of the Witwatersrand, Johannesburg, South Africa. FAU - Motshabi Chakane, Palesa AU - Motshabi Chakane P AD - Department of Anesthesiology, School of Clinical Medicine, University of the Witwatersrand, Johannesburg, South Africa. FAU - Mogane, Palesa AU - Mogane P AD - Department of Anesthesiology, School of Clinical Medicine, University of the Witwatersrand, Johannesburg, South Africa. LA - eng PT - Journal Article DEP - 20260625 PL - Switzerland TA - Front Pediatr JT - Frontiers in pediatrics JID - 101615492 PMC - PMC13346040 OTO - NOTNLM OT - adverse outcomes OT - cardiac catheterisation OT - complications OT - congenital heart disease OT - crisp score OT - paediatrics COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/07/10 06:35 MHDA- 2026/07/10 06:36 PMCR- 2026/06/25 CRDT- 2026/07/10 05:11 PHST- 2026/03/30 00:00 [received] PHST- 2026/05/29 00:00 [revised] PHST- 2026/06/08 00:00 [accepted] PHST- 2026/07/10 06:36 [medline] PHST- 2026/07/10 06:35 [pubmed] PHST- 2026/07/10 05:11 [entrez] PHST- 2026/06/25 00:00 [pmc-release] AID - 10.3389/fped.2026.1843252 [doi] PST - epublish SO - Front Pediatr. 2026 Jun 25;14:1843252. doi: 10.3389/fped.2026.1843252. eCollection 2026. PMID- 42427483 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260710 LR - 20260813 IS - 2522-6711 (Electronic) IS - 2522-6711 (Linking) VI - 10 DP - 2026 TI - Preoperative and anesthetic management of high-risk cardiovascular complications of mediastinal masses: a narrative review. PG - 20 LID - 10.21037/med-2025-1-66 [doi] LID - 20 AB - BACKGROUND AND OBJECTIVE: The mediastinum is a complex anatomical region that includes the heart, aorta, superior vena cava, trachea, and mainstem bronchi. Mediastinal masses, while relatively uncommon, can cause life-threatening cardiovascular symptoms from mass effect, including cardiac tamponade, superior vena cava syndrome, mediastinal mass syndrome, and right ventricular outflow tract obstruction, requiring prompt identification and management. Currently, there are no guidelines that discuss the optimal management of these cardiovascular complications, and our review aims to address this. METHODS: A database search in PubMed was conducted from September 2025 to November 2025, including articles related to mediastinal masses and the various cardiovascular complications that can arise. Selected articles were compiled and reviewed to help compose this review. KEY CONTENT AND FINDINGS: This review aims to outline the incidence and etiology of different mediastinal masses, review the presentation and diagnostic workup, highlight key life-threatening syndromes related to mass effect, and discuss definitive management of these lesions. Given the complexity of the mediastinum and potential for several life-threatening complications without appropriate identification, timely diagnosis is needed to guide management. CONCLUSIONS: A multidisciplinary approach is crucial in the stabilization and management of these patients with mediastinal masses and should be considered the standard of care in all patients. This review aims to summarize current literature for the management of cardiovascular complications related to mediastinal masses. CI - (c) AME Publishing Company. FAU - Nishihara, Keith AU - Nishihara K AD - Department of Medicine, University of California Irvine Medical Center, Orange, CA, USA. FAU - Reddy, Nikitha AU - Reddy N AD - Department of Medicine, University of California Irvine Medical Center, Orange, CA, USA. FAU - Tang, Kevin S AU - Tang KS AUID- ORCID: 0000-0003-4160-1868 AD - Department of Medicine, University of California Irvine Medical Center, Orange, CA, USA. AD - Division of Cardiology, UCSF, San Francisco, CA, USA. LA - eng PT - Journal Article PT - Review DEP - 20260610 PL - China TA - Mediastinum JT - Mediastinum (Hong Kong, China) JID - 101731833 PMC - PMC13346010 OTO - NOTNLM OT - Mediastinal mass OT - cardiac tamponade OT - superior vena cava syndrome (SVC syndrome) COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://med.amegroups.com/article/view/10.21037/med-2025-1-66/coif). The authors have no conflicts of interest to declare. EDAT- 2026/07/10 06:34 MHDA- 2026/07/10 06:35 PMCR- 2026/06/10 CRDT- 2026/07/10 05:05 PHST- 2025/11/26 00:00 [received] PHST- 2026/03/10 00:00 [accepted] PHST- 2026/07/10 06:35 [medline] PHST- 2026/07/10 06:34 [pubmed] PHST- 2026/07/10 05:05 [entrez] PHST- 2026/06/10 00:00 [pmc-release] AID - med-10-20 [pii] AID - 10.21037/med-2025-1-66 [doi] PST - epublish SO - Mediastinum. 2026 Jun 10;10:20. doi: 10.21037/med-2025-1-66. eCollection 2026. PMID- 42426370 OWN - NLM STAT- MEDLINE DCOM- 20260929 LR - 20261001 IS - 1525-1594 (Electronic) IS - 0160-564X (Linking) VI - 50 IP - 10 DP - 2026 Oct TI - National Practice Patterns of VA ECMO and Left Ventricular Mechanical Unloading for Cardiogenic Shock. PG - 1443-1452 LID - 10.1111/aor.70188 [doi] AB - BACKGROUND: Cardiogenic shock (CS) remains highly morbid despite significant advancements in management. A cornerstone of this management is Venoarterial Extracorporeal Membrane Oxygenation (VA ECMO). However, consensus surrounding the management of VA ECMO for CS, including the use of concomitant Left Ventricular Mechanical Unloading (LVMU), remains limited. METHODS: We thus conducted a national survey of practice patterns in the treatment of CS to characterize such variability. Surveys were distributed to physicians involved in management of VA ECMO across a variety of center types. RESULTS: Responses representing 67 institutions were analyzed. VA ECMO was used for a median of 10% of CS patients at each institution. Formal shock teams were present at 64.1% of centers and were associated with both higher annual VA ECMO volume (P⟨0.01) and greater intra-aortic balloon pump use prior to VA ECMO (p = 0.03). LVMU was employed by 63.4% of centers, most commonly using Impella (93.3%), with unloading initiated at ECMO cannulation in a median of 30% of cases. Triggers and targets for LVMU varied widely, though pulmonary capillary wedge pressure was the most common endpoint. CONCLUSIONS: These findings highlight substantial heterogeneity in CS diagnosis, VA ECMO initiation, and LVMU strategies, underscoring the need for prospective studies to define optimal care. CI - (c) 2026 The Author(s). Artificial Organs published by International Center for Artificial Organ and Transplantation (ICAOT) and Wiley Periodicals LLC. FAU - Anderson-Bell, Dustin M AU - Anderson-Bell DM AUID- ORCID: 0000-0002-3495-7033 AD - Division of Respiratory, Critical Care, and Occupational Pulmonary Medicine, Department of Medicine, University of Utah Health, Salt Lake City, Utah, USA. FAU - Millar, Morgan M AU - Millar MM AD - Division of Epidemiology, Department of Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA. FAU - Codden, Rachel R AU - Codden RR AD - Division of Epidemiology, Department of Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA. FAU - Drakos, Stavros AU - Drakos S AD - Division of Cardiovascular Medicine, Department of Medicine, University of Utah Health, Salt Lake City, Utah, USA. AD - Nora Eccles Harrison Cardiovascular Research and Training Institute (CVRTI), University of Utah School of Medicine, Salt Lake City, Utah, USA. FAU - Selzman, Craig AU - Selzman C AD - Division of Cardiothoracic Surgery, Department of Surgery, University of Utah Health, Salt Lake City, Utah, USA. FAU - Skidmore, Chloe R AU - Skidmore CR AD - Division of Cardiothoracic Surgery, Department of Surgery, University of Utah Health, Salt Lake City, Utah, USA. FAU - Carlson, Margaret AU - Carlson M AD - Division of Cardiothoracic Surgery, Department of Surgery, University of Utah Health, Salt Lake City, Utah, USA. FAU - Welt, Frederick AU - Welt F AD - Division of Cardiovascular Medicine, Department of Medicine, University of Utah Health, Salt Lake City, Utah, USA. FAU - Hanff, Tom AU - Hanff T AD - Division of Cardiovascular Medicine, Department of Medicine, University of Utah Health, Salt Lake City, Utah, USA. FAU - Kagawa, Hiroshi AU - Kagawa H AUID- ORCID: 0009-0002-4969-3795 AD - Division of Cardiothoracic Surgery, Department of Surgery, University of Utah Health, Salt Lake City, Utah, USA. FAU - Glotzbach, Jason AU - Glotzbach J AD - Division of Cardiothoracic Surgery, Department of Surgery, University of Utah Health, Salt Lake City, Utah, USA. FAU - Steely, Andrea AU - Steely A AD - Division of Cardiothoracic Surgery, Department of Surgery, University of Utah Health, Salt Lake City, Utah, USA. FAU - Sharma, Vikas AU - Sharma V AD - Division of Cardiothoracic Surgery, Department of Surgery, University of Utah Health, Salt Lake City, Utah, USA. FAU - Goodwin, Matt AU - Goodwin M AD - Division of Cardiothoracic Surgery, Department of Surgery, University of Utah Health, Salt Lake City, Utah, USA. FAU - Haase, Daniel AU - Haase D AD - Division of Cardiothoracic Surgery, Department of Surgery, University of Utah Health, Salt Lake City, Utah, USA. AD - Department of Emergency Medicine, University of Utah Health, Salt Lake City, Utah, USA. FAU - Carr, Jason AU - Carr J AD - Division of Pulmonary, Critical Care, and Occupational Pulmonary Medicine, Intermountain Medical Center, Murray, Utah, USA. FAU - Tonna, Joseph E AU - Tonna JE AUID- ORCID: 0000-0001-8879-2628 AD - Division of Cardiothoracic Surgery, Department of Surgery, University of Utah Health, Salt Lake City, Utah, USA. AD - Department of Emergency Medicine, University of Utah Health, Salt Lake City, Utah, USA. LA - eng GR - Utah Clinical and Translational Science Institute (CTSI) through Translational Science: Implementation, Analysis, and Design (TRIAD)/ GR - R01 HL168510/HL/NHLBI NIH HHS/United States GR - 5T32HL105321/The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH)/ GR - 1K23HL141596-01/The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH)/ GR - T32 HL105321/HL/NHLBI NIH HHS/United States GR - K23 HL141596/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Multicenter Study DEP - 20260709 PL - United States TA - Artif Organs JT - Artificial organs JID - 7802778 SB - IM MH - Humans MH - *Shock, Cardiogenic/therapy/physiopathology/diagnosis MH - *Extracorporeal Membrane Oxygenation/methods/statistics & numerical data MH - *Heart-Assist Devices/statistics & numerical data MH - *Practice Patterns, Physicians'/statistics & numerical data MH - Intra-Aortic Balloon Pumping MH - Ventricular Function, Left MH - United States PMC - PMC13599474 MID - NIHMS2207850 OTO - NOTNLM OT - cardiogenic shock OT - critical care OT - extracorporeal membrane oxygenation OT - left ventricular mechanical unloading OT - shock team EDAT- 2026/07/10 00:35 MHDA- 2026/09/29 19:03 CRDT- 2026/07/09 23:37 PHST- 2026/06/05 00:00 [revised] PHST- 2026/02/10 00:00 [received] PHST- 2026/06/10 00:00 [accepted] PHST- 2026/09/29 19:03 [medline] PHST- 2026/07/10 00:35 [pubmed] PHST- 2026/07/09 23:37 [entrez] AID - 10.1111/aor.70188 [doi] PST - ppublish SO - Artif Organs. 2026 Oct;50(10):1443-1452. doi: 10.1111/aor.70188. Epub 2026 Jul 9. PMID- 42425270 OWN - NLM STAT- MEDLINE DCOM- 20261029 LR - 20261029 IS - 1885-5857 (Electronic) IS - 1885-5857 (Linking) VI - 79 IP - 11 DP - 2026 Nov TI - SYNTAX score for assessing coronary artery disease burden and complexity: past, present, and future. PG - 964-977 LID - S1885-5857(26)00151-9 [pii] LID - 10.1016/j.rec.2026.06.010 [doi] AB - The anatomical synergy between percutaneous coronary intervention with TAXUS and cardiac surgery (SYNTAX) score remains a cornerstone for quantifying coronary artery disease complexity and guiding decisions between percutaneous coronary intervention and coronary artery bypass grafting. Developed from the SYNTAX trial in 2009, the score uses a standard methodological approach to systematically define coronary lesion attributes and yields an overall score that allows stratification of coronary complexity. A commonly accepted stratification divides patients into low (/= 33) SYNTAX score, with higher categories associated with an increased risk of adverse cardiovascular events. This review article traces the history, evolution, and integration of the SYNTAX score in ESC and ACC/AHA guidelines. We also discuss its role in clinical trials and its contribution to Heart Team deliberations in patients with complex coronary artery disease. Patient benefits include adding precision for treatment selection with a historical potential to lower mortality in high-score cases by favoring coronary artery bypass grafting. Artificial intelligence and advanced imaging, such as coronary computed tomography angiography, are advancing automated, noninvasive SYNTAX score computation with superior accuracy. Future directions involve artificial intelligence-hybrid models for real-time, personalized assessments. This review article evaluates the enduring impact of the SYNTAX score and its evolving role in precision medicine. CI - Copyright (c) 2026 Sociedad Espanola de Cardiologia. Published by Elsevier Espana, S.L.U. All rights reserved. FAU - Ye, Zixiang AU - Ye Z AD - Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Cardialysis, Rotterdam, The Netherlands. FAU - Cheng, Jiaxi AU - Cheng J AD - Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Daemen, Joost AU - Daemen J AD - Cardialysis, Rotterdam, The Netherlands; Department of Cardiology, Erasmus University Medical Center, Rotterdam, Thoraxcenter, The Netherlands. FAU - Diletti, Roberto AU - Diletti R AD - Department of Cardiology, Erasmus University Medical Center, Rotterdam, Thoraxcenter, The Netherlands. FAU - Testa, Luca AU - Testa L AD - Department of Cardiology, IRCCS San Donato, Milan, Italy. FAU - de la Torre-Hernandez, Jose M AU - de la Torre-Hernandez JM AD - Departamento de Cardiologia, Hospital Universitario Marques de Valdecilla, Instituto de Investigacion Valdecilla (IDIVAL), Santander, Cantabria, Spain. FAU - Liu, Shengnan AU - Liu S AD - Cardialysis, Rotterdam, The Netherlands. FAU - Wang, Haoyu AU - Wang H AD - Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Xie, Enmin AU - Xie E AD - Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Banning, Adrian P AU - Banning AP AD - Department of Cardiology, John Radcliffe Hospital, Oxford University Hospitals, Oxford, United Kingdom; European Cardiovascular Research Institute, Rotterdam, the Netherlands. FAU - Dou, Kefei AU - Dou K AD - Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Electronic address: drdoukefei@126.com. FAU - Spitzer, Ernest AU - Spitzer E AD - Cardialysis, Rotterdam, The Netherlands; European Cardiovascular Research Institute, Rotterdam, the Netherlands. Electronic address: espitzer@cardialysis.nl. LA - eng LA - spa PT - Journal Article PT - Review DEP - 20260709 PL - Spain TA - Rev Esp Cardiol (Engl Ed) JT - Revista espanola de cardiologia (English ed.) JID - 101587954 SB - IM MH - Humans MH - *Coronary Artery Disease/surgery/diagnosis MH - *Percutaneous Coronary Intervention/methods MH - Severity of Illness Index MH - Coronary Artery Bypass MH - Risk Assessment/methods MH - Coronary Angiography/methods OTO - NOTNLM OT - Anatomical SYNTAX score OT - Cirugia de revascularizacion coronaria OT - Coronary artery bypass grafting OT - Coronary artery disease OT - Enfermedad arterial coronaria OT - Intervencion coronaria percutanea OT - Percutaneous coronary intervention OT - Puntuacion SYNTAX anatomica EDAT- 2026/07/10 04:10 MHDA- 2026/10/29 23:28 CRDT- 2026/07/09 19:12 PHST- 2026/04/14 00:00 [received] PHST- 2026/06/16 00:00 [accepted] PHST- 2026/10/29 23:28 [medline] PHST- 2026/07/10 04:10 [pubmed] PHST- 2026/07/09 19:12 [entrez] AID - S1885-5857(26)00151-9 [pii] AID - 10.1016/j.rec.2026.06.010 [doi] PST - ppublish SO - Rev Esp Cardiol (Engl Ed). 2026 Nov;79(11):964-977. doi: 10.1016/j.rec.2026.06.010. Epub 2026 Jul 9. PMID- 42422934 OWN - NLM STAT- MEDLINE DCOM- 20260930 LR - 20260930 IS - 1467-1107 (Electronic) IS - 1047-9511 (Linking) VI - 36 IP - 7 DP - 2026 Jul TI - Programme-building aspects with introducing minimally invasive axillary thoracotomy repairs in children. PG - 1423-1427 LID - 10.1017/S1047951126123488 [doi] AB - INTRODUCTION: Minimally invasive vertical right axillary thoracotomy offers an excellent cosmetic and functional alternative to standard median sternotomy for congenital heart repairs in children. We report the steps taken and challenges involved in building an emerging programmes and outcomes in repairing diverse CHDs. MATERIALS AND METHODS: We performed a retrospective review of the first 152 paediatric patients who underwent repair of selected CHDs using the minimal invasive vertical right axillary thoracotomy approach between April 2022 and December 2025 at our institution and outline our multi-disciplinary team-building protocol. RESULTS: Pre-commencement protocolar team teaching was implicated 2 months prior to the first case, using information gained through a combination of surgical site visits abroad by the surgeons, protocolar experience exchange with foreign experts, and multimedia educational platforms. The median age was 4.9 years (range: 4 months-13 years), and median weight was 16 kg (6-41 kg). The median lengths of ICU stay and hospital stay were 1.2 and 4.6 days, respectively. No in-hospital deaths or conversions to median sternotomy occurred. No late deaths or reoperations occurred during a median follow-up of 16 months (range 5 months-4 years). DISCUSSION: The minimal invasive vertical right axillary thoracotomy can be safely introduced for a broad spectrum of CHDs. Educating all team members is critical to achieving excellent outcomes in a short-time frame. This approach provides excellent cosmetic results with a small "hidden" scar and stands as a good alternative to median sternotomy in selected paediatric patients. FAU - Musayev, Kamran AU - Musayev K AD - Department of Cardiovascular Surgery, Merkezi Klinika, Azerbaijan. FAU - Ahmadov, Kamran AU - Ahmadov K AUID- ORCID: 0000-0001-6096-6729 AD - Department of Cardiovascular Surgery, Merkezi Klinika, Azerbaijan. FAU - Dodge-Khatami, Ali AU - Dodge-Khatami A AUID- ORCID: 0000-0002-4189-0551 AD - Pediatric & Congenital Heart Surgery, RWTH University Clinic Aachen, Germany. LA - eng PT - Journal Article DEP - 20260709 PL - England TA - Cardiol Young JT - Cardiology in the young JID - 9200019 SB - IM MH - Humans MH - *Thoracotomy/methods/education MH - Child, Preschool MH - Retrospective Studies MH - *Minimally Invasive Surgical Procedures/methods/education MH - Infant MH - Child MH - *Heart Defects, Congenital/surgery MH - Female MH - Male MH - Adolescent MH - Axilla/surgery MH - Length of Stay MH - *Cardiac Surgical Procedures/methods OTO - NOTNLM OT - CHD OT - mini thoracotomy OT - minimally invasive surgery OT - programme development EDAT- 2026/07/09 06:33 MHDA- 2026/09/30 23:29 CRDT- 2026/07/09 05:03 PHST- 2026/09/30 23:29 [medline] PHST- 2026/07/09 06:33 [pubmed] PHST- 2026/07/09 05:03 [entrez] AID - S1047951126123488 [pii] AID - 10.1017/S1047951126123488 [doi] PST - ppublish SO - Cardiol Young. 2026 Jul;36(7):1423-1427. doi: 10.1017/S1047951126123488. Epub 2026 Jul 9. PMID- 42420351 OWN - NLM STAT- Publisher LR - 20260708 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) DP - 2026 Jul 8 TI - Effectiveness of a multidisciplinary "crisis checklist" on nursing performance during intraoperative cardiac arrest: A simulation-based study. LID - 10.1038/s41598-026-60073-0 [doi] AB - Intraoperative cardiac arrest (IOCA) is a high-acuity surgical crisis demanding flawless execution of technical and behavioral skills. Traditional crisis management often lacks structured, nursing-specific cognitive tools, leaving teams vulnerable to fixation errors and communication breakdown under stress. The objectives of the study were to determine whether a structured multidisciplinary crisis checklist improves critical resuscitation timelines, nursing performance adherence, behavioral teamwork dynamics, and provider subjective stress mitigation during simulated IOCA events. This prospective, comparative cohort study evaluated 40 operating room teams (N = 120 healthcare professionals: anesthesiologists, scrub nurses, and circulating nurses) sequentially allocated to either the Multidisciplinary Checklist group (MC; n = 20 teams) or the Standard Resuscitation group (SR; n = 20 teams) following traditional Advanced Cardiovascular Life Support (ACLS) guidelines. Teams managed a standardized intraoperative ventricular fibrillation scenario. Outcome parameters included a novel, validated Nursing Performance Adherence Score (NPAS), time-to-critical-interventions, Mayo High Performance Teamwork Scale (MHPTS) scores, and provider subjective stress levels mapped via a 10-point Visual Analog Scale. The team was designated as the primary unit of analysis. Total NPAS was significantly superior in the MC group compared to the SR group (9.25 +/- 0.79 vs. 6.4 +/- 1.43, p < 0.001), correlating tightly with checklist utilization (R = 0.86, p < 0.001). For critical technical workflows, the MC group achieved an 8.4-fold higher probability of rapid epinephrine delivery, decreasing median administration time by 51 s (143.5 s vs.194.5 s; Hazard Ratio = 8.42, Log-rank, p < 0.001). Teamwork quality was significantly enhanced in the MC group, yielding superior total MHPTS scores (28.60 +/- 1.96 vs. 22.30 +/- 3.31, p < 0.001). Subjective provider stress levels were significantly reduced via checklist implementation (p < 0.001). Integrating a structured multidisciplinary crisis checklist into simulated IOCA workflows significantly accelerates life-saving interventions, optimizes nursing task execution, alleviates clinician stress, and ensures high-performance team collaboration. These empirical simulation findings strongly support the implementation of specialized emergency manuals in perioperative safety training. CI - (c) 2026. The Author(s). FAU - Liao, Can AU - Liao C AUID- ORCID: 0009-0007-7425-7692 AD - Surgical Center, Affiliated Hospital of North Sichuan Medical College, Qingquan Temple North Road, Shunqing District, Nanchong City, 637000, Sichuan Province, China. FAU - Ma, Huan AU - Ma H AUID- ORCID: 0009-0003-2418-2064 AD - Department of Geriatrics, Affiliated Hospital of North Sichuan Medical College, Nanchong City, 637000, Sichuan Province, China. FAU - Wen, Xiaodong AU - Wen X AUID- ORCID: 0009-0002-1016-3324 AD - Surgical Center, Affiliated Hospital of North Sichuan Medical College, Qingquan Temple North Road, Shunqing District, Nanchong City, 637000, Sichuan Province, China. FAU - Zhou, Qianyu AU - Zhou Q AUID- ORCID: 0009-0000-2044-6884 AD - Surgical Center, Affiliated Hospital of North Sichuan Medical College, Qingquan Temple North Road, Shunqing District, Nanchong City, 637000, Sichuan Province, China. qianyu2zhou@hotmail.com. LA - eng PT - Journal Article DEP - 20260708 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 SB - IM OTO - NOTNLM OT - Advanced cardiovascular life support OT - Clinical adherence OT - Cognitive aids OT - Crisis checklist OT - Intraoperative cardiac arrest OT - Nursing performance OT - Patient safety OT - Simulation-based training COIS- Declarations. Competing interests: The authors declare no competing interests. Ethics approval and consent to participate: Ethical approval for this study was conducted by the Affiliated Hospital of North Sichuan Medical College Ethics Committee (Approval No: 2024-AH-NSMC-012, dated May 15, 2024). The study was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki. All participants were informed about the purpose of the study, assured of confidentiality, and provided written informed consent prior to participation. Participation was voluntary, and respondents could withdraw at any time without consequence. Use of artificial intelligence tools: We have used Gemini version 1.5 (Google LLC, Mountain View, CA, USA) for English language corrections. EDAT- 2026/07/09 00:39 MHDA- 2026/07/09 00:39 CRDT- 2026/07/08 23:35 PHST- 2026/04/07 00:00 [received] PHST- 2026/06/25 00:00 [accepted] PHST- 2026/07/09 00:39 [medline] PHST- 2026/07/09 00:39 [pubmed] PHST- 2026/07/08 23:35 [entrez] AID - 10.1038/s41598-026-60073-0 [pii] AID - 10.1038/s41598-026-60073-0 [doi] PST - aheadofprint SO - Sci Rep. 2026 Jul 8. doi: 10.1038/s41598-026-60073-0. PMID- 42419873 OWN - NLM STAT- MEDLINE DCOM- 20260708 LR - 20260925 IS - 2053-3624 (Print) IS - 2053-3624 (Electronic) IS - 2053-3624 (Linking) VI - 13 IP - 2 DP - 2026 Jul 8 TI - Coronary artery fistulas: a systematic review and pooled analysis of anatomy, risk stratification and contemporary management. LID - 10.1136/openhrt-2026-004055 [doi] LID - e004055 AB - OBJECTIVE: Coronary artery fistulas (CAFs) are rare congenital or acquired anomalies characterised by abnormal coronary communications, with variable natural history and no consensus on optimal management. METHODS: A comprehensive state-of-the-art review and pooled analysis of published literature was conducted, integrating clinical, anatomical, imaging, management and outcome data from 1966 patients with 1986 CAFs. Comparative descriptive analyses between complicated and uncomplicated cases were performed to identify recurring features associated with adverse clinical outcomes. RESULTS: Specific anatomical and clinical patterns were more frequently observed in patients with complications, including fistulas originating from the right coronary artery or left main coronary artery, drainage into venous or left-sided structures, large-calibre fistulas and reduced ventricular function. Based on these recurring patterns, two pragmatic phenotypes of CAFs (higher-risk and lower-risk) were identified. Given the descriptive nature of the available evidence and the absence of formal multivariable modelling, these findings should be considered hypothesis-generating rather than indicative of independent predictors. CONCLUSIONS: CAFs are heterogeneous vascular anomalies with variable clinical presentation and substantial potential for complications. An integrated assessment of anatomical configuration, fistula size, drainage pattern and ventricular function may support structured clinical evaluation and individualised management. We propose a practical anatomy- and risk-informed framework to guide multidisciplinary decision-making and follow-up strategies. CI - (c) Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. FAU - Vinciguerra, Mattia AU - Vinciguerra M AD - Department of Clinical, Internal Medicine, Anaesthesiology and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy. AD - Department of Health and Life Sciences, European University of Rome, Rome, Italy. FAU - Pisani, Angelo AU - Pisani A AD - Department of Clinical, Internal Medicine, Anaesthesiology and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy. FAU - Caldaroni, Federica AU - Caldaroni F AD - Department of Cardiothoracic Surgery, Royal Melbourne Hospital, Melbourne, Victoria, Australia. FAU - Garofalo, Giulio AU - Garofalo G AD - Department of Cardiac Surgery, S. G. Moscati Hospital, Avellino, Italy. FAU - Tennyson, Charlene AU - Tennyson C AD - Division of Cardiothoracic Surgery, Department of Surgery, University of Washington Medical Center, Seattle, Washington DC, USA. FAU - Karuppannan, Mukesh AU - Karuppannan M AD - Department of Cardiothoracic Surgery, Lancashire Cardiac Centre, Blackpool Victoria Hospital, Blackpool, UK. FAU - Garg, Scot AU - Garg S AD - Department of Cardiology, Royal Blackburn Teaching Hospital, Blackburn, UK. FAU - D'Ambrosio, Luca AU - D'Ambrosio L AD - Department of Angiocardioneurology, IRCCS Neuromed, Pozzilli (IS), Italy. FAU - Saltarocchi, Sara AU - Saltarocchi S AD - Department of General Surgery, Surgical Specialty and Anesthesiology "Paride Stefanini", Sapienza University of Rome, Rome, Italy. FAU - Galli, Mattia AU - Galli M AUID- ORCID: 0000-0003-3909-182X AD - Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy. AD - IRCCS Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy. FAU - Schirone, Leonardo AU - Schirone L AD - Department of Health and Life Sciences, European University of Rome, Rome, Italy. AD - Department of Angiocardioneurology, IRCCS Neuromed, Pozzilli (IS), Italy. FAU - Greco, Ernesto AU - Greco E AD - Department of Health and Life Sciences, European University of Rome, Rome, Italy. FAU - Spadaccio, Cristiano AU - Spadaccio C AD - Department of Cardiovascular Surgery, Mayo Clinic, Rochester, MN, USA. FAU - Rose, David AU - Rose D AUID- ORCID: 0000-0001-7616-6283 AD - Department of Cardiothoracic Surgery, Lancashire Cardiac Centre, Blackpool Victoria Hospital, Blackpool, UK mr.rose@nhs.net. AD - Lancaster University, Lancaster, UK. LA - eng PT - Journal Article PT - Systematic Review DEP - 20260708 PL - England TA - Open Heart JT - Open heart JID - 101631219 SB - IM MH - Humans MH - Risk Assessment MH - *Coronary Vessel Anomalies/therapy/diagnosis/diagnostic imaging/physiopathology MH - *Coronary Vessels/diagnostic imaging/surgery MH - Risk Factors MH - *Vascular Fistula/therapy/diagnosis MH - Treatment Outcome MH - Coronary Angiography PMC - PMC13347944 OTO - NOTNLM OT - Cardiac Surgical Procedures OT - Coronary Aneurysm OT - Coronary Vessels OT - Multidetector Computed Tomography OT - Percutaneous Coronary Intervention COIS- Competing interests: None declared. EDAT- 2026/07/09 00:40 MHDA- 2026/07/09 00:41 PMCR- 2026/07/08 CRDT- 2026/07/08 21:12 PHST- 2026/02/19 00:00 [received] PHST- 2026/05/12 00:00 [accepted] PHST- 2026/07/09 00:41 [medline] PHST- 2026/07/09 00:40 [pubmed] PHST- 2026/07/08 21:12 [entrez] PHST- 2026/07/08 00:00 [pmc-release] AID - openhrt-2026-004055 [pii] AID - 10.1136/openhrt-2026-004055 [doi] PST - epublish SO - Open Heart. 2026 Jul 8;13(2):e004055. doi: 10.1136/openhrt-2026-004055. PMID- 42416597 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260708 LR - 20260813 IS - 2153-8174 (Electronic) IS - 1530-6550 (Print) IS - 1530-6550 (Linking) VI - 27 IP - 6 DP - 2026 Jun TI - International Age and Use Criteria for Transcatheter and Surgical Aortic Valve Replacement. PG - 49368 LID - 10.31083/RCM49368 [doi] LID - 49368 AB - Transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) have transformed the management of severe aortic stenosis across a wide range of patient risk profiles. As populations age and indications extend to lower-risk and younger patients, determining the appropriate role of age in selecting TAVR versus SAVR has become increasingly complex. Current guidelines emphasize individualized decision-making, yet age-based referral patterns remain common in clinical practice. This review examines how age thresholds are applied in contemporary guidance from the United States (US), Europe, and the Asia-Pacific region. Additionally, this review evaluates whether chronological age alone is a defensible basis for referral or treatment selection. This evidence-based narrative review queried PubMed, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) from January 1, 2013, through December 31, 2025, using the search terms: ("aortic stenosis" AND ("TAVR" OR "transcatheter aortic valve implantation (TAVI)" OR "SAVR")) AND ("age" OR "appropriateness"). English-language abstracts and full texts were screened in duplicate. Eligible studies included randomized controlled trials, national or continental registries, health economic simulations, and clinical practice guidelines that reported age-stratified outcomes or recommendations. Single-case reports, editorials, and animal studies were excluded. Of the 1628 titles screened, 87 full texts were reviewed, and 45 studies were retained. Across regions, guidelines converge on a core principle: age is informative but insufficient in isolation. U.S. guidance generally favors SAVR in patients younger than 65 years or those with a life expectancy greater than 20 years, and favors transfemoral TAVR in patients older than 80 years or with a life expectancy shorter than 10 years. European guidance typically favors SAVR in patients younger than 75 years and TAVR in those older than 75 years. Meanwhile, Asia-Pacific recommendations adopt a similarly individualized approach but place greater emphasis on bicuspid anatomy, rheumatic disease, local health system infrastructure, and cost. Recent data support a cautious approach in younger patients. In observational U.S. analyses of patients younger than 65 years, TAVR use increased substantially despite guideline preference for surgery, and TAVR was associated with higher long-term mortality or higher pacemaker and readmission burdens in selected cohorts. Contemporary randomized data suggest broadly similar outcomes between TAVR and SAVR in older or intermediate-age populations; however, uncertainty persists in younger low-risk patients, particularly those with bicuspid anatomy and long projected survival. Age-based cutoffs should be interpreted as decision anchors rather than rigid rules. The most defensible framework integrates age with life expectancy, valve durability, anatomy, frailty, comorbidity burden, coronary artery disease, feasibility of future valve-in-valve therapy, and patient preferences within a multidisciplinary heart team. Expansion of TAVR into younger populations should remain measured until more robust long-term durability and lifetime management data become available. CI - Copyright: (c) 2026 The Author(s). Published by IMR Press. FAU - Sharma, Rohit AU - Sharma R AUID- ORCID: 0000-0001-7043-7185 AD - Department of Medicine, Mass General Brigham-Salem Hospital, Salem, MA 01970, USA. FAU - Srivats, Sudarshan AU - Srivats S AUID- ORCID: 0009-0000-2487-7219 AD - Department of Hospital Medicine, Catholic Medical Center, Manchester, NH 03102, USA. FAU - Ata, Fateen AU - Ata F AUID- ORCID: 0000-0001-7121-8574 AD - Department of Medicine, Hamad Medical Corporation, 3050 Doha, Qatar. FAU - Shuhaiber, Jeffrey AU - Shuhaiber J AUID- ORCID: 0000-0003-2082-2637 AD - The Wellman Institute of Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. LA - eng PT - Journal Article PT - Review DEP - 20260629 PL - Singapore TA - Rev Cardiovasc Med JT - Reviews in cardiovascular medicine JID - 100960007 PMC - PMC13339240 OTO - NOTNLM OT - SAVR OT - TAVR OT - age-criteria OT - comparison OT - international COIS- The authors declare no conflicts of interest. EDAT- 2026/07/08 06:51 MHDA- 2026/07/08 06:52 PMCR- 2026/06/29 CRDT- 2026/07/08 04:44 PHST- 2025/12/23 00:00 [received] PHST- 2026/03/23 00:00 [revised] PHST- 2026/04/16 00:00 [accepted] PHST- 2026/07/08 06:52 [medline] PHST- 2026/07/08 06:51 [pubmed] PHST- 2026/07/08 04:44 [entrez] PHST- 2026/06/29 00:00 [pmc-release] AID - S1530-6550(26)02369-0 [pii] AID - 10.31083/RCM49368 [doi] PST - epublish SO - Rev Cardiovasc Med. 2026 Jun 29;27(6):49368. doi: 10.31083/RCM49368. eCollection 2026 Jun. PMID- 42411811 OWN - NLM STAT- Publisher LR - 20260707 IS - 1879-3479 (Electronic) IS - 0020-7292 (Linking) DP - 2026 Jul 7 TI - Brugada syndrome in pregnancy. LID - 10.1002/ijgo.71193 [doi] AB - Brugada syndrome is a rare inherited cardiac channelopathy, affecting cardiac sodium channels, with an increased risk of syncopal attacks and arrhythmia. The most commonly related genetic mutation is in the SCN5A gene. Brugada syndrome could be precipitated by various factors, such as fever, electrolyte imbalances, and drugs. Management focuses on avoiding precipitating factors, fever management, and implantable cardioverter-defibrillator placement in high-risk patients. Most pregnancies result in favorable maternal and fetal outcomes, and management of Brugada syndrome during pregnancy requires a multidisciplinary team approach. This narrative review summarizes the pathogenesis, risk factors, precipitating factors, clinical features, diagnosis, management during pregnancy, anesthesia concerns, and maternal and fetal outcomes in Brugada syndrome. CI - (c) 2026 International Federation of Gynecology and Obstetrics. FAU - Shirodkar, Shruti P AU - Shirodkar SP AD - Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, Deoghar, India. FAU - Balachandran, Divya Mecheril AU - Balachandran DM AUID- ORCID: 0000-0002-9037-3024 AD - Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, Deoghar, India. FAU - Singh, Vineeta AU - Singh V AD - Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, Deoghar, India. FAU - Rai, Priyanka AU - Rai P AD - Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, Deoghar, India. FAU - Aakanksha, Aakanksha AU - Aakanksha A AD - Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, Deoghar, India. FAU - Bhattachariya, Abhipreet AU - Bhattachariya A AD - Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, Deoghar, India. LA - eng PT - Journal Article PT - Review DEP - 20260707 PL - United States TA - Int J Gynaecol Obstet JT - International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics JID - 0210174 SB - IM OTO - NOTNLM OT - Brugada syndrome OT - arrhythmia OT - cardiac channelopathy OT - maternal outcome OT - pregnancy EDAT- 2026/07/07 16:09 MHDA- 2026/07/07 16:09 CRDT- 2026/07/07 09:13 PHST- 2026/06/02 00:00 [revised] PHST- 2026/01/06 00:00 [received] PHST- 2026/06/15 00:00 [accepted] PHST- 2026/07/07 16:09 [medline] PHST- 2026/07/07 16:09 [pubmed] PHST- 2026/07/07 09:13 [entrez] AID - 10.1002/ijgo.71193 [doi] PST - aheadofprint SO - Int J Gynaecol Obstet. 2026 Jul 7. doi: 10.1002/ijgo.71193. PMID- 42405660 OWN - NLM STAT- MEDLINE DCOM- 20260901 LR - 20260903 IS - 1522-726X (Electronic) IS - 1522-1946 (Print) IS - 1522-1946 (Linking) VI - 108 IP - 3 DP - 2026 Sep TI - Current Advances and Navigating the Complexities of SVG-PCI. PG - 856-874 LID - 10.1002/ccd.70740 [doi] AB - Saphenous vein graft (SVG) percutaneous coronary intervention (PCI) remains technically challenging and clinically high risk due to the friable, thrombus-rich nature of SVG lesions, which predispose to distal embolization, no-reflow, and periprocedural myocardial infarction (MI). The role of embolic protection devices in contemporary practice remains unclear. Although early randomized trials demonstrated significant reductions in periprocedural MI and no-reflow, contemporary observational studies and meta-analyses have not shown consistent clinical benefit. Similarly, while intracoronary imaging modalities provide detailed plaque characterization, their clinical application in guiding SVG-PCI remains unclear. Revascularization after prior coronary artery bypass grafting (CABG) requires individualized, multidisciplinary decision-making. Factors favoring PCI include a patent left internal mammary artery (IMA)-left anterior descending artery graft and suitable coronary anatomy, whereas redo-CABG may be preferred in patients with multiple failing grafts or complex anatomy in which an IMA conduit can be used. Although guidelines have historically favored native-vessel PCI when feasible, the only randomized trial comparing SVG-PCI with native-vessel PCI in a contemporary setting demonstrated that SVG-PCI may offer superior outcomes in certain patient populations, particularly when native coronary disease is complex, and the chronic total occlusion burden is high. Predictors of adverse outcomes have been identified across patient-, lesion-, and procedure-related characteristics; however, their integration into clinical decision-making is limited by the lack of validated risk-stratification tools. Future randomized studies in the contemporary PCI era are needed. Additionally, the integration of imaging technologies, together with artificial intelligence and machine-learning-enhanced risk prediction models, may help individualize patient selection and optimize procedural strategy. CI - (c) 2026 Wiley Periodicals LLC. FAU - Attachaipanich, Tanawat AU - Attachaipanich T AD - Department of Internal Medicine, University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, USA. FAU - Virk, Hafeez Ul Hassan AU - Virk HUH AUID- ORCID: 0000-0002-9835-942X AD - Division of Cardiovascular Disease, Case Western Reserve University, Cleveland, Ohio, USA. FAU - Khawaja, Muzamil AU - Khawaja M AD - Department of Cardiology, Emory University, Atlanta, Georgia, USA. FAU - Alam, Mahboob AU - Alam M AUID- ORCID: 0000-0001-9230-9555 AD - Texas Heart Institute and Baylor College of Medicine, Houston, Texas, USA. FAU - Krittanawong, Chayakrit AU - Krittanawong C AD - HumanX, Delaware, Delaware, USA. LA - eng PT - Journal Article PT - Review DEP - 20260706 PL - United States TA - Catheter Cardiovasc Interv JT - Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions JID - 100884139 SB - IM MH - Humans MH - *Percutaneous Coronary Intervention/adverse effects/instrumentation MH - Risk Factors MH - Treatment Outcome MH - *Graft Occlusion, Vascular/therapy/physiopathology/diagnostic imaging/etiology MH - *Saphenous Vein/transplantation/physiopathology/diagnostic imaging MH - *Coronary Artery Bypass/adverse effects MH - Clinical Decision-Making MH - Patient Selection MH - Myocardial Infarction/etiology MH - Risk Assessment MH - Embolic Protection Devices MH - Predictive Value of Tests MH - *Coronary Artery Disease/diagnostic imaging/surgery/physiopathology PMC - PMC13532512 COIS- The authors declare no conflicts of interest. EDAT- 2026/07/06 12:41 MHDA- 2026/09/01 11:40 PMCR- 2026/09/01 CRDT- 2026/07/06 08:23 PHST- 2026/05/19 00:00 [revised] PHST- 2026/01/06 00:00 [received] PHST- 2026/06/26 00:00 [accepted] PHST- 2026/09/01 11:40 [medline] PHST- 2026/07/06 12:41 [pubmed] PHST- 2026/07/06 08:23 [entrez] PHST- 2026/09/01 00:00 [pmc-release] AID - CCD70740 [pii] AID - 10.1002/ccd.70740 [doi] PST - ppublish SO - Catheter Cardiovasc Interv. 2026 Sep;108(3):856-874. doi: 10.1002/ccd.70740. Epub 2026 Jul 6. PMID- 42405450 OWN - NLM STAT- MEDLINE DCOM- 20261013 LR - 20261014 IS - 1365-2044 (Electronic) IS - 0003-2409 (Linking) VI - 81 IP - 11 DP - 2026 Nov TI - Management of major thoracic trauma: a narrative review. PG - 1535-1548 LID - 10.1111/anae.70284 [doi] AB - INTRODUCTION: Traumatic thoracic injuries are a leading cause of morbidity and mortality worldwide, not only as a direct consequence of the injury itself, but also due to development of secondary insults such as infection; acute kidney injury; acute respiratory distress syndrome; and shock. The thorax houses vital structures, and even seemingly trivial trauma may result in catastrophic damage particularly in children or older patients. This review aims to highlight important considerations in diagnosis and management of major thoracic injuries and the crucial role of appropriate supportive interventions such as airway control, ventilation strategies and optimal pain management to aid in recovery. METHODS: We undertook a narrative review of the contemporary literature. We synthesised evidence related to mechanisms of thoracic trauma and initial assessment and diagnosis of major thoracic injuries. We also highlight key considerations in chest wall, pulmonary, cardiac and diaphragmatic injuries; supportive management strategies for patients with thoracic trauma; and special considerations in older patients. RESULTS: Thoracic injuries are broadly classified by the mechanism of trauma (blunt, penetrating or blast) or by the anatomical structure involved. Initial assessment and diagnosis follows general trauma principles. Depending on the injuries sustained, surgical intervention may be indicated. Equally important is appropriate supportive management. Older patients are often overlooked as a high-risk group and a lower threshold for specialised trauma care or critical care services is recommended in this cohort. DISCUSSION: A multidisciplinary approach is key in management of patients with thoracic trauma due to their numerous needs, ranging from surgical intervention and critical care support to physiotherapy and rehabilitation. CI - (c) 2026 Association of Anaesthetists. FAU - Kaur, Navniel AU - Kaur N AD - Department of Anaesthesia, Mbagathi County Referral Hospital, Nairobi, Kenya. FAU - Lewis, Sophie AU - Lewis S AD - Critical Care Department, Aintree University Hospital, University Hospitals of Liverpool Group, Liverpool, UK. FAU - Jenkinson, Hollie AU - Jenkinson H AD - Trauma and Emergency General Surgery Service, Aintree University Hospital, University Hospitals of Liverpool Group, Liverpool, UK. FAU - Keegan, Christopher AU - Keegan C AD - Department of Radiology, Aintree University Hospital, University Hospitals of Liverpool Group, Liverpool, UK. FAU - Misra, Nikhil AU - Misra N AD - Trauma and Emergency General Surgery Service, Aintree University Hospital, University Hospitals of Liverpool Group, Liverpool, UK. FAU - Neequaye, Simon AU - Neequaye S AD - Liverpool Vascular & Endovascular Service, Aintree University Hospital, University Hospitals of Liverpool Group, Liverpool, UK. FAU - Scott, Simon AU - Scott S AD - Cheshire & Mersey Major Trauma Centre Collaborative, Aintree University Hospital, University Hospitals of Liverpool Group, Liverpool, UK. FAU - Astles, Tim AU - Astles T AD - Critical Care Department, Aintree University Hospital, University Hospitals of Liverpool Group, Liverpool, UK. FAU - Morton, Ben AU - Morton B AD - Critical Care Department, Aintree University Hospital, University Hospitals of Liverpool Group, Liverpool, UK. AD - Department of Clinical Sciences, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, UK. LA - eng PT - Journal Article PT - Review DEP - 20260706 PL - England TA - Anaesthesia JT - Anaesthesia JID - 0370524 SB - IM MH - Humans MH - *Thoracic Injuries/therapy/diagnosis OAB - WHAT WE DID: We reviewed many recent research papers about serious injuries to the chest. We looked at how these injuries happen, how doctors find and diagnose them, and how patients are treated. We also examined the different types of chest injuries, such as injuries to the ribs, lungs, heart and diaphragm, and the care patients may need to help them recover. WHY DID WE DO IT: Chest injuries can be very dangerous because the chest contains important organs like the heart and lungs. Even injuries that seem small can cause serious problems, especially for children and older people. We wanted to explain the key things doctors need to think about when treating chest injuries so that patients can receive the best care and recover as well as possible. WHAT WE FOUND: We found that chest injuries can happen in different ways, such as from blunt force, penetrating objects or explosions. Doctors must carefully assess patients and sometimes perform surgery if the injury is severe. Good supportive care is also very important. This includes helping patients breathe, managing pain and treating other problems that may develop. Older patients are often at higher risk of serious complications, so they may need specialist trauma care sooner. Treating chest injuries works best when different healthcare professionals work together to support the patient's recovery. OABL- eng OTO - NOTNLM OT - diagnosis OT - management OT - mechanisms OT - multidisciplinary OT - thoracic trauma EDAT- 2026/07/06 10:10 MHDA- 2026/10/13 17:37 CRDT- 2026/07/06 05:54 PHST- 2026/04/15 00:00 [accepted] PHST- 2026/10/13 17:37 [medline] PHST- 2026/07/06 10:10 [pubmed] PHST- 2026/07/06 05:54 [entrez] AID - 10.1111/anae.70284 [doi] PST - ppublish SO - Anaesthesia. 2026 Nov;81(11):1535-1548. doi: 10.1111/anae.70284. Epub 2026 Jul 6. PMID- 42403557 OWN - NLM STAT- MEDLINE DCOM- 20260706 LR - 20260813 IS - 1947-6108 (Electronic) IS - 1947-6094 (Print) IS - 1947-6108 (Linking) VI - 22 IP - 3 DP - 2026 TI - The Initial Diagnostic Approach to Adult Congenital Heart Disease: A Practical Imaging Pathway for General Cardiologists and Cardiac Imagers. PG - 5-27 LID - 10.14797/mdcvj.1868 [doi] AB - Adult congenital heart disease (ACHD) is among the most anatomically and physiologically complex domains in cardiovascular medicine. Advances in pediatric cardiac surgery and cardiology have shifted congenital heart disease (CHD) from a predominantly pediatric condition to a lifelong disease, resulting in a growing adult population that now outnumbers the affected children. In addition, increased detection of CHD in adulthood has broadened the spectrum of ACHD encountered outside specialized centers, underscoring the importance of familiarity among general cardiologists and cardiac imagers. This state-of-the-art review outlines a structured imaging approach for adults with suspected or known CHD. The proposed pathway includes four stages: (1) clinical-anatomic orientation with systematic review of prior data including operative notes and prior imaging; (2) protocolized adult congenital transthoracic echocardiography using sequential segmental analysis; (3) question-driven cardiac magnetic resonance (CMR) with flow quantification; and (4) selective use of cardiac computed tomography (CCT) for detailed cardiac and extracardiac anatomy, coronary artery origins, surgical planning, sternal re-entry and cannulation or in cases of hardware-related imaging limitations. Beyond modality selection, we address the specialized protocol requirements, training milestones, and competency standards expected of ACHD sonographers, CMR, and CCT technologists-all personnel whose expertise is central to diagnostic quality and accuracy in this patient population. Lesion-specific scenarios and case examples illustrate application in practice. A multimodality and team-based strategy supported by standardized protocols and structured reporting is the foundation of accurate, safe, and efficient ACHD imaging in contemporary cardiovascular practice. CI - Copyright: (c) 2026 The Author(s). FAU - Rangosch, Alicia AU - Rangosch A AUID- ORCID: 0009-0007-2476-4936 AD - Houston Methodist Adult Congenital Heart Program, Houston Methodist Hospital, Houston, Texas, United States. FAU - Dhore-Patil, Aneesh AU - Dhore-Patil A AUID- ORCID: 0000-0002-5437-3270 AD - Wake Forest University, Sanger Heart and Vascular Institute, Atrium Health, Charlotte, North Carolina. FAU - Duarte, Valeria E AU - Duarte VE AUID- ORCID: 0000-0001-6616-5412 AD - Houston Methodist DeBakey Heart & Vascular Center, Houston Methodist, Houston, Texas, United States. LA - eng PT - Journal Article PT - Review DEP - 20260630 PL - United States TA - Methodist Debakey Cardiovasc J JT - Methodist DeBakey cardiovascular journal JID - 101508600 SB - IM MH - Humans MH - *Heart Defects, Congenital/diagnostic imaging/physiopathology/therapy MH - Predictive Value of Tests MH - Adult MH - *Cardiologists MH - Age Factors MH - *Cardiac Imaging Techniques MH - Clinical Competence MH - Prognosis MH - Echocardiography PMC - PMC13330995 OTO - NOTNLM OT - adult congenital heart disease (ACHD) OT - cardiac computed tomography (CCT) OT - cardiac magnetic resonance (CMR) OT - multimodality imaging OT - transthoracic echocardiography (TTE) COIS- Dr. Duarte is a member of the editorial board of the Journal, serving on a voluntary basis. The other authors have no competing interests to declare. EDAT- 2026/07/06 06:31 MHDA- 2026/07/06 06:32 PMCR- 2026/06/30 CRDT- 2026/07/06 05:25 PHST- 2026/05/10 00:00 [received] PHST- 2026/06/12 00:00 [accepted] PHST- 2026/07/06 06:32 [medline] PHST- 2026/07/06 06:31 [pubmed] PHST- 2026/07/06 05:25 [entrez] PHST- 2026/06/30 00:00 [pmc-release] AID - 10.14797/mdcvj.1868 [doi] PST - epublish SO - Methodist Debakey Cardiovasc J. 2026 Jun 30;22(3):5-27. doi: 10.14797/mdcvj.1868. eCollection 2026. PMID- 42403547 OWN - NLM STAT- MEDLINE DCOM- 20260706 LR - 20260813 IS - 1947-6108 (Electronic) IS - 1947-6094 (Print) IS - 1947-6108 (Linking) VI - 22 IP - 3 DP - 2026 TI - Endocarditis in Adults with Congenital Heart Disease. PG - 136-149 LID - 10.14797/mdcvj.1799 [doi] AB - Infective endocarditis (IE) remains a major cause of morbidity and mortality in patients with congenital heart disease (CHD). Advances in medical and surgical care have led to a growing population of adults with CHD who carry a substantially higher lifetime risk of IE than the general population. This increased susceptibility reflects the combined effects of abnormal intracardiac flow patterns, the frequent presence of prosthetic material or intracardiac devices, and repeated surgical and transcatheter interventions. The epidemiology, microbiology, clinical presentation, and management of IE in CHD differ in several important aspects from those observed in patients without CHD. Streptococcal species and Staphylococcus aureus account for the majority of IE cases. Diagnosis is often challenging due to complex cardiac anatomy and the presence of prosthetic material, and therefore it requires a high index of suspicion and multimodality imaging. Medical therapy usually requires prolonged antimicrobial therapy. Surgical intervention is more frequently required than in non-CHD populations, reflecting both the burden of prosthetic material and the higher rate of complications at presentation. Preventive strategies, including meticulous dental and skin hygiene and appropriate antibiotic prophylaxis, remain the cornerstone of IE management in this high-risk population. CI - Copyright: (c) 2026 The Author(s). FAU - Busti, Andrea AU - Busti A AUID- ORCID: 0000-0002-4303-5049 AD - Pediatric and Congenital Cardiology, Regina Margherita Children's Hospital, Torino, Italy. FAU - Annoni, Giuseppe AU - Annoni G AUID- ORCID: 0000-0003-2059-2421 AD - Pediatric and Congenital Cardiology, Regina Margherita Children's Hospital, Torino, Italy. FAU - Napoleone, Carlo Pace AU - Napoleone CP AUID- ORCID: 0000-0001-7039-5309 AD - Pediatric and Congenital Cardiac Surgery, Regina Margherita Children's Hospital, Torino, Italy. LA - eng PT - Journal Article PT - Review DEP - 20260630 PL - United States TA - Methodist Debakey Cardiovasc J JT - Methodist DeBakey cardiovascular journal JID - 101508600 RN - 0 (Anti-Bacterial Agents) SB - IM MH - Humans MH - *Heart Defects, Congenital/epidemiology/diagnosis/therapy/complications MH - *Endocarditis, Bacterial/therapy/diagnosis/epidemiology/microbiology MH - Risk Factors MH - Adult MH - *Prosthesis-Related Infections/therapy/diagnosis/microbiology/epidemiology MH - Anti-Bacterial Agents/therapeutic use MH - Treatment Outcome MH - *Endocarditis/therapy/diagnosis/epidemiology/microbiology PMC - PMC13330854 OTO - NOTNLM OT - adult congenital heart disease OT - infective endocarditis OT - infective endocarditis multidisciplinary team COIS- The authors have no competing interests to declare. EDAT- 2026/07/06 06:31 MHDA- 2026/07/06 06:32 PMCR- 2026/06/30 CRDT- 2026/07/06 05:25 PHST- 2026/02/09 00:00 [received] PHST- 2026/04/28 00:00 [accepted] PHST- 2026/07/06 06:32 [medline] PHST- 2026/07/06 06:31 [pubmed] PHST- 2026/07/06 05:25 [entrez] PHST- 2026/06/30 00:00 [pmc-release] AID - 10.14797/mdcvj.1799 [doi] PST - epublish SO - Methodist Debakey Cardiovasc J. 2026 Jun 30;22(3):136-149. doi: 10.14797/mdcvj.1799. eCollection 2026. PMID- 42403371 OWN - NLM STAT- MEDLINE DCOM- 20260930 LR - 20260930 IS - 1467-1107 (Electronic) IS - 1047-9511 (Linking) VI - 36 IP - 7 DP - 2026 Jul TI - Case-based learning in paediatric cardiology training. PG - 1436-1440 LID - 10.1017/S1047951126113845 [doi] AB - BACKGROUND: Case-based learning (CBL) is increasingly used across health professions education to promote clinical reasoning and professional competencies. In paediatric cardiology, rapid advances in diagnostics, interventions, and multidisciplinary care have intensified the need for educational approaches that integrate complex knowledge with real-world problem-solving. METHODS: This narrative review outlines the theoretical foundations of CBL and examines the available literature on its implementation and effectiveness in medical education generally and paediatric cardiology specifically. Emerging applications of CBL, including simulation, virtual reality, and international collaborative case conferences, were also reviewed. Key design principles for effective CBL were explored, including case selection, alignment with competency-based curricula, faculty development, and assessment strategies. RESULTS: Evidence suggests that CBL enhances clinical reasoning, knowledge integration, learner engagement, and the development of professional competencies. In paediatric cardiology, CBL supports the application of complex diagnostic and management principles within authentic clinical contexts. Emerging technology-enhanced approaches and international collaborative learning initiatives further expand opportunities for interactive and multidisciplinary education. However, challenges remain, including significant time and resource requirements, digital inequities, and the need for more rigorous evaluation of educational outcomes. CONCLUSION: Well-designed CBL appears to be a powerful educational strategy for preparing paediatric cardiology clinicians to deliver increasingly complex, team-based care. Future directions include greater integration of technology-enhanced learning, simulation-based approaches, and global educational networks to support trainees and practitioners across diverse practice settings while strengthening evidence for educational effectiveness. FAU - O'Halloran, Kate AU - O'Halloran K AD - Department of Pediatric Cardiology, Children's Health Ireland, Crumlin, Dublin, Ireland. FAU - McMahon, Colin J AU - McMahon CJ AUID- ORCID: 0000-0003-0337-9338 AD - Department of Pediatric Cardiology, Children's Health Ireland, Crumlin, Dublin, Ireland. AD - School of Medicine, University College Dublin, Dublin, Ireland. LA - eng PT - Journal Article PT - Review DEP - 20260706 PL - England TA - Cardiol Young JT - Cardiology in the young JID - 9200019 SB - IM MH - Humans MH - *Cardiology/education MH - *Pediatrics/education MH - *Clinical Competence MH - *Problem-Based Learning/methods MH - Curriculum OTO - NOTNLM OT - CHD OT - case-based learning OT - education OT - paediatric cardiology OT - training EDAT- 2026/07/06 06:31 MHDA- 2026/09/30 23:29 CRDT- 2026/07/06 05:22 PHST- 2026/09/30 23:29 [medline] PHST- 2026/07/06 06:31 [pubmed] PHST- 2026/07/06 05:22 [entrez] AID - S1047951126113845 [pii] AID - 10.1017/S1047951126113845 [doi] PST - ppublish SO - Cardiol Young. 2026 Jul;36(7):1436-1440. doi: 10.1017/S1047951126113845. Epub 2026 Jul 6. PMID- 42402039 OWN - NLM STAT- Publisher LR - 20260821 IS - 1538-943X (Electronic) IS - 1058-2916 (Linking) DP - 2026 Jul 7 TI - The HELP Score in Non-Asphyxial Hypothermic Cardiac Arrest Treated With Extracorporeal Life Support: External Validation and Clinical Utility. LID - 10.1097/MAT.0000000000002774 [doi] AB - Hypothermic cardiac arrest can result in a good outcome when patients are rewarmed using extracorporeal life support (ECLS), but patient selection for this treatment is challenging. The HELP score (Hemoglobin, Exposure, Lactate, Potassium) is a novel prognostic tool for estimating the survival chances of patients with non-asphyxial hypothermic cardiac arrest rewarmed with ECLS. In this retrospective multicenter study, we performed external validation of the HELP score and evaluated its clinical utility. We calculated predicted survival based on the original HELP equation and assessed overall performance, discrimination, calibration, and decision curve analysis. The study population included 106 patients from eight countries. The survival rate to hospital discharge was 65% (69/106); a favorable neurological outcome was found in 88% of survivors. The HELP score showed excellent discrimination (area under the receiver operating characteristic curve 0.80) and good overall performance (Brier 0.17). Calibration analysis showed a mild underestimation of survival (slope 0.92; intercept 0.64). Decision curve analysis showed a positive net benefit compared with a "treat all" strategy across a wide range of thresholds. The HELP score revealed excellent discrimination, good overall performance, and clinically meaningful positive net benefit in the external validation cohort. This model can be a useful aid in decisions on ECLS application in adult patients with non-asphyxia-related hypothermic cardiac arrest, but it should not replace a team-based, multidisciplinary approach. CI - Copyright (c) 2026 The Author(s). Published by Wolters Kluwer Health, LLC. on behalf of the ASAIO. FAU - Mendrala, Konrad AU - Mendrala K AUID- ORCID: 0000-0002-9019-0420 AD - From the Department of Anaesthesiology and Intensive Care, Medical University of Silesia, Katowice, Poland. FAU - Darocha, Tomasz AU - Darocha T AD - From the Department of Anaesthesiology and Intensive Care, Medical University of Silesia, Katowice, Poland. FAU - Takauji, Shuhei AU - Takauji S AD - Department of Emergency Medicine, Hokkaido University Hospital, Sapporo, Japan. FAU - Brozek, Tomas AU - Brozek T AD - Department of Anaesthesiology and Intensive Care, 1(st) Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czechia. FAU - Rischall, Megan AU - Rischall M AD - Department of Emergency Medicine, Hennepin County Medical Center, Minneapolis, Minnesota. FAU - Soumagnac, Tal AU - Soumagnac T AD - SAMU de Paris and Intensive Care Unit, Necker University Hospital, Assistance Publique-Hopitaux de Paris, Paris, France. FAU - Podsiadlo, Pawel AU - Podsiadlo P AUID- ORCID: 0000-0002-1069-2659 AD - Department of Emergency Medicine, Jan Kochanowski University, Kielce, Poland. LA - eng PT - Journal Article DEP - 20260707 PL - United States TA - ASAIO J JT - ASAIO journal (American Society for Artificial Internal Organs : 1992) JID - 9204109 SB - IM OTO - NOTNLM OT - accidental hypothermia OT - cardiac arrest OT - cardiopulmonary resuscitation OT - extracorporeal life support COIS- Disclosure: The authors have no conflicts of interest to report. EDAT- 2026/07/05 13:29 MHDA- 2026/07/05 13:29 CRDT- 2026/07/05 09:03 PHST- 2026/07/05 13:29 [pubmed] PHST- 2026/07/05 13:29 [medline] PHST- 2026/07/05 09:03 [entrez] AID - 00002480-990000000-01011 [pii] AID - 10.1097/MAT.0000000000002774 [doi] PST - aheadofprint SO - ASAIO J. 2026 Jul 7. doi: 10.1097/MAT.0000000000002774. PMID- 42401224 OWN - NLM STAT- Publisher LR - 20260819 IS - 1552-6259 (Electronic) IS - 0003-4975 (Linking) DP - 2026 Jul 4 TI - Does Prior Percutaneous Coronary Revascularization Negatively Affect the Outcomes of Subsequent Coronary Artery Bypass Grafting? LID - S0003-4975(26)00705-8 [pii] LID - 10.1016/j.athoracsur.2026.06.052 [doi] AB - BACKGROUND: The growing use of percutaneous coronary intervention (PCI) has led to an increasing number of patients referred for coronary artery bypass grafting (CABG) after prior PCI. The impact of previous PCI on CABG outcomes remains controversial, and the prognostic significance of PCI burden has not been fully clarified. This study evaluated the effect of prior PCI on outcomes after CABG. METHODS: Consecutive patients undergoing elective isolated CABG at 6 high-volume centers between 2018 and 2022 were analyzed. Patients were stratified according to PCI history into no prior PCI, single prior PCI, or multiple prior PCIs. Early postoperative outcomes and 1- and 3-year follow-up events were assessed. The primary end point was midterm all-cause mortality. RESULTS: A total of 2823 patients were included. Baseline characteristics were comparable among groups. Patients with multiple prior PCIs more frequently required coronary endarterectomy and grafting of small-caliber target vessels. Early mortality was similar across groups, whereas perioperative myocardial infarction was more frequent in patients with multiple prior PCIs (2.9% vs 0.9% vs 0.6%; P = .015). During follow-up, prior PCI, particularly multiple procedures, was associated with higher rates of myocardial infarction, stroke, and repeat revascularization, whereas midterm survival was similar. CONCLUSIONS: Prior PCI was not associated with increased early or midterm mortality after elective isolated CABG. However, multiple prior PCIs were associated with higher perioperative myocardial infarction and adverse cardiovascular events during follow-up, a finding suggesting that PCI burden should be considered in preoperative risk stratification and heart team decision making. CI - Copyright (c) 2026 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved. FAU - Lodo, Vittoria AU - Lodo V AD - Department of Cardiac Surgery, Mauriziano Hospital, Turin, Italy. Electronic address: vittoria.lodo90@gmail.com. FAU - Capozza, Cecilia AU - Capozza C AD - Cardiac Surgery Unit, San Gerardo dei Tintori Scientific Institute for Research, Hospitalization and Health Care, Monza, Italy. FAU - Barbero, Cristina AU - Barbero C AD - Department of Cardiovascular and Thoracic Surgery, City of Health and Science, San Giovanni Battista Hospital, Turin, Italy. FAU - Brenna, Dario AU - Brenna D AD - Department of Cardiac Surgery, Territorial Social Health Authority Civil Hospitals of Brescia, University of Brescia, Brescia, Italy. FAU - Francica, Alessandra AU - Francica A AD - Department of Cardiac Surgery, University of Verona Medical School, Verona, Italy. FAU - De Donno, Luca AU - De Donno L AD - Cardiac Surgey Unit, Saints Anthony and Biagio and Cesare Arrigo University Hospital, Alessandria, Italy. FAU - Dalbesio, Bianca AU - Dalbesio B AD - Cardiac Surgery Unit, AO Santa Croce e Carle, Cuneo, Italy. FAU - Italiano, Enrico G AU - Italiano EG AD - Department of Cardiac Surgery, Mauriziano Hospital, Turin, Italy. FAU - Boschetti, Vincenzo AU - Boschetti V AD - Department of Cardiac Surgery, University of Verona Medical School, Verona, Italy. FAU - Roberto, Maurizio AU - Roberto M AD - Cardiac Surgery Unit, AO Santa Croce e Carle, Cuneo, Italy. FAU - Audo, Andrea AU - Audo A AD - Cardiac Surgey Unit, Saints Anthony and Biagio and Cesare Arrigo University Hospital, Alessandria, Italy. FAU - Luciani, Giovanni Battista AU - Luciani GB AD - Department of Cardiac Surgery, University of Verona Medical School, Verona, Italy. FAU - Benussi, Stefano AU - Benussi S AD - Department of Cardiac Surgery, Territorial Social Health Authority Civil Hospitals of Brescia, University of Brescia, Brescia, Italy. FAU - Rinaldi, Mauro AU - Rinaldi M AD - Department of Cardiovascular and Thoracic Surgery, City of Health and Science, San Giovanni Battista Hospital, Turin, Italy. FAU - Pollari, Francesco AU - Pollari F AD - Department of Cardiac Surgery, University of Erlangen, Erlangen, Germany. FAU - Barili, Fabio AU - Barili F AD - Cardiac Surgery Unit, Galeazzi-Sant'Ambrogio Scientific Institute for Research, Hospitalization and Health Care Hospital, Milan, Italy. FAU - Pilato, Michele AU - Pilato M AD - Department for the Treatment and Study of Cardiothoracic Diseases and Cardiothoracic Transplantation, Scientific Institute for Research, Hospitalization and Health Care - Mediterranean Institute for Transplants and Highly Specialized Therapies, Palermo, Italy. FAU - Centofanti, Paolo AU - Centofanti P AD - Department of Cardiac Surgery, Mauriziano Hospital, Turin, Italy. CN - Italian Group for Research and Outcomes in Cardiac Surgery of the Italian Society for Cardiac Surgery LA - eng PT - Journal Article DEP - 20260704 PL - Netherlands TA - Ann Thorac Surg JT - The Annals of thoracic surgery JID - 15030100R SB - IM COIS- Disclosures The authors have no conflicts of interest to disclose. EDAT- 2026/07/05 00:37 MHDA- 2026/07/05 00:37 CRDT- 2026/07/04 19:31 PHST- 2026/03/10 00:00 [received] PHST- 2026/05/05 00:00 [revised] PHST- 2026/06/21 00:00 [accepted] PHST- 2026/07/05 00:37 [pubmed] PHST- 2026/07/05 00:37 [medline] PHST- 2026/07/04 19:31 [entrez] AID - S0003-4975(26)00705-8 [pii] AID - 10.1016/j.athoracsur.2026.06.052 [doi] PST - aheadofprint SO - Ann Thorac Surg. 2026 Jul 4:S0003-4975(26)00705-8. doi: 10.1016/j.athoracsur.2026.06.052. PMID- 42399043 OWN - NLM STAT- MEDLINE DCOM- 20260703 LR - 20260703 IS - 1558-2264 (Electronic) IS - 0733-8651 (Linking) VI - 44 IP - 3 DP - 2026 Aug TI - Post-Heart Transplantation Intensive Care Unit Recovery: A Phase-Based Approach. PG - 479-490 LID - S0733-8651(26)00036-6 [pii] LID - 10.1016/j.ccl.2026.04.004 [doi] AB - Heart transplantation is the definitive treatment for end-stage heart failure. Post-transplant care is dynamic and complex, requiring a thoughtful multidisciplinary approach. Invasive hemodynamic monitoring is central to guiding inotrope and vasopressor titration to optimize allograft function and end-organ perfusion. Vigilant assessment for primary graft dysfunction is essential and informs escalation to mechanical circulatory support when needed. As hemodynamics and graft function stabilize, patients are liberated from mechanical ventilation, volume status is optimized, nutrition and mobility are prioritized, and pharmacologic and mechanical supports are weaned. Concurrently, immunosuppression is titrated and patients are monitored closely for infection. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Friedman, Amy L AU - Friedman AL AD - Department of Anesthesiology, Division of Critical Care Medicine, Vanderbilt University Medical Center, 1211 Medical Center Drive, Nashville, TN 37232, USA. FAU - Mery, Marissa W AU - Mery MW AD - Department of Anesthesiology, Division of Critical Care Medicine, Vanderbilt University Medical Center, 1211 Medical Center Drive, Nashville, TN 37232, USA. FAU - Jelly, Christina A AU - Jelly CA AD - Department of Anesthesiology, Division of Critical Care Medicine, Vanderbilt University Medical Center, 1211 Medical Center Drive, Nashville, TN 37232, USA. FAU - Alvis, Bret D AU - Alvis BD AD - Department of Anesthesiology, Division of Critical Care Medicine, Vanderbilt University Medical Center, 1211 Medical Center Drive, Nashville, TN 37232, USA. Electronic address: Bret.d.alvis@vumc.org. LA - eng PT - Journal Article PT - Review DEP - 20260515 PL - Netherlands TA - Cardiol Clin JT - Cardiology clinics JID - 8300331 SB - IM MH - Humans MH - *Heart Transplantation MH - *Intensive Care Units MH - *Heart Failure/surgery MH - *Critical Care/methods MH - *Postoperative Care/methods MH - Hemodynamics/physiology OTO - NOTNLM OT - Coagulopathy OT - Diuresis OT - Heart transplantation OT - Inotropes OT - Mechanical circulatory support OT - Primary graft dysfunction OT - Rejection OT - Vasoplegic syndrome COIS- Disclosure The authors report no conflicts of interest related to the content of this article. EDAT- 2026/07/04 00:33 MHDA- 2026/07/04 00:34 CRDT- 2026/07/03 20:54 PHST- 2026/07/04 00:34 [medline] PHST- 2026/07/04 00:33 [pubmed] PHST- 2026/07/03 20:54 [entrez] AID - S0733-8651(26)00036-6 [pii] AID - 10.1016/j.ccl.2026.04.004 [doi] PST - ppublish SO - Cardiol Clin. 2026 Aug;44(3):479-490. doi: 10.1016/j.ccl.2026.04.004. Epub 2026 May 15. PMID- 42397855 OWN - NLM STAT- Publisher LR - 20260703 IS - 1477-111X (Electronic) IS - 0267-6591 (Linking) DP - 2026 Jul 3 TI - Trileaflet mitral valve in hypertrophic obstructive cardiomyopathy: A rare anatomical variant requiring surgical intervention. PG - 2676591261467978 LID - 10.1177/02676591261467978 [doi] AB - A 68-year-old woman presented with palpitations, though ECG monitoring showed sinus rhythm. Multimodal imaging (cardiac magnetic resonance and echocardiography) showed asymmetric septal hypertrophy with left ventricular outflow tract obstruction (resting gradient of up to 87 mmHg). Echocardiography showed severe mitral regurgitation with multiple regurgitant jets and systolic anterior motion of the mitral valve. Mitral valve anatomy was abnormal, with anterior leaflet restriction and a clefted posterior leaflet. Symptoms persisted despite medical therapy (beta-blockers), and following multidisciplinary discussion, she proceeded to surgery on symptomatic and prognostic grounds. The patient underwent successful septal myectomy and bioprosthetic mitral valve replacement with excellent valve function. Following a generally uneventful postoperative recovery, she was discharged on postoperative day ten with stable cardiac function. This case highlights a rare trileaflet configuration of the mitral valve contributing to severe mitral regurgitation in hypertrophic obstructive cardiomyopathy and underscores the importance of detailed anatomical assessment in guiding surgical decision-making. FAU - Kumar, Ujjawal Aditya AU - Kumar UA AUID- ORCID: 0000-0001-8655-5856 AD - Department of Cardiac Surgery, Royal Papworth Hospital, Cambridge, UK. RINGGOLD: 2144 FAU - Sitaranjan, Daniel Rohairan AU - Sitaranjan DR AD - Department of Cardiac Surgery, Royal Papworth Hospital, Cambridge, UK. RINGGOLD: 2144 AD - Department of Cardiac Surgery, Morriston Hospital, Swansea, UK. FAU - Taghavi, Fouad John AU - Taghavi FJ AD - Department of Cardiac Surgery, Royal Papworth Hospital, Cambridge, UK. RINGGOLD: 2144 LA - eng PT - Journal Article DEP - 20260703 PL - England TA - Perfusion JT - Perfusion JID - 8700166 SB - IM OTO - NOTNLM OT - hypertrophic cardiomyopathy OT - mitral regurgitation OT - mitral valve replacement OT - septal myectomy OT - systolic anterior motion OT - trileaflet mitral valve EDAT- 2026/07/03 18:34 MHDA- 2026/07/03 18:34 CRDT- 2026/07/03 13:42 PHST- 2026/07/03 18:34 [medline] PHST- 2026/07/03 18:34 [pubmed] PHST- 2026/07/03 13:42 [entrez] AID - 10.1177/02676591261467978 [doi] PST - aheadofprint SO - Perfusion. 2026 Jul 3:2676591261467978. doi: 10.1177/02676591261467978. PMID- 42396691 OWN - NLM STAT- MEDLINE DCOM- 20260803 LR - 20260803 IS - 1531-6971 (Electronic) IS - 1070-5287 (Linking) VI - 32 IP - 5 DP - 2026 Sep 1 TI - Multidisciplinary approach in cardiac sarcoidosis: to biopsy or not? PG - 471-481 LID - 10.1097/MCP.0000000000001292 [doi] AB - PURPOSE OF REVIEW: Cardiac sarcoidosis (CS) is associated with significant morbidity and mortality, yet its diagnosis remains challenging due to heterogeneous clinical presentations and patchy myocardial involvement. Although endomyocardial biopsy has historically been regarded as the diagnostic gold standard, its limited sensitivity, tendency to provide false negative and inconclusive results and procedural risks have led to increasing reliance on noninvasive imaging. This review assesses the contemporary role of endomyocardial biopsy (EMB) within a multidisciplinary diagnostic framework and evaluates whether tissue diagnosis remains necessary in modern clinical practice. RECENT FINDINGS: Recent studies highlight the expanding role of cardiac magnetic resonance (CMR) and 18 F-fluorodeoxyglucose positron emission tomography (FDG-PET) imaging in diagnosing, phenotyping, and risk stratifying CS. Targeted biopsy strategies guided by imaging or electroanatomical mapping have demonstrated improved diagnostic yield compared with random sampling. Multidisciplinary team-based decision-making has emerged as a key determinant in selecting patients for biopsy, particularly when histological confirmation is likely to influence immunosuppressive therapy, device implantation, or prognostic assessment. SUMMARY: EMB retains an important but selective role in CS. Integration of multimodality imaging and multidisciplinary assessment optimizes patient selection, enhances procedural safety, and ensures that biopsy findings meaningfully inform management. Future research should refine biopsy indications and integrate imaging with molecular and biomarker-based approaches to improve diagnostic accuracy and prognostication. CI - Copyright (c) 2026 Wolters Kluwer Health, LLC. All rights reserved. FAU - Pericao, Ana AU - Pericao A AD - Department of Cardiology, The Royal Brompton & Harefield Hospitals, part of GSTT. AD - National Heart and Lung Institute, Imperial College London. FAU - Sharma, Rakesh AU - Sharma R AD - Department of Cardiology, The Royal Brompton & Harefield Hospitals, part of GSTT. AD - National Heart and Lung Institute, Imperial College London. AD - King's College, London, UK. LA - eng PT - Journal Article PT - Review DEP - 20260703 PL - United States TA - Curr Opin Pulm Med JT - Current opinion in pulmonary medicine JID - 9503765 RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18) SB - IM MH - Humans MH - *Sarcoidosis/pathology/diagnosis/diagnostic imaging MH - *Cardiomyopathies/pathology/diagnosis/diagnostic imaging MH - Positron-Emission Tomography MH - Biopsy/methods MH - *Myocardium/pathology MH - Magnetic Resonance Imaging MH - Fluorodeoxyglucose F18 MH - Patient Care Team MH - Multimodal Imaging OTO - NOTNLM OT - cardiac magnetic resonance OT - cardiac sarcoidosis OT - endomyocardial biopsy OT - multidisciplinary care EDAT- 2026/07/03 06:30 MHDA- 2026/08/03 06:36 CRDT- 2026/07/03 05:53 PHST- 2026/08/03 06:36 [medline] PHST- 2026/07/03 06:30 [pubmed] PHST- 2026/07/03 05:53 [entrez] AID - 00063198-990000000-00340 [pii] AID - 10.1097/MCP.0000000000001292 [doi] PST - ppublish SO - Curr Opin Pulm Med. 2026 Sep 1;32(5):471-481. doi: 10.1097/MCP.0000000000001292. Epub 2026 Jul 3. PMID- 42392910 OWN - NLM STAT- In-Process LR - 20261029 IS - 1875-2128 (Electronic) IS - 1875-2128 (Linking) VI - 119 IP - 10 DP - 2026 Oct TI - Lessons learned during my collaboration with Alain Carpentier: A 25-year perspective. PG - 621-622 LID - S1875-2136(26)00236-6 [pii] LID - 10.1016/j.acvd.2026.06.001 [doi] FAU - Berrebi, Alain AU - Berrebi A AD - Cardiac Surgery Department, European Georges-Pompidou Hospital, Institut Medico-Chirurgical Montsouris, Universite Paris-Cite, AP-HP, Paris, France. Electronic address: alainberrebi@hotmail.com. LA - eng PT - Journal Article DEP - 20260623 PL - Netherlands TA - Arch Cardiovasc Dis JT - Archives of cardiovascular diseases JID - 101465655 SB - IM OTO - NOTNLM OT - Education OT - Heart team OT - Intraoperative echocardiography OT - Mitral valve reconstruction OT - Transmission COIS- Disclosure of interest The author declares that he has no competing interest. EDAT- 2026/07/03 00:30 MHDA- 2026/07/03 00:30 CRDT- 2026/07/02 21:56 PHST- 2026/05/04 00:00 [received] PHST- 2026/06/09 00:00 [revised] PHST- 2026/06/15 00:00 [accepted] PHST- 2026/07/03 00:30 [pubmed] PHST- 2026/07/03 00:30 [medline] PHST- 2026/07/02 21:56 [entrez] AID - S1875-2136(26)00236-6 [pii] AID - 10.1016/j.acvd.2026.06.001 [doi] PST - ppublish SO - Arch Cardiovasc Dis. 2026 Oct;119(10):621-622. doi: 10.1016/j.acvd.2026.06.001. Epub 2026 Jun 23. PMID- 42384193 OWN - NLM STAT- MEDLINE DCOM- 20260730 LR - 20260831 IS - 1462-0332 (Electronic) IS - 1462-0324 (Print) IS - 1462-0324 (Linking) VI - 65 IP - 7 DP - 2026 Jun 30 TI - Use of advanced cardiovascular imaging in rheumatic immune-mediated inflammatory diseases. LID - 10.1093/rheumatology/keag347 [doi] LID - keag347 AB - OBJECTIVES: To evaluate the real-world use of advanced cardiovascular imaging in less common and rare rheumatic immune-mediated inflammatory diseases (IMIDs) and identify variation in practice to inform future studies and clinical guidelines. METHODS: A retrospective, multicentre quality improvement project was conducted across four major hospitals in the UK. Adults with SLE, SSc, idiopathic inflammatory myopathy, vasculitis or SS who underwent cardiovascular magnetic resonance (CMR), CT coronary angiography (CTCA) or PET between January 2023 and December 2024 were included. Demographics, IMID characteristics, cardiovascular risk factors, imaging indications, findings and management were extracted using a standardized proforma and analysed. RESULTS: A total of 294 imaging studies were performed in 261 patients (72.4% female, 65.9% aged 40-74 years) comprising 137 (46.6%) CMR, 40 (13.6%) CTCA and 117 (39.8%) PET scans. Indications varied by modality and centre. Cardiovascular abnormalities were reported in 175/294 (59.5%), most commonly in vasculitis (53.7%). Notably, 54/63 (85.7%) of abnormal PET and 61/89 (68.5%) of abnormal CMR scans were in asymptomatic patients. Imaging findings prompted cardiology referral/ongoing follow-up in 59.5% and changes to IMID treatment in 31.3%, but only 23.1% were discussed in a formal multidisciplinary team (MDT). CONCLUSION: Advanced cardiovascular imaging frequently identifies cardiovascular involvement in rheumatic IMIDs, including in asymptomatic patients. Treatment adjustments occurred in a third of patients, although largely undertaken outside established MDT processes. These findings emphasize the need for better understanding of imaging-based findings and for cardio-rheumatology MDTs to support integrated decision-making to improve patient outcomes. CI - (c) The Author(s) 2026. Published by Oxford University Press on behalf of the British Society for Rheumatology. FAU - Gumber, Leher AU - Gumber L AUID- ORCID: 0000-0003-0154-1207 AD - Centre for Musculoskeletal Research, Division of Musculoskeletal & Dermatological Sciences, Faculty of Biology, Medicine & Health, University of Manchester, Manchester, UK. AD - NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK. FAU - Meghji, Mohammed Askari AU - Meghji MA AD - Manchester University NHS Foundation Trust, Manchester, UK. FAU - Kakkar, Vishal AU - Kakkar V AUID- ORCID: 0000-0003-0513-8677 AD - Leeds Biomedical Research Centre, National Institute for Health Research, Leeds Teaching Hospital NHS Trust, Leeds, UK. FAU - Sivasankaran, Karthikeyan AU - Sivasankaran K AD - Department of Medicine, Northumbria Healthcare NHS Foundation Trust, Newcastle upon Tyne, UK. FAU - Iftikhar, Zahra M AU - Iftikhar ZM AD - Department of Rheumatology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK. FAU - Elndari, Najla AU - Elndari N AD - Department of Rheumatology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK. FAU - Talbot, Charlotte AU - Talbot C AD - Institute of Inflammation and Aging, University of Birmingham, Birmingham, UK. AD - Department of Rheumatology, Sandwell and West Birmingham NHS Trust, Birmingham, UK. FAU - Tarkin, Jason M AU - Tarkin JM AD - Section of Cardiorespiratory Medicine, Victor Phillip Dahdaleh Heart & Lung Research Institute, University of Cambridge, Cambridge, UK. FAU - Plein, Sven AU - Plein S AUID- ORCID: 0000-0002-0997-4384 AD - Biomedical Imaging Science Department, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK. AD - School of Biomedical Engineering and Imaging Sciences, Kings College London, London, UK. FAU - Dweck, Marc R AU - Dweck MR AD - Centre for Cardiovascular Science, Chancellors Building, Little France Crescent, University of Edinburgh, Edinburgh, UK. FAU - Youngstein, Taryn AU - Youngstein T AUID- ORCID: 0000-0002-8297-556X AD - National Heart & Lung Institute, Imperial College London, London, UK. AD - Department of Rheumatology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK. FAU - Mallat, Ziad AU - Mallat Z AUID- ORCID: 0000-0003-0443-7878 AD - Section of Cardiorespiratory Medicine, Victor Phillip Dahdaleh Heart & Lung Research Institute, University of Cambridge, Cambridge, UK. FAU - Bissell, Lesley-Anne AU - Bissell LA AD - Leeds Biomedical Research Centre, National Institute for Health Research, Leeds Teaching Hospital NHS Trust, Leeds, UK. FAU - Heaney, Jonathan AU - Heaney J AD - Department of Rheumatology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK. FAU - Reynolds, John AU - Reynolds J AUID- ORCID: 0000-0002-8962-4404 AD - Institute of Inflammation and Aging, University of Birmingham, Birmingham, UK. AD - Department of Rheumatology, Sandwell and West Birmingham NHS Trust, Birmingham, UK. FAU - Buch, Maya H AU - Buch MH AUID- ORCID: 0000-0002-8962-5642 AD - Centre for Musculoskeletal Research, Division of Musculoskeletal & Dermatological Sciences, Faculty of Biology, Medicine & Health, University of Manchester, Manchester, UK. AD - NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK. LA - eng PT - Journal Article PT - Multicenter Study PL - England TA - Rheumatology (Oxford) JT - Rheumatology (Oxford, England) JID - 100883501 SB - IM MH - Humans MH - Female MH - Retrospective Studies MH - Middle Aged MH - Aged MH - Adult MH - Male MH - *Cardiovascular Diseases/diagnostic imaging/etiology MH - *Rheumatic Diseases/complications/diagnostic imaging MH - Computed Tomography Angiography MH - Coronary Angiography MH - Magnetic Resonance Imaging MH - United Kingdom MH - Positron-Emission Tomography MH - Vasculitis/diagnostic imaging PMC - PMC13420496 OTO - NOTNLM OT - cardiovascular disease OT - imaging OT - immune-mediated inflammatory diseases EDAT- 2026/07/01 16:11 MHDA- 2026/07/30 06:41 PMCR- 2026/07/01 CRDT- 2026/07/01 11:13 PHST- 2025/12/07 00:00 [received] PHST- 2026/06/16 00:00 [accepted] PHST- 2026/07/30 06:41 [medline] PHST- 2026/07/01 16:11 [pubmed] PHST- 2026/07/01 11:13 [entrez] PHST- 2026/07/01 00:00 [pmc-release] AID - 8722948 [pii] AID - keag347 [pii] AID - 10.1093/rheumatology/keag347 [doi] PST - ppublish SO - Rheumatology (Oxford). 2026 Jun 30;65(7):keag347. doi: 10.1093/rheumatology/keag347. PMID- 42381947 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260701 LR - 20260813 IS - 2666-2736 (Electronic) IS - 2666-2736 (Linking) VI - 31 DP - 2026 Jun TI - How the heart team is portrayed in online news. PG - 101803 LID - 10.1016/j.xjon.2026.101803 [doi] LID - 101803 AB - BACKGROUND: Online news plays a critical role in public health literacy and the dissemination of medical information. As cardiovascular care increasingly relies on multidisciplinary collaboration, understanding how different specialties are represented in public portrayals of the heart team is essential; accordingly, this study examines patterns in online cardiovascular news coverage to assess how these roles are depicted. METHODS: A systematic Google News search was conducted using 7 keywords: "heart attack," "coronary artery disease," "heart failure," "aortic stenosis," "aortic regurgitation," "mitral stenosis," and "mitral regurgitation." Articles published between January 1, 2023, and January 1, 2024, were screened. Press type and physician specialty, gender, and role were analyzed. RESULTS: Of the 1580 articles screened, 1131 met our inclusion criteria for analysis. Cardiologists accounted for more than one-half of all featured specialist appearances (640 of 1200; 53.3%), followed by interventional cardiologists (277 of 1200; 23.1%), other physicians (165 of 1200; 13.8%), and cardiothoracic surgeons (118 of 1200; 9.8%). Cardiothoracic surgeons were least represented in coverage of heart attack, coronary artery disease, and heart failure (2.4%, 3.0%, and 2.9%, respectively) but appeared more frequently in articles focused on valvular disease. Most physicians were academically affiliated and appeared mainly as interviewees. Female physicians were underrepresented overall. CONCLUSIONS: Online cardiovascular news tends to feature cardiologists more often than cardiothoracic surgeons, emphasizing the importance of understanding how cardiovascular medicine is conveyed to the public. CI - (c) 2026 The Author(s). FAU - Chen, Joshua R AU - Chen JR AD - Department of Cardiothoracic Surgery, Thomas Jefferson University Hospital, Philadelphia, Pa. FAU - Shah, Vishal N AU - Shah VN AD - Department of Cardiothoracic Surgery, Thomas Jefferson University Hospital, Philadelphia, Pa. FAU - Kothari, Purab D AU - Kothari PD AD - Department of Cardiothoracic Surgery, Thomas Jefferson University Hospital, Philadelphia, Pa. FAU - Ostrovsky, Adam M AU - Ostrovsky AM AD - Department of Cardiothoracic Surgery, Thomas Jefferson University Hospital, Philadelphia, Pa. FAU - Bavaria, Joseph E AU - Bavaria JE AD - Department of Cardiothoracic Surgery, Thomas Jefferson University Hospital, Philadelphia, Pa. LA - eng PT - Journal Article DEP - 20260408 PL - Netherlands TA - JTCVS Open JT - JTCVS open JID - 101768541 PMC - PMC13316319 OTO - NOTNLM OT - cardiologists OT - cardiothoracic surgeons OT - cardiovascular news ecosystems OT - heart team OT - online health COIS- Dr Bavaria reported consulting for Edwards Lifesciences, Terumo Aortic, Abbott, Medtronic, and Artivion. All other authors reported no conflicts of interest. The Journal policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest. EDAT- 2026/07/01 06:34 MHDA- 2026/07/01 06:35 PMCR- 2026/04/08 CRDT- 2026/07/01 05:06 PHST- 2025/12/24 00:00 [received] PHST- 2026/03/27 00:00 [revised] PHST- 2026/04/03 00:00 [accepted] PHST- 2026/07/01 06:35 [medline] PHST- 2026/07/01 06:34 [pubmed] PHST- 2026/07/01 05:06 [entrez] PHST- 2026/04/08 00:00 [pmc-release] AID - S2666-2736(26)00226-3 [pii] AID - 101803 [pii] AID - 10.1016/j.xjon.2026.101803 [doi] PST - epublish SO - JTCVS Open. 2026 Apr 8;31:101803. doi: 10.1016/j.xjon.2026.101803. eCollection 2026 Jun. PMID- 42381933 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260701 LR - 20260813 IS - 2666-2736 (Electronic) IS - 2666-2736 (Linking) VI - 31 DP - 2026 Jun TI - Early outcomes following multivalve heart operation in octogenarians. PG - 101809 LID - 10.1016/j.xjon.2026.101809 [doi] LID - 101809 AB - BACKGROUND: Despite the rising incidence and complexity of valvular disease in the elderly population, data regarding surgical outcomes in octogenarians remain limited. METHODS: In this single-center, retrospective review of octogenarians who underwent simultaneous multivalve operations at our institution between 2019 and 2025, the primary outcome was in-hospital mortality. Secondary outcomes included postoperative complications, intensive care unit (ICU) and total hospital length of stay (LOS), and discharge disposition. Univariable analyses were performed to assess factors associated with survival and factors associated with discharge disposition among survivors (home vs skilled nursing facility). RESULTS: Forty-three patients (mean age, 82.0 years; 62.8% male; mean EuroSCORE II, 10.5%) underwent multivalve operations. At least 1 major comorbidity was present in all patients. Nine patients (20.9%) underwent redo sternotomy, and 6 (14%) underwent a triple-valve operation. In-hospital mortality occurred in 6 patients (14%). The need for mechanical circulatory support (MCS) was strongly associated with in-hospital mortality (P = .001), as were renal failure (P = .002), prolonged ventilation (P = .004), and prolonged ICU stay (P = .03). Redo sternotomy, triple-valve intervention, and concomitant coronary artery bypass grafting were not associated with increased mortality. Among 37 survivors, 21 (56.8%) were discharged home. Longer total LOS (P = .01), ICU LOS (P = .01), and transfusion requirement (P = .04) were significantly associated with skilled nursing facility (SNF) discharge. CONCLUSIONS: Multivalve operations in select octogenarians are feasible with a multidisciplinary approach. Need for MCS, renal failure, prolonged ventilation, and ICU LOS were associated with in-hospital mortality. Among survivors, transfusion requirement and longer ICU and total hospital LOS were associated with discharge to an SNF rather than home. CI - (c) 2026 The Author(s). FAU - Abdelrehim, Ahmed A AU - Abdelrehim AA AD - Division of Cardiothoracic Surgery, Department of Surgery, University of Alabama Heersink School of Medicine, Birmingham, Ala. FAU - Landrum, Archie AU - Landrum A AD - University of Alabama at Birmingham Heersink School of Medicine, Birmingham, Ala. FAU - Hansen-Estruch, Christophe AU - Hansen-Estruch C AD - Division of Cardiothoracic Surgery, Department of Surgery, University of Alabama Heersink School of Medicine, Birmingham, Ala. FAU - Holman, William AU - Holman W AD - Division of Cardiothoracic Surgery, Department of Surgery, University of Alabama Heersink School of Medicine, Birmingham, Ala. FAU - Davies, James E AU - Davies JE AD - Division of Cardiothoracic Surgery, Department of Surgery, University of Alabama Heersink School of Medicine, Birmingham, Ala. FAU - Vardas, Panos N AU - Vardas PN AD - Division of Cardiothoracic Surgery, Department of Surgery, University of Alabama Heersink School of Medicine, Birmingham, Ala. LA - eng PT - Journal Article DEP - 20260411 PL - Netherlands TA - JTCVS Open JT - JTCVS open JID - 101768541 PMC - PMC13316345 OTO - NOTNLM OT - aortic and mitral valve procedures OT - cardiac surgery in the elderly OT - combined valve surgery OT - early outcomes OT - frailty in cardiac surgery OT - geriatric cardiac care OT - heart failure OT - multivalve heart operation OT - octogenarians COIS- The authors reported no conflicts of interest. The Journal policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest. EDAT- 2026/07/01 06:34 MHDA- 2026/07/01 06:35 PMCR- 2026/04/11 CRDT- 2026/07/01 05:06 PHST- 2026/01/26 00:00 [received] PHST- 2026/03/22 00:00 [revised] PHST- 2026/04/06 00:00 [accepted] PHST- 2026/07/01 06:35 [medline] PHST- 2026/07/01 06:34 [pubmed] PHST- 2026/07/01 05:06 [entrez] PHST- 2026/04/11 00:00 [pmc-release] AID - S2666-2736(26)00232-9 [pii] AID - 101809 [pii] AID - 10.1016/j.xjon.2026.101809 [doi] PST - epublish SO - JTCVS Open. 2026 Apr 11;31:101809. doi: 10.1016/j.xjon.2026.101809. eCollection 2026 Jun. PMID- 42379709 OWN - NLM STAT- MEDLINE DCOM- 20260701 LR - 20260813 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 16 IP - 6 DP - 2026 Jun 30 TI - Cardiopulmonary interactions during paediatric mechanical ventilation: protocol for a scoping review. PG - e119949 LID - 10.1136/bmjopen-2026-119949 [doi] LID - e119949 AB - INTRODUCTION: The heart and lungs are closely linked anatomically and physiologically, sharing the thoracic cavity and jointly ensuring oxygenation and removal of carbon dioxide. With the introduction of positive pressure ventilation, significant changes in cardiopulmonary dynamics were noted. Guyton described these mechanisms of reduced venous return and cardiac output via elevated right atrial pressure. Mechanical ventilation, particularly positive pressure ventilation, is widely used in paediatric critical care, yet data on its clinical effects on children's circulation remain limited. Many principles deduced from experiments on animals and adult physiology are applied to critically ill children. This scoping review will aim to summarise current evidence on the effect of mechanical ventilation on the circulation in critically ill children and to identify knowledge gaps to address in future research. METHODS AND ANALYSIS: The scoping review will follow the Joanna Briggs Institute (JBI) protocol for scoping reviews. PubMed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL) and Web of Science Core Collection will be searched as well as clinical trial registries ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform. Studies will be included if they describe a cardiovascular outcome after changing any ventilatory parameter or mode. The search is scheduled for the first of June 2026, and we plan to finish the paper before 31 December 2026.All search results will be uploaded to EndNote where duplicate records will be identified and removed. Titles/abstracts will be screened by two independent reviewers based on inclusion criteria using the online software of Rayyan. Full texts of potentially relevant sources will be screened by two independent reviewers. Reasons for exclusions will be documented and disagreements resolved through discussion or a third reviewer. Data will be extracted by at least two reviewers using a tool developed by the team based on the JBI guidance. Describing and/or plotting of the results will be an iterative process, but adjustments will be clarified and tested against the PRISMA Extension for Scoping Reviews. ETHICS AND DISSEMINATION: Ethical approval from the Institutional Review Board is not required for this study since all investigations are being carried out on previously published manuscripts. There will be no involvement of new patients or other study participants of any kind. The review will be registered and the protocol published in order to maintain methodological transparency. Final results will be compiled and submitted for publication once the study has been completed and all data has been charted/analysed. CI - (c) Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. FAU - Hollander, Richard A AU - Hollander RA AUID- ORCID: 0000-0002-2168-0645 AD - Department of Paediatrics, Division of Paediatric Critical Care Medicine, University Medical Centre Groningen Beatrix Children's Hospital, Groningen, GR, Netherlands r.a.hollander@umcg.nl. AD - Critical Care, Anesthesiology, Peri-operative & Emergency Medicine (CAPE), University of Groningen, University Medical Centre Groningen, Groningen, GR, Netherlands. FAU - Ter Horst, Jeroen AU - Ter Horst J AD - Department of Paediatrics, Division of Paediatric Critical Care Medicine, University Medical Centre Groningen Beatrix Children's Hospital, Groningen, GR, Netherlands. FAU - van der Werf, Sjoukje AU - van der Werf S AD - Medical Library, University of Groningen, University Medical Centre Groningen, Groningen, GR, Netherlands. FAU - Kneyber, Martin Cj AU - Kneyber MC AD - Department of Paediatrics, Division of Paediatric Critical Care Medicine, University Medical Centre Groningen Beatrix Children's Hospital, Groningen, GR, Netherlands. AD - Critical Care, Anesthesiology, Peri-operative & Emergency Medicine (CAPE), University of Groningen, University Medical Centre Groningen, Groningen, GR, Netherlands. LA - eng PT - Journal Article DEP - 20260630 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 SB - IM MH - Humans MH - Scoping Reviews as Topic MH - *Respiration, Artificial/methods/adverse effects MH - Child MH - Research Design MH - Critical Illness/therapy MH - *Heart/physiopathology MH - *Lung/physiopathology PMC - PMC13330877 OTO - NOTNLM OT - Hemodynamics OT - Paediatric intensive & critical care OT - Review OT - Ventilators, Mechanical COIS- Competing interests: None declared. EDAT- 2026/07/01 00:35 MHDA- 2026/07/01 18:33 PMCR- 2026/06/30 CRDT- 2026/06/30 21:03 PHST- 2026/07/01 18:33 [medline] PHST- 2026/07/01 00:35 [pubmed] PHST- 2026/06/30 21:03 [entrez] PHST- 2026/06/30 00:00 [pmc-release] AID - bmjopen-2026-119949 [pii] AID - 10.1136/bmjopen-2026-119949 [doi] PST - epublish SO - BMJ Open. 2026 Jun 30;16(6):e119949. doi: 10.1136/bmjopen-2026-119949. PMID- 42378211 OWN - NLM STAT- MEDLINE DCOM- 20260630 LR - 20260813 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 21 IP - 6 DP - 2026 TI - Dynamic patterns of communication and workload during cardiac surgery: An explorative study. PG - e0352703 LID - 10.1371/journal.pone.0352703 [doi] LID - e0352703 AB - BACKGROUND: Effective communication amongst operating room (OR) teams is crucial for ensuring patient safety and optimizing surgical outcomes. This study aimed to investigate communication within the context of physiologically assessed workload during cardiac surgeries. Specifically, the relationship between team members' workload and both case-relevant and case-irrelevant communication exchanges was explored, as well as their association with the length of surgical phases. METHODS: Intraoperative communication exchanges were annotated from incision until skin closure across 24 recorded cardiac surgeries (>100h surgery time). OR team members wore heart rate monitors throughout the surgical procedures. HRV was calculated as the RMSSD across 5-minute non-overlapping windows. Mixed effect models were used to assess the relationship between workload and the frequency of communication exchanges across OR roles and surgical phases. RESULTS: Relevant communication was most frequent during the initiation and discontinuation of extracorporeal bypass, while case-irrelevant communication was most frequent during the final closing phase of surgery. Team members were more likely to engage in case-irrelevant communication during periods of reduced workload (chi2 = 30.15, p = .001). However, this did not necessarily align with the workload of other team members, as increased workload was associated with more frequent case-irrelevant communication initiated by other team members (chi2 = 5.97, p = .015). Workload and case-relevant communication had a significant effect on surgical phase length. CONCLUSIONS: The findings highlight the dynamic relationship between workload and intraoperative communication patterns. Integrating observational data with physiological indicators of workload appears a promising approach to studying team dynamics in the operating room, though further research is needed to advance the use of such methods for improving team performance. CI - Copyright: (c) 2026 Wietzorrek et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. FAU - Wietzorrek, Liam AU - Wietzorrek L AUID- ORCID: 0009-0000-8760-9326 AD - Department of Cardiothoracic Surgery, Heart Centre, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands. AD - Department of Artificial Intelligence, Bernoulli Institute of Mathematics, Computer Science and Artificial Intelligence, University of Groningen, Groningen, The Netherlands. FAU - Craenen, Eugenie AU - Craenen E AD - Department of Anaesthesiology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands. FAU - van Boven, Indy AU - van Boven I AD - Department of Artificial Intelligence, Bernoulli Institute of Mathematics, Computer Science and Artificial Intelligence, University of Groningen, Groningen, The Netherlands. FAU - Mariani, Massimo A AU - Mariani MA AD - Department of Cardiothoracic Surgery, Heart Centre, University of Utrecht, University Medical Centre Utrecht, Utrecht, The Netherlands. FAU - Cnossen, Fokie AU - Cnossen F AD - Department of Artificial Intelligence, Bernoulli Institute of Mathematics, Computer Science and Artificial Intelligence, University of Groningen, Groningen, The Netherlands. LA - eng PT - Journal Article DEP - 20260630 PL - United States TA - PLoS One JT - PloS one JID - 101285081 SB - IM MH - Humans MH - *Workload MH - *Cardiac Surgical Procedures MH - *Communication MH - Operating Rooms MH - *Patient Care Team MH - Heart Rate PMC - PMC13318023 COIS- The authors have declared that no competing interests exist. EDAT- 2026/06/30 18:39 MHDA- 2026/06/30 18:40 PMCR- 2026/06/30 CRDT- 2026/06/30 13:33 PHST- 2025/07/18 00:00 [received] PHST- 2026/06/12 00:00 [accepted] PHST- 2026/06/30 18:40 [medline] PHST- 2026/06/30 18:39 [pubmed] PHST- 2026/06/30 13:33 [entrez] PHST- 2026/06/30 00:00 [pmc-release] AID - PONE-D-25-35358 [pii] AID - 10.1371/journal.pone.0352703 [doi] PST - epublish SO - PLoS One. 2026 Jun 30;21(6):e0352703. doi: 10.1371/journal.pone.0352703. eCollection 2026. PMID- 42377562 OWN - NLM STAT- MEDLINE DCOM- 20260630 LR - 20261010 IS - 1432-1076 (Electronic) IS - 0340-6199 (Linking) VI - 185 IP - 7 DP - 2026 Jun 30 TI - Alagille syndrome case series: five new variants and two large deletions. LID - 542 [pii] LID - 10.1007/s00431-026-07204-x [doi] AB - Alagille syndrome (ALGS) is an autosomal dominant disorder characterized by intrahepatic bile duct insufficiency, cardiac, skeletal, ocular, and characteristic facial features, most commonly caused by pathogenic variants in the JAG1gene and, less frequently, in the NOTCH2 gene. This study aimed to expand the existing literature by reporting novel JAG variants identified in our cohort. This retrospective cross-sectional study included 17 patients diagnosed withALGS between 2010-2025 at the Pediatric Gastroenterology, Hepatology, and Nutrition Clinic of Inonu University Faculty of Medicine. Genetic analysis was performed in 12 patients using JAG1 gene sequencing (n = 6), a targeted cholestasis gene panel (n = 4), or whole-exome sequencing (n = 2). Symptom onset ages ranged from 1 to 150 days. Cholestasis was the most common initial presentation, observed in 13 patients (76.5%). Peripheral pulmonary stenosis was the most frequent cardiac anomaly, identified in 12 patients (70.6%). A molecular diagnosis was established in 12 patients, while five were diagnosed clinically due to the unavailability of genetic testing at presentation. All genetically tested patients harbored pathogenic variants in the JAG1 gene. Ten variants were point mutations and two were large deletions. Five point mutations were classified as novel, as they had not been previously reported in the literature or genomic databases. Additionally, two large deletions involving previously undescribed genomic regions were identified and reported for the first time. CONCLUSIONS: Alagille syndrome should be considered in patients with unexplained cholestasis, especially in populations with high rates of consanguineous marriage, and the diagnosis should be confirmed with genetic testing whenever possible. This study introduces 5 novel variants and two major deletions containing previously unidentified genomic regions to the literature for the first time. WHAT IS KNOWN: * Alagille syndrome (ALGS) is a multisystem disorder most commonly caused by pathogenic JAG1 variants. * Syndromic cholestasis requires early multidisciplinary evaluation and genetic confirmation. WHAT IS NEW: * Five point mutations were classified as novel, as they had not been previously reported in the literature or genomic databases. * Two large deletions involving previously undescribed genomic regions were identified and reported for the first time. CI - (c) 2026. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Varol, Fatma Ilknur AU - Varol FI AD - Department of Pediatric Gastroenterology, Hepatology and Nutrition, Inonu University Faculty of Medicine, Malatya, Turkiye. ilknur.varol@inonu.edu.tr. AD - Department of Pediatric Gastroenterology, Hepatology and Nutrition, Inonu University Faculty of Medicine, Malatya, Turkiye. ilknur.varol@inonu.edu.tr. FAU - Gungor, Sukru AU - Gungor S AUID- ORCID: 0000-0002-0433-5970 AD - Department of Pediatric Gastroenterology, Hepatology and Nutrition, Inonu University Faculty of Medicine, Malatya, Turkiye. FAU - Ekici, Cemal AU - Ekici C AUID- ORCID: 0000-0003-1872-3138 AD - Department of Medical Biology and Genetics, Inonu University Faculty of Medicine, Malatya, Turkiye. FAU - Tekedereli, Ibrahim AU - Tekedereli I AUID- ORCID: 0000-0002-3300-8020 AD - Department of Medical Biology and Genetics, Inonu University Faculty of Medicine, Malatya, Turkiye. FAU - Selimoglu, Mukadder Ayse AU - Selimoglu MA AUID- ORCID: 0000-0001-8533-8446 AD - Department of Pediatric Gastroenterology, Hepatology and Nutrition, Inonu University Faculty of Medicine, Malatya, Turkiye. FAU - Erdogan, Selcuk AU - Erdogan S AUID- ORCID: 0009-0008-0778-3163 AD - Department of Pediatric Gastroenterology, Hepatology and Nutrition, Inonu University Faculty of Medicine, Malatya, Turkiye. FAU - Gok, Emre AU - Gok E AUID- ORCID: 0000-0001-9458-8076 AD - Department of Pediatric Gastroenterology, Hepatology and Nutrition, Inonu University Faculty of Medicine, Malatya, Turkiye. LA - eng PT - Journal Article DEP - 20260630 PL - Germany TA - Eur J Pediatr JT - European journal of pediatrics JID - 7603873 RN - 0 (Jagged-1 Protein) RN - 0 (JAG1 protein, human) SB - IM MH - Humans MH - *Alagille Syndrome/genetics/diagnosis MH - Female MH - *Jagged-1 Protein/genetics MH - Male MH - Retrospective Studies MH - Infant MH - Cross-Sectional Studies MH - Infant, Newborn MH - Child, Preschool MH - Sequence Deletion MH - Point Mutation MH - Genetic Testing OTO - NOTNLM OT - Cholestasis OT - Intrahepatic bile duct paucity OT - JAG1 gene OT - Multisystem disorder OT - Pediatric liver disease COIS- Declarations. Ethics statement: The study was approved by the Inonu University Clinical Research Ethics Committee (Approval No: 2025/8664) and conducted in accordance with the Declaration of Helsinki. Competing interests: The authors declare no competing interests. EDAT- 2026/06/30 12:32 MHDA- 2026/06/30 12:33 CRDT- 2026/06/30 11:17 PHST- 2026/02/25 00:00 [received] PHST- 2026/06/22 00:00 [accepted] PHST- 2026/06/19 00:00 [revised] PHST- 2026/06/30 12:33 [medline] PHST- 2026/06/30 12:32 [pubmed] PHST- 2026/06/30 11:17 [entrez] AID - 10.1007/s00431-026-07204-x [pii] AID - 10.1007/s00431-026-07204-x [doi] PST - epublish SO - Eur J Pediatr. 2026 Jun 30;185(7):542. doi: 10.1007/s00431-026-07204-x. PMID- 42374503 OWN - NLM STAT- MEDLINE DCOM- 20260915 LR - 20260917 IS - 1748-717X (Electronic) IS - 1748-717X (Linking) VI - 21 IP - 1 DP - 2026 Jun 29 TI - Failure modes and effects analysis of LINAC-based stereotactic arrhythmia radioablation categorized by segmental targets. LID - 10.1186/s13014-026-02883-0 [doi] LID - 126 AB - BACKGROUND: Stereotactic arrhythmia radioablation (STAR) is an emerging treatment for refractory or recurrent arrhythmias. Compared with conventional stereotactic body radiotherapy (SBRT), STAR involves greater complexity in target delineation, motion management, and organs at risk (OARs) protection, yet it lacks established consensus clinical guidelines, and workflow-specific risk analyses remain limited. OBJECTIVE: To develop a C-arm linear accelerator (LINAC)-based STAR workflow and perform a failure modes and effects analysis (FMEA) with fault tree analysis (FTA), supplemented by an exploratory segment-based anatomical proximity analysis. METHODS: A multidisciplinary team constructed a process map for C-arm LINAC-based STAR and identified potential failure modes across the workflow. Risks were scored using occurrence, severity, and detectability to calculate risk priority numbers (RPNs), and FTA was used to analyze causal pathways. In a predefined exploratory imaging subgroup of eight patients with ventricular tachycardia and simulation-acquired coronary computed tomography angiography (CCTA), we divided the left ventricle according to the 17-segment model and measured the minimum distances from each segment to adjacent OARs as an anatomical surrogate of exposure likelihood. RESULTS: Seventy-nine failure modes were identified, of which 17 were classified as high risk. The highest-risk failure modes were concentrated in target delineation and motion-related steps, including inaccurate multimodal image registration (RPN 432), improper motion evaluation/management (RPN 336), and diagnostic error of arrhythmia substrate definition (RPN 320). In the exploratory imaging subgroup (n = 8), segmental spatial patterns were moderately consistent across patients, with most standard deviations of minimum distance below 2.0 cm, although variability remained for several segment-OAR relationships. Segments 4, 5, and 10 were each located within 2 cm of both the stomach and esophagus, indicating relatively higher anatomical proximity-related risk. CONCLUSION: In this FMEA of C-arm LINAC-based STAR, the principal high-risk workflow steps were concentrated in substrate definition, image registration, and motion management. The segment-based analysis provides an exploratory anatomical risk-mapping framework for OAR awareness. Further multicenter studies are needed to refine workflow risk prioritization and evaluate the clinical relevance of the segment-based anatomical findings. CLINICAL TRIAL NUMBER: Not applicable. CI - (c) 2026. The Author(s). FAU - Li, Jing AU - Li J AD - Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China. AD - Department of Radiotherapy Physics & Technology, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China. FAU - Wu, Yongchang AU - Wu Y AD - Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China. AD - Department of Radiotherapy Physics & Technology, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China. FAU - Chen, Qingyong AU - Chen Q AD - Department of Cardiology, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China. FAU - Guo, Hao AU - Guo H AD - College of Physics, Sichuan University, Chengdu, Sichuan, 610041, China. FAU - Luo, Ran AU - Luo R AD - School of Physics and Technology, Wuhan University, Wuhan, Hubei, 430072, China. FAU - Bai, Long AU - Bai L AD - Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China. AD - Department of Radiotherapy Physics & Technology, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China. FAU - Wei, Weige AU - Wei W AD - Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China. AD - Department of Radiotherapy Physics & Technology, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China. FAU - Hao, Yanmei AU - Hao Y AD - Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China. AD - Department of Radiotherapy Physics & Technology, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China. FAU - Yu, Hang AU - Yu H AD - Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China. AD - Department of Radiotherapy Physics & Technology, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China. FAU - Dai, Guyu AU - Dai G AD - Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China. AD - Department of Radiotherapy Physics & Technology, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China. FAU - Zhang, Xiangyu AU - Zhang X AD - Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China. AD - Department of Radiotherapy Physics & Technology, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China. FAU - Xiao, Qing AU - Xiao Q AD - Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China. AD - Department of Radiotherapy Physics & Technology, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China. FAU - Yang, Qing AU - Yang Q AD - Department of Cardiology, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China. FAU - Bai, Sen AU - Bai S AD - Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China. AD - Department of Radiotherapy Physics & Technology, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China. FAU - Li, Guangjun AU - Li G AUID- ORCID: 0000-0003-2054-1771 AD - Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China. gjnick829@sina.com. AD - Department of Radiotherapy Physics & Technology, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China. gjnick829@sina.com. LA - eng GR - 2023ZYD0098/Sichuan Provincial Science and Technology Support Program/ GR - 12205209/National Natural Science Foundation of China/ GR - 12475348/National Natural Science Foundation of China/ GR - 2022YF0900031SN/Chengdu Municipal Science and Technology Program/ GR - 2022SCUH0021/Sichuan University Innovation Research Project/ GR - 2022HXFH009/West China Hospital, Sichuan University/ PT - Journal Article DEP - 20260629 PL - England TA - Radiat Oncol JT - Radiation oncology (London, England) JID - 101265111 SB - IM MH - Humans MH - *Radiosurgery/methods MH - *Arrhythmias, Cardiac/surgery MH - *Radiotherapy Planning, Computer-Assisted/methods MH - *Particle Accelerators/instrumentation MH - Organs at Risk/radiation effects MH - *Healthcare Failure Mode and Effect Analysis PMC - PMC13576228 OTO - NOTNLM OT - Failure modes and effects analysis OT - Fault tree analysis OT - Quality improvement OT - Segmental targets OT - Stereotactic arrhythmia radioablation OT - Ventricular arrhythmia COIS- Declarations. Ethics approval and consent to participate: This retrospective analysis was conducted on data from a clinical trial that was approved by the Ethics Committee on Biomedical Research, West China Hospital of Sichuan University (Approval No: 2020 (Scientific Review No. 516)). All methods were carried out in accordance with the ethical standards of this committee and with the 1964 Helsinki declaration and its later amendments. Written informed consent was obtained from all individual participants in the original trial, which explicitly stipulated that their data could be used for future research and publication. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2026/06/30 06:31 MHDA- 2026/09/15 05:36 PMCR- 2026/06/29 CRDT- 2026/06/30 00:02 PHST- 2025/10/20 00:00 [received] PHST- 2026/06/22 00:00 [accepted] PHST- 2026/09/15 05:36 [medline] PHST- 2026/06/30 06:31 [pubmed] PHST- 2026/06/30 00:02 [entrez] PHST- 2026/06/29 00:00 [pmc-release] AID - 10.1186/s13014-026-02883-0 [pii] AID - 2883 [pii] AID - 10.1186/s13014-026-02883-0 [doi] PST - epublish SO - Radiat Oncol. 2026 Jun 29;21(1):126. doi: 10.1186/s13014-026-02883-0. PMID- 42372819 OWN - NLM STAT- MEDLINE DCOM- 20260805 LR - 20260828 IS - 2174-2030 (Electronic) IS - 0870-2551 (Linking) VI - 45 IP - 8 DP - 2026 Aug TI - An expert consensus statement on renal denervation for the management of hypertension endorsed by the Portuguese Association of Interventional Cardiology of the Portuguese Society of Cardiology (APIC-SPC) and the Portuguese Society of Hypertension (SPH). PG - 437-446 LID - S0870-2551(26)00204-0 [pii] LID - 10.1016/j.repc.2026.03.011 [doi] AB - This national expert consensus statement, endorsed by the Portuguese Association of Interventional Cardiology of the Portuguese Society of Cardiology (APIC-SPC) and the Portuguese Society of Hypertension (SPH), provides practical guidance on the appropriate use of renal denervation for blood pressure management in adults with uncontrolled hypertension in spite of optimally tolerated guideline-directed therapy and lifestyle measures. It synthesizes evidence from contemporary sham-controlled trials and large real-world registries, which show sustained blood pressure reductions with both radiofrequency and ultrasound systems, and a favorable and consistent safety profile, while acknowledging remaining uncertainties in long-term clinical outcomes and individual response prediction. The document emphasizes rigorous patient selection within a structured pathway coordinated by multidisciplinary hypertension teams. It outlines organizational requirements for centers performing renal denervation, key elements of pre-procedural imaging and peri-procedural management, and a standardized follow-up strategy using office, home, and ambulatory monitoring to enable timely therapy adjustment. Beyond resistant hypertension, this statement discusses carefully selected scenarios in which RDN may be considered as an adjunctive option, while reinforcing that renal denervation is not first-line therapy and should be integrated into a comprehensive hypertension care. This consensus aims to clarify for which patients renal denervation may be a viable therapeutic option, identify the main clinical and procedural considerations for its implementation, and promote its optimal and safe use through appropriate patient selection and multidisciplinary evaluation. CI - Copyright (c) 2026 Sociedade Portuguesa de Cardiologia. Publicado por Elsevier Espana, S.L.U. All rights reserved. FAU - Delgado Silva, Joana AU - Delgado Silva J AD - Cardiology Department, Coimbra's Hospital and University Center, Coimbra Local Health Unit, Portugal. Electronic address: joanadelgadosilva@gmail.com. FAU - Cunha, Vitoria AU - Cunha V AD - Internal Medicine Department, Garcia de Orta Hospital, Almada-Seixal Local Health Unit, Portugal. FAU - Nogueira-Silva, Luis AU - Nogueira-Silva L AD - Internal Medicine Department, Sao Joao Local Health Unit, Portugal; CINTESIS@RISE, Department of Community Medicine, Information and Health Decision Sciences (MEDCIDS), Faculty of Medicine, University of Porto, Portugal. FAU - Cale, Rita AU - Cale R AD - Cardiology Department, Garcia de Orta Hospital, Almada-Seixal Local Health Unit, Portugal. FAU - Abecasis, Francisca AU - Abecasis F AD - Internal Medicine Department, Garcia de Orta Hospital, Almada-Seixal Local Health Unit, Portugal. FAU - Batista, Goncalo AU - Batista G AD - Cardiology Department, Coimbra's Hospital and University Center, Coimbra Local Health Unit, Portugal. FAU - Mesquita Bastos, Jose AU - Mesquita Bastos J AD - Cardiology Department, Baixo Vouga Hospital Center, Aveiro Local Health Unit, Portugal. FAU - Almeida, Manuel AU - Almeida M AD - Cardiology Department, Santa Cruz Hospital, Lisboa Ocidental Local Health Unit, Portugal. FAU - Martos Goncalves, Fernando AU - Martos Goncalves F AD - Internal Medicine Department, Beatriz-Angelo Hospital, Loures Local Health Unit, Portugal. LA - eng LA - por PT - Consensus Statement PT - Journal Article DEP - 20260629 PL - Portugal TA - Rev Port Cardiol JT - Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology JID - 8710716 SB - IM MH - Humans MH - *Hypertension/surgery MH - *Kidney/innervation MH - *Sympathectomy OTO - NOTNLM OT - Catheter-based therapies OT - Desnervacao renal OT - Hipertensao OT - Hipertensao resistente OT - Hypertension OT - Multidisciplinar OT - Multidisciplinary OT - Renal denervation OT - Resistant hypertension OT - Selection OT - Selecao OT - Sistema nervoso simpatico OT - Sympathetic nervous system OT - Tratamentos dirigidos por cateter EDAT- 2026/06/30 00:32 MHDA- 2026/08/06 11:36 CRDT- 2026/06/29 19:28 PHST- 2025/12/02 00:00 [received] PHST- 2026/02/27 00:00 [revised] PHST- 2026/03/06 00:00 [accepted] PHST- 2026/08/06 11:36 [medline] PHST- 2026/06/30 00:32 [pubmed] PHST- 2026/06/29 19:28 [entrez] AID - S0870-2551(26)00204-0 [pii] AID - 10.1016/j.repc.2026.03.011 [doi] PST - ppublish SO - Rev Port Cardiol. 2026 Aug;45(8):437-446. doi: 10.1016/j.repc.2026.03.011. Epub 2026 Jun 29. PMID- 42371433 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260629 LR - 20260813 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 18 IP - 5 DP - 2026 May TI - Multidisciplinary Content Validation of the GiriMok Point-of-Care Protocol for Neonatal Cyanotic Congenital Heart Disease. PG - e109877 LID - 10.7759/cureus.109877 [doi] LID - e109877 AB - Background Neonatal cyanotic congenital heart disease is a time-critical emergency requiring immediate bedside decision-making. Current guidelines lack a validated, comprehensive point-of-care (POC) protocol suitable for frontline clinicians in diverse settings. The GiriMok Protocol was developed to bridge this gap. This study aimed to develop and establish the content validity of the GiriMok POC Protocol through a rigorous four-phase iterative multidisciplinary expert validation process. Methodology This four-phase study comprised two external validation phases and two author-led refinement phases. Phase 1 involved 18 multidisciplinary experts using a 33-parameter mixed-methods instrument. Phase 2 consisted of focused revalidation by five specialists (neonatologists and a pediatric cardiologist) using a 16-item instrument with modified kappa (k*) computation. Phases 3 and 4 involved evidence-referenced enhancements against 2023-2025 guidelines and final quality assurance. Content Validity Index (CVI) was calculated at item (I-CVI) and scale (S-CVI/Ave) levels. Results In total, 18 unique validators participated across 24 episodes. Phase 1 yielded an S-CVI/Ave of 0.927, with all items meeting the I-CVI >/=0.78 threshold and zero safety concerns. Phase 2 achieved perfect scores (S-CVI/Ave = k* = 1.000) following the integration of a 22-item revision agenda. In total, 35 expert-informed corrections resulted in the final publication-ready GiriMok V4.0. Conclusions The GiriMok POC Protocol achieved unanimous multidisciplinary validation. The perfect Phase 2 CVI demonstrates methodological rigor and responsiveness to expert feedback. The protocol is now positioned for prospective clinical evaluation and national dissemination as a neonatal emergency decision-support tool. CI - Copyright (c) 2026, Gupta et al. FAU - Gupta, Girish AU - Gupta G AD - Neonatology, Graphic Era Institute of Medical Sciences, Dehradun, IND. FAU - Ahmed, Syed Moiz AU - Ahmed SM AD - Neonatology, Graphic Era Institute of Medical Sciences, Dehradun, IND. FAU - Joshi, Richa AU - Joshi R AD - Neonatology and Pediatrics, Graphic Era Institute of Medical Sciences, Dehradun, IND. FAU - Shubham, Shantanu AU - Shubham S AD - Neonatology, Graphic Era Institute of Medical Sciences, Dehradun, IND. LA - eng PT - Journal Article DEP - 20260529 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC13310469 OTO - NOTNLM OT - clinical decision support OT - content validity OT - content validity index OT - echocardiography OT - iterative validation OT - neonatal cyanotic congenital heart disease OT - point-of-care protocol OT - prostaglandin e(1) OT - pulse oximetry COIS- Human subjects: Informed consent for treatment and open access publication was obtained or waived by all participants in this study. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. EDAT- 2026/06/29 12:32 MHDA- 2026/06/29 12:33 PMCR- 2026/05/29 CRDT- 2026/06/29 11:30 PHST- 2026/05/28 00:00 [accepted] PHST- 2026/06/29 12:33 [medline] PHST- 2026/06/29 12:32 [pubmed] PHST- 2026/06/29 11:30 [entrez] PHST- 2026/05/29 00:00 [pmc-release] AID - 10.7759/cureus.109877 [doi] PST - epublish SO - Cureus. 2026 May 29;18(5):e109877. doi: 10.7759/cureus.109877. eCollection 2026 May. PMID- 42370157 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260629 LR - 20260813 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 16 DP - 2026 TI - Optimising individualised treatment decisions for locally advanced thymoma: precision selection of minimally invasive surgery and postoperative adjuvant radiotherapy. PG - 1839919 LID - 10.3389/fonc.2026.1839919 [doi] LID - 1839919 AB - Locally advanced thymoma is characterised by significant heterogeneity and complex biological behaviour, and its optimal treatment strategy has long been controversial. The integration of minimally invasive surgical techniques and advanced radiotherapy technologies is refining the standard treatment mode towards individualised decision-making. This article reviews the latest evidence-based medical progress regarding the selection of surgical approaches and postoperative adjuvant treatment decisions for locally advanced thymoma in recent years. Regarding surgical treatment, the application boundaries of robotic and thoracoscopic minimally invasive surgery in locally advanced cases are analysed, indicating that when complete tumour resection (R0) is ensured, minimally invasive surgery can yield oncological outcomes non-inferior to those of open surgery and significantly reduce perioperative complications. Regarding radiation therapy, the evolution of indications for postoperative radiotherapy (PORT) is discussed, emphasising the critical role of risk stratification models based on WHO histological classification, resection margin status, and tumour burden in guiding radiotherapy decisions, and the potential of new technologies such as proton therapy in reducing cardiac toxicity is evaluated. This article aims to construct a dynamic individualised treatment decision-making framework by integrating multidisciplinary perspectives, providing a theoretical basis and practical guidance for clinicians to balance oncological efficacy and patient quality of life. CI - Copyright (c) 2026 Peng, Zhang, Huang, Ding, Huang, Mao, Wu and Zhu. FAU - Peng, Xuyang AU - Peng X AD - Department of Cardiothoracic Surgery, The First Affiliated Hospital of Lishui University, Lishui People's Hospital, Lishui, Zhejiang, China. FAU - Zhang, Qi AU - Zhang Q AD - Hangzhou Normal University, Hangzhou, Zhejiang, China. FAU - Huang, Bin AU - Huang B AD - Department of Cardiothoracic Surgery, The First Affiliated Hospital of Lishui University, Lishui People's Hospital, Lishui, Zhejiang, China. FAU - Ding, Jianyang AU - Ding J AD - Department of Cardiothoracic Surgery, The First Affiliated Hospital of Lishui University, Lishui People's Hospital, Lishui, Zhejiang, China. FAU - Huang, Mingjiang AU - Huang M AD - Department of Cardiothoracic Surgery, The First Affiliated Hospital of Lishui University, Lishui People's Hospital, Lishui, Zhejiang, China. FAU - Mao, Chaofan AU - Mao C AD - Department of Cardiothoracic Surgery, The First Affiliated Hospital of Lishui University, Lishui People's Hospital, Lishui, Zhejiang, China. FAU - Wu, Xuhui AU - Wu X AD - Department of Cardiothoracic Surgery, The First Affiliated Hospital of Lishui University, Lishui People's Hospital, Lishui, Zhejiang, China. FAU - Zhu, Xi AU - Zhu X AD - Department of Head and Neck Surgery, the Fifth Hospital Affiliated to Wenzhou Medical University, Lishui Central Hospital, Lishui, Zhejiang, China. LA - eng PT - Journal Article PT - Review DEP - 20260611 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC13294657 OTO - NOTNLM OT - individualised treatment OT - locally advanced thymoma OT - minimally invasive surgery OT - multidisciplinary team OT - postoperative radiotherapy COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/06/29 16:10 MHDA- 2026/06/29 16:11 PMCR- 2026/06/11 CRDT- 2026/06/29 07:04 PHST- 2026/03/26 00:00 [received] PHST- 2026/05/02 00:00 [revised] PHST- 2026/05/04 00:00 [accepted] PHST- 2026/06/29 16:11 [medline] PHST- 2026/06/29 16:10 [pubmed] PHST- 2026/06/29 07:04 [entrez] PHST- 2026/06/11 00:00 [pmc-release] AID - 10.3389/fonc.2026.1839919 [doi] PST - epublish SO - Front Oncol. 2026 Jun 11;16:1839919. doi: 10.3389/fonc.2026.1839919. eCollection 2026. PMID- 42368216 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260629 LR - 20260813 IS - 1520-765X (Print) IS - 1554-2815 (Electronic) IS - 1520-765X (Linking) VI - 28 IP - Suppl 7 DP - 2026 Jun TI - Impella-protected PCI in a post-CABG patient with advanced biventricular dysfunction and mitral regurgitation. PG - vii58-vii67 LID - 10.1093/eurheartjsupp/suag066 [doi] AB - Patients with advanced coronary artery disease (CAD), severely reduced left ventricular (LV) ejection fraction, and prior coronary artery bypass grafting (CABG) present with complex revascularization challenges requiring individualized, multidisciplinary decision-making and pre-procedural strategy planning. Protected percutaneous coronary intervention (PCI) using percutaneous temporary mechanical circulatory support, such as the Impella microaxial flow pump, may enable complex revascularization in carefully selected patients at high risk of peri-procedural haemodynamic compromise. We describe a male patient with advanced ischaemic cardiomyopathy, severe functional mitral regurgitation, and complex multivessel CAD, including chronic total occlusion (CTO) of the left anterior descending artery, following prior CABG. After Heart Team discussion and in the context of prohibitive surgical risk, a staged strategy was carefully planned pre-procedurally and then pursued with mitral transcatheter edge-to-edge repair, followed by prophylactic Impella-assisted PCI. Under haemodynamic support, retrograde CTO PCI via a patent saphenous vein graft was performed with drug-eluting stent implantation and intravascular ultrasound-confirmed optimization, achieving TIMI 3 flow. The patient remained haemodynamically stable, with an uneventful post-procedural course and no vascular or cardiac complications. This case illustrates how a staged Impella-protected PCI strategy can facilitate revascularization in post-CABG patients with advanced LV dysfunction and be integrated into a timely, planned, and patient-tailored approach accounting for ventricular function, valvular disease, and complex coronary anatomy when surgery is not feasible. CI - (c) The Author(s) 2026. Published by Oxford University Press on behalf of the European Society of Cardiology. FAU - Ayoub, Mohamed AU - Ayoub M AD - Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW, Ruhr-Universitat Bochum, Georgstrasse 11, 32545 Bad Oeynhausen, Germany. FAU - Ezad, Saad AU - Ezad S AD - British Heart Foundation Centre of Research Excellence, School of Cardiovascular and Metabolic Medicine and Sciences, King's College London, Rayne Institute, St Thomas' Hospital, London SE1 7EH, UK. AD - Dorset Heart Centre, Royal Bournemouth Hospital, Bournemouth BH7 7DW, UK. FAU - Lorusso, Roberto AU - Lorusso R AUID- ORCID: 0000-0002-1777-2045 AD - Cardio-Thoracic Surgery Department, Maastricht University Medical Centre+, 6620 ER Maastricht, The Netherlands. AD - Cardiovascular Research Institute Maastricht (CARIM), 6229 ER Maastricht, The Netherlands. FAU - Vriesendorp, Pieter AU - Vriesendorp P AD - Cardiovascular Research Institute Maastricht (CARIM), 6229 ER Maastricht, The Netherlands. FAU - Vandenbriele, Christophe AU - Vandenbriele C AUID- ORCID: 0000-0003-2338-8346 AD - Heart Center AZORG, Campus Moorselbaan, Moorselbaan 164, 9300 Aalst, Belgium. AD - Cardiac Intensive Care, Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London SW3 6NP, UK. AD - Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, Exhibition Road, London SW7 2AZ, UK. FAU - Panoulas, Vasileios AU - Panoulas V AD - Harefield Hospital, Royal Brompton and Harefield Hospitals, part of Guy's and St Thomas' NHS Foundation Trust, Hill End Road, UB9 6JH, Harefield, London, UK. AD - Cardiovascular Sciences, National Heart and Lung Institute, Imperial College London, Royal Brompton Campus, Guy Scadding Building, Cale Street, London SW3 6LY, UK. LA - eng PT - Journal Article DEP - 20260421 PL - England TA - Eur Heart J Suppl JT - European heart journal supplements : journal of the European Society of Cardiology JID - 100886647 PMC - PMC13294563 OTO - NOTNLM OT - Chronic total occlusion OT - High-risk PCI OT - Impella OT - Ischaemic cardiomyopathy OT - Mitral regurgitation OT - Multivessel CAD OT - Protected PCI OT - Reduced LVEF COIS- Conflict of interest: M.A. has received grants or contracts from Johnson & Johnson MedTech and consulting fees from Johnson & Johnson MedTech, Asahi, Boston Scientific, IMDS, Cordis, Teleflex, OrbusNeich, and Terumo. He has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Johnson & Johnson MedTech, Asahi, Boston Scientific, IMDS, Cordis, Teleflex, OrbusNeich, and Terumo. He has also received support for attending meetings and/or travel from Johnson & Johnson MedTech, Boston Scientific, Asahi, Teleflex, Cordis, OrbusNeich, IMDS, and Terumo. S.E. has nothing to disclose. R.L. has received grants from Medtronic and LivaNova and consulting fees from Medtronic, LivaNova, and Johnson & Johnson MedTech HeartRecovery. He has received payment or honoraria for speaker fees from Abiomed and travel support from Medtronic and Johnson & Johnson MedTech HeartRecovery. He has also participated on Advisory Boards for Eurosets, Xenios, and ChinaBridge Medical, and has received materials from Medtronic and LivaNova. P.V. has received grants or contracts from Abbott and Edwards Lifesciences and consulting fees from Medtronic and Abbott. He has also received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Abbott and Medtronic. C.V. has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Johnson & Johnson MedTech. He has received support for attending meetings and/or travel from Johnson & Johnson MedTech. V.P. has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Johnson & Johnson MedTech and has participated on an Advisory Board for Johnson & Johnson MedTech. EDAT- 2026/06/29 13:10 MHDA- 2026/06/29 13:11 PMCR- 2026/04/21 CRDT- 2026/06/29 06:45 PHST- 2026/06/29 13:11 [medline] PHST- 2026/06/29 13:10 [pubmed] PHST- 2026/06/29 06:45 [entrez] PHST- 2026/04/21 00:00 [pmc-release] AID - suag066 [pii] AID - 10.1093/eurheartjsupp/suag066 [doi] PST - epublish SO - Eur Heart J Suppl. 2026 Apr 21;28(Suppl 7):vii58-vii67. doi: 10.1093/eurheartjsupp/suag066. eCollection 2026 Jun. PMID- 42368215 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260629 LR - 20260926 IS - 1520-765X (Print) IS - 1554-2815 (Electronic) IS - 1520-765X (Linking) VI - 28 IP - Suppl 7 DP - 2026 Jun TI - Contemporary evidence in protected percutaneous coronary intervention: a case-based review. PG - vii48-vii57 LID - 10.1093/eurheartjsupp/suag006 [doi] AB - High-risk percutaneous coronary intervention (PCI) in patients with markedly reduced left ventricular ejection fraction (LVEF) carries a substantial risk of haemodynamic collapse, creating an unmet need for strategies that allow complete, optimized revascularization without compromising safety. These cases often fall within the Class IIb-III indications of the 2024 European Society of Cardiology (ESC) Chronic Coronary Syndromes and Revascularization Guidelines, which support PCI in patients with severe left ventricular (LV) dysfunction, complex or multivessel disease, and surgical ineligibility or refusal after Heart Team evaluation. For such individuals, protected PCI using percutaneous mechanical circulatory support (MCS), namely microaxial flow pumps (mAFP), may enable procedural completeness and improve outcomes. Herein, we present a case of a 66-year-old male that illustrates the expanding role of protected PCI in patients who meet Class IIb-III ESC Guidelines criteria, with severe LV dysfunction, multivessel or left main disease, and surgical refusal or ineligibility. Contemporary evidence supports the use of mAFP-assisted PCI to maintain forward flow and ventricular unloading during complex revascularization, thereby minimizing ischaemic and haemodynamic instability. Such an approach allows the operator to pursue meticulous lesion preparation, imaging-guided optimization, and bifurcation PCI techniques while preserving perfusion and procedural safety. In appropriately selected cases, Impella-supported high-risk PCI represents a safe and effective option. It enables complete, optimized revascularization and can promote early functional recovery, bridging a crucial therapeutic gap in contemporary revascularization practice. CI - (c) The Author(s) 2026. Published by Oxford University Press on behalf of the European Society of Cardiology. FAU - De Filippo, Ovidio AU - De Filippo O AUID- ORCID: 0000-0002-4915-9501 AD - Division of Cardiology, Cardiovascular and Thoracic Department, Citta della Salute e della Scienza (AOU), Corso Bramante 88/90, 10126 Turin, Italy. AD - Cardio-Thoracic Surgery Department, Maastricht University Medical Centre+, 6620 ER Maastricht, The Netherlands. FAU - Leick, Jurgen AU - Leick J AD - Heart Centre Trier, Hospital of the Brothers of Mercy, Nordallee 1, 54292 Trier, Germany. FAU - Tarantini, Giuseppe AU - Tarantini G AD - Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Interventional Cardiology Unit, 35121 Padova PD, Italy. FAU - Heng, Ee Ling AU - Heng EL AD - Department of Cardiology, Royal Brompton and Harefield Hospitals, Sydney Street, London SW3 6NP, UK. FAU - Tavazzi, Guido AU - Tavazzi G AUID- ORCID: 0000-0002-9560-5138 AD - Department of Clinical-Surgical, Diagnostic, and Pediatric Sciences, University of Pavia, Viale Golgi 19, 27100 Pavia, Italy. AD - Intensive Care Unit, Fondazione IRCCS Policlinico San Matteo, Viale Golgi 19, 27100 Pavia, Italy. FAU - Lorusso, Roberto AU - Lorusso R AUID- ORCID: 0000-0002-1777-2045 AD - Cardio-Thoracic Surgery Department, Maastricht University Medical Centre+, 6620 ER Maastricht, The Netherlands. AD - Cardiovascular Research Institute Maastricht (CARIM), 6229 ER Maastricht, The Netherlands. FAU - Haneya, Assad AU - Haneya A AD - Heart Centre Trier, Hospital of the Brothers of Mercy, Nordallee 1, 54292 Trier, Germany. FAU - Werner, Nikos AU - Werner N AD - Heart Centre Trier, Hospital of the Brothers of Mercy, Nordallee 1, 54292 Trier, Germany. LA - eng PT - Journal Article DEP - 20260224 PL - England TA - Eur Heart J Suppl JT - European heart journal supplements : journal of the European Society of Cardiology JID - 100886647 PMC - PMC13294559 OTO - NOTNLM OT - Haemodynamic support OT - High-risk PCI OT - IABP OT - Impella CP OT - Left main disease OT - Multivessel CAD OT - Protected PCI OT - Reduced LVEF OT - VA-ECMO COIS- Conflict of interest: O.D.F. has nothing to disclose. J.L. has received support for the present manuscript from Johnson & Johnson. He has received consulting fees from Johnson & Johnson MedTech, Shockwave Medical, Meril, Boston Scientific, AstraZeneca, and Boehringer Ingelheim. He has also received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Shockwave Medical, Boston Scientific, Boehringer Ingelheim, and AstraZeneca. He has received support for travel from Johnson & Johnson. G.T. has received honoraria for lectures from Jhonson & Jhonson and GADA. E.L.H. has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Abbott and Edwards Lifesciences. G.T. has nothing to disclose. R.L. has received grants and materials from Medtronic and LivaNova. He has received consulting fees from Medtronic, LivaNova, and Johnson & Johnson MedTech HeartRecovery. He has received payment or honoraria for speaker fees from Abiomed and travel support from Medtronic and Johnson & Johnson MedTech HeartRecovery. He also participates on the Advisory Board for Eurosets, Xenois, and ChinaBridge Medical. A.H. has nothing to disclose. N.W. has received grants or contracts from Johnson & Johnson MedTech and Shockwave Medical. He has received consulting fees from Johnson & Johnson MedTech, Boston Scientific, Shockwave Medical, and Edwards Lifesciences. He has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Johnson & Johnson MedTech, Boston Scientific, Shockwave Medical, and Edwards Lifesciences. He has received payment for expert testimony from Elixir Medical. He has also received support for travel from Johnson & Johnson MedTech, Boston Scientific, Shockwave Medical, and Edwards Lifesciences. He has participated in a Data Safety Monitoring Board or Advisory Board for Johnson & Johnson MedTech and Cingular. He has also held a leadership or fiduciary role for the European Association of Percutaneous Cardiovascular Interventions. EDAT- 2026/06/29 12:32 MHDA- 2026/06/29 12:33 PMCR- 2026/02/24 CRDT- 2026/06/29 06:45 PHST- 2026/06/29 12:33 [medline] PHST- 2026/06/29 12:32 [pubmed] PHST- 2026/06/29 06:45 [entrez] PHST- 2026/02/24 00:00 [pmc-release] AID - suag006 [pii] AID - 10.1093/eurheartjsupp/suag006 [doi] PST - epublish SO - Eur Heart J Suppl. 2026 Feb 24;28(Suppl 7):vii48-vii57. doi: 10.1093/eurheartjsupp/suag006. eCollection 2026 Jun. PMID- 42368214 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260629 LR - 20260813 IS - 1520-765X (Print) IS - 1554-2815 (Electronic) IS - 1520-765X (Linking) VI - 28 IP - Suppl 7 DP - 2026 Jun TI - Protected complex high-risk indicated percutaneous coronary intervention in severe left ventricular dysfunction: an illustrative case highlighting patient selection, procedural planning, execution, and device management. PG - vii14-vii19 LID - 10.1093/eurheartjsupp/suag008 [doi] AB - Ischaemic left ventricular dysfunction (ILVD) is the leading cause of heart failure and is commonly encountered in cardiac catheterization laboratories. Patients presenting with ILVD are typically older and often have complex coronary anatomy, making revascularization challenging. Although coronary artery bypass grafting improves long-term survival in patients with ILVD compared with medical therapy, the benefit emerges only after a decade and appears limited to younger patients, leaving many older, frail, or comorbid individuals at untenable risk. Such patients are frequently considered for complex high-risk indicated percutaneous coronary intervention (CHIP), where the primary determinant of procedural risk is intra-procedural haemodynamic instability due to limited ventricular reserve and anticipated prolonged ischaemia. Registry data underscore the heightened risk in patients with multiple CHIP features, including ejection fraction /=10). Model discrimination was assessed by the C-statistic and calibration by the Hosmer-Lemeshow test. Subtype comparisons (FWR vs. VSR), early (3 days) rupture analysis, and in-hospital mortality correlates were also evaluated. RESULTS: Patients with CR were older (69.6 +/- 8.5 vs. 59.5 +/- 11.7 years, P < 0.001), more frequently female (40.8% vs. 12.2%, P < 0.001), and had longer onset-to-door times (median 48 vs. 5 h, P < 0.001). In multivariable analysis, absence of emergency percutaneous coronary intervention (PCI) [odds ratio (OR) = 8.23, 95% confidence interval (CI) 3.45-19.66], Killip class III-IV (OR = 6.82, 95% CI 2.68-17.35), female sex (OR = 3.41, 95% CI 1.41-8.26), and lower serum albumin (OR = 0.84 per g/L, 95% CI 0.77-0.91) were independently associated with CR. FWR showed markedly higher mortality than VSR (97.4% vs. 57.1%, P < 0.001). Early rupture (3 days, 60.6%) was associated with lower albumin and markedly delayed presentation, appearing to correspond to different temporal clinical patterns. Surgical repair was the only factor associated with lower in-hospital mortality in the multivariable model (OR = 0.06, 95% CI 0.01-0.36, P = 0.002). CONCLUSIONS: Absence of emergency PCI, Killip class III-IV, female sex, and hypoalbuminemia were independently associated with CR after AMI. FWR and VSR showed different clinical and hemodynamic patterns. Surgical repair was associated with lower in-hospital mortality among selected CR patients, supporting prompt multidisciplinary evaluation while recognizing the likelihood of survivor and indication bias. CI - (c) 2026 Zhang, Huang, Wang, Yu, Zhang and Liu. FAU - Zhang, Dan AU - Zhang D AD - Department of Clinical Laboratory, Wuhan Asia General Hospital, Wuhan Asia General Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, China. FAU - Huang, Chaojie AU - Huang C AD - Department of Critical Care Medicine, Wuhan Asia General Hospital, Wuhan Asia General Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, China. FAU - Wang, Xiaosu AU - Wang X AD - Department of Clinical Laboratory, Wuhan Asia General Hospital, Wuhan Asia General Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, China. FAU - Yu, Jingdan AU - Yu J AD - Department of Clinical Laboratory, Wuhan Asia General Hospital, Wuhan Asia General Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, China. FAU - Zhang, Litao AU - Zhang L AD - Department of Clinical Laboratory, Wuhan Asia General Hospital, Wuhan Asia General Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, China. FAU - Liu, Bo AU - Liu B AD - Department of Critical Care Medicine, Wuhan Asia General Hospital, Wuhan Asia General Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, China. LA - eng PT - Journal Article DEP - 20260610 PL - Switzerland TA - Front Cardiovasc Med JT - Frontiers in cardiovascular medicine JID - 101653388 PMC - PMC13290571 OTO - NOTNLM OT - acute myocardial infarction OT - cardiac rupture OT - case-control study OT - free wall rupture OT - risk factors OT - ventricular septal rupture COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/06/26 16:10 MHDA- 2026/06/26 16:11 PMCR- 2026/06/10 CRDT- 2026/06/26 04:38 PHST- 2026/03/11 00:00 [received] PHST- 2026/05/04 00:00 [revised] PHST- 2026/05/26 00:00 [accepted] PHST- 2026/06/26 16:11 [medline] PHST- 2026/06/26 16:10 [pubmed] PHST- 2026/06/26 04:38 [entrez] PHST- 2026/06/10 00:00 [pmc-release] AID - 10.3389/fcvm.2026.1827832 [doi] PST - epublish SO - Front Cardiovasc Med. 2026 Jun 10;13:1827832. doi: 10.3389/fcvm.2026.1827832. eCollection 2026. PMID- 42356150 OWN - NLM STAT- MEDLINE DCOM- 20260626 LR - 20260813 IS - 1648-9144 (Electronic) IS - 1010-660X (Print) IS - 1010-660X (Linking) VI - 62 IP - 6 DP - 2026 Jun 11 TI - Transcatheter Aortic Valve Implantation in Cancer Patients: A Contemporary Review of the Specific Challenges, the Outcomes, Risk Stratification, and Decision-Making. LID - 10.3390/medicina62061139 [doi] LID - 1139 AB - The coexistence of cancer and severe aortic stenosis (AS) is increasing as a result of population aging and substantial improvements in cancer survival. Transcatheter aortic valve implantation (TAVI) has transformed the management of AS; however, patients with active malignancy or a history of cancer remain markedly under-represented in pivotal randomized trials. This under-representation has resulted in persistent uncertainty regarding patient selection, risk stratification, and the expected benefit of TAVI in this growing and clinically heterogeneous population. This review provides a comprehensive and contemporary synthesis of the evidence on TAVI in patients with cancer, integrating cardiovascular (CV), oncologic, and geriatric perspectives. Available data on epidemiological overlap, cancer-specific procedural challenges, and short- and long-term outcomes following TAVI are critically examined, with particular emphasis on distinctions between active cancer and cancer survivorship. Key modifiers of risk and benefit-including prior thoracic radiotherapy, competing thrombotic and bleeding risk, immunosuppression, frailty, sarcopenia, and nutritional status-are discussed in detail. Limitations of conventional surgical risk scores in oncology populations are highlighted, underscoring the need for individualized assessment beyond traditional CV metrics. Across registries and meta-analyses, TAVI is associated with high procedural success and comparable short-term outcomes in patients with and without cancer. Excess mortality observed during mid- and long-term follow-up is driven predominantly by non-CV causes related to malignancy rather than valve-related complications. Importantly, patients with cancer in remission demonstrate outcomes similar to those of non-cancer populations, whereas prognosis in active cancer is strongly influenced by disease stage, biology, and competing risks. Overall, cancer diagnosis alone should not preclude consideration of TAVI. Optimal management requires multidisciplinary, goal-oriented decision-making that integrates oncologic prognosis, functional status, and patients' priorities. As cancer survivorship continues to expand, prospective studies, integrated risk stratification tools, and closer alignment between cardio-oncology and structural heart programs are essential to guide evidence-based and equitable care. FAU - Keramida, Kalliopi AU - Keramida K AUID- ORCID: 0000-0002-9533-6951 AD - Cardiology Department, General Anticancer Oncological Hospital, Agios Savvas, 11522 Athens, Greece. FAU - Mavraganis, Georgios AU - Mavraganis G AD - Department of Clinical Therapeutics, Alexandra Hospital, School of Medical, National and Kapodistrian University of Athens, 80 Vas. Sofias Str., 11528 Athens, Greece. FAU - Masoura, Constantina AU - Masoura C AD - Department of Cardiology, General Hospital of Athens "Laiko", 11527 Athens, Greece. FAU - Aznaouridis, Konstantinos AU - Aznaouridis K AUID- ORCID: 0000-0002-0706-4424 AD - Department of Cardiology, "Hippokration" General Hospital of Athens, 11527 Athens, Greece. FAU - Androutsopoulou, Vasiliki AU - Androutsopoulou V AUID- ORCID: 0009-0005-2445-0879 AD - Department of Cardiothoracic Surgery, University Hospital of Larissa, 41110 Larissa, Greece. FAU - Tsioufis, Konstantinos AU - Tsioufis K AD - Department of Cardiology, "Hippokration" General Hospital of Athens, 11527 Athens, Greece. LA - eng PT - Journal Article PT - Review DEP - 20260611 PL - Switzerland TA - Medicina (Kaunas) JT - Medicina (Kaunas, Lithuania) JID - 9425208 SB - IM MH - Humans MH - *Transcatheter Aortic Valve Replacement/methods MH - *Neoplasms/complications MH - Risk Assessment/methods MH - *Aortic Valve Stenosis/surgery/complications MH - Decision Making MH - Treatment Outcome MH - Risk Factors PMC - PMC13304342 OTO - NOTNLM OT - aortic stenosis OT - cancer OT - cardio-oncology OT - frailty OT - multidisciplinary decision-making OT - thoracic radiotherapy OT - transcatheter aortic valve implantation COIS- The authors declare no conflicts of interest. EDAT- 2026/06/26 13:10 MHDA- 2026/06/27 07:10 PMCR- 2026/06/11 CRDT- 2026/06/26 01:16 PHST- 2026/02/21 00:00 [received] PHST- 2026/06/06 00:00 [revised] PHST- 2026/06/09 00:00 [accepted] PHST- 2026/06/27 07:10 [medline] PHST- 2026/06/26 13:10 [pubmed] PHST- 2026/06/26 01:16 [entrez] PHST- 2026/06/11 00:00 [pmc-release] AID - medicina62061139 [pii] AID - medicina-62-01139 [pii] AID - 10.3390/medicina62061139 [doi] PST - epublish SO - Medicina (Kaunas). 2026 Jun 11;62(6):1139. doi: 10.3390/medicina62061139. PMID- 42356015 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260626 LR - 20260813 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 15 IP - 12 DP - 2026 Jun 22 TI - Surgical and Transcatheter Approach of a Failed Mitral Valve Repair: A Comprehensive Review on Selecting the Most Suitable Approach. LID - 10.3390/jcm15124847 [doi] LID - 4847 AB - Mitral valve regurgitation is the second most common valvular heart disease in Europe, and an estimated 10% of individuals older than 75 years have severe mitral regurgitation. Mitral valve repair is the preferred strategy to treat mitral regurgitation and is associated with better outcomes than mitral valve replacement. Despite the proven efficacy of surgical repair, available data in functional aetiologies reported a non-negligible rate of echocardiographically detected severe mitral regurgitation within ten years of the index procedure, in some cases resulting in redo interventions. Data on the optimal management of patients with failed mitral repair remain limited. The aim of this review is to present the available approaches for treating failed mitral valve repair and to describe criteria for selecting the most appropriate strategy on the basis of the underlying mechanism of repair failure, with respect to possible surgical re-repair and novel transcatheter edge-to-edge repair techniques in the presence of favourable mitral valve anatomies. FAU - Nerla, Roberto AU - Nerla R AUID- ORCID: 0000-0002-9065-3261 AD - Interventional Cardiology Unit, Maria Cecilia Hospital GVM Care and Research, 48033 Cotignola, Italy. AD - Department of Experimental Diagnostic and Surgical Medicine (DIMEC), University of Bologna, 40126 Bologna, Italy. FAU - Mandas, Martina AU - Mandas M AD - Interventional Cardiology Unit, Maria Cecilia Hospital GVM Care and Research, 48033 Cotignola, Italy. FAU - Pillitteri, Gianluca AU - Pillitteri G AD - Interventional Cardiology Unit, Maria Cecilia Hospital GVM Care and Research, 48033 Cotignola, Italy. FAU - Mikus, Elisa AU - Mikus E AUID- ORCID: 0000-0003-2892-8700 AD - Cardiac Surgery Unit, Maria Cecilia Hospital GVM Care and Research, 48033 Cotignola, Italy. FAU - Bernardoni, Niki AU - Bernardoni N AD - Cardiac Surgery Unit, Maria Cecilia Hospital GVM Care and Research, 48033 Cotignola, Italy. FAU - Squeri, Angelo AU - Squeri A AUID- ORCID: 0000-0001-9115-5443 AD - Interventional Cardiology Unit, Maria Cecilia Hospital GVM Care and Research, 48033 Cotignola, Italy. FAU - Pacini, Davide AU - Pacini D AD - Cardiac Surgery Unit, Policlinico Sant'Orsola, University of Bologna, 40138 Bologna, Italy. FAU - Savini, Carlo AU - Savini C AUID- ORCID: 0000-0003-4197-7486 AD - Cardiac Surgery Unit, Maria Cecilia Hospital GVM Care and Research, 48033 Cotignola, Italy. FAU - Castriota, Fausto AU - Castriota F AD - Interventional Cardiology Unit, Maria Cecilia Hospital GVM Care and Research, 48033 Cotignola, Italy. LA - eng PT - Journal Article PT - Review DEP - 20260622 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC13301895 OTO - NOTNLM OT - heart team OT - mitral regurgitation OT - mitral valve repair OT - mitral valve replacement OT - surgical mitral valve re-repair OT - transcatheter edge-to-edge repair OT - transcatheter mitral valve replacement OT - valve-in-ring OT - valve-in-valve COIS- The authors declare no conflicts of interest. EDAT- 2026/06/26 06:39 MHDA- 2026/06/26 06:40 PMCR- 2026/06/22 CRDT- 2026/06/26 01:16 PHST- 2026/05/08 00:00 [received] PHST- 2026/06/11 00:00 [revised] PHST- 2026/06/12 00:00 [accepted] PHST- 2026/06/26 06:40 [medline] PHST- 2026/06/26 06:39 [pubmed] PHST- 2026/06/26 01:16 [entrez] PHST- 2026/06/22 00:00 [pmc-release] AID - jcm15124847 [pii] AID - jcm-15-04847 [pii] AID - 10.3390/jcm15124847 [doi] PST - epublish SO - J Clin Med. 2026 Jun 22;15(12):4847. doi: 10.3390/jcm15124847. PMID- 42355959 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260626 LR - 20260813 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 15 IP - 12 DP - 2026 Jun 20 TI - Safety of Invasive Procedures During Adult Extracorporeal Membrane Oxygenation: A Systematic Review. LID - 10.3390/jcm15124792 [doi] LID - 4792 AB - Background/Objectives: Adult patients supported with extracorporeal membrane oxygenation (ECMO) frequently require invasive diagnostic, therapeutic, surgical, or bedside procedures during ongoing extracorporeal support. These procedures are clinically challenging because ECMO-related anticoagulation, platelet dysfunction, acquired coagulopathy, and circuit-related coagulation activation may increase both bleeding and thrombotic risks. This systematic review evaluated the safety of invasive procedures performed during adult ECMO support, excluding tracheostomy/tracheotomy because this procedure has recently been addressed in a dedicated systematic review. Methods: A systematic search of PubMed/MEDLINE and Scopus was performed. The final bibliographic data collection was completed in April 2026. Studies were eligible if they included adult ECMO or extracorporeal life support patients undergoing invasive procedures during ongoing ECMO support, or with ECMO used as procedural support, and reported at least one procedure-specific safety outcome. Primary outcomes were procedure-related complications, bleeding, major bleeding, and transfusion requirements. Secondary outcomes included thrombotic and circuit-related complications, oxygenator exchange, reintervention, reoperation, procedural failure, ECMO duration, intensive care unit and hospital length of stay, and mortality. Results: The final qualitative synthesis included 46 studies, comprising 26 studies from PubMed/MEDLINE and 20 additional unique studies from Scopus. Included procedures were grouped into six domains: airway, bronchoscopic, and tracheobronchial procedures; thoracic surgery and lung resections; abdominal surgery, gastrointestinal endoscopy, and decompressive laparotomy; lung transplantation and perioperative extracorporeal life support; cardiovascular, vascular, pulmonary embolism-related, and mechanical circulatory support-related procedures; and mixed non-cardiac surgery. Airway and bronchoscopic procedures generally showed high procedural success in selected cohorts, although registry-level tracheal procedure data reported hemorrhagic complications in 26.0% and surgical-site bleeding in 13.0%. Emergency thoracic and abdominal procedures carried the highest bleeding, transfusion, reintervention, and mortality burden. Lung transplantation studies showed that ECMO can be integrated into perioperative pathways, but hemothorax, transfusion, thromboembolism, and anticoagulation strategy remained central safety issues. Conclusions: Invasive procedures during adult ECMO are feasible in selected patients and experienced centers, but procedural safety varies markedly by procedure type, urgency, baseline disease severity, and anticoagulation strategy. A procedure-centered, multidisciplinary approach with individualized anticoagulation management and careful planning is essential. FAU - Neri, Giuseppe AU - Neri G AUID- ORCID: 0009-0003-2281-6529 AD - Department of Medical and Surgical Sciences, "Magna Graecia" University of Catanzaro, 88100 Catanzaro, Italy. FAU - Mazza, Giuseppe AU - Mazza G AUID- ORCID: 0009-0003-9109-4929 AD - Department of Medical and Surgical Sciences, "Magna Graecia" University of Catanzaro, 88100 Catanzaro, Italy. FAU - Mastrangelo, Helenia AU - Mastrangelo H AD - ASP Catanzaro, 88100 Catanzaro, Italy. FAU - Ielapi, Jessica AU - Ielapi J AUID- ORCID: 0009-0009-8291-284X AD - Department of Medical and Surgical Sciences, "Magna Graecia" University of Catanzaro, 88100 Catanzaro, Italy. FAU - Longhini, Federico AU - Longhini F AUID- ORCID: 0000-0002-6970-7202 AD - Department of Medical and Surgical Sciences, "Magna Graecia" University of Catanzaro, 88100 Catanzaro, Italy. FAU - Bosco, Vincenzo AU - Bosco V AUID- ORCID: 0009-0001-3351-4265 AD - Department of Medical and Surgical Sciences, "Magna Graecia" University of Catanzaro, 88100 Catanzaro, Italy. FAU - Russo, Alessandro AU - Russo A AD - Department of Medical and Surgical Sciences, "Magna Graecia" University of Catanzaro, 88100 Catanzaro, Italy. FAU - Serapide, Francesca AU - Serapide F AUID- ORCID: 0000-0002-5555-3732 AD - Department of Medical and Surgical Sciences, "Magna Graecia" University of Catanzaro, 88100 Catanzaro, Italy. FAU - Aquila, Isabella AU - Aquila I AUID- ORCID: 0000-0002-2481-6050 AD - Department of Medical and Surgical Sciences, "Magna Graecia" University of Catanzaro, 88100 Catanzaro, Italy. FAU - Sacco, Matteo Antonio AU - Sacco MA AD - Department of Medical and Surgical Sciences, "Magna Graecia" University of Catanzaro, 88100 Catanzaro, Italy. FAU - Caroleo, Zaninni AU - Caroleo Z AUID- ORCID: 0009-0002-1805-7921 AD - Department of Pharmacy and Health and Nutrition Sciences, University of Calabria, 87036 Cosenza, Italy. FAU - Bruni, Andrea AU - Bruni A AD - Department of Pharmacy and Health and Nutrition Sciences, University of Calabria, 87036 Cosenza, Italy. FAU - Garofalo, Eugenio AU - Garofalo E AD - Department of Medical and Surgical Sciences, "Magna Graecia" University of Catanzaro, 88100 Catanzaro, Italy. LA - eng PT - Journal Article PT - Review DEP - 20260620 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC13302331 OTO - NOTNLM OT - ECMO OT - abdominal surgery OT - airway procedures OT - bleeding OT - extracorporeal life support OT - extracorporeal membrane oxygenation OT - invasive procedures OT - lung transplantation OT - thoracic surgery OT - thrombosis OT - transfusion COIS- The authors declare no conflicts of interest. EDAT- 2026/06/26 06:39 MHDA- 2026/06/26 06:40 PMCR- 2026/06/20 CRDT- 2026/06/26 01:16 PHST- 2026/05/14 00:00 [received] PHST- 2026/06/04 00:00 [revised] PHST- 2026/06/18 00:00 [accepted] PHST- 2026/06/26 06:40 [medline] PHST- 2026/06/26 06:39 [pubmed] PHST- 2026/06/26 01:16 [entrez] PHST- 2026/06/20 00:00 [pmc-release] AID - jcm15124792 [pii] AID - jcm-15-04792 [pii] AID - 10.3390/jcm15124792 [doi] PST - epublish SO - J Clin Med. 2026 Jun 20;15(12):4792. doi: 10.3390/jcm15124792. PMID- 42355931 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260626 LR - 20260813 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 15 IP - 12 DP - 2026 Jun 18 TI - Kickstarting the First Coronary Artery Bypass Graft Program in Papua New Guinea-History Made, Yet a Long Journey Ahead. LID - 10.3390/jcm15124763 [doi] LID - 4763 AB - Background/Objectives: Papua New Guinea has a population of over 10 million, with its public cardiac surgical service provided by only one tertiary center. Despite the climbing burden of ischemic heart disease, no CABG operation has been performed before 2025 due to limited local surgical capacity. An international collaboration was planned in order to launch a CABG program in the country. Methods: Three cases were shortlisted after a multidisciplinary team discussion. A team-based "On-the-job" mentoring strategy was employed to facilitate skill transfer. The operation was carried out in a "twinning" fashion, with each role of the surgical team being taken up by "a pair"-the trainer (visiting team) and the learner (local team). The trainer demonstrated key skills and tips in the first case, and the "pair" switched positions in the following cases to maximize hands-on learning. The last case was performed entirely by the local team. Results: Three patients underwent CABG operations in this pilot program. A total of 2.33 grafts/case were performed on average, with no 30-day mortality. There were no major complications except for one patient developing right middle cerebral artery infarct on postoperative day 5. The patient was discharged one month later after achieving functional recovery and was started on anticoagulation therapy. Conclusions: International collaborations with strategic planning can play a critical role in starting new cardiac surgical programs in low-middle-income countries, with acceptable surgical outcomes. History has been made with the first-ever CABG operation successfully performed in Papua New Guinea. The journey ahead to sustain local cardiac surgical capacity and to provide safe and accessible cardiac surgical care for the country remains challenging. FAU - Zhu, Ling AU - Zhu L AUID- ORCID: 0009-0004-9316-6153 AD - Department of Cardiothoracic Surgery, National Heart Centre Singapore, 5 Hospital Drive, Singapore 169609, Singapore. FAU - Chua, Kim Chai AU - Chua KC AD - Department of Cardiothoracic Surgery, National Heart Centre Singapore, 5 Hospital Drive, Singapore 169609, Singapore. FAU - Wang, Daobo AU - Wang D AD - Department of Cardiothoracic Surgery, National Heart Centre Singapore, 5 Hospital Drive, Singapore 169609, Singapore. FAU - Kanasa, Daniel AU - Kanasa D AD - Department of Cardiothoracic Surgery, Port Moresby General Hospital, Boroko 111, National Capital District, Port Moresby 111, Papua New Guinea. FAU - Karu, Arvin Wesley AU - Karu AW AUID- ORCID: 0000-0002-7936-3642 AD - Department of Anesthesiology, Port Moresby General Hospital, Boroko 111, National Capital District, Port Moresby 111, Papua New Guinea. FAU - Ng, Oriana AU - Ng O AD - Department of Anesthesiology, Block 2 Level 2 Singapore General Hospital, Singapore 169608, Singapore. FAU - Tapaua, Noah AU - Tapaua N AD - Department of Cardiothoracic Surgery, Port Moresby General Hospital, Boroko 111, National Capital District, Port Moresby 111, Papua New Guinea. FAU - Chua, Yeow Leng AU - Chua YL AUID- ORCID: 0009-0003-0963-3402 AD - Department of Cardiothoracic Surgery, National Heart Centre Singapore, 5 Hospital Drive, Singapore 169609, Singapore. LA - eng PT - Journal Article DEP - 20260618 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC13300736 OTO - NOTNLM OT - CABG OT - Papua New Guinea OT - cardiac surgery program OT - low- and middle-income country COIS- The authors declare no conflicts of interest. EDAT- 2026/06/26 13:10 MHDA- 2026/06/26 13:11 PMCR- 2026/06/18 CRDT- 2026/06/26 01:16 PHST- 2026/05/04 00:00 [received] PHST- 2026/05/31 00:00 [revised] PHST- 2026/06/15 00:00 [accepted] PHST- 2026/06/26 13:11 [medline] PHST- 2026/06/26 13:10 [pubmed] PHST- 2026/06/26 01:16 [entrez] PHST- 2026/06/18 00:00 [pmc-release] AID - jcm15124763 [pii] AID - jcm-15-04763 [pii] AID - 10.3390/jcm15124763 [doi] PST - epublish SO - J Clin Med. 2026 Jun 18;15(12):4763. doi: 10.3390/jcm15124763. PMID- 42353806 OWN - NLM STAT- MEDLINE DCOM- 20260626 LR - 20260823 IS - 2073-4425 (Electronic) IS - 2073-4425 (Linking) VI - 17 IP - 6 DP - 2026 May 31 TI - Multimodal Sequencing and Reanalysis Approaches to End the Diagnostic Odyssey of Individuals with Suspected Rare Monogenic Diseases. LID - 10.3390/genes17060647 [doi] LID - 647 AB - BACKGROUND/OBJECTIVES: Genomic testing has transformed rare-disease diagnostics, yet a substantial proportion of individuals remain without a molecular diagnosis even after short-read exome sequencing (SR-ES) or short-read genome sequencing (SR-GS) and repeated conventional analysis. METHODS: To address this persistent gap, we evaluated a coordinated multimodal reanalysis framework for deeply investigated families with suspected monogenic disease. Six families (20 individuals; 8 affected individuals) that had remained unsolved after prior comprehensive testing were reviewed prospectively in weekly interdisciplinary case conferences over one year. Available data included SR-ES, SR-GS, long-read genome sequencing (LR-GS), RNA-seq, optical genome mapping, mobile-element analysis, and mitochondrial genome analysis. The goal was not to test a single modality in isolation, but to assess whether systematic escalation across complementary assays plus continued reinterpretation could improve case resolution. RESULTS: Three families (50%) achieved a reportable molecular diagnosis, two (33%) yielded strong candidate findings requiring additional evidence, and one (17%) remained without a definitive new molecular diagnosis, although reinterpretation of a previously identified NOTCH3 variant provided a possible partial explanation. Resolved cases included compound-heterozygous variants in KLHL40, a 119 kb multi-exon deletion in TTN, and a recurrent insertion in RNU4-2. Candidate findings included biallelic NARS2 variants and a 1.3 kb intragenic deletion involving ZEB2. Functional transcriptomic analyses supported the KLHL40 and TTN diagnoses but did not demonstrate a splicing consequence for the candidate NARS2 intronic variant in cardiac tissue. CONCLUSIONS: This small pilot cohort is not intended to estimate general diagnostic yield, but it demonstrates that a coordinated multimodal framework can reveal different sources of added value, including structural variant discovery, orthogonal functional support, and reinterpretation of existing short-read data as knowledge evolves. These findings underscore that archived short-read exome and genome data can retain substantial diagnostic value years after initial testing, particularly when reanalyzed with updated pipelines, expanded disease gene knowledge, and orthogonal multimodal evidence. Adoption of iterative, team-based multimodal strategies may help resolve the most complex unsolved rare-disease cases. FAU - Brownstein, Catherine A AU - Brownstein CA AUID- ORCID: 0000-0002-7371-0340 AD - The Manton Center for Orphan Disease Research, Division of Genetics and Genomics, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA. FAU - Madden, Jill A AU - Madden JA AUID- ORCID: 0000-0002-7045-1232 AD - The Manton Center for Orphan Disease Research, Division of Genetics and Genomics, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA. FAU - Shao, Wanqing AU - Shao W AD - Children's Rare Disease Collaborative, Boston Children's Hospital, Boston, MA 02115, USA. FAU - Genetti, Casie A AU - Genetti CA AUID- ORCID: 0000-0003-4173-9947 AD - The Manton Center for Orphan Disease Research, Division of Genetics and Genomics, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA. FAU - Chin, Jason AU - Chin J AUID- ORCID: 0000-0003-4394-2455 AD - GeneDx, LLC, Gaithersburg, MD 20877, USA. FAU - Ustach, Vincent D AU - Ustach VD AUID- ORCID: 0000-0001-8299-3998 AD - GeneDx, LLC, Gaithersburg, MD 20877, USA. FAU - Wojcik, Monica H AU - Wojcik MH AUID- ORCID: 0000-0002-8162-5031 AD - The Manton Center for Orphan Disease Research, Division of Genetics and Genomics, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA. FAU - Madden, Anna AU - Madden A AD - The Manton Center for Orphan Disease Research, Division of Genetics and Genomics, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA. FAU - Edisis, Nathaniel AU - Edisis N AD - The Manton Center for Orphan Disease Research, Division of Genetics and Genomics, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA. FAU - Li, Heng AU - Li H AD - Department of Data Science, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA. FAU - Johnson, Daniel A AU - Johnson DA AD - GeneDx, LLC, Gaithersburg, MD 20877, USA. FAU - McWalter, Kirsty AU - McWalter K AD - GeneDx, LLC, Gaithersburg, MD 20877, USA. FAU - Noya, Jessica AU - Noya J AD - GeneDx, LLC, Gaithersburg, MD 20877, USA. FAU - Schmitz-Abe, Klaus AU - Schmitz-Abe K AD - The Manton Center for Orphan Disease Research, Division of Genetics and Genomics, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA. AD - Division of Neonatology, Department of Pediatrics, University of Miami Miller School of Medicine, Holtz Children's Hospital, Jackson Health System, Miami, FL 33136, USA. FAU - Rockowitz, Shira AU - Rockowitz S AD - The Manton Center for Orphan Disease Research, Division of Genetics and Genomics, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA. AD - Children's Rare Disease Collaborative, Boston Children's Hospital, Boston, MA 02115, USA. FAU - Agrawal, Pankaj B AU - Agrawal PB AD - The Manton Center for Orphan Disease Research, Division of Genetics and Genomics, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA. AD - Division of Neonatology, Department of Pediatrics, University of Miami Miller School of Medicine, Holtz Children's Hospital, Jackson Health System, Miami, FL 33136, USA. FAU - Newman, Scott AU - Newman S AD - GeneDx, LLC, Gaithersburg, MD 20877, USA. FAU - Devaney, Joseph M AU - Devaney JM AUID- ORCID: 0009-0003-7977-4577 AD - GeneDx, LLC, Gaithersburg, MD 20877, USA. FAU - Kruszka, Paul AU - Kruszka P AD - GeneDx, LLC, Gaithersburg, MD 20877, USA. AD - Division of Pediatric Genetics, University of Virginia School of Medicine, Charlottesville, VA 22903, USA. FAU - Beggs, Alan H AU - Beggs AH AUID- ORCID: 0000-0001-8818-0568 AD - The Manton Center for Orphan Disease Research, Division of Genetics and Genomics, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA. LA - eng GR - U54HD090255/Eunice Kennedy Shriver National Institute of Child Health and Human Development/ GR - NA/The Manton Center for Orphan Disease Research/ GR - NA/GeneDX/ GR - NA/Boston Children's Hospital Children's Rare Disease Collaborative/ PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20260531 PL - Switzerland TA - Genes (Basel) JT - Genes JID - 101551097 SB - IM MH - Humans MH - *Rare Diseases/genetics/diagnosis MH - Exome Sequencing/methods MH - Female MH - Male MH - *Genetic Testing/methods MH - High-Throughput Nucleotide Sequencing/methods PMC - PMC13299716 OTO - NOTNLM OT - RNA-seq OT - diagnostic odyssey OT - iterative reanalysis OT - long-read sequencing OT - multimodal genomics OT - rare disease OT - variant interpretation COIS- J.C., V.D.U., D.A.J., K.M., J.N., S.N., J.M.D., and P.K. are or were employees and/or shareholders of GeneDx, LLC. The remaining authors declare no competing interests. EDAT- 2026/06/26 06:38 MHDA- 2026/06/27 04:10 PMCR- 2026/05/31 CRDT- 2026/06/26 01:08 PHST- 2026/02/28 00:00 [received] PHST- 2026/04/22 00:00 [revised] PHST- 2026/04/30 00:00 [accepted] PHST- 2026/06/27 04:10 [medline] PHST- 2026/06/26 06:38 [pubmed] PHST- 2026/06/26 01:08 [entrez] PHST- 2026/05/31 00:00 [pmc-release] AID - genes17060647 [pii] AID - genes-17-00647 [pii] AID - 10.3390/genes17060647 [doi] PST - epublish SO - Genes (Basel). 2026 May 31;17(6):647. doi: 10.3390/genes17060647. PMID- 42350254 OWN - NLM STAT- Publisher LR - 20260625 IS - 1878-0938 (Electronic) IS - 1878-0938 (Linking) DP - 2026 Jun 17 TI - Baseline TRI-SCORE for risk stratification before tricuspid transcatheter edge-to-edge repair: A systematic review and meta-analysis. LID - S1553-8389(26)00275-7 [pii] LID - 10.1016/j.carrev.2026.06.010 [doi] AB - BACKGROUND: Transcatheter edge-to-edge repair (TEER) has expanded treatment options for severe tricuspid regurgitation (TR), but outcomes remain heterogeneous and patient selection remains challenging. TRI-SCORE, a disease-specific score developed for isolated tricuspid valve surgery, may help identify high-risk patients before tricuspid TEER. We performed a systematic review and meta-analysis evaluating the association between baseline TRI-SCORE and outcomes after tricuspid TEER. METHODS: MEDLINE and Embase were searched from inception through January 2026. Eligible studies included adults undergoing tricuspid TEER and reported outcomes according to baseline TRI-SCORE category, most commonly >/=6 versus <6. Random-effects models were used to calculate pooled risk ratios (RRs) with 95% confidence intervals (CIs). RESULTS: Five observational studies including 2074 patients were included. Higher TRI-SCORE was associated with greater all-cause mortality at in-hospital/30-day (RR, 3.17; 95% CI, 1.71-5.89), 3-month (RR, 4.03; 95% CI, 2.62-6.17), 6-month (RR, 2.97; 95% CI, 2.05-4.32), and 1-year follow-up (RR, 2.62; 95% CI, 1.88-3.66). Higher TRI-SCORE was also associated with lower likelihood of residual TR grade /= 15 pmol/L (approximately 125 pg/mL; P < .001). Potential predictors were first selected using least absolute shrinkage and selection operator (LASSO) regression, after which multivariable logistic regression was performed to construct a nomogram for predicting HF risk in patients with T2DM. The multivariable model indicated that ST-T abnormalities, NT-proBNP, ischemic heart disease, and atrial fibrillation were independently related to HF (all P < .05). The nomogram exhibited strong apparent discriminatory ability together with satisfactory calibration, suggesting that NT-proBNP-based risk stratification may be useful for HF screening in individuals with T2DM. CI - Copyright (c) 2026 the Author(s). Published by Wolters Kluwer Health, Inc. FAU - Zhang, Zhe AU - Zhang Z AD - College of Integrated Circuits, Taiyuan University of Technology, Taiyuan, China. FAU - Li, Dengao AU - Li D AUID- ORCID: 0009-0002-6529-0654 AD - College of Computer Science and Technology (College of Data Science), Taiyuan University of Technology, Taiyuan, China. FAU - Zhao, Jumin AU - Zhao J AD - College of Computer Science and Technology (College of Data Science), Taiyuan University of Technology, Taiyuan, China. FAU - Ma, Huiting AU - Ma H AD - College of Computer Science and Technology (College of Data Science), Taiyuan University of Technology, Taiyuan, China. FAU - Wang, Fei AU - Wang F AD - College of Computer Science and Technology (College of Data Science), Taiyuan University of Technology, Taiyuan, China. FAU - Hao, Qinglian AU - Hao Q AD - Department of Cardiovascular Medicine, Shanxi Provincial Integrated TCM and WM Hospital, Taiyuan , China. LA - eng GR - YDZJSX2022A011/Central Government Guided Local Science and Technology Development Fund Project/ GR - 62027819/National Major Scientific Research Instrument Development Project of China/ GR - 202102020101004/Key Research and Development Projects of Shanxi Province/ PT - Journal Article PT - Validation Study PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R RN - 114471-18-0 (Natriuretic Peptide, Brain) RN - 0 (pro-brain natriuretic peptide (1-76)) RN - 0 (Peptide Fragments) SB - IM MH - Humans MH - *Heart Failure/diagnosis/epidemiology/complications MH - Female MH - *Diabetes Mellitus, Type 2/complications/epidemiology MH - *Nomograms MH - Aged MH - Retrospective Studies MH - Male MH - Natriuretic Peptide, Brain/blood MH - Risk Assessment MH - Risk Factors MH - Peptide Fragments/blood MH - Middle Aged MH - Logistic Models PMC - PMC13286452 OTO - NOTNLM OT - LASSO OT - NT-proBNP OT - heart failure OT - logistic regression OT - nomogram OT - risk prediction OT - screening OT - type 2 diabetes mellitus COIS- The authors have no conflicts of interest to disclose. EDAT- 2026/06/23 11:36 MHDA- 2026/06/23 18:33 PMCR- 2026/06/19 CRDT- 2026/06/23 01:02 PHST- 2026/03/06 00:00 [received] PHST- 2026/05/31 00:00 [accepted] PHST- 2026/06/23 18:33 [medline] PHST- 2026/06/23 11:36 [pubmed] PHST- 2026/06/23 01:02 [entrez] PHST- 2026/06/19 00:00 [pmc-release] AID - 00005792-202606190-00028 [pii] AID - MD-D-26-03596 [pii] AID - 10.1097/MD.0000000000049341 [doi] PST - ppublish SO - Medicine (Baltimore). 2026 Jun 19;105(25):e49341. doi: 10.1097/MD.0000000000049341. PMID- 42331656 OWN - NLM STAT- MEDLINE DCOM- 20260903 LR - 20260903 IS - 1768-3122 (Electronic) IS - 0248-8663 (Linking) VI - 47 IP - 9 DP - 2026 Sep TI - Heart involvements in systemic sclerosis beyond pulmonary hypertension: From conduction, rhythm and function defects to coronary artery disease. PG - 500-508 LID - S0248-8663(26)00630-2 [pii] LID - 10.1016/j.revmed.2026.06.005 [doi] AB - Systemic sclerosis (SSc) is a rare systemic disease characterised by progressive fibrosis, vasculopathy, and immune dysregulation, resulting in multiorgan damage. Independently of pulmonary arterial hypertension, cardiac involvement, encompassing myocardial fibrosis, coronary microvascular dysfunction, arrhythmias, conduction disorders, pericardial and valvular disease, and heart failure, represents a frequently underestimated cause of morbidity and mortality. Clinically manifest cardiac disease is observed in 15 to 35% of patients, while subclinical dysfunction is detectable in approximately 70% when advanced screening tools are employed. The annual incidence of sudden cardiac death is estimated at between 1.0% and 3.3%, exceeding the general-population risk by more than tenfold. The pathophysiological framework rests on coronary microvascular dysfunction driven by endothelial injury, ischaemia-reperfusion cycles, and TGF-beta-mediated replacement fibrosis, potentiated by autonomic nervous system imbalance and activation of the renin-angiotensin-aldosterone system. Electrocardiographic abnormalities, detectable in 25 to 85% of patients, are independent predictors of mortality, while diastolic dysfunction, present in 18 to 62% of cases, constitutes a robust prognostic marker. Cardiac magnetic resonance imaging has transformed subclinical detection, revealing late gadolinium enhancement fibrosis in the majority of screened patients without a prior cardiovascular diagnosis. Management requires a multidisciplinary approach, integrating SSc-specific adaptation of guideline-directed heart failure therapies, immunosuppression targeting inflammatory and fibrotic pathways, arrhythmia management with implantable devices, and EULAR-recommended cardiovascular risk reduction. This narrative review synthesises current evidence on the epidemiology, pathogenesis, diagnostic evaluation, and therapeutic strategies of cardiac involvement in SSc, highlighting the need for early, systematic, risk-stratified screening and the establishment of dedicated multidisciplinary cardiac teams. CI - Copyright (c) 2026 Societe Nationale Francaise de Medecine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved. FAU - Barile, Raffaele AU - Barile R AD - Rheumatology Unit, Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy. Electronic address: raffaele_barile.552733@unifg.it. FAU - Rotondo, Cinzia AU - Rotondo C AD - Rheumatology Unit, Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy. FAU - Giancaspro, Giulio AU - Giancaspro G AD - Rheumatology Unit, Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy. FAU - Rella, Valeria AU - Rella V AD - Rheumatology Unit, Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy. FAU - Cantatore, Francesco P AU - Cantatore FP AD - Rheumatology Unit, Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy. FAU - Corrado, Addolorata AU - Corrado A AD - Rheumatology Unit, Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy. LA - eng PT - Journal Article PT - Review DEP - 20260622 PL - France TA - Rev Med Interne JT - La Revue de medecine interne JID - 8101383 SB - IM MH - Humans MH - *Scleroderma, Systemic/complications/epidemiology/physiopathology/diagnosis/therapy MH - Hypertension, Pulmonary/etiology/epidemiology/complications/diagnosis MH - Arrhythmias, Cardiac/etiology/diagnosis/epidemiology MH - *Coronary Artery Disease/etiology/diagnosis/epidemiology/therapy MH - *Heart Diseases/etiology/diagnosis/epidemiology/therapy MH - Heart Conduction System/physiopathology OTO - NOTNLM OT - Arrhythmia OT - Arythmie OT - Atteinte cardiaque OT - Cardiac involvement OT - Fibrose myocardique OT - Heart failure OT - Insuffisance cardiaque OT - Multidisciplinary management OT - Myocardial fibrosis OT - Prise en charge multidisciplinaire OT - Sclerodermie systemique OT - Systemic sclerosis COIS- Disclosure of interest The authors declare that they have no competing interest. EDAT- 2026/06/23 00:34 MHDA- 2026/09/03 23:36 CRDT- 2026/06/22 21:57 PHST- 2026/04/26 00:00 [received] PHST- 2026/06/01 00:00 [revised] PHST- 2026/06/03 00:00 [accepted] PHST- 2026/09/03 23:36 [medline] PHST- 2026/06/23 00:34 [pubmed] PHST- 2026/06/22 21:57 [entrez] AID - S0248-8663(26)00630-2 [pii] AID - 10.1016/j.revmed.2026.06.005 [doi] PST - ppublish SO - Rev Med Interne. 2026 Sep;47(9):500-508. doi: 10.1016/j.revmed.2026.06.005. Epub 2026 Jun 22. PMID- 42331413 OWN - NLM STAT- MEDLINE DCOM- 20260623 LR - 20260725 IS - 1876-7605 (Electronic) IS - 1936-8798 (Linking) VI - 19 IP - 12 DP - 2026 Jun 22 TI - Leaflet Modification to Mitigate Coronary Obstruction Risk During TAVR: Results From the LOFTER-TAVR Registry. PG - 1639-1649 LID - S1936-8798(26)01531-1 [pii] LID - 10.1016/j.jcin.2026.05.011 [doi] AB - BACKGROUND: Coronary obstruction (CO) is a rare but life-threatening complication of transcatheter aortic valve replacement (TAVR). Leaflet modification techniques have been developed to mitigate this risk; however, real-world evidence remains scarce. OBJECTIVES: The aim of this study was to report procedural and 30-day outcomes of patients at high risk for CO undergoing leaflet modification. METHODS: LOFTER-TAVR (Leaflet mOdiFication Techniques to prEvent coRonary obstruction risk during Transcatheter Aortic Valve Replacement) was an international, multicenter registry of consecutive patients undergoing leaflet modification before TAVR (September 2019 to January 2026). Coprimary endpoints were leaflet modification-directed technical success and Valve Academic Research Consortium 3 (VARC-3) technical success. Secondary endpoints included in-hospital and 30-day outcomes. RESULTS: A total of 293 patients underwent leaflet modification, including 202 (68.9%) through a leaflet-splitting approach and 91 (31.1%) through an intraleaflet disruption approach. Overall, 139 of 293 (47.4%) treated valves were natives. Successful leaflet traversal occurred in 310 of 318 leaflets (97.5%; 95% CI: 94.9%-98.9%) and successful leaflet modification in 306 of 318 leaflets (96.2%; 95% CI: 93.3%-97.9%). Leaflet modification-directed technical success was achieved in 251 of 293 patients (85.7%; 95% CI: 81.0%-89.4%) and VARC-3 technical success in 254 of 293 patients (86.7%; 95% CI: 82.1%-90.3%). Notably, 91.1% (95% CI: 87.1%-94.0%) of patients underwent TAVR without CO events. Delayed CO occurred in 3 of 293 patients (1.0%; 95% CI: 0.3%-3.0%). The median follow-up duration was 100 days (Q1-Q3: 30-443 days). At 30 days, freedom from VARC-3 early safety was achieved in 181 of 293 patients (61.8%; 95% CI: 56.5%-67.6%). CONCLUSIONS: Leaflet modification techniques demonstrated high technical feasibility across a broad anatomical spectrum but carried considerable early clinical risk. These findings support its role as an adjunctive strategy for selected patients undergoing TAVR, although in the context of careful preprocedural planning and a structured multidisciplinary approach. CI - Copyright (c) 2026 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. FAU - Occhipinti, Giovanni AU - Occhipinti G AD - Institut Clinic Cardiovascular, Clinic Barcelona, Barcelona, Spain; Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain. Electronic address: https://twitter.com/drgocchipinti. FAU - Laudani, Claudio AU - Laudani C AD - Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico "Rodolico-San Marco," University of Catania, Catania, Italy; Division of Cardiology, University of Florida College of Medicine-Jacksonville, Jacksonville, Florida, USA. Electronic address: https://twitter.com/LaudaniClaudio. FAU - Jabri, Ahmad AU - Jabri A AD - Center for Structural Heart Disease, Henry Ford Hospital, Detroit, Michigan, USA. FAU - Pensotti, Filippo AU - Pensotti F AD - Cardiology Department, University Clinic Hospital, Valladolid, Spain. FAU - Leone, Pier Pasquale AU - Leone PP AD - Montefiore-Einstein Center for Heart and Vascular Care, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA; Interventional Cardiology, White Plains Hospital, White Plains, New York, USA. FAU - Khokhar, Arif A AU - Khokhar AA AD - The Heart Center, Rigshospitalet, Copenhagen, Denmark. FAU - Genereux, Philippe AU - Genereux P AD - Gagnon Cardiovascular Institute, Morristown Medical Center, Morristown, New Jersey, USA. FAU - Beneduce, Alessandro AU - Beneduce A AD - Heart Valve Center, IRCCS San Raffaele Scientific Institute, Milan, Italy. FAU - Wongpraparut, Nattawut AU - Wongpraparut N AD - Division of Cardiology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. FAU - Mangieri, Antonio AU - Mangieri A AD - Humanitas Research Hospital IRCCS, Milan, Italy. FAU - Serra, Vincenc AU - Serra V AD - Cardiology Department, Hospital Universitario Vall d'Hebron, Barcelona, Spain. FAU - Nombela-Franco, Luis AU - Nombela-Franco L AD - Cardiovascular Institute, Hospital Clinico San Carlos, Instituto de Investigacion Sanitaria del Hospital Clinico San Carlos, Madrid, Spain. FAU - Sanchez, Jorge Sanz AU - Sanchez JS AD - Servicio de Cardiologia, Hospital Universitari i Politecnic La Fe, Valencia, Spain; Centro de Investigacion Biomedica en Red Enfermedades Cardiovaculares, Madrid, Spain. FAU - Asmarats, Lluis AU - Asmarats L AD - Department of Cardiology, Hospital de la Santa Creu i Sant Pau, Institut de Recerca Sant Pau, Barcelona, Spain. FAU - Teles, Rui Campante AU - Teles RC AD - Hospital de Santa Cruz, Centro Hospitalar de Lisboa Ocidental, Carnaxide and Comprehensive Health Research Center, Nova Medical School, Lisbon, Portugal. FAU - Chandavimol, Mann AU - Chandavimol M AD - Department of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. FAU - Romaguera, Rafael AU - Romaguera R AD - Department of Cardiology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain; Bioheart Group, Cardiovascular, Respiratory and Systemic Diseases and Cellular Aging Program, Institut d'Investigacio Biomedica de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain; Department of Clinical Sciences, School of Medicine, Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain. FAU - Akodad, Mariama AU - Akodad M AD - Ramsay Generale de Sante, Institut Cardiovasculaire Paris Sud, Massy, France. FAU - Cuisset, Thomas AU - Cuisset T AD - Department of Cardiology, CHU Timone, Marseille, France; C2VN, Thomas University, INSERM, INRA, Marseille, France. FAU - Tayal, Rajiv AU - Tayal R AD - Valley Health System, Paramus, New Jersey, USA. FAU - Algethami, Abdulaziz R AU - Algethami AR AD - King Abdulaziz Cardiac Center, Ministry of the National Guard Health Affairs, Riyadh, Saudi Arabia. FAU - Diaz, Jose F AU - Diaz JF AD - Hospital Universitario Virgen del Rocio, Sevilla, Spain. FAU - Laffond, Ana AU - Laffond A AD - Complejo Asistencial Universitario de Salamanca, Salamanca, Spain. FAU - Martin, Pedro AU - Martin P AD - Hospital Universitario de Gran Canaria, Las Palmas de Gran Canaria, Spain. FAU - Perez, Luis AU - Perez L AD - Hospital Guillermo Grant Benavente, Concepcion, Chile. FAU - Ruiz-Quevedo, Valeriano AU - Ruiz-Quevedo V AD - Hospital Universitario de Navarra, Pamplona, Spain. FAU - Sarno, Giovanna AU - Sarno G AD - Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden; Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden. FAU - Vazquez Alvarez, Maria Eugenia AU - Vazquez Alvarez ME AD - Servicio de Cardiologia, Hospital General Universitario Gregorio Maranon, Madrid, Spain. FAU - Assafin, Manaf AU - Assafin M AD - Montefiore-Einstein Center for Heart and Vascular Care, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA; Interventional Cardiology, White Plains Hospital, White Plains, New York, USA. FAU - Garcia-Gomez, Mario AU - Garcia-Gomez M AD - Cardiology Department, University Clinic Hospital, Valladolid, Spain. FAU - Ruberti, Andrea AU - Ruberti A AD - Department of Cardiology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain. FAU - Sanchis, Laura AU - Sanchis L AD - Institut Clinic Cardiovascular, Clinic Barcelona, Barcelona, Spain; Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain. FAU - Freixa, Xavier AU - Freixa X AD - Institut Clinic Cardiovascular, Clinic Barcelona, Barcelona, Spain; Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain. FAU - Maisano, Francesco AU - Maisano F AD - Heart Valve Center, IRCCS San Raffaele Scientific Institute, Milan, Italy. FAU - Buzzatti, Nicola AU - Buzzatti N AD - Heart Valve Center, IRCCS San Raffaele Scientific Institute, Milan, Italy. FAU - Giustino, Gennaro AU - Giustino G AD - Gagnon Cardiovascular Institute, Morristown Medical Center, Morristown, New Jersey, USA. FAU - De Backer, Ole AU - De Backer O AD - The Heart Center, Rigshospitalet, Copenhagen, Denmark; Institute of Clinical Medicine, University of Copenhagen, Denmark. FAU - Latib, Azeem AU - Latib A AD - Montefiore-Einstein Center for Heart and Vascular Care, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA; Interventional Cardiology, White Plains Hospital, White Plains, New York, USA. FAU - Amat-Santos, Ignacio J AU - Amat-Santos IJ AD - Cardiology Department, University Clinic Hospital, Valladolid, Spain; Centro de Investigacion Biomedica en Red Enfermedades Cardiovaculares, Madrid, Spain. FAU - Villablanca, Pedro A AU - Villablanca PA AD - Center for Structural Heart Disease, Henry Ford Hospital, Detroit, Michigan, USA. FAU - Regueiro, Ander AU - Regueiro A AD - Institut Clinic Cardiovascular, Clinic Barcelona, Barcelona, Spain; Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain. Electronic address: aregueir@clinic.cat. LA - eng PT - Journal Article PT - Multicenter Study PT - Observational Study PT - Research Support, Non-U.S. Gov't PL - United States TA - JACC Cardiovasc Interv JT - JACC. Cardiovascular interventions JID - 101467004 SB - IM MH - Humans MH - Registries MH - Female MH - Risk Factors MH - Aged, 80 and over MH - Time Factors MH - Male MH - *Aortic Valve Stenosis/surgery/diagnostic imaging/physiopathology/mortality MH - *Aortic Valve/surgery/physiopathology/diagnostic imaging MH - Treatment Outcome MH - Risk Assessment MH - Prosthesis Design MH - *Transcatheter Aortic Valve Replacement/adverse effects/instrumentation/mortality MH - *Heart Valve Prosthesis MH - Aged MH - Europe MH - *Coronary Stenosis/etiology/prevention & control/diagnostic imaging OTO - NOTNLM OT - TAVR OT - coronary obstruction OT - leaflet modification OT - transcatheter aortic valve replacement COIS- Funding Support and Author Disclosures Dr Akodad is consultant to Abbott Laboratories, Edwards Lifesciences, and Medtronic. Dr Beneduce has received speaker and consultancy fees from Boston Scientific and Medtronic. Dr Buzzatti is a proctor for Meril Life Sciences; and has received speaker honoraria from Biosensors International. Dr Cuisset has received consulting and lecture fees from Abbott Cardiovascular, Boston Scientific, Edwards Lifesciences, Medtronic, and Terumo. Dr De Backer has received institutional research grants and consulting fees from Abbott Laboratories, Boston Scientific, Medtronic, and MicroPort. Dr Giustino is consultant and proctor for Edwards Lifesciences, Medtronic, Shockwave Medical, and 4C Medical; and is a shareholder and consultant of Antegrade Medical. Dr Khokhar has received speaker and consultancy fees from Abbott Laboratories, Anteris Technologies, Boston Scientific, Machnet Medical, and Medtronic. Dr Mangieri has received consulting fees from Abbott Cardiovascular, Abiomed/Johnson & Johnson MedTech, Edwards Lifesciences, Medtronic, Puzzle Medical, and Shockwave Medical. Dr Maisano has received grant and/or institutional research support from Abbott Laboratories, Medtronic, Edwards Lifesciences, Biotronik, Boston Scientific, NVT, and Terumo; has received consulting fees and personal and institutional honoraria from Abbott Laboratories, Medtronic, Edwards Lifesciences, Xeltis, and Cardiovalve; has received royalty income from and holds intellectual property rights with Edwards Lifesciences; and is a shareholder (including share options) in Cardiogard, Magenta, SwissVortex, Transseptal Solutions, Occlufit, 4Tech, and Perifect. Dr Nombela-Franco is a proctor for Abbott Laboratories, Edwards Lifesciences, Boston Scientific, and MicroPort. Dr Regueiro is a consultant for Abbott Laboratories, Edwards Lifesciences, Haemonetics, Medtronic, and Meril Life Sciences. Dr Romaguera has received honoraria for proctorships from Medtronic, Meril Life Sciences, and Biosensors International; and has received speaker honoraria from Abbott Cardiovascular, Boston Scientific, and SMT. Dr Tayal has received consultancy fees from Abbott Cardiovascular, Abiomed/Johnson & Johnson MedTech, Edwards Lifesciences, Medtronic, Puzzle Medical, and Shockwave Medical. Dr Wongpraparut has received institutional research grant from Abbott Laboratories; and has received consulting and lecture fee from Abbott Laboratories, Boston, Edwards Lifesciences, Medtronic, and Philips. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2026/06/23 00:35 MHDA- 2026/06/23 12:35 CRDT- 2026/06/22 20:53 PHST- 2026/04/23 00:00 [received] PHST- 2026/05/11 00:00 [revised] PHST- 2026/05/12 00:00 [accepted] PHST- 2026/06/23 12:35 [medline] PHST- 2026/06/23 00:35 [pubmed] PHST- 2026/06/22 20:53 [entrez] AID - S1936-8798(26)01531-1 [pii] AID - 10.1016/j.jcin.2026.05.011 [doi] PST - ppublish SO - JACC Cardiovasc Interv. 2026 Jun 22;19(12):1639-1649. doi: 10.1016/j.jcin.2026.05.011. PMID- 42329262 OWN - NLM STAT- MEDLINE DCOM- 20260727 LR - 20260813 IS - 1432-5195 (Electronic) IS - 0341-2695 (Print) IS - 0341-2695 (Linking) VI - 50 IP - 7 DP - 2026 Jul TI - Orthoplastic management of delayed sternal osteomyelitis and non-union: a retrospective case series applying fracture-related infection principles. PG - 1653-1659 LID - 10.1007/s00264-026-06916-x [doi] AB - BACKGROUND: Sternal osteomyelitis (OM), particularly in the context of late-presenting non-union following cardiothoracic surgery, remains a poorly understood and inconsistently managed condition. Delayed presentations involve established infection, sternal instability, and biofilm formation, requiring a multidisciplinary approach. BOAST guidelines for fracture-related infection (FRI) recommend a combined orthoplastic approach to manage these complex cases. METHODS: This retrospective case series identified all patients referred to a specialist bone infection unit with delayed onset sternal OM from March 2015 to March 2025. All patients were managed through a multidisciplinary pathway involving cardiothoracic surgery, orthopaedics, plastic surgery, and microbiology. Each case involved planning through a bone infection MDT, radical debridement, multiple deep tissue sampling, removal of infected foreign material, skeletal stabilisation where indicated, definitive soft tissue reconstruction, and culture-directed antimicrobial therapy. Clinical outcomes, microbiological findings, and recurrence were assessed. RESULTS: Fourteen patients were included (mean age 63.7 years), all with significant comorbidity burden. The interval from index cardiac surgery to definitive debridement ranged from 25 to 3,251 days. Eleven patients underwent single-stage debridement with immediate reconstruction: three required staged procedures. The most commonly isolated organisms were Staphylococcus epidermidis (7/14), Cutibacterium acnes (5/14), and Staphylococcus aureus (4/14); mixed infections were frequent. Mean length of stay following single-stage procedures was 10.5 days. During a mean follow-up of 410 days, one patient experienced recurrence requiring further surgery. CONCLUSION: This case series demonstrates that delayed sternal OM and non-union can be effectively managed through an orthoplastic approach aligned with FRI principles. Isolated soft tissue coverage, which has historically been the default management, fails to address the underlying pathology. Approaches focused solely on soft tissue reconstruction risk, persistent infection, and instability. This study supports the application of fracture-related infection principles to delayed sternal osteomyelitis, emphasising radical debridement, hardware removal, multidisciplinary decision-making, and definitive reconstruction as key components of successful treatment. CI - (c) 2026. The Author(s). FAU - Hutchinson, Katie AU - Hutchinson K AD - St George's University Hospitals NHS Foundation Trust, London, UK. katie.hutchinson16@nhs.net. FAU - Banks, Jamie AU - Banks J AD - Chelsea and Westminster Hospital NHS Foundation Trust, London, UK. FAU - Arnold, Amber AU - Arnold A AD - St George's University Hospitals NHS Foundation Trust, London, UK. FAU - Lohn, Jonathan AU - Lohn J AD - St George's University Hospitals NHS Foundation Trust, London, UK. FAU - Trompeter, Alex AU - Trompeter A AD - St George's University Hospitals NHS Foundation Trust, London, UK. a.trompeter@nhs.net. AD - St George's, University of London, London, UK. a.trompeter@nhs.net. LA - eng PT - Journal Article DEP - 20260622 PL - Germany TA - Int Orthop JT - International orthopaedics JID - 7705431 RN - 0 (Anti-Bacterial Agents) SB - IM MH - Humans MH - *Osteomyelitis/therapy/etiology/microbiology/surgery MH - Retrospective Studies MH - *Sternum/injuries/surgery/microbiology MH - Female MH - Debridement/methods MH - Male MH - Middle Aged MH - Aged MH - *Fractures, Ununited/therapy/surgery MH - *Fractures, Bone/complications MH - Anti-Bacterial Agents/therapeutic use MH - Hardware Removal MH - Surgical Wound Infection/therapy MH - Treatment Outcome MH - Plastic Surgery Procedures/methods PMC - PMC13407707 OTO - NOTNLM OT - Bone infection OT - Fracture related infection OT - Orthoplastic OT - Osteomyelitis COIS- Declarations. Human ethics and consent to participate declarations: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2026/06/22 13:42 MHDA- 2026/07/27 12:36 PMCR- 2026/06/22 CRDT- 2026/06/22 11:03 PHST- 2026/05/17 00:00 [received] PHST- 2026/06/16 00:00 [accepted] PHST- 2026/07/27 12:36 [medline] PHST- 2026/06/22 13:42 [pubmed] PHST- 2026/06/22 11:03 [entrez] PHST- 2026/06/22 00:00 [pmc-release] AID - 10.1007/s00264-026-06916-x [pii] AID - 6916 [pii] AID - 10.1007/s00264-026-06916-x [doi] PST - ppublish SO - Int Orthop. 2026 Jul;50(7):1653-1659. doi: 10.1007/s00264-026-06916-x. Epub 2026 Jun 22. PMID- 42328269 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260622 LR - 20260813 IS - 2673-253X (Electronic) IS - 2673-253X (Linking) VI - 8 DP - 2026 TI - Computational modelling for personalized transcatheter aortic valve replacement planning: a systematic review of complications and decision support. PG - 1832926 LID - 10.3389/fdgth.2026.1832926 [doi] LID - 1832926 AB - Patient-specific digital simulation is emerging as a tool to support personalized planning of transcatheter aortic valve replacement (TAVR), particularly as the procedure expands to younger, lower-risk patients, and more complex anatomies. Despite procedural advances, complications such as paravalvular leak, conduction disturbances, coronary obstruction, and aortic injury remain important determinants of outcome. Current pre-procedural planning relies heavily on computed tomography-based anatomical assessment, which is indispensable but largely static and cannot fully capture dynamic device-tissue interactions, and haemodynamic mechanisms underlying many procedural events. Computational modelling derived from patient-specific imaging can extend this assessment by simulating valve deployment, device-tissue contact, and flow, offering mechanistic insight and potential support for individualized procedural decision-making. This systematic review evaluates modelling approaches addressing TAVR complications and procedural planning, including high-risk scenarios such as bicuspid valves and valve-in-valve procedures. Across the literature, modelling enables patient-specific simulations and exploration of procedural strategies that may reduce complication risk. However, clinical translation remains limited by small study populations, heterogeneous methodologies, limited patient-specific validation, and lack of integration into routine workflows. Future progress will require validation against clinically meaningful endpoints, scalable digital infrastructure, and close collaboration between clinicians and engineers to incorporate simulation outputs into routine Heart Team decision-making. CI - (c) 2026 Rauseo, Bevis, Chen, Petersen, Mathur, Slabaugh and Roney. FAU - Rauseo, Elisa AU - Rauseo E AD - William Harvey Research Institute, NIHR Barts Biomedical Research Centre, Queen Mary University of London, London, United Kingdom. AD - Barts Heart Centre, Barts Health NHS Trust, London, United Kingdom. AD - Digital Environment Research Institute, Queen Mary University of London, London, United Kingdom. FAU - Bevis, Laura AU - Bevis L AD - Digital Environment Research Institute, Queen Mary University of London, London, United Kingdom. AD - School of Engineering and Materials Science, Queen Mary University of London, London, United Kingdom. FAU - Chen, Xu AU - Chen X AD - Digital Environment Research Institute, Queen Mary University of London, London, United Kingdom. AD - Department of Medicine, University of Cambridge, Cambridge, United Kingdom. FAU - Petersen, Steffen E AU - Petersen SE AD - William Harvey Research Institute, NIHR Barts Biomedical Research Centre, Queen Mary University of London, London, United Kingdom. AD - Barts Heart Centre, Barts Health NHS Trust, London, United Kingdom. AD - NIHR Barts Biomedical Research Centre, Queen Mary University of London, London, United Kingdom. FAU - Mathur, Anthony AU - Mathur A AD - Barts Heart Centre, Barts Health NHS Trust, London, United Kingdom. AD - NIHR Barts Biomedical Research Centre, Queen Mary University of London, London, United Kingdom. AD - Centre for Cardiovascular Medicine and Devices, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom. FAU - Slabaugh, Gregory G AU - Slabaugh GG AD - William Harvey Research Institute, NIHR Barts Biomedical Research Centre, Queen Mary University of London, London, United Kingdom. AD - Digital Environment Research Institute, Queen Mary University of London, London, United Kingdom. AD - School of Engineering and Materials Science, Queen Mary University of London, London, United Kingdom. AD - The British Library, John Dodson House, Alan Turing Institute, London, United Kingdom. FAU - Roney, Caroline H AU - Roney CH AD - Digital Environment Research Institute, Queen Mary University of London, London, United Kingdom. AD - School of Engineering and Materials Science, Queen Mary University of London, London, United Kingdom. LA - eng PT - Journal Article PT - Review DEP - 20260604 PL - Switzerland TA - Front Digit Health JT - Frontiers in digital health JID - 101771889 PMC - PMC13275269 OTO - NOTNLM OT - computational simulation OT - decision support OT - digital twin OT - patient-specific modelling OT - personalized medicine OT - procedural planning OT - transcatheter aortic valve replacement COIS- SP provides consultancy to Circle Cardiovascular Imaging, Inc., Calgary, Alberta, Canada. AM has received honoraria and travel bursary from Abbott. GS serves on the Scientific Advisory Board for BioAI Health, Boston, USA. AM, GS, CR., and LB have UK Patent Application No. 2411474.6: "Medical Support Method" describing a pipeline for TAVR digital twin simulation. The remaining authors have nothing to disclose. The remaining author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/06/22 13:43 MHDA- 2026/06/22 13:44 PMCR- 2026/06/04 CRDT- 2026/06/22 07:23 PHST- 2026/03/17 00:00 [received] PHST- 2026/05/11 00:00 [revised] PHST- 2026/05/18 00:00 [accepted] PHST- 2026/06/22 13:44 [medline] PHST- 2026/06/22 13:43 [pubmed] PHST- 2026/06/22 07:23 [entrez] PHST- 2026/06/04 00:00 [pmc-release] AID - 10.3389/fdgth.2026.1832926 [doi] PST - epublish SO - Front Digit Health. 2026 Jun 4;8:1832926. doi: 10.3389/fdgth.2026.1832926. eCollection 2026. PMID- 42328132 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260622 LR - 20260813 IS - 2666-5204 (Electronic) IS - 2666-5204 (Linking) VI - 30 DP - 2026 Jul TI - Improving surgical team confidence for intraoperative cardiac arrest in non-standard positions (sitting beach chair and prone): a prospective in-situ simulation study with three-month follow-up. PG - 101374 LID - 10.1016/j.resplu.2026.101374 [doi] LID - 101374 AB - BACKGROUND: Intraoperative cardiac arrest in non-standard positions, such as the sitting beach chair and prone positions, present unique challenges for surgical teams. Evidence on how to prepare teams for these rare events is limited. To evaluate whether a half-day, multi-station in situ simulation course was associated with changes in interprofessional surgical team members' self-reported confidence and timed repositioning performance, and to describe self-reported application of course content to real patients three months afterwards. METHODS: Prospective single-centre educational intervention at an elective orthopaedic unit. Interprofessional teams rotated through seven in situ stations during a 3.5-h course. Anonymous questionnaires on confidence in managing cardiac arrest were distributed before, immediately after and three months after the course. Exploratory transfer drills (sitting to supine and prone to supine) were timed within session. Confidence scores were analysed with the Mann-Whitney U test (primary comparison: Before versus three months). Effect sizes were reported as r, with |r| approximately 0.1, 0.3 and 0.5 considered small, medium and large. RESULTS: Sixty-three staff in five interprofessional teams participated. Questionnaire response rate was 74-92%, varied across domains. Self-reported confidence was higher at three months than before the course in all four domains (all p < 0.001), with medium to large effect sizes (r 0.39-0.68). The largest shift was for confidence in one's own ability to manage cardiac arrest in the sitting beach-chair position (median 4 before versus 8 at three months). At 3 months, 48/56 (85.7%) respondents reported that course content had been of use for a real patient, including in situations other than cardiac arrest. Repositioning times showed a trend towards improvement in first-to-best transfer attempts, median approximately 35 s (sitting to supine) and approximately 30 s (prone to supine). CONCLUSION: A half-day, multi-station in situ simulation course at an elective surgical unit was associated with higher self-reported confidence at three months, and self-reported application of course content to real patients. Exploratory within-session transfer drills suggested improvements that are hypothesis-generating given the small number of teams. The design may be a feasible use of planned surgical downtime. CI - (c) 2026 The Author(s). FAU - Sundelin, Anna AU - Sundelin A AD - Capio Artro Clinic, Stockholm, Sweden. AD - Department of Physiology and Pharmacology, Section of Anaesthesia and Intensive Care, Karolinska Institutet, Stockholm, Sweden. FAU - Wiklund, Andreas AU - Wiklund A AD - Capio Artro Clinic, Stockholm, Sweden. FAU - Ruiz, Mini AU - Ruiz M AD - Department of CLINTEC, Karolinska Institutet, Stockholm, Sweden. FAU - Stalman, Anders AU - Stalman A AD - Capio Artro Clinic, Stockholm, Sweden. AD - Department of MMK, Karolinska Institutet, Stockholm, Sweden. FAU - Djarv, Therese AU - Djarv T AD - Division for Clinical Medicine, Dept. of Medicine Solna, Karolinska Institutet, Stockholm, Sweden. AD - Internal Medicine & Emergency Medicine, Dept. Emergency Medicine. Karolinska University Hospital, Stockholm, Sweden. LA - eng PT - Journal Article DEP - 20260602 PL - Netherlands TA - Resusc Plus JT - Resuscitation plus JID - 101774410 PMC - PMC13279733 OTO - NOTNLM OT - CPR OT - Critical event preparedness OT - In-situ simulation OT - Interprofessional education OT - Operating room OT - Patient safety OT - Role clarity OT - Simulation curriculum design OT - Sitting beach chair position OT - Surgical team COIS- None declared. EDAT- 2026/06/22 13:43 MHDA- 2026/06/22 13:44 PMCR- 2026/06/02 CRDT- 2026/06/22 07:22 PHST- 2026/03/01 00:00 [received] PHST- 2026/05/26 00:00 [revised] PHST- 2026/05/27 00:00 [accepted] PHST- 2026/06/22 13:44 [medline] PHST- 2026/06/22 13:43 [pubmed] PHST- 2026/06/22 07:22 [entrez] PHST- 2026/06/02 00:00 [pmc-release] AID - S2666-5204(26)00159-1 [pii] AID - 101374 [pii] AID - 10.1016/j.resplu.2026.101374 [doi] PST - epublish SO - Resusc Plus. 2026 Jun 2;30:101374. doi: 10.1016/j.resplu.2026.101374. eCollection 2026 Jul. PMID- 42325169 OWN - NLM STAT- In-Process LR - 20260813 IS - 2055-5822 (Electronic) IS - 2055-5822 (Linking) VI - 13 IP - 4 DP - 2026 Jul 4 TI - Cardiac amyloidosis with apical myocardial infarction: beyond the cherry on top. LID - 10.1093/eschf/xvag173 [doi] LID - xvag173 FAU - Javadi, Niloufar AU - Javadi N AD - Aurora Cardiovascular and Thoracic Services, Aurora Sinai/Aurora St.Luke's Medical Centers, Aurora Health Care, 2801 W. Kinnickinnic River Parkway, Ste. 130, Milwaukee, WI 53215, USA. FAU - Ghafoor, Asad AU - Ghafoor A AD - Aurora Cardiovascular and Thoracic Services, Aurora Sinai/Aurora St.Luke's Medical Centers, Aurora Health Care, 2801 W. Kinnickinnic River Parkway, Ste. 130, Milwaukee, WI 53215, USA. AD - Department of Cardiovascular Medicine, Atrium Health Wake Forest Baptist Medical Center, 1 Medical Center Boulevard, Winston-Salem, NC 27157, USA. FAU - Jan, M Fuad AU - Jan MF AD - Aurora Cardiovascular and Thoracic Services, Aurora Sinai/Aurora St.Luke's Medical Centers, Aurora Health Care, 2801 W. Kinnickinnic River Parkway, Ste. 130, Milwaukee, WI 53215, USA. AD - Department of Cardiovascular Medicine, Atrium Health Wake Forest Baptist Medical Center, 1 Medical Center Boulevard, Winston-Salem, NC 27157, USA. FAU - Howard, Lauren AU - Howard L AD - Aurora Cardiovascular and Thoracic Services, Aurora Sinai/Aurora St.Luke's Medical Centers, Aurora Health Care, 2801 W. Kinnickinnic River Parkway, Ste. 130, Milwaukee, WI 53215, USA. FAU - Peters, Matthew AU - Peters M AD - Aurora Cardiovascular and Thoracic Services, Aurora Sinai/Aurora St.Luke's Medical Centers, Aurora Health Care, 2801 W. Kinnickinnic River Parkway, Ste. 130, Milwaukee, WI 53215, USA. FAU - Hundal, Prabhjot AU - Hundal P AD - Aurora Cardiovascular and Thoracic Services, Aurora Sinai/Aurora St.Luke's Medical Centers, Aurora Health Care, 2801 W. Kinnickinnic River Parkway, Ste. 130, Milwaukee, WI 53215, USA. FAU - Tumuluri, Chaitanya AU - Tumuluri C AD - Aurora Cardiovascular and Thoracic Services, Aurora Sinai/Aurora St.Luke's Medical Centers, Aurora Health Care, 2801 W. Kinnickinnic River Parkway, Ste. 130, Milwaukee, WI 53215, USA. FAU - Jahangir, Arshad AU - Jahangir A AUID- ORCID: 0000-0001-5582-3336 AD - Aurora Cardiovascular and Thoracic Services, Aurora Sinai/Aurora St.Luke's Medical Centers, Aurora Health Care, 2801 W. Kinnickinnic River Parkway, Ste. 130, Milwaukee, WI 53215, USA. AD - Department of Cardiovascular Medicine, Atrium Health Wake Forest Baptist Medical Center, 1 Medical Center Boulevard, Winston-Salem, NC 27157, USA. FAU - Galazka, Patrycja AU - Galazka P AUID- ORCID: 0000-0002-5952-7996 AD - Aurora Cardiovascular and Thoracic Services, Aurora Sinai/Aurora St.Luke's Medical Centers, Aurora Health Care, 2801 W. Kinnickinnic River Parkway, Ste. 130, Milwaukee, WI 53215, USA. AD - Department of Cardiovascular Medicine, Atrium Health Wake Forest Baptist Medical Center, 1 Medical Center Boulevard, Winston-Salem, NC 27157, USA. FAU - Tajik, A Jamil AU - Tajik AJ AUID- ORCID: 0000-0002-4784-1275 AD - Aurora Cardiovascular and Thoracic Services, Aurora Sinai/Aurora St.Luke's Medical Centers, Aurora Health Care, 2801 W. Kinnickinnic River Parkway, Ste. 130, Milwaukee, WI 53215, USA. AD - Department of Cardiovascular Medicine, Atrium Health Wake Forest Baptist Medical Center, 1 Medical Center Boulevard, Winston-Salem, NC 27157, USA. LA - eng GR - Crivello Family Foundation/ GR - Colton Scholar/ PT - Journal Article PL - England TA - ESC Heart Fail JT - ESC heart failure JID - 101669191 SB - IM PMC - PMC13332507 OTO - NOTNLM OT - Cardiac amyloidosis OT - Global longitudinal strain pattern OT - Multidisciplinary approach OT - Relative apical sparing EDAT- 2026/06/22 13:43 MHDA- 2026/06/22 13:43 PMCR- 2026/06/22 CRDT- 2026/06/22 06:43 PHST- 2025/10/28 00:00 [received] PHST- 2026/03/03 00:00 [revised] PHST- 2026/06/17 00:00 [accepted] PHST- 2026/06/22 13:43 [pubmed] PHST- 2026/06/22 13:43 [medline] PHST- 2026/06/22 06:43 [entrez] PHST- 2026/06/22 00:00 [pmc-release] AID - 8713045 [pii] AID - xvag173 [pii] AID - 10.1093/eschf/xvag173 [doi] PST - ppublish SO - ESC Heart Fail. 2026 Jul 4;13(4):xvag173. doi: 10.1093/eschf/xvag173. PMID- 42324992 OWN - NLM STAT- MEDLINE DCOM- 20260721 LR - 20260922 IS - 3068-563X (Electronic) IS - 3068-563X (Linking) VI - 19 IP - 7 DP - 2026 Jul TI - Optimizing Care in Cardiovascular-Kidney-Metabolic Syndrome: Registry Data From the Cardiometabolic Center Alliance. PG - e012828 LID - 10.1161/CIRCOUTCOMES.125.012828 [doi] AB - BACKGROUND: Cardiovascular diseases (CVD) are leading causes of morbidity and mortality among patients with cardiovascular-kidney-metabolic syndrome. Adoption of guideline-directed medical therapy remains suboptimal. Our objective was to evaluate the impact of a team-based multisite care model on improving quality and reducing disparities in patients with cardiovascular-kidney-metabolic syndrome. METHODS: We conducted a prospective clinical cohort study across 9 US sites of the Cardiometabolic Center Alliance, a network of health care organizations with a standardized approach to address CVD risk, between May 2020 and August 2024. Consecutive patients with type 2 diabetes/prediabetes and CVD and chronic kidney disease were enrolled in a clinical program with team care, structured visits, and standardized assessments. Cardiometabolic risk factor levels and proportion of adherence to guideline-directed medical therapy were assessed using longitudinal mixed-effects models accounting for clustering by site. RESULTS: Two thousand two hundred twenty-three individuals were enrolled with a mean (SD) age of 63.9 (11.2) years, 44.2% female, 84.0% White, and 62.5% noncommercially insured; 58.5% had atherosclerotic CVD, 32.6% heart failure, and 29.5% chronic kidney disease. Median follow-up was 6.8 (4.0-9.4) months. Participants had reductions in weight (mean [95% CI], -16.7 [-17.9 to -15.6] lbs), body mass index (-2.6 [-2.8 to -2.4] kg/m(2)), systolic (-5.8 [-7.0 to -4.6] mm Hg) and diastolic (-1.7 [-2.4 to-0.9] mm Hg) blood pressure, total cholesterol (-26.4 [-29.5 to -23.2] mg/dL), low-density lipoprotein cholesterol (-18.8 [-21.4 to -16.2] mg/dL), triglycerides (-45.1 [-54.0 to -36.3] mg/dL), fasting glucose (-30.9 [-35.4 to -26.4] mg/dL), HbA1c (-1.2 [-1.3% to -1.0%]), and insulin dose (-30.4 [-36.1 to -24.8] units/d), P<0.001 for all. Guideline-directed medical therapy increased from 31.0% to 59.6% for atherosclerotic CVD type 2 diabetes and from 33.3% to 63.8% for chronic kidney disease type 2 diabetes, P<0.001. CONCLUSIONS: The Cardiometabolic Center Alliance model is feasible and effective, leading to significant improvement in CVD risk factors and increased utilization of GDMT. Implementation and dissemination of this paradigm remains a priority to close gaps in cardiometabolic care. FAU - Neeland, Ian J AU - Neeland IJ AUID- ORCID: 0000-0003-2831-3618 AD - Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH (I.J.N., S.R.). AD - Division of Cardiovascular Medicine, University Hospitals Harrington Heart and Vascular Institute, University Hospitals Cleveland Medical Center, OH (I.J.N., A.K., S.R.). FAU - Magwire, Melissa L AU - Magwire ML AD - Saint Luke's Michael & Marlys Haverty Cardiometabolic Center of Excellence, Kansas City, MO (M.L.M., A.J.S., M.N.K.). AD - Cardiometabolic Center Alliance, American Heart Association, Dallas, TX (M.L.M., D.S.A., A.S., A.J.S.). FAU - Kwun, Audrey AU - Kwun A AUID- ORCID: 0009-0004-6535-5379 AD - Division of Cardiovascular Medicine, University Hospitals Harrington Heart and Vascular Institute, University Hospitals Cleveland Medical Center, OH (I.J.N., A.K., S.R.). FAU - Aistrope, Daniel S AU - Aistrope DS AUID- ORCID: 0000-0002-8560-3702 AD - Cardiometabolic Center Alliance, American Heart Association, Dallas, TX (M.L.M., D.S.A., A.S., A.J.S.). FAU - Andaya, Emily Ann Kapunan AU - Andaya EAK AD - Major Health Partners, Shelbyville, IN (E.A.K.A., A.B., L.H.). FAU - Bashall, Anthony AU - Bashall A AD - Major Health Partners, Shelbyville, IN (E.A.K.A., A.B., L.H.). FAU - Benziger, Catherine P AU - Benziger CP AUID- ORCID: 0000-0002-8992-6197 AD - Heart and Vascular Center, Essentia Health, Duluth, MN (C.P.B.). FAU - De Albuquerque Rocha, Natalia AU - De Albuquerque Rocha N AUID- ORCID: 0000-0001-9539-8805 AD - Southern Medical Group, Tallahassee, FL (N.D.A.R.). FAU - Butler, Javed AU - Butler J AUID- ORCID: 0000-0001-7683-4720 AD - University of Mississippi Medical Center, Jackson (J.B.). AD - Baylor Scott and White Healthcare, Dallas, TX (J.B.). FAU - Davis, Lisa AU - Davis L AD - Baptist Health South Florida, Miami, FL (L.D., A.I.). FAU - Denicola, Dawn AU - Denicola D AD - Louisiana Cardiology Associates, Baton Rouge, LA (D.D.). FAU - Eckel, Robert H AU - Eckel RH AUID- ORCID: 0000-0001-6420-0595 AD - University of Colorado Anschutz Medical Campus, Aurora (R.H.E.). FAU - Gosch, Kensey AU - Gosch K AUID- ORCID: 0000-0003-2934-6913 AD - Saint Luke's Health System, Kansas City, MO (K.G., S.P.). FAU - Harness, Lacy AU - Harness L AD - Major Health Partners, Shelbyville, IN (E.A.K.A., A.B., L.H.). FAU - Helms, Allyson R AU - Helms AR AUID- ORCID: 0009-0001-5418-3928 AD - Bryan Heart, Lincoln, NE (A.R.H., K.A.M.). FAU - Iluyomade, Adedapo AU - Iluyomade A AUID- ORCID: 0000-0002-7891-0501 AD - Baptist Health South Florida, Miami, FL (L.D., A.I.). FAU - Miller, Keith A AU - Miller KA AD - Bryan Heart, Lincoln, NE (A.R.H., K.A.M.). FAU - Gianos, Eugenia AU - Gianos E AD - Northwell Health, New Hyde Park, NY (E.G., S.D.). FAU - Donahoe, Sean AU - Donahoe S AD - Northwell Health, New Hyde Park, NY (E.G., S.D.). FAU - Patel, Shachi AU - Patel S AD - Saint Luke's Health System, Kansas City, MO (K.G., S.P.). FAU - Plutzky, Jorge AU - Plutzky J AUID- ORCID: 0000-0002-7194-9876 AD - Brigham and Women's Hospital, Boston, MA (J.P.). FAU - Stafos, Andrea AU - Stafos A AUID- ORCID: 0009-0001-8300-9232 AD - Cardiometabolic Center Alliance, American Heart Association, Dallas, TX (M.L.M., D.S.A., A.S., A.J.S.). FAU - Sauer, Andrew J AU - Sauer AJ AUID- ORCID: 0000-0002-9268-2795 AD - Saint Luke's Michael & Marlys Haverty Cardiometabolic Center of Excellence, Kansas City, MO (M.L.M., A.J.S., M.N.K.). AD - Cardiometabolic Center Alliance, American Heart Association, Dallas, TX (M.L.M., D.S.A., A.S., A.J.S.). FAU - Rajagopalan, Sanjay AU - Rajagopalan S AUID- ORCID: 0000-0001-6669-8163 AD - Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH (I.J.N., S.R.). AD - Division of Cardiovascular Medicine, University Hospitals Harrington Heart and Vascular Institute, University Hospitals Cleveland Medical Center, OH (I.J.N., A.K., S.R.). FAU - Kosiborod, Mikhail N AU - Kosiborod MN AUID- ORCID: 0000-0002-3750-9789 AD - Saint Luke's Michael & Marlys Haverty Cardiometabolic Center of Excellence, Kansas City, MO (M.L.M., A.J.S., M.N.K.). AD - AstraZeneca, Boston, MA (M.N.K.). LA - eng GR - R01 HL163627/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Multicenter Study PT - Observational Study DEP - 20260622 PL - United States TA - Circ Popul Health Outcomes JT - Circulation. Population health and outcomes JID - 9919227857106676 SB - IM MH - Aged MH - Female MH - Humans MH - Male MH - Middle Aged MH - *Cardio-Renal Syndrome/therapy/epidemiology/diagnosis MH - *Cardiovascular Diseases/therapy/epidemiology MH - *Diabetes Mellitus, Type 2/therapy/epidemiology MH - Guideline Adherence MH - *Metabolic Syndrome/therapy/epidemiology/diagnosis MH - Prospective Studies MH - Registries MH - *Renal Insufficiency, Chronic/therapy/epidemiology MH - United States/epidemiology PMC - PMC13288766 MID - NIHMS2180061 OTO - NOTNLM OT - blood pressure OT - body mass index OT - cardiovascular diseases OT - insulin OT - minority groups COIS- Dr Neeland has received speaker/consulting fees from Boehringer Ingelheim, Eli Lilly, and Bayer Pharmaceuticals; a research grant from the American Heart Association and the National Institutes of Health; and has been on an advisory board for Novo Nordisk. Dr Benziger is a consultant for Novartis. Dr Eckel has been a consultant or advisory board member for Amgen, Better Co, 89bio, Ionis, Madrigal, Novo Nordisk, Precision BioSciences, Regeneron, The Healthy Aging Co, and served on the data safety and monitoring board for Arrowhead and is a coauthor for Hypertriglyceridemia for UpToDatel. Dr Butler has been a consultant for Abbott, Adaptyx, ADI Analog, American Regent, Amgen, Armgo, AskBio, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardiac Dimension, Cardior, CSL Vifor, CVRx, Cytokinetics, Daxor, Diastol, Edwards, Element Sciences, Faraday, Idorsia, Impulse Dynamics, Imbria, Innolife, Inventiva, Levator, Lexicon, Eli Lilly, Mankind, Medtronic, Merck, New Amsterdam, Novartis, NovoNordisk, Pfizer, Pharmacosmos, Pharmain, Prolaio, Pulnovo, Regeneron, Renibus, Repreive, Roche, Saillent, Salamandra, Salubris, SC Pharma, SQ Innovation, Secretome, Sequanna, Transmural, TekkunLev, Tenex, Tricog, Ultromic, and Zoll. L. Davis is on the speaker's bureau for Amgen. Dr Sauer reports research funding support from the Heart Failure Society of America, AstraZeneca, Boehringer Ingelheim, Bayer, CSL Vifor, Pfizer, Rivus Pharmaceuticals, 35Pharma, Novo Nordisk, Edwards Lifesciences, Story Health; consulting for Abbott, Boston Scientific, Edwards Lifesciences, Impulse Dynamics, Acorai, General Prognostics, Story Health, Amgen, Bayer; stock ownership in ISHI, Pulsli (both privately held digital health companies). Dr Rajagopalan reports consulting and speaker fees from Novo Nordisk and Bayer Healthcare. Dr Kosiborod reports research grant funding (payments to institution) from Astra Zeneca, Boehringer Ingelheim, and Pfizer; consultant/advisory board fees (payments to institution) from 35Pharma, Alnylam, Amgen, Applied Therapeutics, Arrowhead Pharmaceuticals, Astra Zeneca, Bayer, Boehringer Ingelheim, Corcept Therapeutics, Cytokinetics, Dexcom, Eli Lilly, Esperion Therapeutics, Imbria Pharmaceuticals, Janssen, Lexicon Pharmaceuticals, Merck (Diabetes and Cardiovascular), Novo Nordisk, Pfizer, Pharmacosmos, Regeneron, Roche, Sanofi, scPharmaceuticals, Structure Therapeutics, Vifor Pharma, and Youngene Therapeutics; other research support (data analytic center fees-payments to institution) from Astra Zeneca and Vifor Pharma; honorarium (payments to institution) from Astra Zeneca, Boehringer Ingelheim, and Novo Nordisk; stock options (personal) from Artera Health and Saghmos Therapeutics; and employment with AstraZeneca R&D, effective January 6, 2025. The other authors report no conflicts. EDAT- 2026/06/22 06:45 MHDA- 2026/07/21 18:34 PMCR- 2026/06/24 CRDT- 2026/06/22 05:03 PHST- 2026/07/21 18:34 [medline] PHST- 2026/06/22 06:45 [pubmed] PHST- 2026/06/22 05:03 [entrez] PHST- 2026/06/24 00:00 [pmc-release] AID - 10.1161/CIRCOUTCOMES.125.012828 [doi] PST - ppublish SO - Circ Popul Health Outcomes. 2026 Jul;19(7):e012828. doi: 10.1161/CIRCOUTCOMES.125.012828. Epub 2026 Jun 22. PMID- 42323787 OWN - NLM STAT- Publisher LR - 20260621 IS - 1481-8043 (Electronic) IS - 1481-8035 (Linking) DP - 2026 Jun 21 TI - Development and implementation of a severe accidental hypothermia resuscitation pathway in an urban Canadian emergency department: a quality improvement initiative. LID - 10.1007/s43678-026-01193-4 [doi] AB - OBJECTIVES: Severe accidental hypothermia (core temperature < 28 degrees C) is an infrequent but resource‑intensive emergency department (ED) presentation that requires altered Advanced Cardiac Life Support (ACLS) management, aggressive rewarming, and timely consideration of veno-arterial extracorporeal membrane oxygenation (VA-ECMO). Prior to this project, our inner‑city academic ED lacked a standardized approach, contributing to variability in care. We designed, implemented, and achieved >/= 95% real‑time utilization of a bedside pathway for patients with severe accidental hypothermia. METHODS: In response to issues identified in the review of a case of severe hypothermia, a multidisciplinary team developed and revised a severe hypothermia pathway through eight Plan‑Do‑Study‑Act cycles. Implementation strategies included an in situ simulation, targeted nursing skills sessions, and interdepartmental case debriefings. From January 2025 to April 2025, cases of severe hypothermia were reviewed. Our primary outcome was pathway utilization; secondary outcomes were staff perceptions, including timely access to VA-ECMO. RESULTS: Our severe hypothermia pathway includes a flowchart alongside a set of cue cards. The flowchart prompts management in three key realms: modified ACLS, rewarming techniques, and prognostication/VA-ECMO. The cue cards guide step-by-step management, including how to access mechanical CPR and VA-ECMO. Key themes included: development of a streamlined pathway, clinical provider education, and improved interdepartmental communication. 100% (6/6) of cases utilized the pathway. Interdisciplinary feedback suggests providers find the pathway to be useful and that it facilitates timely access to consideration for VA-ECMO. CONCLUSION: A pragmatic hypothermia resuscitation pathway was successfully implemented in our ED, supporting access to VA-ECMO. Our work acknowledges these resuscitations are resource intensive and may disrupt care to other patients. Therefore, cases for VA-ECMO should be carefully selected. Future work includes exploring an ED Code ECMO at our site and a city-wide prehospital VA-ECMO referral pathway. CI - (c) 2026. The Author(s), under exclusive licence to the Canadian Association of Emergency Physicians (CAEP)/ Association Canadienne de Medecine d'Urgence (ACMU). FAU - Dell, Evelyn AU - Dell E AUID- ORCID: 0000-0002-0223-3970 AD - Emergency Department, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada. dell.evelyn@gmail.com. FAU - Vaillancourt, Samuel AU - Vaillancourt S AD - Emergency Department, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada. FAU - Warsi, Farah AU - Warsi F AD - Emergency Department, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada. FAU - Sklar, Michael AU - Sklar M AD - Emergency Department, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada. FAU - Yanagawa, Bobby AU - Yanagawa B AD - Emergency Department, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada. FAU - Alli, Ahmad AU - Alli A AD - Emergency Department, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada. FAU - Mok, Garrick AU - Mok G AD - Emergency Department, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada. LA - eng PT - Journal Article DEP - 20260621 PL - England TA - CJEM JT - CJEM JID - 100893237 SB - IM OTO - NOTNLM OT - Cardiac arrest OT - ECMO OT - Emergency department OT - Hypothermia OT - Quality improvement COIS- Declarations. Conflicts of interest: On behalf of the authors Dell, Vaillancourt, Warsi, Sklar, and Yanagawa, the corresponding author states that there are no conflicts of interest. Two authors have conflicts of interest-author Mok receives a stipend for work with Zoll Medical, and author Alli receives speaking honoraria from Edwards Lifesciences and Becton, Dickinson and Company (BD). EDAT- 2026/06/21 22:31 MHDA- 2026/06/21 22:31 CRDT- 2026/06/21 11:04 PHST- 2025/07/13 00:00 [received] PHST- 2026/05/19 00:00 [accepted] PHST- 2026/06/21 22:31 [medline] PHST- 2026/06/21 22:31 [pubmed] PHST- 2026/06/21 11:04 [entrez] AID - 10.1007/s43678-026-01193-4 [pii] AID - 10.1007/s43678-026-01193-4 [doi] PST - aheadofprint SO - CJEM. 2026 Jun 21. doi: 10.1007/s43678-026-01193-4. PMID- 42323001 OWN - NLM STAT- MEDLINE DCOM- 20260820 LR - 20260821 IS - 1097-6744 (Electronic) IS - 0002-8703 (Linking) VI - 301 DP - 2026 Nov TI - Lessons learned from the feasibility phase of the REvascularization CHoices Among Under-Represented Groups Evaluation (RECHARGE) trial program. PG - 107515 LID - S0002-8703(26)00177-8 [pii] LID - 10.1016/j.ahj.2026.107515 [doi] AB - BACKGROUND: The REvascularization CHoices Among Under-Represented Groups Evaluation (RECHARGE) program is enrolling 1200 women, Black and Hispanic patients, in 2 parallel randomized trials of percutaneous coronary intervention vs coronary artery bypass grafting. METHODS: Funded by a phased Patient-Centered Outcomes Research Institute award, the pilot phase was designed to assess the feasibility of enrolling groups historically under-represented and challenging to enroll in prior revascularization trials, evaluate willingness of patients to accept randomization, refine patient and stakeholder engagement, and scale site infrastructure and data collection across diverse centers. We report key insights from the pilot phase. RESULTS: Physician and patient treatment preferences, often shaped by prior experience and evidence not directly applicable to these cohorts, were the main reasons eligible patients were not randomized. Many sites also lacked consistent multidisciplinary Heart Team processes for coronary disease, requiring new workflows to establish equipoise between percutaneous coronary intervention and coronary artery bypass grafting. Successful recruitment required intentional trust-building and tailored patient-facing materials, while engagement of non-academic centers demanded added financial, educational, and start-up support. During the 2-year pilot phase, 91 US and 17 Canadian sites were selected, and 65 were activated. Median activation time was 10.8 months (Interquartile range [IQR] 9.1-13.6). The pilot enrollment goal of 60 participants was exceeded, with 141 patients randomized within 13 months at a mean rate of 0.27 patients/site/month, prompting expansion to up to 150 sites for the full program. CONCLUSION: The lessons learned from the pilot phase of the REvascularization CHoices Among Under-Represented Groups Evaluation program can inform the design and implementation of future randomized trials seeking to enroll traditionally under-represented populations. TRIAL REGISTRATION: REvascularization CHoices Among Under-Represented Groups Evaluation: The RECHARGE Trial; NCT06399705 (RECHARGE:M) and NCT06399692 (RECHARGE:W). CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Gaudino, Mario AU - Gaudino M AD - Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, NY. Electronic address: mfg9004@med.cornell.edu. FAU - Stone, Gregg W AU - Stone GW AD - Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: gregg.stone@mountsinai.org. FAU - Puskas, John AU - Puskas J AD - Division of Cardiac Surgery, Emory University, Atlanta, GA. FAU - Krieger, Katherine AU - Krieger K AD - Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, NY. FAU - Redfors, Bjorn AU - Redfors B AD - Division of Biostatistics, Department of Population Health Sciences, Weill Cornell Medicine, New York, NY; Department of Molecular and Clinical Medicine, Institute of Medicine, Gothenburg University, Gothenburg, Sweden; Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden. FAU - Bagiella, Emilia AU - Bagiella E AD - Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY. FAU - Gelijns, Annetine AU - Gelijns A AD - Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY. FAU - Bhatt, Deepak L AU - Bhatt DL AD - Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, NY. FAU - Sandner, Sigrid AU - Sandner S AD - Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria. FAU - Barman, Nitin AU - Barman N AD - Division of Cardiology, Mount Sinai Morningside, New York, NY. FAU - Bozinovski, John AU - Bozinovski J AD - The Ohio State University Wexner Medical Center, Columbus, OH. FAU - Gee, Patrick AU - Gee P AD - Healthcare Consultant/Patient Advocate, iAdvocate, North Chesterfield, VA. FAU - Haider, Ali AU - Haider A AD - NewYork-Presbyterian Queens, New York, NY. FAU - Hafiz, Abdul Moiz AU - Hafiz AM AD - Division of Cardiology, Southern Illinois University School of Medicine, IL. FAU - Jolly, Sanjit S AU - Jolly SS AD - Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada. FAU - Li, Ditian AU - Li D AD - Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY. FAU - Mack, Charles AU - Mack C AD - NewYork-Presbyterian Queens, New York, NY. FAU - Madani, Michael M AU - Madani MM AD - Sulpizio Cardiovascular Center, UC San Diego, San Diego, CA. FAU - Mahmud, Ehtisham AU - Mahmud E AD - Sulpizio Cardiovascular Center, UC San Diego, San Diego, CA. FAU - Pineda, Andres M AU - Pineda AM AD - Duke University Medical Center, Durham, NC. FAU - Masoudi, Frederick A AU - Masoudi FA AD - Ascension Clinical Research Institute, St Louis, MO. FAU - Mazzaferri, Ernest AU - Mazzaferri E AD - The Ohio State University Wexner Medical Center, Columbus, OH. FAU - Monroe, Rhonda AU - Monroe R AD - BOOST - Better Outcomes Optimal Scientific Therapies, Washington, DC; Heart Failure Society of America Advocacy Committee, Charlotte, NC. FAU - Nicholson, William AU - Nicholson W AD - Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA. FAU - Pocock, Stuart J AU - Pocock SJ AD - Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, United Kingdom. FAU - Sachdeva, Rajesh AU - Sachdeva R AD - Division of Cardiology, Atlanta VA Medical Center, Decatur, GA. FAU - Yong, Celina AU - Yong C AD - Veterans Affairs Palo Alto Health Care System, Palo Alto, CA; Department of Medicine, Stanford University School of Medicine, Stanford, CA. FAU - Zwischenberger, Brittany A AU - Zwischenberger BA AD - Duke University Medical Center, Durham, NC. FAU - Yancy, Clyde AU - Yancy C AD - Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL. FAU - Creber, Ruth Masterson AU - Creber RM AD - Columbia University School of Nursing, New York, NY. FAU - Spertus, John AU - Spertus J AD - University of Missouri - Kansas City's Healthcare Institute for Innovations in Quality and Saint Luke's Mid America Heart Institute, Saint Luke's Hospital, Kansas City, MO. LA - eng SI - ClinicalTrials.gov/NCT06399705 SI - ClinicalTrials.gov/NCT06399692 PT - Equivalence Trial PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial DEP - 20260620 PL - United States TA - Am Heart J JT - American heart journal JID - 0370465 SB - IM MH - Aged MH - Female MH - Humans MH - Male MH - Middle Aged MH - Black or African American MH - Canada MH - *Coronary Artery Bypass/methods MH - *Coronary Artery Disease/surgery MH - Feasibility Studies MH - Hispanic or Latino MH - Patient Preference MH - *Patient Selection MH - *Percutaneous Coronary Intervention/methods MH - Pilot Projects MH - United States MH - *Minority Groups/psychology/statistics & numerical data EDAT- 2026/06/21 22:40 MHDA- 2026/08/20 23:35 CRDT- 2026/06/20 19:27 PHST- 2026/04/13 00:00 [received] PHST- 2026/06/02 00:00 [revised] PHST- 2026/06/17 00:00 [accepted] PHST- 2026/08/20 23:35 [medline] PHST- 2026/06/21 22:40 [pubmed] PHST- 2026/06/20 19:27 [entrez] AID - S0002-8703(26)00177-8 [pii] AID - 10.1016/j.ahj.2026.107515 [doi] PST - ppublish SO - Am Heart J. 2026 Nov;301:107515. doi: 10.1016/j.ahj.2026.107515. Epub 2026 Jun 20. PMID- 42475461 STAT- Publisher CTDT- 20260620 PB - StatPearls Publishing DP - 2026 Jan TI - Duane-Radial Ray Syndrome (Okihiro Syndrome). BTI - StatPearls AB - Duane-radial ray syndrome (DRRS), also known as Okihiro syndrome, is a rare congenital developmental disorder characterized by the association of Duane retraction syndrome (DRS) with preaxial upper limb malformations, particularly radial ray defects. First described by Okihiro and colleagues in 1977, this condition represents a syndromic form of congenital cranial dysinnervation disorder (CCDD) in which aberrant ocular motor innervation coexists with limb morphogenesis anomalies. The syndrome follows an autosomal dominant inheritance pattern with marked variable expressivity and incomplete penetrance, meaning affected individuals within the same family may display widely differing phenotypes ranging from mild ocular findings to significant limb and systemic involvement. From a developmental perspective, DRRS is categorized among congenital cranial dysinnervation disorders, a group of conditions characterized by primary developmental anomalies of cranial nerve nuclei or their axonal projections rather than primary muscle pathology. This classification underscores the neurodevelopmental origin of the ocular motility disturbance. Recognition of DRRS is clinically important because ocular findings may serve as the first diagnostic clue to an underlying multisystem developmental disorder. At the molecular level, Duane-radial ray syndrome is primarily associated with pathogenic variants in the spalt-like transcription factor 4 (SALL4) gene located on chromosome 20q13.2. SALL4 encodes a zinc finger transcription factor that plays a critical role in embryogenesis, particularly in limb bud formation, ocular development, cardiac morphogenesis, renal differentiation, and neural patterning. Haploinsufficiency of SALL4 disrupts transcriptional regulation during early organogenesis, leading to the constellation of malformations observed in this syndrome. DRRS belongs to the broader spectrum of SALL4-related disorders, which may show phenotypic overlap with conditions such as Holt-Oram syndrome, acro-renal-ocular syndrome, and even thalidomide embryopathy. Because of these overlaps, molecular confirmation through genetic testing is often essential for accurate diagnosis, appropriate counseling, and differentiation from other radial ray syndromes. The hallmark ocular feature of DRRS is Duane retraction syndrome, a congenital strabismus disorder characterized by limited horizontal eye movement due to aberrant innervation of the lateral rectus muscle. In classic DRS, the abducens nerve (cranial nerve VI) is congenitally absent or hypoplastic, with anomalous innervation of the lateral rectus muscle by branches of the oculomotor nerve (cranial nerve III). This miswiring leads to paradoxical co-contraction of the medial and lateral rectus muscles during attempted adduction, resulting in globe retraction and narrowing of the palpebral fissure. Abduction limitation is most common, although adduction limitation or combined forms may also occur. Vertical upshoots or downshoots during adduction can be observed due to mechanical leash effects or anomalous muscle contraction. In DRRS, the DRS is typically unilateral but may be bilateral. Patients often present in infancy or early childhood with strabismus, compensatory head posture, or reduced binocular vision. Amblyopia may develop if fixation preference or significant anisometropia is present. In addition to the classic features of DRS, other ocular anomalies have occasionally been reported in association with DRRS. These findings may include ptosis, epibulbar dermoids, microphthalmia, coloboma, optic disc anomalies, and refractive errors. However, Duane retraction syndrome remains the most consistent and defining ophthalmic manifestation. The second defining feature of Duane-radial ray syndrome is the presence of radial ray malformations of the upper limbs. These anomalies involve the preaxial structures of the forearm and hand and may vary widely in severity. Common manifestations include hypoplastic or absent thumbs, triphalangeal thumbs, radial hypoplasia, shortened forearms, and radioulnar synostosis. The anomalies are often asymmetric and may be unilateral or bilateral. In some individuals, the limb defects may be subtle, such as mild thumb hypoplasia, while the phenotype may be more severe in others, with complete absence of the radius. These skeletal anomalies arise from disrupted mesodermal differentiation and impaired patterning during early limb bud development. The wide variability in limb involvement reflects the variable expressivity of SALL4 mutations. Beyond ocular and limb anomalies, DRRS may involve other organ systems, reflecting SALL4's pleiotropic role in embryogenesis. Renal anomalies are among the most frequently reported systemic associations and may include unilateral renal agenesis, ectopic kidney, horseshoe kidney, vesicoureteral reflux, or structural anomalies detectable on imaging. Cardiac defects have also been documented, including atrial septal defects, ventricular septal defects, and conduction abnormalities. Hearing impairment, particularly sensorineural hearing loss, has been reported in some individuals. Less commonly, gastrointestinal, vertebral, or facial anomalies may be present. Because systemic involvement may not be clinically apparent at birth, a comprehensive evaluation is recommended once DRRS is suspected. The differential diagnosis of Duane-radial ray syndrome includes other radial ray syndromes and conditions associated with congenital strabismus. For example, Holt-Oram syndrome, also caused by mutations in the SALL4 gene, presents with radial ray defects and cardiac anomalies but does not typically include Duane retraction syndrome. Thalidomide embryopathy may mimic DRRS with limb reduction defects and ocular anomalies; however, the etiology is teratogenic rather than genetic. Isolated Duane retraction syndrome lacks associated limb anomalies. Therefore, the coexistence of DRS with radial ray anomalies should prompt consideration of DRRS and genetic testing for SALL4 mutations. Diagnosis of DRRS is initially clinical, based on recognition of the characteristic ocular motility pattern of Duane retraction syndrome in conjunction with radial ray malformations. A detailed family history may reveal autosomal dominant inheritance across generations. Genetic testing confirming a pathogenic SALL4 variant establishes the diagnosis and facilitates genetic counseling. Prenatal diagnosis may be considered in families with known mutations through targeted molecular testing. Management of Duane-radial ray syndrome requires a multidisciplinary approach. Ophthalmologic care focuses on amblyopia prevention, refractive correction, monitoring of binocular vision, and surgical intervention when indicated for significant head posture or cosmetically unacceptable deviation. Orthopedic management addresses limb anomalies and functional limitations. Renal ultrasonography and cardiac evaluation are recommended to screen for associated anomalies. Audiological assessment may be warranted. Genetic counseling plays a crucial role in informing affected individuals and families about inheritance patterns, recurrence risks, and reproductive options. In summary, Duane-radial ray syndrome is a rare but clinically significant developmental disorder characterized by the association of Duane retraction syndrome and radial ray malformations, most commonly caused by mutations in the SALL4 gene. It exemplifies the intersection of neurodevelopmental ocular dysinnervation and limb morphogenesis defects within a broader multisystem embryologic framework. Early recognition, particularly by ophthalmologists encountering Duane retraction syndrome in a child with limb anomalies, is essential for comprehensive systemic evaluation, coordinated multidisciplinary care, and appropriate genetic counseling. CI - Copyright (c) 2026, StatPearls Publishing LLC. FAU - Alahmadi, Mohamed H AU - Alahmadi MH AD - Shalamar Hospital and Avicenna Medical & Dental College and Hospital, Lahore FAU - Kaur, Kirandeep AU - Kaur K AD - Gomabai Netralaya and Research Centre LA - eng PT - Study Guide PT - Book Chapter PL - Treasure Island (FL) COIS- Disclosure: Mohamed H Alahmadi declares no relevant financial relationships with ineligible companies. Disclosure: Kirandeep Kaur declares no relevant financial relationships with ineligible companies. EDAT- 2026/06/20 00:00 CRDT- 2026/06/20 00:00 AID - NBK623728 [bookaccession] PMID- 42320887 OWN - NLM STAT- Publisher LR - 20260930 IS - 1537-6591 (Electronic) IS - 1058-4838 (Linking) DP - 2026 Jun 20 TI - Diagnostic and prognostic relevance of valve strands in patients with suspected infective endocarditis. LID - ciag376 [pii] LID - 10.1093/cid/ciag376 [doi] AB - BACKGROUND: The clinical significance and impact of valve strands, also known as Lambl's excrescences, on management in patients with suspected infective endocarditis (IE) remain unclear. The study aimed to assess the impact of the diagnosis of valve strands on the outcomes of patients investigated for suspected IE. METHODS: We conducted a retrospective study at Lausanne University Hospital (2014-2024) including adult patients with a valve strand identified on cardiac imaging. Episodes were classified as IE or non-IE by a multidisciplinary Endocarditis Team (2018-2024) or by expert clinicians (2014-2017). One-year outcomes included recurrence of bacteremia/candidemia or IE by the same microorganism. RESULTS: Among 305 episodes with valve strands, 101 (33%) were diagnosed as IE by the Endocarditis Team or expert clinicians. Among the 204 episodes without IE, 165 (81%) had bacteremia/candidemia. Valve strands were identified by transthoracic echocardiography in 141 (50%) out of 282 episodes, and by transesophageal echocardiography in 191 (79%) out of 244 episodes. Among the 257 episodes with bacteremia/candidemia, recurrence of bacteremia/candidemia caused by the same microorganism within one year occurred in 7/92 (8%) among those with IE and 11/165 (7%) among those without (P=0.971). Recurrence of IE due to the same microorganism within one year was significantly more frequent among episodes with IE compared to those without (6/92; 7% versus 2/165; 1%; P=0.029). CONCLUSIONS: Most valve strands detected in patients with suspected IE do not represent infectious lesions. Careful evaluation by expert cardiologists and multidisciplinary discussion can safely differentiate valve strands from vegetations, reducing unnecessary treatment. CI - (c) The Author(s) 2026. Published by Oxford University Press on behalf of Infectious Diseases Society of America. FAU - Tzimas, Georgios AU - Tzimas G AUID- ORCID: 0000-0002-2810-8887 AD - Department of Cardiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Monney, Pierre AU - Monney P AUID- ORCID: 0000-0002-3083-7333 AD - Department of Cardiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Ianculescu, Nicoleta AU - Ianculescu N AD - Department of Cardiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Antiochos, Panagiotis AU - Antiochos P AUID- ORCID: 0000-0001-8466-7360 AD - Department of Cardiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Guery, Benoit AU - Guery B AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Niclauss, Lars AU - Niclauss L AUID- ORCID: 0000-0003-4453-5202 AD - Department of Cardiac Surgery, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Kirsch, Matthias AU - Kirsch M AUID- ORCID: 0000-0002-9213-7578 AD - Department of Cardiac Surgery, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Papadimitriou-Olivgeris, Matthaios AU - Papadimitriou-Olivgeris M AUID- ORCID: 0000-0003-0565-5105 AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. AD - Infectious Diseases Service, Hospital of Valais and Institut Central des Hopitaux, Sion, Switzerland. LA - eng PT - Journal Article DEP - 20260620 PL - United States TA - Clin Infect Dis JT - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America JID - 9203213 SB - IM CIN - Clin Infect Dis. 2026 Jul 22:ciag450. doi: 10.1093/cid/ciag450. PMID: 42485615 EIN - Clin Infect Dis. 2026 Sep 30:ciag605. doi: 10.1093/cid/ciag605. PMID: 42814533 OTO - NOTNLM OT - Lambl's excrescences OT - infective endocarditis OT - transesophageal echocardiography OT - transthoracic echocardiography OT - valve strands EDAT- 2026/06/20 00:38 MHDA- 2026/06/20 00:38 CRDT- 2026/06/19 20:03 PHST- 2026/03/05 00:00 [received] PHST- 2026/04/27 00:00 [revised] PHST- 2026/05/05 00:00 [accepted] PHST- 2026/06/20 00:38 [medline] PHST- 2026/06/20 00:38 [pubmed] PHST- 2026/06/19 20:03 [entrez] AID - 8711984 [pii] AID - 10.1093/cid/ciag376 [doi] PST - aheadofprint SO - Clin Infect Dis. 2026 Jun 20:ciag376. doi: 10.1093/cid/ciag376. PMID- 42320015 OWN - NLM STAT- MEDLINE DCOM- 20260917 LR - 20260917 IS - 2561-1011 (Electronic) IS - 2561-1011 (Linking) VI - 10 DP - 2026 Jun 19 TI - Impact of a Cloud-Based Care Coordination Platform on False Cardiac Catheterization Laboratory Activations and Unnecessary Team Mobilization: Retrospective Cohort Study. PG - e76932 LID - 10.2196/76932 [doi] LID - e76932 AB - BACKGROUND: Rapid activation of the cardiac catheterization laboratory (CCL) for ST-segment elevation myocardial infarction (STEMI) is essential to minimize time to reperfusion. However, system-wide efforts to reduce treatment delays have been accompanied by increased false activations, defined as activations that do not result in emergent coronary intervention. False activations contribute to unnecessary team mobilization (UTM), staff fatigue, workflow disruption, and inefficient resource use. OBJECTIVE: This study aimed to evaluate whether the implementation of a cloud-based care coordination platform (Stenoa) was associated with reductions in false activations and UTMs at a high-volume tertiary cardiac center. METHODS: In September 2021, the McGill University Health Centre implemented Stenoa, a mobile, cloud-based STEMI coordination platform enabling systematic case validation using electrocardiographic and clinical data. A retrospective cohort study was conducted, including all CCL activations between September 2020 and December 2022. Activations were grouped as preimplementation (group 0: September 2020 to September 2021) and postimplementation (group 1: September 2021 to December 2022) periods. A false activation was defined as a CCL activation followed by case cancellation before any procedure was performed. The primary outcome was the rate of UTM. RESULTS: In total, 632 activations were analyzed (group 0: n=288; group 1: n=344). UTM decreased from 8.7% (23/265) to 4.4% (14/316) following platform implementation (P=.04). False activation frequency decreased from 10.2% (27/265) to 6.9% (22/316), although this difference did not reach statistical significance (P=.16). Among false activations, the proportion resulting in UTM declined from 85% to 63% (P=.08). CONCLUSIONS: The implementation of a cloud-based STEMI coordination platform was associated with a significant reduction in unnecessary catheterization laboratory team mobilization. Structured digital communication may improve workflow efficiency and resource use in STEMI systems of care. Further multicenter evaluation is warranted. CI - (c) William Gibson, Dawoud Al Kindi, Francois Brouillette, Ahmed Aldajani, Omar Chaabo, Yasmine Lachance, Elie Akl, Kshitij Badal Dandona, Giuseppe Martucci, Jean-Philippe Pelletier, Nicolo Piazza, Jeremy Y Levett, Tomer Moran, Marco Spaziano. Originally published in JMIR Cardio (https://cardio.jmir.org). FAU - Gibson, William AU - Gibson W AUID- ORCID: 0000-0001-7307-4746 AD - Department of Cardiology, McGill University Health Centre, 1001 Decarie Blvd, Montreal, QC, H4A 0B1, Canada, 1 (514) 934-1934. FAU - Al Kindi, Dawoud AU - Al Kindi D AUID- ORCID: 0009-0003-2309-330X AD - Department of Cardiology, McGill University Health Centre, 1001 Decarie Blvd, Montreal, QC, H4A 0B1, Canada, 1 (514) 934-1934. FAU - Brouillette, Francois AU - Brouillette F AUID- ORCID: 0009-0006-4234-0814 AD - Department of Cardiology, McGill University Health Centre, 1001 Decarie Blvd, Montreal, QC, H4A 0B1, Canada, 1 (514) 934-1934. FAU - Aldajani, Ahmed AU - Aldajani A AUID- ORCID: 0000-0001-5058-9683 AD - Department of Internal Medicine, Division of Cardiology, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia. FAU - Chaabo, Omar AU - Chaabo O AUID- ORCID: 0000-0002-9366-971X AD - Department of Cardiology, McGill University Health Centre, 1001 Decarie Blvd, Montreal, QC, H4A 0B1, Canada, 1 (514) 934-1934. FAU - Lachance, Yasmine AU - Lachance Y AUID- ORCID: 0009-0008-6091-2833 AD - Department of Cardiology, Faculty of Medicine, Universite de Montreal, Montreal, QC, Canada. FAU - Akl, Elie AU - Akl E AUID- ORCID: 0000-0001-5676-4171 AD - Department of Cardiology, McGill University Health Centre, 1001 Decarie Blvd, Montreal, QC, H4A 0B1, Canada, 1 (514) 934-1934. FAU - Dandona, Kshitij Badal AU - Dandona KB AUID- ORCID: 0009-0008-3828-2388 AD - Department of Cardiology, McGill University Health Centre, 1001 Decarie Blvd, Montreal, QC, H4A 0B1, Canada, 1 (514) 934-1934. FAU - Martucci, Giuseppe AU - Martucci G AUID- ORCID: 0009-0006-2951-5501 AD - Department of Cardiology, McGill University Health Centre, 1001 Decarie Blvd, Montreal, QC, H4A 0B1, Canada, 1 (514) 934-1934. FAU - Pelletier, Jean-Philippe AU - Pelletier JP AUID- ORCID: 0009-0009-6049-451X AD - Department of Cardiology, McGill University Health Centre, 1001 Decarie Blvd, Montreal, QC, H4A 0B1, Canada, 1 (514) 934-1934. FAU - Piazza, Nicolo AU - Piazza N AUID- ORCID: 0000-0003-2809-3408 AD - Department of Cardiology, McGill University Health Centre, 1001 Decarie Blvd, Montreal, QC, H4A 0B1, Canada, 1 (514) 934-1934. FAU - Levett, Jeremy Y AU - Levett JY AUID- ORCID: 0000-0003-2228-9557 AD - Department of Cardiology, McGill University Health Centre, 1001 Decarie Blvd, Montreal, QC, H4A 0B1, Canada, 1 (514) 934-1934. FAU - Moran, Tomer AU - Moran T AUID- ORCID: 0009-0009-9894-6585 AD - Department of Cardiology, McGill University, Montreal, QC, Canada. FAU - Spaziano, Marco AU - Spaziano M AUID- ORCID: 0000-0002-9762-9133 AD - Department of Cardiology, McGill University Health Centre, 1001 Decarie Blvd, Montreal, QC, H4A 0B1, Canada, 1 (514) 934-1934. LA - eng PT - Journal Article PT - Observational Study DEP - 20260619 PL - Canada TA - JMIR Cardio JT - JMIR cardio JID - 101718325 SB - IM MH - Retrospective Studies MH - *Hospital Rapid Response Team/organization & administration/statistics & numerical data MH - Cardiac Catheterization/statistics & numerical data MH - *Patient Care Planning/statistics & numerical data MH - *Cloud Computing MH - Electrocardiography MH - *ST Elevation Myocardial Infarction/diagnosis/therapy MH - *Unnecessary Procedures/statistics & numerical data MH - Humans MH - Health Plan Implementation MH - Male MH - Female MH - Aged PMC - PMC13282013 OTO - NOTNLM OT - ST-elevated myocardial infarction OT - STEMI OT - acute coronary syndrome OT - catheterization laboratory OT - clinical decision support OT - cloud-based app OT - digital communication OT - digital health OT - false activation OT - mobile health OT - quality improvement OT - reperfusion time OT - resource utilization OT - smartphone app OT - telemedicine COIS- Conflicts of Interest: MS serves as a medical officer for Stenoa and holds equity in the company. JYL holds a leadership position at Stenoa and holds equity in the company. TM has equity in Stenoa. All other authors have no other conflicts of interest to declare. EDAT- 2026/06/19 18:36 MHDA- 2026/06/21 22:42 PMCR- 2026/06/19 CRDT- 2026/06/19 16:13 PHST- 2025/05/08 00:00 [received] PHST- 2026/04/03 00:00 [revised] PHST- 2026/04/03 00:00 [accepted] PHST- 2026/06/21 22:42 [medline] PHST- 2026/06/19 18:36 [pubmed] PHST- 2026/06/19 16:13 [entrez] PHST- 2026/06/19 00:00 [pmc-release] AID - v10i1e76932 [pii] AID - 76932 [pii] AID - 10.2196/76932 [doi] PST - epublish SO - JMIR Cardio. 2026 Jun 19;10:e76932. doi: 10.2196/76932. PMID- 42319702 OWN - NLM STAT- Publisher LR - 20260619 IS - 1875-8312 (Electronic) IS - 1569-5794 (Linking) DP - 2026 Jun 19 TI - Virtual reality modeling for multidisciplinary surgical planning for complex single ventricular physiology. LID - 10.1007/s10554-026-03758-x [doi] AB - The selection of biventricular repair or Fontan completion for single-ventricle patients remains difficult to determine in borderline patients. We report how the use of a 3-dimensional virtual reality model informed an accurate estimation of a 34-month-old child's ventricular chamber size to confirm Fontan completion. Developed from CT scan imaging, the model simulated a virtual biventricular repair and demonstrated inadequate outflow tracts after patching and baffle rerouting. This case demonstrates the implications of virtual reality for congenital heart disease surgical planning, providing a shared, intuitive platform for multidisciplinary discussion and consensus-building among surgeons, cardiologists, imagers, and anesthesiologists. CI - (c) 2026. The Author(s). FAU - Nathan, Anokha AU - Nathan A AUID- ORCID: 0009-0001-2078-4717 AD - College of Biological Sciences, University of Chicago, 5841 S. Maryland Ave, Chicago, IL, 60637, USA. anathan4@uchicago.edu. FAU - Patel, Dhruvil A AU - Patel DA AD - Department of Internal Medicine, University of Chicago Medicine, Chicago, IL, USA. FAU - Nair, Priya AU - Nair P AD - Department of Internal Medicine, University of Chicago Medicine, Chicago, IL, USA. FAU - Earing, Michael G AU - Earing MG AD - Department of Pediatric Cardiology, University of Chicago Medicine, Chicago, IL, USA. FAU - Pophal, Stephen AU - Pophal S AD - Department of Pediatric Cardiology, University of Chicago Medicine, Chicago, IL, USA. FAU - Ganigara, Madhusudan AU - Ganigara M AD - Department of Pediatric Cardiology, University of Chicago Medicine, Chicago, IL, USA. LA - eng PT - Journal Article DEP - 20260619 PL - United States TA - Int J Cardiovasc Imaging JT - The international journal of cardiovascular imaging JID - 100969716 SB - IM OTO - NOTNLM OT - Congenital heart disease OT - Fontan repair OT - Single ventricle OT - Virtual reality COIS- Declarations. Competing interests: The authors declare no competing interests. EDAT- 2026/06/19 12:36 MHDA- 2026/06/19 12:36 CRDT- 2026/06/19 11:21 PHST- 2026/04/28 00:00 [received] PHST- 2026/06/11 00:00 [accepted] PHST- 2026/06/19 12:36 [medline] PHST- 2026/06/19 12:36 [pubmed] PHST- 2026/06/19 11:21 [entrez] AID - 10.1007/s10554-026-03758-x [pii] AID - 10.1007/s10554-026-03758-x [doi] PST - aheadofprint SO - Int J Cardiovasc Imaging. 2026 Jun 19. doi: 10.1007/s10554-026-03758-x. PMID- 42319533 OWN - NLM STAT- MEDLINE DCOM- 20260624 LR - 20261010 IS - 1559-0100 (Electronic) IS - 1355-008X (Linking) VI - 91 IP - 1 DP - 2026 Jun 19 TI - Clinical and laboratory characteristics of pediatric patients diagnosed with thyroid hormone resistance: A single-center experience. LID - 210 [pii] LID - 10.1007/s12020-026-04680-x [doi] AB - BACKGROUND: Thyroid hormone resistance beta (RTHbeta) is a rare genetic disorder characterized by reduced tissue responsiveness to thyroid hormones. This study aimed to describe the clinical, biochemical, and genetic characteristics of pediatric patients diagnosed with RTHbeta. METHODS: Children diagnosed with RTHbeta were retrospectively included in the study. Clinical, biochemical, hormonal, and genetic characteristics of the patients were analyzed RESULTS: A total of 13 patients were included. The mean age at diagnosis was 8.89 +/- 4.80 years. The diagnosis was established based on abnormal thyroid function tests in 53.8% of patients, family screening in 23.1%, investigation of short stature in 7.7%, and elevated TSH detected during newborn screening in 15.4%. Thyroid ultrasonography revealed no abnormalities in 77% of patients. Attention-deficit/hyperactivity disorder (ADHD) was present in 23.1% of patients, learning disabilities in 30.8%, tachycardia in 38.5%, and hypertension in 15.4%. One patient (7.7%) was receiving levothyroxine (LT4) therapy due to a prior misdiagnosis of hypothyroidism. Molecular genetic analysis identified 10 different heterozygous missense variants in the THRB gene, classified as likely pathogenic or pathogenic, one of which was novel. CONCLUSIONS: The combination of elevated free T3 (fT3) and free T4 (fT4) levels with normal or elevated TSH should raise suspicion for RTHbeta. The condition is usually asymptomatic and does not require treatment; however, misdiagnosis as hypo- or hyperthyroidism may lead to unnecessary interventions. Approximately 25-30% of patients present with ADHD and/or learning difficulties. Therefore, multidisciplinary evaluation including child psychiatry and early recognition of neurodevelopmental disorders may improve long-term outcomes. CI - (c) 2026. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Kolbasi, Baris AU - Kolbasi B AD - Diyarbakir Children's Hospital, Department of Pediatric Endocrinology, Diyarbakir, Turkey. drbaris47@gmail.com. FAU - Unal, Edip AU - Unal E AD - Faculty of Medicine, Department of Pediatric Endocrinology, Dicle University, Diyarbakir, Turkey. FAU - Durak, Hasan AU - Durak H AD - Department of Child and Adolescent Psychiatry, Diyarbakir Gazi Yasargil Training and Research Hospital, Diyarbakir, Turkey. FAU - Akalin, Akcahan AU - Akalin A AD - Diyarbakir Children's Hospital, Department of Pediatric Genetics, Diyarbakir, Turkiye. FAU - Gider, Tahsin AU - Gider T AD - Faculty of Medicine, Department of Pediatric Endocrinology, Dicle University, Diyarbakir, Turkey. FAU - Yildirim, Ruken AU - Yildirim R AD - Diyarbakir Children's Hospital, Department of Pediatric Endocrinology, Diyarbakir, Turkey. FAU - Ozalkak, Servan AU - Ozalkak S AD - Diyarbakir Children's Hospital, Department of Pediatric Endocrinology, Diyarbakir, Turkey. FAU - Karakaya, Amine Aktar AU - Karakaya AA AD - Diyarbakir Children's Hospital, Department of Pediatric Endocrinology, Diyarbakir, Turkey. FAU - Bestas, Asli AU - Bestas A AD - Department of Pediatric Endocrinology, Diyarbakir Gazi Yasargil Training and Research Hospital, Diyarbakir, Turkey. LA - eng PT - Journal Article PT - Observational Study DEP - 20260619 PL - United States TA - Endocrine JT - Endocrine JID - 9434444 SB - IM MH - *Thyroid Hormone Resistance Syndrome/diagnosis/genetics/pathology/physiopathology MH - Humans MH - Retrospective Studies MH - Infant, Newborn MH - Infant MH - Child, Preschool MH - Child MH - Adolescent MH - Cohort Studies MH - Male MH - Female MH - *Genes, erbA MH - Attention Deficit Disorder with Hyperactivity/physiopathology MH - Tachycardia/diagnosis/pathology OTO - NOTNLM OT - Attention-Deficit/Hyperactivity Disorder OT - Genetics OT - THRB gene OT - Thyroid Hormone Resistance beta OT - Thyroid hormones COIS- Declarations. Ethics approval: The study was conducted following approval from the Dicle University Faculty of Medicine Non-Interventional Clinical Research Ethics Committee (approval number: 17-01-2024/32). Conflict of interests: The authors declare no competing interests. EDAT- 2026/06/19 12:36 MHDA- 2026/06/19 12:37 CRDT- 2026/06/19 11:16 PHST- 2026/01/01 00:00 [received] PHST- 2026/05/22 00:00 [accepted] PHST- 2026/06/19 12:37 [medline] PHST- 2026/06/19 12:36 [pubmed] PHST- 2026/06/19 11:16 [entrez] AID - 10.1007/s12020-026-04680-x [pii] AID - 10.1007/s12020-026-04680-x [doi] PST - epublish SO - Endocrine. 2026 Jun 19;91(1):210. doi: 10.1007/s12020-026-04680-x. PMID- 42318665 OWN - NLM STAT- MEDLINE DCOM- 20261020 LR - 20261020 IS - 1467-1107 (Electronic) IS - 1047-9511 (Linking) VI - 36 IP - 6 DP - 2026 Jun TI - Transcatheter correction of superior sinus venosus atrial septal defect: single centre experience with short- to medium-term outcomes. PG - 1242-1248 LID - 10.1017/S1047951126113547 [doi] AB - INTRODUCTION: The superior sinus venosus atrial septal defect is situated immediately inferior to the junction of the superior caval vein (SCV) and the right atrium. It is usually associated with partial anomalous pulmonary venous drainage. Surgical correction used to be the only treatment option, but the transcatheter approach using a covered stent has recently evolved substantially. PATIENTS AND METHODS: This is a single-centre retrospective analysis of all patients who underwent transcatheter correction of sinus venosus atrial septal defect in our institution between January 2024 and January 2026. Data was collected from the Adult CHD multidisciplinary meeting records and patients' medical records. The hospital records, including case notes and other electronic data, were reviewed. RESULTS: Five patients were treated with transcatheter correction of sinus venosus atrial septal defect and partial anomalous pulmonary venous drainage. All patients were adults with an age range of 30-61 years. Three were males. One patient received a 100-mm Optimus-CVS polytetrafluoroethylene (PTFE)-Covered Stent XXL, whereas all remaining 4 patients received an 80-mm stent. One patient received a second stent for a residual shunt. There were no mortalities or immediate adverse events. The follow-up period at the time of manuscript submission so far is 3-24 months, and no late complications have been observed. CONCLUSIONS: Transcatheter closure of sinus venosus atrial septal defect is a feasible and safe procedure in selected patients with good results. The learning curve is still to be completed, and surgical options are not to be completely abolished. FAU - Elhedai, Huzeifa AU - Elhedai H AUID- ORCID: 0000-0003-2317-5316 AD - East Midlands Congenital Heart Centre, University Hospitals of Leicester NHS Trust, UK. ROR: https://ror.org/02fha3693 FAU - Shebani, Suhair AU - Shebani S AD - East Midlands Congenital Heart Centre, University Hospitals of Leicester NHS Trust, UK. ROR: https://ror.org/02fha3693 FAU - Kalantre, Atul AU - Kalantre A AD - East Midlands Congenital Heart Centre, University Hospitals of Leicester NHS Trust, UK. ROR: https://ror.org/02fha3693 FAU - Skinner, Gregory AU - Skinner G AD - East Midlands Congenital Heart Centre, University Hospitals of Leicester NHS Trust, UK. ROR: https://ror.org/02fha3693 FAU - Fraisse, Alain AU - Fraisse A AD - Guy's and St Thomas' Hospitals NHS Trust, UK. FAU - Kantzis, Marinos AU - Kantzis M AUID- ORCID: 0000-0001-5080-0119 AD - East Midlands Congenital Heart Centre, University Hospitals of Leicester NHS Trust, UK. ROR: https://ror.org/02fha3693 LA - eng PT - Journal Article DEP - 20260619 PL - England TA - Cardiol Young JT - Cardiology in the young JID - 9200019 RN - Atrial Septal Defect Sinus Venosus SB - IM MH - Humans MH - *Heart Septal Defects, Atrial/surgery/diagnosis MH - Male MH - Adult MH - Retrospective Studies MH - Female MH - *Cardiac Catheterization/methods MH - *Stents MH - Middle Aged MH - Treatment Outcome OTO - NOTNLM OT - Transcatheter correction OT - covered stent OT - sinus venosus atrial septal defect EDAT- 2026/06/19 06:33 MHDA- 2026/10/20 17:34 CRDT- 2026/06/19 05:13 PHST- 2026/10/20 17:34 [medline] PHST- 2026/06/19 06:33 [pubmed] PHST- 2026/06/19 05:13 [entrez] AID - S1047951126113547 [pii] AID - 10.1017/S1047951126113547 [doi] PST - ppublish SO - Cardiol Young. 2026 Jun;36(6):1242-1248. doi: 10.1017/S1047951126113547. Epub 2026 Jun 19. PMID- 30725667 STAT- Publisher CTDT- 20260619 PB - StatPearls Publishing DP - 2026 Jan TI - EMS Quality Improvement Programs. BTI - StatPearls AB - Quality improvement is an intentional process of implementing system-level changes with continuous reassessment to improve product delivery. In emergency medical services (EMS), this product is the delivery of high-quality prehospital care. This approach differs from quality assurance, which emphasizes compliance with protocols, processes, or policies. Quality improvement programs function most effectively in environments that implement change through robust, nonpunitive educational frameworks. Effective quality improvement programs maintain transparency. Administration and clinical staff understand the goals and methods of ongoing quality improvement initiatives. Quality improvement programs commonly use key performance indicators (KPIs) to measure clinical performance, identify areas for improvement, and assess the impact of process changes. EMS systems should base KPIs on clinical evidence, identified system deficits, or operational needs. The goal of quality improvement is the development of a high-reliability organization that operates in a relatively error-free state over extended periods. Quality Improvement in Emergency Medical Services EMS clinical quality as a concept gained prominence in the 2007 Institute of Medicine (IOM) publication, Emergency Medical Services: At the Crossroads. [IOM. Emergency Medical Services: At the Crossroads. 2007] The report identified challenges across many systems, including an inability to accurately characterize the quality of care and overall EMS system performance. The report recommended the development of national performance indicators. Several organizations were engaged in efforts to establish recommended performance measures at the time. Several quality initiatives have emerged in the decades following the IOM report, including EMS Agenda 2050 and the National EMS Quality Alliance (NEMSQA). The EMS Agenda 2050 project and subsequent publication represent a National Highway Traffic Safety Administration-funded initiative developed in conjunction with multiple government agencies. The purpose of the EMS 2050 project was to provide an updated vision for the future of EMS, with quality improvement integrated across all components of the vision statement. EMS 2050 underscores the need for quality improvement in EMS systems, stating, "Many organizations lack the resources, initiative, or desire needed to implement meaningful performance measurement and quality improvement systems, leaving them unable to determine whether the care provided is truly safe or effective." While many EMS systems continue to lack dedicated resources for quality improvement efforts, organizations such as the NEMSQA provide resources intended to make quality improvement more accessible to EMS systems. With input from stakeholder organizations and individuals, NEMSQA has developed and validated multiple quality measures for EMS systems. These measures include recommendations for both processes and outcomes, with emphasis on patient safety, clinical process effectiveness, and patient experience. The guidelines are regularly updated and based on current evidence. While benchmarks, or performance goals, for these measures have not yet been published, NEMSQA aims to develop benchmarks in the future using actual EMS data. These measures are available on the NEMSQA website. A recent publication applied these quality measures to data from the National EMS Information System dataset, demonstrating wide variation in performance across key EMS quality measures. (Source: [NEMSQA. National EMS Quality Alliance Measure Set. 2021] Quality improvement practices vary significantly among EMS agencies across the US. A 2015 survey of EMS agencies nationwide reported that 71% of surveyed agencies had dedicated quality improvement personnel. Examples of quality improvement projects include increasing prehospital aspirin administration rates in patients with acute coronary syndrome (ACS), strengthening paramedic identification of ST-elevation myocardial infarction, and decreasing peri-intubation hypoxia. Developing EMS systems have also successfully implemented continuous quality improvement programs to specifically address prehospital trauma care, with significant improvement in prespecified KPIs following targeted education. Each project began with the identification of a need for improvement. A plan was then developed, incorporating a process change and a mechanism to assess the impact of that change. The following questions should be considered prior to selecting KPIs and implementing any process improvement initiative: What is the aim? How and what should be measured? What changes should be implemented to improve the process, system, or outcome? The aim should be specific, evidence-based, and focused on patient-centric outcomes, with a clearly defined timeline. Measurements should be patient-centered, specific, and quantifiable. Changes to be implemented rely on a predictive assessment of system or process modifications expected to achieve the desired aim. Plan-Do-Study-Act Cycle Many EMS organizations utilize the Institute for Healthcare Improvement's Model for Improvement, which incorporates Plan-Do-Study-Act (PDSA) cycles. Effective PDSA cycles should be structured with participation from staff involved in all aspects of the targeted process. For example, a PDSA cycle aimed at improving cardiac arrest survival should include field paramedics, personnel from the medical director's office, administrative staff, and logistics personnel. Plan The purpose of the Plan step is to establish the objective of the project clearly and concisely and ensure alignment with the aim and measurement statements as previously defined. This step includes brainstorming potential solutions, selecting a single intervention for testing, and developing a structured plan for implementation and evaluation. The quality improvement committee should define the problem using objective data whenever possible and may use adjunct tools such as driver diagrams to guide system-level improvement efforts. The committee should clearly define how both the magnitude of the problem and the presence of improvement will be measured. For example, in a system attempting to improve aspirin administration rates, a measurable improvement may be defined as "aspirin administration is documented in 95% of patient encounters with a chief complaint of chest pain." The Plan step includes identification of potential solutions to the question, "What intervention will lead to improvement?" A structured plan for reevaluation should be developed following the selection of a specific intervention, such as the storage of aspirin in a dedicated pocket on the cardiac monitor. The plan should address the following questions: What is the problem? What is the intervention? How will the problem, change, and outcome be measured? How will the determination of improvement be made? These questions function as a framework to maintain methodological rigor during quality improvement planning. Explicit alignment of problem definition, intervention design, and measurement strategy supports reliable assessment of whether a change produces meaningful improvement. Do This segment is often the least complex in design but frequently the most challenging to execute. The Do step consists of implementing the contemplated intervention once a plan is established. A specific implementation date should be selected in the near future to initiate the process. An initial small-scale trial should be conducted rather than immediate system-wide deployment. This limited implementation, referred to as a "test of change," allows evaluation of whether the intervention produces the intended effect. Small-scale testing often identifies unforeseen issues that may require modification prior to broader implementation. For example, a checklist intended to improve intubation success may be developed and trialed during a single shift at a single ambulance station before expansion to the entire EMS system. Study The purpose of the Study step is to determine whether the implemented plan resulted in a change representing an improvement. Evaluation should reflect the aim established in the Plan step. During the Study phase, participants should also identify any unintended outcomes. The team should analyze which components of the plan were effective and which did not perform as intended. Objective data required to assess change and improvement should be collected as specified in the Plan step. For the intubation checklist example, evaluation may include comparison of intubation success rates before and after implementation, as well as assessment of compliance with checklist use. Feedback regarding the checklist itself should also be obtained from end users. Additional variables, including metrics potentially influenced by changes in intubation practice, such as scene time and cardiac arrest rates, should also be reviewed. The most commonly used tool for evaluating tests of change is the process control chart. These charts plot the proportion of cases meeting the defined success criteria over time and include a marker indicating the point of implementation of the intervention. Act The Act step is intended to implement actions based on findings from the Study step. The process change is either deployed system-wide or modified prior to broader implementation. Deployment is determined by outcomes of the Study phase and achievement of desired outcomes. Following the prior example, actions may include refinement of an airway checklist based on end-user feedback or provision of additional training. Once the Act step is completed, the cycle restarts with planning, including redeployment of an improved checklist, reevaluation of success rates, expansion of implementation to the entire system, or acquisition of additional feedback. This PDSA cycle is continued in an iterative process until the desired improvement is achieved. Key Components of a Quality Improvement Program Quality improvement in healthcare focuses on systematic efforts to enhance processes, outcomes, and overall system reliability. Effective programs integrate continuous evaluation with structured methods for identifying and addressing gaps in performance. Nonpunitive culture A quality improvement program must adopt a nonpunitive approach. A "just culture" strategy is a commonly used framework for this approach. Just culture is an organizational model that emphasizes shared accountability between individuals and the organization in error prevention and quality improvement. This model also recognizes that errors frequently result from multiple contributing factors, including system-level issues. Within a just culture framework, organizational responsibility includes continuous improvement of systems and processes in which providers operate, while providers remain responsible for safe clinical decision-making. Near misses are regarded as significant events comparable in importance to actual errors. A just culture approach promotes reporting of both near misses and adverse events through education-focused processes rather than punitive responses. Providers who submit reports may remain anonymous, receive feedback through closed-loop communication, and be acknowledged for reporting. The framework reinforces accountability for clinical actions and ongoing education, discourages tolerance of unsafe knowledge gaps, and promotes continuous system improvement to enhance safety and outcomes. Education Many quality improvement projects, particularly clinical quality improvement initiatives, require educational components to disseminate information regarding the intervention. An individual or team with an educational focus may facilitate achievement of the desired improvement outcomes. Team-based approach A quality improvement project should include representation from all areas of an organization that may be affected by changes resulting from the improvement initiative. Inclusion of individuals with diverse perspectives increases the pool of potential solutions and contributes to the generation of more effective interventions. A larger number of ideas increases the likelihood of identifying a successful change. Organizational culture must support belief in quality improvement programs at the highest levels of leadership, including executive leadership and supervisory staff, to facilitate effective implementation of change. Clear aims The quality improvement committee should select aims that are clearly defined, evidence-based, and aligned with clinical priorities. The timeline for implementation and PDSA cycles should also be explicitly outlined. Data elements selected for measurement must be appropriate to the defined aim and directly relevant to the intended outcome. CI - Copyright (c) 2026, StatPearls Publishing LLC. FAU - Lincoln, Erin W AU - Lincoln EW AD - University of Texas Southwestern FAU - Kohn, Melissa D AU - Kohn MD FAU - Jarvis, Jeffrey L AU - Jarvis JL AD - Fort Worth EMS. TCU Burnet School of Medicine LA - eng PT - Study Guide PT - Book Chapter PL - Treasure Island (FL) COIS- Disclosure: Erin W Lincoln declares no relevant financial relationships with ineligible companies. Disclosure: Melissa D Kohn declares no relevant financial relationships with ineligible companies. Disclosure: Jeffrey L Jarvis declares no relevant financial relationships with ineligible companies. EDAT- 2026/06/19 00:00 CRDT- 2026/06/19 00:00 AID - NBK536982 [bookaccession] PMID- 42312667 OWN - NLM STAT- MEDLINE DCOM- 20260618 LR - 20260819 IS - 2052-286X (Electronic) IS - 1357-6321 (Linking) VI - 32 IP - 1 DP - 2026 Jan 2 TI - Exploring the palliative care needs of patients with heart failure: A qualitative study. PG - 29-41 LID - 10.12968/ijpn.2025.0013 [doi] AB - BACKGROUND: Despite the increasing recognition of palliative care in the management of heart failure (HF), many patients continue to experience unmet care needs due to the delayed integration of supportive services. Identifying these needs is crucial for enhancing patient-centered care and informing healthcare policies. This qualitative study aimed to explore the palliative care needs of patients with HF. METHODS: This qualitative study employed a directed content analysis approach. Semi-structured in-depth interviews were conducted with 22 adult patients with heart failure in Ahvaz, Iran. Data collection continued until saturation, ensuring no new themes emerged. To ensure the trustworthiness of the findings, Lincoln and Guba's criteria were used. RESULTS: A total of 22 adult patients with heart failure participated in the study, with a mean age of 58.45+/-18.07 years. Data analysis revealed eight main categories of needs, including 'care structures and processes', 'physical aspects', 'psychological aspects', 'social aspects', 'cultural aspects', 'end-of-life care', 'ethical and legal aspects' and 'spiritual and existential aspects' with 30 subcategories. CONCLUSION: This study highlights the urgent need for early and thorough palliative care in heart failure management. By meeting patients' diverse needs with team-based, patient-focused methods, we can enhance quality of life, manage symptoms better and reduce healthcare challenges. These results are important for clinical practices and policies, supporting the creation of specialised palliative care programmes for heart failure patients. FAU - Ghaemizade Shushtari, Sima Sadat AU - Ghaemizade Shushtari SS AD - PhD candidate, Nursing Care Research Center in Chronic Diseases, School of Nursing and Midwifery, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. FAU - Gheibizadeh, Mahin AU - Gheibizadeh M AD - Associate professor, PhD candidate, Nursing Care Research Center in Chronic Diseases, School of Nursing and Midwifery, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. FAU - Rassouli, Maryam AU - Rassouli M AD - Professor, Cancer, Research Center, Shahid Beheshti University of Medical Sciences, Iran; College of Health Sciences, School of Nursing, University of Nizwa, Sultanate of Oman. FAU - Rokhafroz, Dariush AU - Rokhafroz D AD - Associate professor, Nursing Care Research Center in Chronic Diseases, School of Nursing and Midwifery, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. FAU - Jahani, Simin AU - Jahani S AD - Professor, Nursing Care Research Center in Chronic Diseases, School of Nursing and Midwifery, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran FAU - Torfi, Ekhlas AU - Torfi E AD - Assistant Professor, Atherosclerosis Research Center, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran LA - eng PT - Journal Article PL - England TA - Int J Palliat Nurs JT - International journal of palliative nursing JID - 9506762 SB - IM MH - Humans MH - *Heart Failure/nursing/psychology MH - *Palliative Care MH - Male MH - Female MH - Qualitative Research MH - Middle Aged MH - Iran MH - Aged MH - Adult MH - Aged, 80 and over MH - *Health Services Needs and Demand OTO - NOTNLM OT - caregiver burden OT - end-of-life care OT - heart failure OT - palliative care COIS- Statement of interest: None EDAT- 2026/06/18 12:33 MHDA- 2026/06/18 12:34 CRDT- 2026/06/18 07:34 PHST- 2026/06/18 12:34 [medline] PHST- 2026/06/18 12:33 [pubmed] PHST- 2026/06/18 07:34 [entrez] AID - 10.12968/ijpn.2025.0013 [doi] PST - ppublish SO - Int J Palliat Nurs. 2026 Jan 2;32(1):29-41. doi: 10.12968/ijpn.2025.0013. PMID- 42311767 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260618 LR - 20260813 IS - 2297-055X (Print) IS - 2297-055X (Electronic) IS - 2297-055X (Linking) VI - 13 DP - 2026 TI - Circulating biomarkers improve prediction of postoperative outcome after aortic valve surgery. PG - 1813821 LID - 10.3389/fcvm.2026.1813821 [doi] LID - 1813821 AB - BACKGROUND: Predicting adverse outcomes following aortic valve surgery remains challenging. This study aimed to investigate the association between preoperative circulating biomarkers and postoperative mortality and morbidity, with the goal of improving established risk stratification tools. METHODS: Between March 2018 and May 2022, 492 patients underwent surgical aortic valve replacement or repair and were included in a registry. Preoperative blood biomarkers, including hemoglobin, creatinine, high-sensitivity troponin I (hsTrop-I), GOT, GPT, INR, CRP, NT-proBNP and WBC, were sampled at baseline. Logistic regression analysis adjusted for EuroSCORE-II tested associations between biomarker levels and VARC-III adjudicated endpoints. Model fit was assessed using Akaike's Information Criterion, and likelihood ratio tests compared different prediction models. RESULTS: Preoperative hemoglobin (OR 0.70; 95% CI: 0.57, 0.87; p < 0.001), creatinine (OR 4.09; 95% CI: 1.63, 10.26; p = 0.003), high-sensitivity troponin I (OR 1.48; 95% CI: 1.11, 1.95; p = 0.007), GOT (OR 2.49; 95% CI: 1.06, 5.86; p = 0.036), INR (OR 4.74; 95% CI: 1.32, 17.05; p = 0.017), CRP (OR 2.14; 95% CI: 1.53, 3.00; p < 0.001), NT-proBNP (OR 2.06; 95% CI: 1.41, 3.00; p < 0.001), and WBC (OR 5.82; 95% CI: 1.88, 17.97; p = 0.002) were independently associated with 30-day mortality after adjustment for EuroSCORE-II. Models combining biomarkers with EuroSCORE-II outperformed those predicting mortality by EuroSCORE-II or biomarkers alone, as indicated by the lowest Akaike's Information Criterion and likelihood ratio tests. CONCLUSIONS: Combining established risk stratification models with preoperative biomarkers was associated with improved predictive performance for adverse outcomes after aortic valve surgery and may support heart team decision-making when choosing between surgical and transcatheter aortic valve replacement. CI - (c) 2026 Demal, Bialczak, Gossling, Ojeda, Bhadra, Sill, Petersen, Ludwig, Grundmann, Voigtlander, Waldschmidt, Hannen, Schofer, Blankenberg, Kirchhof, Renne, Conradi, Reichenspurner, Girdauskas and Schaefer. FAU - Demal, Till Joscha AU - Demal TJ AD - Department of Cardiovascular Surgery, University Heart and Vascular Center Hamburg, Hamburg, Germany. AD - German Center for Cardiovascular Research, partner site Hamburg/Kiel/Lubeck, Hamburg, Germany. FAU - Bialczak, Jenny AU - Bialczak J AD - Department of Cardiovascular Surgery, University Heart and Vascular Center Hamburg, Hamburg, Germany. FAU - Gossling, Alina AU - Gossling A AD - Department of Cardiology, University Heart and Vascular Center Hamburg, Hamburg, Germany. FAU - Ojeda, Francisco Miguel AU - Ojeda FM AD - Department of Cardiology, University Heart and Vascular Center Hamburg, Hamburg, Germany. FAU - Bhadra, Oliver Daniel AU - Bhadra OD AD - Department of Cardiovascular Surgery, University Heart and Vascular Center Hamburg, Hamburg, Germany. FAU - Sill, Bjorn AU - Sill B AD - Department of Cardiovascular Surgery, University Heart and Vascular Center Hamburg, Hamburg, Germany. FAU - Petersen, Johannes AU - Petersen J AD - Department of Cardiovascular Surgery, University Heart and Vascular Center Hamburg, Hamburg, Germany. FAU - Ludwig, Sebastian AU - Ludwig S AD - Department of Cardiology, University Heart and Vascular Center Hamburg, Hamburg, Germany. FAU - Grundmann, David AU - Grundmann D AD - Department of Cardiology, University Heart and Vascular Center Hamburg, Hamburg, Germany. FAU - Voigtlander, Lisa AU - Voigtlander L AD - Department of Cardiology, University Heart and Vascular Center Hamburg, Hamburg, Germany. FAU - Waldschmidt, Lara AU - Waldschmidt L AD - Department of Cardiology, University Heart and Vascular Center Hamburg, Hamburg, Germany. FAU - Hannen, Laura AU - Hannen L AD - Department of Cardiology, University Heart and Vascular Center Hamburg, Hamburg, Germany. FAU - Schofer, Niklas AU - Schofer N AD - Department of Cardiology, University Heart and Vascular Center Hamburg, Hamburg, Germany. FAU - Blankenberg, Stefan AU - Blankenberg S AD - German Center for Cardiovascular Research, partner site Hamburg/Kiel/Lubeck, Hamburg, Germany. AD - Department of Cardiology, University Heart and Vascular Center Hamburg, Hamburg, Germany. FAU - Kirchhof, Paulus AU - Kirchhof P AD - German Center for Cardiovascular Research, partner site Hamburg/Kiel/Lubeck, Hamburg, Germany. AD - Department of Cardiology, University Heart and Vascular Center Hamburg, Hamburg, Germany. FAU - Renne, Thomas AU - Renne T AD - Department of Clinical Chemistry and Laboratory Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Conradi, Lenard AU - Conradi L AD - Department of Cardiovascular Surgery, University Heart and Vascular Center Hamburg, Hamburg, Germany. FAU - Reichenspurner, Hermann AU - Reichenspurner H AD - Department of Cardiovascular Surgery, University Heart and Vascular Center Hamburg, Hamburg, Germany. AD - German Center for Cardiovascular Research, partner site Hamburg/Kiel/Lubeck, Hamburg, Germany. FAU - Girdauskas, Evaldas AU - Girdauskas E AD - Department of Cardiovascular Surgery, University Heart and Vascular Center Hamburg, Hamburg, Germany. AD - German Center for Cardiovascular Research, partner site Hamburg/Kiel/Lubeck, Hamburg, Germany. FAU - Schaefer, Andreas AU - Schaefer A AD - Department of Cardiovascular Surgery, University Heart and Vascular Center Hamburg, Hamburg, Germany. AD - German Center for Cardiovascular Research, partner site Hamburg/Kiel/Lubeck, Hamburg, Germany. LA - eng PT - Journal Article DEP - 20260602 PL - Switzerland TA - Front Cardiovasc Med JT - Frontiers in cardiovascular medicine JID - 101653388 PMC - PMC13270467 OTO - NOTNLM OT - aortic valve disease OT - biomarkers OT - euro SCORE II OT - risk stratificacion OT - surgical aortic valve replacement (SAVR) COIS- AS is a proctor for Abbott and received speaker honoraria and travel compensation from Abbott, Boston Scientific and Edwards Lifesciences. LC is advisory board member for Abbott, Medtronic, Jena Valve and consultant for Edwards Lifesciences, Boston Scientific, Micro Port, Microinterventions, Neovasc, Venus Medtech and Pi-Cardia. The remaining author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor [MV] declared a past co-authorship with the author [SL]. The author EG declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision. EDAT- 2026/06/18 06:31 MHDA- 2026/06/18 06:32 PMCR- 2026/06/02 CRDT- 2026/06/18 04:40 PHST- 2026/02/19 00:00 [received] PHST- 2026/04/16 00:00 [revised] PHST- 2026/04/21 00:00 [accepted] PHST- 2026/06/18 06:32 [medline] PHST- 2026/06/18 06:31 [pubmed] PHST- 2026/06/18 04:40 [entrez] PHST- 2026/06/02 00:00 [pmc-release] AID - 10.3389/fcvm.2026.1813821 [doi] PST - epublish SO - Front Cardiovasc Med. 2026 Jun 2;13:1813821. doi: 10.3389/fcvm.2026.1813821. eCollection 2026. PMID- 42310551 OWN - NLM STAT- MEDLINE DCOM- 20260827 LR - 20260911 IS - 1471-227X (Electronic) IS - 1471-227X (Linking) VI - 26 IP - 1 DP - 2026 Jun 17 TI - Emergency department eCPR: an exploratory observational study of human factors. LID - 10.1186/s12873-026-01650-4 [doi] LID - 233 AB - BACKGROUND: Extracorporeal cardiopulmonary resuscitation (eCPR) is a low-frequency, high-acuity intervention requiring technical skills and coordinated team performance. This exploratory study observed eCPR cases for elements of teamwork, provider stress, and environmental factors in the Emergency Department (ED). Reid's conceptual framework domains for human factors in healthcare teams were used as an analytical lens for interpreting the data. METHODS: An exploratory two-phase study was conducted across two eCPR hospital sites over 32 months, with an initial simulation and non-eCPR observation phase used to refine study methods. A subsequent eCPR case phase used convenience sampling of adult cardiac arrests to observe actual eCPR events. Following consent, eCPR team members allocated to key roles (such as team leadership and cannulation) were observed in detail during each case. Patient outcomes included Utstein measures and eCPR timings. Provider outcomes included mobile heart rate monitoring, salivary cortisol, and validated psychometric measures. Teamwork was assessed using the Mayo High-Performance Team Score (MHPTS). Environmental outcomes included measurements of ambient noise levels, team headcounts, and observations of eCPR workflow. RESULTS: Eighteen providers were observed during six eCPR events. The mean case age was 44.7 years and most patients presented with a shockable rhythm. System features consistently observed in the eCPR cases included predefined roles, individuals assigned to crowd control, and team leader summaries. Causal interpretations are limited by the small sample size and risk of observational bias. Within these limitations, individual provider salivary cortisol measurements were higher after eCPR copared with paired baseline samples. Teamwork scores (MHPTS) were in a moderate to high range (median = 12; IQR 10-13) and environmental observations reflected noisy ED spaces and crowding (headcount median = 20; IQR 18-29). CONCLUSION: This exploratory study found that human factors outcomes can be feasibly assessed during ED eCPR. Predefined roles and structured communication were observed and warrant further study. CI - (c) 2026. The Author(s). FAU - Coggins, Andrew R AU - Coggins AR AUID- ORCID: 0000-0002-5652-6920 AD - The University of Sydney, Block K, Level 6, Westmead Hospital, Sydney, NSW, Australia. andrewrcoggins@gmail.com. AD - Department of Emergency Medicine, Block K, Level 6, Westmead Hospital, Sydney, NSW, Australia. andrewrcoggins@gmail.com. FAU - Cho, Jeremiah E AU - Cho JE AD - Department of Emergency Medicine, Block K, Level 6, Westmead Hospital, Sydney, NSW, Australia. FAU - Crayton, Henry AU - Crayton H AUID- ORCID: 0000-0003-2367-6663 AD - Department of Emergency Medicine, Block K, Level 6, Westmead Hospital, Sydney, NSW, Australia. FAU - Scott, Amelia AU - Scott A AD - The University of Sydney, Block K, Level 6, Westmead Hospital, Sydney, NSW, Australia. FAU - Kruit, Natalie AU - Kruit N AUID- ORCID: 0000-0002-2904-1610 AD - The University of Sydney, Block K, Level 6, Westmead Hospital, Sydney, NSW, Australia. AD - Department of Anaesthetics, Block K, Level 6, Westmead Hospital, Sydney, NSW, Australia. FAU - Oliver, Matthew AU - Oliver M AUID- ORCID: 0000-0003-0715-3969 AD - Department of Emergency Medicine, Royal Prince Alfred Hospital, Sydney, NSW, Australia. AD - Green Light Institute for Emergency Care, Royal Prince Alfred Hospital, Sydney, NSW, Australia. LA - eng PT - Journal Article PT - Observational Study DEP - 20260617 PL - England TA - BMC Emerg Med JT - BMC emergency medicine JID - 100968543 RN - WI4X0X7BPJ (Hydrocortisone) SB - IM MH - Humans MH - *Emergency Service, Hospital/organization & administration MH - Female MH - *Patient Care Team/organization & administration MH - *Cardiopulmonary Resuscitation/methods MH - Male MH - Adult MH - *Heart Arrest/therapy MH - Middle Aged MH - *Extracorporeal Membrane Oxygenation MH - Leadership MH - Hydrocortisone/analysis MH - Working Conditions PMC - PMC13520427 OTO - NOTNLM OT - Extracorporeal cardiopulmonary resuscitation (eCPR) OT - Extracorporeal membrane oxygenation (ECMO) OT - Human factors OT - Non-technical skills OT - Teamwork COIS- Declarations. Ethics approval and consent to participate: Ethics approval was granted by the Western Sydney Local Health District Human Research Ethics Committee, Western Sydney Local Health District, NSW Health, Australia (Ref 2021/ETH11970). The requirement for informed patient consent was waived by the approving ethics committee due to the impracticality of obtaining consent during cardiac arrest, the observational nature of the study, the absence of any change to clinical management, and the absence of identifiable patient data. Staff members enrolled in the study provided consent for participation. Consent for publication: Written consent for publication was obtained from staff members shown in Fig. 3. Figure 3 has been reviewed and amended to ensure that no patient is identifiable. No identifiable patient information, images, or personal details are included in the manuscript. Competing interests: The authors declare no competing interests. EDAT- 2026/06/18 06:31 MHDA- 2026/08/27 05:35 PMCR- 2026/06/17 CRDT- 2026/06/18 00:15 PHST- 2025/11/26 00:00 [received] PHST- 2026/06/15 00:00 [accepted] PHST- 2026/08/27 05:35 [medline] PHST- 2026/06/18 06:31 [pubmed] PHST- 2026/06/18 00:15 [entrez] PHST- 2026/06/17 00:00 [pmc-release] AID - 10.1186/s12873-026-01650-4 [pii] AID - 1650 [pii] AID - 10.1186/s12873-026-01650-4 [doi] PST - epublish SO - BMC Emerg Med. 2026 Jun 17;26(1):233. doi: 10.1186/s12873-026-01650-4. PMID- 42309294 OWN - NLM STAT- MEDLINE DCOM- 20260925 LR - 20260925 IS - 1552-6259 (Electronic) IS - 0003-4975 (Linking) VI - 122 IP - 4 DP - 2026 Oct TI - Management Algorithm for Vasoplegic Shock After Cardiac Surgery: An Interdisciplinary Collaboration. PG - 909-920 LID - S0003-4975(26)00577-1 [pii] LID - 10.1016/j.athoracsur.2026.06.013 [doi] AB - BACKGROUND: Vasoplegic shock is distributive shock that follows cardiopulmonary bypass, characterized by hypotension, low systemic vascular resistance, and catecholamine resistance despite preserved or elevated cardiac output. Reported incidence ranges from 5% to 50%. Associated adverse outcomes include acute kidney injury, prolonged intensive care unit stay, and mortality. A single, universally accepted consensus definition is lacking, and few evidence-based best-practice management strategies exist. METHODS: A panel of 12 clinicians-cardiac surgeons, anesthesiologists, intensivists, and pharmacists-from 6 institutions conducted a structured expert review. PubMed and Embase were searched for research studies, including clinical trials, retrospective analyses, and mechanistic studies covering epidemiology, risk factors, prevention, and therapeutic strategies. Through iterative discussion and consensus building, the panel developed a pragmatic, algorithmic framework for management. RESULTS: Risk factors include preoperative renin-angiotensin-aldosterone inhibition, prior cardiac surgery, longer bypass duration, and higher transfusion burden. Preventive strategies include adjusting preoperative medications, managing intraoperative anesthetics and perfusion, and judicious transfusion thresholds. First-line therapy remains norepinephrine, with early addition of vasopressin, followed by angiotensin II for escalating support. Adjuncts such as methylene blue, hydroxocobalamin, and corticosteroids are complementary and considered in refractory cases, guided by mechanism and adverse effect profile. CONCLUSIONS: Vasoplegic shock is a common, high-mortality complication after cardiac surgery. We present an expert-derived treatment pathway intended as practical guidance for escalation, and we identify future research priorities. CI - Copyright (c) 2026 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Chatterjee, Subhasis AU - Chatterjee S AD - Division of Cardiothoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas; The Texas Heart Institute at Baylor College of Medicine, Houston, Texas; Division of Trauma and Acute Care Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas. Electronic address: subhasis.chatterjee@bcm.edu. FAU - Ortoleva, Jamel AU - Ortoleva J AD - Department of Anesthesiology, Boston Medical Center, Boston, Massachusetts; Chobanian & Avedisian School of Medicine, Boston University, Boston, Massachusetts. FAU - Arora, Rakesh C AU - Arora RC AD - Department of Surgery, Northwestern University, Feinberg School of Medicine, Chicago, Illinois. FAU - Dalton, Kelci R AU - Dalton KR AD - Department of Clinical Pharmacology, Baylor-St Luke's Medical Center, Houston, Texas. FAU - Engelman, Daniel T AU - Engelman DT AD - Heart & Vascular Program, Baystate Health, University of Massachusetts Chan Medical School-Baystate, Springfield, Massachusetts. FAU - Girardi, Natalia Ivascu AU - Girardi NI AD - Department of Anesthesiology, Weill Cornell Medicine, New York, New York. FAU - Grant, Michael C AU - Grant MC AD - Division of Cardiac Anesthesia, Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD. FAU - Miles, Travis J AU - Miles TJ AD - Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas. FAU - Moon, Marc R AU - Moon MR AD - Division of Cardiothoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas; The Texas Heart Institute at Baylor College of Medicine, Houston, Texas. FAU - Suero, Orlando R AU - Suero OR AD - Divisions of Cardiovascular Anesthesia and Critical Care Medicine, Department of Anesthesiology, Baylor College of Medicine, Houston, Texas. FAU - Wittwer, Erica AU - Wittwer E AD - Division of Critical Care, Department of Anesthesiology, Mayo Clinic, Rochester, Minnesota. FAU - Wieruszewski, Patrick M AU - Wieruszewski PM AD - Department of Pharmacy, Mayo Clinic, Rochester, Minnesota; Department of Anesthesiology, Mayo Clinic, Rochester, Minnesota. LA - eng PT - Journal Article PT - Review DEP - 20260617 PL - Netherlands TA - Ann Thorac Surg JT - The Annals of thoracic surgery JID - 15030100R SB - IM MH - Humans MH - *Algorithms MH - *Cardiac Surgical Procedures/adverse effects MH - *Vasoplegia/therapy/etiology MH - *Shock/therapy/etiology MH - *Postoperative Complications/therapy/etiology MH - Risk Factors MH - Cardiopulmonary Bypass/adverse effects COIS- Disclosures Rakesh C. Arora reports a relationship with Edwards Lifesciences, Medtronic, Serb Pharmaceuticals, HLS Therapeutics, and BioPorto that includes: speaking and lecture fees and travel reimbursement; and with Alexion and Renibus Therapeutics that includes: consulting or advisory. Daniel T. Engelman reports a relationship with Edwards Lifesciences, Renibus Therapeutics, Alexion, Genentech, CardioRenal Systems, Medela, Arthrex, AtriCure, Pharmacosmos, and BioPorto that includes: consulting or advisory. Marc R. Moon reports a relationship with Medtronic and Edwards Lifesciences that includes: consulting or advisory. Patrick M. Wieruszewski reports a relationship with Wolters Kluwer, UpToDate, and Viatris that includes: consulting or advisory. The other authors have no conflicts of interest to disclose. EDAT- 2026/06/18 00:32 MHDA- 2026/09/25 23:47 CRDT- 2026/06/17 19:36 PHST- 2025/09/29 00:00 [received] PHST- 2026/05/29 00:00 [revised] PHST- 2026/06/15 00:00 [accepted] PHST- 2026/09/25 23:47 [medline] PHST- 2026/06/18 00:32 [pubmed] PHST- 2026/06/17 19:36 [entrez] AID - S0003-4975(26)00577-1 [pii] AID - 10.1016/j.athoracsur.2026.06.013 [doi] PST - ppublish SO - Ann Thorac Surg. 2026 Oct;122(4):909-920. doi: 10.1016/j.athoracsur.2026.06.013. Epub 2026 Jun 17. PMID- 42308361 OWN - NLM STAT- Publisher LR - 20260617 IS - 1538-4683 (Electronic) IS - 1061-5377 (Linking) DP - 2026 Jun 18 TI - Native Aortic and Mitral Valve Endocarditis Caused by Brucella: A Rare Case Report and Systematic Review. LID - 10.1097/CRD.0000000000001364 [doi] AB - Brucella endocarditis (BE) is a rare but life-threatening complication of brucellosis, associated with an extremely high mortality rate. Among BE cases, aortic and mitral valve involvement remains poorly characterized due to complex pathophysiology and diagnostic and management challenges.This article describes a 52-year-old male admitted with persistent, intermittent fever and fatigue. Endocarditis of the native aortic and mitral valves caused by Brucella was confirmed via echocardiography and serological testing, with a mitral valve abscess as an additional complication. After combined antibiotic therapy and surgery, the patient recovered well, was discharged in stable condition, and remained healthy during a 1-year follow-up. The key to improving the prognosis of patients with BE lies in the integration of early diagnosis and timely intervention. This requires the establishment of a standardized clinical pathway that incorporates antibiotic-based infection control and timely surgical management, the initiation of early interventions for high-risk complications, and the implementation of a multidisciplinary team approach to optimize treatment outcomes while preserving organ function. CI - Copyright (c) 2026 Wolters Kluwer Health, Inc. All rights reserved. FAU - Abulimiti, Kadeyanmu AU - Abulimiti K AD - From the State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Xinjiang Medical University, Urumqi, Xinjiang, China. AD - Department of Cardiac Surgery, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China. FAU - Yiming, Nadire AU - Yiming N AD - From the State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Xinjiang Medical University, Urumqi, Xinjiang, China. AD - Department of Breast Surgery, The Third Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China. FAU - Zou, Qincun AU - Zou Q AD - From the State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Xinjiang Medical University, Urumqi, Xinjiang, China. AD - The Eighth Clinical Medical College of Xinjiang Medical University, Urumqi, Xinjiang, China. FAU - Waili, Alapati AU - Waili A AD - From the State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Xinjiang Medical University, Urumqi, Xinjiang, China. AD - Department of Pancreatic Surgery, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China. FAU - Chen, Dongliang AU - Chen D AD - From the State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Xinjiang Medical University, Urumqi, Xinjiang, China. AD - Department of Cardiac Surgery, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China. FAU - Zhang, Weimin AU - Zhang W AD - From the State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Xinjiang Medical University, Urumqi, Xinjiang, China. AD - Department of Cardiac Surgery, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China. LA - eng GR - SKLHIDCA-2023-24/Open Research Project of the National Key Laboratory of Etiology and Prevention for High-Incidence Diseases in Central Asia/ PT - Journal Article DEP - 20260618 PL - United States TA - Cardiol Rev JT - Cardiology in review JID - 9304686 SB - IM OTO - NOTNLM OT - Brucella endocarditis OT - antibiotic treatment OT - brucellosis OT - infective endocarditis OT - surgical management COIS- Disclosure: The authors declare no conflicts of interest. EDAT- 2026/06/17 18:35 MHDA- 2026/06/17 18:35 CRDT- 2026/06/17 15:02 PHST- 2026/06/17 18:35 [medline] PHST- 2026/06/17 18:35 [pubmed] PHST- 2026/06/17 15:02 [entrez] AID - 00045415-990000000-00914 [pii] AID - 10.1097/CRD.0000000000001364 [doi] PST - aheadofprint SO - Cardiol Rev. 2026 Jun 18. doi: 10.1097/CRD.0000000000001364. PMID- 42305170 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260617 LR - 20260813 IS - 2950-6050 (Electronic) IS - 2950-6050 (Linking) VI - 8 DP - 2025 Dec TI - Vacuum-assisted thrombectomy for intracardiac and intravascular thrombi: A single-center experience. PG - 100068 LID - 10.1016/j.xjse.2025.100068 [doi] LID - 100068 AB - OBJECTIVE: Percutaneous vacuum-assisted mechanical thrombectomy using venovenous bypass is a potential alternative to open surgery for the removal of intracardiac and intravascular/caval thrombi. We sought to evaluate the unique role and efficacy of this procedure in the treatment of high-risk patients deemed poor candidates for surgical thrombectomy. METHODS: Between May 2015 and October 2023, 40 patients underwent vacuum-assisted thrombectomy for intracardiac or caval thrombi using venovenous bypass at our medical center. Patient and case characteristics, procedural details, and postprocedural outcomes were collected retrospectively. All procedures involved a multidisciplinary approach by cardiac surgeons, interventional radiologists, and cardiac anesthesiologists. Cardiac electrophysiologists also participated in the procedures when patients needed concomitant cardiovascular implantable electronic device system extractions. RESULTS: Mean age of patients was 50 +/- 16 years. Indications included indwelling catheter thrombus (n = 10; 25%), cardiovascular implantable electronic device infection (n = 12, 30%), tricuspid endocarditis (n = 8, 20%), and bland and tumor thrombus (n = 11, 28%, n = 7, 18%, respectively). Successful removal rate (>70% of thrombus removed) was 85% (n = 34). Interventional adjuncts included cardiovascular implantable electronic device lead extraction (n = 10, 25%) and snaring from contralateral access site (n = 7, 18%). In-hospital and 30-day mortality were 5% (n = 2) and 8% (n = 3), respectively. Complications included postoperative red blood cell transfusion (n = 5, 13%), pulmonary embolism (n = 2, 5%), and recurrent thrombosis (n = 2, 5%). Median total follow-up time was 16 +/- 3 months, with either complete resolution or decreased burden of residual thrombus. CONCLUSIONS: Vacuum-assisted thrombectomy is a rapid, effective, and safe technique when treating critically ill patients with acute intracardiac and caval thrombi and vegetation. It can be a highly valuable adjunct when treating poor candidates for open cardiovascular surgery. CI - (c) 2025 The Author(s). FAU - Carroll, Adam M AU - Carroll AM AD - Department of Surgery, University of Colorado, Aurora, Colo. FAU - Bakdash, Kenaz AU - Bakdash K AD - Department of Radiology, University of Colorado, Aurora, Colo. FAU - Ghincea, Christian AU - Ghincea C AD - Department of Surgery, University of Colorado, Aurora, Colo. FAU - Chanes, Nicolas AU - Chanes N AD - Department of Surgery, University of Colorado, Aurora, Colo. FAU - Schramm, Kristofer AU - Schramm K AD - Department of Radiology, University of Colorado, Aurora, Colo. FAU - Seres, Tamas AU - Seres T AD - Department of Anesthesiology, University of Colorado, Aurora, Colo. FAU - Reece, T Brett AU - Reece TB AD - Department of Cardiothoracic Surgery, University of Colorado, Aurora, Colo. FAU - Zipse, Matthew AU - Zipse M AD - Department of Cardiology, University of Colorado, Aurora, Colo. FAU - Reyes, Robert AU - Reyes R AD - Department of Radiology, University of Colorado, Aurora, Colo. FAU - Casadaban, Leigh AU - Casadaban L AD - Department of Radiology, University of Colorado, Aurora, Colo. FAU - Rochon, Paul J AU - Rochon PJ AD - Department of Radiology, University of Colorado, Aurora, Colo. FAU - Aftab, Muhammad AU - Aftab M AD - Department of Cardiothoracic Surgery, University of Colorado, Aurora, Colo. LA - eng PT - Journal Article DEP - 20251106 PL - United States TA - JTCVS Struct Endovasc JT - JTCVS structural and endovascular JID - 9918991787106676 PMC - PMC13244764 OTO - NOTNLM OT - endovascular OT - intracardiac thrombus OT - intravascular thormbus OT - minimally invasive COIS- The authors reported no conflicts of interest. The Journal policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest. EDAT- 2026/06/17 06:31 MHDA- 2026/06/17 06:32 PMCR- 2025/11/06 CRDT- 2026/06/17 05:04 PHST- 2025/03/31 00:00 [received] PHST- 2025/07/28 00:00 [revised] PHST- 2025/07/30 00:00 [accepted] PHST- 2026/06/17 06:32 [medline] PHST- 2026/06/17 06:31 [pubmed] PHST- 2026/06/17 05:04 [entrez] PHST- 2025/11/06 00:00 [pmc-release] AID - S2950-6050(25)00027-0 [pii] AID - 100068 [pii] AID - 10.1016/j.xjse.2025.100068 [doi] PST - epublish SO - JTCVS Struct Endovasc. 2025 Nov 6;8:100068. doi: 10.1016/j.xjse.2025.100068. eCollection 2025 Dec. PMID- 42304811 OWN - NLM STAT- Publisher LR - 20260617 IS - 2515-7949 (Electronic) IS - 1750-4589 (Linking) DP - 2026 Jun 16 TI - Safer local anaesthetic practices through multidisciplinary engagement: A pre-post intervention study. PG - 17504589261454167 LID - 10.1177/17504589261454167 [doi] AB - INTRODUCTION: A fatal cardiac arrest in 2022 caused by a local anaesthetic overdose highlighted significant gaps in local anaesthetic safety, including inconsistent documentation, variable dosing practices, and inadequate communication. This quality improvement project aimed to improve local anaesthetic safety through standardised documentation, ideal body weight-based dosing, and structured multidisciplinary communication. METHODS: A pre-post intervention study was conducted at a district general hospital in South East England. Baseline data were collected using structured questionnaires completed by Operating Department Practitioners during surgical cases. Interventions, informed by national anaesthetic safety guidance, included standardised local anaesthetic documentation, mandatory ideal body weight-based dose calculation, surgeon-led vial checks, and routine discussion of local anaesthetic use during preoperative briefings. Post-intervention data were collected using the same methodology across cases. RESULTS: Documentation of local anaesthetic administration in the anaesthetic chart increased from 68% (19/28) pre-intervention to 91% (29/32) post-intervention. The use of ideal body weight-based dosing increased from 29% (8/28) to 94% (30/32). Discussion of local anaesthetic during the preoperative brief improved from 82% (23/28) to 100% (32/32). The number of local anaesthetic overdoses decreased from two cases pre-intervention to one case post-intervention, with no associated patient harm. CONCLUSION: Targeted multidisciplinary interventions, including standardised documentation, structured communication, and ideal body weight-based dosing, resulted in substantial improvements in local anaesthetic safety. These findings support the adoption of simple, scalable safety measures to reduce dosing errors and enhance perioperative patient safety. FAU - Ozdemir, Cansu AU - Ozdemir C AUID- ORCID: 0009-0008-3454-3624 AD - School of Medicine, Faculty of Life Sciences and Medicine, King's College London, London, UK. FAU - Tailor, Aksh AU - Tailor A AD - School of Medicine, Faculty of Life Sciences and Medicine, King's College London, London, UK. FAU - Mubanga, Chimba AU - Mubanga C AD - School of Medicine, Faculty of Life Sciences and Medicine, King's College London, London, UK. FAU - Clews, George AU - Clews G AD - Medway Maritime Hospital NHS Trust, Kent, UK. FAU - Krishnan, Priya AU - Krishnan P AD - Medway Maritime Hospital NHS Trust, Kent, UK. LA - eng PT - Journal Article DEP - 20260616 PL - England TA - J Perioper Pract JT - Journal of perioperative practice JID - 101271023 SB - IM OTO - NOTNLM OT - Anaesthetics - management and care OT - Anaesthetics - pharmacology OT - Clinical audit OT - Evidence-based practice OT - Patient safety OT - Service improvement OT - outcomes EDAT- 2026/06/17 06:31 MHDA- 2026/06/17 06:31 CRDT- 2026/06/17 02:42 PHST- 2026/06/17 06:31 [medline] PHST- 2026/06/17 06:31 [pubmed] PHST- 2026/06/17 02:42 [entrez] AID - 10.1177/17504589261454167 [doi] PST - aheadofprint SO - J Perioper Pract. 2026 Jun 16:17504589261454167. doi: 10.1177/17504589261454167. PMID- 42303791 OWN - NLM STAT- Publisher LR - 20260616 IS - 1432-0932 (Electronic) IS - 0940-6719 (Linking) DP - 2026 Jun 17 TI - Prediction of progressive local kyphosis following PVP/PKP for osteoporotic vertebral fractures based on the OF classification. LID - 10.1007/s00586-026-10100-5 [doi] AB - PURPOSE: The aim of this study was to identify risk factors for progressive local kyphosis (PLK) following percutaneous vertebroplasty/kyphoplasty (PVP/PKP) in patients with osteoporotic vertebral fracture (OVF) and to develop a predictive model based on the osteoporotic fracture (OF) classification, integrating baseline characteristics, imaging parameters, and surgical factors. This model aims to preoperatively identify high-risk patients for PLK and to optimize perioperative surgical decision-making. METHODS: This retrospective cohort study included 374 OVF patients who underwent single-level PVP/PKP with a >/= 2-year follow-up. Patients were randomly divided into a derivation cohort (n = 267) and a validation cohort (n = 107). Multidimensional data, including demographics, bone mineral density, comorbidities, imaging parameters (local kyphotic angle [LKA], vertebral compression ratio, OF classification, and endplate integrity), surgical details (cement volume/distribution), and clinical outcomes (visual analog scale [VAS]/Oswestry Disability Index [ODI]), were collected. PLK was defined as a >/= 10 degrees increase in the LKA at the final follow-up compared with that on postoperative Day 1. Predictors were identified using random forest, least absolute shrinkage and selection operator (LASSO) regression, and decision tree analyses. A risk scoring system was developed via logistic regression and validated using receiver operating characteristic (ROC) curves, Hosmer-Lemeshow tests, calibration curves, and decision curve analysis (DCA). RESULTS: Among 267 patients in the derivation cohort, 43 (16.1%) developed PLK. Compared with the non-PLK group, the PLK group had significantly greater vertebral height loss and worse final VAS/ODI scores. The key predictors identified included the reclassified OF system (Type I, II, and III), the presence of an intravertebral cleft, the presence of cardiac disease, and the overcorrection of the LKA (> 4.5 degrees intraoperatively). A 9-point risk score was established (AUC = 0.915; cutoff = 2.5), with a sensitivity of 57.8% and specificity of 85.3%. Validation cohort analysis confirmed robust performance (AUC = 0.881). DCA demonstrated superior clinical net benefit within a threshold probability of 10-50%. CONCLUSIONS: In this study, a predictive scoring system integrating the OF classification, imaging features, and surgical factors was developed to identify OVF patients at high risk for PLK. A total score > 2.5 serves as a clinical decision-support threshold, suggesting that these patients may benefit from a multidisciplinary evaluation for alternative stabilization strategies or intensified postoperative surveillance, tailored to clinical judgment and individualized patient factors. CI - (c) 2026. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Wang, JiaDong AU - Wang J AD - Southeast University, Nanjing, China. AD - ZhongDa Hospital, Southeast University, Nanjing, China. FAU - Fan, Pan AU - Fan P AD - Southeast University, Nanjing, China. AD - ZhongDa Hospital, Southeast University, Nanjing, China. FAU - Liu, Lei AU - Liu L AD - Southeast University, Nanjing, China. AD - ZhongDa Hospital, Southeast University, Nanjing, China. FAU - Wang, PeiYang AU - Wang P AD - Southeast University, Nanjing, China. FAU - Tao, Yuao AU - Tao Y AD - Southeast University, Nanjing, China. FAU - Li, Xi AU - Li X AD - Southeast University, Nanjing, China. FAU - Zhang, Lele AU - Zhang L AD - Southeast University, Nanjing, China. FAU - Xie, ZhiYang AU - Xie Z AD - Southeast University, Nanjing, China. AD - ZhongDa Hospital, Southeast University, Nanjing, China. FAU - Wang, YunTao AU - Wang Y AD - Southeast University, Nanjing, China. wangyttod@seu.edu.cn. AD - ZhongDa Hospital, Southeast University, Nanjing, China. wangyttod@seu.edu.cn. LA - eng GR - Grant No. 2024M760450/China Postdoctoral Science Foundation/ GR - Grant No. CZXM-GSP-RC50/Scientific Research Talent Cultivation Project of Zhongda Hospital Affiliated to Southeast University/ GR - Grant No. KD2024KYJJ213/Scientific Research Development Fund of Kangda College of Nanjing Medical University/ PT - Journal Article DEP - 20260617 PL - Germany TA - Eur Spine J JT - European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society JID - 9301980 SB - IM OTO - NOTNLM OT - Osteoporotic vertebral fracture OT - Percutaneous vertebroplasty/kyphoplasty OT - Predictive model OT - Progressive local kyphosis OT - Risk stratification COIS- Declarations. Competing interests: The authors declare no competing interests. Ethical statement: This single-center retrospective study was approved by the Ethics Committee of Zhongda Hospital Southeast University (Approval No. 2024ZDSYLL470-P01). All participants provided informed consent. EDAT- 2026/06/17 00:36 MHDA- 2026/06/17 00:36 CRDT- 2026/06/16 23:24 PHST- 2025/07/01 00:00 [received] PHST- 2026/06/08 00:00 [accepted] PHST- 2026/05/26 00:00 [revised] PHST- 2026/06/17 00:36 [medline] PHST- 2026/06/17 00:36 [pubmed] PHST- 2026/06/16 23:24 [entrez] AID - 10.1007/s00586-026-10100-5 [pii] AID - 10.1007/s00586-026-10100-5 [doi] PST - aheadofprint SO - Eur Spine J. 2026 Jun 17. doi: 10.1007/s00586-026-10100-5. PMID- 28613729 STAT- Publisher CTDT- 20260617 PB - StatPearls Publishing DP - 2026 Jan TI - Transcatheter Aortic Valve Replacement (TAVR). BTI - StatPearls AB - Aortic stenosis is a progressive valvular disorder characterized by increasing fibrosis and calcification of the valve, making it the most common cause of left ventricular outflow tract (LVOT) obstruction. Once the disease reaches a moderate stage, there is a high likelihood of progression to severe aortic stenosis. Historically, surgical aortic valve replacement (SAVR) was the exclusive definitive treatment; however, patients deemed at high surgical risk were often limited to palliative measures like diuretics and balloon valvuloplasty, which failed to improve long-term survival. The emergence of transcatheter aortic valve replacement (TAVR) has provided a vital lifeline for inoperable patients, delivering both immediate symptom relief and a statistically significant mortality benefit. The conceptual foundation of TAVR dates back to 1989, when Danish researcher HR Andersen conducted early testing of balloon-expandable valves in animal models. This clinical breakthrough culminated in 2002, when Dr Alain Cribier performed the first successful human percutaneous aortic valve replacement on an inoperable patient. Regulatory milestones followed rapidly: the United States Food and Drug Administration (FDA) first approved TAVR for prohibitive-risk patients in 2011, then expanded approval to high-risk cohorts in 2012. By 2015, the indication included "valve-in-valve" procedures for failed bioprostheses, and in 2016, it was expanded to include intermediate-risk patients. Following landmark evidence from the PARTNER 3 trial, the FDA further expanded TAVR indications in 2019 to include low-risk patients, establishing it as a preferred first-line therapy for many. Today, TAVR has evolved into a global standard of care, now recognized as noninferior to surgery across the entire surgical risk spectrum. Contemporary 2025 guidelines have further broadened their scope to include the treatment of pure aortic regurgitation in symptomatic patients ineligible for surgery and bicuspid aortic valve stenosis in patients at increased surgical risk, provided anatomical suitability is confirmed. Modern management is directed by a multidisciplinary heart team that uses advanced multimodality imaging to integrate clinical factors, lifetime management considerations, and patient preferences to optimize outcomes. This interprofessional approach ensures that TAVR provides not only a survival advantage but also quicker recovery times and enhanced quality of life compared to traditional open-heart surgery. CI - Copyright (c) 2026, StatPearls Publishing LLC. FAU - Golla, Maheswara Satya G AU - Golla MSG AD - West Virginia University FAU - Tawney, Adam AU - Tawney A AD - Beaumont Hospital FAU - Young, Michael AU - Young M AD - Marian University LA - eng PT - Study Guide PT - Book Chapter PL - Treasure Island (FL) COIS- Disclosure: Maheswara Satya G Golla declares no relevant financial relationships with ineligible companies. Disclosure: Adam Tawney declares no relevant financial relationships with ineligible companies. Disclosure: Michael Young declares no relevant financial relationships with ineligible companies. EDAT- 2026/06/17 00:00 CRDT- 2026/06/17 00:00 AID - NBK431075 [bookaccession] PMID- 42301235 OWN - NLM STAT- MEDLINE DCOM- 20260806 LR - 20260806 IS - 1531-7080 (Electronic) IS - 0268-4705 (Linking) VI - 41 IP - 5 DP - 2026 Sep 1 TI - Minimally invasive approaches to coronary artery bypass grafting: techniques, current evidence, and future directions. PG - 436-444 LID - 10.1097/HCO.0000000000001322 [doi] AB - PURPOSE OF REVIEW: Conventional coronary artery bypass grafting (CABG) is most commonly performed via median sternotomy, an approach that can be associated with postoperative pain, sternal wound complications, and prolonged recovery. Over the past two decades, multiple minimally invasive coronary surgery strategies have been developed, offering sternotomy-sparing alternatives that may reduce surgical trauma and accelerate recovery in appropriately selected patients. This review summarizes contemporary minimally invasive strategies, focusing on their procedural steps, patient selection, clinical outcomes, and evolving role in contemporary coronary revascularization. RECENT FINDINGS: Contemporary techniques include minimally invasive direct coronary artery bypass (MIDCAB), endoscopic/robotic-assisted coronary artery bypass, totally endoscopic coronary artery bypass (TECAB), and hybrid coronary revascularization (HCR), which combines CABG with percutaneous coronary intervention (PCI). Available evidence, largely from observational series and experienced centers, supports favorable graft patency and recovery profiles; however, comparative long-term data remain limited for multivessel and robotic approaches. Owing to their inherent technical complexity, steep learning curves, and high costs of robotic platforms, widespread adoption of MI-CABG has remained limited. SUMMARY: MI-CABG offers an important sternotomy-sparing option for selected patients with coronary artery disease. Wider adoption will depend on careful patient selection, structured training, multidisciplinary Heart Team decision-making, and stronger comparative evidence defining which patients benefit most. CI - Copyright (c) 2026 Wolters Kluwer Health, LLC. All rights reserved. FAU - Hassan, Syed M Ali AU - Hassan SMA AD - Division of Cardiac Surgery, Department of Surgery. FAU - Maatallah, Mohamed AU - Maatallah M AD - Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. FAU - Patel, Shubh AU - Patel S AD - Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. FAU - Verma, Meena AU - Verma M AD - Royal College of Surgeons in Ireland, Dublin, Ireland. FAU - Davierwala, Piroze AU - Davierwala P AD - Division of Cardiac Surgery, Department of Surgery. AD - Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. AD - Division of Cardiovascular Surgery, Peter Munk Cardiac Centre, Toronto General Hospital, University of Toronto, Ontario, Canada. LA - eng PT - Journal Article PT - Review DEP - 20260615 PL - United States TA - Curr Opin Cardiol JT - Current opinion in cardiology JID - 8608087 SB - IM MH - Humans MH - *Coronary Artery Bypass/methods/trends MH - *Minimally Invasive Surgical Procedures/methods/trends MH - *Coronary Artery Disease/surgery MH - Robotic Surgical Procedures/methods MH - Endoscopy/methods MH - Patient Selection MH - Percutaneous Coronary Intervention/methods OTO - NOTNLM OT - hybrid coronary revascularization OT - minimally invasive coronary artery bypass grafting OT - off-pump coronary artery bypass grafting OT - robotic-assisted coronary artery bypass grafting OT - totally endoscopic coronary artery bypass EDAT- 2026/06/16 13:31 MHDA- 2026/08/06 12:37 CRDT- 2026/06/16 10:44 PHST- 2026/08/06 12:37 [medline] PHST- 2026/06/16 13:31 [pubmed] PHST- 2026/06/16 10:44 [entrez] AID - 00001573-990000000-00284 [pii] AID - 10.1097/HCO.0000000000001322 [doi] PST - ppublish SO - Curr Opin Cardiol. 2026 Sep 1;41(5):436-444. doi: 10.1097/HCO.0000000000001322. Epub 2026 Jun 15. PMID- 42298752 OWN - NLM STAT- MEDLINE DCOM- 20260616 LR - 20260817 IS - 1748-0361 (Electronic) IS - 0890-765X (Print) IS - 0890-765X (Linking) VI - 42 IP - 2 DP - 2026 Mar TI - Tailoring the Relational Playbook for Cardiology Teams to the Rural Hospital Medicine Setting: A Multi-Method Pre-Implementation Evaluation. PG - e70165 LID - 10.1111/jrh.70165 [doi] LID - e70165 AB - PURPOSE: The Relational Playbook for Cardiology Teams is a 6-month, evidence-based leadership development program designed to foster supportive learning environments within the Veterans Health Administration (VA). The Playbook features 50 leadership practices and resources, including readings, clinical examples, videos, and podcasts for flexible, asynchronous learning. Participants complete monthly independent study and implement 11 interventions during team meetings or one-on-one interactions. While rural healthcare settings may benefit from the Playbook, adaptations are needed to ensure acceptability, appropriateness, and feasibility. This study aimed to tailor the Playbook for rural hospital medicine using a theory-informed multi-method pre-implementation approach. METHODS: Clinical leaders in medicine, nursing, social work, and pharmacy were recruited from three rural VA hospitals. Facility-level data were drawn from the 2023 VA Support Service Center Capital Assets database and the VA Hospital Medicine Survey. Observational data from site visits were collected using a structured template and analyzed through team-based rapid qualitative content analysis. FINDINGS: In 2024, we conducted three site visits at intermediate-complexity VA hospitals serving rural Veterans. Clinical leaders at each site reported potential barriers to engagement, including leadership instability, physician burnout, and limited time for professional development. Tailoring strategies were recommended, including expanding recruitment to all clinical leaders, streamlining site visits, and using publicly available data to contextualize site-specific challenges. CONCLUSION: A multi-method pre-implementation approach enabled effective adaptation of the Playbook, improving its relevance for rural settings. Early engagement and flexible implementation are key to successful adaptation. Future evaluation will assess impact on team dynamics and Veteran care. CI - (c) 2026 The Author(s). The Journal of Rural Health published by Wiley Periodicals LLC on behalf of National Rural Health Association. FAU - Gilmartin, Heather M AU - Gilmartin HM AD - Denver/Seattle Center of Innovation for Veteran-Centered and Value Driven Care, VA Eastern Colorado Healthcare System, Aurora, Colorado, USA. AD - Department of Health Systems, Management and Policy, Colorado School of Public Health, University of Colorado, Anschutz Medical Campus, Aurora, Colorado, USA. FAU - Perry, Paige AU - Perry P AD - Denver/Seattle Center of Innovation for Veteran-Centered and Value Driven Care, VA Eastern Colorado Healthcare System, Aurora, Colorado, USA. FAU - Connelly, Brigid AU - Connelly B AD - Denver/Seattle Center of Innovation for Veteran-Centered and Value Driven Care, VA Eastern Colorado Healthcare System, Aurora, Colorado, USA. FAU - Daus, Marguerite AU - Daus M AUID- ORCID: 0000-0001-7640-9986 AD - Denver/Seattle Center of Innovation for Veteran-Centered and Value Driven Care, VA Eastern Colorado Healthcare System, Aurora, Colorado, USA. FAU - Ladebue, Amy AU - Ladebue A AD - Denver/Seattle Center of Innovation for Veteran-Centered and Value Driven Care, VA Eastern Colorado Healthcare System, Aurora, Colorado, USA. FAU - Hess, Edward AU - Hess E AD - Denver/Seattle Center of Innovation for Veteran-Centered and Value Driven Care, VA Eastern Colorado Healthcare System, Aurora, Colorado, USA. FAU - Morgan, Brianne AU - Morgan B AD - Denver/Seattle Center of Innovation for Veteran-Centered and Value Driven Care, VA Eastern Colorado Healthcare System, Aurora, Colorado, USA. FAU - Nolan, John P Jr AU - Nolan JP Jr AD - Independent Researcher, Veteran Partner, El Dorado, Arkansas, USA. FAU - Sjoberg, Heidi AU - Sjoberg H AD - Denver/Seattle Center of Innovation for Veteran-Centered and Value Driven Care, VA Eastern Colorado Healthcare System, Aurora, Colorado, USA. FAU - Subramaniam, Soumya AU - Subramaniam S AD - Denver/Seattle Center of Innovation for Veteran-Centered and Value Driven Care, VA Eastern Colorado Healthcare System, Aurora, Colorado, USA. FAU - Anderson, Melver L 3rd AU - Anderson ML 3rd AD - VHA Hospital Medicine, Specialty Care Program Office, Veterans Health Administration, Washington, DC, USA. AD - Hospital Medicine Section, VA Eastern Colorado Healthcare System, Aurora, Colorado, USA. AD - Division of Hospital Medicine, University of Colorado Anschutz School of Medicine, Aurora, Colorado, USA. FAU - Leonard, Chelsea AU - Leonard C AD - Denver/Seattle Center of Innovation for Veteran-Centered and Value Driven Care, VA Eastern Colorado Healthcare System, Aurora, Colorado, USA. LA - eng GR - NOMAD #PRFY-00603/Department of Veterans Affairs, Veterans Health Administration, Office of Rural Health/ GR - Denver/Seattle Center of Innovation for Veteran-Centered and Value Driven Care/ GR - 1IK2HX002567-01A1/Career Development/ GR - VA Office of Research and Development/ PT - Journal Article PL - England TA - J Rural Health JT - The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association JID - 8508122 SB - IM MH - Humans MH - Hospitals, Rural/organization & administration MH - *Cardiology/methods/education MH - United States MH - Leadership MH - *Patient Care Team/standards/trends MH - United States Department of Veterans Affairs/organization & administration PMC - PMC13269670 OTO - NOTNLM OT - high reliability OT - hospital medicine OT - pre-implementation OT - rural workforce OT - training COIS- All authors receive some salary support from the Department of Veterans Affairs. EDAT- 2026/06/16 06:35 MHDA- 2026/06/16 06:36 PMCR- 2026/06/16 CRDT- 2026/06/16 00:50 PHST- 2026/04/08 00:00 [revised] PHST- 2025/09/04 00:00 [received] PHST- 2026/04/17 00:00 [accepted] PHST- 2026/06/16 06:36 [medline] PHST- 2026/06/16 06:35 [pubmed] PHST- 2026/06/16 00:50 [entrez] PHST- 2026/06/16 00:00 [pmc-release] AID - JRH70165 [pii] AID - 10.1111/jrh.70165 [doi] PST - ppublish SO - J Rural Health. 2026 Mar;42(2):e70165. doi: 10.1111/jrh.70165. PMID- 42294519 OWN - NLM STAT- MEDLINE DCOM- 20260806 LR - 20260806 IS - 1522-9645 (Electronic) IS - 0195-668X (Linking) VI - 47 IP - 30 DP - 2026 Aug 7 TI - Great debate: surgical aortic valve replacement is first choice for aortic stenosis in patients with a life expectancy beyond 5 years. PG - 4086-4099 LID - 10.1093/eurheartj/ehag262 [doi] AB - Transcatheter aortic valve implantation (TAVI) is increasingly used for the treatment of aortic stenosis. Recently published guidelines favour now TAVI in all patients 70 years or older who have tricuspid valves and suitable anatomy. However, while a number of randomized controlled trials confirm that TAVI and surgical aortic valve replacement (SAVR) provide equivalent outcomes up to 5 years, data beyond 5 years are still scarce and real-world registry data report indeed conflicting results. Higher rates of complications after TAVI such as pacemaker requirement and paravalvular regurgitation, which have been shown to be associated with worse outcome may become more relevant after 5 years and still favour surgery on long-term. In addition, long-term durability data for TAVI are still insufficient. Thus, the question whether SAVR should still be the first choice for patients with a life expectance beyond 5 years is therefore justified. This debate summarizes the pros and cons for this claim. CI - (c) The Author(s) 2026. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com. FAU - Doenst, Torsten AU - Doenst T AUID- ORCID: 0000-0002-6411-909X AD - Department of Cardiothoracic Surgery, Jena University Hospital, Friedrich Schiller University of Jena, Jena, Germany. FAU - Prendergast, Bernard AU - Prendergast B AD - Cardiology Department, Cleveland Clinic London, London, UK. AD - Cardiology Department, St Thomas' Hospital, London, UK. FAU - Allen, Christopher J AU - Allen CJ AD - Cardiology Department, St Thomas' Hospital, London, UK. AD - Cedars-Sinai Medical Center, Smidt Heart Institute, Los Angeles, CA, USA. FAU - Barili, Fabio AU - Barili F AD - Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA. AD - University Cardiac Surgery Unit, IRCCS Ospedale Galeazzi-Sant'Ambrogio, Milan, Italy. FAU - Falk, Volkmar AU - Falk V AUID- ORCID: 0000-0002-7911-8620 AD - Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charite, Berlin, Germany. FAU - Kirov, Hristo AU - Kirov H AD - Department of Cardiothoracic Surgery, Jena University Hospital, Friedrich Schiller University of Jena, Jena, Germany. FAU - Patterson, Tiffany AU - Patterson T AD - Cardiology Department, St Thomas' Hospital, London, UK. FAU - Redwood, Simon AU - Redwood S AD - Cardiology Department, Cleveland Clinic London, London, UK. AD - Cardiology Department, St Thomas' Hospital, London, UK. FAU - Baumgartner, Helmut AU - Baumgartner H AUID- ORCID: 0000-0002-9542-8821 AD - Department of Cardiology III-Adult Congenital and Valvular Heart Disease, University Hospital Muenster, Albert-Schweitzer-Campus 1, Building A1, Muenster 48149, Germany. LA - eng PT - Journal Article PT - Review PL - England TA - Eur Heart J JT - European heart journal JID - 8006263 SB - IM MH - Humans MH - *Aortic Valve Stenosis/surgery/mortality MH - *Transcatheter Aortic Valve Replacement/methods/mortality/adverse effects MH - *Heart Valve Prosthesis Implantation/methods/mortality MH - Life Expectancy MH - Aged MH - Treatment Outcome MH - Postoperative Complications/etiology OTO - NOTNLM OT - Aortic stenosis OT - Heart team OT - Surgical aortic valve replacement OT - Transcatheter aortic valve implantation EDAT- 2026/06/15 12:55 MHDA- 2026/08/07 00:35 CRDT- 2026/06/15 07:47 PHST- 2025/07/22 00:00 [received] PHST- 2025/12/04 00:00 [revised] PHST- 2026/03/24 00:00 [accepted] PHST- 2026/08/07 00:35 [medline] PHST- 2026/06/15 12:55 [pubmed] PHST- 2026/06/15 07:47 [entrez] AID - 8708077 [pii] AID - 10.1093/eurheartj/ehag262 [doi] PST - ppublish SO - Eur Heart J. 2026 Aug 7;47(30):4086-4099. doi: 10.1093/eurheartj/ehag262. PMID- 42292644 OWN - NLM STAT- MEDLINE DCOM- 20260615 LR - 20260813 IS - 2211-8179 (Electronic) IS - 2211-8160 (Print) IS - 2211-8160 (Linking) VI - 21 IP - 1 DP - 2026 TI - Mortality Outcome Post-MI after PCI and CABG Interventions. PG - 46 LID - 10.5334/gh.1556 [doi] LID - 46 AB - BACKGROUND AND AIM: Worldwide, heart-related conditions, including myocardial infarction (MI), persist as the leading cause of morbidity and mortality. The aim is to compare three-year mortality outcomes and identify causes of death among post-MI patients who received either percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG). METHODS: This registry-based retrospective cohort with follow-up study analyzed data from 3,542 PCI and 3,244 CABG patients treated post-MI between 2020 and 2024 in two hospitals in Baghdad. Kaplan-Meier curves (log-rank test) were used for unadjusted comparison. Cox proportional hazards regression was employed to compare three-year all-cause mortality, adjusting for baseline demographic and clinical covariates. RESULTS: Baseline characteristics differed significantly, with CABG patients being older and having a higher prevalence of certain risk factors. Crude observed mortality during available follow-up was 7.99% for PCI and 11.19% for CABG; Kaplan-Meier analysis showed significantly different unadjusted survival distributions by log-rank test. However, after adjusting for baseline covariates, there was no significant difference in the hazard of three-year all-cause mortality between patients undergoing CABG and PCI (adjusted hazard ratio [aHR] = 1.12, 95% CI = 0.93-1.35, p = 0.280). Significant independent predictors of mortality included age (aHR = 1.04 per year), diabetes mellitus (aHR = 1.45), and renal complications (aHR = 1.70). Non-cardiovascular causes accounted for the majority of deaths in both groups (56.06% post-PCI, 50.11% post-CABG). CONCLUSION: In this observational cohort, adjusted three-year mortality was not significantly different between PCI and CABG, with non-cardiac causes accounting for the largest proportion of deaths. Due to potential confounding by indication, these findings represent observational associations rather than clinical equivalence. Both remain vital revascularization strategies, with selection guided by individualized heart-team assessment. CI - Copyright: (c) 2026 The Author(s). FAU - Al-Naqdi, Mina Muayad Alwan AU - Al-Naqdi MMA AUID- ORCID: 0009-0005-3589-3536 AD - Al-Mustansiriyah Primary Healthcare Center, Baghdad, Iraq. FAU - Alkhammasi, Mohammed Lateef Mohammed AU - Alkhammasi MLM AUID- ORCID: 0009-0004-3817-0280 AD - Al-Shaheed Al-Sadr General Hospital, Baghdad, Iraq. FAU - Al-Naqdi, Bassam Muayad Alwan AU - Al-Naqdi BMA AUID- ORCID: 0009-0002-5347-6857 AD - Al Sheikh Zayed General Hospital, Baghdad, Iraq. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20260610 PL - England TA - Glob Heart JT - Global heart JID - 101584391 SB - IM MH - Aged MH - Female MH - Humans MH - Male MH - Middle Aged MH - Cause of Death/trends MH - *Coronary Artery Bypass/statistics & numerical data MH - Follow-Up Studies MH - *Myocardial Infarction/surgery/mortality MH - *Percutaneous Coronary Intervention/statistics & numerical data MH - *Registries/statistics & numerical data MH - Retrospective Studies MH - Risk Factors MH - Survival Rate/trends PMC - PMC13262651 OTO - NOTNLM OT - CABG OT - Cox regression OT - MI OT - PCI OT - mortality rate OT - survival analysis COIS- The authors have no competing interests to declare. EDAT- 2026/06/15 12:52 MHDA- 2026/06/15 12:53 PMCR- 2026/06/10 CRDT- 2026/06/15 07:30 PHST- 2025/05/10 00:00 [received] PHST- 2026/05/04 00:00 [accepted] PHST- 2026/06/15 12:53 [medline] PHST- 2026/06/15 12:52 [pubmed] PHST- 2026/06/15 07:30 [entrez] PHST- 2026/06/10 00:00 [pmc-release] AID - 10.5334/gh.1556 [doi] PST - epublish SO - Glob Heart. 2026 Jun 10;21(1):46. doi: 10.5334/gh.1556. eCollection 2026. PMID- 42292597 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260615 LR - 20260813 IS - 2225-319X (Print) IS - 2304-1021 (Electronic) IS - 2225-319X (Linking) VI - 15 IP - 3 DP - 2026 May 31 TI - The value of preoperative risk scores prior to tricuspid valve interventions: The TRI-SCORE and beyond. PG - 33 LID - 10.21037/acs-2026-1-0024-tvd [doi] LID - 33 AB - Tricuspid regurgitation (TR) is increasingly recognized as a condition associated with poor clinical outcomes, including reduced quality of life, progressive right-sided heart failure, and increased mortality. Its heterogeneous etiologies and systemic consequences, affecting both cardiac and extracardiac organs such as the kidneys and liver, make patient management particularly challenging. Accurate risk stratification and timely intervention are therefore essential. The 2025 European Society of Cardiology and European Association for Cardio-Thoracic Surgery Guidelines acknowledge the multifaceted nature of TR and emphasize the need for evaluation in expert centers through multidisciplinary Heart Team discussions. In this context, the TRI-SCORE, initially developed to predict in-hospital mortality after isolated tricuspid valve (TV) surgery, has been incorporated into the guideline decision-making algorithm as a key risk assessment tool to support therapeutic selection. This simple eight-variable model demonstrated excellent prognostic predictive performance and has been validated across several international cohorts of patients conservatively treated or who underwent a surgical or transcatheter intervention. Compared with other surgical scores such as EuroSCORE II, Model for End-Stage Liver Disease (MELD)/MELD-XI, or the Society of Thoracic Surgeons isolated TV surgery model, the TRI-SCORE is disease-specific, simple, and offers superior predictive value. It helps identify patients most likely to benefit from intervention, providing a practical framework for integrating disease stage, procedural risk, and expected benefit. Both surgical and transcatheter therapies may improve prognosis when performed early, whereas delayed referral at advanced stages offsets their potential benefit. The systematic use of TRI-SCORE within the Heart Team can therefore refine patient selection, guide the timing of intervention, and support personalized, lifetime management of TR. CI - (c) AME Publishing Company. FAU - Dreyfus, Julien AU - Dreyfus J AD - Department of Cardiology, Centre Cardiologique du Nord, Saint-Denis, France. FAU - Messika-Zeitoun, David AU - Messika-Zeitoun D AD - Division of Cardiology, University of Ottawa Heart Institute, Ottawa, ON, Canada. AD - School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada. LA - eng PT - Journal Article PT - Review DEP - 20260528 PL - China TA - Ann Cardiothorac Surg JT - Annals of cardiothoracic surgery JID - 101605877 PMC - PMC13263479 OTO - NOTNLM OT - Heart Team OT - Tricuspid regurgitation (TR) OT - risk stratification OT - surgery OT - transcatheter COIS- Conflicts of Interest: Julien Dreyfus has received consulting or proctoring fees from Abbott and Edwards. David Messika-Zeitoun has received unrestricted research grant from Edwards, outside the submitted work. The authors have no other conflicts of interest to declare. EDAT- 2026/06/15 12:49 MHDA- 2026/06/15 12:50 PMCR- 2026/05/31 CRDT- 2026/06/15 07:29 PHST- 2026/01/20 00:00 [received] PHST- 2026/05/06 00:00 [accepted] PHST- 2026/06/15 12:50 [medline] PHST- 2026/06/15 12:49 [pubmed] PHST- 2026/06/15 07:29 [entrez] PHST- 2026/05/31 00:00 [pmc-release] AID - acs-15-03-33 [pii] AID - 10.21037/acs-2026-1-0024-tvd [doi] PST - ppublish SO - Ann Cardiothorac Surg. 2026 May 31;15(3):33. doi: 10.21037/acs-2026-1-0024-tvd. Epub 2026 May 28. PMID- 42292596 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260615 LR - 20260813 IS - 2225-319X (Print) IS - 2304-1021 (Electronic) IS - 2225-319X (Linking) VI - 15 IP - 3 DP - 2026 May 31 TI - Three decades evolution of the lifetime management approach to tricuspid valve disease: a multidisciplinary European perspective from a high-volume heart valve center. PG - 36 LID - 10.21037/acs-2025-1-90-tvd [doi] LID - 36 AB - BACKGROUND: The treatment of tricuspid valve (TV) disease has increased over the last decades. This study evaluates trends, patient characteristics, and outcomes of surgical and transcatheter TV interventions over 30 years. METHODS: All consecutive adult patients undergoing TV surgery or transcatheter intervention at the Heart Center Leipzig were included in this unadjusted descriptive analysis. Patients with TV endocarditis were excluded. Surgical data covered 1996-2024, transcatheter edge-to-edge repair (T-TEER) 2016-2024, and transcatheter TV replacement (TTVR) 2021-2025. All information was obtained from the institutional database. RESULTS: A total of 982 patients were analyzed: 450 (46%) surgical, 498 (51%) T-TEER, and 34 (3%) TTVR patients. Surgical patients were younger (67 vs. 79 vs. 81 years, respectively, P<0.001) and had fewer comorbidities than those treated interventionally. Higher-grade TR was more common in T-TEER and TTVR cohorts. Device leads crossing the TV were present in 109 (24%) surgical, 147 (30%) T-TEER, and seven (21%) TTVR patients (P=0.13). Reoperations accounted for 165 (37%) surgical cases, while prior cardiac operations were documented in 148 (30%) T-TEER and 7 (21%) TTVR patients. Surgery after T-TEER was infrequent (n=4, 1%). One-year survival was 88% after surgery, 83% after T-TEER, and 94% after TTVR (log-rank P=0.036). Among surgical patients, 335 (74%) did not require any re-hospitalizations during the first year postoperatively. Surgical reoperations showed survival comparable to primary procedures (actuarial survival at 9 years, 55% vs. 59%, respectively; log-rank P=0.07). Surgical TV replacement was associated with worse survival than surgical TV repair (at 9 years. 55% vs. 65%, respectively; log-rank P=0.03). CONCLUSIONS: Surgical TV repair yields better outcomes than replacement. Long-term survival after reoperation parallels that of primary TV surgery. Surgical and transcatheter therapies address distinct patient populations. Multidisciplinary heart team evaluation remains essential for optimal management of TV disease. CI - (c) AME Publishing Company. FAU - Mazur, Piotr AU - Mazur P AD - University Department of Cardiac Surgery, Heart Center Leipzig, Leipzig, Germany. AD - Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland. FAU - Papakonstantinou, Konstantinos AU - Papakonstantinou K AD - University Department of Cardiac Surgery, Heart Center Leipzig, Leipzig, Germany. FAU - Marin-Cuartas, Mateo AU - Marin-Cuartas M AD - University Department of Cardiac Surgery, Heart Center Leipzig, Leipzig, Germany. FAU - Wolff, Charlotte AU - Wolff C AD - Department of Cardiology, Heart Center Leipzig at Leipzig University, Leipzig, Germany. FAU - Kister, Tobias AU - Kister T AD - Department of Cardiology, Heart Center Leipzig at Leipzig University, Leipzig, Germany. FAU - Dashkevich, Alexey AU - Dashkevich A AD - University Department of Cardiac Surgery, Heart Center Leipzig, Leipzig, Germany. FAU - Holzhey, David AU - Holzhey D AD - University Department of Cardiac Surgery, Heart Center Leipzig, Leipzig, Germany. FAU - Thiele, Holger AU - Thiele H AD - Department of Cardiology, Heart Center Leipzig at Leipzig University, Leipzig, Germany. FAU - Borger, Michael A AU - Borger MA AD - University Department of Cardiac Surgery, Heart Center Leipzig, Leipzig, Germany. FAU - Kiefer, Philipp AU - Kiefer P AD - University Department of Cardiac Surgery, Heart Center Leipzig, Leipzig, Germany. FAU - Noack, Thilo AU - Noack T AD - University Department of Cardiac Surgery, Heart Center Leipzig, Leipzig, Germany. LA - eng PT - Journal Article DEP - 20260519 PL - China TA - Ann Cardiothorac Surg JT - Annals of cardiothoracic surgery JID - 101605877 PMC - PMC13263432 OTO - NOTNLM OT - Tricuspid valve (TV) OT - cardiac surgery OT - transcatheter edge-to-edge repair (T-TEER) OT - transcatheter tricuspid valve replacement (TTVR) OT - tricuspid regurgitation COIS- Conflicts of Interest: The authors have no conflicts of interest to declare. EDAT- 2026/06/15 12:54 MHDA- 2026/06/15 12:55 PMCR- 2026/05/31 CRDT- 2026/06/15 07:29 PHST- 2025/12/29 00:00 [received] PHST- 2026/04/02 00:00 [accepted] PHST- 2026/06/15 12:55 [medline] PHST- 2026/06/15 12:54 [pubmed] PHST- 2026/06/15 07:29 [entrez] PHST- 2026/05/31 00:00 [pmc-release] AID - acs-15-03-36 [pii] AID - 10.21037/acs-2025-1-90-tvd [doi] PST - ppublish SO - Ann Cardiothorac Surg. 2026 May 31;15(3):36. doi: 10.21037/acs-2025-1-90-tvd. Epub 2026 May 19. PMID- 42292592 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260615 LR - 20260813 IS - 2225-319X (Print) IS - 2304-1021 (Electronic) IS - 2225-319X (Linking) VI - 15 IP - 3 DP - 2026 May 31 TI - Tricuspid valve endocarditis in people who inject drugs: strategies to reduce mortality and recurrent infection. PG - 35 LID - 10.21037/acs-2026-1-0008-tvd [doi] LID - 35 AB - Tricuspid valve infective endocarditis (TV-IE) in people who inject drugs (PWID) has become an increasingly important clinical and public health concern, driven largely by the expanding opioid epidemic. Although PWID with TV-IE are typically young and often lack major comorbidities, they experience disproportionately high rates of mortality, reinfection, and recurrent hospitalizations. Repeated intravenous injection introduces contaminated particulate matter and pathogens into the venous circulation, promoting microbial adherence to the tricuspid valve, with Staphylococcus aureus including methicillin-resistant strains remaining the predominant pathogen. Clinical presentation commonly includes fever, chills, and pulmonary symptoms caused by septic emboli, while diagnostic evaluation relies on multiple blood cultures and echocardiographic assessment, complemented by computed tomography when pulmonary complications are suspected. Approximately 90% of right-sided TV-IE cases can be managed medically, highlighting the importance of optimized antimicrobial therapy tailored to the organism, disease severity, and patient-specific factors. Outpatient parenteral antibiotic therapy (OPAT) remains controversial in PWID, warranting individualized strategies to ensure treatment continuity, particularly in patients at risk of leaving the hospital before completing therapy. Surgical intervention follows standard right-sided IE criteria, with tricuspid valve repair preferred when feasible. Tricuspid valvectomy or emerging percutaneous debulking approaches may serve as adjunctive or temporizing strategies. Addiction treatment is central to improving outcomes, as ongoing injection drug use remains the strongest driver of reinfection and preventable mortality. Early involvement of addiction medicine and initiation of medication-assisted treatment can significantly improve long-term engagement. Optimal management requires a multidisciplinary approach that integrates cardiology, cardiac surgery, infectious disease, and early initiated as well as continued addiction treatment follow-up, behavioral health support, and social services to reduce reinfection risk and support recovery. This review summarizes current evidence regarding epidemiology, microbiology, clinical presentation, and management, with a focus on reducing mortality and preventing recurrent infection in PWID with TV-IE. CI - (c) AME Publishing Company. FAU - de Waha, Suzanne AU - de Waha S AD - Department of Cardiac Surgery, Heart Center Leipzig at University of Leipzig, Leipzig, Germany. AD - Department of Rhythmology, University Hospital Schleswig-Holstein, Campus Lubeck, Lubeck, Germany. FAU - Noack, Thilo AU - Noack T AD - Department of Cardiac Surgery, Heart Center Leipzig at University of Leipzig, Leipzig, Germany. FAU - Kister, Tobias AU - Kister T AD - Department of Cardiology, Heart Center Leipzig at University of Leipzig, Leipzig, Germany. FAU - Desch, Steffen AU - Desch S AD - Department of Cardiology, Heart Center Leipzig at University of Leipzig, Leipzig, Germany. FAU - Marin-Cuartas, Mateo AU - Marin-Cuartas M AD - Department of Cardiac Surgery, Heart Center Leipzig at University of Leipzig, Leipzig, Germany. FAU - Kiefer, Philipp AU - Kiefer P AD - Department of Cardiac Surgery, Heart Center Leipzig at University of Leipzig, Leipzig, Germany. FAU - Borger, Michael A AU - Borger MA AD - Department of Cardiac Surgery, Heart Center Leipzig at University of Leipzig, Leipzig, Germany. LA - eng PT - Journal Article PT - Review DEP - 20260525 PL - China TA - Ann Cardiothorac Surg JT - Annals of cardiothoracic surgery JID - 101605877 PMC - PMC13263516 OTO - NOTNLM OT - Tricuspid valve disease OT - infective endocarditis (IE) OT - intravenous drug use (IVDU) OT - management OT - people who inject drugs (PWID) COIS- Conflicts of Interest: S.d.W. has received speaker honoraria from Astra Zeneca, Boehringer Ingelheim, Edwards Lifesciences and TherOx, and has served as a consultant to Pfizer-BMS and TherOx/Zoll Medical. The other authors have no conflicts of interest to declare. EDAT- 2026/06/15 12:52 MHDA- 2026/06/15 12:53 PMCR- 2026/05/31 CRDT- 2026/06/15 07:29 PHST- 2026/01/06 00:00 [received] PHST- 2026/04/02 00:00 [accepted] PHST- 2026/06/15 12:53 [medline] PHST- 2026/06/15 12:52 [pubmed] PHST- 2026/06/15 07:29 [entrez] PHST- 2026/05/31 00:00 [pmc-release] AID - acs-15-03-35 [pii] AID - 10.21037/acs-2026-1-0008-tvd [doi] PST - ppublish SO - Ann Cardiothorac Surg. 2026 May 31;15(3):35. doi: 10.21037/acs-2026-1-0008-tvd. Epub 2026 May 25. PMID- 42291583 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260615 LR - 20260813 IS - 1682-024X (Print) IS - 1681-715X (Electronic) IS - 1681-715X (Linking) VI - 42 IP - 5 DP - 2026 May TI - Peripartum cardiomyopathy: Clinical Predictors of favourable maternal-fetal outcomes. PG - 1228-1233 LID - 10.12669/pjms.42.5.13114 [doi] AB - OBJECTIVES: To evaluate maternal cardiac complications fetal outcomes, and delivery considerations in patients diagnosed with peripartum cardiomyopathy(PPCM) in tertiary hospital. METHODOLOGY: It was a prospective observational study, conducted in the Department of Obstetrics and Gynecology, Lady Reading Hospital, Peshawar, from January 17, 2024 to December 17, 2024 after obtaining ethical approval. It included all patients with PPCM admitted via emergency or OPD. Peripartum cardiomyopathy was diagnosed according to European Society of Cardiology criteria, defined as heart failure occurring toward the end of pregnancy or in the months following delivery, with left ventricular ejection fraction <45%, in the absence of another identifiable cause of cardiomyopathy. A total of 46 patients were enrolled. Patients with pre-existing dilated cardiomyopathy, chronic obstructive pulmonary disease and significant congenital valvular heart disease had been excluded. All patients were managed by a Multidisciplinary team, including a consultant Obstetrician, Consultant Cardiologist, a Cardiac Electrophysiologist, an anaesthetist, an intensivist and a paediatrician in a tertiary hospital. Primary outcome were Maternal cardiac complications and mortality. While secondary outcomes were Fetal outcomes (live birth, preterm birth, IUFD, miscarriage) and mode of delivery. Predictors and outcomes of PPCM in patients were assessed, i.e. ejection fraction, fractional shortening, BMI, pre-eclampsia, multiple pregnancy, parity and age. We categorized our sample into two groups based on presence or absence of defined outcomes of cardiac complications and compare predictors between these two groups. RESULTS: Clinical characteristics observed in patients with relatively stable outcomes included normal BMI, mean age less than 30 years, mean ejection fraction of 37% with no thrombus, no pre-eclampsia or multiple pregnancy. The mode of delivery preferred was elective c-section 65.2% (n=30) decided by MDT (cardiologist, anaesthetist, and obstetrician) to avoid stress of bearing down during labor if EF less than 37.7%. The most common cardiac complication was pulmonary hypertension. The Neonatal outcomes included 71.8% live births, IUFD 19.6% and miscarriages 8.7%. CONCLUSION: Maternal outcomes were generally favorable when patients with peripartum cardiomyopathy were managed at a tertiary care center through a multidisciplinary team approach. Better outcomes were commonly observed in patients with normal BMI, mean left ventricular ejection fraction >/=37.7%, absence of pre-eclapmia and multiple pregnancy. CI - Copyright: (c) Pakistan Journal of Medical Sciences. FAU - Khan, Zahoor Ahmad AU - Khan ZA AD - Zahoor Ahmad Khan, FCPS(Cardiology), FCPS (Clinical Cardiac Electrophysiology).Associate Professor, Department of Cardiac Electrophysiology,MTI, Hayatabad Medical Complex, Peshawar, Pakistan. FAU - Farnaz AU - Farnaz AD - Farnaz, FCPS.Associate Professor, Department of OBGYN, Lady Reading Hospital MTI Peshawar,Peshawar, Pakistan. FAU - Jabeen, Saira AU - Jabeen S AD - Saira Jabeen,Resident OBGYN, Department of OBGYN, Lady Reading Hospital MTI Peshawar,Peshawar, Pakistan. LA - eng PT - Journal Article PL - Pakistan TA - Pak J Med Sci JT - Pakistan journal of medical sciences JID - 100913117 PMC - PMC13263575 OTO - NOTNLM OT - Atrial fibrillation OT - Ejection fraction OT - Peripartum cardiomyopathy OT - Pulmonary hypertension COIS- Conflict of Interest: None. EDAT- 2026/06/15 12:49 MHDA- 2026/06/15 12:50 PMCR- 2026/05/01 CRDT- 2026/06/15 07:21 PHST- 2025/08/22 00:00 [received] PHST- 2026/03/17 00:00 [revised] PHST- 2026/04/14 00:00 [revised] PHST- 2026/04/19 00:00 [accepted] PHST- 2026/06/15 12:50 [medline] PHST- 2026/06/15 12:49 [pubmed] PHST- 2026/06/15 07:21 [entrez] PHST- 2026/05/01 00:00 [pmc-release] AID - PJMS-42-5-1228 [pii] AID - 10.12669/pjms.42.5.13114 [doi] PST - ppublish SO - Pak J Med Sci. 2026 May;42(5):1228-1233. doi: 10.12669/pjms.42.5.13114. PMID- 42283629 OWN - NLM STAT- MEDLINE DCOM- 20260612 LR - 20260923 IS - 2639-8028 (Electronic) IS - 2639-8028 (Linking) VI - 8 IP - 6 DP - 2026 Jun 1 TI - Multiagent First-Person Perspective Analysis for Leadership Assessment in Pediatric Emergency Simulations: A Feasibility Study. PG - e1428 LID - 10.1097/CCE.0000000000001428 [doi] LID - e1428 AB - BACKGROUND: Conventional leadership assessments provide structured ratings but offer limited observer-independent metrics. Because leadership and teamwork are interdependent, capturing team dynamics requires multiagent, time- and space-synchronized analysis. This pilot study examined the feasibility of applying multiagent, spatiotemporally synchronized first-person perspective analysis (FPA) in emergency simulations. METHODS: This exploratory simulation study was conducted in a real patient-care room within the PICU of our institution. Two physicians-a critical care specialist (L1) and a pediatric resident (L2)-each completed one scenario as team leader. Leadership behaviors were evaluated using the Ottawa Global Rating Scale, focusing on Situational Awareness and Communication. Wearable smart glasses recorded first-person video and gaze data, enabling identification of fixations within five predefined areas ("patient," "member," "device," "screen," and "unknown"). Eye-contact events were quantified using face detection based on You Only Look Once, version 8, a deep learning-based object detection model, combined with gaze-vector estimation, and analyzed in relation to the timing of verbal communication. RESULTS: Multiagent, time-synchronized FPA was implemented without device- or software-related interruption, and no critical data loss occurred. The mean analyzable session duration relative to total operating time was 77.1%, and the mean percentage of frames excluded from object tracking was 29.3%, primarily due to target objects being outside the field of view. As secondary, illustrative findings, Ottawa Global Rating Scale scores indicated that both leaders were rated within the competent range. FPA further showed that both leaders spent approximately 80% of the scenario fixating on predefined relevant areas (L1: 599/731 s; L2: 565/693 s). Greater patient-directed fixation and balanced gaze transitions were observed in L1, whereas L2 showed prolonged fixation within nonspecific areas. L1 also established eye contact with team members more frequently during direct orders or information sharing. CONCLUSIONS: This study demonstrates the feasibility of multiagent, time-synchronized FPA for extracting gaze-based behavioral information relevant to leadership assessment in emergency simulations. CI - Copyright (c) 2026 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine. FAU - Nozawa, Hisataka AU - Nozawa H AUID- ORCID: 0000-0002-0969-3304 AD - Department of Pediatrics, The University of Tokyo Hospital, Tokyo, Japan. FAU - Kunikata, Ayumi AU - Kunikata A AD - Department of Pediatrics, The University of Tokyo Hospital, Tokyo, Japan. FAU - Sakai, Yuki AU - Sakai Y AD - Institute of Industrial Science, The University of Tokyo, Tokyo, Japan. FAU - Ouyang, Liangyang AU - Ouyang L AD - Institute of Industrial Science, The University of Tokyo, Tokyo, Japan. FAU - Furuta, Ryosuke AU - Furuta R AD - Institute of Industrial Science, The University of Tokyo, Tokyo, Japan. FAU - Sato, Yoichi AU - Sato Y AD - Institute of Industrial Science, The University of Tokyo, Tokyo, Japan. FAU - Matsui, Hikoro AU - Matsui H AD - Department of Pediatrics, The University of Tokyo Hospital, Tokyo, Japan. LA - eng PT - Journal Article DEP - 20260612 PL - United States TA - Crit Care Explor JT - Critical care explorations JID - 101746347 SB - IM MH - Humans MH - Feasibility Studies MH - Intensive Care Units, Pediatric/organization & administration MH - *Leadership MH - *Patient Care Team/organization & administration MH - *Pediatrics/methods MH - Pilot Projects MH - *Simulation Training/methods MH - Smart Glasses PMC - PMC13263087 OTO - NOTNLM OT - advanced cardiac life support OT - artificial intelligence OT - crew resource management OT - healthcare OT - leadership OT - medical education COIS- Dr. Nozawa has received a research grant from the Japanese Society of Intensive Care Medicine for a different study within the past 36 months; this grant is unrelated to the work submitted in this article. The remaining authors have disclosed that they do not have any potential conflicts of interest. EDAT- 2026/06/12 13:02 MHDA- 2026/06/13 00:39 PMCR- 2026/06/12 CRDT- 2026/06/12 10:22 PHST- 2026/06/13 00:39 [medline] PHST- 2026/06/12 13:02 [pubmed] PHST- 2026/06/12 10:22 [entrez] PHST- 2026/06/12 00:00 [pmc-release] AID - 02107256-202606000-00017 [pii] AID - CCE-D-26-00123 [pii] AID - 10.1097/CCE.0000000000001428 [doi] PST - epublish SO - Crit Care Explor. 2026 Jun 12;8(6):e1428. doi: 10.1097/CCE.0000000000001428. eCollection 2026 Jun 1. PMID- 42279599 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260612 LR - 20260813 IS - 2075-4418 (Print) IS - 2075-4418 (Electronic) IS - 2075-4418 (Linking) VI - 16 IP - 11 DP - 2026 Jun 4 TI - Hidden and Under-Recognized Causes of Sudden Unexpected Death in Infancy (SUDI): A Comprehensive Review of Autopsy Findings. LID - 10.3390/diagnostics16111730 [doi] LID - 1730 AB - Sudden unexpected death in infancy (SUDI) remains a major challenge in pediatric pathology and forensic medicine. Despite advances in diagnostic techniques, many cases are still classified as unexplained and labeled as sudden infant death syndrome (SIDS). Increasing evidence suggests that a proportion of these deaths may be due to "hidden" causes not detectable through routine post-mortem examination. A narrative review of the literature (2000-2026) was conducted using PubMed and Scopus, focusing on under-recognized causes of SUDI and their diagnostic implications. Relevant studies were selected and organized into major pathological and forensic categories. Hidden causes of SUDI include a wide spectrum of conditions. Cardiac disorders-such as myocarditis, cardiomyopathies, and inherited arrhythmogenic syndromes-are frequently implicated and may require molecular autopsy for detection. Infectious diseases, often presenting with minimal or nonspecific findings, represent another important category, particularly viral and bacterial infections. Inborn errors of metabolism, especially fatty acid oxidation defects, may lead to sudden death in the absence of specific autopsy findings, highlighting the role of biochemical analyses. Neuropathological abnormalities involving brainstem regulatory systems may contribute to impaired autonomic control. Environmental, toxicological, and medico-legal factors-including unsafe sleep conditions, toxic exposures, and inflicted injury-must also be considered. SUDI is a multifactorial entity in which many unexplained deaths may be attributable to identifiable but overlooked conditions. A standardized, multidisciplinary approach integrating autopsy, ancillary investigations, and molecular diagnostics is essential to improve diagnostic accuracy and support prevention strategies. FAU - Camatti, Jessika AU - Camatti J AUID- ORCID: 0009-0003-8449-1803 AD - Department of Medicine and Surgery, University of Parma, Via Universita 12, 43121 Parma, Italy. FAU - Santunione, Anna Laura AU - Santunione AL AUID- ORCID: 0000-0001-8828-1895 AD - Department of Biomedical, Metabolic and Neural Sciences, Unit of Legal Medicine, University of Modena and Reggio Emilia, Via Campi 287, 41125 Modena, Italy. FAU - Cecchi, Rossana AU - Cecchi R AUID- ORCID: 0000-0002-8451-7212 AD - Department of Biomedical, Metabolic and Neural Sciences, Unit of Legal Medicine, University of Modena and Reggio Emilia, Via Campi 287, 41125 Modena, Italy. FAU - Radheshi, Erjon AU - Radheshi E AUID- ORCID: 0009-0009-2064-6523 AD - Unit of Legal Medicine and Bioethics, Azienda USL-IRCCS di Reggio Emilia, Via Amendola 2, 42122 Reggio Emilia, Italy. FAU - Carretto, Edoardo AU - Carretto E AD - Local Health Authority 'Papa Giovanni XXIII', 24127 Bergamo, Italy. FAU - Bonasoni, Maria Paola AU - Bonasoni MP AUID- ORCID: 0000-0002-4889-1944 AD - Department of Medical and Surgical Sciences, Unit of Legal Medicine, University of Bologna, Via Irnerio 49, 40126 Bologna, Italy. AD - Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, Via Amendola 2, 42122 Reggio Emilia, Italy. LA - eng PT - Journal Article PT - Review DEP - 20260604 PL - Switzerland TA - Diagnostics (Basel) JT - Diagnostics (Basel, Switzerland) JID - 101658402 PMC - PMC13257070 OTO - NOTNLM OT - medicolegal assessment OT - multidisciplinary investigation OT - post-mortem diagnostics OT - sudden infant death syndrome (SIDS) OT - sudden unexpected death in infancy (SUDI) COIS- The authors declare no conflicts of interest. EDAT- 2026/06/12 06:39 MHDA- 2026/06/12 06:40 PMCR- 2026/06/04 CRDT- 2026/06/12 01:08 PHST- 2026/05/08 00:00 [received] PHST- 2026/05/28 00:00 [revised] PHST- 2026/05/31 00:00 [accepted] PHST- 2026/06/12 06:40 [medline] PHST- 2026/06/12 06:39 [pubmed] PHST- 2026/06/12 01:08 [entrez] PHST- 2026/06/04 00:00 [pmc-release] AID - diagnostics16111730 [pii] AID - diagnostics-16-01730 [pii] AID - 10.3390/diagnostics16111730 [doi] PST - epublish SO - Diagnostics (Basel). 2026 Jun 4;16(11):1730. doi: 10.3390/diagnostics16111730. PMID- 42279588 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260612 LR - 20260813 IS - 2075-4418 (Print) IS - 2075-4418 (Electronic) IS - 2075-4418 (Linking) VI - 16 IP - 11 DP - 2026 Jun 3 TI - Machine Learning-Driven Probability of Permanent Pacemaker Implantation After Transcatheter Aortic Valve Replacement. LID - 10.3390/diagnostics16111720 [doi] LID - 1720 AB - Background/Objectives: Permanent pacemaker implantation (PPI) remains one of the most common complications following transcatheter aortic valve replacement (TAVR). Identifying patients at increased risk for post-procedural conduction disturbances is clinically important for procedural planning and patient management. The aim of this study was to develop and evaluate a machine learning-based model for predicting the risk of PPI after TAVR. Methods: This prospective study was conducted between 2019 and 2025, and included 179 patients with severe aortic stenosis who underwent TAVR. Patient eligibility was determined by a multidisciplinary Heart Team based on clinical, echocardiographic, and imaging criteria. The primary endpoint was PPI occurring during hospitalization or within 30 days after the procedure. Statistical analyses were performed using RStudio (v. 2024.09.1+394)and Python (v.3.12.3), including comparative tests for continuous and categorical variables, receiver operating characteristic analysis to assess model performance, and SHapley Additive exPlanations (SHAP) to evaluate feature importance and model interpretability. Results: A total of 179 patients undergoing TAVR were included in the analysis. PPI occurred in 17 patients (9.5%) within 30 days after the procedure. A machine learning model was developed to predict post-TAVR PPI. The model demonstrated good predictive performance, with an overall accuracy of 0.944 and a weighted F1-score of 0.947. The confusion matrix showed that the model correctly classified 155 patients without PPI and 14 patients with PPI, with only a small number of false predictions. Explainability analyses using SHAP and permutation feature importance revealed that anatomical and procedural variables had the greatest impact on model predictions. The most influential predictors included valve size, right coronary sinus diameter, prosthetic valve diameter, and mean aortic annulus diameter. In contrast, baseline clinical variables such as left ventricular ejection fraction, previous myocardial infarction, and mean transaortic gradient showed a comparatively lower contribution to the prediction of PPI after TAVR. Conclusions: This study demonstrates that machine learning models can effectively predict the risk of PPI after TAVR. Anatomical characteristics of the aortic root and prosthesis-related parameters were the main determinants of PPI, whereas baseline clinical variables had a lower impact. The use of explainable artificial intelligence methods, such as SHAP analysis, may improve risk stratification and support procedural planning in patients undergoing TAVR. FAU - Abras, Marcel AU - Abras M AD - Department of Cardiology, Nicolae Testemitanu State University of Medicine and Pharmacy, MD-2004 Chisinau, Moldova. AD - Department of Interventional Cardiology, Public Healthcare Institution-Institute of Cardiology, MD-2025 Chisinau, Moldova. FAU - Bursacovschi, Daniela AU - Bursacovschi D AUID- ORCID: 0000-0001-7530-3012 AD - Department of Heart Failure, Public Healthcare Institution-Institute of Cardiology, MD-2025 Chisinau, Moldova. FAU - Pasat, Ecaterina AU - Pasat E AD - Department of Interventional Cardiology, Public Healthcare Institution-Institute of Cardiology, MD-2025 Chisinau, Moldova. FAU - Vicol, Maria-Magdalena AU - Vicol MM AD - Department of General Cardiology, Public Healthcare Institution-Institute of Cardiology, MD-2025 Chisinau, Moldova. FAU - Abras, Tatiana AU - Abras T AD - Department of Endocrinology, Public Medico-Sanitary Institution Republican Clinical Hospital "Timofei Mosneaga", MD-2025 Chisinau, Moldova. FAU - Mazur-Nicorici, Lucia AU - Mazur-Nicorici L AD - Department of Cardiology, Nicolae Testemitanu State University of Medicine and Pharmacy, MD-2004 Chisinau, Moldova. FAU - Arnaut, Oleg AU - Arnaut O AUID- ORCID: 0000-0002-5483-8672 AD - Department of Human Physiology and Biophysics, Nicolae Testemitanu State University of Medicine and Pharmacy, MD-2004 Chisinau, Moldova. AD - Bioinformatics and Computational Medicine Laboratory, Nicolae Testemitanu State University of Medicine and Pharmacy, MD-2004 Chisinau, Moldova. AD - National Cancer Registry, Public Healthcare Institution-Oncological Institute, MD-2025 Chisinau, Moldova. LA - eng PT - Journal Article DEP - 20260603 PL - Switzerland TA - Diagnostics (Basel) JT - Diagnostics (Basel, Switzerland) JID - 101658402 PMC - PMC13256166 OTO - NOTNLM OT - TAVR OT - permanent pacemaker implantation OT - prediction model COIS- The authors declare no conflicts of interest. EDAT- 2026/06/12 06:39 MHDA- 2026/06/12 06:40 PMCR- 2026/06/03 CRDT- 2026/06/12 01:08 PHST- 2026/03/16 00:00 [received] PHST- 2026/05/31 00:00 [revised] PHST- 2026/05/31 00:00 [accepted] PHST- 2026/06/12 06:40 [medline] PHST- 2026/06/12 06:39 [pubmed] PHST- 2026/06/12 01:08 [entrez] PHST- 2026/06/03 00:00 [pmc-release] AID - diagnostics16111720 [pii] AID - diagnostics-16-01720 [pii] AID - 10.3390/diagnostics16111720 [doi] PST - epublish SO - Diagnostics (Basel). 2026 Jun 3;16(11):1720. doi: 10.3390/diagnostics16111720. PMID- 42278975 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260612 LR - 20260813 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 15 IP - 11 DP - 2026 May 26 TI - Clinical Utility and Limitations of Traditional Risk Scores (EuroSCORE, EuroSCORE II, and STS-PROM) in Patients Undergoing TAVI: A Narrative Review. LID - 10.3390/jcm15114113 [doi] LID - 4113 AB - The rapid evolution of structural heart interventions, particularly transcatheter aortic valve implantation (TAVI), transcatheter edge-to-edge repair (TEER), and hybrid procedures, has significantly expanded treatment options for elderly, frail, and multimorbid patients previously considered high risk or inoperable. However, perioperative risk stratification in this population remains challenging. Traditional risk scores such as EuroSCORE, EuroSCORE II, STS-PROM, CHA(2)DS(2)-VASc, and HAS-BLED were developed and validated primarily in cohorts undergoing conventional open-heart surgery (CABG and surgical valve replacement) more than 15-25 years ago. This narrative review critically evaluates the performance and limitations of these classical models in contemporary populations undergoing modern structural cardiac interventions. Evidence from registries and meta-analyses indicates only moderate discriminatory ability and systematic calibration errors. EuroSCORE II and STS-PROM frequently overestimate risk in low- and intermediate-risk patients while underestimating it in high-risk and frail individuals, particularly regarding neurological, renal complications, and prolonged hospitalization. Similar limitations apply to CHA(2)DS(2)-VASc and HAS-BLED when used beyond their original scope in the peri-procedural setting of TAVI/TEER. The review highlights the growing role of frailty assessment, procedure-specific variables, and machine learning algorithms, which demonstrate superior predictive performance compared to conventional scores. Until dedicated, regularly updated risk models based on large TAVI/TEER registries become available, traditional scores should be used only as supportive tools within multidisciplinary Heart Team discussions that incorporate individual frailty, quality of life, and patient preferences. FAU - Klausa, Filip AU - Klausa F AD - Department of Cardiac Surgery, Centre for Heart Diseases, 4th Military Hospital, 50-981 Wroclaw, Poland. FAU - Swiatoniowska-Lonc, Natalia AU - Swiatoniowska-Lonc N AD - Department of Cardiology, Centre for Heart Diseases, 4th Military Hospital, 50-981 Wroclaw, Poland. FAU - Skotny, Anna AU - Skotny A AD - Clinical Research Support Center, 4th Military Hospital, 50-981 Wroclaw, Poland. AD - Harvard T.H. Chan School of Public Health-Executive and Continuing Education, Harvard University, Boston, MA 02115, USA. FAU - Mak, Marek A AU - Mak MA AD - Department of Cardiac Surgery, Centre for Heart Diseases, 4th Military Hospital, 50-981 Wroclaw, Poland. FAU - Wysokinska-Kordybach, Agnieszka AU - Wysokinska-Kordybach A AD - Department of Cardiology, Centre for Heart Diseases, 4th Military Hospital, 50-981 Wroclaw, Poland. FAU - Skiba, Jacek AU - Skiba J AD - Department of Cardiac Surgery, Centre for Heart Diseases, 4th Military Hospital, 50-981 Wroclaw, Poland. FAU - Sciborski, Krzysztof AU - Sciborski K AD - Department of Cardiology, Centre for Heart Diseases, 4th Military Hospital, 50-981 Wroclaw, Poland. AD - Clinical Department of Cardiology, Faculty of Medicine, Wroclaw University of Science and Technology, 50-981 Wroclaw, Poland. FAU - Banasiak, Waldemar AU - Banasiak W AUID- ORCID: 0000-0003-0702-7508 AD - Department of Cardiology, Centre for Heart Diseases, 4th Military Hospital, 50-981 Wroclaw, Poland. AD - Clinical Department of Cardiology, Faculty of Medicine, Wroclaw University of Science and Technology, 50-981 Wroclaw, Poland. FAU - Doroszko, Adrian AU - Doroszko A AUID- ORCID: 0000-0001-5472-028X AD - Department of Cardiology, Centre for Heart Diseases, 4th Military Hospital, 50-981 Wroclaw, Poland. AD - Clinical Department of Cardiology, Faculty of Medicine, Wroclaw University of Science and Technology, 50-981 Wroclaw, Poland. LA - eng PT - Journal Article PT - Review DEP - 20260526 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC13257576 OTO - NOTNLM OT - frailty OT - heart valve prosthesis implantation OT - risk assessment OT - transcatheter aortic valve replacement COIS- The authors declare no conflicts of interest. EDAT- 2026/06/12 06:39 MHDA- 2026/06/12 06:40 PMCR- 2026/05/26 CRDT- 2026/06/12 01:06 PHST- 2026/03/31 00:00 [received] PHST- 2026/05/05 00:00 [revised] PHST- 2026/05/07 00:00 [accepted] PHST- 2026/06/12 06:40 [medline] PHST- 2026/06/12 06:39 [pubmed] PHST- 2026/06/12 01:06 [entrez] PHST- 2026/05/26 00:00 [pmc-release] AID - jcm15114113 [pii] AID - jcm-15-04113 [pii] AID - 10.3390/jcm15114113 [doi] PST - epublish SO - J Clin Med. 2026 May 26;15(11):4113. doi: 10.3390/jcm15114113. PMID- 42275940 OWN - NLM STAT- MEDLINE DCOM- 20260714 LR - 20260714 IS - 1872-7654 (Electronic) IS - 0301-2115 (Linking) VI - 324 DP - 2026 Aug TI - A blueprint of an integrated cardio-obstetric preconception care pathway for women with pre-pregnancy intermediate- to high-risk cardiovascular disease. PG - 115213 LID - S0301-2115(26)00281-2 [pii] LID - 10.1016/j.ejogrb.2026.115213 [doi] AB - BACKGROUND: In women with pre-existing cardiovascular disease (CVD), the haemodynamic changes of pregnancy may increase the risk of maternal and fetal complications. Preconception care should use patient-centred counselling to help modifying additional risk factors as part of a comprehensive risk assessment. This will ensure the woman enters pregnancy in an optimised condition. Specialist obstetric cardiology multidisciplinary teams can improve preconception care and decision-making, but access to these services may be inconsistent. The aim of this manuscript was to develop a comprehensive obstetric cardiology pathway for women with intermediate to high-risk CVD. METHODS: A comprehensive review was conducted of scientific literature, registries, international guidelines, consensus statements and recommendations, combined with our research/clinical team's expertise. FINDINGS: Our proposed care pathway starts with referral of women with modified World Health Organisation (m-WHO) 2.0 class II-III to IV and who intent to conceive to specialised, interdisciplinary obstetric cardiac team. Subsequently, three components form the basis of preconception care: 1) comprehensive assessment and risk stratification, 2) person-centred, interdisciplinary counselling and 3) health optimisation. A comprehensive assessment includes evaluation of cardiac condition, an obstetric history, as well as lifestyle, psychosocial and genetic assessments to inform risk stratification. Person-centred, interdisciplinary counselling involves shared decision-making with the patient and should include discussions about risk estimates, follow-up planning and targeted interventions, including cardiac optimisation. Then, health optimisation interventions may be performed based on results of the person-centred interdisciplinary counselling. INTERPRETATION: Preconception care should be a cornerstone of obstetric cardiac care. Our proposed pathway provides structured guidance for cardio-obstetric health professionals to better support women with intermediate to high-risk CVD plan for pregnancy. Further research is needed to co-develop and evaluate strategies that enable routine implementation. CI - Copyright (c) 2026 Elsevier B.V. All rights reserved. FAU - Vanharen, Y AU - Vanharen Y AD - Centre for Research and Innovation in Care (CRIC), Department of Nursing Science and Midwifery, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium. FAU - Stocker, L AU - Stocker L AD - School of Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UK; Department of Fetal and Maternal Medicine, Princess Anne Hospital, University Hospital Southampton NHS Foundation Trust, UK. FAU - Mackillop, L AU - Mackillop L AD - Nuffield Department of Women's and Reproductive Health, University of Oxford, Oxford, UK; Women's Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. FAU - Van Berendoncks, A AU - Van Berendoncks A AD - Department of Cardiology, Antwerp University Hospital/University of Antwerp, Antwerp, Belgium; Research Group Cardiovascular Diseases, Department of Genetics, Pharmacology and Physiopathology of Heart, Blood Vessels and Skeleton, University of Antwerp, Antwerp, Belgium. FAU - Mannaerts, D AU - Mannaerts D AD - Antwerp Surgical Training, Anatomy and Research Center (ASTARC), University of Antwerp, Antwerp, Belgium; Department of Obstetrics and Gynaecology, Antwerp University Hospital, Antwerp, Belgium. FAU - Goossens, E AU - Goossens E AD - Centre for Research and Innovation in Care (CRIC), Department of Nursing Science and Midwifery, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium; Department of Patient Care, Antwerp University Hospital, Antwerp, Belgium. FAU - Mulders, A M AU - Mulders AM AD - Department of Gynaecology and Obstetrics, Erasmus Medical Centre, Rotterdam, the Netherlands. FAU - Kauling, R M AU - Kauling RM AD - Department of Cardiology, Erasmus Medical Centre, Rotterdam, the Netherlands. FAU - Schoenaker, D AU - Schoenaker D AD - MRC Lifecourse Epidemiology Centre, University of Southampton, UK; National Institute for Health and Care Research (NIHR) Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK. Electronic address: d.schoenaker@soton.ac.uk. LA - eng PT - Journal Article PT - Practice Guideline PT - Review DEP - 20260601 PL - Ireland TA - Eur J Obstet Gynecol Reprod Biol JT - European journal of obstetrics, gynecology, and reproductive biology JID - 0375672 SB - IM MH - Humans MH - Female MH - *Preconception Care/methods MH - Pregnancy MH - *Cardiovascular Diseases/prevention & control MH - *Pregnancy Complications, Cardiovascular/prevention & control MH - Risk Assessment MH - Heart Disease Risk Factors MH - Counseling MH - Obstetrics OTO - NOTNLM OT - Cardio-obstetrics OT - Cardiovascular diseases OT - Clinical Pathways OT - Preconception Care OT - Pregnancy COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/06/12 00:37 MHDA- 2026/07/14 12:34 CRDT- 2026/06/11 18:10 PHST- 2026/03/20 00:00 [received] PHST- 2026/05/29 00:00 [accepted] PHST- 2026/07/14 12:34 [medline] PHST- 2026/06/12 00:37 [pubmed] PHST- 2026/06/11 18:10 [entrez] AID - S0301-2115(26)00281-2 [pii] AID - 10.1016/j.ejogrb.2026.115213 [doi] PST - ppublish SO - Eur J Obstet Gynecol Reprod Biol. 2026 Aug;324:115213. doi: 10.1016/j.ejogrb.2026.115213. Epub 2026 Jun 1. PMID- 42270552 OWN - NLM STAT- MEDLINE DCOM- 20260720 LR - 20261004 IS - 1532-8422 (Electronic) IS - 1053-0770 (Linking) VI - 40 IP - 8 DP - 2026 Aug TI - Perioperative Management: HeartMate 3 Left Ventricular Assist Devices in Non-Cardiac Surgery. PG - 2544-2556 LID - S1053-0770(26)00382-4 [pii] LID - 10.1053/j.jvca.2026.05.011 [doi] AB - The HeartMate 3 (HM3) left ventricular assist device is currently the most widely used left ventricular assist device worldwide. Advances in technology have enabled its use both as a bridge to transplant and as destination therapy. The HM3's fully magnetically levitated rotor, wider blood flow pathways, and artificial pulse technology have significantly improved hemocompatibility and reduced the incidence of pump thrombosis, stroke, and gastrointestinal bleeding. As a result, the HM3 offers greater durability and fewer complications than its predecessors. With the growing disparity between organ availability and transplant demand, anesthesiologists are increasingly likely to encounter patients supported by HM3 devices in both cardiac and non-cardiac surgical settings. A thorough understanding of the HM3's function, physiological implications, and potential perioperative complications is essential for safe anesthetic management. This narrative review explores the underlying physical principles of the HM3, key technical parameters necessary for monitoring device function, and perioperative management strategies. Topics include multidisciplinary team coordination, anesthetic approach and monitoring, relevant cardiac physiology, and the management of common emergencies. Although cardiac anesthesiologists are ideally suited to manage these complex cases, this may not always be possible. Therefore, it is imperative that all anesthesiologists, particularly those practicing in mechanical circulatory support centers-develop a comprehensive understanding of the HM3 system. CI - Crown Copyright (c) 2026. Published by Elsevier Inc. All rights reserved. FAU - O'Callaghan, Lauren AU - O'Callaghan L AD - Department of Anaesthesia, Mater Misericordiae University Hospital, Dublin, Ireland. FAU - Walsh, Don AU - Walsh D AD - Department of Anaesthesia, Mater Misericordiae University Hospital, Dublin, Ireland. FAU - Mulligan, Daniel AU - Mulligan D AD - Department of Anaesthesia, Mater Misericordiae University Hospital, Dublin, Ireland. FAU - Merdad, Malek AU - Merdad M AD - Peter Munk Cardiac Centre, Toronto General Hospital, Toronto, Canada. FAU - Luk, Adriana AU - Luk A AD - Peter Munk Cardiac Centre, Toronto General Hospital, Toronto, Canada; University of Toronto, Toronto, Canada. FAU - Billia, Filio AU - Billia F AD - Peter Munk Cardiac Centre, Toronto General Hospital, Toronto, Canada; University of Toronto, Toronto, Canada. FAU - Rao, Vivek AU - Rao V AD - Peter Munk Cardiac Centre, Toronto General Hospital, Toronto, Canada; University of Toronto, Toronto, Canada. FAU - Wasowicz, Marcin AU - Wasowicz M AD - Peter Munk Cardiac Centre, Toronto General Hospital, Toronto, Canada; University of Toronto, Toronto, Canada. FAU - Griffin, Michael AU - Griffin M AD - Department of Anaesthesia, Mater Misericordiae University Hospital, Dublin, Ireland; School of Medicine, University College Dublin, Dublin, Ireland. FAU - Efrimescu, Catalin AU - Efrimescu C AD - Department of Anaesthesia, Mater Misericordiae University Hospital, Dublin, Ireland. Electronic address: catalinefrimescu@mater.ie. LA - eng PT - Journal Article PT - Review DEP - 20260506 PL - United States TA - J Cardiothorac Vasc Anesth JT - Journal of cardiothoracic and vascular anesthesia JID - 9110208 SB - IM MH - Humans MH - *Heart-Assist Devices MH - *Perioperative Care/methods MH - *Surgical Procedures, Operative/methods OTO - NOTNLM OT - HM3, left ventricular assist device OT - HeartMate 3 OT - LVAD, heart failure OT - anesthesia COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/06/11 05:41 MHDA- 2026/07/21 00:35 CRDT- 2026/06/10 22:52 PHST- 2025/05/09 00:00 [received] PHST- 2026/04/20 00:00 [revised] PHST- 2026/05/04 00:00 [accepted] PHST- 2026/07/21 00:35 [medline] PHST- 2026/06/11 05:41 [pubmed] PHST- 2026/06/10 22:52 [entrez] AID - S1053-0770(26)00382-4 [pii] AID - 10.1053/j.jvca.2026.05.011 [doi] PST - ppublish SO - J Cardiothorac Vasc Anesth. 2026 Aug;40(8):2544-2556. doi: 10.1053/j.jvca.2026.05.011. Epub 2026 May 6. PMID- 42268624 OWN - NLM STAT- MEDLINE DCOM- 20260812 LR - 20260813 IS - 2168-6262 (Electronic) IS - 2168-6254 (Print) IS - 2168-6254 (Linking) VI - 161 IP - 8 DP - 2026 Aug 1 TI - Outcomes of Cardiovascular Surgery in Patients With Multiple Sclerosis. PG - 816-821 LID - 10.1001/jamasurg.2026.1951 [doi] AB - IMPORTANCE: Patients with multiple sclerosis (MS) have a higher incidence of heart failure and myocardial infarction. In patients with MS, autonomic dysregulation may cause detrimental hemodynamic instability perioperatively. However, data on outcomes of cardiac surgery in patients with MS are scarce. OBJECTIVES: To describe US nationwide morbidity and mortality in patients with MS undergoing cardiovascular surgery. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study included records of patients who underwent coronary artery bypass grafting, valve, aortic, or combined cardiovascular surgery between 2016 and 2022 in the National Inpatient Sample database. The association between MS and surgical outcomes at admission was evaluated using a balancing-score matched cohort. Data were analyzed between November 1 and 26, 2025. EXPOSURE: Multiple sclerosis. MAIN OUTCOMES AND MEASURES: In-hospital mortality, complications, length of stay, costs, and discharge disposition. RESULTS: Records for 1 766 170 patients (3605 with MS and 1 762 565 without) were included. The MS cohort was younger (median [IQR] age, 63 [57-69] years vs 67 [58-70] years) and had a larger proportion of women (2025 [56%] vs 488 850 [28%]). Patients with MS, vs those without, exhibited higher frequencies of comorbidities, including chronic lung disease, depression, hypothyroidism, paralysis, psychosis, and valvular disease. In the matched cohorts of 3530 patients, mortality did not differ significantly between patients with MS and those without MS (70 [2.0%] vs 130 [3.7%]; P = .05). The prevalence of a composite complication end point was also comparable between groups (1770 [50%] vs 1810 [51%]; P = .67). This included similarities in prevalence of stroke, acute kidney failure, pulmonary embolism, deep vein thrombosis, gastrointestinal (GI) bleeding, non-GI bleeding, prolonged mechanical ventilation, tracheostomy, pneumonia, surgical site infection, sepsis, blood transfusion, pericardial effusion, fluid overload, and pacemaker requirement. However, discharge disposition differed significantly, with a lower prevalence of routine home discharges in the MS cohort (985 [28%] vs 1265 [36%]; P < .001). Median hospitalization cost ($41 285 [IQR, $31 508-$56 040] vs $40 328 [IQR, $30 604-$56 202]; P = .44) and median length of stay (8 [IQR, 6-12] days in both groups; P = .33) did not differ between cohorts. CONCLUSIONS AND RELEVANCE: This cross-sectional study suggests that MS is not associated with increased in-hospital mortality or complications in patients undergoing cardiovascular surgery, although the prevalence of routine home discharges was lower among patients with MS. Surgeons may consider a team approach with neurological experts to optimize perioperative care and increase routine home discharges. FAU - Diz Ferre, Jose L AU - Diz Ferre JL AD - Department of Thoracic and Cardiovascular Surgery, Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio. FAU - Zhou, Guangjin AU - Zhou G AD - Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio. FAU - Cabulong, Alexander AU - Cabulong A AD - Department of Thoracic and Cardiovascular Surgery, Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio. FAU - Deschamps, Jean AU - Deschamps J AD - Department of Thoracic and Cardiovascular Surgery, Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio. FAU - Koroukian, Siran M AU - Koroukian SM AD - Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio. FAU - Schiltz, Nicholas AU - Schiltz N AD - Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio. FAU - Sajatovic, Martha AU - Sajatovic M AD - Department of Psychiatry, Case Western Reserve University School of Medicine, Cleveland, Ohio. FAU - Bakaeen, Faisal AU - Bakaeen F AD - Department of Thoracic and Cardiovascular Surgery, Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio. FAU - Gillinov, Marc AU - Gillinov M AD - Department of Thoracic and Cardiovascular Surgery, Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio. FAU - Soltesz, Edward G AU - Soltesz EG AD - Department of Thoracic and Cardiovascular Surgery, Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio. LA - eng PT - Journal Article PL - United States TA - JAMA Surg JT - JAMA surgery JID - 101589553 SB - IM CIN - JAMA Surg. 2026 Aug 1;161(8):822. doi: 10.1001/jamasurg.2026.1957. PMID: 42268618 EIN - JAMA Surg. 2026 Aug 1;161(8):851. doi: 10.1001/jamasurg.2026.2944. PMID: 42384411 MH - Humans MH - Female MH - *Multiple Sclerosis/complications/epidemiology MH - Cross-Sectional Studies MH - Middle Aged MH - Male MH - Aged MH - *Postoperative Complications/epidemiology MH - United States/epidemiology MH - Hospital Mortality MH - *Cardiovascular Surgical Procedures/mortality MH - Length of Stay/statistics & numerical data MH - *Cardiovascular Diseases/surgery/complications PMC - PMC13254797 COIS- Conflict of Interest Disclosures: Dr Koroukian reported having a contract from the Cleveland Clinic Foundation during the conduct of the study. Dr Sajatovic reported receiving grants from Neurelis, Intra-Cellular, Merck, Otsuka, and Alkermes Research; personal fees from Teva, Medscape, Bristol Myers Squibb, and AbbVie; and publication royalties from Springer Press, Johns Hopkins University Press, Oxford Press, and UpToDate outside the submitted work. Dr Gillinov reported receiving personal fees from Consultant to AtriCure, Edwards Lifesciences, Medtronic, Abbott, ClearFlow, Johnson and Johnson, Baxter, and Artivion Consulting outside the submitted work. No other disclosures were reported. EDAT- 2026/06/10 14:04 MHDA- 2026/08/12 17:35 PMCR- 2027/06/10 CRDT- 2026/06/10 11:33 PHST- 2026/08/12 17:35 [medline] PHST- 2026/06/10 14:04 [pubmed] PHST- 2026/06/10 11:33 [entrez] PHST- 2027/06/10 00:00 [pmc-release] AID - 2850260 [pii] AID - soi260032 [pii] AID - 10.1001/jamasurg.2026.1951 [doi] PST - ppublish SO - JAMA Surg. 2026 Aug 1;161(8):816-821. doi: 10.1001/jamasurg.2026.1951. PMID- 42268578 OWN - NLM STAT- MEDLINE DCOM- 20261029 LR - 20261029 IS - 1932-751X (Electronic) IS - 1932-7501 (Linking) VI - 46 IP - 6 DP - 2026 Nov 1 TI - Frailty Over Time: A 6-Month Follow-up of Multidisciplinary Cardiac and Pulmonary Rehabilitation in Older Adults with Cardiorespiratory Disease. PG - 441-447 LID - 10.1097/HCR.0000000000001041 [doi] AB - PURPOSE: Chronic heart failure (CHF) and chronic obstructive pulmonary disease (COPD) are associated with psychological distress, reduced health-related quality of life (HRQoL), and functional decline, particularly in older adults where frailty is a growing concern. This study primarily evaluated the effects of cardiac and pulmonary rehabilitation on frailty, as measured by the Clinical Frailty Scale, while also examining secondary outcomes including psychological distress, self-efficacy, and HRQoL. METHODS: In this multicentric observational study, participants were evaluated through clinical, psychological, functional, and frailty measures at baseline (T 0 ), discharge (T 1 ), and 6-month follow-up (T 2 ). RESULTS: A total of 195 older inpatients (age >/=65 years) with CHF or COPD were included. Significant improvements were observed over time in psychological distress (T 0 = 3.7 +/- 2.6, T 1 = 2.0 +/- 2.0, T 2 = 2.1 +/- 2.3; P < .0001), HRQoL (T 0 = 58.9 +/- 19.7, T 1 = 68.3 +/- 19.0, T 2 = 63.1 +/- 20.3; P < .0001), and self-efficacy (T 0 = 18.56 +/- 3.16, T 2 = 19.41 +/- 2.87; P = .0005), while frailty remained stable (T 0 = 3.9 +/- 1.1, T 1 = 3.8 +/- 1.0, T 2 = 3.9 +/- 1.0; P = .12). Regression analysis identified age, sex, Barthel Index score, Braden Scale score, HRQoL, self-efficacy, and Short Physical Performance Battery score as significant predictors of frailty at T 2 . CONCLUSION: Despite improvements in psychological and HRQoL outcomes in older adults with CHF or COPD, frailty remains a challenge, emphasizing the need for interventions targeting physical, psychological, and functional domains. Further research is needed to explore novel or improved rehabilitation strategies and their effect on long-term outcomes. CI - Copyright (c) 2026 Wolters Kluwer Health, LLC. All rights reserved. FAU - Granata, Nicolo AU - Granata N AD - Author Affiliations: Department of Cardiac Respiratory Rehabilitation of Tradate Institute, Istituti Clinici Scientifici Maugeri IRCCS, Varese, Italy (Dr Granata and Dr Cremonese); Psychology Unit of Montescano Institute, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy (Dr Vigore and Dr Pierobon); Department of Biomedical Engineering of Montescano Institute, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy (Dr Maestri); Pulmonary Rehabilitation Division of Montescano Institute, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy (Dr Callegari and Dr Piaggi); Cardiac Rehabilitation Division of Montescano Institute, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy (Dr Guazzotti); and Istituti Clinici Scientifici Maugeri IRCCS, Health Direction of Tradate Institute, Varese, Italy (Dr Audifreddi). FAU - Vigore, Martina AU - Vigore M FAU - Maestri, Roberto AU - Maestri R FAU - Callegari, Giovanna AU - Callegari G FAU - Guazzotti, Giampaolo AU - Guazzotti G FAU - Piaggi, Giancarlo AU - Piaggi G FAU - Cremonese, Gioele AU - Cremonese G FAU - Audifreddi, Silvia AU - Audifreddi S FAU - Pierobon, Antonia AU - Pierobon A LA - eng SI - ClinicalTrials.gov/NCT05230927 GR - 2424_20 04 20/Italian National funding (5x1000): project name aeurooeDecadimento cognitivo, fragilitA e outcome riabilitativo in pazienti anziani affetti da patologia cardiorespiratoria. DEC_FRAinRIABaeuro/ PT - Journal Article PT - Multicenter Study PT - Observational Study DEP - 20260610 PL - United States TA - J Cardiopulm Rehabil Prev JT - Journal of cardiopulmonary rehabilitation and prevention JID - 101291247 SB - IM MH - Humans MH - Aged MH - Female MH - Male MH - *Pulmonary Disease, Chronic Obstructive/rehabilitation/psychology/complications MH - Quality of Life MH - Follow-Up Studies MH - *Heart Failure/rehabilitation/psychology/complications MH - *Frailty/psychology/rehabilitation MH - *Cardiac Rehabilitation/methods MH - Aged, 80 and over MH - *Frail Elderly/psychology MH - Self Efficacy OTO - NOTNLM OT - chronic heart failure OT - chronic obstructive pulmonary disease OT - frailty OT - older OT - rehabilitation EDAT- 2026/06/10 14:04 MHDA- 2026/10/29 15:19 CRDT- 2026/06/10 11:23 PHST- 2025/04/26 00:00 [received] PHST- 2026/02/22 00:00 [accepted] PHST- 2026/10/29 15:19 [medline] PHST- 2026/06/10 14:04 [pubmed] PHST- 2026/06/10 11:23 [entrez] AID - 01273116-990000000-00288 [pii] AID - 10.1097/HCR.0000000000001041 [doi] PST - ppublish SO - J Cardiopulm Rehabil Prev. 2026 Nov 1;46(6):441-447. doi: 10.1097/HCR.0000000000001041. Epub 2026 Jun 10. PMID- 42264632 OWN - NLM STAT- MEDLINE DCOM- 20260612 LR - 20260724 IS - 1876-7605 (Electronic) IS - 1936-8798 (Linking) VI - 19 IP - 11 DP - 2026 Jun 8 TI - CT-Based Risk Stratification of Coronary Obstruction During TAVR: Clinical Utility and a New Volumetric Parameter. PG - 1406-1419 LID - S1936-8798(26)01321-X [pii] LID - 10.1016/j.jcin.2026.04.015 [doi] AB - BACKGROUND: Coronary obstruction (CO) during transcatheter aortic valve replacement (TAVR) is rare but potentially fatal. Computed tomography (CT)-based risk assessment algorithms aim to identify high-risk patients, but their utility remains underexplored. OBJECTIVES: The aim of this study was to examine the clinical utility of a CT-derived algorithm for predicting CO during TAVR and identify predictors of CO despite coronary protection (CP). METHODS: In this prospective study, 164 patients at risk for CO during TAVR were enrolled. Preprocedural CT was used to classify risk using a published algorithm. A novel volumetric parameter, valve-to-coronary volume (VTCV), was calculated in high-risk cases using sinus width and valve-to-coronary (VTC) distance. The decision to use CP was left to the heart team. Clinical endpoints followed Valve Academic Research Consortium 3 definitions. RESULTS: According to the CT-based algorithm, 58.5% of patients (96 of 164) were at low risk, 24.4% (40 of 164) at intermediate risk, and 17.1% (28 of 164) at high risk. CP was performed in 12.8% of low-risk patients (16 of 125), 52.8% of intermediate-risk patients (28 of 53), and 93.9% of high-risk patients (31 of 33). All CO events (n = 7) occurred in the high-risk group. VTC distance and VTCV were significantly lower in patients with CO (P = 0.006 and P = 0.005, respectively). VTCV independently predicted CO (area under the curve, 0.841; 95% CI: 0.702-0.979; P < 0.001), outperforming VTC distance alone. The predictive value of VTCV was validated in an external cohort including 11 European centers. CONCLUSIONS: A CT-based algorithm stratifies patients into 3 CO risk categories, though the decision for CP in clinical practice seems to incorporate additional clinical and procedural variables. Although CP reduces CO risk, its efficacy is limited in patients with very small VTCV, which can be predicted preprocedurally via CT. (Leipzig TAVR Registry; NCT05015452). CI - Copyright (c) 2026 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Abdelhafez, Ahmed AU - Abdelhafez A AD - Department of Structural Heart Disease/Cardiology, Heart Center Leipzig at Leipzig University, Leipzig, Germany. FAU - Lankisch, Niklas AU - Lankisch N AD - Department of Structural Heart Disease/Cardiology, Heart Center Leipzig at Leipzig University, Leipzig, Germany. FAU - Iannopollo, Gianmarco AU - Iannopollo G AD - Department of Structural Heart Disease/Cardiology, Heart Center Leipzig at Leipzig University, Leipzig, Germany; Department of Cardiology, Ospedale Maggiore Carlo Alberto Pizzardi, Bologna, Italy. FAU - Dumpies, Oliver AU - Dumpies O AD - Department of Structural Heart Disease/Cardiology, Heart Center Leipzig at Leipzig University, Leipzig, Germany. FAU - Rotta Detto Loria, Johannes AU - Rotta Detto Loria J AD - Department of Structural Heart Disease/Cardiology, Heart Center Leipzig at Leipzig University, Leipzig, Germany. FAU - Richter, Ines AU - Richter I AD - Department of Structural Heart Disease/Cardiology, Heart Center Leipzig at Leipzig University, Leipzig, Germany. FAU - Majunke, Nicolas AU - Majunke N AD - Department of Structural Heart Disease/Cardiology, Heart Center Leipzig at Leipzig University, Leipzig, Germany. FAU - Feistritzer, Hans-Josef AU - Feistritzer HJ AD - Department of Structural Heart Disease/Cardiology, Heart Center Leipzig at Leipzig University, Leipzig, Germany. FAU - Gohmann, Robin AU - Gohmann R AD - Department of Diagnostic and Interventional Radiology, Heart Center Leipzig at Leipzig University, Leipzig, Germany. FAU - Desch, Steffen AU - Desch S AD - Department of Structural Heart Disease/Cardiology, Heart Center Leipzig at Leipzig University, Leipzig, Germany. FAU - Noack, Thilo AU - Noack T AD - Department of Structural Heart Disease/Cardiac Surgery, Heart Center Leipzig at Leipzig University, Leipzig, Germany. FAU - Thiele, Holger AU - Thiele H AD - Department of Structural Heart Disease/Cardiology, Heart Center Leipzig at Leipzig University, Leipzig, Germany. FAU - Abdel-Wahab, Mohamed AU - Abdel-Wahab M AD - Department of Structural Heart Disease/Cardiology, Heart Center Leipzig at Leipzig University, Leipzig, Germany. Electronic address: mohamed.abdel-wahab@medizin.uni-leipzig.de. LA - eng SI - ClinicalTrials.gov/NCT05015452 PT - Journal Article PT - Observational Study PT - Research Support, Non-U.S. Gov't PL - United States TA - JACC Cardiovasc Interv JT - JACC. Cardiovascular interventions JID - 101467004 SB - IM MH - Aged MH - Aged, 80 and over MH - Female MH - Humans MH - Male MH - Algorithms MH - *Aortic Valve/diagnostic imaging/surgery/physiopathology MH - *Aortic Valve Stenosis/diagnostic imaging/surgery/physiopathology/complications MH - Clinical Decision-Making MH - Clinical Relevance MH - *Computed Tomography Angiography MH - *Coronary Angiography/methods MH - *Coronary Stenosis/diagnostic imaging/etiology MH - *Decision Support Techniques MH - *Multidetector Computed Tomography MH - Prediction Algorithms MH - Predictive Value of Tests MH - Prospective Studies MH - Risk Assessment MH - Risk Factors MH - Severity of Illness Index MH - *Transcatheter Aortic Valve Replacement/adverse effects MH - Treatment Outcome OTO - NOTNLM OT - computed tomography OT - coronary obstruction OT - coronary protection OT - transcatheter aortic valve replacement COIS- Funding Support and Author Disclosures Dr Abdel-Wahab has received speaker honoraria and/or consultancy fees paid to his hospital on his behalf from Boston Scientific, Medtronic, and Edwards Lifesciences. Dr Noack has received speaker honoraria and consultancy fees paid to his institution from Medtronic, Abbott Cardiovascular, and Edwards Lifesciences. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2026/06/10 06:53 MHDA- 2026/06/12 13:03 CRDT- 2026/06/09 20:57 PHST- 2026/01/23 00:00 [received] PHST- 2026/03/24 00:00 [revised] PHST- 2026/04/03 00:00 [accepted] PHST- 2026/06/12 13:03 [medline] PHST- 2026/06/10 06:53 [pubmed] PHST- 2026/06/09 20:57 [entrez] AID - S1936-8798(26)01321-X [pii] AID - 10.1016/j.jcin.2026.04.015 [doi] PST - ppublish SO - JACC Cardiovasc Interv. 2026 Jun 8;19(11):1406-1419. doi: 10.1016/j.jcin.2026.04.015. PMID- 42264285 OWN - NLM STAT- MEDLINE DCOM- 20260729 LR - 20260805 IS - 1879-1913 (Electronic) IS - 0002-9149 (Linking) VI - 273 DP - 2026 Aug 15 TI - How to Implement Recommendations on Multidisciplinary Heart Failure Management Program Into Practice? Lithuanian Experience. PG - 11-18 LID - S0002-9149(26)00388-7 [pii] LID - 10.1016/j.amjcard.2026.05.030 [doi] AB - Despite clear guideline recommendation to involve heart failure (HF) patients into multidisciplinary programmes (MP), availability of this specialized care remains insufficient throughout European countries. The aim of this study is to analyse the process of establishment, implementation metrics, and quality indicators (QIs) of heart failure multidisciplinary programme (HF-MP) in Lithuania. We conducted a retrospective analysis of the requisites, steps of initiation and development of HF-MP as a national service reimbursed since 2016. HF-MP is structured as 4 encounters with a specialized HF team during 1 year after HF decompensation. Based on the National Health Insurance Fund (NHIF) administrative data we present the effect of HF-MP intervention on cardiovascular readmissions, survival, and ICD implantations from 2018 to 2022. Aggregated 2018 to 2022 data from the NHIF showed that the odds for 1-year survival were 2.4 to 2.9 times higher in HF-MP cohort compared to usual care (UC), while the chances to survive without readmissions were 1.3 to 1.7 times greater than with UC. Health-related quality of life, index of self-care, and 6-min walk test had improved significantly at the last visit of HF-MP service (p < 0.001). In conclusion, sharing practical experience from HF clinics in Sweden and HF recommendations help to transfer HF multidisciplinary programmes to the national Lithuanian context. The effects of the intervention include reduction of morbidity and early mortality as well as improvement of quality of life of patients with heart failure. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Celutkiene, Jelena AU - Celutkiene J AD - Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania; Centre of Innovative Medicine, Vilnius, Lithuania. Electronic address: jelena.celutkiene@santa.lt. FAU - Lycholip, Edita AU - Lycholip E AD - Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania; Vilnius University Hospital Santaros klinikos, Vilnius, Lithuania. FAU - Burneikaite, Greta AU - Burneikaite G AD - Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania; Vilnius University Hospital Santaros klinikos, Vilnius, Lithuania. FAU - Kalakauskaite, Laura AU - Kalakauskaite L AD - Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania; Vilnius University Hospital Santaros klinikos, Vilnius, Lithuania. FAU - Karaliute, Gintare AU - Karaliute G AD - Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania; Vilnius University Hospital Santaros klinikos, Vilnius, Lithuania. FAU - Kriukelyte, Daiva AU - Kriukelyte D AD - Department of Nursing, Faculty of Nursing, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania. FAU - Barysiene, Jurate AU - Barysiene J AD - Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania; Vilnius University Hospital Santaros klinikos, Vilnius, Lithuania. FAU - Zuoziene, Gitana AU - Zuoziene G AD - Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania; Vilnius University Hospital Santaros klinikos, Vilnius, Lithuania. FAU - Zaliaduonyte, Diana AU - Zaliaduonyte D AD - Cardiology Department, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania. FAU - Kavoliuniene, Ausra AU - Kavoliuniene A AD - Cardiology Department, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania. FAU - Puronaite, Roma AU - Puronaite R AD - Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania; Vilnius University Hospital Santaros klinikos, Vilnius, Lithuania; Institute of Data Science and Digital Technologies, Faculty of Mathematics and Informatics, Vilnius University, Vilnius, Lithuania. FAU - Morkveniene, Vaida AU - Morkveniene V AD - National Health Insurance Fund under the Ministry of Health, Vilnius, Lithuania. FAU - Gircys, Algimantas AU - Gircys A AD - Division of Nursing, Department of Health, Medicine and Caring Science Studies, Linkoping University, Linkoping, Sweden. FAU - Zilinskas, Lukas AU - Zilinskas L AD - National Health Insurance Fund under the Ministry of Health, Vilnius, Lithuania. FAU - Stromberg, Anna AU - Stromberg A AD - Division of Nursing, Department of Health, Medicine and Caring Science Studies, Linkoping University, Linkoping, Sweden; Department of cardiology, Linkoping University, Linkoping, Sweden. FAU - Jaarsma, Tiny AU - Jaarsma T AD - Division of Nursing, Department of Health, Medicine and Caring Science Studies, Linkoping University, Linkoping, Sweden; Julius Center, University Medical Center Utrecht, Utrecht, the Netherlands. LA - eng PT - Journal Article DEP - 20260608 PL - United States TA - Am J Cardiol JT - The American journal of cardiology JID - 0207277 SB - IM MH - Humans MH - *Heart Failure/therapy/epidemiology MH - Lithuania/epidemiology MH - Retrospective Studies MH - Female MH - Male MH - Aged MH - Quality of Life MH - *Patient Care Team/organization & administration MH - *Disease Management MH - Patient Readmission/statistics & numerical data OTO - NOTNLM OT - heart failure OT - heart failure clinic OT - heart failure management OT - heart failure nurse OT - multi-disciplinary program COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/06/10 06:55 MHDA- 2026/07/30 00:38 CRDT- 2026/06/09 19:48 PHST- 2026/04/26 00:00 [received] PHST- 2026/05/19 00:00 [revised] PHST- 2026/05/30 00:00 [accepted] PHST- 2026/07/30 00:38 [medline] PHST- 2026/06/10 06:55 [pubmed] PHST- 2026/06/09 19:48 [entrez] AID - S0002-9149(26)00388-7 [pii] AID - 10.1016/j.amjcard.2026.05.030 [doi] PST - ppublish SO - Am J Cardiol. 2026 Aug 15;273:11-18. doi: 10.1016/j.amjcard.2026.05.030. Epub 2026 Jun 8. PMID- 42263920 OWN - NLM STAT- Publisher LR - 20260714 IS - 1532-9488 (Electronic) IS - 1043-0679 (Linking) DP - 2026 Jun 9 TI - Palliative Care Throughout the Entire Perioperative Pathway in Cardiovascular Surgery. LID - S1043-0679(26)00032-8 [pii] LID - 10.1053/j.semtcvs.2026.04.003 [doi] AB - Cardiovascular surgery has substantially improved survival and quality of life for patients with cardiovascular disease, yet contemporary surgical populations are increasingly older, multimorbid, and affected by advanced disease, rendering procedures and perioperative care more complex. Patients often experience severe physical symptoms, psychological distress, and difficult decisions, which in cases of complications also include escalation, limitation, or withdrawal of life-sustaining treatment. In this article, we argue that palliative care offers a framework to address these complex needs throughout the entire cardiovascular surgery pathway, rather than only at the end of life. Preoperatively, structured shared decision-making, goals-of-care discussions, and advance care planning can help align surgical strategies with patients' values and prepare patients and families for potential complications. Postoperatively, routine assessment and management of physical symptoms, psychological distress, social needs, and spiritual concerns could prevent and alleviate suffering during the hospitalization. In the setting of serious complications, interdisciplinary team support, regular family meetings, and professional communication can support decision-making and reduce distress for patients, families, and clinicians. Most palliative care needs can be addressed by surgical and intensive care teams as primary palliative care, while specialty palliative care should be involved for complex symptoms, decisional conflict, or challenging psychosocial or existential distress. Further research, education, and guideline development are needed to change professional culture and establish palliative care as a routine, complementary component of cardiovascular surgical care. CI - Copyright (c) 2026 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Blum, Moritz AU - Blum M AD - Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charite (DHZC), Berlin, Germany; Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin und Humboldt-Universitat zu Berlin, Berlin, Germany; Berlin Institute of Health at Charite - Universitatsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charite Junior Clinician Scientist Program, Chariteplatz 1, 10117 Berlin, Germany. Electronic address: moritz.blum@charite.de. FAU - Schoenrath, Felix AU - Schoenrath F AD - Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charite (DHZC), Berlin, Germany; Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin und Humboldt-Universitat zu Berlin, Berlin, Germany; DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Berlin, Germany. FAU - Ahn, Johann AU - Ahn J AD - Department of Hematology, Oncology, and Tumor Immunology, Campus Virchow Klinikum, Berlin, Charite - Universitatsmedizin, Berlin, Germany. FAU - Bockbreder, Kathrin AU - Bockbreder K AD - Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin und Humboldt-Universitat zu Berlin, Berlin, Germany; Department of Cardiac Anesthesiology and Intensive Care, Deutsches Herzzentrum der Charite (DHZC), Berlin, Germany. FAU - Ott, Sascha AU - Ott S AD - Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin und Humboldt-Universitat zu Berlin, Berlin, Germany; DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Berlin, Germany; Department of Cardiac Anesthesiology and Intensive Care, Deutsches Herzzentrum der Charite (DHZC), Berlin, Germany. FAU - Schmitt, Katharina AU - Schmitt K AD - Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin und Humboldt-Universitat zu Berlin, Berlin, Germany; Department of Psychocardiology, Deutsches Herzzentrum der Charite (DHZC), Berlin, Germany. FAU - Jobges, Susanne AU - Jobges S AD - Department of Anaesthesiology and Intensive Medicine, Campus Virchow Klinikum, Berlin, Charite - Universitatsmedizin, Berlin, Germany. FAU - Gelfman, Laura AU - Gelfman L AD - Brookdale Department of Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount Sinai, New York, New York. FAU - Falk, Volkmar AU - Falk V AD - Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charite (DHZC), Berlin, Germany; Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin und Humboldt-Universitat zu Berlin, Berlin, Germany; DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Berlin, Germany. LA - eng PT - Journal Article DEP - 20260609 PL - United States TA - Semin Thorac Cardiovasc Surg JT - Seminars in thoracic and cardiovascular surgery JID - 8917640 SB - IM OTO - NOTNLM OT - Cardiovascular surgery OT - Narrative review OT - Palliative care EDAT- 2026/06/10 06:52 MHDA- 2026/06/10 06:52 CRDT- 2026/06/09 19:39 PHST- 2025/12/16 00:00 [received] PHST- 2026/02/19 00:00 [revised] PHST- 2026/04/12 00:00 [accepted] PHST- 2026/06/10 06:52 [pubmed] PHST- 2026/06/10 06:52 [medline] PHST- 2026/06/09 19:39 [entrez] AID - S1043-0679(26)00032-8 [pii] AID - 10.1053/j.semtcvs.2026.04.003 [doi] PST - aheadofprint SO - Semin Thorac Cardiovasc Surg. 2026 Jun 9:S1043-0679(26)00032-8. doi: 10.1053/j.semtcvs.2026.04.003. PMID- 42262752 OWN - NLM STAT- MEDLINE DCOM- 20260612 LR - 20260827 IS - 2574-3805 (Electronic) IS - 2574-3805 (Linking) VI - 9 IP - 6 DP - 2026 Jun 1 TI - Adoption of a Pediatric Acute Care Cardiology Inpatient Model. PG - e2617553 LID - 10.1001/jamanetworkopen.2026.17553 [doi] LID - e2617553 AB - IMPORTANCE: Despite widespread adoption and investment of resources nationally, the pediatric acute care cardiology (ACC) model of care has not been previously evaluated prospectively. OBJECTIVE: To test the hypothesis that adoption of an ACC model will be associated with improved clinical outcomes. DESIGN, SETTING, AND PARTICIPANTS: This single-center prospective quality improvement study was conducted in a 26-bed ACC unit of a high surgical volume, freestanding children's hospital. The baseline period was May 15 to October 31, 2023, and the intervention period was November 1, 2023, to November 30, 2024. All ACC unit encounters during the baseline and intervention periods were included. Data sources were hospital administrative data, local Pediatric Acute Care Cardiology Collaborative registry, and Patient and Family Experience (PFE) scores. EXPOSURE: Full-scale change in the model of care: transitioned unit leadership from hospital pediatrics to cardiology, changed attending of record for medical patients to cardiologist, hired nurse practitioners as frontline clinicians, integrated residents into the team, implemented multidisciplinary family-centered rounding, updated communication processes, and transitioned cardiology fellows to in-house overnight call. MAIN OUTCOMES AND MEASURES: Complication rate and back transfer to the intensive care unit (ICU) were outcome measures, discharge time was a process measure, 7-day unplanned readmissions and length of stay (LOS) were balancing measures. Standard rules for identifying special cause variation (SCV) were applied. The percentage of patients and families with positive PFE scores (defined as scores of 9 or 10) before and after the intervention were compared using an independent t test. Hypothesis was formulated prior to data collection. RESULTS: There were 483 encounters (45.2% among children aged 1-18 years) in the baseline period and 973 (52.7% among children aged 1-18 years) in the intervention period. Outcome and process measures significantly improved showing SCV following adoption of the ACC model (mean complications: baseline, 23.6% vs intervention, 16.0%; mean back transfer to ICU: baseline, 11.4% vs intervention, 6.9%; mean patient discharge time: baseline, 15.37 hours vs intervention, 14.43 hours). LOS and 7-day unplanned readmissions were unchanged, suggesting no major inadvertent negative consequences of the ACC model. Mean LOS for medical patients decreased (7.83 vs 4.97 days). PFE improved after the intervention (median [SD], preintervention: 76.9% [3.7] vs postintervention: 82.9% [4.3]; P = .04). CONCLUSIONS AND RELEVANCE: In this quality improvement study of an ACC model, multiple outcomes improved without evidence of negative consequences. These clinical improvements may justify necessary investment of resources to support ACC models. Adaptation of this model for other subspecialties may help address pediatric resident workforce changes. Ongoing evaluation of resource utilization, sustainability of improvement, and newly embedded improvement efforts is underway. FAU - Gal, Dana B AU - Gal DB AD - Division of Pediatric Cardiology, Department of Pediatrics, Keck School of Medicine at University of Southern California, Los Angeles. AD - Division of Pediatric Cardiology, Children's Hospital Los Angeles, Los Angeles, California. FAU - Georgis, Jessica K AU - Georgis JK AD - Division of Pediatric Cardiology, Children's Hospital Los Angeles, Los Angeles, California. FAU - Alak-DeBergh, Selin AU - Alak-DeBergh S AD - Division of Pediatric Cardiology, Children's Hospital Los Angeles, Los Angeles, California. FAU - Pandjaitan, Ivo AU - Pandjaitan I AD - Division of Pediatric Cardiology, Children's Hospital Los Angeles, Los Angeles, California. FAU - Yanga De Guzman, Aileen AU - Yanga De Guzman A AD - Division of Pediatric Cardiology, Children's Hospital Los Angeles, Los Angeles, California. FAU - Herrington, Cynthia AU - Herrington C AD - Department of Cardiothoracic Surgery, Keck School of Medicine, University of Southern California, Los Angeles. FAU - Madsen, Nicolas L AU - Madsen NL AD - Division of Pediatric Cardiology, Department of Pediatrics, UT Southwestern, Dallas, Texas. FAU - Kantor, Paul F AU - Kantor PF AD - Division of Pediatric Cardiology, Department of Pediatrics, Keck School of Medicine at University of Southern California, Los Angeles. AD - Division of Pediatric Cardiology, Children's Hospital Los Angeles, Los Angeles, California. LA - eng PT - Journal Article DEP - 20260601 PL - United States TA - JAMA Netw Open JT - JAMA network open JID - 101729235 SB - IM MH - Humans MH - Prospective Studies MH - Child MH - Male MH - *Quality Improvement MH - Female MH - *Cardiology/organization & administration/methods MH - Child, Preschool MH - Hospitals, Pediatric/organization & administration MH - Adolescent MH - Infant MH - Length of Stay/statistics & numerical data MH - Models, Organizational MH - *Pediatrics PMC - PMC13250712 COIS- Conflict of Interest Disclosures: None reported. EDAT- 2026/06/09 12:48 MHDA- 2026/06/12 06:39 PMCR- 2026/06/09 CRDT- 2026/06/09 11:32 PHST- 2026/06/12 06:39 [medline] PHST- 2026/06/09 12:48 [pubmed] PHST- 2026/06/09 11:32 [entrez] PHST- 2026/06/09 00:00 [pmc-release] AID - 2850064 [pii] AID - zoi260494 [pii] AID - 10.1001/jamanetworkopen.2026.17553 [doi] PST - epublish SO - JAMA Netw Open. 2026 Jun 1;9(6):e2617553. doi: 10.1001/jamanetworkopen.2026.17553. PMID- 42256994 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260608 LR - 20260922 IS - 2050-0904 (Print) IS - 2050-0904 (Electronic) IS - 2050-0904 (Linking) VI - 14 IP - 6 DP - 2026 Jun TI - Primary Cardiac Angiosarcoma in a Young Male: Rare Presentation With Right Atrial Endocardial Dissection and Right Coronary Artery Tumor Fistula. PG - e72760 LID - 10.1002/ccr3.72760 [doi] LID - e72760 AB - We report the case of a 19-year-old man who presented with several months of exertional dyspnea and recent-onset hemostasis. Initial imaging revealed multiple pulmonary nodules. Days later, he was referred to a specialized center with chest pain and signs of pericarditis. Transthoracic echocardiography (TTE) showed pericardial effusion with hematoma, while transesophageal echocardiography (TEE) revealed a vascularized mass in the right atrial wall supplied by the right coronary artery (RCA), with blood leakage into the pericardial space. Due to concern for cardiac perforation, emergency surgery was decided. Intraoperatively, coronary angiography was performed prior to chest closure due to the anatomical complexity of the RCA. Pathology and immunohistochemistry analysis of cardiac, pericardium, and lung specimens confirmed the diagnosis of primary cardiac angiosarcoma. This case represents the aggressive behavior, diagnostic challenges, and therapeutic complexity of cardiac angiosarcoma, and highlights the importance of early diagnosis, accurate imaging, and a multidisciplinary approach. CI - (c) 2026 The Author(s). Clinical Case Reports published by John Wiley & Sons Ltd. FAU - Akiash, Nehzat AU - Akiash N AD - Atherosclerosis Research Center Ahvaz Jundishapur University of Medical Sciences Ahvaz Iran. FAU - Rezaee Kalantari, Ramtin AU - Rezaee Kalantari R AD - Department of Cardiac Surgery, Atherosclerosis Research Center Ahvaz Jundishapur University of Medical Sciences Ahvaz Iran. FAU - Abbaspour, Somayeh AU - Abbaspour S AD - Atherosclerosis Research Center Ahvaz Jundishapur University of Medical Sciences Ahvaz Iran. FAU - Masoumi, Mahlasadat AU - Masoumi M AD - Atherosclerosis Research Center Ahvaz Jundishapur University of Medical Sciences Ahvaz Iran. FAU - Eslami, Narges AU - Eslami N AD - Clinical Research Development Unit Ahvaz Jundishapur University of Medical Sciences Ahvaz Iran. FAU - Akiash, Nasibeh AU - Akiash N AD - Golestan Hospital Ahvaz Jundishapur University of Medical Sciences Ahvaz Iran. FAU - Pazoki, Mahboubeh AU - Pazoki M AD - Department of Cardiology, School of Medicine Hazrat-e Rasool General Hospital, Iran University of Medical Sciences (IUMS) Tehran Iran. FAU - Rajabzadeh, Shahab AU - Rajabzadeh S AD - Department of Cardiology, School of Medicine Hazrat-e Rasool General Hospital, Iran University of Medical Sciences (IUMS) Tehran Iran. FAU - Mostafavi, Soroush AU - Mostafavi S AUID- ORCID: 0000-0002-8342-7821 AD - Department of Cardiology, School of Medicine Hazrat-e Rasool General Hospital, Iran University of Medical Sciences (IUMS) Tehran Iran. LA - eng PT - Journal Article DEP - 20260529 PL - England TA - Clin Case Rep JT - Clinical case reports JID - 101620385 PMC - PMC13238764 OTO - NOTNLM OT - cardiac angiosarcoma OT - cardiac surgery OT - endocardial dissection OT - hemopericardium OT - tumor fistula EDAT- 2026/06/08 12:38 MHDA- 2026/06/08 12:39 PMCR- 2026/05/29 CRDT- 2026/06/08 07:45 PHST- 2025/11/11 00:00 [received] PHST- 2026/04/25 00:00 [revised] PHST- 2026/05/03 00:00 [accepted] PHST- 2026/06/08 12:39 [medline] PHST- 2026/06/08 12:38 [pubmed] PHST- 2026/06/08 07:45 [entrez] PHST- 2026/05/29 00:00 [pmc-release] AID - CCR372760 [pii] AID - 10.1002/ccr3.72760 [doi] PST - epublish SO - Clin Case Rep. 2026 May 29;14(6):e72760. doi: 10.1002/ccr3.72760. eCollection 2026 Jun. PMID- 42256905 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260608 LR - 20260813 IS - 2090-6382 (Print) IS - 2090-6390 (Electronic) IS - 2090-6390 (Linking) VI - 2026 DP - 2026 TI - Repair of Double-Chamber Right Ventricle and Subvalvular Pulmonic Stenosis in a 78-Year-Old With Repaired Tetralogy of Fallot: Anesthetic Considerations and Review of the Literature. PG - 8376547 LID - 10.1155/cria/8376547 [doi] LID - 8376547 AB - BACKGROUND: Double-chambered right ventricle (DCRV) is a rare congenital anomaly characterized by hypertrophied muscular bundles dividing the right ventricle into high- and low-pressure chambers. It is frequently associated with congenital heart disease, particularly tetralogy of Fallot (TOF), but rarely presents in late adulthood. CASE PRESENTATION: We report the case of a 78-year-old man with a history of prior pulmonary valvotomy who presented with progressive dyspnea and was found to have severe subvalvular right ventricular outflow tract obstruction. Multimodal imaging and cardiac catheterization confirmed DCRV with near-systemic right ventricular pressures and an anomalous left anterior descending coronary artery arising from the right coronary cusp. The patient underwent surgical resection of hypertrophied infundibular muscle bundles with patch augmentation of the main pulmonary artery. Intraoperative transesophageal echocardiography guided management and confirmed successful relief of obstruction. The patient had an uncomplicated postoperative course with resolution of symptoms. DISCUSSION: This case highlights the late presentation of DCRV as a sequela of incompletely repaired TOF and underscores the importance of comprehensive imaging and careful surgical planning in the presence of anomalous coronary anatomy. Anesthetic management focused on maintaining right ventricular preload and coronary perfusion while avoiding dynamic right ventricular outflow tract obstruction. CONCLUSION: DCRV can present late in life in patients with prior congenital heart disease. Successful management requires a multidisciplinary approach with careful perioperative hemodynamic optimization. CI - Copyright (c) 2026 Robert Ricketts et al. Case Reports in Anesthesiology published by John Wiley & Sons Ltd. FAU - Ricketts, Robert AU - Ricketts R AUID- ORCID: 0009-0001-4515-261X AD - Department of Anesthesiology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, Ohio, 45229, USA, cincinnatichildrens.org. FAU - Caruso, Joseph AU - Caruso J AUID- ORCID: 0000-0001-8394-4258 AD - Department of Anesthesia & Perioperative Medicine, The Medical University of South Carolina, 167 Ashley Avenue, Charleston, South Carolina, 29425, USA, musc.edu. FAU - Scott, Erik AU - Scott E AD - Tallahassee Memorial Healthcare, Florida State University College of Medicine, 1300 Miccosukee Road, Tallahassee, Florida, 32308, USA, fsu.edu. FAU - Habib, Asma AU - Habib A AD - Department of Medicine, Division of Cardiovascular Medicine, University of Virginia, 200 Jeanette Lancaster Way, Charlottesville, Virginia, 22903, USA, virginia.edu. FAU - Beller, Jared P AU - Beller JP AUID- ORCID: 0000-0001-7385-2819 AD - Department of Surgery, Division of Cardiothoracic Surgery, University of Virginia, 200 Jeanette Lancaster Way, Charlottesville, Virginia, 22903, USA, virginia.edu. LA - eng PT - Journal Article DEP - 20260528 PL - United States TA - Case Rep Anesthesiol JT - Case reports in anesthesiology JID - 101581025 PMC - PMC13240376 OTO - NOTNLM OT - adult congenital heart disease OT - anomalous coronary arteries OT - double-chamber right ventricle OT - right ventricular outflow tract obstruction OT - tetralogy of Fallot COIS- The authors declare no conflicts of interest. EDAT- 2026/06/08 12:38 MHDA- 2026/06/08 12:39 PMCR- 2026/05/28 CRDT- 2026/06/08 07:45 PHST- 2025/01/28 00:00 [received] PHST- 2026/05/02 00:00 [revised] PHST- 2026/05/07 00:00 [accepted] PHST- 2026/06/08 12:39 [medline] PHST- 2026/06/08 12:38 [pubmed] PHST- 2026/06/08 07:45 [entrez] PHST- 2026/05/28 00:00 [pmc-release] AID - CRIA8376547 [pii] AID - 10.1155/cria/8376547 [doi] PST - epublish SO - Case Rep Anesthesiol. 2026 May 28;2026:8376547. doi: 10.1155/cria/8376547. eCollection 2026. PMID- 42256238 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260608 LR - 20260813 IS - 2950-1334 (Electronic) IS - 2950-1334 (Linking) VI - 13 DP - 2026 Aug TI - Pulmonary thromboendarterectomy at leading high-volume centers: International perspectives. PG - 100550 LID - 10.1016/j.jhlto.2026.100550 [doi] LID - 100550 AB - BACKGROUND: Chronic thromboembolic pulmonary hypertension (CTEPH) is a potentially curable pulmonary hypertension, caused by persistent obstruction of the pulmonary arteries due to organized thromboembolic material. Pulmonary thromboendarterectomy (PTE) remains the gold standard treatment for eligible patients, offering significant symptomatic relief, improved hemodynamics, and long-term survival. As a complex surgical procedure requiring cardiopulmonary bypass and deep hypothermic circulatory arrest, management of PTE demands a highly specialized, multidisciplinary approach. METHODS: This review represents a collaborative effort from four leading international centers with extensive experience in CTEPH management. We provide a practical overview of perioperative strategies including patient selection, surgical technique, anesthetic management, cardiopulmonary bypass considerations, and postoperative intensive care management. Institutional variations in practice were also compared. RESULTS: Shared principles across centers included careful hemodynamic optimization, advanced perioperative monitoring, and structured postoperative critical care. Areas of institutional variation included anticoagulation approaches, monitoring practices, neuroprotection techniques, blood conservation strategies, postoperative ventilation, and hemodynamic management. These differences reflected local protocols developed in the setting of limited comparative evidence. CONCLUSIONS: PTE remains the definitive treatment for operable CTEPH at experienced centers. Successful outcomes rely not only on surgical expertise but also on coordinated anesthetic and critical care management. This review summarizes current international practice, highlights areas of consensus and variability, and identifies priorities for future multicenter evaluation and quality improvement initiatives. CI - (c) 2026 The Authors. FAU - Fong, Justin AU - Fong J AD - Department of Anaesthesia and Intensive Care Medicine, Royal Papworth Hospital, Cambridge, UK. FAU - Choi, Christine AU - Choi C AD - Sulpizio Cardiovascular Centre, Department of Anesthesiology, University of California San Diego, La Jolla, California. FAU - Kuzmina, Natalia AU - Kuzmina N AD - Department of Anaesthesia, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada. FAU - Thes, Jacques AU - Thes J AD - Department of Anesthesiology, Marie Lannelongue Hospital and Paris Saint Joseph Hospital, Paris, Le Plessis-Robinson, France. FAU - Huang, Alexander AU - Huang A AD - Department of Anaesthesia, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada. FAU - Rubino, Antonio AU - Rubino A AD - Department of Anaesthesia and Intensive Care Medicine, Royal Papworth Hospital, Cambridge, UK. FAU - Diop, Sylvain AU - Diop S AD - Department of Anesthesiology, Marie Lannelongue Hospital and Paris Saint Joseph Hospital, Paris, Le Plessis-Robinson, France. FAU - Banks, Dalia AU - Banks D AD - Sulpizio Cardiovascular Centre, Department of Anesthesiology, University of California San Diego, La Jolla, California. LA - eng PT - Journal Article DEP - 20260328 PL - United States TA - JHLT Open JT - JHLT open JID - 9918716187806676 PMC - PMC13240734 OTO - NOTNLM OT - chronic thromboembolic pulmonary hypertension OT - deep hypothermic cardiac arrest OT - pulmonary embolism OT - pulmonary hypertension OT - pulmonary thromboendarterectomy COIS- All authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/06/08 12:40 MHDA- 2026/06/08 12:41 PMCR- 2026/03/28 CRDT- 2026/06/08 07:39 PHST- 2026/06/08 12:41 [medline] PHST- 2026/06/08 12:40 [pubmed] PHST- 2026/06/08 07:39 [entrez] PHST- 2026/03/28 00:00 [pmc-release] AID - S2950-1334(26)00071-6 [pii] AID - 100550 [pii] AID - 10.1016/j.jhlto.2026.100550 [doi] PST - epublish SO - JHLT Open. 2026 Mar 28;13:100550. doi: 10.1016/j.jhlto.2026.100550. eCollection 2026 Aug. PMID- 42255973 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260608 LR - 20260813 IS - 2472-0054 (Electronic) IS - 2472-0054 (Linking) VI - 11 IP - 3 DP - 2026 May-Jun TI - Multidisciplinary Timely Debrief Sessions after Cardiac Arrests and Endotracheal Intubations in the Pediatric Emergency Department. PG - e891 LID - 10.1097/pq9.0000000000000891 [doi] LID - e891 AB - INTRODUCTION: Multidisciplinary clinical debriefs are structured discussions following critical events to assess performance, identify improvement opportunities, and provide team support. Despite known benefits, debriefs are underused. We aimed to increase debrief completion following pediatric emergency department (ED) cardiac arrests and endotracheal intubations. The primary outcome was the percentage of critical events with a completed debrief form. To assess potential workflow disruptions, we assessed 2 balancing measures: room-to-provider and door-to-provider times among Emergency Severity Index level 1 and 2 patients. METHODS: A key driver diagram guided targeted interventions. We implemented a standardized Research Electronic Data Capture (REDCap) debrief form using a plus-delta framework with scripted prompts, accessible via quick response codes throughout the ED. As part of the intervention design, debriefs were encouraged within 30 minutes of the event and were designed to last 7 minutes or less. Educational initiatives included staff meetings, email reminders, newsletters, signage, and designated nursing champions. We used statistical process control to assess changes over time. RESULTS: Debrief completion increased from 4% to 52% during 15 months, showing special-cause variation. Median room-to-provider times remained unchanged. Median door-to-provider times decreased during the intervention period. CONCLUSIONS: Multiple interventions significantly increased the use of structured debriefing without adversely affecting patient flow. Structured debriefing is both feasible and sustainable in high-acuity ED settings, particularly when supported by ongoing education and active team engagement. CI - Copyright (c) 2026 the Author(s). Published by Wolters Kluwer Health, Inc. FAU - Hermel, Jonathan A AU - Hermel JA AD - From the Division of Neonatology, Department of Pediatrics, UCLA David Geffen School of Medicine, Los Angeles, CA. AD - Department of Pediatrics, University of California, San Diego, CA. AD - Rady Children's Hospital San Diego, San Diego, CA. FAU - Wang, Yvette AU - Wang Y AD - Department of Pediatrics, University of California, San Diego, CA. AD - Rady Children's Hospital San Diego, San Diego, CA. AD - Department of Emergency Medicine, Rady Children's Hospital San Diego, San Diego, CA. FAU - Klapp, Jamie M AU - Klapp JM AD - Department of Pediatrics, University of California, San Diego, CA. AD - Rady Children's Hospital San Diego, San Diego, CA. FAU - Bryl, Amy AU - Bryl A AD - Department of Pediatrics, University of California, San Diego, CA. AD - Rady Children's Hospital San Diego, San Diego, CA. AD - Department of Emergency Medicine, Rady Children's Hospital San Diego, San Diego, CA. FAU - Pannepacker, Martha AU - Pannepacker M AD - Rady Children's Hospital San Diego, San Diego, CA. AD - Department of Emergency Medicine, Rady Children's Hospital San Diego, San Diego, CA. FAU - Zimmerman, Elise AU - Zimmerman E AD - Department of Pediatrics, University of California, San Diego, CA. AD - Rady Children's Hospital San Diego, San Diego, CA. AD - Department of Emergency Medicine, Rady Children's Hospital San Diego, San Diego, CA. LA - eng PT - Journal Article DEP - 20260605 PL - United States TA - Pediatr Qual Saf JT - Pediatric quality & safety JID - 101702480 PMC - PMC13241288 EDAT- 2026/06/08 12:39 MHDA- 2026/06/08 12:40 PMCR- 2026/06/05 CRDT- 2026/06/08 07:36 PHST- 2025/12/02 00:00 [received] PHST- 2026/05/21 00:00 [accepted] PHST- 2026/06/08 12:40 [medline] PHST- 2026/06/08 12:39 [pubmed] PHST- 2026/06/08 07:36 [entrez] PHST- 2026/06/05 00:00 [pmc-release] AID - PQS-D-25-00185 [pii] AID - 10.1097/pq9.0000000000000891 [doi] PST - epublish SO - Pediatr Qual Saf. 2026 Jun 5;11(3):e891. doi: 10.1097/pq9.0000000000000891. eCollection 2026 May-Jun. PMID- 42253749 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260608 LR - 20260922 IS - 2090-6404 (Print) IS - 2090-6412 (Electronic) IS - 2090-6404 (Linking) VI - 2026 DP - 2026 TI - Revealing the Hidden Severity: A Case Report on Managing Complex Aortic Stenosis With TAVI. PG - 1945506 LID - 10.1155/cric/1945506 [doi] LID - 1945506 AB - Aortic stenosis (AS) is a progressive condition prevalent in older adults, with severity determined through clinical evaluation and imaging. However, diagnostic dilemmas arise when imaging results conflict with clinical symptoms. This report examines an 84-year-old male with chronic kidney disease, prior abdominal aortic aneurysm repair and other comorbidities, presenting with decompensated heart failure. Initial echocardiography findings suggested moderate AS, insufficient to qualify for transcatheter aortic valve implantation (TAVI) under national guidelines, despite clinical evidence of worsening heart failure. A multimodal diagnostic approach, incorporating Agatston scoring, dobutamine stress echocardiography (DSE), and invasive haemodynamics, was undertaken to resolve this discordance. DSE demonstrated persistent discordance between Doppler- and Simpson-derived flow estimates, whereas CT calcium scoring and left heart catheterisation ultimately confirmed severe AS, with an aortic valve area of 0.75 cm(2). The patient underwent preoperative optimisation, including multidisciplinary team (MDT) input and targeted interventions to manage comorbidities and optimise haemodynamics. TAVI was performed successfully, resulting in significant improvements in symptoms, exercise tolerance and renal function. This case highlights the necessity of a multimodal diagnostic strategy when initial investigations do not align with clinical presentation, emphasising MDT collaboration and preoperative optimisation. It demonstrates how multimodality imaging can prevent underestimation of AS severity and support timely intervention in clinically complex patients. CI - Copyright (c) 2026 Thomas Stefoulis et al. Case Reports in Cardiology published by John Wiley & Sons Ltd. FAU - Stefoulis, Thomas AU - Stefoulis T AUID- ORCID: 0000-0002-9655-1741 AD - Junior Medical Workforce, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia, nsw.gov.au. FAU - Sindone, James AU - Sindone J AUID- ORCID: 0000-0002-7564-0737 AD - Cardiology Department, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia, nsw.gov.au. FAU - Mahjoub, Mahiar AU - Mahjoub M AUID- ORCID: 0000-0003-0951-9629 AD - Junior Medical Workforce, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia, nsw.gov.au. FAU - Pack, Samuel Jay-Jackson AU - Pack SJ AUID- ORCID: 0009-0001-2001-6347 AD - Junior Medical Workforce, Bankstown Hospital, Sydney, New South Wales, Australia. FAU - Lal, Sean AU - Lal S AUID- ORCID: 0000-0002-5841-560X AD - Cardiology Department, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia, nsw.gov.au. LA - eng PT - Journal Article DEP - 20260603 PL - United States TA - Case Rep Cardiol JT - Case reports in cardiology JID - 101576452 PMC - PMC13239360 OTO - NOTNLM OT - Agatston score OT - TAVI OT - aortic stenosis OT - case report OT - multimodal diagnostic approach OT - valvular disease COIS- The authors declare no conflicts of interest. EDAT- 2026/06/08 12:38 MHDA- 2026/06/08 12:39 PMCR- 2026/06/03 CRDT- 2026/06/08 07:18 PHST- 2025/01/16 00:00 [received] PHST- 2026/04/25 00:00 [revised] PHST- 2026/05/26 00:00 [accepted] PHST- 2026/06/08 12:39 [medline] PHST- 2026/06/08 12:38 [pubmed] PHST- 2026/06/08 07:18 [entrez] PHST- 2026/06/03 00:00 [pmc-release] AID - CRIC1945506 [pii] AID - 10.1155/cric/1945506 [doi] PST - epublish SO - Case Rep Cardiol. 2026 Jun 3;2026:1945506. doi: 10.1155/cric/1945506. eCollection 2026. PMID- 42253699 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260608 LR - 20260926 IS - 2772-7076 (Electronic) IS - 2772-7076 (Linking) VI - 19 DP - 2026 Jun TI - Mortality and prognostic factors in infective endocarditis: A Colombian multicenter cohort. PG - 100913 LID - 10.1016/j.ijregi.2026.100913 [doi] LID - 100913 AB - OBJECTIVES: This study aimed to estimate in-hospital mortality and identify prognostic factors in infective endocarditis (IE) in a Colombian multicenter cohort. METHODS: This was a retrospective cohort study of 308 consecutive patients with definitive IE (modified Duke criteria) across four Colombian hospitals (2007-2017). Multivariate logistic regression identified independent mortality predictors. The primary outcome was in-hospital death. RESULTS: In-hospital mortality was 32.7% (101 of 308), with substantial across-center heterogeneity (9.6-45.9%), contrasting with European (EURO-ENDO 17.1%) and Latin American (25.1%) registries. Independent predictors of death in multivariable logistic regression were renal replacement therapy (adjusted odds ratio [aOR] 9.19, 95% confidence interval [CI] 4.61-18.34), perivalvular abscess (aOR 6.42, 95% CI 2.69-15.35), central nervous system embolism (aOR 3.07, 95% CI 1.63-5.80), older age (aOR 1.03 per year, 95% CI 1.01-1.05), and Staphylococcus aureus etiology (aOR 1.87, 95% CI 0.99-3.51). Surgery was independently protective (aOR 0.34, 95% CI 0.18-0.63), an estimate that persisted after propensity score adjustment. Of 199 patients with surgical indication, 78.9% underwent surgery; non-operated cases had prohibitive risk profiles. Model discrimination was good (area under receiver operating characteristic curve 0.842, 95% CI 0.791-0.894). CONCLUSION: Renal replacement therapy and perivalvular abscess are the strongest independent predictors of in-hospital mortality in this Colombian multicenter IE cohort, whereas cardiac surgery is protective but frequently precluded by prohibitive risk profiles. The 32.7% mortality reflects the high-severity spectrum of a tertiary referral population and is not generalizable to lower-complexity settings. Early identification of patients at risk for dialysis-requiring acute kidney injury and timely multidisciplinary surgical evaluation represent priority clinical intervention targets. In this Colombian multicenter cohort, in-hospital mortality was 32.7%, with substantial across-center heterogeneity. Renal replacement therapy and perivalvular abscess emerged as the strongest independent mortality predictors, identifying patients with limited physiological reserve and advanced infection. Surgery was strongly and consistently protective, including after propensity score adjustment, although unmeasured confounding by indication cannot be fully excluded. Whether multidisciplinary endocarditis team implementation can translate this prognostic information into mortality reduction in Colombian tertiary settings is a hypothesis that should be tested prospectively. CI - (c) 2026 The Author(s). FAU - Zuluaga Monroy, Juan David AU - Zuluaga Monroy JD AD - Department of Cardiology, Fundacion Abood Shaio, Bogota, Colombia. FAU - Perez Ardila, Maria Alejandra AU - Perez Ardila MA AD - Department of Infectious Diseases, Fundacion CardioInfantil - LaCardio, Bogota, Colombia. FAU - Millan Prada, Henry Augusto AU - Millan Prada HA AD - Department of Infectious Diseases, Fundacion CardioInfantil - LaCardio, Bogota, Colombia. FAU - Pena Giraldo, Maria Estefania AU - Pena Giraldo ME AD - Fundacion Universitaria Juan N. Corpas, Bogota, Colombia. FAU - Kock Sierra, Joshua AU - Kock Sierra J AD - Universidad de La Sabana, Km 7, Chia, Colombia. FAU - Ospina Navarro, Leonardo AU - Ospina Navarro L AD - Department of Infectious Diseases, Hospital Universitario Mayor Mederi, Bogota, Colombia. FAU - Arias, Gerson AU - Arias G AD - Department of Infectious Diseases, Fundacion Abood Shaio, Bogota, Colombia. FAU - Uribe, Luis Guillermo AU - Uribe LG AD - Department of Infectious Diseases, Fundacion Cardiovascular de Colombia, Floridablanca, Santander, Colombia. LA - eng PT - Journal Article DEP - 20260510 PL - England TA - IJID Reg JT - IJID regions JID - 9918418183106676 PMC - PMC13241843 OTO - NOTNLM OT - Hospital mortality OT - Infective endocarditis OT - Multicenter cohort OT - Prognosis OT - Renal replacement therapy COIS- The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/06/08 12:39 MHDA- 2026/06/08 12:40 PMCR- 2026/05/10 CRDT- 2026/06/08 07:18 PHST- 2026/03/18 00:00 [received] PHST- 2026/05/07 00:00 [revised] PHST- 2026/05/08 00:00 [accepted] PHST- 2026/06/08 12:40 [medline] PHST- 2026/06/08 12:39 [pubmed] PHST- 2026/06/08 07:18 [entrez] PHST- 2026/05/10 00:00 [pmc-release] AID - S2772-7076(26)00076-7 [pii] AID - 100913 [pii] AID - 10.1016/j.ijregi.2026.100913 [doi] PST - epublish SO - IJID Reg. 2026 May 10;19:100913. doi: 10.1016/j.ijregi.2026.100913. eCollection 2026 Jun. PMID- 42250489 OWN - NLM STAT- MEDLINE DCOM- 20260829 LR - 20260901 IS - 1527-3288 (Electronic) IS - 0147-9563 (Linking) VI - 79 DP - 2026 Sep-Oct TI - Unmet needs of heart failure patients across the different domains of palliative care - a qualitative interview study. PG - 102871 LID - S0147-9563(26)00155-X [pii] LID - 10.1016/j.hrtlng.2026.102871 [doi] AB - BACKGROUND: Currently, palliative care provision for patients with heart failure (HF) is limited and usually not tailored to the specific needs they might have. In this study, we sought to gain a better understanding of the needs and expectations expressed by patients with HF regarding palliative care. METHODS: We conducted semi-structured interviews with inpatients and outpatients across the entire HF trajectory. The interview guide was developed in a multidisciplinary team with input from patient representatives and covered all eight domains of palliative care according to the National Consensus Project Guidelines on Quality Palliative Care. Interviews were digitally recorded, transcribed, coded and analyzed based on the thematic analysis approach by Braun and Clarke. RESULTS: A total of 18 interviews were conducted with patients spanning NYHA classes I-IV and INTERMACS profiles 2-7. Six patients were currently on durable and three on temporary mechanical circulatory support. Participants expressed needs and expectations across all eight domains of palliative care. Some needs were specific to HF, e.g. for more HF expertise among all healthcare providers. Other needs were more generally associated with serious illnesses, e.g. long term access to psychological counselling for patients and caregivers, help with coming to terms with limited life expectancy, or provision of information in accessible language. CONCLUSION: Patients with HF express a host of unmet needs, many of which could be addressed by palliative care. Our study offers a nuanced description of patient needs that can inform the development of services and interventions in the future. TRIAL REGISTRATION NUMBER: German Clinical Trials Registry DRKS000334836. CI - Copyright (c) 2026 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Pfeffer, Chiara AU - Pfeffer C AD - Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charite (DHZC), Berlin, Germany; Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin und Humboldt-Universitat zu Berlin, Berlin, Germany. Electronic address: chiara.pfeffer@charite.de. FAU - Schoenrath, Felix AU - Schoenrath F AD - Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charite (DHZC), Berlin, Germany; Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin und Humboldt-Universitat zu Berlin, Berlin, Germany; DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany. FAU - Tugend, Lennart AU - Tugend L AD - Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charite (DHZC), Berlin, Germany; Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin und Humboldt-Universitat zu Berlin, Berlin, Germany. FAU - Khamseh, Anahita AU - Khamseh A AD - Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charite (DHZC), Berlin, Germany; Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin und Humboldt-Universitat zu Berlin, Berlin, Germany. FAU - Jobges, Susanne AU - Jobges S AD - Department of Anaesthesiology and Intensive Medicine, Campus Virchow Klinikum, Berlin, Charite - Universitatsmedizin Berlin, Berlin, Germany. FAU - Ahn, Johann AU - Ahn J AD - Department of Hematology, Oncology, and Tumor Immunology, Campus Virchow Klinikum, Berlin, Charite - Universitatsmedizin Berlin, Berlin, Germany. FAU - Behzadi, Asita AU - Behzadi A AD - Department of Hematology, Oncology, and Tumor Immunology, Campus Virchow Klinikum, Berlin, Charite - Universitatsmedizin Berlin, Berlin, Germany. FAU - Blum, Moritz AU - Blum M AD - Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charite (DHZC), Berlin, Germany; Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin und Humboldt-Universitat zu Berlin, Berlin, Germany; DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany; Berlin Institute of Health at Charite - Universitatsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charite Junior Clinician Scientist Program, Chariteplatz 1, 10117 Berlin, Germany. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20260606 PL - United States TA - Heart Lung JT - Heart & lung : the journal of critical care JID - 0330057 SB - IM MH - Humans MH - *Heart Failure/therapy/psychology MH - *Palliative Care/methods/standards MH - Female MH - Male MH - Aged MH - Qualitative Research MH - Middle Aged MH - Interviews as Topic MH - *Health Services Needs and Demand MH - Aged, 80 and over MH - *Needs Assessment OTO - NOTNLM OT - Caregivers OT - Heart failure OT - Palliative care OT - Patient needs OT - Qualitative study COIS- Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Felix Schoenrath reports a relationship with Novartis AG that includes: funding grants. Felix Schoenrath reports a relationship with Abbott that includes: funding grants. Felix Schoenrath reports a relationship with Medtronic that includes: non-financial support. Felix Schoenrath reports a relationship with Orion Pharma that includes: speaking and lecture fees. Felix Schoenrath reports a relationship with AbioMed Inc that includes: speaking and lecture fees. Felix Schoenrath reports a relationship with AstraZeneca that includes: speaking and lecture fees. Felix Schoenrath reports a relationship with Bayer Pharma AG that includes: speaking and lecture fees. Felix Schoenrath reports a relationship with Novartis that includes: speaking and lecture fees. Moritz Blum reports a relationship with Berlin Institute of Health at Charite that includes: funding grants. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/06/07 00:34 MHDA- 2026/08/29 23:35 CRDT- 2026/06/06 18:07 PHST- 2026/02/14 00:00 [received] PHST- 2026/05/05 00:00 [revised] PHST- 2026/05/31 00:00 [accepted] PHST- 2026/08/29 23:35 [medline] PHST- 2026/06/07 00:34 [pubmed] PHST- 2026/06/06 18:07 [entrez] AID - S0147-9563(26)00155-X [pii] AID - 10.1016/j.hrtlng.2026.102871 [doi] PST - ppublish SO - Heart Lung. 2026 Sep-Oct;79:102871. doi: 10.1016/j.hrtlng.2026.102871. Epub 2026 Jun 6. PMID- 42248416 OWN - NLM STAT- MEDLINE DCOM- 20260819 LR - 20260904 IS - 1538-7836 (Electronic) IS - 1538-7836 (Linking) VI - 24 IP - 9 DP - 2026 Sep TI - Management of anticoagulation in patients with heparin-induced thrombocytopenia requiring cardiac surgery with cardiopulmonary bypass: guidance from the ISTH SSC on Perioperative and Critical Care Haemostasis and Thrombosis. PG - 3369-3391 LID - S1538-7836(26)00353-3 [pii] LID - 10.1016/j.jtha.2026.05.029 [doi] AB - Heparin-induced thrombocytopenia (HIT) is an immune-mediated adverse drug reaction characterized by thrombocytopenia and a high risk of thrombosis. Patients with HIT and a need for cardiac surgery with cardiopulmonary bypass represent a challenging group, as anticoagulation with unfractionated heparin (UFH) is the primary treatment choice. We conducted a systematic review evaluating intraoperative anticoagulation strategies for patients with a history of HIT who required cardiac surgery with cardiopulmonary bypass. Guidance statements were generated through consensus of the writing group. Of 1732 screened articles, 30 studies were included. Strategies evaluated were (1) direct thrombin inhibitors; (2) UFH after preoperative or intraoperative therapeutic plasma exchange (TPE); (3) UFH in combination with a potent antiplatelet agent; and (4) heparin reexposure in patients with negative functional assays. Of these, bivalirudin has the strongest supporting data and appears effective; still, its association with increased bleeding and practical limitations, including a lack of a reversal agent, limit its use. TPE with or without intravenous immunoglobulin reduces antiplatelet factor 4/heparin antibody titers and allows for intraoperative UFH use, although protocols are heterogeneous. Use of potent antiplatelet agents with UFH reexposure show promise but carry risks of bleeding and hypotension. Thus, alternative strategies of using UFH in combination with TPE or potent antiplatelet agents may be considered on a case-by-case basis. For patients with negative functional assays, evidence suggests that limited intraoperative UFH reexposure carries a low risk of HIT recurrence, provided postoperative monitoring is performed. These guidance statements provide a framework for multidisciplinary decision making in a complex clinical scenario. CI - Copyright (c) 2026. Published by Elsevier Inc. FAU - Pishko, Allyson M AU - Pishko AM AD - Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. FAU - Frere, Corinne AU - Frere C AD - Department of Hematology, Pitie-Salpetriere Hospital, Assistance Publique-Hopitaux de Paris, Sorbonne Universite, INSERM UMR_S 1166, Paris, France. FAU - Maier, Cheryl L AU - Maier CL AD - Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA. FAU - Levy, Jerrold H AU - Levy JH AD - Department of Anesthesiology, Critical Care and Surgery, Duke University School of Medicine, Durham, North Carolina, USA. FAU - Connors, Jean M AU - Connors JM AD - Hematology Division, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA. Electronic address: Jean_connors@dfci.harvard.edu. LA - eng PT - Journal Article PT - Practice Guideline PT - Systematic Review DEP - 20260604 PL - England TA - J Thromb Haemost JT - Journal of thrombosis and haemostasis : JTH JID - 101170508 RN - 9005-49-6 (Heparin) RN - 0 (Anticoagulants) RN - 0 (Hirudins) RN - 0 (Platelet Aggregation Inhibitors) RN - TN9BEX005G (bivalirudin) RN - 0 (Recombinant Proteins) RN - 0 (Peptide Fragments) SB - IM MH - Humans MH - *Heparin/adverse effects MH - *Thrombocytopenia/chemically induced/blood/diagnosis MH - *Cardiopulmonary Bypass/adverse effects MH - *Anticoagulants/adverse effects/therapeutic use/administration & dosage MH - *Thrombosis/prevention & control/blood MH - *Cardiac Surgical Procedures/adverse effects MH - *Perioperative Care MH - Risk Factors MH - *Critical Care/standards MH - *Hemostasis/drug effects MH - *Blood Coagulation/drug effects MH - Treatment Outcome MH - Hirudins MH - Platelet Aggregation Inhibitors/therapeutic use/adverse effects MH - Recombinant Proteins/therapeutic use MH - Peptide Fragments OTO - NOTNLM OT - cardiopulmonary bypass OT - heparin induced thrombocytopenia OT - unfractionated heparin COIS- Declaration of competing interests A.M.P. receives royalties from UpToDate and research funding for clinical trials to her institution from Veralox, Jannsen Therapeutics, and Novartis. J.H.L. has received fees for participation in advisory board meetings and is on steering committees for Bayer, Grifols, Octapharma, Takeda, and Werfen. J.M.C. has received fees for scientific advisory boards, consulting, and data monitoring committees from Abbott, Alexion, Anthos, Bayer, Bristol Myers Squibb, Cerus Corporation, Janssen, Novartis, Pfizer, Perosphere Technologies, and Regeneron. All other authors have no competing interests to declare. EDAT- 2026/06/06 00:35 MHDA- 2026/08/20 03:59 CRDT- 2026/06/05 19:34 PHST- 2026/01/05 00:00 [received] PHST- 2026/05/04 00:00 [revised] PHST- 2026/05/26 00:00 [accepted] PHST- 2026/08/20 03:59 [medline] PHST- 2026/06/06 00:35 [pubmed] PHST- 2026/06/05 19:34 [entrez] AID - S1538-7836(26)00353-3 [pii] AID - 10.1016/j.jtha.2026.05.029 [doi] PST - ppublish SO - J Thromb Haemost. 2026 Sep;24(9):3369-3391. doi: 10.1016/j.jtha.2026.05.029. Epub 2026 Jun 4. PMID- 42247287 OWN - NLM STAT- MEDLINE DCOM- 20260630 LR - 20260711 IS - 1744-8409 (Electronic) IS - 1744-666X (Linking) VI - 22 IP - 6 DP - 2026 Jun TI - Measuring disease activity in juvenile systemic sclerosis: a multidisciplinary consensus from the Hamburg 2024 symposium. PG - 645-660 LID - 10.1080/1744666X.2026.2685050 [doi] AB - INTRODUCTION: Assessment of disease activity in juvenile systemic sclerosis (jSSc) is essential for clinical care and trial readiness, yet no validated pediatric activity measures exist. Adult systemic sclerosis activity tools, including the Scleroderma Clinical Trials Consortium Activity Index, revised CRISS, and revised EUSTAR, provide conceptual frameworks but require adaptation for developmental, physiologic, and feasibility considerations for children. At the 17th Hamburg Symposium on JSSc, an international multidisciplinary panel reviewed adult indices, evaluated corresponding variables in the jSSc Inception Cohort and the NRCOS registry, and conducted a structured Delphi process to define organ-specific indicators of clinically meaningful activity in jSSc. AREAS COVERED: Across skin, pulmonary, cardiac, vascular, musculoskeletal, gastrointestinal, renal, and global domains, the panel reached broad and often unanimous consensus on variables reflecting active, potentially reversible disease. Key endorsed measures included mRSS progression, new ILD on HRCT, >/=10% declines in FVC or DLCO, new cardiac abnormalities, active digital ulcers, synovitis, myositis, nutritional decline, and physician global assessment. Patient-reported outcomes were strongly supported across domains. EXPERT OPINION: These consensus-derived indicators provide the first comprehensive pediatric-specific foundation for defining disease activity in jSSc and represent a critical step toward developing and validating a unified pediatric activity index suitable for future clinical trials. FAU - Foeldvari, Ivan AU - Foeldvari I AUID- ORCID: 0000-0003-0659-5298 AD - Hamburg Centre for Pediatric and Adolescent Rheumatology, Schon Klinik Hamburg Eilbek, Hamburg, Germany. FAU - Torok, Kathryn S AU - Torok KS AD - Division of Pediatric Rheumatology, UPMC & University of Pittsburgh Scleroderma Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. FAU - Klotsche, Jens AU - Klotsche J AD - German Rheumatism Research Center, Berlin, Germany. FAU - Li, Jonathan C AU - Li JC AD - Division of Pediatric Rheumatology, UPMC & University of Pittsburgh Scleroderma Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. FAU - Bruni, Cosimo AU - Bruni C AD - Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. FAU - Costa-Reis, Patricia AU - Costa-Reis P AD - Pediatrics Department, Hospital de Santa Maria, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal. FAU - Cutolo, Maurizio AU - Cutolo M AD - Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology-Department of Internal Medicine and Specialties, University of Genoa and IRCCS San Martino Polyclinic Hospital, Genoa, Italy. FAU - Denton, Christopher P AU - Denton CP AD - UCL Division of Medicine, Royal Free London NHS Foundation Trust, London, UK. FAU - Fligelstone, Kim AU - Fligelstone K AD - Scleroderma & Raynaud's United Kindgom (SRUK) (Research Subcommittee, Patient Research Partner), FESCA, London, UK. FAU - Del Galdo, Francesco AU - Del Galdo F AD - Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Biomedical Research Centre, Leeds Teaching Hospital Trust, Leeds, UK. FAU - Gimenez-Roca, Clara AU - Gimenez-Roca C AD - Department of Pediatric Rheumatology, Hospital Sant Joan de Deu, Esplugues de Llobregat (Barcelona), Spain. FAU - Henes, Jorg AU - Henes J AD - Centre for Interdisciplinary Clinical Immunology, Rheumatology and Autoinflammatory Diseases and Department for Internal Medicine II, University Hospital Tubingen, Tubingen, Germany. FAU - Kasapcopur, Ozgur AU - Kasapcopur O AD - Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University - Cerrahpasa, Istanbul, Turkey. FAU - Li, Suzanne C AU - Li SC AD - Joseph M Sanzari Children's Hospital, Hackensack Meridian School of Medicine, Hackensack, NJ, USA. FAU - Marrani, Edoardo AU - Marrani E AD - Pediatric Rheumatology, Meyer Children's Hospital IRCCS, Firenze, Italy. FAU - Orteu, Catherine H AU - Orteu CH AD - UCL Institute of Immunity and Transplantation, Royal Free London NHS Foundation Trust, London, UK. FAU - Pauling, John D AU - Pauling JD AD - North Bristol NHS Trust, Bristol, UK. FAU - Pilkington, Clarissa AU - Pilkington C AD - Pediatric Rheumatology, Great Ormond Street Hospital, London, UK. FAU - Ross, Laura AU - Ross L AD - Department of Medicine, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia. AD - Department of Rheumatology, St Vincent's Hospital Melbourne, Fitzroy, Australia. FAU - Schonenberg-Meinema, Dieneke AU - Schonenberg-Meinema D AD - Department of Pediatric Immunology, Rheumatology and Infectious Diseases, Emma Children's Hospital, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands. FAU - Furst, Daniel E AU - Furst DE AD - Rheumatology, University of California, Los Angeles, CA, USA. AD - University of Washington, Seattle, WA, USA. AD - Pediatric Rheumatology, University of Florence, Florence, Italy. FAU - Smith, Vanessa AU - Smith V AD - Department of Internal Medicine, Ghent University, Ghent, Belgium. AD - Department of Rheumatology, Ghent University Hospital, Ghent, Belgium. AD - Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Center (IRC), Ghent, Belgium. AD - Rheumatology, ERN ReCONNET, Ghent, Belgien. LA - eng GR - Scleroderma Clinical Trial Consortium/ GR - National Scleroderma Foundation/ PT - Consensus Statement PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20260622 PL - England TA - Expert Rev Clin Immunol JT - Expert review of clinical immunology JID - 101271248 RN - Juvenile systemic scleroderma SB - IM MH - Child MH - Humans MH - Disease Progression MH - *Scleroderma, Systemic/diagnosis MH - Severity of Illness Index OTO - NOTNLM OT - Clinical trials OT - consensus OT - disease activity OT - disease activity index OT - juvenile systemic sclerosis OT - outcome measures OT - pediatric rheumatology EDAT- 2026/06/05 18:36 MHDA- 2026/06/30 06:30 CRDT- 2026/06/05 12:33 PHST- 2026/06/30 06:30 [medline] PHST- 2026/06/05 18:36 [pubmed] PHST- 2026/06/05 12:33 [entrez] AID - 10.1080/1744666X.2026.2685050 [doi] PST - ppublish SO - Expert Rev Clin Immunol. 2026 Jun;22(6):645-660. doi: 10.1080/1744666X.2026.2685050. Epub 2026 Jun 22. PMID- 42247091 OWN - NLM STAT- Publisher LR - 20260605 IS - 1863-4362 (Electronic) IS - 0021-1265 (Linking) DP - 2026 Jun 5 TI - Using a cardiac registry to highlight multidisciplinary care in pregnancy. LID - 10.1007/s11845-026-04462-4 [doi] AB - BACKGROUND: Cardiac disease in pregnancy is linked to significant maternal and fetal risks. A cardiac registry provides a way to systematically collect data on pregnant women with cardiac disease, enabling analysis of outcomes, care approaches, and the development of improved clinical protocols. AIM: To assess the role of a Pregnancy Heart Team (PHT) in managing cardiac disease during pregnancy, using data from a newly established registry at the National Maternity Hospital (NMH). METHODS: This was a prospective study analysing registry data from women attending the joint obstetric-cardiology clinic at NMH between January 2021 and September 2024. The registry included pregnant and pre-pregnancy patients. Demographics, cardiac diagnoses, risk classification, and maternal and neonatal outcomes were collected. RESULTS: A total of 111 women with cardiac disease were captured, encompassing 153 pregnancies. Most women (87.6%, n = 134) had pre-existing cardiac disease, while 12.4% (n = 19) were newly diagnosed during pregnancy. Rhythm disorders were the most common diagnosis (60.3%, n = 91). 12.4% (n = 19) of women received pre-conceptual counselling. Risk stratification using the modified World Health Organization (mWHO) classification showed that 33.3% (n = 44) were class I, 34.1% (n = 45) class II, 25% (n = 33) class II-III, and 7.6% (n = 10) class III; no women were classified as mWHO IV. Cardiac events occurred in 16.4% (n = 26), most frequently in the third trimester (42.3%, n = 11), highlighting this as a high-risk period. CONCLUSIONS: Registry findings highlights the importance of early, structured PHT care, to ensure optimal maternal and fetal outcomes. CI - (c) 2026. The Author(s). FAU - Smyth, Aoibhinn AU - Smyth A AD - UCD Perinatal Research Centre, Obstetrics and Gynaecology National Maternity Hospital University College Dublin, Dublin, Ireland. aoibhsmyth@gmail.com. AD - Department of Obstetrics & Gynaecology, National Maternity Hospital, Dublin, Ireland. aoibhsmyth@gmail.com. FAU - O'Brien, C AU - O'Brien C AD - Midwifery, National Maternity Hospital, Dublin, Ireland. FAU - Higgins, M AU - Higgins M AD - UCD Perinatal Research Centre, Obstetrics and Gynaecology National Maternity Hospital University College Dublin, Dublin, Ireland. FAU - Corcoran, S AU - Corcoran S AD - UCD Perinatal Research Centre, Obstetrics and Gynaecology National Maternity Hospital University College Dublin, Dublin, Ireland. AD - Department of Obstetrics & Gynaecology, National Maternity Hospital, Dublin, Ireland. FAU - McAuliffe, F AU - McAuliffe F AD - UCD Perinatal Research Centre, Obstetrics and Gynaecology National Maternity Hospital University College Dublin, Dublin, Ireland. AD - Department of Obstetrics & Gynaecology, National Maternity Hospital, Dublin, Ireland. FAU - Canniffe, C AU - Canniffe C AD - UCD Perinatal Research Centre, Obstetrics and Gynaecology National Maternity Hospital University College Dublin, Dublin, Ireland. AD - Department of Obstetrics & Gynaecology, National Maternity Hospital, Dublin, Ireland. AD - Department of Cardiology, St Vincent's University Hospital, University College Dublin, Dublin, Ireland. LA - eng PT - Journal Article DEP - 20260605 PL - Ireland TA - Ir J Med Sci JT - Irish journal of medical science JID - 7806864 SB - IM OTO - NOTNLM OT - Cardiac disease in pregnancy OT - Cardiac registry OT - Maternal and neonatal outcomes OT - Multidisciplinary care OT - Pregnancy heart team OT - Risk stratification COIS- Declarations. Conflicts of interest: The authors declare no conflict of interest. EDAT- 2026/06/05 12:41 MHDA- 2026/06/05 12:41 CRDT- 2026/06/05 11:06 PHST- 2025/11/04 00:00 [received] PHST- 2026/05/16 00:00 [accepted] PHST- 2026/06/05 12:41 [medline] PHST- 2026/06/05 12:41 [pubmed] PHST- 2026/06/05 11:06 [entrez] AID - 10.1007/s11845-026-04462-4 [pii] AID - 10.1007/s11845-026-04462-4 [doi] PST - aheadofprint SO - Ir J Med Sci. 2026 Jun 5. doi: 10.1007/s11845-026-04462-4. PMID- 42245199 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260605 LR - 20260813 IS - 2516-8290 (Electronic) IS - 2516-8290 (Linking) VI - 8 IP - 6 DP - 2026 TI - Management of infective endocarditis in a secondary care trust: a service evaluation of treatment outcomes and multidisciplinary involvement. LID - 001153.v3 [pii] LID - 10.1099/acmi.0.001153.v3 [doi] AB - Background. Infective endocarditis (IE) is a complex and life-threatening condition, requiring multidisciplinary team (MDT) input for optimal management. Objectives. This study aimed to review the demographics, infection management and clinical outcomes of patients treated for IE at Chelsea and Westminster Hospital NHS Foundation Trust (CWFT), a secondary care provider in London. This study evaluated local IE service provision against national and international guidelines to identify areas for service improvement. Methods. A retrospective cohort study was conducted, identifying adult patients (>/=18 years) treated for IE at CWFT between September 2023 and August 2024. Patients who received >10 days of intravenous amoxicillin, flucloxacillin, cefazolin or vancomycin were screened. Patients who received a full course of IE treatment were included. Clinical records were reviewed for demographic, microbiological, imaging, MDT involvement and clinical outcome data. Results. Thirty-one patients met the inclusion criteria. The median age was 77 years (interquartile range 53-85), and 74% were male. Staphylococcus aureus (35%) and Enterococcus faecalis (29%) were the most common pathogens. Only 12 patients (39%) were discussed at a cardiothoracic MDT, and 2 patients lacked cardiology input. Microbiology consultations occurred in all cases, but only 55% had documented antimicrobial plans. Outpatient therapy was used in 36% of cases. Adverse outcomes of IE treatment included in-hospital mortality in 12.9% (n=4) and decline in functional baseline in 29% (n=9). Conclusions. Whilst key treatment standards were largely met, gaps in MDT involvement and documentation were identified. Implementation of a dedicated IE MDT may increase adherence to guidelines and improve secondary care service provision. CI - Copyright (c) 2026 The Authors. FAU - Dwyer-Joyce, Lisa AU - Dwyer-Joyce L AUID- ORCID: 0009-0009-7307-4071 AD - Chelsea and Westminster NHS Foundation Trust, West Middlesex University Hospital, Twickenham Road, Isleworth, Middlesex, TW7 6AF, UK. FAU - Kwok, Mo Chung AU - Kwok MC AD - Chelsea and Westminster NHS Foundation Trust, West Middlesex University Hospital, Twickenham Road, Isleworth, Middlesex, TW7 6AF, UK. FAU - Hughes, Stephen AU - Hughes S AD - Chelsea and Westminster NHS Foundation Trust, West Middlesex University Hospital, Twickenham Road, Isleworth, Middlesex, TW7 6AF, UK. FAU - Goel, Nupur AU - Goel N AD - Chelsea and Westminster NHS Foundation Trust, West Middlesex University Hospital, Twickenham Road, Isleworth, Middlesex, TW7 6AF, UK. LA - eng PT - Journal Article DEP - 20260603 PL - England TA - Access Microbiol JT - Access microbiology JID - 101746927 PMC - PMC13232865 OTO - NOTNLM OT - antimicrobial management OT - infective endocarditis OT - multidisciplinary team OT - secondary care OT - service evaluation COIS- The authors declare that there are no conflicts of interest. EDAT- 2026/06/05 06:36 MHDA- 2026/06/05 06:37 PMCR- 2026/06/03 CRDT- 2026/06/05 05:01 PHST- 2025/12/11 00:00 [received] PHST- 2026/04/22 00:00 [accepted] PHST- 2026/06/05 06:37 [medline] PHST- 2026/06/05 06:36 [pubmed] PHST- 2026/06/05 05:01 [entrez] PHST- 2026/06/03 00:00 [pmc-release] AID - 001153.v3 [pii] AID - 10.1099/acmi.0.001153.v3 [doi] PST - epublish SO - Access Microbiol. 2026 Jun 3;8(6):001153.v3. doi: 10.1099/acmi.0.001153.v3. eCollection 2026. PMID- 42242357 OWN - NLM STAT- MEDLINE DCOM- 20260831 LR - 20260831 IS - 2352-5568 (Electronic) IS - 2352-5568 (Linking) VI - 45 IP - 5 DP - 2026 Sep TI - Perioperative management of adult sickle cell disease patients requiring cardiac surgery: A 25-year experience in a referral center. PG - 101870 LID - S2352-5568(26)00128-1 [pii] LID - 10.1016/j.accpm.2026.101870 [doi] AB - INTRODUCTION: Cardiac surgery with cardiopulmonary bypass (CPB) induces extreme disturbances in physiological homeostasis, which may trigger vaso‑occlusive crises and hemolysis in patients with sickle cell disease (SCD). The aim was to describe perioperative management, complications and outcomes in SCD patients undergoing cardiac surgery. MATERIAL AND METHODS: Retrospective study including all adult SCD patients who underwent cardiac surgery with CPB from 1996 to 2021 in a French referral center. RESULTS: Twenty‑nine procedures were performed in 21 patients aged 36 [28-43] years. Baseline hemoglobin S (HbS) fraction and hemoglobin levels were 67 [56-83] % and 9 [8-9] g/dL, respectively. After preoperative transfusion management, HbS and hemoglobin were 25 [21-29] % and 10 [10-11] g/dL, respectively. Procedures mainly included valvular repair or replacement (n = 23) or heart transplantation (n = 3). Twenty‑six procedures required intraoperative red blood cell transfusion, with 4 [3-6] units administered. Minimum intraoperative temperature, arterial oxygen partial pressure, and hematocrit were 35.0 [34.4-35.8] degrees C, 192 [169-207] mmHg, and 19 [18-20.5] %, respectively. Maximum lactate level during CPB was 3.5 [2.9-5.1] mmol/L. Four patients developed infectious complications during the ICU stay; no vaso‑occlusive crisis occurred. ICU length of stay was 5 [3-9] days. Three patients died during the ICU course (two after heart transplantation and one after double valve replacement), all from septic shock. One‑year, five‑year and ten-year survival rates were 85.7%, 64.0% and 54.9%, respectively. DISCUSSION: Despite the acute stress associated with CPB, adult SCD patients experienced acceptable postoperative complications and showed reasonable long‑term outcomes when managed with careful preoperative HbS optimization and a multidisciplinary approach. CI - Copyright (c) 2026 The Authors. Published by Elsevier Masson SAS.. All rights reserved. FAU - de Roux, Quentin AU - de Roux Q AD - Service d'Anesthesie-Reanimation et Medecine Peri-Operatoire, Assistance Publique-Hopitaux de Paris (AP-HP), Hopitaux Universitaires Henri Mondor, F-94010 Creteil, France; Univ Paris Est Creteil, Faculte de Sante, F-94010 Creteil, France; U955-IMRB, Equipe 03 "Pharmacologie et Technologies pour les Maladies Cardiovasculaires (PROTECT)", Inserm, Univ Paris Est Creteil (UPEC), Ecole Nationale Veterinaire d'Alfort (EnvA), F-94700 Maisons-Alfort, France; GRCT OPTIMA, Universite Paris Est Creteil, Hopitaux Universitaires Henri Mondor, F-94010 Creteil, France. FAU - Zanoun, Nabil AU - Zanoun N AD - Service d'Anesthesie-Reanimation et Medecine Peri-Operatoire, Assistance Publique-Hopitaux de Paris (AP-HP), Hopitaux Universitaires Henri Mondor, F-94010 Creteil, France. FAU - Habibi, Anoosha AU - Habibi A AD - Unite des Maladies Genetiques du Globule Rouge, UPEC, Institut Mondor de Recherche Biomedicale (IMRB), Institut National de la Sante et de le Recherche Medicale (INSERM) U955, Assistance Publique-Hopitaux de Paris (AP-HP), Hopitaux Universitaires Henri Mondor, F-94010 Creteil, France; Univ Paris Est Creteil, Faculte de Sante, F-94010 Creteil, France. FAU - Cherait, Chamsedine AU - Cherait C AD - Service d'Anesthesie-Reanimation et Medecine Peri-Operatoire, Assistance Publique-Hopitaux de Paris (AP-HP), Hopitaux Universitaires Henri Mondor, F-94010 Creteil, France. FAU - Alessandri, Claire AU - Alessandri C AD - Service d'Anesthesie-Reanimation et Medecine Peri-Operatoire, Assistance Publique-Hopitaux de Paris (AP-HP), Hopitaux Universitaires Henri Mondor, F-94010 Creteil, France. FAU - Merle, Jean-Claude AU - Merle JC AD - Service d'Anesthesie-Reanimation et Medecine Peri-Operatoire, Assistance Publique-Hopitaux de Paris (AP-HP), Hopitaux Universitaires Henri Mondor, F-94010 Creteil, France. FAU - Picard, Lucile AU - Picard L AD - Service d'Anesthesie-Reanimation et Medecine Peri-Operatoire, Assistance Publique-Hopitaux de Paris (AP-HP), Hopitaux Universitaires Henri Mondor, F-94010 Creteil, France. FAU - Avram, Roxana AU - Avram R AD - Service d'Anesthesie-Reanimation et Medecine Peri-Operatoire, Assistance Publique-Hopitaux de Paris (AP-HP), Hopitaux Universitaires Henri Mondor, F-94010 Creteil, France. FAU - Bergoend, Eric AU - Bergoend E AD - Service de Chirurgie Cardiaque, Assistance Publique-Hopitaux de Paris (AP-HP), Hopitaux Universitaires Henri Mondor, F-94010 Creteil, France. FAU - Fiore, Antonio AU - Fiore A AD - Service de Chirurgie Cardiaque, Assistance Publique-Hopitaux de Paris (AP-HP), Hopitaux Universitaires Henri Mondor, F-94010 Creteil, France. FAU - Radu, Costin AU - Radu C AD - Service de Chirurgie Cardiaque, Assistance Publique-Hopitaux de Paris (AP-HP), Hopitaux Universitaires Henri Mondor, F-94010 Creteil, France. FAU - Damy, Thibaud AU - Damy T AD - Service de Cardiologie, Assistance Publique-Hopitaux de Paris (AP-HP), Hopitaux Universitaires Henri Mondor, F-94010 Creteil, France; Univ Paris Est Creteil, Faculte de Sante, F-94010 Creteil, France. FAU - Pirenne, France AU - Pirenne F AD - Institut Mondor de Recherche Biomedicale, Unite 955, Equipe 2: Transfusion et Maladies du Globule Rouge, INSERM, Etablissement Francais du Sang, F-94010 Creteil, France; Univ Paris Est Creteil, Faculte de Sante, F-94010 Creteil, France. FAU - Audureau, Etienne AU - Audureau E AD - Unite de Recherche Clinique, Assistance Publique-Hopitaux de Paris (AP-HP), Hopitaux Universitaires Henri-Mondor, F-94010, Creteil, France; Univ Paris Est Creteil, Faculte de Sante, F-94010 Creteil, France. FAU - Galacteros, Frederic AU - Galacteros F AD - Unite des Maladies Genetiques du Globule Rouge, UPEC, Institut Mondor de Recherche Biomedicale (IMRB), Institut National de la Sante et de le Recherche Medicale (INSERM) U955, Assistance Publique-Hopitaux de Paris (AP-HP), Hopitaux Universitaires Henri Mondor, F-94010 Creteil, France; Univ Paris Est Creteil, Faculte de Sante, F-94010 Creteil, France. FAU - Folliguet, Thierry AU - Folliguet T AD - Service de Chirurgie Cardiaque, Assistance Publique-Hopitaux de Paris (AP-HP), Hopitaux Universitaires Henri Mondor, F-94010 Creteil, France; Univ Paris Est Creteil, Faculte de Sante, F-94010 Creteil, France. FAU - Bartolucci, Pablo AU - Bartolucci P AD - Unite des Maladies Genetiques du Globule Rouge, UPEC, Institut Mondor de Recherche Biomedicale (IMRB), Institut National de la Sante et de le Recherche Medicale (INSERM) U955, Assistance Publique-Hopitaux de Paris (AP-HP), Hopitaux Universitaires Henri Mondor, F-94010 Creteil, France; Univ Paris Est Creteil, Faculte de Sante, F-94010 Creteil, France. FAU - Plaud, Benoit AU - Plaud B AD - Universite Paris Cite Nord, Service d'Anesthesie-Reanimation Chirurgicale-Centre de Traitement des Brules, DMU PARABOL, Hopital Saint-Louis, APHP Nord, Assistance Publique-Hopitaux de Paris (AP-HP), F-75010 Paris, France. FAU - Mongardon, Nicolas AU - Mongardon N AD - Service d'Anesthesie-Reanimation et Medecine Peri-Operatoire, Assistance Publique-Hopitaux de Paris (AP-HP), Hopitaux Universitaires Henri Mondor, F-94010 Creteil, France; Univ Paris Est Creteil, Faculte de Sante, F-94010 Creteil, France; U955-IMRB, Equipe 03 "Pharmacologie et Technologies pour les Maladies Cardiovasculaires (PROTECT)", Inserm, Univ Paris Est Creteil (UPEC), Ecole Nationale Veterinaire d'Alfort (EnvA), F-94700 Maisons-Alfort, France; GRCT OPTIMA, Universite Paris Est Creteil, Hopitaux Universitaires Henri Mondor, F-94010 Creteil, France. Electronic address: nicolas.mongardon@aphp.fr. LA - eng PT - Journal Article DEP - 20260603 PL - France TA - Anaesth Crit Care Pain Med JT - Anaesthesia, critical care & pain medicine JID - 101652401 SB - IM MH - Humans MH - *Anemia, Sickle Cell/complications/therapy MH - Adult MH - Female MH - Male MH - Retrospective Studies MH - *Cardiac Surgical Procedures/methods MH - *Perioperative Care/methods MH - Postoperative Complications/epidemiology MH - Erythrocyte Transfusion MH - France MH - Vaso-Occlusive Crises MH - Cardiopulmonary Bypass MH - Treatment Outcome OTO - NOTNLM OT - Cardiac surgery OT - Critical care medicine OT - Outcomes OT - Sickle cell disease OT - Transfusion COIS- Declaration of competing interest The authors declare that they have no known competing financial or personal relationships that could be viewed as influencing the work reported in this paper. EDAT- 2026/06/05 00:34 MHDA- 2026/08/31 23:43 CRDT- 2026/06/04 19:33 PHST- 2026/03/01 00:00 [received] PHST- 2026/05/20 00:00 [revised] PHST- 2026/05/21 00:00 [accepted] PHST- 2026/08/31 23:43 [medline] PHST- 2026/06/05 00:34 [pubmed] PHST- 2026/06/04 19:33 [entrez] AID - S2352-5568(26)00128-1 [pii] AID - 10.1016/j.accpm.2026.101870 [doi] PST - ppublish SO - Anaesth Crit Care Pain Med. 2026 Sep;45(5):101870. doi: 10.1016/j.accpm.2026.101870. Epub 2026 Jun 3. PMID- 42241626 OWN - NLM STAT- MEDLINE DCOM- 20260611 LR - 20260611 IS - 1526-744X (Print) IS - 1526-744X (Linking) VI - 53 IP - 2 DP - 2026 Mar-Apr TI - Improving CKRT Outcomes in Neonates and Infants through Interdisciplinary Collaboration (ICONIIC): Education Practices and Care Delivery Models. PG - 179-188 AB - Improving Continuous kidney replacement therapy (CKRT) Outcomes in Neonates and Infants Through Interdis ciplinary Collaboration (ICONIIC) is a multicenter quality improvement and research registry. We aimed to identify programmatic structures and educational practices for neonatal and infant CKRT. A survey focusing on care delivery and models, units offering therapy, staff-to-patient ratios, and education protocols was distributed to institutions in ICONIIC using the Carpediem machine. Of the 13 responding sites, 11 used the Carpediem machine in Pediatric Intensive Care Units (ICUs), 9 in Neonatal ICUs, and 8 in Cardiac ICUs. A collaborative care model was most common (69.2%). While education practices varied, all sites required nurse-specific training, and all but one mandated provider oversight during CKRT initiation. Understanding these practices may inform best practices for neonatal and infant CKRT. CI - Copyright(c) by the American Nephrology Nurses Association. FAU - Plomaritas, Katie AU - Plomaritas K AD - CRRT and TPE Clinical Care Coordinator, Pediatric, Nephrology, C.S. Mott Children's Hospital, University of Michigan, Ann Arbor, MI. FAU - Snyder, Amanda AU - Snyder A AD - Acute Care Pediatric Nurse Practitioner, Center for Acute Care Nephrology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH. FAU - Ramirez, David AU - Ramirez D AD - Certified Clinical Nurse Specialist Dialysis (Inpatient, Outpatient, Home), Pediatric Nephrology, Mayo Clinic, Rochester, MN. FAU - Yalon, Larissa AU - Yalon L AD - Clinical Practice Manager ECMO, CRRT, and CCFP, Pediatric Critical Care Medicine, Seattle Children's Hospital, Seattle, WA. FAU - Hoatlin, Sara AU - Hoatlin S AD - CRRT Educational Nurse Coordinator, Pediatric ICU, C.S. Mott Children's Hospital, University of Michigan, Ann Arbor, MI. FAU - Casey, Lauren AU - Casey L AD - Critical Care Nephrology Nurse Practitioner, Pediatric Nephrology, Texas Children's Hospital, Houston, TX. FAU - Slagle, Cara AU - Slagle C AD - Associate Professor of Clinical Pediatrics, Neonatal-Perinatal Medicine, Division of Pediatrics, Indiana School of Medicine, Indianapolis, IN. FAU - Morgan, Jolyn AU - Morgan J AD - Acute Care Pediatric Nurse Practitioner, Clinical Nurse Manager, and APRN Lead, Center for Acute Care Nephrology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH. FAU - Martin, Susan AU - Martin S AD - ICONIIC Collaborative. AD - Associate Professor of Pediatrics, Medical Director Pediatric Acute Renal Care Team, University of Rochester and Golisano Children's Hospital, Rochester, NY. FAU - Tran, Cheryl AU - Tran C AD - ICONIIC Collaborative. AD - Physician at Mayo Clinic, Mayo Clinic, Rochester, MN. FAU - Jetton, Jennifer AU - Jetton J AD - ICONIIC Collaborative. AD - Professor of Pediatrics and Chief, Division of Pediatric Nephrology, Medical College of Wisconsin, Department of Pediatrics, Milwaukee, WI. FAU - Merrill, Kyle AU - Merrill K AD - ICONIIC Collaborative. AD - Clinical Assistant Professor, University of Iowa Stead Family Children's Hospital, Iowa City, IA. FAU - Van Wyk, Brynna AU - Van Wyk B AD - ICONIIC Collaborative. AD - Pediatric Nephrology, University of Iowa Stead Family Children's Hospital, Iowa City, IA. FAU - Gist, Katja M AU - Gist KM AD - ICONIIC Collaborative. AD - Visiting Professor, Department of Pediatrics, University of Colorado Anschutz, School of Medicine, Auroa, CO. FAU - Goldstein, Stuart AU - Goldstein S AD - ICONIIC Collaborative. AD - Director, Center for Acute Care Nephrology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH. AD - University of Cincinnati College of Medicine, Department of Pediatrics, Cincinnati, OH. FAU - Luckritz, Kera AU - Luckritz K AD - ICONIIC Collaborative. AD - Clinical Associate Professor Pediatric Nephrology, C.S. Mott Children's Hospital, University of Michigan, Ann Arbor, MI. FAU - Joesph, Catherine AU - Joesph C AD - ICONIIC Collaborative. AD - MD, Associate Professor, Baylor College of Medicine, Texas Children's Hospital, Texas Children's Hospital, Houston, TX. FAU - Vuong, Kim T AU - Vuong KT AD - ICONIIC Collaborative. AD - Combined Neonatology and Pediatric Nephrology, current Neonatology Fellow, Baylor College of Medicine, Texas Children's Hospital, Houston, TX. FAU - Krallman, Kelli AU - Krallman K AD - ICONIIC Collaborative. AD - Clinical Research Manager, Cincinnati Children's Hospital Medical Center, Cincinnati, OH. FAU - Menon, Shina AU - Menon S AD - ICONIIC Collaborative. AD - Associate Professor of Pediatrics, Stanford University, Palo Alto, CA. LA - eng PT - Journal Article PL - United States TA - Nephrol Nurs J JT - Nephrology nursing journal : journal of the American Nephrology Nurses' Association JID - 100909377 SB - IM MH - Humans MH - Infant, Newborn MH - Infant MH - *Renal Replacement Therapy/standards/methods MH - *Quality Improvement MH - Surveys and Questionnaires MH - Intensive Care Units, Pediatric OTO - NOTNLM OT - CKRT OT - ICONIIC OT - carpediem OT - continuous kidney replacement therapy OT - education OT - infant COIS- All authors declare no real or perceived conflicts of interest that could affect the study design, collection, analysis, and interpretation of data, writing of the report, or the decision to submit for publication. EDAT- 2026/06/04 18:41 MHDA- 2026/06/11 06:37 CRDT- 2026/06/04 15:43 PHST- 2026/06/11 06:37 [medline] PHST- 2026/06/04 18:41 [pubmed] PHST- 2026/06/04 15:43 [entrez] PST - ppublish SO - Nephrol Nurs J. 2026 Mar-Apr;53(2):179-188. PMID- 42239549 OWN - NLM STAT- MEDLINE DCOM- 20260608 LR - 20260813 IS - 1658-3175 (Electronic) IS - 0379-5284 (Print) IS - 0379-5284 (Linking) VI - 47 IP - 5 DP - 2026 May TI - Middle East Bifurcation Club Consensus Document on Percutaneous Revascularization of Bifurcation Lesions in Association with the National Heart Center - Saudi Health Council. PG - 903-919 LID - 10.15537/1658-3175.8774 [doi] AB - Bifurcation lesions are among the most challenging in percutaneous coronary intervention (PCI), with outcomes affected by anatomy, side-branch disease, and procedural variability. Existing European definitions and strategies require adaptation for Middle Eastern populations, where diabetes, obesity, and hypertension are highly prevalent and present earlier. The Middle East Bifurcation Club (MEBC), with the National Heart Center, used the Nominal Group Technique to standardize bifurcation PCI terminology, techniques, and treatment pathways tailored to regional demographics. The consensus provides evidence-based recommendations on imaging, provisional and 2-stent strategies, POT, and left main versus non-left main bifurcations, alongside practical algorithms and heart team guidance, highlighting the need for regional outcome data to optimize care. CI - Copyright: (c) Saudi Medical Journal. FAU - Al-Shaibi, Khaled AU - Al-Shaibi K AD - Cardiac Center King Fahd Armed Forces Hospital, Jeddah, Kingdom of Saudi Arabia. FAU - Alasnag, Mirvat AU - Alasnag M AD - Cardiac Center King Fahd Armed Forces Hospital, Jeddah, Kingdom of Saudi Arabia. FAU - Amin, Haitham AU - Amin H AD - Mohammed bin Khalifa Cardiac Center, Awali, Bahrain. FAU - Calik, Ali Nazmi AU - Calik AN AD - UHS, Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital, Cardiology Department, Istanbul, Turkey. FAU - AlMasood, Ali AU - AlMasood A AD - Specialist Medical Center, Riyadh, Kingdom of Saudi Arabia. FAU - Alenezi, Abdullah AU - Alenezi A AD - Chest Diseases Hospital, Kuwait City - Kuwait. FAU - Alanazi, Nouf AU - Alanazi N AD - King Saud University, Riyadh, Kingdom of Saudi Arabia. FAU - AlMoghairi, Abdulrahman AU - AlMoghairi A AD - Adult Cardiology Department, Prince Sultan Cardiac Center, Riyadh, Kingdom of Saudi Arabia. FAU - Abu-Hantash, Hadi AU - Abu-Hantash H AD - University of Jordan, Amman, Jordan. FAU - AlMerri, Khaled AU - AlMerri K AD - Chest Diseases Hospital, Kuwait City - Kuwait. LA - eng PT - Consensus Statement PT - Journal Article DEP - 20260427 PL - Saudi Arabia TA - Saudi Med J JT - Saudi medical journal JID - 7909441 SB - IM MH - Humans MH - *Percutaneous Coronary Intervention/methods MH - Saudi Arabia MH - *Coronary Artery Disease/surgery MH - Stents MH - Middle East PMC - PMC13227445 OTO - NOTNLM OT - Bifurcation OT - Left main OT - Outcomes OT - Revascularization OT - Techniques COIS- Assess side branch relevance: -Reference diameter >/= 2.0 mm-Supplies >/= 10% of myocardiumIf low risk of SB compromise: Initiate stepwise provisional strategy.If SB becomes compromised after MV stenting (>/=90% stenosis, dissection, TIMI <3, or FFR <0.80): -Perform SB ballooning --> Kissing balloon inflation --> Re-POT.If high risk of SB occlusion upfront (DEFINITION criteria, long/severe SB lesion): -Proceed with planned 2-stent technique.-70-90 degrees angle: T/TAP-<70 degrees angle: Culotte or DK-crushPerform POT in all cases for optimal stent expansion and rewiring (see Fig. 5).Heart team discussion for all complex LM disease (high Syntax score, multivessel disease).Use intravascular imaging (IVUS) whenever feasible to guide lesion assessment and stent sizing.Default strategy: Stepwise provisional stenting.Indications for upfront 2-stent approach: -True Medina 1,1,1 with a long segment of disease in the LCx (>10 mm)-Difficult SB access-High-risk anatomical featuresPreferred technique: DK-crush for planned 2-stent LM interventions.Mandatory steps for all 2 stent techniques: -Final kissing balloon inflation-Final POT to ensure appropriate expansion and reduce malposition. EDAT- 2026/06/04 06:34 MHDA- 2026/06/08 12:40 PMCR- 2026/05/01 CRDT- 2026/06/04 05:41 PHST- 2025/09/17 00:00 [received] PHST- 2025/12/23 00:00 [accepted] PHST- 2026/06/08 12:40 [medline] PHST- 2026/06/04 06:34 [pubmed] PHST- 2026/06/04 05:41 [entrez] PHST- 2026/05/01 00:00 [pmc-release] AID - saudimedj-47-5-903 [pii] AID - 10.15537/1658-3175.8774 [doi] PST - ppublish SO - Saudi Med J. 2026 May;47(5):903-919. doi: 10.15537/1658-3175.8774. Epub 2026 Apr 27. PMID- 42238629 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260604 LR - 20260813 IS - 2153-8174 (Electronic) IS - 1530-6550 (Print) IS - 1530-6550 (Linking) VI - 27 IP - 5 DP - 2026 May TI - General Anaesthesia Versus Conscious Sedation in Transcatheter Aortic Valve Implantation: Differences in Pulmonary Infections. PG - 48924 LID - 10.31083/RCM48924 [doi] LID - 48924 AB - BACKGROUND: Patients undergoing transfemoral aortic valve replacement are particularly vulnerable and require a more sophisticated anesthetic therapeutic approach. According to the literature, no study has directly compared general anaesthesia with conscious analgosedation using postoperative infections as the primary endpoint. METHODS: Patients undergoing transcatheter aortic valve implantation (TAVI) were analyzed retrospectively. A total of 3313 patients from a large heart center in Western Europe were included in this study. One group received general anaesthesia, and the other group received analgosedation for TAVI. The primary outcome was postinterventional pneumonia; secondary outcomes included myocardial infarction, renal failure, stroke, and 30-day mortality. Propensity score matching using 16 matching criteria yielded over 1000 pairs. RESULTS: No difference was observed in the incidence of postinterventional pneumonia (p = 0.148). The occurrence of myocardial infarction (p = 0.2) and stroke (p = 0.4) also did not differ significantly between the two groups. In contrast, the need for transient renal replacement therapy (p = 0.02) and 30-day mortality (p = 0.02) were lower in the analgosedation group. CONCLUSIONS: Regarding postinterventional pneumonia, general anaesthesia can be used as safely as analgosedation during TAVI. However, since renal failure requiring temporary replacement therapy and mortality are both increased with general anaesthesia, analgosedation should be the standard of care for TAVI in high-volume centers. The anesthetic regimen must be determined on an individual basis and discussed during the heart team briefing. The conversion to, or primary use of, general anaesthesia when clinically indicated is safe. Overall, ensuring the continuous presence of a senior consultant anesthetist, specifically trained in cardiac anaesthesia, throughout the procedure is essential. CI - Copyright: (c) 2026 The Author(s). Published by IMR Press. FAU - Bergmann, Astrid AU - Bergmann A AD - Ruhr-University Bochum, Heart- and Diabetes-Center, 32545 Bad Oeynhausen, Germany. AD - University Bielefeld, Medical Center East Westphalia-Lippe, Heart- and Diabetes-Center, 32545 Bad Oeynhausen, Germany. FAU - Warkentin, Helmut AU - Warkentin H AD - Ruhr-University Bochum, Heart- and Diabetes-Center, 32545 Bad Oeynhausen, Germany. AD - University Bielefeld, Medical Center East Westphalia-Lippe, Heart- and Diabetes-Center, 32545 Bad Oeynhausen, Germany. FAU - Hildebrandt, Florian AU - Hildebrandt F AD - Telehealth Competence Center (TCC), 22083 Hamburg, Germany. FAU - Fliegenschmidt, Janis AU - Fliegenschmidt J AD - Ruhr-University Bochum, Heart- and Diabetes-Center, 32545 Bad Oeynhausen, Germany. AD - University Bielefeld, Medical Center East Westphalia-Lippe, Heart- and Diabetes-Center, 32545 Bad Oeynhausen, Germany. FAU - Hulde, Nikolai AU - Hulde N AD - Ruhr-University Bochum, Heart- and Diabetes-Center, 32545 Bad Oeynhausen, Germany. AD - University Bielefeld, Medical Center East Westphalia-Lippe, Heart- and Diabetes-Center, 32545 Bad Oeynhausen, Germany. FAU - Rudolph, Tanja AU - Rudolph T AD - Ruhr-University Bochum, Heart- and Diabetes-Center, 32545 Bad Oeynhausen, Germany. AD - University Bielefeld, Medical Center East Westphalia-Lippe, Heart- and Diabetes-Center, 32545 Bad Oeynhausen, Germany. FAU - Scholtz, Smita AU - Scholtz S AD - Ruhr-University Bochum, Heart- and Diabetes-Center, 32545 Bad Oeynhausen, Germany. AD - University Bielefeld, Medical Center East Westphalia-Lippe, Heart- and Diabetes-Center, 32545 Bad Oeynhausen, Germany. FAU - Piper, Cornelia AU - Piper C AD - Ruhr-University Bochum, Heart- and Diabetes-Center, 32545 Bad Oeynhausen, Germany. AD - University Bielefeld, Medical Center East Westphalia-Lippe, Heart- and Diabetes-Center, 32545 Bad Oeynhausen, Germany. FAU - Bleiziffer, Sabine AU - Bleiziffer S AD - Department of Cardiac Surgery, Zentralklinik Bad Berka, Rhon Klinikum AG, 99438 Bad Berka, Germany. FAU - von Dossow, Vera AU - von Dossow V AD - Ruhr-University Bochum, Heart- and Diabetes-Center, 32545 Bad Oeynhausen, Germany. AD - University Bielefeld, Medical Center East Westphalia-Lippe, Heart- and Diabetes-Center, 32545 Bad Oeynhausen, Germany. LA - eng PT - Journal Article DEP - 20260526 PL - Singapore TA - Rev Cardiovasc Med JT - Reviews in cardiovascular medicine JID - 100960007 PMC - PMC13227367 OTO - NOTNLM OT - conscious sedation OT - general anaesthesia OT - pneumonia OT - propensity score matching OT - renal replacement therapy OT - transcatheter aortic valve replacement COIS- The authors declare no conflicts of interest. EDAT- 2026/06/04 06:35 MHDA- 2026/06/04 06:36 PMCR- 2026/05/26 CRDT- 2026/06/04 05:30 PHST- 2025/12/09 00:00 [received] PHST- 2026/02/28 00:00 [revised] PHST- 2026/03/05 00:00 [accepted] PHST- 2026/06/04 06:36 [medline] PHST- 2026/06/04 06:35 [pubmed] PHST- 2026/06/04 05:30 [entrez] PHST- 2026/05/26 00:00 [pmc-release] AID - S1530-6550(26)02907-0 [pii] AID - 10.31083/RCM48924 [doi] PST - epublish SO - Rev Cardiovasc Med. 2026 May 26;27(5):48924. doi: 10.31083/RCM48924. eCollection 2026 May. PMID- 42238291 OWN - NLM STAT- MEDLINE DCOM- 20260610 LR - 20260813 IS - 1658-3175 (Electronic) IS - 0379-5284 (Print) IS - 0379-5284 (Linking) VI - 47 IP - 3 DP - 2026 Mar TI - Reengineering Cardiac Rehabilitation for Women: From Access to Equity. PG - 563-564 LID - 10.15537/1658-3175.1054 [doi] AB - Cardiac rehabilitation (CR) is a corner stone intervention in secondary prevention of cardiovascular disease where a multidisciplinary team provides tailored management of lifestyle interventions, exercise and behavioural counselling. Participating in CR resulted in better rates of tobacco cessation, blood pressure and cholesterol lowering and better glycaemic control [1]. CR participation results in significant lower mortality and hospitalizationand improved quality of life. Despite the body of evidence and the robust recommendation by international guidelines it remains underutilized especially by women. CI - Copyright: (c) Saudi Medical Journal. FAU - Alali, Juwairia AU - Alali J AUID- ORCID: 0000-0001-6559-2631 AD - Rashid Hospital, Dubai health, Uniited Arab Emirates. LA - eng PT - Journal Article PT - Review DEP - 20260310 PL - Saudi Arabia TA - Saudi Med J JT - Saudi medical journal JID - 7909441 SB - IM MH - Humans MH - Female MH - *Cardiac Rehabilitation/methods MH - *Women's Health MH - Secondary Prevention MH - *Health Services Accessibility MH - *Health Equity PMC - PMC13227431 OTO - NOTNLM OT - Cardiac rehabilitation OT - Health equity OT - Home-based cardiac rehabilitation OT - Hybrid rehabilitation models OT - Implementation science OT - Performance measures OT - Quality improvement OT - Secondary prevention OT - Sex disparities OT - Women's cardiovascular health OT - Women-focused care EDAT- 2026/06/04 06:32 MHDA- 2026/06/10 11:44 PMCR- 2026/03/01 CRDT- 2026/06/04 05:27 PHST- 2026/01/19 00:00 [received] PHST- 2026/02/23 00:00 [accepted] PHST- 2026/06/10 11:44 [medline] PHST- 2026/06/04 06:32 [pubmed] PHST- 2026/06/04 05:27 [entrez] PHST- 2026/03/01 00:00 [pmc-release] AID - saudimedj-47-3-563 [pii] AID - 10.15537/1658-3175.1054 [doi] PST - ppublish SO - Saudi Med J. 2026 Mar;47(3):563-564. doi: 10.15537/1658-3175.1054. Epub 2026 Mar 10. PMID- 42238290 OWN - NLM STAT- MEDLINE DCOM- 20260611 LR - 20260813 IS - 1658-3175 (Electronic) IS - 0379-5284 (Print) IS - 0379-5284 (Linking) VI - 47 IP - 3 DP - 2026 Mar TI - National Heart Center - Saudi Health Council Acute Myocardial Infarction-Related Cardiogenic Shock Consensus Document. PG - 513-529 LID - 10.15537/1658-3175.1048 [doi] AB - OBJECTIVE: Cardiogenic shock (CS) remains a serious complication of acute myocardial infarction (AMI) with persistently high mortality and significant variability in management across centers. METHODS: A multidisciplinary panel convened by the National Heart Center used the GRADE framework to review evidence and develop consensus recommendations tailored to AMI-related CS. RESULTS: The document emphasizes standardized CS definition and staging, prioritizing the SCAI classification. Key components include early recognition, haemodynamic assessment, lactate monitoring, and the central role of echocardiography. Recommendations support rapid culprit-vessel revascularization, early consideration of mechanical circulatory support, and structured Heart Team activation. The document also highlights the need for protocolized care pathways and CS registries. CONCLUSION: These consensus recommendations provide a unified approach to AMI-related CS aimed at reducing practice variation and improving clinical outcomes. CI - Copyright: (c) Saudi Medical Journal. FAU - Alasnag, Mirvat AU - Alasnag M AUID- ORCID: 0000-0002-8714-0334 AD - Cardiac Center, King Fahd Armed Forces Hospital, Jeddah-Saudi Arabia. FAU - Asiri, Abdulrahman AU - Asiri A AD - College of Medicine, King Khaled University, Abha-Saudi Arabia. FAU - Alrahbi, Hazim AU - Alrahbi H AD - King Saud Medical City, Riyadh, Saudi Arabia. FAU - Aloui, nHatem AU - Aloui N AD - King Saud Medical City, Riyadh, Saudi Arabia. FAU - Anwar, Ashraf M AU - Anwar AM AD - Cardiac Center, King Fahd Armed Forces Hospital, Jeddah-Saudi Arabia. FAU - Alhassani, Saad AU - Alhassani S AD - King Abdullah Medical City, Makkah-Saudi Arabia. FAU - AlQaseer, Maryam Mohamed AU - AlQaseer MM AD - King Fahad Specialist Hospital, Dammam, Saudi Arabia. FAU - Raslan, Ismail Raid AU - Raslan IR AD - Department of Cardiac Sciences, College of Medicine, King Saud University, Riyadh, Saudi Arabia. FAU - AlBakri, Ibrahim AU - AlBakri I AD - Cardiac Center, King Fahd Armed Forces Hospital, Jeddah-Saudi Arabia. FAU - Almustafa, Ahmed AU - Almustafa A AD - King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia. FAU - Attar, Rowa AU - Attar R AD - King Abdulaziz University Hospital, Jeddah-Saudi Arabia. FAU - Katbi, Faisal AU - Katbi F AD - College of Medicine, Imam Abdulrahman bin Faisal University, Dammam-Saudi Arabia. FAU - Khaleil, Feras AU - Khaleil F AD - King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia. FAU - Elhazmi, Alyaa AU - Elhazmi A AD - College of Medicine, Alfaisal University, Riyadh, Saudi Arabia. FAU - Tash, Adel AU - Tash A AD - King Abdullah Medical City, Makkah-Saudi Arabia. FAU - Alburaiki, Jehad AU - Alburaiki J AD - King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia. LA - eng PT - Consensus Statement PT - Journal Article DEP - 20260310 PL - Saudi Arabia TA - Saudi Med J JT - Saudi medical journal JID - 7909441 SB - IM MH - *Shock, Cardiogenic/etiology/therapy/diagnosis MH - Humans MH - *Myocardial Infarction/complications/therapy MH - Echocardiography PMC - PMC13227443 OTO - NOTNLM OT - Cardiogenic shock OT - mechanical circulatory support OT - myocardial infarction OT - revascularization OT - vasoactive drugs EDAT- 2026/06/04 06:34 MHDA- 2026/06/11 06:39 PMCR- 2026/03/01 CRDT- 2026/06/04 05:27 PHST- 2025/09/17 00:00 [received] PHST- 2025/12/24 00:00 [accepted] PHST- 2026/06/11 06:39 [medline] PHST- 2026/06/04 06:34 [pubmed] PHST- 2026/06/04 05:27 [entrez] PHST- 2026/03/01 00:00 [pmc-release] AID - saudimedj-47-3-513 [pii] AID - 10.15537/1658-3175.1048 [doi] PST - ppublish SO - Saudi Med J. 2026 Mar;47(3):513-529. doi: 10.15537/1658-3175.1048. Epub 2026 Mar 10. PMID- 42237014 OWN - NLM STAT- MEDLINE DCOM- 20260608 LR - 20261010 IS - 1546-9549 (Electronic) IS - 1546-9530 (Linking) VI - 23 IP - 1 DP - 2026 Jun 4 TI - Palliative Care in Advanced Heart Failure. LID - 26 [pii] LID - 10.1007/s11897-026-00767-8 [doi] AB - PURPOSE OF REVIEW: Advanced heart failure (HF) is characterized by high symptom burden, poor quality of life (QoL), and recurrent hospitalizations. As survival improves, an increasing proportion of patients progresses to advanced stages, leading to a growing population of individuals with end-stage HF, many of whom are ineligible for heart transplantation or mechanical circulatory support due to age, comorbidities, frailty, or limited social support. This review aims to synthesize current evidence on palliative care (PC) integration in advanced HF, focusing on indications, timing of referral, and the role of multidisciplinary care in optimizing patient management. RECENT FINDINGS: Recent evidence supports early integration of PC across the HF trajectory, demonstrating reductions in hospital readmissions and improvements in QoL. Screening tools, patient reported outcome measures, and frailty assessments have emerged as key instruments to identify unmet needs and appropriate referral. Multidisciplinary models involving cardiology, palliative specialists, nurses, and community care providers have shown benefits in symptom control, care coordination, and advance care planning. PC represents a fundamental component of advanced HF management and should be integrated early in the disease trajectory. A structured, multidisciplinary approach that supports holistic care, improves patient outcomes, and aligns treatment strategies with patient preferences should be routinely adopted by HF clinicians. CI - (c) 2026. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Colombo, Giada AU - Colombo G AD - De Gasperis Cardio Center and Transplant Center, Niguarda Hospital, Milan, Italy. FAU - Fazzini, Luca AU - Fazzini L AD - Cardiovascular Department, ASST Papa Giovanni XXIII, Bergamo, Italy. FAU - Perna, Enrico AU - Perna E AD - De Gasperis Cardio Center and Transplant Center, Niguarda Hospital, Milan, Italy. FAU - Mentz, Robert AU - Mentz R AD - Duke University Medical Center and Duke Clinical Research Institute, Durham, NC, USA. FAU - Hill, Loreena AU - Hill L AD - School of Nursing and Paramedic Science, Ulster University, Londonderry, UK. FAU - D'Elia, Emilia AU - D'Elia E AD - Cardiovascular Department, ASST Papa Giovanni XXIII, Bergamo, Italy. FAU - Barisone, Michela AU - Barisone M AUID- ORCID: 0000-0003-4224-8779 AD - Humanitas Mirasole S.p.A - IRCCS Humanitas Research Hospital, Milan, Italy. michelabarisone78@gmail.com. LA - eng PT - Journal Article PT - Review DEP - 20260604 PL - United States TA - Curr Heart Fail Rep JT - Current heart failure reports JID - 101196487 SB - IM MH - Humans MH - *Heart Failure/therapy MH - *Palliative Care/methods MH - *Quality of Life MH - Patient Care Team OTO - NOTNLM OT - Advanced heart failure OT - Frailty OT - Multidisciplinary team OT - Palliative care COIS- Declarations. Conflict of interest: The authors declare no competing interests. Human and Animal Rights and Informed Consent: This article does not contain any studies with human or animal subjects performed by any of the authors. EDAT- 2026/06/04 00:39 MHDA- 2026/06/08 12:39 CRDT- 2026/06/03 23:39 PHST- 2026/03/20 00:00 [received] PHST- 2026/05/28 00:00 [accepted] PHST- 2026/06/08 12:39 [medline] PHST- 2026/06/04 00:39 [pubmed] PHST- 2026/06/03 23:39 [entrez] AID - 10.1007/s11897-026-00767-8 [pii] AID - 10.1007/s11897-026-00767-8 [doi] PST - epublish SO - Curr Heart Fail Rep. 2026 Jun 4;23(1):26. doi: 10.1007/s11897-026-00767-8. PMID- 42235957 OWN - NLM STAT- MEDLINE DCOM- 20260701 LR - 20260701 IS - 2154-1671 (Electronic) IS - 2154-1671 (Linking) VI - 16 IP - 7 DP - 2026 Jul 1 TI - Characterizing Team Structure in the Pediatric Intensive Care Unit. PG - e480-e487 LID - 10.1542/hpeds.2026-009254 [doi] AB - OBJECTIVE: Complex and fluctuating care teams are a known obstacle to optimal patient care in the pediatric intensive care unit (PICU), particularly for long stay patients (LSP). Overcoming this obstacle requires understanding more about how PICU teams are structured and function. Our objective is to empirically define the dynamic composition of PICU care teams for LSP and non-LSP. PATIENTS AND METHODS: We conducted a retrospective chart review of patients aged 0 to 21 years admitted to medical/surgical and cardiovascular PICUs of a Midwestern tertiary care academic children's hospital in March and September 2019. Patients were divided between PICU LOS of 7 days or fewer and LOS of more than 7 days. Patients who were admitted for cardiac surgery and those patients who had opted out of research were excluded. The main outcome of the study was the number and specialty composition of teams caring for long stay vs short stay patients. RESULTS: A total of 35 patients were identified (51.4% female, median age 1.8 years); 20 patients were identified with LOS of greater than 7 days ("long stay") and 15 patients with LOS of 7 days or fewer ("short stay"). We present sociometric network models to visualize the complexity of team composition and structure over time. CONCLUSIONS: As illustrated by the complex web of physician interactions revolving around the patients, PICU teams are dynamic and members are ever changing, highlighting the importance of transmitting accurate, relevant and timely information when caring for complex patients. This work clearly demonstrates why it is vital to study both the structure and processes of these dynamic PICU teams. CI - Copyright (c) 2026 by the American Academy of Pediatrics. FAU - Shapiro, Miriam C AU - Shapiro MC AD - Division of Critical Care Medicine, Department of Pediatrics, University of Minnesota Medical School, Minneapolis, Minnesota. AD - Center for Bioethics, University of Minnesota, Minneapolis, Minnesota. FAU - Shah, Priti P AU - Shah PP AD - Carlson School of Management, University of Minnesota, Minneapolis, Minnesota. FAU - Cross, Dori A AU - Cross DA AD - Division of Health Policy and Management, School of Public Health, University of Minnesota, Minneapolis, Minnesota. FAU - Ehlen, Quinn T AU - Ehlen QT AD - Carlson School of Management, University of Minnesota, Minneapolis, Minnesota. FAU - Kerfeld, Morgan AU - Kerfeld M AD - Carlson School of Management, University of Minnesota, Minneapolis, Minnesota. FAU - Olson, Andrew P J AU - Olson APJ AD - Division of Hospital Medicine, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota. AD - Department of Pediatrics, University of Minnesota Medical School, Minneapolis, Minnesota. LA - eng PT - Journal Article PL - United States TA - Hosp Pediatr JT - Hospital pediatrics JID - 101585349 SB - IM MH - Humans MH - Female MH - *Intensive Care Units, Pediatric/organization & administration MH - Infant MH - Child, Preschool MH - Retrospective Studies MH - Child MH - *Patient Care Team/organization & administration MH - Length of Stay/statistics & numerical data MH - Male MH - Adolescent MH - Infant, Newborn MH - Young Adult EDAT- 2026/06/04 00:38 MHDA- 2026/07/01 12:49 CRDT- 2026/06/03 20:13 PHST- 2026/01/21 00:00 [received] PHST- 2026/02/28 00:00 [accepted] PHST- 2026/07/01 12:49 [medline] PHST- 2026/06/04 00:38 [pubmed] PHST- 2026/06/03 20:13 [entrez] AID - 207816 [pii] AID - 10.1542/hpeds.2026-009254 [doi] PST - ppublish SO - Hosp Pediatr. 2026 Jul 1;16(7):e480-e487. doi: 10.1542/hpeds.2026-009254. PMID- 42234307 OWN - NLM STAT- MEDLINE DCOM- 20260630 LR - 20261010 IS - 0973-7693 (Electronic) IS - 0019-5456 (Linking) VI - 93 IP - 7 DP - 2026 Jul TI - Cardiac Interventions in Neonates: State of the Art. PG - 733-739 LID - 10.1007/s12098-026-06232-7 [doi] AB - Percutaneous cardiac interventions in neonates and young infants have fundamentally altered the management paradigm of critical congenital heart disease, offering minimally invasive alternatives to surgery as definitive therapies or as bridges to later repair. Advances in catheter technology, device miniaturization, and imaging have enabled increasingly complex interventions to be performed safely in this highly vulnerable population. This review provides a comprehensive overview of commonly performed neonatal cardiac interventions, including balloon atrial septostomy, balloon dilatation of the aortic and pulmonary valves, ductal stenting, transcatheter patent ductus arteriosus closure in preterm infants, coarctation interventions, pulmonary valve perforation, right ventricular outflow tract stenting, pulmonary vein interventions, and emerging techniques such as percutaneous pulmonary artery banding. For each intervention, the authors outline indications, technical considerations, procedural outcomes, and limitations, with emphasis on neonatal-specific anatomical and physiological challenges. Neonatal cardiac interventions are inherently unforgiving, mandating meticulous patient selection and a structured multidisciplinary heart team approach to ensure ethical, evidence-based decision-making. The review also addresses unique challenges relevant to low- and middle-income settings, particularly India, including disparities in access to specialized care, affordability, reliance on off-label device use, and the critical role of fetal diagnosis. In conclusion, neonatal transcatheter interventions continue to expand in scope and efficacy, driven by technological innovation and collaborative care models. Addressing systemic barriers and strengthening fetal and neonatal cardiac services are essential to optimizing outcomes and ensuring equitable access to these life-saving therapies in resource-limited settings. CI - (c) 2026. The Author(s), under exclusive licence to Dr. K C Chaudhuri Foundation. FAU - Handa, Ankur AU - Handa A AD - Department of Cardiology, All India Institute of Medical Sciences, New Delhi, 110029, India. FAU - Kadiyani, Lamk AU - Kadiyani L AD - Department of Cardiology, All India Institute of Medical Sciences, New Delhi, 110029, India. FAU - Ramakrishnan, Sivasubramanian AU - Ramakrishnan S AD - Department of Cardiology, All India Institute of Medical Sciences, New Delhi, 110029, India. ramaaiims@gmail.com. LA - eng PT - Journal Article PT - Review DEP - 20260603 PL - India TA - Indian J Pediatr JT - Indian journal of pediatrics JID - 0417442 SB - IM MH - Humans MH - Infant, Newborn MH - *Heart Defects, Congenital/surgery/therapy MH - *Cardiac Surgical Procedures/methods MH - Cardiac Catheterization/methods MH - Ductus Arteriosus, Patent/surgery OTO - NOTNLM OT - Balloon atrial septostomy OT - Patent ductus arteriosus OT - Preterm neonates OT - RVOT stenting OT - Valve interventions COIS- Declarations. Conflict of Interest: None. EDAT- 2026/06/03 12:39 MHDA- 2026/06/30 12:32 CRDT- 2026/06/03 11:20 PHST- 2026/02/02 00:00 [received] PHST- 2026/05/14 00:00 [accepted] PHST- 2026/06/30 12:32 [medline] PHST- 2026/06/03 12:39 [pubmed] PHST- 2026/06/03 11:20 [entrez] AID - 10.1007/s12098-026-06232-7 [pii] AID - 10.1007/s12098-026-06232-7 [doi] PST - ppublish SO - Indian J Pediatr. 2026 Jul;93(7):733-739. doi: 10.1007/s12098-026-06232-7. Epub 2026 Jun 3. PMID- 42234089 OWN - NLM STAT- MEDLINE DCOM- 20261028 LR - 20261028 IS - 1827-1596 (Electronic) IS - 0375-9393 (Linking) VI - 92 IP - 10 DP - 2026 Oct TI - Perioperative antithrombotic management in elective neurosurgery: a survey from the Lombardia Neurocritical Care Network, Italy. PG - 997-1005 LID - 10.23736/S0375-9393.26.19833-2 [doi] AB - BACKGROUND: Perioperative antithrombotic management in neurosurgery carries significant bleeding and thrombosis risks. This survey aimed to provide the first structured analysis of current practices, resource availability, and decision-making heterogeneity across the coordinated neurocritical care network in Lombardia (Lombardy) an administrative region in Northern Italy. METHODS: This cross-sectional, region-wide survey involved all 19 hospitals performing neurosurgery in Lombardy. It analyzed multiple domains of perioperative anticoagulant management, including preoperative risk assessment, laboratory monitoring, use of bridging therapy, reversal strategies, and timing of pharmacologic thromboprophylaxis. The head of service collected responses from two to four experienced colleagues at each center. Participation was voluntary and anonymous, and no patient-level data were collected. Data were analyzed descriptively using R software; categorical variables are expressed as number (percentage) and continuous variables as mean+/- (SD)[median (IQR)]. RESULTS: The survey revealed marked variability across all domains, with clinical approaches remaining fragmented and largely driven by institutional culture rather than standardized protocols. A systemic lack of data collection on institutional postoperative hemorrhage and deep vein thrombosis epidemiology was found, with available data often based on subjective estimates. There is underutilization of formal thrombotic risk scores (e.g., Padua, IMPROVE) and predominantly reactive use of viscoelastic testing (ROTEM/TEG). Only 20.7% of respondents routinely involve both a Cardiologist and a Hematologist for multidisciplinary assessment. Furthermore, the timing of low-molecular-weight heparin administration varies widely: most responders delay initiation until postoperative day two to four after intracranial procedures, often deviating from guidelines recommending initiation within 24 hours when safe. CONCLUSIONS: The findings highlight the urgent need for structured, consensus-based perioperative anticoagulation pathways tailored to neurosurgical populations. Priority areas include standardizing venous thromboembolism prophylaxis timing and modality, promoting the systematic use of viscoelastic testing, and creating regional registries to track hemorrhagic and thrombotic events and improve evidence-based decision-making. FAU - Iaquaniello, Carolina AU - Iaquaniello C AD - Department of Neuroanesthesia and Intensive Care Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy - carolina.iaquaniello@istituto-besta.it. FAU - Iapichino, Giacomo AU - Iapichino G AD - Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy. FAU - Citerio, Giuseppe AU - Citerio G AD - NeuroIntensive Care Unit, Department of Neuroscience, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy. AD - School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy. FAU - Villa, Federico AU - Villa F AD - Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy. FAU - Berselli, Angela AU - Berselli A AD - Department of Anesthesiology and Intensive Care, Carlo Poma Hospital, Mantova, Italy. FAU - Cabrini, Luca AU - Cabrini L AD - General and Neurosurgical Intensive Care Units, Ospedale di Circolo, ASST Sette Laghi, Varese, Italy. AD - Department of Biotechnologies and Life Sciences, University of Insubria, Varese, Italy. FAU - Chieregato, Arturo AU - Chieregato A AD - Neurocritical Care Unit, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy. FAU - Dell'acqua, Antonio AU - Dell'acqua A AD - Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy. FAU - Dell'avanzo, Giacomo AU - Dell'avanzo G AD - Department of Anesthesia and Critical Care Medicine, Papa Giovanni XXIII Hospital, Bergamo, Italy. FAU - Fassini, Paola AU - Fassini P AD - Department of Anesthesia and Intensive Care, Legnano Hospital, ASST Ovest Milanese, Legnano, Milan, Italy. FAU - Galassini, Elena AU - Galassini E AD - Department of Anesthesiology and Intensive Care, ASST Fatebenefratelli Sacco, University of Milan, Milan, Italy. FAU - Grappa, Elena AU - Grappa E AD - Intensive Care Unit, Ospedale di Cremona, ASST Cremona, Cremona, Italy. FAU - Gritti, Paolo AU - Gritti P AD - Department of Anesthesia and Critical Care Medicine, Papa Giovanni XXIII Hospital, Bergamo, Italy. FAU - Guglielmi, Angelo AU - Guglielmi A AD - University of Pavia, PhD in Experimental Medicine, Pavia, Italy. AD - Anesthesia and Intensive Care Department1, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. FAU - Mangili, Paolo AU - Mangili P AD - NeuroIntensive Care Unit, Department of Neuroscience, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy. FAU - Mazza, Giovanni Maria AU - Mazza GM AD - Anesthesia and Intensive Care Department1, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. FAU - Mistraletti, Giovanni AU - Mistraletti G AD - Department of Anesthesia and Intensive Care, Legnano Hospital, ASST Ovest Milanese, Legnano, Milan, Italy. AD - Department of Medical-Surgical and Transplant Pathophysiology, University of Milan, Milan, Italy. FAU - Muttini, Stefano AU - Muttini S AD - SC Terapia Intensiva Neurochirurgica, San Carlo Borromeo Hospital, ASST Santi Paolo e Carlo, Milan, Italy. FAU - Nguyen, Maia AU - Nguyen M AD - Department of Anesthesia and Intensive Care, Fondazione Poliambulanza Hospital, Brescia, Italy. FAU - Ortolano, Fabrizio AU - Ortolano F AD - Department of Anesthesia and Critical Care, Neuroscience Intensive Care Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. FAU - Pagani, Michele AU - Pagani M AD - Anesthesia and Intensive Care Department1, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. FAU - Panzeri, Cristina AU - Panzeri C AD - Department of Neurosciences, Ospedale Alessandro Manzoni Hospital - ASST Lecco, Lecco, Italy. FAU - Piva, Simone AU - Piva S AD - Department of Emergency, ASST Spedali Civili University Hospital, Brescia, Italy. AD - Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy. FAU - Pressato, Lorenzo S AU - Pressato LS AD - Neurocritical Care Unit, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy. FAU - Rasulo, Francesco A AU - Rasulo FA AD - Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy. AD - Neuroanesthesia, Neurocritical and Post-Operative Care, ASST Spedali Civili University Hospital, Brescia, Italy. FAU - Sangalli, Fabio AU - Sangalli F AD - NeuroIntensive Care Unit, Department of Neuroscience, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy. AD - Department of Anaesthesia and Intensive Care, ASST Valtellina e Alto Lario, Sondrio, Italy. FAU - Viscone, Andrea AU - Viscone A AD - Department of Anesthesia and Critical Care Medicine, Papa Giovanni XXIII Hospital, Bergamo, Italy. FAU - Zerbi, Simone M AU - Zerbi SM AD - Neurocritical Care Unit, Department of Emergency Medicine, ASST Lariana Sant'Anna Como Hospital, San Fermo della Battaglia, Como, Italy. FAU - Zoerle, Tommaso AU - Zoerle T AD - Department of Medical-Surgical and Transplant Pathophysiology, University of Milan, Milan, Italy. AD - Department of Anesthesia and Critical Care, Neuroscience Intensive Care Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. FAU - Gemma, Marco AU - Gemma M AD - Department of Neuroanesthesia and Intensive Care Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy. CN - LINK Working Group LA - eng PT - Journal Article DEP - 20260603 PL - Italy TA - Minerva Anestesiol JT - Minerva anestesiologica JID - 0375272 RN - 0 (Fibrinolytic Agents) RN - 0 (Anticoagulants) SB - IM MH - Humans MH - Italy MH - *Perioperative Care/methods MH - Cross-Sectional Studies MH - *Fibrinolytic Agents/therapeutic use MH - *Neurosurgical Procedures/methods MH - *Critical Care MH - *Elective Surgical Procedures MH - Anticoagulants/therapeutic use FIR - Alongi, Salvatore F IR - Alongi SF FIR - Berselli, Angela IR - Berselli A FIR - Benedetti, Stefania IR - Benedetti S FIR - Biondo, Alberto IR - Biondo A FIR - Cabrini, Luca IR - Cabrini L FIR - Chieregato, Arturo IR - Chieregato A FIR - Citerio, Giuseppe IR - Citerio G FIR - Ciceri, Rita IR - Ciceri R FIR - Daniele, Francesca IR - Daniele F FIR - Della Morte, Mauro IR - Della Morte M FIR - Dell'acqua, Antonio IR - Dell'acqua A FIR - Dell'avanzo, Giacomo IR - Dell'avanzo G FIR - Fassini, Paola IR - Fassini P FIR - Galassini, Elena IR - Galassini E FIR - Gemma, Marco IR - Gemma M FIR - Grappa, Elena IR - Grappa E FIR - Graziano, Francesca IR - Graziano F FIR - Gritti, Paolo IR - Gritti P FIR - Guglielmi, Angelo IR - Guglielmi A FIR - Hurpet, Marion IR - Hurpet M FIR - Iaquaniello, Carolina IR - Iaquaniello C FIR - Lagana, Maria Cristina IR - Lagana MC FIR - Mangili, Paolo IR - Mangili P FIR - Mazza, Giovanni M IR - Mazza GM FIR - Mistraletti, Giovanni IR - Mistraletti G FIR - Muttini, Stefano IR - Muttini S FIR - Nguyen, Maia IR - Nguyen M FIR - Ogliari, Giorgia IR - Ogliari G FIR - Ortolano, Fabrizio IR - Ortolano F FIR - Pagani, Michele IR - Pagani M FIR - Panzeri, Cristina IR - Panzeri C FIR - Piva, Simone IR - Piva S FIR - Pressato, Lorenzo S IR - Pressato LS FIR - Rasulo, Francesco A IR - Rasulo FA FIR - Ruggieri, Francesco IR - Ruggieri F FIR - Sangalli, Fabio IR - Sangalli F FIR - Vargiolu, Alessia IR - Vargiolu A FIR - Villa, Federico IR - Villa F FIR - Viscone, Andrea IR - Viscone A FIR - Zerbi, Simone M IR - Zerbi SM FIR - Zoerle, Tommaso IR - Zoerle T EDAT- 2026/06/03 12:39 MHDA- 2026/10/28 11:34 CRDT- 2026/06/03 11:11 PHST- 2026/10/28 11:34 [medline] PHST- 2026/06/03 12:39 [pubmed] PHST- 2026/06/03 11:11 [entrez] AID - S0375-9393.26.19833-2 [pii] AID - 10.23736/S0375-9393.26.19833-2 [doi] PST - ppublish SO - Minerva Anestesiol. 2026 Oct;92(10):997-1005. doi: 10.23736/S0375-9393.26.19833-2. Epub 2026 Jun 3. PMID- 42233907 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260806 LR - 20260814 IS - 2666-0849 (Electronic) IS - 2666-0849 (Linking) VI - 31 IP - 31 DP - 2026 Aug 5 TI - Mitral Valve Entrapment of Preshaped Guidewire During TAVI. PG - 108683 LID - S2666-0849(26)01842-5 [pii] LID - 10.1016/j.jaccas.2026.108683 [doi] LID - 108683 AB - CASE SUMMARY: We report a case of acute mitral regurgitation caused by a stiff guidewire entrapment in the subvalvular apparatus during transcatheter aortic valve implantation. Early detection by the multidisciplinary Heart Team enabled prompt conversion to successful minimally invasive surgery for mitral repair. TAKE-HOME MESSAGE: Mitral injury due to guidewire entrapment is a rare, life-threatening transcatheter aortic valve implantation complication. Key to success is the early recognition of pathognomonic echocardiographic features and immediate surgical bailout. Minimally invasive surgery is a safe, effective rescue strategy. Maintaining a hybrid environment with a scrubbed cardiac surgeon is essential to optimize outcomes in such high-risk, unexpected scenarios. CI - Copyright (c) 2026 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Parrella, Barbara AU - Parrella B AD - Division of Cardiac Surgery, Citta Della Salute e della Scienza Hospital, University of Turin, Turin, Italy. Electronic address: barbara.parrella@unito.it. FAU - Barbero, Cristina AU - Barbero C AD - Division of Cardiac Surgery, Citta Della Salute e della Scienza Hospital, University of Turin, Turin, Italy. FAU - Conrotto, Federico AU - Conrotto F AD - Division of Cardiology, Citta Della Salute e della Scienza Hospital, University of Turin, Turin, Italy. FAU - Vairo, Alessandro AU - Vairo A AD - Division of Cardiology, Citta Della Salute e della Scienza Hospital, University of Turin, Turin, Italy. FAU - Salizzoni, Stefano AU - Salizzoni S AD - Department of Surgical Sciences, University of Torino, Turin, Italy. LA - eng PT - Journal Article DEP - 20260603 PL - Netherlands TA - JACC Case Rep JT - JACC. Case reports JID - 101757292 PMC - PMC13464264 OTO - NOTNLM OT - anterior mitral leaflet (AML) OT - bailout OT - minimally invasive OT - mitral injury OT - mitral regurgitation (MR) OT - rescue OT - transcatheter aortic valve implantation (TAVI) OT - transcatheter aortic valve replacement (TAVR) COIS- Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2026/06/03 12:38 MHDA- 2026/06/03 12:39 PMCR- 2026/06/03 CRDT- 2026/06/03 10:30 PHST- 2026/04/23 00:00 [received] PHST- 2026/04/24 00:00 [accepted] PHST- 2026/06/03 12:39 [medline] PHST- 2026/06/03 12:38 [pubmed] PHST- 2026/06/03 10:30 [entrez] PHST- 2026/06/03 00:00 [pmc-release] AID - S2666-0849(26)01842-5 [pii] AID - 108683 [pii] AID - 10.1016/j.jaccas.2026.108683 [doi] PST - ppublish SO - JACC Case Rep. 2026 Aug 5;31(31):108683. doi: 10.1016/j.jaccas.2026.108683. Epub 2026 Jun 3. PMID- 42233689 OWN - NLM STAT- MEDLINE DCOM- 20260619 LR - 20260813 IS - 1744-8298 (Electronic) IS - 1479-6678 (Print) IS - 1479-6678 (Linking) VI - 22 IP - 6 DP - 2026 Jun TI - Multidisciplinary approach to implementing ferric carboxymaltose for IV iron replacement in heart failure with iron deficiency. PG - 567-574 LID - 10.1080/14796678.2026.2683489 [doi] AB - Iron deficiency (ID) is a common comorbidity in patients with heart failure (HF). Treatment with intravenous (IV) iron is recommended by the ACC/AHA/HFSA and ESC guidelines to improve HF symptoms, exercise capacity, and quality of life, and to reduce the risk of hospitalization. Ferric carboxymaltose (FCM) is indicated for ID in adults with HF (NYHA class II/III) to improve exercise capacity. There are challenges in ensuring that eligible patients with HF and ID achieve iron repletion and associated optimal outcomes in routine practice. These challenges include inpatient formulary restrictions which only allow for low-dose IV irons and care transitions when the course of IV iron treatment spans the inpatient and outpatient setting. Despite the ease of administration as a single rapid infusion of up to 1000 mg of iron, inpatient and outpatient formularies do not always include FCM. This guide shares a general workflow used at university-based and private hospital systems, to facilitate routine iron assessment and IV iron repletion in a typical HF care pathway. Perspectives from the cardiologist, nurse, advanced practice provider (APP), and pharmacist roles provide a comprehensive view and emphasize the importance of a multidisciplinary, collaborative approach to optimize outcomes for patients with HF and ID. FAU - Fudim, Marat AU - Fudim M AUID- ORCID: 0000-0002-8671-7007 AD - Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA. AD - Duke Clinical Research Institute, Durham, NC, USA. FAU - Ferrante, Francesco AU - Ferrante F AUID- ORCID: 0009-0008-5471-5999 AD - Department of Pharmacy, Northwestern Medicine, Chicago, IL, USA. FAU - Vorgang, Cassandra M AU - Vorgang CM AUID- ORCID: 0009-0000-9987-4549 AD - Department of Advanced Heart Failure and Transplant, Inova Health Systems, Falls Church, VA, USA. FAU - Rosner, Carolyn M AU - Rosner CM AUID- ORCID: 0000-0002-7742-9628 AD - Department of Advanced Heart Failure and Transplant, Inova Health Systems, Falls Church, VA, USA. FAU - Mentz, Robert J AU - Mentz RJ AUID- ORCID: 0000-0002-3222-1719 AD - Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA. AD - Duke Clinical Research Institute, Durham, NC, USA. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20260603 PL - England TA - Future Cardiol JT - Future cardiology JID - 101239345 RN - 6897GXD6OE (ferric carboxymaltose) RN - 0 (Ferric Compounds) RN - 69-79-4 (Maltose) RN - E1UOL152H7 (Iron) SB - IM MH - Humans MH - *Ferric Compounds/administration & dosage/therapeutic use MH - *Maltose/analogs & derivatives/administration & dosage/therapeutic use MH - *Heart Failure/complications MH - *Anemia, Iron-Deficiency/drug therapy/complications MH - *Iron PMC - PMC13285543 OAB - Iron deficiency is common in people with heart failure, and can cause increased tiredness, difficulty breathing, reduced physical functioning, and an overall decline in quality of life. It is also related to a higher risk of hospitalization and death. To treat symptoms and reduce these risks, clinical guidelines recommend giving iron directly into the vein (intravenously), which allows quick entry into the bloodstream. Taking iron by mouth has shown to be ineffective for people with heart failure.This guide shows how a healthcare team can work together to better identify and treat iron deficiency in heart failure patients. There are two types of intravenous (IV) irons: low-dose and high-dose. During treatment, a patient is watched for any unusual symptoms to ensure they can tolerate the medication.Ferric carboxymaltose (FCM) is an IV iron that can deliver a large amount of iron in a single dose over a short timeframe. This allows for a better treatment option for patients with fewer clinic visits. However, there can be challenges to receiving IV iron due to a lack of screening for iron deficiency, or insurance coverage gaps that require a healthcare team to work closely together.Throughout the patient journey, those included on the healthcare team are cardiologists (heart doctors), pharmacists, nurse practitioners (NPs), nurses, and others. The care plan includes testing for iron deficiency, treatment, and proper follow-up. Strengthening teamwork and including approved medications like FCM in a treatment plan will help patients feel better and improve outcomes. OABL- eng OTO - NOTNLM OT - Iron deficiency OT - ferric carboxymaltose OT - heart failure OT - intravenous iron OT - multidisciplinary approach COIS- MF has been supported by the NIH, Alleviant, Gradient, Reprieve, Sardocor, and Doris Duke. He is a consultant and/or has ownership interest in Abbott, Acorai, Ajax, Alio Health, Alleviant, Artha, Astellas, Audicor, AxonTherapies, Bodyguide, Bodyport, Boston Scientific, Broadview, Cadence, Cardiosense, Cardioflow, Clinical Accelerator, CVRx, Daxor, Edwards LifeSciences, Echosens, EKO, Endotronix, Feldschuh Foundation, Fire1, FutureCardia, Gradient, Hatteras, HemodynamiQ, Impulse Dynamics, ISHI, Lumina Health, Medtronic, NovoNordisk, NucleusRx, Omega, Orchestra, Parasym, Pharmacosmos, Presidio, Procyreon, Proton Intelligence, Puzzle, ReCor, Scirent, SCPharma, Shifamed, Splendo, Summacor, SyMap, Terumo, Vascular Dynamics, Vifor Pharma, Vironix, Viscardia, Zoll. FF has received consulting fees from Daiichi-Sankyo, Inc. CR has received consulting fees from Novartis Pharma, and has received grants or contracts from American Regent, Inc. RM has received consulting fees from Abbott, Amgen, Bayer, Boehringer Ingelheim, Eli Lilly and Company, Merck, Novartis Pharma, Pharmacosmos Therapeutics Inc., Relypsa Inc., and Vifor Pharma, and has received grants or contracts from American Regent, Inc., AstraZeneca, Cytokinetics, and Medtronic. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Medical writing support was provided by Annick Moon on behalf of Springer Health+, and Subhashini Muralidharan, of Springer Health+, and was funded by American Regent, Inc. EDAT- 2026/06/03 12:38 MHDA- 2026/06/19 12:36 PMCR- 2026/06/03 CRDT- 2026/06/03 09:12 PHST- 2026/06/19 12:36 [medline] PHST- 2026/06/03 12:38 [pubmed] PHST- 2026/06/03 09:12 [entrez] PHST- 2026/06/03 00:00 [pmc-release] AID - 2683489 [pii] AID - 10.1080/14796678.2026.2683489 [doi] PST - ppublish SO - Future Cardiol. 2026 Jun;22(6):567-574. doi: 10.1080/14796678.2026.2683489. Epub 2026 Jun 3. PMID- 42232037 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260603 LR - 20260813 IS - 2221-2965 (Electronic) IS - 2221-2965 (Linking) VI - 12 DP - 2026 TI - Endoscopic techniques in redo mitral and tricuspid valve surgery. PG - 3 LID - 10.21037/jovs-25-28 [doi] LID - 3 AB - Redo mitral and tricuspid valve surgery presents considerable technical challenges due to dense adhesions, previous surgical alterations, and distortion of normal anatomical landmarks. Traditionally, these complex reoperative procedures have been approached through repeat median sternotomy, a strategy that, while familiar, carries heightened risks of cardiac or great vessel injury during re-entry, increased bleeding, longer operative times, and prolonged recovery. As minimally invasive cardiac surgery has evolved, endoscopic techniques have emerged as a viable and increasingly attractive alternative, offering surgeons enhanced visualization and patients a less traumatic operative experience. In this technical paper, we outline our institutional approach with endoscopic redo mitral and tricuspid valve surgery, emphasizing comprehensive preoperative planning, thoughtful patient selection, and meticulous intraoperative strategy. Critical components of preparation include detailed imaging assessment, analysis of previous operative notes, and formulation of a cannulation strategy tailored to each patient's anatomy and prior interventions. Myocardial protection remains a fundamental priority, and we describe the methods we have found most effective in achieving consistent and safe cardiac preservation in a reoperative setting. Our stepwise operative approach focuses on minimizing dissection, utilizing enhanced visualization, and employing targeted techniques to navigate scar tissue and restored anatomy while preserving procedural safety. In the experience of expert surgeons and teams, endoscopic access has translated into meaningful clinical benefits, including reduced transfusion requirements, shorter intensive care and hospital stays, and excellent early postoperative outcomes compared with traditional redo sternotomy as previously published. With proper preparation, a multidisciplinary team, and intraoperative vigilance, endoscopic redo mitral and tricuspid valve surgery represents a reliable, reproducible, and patient-centered option for complex valve reoperations. CI - (c) AME Publishing Company. FAU - Abdelbar, Abdelrahman AU - Abdelbar A AUID- ORCID: 0000-0002-0052-2568 AD - Cardiac Surgery Department, Wythenshawe Hospital, Manchester Foundation Trust, Manchester, UK. FAU - Aliar, Afsar AU - Aliar A AD - Cardiac Surgery Department, Wythenshawe Hospital, Manchester Foundation Trust, Manchester, UK. FAU - Fedor, Igor AU - Fedor I AD - Cardiac Surgery Department, Wythenshawe Hospital, Manchester Foundation Trust, Manchester, UK. FAU - Zacharias, Joseph AU - Zacharias J AD - Cardiothoracic Surgery Department, Blackpool Teaching Hospitals Foundation Trust, Lancashire, UK. LA - eng PT - Journal Article DEP - 20260127 PL - China TA - J Vis Surg JT - Journal of visualized surgery JID - 101677561 PMC - PMC13225031 OTO - NOTNLM OT - Endoscopic cardiac surgery OT - redo mitral valve surgery OT - redo tricuspid valve surgery COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jovs.amegroups.com/article/view/10.21037/jovs-25-28/coif). The series "Endoscopic Cardiac Surgery" was commissioned by the editorial office without any funding or sponsorship. J.Z. reports consulting fees from Cambridge Medical Robotic and Intuitive Surgical; honoraria from Edwards Lifesciences, Abbott, Medtronic, and Terumo; support for attending meeting from LSI; participation on a Data Safety Monitoring Board or Advisory Board for Artivion; and an unpaid leadership or fiduciary role for the British and Irish Society of Minimally Invasive surgeons. The authors have no other conflicts of interest to declare. EDAT- 2026/06/03 06:35 MHDA- 2026/06/03 06:36 PMCR- 2026/01/27 CRDT- 2026/06/03 04:45 PHST- 2025/07/30 00:00 [received] PHST- 2026/01/09 00:00 [accepted] PHST- 2026/06/03 06:36 [medline] PHST- 2026/06/03 06:35 [pubmed] PHST- 2026/06/03 04:45 [entrez] PHST- 2026/01/27 00:00 [pmc-release] AID - jovs-12-3 [pii] AID - 10.21037/jovs-25-28 [doi] PST - epublish SO - J Vis Surg. 2026 Jan 27;12:3. doi: 10.21037/jovs-25-28. eCollection 2026. PMID- 42229913 OWN - NLM STAT- MEDLINE DCOM- 20260701 LR - 20260714 IS - 1098-4275 (Electronic) IS - 0031-4005 (Linking) VI - 158 IP - 1 DP - 2026 Jul 1 TI - Longitudinal Telesimulation Program and Rural Clinicians' Neonatal Resuscitation Performance. LID - e2025074251 [pii] LID - 10.1542/peds.2025-074251 [doi] AB - BACKGROUND: Telesimulation (TS) addresses barriers to delivering simulation training in rural environments. We implemented a longitudinal TS program, Maine Ongoing Outreach Simulation Education (MOOSE), across 5 hospitals. We aimed to improve team adherence to the Neonatal Resuscitation Program (NRP) and assess the impact of team composition and training intervals. METHODS: Teams at 5 hospitals participated in monthly TS. TS recordings were assessed for adherence to NRP. NRP adherence was regressed against the number of TS in a linear regression model. NRP adherence was also regressed against team composition variables to determine how the experience and training of nurses, physicians, and respiratory therapists impacted performance. RESULTS: Hospitals participated in a total of 6, 7, 8, 10, and 18 sessions reaching 121 unique clinicians, with some participating more than once. On average, NRP score increased 1.3 percentage points with each training. Significant improvements were noted in cardiac compressions and positive pressure ventilation. NRP score was associated with the maximum number of TS sessions completed by team members, the average number of TS sessions completed by team members, and training sessions completed by the physician. CONCLUSIONS: Expanding an in situ longitudinal program showed improvement in team adherence to NRP across 5 hospitals. Each additional training for individual members improved team performance. Longitudinal in situ TS is a feasible model to improve interprofessional neonatal resuscitation performance and enhance neonatal emergency readiness. CI - Copyright (c) 2026 by the American Academy of Pediatrics. FAU - Melendi, Misty AU - Melendi M AD - Barbara Bush Children's Hospital at Maine Medical Center, MaineHealth, Portland, Maine. FAU - Zanno, Allison AU - Zanno A AD - Barbara Bush Children's Hospital at Maine Medical Center, MaineHealth, Portland, Maine. FAU - Martens, Sophie AU - Martens S AD - Tufts University School of Medicine, Boston, Massachusetts. FAU - Cutler, Anya AU - Cutler A AD - Center for Interprofessional Population Health Research at MaineHealth Institute for Research at MaineHealth, Scarborough, Maine. FAU - Chipman, Micheline AU - Chipman M AD - Hannaford Center for Safety, Innovation, and Simulation, Portland, Maine. FAU - Seften, Leah Marie AU - Seften LM AD - Barbara Bush Children's Hospital at Maine Medical Center, MaineHealth, Portland, Maine. FAU - Palnitkar, Tara AU - Palnitkar T AD - Barbara Bush Children's Hospital at Maine Medical Center, MaineHealth, Portland, Maine. FAU - Ottolini, Mary AU - Ottolini M AD - Barbara Bush Children's Hospital at Maine Medical Center, MaineHealth, Portland, Maine. FAU - Mallory, Leah AU - Mallory L AD - Barbara Bush Children's Hospital at Maine Medical Center, MaineHealth, Portland, Maine. AD - Hannaford Center for Safety, Innovation, and Simulation, Portland, Maine. LA - eng PT - Journal Article PT - Multicenter Study PL - United States TA - Pediatrics JT - Pediatrics JID - 0376422 SB - IM MH - Humans MH - Infant, Newborn MH - *Clinical Competence MH - *Resuscitation/education/standards MH - *Simulation Training/methods MH - Longitudinal Studies MH - Patient Care Team MH - *Rural Health Services EDAT- 2026/06/03 00:40 MHDA- 2026/07/01 12:47 CRDT- 2026/06/02 20:14 PHST- 2025/09/10 00:00 [received] PHST- 2026/04/06 00:00 [accepted] PHST- 2026/07/01 12:47 [medline] PHST- 2026/06/03 00:40 [pubmed] PHST- 2026/06/02 20:14 [entrez] AID - 207690 [pii] AID - 10.1542/peds.2025-074251 [doi] PST - ppublish SO - Pediatrics. 2026 Jul 1;158(1):e2025074251. doi: 10.1542/peds.2025-074251. PMID- 42228965 OWN - NLM STAT- MEDLINE DCOM- 20260605 LR - 20260605 IS - 1559-7776 (Electronic) IS - 1559-7768 (Linking) VI - 37 IP - 2 DP - 2026 Jun 15 TI - Role of the Nurse Practitioner in Caring for Heart Transplant Patients: From Hospitalization Through Reintegration Into the Community. PG - 229-240 LID - 10.4037/aacnacc2026108 [doi] AB - Nurse practitioners are essential members of the multidisciplinary team managing heart transplant candidates and recipients, a patient population with highly specialized, complex care needs. Nurse practitioners contribute to successful patient outcomes by delivering expert care, facilitating smooth transitions, and maintaining continuity of care throughout the patient's journey. This continuum of care progresses from pretransplant evaluation and optimization, to the vulnerable perioperative and recovery period, and throughout the patient's transition back into the community, which entails lifelong prevention, surveillance, and management of long-term complications. The deep familiarity of nurse practitioners with program protocols, stewardship of collaboration, and consistent presence positions them as trusted resources for nurses, trainees, allied health professionals, and consulting specialists involved in the heart transplant recipient's care. Overall, nurse practitioners help to streamline care, mitigate risk, bring forth best outcomes, and optimize patient well-being in the ever-evolving heart transplant population. CI - (c)2026 American Association of Critical-Care Nurses. FAU - Jamero, Gina AU - Jamero G AD - Gina Jamero is Lead Nurse Practitioner, Heart Transplant and Mechanical Circulatory Support Cardiology, Cedars-Sinai Smidt Heart Institute, 127 S San Vicente Blvd A-3100, Los Angeles, CA 90048 (gina.jamero@cshs.org). FAU - Welton, Monet AU - Welton M AD - Monet Welton is Lead Nurse Practitioner, Heart Transplant Cardiology, Cedars-Sinai Medical Center, Los Angeles, California. LA - eng PT - Journal Article PL - United States TA - AACN Adv Crit Care JT - AACN advanced critical care JID - 101269322 SB - IM MH - Humans MH - *Heart Transplantation/nursing MH - *Nurse Practitioners/standards MH - *Nurse's Role MH - Female MH - Male MH - Middle Aged MH - Adult MH - Aged MH - Hospitalization MH - Patient Care Team MH - *Continuity of Patient Care OTO - NOTNLM OT - heart transplantation OT - multidisciplinary care team OT - nurse practitioners EDAT- 2026/06/02 18:40 MHDA- 2026/06/05 18:36 CRDT- 2026/06/02 17:33 PHST- 2026/06/05 18:36 [medline] PHST- 2026/06/02 18:40 [pubmed] PHST- 2026/06/02 17:33 [entrez] AID - 33042 [pii] AID - 10.4037/aacnacc2026108 [doi] PST - ppublish SO - AACN Adv Crit Care. 2026 Jun 15;37(2):229-240. doi: 10.4037/aacnacc2026108. PMID- 42219979 OWN - NLM STAT- MEDLINE DCOM- 20260717 LR - 20260820 IS - 1969-6213 (Electronic) IS - 1774-024X (Print) IS - 1774-024X (Linking) VI - 22 IP - 11 DP - 2026 Jun 1 TI - Early outcomes of redo-TAVI with the SAPIEN 3 platform: the prospective, multicentre ReTAVI registry. PG - e629-e641 LID - EIJ-D-25-01268 [pii] LID - 10.4244/EIJ-D-25-01268 [doi] AB - BACKGROUND: Transcatheter aortic valve implantation (TAVI) is increasingly performed in younger and lower-risk patients. Since many of these patients will outlive their transcatheter heart valve (THV), redo-TAVI procedures are expected to rise in number. Yet, real-world evidence on the procedural safety and efficacy of redo-TAVI remains limited. AIMS: We aimed to evaluate the 30-day procedural and clinical outcomes of redo-TAVI using the balloon-expandable SAPIEN 3 platform. METHODS: The ReTAVI registry is a prospective, international study enrolling consecutive patients with a failed aortic THV undergoing redo-TAVI with a balloon-expandable SAPIEN 3 THV. Data were collected across 59 international centres. All imaging was centrally analysed, and major clinical events were adjudicated by an independent committee. RESULTS: a A total of 143 patients (median age 84 years; 40.6% female; median Society of Thoracic Surgeons risk score 7.0%) were enrolled. The predominant failing THVs were balloon-expandable SAPIEN 3 (30.1%), self-expanding CoreValve/Evolut (53.1%), and ACURATE (14.0%) platforms. The most common failure mode was isolated regurgitation (48.6%), followed by stenosis (35.2%) and a mixed pathology (16.2%). The replacement valve was successfully implanted in 95.1% of patients, with a 30-day mortality rate of 3.5%. The 30-day stroke and pacemaker implantation rates were 0.7% and 6.3%, respectively. Redo-TAVI significantly improved valve haemodynamics, with mean gradients decreasing overall (Delta=-12.0 mmHg), and a more pronounced reduction in stenotic failures (Delta=-29.0 mmHg). Coronary obstruction was observed in 1.4% of cases. CONCLUSIONS: Redo-TAVI with a balloon-expandable SAPIEN 3 THV platform is a safe and effective reintervention strategy across diverse failed THV types, when guided by the Heart Team, standardised procedural planning, and comprehensive imaging. CLINICALTRIALS: gov: NCT05601453. FAU - Tarantini, Giuseppe AU - Tarantini G AD - Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy. FAU - Fovino, Luca Nai AU - Fovino LN AD - Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy. FAU - Alvarez Covarrubias, Hector Alfonso AU - Alvarez Covarrubias HA AD - Department of Cardiology, TUM University Hospital German Heart Centre, School of Medicine and Health, Technical University Munich, Munich, Germany. FAU - Wolny, Rafal AU - Wolny R AD - Department of Interventional Cardiology and Angiology, National Institute of Cardiology, Warsaw, Poland. FAU - Fabris, Tommaso AU - Fabris T AD - Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy. FAU - Skipirzepa, Joanna Nawara AU - Skipirzepa JN AD - Department of Cardiology and Structural Heart Disease, Medical University of Silesia, Katowice, Poland. FAU - Eden, Matthias AU - Eden M AD - Department of Internal Medicine III (Cardiology, Angiology, Pneumology), Heidelberg University Clinic, Heidelberg, Germany. FAU - Zamorano, Jose Luis AU - Zamorano JL AD - University Hospital Ramon y Cajal, Madrid, Spain. FAU - Joner, Michael AU - Joner M AD - Department of Cardiology, TUM University Hospital German Heart Centre, School of Medicine and Health, Technical University Munich, Munich, Germany. FAU - Cuisset, Thomas AU - Cuisset T AD - Department of Cardiology, CHU Timone, Marseille, France. AD - CV2N, Aix-Marseille University, INSERM, INRAE, Marseille, France. FAU - Delgado, Victoria AU - Delgado V AD - Department of Cardiology, University Hospital Germans Trias i Pujol, Badalona, Spain. FAU - Rodes-Cabau, Josep AU - Rodes-Cabau J AD - Department of Cardiology, Quebec Heart and Lung Institute, Laval University, Quebec City, QC, Canada. FAU - Saia, Francesco AU - Saia F AD - Department of Interventional Cardiology, IRCCS University Hospital of Bologna, Policlinico S. Orsola, Bologna, Italy. FAU - Bieliauskas, Gintautas AU - Bieliauskas G AD - Department of Interventional Cardiology, The Heart Center, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. FAU - Van Belle, Eric AU - Van Belle E AD - Interventional Cardiology, Centre Hospitalier Universitaire de Lille, Lille, France. FAU - Modine, Thomas AU - Modine T AD - Department of Cardiology, Hospital Haut Leveque - Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France. FAU - Rheude, Tobias AU - Rheude T AD - Department of Cardiology, TUM University Hospital German Heart Centre, School of Medicine and Health, Technical University Munich, Munich, Germany. FAU - Garot, Philippe AU - Garot P AD - Institut Cardiovasculaire Paris-Sud, Hopital Prive Jacques Cartier, Ramsay-Sante, Massy, France. FAU - Jung, Christian AU - Jung C AD - Department of Cardiology, Pulmonology and Vascular Medicine, Medical Faculty, University Hospital and Heinrich-Heine University, Dusseldorf, Germany. FAU - Rudolph, Tanja K AU - Rudolph TK AD - Department of General and Interventional Cardiology/Angiology, Heart and Diabetes Center North Rhine-Westphalia, Ruhr-University Bochum, Bad Oeynhausen, Germany. FAU - Leroux, Lionel AU - Leroux L AD - Department of Interventional Cardiology, Cardiology Hospital of the Haut-Leveque, University of Bordeaux, Pessac, France. FAU - Rottbauer, Wolfgang AU - Rottbauer W AD - Department of Internal Medicine II, University of Ulm, Ulm, Germany. FAU - Nestelberger, Thomas AU - Nestelberger T AD - Department of Cardiology and Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, University of Basel, Basel, Switzerland. FAU - Lhermusier, Thibault AU - Lhermusier T AD - Department of Cardiology, Centre Hospitalier Universitaire de Toulouse Rangueil, Toulouse, France. FAU - Nejjari, Mohammed AU - Nejjari M AD - Department of Cardiology, Centre Cardiologique du Nord, Saint-Denis, France. FAU - Regueiro, Ander AU - Regueiro A AD - Department of Cardiology, Hospital Clinico de Barcelona, Barcelona, Spain. FAU - Meier, David AU - Meier D AD - Department of Cardiology, Lausanne University Hospital, Lausanne, Switzerland. FAU - Fraccaro, Chiara AU - Fraccaro C AD - Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy. FAU - Hartikainen, Tau AU - Hartikainen T AD - Department of Cardiology and Angiology, University Heart Center Freiburg - Bad Krozingen, Bad Krozingen, Germany. FAU - Karam, Nicole AU - Karam N AD - Department of Cardiology, European Hospital Georges Pompidou, Paris, France. FAU - Swaans, Martin AU - Swaans M AD - Department of Cardiology, St. Antonius Hospital, Nieuwegein, the Netherlands. FAU - Rodrigues, Alberto AU - Rodrigues A AD - Department of Cardiology, Centro Hospitalario de Gaia Espinho, Vila Nova de Gaia, Portugal. FAU - Dreger, Henryk AU - Dreger H AD - Department of Cardiology, Angiology and Intensive Care Medicine, Deutsches Herzzentrum der Charite, Campus Virchow Klinikum, Berlin, Germany. AD - Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany. FAU - Hengstenberg, Christian AU - Hengstenberg C AD - Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Vienna, Austria. FAU - Schmitz, Thomas AU - Schmitz T AD - Department of Cardiology and Angiology, Elisabeth Hospital Essen, Essen, Germany. FAU - Mauler-Wittwer, Sarah AU - Mauler-Wittwer S AD - Department of Medicine, Cardiology Division, Structural Heart Unit, University Hospital of Geneva, Geneva, Switzerland. FAU - Piazza, Nicolo AU - Piazza N AD - Division of Cardiology, McGill University Health Centre, Montreal, QC, Canada. FAU - Combaret, Nicolas AU - Combaret N AD - Department of Cardiology, Clermont-Ferrand University Hospital, Clermont-Ferrand, France. FAU - Letocart, Vincent AU - Letocart V AD - Department of Cardiology, Centre Hospitalier Universitaire de Nantes, Nantes, France. FAU - Auffret, Vincent AU - Auffret V AD - Department of Cardiology, Centre Hospitalier Universitaire de Rennes, Rennes, France. FAU - Durand, Eric AU - Durand E AD - Department of Cardiology, Rouen University Hospital, Rouen, France. FAU - Urena-Alcazar, Marina AU - Urena-Alcazar M AD - Department of Cardiology, Hopital Bichat Claude Bernard, Paris, France. FAU - Del Valle-Fernandez, Raquel AU - Del Valle-Fernandez R AD - Department of Cardiology, Asturias Central University Hospital, Oviedo, Spain. FAU - Drago, Andrea AU - Drago A AD - Department of Cardiology, San Bortolo Hospital, Vicenza, Italy. FAU - De Carlo, Marco AU - De Carlo M AD - Cardiothoracic and Vascular Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy. FAU - Jimenez Diaz, Victor Alfonso AU - Jimenez Diaz VA AD - Cardiology Department, Hospital Alvaro Cunqueiro, University Hospital of Vigo, Vigo, Spain. FAU - Dabrowski, Maciej AU - Dabrowski M AD - Department of Interventional Cardiology and Angiology, National Institute of Cardiology, Warsaw, Poland. FAU - Mascherbauer, Julia AU - Mascherbauer J AD - Department of Cardiology, University Hospital Sankt Polten, Karl Landsteiner University of Health Sciences, Krems, Austria. FAU - Sudre, Arnaud AU - Sudre A AD - Heart and Lung Institute, University Hospital Lille, Lille, France. FAU - Ong, Peter AU - Ong P AD - Department of Cardiology and Angiology, Robert Bosch Medical Centre, Stuttgart, Germany. FAU - Gonska, Birgid AU - Gonska B AD - Department of Cardiology, Kerckhoff-Heart and Thorax Center, Bad Nauheim, Germany. FAU - Mancone, Massimo AU - Mancone M AD - Department of Internal Clinical Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy. FAU - Fabris, Enrico AU - Fabris E AD - Cardiothoracovascular Department, University of Trieste, Trieste, Italy. FAU - Teles, Rui Campante AU - Teles RC AD - Department of Cardiology, Hospital de Santa Cruz, Centro Hospitalar de Lisboa Ocidental, Carnaxide, Portugal. AD - Comprehensive Health Research Center (CHRC), NOVA Medical School, Lisbon, Portugal. FAU - Nombela-Franco, Luis AU - Nombela-Franco L AD - Department of Cardiology, Cardiovascular Institute, Hospital Clinico San Carlos, IdISSC, Madrid, Spain. FAU - Asmarats, Lluis AU - Asmarats L AD - Department of Cardiology, Hospital de la Santa Creu I Sant Pau, Institut de Recerca Sant Pau (IR Sant Pau), Barcelona, Spain. FAU - Vilalta, Victoria AU - Vilalta V AD - Department of Cardiology, University Hospital Germans Trias i Pujol, Badalona, Spain. FAU - Protasiewicz, Marcin AU - Protasiewicz M AD - Department of Cardiology, Institute of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland. FAU - Webb, John Graydon AU - Webb JG AD - Centre for Heart Valve Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada. FAU - Toth-Gayor, Gabor AU - Toth-Gayor G AD - Department of Cardiology, University Heart Center Graz, Medical University of Graz, Graz, Austria. FAU - Zierer, Andreas AU - Zierer A AD - Department of Cardiovascular and Thoracic Surgery, Medical Faculty, Johannes Kepler University Linz, Kepler University Hospital Linz, Linz, Austria. AD - Department of Cardiovascular and Thoracic Surgery, Hospital Wels-Grieskirchen GmbH, Wels, Austria. AD - Clinical Research Institute for Cardiovascular and Metabolic Diseases, Medical Faculty, Johannes Kepler University Linz, Linz, Austria. FAU - Rioufol, Gilles AU - Rioufol G AD - Hospices Civils de Lyon, Lyon, France. FAU - Seiffert, Moritz AU - Seiffert M AD - Department of Cardiology and Angiology, BG University Hospital Bergmannsheil, Ruhr-University Bochum, Bochum, Germany. FAU - Adamo, Marianna AU - Adamo M AD - Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Cardiac Catheterization Laboratory and Cardiology, ASST Spedali Civili Brescia, University of Brescia, Brescia, Italy. FAU - Meucci, Francesco AU - Meucci F AD - Cardiothoracovascular Department, Careggi University Hospital, Florence, Italy. FAU - Ielasi, Alfonso AU - Ielasi A AD - Department of Cardiology, IRCCS Ospedale Galeazzi-Sant'Ambrogio, Milan, Italy. FAU - Burzotta, Francesco AU - Burzotta F AD - Department of Cardiovascular Sciences-CUORE, Fondazione Policlinico Universitario A. Gemelli IRCCS, Universita Cattolica del Sacro Cuore, Rome, Italy. FAU - Lopez Benito, Maria AU - Lopez Benito M AD - Department of Cardiology, University Hospital of Leon, Leon, Spain. FAU - Loewenstein, Itamar AU - Loewenstein I AD - Department of Cardiology, Tel Aviv Medical Center, Tel Aviv, Israel. FAU - Kralisz, Pawel AU - Kralisz P AD - Department of Invasive Cardiology, University Hospital, Bialystok, Poland. FAU - Legutko, Jacek AU - Legutko J AD - Department of Interventional Cardiology, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland. AD - Clinical Department of Interventional Cardiology, Saint John Paul II Hospital, Krakow, Poland. FAU - Huczek, Zenon AU - Huczek Z AD - Department of Cardiology, Medical University of Warsaw, Warsaw, Poland. FAU - Pavei, Andrea AU - Pavei A AD - Edwards Lifesciences, Prague, Czech Republic. FAU - Rakova, Radka AU - Rakova R AD - Edwards Lifesciences, Prague, Czech Republic. FAU - Wesselink, Wilbert AU - Wesselink W AD - Edwards Lifesciences, Prague, Czech Republic. FAU - Zielinski, Marie AU - Zielinski M AD - IPPMed - Institute for Pharmacology and Preventive Medicine GmbH, Cloppenburg, Germany. FAU - Trushina, Nataliya AU - Trushina N AD - IPPMed - Institute for Pharmacology and Preventive Medicine GmbH, Cloppenburg, Germany. FAU - Bramlage, Peter AU - Bramlage P AD - IPPMed - Institute for Pharmacology and Preventive Medicine GmbH, Cloppenburg, Germany. FAU - Parma, Radoslaw AU - Parma R AD - Department of Cardiology and Structural Heart Disease, Medical University of Silesia, Katowice, Poland. LA - eng SI - ClinicalTrials.gov/NCT05601453 PT - Journal Article PT - Multicenter Study DEP - 20260601 PL - France TA - EuroIntervention JT - EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology JID - 101251040 SB - IM MH - Humans MH - Female MH - Aged, 80 and over MH - Registries MH - Prospective Studies MH - Treatment Outcome MH - Male MH - Aged MH - *Transcatheter Aortic Valve Replacement/methods/adverse effects/instrumentation MH - *Aortic Valve Stenosis/surgery MH - Reoperation MH - *Heart Valve Prosthesis MH - *Aortic Valve/surgery MH - Prosthesis Design PMC - PMC13207894 COIS- G. Tarantini received honoraria for lectures from Abbott, Boston Scientific, Edwards Lifesciences, Medtronic, and GADA. L.N. Fovino received lecture fees from Edwards Lifesciences and Shockwave Medical. H.A.A. Covarrubias received lecture fees from SIS Medical AG and Translumina; speaker fees from Lifetech; consulting fees from Lifetech; and travel expenses from Lifetech and Abbott. M. Eden received grants from IPPMed. J.L. Zamorano received honoraria for lectures from Pfizer, Amgen, and Novartis. M. Joner received speaker fees from Abbott, Biotronik, Boston Scientific, Edwards Lifesciences, Medtronic, and Recor Medical; consulting fees from Biotronik, Boston Scientific, TRiCares, and Veryan; and travel support from SIS Medical, Edwards Lifesciences, Boston Scientific, and Medtronic; he also received grant support from Boston Scientific and Edwards Lifesciences, outside the submitted work; and participated in a steering committee for Biotronik and Edwards Lifesciences. T. Cuisset received consulting and lecture fees from Abbott, Boston Scientific, Edwards Lifesciences, Medtronic, and Terumo Medical Corporation; and stocks at CERC. V. Delgado received speaker fees from Abbott, Edwards Lifesciences, GE HealthCare, JenaValve, Medtronic, Philips, P&F Products & Features GmbH, and Siemens; she also received institutional research grants from Philips. J. Rodes-Cabau received grant support from Edwards Lifesciences and Medtronic; speaker fees from Edwards Lifesciences; and consulting fees from Medtronic and Abbott. F. Saia received consulting fees and lecture fees from Abbott, Boston Scientific, Edwards Lifesciences, and Medtronic. G. Bieliauskas received consultant fees from Abbott, Boston Scientific, Edwards Lifesciences, and Medtronic; and lecture fees from Medtronic, Abbott, and Boston Scientific; he also received travel support from Medtronic, Abbott, and Boston Scientific. T. Modine received consulting and lecture fees as well as travel support Abbott, Medtronic, and Edwards Lifesciences; he also is a member of the Cardiovascular Research Foundation. T. Rheude received lecture fees from AstraZeneca, Boston Scientific, Edwards Lifesciences, SIS Medical AG, Terumo Medical Corporation, and Translumina; he also received travel support from Boehringer Ingelheim, Edwards Lifesciences, Lifetech, and SIS Medical AG. P. Garot received consultant fees from Abbott, Biosensors, Boston Scientific, Cordis, Edwards Lifesciences, GE Healthcare, and Terumo; and speaker fees from Abbott, Biosensors, Boston Scientific, Cordis, Edwards Lifesciences, GE HealthCare, and Terumo; he is also a shareholder and medical director of the Cardiovascular European Research Center (CERC) in Massy, France. C. Jung received institutional grants from the German Research Foundation, German Ministry for Economy and Energy, State of North Rhine-Westphalia, German Space Agency, European Union, and Edwards Lifesciences; and received speaker fees from Bristol-Myers Squibb, Daiichi Sankyo, and Boehringer Ingelheim; he is also an unpaid member of the German cardiac society, German society for internal medicine, German society for medical intensive care, and European Society for Intensive Care Medicine. T.K. Rudolph received honoraria for lectures from Edwards Lifesciences, Boston Scientific, JenaValve, Medtronic, and Abbott; and is participating on the Advisory Board of Edwards Lifesciences. L. Leroux received consulting fees from Abbott, Medtronic, and Edwards Lifesciences. W. Rottbauer received speaker fees, consultant fees, and travel support from IPPMed and Edwards Lifesciences. T. Nestelberger has received research support from the Swiss National Science Foundation (P400PM_191037/1), the Prof. Dr. Max Cloetta Foundation, the Margarete und Walter Lichtenstein-Stiftung (3MS1038), the Freiwillige Akademische Gesellschaft Basel, the Stiftung kardiovaskulare Forschung Basel, the University of Basel, and the University Hospital Basel; as well as speaker/consulting honoraria or research support from Edwards Lifesciences, Pronova Medical, Meril Life Sciences, Boston Scientific, Medtronic, Abbott, Beckman Coulter, Bayer, Ortho Clinical Diagnostics, and Orion Pharma, outside the submitted work. T. Lhermusier received lecture and consulting fees, and travel support from Abbott, Edwards Lifesciences, and Medtronic; he also received support for the present manuscript from Edwards Lifesciences. M. Nejjari received consulting fees and travel support from Abbott, Medtronic, and Robocath; and lecture fees from Abbott, Medtronic, and Edwards Lifesciences. A. Regueiro received consulting fees from Abbott, Edwards Lifesciences, Haemonetics, Medtronic, and Meril Life Sciences. D. Meier received institutional consulting fees from Anteris Technologies and Abbott; and institutional grants and travel support from Edwards Lifesciences. C. Fraccaro received lecture fees from Edwards Lifesciences. T. Hartikainen received grant support for a clinical fellowship from Edwards Lifesciences; and received travel fees from Boston Scientific and Meril Life Sciences. N. Karam received consultant fees from Abbott, Boston Scientific, HighLife, and Medtronic; and lecture fees and travel support from Abbott and Boston Scientific. M. Swaans is a proctor for Abbott, Boston Scientific, Cardiac Dimensions, Edwards Lifesciences, P&F Products & Features GmbH, Medtronic, Philips, GE HealthCare, Simulands, and Siemens; he also received grants from ZonMw. A. Rodrigues received personal lecture fees from Cordis, Boston Scientific, Abbott, and Cardiva; and institutional travel support from Medtronic. H. Dreger received research support, speaker and consulting fees from Abbott and Edwards Lifesciences; and trial sponsorship from Edwards Lifesciences. C. Hengstenberg received consulting and lecture fees from Boston Scientific, Edwards Lifesciences, and Medtronic; and reports support for attending meetings from Boston Scientific, Edwards Lifesciences, Medtronic, and Daiichi Sankyo; and advisory board participation for HighLife. S. Mauler-Wittwer received travel grants from Edwards Lifesciences, Medtronic, and Abbott. N. Combaret received consulting and lecture fees from Medtronic. V. Auffret received lecture fees from Abbott, Edwards Lifesciences, and Medtronic; and consulting fees from Medtronic; he also received consultant grants from Medtronic and Abbott. M. Urena-Alcazar is a proctor for Edwards Lifesciences, Medtronic, and Abbott; and received consultant fees from iVascular; she also received travel support and lecture fees from Edwards Lifesciences and Medtronic; and has received equipment from Medtronic. R. del Valle-Fernandez received a speaker fee from Edwards Lifesciences, Medtronic, and Merce V. Electromedicina; and received consultant fees from Medtronic; she also reports support for travelling from Abbott and Boston Scientific. M. De Carlo received speaker fees from Boston Scientific, Medtronic, Meril Life Sciences, and MicroPort; and reports support for travelling from Meril Life Sciences and MicroPort. P. Ong received speaker fees and travel support from Edwards Lifesciences and Medtronic. B. Gonska received speaker fees from Medtronic, Boston Scientific, Pfizer, and Abbott; and consulting fees from Medtronic. L. Nombela-Franco received consulting and lecture fees from Edwards Lifesciences, Abbott, Vitaflow, Boston Scientific, and Palex. L. Asmarats is a proctor for Abbott; and a consultant for Edwards Lifesciences. M. Protasiewicz reports sponsorship from Edwards Lifesciences, Medtronic, Meril Life Sciences, and Abbott. J.G. Webb received payment for MD training from Meril Life Sciences; and received a grant support/research contract from Abbott, Edwards Lifesciences, and Medtronic; he is also a consultant for Edwards Lifesciences. G. Toth-Gayor received non-financial project support and fees for workshop presentations from Biotronik, Medtronic, Abbott, Cordis, Johnson & Johnson, and Terumo. M. Seiffert reports lecture fees from Abbott, Abiomed, AstraZeneca, Boston Scientific, Bristol-Myers Squibb, Edwards Lifesciences, Medtronic, Amgen, Shockwave Medical, Daiichi Sankyo, Pfizer, Inari Medical, and Bayer. M. Adamo received a speaker fee from Abbott, Edwards Lifesciences, and Medtronic. F. Meucci received lecture fees from Medtronic; serves as a proctor for Boston Scientific and Edwards Lifesciences; and receives travel support from Boston Scientific and Medtronic. F. Burzotta received a speaker fee from Abbott, Edwards Lifesciences, Abiomed, Medtronic, and Terumo Medical Corporation. J. Legutko received a speaker fee from Abbott, Medtronic, Meril Life Sciences, and Boston Scientific. A. Pavei is an employee of Edwards Lifesciences; and received stocks at Edwards Lifesciences. R. Rakova and W. Wesselink are employees of Edwards Lifesciences. P. Bramlage represents the sponsor IPPMed; and received funding from Edwards Lifesciences to support his institution for the present manuscript, study-related activities, consulting fees, and support for attending meetings. M. Zielinski and N. Trushina are employees of IPPMed; and received funding from Edwards Lifesciences to the institution for conducting the registry. The other authors have no conflicts of interest to declare. EDAT- 2026/06/01 08:05 MHDA- 2026/06/01 08:06 PMCR- 2027/06/01 CRDT- 2026/06/01 03:03 PHST- 2026/06/01 08:06 [medline] PHST- 2026/06/01 08:05 [pubmed] PHST- 2026/06/01 03:03 [entrez] PHST- 2027/06/01 00:00 [pmc-release] AID - EIJ-D-25-01268 [pii] AID - 10.4244/EIJ-D-25-01268 [doi] PST - epublish SO - EuroIntervention. 2026 Jun 1;22(11):e629-e641. doi: 10.4244/EIJ-D-25-01268. PMID- 42219916 OWN - NLM STAT- MEDLINE DCOM- 20260717 LR - 20260922 IS - 1369-7625 (Electronic) IS - 1369-6513 (Print) IS - 1369-6513 (Linking) VI - 29 IP - 3 DP - 2026 Jun TI - Mental Health Experiences and Needs of Women With Congenital Heart Disease in Pregnancy and Postpartum: A Qualitative Participatory Study. PG - e70676 LID - 10.1111/hex.70676 [doi] LID - e70676 AB - BACKGROUND AND AIM: In the United Kingdom, mental health and maternal health are now key priorities for research among adults with congenital heart disease. However, worldwide, research on the mental health of pregnant and postpartum women with congenital heart disease is scant, and no UK-based participatory studies on the topic have been conducted. Our research aim is to explore the mental health experiences and needs of UK women with lived experiences of pregnancy and congenital heart disease. METHODS: We conducted a qualitative participatory study, in which women with lived experiences of congenital heart disease, pregnancy, and birth participated in a series of semi-structured online group discussions focused on their mental health experiences and needs and on co-designing future research on the topic. Discussions were recorded and automatically transcribed; transcripts were analysed using inductive thematic analysis. RESULTS: Eleven women with a range of congenital heart disease diagnoses and experiences took part. Five themes were developed through the analysis: women with congenital heart disease (1) feel they have very little control over preconception-, pregnancy-, and birth-planning; (2) experience anxiety around pregnancy and childbirth; (3) feel that experiencing a high risk, complex pregnancy can be isolating; (4) experience complex relationships with healthcare professionals during pregnancy; and (5) need more postpartum support. A thread running through the first four themes is the need for additional support during the pregnancy journey, in both healthcare and social contexts. CONCLUSION: Distress and anxiety were common experiences during preconception, pregnancy, and the postnatal period. These experiences were exacerbated by wider relational and systemic stressors, namely, social isolation, traumatic healthcare experiences, and lack of psychological support during pregnancy and postpartum. Future research should investigate service gaps and points of intervention for improved cardiac maternity care, as well as explore the potential of peer support programmes to reduce the social isolation experienced by women with congenital heart disease. PATIENT OR PUBLIC CONTRIBUTION: The study followed a participatory design, whereby lived experience participants co-produced the research with the study team. The lived experience participants took part in a series of four small-group meetings, focused on sharing experiences and critically reviewing a draft research agenda and questionnaire, developed by the research team based on the groups' shared experiences. Following these meetings, the lived experience participants provided feedback on our analysis and contributed to this manuscript as co-authors. CI - (c) 2026 The Author(s). Health Expectations published by John Wiley & Sons Ltd. FAU - Huxley, Caroline J AU - Huxley CJ AD - Warwick Medical School, University of Warwick, Coventry, UK. FAU - Drury, Nigel E AU - Drury NE AD - Department of Paediatric Cardiac Surgery, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK. AD - Department of Cardiovascular Sciences, University of Birmingham, Birmingham, UK. FAU - Lavis, Anna C AU - Lavis AC AD - Department of Applied Health Sciences, University of Birmingham, Birmingham, UK. AD - Institute for Mental Health, University of Birmingham, Birmingham, UK. FAU - Giles, Donna AU - Giles D AD - Lived Experience Participant. FAU - Harrison, Jo AU - Harrison J AD - Lived Experience Participant. FAU - Kaplan, Katharina AU - Kaplan K AD - Lived Experience Participant. FAU - Lloyd, Joanne AU - Lloyd J AD - Lived Experience Participant. FAU - Nugent, Tracey AU - Nugent T AD - Lived Experience Participant. FAU - Powell, Charlene AU - Powell C AD - Lived Experience Participant. FAU - Rama, Pameljit AU - Rama P AD - Lived Experience Participant. FAU - Rigby, Debbie AU - Rigby D AD - Lived Experience Participant. FAU - Still, Heather AU - Still H AD - Lived Experience Participant. FAU - Tacey-Green, Imogen AU - Tacey-Green I AD - Lived Experience Participant. FAU - Eli, Karin AU - Eli K AD - Warwick Medical School, University of Warwick, Coventry, UK. LA - eng GR - Participatory Research Fund grant from the University of Warwick/ PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Health Expect JT - Health expectations : an international journal of public participation in health care and health policy JID - 9815926 SB - IM MH - Humans MH - Female MH - *Heart Defects, Congenital/psychology MH - Pregnancy MH - Qualitative Research MH - *Postpartum Period/psychology MH - United Kingdom MH - *Mental Health MH - Adult MH - *Pregnancy Complications, Cardiovascular/psychology MH - Anxiety PMC - PMC13239756 OTO - NOTNLM OT - adult congenital heart disease OT - mental health OT - participatory methods OT - postpartum OT - pregnancy OT - qualitative research COIS- The authors declare no conflicts of interest. EDAT- 2026/06/01 08:04 MHDA- 2026/06/01 08:05 PMCR- 2026/05/31 CRDT- 2026/06/01 02:33 PHST- 2026/04/05 00:00 [revised] PHST- 2025/10/16 00:00 [received] PHST- 2026/04/07 00:00 [accepted] PHST- 2026/06/01 08:05 [medline] PHST- 2026/06/01 08:04 [pubmed] PHST- 2026/06/01 02:33 [entrez] PHST- 2026/05/31 00:00 [pmc-release] AID - HEX70676 [pii] AID - 10.1111/hex.70676 [doi] PST - ppublish SO - Health Expect. 2026 Jun;29(3):e70676. doi: 10.1111/hex.70676. PMID- 42217350 OWN - NLM STAT- MEDLINE DCOM- 20260904 LR - 20260918 IS - 1532-4036 (Electronic) IS - 0964-3397 (Linking) VI - 95 DP - 2026 Aug TI - Rapid response systems in hospital settings: an umbrella review. PG - 104463 LID - S0964-3397(26)00131-X [pii] LID - 10.1016/j.iccn.2026.104463 [doi] AB - OBJECTIVES: To synthesise review-level evidence on rapid response systems (RRS; encompassing rapid response teams [RRTs], medical emergency teams [METs], and critical care outreach [CCO]), evaluate the effectiveness-implementation gap, and identify multilevel activation barriers, nursing roles, and organisational determinants. METHODS: Following PRISMA 2020 and Joanna Briggs Institute umbrella review methodology, five databases were searched to January 2025. Review articles examining RRS in acute care hospitals were eligible. Methodological quality was assessed with A MeaSurement Tool to Assess systematic Reviews 2 (AMSTAR 2); primary-study overlap was quantified via corrected covered area (CCA). RESULTS: Forty-eight reviews (2006-2025) were included, with publication accelerating in 2021-2025 (37.5%). AMSTAR 2 of 24 systematic reviews yielded high (n = 8), moderate (n = 9), low (n = 4), and critically low (n = 3) confidence. CCA indicated very high overlap (31.0%) among seven traditional meta-analyses, attenuated to 19.5% with an automated-alert meta-analysis. Meta-analyses showed consistent cardiac-arrest reductions (RR 0.60-0.73) and mortality reductions (RR 0.80-0.96; significant in five of eight estimates). Hierarchical interprofessional culture was identified in 14 of 15 barrier-focused reviews (93.3%). CONCLUSIONS: Convergent evidence supports RRS effectiveness, yet persistent multilevel barriers produce a substantial effectiveness-implementation gap. We propose a Multilevel Escalation Failure Model integrating individual, interprofessional, and organisational determinants to guide targeted strategies addressing the structurally paradoxical position of nurses within RRS. IMPLICATIONS FOR CLINICAL PRACTICE: Findings support targeted nursing interventions: simulation-based escalation training, role clarification, policies enabling nurse-initiated activation without mandatory physician endorsement, and multi-component strategies addressing interprofessional power dynamics and culture. CI - Copyright (c) 2026. Published by Elsevier Ltd. FAU - Lee, Sunghyun AU - Lee S AD - Department of Nursing, Graduate School, Keimyung University, Daegu, the Republic of Korea; Department of Nursing, Keimyung University Dongsan Hospital, Daegu, the Republic of Korea. FAU - Kim, Gaeun AU - Kim G AD - College of Nursing, Keimyung University, Daegu, the Republic of Korea. Electronic address: eun0325@kmu.ac.kr. LA - eng PT - Journal Article PT - Systematic Review DEP - 20260530 PL - Netherlands TA - Intensive Crit Care Nurs JT - Intensive & critical care nursing JID - 9211274 SB - IM MH - Humans MH - *Hospital Rapid Response Team/standards/trends MH - *Hospitals/standards/trends/statistics & numerical data OTO - NOTNLM OT - Cardiac arrest OT - Clinical deterioration OT - Critical care nursing OT - Early warning score OT - Hospital mortality OT - Patient safety OT - Rapid response system COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/05/31 05:33 MHDA- 2026/09/04 23:36 CRDT- 2026/05/30 18:09 PHST- 2026/04/06 00:00 [received] PHST- 2026/05/19 00:00 [revised] PHST- 2026/05/22 00:00 [accepted] PHST- 2026/09/04 23:36 [medline] PHST- 2026/05/31 05:33 [pubmed] PHST- 2026/05/30 18:09 [entrez] AID - S0964-3397(26)00131-X [pii] AID - 10.1016/j.iccn.2026.104463 [doi] PST - ppublish SO - Intensive Crit Care Nurs. 2026 Aug;95:104463. doi: 10.1016/j.iccn.2026.104463. Epub 2026 May 30. PMID- 42217208 OWN - NLM STAT- Publisher LR - 20260530 IS - 1873-1953 (Electronic) IS - 1474-5151 (Linking) DP - 2026 May 30 TI - Evaluating the feasibility of a novel multidisciplinary residential rehabilitation program for managing fatigue in patients with spontaneous coronary artery dissection. LID - zvag135 [pii] LID - 10.1093/eurjcn/zvag135 [doi] AB - AIM: This study investigated the feasibility of a novel multidisciplinary residential rehabilitation programme for managing fatigue and psychological consequences in patients with SCAD. METHODS AND RESULTS: A prospective single-arm feasibility study was conducted as the "SCAD, Fatigue, and Everyday Life" programme, a four-day residential intervention, at the Danish Knowledge Centre for Rehabilitation and Palliative Care (REHPA). Fatigue management was addressed through individual and group-based sessions, including energy conservation strategies, nervous system regulating techniques and psychological approaches incorporating value-based, goal-oriented approaches. Feasibility was evaluated using Bowen's framework focusing on demand, acceptability and practicality. Demand was assessed through adherence and attendance rates, acceptability through satisfaction rates and practicality through available resources. Fatigue and psychological associations were assessed using patient reported outcome measures (PROMs): the Modified Fatigue Impact Scale (MFIS), Brief Fatigue Inventory (BFI), Insomnia Severity Index (ISI), the General Anxiety Disorder (GAD-7), Patient Health Questionnaire (PHQ-9) and EQ-5D-5L. Data were collected at baseline and 8 weeks post-intervention. Participant satisfaction was high (median 4.5/5), and completion rate was 78.5%, exceeding the defined threshold of 70%. Modest improvements were observed across PROMs, with small effect sizes and statistically significant changes limited to selected outcomes. CONCLUSION: The rehabilitation programme was found feasible in terms of high participant satisfaction, satisfying attendance and adherence rates. Intervention elements show potential in reducing fatigue and other psychological consequences following SCAD, taking the small sample size and the single-armed design into account. CI - (c) The Author(s) 2026. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com. FAU - Gulstad, Verena Elisabeth AU - Gulstad VE AUID- ORCID: 0009-0003-4518-5299 AD - Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen N, Permanent address: Bornholms Sundheds- og Sygeplejeskole, Minervavej 1, 3700 Ronne, Denmark. FAU - Svendsen, Julie Cecilie AU - Svendsen JC AUID- ORCID: 0009-0001-5080-5080 AD - Department of Cardiology, Copenhagen University Hospital Rigshospitalet, Inge Lehmanns vej 7, 2100 Copenhagen OE. Denmark. FAU - Madsen, Helene Beyer AU - Madsen HB AUID- ORCID: 0009-0007-7093-6639 AD - Department of Cardiology, Odense University Hospital, J.B. Winslows Vej 4, 5000 Odense, Denmark. FAU - Andersen, Dorrit Grosen AU - Andersen DG AUID- ORCID: 0009-0001-6334-4033 AD - Department of Cardiology, University Hospital, Skejby, Palle Juul-Jensens Boulevard 99, 8200 Aarhus N, Denmark. FAU - Wagner, Mette Kirstine AU - Wagner MK AUID- ORCID: 0000-0001-9461-1416 AD - Department of Cardiology, Copenhagen University Hospital Rigshospitalet, Inge Lehmanns vej 7, 2100 Copenhagen OE. Denmark. FAU - Kirk, Bettina Hojberg AU - Kirk BH AUID- ORCID: 0000-0002-4493-8936 AD - Department of Cardiology, Copenhagen University Hospital Rigshospitalet, Inge Lehmanns vej 7, 2100 Copenhagen OE. Denmark. FAU - Larsen, Jane AU - Larsen J AUID- ORCID: 0009-0001-3863-6085 AD - REHPA, The Danish Knowledge Centre for Rehabilitation and Palliative Care, Odense University Hospital, Vestergade 17, 5800 Nyborg, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, Denmark. FAU - Zwisler, Ann-Dorthe AU - Zwisler AD AUID- ORCID: 0000-0002-9241-2090 AD - Clinic for Palliative medicine, Rehabilitation and Patient-centred Care, Department of Oncology, Rigshospitalet, Blegdamsvej 9, 2100 Kobenhavn O, Denmark. AD - Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen N. Denmark. FAU - Palm, Pernille AU - Palm P AUID- ORCID: 0000-0002-8437-5445 AD - Department of Cardiology, Copenhagen University Hospital Rigshospitalet, Inge Lehmanns vej 7, 2100 Copenhagen OE. Denmark. AD - Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen N. Denmark. LA - eng PT - Journal Article DEP - 20260530 PL - England TA - Eur J Cardiovasc Nurs JT - European journal of cardiovascular nursing JID - 101128793 SB - IM OTO - NOTNLM OT - Cardiac rehabilitation OT - Fatigue OT - Feasibility study OT - Patient reported outcomes OT - Spontaneous coronary artery dissection EDAT- 2026/05/31 05:33 MHDA- 2026/05/31 05:33 CRDT- 2026/05/30 13:43 PHST- 2025/10/30 00:00 [received] PHST- 2026/02/23 00:00 [revised] PHST- 2026/05/31 05:33 [medline] PHST- 2026/05/31 05:33 [pubmed] PHST- 2026/05/30 13:43 [entrez] AID - 8698743 [pii] AID - 10.1093/eurjcn/zvag135 [doi] PST - aheadofprint SO - Eur J Cardiovasc Nurs. 2026 May 30:zvag135. doi: 10.1093/eurjcn/zvag135. PMID- 42216601 OWN - NLM STAT- MEDLINE DCOM- 20260717 LR - 20260717 IS - 1759-7390 (Electronic) IS - 1750-8460 (Linking) VI - 87 IP - 5 DP - 2026 May 20 TI - Cardiac Valve Repair and Replacement: Are Transcatheter Options Here to Stay? PG - 54067 LID - 10.31083/BJHM54067 [doi] AB - Valvular heart disease (VHD) affects millions worldwide and remains a major cause of morbidity and mortality, placing a substantial and growing burden on healthcare systems. Over the past two decades, transcatheter therapies have emerged to meet this challenge, transforming the management of aortic, mitral, and tricuspid valve disease. Initially developed for inoperable or high-risk surgical patients, procedures such as transcatheter aortic valve implantation (TAVI) and mitral transcatheter edge-to-edge repair (M-TEER) are now routinely offered across a broader risk spectrum. More recently, tricuspid therapies, including tricuspid transcatheter edge-to-edge repair (T-TEER) and transcatheter valve replacement (TTVR), have emerged to address a significant unmet clinical need. With transcatheter interventions becoming more widely available, clinicians across general and acute medical specialities are increasingly likely to encounter patients before and after these procedures. Familiarity with these therapies will support better decision-making and coordinated care. This review summarises the evolution of transcatheter valve therapy, its role alongside surgery, and the evidence supporting its use. Surgery remains the gold standard for younger or low-risk patients, particularly where long-term durability is essential. Transcatheter therapies now offer safe and effective treatment for older patients, including those with frailty or significant comorbidity, supported by landmark trials, which have demonstrated favourable clinical outcomes in carefully selected populations and underpinned guideline endorsement across risk categories. The importance of the multidisciplinary Heart Team is emphasised, ensuring treatment decisions reflect individual anatomy, comorbidity burden, life expectancy, and procedural risk. As device technology, imaging, and procedural expertise continue to advance, the integration of surgical and transcatheter approaches will support more individualised care and broaden access to definitive treatment for patients across the clinical spectrum. CI - (c) 2026 The Author(s). Published by IMR Press. FAU - Panday, Samuel Rustem AU - Panday SR AD - Department of Cardiology, King's College Hospital, SE5 9RS London, UK. AD - School of Cardiovascular and Metabolic Medicine & Sciences, King's College London, SE5 9RS London, UK. FAU - Nameghi, Fatemeh Habibi AU - Nameghi FH AD - School of Cardiovascular and Metabolic Medicine & Sciences, King's College London, SE5 9RS London, UK. FAU - Giacobbe, Federico AU - Giacobbe F AD - Department of Cardiology, Royal Brompton Hospital, SW3 6NP London, UK. FAU - Eskandari, Mehdi AU - Eskandari M AD - Department of Cardiology, King's College Hospital, SE5 9RS London, UK. AD - School of Cardiovascular and Metabolic Medicine & Sciences, King's College London, SE5 9RS London, UK. FAU - Papachristidis, Alexandros AU - Papachristidis A AD - Department of Cardiology, King's College Hospital, SE5 9RS London, UK. AD - School of Cardiovascular and Metabolic Medicine & Sciences, King's College London, SE5 9RS London, UK. FAU - O'Gallagher, Kevin AU - O'Gallagher K AD - Department of Cardiology, King's College Hospital, SE5 9RS London, UK. AD - School of Cardiovascular and Metabolic Medicine & Sciences, King's College London, SE5 9RS London, UK. FAU - MacCarthy, Philip AU - MacCarthy P AD - Department of Cardiology, King's College Hospital, SE5 9RS London, UK. AD - School of Cardiovascular and Metabolic Medicine & Sciences, King's College London, SE5 9RS London, UK. FAU - Byrne, Jonathan AU - Byrne J AD - Department of Cardiology, King's College Hospital, SE5 9RS London, UK. AD - School of Cardiovascular and Metabolic Medicine & Sciences, King's College London, SE5 9RS London, UK. FAU - Baghai, Max AU - Baghai M AD - Department of Cardiothoracic Surgery, King's College Hospital, SE5 9RS London, UK. LA - eng PT - Journal Article PT - Review PL - Singapore TA - Br J Hosp Med (Lond) JT - British journal of hospital medicine (London, England : 2005) JID - 101257109 SB - IM MH - Humans MH - *Heart Valve Diseases/surgery MH - *Heart Valve Prosthesis Implantation/methods MH - *Transcatheter Aortic Valve Replacement/methods MH - Cardiac Catheterization/methods OTO - NOTNLM OT - cardiac surgical procedures OT - heart valve diseases OT - heart valve prosthesis implantation OT - mitral valve insufficiency OT - transcatheter aortic valve replacement OT - tricuspid valve insufficiency EDAT- 2026/05/30 06:36 MHDA- 2026/05/30 06:37 CRDT- 2026/05/30 04:03 PHST- 2025/08/13 00:00 [received] PHST- 2025/12/30 00:00 [revised] PHST- 2026/01/22 00:00 [accepted] PHST- 2026/05/30 06:37 [medline] PHST- 2026/05/30 06:36 [pubmed] PHST- 2026/05/30 04:03 [entrez] AID - S1750-8460(26)02842-0 [pii] AID - 10.31083/BJHM54067 [doi] PST - ppublish SO - Br J Hosp Med (Lond). 2026 May 20;87(5):54067. doi: 10.31083/BJHM54067. PMID- 42216595 OWN - NLM STAT- MEDLINE DCOM- 20260717 LR - 20260717 IS - 1759-7390 (Electronic) IS - 1750-8460 (Linking) VI - 87 IP - 5 DP - 2026 May 22 TI - The Groin and People Who Inject Drugs-Management and Pitfalls. PG - 54135 LID - 10.31083/BJHM54135 [doi] AB - Globally and within the United Kingdom, there has been an increase in the number of people who inject drugs (PWID). PWID are at increased risk of injection site and systemic infections, which include abscesses, necrotising soft tissue infections, arterial pseudoaneurysms and infective endocarditis. Initial diagnosis and treatment of groin-related complications can be complex and frequently require emergent surgical input while ensuring adequate antimicrobial therapy. The importance of utilising a patient-centred multidisciplinary approach to promote patient engagement, while using each healthcare interaction as an opportunity to mitigate further harm, should not be underestimated. This review will examine acute presentations in PWID and provide a practical approach to diagnosing and managing groin-related complications. It is essential to maintain a high index of suspicion, promptly recognise symptoms, and initiate specific management protocols. CI - (c) 2026 The Author(s). Published by IMR Press. FAU - Jackman, Jamaall AU - Jackman J AD - Department of Vascular Surgery, Queen Elizabeth University Hospital, G51 4TF Glasgow, UK. FAU - Guthrie, Graeme James Kevin AU - Guthrie GJK AD - Department of Vascular Surgery, Ninewells Hospital and Medical School, DD1 9SY Dundee, UK. FAU - Suttie, Stuart Alistair AU - Suttie SA AD - Department of Vascular Surgery, Ninewells Hospital and Medical School, DD1 9SY Dundee, UK. LA - eng PT - Journal Article PT - Review PL - Singapore TA - Br J Hosp Med (Lond) JT - British journal of hospital medicine (London, England : 2005) JID - 101257109 SB - IM MH - Humans MH - *Substance Abuse, Intravenous/complications MH - *Groin MH - Aneurysm, False/therapy/etiology/diagnosis MH - Abscess/therapy/etiology/diagnosis MH - Soft Tissue Infections/therapy/etiology/diagnosis MH - Endocarditis/etiology/therapy/diagnosis OTO - NOTNLM OT - drug users OT - endocarditis OT - groin OT - injecting OT - necrotising OT - pseudoaneurysm OT - thrombophlebitis EDAT- 2026/05/30 06:36 MHDA- 2026/05/30 06:37 CRDT- 2026/05/30 04:03 PHST- 2025/02/22 00:00 [received] PHST- 2025/06/03 00:00 [revised] PHST- 2025/06/11 00:00 [accepted] PHST- 2026/05/30 06:37 [medline] PHST- 2026/05/30 06:36 [pubmed] PHST- 2026/05/30 04:03 [entrez] AID - S1750-8460(26)02878-0 [pii] AID - 10.31083/BJHM54135 [doi] PST - ppublish SO - Br J Hosp Med (Lond). 2026 May 22;87(5):54135. doi: 10.31083/BJHM54135. PMID- 42215395 OWN - NLM STAT- MEDLINE DCOM- 20260720 LR - 20261004 IS - 1532-8422 (Electronic) IS - 1053-0770 (Linking) VI - 40 IP - 8 DP - 2026 Aug TI - The Year in Electrophysiology: Selected Highlights From 2025. PG - 2289-2301 LID - S1053-0770(26)00366-6 [pii] LID - 10.1053/j.jvca.2026.04.044 [doi] AB - This special article represents the eighth installment in an annual Journal of Cardiothoracic and Vascular Anesthesia series highlighting key advances in cardiac electrophysiology relevant to cardiothoracic anesthesiologists. The authors extend their gratitude to Editor-in-Chief Dr. Kaplan, Associate Editor-in-Chief Dr. Augoustides, and the editorial board for the opportunity to contribute to this series. Rapid innovations in electrophysiology continue to reshape perioperative care and expand the anesthesiologist's role. This 2025 update synthesizes developments in atrial fibrillation guidelines across major societies, emerging cardiac implantable electronic device technologies, and evolving evidence in pulsed field ablation, transcatheter left atrial appendage occlusion, and stereotactic arrhythmia radioablation. Advances in wearable technologies and artificial intelligence are also highlighted. Collectively, these developments underscore the anesthesiologist's integral role within the multidisciplinary electrophysiology team. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Poorsattar, Sophia P AU - Poorsattar SP AD - Department of Anesthesiology, David Geffen School of Medicine at UCLA, Los Angeles, CA. FAU - Kumar, Nicolas AU - Kumar N AD - Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, MA. FAU - Vanneman, Matthew W AU - Vanneman MW AD - Department of Anesthesiology, Stanford University School of Medicine, Stanford, CA. FAU - Kinney, Daniel A AU - Kinney DA AD - Department of Anesthesiology, Yale Medical School, New Haven, CT. FAU - Tang, Jonathan AU - Tang J AD - Department of Anesthesiology, Wexner Medical Center, Ohio State University, Columbus, OH. FAU - Jelly, Christina A AU - Jelly CA AD - Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, TN. FAU - Bodmer, Natalie J AU - Bodmer NJ AD - Department of Anesthesiology, Stanford University School of Medicine, Stanford, CA. FAU - Bryant, John AU - Bryant J AD - Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, TN. FAU - Bardia, Amit AU - Bardia A AD - Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, MA. Electronic address: abardia@mgb.org. LA - eng GR - R01 HS029172/HS/AHRQ HHS/United States PT - Introductory Journal Article PT - Research Support, N.I.H., Extramural DEP - 20260501 PL - United States TA - J Cardiothorac Vasc Anesth JT - Journal of cardiothoracic and vascular anesthesia JID - 9110208 SB - IM MH - Humans MH - *Atrial Fibrillation/surgery/physiopathology MH - *Cardiac Electrophysiology/trends MH - Catheter Ablation/trends/methods MH - *Electrophysiologic Techniques, Cardiac/trends/methods MH - Forecasting MH - Left Atrial Appendage Closure OTO - NOTNLM OT - atrial fibrillation OT - conduction system pacing OT - electrophysiology OT - leadless pacemaker COIS- Declaration of competing interest No author has any conflict of interest related to the manuscript. EDAT- 2026/05/30 00:33 MHDA- 2026/07/21 00:35 CRDT- 2026/05/29 21:58 PHST- 2026/04/23 00:00 [received] PHST- 2026/04/27 00:00 [accepted] PHST- 2026/07/21 00:35 [medline] PHST- 2026/05/30 00:33 [pubmed] PHST- 2026/05/29 21:58 [entrez] AID - S1053-0770(26)00366-6 [pii] AID - 10.1053/j.jvca.2026.04.044 [doi] PST - ppublish SO - J Cardiothorac Vasc Anesth. 2026 Aug;40(8):2289-2301. doi: 10.1053/j.jvca.2026.04.044. Epub 2026 May 1. PMID- 42212184 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260529 LR - 20260813 IS - 2949-9232 (Electronic) IS - 2949-9232 (Linking) VI - 4 DP - 2026 TI - No patient left behind: Developing an interdisciplinary transition clinic for young adult patients with congenital heart disease. PG - 100140 LID - 10.1016/j.hctj.2026.100140 [doi] LID - 100140 AB - BACKGROUND: Advances in pediatric cardiology care have improved survival rates among children with congenital heart disease (CHD), resulting in a growing number of adults with CHD (ACHD). Many of these individuals encounter difficulty maintaining cardiac follow-up as they transfer into adult care. Transition clinics have emerged to support continuity of care, though best practices for their design remain unclear, and implementation varies widely across institutions. OBJECTIVE: This article describes the development and implementation of an interdisciplinary Cardiology Transition Clinic at an academic medical center, detailing replicable processes, highlighting challenges and successes, and reviewing implications for models of care. RESULTS: Collaboration amongst the Divisions of Adult and Pediatric Cardiology, as well as Departments of Psychology and Social Work, led to the development of a monthly Transition Clinic at the Pediatric Heart Center (PHC). Our clinical model and standardized intake forms, used to assess patients' transition readiness, psychosocial needs, and potential transition barriers, evolved from literature review and interdisciplinary planning. Patient transition visits include assessments from an ACHD cardiologist and a pediatric psychologist. Clear communication between clinicians and medical staff has proven vital to maintaining a smooth transition and transfer process. CONCLUSIONS: PHC's Transition Clinic offers a structured, interdisciplinary approach to assessing readiness and addressing barriers to the transfer to adult cardiac care. Our model of transition services may contribute to the further development of standardized, evidence-based approaches, helping to navigate this critical stage in patient care across institutions. CI - (c) 2026 The Authors. FAU - Shah, Khadija AU - Shah K AD - University of Maryland School of Medicine, Baltimore, MD, USA. FAU - Klaver, Samantha J AU - Klaver SJ AD - Harvard University School of Medicine, Boston, MA, USA. FAU - Ford, Sara R AU - Ford SR AD - Division of Pediatric Cardiology, Hasbro Children's, Providence, RI, USA. AD - Department of Pediatrics, Warren Alpert Medical School at Brown University, Providence, RI, USA. FAU - McLaughlin, Suzanne AU - McLaughlin S AD - Department of Pediatrics, Warren Alpert Medical School at Brown University, Providence, RI, USA. AD - Division of Medicine and Pediatrics, Rhode Island Hospital & Hasbro Children's, Providence, RI, USA. FAU - Spates, Toi AU - Spates T AD - Division of Pediatric Cardiology, Hasbro Children's, Providence, RI, USA. AD - Division of Adult Cardiology and Adult Congenital Cardiology, Providence, RI, USA. AD - Department of Medicine, Warren Alpert Medical School at Brown University, Providence, RI, USA. FAU - Jandasek, Barbara AU - Jandasek B AD - Department of Pediatrics, Warren Alpert Medical School at Brown University, Providence, RI, USA. AD - Department of Child and Family Psychiatry, Hasbro Children's, Providence, RI, USA. AD - Department of Psychiatry and Human Behavior, Warren Alpert Medical School at Brown University, Providence, RI, USA. FAU - Waycuilis, Marisa AU - Waycuilis M AD - Division of Pediatric Cardiology, Hasbro Children's, Providence, RI, USA. FAU - Anderson, Janet AU - Anderson J AD - Division of Pediatric Cardiology, Hasbro Children's, Providence, RI, USA. AD - Department of Child and Family Psychiatry, Hasbro Children's, Providence, RI, USA. AD - Department of Psychiatry and Human Behavior, Warren Alpert Medical School at Brown University, Providence, RI, USA. LA - eng PT - Journal Article DEP - 20260520 PL - United States TA - Health Care Transit JT - Health care transitions JID - 9918842988406676 PMC - PMC13213634 OTO - NOTNLM OT - Adolescent health services OT - Clinical psychology OT - Congenital heart disease OT - Healthcare transitions OT - Multi-disciplinary clinic OT - Psychosocial assessment OT - Transition readiness COIS- The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/05/29 15:45 MHDA- 2026/05/29 15:46 PMCR- 2026/05/20 CRDT- 2026/05/29 04:57 PHST- 2025/08/15 00:00 [received] PHST- 2026/05/09 00:00 [revised] PHST- 2026/05/09 00:00 [accepted] PHST- 2026/05/29 15:46 [medline] PHST- 2026/05/29 15:45 [pubmed] PHST- 2026/05/29 04:57 [entrez] PHST- 2026/05/20 00:00 [pmc-release] AID - S2949-9232(26)00013-9 [pii] AID - 100140 [pii] AID - 10.1016/j.hctj.2026.100140 [doi] PST - epublish SO - Health Care Transit. 2026 May 20;4:100140. doi: 10.1016/j.hctj.2026.100140. eCollection 2026. PMID- 42209870 OWN - NLM STAT- MEDLINE DCOM- 20260717 LR - 20261010 IS - 1573-7322 (Electronic) IS - 1382-4147 (Linking) VI - 31 IP - 1 DP - 2026 May 29 TI - State-of-the-art management of ischemic cardiomyopathy: integrating diagnostic pathways, revascularization strategies, and guideline-directed therapy. LID - 69 [pii] LID - 10.1007/s10741-026-10640-4 [doi] AB - Ischemic cardiomyopathy (ICM) is a major cause of cardiovascular morbidity and mortality, characterized by a complex pathophysiological substrate and heterogeneous clinical trajectories. Despite decades of investigation, its diagnosis and management remain challenging, particularly regarding the role of coronary revascularization in addition to optimal medical therapy. Recent advances in pharmacotherapy, device-based interventions, and percutaneous techniques have expanded treatment options, but important evidence gaps persist. This state-of-the-art review critically appraises the contemporary diagnosis and management of ICM. Particular emphasis is placed on the integration of multimodality non-invasive imaging into clinical decision-making, the reinterpretation of myocardial viability and revascularization in light of recent randomized evidence, and the interface between chronic coronary syndrome guidance and heart failure with reduced ejection fraction care in patients with ischemic LV dysfunction. By integrating these domains, the review supports a management approach in which guideline-directed medical and device therapy remain foundational, whereas revascularization is individualized according to myocardial substrate, coronary anatomy, symptoms, comorbidities, procedural risk, and multidisciplinary Heart Team assessment. CI - (c) 2026. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Busti, Matteo AU - Busti M AD - CHRU de Nancy, Centre d'Investigation Clinique Plurithematique 1433, INSERM, Universite de Lorraine, INSERM U1116 - DCAC, and F-CRIN INI- CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France. AD - Catholic University of the Sacred Heart, Rome, Italy. FAU - Melenovsky, Vojtech AU - Melenovsky V AD - Institute for Clinical and Experimental Medicine, Prague, Czech Republic. FAU - Savarese, Gianluigi AU - Savarese G AD - Department of Clinical Science and Education, Sodersjukhuset, Karolinska Institutet, Stockholm, Sweden. FAU - Chioncel, Ovidiu AU - Chioncel O AD - Emergency Institute for Cardiovascular Diseases 'Prof. C.C. Iliescu', Bucharest, Romania. AD - University of Medicine Carol Davila, Bucharest, Romania. FAU - Colli, Andrea AU - Colli A AD - Cardiac Surgery Unit, Department of Surgical, Medical and Molecular Pathology and Critical Care, University of Pisa, Pisa, Italy. FAU - Ambrosy, Andrew P AU - Ambrosy AP AD - Department of Cardiology, Kaiser Permanente Medical Centre, San Francisco, CA, USA. AD - Division of Research, Kaiser Permanente Northern California, Pleasanton, CA, USA. FAU - Crea, Filippo AU - Crea F AD - Catholic University of the Sacred Heart, Rome, Italy. AD - Center of Excellence of Cardiovascular Sciences, Ospedale Isola Tiberina - Gemelli Isola, Rome, Italy. FAU - Girerd, Nicolas AU - Girerd N AD - CHRU de Nancy, Centre d'Investigation Clinique Plurithematique 1433, INSERM, Universite de Lorraine, INSERM U1116 - DCAC, and F-CRIN INI- CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France. FAU - Monzo, Luca AU - Monzo L AD - CHRU de Nancy, Centre d'Investigation Clinique Plurithematique 1433, INSERM, Universite de Lorraine, INSERM U1116 - DCAC, and F-CRIN INI- CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France. l.monzo@tiscali.it. LA - eng PT - Journal Article PT - Review DEP - 20260529 PL - United States TA - Heart Fail Rev JT - Heart failure reviews JID - 9612481 SB - IM MH - Humans MH - *Myocardial Ischemia/diagnosis/therapy/complications MH - *Myocardial Revascularization/methods MH - *Cardiomyopathies/therapy/diagnosis/etiology MH - *Practice Guidelines as Topic MH - *Disease Management MH - Stroke Volume/physiology OTO - NOTNLM OT - Coronary artery diseases OT - Guideline-directed medical therapy OT - Heart failure OT - Ischemic cardiomyopathy OT - Myocardial revascularization COIS- Declarations. Human ethics and consent to participate: Not applicable. Competing interests: V. M. serves as consultant for Bayer, Novo Nordisk, Boehringer-Ingelheim, Abbott and receives grant support from Regeneron. G.S. reports grants and personal fees from CSL Vifor, Boehringer Ingelheim, AstraZeneca, Servier, Novartis, Cytokinetics, Pharmacosmos, Medtronic, Bayer, and personal fees from Roche, Abbott, Edwards Lifescience, TEVA, Menarini, INTAS, GETZ, Hikma, Laboratori Guidotti, and grants from Boston Scientific, Merck. O.C. reports speaker fee from ELLY LILY and grant from Boehringer Ingelheim. A.P.A. has received relevant research support through grants from the NIH (R01HL173866 and R01AG091005), the FDA (U01FD008704), the AHA, The Permanente Medical Group, Kaiser Permanente Northern California Community Health Programs, Garfield Memorial Fund, Abbott Laboratories, Abiomed, Amarin Pharma, Inc., Bayer Pharma AG, Boehringer Ingelheim, Cordio Medical, Edwards Lifesciences LLC, Esperion Therapeutics, Inc., Merck, and Novartis. Consulting for Bristol Meyer Squibb, Bayer Pharma AG, Corstasis, Merck, Novo Nordisk, Pharmacosmos A/S, Pfizer, scPharma, SQ Innovation, Reprieve Cardiovascular, and VisCardia. N.G. reports honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, Lilly, Novartis, NovoNordisk, Roche Diagnostics, NP Medical and Echosens. L.M. has received a travel grant from Boehringer Ingelheim. All conflicts of interest have been declared outside the present work. EDAT- 2026/05/29 15:45 MHDA- 2026/05/29 15:46 CRDT- 2026/05/28 23:32 PHST- 2026/03/20 00:00 [received] PHST- 2026/05/19 00:00 [accepted] PHST- 2026/04/27 00:00 [revised] PHST- 2026/05/29 15:46 [medline] PHST- 2026/05/29 15:45 [pubmed] PHST- 2026/05/28 23:32 [entrez] AID - 10.1007/s10741-026-10640-4 [pii] AID - 10.1007/s10741-026-10640-4 [doi] PST - epublish SO - Heart Fail Rev. 2026 May 29;31(1):69. doi: 10.1007/s10741-026-10640-4. PMID- 42209073 OWN - NLM STAT- MEDLINE DCOM- 20260717 LR - 20260717 IS - 2211-7466 (Electronic) IS - 2211-7458 (Linking) VI - 15 IP - 3 DP - 2026 Jul TI - Systems of Care in Cardiogenic Shock: Team-Based Management, Shock Networks, and Post Discharge Pathways. PG - 421-433 LID - S2211-7458(26)00022-2 [pii] LID - 10.1016/j.iccl.2026.03.009 [doi] AB - Cardiogenic shock (CS) remains the leading cause of mortality in modern cardiac intensive care unit, most often precipitated by acute or chronically decompensated heart failure or acute myocardial infarction. Despite technologic advances, timely recognition and effective management of CS remain challenging and demand a coordinated, patient-centered and multidisciplinary approach. In this review, we examine the spectrum of stabilizing measures, define the structure and operational workflows of team-based models in hub-and-spoke networks, explore key feasibility barriers, and we further highlight emerging innovations including artificial intelligence-enabled decision support, mobile extracorporeal membrane oxygenation retrieval, telemedicine, and biomarker-guided phenotyping. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Jamil, Yasser AU - Jamil Y AD - Inova Center of Outcomes Research, Falls Church, VA 22042, USA. FAU - Nguyen, Andrew H AU - Nguyen AH AD - Inova Center of Outcomes Research, Falls Church, VA 22042, USA. FAU - Vavilin, Ilan AU - Vavilin I AD - Inova Center of Outcomes Research, Falls Church, VA 22042, USA. FAU - Tehrani, Behnam N AU - Tehrani BN AD - Inova Center of Outcomes Research, Falls Church, VA 22042, USA; Inova Schar Heart and Vascular, Falls Church, VA 22042, USA. Electronic address: behnam.tehrani@inova.org. LA - eng PT - Journal Article PT - Review DEP - 20260429 PL - Netherlands TA - Interv Cardiol Clin JT - Interventional cardiology clinics JID - 101615153 SB - IM MH - Humans MH - *Shock, Cardiogenic/therapy MH - *Patient Care Team/organization & administration MH - Extracorporeal Membrane Oxygenation/methods MH - *Patient Discharge OTO - NOTNLM OT - Cardiogenic shock OT - Mechanical circulatory support OT - Shock team OT - Spoke-hub network OT - Temporary MCS COIS- Disclosure All authors have nothing to disclose. EDAT- 2026/05/29 15:44 MHDA- 2026/05/29 15:45 CRDT- 2026/05/28 20:55 PHST- 2026/05/29 15:45 [medline] PHST- 2026/05/29 15:44 [pubmed] PHST- 2026/05/28 20:55 [entrez] AID - S2211-7458(26)00022-2 [pii] AID - 10.1016/j.iccl.2026.03.009 [doi] PST - ppublish SO - Interv Cardiol Clin. 2026 Jul;15(3):421-433. doi: 10.1016/j.iccl.2026.03.009. Epub 2026 Apr 29. PMID- 42209072 OWN - NLM STAT- MEDLINE DCOM- 20260717 LR - 20260717 IS - 2211-7466 (Electronic) IS - 2211-7458 (Linking) VI - 15 IP - 3 DP - 2026 Jul TI - Cardiogenic Shock Protocols and Teams. PG - 413-419 LID - S2211-7458(26)00021-0 [pii] LID - 10.1016/j.iccl.2026.03.008 [doi] AB - Over the last decade, care for cardiogenic shock has evolved from early recognition to timely mechanical support and escalation. A central driver of improvements has been the adoption of best-practice protocols and the formation of dedicated shock teams. Recent studies show that protocolized care improves outcomes by enabling rapid identification of patients at risk of deterioration, delivering appropriate support, revascularization with or without mechanical support, and ensuring swift transfer to a tertiary center when escalation is necessary. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Lemor, Alejandro AU - Lemor A AD - Division of Cardiology, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216, USA. Electronic address: alejandrolemor@hotmail.com. FAU - Hernandez, Gabriel A AU - Hernandez GA AD - Division of Cardiology, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216, USA. LA - eng PT - Journal Article PT - Review DEP - 20260422 PL - Netherlands TA - Interv Cardiol Clin JT - Interventional cardiology clinics JID - 101615153 SB - IM MH - Humans MH - *Shock, Cardiogenic/therapy/etiology MH - *Patient Care Team MH - *Clinical Protocols OTO - NOTNLM OT - Cardiogenic shock OT - Infarction-related cardiogenic shock OT - Mechanical support OT - ST-Elevation myocardial infarction OT - Shock protocols OT - Shock team COIS- Disclosures Both authors have nothing to disclose. EDAT- 2026/05/29 15:41 MHDA- 2026/05/29 15:42 CRDT- 2026/05/28 20:55 PHST- 2026/05/29 15:42 [medline] PHST- 2026/05/29 15:41 [pubmed] PHST- 2026/05/28 20:55 [entrez] AID - S2211-7458(26)00021-0 [pii] AID - 10.1016/j.iccl.2026.03.008 [doi] PST - ppublish SO - Interv Cardiol Clin. 2026 Jul;15(3):413-419. doi: 10.1016/j.iccl.2026.03.008. Epub 2026 Apr 22. PMID- 42209070 OWN - NLM STAT- MEDLINE DCOM- 20260717 LR - 20260717 IS - 2211-7466 (Electronic) IS - 2211-7458 (Linking) VI - 15 IP - 3 DP - 2026 Jul TI - The Role of Mechanical Circulatory Support Devices in Pulmonary Embolism: A Comprehensive Review. PG - 387-400 LID - S2211-7458(26)00019-2 [pii] LID - 10.1016/j.iccl.2026.03.006 [doi] AB - Pulmonary embolism (PE) remains a leading cause of cardiovascular mortality, particularly in its high-risk and intermediate-high risk presentations where acute right ventricular (RV) failure is the primary driver of hemodynamic collapse. This review comprehensively examines the pathophysiology of RV failure in PE, their indications based on current evidence and guidelines, practical considerations for implementation, management strategies, complications, and integration with other therapeutic modalities. We also highlight the crucial role of a multidisciplinary team and discuss future directions in this rapidly evolving field. Emphasis is placed on practical application for the interventional cardiologist. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Jabri, Ahmad AU - Jabri A AD - Department of Cardiovascular Medicine, William Beaumont University Hospital, Royal Oak, MI, USA. Electronic address: ahmad.jabri@corewellhealth.org. FAU - Nasser, Mohamed Farhan AU - Nasser MF AD - Heart and Vascular Center, Case Western Reserve University/MetroHealth Medical Center, Cleveland, OH, USA. FAU - Fang, Jonathan X AU - Fang JX AD - Division of Cardiovascular Medicine, Henry Ford Hospital, Detroit, MI, USA. FAU - Villablanca, Pedro AU - Villablanca P AD - Division of Cardiovascular Medicine, Henry Ford Hospital, Detroit, MI, USA. FAU - Kado, Herman Simon AU - Kado HS AD - Department of Cardiovascular Medicine, William Beaumont University Hospital, Royal Oak, MI, USA. FAU - Aggarwal, Vikas AU - Aggarwal V AD - Division of Cardiovascular Medicine, Henry Ford Hospital, Detroit, MI, USA. LA - eng PT - Journal Article PT - Review DEP - 20260429 PL - Netherlands TA - Interv Cardiol Clin JT - Interventional cardiology clinics JID - 101615153 SB - IM MH - Humans MH - *Pulmonary Embolism/therapy/complications/physiopathology MH - *Extracorporeal Membrane Oxygenation/methods/instrumentation MH - *Ventricular Dysfunction, Right/etiology/physiopathology/therapy MH - *Heart-Assist Devices MH - *Heart Failure/etiology/therapy/physiopathology MH - *Shock, Cardiogenic/therapy/etiology OTO - NOTNLM OT - Cardiogenic shock OT - Catheter-directed therapy OT - ECMO OT - ProtekDuo OT - Pulmonary embolism OT - Right ventricular failure OT - TandemHeart OT - VA-ECMO EDAT- 2026/05/29 15:44 MHDA- 2026/05/29 15:45 CRDT- 2026/05/28 20:55 PHST- 2026/05/29 15:45 [medline] PHST- 2026/05/29 15:44 [pubmed] PHST- 2026/05/28 20:55 [entrez] AID - S2211-7458(26)00019-2 [pii] AID - 10.1016/j.iccl.2026.03.006 [doi] PST - ppublish SO - Interv Cardiol Clin. 2026 Jul;15(3):387-400. doi: 10.1016/j.iccl.2026.03.006. Epub 2026 Apr 29. PMID- 42209065 OWN - NLM STAT- MEDLINE DCOM- 20260717 LR - 20260813 IS - 2211-7466 (Electronic) IS - 2211-7458 (Linking) VI - 15 IP - 3 DP - 2026 Jul TI - The Role of Mechanical Circulatory Support in Acute Myocardial Infarction Complicated by Cardiogenic Shock-Part 1: Pathophysiology and Current Evidence. PG - 319-329 LID - S2211-7458(26)00014-3 [pii] LID - 10.1016/j.iccl.2026.03.001 [doi] AB - Acute myocardial infarction complicated by cardiogenic shock (AMI-CS) carries high mortality despite improvement in contemporary revascularization. The pathophysiology is complex, involving impaired left ventricular function, systemic inflammation, metabolic derangements, and mechanical complications, which often progress to multiorgan failure. Mechanical circulatory support (MCS) devices provide temporary hemodynamic stabilization by unloading the left ventricle and maintaining systemic perfusion, but their role remains debated. Landmark trials have shown no mortality benefit with MCS. This review summarizes the evolving evidence, guideline updates, and practical considerations for MCS use in AMI-CS, emphasizing the importance of patient selection, timing, and multidisciplinary management in optimizing outcomes. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Patail, Haris AU - Patail H AD - Department of Cardiology, Westchester Medical Center, New York Medical College, Valhalla, NY, USA. Electronic address: https://twitter.com/harispatail. FAU - Sharma, Tanya AU - Sharma T AD - Interventional Cardiology, Department of Interventional Cardiology, Lennox Hill Hospital, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hofstra University, Hempstead, NY, USA. Electronic address: https://twitter.com/TanyaSh112. FAU - Chand, Swati AU - Chand S AD - Department of Cardiology, Westchester Medical Center, New York Medical College, Valhalla, NY, USA. Electronic address: https://twitter.com/SwatiChand_. FAU - Radwan, Yasser AU - Radwan Y AD - Department of Cardiology, Westchester Medical Center, New York Medical College, Valhalla, NY, USA. Electronic address: https://twitter.com/YasserRadwan_. FAU - Naidu, Srihari S AU - Naidu SS AD - Department of Cardiology, Westchester Medical Center, New York Medical College, Valhalla, NY, USA; Department of Interventional Cardiology, Westchester Medical Center, New York Medical College, Valhalla, NY, USA. Electronic address: srihari.naidu@wmchealth.org. LA - eng PT - Journal Article PT - Review DEP - 20260420 PL - Netherlands TA - Interv Cardiol Clin JT - Interventional cardiology clinics JID - 101615153 SB - IM MH - Humans MH - *Extracorporeal Membrane Oxygenation/instrumentation/methods/standards MH - Heart Ventricles/physiopathology MH - *Heart-Assist Devices/standards MH - Hemodynamics/physiology MH - *Myocardial Infarction/complications/physiopathology/therapy MH - Patient Care Team MH - Patient Selection MH - Practice Guidelines as Topic MH - *Shock, Cardiogenic/etiology/physiopathology/therapy MH - Ventricular Function, Left/physiology MH - Treatment Outcome OTO - NOTNLM OT - Acute myocardial infarction OT - Cardiogenic shock OT - Mechanical circulatory support COIS- Disclosure None. EDAT- 2026/05/29 15:42 MHDA- 2026/05/29 15:43 CRDT- 2026/05/28 20:55 PHST- 2026/05/29 15:43 [medline] PHST- 2026/05/29 15:42 [pubmed] PHST- 2026/05/28 20:55 [entrez] AID - S2211-7458(26)00014-3 [pii] AID - 10.1016/j.iccl.2026.03.001 [doi] PST - ppublish SO - Interv Cardiol Clin. 2026 Jul;15(3):319-329. doi: 10.1016/j.iccl.2026.03.001. Epub 2026 Apr 20. PMID- 42207983 OWN - NLM STAT- Publisher LR - 20260528 IS - 2047-4881 (Electronic) IS - 2047-4873 (Linking) DP - 2026 May 28 TI - Staffing, Accepted Indications and Dose of Phase II Cardiac Rehabilitation: Country Income Class and Time-Based Comparisons from the International Council of Cardiovascular Prevention and Rehabilitation's (ICCPR) 2025 Audit Update. LID - zwag292 [pii] LID - 10.1093/eurjpc/zwag292 [doi] AB - AIMS: To characterize global variation in cardiac rehabilitation (CR) staffing, indications, and prescribed dose by country income classification, and compare findings with the International Council of Cardiovascular Prevention and Rehabilitation's (ICCPR) 2016 Global Audit. METHODS: Cross-sectional REDCap survey of phase II/post-discharge CR programs (May-September 2025). Outcomes were multidisciplinary team size/composition, accepted cardiac and non-cardiac indications, and centre-based CR dose. Comparisons were made across World Bank country income classifications and Audit decade (2016 vs 2025). RESULTS: Of 7,025 programs identified globally, 1,505 (median program response rate=62%/country) initiated a survey, from 90/113 (80%) countries with CR. CR was delivered by a multidisciplinary team of 7 (median; P25-P75=5-8; nurses, physiotherapists, cardiologists, and dietitians most common); teams were smaller in low-income countries (median=4; p<0.001), and physician specialty varied. Non-low-income programs consistently accepted (>/=90%) patients with acute coronary syndrome, with programs in low-income countries less often accepting related interventions (e.g., surgery: low-income 0% vs high-income 97%; p<0.01), but non-cardiac indications were more frequently accepted (e.g., primary prevention, diabetes, lung disease). Acceptance of heart failure increased compared with the previous Audit (70% vs 87%; p<0.001). Centre-based programs prescribed a median of 20 hours (P25-P75=12-30), typically two sessions/week over eight weeks. Globally, 65 (72%) countries prescribed a median >/=12 sessions/program. Programs in upper-middle-income countries prescribed more sessions (median=24, P25-P75=12-36; p<0.001). Dose did not differ meaningfully between Audits (p=0.07). CONCLUSION: CR programs globally are offered by small, but multidisciplinary teams. They accept guideline-indicated patients, with applicable variation by context. Insufficient dose in one-quarter of countries underscores investment need. CI - (c) The Author(s) 2026. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com. FAU - Ghisi, Gabriela L M AU - Ghisi GLM AUID- ORCID: 0000-0001-7946-3718 AD - KITE Research Institute, University Health Network, Toronto, Canada. Department of Physical Therapy, University of Toronto, Toronto, Canada. FAU - Turk-Adawi, Karam AU - Turk-Adawi K AUID- ORCID: 0000-0002-4162-7761 AD - Department of Public Health, College of Health Science, QU Health, Qatar University, Doha, Qatar. FAU - Mampuya, Warner M AU - Mampuya WM AUID- ORCID: 0000-0003-0994-932X AD - Department of Medicine, Faculty of Medicine and Health Sciences, Universite de Sherbrooke, Sherbrooke, Canada. FAU - Jiandani, Mariya P AU - Jiandani MP AUID- ORCID: 0000-0002-9884-8055 AD - Department of Physical Therapy, Seth GS Medical College and KEM Hospital, Mumbai, India. FAU - Mbau, Lilian AU - Mbau L AUID- ORCID: 0000-0003-2086-4562 AD - Cardiac Rehabilitation, Centre for Cardiovascular Prevention and Rehabilitation, Nairobi, Kenya. FAU - Cruz Rivero, Monserrat AU - Cruz Rivero M AUID- ORCID: 0009-0004-2319-1150 AD - CRFC. Casa Corazon Otoch Puksikal, Merida, Mexico. FAU - Anchique, Claudia V AU - Anchique CV AUID- ORCID: 0000-0001-8649-7289 AD - Mediagnostica Tecmedi SAS, Duitama, Colombia. FAU - Ding, Rongjing AU - Ding R AD - Cardiac Rehabilitation Center, Peking Union Medical College Hospital, Beijing, China. FAU - van Schalkwijk, Dinah L AU - van Schalkwijk DL AD - Department of Cardiology, Radboud University Medical Center, Nijmegen, The Netherlands, Department of Medical and Clinical Psychology, Tilburg University, Tilburg, The Netherlands. FAU - Gallagher, Jonathan AU - Gallagher J AUID- ORCID: 0000-0002-2342-8013 AD - Department of Cardiology (Cardiac Rehabilitation), Beaumont Hospital, Dublin, Ireland. FAU - Mettananda, Chamila AU - Mettananda C AD - Department of Pharmacology, University of Kelaniya, Faculty of Medicine, Ragama, Sri Lanka. FAU - Fernandez, Rosalia AU - Fernandez R AD - Cardiac Rehabilitation, National Cardiovascular Institute - INCOR, Lima, Peru. San Fernando Medical School, National University of San Marcos, Lima, Peru. FAU - Gaye, Ngone Diaba AU - Gaye ND AUID- ORCID: 0000-0002-4758-9225 AD - Cardiac Rehabilitation, Ibra Mamadou Wane Medical Center, Dakar, Senegal. FAU - Kim, Won-Seok AU - Kim WS AUID- ORCID: 0000-0002-1199-5707 AD - Department of Rehabilitation Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam-si, South Korea. Gyeonggi Regional Cardiocerebrovascular Disease Center, Seoul National University Bundang Hospital, Seongnam-si, South Korea. FAU - Seron, Pamela AU - Seron P AUID- ORCID: 0000-0003-0190-8988 AD - Department of Rehabilitation Sciences, University of La Frontera, Temuco, Chile. FAU - Maskhulia, Lela AU - Maskhulia L AUID- ORCID: 0000-0002-8893-374X AD - Physical Medicine, Tbilisi State Medical University, Tbilisi, Georgia. FAU - Batalik, Ladislav AU - Batalik L AUID- ORCID: 0000-0003-2147-1541 AD - Department of Rehabilitation, University Hospital Brno, Brno, Czech Republic; Rehabilitation Clinic, Faculty of Medicine, Masaryk University, Brno, Czech Republic. FAU - Martinez, Jimena AU - Martinez J AD - Instituto Medico DAMIC, Cordoba, Argentina. FAU - Chen, Ssu-Yuan AU - Chen SY AUID- ORCID: 0000-0002-8025-6211 AD - Cardiovascular and Pulmonary Rehabilitation Center and Division of Physical Medicine & Rehabilitation, Fu Jen Catholic University Hospital, New Taipei City, Taiwan. Department of Physical Medicine and Rehabilitation, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan. FAU - Supervia, Marta AU - Supervia M AD - Department of Physical Medicine and Rehabilitation, Gregorio Maranon General University Hospital, Gregorio Maranon Health Research Institute, Madrid, Spain. Radiology, Rehabilitation and Physiotherapy Department, Complutense University School of Medicine, Madrid, Spain. Division of Preventive Cardiology, Department of Cardiovascular Medicine, Mayo Clinic, Rochester, USA. FAU - Botha, Noel V Hau AU - Botha NVH AD - PT. Kamuzu Central Hospital, Lilongwe, Malawi. FAU - Champaiboon, Jirapa AU - Champaiboon J AUID- ORCID: 0000-0001-5901-5619 AD - Department of Rehabilitation Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. FAU - Yokoyama, Miho AU - Yokoyama M AD - Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan. FAU - Grace, Sherry L AU - Grace SL AUID- ORCID: 0000-0001-7063-3610 AD - CRFC. Faculty of Health, York University, Toronto, Canada. KITE - Toronto Rehab & Peter Munk Cardiac Centre, University Health Network, University of Toronto, Toronto, Canada. CN - ICCPR Global Cardiac Rehabilitation Audit Update Investigators LA - eng PT - Journal Article DEP - 20260528 PL - England TA - Eur J Prev Cardiol JT - European journal of preventive cardiology JID - 101564430 SB - IM OAB - On average, cardiac rehabilitation programs had seven staff members, commonly nurses, physiotherapists, cardiologists and dietitians.Most cardiac rehabilitation programs treat patients with heart attacks, stents and heart surgery, with some expected differences among programs in patient types by resource context.In about one-quarter of countries, programs prescribe fewer than the recommended minimum number of rehabilitation sessions, highlighting a need for greater resourcing. OABL- eng OTO - NOTNLM OT - cardiac rehabilitation; exercise OT - global health OT - health services OT - physical OT - secondary prevention FIR - Akinci, Buket IR - Akinci B FIR - Carson, Rachael P IR - Carson RP FIR - Candelaria, Dion IR - Candelaria D FIR - Quesada-Chaves, Daniel F IR - Quesada-Chaves DF FIR - Norekval, Tone M IR - Norekval TM FIR - Szadkowska, Iwona IR - Szadkowska I FIR - Jug, Borut IR - Jug B FIR - Kouidi, Evangelia IR - Kouidi E FIR - Aimakova, Gulsim T IR - Aimakova GT FIR - Radi, Basuni IR - Radi B FIR - Quito, Benjamin Jose IR - Quito BJ EDAT- 2026/05/29 15:41 MHDA- 2026/05/29 15:41 CRDT- 2026/05/28 15:43 PHST- 2026/02/02 00:00 [received] PHST- 2026/04/02 00:00 [revised] PHST- 2026/05/29 15:41 [medline] PHST- 2026/05/29 15:41 [pubmed] PHST- 2026/05/28 15:43 [entrez] AID - 8697559 [pii] AID - 10.1093/eurjpc/zwag292 [doi] PST - aheadofprint SO - Eur J Prev Cardiol. 2026 May 28:zwag292. doi: 10.1093/eurjpc/zwag292. PMID- 42207591 OWN - NLM STAT- MEDLINE DCOM- 20260717 LR - 20260717 IS - 1538-8646 (Electronic) IS - 0730-4625 (Linking) VI - 45 IP - 4 DP - 2026 Jul-Aug 01 TI - Identifying Early Predictive Factors of Unexpected Clinical Deterioration in Postoperative Pediatric Surgical Patients. PG - 176-180 LID - 10.1097/DCC.0000000000000774 [doi] AB - BACKGROUND: Postoperative patients are at a higher risk for unexpected clinical changes in the immediate postoperative period that may necessitate escalation of care. OBJECTIVE: The study aimed to identify the characteristics, triggers, potential risk factors, and outcomes associated with clinical deterioration necessitating rapid response (RR) activation in post-surgical patients. METHODS: A 5-year retrospective review was performed at a large tertiary academic hospital of clinical characteristics and outcomes of postoperative pediatric surgical patients admitted to the ward who had a RR within 30 days after surgery. The study utilized the National Surgical Quality Improvement Program (NSQUIP) calculator as a predictor tool to compare individual patients' risk to the average population risk. RESULTS: Of the 435 surgical patients, the predominant reasons for RR activation were: multisystem 136 (34.1%) and respiratory 114 (28.6%). Two hundred thirty-eight (55.7%) were elective cases, and the most common surgical category was otolaryngology, 55 (12.8%). Patient comorbidities included: developmental delay (135, 31.5%) and cardiac anomalies (102, 23.8%). After RR, transfer to the PICU occurred in 248 events (57%); 63.7% (158) required intravenous fluid therapy, 19.8% (47) required mechanical ventilation within 24 hours, and 46 (12.3%) underwent reoperation. The median PICU length of stay (LOS) was 2 days (IQR: 0.0, 7.0), and mortality of 23 (5.9%). This patient cohort had a higher NSQUIP risk for any complications, pneumonia, surgical site infection, venous thrombosis, renal failure, and reintubation versus the average population risk. CONCLUSIONS: Postoperative RR activation with PICU transfer is associated with longer LOS, higher rate of reoperation, and higher mortality. The NSQUIP predictor tool should be explored further to guide postoperative clinical management and resource allocation for future surgical patients. CI - Copyright (c) 2026 Wolters Kluwer Health, Inc. All rights reserved. FAU - Thomas, Jenilea K AU - Thomas JK AD - Baylor University LHSON/St. Luke's Children's Hospital, Dallas, TX. FAU - Bavare, Aarti C AU - Bavare AC AD - Texas Children's Hospital/Baylor College of Medicine, Houston, TX. FAU - Guyton, Brandi AU - Guyton B AD - University of Michigan/CS Mott Children's Hospital, Ann Arbor, MI. FAU - Justus, Caitlin AU - Justus C AD - HCA Healthcare, Houston, TX. FAU - Vogel, Adam M AU - Vogel AM AD - Texas Children's Hospital/Baylor College of Medicine, Houston, TX. FAU - Guffey, Danielle AU - Guffey D AUID- ORCID: 0000-0003-3721-614 AD - Department of Pediatrics, Baylor College of Medicine, Houston, TX. FAU - Kritz, Erin AU - Kritz E AUID- ORCID: 0000-0003-2131-8416 AD - Rapid Response System, Texas Children's Hospital/Baylor College of Medicine, Houston, TX. LA - eng PT - Journal Article DEP - 20260528 PL - United States TA - Dimens Crit Care Nurs JT - Dimensions of critical care nursing : DCCN JID - 8211489 SB - IM MH - Humans MH - Retrospective Studies MH - Female MH - *Postoperative Complications MH - Male MH - Risk Factors MH - *Clinical Deterioration MH - Child MH - Child, Preschool MH - Infant MH - Intensive Care Units, Pediatric MH - Hospital Rapid Response Team MH - Adolescent OTO - NOTNLM OT - Adverse events OT - National Surgical Quality Improvement Program OT - Pediatric surgery OT - Rapid response EDAT- 2026/05/29 15:42 MHDA- 2026/05/29 15:43 CRDT- 2026/05/28 12:13 PHST- 2025/04/21 00:00 [received] PHST- 2026/03/10 00:00 [accepted] PHST- 2026/05/29 15:43 [medline] PHST- 2026/05/29 15:42 [pubmed] PHST- 2026/05/28 12:13 [entrez] AID - 00003465-202607000-00003 [pii] AID - 10.1097/DCC.0000000000000774 [doi] PST - ppublish SO - Dimens Crit Care Nurs. 2026 Jul-Aug 01;45(4):176-180. doi: 10.1097/DCC.0000000000000774. Epub 2026 May 28. PMID- 42206175 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260528 LR - 20260813 IS - 1663-9812 (Print) IS - 1663-9812 (Electronic) IS - 1663-9812 (Linking) VI - 17 DP - 2026 TI - Efficacy and safety of Songjiao Dihuang Tang decoction for the dynamic/adaptive treatment of immune checkpoint inhibitor-associated myocarditis: study protocol and statistical analysis plan for a stop&go, multicentre, randomized, parallel-controlled, double-blind, superiority clinical trial. PG - 1797368 LID - 10.3389/fphar.2026.1797368 [doi] LID - 1797368 AB - BACKGROUND: While immune checkpoint inhibitors (ICIs) enhance tumour therapy, immune checkpoint inhibitor-associated myocarditis (ICIAM) pose risks of mortality because of their low incidence and rapid progression. Existing guidelines focus mostly on tiered management, with corticosteroid therapy serving as the primary treatment for the mild stage. Preliminary data suggest that Songjiao Dihuang Tang (SJDHT) may shorten disease duration, alleviate symptoms, and reduce glucocorticoid use. However, prospective multicentre studies remain rare because of sample scarcity, underdiagnosis of early-stage cases, centre-specific variability, and rapid clinical evolution. Consequently, in this study patients with mild ICIAM based on 2020 Chinese Expert Consensus criteria were recruited and it follows the 2023 clinical implementation recommendations. This prospective, multicentre RCT aims to verify whether SJDHT combined with conventional treatment reduces the disease duration, progression, and mortality. METHODS AND ANALYSIS: In this 1:1 randomized controlled trial, 200 patients with mild IC-IAM will receive either SJDHT (30 mL bid for 28 days) or a placebo. Both groups will receive standard care: initial methylprednisolone (1-2 mg/kg/d), tapered by 25%-40% every 3-5 days, and a switch to oral equivalent prednisone at /= 75 years. Early intervention for AS is critical, as untreated moderate and severe AS are associated with high mortality rates. Evolving patient demographics and procedural trends in surgical aortic valve replacement (SAVR) and transcatheter aortic valve implantation (TAVI) call for a structured framework of favorable treatment options for AS comorbidities and cardiac anatomic variants. METHODS: The Taiwan Association of Thoracic and Cardiovascular Surgery held multiple meetings in 2024-2025 for local experts to examine the latest evidence and current trends and to facilitate discussion on the management of isolated severe AS in Taiwan. RESULTS: Patient age, comorbidities, and unique cardiac structure frequently involve complex situations requiring treatment beyond SAVR or TAVI in AS management, emphasizing the need for thorough patient evaluation, accurate valvular imaging, and comprehensive patient-centered care with a multi-disciplinary heart team. CONCLUSIONS: Treatment options for individual patients must be carefully considered regarding their risk factors, anticipated life expectancy, and baseline health status. The cardiac surgeon provides valuable insights into surgical and alternative treatment methods tailored to individual patient conditions, and plays a critical role in the shared decision-making process in AS management. FAU - Chang, Chung-Yi AU - Chang CY AD - Department of Cardiovascular Surgery, Cheng Hsin General Hospital. FAU - Lee, Yung-Tsai AU - Lee YT AD - Department of Cardiovascular Surgery, Cheng Hsin General Hospital. AD - Department of Exercise and Health Science, National University of Nursing and Health Sciences. FAU - Lin, Chih-Yuan AU - Lin CY AD - Division of Cardiovascular Surgery, Department of Surgery, Tri-Service General Hospital. AD - College of Biomedical Science, Institute of Biochemistry, National Defense Medical University, Taipei. FAU - Chang, Jui-Chih AU - Chang JC AD - Division of Cardiovascular Surgery, Department of Surgery, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation. AD - School of Medicine, Tzu Chi University, Hualien. FAU - Chen, I-Chen AU - Chen IC AD - Department of Cardiovascular Surgery, Cheng Hsin General Hospital. FAU - Chen, Shao-Wei AU - Chen SW AD - Department of Thoracic and Cardiovascular Surgery, Chang Gung Memorial Hospital at Linkou. AD - College of Medicine, Chang Gung University, Taoyuan. FAU - Chen, Ying-Cheng AU - Chen YC AD - Division of Cardiovascular Surgery, Department of Surgery, Changhua Christian Hospital, Changhua. FAU - Cheng, Bor-Chih AU - Cheng BC AD - Department of Cardiovascular Surgery, Chi Mei Medical Center, Tainan. FAU - Chi, Nai-Hsin AU - Chi NH AD - Cardiovascular Surgery, Department of Surgery, National Taiwan University Hospital, Taipei. FAU - Hsieh, Chong-Chao AU - Hsieh CC AD - Department of Cardiovascular Surgery, Kaohsiung Medical University Hospital. AD - Graduate Institute of Clinical Medicine. AD - Department of Surgery, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung. FAU - Hsu, Chiao-Po AU - Hsu CP AD - Cardiovascular Center, Taipei Veterans General Hospital, Taipei. FAU - Kang, Pei-Leun AU - Kang PL AD - Department of Cardiovascular Surgery, Pingtung Veterans General Hospital, Pingtung City. FAU - Ke, Hung-Yen AU - Ke HY AD - Division of Cardiovascular Surgery, Department of Surgery, Tri-Service General Hospital. FAU - Li, Ping-Chun AU - Li PC AD - Department of Cardiovascular Surgery, China Medical University Hospital, Taichung. FAU - Lin, Chia-Hsun AU - Lin CH AD - Department of Cardiovascular Surgery, Shin Kong Wu Ho-Su Memorial Hospital, Taipei. FAU - Roan, Jun-Neng AU - Roan JN AD - Division of Cardiovascular Surgery, Department of Surgery, National Cheng Kung University Hospital. AD - College of Medicine, National Cheng Kung University, Tainan. FAU - Shen, Ta-Chung AU - Shen TC AD - Division of Cardiovascular Surgery, Department of Surgery, Buddhist Tzu Chi General Hospital, Taipei Branch, New Taipei City. FAU - Tsai, Yi-Ting AU - Tsai YT AD - Division of Cardiovascular Surgery, Department of Surgery, Tri-Service General Hospital. AD - School of Medicine, National Defense Medical Center. FAU - Wang, Chih-Hsien AU - Wang CH AD - Cardiovascular Surgery, Department of Surgery, National Taiwan University Hospital, Taipei. AD - College of Medicine, National Taiwan University, Taipei. AD - Cardiovascular Center, National Taiwan University Hospital - Yunlin Branch, Yunlin County. FAU - Wu, Nan-Chun AU - Wu NC AD - Department of Cardiovascular Surgery, Chi Mei Medical Center, Tainan. FAU - Shih, Chun-Che AU - Shih CC AD - Division of Cardiovascular Surgery, Department of Surgery, Taipei Municipal Wanfang Hospital, Taipei Medical University. AD - Taipei Heart Institute, Taipei Medical University. AD - Department of Surgery, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan. LA - eng PT - Journal Article PL - China (Republic : 1949- ) TA - Acta Cardiol Sin JT - Acta Cardiologica Sinica JID - 101687085 PMC - PMC13202334 OTO - NOTNLM OT - Aortic valve replacement OT - Taiwan guidelines OT - Valvular heart disease COIS- The authors have no relevant potential conflicts of interest to declare. EDAT- 2026/05/28 06:31 MHDA- 2026/05/28 06:32 PMCR- 2026/05/01 CRDT- 2026/05/28 04:33 PHST- 2025/10/14 00:00 [received] PHST- 2025/12/16 00:00 [accepted] PHST- 2026/05/28 06:32 [medline] PHST- 2026/05/28 06:31 [pubmed] PHST- 2026/05/28 04:33 [entrez] PHST- 2026/05/01 00:00 [pmc-release] AID - 10.6515/ACS.202605_42(3).20251216A [doi] PST - ppublish SO - Acta Cardiol Sin. 2026 May;42(3):479-485. doi: 10.6515/ACS.202605_42(3).20251216A. PMID- 42202604 OWN - NLM STAT- MEDLINE DCOM- 20260714 LR - 20260825 IS - 1532-8449 (Electronic) IS - 0882-5963 (Linking) VI - 89 DP - 2026 Jul-Aug TI - Preparation of pediatric patients with the "Super Heart Team Ready for Action" virtual reality animated film before cardiac catheterization: A randomized controlled trial. PG - 509-519 LID - S0882-5963(26)00226-5 [pii] LID - 10.1016/j.pedn.2026.05.020 [doi] AB - AIM: This study aimed to investigate the impact of a virtual reality (VR) based educational animated film on preoperative anxiety and fear, and postoperative pain levels among children undergoing cardiac catheterization. METHODS: This parallel group randomized controlled study was conducted between February and September 2025 in the Pediatric Cardiology Clinic of a university hospital in western Turkey. Children aged 5-10 years were randomly assigned to the control group (n = 21), which received standard clinical care, or to the experimental group (n = 21), which watched an animated film via VR glasses in addition to standard care. Anxiety, fear, pain, and vital signs were assessed using validated instruments. Nonparametric analyses were used for inter- and intra-group comparisons. RESULTS: There was no significant difference between the descriptive characteristics of the groups. However, a significant difference was found between the Children Fear Scale (CFS) and Children Anxiety Scale-State (CSA) scores of the experimental and control groups after cardiac catheterization (p < 0.05), and post-procedure CFS and CSA scores were significantly lower in the experimental group (p < 0.05). In addition, pain levels assessed using the Wong-Baker FACES Pain Scale showed a significant difference between the experimental and control groups after cardiac catheterization (p < 0.05). CONCLUSION: The study showed that watching the virtual reality-supported educational animation film significantly reduced children's pre-procedure fear and anxiety levels and alleviated their post-procedure pain levels. CLINICAL IMPLICATIONS: This result demonstrated that the use of visual-auditory, interactive, and developmentally appropriate materials is an effective method in preparing children for invasive or surgical procedures. CLINICAL TRIAL NUMBER: NCT07276893https://clinicaltrials.gov/study/NCT07276893. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Zengin, Dilek AU - Zengin D AD - Ege University, Nursing Faculty, Department of Pediatric Nursing, 35100 Izmir, Turkey. FAU - Onel, Aycin Ezgi AU - Onel AE AD - Ege University, Nursing Faculty, Department of Pediatric Nursing, 35100 Izmir, Turkey. Electronic address: aycin.ezgi.onel@ege.edu.tr. FAU - Uzsen, Hatice AU - Uzsen H AD - Ondokuz Mayis University, Health Sciences Faculty, Department of Pediatric Nursing, 55100 Samsun, Turkey. Electronic address: hatice.uzsen@omu.edu.tr. FAU - Bal Yilmaz, Hatice AU - Bal Yilmaz H AD - Ege University, Nursing Faculty, Department of Pediatric Nursing, 35100 Izmir, Turkey. FAU - Levent, Erturk AU - Levent E AD - Ege University, Faculty of Medicine, Pediatric Cardiology, 35100 Izmir, Turkey. Electronic address: erturk.levent@ege.edu.tr. LA - eng SI - ClinicalTrials.gov/NCT07276893 PT - Journal Article PT - Randomized Controlled Trial DEP - 20260527 PL - United States TA - J Pediatr Nurs JT - Journal of pediatric nursing JID - 8607529 SB - IM MH - Child MH - Child, Preschool MH - Female MH - Humans MH - Male MH - *Anxiety/prevention & control/psychology MH - *Cardiac Catheterization/psychology MH - *Fear/psychology MH - *Motion Pictures MH - Pain Measurement MH - *Patient Education as Topic/methods MH - Postoperative Pain/prevention & control MH - *Preoperative Care/methods MH - Turkey MH - *Virtual Reality OTO - NOTNLM OT - Animated film OT - Anxiety OT - Cardiac catheterization OT - Fear OT - Pain OT - Pediatric nursing COIS- Declaration of competing interest The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2026/05/28 00:29 MHDA- 2026/07/14 12:34 CRDT- 2026/05/27 18:06 PHST- 2025/12/24 00:00 [received] PHST- 2026/05/16 00:00 [revised] PHST- 2026/05/18 00:00 [accepted] PHST- 2026/07/14 12:34 [medline] PHST- 2026/05/28 00:29 [pubmed] PHST- 2026/05/27 18:06 [entrez] AID - S0882-5963(26)00226-5 [pii] AID - 10.1016/j.pedn.2026.05.020 [doi] PST - ppublish SO - J Pediatr Nurs. 2026 Jul-Aug;89:509-519. doi: 10.1016/j.pedn.2026.05.020. Epub 2026 May 27. PMID- 42201001 OWN - NLM STAT- MEDLINE DCOM- 20260717 LR - 20260813 IS - 2076-3271 (Electronic) IS - 2076-3271 (Linking) VI - 14 IP - 2 DP - 2026 Apr 23 TI - Kounis Syndrome in Cardiac Surgery: Pathophysiology, Antimicrobial Triggers, and Perioperative Recognition and Management. LID - 10.3390/medsci14020207 [doi] LID - 207 AB - BACKGROUND: Kounis syndrome is an allergic acute coronary syndrome precipitated by coronary vasospasm, plaque destabilization, stent thrombosis, or bypass occlusion. Cardiac surgery represents a uniquely high-risk setting due to cardiopulmonary bypass-associated inflammation and exposure to multiple pharmaceutical agents. Importantly, Kounis syndrome remains underrecognized in this context, as classical signs of anaphylaxis may be masked under general anesthesia and cardiopulmonary bypass, while ischemic manifestations may be misattributed to other perioperative conditions. METHODS: A narrative review of PubMed-indexed literature was conducted to synthesize current evidence on the pathophysiology, perioperative triggers, clinical presentation, diagnostic strategies, and management of Kounis syndrome in cardiac surgery, with emphasis on intraoperative recognition and surgical decision-making. Published cases were retrieved involving perioperative cardiac surgery patients with a definite diagnosis of Kounis syndrome. Additionally, cases presenting with severe perioperative anaphylaxis and life-threatening cardiovascular involvement (grade III with cardiovascular collapse and grade IV with cardiac arrest) were included as possible Kounis syndrome, reflecting real-world diagnostic uncertainty in the intraoperative setting. RESULTS: The literature review identified five cases of definite Kounis syndrome and ten cases of possible Kounis syndrome, including three cases with cardiovascular collapse and seven cases with cardiac arrest. Recurrent episodes were reported in several patients, particularly due to re-exposure to the triggering agent. In the context of cardiac surgery, Kounis syndrome is most frequently triggered by chlorhexidine, protamine, antibiotic prophylaxis, and anesthetic agents. The clinical presentation is often subtle during cardiopulmonary bypass. Vasoplegia, pulmonary hypertension, ventricular dysfunction, new regional wall-motion abnormalities, and hyperdynamic ventricles on transesophageal echocardiography commonly precede overt electrocardiographic changes. Diagnosis is primarily clinical and relies on intraoperative ultrasound, hemodynamic monitoring, serum tryptase, serum troponin, and, when indicated, coronary angiography. A dual-pathway approach addressing both anaphylaxis and myocardial ischemia is essential; however, one component may predominate, particularly in perioperative patients with limited clinical information, potentially leading to misdiagnosis. A multidisciplinary approach is therefore required for rapid diagnosis and individualized management. In refractory cases, cardiopulmonary bypass or ventricular assist devices may provide lifesaving support. CONCLUSIONS: Kounis syndrome remains underrecognized in cardiac surgery but carries significant morbidity. Increased clinical awareness, multidisciplinary collaboration, structured diagnostic approaches, and preventive strategies are essential to improve outcomes and reduce the risk of recurrence during future procedures. FAU - Leivaditis, Vasileios AU - Leivaditis V AUID- ORCID: 0000-0001-8692-0059 AD - Department of Cardiothoracic and Vascular Surgery, Westpfalz Klinikum, 67655 Kaiserslautern, Germany. FAU - Chatzigrigoriadis, Christodoulos AU - Chatzigrigoriadis C AUID- ORCID: 0009-0004-5449-0911 AD - Department of Internal Medicine, Division of Infectious Diseases, General University Hospital of Patras, 26504 Patras, Greece. FAU - Koletsis, Efstratios AU - Koletsis E AUID- ORCID: 0000-0003-1660-4047 AD - Department of Cardiothoracic Surgery, General University Hospital of Patras, 26504 Patras, Greece. FAU - Mplani, Virginia AU - Mplani V AUID- ORCID: 0000-0003-1610-0156 AD - Intensive Care Unit, General University Hospital of Patras, 26504 Patras, Greece. FAU - Dousdampanis, Periklis AU - Dousdampanis P AD - Department of Nephrology, Saint Andrews State General Hospital, 26221 Patras, Greece. FAU - Mulita, Francesk AU - Mulita F AUID- ORCID: 0000-0001-7198-2628 AD - Department of General Surgery, General Hospital of Eastern Achaia-Unit of Aigio, 25100 Aigio, Greece. FAU - Kounis, Nicholas G AU - Kounis NG AUID- ORCID: 0000-0002-9751-6710 AD - Department of Internal Medicine, Division of Cardiology, General University Hospital of Patras, 26504 Patras, Greece. FAU - Assimakopoulos, Stelios F AU - Assimakopoulos SF AUID- ORCID: 0000-0002-6901-3681 AD - Department of Internal Medicine, Division of Infectious Diseases, General University Hospital of Patras, 26504 Patras, Greece. LA - eng PT - Journal Article PT - Review DEP - 20260423 PL - Switzerland TA - Med Sci (Basel) JT - Medical sciences (Basel, Switzerland) JID - 101629322 RN - 0 (Anti-Infective Agents) SB - IM MH - Humans MH - *Kounis Syndrome/diagnosis/physiopathology/therapy/etiology MH - *Cardiac Surgical Procedures/adverse effects MH - Perioperative Care MH - *Anti-Infective Agents/adverse effects/therapeutic use PMC - PMC13214872 OTO - NOTNLM OT - Kounis syndrome OT - allergic acute coronary syndrome OT - allergic angina OT - beta-lactam OT - cardiac surgery OT - cardiopulmonary bypass OT - cefazolin OT - cefuroxime OT - chlorhexidine OT - coronary artery bypass graft OT - coronary vasoconstriction OT - extracorporeal membrane oxygenation OT - perioperative anaphylaxis OT - protamine OT - teicoplanin OT - transesophageal echocardiography OT - valve replacement OT - vancomycin COIS- The authors declare no conflicts of interest. EDAT- 2026/05/27 12:34 MHDA- 2026/05/27 12:35 PMCR- 2026/04/23 CRDT- 2026/05/27 10:13 PHST- 2026/02/23 00:00 [received] PHST- 2026/04/06 00:00 [revised] PHST- 2026/04/21 00:00 [accepted] PHST- 2026/05/27 12:35 [medline] PHST- 2026/05/27 12:34 [pubmed] PHST- 2026/05/27 10:13 [entrez] PHST- 2026/04/23 00:00 [pmc-release] AID - medsci14020207 [pii] AID - medsci-14-00207 [pii] AID - 10.3390/medsci14020207 [doi] PST - epublish SO - Med Sci (Basel). 2026 Apr 23;14(2):207. doi: 10.3390/medsci14020207. PMID- 42196207 OWN - NLM STAT- MEDLINE DCOM- 20260811 LR - 20260813 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 27 IP - 10 DP - 2026 May 9 TI - Cardiovascular Risk in Psoriatic Arthritis: Mechanisms, Risk Assessment, and Long-Term Management Implications. LID - 10.3390/ijms27104226 [doi] LID - 4226 AB - Beyond its typical synovio-entheseal manifestations, psoriatic arthritis (PsA) is a systemic immune-mediated disease that carries a substantial, independent risk of major adverse cardiovascular events (MACE). The complex interaction of chronic systemic inflammation, a high prevalence of traditional risk factors, and PsA treatment drugs results in this increased cardiovascular burden, which is commonly underestimated in cardiology practice. Adipokine balance, insulin signalling, and lipid metabolism are all impacted by cytokine-driven systemic inflammation, which promotes metabolic abnormalities and accelerated atherogenesis. PsA-specific therapy has a complex and significant effect on cardiovascular risk. While there is evidence that strong inflammation suppression with tumour necrosis factor-alpha (TNF-alpha) inhibitors may reduce cardiovascular risk, some medications, such as Janus kinase (JAK) inhibitors, should be carefully considered due to potential side effects. In order to outline the epidemiology and pathophysiology of the PsA-cardiovascular risk nexus, this narrative review synthesises recent data. It also offers a critical framework for managing cardiovascular risk in this susceptible group, advocating for a multidisciplinary approach that incorporates strict management of both inflammation and traditional risk factors to lessen the excessive burden of MACE. FAU - Totolici, Stefan AU - Totolici S AD - Cardiology Department, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania. AD - Colentina Clinical Hospital, 020125 Bucharest, Romania. FAU - Vrabie, Ana-Maria AU - Vrabie AM AD - Cardiology Department, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania. AD - Colentina Clinical Hospital, 020125 Bucharest, Romania. FAU - Buzea, Catalin Adrian AU - Buzea CA AUID- ORCID: 0000-0002-3365-9149 AD - Cardiology Department, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania. AD - Colentina Clinical Hospital, 020125 Bucharest, Romania. FAU - Badila, Elisabeta AU - Badila E AUID- ORCID: 0000-0003-2683-3054 AD - Cardiology Department, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania. AD - Colentina Clinical Hospital, 020125 Bucharest, Romania. LA - eng PT - Journal Article PT - Review DEP - 20260509 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 SB - IM MH - *Heart Disease Risk Factors MH - *Arthritis, Psoriatic/complications/drug therapy/immunology/metabolism MH - Humans MH - *Cardiovascular Diseases/chemically induced/immunology/metabolism MH - Risk Assessment/methods PMC - PMC13207636 OTO - NOTNLM OT - atherosclerosis OT - cardio-rheumatology OT - cardiovascular disease OT - cardiovascular risk OT - major adverse cardiovascular events OT - psoriatic arthritis OT - systemic inflammation COIS- The authors declare no conflicts of interest. EDAT- 2026/05/27 06:38 MHDA- 2026/05/27 06:39 PMCR- 2026/05/09 CRDT- 2026/05/27 01:16 PHST- 2026/04/05 00:00 [received] PHST- 2026/05/05 00:00 [revised] PHST- 2026/05/07 00:00 [accepted] PHST- 2026/05/27 06:39 [medline] PHST- 2026/05/27 06:38 [pubmed] PHST- 2026/05/27 01:16 [entrez] PHST- 2026/05/09 00:00 [pmc-release] AID - ijms27104226 [pii] AID - ijms-27-04226 [pii] AID - 10.3390/ijms27104226 [doi] PST - epublish SO - Int J Mol Sci. 2026 May 9;27(10):4226. doi: 10.3390/ijms27104226. PMID- 42194711 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260527 LR - 20260813 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 15 IP - 10 DP - 2026 May 13 TI - FOOPAS Study: Functional Assessment and Prognostic Value in Aortic Valve Replacement for Patients >/= 75 Years. LID - 10.3390/jcm15103750 [doi] LID - 3750 AB - Background: Because of demographic changes, the number of older patients undergoing cardiac interventions has increased. The most common indication in this group is aortic valve stenosis, treated with either surgical aortic valve replacement (SAVR) or transcatheter aortic valve implantation (TAVR), with good outcomes. Our study investigated whether the heart team's choice of intervention (TAVI, SAVR, or conservative) is influenced by geriatric assessment results. Methods: This study was a single-centre, prospective, longitudinal case-control study conducted over 12 months and did not affect routine diagnostic examinations or clinical decisions. After risk stratification and clinical evaluation, patients were assigned to undergo TAVI, SAVR, or conservative management. Cardiological evaluation and geriatric assessment were performed for up to 12 months. Results: Of 135 patients (mean age 81 +/- 4.6 years), 60% underwent TAVI, 29% SAVR, and 11% conservative therapy. Age, Frailty Score, cognition, and nutritional status were significantly associated with the heart team's decision, whereas EuroSCORE II remained the only independent predictor of one-year mortality (OR 1.58, 95% CI 1.13-2.19, p = 0.007). One-year mortality was 9.9% (n = 11). Compared to the literature, one-year mortality was lower than expected, particularly in the intervention group. Conclusions: Single assessment tools did not have the power to predict mortality. Similar to other trials, a combination of different scores can assess the risk of mortality. FAU - Eckner, Dennis AU - Eckner D AUID- ORCID: 0000-0003-4791-0098 AD - Department of Cardiology, Klinikum Nurnberg Paracelsus Medical University Nuremberg, 90471 Nuremberg, Germany. FAU - Wicklein, Susanne AU - Wicklein S AD - Department of Geriatric Medicine, Paracelsus Medical University Nuremberg, 90419 Nuremberg, Germany. FAU - Gosch, Markus AU - Gosch M AD - Department of Geriatric Medicine, Paracelsus Medical University Nuremberg, 90419 Nuremberg, Germany. FAU - Fischlein, Theodor AU - Fischlein T AD - Department of Cardiac Surgery, Paracelsus Medical University Nuremberg, 90419 Nurnberg, Germany. FAU - Habboub, Basel AU - Habboub B AD - Department of Geriatric Medicine, Paracelsus Medical University Nuremberg, 90419 Nuremberg, Germany. FAU - Jessl, Jurgen AU - Jessl J AD - Department of Cardiology, Klinikum Nurnberg Paracelsus Medical University Nuremberg, 90471 Nuremberg, Germany. FAU - Pauschinger, Matthias AU - Pauschinger M AD - Department of Cardiology, Klinikum Nurnberg Paracelsus Medical University Nuremberg, 90471 Nuremberg, Germany. FAU - Vogt, Ferdinand AU - Vogt F AUID- ORCID: 0000-0002-1924-6823 AD - Department of Cardiac Surgery, Paracelsus Medical University Nuremberg, 90419 Nurnberg, Germany. LA - eng GR - 300000euro/Theo und Friedl Scholler-Stiftung/ PT - Journal Article DEP - 20260513 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC13207252 OTO - NOTNLM OT - aortic stenosis (AS) OT - geriatric assessment OT - risk stratification OT - surgical aortic valve replacement (SAVR) OT - transcatheter aortic valve replacement (TAVR) COIS- The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. EDAT- 2026/05/27 06:36 MHDA- 2026/05/27 06:37 PMCR- 2026/05/13 CRDT- 2026/05/27 01:11 PHST- 2026/04/19 00:00 [received] PHST- 2026/05/11 00:00 [revised] PHST- 2026/05/12 00:00 [accepted] PHST- 2026/05/27 06:37 [medline] PHST- 2026/05/27 06:36 [pubmed] PHST- 2026/05/27 01:11 [entrez] PHST- 2026/05/13 00:00 [pmc-release] AID - jcm15103750 [pii] AID - jcm-15-03750 [pii] AID - 10.3390/jcm15103750 [doi] PST - epublish SO - J Clin Med. 2026 May 13;15(10):3750. doi: 10.3390/jcm15103750. PMID- 42194636 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260527 LR - 20260813 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 15 IP - 10 DP - 2026 May 10 TI - Current and Emerging Treatments for Isolated Aortic Stenosis and Concomitant Mitral Stenosis: A Comprehensive Narrative Review. LID - 10.3390/jcm15103674 [doi] LID - 3674 AB - Aortic stenosis (AS) and mitral stenosis (MS) are progressive valvular heart diseases associated with substantial morbidity and mortality once symptoms develop. Over the past decade, the management of isolated AS has undergone profound evolution, driven by refinements in surgical aortic valve replacement, the adoption of minimally invasive techniques, and the rapid expansion of transcatheter aortic valve replacement across all surgical risk categories. In contrast, patients with concomitant AS and MS represent a complex and understudied population, frequently excluded from randomized trials and only marginally addressed in contemporary clinical practice guidelines. The management requires individualized guideline-directed decision-making led by a multidisciplinary Heart Team. The paucity of high-quality data in combined AS-MS underscores the need for dedicated prospective studies and international registries. The aim of this narrative review is to describe current strategies to treat AS both when isolated and concomitant with MS. We also discuss the need for updated, specific guidelines. FAU - Martini, Kevin AU - Martini K AD - Division of Cardiac Surgery, University of Verona Medical Center, 37126 Verona, Italy. FAU - Poddi, Salvatore AU - Poddi S AUID- ORCID: 0000-0003-2484-2387 AD - Division of Cardiac Surgery, University of Verona Medical Center, 37126 Verona, Italy. FAU - Rungatscher, Alessio AU - Rungatscher A AD - Division of Cardiac Surgery, University of Verona Medical Center, 37126 Verona, Italy. LA - eng PT - Journal Article PT - Review DEP - 20260510 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC13207965 OTO - NOTNLM OT - aortic stenosis OT - aortic valve replacement OT - cardiac surgery OT - mitral stenosis OT - multivalvular disease OT - transcatheter aortic valve replacement COIS- The authors declare no conflicts of interest. EDAT- 2026/05/27 06:42 MHDA- 2026/05/27 06:43 PMCR- 2026/05/10 CRDT- 2026/05/27 01:10 PHST- 2026/03/26 00:00 [received] PHST- 2026/04/25 00:00 [revised] PHST- 2026/05/05 00:00 [accepted] PHST- 2026/05/27 06:43 [medline] PHST- 2026/05/27 06:42 [pubmed] PHST- 2026/05/27 01:10 [entrez] PHST- 2026/05/10 00:00 [pmc-release] AID - jcm15103674 [pii] AID - jcm-15-03674 [pii] AID - 10.3390/jcm15103674 [doi] PST - epublish SO - J Clin Med. 2026 May 10;15(10):3674. doi: 10.3390/jcm15103674. PMID- 42194195 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260527 LR - 20260813 IS - 2227-9067 (Print) IS - 2227-9067 (Electronic) IS - 2227-9067 (Linking) VI - 13 IP - 5 DP - 2026 May 12 TI - Hidden Cardiac Channelopathies in Children Presenting with Syncope and Seizure-like Events. LID - 10.3390/children13050669 [doi] LID - 669 AB - Background: Cardiac channelopathies are rare but potentially life-threatening disorders that may present with syncope or seizure-like episodes in children, often leading to misdiagnosis and delayed recognition. Other arrhythmia-associated cardiac conditions may also present with similar clinical manifestations and require careful cardiac evaluation. Objective: To evaluate the prevalence of cardiac channelopathies and inherited arrhythmogenic cardiac disorders in pediatric patients presenting with syncope and seizure-like events and to identify associated clinical and electrocardiographic features. Methods: This retrospective cross-sectional study included pediatric patients presenting with syncope, presyncope, seizures, or seizure-like episodes who underwent cardiac evaluation at Ankara Dr. Sami Ulus Maternity and Children's Health and Diseases Training and Research Hospital between January 2015 and April 2019. Cardiac evaluation was performed using a standard 12-lead electrocardiogram and was complemented by additional investigations, including 24 h Holter monitoring, exercise testing, pharmacological provocation, electrophysiological studies, and genetic analysis, when clinically indicated. Demographic, clinical, and diagnostic parameters were systematically evaluated. Results: A total of 363 patients were included in the final analysis. The mean age was 12.2 +/- 4.7 years, and 58.7% were female. The most common diagnosis was vasovagal syncope (n = 160, 44.1%), followed by epilepsy (n = 53, 14.6%). Cardiac channelopathies, and arrhythmogenic right ventricular dysplasia (ARVD) were identified in 18 patients, corresponding to 4.9% of the pediatric cardiology-evaluated patients and 0.82% of the initial screened population. These diagnoses included long QT syndrome (n = 8), Brugada syndrome (n = 3), short QT syndrome (n = 3), catecholaminergic polymorphic ventricular tachycardia (n = 2), ARVD (n = 1), and malignant-type early repolarization (n = 1). Compared with other patients, those with cardiac channelopathies, malignant-type early repolarization, and ARVD more frequently had exercise-related triggers (p < 0.001), ventricular extrasystoles and ventricular tachycardia (p < 0.001), and abnormal exercise test findings (p < 0.001). Conclusions: Cardiac channelopathies are not uncommon in pediatric patients presenting with syncope and seizure-like events and should be considered in the differential diagnosis. Clinical triggers, family history, and electrocardiographic abnormalities may serve as important clues for early identification. A multidisciplinary approach, including detailed cardiac evaluation, is essential to prevent misdiagnosis and reduce the risk of sudden cardiac death. FAU - Aytekin Guvenir, Funda AU - Aytekin Guvenir F AD - Department of Pediatric Allergy and Immunology, Ankara Bilkent City Hospital, Ankara 06800, Turkey. FAU - Ozgur, Senem AU - Ozgur S AD - Department of Pediatric Cardiology, Ankara Etlik City Hospital, Ankara 06170, Turkey. LA - eng PT - Journal Article DEP - 20260512 PL - Switzerland TA - Children (Basel) JT - Children (Basel, Switzerland) JID - 101648936 PMC - PMC13204148 OTO - NOTNLM OT - cardiac channelopathies OT - long QT syndrome OT - pediatric OT - seizures OT - syncope COIS- The authors declare no conflicts of interest. EDAT- 2026/05/27 06:36 MHDA- 2026/05/27 06:37 PMCR- 2026/05/12 CRDT- 2026/05/27 01:09 PHST- 2026/04/19 00:00 [received] PHST- 2026/05/03 00:00 [revised] PHST- 2026/05/09 00:00 [accepted] PHST- 2026/05/27 06:37 [medline] PHST- 2026/05/27 06:36 [pubmed] PHST- 2026/05/27 01:09 [entrez] PHST- 2026/05/12 00:00 [pmc-release] AID - children13050669 [pii] AID - children-13-00669 [pii] AID - 10.3390/children13050669 [doi] PST - epublish SO - Children (Basel). 2026 May 12;13(5):669. doi: 10.3390/children13050669. PMID- 42190098 OWN - NLM STAT- MEDLINE DCOM- 20260717 LR - 20260717 IS - 1547-1896 (Print) IS - 0893-7400 (Linking) VI - 39 IP - 6 DP - 2026 Jun 1 TI - Mechanical support for decompensated heart failure. PG - e10-e14 LID - 10.1097/01.JAA.0000000000000358 [doi] AB - Advanced heart failure (AHF) poses a significant challenge in modern cardiology, often necessitating surgical interventions to alleviate symptoms and improve patient outcomes. This article provides an overview of surgical interventions available for treating AHF, with a primary focus on established procedures such as heart transplantation, ventricular assist device implantation, and emerging techniques including minimally invasive approaches and novel device therapies. The efficacy, indications, and potential complications of these interventions are discussed, along with their roles in the comprehensive management of patients with AHF. Recent advancements in surgical techniques, patient criteria, and perioperative care strategies are highlighted. Within a multidisciplinary approach encompassing surgical expertise, medical management, and supportive care, surgical interventions play a crucial role in the holistic management of AHF, offering hope and improved prognosis for affected patients. CI - Copyright (c) 2026 American Academy of Physician Associates. FAU - Williams, Andre'lyn AU - Williams A AD - Andre'lyn Williams practices intensive care at the Michael E. DeBakey Veterans Affairs Medical Center in Houston, TX. The author has disclosed no potential conflicts of interest, financial or otherwise. LA - eng PT - Journal Article PT - Review DEP - 20260526 PL - United States TA - JAAPA JT - JAAPA : official journal of the American Academy of Physician Assistants JID - 9513102 SB - IM MH - Humans MH - *Heart Failure/surgery/therapy MH - *Heart-Assist Devices MH - Heart Transplantation/methods OTO - NOTNLM OT - INTERMACS OT - cardiogenic shock OT - heart failure OT - heart transplant OT - left ventricular assist device OT - mechanical circulatory support EDAT- 2026/05/26 23:34 MHDA- 2026/05/26 23:35 CRDT- 2026/05/26 15:22 PHST- 2026/05/26 23:35 [medline] PHST- 2026/05/26 23:34 [pubmed] PHST- 2026/05/26 15:22 [entrez] AID - 01720610-202606000-00013 [pii] AID - 10.1097/01.JAA.0000000000000358 [doi] PST - ppublish SO - JAAPA. 2026 Jun 1;39(6):e10-e14. doi: 10.1097/01.JAA.0000000000000358. Epub 2026 May 26. PMID- 42188073 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260526 LR - 20260813 IS - 2308-3425 (Electronic) IS - 2308-3425 (Linking) VI - 13 IP - 5 DP - 2026 Apr 29 TI - Cardiac Myosin Inhibitors (CMIs) and Surgical Referral in Patients with Hypertrophic Cardiomyopathy. LID - 10.3390/jcdd13050187 [doi] LID - 187 AB - The management of obstructive hypertrophic cardiomyopathy (HCM) has been transformed by the advent of cardiac myosin inhibitors (CMIs), such as mavacamten and aficamten. Unlike traditional pharmacotherapy, which primarily addresses symptoms, CMIs target the underlying mechanism of sarcomeric hypercontractility, offering significant reductions in left ventricular outflow tract (LVOT) gradients and improved functional capacity. This review evaluates the evolving role of CMIs in refining surgical candidate selection and postoperative care. Clinically, CMIs function as an in vivo "biological test" to distinguish between dynamic, functional obstruction-often manageable with medication-and fixed anatomical obstruction driven by complex septal or mitral substrates. While clinical trials demonstrate that CMIs can delay or prevent the need for SRT in a significant proportion of patients, surgery remains the definitive solution for those with dominant structural anomalies or drug intolerance. Consequently, the therapeutic paradigm is shifting from a binary "drugs or surgery" approach to a synergistic model. In this framework, CMIs optimize the identification of patients truly requiring structural myectomy while serving as a valuable adjunct for managing residual hypercontractility, ultimately facilitating a personalized, multidisciplinary approach to HCM treatment. FAU - Ferraresi, Benedetto AU - Ferraresi B AUID- ORCID: 0009-0003-4801-0005 AD - Cardiac Surgery, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo 200, 00128 Rome, Italy. AD - Unit of Cardiac Surgery, Department of Medicine and Surgery, Universita Campus Bio-Medico di Roma, 00128 Rome, Italy. FAU - Nenna, Antonio AU - Nenna A AUID- ORCID: 0000-0002-4069-6781 AD - Department of Cardio-Thoracic-Vascular Diseases, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy. FAU - Jawabra, Mohamad AU - Jawabra M AD - Cardiac Surgery, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo 200, 00128 Rome, Italy. AD - Unit of Cardiac Surgery, Department of Medicine and Surgery, Universita Campus Bio-Medico di Roma, 00128 Rome, Italy. FAU - Corrado, Diletta AU - Corrado D AUID- ORCID: 0009-0006-5183-455X AD - Cardiac Surgery, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo 200, 00128 Rome, Italy. AD - Unit of Cardiac Surgery, Department of Medicine and Surgery, Universita Campus Bio-Medico di Roma, 00128 Rome, Italy. FAU - Faggiano, Andrea AU - Faggiano A AD - Department of Cardio-Thoracic-Vascular Diseases, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy. FAU - Carugo, Stefano AU - Carugo S AD - Department of Cardio-Thoracic-Vascular Diseases, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy. AD - Department of Clinical Sciences and Community Health, Universita degli Studi di Milano, 20122 Milan, Italy. FAU - Dominici, Carmelo AU - Dominici C AD - Department of Cardio-Thoracic-Vascular Diseases, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy. FAU - Casali, Giovanni AU - Casali G AD - Cardiac Surgery, Azienda Ospedaliero Universitaria Maggiore Della Carita di Novara, Corso Mazzini 18, 28100 Novara, Italy. FAU - Chello, Massimo AU - Chello M AD - Cardiac Surgery, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo 200, 00128 Rome, Italy. AD - Unit of Cardiac Surgery, Department of Medicine and Surgery, Universita Campus Bio-Medico di Roma, 00128 Rome, Italy. FAU - Lusini, Mario AU - Lusini M AUID- ORCID: 0000-0003-0982-0550 AD - Cardiac Surgery, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo 200, 00128 Rome, Italy. AD - Unit of Cardiac Surgery, Department of Medicine and Surgery, Universita Campus Bio-Medico di Roma, 00128 Rome, Italy. LA - eng PT - Journal Article PT - Review DEP - 20260429 PL - Switzerland TA - J Cardiovasc Dev Dis JT - Journal of cardiovascular development and disease JID - 101651414 PMC - PMC13206893 OTO - NOTNLM OT - cardiac myosin inhibitors OT - hypertrophic cardiomyopathy OT - mavacamten OT - septal reduction therapy OT - surgical myectomy COIS- The authors declare no conflicts of interest. EDAT- 2026/05/26 17:41 MHDA- 2026/05/26 17:42 PMCR- 2026/04/29 CRDT- 2026/05/26 09:44 PHST- 2026/03/21 00:00 [received] PHST- 2026/04/23 00:00 [revised] PHST- 2026/04/28 00:00 [accepted] PHST- 2026/05/26 17:42 [medline] PHST- 2026/05/26 17:41 [pubmed] PHST- 2026/05/26 09:44 [entrez] PHST- 2026/04/29 00:00 [pmc-release] AID - jcdd13050187 [pii] AID - jcdd-13-00187 [pii] AID - 10.3390/jcdd13050187 [doi] PST - epublish SO - J Cardiovasc Dev Dis. 2026 Apr 29;13(5):187. doi: 10.3390/jcdd13050187. PMID- 42185611 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260525 LR - 20260813 IS - 2948-2836 (Electronic) IS - 2948-2836 (Linking) VI - 3 IP - 1 DP - 2026 May 25 TI - Lifetime management of primary mitral regurgitation through integrated surgical and transcatheter reinterventions. LID - 10.1038/s44325-026-00129-2 [doi] LID - 28 AB - Lifetime management of primary mitral regurgitation requires integrating surgical and transcatheter strategies. This review evaluates initial interventions, emphasizing early timing and repair durability, and outlines subsequent reintervention pathways. Synthesizing contemporary evidence, it highlights how a multidisciplinary Heart Team must design the index procedure to preserve future therapeutic options and ensure structured longitudinal care across the patient lifespan. CI - (c) 2026. The Author(s). FAU - Tabata, Minoru AU - Tabata M AD - Department of Cardiovascular Surgery, Juntendo University, Tokyo, Japan. minorutabata@juntendo.ac.jp. LA - eng PT - Journal Article PT - Review DEP - 20260525 PL - England TA - NPJ Cardiovasc Health JT - NPJ cardiovascular health JID - 9918898840606676 PMC - PMC13201851 COIS- Competing interests: The author declares no competing interests. EDAT- 2026/05/26 00:31 MHDA- 2026/05/26 00:32 PMCR- 2026/05/25 CRDT- 2026/05/25 23:29 PHST- 2025/11/30 00:00 [received] PHST- 2026/04/23 00:00 [accepted] PHST- 2026/05/26 00:32 [medline] PHST- 2026/05/26 00:31 [pubmed] PHST- 2026/05/25 23:29 [entrez] PHST- 2026/05/25 00:00 [pmc-release] AID - 10.1038/s44325-026-00129-2 [pii] AID - 129 [pii] AID - 10.1038/s44325-026-00129-2 [doi] PST - epublish SO - NPJ Cardiovasc Health. 2026 May 25;3(1):28. doi: 10.1038/s44325-026-00129-2. PMID- 32119466 STAT- Publisher CTDT- 20260526 PB - StatPearls Publishing DP - 2026 Jan TI - Antihypertensive Medications. BTI - StatPearls AB - Hypertension remains one of the most prevalent and clinically significant modifiable risk factors for cardiovascular disease. This activity reviews contemporary hypertension management based on the 2025 American College of Cardiology/American Heart Association guideline, with emphasis on accurate evidence-based diagnosis, cardiovascular risk stratification, pharmacologic therapy selection, medication optimization, treatment adherence, and long-term longitudinal blood pressure monitoring to reduce morbidity and mortality. This activity addresses these challenges by integrating evidence from clinical trials, practical treatment algorithms, and patient-centered management strategies, including home and ambulatory blood pressure monitoring and team-based care models. In addition, this activity helps clinicians to develop skills in optimizing antihypertensive therapy, interpreting blood pressure monitoring data, managing medication-related adverse effects, and improving adherence through simplified treatment regimens. The activity also emphasizes interprofessional collaboration and the expanding role of digital health technologies in hypertension management, equipping clinicians to deliver coordinated, evidence-based care to reduce cardiovascular complications and improve long-term outcomes. CI - Copyright (c) 2026, StatPearls Publishing LLC. FAU - Regalla, Dileep Kumar Reddy AU - Regalla DKR AD - OSF St. Anthony Medical Center Rockford, IL FAU - Patel, Preeti AU - Patel P LA - eng PT - Study Guide PT - Book Chapter PL - Treasure Island (FL) COIS- Disclosure: Dileep Kumar Reddy Regalla declares no relevant financial relationships with ineligible companies. Disclosure: Preeti Patel declares no relevant financial relationships with ineligible companies. EDAT- 2026/05/26 00:00 CRDT- 2026/05/26 00:00 AID - NBK554579 [bookaccession] PMID- 42184038 OWN - NLM STAT- Publisher LR - 20260525 IS - 1432-1971 (Electronic) IS - 0172-0643 (Linking) DP - 2026 May 25 TI - Teamwork as a Clinical Competency in Pediatric Cardiology: A Measurement-Feedback-Simulation Framework for Improving Decision-Making and Outcomes. LID - 10.1007/s00246-026-04314-z [doi] AB - The care of patients with pediatric and congenital heart disease is intrinsically complex and relies on coordinated multidisciplinary teamwork. While advances in diagnostics and intervention have improved survival, variability in outcomes persists and is increasingly linked to team performance, decision-making, and organizational culture. This Perspective draws on evidence from pediatric cardiology, healthcare systems research, and organizational science to examine the role of team-based care in pediatric and congenital cardiology. Emphasis is placed on multidisciplinary decision-making, team dynamics, leadership, and organizational culture, with the aim of stimulating reflection and informing everyday clinical practice rather than providing a systematic or exhaustive review. Effective teamwork is associated with improvements in patient safety, clinical outcomes, patient and family experience, and staff well-being. Multidisciplinary decision-making forums, empowered nursing roles, and psychologically safe cultures emerge as central to high performance. Leadership, accountability, and transparency of outcomes data strongly influence team behaviour, while evidence from pediatric cardiology highlights the vulnerability of clinical decision-making to cognitive bias, heuristics, and organizational context. Optimising decision-making processes, fostering supportive organizational cultures, and investing in team development represent important opportunities to improve outcomes. We propose a practical Measurement-Feedback-Simulation (MFS) framework to support the measurement and improvement of teamwork as a clinical competency. CI - (c) 2026. The Author(s). FAU - McMahon, Colin J AU - McMahon CJ AD - Department of Paediatric Cardiology, Children's Health Ireland at Crumlin, Dublin 12, Ireland. cmcmahon992004@yahoo.com. AD - School of Medicine, University College Dublin, Belfield, Ireland. cmcmahon992004@yahoo.com. FAU - Rossano, Joseph AU - Rossano J AD - The Cardiac Center, Children's Hospital of Philadelphia, Philadelphia, PA, USA. LA - eng PT - Journal Article PT - Review DEP - 20260525 PL - United States TA - Pediatr Cardiol JT - Pediatric cardiology JID - 8003849 SB - IM OTO - NOTNLM OT - Clinical competence OT - Congenital heart defects OT - Decision making OT - Organizational culture OT - Patient care team OT - Patient safety OT - Pediatric cardiology COIS- Declarations. Competing Interests: The authors declare no competing interests. EDAT- 2026/05/25 12:35 MHDA- 2026/05/25 12:35 CRDT- 2026/05/25 11:14 PHST- 2026/03/20 00:00 [received] PHST- 2026/05/11 00:00 [accepted] PHST- 2026/05/25 12:35 [medline] PHST- 2026/05/25 12:35 [pubmed] PHST- 2026/05/25 11:14 [entrez] AID - 10.1007/s00246-026-04314-z [pii] AID - 10.1007/s00246-026-04314-z [doi] PST - aheadofprint SO - Pediatr Cardiol. 2026 May 25. doi: 10.1007/s00246-026-04314-z. PMID- 42182773 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260525 LR - 20260813 IS - 2072-1439 (Print) IS - 2077-6624 (Electronic) IS - 2072-1439 (Linking) VI - 18 IP - 4 DP - 2026 Apr 30 TI - Characteristics of patients qualified for aortic valve replacement combined with coronary artery bypass grafting surgery in the era of transcatheter aortic valve implantation dominance study (CAPTOR study). PG - 337 LID - 10.21037/jtd-2025-aw-2100 [doi] LID - 337 AB - BACKGROUND: The growing use of transcatheter aortic valve implantation (TAVI) has significantly changed treatment strategies for patients with aortic stenosis (AS), especially those with coexisting coronary artery disease (CAD). However, the impact of this shift on surgical aortic valve replacement combined with coronary artery bypass grafting (AVR + CABG) remains unclear. This study aimed to evaluate temporal trends, clinical characteristics, perioperative outcomes, and 5-year survival in patients undergoing AVR + CABG in the context of increasing TAVI adoption in Poland between 2014 and 2023. METHODS: This retrospective, multicenter cohort study used data from the Polish National Cardiac Surgery Database. A total of 65,085 patients qualified for aortic valve intervention between 2014 and 2023 were analyzed. Baseline characteristics, procedural details, complication rates, and 5-year survival (Kaplan-Meier method) were assessed. AVR + CABG trends were compared to TAVI volumes over time. RESULTS: The proportion of patients undergoing AVR + CABG decreased by 25% over the study period, while TAVI procedures increased fivefold. AVR + CABG patients became younger and predominantly male, with higher prevalence of hypertension and hyperlipidemia but improved functional status. Despite longer cross-clamp times and changes in prosthesis size, perioperative mortality and complication rates remained stable. Mid-term survival was not significantly affected. The growing use of percutaneous coronary intervention (PCI) with TAVI likely influenced these trends. CONCLUSIONS: Despite declining volumes, AVR + CABG remains an effective and safe option for selected patients. In the evolving landscape of valve disease treatment, multidisciplinary Heart Team decision-making and further comparative studies are essential. CI - (c) AME Publishing Company. FAU - Reszczynski, Marek AU - Reszczynski M AUID- ORCID: 0009-0004-1849-6988 AD - Department of Cardiac Surgery, Regional Specialist Hospital, Grudziadz, Poland. FAU - Litwinowicz, Radoslaw AU - Litwinowicz R AD - Department of Cardiac Surgery, Regional Specialist Hospital, Grudziadz, Poland. AD - Faculty of Medicine, Bydgoszcz University of Science and Technology, Bydgoszcz, Poland. FAU - Brzezinski, Maciej AU - Brzezinski M AD - Department of Cardiovascular Surgery, Medical University of Gdansk, Gdansk, Poland. FAU - Perek, Bartlomiej AU - Perek B AD - Department of Cardiac Surgery, Poznan University of Medical Sciences, Poznan Poland. FAU - Kowalewski, Mariusz AU - Kowalewski M AD - Department of Cardiac Surgery and Transplantology, National Medical Institute of the Ministry of Interior and Administration, Warszawa, Poland. AD - Thoracic Research Centre, Collegium Medicum Nicolaus Copernicus University, Innovative Medical Forum, Bydgoszcz, Poland. FAU - Widenka, Kazimierz AU - Widenka K AD - Clinical Department of Cardiac Surgery, District Hospital No. 2, University of Rzeszow, Rzeszow, Poland. FAU - Bartus, Krzysztof AU - Bartus K AD - Department of Cardiovascular Surgery and Transplantology, Jagiellonian University Medical College, John Paul II Hospital, Krakow, Poland. FAU - Burysz, Marian AU - Burysz M AD - Department of Cardiac Surgery, Regional Specialist Hospital, Grudziadz, Poland. AD - Faculty of Medicine, Bydgoszcz University of Science and Technology, Bydgoszcz, Poland. LA - eng PT - Journal Article DEP - 20260324 PL - China TA - J Thorac Dis JT - Journal of thoracic disease JID - 101533916 PMC - PMC13190086 OTO - NOTNLM OT - Aortic stenosis (AS) OT - coronary artery bypass grafting (CABG) OT - outcomes OT - surgery OT - transcatheter valve implantation COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-2025-aw-2100/coif). The authors have no conflicts of interest to declare. EDAT- 2026/05/25 12:35 MHDA- 2026/05/25 12:36 PMCR- 2026/04/30 CRDT- 2026/05/25 08:12 PHST- 2025/10/14 00:00 [received] PHST- 2026/01/05 00:00 [accepted] PHST- 2026/05/25 12:36 [medline] PHST- 2026/05/25 12:35 [pubmed] PHST- 2026/05/25 08:12 [entrez] PHST- 2026/04/30 00:00 [pmc-release] AID - jtd-18-04-337 [pii] AID - 10.21037/jtd-2025-aw-2100 [doi] PST - ppublish SO - J Thorac Dis. 2026 Apr 30;18(4):337. doi: 10.21037/jtd-2025-aw-2100. Epub 2026 Mar 24. PMID- 42179149 OWN - NLM STAT- MEDLINE DCOM- 20260803 LR - 20260824 IS - 1522-726X (Electronic) IS - 1522-1946 (Print) IS - 1522-1946 (Linking) VI - 108 IP - 2 DP - 2026 Aug TI - Intravascular Ultrasound in Chronic Limb-Threatening Ischemia Endovascular Revascularization: A Multidisciplinary Survey of Clinical Practices and Operator Perceptions. PG - 402-408 LID - 10.1002/ccd.70665 [doi] AB - BACKGROUND: Intravascular ultrasound (IVUS) may be beneficial for guiding endovascular revascularization in patients with chronic limb-threatening ischemia (CLTI); however, its use remains limited. METHODS: We surveyed interventional radiologists, vascular surgeons, and interventional cardiologists in the United States, Canada, and the United Kingdom using a 13-question, anonymous online questionnaire to evaluate clinical equipoise, willingness to randomize, and opinions and perceptions regarding IVUS use in patients with CLTI undergoing endovascular revascularization. RESULTS: A total of 105 operators (5.7% response rate) participated in the survey: 42 interventional radiologists, 40 vascular surgeons and 23 interventional cardiologists. Operators indicated the main obstacles to adopting or expanding IVUS for endovascular revascularization were cost or lack of reimbursement (69.5%), concerns about longer procedural time (47.6%), and the absence of randomized data supporting its benefit (39.0%). Overall, 80.0% of operators agreed that a large, multicenter, randomized trial was required, and 77.1% were willing to randomize patients in such a trial. CONCLUSION: In this multidisciplinary survey, the identified barriers for IVUS use in CLTI revascularization were cost/non-reimbursement, increased procedural time, and lack of randomized evidence. Given respondents' clinical equipoise and willingness to randomize, large randomized controlled trials are needed to inform clinical practice. CI - (c) 2026 The Author(s). Catheterization and Cardiovascular Interventions published by Wiley Periodicals LLC. FAU - d'Entremont, Marc-Andre AU - d'Entremont MA AUID- ORCID: 0000-0002-1432-7384 AD - Population Health Research Institute, Hamilton, Ontario, Canada. AD - Division of Cardiology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada. AD - Division of Cardiology, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada. FAU - Secemsky, Eric A AU - Secemsky EA AD - Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA. AD - Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA. FAU - McClure, Graham R AU - McClure GR AUID- ORCID: 0000-0002-1639-6359 AD - Population Health Research Institute, Hamilton, Ontario, Canada. AD - Division of Vascular Surgery, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada. FAU - Kowalik, Krzysztof AU - Kowalik K AD - Division of Vascular Surgery, McMaster University, Hamilton, Ontario, Canada. FAU - Drudi, Laura M AU - Drudi LM AD - Division of Vascular Surgery, Centre Hospitalier de l'Universite de Montreal (CHUM), Montreal, Quebec, Canada. FAU - Lemaire-Paquette, Samuel AU - Lemaire-Paquette S AD - Division of Cardiology, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada. FAU - Brown, Andrew D AU - Brown AD AD - Division of Vascular and Interventional Radiology, Department of Medical Imaging, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada. FAU - Greco, Elisa AU - Greco E AD - Division of Vascular Surgery, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada. FAU - Benko, Andrew AU - Benko A AD - Department of Radiology, Universite de Sherbrooke, Sherbrooke, Quebec, Canada. FAU - Mirakhur, Anirudh AU - Mirakhur A AD - Department of Radiology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. FAU - Girsowicz, Elie AU - Girsowicz E AD - Division of Vascular Surgery, Jewish General Hospital, McGill University, Montreal, Quebec, Canada. FAU - Newman, Jane AU - Newman J AD - Division of Vascular Surgery, London Health Sciences Centre, Western University, London, Ontario, Canada. FAU - Misskey, Jonathan AU - Misskey J AD - Division of Vascular Surgery, Vancouver General Hospital, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Berube, Simon AU - Berube S AD - Division of Cardiology, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada. FAU - Harlock, John AU - Harlock J AD - Division of Vascular Surgery, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada. FAU - Jolly, Sanjit S AU - Jolly SS AD - Population Health Research Institute, Hamilton, Ontario, Canada. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20260525 PL - United States TA - Catheter Cardiovasc Interv JT - Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions JID - 100884139 SB - IM MH - Humans MH - *Ultrasonography, Interventional/trends/economics MH - Health Care Surveys MH - *Endovascular Procedures/trends/adverse effects/economics MH - *Practice Patterns, Physicians'/trends/economics MH - *Attitude of Health Personnel MH - Chronic Disease MH - United States MH - *Ischemia/diagnostic imaging/therapy/economics MH - Cardiologists/trends MH - Predictive Value of Tests MH - Surgeons/trends/psychology MH - *Peripheral Arterial Disease/therapy/diagnostic imaging/economics MH - *Radiologists/trends/psychology MH - Treatment Outcome MH - Canada MH - *Health Knowledge, Attitudes, Practice MH - United Kingdom MH - Time Factors MH - Surveys and Questionnaires MH - *Perception MH - Health Care Costs MH - Cost-Benefit Analysis PMC - PMC13432598 COIS- The authors declare no conflicts of interest. EDAT- 2026/05/25 06:31 MHDA- 2026/08/03 18:37 PMCR- 2026/08/03 CRDT- 2026/05/25 05:22 PHST- 2026/03/26 00:00 [revised] PHST- 2025/12/02 00:00 [received] PHST- 2026/05/20 00:00 [accepted] PHST- 2026/08/03 18:37 [medline] PHST- 2026/05/25 06:31 [pubmed] PHST- 2026/05/25 05:22 [entrez] PHST- 2026/08/03 00:00 [pmc-release] AID - CCD70665 [pii] AID - 10.1002/ccd.70665 [doi] PST - ppublish SO - Catheter Cardiovasc Interv. 2026 Aug;108(2):402-408. doi: 10.1002/ccd.70665. Epub 2026 May 25. PMID- 42176848 OWN - NLM STAT- MEDLINE DCOM- 20261008 LR - 20261008 IS - 1931-3543 (Electronic) IS - 0012-3692 (Linking) VI - 170 IP - 4 DP - 2026 Oct TI - Managing a Critically Ill Patient With Pulmonary Arterial Hypertension. PG - 1260-1271 LID - S0012-3692(26)00651-3 [pii] LID - 10.1016/j.chest.2026.05.018 [doi] AB - Management of critically ill patients with pulmonary hypertension presents significant clinical challenges. Regardless of the underlying etiology or chronicity of pulmonary hypertension, superimposed acute illness can precipitate decompensated right ventricular failure (RVF) and death. Hospitalization, particularly in the ICU, is associated with high mortality, with RVF serving as the direct or indirect cause in most cases. In this article, we will focus on the management of acute decompensated RVF in patients with known pulmonary arterial hypertension (PAH). ICU management of the patient with PAH with RVF centers on the recognition and treatment of potentially reversible precipitants for decompensation and supportive strategies to optimize right ventricular (RV) function. Key goals include maintaining adequate oxygenation and tissue perfusion, correcting electrolyte and other metabolic abnormalities, optimizing fluid balance and RV preload, enhancing RV contractility, and reducing RV afterload. Continuous monitoring of cardiac function is essential, as is identifying and treating potential complications (eg, arrhythmia, acute kidney injury). When RVF persists despite maximal medical therapy, extracorporeal life support may be considered as a bridge to recovery or transplantation. In patients with advanced disease, multidisciplinary discussions aligned with patient and family preferences should guide the goals of care. Integration of palliative care specialists to manage symptoms and support caregivers remains a critical component of comprehensive ICU management for patients with PAH. CI - Copyright (c) 2026 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved. FAU - Sulica, Roxana AU - Sulica R AD - NYU Langone Health, New York University, New York, NY. FAU - De Marco, Teresa AU - De Marco T AD - UCSF Medical Center, University of California, San Francisco (UCSF), San Francisco, CA. FAU - Elwing, Jean M AU - Elwing JM AD - UC Medical Center, University of Cincinnati, Cincinnati, OH. FAU - Bartolome, Sonia AU - Bartolome S AD - UT Southwestern Medical Center, University of Texas, Dallas, TX. FAU - Sood, Namita AU - Sood N AD - UC Davis Medical Center, University of California, Davis, Sacramento, CA. Electronic address: nsood@health.ucdavis.edu. LA - eng PT - Journal Article PT - Review DEP - 20260522 PL - United States TA - Chest JT - Chest JID - 0231335 SB - IM MH - Humans MH - *Critical Illness/therapy MH - *Ventricular Dysfunction, Right/therapy/etiology/physiopathology MH - *Heart Failure/therapy/etiology/physiopathology MH - *Hypertension, Pulmonary/therapy/complications MH - *Pulmonary Arterial Hypertension/therapy/complications/physiopathology MH - *Critical Care/methods MH - Intensive Care Units OTO - NOTNLM OT - ICU OT - pulmonary arterial hypertension OT - pulmonary hypertension OT - right ventricular failure EDAT- 2026/05/24 04:38 MHDA- 2026/10/08 23:31 CRDT- 2026/05/23 19:32 PHST- 2025/11/10 00:00 [received] PHST- 2026/05/12 00:00 [revised] PHST- 2026/05/13 00:00 [accepted] PHST- 2026/10/08 23:31 [medline] PHST- 2026/05/24 04:38 [pubmed] PHST- 2026/05/23 19:32 [entrez] AID - S0012-3692(26)00651-3 [pii] AID - 10.1016/j.chest.2026.05.018 [doi] PST - ppublish SO - Chest. 2026 Oct;170(4):1260-1271. doi: 10.1016/j.chest.2026.05.018. Epub 2026 May 22. PMID- 42176004 OWN - NLM STAT- MEDLINE DCOM- 20260717 LR - 20260910 IS - 1433-0350 (Electronic) IS - 0256-7040 (Print) IS - 0256-7040 (Linking) VI - 42 IP - 1 DP - 2026 May 23 TI - The relation between cerebral arteriovenous malformations and heart diseases in the pediatric population: a systematic review and meta-analysis. LID - 10.1007/s00381-026-07307-8 [doi] LID - 227 AB - Cerebral arteriovenous malformations (AVMs) and congenital heart diseases (CHDs) are rare, complex conditions that often present diagnostic and therapeutic challenges-especially when they coexist in pediatric patients. Though individually uncommon, their association raises important questions about shared developmental origins, systemic implications, and long-term outcomes. Understanding this relationship is crucial for improving early recognition, tailoring treatment strategies, and reducing morbidity and mortality in affected children. This systematic review and meta-analysis explored the relationship between AVMs and CHDs in the pediatric population, analyzing 139 studies published between 1971 and 2023. Together, these studies included data from 1042 patients. The co-occurrence of these two conditions highlights a potential interplay between cerebral and cardiac vascular development. By clarifying their association, this study aims to support earlier recognition, improve multidisciplinary management, and ultimately enhance clinical outcomes. The results revealed important patterns in how specific types and locations of AVMs relate to different forms of heart disease. AVMs located in infratentorial regions-such as the brainstem and cerebellum-were generally associated with lower risks of complications, while those in deep cerebral areas showed stronger links to adverse outcomes. Among the heart conditions evaluated, atrial septal defects (ASDs), cardiomyopathies, and high-output cardiac failure were most frequently associated with AVMs, suggesting overlapping embryologic and hemodynamic mechanisms. The most commonly reported complications included hydrocephalus, hemorrhage, and mortality. ROC curve analysis showed that mortality had the highest predictive value (AUC 0.62), followed by hydrocephalus (0.53) and hemorrhage (0.48). A composite risk model (AUC 0.59) suggested that combining clinical variables could improve prognostication. Neurological sequelae such as seizures, developmental delay, and microcephaly were frequent, particularly in hemorrhagic cases. Interestingly, in some patients, AVM treatment led to improvement in cardiac symptoms, suggesting a bidirectional relationship between cerebral and cardiac function. Despite variability in study quality, results were consistent across analyses, even when lower-quality studies were excluded. Most studies were rated moderate to high quality, though classification challenges were noted. Overall, the findings support a meaningful association between specific AVM and CHD subtypes and highlight the importance of early diagnosis and collaborative care involving multidisciplinary approach. CI - (c) 2026. The Author(s). FAU - Ponchio, Valentina AU - Ponchio V AD - Santa Casa de Sao Paulo School of Medical Sciences, Sao Paulo, Brazil. valenponchio@gmail.com. FAU - Hussin, Reem AU - Hussin R AD - Santa Casa de Sao Paulo School of Medical Sciences, Sao Paulo, Brazil. FAU - Harati, Wassim AU - Harati W AD - Santa Casa de Sao Paulo School of Medical Sciences, Sao Paulo, Brazil. FAU - Gerhardt, Maria Eduarda AU - Gerhardt ME AD - Santa Casa de Sao Paulo School of Medical Sciences, Sao Paulo, Brazil. FAU - Dias, Fernanda Boyadjian AU - Dias FB AD - Universidade Metropolitana de Santos, Santos, Sao paulo, Brazil. FAU - Hussin, Anas AU - Hussin A AD - Santa Casa de Sao Paulo School of Medical Sciences, Sao Paulo, Brazil. FAU - Fenner, Fernanda AU - Fenner F AD - Division of Neurosurgery, Department of Surgery, Santa Casa de Sao Paulo School of Medical Sciences, Sao Paulo, Brazil. FAU - de Souza Vasconcelos, Matheus Felipe AU - de Souza Vasconcelos MF AD - Division of Neurosurgery, Department of Surgery, Santa Casa de Sao Paulo School of Medical Sciences, Sao Paulo, Brazil. FAU - Bertani, Raphael AU - Bertani R AD - Department of Neurosurgery, University of Sao Paulo, Sao Paulo, Brazil. LA - eng PT - Journal Article PT - Meta-Analysis PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20260523 PL - Germany TA - Childs Nerv Syst JT - Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery JID - 8503227 SB - IM MH - Humans MH - *Intracranial Arteriovenous Malformations/complications/epidemiology MH - Child MH - *Heart Diseases/complications/epidemiology MH - *Heart Defects, Congenital/complications/epidemiology PMC - PMC13198478 OTO - NOTNLM OT - Cerebral arteriovenous malformations OT - Heart diseases OT - Outcomes OT - Pediatric population COIS- Declarations. Competing interests: The authors declare no competing interests. EDAT- 2026/05/24 04:35 MHDA- 2026/05/24 04:36 PMCR- 2026/05/23 CRDT- 2026/05/23 11:03 PHST- 2025/11/07 00:00 [received] PHST- 2026/04/29 00:00 [accepted] PHST- 2026/05/24 04:36 [medline] PHST- 2026/05/24 04:35 [pubmed] PHST- 2026/05/23 11:03 [entrez] PHST- 2026/05/23 00:00 [pmc-release] AID - 10.1007/s00381-026-07307-8 [pii] AID - 7307 [pii] AID - 10.1007/s00381-026-07307-8 [doi] PST - epublish SO - Childs Nerv Syst. 2026 May 23;42(1):227. doi: 10.1007/s00381-026-07307-8. PMID- 42174953 OWN - NLM STAT- MEDLINE DCOM- 20260717 LR - 20260717 IS - 1879-8365 (Electronic) IS - 0926-9630 (Linking) VI - 336 DP - 2026 May 21 TI - Visualization of Clinical Case Similarities in Pediatric Cardiology Using Structured Case Conference Reports. PG - 770-771 LID - 10.3233/SHTI260278 [doi] AB - We present a visualization and comparison tool to support the assessment of case similarities in pediatric cardiology. The web-based application allows experts to compare one reference case with two others and decide which of these is more similar to the reference or if none applies. Efficiency is enhanced by synchronous scrolling, highlighted medical terms, and section-wise comparison. The resulting expert annotations form the training data for an AI model that will automatically determine case similarities, enabling the retrieval and visualization of relevant historical cases during clinical conferences. FAU - Schroder, Tom AU - Schroder T AD - Data|H - Institute for Applied Data Science Hannover, University of Applied Sciences and Arts Hannover, Germany. FAU - Liehr, Darian AU - Liehr D AD - Data|H - Institute for Applied Data Science Hannover, University of Applied Sciences and Arts Hannover, Germany. FAU - Uden, Theodor AU - Uden T AD - Clinical Department of Pediatric Cardiology and Intensive Care Medicine, Hannover Medical School, Germany. FAU - Beerbaum, Philipp AU - Beerbaum P AD - Clinical Department of Pediatric Cardiology and Intensive Care Medicine, Hannover Medical School, Germany. FAU - Bott, Oliver J AU - Bott OJ AD - Data|H - Institute for Applied Data Science Hannover, University of Applied Sciences and Arts Hannover, Germany. FAU - Wartena, Christian AU - Wartena C AD - Data|H - Institute for Applied Data Science Hannover, University of Applied Sciences and Arts Hannover, Germany. FAU - Marschollek, Michael AU - Marschollek M AD - Peter L. Reichertz Institute for Medical Informatics of TU Braunschweig and Hannover Medical School, Germany. FAU - Oeltze-Jafra, Steffen AU - Oeltze-Jafra S AD - Peter L. Reichertz Institute for Medical Informatics of TU Braunschweig and Hannover Medical School, Germany. FAU - Ahlers, Volker AU - Ahlers V AD - Data|H - Institute for Applied Data Science Hannover, University of Applied Sciences and Arts Hannover, Germany. LA - eng PT - Journal Article PL - Netherlands TA - Stud Health Technol Inform JT - Studies in health technology and informatics JID - 9214582 SB - IM MH - *Cardiology/methods MH - Humans MH - *Pediatrics MH - *Case Reports as Topic MH - User-Computer Interface OTO - NOTNLM OT - case conference OT - patient similarity OT - pediatric cardiology OT - visualization EDAT- 2026/05/23 06:32 MHDA- 2026/05/23 06:33 CRDT- 2026/05/23 01:01 PHST- 2026/05/23 06:33 [medline] PHST- 2026/05/23 06:32 [pubmed] PHST- 2026/05/23 01:01 [entrez] AID - SHTI260278 [pii] AID - 10.3233/SHTI260278 [doi] PST - ppublish SO - Stud Health Technol Inform. 2026 May 21;336:770-771. doi: 10.3233/SHTI260278. PMID- 42169157 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260730 LR - 20260813 IS - 2057-3804 (Electronic) IS - 2057-3804 (Linking) VI - 12 IP - 1 DP - 2026 May 22 TI - Rapid symptomatic and metabolic response to emergency radiotherapy in a critically ill patient with primary cardiac lymphoma: a multidisciplinary case report. LID - 10.1186/s40959-026-00509-8 [doi] LID - 99 AB - Primary cardiac lymphoma (PCL), an exceptionally rare and aggressive malignancy with median survival under one month, often presents with contraindications to first-line chemotherapy in critically ill patients. We report a 66-year-old woman with acute heart failure, pulmonary embolism, and ECOG performance status 4, diagnosed with right atrial diffuse large B-cell lymphoma (76 x 75 mm, SUVmax = 29.1). Due to chemotherapy contraindications, emergency radiotherapy (18 Gy/10 fractions) was initiated. Within five fractions, significant symptomatic improvement occurred with resolution of dyspnea and edema, accompanied by improved oxygenation (SpO(2) 86%-->95%) and ECOG status (4-->3). Post-treatment PET/CT demonstrated a profound metabolic response (SUVmax = 2.9-3.6), enabling successful transition to systemic chemotherapy. This case underscores emergency radiotherapy as an effective bridge therapy for critically ill PCL patients, facilitated by multidisciplinary coordination. CI - (c) 2026. The Author(s). FAU - Yu, Chengqi AU - Yu C AD - National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Liu, Weiping AU - Liu W AD - Departments of Lymphoma, Peking University Cancer Hospital and Institute, Beijing, China. FAU - Yu, Huiming AU - Yu H AD - Department of Radiation Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, No. 52, Fucheng Road, Haidian District, Beijing, 100142, China. huiming740512@126.com. LA - eng GR - 2023ZD 0502702/National Science and Technology Major Project of the Ministry of Science and Technology of China/ PT - Journal Article DEP - 20260522 PL - England TA - Cardiooncology JT - Cardio-oncology (London, England) JID - 101689938 PMC - PMC13412123 OTO - NOTNLM OT - Case report OT - Metabolic response OT - Multidisciplinary OT - PET/CT OT - Primary cardiac lymphoma OT - Radiotherapy COIS- Declarations. Ethics approval and consent to participate: This study involving human data was conducted in accordance with the ethical standards of the institutional and/or national research committee and with the Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study. Competing interests: The authors declare no competing interests. EDAT- 2026/05/22 06:37 MHDA- 2026/05/22 06:38 PMCR- 2026/05/22 CRDT- 2026/05/22 00:37 PHST- 2025/08/27 00:00 [received] PHST- 2026/05/15 00:00 [accepted] PHST- 2026/05/22 06:38 [medline] PHST- 2026/05/22 06:37 [pubmed] PHST- 2026/05/22 00:37 [entrez] PHST- 2026/05/22 00:00 [pmc-release] AID - 10.1186/s40959-026-00509-8 [pii] AID - 509 [pii] AID - 10.1186/s40959-026-00509-8 [doi] PST - epublish SO - Cardiooncology. 2026 May 22;12(1):99. doi: 10.1186/s40959-026-00509-8. PMID- 42166484 OWN - NLM STAT- Publisher LR - 20260521 IS - 1879-0844 (Electronic) IS - 1388-9842 (Linking) DP - 2026 May 21 TI - Current state of knowledge on the epidemiology, aetiology, diagnosis, and management of heart involvement in eosinophilia. A Clinical Consensus Statement of the ESC Working Group on Myocardial & Pericardial Diseases. LID - xuag043 [pii] LID - 10.1093/ejhf/xuag043 [doi] AB - Heart involvement in eosinophilia represents a rare entity with substantial cardiac morbidity and mortality. This disorder is often overlooked and diagnosed in its advanced stages. In a subgroup of patients with eosinophilic heart disease, peripheral blood eosinophilia may not be present, and the biopsy of the affected organ or tissue is essential to establish the correct diagnosis. In this clinical consensus statement, an expert consensus group reviews the epidemiology, aetiology, diagnosis, and management of eosinophilic heart disease. The aim of the document is to increase awareness about the cardiac involvement associated with eosinophilia in order to diagnose the disease in early phases and prevent deleterious heart damage and adverse outcomes of affected individuals. The spectrum of physiological and immunological derangements requires a multidisciplinary approach for optimal management of affected individuals. CI - (c) The Author(s) 2026. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com. FAU - Kuchynka, Petr AU - Kuchynka P AD - 2nd Department of Medicine, Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, 128 08, U Nemocnice 2, Prague 2, Czech Republic. FAU - Brucato, Antonio AU - Brucato A AUID- ORCID: 0000-0002-7566-5600 AD - Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy. FAU - Tschope, Carsten AU - Tschope C AUID- ORCID: 0000-0001-5243-8985 AD - German Heart Center at Charite (DHZC), Clinic for Cardiology, Angiology, and Intensive Medicine, Germany. AD - Charite - Universitatsmedizin Berlin, Germany. AD - Berlin Institute of Health at Charite (BIH), Germany. AD - German Centre for Cardiovascular Research (DZHK), Partner Site Berlin, Germany. AD - Center for Regenerative Therapies (BCRT) - Berlin, Germany. FAU - Cameli, Matteo AU - Cameli M AUID- ORCID: 0000-0003-3872-8964 AD - Department of Medical Biotechnologies, Division of Cardiology, University of Siena, Siena, Italy. FAU - Castelleti, Silvia AU - Castelleti S AD - IRCCS, Istituto Auxologico Italiano, Department of Cardiology, San Luca Hospital, Cardiomyopathy Unit, Milan, Italy. FAU - Cooper, Leslie T AU - Cooper LT AD - Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, FL, USA. FAU - Dweck, Marc R AU - Dweck MR AD - British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK. FAU - Frustaci, Andrea AU - Frustaci A AUID- ORCID: 0000-0002-5748-0725 AD - Cellular and Molecular Cardiology Lab, IRCCS L. Spallanzani, Rome, Italy. FAU - Heidecker, Bettina AU - Heidecker B AD - German Heart Center at Charite (DHZC), Clinic for Cardiology, Angiology, and Intensive Medicine, Germany. AD - Charite - Universitatsmedizin Berlin, Germany. AD - Berlin Institute of Health at Charite (BIH), Germany. AD - German Centre for Cardiovascular Research (DZHK), Partner Site Berlin, Germany. FAU - Klingel, Karin AU - Klingel K AUID- ORCID: 0000-0003-0203-2498 AD - Cardiopathology, Institute for Pathology and Neuropathology, University Hospital Tuebingen, Tuebingen, Germany. FAU - Kuusisto, Johanna AU - Kuusisto J AD - Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland, Kuopio, Finland. FAU - Lazaros, George AU - Lazaros G AUID- ORCID: 0000-0003-2802-9617 AD - 1st Cardiology Department, Hippokration Hospital, National and Kapodistrian University of Athens, Greece. FAU - Merlo, Marco AU - Merlo M AD - Center for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste, Trieste, Italy. AD - Member of ERN-Guard HEART, Trieste, Italy. FAU - Pantazis, Antonis AU - Pantazis A AD - Royal Brompton and Harefield NHS Foundation Trust, London, UK. FAU - Petersen, Steffen E AU - Petersen SE AD - William Harvey Research Institute, NIHR Barts Biomedical Research Centre, Queen Mary University London, Charterhouse Square, London, UK. AD - Barts Heart Centre, St Bartholomew's Hospital, , London, UK. FAU - Rigopoulos, Angelos G AU - Rigopoulos AG AD - Department of Adult Cardiology, Mitera General Hospital, Hygeia Group, Athens, Greece. FAU - Ristic, Arsen D AU - Ristic AD AD - Department of Cardiology, University of Belgrade, Belgrade, Serbia. FAU - Sedlak, Frantisek AU - Sedlak F AD - 1st Department of Medicine, Department of Hematology, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic. FAU - Sheppard, Mary N AU - Sheppard MN AD - Department of Cardiovascular Pathology, Cardiovascular and Genetics Research Institute, St Georges Medical School, London, UK. FAU - Imazio, Massimo AU - Imazio M AD - Department of Medicine, University of Udine, Udine, Italy. AD - Cardiothoracic Department, University Hospital Santa Maria della Misericordia, Udine, Italy. LA - eng PT - Journal Article DEP - 20260521 PL - England TA - Eur J Heart Fail JT - European journal of heart failure JID - 100887595 SB - IM OTO - NOTNLM OT - Cardiac magnetic resonance OT - Endomyocardial biopsy OT - Endomyocardial fibrosis OT - Eosinophilia OT - Immunosuppression OT - Myocarditis EDAT- 2026/05/21 18:32 MHDA- 2026/05/21 18:32 CRDT- 2026/05/21 13:43 PHST- 2025/06/03 00:00 [received] PHST- 2025/10/05 00:00 [revised] PHST- 2026/02/03 00:00 [accepted] PHST- 2026/05/21 18:32 [medline] PHST- 2026/05/21 18:32 [pubmed] PHST- 2026/05/21 13:43 [entrez] AID - 8690085 [pii] AID - 10.1093/ejhf/xuag043 [doi] PST - aheadofprint SO - Eur J Heart Fail. 2026 May 21:xuag043. doi: 10.1093/ejhf/xuag043. PMID- 42162704 OWN - NLM STAT- In-Process LR - 20260908 IS - 1532-2165 (Electronic) IS - 1078-5884 (Linking) VI - 72 IP - 3 DP - 2026 Sep TI - A Multidisciplinary Approach for Safe Transfemoral Transcatheter Aortic Valve Implantation in Patients with High Risk Features for Access Complications. PG - 548-549 LID - S1078-5884(26)00492-2 [pii] LID - 10.1016/j.ejvs.2026.05.018 [doi] FAU - Smeets, Reinier R AU - Smeets RR AD - Department of Vascular Surgery, Maastricht University Medical Centre, Maastricht, The Netherlands. Electronic address: rr.smeets@gmail.com. FAU - Prent, Anna AU - Prent A AD - Department of Vascular Surgery, Maastricht University Medical Centre, Maastricht, The Netherlands. FAU - Maesen, Bart AU - Maesen B AD - Department of Cardiothoracic Surgery, Maastricht University Medical Centre, Maastricht, The Netherlands; Cardiovascular Research Institute Maastricht University, Maastricht, The Netherlands. FAU - van 't Hof, Arnoud W J AU - van 't Hof AWJ AD - Department of Cardiology, Maastricht University Medical Centre, Maastricht, The Netherlands; Cardiovascular Research Institute Maastricht University, Maastricht, The Netherlands. FAU - Vriesendorp, Pieter A AU - Vriesendorp PA AD - Department of Cardiology, Maastricht University Medical Centre, Maastricht, The Netherlands; Cardiovascular Research Institute Maastricht University, Maastricht, The Netherlands. FAU - Mees, Barend M E AU - Mees BME AD - Department of Vascular Surgery, Maastricht University Medical Centre, Maastricht, The Netherlands; Cardiovascular Research Institute Maastricht University, Maastricht, The Netherlands. LA - eng PT - Journal Article DEP - 20260519 PL - England TA - Eur J Vasc Endovasc Surg JT - European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery JID - 9512728 SB - IM OTO - NOTNLM OT - Multidisciplinary care team OT - Risk assessment OT - Transcatheter aortic valve replacement OT - Vascular access complications EDAT- 2026/05/21 05:33 MHDA- 2026/05/21 05:33 CRDT- 2026/05/20 23:55 PHST- 2026/02/09 00:00 [received] PHST- 2026/04/12 00:00 [revised] PHST- 2026/05/13 00:00 [accepted] PHST- 2026/05/21 05:33 [pubmed] PHST- 2026/05/21 05:33 [medline] PHST- 2026/05/20 23:55 [entrez] AID - S1078-5884(26)00492-2 [pii] AID - 10.1016/j.ejvs.2026.05.018 [doi] PST - ppublish SO - Eur J Vasc Endovasc Surg. 2026 Sep;72(3):548-549. doi: 10.1016/j.ejvs.2026.05.018. Epub 2026 May 19. PMID- 20301365 STAT- Publisher DRDT- 20260521 CTDT- 20070118 PB - University of Washington, Seattle DP - 1993 TI - Cardiofaciocutaneous Syndrome. BTI - GeneReviews((R)) AB - CLINICAL CHARACTERISTICS: Cardiofaciocutaneous (CFC) syndrome is characterized by cardiac abnormalities (pulmonic stenosis and other valve dysplasias, septal defects, hypertrophic cardiomyopathy, rhythm disturbances), distinctive craniofacial appearance, and cutaneous abnormalities (including xerosis, hyperkeratosis, ichthyosis, keratosis pilaris, ulerythema ophryogenes, eczema, pigmented moles, hemangiomas, and palmoplantar hyperkeratosis). The hair is typically sparse, curly, fine or thick, and woolly or brittle; eyelashes and eyebrows may be absent or sparse. Nails may be dystrophic or fast growing. Affected individuals typically have some form of neurologic and/or cognitive delay (ranging from mild to severe). Most individuals have severe feeding issues, which can contribute to poor growth, and many require nasogastric or gastrostomy tube feeding. Many affected individuals have eye findings, including strabismus, nystagmus, refractive errors, and optic nerve hypoplasia. Seizures may be present and can be refractory to therapy. DIAGNOSIS/TESTING: The diagnosis of CFC syndrome is established in a proband with suggestive clinical findings by the identification of a heterozygous pathogenic variant in BRAF, MAP2K1, MAP2K2, or KRAS by molecular genetic testing. MANAGEMENT: Treatment of manifestations: Consensus medical management guidelines have been published. Care by a multidisciplinary team; increased caloric intake and a nasogastric or gastrostomy tube for severe feeding issues; surgical intervention for severe gastroesophageal reflux or malrotation; management of cardiac structural defects, hypertrophic cardiomyopathy, and arrhythmias as in the general population; increased ambient humidity or hydrating lotions for xerosis and pruritus; management of seizures may require polytherapy; routine management of growth hormone deficiency; standard treatment for peripheral neuropathy, Chiari I malformation, developmental delay / intellectual disability, constipation, musculoskeletal anomalies, hypotonia, chronic/recurrent otitis media, hearing loss, cryptorchidism, hydronephrosis, bleeding disorders / thrombocytopenia, and sleep disorders. Surveillance: At each visit: measure blood pressure; measure growth parameters; evaluate nutritional status and safety of oral intake; monitor for GERD, constipation, generalized dysmotility; assess for new manifestations such as seizures or changes in tone; monitor developmental progress, behavior, and educational needs; monitor for signs and symptoms of thyroid and/or growth hormone deficiency. Assess for scoliosis at each visit until skeletal maturity. Monitor for signs/symptoms of precocious or delayed puberty at each visit in childhood and adolescence. Refer to endocrinologist between the ages of two to three years (or earlier if there are concerns about growth) to monitor growth velocity. Monitor for ocular issues every six to 12 months as directed by ophthalmologist. Hearing evaluation every two to three years, or as clinically indicated. Echocardiogram every two to three years up to age 20 years in those who have an initial cardiac evaluation that is normal. Echocardiogram every three to five years in individuals older than age 20 years who have no previous heart disease found. Annual dermatologic evaluation. DXA scan in early adulthood. Reassess platelet count for evidence of thrombocytopenia in those who have evidence of easy bruising or bleeding. Agents/circumstances to avoid: Avoid overexposure to heat, strenuous activity, and dehydration. In individuals with evidence of peripheral neuropathy, avoid drugs with a neurotoxic effect. Pregnancy management: A pregnant female suspected of having CFC syndrome warrants high-risk obstetric care from a trained maternal-fetal medicine physician due to possible polyhydramnios, maternal cardiac issues, and/or maternal hypertension. GENETIC COUNSELING: CFC syndrome is inherited in an autosomal dominant manner. The majority of individuals with CFC syndrome reported to date have the disorder as the result of a de novo BRAF, MAP2K1, MAP2K2, or KRAS pathogenic variant. However, instances of familial recurrence of CFC have been reported. Each child of an individual with CFC syndrome has a 50% chance of inheriting the BRAF, MAP2K1, MAP2K2, or KRAS pathogenic variant. Once the CFC syndrome-causing pathogenic variant has been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic testing for CFC are possible. CI - Copyright (c) 1993-2026, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved. Test. FED - Adam, Margaret P ED - Adam MP FED - Bick, Sarah ED - Bick S FED - Mirzaa, Ghayda M ED - Mirzaa GM FED - Pagon, Roberta A ED - Pagon RA FED - Wallace, Stephanie E ED - Wallace SE FED - Amemiya, Anne ED - Amemiya A FAU - Rauen, Katherine A AU - Rauen KA AD - Professor, Department of Pediatrics, Division of Genomic Medicine, University of California, Davis, UC Davis MIND Institute, Sacramento, California LA - eng PT - Review PT - Book Chapter PL - Seattle (WA) OTO - NLM OT - CFC Syndrome OT - CFC Syndrome OT - Dual specificity mitogen-activated protein kinase kinase 1 OT - Dual specificity mitogen-activated protein kinase kinase 2 OT - GTPase KRas OT - Serine/threonine-protein kinase B-raf OT - BRAF OT - KRAS OT - MAP2K1 OT - MAP2K2 OT - Cardiofaciocutaneous Syndrome EDAT- 2026/05/21 00:00 CRDT- 2026/05/21 00:00 AID - NBK1186 [bookaccession] PMID- 42159735 OWN - NLM STAT- Publisher LR - 20260520 IS - 1861-0692 (Electronic) IS - 1861-0684 (Linking) DP - 2026 May 20 TI - Telepharmacy-supported multidisciplinary management and clinical outcomes in patients with transthyretin amyloid cardiomyopathy treated with tafamidis: a real-world study. LID - 10.1007/s00392-026-02941-3 [doi] AB - BACKGROUND: Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive cause of heart failure in an elderly and multimorbid population. Although tafamidis improves clinical outcomes, its real-world effectiveness relies on long-term treatment persistence, which may be compromised by therapeutic complexity and drug-related issues. Evidence on integrated care models addressing these challenges in routine cardiology practice remains limited. AIMS: Patients with transthyretin amyloid cardiomyopathy (ATTR-CM) treated with tafamidis are typically elderly, multimorbid, and exposed to high pharmacological complexity, which may compromise long-term treatment persistence and safety. We aimed to characterize the therapeutic complexity and pharmacological profile of a real-world ATTR-CM population and to evaluate the association between a structured telepharmacy-supported multidisciplinary management model and medication adherence, treatment persistence, and clinical outcomes. METHODS AND RESULTS: We conducted a retrospective observational study including 125 patients with ATTR-CM treated with tafamidis between December 2021 and December 2024. Ninety-seven patients received at least one structured telepharmacy consultation, while 28 patients received standard cardiology care alone. Baseline disease severity was assessed using New York Heart Association (NYHA) class and National Amyloidosis Centre (NAC) staging. The study population is limited to patients in NYHA class I-II, as per Italian reimbursement criteria which require treatment discontinuation upon progression to NYHA class III-IV. Adherence and the composite outcome were assessed for all patients, while therapeutic complexity and drug-drug interactions were systematically evaluated only in the telepharmacy group, as these assessments were part of the intervention and not available for controls from the Italian Medicines Agency (AIFA) registry. Patients in the telepharmacy group exhibited high therapeutic complexity, with a median Medication Regimen Complexity Index (MRCI) of 15 (interquartile range [IQR] 12-19), and frequent clinically relevant drug-drug interactions. Despite a significantly longer observation period, adherence remained excellent in telepharmacy-managed patients (median proportion of days covered 95.2%, IQR 92.7-97.5). Over follow-up, telepharmacy support was associated with a lower incidence of the composite endpoint of treatment discontinuation for clinical decision or all-cause death. Kaplan-Meier analysis showed early and sustained separation of event-free probability curves, and Cox regression adjusted for age and NAC stage confirmed an independent association between telepharmacy management and reduced risk of the composite endpoint. CONCLUSIONS: In this real-world cohort of patients with early-stage ATTR-CM (NYHA class I-II), a multidisciplinary care model including telepharmacy was associated with more favorable tafamidis persistence and clinical outcomes compared to standard care in exploratory analyses. These findings suggest that integrating structured pharmacological surveillance into cardiology pathways may support long-term disease-modifying therapy management. Given the observational, non-randomized design, the small control group, and the incomplete data for controls, these results are preliminary and hypothesis-generating; they require confirmation in larger, prospective studies with balanced comparator groups. CI - (c) 2026. Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Cordiano, L AU - Cordiano L AD - Hospital Pharmacy Unit, University Hospital of Padua, Padua, Italy. luisella.cordiano@aopd.veneto.it. FAU - Condello, D AU - Condello D AD - Hospital Pharmacy Unit, University Hospital of Padua, Padua, Italy. FAU - Chinellato, G AU - Chinellato G AD - Hospital Pharmacy Unit, University Hospital of Padua, Padua, Italy. FAU - Berti, G AU - Berti G AD - Hospital Pharmacy Unit, University Hospital of Padua, Padua, Italy. FAU - Mengato, D AU - Mengato D AD - Hospital Pharmacy Unit, University Hospital of Padua, Padua, Italy. FAU - Bucciol, C AU - Bucciol C AD - Hospital Pharmacy Unit, University Hospital of Padua, Padua, Italy. FAU - Nistor, R A AU - Nistor RA AD - Hospital Pharmacy Unit, University Hospital of Padua, Padua, Italy. FAU - Poliseno, V AU - Poliseno V AD - Hospital Pharmacy Unit, University Hospital of Padua, Padua, Italy. FAU - Pivato, L AU - Pivato L AD - Hospital Pharmacy Unit, University Hospital of Padua, Padua, Italy. FAU - Tietto, A AU - Tietto A AD - Department of Cardio-Thoraco-Vascular Sciences and Public Health, University of Padua, Padua, Italy. FAU - Sinigiani, G AU - Sinigiani G AD - Department of Cardio-Thoraco-Vascular Sciences and Public Health, University of Padua, Padua, Italy. FAU - De Michieli, L AU - De Michieli L AD - Department of Cardio-Thoraco-Vascular Sciences and Public Health, University of Padua, Padua, Italy. AD - Cardiology Unit, University Hospital of Padua, Padua, Italy. FAU - Cipriani, A AU - Cipriani A AD - Department of Cardio-Thoraco-Vascular Sciences and Public Health, University of Padua, Padua, Italy. AD - Cardiology Unit, University Hospital of Padua, Padua, Italy. FAU - Venturini, F AU - Venturini F AD - Hospital Pharmacy Unit, University Hospital of Padua, Padua, Italy. LA - eng PT - Journal Article DEP - 20260520 PL - Germany TA - Clin Res Cardiol JT - Clinical research in cardiology : official journal of the German Cardiac Society JID - 101264123 SB - IM OTO - NOTNLM OT - Clinical pharmacy OT - Rare diseases OT - Telepharmacy OT - Transthyretin amyloid cardiomyopathy OT - Treatment persistence COIS- Declarations. Ethics approval: According to local regulations and institutional policy, studies based exclusively on anonymized administrative and routine clinical data do not require formal ethics committee approval. The study was performed in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments. No patient-identifiable information was used. Consent to participate: Not applicable because this is a retrospective study based on anonymized administrative and clinical data. Consent for publication: All authors approved the final manuscript. Competing interests: The authors declare no competing interests. EDAT- 2026/05/20 12:39 MHDA- 2026/05/20 12:39 CRDT- 2026/05/20 11:14 PHST- 2025/12/20 00:00 [received] PHST- 2026/05/07 00:00 [accepted] PHST- 2026/05/20 12:39 [medline] PHST- 2026/05/20 12:39 [pubmed] PHST- 2026/05/20 11:14 [entrez] AID - 10.1007/s00392-026-02941-3 [pii] AID - 10.1007/s00392-026-02941-3 [doi] PST - aheadofprint SO - Clin Res Cardiol. 2026 May 20. doi: 10.1007/s00392-026-02941-3. PMID- 42159519 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260702 LR - 20260813 IS - 2666-0849 (Electronic) IS - 2666-0849 (Linking) VI - 31 IP - 26 DP - 2026 Jul 1 TI - Left Main Coronary Dissection Masquerading in Pediatric Polytrauma: A Diagnostic Challenge. PG - 108390 LID - S2666-0849(26)01549-4 [pii] LID - 10.1016/j.jaccas.2026.108390 [doi] LID - 108390 AB - BACKGROUND: Traumatic coronary artery dissection is an uncommon yet catastrophic sequela of blunt chest trauma, posing significant diagnostic and therapeutic challenges, particularly in young patients without pre-existing coronary disease. CASE SUMMARY: A 16-year-old male adolescent presented after an electric bicycle accident with severe polytrauma and developed unexpected cardiogenic shock. Investigation revealed a left main coronary artery dissection extending into the proximal left anterior descending artery. Despite emergency coronary artery bypass grafting and full mechanical circulatory support, he succumbed to complications. TAKE-HOME MESSAGES: High-energy deceleration alone can cause coronary dissection. Early suspicion and multidisciplinary approach for managing this life-threatening condition is crucial. CI - Copyright (c) 2026 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Wu, Peng AU - Wu P AD - Department of Cardiology, First Affiliated Hospital With Nanjing Medical University, Nanjing, China. FAU - Zhang, Dingguo AU - Zhang D AD - Department of Cardiology, First Affiliated Hospital With Nanjing Medical University, Nanjing, China. Electronic address: zhdg0223@126.com. LA - eng PT - Journal Article DEP - 20260520 PL - Netherlands TA - JACC Case Rep JT - JACC. Case reports JID - 101757292 PMC - PMC13326205 OTO - NOTNLM OT - coronary artery bypass OT - dissection OT - myocardial infarction COIS- Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2026/05/20 12:39 MHDA- 2026/05/20 12:40 PMCR- 2026/05/20 CRDT- 2026/05/20 10:30 PHST- 2026/03/23 00:00 [received] PHST- 2026/04/14 00:00 [accepted] PHST- 2026/05/20 12:40 [medline] PHST- 2026/05/20 12:39 [pubmed] PHST- 2026/05/20 10:30 [entrez] PHST- 2026/05/20 00:00 [pmc-release] AID - S2666-0849(26)01549-4 [pii] AID - 108390 [pii] AID - 10.1016/j.jaccas.2026.108390 [doi] PST - ppublish SO - JACC Case Rep. 2026 Jul 1;31(26):108390. doi: 10.1016/j.jaccas.2026.108390. Epub 2026 May 20. PMID- 42159445 OWN - NLM STAT- MEDLINE DCOM- 20260630 LR - 20261022 IS - 1529-7535 (Print) IS - 1529-7535 (Linking) VI - 27 IP - 7 DP - 2026 Jul 1 TI - Real-Time Assessment of Factors Impacting Prognostic Predictions After Pediatric Cardiac Arrest: A Single-Center Prospective Study. PG - 835-844 LID - 10.1097/PCC.0000000000003965 [doi] AB - OBJECTIVES: Children who suffer cardiac arrest are at risk of mortality and morbidity, with survivors often experiencing a severe decline in neurobehavioral function. Despite challenges in neuroprognostication, providers frequently make predictions regarding patient recovery that influence outcomes. We aimed to determine the clinical factors providers report using in real time to predict patient survival and neurologic outcomes at discharge, and how these factors differ by provider and patient characteristics, and time from arrest. DESIGN: Single center prospective observational study. SETTING: The Children's Hospital of Philadelphia PICU over 12 months, 2023-2024. PATIENTS: Children resuscitated from in-hospital cardiac arrest and out-of-hospital cardiac arrest (OHCA) who received post-arrest care in the PICU. SUBJECTS: Multidisciplinary providers of post-cardiac arrest patients. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Multidisciplinary team members completed questionnaires on post-arrest days 1, 2, 3, and 7, eliciting demographic data and factors used to form their prediction. Descriptive statistics summarized patient characteristics, provider demographics, and survey data. Mixed-effect models explored changes in factors used for the prediction of patient discharge outcome over survey time points, as well as differences by provider and patient characteristics. Overall, 64 patients (median age, 4.1 yr [interquartile range, 1.2-9.4 yr]; 60% OHCA; and 55% pre-arrest Pediatric Cerebral Performance Category = 1) were analyzed. Five hundred forty-eight questionnaires were completed by 245 unique providers. Across all time points, baseline neurologic function and clinical neurologic examination were the most frequently reported factors used to inform prognosis. Use of intra-arrest factors decreased, while reliance on neuromonitoring and neuroimaging increased over time. Factor use varied by provider discipline and patient and arrest characteristics. CONCLUSIONS: Prognostic predictions after pediatric cardiac arrest were dynamic and influenced by both patient characteristics and provider discipline. Future efforts should aim to understand how the integration of patient data impacts prognostic accuracy and clarify how prognostic impressions shape communication and decision-making with caregivers. CI - Copyright (c) 2026 by the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies. FAU - McSherry, Megan L AU - McSherry ML AUID- ORCID: 0009-0003-8930-1490 AD - Department of Anesthesiology and Critical Care Medicine, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. FAU - Zhang, Bingqing AU - Zhang B AD - Department of Biomedical and Health Informatics, Data Science and Biostatistics Unit, Children's Hospital of Philadelphia, Philadelphia, PA. FAU - Louderback, Lauren AU - Louderback L AD - Department of Anesthesiology and Critical Care Medicine, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. FAU - Little, Aubree AU - Little A AD - Department of Anesthesiology and Critical Care Medicine, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. FAU - Walsh, Kathleen E AU - Walsh KE AD - Division of Neurology, Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. FAU - Press, Craig A AU - Press CA AD - Division of Neurology, Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. FAU - McGuire, Jennifer AU - McGuire J AD - Division of Neurology, Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. FAU - Ichord, Rebecca AU - Ichord R AD - Division of Neurology, Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. FAU - Kirschen, Matthew P AU - Kirschen MP AD - Department of Anesthesiology and Critical Care Medicine, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. AD - Division of Neurology, Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. FAU - Woods-Hill, Charlotte AU - Woods-Hill C AD - Department of Anesthesiology and Critical Care Medicine, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. FAU - Topjian, Alexis AU - Topjian A AD - Department of Anesthesiology and Critical Care Medicine, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. LA - eng GR - K23 HL151381/HL/NHLBI NIH HHS/United States GR - K23 NS116120/NS/NINDS NIH HHS/United States GR - T32 GM112596/GM/NIGMS NIH HHS/United States PT - Journal Article PT - Observational Study DEP - 20260520 PL - United States TA - Pediatr Crit Care Med JT - Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies JID - 100954653 SB - IM MH - Humans MH - Prospective Studies MH - Prognosis MH - Female MH - Child, Preschool MH - Infant MH - Male MH - *Heart Arrest/therapy/mortality/complications MH - Child MH - Intensive Care Units, Pediatric MH - Time Factors MH - *Out-of-Hospital Cardiac Arrest/therapy/mortality MH - Cardiopulmonary Resuscitation PMC - PMC13682271 MID - NIHMS2213560 OTO - NOTNLM OT - cardiac arrest OT - goals-of-care conversations OT - neuroprognostication OT - prediction OT - prognosis COIS- Dr. McSherry received funding from the National Institute of General Medical Sciences (5T32GM112596-09). Dr. Kirschen's institution received funding from the National Institutes of Health (NIH; K23NS116120). Drs. McSherry, Woods-Hill, Kirschen, and Topjian received support for article research from the NIH. The remaining authors have disclosed that they do not have any potential conflicts of interest. EDAT- 2026/05/20 12:39 MHDA- 2026/06/30 18:42 PMCR- 2026/10/20 CRDT- 2026/05/20 09:33 PHST- 2026/06/30 18:42 [medline] PHST- 2026/05/20 12:39 [pubmed] PHST- 2026/05/20 09:33 [entrez] PHST- 2026/10/20 00:00 [pmc-release] AID - 00130478-202607000-00004 [pii] AID - 10.1097/PCC.0000000000003965 [doi] PST - ppublish SO - Pediatr Crit Care Med. 2026 Jul 1;27(7):835-844. doi: 10.1097/PCC.0000000000003965. Epub 2026 May 20. PMID- 42158364 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260520 LR - 20260813 IS - 2296-2360 (Print) IS - 2296-2360 (Electronic) IS - 2296-2360 (Linking) VI - 14 DP - 2026 TI - Early cardiac rehabilitation in ICU for infants after complex congenital heart disease surgery: a retrospective case series. PG - 1790456 LID - 10.3389/fped.2026.1790456 [doi] LID - 1790456 AB - BACKGROUND: Complex congenital heart disease (CHD) has long been a significant cause of infant mortality and severe morbidity. However, pediatric cardiac rehabilitation (CR) is gaining recognition, and evidence regarding postoperative ICU phase CR for infants with CHD remains scarce. METHODS: This was a retrospective case series, we reviewed clinical data for 10 infants with complex CHD who received an early, individualized CR program during the postoperative ICU phase. The rehabilitation was initiated between postoperative days 5-15 (median 9). The program was based on an exercise prescription, and integrated multidimensional interventions, including respiratory training, gross motor function training, nutritional support, and developmental care. RESULTS: All infants were critically ill postoperatively requiring various forms of life-support therapy in the ICU. No serious adverse events related to rehabilitation occurred; transient fluctuations in vital signs resolved promptly with temporary pauses in therapy. Eight infants were discharged home after recovery, and two were transferred to other institutions. Functional improvements were observed across respiratory, feeding, neuromotor, and circulatory domains during the ICU stay. CONCLUSION: For infants with complex CHD, early initiation of a cardiac rehabilitation program during the ICU phase appears safe and feasible when implemented under multidisciplinary assessment and close clinical monitoring. This approach may support functional recovery across cardiopulmonary and neuromotor domains during a critical developmental window. CI - (c) 2026 Yue, Deng, Shi, Hu, Liu and Wang. FAU - Yue, Mingye AU - Yue M AD - Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. FAU - Deng, Hongjun AU - Deng H AD - Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. FAU - Shi, Jiawei AU - Shi J AD - Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. FAU - Hu, Yuting AU - Hu Y AD - Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. FAU - Liu, Xinghong AU - Liu X AD - Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. FAU - Wang, Huihua AU - Wang H AD - Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. LA - eng PT - Journal Article DEP - 20260504 PL - Switzerland TA - Front Pediatr JT - Frontiers in pediatrics JID - 101615492 PMC - PMC13180908 OTO - NOTNLM OT - cardiac rehabilitation OT - congenital heart disease OT - early rehabilitation OT - infant OT - intensive care unit COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/05/20 06:31 MHDA- 2026/05/20 06:32 PMCR- 2026/05/04 CRDT- 2026/05/20 04:40 PHST- 2026/01/18 00:00 [received] PHST- 2026/03/18 00:00 [revised] PHST- 2026/04/13 00:00 [accepted] PHST- 2026/05/20 06:32 [medline] PHST- 2026/05/20 06:31 [pubmed] PHST- 2026/05/20 04:40 [entrez] PHST- 2026/05/04 00:00 [pmc-release] AID - 10.3389/fped.2026.1790456 [doi] PST - epublish SO - Front Pediatr. 2026 May 4;14:1790456. doi: 10.3389/fped.2026.1790456. eCollection 2026. PMID- 42155636 OWN - NLM STAT- MEDLINE DCOM- 20260907 LR - 20260923 IS - 1916-7075 (Electronic) IS - 0828-282X (Linking) VI - 42 IP - 9 DP - 2026 Sep TI - Clinical Profile and Outcomes of Patients Deemed Ineligible for Transcatheter Tricuspid Valve Intervention. PG - 2076-2084 LID - S0828-282X(26)00407-1 [pii] LID - 10.1016/j.cjca.2026.05.004 [doi] AB - BACKGROUND: Transcatheter tricuspid valve intervention (TTVI) has expanded therapeutic options for tricuspid regurgitation (TR); however, a substantial proportion of patients remain ineligible because of anatomical and clinical constraints. We sought to characterize patients screened out from TTVI and evaluate their clinical outcomes. METHODS: In this single-centre retrospective cohort study (January 2021 to May 2025), we included consecutive patients with symptomatic severe TR referred for TTVI evaluation who were deemed ineligible by a multidisciplinary heart team. Patients were identified through institutional logs and clinical trial screening databases. Baseline clinical, echocardiographic, and hemodynamic data were collected. Outcomes included 1-year all-cause mortality, heart failure hospitalization (HFH), and their composite. RESULTS: Among 205 patients evaluated, 83 (40.5%) were deemed ineligible. The mean age was 72.2 years, with a high burden of comorbidities. Severe or torrential TR was present in 84.4% of patients. The most frequent reasons for exclusion were unfavourable anatomy, including significant tricuspid annular dilation (69.5%) and a coaptation gap >/= 7-10 mm (59.8%). Patients who died within 1 year had higher right-sided filling pressures on invasive hemodynamic assessment. At 1 year, all-cause mortality was 20.5%, HFH occurred in 31.3%, and the composite end point in 51.8%. Kaplan-Meier estimates showed survival of 77.5% and freedom from HFH of 58.3% at 12 months. CONCLUSIONS: Patients deemed ineligible for TTVI represent a high-risk cohort with substantial morbidity and mortality at 1 year. These findings underscore the importance of earlier referral, optimized screening strategies, and continued device innovation to expand treatment eligibility. CI - Copyright (c) 2026 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Kharsa, Chloe AU - Kharsa C AD - Houston Methodist DeBakey Heart and Vascular Center, Houston, Texas, USA. Electronic address: https://x.com/KharsaChloe. FAU - Sella, Gal AU - Sella G AD - Houston Methodist DeBakey Heart and Vascular Center, Houston, Texas, USA. FAU - Kritya, Mangesh AU - Kritya M AD - Houston Methodist DeBakey Heart and Vascular Center, Houston, Texas, USA. Electronic address: https://x.com/KrityaMangesh. FAU - Hatab, Taha AU - Hatab T AD - Houston Methodist DeBakey Heart and Vascular Center, Houston, Texas, USA. FAU - Samimi, Sahar AU - Samimi S AD - Houston Methodist DeBakey Heart and Vascular Center, Houston, Texas, USA. FAU - Bhimaraj, Arvin AU - Bhimaraj A AD - Houston Methodist DeBakey Heart and Vascular Center, Houston, Texas, USA. FAU - Guha, Ashrith AU - Guha A AD - Houston Methodist DeBakey Heart and Vascular Center, Houston, Texas, USA. FAU - Gorthi, Janardhana R AU - Gorthi JR AD - Houston Methodist DeBakey Heart and Vascular Center, Houston, Texas, USA. FAU - Fernando, Ramirez Del Val AU - Fernando RDV AD - Houston Methodist DeBakey Heart and Vascular Center, Houston, Texas, USA. FAU - Faza, Nadeen N AU - Faza NN AD - Houston Methodist DeBakey Heart and Vascular Center, Houston, Texas, USA. Electronic address: https://x.com/NadeenFaza. FAU - Little, Stephen H AU - Little SH AD - Houston Methodist DeBakey Heart and Vascular Center, Houston, Texas, USA. Electronic address: https://x.com/SLittleMD. FAU - Atkins, Marvin D AU - Atkins MD AD - Houston Methodist DeBakey Heart and Vascular Center, Houston, Texas, USA. Electronic address: https://x.com/mdatkins. FAU - Zoghbi, William AU - Zoghbi W AD - Houston Methodist DeBakey Heart and Vascular Center, Houston, Texas, USA. Electronic address: https://x.com/WilliamZoghbi. FAU - Aoun, Joe AU - Aoun J AD - Houston Methodist DeBakey Heart and Vascular Center, Houston, Texas, USA. Electronic address: https://x.com/Joe_Aoun_. FAU - Kleiman, Neal S AU - Kleiman NS AD - Houston Methodist DeBakey Heart and Vascular Center, Houston, Texas, USA. FAU - Reardon, Michael J AU - Reardon MJ AD - Houston Methodist DeBakey Heart and Vascular Center, Houston, Texas, USA. FAU - Goel, Sachin S AU - Goel SS AD - Houston Methodist DeBakey Heart and Vascular Center, Houston, Texas, USA. Electronic address: ssgoel@houstonmethodist.org. LA - eng PT - Journal Article DEP - 20260518 PL - England TA - Can J Cardiol JT - The Canadian journal of cardiology JID - 8510280 SB - IM MH - Humans MH - *Tricuspid Valve Insufficiency/surgery/diagnosis/mortality MH - Female MH - Retrospective Studies MH - Male MH - *Cardiac Catheterization/methods MH - Aged MH - *Tricuspid Valve/surgery/diagnostic imaging MH - *Heart Valve Prosthesis Implantation/methods MH - Echocardiography MH - *Patient Selection MH - Heart Failure/epidemiology MH - Treatment Outcome OTO - NOTNLM OT - Tricuspid valve repair OT - heart failure OT - transcatheter tricuspid edge-to-edge repair OT - tricuspid regurgitation OT - tricuspid valve replacement EDAT- 2026/05/20 00:33 MHDA- 2026/09/07 23:34 CRDT- 2026/05/19 19:34 PHST- 2026/01/15 00:00 [received] PHST- 2026/04/18 00:00 [revised] PHST- 2026/05/06 00:00 [accepted] PHST- 2026/09/07 23:34 [medline] PHST- 2026/05/20 00:33 [pubmed] PHST- 2026/05/19 19:34 [entrez] AID - S0828-282X(26)00407-1 [pii] AID - 10.1016/j.cjca.2026.05.004 [doi] PST - ppublish SO - Can J Cardiol. 2026 Sep;42(9):2076-2084. doi: 10.1016/j.cjca.2026.05.004. Epub 2026 May 18. PMID- 42154863 OWN - NLM STAT- MEDLINE DCOM- 20260717 LR - 20260813 IS - 1678-4170 (Electronic) IS - 0066-782X (Print) IS - 0066-782X (Linking) VI - 123 IP - 3 DP - 2026 TI - Danon Disease: Understanding the Role of LAMP2 Variants in Cardiomyopathy and Multisystemic Involvement. PG - e20250186 LID - S0066-782X2026000301402 [pii] LID - 10.36660/abc.20250186 [doi] LID - e20250186 AB - Danon disease (DD) is a rare X-linked disorder caused by pathogenic or likely pathogenic variants in the lysosome-associated membrane protein 2 (LAMP2) gene. It primarily manifests as hypertrophic cardiomyopathy, myopathy, intellectual disability, and retinopathy, with males typically experiencing a more severe and early-onset phenotype. The pathophysiology of DD is linked to defective autophagy due to LAMP2 deficiency, leading to the accumulation of glycogen-filled vacuoles within cardiomyocytes and other tissues. This results in progressive cardiac hypertrophy, conduction abnormalities, and eventual heart failure, often necessitating heart transplantation. Skeletal muscle involvement is common in males, while cognitive impairments are observed in both genders, though more prevalent in males. Diagnosis is challenging due to the condition's rarity and variable presentation, highlighting the need for a multidisciplinary approach, including genetic testing for definitive diagnosis. Genetic testing must be performed only after proper genetic counseling is done. Differential diagnosis must be considered when DD is suspected, depending on the signs and symptoms, such as Fabry disease, PRKAG2, Pompe disease, and others. Management strategies currently focus on symptomatic treatment, with cardiac transplantation as a critical intervention for advanced cases. Emerging therapies, such as gene therapy targeting LAMP2, could help in altering disease progression. This review provides a comprehensive overview of DD, discussing its clinical manifestations, underlying mechanisms, diagnostic challenges, and potential therapeutic approaches in improving outcomes. Our goal is to increase the recognition of DD so that the prevention of possible complications and early diagnosis becomes feasible, ultimately leading to more favorable patient outcomes. FAU - Ribeiro, Giovanna Napolitano Pereira AU - Ribeiro GNP AUID- ORCID: 0009-0003-6036-5474 AD - Laboratorio de genetica e cardiologia molecular - Instituto do Coracao do Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, SP - Brasil. FAU - Lipari, Layara Fernanda Vicente Pereira AU - Lipari LFVP AUID- ORCID: 0000-0003-0982-0307 AD - Laboratorio de genetica e cardiologia molecular - Instituto do Coracao do Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, SP - Brasil. FAU - Senra, Paula Mendonca AU - Senra PM AD - Laboratorio de genetica e cardiologia molecular - Instituto do Coracao do Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, SP - Brasil. FAU - Pires, Lucas Vieira Lacerda AU - Pires LVL AUID- ORCID: 0000-0001-8649-976X AD - Laboratorio de genetica e cardiologia molecular - Instituto do Coracao do Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, SP - Brasil. FAU - Mizuta, Marjorie Hayashida AU - Mizuta MH AUID- ORCID: 0000-0001-9107-052X AD - Laboratorio de genetica e cardiologia molecular - Instituto do Coracao do Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, SP - Brasil. FAU - Olivetti, Natalia Quintella Sangiorgi AU - Olivetti NQS AUID- ORCID: 0000-0003-1061-8982 AD - Laboratorio de genetica e cardiologia molecular - Instituto do Coracao do Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, SP - Brasil. FAU - Aiello, Vera Demarchi AU - Aiello VD AD - Laboratorio de genetica e cardiologia molecular - Instituto do Coracao do Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, SP - Brasil. FAU - Krieger, Jose Eduardo AU - Krieger JE AD - Laboratorio de genetica e cardiologia molecular - Instituto do Coracao do Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, SP - Brasil. LA - por LA - eng PT - Journal Article PT - Review TT - Doenca de Danon: Compreendendo o Papel das Variantes do LAMP2 na Miocardiopatia e no Envolvimento Multissistemico. DEP - 20260515 PL - Brazil TA - Arq Bras Cardiol JT - Arquivos brasileiros de cardiologia JID - 0421031 RN - 0 (Lysosomal-Associated Membrane Protein 2) RN - 0 (LAMP2 protein, human) SB - IM MH - Humans MH - *Glycogen Storage Disease Type IIb/genetics/diagnosis/therapy/physiopathology/complications MH - *Lysosomal-Associated Membrane Protein 2/genetics MH - Male MH - Phenotype MH - Diagnosis, Differential MH - *Cardiomyopathies/genetics MH - Female PMC - PMC13128213 OAB - Danon disease (DD) is a rare X-linked disorder caused by pathogenic or likely pathogenic variants in the lysosome-associated membrane protein 2 (LAMP2) gene. It primarily manifests as hypertrophic cardiomyopathy, myopathy, intellectual disability, and retinopathy, with males typically experiencing a more severe and early-onset phenotype. The pathophysiology of DD is linked to defective autophagy due to LAMP2 deficiency, leading to the accumulation of glycogen-filled vacuoles within cardiomyocytes and other tissues. This results in progressive cardiac hypertrophy, conduction abnormalities, and eventual heart failure, often necessitating heart transplantation. Skeletal muscle involvement is common in males, while cognitive impairments are observed in both genders, though more prevalent in males. Diagnosis is challenging due to the condition's rarity and variable presentation, highlighting the need for a multidisciplinary approach, including genetic testing for definitive diagnosis. Genetic testing must be performed only after proper genetic counseling is done. Differential diagnosis must be considered when DD is suspected, depending on the signs and symptoms, such as Fabry disease, PRKAG2, Pompe disease, and others. Management strategies currently focus on symptomatic treatment, with cardiac transplantation as a critical intervention for advanced cases. Emerging therapies, such as gene therapy targeting LAMP2, could help in altering disease progression. This review provides a comprehensive overview of DD, discussing its clinical manifestations, underlying mechanisms, diagnostic challenges, and potential therapeutic approaches in improving outcomes. Our goal is to increase the recognition of DD so that the prevention of possible complications and early diagnosis becomes feasible, ultimately leading to more favorable patient outcomes. OABL- eng COIS- Potencial conflito de interesse: Nao ha conflito com o presente artigo. EDAT- 2026/05/19 18:32 MHDA- 2026/05/19 18:33 PMCR- 2026/04/17 CRDT- 2026/05/19 14:04 PHST- 2025/03/18 00:00 [received] PHST- 2026/01/13 00:00 [accepted] PHST- 2026/05/19 18:33 [medline] PHST- 2026/05/19 18:32 [pubmed] PHST- 2026/05/19 14:04 [entrez] PHST- 2026/04/17 00:00 [pmc-release] AID - S0066-782X2026000301402 [pii] AID - 10.36660/abc.20250186 [doi] PST - epublish SO - Arq Bras Cardiol. 2026 May 15;123(3):e20250186. doi: 10.36660/abc.20250186. eCollection 2026. PMID- 42154163 OWN - NLM STAT- MEDLINE DCOM- 20260716 LR - 20260813 IS - 1534-3170 (Electronic) IS - 1523-3782 (Print) IS - 1523-3782 (Linking) VI - 28 IP - 1 DP - 2026 May 19 TI - Long-Term Care in Fontan Circulation: Surveillance and Management of Fontan-Associated Liver Disease and Protein-Losing Enteropathy. LID - 10.1007/s11886-026-02378-0 [doi] LID - 56 AB - PURPOSE OF REVIEW: This manuscript reviews the clinical spectrum and management of Fontan-associated liver disease (FALD) and protein-losing enteropathy (PLE), examining how chronic venous hypertension leads to multisystem injury. RECENT FINDINGS: Liver fibrosis is now recognized as an early and nearly universal complication after the Fontan procedure, with cirrhosis affecting approximately 43% of patients by 30 years post-operation. Although post-2001 survival exceeds 90%, standard biomarkers and imaging frequently underestimate disease severity, as liver stiffness measurements are confounded by hepatic congestion. Liver biopsy remains the gold standard for staging. FALD is an inevitable consequence of Fontan physiology, characterized by sinusoidal congestion and progressive fibrosis, while PLE results from multifactorial gastrointestinal protein loss. The key clinical implication is the importance of a multidisciplinary approach, particularly when considering transition from isolated heart transplantation to combined heart-liver transplantation in advanced disease. Future research should prioritize standardized staging systems and targeted therapies to reduce lymphatic dysfunction and fibrosis progression. CI - (c) 2026. The Author(s). FAU - Jarasvaraparn, Chaowapong AU - Jarasvaraparn C AD - Division of Pediatric Gastroenterology, Hepatology and Nutrition, Indiana University, 705 Riley Hospital Drive, ROC 4210, Indianapolis, IN, 46202, USA. cjarasva@iu.edu. FAU - Schooler, Gary R AU - Schooler GR AD - Department of Radiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. FAU - Gonzalez, Ivan A AU - Gonzalez IA AD - Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indiana, USA. FAU - Ginde, Salil AU - Ginde S AD - Department of Pediatric Cardiology, Medical College of Wisconsin, Milwaukee, WI, USA. FAU - Mavis, Alisha AU - Mavis A AD - Department of Pediatric Gastroenterology, Hepatology and Nutrition, Levine Children's Hospital, Advocate Health, Charlotte, NC, USA. LA - eng PT - Journal Article PT - Review DEP - 20260519 PL - United States TA - Curr Cardiol Rep JT - Current cardiology reports JID - 100888969 SB - IM MH - Humans MH - *Fontan Procedure/adverse effects MH - *Protein-Losing Enteropathies/etiology/therapy/diagnosis MH - *Liver Cirrhosis/etiology/therapy MH - Long-Term Care MH - *Heart Defects, Congenital/surgery MH - Liver Transplantation MH - *Liver Diseases/etiology/therapy MH - *Postoperative Complications/therapy PMC - PMC13186934 OTO - NOTNLM OT - Fontan procedure OT - Fontan-associated liver disease OT - Protein losing enteropathy COIS- Declarations. Financial Disclosure: No financial relationships relevant to this article to disclose. Human and Animal Rights and Informed Consent: This article does not contain any studies with human or animal subjects performed by any of the authors. Conflicts of interest: The authors declare no competing interests. EDAT- 2026/05/19 12:36 MHDA- 2026/05/19 12:37 PMCR- 2026/05/19 CRDT- 2026/05/19 11:07 PHST- 2026/02/18 00:00 [received] PHST- 2026/05/08 00:00 [accepted] PHST- 2026/05/19 12:37 [medline] PHST- 2026/05/19 12:36 [pubmed] PHST- 2026/05/19 11:07 [entrez] PHST- 2026/05/19 00:00 [pmc-release] AID - 10.1007/s11886-026-02378-0 [pii] AID - 2378 [pii] AID - 10.1007/s11886-026-02378-0 [doi] PST - epublish SO - Curr Cardiol Rep. 2026 May 19;28(1):56. doi: 10.1007/s11886-026-02378-0. PMID- 42153510 OWN - NLM STAT- Publisher LR - 20260519 IS - 2058-1742 (Electronic) IS - 2058-1742 (Linking) DP - 2026 May 19 TI - Adult congenital cardiac interventional training, competencies, and organization. A Statement of the ESC ACHD Working Group, the EAPCI, the AEPC, and the PICS-Society. LID - qcag078 [pii] LID - 10.1093/ehjqcco/qcag078 [doi] AB - AIMS: The growing population of adults with congenital heart disease (ACHD) has prompted global initiatives to define standards of care, training pathways, and institutional requirements for catheter-based interventions. High-quality care and effective training rely on specialized, multidisciplinary centres integrating paediatric and adult cardiologists, surgeons, and anaesthesiologists with congenital expertise, supported by advanced catheter labs and hybrid theatres. This work outlines essential elements for optimal ACHD catheterization training, emphasizing a structured, competency-based curriculum covering theory, procedural skills, and post-procedural care. METHODS AND RESULTS: Collaboration between paediatric and adult cardiologists is highlighted as vital for comprehensive care. To meet national and regional needs, a two-tier model of 'level 1' and 'level 2' centres-each with specific capacities-is proposed. Scientific societies play a key role in establishing guidelines, certifications, and facilitating trainee mobility and international collaboration. Emerging tools such as augmented reality and virtual case libraries can improve accessibility and quality of training. The framework also addresses global equity, considering regional and socio-economic differences. Proctorships and partnerships with industry are integral for introducing innovations and maintaining skills in evolving techniques. CONCLUSION: By fostering collaboration, harmonized standards, and multidisciplinary expertise, this model aims to improve ACHD training and meet growing patient needs. CI - (c) The European Society of Cardiology 2026. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com. FAU - Chessa, Massimo AU - Chessa M AUID- ORCID: 0000-0001-7432-4815 AD - Pediatric and Adult Congenital Heart Centre, IRCCS Policlinico San Donato, Milan, Italy. AD - Vita-Salute San Raffaele University, Milan, Italy. FAU - Brida, Margarita AU - Brida M AUID- ORCID: 0000-0001-8754-8156 AD - Adult Congenital Heart Centre and National Centre for Pulmonary Hypertension, Royal Brompton and Harefield Hospitals, Guys & St Thomas's NHS Trust, Sydney Street, London SW3 6NP, UK. AD - Medical Faculty University of Rijeka, Rijeka, Croatia. AD - National Heart & Lung Institute, Imperial College, Dovehouse St, London SW3 6LY, UK. FAU - Budts, Werner AU - Budts W AD - Department of Cardiology, University Hospitals Leuven, Leuven, Belgium. FAU - Chieffo, Alaide AU - Chieffo A AD - Department of Cardiology Vita-Salute San Raffaele University, Milan, Italy. FAU - Dua, Jaspal AU - Dua J AD - Adult Congenital Heart Disease Centre, Liverpool Heart and Chest Hospital, Liverpool L14 3PE, UK. FAU - Kaleschke, Gerrit AU - Kaleschke G AUID- ORCID: 0000-0002-8782-0401 AD - Department of Cardiology III-Adult Congenital and Valvular Heart Disease, University Hospital Munster, Munster, Germany. FAU - Kempny, Alexander AU - Kempny A AD - Adult Congenital Heart Centre and National Centre for Pulmonary Hypertension, Royal Brompton and Harefield Hospitals, Guys & St Thomas's NHS Trust, Sydney Street, London SW3 6NP, UK. AD - National Heart & Lung Institute, Imperial College, Dovehouse St, London SW3 6LY, UK. FAU - Kenny, Damien AU - Kenny D AD - Department of Cardiology and Cardiac Surgery, Children's Health Ireland at Crumlin, and Department of Cardiology, Mater University Hospital, Dublin, Ireland. FAU - Krasemann, Thomas AU - Krasemann T AD - Department of Pediatric Cardiology, Erasmus MC - Sophia Children's Hospital, Rotterdam, The Netherlands. FAU - Rahbek Schmidt, Michael AU - Rahbek Schmidt M AD - Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Inge Lehmanns Vej 7, Copenhagen 2100, Denmark. FAU - Aboulhosn, Jamil AU - Aboulhosn J AUID- ORCID: 0000-0002-0209-9505 AD - Department of Medicine, Division of Cardiology, University of California Los Angeles, Ahmanson/UCLA Adult Congenital Heart Center, Los Angeles, CA, USA. LA - eng PT - Journal Article DEP - 20260519 PL - England TA - Eur Heart J Qual Care Clin Outcomes JT - European heart journal. Quality of care & clinical outcomes JID - 101677796 SB - IM OTO - NOTNLM OT - Adult congenital heart disease (ACHD) OT - Cardiac catheterization OT - Competency-based training OT - Interventional cardiology OT - Multidisciplinary team COIS- Conflict of interest: None declared. EDAT- 2026/05/19 12:38 MHDA- 2026/05/19 12:38 CRDT- 2026/05/19 07:52 PHST- 2025/08/08 00:00 [received] PHST- 2025/11/09 00:00 [revised] PHST- 2026/04/19 00:00 [accepted] PHST- 2026/05/19 12:38 [medline] PHST- 2026/05/19 12:38 [pubmed] PHST- 2026/05/19 07:52 [entrez] AID - 8687345 [pii] AID - 10.1093/ehjqcco/qcag078 [doi] PST - aheadofprint SO - Eur Heart J Qual Care Clin Outcomes. 2026 May 19:qcag078. doi: 10.1093/ehjqcco/qcag078. PMID- 42152546 OWN - NLM STAT- MEDLINE DCOM- 20261020 LR - 20261020 IS - 1467-1107 (Electronic) IS - 1047-9511 (Linking) VI - 36 IP - 5 DP - 2026 May TI - Frequency of non-cardiac surgical procedures in neonates undergoing cardiac surgery: potential use of setting family and care team expectations. PG - 931-935 LID - 10.1017/S1047951126112918 [doi] AB - INTRODUCTION: Most children with CHD who undergo cardiac surgery in infancy require anaesthesia for additional non-cardiac procedures early in childhood. The purpose of our study was to characterise the use of non-cardiac procedures during the first year of life among neonates requiring cardiac surgery in order to set family and care team expectations. MATERIALS AND METHODS: We conducted a retrospective descriptive study comprising data collection from the medical record since programme inception from September 1, 2018, to November 3, 2025. The records of all patients undergoing neonatal cardiac surgery were reviewed if they reached their first birthday during the study period. Infants who died during hospitalisation were excluded. RESULTS: Three hundred fourteen unique neonates underwent 862 procedures (Figure ). The typical neonate underwent 2.75 procedures during the first year of life (not including cardiac surgery). The surgical complexity STAT scores of the neonatal operation categories 1-5 had 48, 57, 92, 78, and 39 participants, respectively. The STAT category associated with the most frequent use of anaesthetics was STAT 5. The most common procedures were peripherally inserted central catheter line, cardiac catheterisation, CT with angiography, and gastrostomy tube placement. COMMENT: We conducted a retrospective descriptive study comprising data collection from the medical record since programme inception from September 1, 2018, to November 3, 2025. A requirement for non-cardiac procedures in the first year of life is common but not universal. Neonates undergoing more complex cardiac procedures (STAT 3-5) underwent more frequent non-cardiac anaesthetics compared with STAT 1-2. FAU - Sinton, Jamie Wingate AU - Sinton JW AUID- ORCID: 0000-0002-9906-1895 AD - Cardiothoracic and Vascular Surgery, University of Texas at Austin, Dell Children's Medical Center, USA. ROR: https://ror.org/00hj54h04 FAU - Schukei, Sarah AU - Schukei S AUID- ORCID: 0009-0008-8878-2882 AD - Texas Center for Pediatric and Congenital Heart Disease, Outcomes Team, USA. FAU - Keene, Cynthia AU - Keene C AD - Cardiothoracic and Vascular Surgery, University of Texas at Austin, Dell Children's Medical Center, USA. ROR: https://ror.org/00hj54h04 FAU - Stayer, Stephen AU - Stayer S AD - Cardiothoracic and Vascular Surgery, University of Texas at Austin, Dell Children's Medical Center, USA. ROR: https://ror.org/00hj54h04 FAU - Nguyen, Linh M AU - Nguyen LM AD - University of the Incarnate Word, USA. FAU - Fraser, Charles D Jr AU - Fraser CD Jr AD - Cardiothoracic and Vascular Surgery, University of Texas at Austin, Dell Children's Medical Center, USA. ROR: https://ror.org/00hj54h04 FAU - Gottlieb, Erin AU - Gottlieb E AD - Cardiothoracic and Vascular Surgery, University of Texas at Austin, Dell Children's Medical Center, USA. ROR: https://ror.org/00hj54h04 LA - eng PT - Journal Article DEP - 20260519 PL - England TA - Cardiol Young JT - Cardiology in the young JID - 9200019 SB - IM MH - Humans MH - Retrospective Studies MH - Infant, Newborn MH - Female MH - *Heart Defects, Congenital/surgery MH - Male MH - *Cardiac Surgical Procedures MH - Infant MH - *Patient Care Team MH - Pediatric Anesthesia OTO - NOTNLM OT - CHD OT - anaesthesia OT - congenital heart surgery EDAT- 2026/05/19 06:31 MHDA- 2026/10/20 17:34 CRDT- 2026/05/19 02:03 PHST- 2026/10/20 17:34 [medline] PHST- 2026/05/19 06:31 [pubmed] PHST- 2026/05/19 02:03 [entrez] AID - S1047951126112918 [pii] AID - 10.1017/S1047951126112918 [doi] PST - ppublish SO - Cardiol Young. 2026 May;36(5):931-935. doi: 10.1017/S1047951126112918. Epub 2026 May 19. PMID- 42147574 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260518 LR - 20260813 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 18 IP - 4 DP - 2026 Apr TI - Transcatheter Therapy in Secondary Mitral Regurgitation: Recent Clinical Evidence and Emerging Frontiers. PG - e106989 LID - 10.7759/cureus.106989 [doi] LID - e106989 AB - Secondary mitral regurgitation (SMR) is a common valvular disorder in patients with heart failure and is associated with poor prognosis. Transcatheter edge-to-edge repair (TEER), particularly with the MitraClip device, has emerged as a less invasive alternative to surgery, with growing evidence supporting its clinical role. However, trial results have been heterogeneous, and optimal patient selection remains under debate. A narrative literature review was conducted using a targeted manual search of PubMed (2018-2026), with the terms ("secondary mitral regurgitation" OR "functional mitral regurgitation") AND (transcatheter OR MitraClip) AND (randomized OR trial OR meta-analysis). A total of 13 key studies were included, comprising randomized clinical trials, meta-analyses, and relevant prospective series, complemented by 30 selected supporting studies used for contextualization. Recent trials such as COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation) and RESHAPE-HF2 (Randomized Study of the MitraClip Device in Heart Failure Patients with Clinically Significant Functional Mitral Regurgitation) suggest that TEER reduces heart failure hospitalizations in selected patients, while MATTERHORN (Multicenter Mitral Valve Reconstruction for Advanced Insufficiency of Functional or Ischemic Origin) supports transcatheter repair as a safer short-term alternative to surgery in appropriate cases. The concept of disproportionate mitral regurgitation has become central to identifying candidates most likely to benefit. Alternative devices such as PASCAL (Edwards Lifesciences, Irvine, California) and emerging technologies, including transcatheter mitral valve replacement (TMVR), are expanding therapeutic options. TEER is a valuable and safe therapeutic option for patients with SMR who remain symptomatic despite optimal medical therapy, particularly when careful clinical and anatomical selection is applied. Although this review has methodological limitations inherent to its narrative design, it provides an updated and clinically relevant overview of current evidence and future directions in SMR management. CI - Copyright (c) 2026, Torres et al. FAU - Torres, Alvaro AU - Torres A AD - School of Medicine, Faculty of Medicine, Pontificia Universidad Catolica de Chile, Santiago, CHL. FAU - Jochava, Renato AU - Jochava R AD - School of Medicine, Faculty of Medicine, Pontificia Universidad Catolica de Chile, Santiago, CHL. FAU - Quintanilla, Francisca AU - Quintanilla F AD - School of Medicine, Faculty of Medicine, Pontificia Universidad Catolica de Chile, Santiago, CHL. FAU - Cordova, Catalina AU - Cordova C AD - School of Medicine, Faculty of Medicine, Pontificia Universidad Catolica de Chile, Santiago, CHL. FAU - Krogh, Gunther AU - Krogh G AD - Department of Cardiac Surgery, Division of Surgery, Faculty of Medicine, Pontificia Universidad Catolica de Chile, Santiago, CHL. FAU - Besa, Santiago AU - Besa S AD - Department of Cardiac Surgery, Division of Surgery, Faculty of Medicine, Pontificia Universidad Catolica de Chile, Santiago, CHL. LA - eng PT - Journal Article PT - Review DEP - 20260413 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC13171469 OTO - NOTNLM OT - chronic heart failure OT - functional mitral regurgitation OT - heart team OT - mitraclip(R) OT - mitral valve insufficiency OT - secondary mitral regurgitation (smr) OT - structural heart disease intervention OT - transcatheter edge-to-edge repair OT - transcatheter mitral valve replacement OT - valvular-heart disease COIS- Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. EDAT- 2026/05/18 12:42 MHDA- 2026/05/18 12:43 PMCR- 2026/04/13 CRDT- 2026/05/18 06:55 PHST- 2026/04/13 00:00 [accepted] PHST- 2026/05/18 12:43 [medline] PHST- 2026/05/18 12:42 [pubmed] PHST- 2026/05/18 06:55 [entrez] PHST- 2026/04/13 00:00 [pmc-release] AID - 10.7759/cureus.106989 [doi] PST - epublish SO - Cureus. 2026 Apr 13;18(4):e106989. doi: 10.7759/cureus.106989. eCollection 2026 Apr. PMID- 42146870 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260518 LR - 20260926 IS - 2090-6900 (Print) IS - 2090-6919 (Electronic) IS - 2090-6919 (Linking) VI - 2026 DP - 2026 TI - Heartburn Takes a Whole New Meaning: Multidisciplinary Management of a Gastropericardial Fistula. PG - 5597348 LID - 10.1155/cris/5597348 [doi] LID - 5597348 AB - Gastropericardial fistulas (GCs) are exceedingly rare in the reported literature. Etiologies include prior abdominal surgery, malignancy, and perforated gastric ulcers. Presenting symptoms range from chest pain to cardiac tamponade. Early imaging can help delineate the origin of the fistula. Management involves a multidisciplinary team, involving endoscopic stenting for temporization followed by definitive surgery for fistula closure. Robotic, video-assisted thoracoscopic surgery (VATS) with pericardial window has only been reported once in modern literature as definitive management for GCs. Thus, we present a case of a gastro-pericardial fistula that was temporized with endoscopic stenting and surgically managed with right robotic VATS with a pericardial window and definitive fistula closure. The patient had presented in cardiac tamponade with initial imaging demonstrating a large, loculated hydropneumopericardium and GC. The patient's postoperative course was unremarkable, and she was discharged on postoperative day 7. Follow-up within our health system is currently 4.5 years, and she continues to do well. CI - Copyright (c) 2026 Jake Sypniewski et al. Case Reports in Surgery published by John Wiley & Sons Ltd. FAU - Sypniewski, Jake AU - Sypniewski J AUID- ORCID: 0009-0000-8471-0218 AD - College of Human Medicine, Michigan State University, Grand Rapids, Michigan, USA, msu.edu. FAU - Kelley, Jesse K AU - Kelley JK AD - Department of General Surgery, Corewell Health West Michigan, Grand Rapids, Michigan, USA. FAU - Fritz, G Dane AU - Fritz GD AD - Division of Cardiothoracic Surgery, Corewell Health West Michigan, Grand Rapids, Michigan, USA. FAU - Lam, Geoffrey AU - Lam G AD - Division of Cardiothoracic Surgery, Corewell Health West Michigan, Grand Rapids, Michigan, USA. FAU - Zolotarevsky, Eugene AU - Zolotarevsky E AD - Department of Gastroenterology, Corewell Health West Michigan, Grand Rapids, Michigan, USA. LA - eng PT - Journal Article DEP - 20260513 PL - United States TA - Case Rep Surg JT - Case reports in surgery JID - 101580191 PMC - PMC13172607 OTO - NOTNLM OT - endoscopic stenting OT - gastropericardial fistula OT - pericardial window OT - video-assisted thoracoscopic surgery (VATS) COIS- The authors declare no conflicts of interest. EDAT- 2026/05/18 12:43 MHDA- 2026/05/18 12:44 PMCR- 2026/05/13 CRDT- 2026/05/18 06:49 PHST- 2025/07/09 00:00 [received] PHST- 2026/04/10 00:00 [revised] PHST- 2026/04/15 00:00 [accepted] PHST- 2026/05/18 12:44 [medline] PHST- 2026/05/18 12:43 [pubmed] PHST- 2026/05/18 06:49 [entrez] PHST- 2026/05/13 00:00 [pmc-release] AID - CRIS5597348 [pii] AID - 10.1155/cris/5597348 [doi] PST - epublish SO - Case Rep Surg. 2026 May 13;2026:5597348. doi: 10.1155/cris/5597348. eCollection 2026. PMID- 42146864 OWN - NLM STAT- MEDLINE DCOM- 20260716 LR - 20260928 IS - 2309-995X (Electronic) IS - 2076-4243 (Print) IS - 2076-4243 (Linking) VI - 18 IP - 2 DP - 2026 TI - A New Quantitative Method for Assessing the Ultrastructure of Cardiomyocyte Mitochondria of the Right Atrial Appendage. PG - 54-60 LID - 10.17691/stm2026.18.2.05 [doi] AB - The aim of this study was to develop a quantitative method for assessing the ultrastructure of cardiomyocyte mitochondria in the right atrial appendage of patients with chronic heart failure (CHF). MATERIALS AND METHODS: A single-center prospective study included 39 patients aged 67 [58; 71] years who underwent coronary artery bypass grafting. The inclusion criteria were as follows: heart failure with a left ventricular ejection fraction of <50%, atherosclerotic plaques in two or more large coronary arteries of 70% or greater, and the cardiac team's decision to perform coronary artery bypass grafting. To perform electron microscopy, biopsy samples were collected from the right atrial appendage during coronary artery bypass grafting. Two calculated parameters were used for the analysis: "total area of interfibrillar mitochondria" and "ratio of outer to inner membrane length". Based on these, the total index was calculated by the formula: the "total area of interfibrillar mitochondria" / the "ratio of outer to inner membrane length". RESULTS: The median values of the calculated parameters characterizing the ultrastructure of cardiomyocyte mitochondria in the right atrial appendage were as follows: 43.7 [35.9; 54.3]% for the "total area of interfibrillar mitochondria", 31 [25; 37]% for the "ratio of outer to inner membrane length", and 1.4 [0.95; 2.00] for the total index accounting for both ultrastructural characteristics of mitochondria: the "total area of interfibrillar mitochondria" / the "ratio of outer to inner membrane length".To assess the clinical significance of the proposed total index, associations between the obtained values and atrial fibrillation (AF) were studied. Mitochondrial ultrastructural changes were more pronounced in patients with both AF and CHF. However, some parameters had no statistically significant differences: the total area of interfibrillar mitochondria was lower in patients with AF (42% vs 49%, p=0.224), and the ratio of outer to inner membrane length was higher in patients with AF (35% vs 31%, p=0.125). The total index was significantly lower in patients with AF (0.96 vs 1.75, p=0.021). ROC analysis was performed to identify a connection between total index and AF, and AUC was 0.773 (p=0.021). CONCLUSION: The proposed total index for analyzing cardiomyocyte micrographs, calculated as the "total area of interfibrillar mitochondria" / the "ratio of outer to inner membrane length", provides a comprehensive characterization of mitochondria that accounts not only for their number and size but also for their internal structure. FAU - Kuzheleva, E A AU - Kuzheleva EA AD - MD, PhD, Senior Researcher, Department of Myocardial Pathology; Cardiology Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, 111a Kievskaya St., Tomsk, 634012, Russia. FAU - Garganeeva, A A AU - Garganeeva AA AD - MD, DSc, Professor, Head of the Department of Myocardial Pathology; Cardiology Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, 111a Kievskaya St., Tomsk, 634012, Russia. FAU - Tukish, O V AU - Tukish OV AD - MD, PhD, Researcher, Department of Myocardial Pathology; Cardiology Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, 111a Kievskaya St., Tomsk, 634012, Russia. FAU - Syromyatnikova, E E AU - Syromyatnikova EE AD - Resident Physician, Department of Myocardial Pathology; Cardiology Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, 111a Kievskaya St., Tomsk, 634012, Russia. FAU - Dorzhieva, B B AU - Dorzhieva BB AD - Resident Physician, Department of Myocardial Pathology; Cardiology Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, 111a Kievskaya St., Tomsk, 634012, Russia. FAU - Kondratiev, M Yu AU - Kondratiev MY AD - Junior Researcher, Department of Myocardial Pathology; Cardiology Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, 111a Kievskaya St., Tomsk, 634012, Russia. FAU - Andreev, S L AU - Andreev SL AD - MD, PhD, Senior Researcher, Department of Cardiovascular Surgery; Cardiology Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, 111a Kievskaya St., Tomsk, 634012, Russia. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20260430 PL - Russia (Federation) TA - Sovrem Tekhnologii Med JT - Sovremennye tekhnologii v meditsine JID - 101604515 SB - IM MH - Humans MH - *Myocytes, Cardiac/ultrastructure MH - *Atrial Appendage/ultrastructure MH - Male MH - *Mitochondria, Heart/ultrastructure MH - Female MH - Aged MH - *Heart Failure/pathology MH - Middle Aged MH - Microscopy, Electron PMC - PMC13178087 OTO - NOTNLM OT - atrial fibrillation OT - chronic heart failure OT - electron microscopy OT - mitochondrial ultrastructure OT - total area of interfibrillar mitochondria COIS- Conflict of interest. All authors declare no conflict of interest. EDAT- 2026/05/18 12:42 MHDA- 2026/05/18 12:43 PMCR- 2026/01/01 CRDT- 2026/05/18 06:49 PHST- 2025/08/12 00:00 [received] PHST- 2026/05/18 12:43 [medline] PHST- 2026/05/18 12:42 [pubmed] PHST- 2026/05/18 06:49 [entrez] PHST- 2026/01/01 00:00 [pmc-release] AID - 10.17691/stm2026.18.2.05 [doi] PST - ppublish SO - Sovrem Tekhnologii Med. 2026;18(2):54-60. doi: 10.17691/stm2026.18.2.05. Epub 2026 Apr 30. PMID- 42144538 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260527 LR - 20260813 IS - 1568-5888 (Print) IS - 1876-6250 (Electronic) IS - 1568-5888 (Linking) VI - 34 IP - 6 DP - 2026 Jun TI - Impact of a multidisciplinary clinical pathway on the management of spontaneous coronary artery dissection. PG - 225-235 LID - 10.1007/s12471-026-02050-w [doi] AB - AIM: To evaluate the clinical impact of a dedicated multidisciplinary spontaneous coronary artery dissection (SCAD) care pathway compared with standard acute coronary syndrome management, focusing on safety, treatment patterns, clinical outcomes, and recurrence rates in patients with SCAD. METHODS: In this retrospective observational cohort study, 117 SCAD patients were included: 63 managed within a SCAD-specific care pathway and 54 receiving standard care prior to or independent of its implementation. The SCAD pathway included protocolized angiographic diagnosis, conservative management when feasible, individualized medical therapy, screening for fibromuscular dysplasia (FMD) and systemic disorders, and SCAD-specific rehabilitation with structured follow-up. The primary endpoint was major adverse cardiovascular events (MACE) at 1‑year follow-up. RESULTS: Patients in the SCAD pathway group were more often managed conservatively in the acute setting (76% vs. 24%, p < 0.001), had significantly lower rates of stent implantation (8% vs. 65%, p < 0.001), and were less frequently prescribed dual antiplatelet therapy (19% vs. 96%, p < 0.001). At 12-month follow-up, beta-blocker adherence was higher (76% vs. 41%, p < 0.001), aspirin use was lower (38% vs. 59%, p < 0.001), and recurrent SCAD occurred numerically less often but not statistically significantly (3% vs. 9%, p = 0.231). MACE rates were similar between groups, and no deaths occurred. FMD screening was more common in the pathway group (92% vs. 17%, p < 0.001), facilitating diagnosis and tailored long-term therapy. CONCLUSION: Implementation of a standardized SCAD care pathway was associated with a safe conservative approach, more targeted secondary prevention, improved beta-blocker adherence, and a trend toward fewer recurrent SCAD events. These findings support integration of SCAD-specific multidisciplinary care into routine clinical practice to improve diagnostic precision and long-term outcomes. CI - (c) 2026. The Author(s). FAU - Al-Gully, Jin AU - Al-Gully J AD - Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands. AD - Women's Heart Health Clinic, Leiden University Medical Center, Leiden, The Netherlands. FAU - Forouzanfar, Jessica P AU - Forouzanfar JP AD - Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands. AD - Women's Heart Health Clinic, Leiden University Medical Center, Leiden, The Netherlands. FAU - Montero-Cabezas, Jose M AU - Montero-Cabezas JM AD - Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands. FAU - Eikenboom, Jeroen AU - Eikenboom J AD - Department of Internal Medicine, Division of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands. FAU - den Exter, Paul L AU - den Exter PL AD - Department of Internal Medicine, Division of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands. FAU - Ter Haar, Sophie AU - Ter Haar S AD - Department of Internal Medicine, Division of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands. FAU - Scheenstra, Bart AU - Scheenstra B AD - Basalt Rehabilitation, Leiden, The Netherlands. FAU - den Haan, Melina C AU - den Haan MC AD - Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands. AD - Women's Heart Health Clinic, Leiden University Medical Center, Leiden, The Netherlands. FAU - van der Kley, Frank AU - van der Kley F AD - Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands. FAU - Wouter Jukema, J AU - Wouter Jukema J AD - Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands. AD - Netherlands Heart Institute, Utrecht, The Netherlands. FAU - Bingen, Brian O AU - Bingen BO AD - Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands. AD - Women's Heart Health Clinic, Leiden University Medical Center, Leiden, The Netherlands. FAU - Al Amri, Ibtihal AU - Al Amri I AD - Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands. i.al_amri@lumc.nl. AD - Women's Heart Health Clinic, Leiden University Medical Center, Leiden, The Netherlands. i.al_amri@lumc.nl. LA - eng PT - Journal Article DEP - 20260518 PL - Netherlands TA - Neth Heart J JT - Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation JID - 101095458 PMC - PMC13216445 OTO - NOTNLM OT - Acute Coronary Syndrome (ACS) OT - Percutaneous Coronary Intervention (PCI) OT - Spontaneous Coronary Artery Dissection (SCAD) OT - Tortuosity COIS- Conflict of interest: I. Al Amri/ her institution received speaker fees from Penumbra Inc. and Medtronic. JW Jukema/his department has received research grants from and/or was speaker (with or without lecture fees) on a.o.(CME accredited) meetings sponsored/supported by Abbott, Amarin, Amgen, Athera, Biotronik, Boston Scientific, Dalcor, Daiichi Sankyo, Edwards Lifesciences, GE Healthcare Johnson and Johnson, Lilly, Medtronic, Merck-Schering-Plough, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi Aventis, Shockwave Medical, the Netherlands Heart Foundation, CardioVascular Research the Netherlands (CVON), the Netherlands Heart Institute and the European Community Framework KP7 Programme. F. van der Kley received consultancy fees from Edwards Lifesciences and Abbott Vascular. The remaining authors have no competing interests. EDAT- 2026/05/18 00:30 MHDA- 2026/05/18 00:31 PMCR- 2026/05/18 CRDT- 2026/05/17 23:21 PHST- 2025/09/23 00:00 [received] PHST- 2026/04/15 00:00 [accepted] PHST- 2026/05/18 00:31 [medline] PHST- 2026/05/18 00:30 [pubmed] PHST- 2026/05/17 23:21 [entrez] PHST- 2026/05/18 00:00 [pmc-release] AID - 10.1007/s12471-026-02050-w [pii] AID - 2050 [pii] AID - 10.1007/s12471-026-02050-w [doi] PST - ppublish SO - Neth Heart J. 2026 Jun;34(6):225-235. doi: 10.1007/s12471-026-02050-w. Epub 2026 May 18. PMID- 42141253 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260903 LR - 20260906 IS - 2193-8261 (Print) IS - 2193-6544 (Electronic) IS - 2193-6544 (Linking) VI - 15 IP - 3 DP - 2026 Sep TI - Concordance of Large Language Model Recommendations with Multidisciplinary Heart Team Decisions in Coronary Revascularization and Aortic Valve Intervention: A Systematic Review and Pooled Analysis. PG - 393-406 LID - 10.1007/s40119-026-00453-9 [doi] AB - INTRODUCTION: The multidisciplinary heart team (HT) remains the cornerstone of decision-making for complex cardiovascular disease. Large language models (LLMs) and other generative artificial intelligence models have recently emerged as potential decision support tools across diverse clinical settings. We sought to synthesize current evidence and quantitatively estimate concordance between LLM recommendations and HT decisions. METHODS: A literature search was performed using PubMed, Scopus, and Web of Science for primary studies published between November 2022 and February 2026 that evaluated recommendations by LLMs against multidisciplinary HT decisions. Studies reporting overall agreement were included for quantitative pooling. Random-effects meta-analysis was performed to determine proportion of agreement. RESULTS: Four retrospective concordance studies were included regarding decision-making in coronary revascularization and aortic valve intervention. LLM-HT concordance ranged from 65% to 82% for coronary revascularization and was 77% for aortic valve intervention. In random-effects meta-analysis, the pooled agreement between LLM recommendations and HT decisions was 0.73 (95% CI 0.60-0.83) with substantial heterogeneity. Discordance stemmed from LLM reliance on outdated trial evidence and limited transparency regarding utilized data, with misclassifications observed in cases of octogenarians with aortic stenosis. Detailed prompts generally improved accuracy and reliability of LLM recommendations. CONCLUSION: These preliminary findings suggest LLMs may have potential as adjunctive decision support tools for multidisciplinary HTs. There remains potential for misclassification when patient-specific factors and conflicting guidelines complicate decision-making. Further prospective evaluation across diverse LLMs is essential before clinical deployment can be recommended. CI - (c) 2026. The Author(s). FAU - Rouhi, Armaun D AU - Rouhi AD AUID- ORCID: 0000-0002-7724-1457 AD - Washington University in St. Louis School of Medicine, St. Louis, MO, USA. FAU - Menon, Shreyas V AU - Menon SV AD - Cooper Medical School of Rowan University, Camden, NJ, USA. FAU - Ghanem, Yazid K AU - Ghanem YK AD - Department of Surgery, Cooper University Hospital, Camden, NJ, USA. FAU - Han, Jason J AU - Han JJ AUID- ORCID: 0000-0001-9288-3725 AD - Division of Cardiac Surgery, Department of Surgery, Cooper University Hospital, 24 S 6th Street, Camden, NJ, 08103, USA. han-jason@cooperhealth.edu. LA - eng PT - Journal Article PT - Review DEP - 20260515 PL - England TA - Cardiol Ther JT - Cardiology and therapy JID - 101634495 PMC - PMC13542011 OTO - NOTNLM OT - Aortic stenosis OT - Aortic valve intervention OT - Artificial intelligence OT - Cardiology OT - Cardiothoracic surgery OT - ChatGPT OT - Coronary artery disease OT - Coronary revascularization OT - Heart team OT - Large language models COIS- Declarations. Conflict of Interest: Armaun D. Rouhi, Shreyas V. Menon, Yazid K. Ghanem, and Jason J. Han have nothing to disclose. Ethical Approval: This article does not contain any new studies with human participants or animals performed by any of the authors. EDAT- 2026/05/16 00:37 MHDA- 2026/05/16 00:38 PMCR- 2026/05/15 CRDT- 2026/05/15 23:23 PHST- 2026/03/17 00:00 [received] PHST- 2026/05/05 00:00 [accepted] PHST- 2026/05/16 00:38 [medline] PHST- 2026/05/16 00:37 [pubmed] PHST- 2026/05/15 23:23 [entrez] PHST- 2026/05/15 00:00 [pmc-release] AID - 10.1007/s40119-026-00453-9 [pii] AID - 453 [pii] AID - 10.1007/s40119-026-00453-9 [doi] PST - ppublish SO - Cardiol Ther. 2026 Sep;15(3):393-406. doi: 10.1007/s40119-026-00453-9. Epub 2026 May 15. PMID- 42136715 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260515 LR - 20260813 IS - 2297-055X (Print) IS - 2297-055X (Electronic) IS - 2297-055X (Linking) VI - 13 DP - 2026 TI - Transcatheter management of cardiogenic shock in severe aortic stenosis. PG - 1803093 LID - 10.3389/fcvm.2026.1803093 [doi] LID - 1803093 AB - Management of cardiogenic shock (CS) in the setting of severe aortic stenosis (AS) remains clinically challenging, owing to the coexistence of fixed valvular obstruction, limited myocardial reserve, and rapidly evolving end-organ hypoperfusion. In this context, early identification of patients unlikely to recover with medical therapy alone and timely transition to definitive valve intervention are critical determinants of outcome. Despite growing clinical experience, decision-making in this setting remains heterogeneous and largely informed by observational evidence. Herein, in the present review, we synthesize contemporary evidence on transcatheter strategies for AS-related CS, with emphasis on clinical decision-making during the acute phase. A physiology-driven approach to early assessment and hemodynamic stabilization is outlined, integrating echocardiography, invasive monitoring, and tailored pharmacologic support to inform escalation pathways. Mechanical circulatory support (MCS) is discussed as a selective, time-limited strategy to achieve stabilization and facilitate procedural planning, while accounting for the unique physiological limitations imposed by fixed valvular obstruction. Available data on balloon aortic valvuloplasty and urgent or emergent transcatheter aortic valve implantation (TAVI) are examined with respect to procedural feasibility, early outcomes, and their positioning within bridging or definitive treatment pathways in CS. Collectively, this work proposes a pathway-oriented framework for AS-related CS that prioritizes early recognition, coordinated multidisciplinary decision-making, and timely progression to definitive valve intervention, tailored to patient risk profile and institutional expertise. CI - (c) 2026 Di Muro, Sarto, Raona, Oliva, Chiarito, Silverio, Sciarretta, Attisano, Vecchione and Galasso. FAU - Di Muro, Francesca Maria AU - Di Muro FM AD - Department of Medicine, Surgery, and Dentistry, University of Salerno, Salerno, Italy. AD - Cardiology Unit, Cardiovascular and Thoracic Department, University Hospital "San Giovanni di Dio e Ruggi d'Aragona", Largo Citta di Ippocrate, Salerno, Italy. FAU - Sarto, Gianmarco AU - Sarto G AD - Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy. AD - Department of Cardiology, ICOT Istituto Marco Pasquali, Latina, Italy. FAU - Raona, Valeria AU - Raona V AD - Department of Biomedical Sciences, Humanitas University, Milan, Italy. FAU - Oliva, Angelo AU - Oliva A AD - Department of Biomedical Sciences, Humanitas University, Milan, Italy. AD - The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States. FAU - Chiarito, Mauro AU - Chiarito M AD - Department of Biomedical Sciences, Humanitas University, Milan, Italy. FAU - Silverio, Angelo AU - Silverio A AD - Department of Medicine, Surgery, and Dentistry, University of Salerno, Salerno, Italy. AD - Cardiology Unit, Cardiovascular and Thoracic Department, University Hospital "San Giovanni di Dio e Ruggi d'Aragona", Largo Citta di Ippocrate, Salerno, Italy. FAU - Sciarretta, Sebastiano AU - Sciarretta S AD - Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy. AD - Department of Cardiology, IRCCS NeuroMed, Pozzilli, Italy. FAU - Attisano, Tiziana AU - Attisano T AD - Department of Medicine, Surgery, and Dentistry, University of Salerno, Salerno, Italy. FAU - Vecchione, Carmine AU - Vecchione C AD - Department of Medicine, Surgery, and Dentistry, University of Salerno, Salerno, Italy. AD - Department of Cardiology, IRCCS NeuroMed, Pozzilli, Italy. FAU - Galasso, Gennaro AU - Galasso G AD - Department of Medicine, Surgery, and Dentistry, University of Salerno, Salerno, Italy. LA - eng PT - Journal Article PT - Review DEP - 20260429 PL - Switzerland TA - Front Cardiovasc Med JT - Frontiers in cardiovascular medicine JID - 101653388 PMC - PMC13167941 OTO - NOTNLM OT - balloon aortic valvuloplasty OT - cardiogenic shock OT - mechanical circulatory support OT - severe aortic stenosis OT - transcatheter aortic valve implantation COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors MC, GG declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision. EDAT- 2026/05/15 06:29 MHDA- 2026/05/15 06:30 PMCR- 2026/04/29 CRDT- 2026/05/15 04:44 PHST- 2026/02/03 00:00 [received] PHST- 2026/03/06 00:00 [revised] PHST- 2026/04/06 00:00 [accepted] PHST- 2026/05/15 06:30 [medline] PHST- 2026/05/15 06:29 [pubmed] PHST- 2026/05/15 04:44 [entrez] PHST- 2026/04/29 00:00 [pmc-release] AID - 10.3389/fcvm.2026.1803093 [doi] PST - epublish SO - Front Cardiovasc Med. 2026 Apr 29;13:1803093. doi: 10.3389/fcvm.2026.1803093. eCollection 2026. PMID- 42133851 OWN - NLM STAT- MEDLINE DCOM- 20261016 LR - 20261016 IS - 1537-7385 (Electronic) IS - 0894-9115 (Linking) VI - 105 IP - 11 DP - 2026 Nov 1 TI - An Initiative to Assess Frailty and Functional Status in Cardiac Transplant Candidates. PG - 1089-1093 LID - 10.1097/PHM.0000000000003015 [doi] AB - The systematic evaluation of frailty is recommended as best practice in heart transplantation, but can be challenging to implement. This initiative assesses the implementation of frailty assessment for heart transplant candidates in the inpatient setting and describes frailty characteristics and content of prehabilitation plans in this population. All patients assessed for heart transplantation while hospitalized at our institution between October 30, 2023 and January 6, 2025, in whom PM&R was consulted, were reviewed. Objective frailty measures, their correlation to listing for transplantation, and the content of prehabilitation plans were assessed. All 56 inpatient consults included completed frailty assessments performed by a multidisciplinary team and interpreted by a PM&R physician. About 32% had mFFP scores in the frail range, and 25% had SPPBs in the frail range. No patients with SPPB in the frail range were listed for transplantation during the review period. All patients received prehabilitation plans with multiple recommendations in the areas of therapy/exercise, nutrition, and enhancing resilience. We conclude it is feasible to implement a sustainable, coordinated multidisciplinary frailty evaluation for hospitalized patients undergoing assessment for heart transplantation under PM&R physician leadership to inform the selection committee for risk stratification and created prehabilitation plans designed to improve patients' functional status. CI - Copyright (c) 2026 Wolters Kluwer Health, LLC. All rights reserved. FAU - Barr, Karen P AU - Barr KP AD - Department of Physical Medicine and Rehabilitation. FAU - Webb, Kalie AU - Webb K AD - Department of Physical Medicine and Rehabilitation UPMC, University of Pittsburgh, Pittsburgh, Pennsylvania. FAU - Lecker, Haylie Kromer AU - Lecker HK AD - Department of Physical Medicine and Rehabilitation UPMC, University of Pittsburgh, Pittsburgh, Pennsylvania. FAU - Matijasich, Paige AU - Matijasich P AD - Department of Physical Medicine and Rehabilitation UPMC, University of Pittsburgh, Pittsburgh, Pennsylvania. FAU - Mesoros, Matthew AU - Mesoros M AD - Department of Physical Medicine and Rehabilitation. FAU - DeLuca, Kerry AU - DeLuca K AD - Department of Physical Medicine and Rehabilitation UPMC, University of Pittsburgh, Pittsburgh, Pennsylvania. LA - eng PT - Journal Article DEP - 20260416 PL - United States TA - Am J Phys Med Rehabil JT - American journal of physical medicine & rehabilitation JID - 8803677 SB - IM MH - Humans MH - *Heart Transplantation MH - *Frailty/diagnosis MH - Female MH - Male MH - *Functional Status MH - Middle Aged MH - Aged MH - *Geriatric Assessment/methods MH - Risk Assessment OTO - NOTNLM OT - Frailty OT - Functional Status OT - Heart Transplantation OT - Prehabilitation COIS- Financial disclosure statements have been obtained, and no conflicts of interest have been reported by the authors or by any individuals in control of the content of this article. EDAT- 2026/05/14 18:36 MHDA- 2026/10/16 19:04 CRDT- 2026/05/14 15:03 PHST- 2025/10/20 00:00 [received] PHST- 2026/03/24 00:00 [accepted] PHST- 2026/10/16 19:04 [medline] PHST- 2026/05/14 18:36 [pubmed] PHST- 2026/05/14 15:03 [entrez] AID - 00002060-990000000-00930 [pii] AID - 10.1097/PHM.0000000000003015 [doi] PST - ppublish SO - Am J Phys Med Rehabil. 2026 Nov 1;105(11):1089-1093. doi: 10.1097/PHM.0000000000003015. Epub 2026 Apr 16. PMID- 42131090 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260514 LR - 20260813 IS - 2297-055X (Print) IS - 2297-055X (Electronic) IS - 2297-055X (Linking) VI - 13 DP - 2026 TI - Onco-hypertension: hypertension induced by VEGF pathway inhibition. PG - 1748445 LID - 10.3389/fcvm.2026.1748445 [doi] LID - 1748445 AB - Cancer therapies are increasingly linked to a wide spectrum of cardiovascular toxicities, presenting significant challenges in the long-term care of oncology patients. Among these, therapy-induced hypertension stands out as one of the most consistent and clinically relevant adverse effects, especially with agents targeting the VEGF pathway. Understanding the mechanisms behind this form of hypertension is critical, as it not only represents a modifiable cardiovascular risk factor but may also serve as a biomarker of therapeutic efficacy in certain cancer treatments. Clinical evidence underscores the importance of early detection and aggressive blood pressure control to improve both cardiovascular and oncologic outcomes. The most well-characterized and clinically significant subtype of therapy-related hypertension is that induced by VEGF pathway inhibitors, owing to its high incidence, rapid onset, and well-defined mechanistic basis. In this review, we specifically examine VEGFi-associated hypertension as a prototypical model of onco-hypertension. Evidence-based strategies for managing therapy-induced hypertension emphasize early detection and individualized treatment plans. Renin-angiotensin system inhibitors (RAAS inhibitors) are frequently recommended as first-line agents due to their favorable cardiovascular profile and potential synergistic effects with some cancer therapies. Calcium-channel blockers (CCBs) also demonstrate strong efficacy and are often used in combination regimens to achieve optimal blood pressure control. Successful management requires a multidisciplinary approach, integrating expertise from oncology, cardiology, and primary care. Proactive surveillance, patient education, and risk stratification are essential components of care. As the field of cardio-oncology continues to evolve, structured blood pressure management remains a cornerstone of safe and effective cancer care, ensuring that patients receive optimal therapeutic benefit while minimizing cardiovascular risk. CI - (c) 2026 Palaskas, Kim, Moreno, Casso-Chapa, Beinart, Nnanna, Mendoza, Deswal, Yusuf, Koutroumpakis, Abe and Ewer. FAU - Palaskas, Nicolas L AU - Palaskas NL AD - Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. FAU - Kim, Jung Hyun AU - Kim JH AD - Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. FAU - Moreno, Silvia Fernanda Lopez AU - Moreno SFL AD - Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. FAU - Casso-Chapa, Bernardo AU - Casso-Chapa B AD - Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. FAU - Beinart, Noah I AU - Beinart NI AD - Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. FAU - Nnanna, Nnenne AU - Nnanna N AD - Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. FAU - Mendoza, Keila Carolina Ostos AU - Mendoza KCO AD - Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. FAU - Deswal, Anita AU - Deswal A AD - Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. FAU - Yusuf, Syed Wamique AU - Yusuf SW AD - Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. FAU - Koutroumpakis, Efstratios AU - Koutroumpakis E AD - Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. FAU - Abe, Jun-Ichi AU - Abe JI AD - Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. FAU - Ewer, Michael S AU - Ewer MS AD - Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. LA - eng PT - Journal Article PT - Review DEP - 20260428 PL - Switzerland TA - Front Cardiovasc Med JT - Frontiers in cardiovascular medicine JID - 101653388 PMC - PMC13160817 OTO - NOTNLM OT - blood pressure OT - cancer OT - cardio-oncology OT - hypertension OT - vascular endothelial growth factor COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author JA declared that they were an editorial board member of Frontiers at the time of submission. This had no impact on the peer review process and the final decision. EDAT- 2026/05/14 14:21 MHDA- 2026/05/14 14:22 PMCR- 2026/04/28 CRDT- 2026/05/14 04:50 PHST- 2025/11/17 00:00 [received] PHST- 2026/02/25 00:00 [revised] PHST- 2026/03/26 00:00 [accepted] PHST- 2026/05/14 14:22 [medline] PHST- 2026/05/14 14:21 [pubmed] PHST- 2026/05/14 04:50 [entrez] PHST- 2026/04/28 00:00 [pmc-release] AID - 10.3389/fcvm.2026.1748445 [doi] PST - epublish SO - Front Cardiovasc Med. 2026 Apr 28;13:1748445. doi: 10.3389/fcvm.2026.1748445. eCollection 2026. PMID- 42130928 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260514 LR - 20260813 IS - 2284-2594 (Electronic) IS - 2284-2594 (Linking) VI - 13 IP - 5 DP - 2026 TI - Cardiac Involvement as First Manifestation of Peripheral T-Cell Not Otherwise Specified Lymphoma. PG - 006099 LID - 10.12890/2026_006099 [doi] LID - 006099 AB - Cardiac involvement as the first manifestation of peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) is extremely rare. We report on a 72-year-old man with hypertension, dyslipidaemia and prediabetes who presented with acute pleuropericarditis, pericardial effusion and conduction abnormalities. Despite initial treatment, his condition worsened. Imaging revealed pericardial/myocardial infiltration and a right atrial mass. Biopsy confirmed PTCL-NOS (CD3+, CD5+, CD7+, high Ki-67). Complications included ileus, pulmonary embolism and neutropaenia. CHOP failed; GemOx was ineffective; he died from hypernatremia. This reported case emphasises the aggressive course, diagnostic challenges and poor treatment response of cardiac PTCL-NOS. LEARNING POINTS: This case represented a significant diagnostic challenge; the clinical problem was documented by multiple imaging modalities, none of which were sufficient to establish a definitive diagnosis.This case is a clear example of how the most challenging cases require a multidisciplinary team, involving professionals from very different specialties (for example cardiologists, cardiac surgeons, general surgeons, haematologists, radiologists, pathologists), to achieve the correct diagnosis and provide the best possible care for the patient. CI - (c) EFIM 2026. FAU - Awamleh Garcia, Paula AU - Awamleh Garcia P AD - Cardiology Department, Hospital Universitario de Getafe, Madrid, Spain. FAU - Monguio Santin, Manuel Emilio AU - Monguio Santin ME AD - Cardiac Surgery Department, Hospital Universitario de la Princesa, Madrid, Spain. FAU - Lopez Martinez, Carla AU - Lopez Martinez C AD - Pathology Department, Hospital Universitario de la Princesa, Madrid, Spain. FAU - Hernandez Muniz, Susana AU - Hernandez Muniz S AD - Radiology Department, Hospital Universitario de la Princesa, Madrid, Spain. FAU - de la Serna Real de Asua, Miguel AU - de la Serna Real de Asua M AD - Cardiology Department, Hospital Universitario de Getafe, Madrid, Spain. FAU - Alonso Trillo, Rosalia AU - Alonso Trillo R AD - Haematology and Haemotherapy Department, Hospital Universitario de Getafe, Madrid, Spain. FAU - Delgado Trillo, Maria Isabel AU - Delgado Trillo MI AD - Haematology and Haemotherapy Department, Hospital Universitario de Getafe, Madrid, Spain. LA - eng PT - Journal Article DEP - 20260427 PL - Italy TA - Eur J Case Rep Intern Med JT - European journal of case reports in internal medicine JID - 101648453 PMC - PMC13166972 OTO - NOTNLM OT - Cardiac lymphoma OT - atrioventricular block OT - chemotherapy COIS- Conflicts of Interests: The Authors declare that there are no competing interests. EDAT- 2026/05/14 14:21 MHDA- 2026/05/14 14:22 PMCR- 2026/04/27 CRDT- 2026/05/14 04:48 PHST- 2025/12/23 00:00 [received] PHST- 2026/01/26 00:00 [accepted] PHST- 2026/05/14 14:22 [medline] PHST- 2026/05/14 14:21 [pubmed] PHST- 2026/05/14 04:48 [entrez] PHST- 2026/04/27 00:00 [pmc-release] AID - 6099 [pii] AID - 10.12890/2026_006099 [doi] PST - epublish SO - Eur J Case Rep Intern Med. 2026 Apr 27;13(5):006099. doi: 10.12890/2026_006099. eCollection 2026. PMID- 42129809 OWN - NLM STAT- MEDLINE DCOM- 20260708 LR - 20260813 IS - 1472-6920 (Electronic) IS - 1472-6920 (Linking) VI - 26 IP - 1 DP - 2026 May 13 TI - Implementing team-based sequential simulation for medical students in clinical clerkship: preliminary findings and learning efficiency evaluation. LID - 10.1186/s12909-026-09412-3 [doi] LID - 1086 AB - BACKGROUND: Simulation is a key teaching tool for preparing medical students for clinical practice. Combining team-based learning with sequential simulation enhances problem-solving skills. The Clinical Learning through Extended Immersion in Medical Simulation (CLEIMS), a week-long program integrating simulated interprofessional education, has shown promising results at Griffith University. However, its application outside Australia remains largely unexamined. This study herein evaluates the feasibility of a modified 'CLEIMS' (mCLEIMS), condensed into a 2-day course, for second-year clinical clerkship (SY-CC) students. We analyze preliminary results, learners' perceptions, and learning efficiency through Advanced Cardiac Life Support (ACLS) certification. MATERIALS AND METHODS: This prospective, non-randomized controlled observational study enrolled 108 SY-CC students across three sessions (36 per session) from August to November 2020. All participants completed the 2-day mCLEIMS program, which included simulated patient assessment, on-call modules, handoff/briefing, suturing, interprofessional ward rounds, and high-fidelity ACLS training for cardiac arrest. Afterward, they completed a questionnaire assessing satisfaction, learning perception, and core competencies. All SY-CC students, including those in mCLEIMS, underwent ACLS training and exams before January 2021. Questionnaire and ACLS exam results were analyzed using appropriate statistical tests, with statistical significance set at a two-sided p value < 0.05. Open-ended responses were analyzed using thematic analysis, in which recurring concepts were coded and grouped into major themes through investigator discussion and consensus. RESULTS: The questionnaire response rate was 99.1% (n = 107), with a global satisfaction score of 4.93 (5-point Likert scale). Most participants reported gaining competencies in interprofessional education (87.0%), communication and clinical needs (84.1%), teamwork and empathy (84.1%), and professional knowledge and skills (76.6%). Open-ended responses highlighted mCLEIMS' role in providing real-world medical experience (51.5%), particularly through simulation patients (32.0%) and interprofessional education (20.6%). ACLS pass rates were higher for mCLEIMS participants (96.8% vs. 84.7%, p = 0.012), who also scored better on the exam (83.1 +/- 7.4 vs. 76.8 +/- 18.1, p = 0.007). CONCLUSION: Our experience suggests that mCLEIMS is a practical teaching tool for SY-CC students, integrating team-based sequential simulation to enhance learning perception and ACLS skill retention before clinical practice. CI - (c) 2026. The Author(s). FAU - Liu, Hsin-Liang AU - Liu HL AD - Department of Emergency Medicine, Kaohsiung Medical University Hospital/Kaohsiung Medical University, No. 100, Tzyou 1st Road, Kaohsiung City, 80756, Taiwan. AD - Department of Clinical Education and Training, Kaohsiung Medical University Hospital/Kaohsiung Medical University, Kaohsiung City, Taiwan. FAU - Lu, Peih-Ying AU - Lu PY AD - Center for Medical Education and Humanizing Health Professional Education, Kaohsiung Medical University, Kaohsiung City, Taiwan. AD - College of Medicine, Kaohsiung Medical University, Kaohsiung City, Taiwan. AD - College of Humanities and Social Sciences, Kaohsiung Medical University, Kaohsiung City, Taiwan. FAU - Hsu, Anna Shan-Chun AU - Hsu AS AD - Center for Medical Education and Humanizing Health Professional Education, Kaohsiung Medical University, Kaohsiung City, Taiwan. FAU - Lin, Yen-Ko AU - Lin YK AD - Department of Emergency Medicine, Kaohsiung Medical University Hospital/Kaohsiung Medical University, No. 100, Tzyou 1st Road, Kaohsiung City, 80756, Taiwan. AD - Department of Clinical Education and Training, Kaohsiung Medical University Hospital/Kaohsiung Medical University, Kaohsiung City, Taiwan. AD - Center for Medical Education and Humanizing Health Professional Education, Kaohsiung Medical University, Kaohsiung City, Taiwan. AD - Department of Medical Humanities and Education, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung City, Taiwan. AD - Division of Trauma and Surgical Critical Care, Department of Surgery, Kaohsiung Medical University Hospital/Kaohsiung Medical University, Kaohsiung City, Taiwan. FAU - Chan, Kwong D AU - Chan KD AD - Griffith Health Institute for the Development of Education and Scholarship (Health IDEAS), Griffith University, Gold Coast, Australia. AD - School of Medicine, Griffith University, Gold Coast, Australia. FAU - Lee, Chien-Hsing AU - Lee CH AD - Department of Pharmacology, Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung City, Taiwan. FAU - Chang, Po-Chih AU - Chang PC AD - Division of Thoracic Surgery, Department of Surgery, Kaohsiung Medical University Hospital/Kaohsiung Medical University, No. 100, Tzyou 1st Road, Kaohsiung City, 80756, Taiwan. dyno910076@hotmail.com. AD - Weight Management Center, Kaohsiung Medical University Hospital/Kaohsiung Medical University, No. 100, Tzyou 1st Road, Kaohsiung City, 80756, Taiwan. dyno910076@hotmail.com. AD - Department of Sports Medicine, College of Medicine, Kaohsiung Medical University, No. 100, Shiquan 1st Rd., Kaohsiung City, 807378, Taiwan. dyno910076@hotmail.com. AD - Ph. D. Program in Biomedical Engineering, College of Medicine, Kaohsiung Medical University, No. 100, Shiquan 1st Rd., Kaohsiung City, 807378, Taiwan. dyno910076@hotmail.com. LA - eng GR - PMN1090395/Teaching Practice Research Program, Taiwan/ PT - Journal Article PT - Observational Study DEP - 20260513 PL - England TA - BMC Med Educ JT - BMC medical education JID - 101088679 SB - IM MH - Humans MH - Prospective Studies MH - *Clinical Clerkship/methods MH - Clinical Competence MH - *Students, Medical MH - *Simulation Training MH - Male MH - Female MH - Advanced Cardiac Life Support/education MH - Curriculum MH - Patient Care Team MH - Problem-Based Learning PMC - PMC13339392 OTO - NOTNLM OT - Clinical Competency OT - Curriculum OT - Medical Education OT - Medical Students OT - Patient Simulation COIS- Declarations. Ethics approval and consent to participate: This study was approved by the Institutional Review Board of Kaohsiung Medical University Hospital (KMUHIRB-F(I)-20200043). All procedures involving human participants were conducted in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. This study involved human participants. Written informed consent was obtained from all individual participants before enrollment. Consent for publication: Consent to Publish declaration: not applicable. This manuscript does not contain any individual person's data, images, or identifying information. Competing interests: The authors declare no competing interests. EDAT- 2026/05/14 06:51 MHDA- 2026/07/08 20:03 PMCR- 2026/05/13 CRDT- 2026/05/14 00:43 PHST- 2025/02/25 00:00 [received] PHST- 2026/05/07 00:00 [accepted] PHST- 2026/07/08 20:03 [medline] PHST- 2026/05/14 06:51 [pubmed] PHST- 2026/05/14 00:43 [entrez] PHST- 2026/05/13 00:00 [pmc-release] AID - 10.1186/s12909-026-09412-3 [pii] AID - 9412 [pii] AID - 10.1186/s12909-026-09412-3 [doi] PST - epublish SO - BMC Med Educ. 2026 May 13;26(1):1086. doi: 10.1186/s12909-026-09412-3. PMID- 42129593 OWN - NLM STAT- MEDLINE DCOM- 20260716 LR - 20260813 IS - 1326-5377 (Electronic) IS - 0025-729X (Print) IS - 0025-729X (Linking) VI - 224 IP - 5 DP - 2026 May TI - Diagnosis and Management of Patent Foramen Ovale for Stroke Prevention: An Australian and New Zealand Consensus Statement Developed by a Modified Nominal Group Approach. PG - e70199 LID - 10.5694/mja2.70199 [doi] LID - e70199 AB - INTRODUCTION: Patent foramen ovale (PFO) is implicated in 25%-50% of cryptogenic strokes in patients aged < 60 years. Recent clinical trials demonstrated the benefit of PFO closure in selected patients. However, there is considerable variability in Australian and New Zealand clinical practice regarding investigation and management approaches. A multidisciplinary consensus group comprising stroke neurologists and an interventional cardiologist from major centres employed a modified nominal group technique to develop evidence-based recommendations for standardising PFO-associated stroke management. MAIN RECOMMENDATIONS: Twelve recommendations were developed across three domains. For patient selection: Universal PFO screening for cryptogenic stroke patients aged 60 years with embolic stroke of undetermined source, absent vascular risk factors and excluded atrial fibrillation. For diagnostic investigations: Transcranial Doppler (TCD) bubble study as preferred first-line screening where available, with transthoracic echocardiography as an alternative when TCD is unavailable and transoesophageal echocardiography for confirmation before closure consideration. For treatment decisions: Incorporation of the PFO-Associated Stroke Causal Likelihood (PASCAL) classification system rather than the Risk of Paradoxical Embolism (RoPE) score alone, consideration of TCD grading results for risk stratification and mandatory multidisciplinary heart-brain team evaluation for all closure decisions. CHANGES IN MANAGEMENT AS A RESULT OF THIS CONSENSUS STATEMENT: These recommendations will standardise practice through enhanced TCD service provision, structured heart-brain team development and evidence-based patient selection using the PASCAL classification. The emphasis on TCD as first-line screening represents a departure from traditional transthoracic echocardiography-based approaches. Implementation will improve patient outcomes through appropriate intervention in suitable candidates while avoiding unnecessary procedures in those unlikely to benefit, thereby promoting equitable access to optimal PFO management across Australia and New Zealand. CI - (c) 2026 The Author(s). Medical Journal of Australia published by John Wiley & Sons Australia, Ltd on behalf of AMPCo Pty Ltd. FAU - Chambers, Brian R AU - Chambers BR AD - Austin Health, Melbourne, Victoria, Australia. AD - University of Melbourne, Melbourne, Victoria, Australia. FAU - Sanders, Lauren M AU - Sanders LM AD - University of Melbourne, Melbourne, Victoria, Australia. AD - St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia. FAU - Gilligan, Amanda AU - Gilligan A AD - University of Melbourne, Melbourne, Victoria, Australia. AD - Epworth Healthcare, Melbourne, Victoria, Australia. FAU - Garcia-Esperon, Carlos AU - Garcia-Esperon C AD - John Hunter Hospital, Newcastle, New South Wales, Australia. AD - Hunter Medical Research Institute, University of Newcastle, Newcastle, New South Wales, Australia. FAU - Ho, Jan AU - Ho J AD - Stroke Research Centre, Perron Institute for Neurological and Translational Science, Perth, Western Australia, Australia. AD - Sir Charles Gairdner Hospital, Perth, Western Australia, Australia. FAU - Fink, John AU - Fink J AD - Christchurch Hospital, Christchurch, Canterbury, New Zealand. FAU - Yudi, Matias AU - Yudi M AD - Austin Health, Melbourne, Victoria, Australia. AD - University of Melbourne, Melbourne, Victoria, Australia. FAU - Lee-Archer, Matthew AU - Lee-Archer M AD - Launceston General Hospital, Launceston, Tasmania, Australia. AD - University of Tasmania, Hobart, Tasmania, Australia. FAU - Stanislaus, Vimal AU - Stanislaus V AD - Alfred Health, Melbourne, Victoria, Australia. AD - Monash University, Melbourne, Victoria, Australia. FAU - Wong, Andrew A AU - Wong AA AD - Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia. AD - University of Queensland, Brisbane, Queensland, Australia. LA - eng PT - Consensus Statement PT - Journal Article PL - Australia TA - Med J Aust JT - The Medical journal of Australia JID - 0400714 SB - IM MH - Humans MH - *Foramen Ovale, Patent/complications/diagnosis/therapy MH - Australia MH - New Zealand MH - *Stroke/prevention & control/etiology MH - Echocardiography, Transesophageal MH - Risk Factors MH - Patient Selection PMC - PMC13172030 OTO - NOTNLM OT - Doppler OT - cardiac imaging techniques OT - cardiovascular abnormalities OT - neuroimaging OT - risk assessment OT - risk factors OT - stroke OT - ultrasonography COIS- Not commissioned; externally peer reviewed. The authors declare no conflicts of interest. EDAT- 2026/05/14 06:51 MHDA- 2026/05/14 06:52 PMCR- 2026/05/14 CRDT- 2026/05/14 00:02 PHST- 2026/03/13 00:00 [revised] PHST- 2025/11/21 00:00 [received] PHST- 2026/03/24 00:00 [accepted] PHST- 2026/05/14 06:52 [medline] PHST- 2026/05/14 06:51 [pubmed] PHST- 2026/05/14 00:02 [entrez] PHST- 2026/05/14 00:00 [pmc-release] AID - MJA270199 [pii] AID - 10.5694/mja2.70199 [doi] PST - ppublish SO - Med J Aust. 2026 May;224(5):e70199. doi: 10.5694/mja2.70199. PMID- 42128260 OWN - NLM STAT- MEDLINE DCOM- 20260710 LR - 20260723 IS - 1879-1913 (Electronic) IS - 0002-9149 (Linking) VI - 272 DP - 2026 Aug 1 TI - Meta-Analysis of Transcatheter Versus Surgical Aortic Valve Replacement in Low Surgical Risk Patients: An Update. PG - 77-86 LID - S0002-9149(26)00338-3 [pii] LID - 10.1016/j.amjcard.2026.05.013 [doi] AB - Transcatheter aortic valve replacement (TAVR) is increasingly considered as an alternative to surgical aortic valve replacement (SAVR) for low-risk patients with aortic stenosis. However, its long-term efficacy remains uncertain. This study aimed to compare clinical outcomes and procedural complications of TAVR versus SAVR in low-risk patients with aortic stenosis. We updated our 2019 systematic review by searching MEDLINE, EMBASE, and Cochrane Central (May 2019-April 2025) for randomized controlled trials (RCTs) comparing TAVR and SAVR in low-risk patients with aortic stenosis. We extracted outcomes at 30 days, 12 months, and >/=5 year follow-up. Risk ratios (RRs) and 95% confidence intervals (CIs) were estimated using random-effects models. Risk of bias was assessed using the Cochrane Risk of Bias (RoB) 2 tool. Five RCTs (n = 4,532) were included. TAVR reduced 30-day all-cause mortality (RR: 0.45, 95% CI: 0.37-0.55), cardiovascular mortality (RR: 0.45, 95% CI: 0.38-0.54), atrial fibrillation (RR: 0.21, 95% CI: 0.10-0.41), and life-threatening bleeding (RR: 0.28, 95% CI: 0.13-0.58), but increased pacemaker implantation (RR: 3.10, 95% CI: 1.23-7.82). Mortality benefits persisted at 12 months. At >/=5 years, results were inconclusive due to wide CIs across outcomes, including all-cause death (RR: 0.99, 95% CI: 0.72-1.35), cardiovascular death (RR: 0.93, 95% CI: 0.64-1.35), atrial fibrillation (RR: 0.44, 95% CI: 0.16-1.22), endocarditis (RR: 0.70, 95% CI: 0.33-1.45) and aortic reintervention (RR: 1.21, 95% CI: 0.59-2.49). TAVR shows early clinical benefits in low-risk patients with aortic stenosis, but long-term outcomes compared to SAVR remain uncertain. Individualized heart team decision-making remains essential. CI - Copyright (c) 2026 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Jarade, Candace AU - Jarade C AD - Faculty of Medicine, American University of Beirut, Lebanon. FAU - Levett, Jeremy Y AU - Levett JY AD - Division of Cardiac Surgery, Department of Surgery, McGill University, Montreal, QC, Canada. FAU - Zolotarova, Tetiana AU - Zolotarova T AD - Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada. FAU - Filion, Kristian B AU - Filion KB AD - Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada; Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada; Department of Medicine, McGill University, Montreal, QC, Canada. FAU - Toutounchi, Helia AU - Toutounchi H AD - Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada. FAU - Eisenberg, Mark J AU - Eisenberg MJ AD - Division of Cardiac Surgery, Department of Surgery, McGill University, Montreal, QC, Canada; Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada; Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada; Department of Medicine, McGill University, Montreal, QC, Canada; Division of Cardiology, Jewish General Hospital/McGill University, Montreal, QC, Canada. Electronic address: mark.eisenberg@ladydavis.ca. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20260512 PL - United States TA - Am J Cardiol JT - The American journal of cardiology JID - 0207277 SB - IM MH - Humans MH - *Transcatheter Aortic Valve Replacement/methods MH - *Aortic Valve Stenosis/surgery MH - *Heart Valve Prosthesis Implantation/methods MH - Postoperative Complications/epidemiology MH - *Aortic Valve/surgery OTO - NOTNLM OT - aortic valve stenosis OT - low surgical risk OT - meta-analysis OT - surgical aortic valve replacement OT - systematic review OT - transcatheter aortic valve replacement COIS- Declaration of competing interest Dr. Filion has received personal fees from Regeneron and Statlog, both unrelated to this work. The other authors declare no conflicts of interest. EDAT- 2026/05/14 00:31 MHDA- 2026/07/10 12:44 CRDT- 2026/05/13 19:14 PHST- 2026/02/27 00:00 [received] PHST- 2026/04/22 00:00 [revised] PHST- 2026/05/05 00:00 [accepted] PHST- 2026/07/10 12:44 [medline] PHST- 2026/05/14 00:31 [pubmed] PHST- 2026/05/13 19:14 [entrez] AID - S0002-9149(26)00338-3 [pii] AID - 10.1016/j.amjcard.2026.05.013 [doi] PST - ppublish SO - Am J Cardiol. 2026 Aug 1;272:77-86. doi: 10.1016/j.amjcard.2026.05.013. Epub 2026 May 12. PMID- 42125939 OWN - NLM STAT- Publisher LR - 20260513 IS - 1540-8159 (Electronic) IS - 0147-8389 (Linking) DP - 2026 May 13 TI - Simultaneous Tricuspid Valve Replacement and Left Bundle Branch Area Pacing With Surgical Lead Refixation. LID - 10.1111/pace.70292 [doi] AB - BACKGROUND: The importance of managing tricuspid regurgitation (TR) has been increasingly recognized, and tricuspid valve replacement (TVR) is now performed more frequently. Conduction system pacing (CSP), including left bundle branch area pacing (LBBAP), offers substantial benefits by improving left ventricular (LV) electrical synchrony. However, combining these two strategies is challenging. CASE: A 58-year-old man underwent dual-chamber pacemaker implantation for complete atrioventricular block. Five years later, he developed severe LV dysfunction due to right ventricular (RV) apical pacing-induced cardiomyopathy. Upgrade to conventional cardiac resynchronization therapy resulted in a persistently prolonged QRS duration (150 msec) and modest improvement in LV ejection fraction (LVEF, 35%). RV lead-related TR progressively worsened, leading to biventricular heart failure. Although tricuspid valve repair was performed, severe TR recurred. Following heart team discussion, both CSP upgrade and TVR were deemed necessary without delay. An LBBAP lead was implanted the day before surgery as an "electrophysiological anchor." During TVR, the lead was dislodged; however, the surgeon identified the insertion ("anchor") site, reinserted the lead, and secured it by jailing it outside the prosthetic valve in a protective position. Postoperatively, the pacing threshold improved (1.5 V@0.4 ms to 0.75V@0.4 ms) with QRS narrowing (135 to 125 ms). At three months, heart failure symptoms were markedly relieved, LVEF improved to 50%, and lead parameters remained stable. CONCLUSION: Although jailing a lead with a prosthetic valve requires great caution to ensure long-term lead survival, we successfully combined LBBAP and surgical TVR with intraoperative refixation. CI - (c) 2026 Wiley Periodicals LLC. FAU - Goto, Kentaro AU - Goto K AUID- ORCID: 0000-0002-0089-9779 AD - Department of Cardiovascular Medicine, Institute of Science Tokyo, Tokyo, Japan. FAU - Miyazaki, Shinsuke AU - Miyazaki S AD - Department of Cardiovascular Medicine, Institute of Science Tokyo, Tokyo, Japan. FAU - Usui, Ayaka AU - Usui A AD - Department of Cardiovascular Medicine, Institute of Science Tokyo, Tokyo, Japan. FAU - Sakurai, Hironobu AU - Sakurai H AD - Department of Cardiovascular Surgery, Institute of Science Tokyo, Tokyo, Japan. FAU - Nagaoka, Eiki AU - Nagaoka E AUID- ORCID: 0000-0002-3768-8692 AD - Department of Cardiovascular Surgery, Institute of Science Tokyo, Tokyo, Japan. FAU - Fujita, Tomoyuki AU - Fujita T AD - Department of Cardiovascular Surgery, Institute of Science Tokyo, Tokyo, Japan. FAU - Sasano, Tetsuo AU - Sasano T AD - Department of Cardiovascular Medicine, Institute of Science Tokyo, Tokyo, Japan. LA - eng PT - Journal Article DEP - 20260513 PL - United States TA - Pacing Clin Electrophysiol JT - Pacing and clinical electrophysiology : PACE JID - 7803944 SB - IM OTO - NOTNLM OT - biventricular heart failure OT - cardiac resynchronization therapy OT - left bundle branch area pacing OT - open-heart surgery OT - tricuspid valve replacement EDAT- 2026/05/13 12:32 MHDA- 2026/05/13 12:32 CRDT- 2026/05/13 06:33 PHST- 2026/03/20 00:00 [revised] PHST- 2025/09/21 00:00 [received] PHST- 2026/05/05 00:00 [accepted] PHST- 2026/05/13 12:32 [medline] PHST- 2026/05/13 12:32 [pubmed] PHST- 2026/05/13 06:33 [entrez] AID - 10.1111/pace.70292 [doi] PST - aheadofprint SO - Pacing Clin Electrophysiol. 2026 May 13. doi: 10.1111/pace.70292. PMID- 42125329 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260513 LR - 20260813 IS - 2752-4191 (Electronic) IS - 2752-4191 (Linking) VI - 5 IP - 5 DP - 2025 Sep TI - Early aortic valve intervention in asymptomatic severe aortic stenosis: a clinical dilemma in evolution. PG - oeaf114 LID - 10.1093/ehjopen/oeaf114 [doi] LID - oeaf114 AB - The management of asymptomatic severe aortic stenosis (AS) has traditionally relied on watchful waiting until the onset of symptoms or left ventricular dysfunction. However, the FDA's approval of transcatheter aortic valve replacement (TAVR) with the Sapien 3 platform in May 2025, based on the EARLY TAVR trial, has intensified the debate over early intervention. This Viewpoint synthesizes evidence from randomized trials (RECOVERY, AVATAR, EVOLVED, EARLY TAVR) and registries (HAVEC, VALVENOR) to evaluate the role of early aortic valve replacement (AVR). Early intervention is associated with reductions in combined endpoints of cardiovascular hospitalizations, stroke, and mortality in selected patients, with the EARLY TAVR demonstrating a 50% reduction in major cardiovascular events. Nonetheless, evidence remains inconsistent, particularly in low-risk populations, as the EVOLVED trial showed no mortality benefit in patients with myocardial fibrosis, warranting cautious interpretation. A conservative surveillance strategy remains appropriate in some cases, supported by the low annual risk of sudden death (i.e. 0.65% per year) and ongoing concerns over valve durability and procedural risks. Given the heterogeneity of patient and valve phenotypes, a personalized risk assessment, combining clinical evaluation, biomarkers (troponin, BNP), and imaging (echocardiography, CMR), is proposed to identify high-risk patients and optimize the timing of early intervention. Expert heart team guidance is essential, and routine early intervention cannot yet be recommended. Further research is needed to refine strategies and improve outcomes in this evolving clinical landscape. CI - (c) The Author(s) 2025. Published by Oxford University Press on behalf of the European Society of Cardiology. FAU - Lancellotti, Patrizio AU - Lancellotti P AUID- ORCID: 0000-0002-0804-8194 AD - GIGA Cardiovascular Sciences, Heart Valve Clinic, University of Liege Hospital, Avenue de l'Hopital 1, 4000 Liege, Belgium. AD - Department of Cardiology, University of Liege Hospital, Domaine Universitaire du Sart Tilman-B.35, Liege 4000, Belgium. FAU - Coisne, Augustin AU - Coisne A AUID- ORCID: 0000-0002-1662-7874 AD - Department of Cardiology, Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, Rue Calmette BP245, Lille 59019, France. AD - Cardiovascular Research Foundation, 1700 Broadway, 9th Floor, New York, NY, USA. FAU - Cosyns, Bernard AU - Cosyns B AD - Centrum Voor Harten Vaatziekten (CHVZ), Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Avenue du Laerbeek 101, 1090 Jette, Brussels, Belgium. AD - In Vivo Cellular and Molecular Imaging (ICMI) Center, Vrije Universiteit Brussel (VUB), Avenue du Laerbeek 101, 1090 Jette, Brussels, Belgium. FAU - Dulgheru, Raluca AU - Dulgheru R AD - GIGA Cardiovascular Sciences, Heart Valve Clinic, University of Liege Hospital, Avenue de l'Hopital 1, 4000 Liege, Belgium. AD - Department of Cardiology, University of Liege Hospital, Domaine Universitaire du Sart Tilman-B.35, Liege 4000, Belgium. FAU - Garbi, Madalina AU - Garbi M AD - Royal Papworth Hospital, Cambridge University Health Partners, Papworth Road, Cambridge Biomedical Campus, Cambridge CB2 0AY, UK. FAU - Hong, Geu-Ru AU - Hong GR AUID- ORCID: 0000-0003-4981-3304 AD - Cardiology Division, Severance Cardiovascular Hospital, Yonsei University College of Medicine, 50-1, Yonsei-Ro, Seodaemun-gu, Seoul 03722, Republic of Korea. FAU - Hanzevacki, Jadranka Separovic AU - Hanzevacki JS AD - Department of Cardiovascular Diseases, University of Zagreb School of Medicine and University Hospital Centre Zagreb, Ulica Mije Kispatica 12, 10000 Zagreb, Croatia. FAU - Moscarelli, Marco AU - Moscarelli M AUID- ORCID: 0000-0002-8373-8486 AD - Department of Surgery & Cancer-Faculty of MedicineThe Faculty Building, Imperial College London, Exhibition Road, South Kensington, London SW7 2AZ, UK. AD - Department of Cardiovascular Surgery, Maria Eleonora Hospital, GVM Care&Research, Viale della Regione Siciliana Nord Ovest, 1571, 90135 Palermo PA, Italy. FAU - Sugimoto, Tadafumi AU - Sugimoto T AD - Department of Cardiology, Nagoya City University Mirai Kousei Hospital, 2 Chome-1501 Sekobo, Meito Ward, Nagoya, Aichi 465-0055, Japan. FAU - Donal, Erwan AU - Donal E AUID- ORCID: 0000-0003-2677-3389 AD - Universite de Rennes, CHU Rennes, Service de Cardiologie Inserm, LTSI-UMR 1099, 2 Rue Henri Le Guilloux, Rennes 35000, France. FAU - Fattouch, Khalil AU - Fattouch K AUID- ORCID: 0000-0002-6556-9519 AD - Department of Cardiovascular Surgery, Maria Eleonora Hospital, GVM Care&Research, Viale della Regione Siciliana Nord Ovest, 1571, 90135 Palermo PA, Italy. FAU - Habib, Gilbert AU - Habib G AD - Cardiology Department, APHM, La Timone Hospital, Boulevard Jean Moulin, Marseille 13005, France. AD - 2 Aix Marseille University, IRD, APHM, MEPHI, IHU-Mediterraneee Infection, 19-21 Boulevard Jean Moulin, Marseille 13005, France. FAU - Vannan, Mani AU - Vannan M AD - Marcus Heart Valve Center, Piedmont Heart Institute, 95 Collier Rd NW Suite 5015, Atlanta, GA 30309, USA. FAU - Pibarot, Philippe AU - Pibarot P AUID- ORCID: 0000-0002-3607-279X AD - Quebec Heart and Lung Institute, Universite Laval, 2725 Ch Ste-Foy, Quebec City, Quebec QC G1V 4G5, Canada. LA - eng PT - Journal Article PT - Review DEP - 20250829 PL - England TA - Eur Heart J Open JT - European heart journal open JID - 9918282081406676 PMC - PMC13158663 OTO - NOTNLM OT - Aortic stenosis OT - Aortic valve replacement OT - Early intervention OT - Risk stratification OT - Transcatheter aortic valve implantation COIS- Conflict of interest: P.L. is part of the Editorial Board of EHJ Open. EDAT- 2026/05/13 06:31 MHDA- 2026/05/13 06:32 PMCR- 2025/08/29 CRDT- 2026/05/13 04:43 PHST- 2025/05/21 00:00 [received] PHST- 2025/07/14 00:00 [revised] PHST- 2025/08/06 00:00 [accepted] PHST- 2026/05/13 06:32 [medline] PHST- 2026/05/13 06:31 [pubmed] PHST- 2026/05/13 04:43 [entrez] PHST- 2025/08/29 00:00 [pmc-release] AID - oeaf114 [pii] AID - 10.1093/ehjopen/oeaf114 [doi] PST - epublish SO - Eur Heart J Open. 2025 Aug 29;5(5):oeaf114. doi: 10.1093/ehjopen/oeaf114. eCollection 2025 Sep. PMID- 42123211 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260513 LR - 20260813 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 15 IP - 9 DP - 2026 May 1 TI - New Horizons in Transcatheter Aortic Valve Replacement: Expectations and Preparations. LID - 10.3390/jcm15093479 [doi] LID - 3479 AB - Transcatheter aortic valve replacement (TAVR) has transformed the management of severe aortic stenosis and is now widely used across a broad spectrum of surgical risk. With expanding indications and increasing use in younger patients, contemporary practice increasingly emphasizes lifetime management of aortic valve disease, a shift further supported by recent developments including findings from the EARLY TAVR trial and the May 2025 U.S. Food and Drug Administration approval of TAVR for asymptomatic severe aortic stenosis. This narrative review summarizes recent developments in TAVR, including advances in device technology, procedural techniques, and patient selection. Focus is placed on the importance of optimal first valve selection, prevention of prosthesis-patient mismatch (PPM), and planning for future reintervention such as valve-in-valve (ViV) TAVR. Emerging procedural strategies including bioprosthetic valve fracture and leaflet modification techniques have expanded treatment options for patients at risk of elevated gradients or coronary obstruction. The review also highlights evolving approaches to TAVR in complex clinical scenarios and discusses future directions in device design and imaging-based procedural planning. As TAVR continues to evolve, careful procedural planning and multidisciplinary heart team collaboration remain essential to optimizing long-term outcomes. FAU - Nawaz, Haleema AU - Nawaz H AD - Department of Internal Medicine, Geisinger Wyoming Valley Medical Centre, Wilkes-Barre, PA 18711, USA. FAU - Dahou, Abdellaziz AU - Dahou A AD - Department of Cardiology, Geisinger Wyoming Valley Medical Centre, Wilkes-Barre, PA 18711, USA. FAU - Ahmad, Tariq AU - Ahmad T AD - Department of Cardiology, Geisinger Wyoming Valley Medical Centre, Wilkes-Barre, PA 18711, USA. LA - eng PT - Journal Article PT - Review DEP - 20260501 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC13163473 OTO - NOTNLM OT - aortic stenosis OT - coronary obstruction OT - prosthesis-patient mismatch OT - structural heart disease OT - transcatheter aortic valve replacement OT - valve-in-valve TAVR COIS- The authors declare no conflicts of interest. EDAT- 2026/05/13 06:31 MHDA- 2026/05/13 06:32 PMCR- 2026/05/01 CRDT- 2026/05/13 01:10 PHST- 2026/03/27 00:00 [received] PHST- 2026/04/18 00:00 [revised] PHST- 2026/04/24 00:00 [accepted] PHST- 2026/05/13 06:32 [medline] PHST- 2026/05/13 06:31 [pubmed] PHST- 2026/05/13 01:10 [entrez] PHST- 2026/05/01 00:00 [pmc-release] AID - jcm15093479 [pii] AID - jcm-15-03479 [pii] AID - 10.3390/jcm15093479 [doi] PST - epublish SO - J Clin Med. 2026 May 1;15(9):3479. doi: 10.3390/jcm15093479. PMID- 42123193 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260513 LR - 20260813 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 15 IP - 9 DP - 2026 May 1 TI - Multidisciplinary Approach to Ventricular Arrhythmias in the CICU: Integrating Mechanical Circulatory Support, Ablation, and Emerging Therapies. LID - 10.3390/jcm15093459 [doi] LID - 3459 AB - Background/Objectives: The management of ventricular arrhythmias (VAs) within cardiac intensive care units (CICUs) is undergoing a significant transformation. This review aims to analyze the historical transition from a narrow focus on arrhythmia-specific treatments toward on the multidisciplinary heart rhythm team. Methods: A narrative revies was conducted. Results: Effective management of electrical storm (ES) requires prompt attenuation of sympathetic hyperactivity, with a preference for non-selective beta-blockers and the implementation of deep sedation. The use of mechanical circulatory support (MCS) has emerged as a mechanical antiarrhythmic strategy by facilitating ventricular unloading and reducing myocardial wall stress. Furthermore, early catheter ablation, guided by 3D electroanatomical mapping and advanced imaging, has proven superior to salvage procedures for stabilizing the arrhythmic substrate. Finally, the integration of palliative care ensures ethical stewardship during refractory shock. Conclusions: Modern VAs management in the CICUs represents a convergence of technology, biology, and multidisciplinary coordination. FAU - Mauriello, Alfredo AU - Mauriello A AUID- ORCID: 0000-0001-7060-6938 AD - S.C. Cardiology, Institute National Cancer, IRCCS, Fondazione "G. Pascale", Via M. Semmola 52, 80131 Naples, Italy. FAU - Correra, Adriana AU - Correra A AD - Cardiology Department, Ospedali Riuniti University Hospital, Viale Pinto 1, 71122 Foggia, Italy. FAU - Maratea, Anna Chiara AU - Maratea AC AD - Department of Cardiovascular Disease, ASL Napoli 1 Centro, Via Comunale del Principe, 13/a, 80145 Naples, Italy. FAU - Cetoretta, Valeria AU - Cetoretta V AUID- ORCID: 0000-0002-2137-0188 AD - Cardiology and Arrhythmology Clinic, Marche Polytechnic University, University Hospital "Ospedali Riuniti", Via Conca 71, 60126 Ancona, Italy. FAU - Giallauria, Francesco AU - Giallauria F AUID- ORCID: 0000-0003-4119-9397 AD - Department of Translational Medical Sciences, "Federico II" University of Naples, Via S. Pansini 5, 80131 Naples, Italy. FAU - Esposito, Giovanni AU - Esposito G AD - Department of Translational Medical Sciences, "Federico II" University of Naples, Via S. Pansini 5, 80131 Naples, Italy. FAU - Desiderio, Alfonso AU - Desiderio A AD - Cardiology and Intensive Care Unit, Department of Cardiology, "Umberto I" Hospital, Via Alfonso De Nicola 1, 84014 Nocera Inferiore, Italy. FAU - Sabatella, Francesco AU - Sabatella F AD - Cardiology and Intensive Care Unit, Department of Cardiology, "Umberto I" Hospital, Via Alfonso De Nicola 1, 84014 Nocera Inferiore, Italy. FAU - Marrazzo, Gemma AU - Marrazzo G AD - Cardiology and Intensive Care Unit, Department of Cardiology, "Umberto I" Hospital, Via Alfonso De Nicola 1, 84014 Nocera Inferiore, Italy. FAU - Liccardo, Biagio AU - Liccardo B AD - Cardiology Unit, Department of Medical and Translational Sciences, University of Campania "Luigi Vanvitelli", "V. Monaldi" Hospital, Via Leonardo Bianchi SNC, 80131 Naples, Italy. FAU - Russo, Vincenzo AU - Russo V AUID- ORCID: 0000-0002-9227-0360 AD - Cardiology Unit, Department of Medical and Translational Sciences, University of Campania "Luigi Vanvitelli", "V. Monaldi" Hospital, Via Leonardo Bianchi SNC, 80131 Naples, Italy. FAU - Trambaiolo, Paolo AU - Trambaiolo P AD - Intensive Cardiac Care Unit, Department of Cardiology, Sandro Pertini Hospital, Via Monti Tiburtini, 287, 00157 Rome, Italy. FAU - D'Andrea, Antonello AU - D'Andrea A AUID- ORCID: 0000-0002-9698-9145 AD - Cardiology and Intensive Care Unit, Department of Cardiology, "Umberto I" Hospital, Via Alfonso De Nicola 1, 84014 Nocera Inferiore, Italy. LA - eng PT - Journal Article PT - Review DEP - 20260501 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC13163420 OTO - NOTNLM OT - cardiac intensive care units OT - electrical storm OT - ventricular arrhythmias OT - ventricular fibrillation OT - ventricular tachycardia COIS- The authors declare no conflicts of interest. EDAT- 2026/05/13 06:32 MHDA- 2026/05/13 06:33 PMCR- 2026/05/01 CRDT- 2026/05/13 01:10 PHST- 2026/03/06 00:00 [received] PHST- 2026/04/27 00:00 [revised] PHST- 2026/04/29 00:00 [accepted] PHST- 2026/05/13 06:33 [medline] PHST- 2026/05/13 06:32 [pubmed] PHST- 2026/05/13 01:10 [entrez] PHST- 2026/05/01 00:00 [pmc-release] AID - jcm15093459 [pii] AID - jcm-15-03459 [pii] AID - 10.3390/jcm15093459 [doi] PST - epublish SO - J Clin Med. 2026 May 1;15(9):3459. doi: 10.3390/jcm15093459. PMID- 42120712 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260903 LR - 20260906 IS - 2193-8261 (Print) IS - 2193-6544 (Electronic) IS - 2193-6544 (Linking) VI - 15 IP - 3 DP - 2026 Sep TI - Cardiogenic Shock Centers and Protocols for Acute Cardiovascular Care: Bridging the Gap Between Spoke and Hub Sites. PG - 377-391 LID - 10.1007/s40119-026-00454-8 [doi] AB - Cardiogenic shock (CS) is a syndrome of low cardiac output associated with high inpatient morbidity and mortality. Studies have supported the early transfer of patients with CS from spoke sites to the nearest regional hub center, forming the basis for the "hub-and-spoke" model. Contemporary CS algorithms revolve around invasive hemodynamic monitoring and temporary mechanical circulatory support guided by a multidisciplinary CS team. However, these protocols have limited applicability to the majority of spoke sites due to the limitations of resources, equipment, and personnel, further contributing to inequities in CS care. In this review, we seek to provide a blueprint for a generalizable approach to CS, an algorithm for intrahospital care escalation based on CS severity, and an example protocol detailing stabilization and monitoring strategies, independent of multidisciplinary CS teams. CI - (c) 2026. The Author(s). FAU - Mehta, Chirag AU - Mehta C AD - Department of Cardiology, Westchester Medical Center, New York Medical College, Valhalla, NY, USA. AD - Brown University Health Cardiovascular Institute, Providence, Rhode Island, USA. FAU - Chandragiri, Sahas AU - Chandragiri S AD - Department of Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA. FAU - Atallah, Carl AU - Atallah C AD - Department of Medicine, Roger Williams Medical Center, Providence, Rhode Island, USA. FAU - Asnani, Heena AU - Asnani H AD - Department of Medicine, Roger Williams Medical Center, Providence, Rhode Island, USA. FAU - Mehta, Aryan AU - Mehta A AD - Brown University Health Cardiovascular Institute, Providence, Rhode Island, USA. AD - Department of Medicine, University of Connecticut School of Medicine, Farmington, CT, USA. FAU - Welling, Brian AU - Welling B AD - Department of Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA. FAU - McCarthy, Colleen AU - McCarthy C AD - Department of Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA. FAU - Sweeting, Alexander AU - Sweeting A AD - Department of Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA. FAU - Cooper, Howard A AU - Cooper HA AD - Department of Cardiology, Westchester Medical Center, New York Medical College, Valhalla, NY, USA. FAU - Naidu, Srihari S AU - Naidu SS AD - Department of Cardiology, Westchester Medical Center, New York Medical College, Valhalla, NY, USA. FAU - Abbott, J Dawn AU - Abbott JD AD - Brown University Health Cardiovascular Institute, Providence, Rhode Island, USA. AD - Division of Cardiology, Department of Medicine, Warren Alpert Medical School of Brown University, 2 Dudley Street, Suite 360, Providence, Rhode Island, 02905, USA. FAU - Vallabhajosyula, Saraschandra AU - Vallabhajosyula S AUID- ORCID: 0000-0002-1631-8238 AD - Brown University Health Cardiovascular Institute, Providence, Rhode Island, USA. svallabhajosyula@brownhealth.org. AD - Division of Cardiology, Department of Medicine, Warren Alpert Medical School of Brown University, 2 Dudley Street, Suite 360, Providence, Rhode Island, 02905, USA. svallabhajosyula@brownhealth.org. LA - eng PT - Journal Article PT - Review DEP - 20260513 PL - England TA - Cardiol Ther JT - Cardiology and therapy JID - 101634495 PMC - PMC13542023 OTO - NOTNLM OT - Acute cardiovascular care OT - Cardiogenic shock OT - Protocols OT - Regionalization OT - Teams COIS- Declarations. Conflicts of Interest: J Dawn Abbott receives research funding from Boston Scientific, Shockwave, Novo Nordisk, and Med Alliance, and serves as a consultant for Abbott, Medtronic, Boston Scientific, and Recor. Chirag Mehta, Sahas Chandragiri, Carl Atallah, Heena Asnani, Aryan Mehta, Brian Welling, Colleen McCarthy, Alexander Sweeting, Howard A Cooper, Srihari S Naidu and Saraschandra Vallabhajosyula have nothing to disclose. Ethical Approval: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. EDAT- 2026/05/13 00:29 MHDA- 2026/05/13 00:30 PMCR- 2026/05/13 CRDT- 2026/05/12 23:33 PHST- 2026/03/13 00:00 [received] PHST- 2026/05/06 00:00 [accepted] PHST- 2026/05/13 00:30 [medline] PHST- 2026/05/13 00:29 [pubmed] PHST- 2026/05/12 23:33 [entrez] PHST- 2026/05/13 00:00 [pmc-release] AID - 10.1007/s40119-026-00454-8 [pii] AID - 454 [pii] AID - 10.1007/s40119-026-00454-8 [doi] PST - ppublish SO - Cardiol Ther. 2026 Sep;15(3):377-391. doi: 10.1007/s40119-026-00454-8. Epub 2026 May 13. PMID- 42119458 OWN - NLM STAT- Publisher LR - 20260813 IS - 1980-5322 (Electronic) IS - 1807-5932 (Print) IS - 1807-5932 (Linking) VI - 81 DP - 2026 May 12 TI - A stepwise diagnostic framework for recurrent unexplained fever in adults: an evidence-based review with focus on Latin America. PG - 100992 LID - S1807-5932(26)00120-1 [pii] LID - 10.1016/j.clinsp.2026.100992 [doi] LID - 100992 AB - BACKGROUND AND METHODS: Recurrent fever is a complex clinical presentation that poses significant diagnostic challenges, particularly when no clear etiology emerges despite extensive investigation. This integrative narrative review provides a comprehensive overview of recurrent fever and proposes a practical diagnostic flowchart focused on the most frequent etiologies, with particular emphasis on the Latin American and Brazilian contexts. Literature from MEDLINE/PubMed, LILACS, and SciELO was reviewed to summarize evidence on epidemiology, differential diagnosis, and diagnostic strategies. RESULTS: Recurrent fever may arise from infectious diseases, autoimmune or autoinflammatory disorders, malignancies, metabolic or occupational conditions, drug-induced etiologies, and factitious causes. Infections, notably tuberculosis, malaria, leishmaniasis, and endocarditis, remain leading contributors in developing countries. Non-infectious causes such as rheumatologic conditions, neoplasms, and inborn errors of immunity must also be considered, especially in persistent or unexplained cases. A structured, tiered approach to diagnosis is recommended, beginning with basic laboratory and imaging studies, progressing to targeted invasive procedures and advanced modalities such as 18F-FDG PET/CT, and, when appropriate, genomic sequencing. The flowchart proposed in this review emphasizes clinical history, frequent reassessment, and the judicious use of diagnostic resources to balance cost-effectiveness and diagnostic yield. Moreover, distinguishing between inflammatory and non-inflammatory patterns, as well as identifying the newly described Syndrome of Undifferentiated Recurrent Fever (SURF), may guide further evaluation. Ultimately, recurrent fever requires a systematic and multidisciplinary approach. Incorporating epidemiological context and advances in molecular and imaging technologies may improve diagnostic accuracy and patient outcomes. CI - Copyright (c) 2026 HCFMUSP. Published by Elsevier Espana, S.L.U. All rights reserved. FAU - Favarato, Maria Helena AU - Favarato MH AD - Universidade Municipal de Sao Caetano do Sul (USCS), Sao Caetano do Sul, SP, Brazil; Discipline of Internal Medicine, Faculdade de Medicina da Universidade de Sao Paulo (FMUSP), Sao Paulo, SP, Brazil. Electronic address: maria.favarato@hc.fm.usp.br. FAU - Aguiar, Victoria Luisa Pereira AU - Aguiar VLP AD - Universidade Municipal de Sao Caetano do Sul (USCS), Sao Caetano do Sul, SP, Brazil. FAU - Paiva, Edison Ferreira AU - Paiva EF AD - Discipline of Internal Medicine, Faculdade de Medicina da Universidade de Sao Paulo (FMUSP), Sao Paulo, SP, Brazil. FAU - Mendonca, Leonardo Oliveira AU - Mendonca LO AD - Discipline of Clinical Immunology and Allergy, Faculdade de Medicina da Universidade de Sao Paulo (FMUSP), Sao Paulo, SP, Brazil. LA - eng PT - Journal Article PT - Review DEP - 20260512 PL - United States TA - Clinics (Sao Paulo) JT - Clinics (Sao Paulo, Brazil) JID - 101244734 SB - IM PMC - PMC13195347 OTO - NOTNLM OT - Adult infectious diseases OT - Autoinflammatory diseases OT - Brazil OT - Clinical decision support OT - Diagnostic algorithm OT - Diagnostic flowchart OT - Fever OT - Fever of unknown origin (FUO) OT - Latin America OT - Recurrent fever OT - Recurrent fever of unknown origin OT - Review OT - Tropical fever COIS- Declaration of competing interest The authors declare no conflicts of interest. EDAT- 2026/05/13 00:29 MHDA- 2026/05/13 00:29 PMCR- 2026/05/12 CRDT- 2026/05/12 18:29 PHST- 2025/09/03 00:00 [received] PHST- 2026/01/27 00:00 [revised] PHST- 2026/02/16 00:00 [accepted] PHST- 2026/05/13 00:29 [medline] PHST- 2026/05/13 00:29 [pubmed] PHST- 2026/05/12 18:29 [entrez] PHST- 2026/05/12 00:00 [pmc-release] AID - S1807-5932(26)00120-1 [pii] AID - 100992 [pii] AID - 10.1016/j.clinsp.2026.100992 [doi] PST - aheadofprint SO - Clinics (Sao Paulo). 2026 May 12;81:100992. doi: 10.1016/j.clinsp.2026.100992. PMID- 42112794 OWN - NLM STAT- MEDLINE DCOM- 20260716 LR - 20260724 IS - 1873-734X (Electronic) IS - 1010-7940 (Linking) VI - 68 IP - 5 DP - 2026 May 11 TI - Ventricular free-wall rupture, ventricular pseudoaneurysm, and papillary muscle rupture complicating acute myocardial infarction. LID - ezag157 [pii] LID - 10.1093/ejcts/ezag157 [doi] AB - The prevalence of mechanical complications following acute myocardial infarction has steadily declined in recent years owing to advances in prompt coronary revascularization, and they now occur in <1% of acute myocardial infarction cases. Nevertheless, significant haemodynamic impairment may already be present at hospital admission, requiring immediate diagnostic evaluation and urgent intervention. Until recently, surgical repair was the only treatment option, with non-negligible in-hospital mortality rates, particularly among patients with acute cardio-circulatory failure. Advances in transcatheter percutaneous procedures have now introduced alternative treatment strategies, especially for high-risk or inoperable patients. Recurrence of post-acute myocardial infarction mechanical complications, even shortly after the repair of the underlying lesion, has a critical impact on patient outcome and underscores the need for careful monitoring during hospitalization as well as after discharge. The role of concomitant coronary revascularization remains controversial, with variable effects on both early and late outcomes, and warrants further investigation. Temporary mechanical circulatory support has shown encouraging results, either for pre-procedural haemodynamic stabilization ('bridge-to-procedure') or for prophylactic, extended peri-procedural support to facilitate myocardial recovery ('bridge-to-recovery'). Optimal management should be guided by a multidisciplinary Heart Team approach (including Shock Team involvement where appropriate) with integration of palliative care into the decision-making process. CI - This article has been co-published with permission in the European Heart Journal and European Journal of Cardio-Thoracic Surgery. All rights reserved. (c) 2026 the European Society of Cardiology and the European Association for Cardio-Thoracic Surgery.The articles are identical except for minor stylistic and spelling differences in keeping with each journal's style. Either citation can be used when citing this article. FAU - Lorusso, Roberto AU - Lorusso R AUID- ORCID: 0000-0002-1777-2045 AD - Department of Cardiothoracic Surgery, Maastricht University Medical Center, P.Debyelaan 25, Maastricht 6202 AZ, The Netherlands. AD - Cardiovascular Research Institute Maastricht (CARIM), Maastricht 6202 AZ, The Netherlands. FAU - Matteucci, Matteo AU - Matteucci M AD - Department of Cardiothoracic Surgery, Maastricht University Medical Center, P.Debyelaan 25, Maastricht 6202 AZ, The Netherlands. AD - Cardiac Surgery Unit, ASST Sette Laghi, Varese, Italy. FAU - Ronco, Daniele AU - Ronco D AUID- ORCID: 0000-0001-5250-1796 AD - Department of Cardiothoracic Surgery, Maastricht University Medical Center, P.Debyelaan 25, Maastricht 6202 AZ, The Netherlands. AD - Cardiac Surgery and Heart Transplant Unit, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy. FAU - Massimi, Giulio AU - Massimi G AUID- ORCID: 0000-0002-9278-1144 AD - Department of Cardiothoracic Surgery, Maastricht University Medical Center, P.Debyelaan 25, Maastricht 6202 AZ, The Netherlands. AD - Cardiac Surgery Unit, Santa Maria Hospital, Terni, Italy. FAU - Price, Susanna AU - Price S AD - Cardiology and Critical Care Unit, Royal Brompton and Harefield Hospitals, London, UK. AD - National Heart and Lung Institute, Imperial College, London, UK. FAU - Czerny, Martin AU - Czerny M AD - Clinic for Cardiac and Vascular Surgery, University Heart Center Freiburg-Bad Krozingen, University Clinic Freiburg, Freiburg, Germany. AD - Faculty of Medicine, Albert Ludwigs University, Freiburg, Germany. FAU - Estevez-Loureiro, Rodrigo AU - Estevez-Loureiro R AD - Department of Interventional Cardiology, University Hospital Alvaro Cunqueiro, Vigo, Spain. FAU - Siepe, Matthias AU - Siepe M AUID- ORCID: 0000-0003-3305-9343 AD - Department of Cardiac Surgery, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. FAU - Pontone, Gianluca AU - Pontone G AUID- ORCID: 0000-0002-1339-6679 AD - Department of Perioperative Cardiology and Cardiovascular Imaging, Centro Cardiologico Monzino IRCCS, Milan, Italy. AD - Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy. FAU - Hassager, Christian AU - Hassager C AUID- ORCID: 0000-0002-1199-0981 AD - Department of Cardiology, Rigshospitalet, Copenhagen, Denmark. FAU - Chioncel, Ovidiu AU - Chioncel O AUID- ORCID: 0000-0002-3197-3628 AD - Emergency Institute for Cardiovascular Diseases 'Prof. C.C. Iliescu', University of Medicine 'Carol Davila', Bucharest, Romania. FAU - Zuin, Marco AU - Zuin M AD - Department of Translational Medicine, University of Ferrara, Ferrara, Italy. FAU - Davos, Constantinos H AU - Davos CH AUID- ORCID: 0000-0002-0321-7569 AD - Cardiovascular Research Laboratory, Biomedical Research Foundation, Academy of Athens, Athens, Greece. FAU - Adamo, Marianna AU - Adamo M AUID- ORCID: 0000-0002-3855-1815 AD - Department of Medical and Surgical Specialties, Catheterization Laboratory and Cardiology, ASST Spedali Civili di Brescia, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy. FAU - Gustafsson, Finn AU - Gustafsson F AUID- ORCID: 0000-0003-2144-341X AD - Department of Cardiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. FAU - Giannakoulas, George AU - Giannakoulas G AUID- ORCID: 0000-0001-7491-6319 AD - Cardiology Department, AHEPA University Hospital, Thessaloniki, Greece. FAU - Amabile, Nicolas AU - Amabile N AUID- ORCID: 0000-0001-9092-4458 AD - Interventional Cardiology Department, Institut Mutualiste Montsouris, Paris, France. FAU - Sionis, Alessandro AU - Sionis A AUID- ORCID: 0000-0003-0843-9512 AD - Cardiology Department, Intensive Cardiac Care Unit, Hospital de Sant Pau, IIB-Sant Pau, Universitat Autonoma de Barcelona, Barcelona Spain. AD - Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain. FAU - Thielmann, Matthias AU - Thielmann M AD - Department of Thoracic and Cardiovascular Surgery, West German Heart & Vascular Center Essen, Essen, Germany. FAU - Petersen, Steffen Erhard AU - Petersen SE AD - Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK. AD - William Harvey Research Institute, NIHR Barts Biomedical Research Centre, Queen Mary University of London, Charterhouse Square, UK. FAU - Cosyns, Bernard AU - Cosyns B AD - Department of Cardiology, Centrum voor Hart-en Vaatziekten (CHVZ), Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB), Brussels, Belgium. FAU - Huber, Kurt AU - Huber K AD - Austrian Heart Foundation, Vienna, and Medical Private University Burgenland, Pinkafeld, Austria. FAU - Tokmakova, Mariya AU - Tokmakova M AD - Section of Cardiology, First Department of Internal Diseases, Medical University of Plovdiv, and Clinic of Cardiology, UMHAT 'Sv. Georgi' EAD, Plovdiv, Bulgaria. FAU - Pacini, Davide AU - Pacini D AUID- ORCID: 0000-0002-4298-3792 AD - Cardiac Surgery Department, IRCCS University Hospital of Bologna, Policlinico S. Orsola, Bologna, Italy. FAU - Klok, Frederikus A AU - Klok FA AUID- ORCID: 0000-0001-9961-0754 AD - Department of Medicine, Section of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands. FAU - Saia, Francesco AU - Saia F AUID- ORCID: 0000-0001-9969-2649 AD - Interventional Cardiology Unit, IRCCS University Hospital of Bologna, Policlinico S. Orsola, Bologna, Italy. FAU - Abreu, Ana AU - Abreu A AUID- ORCID: 0000-0003-0786-7830 AD - Cardiology Department of University Hospital Santa Maria, Faculty of Medicine, ISAMB, University of Lisbon, Lisbon, Portugal. FAU - Grimm, Michael AU - Grimm M AD - University Clinic of Cardiac Surgery, Medical University of Innsbruck, Innsbruck, Austria. FAU - Claeys, Marc J AU - Claeys MJ AD - Department of Cardiology, Hospital Antwerp, Edegem, Belgium. FAU - Garcia-Alvarez, Ana AU - Garcia-Alvarez A AD - Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain. AD - Cardiology Department, Hospital Clinic Barcelona, IDIBAPS, Universitat de Barcelona, Barcelona, Spain. FAU - Gerber, Bernhard AU - Gerber B AD - Division of Cardiology, Department of Cardiovascular Diseases, Cliniques Universitaires St.Luc and Pole de Recherche Cardiovasculaire (CARD), Institut de Recherche Experimentale et Clinique (IREC), Universite Catholique de Louvain, Brussels, Belgium. FAU - Mestres, Carlos A AU - Mestres CA AD - Department of Cardiothoracic Surgery and the Robert WM Frater Cardiovascular Research Centre, The University of the Free State, Bloemfontein, South Africa. FAU - Rosenkranz, Stephan AU - Rosenkranz S AUID- ORCID: 0000-0001-6237-1470 AD - Department of Cardiology, Heart Center, University of Cologne, Cologne, Germany. AD - Faculty of Medicine, Cologne Cardiovascular Research Center (CCRC), Heart Center, University of Cologne, Cologne, Germany. FAU - Adamopoulos, Stamatis AU - Adamopoulos S AUID- ORCID: 0000-0001-5223-5782 AD - Heart Failure and Transplant Units, Onassis Cardiac Surgery Center, Athens, Greece. FAU - Bonaros, Nikolaos AU - Bonaros N AD - Department of Cardiac Surgery, Medical University of Innsbruck, Innsbruck, Austria. LA - eng PT - Journal Article PT - Review PL - Germany TA - Eur J Cardiothorac Surg JT - European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery JID - 8804069 SB - IM MH - Humans MH - *Heart Rupture, Post-Infarction/surgery/etiology/diagnosis MH - *Myocardial Infarction/complications/surgery MH - *Papillary Muscles/surgery/injuries MH - *Aneurysm, False/etiology/surgery/diagnosis MH - Heart Ventricles/surgery MH - *Heart Aneurysm/etiology/surgery OTO - NOTNLM OT - Acute myocardial infarction OT - cardiogenic shock OT - coronary artery disease OT - multidisciplinary heart team OT - papillary muscle rupture OT - temporary mechanical circulatory support OT - ventricular free-wall rupture OT - ventricular pseudo-aneurysm EDAT- 2026/05/11 12:59 MHDA- 2026/05/11 13:00 CRDT- 2026/05/11 08:53 PHST- 2026/05/11 13:00 [medline] PHST- 2026/05/11 12:59 [pubmed] PHST- 2026/05/11 08:53 [entrez] AID - 8675277 [pii] AID - 10.1093/ejcts/ezag157 [doi] PST - ppublish SO - Eur J Cardiothorac Surg. 2026 May 11;68(5):ezag157. doi: 10.1093/ejcts/ezag157. PMID- 42112704 OWN - NLM STAT- MEDLINE DCOM- 20260813 LR - 20260813 IS - 1522-9645 (Electronic) IS - 0195-668X (Linking) VI - 47 IP - 31 DP - 2026 Aug 14 TI - Ventricular free-wall rupture, ventricular pseudoaneurysm, and papillary muscle rupture complicating acute myocardial infarction. PG - 4188-4214 LID - 10.1093/eurheartj/ehag164 [doi] AB - The prevalence of mechanical complications following acute myocardial infarction has steadily declined in recent years owing to advances in prompt coronary revascularization, and they now occur in <1% of acute myocardial infarction cases. Nevertheless, significant haemodynamic impairment may already be present at hospital admission, requiring immediate diagnostic evaluation and urgent intervention. Until recently, surgical repair was the only treatment option, with non-negligible in-hospital mortality rates, particularly among patients with acute cardio-circulatory failure. Advances in transcatheter percutaneous procedures have now introduced alternative treatment strategies, especially for high-risk or inoperable patients. Recurrence of post-acute myocardial infarction mechanical complications, even shortly after the repair of the underlying lesion, has a critical impact on patient outcome and underscores the need for careful monitoring during hospitalization as well as after discharge. The role of concomitant coronary revascularization remains controversial, with variable effects on both early and late outcomes, and warrants further investigation. Temporary mechanical circulatory support has shown encouraging results, either for pre-procedural haemodynamic stabilization ('bridge-to-procedure') or for prophylactic, extended peri-procedural support to facilitate myocardial recovery ('bridge-to-recovery'). Optimal management should be guided by a multidisciplinary Heart Team approach (including Shock Team involvement where appropriate) with integration of palliative care into the decision-making process. CI - This article has been co-published with permission in the European Heart Journal and European Journal of Cardio-Thoracic Surgery. All rights reserved. (c) 2026 the European Society of Cardiology and the European Association for Cardio-Thoracic Surgery The articles are identical except for minor stylistic and spelling differences in keeping with each journal's style. Either citation can be used when citing this article. FAU - Lorusso, Roberto AU - Lorusso R AUID- ORCID: 0000-0002-1777-2045 AD - Department of Cardiothoracic Surgery, Maastricht University Medical Center, P.Debyelaan 25, Maastricht 6202 AZ, The Netherlands. AD - Cardiovascular Research Institute Maastricht (CARIM), Maastricht 6202 AZ, The Netherlands. FAU - Matteucci, Matteo AU - Matteucci M AD - Department of Cardiothoracic Surgery, Maastricht University Medical Center, P.Debyelaan 25, Maastricht 6202 AZ, The Netherlands. AD - Cardiac Surgery Unit, ASST Sette Laghi, Varese, Italy. FAU - Ronco, Daniele AU - Ronco D AUID- ORCID: 0000-0001-5250-1796 AD - Department of Cardiothoracic Surgery, Maastricht University Medical Center, P.Debyelaan 25, Maastricht 6202 AZ, The Netherlands. AD - Cardiac Surgery and Heart Transplant Unit, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy. FAU - Massimi, Giulio AU - Massimi G AUID- ORCID: 0000-0002-9278-1144 AD - Department of Cardiothoracic Surgery, Maastricht University Medical Center, P.Debyelaan 25, Maastricht 6202 AZ, The Netherlands. AD - Cardiac Surgery Unit, Santa Maria Hospital, Terni, Italy. FAU - Price, Susanna AU - Price S AD - Cardiology and Critical Care Unit, Royal Brompton and Harefield Hospitals, London, UK. AD - National Heart and Lung Institute, Imperial College, London, UK. FAU - Czerny, Martin AU - Czerny M AD - Clinic for Cardiac and Vascular Surgery, University Heart Center Freiburg-Bad Krozingen, University Clinic Freiburg, Freiburg, Germany. AD - Faculty of Medicine, Albert Ludwigs University, Freiburg, Germany. FAU - Estevez-Loureiro, Rodrigo AU - Estevez-Loureiro R AD - Department of Interventional Cardiology, University Hospital Alvaro Cunqueiro, Vigo, Spain. FAU - Siepe, Matthias AU - Siepe M AUID- ORCID: 0000-0003-3305-9343 AD - Department of Cardiac Surgery, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. FAU - Pontone, Gianluca AU - Pontone G AUID- ORCID: 0000-0002-1339-6679 AD - Department of Perioperative Cardiology and Cardiovascular Imaging, Centro Cardiologico Monzino IRCCS, Milan, Italy. AD - Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy. FAU - Hassager, Christian AU - Hassager C AUID- ORCID: 0000-0002-1199-0981 AD - Department of Cardiology, Rigshospitalet, Copenhagen, Denmark. FAU - Chioncel, Ovidiu AU - Chioncel O AUID- ORCID: 0000-0002-3197-3628 AD - Emergency Institute for Cardiovascular Diseases 'Prof. C.C. Iliescu', University of Medicine 'Carol Davila', Bucharest, Romania. FAU - Zuin, Marco AU - Zuin M AD - Department of Translational Medicine, University of Ferrara, Ferrara, Italy. FAU - Davos, Constantinos H AU - Davos CH AUID- ORCID: 0000-0002-0321-7569 AD - Cardiovascular Research Laboratory, Biomedical Research Foundation, Academy of Athens, Athens, Greece. FAU - Adamo, Marianna AU - Adamo M AUID- ORCID: 0000-0002-3855-1815 AD - Department of Medical and Surgical Specialties, Catheterization Laboratory and Cardiology, ASST Spedali Civili di Brescia, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy. FAU - Gustafsson, Finn AU - Gustafsson F AUID- ORCID: 0000-0003-2144-341X AD - Department of Cardiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. FAU - Giannakoulas, George AU - Giannakoulas G AUID- ORCID: 0000-0001-7491-6319 AD - Cardiology Department, AHEPA University Hospital, Thessaloniki, Greece. FAU - Amabile, Nicolas AU - Amabile N AUID- ORCID: 0000-0001-9092-4458 AD - Interventional Cardiology Department, Institut Mutualiste Montsouris, Paris, France. FAU - Sionis, Alessandro AU - Sionis A AUID- ORCID: 0000-0003-0843-9512 AD - Cardiology Department, Intensive Cardiac Care Unit, Hospital de Sant Pau, IIB-Sant Pau, Universitat Autonoma de Barcelona, BarcelonaSpain. AD - Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain. FAU - Thielmann, Matthias AU - Thielmann M AD - Department of Thoracic and Cardiovascular Surgery, West German Heart & Vascular Center Essen, Essen, Germany. FAU - Petersen, Steffen Erhard AU - Petersen SE AD - Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK. AD - William Harvey Research Institute, NIHR Barts Biomedical Research Centre, Queen Mary University of London, Charterhouse Square, UK. FAU - Cosyns, Bernard AU - Cosyns B AD - Department of Cardiology, Centrum voor Hart-en Vaatziekten (CHVZ), Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB), Brussels, Belgium. FAU - Huber, Kurt AU - Huber K AUID- ORCID: 0000-0003-1695-3378 AD - Austrian Heart Foundation, Vienna, and Medical Private University Burgenland, Pinkafeld, Austria. FAU - Tokmakova, Mariya AU - Tokmakova M AD - Section of Cardiology, First Department of Internal Diseases, Medical University of Plovdiv, and Clinic of Cardiology, UMHAT 'Sv. Georgi' EAD, Plovdiv, Bulgaria. FAU - Pacini, Davide AU - Pacini D AUID- ORCID: 0000-0002-4298-3792 AD - Cardiac Surgery Department, IRCCS University Hospital of Bologna, Policlinico S. Orsola, Bologna, Italy. FAU - Klok, Frederikus A AU - Klok FA AUID- ORCID: 0000-0001-9961-0754 AD - Department of Medicine, Section of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands. FAU - Saia, Francesco AU - Saia F AUID- ORCID: 0000-0001-9969-2649 AD - Interventional Cardiology Unit, IRCCS University Hospital of Bologna, Policlinico S. Orsola, Bologna, Italy. FAU - Abreu, Ana AU - Abreu A AUID- ORCID: 0000-0003-0786-7830 AD - Cardiology Department of University Hospital Santa Maria, Faculty of Medicine, ISAMB, University of Lisbon, Lisbon, Portugal. FAU - Grimm, Michael AU - Grimm M AD - University Clinic of Cardiac Surgery, Medical University of Innsbruck, Innsbruck, Austria. FAU - Claeys, Marc J AU - Claeys MJ AD - Department of Cardiology, Hospital Antwerp, Edegem, Belgium. FAU - Garcia-Alvarez, Ana AU - Garcia-Alvarez A AD - Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain. AD - Cardiology Department, Hospital Clinic Barcelona, IDIBAPS, Universitat de Barcelona, Barcelona, Spain. FAU - Gerber, Bernhard AU - Gerber B AD - Division of Cardiology, Department of Cardiovascular Diseases, Cliniques Universitaires St.Luc and Pole de Recherche Cardiovasculaire (CARD), Institut de Recherche Experimentale et Clinique (IREC), Universite Catholique de Louvain, Brussels, Belgium. FAU - Mestres, Carlos A AU - Mestres CA AD - Department of Cardiothoracic Surgery and the Robert WM Frater Cardiovascular Research Centre, The University of the Free State, Bloemfontein, South Africa. FAU - Rosenkranz, Stephan AU - Rosenkranz S AUID- ORCID: 0000-0001-6237-1470 AD - Department of Cardiology, Heart Center, University of Cologne, Cologne, Germany. AD - Faculty of Medicine, Cologne Cardiovascular Research Center (CCRC), Heart Center, University of Cologne, Cologne, Germany. FAU - Adamopoulos, Stamatis AU - Adamopoulos S AUID- ORCID: 0000-0001-5223-5782 AD - Heart Failure and Transplant Units, Onassis Cardiac Surgery Center, Athens, Greece. FAU - Bonaros, Nikolaos AU - Bonaros N AD - Department of Cardiac Surgery, Medical University of Innsbruck, Innsbruck, Austria. LA - eng PT - Journal Article PT - Review PL - England TA - Eur Heart J JT - European heart journal JID - 8006263 SB - IM MH - Humans MH - *Heart Rupture, Post-Infarction/etiology/therapy MH - *Aneurysm, False/etiology/therapy MH - *Papillary Muscles/injuries MH - *Myocardial Infarction/complications MH - *Heart Aneurysm/etiology/therapy MH - Recurrence MH - Myocardial Revascularization/methods OTO - NOTNLM OT - Acute myocardial infarction OT - cardiogenic shock OT - coronary artery disease OT - multidisciplinary heart team OT - papillary muscle rupture OT - temporary mechanical circulatory support OT - ventricular free-wall rupture OT - ventricular pseudo-aneurysm EDAT- 2026/05/11 13:00 MHDA- 2026/08/13 23:36 CRDT- 2026/05/11 08:13 PHST- 2026/08/13 23:36 [medline] PHST- 2026/05/11 13:00 [pubmed] PHST- 2026/05/11 08:13 [entrez] AID - 8675017 [pii] AID - 10.1093/eurheartj/ehag164 [doi] PST - ppublish SO - Eur Heart J. 2026 Aug 14;47(31):4188-4214. doi: 10.1093/eurheartj/ehag164. PMID- 42104266 OWN - NLM STAT- Publisher LR - 20260508 IS - 1476-8321 (Electronic) IS - 0887-0446 (Linking) DP - 2026 May 8 TI - Affairs of the heart: couples coping with cardiac rehabilitation. PG - 1-16 LID - 10.1080/08870446.2026.2670014 [doi] AB - METHODS: A dyadic design was used, with partners from 86 couples filling a self-report questionnaire at cardiac rehabilitation admission. FINDINGS: Results from path analysis showed that patient activation was higher when the partner's illness perception was less pessimistic, when the partner was less overprotective, and the couple was more able to cope together. Also, patient activation was higher the better the patient's relationship with the medical staff and the less the partner reported to have a good relationship with the patient's doctor. No associations were found between patient activation and partner's hostility, partner support to patient activation, and dyadic stress appraisal. Finally, no associations were found between patient activation and clarity of information received at intake. DISCUSSION: Research and interventions should take advantage of dyadic and team-based approaches to better understand relational drivers of patient activation and effectively leverage their different roles. FAU - Donato, Silvia AU - Donato S AUID- ORCID: 0000-0002-8406-4604 AD - Universita Cattolica del Sacro Cuore, Milano, Italy. FAU - Demaria, Chiara AU - Demaria C AUID- ORCID: 0009-0002-2435-5984 AD - Universita Cattolica del Sacro Cuore, Milano, Italy. FAU - Gioia, Claudia AU - Gioia C AUID- ORCID: 0009-0008-5150-4029 AD - Universita Cattolica del Sacro Cuore, Milano, Italy. FAU - Gorini, Alessandra AU - Gorini A AUID- ORCID: 0000-0003-3216-1784 AD - Istituti Clinici Scientifici Maugeri IRCCS, Milan, Italy. AD - Dipartimento di Scienze Cliniche e di Comunita, Dipartimento di Eccellenza 2023-2027, Universita degli Studi di Milano, Milan, Italy. FAU - Bussotti, Maurizio AU - Bussotti M AUID- ORCID: 0000-0003-3520-249X AD - Istituti Clinici Scientifici Maugeri IRCCS, Milan, Italy. FAU - Bertoni, Anna AU - Bertoni A AUID- ORCID: 0000-0001-7228-8718 AD - Universita Cattolica del Sacro Cuore, Milano, Italy. LA - eng PT - Journal Article DEP - 20260508 PL - England TA - Psychol Health JT - Psychology & health JID - 8807983 SB - IM OTO - NOTNLM OT - Cardiac rehabilitation OT - Couple relationship OT - Doctor-Patient Relationship OT - Dyadic coping OT - Partner support OT - Patient Activation EDAT- 2026/05/09 00:33 MHDA- 2026/05/09 00:33 CRDT- 2026/05/08 23:44 PHST- 2026/05/09 00:33 [medline] PHST- 2026/05/09 00:33 [pubmed] PHST- 2026/05/08 23:44 [entrez] AID - 10.1080/08870446.2026.2670014 [doi] PST - aheadofprint SO - Psychol Health. 2026 May 8:1-16. doi: 10.1080/08870446.2026.2670014. PMID- 42101437 OWN - NLM STAT- Publisher LR - 20260508 IS - 1477-092X (Electronic) IS - 1078-1552 (Linking) DP - 2026 May 8 TI - Practical considerations in the management of patients with atrial fibrillation/flutter and hematologic malignancies. PG - 10781552261445449 LID - 10.1177/10781552261445449 [doi] AB - ObjectiveThe purpose of this review is to highlight the nuanced approach for managing drug-drug interactions (DDIs), anticoagulation challenges, and overlapping toxicities in patients with atrial fibrillation (AF) and hematologic malignancies through patient case vignettes. While not all inclusive, these principles may be applicable to additional classes of medications not directly covered in this review.Data SourcesA comprehensive literature search was performed in PubMed to identify clinical trials, retrospective and population-based studies, pharmacokinetic analyses, and registry data evaluating atrial fibrillation management, anticoagulation strategies, and hematologic malignancy treatments.Data SummaryPatients with cancer, especially hematologic malignancies, have an increased risk of AF secondary to aging, overlapping risk factors, and cancer treatments and toxicities. In addition to the increased AF incidence, hematologic malignancies and their treatment increase the complexity of AF management. Mitigating drug-drug interactions (DDIs) between treatments for hematologic malignancies and AF, in particular antiarrhythmic drugs, is increasingly relevant as recent literature supports early rhythm control in patients with new-onset AF. Case-based scenarios highlight the importance of individualized decision making, especially for patients with high-risk hematologic malignancies, curative treatment intent, or significant cardiac comorbidity.ConclusionsManagement of AF in patients with hematologic malignancies requires an individualized multidisciplinary approach that carefully balances hematologic malignancy treatment intent, thromboembolic and bleeding risks, DDIs, and patient comorbidities to optimize both cardiovascular and malignancy outcomes. FAU - Ochs, Madeleine A AU - Ochs MA AUID- ORCID: 0000-0001-9593-0603 AD - Department of Pharmacy Services and Clinical Pharmacy, Michigan Medicine, Ann Arbor, MI, USA. RINGGOLD: 21614 FAU - Shabanowitz, Nicholas AU - Shabanowitz N AUID- ORCID: 0009-0004-2102-4789 AD - Department of Pharmacy Services and Clinical Pharmacy, Michigan Medicine, Ann Arbor, MI, USA. RINGGOLD: 21614 AD - Department of Pharmacy Services, UNC Health, Chapel Hill, NC, USA. FAU - Nachar, Victoria R AU - Nachar VR AUID- ORCID: 0000-0002-5906-4733 AD - Department of Pharmacy Services, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA. RINGGOLD: 67159 FAU - Ahmed, Iman AU - Ahmed I AUID- ORCID: 0000-0003-3751-2280 AD - Department of Pharmacy Services, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA. RINGGOLD: 67159 FAU - Hayek, Salim S AU - Hayek SS AUID- ORCID: 0000-0003-0180-349X AD - Division of Cardiology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, Michigan, USA. RINGGOLD: 223232 AD - Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX, USA. FAU - Crawford, Thomas Christopher AU - Crawford TC AD - Division of Cardiology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, Michigan, USA. RINGGOLD: 223232 FAU - Lewis, Sarah AU - Lewis S AD - Department of Pharmacy Services and Clinical Pharmacy, Michigan Medicine, Ann Arbor, MI, USA. RINGGOLD: 21614 LA - eng PT - Journal Article DEP - 20260508 PL - England TA - J Oncol Pharm Pract JT - Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners JID - 9511372 SB - IM OTO - NOTNLM OT - Atrial fibrillation OT - anticoagulation OT - cancer EDAT- 2026/05/08 12:37 MHDA- 2026/05/08 12:37 CRDT- 2026/05/08 10:43 PHST- 2026/05/08 12:37 [medline] PHST- 2026/05/08 12:37 [pubmed] PHST- 2026/05/08 10:43 [entrez] AID - 10.1177/10781552261445449 [doi] PST - aheadofprint SO - J Oncol Pharm Pract. 2026 May 8:10781552261445449. doi: 10.1177/10781552261445449. PMID- 42100236 OWN - NLM STAT- MEDLINE DCOM- 20260716 LR - 20260921 IS - 1735-3688 (Electronic) IS - 0253-0716 (Print) IS - 0253-0716 (Linking) VI - 51 IP - 4 DP - 2026 Apr TI - Adherence to Medication, Mediterranean Diet, and Physical Activity and Their Predictors in Heart Failure Patients. PG - 236-247 LID - 10.30476/ijms.2025.106829.4113 [doi] AB - BACKGROUND: Adherence to prescribed medications, a healthy diet, and regular physical activity is essential for the optimal management of heart failure (HF). Therefore, the present study aimed to determine the level of adherence to medications, the Mediterranean diet (MD), and physical activity, and to identify their correlations. METHODS: In this cross-sectional study, HF patients who were hospitalized from March to November 2022 were enrolled. Medication adherence, the MD, and physical activity were assessed using the 8-item Morisky medication adherence scale, the 14-item MD adherence Screener (MEDAS), and the International Physical Activity Questionnaire (IPAQ), respectively. Univariate analyses were conducted using the Chi square and Kruskal-Wallis tests. Ordinal logistic regression was applied to examine factors associated with adherence levels. Data were analyzed using Stata software (version 17), and P<0.05 was considered statistically significant. RESULTS: Data from 320 patients were analyzed. Suboptimal adherence was observed in 97 (30.3%), 88 (27.5%), and 224 (70%) of participants for medication, MD, and physical activity, respectively, and was linked to lower left ventricular ejection fraction. Multivariable analysis revealed that lower medication adherence was associated with older age, tobacco use, and a higher number of comorbidities. Reduced MD adherence was related to a higher body mass index (BMI), the presence of comorbidities, and a history of cerebrovascular accident or myocardial infarction. Lower physical activity levels were associated with older age, a higher BMI, a greater number of comorbidities, and a lower socioeconomic status. CONCLUSION: In HF patients, nonadherence to medication, the MD, and physical activity were common and associated with poorer cardiac function and a greater comorbid burden. These findings underscore the importance of a multidisciplinary approach to enhance adherence and improve overall patient outcomes. CI - Copyright: (c) Iranian Journal of Medical Sciences. FAU - Afshari, Maryam AU - Afshari M AD - Department of MPH, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. FAU - Sharifi, Mohammad Hossein AU - Sharifi MH AD - Research Center for Traditional Medicine and History of Medicine, Non-Communicable Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. FAU - Molavi Vardanjani, Hossein AU - Molavi Vardanjani H AD - Department of MPH, School of Medicine, Research Center for Traditional Medicine and History of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. FAU - Nikmanesh, Amirreza AU - Nikmanesh A AD - School of Medicine, Fasa University of Medical Sciences, Fasa, Iran. LA - eng PT - Journal Article DEP - 20260401 PL - Iran TA - Iran J Med Sci JT - Iranian journal of medical sciences JID - 8104374 SB - IM MH - Humans MH - *Heart Failure/drug therapy/psychology/therapy MH - Female MH - *Diet, Mediterranean/statistics & numerical data MH - Male MH - Cross-Sectional Studies MH - *Exercise/psychology MH - Aged MH - Middle Aged MH - Surveys and Questionnaires MH - *Medication Adherence/psychology MH - *Drug Monitoring PMC - PMC13144779 OTO - NOTNLM OT - Diet, Mediterranean OT - Exercise OT - Heart failure OT - Medication adherence COIS- None declared. EDAT- 2026/05/08 06:33 MHDA- 2026/05/08 06:34 PMCR- 2026/04/01 CRDT- 2026/05/08 05:03 PHST- 2025/04/27 00:00 [received] PHST- 2025/11/02 00:00 [revised] PHST- 2025/11/22 00:00 [accepted] PHST- 2026/05/08 06:34 [medline] PHST- 2026/05/08 06:33 [pubmed] PHST- 2026/05/08 05:03 [entrez] PHST- 2026/04/01 00:00 [pmc-release] AID - IJMS-51-4 [pii] AID - 10.30476/ijms.2025.106829.4113 [doi] PST - epublish SO - Iran J Med Sci. 2026 Apr 1;51(4):236-247. doi: 10.30476/ijms.2025.106829.4113. eCollection 2026 Apr. PMID- 42099494 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260508 LR - 20260813 IS - 1520-765X (Print) IS - 1554-2815 (Electronic) IS - 1520-765X (Linking) VI - 28 IP - Suppl 5 DP - 2026 May TI - Percutaneous coronary intervention or conservative therapy for chronic total coronary occlusions (CTOs)? Evidence from the ISCHEMIA trial. PG - v106-v110 LID - 10.1093/eurheartjsupp/suag033 [doi] AB - The management of chronic total coronary occlusions (CTOs) remains one of the most debated areas in interventional cardiology because of its technical complexity and the relatively high risk of procedural complications. Although the effectiveness of percutaneous coronary intervention for CTOs (CTO-PCI) in improving symptoms has been demonstrated, its impact on hard clinical outcomes remains controversial. The International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA Trial) and the ISCHEMIA CTO sub-study provide important insights: in patients with stable coronary artery disease and moderate-to-severe ischaemia, an initial invasive strategy does not reduce cardiovascular mortality or myocardial infarction compared with optimized medical therapy. However, the trial was not designed to specifically assess the effectiveness of CTO-PCI, and only a minority of enrolled patients had a CTO, which was revascularized in only few cases. In addition, the ISCHEMIA trial excluded high-risk patients who are frequently encountered in everyday clinical practice, such as those with left main coronary artery disease, severe symptoms, or recent acute coronary syndromes. This article critically analyses the results of the ISCHEMIA Trial in the context of CTOs, comparing them with evidence from dedicated CTO-PCI studies, and proposes an integrated decision-making model based on symptom control, objective demonstration of inducible ischaemia and myocardial viability, multimodal imaging, and discussion within the Heart Team. CI - (c) The Author(s) 2026. Published by Oxford University Press on behalf of the European Society of Cardiology. FAU - Madaudo, Cristina AU - Madaudo C AD - Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, Cardiology Unit, University of Palermo, University Hospital P. Giaccone, Via del vespro 129, 90127 Palermo, Italy. FAU - Vadala, Giuseppe AU - Vadala G AUID- ORCID: 0000-0003-0869-4855 AD - Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, Cardiology Unit, University of Palermo, University Hospital P. Giaccone, Via del vespro 129, 90127 Palermo, Italy. FAU - Astuti, Giuseppe AU - Astuti G AD - Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, Cardiology Unit, University of Palermo, University Hospital P. Giaccone, Via del vespro 129, 90127 Palermo, Italy. FAU - Galassi, Alfredo Ruggero AU - Galassi AR AUID- ORCID: 0000-0002-9366-2251 AD - Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, Cardiology Unit, University of Palermo, University Hospital P. Giaccone, Via del vespro 129, 90127 Palermo, Italy. LA - eng PT - Journal Article DEP - 20260311 PL - England TA - Eur Heart J Suppl JT - European heart journal supplements : journal of the European Society of Cardiology JID - 100886647 PMC - PMC13147274 OTO - NOTNLM OT - Chronic total occlusion OT - Coronary revascularization OT - ISCHEMIA Trial OT - Optimized medical therapy COIS- Conflict of interest: None declared. EDAT- 2026/05/08 06:32 MHDA- 2026/05/08 06:33 PMCR- 2026/03/11 CRDT- 2026/05/08 04:55 PHST- 2026/05/08 06:33 [medline] PHST- 2026/05/08 06:32 [pubmed] PHST- 2026/05/08 04:55 [entrez] PHST- 2026/03/11 00:00 [pmc-release] AID - suag033 [pii] AID - 10.1093/eurheartjsupp/suag033 [doi] PST - epublish SO - Eur Heart J Suppl. 2026 Mar 11;28(Suppl 5):v106-v110. doi: 10.1093/eurheartjsupp/suag033. eCollection 2026 May. PMID- 42099483 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260508 LR - 20260813 IS - 1520-765X (Print) IS - 1554-2815 (Electronic) IS - 1520-765X (Linking) VI - 28 IP - Suppl 5 DP - 2026 May TI - ESC guidelines 2025 on cardiovascular disease and pregnancy: considerations and future perspectives. PG - v5-v13 LID - 10.1093/eurheartjsupp/suag017 [doi] AB - Pregnancy in women with cardiovascular disease (CVD) represents a distinct clinical condition, as the physiological adaptations of pregnancy may interact with underlying cardiac pathology in variable and sometimes unpredictable ways. Consequently, maternal and foetal risk cannot be assumed a priori and requires structured, patient- and disease-specific assessment. The new ESC guidelines on cardiovascular disease and pregnancy incorporate updated evidence following the 2018 version. The contents span from models of multidisciplinary care (the Pregnancy Heart Team, PHT), pre-pregnancy counselling, and pregnancy-related risk assessment, to novel recommendations that are both shared by all pregnancies in women with CVD and specific to each distinct disease. Due to limited prospective or randomized studies largely prevented by ethical reasons, most recommendations are based on evidence level C. This document provides a concise synthesis of innovations in shared management strategies and disease-specific pathways in pregnancy of women with known CVD. It also acknowledges that not all clinical scenarios can be fully captured by guideline-based recommendations. Beyond guidelines, and primarily because approximately 50% of recommendations are Level C evidence, there is considerable decision-making margin for cardiovascular specialists to adhere recommendations. For rare unpredictable complications/events the limited available evidence does not allow recommendations to be made. Looking to the future, the expectation is that AI, which is already generating data and models of care in pregnancy, can help support widespread access to PHT, both in hospitals equipped with the necessary requirements and remotely to all healthcare facilities serving pregnant women with CVDs. CI - (c) The Author(s) 2026. Published by Oxford University Press on behalf of the European Society of Cardiology. FAU - Arbustini, Eloisa AU - Arbustini E AUID- ORCID: 0000-0003-2948-7994 AD - Centre for Inherited Cardiovascular Diseases, Department of Clinical and Experimental Medicine, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. FAU - Beneventi, Fausta AU - Beneventi F AD - Department of Obstetrics and Gynecology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. FAU - Bozzani, Antonio AU - Bozzani A AUID- ORCID: 0000-0003-3274-6248 AD - Vascular and Endovascular Surgery, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. FAU - Cattadori, Barbara AU - Cattadori B AD - Division of Cardiac Surgery, Cardiothoracovascular Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. FAU - Delmonte, Maria Paola AU - Delmonte MP AD - Department of Anesthesia and Intensive Care 1, Unit of Obstetric Anesthesia I, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. FAU - Di Toro, Alessandro AU - Di Toro A AUID- ORCID: 0000-0001-7625-1103 AD - Centre for Inherited Cardiovascular Diseases, Department of Clinical and Experimental Medicine, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. FAU - Giuliani, Lorenzo AU - Giuliani L AD - Centre for Inherited Cardiovascular Diseases, Department of Clinical and Experimental Medicine, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. FAU - Grasso, Maurizia AU - Grasso M AUID- ORCID: 0000-0003-2611-4295 AD - Centre for Inherited Cardiovascular Diseases, Department of Clinical and Experimental Medicine, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. FAU - Pellegrini, Carlo AU - Pellegrini C AD - Division of Cardiac Surgery, Cardiothoracovascular Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. AD - Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy. FAU - Perotti, Francesca AU - Perotti F AD - Department of Obstetrics and Gynecology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. FAU - Rordorf, Roberto AU - Rordorf R AUID- ORCID: 0000-0003-4111-1690 AD - Arrhythmia and Electrophysiology Unit, Division of Cardiology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. FAU - Smirnova, Alexandra AU - Smirnova A AD - Centre for Inherited Cardiovascular Diseases, Department of Clinical and Experimental Medicine, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. FAU - Urtis, Mario AU - Urtis M AUID- ORCID: 0000-0003-3289-9228 AD - Centre for Inherited Cardiovascular Diseases, Department of Clinical and Experimental Medicine, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. FAU - Serio, Alessandra AU - Serio A AD - Centre for Inherited Cardiovascular Diseases, Department of Clinical and Experimental Medicine, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. LA - eng PT - Journal Article DEP - 20260312 PL - England TA - Eur Heart J Suppl JT - European heart journal supplements : journal of the European Society of Cardiology JID - 100886647 PMC - PMC13147266 OTO - NOTNLM OT - Cardiovascular Disease OT - Guidelines OT - Pregnancy OT - Risk Assessment OT - mWHO 2 0 COIS- Conflict of interest: None declared. EDAT- 2026/05/08 06:33 MHDA- 2026/05/08 06:34 PMCR- 2026/03/12 CRDT- 2026/05/08 04:55 PHST- 2026/05/08 06:34 [medline] PHST- 2026/05/08 06:33 [pubmed] PHST- 2026/05/08 04:55 [entrez] PHST- 2026/03/12 00:00 [pmc-release] AID - suag017 [pii] AID - 10.1093/eurheartjsupp/suag017 [doi] PST - epublish SO - Eur Heart J Suppl. 2026 Mar 12;28(Suppl 5):v5-v13. doi: 10.1093/eurheartjsupp/suag017. eCollection 2026 May. PMID- 42094112 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260507 LR - 20260813 IS - 1995-705X (Print) IS - 0976-5123 (Electronic) IS - 1995-705X (Linking) VI - 26 IP - 4 DP - 2025 Oct-Dec TI - Development and Implementation of Cardio-oncology Services at the National Center for Cancer Care and Research and Heart Hospital: The Qatar Experience. PG - 264-271 LID - 10.4103/heartviews.heartviews_118_25 [doi] AB - BACKGROUND: cardiovascular disease and cancer are two leading causes of mortality worldwide. Advances in cancer therapy have improved survival but increased the risk of treatment-related cardiotoxicity. In response, the National Center for Cancer Care and Research (NCCCR) and Heart Hospital (HH) established a dedicated strategic plan for the development of cardio-oncology service in 2015 to address the prevention, early detection, and management of cardiotoxicity through a multidisciplinary approach in Qatar. OBJECTIVES: The objective of this study was to describe the development and implementation of the cardio-oncology service at NCCCR and HH. METHODS: A retrospective descriptive study with a mixed-methods approach was conducted. Quantitative data were extracted from the electronic health records for all patients seen in the Cardio-Oncology Clinic during two key phases of service delivery: HH (January 2019 to August 2020) and NCCCR (September 2020 to July 2023). Descriptive qualitative data were obtained from informal staff feedback and clinical observations. RESULTS: Between 2019 and 2023, 4197 patients attended the cardio-oncology clinics (1524 at HH and 2673 at NCCCR), with 77%-82% being noncitizens. Breast cancer was the most common diagnosis (48%), reflecting its high prevalence and cardiotoxic treatment profile. A total of 5289 echocardiographic studies were performed. In 2023, 494 cardiovascular events were recorded, but therapy was held in three cases (0.06%) due to significant cardiotoxicity. Service expansion included the introduction of a clinical nurse specialist-led clinic and a dedicated echocardiography unit. CONCLUSION: cardio-oncology program demonstrates that early, structured cardiac surveillance within a multidisciplinary framework can effectively minimize therapy interruptions and optimize cancer patient outcomes. CI - Copyright: (c) 2026 Heart Views. FAU - AlBulushi, Asma Mohammad Younus AU - AlBulushi AMY AD - Nursing Administration Department, National Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation (HMC), Doha, Qatar. FAU - Singh, Kalpana AU - Singh K AD - Department of Nursing Research, Hamad Medical Corporation (HMC), Doha, Qatar. FAU - Ibnouf, Salma Suliman AU - Ibnouf SS AD - Department of Cardiology, Heart Hospital (HH), Hamad Medical Corporation (HMC), Doha, Qatar. FAU - Shah, Jassim Zaheen AU - Shah JZ AD - Department of Cardiology, Heart Hospital (HH), Hamad Medical Corporation (HMC), Doha, Qatar. FAU - Kaddoura, Rasha AU - Kaddoura R AD - Department of Pharmacy, Heart Hospital (HH), Hamad Medical Corporation (HMC), Doha, Qatar. FAU - Al Bader, Salha Bujassoum AU - Al Bader SB AD - Department of Medical Oncology, National Center for Cancer Care and Research (NCCCR), HMC, Doha, Qatar. FAU - Dabdoob, Wafer Amen AU - Dabdoob WA AD - Department of Cardiology, Heart Hospital (HH), Hamad Medical Corporation (HMC), Doha, Qatar. FAU - Shehada, Wafaa Naeem AU - Shehada WN AD - Nursing Administration Department, National Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation (HMC), Doha, Qatar. FAU - Tubishat, Eyad Mohammad AU - Tubishat EM AD - Department of Medical Oncology, National Center for Cancer Care and Research (NCCCR), HMC, Doha, Qatar. FAU - Ali, Nima Ahmad AU - Ali NA AD - Nursing Administration Department, National Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation (HMC), Doha, Qatar. LA - eng PT - Journal Article DEP - 20260415 PL - India TA - Heart Views JT - Heart views : the official journal of the Gulf Heart Association JID - 101316474 PMC - PMC13142813 OTO - NOTNLM OT - Cancer survivorship OT - Qatar OT - cardio-oncology OT - cardiotoxicity OT - multidisciplinary care OT - precision medicine COIS- There are no conflicts of interest. EDAT- 2026/05/07 06:33 MHDA- 2026/05/07 06:34 PMCR- 2026/04/15 CRDT- 2026/05/07 05:10 PHST- 2025/09/03 00:00 [received] PHST- 2025/11/18 00:00 [accepted] PHST- 2026/05/07 06:34 [medline] PHST- 2026/05/07 06:33 [pubmed] PHST- 2026/05/07 05:10 [entrez] PHST- 2026/04/15 00:00 [pmc-release] AID - HV-26-264 [pii] AID - 10.4103/heartviews.heartviews_118_25 [doi] PST - epublish SO - Heart Views. 2026 Apr 15;26(4):264-271. doi: 10.4103/heartviews.heartviews_118_25. eCollection 2025 Oct-Dec. PMID- 42092997 OWN - NLM STAT- MEDLINE DCOM- 20260630 LR - 20260813 IS - 1749-8090 (Electronic) IS - 1749-8090 (Linking) VI - 21 IP - 1 DP - 2026 May 6 TI - Left ventricular assist devices and right heart dysfunction: a review of impact mechanisms, evaluation methods, and prevention and management. LID - 10.1186/s13019-026-04003-1 [doi] LID - 453 AB - BACKGROUND: Left ventricular assist devices (LVADs) have become an important treatment option for patients with end-stage heart failure, significantly improving left ventricular function and patient survival rates. However, LVAD implantation has complex effects on right heart function, and right heart dysfunction is a critical factor affecting patient prognosis and quality of life. METHODS: This article systematically reviews the relationship between LVADs and right heart function, focusing on the importance of right heart function in LVAD patients, evaluation methods, impact mechanisms, and prevention and management strategies. Additionally, it introduces emerging technologies and future research directions to provide references for clinical practice. RESULTS: Studies have shown that comprehensive evaluation of right heart function is crucial for predicting the risk of postoperative right heart dysfunction. The impact mechanisms of LVAD implantation on right heart function are complex, including changes in preload and afterload and ventricular interdependence. Prevention and management of right heart dysfunction require comprehensive measures, including preoperative optimization, meticulous intraoperative procedures, close postoperative monitoring, and multidisciplinary team collaboration. Emerging technologies such as improved LVAD designs, biventricular assist devices, gene therapy, and personalized medicine offer new hope for reducing the incidence of right heart dysfunction. CONCLUSION: Right heart function holds undeniable importance in LVAD therapy. Through comprehensive evaluation, prevention, and management of right heart function, as well as the application of new technologies, it is expected to reduce the incidence of right heart dysfunction and improve the prognosis and quality of life of LVAD patients. More high-quality research is needed in the future to promote the clinical application of emerging technologies and provide more comprehensive treatment options for patients with end-stage heart failure. CI - (c) 2026. The Author(s). FAU - Fan, Zhiwei AU - Fan Z AD - Department of Pharmacy, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, 225300, Jiangsu Province, PR China. FAU - Zhou, Pengyu AU - Zhou P AD - Department of Cardiovascular Surgery, NanFang hospital, Southern Medical University, GuangZhou, 515000, Guangdong Province, PR China. FAU - Li, Shiliang AU - Li S AD - Department of Cardiac Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei Province, PR China. FAU - Cheng, Shaopeng AU - Cheng S AD - Department of Cardiac Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, 321 Zhongshan Road, Nanjing, 210008, Jiangsu Province, PR China. FAU - Wang, Yumeng AU - Wang Y AD - Department of Cardiac Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, 321 Zhongshan Road, Nanjing, 210008, Jiangsu Province, PR China. FAU - Pan, Jun AU - Pan J AD - Department of Cardiac Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, 321 Zhongshan Road, Nanjing, 210008, Jiangsu Province, PR China. pj791028@163.com. FAU - Li, Kunsheng AU - Li K AD - Department of Cardiac Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, 321 Zhongshan Road, Nanjing, 210008, Jiangsu Province, PR China. kunsheng.li@outlook.com. LA - eng GR - 2022-N-01-04/China International Medical Foundation/ GR - NZYYXY2023009/Research project on undergraduate education and teaching reform in the School of Integrated Medicine, School of Medicine, Nanjing University of Chinese Medicine/ GR - 2022/The fellowship of Nanjing Postdoctoral Science Foundation/ GR - 2021-LCYJ-PY-31/Fundings for Clinical Trials from the Affiliated Drum Tower Hospital, Medical School of Nanjing University/ PT - Journal Article PT - Review DEP - 20260506 PL - England TA - J Cardiothorac Surg JT - Journal of cardiothoracic surgery JID - 101265113 SB - IM MH - Humans MH - *Heart-Assist Devices/adverse effects MH - *Heart Failure/therapy/physiopathology/surgery MH - *Ventricular Dysfunction, Right/prevention & control/etiology/physiopathology MH - Quality of Life PMC - PMC13317415 COIS- Declarations. Ethics approval and consent to participate: None. Consent for publication: All authors agree to publish. Competing interests: The authors declare no competing interests. EDAT- 2026/05/07 06:39 MHDA- 2026/06/30 06:31 PMCR- 2026/05/06 CRDT- 2026/05/07 00:45 PHST- 2025/03/22 00:00 [received] PHST- 2026/03/25 00:00 [accepted] PHST- 2026/06/30 06:31 [medline] PHST- 2026/05/07 06:39 [pubmed] PHST- 2026/05/07 00:45 [entrez] PHST- 2026/05/06 00:00 [pmc-release] AID - 10.1186/s13019-026-04003-1 [pii] AID - 4003 [pii] AID - 10.1186/s13019-026-04003-1 [doi] PST - epublish SO - J Cardiothorac Surg. 2026 May 6;21(1):453. doi: 10.1186/s13019-026-04003-1. PMID- 42092573 OWN - NLM STAT- MEDLINE DCOM- 20260626 LR - 20260626 IS - 1879-1913 (Electronic) IS - 0002-9149 (Linking) VI - 271 DP - 2026 Jul 15 TI - Severe Low Flow Aortic Stenosis With Preserved Ejection Fraction: Latest Diagnostic and Therapeutic Approach. PG - 182-188 LID - S0002-9149(26)00317-6 [pii] LID - 10.1016/j.amjcard.2026.04.066 [doi] AB - Paradoxical low-flow, low-gradient aortic stenosis (pLF-LG AS) represents a distinct phenotype of severe aortic stenosis characterized by a reduced aortic valve area with low transvalvular gradients despite preserved left ventricular ejection fraction and reduced forward flow. It is associated with concentric remodeling, impaired longitudinal systolic function, and diastolic dysfunction, resulting in reduced stroke volume and potential underestimation of disease severity. This state-of-the-art review synthesizes evidence from registries, observational studies, randomized trial subgroup analyses, guideline recommendations, and mechanistic investigations. Diagnosis requires an integrative multimodality approach combining Doppler echocardiography, low-dose dobutamine stress echocardiography, and computed tomography-based aortic valve calcium scoring to differentiate true-severe from pseudo-severe disease. In symptomatic patients with confirmed severe pLF-LG AS, aortic valve replacement is associated with improved survival, although the magnitude of clinical benefit remains variable. Transcatheter aortic valve implantation represents an effective treatment option in selected patients; however, phenotype-specific comparative data versus surgical valve replacement remain limited. Overall, pLF-LG AS requires accurate diagnostic confirmation and individualized, heart team-guided management to optimize clinical outcomes. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Armonis, Charis AU - Armonis C AD - Department of Cardiology, General Hospital of Athens "EYAGGELISMOS", Athens, Greece. Electronic address: charisarmsfm@gmail.com. FAU - Triantafyllou, Konstantinos AU - Triantafyllou K AD - Department of Cardiology, General Hospital of Athens "EYAGGELISMOS", Athens, Greece. FAU - Papadopoulou, Elektra AU - Papadopoulou E AD - Department of Cardiology, General Hospital of Athens "EYAGGELISMOS", Athens, Greece. FAU - Trikas, Athanasios AU - Trikas A AD - Department of Cardiology, General Hospital of Athens "EYAGGELISMOS", Athens, Greece. LA - eng PT - Journal Article PT - Review DEP - 20260504 PL - United States TA - Am J Cardiol JT - The American journal of cardiology JID - 0207277 SB - IM MH - Humans MH - *Aortic Valve Stenosis/physiopathology/diagnosis/surgery/therapy MH - *Stroke Volume/physiology MH - Severity of Illness Index MH - Echocardiography, Stress MH - Echocardiography, Doppler MH - Transcatheter Aortic Valve Replacement MH - *Aortic Valve/diagnostic imaging OTO - NOTNLM OT - aortic valve calcium scoring OT - dobutamine stress echocardiography OT - multimodality imaging OT - paradoxical low-flow low-gradient aortic stenosis OT - transcatheter aortic valve implantation COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/05/07 06:37 MHDA- 2026/06/27 00:54 CRDT- 2026/05/07 00:09 PHST- 2026/03/11 00:00 [received] PHST- 2026/04/17 00:00 [revised] PHST- 2026/04/28 00:00 [accepted] PHST- 2026/06/27 00:54 [medline] PHST- 2026/05/07 06:37 [pubmed] PHST- 2026/05/07 00:09 [entrez] AID - S0002-9149(26)00317-6 [pii] AID - 10.1016/j.amjcard.2026.04.066 [doi] PST - ppublish SO - Am J Cardiol. 2026 Jul 15;271:182-188. doi: 10.1016/j.amjcard.2026.04.066. Epub 2026 May 4. PMID- 42087600 OWN - NLM STAT- MEDLINE DCOM- 20260716 LR - 20260716 IS - 1477-111X (Electronic) IS - 0267-6591 (Linking) VI - 41 IP - 1_suppl DP - 2026 May TI - Prophylactic temporary mechanical circulatory support: The new paradigm in cardiac surgery. PG - 66S-82S LID - 10.1177/02676591261427298 [doi] AB - BackgroundPost-cardiotomy cardiogenic shock (PCCS) remains one of the most lethal complications of cardiac surgery, with high in-hospital mortality despite major improvements in operative techniques, and intensive care management. Temporary mechanical circulatory support (tMCS) is widely applied as a rescue therapy for refractory PCCS. However, outcomes remain suboptimal, also due to delayed initiation after the onset of severe hemodynamic collapse and irreversible compromised end-organ states. This review summarizes current concepts of PCCS management and evaluates the emerging role of prophylactic tMCS within the framework of "protected cardiac surgery".MethodsA narrative review of the current international guidelines, expert consensus statements, and major observational studies addressing post-cardiotomy tMCS and prophylactic support strategies was carried out. Emphasis was placed on pathophysiology, indications, timing of support, and device selection.ResultsProphylactic tMCS has been applied in selected high-risk scenarios including acute coronary syndromes, acute valvular dysfunction, ventricular septal rupture, papillary muscle rupture, advanced heart failure requiring bridge-to-decision or to-transplant, or difficult and complex weaning from cardiopulmonary bypass. The concepts of preoperative (Type 1), planned intraoperative (Type 2), and unplanned early intraoperative (Type 3) protected cardiac surgery provide a practical framework for a timely evaluation and related action aiming at metabolic stabilization to reduce or prevent postoperative low cardiac output syndrome. Successful implementation depends on multidisciplinary Heart Team decision-making, advanced hemodynamic assessment, and tailored perfusion strategies as well as device selection also based on local resources and expertise.ConclusionsProphylactic tMCS represents a paradigm shift from reactive rescue therapy toward proactive cardio-circulatory protection in selected high-risk patients undergoing cardiac surgery procedures. While early observational data are encouraging, prospective trials, standardized risk stratification tools, and cost-effectiveness analyses are required to define its role in modern cardiac surgery. FAU - Mariani, Silvia AU - Mariani S AUID- ORCID: 0000-0002-2238-1399 AD - Cardiac Surgery Unit, Cardio-Thoracic and Vascular Department, Fondazione IRCCS San Gerardo Dei Tintori, Monza, Italy. AD - Cardiovascular Research Institute Maastricht, University of Maastricht, Maastricht, Netherlands. FAU - Bari, Gabor AU - Bari G AUID- ORCID: 0000-0003-4167-5736 AD - Cardiovascular Research Institute Maastricht, University of Maastricht, Maastricht, Netherlands. AD - Clinic of Internal Medicine, Department of Cardiac Surgery, University of Szeged, Szeged, Hungary. FAU - Meani, Paolo AU - Meani P AUID- ORCID: 0000-0001-7356-9036 AD - Cardiovascular Research Institute Maastricht, University of Maastricht, Maastricht, Netherlands. AD - Cardiothoracic and Vascular Anesthesia and Intensive Care Unit, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy. FAU - Perazzo, Alvaro AU - Perazzo A AD - Cardiovascular Research Institute Maastricht, University of Maastricht, Maastricht, Netherlands. AD - Faculdade de Medicina, Department of Cardiovascular Surgery and Transplant Center, Instituto Do Coracao (InCor), Hospital Das Clinicas, Universidade de Sao Paulo (HC-FMUSP), Sao Paulo, Brazil. FAU - Kowalewski, Mariusz AU - Kowalewski M AUID- ORCID: 0000-0002-5478-3245 AD - Clinical Department of Cardiac Surgery and Transplantology, Central Clinical Hospital of the National Medical Institute of the Ministry of Interior and Administration, Warsaw, Poland. FAU - Ronco, Daniele AU - Ronco D AD - Cardiovascular Research Institute Maastricht, University of Maastricht, Maastricht, Netherlands. AD - Cardiac Surgery Unit, Cardio-Thoraco-Vascular Department, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy. FAU - Matteucci, Matteo AU - Matteucci M AUID- ORCID: 0000-0003-0694-2747 AD - Cardiovascular Research Institute Maastricht, University of Maastricht, Maastricht, Netherlands. AD - Cardiac Surgery Unit, ASST Sette Laghi Circolo Hospital, Varese, Italy. FAU - Massimi, Giulio AU - Massimi G AD - Cardiovascular Research Institute Maastricht, University of Maastricht, Maastricht, Netherlands. AD - Cardiothoracic and Vascular Department, Santa Maria Hospital, Terni, Italy. FAU - Salazar, Leonardo AU - Salazar L AD - Cardiovascular Research Institute Maastricht, University of Maastricht, Maastricht, Netherlands. AD - Departamento de Medicina Critica y Cuidado Intensivo, Fundacion Cardiovascular de Colombia, Bucaramanga, Colombia. FAU - Lorusso, Roberto AU - Lorusso R AUID- ORCID: 0000-0002-1777-2045 AD - Cardiovascular Research Institute Maastricht, University of Maastricht, Maastricht, Netherlands. AD - Cardio-Thoracic Surgery Department, Heart and Vascular Centre, Maastricht University Medical Centre (MUMC+), Maastricht, The Netherlands. LA - eng PT - Journal Article PT - Review DEP - 20260505 PL - England TA - Perfusion JT - Perfusion JID - 8700166 SB - IM MH - Humans MH - *Cardiac Surgical Procedures/methods/adverse effects MH - *Shock, Cardiogenic/prevention & control/etiology MH - *Extracorporeal Membrane Oxygenation/methods OTO - NOTNLM OT - cardiac surgery OT - cardiogenic shock OT - extracorporeal life support OT - heart failure OT - prophylactic OT - temporary mechanical circulatory support COIS- Declaration of conflicting interestsThe authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: BG: consultant for Corcym, RL:consultant for Medtronic-Abiomed-LivaNova; Speaker for Abiomed; Advisory Board Member of Eurosets-Hemocue-Xenios (honoraria as research funding) EDAT- 2026/05/06 06:40 MHDA- 2026/05/06 06:41 CRDT- 2026/05/06 02:56 PHST- 2026/05/06 06:41 [medline] PHST- 2026/05/06 06:40 [pubmed] PHST- 2026/05/06 02:56 [entrez] AID - 10.1177/02676591261427298 [doi] PST - ppublish SO - Perfusion. 2026 May;41(1_suppl):66S-82S. doi: 10.1177/02676591261427298. Epub 2026 May 5. PMID- 42087322 OWN - NLM STAT- MEDLINE DCOM- 20260824 LR - 20260828 IS - 1873-734X (Electronic) IS - 1010-7940 (Linking) VI - 68 IP - 8 DP - 2026 Aug 3 TI - Transapical Transcatheter Valve Implantation for Aortic Regurgitation: A Multicentre, Prospective Trial. LID - ezag065 [pii] LID - 10.1093/ejcts/ezag065 [doi] AB - OBJECTIVES: We evaluated the safety and efficacy of transcatheter aortic valve replacement (TAVR) up to 1-year follow-up for patients with severe pure aortic valve regurgitation (AR) or mixed severe aortic valve regurgitation and aortic valve stenosis (AR+AS) using a novel self-expandable bioprosthesis. METHODS: From 2021 to 2022, transapical TAVR using Ken-Valve (Jenscare Biotechnology Ltd, Ningbo, China) was performed in 142 symptomatic patients (mean age 70.3 +/- 5.5 years) with pure AR (n = 109) or AR+AS (n = 33) across 15 hospitals in China. All patients were considered high-risk or inoperable after heart team evaluation, with a mean Society of Thoracic Surgeons score of 5.9 +/- 3.0%, and 99.3% in NYHA class III/IV. Procedural characteristics, echocardiography data, and clinical outcomes up to 1-year were analysed. RESULTS: Technical success was achieved in 97.2% of cases. Two (1.4%) patients were converted to open surgery due to unsuitable anatomy or valve migration during the procedure. New permanent pacemakers were implanted in 20 (14.1%) patients. Three (2.1%) patients had stroke, and 3 (2.1%) patients had major bleeding. Thirty-day mortality was 2.1%, and all-cause mortality at 1-year was 5.6% (8/142). Mean aortic valve gradient and effective orifice area (EOA) at 1-year postoperatively were 9.4 +/- 5.4 mmHg and 1.9 +/- 0.6 cm2, respectively. Significant improvement in clinical symptoms, positive left ventricular remodelling, and quality of life were observed up to 1-year. There was no significant difference in mortality, complications, and haemodynamic performance between patients with pure AR and AR+AS at 1-year. CONCLUSIONS: TAVR using the Ken-Valve was safe and effective in patients with pure AR or mixed AR+AS in mid-term. CLINICAL REGISTRATION NUMBER: NCT03788590. CI - (c) The Author(s) 2026. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com. FAU - Xiao, Bowen AU - Xiao B AUID- ORCID: 0000-0002-0197-1242 AD - Department of Cardiovascular Surgery, West China Hospital/West China School of Medicine, Sichuan University, Chengdu, 610041, China. AD - Cardiovascular Research Laboratory, West China Hospital/West China School of Medicine, Sichuan University, Chengdu, 610041, China. FAU - Li, Ming AU - Li M AD - Department of Cardiovascular Surgery, West China Hospital/West China School of Medicine, Sichuan University, Chengdu, 610041, China. AD - Cardiovascular Research Laboratory, West China Hospital/West China School of Medicine, Sichuan University, Chengdu, 610041, China. FAU - Liu, Lulu AU - Liu L AD - Department of Cardiovascular Surgery, West China Hospital/West China School of Medicine, Sichuan University, Chengdu, 610041, China. AD - Cardiovascular Research Laboratory, West China Hospital/West China School of Medicine, Sichuan University, Chengdu, 610041, China. FAU - Shi, Jun AU - Shi J AD - Department of Cardiovascular Surgery, West China Hospital/West China School of Medicine, Sichuan University, Chengdu, 610041, China. AD - Cardiovascular Research Laboratory, West China Hospital/West China School of Medicine, Sichuan University, Chengdu, 610041, China. FAU - Zhang, Haibo AU - Zhang H AD - Department of Cardiovascular Surgery, Beijing Anzhen Hospital, Capital Medical University, No. 2 Anzhen Road, Chaoyang District, Beijing 100029, China. FAU - Meng, Xu AU - Meng X AD - Department of Cardiovascular Surgery, Beijing Anzhen Hospital, Capital Medical University, No. 2 Anzhen Road, Chaoyang District, Beijing 100029, China. FAU - Chen, Liangwan AU - Chen L AUID- ORCID: 0000-0002-9359-4754 AD - Department of Cardiovascular Surgery, Fujian Union Hospital, Fujian Medical University, 29 Xinquan Road, Gulou District, Fuzhou, 350001, Fujian, China. FAU - Zhang, Xiquan AU - Zhang X AD - Department of Cardiovascular Surgery, Qilu Hospital of Shandong University, 107 Wenhuaxi Road, Jinan, 250012, Shandong, China. FAU - Ma, Liang AU - Ma L AD - Department of Cardiovascular Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Shangcheng District, Hangzhou, 310003, Zhejiang, China. FAU - Dong, Nianguo AU - Dong N AUID- ORCID: 0000-0001-5437-599X AD - Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Jianghan District, Wuhan, 430022, Hubei, China. FAU - Shang, Xiaoke AU - Shang X AD - Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Jianghan District, Wuhan, 430022, Hubei, China. FAU - Yang, Jian AU - Yang J AUID- ORCID: 0000-0003-2059-1912 AD - Department of Cardiovascular Surgery, Xijing Hospital, Air Force Medical University, 127 Changle West Road, Xincheng District, Xi'an, 710032, Shaanxi, China. FAU - Liu, Yang AU - Liu Y AD - Department of Cardiovascular Surgery, Xijing Hospital, Air Force Medical University, 127 Changle West Road, Xincheng District, Xi'an, 710032, Shaanxi, China. FAU - Wang, Pingfan AU - Wang P AD - Department of Cardiovascular Surgery, Henan Provincial Chest Hospital, 1 Weiwu Road, Jinshui District, Zhengzhou, 450008, Henan, China. FAU - Xiao, Yingbin AU - Xiao Y AD - Department of Cardiovascular Surgery, Xinqiao Hospital, Army Medical University, 83 Xinqiao Street, Shapingba District, Chongqing, 400037, China. FAU - Pan, Xiangbin AU - Pan X AD - Department of Cardiovascular Surgery, Yunnan Fuwai Cardiovascular Hospital, 528 Shahai Road, Wuhua District, Kunming, 650102, Yunnan, China. FAU - Wang, Jian'an AU - Wang J AD - Department of Cardiovascular Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, 88 Jiefang Road, Shangcheng District, Hangzhou, 310009, Zhejiang, China. FAU - Zhu, Dan AU - Zhu D AD - Department of Cardiovascular Surgery, Shanghai Chest Hospital, 241 Huaihai West Road, Xuhui District, Shanghai, 200030, China. FAU - Guo, Huiming AU - Guo H AD - Department of Cardiovascular Surgery, Guangdong Provincial People's Hospital, 106 Zhongshan Second Road, Yuexiu District, Guangzhou, 510080, Guangdong, China. FAU - Liu, Jian AU - Liu J AD - Department of Cardiovascular Surgery, Guangdong Provincial People's Hospital, 106 Zhongshan Second Road, Yuexiu District, Guangzhou, 510080, Guangdong, China. FAU - Wang, Dongjin AU - Wang D AD - Department of Cardiovascular Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, 321 Zhongshan Road, Gulou District, Nanjing, 210008, Jiangsu, China. FAU - Xu, Zhiyun AU - Xu Z AUID- ORCID: 0000-0003-4573-5441 AD - Department of Cardiovascular Surgery, Changhai Hospital, Naval Medical University, 168 Changhai Road, Yangpu District, Shanghai, 200433, China. FAU - Song, Zhigang AU - Song Z AD - Department of Cardiovascular Surgery, Changhai Hospital, Naval Medical University, 168 Changhai Road, Yangpu District, Shanghai, 200433, China. FAU - Guo, Yingqiang AU - Guo Y AUID- ORCID: 0000-0003-4894-2614 AD - Department of Cardiovascular Surgery, West China Hospital/West China School of Medicine, Sichuan University, Chengdu, 610041, China. AD - Cardiovascular Research Laboratory, West China Hospital/West China School of Medicine, Sichuan University, Chengdu, 610041, China. LA - eng SI - ClinicalTrials.gov/NCT03788590 PT - Clinical Trial PT - Journal Article PT - Multicenter Study PL - Germany TA - Eur J Cardiothorac Surg JT - European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery JID - 8804069 SB - IM MH - Aged MH - Female MH - Humans MH - Male MH - *Aortic Valve/surgery MH - *Aortic Valve Insufficiency/surgery MH - *Aortic Valve Stenosis/surgery MH - Bioprosthesis MH - Heart Valve Prosthesis MH - Prospective Studies MH - *Transcatheter Aortic Valve Replacement/methods/adverse effects MH - Treatment Outcome OTO - NOTNLM OT - aortic valve regurgitation OT - transcatheter aortic valve replacement OT - transcatheter heart valve EDAT- 2026/05/06 06:39 MHDA- 2026/08/24 23:34 CRDT- 2026/05/06 00:14 PHST- 2025/10/02 00:00 [received] PHST- 2025/12/20 00:00 [revised] PHST- 2026/01/08 00:00 [accepted] PHST- 2026/08/24 23:34 [medline] PHST- 2026/05/06 06:39 [pubmed] PHST- 2026/05/06 00:14 [entrez] AID - 8670103 [pii] AID - 10.1093/ejcts/ezag065 [doi] PST - ppublish SO - Eur J Cardiothorac Surg. 2026 Aug 3;68(8):ezag065. doi: 10.1093/ejcts/ezag065. PMID- 42086259 OWN - NLM STAT- MEDLINE DCOM- 20260716 LR - 20260813 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 16 IP - 5 DP - 2026 May 5 TI - Effects of a multidisciplinary transitional care programme on self-management and quality of life in patients undergoing percutaneous coronary intervention: a propensity score-matched analysis. PG - e116363 LID - 10.1136/bmjopen-2026-116363 [doi] LID - e116363 AB - OBJECTIVES: Adequate self-management support following percutaneous coronary intervention (PCI) remains a recognised challenge. This study evaluated the Integrated Psychocardiology Transitional Care (IPTC) programme's effect on self-management and quality of life, and the mechanism of their interaction. DESIGN: Retrospective cohort study. PARTICIPANTS: Outcomes were analysed for 697 patients after propensity score matching from an initial PCI registry cohort of 1148. PRIMARY AND SECONDARY OUTCOME MEASURES: The primary outcome was change in Coronary Artery Disease Self-Management Scale Score over 12 months. Secondary outcomes included the Seattle Angina Questionnaire (SAQ), 36-Item Short Form Health Survey (SF-36), Generalised Anxiety Disorder 7 and Patient Health Questionnaire 9 scores. Mixed-effects models and time-lagged mediation analysis were used to examine longitudinal changes and the mediating role of self-management. RESULTS: No between-group difference in self-management was observed at 1 month. Significant differences in self-management emerged at 3 months, 6 months and 12 months (all p<0.001). The mixed-effects model for repeated measures analysis revealed significant group x time interaction effects (F=183.1, p<0.001), indicating differential improvement trajectories favouring the IPTC group. The IPTC group showed significantly better SF-36 physical (45.6+/-9.6 vs 39.8+/-8.4, 95% CI 4.5 to 7.2, p<0.001) and mental (44.9+/-8.3 vs 41.7+/-8.1, 95% CI 2.0 to 4.4, p<0.001) scores at 12 months. Time-lagged mediation analysis confirmed self-management improvement mediated quality of life effects. CONCLUSIONS: The IPTC programme is associated with improved quality of life in PCI patients, and this association appears to be partly explained by enhanced self-management. These findings suggest that integrating psychology-informed transitional care into post-PCI care may be beneficial. CI - (c) Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. FAU - Tao, Lei AU - Tao L AD - Cardiovascular Medicine Center, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, Hubei, China. FAU - Luo, Dan AU - Luo D AD - Cardiovascular Medicine Center, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, Hubei, China. FAU - Tan, Limin AU - Tan L AD - Cardiovascular Medicine Center, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, Hubei, China. FAU - Zhang, Cangyun AU - Zhang C AD - Cardiovascular Medicine Center, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, Hubei, China. FAU - Li, Yuci AU - Li Y AUID- ORCID: 0009-0002-0404-1371 AD - Cardiovascular Medicine Center, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, Hubei, China liyuci2026@163.com. LA - eng PT - Journal Article DEP - 20260505 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 SB - IM MH - Humans MH - *Quality of Life MH - Female MH - Male MH - Retrospective Studies MH - Propensity Score MH - Middle Aged MH - Aged MH - *Percutaneous Coronary Intervention MH - *Self-Management/methods MH - *Transitional Care MH - *Coronary Artery Disease/surgery/therapy/psychology MH - Surveys and Questionnaires PMC - PMC13150886 OTO - NOTNLM OT - Coronary intervention OT - Nursing Care OT - Quality of Life OT - Self-Management COIS- Competing interests: None declared. EDAT- 2026/05/06 00:33 MHDA- 2026/05/06 00:34 PMCR- 2026/05/05 CRDT- 2026/05/05 20:42 PHST- 2026/05/06 00:34 [medline] PHST- 2026/05/06 00:33 [pubmed] PHST- 2026/05/05 20:42 [entrez] PHST- 2026/05/05 00:00 [pmc-release] AID - bmjopen-2026-116363 [pii] AID - 10.1136/bmjopen-2026-116363 [doi] PST - epublish SO - BMJ Open. 2026 May 5;16(5):e116363. doi: 10.1136/bmjopen-2026-116363. PMID- 42082894 OWN - NLM STAT- MEDLINE DCOM- 20260716 LR - 20260813 IS - 1478-5153 (Electronic) IS - 1362-1017 (Print) IS - 1362-1017 (Linking) VI - 31 IP - 3 DP - 2026 May TI - Expert Consensus on Key Attributes of Nurses in Resuscitation Teams: Findings From a Delphi Study. PG - e70506 LID - 10.1111/nicc.70506 [doi] LID - e70506 AB - BACKGROUND: In-hospital cardiac arrest (IHCA) requires coordinated interdisciplinary action. Nurses are often first responders and essential members of resuscitation teams, yet the attributes that define their effectiveness remain unclear. Although team performance has been widely studied, few works have systematically examined nursing competencies in this context. This is the first Delphi-based study in Greece defining key nursing attributes within in-hospital resuscitation teams. AIM: To achieve expert consensus on the key attributes characterizing effective nursing participation in IHCA teams. STUDY DESIGN: A two-round Delphi study was conducted with experts in resuscitation and critical care. Round one involved thematic analysis of semi-structured interviews. In round two, experts rated attributes on a 10-point Likert scale. Consensus was defined as mean (M) > 8 and coefficient of variation (CV) < 20%. Descriptive statistics and Kendall's W assessed agreement across domains. RESULTS: Thirty-nine attributes were identified and grouped into seven domains: education, experience, physical condition, psychological resilience, technical skills and non-technical skills. Thirty-five attributes met the consensus criteria. Highest agreement was observed for ALS certification, stress resilience, closed-loop communication, adaptability and teamwork. Strongest consensus emerged in non-technical (M = 9.75, CV = 3.79%) and technical (M = 9.61, CV = 5.62%) domains. CONCLUSIONS: This study provides an evidence-informed framework of competencies and personal qualities underpinning nurses' effectiveness in resuscitation teams, emphasizing both technical expertise and non-technical skills-especially closed-loop communication, composure and collaboration. RELEVANCE TO CLINICAL PRACTICE: The framework supports clearer role delineation, structured competency development and enhanced team effectiveness in IHCA management. CI - (c) 2026 The Author(s). Nursing in Critical Care published by John Wiley & Sons Ltd on behalf of British Association of Critical Care Nurses. FAU - Kipourgos, George AU - Kipourgos G AUID- ORCID: 0000-0002-5538-5548 AD - Surgical Cardiac Intensive Care Unit, Department of Cardiac Surgery, University of Patras, Patras, Greece. FAU - Bakalis, Nick AU - Bakalis N AUID- ORCID: 0000-0002-4786-2236 AD - Nursing Department, University of Patras, Patras, Greece. FAU - Albani, Eleni AU - Albani E AUID- ORCID: 0000-0001-9698-8276 AD - Nursing Department, University of Patras, Patras, Greece. FAU - Stefanopoulos, Nikolaos AU - Stefanopoulos N AUID- ORCID: 0000-0002-5585-9379 AD - Nursing Department, University of Patras, Patras, Greece. FAU - Lakoumentas, John AU - Lakoumentas J AUID- ORCID: 0000-0003-0869-736X AD - Nursing Department, University of Patras, Patras, Greece. FAU - Tzenalis, Anastasios AU - Tzenalis A AUID- ORCID: 0000-0002-6853-8953 AD - Nursing Department, University of Patras, Patras, Greece. LA - eng PT - Consensus Statement PT - Journal Article PL - England TA - Nurs Crit Care JT - Nursing in critical care JID - 9808649 SB - IM MH - Humans MH - *Cardiopulmonary Resuscitation/nursing MH - *Clinical Competence MH - Delphi Technique MH - Greece MH - *Heart Arrest/nursing/therapy MH - *Patient Care Team MH - *Resuscitation PMC - PMC13139511 OTO - NOTNLM OT - ALS OT - Delphi method OT - emergency nursing OT - expert consensus OT - in-hospital cardiac arrest OT - non-technical skills OT - nursing competencies OT - resuscitation team COIS- The authors declare no conflicts of interest. EDAT- 2026/05/05 00:32 MHDA- 2026/05/05 00:33 PMCR- 2026/05/05 CRDT- 2026/05/04 23:33 PHST- 2026/04/03 00:00 [revised] PHST- 2025/12/02 00:00 [received] PHST- 2026/04/14 00:00 [accepted] PHST- 2026/05/05 00:33 [medline] PHST- 2026/05/05 00:32 [pubmed] PHST- 2026/05/04 23:33 [entrez] PHST- 2026/05/05 00:00 [pmc-release] AID - NICC70506 [pii] AID - 10.1111/nicc.70506 [doi] PST - ppublish SO - Nurs Crit Care. 2026 May;31(3):e70506. doi: 10.1111/nicc.70506. PMID- 42082006 OWN - NLM STAT- MEDLINE DCOM- 20260716 LR - 20260817 IS - 1874-1754 (Electronic) IS - 0167-5273 (Linking) VI - 457 DP - 2026 Aug 15 TI - Optimizing cardiogenic shock outcomes: A system-based network approach. PG - 134535 LID - S0167-5273(26)00384-0 [pii] LID - 10.1016/j.ijcard.2026.134535 [doi] AB - BACKGROUND: Cardiogenic shock (CS) is a life-threatening syndrome with persistently high mortality rates despite therapeutic advances. Structured regional networks may offer improved outcomes through standardized care and early advanced support.This study evaluates the impact of a structured regional cardiogenic shock network on in-hospital mortality and clinical outcomes. METHODS: We conducted a prospective observational study at the University Siena Hospital, enrolling CS patients (SCAI stage C-D-E) between September 2020 and November 2024. The study population was divided into patients directly admitted to the shock center (hub group) and those initially admitted to a referring network hospital (spoke group). RESULTS: We enrolled 145 consecutive patients with CS (mean age 61.0 +/- 14.2 years; 81.4% male), predominantly due to acute coronary syndrome (46.9%) or acute on chronic heart failure (32.4%). The majority (61.4%) were transferred from referring network regional hospitals. Despite a high-risk profile (SCAI stage D + E in 48.3%, phenotype II + III in 62.1%), 73.5% of patients achieved a successful outcome, defined as hospital discharge or cardiac replacement therapy (23 heart transplants, 9 LVADs). The overall in-hospital mortality was 26.5%. Mortality increased with SCAI stage (p = 0.001) according to literature data. A vaso-inotropic score (VIS score) major than 21 at 48 h after admission was predictive of mortality (AUC = 0.722). CONCLUSIONS: In this observational study CS population presented low in-hospital mortality rate without any difference in hub and spoke group. It may be determined by the benefits of a structured regional network for CS and multidisciplinary approach management with early MCS implantation. CI - Copyright (c) 2026. Published by Elsevier B.V. FAU - Pesce, Federica AU - Pesce F AD - Cardiac Intensive Care Unit, Cardio-Thoracic-Vascular Department, University Siena Hospital, Siena, Italy. FAU - Dini, Carlotta Sorini AU - Dini CS AD - Cardiac Intensive Care Unit, Cardio-Thoracic-Vascular Department, University Siena Hospital, Siena, Italy. Electronic address: carlotta.sorinidini@gmail.com. FAU - Righini, Francesca Maria AU - Righini FM AD - Cardiac Intensive Care Unit, Cardio-Thoracic-Vascular Department, University Siena Hospital, Siena, Italy. FAU - Stefanini, Andrea AU - Stefanini A AD - Cardiac Intensive Care Unit, Cardio-Thoracic-Vascular Department, University Siena Hospital, Siena, Italy. FAU - Ghionzoli, Nicolo AU - Ghionzoli N AD - Cardiac Intensive Care Unit, Cardio-Thoracic-Vascular Department, University Siena Hospital, Siena, Italy. FAU - Maielli, Michela AU - Maielli M AD - Head of Hospital Care, Quality, and Tuscany Clinical Networks, Florence, Italy. FAU - Maccherini, Massimo AU - Maccherini M AD - Cardiac Surgery, Cardio-Thoracic-Vascular Department, University Siena Hospital, Siena, Italy. FAU - Bernazzali, Sonia AU - Bernazzali S AD - Cardiac Surgery, Cardio-Thoracic-Vascular Department, University Siena Hospital, Siena, Italy. FAU - Cameli, Matteo AU - Cameli M AD - Cardiac Intensive Care Unit, Cardio-Thoracic-Vascular Department, University Siena Hospital, Siena, Italy. FAU - Valente, Serafina AU - Valente S AD - Cardiac Intensive Care Unit, Cardio-Thoracic-Vascular Department, University Siena Hospital, Siena, Italy. LA - eng PT - Journal Article PT - Observational Study DEP - 20260502 PL - Netherlands TA - Int J Cardiol JT - International journal of cardiology JID - 8200291 SB - IM MH - Humans MH - *Shock, Cardiogenic/mortality/therapy/diagnosis MH - Hospital Mortality/trends MH - Female MH - Prospective Studies MH - Male MH - Middle Aged MH - Aged MH - Treatment Outcome MH - Italy/epidemiology OTO - NOTNLM OT - Cardiac intensive care unit OT - Cardiogenic shock OT - Mechanical circulatory support OT - Outcome OT - Regional network OT - Shock team EDAT- 2026/05/05 00:32 MHDA- 2026/05/23 05:36 CRDT- 2026/05/04 19:12 PHST- 2025/09/06 00:00 [received] PHST- 2026/03/18 00:00 [revised] PHST- 2026/04/29 00:00 [accepted] PHST- 2026/05/23 05:36 [medline] PHST- 2026/05/05 00:32 [pubmed] PHST- 2026/05/04 19:12 [entrez] AID - S0167-5273(26)00384-0 [pii] AID - 10.1016/j.ijcard.2026.134535 [doi] PST - ppublish SO - Int J Cardiol. 2026 Aug 15;457:134535. doi: 10.1016/j.ijcard.2026.134535. Epub 2026 May 2. PMID- 42079943 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260504 LR - 20260813 IS - 2666-2736 (Electronic) IS - 2666-2736 (Linking) VI - 30 DP - 2026 Apr TI - The surgical management of mediastinal paragangliomas: A modern series reflecting true collaboration between cardiac and thoracic surgeons. PG - 101520 LID - 10.1016/j.xjon.2025.10.034 [doi] LID - 101520 AB - OBJECTIVE: The study objective was to evaluate the perioperative management and outcomes of operation for patients undergoing mediastinal paraganglioma resection at Keck Medical Center of University of Southern California. METHODS: Six patients underwent surgical management for mediastinal paraganglioma from 2018 to 2024. Perioperative data were collected through retrospective review of the electronic medical record. RESULTS: The median age was 61 years (range, 27-69). Five patients (83%) demonstrated elevated levels of urinary or plasma metanephrines. Germline genetic testing demonstrated a pathogenic mutation consistent with paraganglioma-pheochromocytoma syndrome in 3 patients (50%). A multidisciplinary approach was used in all cases, with cardiac and thoracic surgical staff attending to each patient. Operative approach was via median sternotomy in 4 patients (67%), clamshell thoracotomy in 1 patient (17%), and right posterolateral thoracotomy in 1 patient (17%). Cardiopulmonary bypass was used in 3 patients (50%); 2 patients required great vessel transection for exposure, and 1 patient required en bloc resection of the right main coronary due to tumor encasement. R0 resection was achieved in all patients. Median intensive care unit and hospital length of stay were 2.5 days (range, 1-4) and 5 days (range, 4-9), respectively. The predominant method of postoperative surveillance was biannual chest computed tomography, with no patients demonstrating radiographic evidence of recurrence during a median follow-up of 22.5 months (range, 6.5-85). CONCLUSIONS: Surgical resection of mediastinal paraganglioma is safe and feasible with a multidisciplinary approach. The use of cardiopulmonary bypass, although occasionally necessary, did not result in adverse outcomes. All patients achieved an R0 resection with minimal postoperative complications, and no evidence of recurrence has been observed during the follow-up period. CI - (c) 2025 The Authors. FAU - Kazerouni, Kayvan AU - Kazerouni K AD - Division of Cardiac Surgery, Cardiovascular Institute, Los Angeles, Calif. FAU - Abt, Brittany G AU - Abt BG AD - Division of Cardiac Surgery, Cardiovascular Institute, Los Angeles, Calif. FAU - Wightman, Sean C AU - Wightman SC AD - Division of Thoracic Surgery, Department of Surgery, University of Southern California, Keck School of Medicine, Los Angeles, Calif. FAU - Harano, Takashi AU - Harano T AD - Division of Thoracic Surgery, Department of Surgery, University of Southern California, Keck School of Medicine, Los Angeles, Calif. FAU - Udelsman, Brooks V AU - Udelsman BV AD - Division of Thoracic Surgery, Department of Surgery, University of Southern California, Keck School of Medicine, Los Angeles, Calif. FAU - Rosenberg, Graeme M AU - Rosenberg GM AD - Division of Thoracic Surgery, Department of Surgery, University of Southern California, Keck School of Medicine, Los Angeles, Calif. FAU - Praeger, Jonathan AU - Praeger J AD - Division of Cardiac Surgery, Cardiovascular Institute, Los Angeles, Calif. FAU - Baker, Craig J AU - Baker CJ AD - Division of Cardiac Surgery, Cardiovascular Institute, Los Angeles, Calif. FAU - Starnes, Vaughn A AU - Starnes VA AD - Division of Cardiac Surgery, Cardiovascular Institute, Los Angeles, Calif. FAU - McFadden, Paul Michael AU - McFadden PM AD - Division of Thoracic Surgery, Department of Surgery, University of Southern California, Keck School of Medicine, Los Angeles, Calif. FAU - Kim, Anthony W AU - Kim AW AD - Division of Thoracic Surgery, Department of Surgery, University of Southern California, Keck School of Medicine, Los Angeles, Calif. FAU - Atay, Scott M AU - Atay SM AD - Division of Thoracic Surgery, Department of Surgery, University of Southern California, Keck School of Medicine, Los Angeles, Calif. LA - eng PT - Journal Article DEP - 20251119 PL - Netherlands TA - JTCVS Open JT - JTCVS open JID - 101768541 PMC - PMC13131156 OTO - NOTNLM OT - Surgical resection OT - cardiopulmonary bypass OT - mediastinal paraganglioma OT - multidisciplinary approach COIS- The authors reported no conflicts of interest. The Journal policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest. EDAT- 2026/05/04 12:33 MHDA- 2026/05/04 12:34 PMCR- 2025/11/19 CRDT- 2026/05/04 06:39 PHST- 2025/06/24 00:00 [received] PHST- 2025/10/02 00:00 [revised] PHST- 2025/10/17 00:00 [accepted] PHST- 2026/05/04 12:34 [medline] PHST- 2026/05/04 12:33 [pubmed] PHST- 2026/05/04 06:39 [entrez] PHST- 2025/11/19 00:00 [pmc-release] AID - S2666-2736(25)00413-9 [pii] AID - 101520 [pii] AID - 10.1016/j.xjon.2025.10.034 [doi] PST - epublish SO - JTCVS Open. 2025 Nov 19;30:101520. doi: 10.1016/j.xjon.2025.10.034. eCollection 2026 Apr. PMID- 42074841 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260504 LR - 20260926 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 15 IP - 8 DP - 2026 Apr 16 TI - Postoperative Complications in Patients with Frailty Syndrome Undergoing Esophagectomy-A Systematic Review with Meta-Analysis. LID - 10.3390/jcm15083040 [doi] LID - 3040 AB - Introduction: Frailty syndrome is an increasingly recognized condition that affects a considerable proportion of elderly patients, particularly those undergoing major surgeries. In this meta-analysis, we aimed to systematically review and pool data from cohort studies to assess the effect of frailty on the clinical outcomes of patients undergoing esophagectomy for esophageal cancer. Methods: Major online medical databases such as PubMed, Embase, Scopus, and Web of Science were searched to gather all studies on the clinical outcomes of patients with frailty syndrome who underwent esophagectomy due to esophageal cancer. The study included articles published up to March 2026. Finally, 15 articles matched the required criteria and were included in this meta-analysis. Results: The pooled odds ratio for surgery-related mortality in patients with frailty syndrome and esophageal cancer undergoing esophagectomy has been established at 4.03 (Lower Limit: 2.20; Upper Limit: 7.38; p-value < 0.05). The pooled odds ratio for surgery-related postoperative pneumonia in patients with frailty syndrome and esophageal cancer undergoing esophagectomy has been established at 1.86 (Lower Limit: 1.16; Upper Limit: 2.98; p-value < 0.05). The pooled odds ratio for surgery-related postoperative cardiac complications in patients with frailty syndrome and esophageal cancer undergoing esophagectomy has been established at 1.73 (Lower Limit: 1.54; Upper Limit: 1.94; p-value < 0.05). Conclusions: Frailty is a powerful predictor of mortality in patients undergoing esophagectomy, with frail individuals facing nearly four times higher odds of death. This underscores the urgent need to integrate frailty assessments into standard preoperative screening to enhance risk stratification and optimize perioperative decision-making. A multidisciplinary approach is essential to improving resilience, recovery, and long-term survival in frail esophageal cancer patients. Future large-scale prospective trials should focus on standardizing assessment tools and evaluating the lasting impact of tailored interventions to ultimately enhance patient outcomes. FAU - Kaminska, Anna AU - Kaminska A AD - Doctoral School of Medical and Health Sciences, Jagiellonian University Medical College Krakow, University Hospital in Krakow, 31-530 Krakow, Poland. FAU - Bonczar, Michal AU - Bonczar M AUID- ORCID: 0000-0003-2080-165X AD - Department of Anatomy, Jagiellonian University Medical College Cracow, 33-332 Krakow, Poland. AD - Youthoria, Youth Research Organization, 30-363 Krakow, Poland. FAU - Plutecki, Dawid AU - Plutecki D AUID- ORCID: 0000-0002-4485-9250 AD - Department of Anatomy, Jagiellonian University Medical College Cracow, 33-332 Krakow, Poland. AD - Youthoria, Youth Research Organization, 30-363 Krakow, Poland. FAU - Ostrowski, Patryk AU - Ostrowski P AUID- ORCID: 0000-0003-2745-9471 AD - Department of Anatomy, Jagiellonian University Medical College Cracow, 33-332 Krakow, Poland. AD - Youthoria, Youth Research Organization, 30-363 Krakow, Poland. FAU - Koziej, Mateusz AU - Koziej M AD - Department of Anatomy, Jagiellonian University Medical College Cracow, 33-332 Krakow, Poland. AD - Youthoria, Youth Research Organization, 30-363 Krakow, Poland. FAU - Konturek, Aleksander AU - Konturek A AUID- ORCID: 0000-0001-8103-4082 AD - Doctoral School of Medical and Health Sciences, Jagiellonian University Medical College Krakow, University Hospital in Krakow, 31-530 Krakow, Poland. LA - eng PT - Journal Article PT - Review DEP - 20260416 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC13117033 OTO - NOTNLM OT - esophageal cancer OT - esophagectomy OT - frailty syndrome OT - mortality OT - surgery COIS- The authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2026/05/04 06:33 MHDA- 2026/05/04 06:34 PMCR- 2026/04/16 CRDT- 2026/05/04 01:16 PHST- 2026/03/20 00:00 [received] PHST- 2026/04/07 00:00 [revised] PHST- 2026/04/13 00:00 [accepted] PHST- 2026/05/04 06:34 [medline] PHST- 2026/05/04 06:33 [pubmed] PHST- 2026/05/04 01:16 [entrez] PHST- 2026/04/16 00:00 [pmc-release] AID - jcm15083040 [pii] AID - jcm-15-03040 [pii] AID - 10.3390/jcm15083040 [doi] PST - epublish SO - J Clin Med. 2026 Apr 16;15(8):3040. doi: 10.3390/jcm15083040. PMID- 42074641 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260504 LR - 20260813 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 15 IP - 8 DP - 2026 Apr 9 TI - Clinical Factors Associated with Termination of Pregnancy Recommendations Following Prenatal Diagnosis of Congenital Heart Disease: A Multidisciplinary Council-Based Study. LID - 10.3390/jcm15082838 [doi] LID - 2838 AB - Objective: To evaluate clinical factors associated with termination of pregnancy (TOP) recommendations following prenatal diagnosis of congenital heart disease (CHD) within a multidisciplinary fetal council model. Methods: This retrospective cohort study included 146 fetuses with prenatally diagnosed CHD discussed in a tertiary referral center fetal council between October 2023 and December 2025. The primary outcome was council-issued recommendation for TOP (yes/no). Variables included gestational age (GA) at diagnosis, cardiac severity (Davey scale grouped as low, moderate, high), extracardiac anomalies, fetal growth restriction (FGR), and genetic evaluation/results. Group comparisons were performed using Mann-Whitney U and chi(2) tests. Independent associations were assessed using binary logistic regression. A subgroup analysis was conducted in isolated CHD cases (no extracardiac structural anomalies). Results: A total of 146 fetuses with prenatal CHD were included in the analysis. TOP was recommended in 71 cases (48.6%). GA at diagnosis did not differ between groups when analyzed continuously; however, categorical GA showed significant differences, with earlier diagnoses more frequent among TOP-recommended cases. Cardiac severity distribution differed significantly between groups. In multivariable analysis, GA at diagnosis and cardiac severity were independently associated with TOP recommendation. Compared with <20 weeks, diagnosis at 20-23+6 weeks (OR 17.96, 95% CI 3.50-92.22) and >/=24 weeks (OR 3.92, 95% CI 1.53-10.06) increased the odds of TOP recommendation. Relative to high severity, moderate (OR 0.23, 95% CI 0.07-0.72) and low severity (OR 0.20, 95% CI 0.08-0.50) were associated with lower odds of TOP recommendation. Extracardiac anomalies, genetic findings, and FGR were not independently associated after adjustment. Similar patterns were observed in isolated CHD cases. Conclusions: In a multidisciplinary prenatal counseling setting, TOP recommendations after prenatal CHD diagnosis were primarily driven by cardiac severity and GA at diagnosis, rather than extracardiac or genetic findings alone. FAU - Gercik Arzik, Ilayda AU - Gercik Arzik I AUID- ORCID: 0000-0001-7308-352X AD - Department of Perinatology, Izmir City Hospital, Izmir 35540, Turkey. FAU - Golbasi, Hakan AU - Golbasi H AUID- ORCID: 0000-0001-8682-5537 AD - Department of Perinatology, Izmir City Hospital, Izmir 35540, Turkey. FAU - Emiralioglu Cakir, Zubeyde AU - Emiralioglu Cakir Z AUID- ORCID: 0000-0001-8298-8363 AD - Division of Perinatology, Department of Obstetrics and Gynecology, Buca Seyfi Demirsoy Education and Research Hospital, Izmir 35390, Turkey. FAU - Ankara Aktas, Hale AU - Ankara Aktas H AUID- ORCID: 0000-0002-0723-4948 AD - Department of Perinatology, Izmir City Hospital, Izmir 35540, Turkey. FAU - Konuralp Atakul, Bahar AU - Konuralp Atakul B AD - Department of Perinatology, Izmir City Hospital, Izmir 35540, Turkey. FAU - Gul Saritas, Didem AU - Gul Saritas D AUID- ORCID: 0000-0002-6455-2328 AD - Department of Perinatology, Izmir City Hospital, Izmir 35540, Turkey. FAU - Boz Eravci, Deniz AU - Boz Eravci D AUID- ORCID: 0000-0002-8336-5501 AD - Centre for Labor and Social Security Training and Research, Ministry of Labor and Social Security, Ankara 06510, Turkey. FAU - Ekin, Atalay AU - Ekin A AD - Department of Perinatology, Izmir City Hospital, Izmir 35540, Turkey. LA - eng PT - Journal Article DEP - 20260409 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC13116180 OTO - NOTNLM OT - congenital heart disease OT - multidisciplinary counseling OT - prenatal diagnosis OT - termination of pregnancy COIS- The authors declare no conflicts of interest. EDAT- 2026/05/04 06:33 MHDA- 2026/05/04 06:34 PMCR- 2026/04/09 CRDT- 2026/05/04 01:15 PHST- 2026/02/26 00:00 [received] PHST- 2026/03/20 00:00 [revised] PHST- 2026/04/01 00:00 [accepted] PHST- 2026/05/04 06:34 [medline] PHST- 2026/05/04 06:33 [pubmed] PHST- 2026/05/04 01:15 [entrez] PHST- 2026/04/09 00:00 [pmc-release] AID - jcm15082838 [pii] AID - jcm-15-02838 [pii] AID - 10.3390/jcm15082838 [doi] PST - epublish SO - J Clin Med. 2026 Apr 9;15(8):2838. doi: 10.3390/jcm15082838. PMID- 42073412 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260504 LR - 20260813 IS - 2075-1729 (Print) IS - 2075-1729 (Electronic) IS - 2075-1729 (Linking) VI - 16 IP - 4 DP - 2026 Apr 4 TI - Screening and Qualification for Transcatheter Tricuspid Valve Interventions-Preliminary Findings from the CAPTURE Pilot Study. LID - 10.3390/life16040602 [doi] LID - 602 AB - Background: Transcatheter tricuspid edge-to-edge repair (T-TEER) is the most widely used treatment option for patients with tricuspid regurgitation (TR). In real-world practice, a substantial proportion of referred patients are not eligible for T-TEER or do not achieve an adequate early TR reduction and may therefore require alternative transcatheter tricuspid valve interventions (TTVI)-orthotopic or heterotopic tricuspid valve implantation. The aim of the study was to characterize patients with severe TR referred for transcatheter treatment, and identify patients in whom alternative TTVI strategies may be required. Methods: The CAPTURE Study (NCT06838611) enrolls consecutive patients referred for TR treatment. All patients undergo clinical and echocardiographic assessment to determine eligibility for T-TEER. Candidates for alternative TTVI strategies were defined as patients disqualified from T-TEER due to anatomical ineligibility or those with unsuccessful T-TEER, defined as next-day TTE showing TR more than moderate. This pilot analysis includes patients enrolled from November 2023 to December 2024. Results: 147 patients were enrolled, 77 (52.4%) patients were qualified for T-TEER and the procedure was performed in 71 (48.3%) patients, with successful TR reduction in 55 cases (77.5% of treated patients); a subset of 34 patients (23.1%) was identified as potential candidates for alternative TTVI strategies. These patients exhibited more advanced TR (torrential TR 76.5% vs. 18.2%; p < 0.001) and right heart failure symptoms (ascites 44.1% vs. 12.7%; p < 0.001). Additionally, they had significantly higher bilirubin concentration (1.09 [1.20] mg/dL vs. 0.61 [0.42] mg/dL; p = 0.003), lower hemoglobin level (11.8 [1.7] g/dL vs. 12.3 [1.7] g/dL; p = 0.017) and platelet count (161.0 [51.0] x 109/L vs. 183.0 [79.0] x 109/L; p = 0.015), suggesting an increased bleeding risk. Conclusions: In this preliminary single-center real-world cohort, approximately half of the patients with severe TR were eligible for T-TEER, whereas more than 20% emerged as potential candidates for alternative TTVI strategies. This subgroup was characterized by more advanced right-sided remodeling and laboratory features suggestive of hepatic dysfunction and increased bleeding risk, which may have important implications for Heart Team decision-making and procedural planning. FAU - Rdzanek, Adam AU - Rdzanek A AUID- ORCID: 0009-0003-3494-7489 AD - 1st Chair and Department of Cardiology, Medical University of Warsaw, 02-097 Warsaw, Poland. FAU - Piasecki, Adam AU - Piasecki A AUID- ORCID: 0009-0002-5614-6415 AD - 1st Chair and Department of Cardiology, Medical University of Warsaw, 02-097 Warsaw, Poland. FAU - Pedzich, Ewa AU - Pedzich E AUID- ORCID: 0000-0001-8965-0736 AD - 1st Chair and Department of Cardiology, Medical University of Warsaw, 02-097 Warsaw, Poland. FAU - Ostrowska, Ewa AU - Ostrowska E AD - 1st Chair and Department of Cardiology, Medical University of Warsaw, 02-097 Warsaw, Poland. FAU - Pawlowicz, Pawel AU - Pawlowicz P AUID- ORCID: 0009-0006-7683-8899 AD - 1st Chair and Department of Cardiology, Medical University of Warsaw, 02-097 Warsaw, Poland. FAU - Borowiak, Ewa AU - Borowiak E AD - 1st Chair and Department of Cardiology, Medical University of Warsaw, 02-097 Warsaw, Poland. FAU - Kaplon-Cieslicka, Agnieszka AU - Kaplon-Cieslicka A AD - 1st Chair and Department of Cardiology, Medical University of Warsaw, 02-097 Warsaw, Poland. FAU - Kochman, Janusz AU - Kochman J AD - 1st Chair and Department of Cardiology, Medical University of Warsaw, 02-097 Warsaw, Poland. FAU - Tomaniak, Mariusz AU - Tomaniak M AUID- ORCID: 0000-0001-8289-1393 AD - 1st Chair and Department of Cardiology, Medical University of Warsaw, 02-097 Warsaw, Poland. FAU - Scislo, Piotr AU - Scislo P AD - 1st Chair and Department of Cardiology, Medical University of Warsaw, 02-097 Warsaw, Poland. FAU - Maisano, Francesco AU - Maisano F AD - Department of Cardiac Surgery, San Raffaele University Hospital, 20132 Milan, Italy. LA - eng PT - Journal Article DEP - 20260404 PL - Switzerland TA - Life (Basel) JT - Life (Basel, Switzerland) JID - 101580444 PMC - PMC13117777 OTO - NOTNLM OT - heart failure OT - transcatheter edge-to-edge repair OT - transcatheter tricuspid valve interventions OT - tricuspid regurgitation COIS- All authors declare no conflicts of interest regarding the contents of this article. EDAT- 2026/05/04 06:33 MHDA- 2026/05/04 06:34 PMCR- 2026/04/04 CRDT- 2026/05/04 01:10 PHST- 2026/02/18 00:00 [received] PHST- 2026/03/23 00:00 [revised] PHST- 2026/03/31 00:00 [accepted] PHST- 2026/05/04 06:34 [medline] PHST- 2026/05/04 06:33 [pubmed] PHST- 2026/05/04 01:10 [entrez] PHST- 2026/04/04 00:00 [pmc-release] AID - life16040602 [pii] AID - life-16-00602 [pii] AID - 10.3390/life16040602 [doi] PST - epublish SO - Life (Basel). 2026 Apr 4;16(4):602. doi: 10.3390/life16040602. PMID- 42069784 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260630 LR - 20260813 IS - 2057-3804 (Electronic) IS - 2057-3804 (Linking) VI - 12 IP - 1 DP - 2026 May 2 TI - Cardiotoxicity of monoclonal antibody-based therapies in breast cancer: a contemporary narrative review. LID - 10.1186/s40959-026-00490-2 [doi] LID - 82 AB - Monoclonal antibody-based therapies have substantially improved outcomes in breast cancer, particularly through HER2-directed treatment strategies, but have also introduced important cardiovascular toxicities that require careful recognition and management. This narrative review summarizes current evidence on cardiotoxicity associated with monoclonal antibody therapies used in breast cancer, with emphasis on HER2-targeted antibodies, antibody-drug conjugates, and selected immune checkpoint inhibitors.Trastuzumab remains the best-characterized monoclonal antibody associated with cancer therapy-related cardiac dysfunction, most commonly presenting as left ventricular systolic dysfunction, particularly in patients previously exposed to anthracyclines or with baseline cardiovascular risk factors. Pertuzumab and currently available antibody-drug conjugates have not shown a major increase in cardiotoxic risk beyond that observed with established HER2-directed therapy, although long-term data remain limited for some newer agents. Immune checkpoint inhibitors are less commonly associated with cardiovascular toxicity, but may rarely cause severe immune-mediated complications, particularly myocarditis and also non-immune mediated toxicity such as cardiac dysfunction.Contemporary evaluation of cardiotoxicity increasingly relies on an integrated cardio-oncology framework incorporating left ventricular ejection fraction, global longitudinal strain, and cardiac biomarkers, with growing recognition of subclinical dysfunction and right ventricular involvement. Current management strategies emphasize baseline cardiovascular risk assessment, risk-adapted surveillance, early initiation of heart failure therapy when indicated, and individualized multidisciplinary decision-making regarding continuation of anticancer treatment, including permissive cardiotoxicity in selected patients.As the use of monoclonal antibody therapies continues to expand, optimizing the balance between oncologic efficacy and cardiovascular safety remains a central goal of modern breast cancer care. CI - (c) 2026. The Author(s). FAU - Santos Nussbaum, Ana Claudia Aparecida AU - Santos Nussbaum ACA AD - Hcor, Sao Paulo, Brazil. dra.ana.nussbaum@gmail.com. FAU - Antonini, Marcelo AU - Antonini M AD - Hospital Do Servidor Publico Estadual Francisco Morato de Oliveira, Sao Paulo, Brazil. AD - BREAST Group: Brazilian Breast Cancer Associate Research Team, Sao Paulo, Brazil. FAU - Mattar, Andre AU - Mattar A AD - BREAST Group: Brazilian Breast Cancer Associate Research Team, Sao Paulo, Brazil. AD - Centro de Referencia da Saude da Mulher - Hospital da Mulher, Sao Paulo, Brazil. FAU - Bacal, Fernando AU - Bacal F AD - Faculdade de Medicina, Instituto Do Coracao (InCor), Hospital das Clinicas HCFMUSP, Universidade de Sao Paulo, Sao Paulo, Brazil. AD - Hospital Israelita Albert Einstein, Sao Paulo, Brazil. FAU - Monte Real, Juliana AU - Monte Real J AD - Programa de Pos-Graduacao Em Ciencias da Saude, Instituto de Assistencia Medica Ao Servidor Publico Estadual, Sao Paulo, Brazil. AD - Laboratorio Neugen Solucoes Diagnosticas, Sao Paulo, Brazil. LA - eng PT - Journal Article PT - Review DEP - 20260502 PL - England TA - Cardiooncology JT - Cardio-oncology (London, England) JID - 101689938 PMC - PMC13312650 OTO - NOTNLM OT - Antibody‒drug conjugate OT - Breast cancer OT - Cardiotoxicity OT - Monoclonal antibody COIS- Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2026/05/03 05:27 MHDA- 2026/05/03 05:28 PMCR- 2026/05/02 CRDT- 2026/05/02 23:21 PHST- 2025/11/28 00:00 [received] PHST- 2026/04/08 00:00 [accepted] PHST- 2026/05/03 05:28 [medline] PHST- 2026/05/03 05:27 [pubmed] PHST- 2026/05/02 23:21 [entrez] PHST- 2026/05/02 00:00 [pmc-release] AID - 10.1186/s40959-026-00490-2 [pii] AID - 490 [pii] AID - 10.1186/s40959-026-00490-2 [doi] PST - epublish SO - Cardiooncology. 2026 May 2;12(1):82. doi: 10.1186/s40959-026-00490-2. PMID- 42069489 OWN - NLM STAT- MEDLINE DCOM- 20260901 LR - 20260923 IS - 1879-0828 (Electronic) IS - 0953-6205 (Linking) VI - 151 DP - 2026 Sep TI - Hospital-to-community care pathways for patients with heart failure, an inter-society consensus document. PG - 106881 LID - S0953-6205(26)00186-X [pii] LID - 10.1016/j.ejim.2026.106881 [doi] AB - Heart failure (HF) remains one of the most prevalent and burdensome chronic conditions worldwide, with rising incidence and poor prognosis despite major therapeutic advances. Effective management requires a comprehensive, multidisciplinary approach that ensures diagnostic accuracy, therapeutic optimization, and continuity of care from hospital to community settings. This consensus document outlines an integrated model for HF care in Italy, developed to improve patient outcomes and resource efficiency. HF should be diagnosed and phenotyped through clinical evaluation, electrocardiography, echocardiography, biomarkers, and, when indicated, advanced imaging. Guideline-directed medical therapy, including sodium-glucose cotransporter-2 inhibitors, angiotensin receptor-neprilysin inhibitors, beta-blockers, and mineralocorticoid receptor antagonists, remains the cornerstone of treatment across the ejection-fraction spectrum. Device therapy, cardiac rehabilitation, and iron supplementation complement pharmacological management. Telemedicine and remote monitoring enable early detection of clinical deterioration and strengthen hospital-community integration, while multidisciplinary HF clinics coordinate pharmacological care, rehabilitation, and patient education. Structured training of healthcare professionals and caregivers, along with therapeutic education programs, enhances adherence, empowers patients, and promotes self-management. Community-based associations further support cardiovascular prevention through educational and screening initiatives. The integration of hospital, community, and digital health resources, combined with continuous professional training and patient empowerment, represents a sustainable and effective model to improve survival, reduce hospitalizations, and enhance quality of life for patients with HF. CI - Copyright (c) 2026 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved. FAU - Mallardo, Mario AU - Mallardo M AD - Cardiac Rehabilitation Unit, "San Gennaro" Hospital, ASL NA 1, Via S. Gennaro dei Poveri, 25, 80136, Naples, Italy. Electronic address: mario-mallardo@virgilio.it. FAU - Filardi, Pasquale Perrone AU - Filardi PP AD - Department of Advanced Biomedical Sciences, "Federico II" University, Naples, Italy. FAU - Micheletto, Claudio AU - Micheletto C AD - Cardio-Thoracic Department, Respiratory Unit, Verona Integrated University Hospital, University of Verona, Verona, Italy. FAU - Montano, Nicola AU - Montano N AD - Foundation IRCSS Ca' Granda, Ospedale Maggiore Policlinico, Milan, , Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy; International Clinical Research Center, St. Anne University Hospital, Brno, Czech Republic, Italy. FAU - Spampinato, Andrea AU - Spampinato A AD - Unit of Cardiology, Policlinico Casilino, Rome, Italy. FAU - Volterrani, Maurizio AU - Volterrani M AD - Cardiopulmonary Department, IRCCS San Raffaele Roma, Rome, Italy. FAU - Zito, Giovanni Battista AU - Zito GB AD - Cardiology Service, Local Health Unit (LHU) Naples 3 South, Italy. FAU - Agosti, Sergio AU - Agosti S AD - The Cardiology Unit, Micone Hospital, ASL3, Sestri Ponente, Italy. FAU - Avogadri, Enrico AU - Avogadri E AD - Department of Rehabilitative Cardiology, SS Trinita Hospital, Fossano, CN, Italy. FAU - Basile, Christian AU - Basile C AD - Department of Clinical Science and Education, Karolinska Institutet, Stockholm, Sweden; ANMCO Research Center, Heart Care Foundation, Florence, Italy. FAU - Gabriele, Michele AU - Gabriele M AD - Cardiology Department, "P. Abele Ajello" Hospital, Via B. Salemi, 175, Mazzara del Vallo 91026, Trapani, Italy. FAU - Marra, Alberto M AU - Marra AM AD - Department of Translational Medical Sciences, "Federico II" University, Naples, Italy. FAU - Mattioli, Anna Vittoria AU - Mattioli AV AD - Department of Quality of Life Sciences, University of Bologna - Alma Mater Studiorum Bologna, Italy. FAU - Micanti, Alex AU - Micanti A AD - Cardiorespiratory and Neuromotor Rehabilitation Center, Villa Serena Private Clinic, Piossasco Turin, Italy. FAU - Nodari, Savina AU - Nodari S AD - Department of Cardiology, University of Brescia and ASST "Ospedali Civili" Hospital, Brescia, Italy. FAU - Oliviero, Ugo AU - Oliviero U AD - Department of Translational Medical Sciences, "Federico II" University, Naples, Italy. FAU - Paolillo, Stefania AU - Paolillo S AD - Department of Advanced Biomedical Sciences, "Federico II" University, Naples, Italy. FAU - Ratti, Gennaro AU - Ratti G AD - Cardiology Unit, San Giovanni Bosco Hospital, Health Authority Naples 1, 80144 Naples, Italy. FAU - Ruvolo, Antonio AU - Ruvolo A AD - Cardiac Rehabilitation Unit, "San Gennaro" Hospital, ASL NA 1, Via S. Gennaro dei Poveri, 25, 80136, Naples, Italy. FAU - Salzano, Andrea AU - Salzano A AD - Department of Translational Medical Sciences, "Federico II" University, Naples, Italy. FAU - Sorrentino, Regina AU - Sorrentino R AD - Cardiac Rehabilitation Unit, "San Gennaro" Hospital, ASL NA 1, Via S. Gennaro dei Poveri, 25, 80136, Naples, Italy. FAU - Cittadini, Antonio AU - Cittadini A AD - Department of Translational Medical Sciences, "Federico II" University, Naples, Italy. LA - eng PT - Consensus Statement PT - Journal Article DEP - 20260501 PL - Netherlands TA - Eur J Intern Med JT - European journal of internal medicine JID - 9003220 SB - IM MH - Humans MH - *Heart Failure/therapy/diagnosis MH - Telemedicine MH - Italy MH - Digital Health MH - Remote Patient Monitoring MH - *Community Health Services OTO - NOTNLM OT - Cardiac rehabilitation OT - Care pathways OT - Heart failure OT - Inter-society consensus document OT - Telemedicine COIS- Declaration of competing interest The authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria, educational grants, participation in speakers' bureaus, membership, employment, consultancies, stock ownership, or other equity interest) or non-financial interest (such as personal or professional relationships, affiliations, or beliefs) in the subject matter or materials discussed in the manuscript entitled "Hospital-to-Community Care Pathways for Patients with Heart Failure in Italy: An Inter-Society Consensus Document", submitted to the European Journal of Internal and Emergency Medicine (EIJIM). EDAT- 2026/05/03 05:27 MHDA- 2026/09/01 23:34 CRDT- 2026/05/02 21:53 PHST- 2025/12/11 00:00 [received] PHST- 2026/03/10 00:00 [revised] PHST- 2026/04/08 00:00 [accepted] PHST- 2026/09/01 23:34 [medline] PHST- 2026/05/03 05:27 [pubmed] PHST- 2026/05/02 21:53 [entrez] AID - S0953-6205(26)00186-X [pii] AID - 10.1016/j.ejim.2026.106881 [doi] PST - ppublish SO - Eur J Intern Med. 2026 Sep;151:106881. doi: 10.1016/j.ejim.2026.106881. Epub 2026 May 1. PMID- 42069182 OWN - NLM STAT- MEDLINE DCOM- 20260607 LR - 20260608 IS - 2666-9919 (Electronic) IS - 2666-9919 (Linking) VI - 56 IP - 4 DP - 2026 May TI - Diagnostic value of echocardiography for infective endocarditis in older adults. PG - 105280 LID - S2666-9919(26)00037-0 [pii] LID - 10.1016/j.idnow.2026.105280 [doi] AB - BACKGROUND: Diagnosing infective endocarditis (IE) in older adults remains challenging. We aimed to assess the diagnostic contribution of echocardiography in geriatric patients with suspected IE. METHODS: We conducted a retrospective multicenter cohort study in three university hospitals between May 2016 and April 2021. All consecutive episodes of suspected IE discussed by a multidisciplinary endocarditis team were included. Final team adjudication served as the reference standard. Duke classification was assessed before and after transthoracic (TTE) and/or transesophageal echocardiography (TEE). Patients were compared according to age (<75 versus >/= 75 years). RESULTS: A total of 184 suspected IE episodes (181 patients) were analyzed; median age was 74 years, and 49% were aged >/= 75 years. Older patients had a higher Charlson comorbidity index (7.5 vs 4.5) and a higher 12-month mortality rate (37% vs 26% overall). TTE was performed in 96% of cases, whereas TEE was performed in only 38%, significantly less frequently in patients >/= 75 years (23% vs 51%) and after a longer time (10.3 vs 5.6 days). Echocardiography modified Duke classification in 30% of cases overall, including 24% in patients >/= 75 years. The proportion of definite IE increased from 8% before echocardiography to 33% after imaging, and from 9% to 28% in older patients. Echocardiography provided a major Duke criterion in 33% of cases, while findings were inconclusive in 25%. Neurological disorders and biological prosthetic valves were independently associated with echocardiographic diagnosis of IE. CONCLUSIONS: Despite underuse and delayed TEE, echocardiography improved diagnostic classification. CI - Copyright (c) 2026 The Author(s). Published by Elsevier Masson SAS.. All rights reserved. FAU - Joffre, Pierre-Alain AU - Joffre PA AD - Geriatry Department, Ambroise Pare Hospital, Universite de Versailles Saint Quentin (UVSQ), Assistance Publique-Hopitaux de Paris (APHP), Boulogne-Billancourt, France. FAU - Gautier, Sylvain AU - Gautier S AD - Public Health Department, Ambroise Pare Hospital, UVSQ, APHP, Boulogne-Billancourt, France. FAU - de Chazournes, Pierre Boisson AU - de Chazournes PB AD - Cardiology Department, Ambroise Pare Hospital, UVSQ, APHP, Boulogne-Billancourt, France. FAU - Jaffal, Karim AU - Jaffal K AD - Infectious Disease Department, Ambroise Pare and Raymond Poincare Hospitals, APHP, Boulogne-Billancourt and Garches, France. FAU - Perrineau, Segolene AU - Perrineau S AD - Infectious Disease Department, Ambroise Pare and Raymond Poincare Hospitals, APHP, Boulogne-Billancourt and Garches, France. FAU - Duran, Clara AU - Duran C AD - Infectious Disease Department, Ambroise Pare and Raymond Poincare Hospitals, APHP, Boulogne-Billancourt and Garches, France. FAU - Tardy, Valerie Sivadon AU - Tardy VS AD - Microbiology Department, Ambroise Pare Hospital, APHP, Boulogne-Billancourt, France. FAU - Coutte, Laetitia AU - Coutte L AD - Internal Medicine Department, Ambroise Pare Hospital, APHP, Boulogne-Billancourt, France. FAU - Charron, Cyril AU - Charron C AD - Intensive Care Unit, Ambroise Pare Hospital, APHP, Boulogne-Billancourt, France. FAU - Mansencal, Nicolas AU - Mansencal N AD - Cardiology Department, Ambroise Pare Hospital, UVSQ, APHP, Boulogne-Billancourt, France; Clinical Epidemiology, INSERM 1018 CESP, Paris Saclay University, Villejuif, France. FAU - Dinh, Aurelien AU - Dinh A AD - Infectious Disease Department, Ambroise Pare and Raymond Poincare Hospitals, APHP, Boulogne-Billancourt and Garches, France. Electronic address: aurelien.dinh@aphp.fr. FAU - Pepin, Marion AU - Pepin M AD - Geriatry Department, Ambroise Pare Hospital, Universite de Versailles Saint Quentin (UVSQ), Assistance Publique-Hopitaux de Paris (APHP), Boulogne-Billancourt, France; Clinical Epidemiology, INSERM 1018 CESP, Paris Saclay University, Villejuif, France. CN - endocarditis team of Ambroise Pare Hospital LA - eng PT - Journal Article PT - Multicenter Study DEP - 20260430 PL - France TA - Infect Dis Now JT - Infectious diseases now JID - 101775152 SB - IM MH - Humans MH - Aged MH - Retrospective Studies MH - *Endocarditis/diagnostic imaging/diagnosis MH - Female MH - Aged, 80 and over MH - *Echocardiography/methods MH - Echocardiography, Transesophageal MH - Male MH - Middle Aged MH - Age Factors OTO - NOTNLM OT - Duke classification OT - Echocardiography OT - Infective endocarditis OT - Older adults OT - Transesophageal echocardiography COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/05/03 05:27 MHDA- 2026/06/07 06:33 CRDT- 2026/05/02 19:14 PHST- 2026/01/09 00:00 [received] PHST- 2026/04/12 00:00 [revised] PHST- 2026/04/27 00:00 [accepted] PHST- 2026/06/07 06:33 [medline] PHST- 2026/05/03 05:27 [pubmed] PHST- 2026/05/02 19:14 [entrez] AID - S2666-9919(26)00037-0 [pii] AID - 10.1016/j.idnow.2026.105280 [doi] PST - ppublish SO - Infect Dis Now. 2026 May;56(4):105280. doi: 10.1016/j.idnow.2026.105280. Epub 2026 Apr 30. PMID- 42066882 OWN - NLM STAT- MEDLINE DCOM- 20260826 LR - 20260912 IS - 1556-3871 (Electronic) IS - 1547-5271 (Linking) VI - 23 IP - 9 DP - 2026 Sep TI - The importance of lead management in the transcatheter tricuspid valve intervention era. PG - e2110-e2115 LID - S1547-5271(26)02312-X [pii] LID - 10.1016/j.hrthm.2026.04.045 [doi] AB - BACKGROUND: Percutaneous transcatheter tricuspid valve replacement (TTVR) has emerged as an effective treatment for severe tricuspid regurgitation (TR). Management of TR in the setting of transvenous leads is complex, requiring a multidisciplinary team-based approach. Transvenous lead extraction (TLE) may improve or worsen lead-related TR and is important when considering TTVR to avoid "jailing" leads between the transcatheter and native tricuspid valve. Data and guidance in these settings are limited. OBJECTIVE: This study aimed to describe the outcomes of a strategy using TLE in patients with severe TR and a lead crossing the tricuspid valve who were being considered for catheter-based tricuspid valve intervention (TTVR or tricuspid transcatheter edge-to-edge repair). METHODS: This study included all patients who underwent TLE for TR between July 2020 and July 2025 at a single high-volume extraction center. Demographic characteristics, procedural details, and clinical outcomes were analyzed. RESULTS: The study included 24 patients, with 14 women (58.3%) with a mean age of 73.7 years, with severe TR and transvenous leads being considered for tricuspid valve intervention. Complete TLE procedural success was achieved in all patients. 11 patients (46%) experienced a reduction in TR after extraction, eliminating the need for further tricuspid intervention in 8 patients (33%). Of the remaining patients, 12 (75%) underwent subsequent tricuspid valve intervention. There were 3 mortalities during the study, none of which were procedure related. CONCLUSION: In our series, TLE was a safe and efficacious approach to reduce the degree of TR or serve as a bridge to tricuspid intervention. CI - Copyright (c) 2026 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved. FAU - Beccarino, Nicholas J AU - Beccarino NJ AD - Northwell, New Hyde Park, New York, and Department of Cardiology and Cardiac Surgery, Zucker School of Medicine at Hofstra/Northwell, North Shore University Hospital, Manhasset, New York. Electronic address: nbeccarino@northwell.edu. FAU - Goyal, Aditya AU - Goyal A AD - Northwell, New Hyde Park, New York, and Department of Cardiology and Cardiac Surgery, Zucker School of Medicine at Hofstra/Northwell, North Shore University Hospital, Manhasset, New York. FAU - Ostreicher, Zachary AU - Ostreicher Z AD - Northwell, New Hyde Park, New York, and Department of Cardiology and Cardiac Surgery, Zucker School of Medicine at Hofstra/Northwell, North Shore University Hospital, Manhasset, New York. FAU - Gabriels, James K AU - Gabriels JK AD - Northwell, New Hyde Park, New York, and Department of Cardiology and Cardiac Surgery, Zucker School of Medicine at Hofstra/Northwell, North Shore University Hospital, Manhasset, New York. FAU - Saleh, Moussa AU - Saleh M AD - Northwell, New Hyde Park, New York, and Department of Cardiology and Cardiac Surgery, Zucker School of Medicine at Hofstra/Northwell, North Shore University Hospital, Manhasset, New York. FAU - Koss, Elana AU - Koss E AD - Northwell, New Hyde Park, New York, and Department of Cardiology and Cardiac Surgery, Zucker School of Medicine at Hofstra/Northwell, North Shore University Hospital, Manhasset, New York. FAU - Rutkin, Bruce AU - Rutkin B AD - Northwell, New Hyde Park, New York, and Department of Cardiology and Cardiac Surgery, Zucker School of Medicine at Hofstra/Northwell, North Shore University Hospital, Manhasset, New York. FAU - Epstein, Laurence M AU - Epstein LM AD - Northwell, New Hyde Park, New York, and Department of Cardiology and Cardiac Surgery, Zucker School of Medicine at Hofstra/Northwell, North Shore University Hospital, Manhasset, New York. LA - eng PT - Journal Article DEP - 20260429 PL - United States TA - Heart Rhythm JT - Heart rhythm JID - 101200317 SB - IM MH - Humans MH - *Tricuspid Valve Insufficiency/surgery/diagnosis MH - Female MH - Device Lead Extraction/methods MH - *Tricuspid Valve/surgery/diagnostic imaging MH - *Cardiac Catheterization/methods MH - Aged MH - Male MH - *Heart Valve Prosthesis Implantation/methods MH - Retrospective Studies MH - Treatment Outcome OTO - NOTNLM OT - Jailed leads OT - Transcatheter tricuspid valve replacement OT - Transvenous lead extraction OT - Tricuspid regurgitation OT - Tricuspid transcatheter edge-to-edge repair COIS- Disclosures Laurence M. Epstein is a consultant for Philips and Boston Scientific and a consultant/speaker for Medtronic. The other authors have no conflicts of interest to disclose. EDAT- 2026/05/02 00:33 MHDA- 2026/08/26 23:35 CRDT- 2026/05/01 19:12 PHST- 2026/03/01 00:00 [received] PHST- 2026/04/03 00:00 [revised] PHST- 2026/04/18 00:00 [accepted] PHST- 2026/08/26 23:35 [medline] PHST- 2026/05/02 00:33 [pubmed] PHST- 2026/05/01 19:12 [entrez] AID - S1547-5271(26)02312-X [pii] AID - 10.1016/j.hrthm.2026.04.045 [doi] PST - ppublish SO - Heart Rhythm. 2026 Sep;23(9):e2110-e2115. doi: 10.1016/j.hrthm.2026.04.045. Epub 2026 Apr 29. PMID- 42065941 OWN - NLM STAT- MEDLINE DCOM- 20260518 LR - 20260518 IS - 1558-2035 (Electronic) IS - 1558-2027 (Linking) VI - 27 IP - 4 DP - 2026 Apr 1 TI - Long-term clinical outcomes of TAVI in hospitals without on-site cardiac surgery: insights from the MURGIA-TAVI Registry. PG - 268-276 LID - 10.2459/JCM.0000000000001875 [doi] AB - AIMS: Transcatheter aortic valve implantation (TAVI) is the standard of care for elderly (>/=70 years) or high-risk patients with severe aortic stenosis, yet current guidelines recommend its performance only in Heart Valve Centres with on-site cardiac surgery. This study evaluated procedural safety and long-term outcomes of TAVI performed in selected non-surgical centres. METHODS: We retrospectively analysed 186 consecutive patients undergoing TAVI at 'F. Miulli' Hospital between 2016 and 2024, enrolled in the MURGIA-TAVI Registry. The programme operated without institutional on-site cardiac surgery, supported by a structured Heart Team approach and a visiting surgical back-up. Outcomes were assessed according to Valve Academic Research Consortium-3 definitions and survival was evaluated up to 5 years. RESULTS: Among 186 patients (mean age 82 years; STS score 7%), transfemoral access was used in 93%. Technical success was 98.9%, with no intraprocedural deaths. Conversion to emergent cardiac surgery occurred in two patients (1.1%); both survived at 30 days. In-hospital mortality was 1.6%, never valve-related. Major complications included cardiac tamponade (1.6%), major bleeding (2.2%) and major vascular complications (1.1%). At 1 year, mortality was 15.6% with no valve-related deaths, and valve dysfunction occurred in 1.9% of patients. Five-year survival reached 52.5%. Outcomes, including rates of emergent cardiac surgery, were comparable to those reported in published registries from centres without institutional on-site cardiac surgery. CONCLUSIONS: Our findings suggest that TAVI can be safely performed in selected hospitals without on-site cardiac surgery within a structured Heart Team framework and a visiting surgical back-up, potentially expanding access, shortening waiting times, and meeting the growing demand for TAVI. CI - Copyright (c) 2026 Italian Federation of Cardiology - I.F.C. All rights reserved. FAU - Mancini, Giandomenico AU - Mancini G AD - Department of Cardiology, Ente Ecclesiastico Ospedale Generale Regionale 'F. Miulli', Acquaviva delle Fonti. FAU - Scarcia, Maria AU - Scarcia M AD - Department of Cardiology, Ente Ecclesiastico Ospedale Generale Regionale 'F. Miulli', Acquaviva delle Fonti. FAU - Basile, Eloisa AU - Basile E AD - Department of Cardiology, Ente Ecclesiastico Ospedale Generale Regionale 'F. Miulli', Acquaviva delle Fonti. FAU - Martimucci, Marcello AU - Martimucci M AD - Department of Cardiology, Ente Ecclesiastico Ospedale Generale Regionale 'F. Miulli', Acquaviva delle Fonti. FAU - Guida, Pietro AU - Guida P AD - Department of Cardiology, Ente Ecclesiastico Ospedale Generale Regionale 'F. Miulli', Acquaviva delle Fonti. FAU - Casamassima, Vito AU - Casamassima V AD - Department of Cardiology, Ente Ecclesiastico Ospedale Generale Regionale 'F. Miulli', Acquaviva delle Fonti. FAU - Xhelo, Alessandro AU - Xhelo A AD - Department of Cardiology, Ente Ecclesiastico Ospedale Generale Regionale 'F. Miulli', Acquaviva delle Fonti. FAU - Speziale, Giuseppe AU - Speziale G AD - Department of Cardiac Surgery, Santa Maria Hospital, Bari. FAU - Visicchio, Giuseppe AU - Visicchio G AD - Department of Cardiac Surgery, Santa Maria Hospital, Bari. FAU - Massaro, Fabrizia AU - Massaro F AD - Department of Anaesthesia and Intensive Care, Ente Ecclesiastico Ospedale Generale Regionale 'F. Miulli', Acquaviva delle Fonti, Italy. FAU - Magnesa, Giovanna AU - Magnesa G AD - Department of Anaesthesia and Intensive Care, Ente Ecclesiastico Ospedale Generale Regionale 'F. Miulli', Acquaviva delle Fonti, Italy. FAU - Langialonga, Tommaso AU - Langialonga T AD - Department of Cardiology, Ente Ecclesiastico Ospedale Generale Regionale 'F. Miulli', Acquaviva delle Fonti. FAU - Paradies, Valeria AU - Paradies V AD - Department of Cardiology, Maasstad Hospital, Rotterdam, The Netherlands. FAU - Iorio, Elia AU - Iorio E AD - Department of Cardiology, Ente Ecclesiastico Ospedale Generale Regionale 'F. Miulli', Acquaviva delle Fonti. FAU - Grimaldi, Massimo AU - Grimaldi M AD - Department of Cardiology, Ente Ecclesiastico Ospedale Generale Regionale 'F. Miulli', Acquaviva delle Fonti. LA - eng PT - Journal Article DEP - 20260410 PL - United States TA - J Cardiovasc Med (Hagerstown) JT - Journal of cardiovascular medicine (Hagerstown, Md.) JID - 101259752 SB - IM MH - *Transcatheter Aortic Valve Replacement/adverse effects/methods/statistics & numerical data MH - Registries/statistics & numerical data MH - Retrospective Studies MH - *Aortic Valve Stenosis/diagnosis/mortality/surgery MH - Hospital Mortality MH - *Postoperative Complications/epidemiology MH - Risk Factors MH - Emergency Treatment/statistics & numerical data MH - Treatment Outcome MH - Severity of Illness Index MH - Femoral Artery/surgery MH - Subclavian Artery/surgery MH - Computed Tomography Angiography MH - Electrocardiography MH - Aortic Valve/diagnostic imaging/surgery MH - Humans MH - Male MH - Female MH - Aged MH - Aged, 80 and over MH - Follow-Up Studies OTO - NOTNLM OT - Heart Team OT - Valve Academic Research Consortium-3 OT - aortic stenosis OT - on-site cardiac surgery OT - outcomes OT - transcatheter aortic valve implantation EDAT- 2026/05/01 18:44 MHDA- 2026/05/01 18:45 CRDT- 2026/05/01 12:22 PHST- 2025/12/19 00:00 [received] PHST- 2026/03/04 00:00 [accepted] PHST- 2026/05/01 18:45 [medline] PHST- 2026/05/01 18:44 [pubmed] PHST- 2026/05/01 12:22 [entrez] AID - 01244665-202604000-00003 [pii] AID - 10.2459/JCM.0000000000001875 [doi] PST - ppublish SO - J Cardiovasc Med (Hagerstown). 2026 Apr 1;27(4):268-276. doi: 10.2459/JCM.0000000000001875. Epub 2026 Apr 10. PMID- 42062387 OWN - NLM STAT- MEDLINE DCOM- 20260701 LR - 20260813 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 16 IP - 1 DP - 2026 Apr 30 TI - Management and outcomes of infective endocarditis in a community hospital and its cardiac surgery referral centre. LID - 10.1038/s41598-026-50918-z [doi] LID - 20049 AB - Despite advances in diagnosis and management, infective endocarditis (IE) remains a life-threatening condition with a high mortality rate. Most data originate from cardiac surgery centres, limiting our understanding of outcomes in community settings. Our aim was to compare the management and clinical outcomes of IE in a community hospital (HSJD) and its surgical referral centre (HSP) and to identify predictors of mortality. We conducted a retrospective cohort study (2018-2024) including all adult patients meeting the diagnostic criteria for IE. Mortality rates were compared across centres. Predictors of mortality were identified using Cox proportional hazards models. A total of 137 patients were included: 53 at HSJD and 84 at HSP. Definite IE was diagnosed more frequently at HSP (83.3% vs. 54.7%), and multidisciplinary endocarditis team discussions and use of advanced imaging were also more common. Thirty-day mortality did not differ significantly between centres (17.0% vs. 11.9%), nor during longer follow-up. Independent predictors of 30-day mortality included a higher Charlson Comorbidity Index, Staphylococcus aureus infection, and sepsis-related complications. Surgery was performed in 30% of patients diagnosed at HSJD and 43% of HSP patients. Among patients with a surgical indication, undergoing surgery was associated with a reduced risk of death across all follow-up periods. Patients who were not transferred to HSP were older, had higher comorbidity scores, and had a twofold increased risk of death compared with transferred patients. Mortality did not differ significantly between centres. These findings suggest that decentralised management of IE may be feasible while highlighting the importance of multidisciplinary collaboration, coordinated referral pathways, and access to advanced diagnostic resources. CI - (c) 2026. The Author(s). FAU - Jufresa-Michavila, Belen AU - Jufresa-Michavila B AD - Infectious Diseases Unit-Internal Medicine, Althaia Xarxa Assistencial Universitaria de Manresa, Manresa, Spain. AD - Fundacio Institut de Recerca i Innovacio en Ciencies de la Vida i de la Salut a la Catalunya Central (IRIS-CC), Vic, Spain. FAU - Bayes-Ricart, Cristina AU - Bayes-Ricart C AD - Facultat de Medicina, Universitat de Vic - Universitat Central de Catalunya, Vic, Spain. FAU - Grillo, Sara AU - Grillo S AD - Infectious Diseases Department, Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Spain. sgrillo@santpau.cat. AD - Servei de Malalties Infeccioses, Hospital de la Santa Creu i Sant Pau, Carrer de Sant Quinti, 89, Barcelona, 08025, Spain. sgrillo@santpau.cat. FAU - Consuegra-Perez, Miguel A AU - Consuegra-Perez MA AD - Infectious Diseases Department, Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Trujillo-Isern, Gloria AU - Trujillo-Isern G AD - Fundacio Institut de Recerca i Innovacio en Ciencies de la Vida i de la Salut a la Catalunya Central (IRIS-CC), Vic, Spain. AD - Microbiology Unit, Althaia Xarxa Assistencial Universitaria de Manresa, Manresa, Spain. FAU - Flor-Perez, Antonia AU - Flor-Perez A AD - Infectious Diseases Unit-Internal Medicine, Althaia Xarxa Assistencial Universitaria de Manresa, Manresa, Spain. AD - Fundacio Institut de Recerca i Innovacio en Ciencies de la Vida i de la Salut a la Catalunya Central (IRIS-CC), Vic, Spain. FAU - El Boutrouki, Omar AU - El Boutrouki O AD - Infectious Diseases Unit-Internal Medicine, Althaia Xarxa Assistencial Universitaria de Manresa, Manresa, Spain. AD - Fundacio Institut de Recerca i Innovacio en Ciencies de la Vida i de la Salut a la Catalunya Central (IRIS-CC), Vic, Spain. FAU - Villalba-Blanco, Naiara AU - Villalba-Blanco N AD - Infectious Diseases Unit-Internal Medicine, Althaia Xarxa Assistencial Universitaria de Manresa, Manresa, Spain. AD - Fundacio Institut de Recerca i Innovacio en Ciencies de la Vida i de la Salut a la Catalunya Central (IRIS-CC), Vic, Spain. FAU - Mico-Garcia, Miquel AU - Mico-Garcia M AD - Fundacio Institut de Recerca i Innovacio en Ciencies de la Vida i de la Salut a la Catalunya Central (IRIS-CC), Vic, Spain. AD - Microbiology Unit, Althaia Xarxa Assistencial Universitaria de Manresa, Manresa, Spain. FAU - Fernandez-Del Prado, Cesar AU - Fernandez-Del Prado C AD - Fundacio Institut de Recerca i Innovacio en Ciencies de la Vida i de la Salut a la Catalunya Central (IRIS-CC), Vic, Spain. AD - Cardiology Service, Althaia Xarxa Assistencial Universitaria de Manresa, Manresa, Spain. FAU - Escola-Verge, Laura AU - Escola-Verge L AD - Infectious Diseases Department, Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Crespo-Casal, Manuel AU - Crespo-Casal M AD - Infectious Diseases Unit-Internal Medicine, Althaia Xarxa Assistencial Universitaria de Manresa, Manresa, Spain. mcrespoc@althaia.cat. AD - Fundacio Institut de Recerca i Innovacio en Ciencies de la Vida i de la Salut a la Catalunya Central (IRIS-CC), Vic, Spain. mcrespoc@althaia.cat. AD - Facultat de Medicina, Universitat de Vic - Universitat Central de Catalunya, Vic, Spain. mcrespoc@althaia.cat. AD - Servei de Medicina Interna, Unitat de Malalties Infeccioses. Hospital San Joan de Deu, C/Dr. Joan Soler, 1-3, Manresa (Barcelona), 08243, Spain. mcrespoc@althaia.cat. LA - eng PT - Journal Article DEP - 20260430 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 SB - IM MH - Humans MH - *Hospitals, Community/statistics & numerical data MH - Retrospective Studies MH - Female MH - Male MH - *Endocarditis/mortality/surgery/therapy/diagnosis MH - *Cardiac Surgical Procedures MH - Referral and Consultation MH - Aged MH - Middle Aged MH - Treatment Outcome PMC - PMC13319464 OTO - NOTNLM OT - Cardiac surgical procedures OT - Community hospital OT - Infective endocarditis OT - Mortality OT - Referral hospital COIS- Declarations. Competing interests: The authors declare no competing interests. EDAT- 2026/05/01 00:32 MHDA- 2026/07/01 18:33 PMCR- 2026/04/30 CRDT- 2026/04/30 23:23 PHST- 2025/12/08 00:00 [received] PHST- 2026/04/24 00:00 [accepted] PHST- 2026/07/01 18:33 [medline] PHST- 2026/05/01 00:32 [pubmed] PHST- 2026/04/30 23:23 [entrez] PHST- 2026/04/30 00:00 [pmc-release] AID - 10.1038/s41598-026-50918-z [pii] AID - 50918 [pii] AID - 10.1038/s41598-026-50918-z [doi] PST - epublish SO - Sci Rep. 2026 Apr 30;16(1):20049. doi: 10.1038/s41598-026-50918-z. PMID- 42061508 OWN - NLM STAT- MEDLINE DCOM- 20260613 LR - 20260713 IS - 2174-2030 (Electronic) IS - 0870-2551 (Linking) VI - 45 IP - 6 DP - 2026 Jun TI - Myocarditis in athletes: Challenges for return to play. PG - 307-317 LID - S0870-2551(26)00123-X [pii] LID - 10.1016/j.repc.2026.02.006 [doi] AB - Myocarditis is a condition characterized by heterogeneous etiologies, clinical manifestations, and natural history. Its diagnosis remains challenging and requires a multidisciplinary approach that integrates clinical evaluation, biomarkers, electrocardiography, echocardiography, and advanced imaging modalities. Cardiac magnetic resonance has emerged as the non-invasive gold-standard test that together with endomyocardial biopsy, constitutes the foundation of the current diagnostic classification. Myocarditis is also a frequent acquired cause of sudden cardiac death in young individuals, including athletes. In this setting, the evaluation of return-to-play eligibility in athletes after acute myocarditis is complex and often limited by scarce evidence-based data. Accurate risk stratification, guided by a comprehensive multiparametric evaluation and a shared decision-making process that considers the potential risks of resuming competitive sport, is fundamental to ensuring athlete safety. This review aims to discuss the management of athletes with myocarditis and to address the challenges associated with return-to-play decisions. CI - Copyright (c) 2026 Sociedade Portuguesa de Cardiologia. Publicado por Elsevier Espana, S.L.U. All rights reserved. FAU - Dores, Helder AU - Dores H AD - Department of Cardiology, Hospital da Luz, Lisbon, Portugal; NOVA Medical School, Lisbon, Portugal; CHRC, Comprehensive Health Research Center; Associate Laboratory REAL (LA-REAL), Lisbon, Portugal; Health and Performance Department, Sport Lisboa e Benfica, Lisbon, Portugal; Centro de Medicina Desportiva de Lisboa, Lisbon, Portugal. Electronic address: heldores@hotmail.com. FAU - Dinis, Paulo AU - Dinis P AD - Department of Cardiology, Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal; Centro de Saude Militar de Coimbra, Exercito Portugues, Coimbra, Portugal. FAU - Puga, Luis AU - Puga L AD - Cardiology Department, Centro Hospitalar de Entre Douro e Vouga, Santa Maria da Feira, Portugal; Cardiology Department, Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal. FAU - Freitas, Antonio AU - Freitas A AD - Centro de Medicina Desportiva de Lisboa, Lisbon, Portugal; Department of Cardiology, Hospital Professor Doutor Fernando Fonseca, Lisbon, Portugal. FAU - Cardim, Nuno AU - Cardim N AD - NOVA Medical School, Lisbon, Portugal; Cardiology Department, Hospital CUF Descobertas, Lisbon, Portugal. LA - eng LA - por PT - Journal Article PT - Review DEP - 20260428 PL - Portugal TA - Rev Port Cardiol JT - Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology JID - 8710716 SB - IM MH - Humans MH - *Myocarditis/diagnosis/therapy MH - *Return to Sport MH - Athletes OTO - NOTNLM OT - Athlete OT - Atleta OT - Miocardite OT - Morte subita cardiaca OT - Myocarditis OT - Retorno a pratica desportiva OT - Return to play OT - Shared-decision OT - Sudden cardiac death OT - Tomada de decisao partilhada EDAT- 2026/05/01 00:32 MHDA- 2026/06/15 11:33 CRDT- 2026/04/30 19:13 PHST- 2026/01/29 00:00 [received] PHST- 2026/02/13 00:00 [revised] PHST- 2026/02/23 00:00 [accepted] PHST- 2026/06/15 11:33 [medline] PHST- 2026/05/01 00:32 [pubmed] PHST- 2026/04/30 19:13 [entrez] AID - S0870-2551(26)00123-X [pii] AID - 10.1016/j.repc.2026.02.006 [doi] PST - ppublish SO - Rev Port Cardiol. 2026 Jun;45(6):307-317. doi: 10.1016/j.repc.2026.02.006. Epub 2026 Apr 28. PMID- 42061505 OWN - NLM STAT- MEDLINE DCOM- 20260928 LR - 20261002 IS - 1885-5857 (Electronic) IS - 1885-5857 (Linking) VI - 79 IP - 10 DP - 2026 Oct TI - Management and follow-up of patients with infective endocarditis: an international cross-sectional survey. PG - 850-862 LID - S1885-5857(26)00078-2 [pii] LID - 10.1016/j.rec.2026.04.001 [doi] AB - INTRODUCTION AND OBJECTIVES: To describe international practices in the management and follow-up of infective endocarditis. METHODS: We conducted an anonymous web-based survey between October 15 and November 15, 2025, disseminated through European Society of Clinical Microbiology and Infectious Diseases (ESCMID) study groups and national and international societies. The questionnaire comprised 7 sections covering endocarditis team and cardiac surgery availability, inpatient management, and follow-up. Responses were described and compared according to country income (chi-square or Fisher's exact test, P<.05). RESULTS: In total, 298 respondents from 49 countries completed the survey. An onsite endocarditis team and onsite cardiac surgery were reported by 53% (159) and 67% (200) of respondents, respectively. In addition, 81% of respondents (242) stated that blood cultures were obtained until clearance of bacteremia, and 61% (183) indicated that echocardiography was performed during treatment. Postdischarge follow-up was mainly coordinated by infectious diseases specialists (70% of respondents, 207). Moreover, 56% of respondents (168) reported that a final echocardiogram was performed, and 25% (74) reported that post-treatment blood cultures were performed. Follow-up duration was up to 6 months for 56% of respondents (169) and> 6 months for 44% (129). Centers in high-income countries more frequently had an endocarditis team (138/218 [63%] vs 21/80 [26%]; P <.001), transesophageal echocardiography (210/218 [96%] vs 61/80 [76%]; P <.001), and positron emission tomography-computed tomography (175/218 [80%] vs 36/80 [45%]; P <.001) and performed serial blood cultures (186/218 [85%] vs 56/80 [70%]; P=.007) and post-treatment blood cultures (67/218 [31%] vs 7/80 [9%]; P <.001). CONCLUSIONS: Substantial variability exists in the organization, monitoring, and follow-up of endocarditis. Consensus-based and evidence-informed strategies are needed to harmonize care. CI - Copyright (c) 2026 Sociedad Espanola de Cardiologia. Published by Elsevier Espana, S.L.U. All rights reserved. FAU - Escola-Verge, Laura AU - Escola-Verge L AD - Servicio de Enfermedades Infecciosas, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Institut de Recerca Sant Pau (IR SANT PAU), Barcelona, Spain; Departamento de Medicina, Universidad Autonoma de Barcelona, Barcelona, Spain; Centro de Investigacion Biomedica en Red de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain. Electronic address: lescola@santpau.cat. FAU - Mathe, Philipp AU - Mathe P AD - Division of Infectious Diseases, Department of Medicine II, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany. FAU - Isler, Burcu AU - Isler B AD - Infectious Diseases Department, Gold Coast University Hospital, Australia; Faculty of Health, Medicine and Behavioural Sciences, University of Queensland, Brisbane, Australia; Department of Medicine, School of Medicine and Dentistry, Griffith University, Gold Coast Campus, Australia. FAU - Bartoletti, Michele AU - Bartoletti M AD - Department of Biomedical Sciences, Humanitas University, Milan, Italy; Infectious Disease Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. FAU - Rieg, Siegbert AU - Rieg S AD - Division of Infectious Diseases, Department of Medicine II, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany. FAU - Lamy, Brigitte AU - Lamy B AD - Universite Sorbonne Paris Nord and Universite Paris Cite, Inserm Infection Antimicrobials Modelling Evolution (IAME), Hopitaux Universitaires Paris Seine Saint-Denis, Service de Microbiologie, Bobigny, France. FAU - Grillo, Sara AU - Grillo S AD - Servicio de Enfermedades Infecciosas, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Institut de Recerca Sant Pau (IR SANT PAU), Barcelona, Spain; Departamento de Medicina, Universidad Autonoma de Barcelona, Barcelona, Spain. FAU - Villamarin, Miguel AU - Villamarin M AD - Servicio de Enfermedades Infecciosas, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Institut de Recerca Sant Pau (IR SANT PAU), Barcelona, Spain; Departamento de Medicina, Universidad Autonoma de Barcelona, Barcelona, Spain. FAU - Tattevin, Pierre AU - Tattevin P AD - Department of Infectious Diseases and Intensive Care Unit, Pontchaillou University Hospital, Rennes, France. FAU - Fernandez-Hidalgo, Nuria AU - Fernandez-Hidalgo N AD - Departamento de Medicina, Universidad Autonoma de Barcelona, Barcelona, Spain; Centro de Investigacion Biomedica en Red de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain; Servicio de Enfermedades Infecciosas, Hospital Universitari Vall d'Hebron, Barcelona, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain. CN - ESCMID Study Group for Bloodstream Infections, Endocarditis, Sepsis (ESGBIES) LA - eng LA - spa PT - Journal Article PT - Multicenter Study DEP - 20260428 PL - Spain TA - Rev Esp Cardiol (Engl Ed) JT - Revista espanola de cardiologia (English ed.) JID - 101587954 SB - IM MH - Humans MH - Cross-Sectional Studies MH - *Endocarditis/therapy/diagnosis/epidemiology MH - Follow-Up Studies MH - Surveys and Questionnaires MH - *Disease Management MH - Echocardiography MH - Cardiac Surgical Procedures OTO - NOTNLM OT - Abordaje OT - Clinical practice OT - Encuesta OT - Endocarditis infecciosa OT - Follow-up OT - Infective endocarditis OT - Low- and middle-income countries OT - Management OT - Paises de ingreso medio-bajo OT - Practica clinica OT - Seguimiento OT - Survey EDAT- 2026/05/01 00:31 MHDA- 2026/09/28 23:28 CRDT- 2026/04/30 19:13 PHST- 2026/02/06 00:00 [received] PHST- 2026/04/13 00:00 [accepted] PHST- 2026/09/28 23:28 [medline] PHST- 2026/05/01 00:31 [pubmed] PHST- 2026/04/30 19:13 [entrez] AID - S1885-5857(26)00078-2 [pii] AID - 10.1016/j.rec.2026.04.001 [doi] PST - ppublish SO - Rev Esp Cardiol (Engl Ed). 2026 Oct;79(10):850-862. doi: 10.1016/j.rec.2026.04.001. Epub 2026 Apr 28. PMID- 42061288 OWN - NLM STAT- MEDLINE DCOM- 20260714 LR - 20260813 IS - 1808-8686 (Electronic) IS - 1808-8694 (Print) IS - 1808-8686 (Linking) VI - 92 IP - 4 DP - 2026 Jul-Aug TI - Siltation and tidal effects: a comprehensive, clinical, and didactic approach to reasoning about vertebrobasilar hypoflow conditions. PG - 101822 LID - S1808-8694(26)00071-6 [pii] LID - 10.1016/j.bjorl.2026.101822 [doi] LID - 101822 AB - OBJECTIVES: To propose a clinically applicable model for understanding vertebrobasilar hypoperfusion by categorizing its causes into two mechanisms: the siltation effect, related to local vascular obstruction, and the tidal effect, related to systemic reduction in posterior circulation blood flow. METHODS: A non-systematic narrative review was conducted using selected literature in the fields of neurotology, vascular neurology, and cardiovascular medicine. The analogy of coastal rivers affected by sedimentation and tides was used to explain the proposed classification. Clinical examples were drawn from studies on vertebral artery narrowing, subclavian steal syndrome, dolichoectasia, small vessel pathology, orthostatic hypotension, cardiac disorders, anemia, and abnormal blood pressure regulation. RESULTS: The siltation effect includes conditions that block or reduce blood flow within the vertebrobasilar system, such as atherosclerosis, vessel compression, and dissection. The tidal effect includes disorders that globally impair perfusion, such as heart failure, low blood pressure, reduced oxygen delivery, and circadian blood pressure extremes. Combined situations, such as arterial hypotension, vessel stenosis, sleep disorders and migraine are common and may increase the risk of transient ischemic events or stroke. CONCLUSION: The distinction between siltation and tidal effects provides a useful clinical reasoning model for diagnosing and managing patients with symptoms suggestive of vertebrobasilar hypoflow, including vertigo, dizziness, and transient brainstem symptoms. Recognizing the frequent coexistence of these mechanisms reinforces the need for a comprehensive, multidisciplinary approach to ensure accurate diagnosis and guide appropriate therapeutic decision-making. CI - Copyright (c) 2026 The Author(s). Published by Elsevier Espana S.L.U. All rights reserved. FAU - Neto, Arlindo Cardoso Lima AU - Neto ACL AD - Universidade de Sao Paulo, Department of Otorhinolaryngology, Sao Paulo, SP, Brazil. Electronic address: aclimanetoent@gmail.com. FAU - Mezzalira, Raquel AU - Mezzalira R AD - Universidade de Campinas, Faculdade de Ciencias Medicas, Discipline of Otorhinolaryngology, Head and Neck, Campinas, SP, Brazil. FAU - Bittar, Roseli Saraiva Moreira AU - Bittar RSM AD - Universidade de Sao Paulo, Department of Otorhinolaryngology, Sao Paulo, SP, Brazil. LA - eng PT - Journal Article PT - Review DEP - 20260429 PL - Brazil TA - Braz J Otorhinolaryngol JT - Brazilian journal of otorhinolaryngology JID - 101207337 SB - IM MH - Humans MH - *Vertebrobasilar Insufficiency/physiopathology/etiology/diagnosis MH - Cerebrovascular Circulation/physiology PMC - PMC13141512 OTO - NOTNLM OT - Cerebrovascular circulation OT - Hemodynamics OT - Vertebrobasilar insufficiency OT - Vertigo dizziness COIS- Declaration of competing interest The authors declare no conflicts of interest. EDAT- 2026/05/01 00:32 MHDA- 2026/07/14 06:34 PMCR- 2026/04/29 CRDT- 2026/04/30 18:19 PHST- 2025/07/28 00:00 [received] PHST- 2025/11/17 00:00 [revised] PHST- 2026/01/19 00:00 [accepted] PHST- 2026/07/14 06:34 [medline] PHST- 2026/05/01 00:32 [pubmed] PHST- 2026/04/30 18:19 [entrez] PHST- 2026/04/29 00:00 [pmc-release] AID - S1808-8694(26)00071-6 [pii] AID - 101822 [pii] AID - 10.1016/j.bjorl.2026.101822 [doi] PST - ppublish SO - Braz J Otorhinolaryngol. 2026 Jul-Aug;92(4):101822. doi: 10.1016/j.bjorl.2026.101822. Epub 2026 Apr 29. PMID- 42060546 OWN - NLM STAT- MEDLINE DCOM- 20260716 LR - 20260818 IS - 1816-5370 (Electronic) IS - 0218-4923 (Linking) VI - 34 IP - 5 DP - 2026 Jun TI - The 2025 Accra Declaration on Upskilling and Cost- Effective Cardiac Surgery in Africa. PG - 419-429 LID - 10.1177/02184923251369134 [doi] AB - The Pan-African Society for Cardiothoracic Surgery (PASCaTS) organized the 1st Pan-African Cardiothoracic Surgery Summit on 21 to 24 February 2025 in Accra, Ghana. The summit brought together leading specialists from across Africa, China, Europe, South America and the USA to address the growing burden of cardiovascular disease, to share their vision for the fi ght against cardiovascular disease, to raise standards in the diagnosis, treatment and recovery of patients thereby improving procedural safety and clinical outcomes in Africa. The experts agreed on the need for cost effectiveness in cardiac surgery, simulation skills training, an African regional cardiothoracic surgery database, African heart team fellowship programs and specialized working groups to guide cardiovascular diagnostics and treatments focusing on critical areas such as congenital heart surgery, valve surgery and coronary artery bypass surgery (CABG) procedures which are becoming increasingly necessary in Africa due to the rise in cardiovascular emergencies, and fi nally explore solutions tailored to the continent's unique healthcare challenges. The incentives generated from the summit are formulated as the "2025 Accra Declaration" to serve as roadmaps and implementable guidelines for promoting high-level cardiovascular surgery and reforms in Africa in collaboration with cardiologists and other allied cardiovascular professionals. FAU - Yankah, A Charles AU - Yankah AC AD - Humanitarian Cardiac Surgery, Global Heart Care, Berlin, Germany. AD - Department of Cardiothoracic Surgery, German Heart Center Charite, Berlin, Germany. FAU - Nwiloh, Jonathan AU - Nwiloh J AD - Department of Cardiothoracic Surgery, Dr. Joe Nwiloh Heart Center, Adazi Nnukwu, Nigeria. FAU - Mestres, Carlos A AU - Mestres CA AUID- ORCID: 0000-0001-8148-9044 AD - Department of Cardiothoracic Surgery, University of the Free State, Bloemfontein, South Africa. RINGGOLD: 37702 FAU - Bouzid, Abdelmalek AU - Bouzid A AD - Department of Cardiovascular Surgery, University of Algiers, Algiers, Algeria. FAU - Mwambu, Tom Philip AU - Mwambu TP AD - Department of Cardiothoracic Surgery, Uganda Heart Institute, Kampala, Uganda. RINGGOLD: 249322 FAU - Duncan, Andrew J AU - Duncan AJ AD - Department of Cardiothoracic Surgery, Aga Khan University, Nairobi, Kenya. FAU - Debieche, Mohamed AU - Debieche M AD - Department of Cardiovascular Surgery, University of Blida, Blida, Algeria. FAU - Omokhodion, Samuel I AU - Omokhodion SI AD - Institute of Cardiovascular Diseases, University of Ibadan, Ibadan, Nigeria. RINGGOLD: 58987 FAU - Onakpoya, Uvie U AU - Onakpoya UU AD - Department of Cardiothoracic Surgery, Obafemi Awolowo University, Ile-Ife, Nigeria. RINGGOLD: 54715 FAU - Angres, Matthias AU - Angres M AD - Aswan Heart Center, Intensive Care Unit, Aswan, Egypt. RINGGOLD: 470323 FAU - Nademo, Siyasebow M AU - Nademo SM AD - Department of Cardiothoracic Surgery, Hawassa University, Sidama, Ethiopia. RINGGOLD: 128167 FAU - Oburu, Gilbert AU - Oburu G AD - Department of Cardiothoracic Surgery, Kenyatta National University, Nairobi, Kenya. FAU - Yao, Nana-Akyaa AU - Yao NA AD - Congenital & Pediatric Cardiology, Korle Bu Teaching Hospital, National Cardiothoracic Center, Accra, Ghana. RINGGOLD: 285284 FAU - Entsua-Mensah, Kow AU - Entsua-Mensah K AD - National Cardiothoracic Center, Accra, Ghana. FAU - Reddy, Darshan AU - Reddy D AUID- ORCID: 0009-0001-3868-1695 AD - Lenmed Ethekwini Hospital & Heart Center, Durban, South Africa. FAU - Antunes, Manuel AU - Antunes M AUID- ORCID: 0000-0002-6192-9134 AD - Cardiothoracic Surgery, University of Coimbra, Portugal. RINGGOLD: 37830 FAU - Gomes, Walter J AU - Gomes WJ AD - Department of Cardiovascular Surgery, Federal University of Sao Paulo, Sao Paulo, Brazil. FAU - Akamah, Joseph A AU - Akamah JA AD - Department of Cardiology, University of Nashville, Nashville, United States. FAU - Yigitbasi, Mustafa AU - Yigitbasi M AD - Pediatric Cardiology Clinic, Berlin, Germany. FAU - Buys, Daniel Gerhard AU - Buys DG AD - Department of Pediatric Cardiology, University of the Free State, Bloemfontein, South Africa. RINGGOLD: 37702 FAU - Bokenkamp, Regina AU - Bokenkamp R AD - Department of Pediatric Cardiology, University Medical Center Leiden, Leiden, Netherlands. FAU - Koen, Willie AU - Koen W AD - Department of Cardiothoracic Surgery, Christiaan Barnard Memorial Hospital, Cardiac, Transplant Program, Cape Town, South Africa. FAU - Smit, Francis E AU - Smit FE AUID- ORCID: 0000-0002-2398-0617 AD - Department of Cardiothoracic Surgery, University of the Free State, Bloemfontein, South Africa. RINGGOLD: 37702 FAU - Chikwe, Joanna AU - Chikwe J AD - Department of Cardiac Surgery, Cedars Sinai Medical Center, Smidt Heart Institute, Los Angeles, United States. RINGGOLD: 22494 LA - eng PT - Conference Proceedings DEP - 20260430 PL - England TA - Asian Cardiovasc Thorac Ann JT - Asian cardiovascular & thoracic annals JID - 9503417 SB - IM MH - Humans MH - Africa/epidemiology MH - *Cardiac Surgical Procedures/economics/education/standards/adverse effects MH - Cost-Benefit Analysis MH - *Health Care Costs MH - Treatment Outcome MH - Value-Based Health Care OTO - NOTNLM OT - Accra declaration OT - Africa OT - access to cardiac surgery OT - cost effective cardiac surgery OT - global heart forum OT - pan-African society for cardiothoracic surgery OT - structural heart disease EDAT- 2026/04/30 18:32 MHDA- 2026/05/29 15:44 CRDT- 2026/04/30 13:23 PHST- 2026/05/29 15:44 [medline] PHST- 2026/04/30 18:32 [pubmed] PHST- 2026/04/30 13:23 [entrez] AID - 10.1177/02184923251369134 [doi] PST - ppublish SO - Asian Cardiovasc Thorac Ann. 2026 Jun;34(5):419-429. doi: 10.1177/02184923251369134. Epub 2026 Apr 30. PMID- 42059910 OWN - NLM STAT- Publisher LR - 20260505 IS - 1538-4683 (Electronic) IS - 1061-5377 (Linking) DP - 2026 Apr 29 TI - Mitral Annular Calcification. LID - 10.1097/CRD.0000000000001286 [doi] AB - Mitral annular calcification (MAC) is a chronic degenerative process strongly associated with aging that predominantly affects the posterior mitral annulus. Its pathogenesis is linked to traditional cardiovascular risk factors that increase mechanical stress and inflammation, promoting pathological cellular differentiation within the annulus. MAC prevalence in the general population is approximately 8-15%, with 8% of affected patients developing clinically significant valvular disease, defined as mitral stenosis or moderate or greater mitral regurgitation. Patients with MAC are at higher risk of cardiovascular mortality and complications, including the development of atrial fibrillation, the development of conduction disorders, and often have signs of coronary or systemic atherosclerosis. Transthoracic echocardiogram remains the first-line imaging modality for the diagnosis of MAC, while cardiac-gated computed tomography is valuable for quantifying severity and progression while also guiding procedural planning. Though management is often conservative, in patients who have clinically significant valvular dysfunction, MAC can present a challenge when planning valvular interventions, and a multidisciplinary approach is often required. CI - Copyright (c) 2026 Wolters Kluwer Health, Inc. All rights reserved. FAU - Oprysko, Carson AU - Oprysko C AD - From the Department of Cardiology, Nassau University Medical Center, East Meadow, NY. FAU - Prabhakar, Chinmayi AU - Prabhakar C AD - Department of Medicine, Nassau University Medical Center, East Meadow, NY. FAU - Berman, Lorin AU - Berman L AD - From the Department of Cardiology, Nassau University Medical Center, East Meadow, NY. FAU - Staroselsky, Mark AU - Staroselsky M AD - From the Department of Cardiology, Nassau University Medical Center, East Meadow, NY. FAU - Fishkin, Tzvi AU - Fishkin T AD - From the Department of Cardiology, Nassau University Medical Center, East Meadow, NY. FAU - Hai, Ofek AU - Hai O AD - From the Department of Cardiology, Nassau University Medical Center, East Meadow, NY. FAU - Frishman, William H AU - Frishman WH AD - Department of Medicine, Westchester Medical Center, New York Medical College, Valhalla, NY. FAU - Aronow, Wilbert S AU - Aronow WS AD - Department of Medicine, Westchester Medical Center, New York Medical College, Valhalla, NY. LA - eng PT - Journal Article DEP - 20260429 PL - United States TA - Cardiol Rev JT - Cardiology in review JID - 9304686 SB - IM OTO - NOTNLM OT - mitral annular calcification OT - mitral regurgitation OT - mitral stenosis COIS- Disclosure: The authors declare no conflicts of interest. EDAT- 2026/04/30 12:35 MHDA- 2026/04/30 12:35 CRDT- 2026/04/30 11:03 PHST- 2026/04/30 12:35 [pubmed] PHST- 2026/04/30 12:35 [medline] PHST- 2026/04/30 11:03 [entrez] AID - 00045415-990000000-00831 [pii] AID - 10.1097/CRD.0000000000001286 [doi] PST - aheadofprint SO - Cardiol Rev. 2026 Apr 29. doi: 10.1097/CRD.0000000000001286. PMID- 42059855 OWN - NLM STAT- MEDLINE DCOM- 20260616 LR - 20260620 IS - 1558-3597 (Electronic) IS - 0735-1097 (Linking) VI - 87 IP - 23 DP - 2026 Jun 16 TI - Automated Alerts to Improve Timely Evaluation and Treatment of Valvular Heart Disease: The ALERT Trial. PG - 3335-3346 LID - S0735-1097(26)05833-X [pii] LID - 10.1016/j.jacc.2026.03.037 [doi] AB - BACKGROUND: Severe aortic stenosis (AS) and mitral regurgitation (MR) are frequently undertreated and characterized by persistent sex, racial and ethnic, socioeconomic, and geographic disparities despite effective valve therapies. Whether automated electronic clinician notification (ECN) alerts improve the evaluation and treatment of AS and MR across health systems is unknown. OBJECTIVES: The purpose of this study was to evaluate whether ECN alerts improve guideline-directed evaluation and treatment of significant AS and MR across multiple health systems. METHODS: ALERT is a multisystem, cluster-randomized clinical trial including clinicians ordering echocardiograms across 5 U.S. health systems encompassing 35 hospitals between August 2024 and September 2025. Clinicians were randomized 1:1 to receive an ECN alert identifying significant AS or MR with accompanying care recommendations or to no alert with usual care. The primary endpoint was a hierarchical composite of time to surgical or transcatheter valve intervention, followed by time to multidisciplinary heart team clinic evaluation within 90 days, analyzed using the stratified win-ratio method. Secondary outcomes included individual components of the composite. RESULTS: A total of 765 clinicians ordering 2,016 echocardiograms were included. In the win-ratio analysis of the primary endpoint, ECN alert was superior to usual care (win ratio: 1.27; 95% CI: 1.05-1.54; P = 0.007), including higher rates of valve intervention (13.4% vs 9.6%; P = 0.005) and multidisciplinary heart team evaluation (22.7% vs 17.9%; P = 0.005) and shorter times to both endpoint components. Effect sizes were similar in AS (win ratio: 1.29) and MR patients (win ratio: 1.23). No evidence of heterogeneity was noted by valve pathology (P(int) = 0.821) or across prespecified subgroups (age, sex, race, social deprivation index, inpatient vs outpatient setting, provider specialty, and rurality; P(int) > 0.100 for all) and sensitivity analyses yielded consistent results across modified intention-to-treat, intention-to-treat, and per-protocol populations. CONCLUSIONS: In this multisystem cluster randomized trial, automated ECN alerts improved timely guideline-directed evaluation and valve intervention for clinically significant AS and MR. These findings suggest that electronic health record-integrated clinical decision support may represent a scalable strategy to reduce undertreatment and improve access to specialized valve care. (Addressing Under-treatment and Health Equity in AS and MR Using an Integrated EHR Platform; NCT06099665). CI - Copyright (c) 2026 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Batchelor, Wayne B AU - Batchelor WB AD - Inova Medicine Service Line and Schar Heart and Vascular, Inova Health System, Fairfax, Virginia, USA. Electronic address: Wayne.Batchelor@inova.org. FAU - Lindman, Brian R AU - Lindman BR AD - Cardiovascular Disease, Structural Heart and Valve Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA. FAU - Coylewright, Megan AU - Coylewright M AD - Heart and Vascular Center, Essentia Health, Duluth, Minnesota, USA. FAU - Keller, Antoine AU - Keller A AD - Oschner Lafayette General, Lafayette, Louisiana, USA. FAU - Wehman, Brody AU - Wehman B AD - Heart and Vascular Institute, Bon Secours Mercy Health, Richmond, Virginia, USA. FAU - Chhatriwalla, Adnan AU - Chhatriwalla A AD - Department of Cardiovascular Medicine, Saint Luke's Mid America Heart Institute, Kansas City, Missouri, USA. FAU - Patel, Sandeep M AU - Patel SM AD - Department of Interventional Cardiology, Division of Cardiology, Bon Secours Mercy Health, Lima, Ohio, USA. FAU - Stiver, Kevin AU - Stiver K AD - Department of Cardiology, OhioHealth, Columbus, Ohio, USA. FAU - Zahr, Firas AU - Zahr F AD - Interventional Cardiology, Oregon Health and Science University, Portland, Oregon, USA. FAU - Sotelo, Miguel AU - Sotelo M AD - Data Science, Tempus AI, Inc. Chicago, Illinois, USA. FAU - Shin, Dongho AU - Shin D AD - Biostats, Tempus AI, Inc, Chicago, Illinois, USA. FAU - Rogers, Chris AU - Rogers C AD - Cardiovascular, Tempus AI, Inc, Chicago, Illinois, USA. FAU - Hickey, Graeme L AU - Hickey GL AD - Structural Heart and Aortic, Medtronic, Minneapolis, Minnesota, USA. FAU - Williams, Jamie AU - Williams J AD - Structural Heart and Aortic, Medtronic, Minneapolis, Minnesota, USA. FAU - Fan, Myra AU - Fan M AD - Structural Heart and Aortic, Medtronic, Minneapolis, Minnesota, USA. FAU - Vemulapalli, Sreekanth AU - Vemulapalli S AD - Department of Medicine, Division of Cardiology, Duke University School of Medicine, Durham, North Carolina, USA. LA - eng SI - ClinicalTrials.gov/NCT06099665 PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial DEP - 20260329 PL - United States TA - J Am Coll Cardiol JT - Journal of the American College of Cardiology JID - 8301365 SB - IM MH - Humans MH - Female MH - Male MH - *Mitral Valve Insufficiency/diagnosis/therapy MH - Echocardiography MH - Aged MH - United States MH - *Aortic Valve Stenosis/diagnosis/therapy MH - *Heart Valve Diseases/diagnosis/therapy OTO - NOTNLM OT - aortic stenosis OT - automated notifications OT - clinician decision support OT - electronic health record OT - health equity OT - mitral regurgitation COIS- Funding Support and Author Disclosures This study was funded by Tempus AI, Inc (Chicago, Illinois), and Medtronic, Plc (Minneapolis, Minnesota). Dr Batchelor has served as a consultant for Medtronic, Boston Scientific, Edwards Lifesciences, and Abbott; and has received investigator-initiated grants from Abbott and Boston Scientific. Dr Lindman has received investigator-initiated research grants from Edwards Lifesciences; and has consulted for Edwards Lifesciences, Medtronic, Anteris, AstraZeneca, and Kardigan. Dr Coylewright has served as a consultant for Medtronic, Boston Scientific, Edwards Lifesciences, Alleviant, and Recor Medical; and has received investigator-initiated grants from Edwards Lifesciences. Dr Chhatriwalla has received an investigator-initiated research grant from Boston Scientific; and has served as a consultant for Abbott Vascular, Edwards Lifesciences, and Medtronic Inc. Dr Patel has served as a speaker/consultant for Medtronic and Boston Scientific. Dr Zahr serves as consultant and research and educational grant recipient from Edwards, Medtronic, Philips, and GE. Prof Hickey, Jamie Williams, and Myra Fan are employees and shareholders of Medtronic. Prof Sotelo, Prof Shin, and Chris Rogers are employees of and hold stock in Tempus AI, Inc. Dr Vemulapalli has received grants/contracts from Edwards Lifesciences, Abbott, Boston Scientific, and Cytokinetics; and has received consulting/advisory from Medtronic, Edwards Lifesciences, and Abbott. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2026/04/30 12:35 MHDA- 2026/06/16 13:31 CRDT- 2026/04/30 10:28 PHST- 2026/02/17 00:00 [received] PHST- 2026/03/11 00:00 [revised] PHST- 2026/03/13 00:00 [accepted] PHST- 2026/06/16 13:31 [medline] PHST- 2026/04/30 12:35 [pubmed] PHST- 2026/04/30 10:28 [entrez] AID - S0735-1097(26)05833-X [pii] AID - 10.1016/j.jacc.2026.03.037 [doi] PST - ppublish SO - J Am Coll Cardiol. 2026 Jun 16;87(23):3335-3346. doi: 10.1016/j.jacc.2026.03.037. Epub 2026 Mar 29. PMID- 42058876 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260430 LR - 20260813 IS - 2666-5204 (Electronic) IS - 2666-5204 (Linking) VI - 29 DP - 2026 May TI - The impact of interdisciplinary cardiac arrest teams on paramedic practise: an interpretive qualitative study using reflexive thematic analysis. PG - 101317 LID - 10.1016/j.resplu.2026.101317 [doi] LID - 101317 AB - OBJECTIVES: This study examined paramedics' perceptions of the influence of a specialist out-of-hospital cardiac arrest (OHCA) extracorporeal cardiopulmonary resuscitation (ECPR) team on their resuscitation practise and professional development. METHODS: An interpretive qualitative methodology was employed. A purposive sample of 379 NSW Ambulance paramedics who attended an OHCA alongside the PRECARE team was invited to complete an anonymous online survey, of whom 67 participated. The survey included demographic questions for sample context and open-ended, non-leading questions designed to capture in-depth insights. Reflexive thematic analysis was conducted collaboratively by multiple authors, guided by the principle of theoretical sufficiency. RESULTS: Five themes were identified: Mentorship, Empowerment, Understanding and Development, Cause-Directed Care and Collaborative Care. Participants frequently described PRECARE's real-time mentoring and post-event debriefs as influential in shaping their clinical confidence and skill development. Working alongside PRECARE teams was reported to enhance participants' understanding of OHCA physiology and pathophysiology, evidence-based interventions, and the importance of cause-directed and individualised care. Paramedics also described changes in motivation, accountability, and non-technical skills such as leadership and communication. Alongside these perspectives, some participants described challenges related to role clarity, leadership dynamics, and operational priorities. CONCLUSIONS: The integration of specialist interdisciplinary OHCA teams was perceived to influence paramedics' clinical practise and professional development by contributing to a psychologically safe working environment and providing experiential learning opportunities, including real-time mentorship and reflective post-event debriefing. This interdisciplinary collaboration was associated with increased confidence, perceived strengthening of non-technical skills, and a shift toward more nuanced, cause-directed care, while also highlighting the importance of clear role delineation and alignment of operational priorities when integrating specialist teams into established EMS systems. CI - (c) 2026 The Author(s). FAU - Tant, Jacob AU - Tant J AD - Aeromedical Operations, New South Wales Ambulance, Sydney, New South Wales, Australia. AD - School of Health Sciences, Western Sydney University, Sydney, New South Wales, Australia. FAU - Buckthought, Jackie AU - Buckthought J AD - Aeromedical Operations, New South Wales Ambulance, Sydney, New South Wales, Australia. FAU - Scianski, Ashleigh AU - Scianski A AD - School of Health Sciences, Western Sydney University, Sydney, New South Wales, Australia. AD - Clinical Operations, New South Wales Ambulance, Sydney, New South Wales, Australia. FAU - Xu, Izabelle AU - Xu I AD - Clinical Operations, New South Wales Ambulance, Sydney, New South Wales, Australia. FAU - Burns, Brian AU - Burns B AD - Aeromedical Operations, New South Wales Ambulance, Sydney, New South Wales, Australia. AD - Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia. FAU - Kruit, Natalie AU - Kruit N AD - Aeromedical Operations, New South Wales Ambulance, Sydney, New South Wales, Australia. AD - Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia. LA - eng PT - Journal Article DEP - 20260407 PL - Netherlands TA - Resusc Plus JT - Resuscitation plus JID - 101774410 PMC - PMC13123611 OTO - NOTNLM OT - ECPR OT - Interprofessional teams OT - Multidisciplinary teams OT - OHCA OT - Paramedic COIS- The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/04/30 06:34 MHDA- 2026/04/30 06:35 PMCR- 2026/04/07 CRDT- 2026/04/30 04:56 PHST- 2025/12/10 00:00 [received] PHST- 2026/04/01 00:00 [revised] PHST- 2026/04/02 00:00 [accepted] PHST- 2026/04/30 06:35 [medline] PHST- 2026/04/30 06:34 [pubmed] PHST- 2026/04/30 04:56 [entrez] PHST- 2026/04/07 00:00 [pmc-release] AID - S2666-5204(26)00102-5 [pii] AID - 101317 [pii] AID - 10.1016/j.resplu.2026.101317 [doi] PST - epublish SO - Resusc Plus. 2026 Apr 7;29:101317. doi: 10.1016/j.resplu.2026.101317. eCollection 2026 May. PMID- 42057615 OWN - NLM STAT- MEDLINE DCOM- 20260827 LR - 20260829 IS - 2690-7097 (Electronic) IS - 2690-7097 (Linking) VI - 7 IP - 3 DP - 2026 Sep 1 TI - Right heart catheterization blended training program: quality improvement and educational outcomes. PG - 192-200 LID - 10.1093/atsscholar/aapag022 [doi] AB - BACKGROUND: Accurate measurement and reporting of pulmonary arterial wedge pressure (PAWP) and cardiac output (CO) are essential for diagnosing and managing pulmonary hypertension and pulmonary arterial hypertension (PAH). Errors in these parameters can lead to misclassification and inappropriate treatment. Recent updates from the 2023 European Respiratory Society/European Society of Cardiology guidelines and the 2024 Seventh World Symposium on Pulmonary Hypertension emphasize the need for standardized right heart catheterization (RHC) practices. OBJECTIVE: To identify knowledge gaps in RHC practices among interprofessional team members and implement a targeted blended learning program developed for pulmonary critical care and cardiology fellows, with a focus on accurate acquisition and interpretation of PAWP and CO. METHODS: Using the SQUIRE framework, we conducted a baseline survey assessing RHC practices and knowledge among pulmonary critical care and cardiology attending physicians and fellows and critical care nurses at an academic medical center. Respondents were actively involved in RHC procedures across the cardiac catheterization laboratory, medical intensive care unit, and cardiac care unit. Survey items with < 70% correct response were used to guide development of a 120-minute blended learning program incorporating lectures, video instruction, and hands-on-simulation. Pre- and posttraining assessments were conducted. RESULTS: Of 141 invited participants, 85 responded to the survey (60.3% response rate). Baseline data revealed knowledge gaps and therefore opportunities for learning in CO measurement methods and PAWP interpretation. Assessment postblended learning program demonstrated knowledge improvements in key areas including identification of indirect Fick (iFick) as the most common CO method, confirmation of zero-reference level by the proceduralist-nurse team, acquisition of PAWP, and obtaining at least 3 measurements of CO via thermodilution. However, correct identification of end-expiratory PAWP declined, highlighting the need for greater emphasis on this skill in future training sessions. CONCLUSION: This is the first reported interprofessional training initiative to target CO and PAWP measurement accuracy in RHC. This study identified key knowledge gaps and therefore opportunities for learning. Knowledge improvements measured after the educational intervention support the need for ongoing, structured, and interprofessional training to enhance procedural competency and interpretation of RHC hemodynamic data to optimize pulmonary hypertension and PAH care. CI - (c) The Author(s) 2026. Published by Oxford University Press on behalf of the American Thoracic Society. FAU - Farmer, Mary Jo S AU - Farmer MJS AUID- ORCID: 0000-0003-0837-398X AD - Division of Pulmonary, Critical Care, and Sleep Medicine, Mass General Brigham, Salem, MA, United States. FAU - Asghar, Aleezay AU - Asghar A AUID- ORCID: 0009-0007-6832-0050 AD - Division of Pulmonary, Critical Care, Sleep, and Allergy, University of Illinois Chicago, Chicago, IL, United States. LA - eng GR - Shaw Fund/ PT - Journal Article PL - England TA - ATS Sch JT - ATS scholar JID - 101774447 SB - IM MH - Humans MH - *Cardiac Catheterization/methods/standards MH - *Quality Improvement MH - *Cardiology/education MH - Clinical Competence MH - Hypertension, Pulmonary/diagnosis MH - Cardiac Output MH - Pulmonary Wedge Pressure MH - Critical Care PMC - PMC13519314 OTO - NOTNLM OT - Fick OT - cardiac output OT - education OT - hemodynamics OT - pulmonary arterial hypertension OT - pulmonary arterial wedge pressure OT - pulmonary hypertension OT - thermodilution COIS- Please see the ICMJE disclosure forms, which have been provided as supplementary material. EDAT- 2026/04/30 06:34 MHDA- 2026/08/27 12:36 PMCR- 2026/04/28 CRDT- 2026/04/30 03:44 PHST- 2025/07/12 00:00 [received] PHST- 2026/03/18 00:00 [accepted] PHST- 2026/08/27 12:36 [medline] PHST- 2026/04/30 06:34 [pubmed] PHST- 2026/04/30 03:44 [entrez] PHST- 2026/04/28 00:00 [pmc-release] AID - 8665283 [pii] AID - aapag022 [pii] AID - 10.1093/atsscholar/aapag022 [doi] PST - ppublish SO - ATS Sch. 2026 Sep 1;7(3):192-200. doi: 10.1093/atsscholar/aapag022. PMID- 42057232 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260617 LR - 20260813 IS - 2057-3804 (Electronic) IS - 2057-3804 (Linking) VI - 12 IP - 1 DP - 2026 Apr 30 TI - Endoscopic ultrasound-guided transoesophageal pericardiocentesis: a case report on a therapeutic solution for pericardial tamponade with malignant posterior pericardial effusion. LID - 10.1186/s40959-026-00460-8 [doi] LID - 78 AB - BACKGROUND: Treatment options for malignant loculated pericardial effusions are limited and effusions often reaccumulate following surgical management. For posterior effusions, access percutaneously is challenging, hence alternative approaches may be needed. Here, we report a rare case of transoesophageal endoscopic ultrasound (EUS)-guided pericardiocentesis for recurrent loculated posterior malignant pericardial effusion causing haemodynamic compromise. CASE PRESENTATION: A 65-year-old male was diagnosed with metastatic lung adenocarcinoma following an emergency admission with malignant cardiac tamponade. He underwent percutaneous pericardiocentesis under transthoracic ultrasound guidance and was started on osimertinib for an EGFR-exon-19 sensitising mutation. 6 weeks later, he was readmitted with symptomatic pericardial effusion and underwent an urgent pericardial window. The procedure was complicated due to multiple loculations, densely adherent sac, and poor respiratory reserve. Re-staging CT scan at the time showed partial response to osimertinib. Two weeks post-discharge, repeat echocardiography showed a 4.0 cm loculated posterior pericardial effusion compressing the left atrium, with evidence of haemodynamic compromise. Further percutaneous drainage was not feasible due to the posterior location, and his anaesthetic risk for repeat thoracotomy was considered prohibitively high. Due to his good pre-morbid baseline, favourable genomic profile, and ongoing response to osimertinib, the multidisciplinary team trialled an unconventional approach using transoesophageal pericardiocentesis under endoscopic ultrasound (EUS) guidance under conscious sedation. The procedure was uncomplicated and 100mL of haemosanguinous fluid was drained with immediate symptomatic relief. Pericardial cytology was negative for malignant cells and extended pericardial culture grew Klebsiella, a contaminant from the gastrointestinal tract. The effusion reaccumulated four weeks later and restaging CT eight weeks post-drainage suggested early progressive disease. The patient further deteriorated and passed away, six months from his initial presentation with malignant pericardial tamponade. CONCLUSION: We present one of few reported cases of successful transoesophageal EUS-guided pericardiocentesis as a potential alternative for pericardial effusion drainage. Improved prognosis in patients with metastatic lung cancer, especially those with actionable genomic aberrations, should be considered for more aggressive therapeutic approaches when no other alternatives exist following clear discussion regarding risks and benefits. CI - (c) 2026. The Author(s). FAU - So, Alfred Chung Pui AU - So ACP AD - Department of Oncology, St Bartholomew's Hospital, Barts NHS Trust, London, UK. alfred.so@nhs.net. FAU - Conibear, John AU - Conibear J AD - Department of Oncology, St Bartholomew's Hospital, Barts NHS Trust, London, UK. AD - Barts Cancer Institute, Queen Mary University of London, London, UK. FAU - Januszweski, Adam AU - Januszweski A AD - Department of Oncology, St Bartholomew's Hospital, Barts NHS Trust, London, UK. FAU - Manisty, Charlotte AU - Manisty C AD - Department of Cardio-Oncology, St Bartholomew's Hospital, Barts NHS Trust, London, UK. AD - Institute of Cardiovascular Science, University College London, London, UK. FAU - Ricketts, William AU - Ricketts W AD - Department of Respiratory Medicine, St Bartholomew's Hospital, Barts NHS Trust, London, UK. FAU - Waller, David AU - Waller D AD - Department of Thoracic Surgery, St Bartholomew's Hospital, Barts NHS Trust, London, UK. FAU - Wilson, Patrick AU - Wilson P AD - Department of Gastroenterology, St Bartholomew's Hospital, Barts NHS Trust, London, UK. FAU - Lau, Kelvin AU - Lau K AD - Department of Thoracic Surgery, St Bartholomew's Hospital, Barts NHS Trust, London, UK. LA - eng PT - Journal Article DEP - 20260430 PL - England TA - Cardiooncology JT - Cardio-oncology (London, England) JID - 101689938 PMC - PMC13274056 OTO - NOTNLM OT - Cardio-oncology OT - Malignant pericardial effusion OT - Non-small cell lung cancer OT - Transoesophageal pericardiocentesis COIS- Declarations. Ethics approval and consent to participate: This study complied with all relevant ethical regulations as outlined by the Declaration of Helsinki. Verbal and written consent was obtained by the patient before he passed away for publication. Consent for publication: Verbal and written consent was obtained by the patient before he passed away for publication. Competing interests: The authors declare no competing interests. EDAT- 2026/04/30 06:34 MHDA- 2026/04/30 06:35 PMCR- 2026/04/30 CRDT- 2026/04/30 00:32 PHST- 2025/05/15 00:00 [received] PHST- 2026/02/18 00:00 [accepted] PHST- 2026/04/30 06:35 [medline] PHST- 2026/04/30 06:34 [pubmed] PHST- 2026/04/30 00:32 [entrez] PHST- 2026/04/30 00:00 [pmc-release] AID - 10.1186/s40959-026-00460-8 [pii] AID - 460 [pii] AID - 10.1186/s40959-026-00460-8 [doi] PST - epublish SO - Cardiooncology. 2026 Apr 30;12(1):78. doi: 10.1186/s40959-026-00460-8. PMID- 42057182 OWN - NLM STAT- MEDLINE DCOM- 20260616 LR - 20260926 IS - 1749-8090 (Electronic) IS - 1749-8090 (Linking) VI - 21 IP - 1 DP - 2026 Apr 29 TI - Impact of surgical timing on outcomes after transcatheter aortic valve explantation: insights from a French multicenter retrospective study. LID - 10.1186/s13019-026-04137-2 [doi] LID - 426 AB - BACKGROUND: Surgical explantation of transcatheter aortic valves (TAV-explant) is an emerging but uncommon procedure, increasingly required as TAVI is performed in younger and lower-risk patients. Contemporary evidence on outcomes, timing, and valve type remains limited. METHODS: We conducted a multicenter retrospective study of patients undergoing surgical TAV-explant. Clinical characteristics, indications, surgical strategies, and outcomes were analyzed. Outcomes were compared according to the interval between index TAVI and explantation (< 1 month, 1-12 months, > 12 months). The indication and the type of initial transcatheter valve (balloon-expandable vs. self-expanding) were also analyzed. The primary outcome was 30-day mortality. RESULTS: A total of 62 patients were included. Indications for TAV-explantation were predominantly bioprosthetic valve dysfunction (45.2%), infective endocarditis. (21%), and procedural failure (33.9%)The 30-day mortality was 16.1% and did not differ according to the delay of explantation (p = 0.816). Overall mortality did not differ according to the indication of explantation, nor by type of explanted valve. Concomitant aortic surgery was required in 18% of cases. Although EuroSCORE II values were elevated in this cohort, this tool underestimated the operative risk, as it was not designed for complex redo surgery. CONCLUSIONS: TAV-explantation is technically feasible but remains associated with substantial early mortality. Outcomes are not influenced by the timing of explantation or by valve type. These findings highlight the limitations of current surgical risk scores and underscore the importance of thorough pre-operative planning and Heart Team evaluation. Continued multicenter data collection is essential to optimize patient selection and refine management strategies. CI - (c) 2026. The Author(s). FAU - Eid, Maroua AU - Eid M AD - Department of Cardiac Surgery, University Hospital of Angers, 4 rue Larrey 49933, Angers Cedex 09, France. maroua.eid@gmail.com. AD - Faculty of Medicine, MITOVASC Institute INSERM U1083 UMR-CNRS 6214, University Hospital of Angers, 2 rue Haute de Reculee, Angers Cedex, 49045, France. maroua.eid@gmail.com. FAU - Allain, Geraldine AU - Allain G AD - Department of Cardio-Thoracic and Vascular Surgery, University Hospital of Poitiers, 2 rue de la Miletrie, Poitiers, 86000, France. FAU - Guimbretiere, Guillaume AU - Guimbretiere G AD - Department of Thoracic and Cardio-Vascular Surgery, Univeristy Hopital of Nantes, Hopital Nord Laennec Boulevard Jacques-Monod, Saint-Herblain, Nantes Cedex 1, 44093, France. FAU - Escrig, Pierre AU - Escrig P AD - Department of Thoracic and Cardio-Vascular Surgery, University Hospital of Rennes, 2 rue Henri Le Guilloux, Rennes Cedex 9, 35033, France. FAU - Pluchon, Kevin AU - Pluchon K AD - Department of Cardio-Thoracic and Vascular Surgery, Boulevard Tanguy Prigent, University Hospital of Brest, Hopital de la Cavale Blanche, Brest, 29200, France. FAU - Kermen, Stephane AU - Kermen S AD - Department of Cardiac Surgery, Regional University Hospital of Tours, Hopital Trousseau, Tours Cedex 9, 37044, France. FAU - Tomasi, Jacques AU - Tomasi J AD - Department of Thoracic and Cardio-Vascular Surgery, University Hospital of Rennes, 2 rue Henri Le Guilloux, Rennes Cedex 9, 35033, France. FAU - Jayle, Christophe AU - Jayle C AD - Department of Cardio-Thoracic and Vascular Surgery, University Hospital of Poitiers, 2 rue de la Miletrie, Poitiers, 86000, France. FAU - Roussel, Jean-Christian AU - Roussel JC AD - Department of Thoracic and Cardio-Vascular Surgery, Univeristy Hopital of Nantes, Hopital Nord Laennec Boulevard Jacques-Monod, Saint-Herblain, Nantes Cedex 1, 44093, France. FAU - Bezon, Eric AU - Bezon E AD - Department of Cardio-Thoracic and Vascular Surgery, Boulevard Tanguy Prigent, University Hospital of Brest, Hopital de la Cavale Blanche, Brest, 29200, France. FAU - Bourguignon, Thierry AU - Bourguignon T AD - Department of Cardiac Surgery, Regional University Hospital of Tours, Hopital Trousseau, Tours Cedex 9, 37044, France. FAU - Fouquet, Olivier AU - Fouquet O AD - Department of Cardiac Surgery, University Hospital of Angers, 4 rue Larrey 49933, Angers Cedex 09, France. AD - Faculty of Medicine, MITOVASC Institute INSERM U1083 UMR-CNRS 6214, University Hospital of Angers, 2 rue Haute de Reculee, Angers Cedex, 49045, France. LA - eng PT - Journal Article PT - Multicenter Study PT - Observational Study DEP - 20260429 PL - England TA - J Cardiothorac Surg JT - Journal of cardiothoracic surgery JID - 101265113 SB - IM MH - Aged MH - Aged, 80 and over MH - Female MH - Humans MH - Male MH - *Aortic Valve/surgery MH - *Aortic Valve Stenosis/surgery/mortality MH - *Device Removal/methods MH - France/epidemiology MH - Heart Valve Prosthesis MH - Retrospective Studies MH - Time Factors MH - *Transcatheter Aortic Valve Replacement/methods MH - Treatment Outcome PMC - PMC13270761 OTO - NOTNLM OT - Surgical aortic valve replacement OT - Surgical explantation OT - Transcatheter aortic valve implantation COIS- Declarations. Competing interests: The authors declare no competing interests. EDAT- 2026/04/30 06:34 MHDA- 2026/06/16 06:35 PMCR- 2026/04/29 CRDT- 2026/04/30 00:29 PHST- 2025/09/15 00:00 [received] PHST- 2026/04/11 00:00 [accepted] PHST- 2026/06/16 06:35 [medline] PHST- 2026/04/30 06:34 [pubmed] PHST- 2026/04/30 00:29 [entrez] PHST- 2026/04/29 00:00 [pmc-release] AID - 10.1186/s13019-026-04137-2 [pii] AID - 4137 [pii] AID - 10.1186/s13019-026-04137-2 [doi] PST - epublish SO - J Cardiothorac Surg. 2026 Apr 29;21(1):426. doi: 10.1186/s13019-026-04137-2. PMID- 42051893 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260429 LR - 20260813 IS - 2772-9303 (Electronic) IS - 2772-9303 (Linking) VI - 5 IP - 3 Suppl DP - 2026 Mar TI - Synergizing Process to Optimize Myocardial Infarction Patient Outcomes: Results of the Myocardial Infarction Delhi Primary Angioplasty Study (MIDAS). PG - 103667 LID - 10.1016/j.jscai.2025.103667 [doi] LID - 103667 AB - BACKGROUND: The prevalence and case fatality of ischemic heart disease in India has increased over the past 2 decades. ST-segment elevation myocardial infarction (STEMI) accounts for up to 60% of all myocardial infarctions in India, with only 25% to 40% of patients undergoing primary percutaneous coronary intervention (PPCI). A national access gap persists in India that needs to be bridged with the implementation of in-hospital processes and regional systems of collaborative care. METHODS: The single-center, observational, retrospective Myocardial Infarction Delhi Primary Angioplasty Study (MIDAS) was conducted at Max Super Specialty Hospital (New Delhi, India) between January 1, 2015, and December 31, 2019. All patients presenting to the emergency department with ongoing chest discomfort suggestive of ischemia and ST elevation on electrocardiogram were included. PPCI, initiated by a "CODE STEMI" team activation call, was employed as a single reperfusion strategy to treat all patients and minimize system delays. Systematic data collection of door-to-balloon (D2B) time regular audit, feedback, and multidisciplinary team engagement was implemented to refine processes and improve efficiency. The consistency of the process in maintaining D2B time during day and night hours, as well as on weekends and holidays was evaluated. Data from the electronic health record were collected and summarized to evaluate the impact of processes on in-hospital patient outcomes. RESULTS: A total of 887 patients meeting eligibility criteria were included in the analysis, of whom 45.2% were admitted during off hours, weekends, or holidays, and 92.3% underwent PPCI, 2.8% underwent PPCI followed by CABG, 1.8% underwent CABG, and 2.6% required medical therapy. The median D2B was 51 minutes (interquartile range, 40-60 minutes), and on holidays the mean D2B was 55 minutes (interquartile range, 40-75 minutes). The overall mortality was 5.2%. CONCLUSIONS: This study demonstrates that implementing a team-based standardized protocol can achieve guideline-recommended D2B times in a diverse STEMI population presenting to a percutaneous coronary intervention-capable hospital. Protocols reduce variation in care and enable the delivery of equitable high-quality care consistently across diverse demographic groups. CI - (c) 2025 The Author(s). FAU - Salwan, Roopa AU - Salwan R AD - Interventional Cardiology, Max Super Speciality Hospital, New Delhi, India. FAU - Lansky, Alexandra AU - Lansky A AD - Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut. FAU - Singh, Kalpana AU - Singh K AD - Hamad Medical Corporation, Doha, Qatar. FAU - Dubey, Kritya AU - Dubey K AD - Emergency Department, Max Super Speciality Hospital, New Delhi, India. FAU - Sharma, Surbhit AU - Sharma S AD - Max Super Speciality Hospital, New Delhi, India. FAU - Mehta, Sameer AU - Mehta S AD - Lumen Foundation & GLOW, Lumen Global, Miami, Florida. LA - eng PT - Journal Article DEP - 20251014 PL - United States TA - J Soc Cardiovasc Angiogr Interv JT - Journal of the Society for Cardiovascular Angiography & Interventions JID - 9918419271306676 PMC - PMC13112790 OTO - NOTNLM OT - ST-segment elevation myocardial infarction OT - door-to-balloon time OT - ischemic heart disease OT - primary percutaneous coronary intervention OT - reperfusion therapy EDAT- 2026/04/29 12:25 MHDA- 2026/04/29 12:26 PMCR- 2025/10/14 CRDT- 2026/04/29 04:50 PHST- 2025/01/10 00:00 [received] PHST- 2025/04/02 00:00 [revised] PHST- 2025/04/07 00:00 [accepted] PHST- 2026/04/29 12:26 [medline] PHST- 2026/04/29 12:25 [pubmed] PHST- 2026/04/29 04:50 [entrez] PHST- 2025/10/14 00:00 [pmc-release] AID - S2772-9303(25)01109-3 [pii] AID - 103667 [pii] AID - 10.1016/j.jscai.2025.103667 [doi] PST - epublish SO - J Soc Cardiovasc Angiogr Interv. 2025 Oct 14;5(3 Suppl):103667. doi: 10.1016/j.jscai.2025.103667. eCollection 2026 Mar. PMID- 42051890 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260429 LR - 20260813 IS - 2772-9303 (Electronic) IS - 2772-9303 (Linking) VI - 5 IP - 3 Suppl DP - 2026 Mar TI - Delivering Multidisciplinary Cardiac Care in Conflict Zones: A Cardiology Mission to Homs, Syria. PG - 104057 LID - 10.1016/j.jscai.2025.104057 [doi] LID - 104057 FAU - Al-Akchar, Mohammad AU - Al-Akchar M AD - Southern Illinois University, Springfield, Illinois. FAU - El-Atassi, Rafel S AU - El-Atassi RS AD - Mercy Health, Toledo, Ohio. FAU - Alrifai, Abdulah AU - Alrifai A AD - Advocate Heart Institute, Hazel Crest, Illinois. FAU - Al-Tabbal, Ghiyath A AU - Al-Tabbal GA AD - Wesley Healthcare, Wichita, Kansas. FAU - Sayfo, Sameh AU - Sayfo S AD - Department of Cardiovascular Medicine, Baylor Scott & White The Heart Hospital - Plano, Plano, Texas. AD - Texas A&M University School of Medicine, Bryan, Texas. LA - eng PT - Journal Article DEP - 20251230 PL - United States TA - J Soc Cardiovasc Angiogr Interv JT - Journal of the Society for Cardiovascular Angiography & Interventions JID - 9918419271306676 PMC - PMC13112798 OTO - NOTNLM OT - Syria OT - cardiology OT - conflict zones OT - medical missions COIS- The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2026/04/29 12:25 MHDA- 2026/04/29 12:26 PMCR- 2025/12/30 CRDT- 2026/04/29 04:50 PHST- 2025/08/19 00:00 [received] PHST- 2025/10/06 00:00 [revised] PHST- 2025/10/10 00:00 [accepted] PHST- 2026/04/29 12:26 [medline] PHST- 2026/04/29 12:25 [pubmed] PHST- 2026/04/29 04:50 [entrez] PHST- 2025/12/30 00:00 [pmc-release] AID - S2772-9303(25)01503-0 [pii] AID - 104057 [pii] AID - 10.1016/j.jscai.2025.104057 [doi] PST - epublish SO - J Soc Cardiovasc Angiogr Interv. 2025 Dec 30;5(3 Suppl):104057. doi: 10.1016/j.jscai.2025.104057. eCollection 2026 Mar. PMID- 42051888 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260429 LR - 20260813 IS - 2772-9303 (Electronic) IS - 2772-9303 (Linking) VI - 5 IP - 3 Suppl DP - 2026 Mar TI - A Randomized Trial Evaluating Automated Notifications for the Identification and Treatment of Aortic Stenosis and Mitral Regurgitation: The ALERT Study. PG - 104040 LID - 10.1016/j.jscai.2025.104040 [doi] LID - 104040 AB - BACKGROUND: Aortic stenosis (AS) and mitral regurgitation (MR) are common cardiac conditions associated with significant morbidity and mortality if left untreated. Despite the availability of effective therapies, many patients with severe AS and MR do not receive timely interventions, with disparities particularly affecting minority populations, women, and those in rural areas. METHODS: The Addressing undertreatment and heaLth Equity in aortic stenosis and mitral regurgitation using an integrated ehR plaTform (ALERT) study is a multicenter, prospective, cluster-randomized controlled trial designed to evaluate the impact of automated electronic health record notifications on the management of severe AS and MR. This cluster-randomized controlled trial involves at least 5 US hospital systems. Providers are randomized to receive automated notifications or not receive notifications, based on echocardiogram report findings. The primary end point is a hierarchical composite of transcatheter or surgical valve intervention (valve intervention) or multidisciplinary heart team clinic visit within 90 days. The study aims to randomize at least 600 providers and 1500 total patients 1:1 into each study arm, hypothesizing that automated notifications increase the proportion of patients receiving appropriate evaluation and treatment. RESULTS: The results of the study are pending completion of enrollment and should be available in Q2 2026. CONCLUSIONS: The ALERT study leverages integrated electronic health record platforms to address undertreatment in severe AS and MR, with the potential to improve patient outcomes and reduce disparities in care. CI - (c) 2025 The Author(s). FAU - Batchelor, Wayne B AU - Batchelor WB AD - Inova Health System and Inova Schar Heart and Vascular, Fairfax, Virginia. FAU - Lindman, Brian R AU - Lindman BR AD - Vanderbilt University Medical Center, Nashville, Tennessee. FAU - Coylewright, Megan AU - Coylewright M AD - Cardiology Division, Essentia Health, Duluth, Minnesota. FAU - Keller, Antoine AU - Keller A AD - Ochsner Lafayette General, Ochsner Health, Lafayette, Louisiana. FAU - Sotelo, Miguel AU - Sotelo M AD - Tempus AI, Chicago, Illinois. FAU - Wagner, Loren AU - Wagner L AD - Tempus AI, Chicago, Illinois. FAU - Rogers, Chris AU - Rogers C AD - Tempus AI, Chicago, Illinois. FAU - Hickey, Graeme L AU - Hickey GL AD - Medtronic, Minneapolis, Minnesota. FAU - Williams, Jamie AU - Williams J AD - Medtronic, Minneapolis, Minnesota. FAU - Chang, Yanping AU - Chang Y AD - Medtronic, Minneapolis, Minnesota. FAU - Vemulapalli, Sreekanth AU - Vemulapalli S AD - Division of Cardiology, Duke University Department of Medicine, Duke Health, Durham, North Carolina. LA - eng PT - Journal Article DEP - 20251118 PL - United States TA - J Soc Cardiovasc Angiogr Interv JT - Journal of the Society for Cardiovascular Angiography & Interventions JID - 9918419271306676 PMC - PMC13112826 OTO - NOTNLM OT - aortic stenosis OT - automated notifications OT - clinician decision support OT - electronic health record OT - health equity OT - mitral regurgitation EDAT- 2026/04/29 12:25 MHDA- 2026/04/29 12:26 PMCR- 2025/11/18 CRDT- 2026/04/29 04:50 PHST- 2025/06/29 00:00 [received] PHST- 2025/09/17 00:00 [revised] PHST- 2025/09/22 00:00 [accepted] PHST- 2026/04/29 12:26 [medline] PHST- 2026/04/29 12:25 [pubmed] PHST- 2026/04/29 04:50 [entrez] PHST- 2025/11/18 00:00 [pmc-release] AID - S2772-9303(25)01486-3 [pii] AID - 104040 [pii] AID - 10.1016/j.jscai.2025.104040 [doi] PST - epublish SO - J Soc Cardiovasc Angiogr Interv. 2025 Nov 18;5(3 Suppl):104040. doi: 10.1016/j.jscai.2025.104040. eCollection 2026 Mar. PMID- 42051434 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260429 LR - 20260813 IS - 2297-055X (Print) IS - 2297-055X (Electronic) IS - 2297-055X (Linking) VI - 13 DP - 2026 TI - Beyond daylight: emergent cardiac catheterization in congenital heart disease during evenings and nights: clinical demand and logistical realities. PG - 1752520 LID - 10.3389/fcvm.2026.1752520 [doi] LID - 1752520 AB - BACKGROUND: Emergency cardiac catheterizations (ECC) during off-hours are high risk due to limited staffing and resources. To date, no systematic data are available on the outcomes of such emergent procedures for congenital heart disease (CHD). OBJECTIVES: To the best of our knowledge, this study is among the first to systematically evaluate outcomes, procedural characteristics, and multidisciplinary involvement in off-hours ECC among patients with CHD. METHODS: We retrospectively analyzed all ECC performed during evenings and nights over two and half years at a single tertiary center. Data included demographics, indications, interventions, staffing, and outcomes. RESULTS: Between January 2023 and November 2025, a total of 2,050 procedures were performed; of these, 37 (1.8%) were emergent off-hours cases. Median age was 25 days (range: 1 day-14 years); median weight was 3.9 kg (range: 2-50 kg). Indications included critical cyanosis (40.5%), cardiogenic shock (19%), postoperative instability (37.8%), and interventional complications (2.7%). Interventions included Rashkind atrioseptostomy, pulmonary/aortic balloon angioplasty, shunt, pulmonary and coarctation stenting, and postoperative rescue procedures, accounting for 89% of cases. All ECCs were performed by a single interventionalist. Nursing staff support was required in 48% of performed interventions, primarily those involving stenting and dilation. Rashkind-guided echocardiography was performed by anesthesiology (n = 7). The surgical team was on-site in 40% of cases. All patients who underwent intervention showed clinical improvement; ECMO was avoided in four cases and weaned in two. No early complications were observed. One late femoral arteriovenous fistula required surgical revision. CONCLUSIONS: Emergent off-hours catheterizations in CHD can achieve favorable outcomes when performed by a skilled multidisciplinary team. Success depends not only on physician expertise but also on institutional readiness, effective organization, and seamless team coordination. CI - (c) 2026 Mini, Schneider, Schindler, Asfour and Mikus. FAU - Mini, Nathalie AU - Mini N AD - Cardiac Catheterization Laboratories, German Paediatric Heart Center, University Hospital Bonn, Bonn, Germany. FAU - Schneider, Martin B E AU - Schneider MBE AD - Cardiac Catheterization Laboratories, German Paediatric Heart Center, University Hospital Bonn, Bonn, Germany. FAU - Schindler, Ehrenfried AU - Schindler E AD - Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn, Bonn, Germany. FAU - Asfour, Boulos AU - Asfour B AD - Department of Pediatric Cardiac Surgery, German Pediatric Heart Centre, University Hospital Bonn, Bonn, Germany. FAU - Mikus, Marian AU - Mikus M AD - Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn, Bonn, Germany. LA - eng PT - Journal Article DEP - 20260413 PL - Switzerland TA - Front Cardiovasc Med JT - Frontiers in cardiovascular medicine JID - 101653388 PMC - PMC13111423 OTO - NOTNLM OT - congenital heart disease OT - emergency cardiac catheterization OT - neonatal cardiac intervention OT - off-hours intervention OT - pediatric interventional cardiology COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/04/29 12:25 MHDA- 2026/04/29 12:26 PMCR- 2026/04/13 CRDT- 2026/04/29 04:45 PHST- 2025/11/23 00:00 [received] PHST- 2026/03/14 00:00 [revised] PHST- 2026/03/23 00:00 [accepted] PHST- 2026/04/29 12:26 [medline] PHST- 2026/04/29 12:25 [pubmed] PHST- 2026/04/29 04:45 [entrez] PHST- 2026/04/13 00:00 [pmc-release] AID - 10.3389/fcvm.2026.1752520 [doi] PST - epublish SO - Front Cardiovasc Med. 2026 Apr 13;13:1752520. doi: 10.3389/fcvm.2026.1752520. eCollection 2026. PMID- 42049973 OWN - NLM STAT- MEDLINE DCOM- 20260627 LR - 20261010 IS - 1619-0904 (Electronic) IS - 1434-7229 (Linking) VI - 29 IP - 2 DP - 2026 Apr 28 TI - Pathophysiology, diagnosis, and management of hemolysis in patients with prosthetic valve related paravalvular leaks. LID - 27 [pii] LID - 10.1007/s10047-026-01556-9 [doi] AB - Paravalvular leak (PVL) is a recognized complication after prosthetic valve implantation, occurring in up to 17% of cases. While small leaks are often clinically silent, moderate or severe PVLs may result in significant hemolysis or heart failure. Hemolysis is driven by turbulent flow through the defect, leading to red blood cell fragmentation. Laboratory features include anemia, elevated lactate dehydrogenase, low haptoglobin, indirect hyperbilirubinemia, and schistocytes on peripheral smear. Diagnosis relies primarily on echocardiography, with transesophageal imaging providing superior sensitivity. Cardiac computed tomography may be helpful in complex or recurrent cases. Management depends on symptom burden and hemolytic severity. Conservative therapy with transfusions, iron and folate supplementation, or beta-blockade may stabilize mild cases, but persistent hemolysis or heart failure generally requires intervention. Redo surgery offers definitive repair but carries high operative risk, particularly in patients with comorbidities. In recent years, transcatheter PVL closure has emerged as a less invasive alternative, with high procedural success and improvement in hematologic and clinical outcomes, although residual leakage remains a limitation. Long-term prognosis is determined by early recognition and individualized treatment. A multidisciplinary heart team approach is essential, and future research should refine patient selection and improve closure outcomes. FAU - Kalcik, Macit AU - Kalcik M AUID- ORCID: 0000-0002-8791-4475 AD - Department of Cardiology, Faculty of Medicine, Hitit University, Buharaevler Mah. Buhara 25. Sok. No:1 /A, Daire:22, Corum, Turkey. macitkalcik@yahoo.com. FAU - Bayam, Emrah AU - Bayam E AD - Department of Cardiology, University of Medical Sciences, Kartal Kosuyolu High Specialty Training and Research Hospital, Istanbul, Turkey. FAU - Guner, Ahmet AU - Guner A AD - Department of Cardiology, Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and Research Hospital, Istanbul, Turkey. FAU - Ozkan, Mehmet AU - Ozkan M AD - Division of Health Sciences, Ardahan University, Ardahan, Turkey. LA - eng PT - Journal Article PT - Review DEP - 20260428 PL - Japan TA - J Artif Organs JT - Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs JID - 9815648 SB - IM MH - Humans MH - *Hemolysis MH - *Heart Valve Prosthesis/adverse effects MH - *Heart Valve Prosthesis Implantation/adverse effects MH - *Prosthesis Failure/adverse effects MH - Reoperation OTO - NOTNLM OT - Cardiac surgery OT - Hemolysis OT - Paravalvular leak OT - Prosthetic valve OT - Transcatheter closure COIS- Declarations. Conflict of interest: All of the authors have no conflict of interest. EDAT- 2026/04/29 00:34 MHDA- 2026/06/27 18:37 CRDT- 2026/04/28 23:27 PHST- 2026/01/21 00:00 [received] PHST- 2026/04/08 00:00 [accepted] PHST- 2026/06/27 18:37 [medline] PHST- 2026/04/29 00:34 [pubmed] PHST- 2026/04/28 23:27 [entrez] AID - 10.1007/s10047-026-01556-9 [pii] AID - 10.1007/s10047-026-01556-9 [doi] PST - epublish SO - J Artif Organs. 2026 Apr 28;29(2):27. doi: 10.1007/s10047-026-01556-9. PMID- 42049588 OWN - NLM STAT- MEDLINE DCOM- 20260802 LR - 20260827 IS - 1879-0828 (Electronic) IS - 0953-6205 (Linking) VI - 150 DP - 2026 Aug TI - Assessment and management of cardiovascular-kidney-liver metabolic-syndrome in the primary care setting: A multidisciplinary consensus statement. PG - 106902 LID - S0953-6205(26)00207-4 [pii] LID - 10.1016/j.ejim.2026.106902 [doi] AB - The recently introduced cardiovascular-kidney-metabolic (CKM) syndrome captures the close interplay between metabolic risk factors, chronic kidney disease, and cardiovascular disease, but insufficiently reflects the important additional role of the liver. Metabolic dysfunction-associated steatotic liver disease (MASLD), the most prevalent chronic liver disease worldwide, is strongly associated with cardiovascular events, kidney disease progression, and all-cause mortality, yet remains frequently under-recognized in routine clinical practice. We propose the concept of a cardiovascular-kidney-liver-metabolic syndrome (CKLMS) and present a multidisciplinary, primary care-centered framework for its assessment and management. Based on expert consensus and current evidence, the framework integrates cardiovascular, renal, hepatic, and metabolic risk stratification using accessible, validated tools feasible in primary care, including blood pressure and lipid profiling, assessment of kidney function and albuminuria, non-invasive liver fibrosis testing, and systematic screening for diabetes and obesity. Management emphasizes early lifestyle intervention, use of pharmacological therapies with multi-organ benefit, and clearly defined referral pathways to specialist care. Primary care professionals are positioned as coordinators of longitudinal, patient-centered, multidisciplinary management. Early, integrated identification and treatment of CKLMS in primary care represents a pragmatic and effective strategy to prevent disease progression, reduce cardiovascular and kidney events, and improve long-term outcomes. CI - Copyright (c) 2026 The Author(s). Published by Elsevier B.V. All rights reserved. FAU - Kreutz, Reinhold AU - Kreutz R AD - Charite -University Medicine, Department of Clinical Pharmacology and Toxicology, Berlin, Germany. Electronic address: reinhold.kreutz@charite.de. FAU - Canbay, Ali AU - Canbay A AD - Department of Internal Medicine, University Hospital Knappschaftskrankenhaus Bochum, Ruhr University Bochum, Bochum, Germany. FAU - Haluzik, Martin AU - Haluzik M AD - Diabetes Centre, Institute for Clinical and Experimental Medicine in Prague, Czech Republic. FAU - Januszewicz, Andrzej AU - Januszewicz A AD - Department of Hypertension, National Institute of Cardiology, Warsaw, Poland. FAU - Mendive, Juan M AU - Mendive JM AD - La Mina Primary Health Care Academic Centre, University of Barcelona, Spain. FAU - Sarafidis, Pantelis AU - Sarafidis P AD - 1st Department of Nephrology, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece. FAU - Schattenberg, Jorn M AU - Schattenberg JM AD - Department of Internal Medicine II, Saarland University Medical Center, Homburg, Germany. LA - eng PT - Consensus Statement PT - Journal Article PT - Review DEP - 20260428 PL - Netherlands TA - Eur J Intern Med JT - European journal of internal medicine JID - 9003220 SB - IM MH - Humans MH - *Metabolic Syndrome/therapy/diagnosis/complications MH - Primary Health Care MH - *Cardio-Renal Syndrome/therapy/diagnosis MH - *Cardiovascular Diseases/therapy MH - Risk Factors MH - Obesity MH - Risk Assessment OTO - NOTNLM OT - Blood pressure OT - Cardiovascular risk OT - Cardiovascular-kidney-metabolic syndrome (CKM) OT - Diabetes OT - Hypertension OT - Kidney OT - Liver OT - Metabolic dysfunction associated steatotic liver disease (MASLD) OT - Obesity COIS- Declaration of competing interest This article resulted from discussion among the authors during two meetings in 2024 and 2025, respectively, that were sponsored by PRO.MED.CS Praha a.s. AC has received Research funding and/or serve as consultant to, Boehringer Ingelheim, Ipsen, BMS, GSK, Lilly, Madridgal, Falk, Gilead, Sanofi, Takeda. RK reports honoraria for consultancy, lectures and support for research from AstraZeneca, Bayer, Krka, Menarini Group, Merck, PRO.MED, PolPharma, Recor, Servier, and Zentiva MH reports honoraria for lectures from Sanofi, Eli Lilly, Novo Nordisk, Astra Zeneca, Berlin Chemie, Zentiva, Boehringer Ingelheim, Merck, Abbott, Johnson&Johnson, Bausch, GSK, PRO.MED; grants from Sanofi; consultations/AB Membership from Sanofi, Eli Lilly, Novo Nordisk, Astra Zeneca, Merck, Abbott, Bausch, PRO.MED AJ reports consulting fees & honoraria from AstraZeneca, Krka, Menarini Group, PRO.MED, Polpharma, Servier, ADAMED, Medtronic, Boehringer, Baush, Hasco JM reports honoraria for consultancy or educational materials from Novo Nordisk, Reckitt. Boehringer Ingelheim, Lainco, and PRO.MED PS reports honoraria for consultancy or lectures from Astra-Zeneca, Bayer, Boehringer Ingelheim, Astellas, TEVA, Specialty Therapeutics, PRO.MED, F. Hoffmann-La Roche, Genesis Pharma, Winmedica, Baxter/Vantive and SOBI and institutional research support received from Astra-Zeneca, Boehringer Ingelheim, Genesis Pharma, Vianex and Menarini.JMS declares consultant honorary from Akero, Alentis, Alexion, Altimmune, Astra Zeneca, 89Bio, Bionorica, Boehringer Ingelheim, Boston Pharmaceuticals, Gilead Sciences, GSK, HistoIndex, Ipsen, Inventiva Pharma, Madrigal Pharmaceuticals, Kriya Therapeutics, Eli Lilly, MSD Sharp & Dohme GmbH, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, Siemens Healthineers; speaker honorarium from AbbVie, Boehringer Ingelheim, Gilead Sciences, Ipsen, Lilly, Madrigal Pharmaceuticals, Novo Nordisk. Stockholder options: Hepta Bio. EDAT- 2026/04/29 00:34 MHDA- 2026/08/03 00:35 CRDT- 2026/04/28 21:53 PHST- 2026/01/14 00:00 [received] PHST- 2026/03/31 00:00 [revised] PHST- 2026/04/20 00:00 [accepted] PHST- 2026/08/03 00:35 [medline] PHST- 2026/04/29 00:34 [pubmed] PHST- 2026/04/28 21:53 [entrez] AID - S0953-6205(26)00207-4 [pii] AID - 10.1016/j.ejim.2026.106902 [doi] PST - ppublish SO - Eur J Intern Med. 2026 Aug;150:106902. doi: 10.1016/j.ejim.2026.106902. Epub 2026 Apr 28. PMID- 42048177 OWN - NLM STAT- MEDLINE DCOM- 20260702 LR - 20260813 IS - 1537-1948 (Electronic) IS - 0025-7079 (Print) IS - 0025-7079 (Linking) VI - 64 IP - 8 DP - 2026 Aug 1 TI - Association Between Team-Based Continuity of Care Measures and End-of-Life Health Care Outcomes: A Retrospective Cohort Study in Ontario, Canada. PG - 483-491 LID - 10.1097/MLR.0000000000002334 [doi] AB - BACKGROUND: Continuity of care (COC) measurements that reflect relational continuity have been used as quality indicators, yet their applicability near the end of life may be limited. Modified continuity indices-UPC-Team (Usual Provider of Care) and BB-Team (Bice-Boxerman)-were developed to reflect escalating care needs and capture associations with patient-centered outcomes. OBJECTIVES: To measure associations between the modified COC indices, UPC-Team, and BB-Team during the last year of life and end-of-life (EOL) health care outcomes. METHODS: Retrospective cohort study of adults who died between January 1, 2018, and December 31, 2022, with advanced chronic obstructive pulmonary disease and/or heart failure prevalent >/=2 years before death, using health administrative data from Ontario, Canada. Multivariate regressions measured associations between the indices and days spent in community during the last 30 and 14 days of life, and place of death. RESULTS: Among 175,323 included individuals (median age at death=80; 55.4% male), the median number of community days was 23 and 10 in the last 30 and 14 days of life; 56.5% died in a health care institution. Higher UPC-Team and BB-Team scores were associated with increased odds of institutional deaths and fewer community days. CONCLUSIONS: Higher continuity scores were associated with increased odds of institutional death and fewer days spent in the community, suggesting limited utility of these modified indices in predicting favorable EOL health care outcomes. Findings highlight the need for future research to incorporate all aspects of continuity (ie, relational, informational, and management) to better capture care coordination in this context. CI - Copyright (c) 2026 The Author(s). Published by Wolters Kluwer Health, Inc. FAU - Hafid, Shuaib AU - Hafid S AUID- ORCID: 0000-0002-2853-6881 AD - Department of Family Medicine, McMaster University, Hamilton, ON, Canada. AD - Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada. FAU - Isenberg, Sarina AU - Isenberg S AD - Bruyere Health Research Institute, Ottawa, ON, Canada. AD - Department of Medicine, University of Ottawa, Ottawa, ON, Canada. FAU - Jones, Aaron AU - Jones A AD - Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada. AD - ICES McMaster University, Hamilton, ON, Canada. FAU - Wills, Aria AU - Wills A AD - Bruyere Health Research Institute, Ottawa, ON, Canada. FAU - Shorting, Taylor AU - Shorting T AD - Bruyere Health Research Institute, Ottawa, ON, Canada. FAU - Gayowsky, Ana AU - Gayowsky A AD - ICES McMaster University, Hamilton, ON, Canada. FAU - Fernandes, Aleisha AU - Fernandes A AD - Department of Family Medicine, McMaster University, Hamilton, ON, Canada. AD - Ottawa Methods Centre, Ottawa Hospital Research Institute, Ottawa, ON, Canada. FAU - Quinn, Kieran L AU - Quinn KL AD - Temmy Latner Center for Palliative Care, Department of Medicine, Sinai Health, University of Toronto, Toronto, ON, Canada. FAU - Webber, Colleen AU - Webber C AD - Bruyere Health Research Institute, Ottawa, ON, Canada. FAU - Gallagher, Erin AU - Gallagher E AD - Department of Family Medicine, McMaster University, Hamilton, ON, Canada. FAU - Tanuseputro, Peter AU - Tanuseputro P AD - Department of Family Medicine and Primary Care, University of Hong Kong, Hong Kong, China. FAU - Howard, Michelle AU - Howard M AD - Department of Family Medicine, McMaster University, Hamilton, ON, Canada. LA - eng PT - Journal Article DEP - 20260428 PL - United States TA - Med Care JT - Medical care JID - 0230027 SB - IM MH - Humans MH - Ontario MH - Retrospective Studies MH - *Terminal Care/statistics & numerical data/organization & administration MH - *Continuity of Patient Care/organization & administration/statistics & numerical data/standards MH - Male MH - Female MH - Aged MH - Aged, 80 and over MH - Quality Indicators, Health Care MH - Pulmonary Disease, Chronic Obstructive/therapy MH - Heart Failure/therapy MH - *Outcome Assessment, Health Care MH - *Patient Care Team PMC - PMC13331261 OTO - NOTNLM OT - Bice-Boxerman OT - continuity of care OT - end-of-life OT - family medicine OT - health care quality OT - usual provider concentration COIS- The authors declare no conflict of interest. EDAT- 2026/04/28 18:33 MHDA- 2026/07/03 04:10 PMCR- 2026/07/03 CRDT- 2026/04/28 12:23 PHST- 2025/11/21 00:00 [received] PHST- 2026/03/31 00:00 [accepted] PHST- 2026/07/03 04:10 [medline] PHST- 2026/04/28 18:33 [pubmed] PHST- 2026/04/28 12:23 [entrez] PHST- 2026/07/03 00:00 [pmc-release] AID - 00005650-990000000-00459 [pii] AID - MDC-D-25-00639 [pii] AID - 10.1097/MLR.0000000000002334 [doi] PST - ppublish SO - Med Care. 2026 Aug 1;64(8):483-491. doi: 10.1097/MLR.0000000000002334. Epub 2026 Apr 28. PMID- 42041998 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260427 LR - 20260813 IS - 2308-3425 (Electronic) IS - 2308-3425 (Linking) VI - 13 IP - 4 DP - 2026 Apr 19 TI - Surgical and Transcatheter Tricuspid Valve Interventions: An Electrophysiology-Focused Review. LID - 10.3390/jcdd13040172 [doi] LID - 172 AB - Increasing recognition of the clinical impact of isolated tricuspid regurgitation has led to rapid expansion of surgical and transcatheter tricuspid valve interventions. Given the close anatomic relationship between the tricuspid valve and the atrioventricular conduction system, both surgical and transcatheter approaches carry a significant risk of new conduction disturbances and permanent pacemaker implantation. A three-dimensional understanding of the atrioventricular conduction axis is essential to anticipate and mitigate these complications. This review provides a comprehensive overview of conduction system anatomy and physiology in the context of tricuspid valve interventions, highlighting the mechanisms underlying procedure-related conduction abnormalities. We also discuss contemporary management strategies, including approaches to pre-existing transvalvular leads, valve-sparing pacing alternatives, and the evolving role of electrophysiologists within the multidisciplinary heart team. FAU - Tang, Kevin S AU - Tang KS AD - Mary & Steve Wen Cardiovascular Division, University of California Irvine, Irvine, CA 92697, USA. AD - Division of Cardiology, University of California San Francisco, San Francisco, CA 94143, USA. FAU - Abdelnour, Mark W AU - Abdelnour MW AUID- ORCID: 0009-0009-3584-9825 AD - Mary & Steve Wen Cardiovascular Division, University of California Irvine, Irvine, CA 92697, USA. FAU - Tungate, Robert M AU - Tungate RM AD - Division of Cardiology, Department of Medicine, Columbia University, New York, NY 10032, USA. FAU - Mansour, Christina AU - Mansour C AD - Mary & Steve Wen Cardiovascular Division, University of California Irvine, Irvine, CA 92697, USA. FAU - Sagebin, Fabio AU - Sagebin F AD - Division of Cardiothoracic Surgery, Department of Surgery, University of California Irvine, Orange, CA 92868, USA. FAU - Frangieh, Antonio H AU - Frangieh AH AUID- ORCID: 0000-0001-6645-6367 AD - Mary & Steve Wen Cardiovascular Division, University of California Irvine, Irvine, CA 92697, USA. FAU - Donaldson, David M AU - Donaldson DM AD - Mary & Steve Wen Cardiovascular Division, University of California Irvine, Irvine, CA 92697, USA. LA - eng PT - Journal Article PT - Review DEP - 20260419 PL - Switzerland TA - J Cardiovasc Dev Dis JT - Journal of cardiovascular development and disease JID - 101651414 PMC - PMC13116597 OTO - NOTNLM OT - atrioventricular conduction system OT - conduction disturbances OT - lead management OT - transcatheter tricuspid valve intervention OT - tricuspid regurgitation COIS- Dr. Frangieh is a proctor and consultant for Edwards Lifesciences. Dr. Donaldson is a consultant for Edwards Lifesciences. The other authors declare no conflicts of interest. EDAT- 2026/04/27 12:34 MHDA- 2026/04/27 12:35 PMCR- 2026/04/19 CRDT- 2026/04/27 09:26 PHST- 2026/03/15 00:00 [received] PHST- 2026/04/16 00:00 [revised] PHST- 2026/04/16 00:00 [accepted] PHST- 2026/04/27 12:35 [medline] PHST- 2026/04/27 12:34 [pubmed] PHST- 2026/04/27 09:26 [entrez] PHST- 2026/04/19 00:00 [pmc-release] AID - jcdd13040172 [pii] AID - jcdd-13-00172 [pii] AID - 10.3390/jcdd13040172 [doi] PST - epublish SO - J Cardiovasc Dev Dis. 2026 Apr 19;13(4):172. doi: 10.3390/jcdd13040172. PMID- 42041981 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260427 LR - 20260813 IS - 2308-3425 (Electronic) IS - 2308-3425 (Linking) VI - 13 IP - 4 DP - 2026 Mar 30 TI - Current Management of Infective Endocarditis: A Narrative Review Focused on Unmet Clinical Needs and the Multidisciplinary Approach. LID - 10.3390/jcdd13040155 [doi] LID - 155 AB - Infective endocarditis (IE) is a severe infectious disease affecting cardiac valves (either native or prosthetic) or implantable cardiac devices, and it is associated with high rates of morbidity and mortality. Recent data from the Global Burden of Disease study have shown a significant increase in both the incidence and mortality of IE. One-year mortality following diagnosis can reach up to 30%. IE can present with a wide range of clinical manifestations, and its course may be complicated by systemic embolic events or intracardiac complications such as abscess formation or prosthetic valve dehiscence. Echocardiography remains the first-line imaging modality; however, an integrated multimodality imaging approach is increasingly adopted in contemporary practice, incorporating both cardiac computed tomography and positron emission tomography. A multidisciplinary approach involving cardiologists, cardiac surgeons, internists, infectious disease specialists, and nuclear medicine physicians is often required to ensure accurate diagnosis and effective treatment of IE. The prognosis of infective endocarditis depends on early diagnosis, appropriate antimicrobial therapy, and timely surgical intervention when indicated. This review aims to summarize the current knowledge on IE, from pathophysiological insights to surgical strategies. It also focuses on practical recommendations to address the most pressing unmet clinical needs through a multidisciplinary approach. FAU - Di Vito, Luca AU - Di Vito L AUID- ORCID: 0000-0002-6572-4590 AD - Cardiology Unit, C. and G. Mazzoni Hospital, AST Ascoli Piceno, 63100 Ascoli Piceno, Italy. FAU - D'Amato, Giuseppina AU - D'Amato G AD - Infectious Disease Unit, C. and G. Mazzoni Hospital, AST Ascoli Piceno, 63100 Ascoli Piceno, Italy. FAU - Pascucci, Riccardo AU - Pascucci R AD - Cardiology Unit, C. and G. Mazzoni Hospital, AST Ascoli Piceno, 63100 Ascoli Piceno, Italy. FAU - D'Antonio, Antonella AU - D'Antonio A AD - Cardiology Unit, C. and G. Mazzoni Hospital, AST Ascoli Piceno, 63100 Ascoli Piceno, Italy. FAU - Scalone, Giancarla AU - Scalone G AD - Cardiology Unit, C. and G. Mazzoni Hospital, AST Ascoli Piceno, 63100 Ascoli Piceno, Italy. FAU - Boni, Mariavirginia AU - Boni M AD - Internal Medicine Unit, C. and G. Mazzoni Hospital, AST Ascoli Piceno, 63100 Ascoli Piceno, Italy. FAU - Rossi, Brunella AU - Rossi B AD - Nuclear Medicine Unit, C. and G. Mazzoni Hospital, AST Ascoli Piceno, 63100 Ascoli Piceno, Italy. FAU - Cimaroli, Ilaria AU - Cimaroli I AD - Internal Medicine Unit, C. and G. Mazzoni Hospital, AST Ascoli Piceno, 63100 Ascoli Piceno, Italy. FAU - Acciarri, Claudia AU - Acciarri C AD - Cardiology Unit, C. and G. Mazzoni Hospital, AST Ascoli Piceno, 63100 Ascoli Piceno, Italy. FAU - Andreucci, Marida AU - Andreucci M AD - Cardiology Unit, C. and G. Mazzoni Hospital, AST Ascoli Piceno, 63100 Ascoli Piceno, Italy. FAU - Romandini, Andrea AU - Romandini A AD - Cardiology Unit, C. and G. Mazzoni Hospital, AST Ascoli Piceno, 63100 Ascoli Piceno, Italy. FAU - Silenzi, Simona AU - Silenzi S AD - Cardiology Unit, C. and G. Mazzoni Hospital, AST Ascoli Piceno, 63100 Ascoli Piceno, Italy. FAU - Marchese, Procolo AU - Marchese P AUID- ORCID: 0000-0002-2677-9214 AD - Cardiology Unit, C. and G. Mazzoni Hospital, AST Ascoli Piceno, 63100 Ascoli Piceno, Italy. FAU - Grossi, Pierfrancesco AU - Grossi P AD - Cardiology Unit, C. and G. Mazzoni Hospital, AST Ascoli Piceno, 63100 Ascoli Piceno, Italy. LA - eng PT - Journal Article PT - Review DEP - 20260330 PL - Switzerland TA - J Cardiovasc Dev Dis JT - Journal of cardiovascular development and disease JID - 101651414 PMC - PMC13116544 OTO - NOTNLM OT - Staphylococcus aureus OT - echocardiography OT - infective endocarditis OT - intracardiac device OT - nuclear medicine OT - prosthetic heart valve COIS- The authors declare no conflicts of interest. EDAT- 2026/04/27 12:33 MHDA- 2026/04/27 12:34 PMCR- 2026/03/30 CRDT- 2026/04/27 09:26 PHST- 2026/02/11 00:00 [received] PHST- 2026/03/23 00:00 [revised] PHST- 2026/03/25 00:00 [accepted] PHST- 2026/04/27 12:34 [medline] PHST- 2026/04/27 12:33 [pubmed] PHST- 2026/04/27 09:26 [entrez] PHST- 2026/03/30 00:00 [pmc-release] AID - jcdd13040155 [pii] AID - jcdd-13-00155 [pii] AID - 10.3390/jcdd13040155 [doi] PST - epublish SO - J Cardiovasc Dev Dis. 2026 Mar 30;13(4):155. doi: 10.3390/jcdd13040155. PMID- 42040390 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260427 LR - 20260921 IS - 2050-0904 (Print) IS - 2050-0904 (Electronic) IS - 2050-0904 (Linking) VI - 14 IP - 5 DP - 2026 May TI - Primary Cardiac Lymphoma: A Diagnostically Challenging Case Report. PG - e72543 LID - 10.1002/ccr3.72543 [doi] LID - e72543 AB - This case highlights the diagnostic difficulties of PCL, including non-specific symptoms, imaging mimics, and the critical role of histopathological confirmation despite technical and clinical challenges. Early multidisciplinary evaluation is essential to improve outcomes in this aggressive disease. CI - (c) 2026 The Author(s). Clinical Case Reports published by John Wiley & Sons Ltd. FAU - Huang, Yucheng AU - Huang Y AD - Health Management Center Shenzhen Qianhai Taikang Hospital Shenzhen China. FAU - Lao, Minxi AU - Lao M AD - Department of Geriatrics First Affiliated Hospital of Sun Yat-Sen University Guangzhou China. FAU - Ye, Min AU - Ye M AD - Department of Medical Ultrasonics Institute for Diagnostic and Interventional Ultrasound, First Affiliated Hospital of Sun Yat-Sen University Guangzhou China. FAU - Yang, Yang AU - Yang Y AD - Department of Pathology First Affiliated Hospital of Sun Yat-Sen University Guangzhou China. FAU - Ding, Meilin AU - Ding M AD - Department of Geriatrics First Affiliated Hospital of Sun Yat-Sen University Guangzhou China. FAU - Li, Jin AU - Li J AD - Department of Geriatrics First Affiliated Hospital of Sun Yat-Sen University Guangzhou China. FAU - Su, Lei AU - Su L AUID- ORCID: 0000-0002-5569-1991 AD - Department of Geriatrics First Affiliated Hospital of Sun Yat-Sen University Guangzhou China. LA - eng PT - Journal Article DEP - 20260424 PL - England TA - Clin Case Rep JT - Clinical case reports JID - 101620385 PMC - PMC13108408 OTO - NOTNLM OT - cardiac malignancy OT - case report OT - heart failure OT - primary cardiac lymphoma COIS- The authors have nothing to report. EDAT- 2026/04/27 12:34 MHDA- 2026/04/27 12:35 PMCR- 2026/04/24 CRDT- 2026/04/27 07:07 PHST- 2026/03/25 00:00 [received] PHST- 2026/03/25 00:00 [revised] PHST- 2026/04/04 00:00 [accepted] PHST- 2026/04/27 12:35 [medline] PHST- 2026/04/27 12:34 [pubmed] PHST- 2026/04/27 07:07 [entrez] PHST- 2026/04/24 00:00 [pmc-release] AID - CCR372543 [pii] AID - 10.1002/ccr3.72543 [doi] PST - epublish SO - Clin Case Rep. 2026 Apr 24;14(5):e72543. doi: 10.1002/ccr3.72543. eCollection 2026 May. PMID- 42040183 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260427 LR - 20260926 IS - 2090-6609 (Print) IS - 2090-6617 (Electronic) IS - 2090-6617 (Linking) VI - 2026 DP - 2026 TI - Managing Alpha-Gal Allergy in a Case of Bioprosthetic TAVR. PG - 8190714 LID - 10.1155/crii/8190714 [doi] LID - 8190714 AB - Alpha-gal syndrome (AGS) is an uncommon IgE-mediated allergy to mammalian-derived products, caused by sensitization to the oligosaccharide galactose-alpha-1,3-galactose (alpha-gal) after tick exposure. Although AGS is best recognized for delayed anaphylaxis following ingestion of red meat, its implications for exposure to mammalian-derived biomaterials remain poorly characterized. We present an elderly woman with AGS who required transcatheter aortic valve replacement (TAVR) using a bovine bioprosthesis. An 84-year-old woman with serologically confirmed AGS following a Lone Star tick bite in 2012 presented with symptomatic severe aortic stenosis. Her clinical history included multiple allergic reactions to beef, persistently elevated IgE to beef, pork, and lamb, and a specific alpha-gal IgE >100 kU/L. Following a multidisciplinary evaluation, she was not considered a candidate for a mechanical valve. A prophylactic regimen was implemented, including cetirizine, omalizumab, and 60 mg prednisone 6 h prior to TAVR. The procedure was successfully performed with a bovine-derived bioprosthetic valve. Perioperative tryptase levels remained within normal range (5.2 microg/L), and no hypersensitivity reactions occurred. Postoperatively, prednisone was tapered, while fexofenadine and omalizumab were continued for 6 months. This case highlights that bioprosthetic valve replacement can be safely performed in AGS patients through multidisciplinary planning and individualized prophylaxis strategies. Further data are needed to develop standardized perioperative management protocols for this rare but clinically significant condition. CI - Copyright (c) 2026 Ruchi Patel et al. Case Reports in Immunology published by John Wiley & Sons Ltd. FAU - Patel, Ruchi AU - Patel R AUID- ORCID: 0000-0001-8664-6491 AD - Department of Medicine, New Jersey Medical School, Rutgers University, Newark, New Jersey, USA, rutgers.edu. FAU - Patel, Aarav AU - Patel A AUID- ORCID: 0009-0002-2842-6946 AD - Somerset County Vocational and Technical High School, Bridgewater, New Jersey, USA. FAU - Biswas, Ruchi AU - Biswas R AD - Department of Medicine, New Jersey Medical School, Rutgers University, Newark, New Jersey, USA, rutgers.edu. FAU - Hsieh, Benjamin AU - Hsieh B AD - Department of Medicine, New Jersey Medical School, Rutgers University, Newark, New Jersey, USA, rutgers.edu. FAU - Ramasamy, Dhanasekaran AU - Ramasamy D AD - Private Practice, Allied Digestive Health, Union, New Jersey, USA. FAU - Patel, Chirag AU - Patel C AD - Private Practice, Ocean Allergy, Brick, New Jersey, USA. LA - eng PT - Journal Article DEP - 20260424 PL - United States TA - Case Reports Immunol JT - Case reports in immunology JID - 101622188 PMC - PMC13109619 OTO - NOTNLM OT - TAVR OT - alpha-gal syndrome OT - anaphylaxis OT - bioprosthetic valve OT - hypersensitivity OT - omalizumab COIS- The authors declare no conflicts of interest. EDAT- 2026/04/27 12:34 MHDA- 2026/04/27 12:35 PMCR- 2026/04/24 CRDT- 2026/04/27 07:05 PHST- 2025/12/21 00:00 [received] PHST- 2026/02/21 00:00 [revised] PHST- 2026/04/02 00:00 [accepted] PHST- 2026/04/27 12:35 [medline] PHST- 2026/04/27 12:34 [pubmed] PHST- 2026/04/27 07:05 [entrez] PHST- 2026/04/24 00:00 [pmc-release] AID - CRII8190714 [pii] AID - 10.1155/crii/8190714 [doi] PST - epublish SO - Case Reports Immunol. 2026 Apr 24;2026:8190714. doi: 10.1155/crii/8190714. eCollection 2026. PMID- 42036829 OWN - NLM STAT- MEDLINE DCOM- 20260702 LR - 20260702 IS - 1600-0609 (Electronic) IS - 0902-4441 (Linking) VI - 117 IP - 2 DP - 2026 Aug TI - Cardiovascular Complications in Hemoglobinopathies: Pathophysiology, Clinical Spectrum, and Management. PG - 338-350 LID - 10.1111/ejh.70206 [doi] AB - Sickle cell disease and thalassemia syndromes are increasingly recognized as chronic multisystem disorders, with cardiovascular (CV) sequelae representing a significant proportion of long-term morbidity and mortality. Survival has improved considerably due to better transfusion practice, the administration of iron chelation, and disease-modifying treatments; a broad and expanding phenotypic spectrum of cardiac and vascular manifestations is being recognized. These include cardiomyopathy, heart failure, pulmonary hypertension, arrhythmias, microvascular ischemia, and functional valvular disease, often resulting insidiously and progressing over time. CV pathogenesis of hemoglobinopathies is complex and heterogeneous. Chronic anemia induces a long-lasting high-output circulatory state, while iron overload related to transfusion produces myocardial siderosis, oxidative damage, and electrical instability in particular in transfusion-dependent thalassemia. Moreover, hemolysis-mediated endothelial dysfunction, deficiency of nitric oxide, inflammation, and microvascular pathology play a central role in sickle cell disease, resulting in diastolic dysfunction, pulmonary vascular remodeling, and heart failure with preserved ejection fraction. These pathomechanisms create disease-specific CV phenotypes that have important diagnostic and therapeutic implications. This narrative review was performed by searching the PubMed, Cochrane Library, and Google Scholar databases for original studies, systematic reviews, and guidelines for the period of 2009-2025. This review summarizes available data on the epidemiology and pathophysiological mechanisms contributing to CV complications of hemoglobinopathies and clinical manifestations of CV compromise. The review summarizes developments in diagnosis and screening methods such as echocardiography, cardiac magnetic resonance imaging, biomarkers, and functional measures, disease-modifying drugs, and CV lovastatin by phenotype. We finally highlight major evidence gaps and research priorities needed to improve CV outcomes. This multidisciplinary approach is essential for transforming mechanistic insight into improved survival and quality of life for individuals with hemoglobinopathies through a systematic, interdisciplinary, and proactive CV strategy. CI - (c) 2026 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. FAU - Bradach, Daniel AU - Bradach D AUID- ORCID: 0009-0008-5393-6845 AD - St. George's University School of Medicine, University Center Grenada, Grenada, West Indies. FAU - Salavarria, Karla Calderon AU - Salavarria KC AUID- ORCID: 0009-0005-5135-3214 AD - Catholic University Santiago of Guayaquil, Guayaquil, Ecuador. FAU - Diaz-Arribasplata, Santiago AU - Diaz-Arribasplata S AUID- ORCID: 0000-0002-4053-9137 AD - Faculty of Health Sciences, Peruvian University of Applied Sciences (UPC), Lima, Peru. FAU - Ibraheem Almahdi, Rahaf Saliem AU - Ibraheem Almahdi RS AUID- ORCID: 0009-0006-7093-322X AD - Faculty of Medicine, Albalqa Applied University, Albalqa, Jordan. FAU - Mavus, Nur Bengisu AU - Mavus NB AD - Lokman Hekim University, Faculty of Medicine, Ankara, Turkey. FAU - Sangaraju, Sai Lahari AU - Sangaraju SL AUID- ORCID: 0009-0001-1310-5923 AD - Berkshire Medical Center, Pittsfield, Massachusetts, USA. FAU - Sam, Arushi Ann AU - Sam AA AUID- ORCID: 0009-0008-5935-9348 AD - St. George's University School of Medicine, University Center Grenada, Grenada, West Indies. FAU - Mohamed, Mohamed Salah AU - Mohamed MS AUID- ORCID: 0009-0004-1915-8542 AD - University of Medical Sciences and Technology (UMST), Khartoum, Sudan. FAU - Brutus, Coatsiana AU - Brutus C AD - Washington University of Health Sciences, San Pedro, Belize. FAU - Poojary, Pratheeksha S AU - Poojary PS AD - SDM College of Medical Sciences, Dharwad, India. FAU - Rai, Manju AU - Rai M AUID- ORCID: 0009-0007-0627-3287 AD - Shri Venkateshwara University, Gajraula, India. LA - eng PT - Journal Article PT - Review DEP - 20260426 PL - England TA - Eur J Haematol JT - European journal of haematology JID - 8703985 SB - IM MH - Humans MH - *Hemoglobinopathies/complications/therapy/diagnosis MH - *Cardiovascular Diseases/etiology/therapy/diagnosis/epidemiology MH - Disease Management OTO - NOTNLM OT - cardiac magnetic resonance imaging OT - cardiomyopathy OT - cardiovascular consequences OT - heart failure OT - hemoglobinopathies OT - hemolysis OT - iron overload OT - pulmonary hypertension OT - sickle cell disease OT - thalassemia EDAT- 2026/04/27 06:31 MHDA- 2026/07/02 12:34 CRDT- 2026/04/27 00:32 PHST- 2026/04/12 00:00 [revised] PHST- 2026/02/18 00:00 [received] PHST- 2026/04/17 00:00 [accepted] PHST- 2026/07/02 12:34 [medline] PHST- 2026/04/27 06:31 [pubmed] PHST- 2026/04/27 00:32 [entrez] AID - 10.1111/ejh.70206 [doi] PST - ppublish SO - Eur J Haematol. 2026 Aug;117(2):338-350. doi: 10.1111/ejh.70206. Epub 2026 Apr 26. PMID- 42031431 OWN - NLM STAT- MEDLINE DCOM- 20260715 LR - 20260813 IS - 2053-3624 (Print) IS - 2053-3624 (Electronic) IS - 2053-3624 (Linking) VI - 13 IP - 1 DP - 2026 Apr 24 TI - Sex differences in the diagnosis, management and outcomes of patients with infective endocarditis. LID - 10.1136/openhrt-2026-004026 [doi] LID - e004026 AB - BACKGROUND: Despite growing interest in male-female differences in cardiovascular disease, evidence in infective endocarditis (IE) is limited and contradictory. METHODS: This prospective study included all patients with definite or possible valvular IE discussed by the endocarditis team from 2016 to 2025. Baseline characteristics, diagnostics, treatment and outcomes were compared between sexes. A Cox model was conducted to assess survival adjusted for baseline characteristics, IE type and treatment. RESULTS: The cohort included 791 patients with definite or possible IE (72.8% males, 27.2% females). Age was not different (male: 67 (IQR 56-75), female: 71 (IQR 55-78) years, p=0.07). Females more often had hypertension (46.0% vs 35.2%, p=0.07) and mitral valve IE (45.6% vs 32.3%, p<0.001). Males had more predisposing conditions (71.5% vs 60.5%, p=0.004) and more aortic valve IE (71.0% vs 62.3%, p=0.02) and Cutibacterium species (5.7% vs 1.4%, p=0.007). There was no difference in indication for surgery. However, males were more often treated surgically (41.1% vs 29.3%, p=0.002), and females with an indication for surgery were more often treated conservatively (22.5% vs 37.0%, p=0.006). After a median follow-up of 2.1 (IQR 0.4-4.4) years, females had higher mortality (adjusted HR (aHR) 1.39 (95% CI 1.03 to 1.89), p=0.03). Surgery was associated with higher mortality in males (aHR 1.32 (95% CI 0.90 to 1.94) vs aHR 0.62 (95% CI 0.32 to 1.20), p value for interaction=0.03). CONCLUSIONS: Differences were observed in baseline characteristics, IE type and survival. Females had worse overall adjusted survival, suggesting a less favourable overall prognosis. In terms of surgical decision-making, surgery was withheld more often in females despite surgical indication, and after excluding these patients, surgery appeared more protective in females than in males. These findings may reflect sex differences in surgical selection. CI - (c) Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. FAU - Dalebout, Eefje M AU - Dalebout EM AUID- ORCID: 0009-0009-0871-2233 AD - Department of Cardiology, Erasmus MC, Rotterdam, The Netherlands. AD - Department of Cardiothoracic Surgery, Erasmus MC, Rotterdam, The Netherlands. AD - Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands. FAU - Budde, Ricardo P J AU - Budde RPJ AD - Department of Cardiology, Erasmus MC, Rotterdam, The Netherlands. AD - Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands. FAU - Galema, Tjebbe W AU - Galema TW AD - Department of Cardiology, Erasmus MC, Rotterdam, The Netherlands. FAU - Wahadat, Ali R AU - Wahadat AR AD - Department of Cardiology, Erasmus MC, Rotterdam, The Netherlands. AD - Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands. FAU - Swart, Laurens E AU - Swart LE AD - Department of Cardiology, Erasmus MC, Rotterdam, The Netherlands. AD - Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands. AD - Department of Cardiology, Spaarne Gasthuis, Haarlem, The Netherlands. FAU - Veen, Kevin M AU - Veen KM AD - Department of Cardiothoracic Surgery, Erasmus MC, Rotterdam, The Netherlands. FAU - Verkaik, Nelianne J AU - Verkaik NJ AD - Department of Medical Microbiology and Infectious Diseases, Erasmus MC, Rotterdam, The Netherlands. FAU - Hirsch, Alexander AU - Hirsch A AUID- ORCID: 0000-0002-3315-2006 AD - Department of Cardiology, Erasmus MC, Rotterdam, The Netherlands. AD - Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands. FAU - Kluin, Jolanda AU - Kluin J AD - Department of Cardiothoracic Surgery, Erasmus MC, Rotterdam, The Netherlands. FAU - Roos-Hesselink, Jolien W AU - Roos-Hesselink JW AUID- ORCID: 0000-0002-6770-3830 AD - Department of Cardiology, Erasmus MC, Rotterdam, The Netherlands j.roos@erasmusmc.nl. LA - eng PT - Comparative Study PT - Journal Article DEP - 20260424 PL - England TA - Open Heart JT - Open heart JID - 101631219 SB - IM MH - Humans MH - Female MH - Male MH - Sex Factors MH - Prospective Studies MH - *Endocarditis/diagnosis/therapy/mortality/epidemiology MH - Aged MH - Middle Aged MH - Risk Factors MH - Follow-Up Studies MH - Prognosis MH - Survival Rate/trends PMC - PMC13110707 OTO - NOTNLM OT - Endocarditis OT - Heart Valve Diseases OT - Sex COIS- Competing interests: No disclosures in relation to this article. EMD, TWG, ARW, KV, NJV, JK and JWR-H have nothing to declare. RPJB received speakers' fees from Bayer and Siemens and served on an advisory board for Bayer (all payments to Erasmus MC). Institutional support to Erasmus MC by Siemens, Heartflow and Bracco by research grants. LES has received consultancy fees from Amgen, Sanofi and Novo Nordisk that are not relevant to the contents of this paper. AH received a research grant and consultancy fees from GE Healthcare and speaker fees from GE Healthcare, Bristol Myers Squibb, Bayer, Siemens Healthineers and Heartflow. He is a member of the medical advisory board of Medis Medical Imaging Systems and was MRI core lab supervisor of Cardialysis BV until 2022. EDAT- 2026/04/25 00:34 MHDA- 2026/04/25 00:35 PMCR- 2026/04/24 CRDT- 2026/04/24 20:53 PHST- 2026/02/03 00:00 [received] PHST- 2026/04/04 00:00 [accepted] PHST- 2026/04/25 00:35 [medline] PHST- 2026/04/25 00:34 [pubmed] PHST- 2026/04/24 20:53 [entrez] PHST- 2026/04/24 00:00 [pmc-release] AID - openhrt-2026-004026 [pii] AID - 10.1136/openhrt-2026-004026 [doi] PST - epublish SO - Open Heart. 2026 Apr 24;13(1):e004026. doi: 10.1136/openhrt-2026-004026. PMID- 42031156 OWN - NLM STAT- Publisher LR - 20260530 IS - 1552-6259 (Electronic) IS - 0003-4975 (Linking) DP - 2026 Apr 22 TI - The Society of Thoracic Surgeons/World Society for Pediatric and Congenital Heart Surgery/European Congenital Heart Surgeons Association 2026 Clinical Practice Guidelines on Indications and Timing of Pulmonary Valve Replacement in Repaired Tetralogy of Fallot. LID - S0003-4975(26)00357-7 [pii] LID - 10.1016/j.athoracsur.2026.04.011 [doi] AB - The Society of Thoracic Surgeons/World Society for Pediatric and Congenital Heart Surgery/European Congenital Heart Surgeons Association 2026 Clinical Practice Guidelines on Indications and Timing of Pulmonary Valve Replacement in Repaired Tetralogy of Fallot incorporate the most recent evidence for pulmonary valve replacement in this growing population. New evidence related to advanced imaging, electrophysiology testing, exercise testing, and transcatheter pulmonary valve replacement has emerged in the last 5 years. Compared with existing guidelines, the current update places emphasis on symptoms (children and adults), ventricular volumes (adults), and the need for invasive electrophysiology study before replacing the pulmonary valve (adults). This document is Part 1 and is accompanied by 2 other multisociety documents: Part 2: Society of Thoracic Surgeons/World Society for Pediatric and Congenital Heart Surgery/European Congenital Heart Surgeons Association 2026 Expert Consensus Document on Timing, Indications, and Options for Pulmonary Valve Replacement in Children with Repaired Tetralogy of Fallot, and Part 3: Society of Thoracic Surgeons/World Society for Pediatric and Congenital Heart Surgery/European Congenital Heart Surgeons Association 2026 Expert Opinion on the Role of Exercise Testing in Determining Optimal Timing of Pulmonary Valve Replacement in Tetralogy of Fallot. With this 3-part series, multidisciplinary team assessment, treatment planning, and long-term surveillance are also reinforced. CI - Copyright (c) 2026 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved. FAU - Nelson, Jennifer S AU - Nelson JS AD - Department of Cardiovascular Services, Nemours Children's Hospital, Florida, Orlando, Florida; Department of Surgery, University of Central Florida College of Medicine, Orlando, Florida. Electronic address: jennifer.nelson@nemours.org. FAU - Lu, Jimmy C AU - Lu JC AD - Division of Cardiology, Department of Pediatrics, University of Michigan, Ann Arbor, Michigan. FAU - Ashfaq, Awais AU - Ashfaq A AD - Department of Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. FAU - Kwon, Michael H AU - Kwon MH AD - Department of Cardiac Surgery, Boston Children's Hospital, Boston, Massachusetts. FAU - Kamp, Anna AU - Kamp A AD - Division of Cardiology, Department of Pediatrics, Nationwide Children's Hospital and The Ohio State University, Columbus, Ohio. FAU - Stephens, Elizabeth AU - Stephens E AD - Department of Cardiovascular Surgery, Mayo Clinic, Rochester, Minnesota. FAU - Cohen, Mitchell I AU - Cohen MI AD - Department of Pediatric Cardiology, Inova LJ Murphy Children's Hospital, Fairfax, Virginia. FAU - Rossi, Camilla AU - Rossi C AD - Department of Cardiothoracic Surgery, Weill Cornell Medical Center, NewYork-Presbyterian, New York, New York. FAU - Sood, Pallavi AU - Sood P AD - The Society of Thoracic Surgeons, Chicago, Illinois. FAU - Sandoval, Nestor AU - Sandoval N AD - Department of Cardiac Surgery, Fundacion Cardioinfantil Instituto de Cardiologia, Bogota, Colombia. FAU - Vida, Vladimiro AU - Vida V AD - Department of Cardiac Thoracic Vascular Sciences and Public Health, Pediatric and Congenital Cardiac Surgery Unit, University of Padua, Padua, Italy. FAU - Lee, Cheul AU - Lee C AD - Department of Thoracic and Cardiovascular Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. FAU - Khanna, Amber D AU - Khanna AD AD - The Canberra Hospital, Canberra, Australian Capital Territory, Australia; Royal Prince Alfred Hospital, Sydney, New South Wales, Australia. FAU - Bhamidipati, Castigliano AU - Bhamidipati C AD - Division of Cardiothoracic Surgery, Department of Surgery, Oregon Health & Science University, Portland, Oregon. FAU - Lotto, Attilio AU - Lotto A AD - Alder Hey Children's Hospital-Liverpool John Moores University, Liverpool, United Kingdom. FAU - Zampi, Jeffrey D AU - Zampi JD AD - Division of Cardiology, Department of Pediatrics, University of Michigan, Ann Arbor, Michigan. FAU - Protopapas, Eleftherios AU - Protopapas E AD - Athens Heart Surgery Institute and 2nd Department of Pediatric and Congenital Heart Surgery, Mitera Children's Hospital, Athens, Greece. FAU - Polimenakos, Anastasios C AU - Polimenakos AC AD - Department of Surgery, Pediatric and Congenital Cardiothoracic Surgery, Medical College of Georgia, Augusta, Georgia. FAU - Cruz Beltran, Susana AU - Cruz Beltran S AD - Pediatric and Congenital Heart Divisions, Department of Anesthesiology, University of Florida, Gainesville, Florida. FAU - Orr, Yishay AU - Orr Y AD - Congenital Heart Surgery, Texas Children's Hospital & Baylor College of Medicine, Houston, Texas. FAU - Ahmad, Danial AU - Ahmad D AD - Department of Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania. FAU - Tchervenkov, Christo AU - Tchervenkov C AD - Division of Cardiovascular Surgery, The Montreal Children's Hospital of the McGill University Health Centre, Montreal, Quebec, Canada. FAU - Sarris, George AU - Sarris G AD - Athens Heart Surgery Institute, Athens, Greece. FAU - Jacobs, Jeffrey P AU - Jacobs JP AD - Congenital Heart Center, University of Florida Health Shands Children's Hospital, Gainesville, Florida. FAU - St Louis, James D AU - St Louis JD AD - Department of Surgery, Pediatric and Congenital Cardiothoracic Surgery, Medical College of Georgia, Augusta, Georgia. LA - eng PT - Journal Article PT - Practice Guideline DEP - 20260422 PL - Netherlands TA - Ann Thorac Surg JT - The Annals of thoracic surgery JID - 15030100R SB - IM COIS- Disclosures Jeffrey Zampi reports a relationship with W. L. Gore & Associates that includes: consulting or advisory and travel reimbursement; with Medtronic that includes: consulting or advisory and travel reimbursement; with Encore Medical Education LLC that includes: board membership; and with Starlight Cardiovascular that includes: nonfinancial support. Dominic Zanaboni reports a relationship with B. Braun Medical Inc that includes: consulting or advisory. Jeffrey Jacobs reports a relationship with SpecialtyCare that includes: consulting or advisory; and with the American Academy of Dermatology that includes: consulting or advisory. Anna Kamp reports a relationship with Edwards Lifesciences Corporation that includes: speaking and lecture fees; and with Medtronic that includes: speaking and lecture fees. Given their roles as Editorial Board members of The Annals of Thoracic Surgery, Jennifer Nelson and Jeffrey Jacobs had no involvement in the peer review of this article and had no access to information regarding its peer review. This is an invited manuscript. Full responsibility for the editorial process for this article was delegated to another Annals editor. The other authors have no conflicts of interest to disclose. EDAT- 2026/04/25 00:34 MHDA- 2026/04/25 00:34 CRDT- 2026/04/24 19:13 PHST- 2025/08/31 00:00 [received] PHST- 2026/03/12 00:00 [revised] PHST- 2026/04/06 00:00 [accepted] PHST- 2026/04/25 00:34 [pubmed] PHST- 2026/04/25 00:34 [medline] PHST- 2026/04/24 19:13 [entrez] AID - S0003-4975(26)00357-7 [pii] AID - 10.1016/j.athoracsur.2026.04.011 [doi] PST - aheadofprint SO - Ann Thorac Surg. 2026 Apr 22:S0003-4975(26)00357-7. doi: 10.1016/j.athoracsur.2026.04.011. PMID- 42029600 OWN - NLM STAT- MEDLINE DCOM- 20260715 LR - 20260813 IS - 2076-3271 (Electronic) IS - 2076-3271 (Linking) VI - 14 IP - 2 DP - 2026 Mar 31 TI - Postoperative Delirium After Cardiac Surgery: Psychiatric Vulnerability, Biological Mechanisms, and Prevention Strategies. LID - 10.3390/medsci14020176 [doi] LID - 176 AB - INTRODUCTION: Delirium is one of the most common and serious neuropsychiatric complications following cardiac surgery. It is associated with increased mortality, prolonged intensive care unit (ICU) and hospital stay, long-term cognitive decline, and reduced quality of life. AIMS AND OBJECTIVES: The aim of this study is to synthesize current evidence on the epidemiology, psychiatric and psychosocial risk factors, biological mechanisms, perioperative modifiers, prevention strategies, and long-term outcomes of delirium after cardiac surgery, with particular emphasis on its role as a marker of brain vulnerability. MATERIALS AND METHODS: A narrative literature review was conducted using articles published between 1990 and 2025, identified through the PubMed and ScienceDirect databases. The search strategy included the terms "delirium," "cardiac surgery," "psychiatric disorders," and "cognitive impairment." RESULTS: Recent evidence suggests that approximately one quarter of patients undergoing cardiac surgery develop delirium, with hypoactive forms frequently remaining underrecognized in clinical practice. Pre-existing depression, cognitive impairment, substance use disorders, low educational level, frailty, and social isolation significantly increase the risk of postoperative delirium. Within a stress-diathesis framework, peripheral physiological insults may be reflected centrally as acute brain dysfunction in vulnerable individuals. Modifiable perioperative factors include sedative choice and depth, as well as sleep and circadian disruption. Multicomponent non-pharmacological interventions, early mobilization, structured psychiatric and cognitive screening, and dexmedetomidine-based sedation have demonstrated consistent efficacy in reducing the incidence and/or duration of delirium. Furthermore, delirium has been associated with persistent cognitive and psychiatric morbidity, functional decline, and increased long-term mortality. CONCLUSIONS: Delirium following cardiac surgery is a multifactorial syndrome with significant short- and long-term consequences. A comprehensive, multidisciplinary approach integrating biological, psychiatric, and perioperative perspectives is essential for effective risk stratification, prevention, and long-term follow-up. FAU - Leivaditis, Vasileios AU - Leivaditis V AUID- ORCID: 0000-0001-8692-0059 AD - Department of Cardiothoracic and Vascular Surgery, Westpfalz Klinikum, 67655 Kaiserslautern, Germany. FAU - Sepetis, Anastasios AU - Sepetis A AUID- ORCID: 0000-0002-8882-7242 AD - Postgraduate Health and Social Care Management Program, Department of Business Administration, University of West Attica, 12244 Athens, Greece. FAU - Mulita, Francesk AU - Mulita F AUID- ORCID: 0000-0001-7198-2628 AD - Department of General Surgery, General Hospital of Eastern Achaia-Unit of Aigio, 25100 Aigio, Greece. FAU - Papatriantafyllou, Athanasios AU - Papatriantafyllou A AD - Department of Cardiothoracic and Vascular Surgery, Westpfalz Klinikum, 67655 Kaiserslautern, Germany. FAU - Mitsos, Sofoklis AU - Mitsos S AUID- ORCID: 0000-0002-0606-7287 AD - Department of Thoracic Surgery, Attikon General Hospital, National and Kapodistrian University of Athens, 12462 Athens, Greece. FAU - Tomos, Periklis AU - Tomos P AD - Department of Thoracic Surgery, Attikon General Hospital, National and Kapodistrian University of Athens, 12462 Athens, Greece. FAU - Grapatsas, Konstantinos AU - Grapatsas K AD - Department of Thoracic Surgery and Thoracic Endoscopy, Ruhrlandklinik, West German Lung Center, University Hospital Essen, University Duisburg-Essen, 45141 Essen, Germany. FAU - Shaska, Ejona AU - Shaska E AD - Department of Psychiatry, "Ali Mihali" Psychiatric Hospital, 9401 Vlora, Albania. FAU - Liolis, Elias AU - Liolis E AD - Department of Oncology, General University Hospital of Patras, 26504 Patras, Greece. FAU - Koletsis, Efstratios AU - Koletsis E AUID- ORCID: 0000-0003-1660-4047 AD - Department of Cardiothoracic Surgery, General University Hospital of Patras, 26504 Patras, Greece. FAU - Baikoussis, Nikolaos AU - Baikoussis N AUID- ORCID: 0000-0001-5645-662X AD - Department of Cardiac Surgery, Ippokrateio General Hospital of Athens, 11527 Athens, Greece. LA - eng PT - Journal Article PT - Review DEP - 20260331 PL - Switzerland TA - Med Sci (Basel) JT - Medical sciences (Basel, Switzerland) JID - 101629322 SB - IM MH - Humans MH - *Cardiac Surgical Procedures/adverse effects MH - *Delirium/prevention & control/etiology/psychology/epidemiology MH - *Postoperative Complications/prevention & control/psychology/etiology MH - Risk Factors MH - Quality of Life PMC - PMC13108142 OTO - NOTNLM OT - ICU OT - cardiac surgery OT - cognitive impairment OT - delirium OT - depression OT - dexmedetomidine OT - neuroinflammation OT - postoperative cognitive dysfunction COIS- The authors declare no conflicts of interest. EDAT- 2026/04/24 12:36 MHDA- 2026/04/24 12:37 PMCR- 2026/03/31 CRDT- 2026/04/24 10:44 PHST- 2026/03/09 00:00 [received] PHST- 2026/03/29 00:00 [revised] PHST- 2026/03/30 00:00 [accepted] PHST- 2026/04/24 12:37 [medline] PHST- 2026/04/24 12:36 [pubmed] PHST- 2026/04/24 10:44 [entrez] PHST- 2026/03/31 00:00 [pmc-release] AID - medsci14020176 [pii] AID - medsci-14-00176 [pii] AID - 10.3390/medsci14020176 [doi] PST - epublish SO - Med Sci (Basel). 2026 Mar 31;14(2):176. doi: 10.3390/medsci14020176. PMID- 42027837 OWN - NLM STAT- Publisher LR - 20260813 IS - 1179-5565 (Print) IS - 1179-5565 (Electronic) IS - 1179-5565 (Linking) DP - 2026 Apr 21 TI - Oral Health in Children With Congenital Heart Diseases: A Comprehensive Narrative Review. PG - 11795565261432835 LID - 10.1177/11795565261432835 [doi] LID - 11795565261432835 AB - Congenital heart disease (CHD) is the most common congenital anomaly among live births, and can present in different forms. Due to significant improvements in the surgical treatment of CHDs, the population of children with CHDs is increasing. Studies have shown that these children have worse oral health than their healthy counterparts. This is mainly due to a lack of oral hygiene measures, a lack of fluoride exposure, insufficient water intake, sugar intake, and the effect of cardiac medications. Due to poor oral health, they also have a prevalence of caries and gingival diseases, and need comprehensive dental treatment. This narrative review was motivated by a lack of clear guidelines for dentists, pediatric cardiologists, and parents on preventing poor oral health in children with CHDs. A comprehensive search strategy was employed, utilizing databases such as PubMed, Scopus, Web of Science, and Google Scholar, to identify relevant literature on oral manifestations and dental management of children with CHDs. We highlighted the necessity of the multidisciplinary team for optimal dental management of children with CHDs. In addition, we discussed optimal dental management strategies to improve their overall health outcomes and quality of life. CI - (c) The Author(s) 2026. FAU - Saleh, Wafaa AU - Saleh W AUID- ORCID: 0000-0003-4143-7084 AD - Oral Medicine, Periodontology, Diagnosis and Oral Radiology Department, Faculty of Dentistry, Mansoura University, Egypt. FAU - Elhusseiny, Ghada A AU - Elhusseiny GA AUID- ORCID: 0000-0002-9329-6597 AD - Oral Medicine, Periodontology, Diagnosis and Oral Radiology Department, Faculty of Dentistry, Mansoura University, Egypt. FAU - Alharbi, Hamad AU - Alharbi H AD - Department of Oral and Maxillofacial Surgery, King Abdulaziz University, Jeddah, Saudi Arabia. LA - eng PT - Journal Article PT - Review DEP - 20260421 PL - United States TA - Clin Med Insights Pediatr JT - Clinical medicine insights. Pediatrics JID - 101595023 PMC - PMC13099730 OTO - NOTNLM OT - children OT - congenital heart diseases OT - narrative review OT - oral health COIS- The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2026/04/24 12:20 MHDA- 2026/04/24 12:20 PMCR- 2026/04/21 CRDT- 2026/04/24 04:51 PHST- 2025/01/30 00:00 [received] PHST- 2026/01/22 00:00 [accepted] PHST- 2026/04/24 12:20 [medline] PHST- 2026/04/24 12:20 [pubmed] PHST- 2026/04/24 04:51 [entrez] PHST- 2026/04/21 00:00 [pmc-release] AID - 10.1177_11795565261432835 [pii] AID - 10.1177/11795565261432835 [doi] PST - aheadofprint SO - Clin Med Insights Pediatr. 2026 Apr 21:11795565261432835. doi: 10.1177/11795565261432835. PMID- 42027521 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260424 LR - 20260813 IS - 2772-9931 (Electronic) IS - 2772-9931 (Linking) VI - 4 IP - 1 DP - 2026 Mar TI - The University of Kansas Cardiac Surgery Readmissions Committee: A Multidisciplinary Collaborative to Reduce Unplanned Readmissions. PG - 340-345 LID - 10.1016/j.atssr.2025.07.012 [doi] AB - BACKGROUND: Unplanned readmissions negatively affect hospital reimbursement and mortality. The purpose of this study was to describe the inception of a multidisciplinary readmissions group designed to reduce unplanned cardiac surgery readmissions. METHODS: Unplanned cardiac surgery readmissions within 30 days of discharge between 2021 and 2024 were analyzed by the University of Kansas Cardiac Surgery Readmissions Committee, consisting of inpatient and outpatient advanced practice providers, data managers, emergency department personnel, and cardiac surgeons. In 2023, a goal-oriented working group was established to reduce readmissions. Cardiac surgery readmissions are reviewed daily, and the readmissions committee meets quarterly to discuss their findings and opportunities for improvement. RESULTS: The working group's detailed investigation determined that arrhythmias, pleural effusions, and deep vein thrombosis or pulmonary embolism were the most common causes of readmission. The group then instituted postoperative amiodarone prophylaxis in their cardiac surgery patients, pursued aggressive postoperative drainage of the pleural spaces, and started prophylactic subcutaneous heparin on postoperative day 3 to reduce thromboembolic events. The group created a discharge checklist addressing rhythm issues, fluid balance, wound care, and clinic and on-call contact information. From 2021 to 2024, cardiac surgery readmissions declined from 10.9% to 9.6%, and similarly isolated readmissions after coronary artery bypass grafting declined from 10.2% to 6.1%, despite an increase in total operative volume and an increased case-mix index. CONCLUSIONS: The creation of an integrated, multidisciplinary Cardiac Surgery Readmissions Committee Working Group allowed the group to design targeted interventions for the most common reasons for readmission, which in turn led to a reduction in readmission rates. CI - (c) 2025 The Authors. FAU - Doonan, Regina AU - Doonan R AD - Department of Thoracic and Cardiovascular Surgery, University of Kansas Hospital, Kansas City, Kansas. FAU - Rice, Kelsy AU - Rice K AD - Department of Thoracic and Cardiovascular Surgery, University of Kansas Hospital, Kansas City, Kansas. FAU - Baldwin, Jessica AU - Baldwin J AD - Department of Thoracic and Cardiovascular Surgery, University of Kansas Hospital, Kansas City, Kansas. FAU - Whisenhunt, Morgan AU - Whisenhunt M AD - Office of Quality and Safety, University of Kansas Hospital, Kansas City, Kansas. FAU - Clarke, Alicia AU - Clarke A AD - Department of Thoracic and Cardiovascular Surgery, University of Kansas Hospital, Kansas City, Kansas. FAU - Winkler, Kate AU - Winkler K AD - Department of Thoracic and Cardiovascular Surgery, University of Kansas Hospital, Kansas City, Kansas. FAU - Zorn, George 3rd AU - Zorn G 3rd AD - Department of Thoracic and Cardiovascular Surgery, University of Kansas Hospital, Kansas City, Kansas. FAU - Crawford, Todd C AU - Crawford TC AD - Department of Thoracic and Cardiovascular Surgery, University of Kansas Hospital, Kansas City, Kansas. LA - eng PT - Journal Article DEP - 20250731 PL - United States TA - Ann Thorac Surg Short Rep JT - Annals of thoracic surgery short reports JID - 9918506088006676 PMC - PMC13100770 EDAT- 2026/04/24 12:20 MHDA- 2026/04/24 12:21 PMCR- 2025/07/31 CRDT- 2026/04/24 04:46 PHST- 2025/07/21 00:00 [accepted] PHST- 2026/04/24 12:21 [medline] PHST- 2026/04/24 12:20 [pubmed] PHST- 2026/04/24 04:46 [entrez] PHST- 2025/07/31 00:00 [pmc-release] AID - S2772-9931(25)00283-9 [pii] AID - 10.1016/j.atssr.2025.07.012 [doi] PST - epublish SO - Ann Thorac Surg Short Rep. 2025 Jul 31;4(1):340-345. doi: 10.1016/j.atssr.2025.07.012. eCollection 2026 Mar. PMID- 42026909 OWN - NLM STAT- MEDLINE DCOM- 20260615 LR - 20260615 IS - 1559-0879 (Electronic) IS - 1556-9845 (Linking) VI - 21 IP - 2 DP - 2026 Mar-Apr TI - Comparison of Surgical Outcomes and Long-Term Follow-Up in One-Stage Versus Two-Stage Hybrid Coronary Revascularization With DES. PG - 129-137 LID - 10.1177/15569845261425652 [doi] AB - OBJECTIVE: To compare perioperative outcomes in patients who receive complete revascularization in one-stage or two-stage hybrid coronary revascularization (HCR) with initial angioplasty. METHODS: The research is a retrospective subanalysis of the HYBRID-COR feasibility study. Thirty patients who underwent one-stage HCR (endoscopic atraumatic coronary artery bypass grafting [EACAB] and percutaneous coronary intervention [PCI]; group 1) were compared with 121 patients who underwent EACAB procedure as a final stage of HCR (group 2). Observations of bleeding, transfusion requirements, kidney injury, and other complications were conducted. Long-term outcomes were evaluated. RESULTS: Median (interquartile range [IQR]) perioperative drainage was higher in group 1 (750.0 [422.5 to 1,112.5] mL vs 400.0 [252.5 to 650.0] mL, P = 0.004), as was mechanical ventilation time (430.0 [300.0 to 600.0] min vs 300.0 [225.0 to 410.0] min, P = 0.001). Patients in group 1 required pleurocentesis more often (36.7% vs 13.2%, P = 0.003), as well as blood transfusions (26.7% vs 9%, P = 0.009). No significant differences were found for kidney injury incidence (20% vs 14.9%, P = 0.493). Two deaths (1.6%) and 1 myocardial infarction (0.8%) were noted in group 2 in the perioperative period. In a median long-term follow-up of 1,378.5 (758.0 to 2,033.0) days, no significant differences were noted in major adverse cardiac and cerebrovascular events, mortality, myocardial infarction occurrence, repeat revascularization, or incidence of stroke. CONCLUSIONS: PCI-first HCR is associated with less postoperative drainage, shorter mechanical ventilation time, fewer pleurocenteses, and less transfusion requirements when compared with one-stage HCR. The heart team decision is essential in choosing individual strategy, as the risk of postponing complete revascularization and temporary dual antiplatelet therapy withdrawal must be evaluated. Further studies are required, particularly on long-term outcomes. FAU - Synak, Magdalena AU - Synak M AUID- ORCID: 0009-0001-6266-2769 AD - Department of Cardiology, Andrzej Frycz Modrzewski Krakow University, Poland. FAU - Jankowska-Sanetra, Justyna AU - Jankowska-Sanetra J AD - Department of Cardiology, American Heart of Poland, Bielsko-Biala, Poland. FAU - Stankiewicz, Wiktoria AU - Stankiewicz W AD - Department of Cardiology, Andrzej Frycz Modrzewski Krakow University, Poland. FAU - Mazur, Marta AU - Mazur M AD - Department of Cardiology, American Heart of Poland, Bielsko-Biala, Poland. FAU - Kepa, Krzysztof AU - Kepa K AD - Department of Cardiac Surgery, American Heart of Poland, Bielsko-Biala, Poland. AD - Department of Cardiac Surgery, Academy of Silesia, Katowice, Poland. FAU - Gerber, Witold AU - Gerber W AD - Department of Cardiac Surgery, American Heart of Poland, Bielsko-Biala, Poland. AD - Department of Cardiac Surgery, Academy of Silesia, Katowice, Poland. FAU - Milewski, Krzysztof AU - Milewski K AD - Department of Cardiology, American Heart of Poland, Bielsko-Biala, Poland. AD - Department of Cardiology, Academy of Silesia, Katowice, Poland. AD - Center for Cardiovascular Research and Development, American Heart of Poland, Katowice, Poland. FAU - Kazmierczak, Pawel AU - Kazmierczak P AD - American Heart of Poland, Katowice, Poland. FAU - Buszman, Pawel Eugeniusz AU - Buszman PE AD - Cardiology Department, Collegium Medicum, Jan Dlugosz University, Czestochowa, Poland. FAU - Bochenek, Andrzej AU - Bochenek A AD - Department of Cardiac Surgery, American Heart of Poland, Bielsko-Biala, Poland. AD - Department of Cardiac Surgery, Academy of Silesia, Katowice, Poland. FAU - Cisowski, Marek AU - Cisowski M AD - Department of Cardiac Surgery, University Hospital, Institute of Medical Sciences, University of Opole, Poland. FAU - Buszman, Piotr Pawel AU - Buszman PP AD - Department of Cardiology, Andrzej Frycz Modrzewski Krakow University, Poland. AD - Department of Cardiology, American Heart of Poland, Bielsko-Biala, Poland. AD - Center for Cardiovascular Research and Development, American Heart of Poland, Katowice, Poland. FAU - Sanetra, Krzysztof AU - Sanetra K AD - Department of Cardiac Surgery, American Heart of Poland, Bielsko-Biala, Poland. AD - Division of Cardiovascular Surgery, Collegium Medicum, Andrzej Frycz Modrzewski Krakow University, Poland. LA - eng PT - Comparative Study PT - Journal Article DEP - 20260423 PL - United States TA - Innovations (Phila) JT - Innovations (Philadelphia, Pa.) JID - 101257528 SB - IM MH - Humans MH - Female MH - Retrospective Studies MH - *Coronary Artery Bypass/methods/adverse effects MH - Male MH - Treatment Outcome MH - Aged MH - Follow-Up Studies MH - *Percutaneous Coronary Intervention/methods/adverse effects MH - Middle Aged MH - Drug-Eluting Stents MH - Postoperative Complications/epidemiology MH - *Coronary Artery Disease/surgery MH - Feasibility Studies MH - Blood Transfusion/statistics & numerical data OTO - NOTNLM OT - angioplasty OT - coronary artery bypass grafting OT - drug-eluting stent OT - hybrid coronary revascularization COIS- Declaration of Conflicting InterestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2026/04/24 06:33 MHDA- 2026/06/15 11:37 CRDT- 2026/04/24 02:03 PHST- 2026/06/15 11:37 [medline] PHST- 2026/04/24 06:33 [pubmed] PHST- 2026/04/24 02:03 [entrez] AID - 10.1177/15569845261425652 [doi] PST - ppublish SO - Innovations (Phila). 2026 Mar-Apr;21(2):129-137. doi: 10.1177/15569845261425652. Epub 2026 Apr 23. PMID- 42024483 OWN - NLM STAT- MEDLINE DCOM- 20260624 LR - 20260813 IS - 1538-943X (Electronic) IS - 1058-2916 (Print) IS - 1058-2916 (Linking) VI - 72 IP - 7 DP - 2026 Jul 1 TI - Ethical Challenges of Extracorporeal Membrane Oxygenation: Enhanced Recovery After Surgery Cardiac Society Consensus on Key Issues and Practical Recommendations. PG - 544-552 LID - 10.1097/MAT.0000000000002707 [doi] AB - Extracorporeal membrane oxygenation (ECMO) provides lifesaving support for patients with cardiopulmonary failure but poses complex ethical challenges that may generate moral distress for clinicians, patients, and families. We convened a multidisciplinary panel of experts in cardiothoracic surgery, critical care, and palliative medicine to identify recurring ethical issues. The panel includes ECMO specialists working in the US, Canada, and the UK. The panel was nominated by organizers of a national critical care meeting. We analyzed four domains of ethical tension: 1) equitable ECMO candidacy decisions; 2) integration of palliative care and clinical ethics; 3) preservation of patient autonomy when institutional or benchmarking pressures influence care; and 4) responding to requests to continue ECMO when there is no exit strategy. Consensus recommendations emphasize transparent, team-based decisions, early involvement of ethics and palliative care, and consistent processes for ongoing review of candidacy and continuation of ECMO. Programs should recognize and mitigate institutional pressures that may undermine patient-centered care. As ECMO use expands, the development of ethical care frameworks is essential to ensure equity, uphold autonomy, and align treatments with patients' goals and values. This work provides a practical, consensus-based guide for addressing the ethical complexities of ECMO in contemporary critical care. CI - Copyright (c) 2026 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the ASAIO. FAU - Griffee, Matthew J AU - Griffee MJ AUID- ORCID: 0000-0002-4217-4565 AD - From the Department of Anesthesiology, University of Utah, Salt Lake City, Utah. FAU - Kirsch, Roxanne E AU - Kirsch RE AD - Department of Critical Care and Department of Bioethics, The Hospital for Sick Children, Toronto, Canada. AD - Department of Pediatrics, Temerty School of Medicine, University of Toronto, Toronto, Canada. FAU - Rubin, Jonah AU - Rubin J AD - Division of Pulmonary & Critical Care Medicine, Massachusetts General Hospital, Boston, Massachusetts. AD - Center for Bioethics and Department of Medicine, Harvard Medical School, Boston, Massachusetts. FAU - Peeler, Anna AU - Peeler A AD - Kings College, London, UK. FAU - Hayanga, Jeremiah W AU - Hayanga JW AD - Department of Surgery, West Virginia University, Morgantown, West Virginia. FAU - Chatterjee, Subhasis AU - Chatterjee S AD - Department of Surgery, Baylor College of Medicine. FAU - Dorsey, David AU - Dorsey D AD - Department of Anesthesiology, University of Utah, Salt Lake City, Utah. FAU - Emeruwa, I Obi AU - Emeruwa IO AD - Division of Pulmonary, Critical Care, and Sleep Medicine, University of California, Los Angeles, California. FAU - Goodwin, Matthew L AU - Goodwin ML AD - Department of Surgery, University of Utah, Salt Lake City, Utah. FAU - Rubin, Emily B AU - Rubin EB AD - Department of Medicine, Harvard Medical School, Mass Gen Hospital, Boston, Massachusetts. FAU - Kim, Bo S AU - Kim BS AD - Kings College, London, UK. FAU - Grant, Michael C AU - Grant MC AD - Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland. FAU - Zaaqoq, Akram M AU - Zaaqoq AM AD - Division of Critical Care, Department of Anesthesiology, University of Virginia, Charlottesville, Virginia. FAU - Vogelsong, Melissa A AU - Vogelsong MA AD - Department of Anesthesiology, Stanford University, Stanford, California. FAU - Hirshberg, Eliotte L AU - Hirshberg EL AD - Intermountain Health and the University of Utah, Pulmonary and Critical Care Medicine, Salt Lake City, Utah. FAU - Engelman, Daniel T AU - Engelman DT AD - Baystate Medical Center, Department of Surgery, University of Massachusetts Chan Medical School-Baystate, Springfield, Massachusetts. FAU - Cho, Sung-Min AU - Cho SM AD - Departments of Neurology, Anesthesiology, Critical Care Medicine and Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland. FAU - Arora, Rakesh C AU - Arora RC AD - Department of Surgery, Northwestern University, Chicago, Illinois. LA - eng PT - Consensus Statement PT - Journal Article DEP - 20260423 PL - United States TA - ASAIO J JT - ASAIO journal (American Society for Artificial Internal Organs : 1992) JID - 9204109 SB - IM MH - *Extracorporeal Membrane Oxygenation/ethics MH - Humans MH - Palliative Care/ethics MH - Critical Care/ethics MH - Ethical Dilemmas MH - Societies, Medical PMC - PMC13299034 OTO - NOTNLM OT - benchmarking OT - bioethics OT - ethical dilemmas OT - extracorporeal membrane oxygenation OT - medical futility OT - palliative care COIS- Disclosure: The authors have no conflicts of interest to report. EDAT- 2026/04/23 18:34 MHDA- 2026/06/25 00:33 PMCR- 2026/06/25 CRDT- 2026/04/23 12:23 PHST- 2026/06/25 00:33 [medline] PHST- 2026/04/23 18:34 [pubmed] PHST- 2026/04/23 12:23 [entrez] PHST- 2026/06/25 00:00 [pmc-release] AID - 00002480-990000000-00945 [pii] AID - ASAIO-25-0607 [pii] AID - 10.1097/MAT.0000000000002707 [doi] PST - ppublish SO - ASAIO J. 2026 Jul 1;72(7):544-552. doi: 10.1097/MAT.0000000000002707. Epub 2026 Apr 23. PMID- 42022168 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260423 LR - 20260813 IS - 2577-171X (Electronic) IS - 2577-171X (Linking) VI - 9 IP - 2 DP - 2026 Mar TI - Successful Emergency Cardiac Surgery for Intraoperative Pulmonary Artery Tumor Embolism During Renal Cell Carcinoma Surgery: A Case Report. PG - e70168 LID - 10.1002/iju5.70168 [doi] LID - e70168 AB - INTRODUCTION: Intraoperative tumor thrombus embolization during renal cell carcinoma (RCC) surgery with inferior vena cava (IVC) tumor thrombus is a rare but potentially fatal complication. We report successful emergency cardiac surgery for massive pulmonary artery tumor embolism. CASE PRESENTATION: A 75-year-old female with left RCC and IVC tumor thrombus underwent radical nephrectomy. Pre-existing left pulmonary artery tumor embolism was noted preoperatively. During IVC manipulation, the tumor thrombus dislodged and migrated through the right heart to completely occlude the right pulmonary artery, causing cardiac arrest. Through multidisciplinary collaboration, nephrectomy was completed under cardiac massage, followed by emergency cardiopulmonary bypass and pulmonary artery thrombectomy. The patient recovered completely without neurological sequelae. CONCLUSION: This case demonstrates the critical importance of preoperative risk assessment, intraoperative transesophageal echocardiography monitoring, and immediate multidisciplinary decision-making in managing this life-threatening complication. The "double hit" mechanism of pre-existing and acute pulmonary embolism significantly worsened the clinical course. CI - (c) 2026 The Author(s). IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of Japanese Urological Association. FAU - Kijima, Toshiki AU - Kijima T AUID- ORCID: 0000-0002-4380-9294 AD - Department of Urology Dokkyo Medical University Tochigi Japan. FAU - Nagoshi, Akihiko AU - Nagoshi A AD - Department of Urology Dokkyo Medical University Tochigi Japan. FAU - Kobayashi, Kento AU - Kobayashi K AD - Department of Urology Dokkyo Medical University Tochigi Japan. FAU - Nagaoka, Ryo AU - Nagaoka R AD - Department of Anesthesiology and Pain Medicine Dokkyo Medical University Tochigi Japan. FAU - Sato, Yuya AU - Sato Y AD - Department of Anesthesiology and Pain Medicine Dokkyo Medical University Tochigi Japan. FAU - Kato, Takashi AU - Kato T AD - Department of Cardiac and Vascular Surgery Dokkyo Medical University Tochigi Japan. FAU - Hamagchi, Shinsuke AU - Hamagchi S AD - Department of Anesthesiology and Pain Medicine Dokkyo Medical University Tochigi Japan. FAU - Yamaguchi, Shigeki AU - Yamaguchi S AD - Department of Anesthesiology and Pain Medicine Dokkyo Medical University Tochigi Japan. FAU - Fukuda, Hirotsugu AU - Fukuda H AD - Department of Cardiac and Vascular Surgery Dokkyo Medical University Tochigi Japan. FAU - Kamai, Takao AU - Kamai T AD - Department of Urology Dokkyo Medical University Tochigi Japan. LA - eng PT - Journal Article DEP - 20260316 PL - Australia TA - IJU Case Rep JT - IJU case reports JID - 101764958 PMC - PMC13097613 OTO - NOTNLM OT - emergency cardiac surgery OT - multidisciplinary team OT - pulmonary embolism OT - renal cell carcinoma OT - tumor thrombus COIS- The authors declare no conflicts of interest. EDAT- 2026/04/23 06:32 MHDA- 2026/04/23 06:33 PMCR- 2026/03/16 CRDT- 2026/04/23 05:08 PHST- 2025/10/23 00:00 [received] PHST- 2026/02/17 00:00 [revised] PHST- 2026/03/10 00:00 [accepted] PHST- 2026/04/23 06:33 [medline] PHST- 2026/04/23 06:32 [pubmed] PHST- 2026/04/23 05:08 [entrez] PHST- 2026/03/16 00:00 [pmc-release] AID - IJU570168 [pii] AID - 10.1002/iju5.70168 [doi] PST - epublish SO - IJU Case Rep. 2026 Mar 16;9(2):e70168. doi: 10.1002/iju5.70168. eCollection 2026 Mar. PMID- 42022061 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260423 LR - 20260921 IS - 1658-354X (Print) IS - 0975-3125 (Electronic) VI - 20 IP - 2 DP - 2026 Apr-Jun TI - Intraoperative cardiac complications in liver transplantation: A comprehensive review of management strategies. PG - 389-398 LID - 10.4103/sja.sja_546_25 [doi] AB - Liver transplantation (LT) stands as the definitive treatment for end-stage liver disease (ESLD), but its perioperative management poses formidable challenges for anesthesiologists. Among the myriad complexities, cardiac actions emerge as pivotal determinants of mortality and overall outcomes. Understanding the multifaceted pathogenesis of ESLD and its profound impact on the circulatory system is paramount for effective anesthesia administration during LT. LT represents a dynamic process and constitutes one of the most taxing cardiovascular events for ESLD patients. The intricate nature of anesthesia management demands a precise multidisciplinary approach, requiring anesthesiologists to remain attuned to the swiftly evolving physiological, metabolic, hemodynamic, and bleeding-coagulation dynamics. Central to successful outcomes is a thorough preoperative evaluation and optimization of the cardiovascular system to mitigate potential intraoperative cardiac complications (ICCs). Through a meticulous review of the literature, our focus is to illuminate key ICCs encountered during the intraoperative phase of LT, offering insights into effective anesthesia management strategies. CI - Copyright: (c) 2026 Saudi Journal of Anesthesia. FAU - Cekmen, Nedim AU - Cekmen N AD - Department of Anesthesiology and Intensive Care Unit, Baskent University, Faculty of Medicine, Ankara, Turkey. FAU - Uslu, Ahmed AU - Uslu A AD - Department of Anesthesiology and Intensive Care Unit, Baskent University, Faculty of Medicine, Ankara, Turkey. LA - eng PT - Journal Article PT - Review DEP - 20260402 PL - India TA - Saudi J Anaesth JT - Saudi journal of anaesthesia JID - 101500601 PMC - PMC13099037 OTO - NOTNLM OT - Anesthesia management OT - cardiac complications OT - early recognition OT - liver transplantation OT - multidisciplinary approach COIS- There are no conflicts of interest. EDAT- 2026/04/23 12:36 MHDA- 2026/04/23 12:37 PMCR- 2026/04/02 CRDT- 2026/04/23 05:07 PHST- 2025/07/04 00:00 [received] PHST- 2025/08/04 00:00 [revised] PHST- 2025/08/18 00:00 [accepted] PHST- 2026/04/23 12:37 [medline] PHST- 2026/04/23 12:36 [pubmed] PHST- 2026/04/23 05:07 [entrez] PHST- 2026/04/02 00:00 [pmc-release] AID - SJA-20-389 [pii] AID - 10.4103/sja.sja_546_25 [doi] PST - epublish SO - Saudi J Anaesth. 2026 Apr 2;20(2):389-398. doi: 10.4103/sja.sja_546_25. eCollection 2026 Apr-Jun. PMID- 42021328 OWN - NLM STAT- MEDLINE DCOM- 20260627 LR - 20260813 IS - 1749-8090 (Electronic) IS - 1749-8090 (Linking) VI - 21 IP - 1 DP - 2026 Apr 22 TI - Prehabilitation clinic in cardiac surgery: multidisciplinary protocol for the improvement of postoperative outcomes. LID - 10.1186/s13019-026-04110-z [doi] LID - 443 AB - BACKGROUND: Prehabilitation in cardiac surgery is a multidisciplinary approach aimed at optimizing the clinical and functional status of patients awaiting elective procedures. Interventions addressing nutrition, physical activity, psychological support and comorbidity management may improve postoperative outcomes, reduce complications and accelerate recovery. Despite its potential, prehabilitation in cardiac surgery remains scarcely explored and not routinely implemented. OBJECTIVES: The primary objective is to evaluate the impact of a multidisciplinary prehabilitation program in patients undergoing elective cardiac surgery. The study will assess its effect on perioperative clinical outcomes, including the number of red blood cell units transfused from surgical incision until hospital discharge (primary outcome), as well as duration of postoperative mechanical ventilation (hours), length of stay in the intensive care unit and ward (days), total hospital length of stay and the incidence of hospital-acquired infectious complications. METHODS: This single-center prospective observational study includes a historical control group. Adult patients undergoing elective cardiac surgery at Citta di Lecce Hospital, GVM Care & Research, will be consecutively enrolled over six months. Outcomes will be compared with patients treated during the corresponding period of the previous year. EXPECTED RESULTS: We hypothesize that a proportion of patients within the study sample will present with unrecognized iron deficiency and that its correction may reduce the number of perioperative red blood cell units administered. Respiratory training, smoking cessation and controlled physical activity with telemedicine monitoring may be associated with shorter postoperative intubation time. Nutritional supplementation, especially in frail patients, is expected to improve immune competence and reduce surgical site infections. Psychological support may improve adherence and decrease surgery withdrawal while on the waiting list. An economic analysis will assess the feasibility of institutionalizing this clinic in both hospital and online settings. CONCLUSION: This study may provide evidence supporting prehabilitation as a means to improve perioperative clinical outcomes in cardiac surgery. Positive results could pave the way for systematic implementation of a tele-prehabilitation platform, enabling remote participation and representing an evolution of the perioperative care model. TRIAL REGISTRATION: This study protocol has been approved by the local Ethics Committee of Bari (Study ID: 2717/CEL). Registration on ClinicalTrials.gov is ongoing. CI - (c) 2026. The Author(s). FAU - Santarpino, Giuseppe AU - Santarpino G AD - Department of Clinical and Experimental Medicine, Magna Graecia University, Viale Europa, Catanzaro, 88100, Italy. santarpino@unicz.it. AD - Department of Cardiac Surgery, Citta di Lecce Hospital, GVM Care & Research, Lecce, Italy. santarpino@unicz.it. AD - Paracelsus Medical University, Nuremberg, Germany. santarpino@unicz.it. FAU - D'Anna, Veronica AU - D'Anna V AD - Department of Cardiac Surgery, Citta di Lecce Hospital, GVM Care & Research, Lecce, Italy. FAU - Prencipe, Chiara Maria AU - Prencipe CM AD - Department of Clinical and Experimental Medicine, Magna Graecia University, Viale Europa, Catanzaro, 88100, Italy. FAU - Cavone, Monica AU - Cavone M AD - Department of Clinical Nutrition, Citta di Lecce Hospital, GVM Care & Research, Lecce, Italy. FAU - Palisi, Giulia AU - Palisi G AD - Department of Clinical Nutrition, Citta di Lecce Hospital, GVM Care & Research, Lecce, Italy. AD - Department of Biosciences, Biotechnology and Environment, University of Bari Aldo Moro, Bari, Italy. FAU - Francia, Michela AU - Francia M AD - Department of Cardiac Surgery, Citta di Lecce Hospital, GVM Care & Research, Lecce, Italy. AD - Department of Hospital Psychology, Citta di Lecce Hospital, GVM Care & Research, Lecce, Italy. FAU - Patera, Silvia AU - Patera S AD - Department of Hospital Psychology, Citta di Lecce Hospital, GVM Care & Research, Lecce, Italy. FAU - Nestola, Nadia AU - Nestola N AD - Department of Cardiac Surgery, Citta di Lecce Hospital, GVM Care & Research, Lecce, Italy. FAU - Maniglio, Luana AU - Maniglio L AD - Department of Cardiac Surgery, Citta di Lecce Hospital, GVM Care & Research, Lecce, Italy. FAU - Verghi, Emanuele AU - Verghi E AD - Department of Cardiac Surgery, Citta di Lecce Hospital, GVM Care & Research, Lecce, Italy. FAU - Specchia, Luigi AU - Specchia L AD - Department of Cardiac Surgery, Citta di Lecce Hospital, GVM Care & Research, Lecce, Italy. FAU - Fiorentino, Alessandro AU - Fiorentino A AD - Department of Cardiac Surgery, Citta di Lecce Hospital, GVM Care & Research, Lecce, Italy. FAU - Cosco, Valeria AU - Cosco V AD - Department of Cardiology, Bassini Hospital, Milano, Italy. FAU - Calassanzio, Marta AU - Calassanzio M AD - Personal Management Department, Citta di Lecce Hospital, GVM Care & Research, Lecce, Italy. FAU - Arima, Serena AU - Arima S AD - Department of Human and Social Sciences, University of Salento, Lecce, Italy. FAU - Barbato, Raffaele AU - Barbato R AD - Department of Cardiac Surgery, Campus Bio-Medico University of Rome, Rome, Italy. FAU - Speziale, Giuseppe AU - Speziale G AD - Department of Cardiac Surgery, Santa Maria Hospital, GVM Care & Research, Bari, Italy. LA - eng PT - Journal Article PT - Observational Study DEP - 20260422 PL - England TA - J Cardiothorac Surg JT - Journal of cardiothoracic surgery JID - 101265113 SB - IM MH - Humans MH - *Cardiac Surgical Procedures/rehabilitation/methods MH - Prospective Studies MH - *Postoperative Complications/prevention & control/epidemiology MH - *Preoperative Care/methods MH - *Preoperative Exercise MH - Treatment Outcome MH - Length of Stay MH - Female MH - Male PMC - PMC13289330 OTO - NOTNLM OT - Cardiac surgery OT - Exercise OT - Nutrition OT - Prehabilitation OT - Psychology OT - Telemedicine COIS- Declarations. Ethics approval and consent to participate: The study has been approved by the Ethics Committee of Bari, Italy. Written informed consent will be obtained from all participants prior to enrollment. Consent for publication: Not applicable. Competing interests: Supplements intended to address potential deficiencies were provided by Essecore. EDAT- 2026/04/23 06:32 MHDA- 2026/06/23 12:35 PMCR- 2026/04/22 CRDT- 2026/04/23 00:53 PHST- 2025/09/30 00:00 [received] PHST- 2026/04/10 00:00 [accepted] PHST- 2026/06/23 12:35 [medline] PHST- 2026/04/23 06:32 [pubmed] PHST- 2026/04/23 00:53 [entrez] PHST- 2026/04/22 00:00 [pmc-release] AID - 10.1186/s13019-026-04110-z [pii] AID - 4110 [pii] AID - 10.1186/s13019-026-04110-z [doi] PST - epublish SO - J Cardiothorac Surg. 2026 Apr 22;21(1):443. doi: 10.1186/s13019-026-04110-z. PMID- 42020654 OWN - NLM STAT- MEDLINE DCOM- 20260627 LR - 20260813 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 16 IP - 1 DP - 2026 Apr 22 TI - Delphi consensus recommendations for preventing and treating cardiac implantable electronic device infections beyond current guidelines. LID - 10.1038/s41598-026-49515-x [doi] LID - 13135 AB - Infections associated with cardiac implantable electronic devices (CIEDs) pose significant clinical challenges due to their life-threatening nature and complex management. Recent advancements in prevention, diagnosis, and treatment have been driven by landmark trials such as PADIT and WRAP-IT, alongside evolving diagnostic tools like [18 F]FDG PET/CT and updated diagnostic criteria (e.g., 2023 Duke-ISCVID). A combination of well-established approaches-such as leadless pacemakers, subcutaneous ICDs, and an antibiotic-eluting envelope-and evolving adjunctive strategies, including a taurolidine-containing antimicrobial agent, incision drapes, fascial plane blocks or double gloving, have broadened the spectrum of options to reduce and potentially mitigate the risk of CIED infection. While devices like leadless pacemakers, subcutaneous ICDs, and antibiotic envelopes are supported by randomized controlled trials, adjunctive measures such as taurolidine rely predominantly on observational data. To address this variation in the strength of available evidence, a modified Delphi consensus process was conducted, bringing together cardiologists and infectious disease experts to define experience-based best practices in areas where current guidelines offer limited or no specific recommendations. The consensus achieved strong agreement (>/= 80%) on key strategies, including mandatory double-gloving to reduce contamination, the use of validated risk models (e.g., PADIT, BLISTER) for tailored infection prevention employing an antibiotic eluting envelope, multidisciplinary decision-making for non-extractable infections and the use of taurolidine solutions as adjuncts to prevent CIED infection. Moderate consensus (60-79%) supported non-delayed reimplantation after lead-related endocarditis and single-session reimplantation in pacing-dependent patients under specific circumstances. However, no consensus was reached on mandating a minimum annual procedural volume (>/= 500 cases) for CIED centers, reflecting concerns about access and operator expertise. The findings emphasize the importance of personalized risk stratification, procedural innovations, and multidisciplinary collaboration in optimizing CIED infection outcomes. Areas requiring further research include the efficacy of iodophor-impregnated drapes, fascial plane blocks, and taurolidine solutions. This consensus provides a pragmatic framework for clinicians, highlighting evidence-informed strategies to mitigate infection risks and improve care for patients undergoing CIED procedures. FAU - Baldauf, Benito AU - Baldauf B AD - Christian-Albrechts-University, Kiel, Germany. benito.baldauf@hs-bremerhaven.de. AD - University of Applied Sciences, Bremerhaven, Germany. benito.baldauf@hs-bremerhaven.de. AD - University of Applied Sciences Bremerhaven, An der Karlstadt 8, 27568, Bremerhaven, Germany. benito.baldauf@hs-bremerhaven.de. AD - Medical Faculty, Christian Albrechts University Kiel, 24211, Bremerhaven, Germany. benito.baldauf@hs-bremerhaven.de. FAU - Bode, Kerstin AU - Bode K AD - Heart Center, Leipzig, Germany. FAU - Biffi, Mauro AU - Biffi M AD - Policlinic S. Orsola-Malpighi, University of Bologna, Bologna, Italy. FAU - Rapacciuolo, Antonio AU - Rapacciuolo A AD - Federico II University of Naples, Naples, Italy. AD - Ospedale Evangelico Betania, Naples, Italy. FAU - Zucchelli, Giulio AU - Zucchelli G AD - Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy. FAU - Bongiorni, Maria Grazia AU - Bongiorni MG AD - Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy. FAU - Casorelli, Ernesto AU - Casorelli E AD - Santa Maria della Misericordia Hospital, Montepulciano, Italy. FAU - Mitacchione, Gianfranco AU - Mitacchione G AD - Spedali Civili di Brescia, Brescia, Italy. FAU - Hohendanner, Felix AU - Hohendanner F AD - German Heart Center Berlin, Berlin, Germany. FAU - Mangoni, Emanuele Durante AU - Mangoni ED AD - University Hospital Federico II, Naples, Italy. FAU - Dusi, Veronica AU - Dusi V AD - University Hospital of Turin, Turin, Italy. FAU - Foley, Paul William Xavier AU - Foley PWX AD - Great Western Hospitals, Swindon, UK. FAU - Pan, Angelo AU - Pan A AD - Azienda Socio Sanitaria Territoriale di Cremona, Cremona, Italy. FAU - Arena, Giuseppe AU - Arena G AD - Nuovo Ospedale delle Apuane, Massa Carrara, Italy. FAU - Rao, Archana AU - Rao A AD - Liverpool Heart and Chest Hospital, Liverpool, UK. FAU - Spencker, Sebastian AU - Spencker S AD - Jewish Hospital, Berlin, Germany. FAU - Steger, Alexander AU - Steger A AD - University Hospital, Technical University of Munich, Munich, Germany. FAU - Tascini, Carlo AU - Tascini C AD - University Hospital, Udine, Italy. FAU - Zaca, Valerio AU - Zaca V AD - University of Siena, Siena, Italy. FAU - Migliore, Federico AU - Migliore F AD - University of Padova, Padova, Italy. AD - Azienda Ospedaliera, Universita di Padova, Padova, Italy. FAU - Assadian, Ojan AU - Assadian O AD - University of Huddersfield, Huddersfield, UK. AD - University Hospital, Wiener Neustadt, Austria. FAU - Cemin, Roberto AU - Cemin R AD - San Maurizio Regional Hospital, Bolzano, Italy. FAU - Giaccardi, Marzia AU - Giaccardi M AD - Ospedale Santa Maria Annunziata, Florence, Italy. AD - University Hospital Meyer, Florence, Italy. FAU - Bonnemeier, Hendrik AU - Bonnemeier H AD - Christian-Albrechts-University, Kiel, Germany. AD - University of Applied Sciences, Bremerhaven, Germany. AD - Asklepios Hospital Schildautal, Seesen, Germany. LA - eng PT - Consensus Statement PT - Journal Article DEP - 20260422 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 0 (Anti-Bacterial Agents) RN - 1EQV5MLY3D (Taurine) SB - IM MH - Humans MH - *Defibrillators, Implantable/adverse effects MH - *Pacemaker, Artificial/adverse effects MH - *Prosthesis-Related Infections/prevention & control/therapy/etiology MH - Practice Guidelines as Topic MH - Anti-Bacterial Agents/therapeutic use MH - Taurine/analogs & derivatives/therapeutic use PMC - PMC13102974 OTO - NOTNLM OT - Cardiac implantable electronic device OT - Consensus OT - Expert panel OT - Guidelines OT - Infection OT - Knowledge gaps OT - Recommendations OT - Treatment COIS- Declarations. Competing interests: BB is a medical consultant for/part of the advisory board of: Abbott, Bioline Supply, Biotronik, Cablon NL, CRM Microport, Crosstec GmbH, Drugsales Limited, DSE Turkiye, Implicity, Kappamed, Kimal PLC, M3 Medical/Ecclipse Medical, Medival SRL, Medtronic, Philips/Spectranetics, Sintec SRL, Tauro-Implant GmbH, Tauropharm GmbH, Transcutan, Transaxis. The other authors have no conflicts of interest to declareFunding: Open access publishing for this article was supported through a transformative agreement between the DEAL Consortium and Springer Nature. Ethical approval: All methods were carried out in accordance with relevant guidelines and regulations, including the ethical principles set forth in the latest version of the Declaration of Helsinki. This Delphi consensus study was conducted exclusively among faculty members attending the 360 CIED Infection Congress on May 9th, 2025, in Florence, Italy.The survey was conducted fully anonymously; no personal identifiers, digital signatures, or traceable metadata were collected or stored. In accordance with EU GDPR Recital 26 and the guidance of the "Garante per la Protezione dei Dati Personali", anonymous data that do not allow for the identification of individuals are not subject to data protection obligations. As such, the survey data qualify as anonymous, and a waiver of formal data protection review is granted. Although all participating faculty members are co-authors of this manuscript, the survey data were collected and analyzed in such a way that individual responses cannot be linked to any participant, thereby maintaining full anonymity throughout the consensus process. All experimental protocols were reviewed for compliance with institutional standards. Informed consent was obtained from all participating faculty members prior to the start of the survey, during the congress itself. EDAT- 2026/04/23 00:31 MHDA- 2026/06/27 18:38 PMCR- 2026/04/22 CRDT- 2026/04/22 23:37 PHST- 2025/07/25 00:00 [received] PHST- 2026/04/15 00:00 [accepted] PHST- 2026/06/27 18:38 [medline] PHST- 2026/04/23 00:31 [pubmed] PHST- 2026/04/22 23:37 [entrez] PHST- 2026/04/22 00:00 [pmc-release] AID - 10.1038/s41598-026-49515-x [pii] AID - 49515 [pii] AID - 10.1038/s41598-026-49515-x [doi] PST - epublish SO - Sci Rep. 2026 Apr 22;16(1):13135. doi: 10.1038/s41598-026-49515-x. PMID- 42012719 OWN - NLM STAT- MEDLINE DCOM- 20260627 LR - 20261010 IS - 1573-7322 (Electronic) IS - 1382-4147 (Linking) VI - 31 IP - 1 DP - 2026 Apr 21 TI - CalShock: beyond the shock team, building on California's cardiogenic shock system of care. LID - 60 [pii] LID - 10.1007/s10741-026-10628-0 [doi] AB - Regional cardiogenic shock (CS) response systems are strong in concept but remain inconsistently implemented in the United States, with persistent heterogeneity in shock classification, mechanical circulatory support (MCS) deployment, hemodynamic monitoring, and transfer pathways. In California, these challenges are magnified by geography and fragmented hospital networks. The inaugural CALShock conference, convened in Los Angeles in February 2025 by the California Chapter of the American College of Cardiology, brought together multidisciplinary experts to synthesize emerging evidence and operational strategies for scalable improvements to shock systems of care. Key themes included routine use of shared classification and phenotyping frameworks, streamlined shock team activation and escalation workflows, transport as essential infrastructure, standardized prevention and management of MCS-related complications with clear exit strategies, broader registry participation, and integration of survivorship and post-discharge planning into comprehensive shock care. We describe the conference framework as a replicable model for other states and regions seeking to advance cardiogenic shock systems of care. FAU - Bell, Fletcher M AU - Bell FM AD - Department of Cardiology, University of California, CA, San Francisco, USA. fletcher.bell@ucsf.edu. FAU - Holtzman, Jessica N AU - Holtzman JN AD - Department of Cardiology, University of California, CA, San Francisco, USA. FAU - Chandrakumar, Harshith P AU - Chandrakumar HP AD - Department of Cardiology, Loma Linda University Medical Center, Loma Linda, CA, USA. FAU - Marogi, Emily P AU - Marogi EP AD - Department of Cardiology, University of California, CA, San Francisco, USA. FAU - Khedraki, Rola AU - Khedraki R AD - SUNY Downstate Medical Center, Brooklyn, NY, USA. FAU - Cheng, Richard AU - Cheng R AD - Division of Cardiovascular Medicine, Scripps Clinic, La Jolla, CA, USA. FAU - Elliott, Andrea AU - Elliott A AD - Department of Cardiology, UCLA Medical Center, Santa Monica, CA, USA. FAU - Hilliard, Anthony A AU - Hilliard AA AD - University of Minnesota, MN, Minneapolis, USA. FAU - Itchhaporia, Dipti AU - Itchhaporia D AD - Hoag Memorial Hospital Presbyterian, Newport Beach, CA, USA. FAU - Chonde, Meshe D AU - Chonde MD AD - Department of Cardiology, Cedars-Sinai Medical Center, Los Angeles, CA, USA. FAU - Naidu, Srihari S AU - Naidu SS AD - Westchester Medical Center, Valhalla, NY, USA. FAU - Egrie, Glenn AU - Egrie G AD - California Pacific Medical Center, San Francisco, CA, USA. FAU - Mahmud, Ehtisham AU - Mahmud E AD - Division of Cardiovascular Medicine, University of California, San Diego, CA, USA. FAU - Tyler, Jeffrey M AU - Tyler JM AD - Orange County Heart Institute and Research Center, Orange, CA, USA. FAU - Morrow, David A AU - Morrow DA AD - Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA. FAU - Sakr, Antoine AU - Sakr A AD - University of Minnesota, MN, Minneapolis, USA. FAU - Marano, Paul AU - Marano P AD - Department of Cardiology, Cedars-Sinai Medical Center, Los Angeles, CA, USA. FAU - Thomas, Joseph L AU - Thomas JL AD - Division of Cardiology, Harbor-UCLA Medical Center, Torrance, CA, USA. FAU - Soni, Krishnan AU - Soni K AD - Department of Cardiology, University of California, CA, San Francisco, USA. FAU - Campbell, Lundy AU - Campbell L AD - Department of Cardiology, University of California, CA, San Francisco, USA. FAU - Klein, Alyssa AU - Klein A AD - School of Medicine, Tufts University, Medford, OR, USA. FAU - Bharadwaj, Aditya S AU - Bharadwaj AS AD - University of Minnesota, MN, Minneapolis, USA. FAU - O'Brien, Connor G AU - O'Brien CG AD - Department of Cardiology, University of California, CA, San Francisco, USA. LA - eng PT - Journal Article DEP - 20260421 PL - United States TA - Heart Fail Rev JT - Heart failure reviews JID - 9612481 SB - IM MH - Humans MH - California MH - *Patient Care Team/organization & administration MH - *Shock, Cardiogenic/therapy MH - Congresses as Topic COIS- Declarations. Ethical approval, Accordance, Consent to Participate, and Consent to Publish declarations: not applicable. Competing interests: The authors declare no competing interests. EDAT- 2026/04/21 18:33 MHDA- 2026/06/27 18:39 CRDT- 2026/04/21 11:16 PHST- 2026/01/20 00:00 [received] PHST- 2026/04/06 00:00 [accepted] PHST- 2026/04/02 00:00 [revised] PHST- 2026/06/27 18:39 [medline] PHST- 2026/04/21 18:33 [pubmed] PHST- 2026/04/21 11:16 [entrez] AID - 10.1007/s10741-026-10628-0 [pii] AID - 10.1007/s10741-026-10628-0 [doi] PST - epublish SO - Heart Fail Rev. 2026 Apr 21;31(1):60. doi: 10.1007/s10741-026-10628-0. PMID- 42001462 OWN - NLM STAT- MEDLINE DCOM- 20260715 LR - 20260715 IS - 1502-7686 (Electronic) IS - 0036-5513 (Linking) VI - 86 IP - 3 DP - 2026 TI - Less testing, more yield: a multicomponent intervention halves inpatient biochemistry. PG - 285-292 LID - 10.1080/00365513.2026.2659590 [doi] AB - Routine inpatient biochemical testing is often repeated without clinical indication. This quality improvement project aimed to reduce low-value biochemical testing in a Danish cardiology ward, targeting a 5% reduction within 6 months and sustainment for 12 months, without adverse changes in length of stay, discharges after noon, or 30-day readmissions. In a quality improvement project using the Model for Improvement and conducted through Plan-Do-Study-Act cycles, a multidisciplinary team implemented the following interventions: (i)targeted education for physicians and nurses e.g. clarifying of ordering responsibility; (ii)refinement of default biochemical profiles by removing non-essential tests (e.g. leukocyte count with differential, urea, hemoglobin) and curbing premature orders placed before the minimum re-testing interval; and (III)a centrally placed feedback dashboard. The primary outcome was the number of biochemical tests, adjusted for hours of hospitalization and caseload. Secondary outcomes were the proportion of results outside reference intervals and re‑testing intervals for common biochemical tests. Safety balancing measures were length of stay, discharges after noon, and 30-day readmissions. The pre-intervention period ran from February 27th, 2022, to February 26th, 2023, post-intervention period from March 5th, 2023, to February 2nd, 2025. After biochemical profile refinement in June 2023, median number of biochemical tests decreased 54% (hours of hospitalization adjusted) and 48% (caseload adjusted). The proportion of test results outside reference ranges increased 21%. Re-testing intervals lengthened for hemoglobin and troponin-I. Balancing measures showed no adverse signals, and effects persisted into February 2025. A pragmatic, simple bundle halved routine biochemical tests and increased diagnostic yield without measurable harm. FAU - Jacobsen, Malene S AU - Jacobsen MS AD - Medical Diagnostic Centre, Regional Hospital Central Jutland, Denmark. FAU - Albertsen, Andi E AU - Albertsen AE AD - Department of Cardiology, Regional Hospital Central Jutland, Denmark. FAU - Trolle, Christian AU - Trolle C AUID- ORCID: 0000-0003-4556-9113 AD - Medical Diagnostic Centre, Regional Hospital Central Jutland, Denmark. AD - University Research Clinic for Innovative Patient Pathways, Regional Hospital Central Jutland. AD - Institute of Clinical Medicine, Aarhus University, Denmark. LA - eng PT - Journal Article DEP - 20260419 PL - England TA - Scand J Clin Lab Invest JT - Scandinavian journal of clinical and laboratory investigation JID - 0404375 SB - IM MH - Humans MH - Quality Improvement MH - *Inpatients MH - Length of Stay MH - Denmark OTO - NOTNLM OT - Inpatient OT - blood draws OT - cardiology OT - electronic dashboard OT - length of stay OT - patient safety OT - quality improvement OT - workflow EDAT- 2026/04/20 13:10 MHDA- 2026/05/05 18:32 CRDT- 2026/04/19 14:23 PHST- 2026/05/05 18:32 [medline] PHST- 2026/04/20 13:10 [pubmed] PHST- 2026/04/19 14:23 [entrez] AID - 10.1080/00365513.2026.2659590 [doi] PST - ppublish SO - Scand J Clin Lab Invest. 2026;86(3):285-292. doi: 10.1080/00365513.2026.2659590. Epub 2026 Apr 19. PMID- 42001181 OWN - NLM STAT- MEDLINE DCOM- 20260627 LR - 20260813 IS - 1749-8090 (Electronic) IS - 1749-8090 (Linking) VI - 21 IP - 1 DP - 2026 Apr 18 TI - Sex differences in outcomes of a two-stage approach to aortic arch surgery: 8-year experience of a national aortovascular centre. LID - 10.1186/s13019-026-04090-0 [doi] LID - 312 AB - BACKGROUND: Hybrid surgery for aortic arch pathology consisting of a combined frozen elephant trunk (FET) and endovascular (TEVAR) treatment, confers a good prognosis with excellent outcomes. It is known that females, who often have higher risk profiles and more advanced disease at presentation, confer a worse prognosis post cardiac surgery compared to their male counterparts. We compare our outcomes of male and female patients after a two-stage approach. METHODS: Demographic, survival and outcome data were retrospectively analysed in patients undergoing two-staged FET and endovascular surgery between January 2018 and January 2025. RESULTS: 32 patients with mean age 60.8 years, underwent a two-stage surgery (endovascular N = 18 (56.2%) vs. open thoracoabdominal approach N = 14 (43.8%) 2nd stage)). 16 males (50%), with comparable demographics. Indications for FET surgery: incidence of chronic type A dissections were similar but females had fewer chronic type B dissections (2 vs. 9; p = 0.02; 0.1[0.02-0.6]); and more aneurysms (13 vs. 8; p = 0.14; 4.3[0.9-17.8]. Overall mortality: No in-hospital or 90-day mortality. Overall survival (OS) at 5-years was 87.1% vs. 77.9% for males and females respectively (p = 0.76). Complications: Females had more returns to theatre (4 vs. 2; p = 0.65; 2.3 [0.4-13.4]). LOS 16.0 vs. 13.5 days for males vs. females respectively (p = 0.54). 2nd stage surgery: Median interval between operations: 240 (males) vs. 140 days (females). OS correlated positively with increasing intervals in both males (p = 0.79; r = 0.07) and females (0.29; r-0.28). Overall complications were comparable. Females had more spinal ischaemia (7 vs. 3; p = 0.25; 3.3 [0.7-14]; but fewer females required renal replacement therapy (2 vs. 4; p = 0.65; 0.4[0.07-2.3]. CONCLUSION: Survival and complications are comparable in males and females, with good long-term results, therefore a two-stage approach should be offered to all patients along with aortovascular multidisciplinary team (MDT) surveillance. Larger studies are required to validate our results. FAU - Jhala, Hiral AU - Jhala H AD - Department of Cardiothoracic Surgery, Edinburgh Royal Infirmary, Edinburgh, UK. hiraljhala.hj@gmail.com. FAU - Avtaar Singh, Sanjeet Singh AU - Avtaar Singh SS AD - Department of Cardiothoracic Surgery, Edinburgh Royal Infirmary, Edinburgh, UK. FAU - El-Bakbak, Walid AU - El-Bakbak W AD - Department of Cardiothoracic Surgery, Edinburgh Royal Infirmary, Edinburgh, UK. FAU - Koutsogiannidis, Charilaos Panagiotis AU - Koutsogiannidis CP AD - Department of Cardiothoracic Surgery, Edinburgh Royal Infirmary, Edinburgh, UK. FAU - Zamvar, Vipin AU - Zamvar V AD - Department of Cardiothoracic Surgery, Edinburgh Royal Infirmary, Edinburgh, UK. FAU - Lim, Kelvin AU - Lim K AD - Department of Cardiothoracic Surgery, Edinburgh Royal Infirmary, Edinburgh, UK. FAU - Pessotto, Renzo AU - Pessotto R AD - Department of Cardiothoracic Surgery, Edinburgh Royal Infirmary, Edinburgh, UK. FAU - Falah, Orwa AU - Falah O AD - Department of Vascular Surgery, Edinburgh Royal Infirmary, Edinburgh, UK. FAU - Giordano, Vincenzo AU - Giordano V AD - Department of Cardiothoracic Surgery, Edinburgh Royal Infirmary, Edinburgh, UK. LA - eng PT - Journal Article DEP - 20260418 PL - England TA - J Cardiothorac Surg JT - Journal of cardiothoracic surgery JID - 101265113 SB - IM MH - Humans MH - Female MH - Male MH - Retrospective Studies MH - *Aorta, Thoracic/surgery MH - Middle Aged MH - Treatment Outcome MH - Sex Factors MH - *Blood Vessel Prosthesis Implantation/methods MH - *Aortic Aneurysm, Thoracic/surgery MH - *Endovascular Procedures/methods MH - Postoperative Complications/epidemiology MH - *Aortic Dissection/surgery MH - Aged MH - Dissection, Thoracic Aorta MH - Survival Rate/trends PMC - PMC13231548 OTO - NOTNLM OT - Aortic arch replacement OT - Frozen elephant trunk OT - Hybrid aortic OT - Two-stage COIS- Declarations. Ethics approval: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All procedures in this study were in accordance with the ethical standards of the institutional and/or national research committee(s) and with the Declaration of Helsinki (as revised in 2013). The Authors have ensured this article has been sufficiently anonymised to cause no harm to the patients or their families. Competing interests: The authors declare no competing interests. EDAT- 2026/04/19 13:11 MHDA- 2026/06/27 18:39 PMCR- 2026/04/18 CRDT- 2026/04/18 23:28 PHST- 2025/12/19 00:00 [received] PHST- 2026/04/07 00:00 [accepted] PHST- 2026/06/27 18:39 [medline] PHST- 2026/04/19 13:11 [pubmed] PHST- 2026/04/18 23:28 [entrez] PHST- 2026/04/18 00:00 [pmc-release] AID - 10.1186/s13019-026-04090-0 [pii] AID - 4090 [pii] AID - 10.1186/s13019-026-04090-0 [doi] PST - epublish SO - J Cardiothorac Surg. 2026 Apr 18;21(1):312. doi: 10.1186/s13019-026-04090-0. PMID- 42001143 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260627 LR - 20260813 IS - 2057-3804 (Electronic) IS - 2057-3804 (Linking) VI - 12 IP - 1 DP - 2026 Apr 18 TI - Chemotherapy-responsive primary cardiac lymphoma presenting as pericarditis and acute heart failure. LID - 10.1186/s40959-026-00487-x [doi] LID - 69 AB - BACKGROUND: Primary cardiac lymphomas (PCLs) are a rare subset of malignancies, representing a very small percentage of reported cancer patients. Even among primary cardiac tumors a diagnosis of lymphoma is rare, making a standard of care difficult to establish. CASE PRESENTATION: Here we report the case of a patient who presented with chest pain and dyspnea who was initially diagnosed with pericarditis. Further imaging revealed a large obstructive right atrial mass with pathologic diagnosis of aggressive B-cell lymphoma. The patient was initiated on multiagent chemotherapy with daEPOCH-R comprising etoposide, prednisone, cyclophosphamide, vincristine, and rituximab with subsequent improvement in heart failure symptoms and tumor markers. Doxorubicin was added upon normalization of ejection fraction. The patient developed central nervous system relapse three months after completion of chemotherapy. CONCLUSIONS: This case describes the diagnostic evaluation and treatment of a patient with primary cardiac lymphoma. In contrast to other cardiac tumors, most patients with PCLs are treated with chemotherapy alone. Despite this, mortality remains high. When aggressive tumor biology is present, rapid initiation of high intensity chemotherapy is feasible. Our patient showed rapid clinical improvement and resolution of his cardiac mass in response to the daEPOCH-R regimen. This case illustrates the value of a multidisciplinary approach to establish a rare diagnosis and initiate prompt treatment for an unstable patient. FAU - Schilthuis, Meghan AU - Schilthuis M AD - Indiana University School of Medicine, Indianapolis , Indiana , USA. mschilt@iu.edu. FAU - Fischer, Benjamin AU - Fischer B AD - Indiana University School of Medicine, Indianapolis , Indiana , USA. FAU - De Lancy, Shanelle AU - De Lancy S AD - Clinical Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis , Indiana , USA. FAU - Stohler, Ryan AU - Stohler R AD - Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis , Indiana , USA. FAU - Dave, Utpal P AU - Dave UP AD - Microbiology and Immunology, Indiana University School of Medicine, R. L. Roudebush VA Medical Center, and IU Simon Comprehensive Cancer Center, Indianapolis, IN, USA. LA - eng PT - Journal Article DEP - 20260418 PL - England TA - Cardiooncology JT - Cardio-oncology (London, England) JID - 101689938 PMC - PMC13220512 OTO - NOTNLM OT - Cardiac lymphoma OT - Cardiac magnetic resonance imaging OT - Chemotherapy OT - Heart failure OT - Pericarditis COIS- Declarations. Ethics approval and consent to participate: The patient has provided consent for their case to be published. Consent for publication: The patient described in this article has granted permission for the publication of their case. Competing interests: The authors declare no competing interests. EDAT- 2026/04/19 13:11 MHDA- 2026/04/19 13:12 PMCR- 2026/04/18 CRDT- 2026/04/18 23:27 PHST- 2025/09/05 00:00 [received] PHST- 2026/04/08 00:00 [accepted] PHST- 2026/04/19 13:12 [medline] PHST- 2026/04/19 13:11 [pubmed] PHST- 2026/04/18 23:27 [entrez] PHST- 2026/04/18 00:00 [pmc-release] AID - 10.1186/s40959-026-00487-x [pii] AID - 487 [pii] AID - 10.1186/s40959-026-00487-x [doi] PST - epublish SO - Cardiooncology. 2026 Apr 18;12(1):69. doi: 10.1186/s40959-026-00487-x. PMID- 42000016 OWN - NLM STAT- MEDLINE DCOM- 20260826 LR - 20260826 IS - 1555-7162 (Electronic) IS - 0002-9343 (Linking) VI - 139 IP - 10 DP - 2026 Oct TI - Lifetime management of aortic stenosis: A primer for the generalist. PG - 1294-1304 LID - S0002-9343(26)00287-1 [pii] LID - 10.1016/j.amjmed.2026.04.010 [doi] AB - Aortic stenosis affects millions globally and untreated disease approaches a one-year mortality of 50%. While surgical aortic valve replacement (SAVR) was historically the only life-prolonging treatment, transcatheter aortic valve replacement (TAVR) has revolutionized management, initially for inoperable patients and now extending to lower-risk populations. This review provides an overview of aortic stenosis, from pathophysiology through diagnosis. Disease progression, emerging pharmacological therapies, and surveillance strategies are discussed. Finally, the approach to intervention has evolved from surgical risk-based decision-making to a framework centered on age, life expectancy, and valve durability. Timely recognition and referral to a multidisciplinary heart team remain essential for shared decision making. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Safdar, Nawaz Z AU - Safdar NZ AD - Pennsylvania Hospital of the University of Pennsylvania Health System, Philadelphia, PA, USA. FAU - Khedro, Tarek AU - Khedro T AD - Pennsylvania Hospital of the University of Pennsylvania Health System, Philadelphia, PA, USA. FAU - Khan, Sabir A AU - Khan SA AD - Pennsylvania Hospital of the University of Pennsylvania Health System, Philadelphia, PA, USA. FAU - Khan, Aarish H AU - Khan AH AD - Pennsylvania Hospital of the University of Pennsylvania Health System, Philadelphia, PA, USA. FAU - Goldberg, David AU - Goldberg D AD - Pennsylvania Hospital of the University of Pennsylvania Health System, Philadelphia, PA, USA. FAU - Fiorilli, Paul N AU - Fiorilli PN AD - Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA. FAU - Goldberg, Sheldon AU - Goldberg S AD - Pennsylvania Hospital of the University of Pennsylvania Health System, Philadelphia, PA, USA. Electronic address: sheldongoldberg66@gmail.com. LA - eng PT - Journal Article PT - Review DEP - 20260416 PL - United States TA - Am J Med JT - The American journal of medicine JID - 0267200 SB - IM MH - Humans MH - *Aortic Valve Stenosis/diagnosis/therapy/physiopathology/surgery MH - *Transcatheter Aortic Valve Replacement/methods MH - Disease Progression MH - Aortic Valve/surgery OTO - NOTNLM OT - Aortic stenosis OT - Aortic valve replacement OT - Lifetime management OT - Surgical OT - Transcatheter COIS- Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests.PNF has received consulting feeds from Edwards Lifesciences. Given SG's involvement on the editorial board of the American Journal of Medicine, he was not involved in the peer review of this article and had no access to information regarding its peer review. Full responsibility for the editorial process for this article was delegated to another journal editor. NZS, TK, SAK, AHK, and DG declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/04/19 13:11 MHDA- 2026/08/26 23:35 CRDT- 2026/04/18 19:15 PHST- 2026/04/02 00:00 [received] PHST- 2026/04/07 00:00 [revised] PHST- 2026/04/08 00:00 [accepted] PHST- 2026/08/26 23:35 [medline] PHST- 2026/04/19 13:11 [pubmed] PHST- 2026/04/18 19:15 [entrez] AID - S0002-9343(26)00287-1 [pii] AID - 10.1016/j.amjmed.2026.04.010 [doi] PST - ppublish SO - Am J Med. 2026 Oct;139(10):1294-1304. doi: 10.1016/j.amjmed.2026.04.010. Epub 2026 Apr 16. PMID- 41997521 OWN - NLM STAT- MEDLINE DCOM- 20260827 LR - 20260827 IS - 1552-6259 (Electronic) IS - 0003-4975 (Linking) VI - 122 IP - 3 DP - 2026 Sep TI - Analysis of the First 1000 Operations Performed by a Local Surgical Cardiac Team in Ethiopia: Challenges Faced and Lessons Learned. PG - 752-758 LID - S0003-4975(26)00342-5 [pii] LID - 10.1016/j.athoracsur.2026.03.072 [doi] AB - BACKGROUND: Cardiac surgical capacity in sub-Saharan Africa remains severely limited, and sustainable locally led programs are scarce. This report describes the first 1000 consecutive cardiac operations performed by a fully local cardiac surgical team in Ethiopia, with a focus on implementation experience, service development, and outcomes. METHODS: Study investigators conducted a retrospective descriptive cohort review of 1000 consecutive cardiac surgical procedures performed between June 2017 and January 2025 in Addis Ababa, Ethiopia. The same local team undertook all procedures using standardized protocols. Demographic and operative data were extracted from institutional records. Programmatic challenges and mitigation strategies were identified from team documentation and mapped to a structure-process-outcome framework. Primary outcomes were 30-day all-cause mortality and permanent pacemaker implantation. RESULTS: Rheumatic valve disease accounted for 424 procedures (42.4%), and congenital heart disease accounted for 407 (40.7%). Overall 30-day mortality was 2.9%, and permanent pacemaker implantation occurred in 0.2% of patients. Annual surgical volume increased from 31 procedures in 2017 to 204 in 2025. Major challenges included limited access to repair-enabling consumables and intraoperative transesophageal echocardiography, constrained intensive care capacity, advanced disease at presentation, and public and professional hesitancy. Mitigation strategies included phased risk-stratified case selection, protocol standardization, public engagement, and establishment of a locally governed charitable platform to support access to rheumatic valve surgery. CONCLUSIONS: A locally led cardiac surgery program can be established and scaled in a resource-limited setting with acceptable outcomes. Explicit alignment of structural capacity, clinical processes, and programmatic strategies is essential for sustainable cardiac surgical service development. CI - Copyright (c) 2026 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Agwar, Fekede D AU - Agwar FD AD - Cardiac Center of Ethiopia, Addis Ababa, Ethiopia; St. Paul Hospital Millennium Medical College, Addis Ababa, Ethiopia. Electronic address: kefedb@gmail.com. FAU - Tamerat, Lidet Y AU - Tamerat LY AD - Healing Valves Ethiopia, Addis Ababa, Ethiopia. FAU - Ali, Jemil M AU - Ali JM AD - College of Health Science, Addis Ababa University, Addis Ababa, Ethiopia. FAU - Kassa, Mihret Y AU - Kassa MY AD - St. Paul Hospital Millennium Medical College, Addis Ababa, Ethiopia. FAU - Gebreyesus, Samson A AU - Gebreyesus SA AD - Cardiac Center of Ethiopia, Addis Ababa, Ethiopia; St. Paul Hospital Millennium Medical College, Addis Ababa, Ethiopia. FAU - Tilahun, Zekarias B AU - Tilahun ZB AD - Cardiac Center of Ethiopia, Addis Ababa, Ethiopia. LA - eng PT - Journal Article DEP - 20260415 PL - Netherlands TA - Ann Thorac Surg JT - The Annals of thoracic surgery JID - 15030100R SB - IM MH - Humans MH - Ethiopia/epidemiology MH - Retrospective Studies MH - Female MH - *Cardiac Surgical Procedures/statistics & numerical data MH - Male MH - Adult MH - Middle Aged MH - Adolescent MH - *Patient Care Team/organization & administration MH - Young Adult MH - Child MH - Resource-Limited Settings MH - Aged MH - Heart Defects, Congenital/surgery MH - Child, Preschool COIS- Disclosures The authors have no conflicts of interest to disclose. EDAT- 2026/04/18 13:10 MHDA- 2026/08/28 11:40 CRDT- 2026/04/17 19:18 PHST- 2025/12/28 00:00 [received] PHST- 2026/02/15 00:00 [revised] PHST- 2026/03/30 00:00 [accepted] PHST- 2026/08/28 11:40 [medline] PHST- 2026/04/18 13:10 [pubmed] PHST- 2026/04/17 19:18 [entrez] AID - S0003-4975(26)00342-5 [pii] AID - 10.1016/j.athoracsur.2026.03.072 [doi] PST - ppublish SO - Ann Thorac Surg. 2026 Sep;122(3):752-758. doi: 10.1016/j.athoracsur.2026.03.072. Epub 2026 Apr 15. PMID- 41995635 OWN - NLM STAT- MEDLINE DCOM- 20260827 LR - 20260903 IS - 1552-6259 (Electronic) IS - 0003-4975 (Linking) VI - 122 IP - 3 DP - 2026 Sep TI - Long-Term Survival Advantage of Reoperative Surgical Mitral Valve Replacement Over Transcatheter Mitral Valve-in-Valve: A Multicenter Cohort. PG - 630-639 LID - S0003-4975(26)00250-X [pii] LID - 10.1016/j.athoracsur.2026.03.032 [doi] AB - BACKGROUND: Although transcatheter mitral valve-in-valve replacement (mViV) is safe, long-term outcomes compared with reoperative surgical mitral valve replacement (rSMVR) remains unknown. This study compared long-term outcomes between mViV and rSMVR in patients with failing mitral bioprostheses. METHODS: This retrospective, cohort study analyzed patients undergoing mViV or rSMVR for failing bioprosthetic mitral valves without active endocarditis at 2 quaternary care centers from 2004 to 2023. Primary end points included 30-day Mitral Valve Academic Research Consortium (MVARC) procedural success, 5-year cumulative incidence of death, freedom from reintervention, and cumulative incidence of heart failure. Echocardiographic evaluation of mean mitral valve gradients was assessed at baseline and 5-year follow-up. RESULTS: Of 229 patients (90 rSMVR, 139 mViV; mean age, 66.0 vs 68.7 years), MVARC 30-day outcomes were similar except for higher prolonged ventilation with rSMVR. At 5 years, rSMVR had significantly lower mortality (20.3% vs 40.9%; P = .01) and lower mean (standard deviation) mitral gradients (immediate postprocedure: 5.1 [2.3] mm Hg vs 7.8 [3.0] mm Hg; 5-year: 5.3 [2.0] mm Hg vs 9.8 [5.3] mm Hg; P < .001). Freedom from mitral valve reintervention (5.8% vs 6.1%; P = .97) and cumulative heart failure incidence (14.3% vs 22.9%; P = .17) were similar. CONCLUSIONS: Although mViV demonstrated comparable 30-day MVARC outcomes, rSMVR was associated with superior long-term survival and hemodynamic durability among patients deemed appropriate surgical candidates by a multidisciplinary heart team. Treatment decisions should balance short-term risk with long-term outcomes. CI - Copyright (c) 2026. Published by Elsevier Inc. FAU - Won, Daniel AU - Won D AD - Division of Cardiac Surgery, Northwestern University and Bluhm Cardiovascular Institute, Northwestern Medicine, Chicago, Illinois. FAU - Bolling, Steven F AU - Bolling SF AD - Department of Cardiovascular Surgery, University of Michigan, Ann Arbor, Michigan. FAU - Romano, Matthew A AU - Romano MA AD - Department of Cardiovascular Surgery, University of Michigan, Ann Arbor, Michigan. FAU - Johnston, Douglas R AU - Johnston DR AD - Division of Cardiac Surgery, Northwestern University and Bluhm Cardiovascular Institute, Northwestern Medicine, Chicago, Illinois. FAU - Ailawadi, Gorav AU - Ailawadi G AD - Department of Cardiovascular Surgery, University of Michigan, Ann Arbor, Michigan. FAU - Mehta, Christopher K AU - Mehta CK AD - Division of Cardiac Surgery, Northwestern University and Bluhm Cardiovascular Institute, Northwestern Medicine, Chicago, Illinois. FAU - Baldridge, Abigail S AU - Baldridge AS AD - Division of Cardiac Surgery, Northwestern University and Bluhm Cardiovascular Institute, Northwestern Medicine, Chicago, Illinois. FAU - An, Seokyung AU - An S AD - Division of Cardiac Surgery, Northwestern University and Bluhm Cardiovascular Institute, Northwestern Medicine, Chicago, Illinois. FAU - Kruse, Jane AU - Kruse J AD - Division of Cardiac Surgery, Northwestern University and Bluhm Cardiovascular Institute, Northwestern Medicine, Chicago, Illinois. FAU - Byrd, Heather AU - Byrd H AD - Division of Cardiac Surgery, Northwestern University and Bluhm Cardiovascular Institute, Northwestern Medicine, Chicago, Illinois. FAU - Green, China AU - Green C AD - Department of Cardiovascular Surgery, University of Michigan, Ann Arbor, Michigan. FAU - Malaisrie, S Chris AU - Malaisrie SC AD - Division of Cardiac Surgery, Northwestern University and Bluhm Cardiovascular Institute, Northwestern Medicine, Chicago, Illinois. Electronic address: chris.malaisrie@nm.org. LA - eng PT - Comparative Study PT - Journal Article PT - Multicenter Study DEP - 20260417 PL - Netherlands TA - Ann Thorac Surg JT - The Annals of thoracic surgery JID - 15030100R SB - IM MH - Aged MH - Female MH - Humans MH - Male MH - Middle Aged MH - Bioprosthesis MH - *Heart Valve Prosthesis MH - *Heart Valve Prosthesis Implantation/methods/mortality MH - *Mitral Valve/surgery MH - *Mitral Valve Insufficiency/surgery/mortality MH - Prosthesis Failure MH - *Reoperation/mortality MH - Retrospective Studies MH - *Transcatheter Mitral Valve Replacement/mortality MH - Cohort Studies COIS- Disclosures Steven F. Bolling reports a relationship with Edwards Lifesciences Corporation that includes: consulting or advisory; with Abbott that includes: consulting or advisory; with Medtronic Inc that includes: consulting or advisory; and with Boston Scientific Corporation that includes: consulting or advisory. Matthew A. Romano reports a relationship with Edwards Lifesciences Corporation that includes: consulting or advisory. Douglas R. Johnston reports a relationship with Abbott Laboratories Inc that includes: consulting or advisory; with Artivion, Inc that includes: consulting or advisory; with Edwards Lifesciences Corporation that includes: consulting or advisory; with LivaNova USA, Inc that includes: consulting or advisory; and with Terumo that includes: consulting or advisory. Gorav Ailawadi reports a relationship with Abbott that includes: consulting or advisory; with Anteris that includes: consulting or advisory; with Arthrex that includes: consulting or advisory; with Avania that includes: consulting or advisory; with Capstan that includes: consulting or advisory; with Edwards Lifesciences Corporation that includes: consulting or advisory; with Johnson & Johnson that includes: consulting or advisory; with Philips that includes: consulting or advisory; and with Cultiv8 Medical that includes: consulting or advisory. Gorav Ailawadi reports a relationship with Nyra Medical, Inc that includes: consulting or advisory; with JenaValve that includes: consulting or advisory; with Medtronic Inc that includes: consulting or advisory; and with W. L. Gore & Associates that includes: consulting or advisory. Christopher K. Mehta reports a relationship with W. L. Gore & Associates that includes: consulting or advisory, funding grants, and speaking and lecture fees; and with Baxter that includes: consulting or advisory and speaking and lecture fees. S. Chris Malaisrie reports a relationship with Edwards Lifesciences Corporation that includes: consulting or advisory, funding grants, and speaking and lecture fees; with Medtronic that includes: consulting or advisory, funding grants, and speaking and lecture fees; with Artivion, Inc that includes: consulting or advisory, funding grants, and speaking and lecture fees; and with Terumo that includes: consulting or advisory, funding grants, and speaking and lecture fees. The other authors have no conflicts of interest to disclose. EDAT- 2026/04/18 13:10 MHDA- 2026/08/28 11:40 CRDT- 2026/04/17 10:27 PHST- 2025/06/04 00:00 [received] PHST- 2026/03/10 00:00 [revised] PHST- 2026/03/16 00:00 [accepted] PHST- 2026/08/28 11:40 [medline] PHST- 2026/04/18 13:10 [pubmed] PHST- 2026/04/17 10:27 [entrez] AID - S0003-4975(26)00250-X [pii] AID - 10.1016/j.athoracsur.2026.03.032 [doi] PST - ppublish SO - Ann Thorac Surg. 2026 Sep;122(3):630-639. doi: 10.1016/j.athoracsur.2026.03.032. Epub 2026 Apr 17. PMID- 41994758 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260417 LR - 20260813 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 18 IP - 3 DP - 2026 Mar TI - Time From First Contact With the Heart Team to Transcatheter Aortic Valve Replacement (TAVR) and the Area Deprivation Index (ADI). PG - e105110 LID - 10.7759/cureus.105110 [doi] LID - e105110 AB - Introduction Transcatheter aortic valve replacement (TAVR) is an increasingly used form of aortic valve replacement. Prolonged wait time prior to TAVR is associated with an increased mortality rate. This study examines whether the extent of neighborhood disadvantage of patients has any impact on time to TAVR, and if so, to what degree. Methods After institutional review board approval, we conducted a retrospective review of a prospectively maintained database to assess time to TAVR. Time to TAVR was defined from first contact with the structural heart team until implant. Inclusion criteria involved patients undergoing TAVR from January 2019 until January 2024. The area deprivation index (ADI) was determined utilizing the patient's listed home address and the Neighborhood Atlas developed by the Center for Health Disparities Research of the University of Wisconsin School of Medicine and Public Health. Results The patient population included 708 patients. No significant correlation between time to TAVR and ADI was found for patients with a time to TAVR one or two standard deviations from the mean. For patients with time to TAVR greater than three standard deviations from the mean, positive correlations were found between time to TAVR and ADI, as well as time to TAVR and national percentile. The national percentile was obtained by comparing ADI scores for the entire United States, which were then ranked and divided into percentiles. Conclusions Patients from the most disadvantaged neighborhoods experience a longer time to TAVR than others. We hypothesized that a low socioeconomic status would potentially cause barriers with follow-up; however the prolonged time to TAVR in this study was not shown to be secondary to that. CI - Copyright (c) 2026, Chen et al. FAU - Chen, Caroline K AU - Chen CK AD - General Surgery, Geisinger Health System, Scranton, USA. FAU - Billy, Matthew J AU - Billy MJ AD - General Surgery, Geisinger Health System, Scranton, USA. FAU - Summa, Christian AU - Summa C AD - General Surgery, Geisinger Health System, Wilkes-Barre, USA. FAU - Brennan, Zachary AU - Brennan Z AD - Cardiac Surgery, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, USA. FAU - Dean, Harrison AU - Dean H AD - Medicine, New York Institute of Technology College of Osteopathic Medicine, Jonesboro, USA. FAU - Ahmad, Tariq AU - Ahmad T AD - Interventional Cardiology, Geisinger Wyoming Valley Medical Center, Wilkes-Barre, USA. FAU - Wallen, Tyler J AU - Wallen TJ AD - Cardiovascular Surgery, Geisinger Health System, Wilkes-Barre, USA. LA - eng PT - Journal Article DEP - 20260312 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC13081034 OTO - NOTNLM OT - area deprivation index OT - cardiothoracic surgery OT - socioeconomic status OT - surgical aortic valve repair OT - transcatheter aortic valve repair COIS- Human subjects: Informed consent for treatment and open access publication was obtained or waived by all participants in this study. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. EDAT- 2026/04/17 13:25 MHDA- 2026/04/17 13:26 PMCR- 2026/03/12 CRDT- 2026/04/17 05:36 PHST- 2026/03/12 00:00 [accepted] PHST- 2026/04/17 13:26 [medline] PHST- 2026/04/17 13:25 [pubmed] PHST- 2026/04/17 05:36 [entrez] PHST- 2026/03/12 00:00 [pmc-release] AID - 10.7759/cureus.105110 [doi] PST - epublish SO - Cureus. 2026 Mar 12;18(3):e105110. doi: 10.7759/cureus.105110. eCollection 2026 Mar. PMID- 41994317 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260417 LR - 20260921 IS - 2110-5820 (Print) IS - 2110-5820 (Electronic) IS - 2110-5820 (Linking) VI - 16 DP - 2026 TI - Experts' recommendations for the management of adult patients with cardiogenic shock. PG - 100038 LID - 10.1016/j.aicoj.2026.100038 [doi] LID - 100038 AB - The last specific international European recommendations regarding the management of cardiogenic shock (CS) regardless of the etiology were issued over 10 years ago. We present herein recommendations for the management of CS in adults, developed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system by an expert group of from the French Intensive Care Society [Societe de Reanimation de Langue Francaise (SRLF)] and the French Society of Cardiology [Societe Francaise de Cardiologie (SFC)], with the participation of the French Society of Anesthesia and Intensive Care [Societe Francaise d'Anesthesie et de Reanimation (SFAR)], and the French Society of Thoracic and Cardiovascular Surgery [Societe Francaise de Chirurgie Thoracique et Cardio-Vasculaire (SFCTCV)]. The recommendations covered six fields of application: CS teams and expert centers, symptomatic medical management, etiological management, organ support, temporary circulatory support and de-escalation and early post-CS management. Twenty-three "Patient Intervention Comparator Outcome" (PICO) questions were identified, leading to 41 recommendations regarding management of CS in adult patients. Seven recommendations were scored with high level of evidence (Grade 1), 11 with moderate level of evidence (Grade 2) and 17 with low level of evidence (Expert opinion). In 6 cases, the experts were not able to give an answer. All of the recommendations obtained strong agreement from the expert committee. The experts highlight the fact that optimal management of CS requires organization including a structured, multidisciplinary shock team and regional referral network, applying standardized protocols for diagnosis and staging. Early etiological treatment-such as culprit-lesion revascularization or urgent valve intervention-is central to improve outcomes. Hemodynamic support should prioritize norepinephrine as first-line vasopressor and privilege selective inotrope use. Temporary mechanical circulatory support (Impella, VA-ECMO) should be reserved for carefully selected patients following discussion by the expert team. CI - (c) 2026 The Author(s). FAU - Aissaoui, Nadia AU - Aissaoui N AD - Intensive Cardiac Care Unit, Cardiology Department, Hopital Europeen Georges Pompidou, Assistance Publqiue des Hopitaux de Paris, Universite Paris Cite, Paris, France. FAU - Delmas, Clement AU - Delmas C AD - Intensive Cardiac Care Unit, Cardiology Department, Toulouse University Hospital, Toulouse University, INSERM, UMR 1297, Institut des Maladies Metaboliques et Cardiovasculaires - I2MC, Toulouse, France. AD - REICATRA, Institu Saint Jacques, Toulouse, France. FAU - Merdji, Hamid AU - Merdji H AD - Department of Medical Intensive Care, University Hospital of Strasbourg, Nouvel Hopital Civil, INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, Strasbourg, France. FAU - Schurtz, Guillaume AU - Schurtz G AD - Cardiac Intensive Care Unit, Insitut Coeur Poumon, CHU Lille, Lille, France. FAU - Baudry, Guillaume AU - Baudry G AD - Universite de Lorraine, INSERM, Centre d'Investigation Clinique Plurithematique 1433, Inserm U1116, CHRU de Nancy, Nancy, France. AD - INI-CRCT (Cardiovascular and Renal Clinical Trialists) F-CRIN Network, Nancy, France. AD - REICATRA, France. FAU - Beurton, Antoine AU - Beurton A AD - CHU Bordeaux, Department of Cardiovascular Anesthesia and Critical Care, CHU de Bordeaux, F-33000 Bordeaux, France. AD - Univ. Bordeaux, INSERM, BMC, U1034, F-33600 Pessac, France. FAU - Boissier, Florence AU - Boissier F AD - CHU de Poitiers, Medecine Intensive Reanimation, Poitiers, France. AD - INSERM, Centre d'Investigation Clinique CIC 14-02 IS-ALIVE, Universite de Poitiers, F-86000 Poitiers, France. FAU - Bonello, Laurent AU - Bonello L AD - Unite de Soins Intensifs de Cardiologie, Hopital Nord de Marseille, Aix-Marseille Universite, Marseille 13015 France. FAU - Cholley, Bernard AU - Cholley B AD - Service d'Anesthesie-Reanimation & Medecine Peri-Operatoire, Hopital Europeen Georges Pompidou, APHP, Paris, France. AD - INSERM UMR-S1140, Universite Paris Cite, Paris, France. FAU - Combaret, Nicolas AU - Combaret N AD - Universite de Lorraine, INSERM, Centre d'Investigation Clinique Plurithematique 1433, Inserm U1116, CHRU de Nancy, Nancy, France. AD - INI-CRCT (Cardiovascular and Renal Clinical Trialists) F-CRIN Network, Nancy, France. AD - REICATRA, France. FAU - Combes, Alain AU - Combes A AD - Sorbonne Universite, INSERM, UMRS_1166-ICAN, Institute of Cardiometabolism and Nutrition, AP-HP, Service de Medecine Intensive-Reanimation, Institut de Cardiologie, Hopital Pitie Salpetriere, Paris, France. FAU - David, Charles-Henri AU - David CH AD - Nantes Universite, CHU Nantes, Chirurgie Thoracique et Cardiovasculaire, l'Institut du Thorax, F-44000 Nantes, France. FAU - De Backer, Daniel AU - De Backer D AD - Department of Intensive Care, CHIREC Hospitals, Universite Libre de Bruxelles, Brussels, Belgium. FAU - Guinot, Pierre Gregoire AU - Guinot PG AD - Department of Anesthesiology and Intensive Care, Dijon University Hospital, University of Burgundy Europe, LNC UMR1231, F-21000 Dijon, France. FAU - Hamzaoui, Olfa AU - Hamzaoui O AD - CHU Reims, Unite de Medecine Intensive et Reanimation Polyvalente, Universite de Reims Champagne-Ardenne, UR 3801 PPF, Reims, France. FAU - Harbaoui, Brahim AU - Harbaoui B AD - Interventional Cardiology Department, Hopital Croix-Rousse, and Hopital Louis Pradel, Hospices Civils de Lyon, Lyon, France. AD - University of Lyon, CREATIS UMR5220, INSERM U1044, INSA-15 Lyon, France. FAU - Imbault, Julien AU - Imbault J AD - CHU Bordeaux, Department of Cardiovascular Anesthesia and Critical Care, CHU de Bordeaux, F-33000 Bordeaux, France. AD - Univ. Bordeaux, INSERM, BMC, U1034, F-33600 Pessac, France. FAU - Nesseler, Nicolas AU - Nesseler N AD - Department of Anesthesia and Critical Care, Pontchaillou, University Hospital of Rennes, Univ Rennes, CHU Rennes, Inserm, CIC 1414 (Centre d'Investigation Clinique de Rennes), Inrae, Institut NUMECAN - UMR_A 1341, UMR_S 1241, FHU SUPORT, F-35000 Rennes, France. FAU - Kimmoun, Antoine AU - Kimmoun A AD - Universite de Lorraine, CHRU de Nancy, Service de Medecine Intensive et Reanimation Brabois, U1116, F-CRIN INI CRCT, Nancy, France. FAU - Kindo, Michel AU - Kindo M AD - Department of Cardiac Surgery, Hopitaux Universitaires de Strasbourg, Nouvel Hopital Civil, Strasbourg, France. FAU - Lebreton, Guillaume AU - Lebreton G AD - Sorbonne Universite, AP-HP, Service de Chrirugie Cardiaque, Institut de Cardiologie, Hopital Pitie Salpetriere, Paris, France. FAU - Leurent, Guillaume AU - Leurent G AD - Department of Cardiology, Univ Rennes 1, CHU Rennes, Inserm, LTSI - UMR 1099, Rennes, France. FAU - Levy, Bruno AU - Levy B AD - Institut du Coeur et des Vaisseaux, CHU Nancy-Brabois, Groupe Choc, equipe 2, Inserm U1116. Faculte de Medecine, Nancy, France. FAU - Manzo-Silberman, Stephane AU - Manzo-Silberman S AD - AP-HP, Cardiology Department, Cardiology Institut, Hopital Pitie Salpetriere, Paris, France. AD - Sorbonne University, INSERM, UMRS_1166-ICAN; ACTION Study Group, Paris, France. FAU - Martin, Anne-Celine AU - Martin AC AD - Division of Cardiology, Advanced Heart Failure Unit, AP-HP, Hopital Europeen Georges-Pompidou, F-75015, Paris, France. AD - Universite Paris Cite, INSERM, PARCC, F-75015 Paris, France. FAU - Mekontso-Dessap, Armand AU - Mekontso-Dessap A AD - AP-HP, Hopitaux Universitaires Henri-Mondor, Service de Medecine Intensive Reanimation, Univ Paris Est Creteil, INSERM, Institut Mondor, CARMAS, Creteil, F-94010, France. AD - Department of Cardiac Surgery, Louis Pradel Hospital, Lyon, France. FAU - Adda, Imane AU - Adda I AD - Department of Research, One Clinic, PointGyn, Paris, France. FAU - Mootien, Joy AU - Mootien J AD - Unite Fonctionnelle de Conseil en Antibiotherapie, CHU Mulhouse, Mulhouse, France. FAU - Ouattara, Alexandre AU - Ouattara A AD - 1CHU Bordeaux, Department of Cardiovascular Anesthesia and Critical Care, CHU de Bordeaux, Univ. Bordeaux, INSERM, BMC, U1034, France. FAU - Pozzi, Matteo AU - Pozzi M AD - Department of Cardiac Surgery, Louis Pradel Hospital, Hospices Civils de Lyon, Research on Healthcare Performance Reshape, Inserm U1290, Universite Claude Bernard Lyon 1, Lyon, France. FAU - Puymirat, Etienne AU - Puymirat E AD - Assistance Publique-Hopitaux de Paris (AP-HP), Hopital Europeen Georges Pompidou, Department of Cardiology, 75015 Paris, France. AD - PARCC, Universite de Paris Cite, 75006 Paris, France. FAU - Roubille, Francois AU - Roubille F AD - PhyMedExp, Cardiology Department, Universite de Montpellier, INSERM, CNRS, INI-CRT, CHU de Montpellier, Montpellier, France. FAU - Trimaille, Antonin AU - Trimaille A AD - Department of Cardiovascular Medicine Nouvel Hopital Civil, 2UR 3074, Translational Cardiovascular Medicine Biomedicine Research Centre of Strasbourg, University of Strasbourg, Strasbourg, France. FAU - Ughetto, Aurore AU - Ughetto A AD - Department of Cardiothoracic Anesthesia and Critical Care Medicine, Montpellier University Hospital, Montpellier, France. FAU - Van Belle, Eric AU - Van Belle E AD - Cardiac Intensive Care Unit, Insitut Coeur Poumon, CHU Lille, Lille, France. FAU - Bonnefoy, Eric AU - Bonnefoy E AD - Department of Cardiology, Louis Pradel Hospital, Hospices Civils de Lyon, University of Lyon, INSA-Lyon, University Claude Bernard Lyon 1, Lyon, France. FAU - Kuteifan, Khaldoun AU - Kuteifan K AD - Medical Intensive Care Unit, GHRMSA, Mulhouse, France. LA - eng PT - Journal Article DEP - 20260331 PL - France TA - Ann Intensive Care JT - Annals of intensive care JID - 101562873 PMC - PMC13081668 OTO - NOTNLM OT - Cardiogenic shock OT - Guidelines OT - Heart team OT - Temporary circulatory support EDAT- 2026/04/17 13:25 MHDA- 2026/04/17 13:26 PMCR- 2026/03/31 CRDT- 2026/04/17 05:30 PHST- 2026/02/12 00:00 [revised] PHST- 2026/04/17 13:26 [medline] PHST- 2026/04/17 13:25 [pubmed] PHST- 2026/04/17 05:30 [entrez] PHST- 2026/03/31 00:00 [pmc-release] AID - S2110-5820(26)00073-7 [pii] AID - 100038 [pii] AID - 10.1016/j.aicoj.2026.100038 [doi] PST - epublish SO - Ann Intensive Care. 2026 Mar 31;16:100038. doi: 10.1016/j.aicoj.2026.100038. eCollection 2026. PMID- 41988792 OWN - NLM STAT- MEDLINE DCOM- 20260717 LR - 20260919 IS - 1530-0366 (Electronic) IS - 1098-3600 (Linking) VI - 28 IP - 7 DP - 2026 Jul TI - Loeys-Dietz syndrome: 2026 updated care management primer. PG - 102577 LID - S1098-3600(26)00895-6 [pii] LID - 10.1016/j.gim.2026.102577 [doi] AB - Loeys-Dietz syndrome (LDS) represents a clinically and genetically heterogeneous group of connective tissue disorders that share features similar to Marfan syndrome, first identified in 2005. Characterized by significant manifestations, such as aortic aneurysms, arterial tortuosity, craniofacial and skeletal anomalies, LDS results from pathogenic variants in key genes of the transforming growth factor-beta signaling pathway. Given its variable expressivity, a multidisciplinary approach to management is critical. The article provides an updated overview of effective management practices since the first LDS primer in 2014. It aims to enhance clinical awareness, inform health care providers, and improve patient outcomes through individualized care strategies for those living with LDS. CI - Copyright (c) 2026 The Authors. Published by Elsevier Inc. All rights reserved. FAU - MacCarrick, Gretchen AU - MacCarrick G AD - McKusick Nathans Department of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD. Electronic address: goswald1@jhmi.edu. FAU - Afifi, Rana O AU - Afifi RO AD - McGovern Medical School at UTHealth, Houston, TX. FAU - Allen, Rebecca AU - Allen R AD - Department of Obstetrics and Gynecology, Warren Alpert Medical School of Brown University, Providence, RI. FAU - Almpani, Konstantinia AU - Almpani K AD - Craniofacial Anomalies and Regeneration Section, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD. FAU - Black, James H 3rd AU - Black JH 3rd AD - Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD. FAU - Boyce, Alison M AU - Boyce AM AD - National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD. FAU - Braverman, Alan C AU - Braverman AC AD - Cardiovascular Division, Department of Medicine, Washington University School of Medicine, St. Louis, MO. FAU - Cameron, Duke E AU - Cameron DE AD - Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD. FAU - Caplan, Justin AU - Caplan J AD - Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD. FAU - Cervi, Elena AU - Cervi E AD - Centre for Inherited Cardiovascular Diseases, Great Ormond Street Hospital, London, UK. FAU - Cha, Myung-Jin AU - Cha MJ AD - Department of Orthopedic Surgery, Johns Hopkins University School of Medicine, Baltimore, MD. FAU - Christensen, Julie AU - Christensen J AD - National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, MD. FAU - van de Laar, Ingrid Mbh AU - van de Laar IM AD - Department of Clinical Genetics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. FAU - Demo, Erin AU - Demo E AD - Children's Healthcare of Atlanta Cardiology, Atlanta, GA. FAU - Dewals, Wendy AU - Dewals W AD - Laboratory of Experimental Medicine and Pediatrics, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium. FAU - Doyle, Alexander J AU - Doyle AJ AD - Department of Anesthesia and Pain Medicine, Royal Cornwall Hospital, Truro, UK. FAU - Doyle, Jefferson J AU - Doyle JJ AD - Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD. FAU - Fischbein, Michael P AU - Fischbein MP AD - Department of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA. FAU - Fleischer, Julie AU - Fleischer J AD - Division of Genetics, Department of Pediatrics, Southern Illinois University School of Medicine, Springfield, IL. FAU - Fleischman, Fernando AU - Fleischman F AD - Department of Surgery, Keck School of Medicine at University of Southern California, Los Angeles, CA. FAU - Frischmeyer-Guerrerio, Pamela A AU - Frischmeyer-Guerrerio PA AD - Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD. FAU - Guerrerio, Anthony L AU - Guerrerio AL AD - Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD. FAU - Huguenard, Anna L AU - Huguenard AL AD - Department of Neurosurgery, Washington University School of Medicine, St. Louis, MO. FAU - Jani, Priyam H AU - Jani PH AD - University of Maryland School of Dentistry, Baltimore, MD. FAU - Jordan, Christopher P AU - Jordan CP AD - Inova Health System, Washington, DC. FAU - Kim, H Jeffrey AU - Kim HJ AD - Office of Clinical Director, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, MD; Department of Otolaryngology-Head and Neck Surgery, Georgetown University Medical Center, Washington, DC. FAU - Krebsova, Alice AU - Krebsova A AD - Department of Cardiology, Center of Inherited Cardiovascular Disorders, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic. FAU - Kockova, Radka AU - Kockova R AD - Center for Congenital Heart Disease in Adults, Department of Cardiac Surgery, Na Homolce Hospital, Prague, Czechia. FAU - Lee, Janice S AU - Lee JS AD - Craniofacial Anomalies and Regeneration Section, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD. FAU - Lobner, Katie AU - Lobner K AD - Welch Medical Library, Johns Hopkins University School of Medicine, Baltimore, MD. FAU - Narula, Nupoor AU - Narula N AD - Division of Cardiology, Weill Cornell Medicine, New York, NY. FAU - Niknahad, Ava AU - Niknahad A AD - Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD. FAU - Neptune, Enid AU - Neptune E AD - Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD. FAU - Pedroza, Albert J AU - Pedroza AJ AD - Department of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA. FAU - Perry, Monique AU - Perry M AD - Rehabilitation Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD. FAU - Richer, Julie AU - Richer J AD - Department of Medical Genetics, Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada. FAU - Rios-Sanchez, Jennifer AU - Rios-Sanchez J AD - Department of Surgery, Keck School of Medicine at University of Southern California, Los Angeles, CA. FAU - Roman, Mary J AU - Roman MJ AD - Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD. FAU - Russo, Melissa AU - Russo M AD - Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, Brown University Warren Alpert School of Medicine, Providence, RI. FAU - Schweber, Jonathan AU - Schweber J AD - Division of Cardiology, The Hospital for Sick Children, Toronto, ON, Canada. FAU - Shalhub, Sherene AU - Shalhub S AD - Division of Vascular and Endovascular Surgery, Department of Surgery, Oregon Health and Science University, Portland, OR; Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland, OR. FAU - Sorber, Rebecca AU - Sorber R AD - Division of Vascular Surgery, Washington University School of Medicine, St. Louis, MO. FAU - Speed, Traci AU - Speed T AD - Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, MD. FAU - Sponseller, Paul D AU - Sponseller PD AD - Department of Orthopedic Surgery, Johns Hopkins University School of Medicine, Baltimore, MD. FAU - Vincent, T L AU - Vincent TL AD - Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK. FAU - Whelan, Anna AU - Whelan A AD - Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, UMass Chan Medical School, Worcester, MA. FAU - Zeiler, Steven R AU - Zeiler SR AD - Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD. FAU - Loeys, Bart AU - Loeys B AD - Cardiogenomics Research Group, Center of Medical Genetics, University of Antwerp and Antwerp University Hospital, Antwerp, Belgium. FAU - Dietz, Harry C 3rd AU - Dietz HC 3rd AD - McKusick Nathans Department of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD. LA - eng GR - R01 DC000064/DC/NIDCD NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, N.I.H., Intramural PT - Review DEP - 20260415 PL - United States TA - Genet Med JT - Genetics in medicine : official journal of the American College of Medical Genetics JID - 9815831 RN - 0 (Transforming Growth Factor beta) SB - IM MH - Humans MH - *Loeys-Dietz Syndrome/genetics/therapy/diagnosis MH - Signal Transduction/genetics MH - Transforming Growth Factor beta/genetics MH - Marfan Syndrome/genetics MH - Aortic Aneurysm/genetics MH - Precision Medicine OTO - NOTNLM OT - Aortic aneurysm OT - Loeys-Dietz syndrome OT - Precision medicine COIS- Conflict of Interest The authors declare no conflicts of interest. EDAT- 2026/04/16 13:09 MHDA- 2026/07/17 23:02 CRDT- 2026/04/16 05:58 PHST- 2025/08/01 00:00 [received] PHST- 2026/03/10 00:00 [revised] PHST- 2026/04/02 00:00 [accepted] PHST- 2026/07/17 23:02 [medline] PHST- 2026/04/16 13:09 [pubmed] PHST- 2026/04/16 05:58 [entrez] AID - S1098-3600(26)00895-6 [pii] AID - 10.1016/j.gim.2026.102577 [doi] PST - ppublish SO - Genet Med. 2026 Jul;28(7):102577. doi: 10.1016/j.gim.2026.102577. Epub 2026 Apr 15. PMID- 41988550 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260416 LR - 20260813 IS - 2284-2594 (Electronic) IS - 2284-2594 (Linking) VI - 13 IP - 4 DP - 2026 TI - First-Trimester Aortic Root Replacement in a Pregnant Woman with Previously Undiagnosed Marfan Syndrome. PG - 006137 LID - 10.12890/2026_006137 [doi] LID - 006137 AB - Aortopathy encompasses a spectrum of aortic aneurysms and dissections and represents a major cause of cardiovascular morbidity during pregnancy, particularly in women with heritable connective tissue disorders such as Marfan syndrome. Evidence guiding the management of severe aortopathy diagnosed in early pregnancy remains limited. We report the case of a pregnant woman with previously undiagnosed Marfan syndrome who presented at 10 weeks' gestation with decompensated heart failure due to severe aortic regurgitation and a massive aortic root aneurysm. Transthoracic echocardiography revealed marked dilatation of the aortic root and ascending aorta, accompanied by left ventricular dilatation and systolic dysfunction. Following multidisciplinary evaluation, urgent surgical intervention was deemed necessary because of prohibitive maternal risk. The patient successfully underwent aortic root and valve replacement during the first trimester. Postoperatively, cardiac function improved, and the pregnancy was continued without major cardiovascular complications, ultimately resulting in the delivery of a healthy neonate. This case highlights the complexity of managing severe Marfan-associated aortopathy diagnosed during early pregnancy and demonstrates that life-saving aortic surgery may be considered in carefully selected patients when maternal risk is extreme, emphasizing the importance of individualized, multidisciplinary decision-making. LEARNING POINTS: Pregnancy may unmask previously undiagnosed Marfan syndrome and carries a high risk of life-threatening aortic complications.Current guidelines recommend pre-pregnancy surgery when the aortic root diameter reaches >/=4.5 cm; however, management of severe aortopathy detected during pregnancy remains challenging and individualized.In carefully selected high-risk patients, severe aortic root aneurysm complicated by heart failure may necessitate life-saving aortic surgery even during the first trimester, guided by multidisciplinary decision-making and European Society of Cardiology recommendations. CI - (c) EFIM 2026. FAU - Abbay, Anara AU - Abbay A AD - Department of Medicine, Nazarbayev University School of Medicine, Astana, Kazakhstan. FAU - Ibrayev, Talgat AU - Ibrayev T AD - Department of Cardiac Anesthesiology, Mother and Child Center, Corporate Fund "University Medical Center", Astana, Kazakhstan. FAU - Mukarov, Murat AU - Mukarov M AD - Cardiology Department, UMC Heart Center, Astana, Kazakhstan. FAU - Talkhatova, Sandugash AU - Talkhatova S AD - Department of Cardiac Surgery, UMC Heart Center, Corporate Fund "University Medical Center", Astana, Kazakhstan. FAU - Murzagaliyev, Muradym AU - Murzagaliyev M AD - Department of Cardiac Surgery, UMC Heart Center, Corporate Fund "University Medical Center", Astana, Kazakhstan. LA - eng PT - Journal Article DEP - 20260310 PL - Italy TA - Eur J Case Rep Intern Med JT - European journal of case reports in internal medicine JID - 101648453 PMC - PMC13078751 OTO - NOTNLM OT - Marfan syndrome OT - aortic root replacement OT - aortopathy OT - multidisciplinary management OT - pregnancy COIS- Conflicts of Interests: The Authors declare that there are no competing interests. EDAT- 2026/04/16 13:09 MHDA- 2026/04/16 13:10 PMCR- 2026/03/10 CRDT- 2026/04/16 04:30 PHST- 2026/01/03 00:00 [received] PHST- 2026/01/13 00:00 [accepted] PHST- 2026/04/16 13:10 [medline] PHST- 2026/04/16 13:09 [pubmed] PHST- 2026/04/16 04:30 [entrez] PHST- 2026/03/10 00:00 [pmc-release] AID - 6137 [pii] AID - 10.12890/2026_006137 [doi] PST - epublish SO - Eur J Case Rep Intern Med. 2026 Mar 10;13(4):006137. doi: 10.12890/2026_006137. eCollection 2026. PMID- 41988456 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260416 LR - 20260813 IS - 2225-319X (Print) IS - 2304-1021 (Electronic) IS - 2225-319X (Linking) VI - 15 IP - 2 DP - 2026 Mar 31 TI - Transcatheter and surgical management of tricuspid valve disease: multidisciplinary lifetime management considerations. PG - 18 LID - 10.21037/acs-2025-1-74-tvd [doi] LID - 18 AB - Tricuspid valve disease (TVD) has long been underrecognized compared with left-sided valvular disorders, yet it represents a major determinant of cardiovascular morbidity and mortality. Tricuspid regurgitation (TR), the predominant manifestation of TVD, is being recognized with increasing frequency as populations age and the burden of left-sided heart disease rises. While mild TR is often physiological, moderate and severe TR are associated with adverse outcomes, independent of left ventricular function or pulmonary pressures. Secondary TR, driven by right atrial or right ventricular remodeling, constitutes the majority of cases, whereas primary TR due to intrinsic valvular pathology is less frequent. Cardiac implantable electronic device (CIED)-related TR represents a distinct and increasingly prevalent mechanism that often requires dedicated management considerations. Historically, management of TVD has often been delayed until the onset of advanced right heart failure or end-organ dysfunction, resulting in poor outcomes. Contemporary evidence emphasizes the importance of early recognition, precise etiologic characterization, and timely intervention within a multidisciplinary framework. Surgical repair, particularly annuloplasty, remains the reference standard in suitable candidates, offering durable results when performed before irreversible right ventricular remodeling develops. Transcatheter tricuspid valve interventions have expanded therapeutic options for high-risk or inoperable patients, demonstrating symptomatic and hemodynamic improvement in early studies. Optimal management of TVD follows a lifetime approach, integrating multimodality imaging, risk stratification, and individualized treatment strategies. General physicians and cardiologists play a key role in early detection, while coordinated collaboration among imaging specialists, electrophysiologists, heart failure experts, interventional cardiologists, cardiac surgeons, and anesthesiologists is essential for comprehensive care. Ultimately, a patient-centered lifetime management strategy initiated early and adapted to disease progression offers the best opportunity to preserve right heart function, improve survival, and maintain quality of life in patients with TVD. CI - (c) AME Publishing Company. FAU - de Waha, Suzanne AU - de Waha S AD - Department of Cardiac Surgery, Heart Center Leipzig at University of Leipzig, Leipzig, Germany. AD - Department of Rhythmology, University Hospital Schleswig-Holstein, Campus Lubeck, Lubeck, Germany. FAU - Noack, Thilo AU - Noack T AD - Department of Cardiac Surgery, Heart Center Leipzig at University of Leipzig, Leipzig, Germany. FAU - Kister, Tobias AU - Kister T AD - Department of Cardiology, Heart Center Leipzig at University of Leipzig, Leipzig, Germany. FAU - Desch, Steffen AU - Desch S AD - Department of Cardiology, Heart Center Leipzig at University of Leipzig, Leipzig, Germany. FAU - Marin-Cuartas, Mateo AU - Marin-Cuartas M AD - Department of Cardiac Surgery, Heart Center Leipzig at University of Leipzig, Leipzig, Germany. FAU - Kiefer, Philipp AU - Kiefer P AD - Department of Cardiac Surgery, Heart Center Leipzig at University of Leipzig, Leipzig, Germany. FAU - Borger, Michael A AU - Borger MA AD - Department of Cardiac Surgery, Heart Center Leipzig at University of Leipzig, Leipzig, Germany. LA - eng PT - Journal Article PT - Review DEP - 20260327 PL - China TA - Ann Cardiothorac Surg JT - Annals of cardiothoracic surgery JID - 101605877 PMC - PMC13077619 OTO - NOTNLM OT - Tricuspid valve disease (TVD) OT - intervention OT - management OT - prognosis OT - surgery COIS- Conflicts of Interest: Dr. de Waha has received speaker honoraria from AstraZeneca, Boehringer Ingelheim, Edwards Lifesciences and TherOx, and has served as a consultant to Pfizer-BMS and TherOx/Zoll Medical. The other authors have no conflicts of interest to declare. EDAT- 2026/04/16 13:09 MHDA- 2026/04/16 13:10 PMCR- 2026/03/31 CRDT- 2026/04/16 04:30 PHST- 2025/12/08 00:00 [received] PHST- 2026/03/06 00:00 [accepted] PHST- 2026/04/16 13:10 [medline] PHST- 2026/04/16 13:09 [pubmed] PHST- 2026/04/16 04:30 [entrez] PHST- 2026/03/31 00:00 [pmc-release] AID - acs-15-02-18 [pii] AID - 10.21037/acs-2025-1-74-tvd [doi] PST - ppublish SO - Ann Cardiothorac Surg. 2026 Mar 31;15(2):18. doi: 10.21037/acs-2025-1-74-tvd. Epub 2026 Mar 27. PMID- 41988451 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260416 LR - 20260813 IS - 2225-319X (Print) IS - 2304-1021 (Electronic) IS - 2225-319X (Linking) VI - 15 IP - 2 DP - 2026 Mar 31 TI - Percutaneous mechanical aspiration in tricuspid valve infective endocarditis. PG - 19 LID - 10.21037/acs-2025-aw-41-tvd [doi] LID - 19 AB - Tricuspid valve infective endocarditis (TVIE) is increasing, largely driven by rising injection drug use and the expanding use of cardiac implantable electronic devices (CIEDs). Percutaneous mechanical aspiration (PMA) has emerged as a viable catheter-based therapy to achieve source control through vegetation debulking in patients with a suboptimal response to antimicrobial therapy or those deemed at high risk for surgery. An expanding literature has demonstrated favorable feasibility and promising outcomes, and recent societal guidelines recognized PMA as a therapeutic option for carefully selected cases. Optimal results rely on multidisciplinary evaluation, rigorous patient selection, appropriate device choice, and meticulous procedural technique. This review summarizes the growing evidence base, outlines patient selection and technical considerations, and highlights future directions for PMA in the management of TVIE. CI - (c) AME Publishing Company. FAU - El Sabbagh, Abdallah AU - El Sabbagh A AD - Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, FL, USA. FAU - Landolfo, Kevin AU - Landolfo K AD - Division of Cardiovascular Surgery, Mayo Clinic, Jacksonville, FL, USA. FAU - Yucel, Evin AU - Yucel E AD - Division of Cardiovascular Disease, Department of Internal Medicine, Massachusetts General Hospital, Boston, MA, USA. FAU - Hamid, Nadira AU - Hamid N AD - Divison of Cardiovascular Medicine, Minneapolis Heart Institute, Minneapolis, MN, USA. FAU - Baddour, Larry M AU - Baddour LM AD - Departments of Medicine and Cardiovascular Medicine, Division of Public Health, Infectious Diseases and Occupational Medicine, Mayo Clinic, Rochester, MN, USA. FAU - Sethi, Sanjum S AU - Sethi SS AD - Department of Medicine, Division of Cardiology, Columbia University Irving Medical Center, New York, NY, USA. LA - eng PT - Journal Article PT - Review PL - China TA - Ann Cardiothorac Surg JT - Annals of cardiothoracic surgery JID - 101605877 PMC - PMC13077616 OTO - NOTNLM OT - Percutaneous mechanical aspiration (PMA) OT - indications OT - infective endocarditis OT - tricuspid valve (TV) COIS- Conflicts of Interest: S.S.S. reports honoraria from Janssen and Chiesi. N.H. consults for Abbott Structural, Anteris, AMX, 4C Medical Technologies, Alleviant Medical, Edwards Lifesciences, Philips, GE, Valcare Med Ltd, Vdyne and WL Gore. The other authors have no conflicts of interest to declare. EDAT- 2026/04/16 13:09 MHDA- 2026/04/16 13:10 PMCR- 2026/03/31 CRDT- 2026/04/16 04:30 PHST- 2025/11/04 00:00 [received] PHST- 2026/02/11 00:00 [accepted] PHST- 2026/04/16 13:10 [medline] PHST- 2026/04/16 13:09 [pubmed] PHST- 2026/04/16 04:30 [entrez] PHST- 2026/03/31 00:00 [pmc-release] AID - acs-15-02-19 [pii] AID - 10.21037/acs-2025-aw-41-tvd [doi] PST - ppublish SO - Ann Cardiothorac Surg. 2026 Mar 31;15(2):19. doi: 10.21037/acs-2025-aw-41-tvd. PMID- 41988322 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260416 LR - 20260813 IS - 2072-1439 (Print) IS - 2077-6624 (Electronic) IS - 2072-1439 (Linking) VI - 18 IP - 3 DP - 2026 Mar 31 TI - Application of bedside ultrasound assessment of diaphragmatic function in preparing tracheostomised patients for ventilator liberation and decannulation: a narrative review. PG - 246 LID - 10.21037/jtd-2025-1-2737 [doi] LID - 246 AB - BACKGROUND AND OBJECTIVE: In tracheostomised patients, achieving successful liberation from mechanical ventilation (MV) and subsequent decannulation remains challenging. Diaphragmatic performance directly affects decannulation outcomes, and its monitoring is especially useful in prolonged MV. Bedside ultrasound is non‑invasive, dynamic, and repeatable, enabling quantitative assessment of diaphragmatic excursion, thickness, and thickening fraction. This narrative review summarises current evidence on diaphragm ultrasound during weaning preparation in tracheostomised patients and clarifies how evidence from endotracheal tube (ETT) extubation studies may translate to this population. METHODS: A literature search of PubMed, Web of Science, and Wanfang Data identified 87 records. After screening, 17 studies were included. Data were extracted on ultrasound parameters [diaphragmatic thickening fraction (DTF), diaphragmatic excursion (DE), thickness] and ventilator liberation outcomes. The search used keywords "bedside ultrasound", "diaphragmatic function", "tracheotomy", "MV", and "decannulation", limited to English/Chinese publications within the last 10 years, with no age or country restrictions. KEY CONTENT AND FINDINGS: Main ultrasound parameters include DE and DTF. Higher DTF and adequate DE are generally associated with successful ventilator liberation, yet reported thresholds vary by patient population, ventilator support level, spontaneous breathing trial (SBT) protocol, and measurement technique. Evidence directly derived from tracheostomised cohorts is limited; thus, external validity of cut‑offs derived from extubation cohorts should be interpreted with caution in tracheostomised patients. Integrating diaphragm ultrasound with lung and cardiac ultrasound may improve prediction of weaning outcomes. CONCLUSIONS: Bedside diaphragm ultrasound is a practical adjunct for assessing respiratory pump function during ventilator liberation planning. In tracheostomised patients, it should be used to support multidisciplinary decision-making for ventilator liberation and, as a separate step, decannulation readiness. Reported ultrasound cut-offs are context-dependent and should not be used as standalone criteria. Future research should prioritize standardized measurement protocols and prospective validation in tracheostomised populations. CI - (c) AME Publishing Company. FAU - Li, Yan AU - Li Y AD - Graduate School, Shanghai University of Traditional Chinese Medicine, Shanghai, China. AD - Department of Respiratory and Critical Care Rehabilitation, The Second Rehabilitation Hospital of Shanghai, Shanghai, China. FAU - Wang, Shan-Shan AU - Wang SS AD - Department of Respiratory and Critical Care Rehabilitation, The Second Rehabilitation Hospital of Shanghai, Shanghai, China. FAU - Li, Kai-Yi AU - Li KY AD - Department of Respiratory and Critical Care Rehabilitation, The Second Rehabilitation Hospital of Shanghai, Shanghai, China. FAU - Zhang, Zi-Nan AU - Zhang ZN AD - Graduate School, Shanghai University of Traditional Chinese Medicine, Shanghai, China. AD - Department of Respiratory and Critical Care Rehabilitation, The Second Rehabilitation Hospital of Shanghai, Shanghai, China. FAU - Chen, Ye-Ping AU - Chen YP AD - Department of Respiratory and Critical Care Rehabilitation, The Second Rehabilitation Hospital of Shanghai, Shanghai, China. FAU - Xia, Jia-Yi AU - Xia JY AD - Department of Respiratory and Critical Care Rehabilitation, The Second Rehabilitation Hospital of Shanghai, Shanghai, China. LA - eng PT - Journal Article PT - Review DEP - 20260227 PL - China TA - J Thorac Dis JT - Journal of thoracic disease JID - 101533916 PMC - PMC13077354 OTO - NOTNLM OT - Bedside ultrasound OT - decannulation OT - diaphragmatic function OT - mechanical ventilation (MV) OT - tracheostomy COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-2025-1-2737/coif). The authors have no conflicts of interest to declare. EDAT- 2026/04/16 13:09 MHDA- 2026/04/16 13:10 PMCR- 2026/03/31 CRDT- 2026/04/16 04:28 PHST- 2025/12/26 00:00 [received] PHST- 2026/02/06 00:00 [accepted] PHST- 2026/04/16 13:10 [medline] PHST- 2026/04/16 13:09 [pubmed] PHST- 2026/04/16 04:28 [entrez] PHST- 2026/03/31 00:00 [pmc-release] AID - jtd-18-03-246 [pii] AID - 10.21037/jtd-2025-1-2737 [doi] PST - ppublish SO - J Thorac Dis. 2026 Mar 31;18(3):246. doi: 10.21037/jtd-2025-1-2737. Epub 2026 Feb 27. PMID- 41986641 OWN - NLM STAT- Publisher LR - 20260415 IS - 1861-0692 (Electronic) IS - 1861-0684 (Linking) DP - 2026 Apr 15 TI - Cardiac biomarkers in women with high-risk pregnancies: short-term outcomes from the Heidelberg Cardio-Obstetrics Registry. LID - 10.1007/s00392-026-02920-8 [doi] AB - BACKGROUND: Pregnancy leads to profound physiological changes within the cardiovascular system. However, in women with pre-existing or pregnancy-associated cardiovascular disease (CVD) these adaptations may be insufficient and lead to maternal or fetal complications. The prognostic value of cardiac biomarkers such as N-terminal B-type natriuretic peptide (NTproBNP) and high-sensitivity cardiac troponin-T (hscTnT) in this population remains unclear. MATERIAL AND METHODS: In this prospective, single-center cohort study, we included women with pre-existing CVD or who developed CVD during pregnancy. Patients were assessed before pregnancy, during each trimester, and in the postpartum period, when feasible. Biomarker trajectories (NT-proBNP, hs-cTnT) were recorded and their association with maternal complications at delivery was evaluated. Diagnostic accuracy was estimated using receiver operating characteristic curves (ROC). RESULTS: 67 women were included (median age 33.0 years, IQR 30.0-37.0): 46 patients (73.1%) with pre-existing CVD and 21 patients (31.3%) who developed CVD during pregnancy. 50 women were observed until delivery and in 30 cases (60%) a maternal and/or fetal complication occurred at birth. Peak NT-proBNP demonstrated good discrimination for maternal complications (AUC 0.722; 95% CI 0.552-0.892) with an optimal cut-off of 209 ng/L (sensitivity 72%, specificity 67%, Youden 0.39). Peak hs-cTnT showed good discrimination as well (AUC 0.729; 95% CI 0.568-0.890) with a cut-off of 22.0 pg/mL (sensitivity 55%, specificity 84%, Youden 0.39). DISCUSSION: In this high-risk real-world cohort of pregnant women with CVD, maternal and/or fetal complications at delivery were common. Elevated NT-proBNP-and to a lesser extent hs-cTnT-was associated with higher complication rates and showed potential for improving risk stratification and monitoring. These findings support multidisciplinary surveillance of pregnant women with CVD and warrant further investigation in larger, multicenter studies. CI - (c) 2026. The Author(s). FAU - Siry, Deborah AU - Siry D AUID- ORCID: 0000-0002-2200-6484 AD - Department of Internal Medicine III, Division of Cardiology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany. deborah.siry@med.uni-heidelberg.de. FAU - Haney, Ailis Ceara AU - Haney AC AD - Department of Internal Medicine III, Division of Cardiology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany. FAU - Ehlermann, Philipp AU - Ehlermann P AD - Department of Internal Medicine III, Division of Cardiology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany. FAU - Frey, Norbert AU - Frey N AD - Department of Internal Medicine III, Division of Cardiology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany. FAU - Horbrand, Isabel Amber-Rose AU - Horbrand IA AD - Department of Internal Medicine III, Division of Cardiology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany. AD - DZHK (German Centre for Cardiovascular Research), Partner Site Heidelberg/Mannheim, Heidelberg, Germany. FAU - Beckendorf, Jan AU - Beckendorf J AD - Department of Internal Medicine III, Division of Cardiology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany. AD - DZHK (German Centre for Cardiovascular Research), Partner Site Heidelberg/Mannheim, Heidelberg, Germany. LA - eng PT - Journal Article DEP - 20260415 PL - Germany TA - Clin Res Cardiol JT - Clinical research in cardiology : official journal of the German Cardiac Society JID - 101264123 SB - IM OTO - NOTNLM OT - Cardiac biomarkers OT - Cardio-obstetrics OT - Pregnancy OT - Pregnancy heart team OT - Sex and gender COIS- Declarations. Ethical approval: The study was approved by the local ethics committee (S-120/2023) and was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. All patients provided written informed consent. Competing interests: MD Jan Beckendorf declares receiving two grants from AstraZeneca and Boehringer Ingelheim, as well as speaker honoraria from AstraZeneca, Bayer, B.Braun, Boehringer Ingelheim, and Novartis. EDAT- 2026/04/16 07:09 MHDA- 2026/04/16 07:09 CRDT- 2026/04/15 23:36 PHST- 2025/10/22 00:00 [received] PHST- 2026/04/03 00:00 [accepted] PHST- 2026/04/16 07:09 [medline] PHST- 2026/04/16 07:09 [pubmed] PHST- 2026/04/15 23:36 [entrez] AID - 10.1007/s00392-026-02920-8 [pii] AID - 10.1007/s00392-026-02920-8 [doi] PST - aheadofprint SO - Clin Res Cardiol. 2026 Apr 15. doi: 10.1007/s00392-026-02920-8. PMID- 41979786 OWN - NLM STAT- Publisher LR - 20260414 IS - 1563-258X (Electronic) IS - 0043-5341 (Linking) DP - 2026 Apr 14 TI - Analysis of patients with erectile dysfunction undergoing coronary angiography in Austria-a cross-sectional study. LID - 10.1007/s10354-026-01143-w [doi] AB - BACKGROUND: Erectile dysfunction coexists with a spectrum of health issues and is a significant experience in a man's life. In young men, erectile dysfunction is considered a predictor of silent coronary artery disease, highlighting its potential as a simple and accessible marker. OBJECTIVE: The overall health status of patients with and without erectile dysfunction undergoing an elective coronary angiography is unclear and is addressed in this publication. METHODS: A total of 700 patients were recruited to this study, of whom 419 male patients were evaluated for health issues related to erectile dysfunction. All participants underwent elective coronary angiography based on clinical indications to assess established or suspected stable coronary artery disease. Particular attention was given to current medication use, medication adherence, health literacy, and health-related quality of life. RESULTS: Erectile dysfunction was present in 43% (n = 181) of the patients evaluated. Significant associations were found with increasing age, type 2 diabetes mellitus, elevated HbA1c levels, and reduced estimated glomerular filtration rate but not with angiographic findings. Medication analysis revealed that 25.4% of patients with both erectile dysfunction and type 2 diabetes mellitus were not receiving glucose-lowering treatment. Additionally, patients with erectile dysfunction exhibited lower levels of health literacy and reduced health-related quality of life. CONCLUSION: This study provides important insights into the multifactorial nature of erectile dysfunction in a high-risk population. It addresses patients' health-related quality of life and medication management, and it raises awareness of the far-reaching consequences of a topic often associated with shame. These findings reflect the importance of a multidisciplinary approach involving physicians, pharmacists, and public health initiatives to support prevention efforts and improve care for patients affected by erectile dysfunction. CI - (c) 2026. Der/die Autor(en), exklusiv lizenziert an Springer-Verlag GmbH Austria, ein Teil von Springer Nature. FAU - Elsner, Pascal AU - Elsner P AUID- ORCID: 0009-0000-2704-1572 AD - Vorarlberg Institute for Vascular Investigation & Treatment (VIVIT), Carinagasse 47, 6800, Feldkirch, Austria. vivit@lkhf.at. AD - Private University in the Principality of Liechtenstein, Triesen, Liechtenstein. vivit@lkhf.at. FAU - Neyer, Magdalena AU - Neyer M AUID- ORCID: 0009-0007-8962-0749 AD - Vorarlberg Institute for Vascular Investigation & Treatment (VIVIT), Carinagasse 47, 6800, Feldkirch, Austria. AD - Private University in the Principality of Liechtenstein, Triesen, Liechtenstein. FAU - Vogel, Johannes B AU - Vogel JB AUID- ORCID: 0009-0009-5443-860X AD - Vorarlberg Institute for Vascular Investigation & Treatment (VIVIT), Carinagasse 47, 6800, Feldkirch, Austria. AD - Private University in the Principality of Liechtenstein, Triesen, Liechtenstein. FAU - Schnetzer, Laura AU - Schnetzer L AUID- ORCID: 0000-0001-8152-7186 AD - Vorarlberg Institute for Vascular Investigation & Treatment (VIVIT), Carinagasse 47, 6800, Feldkirch, Austria. FAU - Drexel, Heinz AU - Drexel H AUID- ORCID: 0000-0002-4677-9756 AD - Vorarlberg Institute for Vascular Investigation & Treatment (VIVIT), Carinagasse 47, 6800, Feldkirch, Austria. AD - Private University in the Principality of Liechtenstein, Triesen, Liechtenstein. AD - Vorarlberger Landeskrankenhausbetriebsgesellschaft, Feldkirch, Austria. AD - Drexel University College of Medicine, Philadelphia, USA. FAU - Saely, Christoph H AU - Saely CH AD - Vorarlberg Institute for Vascular Investigation & Treatment (VIVIT), Carinagasse 47, 6800, Feldkirch, Austria. AD - Private University in the Principality of Liechtenstein, Triesen, Liechtenstein. AD - Medicine I, Academic Teaching Hospital Feldkirch, Feldkirch, Austria. FAU - Festa, Andreas AU - Festa A AUID- ORCID: 0009-0009-4278-2964 AD - Vorarlberg Institute for Vascular Investigation & Treatment (VIVIT), Carinagasse 47, 6800, Feldkirch, Austria. AD - Private University in the Principality of Liechtenstein, Triesen, Liechtenstein. LA - eng PT - Journal Article TT - Analyse von Patienten mit erektiler Dysfunktion im Rahmen einer Koronarangiographie in Osterreich - eine Querschnittstudie. DEP - 20260414 PL - Austria TA - Wien Med Wochenschr JT - Wiener medizinische Wochenschrift (1946) JID - 8708475 SB - IM OTO - NOTNLM OT - Adherence OT - Health literacy OT - Health-related quality of life OT - Medication analysis OT - Polypharmacy COIS- Conflict of interest: P. Elsner, M. Neyer, J.B. Vogel, L. Schnetzer, H. Drexel, C.H. Saely, and A. Festa declare that they have no competing interests. EDAT- 2026/04/14 12:35 MHDA- 2026/04/14 12:35 CRDT- 2026/04/14 11:08 PHST- 2025/07/14 00:00 [received] PHST- 2026/03/11 00:00 [accepted] PHST- 2026/04/14 12:35 [medline] PHST- 2026/04/14 12:35 [pubmed] PHST- 2026/04/14 11:08 [entrez] AID - 10.1007/s10354-026-01143-w [pii] AID - 10.1007/s10354-026-01143-w [doi] PST - aheadofprint SO - Wien Med Wochenschr. 2026 Apr 14. doi: 10.1007/s10354-026-01143-w. PMID- 41979519 OWN - NLM STAT- MEDLINE DCOM- 20260715 LR - 20260715 IS - 1066-2936 (Print) IS - 1066-2936 (Linking) VI - 53 IP - 1 DP - 2026 First Quarter TI - Multifactorial determinants of diving-associated deaths in Turkey: autopsy-based insights and the imperative of integrated forensic assessment. PG - 1-14 AB - INTRODUCTION: This autopsy-based study aims to investigate the underlying causes and forensic characteristics of fatal diving incidents in Turkey, emphasizing the autopsy-based strategies employed to distinguish drowning from other diving-related pathologies such as decompression illness and arterial gas embolism. METHODS: A retrospective analysis was conducted on 11 fatal diving cases evaluated by the First Forensic Medicine Specialization Board between 2002 and 2023. Data were retrieved from judicial records, including detailed autopsy reports, histopathological findings, toxicological analyses, and scene investigations. RESULTS: The decedents consisted of ten males and one female (median age: 45), reflecting the male-dominant profile of diving activity. Diving modalities included SCUBA (n=7), breath-hold (n=2), and surface-supplied compressor diving (n=2). The leading cause of death was drowning (n=5), followed by arterial gas embolism (AGE; n=2), sudden cardiac death (n=2), subarachnoid hemorrhage (n=1), and asphyxia due to mechanical entrapment (n=1). AGE cases demonstrated intravascular gas via specialized autopsy techniques. Cardiovascular comorbidities were identified in four cases, while medications- primarily prescribed-were detected in five. Alcohol and illicit drugs were absent in all cases. DISCUSSION: Diving fatalities pose complex medicolegal challenges that require a multidisciplinary approach. Drowning and AGE were the most frequent causes, often accompanied by cardiovascular pathology. Proper autopsy techniques, scene correlation, and pre-dive medical screening remain critical for accurate diagnosis and prevention. The findings underscore the need for standardized forensic protocols, especially in regions with limited access to postmortem imaging. CI - Copyright(c) Undersea and Hyperbaric Medical Society. FAU - Dogan, Mehmet AU - Dogan M AD - Council of Forensic Medicine, Ministry of Justice, Republic of Turkey, Istanbul/Turkey. FAU - Atan, Yusuf AU - Atan Y AD - Council of Forensic Medicine, Ministry of Justice, Republic of Turkey, Istanbul/Turkey. AD - Department of Forensic Medicine, Faculty of Medicine, Bilecik Seyh Edebali University, Bilecik/Turkey. FAU - Dag, Mehmet Ali AU - Dag MA AD - Council of Forensic Medicine, Ministry of Justice, Republic of Turkey, Istanbul/Turkey. FAU - Uzun, Ibrahim AU - Uzun I AD - Council of Forensic Medicine, Ministry of Justice, Republic of Turkey, Istanbul/Turkey. AD - Istanbul Universtiy, Cerrahpasa Faculty of Medicine, Forensic Medicine Department, Istanbul/Turkey. LA - eng PT - Journal Article PL - United States TA - Undersea Hyperb Med JT - Undersea & hyperbaric medicine : journal of the Undersea and Hyperbaric Medical Society, Inc JID - 9312954 SB - IM MH - Humans MH - Male MH - Turkey/epidemiology MH - *Diving/adverse effects/statistics & numerical data MH - Female MH - *Drowning/mortality/diagnosis/pathology/etiology MH - Retrospective Studies MH - Embolism, Air/mortality/pathology/diagnosis MH - Autopsy/methods MH - Middle Aged MH - Adult MH - Death, Sudden, Cardiac/etiology MH - Cause of Death MH - Asphyxia/mortality/etiology MH - Diving and Hyperbaric Medicine MH - Decompression Sickness/mortality/diagnosis MH - Breath Holding MH - Aged MH - Forensic Pathology OTO - NOTNLM OT - arterial gas embolism OT - SCUBA OT - autopsy OT - cardiovascular disease OT - compressor diving OT - decompression illness OT - diving fatalities OT - drowning OT - forensic pathology OT - postmortem diagnosis COIS- The authors of this paper declare no conflicts of interest exist with this submission. EDAT- 2026/04/14 12:35 MHDA- 2026/04/14 12:36 CRDT- 2026/04/14 10:22 PHST- 2026/04/14 12:36 [medline] PHST- 2026/04/14 12:35 [pubmed] PHST- 2026/04/14 10:22 [entrez] PST - ppublish SO - Undersea Hyperb Med. 2026 First Quarter;53(1):1-14. PMID- 41978475 OWN - NLM STAT- MEDLINE DCOM- 20260715 LR - 20260715 IS - 1744-8298 (Electronic) IS - 1479-6678 (Print) IS - 1479-6678 (Linking) VI - 22 IP - 5 DP - 2026 May TI - Recent advances in predicting and improving outcomes in patients undergoing transcatheter tricuspid valve intervention. PG - 515-527 LID - 10.1080/14796678.2026.2652420 [doi] AB - Tricuspid regurgitation (TR) has long been underestimated, traditionally viewed as a benign condition, yet contemporary evidence demonstrates its high prevalence and substantial adverse prognostic implications. Medical therapy remains limited, and although surgery has historically been the standard of care, many patients are referred at advanced stages, contributing to poor operative outcomes. Transcatheter tricuspid valve interventions (TTVI) have emerged as a valuable therapeutic option, showing consistent improvements in symptoms, quality of life (QoL), and heart failure hospitalizations (HFH), although a definitive survival benefit has not yet been established. Optimal management requires a comprehensive, multiparametric, and multidisciplinary approach. Key elements include careful assessment of TR etiology, clinical status, right heart failure stage, multimodality imaging, risk scores, and invasive hemodynamics. Integrating these factors enables appropriate patient selection, individualized treatment strategies, and avoidance of futile procedures. Ultimately, decisions regarding intervention and device choice should be guided by a dedicated multidisciplinary Heart Team within a specialized Heart Valve Center. FAU - Serafini, Lisa AU - Serafini L AD - Institute of Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, ASST Spedali Civili di Brescia, Brescia, Italy. AD - Medical Department, Institute of Cardiology, ASST Cremona, Cremona, Italy. FAU - Ricci, Alessandra AU - Ricci A AD - Institute of Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, ASST Spedali Civili di Brescia, Brescia, Italy. FAU - Pezzola, Elisa AU - Pezzola E AD - Institute of Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, ASST Spedali Civili di Brescia, Brescia, Italy. FAU - Legati, Michele AU - Legati M AD - Institute of Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, ASST Spedali Civili di Brescia, Brescia, Italy. FAU - Capasso, Francesca AU - Capasso F AD - Institute of Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, ASST Spedali Civili di Brescia, Brescia, Italy. FAU - Pugno Vanoni, Francesca AU - Pugno Vanoni F AD - Institute of Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, ASST Spedali Civili di Brescia, Brescia, Italy. FAU - Geavlete, Oliviana AU - Geavlete O AD - Department of Cardiology, Emergency Institute of Cardiovascular Disease, Bucharest, Romania. FAU - Chioncel, Ovidiu AU - Chioncel O AD - Department of Cardiology, Emergency Institute of Cardiovascular Disease, Bucharest, Romania. FAU - Metra, Marco AU - Metra M AD - Institute of Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, ASST Spedali Civili di Brescia, Brescia, Italy. FAU - Adamo, Marianna AU - Adamo M AD - Institute of Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, ASST Spedali Civili di Brescia, Brescia, Italy. LA - eng PT - Journal Article PT - Review DEP - 20260414 PL - England TA - Future Cardiol JT - Future cardiology JID - 101239345 SB - IM MH - Humans MH - *Tricuspid Valve Insufficiency/surgery/diagnosis MH - *Cardiac Catheterization/methods MH - *Heart Valve Prosthesis Implantation/methods MH - *Tricuspid Valve/surgery MH - Treatment Outcome MH - Quality of Life MH - Prognosis PMC - PMC13215622 OAB - For many years, tricuspid regurgitation was considered a minor and generally benign condition. More recent studies have shown that this disease is much more common than previously thought and has serious consequences for patients' health and survival. Available medical therapies are limited and often unable to adequately control symptoms. Surgery has long been the standard treatment, but in real-world practice many patients are referred at advanced stages of the disease, when surgical risk is high and outcomes are unsatisfactory.Recently, new percutaneous techniques, known as transcatheter tricuspid valve interventions, have been developed. These procedures represent an important therapeutic alternative, especially for frail patients or those who are not eligible for conventional surgery.Available data show consistent benefits, including symptom relief, improved quality of life, and fewer hospitalizations for heart failure. However, a clear long-term survival benefit has not yet been definitively demonstrated.Optimal management of tricuspid regurgitation requires a comprehensive and personalized approach. It is essential to carefully evaluate the underlying cause of the disease, the patient's clinical condition, the degree of right heart involvement, imaging findings, and invasive hemodynamic measurements, as well as the patient-specific procedural risk. Considering all these elements, clinicians can define the most appropriate treatment strategy, and avoid unnecessary or futile interventions. Final decisions should be made by a dedicated multidisciplinary heart team within specialized heart valve centers. OABL- eng OTO - NOTNLM OT - TTVI OT - Tricuspid regurgitation OT - multiparametric evaluation OT - outcomes OT - pre-procedural evaluation OT - risk scores OT - transcatheter tricuspid valve intervention COIS- MA and MM received consultation and speaker fees from Abbott Vascular outside the submitted work. OG received speaker fees from Servier, AstraZeneca, Bayer, Boehringer Ingelheim, Chesi, Novartis, NovoNordisk. OC is a member of the Boehringer Ingelheim Advisory Board. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. EDAT- 2026/04/14 06:32 MHDA- 2026/05/26 23:33 PMCR- 2027/04/14 CRDT- 2026/04/14 03:23 PHST- 2026/05/26 23:33 [medline] PHST- 2026/04/14 06:32 [pubmed] PHST- 2026/04/14 03:23 [entrez] PHST- 2027/04/14 00:00 [pmc-release] AID - 2652420 [pii] AID - 10.1080/14796678.2026.2652420 [doi] PST - ppublish SO - Future Cardiol. 2026 May;22(5):515-527. doi: 10.1080/14796678.2026.2652420. Epub 2026 Apr 14. PMID- 41977162 OWN - NLM STAT- MEDLINE DCOM- 20260715 LR - 20260813 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 27 IP - 7 DP - 2026 Mar 25 TI - Cardiotoxicity of Antitumor Agents: Therapeutic Challenges in Heart Failure with Reduced and Preserved Ejection Fraction. LID - 10.3390/ijms27072973 [doi] LID - 2973 AB - The remarkable evolution of oncological therapies has dramatically improved cancer survival rates but has simultaneously introduced a significant burden of cardiovascular complications. Cardio-oncology has emerged as a critical multidisciplinary field focused on mitigating the "collateral damage" of life-saving anticancer treatments, ranging from traditional chemotherapeutics to novel immunotherapies. This review provides a comprehensive analysis of the pathophysiological mechanisms, clinical phenotypes, and evolving management strategies for cancer therapy-related cardiac dysfunction (CTRCD). An extensive synthesis of the current literature was conducted, focusing on the molecular pathways of cardiotoxicity, including Topoisomerase IIbeta inhibition by anthracyclines, HER2 signaling disruption by targeted agents, and immune-mediated myocarditis triggered by checkpoint inhibitors (ICIs). Cardiotoxicity is increasingly recognized as a spectrum of phenotypes. Heart failure with reduced ejection fraction (HFrEF) remains a primary concern with cytotoxic agents, while heart failure with preserved ejection fraction (HFpEF) is emerging as a critical complication of radiation therapy and tyrosine kinase inhibitors (TKIs). The integration of advanced diagnostic tools-specifically Global Longitudinal Strain (GLS) and Cardiac Magnetic Resonance (CMR) mapping-has shifted the clinical focus toward subclinical detection. Furthermore, pivotal clinical trials such as PRADA and SUCCOUR have validated early pharmacological prophylaxis and strain-guided interventions. Emerging challenges, including the management of CAR-T cell-induced cytokine release syndrome and the specific cardiovascular needs of pediatric and geriatric populations, are also explored. The future of cardio-oncology lies in precision medicine, leveraging genomic profiling and artificial intelligence to identify high-risk individuals. A proactive, multidisciplinary approach is essential to ensure that the success of modern oncology is not compromised by irreversible cardiovascular morbidity. FAU - Tana, Marco AU - Tana M AUID- ORCID: 0000-0002-0899-9870 AD - Internal Medicine and Cardiovascular Ultrasound Unit, Medical Department, Saint Annunziata Hospital, 66100 Chieti, Italy. AD - School of Internal Medicine, Faculty of Medicine, G. D'Annunzio University, 66100 Chieti, Italy. FAU - Piccinini, Rachele AU - Piccinini R AD - School of Oncology Diseases, Polytechnic University of Marche, 60131 Ancona, Italy. FAU - Pinterpe, Giada AU - Pinterpe G AUID- ORCID: 0000-0001-9395-2104 AD - School of Oncology Diseases, Polytechnic University of Marche, 60131 Ancona, Italy. FAU - Porreca, Ettore AU - Porreca E AD - Internal Medicine and Cardiovascular Ultrasound Unit, Medical Department, Saint Annunziata Hospital, 66100 Chieti, Italy. AD - School of Internal Medicine, Faculty of Medicine, G. D'Annunzio University, 66100 Chieti, Italy. FAU - Berardi, Rossana AU - Berardi R AUID- ORCID: 0000-0002-9529-2960 AD - School of Oncology Diseases, Polytechnic University of Marche, 60131 Ancona, Italy. FAU - Tana, Claudio AU - Tana C AUID- ORCID: 0000-0002-9162-7866 AD - Internal Medicine Unit, ASL Taranto, 74121 Taranto, Italy. LA - eng PT - Journal Article PT - Review DEP - 20260325 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (Antineoplastic Agents) SB - IM MH - Humans MH - *Cardiotoxicity/etiology/physiopathology/therapy MH - *Heart Failure/physiopathology/chemically induced/etiology/therapy MH - *Antineoplastic Agents/adverse effects MH - *Stroke Volume/drug effects MH - Animals MH - Neoplasms/drug therapy PMC - PMC13073610 OTO - NOTNLM OT - anthracyclines OT - cardio-oncology OT - cardioprotection OT - cardiotoxicity OT - heart failure OT - immune checkpoint inhibitors OT - strain imaging COIS- The authors declare no conflict of interest. EDAT- 2026/04/14 06:31 MHDA- 2026/04/14 06:32 PMCR- 2026/03/25 CRDT- 2026/04/14 01:07 PHST- 2025/12/18 00:00 [received] PHST- 2026/01/25 00:00 [revised] PHST- 2026/01/26 00:00 [accepted] PHST- 2026/04/14 06:32 [medline] PHST- 2026/04/14 06:31 [pubmed] PHST- 2026/04/14 01:07 [entrez] PHST- 2026/03/25 00:00 [pmc-release] AID - ijms27072973 [pii] AID - ijms-27-02973 [pii] AID - 10.3390/ijms27072973 [doi] PST - epublish SO - Int J Mol Sci. 2026 Mar 25;27(7):2973. doi: 10.3390/ijms27072973. PMID- 41976827 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260414 LR - 20260813 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 15 IP - 7 DP - 2026 Mar 26 TI - Knowledge Assessment on the Management of Acute Cor Pulmonale: An Interdisciplinary Survey Study. LID - 10.3390/jcm15072527 [doi] LID - 2527 AB - Background/Objectives: Acute cor pulmonale is a critical clinical condition often encountered in acute care settings. Optimal management demands coordinated, interdisciplinary care. The aim of this study was to assess the current knowledge and management strategies for acute cor pulmonale among different groups of physicians involved in acute care in Switzerland. Methods: A structured questionnaire, extrapolated from the Acute Cardiovascular Care Association of the European Society of Cardiology clinical consensus statement on the diagnosis and treatment of cor pulmonale, was distributed among physicians of four specialties. Results: A total of 110 physicians participated in this multicenter survey, including 15 "experts," 71 "generalists" (internal and emergency medicine), and 24 "specialists" (cardiology and intensive care). Experts validated 29 out of 40 questionnaire items (Fleiss Kappa 0.63), which were then used for analysis. Overall, there was substantial agreement with the experts' answers among non-experts, with most correct response rates exceeding 60%. Significant differences were observed for only two items: experts more frequently recognized the prognostic value of clinical models (87% vs. 59%, p = 0.046) and the correct indications for systemic thrombolysis (100% vs. 76%, p = 0.037). Between generalists and specialists, differences in knowledge were minimal. Specialists more accurately identified the role of repeated arterial blood gas analysis, while generalists showed better awareness of clinical prognostic models. Conclusions: The study highlights a sound knowledge of acute cor pulmonale among acute care physicians, regardless of specialty. Despite comparable levels of knowledge, some variations reflect their clinical roles and information sources. The results emphasize the value of existing educational efforts and support the need for comprehensive, accessible guidelines to standardize care in complex conditions like acute cor pulmonale. FAU - Bolt, Levin AU - Bolt L AUID- ORCID: 0009-0009-2988-0885 AD - Department of Internal Medicine, Stadtspital Zurich Triemli, 8063 Zurich, Switzerland. FAU - Rudiger, Alain AU - Rudiger A AD - Department of Internal Medicine, Spital Limmattal, 8952 Schlieren, Switzerland. FAU - Turk, Alexander AU - Turk A AD - Department of Internal Medicine, See-Spital Horgen, 8810 Horgen, Switzerland. FAU - Arrigo, Mattia AU - Arrigo M AUID- ORCID: 0000-0003-4028-2869 AD - Division of Internal Medicine, EOC-Ospedale Regionale di Lugano, 6900 Lugano, Switzerland. AD - Facolta di Scienze Biomediche, Universita della Svizzera Italiana, 6900 Lugano, Switzerland. FAU - Huber, Lars C AU - Huber LC AD - Department of Internal Medicine, University Hospital Zurich, 8091 Zurich, Switzerland. AD - Faculty of Medicine, University of Zurich, 8032 Zurich, Switzerland. LA - eng PT - Journal Article DEP - 20260326 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC13073427 OTO - NOTNLM OT - acute cor pulmonale OT - acute right heart failure OT - cardiology OT - clinical consensus OT - emergency medicine OT - interdisciplinary management OT - internal medicine COIS- The authors declare no conflicts of interest. EDAT- 2026/04/14 06:31 MHDA- 2026/04/14 06:32 PMCR- 2026/03/26 CRDT- 2026/04/14 01:06 PHST- 2026/02/28 00:00 [received] PHST- 2026/03/20 00:00 [revised] PHST- 2026/03/24 00:00 [accepted] PHST- 2026/04/14 06:32 [medline] PHST- 2026/04/14 06:31 [pubmed] PHST- 2026/04/14 01:06 [entrez] PHST- 2026/03/26 00:00 [pmc-release] AID - jcm15072527 [pii] AID - jcm-15-02527 [pii] AID - 10.3390/jcm15072527 [doi] PST - epublish SO - J Clin Med. 2026 Mar 26;15(7):2527. doi: 10.3390/jcm15072527. PMID- 41975262 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260627 LR - 20260813 IS - 1865-1372 (Print) IS - 1865-1380 (Electronic) IS - 1865-1372 (Linking) VI - 19 IP - 1 DP - 2026 Apr 13 TI - Unravelling technical domain barriers and non-technical skill barriers among interprofessional teams during in-hospital cardiac arrest: a questionnaire-based survey. LID - 10.1186/s12245-026-01224-y [doi] LID - 97 AB - BACKGROUND: In spite of focused cardiopulmonary resuscitation (CPR) training, the in-hospital cardio-pulmonary resuscitation (CPR) performance often remains suboptimal, due to technical domain barriers and non-technical skill (NTS) barriers. We aimed to determine the technical domain and NTS barriers encountered by the in-hospital interprofessional (IP) CPR resuscitation teams through a cross-sectional, quantitative, analytical survey, and to determine whether a poor NTS score alone is associated with non-adherence to high-quality CPR. METHODS: A validated questionnaire was developed comprising 17 items on technical domain barriers and 9 on the NTS barrier domain. A web-based Likert-scale questionnaire was administered to assess perception-based barriers among 400 IP team members across healthcare settings in India, focusing on technical domain barriers and NTS domain barriers. IP members with at least 1 year of work experience, hands-on CPR training, and in-hospital CPR experience were recruited. RESULTS: There were 32.75% doctors, 29.75% nurses, 24% respiratory therapists, 10.25% emergency technicians, and 2.25% ICU technicians. The logistic regression analysis revealed that only five items independently predicted a poor technical domain score: inability to identify cardiac rhythm, non-working defibrillator, unavailability of a supraglottic airway device, unavailability of a correct-size laryngoscope blade, and a delay in loading medications. Five NTS items independently predicted a poor NTS score: lack of clear instructions from the team leader, lack of awareness of the dynamic nature of resuscitation, lack of closed-loop communication, lack of assigned tasks completed by a team member, and lack of knowledge sharing among team members. A poor NTS score is associated with perceived non-adherence to high-quality CPR (Chi-Square test, p-value < 0.001). CONCLUSION: Both NTS barriers and technical domain barriers were associated with perceived non-adherence to high-quality CPR. TRIAL REGISTRATION: Clinical Trial Registry of India CTRI/2025/05/086727 registered on 13/05/2025. FAU - Prakash, Prabha AU - Prakash P AUID- ORCID: 0000-0001-8681-1821 AD - Department of Emergency Medicine, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, India. FAU - Nayak, Kirtana Raghurama AU - Nayak KR AUID- ORCID: 0000-0001-6124-2239 AD - Department of Physiology, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, India. FAU - Devi, Elsa Sanatombi AU - Devi ES AUID- ORCID: 0000-0002-0738-8912 AD - Department of Medical Surgery, Manipal College of Nursing, Manipal Academy of Higher Education, Manipal, India. FAU - Chaudhuri, Souvik AU - Chaudhuri S AUID- ORCID: 0000-0001-8392-2366 AD - Department of Critical Care Medicine, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, India. FAU - Babu, Abraham Samuel AU - Babu AS AUID- ORCID: 0000-0003-1084-0137 AD - Department of Physiotherapy, Manipal College of Health Professions, Manipal Academy of Higher Education, Manipal, India. FAU - Pai, Dinker Ramananda AU - Pai DR AUID- ORCID: 0000-0001-9204-5721 AD - Department of Surgery, Mahatma Gandhi Medical College and Research Institute, Sri Balaji Vidyapeeth, Puducherry, India. FAU - Krishnan S, Vimal AU - Krishnan S V AUID- ORCID: 0000-0002-0100-2396 AD - Department of Emergency Medicine, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, India. vimal.krishnan@manipal.edu. LA - eng PT - Journal Article DEP - 20260413 PL - England TA - Int J Emerg Med JT - International journal of emergency medicine JID - 101469435 PMC - PMC13077877 OTO - NOTNLM OT - Barriers OT - Cardiopulmonary resuscitation OT - Interprofessional team OT - Non-technical skills OT - Technical skills COIS- Declarations. Ethics approval and consent to participate: The study protocol was approved by Kasturba Medical College, Manipal, and Kasturba Hospital Institutional Ethics Committee (IEC1: 107/2025) and is registered with the Clinical Trials Registry of India (CTRI/2025/05/086727). Dated- 13/05/2025. All participants provided consent before participating in the survey. Consent for publication: Not applicable. Use of Artificial Intelligence (AI) tools for figure: The authors used Google NotebookLM to generate the infographic in Figs. 1 and 3 based on author-developed concepts. All outputs were reviewed and verified by the authors. Competing interests: The authors declare no competing interests. EDAT- 2026/04/14 00:30 MHDA- 2026/04/14 00:31 PMCR- 2026/04/13 CRDT- 2026/04/13 23:53 PHST- 2026/01/16 00:00 [received] PHST- 2026/04/02 00:00 [accepted] PHST- 2026/04/14 00:31 [medline] PHST- 2026/04/14 00:30 [pubmed] PHST- 2026/04/13 23:53 [entrez] PHST- 2026/04/13 00:00 [pmc-release] AID - 10.1186/s12245-026-01224-y [pii] AID - 1224 [pii] AID - 10.1186/s12245-026-01224-y [doi] PST - epublish SO - Int J Emerg Med. 2026 Apr 13;19(1):97. doi: 10.1186/s12245-026-01224-y. PMID- 41974182 OWN - NLM STAT- MEDLINE DCOM- 20260827 LR - 20260902 IS - 1439-1902 (Electronic) IS - 0171-6425 (Linking) VI - 74 IP - 6 DP - 2026 Sep TI - Physician Assistants in Cardiac Surgery: Insights from a German University Hospital. PG - 450-454 LID - 10.1055/a-2836-2282 [doi] AB - BACKGROUND: The rising complexity of cardiac surgery patients, coupled with new regulations reducing working hours for surgical residents, and increased healthcare costs, has led to the growing introduction of physician assistants (PAs) into cardiacsurgery teams in German hospitals. This study aims to systematically explore the experience of introducing PAs into the cardiac surgery workforce in a tertiary university hospital in Germany, identifying what is working well and areas for improvement, as well as offering suggestions for appropriate measures. METHODS: The study was of an observational nature and comprised both quantitative assessments and qualitative interviews. For the quantitative component, a survey was distributed internally to employees of the cardiovascular surgery department. The survey was first distributed within 1 month of the first PAs starting in our department ("baseline") and again 1 year later ("follow-up" [FU]). RESULTS: Forty-one healthcare professionals completed the baseline, and 37 completed the FU survey. Overall satisfaction with PAs was high across all professional groups. Among residents,73.3% reported being satisfied at baseline and 70% at FU. All cardiovascular surgeons (6/6) and PAs (10/10) reported high satisfaction at both time points, and 90% of nursing staff reported being satisfied or very satisfied at baseline, with no dissatisfaction reported at baseline or FU. All PAs reported providing workload relief and feeling fully integrated into the team, while two-thirds of residents reported workload relief due to PAs assuming ward-based clinical and administrative tasks. PAs were consistently perceived as improving continuity of care as a stable point of contact for patients and nursing staff. CONCLUSION: PAs substantially strengthen cardiac surgery teams in the German healthcare system. To successfully establish the implementation of PAs, the challenges of long-term retention incentives and clear delineation of responsibilities have to be addressed. CI - Thieme. All rights reserved. FAU - Jenkins, Freya S AU - Jenkins FS AD - Department of Cardiac Surgery, Medical Faculty, Heinrich Heine University, Dusseldorf, Germany. FAU - Assmann, Anna Kathrin AU - Assmann AK AD - Department of Cardiac Surgery, Medical Faculty, Heinrich Heine University, Dusseldorf, Germany. FAU - Pellegrino, Giuseppina P AU - Pellegrino GP AD - Department of Cardiac Surgery, Medical Faculty, Heinrich Heine University, Dusseldorf, Germany. FAU - Lichtenberg, Artur AU - Lichtenberg A AD - Department of Cardiac Surgery, Medical Faculty, Heinrich Heine University, Dusseldorf, Germany. FAU - Assmann, Alexander AU - Assmann A AD - Department of Cardiac Surgery, Medical Faculty, Heinrich Heine University, Dusseldorf, Germany. LA - eng PT - Journal Article PT - Observational Study DEP - 20260413 PL - Germany TA - Thorac Cardiovasc Surg JT - The Thoracic and cardiovascular surgeon JID - 7903387 SB - IM MH - Humans MH - *Physician Assistants/organization & administration/psychology MH - *Hospitals, University/organization & administration MH - Germany MH - *Cardiac Surgical Procedures MH - Attitude of Health Personnel MH - *Patient Care Team/organization & administration MH - Job Satisfaction MH - Workload MH - *Surgeons/organization & administration/psychology MH - Health Care Surveys MH - Personnel Staffing and Scheduling/organization & administration MH - Workforce MH - Task Shifting MH - Time Factors MH - Professional Role COIS- The authors declare that they have no conflict of interest. EDAT- 2026/04/14 00:31 MHDA- 2026/08/28 11:40 CRDT- 2026/04/13 19:03 PHST- 2026/08/28 11:40 [medline] PHST- 2026/04/14 00:31 [pubmed] PHST- 2026/04/13 19:03 [entrez] AID - 10.1055/a-2836-2282 [doi] PST - ppublish SO - Thorac Cardiovasc Surg. 2026 Sep;74(6):450-454. doi: 10.1055/a-2836-2282. Epub 2026 Apr 13. PMID- 41973800 OWN - NLM STAT- MEDLINE DCOM- 20260626 LR - 20260926 IS - 1532-2092 (Electronic) IS - 1099-5129 (Print) IS - 1099-5129 (Linking) VI - 28 IP - 6 DP - 2026 Jun 2 TI - Digitally assisted learning in cardiac electrophysiology and cardiac implantable electronic devices: a Scientific Statement of the European Heart Rhythm Association of the ESC. LID - 10.1093/europace/euag081 [doi] LID - euag081 AB - The rapid expansion of interventional electrophysiology (EP) and cardiac implantable electronic device (CIED) therapies has outpaced the capacity of traditional apprenticeship-based training to deliver standardized, equitable, and patient-safe skill acquisition across Europe. This scientific statement of European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC) synthesizes the current landscape of digitally assisted learning for EP/CIED, provides a structured framework for implementation, and defines the responsibilities of scientific societies in establishing trustworthy, competency-based pathways. The document first reviews the technical principles and available digital modalities, emphasizing alignment of tool selection with learning objectives and staged progression. It then contrasts these capabilities with real-world uptake, highlighting fragmented access and strong reliance on industry-mediated training, alongside the emergence of neutral access models such as the EHRA Simulation Village. A central suggestion is the adoption of proficiency-based progression supported by protocolized evaluation: predefined and validated performance metrics, benchmarking against expert standards, deliberate practice with structured feedback, and summative assessment prior to patient procedures. Key implementation challenges include resource disparities and geographic inequities, limits in simulation fidelity for team-based and contextual decision-making, governance of industry relationships, and the need for protected educational time. Pragmatic solutions include tiered certification tracks, hybrid models combining digital and supervised clinical training, regional simulation hubs, minimum simulator specifications, ongoing curriculum updates, and coordinated stakeholder collaboration. Priority research needs are defined around clinical outcome validation, optimal curriculum design, technology development, and implementation science. CI - (c) The Author(s) 2026. Published by Oxford University Press on behalf of the European Society of Cardiology. FAU - Ernst, Sabine AU - Ernst S AUID- ORCID: 0000-0003-1258-2477 AD - Department of Cardiology, Royal Brompton and Harefield NHS Foundation Trust/National Heart and Lung Institute, Imperial College London, SW3 6NP London, UK. FAU - Almorad, Alexandre AU - Almorad A AUID- ORCID: 0000-0002-9743-1661 AD - Department of Cardiology, Heart Rhythm Management Center, CHU St Pierre, 1000 Brussels, Belgium. FAU - Badertscher, Patrick AU - Badertscher P AUID- ORCID: 0000-0001-9751-0557 AD - Department of Cardiology, University Hospital Basel, 4031 Basel, Switzerland. FAU - Duncker, David AU - Duncker D AUID- ORCID: 0000-0003-2996-6338 AD - Department of Cardiology and Angiology, Hannover Heart Rhythm Center, Hannover Medical School, 30625 Hannover, Germany. FAU - Gallagher, Anthony G AU - Gallagher AG AUID- ORCID: 0000-0003-0887-5613 AD - Faculty of Life and Health Sciences, School of Medicine, Ulster University, BT15 1AP Belfast, UK. FAU - Li, Anthony AU - Li A AUID- ORCID: 0000-0001-5516-1117 AD - Department of Cardiology, St George's University Hospitals NHS Foundation Trust, SW1 7 0QT London, UK. FAU - Nisbet, Ashley AU - Nisbet A AD - Bristol Heart Institute, Bristol Royal Infirmary, BS2 8HW Bristol, UK. FAU - De Ponti, Roberto AU - De Ponti R AUID- ORCID: 0000-0003-3278-1721 AD - Department of Medicine and Surgery, University of Insubria, 21100 Varese, Italy. FAU - Porta-Sanchez, Andreu AU - Porta-Sanchez A AUID- ORCID: 0000-0003-3510-1488 AD - Arrhythmia Unit, Department of Cardiology, Hospital Clinic de Barcelona, 08036 Barcelona, Catalonia, Spain. FAU - Mont, Lluis AU - Mont L AUID- ORCID: 0000-0002-8115-5906 AD - Arrhythmia Unit, Department of Cardiology, Hospital Clinic de Barcelona, 08036 Barcelona, Catalonia, Spain. FAU - De Riva, Marta AU - De Riva M AUID- ORCID: 0000-0002-5878-6750 AD - Department of Cardiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands. FAU - Sarkozy, Andrea AU - Sarkozy A AUID- ORCID: 0000-0001-6327-0487 AD - Heart Rhythm Management Centre, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, 1090 Jette, Belgium. FAU - Schamroth, Nili AU - Schamroth N AUID- ORCID: 0000-0002-0989-187X AD - Department of Cardiology, Rabin Medamical Center, 4941492 Petah Tikva, Israel. FAU - Svennberg, Emma AU - Svennberg E AUID- ORCID: 0000-0002-6413-0870 AD - Department of Cardiology, Karolinska Institutet, Karolinska University Hospital Huddinge, SE-141 86 Stockholm, Sweden. FAU - Tjong, Fleur AU - Tjong F AUID- ORCID: 0000-0001-9608-0081 AD - Department of Cardiology, Heart Center, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands. FAU - Trines, Serge A AU - Trines SA AUID- ORCID: 0000-0001-7715-9536 AD - Department of Cardiology, Heart Lung Center, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands. FAU - Vitali-Serdoz, Laura AU - Vitali-Serdoz L AUID- ORCID: 0000-0003-3914-4119 AD - Arrhythmia and Electrophysiology Division, Department of Heart and Lung, Klinikum Fuerth, 90766 Fuerth, Germany. FAU - Boveda, Serge AU - Boveda S AUID- ORCID: 0000-0002-1280-7042 AD - Cardiology-Heart Rhythm Management Department, Clinique Pasteur, 45 Avenue de Lombez, 31076 Toulouse, France. LA - eng PT - Journal Article PT - Review PL - England TA - Europace JT - Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology JID - 100883649 SB - IM MH - Humans MH - *Defibrillators, Implantable MH - Europe MH - Clinical Competence MH - *Computer-Assisted Instruction/standards/methods MH - *Cardiac Electrophysiology/education MH - Curriculum MH - *Pacemaker, Artificial MH - *Electrophysiologic Techniques, Cardiac MH - Digital Health MH - *Cardiology/education MH - *Education, Medical, Graduate/standards/methods PMC - PMC13303083 OTO - NOTNLM OT - Cardiac electrophysiology OT - Cardiac implantable electronic devices OT - Catheter ablation OT - Digital Training OT - Proficiency-based progression OT - Simulation Training COIS- Conflict of interest: none declared. EDAT- 2026/04/13 18:32 MHDA- 2026/06/27 00:54 PMCR- 2026/04/13 CRDT- 2026/04/13 13:54 PHST- 2026/02/26 00:00 [received] PHST- 2026/03/19 00:00 [accepted] PHST- 2026/06/27 00:54 [medline] PHST- 2026/04/13 18:32 [pubmed] PHST- 2026/04/13 13:54 [entrez] PHST- 2026/04/13 00:00 [pmc-release] AID - 8651482 [pii] AID - euag081 [pii] AID - 10.1093/europace/euag081 [doi] PST - ppublish SO - Europace. 2026 Jun 2;28(6):euag081. doi: 10.1093/europace/euag081. PMID- 41973411 OWN - NLM STAT- MEDLINE DCOM- 20260512 LR - 20261014 IS - 1538-3598 (Electronic) IS - 0098-7484 (Print) IS - 0098-7484 (Linking) VI - 335 IP - 18 DP - 2026 May 12 TI - Real-World Outcomes of Transcatheter Tricuspid Valve Replacement: Analysis From the STS/ACC TVT Registry. PG - 1606-1615 LID - 10.1001/jama.2026.3446 [doi] AB - IMPORTANCE: Transcatheter tricuspid valve replacement (TTVR) demonstrated superior outcomes over medical therapy in patients with severe tricuspid regurgitation (TR) in the Edwards EVOQUE Transcatheter Tricuspid Valve Replacement: Pivotal Clinical Investigation of Safety and Clinical Efficacy Using a Novel Device II (TRISCEND II) randomized clinical trial, and received regulatory approval in the US in 2024. Contemporary real-world data on its effectiveness and safety remain limited. OBJECTIVE: To evaluate 30-day clinical, echocardiographic, and health status outcomes of TTVR in real-world use. DESIGN, SETTING, AND POPULATION: Retrospective cohort study of all consecutive patients who underwent TTVR in the US from February 2024 through March 2025 in the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. Patients had symptomatic, severe TR despite optimal medical therapy and TTVR was deemed appropriate by a heart team. Statistical analysis was conducted from September 2025 to February 2026. EXPOSURE: Device-enabled TTVR. MAIN OUTCOMES AND MEASURES: Thirty-day event rates (all-cause death, stroke, bleeding, new cardiac implantable electronic device [CIED] implantation, heart failure hospitalizations), TR reduction, and changes in health status (New York Heart Association [NYHA] functional class and Kansas City Cardiomyopathy Questionnaire Overall Summary [KCCQ-OS] score) are reported. Subgroup analyses examined the impact of baseline CIED status on outcomes. RESULTS: Among 1034 attempted procedures at 82 centers (mean [SD] age, 77.1 [10.6] years; 69.1% female; 73.2% NYHA functional class III/IV), a valve was successfully implanted in 1017 patients (98.4%). Mild or less TR was achieved in 98.4% of patients post procedure and in 97.7% at 30 days. At 30 days, all-cause mortality was 3.1%; stroke, 0.2%; bleeding, 7.9%; new CIED, 15.9% in CIED-naive patients; and heart failure hospitalization, 3.1%. There were significant improvements in NYHA functional class (class I/II, 82.7%; P < .001) and mean KCCQ-OS score (22.4 points; P < .001) from baseline to 30 days. There were no significant differences in 30-day mortality (P = .47), heart failure hospitalization (P > .99), and functional outcomes (P = .55) when patients were stratified by baseline CIED status. CONCLUSIONS AND RELEVANCE: Early US real-world experience with TTVR confirms safety and effectiveness in patients with severe TR. Thirty-day outcomes are consistent with the TRISCEND II pivotal trial, demonstrating acceptable safety, near-complete TR elimination, and significant health status improvements in an older, comorbid population. Rates of new CIED implantation and bleeding were lower than randomized clinical trial experience. FAU - Makkar, Raj R AU - Makkar RR AD - Cedars-Sinai Medical Center, Los Angeles, California. FAU - Gupta, Aakriti AU - Gupta A AD - Cedars-Sinai Medical Center, Los Angeles, California. FAU - O'Neill, Brian P AU - O'Neill BP AD - Henry Ford Heart & Vascular Institute, Henry Ford Hospital, Detroit, Michigan. FAU - Lalani, Christina AU - Lalani C AD - Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts. FAU - Sharma, Rahul P AU - Sharma RP AD - Division of Cardiovascular Medicine, Stanford University/Stanford Health Care, Stanford, California. FAU - Yadav, Pradeep AU - Yadav P AD - Piedmont Heart Institute, Piedmont Atlanta Hospital, Atlanta, Georgia. FAU - Frisoli, Tiberio M AU - Frisoli TM AD - Henry Ford Heart & Vascular Institute, Henry Ford Hospital, Detroit, Michigan. FAU - Thourani, Vinod AU - Thourani V AD - Piedmont Heart Institute, Piedmont Atlanta Hospital, Atlanta, Georgia. FAU - Makar, Moody AU - Makar M AD - Cedars-Sinai Medical Center, Los Angeles, California. FAU - Eleid, Mackram F AU - Eleid MF AD - Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota. FAU - Lee, James AU - Lee J AD - Henry Ford Heart & Vascular Institute, Henry Ford Hospital, Detroit, Michigan. FAU - Babaliaros, Vasilis C AU - Babaliaros VC AD - Structural Heart and Valve Center, Emory University School of Medicine, Atlanta, Georgia. FAU - Haeffele, Christiane AU - Haeffele C AD - Division of Cardiovascular Medicine, Stanford University/Stanford Health Care, Stanford, California. FAU - Bajwa, Tanvir K AU - Bajwa TK AD - Aurora St Luke's Medical Center, Milwaukee, Wisconsin. FAU - Flueckiger, Peter AU - Flueckiger P AD - Piedmont Heart Institute, Piedmont Atlanta Hospital, Atlanta, Georgia. FAU - Cubeddu, Robert J AU - Cubeddu RJ AD - Naples Comprehensive Health Heart Institute, Naples, Florida. FAU - Davidson, Laura J AU - Davidson LJ AD - Bluhm Cardiovascular Institute, Northwestern University Feinberg School of Medicine/Northwestern Medicine, Chicago, Illinois. AD - Edwards Lifesciences, Irvine, California. FAU - Padang, Ratnasari AU - Padang R AD - Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota. FAU - Spinetto, Pedro Villablanca AU - Spinetto PV AD - Henry Ford Heart & Vascular Institute, Henry Ford Hospital, Detroit, Michigan. FAU - Allaqaband, Suhail AU - Allaqaband S AD - Aurora St Luke's Medical Center, Milwaukee, Wisconsin. FAU - Narang, Akhil AU - Narang A AD - Bluhm Cardiovascular Institute, Northwestern University Feinberg School of Medicine/Northwestern Medicine, Chicago, Illinois. FAU - Williams, Mathew AU - Williams M AD - New York University Langone Medical Center, New York. FAU - Gleason, Patrick AU - Gleason P AD - Structural Heart and Valve Center, Emory University School of Medicine, Atlanta, Georgia. FAU - Tang, Gilbert H L AU - Tang GHL AD - Mount Sinai Health System, New York, New York. FAU - Khera, Sahil AU - Khera S AD - Mount Sinai Health System, New York, New York. FAU - Vavalle, John P AU - Vavalle JP AD - Division of Cardiology, University of North Carolina at Chapel Hill. FAU - Byku, Isida AU - Byku I AD - Structural Heart and Valve Center, Emory University School of Medicine, Atlanta, Georgia. FAU - Depta, Jeremiah P AU - Depta JP AD - Division of Cardiovascular Medicine, Medical College of Wisconsin, Milwaukee. FAU - Garcia, Santiago AU - Garcia S AD - The Christ Hospital, Cincinnati, Ohio. FAU - Kapadia, Samir AU - Kapadia S AD - Department of Cardiovascular Medicine and Heart, Vascular & Thoracic Institute, Cleveland Clinic, Cleveland, Ohio. FAU - Zajarias, Alan AU - Zajarias A AD - Cardiovascular Division, Washington University School of Medicine, St Louis, Missouri. FAU - Chanin, Jake M AU - Chanin JM AD - Intermountain Health Heart & Vascular Institute, Denver, Colorado. FAU - Kodali, Susheel K AU - Kodali SK AD - Columbia University Irving Medical Center and Cardiovascular Research Foundation, New York, New York. FAU - Herrmann, Howard C AU - Herrmann HC AD - Hospital of the University of Pennsylvania, Philadelphia. FAU - Morse, M Andrew AU - Morse MA AD - Ascension Saint Thomas Hospital, Nashville, Tennessee. FAU - Petrossian, George AU - Petrossian G AD - St Francis Hospital & Heart Center, Roslyn, New York. FAU - Sivak, Joseph A AU - Sivak JA AD - Division of Cardiology, University of North Carolina at Chapel Hill. FAU - Hahn, Rebecca T AU - Hahn RT AD - Columbia University Irving Medical Center and Cardiovascular Research Foundation, New York, New York. FAU - Song, Yang AU - Song Y AD - Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts. FAU - Leon, Martin B AU - Leon MB AD - Columbia University Irving Medical Center and Cardiovascular Research Foundation, New York, New York. FAU - Yeh, Robert W AU - Yeh RW AD - Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts. FAU - Davidson, Charles J AU - Davidson CJ AD - Bluhm Cardiovascular Institute, Northwestern University Feinberg School of Medicine/Northwestern Medicine, Chicago, Illinois. LA - eng PT - Journal Article PT - Observational Study PL - United States TA - JAMA JT - JAMA JID - 7501160 SB - IM CIN - doi: 10.1001/jamacardio.2024.3486 CIN - doi: 10.1001/jama.2021.13346 MH - Aged MH - Aged, 80 and over MH - Female MH - Humans MH - Male MH - Defibrillators, Implantable/statistics & numerical data MH - Health Status MH - Heart Failure/epidemiology/etiology MH - Heart Valve Prosthesis MH - *Heart Valve Prosthesis Implantation/methods/adverse effects MH - Hospitalization/statistics & numerical data MH - Registries/statistics & numerical data MH - Retrospective Studies MH - Stroke/epidemiology/etiology MH - Treatment Outcome MH - *Tricuspid Valve/diagnostic imaging/surgery MH - *Tricuspid Valve Insufficiency/complications/diagnosis/mortality/surgery MH - *Endovascular Procedures/adverse effects/methods MH - Echocardiography MH - United States/epidemiology MH - Postoperative Hemorrhage/epidemiology/etiology MH - Severity of Illness Index PMC - PMC13077572 COIS- Conflict of Interest Disclosures: Dr Makkar reported receiving grants from JenaValve, Edwards Lifesciences, Boston Scientific, Medtronic, and Abbott during the conduct of the study and equity from iCardio.ai outside the submitted work. Dr Gupta reported receiving personal fees from Edwards Lifesciences and Boston Scientific outside the submitted work and being a cofounder of Heartbeat Health and iCardio.ai. Dr O'Neill reported receiving personal fees from Edwards Lifesciences outside the submitted work. Dr Lalani reported receiving grants from National Heart, Lung, and Blood Institute (T32 HL160522) outside the submitted work. Dr Sharma reported receiving personal fees from Edwards Lifesciences outside the submitted work. Dr Yadav reported receiving personal fees from Edwards Lifesciences, Abbott, Boston Scientific, DASI Simulations, TRICARE, Trisol, Versa, and Pi-Cardia; serving on the advisory board of Excision Medical; and holding investments in Excision Medical and DASI Simulations during the conduct of the study. Dr Frisoli reported serving as a consultant for Edwards Lifesciences outside the submitted work. Dr Makar reported receiving personal fees from Abbott Vascular, Boston Scientific, and Edwards Lifesciences outside the submitted work. Dr Eleid reported receiving grants from Edwards Lifesciences outside the submitted work. Dr Lee reported receiving grants from Edwards Lifesciences to his institution during the conduct of the study and personal fees from Edwards Lifesciences and Abbott outside the submitted work. Dr Babaliaros reported receiving personal fees from Edwards Lifesciences during the conduct of the study. Dr Haeffele reported receiving personal fees from Edwards Lifesciences during the conduct of the study. Dr Flueckiger reported receiving an honorarium from Siemens Healthineers outside the submitted work. Dr L. J. Davidson reported receiving personal fees, grants, equity, and stock options from Edwards Lifesciences during the conduct of the study and outside the submitted work and being an employee of Edwards Lifesciences during the conduct of the study. Dr Villablanca reported receiving personal fees from Edwards Lifesciences outside the submitted work. Dr Narang reported consulting for Edwards Lifesciences, Philips, and GE and education from Abbott and BMS outside the submitted work. Dr Williams reported receiving grants from Edwards Lifesciences during the conduct of the study. Dr Tang reported receiving personal fees from Edwards Lifesciences, Medtronic, Abbott Structural Heart, Siemens Healthineers, Philips, Boston Scientific, Peijia Medical, Shenqi Medical Technology, Shockwave Medical (no payment received), and JenaValve (no payment received) outside the submitted work. Dr Khera reported receiving personal fees from Edwards Lifesciences, Abbott Structural Heart, and Medtronic outside the submitted work. Dr Vavalle reported receiving personal fees from Edwards Lifesciences and grants from Edwards Lifesciences, Medtronic, Abbott, and Boston Scientific during the conduct of the study. Dr Byku reported receiving personal fees from Edwards Lifesciences and institutional grant support from Edwards Lifesciences, Medtronic, and Abbott outside the submitted work. Dr Depta reported proctoring and consulting for Edwards Lifesciences and Boston Scientific during the conduct of the study. Dr Garcia reported receiving grants from Edwards Lifesciences outside the submitted work. Dr Zajarias reported receiving personal fees from Edwards Lifesciences outside the submitted work. Dr Kodali reported receiving research support from Edwards Lifesciences, Abbott Vascular, Medtronic, Anteris, TRiCares, VDyne, Trisol, and JenaValve; grants from Boston Scientific; and consulting for Abbott Vascular, Triflo, Micro Interventional Devices, Dura Biotech, Thubrikar Aortic Valve, Tioga, Cardiomech, Meacor, Nyra, Trajector Medical, and Helix Valve Repair outside the submitted work. Dr Herrmann reported receiving grants from Abbott, Boston Scientific, Edwards Lifesciences, Johnson & Johnson, and Medtronic; personal fees from Abbott, Affluent Medical, Edwards Lifesciences, Medtronic, and Micro Interventional Devices; and stock options from Affluent Medical, Artedrone, Caranx, and Micro Interventional Devices during the conduct of the study. Dr Morse reported receiving personal fees from Edwards Lifesciences outside the submitted work. Dr Hahn reported receiving personal fees from Edwards Lifesciences and Philips outside the submitted work; having institutional consulting contracts with Abbott Structural Heart, Anteris, Boston Scientific, Edwards Lifesciences, Medtronic, Novartis, and ROB'E; and holding equity in Trajector Medical. Dr Leon reported receiving grants from Columbia/NewYork-Presbyterian - Cardiovascular Research Foundation during the conduct of the study. Dr Yeh reported receiving grants from Edwards Lifesciences to his institution during the conduct of the study; personal fees from Edwards Lifesciences, Boston Scientific, and Medtronic; and grants from Boston Scientific and Medtronic outside the submitted work. Dr C. J. Davidson reported receiving grants from Edwards Lifesciences during the conduct of the study. No other disclosures were reported. EDAT- 2026/04/13 12:38 MHDA- 2026/05/12 12:35 PMCR- 2026/10/13 CRDT- 2026/04/13 11:33 PHST- 2026/05/12 12:35 [medline] PHST- 2026/04/13 12:38 [pubmed] PHST- 2026/04/13 11:33 [entrez] PHST- 2026/10/13 00:00 [pmc-release] AID - 2847572 [pii] AID - joi260018 [pii] AID - 10.1001/jama.2026.3446 [doi] PST - ppublish SO - JAMA. 2026 May 12;335(18):1606-1615. doi: 10.1001/jama.2026.3446. PMID- 41971466 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260413 LR - 20260926 IS - 2090-6684 (Print) IS - 2090-6692 (Electronic) IS - 2090-6692 (Linking) VI - 2026 DP - 2026 TI - Third Delivery in a Chinese Patient With Anomalous Origin of Left Coronary Artery From Pulmonary Artery (ALCAPA): A Case Report. PG - 4830284 LID - 10.1155/crog/4830284 [doi] LID - 4830284 AB - BACKGROUND: Anomalous origin of the left coronary artery from the pulmonary artery (ALCAPA) is a rare congenital defect that poses a significant risk of myocardial ischemia and sudden death, especially during the hemodynamic stresses of pregnancy. Although surgical correction is standard, the management of asymptomatic adult-type ALCAPA diagnosed during pregnancy remains a high-stakes clinical challenge. CASE PRESENTATION: We report the case of a 36-year-old multiparous woman with incidentally diagnosed adult-type ALCAPA during her third pregnancy. Serial echocardiography revealed moderate mitral regurgitation. The pregnancy was complicated by superimposed preeclampsia at 33 weeks. A dedicated multidisciplinary team implemented a tailored plan for labor induction at 37 weeks in a hybrid operating room, employing epidural analgesia and continuous hemodynamic monitoring. The patient underwent a successful vaginal delivery of a healthy infant. Intriguingly, mitral regurgitation transiently worsened to severe on postpartum Day 3 but significantly improved to mild by Day 7, correlating with resolution of the pregnancy-induced volume load. Coronary CTA postpartum confirmed the diagnosis. DISCUSSION: Multidisciplinary planning enables safe vaginal delivery in select ALCAPA pregnancies. Dynamic peripartum changes in mitral regurgitation underline the role of volume shifts and the need for serial echocardiography to guide management and time definitive surgery. CI - Copyright (c) 2026 He Zhao et al. Case Reports in Obstetrics and Gynecology published by John Wiley & Sons Ltd. FAU - Zhao, He AU - Zhao H AUID- ORCID: 0000-0001-5095-1777 AD - Department of Obstetrics and Gynecology of Beijing Anzhen Hospital affiliated to Capital Medical University, Beijing, China. AD - Obstetrics and Gynecology Medical Center of Severe Cardiovascular of Beijing Anzhen Hospital affiliated to Capital Medical University, Beijing, China. FAU - Zhang, Dawei AU - Zhang D AD - Department of Obstetrics and Gynecology of Beijing Anzhen Hospital affiliated to Capital Medical University, Beijing, China. AD - Obstetrics and Gynecology Medical Center of Severe Cardiovascular of Beijing Anzhen Hospital affiliated to Capital Medical University, Beijing, China. FAU - Li, Yanna AU - Li Y AD - Department of Obstetrics and Gynecology of Beijing Anzhen Hospital affiliated to Capital Medical University, Beijing, China. AD - Obstetrics and Gynecology Medical Center of Severe Cardiovascular of Beijing Anzhen Hospital affiliated to Capital Medical University, Beijing, China. FAU - Fang, Zhen AU - Fang Z AD - Department of Obstetrics and Gynecology of Beijing Anzhen Hospital affiliated to Capital Medical University, Beijing, China. AD - Obstetrics and Gynecology Medical Center of Severe Cardiovascular of Beijing Anzhen Hospital affiliated to Capital Medical University, Beijing, China. FAU - Zhang, Nan AU - Zhang N AD - Department of Radiology of Beijing Anzhen Hospital affiliated to Capital Medical University, Beijing, China. FAU - Zhang, Jun AU - Zhang J AUID- ORCID: 0000-0002-5351-051X AD - Department of Obstetrics and Gynecology of Beijing Anzhen Hospital affiliated to Capital Medical University, Beijing, China. AD - Obstetrics and Gynecology Medical Center of Severe Cardiovascular of Beijing Anzhen Hospital affiliated to Capital Medical University, Beijing, China. LA - eng PT - Journal Article DEP - 20260409 PL - United States TA - Case Rep Obstet Gynecol JT - Case reports in obstetrics and gynecology JID - 101576454 PMC - PMC13062753 COIS- The authors declare no conflicts of interest. EDAT- 2026/04/13 18:17 MHDA- 2026/04/13 18:18 PMCR- 2026/04/09 CRDT- 2026/04/13 06:42 PHST- 2024/11/08 00:00 [received] PHST- 2025/12/11 00:00 [revised] PHST- 2026/01/06 00:00 [accepted] PHST- 2026/04/13 18:18 [medline] PHST- 2026/04/13 18:17 [pubmed] PHST- 2026/04/13 06:42 [entrez] PHST- 2026/04/09 00:00 [pmc-release] AID - CROG4830284 [pii] AID - 10.1155/crog/4830284 [doi] PST - epublish SO - Case Rep Obstet Gynecol. 2026 Apr 9;2026:4830284. doi: 10.1155/crog/4830284. eCollection 2026. PMID- 41969358 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260413 LR - 20260926 IS - 2090-6404 (Print) IS - 2090-6412 (Electronic) IS - 2090-6404 (Linking) VI - 2026 DP - 2026 TI - Unveiling the Invisible: Inferior STEMI With an Absent Right Coronary Artery Rescued by PCI to the Left Circumflex Artery. PG - 8887458 LID - 10.1155/cric/8887458 [doi] LID - 8887458 AB - Coronary artery anomalies, though uncommon, can pose significant diagnostic and therapeutic challenges, especially during acute coronary syndromes (ACS). We present a rare case of a 57-year-old male who presented with classical symptoms of inferior ST-segment elevation myocardial infarction (STEMI). Initial coronary angiography failed to identify the right coronary artery (RCA), eventually revealing an absent RCA ostium. The superdominant left circumflex artery (LCX) was found to be entirely occluded, supplying the territory typically serviced by the absent RCA. Successful primary percutaneous coronary intervention (PCI) was performed using a drug-eluting stent (DES), restoring TIMI-III flow and resolving symptoms promptly. Further imaging with contrast-enhanced computed tomography coronary angiography (CTCA) confirmed the congenital absence of the RCA, emphasising the critical role of advanced imaging in diagnosing coronary anomalies. Our case underscores the importance of considering rare congenital anomalies in acute cardiac presentations. It highlights the pivotal role of rapid recognition, targeted imaging and intervention in such anomalies to ensure optimal patient outcomes. It advocates a multidisciplinary approach, integrating cardiologists, radiologists and interventional specialists to enhance clinical decision-making and management effectiveness in similar complex scenarios. CI - Copyright (c) 2026 Jehan Dad Khan et al. Case Reports in Cardiology published by John Wiley & Sons Ltd. FAU - Khan, Jehan Dad AU - Khan JD AD - Department of Cardiology, Kettering General Hospital, Kettering, UK, nhs.uk. FAU - Bajmmal, Omar AU - Bajmmal O AD - Department of Cardiology, Kettering General Hospital, Kettering, UK, nhs.uk. FAU - Antoun, Ibrahim AU - Antoun I AUID- ORCID: 0000-0002-4374-7476 AD - Department of Cardiology, Kettering General Hospital, Kettering, UK, nhs.uk. AD - Division of Cardiovascular Sciences, College of Life Sciences, University of Leiceste, Leicester, UK, le.ac.uk. LA - eng PT - Journal Article DEP - 20260409 PL - United States TA - Case Rep Cardiol JT - Case reports in cardiology JID - 101576452 PMC - PMC13062653 OTO - NOTNLM OT - absent coronary artery OT - acute coronary syndrome OT - coronary angiogram OT - myocardial infarction OT - right coronary artery COIS- The authors declare no conflicts of interest. EDAT- 2026/04/13 18:17 MHDA- 2026/04/13 18:18 PMCR- 2026/04/09 CRDT- 2026/04/13 06:25 PHST- 2025/04/23 00:00 [received] PHST- 2026/03/23 00:00 [revised] PHST- 2026/03/31 00:00 [accepted] PHST- 2026/04/13 18:18 [medline] PHST- 2026/04/13 18:17 [pubmed] PHST- 2026/04/13 06:25 [entrez] PHST- 2026/04/09 00:00 [pmc-release] AID - CRIC8887458 [pii] AID - 10.1155/cric/8887458 [doi] PST - epublish SO - Case Rep Cardiol. 2026 Apr 9;2026:8887458. doi: 10.1155/cric/8887458. eCollection 2026. PMID- 41968402 OWN - NLM STAT- Publisher LR - 20260413 IS - 1538-4683 (Electronic) IS - 1061-5377 (Linking) DP - 2026 Apr 13 TI - Barriers to Electrocardiographic Monitoring Practice Among Nurses: A Scoping Review. LID - 10.1097/CRD.0000000000001261 [doi] AB - Despite the evidence of the importance of a good use of the electrocardiographic monitoring (ECG-M) to safe and quality patient care, best practices on ECG-M seem to remain a problem for nurses. The aim of this study was to identify and map the barriers faced by the nursing team in performing ECG-M, as well as the strategies to overcome them. Scoping review according to the recommendations of the Joanna Briggs Institute Manual. The databases used were: Medline, Web of Science, Embase, Cumulative Index to Nursing and Allied Health Literature (CINAHAL), Latin American and Caribbean Literature in Health Sciences (LILACS), Scopus, and Cochrane. The keywords "Electrocardiography," "Hemodynamic Monitoring," "Nursing," and "Nursing Team" and associated terms were used to find articles published from January 2014 to December 2022, without language restriction. An iterative team approach enabled screening, data selection, and extraction studies that were mapped. Twenty-nine articles were selected and analyzed, and the main barriers were a lack of knowledge and/or skills, as well as difficulty in retaining capacity after an educational intervention. Barriers to adequate cardiac monitoring were related to knowledge and interpretation of ECG-M data, as well as technical aspects related to monitoring. Continuing education strategies, establishment of institutional protocols, and customization of monitoring parameters have been shown to be effective in implementing best practices for ECM. CI - Copyright (c) 2026 Wolters Kluwer Health, Inc. All rights reserved. FAU - Giusti, Angela Carolina Brandao de Souza AU - Giusti ACBS AD - From the School of Nursing, Universidade Estadual de Campinas, Brazil. FAU - Medeiros, Kleyton Santos de AU - Medeiros KS AD - Instituto de Ensino, Pesquisa e Inovacao, Liga Contra o Cancer, Natal, Brazil. FAU - Chiavone, Flavia Barreto Tavares AU - Chiavone FBT AD - Instituto de Ensino, Pesquisa e Inovacao, Liga Contra o Cancer, Natal, Brazil. FAU - Silva, Wellington Pereira da AU - Silva WPD AD - School of Nursing, Universidade Estadual de Campinas, Brazil. FAU - Cornelio, Marilia Estevam AU - Cornelio ME AD - School of Nursing, Universidade Estadual de Campinas, Brazil. FAU - Gallani, Maria Cecilia Bueno Jayme AU - Gallani MCBJ AD - Faculte des Sciences Infirmieres, Universite Laval, Quebec, Canada. LA - eng PT - Journal Article DEP - 20260413 PL - United States TA - Cardiol Rev JT - Cardiology in review JID - 9304686 SB - IM OTO - NOTNLM OT - cardiac monitoring OT - electrocardiography OT - nursing OT - scoping review COIS- Disclosure: The authors declare no conflict of interest. EDAT- 2026/04/13 06:32 MHDA- 2026/04/13 06:32 CRDT- 2026/04/13 00:02 PHST- 2026/04/13 06:32 [medline] PHST- 2026/04/13 06:32 [pubmed] PHST- 2026/04/13 00:02 [entrez] AID - 00045415-990000000-00811 [pii] AID - 10.1097/CRD.0000000000001261 [doi] PST - aheadofprint SO - Cardiol Rev. 2026 Apr 13. doi: 10.1097/CRD.0000000000001261. PMID- 41968183 OWN - NLM STAT- MEDLINE DCOM- 20260627 LR - 20260813 IS - 1863-2491 (Electronic) IS - 1863-2483 (Print) IS - 1863-2483 (Linking) VI - 20 IP - 1 DP - 2026 Apr 13 TI - Resuscitation during robotic-assisted pelvic surgery: impact of simulation training and system-specific factors. LID - 10.1007/s11701-026-03399-1 [doi] LID - 434 AB - Intraoperative cardiac arrest during robotic-assisted surgery is rare but poses challenges due to limited patient access and the need for undocking. Evidence on structured team training and system-specific factors affecting time to cardiopulmonary resuscitation (CPR) remains limited. This prospective single-center simulation study evaluated six multidisciplinary teams managing standardized cardiac arrest scenarios with the daVinci(R) and HugoRAS(R) system. Teams completed three simulations: an unannounced baseline scenario, a second scenario following structured debriefing and introduction of a standardized emergency flowchart, and a third scenario after 3-5 months to assess skill retention. Primary endpoint was time to CPR initiation. Secondary endpoints were protocol adherence and undocking time. Repeated training significantly reduced time to CPR (58.2 +/- 26.2 s vs. 31.8 +/- 8.9 s; p = 0.03) and improved compliance with the emergency flowchart (p = 0.03). While overall time to CPR initiation did not differ between robotic systems (daVinci(R): 48.0 +/- 23.5 vs. HugoRAS(R): 43.2 +/- 16.1, p = 0.6), undocking time was significantly shorter with the daVinci(R) compared to the HugoRAS(R) system (20.8 +/- 2.4 s vs. 41.0 +/- 7.5 s; p < 0.001). Undocking phase accounted for 48.9 +/- 14.0% of the time leading up to the CPR in DaVinci(R) and 69.8 +/- 13.1% in HugoRAS(R). Simulation-based multidisciplinary team training may improve resuscitation performance during robotic-assisted surgery. Undocking was the main source of delay with system-specific differences. Standardized emergency protocols and regular simulation training should be implemented to enhance patient safety in robotic operating rooms. FAU - Hubler, Anke AU - Hubler A AD - Department of Anaesthesiology and Intensive Care Medicine, Medical Faculty Carl Gustav Carus, TU Dresden, Dresden, Germany. FAU - Hensel, Fabian AU - Hensel F AD - Department of Anaesthesiology and Intensive Care Medicine, Medical Faculty Carl Gustav Carus, TU Dresden, Dresden, Germany. FAU - Niebhagen, Felix AU - Niebhagen F AD - Department of Anaesthesiology and Intensive Care Medicine, Medical Faculty Carl Gustav Carus, TU Dresden, Dresden, Germany. FAU - Herout, Roman AU - Herout R AD - Department of Urology, Medical Faculty Carl Gustav Carus, TU Dresden, Fetscherstr. 74, 01307, Dresden, Germany. FAU - Mehralivand, Sherif AU - Mehralivand S AD - Department of Urology, Medical Faculty Carl Gustav Carus, TU Dresden, Fetscherstr. 74, 01307, Dresden, Germany. FAU - Hoeh, Robert Benedikt AU - Hoeh RB AD - Department of Urology, Medical Faculty Carl Gustav Carus, TU Dresden, Fetscherstr. 74, 01307, Dresden, Germany. FAU - Weber, Anne AU - Weber A AD - Department of Urology, Medical Faculty Carl Gustav Carus, TU Dresden, Fetscherstr. 74, 01307, Dresden, Germany. FAU - Koch, Thea AU - Koch T AD - Department of Anaesthesiology and Intensive Care Medicine, Medical Faculty Carl Gustav Carus, TU Dresden, Dresden, Germany. FAU - Thomas, Christian AU - Thomas C AD - Department of Urology, Medical Faculty Carl Gustav Carus, TU Dresden, Fetscherstr. 74, 01307, Dresden, Germany. FAU - Baunacke, Martin AU - Baunacke M AUID- ORCID: 0000-0002-5601-7587 AD - Department of Urology, Medical Faculty Carl Gustav Carus, TU Dresden, Fetscherstr. 74, 01307, Dresden, Germany. martin.baunacke@ukdd.de. LA - eng PT - Journal Article DEP - 20260413 PL - England TA - J Robot Surg JT - Journal of robotic surgery JID - 101300401 SB - IM MH - Humans MH - *Robotic Surgical Procedures/education/methods MH - *Cardiopulmonary Resuscitation/education/methods MH - *Simulation Training/methods MH - Prospective Studies MH - *Pelvis/surgery MH - *Heart Arrest/therapy MH - Clinical Competence MH - Time Factors MH - Patient Care Team MH - *Intraoperative Complications/therapy PMC - PMC13070981 OTO - NOTNLM OT - CPR OT - Emergency management OT - Resuscitation OT - Robotic-assisted surgery OT - Simulation COIS- Declarations. Competing interests: The authors declare no competing interests. Ethics approval: This study was performed in line with the principles of the Declaration of Helsinki. The study was approved by the local ethics committee (BO-EK-73022024). Ethical approval involved consultation with a data protection officer, ensuring secure data handling. Consent to participate: Informed consent was obtained from all individual participants included in the study. EDAT- 2026/04/13 00:31 MHDA- 2026/06/27 22:35 PMCR- 2026/04/13 CRDT- 2026/04/12 23:15 PHST- 2026/03/08 00:00 [received] PHST- 2026/03/30 00:00 [accepted] PHST- 2026/06/27 22:35 [medline] PHST- 2026/04/13 00:31 [pubmed] PHST- 2026/04/12 23:15 [entrez] PHST- 2026/04/13 00:00 [pmc-release] AID - 10.1007/s11701-026-03399-1 [pii] AID - 3399 [pii] AID - 10.1007/s11701-026-03399-1 [doi] PST - epublish SO - J Robot Surg. 2026 Apr 13;20(1):434. doi: 10.1007/s11701-026-03399-1. PMID- 41968100 OWN - NLM STAT- MEDLINE DCOM- 20260715 LR - 20260813 IS - 2055-6845 (Electronic) IS - 2055-6837 (Print) VI - 12 IP - 3 DP - 2026 May 19 TI - Implementing sodium-glucose co-transporter 2 inhibitors in cardiovascular-kidney-metabolic syndrome: a multidisciplinary expert perspective. PG - 209-221 LID - 10.1093/ehjcvp/pvag020 [doi] AB - AIMS: Cardiovascular-kidney-metabolic (CKM) syndrome defines a pathophysiological continuum driven by reciprocal dysfunction across the cardiovascular, renal and metabolic systems. Although sodium-glucose co-transporter 2 inhibitors (SGLT2i) provide consistent, organ-protective benefits across this spectrum, clinical implementation remains suboptimal. This expert opinion, developed by a multidisciplinary Italian board, aims to translate current evidence and guideline recommendations into practical, integrated strategies for the early and effective implementation of SGLT2i in patients at risk of or affected by CKM syndrome. METHODS AND RESULTS: The panel reviewed the latest clinical trial data, international guidelines, and real-world evidence to identify implementation gaps and propose actionable solutions across diabetology, cardiology, and nephrology. Clinical recommendations were formulated via informal multidisciplinary roundtable discussions. Despite strong evidence and broad guideline endorsement, SGLT2i remain underutilized due to fragmented care, therapeutic inertia, and misconceptions regarding safety. To address these barriers, we advocate for early risk-based screening, simplified treatment algorithms, cross-specialty collaboration, and educational efforts to empower both clinicians and patients. CONCLUSION: Shifting from reactive to proactive CKM management requires an integrated care model aligning specialties around early, organ-protective interventions. SGLT2i should be recognized as foundational, disease-modifying therapy, supported by multidisciplinary coordination, clear clinical algorithms, and patient-centered communication. CI - (c) The Author(s) 2026. Published by Oxford University Press on behalf of European Society of Cardiology. FAU - Avogaro, Angelo AU - Avogaro A AUID- ORCID: 0000-0002-1177-0516 AD - Laboratory of Experimental Diabetology, Veneto Institute of Molecular Medicine, Via Giuseppe Orus 2, 35129 Padua, Italy. FAU - Gori, Mauro AU - Gori M AUID- ORCID: 0000-0001-5509-8867 AD - Division of Cardiology, Cardiovascular Department, Papa Giovanni XXIII Hospital, 24127 Bergamo, Italy. FAU - Grandaliano, Giuseppe AU - Grandaliano G AUID- ORCID: 0000-0003-1213-2177 AD - Department of Translational Medicine and Surgery, Universita Cattolica del Sacro Cuore, 00168 Rome, Italy. AD - Nephrology, Dialysis and Transplantation Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy. FAU - Iacoviello, Massimo AU - Iacoviello M AUID- ORCID: 0000-0001-9613-5062 AD - Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy. FAU - Trevisan, Roberto AU - Trevisan R AUID- ORCID: 0000-0003-0420-4468 AD - Endocrinology and Diabetes Unit, Azienda Ospedaliera Papa Giovanni XXIII, 24127 Bergamo, Italy. AD - Department of Medicine and Surgery, University of Milano Bicocca, 20126 Milan, Italy. LA - eng GR - Boehringer Ingelheim/ PT - Journal Article PT - Review PL - England TA - Eur Heart J Cardiovasc Pharmacother JT - European heart journal. Cardiovascular pharmacotherapy JID - 101669491 RN - 0 (Sodium-Glucose Transporter 2 Inhibitors) SB - IM CIN - Eur Heart J Cardiovasc Pharmacother. 2026 Sep 22;12(6):496-497. doi: 10.1093/ehjcvp/pvag057. PMID: 42504141 MH - Humans MH - *Sodium-Glucose Transporter 2 Inhibitors/therapeutic use/adverse effects MH - *Cardio-Renal Syndrome/diagnosis/drug therapy/epidemiology/physiopathology MH - Treatment Outcome MH - *Metabolic Syndrome/drug therapy/diagnosis/epidemiology/physiopathology MH - Risk Assessment MH - Consensus MH - Risk Factors MH - *Cardiovascular Diseases/diagnosis/epidemiology MH - Interdisciplinary Communication MH - Practice Guidelines as Topic MH - *Diabetes Mellitus, Type 2/drug therapy/diagnosis/epidemiology MH - Undertreatment PMC - PMC13185741 OTO - NOTNLM OT - CKM syndrome OT - Cardiovascular OT - Cardiovascular-kidney-metabolic syndrome OT - Cardio-kidney-metabolic syndrome OT - Cardio-renal-metabolic syndrome OT - SGLT2 inhibitors OT - Sodium-glucose co-transporter 2 inhibitors OT - and metabolic disorders OT - renal COIS- Conflict of interest: A.A. received honoraria for speaker activities, for serving on advisory boards, or consultancy from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Amarin, Bruno Farmaceutici, Amgen, Novo Nordisk, and Sanofi. M.G. received honoraria for speaker activities, for serving on advisory boards, or consultancy from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Amgen, Novo Nordisk, Menarini, and Novartis. G.G. received honoraria for speaker activities, for serving on advisory boards, or consultancy from Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, GSK, Novartis, Novo Nordisk, Sanofi, Sobi and Stada. M.I. received honoraria for speaker activities, for serving on advisory boards, or consultancy from AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, and Novartis. EDAT- 2026/04/13 00:31 MHDA- 2026/05/19 18:32 PMCR- 2026/04/10 CRDT- 2026/04/12 22:23 PHST- 2026/02/02 00:00 [received] PHST- 2026/03/19 00:00 [revised] PHST- 2026/03/31 00:00 [accepted] PHST- 2026/05/19 18:32 [medline] PHST- 2026/04/13 00:31 [pubmed] PHST- 2026/04/12 22:23 [entrez] PHST- 2026/04/10 00:00 [pmc-release] AID - 8651384 [pii] AID - pvag020 [pii] AID - 10.1093/ehjcvp/pvag020 [doi] PST - ppublish SO - Eur Heart J Cardiovasc Pharmacother. 2026 May 19;12(3):209-221. doi: 10.1093/ehjcvp/pvag020. PMID- 41967198 OWN - NLM STAT- MEDLINE DCOM- 20260617 LR - 20260910 IS - 1527-3288 (Electronic) IS - 0147-9563 (Linking) VI - 78 DP - 2026 Jul-Aug TI - Best evidence summary for exercise adherence management in outpatient rehabilitation following coronary artery bypass graft surgery. PG - 102787 LID - S0147-9563(26)00071-3 [pii] LID - 10.1016/j.hrtlng.2026.102787 [doi] AB - BACKGROUND: Coronary artery bypass grafting (CABG) is a common procedure for treating coronary artery disease. Exercise rehabilitation is essential for secondary prevention, but patient adherence remains low. High-quality evidence is needed to guide effective adherence management strategies. OBJECTIVE: To evaluate and summarize the existing evidence on adherence management in phase II exercise rehabilitation following CABG, providing a foundation for the development of evidence-based clinical practice. METHODS: Following the 6S pyramid model, a comprehensive top-down search was conducted to retrieve evidence related to adherence management in phase II exercise rehabilitation following CABG. The literature types included clinical decisions, guidelines, expert consensus, systematic reviews, evidence summaries, and the latest randomized controlled trials. The search period ranged from July 2015 to July 2025. Two researchers trained in evidence-based nursing graded the evidence according to the Joanna Briggs Institute evidence pre-classification and evidence recommendation level system (2014 version). RESULTS: A total of 19 high-quality studies were included, from which 26 pieces of evidence were summarized. These pieces of evidence covered five aspects: overall approach, exercise plan, patient education, feedback and supervision, and management of special populations. Key strategies consistently highlighted included establishing a multidisciplinary rehabilitation team and a structured follow-up pathway, delivering individualized and progressive exercise prescriptions, providing multimodal education to enhance patients' understanding and self-efficacy, and strengthening monitoring/feedback mechanisms to support sustained self-management. Collectively, these strategies may facilitate long-term exercise adherence during phase II rehabilitation and improve the continuity and safety of post-discharge care. CONCLUSIONS: Evidence supports a comprehensive, integrated phase II exercise adherence-management approach for post-CABG patients, emphasizing multidisciplinary collaboration, individualized progressive exercise prescription, multimodal education, and monitoring/feedback to promote sustained self-management and adherence. Strategies should be adapted to local resources and vulnerable groups. Future research should validate these strategies in CABG-specific populations and evaluate implementation feasibility and cost-effectiveness using standardized adherence outcomes. PROTOCOL REGISTRATION: http://ebn.nursing.fudan.edu.cn/registerResources, identifier ES20246232. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Xiu, Meng AU - Xiu M AD - Tongji University School of Medicine, Shanghai, China; Department of Nursing, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China. FAU - Wang, Hang AU - Wang H AD - Tongji University School of Medicine, Shanghai, China; Department of Nursing, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China. FAU - Zhang, Meijie AU - Zhang M AD - Department of Nursing, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China; School of Nursing, Suzhou Medical College of Soochow University, Suzhou, China. FAU - Yang, Fei AU - Yang F AD - Tongji University School of Medicine, Shanghai, China; Department of Nursing, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China. FAU - Wang, Chenwei AU - Wang C AD - Tongji University School of Medicine, Shanghai, China; Department of Nursing, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China. FAU - Zhang, Weiying AU - Zhang W AD - Department of Nursing, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China. Electronic address: zhangwy_cn@126.com. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20260413 PL - United States TA - Heart Lung JT - Heart & lung : the journal of critical care JID - 0330057 SB - IM MH - Humans MH - *Coronary Artery Bypass/rehabilitation MH - *Patient Compliance MH - *Exercise Therapy/methods MH - *Coronary Artery Disease/surgery/rehabilitation MH - Adherence Interventions MH - *Cardiac Rehabilitation/methods MH - Patient Education as Topic OTO - NOTNLM OT - Best evidence OT - Coronary artery bypass graft OT - Evidence-based nursing OT - Exercise adherence OT - Rehabilitation COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/04/13 00:31 MHDA- 2026/06/18 00:32 CRDT- 2026/04/12 18:02 PHST- 2025/11/14 00:00 [received] PHST- 2026/03/03 00:00 [revised] PHST- 2026/04/06 00:00 [accepted] PHST- 2026/06/18 00:32 [medline] PHST- 2026/04/13 00:31 [pubmed] PHST- 2026/04/12 18:02 [entrez] AID - S0147-9563(26)00071-3 [pii] AID - 10.1016/j.hrtlng.2026.102787 [doi] PST - ppublish SO - Heart Lung. 2026 Jul-Aug;78:102787. doi: 10.1016/j.hrtlng.2026.102787. Epub 2026 Apr 13. PMID- 41966296 OWN - NLM STAT- MEDLINE DCOM- 20260623 LR - 20260707 IS - 1552-6259 (Electronic) IS - 0003-4975 (Linking) VI - 122 IP - 1 DP - 2026 Jul TI - Anomalous Left Circumflex Artery in Valve Interventions: Surgical and Transcatheter Challenges. PG - 233-241 LID - S0003-4975(26)00311-5 [pii] LID - 10.1016/j.athoracsur.2026.03.048 [doi] AB - BACKGROUND: Anomalous origin of the left circumflex coronary artery (AOLCX) with a retroaortic course is at risk of compression during valve interventions. Although AOLCX is typically benign, iatrogenic injury can cause catastrophic ischemia. As transcatheter aortic valve replacement (TAVR) expands to lower-risk populations, understanding mechanisms of injury in both surgical and transcatheter settings is becoming crucial. METHODS: A narrative review was performed focusing on anatomic risks, injury mechanisms, and management of AOLCX. Forty-five relevant publications were synthesized to integrate technical and anatomic evidence. RESULTS: Left circumflex artery compromise is determined by the vessel's proximity to the aortic and mitral annuli. In surgery, deep sutures and prosthetic rings are the primary causes. In TAVR, mechanisms involve retroaortic compression and ostial occlusion, necessitating preprocedural assessment of coronary height, sinus dimensions, calcification, and annular proximity. Preventive strategies include surgical mobilization, prophylactic bypass, and guidewire protection. Bailout strategies include bypass and emergency stenting. For aortic stenosis, procedure selection between surgery and TAVR should be individualized on the basis of age, calcification, and anatomic metrics. Late complications such as delayed coronary obstruction necessitate longitudinal surveillance. CONCLUSIONS: Preprocedural computed tomographic angiography is essential to quantify anatomic risk. A heart team approach is required to select the optimal intervention and implement mechanism-specific protection. Long-term clinical and imaging surveillance is warranted to prevent both acute and delayed left circumflex artery compromise. CI - Copyright (c) 2026 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Furukawa, Koji AU - Furukawa K AD - Division of Cardiovascular Surgery, Department of Surgery, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan. Electronic address: koji_furukawa@med.miyazaki-u.ac.jp. FAU - Ishii, Hirohito AU - Ishii H AD - Division of Cardiovascular Surgery, Department of Surgery, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan. FAU - Sakaguchi, Shuhei AU - Sakaguchi S AD - Division of Cardiovascular Surgery, Department of Surgery, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan. FAU - Mori, Kousuke AU - Mori K AD - Division of Cardiovascular Surgery, Department of Surgery, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan. FAU - Iwasaki, Ayaka AU - Iwasaki A AD - Division of Cardiovascular Surgery, Department of Surgery, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan. FAU - Meiri, Risa AU - Meiri R AD - Division of Cardiovascular Surgery, Department of Surgery, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan. LA - eng PT - Journal Article PT - Review DEP - 20260409 PL - Netherlands TA - Ann Thorac Surg JT - The Annals of thoracic surgery JID - 15030100R SB - IM MH - Humans MH - *Transcatheter Aortic Valve Replacement/adverse effects/methods MH - *Coronary Vessel Anomalies/surgery/complications/diagnostic imaging MH - *Aortic Valve Stenosis/surgery COIS- Disclosures The authors have no conflicts of interest to disclose. EDAT- 2026/04/12 12:32 MHDA- 2026/06/23 12:36 CRDT- 2026/04/12 10:28 PHST- 2025/12/30 00:00 [received] PHST- 2026/03/05 00:00 [revised] PHST- 2026/03/16 00:00 [accepted] PHST- 2026/06/23 12:36 [medline] PHST- 2026/04/12 12:32 [pubmed] PHST- 2026/04/12 10:28 [entrez] AID - S0003-4975(26)00311-5 [pii] AID - 10.1016/j.athoracsur.2026.03.048 [doi] PST - ppublish SO - Ann Thorac Surg. 2026 Jul;122(1):233-241. doi: 10.1016/j.athoracsur.2026.03.048. Epub 2026 Apr 9. PMID- 41962317 OWN - NLM STAT- MEDLINE DCOM- 20260714 LR - 20260810 IS - 1365-229X (Electronic) IS - 0009-9260 (Linking) VI - 96 DP - 2026 May TI - Computed tomography (CT) planning for Redo-transcatheter aortic valve implantation (TAVI): a step-by-step approach and structured reporting. PG - 107298 LID - S0009-9260(26)00074-7 [pii] LID - 10.1016/j.crad.2026.107298 [doi] AB - The expansion of transcatheter aortic valve implantation (TAVI) indications to younger and lower-risk patients has led to an increasing incidence of late transcatheter valve failure. In this setting, redo-TAVI (TAV-in-TAV) has emerged as a less invasive alternative to surgical valve explantation, albeit with specific anatomical and technical challenges, particularly related to the risk of coronary obstruction. Computed tomography (CT) plays a pivotal role in preprocedural planning by enabling detailed characterisation of the index valve, identification of the failure mechanism, assessment of commissural and coronary alignment, accurate internal valve measurements, and definition of the neoskirt plane. This pictorial essay presents a step-by-step CT-based approach to redo-TAVI planning, illustrating the main implantation strategies and their relationship with the coronary risk plane. In addition, a structured reporting template is proposed to standardise CT interpretation and support multidisciplinary Heart Team decision-making. CI - Copyright (c) 2026 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Vaz, A AU - Vaz A AD - Instituto do Coracao do Hospital de Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Av. Dr. Eneas Carvalho de Aguiar, 44, Cerqueira Cesar, Sao Paulo, Sao Paulo, 05403-900, Brazil. Electronic address: andrevaz7@gmail.com. FAU - Serra, V C AU - Serra VC AD - Instituto do Coracao do Hospital de Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Av. Dr. Eneas Carvalho de Aguiar, 44, Cerqueira Cesar, Sao Paulo, Sao Paulo, 05403-900, Brazil. Electronic address: viniciuscserra@hotmail.com. FAU - Ramos, D de O S AU - Ramos DOS AD - Instituto do Cancer do Estado de Sao Paulo do Hospital de Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Av. Dr. Eneas Carvalho de Aguiar, 44, Cerqueira Cesar, Sao Paulo, Sao Paulo, 05403-900, Brazil. Electronic address: danramo@gmail.com. LA - eng PT - Journal Article PT - Review DEP - 20260311 PL - England TA - Clin Radiol JT - Clinical radiology JID - 1306016 SB - IM MH - Humans MH - *Transcatheter Aortic Valve Replacement/methods MH - *Tomography, X-Ray Computed/methods MH - Reoperation MH - Aortic Valve/diagnostic imaging/surgery MH - *Aortic Valve Stenosis/surgery/diagnostic imaging COIS- Conflict of Interest The authors declare no conflict of interest. EDAT- 2026/04/11 00:32 MHDA- 2026/04/28 00:35 CRDT- 2026/04/10 18:05 PHST- 2026/01/08 00:00 [received] PHST- 2026/02/25 00:00 [revised] PHST- 2026/03/02 00:00 [accepted] PHST- 2026/04/28 00:35 [medline] PHST- 2026/04/11 00:32 [pubmed] PHST- 2026/04/10 18:05 [entrez] AID - S0009-9260(26)00074-7 [pii] AID - 10.1016/j.crad.2026.107298 [doi] PST - ppublish SO - Clin Radiol. 2026 May;96:107298. doi: 10.1016/j.crad.2026.107298. Epub 2026 Mar 11. PMID- 41960114 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260410 LR - 20260813 IS - 2666-2736 (Electronic) IS - 2666-2736 (Linking) VI - 29 DP - 2026 Feb TI - A comprehensive multidisciplinary thoracic aortic program improves patient quality metrics after type A aortic dissection repair. PG - 101514 LID - 10.1016/j.xjon.2025.11.005 [doi] LID - 101514 AB - OBJECTIVE: To evaluate the impact of a multidisciplinary thoracic aortic program on quality care metrics among survivors of type A aortic dissection. METHODS: In 2019 our center implemented a comprehensive multidisciplinary thoracic aortic program (MTAP) comprising aortic-trained cardiac surgeons, vascular surgeons, cardiologists, medical geneticists, and dedicated support personnel. In this study, we compared quality-care metrics for patients who underwent type A aortic dissection repair at a single academic institution in the 5 years before (2014-2018, "pre-MTAP," n = 87) and 4 years after (2019-2022, "MTAP," n = 126) the implementation of our MTAP program. RESULTS: Process-of-care metrics were defined as postoperative clinical follow-up, aortic imaging surveillance rates, rates of appropriate genetic testing, and planned versus unplanned aortic reintervention. Patients in the MTAP cohort were more likely to undergo genetic testing (34% vs 15%, P = .002), had a greater per-year aortic surveillance imaging rate (1.3 scans vs 0.49 scans, P < .001), and more frequently followed up with a vascular surgeon (62% vs 46%, P = .022) compared with the pre-MTAP group. Additionally, fewer patients in the MTAP group had no follow-up or were lost to follow-up during the study period (25% vs 38%, P = .05). Aortic reinterventions in the MTAP group were more commonly planned at the index Type A dissection operation as part of a multistage procedure (33% vs 11%, P = .040) and were more likely performed endovascularly (91% vs 54%, P = .002). No patients in the MTAP group required emergent reintervention compared to 2 patients (7.1%) in the pre-MTAP group. No between group difference in survival was noted. CONCLUSIONS: Establishment of an MTAP program improved clinical follow-up and diagnostic testing and allowed planned reintervention in survivors of type A aortic dissection. CI - (c) 2025 The Author(s). FAU - Burke, Christopher R AU - Burke CR AD - Division of Cardiothoracic Surgery, University of Washington, Seattle, Wash. FAU - Sweet, Matthew P AU - Sweet MP AD - Division of Vascular Surgery, University of Washington, Seattle, Wash. FAU - DeGraaff, Bret AU - DeGraaff B AD - Division of Anesthesia, University of Washington, Seattle, Wash. FAU - Dhanekula, Arjune AU - Dhanekula A AD - Division of Cardiothoracic Surgery, University of Washington, Seattle, Wash. FAU - Tugan, Dariga AU - Tugan D AD - Division of Cardiothoracic Surgery, University of Washington, Seattle, Wash. FAU - Flodin, Rachel AU - Flodin R AD - Division of Cardiothoracic Surgery, University of Washington, Seattle, Wash. FAU - Otto, Catherine M AU - Otto CM AD - Division of Cardiology, University of Washington, Seattle, Wash. FAU - Buber, Jonathan AU - Buber J AD - Division of Cardiology, University of Washington, Seattle, Wash. FAU - Byers, Peter H AU - Byers PH AD - Division of Medical Genetics, University of Washington, Seattle, Wash. FAU - Schwarze, Ulrike AU - Schwarze U AD - Division of Medical Genetics, University of Washington, Seattle, Wash. FAU - Upson, Melissa AU - Upson M AD - Division of Cardiothoracic Surgery, University of Washington, Seattle, Wash. FAU - Zettervall, Sara L AU - Zettervall SL AD - Division of Vascular Surgery, University of Washington, Seattle, Wash. FAU - DeRoo, Scott AU - DeRoo S AD - Division of Cardiothoracic Surgery, University of Washington, Seattle, Wash. LA - eng PT - Journal Article DEP - 20251117 PL - Netherlands TA - JTCVS Open JT - JTCVS open JID - 101768541 PMC - PMC13059997 OTO - NOTNLM OT - aortic dissection OT - aortic teams OT - quality improvement COIS- The authors reported no conflicts of interest. The Journal policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest. EDAT- 2026/04/10 06:33 MHDA- 2026/04/10 06:34 PMCR- 2025/11/17 CRDT- 2026/04/10 05:39 PHST- 2025/06/24 00:00 [received] PHST- 2025/10/29 00:00 [revised] PHST- 2025/10/31 00:00 [accepted] PHST- 2026/04/10 06:34 [medline] PHST- 2026/04/10 06:33 [pubmed] PHST- 2026/04/10 05:39 [entrez] PHST- 2025/11/17 00:00 [pmc-release] AID - S2666-2736(25)00406-1 [pii] AID - 101514 [pii] AID - 10.1016/j.xjon.2025.11.005 [doi] PST - epublish SO - JTCVS Open. 2025 Nov 17;29:101514. doi: 10.1016/j.xjon.2025.11.005. eCollection 2026 Feb. PMID- 41958770 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260410 LR - 20260813 IS - 0971-9261 (Print) IS - 1998-3891 (Electronic) IS - 0971-9261 (Linking) VI - 31 IP - 2 DP - 2026 Mar-Apr TI - Clinical Spectrum and Surgical Outcomes of Parasitic Twins in Early Infancy: Case Series and Experience from a Tertiary Care Center. PG - 180-186 LID - 10.4103/jiaps.jiaps_170_25 [doi] AB - BACKGROUND: Parasitic or heteropagus conjoined twins are an exceptionally rare congenital anomaly, with an estimated incidence of 1 in 1-2 million live births. These anomalies pose complex clinical and surgical challenges due to their varied anatomical presentations. Multidisciplinary evaluation and timely intervention are essential for favorable outcomes. The study aimed at clinical presentation, anatomical description, management, and outcomes of various heteropagus twins that were managed in a single tertiary care center. METHODS: This retrospective study included six patients diagnosed with heteropagus twinning. Antenatal ultrasonography (USG) findings were reviewed where available. Postnatal investigations included USG, magnetic resonance imaging, and two-dimensional echocardiography for anatomical delineation and cardiac evaluation. Surgical intervention was performed based on the anatomical site and complexity of attachment. Resected specimens were sent for histopathological examination. RESULTS: All patients presented in early infancy. Presentations were diverse: one had a sacral mass mimicking a myelomeningocele (rachipagus) containing intestinal loops; another had a limb, phallus, and testis with lipomeningocele; the third baby had an extra lower limb attached to the pelvis; the fourth baby had an accessory digit on the back; the fifth baby had rudimentary parasitic tissue near the perineum, and the last baby had a mandibular outgrowth resembling a distorted ill-formed face. All cases underwent successful surgical separation with good postoperative recovery. One of the babies succumbed to neonatal sepsis. All the patients are under a strict surveillance protocol with a minimum follow-up period of 3 years and longest being 8 years. CONCLUSION: Heteropagus twins exhibit a wide range of anatomical variations. Early antenatal diagnosis, detailed imaging, and prompt surgical management are key to achieving favorable outcomes. In addition, preoperative planning must include a detailed anatomical survey through the radiological scans and also cardiac evaluation. Surgical procedure to separate the parasitic twin varies from a simple to a more complex approach, so a multidisciplinary approach ensures comprehensive care and minimizes morbidity. CI - Copyright: (c) 2026 Journal of Indian Association of Pediatric Surgeons. FAU - Chhabra, Ashish AU - Chhabra A AD - Department of Pediatric Surgery, Guru Gobind Singh Medical College, Faridkot, Punjab, India. FAU - Nazki, Saalim AU - Nazki S AD - Department of Pediatric Surgery, Government Medical College, Jammu, Jammu and Kashmir, India. FAU - Galhotra, Shipra AU - Galhotra S AD - Department of Microbiology, Guru Gobind Singh Medical College, Faridkot, Punjab, India. FAU - Samad, Lubna AU - Samad L AD - Department of Microbiology, Acharya Shri Chander College of Medical Sciences and Hospital, Jammu, Jammu and Kashmir, India. FAU - Behera, Saswati AU - Behera S AD - Department of Pediatric Surgery, All India Institute of Medical Sciences, Bathinda, Punjab, India. LA - eng PT - Journal Article DEP - 20260309 PL - India TA - J Indian Assoc Pediatr Surg JT - Journal of Indian Association of Pediatric Surgeons JID - 101179870 PMC - PMC13061470 OTO - NOTNLM OT - Asymmetric twins OT - autosite OT - conjoined twins OT - exoparasitic twins OT - heteropagus twins OT - parasitic twins COIS- There are no conflicts of interest. EDAT- 2026/04/10 06:33 MHDA- 2026/04/10 06:34 PMCR- 2026/03/01 CRDT- 2026/04/10 05:27 PHST- 2025/05/30 00:00 [received] PHST- 2025/09/22 00:00 [revised] PHST- 2025/10/12 00:00 [accepted] PHST- 2026/04/10 06:34 [medline] PHST- 2026/04/10 06:33 [pubmed] PHST- 2026/04/10 05:27 [entrez] PHST- 2026/03/01 00:00 [pmc-release] AID - JIAPS-31-180 [pii] AID - 10.4103/jiaps.jiaps_170_25 [doi] PST - ppublish SO - J Indian Assoc Pediatr Surg. 2026 Mar-Apr;31(2):180-186. doi: 10.4103/jiaps.jiaps_170_25. Epub 2026 Mar 9. PMID- 41954757 OWN - NLM STAT- MEDLINE DCOM- 20260714 LR - 20261004 IS - 2731-6866 (Electronic) IS - 2731-6858 (Print) IS - 2731-6858 (Linking) VI - 75 IP - 6 DP - 2026 Jun TI - Anesthesia during cesarean section in women with congenital heart disease : Experience from a certified university hospital for adults with congenital heart disease in Germany-Retrospective analysis from 2013-2023. PG - 399-412 LID - 10.1007/s00101-026-01670-6 [doi] AB - BACKGROUND: Women with congenital heart disease (CHD) often reach childbearing age and may become pregnant. In this study we examine the anesthetic management of cesarean section (C-section) in a university hospital certified for CHD. METHODS: The anesthesiological care for women with CHD who presented at our certified university hospital between January 2013 and December 2023 was descriptively analyzed. We restricted analysis to women who underwent C‑section (n = 38) and the women were classified according to the complexity of the CHD based on the WHO classification of CHD into I mild (A; n = 6), II moderate (B; n = 13) or III severe (C; n = 19). This study is mainly descriptive and serves as a preliminary study for a larger prospective multicenter study. RESULTS: Most of the C‑sections were planned and scheduled (A: n = 3; 50%; B: n = 11; 85% and C: n = 16; 84%) for the dayshift. Anesthesia was performed in more than two thirds of cases by two anesthesiologists. Neuraxial anesthesia was most often performed to achieve adequate surgical tolerance. The frequency of arterial catheter and central venous catheter placements were similar among the groups. Although sometimes introducer sheaths were placed to enable faster introduction of a cannula for extracorporeal membrane oxygenation (ECMO), no use of ECMO was necessary. Postpartum women with severe CHD were more likely to be admitted to the ICU. None of the mothers or newborns died. CONCLUSION: This study aimed to describe the anesthesiological management in women with different severity of CHD undergoing C‑section. This management requires a multidisciplinary approach within a pregnancy heart team. Due to the overall low frequencies and heterogeneity of the CHDs larger multicenter studies are necessary to develop recommendations for obstetric anesthesia in pregnant women with CHD. CI - (c) 2026. The Author(s). FAU - Greve, Susanne AU - Greve S AD - Department of Anaesthesiology and Intensive Care Medicine, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. FAU - Weigt, Nathalie AU - Weigt N AD - Department of Anaesthesiology and Intensive Care Medicine, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. FAU - Beck, Christiane E AU - Beck CE AD - Department of Anaesthesiology and Intensive Care Medicine, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. FAU - Fischbach, Anna AU - Fischbach A AD - Department of Anaesthesiology, RWTH Aachen University, 52074, Aachen, Germany. FAU - Heusinger von Waldegg, Tim AU - Heusinger von Waldegg T AD - Department of Anaesthesiology and Intensive Care Medicine, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. FAU - Heiderich, Sebastian AU - Heiderich S AD - Department of Anaesthesiology and Intensive Care Medicine, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. FAU - Rigterink, Vanessa AU - Rigterink V AD - Department of Anaesthesiology and Intensive Care Medicine, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. FAU - Wiegand, Steffen B AU - Wiegand SB AD - Department of Anaesthesiology and Intensive Care Medicine, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. wiegand.steffen@mh-hannover.de. LA - eng SI - ClinicalTrials.gov/DRKS00033197 PT - Journal Article TT - Anasthesie im Rahmen von Kaiserschnitten bei Frauen mit angeborenem Herzfehler : Erfahrungen aus einem deutschen Universitatsklinikum zertifiziert fur Erwachsene mit angeborenem Herzfehler - retrospektive Analyse von 2013 bis 2023. DEP - 20260409 PL - Germany TA - Anaesthesiologie JT - Die Anaesthesiologie JID - 9918384886806676 SB - IM MH - Humans MH - Female MH - *Heart Defects, Congenital/complications MH - Pregnancy MH - *Cesarean Section/methods MH - Adult MH - Hospitals, University MH - *Anesthesia, Obstetrical/methods MH - Retrospective Studies MH - Germany MH - *Pregnancy Complications, Cardiovascular PMC - PMC13226378 OTO - NOTNLM OT - Cardiovascular complications OT - Congenital heart disease OT - C‑section OT - ECMO OT - Obstetric anesthesia COIS- Declarations. Conflict of interest: S. Greve, N. Weigt, C.E. Beck, A. Fischbach, T. Heusinger von Waldegg, S. Heiderich, V. Rigterink and S.B. Wiegand declare that they have no competing interests. Consent for publication: Not applicable. The local ethics committee of Hannover Medical School approved this retrospective analysis of patient data (11163_BO_K_2023). This study was registered online in the German Clinical Trials Register (DRKS00033197). EDAT- 2026/04/09 12:46 MHDA- 2026/06/01 12:39 PMCR- 2026/04/09 CRDT- 2026/04/09 11:13 PHST- 2025/11/17 00:00 [received] PHST- 2026/03/05 00:00 [accepted] PHST- 2026/06/01 12:39 [medline] PHST- 2026/04/09 12:46 [pubmed] PHST- 2026/04/09 11:13 [entrez] PHST- 2026/04/09 00:00 [pmc-release] AID - 10.1007/s00101-026-01670-6 [pii] AID - 1670 [pii] AID - 10.1007/s00101-026-01670-6 [doi] PST - ppublish SO - Anaesthesiologie. 2026 Jun;75(6):399-412. doi: 10.1007/s00101-026-01670-6. Epub 2026 Apr 9. PMID- 41954543 OWN - NLM STAT- MEDLINE DCOM- 20260714 LR - 20260817 IS - 1876-7605 (Electronic) IS - 1936-8798 (Linking) VI - 19 IP - 7 DP - 2026 Apr 13 TI - Applying the 2025 ESC/EACTS Recommendations for the Treatment of Severe Tricuspid Regurgitation to Real-World Practice. PG - 843-853 LID - S1936-8798(26)00885-X [pii] LID - 10.1016/j.jcin.2026.02.024 [doi] AB - BACKGROUND: According to the 2025 ESC/EACTS guidelines for the management of valvular heart disease, transcatheter tricuspid valve interventions (TTVI) have received a Class IIa recommendation (Level of Evidence: A) for the treatment of patients with severe symptomatic tricuspid regurgitation. However, in patients with severe left ventricular dysfunction (LVD) or right ventricular dysfunction (RVD) or precapillary pulmonary hypertension (pcPH), optimal medical therapy (OMT) is preferred because of the potential risk for futility. OBJECTIVES: The aim of this study was to evaluate clinical and symptomatic outcomes in such "OMT candidate" patients. METHODS: Using data from EuroTR (European Registry of Transcatheter Repair for Tricuspid Regurgitation), guideline-based thresholds for LVD, RVD, and pcPH were applied to patients undergoing tricuspid valve transcatheter edge-to-edge repair (T-TEER). Patients meeting >/=1 exclusion criterion ("OMT candidates") were compared with those meeting current recommendations ("TTVI appropriate") regarding NYHA functional class improvement and 2-year survival free from heart failure hospitalization (HFH). RESULTS: Among 1,626 T-TEER patients, 213 (13.1%) met >/=1 exclusion criterion (4.2% of those with LVD, 6.8% of those with RVD, and 3.6% of those with pcPH). Severe LVD, RVD, and pcPH were each associated with significantly lower 1-year HFH-free survival (LVD, 54.6% vs 72.9% [P < 0.001]; RVD, 59.0% vs 73.2% [P = 0.003]; pcPH, 56.2% vs 73.4% [P = 0.021]; median survival follow-up 446 days [Q1-Q3: 192-805 days]). Despite higher NYHA functional class at baseline and follow-up, the rate of >/=1-class improvement was comparable across subgroups (LVD, 51.1% vs 59.4% [P = 0.25]; RVD, 59.7% vs 59.0% [P = 0.90]; pcPH, 51.3% vs 59.4% [P = 0.31]). Overall, "OMT candidates" had lower HFH-free survival than "TTVI-appropriate" patients (58.7% vs 74.3%; P < 0.001) but showed comparable symptomatic relief (>/=1 NYHA functional class in 56.2% vs 59.5%; P = 0.68). CONCLUSIONS: T-TEER may provide symptomatic benefit in selected high-risk patients with severe LVD, RVD, or pcPH. In the absence of randomized evidence, multidisciplinary evaluation at experienced heart valve centers remains essential to balance potential benefit against procedural futility. Further studies are warranted to refine patient selection and optimize outcomes in this challenging cohort. CI - Copyright (c) 2026 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Stolz, Lukas AU - Stolz L AD - Medizinische Klinik und Poliklinik I, LMU Klinikum, LMU Munchen, Munich, Germany; German Center for Cardiovascular Research, Partner Site Munich Heart Alliance, Munich, Germany. Electronic address: lukas.stolz@med.uni-muenchen.de. FAU - Kresoja, Karl-Patrik AU - Kresoja KP AD - Department of Cardiology, Cardiology I, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany. FAU - von Stein, Jennifer AU - von Stein J AD - Department of Cardiology, Heart Center, University of Cologne, Cologne, Germany. FAU - Fortmeier, Vera AU - Fortmeier V AD - Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW, Universitatsklinik der Ruhr-Universitat Bochum, Medizinische Fakultat OWL (Universitat Bielefeld), Bad Oeynhausen, Germany. FAU - Pauschinger, Christoph AU - Pauschinger C AD - Department of Cardiology, University Heart and Vascular Centre Hamburg, Hamburg, Germany; German Center of Cardiovascular Research, Partner Site Hamburg/Kiel/Lubeck, Hamburg, Germany. FAU - Rottbauer, Wolfgang AU - Rottbauer W AD - Ulm University Heart Center, Ulm, Germany. FAU - Kassar, Mohammad AU - Kassar M AD - Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW, Universitatsklinik der Ruhr-Universitat Bochum, Medizinische Fakultat OWL (Universitat Bielefeld), Bad Oeynhausen, Germany; Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; Graduate School for Health Sciences, University of Bern, Bern, Switzerland. FAU - Goebel, Bjoern AU - Goebel B AD - Department of Cardiology, Heart Center, Zentralklinik Bad Berka, Bad Berka, Germany. FAU - Denti, Paolo AU - Denti P AD - Heart Valve Center, Cardio-Thoracic-Vascular Department, IRCCS San Raffaele Scientific Institute, Milan, Italy. FAU - Achouh, Paul AU - Achouh P AD - Cardiology Department, European Hospital Georges Pompidou, Universite Paris Cite, Paris, France. FAU - Rassaf, Tienush AU - Rassaf T AD - University Hospital Essen, University of Duisburg-Essen, West German Heart and Vascular Center, Department of Cardiology and Vascular Medicine, Essen, Germany. FAU - Barreiro-Perez, Manuel AU - Barreiro-Perez M AD - Hospital Alvaro Cunqueiro, Vigo, Spain. FAU - Boekstegers, Peter AU - Boekstegers P AD - Department of Cardiology, Helios Klinikum Siegburg, Siegburg, Germany. FAU - Ruck, Andreas AU - Ruck A AD - Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden. FAU - Zdanyte, Monika AU - Zdanyte M AD - Medical Clinic III, University Hospital Tubingen, Tubingen, Germany. FAU - Adamo, Marianna AU - Adamo M AD - ASST Spedali Civili di Brescia and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy. FAU - Vincent, Flavien AU - Vincent F AD - Cardiology Department, Centre Hospitalier Universitaire de Lille, Lille, France. FAU - Schlegel, Philipp AU - Schlegel P AD - Department of Internal Medicine III, Division of Cardiology, University Hospital Heidelberg, Ruprecht-Karl University Heidelberg, Heidelberg, Germany. FAU - Rosch, Sebastian AU - Rosch S AD - Department of Cardiology, Cardiology I, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany. FAU - Wild, Mirjam G AU - Wild MG AD - University Heart Center Freiburg/Bad Krozingen, Bad Krozingen, Germany. FAU - Besler, Christian AU - Besler C AD - University Heart Center Freiburg/Bad Krozingen, Bad Krozingen, Germany. FAU - Toggweiler, Stefan AU - Toggweiler S AD - Heart Center Lucerne, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Brunner, Stephanie AU - Brunner S AD - Heart Center Lucerne, Luzerner Kantonsspital, Lucerne, Switzerland. FAU - Grapsa, Julia AU - Grapsa J AD - Department of Cardiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. FAU - Patterson, Tiffany AU - Patterson T AD - Department of Cardiology, Guy's and St. Thomas' NHS Trust, London, United Kingdom. FAU - Thiele, Holger AU - Thiele H AD - Department of Cardiology, Heart Center Leipzig at Leipzig University, Leipzig, Germany. FAU - Kister, Tobias AU - Kister T AD - Department of Cardiology, Heart Center Leipzig at Leipzig University, Leipzig, Germany. FAU - Tarantini, Giuseppe AU - Tarantini G AD - Department of Cardiac, Thoracic Vascular Sciences and Public Health, University of Padua, Padua, Italy. FAU - Masiero, Giulia AU - Masiero G AD - Department of Cardiac, Thoracic Vascular Sciences and Public Health, University of Padua, Padua, Italy. FAU - Kempton, Hannah AU - Kempton H AD - Medizinische Klinik und Poliklinik I, LMU Klinikum, LMU Munchen, Munich, Germany. FAU - De Carlo, Marco AU - De Carlo M AD - University of Pisa, Pisa, Italy. FAU - Giannini, Cristina AU - Giannini C AD - University of Pisa, Pisa, Italy. FAU - Voss, Fabian AU - Voss F AD - Department of Cardiology, Pulmonology and Angiology, Medical Faculty, Heinrich Heine University of Dusseldorf, Dusseldorf, Germany. FAU - Polzin, Amin AU - Polzin A AD - Department of Cardiology, Pulmonology and Angiology, Medical Faculty, Heinrich Heine University of Dusseldorf, Dusseldorf, Germany. FAU - Rubbio, Antonio Popolo AU - Rubbio AP AD - Department of Cardiology, IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy. FAU - Bedogni, Francesco AU - Bedogni F AD - Department of Cardiology, IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy. FAU - Stolte, Thorald AU - Stolte T AD - Cardiovascular Research Institute Basel and Department of Cardiology, University Hospital Basel, University of Basel, Basel, Switzerland. FAU - Nestelberger, Thomas AU - Nestelberger T AD - Cardiovascular Research Institute Basel and Department of Cardiology, University Hospital Basel, University of Basel, Basel, Switzerland. FAU - Benito-Gonzalez, Tomas AU - Benito-Gonzalez T AD - Departamento de Cardiologia, Complejo Asistencial Universitario de Leon, Leon, Spain. FAU - Sanchez-Munoz, Enrique AU - Sanchez-Munoz E AD - Departamento de Cardiologia, Complejo Asistencial Universitario de Leon, Leon, Spain. FAU - Vrijkorte, Martijn AU - Vrijkorte M AD - Department of Cardiology, St. Antonius Hospital, Nieuwegein, the Netherlands. FAU - Swaans, Martin AU - Swaans M AD - Department of Cardiology, St. Antonius Hospital, Nieuwegein, the Netherlands. FAU - Konstandin, Mathias H AU - Konstandin MH AD - Department of Internal Medicine III, Division of Cardiology, University Hospital Heidelberg, Ruprecht-Karl University Heidelberg, Heidelberg, Germany. FAU - Van Belle, Eric AU - Van Belle E AD - Cardiology Department, Centre Hospitalier Universitaire de Lille, Lille, France. FAU - Metra, Marco AU - Metra M AD - ASST Spedali Civili di Brescia and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy. FAU - Geisler, Tobias AU - Geisler T AD - Medical Clinic III, University Hospital Tubingen, Tubingen, Germany. FAU - Estevez-Loureiro, Rodrigo AU - Estevez-Loureiro R AD - Hospital Alvaro Cunqueiro, Vigo, Spain. FAU - Mahabadi, Amir Abbas AU - Mahabadi AA AD - University Hospital Essen, University of Duisburg-Essen, West German Heart and Vascular Center, Department of Cardiology and Vascular Medicine, Essen, Germany. FAU - Karam, Nicole AU - Karam N AD - Cardiology Department, European Hospital Georges Pompidou, Universite Paris Cite, Paris, France. FAU - Maisano, Francesco AU - Maisano F AD - Heart Valve Center, Cardio-Thoracic-Vascular Department, IRCCS San Raffaele Scientific Institute, Milan, Italy. FAU - Lauten, Philipp AU - Lauten P AD - Department of Cardiology, Heart Center, Zentralklinik Bad Berka, Bad Berka, Germany. FAU - Kessler, Mirjam AU - Kessler M AD - Ulm University Heart Center, Ulm, Germany. FAU - Kalbacher, Daniel AU - Kalbacher D AD - Department of Cardiology, University Heart and Vascular Centre Hamburg, Hamburg, Germany; German Center of Cardiovascular Research, Partner Site Hamburg/Kiel/Lubeck, Hamburg, Germany. FAU - Rudolph, Volker AU - Rudolph V AD - Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW, Universitatsklinik der Ruhr-Universitat Bochum, Medizinische Fakultat OWL (Universitat Bielefeld), Bad Oeynhausen, Germany. FAU - Iliadis, Christos AU - Iliadis C AD - Department of Cardiology, Heart Center, University of Cologne, Cologne, Germany. FAU - Lurz, Philipp AU - Lurz P AD - Department of Cardiology, Cardiology I, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany. FAU - Praz, Fabien AU - Praz F AD - Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. FAU - Hausleiter, Jorg AU - Hausleiter J AD - Medizinische Klinik und Poliklinik I, LMU Klinikum, LMU Munchen, Munich, Germany; German Center for Cardiovascular Research, Partner Site Munich Heart Alliance, Munich, Germany. Electronic address: joerg.hausleiter@med.uni-muenchen.de. CN - EuroTR Investigators LA - eng PT - Journal Article PT - Multicenter Study PT - Observational Study PT - Research Support, Non-U.S. Gov't PL - United States TA - JACC Cardiovasc Interv JT - JACC. Cardiovascular interventions JID - 101467004 RN - 0 (Cardiovascular Agents) SB - IM MH - Aged MH - Aged, 80 and over MH - Female MH - Humans MH - Male MH - Middle Aged MH - *Cardiac Catheterization/adverse effects/mortality/standards MH - *Cardiovascular Agents/adverse effects/therapeutic use MH - Clinical Decision-Making MH - Europe MH - *Heart Valve Prosthesis Implantation/adverse effects/mortality/standards/instrumentation MH - Hypertension, Pulmonary/physiopathology/mortality MH - *Practice Guidelines as Topic/standards MH - Progression-Free Survival MH - Recovery of Function MH - Registries MH - Risk Assessment MH - Risk Factors MH - Severity of Illness Index MH - Time Factors MH - Treatment Outcome MH - *Tricuspid Valve/physiopathology/surgery/diagnostic imaging MH - *Tricuspid Valve Insufficiency/physiopathology/diagnostic imaging/mortality/surgery/therapy MH - Ventricular Dysfunction, Left/physiopathology/mortality MH - Ventricular Dysfunction, Right/physiopathology/mortality MH - Ventricular Function, Left MH - Ventricular Function, Right OTO - NOTNLM OT - T-TEER OT - left ventricular dysfunction OT - pulmonary hypertension OT - right ventricular dysfunction OT - treatment algorithm COIS- Funding Support and Author Disclosures Among the full cohort of patients in the registry, data collection for the Hamburg patients was supported by a grant from the German Heart Foundation. Dr Stolz has received speaker honoraria from Edwards Lifesciences. Dr Kresoja has received travel expenses from Edwards Lifesciences. Dr von Stein has received lecture honoraria from Edwards Lifesciences. Dr Rottbauer has received speaker honoraria Edwards Lifesciences and Abbott Laboratories. Dr Denti has served as a consultant for InnovHeart, Pi-Cardia, HVR, and Approxima; and has received speaker honoraria from Abbott Laboratories and Edwards Lifesciences. Dr Rassaf has received speaker honoraria and consulting fees from AstraZeneca, Bayer, Pfizer, and Daiichi-Sankyo. Dr Barreiro-Perez has received speaker fees from Abbott Cardiovascular, Edwards Lifesciences, and Venus Medtech. Dr Adamo has received consulting fees in the past 3 years from Abbott Structural Heart and Edwards Lifesciences. Dr Toggweiler has received honoraria from Medtronic, Boston Scientific, Biosensors, Edwards Lifesciences, MicroPort, Products + Features, Hi-D Imaging, Abbott Cardiovascular, Medira, Shockwave Medical, Teleflex, atHeart Medical, Cardiac Dimensions, Polares Medical, Amarin, Sanofi, AstraZeneca, ReCor Medical, Daiichi-Sankyo, Bayer, and Armira; has received institutional research grants from Medtronic, Edwards Lifesciences, Abbott Cardiovascular, Boston Scientific, Fumedica, Novartis, Boehringer Ingelheim, and Polares Medical; and holds equity in Hi-D Imaging. Dr Metra has received consulting fees in the past 3 years from Abbott Structural Heart, AstraZeneca, Bayer, Boehringer Ingelheim, Edwards Lifesciences, and Roche Diagnostics. Dr Geisler has received speaker honoraria and research grants from AstraZeneca, Bayer, Bristol Myers Squibb/Pfizer, Ferrer/Chiesi, Medtronic, and Edwards Lifesciences, all unrelated to this study. Dr Estevez-Loureiro has received speaker fees from Abbott Cardiovascular, Edwards Lifesciences, Boston Scientific, and Venus Medtech. Dr Maisano has received grant and/or research institutional support from Abbott Laboratories, Medtronic, Edwards Lifesciences, Biotronik, Boston Scientific Corporation, NVT, Terumo, and Venus; has received consulting fees and personal and institutional honoraria from Abbott Laboratories, Medtronic, Edwards Lifesciences, Xeltis, Cardiovalve, Occlufit, Simulands, Mtex, Venus, Squadra, and Valgen; has received royalty income from and holds intellectual property rights with Edwards Lifesciences; and is a shareholder (including share options) in Magenta, Transseptal Solutions, and 4Tech. Dr Kessler has received speaker honoraria from Edwards Lifesciences and Abbott Laboratories. Dr Kalbacher has received personal fees from Abbott Laboratories, Edwards Lifesciences, Pi-Cardia, and Medtronic. Dr Rudolph has received research grants from Abbott Laboratories, Boston Scientific, and Edwards Lifesciences. Dr Iliadis has received consultant fees and travel expenses from Abbott Laboratories and Edwards Lifesciences. Dr Sticchi has served on an advisory board for Edwards Lifesciences. Dr Lurz has received institutional grants from Edwards Lifesciences; and has received honoraria from Innoventrics. Dr Hausleiter has received research grant support and speaker honoraria from Edwards Lifesciences. Dr Tarantini has received speaker fees from Abbott Cardiovascular and Edwards Lifesciences. Dr Mahabadi has received speaker fees from and/or participated on advisory boards for Amgen, Berlin Chemie, Daiichi-Sankyo, Edwards Lifesciences, Novartis, and Sanofi; and has received research funding from Daiichi-Sankyo and Edwards Lifesciences, all outside the submitted work. Dr Nestelberger has received research support from the Swiss National Science Foundation (P400PM_191037/1), the Prof Dr Max Cloetta Foundation, Margarete und Walter Lichtenstein-Stiftung (3MS1038), Freiwillige Akademische Gesellschaft Basel, Stiftung Kardiovaskulare Forschung Basel, the University of Basel, and University Hospital Basel; and has received speaker or consulting honoraria or research support from Edwards Lifesciences, Pronova Medical, Meril, Boston Scientific, Medtronic, Abbott Laboratories, Beckman Coulter, Bayer, Ortho Clinical Diagnostics, and Orion Pharma, outside the submitted work. Dr Swaans has served as a proctor or lecturer for Abbott Cardiovascular, BioVentrix, Boston Scientific, Cardiac Dimensions, Edwards Lifesciences, GE Healthcare, Medtronic, Products + Features, Philips Healthcare, and Siemens Healthineers. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. FIR - Doldi, Philipp IR - Doldi P IRAD- Medizinische Klinik und Poliklinik I, LMU Klinikum, LMU Munchen, Munich, Germany. FIR - Weckbach, Ludwig T IR - Weckbach LT IRAD- Medizinische Klinik und Poliklinik I, LMU Klinikum, LMU Munchen, Munich, Germany. FIR - Stocker, Thomas J IR - Stocker TJ IRAD- Medizinische Klinik und Poliklinik I, LMU Klinikum, LMU Munchen, Munich, Germany. FIR - Novotny, Julia IR - Novotny J IRAD- Medizinische Klinik und Poliklinik I, LMU Klinikum, LMU Munchen, Munich, Germany. FIR - Volz, Kaspar IR - Volz K IRAD- Medizinische Klinik und Poliklinik I, LMU Klinikum, LMU Munchen, Munich, Germany. FIR - Med, Cand IR - Med C IRAD- Medizinische Klinik und Poliklinik I, LMU Klinikum, LMU Munchen, Munich, Germany. FIR - Berschiminski, Katalin IR - Berschiminski K IRAD- Medizinische Klinik und Poliklinik I, LMU Klinikum, LMU Munchen, Munich, Germany. FIR - Med, Cand IR - Med C IRAD- Medizinische Klinik und Poliklinik I, LMU Klinikum, LMU Munchen, Munich, Germany. FIR - Rommel, Karl-Philip IR - Rommel KP IRAD- Department of Cardiology, Cardiology I, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany. FIR - Stephan von Bardeleben, Ralph IR - Stephan von Bardeleben R IRAD- Department of Cardiology, Cardiology I, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany. FIR - Pfister, Roman IR - Pfister R IRAD- Department of Cardiology, Heart Center, University of Cologne, Cologne, Germany. FIR - Baldus, Stephan IR - Baldus S IRAD- Department of Cardiology, Heart Center, University of Cologne, Cologne, Germany. FIR - von Stein, Philipp IR - von Stein P IRAD- Department of Cardiology, Heart Center, University of Cologne, Cologne, Germany. FIR - Gercek, Muhammed IR - Gercek M IRAD- Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW, Universitatsklinik der Ruhr-Universitat Bochum, Medizinische Fakultat OWL (Universitat Bielefeld), Bad Oeynhausen, Germany. FIR - Rudolph, Felix IR - Rudolph F IRAD- Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW, Universitatsklinik der Ruhr-Universitat Bochum, Medizinische Fakultat OWL (Universitat Bielefeld), Bad Oeynhausen, Germany. FIR - Omran, Hazem IR - Omran H IRAD- Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW, Universitatsklinik der Ruhr-Universitat Bochum, Medizinische Fakultat OWL (Universitat Bielefeld), Bad Oeynhausen, Germany. FIR - Ludwig, Sebastian IR - Ludwig S IRAD- Department of Cardiology, University Heart and Vascular Centre Hamburg, Hamburg, Germany; German Center of Cardiovascular Research, Partner Site Hamburg/Kiel/Lubeck, Hamburg, Germany. FIR - Koell, Benedikt IR - Koell B IRAD- Department of Cardiology, University Heart and Vascular Centre Hamburg, Hamburg, Germany; German Center of Cardiovascular Research, Partner Site Hamburg/Kiel/Lubeck, Hamburg, Germany. FIR - Schneider, Leonhard-Moritz IR - Schneider LM IRAD- Ulm University Heart Center, Ulm, Germany. FIR - Felbel, Dominik IR - Felbel D IRAD- Ulm University Heart Center, Ulm, Germany. FIR - Salomon, Carsten IR - Salomon C IRAD- Department of Cardiology, Heart Center, Zentralklinik Bad Berka, Bad Berka, Germany. FIR - Lapp, Harald IR - Lapp H IRAD- Department of Cardiology, Heart Center, Zentralklinik Bad Berka, Bad Berka, Germany. FIR - de Baynast, Quentin IR - de Baynast Q IRAD- Cardiology Department, European Hospital Georges Pompidou, Universite Paris Cite, Paris, France. FIR - Berrebi, Alain IR - Berrebi A IRAD- Cardiology Department, European Hospital Georges Pompidou, Universite Paris Cite, Paris, France. FIR - Schindhelm, Florian IR - Schindhelm F IRAD- University Hospital Essen, University of Duisburg-Essen, West German Heart and Vascular Center, Department of Cardiology and Vascular Medicine, Essen, Germany. FIR - Caneiro-Queija, Berenice IR - Caneiro-Queija B IRAD- Hospital Alvaro Cunqueiro, Vigo, Spain. FIR - Echarte-Morales, Julio IR - Echarte-Morales J IRAD- Hospital Alvaro Cunqueiro, Vigo, Spain. FIR - Goldschmied, Andreas IR - Goldschmied A IRAD- Medical Clinic III, University Hospital Tubingen, Tubingen, Germany. FIR - Pancaldi, Edoardo IR - Pancaldi E IRAD- ASST Spedali Civili di Brescia and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy. FIR - Pezzola, Elisa IR - Pezzola E IRAD- ASST Spedali Civili di Brescia and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy. FIR - Massussi, Mauro IR - Massussi M IRAD- ASST Spedali Civili di Brescia and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy. FIR - Lupi, Laura IR - Lupi L IRAD- ASST Spedali Civili di Brescia and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy. FIR - Rousse, Natacha IR - Rousse N IRAD- Cardiology Department, Centre Hospitalier Universitaire de Lille, Lille, France. FIR - Aghezzaf, Samy IR - Aghezzaf S IRAD- Cardiology Department, Centre Hospitalier Universitaire de Lille, Lille, France. FIR - Frey, Norbert IR - Frey N IRAD- Department of Internal Medicine III, Division of Cardiology, University Hospital Heidelberg, Ruprecht-Karl University Heidelberg, Heidelberg, Germany. FIR - Kraus, Martin IR - Kraus M IRAD- Department of Internal Medicine III, Division of Cardiology, University Hospital Heidelberg, Ruprecht-Karl University Heidelberg, Heidelberg, Germany. FIR - Westermann, Dirk IR - Westermann D IRAD- University Heart Center Freiburg/Bad Krozingen, Bad Krozingen, Germany. FIR - Ziegler, Leonie IR - Ziegler L IRAD- University Heart Center Freiburg/Bad Krozingen, Bad Krozingen, Germany. FIR - Wolff, Charlotte IR - Wolff C IRAD- Department of Cardiology, Heart Center Leipzig at Leipzig University, Leipzig, Germany. FIR - Arturi, Federico IR - Arturi F IRAD- Department of Cardiac, Thoracic Vascular Sciences and Public Health, University of Padua, Padua, Italy. FIR - Sticchi, Alessandro IR - Sticchi A IRAD- Medizinische Klinik und Poliklinik I, LMU Klinikum, LMU Munchen, Munich, Germany; German Center for Cardiovascular Research, Partner Site Munich Heart Alliance, Munich, Germany. FIR - Mazzola, Matteo IR - Mazzola M IRAD- Medizinische Klinik und Poliklinik I, LMU Klinikum, LMU Munchen, Munich, Germany; German Center for Cardiovascular Research, Partner Site Munich Heart Alliance, Munich, Germany. FIR - von Peter, Anke IR - von Peter A IRAD- Cardiovascular Research Institute Basel and Department of Cardiology, University Hospital Basel, University of Basel, Basel, Switzerland. EDAT- 2026/04/09 12:45 MHDA- 2026/04/19 17:48 CRDT- 2026/04/09 10:28 PHST- 2025/10/28 00:00 [received] PHST- 2026/01/28 00:00 [revised] PHST- 2026/02/06 00:00 [accepted] PHST- 2026/04/19 17:48 [medline] PHST- 2026/04/09 12:45 [pubmed] PHST- 2026/04/09 10:28 [entrez] AID - S1936-8798(26)00885-X [pii] AID - 10.1016/j.jcin.2026.02.024 [doi] PST - ppublish SO - JACC Cardiovasc Interv. 2026 Apr 13;19(7):843-853. doi: 10.1016/j.jcin.2026.02.024. PMID- 41949011 OWN - NLM STAT- MEDLINE DCOM- 20260714 LR - 20260714 IS - 2635-0114 (Electronic) IS - 2635-0106 (Linking) VI - 52 IP - 3 DP - 2026 Jun TI - Implementation of a Pharmacist-Led Service to Expand SGLT2 Inhibitor Use Beyond Diabetes in the Primary Care Setting. PG - 243-250 LID - 10.1177/26350106261431283 [doi] AB - PURPOSE: The purpose of this report is to evaluate the impact of a pharmacist-led quality improvement initiative on the use of sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients with chronic kidney disease (CKD) and heart failure (HF) at a primary care clinic. METHODS: As part of a pharmacist-led quality improvement initiative between March 1, 2022, and March 1, 2023, patients with CKD and HF were considered for SGLT2 inhibitor therapy by a primary care provider or referred to the pharmacy team for potential initiation of treatment using a collaborative practice agreement. The pharmacy team was led by a diabetes care and education specialist (DCES) who regularly manages drug therapy, including SGLT2 inhibitors, for people with diabetes. Predefined criteria for appropriate SGLT2 inhibitor use in patients with CKD and HF was developed to identify eligible patients. The primary outcome of this initiative was the change in the proportion of patients appropriately receiving SGLT2 inhibitor therapy. RESULTS: A total of 71 patients met treatment criteria. Of the 71 patients identified, 57 were not receiving treatment at baseline. By the end of the initiative, the proportion of patients receiving SGLT2 inhibitor therapy increased from 19.7% to 50.7%. Treatment was initiated by the pharmacist in 64% of patients. CONCLUSION: This initiative resulted in a significant improvement in SGLT2 inhibitor use for patients with CKD and HF. The findings highlight the feasibility of using DCES-credentialed pharmacists in an interprofessional care team to initiate SGLT2 inhibitor therapy for patients with these conditions in the primary care setting. FAU - Cutrell, Stacey AU - Cutrell S AUID- ORCID: 0009-0005-5788-1130 AD - From High Point University, High Point, North Carolina. FAU - Patino, Kiara AU - Patino K AUID- ORCID: 0009-0005-5760-4715 AD - Virginia Commonwealth University School of Pharmacy, Richmond, Virginia. AD - Emory Healthcare, Atlanta, Georgia. FAU - Babalola, R Oluwafunmito AU - Babalola RO AUID- ORCID: 0009-0004-5654-9817 AD - University of North Texas System College of Pharmacy, Fort Worth, Texas. FAU - Murchie, Michael AU - Murchie M AD - CrossOver Healthcare Ministry, Richmond, Virginia. FAU - D Bucheit, John AU - D Bucheit J AUID- ORCID: 0000-0003-3396-2612 AD - Virginia Commonwealth University School of Pharmacy, Richmond, Virginia. LA - eng PT - Journal Article DEP - 20260408 PL - United States TA - Sci Diabetes Self Manag Care JT - The science of diabetes self-management and care JID - 101775189 RN - 0 (Sodium-Glucose Transporter 2 Inhibitors) SB - IM MH - Humans MH - *Sodium-Glucose Transporter 2 Inhibitors/therapeutic use MH - *Primary Health Care MH - *Pharmacists MH - *Heart Failure/drug therapy/complications MH - Female MH - *Renal Insufficiency, Chronic/drug therapy/complications MH - Male MH - *Diabetes Mellitus, Type 2/drug therapy/complications MH - Aged MH - Quality Improvement MH - Middle Aged COIS- Declaration of Conflicting InterestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2026/04/08 12:34 MHDA- 2026/05/28 12:33 CRDT- 2026/04/08 06:53 PHST- 2026/05/28 12:33 [medline] PHST- 2026/04/08 12:34 [pubmed] PHST- 2026/04/08 06:53 [entrez] AID - 10.1177/26350106261431283 [doi] PST - ppublish SO - Sci Diabetes Self Manag Care. 2026 Jun;52(3):243-250. doi: 10.1177/26350106261431283. Epub 2026 Apr 8. PMID- 41948511 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260408 LR - 20260921 IS - 2045-8932 (Print) IS - 2045-8940 (Electronic) IS - 2045-8932 (Linking) VI - 16 IP - 2 DP - 2026 Jun TI - Lifesaving Compassionate-Use of Sotatercept in a 12-Year-old With Idiopathic Pulmonary Arterial Hypertension. PG - e70293 LID - 10.1002/pul2.70293 [doi] LID - e70293 AB - Pediatric idiopathic pulmonary arterial hypertension (IPAH) refractory to maximal medical therapy is associated with high morbidity and mortality, and therapeutic options remain limited. We describe a 12-year-old girl with end-stage IPAH who developed acute decompensated right heart failure despite triple combination therapy, including high-dose prostacyclin. Escalation to intravenous epoprostenol failed to result in clinical or hemodynamic improvement. Following multidisciplinary discussion, ethical approval, and informed consent, sotatercept was initiated under compassionate use. Sotatercept therapy resulted in rapid and marked clinical recovery, including improvement in World Health Organization functional class (WHO FC) from IV to II, substantial increase in 6-min walk distance, normalization of NT-proBNP levels, and significant echocardiographic and invasive hemodynamic improvement. This case highlights the potential role of sotatercept as a rescue therapy in pediatric IPAH refractory to conventional treatment. CI - (c) 2026 The Author(s). Pulmonary Circulation published by John Wiley & Sons Ltd on behalf of Pulmonary Vascular Research Institute. FAU - Pelczar-Plachta, Weronika AU - Pelczar-Plachta W AUID- ORCID: 0000-0002-1175-1745 AD - Department of Pediatric Cardiology Poznan University of Medical Sciences Poznan Poland. FAU - Surmacz, Rafal AU - Surmacz R AUID- ORCID: 0000-0002-8494-4943 AD - Department of Pediatric Cardiology Poznan University of Medical Sciences Poznan Poland. FAU - Bobkowski, Waldemar AU - Bobkowski W AD - Department of Pediatric Cardiology Poznan University of Medical Sciences Poznan Poland. LA - eng PT - Journal Article DEP - 20260402 PL - United States TA - Pulm Circ JT - Pulmonary circulation JID - 101557243 PMC - PMC13052013 OTO - NOTNLM OT - activin A receptor IIA inhibitor OT - pediatric cardiology OT - severe pulmonary hypertension COIS- The authors declare no conflicts of interest. EDAT- 2026/04/08 12:16 MHDA- 2026/04/08 12:17 PMCR- 2026/04/02 CRDT- 2026/04/08 04:31 PHST- 2026/01/20 00:00 [received] PHST- 2026/03/16 00:00 [revised] PHST- 2026/03/27 00:00 [accepted] PHST- 2026/04/08 12:17 [medline] PHST- 2026/04/08 12:16 [pubmed] PHST- 2026/04/08 04:31 [entrez] PHST- 2026/04/02 00:00 [pmc-release] AID - PUL270293 [pii] AID - 10.1002/pul2.70293 [doi] PST - epublish SO - Pulm Circ. 2026 Apr 2;16(2):e70293. doi: 10.1002/pul2.70293. eCollection 2026 Jun. PMID- 41945887 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260407 LR - 20260407 IS - 1758-1974 (Electronic) IS - 1758-1966 (Linking) VI - 15 IP - 1 DP - 2026 Dec TI - Surgical management of concomitant lung cancer and cardiovascular diseases: a multidisciplinary perspective. PG - 2654371 LID - 10.1080/17581966.2026.2654371 [doi] AB - Lung cancer and cardiovascular diseases (CVDs) frequently coexist due to shared risk factors such as aging, smoking, and chronic inflammation. The growing prevalence of elderly surgical candidates with concomitant lung cancer and CVDs presents unique diagnostic and therapeutic challenges. This review explores current strategies for managing such patients, emphasizing the importance of individualized, multidisciplinary treatment planning. Advances in minimally invasive pulmonary resection and parenchymal -sparing surgery-such as segmentectomy-have expanded surgical options, especially in frail patients. Simultaneously, improvements in cardiovascular therapies, including transcatheter aortic valve implantation (TAVI), thoracic endovascular aortic repair (TEVAR), and off-pump coronary artery bypass grafting (OPCAB), have enabled safer, staged approaches. Guideline-directed preoperative risk assessment from Japanese, American, and European societies underscores the need for tailored sequencing of cardiac and oncologic interventions. In general, a staged approach with initial cardiac stabilization followed by pulmonary resection is preferred. However, simultaneous surgery, especially OPCAB combined with pulmonary resection, may be feasible in carefully selected patients. Additionally, the cardiac toxicity of immune checkpoint inhibitors and EGFR-TKIs must be considered when planning neoadjuvant treatment. Integrating cardiovascular expertise into thoracic oncology is crucial to optimizing outcomes in this complex population. FAU - Kanzaki, Ryu AU - Kanzaki R AD - Department of General Thoracic Surgery, Osaka International Cancer Institute, Osaka, Japan. FAU - Okami, Jiro AU - Okami J AD - Department of General Thoracic Surgery, Osaka International Cancer Institute, Osaka, Japan. LA - eng PT - Journal Article PT - Review DEP - 20260407 PL - England TA - Lung Cancer Manag JT - Lung cancer management JID - 101588392 OAB - Lung cancer and cardiovascular diseases frequently coexist in older adults due to shared risk factors like smoking.Minimally invasive lung surgery, including video- and robotic-assisted techniques and segmentectomy, improves safety in high-risk patients.Major international guidelines support individualized cardiovascular assessment and multidisciplinary planning.Thoracic endovascular aortic repair enables lung resection within 2-3 months with lower procedural risk.Transcatheter aortic valve implantation allows safe lung surgery without cardiopulmonary bypass in selected patients.Lung surgery after percutaneous coronary intervention is safe with aspirin alone; simultaneous surgery with off-pump bypass is selective.Immune checkpoint inhibitors and epidermal growth factor receptor-tyrosine kinase inhibitors increase cardiac risk, requiring cardiac-first sequencing.Treatment order should reflect cancer stage and surgical invasiveness; a cardiac-first, staged approach is usually best. OABL- eng OTO - NOTNLM OT - Lung cancer OT - cardiovascular diseases OT - off pump coronary artery bypass grafting OT - pulmonary resection OT - surgery EDAT- 2026/04/07 18:32 MHDA- 2026/04/07 18:33 CRDT- 2026/04/07 16:13 PHST- 2026/04/07 18:33 [medline] PHST- 2026/04/07 18:32 [pubmed] PHST- 2026/04/07 16:13 [entrez] AID - 10.1080/17581966.2026.2654371 [doi] PST - ppublish SO - Lung Cancer Manag. 2026 Dec;15(1):2654371. doi: 10.1080/17581966.2026.2654371. Epub 2026 Apr 7. PMID- 41940644 OWN - NLM STAT- MEDLINE DCOM- 20260827 LR - 20260908 IS - 1524-4725 (Electronic) IS - 1076-0512 (Linking) VI - 52 IP - 9 DP - 2026 Sep 1 TI - Antibiotic Prophylaxis in Dermatologic Surgery: Advisory Statement 2025 (APDSAS 2025). PG - 846-851 LID - 10.1097/DSS.0000000000005056 [doi] AB - BACKGROUND: Guidelines and evidence related to antibiotic prophylaxis in dermatologic surgery have evolved since the authors' previously published advisory statement. OBJECTIVE: To provide an updated advisory statement on antibiotic prophylaxis in dermatologic surgery as guided by updated recommendations from the American Heart Association and the American Dental Association with the American Academy of Orthopaedic Surgeons guidelines. METHODS: A structured literature review was performed. A multidisciplinary team of specialists from dermatologic surgery, infectious diseases, and pharmacy were convened to review up-to-date data and develop updated comprehensive evidence-based recommendations. RESULTS: Consistent with the previous advisory statement, prophylactic antibiotics are recommended for patients with high-risk cardiac or prosthetic joint conditions, when the dermatologic surgical site is infected or if the procedure breaches the mucosa. Significant changes were made for prophylaxis of surgical site infection. Updated recommendations were made regarding antibiotic selection in penicillin-allergic patients and intraoperative use of intraincisional clindamycin in the local anesthetic. LIMITATIONS: Reviewed data are predominantly limited to retrospective data. CONCLUSION: Recommendations regarding antibiotic prophylaxis around dermatologic surgery are evolving as new data and practices are introduced. The 2025 advisory statement provides the latest recommendations for appropriate use of antibiotic prophylaxis in dermatologic surgery. CI - Copyright (c) 2026 by the American Society for Dermatologic Surgery, Inc. Published by Wolters Kluwer Health, LLC. All rights reserved. FAU - Campbell, Elliott AU - Campbell E AD - Dermatology Associates of Northern Kentucky, Florence, Kentucky. FAU - Virk, Abinash AU - Virk A AD - Division of Public Health, Infectious Diseases and Occupational Medicine, Mayo Clinic, Rochester, Minnesota. FAU - Lessard, Sarah AU - Lessard S AD - Department of Pharmacy, Mayo Clinic Health System, La Crosse, Wisconsin. FAU - Lohman, Mary E AU - Lohman ME AD - Division of Dermatologic Surgery, Department of Dermatology, Mayo Clinic, Rochester, Minnesota. FAU - Otley, Clark AU - Otley C AD - Division of Dermatologic Surgery, Department of Dermatology, Mayo Clinic, Rochester, Minnesota. LA - eng PT - Journal Article PT - Practice Guideline PT - Review DEP - 20260406 PL - United States TA - Dermatol Surg JT - Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] JID - 9504371 RN - 0 (Anti-Bacterial Agents) RN - 3U02EL437C (Clindamycin) SB - IM MH - Humans MH - *Antibiotic Prophylaxis/standards/methods MH - *Surgical Wound Infection/prevention & control MH - *Dermatologic Surgical Procedures/adverse effects/standards MH - *Anti-Bacterial Agents/administration & dosage MH - Clindamycin/administration & dosage MH - Practice Guidelines as Topic EDAT- 2026/04/06 12:36 MHDA- 2026/08/27 05:35 CRDT- 2026/04/06 09:02 PHST- 2026/08/27 05:35 [medline] PHST- 2026/04/06 12:36 [pubmed] PHST- 2026/04/06 09:02 [entrez] AID - 00042728-990000000-01623 [pii] AID - 10.1097/DSS.0000000000005056 [doi] PST - ppublish SO - Dermatol Surg. 2026 Sep 1;52(9):846-851. doi: 10.1097/DSS.0000000000005056. Epub 2026 Apr 6. PMID- 41939929 OWN - NLM STAT- MEDLINE DCOM- 20260714 LR - 20260826 IS - 1178-2005 (Electronic) IS - 1176-9106 (Print) IS - 1176-9106 (Linking) VI - 21 DP - 2026 TI - Optimizing COPD Care in Belgium: A Multidisciplinary Expert Consensus on Cardiopulmonary Risk Management. PG - 578651 LID - 10.2147/COPD.S578651 [doi] LID - 578651 AB - INTRODUCTION: Chronic obstructive pulmonary disease (COPD) represents a major health and economic challenge in Belgium, affecting approximately 800,000 individuals, half of whom remain undiagnosed. Beyond respiratory morbidity, COPD patients face substantial cardiopulmonary (CP) risk-encompassing severe exacerbations and cardiovascular (CV) events-that is often under-recognized and insufficiently addressed due to limited clinical awareness, fragmented care, and the absence of national guidance. METHODS: A multidisciplinary Belgian taskforce (general practitioners, pulmonologists, cardiologists, pharmacists, epidemiologists) convened through structured workshops and iterative consensus-building to develop a pragmatic, evidence-informed care pathway. The recommendations focus on COPD patients with at least one moderate or severe exacerbation, who are at heightened CP risk. RESULTS: This consensus introduces an integrated, stepwise framework that positions CP risk as a central component of COPD management after exacerbation and operationalizes it across primary care, hospitalization, and post-exacerbation follow-up. Core elements include systematic and proactive CP risk identification in primary care, standardized diagnostic workups during hospitalization, and multidisciplinary discharge planning. Pharmacological strategies combine eosinophil-guided inhaler therapy with guideline-directed CV treatment, while non-pharmacological measures reinforce smoking cessation, vaccination, physical activity, and pulmonary rehabilitation. Clear referral thresholds between primary care, pulmonology, and cardiology are defined, supported by patient education and digital monitoring tools. CONCLUSION: This Belgian consensus complements international guidelines by consolidating fragmented recommendations into coherent, actionable algorithms that bridge gaps in routine practice. Its contribution lies in translating emerging evidence into structured, real-world pathways that integrate respiratory and cardiac care. Adoption of this framework may help reduce exacerbations, improve CV outcomes, and support multidisciplinary COPD care in Belgium. CI - (c) 2026 Michotte et al. FAU - Michotte, Naomi AU - Michotte N AUID- ORCID: 0000-0003-1235-2292 AD - Department of Respiratory Medicine, Universitair Ziekenhuis Brussel, Brussels, Belgium. AD - Lung Research Unit, Vitality Research Group, Vrije Universiteit Brussel, Brussels, Belgium. FAU - Demeure, Fabian AU - Demeure F AD - Department of Cardiology, CHU UCL Namur, Yvoir, Belgium. FAU - Guiot, Julien AU - Guiot J AD - Department of Respiratory Medicine, CHU Liege, Liege, Belgium. AD - Faculty of Medicine, University of Liege, Liege, Belgium. FAU - Trenson, Sander AU - Trenson S AD - Department of Cardiology, AZ Sint-Jan, Bruges, Belgium. FAU - Vanfleteren, Michiel J E G W AU - Vanfleteren MJEGW AD - Department of Respiratory Medicine, Sint-Josefskliniek, Izegem, Belgium. FAU - Lahousse, Lies AU - Lahousse L AUID- ORCID: 0000-0002-3494-4363 AD - Department of Bioanalysis, Ghent University, Gent, Belgium. AD - Department of Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands. FAU - Raskin, Jo AU - Raskin J AD - Department of Pulmonology and Thoracic Oncology, Antwerp University Hospital, Edegem, Belgium. AD - Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium. FAU - Cataldo, Didier AU - Cataldo D AUID- ORCID: 0000-0002-3079-7941 AD - Department of Respiratory Medicine, CHU Liege, Liege, Belgium. AD - Laboratory of Tumours and Development, University of Liege, Liege, Belgium. FAU - Lapperre, Therese AU - Lapperre T AD - Department of Respiratory Medicine, Antwerp University Hospital, Antwerp, Belgium. AD - Laboratory of Experimental Medicine and Pediatrics, University of Antwerp, Antwerp, Belgium. FAU - Marchand, Eric AU - Marchand E AD - Department of Respiratory Medicine, CHU-UCL Namur, Yvoir, Belgium. AD - Institute of Experimental and Clinical Research, UCLouvain, Brussels, Belgium. AD - Namur Research Institute for Life Sciences (NARILIS), University of Namur, Namur, Belgium. FAU - Leys, Mathias AU - Leys M AD - Department of Respiratory Medicine, AZ Groeninge, Kortrijk, Belgium. FAU - Janssens, Wim AU - Janssens W AUID- ORCID: 0000-0003-1830-2982 AD - Department of Respiratory Medicine, University Hospital of Leuven, Leuven, Belgium. FAU - Bruyneel, Marie AU - Bruyneel M AUID- ORCID: 0000-0002-7035-1266 AD - Department of Respiratory Medicine, CHU Saint-Pierre, Brussels, Belgium. AD - Department of Respiratory Medicine, CHU Brugmann, Brussels, Belgium. FAU - Vanfleteren, Lowie E G W AU - Vanfleteren LEGW AD - Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium. AD - Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium. FAU - Vanderhelst, Eef AU - Vanderhelst E AD - Department of Respiratory Medicine, Universitair Ziekenhuis Brussel, Brussels, Belgium. AD - Lung Research Unit, Vitality Research Group, Vrije Universiteit Brussel, Brussels, Belgium. FAU - Goeminne, Pieter AU - Goeminne P AD - Department of Respiratory Medicine, VITAZ Hospitals, Sint-Niklaas, Belgium. FAU - Teughels, Stefan AU - Teughels S AD - Domus Medica, Antwerp, Belgium. FAU - Lins, Muriel AU - Lins M AD - Department of Respiratory Medicine, AZ Sint-Maarten, Mechelen, Belgium. FAU - Van Rossem, Ines AU - Van Rossem I AD - Department of Family Medicine and Chronic Care, Vrije Universiteit Brussel, Brussels, Belgium. FAU - Peche, Rudi AU - Peche R AUID- ORCID: 0000-0003-1447-3442 AD - Department of Respiratory Medicine, Humani Network, CHU Charleroi, Charleroi, Belgium. LA - eng PT - Consensus Statement PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20260113 PL - New Zealand TA - Int J Chron Obstruct Pulmon Dis JT - International journal of chronic obstructive pulmonary disease JID - 101273481 SB - IM MH - Humans MH - Belgium/epidemiology MH - *Cardiovascular Diseases/diagnosis/epidemiology/physiopathology/prevention & control MH - Cooperative Behavior MH - Critical Pathways/standards MH - *Delivery of Health Care, Integrated/standards MH - Disease Progression MH - Heart Disease Risk Factors MH - Interdisciplinary Communication MH - *Patient Care Team/standards MH - *Pulmonary Disease, Chronic Obstructive/therapy/diagnosis/epidemiology/physiopathology MH - Risk Assessment MH - Risk Factors MH - *Risk Management/standards MH - Treatment Outcome MH - Practice Guidelines as Topic PMC - PMC13047776 OTO - NOTNLM OT - cardiovascular diseases OT - chronic obstructive pulmonary disease OT - comorbidity OT - exacerbations OT - patient discharge OT - practice guidelines COIS- NM reports participation in advisory boards for AstraZeneca, fees paid to her institution, non-financial support from AstraZeneca and Chiesi for conference attendance; and a research grant from Sanofi paid to her institution. FD reports consulting fees and/or honoraria for lectures and for consultancy/advisory board from Amgen, Astra-Zeneca, Daiichi-Sankyo, Johnson & Johnson, MSD, Novartis, NovoNordisk, Roche, Sanofi, Servier, and Viatris. JG reports within 36 months grants from Win2Wall (SPW Wallonia), BioWin (SPW Wallonia), La Foundation Leon Fredericq, Le fonds d'investissement pour la recherche scientifique (CHU Liege), Le service public federal (SPF) Belgium, Roche, Chiesi, Janssen, AstraZeneca, Daiichi-Sankyo, MSD, SMB, Boehringer Ingelheim (BI), GSK paid to his institution (Uliege / Chuliege). Personal fees for advisory board, work and lectures from BI, Janssen, SMB, BMS, GSK, Roche, AstraZeneca, Volition, Kinevant science, Exobiologics, Daiichi-Sankyo and Chiesi, non-financial support for meeting attendance from AstraZeneca, Chiesi, MSD, Roche, Boehringer Ingelheim and Janssen. He is co-inventor of one issued patent on exosomes-based biomarkers and on radiomics licensed to Radiomics (Oncoradiomics SA). SanderT reports travel grants and speaker fees from NovoNordisk, Novartis, AstraZeneca, Boehringer Ingelheim, Biotronik, Bayer, Servier, Menarini, Daiichi Sankyo, and Bristol Myers Squibb. MJEGWV reports receiving consulting fees from Chiesi and AstraZeneca, and payments for lectures from GSK, Pfizer, and AstraZeneca.MV received travel support for attending meetings from AstraZeneca and Chiesi. LL reports consulting fees for AstraZeneca, GSK, and Sanofi; honoraria for lectures for IPSA vzw, Domus Medica vzw, Chiesi, and Johnson & Johnson Services, Inc; travel support from AstraZeneca (GRLF meetings) and Menarini. JR received consultancy or lecturing fees from Roche, AstraZeneca, Janssen, Merck, Pfizer, MSD, BMS and GSK, outside the submitted work. DC reports participation in advisory boards for AstraZeneca, Sanofi, and Chiesi, and speaker fees from the same companies; he is also the founder of Aquilon Pharmaceuticals. TL reports research support from Genentech and Chiesi; participation in advisory boards for AstraZeneca, Chiesi, Sanofi, and GSK; support for attending meetings and/or travel from AstraZeneca and Sanofi; and received payment or honoraria for lectures, presentations, manuscript writing, or educational events from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Novartis, Sanofi, Genentech, and Roche. EM reports research grants from Chiesi Belgium, consulting fees from Sanofi Belgium, Astra Zeneca Belgium, honoraria for lectures from Astra Zeneca Belgium, Chiesi Belgium, GSK Belgium, payment for expert testimony from Chiesi Belgium and GSK Belgium, support for attending scientific meetings from Astra Zeneca Belgium and Chiesi Belgium. Mathias L received fees for presentations from AstraZeneca. WJ received grants or contracts from Chiesi and GSK, consulting fees from Chiesi, GSK, Sanofi, Roche and AstraZeneca, and support for attending meetings from AstraZeneca and Chiesi. WJ was co-founder and board member of ArtiQ (2019-2024). MB reports institutional grants or contracts from AstraZeneca, Chiesi, and GSK; consulting fees from Pfizer, Sanofi, GSK, and MSD; honoraria for lectures or educational events from AstraZeneca, GSK, and Chiesi; travel support from AstraZeneca, Sanofi, and Chiesi; and has served on advisory boards for GSK, AstraZeneca, and Chiesi. LEGWV received fees for advisory board, consulting and/or lecturing from AstraZeneca, GSK, Chiesi, Sanofi, Boehringer Ingelheim, Novartis, Grifols and PulmonX, outside the submitted work. EV reports participation in advisory boards for AstraZeneca, Chiesi, GSK, Sanofi, fees paid to her institution, non-financial support from AstraZeneca, Chiesi and Sanofi for conference attendance. She has received travel grants from GSK. PG received lecture fees from AstraZeneca, GSK, Chiesi, CSL Behring, Insmed, and Pfizer. He has served on advisory boards for AstraZeneca, Pfizer, MSD, and Insmed. He has also received non-financial support from AstraZeneca to attend conferences. StefanT reports personal fees to his organization from MSD, Novo Nordisk, Astra Zeneca, Chiesi, GSK, Novartis, Sandoz, Viatris, Lilly, Theramex, Kenvue, Sanofi, and CSL Vifor. Through his role at Domus Medica, he provides advice to partner companies, including AstraZeneca, and has participated in several advisory boards. Muriel L reports research grants from GSK, Sanofi, Chiesi, AstraZeneca, Roche, Johnson & Johnson, Biophytis, Bayer, MSD, Insmed, Abbott, and Moderna; has served on advisory boards for AstraZeneca, GSK, Sanofi, Chiesi, Novartis, Biophytis, and Oxypoint; and has received honoraria for lectures from GSK, AstraZeneca, Boehringer Ingelheim, Chiesi, ALK, Pfizer, Nyxoah, Novartis, and Sanofi. IVR received speaker fees from AstraZeneca, Chiesi and GSK. RP received speaker fees and/or served as an advisory board member for AstraZeneca, Chiesi, GSK, MSD, and Sanofi. He has received travel grants from AstraZeneca, Chiesi, and Sanofi. The authors report no other conflicts of interest in this work. EDAT- 2026/04/06 12:35 MHDA- 2026/04/06 12:36 PMCR- 2026/01/13 CRDT- 2026/04/06 06:21 PHST- 2025/11/26 00:00 [received] PHST- 2026/01/09 00:00 [accepted] PHST- 2026/04/06 12:36 [medline] PHST- 2026/04/06 12:35 [pubmed] PHST- 2026/04/06 06:21 [entrez] PHST- 2026/01/13 00:00 [pmc-release] AID - 578651 [pii] AID - 10.2147/COPD.S578651 [doi] PST - epublish SO - Int J Chron Obstruct Pulmon Dis. 2026 Jan 13;21:578651. doi: 10.2147/COPD.S578651. eCollection 2026. PMID- 41939102 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260406 LR - 20260813 IS - 2049-0801 (Print) IS - 2049-0801 (Electronic) IS - 2049-0801 (Linking) VI - 88 IP - 4 DP - 2026 Apr TI - Association between atrial fibrillation and gastrointestinal bleeding: pathophysiology, risk stratification, and management - a narrative review. PG - 2566-2573 LID - 10.1097/MS9.0000000000004806 [doi] AB - Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, significantly increasing the risk of thromboembolic events, necessitating anticoagulation therapy. However, anticoagulation, particularly with novel oral anticoagulants, elevates the risk of gastrointestinal bleeding (GIB), creating a clinical dilemma in managing AF patients. This narrative review explores the pathophysiology linking AF and GIB, emphasizing the hypercoagulable state in AF and the mucosal damage caused by anticoagulants. Epidemiological data reveal that GIB incidence in AF patients ranges from 1.32% to 5.4% annually, with risk factors including older age, prior GIB, and concomitant antiplatelet use. Risk stratification tools such as CHA(2)DS(2)-VASc and HAS-BLED aid in balancing thromboembolic and bleeding risks, though their predictive performance remains modest. Comparative studies highlight that rivaroxaban carries a higher GIB risk, while apixaban offers a safer profile. Management strategies include proton pump inhibitors for prophylaxis, endoscopic interventions for acute bleeding, and individualized decisions on resuming anticoagulation post-GIB, typically within 7-30 days. Emerging research on the gut microbiome's role in AF pathogenesis suggests potential novel therapeutic avenues. A multidisciplinary approach involving cardiologists, gastroenterologists, and hematologists is essential to optimize outcomes. Future directions include developing safer anticoagulants, refining risk prediction models, and exploring microbiome-targeted therapies. CI - Copyright (c) 2026 The Author(s). Published by Wolters Kluwer Health, Inc. FAU - Mohan, Anmol AU - Mohan A AD - Department of Internal Medicine, Carle Foundation Hospital, Urbana, IL, USA. FAU - Sultany, Abdullah AU - Sultany A AD - Department of Medicine, Robert Packer Hospital/Guthrie, PA, USA. FAU - Fatima, Syeda Bisma AU - Fatima SB AD - Department of Internal Medicine, Karachi Medical and Dental College, Karachi, Pakistan. FAU - Hasan, Zim Warda AU - Hasan ZW AD - Department of Internal Medicine, Clinical and Translational Science, School of Medicine, West Virginia University, Morgantown, WV, USA. FAU - Butt, Muhammad Danish AU - Butt MD AD - Department of Internal Medicine, CMH Lahore Medical College, Lahore, Pakistan. FAU - Alkhazender, Aliaa H J AU - Alkhazender AHJ AD - Department of Internal Medicine, The Islamic University of Gaza, Gaza, Palestine. FAU - Lal, Priyanka Mohan AU - Lal PM AD - Department of Internal Medicine, Ziauddin University, Karachi, Pakistan. FAU - Aminpoor, Hasibullah AU - Aminpoor H AUID- ORCID: 0000-0003-1817-7800 AD - Faculty of Medicine, Kabul University of Medical Sciences, Kabul, Afghanistan. FAU - Karimi, Hasiba AU - Karimi H AD - Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey. FAU - Kumar, Vikash AU - Kumar V AUID- ORCID: 0000-0002-0058-2421 AD - Department of Gastroenterology, The Brooklyn Hospital Center, Brooklyn, New York, USA. FAU - Tejwaney, Usha AU - Tejwaney U AUID- ORCID: 0000-0001-5645-1861 AD - Department of Internal Oncology, Valley Health System, Ridgewood, New Jersey, USA. FAU - Kumar, Sarwan AU - Kumar S AD - Department of Internal Medicine, Wayne State University, Detroit, Michigan, USA. LA - eng PT - Journal Article PT - Review DEP - 20260303 PL - England TA - Ann Med Surg (Lond) JT - Annals of medicine and surgery (2012) JID - 101616869 PMC - PMC13048643 OTO - NOTNLM OT - anticoagulation OT - atrial fibrillation OT - gastrointestinal bleeding OT - multidisciplinary management COIS- Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article. The authors declare no conflicts of interest. EDAT- 2026/04/06 12:36 MHDA- 2026/04/06 12:37 PMCR- 2026/03/03 CRDT- 2026/04/06 06:15 PHST- 2025/04/03 00:00 [received] PHST- 2025/12/25 00:00 [accepted] PHST- 2026/04/06 12:37 [medline] PHST- 2026/04/06 12:36 [pubmed] PHST- 2026/04/06 06:15 [entrez] PHST- 2026/03/03 00:00 [pmc-release] AID - AMSU-D-25-00721 [pii] AID - 10.1097/MS9.0000000000004806 [doi] PST - epublish SO - Ann Med Surg (Lond). 2026 Mar 3;88(4):2566-2573. doi: 10.1097/MS9.0000000000004806. eCollection 2026 Apr. PMID- 41939008 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260406 LR - 20260813 IS - 2051-3380 (Print) IS - 2051-3380 (Electronic) IS - 2051-3380 (Linking) VI - 14 IP - 4 DP - 2026 Apr TI - Aortic Valve Endocarditis Caused by Streptococcus acidominimus Following Community-Acquired Pneumonia in a Patient With Diabetes Mellitus: A Case Report. PG - e70563 LID - 10.1002/rcr2.70563 [doi] LID - e70563 AB - Infective endocarditis (IE) due to Streptococcus acidominimus is exceedingly rare and poses diagnostic and therapeutic challenges. Traditionally regarded as an animal commensal, this organism is increasingly recognised as a cause of invasive human infections, especially in immunocompromised patients. We report a 40-year-old Cambodian man with diabetes mellitus who presented with persistent fever initially managed as community-acquired pneumonia. Blood cultures later grew S. acidominimus, and he was discharged on oral antibiotics after transient improvement. He was readmitted with recurrent fever, and transesophageal echocardiography revealed aortic valve vegetations with severe regurgitation. The patient received targeted intravenous antibiotics and underwent successful aortic valve replacement, achieving full recovery after six weeks of therapy. This case underscores the need to consider rare pathogens in persistent bacteraemia, repeat cardiac imaging when suspicion remains high despite inconclusive findings, and adopt a multidisciplinary approach to optimise outcomes, particularly in diabetic patients and resource-limited settings. CI - (c) 2026 The Author(s). Respirology Case Reports published by John Wiley & Sons Australia, Ltd on behalf of The Asian Pacific Society of Respirology. FAU - Heng, Menghak AU - Heng M AUID- ORCID: 0009-0009-5155-6563 AD - Pulmonology Unit, Medical Ward "A" Calmette Hospital Phnom Penh Cambodia. AD - Faculty of Medicine University of Health Sciences Phnom Penh Cambodia. FAU - Chheang, Chhayhout AU - Chheang C AD - Faculty of Medicine University of Health Sciences Phnom Penh Cambodia. FAU - Chit, Sophou AU - Chit S AD - Faculty of Medicine University of Health Sciences Phnom Penh Cambodia. FAU - Ton, Kimhun AU - Ton K AD - Faculty of Medicine University of Health Sciences Phnom Penh Cambodia. AD - Outpatient Department Calmette Hospital Phnom Penh Cambodia. FAU - Saint, Saly AU - Saint S AD - Faculty of Medicine University of Health Sciences Phnom Penh Cambodia. FAU - Uy, Sopha AU - Uy S AD - Obstetrics & Gynecology Department Calmette Hospital Phnom Penh Cambodia. FAU - Cheng, Ing AU - Cheng I AUID- ORCID: 0009-0000-4187-0246 AD - Faculty of Medicine University of Health Sciences Phnom Penh Cambodia. AD - Neurosurgery Department Calmette Hospital Phnom Penh Cambodia. FAU - Try, Thy AU - Try T AD - Faculty of Medicine University of Health Sciences Phnom Penh Cambodia. AD - Neurosurgery Department Calmette Hospital Phnom Penh Cambodia. FAU - Ean, Sarin AU - Ean S AD - Pediatric Department Jayavarman VII Hospital Siem Reap Cambodia. FAU - Khor, Chheang AU - Khor C AD - Faculty of Medicine University of Health Sciences Phnom Penh Cambodia. AD - Anesthesiology Department Luang Me Hospital Phnom Penh Cambodia. FAU - Hem, Borin AU - Hem B AD - Obstetrics & Gynecology Department Calmette Hospital Phnom Penh Cambodia. FAU - Srey, Vibopha AU - Srey V AD - ICU "B" Department Calmette Hospital Phnom Penh Cambodia. FAU - Phy, Sopheak AU - Phy S AD - ICU "A" Department Calmette Hospital Phnom Penh Cambodia. FAU - Leang, Heng AU - Leang H AD - Faculty of Medicine University of Health Sciences Phnom Penh Cambodia. AD - Medical Imaging Department Calmette Hospital Phnom Penh Cambodia. FAU - Chhar, Bunpaul AU - Chhar B AD - Pulmonology Unit, Medical Ward "A" Calmette Hospital Phnom Penh Cambodia. AD - Faculty of Medicine University of Health Sciences Phnom Penh Cambodia. LA - eng PT - Journal Article DEP - 20260402 PL - United States TA - Respirol Case Rep JT - Respirology case reports JID - 101631052 PMC - PMC13045215 OTO - NOTNLM OT - Streptococcus acidominimus OT - antibiotic OT - aortic valve OT - community-acquired pneumonia OT - endocarditis COIS- The authors declare no conflicts of interest. EDAT- 2026/04/06 12:36 MHDA- 2026/04/06 12:37 PMCR- 2026/04/02 CRDT- 2026/04/06 06:15 PHST- 2026/02/18 00:00 [received] PHST- 2026/03/02 00:00 [revised] PHST- 2026/03/11 00:00 [accepted] PHST- 2026/04/06 12:37 [medline] PHST- 2026/04/06 12:36 [pubmed] PHST- 2026/04/06 06:15 [entrez] PHST- 2026/04/02 00:00 [pmc-release] AID - RCR270563 [pii] AID - 10.1002/rcr2.70563 [doi] PST - epublish SO - Respirol Case Rep. 2026 Apr 2;14(4):e70563. doi: 10.1002/rcr2.70563. eCollection 2026 Apr. PMID- 41937648 OWN - NLM STAT- MEDLINE DCOM- 20260714 LR - 20260714 IS - 1557-055X (Electronic) IS - 1557-0541 (Linking) VI - 20 IP - 1 DP - 2026 TI - Developing an Interdisciplinary Community Action Team for Reduction in Maternal Mortality Related to Cardiovascular Disease. PG - 77-84 LID - 10.1353/cpr.2026.a987074 [doi] AB - BACKGROUND: Pregnancy-associated deaths involving cardiovascular disease (CVD) often occur beyond six weeks postpartum and are associated with delayed recognition. OBJECTIVES: We report on a community-informed approach to create an issue-specific community action team (CAT), which selected and tailored an intervention for CVD in pregnancy and postpartum. METHODS: City-based maternal mortality review committee data on pregnancy-associated deaths involving CVD was leveraged to build an issue-specific CAT. RESULTS: Maternal mortality review committee data highlighted the high frequency of cardiac-related symptoms as well as hospital-based evaluations among individuals during the year before death. The CAT identified and optimized a quality improvement intervention for CVD screening in pregnancy and postpartum. This process integrated feedback from stakeholders from multiple care settings across the city and created a foundation for rapid citywide dissemination of the revised algorithm and supplementary materials. CONCLUSIONS: CATs may be an effective organizational strategy to center community perspectives and build partnerships for intervention development to address pregnancy-associated mortality. FAU - Kumar, Natasha R AU - Kumar NR FAU - Davis, Imani AU - Davis I FAU - Kamarajugadda, Sneha AU - Kamarajugadda S FAU - Levine, Lisa AU - Levine L FAU - Mehta, Aasta AU - Mehta A LA - eng PT - Journal Article PL - United States TA - Prog Community Health Partnersh JT - Progress in community health partnerships : research, education, and action JID - 101273946 SB - IM MH - Humans MH - Female MH - Pregnancy MH - *Maternal Mortality MH - *Cardiovascular Diseases/mortality/prevention & control MH - *Community-Based Participatory Research/organization & administration MH - *Pregnancy Complications, Cardiovascular/mortality/prevention & control MH - Quality Improvement EDAT- 2026/04/06 06:30 MHDA- 2026/04/06 06:31 CRDT- 2026/04/06 05:03 PHST- 2026/04/06 06:31 [medline] PHST- 2026/04/06 06:30 [pubmed] PHST- 2026/04/06 05:03 [entrez] AID - S1557055X26100126 [pii] AID - 10.1353/cpr.2026.a987074 [doi] PST - ppublish SO - Prog Community Health Partnersh. 2026;20(1):77-84. doi: 10.1353/cpr.2026.a987074. PMID- 41937005 OWN - NLM STAT- MEDLINE DCOM- 20260714 LR - 20260714 IS - 1535-6280 (Electronic) IS - 0146-2806 (Linking) VI - 51 IP - 8 DP - 2026 Aug TI - Multidimensional care in transthyretin cardiac amyloidosis: Integrating extracardiac organ involvement and comorbidity management. PG - 103338 LID - S0146-2806(26)00080-0 [pii] LID - 10.1016/j.cpcardiol.2026.103338 [doi] AB - BACKGROUND: Transthyretin amyloidosis (ATTR) is a progressive multisystem disorder caused by extracellular deposition of amyloid fibrils derived from mutant (hATTR) or wild-type (ATTRwt) transthyretin. Cardiac involvement is the main determinant of prognosis and typically manifests as restrictive cardiomyopathy (ATTR-CM), leading to heart failure, arrhythmias, and conduction disturbances. However, ATTR frequently extends beyond the heart, involving peripheral and autonomic neuropathy, renal impairment, gastrointestinal dysfunction, musculoskeletal manifestations, anemia, nutritional decline, and frailty, all of which significantly contribute to clinical complexity, poorer outcomes, and reduced quality of life. AIM: To highlight the clinical relevance of extracardiac organ involvement in ATTR-CM and to support a multidimensional, patient-centered approach to care. EVIDENCE SYNTHESIS / MAIN FINDINGS: The effectiveness of disease-modifying therapies is maximized when incorporated into a comprehensive care model that balances therapeutic benefit with treatment tolerance and addresses both amyloid-related systemic organ damage and coexisting cardiac and extracardiac comorbidities. Optimal management therefore requires a coordinated multidisciplinary team including cardiology, neurology, nephrology, pulmonology, nutrition, geriatrics, psychology, rehabilitation, and social support services. CONCLUSIONS: A comprehensive strategy integrating early diagnosis, systematic assessment of organ damage, frailty evaluation, and individualized therapeutic planning is essential to improve outcomes and deliver holistic, high-quality care for individuals with ATTR-CM. This review synthesizes current evidence on diagnosis and management of ATTR-CM and proposes a structured framework for evaluating and treating systemic complications associated with transthyretin amyloid disease. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Magnano, Roberta AU - Magnano R AD - Cardiology and ICCU Department, Santo Spirito Hospital 65124 Pescara, Italy. Electronic address: roberta.magnano@asl.pe.it. FAU - Rossi, Davide AU - Rossi D AD - Cardiology and ICCU Department, Santo Spirito Hospital 65124 Pescara, Italy. Electronic address: davide.rossi@asl.pe.it. FAU - Saraullo, Silvio AU - Saraullo S AD - Cardiology and ICCU Department, Santo Spirito Hospital 65124 Pescara, Italy. Electronic address: silvio.saraullo@studenti.unich.it. FAU - Pezzi, Laura AU - Pezzi L AD - Cardiology and ICCU Department, Santo Spirito Hospital 65124 Pescara, Italy. Electronic address: laura.pezzi@asl.pe.it. FAU - D'Alleva, Alberto AU - D'Alleva A AD - Cardiology and ICCU Department, Santo Spirito Hospital 65124 Pescara, Italy. Electronic address: alberto.dalleva@asl.pe.it. FAU - Scollo, Claudio AU - Scollo C AD - Cardiology and ICCU Department, Santo Spirito Hospital 65124 Pescara, Italy. Electronic address: claudio.scollo@asl.pe.it. FAU - Marino, Mario Di AU - Marino MD AD - Cardiology and ICCU Department, Santo Spirito Hospital 65124 Pescara, Italy. Electronic address: mario.dimarino@asl.pe.it. FAU - Genovesi, Eugenio AU - Genovesi E AD - Cardiology and ICCU Department, Santo Spirito Hospital 65124 Pescara, Italy. Electronic address: eugenio.genovesi@asl.pe.it. FAU - Vitulli, Piergiusto AU - Vitulli P AD - Cardiology and ICCU Department, Santo Spirito Hospital 65124 Pescara, Italy. Electronic address: piergiusto.vitulli@asl.pe.it. FAU - Fortuni, Federico AU - Fortuni F AD - Cardiology and Cardiovascular Pathophysiology, S. Maria della Misericordia Hospital, University of Perugia 06129, Italy. FAU - Forlani, Daniele AU - Forlani D AD - Cardiology and ICCU Department, Santo Spirito Hospital 65124 Pescara, Italy. Electronic address: daniele.forlani@asl.pe.it. FAU - Marco, Massimo Di AU - Marco MD AD - Cardiology and ICCU Department, Santo Spirito Hospital 65124 Pescara, Italy. Electronic address: massimo.dimarco@asl.pe.it. LA - eng PT - Journal Article PT - Review DEP - 20260403 PL - Netherlands TA - Curr Probl Cardiol JT - Current problems in cardiology JID - 7701802 RN - Amyloidosis, Hereditary, Transthyretin-Related SB - IM MH - Humans MH - *Amyloid Neuropathies, Familial/therapy/complications/diagnosis/epidemiology MH - Comorbidity MH - *Cardiomyopathies/therapy/diagnosis/epidemiology/etiology MH - *Disease Management OTO - NOTNLM OT - ATTR-CM OT - Comorbidities OT - Gene-silencing therapies OT - TTR stabilizers OT - Transthyretin cardiac amyloidosis OT - frailty COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/04/06 00:31 MHDA- 2026/05/13 00:29 CRDT- 2026/04/05 23:20 PHST- 2026/03/25 00:00 [received] PHST- 2026/04/02 00:00 [accepted] PHST- 2026/05/13 00:29 [medline] PHST- 2026/04/06 00:31 [pubmed] PHST- 2026/04/05 23:20 [entrez] AID - S0146-2806(26)00080-0 [pii] AID - 10.1016/j.cpcardiol.2026.103338 [doi] PST - ppublish SO - Curr Probl Cardiol. 2026 Aug;51(8):103338. doi: 10.1016/j.cpcardiol.2026.103338. Epub 2026 Apr 3. PMID- 41936368 OWN - NLM STAT- MEDLINE DCOM- 20260405 LR - 20260924 IS - 1474-547X (Electronic) IS - 0140-6736 (Linking) VI - 407 IP - 10536 DP - 2026 Apr 4 TI - Percutaneous coronary intervention versus coronary artery bypass grafting for unprotected left main stenosis: 10-year final results from the randomised, open-label, non-inferiority NOBLE trial. PG - 1374-1382 LID - S0140-6736(26)00205-9 [pii] LID - 10.1016/S0140-6736(26)00205-9 [doi] AB - BACKGROUND: Coronary artery bypass grafting (CABG) is recommended over percutaneous coronary intervention (PCI) for patients with significant unprotected left main coronary artery disease. We aim to provide long-term outcome data comparing PCI with newer generation drug-eluting stents and CABG, which are scarce. METHODS: This previously published, prospective, randomised, open-label, non-inferiority trial enrolled patients with unprotected left main coronary artery stenosis at 36 hospitals in Denmark, Estonia, Finland, Germany, Latvia, Lithuania, Norway, Sweden, and the UK. Eligibility was determined by a multidisciplinary heart team and defined by clinical criteria (chronic or acute coronary syndrome and a life expectancy of >1 year) and angiographic criteria (left main coronary artery diameter stenosis >/=50% or fractional flow reserve /=80% agreement among the physicians. RESULTS: The importance of a multimodal approach to screening and early detection of PAH through combining echocardiography, biomarker tests and symptom evaluation was emphasised. Consensus agreement was also reached on the usefulness and increased access of echocardiography for optimising screening and early detection processes, noting the importance of cardiology expertise for accurate assessment of right-heart variables. Panellists reached consensus agreement on the importance of a multidisciplinary approach to managing SSc- and other CTD-PAHs through collaboration between rheumatologists and pulmonary hypertension (PH) specialists, NPs and patients. Rheumatologists aligned on the usefulness of the DETECT screening algorithm, whereas cardiologists and pulmonologists remained divided, with consensus not being reached, thus highlighting the lack of agreement regarding the relevance of a stepwise approach. Similarly, no consensus was reached on the impact of the new haemodynamic definition of PH in CTD-PAH management, where greater evidence is required. CONCLUSIONS: Consensus was reached on key recommendations for optimising CTD-PAH management, including the standardisation of multimodal screening and promotion of closer collaboration between healthcare specialties and patients. CI - (c) The Author(s) 2026. Published by Oxford University Press on behalf of the British Society for Rheumatology. FAU - Del Galdo, Francesco AU - Del Galdo F AUID- ORCID: 0000-0002-8528-2283 AD - Leeds Institute of Rheumatic and Musculoskeletal Medicine, and NIHR Biomedical Research Centre, University of Leeds, Leeds, UK. FAU - Coghlan, John Gerry AU - Coghlan JG AD - Pulmonary Artery Hypertension Centre, Royal Free Hospital, London, UK. FAU - Gaine, Sean AU - Gaine S AD - Respiratory Unit, Mater Misericordiae University Hospital, Dublin, Ireland. FAU - de Miguel, Irene Martin AU - de Miguel IM AD - Pulmonary Hypertension Multidisciplinary Unit, Cardiology Department, University Hospital 12 de Octubre, Madrid, Spain. AD - CIBERCV, Madrid, Spain. FAU - Smith, Vanessa AU - Smith V AUID- ORCID: 0000-0001-6271-7945 AD - Department of Internal Medicine, Ghent University, Ghent, Belgium. AD - Department of Rheumatology, Ghent University Hospital, Ghent, Belgium. FAU - Giuggioli, Dilia AU - Giuggioli D AUID- ORCID: 0000-0002-0041-3695 AD - University of Modena and Reggio Emilia, Emilia-Romagna, UNIMORE, Modena, Italy. FAU - Perry, Richard AU - Perry R AUID- ORCID: 0000-0001-8790-3170 AD - Adelphi Values PROVE, Bollington, UK. FAU - Grunig, Ekkehard AU - Grunig E AUID- ORCID: 0000-0001-7318-3918 AD - Centre for Pulmonary Hypertension, Thoraxklinik-Heidelberg at Heidelberg University Hospital, Heidelberg, Germany. LA - eng PT - Journal Article DEP - 20260114 PL - England TA - Rheumatol Adv Pract JT - Rheumatology advances in practice JID - 101736676 PMC - PMC13006206 OTO - NOTNLM OT - connective tissue disease OT - consensus OT - management OT - pulmonary arterial hypertension OT - systemic sclerosis EDAT- 2026/03/25 07:09 MHDA- 2026/03/25 07:10 PMCR- 2026/01/14 CRDT- 2026/03/25 04:32 PHST- 2025/08/26 00:00 [received] PHST- 2025/12/07 00:00 [accepted] PHST- 2026/03/25 07:10 [medline] PHST- 2026/03/25 07:09 [pubmed] PHST- 2026/03/25 04:32 [entrez] PHST- 2026/01/14 00:00 [pmc-release] AID - rkag003 [pii] AID - 10.1093/rap/rkag003 [doi] PST - epublish SO - Rheumatol Adv Pract. 2026 Jan 14;10(2):rkag003. doi: 10.1093/rap/rkag003. eCollection 2026. PMID- 41876324 OWN - NLM STAT- MEDLINE DCOM- 20260713 LR - 20260813 IS - 1875-2128 (Electronic) IS - 1875-2128 (Linking) VI - 119 IP - 5 DP - 2026 May TI - Experts' recommendations for the management of adult patients with cardiogenic shock. PG - 370-389 LID - S1875-2136(26)00051-3 [pii] LID - 10.1016/j.acvd.2026.02.001 [doi] AB - The last specific international European recommendations regarding the management of cardiogenic shock (CS) regardless of the etiology were issued over 10years ago. We present herein recommendations for the management of CS in adults, developed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system by an expert group of from the French Intensive Care Society [Societe de reanimation de langue francaise (SRLF)] and the French Society of Cardiology [Societe francaise de cardiologie (SFC)], with the participation of the French Society of Anesthesia and Intensive Care [Societe francaise d'anesthesie et de reanimation (SFAR)], and the French Society of Thoracic and Cardiovascular Surgery [Societe francaise de chirurgie thoracique et cardio-vasculaire (SFCTCV)]. The recommendations covered six fields of application: CS teams and expert centers, symptomatic medical management, etiological management, organ support, temporary circulatory support and de-escalation and early post-CS management. Twenty-three "Patient Intervention Comparator Outcome" (PICO) questions were identified, leading to 41 recommendations regarding management of CS in adult patients. Seven recommendations were scored with high level of evidence (Grade 1), 11 with moderate level of evidence (Grade 2) and 17 with low level of evidence (Expert opinion). In 6 cases, the experts were not able to give an answer. All of the recommendations obtained strong agreement from the expert committee. The experts highlight the fact that optimal management of CS requires organization including a structured, multidisciplinary shock team and regional referral network, applying standardized protocols for diagnosis and staging. Early etiological treatment-such as culprit-lesion revascularization or urgent valve intervention-is central to improve outcomes. Hemodynamic support should prioritize norepinephrine as first-line vasopressor and privilege selective inotrope use. Temporary mechanical circulatory support (Impella, VA-ECMO) should be reserved for carefully selected patients following discussion by the expert team. CI - Copyright (c) 2026 The Author(s). Published by Elsevier Masson SAS.. All rights reserved. FAU - Aissaoui, Nadia AU - Aissaoui N AD - Intensive Cardiac Care Unit, Cardiology department, Hopital europeen Georges-Pompidou, Assistance publique des Hopitaux de Paris, Universite Paris Cite, Paris, France. Electronic address: Nadia.aissaoui@aphp.fr. FAU - Delmas, Clement AU - Delmas C AD - Intensive Cardiac Care Unit, Cardiology Department, Toulouse University Hospital, Toulouse University, Inserm, UMR 1297, Institut des Maladies Metaboliques et Cardiovasculaires (I2MC), Toulouse, France; REICATRA, Institut Saint-Jacques, Toulouse, France. FAU - Merdji, Hamid AU - Merdji H AD - Department of Medical Intensive Care, University Hospital of Strasbourg, Nouvel Hopital Civil, Inserm (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, Strasbourg, France. FAU - Schurtz, Guillaume AU - Schurtz G AD - Cardiac Intensive Care Unit, Institut Coeur Poumon, CHU de Lille, Lille, France. FAU - Baudry, Guillaume AU - Baudry G AD - Universite de Lorraine, Inserm, Centre d'Investigation Clinique Plurithematique 1433, Inserm U1116, CHRU de Nancy, Nancy, France; INI-CRCT (Cardiovascular and Renal Clinical Trialists) F-CRIN Network, REICATRA, Nancy, France. FAU - Beurton, Antoine AU - Beurton A AD - Department of Cardiovascular Anesthesia and Critical Care, CHU de Bordeaux, 33000 Bordeaux, France; Universite de Bordeaux, Inserm, BMC, U1034, 33600 Pessac, France. FAU - Boissier, Florence AU - Boissier F AD - CHU de Poitiers, Medecine Intensive-Reanimation, Poitiers, France; Inserm, Centre d'investigation Clinique (CIC) 14-02 IS-ALIVE, Universite de Poitiers, 86000 Poitiers, France. FAU - Bonello, Laurent AU - Bonello L AD - Unite de soins intensifs de cardiologie, Hopital nord de Marseille, Aix-Marseille universite, 13015 Marseille, France. FAU - Cholley, Bernard AU - Cholley B AD - Service d'Anesthesie-Reanimation & Medecine Peri-Operatoire, Hopital europeen Georges-Pompidou, AP-HP, Paris, France; Inserm UMR-S1140, Universite Paris Cite, Paris, France. FAU - Combaret, Nicolas AU - Combaret N AD - Universite de Lorraine, Inserm, Centre d'Investigation Clinique Plurithematique 1433, Inserm U1116, CHRU de Nancy, Nancy, France; INI-CRCT (Cardiovascular and Renal Clinical Trialists) F-CRIN Network, REICATRA, Nancy, France. FAU - Combes, Alain AU - Combes A AD - Sorbonne Universite, Inserm, UMRS_1166-ICAN, Institute of Cardiometabolism and Nutrition, AP-HP, Service de medecine intensive-reanimation, Institut de Cardiologie, Hopital Pitie-Salpetriere, Paris, France. FAU - David, Charles-Henri AU - David CH AD - Nantes Universite, CHU de Nantes, chirurgie thoracique et cardiovasculaire, l'institut du thorax, 44000 Nantes, France. FAU - De Backer, Daniel AU - De Backer D AD - Department of Intensive Care, CHIREC Hospitals, Universite Libre de Bruxelles, Brussels, Belgium. FAU - Guinot, Pierre Gregoire AU - Guinot PG AD - Department of Anesthesiology and Intensive Care, Dijon University Hospital, University of Burgundy Europe, LNC UMR1231, 21000 Dijon, France. FAU - Hamzaoui, Olfa AU - Hamzaoui O AD - CHU de Reims, Unite de Medecine Intensive et Reanimation Polyvalente, Universite de Reims Champagne-Ardenne, UR 3801 PPF, Reims, France. FAU - Harbaoui, Brahim AU - Harbaoui B AD - Interventional Cardiology Department, Hopital Croix-Rousse, Hopital Louis-Pradel, Hospices Civils de Lyon, Lyon, France; University of Lyon, CREATIS UMR5220, Inserm U1044, INSA-15, Lyon, France. FAU - Imbault, Julien AU - Imbault J AD - Department of Cardiovascular Anesthesia and Critical Care, CHU de Bordeaux, 33000 Bordeaux, France; Universite de Bordeaux, Inserm, BMC, U1034, 33600 Pessac, France. FAU - Nesseler, Nicolas AU - Nesseler N AD - Department of Anesthesia and Critical Care, Pontchaillou, University Hospital of Rennes, Universite de Rennes, CHU de Rennes, Inserm, CIC 1414 (Centre d'Investigation Clinique de Rennes), Inrae, Institut NUMECAN - UMR_A 1341, UMR_S 1241, FHU SUPORT, 35000 Rennes, France. FAU - Kimmoun, Antoine AU - Kimmoun A AD - Universite de Lorraine, CHRU de Nancy, Service de medecine intensive et reanimation Brabois, U1116, F-CRIN INI-CRCT, Nancy, France. FAU - Kindo, Michel AU - Kindo M AD - Department of Cardiac Surgery, Hopitaux Universitaires de Strasbourg, Nouvel Hopital Civil, Strasbourg, France. FAU - Lebreton, Guillaume AU - Lebreton G AD - Sorbonne Universite, AP-HP, Service de chrirugie cardiaque, Institut de Cardiologie, Hopital Pitie-Salpetriere, Paris, France. FAU - Leurent, Guillaume AU - Leurent G AD - Department of Cardiology, Universite Rennes 1, CHU de Rennes, Inserm, LTSI, UMR 1099, Rennes, France. FAU - Levy, Bruno AU - Levy B AD - Institut du Coeur et des Vaisseaux, CHU Nancy-Brabois, Groupe Choc, equipe 2, Inserm U1116, Faculte de Medecine, Nancy, France. FAU - Manzo-Silberman, Stephane AU - Manzo-Silberman S AD - AP-HP, Cardiology Department, Cardiology Institut, Hopital Pitie-Salpetriere, Paris, France; Sorbonne University, Inserm, UMRS_1166-ICAN, ACTION Study Group, Paris, France. FAU - Martin, Anne-Celine AU - Martin AC AD - Division of Cardiology, Advanced Heart Failure Unit, AP-HP, Hopital europeen Georges-Pompidou, 75015 Paris, France; Universite Paris Cite, Inserm, PARCC, 75015 Paris, France. FAU - Mekontso-Dessap, Armand AU - Mekontso-Dessap A AD - AP-HP, Hopitaux Universitaires Henri-Mondor, Service de medecine intensive-reanimation, Universite Paris Est Creteil, Inserm, Institut Mondor, CARMAS, 94010 Creteil, France; Department of Cardiac Surgery, Louis-Pradel Hospital, Lyon, France. FAU - Adda, Imane AU - Adda I AD - Department of Research, One Clinic, PointGyn, Paris, France. FAU - Mootien, Joy AU - Mootien J AD - Unite Fonctionnelle de Conseil en Antibiotherapie, CHU de Mulhouse, Mulhouse, France. FAU - Ouattara, Alexandre AU - Ouattara A AD - Department of Cardiovascular Anesthesia and Critical Care, CHU de Bordeaux, Universite de Bordeaux, Inserm, BMC, U1034, Bordeaux, France. FAU - Pozzi, Matteo AU - Pozzi M AD - Department of Cardiac Surgery, Louis-Pradel Hospital, Hospices Civils de Lyon, Research on Healthcare Performance Reshape, Inserm U1290, Universite Claude-Bernard Lyon 1, Lyon, France. FAU - Puymirat, Etienne AU - Puymirat E AD - Assistance publique-Hopitaux de Paris (AP-HP), Hopital europeen Georges-Pompidou, Department of Cardiology, 75015 Paris, France; PARCC, Universite de Paris Cite, 75006 Paris, France. FAU - Roubille, Francois AU - Roubille F AD - PhyMedExp, Cardiology Department, Universite de Montpellier, Inserm, CNRS, INI-CRT, CHU de Montpellier, Montpellier, France. FAU - Trimaille, Antonin AU - Trimaille A AD - Department of Cardiovascular Medicine, Nouvel Hopital Civil, 2UR 3074, Translational Cardiovascular Medicine Biomedicine Research Centre of Strasbourg, University of Strasbourg, Strasbourg, France. FAU - Ughetto, Aurore AU - Ughetto A AD - Department of Cardiothoracic Anesthesia and Critical Care Medicine, Montpellier University Hospital, Montpellier, France. FAU - Van Belle, Eric AU - Van Belle E AD - Cardiac Intensive Care Unit, Institut Coeur Poumon, CHU de Lille, Lille, France. FAU - Bonnefoy, Eric AU - Bonnefoy E AD - Department of Cardiology, Louis-Pradel Hospital, Hospices Civils de Lyon, University of Lyon, INSA-Lyon, University Claude-Bernard Lyon 1, Lyon, France. FAU - Kuteifan, Khaldoun AU - Kuteifan K AD - Medical Intensive Care Unit, GHRMSA, Mulhouse, France. LA - eng PT - Journal Article PT - Practice Guideline PT - Review DEP - 20260323 PL - Netherlands TA - Arch Cardiovasc Dis JT - Archives of cardiovascular diseases JID - 101465655 SB - IM MH - Humans MH - *Shock, Cardiogenic/therapy/diagnosis/physiopathology/mortality MH - Treatment Outcome MH - Consensus MH - Adult MH - Risk Factors MH - Evidence-Based Medicine/standards MH - *Hemodynamics MH - Extracorporeal Membrane Oxygenation/standards OTO - NOTNLM OT - Cardiogenic shock OT - Guidelines OT - Heart team OT - Temporary circulatory support COIS- Disclosure of interest Aissaoui reports were provided by Public Assistance Hospitals Paris. Aissaoui reports a relationship with Public Assistance Hospitals Paris. Aissaoui has patent pending to NA. Given my previous role as associate editor in AOIC, I had no involvement in the peer review of this article and had no access to information regarding its peer review. Full responsibility for the editorial process for this article was delegated to another journal editor. CD received consulting and lecture fees from Abbott. DDB received fees for lectures and/or consulting from AOP Pharma, Edwards Lifesciences, Abbott, Pharmazz, Viatris. PGG received fees for lectures from AOP, Medtronic, Edwards and Vygon. PGG is consultant for ABBOT. EP received grants from Abbott, AstraZeneca, Bayer and fees and/or consulting from Abbott, Amarin, Amgen, AstraZeneca, Bayer, Bouchara-Recordati, Biotronik, BMS, Boehringer Ingelheim, Bracco, Daiichi-Sankyo, Lilly, MSD, Novartis, Novo, Organon, Pfizer, Sanofi, Servier, Sunpharm, Vifor Pharma. BC received research grants from Edwards Life Sciences and Orion Pharma, and consulting/lecturing fees from Edwards, AOP Health, Nordic Pharma, and Orion Pharma. The other authors declare that they have no competing interest. EDAT- 2026/03/25 01:05 MHDA- 2026/05/10 05:18 CRDT- 2026/03/24 22:52 PHST- 2026/01/09 00:00 [received] PHST- 2026/02/12 00:00 [revised] PHST- 2026/02/12 00:00 [accepted] PHST- 2026/05/10 05:18 [medline] PHST- 2026/03/25 01:05 [pubmed] PHST- 2026/03/24 22:52 [entrez] AID - S1875-2136(26)00051-3 [pii] AID - 10.1016/j.acvd.2026.02.001 [doi] PST - ppublish SO - Arch Cardiovasc Dis. 2026 May;119(5):370-389. doi: 10.1016/j.acvd.2026.02.001. Epub 2026 Mar 23. PMID- 41873893 OWN - NLM STAT- MEDLINE DCOM- 20260923 LR - 20260923 IS - 1551-3823 (Electronic) IS - 1551-3815 (Linking) VI - 45 IP - 3 DP - 2026 May-Jun TI - Retrospective Analysis of Morphological Anomalies in Fetuses from Spontaneous Abortions: A Clinical and Pathological Study. PG - 161-178 LID - 10.1080/15513815.2026.2647915 [doi] AB - BACKGROUND: Spontaneous abortion affects up to 30% of conceptions, andfetal anomalies are frequently an underlying cause. This study aimed to characterize morphological anomalies in spontaneous abortions to clarify underlying etiologies and related factors. METHODS: A retrospective cohort of 180 spontaneous abortions (10-23 + 6 weeks) was analyzed at a tertiary hospital. All cases underwent fetal autopsy with clinical, pathological, and genetic review. Cases with and without anomalies were compared. RESULTS: Fetal anomalies were found in 39.4% of cases. Morphological anomalies were most frequent (57.7%), particularly fetal growth restriction, cardiac defects, and complications of monochorionic twin pregnancies. Trisomies 21, 13 and 18 accounted for 54.6% of chromosomal anomalies. No significant associations were found with maternal factors. Gestational age at fetal loss was significantly lower in chromosomal than in morphological anomalies (p = 0.004). CONCLUSION: This study highlights the value of autopsy and multidisciplinary assessment in identifying fetal anomalies and improving diagnostic accuracy and reproductive counseling. FAU - Rodrigues, Iris Costa AU - Rodrigues IC AD - 6th year student of a master's degree in medicine at the Faculty of Medicine, University of Porto, Portugal. FAU - Guimaraes, Susana AU - Guimaraes S AD - Department of Pathology, Faculty of Medicine, University of Porto, Unidade Local de Saude de Sao Joao, Porto, Portugal. FAU - Doria, Sofia AU - Doria S AD - Department of Pathology, Genetics Unit, Faculty of Medicine, University of Porto, Rise-Health, Porto, Portugal. FAU - Ramalho, Carla AU - Ramalho C AUID- ORCID: 0000-0002-3977-3946 AD - Department of Gynecology, Obstetrics and Pediatrics, Faculty of Medicine, University of Porto, Unidade Local de Saude de Sao Joao, RISE-Health, Porto, Portugal. LA - eng PT - Journal Article DEP - 20260324 PL - England TA - Fetal Pediatr Pathol JT - Fetal and pediatric pathology JID - 101230972 SB - IM MH - Humans MH - Female MH - *Abortion, Spontaneous/pathology MH - Pregnancy MH - Retrospective Studies MH - *Fetus/pathology/abnormalities MH - Adult MH - Autopsy MH - Chromosome Aberrations MH - Gestational Age OTO - NOTNLM OT - Spontaneous abortion OT - chromosomal anomalies OT - fetal autopsy OT - genetic testing OT - morphological anomalies EDAT- 2026/03/24 12:36 MHDA- 2026/09/23 05:34 CRDT- 2026/03/24 08:22 PHST- 2026/09/23 05:34 [medline] PHST- 2026/03/24 12:36 [pubmed] PHST- 2026/03/24 08:22 [entrez] AID - 10.1080/15513815.2026.2647915 [doi] PST - ppublish SO - Fetal Pediatr Pathol. 2026 May-Jun;45(3):161-178. doi: 10.1080/15513815.2026.2647915. Epub 2026 Mar 24. PMID- 41873734 OWN - NLM STAT- MEDLINE DCOM- 20260713 LR - 20260908 IS - 1555-824X (Electronic) IS - 1062-8606 (Linking) VI - 41 IP - 3 DP - 2026 May-Jun 01 TI - An Algorithmic Framework for Reducing Near-Fatal Aspiration Events: A Single-Institution Experience. PG - 126-132 LID - 10.1097/JMQ.0000000000000291 [doi] AB - Aspiration-related cardiopulmonary arrests (CPAs) in hospitalized patients have a survival rate under 10%, representing a serious preventable complication. In October 2023, a multidisciplinary group of physicians, nurses, and safety specialists was formed. Review of aspiration cases from 2020 to 2024 and root cause analysis identified 3 factors: unrecognized risk, refusal of nasogastric (NG) tubes, and inconsistent application of aspiration precautions. Targeted interventions included nurse and resident education, expanded swallow screens, revised NG tubes management, and new signage to flag high-risk patients. From 2020 to 2023, there were 72 aspiration-related CPAs. Following the implementation of the countermeasures, aspiration-related CPAs decreased by 52% between 2023 and 2024 (27 events vs 13 events). Statistical process control analysis using a c-chart demonstrated a significant shift below the median with 12 consecutive points under the centerline. A multipronged, multidisciplinary approach effectively reduced fatal aspiration events, suggesting comprehensive education, improved screening, and standardized precautions can lower the incidence of aspiration-related CPAs. CI - Copyright (c) 2026 the American College of Medical Quality. FAU - Srivatsa, Shaarada AU - Srivatsa S AD - Department of Neurosurgery, Cleveland Clinic Foundation, Cleveland Clinic Lerner College of Medicine, Cleveland, OH. FAU - Glauser, Gregory AU - Glauser G AD - Department of Neurosurgery, Cleveland Clinic Foundation, Cleveland Clinic Lerner College of Medicine, Cleveland, OH. FAU - Gross, Abby AU - Gross A AD - Department of General Surgery, Digestive Disease Institute, Cleveland Clinic Foundation, Cleveland Clinic Lerner College of Medicine, Cleveland, OH. FAU - Nimylowycz, Kelly AU - Nimylowycz K AD - Department of Neurosurgery, Cleveland Clinic Foundation, Cleveland Clinic Lerner College of Medicine, Cleveland, OH. AD - Department of General Surgery, Digestive Disease Institute, Cleveland Clinic Foundation, Cleveland Clinic Lerner College of Medicine, Cleveland, OH. FAU - Gentle, Corey AU - Gentle C AD - Department of General Surgery, Digestive Disease Institute, Cleveland Clinic Foundation, Cleveland Clinic Lerner College of Medicine, Cleveland, OH. FAU - Moyse, Tonya AU - Moyse T AD - Department of General Surgery, Nursing Institute, Cleveland Clinic Foundation, Cleveland Clinic Lerner College of Medicine, Cleveland, OH. FAU - Claus, Stacey AU - Claus S AD - Department of General Surgery, Nursing Institute, Cleveland Clinic Foundation, Cleveland Clinic Lerner College of Medicine, Cleveland, OH. FAU - Augustin, Toms AU - Augustin T AD - Department of General Surgery, Digestive Disease Institute, Cleveland Clinic Foundation, Cleveland Clinic Lerner College of Medicine, Cleveland, OH. LA - eng PT - Journal Article DEP - 20260325 PL - Netherlands TA - Am J Med Qual JT - American journal of medical quality : the official journal of the American College of Medical Quality JID - 9300756 SB - IM MH - Humans MH - *Heart Arrest/prevention & control/etiology MH - *Algorithms MH - *Respiratory Aspiration/prevention & control MH - Intubation, Gastrointestinal/adverse effects MH - Risk Factors OTO - NOTNLM OT - PDSA cycle OT - aspiration prevention OT - near-fatal aspiration OT - process improvement EDAT- 2026/03/24 12:37 MHDA- 2026/05/01 06:34 CRDT- 2026/03/24 06:53 PHST- 2026/05/01 06:34 [medline] PHST- 2026/03/24 12:37 [pubmed] PHST- 2026/03/24 06:53 [entrez] AID - 00008488-990000000-00142 [pii] AID - 10.1097/JMQ.0000000000000291 [doi] PST - ppublish SO - Am J Med Qual. 2026 May-Jun 01;41(3):126-132. doi: 10.1097/JMQ.0000000000000291. Epub 2026 Mar 25. PMID- 41871718 OWN - NLM STAT- MEDLINE DCOM- 20260713 LR - 20260713 IS - 1873-2968 (Electronic) IS - 0006-2952 (Linking) VI - 249 DP - 2026 Jul TI - Identification of a new selective ligand for targeting neuronal K(V)4.3/KChIP3 over cardiac K(V)4.3/KChIP2 channels. PG - 117921 LID - S0006-2952(26)00254-6 [pii] LID - 10.1016/j.bcp.2026.117921 [doi] AB - The present study aimed to discover novel KChIP ligands as pharmacological tools for modulating the K(V)4.3/KChIP channels. A multidisciplinary approach, combining medicinal chemistry and electrophysiology studies, led to the successfully identification of a novel K(V)4.3/KChIP modulator (IQM-22110). Its design was guided by the previous knowledge of the (phenylacetamido)benzoic acid moiety as suitable scaffold, along with virtual screening of a focused chemical library that suggested improved KChIP3 binding upon incorporation of an additional aromatic ring. IQM-22110 was selected for synthesis and identified as a potent KChIP3 ligand. Its electrophysiological effects on K(V)4.3/KChIP3 currents indicate that IQM-22110 binds to a high affinity site in K(V)4.3/KChIP3 channels that it is not present in K(V)4.3/KChIP2 or K(V)4.3. To the best of our knowledge, here we describe the first KChIP3 ligand that selectively modulates K(V)4.3/KChIP3 versus K(V)4.3/KChIP2 and K(V)4.3 channels at nanomolar concentration. Since KChIP2 is predominantly expressed in cardiac tissue, this selectivity may enable the development of K(V)4.3/KChIP3-targeted therapeutics with reduced risk of cardiac side effects. Computational and site-directed mutagenesis studies allowed the identification of IQM-22110's binding site on KChIP3. Knowledge gained from structural and functional studies with this novel KChIP3 ligand could establish the basis for drug discovery programs fostering treatments for diseases in which K(V)4.3/KChIPs channels are involved. CI - Copyright (c) 2026 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Socuellamos, Paula G AU - Socuellamos PG AD - Instituto de Investigaciones Biomedicas Alberto Sols-Morreale (CSIC-UAM), 28029 Madrid, Spain. FAU - Viedma-Barba, Carmen AU - Viedma-Barba C AD - Instituto de Quimica Medica (IQM-CSIC), 28006 Madrid, Spain. FAU - de Benito-Bueno, Angela AU - de Benito-Bueno A AD - Instituto de Investigaciones Biomedicas Alberto Sols-Morreale (CSIC-UAM), 28029 Madrid, Spain. FAU - Bonache, Maria Angeles AU - Bonache MA AD - Instituto de Quimica Medica (IQM-CSIC), 28006 Madrid, Spain. FAU - Ropero, Maria AU - Ropero M AD - Instituto de Investigaciones Biomedicas Alberto Sols-Morreale (CSIC-UAM), 28029 Madrid, Spain. FAU - Diez, Sara AU - Diez S AD - Instituto de Investigaciones Biomedicas Alberto Sols-Morreale (CSIC-UAM), 28029 Madrid, Spain. FAU - Elizalde, Pablo AU - Elizalde P AD - Instituto de Quimica Medica (IQM-CSIC), 28006 Madrid, Spain. FAU - Marin-Olivero, Irene AU - Marin-Olivero I AD - Nanoscopy-UGR Laboratory, Departamento de Fisicoquimica, Unidad de Excelencia de Quimica Aplicada a Biomedicina y Medioambiente, Facultad de Farmacia, Universidad de Granada, Campus Cartuja, 18071 Granada, Spain. FAU - Redondo-Moya, Maria AU - Redondo-Moya M AD - Instituto de Investigaciones Biomedicas Alberto Sols-Morreale (CSIC-UAM), 28029 Madrid, Spain. FAU - Naranjo, Jose Ramon AU - Naranjo JR AD - Centro Nacional de Biotecnologia (CNB-CSIC), 28049 Madrid, Spain; Spanish Network for Biomedical Research in Neurodegenerative diseases (CIBERNED), Instituto de Salud Carlos III, 28029 Madrid, Spain. FAU - Gonzalez-Vera, Juan A AU - Gonzalez-Vera JA AD - Nanoscopy-UGR Laboratory, Departamento de Fisicoquimica, Unidad de Excelencia de Quimica Aplicada a Biomedicina y Medioambiente, Facultad de Farmacia, Universidad de Granada, Campus Cartuja, 18071 Granada, Spain. FAU - Orte, Angel AU - Orte A AD - Nanoscopy-UGR Laboratory, Departamento de Fisicoquimica, Unidad de Excelencia de Quimica Aplicada a Biomedicina y Medioambiente, Facultad de Farmacia, Universidad de Granada, Campus Cartuja, 18071 Granada, Spain. FAU - Perez-Lara, Angel AU - Perez-Lara A AD - Nanoscopy-UGR Laboratory, Departamento de Fisicoquimica, Unidad de Excelencia de Quimica Aplicada a Biomedicina y Medioambiente, Facultad de Farmacia, Universidad de Granada, Campus Cartuja, 18071 Granada, Spain. FAU - Martin-Martinez, Mercedes AU - Martin-Martinez M AD - Instituto de Quimica Medica (IQM-CSIC), 28006 Madrid, Spain. FAU - Valenzuela, Carmen AU - Valenzuela C AD - Instituto de Investigaciones Biomedicas Alberto Sols-Morreale (CSIC-UAM), 28029 Madrid, Spain; Spanish Network for Biomedical Research in Cardiovascular Research (CIBERCV), Instituto de Salud Carlos III, 28029 Madrid, Spain. Electronic address: cvalenzuela@iib.uam.es. FAU - Gutierrez-Rodriguez, Marta AU - Gutierrez-Rodriguez M AD - Instituto de Quimica Medica (IQM-CSIC), 28006 Madrid, Spain. Electronic address: mgutierrez@iqm.csic.es. LA - eng PT - Journal Article DEP - 20260321 PL - England TA - Biochem Pharmacol JT - Biochemical pharmacology JID - 0101032 RN - 0 (Shal Potassium Channels) RN - 0 (Kv Channel-Interacting Proteins) RN - 0 (Ligands) RN - 0 (KCND3 protein, human) RN - 0 (KCNIP2 protein, human) SB - IM MH - *Shal Potassium Channels/metabolism/genetics/chemistry MH - *Kv Channel-Interacting Proteins/metabolism/genetics/chemistry/antagonists & inhibitors MH - Ligands MH - Animals MH - Humans MH - HEK293 Cells MH - *Neurons/metabolism/drug effects OTO - NOTNLM OT - Cardiac potassium channels currents OT - K(V)4.3/KChIP3 channel modulators OT - K(V)4channelopathies OT - KChIP3 ligands COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/03/24 00:30 MHDA- 2026/05/15 00:31 CRDT- 2026/03/23 20:12 PHST- 2025/10/30 00:00 [received] PHST- 2026/03/17 00:00 [revised] PHST- 2026/03/17 00:00 [accepted] PHST- 2026/05/15 00:31 [medline] PHST- 2026/03/24 00:30 [pubmed] PHST- 2026/03/23 20:12 [entrez] AID - S0006-2952(26)00254-6 [pii] AID - 10.1016/j.bcp.2026.117921 [doi] PST - ppublish SO - Biochem Pharmacol. 2026 Jul;249:117921. doi: 10.1016/j.bcp.2026.117921. Epub 2026 Mar 21. PMID- 41868587 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260323 LR - 20260813 IS - 2474-8714 (Electronic) IS - 2474-8706 (Print) IS - 2474-8706 (Linking) VI - 10 IP - 3 DP - 2026 Mar TI - Performance of a Dedicated Radioprotection Cabin for the Interventional Echocardiographer During Structural Heart Procedures. PG - 100756 LID - 10.1016/j.shj.2025.100756 [doi] LID - 100756 AB - BACKGROUND: Structural heart procedures performed under fluoroscopy and transesophageal echocardiography guidance require the expertise of an interventional echocardiographer in the heart team. Due to the proximity with the radiation source, the physician might be exposed to high radiation doses. This study aims to assess the interventional echocardiographer radioprotection by means of a dedicated cabin and evaluate its ergonomic characteristics. METHODS: This is an observational nonrandomized study comparing cumulative radiation exposure between a control arm, consisting of a standard lead glass panel, and the experimental arm using the dedicated radioprotective Echosafe cabin. All structural heart procedures requiring transesophageal echocardiography between July 2021 and April 2022 were included. Cumulative radiation exposure of the interventional echocardiographer was collected by the body part and the satisfaction of the heart team with the cabin was assessed with a questionnaire. RESULTS: A total of 64 procedures were included (24 controls and 40 with the cabin). The irradiation (as estimated by dose area product per procedure) was similar between the two groups (p = 0.94). The use of the cabin resulted in a numerically lower cumulative radiation dose to each body part. The mean overall reduction in radiation dose was estimated to be between 56 and 78% with the cabin. The most frequent negative aspects reported by the cabin users included difficulty moving the transesophageal echocardiography probe and the physical burden associated with initial installation. CONCLUSIONS: This preliminary study suggests that radioprotection of the interventional echocardiographer can be increased during structural procedures by using a dedicated cabin. Further studies with larger sample sizes and different design will be needed to confirm the reduction in irradiation of the echocardiographer. CI - (c) 2025 The Authors. FAU - Magniez, Francois AU - Magniez F AD - Department of Cardiology, Institut du Thorax, Nantes University Hospital, Nantes, France. FAU - Ammour, Luis AU - Ammour L AD - Department of Cardiology, Institut du Thorax, Nantes University Hospital, Nantes, France. FAU - Piriou, Pierre-Guillaume AU - Piriou PG AD - Department of Cardiology, Institut du Thorax, Nantes University Hospital, Nantes, France. FAU - Piriou, Nicolas AU - Piriou N AD - Department of Cardiology, Institut du Thorax, Nantes University Hospital, Nantes, France. FAU - Stevant, David AU - Stevant D AD - Department of Cardiology, Institut du Thorax, Nantes University Hospital, Nantes, France. FAU - Bernard, Quentin AU - Bernard Q AD - Department of Cardiology, Institut du Thorax, Nantes University Hospital, Nantes, France. FAU - Le Gloan, Laurianne AU - Le Gloan L AD - Department of Cardiology, Institut du Thorax, Nantes University Hospital, Nantes, France. FAU - Jaafar, Philippe AU - Jaafar P AD - Department of Cardiology, Institut du Thorax, Nantes University Hospital, Nantes, France. FAU - Letocart, Vincent AU - Letocart V AD - Department of Cardiology, Institut du Thorax, Nantes University Hospital, Nantes, France. FAU - Plessis, Julien AU - Plessis J AD - Department of Cardiology, Institut du Thorax, Nantes University Hospital, Nantes, France. FAU - Manigold, Thibaut AU - Manigold T AD - Department of Cardiology, Institut du Thorax, Nantes University Hospital, Nantes, France. FAU - Ruz, Robin Le AU - Ruz RL AD - Department of Cardiology, Institut du Thorax, Nantes University Hospital, Nantes, France. FAU - Turgeon, Pierre Yves AU - Turgeon PY AD - Department of Cardiology, Institut Universitaire de Cardiologie et de Pneumologie de Quebec (IUCPQ), Quebec, Canada. FAU - Guerin, Patrice AU - Guerin P AD - Department of Cardiology, Institut du Thorax, Nantes University Hospital, Nantes, France. LA - eng PT - Journal Article DEP - 20251110 PL - United States TA - Struct Heart JT - Structural heart : the journal of the Heart Team JID - 101743256 PMC - PMC13000915 OTO - NOTNLM OT - Cardiology OT - Echocardiography OT - Interventional OT - Occupational exposure OT - Radiation protection OT - Transesophageal COIS- Pierre-Guillaume Piriou has a consultancy agreement with Lemerpax. The other authors had no conflicts to declare. EDAT- 2026/03/23 06:32 MHDA- 2026/03/23 06:33 PMCR- 2025/11/10 CRDT- 2026/03/23 05:55 PHST- 2025/05/09 00:00 [received] PHST- 2025/10/22 00:00 [revised] PHST- 2025/10/31 00:00 [accepted] PHST- 2026/03/23 06:33 [medline] PHST- 2026/03/23 06:32 [pubmed] PHST- 2026/03/23 05:55 [entrez] PHST- 2025/11/10 00:00 [pmc-release] AID - S2474-8706(25)00348-3 [pii] AID - 100756 [pii] AID - 10.1016/j.shj.2025.100756 [doi] PST - epublish SO - Struct Heart. 2025 Nov 10;10(3):100756. doi: 10.1016/j.shj.2025.100756. eCollection 2026 Mar. PMID- 41867424 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260323 LR - 20260813 IS - 1178-2390 (Print) IS - 1178-2390 (Electronic) IS - 1178-2390 (Linking) VI - 19 DP - 2026 TI - A Nurse-Guided, Family-Involved Individualized Perioperative Management Multidisciplinary Team Model in Older Patients Underwent Cardiac Surgery. PG - 568010 LID - 10.2147/JMDH.S568010 [doi] LID - 568010 AB - INTRODUCTION: This study evaluated a novel multidisciplinary team (MDT) approach-integrating nurse guidance, family involvement, and individualized perioperative care-on outcomes in older cardiac surgery patients. METHODS: A retrospective analysis included 198 patients aged >/=60 years (99 conventional care, 99 MDT) from November 2021 to January 2024. Outcomes included pneumonia, delirium, functional recovery (Barthel Index), and hospitalization metrics. RESULTS : Baseline characteristics were comparable. The MDT group had significantly shorter ICU stay (2.5+/-1.9 vs 3.7+/-4.8 days, p=0.019) and lower pneumonia incidence (29.3% vs 60.6%, p<0.001). Total hospital stay and delirium rates did not differ significantly, but the MDT group showed a trend toward greater functional improvement (Barthel change: 20.6+/-13.9 vs 15.6+/-22.6). CONCLUSION: The MDT model significantly improved critical postoperative outcomes, notably reducing ICU stay and pneumonia. These results advocate for nurse-led, family-centered multidisciplinary care in geriatric surgery, warranting further prospective validation. CI - (c) 2026 Cao et al. FAU - Cao, Miaomiao AU - Cao M AD - Department of Cardiac Surgery, the First Affiliated Hospital of USTC, Hefei, 230001, People's Republic of China. FAU - Wang, Tingting AU - Wang T AUID- ORCID: 0000-0002-5372-6433 AD - Department of Cardiology, the First Affiliated Hospital of USTC, Hefei, 230001, People's Republic of China. FAU - Tang, Yangchen AU - Tang Y AD - Department of Geriatrics, the First Affiliated Hospital of USTC, Hefei, 230001, People's Republic of China. FAU - Wang, Juan AU - Wang J AUID- ORCID: 0009-0007-0261-6115 AD - Department of Geriatrics, the First Affiliated Hospital of USTC, Hefei, 230001, People's Republic of China. FAU - Jin, Song AU - Jin S AD - Department of Geriatrics, the First Affiliated Hospital of USTC, Hefei, 230001, People's Republic of China. LA - eng PT - Journal Article DEP - 20260124 PL - New Zealand TA - J Multidiscip Healthc JT - Journal of multidisciplinary healthcare JID - 101512691 PMC - PMC13005189 OTO - NOTNLM OT - cardiac surgery OT - multidisciplinary team OT - nursing OT - older adults OT - perioperative COIS- The authors declare that they have no competing interests in this work. EDAT- 2026/03/23 06:31 MHDA- 2026/03/23 06:32 PMCR- 2026/01/24 CRDT- 2026/03/23 05:46 PHST- 2025/09/16 00:00 [received] PHST- 2026/01/20 00:00 [accepted] PHST- 2026/03/23 06:32 [medline] PHST- 2026/03/23 06:31 [pubmed] PHST- 2026/03/23 05:46 [entrez] PHST- 2026/01/24 00:00 [pmc-release] AID - 568010 [pii] AID - 10.2147/JMDH.S568010 [doi] PST - epublish SO - J Multidiscip Healthc. 2026 Jan 24;19:568010. doi: 10.2147/JMDH.S568010. eCollection 2026. PMID- 41867420 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260323 LR - 20260813 IS - 1178-2390 (Print) IS - 1178-2390 (Electronic) IS - 1178-2390 (Linking) VI - 19 DP - 2026 TI - Multidisciplinary Collaborative Nursing Management Improves Health Behaviors and Psychological Status in Patients with Diabetes Mellitus and Coronary Heart Disease. PG - 574565 LID - 10.2147/JMDH.S574565 [doi] LID - 574565 AB - OBJECTIVE: To evaluate the effectiveness of a multidisciplinary collaborative nursing management model in patients with diabetes mellitus and coronary heart disease, focusing on blood glucose control, cardiac function, psychological adjustment, and health-promoting behaviors. METHODS: A retrospective controlled study was conducted including 150 patients admitted from April 2022 to April 2025. Patients were divided into a control group (n=75, routine nursing) and an observation group (n=75, multidisciplinary collaborative nursing). Outcomes included blood glucose [fasting plasma glucose (FPG), 2-hour postprandial glucose (2 h PG), HbA1c], cardiac function [LVEF, LVESD, LVEDD], psychological status [SAS, SDS], health behaviors [HPLP-II], and nursing satisfaction [NSNS]. RESULTS: After intervention, both groups showed improvements in all outcomes, with the observation group achieving significantly greater improvements (P<0.05). Specifically, blood glucose levels decreased, LVEF increased while LVESD and LVEDD decreased, SAS and SDS scores improved, health behavior scores increased, and nursing satisfaction was higher in the observation group (93.3% vs 81.3%, P<0.05). CONCLUSION: Multidisciplinary collaborative nursing management effectively improves clinical and psychological outcomes, enhances health behaviors, and increases nursing satisfaction in patients with diabetes mellitus and coronary heart disease. CI - (c) 2026 Liu and Li. FAU - Liu, Qingwen AU - Liu Q AD - Department of Geratology, the First Affiliated Hospital of China Medical University, Shenyang, 110001, People's Republic of China. FAU - Li, Zeyin AU - Li Z AD - Department of Cardiac Surgery, the First Affiliated Hospital of China Medical University, Shenyang, 110001, People's Republic of China. LA - eng PT - Journal Article DEP - 20260119 PL - New Zealand TA - J Multidiscip Healthc JT - Journal of multidisciplinary healthcare JID - 101512691 PMC - PMC13003807 OTO - NOTNLM OT - blood glucose control OT - cardiac function OT - coronary heart disease OT - diabetes mellitus OT - health behavior OT - multidisciplinary collaborative nursing OT - psychological status COIS- The authors report no conflicts of interest in this work. EDAT- 2026/03/23 06:32 MHDA- 2026/03/23 06:33 PMCR- 2026/01/19 CRDT- 2026/03/23 05:46 PHST- 2025/10/15 00:00 [received] PHST- 2026/01/08 00:00 [accepted] PHST- 2026/03/23 06:33 [medline] PHST- 2026/03/23 06:32 [pubmed] PHST- 2026/03/23 05:46 [entrez] PHST- 2026/01/19 00:00 [pmc-release] AID - 574565 [pii] AID - 10.2147/JMDH.S574565 [doi] PST - epublish SO - J Multidiscip Healthc. 2026 Jan 19;19:574565. doi: 10.2147/JMDH.S574565. eCollection 2026. PMID- 41864764 OWN - NLM STAT- MEDLINE DCOM- 20260911 LR - 20260911 IS - 1532-1770 (Electronic) IS - 1521-6942 (Linking) VI - 40 IP - 3 DP - 2026 Sep TI - Definition, diagnosis, treatment for scleroderma primary heart involvement. PG - 102134 LID - S1521-6942(26)00019-7 [pii] LID - 10.1016/j.berh.2026.102134 [doi] AB - Systemic sclerosis (SSc) is an autoimmune disease characterized by chronic inflammation leading to fibrosis in the skin and organs, including the heart. It is classified as SSc-primary heart involvement (pHI), defined as heart dysfunction primarily caused by SSc, excluding other causes. Several disease manifestations, including conduction abnormalities, cardiac arrythmias, myocarditis/pericardial involvement, heart failure (systolic and diastolic) and valvular dysfunction, are categorized within SSc-pHI. SSc-pHI has a high prevalence, high mortality, and increased risk for sudden cardiac death. Serum biomarkers, high sensitivity troponin and NT-proBNP, may help in screening, with electrocardiography, echocardiography, and Holter monitoring. Cardiac magnetic resonance imaging (cMRI) can confirm SSc-pHI and is considered gold standard for diagnosis, with limited use due to cost and availability. Treatment approaches are multifaceted depending on the manifestation of SSc-pHI but often require immunosuppression at a minimum. A multidisciplinary team including rheumatologists and cardiologists offers the best approach for diagnosis, management, and monitoring. CI - Copyright (c) 2026. Published by Elsevier Ltd. FAU - Baker Frost, DeAnna AU - Baker Frost D AD - Department of Medicine, Division of Rheumatology, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 833, MSC 637, Charleston, SC, 29425, USA. Electronic address: bakerde@musc.edu. FAU - Tedford, Ryan J AU - Tedford RJ AD - Department of Medicine, Division of Cardiology, Medical University of South Carolina, 30 Courtenay Dr. BM215, MSC 592 Room Strom Thurmond Gazes Building, Room 215, Charleston, SC, 29425, USA. Electronic address: tedfordr@musc.edu. FAU - Silver, Richard AU - Silver R AD - Department of Medicine, Division of Rheumatology, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 833, MSC 637, Charleston, SC, 29425, USA. Electronic address: silverr@musc.edu. LA - eng GR - K08 AR078372/AR/NIAMS NIH HHS/United States PT - Journal Article PT - Review DEP - 20260320 PL - Netherlands TA - Best Pract Res Clin Rheumatol JT - Best practice & research. Clinical rheumatology JID - 101121149 RN - 0 (Biomarkers) SB - IM MH - Humans MH - *Scleroderma, Systemic/complications/diagnosis/therapy MH - *Heart Diseases/etiology/diagnosis/therapy MH - Magnetic Resonance Imaging MH - Biomarkers/blood MH - Echocardiography OTO - NOTNLM OT - Cardiac magnetic resonance imaging OT - Systemic sclerosis OT - Systemic sclerosis primary heart involvement COIS- Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:DeAnna Baker Frost reports financial support was provided by National Institutes of Health. DeAnna Baker Frost reports financial support was provided by Alzheimer's Association. DeAnna Baker Frost reports a relationship with Boehringer Ingelheim Ltd that includes: consulting or advisory. DeAnna Baker Frost reports a relationship with Allogene Therapeutics Inc that includes: consulting or advisory. DeAnna Baker Frost reports a relationship with Aurinia Pharma U.S., Inc. That includes: consulting or advisory. Ryan J. Tedford reports a relationship with Abbott that includes: consulting or advisory. Ryan J. Tedford reports a relationship with Acorai that includes: consulting or advisory. Ryan J. Tedford reports a relationship with Adona that includes: consulting or advisory. Ryan J. Tedford reports a relationship with Aria CV Inc. That includes: consulting or advisory. Ryan J. Tedford reports a relationship with Boston Scientific Corporation that includes: consulting or advisory. Ryan J. Tedford reports a relationship with CVRx Inc that includes: consulting or advisory. Ryan J. Tedford reports a relationship with Endotronix Inc that includes: consulting or advisory. Ryan J. Tedford reports a relationship with Edwards Lifesciences Corporation that includes: consulting or advisory. Ryan J. Tedford reports a relationship with Fauna Bio that includes: consulting or advisory. Ryan J. Tedford reports a relationship with Gradient that includes: consulting or advisory. Ryan J. Tedford reports a relationship with Imbria Pharmaceuticals Inc that includes: consulting or advisory. Ryan J. Tedford reports a relationship with Medtronic that includes: consulting or advisory. Ryan J. Tedford reports a relationship with Merck & Co Inc that includes: consulting or advisory. Ryan J. Tedford reports a relationship with Mitre that includes: consulting or advisory. Ryan J. Tedford reports a relationship with Morphic Therapeutics that includes: consulting or advisory. Ryan J. Tedford reports a relationship with Pulmovant Inc that includes: consulting or advisory. Ryan J. Tedford reports a relationship with Restore Medical that includes: consulting or advisory. Ryan J. Tedford reports a relationship with Tempus AI Inc that includes: consulting or advisory. Ryan J. Tedford reports a relationship with 35Pharma that includes: consulting or advisory. Ryan J. Tedford reports a relationship with United Therapeutics Corporation that includes: consulting or advisory. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/03/22 06:07 MHDA- 2026/09/11 23:36 CRDT- 2026/03/21 22:52 PHST- 2026/02/02 00:00 [received] PHST- 2026/03/12 00:00 [accepted] PHST- 2026/09/11 23:36 [medline] PHST- 2026/03/22 06:07 [pubmed] PHST- 2026/03/21 22:52 [entrez] AID - S1521-6942(26)00019-7 [pii] AID - 10.1016/j.berh.2026.102134 [doi] PST - ppublish SO - Best Pract Res Clin Rheumatol. 2026 Sep;40(3):102134. doi: 10.1016/j.berh.2026.102134. Epub 2026 Mar 20. PMID- 41864530 OWN - NLM STAT- MEDLINE DCOM- 20260827 LR - 20260923 IS - 1552-6259 (Electronic) IS - 0003-4975 (Print) IS - 0003-4975 (Linking) VI - 122 IP - 3 DP - 2026 Sep TI - Transcatheter vs Surgical Tricuspid Valve Repair: An Analysis of Medicare Beneficiaries. PG - 641-649 LID - S0003-4975(26)00230-4 [pii] LID - 10.1016/j.athoracsur.2026.03.013 [doi] AB - BACKGROUND: In patients with tricuspid regurgitation, surgical and transcatheter interventions aim to impact outcomes and symptomatic quality of life. We compared tricuspid transcatheter edge-to-edge repair (T-TEER) to isolated surgical tricuspid valve repair (TVr). METHODS: Assessing US Medicare data (2018-2022), excluding endocarditis and rheumatic disease, we evaluated all patients undergoing isolated T-TEER (n = 1540) or isolated TVr (n = 1221). International Classification of Diseases 10th revision codes were used to define comorbidities and frailty using validated metrics. Doubly robust risk adjustment was performed with inverse probability weighting, multilevel regression, and competing-risk time-to-event analyses. Outcomes of interest include procedural mortality, pacemaker, and kidney injury as well as 3-year freedom from death, valve reintervention, and heart failure readmission. RESULTS: Surgical TVr was associated with higher unadjusted hospital mortality (8.8% vs 2.1%, P < .001), but lower 3-year mortality (20.8% vs 26.2%, P = .025) and valve reintervention (0.9% vs 2.1%, P = .015). After risk adjustment, surgical TVr was associated with higher hospital mortality (odds ratio, 2.83, P < .001) but improved longitudinal survival compared with T-TEER (hazard ratio [HR], 0.76; P = .012). Surgical TVr was associated with lower rates of overall readmission (HR, 0.87; P = .040), heart failure-related readmission (HR, 0.79; P = .001), and valve reintervention (HR, 0.83; P = .003) at 3 years compared with T-TEER. CONCLUSIONS: Among Medicare patients with symptomatic tricuspid regurgitation, surgical TVr was associated with higher perioperative risk, but improved risk-adjusted 3-year survival, heart failure readmission, and valve reintervention compared with T-TEER. These contemporary data may inform future trial designs and heart team decision-making for patients with severe symptomatic tricuspid regurgitation. CI - Copyright (c) 2026 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved. FAU - Mehaffey, J Hunter AU - Mehaffey JH AD - Department of Cardiovascular and Thoracic Surgery, West Virginia University Morgantown, West Virginia. Electronic address: james.mehaffey@wvumedicine.org. FAU - Daggubati, Ramesh AU - Daggubati R AD - Department of Cardiology, West Virginia University Morgantown, West Virginia. FAU - Jagadeesan, Vikrant AU - Jagadeesan V AD - Department of Cardiology, West Virginia University Morgantown, West Virginia. FAU - Hayanga, J W Awori AU - Hayanga JWA AD - Department of Cardiovascular and Thoracic Surgery, West Virginia University Morgantown, West Virginia. FAU - Rankin, J Scott AU - Rankin JS AD - Department of Cardiovascular and Thoracic Surgery, West Virginia University Morgantown, West Virginia. FAU - Sattar, Yasar AU - Sattar Y AD - Department of Cardiology, West Virginia University Morgantown, West Virginia. FAU - Sokos, George AU - Sokos G AD - Department of Cardiology, West Virginia University Morgantown, West Virginia. FAU - Badhwar, Vinay AU - Badhwar V AD - Department of Cardiovascular and Thoracic Surgery, West Virginia University Morgantown, West Virginia. LA - eng GR - UM1 HL088925/HL/NHLBI NIH HHS/United States PT - Comparative Study PT - Journal Article DEP - 20260319 PL - Netherlands TA - Ann Thorac Surg JT - The Annals of thoracic surgery JID - 15030100R SB - IM MH - Humans MH - United States MH - Female MH - Medicare MH - *Tricuspid Valve Insufficiency/surgery/mortality MH - Male MH - Aged MH - *Tricuspid Valve/surgery MH - *Cardiac Catheterization/methods MH - Aged, 80 and over MH - *Heart Valve Prosthesis Implantation/methods MH - Hospital Mortality MH - Treatment Outcome MH - Retrospective Studies MH - Postoperative Complications/epidemiology PMC - PMC13454764 MID - NIHMS2201092 COIS- Disclosures The authors have no conflicts of interest to disclose. EDAT- 2026/03/22 06:06 MHDA- 2026/08/28 11:49 PMCR- 2026/08/11 CRDT- 2026/03/21 20:18 PHST- 2025/07/24 00:00 [received] PHST- 2026/02/13 00:00 [revised] PHST- 2026/03/02 00:00 [accepted] PHST- 2026/08/28 11:49 [medline] PHST- 2026/03/22 06:06 [pubmed] PHST- 2026/03/21 20:18 [entrez] PHST- 2026/08/11 00:00 [pmc-release] AID - S0003-4975(26)00230-4 [pii] AID - 10.1016/j.athoracsur.2026.03.013 [doi] PST - ppublish SO - Ann Thorac Surg. 2026 Sep;122(3):641-649. doi: 10.1016/j.athoracsur.2026.03.013. Epub 2026 Mar 19. PMID- 41864422 OWN - NLM STAT- MEDLINE DCOM- 20261005 LR - 20261005 IS - 1916-7075 (Electronic) IS - 0828-282X (Linking) VI - 42 IP - 10 DP - 2026 Oct TI - Characteristics and Outcomes of Operated Versus Nonoperated Patients With Infective Endocarditis and Cerebral Complications: The COOPER Study. PG - 2501-2510 LID - S0828-282X(26)00271-0 [pii] LID - 10.1016/j.cjca.2026.03.022 [doi] AB - BACKGROUND: Cerebral complications in patients with infective endocarditis (IE) are common and worsen prognosis. Determining the optimal timing for cardiac surgery in this context remains challenging. In this study we describe the characteristics and outcomes of IE patients with cerebral complications who were managed either surgically or medically. METHODS: We analyzed all consecutive patients with IE-related cerebral complications enrolled in a prospective cohort study in Aquitaine, France (2013-2021). Patients were classified as operated or nonoperated. The primary outcome was all-cause mortality at 1 month; secondary outcomes included all-cause mortality up to 1 year and the impact of cerebral lesion type and surgical timing. RESULTS: Among 1230 IE patients, 288 had cerebral complications (age 65 +/- 14 years, 74% male). Ischemic and hemorrhagic cerebral lesions occurred in 76% and 19% of patients, respectively. Severe valvular damages were present in 43% and cardiac surgery was indicated in 86% of cases. One-month mortality was significantly higher among nonoperated vs operated patients (27% vs 5.9%, P < 0.001). Multivariate analysis identified heart failure, coma, and cardiac surgery (odds ratio 0.24, 95% confidence interval 0.10-0.56, P < 0.001) as independent predictors of mortality. Neither the type of cerebral lesion nor surgical timing appeared to affect prognosis. CONCLUSIONS: When indicated, cardiac surgery should be systematically discussed in IE patients with cerebral complications. Early intervention guided by a multidisciplinary endocarditis team with neurology expertise may improve outcomes. CI - Copyright (c) 2026 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved. FAU - Graveleau, Olivia AU - Graveleau O AD - Valvular Heart Disease Unit, Bordeaux University Hospital-Haut-Leveque, Pessac, France. FAU - Cattan, Johann AU - Cattan J AD - Valvular Heart Disease Unit, Bordeaux University Hospital-Haut-Leveque, Pessac, France. FAU - Marnat, Gaultier AU - Marnat G AD - Neuroradiology Department, Bordeaux University Hospital-Pellegrin, Bordeaux, France. FAU - Jonveaux, Melchior AU - Jonveaux M AD - Valvular Heart Disease Unit, Bordeaux University Hospital-Haut-Leveque, Pessac, France. FAU - Dijos, Marina AU - Dijos M AD - Valvular Heart Disease Unit, Bordeaux University Hospital-Haut-Leveque, Pessac, France. FAU - Bouchat, Marine AU - Bouchat M AD - Valvular Heart Disease Unit, Bordeaux University Hospital-Haut-Leveque, Pessac, France. FAU - Bonnet, Guillaume AU - Bonnet G AD - Valvular Heart Disease Unit, Bordeaux University Hospital-Haut-Leveque, Pessac, France. FAU - Leroux, Lionel AU - Leroux L AD - Valvular Heart Disease Unit, Bordeaux University Hospital-Haut-Leveque, Pessac, France. FAU - Pernot, Mathieu AU - Pernot M AD - Valvular Heart Disease Unit, Bordeaux University Hospital-Haut-Leveque, Pessac, France. FAU - Peltan, Julien AU - Peltan J AD - Valvular Heart Disease Unit, Bordeaux University Hospital-Haut-Leveque, Pessac, France. FAU - Nesseris, Georgios AU - Nesseris G AD - Valvular Heart Disease Unit, Bordeaux University Hospital-Haut-Leveque, Pessac, France. FAU - Labrousse, Louis AU - Labrousse L AD - Valvular Heart Disease Unit, Bordeaux University Hospital-Haut-Leveque, Pessac, France. FAU - Seguy, Benjamin AU - Seguy B AD - Cardiac Intensive Care Unit, Bordeaux University Hospital-Haut-Leveque, Pessac, France. FAU - Gerbaud, Edouard AU - Gerbaud E AD - Cardiac Intensive Care Unit, Bordeaux University Hospital-Haut-Leveque, Pessac, France. FAU - Sridi-Cheniti, Soumaya AU - Sridi-Cheniti S AD - Radiology Department, Bordeaux University Hospital-Haut-Leveque, Pessac, France. FAU - Chaussade, Helene AU - Chaussade H AD - Internal Medicine and Infectious Disease Unit, Groupe Saint-Andre, University Hospital, Bordeaux, France. FAU - Greib, Carine AU - Greib C AD - Internal Medicine and Infectious Diseases Department, Bordeaux University Hospital-Haut-Leveque, Pessac, France. FAU - Camou, Fabrice AU - Camou F AD - Internal Medicine and Infectious Diseases Department, Bordeaux University Hospital-Haut-Leveque, Pessac, France. FAU - Peuchant, Olivia AU - Peuchant O AD - Bacteriology Department, Bordeaux University Hospital-Pellegrin, Bordeaux, France. FAU - Wirth, Gaetane AU - Wirth G AD - Infectious Diseases Department, Bordeaux University Hospital-Pellegrin, Bordeaux, France. FAU - Roubaud-Baudron, Claire AU - Roubaud-Baudron C AD - Clinical Gerontology Department, Bordeaux University Hospital, Bordeaux, France; INSERM BRIC UMR 1312, University of Bordeaux, Bordeaux, France. FAU - Beurton, Antoine AU - Beurton A AD - Department of Cardiovascular Anesthesia and Critical Care, Hopital Cardiologique de Haut-Leveque, Bordeaux University Hospital, Pessac, France. FAU - Cariou, Tanguy AU - Cariou T AD - Biostatistic unit of the Clinical Research and Innovation Department, Bordeaux University Hospital-Haut-Leveque, Pessac, France. FAU - Renou, Pauline AU - Renou P AD - Neurovascular Unit, Bordeaux University Hospital-Pellegrin, Bordeaux, France. FAU - Modine, Thomas AU - Modine T AD - Valvular Heart Disease Unit, Bordeaux University Hospital-Haut-Leveque, Pessac, France. FAU - Issa, Nahema AU - Issa N AD - Valvular Heart Disease Unit, Bordeaux University Hospital-Haut-Leveque, Pessac, France; Internal Medicine and Infectious Disease Unit, Groupe Saint-Andre, University Hospital, Bordeaux, France. FAU - Ternacle, Julien AU - Ternacle J AD - Valvular Heart Disease Unit, Bordeaux University Hospital-Haut-Leveque, Pessac, France. Electronic address: julien.ternacle.hmn@gmail.com. LA - eng PT - Journal Article DEP - 20260319 PL - England TA - Can J Cardiol JT - The Canadian journal of cardiology JID - 8510280 SB - IM MH - Humans MH - Male MH - Aged MH - Female MH - *Endocarditis/complications/mortality/surgery/therapy MH - France/epidemiology MH - *Cardiac Surgical Procedures/methods MH - Prospective Studies MH - Middle Aged MH - Prognosis OTO - NOTNLM OT - cardiac surgery OT - cerebral complications OT - infective endocarditis OT - stroke EDAT- 2026/03/22 06:06 MHDA- 2026/10/05 23:29 CRDT- 2026/03/21 20:15 PHST- 2025/10/25 00:00 [received] PHST- 2026/03/04 00:00 [revised] PHST- 2026/03/12 00:00 [accepted] PHST- 2026/10/05 23:29 [medline] PHST- 2026/03/22 06:06 [pubmed] PHST- 2026/03/21 20:15 [entrez] AID - S0828-282X(26)00271-0 [pii] AID - 10.1016/j.cjca.2026.03.022 [doi] PST - ppublish SO - Can J Cardiol. 2026 Oct;42(10):2501-2510. doi: 10.1016/j.cjca.2026.03.022. Epub 2026 Mar 19. PMID- 41860325 OWN - NLM STAT- MEDLINE DCOM- 20260711 LR - 20260727 IS - 1529-7535 (Print) IS - 1529-7535 (Linking) VI - 27 IP - 4 DP - 2026 Apr 1 TI - Society of Critical Care Medicine 2026 Guidelines on the Care and Management of Pediatric and Neonatal Intensive Care Patients at the End of Life. PG - 518-536 LID - 10.1097/PCC.0000000000003914 [doi] AB - RATIONALE: Ensuring high-quality end-of-life (EOL) care for neonatal and pediatric patients and their families in the ICU requires a comprehensive, evidence-based, multidisciplinary approach. OBJECTIVES: To develop and provide evidence-based recommendations for EOL care and management of critically ill neonatal and pediatric patients and their families. DESIGN: The American College of Critical Care Medicine Board convened a 21-member multidisciplinary panel of experts in pediatric critical care medicine, nursing, neonatology, psychology, spiritual care, social work, child life, respiratory care, bioethics, cardiology/cardiac intensive care, palliative care, and bereaved parents. The panel included two expert methodologists specialized in developing evidence-based recommendations in alignment with the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology. Conflict-of-interest policies were followed during all phases of guidelines development including task force selection and voting. METHODS: The panel members identified and formulated five Population, Intervention, Comparator, and Outcome questions. We conducted a systematic review of literature (2000-2025) for each question to identify best available evidence, then statistically analyzed and assessed the certainty of evidence using the GRADE methodology. We used the GRADE evidence-to-decision framework to formulate the recommendations. RESULTS: The panel generated five conditional recommendations and one good practice statement, focused on advance care planning, pediatric palliative care consultation and education, systematic symptom management, bereavement support, and health equity in EOL care. CONCLUSIONS: The recommendations were derived from the best available evidence at time of publication and provide valuable guidance to support EOL care for PICU and neonatal ICU patients and their families. CI - Copyright (c) 2026 by the Society of Critical Care Medicine. FAU - Derrington, Sabrina AU - Derrington S AUID- ORCID: 0000-0003-1354-902 AD - Department of Anesthesiology Critical Care Medicine and Center for Bioethics, Children's Hospital Los Angeles, Los Angeles, CA. AD - Department of Pediatrics, Keck School of Medicine of USC, Los Angeles, CA. FAU - Broden Arciprete, Elizabeth G AU - Broden Arciprete EG AD - Boston College Connell School of Nursing, Chestnut Hill, MA. FAU - Lin, Matthew C AU - Lin MC AD - NYU Grossman School of Medicine, New York, NY. FAU - Oczkowski, Simon J W AU - Oczkowski SJW AD - McMaster University, Hamilton, ON, Canada. FAU - Alladin, Amanda AU - Alladin A AD - Division of Pediatric Critical Care, Department of Pediatrics, University of Miami Miller School of Medicine and Holtz Children's Hospital, Miami, FL. AD - University of Miami Institute for Bioethics and Health Policy, Miami, FL. FAU - Anani, Uchenna E AU - Anani UE AD - Division of Neonatology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN. FAU - Borchik, Amanda K AU - Borchik AK AD - Department of Spiritual Care, Monroe Carell Jr. Children's Hospital, Vanderbilt University Medical Center, Nashville, TN. AD - Transforming Chaplaincy at Rush University, Chicago, IL. FAU - Collins, Cassandra A AU - Collins CA AD - OSF Healthcare Children's Hospital of Illinois, Peoria, IL. FAU - Delgado-Corcoran, Claudia AU - Delgado-Corcoran C AD - University of Utah, Salt Lake City, UT. FAU - Dickerman, Mindy J AU - Dickerman MJ AD - Nemour's Children's Health, Wilmington, DE. FAU - Harrod, Christopher G AU - Harrod CG AD - Society for Critical Care Medicine, Mount Prospect, IL. FAU - Henner, Natalia AU - Henner N AD - Lurie Children's Hospital, Chicago, IL. FAU - Kon, Alexander A AU - Kon AA AD - Ethics Consultants, Inc., San Diego, CA. AD - University of Washington School of Medicine, Seattle, WA. FAU - Lewis-Newby, Mithya AU - Lewis-Newby M AD - Seattle Children's Hospital and University of Washington, Seattle, WA. FAU - Lord, Blyth T AU - Lord BT AD - Courageous Parents Network, Boston, MA. FAU - Masters, Ashley-Anne AU - Masters AA AD - Presbyterian Campus Ministry of Raleigh, Raleigh, NC. FAU - McCarthy, Sarah AU - McCarthy S AD - Boston Children's Hospital, Boston, MA. AD - Department of Pediatrics, Harvard Medical School, Boston, MA. FAU - Moynihan, Katie M AU - Moynihan KM AD - Boston Children's Hospital, Boston, MA. AD - Department of Pediatrics, Harvard Medical School, Boston, MA. FAU - Munoz-Blanco, Sara M AU - Munoz-Blanco SM AD - Johns Hopkins School of Medicine, Baltimore, MD. FAU - Rissman, Lauren AU - Rissman L AD - Advocate Children's Hospital, Park Ridge, IL. FAU - Roberts, Kathryn E AU - Roberts KE AD - Nemour's Children's Health, Wilmington, DE. FAU - Schlegel, Amy B AU - Schlegel AB AD - Nationwide Children's Hospital and The Ohio State University College of Medicine, Columbus, OH. FAU - Schopen, Ashleigh AU - Schopen A AD - Child Life Consulting, LLC, Philadelphia, PA. FAU - Siegel, Linda B AU - Siegel LB AD - Northwell Health, New Hyde Park, NY. AD - Division of Pediatric Critical Care Medicine, Cohen Children's Medical Center, New Hyde Park, NY. FAU - Swasey, Harriett AU - Swasey H AD - Boston Children's Hospital, Boston, MA. FAU - Wawrzynski, Sarah E AU - Wawrzynski SE AD - Nemour's Children's Health, Wilmington, DE. FAU - Zorko, David J AU - Zorko DJ AD - McMaster University, Hamilton, ON, Canada. FAU - DeCourcey, Danielle D AU - DeCourcey DD AD - Boston Children's Hospital, Boston, MA. AD - Department of Pediatrics, Harvard Medical School, Boston, MA. LA - eng PT - Journal Article PT - Practice Guideline DEP - 20260320 PL - United States TA - Pediatr Crit Care Med JT - Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies JID - 100954653 SB - IM MH - Humans MH - *Terminal Care/standards/methods MH - Infant, Newborn MH - *Critical Care/standards MH - Child MH - *Intensive Care Units, Pediatric/standards MH - Infant MH - Palliative Care/standards MH - Intensive Care Units, Neonatal/standards MH - *Intensive Care, Neonatal/standards OTO - NOTNLM OT - critical care OT - critical illness OT - end-of-life OT - neonatal intensive care unit OT - pediatric palliative care OT - practice guidelines COIS- Dr. Lewis-Newby received funding from the National Institutes of Health and served as an Ethics Advisor for the project. The funding has now ended. Dr. Wawrzynski received funding from Family Caregiving Collaborative at the University of Utah and served as co-investigator for a project examining the impact of a child's death in the ICU on surviving family members using population data. Dr. Broden Arciprete received funding from Hillman Foundation and National Institute of Nursing. Dr. Moynihan was a consultant for Edward Life Sciences. Dr. Oczkowski is a speaker for Fisher & Paykel and a consultant for VitalAire. Dr. Kon owns stocks from ROMTech. The remaining authors have disclosed that they do not have any potential conflicts of interest. EDAT- 2026/03/20 13:22 MHDA- 2026/04/09 12:45 CRDT- 2026/03/20 09:33 PHST- 2026/04/09 12:45 [medline] PHST- 2026/03/20 13:22 [pubmed] PHST- 2026/03/20 09:33 [entrez] AID - 00130478-990000000-00645 [pii] AID - 10.1097/PCC.0000000000003914 [doi] PST - ppublish SO - Pediatr Crit Care Med. 2026 Apr 1;27(4):518-536. doi: 10.1097/PCC.0000000000003914. Epub 2026 Mar 20. PMID- 41859559 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260320 LR - 20260926 IS - 2050-0904 (Print) IS - 2050-0904 (Electronic) IS - 2050-0904 (Linking) VI - 13 IP - 10 DP - 2025 Oct TI - Hemiplegia From Disseminated Emboli due to Infective Endocarditis Secondary to Acute Rheumatic Fever in a 10-Year-Old. PG - e71324 LID - 10.1002/ccr3.71324 [doi] LID - e71324 AB - Hemiplegia in children needs early cardiology evaluations, just as it does for neurological assessments. Early recognition, evaluation, management, and prophylaxis by a multidisciplinary team for infective endocarditis in pediatric groups with rheumatic heart disease are crucial to prevent complications like embolic stroke in resource-limited settings. CI - (c) 2025 The Author(s). Clinical Case Reports published by John Wiley & Sons Ltd. FAU - Pokhrel, Santosh AU - Pokhrel S AD - Siddhartha Children and Women Hospital Butwal Nepal. FAU - Yadav, Hira Nand AU - Yadav HN AD - Siddhartha Children and Women Hospital Butwal Nepal. FAU - Neupane, Sundar AU - Neupane S AD - Siddhartha Children and Women Hospital Butwal Nepal. FAU - Pahari, Sagar AU - Pahari S AUID- ORCID: 0009-0002-1444-6065 AD - Tribhuvan University Teaching Hospital Kathmandu Nepal. FAU - Karki, Prakriti AU - Karki P AD - B&B Hospital Lalitpur Nepal. FAU - Singh, Mirab AU - Singh M AD - Nepal Mediciti Hospital Lalitpur Nepal. FAU - Teli, Jagadamba Gupta AU - Teli JG AD - Kathmandu University School of Medical Sciences Kavre Nepal. FAU - Sharma, Bishnu Dhakal AU - Sharma BD AD - Lumbini Provincial Hospital Butwal Nepal. LA - eng PT - Journal Article DEP - 20251016 PL - England TA - Clin Case Rep JT - Clinical case reports JID - 101620385 PMC - PMC12998245 OTO - NOTNLM OT - acute rheumatic fever OT - hemiplegia OT - infective endocarditis OT - stroke COIS- The authors declare no conflicts of interest. EDAT- 2026/03/20 07:10 MHDA- 2026/03/20 07:11 PMCR- 2025/10/16 CRDT- 2026/03/20 04:55 PHST- 2025/02/18 00:00 [received] PHST- 2025/06/04 00:00 [revised] PHST- 2025/10/04 00:00 [accepted] PHST- 2026/03/20 07:11 [medline] PHST- 2026/03/20 07:10 [pubmed] PHST- 2026/03/20 04:55 [entrez] PHST- 2025/10/16 00:00 [pmc-release] AID - CCR371324 [pii] AID - 10.1002/ccr3.71324 [doi] PST - epublish SO - Clin Case Rep. 2025 Oct 16;13(10):e71324. doi: 10.1002/ccr3.71324. eCollection 2025 Oct. PMID- 41856546 OWN - NLM STAT- MEDLINE DCOM- 20260711 LR - 20260813 IS - 2399-6641 (Electronic) IS - 2399-6641 (Linking) VI - 13 IP - Suppl 1 DP - 2026 Mar 19 TI - Enhancing hand hygiene compliance to reduce healthcare-associated infections in a coronary care unit: a quality improvement initiative in a tertiary hospital in South India. LID - 10.1136/bmjoq-2025-003838 [doi] LID - e003838 AB - BACKGROUND: Healthcare-associated infections remain a major concern in critical care environments. Hand hygiene (HH) compliance is a key preventive measure, yet maintaining consistent adherence remains challenging. A quality improvement (QI) initiative was undertaken to enhance HH practices among healthcare providers in a tertiary hospital in South India. METHODS: From August to December 2023, a QI project was implemented in Coronary Care Units (CCU) at KLE's Dr. Prabhakar Kore Hospital. Using the Point of Care Quality Improvement (PoCQI) methodology, a multidisciplinary team applied WHO's multimodal HH strategy through iterative Plan-Do-Study-Act (PDSA) cycles. Interventions included: (1) installation of centralised scrub stations with sterile footwear, (2) bedside multilingual posters, (3) structured staff training with night-shift monitoring and (4) real-time observation with feedback supported by leadership engagement. Weekly HH compliance and infection outcomes were tracked. RESULTS: Five PDSA cycles were conducted. Mean HH compliance improved from a baseline of 63.8% to 80.5% by week 20, reflecting a 26.7% relative increase and remained above 78% through week 30, confirming sustained gains postintervention. No methicillin-resistant Staphylococcus aureus, Pseudomonas or Klebsiella infections were reported during the intervention period. Blood culture positivity after 48 hours of CCU stay remained at 0%. Mortality trends varied and showed no consistent pattern attributable to the intervention. CONCLUSIONS: Integrating WHO's multimodal strategy with PoCQI led to a significant, low-cost improvement in HH compliance in a high-risk setting. This team-led approach demonstrated the impact of QI strategies in implementing cost-effective infection prevention practices in critical care settings. CI - (c) Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. FAU - Datta, Vikram AU - Datta V AUID- ORCID: 0000-0002-1047-6884 AD - Neonatology, Kalawati Saran Children's Hospital, New Delhi, India drvikramdatta@gmail.com. AD - Neonatology, Lady Hardinge Medical College, New Delhi, India. FAU - Pradeep, Jeena AU - Pradeep J AD - Nursing, Government of India Ministry of Health & Family Welfare, New Delhi, India. FAU - Srivastava, Sushil AU - Srivastava S AD - Pediatrics, University College of Medical Sciences, New Delhi, India. FAU - Kambar, Sanjay AU - Kambar S AD - Preventive Medicine, Jawaharlal Nehru Medical College, Belagavi, Karnataka, India. FAU - Hesarur, Vishwanath AU - Hesarur V AD - Cardiology, Jawaharlal Nehru Medical College, Belagavi, Karnataka, India. FAU - Bhandankar, Manisha AU - Bhandankar M AD - Department of Neonatology, Jawaharlal Nehru Medical College, Belagavi, Karnataka, India. FAU - Lalwani, Komal AU - Lalwani K AUID- ORCID: 0000-0001-6758-3093 AD - NQOCN, New Delhi, India. FAU - Garde, Rahul AU - Garde R AUID- ORCID: 0000-0002-6967-3217 AD - NQOCN, New Delhi, India. LA - eng PT - Journal Article DEP - 20260319 PL - England TA - BMJ Open Qual JT - BMJ open quality JID - 101710381 SB - IM MH - Humans MH - *Hand Hygiene/standards/methods/statistics & numerical data MH - Quality Improvement MH - India MH - *Cross Infection/prevention & control/epidemiology MH - Tertiary Care Centers/organization & administration/statistics & numerical data MH - Coronary Care Units/organization & administration/statistics & numerical data/standards MH - *Guideline Adherence/standards/statistics & numerical data MH - Infection Control/methods/standards/statistics & numerical data MH - Adherence Interventions PMC - PMC13007196 OTO - NOTNLM OT - Attitude of Health Personnel OT - Critical care OT - Hand Hygiene OT - Healthcare quality improvement OT - Patient safety COIS- Competing interests: None declared. EDAT- 2026/03/20 00:59 MHDA- 2026/03/20 01:00 PMCR- 2026/03/19 CRDT- 2026/03/19 21:02 PHST- 2025/09/18 00:00 [received] PHST- 2026/02/17 00:00 [accepted] PHST- 2026/03/20 01:00 [medline] PHST- 2026/03/20 00:59 [pubmed] PHST- 2026/03/19 21:02 [entrez] PHST- 2026/03/19 00:00 [pmc-release] AID - bmjoq-2025-003838 [pii] AID - 10.1136/bmjoq-2025-003838 [doi] PST - epublish SO - BMJ Open Qual. 2026 Mar 19;13(Suppl 1):e003838. doi: 10.1136/bmjoq-2025-003838. PMID- 41853094 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260319 LR - 20260813 IS - 2772-4875 (Electronic) IS - 2772-4875 (Linking) VI - 29 DP - 2026 Jun TI - Renal denervation for hypertension management: convergence and divergence across international guidelines. PG - 200618 LID - 10.1016/j.ijcrp.2026.200618 [doi] LID - 200618 AB - BACKGROUND: Renal denervation (RDN) has emerged as an interventional option for hypertension management. Three major international guidelines have recently addressed RDN indications and recommendations. OBJECTIVES: To compare and synthesize the positions of the European Society of Cardiology (ESC) 2024, European Society of Hypertension (ESH) 2023, and American College of Cardiology/American Heart Association (ACC/AHA) 2025 guidelines regarding RDN. METHODS: Structured comparative analysis of guideline recommendations using predefined domains: patient selection criteria, recommendation strength and level of evidence, procedural requirements, and clinical positioning. Each guideline was independently reviewed by two authors, with discrepancies resolved by consensus. CONCLUSIONS: All three guidelines converge on four major indications: uncontrolled hypertension, resistant hypertension, drug intolerance, and patient preference. Key divergences relate to the strength of recommendations and specific patient selection criteria. Although differences in recommendation classes (ACC/AHA 2b vs. ESC/ESH IIb) appear discordant, they largely reflect structural variations in grading frameworks rather than genuine differences in evidence appraisal. The modest expected blood pressure reduction (4-6 mmHg ambulatory systolic), equivalent to approximately one antihypertensive medication, translates into an estimated 10% reduction in major cardiovascular events, though individual responses vary considerably. RDN represents a complementary therapeutic option requiring multidisciplinary evaluation and shared decision-making. CI - (c) 2026 The Authors. FAU - Stephan, Dominique AU - Stephan D AD - Hypertension and Vascular Diseases, ESH Blood Pressure Clinic, University Hospital of Strasbourg, France. FAU - Morisot, Emma AU - Morisot E AD - Hypertension and Vascular Diseases, ESH Blood Pressure Clinic, University Hospital of Strasbourg, France. FAU - Cordeanu, Elena-Mihaela AU - Cordeanu EM AD - Hypertension and Vascular Diseases, ESH Blood Pressure Clinic, University Hospital of Strasbourg, France. LA - eng PT - Journal Article DEP - 20260303 PL - Netherlands TA - Int J Cardiol Cardiovasc Risk Prev JT - International journal of cardiology. Cardiovascular risk and prevention JID - 9918282077306676 PMC - PMC12993013 OTO - NOTNLM OT - Guidelines OT - Renal denervation OT - Resistant hypertension EDAT- 2026/03/19 07:10 MHDA- 2026/03/19 07:11 PMCR- 2026/03/03 CRDT- 2026/03/19 05:01 PHST- 2026/01/29 00:00 [received] PHST- 2026/02/22 00:00 [revised] PHST- 2026/03/02 00:00 [accepted] PHST- 2026/03/19 07:11 [medline] PHST- 2026/03/19 07:10 [pubmed] PHST- 2026/03/19 05:01 [entrez] PHST- 2026/03/03 00:00 [pmc-release] AID - S2772-4875(26)00048-6 [pii] AID - 200618 [pii] AID - 10.1016/j.ijcrp.2026.200618 [doi] PST - epublish SO - Int J Cardiol Cardiovasc Risk Prev. 2026 Mar 3;29:200618. doi: 10.1016/j.ijcrp.2026.200618. eCollection 2026 Jun. PMID- 41851641 OWN - NLM STAT- MEDLINE DCOM- 20260627 LR - 20261008 IS - 1471-2318 (Electronic) IS - 1471-2318 (Linking) VI - 26 IP - 1 DP - 2026 Mar 18 TI - The role of sleep disorders in the motoric and cognitive trajectories of older physically frail sarcopenic and healthy active subjects: SOMNUS-DARE, a prospective cohort study. LID - 10.1186/s12877-026-07275-3 [doi] LID - 588 AB - BACKGROUND: Sarcopenia, altered bone and systemic metabolism, physical frailty and cognitive decline are age-dependent and interrelated phenomena. Sleep disorders which are erroneously considered as part of the aging process might be the unifying underlying mechanism of accelerated aging. It is well-known that impaired sleep health could predict neurodegeneration and functional decline. However, in current clinical practice, sleep disorders are not routinely screened and only a minority of cases require second-tier specialist techniques. The delay of their assessment, without a comprehensive evaluation, results in higher healthcare costs. The aim of SOMNUS-DARE project is to detect, in a translational manner, the role of sleep disorders in the genesis of physical frailty, sarcopenia, mild cognitive impairment, and to measure their contribution to the progression of these phenomena towards mobility-disability and dementia. METHODS: SOMNUS-DARE project will evaluate a sample of 300 community-dwelling healthy active and physically frail sarcopenic subjects, aged 65 years or older, free of cognitive impairment and self-sufficient in basic activities of daily living. The effect of sleep disorders on physical, cognitive and cardiovascular function, systemic, bone and muscle metabolism and body composition will be prospectively assessed by performing: comprehensive geriatric assessment; sleep analysis and environmental monitoring; brain MRI, amyloid positron emission tomography; bone densitometry; radiofrequency echographic multi spectrometry; muscle ultrasound; bioimpedance analysis; cardiac ultrasound; dynamic blood pressure monitoring; blood and saliva measurements. DISCUSSION: The project will make it possible to analyse an extremely relevant public health problem which is still underestimated in the current clinical practice. The combination of traditional diagnostics and innovative digital health techniques, will allow a translational and multidimensional analysis of sleep disorders and to weigh their impact on physical and cognitive decline and quality-of-life trajectories. The expected results will highlight the importance of sleep as a fundamental determinant of health and will contribute to the activation of clinical diagnostic and therapeutic pathways in older individuals where the tailored approach might contribute to substantial benefit. TRIAL REGISTRATION: Clinical Trial Number: NCT06944600; Clinical Trial Registry: ClinicalTrials.gov; Registration Date: April 17th, 2025. FAU - Salvi, Marco AU - Salvi M AD - Geriatric Clinic Unit, University Hospital of Parma, Parma, Italy. marco.salvi@unipr.it. AD - Department of Medicine and Surgery, University of Parma, Parma, Italy. marco.salvi@unipr.it. FAU - Zucchini, Irene AU - Zucchini I AD - Geriatric Clinic Unit, University Hospital of Parma, Parma, Italy. AD - Department of Medicine and Surgery, University of Parma, Parma, Italy. FAU - Lauretani, Fulvio AU - Lauretani F AD - Geriatric Clinic Unit, University Hospital of Parma, Parma, Italy. AD - Department of Medicine and Surgery, University of Parma, Parma, Italy. AD - Interdepartmental Centre for Sleep Medicine, University of Parma, Parma, Italy. FAU - Tanzi, Beatrice AU - Tanzi B AD - Geriatric Clinic Unit, University Hospital of Parma, Parma, Italy. AD - Department of Medicine and Surgery, University of Parma, Parma, Italy. FAU - Testa, Crescenzo AU - Testa C AD - Department of Medicine and Surgery, University of Parma, Parma, Italy. FAU - Ughetti, Giorgio AU - Ughetti G AD - Department of Medicine and Surgery, University of Parma, Parma, Italy. FAU - Parrino, Liborio AU - Parrino L AD - Department of Medicine and Surgery, University of Parma, Parma, Italy. AD - Interdepartmental Centre for Sleep Medicine, University of Parma, Parma, Italy. AD - Sleep Disorders Center, University Hospital of Parma, Parma, Italy. FAU - Mutti, Carlotta AU - Mutti C AD - Department of Medicine and Surgery, University of Parma, Parma, Italy. AD - Interdepartmental Centre for Sleep Medicine, University of Parma, Parma, Italy. AD - Sleep Disorders Center, University Hospital of Parma, Parma, Italy. FAU - Rausa, Francesco AU - Rausa F AD - Department of Medicine and Surgery, University of Parma, Parma, Italy. AD - Interdepartmental Centre for Sleep Medicine, University of Parma, Parma, Italy. AD - Sleep Disorders Center, University Hospital of Parma, Parma, Italy. FAU - Pollara, Irene AU - Pollara I AD - Interdepartmental Centre for Sleep Medicine, University of Parma, Parma, Italy. FAU - Soglia, Margherita AU - Soglia M AD - Interdepartmental Centre for Sleep Medicine, University of Parma, Parma, Italy. FAU - Sverzellati, Nicola AU - Sverzellati N AD - Department of Medicine and Surgery, University of Parma, Parma, Italy. AD - Radiological Sciences Unit, University Hospital of Parma, Parma, Italy. FAU - Bozzetti, Francesca AU - Bozzetti F AD - Department of Medicine and Surgery, University of Parma, Parma, Italy. AD - Neuroradiology Unit, University Hospital of Parma, Parma, Italy. FAU - Ruffini, Livia AU - Ruffini L AD - Nuclear Medicine Division, University Hospital of Parma, Parma, Italy. FAU - Ghetti, Caterina AU - Ghetti C AD - Medical Physics Unit, University Hospital of Parma, Parma, Italy. FAU - Aloe, Rosalia AU - Aloe R AD - Laboratory of Clinical Chemistry and Haematology, University Hospital of Parma, Parma, Italy. FAU - Niccoli, Giampaolo AU - Niccoli G AD - Department of Medicine and Surgery, University of Parma, Parma, Italy. AD - Division of Cardiology, University Hospital of Parma, Parma, Italy. FAU - Caminiti, Caterina AU - Caminiti C AD - Clinical and Epidemiological Research Unit, University Hospital of Parma, Parma, Italy. FAU - Puntoni, Matteo AU - Puntoni M AD - Clinical and Epidemiological Research Unit, University Hospital of Parma, Parma, Italy. FAU - Maglietta, Giuseppe AU - Maglietta G AD - Clinical and Epidemiological Research Unit, University Hospital of Parma, Parma, Italy. FAU - Maggio, Marcello AU - Maggio M AD - Geriatric Clinic Unit, University Hospital of Parma, Parma, Italy. marcellogiuseppe.maggio@unipr.it. AD - Department of Medicine and Surgery, University of Parma, Parma, Italy. marcellogiuseppe.maggio@unipr.it. AD - Interdepartmental Centre for Sleep Medicine, University of Parma, Parma, Italy. marcellogiuseppe.maggio@unipr.it. CN - SOMNUS-DARE Investigators LA - eng SI - ClinicalTrials.gov/NCT06944600 GR - B53C22006240001/Italian Complementary National Plan PNC-I.1 "Research initiatives for innovative technologies and pathways in the health and welfare sector" D.D. 931 of 06/06/2022, "DARE - DigitAl lifelong pRevEntion" initiative, code PNC0000002/ PT - Clinical Trial Protocol PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20260318 PL - England TA - BMC Geriatr JT - BMC geriatrics JID - 100968548 SB - IM MH - Aged MH - Aged, 80 and over MH - Female MH - Humans MH - Male MH - *Cognition/physiology MH - Cognitive Dysfunction MH - Cohort Studies MH - *Frail Elderly/psychology MH - Geriatric Assessment/methods MH - *Motor Activity/physiology MH - Prospective Studies MH - *Sarcopenia/psychology/diagnosis/physiopathology/epidemiology MH - *Sleep Wake Disorders/psychology/epidemiology/diagnosis/physiopathology PMC - PMC13112712 OTO - NOTNLM OT - Ageing trajectories OT - Digital health OT - Multidisciplinary approach OT - Sleep disorders COIS- Declarations. Ethics approval and consent to participate: The SOMNUS-DARE study was approved by the AVEN (Area Vasta Emilia Nord) Ethics Committee (ethic approval with protocol number 12149, March 12th, 2025). All participants have to provide their written informed consent before they can participate in the study. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. FIR - Triglia, Laura Torlai IR - Triglia LT FIR - Stefanizzi, Andrea IR - Stefanizzi A FIR - Gurgoglione, Filippo Luca IR - Gurgoglione FL FIR - Cattabiani, Chiara IR - Cattabiani C FIR - Spaggiari, Sabrina IR - Spaggiari S FIR - Cagna, Patrizia IR - Cagna P FIR - Rrapaj, Gertila IR - Rrapaj G FIR - Ribattezzato, Valeria IR - Ribattezzato V FIR - Galli, Elisa IR - Galli E FIR - Leone, Marta IR - Leone M FIR - Imperatore, Elisabeth IR - Imperatore E FIR - Anfuso, Salvatore Vincenzo IR - Anfuso SV FIR - Lazzarelli, Silvia IR - Lazzarelli S FIR - Balan, Denisa IR - Balan D EDAT- 2026/03/19 07:10 MHDA- 2026/06/27 12:38 PMCR- 2026/03/18 CRDT- 2026/03/19 00:45 PHST- 2025/04/22 00:00 [received] PHST- 2026/02/26 00:00 [accepted] PHST- 2026/06/27 12:38 [medline] PHST- 2026/03/19 07:10 [pubmed] PHST- 2026/03/19 00:45 [entrez] PHST- 2026/03/18 00:00 [pmc-release] AID - 10.1186/s12877-026-07275-3 [pii] AID - 7275 [pii] AID - 10.1186/s12877-026-07275-3 [doi] PST - epublish SO - BMC Geriatr. 2026 Mar 18;26(1):588. doi: 10.1186/s12877-026-07275-3. PMID- 41850889 OWN - NLM STAT- MEDLINE DCOM- 20260711 LR - 20260813 IS - 1759-7714 (Electronic) IS - 1759-7706 (Print) IS - 1759-7706 (Linking) VI - 17 IP - 6 DP - 2026 Mar TI - Clinical Versus Pathologic Staging in Early-Stage Non-Small Cell Lung Cancer Assessed by an Established Lung Cancer Multidisciplinary Meeting. PG - e70267 LID - 10.1111/1759-7714.70267 [doi] LID - e70267 AB - INTRODUCTION: Accurate clinical staging of early-stage non-small cell lung cancer (NSCLC) is critical to guide treatment recommendations. Clinical and pathological staging concordance for NSCLC is a quality indicator of lung cancer care. We compared clinical and pathological staging of early-stage NSCLC assessed by an established lung cancer multidisciplinary team (MDT), focusing on clinical under-staging. METHOD: Retrospective review of all patients with early-stage NSCLC referred by our lung cancer MDT for definitive surgical management between January 2019 and December 2023. RESULTS: The cohort included 259 patients. The median time from review by respiratory service and referral to cardiothoracic surgery was 82 (IQR 59-132) days. Time from MDT discussion to surgery was 28 (IQR 18-41.5) days. Overall clinical and pathologic staging concordance occurred in 73% of cases, with 18.9% of cases clinically under-staged. Factors associated with clinical under-staging were time between sentinel CT imaging and surgery (p = 0.01) and histopathologic evidence of visceral pleural (p = 0.003), vessel (p = 0.031) and lymphatic (p = 0.014) invasion. At follow-up there was a significantly increased risk of mortality (OR 2.06, p = 0.003) and disease recurrence (OR 2.06, p = 0.037) for clinically under-staged patients. Discrepancies which may have led to different treatment decisions occurred in 18 (7%) patients. CONCLUSION: For patients diagnosed with early-stage NSCLC referred for curative surgical management, disagreement between clinical and pathologic staging may be due to treatment delay and malignancy histopathological features. Clinically under-staging increases risk of morbidity and mortality, which could be addressed through improved timeliness of care. Concordance of clinical and pathologic staging should be a routinely assessed benchmark for all lung cancer MDTs. CI - (c) 2026 The Author(s). Thoracic Cancer published by John Wiley & Sons Australia, Ltd. FAU - Nolan, James AU - Nolan J AUID- ORCID: 0009-0009-0092-8216 AD - Respiratory Sleep and Mycobacterial Medicine, The Princess Alexandra Hospital, Woolloongabba, Queensland, Australia. AD - School of Medicine, University of Queensland, Herston, Queensland, Australia. FAU - Sather, Theron AU - Sather T AD - Respiratory Sleep and Mycobacterial Medicine, The Princess Alexandra Hospital, Woolloongabba, Queensland, Australia. FAU - Hukins, Craig AU - Hukins C AD - Respiratory Sleep and Mycobacterial Medicine, The Princess Alexandra Hospital, Woolloongabba, Queensland, Australia. AD - School of Medicine, University of Queensland, Herston, Queensland, Australia. FAU - Murphy, Michelle AU - Murphy M AD - Respiratory Sleep and Mycobacterial Medicine, The Princess Alexandra Hospital, Woolloongabba, Queensland, Australia. AD - School of Medicine, University of Queensland, Herston, Queensland, Australia. LA - eng PT - Journal Article PL - Singapore TA - Thorac Cancer JT - Thoracic cancer JID - 101531441 SB - IM MH - Humans MH - *Carcinoma, Non-Small-Cell Lung/pathology/surgery MH - Female MH - *Lung Neoplasms/pathology/surgery MH - Neoplasm Staging MH - Male MH - Retrospective Studies MH - Aged MH - Middle Aged PMC - PMC13097408 COIS- The authors declared no conflicts of interest. EDAT- 2026/03/19 01:32 MHDA- 2026/03/19 01:33 PMCR- 2026/03/18 CRDT- 2026/03/18 22:23 PHST- 2026/02/11 00:00 [revised] PHST- 2025/09/24 00:00 [received] PHST- 2026/02/27 00:00 [accepted] PHST- 2026/03/19 01:33 [medline] PHST- 2026/03/19 01:32 [pubmed] PHST- 2026/03/18 22:23 [entrez] PHST- 2026/03/18 00:00 [pmc-release] AID - TCA70267 [pii] AID - 10.1111/1759-7714.70267 [doi] PST - ppublish SO - Thorac Cancer. 2026 Mar;17(6):e70267. doi: 10.1111/1759-7714.70267. PMID- 41850707 OWN - NLM STAT- MEDLINE DCOM- 20260711 LR - 20260813 IS - 2399-6641 (Electronic) IS - 2399-6641 (Linking) VI - 15 IP - 1 DP - 2026 Mar 18 TI - Scalable treatment algorithm focused on hypertension management for the University of California. LID - 10.1136/bmjoq-2025-003753 [doi] LID - e003753 AB - Uncontrolled hypertension remains a leading contributor to morbidity and mortality, particularly among underserved populations. To address care variability and disparities in treatment, the University of California Health system developed and implemented the UC Way Hypertension Medication Algorithm across six academic health centres. This standardised, evidence-based protocol was co-developed by a team of multidisciplinary experts in pharmacy, cardiology, primary care and data science, with an emphasis on medication affordability and the use of two-drug fixed dose combinations as first-line therapy. Implementation strategies included stakeholder engagement, clinician education and integration into electronic health records and routine workflows. The algorithm now informs treatment decisions for over 90000 patients with hypertension and has been associated with improvements in hypertension control. The manuscript focuses on the process of algorithm development, adaptation within a complex multi-payer environment and lessons learned in promoting standardisation, clinician uptake and health equity at scale. This model may inform similar efforts across other decentralised health systems seeking to optimise chronic disease management. CI - (c) Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. FAU - Kishore, Sandeep P AU - Kishore SP AD - Department of Medicine, University of California San Francisco, San Francisco, California, USA sandeep.kishore@ucsf.edu. FAU - Martin, Heather E AU - Martin HE AD - Department of Pharmacy, University of California Davis Health, Sacramento, California, USA. FAU - Friedberg, Nicki AU - Friedberg N AD - University of California Health, Oakland, California, USA. FAU - Narang, Pranay AU - Narang P AUID- ORCID: 0000-0001-8592-1607 AD - University of California Berkeley University of California San Francisco Joint Medical Program, Berkeley, California, USA. FAU - Sak, Rachael AU - Sak R AD - University of California Health, Oakland, California, USA. FAU - Skootsky, Samuel A AU - Skootsky SA AD - University of California Health, Oakland, California, USA. AD - Department of Medicine, University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, USA. CN - UC Way Hypertension Initiative Medication Use Collaborators LA - eng PT - Journal Article DEP - 20260318 PL - England TA - BMJ Open Qual JT - BMJ open quality JID - 101710381 RN - 0 (Antihypertensive Agents) SB - IM MH - Humans MH - *Hypertension/drug therapy/therapy MH - California MH - *Algorithms MH - Universities/organization & administration/statistics & numerical data MH - Antihypertensive Agents/therapeutic use MH - Disease Management PMC - PMC13007186 OTO - NOTNLM OT - Clinical Protocols OT - Clinical practice guidelines OT - Evidence-Based Practice OT - Evidence-based medicine OT - Health Equity COIS- Competing interests: Dr Kishore reports advisory fees from Redesign Health; grants and equity in CareX.AI. FIR - Patel, Ayan IR - Patel A FIR - Atreja, Surabhi IR - Atreja S FIR - Ben Rasmussen, Connie Abdo IR - Ben Rasmussen CA FIR - Entsuah, Nana IR - Entsuah N FIR - Phan, Alan IR - Phan A FIR - Rahimi, Maryam IR - Rahimi M FIR - Barakat, Peter IR - Barakat P FIR - Chima-Melton, Chidinma IR - Chima-Melton C FIR - Kwak, Hannah IR - Kwak H FIR - Roney, Linda IR - Roney L FIR - Halanski, Natalie IR - Halanski N FIR - Lunde, Ottar IR - Lunde O FIR - Medders, Kathryn IR - Medders K FIR - Morn, Cassandra IR - Morn C FIR - Leon, Rebecca Chung-Yan IR - Leon RC FIR - Wong, Shirley IR - Wong S FIR - Huang, Lily IR - Huang L FIR - Shimatsu, Kaumakaokalani IR - Shimatsu K EDAT- 2026/03/19 01:32 MHDA- 2026/03/19 01:33 PMCR- 2026/03/18 CRDT- 2026/03/18 20:52 PHST- 2025/08/16 00:00 [received] PHST- 2026/02/17 00:00 [accepted] PHST- 2026/03/19 01:33 [medline] PHST- 2026/03/19 01:32 [pubmed] PHST- 2026/03/18 20:52 [entrez] PHST- 2026/03/18 00:00 [pmc-release] AID - bmjoq-2025-003753 [pii] AID - 10.1136/bmjoq-2025-003753 [doi] PST - epublish SO - BMJ Open Qual. 2026 Mar 18;15(1):e003753. doi: 10.1136/bmjoq-2025-003753. PMID- 41848339 OWN - NLM STAT- MEDLINE DCOM- 20260623 LR - 20260813 IS - 1445-5994 (Electronic) IS - 1444-0903 (Print) IS - 1444-0903 (Linking) VI - 56 IP - 6 DP - 2026 Jun TI - Practical recommendations for treating patients with chronic kidney disease in Australia: a multidisciplinary approach. PG - 966-975 LID - 10.1111/imj.70403 [doi] AB - BACKGROUND: Chronic kidney disease (CKD) is a significant public health challenge in Australia, affecting ~10% of the adult population and contributing to substantial morbidity and mortality. Diabetes, hypertension, cardiovascular disease and CKD frequently co-exist; therefore, a multidisciplinary approach is necessary to manage these conditions. Recent advances in pharmacological therapies, particularly for diabetic kidney disease (DKD), can improve clinical outcomes. Current guidelines may not fully address the complexities of CKD management across all levels of care in the Australian context. OBJECTIVE: To develop simple, practical, evidence-based recommendations to guide healthcare practitioners in improving CKD management across Australia. METHODS: A multidisciplinary panel of eight healthcare practitioners (nephrologists, cardiologists, endocrinologists and general practitioners) employed an adapted virtual nominal group technique to achieve consensus on CKD management recommendations. RESULTS: The panel developed nine unique recommendations; five achieved consensus, and four were in accordance with GRADE guidance: Both urine albumin-to-creatinine ratio (uACR) and estimated glomerular filtration rate (eGFR) should be assessed regularly in patients at increased CKD risk. Most patients with CKD can be managed in primary care, with specialist referral when required. Ensure all cardiometabolic risk factors are assessed and managed proactively. For patients with diabetic kidney disease, consider the four pillars of therapy. CONCLUSION: These multidisciplinary consensus recommendations provide actionable guidance for Australian healthcare practitioners to improve CKD management across all levels of care, addressing the unique needs of the Australian healthcare landscape. CI - (c) 2026 The Author(s). Internal Medicine Journal published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Physicians. FAU - Schlaich, M P AU - Schlaich MP AD - Dobney Hypertension Centre, Medical School, University of Western Australia - Royal Perth Hospital and RPH Research Foundation, Perth, Western Australia, Australia. FAU - Abhayaratna, W P AU - Abhayaratna WP AD - School of Medicine and Psychology, The Australian National University, Canberra, Australian Capital Territory, Australia. FAU - Audehm, R AU - Audehm R AD - Department of General Practice and Primary Care, University of Melbourne, Melbourne, Victoria, Australia. FAU - Ekinci, E I AU - Ekinci EI AD - Department of Medicine, Melbourne Medical School, University of Melbourne, Melbourne, Victoria, Australia. AD - Department of Endocrinology, Austin Health, Melbourne, Victoria, Australia. AD - The Australian Centre for Accelerating Diabetes Innovations (ACADI), University of Melbourne, Melbourne, Victoria, Australia. FAU - MacIsaac, R J AU - MacIsaac RJ AD - The Australian Centre for Accelerating Diabetes Innovations (ACADI), University of Melbourne, Melbourne, Victoria, Australia. AD - Department of Endocrinology and Diabetes, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia. AD - Department of Medicine, St Vincent's Hospital Melbourne, University of Melbourne, Fitzroy, Victoria, Australia. FAU - Nelson, A J AU - Nelson AJ AD - Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia. FAU - Sharma, A AU - Sharma A AD - Platinum Medical Centre, Brisbane, Queensland, Australia. FAU - Pollock, C AU - Pollock C AD - Kolling Institute, University of Sydney, Royal North Shore Hospital, St Leonards, New South Wales, Australia. LA - eng GR - Novo Nordisk/ GR - Boehringer Ingelheim/ PT - Journal Article DEP - 20260318 PL - Australia TA - Intern Med J JT - Internal medicine journal JID - 101092952 SB - IM MH - Humans MH - Australia/epidemiology MH - *Renal Insufficiency, Chronic/therapy/epidemiology/diagnosis MH - Glomerular Filtration Rate MH - *Practice Guidelines as Topic/standards MH - Diabetic Nephropathies/therapy/epidemiology MH - *Patient Care Team/standards MH - Risk Factors PMC - PMC13288315 OTO - NOTNLM OT - albuminuria OT - cardiometabolic OT - chronic kidney disease OT - diabetes OT - hypertension OT - risk assessment EDAT- 2026/03/18 12:53 MHDA- 2026/06/23 18:34 PMCR- 2026/06/23 CRDT- 2026/03/18 09:13 PHST- 2025/08/21 00:00 [received] PHST- 2026/02/25 00:00 [accepted] PHST- 2026/06/23 18:34 [medline] PHST- 2026/03/18 12:53 [pubmed] PHST- 2026/03/18 09:13 [entrez] PHST- 2026/06/23 00:00 [pmc-release] AID - IMJ70403 [pii] AID - 10.1111/imj.70403 [doi] PST - ppublish SO - Intern Med J. 2026 Jun;56(6):966-975. doi: 10.1111/imj.70403. Epub 2026 Mar 18. PMID- 41847464 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260318 LR - 20260926 IS - 1016-7315 (Print) IS - 2212-5043 (Electronic) IS - 1016-7315 (Linking) VI - 37 IP - 3 DP - 2025 TI - Transcatheter Pulmonary Valve Replacement (TPVR): A Saudi Consensus Statement. PG - 14 LID - 10.37616/2212-5043.1448 [doi] LID - 14 AB - OBJECTIVES: To provide an expert consensus on the appropriate use of transcatheter pulmonary valve replacement (TPVR) in managing chronic pulmonary regurgitation (PR), particularly in patients with congenital heart defects such as Tetralogy of Fallot (TOF). The consensus aims to address current practices, patient selection criteria, procedural planning, and device-specific considerations to guide clinicians in optimizing outcomes. METHODS: A multidisciplinary panel reviewed existing literature, clinical guidelines, and real-world practices. Key domains covered include epidemiology, anatomical and hemodynamic evaluation, pre- and post-procedural imaging, device characteristics, and patient selection. Imaging modalities such as echocardiography, cardiac magnetic resonance (CMR), and computed tomography (CT) were critically appraised for their role in procedural planning. Recommendations were structured to reflect best practices across varied healthcare settings. RESULTS: TPVR is increasingly adopted as a less invasive alternative to surgical pulmonary valve replacement. Devices such as Melody, SAPIEN, Harmony, and Venus P-valve are used based on RVOT anatomy and size. Pre-procedural imaging and multidisciplinary assessment are critical for safe deployment and optimal valve positioning. TPVR demonstrated favourable outcomes in terms of RV remodelling, PR and PS reduction, functional improvement, and reduced hospital stay compared to surgical approaches. Complications such as tricuspid valve injury, stent fracture, and infective endocarditis remain concerns. CONCLUSIONS: TPVR offers a safe and effective treatment for selected patients with PR or PS following congenital heart disease repair. A standardized, imaging-guided approach with multidisciplinary oversight is essential. Further research is needed to assess long-term valve durability and to refine strategies for high-risk and paediatric populations. CI - (c) 2025 Saudi Heart Association. FAU - AlNajashi, Khalid AU - AlNajashi K AD - Prince Sultan Cardiac Center, Riyadh, Kingdom of Saudi Arabia. FAU - Al Zahrani, Ahmed AU - Al Zahrani A AD - Prince Sultan Cardiac Center, Riyadh, Kingdom of Saudi Arabia. FAU - Al Qabani, Atif AU - Al Qabani A AD - King Faisal Cardiac Center, King Abdulaziz Medical City, Jeddah, Kingdom of Saudi Arabia. FAU - Al Humaid, Mohamed AU - Al Humaid M AD - King Salman Cardiac Center, King Fahad Medical City, Riyadh, Kingdom of Saudi Arabia. FAU - Binobaidan, Mishael AU - Binobaidan M AD - Prince Sultan Cardiac Center, Ministry of Health, Al Ahsa, Kingdom of Saudi Arabia. FAU - Krimley, Ahmed AU - Krimley A AD - King Faisal Cardiac Center, King Abdulaziz Medical City, Jeddah, Kingdom of Saudi Arabia. FAU - Al Omrani, Ahmed AU - Al Omrani A AD - King Abdulaziz Cardiac Center, Riyadh, Kingdom of Saudi Arabia. FAU - Al Shahrani, Dhafer AU - Al Shahrani D AD - King Abdulaziz Cardiac Center, Riyadh, Kingdom of Saudi Arabia. FAU - Al Samman, Ahmed AU - Al Samman A AD - King Abdullah Medical City Specialist Hospital, Makkah, Kingdom of Saudi Arabia. FAU - Al Quei, Abdullah AU - Al Quei A AD - Prince Sultan Cardiac Center, Ministry of Health, Alqasim, Kingdom of Saudi Arabia. FAU - Al Twirqi, Khalid AU - Al Twirqi K AD - Heart Center, King Faisal Specialist Hospital and Research Center, Riyadh, Kingdom of Saudi Arabia. FAU - Alkashkari, Wail AU - Alkashkari W AD - King Faisal Cardiac Center, King Abdulaziz Medical City, Jeddah, Kingdom of Saudi Arabia. FAU - Tash, Adel AU - Tash A AD - Seha Virtual Hospital, Riyadh, Kingdom of Saudi Arabia. AD - National Heart Center, Riyadh, Kingdom of Saudi Arabia. AD - Saudi Health Council, Riyadh, Kingdom of Saudi Arabia. LA - eng PT - Journal Article DEP - 20250806 PL - Saudi Arabia TA - J Saudi Heart Assoc JT - Journal of the Saudi Heart Association JID - 9887261 PMC - PMC12991821 OTO - NOTNLM OT - Congenital heart disease OT - Imaging evaluation OT - Pulmonary regurgitation OT - Right ventricular dysfunction OT - Transcatheter pulmonary valve replacement OT - Valve durability COIS- Conflict of interest: All authors have no disclosures. EDAT- 2026/03/18 07:26 MHDA- 2026/03/18 07:27 PMCR- 2025/08/06 CRDT- 2026/03/18 04:41 PHST- 2025/05/12 00:00 [received] PHST- 2025/06/25 00:00 [accepted] PHST- 2026/03/18 07:27 [medline] PHST- 2026/03/18 07:26 [pubmed] PHST- 2026/03/18 04:41 [entrez] PHST- 2025/08/06 00:00 [pmc-release] AID - sha36 [pii] AID - 10.37616/2212-5043.1448 [doi] PST - epublish SO - J Saudi Heart Assoc. 2025 Aug 6;37(3):14. doi: 10.37616/2212-5043.1448. eCollection 2025. PMID- 41843050 OWN - NLM STAT- MEDLINE DCOM- 20260627 LR - 20260813 IS - 1534-3111 (Electronic) IS - 1522-6417 (Print) IS - 1522-6417 (Linking) VI - 28 IP - 1 DP - 2026 Mar 17 TI - Updates in the 2025 AHA/ACC Hypertension Guideline. LID - 10.1007/s11906-026-01372-9 [doi] LID - 19 AB - PURPOSE OF REVIEW: Hypertension remains a leading cause of cardiovascular morbidity and mortality in the United States. The 2025 American Heart Association (AHA)/American College of Cardiology (ACC) Guideline for the Management of High Blood Pressure in Adults provides the first major update since 2017. It reveals new evidence in the diagnosis, risk assessment, and treatment of hypertension. This review summarizes key updates, contrasts them with prior recommendations, and discusses implications for clinical practice. RECENT FINDINGS: The 2025 AHA/ACC Hypertension Guideline introduces several major updates that reshape risk assessment, diagnosis, and treatment strategy. Adoption of the PREVENT risk calculator replaces the pooled cohort equations, improving cardiovascular risk estimation by incorporating renal function, statin use, and social drivers of health. Screening for primary aldosteronism is expanded to all patients with stage 2 or resistant hypertension, addressing underdiagnosis of this secondary cause. Renal denervation is introduced as an adjunctive option for select patients with resistant hypertension. The guideline also provides expanded recommendations for special populations, including those with chronic kidney disease, diabetes, pregnancy, and neurologic disorders. Enhanced emphasis on home blood pressure monitoring, lifestyle modification, and team-based care highlights the growing importance of patient engagement and coordinated care. The 2025 AHA/ACC Hypertension Guideline marks a pivotal shift toward risk-based, patient-centered hypertension management. It reinforces the need for tailored strategies that bridge clinical practice and population health. Effective implementation will depend on interdisciplinary collaboration and equitable access to preventative and therapeutic resources. FAU - Brown, Carly AU - Brown C AD - IMPACT Center for Pharmacy Transformation, University of Mississippi School of Pharmacy, Jackson, MS, USA. FAU - Clark, Donald 3rd AU - Clark D 3rd AD - Department of Medicine, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS, 39216, USA. FAU - Jones, Daniel W AU - Jones DW AD - Department of Medicine, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS, 39216, USA. djones@umc.edu. LA - eng PT - Journal Article PT - Review DEP - 20260317 PL - United States TA - Curr Hypertens Rep JT - Current hypertension reports JID - 100888982 RN - 0 (Antihypertensive Agents) SB - IM MH - Humans MH - *Hypertension/diagnosis/therapy MH - *Practice Guidelines as Topic MH - United States MH - *Antihypertensive Agents/therapeutic use MH - American Heart Association MH - Risk Assessment PMC - PMC12995957 OTO - NOTNLM OT - AHA/ACC 2025 guideline OT - Cardiovascular risk assessment OT - Hypertension management OT - Patient-centered care OT - Resistant hypertension COIS- Declarations. Competing interests: The authors declare no competing interests. EDAT- 2026/03/17 14:25 MHDA- 2026/06/27 12:36 PMCR- 2026/03/17 CRDT- 2026/03/17 12:06 PHST- 2025/10/30 00:00 [received] PHST- 2026/03/06 00:00 [accepted] PHST- 2026/06/27 12:36 [medline] PHST- 2026/03/17 14:25 [pubmed] PHST- 2026/03/17 12:06 [entrez] PHST- 2026/03/17 00:00 [pmc-release] AID - 10.1007/s11906-026-01372-9 [pii] AID - 1372 [pii] AID - 10.1007/s11906-026-01372-9 [doi] PST - epublish SO - Curr Hypertens Rep. 2026 Mar 17;28(1):19. doi: 10.1007/s11906-026-01372-9. PMID- 41840128 OWN - NLM STAT- MEDLINE DCOM- 20260805 LR - 20260805 IS - 1532-1827 (Electronic) IS - 0007-0920 (Print) IS - 0007-0920 (Linking) VI - 134 IP - 10 DP - 2026 May TI - Patient-centered outcomes according to cancer status in cardiac surgery patients: a population-based cohort study. PG - 1447-1458 LID - 10.1038/s41416-026-03358-5 [doi] AB - BACKGROUND: More cancer survivors are undergoing cardiac surgery, but their postoperative outcomes remain poorly understood. We aimed to describe the incidence and predictors of postoperative major adverse cardiovascular events (MACE) and patient-defined cardiovascular and non-cardiovascular events (PACE) by cancer status. METHODS: We conducted a retrospective cohort study (2016-2022) among U.S. adults (>/=18 years) undergoing cardiac surgery in MarketScan and Medicare databases. Co-primary outcomes were MACE (stroke, heart failure, myocardial infarction, repeat revascularization) and PACE (stroke, heart failure, new-onset dialysis, long-term care admission, ventilator-dependence). Cox regression evaluated the association of cancer status with postoperative outcomes. RESULTS: Among 61,581 patients (74.1% male; mean age 61 +/- 10.9 years), 5381 (8.7%) had cancer. Although cancer patients exhibited higher unadjusted MACE and PACE over 2.0 +/- 1.7 years (p < 0.001), multivariable analyses showed no significant association between cancer status and MACE or PACE at 30-days or at long-term follow-up MACE (aHR 1.05, 95%CI [0.99-1.10]) and PACE (aHR 1.02, [0.96-1.08]). Blood (aHR 1.13, [1.01-1.26]) and lung cancers (aHR 1.32, [1.08-1.62]) were associated with increased MACE risk, while digestive (aHR 1.17, [1.00-1.36]) and blood (aHR 1.14, [1.01-1.28]) cancers were linked to higher PACE risk. Factors more strongly predictive of PACE than MACE included older age, female sex and valvular/complex surgeries. DISCUSSION: Cancer status alone should not preclude cardiac surgery. A personalised, multidisciplinary approach may help optimise outcomes and better manage risks in this high-risk population. CI - (c) 2026. The Author(s), under exclusive licence to Springer Nature Limited. FAU - Jabagi, Habib AU - Jabagi H AUID- ORCID: 0000-0003-2326-8336 AD - Division of Cardiothoracic Surgery, The Valley Hospital, Ridgewood, NJ, USA. AD - Department of Cardiovascular Surgery, Mt. Sinai Hospital, Icahn School of Medicine, New York, NY, USA. FAU - Lee, Joshua G AU - Lee JG AD - Faculty of Medical Sciences, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada. FAU - Yasui, Osamu W AU - Yasui OW AD - Division of Cardiothoracic Anesthesiology, Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine, Stanford, CA, USA. FAU - Mamas, Mamas A AU - Mamas MA AD - Keele Cardiovascular Research Group, Keele University, Staffordshire, UK. FAU - Sun, Louise Y AU - Sun LY AUID- ORCID: 0000-0003-3381-3115 AD - Division of Cardiothoracic Anesthesiology, Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine, Stanford, CA, USA. sunl@stanford.edu. LA - eng PT - Journal Article PT - Observational Study DEP - 20260316 PL - England TA - Br J Cancer JT - British journal of cancer JID - 0370635 SB - IM MH - Retrospective Studies MH - Humans MH - Treatment Outcome MH - Male MH - Female MH - Middle Aged MH - Aged MH - Patient Reported Outcome Measures MH - Follow-Up Studies MH - Incidence MH - *Postoperative Complications/epidemiology/etiology MH - *Cardiovascular Diseases/epidemiology/etiology MH - *Neoplasms/complications/epidemiology MH - *Cardiac Surgical Procedures/adverse effects MH - United States/epidemiology MH - Risk Factors PMC - PMC13133156 COIS- Competing interests: The authors declare no competing interests. Ethics approval and consent to participate: The Stanford University IRB approved this study and waived the need for informed consent. This study was performed in accordance with the Declaration of Helsinki. EDAT- 2026/03/17 06:48 MHDA- 2026/05/01 00:31 PMCR- 2027/03/16 CRDT- 2026/03/17 00:28 PHST- 2025/04/19 00:00 [received] PHST- 2026/02/10 00:00 [accepted] PHST- 2025/12/25 00:00 [revised] PHST- 2026/05/01 00:31 [medline] PHST- 2026/03/17 06:48 [pubmed] PHST- 2026/03/17 00:28 [entrez] PHST- 2027/03/16 00:00 [pmc-release] AID - 10.1038/s41416-026-03358-5 [pii] AID - 3358 [pii] AID - 10.1038/s41416-026-03358-5 [doi] PST - ppublish SO - Br J Cancer. 2026 May;134(10):1447-1458. doi: 10.1038/s41416-026-03358-5. Epub 2026 Mar 16. PMID- 41839492 OWN - NLM STAT- MEDLINE DCOM- 20260711 LR - 20260920 IS - 2053-3624 (Print) IS - 2053-3624 (Electronic) IS - 2053-3624 (Linking) VI - 13 IP - 1 DP - 2026 Mar 16 TI - Value of cinematic rendering in cardiac and vascular imaging. LID - 10.1136/openhrt-2026-004015 [doi] LID - e004015 AB - Cinematic rendering (CR) is a three-dimensional visualisation technique that applies physically based lighting to standard volumetric CT and MRI datasets, producing images with enhanced depth and spatial realism. Although often regarded as primarily aesthetic, we believe CR offers practical clinical value in selected cardiac and vascular imaging scenarios. It can provide continuity of volumetric visualisation of structures leading to improved understanding of complex anatomy, enhance multidisciplinary communication, for example, in multidisciplinary conferences, and support procedural planning. This viewpoint discusses where CR adds meaningful insight into cardiovascular care and argues that its potential remains underused. Rather than replacing conventional imaging techniques, CR should be viewed as a complementary tool that enhances interpretation when spatial relationships are critical. As cardiovascular imaging becomes increasingly central to complex interventions and team-based decision-making, CR may play an important supporting role. CI - (c) Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. FAU - Avakian, Amy AU - Avakian A AUID- ORCID: 0009-0007-1387-9703 AD - Southern Hills Hospital & Medical Center, Las Vegas, Nevada, USA amyavakian1@gmail.com. FAU - Umair, Muhammad AU - Umair M AUID- ORCID: 0000-0001-6113-8335 AD - Johns Hopkins University Russell H Morgan Department of Radiology and Radiological Science, Baltimore, Maryland, USA. AD - Department of Radiology, New York-Presbyterian/Columbia University Irving Medical Center, New York, New York, USA. LA - eng PT - Journal Article PT - Review DEP - 20260316 PL - England TA - Open Heart JT - Open heart JID - 101631219 SB - IM MH - Humans MH - Predictive Value of Tests MH - *Imaging, Three-Dimensional/methods MH - *Computed Tomography Angiography/methods MH - *Magnetic Resonance Imaging, Cine/methods MH - *Coronary Angiography/methods PMC - PMC12993358 OTO - NOTNLM OT - Cardiac Imaging Techniques OT - Computed Tomography Angiography OT - Diagnostic Imaging COIS- Competing interests: None declared. EDAT- 2026/03/16 21:57 MHDA- 2026/03/16 21:58 PMCR- 2026/03/16 CRDT- 2026/03/16 20:42 PHST- 2026/03/03 00:00 [accepted] PHST- 2026/03/16 21:58 [medline] PHST- 2026/03/16 21:57 [pubmed] PHST- 2026/03/16 20:42 [entrez] PHST- 2026/03/16 00:00 [pmc-release] AID - openhrt-2026-004015 [pii] AID - 10.1136/openhrt-2026-004015 [doi] PST - epublish SO - Open Heart. 2026 Mar 16;13(1):e004015. doi: 10.1136/openhrt-2026-004015. PMID- 41839106 OWN - NLM STAT- MEDLINE DCOM- 20260711 LR - 20260807 IS - 1532-0650 (Electronic) IS - 0002-838X (Linking) VI - 113 IP - 2 DP - 2026 Feb TI - Infective Endocarditis: Diagnosis and Treatment. PG - 145-152 AB - Infective endocarditis develops when aggravating conditions damage the endothelial lining of the heart and create a nidus of infection. The nidus triggers a cytokine-mediated inflammatory response, which can lead to platelet aggregation and thrombus formation. Bacteria or fungi in the blood can then adhere to the thrombus and colonize, proliferate, and form vegetations. Staphylococcus aureus, Streptococcus species, and Enterococcus species comprise more than 80% of identified bacterial pathogens in cases of infective endocarditis. Endocarditis should be considered in any patient with fever or sepsis of unknown origin. Fever is the most common presenting feature in acute endocarditis, although it is uncommon in subacute cases. New or worsening heart murmur is a typical feature. Initial evaluation includes obtaining blood cultures and echocardiography. Use of the 2023 Duke Criteria is recommended to confirm diagnosis. Empiric intravenous antimicrobial therapy, infectious source control, and expert consultation from a multi-disciplinary team are the mainstays of initial treatment. Patients should also be monitored for surgical indications and development of complications. Patients with a history of endocarditis may benefit from antibiotic prophylaxis before certain procedures and should be counseled on the importance of maintaining oral and skin hygiene to reduce risk. FAU - Nohria, Raman AU - Nohria R AD - Duke University School of Medicine, Durham, North Carolina. FAU - Romaine, Andrew AU - Romaine A AD - Duke University School of Medicine, Durham, North Carolina. FAU - Garcia-Sampson, Gabryel AU - Garcia-Sampson G AD - Duke University School of Medicine, Durham, North Carolina. LA - eng PT - Journal Article PL - United States TA - Am Fam Physician JT - American family physician JID - 1272646 RN - 0 (Anti-Bacterial Agents) SB - IM MH - Humans MH - *Anti-Bacterial Agents/therapeutic use MH - Echocardiography MH - *Endocarditis/diagnosis/microbiology/therapy MH - Endocarditis, Bacterial/diagnosis/therapy EDAT- 2026/03/16 21:57 MHDA- 2026/03/16 21:58 CRDT- 2026/03/16 18:06 PHST- 2026/03/16 21:58 [medline] PHST- 2026/03/16 21:57 [pubmed] PHST- 2026/03/16 18:06 [entrez] AID - b7d818fd-e85d-475c-9dcd-4b9f47c65d4c [pii] PST - ppublish SO - Am Fam Physician. 2026 Feb;113(2):145-152. PMID- 41838884 OWN - NLM STAT- MEDLINE DCOM- 20260711 LR - 20260923 IS - 2369-3762 (Electronic) IS - 2369-3762 (Linking) VI - 12 DP - 2026 Mar 16 TI - Remote Augmented Reality Versus Traditional Simulation for Team Leader Assessment in a Cardiac Arrest Scenario: Noninferiority Randomized Controlled Trial. PG - e84367 LID - 10.2196/84367 [doi] LID - e84367 AB - BACKGROUND: Simulation-based education is crucial for training health care professionals in advanced cardiac life support. However, access to high-fidelity in-person simulation is frequently limited by geographic, logistical, and financial constraints. Augmented reality (AR) offers the potential to deliver remote, immersive training experiences that may overcome these barriers, but its effectiveness compared with traditional simulation remains uncertain. OBJECTIVE: This study aimed to determine whether remote AR simulation is noninferior to traditional in-person simulation for assessing team leader performance during a ventricular fibrillation cardiac arrest scenario. METHODS: This noninferiority randomized trial enrolled participants at the State University of Campinas (UNICAMP), Brazil, and used cross-continental remote instruction from Stanford University (in the United States) for the AR arm. A total of 50 health care professionals were randomized to either remote AR simulation with a geographically distant instructor (n=25) or traditional in-person simulation (n=25). All participants completed an identical ventricular fibrillation cardiac arrest case as team leaders. Leader performance was assessed using an adapted, validated checklist-based instrument for cognitive leadership and an observational behavioral measure (Behaviorally Anchored Rating Scale). Secondary outcomes included AR participants' evaluations of usability and ergonomics. RESULTS: A total of 42 participants fully completed the study procedures (remote AR group: n=22; traditional in-person group: n=20). The AR group demonstrated noninferior performance compared to the traditional group across all outcomes. The mean checklist scores were 41.6 (SD 6.2) and 42.6 (SD 5.8) in the remote AR group and traditional in-person group, respectively. The AR group's 95% CI (38.9-44.4) was above the 20% noninferiority threshold of 34.1. Usability and ergonomics were favorably reported by most participants. CONCLUSIONS: Participants in the remote AR simulation demonstrated noninferior team leader decision-making and behavioral performance compared with those in traditional in-person simulation. These findings suggest that remote AR may be a viable strategy to expand access to scenario-based assessment of cardiac arrest leadership, particularly in resource-limited settings. AR participants also reported high usability and low ergonomic burden, indicating comfortable headset use. CI - (c) Renan Gianotto-Oliveira, Marcos Rojas, Maria Queiroz, Flavia Zanchetta, Anabel Ferrari, Lucas Kojima, Alexandre Paula, Bruno Campos, Dario Cecilio-Fernandes, Thomas J Caruso. Originally published in JMIR Medical Education (https://mededu.jmir.org). FAU - Gianotto-Oliveira, Renan AU - Gianotto-Oliveira R AUID- ORCID: 0000-0002-0351-6702 AD - School of Medical Sciences, University of Campinas, Campinas, Brazil. FAU - Rojas, Marcos AU - Rojas M AUID- ORCID: 0000-0001-6352-4547 AD - Department of Anesthesiology, Perioperative, and Pain Medicine, Stanford School of Medicine, 453 Quarry Road, office 422A, Palo Alto, CA, 94305, United States, 1 (650) 723-2300. FAU - Queiroz, Maria AU - Queiroz M AUID- ORCID: 0009-0008-8964-0499 AD - School of Medical Sciences, University of Campinas, Campinas, Brazil. FAU - Zanchetta, Flavia AU - Zanchetta F AUID- ORCID: 0000-0002-5934-9683 AD - School of Medical Sciences, University of Campinas, Campinas, Brazil. FAU - Ferrari, Anabel AU - Ferrari A AUID- ORCID: 0009-0001-4445-7411 AD - School of Medical Sciences, University of Campinas, Campinas, Brazil. FAU - Kojima, Lucas AU - Kojima L AUID- ORCID: 0009-0004-7855-1918 AD - School of Medical Sciences, University of Campinas, Campinas, Brazil. FAU - Paula, Alexandre AU - Paula A AUID- ORCID: 0009-0003-8501-227X AD - School of Medical Sciences, University of Campinas, Campinas, Brazil. FAU - Campos, Bruno AU - Campos B AUID- ORCID: 0000-0001-8423-2113 AD - School of Medical Sciences, University of Campinas, Campinas, Brazil. FAU - Cecilio-Fernandes, Dario AU - Cecilio-Fernandes D AUID- ORCID: 0000-0002-8746-1680 AD - School of Medical Sciences, University of Campinas, Campinas, Brazil. AD - Erasmus MC University Medical Centre Rotterdam, Institute of Medical Education Research Rotterdam, Rotterdam, The Netherlands. FAU - Caruso, Thomas J AU - Caruso TJ AUID- ORCID: 0000-0002-0723-5262 AD - Department of Anesthesiology, Perioperative, and Pain Medicine, Stanford School of Medicine, 453 Quarry Road, office 422A, Palo Alto, CA, 94305, United States, 1 (650) 723-2300. LA - eng PT - Equivalence Trial PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20260316 PL - Canada TA - JMIR Med Educ JT - JMIR medical education JID - 101684518 SB - IM MH - Humans MH - *Heart Arrest/therapy MH - Female MH - Male MH - *Simulation Training/methods/standards MH - *Leadership MH - Brazil MH - Adult MH - Middle Aged MH - Patient Care Team PMC - PMC12991189 OTO - NOTNLM OT - AR OT - advanced cardiac life support OT - augmented reality OT - digital health education OT - randomized controlled trial OT - resuscitation OT - simulation-based education COIS- Conflicts of Interest: None declared. EDAT- 2026/03/16 21:57 MHDA- 2026/03/16 21:58 PMCR- 2026/03/16 CRDT- 2026/03/16 14:52 PHST- 2025/09/19 00:00 [received] PHST- 2025/12/27 00:00 [revised] PHST- 2026/01/15 00:00 [accepted] PHST- 2026/03/16 21:58 [medline] PHST- 2026/03/16 21:57 [pubmed] PHST- 2026/03/16 14:52 [entrez] PHST- 2026/03/16 00:00 [pmc-release] AID - v12i1e84367 [pii] AID - 84367 [pii] AID - 10.2196/84367 [doi] PST - epublish SO - JMIR Med Educ. 2026 Mar 16;12:e84367. doi: 10.2196/84367. PMID- 41836839 OWN - NLM STAT- In-Process DCOM- 20260316 LR - 20260813 IS - 0899-8280 (Print) IS - 1525-3252 (Electronic) IS - 0899-8280 (Linking) VI - 39 IP - 2 DP - 2026 TI - Insights from a multidisciplinary heart team for highest-risk valve disease. PG - 227-236 LID - 10.1080/08998280.2025.2591518 [doi] AB - BACKGROUND: Multidisciplinary heart team (MHT) evaluation is a class I recommendation for coronary and structural heart disease, yet limited outcomes data exist for high-risk and complex valvular heart disease (VHD) patients referred for surgery. METHODS: From June 2021 to August 2022, our institutional MHT-comprising cardiac surgeons, interventional cardiologists, heart failure specialists, advanced imaging specialists, intensivists, and palliative care specialists-evaluated the highest-risk or complex VHD patients. Patient demographics, Society of Thoracic Surgeons Predicted Risk of Mortality scores, initial treatment plans, final team recommendations, and outcomes, including adherence to recommendations, 30-day readmission, and mortality at 30 days, 1 year, and 2 years were analyzed. RESULTS: Among 121 patients, the MHT recommended surgery for 67%, transcatheter intervention for 14%, a hybrid approach for 3%, and medical management (MM) for 17%. Overall adherence to MHT recommendations was 89%. Thirty-day mortality was 7/81 (9%) for surgical patients, 3/17 (18%) for transcatheter, 0/3 for hybrid, and 4/20 (20%) for MM. By 2 years, mortality rose to 17/81 (21%) for surgery, 9/17 (53%) for transcatheter, 1/3 (33%) for hybrid, and 11/20 (55%) for MM. CONCLUSION: MHT evaluation facilitates individualized treatment strategies by distinguishing patients who may benefit from intervention despite high procedural risk, while sparing those unlikely to benefit. CI - Copyright (c) 2025 Baylor University Medical Center. FAU - Pickering, Taylor AU - Pickering T AUID- ORCID: 0009-0001-6369-3807 AD - Baylor Scott & White Research Institute, Plano, Texas, USA. FAU - Eisenga, John AU - Eisenga J AD - Baylor Scott & White Research Institute, Plano, Texas, USA. FAU - McCullough, Kyle AU - McCullough K AD - Baylor Scott & White Research Institute, Plano, Texas, USA. FAU - Dorton, Cody AU - Dorton C AD - Baylor Scott & White Research Institute, Plano, Texas, USA. FAU - Kluis, Austin AU - Kluis A AD - Baylor Scott & White Research Institute, Plano, Texas, USA. FAU - Moubarak, Ghadi AU - Moubarak G AD - Baylor Scott & White Research Institute, Plano, Texas, USA. FAU - Squiers, John J AU - Squiers JJ AD - Baylor Scott & White Research Institute, Plano, Texas, USA. FAU - Shih, Emily AU - Shih E AD - Baylor Scott & White Research Institute, Plano, Texas, USA. FAU - Klutts, Garrett AU - Klutts G AD - Baylor Scott & White Research Institute, Plano, Texas, USA. FAU - Sawhney, Rahul AU - Sawhney R AD - Baylor Scott & White Research Institute, Plano, Texas, USA. FAU - Hocking, Jennie AU - Hocking J AD - Baylor Scott & White Research Institute, Plano, Texas, USA. FAU - Cohen Meidan, Talia AU - Cohen Meidan T AD - Baylor Scott & White Research Institute, Plano, Texas, USA. FAU - Potluri, Srini AU - Potluri S AD - Department of Cardiology, Baylor Scott & White The Heart Hospital Plano, Plano, Texas, USA. FAU - Al-Azizi, Karim AU - Al-Azizi K AD - Department of Cardiology, Baylor Scott & White The Heart Hospital Plano, Plano, Texas, USA. FAU - Moore, David AU - Moore D AD - Department of Cardiac Surgery, Baylor Scott & White The Heart Hospital Plano, Plano, Texas, USA. FAU - Brinkman, William AU - Brinkman W AD - Department of Cardiac Surgery, Baylor Scott & White The Heart Hospital Plano, Plano, Texas, USA. FAU - Hafen, Lee AU - Hafen L AD - Department of Cardiac Surgery, Baylor Scott & White The Heart Hospital Plano, Plano, Texas, USA. FAU - Harrington, Katherine AU - Harrington K AD - Department of Cardiac Surgery, Baylor Scott & White The Heart Hospital Plano, Plano, Texas, USA. FAU - George, Timothy AU - George T AD - Department of Cardiac Surgery, Baylor Scott & White The Heart Hospital Plano, Plano, Texas, USA. FAU - Schaffer, Justin AU - Schaffer J AD - Department of Cardiac Surgery, Baylor Scott & White The Heart Hospital Plano, Plano, Texas, USA. FAU - Ejiofor, Julius AU - Ejiofor J AD - Department of Cardiac Surgery, Baylor Scott & White The Heart Hospital Plano, Plano, Texas, USA. FAU - Smith, Robert L AU - Smith RL AD - Department of Cardiac Surgery, Baylor Scott & White The Heart Hospital Plano, Plano, Texas, USA. FAU - Ryan, William AU - Ryan W AD - Department of Cardiac Surgery, Baylor Scott & White The Heart Hospital Plano, Plano, Texas, USA. FAU - DiMaio, J Michael AU - DiMaio JM AD - Department of Cardiac Surgery, Baylor Scott & White The Heart Hospital Plano, Plano, Texas, USA. AD - Department of Biomedical Engineering, Texas A&M University, College Station, Texas, USA. FAU - Szerlip, Molly AU - Szerlip M AD - Department of Cardiology, Baylor Scott & White The Heart Hospital Plano, Plano, Texas, USA. FAU - Hutcheson, Kelley AU - Hutcheson K AD - Department of Cardiac Surgery, Baylor Scott & White The Heart Hospital Plano, Plano, Texas, USA. LA - eng PT - Journal Article DEP - 20251208 PL - United States TA - Proc (Bayl Univ Med Cent) JT - Proceedings (Baylor University. Medical Center) JID - 9302033 PMC - PMC12981584 OTO - NOTNLM OT - High-risk structural heart disease OT - multidisciplinary heart team OT - patient selection and decision-making OT - surgical outcomes OT - transcatheter valve therapy COIS- Disclosure: Dr. Potluri: Advisory board member, proctor, and speaker for Medtronic, Boston Scientific, Abbott, and Cordis; proctor and speaker for Edwards Lifesciences, Terumo, and AstraZeneca. Dr. Szerlip: Proctor, speaker, and consultant for Edwards Lifesciences; advisory board member, consultant, and proctor for Abbott Vascular; steering committee member for Medtronic; speaker for Boston Scientific. Dr. Al-Azizi: Proctor and consultant for Edwards Lifesciences; consultant and advisory board member for Medtronic; consultant for Boston Scientific; speaker bureau member. Dr. Harrington: Consultant for Abbott Laboratories and Maquet Cardiovascular; speaker for Artivion, Inc. and Medtronic, Inc.; speaker and advisory board member for Boston Scientific; speaker and proctor for Edwards Lifesciences Corporation. Dr. Brinkman: Teaching and travel support from Artivion; consultant for Bolton Medical, Inc., Maquet Cardiovascular, Medtronic, Terumo Medical Corporation, and W.L. Gore; advisory board member for Medtronic. Dr. Smith: Grant support recipient from Edwards Lifesciences; speaker honoraria recipient from Edwards Lifesciences, Abbott, and CryoLife. Dr. George: Speaker for Abiomed. Dr. DiMaio: Investment and ownership interests in HeartFlow, Inc. and Spectral MD. The remaining authors have no competing interests to declare. Disclosure: Dr. Potluri: Advisory board member, proctor, and speaker for Medtronic, Boston Scientific, Abbott, and Cordis; proctor and speaker for Edwards Lifesciences, Terumo, and AstraZeneca. Dr. Szerlip: Proctor, speaker, and consultant for Edwards Lifesciences; advisory board member, consultant, and proctor for Abbott Vascular; steering committee member for Medtronic; speaker for Boston Scientific. Dr. Al-Azizi: Proctor and consultant for Edwards Lifesciences; consultant and advisory board member for Medtronic; consultant for Boston Scientific; speaker bureau member. Dr. Harrington: Consultant for Abbott Laboratories and Maquet Cardiovascular; speaker for Artivion, Inc. and Medtronic, Inc.; speaker and advisory board member for Boston Scientific; speaker and proctor for Edwards Lifesciences Corporation. Dr. Brinkman: Teaching and travel support from Artivion; consultant for Bolton Medical, Inc., Maquet Cardiovascular, Medtronic, Terumo Medical Corporation, and W.L. Gore; advisory board member for Medtronic. Dr. Smith: Grant support recipient from Edwards Lifesciences; speaker honoraria recipient from Edwards Lifesciences, Abbott, and CryoLife. Dr. George: Speaker for Abiomed. Dr. DiMaio: Investment and ownership interests in HeartFlow, Inc. and Spectral MD. The remaining authors have no competing interests to declare.This study was funded by a grant from the Cardiovascular Research Review Committee at Baylor Scott & White Research Institute. Additional support was provided via generous philanthropic donations by the Satish and Yasmin Gupta Family Foundation, the Baylor Scott & White Foundation, and the Roberts Foundation. EDAT- 2026/03/16 21:58 MHDA- 2026/03/16 21:59 PMCR- 2025/12/08 CRDT- 2026/03/16 06:10 PHST- 2026/03/16 21:59 [medline] PHST- 2026/03/16 21:58 [pubmed] PHST- 2026/03/16 06:10 [entrez] PHST- 2025/12/08 00:00 [pmc-release] AID - 2591518 [pii] AID - 10.1080/08998280.2025.2591518 [doi] PST - epublish SO - Proc (Bayl Univ Med Cent). 2025 Dec 8;39(2):227-236. doi: 10.1080/08998280.2025.2591518. eCollection 2026. PMID- 41832989 OWN - NLM STAT- MEDLINE DCOM- 20260711 LR - 20260711 IS - 1464-3677 (Electronic) IS - 1353-4505 (Linking) VI - 38 IP - 1 DP - 2026 Jan 10 TI - Evaluating emergency code use and integrating clinical codes for emergency conditions to improve coordination in a tertiary care hospital. LID - mzag039 [pii] LID - 10.1093/intqhc/mzag039 [doi] AB - BACKGROUND: Hospital emergency response systems are critical for patient safety, yet traditional models relying solely on generic codes (e.g. Code Blue, Code Yellow) often face communication challenges, delayed responses, and unclear escalation protocols. To address these systemic gaps, a structured set of clinical codes for emergency conditions were introduced, with training, survey and evaluation of these codes. METHODS: A single-center quality improvement study was conducted in 2024 at a 260-bed tertiary care teaching hospital in North India, with approximately 23 000 inpatient and 240 000 outpatient visits annually. A cross-sectional survey of 612 frontline staff assessed knowledge and confidence in emergency codes. After baseline assessments, five condition-specific clinical codes (STEMI, FAST, Polytrauma, Vascular, Green for Organ Donation) were implemented hospital-wide. Data from 642 emergency code activations and 74 mock drills were analyzed over 12 months. Specialist response times were tracked via PA system logs, arrival notes, and WhatsApp communications. Primary outcomes included escalation rates from Code Yellow to Blue, ICU transfers, and response times, with results compared to published benchmarks. RESULTS: Survey response rate was 91.2% (612/671), with 93.1% reporting awareness of emergency codes and 88.7% confidence in performing first-response actions. Among 642 actual activations, the most frequent were Code STEMI (n = 246, 38.3%), Code FAST (n = 138, 21.5%), and Code Yellow Adult (n = 129, 20.1%); other notable activations included Code Violet (n = 34, 5.3%), Code Polytrauma (n = 30, 4.7%), and Code Blue Adult (n = 28, 4.4%) (with pediatric codes: Code Blue Paeds n = 2; Code Yellow Paeds n = 5). Mock drills (n = 74) emphasized preparedness for mass casualty and resuscitation scenarios, with Code Orange (n = 16, 21.6%) and Code Blue Adult (n = 13, 17.6%) with Mortality remained at 3.3%, most frequently tested. Escalation from Code Yellow to Code Blue occurred in 4.5% of Code Yellow activations (95% CI, 3.6-7.3), lower than published escalation rates of 15%-20%. Intensive care transfers occurred in 11.2% (95% CI, 8.7-13.9), while emergency department transfers accounted for 4.5% (95% CI, 3.1-6.4). Average specialist response time following code activation was <3 minutes across categories. CONCLUSION: Integration of condition-specific clinical codes alongside standard codes improved hospital wide awareness, facilitated rapid specialist mobilization, and was associated with fewer escalations to cardiac arrest compared with published benchmarks. While these findings are promising, this single-center descriptive study is limited by lack of pre-intervention baseline data and absence of patient level outcomes. Future multicenter evaluations with outcome linkage are recommended. CI - (c) The Author(s) 2026. Published by Oxford University Press on behalf of International Society for Quality in Health Care. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com. FAU - Bora, Tanushree AU - Bora T AD - Department of Quality Services, Aakash Healthcare Super Specialty Hospital, New Delhi, India. FAU - Chaudhry, Aashish AU - Chaudhry A AD - Department of Orthopedics & Joint replacement Surgery, Aakash Healthcare Super Specialty Hospital, New Delhi, India. FAU - Sachdev, Shaarang AU - Sachdev S AD - Department of Emergency Services, Aakash Healthcare Super Specialty Hospital, New Delhi, India. FAU - Pandey, Mani AU - Pandey M AD - Department of Audit & Clinical Research, Aakash Healthcare Super Specialty Hospital, New Delhi, India. FAU - Singh, Shubhi AU - Singh S AD - Department of Quality Services, Aakash Healthcare Super Specialty Hospital, New Delhi, India. LA - eng PT - Journal Article PL - England TA - Int J Qual Health Care JT - International journal for quality in health care : journal of the International Society for Quality in Health Care JID - 9434628 SB - IM MH - *Tertiary Care Centers/organization & administration MH - Humans MH - Cross-Sectional Studies MH - *Quality Improvement/organization & administration MH - *Emergency Service, Hospital/organization & administration MH - India MH - *Clinical Coding/standards MH - Hospital Rapid Response Team/organization & administration EDAT- 2026/03/15 19:32 MHDA- 2026/03/23 19:54 CRDT- 2026/03/15 13:54 PHST- 2025/09/11 00:00 [received] PHST- 2025/12/12 00:00 [revised] PHST- 2026/02/22 00:00 [accepted] PHST- 2026/03/23 19:54 [medline] PHST- 2026/03/15 19:32 [pubmed] PHST- 2026/03/15 13:54 [entrez] AID - 8524328 [pii] AID - 10.1093/intqhc/mzag039 [doi] PST - ppublish SO - Int J Qual Health Care. 2026 Jan 10;38(1):mzag039. doi: 10.1093/intqhc/mzag039. PMID- 41832729 OWN - NLM STAT- Publisher LR - 20260315 IS - 1875-6557 (Electronic) IS - 1573-403X (Linking) DP - 2026 Mar 9 TI - Chemotherapy-Induced Cardiotoxicity: A Comprehensive Review of Current Understanding and Future Directions. LID - 10.2174/011573403X392956251210124152 [doi] AB - INTRODUCTION: Chemotherapy-Induced Cardiotoxicity (CIC) has become a growing concern in modern oncology. While chemotherapy remains one of the most effective treatments against cancer, its potential to harm the heart often limits its use. The underlying mechanisms involve oxidative stress, mitochondrial dysfunction, and inflammation, all contributing to the gradual weakening of cardiac muscle. As cancer survival improves, the burden of cardiovascular complications is more visible than ever, emphasizing the need for early recognition, prevention, and long-term management. METHODS: This review draws upon published literature, recent clinical trials, and translational research to explore current understanding and future directions in CIC. Studies on anthracyclines and HER2 inhibitors were reviewed in depth, along with new data on diagnostic biomarkers, imaging techniques, and evolving therapeutic strategies. Particular attention was given to the role of pharmacogenomics, preventive interventions, and emerging therapies aimed at protecting or restoring cardiac function in patients undergoing chemotherapy. RESULTS: CIC can present as heart failure, arrhythmia, hypertension, myocardial ischemia, or thromboembolism. Factors such as age, obesity, cumulative drug exposure, and genetic predisposition significantly raise the risk. Recent advances have improved early detection-troponins, natriuretic peptides, and echocardiography with Global Longitudinal Strain (GLS) allow for identification before overt symptoms appear. Preventive strategies, including dose adjustments, liposomal formulations, and the cardioprotective agent dexrazoxane, have shown measurable benefits. Established cardiotoxicity can be managed with conventional heart failure medications, antihypertensives, and anticoagulants. Experimental approaches-ranging from mitochondrial stabilizers and histone deacetylase inhibitors to mesenchymal stem cell therapy-show promise in reversing cardiac injury. DISCUSSION: CIC reflects a complex interaction between cancer biology, treatment intensity, and patientspecific vulnerability. A proactive, multidisciplinary approach involving both oncologists and cardiologists is key to balancing cancer control with heart health. Lifestyle measures such as regular exercise and dietary optimization can further strengthen cardiovascular resilience. Advances in genetic testing, molecular imaging, and regenerative therapy are gradually shifting the field toward more personalized cardio-oncology care. CONCLUSION: Chemotherapy-induced cardiotoxicity continues to challenge clinicians striving for a cure without compromise. The future of cancer care lies in integrating precision medicine with preventive cardiology to minimize cardiac injury while maintaining therapeutic efficacy. Continued research into molecular targets, biomarkers, and cell-based therapies offers genuine hope for improving both survival and quality of life in cancer patients. CI - Copyright(c) Bentham Science Publishers; For any queries, please email at epub@benthamscience.net. FAU - Rama Rao, Lavanya AU - Rama Rao L AD - Department of Internal Medicine, MVJ Medical College and Research Hospital, Bangalore, India. FAU - Mylavarapu, Maneeth AU - Mylavarapu M AD - Department of Public Health, Adelphi University, NY, USA. FAU - Prakash, Karthik AU - Prakash K AD - Department of Internal Medicine, MVJ Medical College and Research Hospital, Bangalore, India. FAU - Manoukian, Gevorg AU - Manoukian G AD - Department of Anatomy, St. George's University School of Medicine, West Indies, Grenada. FAU - Abraham, Aaron Titus AU - Abraham AT AD - Department of Internal Medicine, Pondicherry Institute of Medical Sciences, Pondicherry University, Pondicherry, India. FAU - Kabassakalian, Edouard AU - Kabassakalian E AD - Department of Internal Medicine, Faculty of General Medicine, Yerevan State Medical University after Mikhtar Heratsi, Yerevan, Armenia. FAU - Sreekumar, Anagha AU - Sreekumar A AD - Department of Internal Medicine, Rohini Hospital, Thrissur, Kerala, India. FAU - Sara Dileep, Heba AU - Sara Dileep H AD - Department of Internal Medicine, MES Medical College, Perinthalmanna, Kerala, India. FAU - Arshad, Adiena AU - Arshad A AD - Department of Internal Medicine, Shalamar Hospital, Shalamar Institute of Health Sciences, Lahore, Pakistan. FAU - Bilgi, Asifa Tabassum AU - Bilgi AT AD - Department of Internal Medicine, Ayaan Institute of Medical Sciences, Moinabad, Telangana, India. FAU - Usman, Rafay AU - Usman R AD - Department of Internal Medicine, Dow International Medical College, Karachi, Pakistan. FAU - Azhar, Mahnoor AU - Azhar M AD - Department of Internal Medicine, Allama Iqbal Medical College, Lahore, Pakistan. FAU - Majumder, Kaustav AU - Majumder K AD - Department of Internal Medicine, R.G. Kar Medical College and Hospital, Kolkata, West Bengal, India. LA - eng PT - Journal Article DEP - 20260309 PL - United Arab Emirates TA - Curr Cardiol Rev JT - Current cardiology reviews JID - 101261935 SB - IM OTO - NOTNLM OT - Chemotherapy-induced cardiotoxicity OT - cardiomyopathy OT - heart failure OT - mesenchymal cell therapy OT - orthotopic heart transplant. EDAT- 2026/03/15 15:07 MHDA- 2026/03/15 15:07 CRDT- 2026/03/15 07:23 PHST- 2025/03/24 00:00 [received] PHST- 2025/07/27 00:00 [revised] PHST- 2025/08/04 00:00 [accepted] PHST- 2026/03/15 15:07 [medline] PHST- 2026/03/15 15:07 [pubmed] PHST- 2026/03/15 07:23 [entrez] AID - CCR-EPUB-153310 [pii] AID - 10.2174/011573403X392956251210124152 [doi] PST - aheadofprint SO - Curr Cardiol Rev. 2026 Mar 9. doi: 10.2174/011573403X392956251210124152. PMID- 41831118 OWN - NLM STAT- MEDLINE DCOM- 20260627 LR - 20260627 IS - 1868-4297 (Electronic) IS - 1868-4297 (Linking) VI - 41 IP - 3 DP - 2026 Jul TI - Temporal trends and long-term clinical outcomes of transcatheter aortic valve implantation. PG - 690-702 LID - 10.1007/s12928-026-01254-6 [doi] AB - Progress in transcatheter aortic valve implantation (TAVI) devices has been remarkable. Although the indications for TAVI have expanded to younger or lower-risk patients, reports on temporal trends are scarce. This study aimed to investigate temporal trends in the patient cohort and clinical outcomes of TAVI between 2013 and 2025 at a high-volume center. We included 2,000 consecutive patients who underwent TAVI between 2013 and 2025. Patient characteristics, periprocedural outcomes, and long-term all-cause mortality rates were analyzed. Over 12 years, annual TAVI volumes have increased approximately fourfold, from 73 in 2013 to 275 in 2024. Although the surgical risk estimated by the Society of Thoracic Surgeons score remained high in 2024, the 30-day mortality rate remained low (2013: 2.8%; 2024: 0.4%; p = 0.112), and was notably low among patients at low risk (0.2%) and at intermediate risk (0.1%). The incidence of periprocedural bleeding decreased (2013: 8.3%; 2024: 2.5%; p = 0.004), and other safety outcomes showed no significant differences, remaining low throughout the study period. During a median follow-up of 891 (interquartile range: 363-1705) days, mortality rate at 10 years after TAVI was 83.8%, with paravalvular leakage >/=mild identified as an independent risk factor. In conclusion, from 2013 to 2025, the case volume significantly increased. Regardless of the risk profile, mortality and procedural complications following TAVI remained low. The advantages of TAVI will be maximized not only through device advancements but also through the operator skill and patient management by the Heart Team. FAU - Iwata, Juri AU - Iwata J AD - Department of Cardiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan. FAU - Hayashida, Kentaro AU - Hayashida K AUID- ORCID: 0000-0002-1750-1982 AD - Department of Cardiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan. khayashidamd@gmail.com. FAU - Kamata, Kei AU - Kamata K AD - Department of Cardiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan. FAU - Arita, Ryo AU - Arita R AD - Department of Cardiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan. FAU - Moriizumi, Tomonari AU - Moriizumi T AD - Department of Cardiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan. FAU - Ryuzaki, Toshinobu AU - Ryuzaki T AD - Department of Cardiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan. FAU - Numasawa, Yohei AU - Numasawa Y AD - Department of Cardiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan. FAU - Shinada, Keitaro AU - Shinada K AD - Department of Cardiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan. FAU - Shirakawa, Kohsuke AU - Shirakawa K AD - Department of Cardiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan. FAU - Tsuruta, Hikaru AU - Tsuruta H AD - Department of Cardiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan. FAU - Takahashi, Tatsuo AU - Takahashi T AD - Department of Cardiovascular Surgery, Saitama Medical University International Medical Center, Saitama, Japan. FAU - Matsumoto, Yorihiko AU - Matsumoto Y AD - Department of Cardiovascular Surgery, Keio University School of Medicine, Tokyo, Japan. FAU - Yamazaki, Masataka AU - Yamazaki M AD - Department of Cardiovascular Surgery, Keio University School of Medicine, Tokyo, Japan. FAU - Kato, Jungo AU - Kato J AD - Department of Anesthesiology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan. FAU - Yamada, Takashige AU - Yamada T AD - Department of Anesthesiology, Keio University School of Medicine, Tokyo, Japan. FAU - Shimizu, Hideyuki AU - Shimizu H AD - Department of Cardiovascular Surgery, Keio University School of Medicine, Tokyo, Japan. FAU - Fukuda, Keiichi AU - Fukuda K AD - Department of Cardiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan. FAU - Ieda, Masaki AU - Ieda M AD - Department of Cardiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan. LA - eng PT - Journal Article DEP - 20260314 PL - Japan TA - Cardiovasc Interv Ther JT - Cardiovascular intervention and therapeutics JID - 101522043 SB - IM EIN - Cardiovasc Interv Ther. 2026 Jul;41(3):703-704. doi: 10.1007/s12928-026-01285-z. PMID: 42018216 MH - Humans MH - *Transcatheter Aortic Valve Replacement/trends/adverse effects/mortality MH - Female MH - Aged, 80 and over MH - *Aortic Valve Stenosis/surgery/mortality MH - Male MH - Treatment Outcome MH - Risk Factors MH - Aged MH - Time Factors MH - Retrospective Studies MH - Postoperative Complications/epidemiology OTO - NOTNLM OT - Aortic stenosis OT - Long-term outcomes OT - Temporal trend OT - Transcatheter aortic valve implantation COIS- Declarations. Conflict of interest: Dr. Hayashida is a clinical proctor at Edwards Lifesciences, Abbott Medical, and Medtronic. Dr Tsuruta is a screening proctor at Edwards Life Sciences. Drs. Shimizu and Takahashi are clinical proctors at Edwards Life Sciences. The remaining authors declare no conflict of interest. EDAT- 2026/03/15 05:36 MHDA- 2026/06/27 12:39 CRDT- 2026/03/14 12:17 PHST- 2025/12/16 00:00 [received] PHST- 2026/01/26 00:00 [accepted] PHST- 2026/06/27 12:39 [medline] PHST- 2026/03/15 05:36 [pubmed] PHST- 2026/03/14 12:17 [entrez] AID - 10.1007/s12928-026-01254-6 [pii] AID - 10.1007/s12928-026-01254-6 [doi] PST - ppublish SO - Cardiovasc Interv Ther. 2026 Jul;41(3):690-702. doi: 10.1007/s12928-026-01254-6. Epub 2026 Mar 14. PMID- 41831012 OWN - NLM STAT- Publisher LR - 20260615 IS - 1432-1971 (Electronic) IS - 0172-0643 (Linking) DP - 2026 Mar 14 TI - Technical Feasibility of Virtual Reality-Enhanced Three-Dimensional Rotational Angiography: A Retrospective Analysis of a Novel Imaging Approach for Interventional Procedures in the Pediatric Cardiac Catheterization Laboratory. LID - 10.1007/s00246-026-04225-z [doi] AB - Three-dimensional rotational angiography (3DRA) is useful in congenital interventional cardiology but remains limited by two-dimensional screen visualization, which may restrict comprehensive analysis of complex cardiovascular anatomy. Virtual reality (VR) enables immersive visualization of volumetric data. However, the technical feasibility of VR models derived from intraprocedural 3DRA remains insufficiently explored. To evaluate the technical feasibility and processing time of VR models generated from 3DRA in pediatric cardiac catheterizations, focusing on anatomical assessment, procedural simulation and fluoroscopic projection planning. This retrospective single-centre study included 62 3DRA guided procedures performed in 2024. Virtual and conventional work station based (C-3D) models were generated from anonymized 3DRA-datasets. Models were evaluated using a structured framework across four predefined categories: assessment of target-site anatomy, visualization beyond the target region, procedural simulation capability, and theoretical fluoroscopic projection planning. All assessments were performed by a multidisciplinary clinical team. VR models were successfully generated in all cases. Median VR processing times were 3.0 min for model generation, 5.0 min for refinement, 4.0 min for procedural simulation, and 7.0 min for extended anatomical analysis, defined as immersive evaluation of anatomical structures beyond the primary contrast-opacified target region. Visualization of target anatomy was feasible in 98%, beyond-target region in 84%, procedural simulation in 94%, and projection planning in all cases. Semi-quantitative comparative analysis demonstrated statistically significant deviation from the neutral reference value for target-site anatomy (p = 0.0318) and beyond-target visualization (p = 0.0495). VR-based assessment of 3DRA datasets is technically feasible and enables immersive anatomical evaluation in a heterogeneous pediatric population with congenital heart disease, providing a technical basis for future prospective studies of VR-enhanced analysis of intraprocedural 3DRA data. FAU - Szeliga, Judyta AU - Szeliga J AUID- ORCID: 0009-0009-3186-1691 AD - Department of Paediatric Cardiology, Faculty of Medicine, University Children's Hospital, Jagiellonian University Medical College, 265 Wielicka St, Krakow, 30-669, Poland. judyta.szeliga@uj.edu.pl. FAU - Cabaj-Wlodarczyk, Karolina AU - Cabaj-Wlodarczyk K AD - Department of Paediatric Cardiology, Faculty of Medicine, University Children's Hospital, Jagiellonian University Medical College, 265 Wielicka St, Krakow, 30-669, Poland. FAU - Goreczny, Sebastian AU - Goreczny S AUID- ORCID: 0000-0002-6825-6745 AD - Department of Paediatric Cardiology, Faculty of Medicine, University Children's Hospital, Jagiellonian University Medical College, 265 Wielicka St, Krakow, 30-669, Poland. LA - eng GR - (Grant No.N41/DBS/001219)/This work was supported by the internal grant of Jagiellonian University Medical College (Grant No.N41/DBS/001219), which funded the Virtual Reality project during 2023-2024. Judyta Szeliga served as the grant supervisor./ GR - (Grant No.N41/DBS/001219)/This work was supported by the internal grant of Jagiellonian University Medical College (Grant No.N41/DBS/001219), which funded the Virtual Reality project during 2023-2024. Judyta Szeliga served as the grant supervisor./ PT - Journal Article DEP - 20260314 PL - United States TA - Pediatr Cardiol JT - Pediatric cardiology JID - 8003849 SB - IM OTO - NOTNLM OT - Congenital interventions OT - Interventional cardiology OT - Three-dimensional rotational angiography OT - VR-planning OT - VR-simulation OT - Virtual reality COIS- Declarations. Competing Interests: The authors declare no competing interests. Ethical Approval: This retrospective study was approved by the Institutional Medical Research Ethics Committee of Jagiellonian University Medical College (Approval No. 118.6120.09.2023). Informed consent for cardiac catheterization was obtained from patient's parents or legal guardians, and from and patients themselves (when applicable). EDAT- 2026/03/15 05:36 MHDA- 2026/03/15 05:36 CRDT- 2026/03/14 12:13 PHST- 2025/08/26 00:00 [received] PHST- 2026/03/01 00:00 [accepted] PHST- 2026/03/15 05:36 [medline] PHST- 2026/03/15 05:36 [pubmed] PHST- 2026/03/14 12:13 [entrez] AID - 10.1007/s00246-026-04225-z [pii] AID - 10.1007/s00246-026-04225-z [doi] PST - aheadofprint SO - Pediatr Cardiol. 2026 Mar 14. doi: 10.1007/s00246-026-04225-z. PMID- 41828061 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260314 LR - 20260813 IS - 2075-4418 (Print) IS - 2075-4418 (Electronic) IS - 2075-4418 (Linking) VI - 16 IP - 5 DP - 2026 Mar 6 TI - Surgical Versus Conservative Treatment of Post-Sternotomy Mediastinitis: Clinical Characteristics, Microbiology, and Outcomes from a 10-Year Cohort. LID - 10.3390/diagnostics16050785 [doi] LID - 785 AB - Background: Post-sternotomy mediastinitis (PSM) remains one of the most serious complications of cardiac surgery. This study aimed to evaluate the clinical features, management strategies, and outcomes of patients with PSM, comparing surgical and conservative treatment approaches. Methods: We retrospectively reviewed all cases of PSM (March 2014-July 2024) at our tertiary referral centre. Results: A total of 81 patients were included (39 surgically treated, 42 conservatively managed). The length of hospital stay was significantly longer in the surgical group (p = 0.003), and blood transfusions were more frequent (p = 0.005). Patients in the conservative group had higher DSW-STS risk scores (p = 0.014). Positive blood cultures were significantly more common among surgically treated patients (p < 0.001). The in-hospital mortality rate was 2.5% overall, with no difference between groups. Conclusions: These results likely reflect the greater clinical severity and complexity of patients selected for surgery, rather than an adverse effect of the procedure itself. Surgical treatment of PSM is associated with longer hospitalisation and greater need for blood transfusion, reflecting the higher clinical complexity of these cases. Nevertheless, outcomes in terms of survival were comparable to conservative management, supporting an individualised, multidisciplinary approach to optimise care for patients with post-sternotomy mediastinitis. FAU - Serapide, Francesca AU - Serapide F AUID- ORCID: 0000-0002-5555-3732 AD - Infectious and Tropical Diseases Unit, "Renato Dulbecco" Teaching Hospital, Viale Europa, 88100 Catanzaro, Italy. AD - Department of Medical and Surgical Sciences, "Magna Graecia" University of Catanzaro, Viale Europa, 88100 Catanzaro, Italy. FAU - Berardelli, Lavinia AU - Berardelli L AUID- ORCID: 0009-0000-6864-1216 AD - Infectious and Tropical Diseases Unit, "Renato Dulbecco" Teaching Hospital, Viale Europa, 88100 Catanzaro, Italy. AD - Department of Medical and Surgical Sciences, "Magna Graecia" University of Catanzaro, Viale Europa, 88100 Catanzaro, Italy. FAU - Perrotta, Girolamo AU - Perrotta G AD - Department of Experimental and Clinical Medicine, "Magna Graecia" University of Catanzaro, Viale Europa, 88100 Catanzaro, Italy. FAU - Mongiardi, Simona AU - Mongiardi S AD - Infectious and Tropical Diseases Unit, "Renato Dulbecco" Teaching Hospital, Viale Europa, 88100 Catanzaro, Italy. AD - Department of Medical and Surgical Sciences, "Magna Graecia" University of Catanzaro, Viale Europa, 88100 Catanzaro, Italy. FAU - Di Virgilio, Antonio AU - Di Virgilio A AD - Cardiac Surgery Unit, "Renato Dulbecco" Teaching Hospital, Viale Europa, 88100 Catanzaro, Italy. FAU - Musolino, Giuseppe AU - Musolino G AD - Cardiac Surgery Unit, "Renato Dulbecco" Teaching Hospital, Viale Europa, 88100 Catanzaro, Italy. FAU - Serraino, Giuseppe Filiberto AU - Serraino GF AUID- ORCID: 0000-0002-4804-9570 AD - Department of Experimental and Clinical Medicine, "Magna Graecia" University of Catanzaro, Viale Europa, 88100 Catanzaro, Italy. AD - Cardiac Surgery Unit, "Renato Dulbecco" Teaching Hospital, Viale Europa, 88100 Catanzaro, Italy. FAU - Mastroroberto, Pasquale AU - Mastroroberto P AUID- ORCID: 0000-0002-3060-0520 AD - Department of Experimental and Clinical Medicine, "Magna Graecia" University of Catanzaro, Viale Europa, 88100 Catanzaro, Italy. AD - Cardiac Surgery Unit, "Renato Dulbecco" Teaching Hospital, Viale Europa, 88100 Catanzaro, Italy. FAU - Russo, Alessandro AU - Russo A AUID- ORCID: 0000-0003-3846-4620 AD - Infectious and Tropical Diseases Unit, "Renato Dulbecco" Teaching Hospital, Viale Europa, 88100 Catanzaro, Italy. AD - Department of Medical and Surgical Sciences, "Magna Graecia" University of Catanzaro, Viale Europa, 88100 Catanzaro, Italy. LA - eng PT - Journal Article DEP - 20260306 PL - Switzerland TA - Diagnostics (Basel) JT - Diagnostics (Basel, Switzerland) JID - 101658402 PMC - PMC12984783 OTO - NOTNLM OT - cardiac infections OT - cardiac surgery OT - chest infections OT - mediastinitis OT - post-surgical complications COIS- The authors declare no conflicts of interest. EDAT- 2026/03/14 06:33 MHDA- 2026/03/14 06:34 PMCR- 2026/03/06 CRDT- 2026/03/14 01:04 PHST- 2025/12/29 00:00 [received] PHST- 2026/02/17 00:00 [revised] PHST- 2026/03/04 00:00 [accepted] PHST- 2026/03/14 06:34 [medline] PHST- 2026/03/14 06:33 [pubmed] PHST- 2026/03/14 01:04 [entrez] PHST- 2026/03/06 00:00 [pmc-release] AID - diagnostics16050785 [pii] AID - diagnostics-16-00785 [pii] AID - 10.3390/diagnostics16050785 [doi] PST - epublish SO - Diagnostics (Basel). 2026 Mar 6;16(5):785. doi: 10.3390/diagnostics16050785. PMID- 41827684 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260314 LR - 20260813 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 18 IP - 5 DP - 2026 Feb 26 TI - Cardiac Surgery in Cancer Patients: Clinical Dilemmas and Decision-Making Challenges. LID - 10.3390/cancers18050748 [doi] LID - 748 AB - Background: Improvements in cancer detection and treatment have led to a growing population of cancer survivors who subsequently develop cardiovascular (CV) disease requiring cardiac surgery. Methods: This narrative review synthesizes contemporary evidence from observational studies, registries, meta-analyses, and international guidelines addressing cardiac surgery in patients with active or prior cancer. Results: Cancer patients undergoing cardiac surgery face heightened risks related to hypercoagulability, bleeding, immunosuppression, frailty, and prior exposure to chemotherapy or radiotherapy. Conventional surgical risk scores inadequately capture cancer-specific factors such as tumor biology, prognosis, treatment trajectory, and frailty, often underestimating operative risk. Timing of surgery must balance CV urgency against oncologic priorities, with urgent cardiac conditions necessitating prompt intervention irrespective of cancer status, while stable disease allows individualized sequencing. Transcatheter and minimally invasive approaches increasingly play a key role, particularly in patients with limited life expectancy, hostile thoracic anatomy, or high surgical risk. Outcomes are heterogeneous and largely driven by cancer stage and prognosis rather than cardiac pathology alone. Conclusions: Cardiac surgery can be lifesaving and restore eligibility for definitive oncologic therapy in carefully selected patients, particularly those with early-stage or potentially curable malignancies. In advanced cancer, the benefits of invasive intervention must be weighed against perioperative burden, quality of life impact, and overall prognosis. Multidisciplinary, patient-centered decision-making within specialized cardio-oncology teams is essential. Future priorities include the development of cancer-specific risk prediction models, prospective surgical registries, and greater integration of quality-of-life outcomes into clinical decision-making. FAU - Keramida, Kalliopi AU - Keramida K AUID- ORCID: 0000-0002-9533-6951 AD - General Anticancer Oncological Hospital, Agios Savvas, 11522 Athens, Greece. FAU - Tsekoura, Dorothea AU - Tsekoura D AUID- ORCID: 0000-0002-9896-964X AD - 2nd Department of Surgery, Aretaieio University Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece. FAU - Roubelakis, Apostolomicrons AU - Roubelakis A AD - 3rd Department of Cardiac Surgery, Athens Medical Center, 11526 Athens, Greece. FAU - Michalopoulou, Helena AU - Michalopoulou H AUID- ORCID: 0000-0002-6961-3580 AD - Department of Cardiology, Laiko General Hospital of Athens, 11527 Athens, Greece. FAU - Androutsopoulou, Vasiliki AU - Androutsopoulou V AUID- ORCID: 0009-0005-2445-0879 AD - Department of Cardiothoracic Surgery, University Hospital of Larissa, 41110 Larissa, Greece. LA - eng PT - Journal Article PT - Review DEP - 20260226 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC12984672 OTO - NOTNLM OT - cancer survivors OT - cardiac surgery OT - cardio-oncology OT - frailty OT - multidisciplinary decision-making OT - perioperative management OT - surgical risk stratification OT - transcatheter cardiac interventions COIS- The authors declare no conflicts of interest. EDAT- 2026/03/14 06:34 MHDA- 2026/03/14 06:35 PMCR- 2026/02/26 CRDT- 2026/03/14 01:03 PHST- 2026/01/25 00:00 [received] PHST- 2026/02/20 00:00 [revised] PHST- 2026/02/22 00:00 [accepted] PHST- 2026/03/14 06:35 [medline] PHST- 2026/03/14 06:34 [pubmed] PHST- 2026/03/14 01:03 [entrez] PHST- 2026/02/26 00:00 [pmc-release] AID - cancers18050748 [pii] AID - cancers-18-00748 [pii] AID - 10.3390/cancers18050748 [doi] PST - epublish SO - Cancers (Basel). 2026 Feb 26;18(5):748. doi: 10.3390/cancers18050748. PMID- 41827174 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260314 LR - 20260813 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 15 IP - 5 DP - 2026 Feb 26 TI - Additional Stroke Risk Factors Beyond the CHA(2)DS(2)-VA Score in Non-Valvular Atrial Fibrillation: An Interdisciplinary Expert Opinion. LID - 10.3390/jcm15051758 [doi] LID - 1758 AB - Background/Objectives: Comorbidity and risk factor management and avoiding stroke are pillars of optimal atrial fibrillation management. In this article, the latest literature on additional stroke risk factors not included in the CHA(2)DS(2)-VA score is reviewed in patients with non-valvular atrial fibrillation (NVAF). The possible clinical impacts of the additional risk factors in NVAF patients with a CHA(2)DS(2)-VA score of 1 are compiled with insights in an interdisciplinary panel discussion to refine daily clinical practice. Methods: The panel was composed of three cardiologists, one endocrinologist, and a nephrologist. The panel members finalized twenty open-ended questions covering major problems in stroke risk stratification in NVAF patients with a score of 1. The shortcomings of this clinical-based model for stroke prevention and its possible outcomes were discussed with evidence-based recommendations. The meeting outcomes are addressed for daily clinical adaptation in the present article. Results: Recent evidence suggests that the CHA(2)DS(2)-VA score may have shortcomings in a striking rate of NVAF patients with a score of 1. The growing body of evidence suggests that combining clinical, laboratory, and imaging predictors with the CHA(2)DS(2)-VA score may further refine stroke risk prediction and aid in decision-making for anticoagulation of NVAF patients with a score of 1. Conclusions: The interdisciplinary expert panel offered several recommendations based on the assessment of additional risk factors, which may enable clinicians to identify individualized patient characteristics and early multidisciplinary prevention of disease progression and personalized improvements in the long-term cardiovascular outcomes in NVAF patients with a CHA(2)DS(2)-VA score of 1. FAU - Simsek, Ersin Cagri AU - Simsek EC AUID- ORCID: 0000-0001-6084-0982 AD - Cardiology Clinic, Health Sciences University, Izmir Tepecik Education and Research Hospital, 35120 Izmir, Turkiye. FAU - Sert Sekerci, Sena AU - Sert Sekerci S AD - Cardiology Clinic, Altunizade Acibadem Hospital, 34662 Istanbul, Turkiye. FAU - Gucun, Murat AU - Gucun M AD - Nephrology Clinic, Kosuyolu High Specialization Education and Research Hospital, 34865 Istanbul, Turkiye. FAU - Tanrikulu, Seher AU - Tanrikulu S AUID- ORCID: 0000-0001-9220-6118 AD - Department of Endocrinology and Metabolism, Acibadem Atasehir Hospital, 34750 Istanbul, Turkiye. FAU - Dundar Ahi, Emine AU - Dundar Ahi E AD - Primary Care Medical Team, Pfizer Turkiye, 34394 Istanbul, Turkiye. FAU - Ozdengulsun, Begum AU - Ozdengulsun B AUID- ORCID: 0000-0001-8751-6664 AD - Primary Care Medical Team, Pfizer Turkiye, 34394 Istanbul, Turkiye. FAU - Aras, Dursun AU - Aras D AD - Department of Cardiology, Medipol University Hospital, 34196 Istanbul, Turkiye. LA - eng PT - Journal Article DEP - 20260226 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC12985467 OTO - NOTNLM OT - anticoagulation OT - atrial fibrillation OT - cardiometabolic risk factors OT - chronic renal insufficiency OT - ischemic stroke OT - obesity OT - prevention COIS- E. Ahi-Dundar and B. Ozdengulsun are Pfizer employees. The other authors declare no conflicts of interest. EDAT- 2026/03/14 06:31 MHDA- 2026/03/14 06:32 PMCR- 2026/02/26 CRDT- 2026/03/14 01:01 PHST- 2026/01/12 00:00 [received] PHST- 2026/02/19 00:00 [revised] PHST- 2026/02/21 00:00 [accepted] PHST- 2026/03/14 06:32 [medline] PHST- 2026/03/14 06:31 [pubmed] PHST- 2026/03/14 01:01 [entrez] PHST- 2026/02/26 00:00 [pmc-release] AID - jcm15051758 [pii] AID - jcm-15-01758 [pii] AID - 10.3390/jcm15051758 [doi] PST - epublish SO - J Clin Med. 2026 Feb 26;15(5):1758. doi: 10.3390/jcm15051758. PMID- 41826669 OWN - NLM STAT- MEDLINE DCOM- 20260730 LR - 20261010 IS - 1476-5543 (Electronic) IS - 0743-8346 (Linking) VI - 46 IP - 7 DP - 2026 Jul TI - Improving preoperative enteral feeding for newborns with congenital heart disease. PG - 1337-1343 LID - 10.1038/s41372-026-02606-z [doi] AB - OBJECTIVE: The aim of this quality improvement project was to increase preoperative enteral feeding and breastfeeding rates in term neonates with congenital heart disease (CHD). METHODS: A multidisciplinary team developed and implemented a preoperative feeding protocol for neonates with congenital heart disease. The primary outcome was the presence of preoperative enteral feeding by May 2025. Secondary outcomes included breastfeeding rates and time to first feed. The process measure was the rate of reference to the feeding protocol in provider notes. Our balancing measure was a rule out or diagnosis of necrotizing enterocolitis requiring medical or surgical treatment in the preoperative period. Infants were identified using the Pediatric Cardiac Critical Care Collaborative (PC4). Data was collected from chart review and analyzed with statistical process control charts. The pre-implementation period was from June 2022 to June 2023, the implementation period was from July 2023 to June 2024, and the sustainment period was from July 2024 through May 2025. RESULTS: The number of neonates that met the inclusion criteria was 121. The rate of overall enteral feeding increased significantly from 72% in the pre-implementation phase (June 2022-June 2023) to 93% in the sustainment phase (July 2024-May 2025) (p = 0.026). Additionally, we found an improvement in our secondary outcomes and no change to the balancing measures. CONCLUSION: This quality improvement initiative, which centered on creating and implementing a clear, standardized, evidence-based feeding protocol while utilizing interdisciplinary collaboration, led to an increase in overall rates of preoperative enteral feeding for newborns with CHD in a level IV intensive care nursery. CI - (c) 2026. The Author(s), under exclusive licence to Springer Nature America, Inc. FAU - Brandfonbrener, Paul B AU - Brandfonbrener PB AUID- ORCID: 0009-0008-3959-2169 AD - Department of Pediatrics, University of California, San Francisco, San Francisco, CA, USA. paul.brandfonbrener@ucsf.edu. FAU - Gorsky, Katharine G AU - Gorsky KG AD - Department of Pediatrics, University of California, San Francisco, San Francisco, CA, USA. FAU - Marks, Catherine AU - Marks C AD - UCSF Benioff Children's Hospital, San Francisco, CA, USA. FAU - Hetherton, Maria AU - Hetherton M AUID- ORCID: 0009-0007-5141-5475 AD - UCSF Benioff Children's Hospital, San Francisco, CA, USA. FAU - Kramer, Katelin P AU - Kramer KP AD - Department of Pediatrics, University of California, San Francisco, San Francisco, CA, USA. FAU - Steurer, Martina A AU - Steurer MA AUID- ORCID: 0000-0002-0794-160X AD - Department of Pediatrics, University of California, San Francisco, San Francisco, CA, USA. LA - eng PT - Journal Article DEP - 20260313 PL - United States TA - J Perinatol JT - Journal of perinatology : official journal of the California Perinatal Association JID - 8501884 SB - IM MH - Humans MH - Infant, Newborn MH - *Heart Defects, Congenital/surgery/therapy MH - *Enteral Nutrition/methods/statistics & numerical data/standards MH - *Quality Improvement MH - Female MH - *Preoperative Care/methods/standards MH - *Breast Feeding/statistics & numerical data MH - Male MH - Enterocolitis, Necrotizing/diagnosis COIS- Competing interests: The authors declare no competing interests. EDAT- 2026/03/14 06:33 MHDA- 2026/07/31 00:37 CRDT- 2026/03/14 00:27 PHST- 2025/10/28 00:00 [received] PHST- 2026/02/25 00:00 [accepted] PHST- 2026/01/14 00:00 [revised] PHST- 2026/07/31 00:37 [medline] PHST- 2026/03/14 06:33 [pubmed] PHST- 2026/03/14 00:27 [entrez] AID - 10.1038/s41372-026-02606-z [pii] AID - 10.1038/s41372-026-02606-z [doi] PST - ppublish SO - J Perinatol. 2026 Jul;46(7):1337-1343. doi: 10.1038/s41372-026-02606-z. Epub 2026 Mar 13. PMID- 41826200 OWN - NLM STAT- MEDLINE DCOM- 20260508 LR - 20260620 IS - 1532-8422 (Electronic) IS - 1053-0770 (Linking) VI - 40 IP - 6 DP - 2026 Jun TI - The ISHLT Consensus Statement on the Perioperative Use of ECLS in Lung Transplantation: Highlights and Perioperative Implications. PG - 1840-1848 LID - S1053-0770(26)00145-X [pii] LID - 10.1053/j.jvca.2026.02.026 [doi] AB - To provide guidance on the use of extracorporeal life support in lung transplant patients, a 3-part consensus statement by a multidisciplinary team was developed and approved by the International Society for Heart and Lung Transplantation standard and guidelines committee, with each part focusing on a different phase of care: preoperative, intraoperative, and postoperative care. This review will highlight and summarize the key points most relevant to the cardiac anesthesiologist when caring for these patients. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Wanar, Harry AU - Wanar H AD - Department of Anesthesiology, Perioperative, and Pain Medicine, Icahn School of Medicine at Mount Sinai, New York, NY. FAU - Weiner, Menachem M AU - Weiner MM AD - Department of Anesthesiology, Perioperative, and Pain Medicine, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: menachem.weiner@mountsinai.org. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20260218 PL - United States TA - J Cardiothorac Vasc Anesth JT - Journal of cardiothoracic and vascular anesthesia JID - 9110208 SB - IM MH - Humans MH - *Extracorporeal Membrane Oxygenation/methods/standards MH - *Lung Transplantation/methods/standards MH - *Perioperative Care/methods/standards MH - Societies, Medical/standards MH - Consensus Statements as Topic OTO - NOTNLM OT - ECMO OT - lung transplant OT - perioperative COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/03/14 00:31 MHDA- 2026/05/09 00:34 CRDT- 2026/03/13 22:55 PHST- 2025/12/29 00:00 [received] PHST- 2026/02/05 00:00 [revised] PHST- 2026/02/17 00:00 [accepted] PHST- 2026/05/09 00:34 [medline] PHST- 2026/03/14 00:31 [pubmed] PHST- 2026/03/13 22:55 [entrez] AID - S1053-0770(26)00145-X [pii] AID - 10.1053/j.jvca.2026.02.026 [doi] PST - ppublish SO - J Cardiothorac Vasc Anesth. 2026 Jun;40(6):1840-1848. doi: 10.1053/j.jvca.2026.02.026. Epub 2026 Feb 18. PMID- 41824952 OWN - NLM STAT- MEDLINE DCOM- 20260711 LR - 20260925 IS - 2369-3762 (Electronic) IS - 2369-3762 (Linking) VI - 12 DP - 2026 Mar 13 TI - Enhancing Interprofessional Team Performance to Prevent Medication Errors in Emergency Care: Quasi-Experimental Study Using Multimodal Virtual Simulation-Based Interprofessional Education. PG - e66999 LID - 10.2196/66999 [doi] LID - e66999 AB - BACKGROUND: Effective interprofessional collaboration (IPC) is essential for patient safety; yet, poor teamwork and communication remain key challenges in high-pressure settings like the emergency department (ED), contributing to medication errors. Although Team Strategies and Tools to Enhance Performance and Patient Safety (TeamSTEPPS)-based interprofessional education addresses these issues, adaptation in clinical settings remains difficult. To bridge this gap, we developed Emergency Room Virtual Simulation-Based Interprofessional Education (ER-VIPE), a multimodal, TeamSTEPPS-integrated intervention designed to enhance IPC and reduce medication errors. OBJECTIVE: The aim of the study is to evaluate the effectiveness of ER-VIPE in enhancing IPC performance among emergency physicians, nurses, and pharmacists and in reducing medication errors. The primary objective is to assess changes in IPC performance in both real-world ED settings and in computer-based simulations. The secondary objective is to examine the intervention's impact on medication error rates in the ED. METHODS: This quasi-experimental study involved 15 interprofessional teams (each comprising 1 physician, 1 pharmacist, and 2 nurses), undergoing the ER-VIPE training. This multimodal intervention included 2 medical films, a massive open online course on TeamSTEPPS and IPC, and a computer-based simulation session on acute chest pain and cardiac arrest scenarios via the simulation-based interprofessional education (SIMBIE) platform. Co-debriefings were provided as a complement to the SIMBIE session, guiding participants through positive feedback and areas of improvement. TeamSTEPPS performance was measured using the Modified TeamSTEPPS and Team Performance Observation Tool (mTPOT) in both simulation and real-world ED settings. Generalized estimating equations with a Gaussian family, identity link, and exchangeable correlation structure were used to evaluate IPC score changes. Chi-square and Fisher exact tests were applied to compare near-miss and actual medication errors before and after the intervention. A 2-tailed P value <.05 was considered statistically significant. RESULTS: The study was conducted from November 2023 to January 2024 at a university hospital with 60 participants. Following the co-debriefing session in the simulation, overall mTPOT scores increased by 2.00 points (P<.001), with the greatest improvement among physicians (+2.70), followed by nurses (+1.75) and pharmacists (+1.56). In the ED, most mTPOT domains improved significantly across all professions 2 months after the intervention (P<.001). Although no significant reduction in harmful medication errors was observed, reporting of near-miss prescription errors increased significantly (P=.01). CONCLUSIONS: ER-VIPE enhanced IPC among ED physicians, nurses, and pharmacists, with sustained effects observed up to 2 months in real-world settings. The combination of medical films and massive open online courses provided accessible foundational knowledge, while computer-based virtual SIMBIE with co-debriefing reinforced practical communication and teamwork. Increased near-miss reporting suggests improved situational awareness and a more transparent safety culture. This multimodal training model shows promise for advancing collaboration and patient safety in emergency care. CI - (c)Ora-In Chu, Phanupong Phutrakool, Khrongwong Musikatavorn, Thitiporn Kongchim, Lapol Herabat, Jiraphan Ritsamdang, Krittin Bunditanukul, Kanittha Triamamornwooth, Khuansiri Narajeenron. Originally published in JMIR Medical Education (https://mededu.jmir.org), 13.03.2026. FAU - Chu, Ora-In AU - Chu OI AUID- ORCID: 0009-0004-0279-7989 AD - Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. FAU - Phutrakool, Phanupong AU - Phutrakool P AUID- ORCID: 0000-0003-0792-0275 AD - Chula Data Management Center, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. FAU - Musikatavorn, Khrongwong AU - Musikatavorn K AUID- ORCID: 0000-0002-5746-0724 AD - Department of Emergency Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. AD - Department of Emergency Medicine, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand. FAU - Kongchim, Thitiporn AU - Kongchim T AUID- ORCID: 0009-0002-4564-7193 AD - Emergency Department of the Nurse Department, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand. FAU - Herabat, Lapol AU - Herabat L AUID- ORCID: 0009-0008-8359-1454 AD - Department of Emergency Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. AD - Department of Emergency Medicine, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand. FAU - Ritsamdang, Jiraphan AU - Ritsamdang J AUID- ORCID: 0009-0006-8996-5352 AD - Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand. FAU - Bunditanukul, Krittin AU - Bunditanukul K AUID- ORCID: 0000-0003-4835-0897 AD - Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand. FAU - Triamamornwooth, Kanittha AU - Triamamornwooth K AUID- ORCID: 0009-0002-1769-956X AD - Clinical Pharmacy Services, Pharmacy Division, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand. FAU - Narajeenron, Khuansiri AU - Narajeenron K AUID- ORCID: 0000-0002-5191-6153 AD - Department of Emergency Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. AD - Department of Emergency Medicine, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20260313 PL - Canada TA - JMIR Med Educ JT - JMIR medical education JID - 101684518 SB - IM MH - Humans MH - *Medication Errors/prevention & control MH - *Patient Care Team/standards MH - *Simulation Training/methods MH - *Interprofessional Relations MH - *Interprofessional Education/methods MH - Emergency Service, Hospital MH - *Emergency Medical Services MH - Cooperative Behavior MH - Computer Simulation PMC - PMC13032089 OTO - NOTNLM OT - Team Strategies and Tools to Enhance Performance and Patient Safety OT - TeamSTEPPS OT - co-debriefing OT - computer-based simulation OT - emergency medicine OT - interprofessional collaboration OT - interprofessional education OT - massive open online courses OT - medical movie OT - medication error OT - virtual simulation-based interprofessional education COIS- Conflicts of Interest: None declared. EDAT- 2026/03/13 19:31 MHDA- 2026/03/13 19:32 PMCR- 2026/03/13 CRDT- 2026/03/13 16:53 PHST- 2024/09/30 00:00 [received] PHST- 2026/02/02 00:00 [accepted] PHST- 2026/01/12 00:00 [revised] PHST- 2026/03/13 19:32 [medline] PHST- 2026/03/13 19:31 [pubmed] PHST- 2026/03/13 16:53 [entrez] PHST- 2026/03/13 00:00 [pmc-release] AID - v12i1e66999 [pii] AID - 10.2196/66999 [doi] PST - epublish SO - JMIR Med Educ. 2026 Mar 13;12:e66999. doi: 10.2196/66999. PMID- 41824037 OWN - NLM STAT- MEDLINE DCOM- 20260710 LR - 20260926 IS - 1938-2723 (Electronic) IS - 1076-0296 (Print) IS - 1076-0296 (Linking) VI - 32 DP - 2026 Jan-Dec TI - Left Atrial Appendage Occlusion in Cancer-Associated Atrial Fibrillation: Who, When, and How to Manage Antithrombotic Therapy. PG - 10760296261429249 LID - 10.1177/10760296261429249 [doi] LID - 10760296261429249 AB - BackgroundCancer-associated atrial fibrillation (AF) is increasingly common, posing dual risks of thrombosis and bleeding. Long-term oral anticoagulation is often limited in these patients due to drug interactions, thrombocytopenia, and treatment-related bleeding. Left atrial appendage occlusion (LAAO) offers a non-pharmacological alternative for stroke prevention, yet its optimal use in cancer remains uncertain.MethodsWe conducted a narrative review of studies from 2009 to October 2025 across PubMed, Embase, and Google Scholar, including randomized trials, observational studies, registries, clinical guidelines, and expert statements addressing LAAO in AF patients, with emphasis on cancer and cardio-oncology populations. Case reports, non-English studies, abstracts without full text, and non-oncologic studies were excluded.ResultsRecent evidence suggests LAAO achieves high procedural success in selected cancer patients and reduces long-term bleeding compared with oral anticoagulants. Post-procedure management typically involves individualized anticoagulant or antiplatelet regimens adjusted for bleeding risk and hematologic status. However, short-term complications may be more frequent, likely reflecting cytopenias and patient frailty.ConclusionLAAO represents a promising stroke-prevention strategy for cancer-related AF when anticoagulation is unsafe or ineffective. Optimal outcomes require multidisciplinary evaluation, timing aligned with cancer status, and tailored post-implant antithrombotic therapy. Prospective studies are still needed to define patient selection, procedural timing, and post-procedural management in this high-risk population. FAU - Awashra, Ameer AU - Awashra A AUID- ORCID: 0009-0002-5122-8200 AD - Department of Medicine, An-Najah National University, Nablus, Palestine. RINGGOLD: 61284 FAU - Emara, Ahmed AU - Emara A AUID- ORCID: 0009-0001-2718-8627 AD - Faculty of Medicine, Al-Azhar University, Cairo, Egypt. RINGGOLD: 68820 FAU - AbuBaha, Mohammed AU - AbuBaha M AD - Department of Medicine, An-Najah National University, Nablus, Palestine. RINGGOLD: 61284 FAU - Istetieh, Kareem AU - Istetieh K AD - Department of Medicine, An-Najah National University, Nablus, Palestine. RINGGOLD: 61284 FAU - Aldarak, Shahd AU - Aldarak S AD - Department of Medicine, An-Najah National University, Nablus, Palestine. RINGGOLD: 61284 FAU - Nasser Shaheen, Mays AU - Nasser Shaheen M AD - Department of Medicine, An-Najah National University, Nablus, Palestine. RINGGOLD: 61284 FAU - Alwisi, Nouran AU - Alwisi N AD - College of Medicine, QU health, Qatar University, Doha, Qatar. RINGGOLD: 473226 FAU - Mahafdah, Bayan AU - Mahafdah B AD - Faculty of Medicine, Yarmouk University, Irbid, Jordan. RINGGOLD: 59179 FAU - AbuBaha, Bara AU - AbuBaha B AD - Department of Medicine, An-Najah National University, Nablus, Palestine. RINGGOLD: 61284 FAU - Abdul-Hafez, Hamza A AU - Abdul-Hafez HA AUID- ORCID: 0009-0003-6089-240X AD - Department of Medicine, An-Najah National University, Nablus, Palestine. RINGGOLD: 61284 FAU - Elgendy, Mohamed S AU - Elgendy MS AD - Faculty of Medicine, Tanta University, Tanta, Egypt. RINGGOLD: 68781 FAU - Shubietah, Abdalhakim AU - Shubietah A AD - Department of Medicine, Advocate Illinois Medical Center, Chicago, IL, USA. RINGGOLD: 21888 FAU - Baniowda, Muath AU - Baniowda M AD - Department of Internal Medicine, University of Missouri-Kansas City, Kansas City, MO, USA. RINGGOLD: 12273 LA - eng PT - Journal Article PT - Review DEP - 20260313 PL - United States TA - Clin Appl Thromb Hemost JT - Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis JID - 9508125 RN - 0 (Fibrinolytic Agents) SB - IM MH - Humans MH - *Atrial Fibrillation/drug therapy/complications/etiology MH - *Left Atrial Appendage Closure/methods MH - *Neoplasms/complications MH - *Fibrinolytic Agents/therapeutic use/pharmacology MH - Stroke/prevention & control MH - *Atrial Appendage/surgery PMC - PMC12988282 OTO - NOTNLM OT - antithrombotic therapy OT - cancer-associated atrial fibrillation OT - cardio-oncology OT - left atrial appendage occlusion OT - stroke prevention OT - thrombocytopenia COIS- Declaration of Conflicting InterestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2026/03/13 19:31 MHDA- 2026/03/13 19:32 PMCR- 2026/03/13 CRDT- 2026/03/13 12:13 PHST- 2026/03/13 19:32 [medline] PHST- 2026/03/13 19:31 [pubmed] PHST- 2026/03/13 12:13 [entrez] PHST- 2026/03/13 00:00 [pmc-release] AID - 10.1177_10760296261429249 [pii] AID - 10.1177/10760296261429249 [doi] PST - ppublish SO - Clin Appl Thromb Hemost. 2026 Jan-Dec;32:10760296261429249. doi: 10.1177/10760296261429249. Epub 2026 Mar 13. PMID- 41822366 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260313 LR - 20260926 IS - 2090-6404 (Print) IS - 2090-6412 (Electronic) IS - 2090-6404 (Linking) VI - 2026 DP - 2026 TI - Fetal Long QT Syndrome: Case Series and Literature Review With Focus on Multidisciplinary Care Coordination. PG - 5600959 LID - 10.1155/cric/5600959 [doi] LID - 5600959 AB - Congenital long QT syndrome (LQTS) is a group of heritable conditions that are associated with cardiac repolarization abnormality characterized by QT prolongation on ECG and risk of life-threatening arrhythmias. Prenatal detection of LQTS presents many challenges for clinicians and a multidisciplinary approach is needed for optimal prenatal and postnatal management. We describe five cases of fetal diagnosis of LQTS with variable initial presentation, diagnostic strategies, and management approaches. A multidisciplinary team approach including fetal cardiologist, adult and pediatric electrophysiologists, medical physicists, neonatologists, maternal-fetal medicine specialists, fetal cardiac nurse coordinators, and genetic counselors allowed for comprehensive prenatal management and well-planned postnatal treatment to optimize neonatal and maternal outcomes. CI - Copyright (c) 2026 Stefani Samples et al. Case Reports in Cardiology published by John Wiley & Sons Ltd. FAU - Samples, Stefani AU - Samples S AUID- ORCID: 0000-0002-2906-0651 AD - Pediatric Cardiology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA. AD - Department of Pediatrics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA, northwestern.edu. FAU - Cherny, Sara AU - Cherny S AUID- ORCID: 0000-0002-1453-6055 AD - Pediatric Cardiology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA. AD - Department of Pediatrics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA, northwestern.edu. FAU - Chandler, Stephanie AU - Chandler S AD - Pediatric Cardiology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA. AD - Department of Pediatrics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA, northwestern.edu. FAU - Wakai, Ronald T AU - Wakai RT AUID- ORCID: 0000-0002-9894-0484 AD - Department of Medical Physics, University of Wisconsin-Madison, Madison, Wisconsin, USA, wisc.edu. FAU - Strasburger, Janette F AU - Strasburger JF AUID- ORCID: 0000-0002-6986-2544 AD - Pediatric Cardiology, Children's Wisconsin-Milwaukee, Milwaukee, Wisconsin, USA. FAU - Patel, Sheetal AU - Patel S AUID- ORCID: 0000-0003-4257-1103 AD - Pediatric Cardiology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA. AD - Department of Pediatrics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA, northwestern.edu. LA - eng PT - Journal Article DEP - 20260311 PL - United States TA - Case Rep Cardiol JT - Case reports in cardiology JID - 101576452 PMC - PMC12976972 COIS- The authors declare no conflicts of interest. EDAT- 2026/03/13 06:52 MHDA- 2026/03/13 06:53 PMCR- 2026/03/11 CRDT- 2026/03/13 04:51 PHST- 2025/01/19 00:00 [received] PHST- 2026/02/18 00:00 [revised] PHST- 2026/02/27 00:00 [accepted] PHST- 2026/03/13 06:53 [medline] PHST- 2026/03/13 06:52 [pubmed] PHST- 2026/03/13 04:51 [entrez] PHST- 2026/03/11 00:00 [pmc-release] AID - CRIC5600959 [pii] AID - 10.1155/cric/5600959 [doi] PST - epublish SO - Case Rep Cardiol. 2026 Mar 11;2026:5600959. doi: 10.1155/cric/5600959. eCollection 2026. PMID- 41819551 OWN - NLM STAT- In-Process LR - 20260926 IS - 2753-670X (Electronic) IS - 2753-670X (Linking) VI - 41 IP - 3 DP - 2026 Mar 12 TI - The Role of the Cardiac Anaesthetist in Core Interdisciplinary Heart Teams. LID - 10.1093/icvts/ivag058 [doi] LID - ivag058 FAU - Paternoster, Gianluca AU - Paternoster G AUID- ORCID: 0000-0002-4032-0821 AD - Department of Health Sciences, University of Basilicata, Anesthesia and ICU, San Carlo Hospital, 85100 Potenza, Italy. FAU - Milojevic, Milan AU - Milojevic M AUID- ORCID: 0000-0003-0984-9011 AD - Department of Cardiac Surgery and Cardiovascular Research, Dedinje Cardiovascular Institute, 11000 Belgrade, Serbia. AD - Department of Cardiac Surgery, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland. FAU - Mukherjee, Chirojit AU - Mukherjee C AD - Department of Anaesthesia, HELIOS Clinic for Cardiac Surgery Karlsruhe, 76185 Karlsruhe, Germany. FAU - Kunst, Gudrun AU - Kunst G AUID- ORCID: 0000-0002-9789-1334 AD - Department of Anaesthesia and Pain Medicine, King's College Hospital NHS Foundation Trust, London SE5 9RS, United Kingdom. AD - School of Cardiovascular & Metabolic Medicine & Sciences, King's College London, London SE5 9NU, United Kingdom. LA - eng GR - NIHR306274/National Institute for Health and Care Research Senior Clinical Practitioner and Research Award/ PT - Journal Article PL - England TA - Interdiscip Cardiovasc Thorac Surg JT - Interdisciplinary cardiovascular and thoracic surgery JID - 9918540787006676 SB - IM PMC - PMC12981909 COIS- G.P. is president-elect of the European Association of Cardiothoracic Anaesthesiology and Intensive Care (EACTAIC). M.M. is the medical director for clinical practice guidelines at the European Association for Cardio-Thoracic Surgery. C.M. is immediate past-president of EACTAIC. G.K. is Chair of the Scientific Committee of EACTAIC. EDAT- 2026/03/13 00:50 MHDA- 2026/03/13 00:50 PMCR- 2026/03/05 CRDT- 2026/03/12 20:43 PHST- 2025/12/06 00:00 [received] PHST- 2026/01/23 00:00 [revised] PHST- 2026/02/17 00:00 [accepted] PHST- 2026/03/13 00:50 [medline] PHST- 2026/03/13 00:50 [pubmed] PHST- 2026/03/12 20:43 [entrez] PHST- 2026/03/05 00:00 [pmc-release] AID - 8516736 [pii] AID - ivag058 [pii] AID - 10.1093/icvts/ivag058 [doi] PST - ppublish SO - Interdiscip Cardiovasc Thorac Surg. 2026 Mar 12;41(3):ivag058. doi: 10.1093/icvts/ivag058. PMID- 41818712 OWN - NLM STAT- MEDLINE DCOM- 20260915 LR - 20260921 IS - 1879-0844 (Electronic) IS - 1388-9842 (Linking) VI - 28 IP - 3 DP - 2026 Sep 15 TI - Comprehensive evaluation of hypertrophic cardiomyopathy: European Journal of Heart Failure expert consensus document. PG - 374-384 LID - 10.1093/ejhf/xuag035 [doi] AB - Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease and a leading cause of heart failure and sudden cardiac death (SCD) in young adults. Given its complex pathophysiology, phenotypic diversity, and rapidly evolving therapeutic landscape, a structured and multidisciplinary approach to care is essential. This manuscript outlines a six-pillar framework to standardize and optimize evaluation and management of HCM. The proposed model organizes HCM care into six key domains. (i) Establishing the correct diagnosis, which requires differentiation between sarcomeric HCM and phenocopies such as amyloidosis, Fabry, or mitochondrial disease, using multimodal imaging and genetic testing. (ii) Establish presence of symptoms and of left ventricular outflow tract obstruction (LVOTO), which is central to symptom evaluation, prognostication, and treatment. Dynamic assessment with exercise echocardiography when required is essential to guide management, including pharmacotherapy or septal reduction therapy. (iii) Risk stratification for SCD integrates risk scores with adjunctive imaging data to support patient-centred implantable cardioverter defibrillator decisions. (iv) Genetic evaluation and family management enable cascade testing, early detection, and counselling. (v) Management of comorbidities-including atrial fibrillation, hypertension, obesity, and sleep-disordered breathing-is integral to holistic care and symptom control. (vi) Education and lifestyle guidance focus on safe sport participation, avoidance of dehydration and vasodilators, and reproductive counselling within a multidisciplinary setting. CI - (c) The Author(s) 2026. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com. FAU - Martens, Pieter AU - Martens P AUID- ORCID: 0000-0002-6036-2113 AD - Ziekenhuis Oost Limburg, synapspark 1, 3600 Genk, Belgium - University Hasselt, 3500 Hasselt, Belgium. FAU - Olivotto, Iacopo AU - Olivotto I AD - Department of cardiology, Meyer Children's Hospital IRCCS, Florence, Italy. FAU - Garcia-Pavia, Pablo AU - Garcia-Pavia P AUID- ORCID: 0000-0002-5470-2257 AD - Department of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, CIBERCV, Majadahonda, Spain. AD - Department Inherited Cardiomyopathy,Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain. FAU - Michels, Michelle AU - Michels M AUID- ORCID: 0000-0001-6432-0431 AD - Department of Cardiology, Thoraxcenter, Cardiovascular Institute, Erasmus Medical Center, Rotterdam, The Netherlands. FAU - Desai, Milind Y AU - Desai MY AD - Hypertrophic Cardiomyopathy Center, Heart Vascular Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA. FAU - Mullens, Wilfried AU - Mullens W AD - Ziekenhuis Oost Limburg, synapspark 1, 3600 Genk, Belgium - University Hasselt, 3500 Hasselt, Belgium. LA - eng PT - Consensus Statement PT - Journal Article PL - England TA - Eur J Heart Fail JT - European journal of heart failure JID - 100887595 SB - IM MH - Humans MH - *Cardiomyopathy, Hypertrophic/diagnosis/therapy/complications MH - *Death, Sudden, Cardiac/prevention & control/etiology MH - Europe MH - Genetic Testing MH - *Heart Failure/etiology MH - Risk Assessment MH - Ventricular Outflow Obstruction, Left/diagnosis OTO - NOTNLM OT - Cardiac myosin inhibitors OT - Genetic testing OT - Hypertrophic cardiomyopathy OT - Left ventricular outflow tract obstruction OT - Multidisciplinary care EDAT- 2026/03/12 18:53 MHDA- 2026/09/15 11:37 CRDT- 2026/03/12 16:33 PHST- 2025/12/01 00:00 [received] PHST- 2026/01/21 00:00 [revised] PHST- 2026/01/30 00:00 [accepted] PHST- 2026/09/15 11:37 [medline] PHST- 2026/03/12 18:53 [pubmed] PHST- 2026/03/12 16:33 [entrez] AID - 8516689 [pii] AID - 10.1093/ejhf/xuag035 [doi] PST - ppublish SO - Eur J Heart Fail. 2026 Sep 15;28(3):374-384. doi: 10.1093/ejhf/xuag035. PMID- 41818218 OWN - NLM STAT- MEDLINE DCOM- 20260711 LR - 20260813 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 21 IP - 3 DP - 2026 TI - The impact of CPR coach presence and position on team leader and team performance during asystole simulation scenario: a randomized simulation-based trial. PG - e0344568 LID - 10.1371/journal.pone.0344568 [doi] LID - e0344568 AB - BACKGROUND: High-quality cardiopulmonary resuscitation is critical for patient survival, and its effectiveness depends on compression quality, team coordination, and leadership. The CPR coach provides real-time feedback aimed at optimizing chest compressions and enhancing the overall resuscitation process. The primary aim is to evaluate whether the presence and the position of a CPR coach are equivalent compared to the absence of a CPR coach regarding the team leader's performance. As a secondary objective, it was investigated whether the presence and the position of the CPR coach influence the teams' performance. METHODS: This is single-center, randomized, controlled, three-arm, simulation-based equivalence trial. Teams of residents participated in standardized asystole scenarios, randomized to one of three groups: Group A (CPR coach positioned near the defibrillator), Group B (CPR coach allowed to move freely), and Group C (no CPR coach). The primary outcome was assessed using the Resuscitation Team Leader Evaluation Scale. The secondary outcome was measured by the Clinical Performance Tool and a CPR execution quality score derived from simulation manikin feedback. RESULTS: A total of 42 teams were included in the analysis. With respect to the primary outcome, team leader performance was statistically equivalent across Groups A, B, and C. As for the secondary outcome, no significant differences were observed in overall team performance. CONCLUSION: The presence and position of a CPR coach did not significantly influence team leader or team performance. Further research is needed to explore the role of CPR coaches in real-life settings and among more experienced teams. TRIAL REGISTRATION: Trial registration: NCT05309434. Registered 15/04/2022. CI - Copyright: (c) 2026 Mormando et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. FAU - Mormando, Giulia AU - Mormando G AUID- ORCID: 0000-0001-9516-9885 AD - Department of Medicine (DIMED), University of Padova, Padova, Italy. FAU - Capogna, Emanuele AU - Capogna E AUID- ORCID: 0000-0002-4053-1274 AD - EESOA Simulation Center, Rome, Italy. FAU - Costantini, Ilaria AU - Costantini I AD - UOC Pronto Soccorso Ospedale Cazzavillan Arzignano ULSS 8 Berica Vicenza, Vicenza, Italy. FAU - Savino, Sandro AU - Savino S AUID- ORCID: 0000-0003-0184-7580 AD - Department of Medicine (DIMED), University of Padova, Padova, Italy. FAU - Vittadello, Anna AU - Vittadello A AD - UOC Pronto Soccorso Azienda Ospedale Universita di Padova, Padova, Italy. FAU - Campione, Marina AU - Campione M AD - Faculty of Economics and Law, University of Enna Kore, Enna, Italy. FAU - Boscolo, Annalisa AU - Boscolo A AUID- ORCID: 0000-0003-3409-4159 AD - Department of Medicine (DIMED), University of Padova, Padova, Italy. AD - Institute of Anaesthesia and Intensive Care, Padova University Hospital, Padova, Italy. FAU - Bressan, Silvia AU - Bressan S AD - Department of Women's and Children's Health (SDB) - University of Padua, Padova, Italy. FAU - Navalesi, Paolo AU - Navalesi P AD - Department of Medicine (DIMED), University of Padova, Padova, Italy. AD - Institute of Anaesthesia and Intensive Care, Padova University Hospital, Padova, Italy. LA - eng SI - ClinicalTrials.gov/NCT05309434 PT - Equivalence Trial PT - Journal Article DEP - 20260312 PL - United States TA - PLoS One JT - PloS one JID - 101285081 SB - IM MH - Adult MH - Female MH - Humans MH - Male MH - *Cardiopulmonary Resuscitation/methods/education MH - *Heart Arrest/therapy MH - *Leadership MH - Manikins MH - *Patient Care Team PMC - PMC12981441 COIS- NO authors have competing interests. EDAT- 2026/03/12 18:53 MHDA- 2026/03/12 18:54 PMCR- 2026/03/12 CRDT- 2026/03/12 13:34 PHST- 2025/11/10 00:00 [received] PHST- 2026/02/16 00:00 [accepted] PHST- 2026/03/12 18:54 [medline] PHST- 2026/03/12 18:53 [pubmed] PHST- 2026/03/12 13:34 [entrez] PHST- 2026/03/12 00:00 [pmc-release] AID - PONE-D-25-55127 [pii] AID - 10.1371/journal.pone.0344568 [doi] PST - epublish SO - PLoS One. 2026 Mar 12;21(3):e0344568. doi: 10.1371/journal.pone.0344568. eCollection 2026. PMID- 41817232 OWN - NLM STAT- MEDLINE DCOM- 20260817 LR - 20260817 IS - 1473-6500 (Electronic) IS - 0952-7907 (Print) IS - 0952-7907 (Linking) VI - 39 IP - 3 DP - 2026 Jun 1 TI - Updates to perioperative and anesthetic management of the left ventricular assist device patient presenting for noncardiac surgery. PG - 417-424 LID - 10.1097/ACO.0000000000001645 [doi] AB - PURPOSE OF REVIEW: In an era of improved outcomes and expanding use of left ventricular assist devices (LVADs) among patients with end-stage heart failure, anesthesiologists increasingly encounter such patients presenting for noncardiac surgery. This review synthesizes current advances in the perioperative and anesthetic management of patients with LVADs in the noncardiac surgical setting, providing actionable, evidence-based recommendations. RECENT FINDINGS: Although a range of durable mechanical circulatory support options currently exist for patients, third-generation continuous-flow LVADs are now the predominant devices, demonstrating improved survival but posing unique perioperative challenges. A multidisciplinary approach - including heart failure and device specialists - is essential for preoperative assessment, medical management, and optimal care coordination in anticipation of the surgical admission. Intraoperative care requires nuanced monitoring strategies and vigilance for complications such as suction events or right ventricular failure; the anesthetic plan should carefully consider preload/afterload dependency and anticoagulation. Postoperative management includes tailored hemodynamic, device, and anticoagulation strategies to minimize complications. SUMMARY: Optimal outcomes for LVAD patients undergoing noncardiac surgery require multidisciplinary planning, device-specific knowledge, and meticulous management of anticoagulation, hemodynamics, and right ventricular function. Future research should standardize protocols for perioperative LVAD management in nonspecialist centers. CI - Copyright (c) 2026 The Author(s). Published by Wolters Kluwer Health, Inc. FAU - Burcar, Kimberly H AU - Burcar KH AD - Department of Anesthesiology, University of Michigan Medical School, Ann Arbor, Michigan, USA. FAU - Korenke, Mark M AU - Korenke MM FAU - Ebadi-Tehrani, Mehran M AU - Ebadi-Tehrani MM FAU - Mathis, Michael R AU - Mathis MR FAU - Toton, Monika P AU - Toton MP LA - eng GR - R01 HL167790/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Review DEP - 20260311 PL - United States TA - Curr Opin Anaesthesiol JT - Current opinion in anaesthesiology JID - 8813436 SB - IM MH - *Heart-Assist Devices/adverse effects MH - Heart Ventricles MH - *Perioperative Care/methods MH - *Anesthesia/methods MH - *Surgical Procedures, Operative/adverse effects/methods MH - *Postoperative Complications/etiology/prevention & control MH - Heart Failure/complications/surgery MH - Humans PMC - PMC13084291 MID - NIHMS2164883 OTO - NOTNLM OT - heart failure OT - left ventricular assist devices OT - mechanical circulatory support OT - perioperative management COIS- M.R.M. has received a research grant from the US National Institutes of Health (NIDDK) and research support from Chiesi, USA, paid to the University of Michigan, and unrelated to this present work. No other relationships or activities that could appear to have influenced the submitted work are reported. For the remaining authors, there are no conflicts of interest. EDAT- 2026/03/12 13:55 MHDA- 2026/04/29 06:33 PMCR- 2026/04/28 CRDT- 2026/03/12 09:23 PHST- 2026/04/29 06:33 [medline] PHST- 2026/03/12 13:55 [pubmed] PHST- 2026/03/12 09:23 [entrez] PHST- 2026/04/28 00:00 [pmc-release] AID - 00001503-990000000-00401 [pii] AID - ACO390306 [pii] AID - 10.1097/ACO.0000000000001645 [doi] PST - ppublish SO - Curr Opin Anaesthesiol. 2026 Jun 1;39(3):417-424. doi: 10.1097/ACO.0000000000001645. Epub 2026 Mar 11. PMID- 41815879 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260312 LR - 20260813 IS - 2050-0904 (Print) IS - 2050-0904 (Electronic) IS - 2050-0904 (Linking) VI - 14 IP - 3 DP - 2026 Mar TI - VV-ECMO Combined With M-TEER for the Treatment of Mitral Valve Papillary Muscle Rupture Following Acute Myocardial Infarction PCI: A Case Report. PG - e72252 LID - 10.1002/ccr3.72252 [doi] LID - e72252 AB - Mitral valve papillary muscle rupture represents a rare yet critical complication of acute myocardial infarction, often leading to severe mitral regurgitation and subsequent pulmonary edema with high mortality. Despite optimal ventilatory support and pharmacological management, patients often exhibit refractory hypoxemia, rendering surgical intervention both technically demanding and high-risk. A 40-year-old Asian male presented to the emergency department of Liaocheng People's Hospital following percutaneous coronary intervention (PCI) for acute myocardial infarction at an outside facility. Shortly post-procedure, the patient developed dyspnea and oliguria. Despite endotracheal intubation, mechanical ventilation, and medical therapy, his condition deteriorated, necessitating transfer. Echocardiography and transesophageal echocardiography confirmed mitral valve papillary muscle rupture with severe regurgitation, complicated by profound pulmonary edema and refractory hypoxemia. Venovenous extracorporeal membrane oxygenation (VV-ECMO) was promptly initiated, resulting in gradual improvement in oxygenation. Following a multidisciplinary evaluation, edge-to-edge mitral valve repair was successfully performed under VV-ECMO support. ECMO was discontinued on postoperative day 4, and the patient was discharged after 14 days with marked clinical improvement. In cases of severe pulmonary edema secondary to mitral valve papillary muscle rupture post-PCI for acute myocardial infarction, early VV-ECMO implementation combined with edge-to-edge mitral valve repair under ECMO support may mitigate surgical risk and enhance outcomes. This integrated approach presents a viable therapeutic alternative for such high-risk patients. CI - (c) 2026 The Author(s). Clinical Case Reports published by John Wiley & Sons Ltd. FAU - Liu, Zhenjiang AU - Liu Z AUID- ORCID: 0009-0006-1614-9418 AD - Emergency Department Liaocheng People's Hospital Liaocheng China. LA - eng PT - Journal Article DEP - 20260309 PL - England TA - Clin Case Rep JT - Clinical case reports JID - 101620385 PMC - PMC12971378 OTO - NOTNLM OT - M-TEER OT - VV-ECMO OT - acute myocardial infarction OT - pulmonary edema COIS- The author declares no conflicts of interest. EDAT- 2026/03/12 07:04 MHDA- 2026/03/12 07:05 PMCR- 2026/03/09 CRDT- 2026/03/12 05:12 PHST- 2025/12/06 00:00 [received] PHST- 2026/02/24 00:00 [revised] PHST- 2026/02/26 00:00 [accepted] PHST- 2026/03/12 07:05 [medline] PHST- 2026/03/12 07:04 [pubmed] PHST- 2026/03/12 05:12 [entrez] PHST- 2026/03/09 00:00 [pmc-release] AID - CCR372252 [pii] AID - 10.1002/ccr3.72252 [doi] PST - epublish SO - Clin Case Rep. 2026 Mar 9;14(3):e72252. doi: 10.1002/ccr3.72252. eCollection 2026 Mar. PMID- 41813287 OWN - NLM STAT- MEDLINE DCOM- 20260710 LR - 20260710 IS - 1879-1913 (Electronic) IS - 0002-9149 (Linking) VI - 264 DP - 2026 Apr 1 TI - The 2025 Accra Declaration on Upskilling and Cost- Effective Cardiac Surgery in Africa. PG - 76-83 LID - S0002-9149(25)00732-5 [pii] LID - 10.1016/j.amjcard.2025.09.067 [doi] AB - The Pan-African Society for Cardiothoracic Surgery (PASCaTS) organized the 1st Pan-African Cardiothoracic Surgery Summit on 21 to 24 February 2025 in Accra, Ghana. The summit brought together leading specialists from across Africa, China, Europe, South America and the USA to address the growing burden of cardiovascular disease, to share their vision for the fight against cardiovascular disease, to raise standards in the diagnosis, treatment and recovery of patients thereby improving procedural safety and clinical outcomes in Africa. The experts agreed on the need for cost effectiveness in cardiac surgery, simulation skills training, an African regional cardiothoracic surgery database, African heart team fellowship programs and specialized working groups to guide cardiovascular diagnostics and treatments focusing on critical areas such as congenital heart surgery, valve surgery and coronary artery bypass surgery (CABG) procedures which are becoming increasingly necessary in Africa due to the rise in cardiovascular emergencies, and finally explore solutions tailored to the continent's unique healthcare challenges. The incentives generated from the summit are formulated as the "2025 Accra Declaration" to serve as roadmaps and implementable guidelines for promoting high-level cardiovascular surgery and reforms in Africa in collaboration with cardiologists and other allied cardiovascular professionals. CI - Copyright (c) 2026 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Yankah, A Charles AU - Yankah AC AD - Humanitarian Cardiac Surgery, Global Heart Care, Berlin, Germany; Department of Cardiothoracic Surgery, German Heart Center Charite Berlin, Germany. Electronic address: cyankah@web.de. FAU - Nwiloh, Jonathan AU - Nwiloh J AD - Department of Cardiothoracic Surgery, Dr. Joe Nwiloh Heart Center, Adazi Nnukwu, Nigeria. FAU - Mestres, Carlos A AU - Mestres CA AD - Department of Cardiothoracic Surgery, University of the Free State, Bloemfontein, South Africa. FAU - Bouzid, Abdelmalek AU - Bouzid A AD - Department of Cardiovascular Surgery, University of Algiers, Algiers, Algeria. FAU - Mwambu, Tom Philip AU - Mwambu TP AD - Department of Cardiothoracic Surgery, Uganda Heart Institute, Kampala, Uganda. FAU - Duncan, Andrew J AU - Duncan AJ AD - Department of Cardiothoracic Surgery, Aga Khan University, Nairobi, Kenya. FAU - Debieche, Mohamed AU - Debieche M AD - Department of Cardiovascular Surgery, University of Blida, Blida, Algeria. FAU - Omokhodion, Samuel I AU - Omokhodion SI AD - Institute of Cardiovascular Diseases, University of Ibadan, Ibadan, Nigeria. FAU - Onakpoya, Uvie U AU - Onakpoya UU AD - Department of Cardiothoracic Surgery, Obafemi Awolowo University, Ile-Ife, Nigeria. FAU - Angres, Matthias AU - Angres M AD - Aswan Heart Center, Intensive Care Unit, Aswan, Egypt. FAU - Nademo, Siyasebow M AU - Nademo SM AD - Department of Cardiothoracic Surgery, Hawassa University, Sidama, Ethiopia. FAU - Oburu, Gilbert AU - Oburu G AD - Department of Cardiothoracic Surgery, Kenyatta National University, Nairobi, Kenya. FAU - Yao, Nana-Akyaa AU - Yao NA AD - Congenital & Pediatric Cardiology, Korle Bu Teaching Hospital, National Cardiothoracic Center, Accra, Ghana. FAU - Entsua-Mensah, Kow AU - Entsua-Mensah K AD - National Cardiothoracic Center, Accra, Ghana. FAU - Reddy, Darshan AU - Reddy D AD - Lenmed Ethekwini Hospital & Heart Center, Durban, South Africa. FAU - Antunes, Manuel AU - Antunes M AD - Cardiothoracic Surgery, University of Coimbra, Portugal. FAU - Gomes, Walter J AU - Gomes WJ AD - Department of Cardiovascular Surgery, Federal University of Sao Paulo, Sao Paulo, Brazil. FAU - Akamah, Joseph A AU - Akamah JA AD - Department of Cardiology, University of Nashville, Nashville, United States. FAU - Yigitbasi, Mustafa AU - Yigitbasi M AD - Pediatric Cardiology Clinic, Berlin, Germany. FAU - Buys, Daniel Gerhard AU - Buys DG AD - Department of Pediatric Cardiology, University of the Free State, Bloemfontein, South Africa. FAU - Bokenkamp, Regina AU - Bokenkamp R AD - Department of Pediatric Cardiology, University Medical Center Leiden, Leiden, Netherlands. FAU - Koen, Willie AU - Koen W AD - Department of Cardiothoracic Surgery, Christiaan Barnard Memorial Hospital, Cardiac, Transplant Program, Cape Town, South Africa. FAU - Smit, Francis E AU - Smit FE AD - Department of Cardiothoracic Surgery, University of the Free State, Bloemfontein, South Africa. FAU - Chikwe, Joanna AU - Chikwe J AD - Department of Cardiac Surgery, Cedars Sinai Medical Center, Smidt Heart Institute, Los Angeles, United States. LA - eng PT - Journal Article PT - Review DEP - 20260223 PL - United States TA - Am J Cardiol JT - The American journal of cardiology JID - 0207277 SB - IM MH - Humans MH - Africa MH - *Cardiac Surgical Procedures/economics/education MH - Cost-Benefit Analysis MH - *Thoracic Surgery/economics/education MH - *Cardiovascular Diseases/surgery MH - Societies, Medical OTO - NOTNLM OT - Accra declaration OT - Africa OT - access to cardiac surgery OT - cost effective cardiac surgery OT - global heart forum OT - pan-African society for cardiothoracic surgery OT - structural heart disease COIS- Declaration of competing interest The authors have no competing interests to declare. EDAT- 2026/03/12 01:09 MHDA- 2026/03/12 07:03 CRDT- 2026/03/11 22:13 PHST- 2025/07/18 00:00 [received] PHST- 2025/09/16 00:00 [revised] PHST- 2025/09/26 00:00 [accepted] PHST- 2026/03/12 07:03 [medline] PHST- 2026/03/12 01:09 [pubmed] PHST- 2026/03/11 22:13 [entrez] AID - S0002-9149(25)00732-5 [pii] AID - 10.1016/j.amjcard.2025.09.067 [doi] PST - ppublish SO - Am J Cardiol. 2026 Apr 1;264:76-83. doi: 10.1016/j.amjcard.2025.09.067. Epub 2026 Feb 23. PMID- 41813098 OWN - NLM STAT- Publisher LR - 20260311 IS - 1468-201X (Electronic) IS - 1355-6037 (Linking) DP - 2026 Mar 11 TI - Advanced cardiac imaging in cardiac sarcoidosis: current evidence and future directions. LID - heartjnl-2025-326694 [pii] LID - 10.1136/heartjnl-2025-326694 [doi] AB - Cardiac sarcoidosis (CS) is a rare and complex disease that requires a multidisciplinary approach for diagnosis and treatment. The diagnosis of CS can be confirmed by histological examination of non-caseating granulomas in cardiac or extracardiac tissue, along with supportive clinical and imaging findings. Symptoms are often non-specific, and the yield of endomyocardial biopsy is low due to the patchy nature of cardiac involvement-thus, many cases are not straightforward to diagnose, especially when pulmonary or extracardiac features are absent. Modern non-invasive imaging modalities have unique strengths in assessing the myocardium's structure, function, perfusion, inflammation and fibrosis-abnormalities of all these features exist in CS in varying degrees and can be integrated to assist in the diagnosis. Echocardiography is universally used as the initial imaging test when CS is suspected and provides information on cardiac structure and function, but is limited by inadequate tissue characterisation and differentiation from other infiltrative or restrictive cardiomyopathies. Positron emission tomography (PET) and cardiovascular magnetic resonance (CMR) have good accuracy in diagnosing CS. With current tissue characterisation techniques, such as T1 and T2 parametric mapping, CMR imaging can detect subclinical or early CS. While CMR has better overall prognostic utility for arrhythmic risk and cardiac mortality, fluorodeoxyglucose (FDG)-PET is superior in monitoring disease activity and guiding anti-inflammatory therapy. Hybrid FDG-PET/CMR imaging is a newer, complementary approach that is being increasingly used in centres of excellence. It combines the unique strengths of both modalities, thereby achieving superior sensitivity and specificity. CI - (c) Author(s) (or their employer(s)) 2026. No commercial re-use. See rights and permissions. Published by BMJ Group. FAU - Aslam, Awais AU - Aslam A AUID- ORCID: 0009-0001-6052-3183 AD - Department of Cardiovascular Medicine, Sanford Health North, Fargo, North Dakota, USA. FAU - Khan, Wahab Jahangir AU - Khan WJ AUID- ORCID: 0000-0002-0275-731X AD - Department of Cardiology, University of Kentucky College of Medicine, Bowling Green, Kentucky, USA wahab.khan@uky.edu. FAU - Haq, Syed H AU - Haq SH AUID- ORCID: 0000-0002-6143-2101 AD - Mercy Health St Rita's Medical Center, Lima, Ohio, USA. FAU - Nadeem, Ifrah AU - Nadeem I AUID- ORCID: 0000-0001-9016-1438 AD - Franciscan Health Olympia Fields, Olympia Fields, Illinois, USA. FAU - Khan, Salman J AU - Khan SJ AD - Guthrie Lourdes Hospital, Binghamton, New York, USA. FAU - Asif, Anim AU - Asif A AUID- ORCID: 0009-0002-7463-1174 AD - New York City Health and Hospitals Corporation, New York City, New York, USA. FAU - Shah, Sidra AU - Shah S AUID- ORCID: 0000-0001-6122-3484 AD - Mercy Health St Rita's Medical Center, Lima, Ohio, USA. FAU - Fatima, Aqsa AU - Fatima A AUID- ORCID: 0009-0006-0349-5282 AD - Franciscan Health Olympia Fields, Olympia Fields, Illinois, USA. FAU - Haldis, Jack AU - Haldis J AD - College of Liberal Arts and Sciences, Villanova University College of Liberal Arts and Sciences, Villanova, Pennsylvania, USA. FAU - Smith, Aaron Andrew Heigaard AU - Smith AAH AUID- ORCID: 0000-0003-0559-3768 AD - Department of Cardiovascular Medicine, Sanford Health North, Fargo, North Dakota, USA. LA - eng PT - Journal Article PT - Review DEP - 20260311 PL - England TA - Heart JT - Heart (British Cardiac Society) JID - 9602087 SB - IM COIS- Competing interests: None declared. EDAT- 2026/03/12 01:09 MHDA- 2026/03/12 01:09 CRDT- 2026/03/11 21:25 PHST- 2026/03/02 00:00 [received] PHST- 2026/02/03 00:00 [accepted] PHST- 2026/03/12 01:09 [medline] PHST- 2026/03/12 01:09 [pubmed] PHST- 2026/03/11 21:25 [entrez] AID - heartjnl-2025-326694 [pii] AID - 10.1136/heartjnl-2025-326694 [doi] PST - aheadofprint SO - Heart. 2026 Mar 11:heartjnl-2025-326694. doi: 10.1136/heartjnl-2025-326694. PMID- 41809977 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260311 LR - 20260813 IS - 2950-1334 (Electronic) IS - 2950-1334 (Linking) VI - 12 DP - 2026 May TI - Long-term pediatric heart transplantation. PG - 100515 LID - 10.1016/j.jhlto.2026.100515 [doi] LID - 100515 AB - Pediatric heart transplantation remains the definitive therapy for selected children with end-stage heart failure. Short-term outcomes over the last decades have shown excellent survival; however, long-term outcomes remain a challenge. Cardiac allograft vasculopathy is the leading cause of late graft failure and mortality beyond the first year post-transplant. Chronic rejection, renal dysfunction related to lifelong immunosuppression, and post-transplant lymphoproliferative disorders are major contributors to late morbidity. Adolescents face an increased risk of graft loss, largely driven by nonadherence, which is most frequent during the transition to adult care. Growth, neurodevelopment, and quality of life are generally favorable, especially in children who undergo transplantation at younger ages. Re-transplantation is an option when graft dysfunction, but it is associated with inferior outcomes compared with primary transplant. This article explores detailed chronic post-transplant complications, including rejection, cardiac allograft vasculopathy (CAV), graft failure, infection, renal dysfunction, and malignancy, which influence long-term results. We highlight that a multidisciplinary approach with a special focus on the transition from pediatric to adult care, individualized immunosuppression, adherence support, cardiac rehabilitation, and early detection of graft vasculopathy is essential to further optimize long-term outcomes. CI - (c) 2026 The Author(s). FAU - Albert-Brotons, Dimpna C AU - Albert-Brotons DC AD - Heart Center of Excellence, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia. FAU - AlHaddad, Mohammad AU - AlHaddad M AD - Heart Center of Excellence, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia. FAU - Alyami, Mansour AU - Alyami M AD - Heart Center of Excellence, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia. FAU - Alali, Yasser AU - Alali Y AD - Heart Center of Excellence, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia. FAU - Buraiki, Jehad AU - Buraiki J AD - Heart Center of Excellence, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia. LA - eng PT - Journal Article DEP - 20260216 PL - United States TA - JHLT Open JT - JHLT open JID - 9918716187806676 PMC - PMC12969388 OTO - NOTNLM OT - Cardiac allograft vasculopathy OT - Outcomes OT - Pediatric heart transplant OT - Rejection OT - Surveillance COIS- The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/03/11 06:56 MHDA- 2026/03/11 06:57 PMCR- 2026/02/16 CRDT- 2026/03/11 05:26 PHST- 2026/03/11 06:57 [medline] PHST- 2026/03/11 06:56 [pubmed] PHST- 2026/03/11 05:26 [entrez] PHST- 2026/02/16 00:00 [pmc-release] AID - S2950-1334(26)00036-4 [pii] AID - 100515 [pii] AID - 10.1016/j.jhlto.2026.100515 [doi] PST - epublish SO - JHLT Open. 2026 Feb 16;12:100515. doi: 10.1016/j.jhlto.2026.100515. eCollection 2026 May. PMID- 41809976 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260311 LR - 20260813 IS - 2950-1334 (Electronic) IS - 2950-1334 (Linking) VI - 12 DP - 2026 May TI - Heart transplantation in pediatric oncology patients. PG - 100514 LID - 10.1016/j.jhlto.2026.100514 [doi] LID - 100514 AB - Advances in pediatric oncology have dramatically improved survival, leading to a growing population of childhood cancer survivors (CCS). However, many of these individuals are at risk for late cardiac complications from cancer therapy. A known complication coined cancer therapy-related cardiac dysfunction (CTRCD) can progress to end-stage heart failure. This review examines the evolving role of heart transplantation in CCS with advanced heart failure, including, addressing patient selection, clinical outcomes, and unique management considerations. CTRCD most often results from anthracycline chemotherapy and chest radiation. Newer therapies have emerged to improve survival and include immunotherapy and targeted agents. These newer agents also pose cardiotoxic risks. CTRCD is often irreversible and progressive; it is imperative that such damage be prevented with strategies such as limiting cumulative anthracycline exposures, utilizing anthracycline-sparing regimens when feasible, and increasing the use of cardioprotective agents like dexrazoxane. With refractory heart failure, mechanical circulatory support and heart transplantation may be appropriate, though the decision making requires a multidisciplinary collaboration. Although CCS present unique challenges-such as immunosuppression risks, and elevated infection or secondary cancer risk-current data demonstrate comparable post-transplant survival to non-oncology patients. Heart transplantation is a viable and effective treatment for select CCS with end-stage heart failure. Careful multidisciplinary evaluation, tailored immunosuppression, and vigilant long-term surveillance are essential to optimize outcomes in this complex population. CI - (c) 2026 The Author(s). FAU - Marshall, Molly K AU - Marshall MK AD - Division of Pediatric Cardiology, Icahn School of Medicine at Mount Sinai Mount Sinai Kravis Children's Hospital, New York, NY. FAU - Tolani, Drishti AU - Tolani D AD - Division of Pediatric Cardiology, Cleveland Clinic Children's Institute, Cleveland, OH. FAU - Bender, Jonathan D AU - Bender JD AD - Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH. AD - Division of Oncology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH. FAU - Lamour, Jacqueline M AU - Lamour JM AD - Division of Pediatric Cardiology, Icahn School of Medicine at Mount Sinai Mount Sinai Kravis Children's Hospital, New York, NY. FAU - Bansal, Neha AU - Bansal N AD - Division of Pediatric Cardiology, Icahn School of Medicine at Mount Sinai Mount Sinai Kravis Children's Hospital, New York, NY. LA - eng PT - Journal Article DEP - 20260213 PL - United States TA - JHLT Open JT - JHLT open JID - 9918716187806676 PMC - PMC12969437 OTO - NOTNLM OT - Anthracycline OT - Cardiotoxicity OT - Childhood cancer OT - Heart failure OT - Heart transplantation OT - Pediatric cardio-oncology OT - Survivorship COIS- The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/03/11 06:57 MHDA- 2026/03/11 06:58 PMCR- 2026/02/13 CRDT- 2026/03/11 05:26 PHST- 2026/03/11 06:58 [medline] PHST- 2026/03/11 06:57 [pubmed] PHST- 2026/03/11 05:26 [entrez] PHST- 2026/02/13 00:00 [pmc-release] AID - S2950-1334(26)00035-2 [pii] AID - 100514 [pii] AID - 10.1016/j.jhlto.2026.100514 [doi] PST - epublish SO - JHLT Open. 2026 Feb 13;12:100514. doi: 10.1016/j.jhlto.2026.100514. eCollection 2026 May. PMID- 41808929 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260311 LR - 20260813 IS - 1478-4726 (Electronic) IS - 1478-4726 (Linking) VI - 10 IP - 4 DP - 2026 Mar 1 TI - Mapping pre-hospital research presented at UK conferences between 2010 and 2023: a bibliometric study. PG - 18-24 LID - 10.29045/14784726.2026.3.10.4.18 [doi] AB - INTRODUCTION: The growth of the paramedic profession over recent years is reflected in the growing body of publications by paramedics or related to paramedics, ambulance services and pre-hospital care. Publications are not the only method by which new knowledge can be disseminated, and conferences represent another method of dissemination. Conference presentations may or may not be published, so studying these presents a different perspective on topics of interest and research happening within the profession. This study set out to report on material presented at large conferences relevant to UK paramedics between 2010 and 2023. METHODS: The project comprised a bibliometric study describing presentations from UK conferences relevant to paramedics between 2010 and 2023. Conferences relevant to paramedic practice were selected by the study team based on pre-determined criteria. Standardised forms were used to extract data on presentations and presenters. Data are presented descriptively. RESULTS: Six large conferences (999 EMS Research Forum, Ambulance Leadership Forum, Faculty of Pre-Hospital Care Conference, College of Paramedics National Conference, Research Conference and Student Conference) were selected, and data from 43 individual conferences were collected, representing 70% of the potential conferences during this time frame. The data include 690 presentations given by 551 individual presenters. Paramedics were the most common professional group presenting. The London Ambulance Service, North East Ambulance Service and University of Sheffield were the most common institutions represented. The most common topics under discussion were policy and practice, research and trauma. The most common methodologies were qualitative. CONCLUSION: This study provides an overview of research presented at paramedic, ambulance service and pre-hospital conferences. A wide range of research was presented at the selected conferences by many individuals. A wide range of topics feature in the data, but high-impact, low-frequency clinical conditions, such as cardiac arrest and major trauma, feature highly. CI - (c) 2026 The Author(s). FAU - McClelland, Graham AU - McClelland G AD - Northumbria University ORCID iD: https://orcid.org/0000-0002-4502-5821. FAU - Haworth, Dan AU - Haworth D AD - North East Ambulance Service NHS Foundation Trust ORCID iD: https://orcid.org/0000-0003-0334-3300. FAU - Charlton, Karl AU - Charlton K AD - North East Ambulance Service NHS Foundation Trust ORCID iD: https://orcid.org/0000-0002-9601-1083. FAU - Thompson, Lee AU - Thompson L AD - North East Ambulance Service NHS Foundation Trust ORCID iD: https://orcid.org/0000-0002-0820-1662. FAU - Finch, Tracy AU - Finch T AD - Northumbria University ORCID id: https://orcid.org/0000-0001-8647-735X. FAU - Williams, Julia AU - Williams J AD - University of Hertfordshire ORCID iD: https://orcid.org/0000-0003-0796-5465. LA - eng PT - Journal Article PL - England TA - Br Paramed J JT - British paramedic journal JID - 101697267 PMC - PMC12969948 OTO - NOTNLM OT - conference OT - mapping OT - paramedic COIS- GM and JW are Associate Editors of the British Paramedic Journal. EDAT- 2026/03/11 06:56 MHDA- 2026/03/11 06:57 PMCR- 2026/03/01 CRDT- 2026/03/11 05:16 PHST- 2026/03/11 06:57 [medline] PHST- 2026/03/11 06:56 [pubmed] PHST- 2026/03/11 05:16 [entrez] PHST- 2026/03/01 00:00 [pmc-release] AID - 10.29045/14784726.2026.3.10.4.18 [doi] PST - ppublish SO - Br Paramed J. 2026 Mar 1;10(4):18-24. doi: 10.29045/14784726.2026.3.10.4.18. PMID- 41808594 OWN - NLM STAT- MEDLINE DCOM- 20260710 LR - 20260710 IS - 1421-9778 (Electronic) IS - 1015-8987 (Linking) VI - 59 IP - 6 DP - 2025 Dec 31 TI - The Impact of Aging on Organ Systems in Sickle Cell Disease: a Comparative Review of Physiological Adaptation and Dysfunction. PG - 930-939 LID - 10.33594/000000839 [doi] AB - Sickle cell anemia (SCA) is a progressive, systemic disorder that can lead to multi-organ dysfunction. While it has traditionally been most prevalent in regions where malaria is endemic, recent epidemiological studies have shown an increasing disease prevalence in non-endemic areas, primarily attributed to global human migration patterns. The severity of SCA typically worsens with age. In early childhood, affected individuals may present with renal hyperfiltration, neurocognitive delays, cardiac remodeling, and skeletal fragility. The presence of these early manifestations often predicts the development of chronic complications later in life, including splenic atrophy, neurodegeneration, and impaired cerebral perfusion. Adequate management of SCA begins with universal newborn screening programs, enabling early detection and the initiation of appropriate interventions. Therapeutic advancements, ranging from disease-modifying agents such as hydroxyurea to curative options including gene therapy and stem cell transplantation, have significantly improved clinical outcomes; however, long-term morbidity remains a significant challenge. This review aimed to explore the effect of aging on pathophysiological changes and the onset of organ-specific complications in SCA patients. It highlights the importance of age-tailored monitoring and a multidisciplinary approach to detect early signs of organ damage, prevent irreversible complications, and consequently improve overall quality of life. CI - (c) Copyright by the Author(s). Published by Cell Physiol Biochem Press. FAU - Alzahrani, Hind A AU - Alzahrani HA AD - Department of Basic Sciences, Faculty of Applied Medical Sciences, Al-Baha University, Al-Baha 65431, Saudi Arabia. LA - eng PT - Journal Article PT - Review PL - Germany TA - Cell Physiol Biochem JT - Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology JID - 9113221 SB - IM MH - Humans MH - *Anemia, Sickle Cell/pathology/complications/physiopathology MH - *Aging/pathology MH - *Adaptation, Physiological OTO - NOTNLM OT - Sickle cell anemia ; Organ dysfunction ; Age-related complications ; Multisystem involvement COIS- The author declares no competing financial interests. EDAT- 2026/03/11 06:57 MHDA- 2026/03/11 13:20 CRDT- 2026/03/11 04:43 PHST- 2025/11/24 00:00 [accepted] PHST- 2026/03/11 13:20 [medline] PHST- 2026/03/11 06:57 [pubmed] PHST- 2026/03/11 04:43 [entrez] AID - 10.33594/000000839 [doi] PST - ppublish SO - Cell Physiol Biochem. 2025 Dec 31;59(6):930-939. doi: 10.33594/000000839. PMID- 41806714 OWN - NLM STAT- MEDLINE DCOM- 20260710 LR - 20260710 IS - 1472-6491 (Electronic) IS - 1472-6483 (Linking) VI - 52 IP - 4 DP - 2026 Apr TI - Fertility preservation in patients with Turner syndrome: a SWOT analysis. PG - 105438 LID - S1472-6483(25)00645-5 [pii] LID - 10.1016/j.rbmo.2025.105438 [doi] AB - Turner syndrome, a chromosomal disorder characterized by premature ovarian insufficiency and infertility, presents significant reproductive challenges. Fertility preservation is critical for enabling individuals with Turner syndrome to pursue biological parenthood. However, implementation is hindered by limited provider awareness, ethical concerns, and restricted access to specialized care. This review underscores the importance of fertility preservation in Turner syndrome, evaluates current methods, and addresses barriers and ethical complexities. Methods such as ovarian tissue cryopreservation, in-vitro maturation, and vitrification offer promise, while novel strategies such as in-vitro activation and gene expression profiling may improve outcomes. Nevertheless, success rates remain variable, and accessibility is limited. Major barriers include delayed diagnosis of Turner syndrome, inadequate fertility counselling, and insufficient provider training. Ethical challenges involve assessing the autonomy and psychological readiness of paediatric patients. Socio-economic disparities and inconsistent insurance coverage further impede access. Effective fertility preservation in patients with Turner syndrome requires early diagnosis, timely counselling, and a coordinated multidisciplinary approach. While advancements in fertility preservation are promising, broader implementation demands improved provider education, ethical guidance, and public policy reform. Ensuring equitable access to fertility preservation can significantly enhance reproductive autonomy and quality of life for individuals with Turner syndrome. CI - Copyright (c) 2026 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Ferro, Rafael AU - Ferro R AD - Division for Gynaecology and Unit of Reproductive Medicine, Department of Gynaecology and Obstetrics, University Hospitals of Geneva, Faculty of Medicine of Geneva University, Geneva, Switzerland. Electronic address: rafael21ferro@gmail.com. FAU - Vento, Federico Del AU - Vento FD AD - Division for Gynaecology and Unit of Reproductive Medicine, Department of Gynaecology and Obstetrics, University Hospitals of Geneva, Faculty of Medicine of Geneva University, Geneva, Switzerland. FAU - Streuli, Isabelle AU - Streuli I AD - Division for Gynaecology and Unit of Reproductive Medicine, Department of Gynaecology and Obstetrics, University Hospitals of Geneva, Faculty of Medicine of Geneva University, Geneva, Switzerland. LA - eng PT - Journal Article PT - Review DEP - 20251222 PL - Netherlands TA - Reprod Biomed Online JT - Reproductive biomedicine online JID - 101122473 SB - IM MH - Humans MH - *Turner Syndrome/complications MH - *Fertility Preservation/methods/ethics MH - Female MH - Cryopreservation/methods MH - Ovary MH - Infertility, Female/etiology OTO - NOTNLM OT - Ethical considerations OT - Fertility preservation OT - Oocyte cryopreservation OT - Ovarian tissue cryopreservation OT - Turner syndrome EDAT- 2026/03/11 01:12 MHDA- 2026/04/21 17:42 CRDT- 2026/03/10 19:09 PHST- 2025/06/12 00:00 [received] PHST- 2025/11/25 00:00 [revised] PHST- 2025/12/17 00:00 [accepted] PHST- 2026/04/21 17:42 [medline] PHST- 2026/03/11 01:12 [pubmed] PHST- 2026/03/10 19:09 [entrez] AID - S1472-6483(25)00645-5 [pii] AID - 10.1016/j.rbmo.2025.105438 [doi] PST - ppublish SO - Reprod Biomed Online. 2026 Apr;52(4):105438. doi: 10.1016/j.rbmo.2025.105438. Epub 2025 Dec 22. PMID- 41802778 OWN - NLM STAT- MEDLINE DCOM- 20260710 LR - 20260813 IS - 2399-9772 (Electronic) IS - 2399-9772 (Linking) VI - 10 IP - 1 DP - 2026 Mar 9 TI - Paediatric inherited arrhythmia clinic: developing a new model of care. LID - 10.1136/bmjpo-2025-004403 [doi] LID - e004403 AB - OBJECTIVE: To describe the development and utilisation of a paediatric inherited arrhythmia clinic (IAC) from 2014 to 2024, including service developments following the introduction of cardiac genetic coordinators (CGC). DESIGN: Retrospective cohort study. SETTING: The IAC at Children's Hospital Westmead, New South Wales, Australia (approximately 8 million people). PATIENTS: Children (aged 0-18 years) referred to the IAC. INTERVENTIONS: Clinical and genetic data were extracted and analysed. MAIN OUTCOME MEASURES: Description of the development and cohort of the clinic. RESULTS: A monthly clinic preceded by a team meeting (multidisciplinary team) led by a paediatric cardiologist and clinical geneticist was established. Attendees included a genetic counsellor, senior arrhythmia nurse and clinical psychologist.A total of 301 individuals aged 0-18 years were seen over 11 years: 32 in 2014 and 128 in 2024. 85 probands presented with cardiac arrest (37; 44%), syncope (23; 27%) and others (25; 29%). The most common diagnoses were Long QT syndrome 33 (38%), catecholaminergic polymorphic ventricular tachycardia 24 (28%) and Brugada syndrome 6 (7%). 226/301 children had genetic testing; pathogenic/likely pathogenic variants were found in 173/226 (77%), including 121 family members. The most common genes implicated were KCNQ1 (67), KCNH2 (39), SCN5A (28) and RyR2 (15).Dedicated allied health/nursing CGCs appointed in 2023 improved the collation of clinical/family data (particularly new referrals), links to adult cardiology, forensic and regional genetic and paediatric services. CONCLUSIONS: The multidisciplinary IAC achieves the phenotyping, genotyping and holistic care of large numbers of children, mostly with cardiac ion channelopathies. Dedicated coordinators provided an incremental improvement to the service. CI - (c) Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. FAU - Robinson, Karen M AU - Robinson KM AUID- ORCID: 0009-0006-4860-0568 AD - The Heart Centre for Children Westmead, The Sydney Children's Hospitals Network, Sydney, New South Wales, Australia Karen.Robinson2@health.nsw.gov.au jonathan.skinner@health.nsw.gov.au. FAU - Asakai, Hiroko AU - Asakai H AD - The Heart Centre for Children Westmead, The Sydney Children's Hospitals Network, Sydney, New South Wales, Australia. AD - Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia. FAU - Turner, Christian AU - Turner C AD - The Heart Centre for Children Westmead, The Sydney Children's Hospitals Network, Sydney, New South Wales, Australia. FAU - Lawley, Claire AU - Lawley C AD - The Heart Centre for Children Westmead, The Sydney Children's Hospitals Network, Sydney, New South Wales, Australia. AD - Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia. FAU - Dengler, Lexi AU - Dengler L AD - The Heart Centre for Children Westmead, The Sydney Children's Hospitals Network, Sydney, New South Wales, Australia. FAU - Scarfe, Gabbie AU - Scarfe G AD - The Heart Centre for Children Westmead, The Sydney Children's Hospitals Network, Sydney, New South Wales, Australia. FAU - Morrish, Ansley AU - Morrish A AD - Department of Clinical Genetics, The Children's Hospital, Sydney, New South Wales, Australia. FAU - Hayward, Janette AU - Hayward J AD - Department of Clinical Genetics, The Children's Hospital, Sydney, New South Wales, Australia. FAU - Woo, Ngai Lam AU - Woo NL AD - The Heart Centre for Children Westmead, The Sydney Children's Hospitals Network, Sydney, New South Wales, Australia. AD - Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia. FAU - Smith, Janine AU - Smith J AD - Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia. AD - Department of Clinical Genetics, The Children's Hospital, Sydney, New South Wales, Australia. FAU - Skinner, Jonathan R AU - Skinner JR AD - The Heart Centre for Children Westmead, The Sydney Children's Hospitals Network, Sydney, New South Wales, Australia Karen.Robinson2@health.nsw.gov.au jonathan.skinner@health.nsw.gov.au. AD - Faculty of Child and Adolescent Health, The University of Sydney, Sydney, New South Wales, Australia, Sydney, New South Wales, Australia. LA - eng PT - Journal Article DEP - 20260309 PL - England TA - BMJ Paediatr Open JT - BMJ paediatrics open JID - 101715309 SB - IM MH - Humans MH - Child MH - Child, Preschool MH - Adolescent MH - Infant MH - Female MH - Retrospective Studies MH - *Arrhythmias, Cardiac/genetics/therapy/diagnosis MH - Male MH - Infant, Newborn MH - Genetic Testing MH - New South Wales MH - Polymorphic Catecholaminergic Ventricular Tachycardia MH - Patient Care Team PMC - PMC12983881 OTO - NOTNLM OT - Cardiology OT - Data Collection OT - Genetics COIS- Competing interests: No, there are no competing interests. EDAT- 2026/03/10 01:06 MHDA- 2026/03/10 01:07 PMCR- 2026/03/09 CRDT- 2026/03/09 20:54 PHST- 2025/12/16 00:00 [received] PHST- 2026/02/09 00:00 [accepted] PHST- 2026/03/10 01:07 [medline] PHST- 2026/03/10 01:06 [pubmed] PHST- 2026/03/09 20:54 [entrez] PHST- 2026/03/09 00:00 [pmc-release] AID - 10.1136/bmjpo-2025-004403 [pii] AID - bmjpo-2025-004403 [pii] AID - 10.1136/bmjpo-2025-004403 [doi] PST - epublish SO - BMJ Paediatr Open. 2026 Mar 9;10(1):e004403. doi: 10.1136/bmjpo-2025-004403. PMID- 41802098 OWN - NLM STAT- MEDLINE DCOM- 20261007 LR - 20261007 IS - 1664-5502 (Electronic) IS - 1664-3828 (Print) IS - 1664-5502 (Linking) VI - 16 IP - 1 DP - 2026 TI - A State-of-the-Art Review Exploring the Cardiovascular Outcomes of Renin-Angiotensin Inhibitors in Acute Kidney Injury. PG - 201-209 LID - 10.1159/000551326 [doi] AB - BACKGROUND: Renin-angiotensin system (RAS) inhibitors, including ACE inhibitors, ARBs, and angiotensin receptor-neprilysin inhibitors (ARNIs), are essential in managing cardiovascular and renal diseases. SUMMARY: The purpose of this narrative review was to comprehensively evaluate the cardiovascular outcomes associated with the use of RAS inhibitors in patients who have experienced acute kidney injury (AKI). The study highlighted cardiovascular complications of AKI, role of renin-angiotensin inhibitors for cardioprotection post-AKI, reviewed clinical considerations for RAS inhibitor use post-AKI to prevent cardiovascular complications, and discussed mechanistic basis of RAS inhibitors in post-AKI cardioprotection as well as cardiovascular safety concerns of RAS inhibitors post-AKI. KEY MESSAGES: By highlighting areas for future research, this review intended to stimulate further studies that will ultimately enhance patient care and outcomes. CI - (c) 2026 The Author(s). Published by S. Karger AG, Basel. FAU - Yasmin, Farah AU - Yasmin F AD - Dow University of Health Sciences, Karachi, Pakistan. FAU - Ahmad, Sharjeel AU - Ahmad S AD - Aga Khan University Hospital, Karachi, Pakistan. FAU - Jabeen, Adina AU - Jabeen A AD - Dow University of Health Sciences, Karachi, Pakistan. FAU - Moeed, Abdul AU - Moeed A AD - Dow University of Health Sciences, Karachi, Pakistan. FAU - Asghar, Muhammad Sohaib AU - Asghar MS AD - AdventHealth Sebring, Sebring, Florida, USA. FAU - Shaik, Afsana Ansari AU - Shaik AA AD - Mayo Clinic Rochester, Rochester, Minnesota, USA. FAU - Fadelallah Eljack, Mohammed Mahmmoud AU - Fadelallah Eljack MM AD - University of Khartoum, Faculty of Science.Ad-Dwayem, Khartoum, Sudan, m.mahmmoud96@gmail.com. FAU - Alraies, M Chadi AU - Alraies MC AD - Detroit Medical Centre, Detroit, Michigan, USA. LA - eng PT - Journal Article PT - Review DEP - 20260309 PL - Switzerland TA - Cardiorenal Med JT - Cardiorenal medicine JID - 101554863 RN - 0 (Angiotensin-Converting Enzyme Inhibitors) RN - 0 (Angiotensin Receptor Antagonists) SB - IM MH - *Renin-Angiotensin System/drug effects/physiology MH - *Acute Kidney Injury/complications/drug therapy/physiopathology MH - *Cardiovascular Diseases/epidemiology/etiology/prevention & control MH - Humans MH - *Angiotensin-Converting Enzyme Inhibitors/adverse effects/therapeutic use MH - *Angiotensin Receptor Antagonists/adverse effects/therapeutic use MH - Cardio-Renal Syndrome/drug therapy/physiopathology MH - Evidence-Based Medicine/standards MH - Practice Guidelines as Topic MH - Treatment Interruption MH - Patient Care Team/standards PMC - PMC13221169 OTO - NOTNLM OT - Aldosterone synthesis OT - Cardiorenal syndrome OT - Cardiovascular disease OT - Regulation of blood pressure OT - Renal metabolism COIS- The authors declare no conflicts of interest. EDAT- 2026/03/09 19:00 MHDA- 2026/05/29 18:33 PMCR- 2026/03/09 CRDT- 2026/03/09 15:15 PHST- 2025/03/23 00:00 [received] PHST- 2026/02/12 00:00 [accepted] PHST- 2026/05/29 18:33 [medline] PHST- 2026/03/09 19:00 [pubmed] PHST- 2026/03/09 15:15 [entrez] PHST- 2026/03/09 00:00 [pmc-release] AID - 000551326 [pii] AID - 551326 [pii] AID - 10.1159/000551326 [doi] PST - ppublish SO - Cardiorenal Med. 2026;16(1):201-209. doi: 10.1159/000551326. Epub 2026 Mar 9. PMID- 41794950 OWN - NLM STAT- MEDLINE DCOM- 20260710 LR - 20260920 IS - 1433-7339 (Electronic) IS - 0941-4355 (Print) IS - 0941-4355 (Linking) VI - 34 IP - 4 DP - 2026 Mar 8 TI - Fluoropyrimidine-induced cardiotoxicity: outcomes and safety of chemotherapy reintroduction in a retrospective cohort study. LID - 10.1007/s00520-026-10531-2 [doi] LID - 293 AB - AIMS: Fluoropyrimidines, including 5-fluorouracil (5-FU) and capecitabine, remain foundational in the treatment of various cancers, despite their well-documented risk of cardiotoxicity. This study aimed to characterize cardiovascular events associated with fluoropyrimidine use, evaluate their management, and assess the prognostic impact of fluoropyrimidine reintroduction. METHODS: We conducted a retrospective cohort study of patients admitted for cardiovascular events between January 2014 and October 2024 at Croix-Rousse and Lyon Sud University Hospitals (Hospices Civils de Lyon, France), who had received fluoropyrimidine-based chemotherapy within the preceding year. RESULTS: Among 141 patients, the most frequent cardiovascular events were coronary artery disease (30.5%), atrial fibrillation (28.4%), and heart failure (19.9%). Post-event, three primary therapeutic strategies were implemented in the follow-up cohort (n = 114): fluoropyrimidine reintroduction (n = 54, 38.3%), switch to alternative chemotherapy (n = 25, 17.7%), and transition to palliative care (n = 36, 25.5%). Recurrent cardiotoxicity after reintroduction occurred in eight patients (14.8%), with only one recurrent coronary event. At 2-year follow-up, overall survival tended to be higher in the reintroduction group compared to the group of patients switching to an alternative chemotherapy (HR = 1.77 [0.92-3.42]; p = 0.088) and to palliative care (HR = 8.31 [4.67-14.79]; p < 0.001). No significant increase in unplanned hospitalizations was observed in the reintroduction group compared to the alternative chemotherapy group (HR = 1.48 [0.83-2.66]; p = 0.185). CONCLUSION: Our findings suggest that fluoropyrimidine reintroduction-guided by multidisciplinary evaluation, cardiovascular management, and close monitoring-appears to have a favorable benefit/risk balance for selected patients. CI - (c) 2026. The Author(s). FAU - Rea, Oceane AU - Rea O AD - Institut de Cardiologie, Hospices Civils de Lyon, Lyon, France. FAU - Bouali, Anissa AU - Bouali A AD - Institut de Cardiologie, Hospices Civils de Lyon, Lyon, France. FAU - Serraille, Michael AU - Serraille M AD - Institut de Cardiologie, Hospices Civils de Lyon, Lyon, France. FAU - Peron, Julien AU - Peron J AD - Institut de Cancerologie, Hospices Civils de Lyon, Lyon, France. AD - Reshape Laboratory, U1290 INSERM, Lyon, France. FAU - Falandry, Claire AU - Falandry C AD - Institut de Cancerologie, Hospices Civils de Lyon, Lyon, France. AD - Institut du Vieillissement, Service de Geriatrie Croix-Rousse/Dugoujon, Hospices Civils de Lyon, Lyon, France. AD - Laboratoire CarMeN, INSERM U1060, Universite Lyon 1/INRAE U1397/Hospices Civils de Lyon, Pierre-Benite, France. FAU - Fort, Justine AU - Fort J AD - Institut de Cardiologie, Hospices Civils de Lyon, Lyon, France. FAU - Francois, Laurent AU - Francois L AD - Institut de Cardiologie, Hospices Civils de Lyon, Lyon, France. FAU - Harbaoui, Brahim AU - Harbaoui B AD - Institut de Cardiologie, Hospices Civils de Lyon, Lyon, France. AD - CREATIS, CNRS UMR5220, INSERM U1044, INSA-Lyon, Universite Claude Bernard Lyon 1, Universite de Lyon, Lyon, France. FAU - Lantelme, Pierre AU - Lantelme P AD - Institut de Cardiologie, Hospices Civils de Lyon, Lyon, France. AD - CREATIS, CNRS UMR5220, INSERM U1044, INSA-Lyon, Universite Claude Bernard Lyon 1, Universite de Lyon, Lyon, France. FAU - Courand, Pierre-Yves AU - Courand PY AD - Institut de Cardiologie, Hospices Civils de Lyon, Lyon, France. pierre-yves.courand@chu-lyon.fr. AD - CREATIS, CNRS UMR5220, INSERM U1044, INSA-Lyon, Universite Claude Bernard Lyon 1, Universite de Lyon, Lyon, France. pierre-yves.courand@chu-lyon.fr. AD - Federation de Cardiologie, Hopital de La Croix-Rousse Et Lyon Sud, 103 Grande Rue de La Croix-Rousse, Lyon, 69004, France. pierre-yves.courand@chu-lyon.fr. LA - eng PT - Journal Article DEP - 20260308 PL - Germany TA - Support Care Cancer JT - Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer JID - 9302957 RN - U3P01618RT (Fluorouracil) RN - 6804DJ8Z9U (Capecitabine) RN - 0 (Antimetabolites, Antineoplastic) SB - IM MH - Humans MH - Retrospective Studies MH - Female MH - Male MH - Fluorouracil/adverse effects/administration & dosage MH - Aged MH - *Cardiotoxicity/etiology/epidemiology MH - Middle Aged MH - Neoplasms/drug therapy MH - Capecitabine/adverse effects/administration & dosage MH - *Antimetabolites, Antineoplastic/adverse effects/administration & dosage MH - France MH - Cohort Studies MH - Prognosis MH - Aged, 80 and over MH - Follow-Up Studies PMC - PMC12967614 OTO - NOTNLM OT - 5-Fluorouracil OT - Atrial fibrillation OT - Cancer OT - Cardiac toxicity OT - Fluoropyrimidine OT - Myocardial infarction COIS- Declarations. Generative artificial intelligence: The central figure has been generated with Google Notebook LM then modified by the authors. Disclosure statement: All other authors have nothing to disclose in connection with the submitted article. Conflict of interest: Dr Courand has received consulting fees and honoraria outside the present work from Abbvie, Astra-Zeneca, Astellas, Boehringer Ingelheim/Lilly, Bristol Myers Squibb, Medtronic, Organon, Pfizer, Roche and Viatris. EDAT- 2026/03/08 01:38 MHDA- 2026/03/08 06:38 PMCR- 2026/03/08 CRDT- 2026/03/07 23:21 PHST- 2025/11/22 00:00 [received] PHST- 2026/03/02 00:00 [accepted] PHST- 2026/03/08 06:38 [medline] PHST- 2026/03/08 01:38 [pubmed] PHST- 2026/03/07 23:21 [entrez] PHST- 2026/03/08 00:00 [pmc-release] AID - 10.1007/s00520-026-10531-2 [pii] AID - 10531 [pii] AID - 10.1007/s00520-026-10531-2 [doi] PST - epublish SO - Support Care Cancer. 2026 Mar 8;34(4):293. doi: 10.1007/s00520-026-10531-2. PMID- 41792382 OWN - NLM STAT- MEDLINE DCOM- 20260827 LR - 20260827 IS - 1573-9686 (Electronic) IS - 0090-6964 (Linking) VI - 54 IP - 9 DP - 2026 Sep TI - Multidisciplinary Optimization Design of pVADs Using Analytical Target Cascading-Guided Genetic Algorithm. PG - 3026-3042 LID - 10.1007/s10439-026-03997-y [doi] AB - PURPOSE: The purpose of this article is to address the limitations of inconsistency between the impeller and motor when designing Percutaneous ventricular assist devices for different clinical scenarios, such as cardiogenic shock and high-risk percutaneous coronary intervention surgery. This inefficiency results in the waste of computational and experimental resources. This work presents a novel optimization method for systematically designing the pVAD. METHODS: The system-level optimization framework combines artificial neural networks (ANN), analytical target cascading (ATC), and NSGA-II. ATC ensures coordinated parameter matching between the motor and blade, NSGA-II refines specific design parameters, and ANN reduces computational overhead. The approach streamlines key design parameters. RESULTS: The integrated optimization method successfully achieves balanced performance between cardiac output and motor power demand. The prototype achieves a pressure head of > 80 mmHg at 5 L/min with a hemolysis index < 0.02. The total efficiency of the pVAD reaches 33.65%, compared to the baseline design's 7.59%; the algorithm significantly improves the design. CONCLUSION: The proposed framework resolves the trade-off between blade performance and motor power in pVAD design, enabling more efficient and feasible device optimization. The results also revealed that the proper design of blades is vital. Proper inlet and outlet angles will yield optimal hydraulic performance, while a shorter blade chord may reduce the risk of hemolysis. The two aspects are not independent, and design points should be chosen comprehensively. CI - (c) 2026. The Author(s) under exclusive licence to Biomedical Engineering Society. FAU - Chen, Chenghan AU - Chen C AD - Applied Mechanics Laboratory, Department of Engineering Mechanics, School of Aerospace Engineering, Tsinghua University, Beijing, PR China. FAU - Shi, Yuyang AU - Shi Y AD - Applied Mechanics Laboratory, Department of Engineering Mechanics, School of Aerospace Engineering, Tsinghua University, Beijing, PR China. FAU - Chaoran, E AU - Chaoran E AD - Applied Mechanics Laboratory, Department of Engineering Mechanics, School of Aerospace Engineering, Tsinghua University, Beijing, PR China. FAU - Qian, Hao AU - Qian H AD - Department of Cardiology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, PR China. FAU - Hao, Pengfei AU - Hao P AD - Applied Mechanics Laboratory, Department of Engineering Mechanics, School of Aerospace Engineering, Tsinghua University, Beijing, PR China. FAU - He, Feng AU - He F AD - Applied Mechanics Laboratory, Department of Engineering Mechanics, School of Aerospace Engineering, Tsinghua University, Beijing, PR China. FAU - Zhang, Mingkui AU - Zhang M AD - Department of Cardiovascular Surgery, First Hospital of Tsinghua University, Beijing, PR China. zhangmingkui@tsinghua.edu.cn. FAU - Zhang, Xiwen AU - Zhang X AUID- ORCID: 0000-0002-3706-4484 AD - Applied Mechanics Laboratory, Department of Engineering Mechanics, School of Aerospace Engineering, Tsinghua University, Beijing, PR China. zhangxiw@tsinghua.edu.cn. AD - Beijing Key Laboratory of Intelligent Organ Biofabrication and Regenerative Repair, Beijing, PR China. zhangxiw@tsinghua.edu.cn. LA - eng GR - HXY-Med-20240627-02/Cross-strait Tsinghua Research Institute (Xiamen)/ PT - Journal Article DEP - 20260306 PL - United States TA - Ann Biomed Eng JT - Annals of biomedical engineering JID - 0361512 SB - IM MH - Genetic Algorithms MH - *Heart-Assist Devices MH - Humans MH - *Neural Networks, Computer MH - Algorithms OTO - NOTNLM OT - Computational fluid dynamics OT - Genetic algorithm OT - Hemolysis OT - Microelectromechanical devices OT - Non-hierarchical systems OT - Ventricular assist devices COIS- Declarations. Competing interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Ethical Approval: The animal in-vivo tests discussed in the section of discussion are conducted following the Guide for the Registration and Review of Animal Testing and Research of Medical Devices ( https://www.nmpa.gov.cn/ylqx/ylqxggtg/20210927153130147.html ). The Medical Institutional Review Board of Tsinghua University approved all conditions for animal surgery and care. EDAT- 2026/03/07 01:38 MHDA- 2026/08/27 17:35 CRDT- 2026/03/06 23:26 PHST- 2025/07/22 00:00 [received] PHST- 2026/01/21 00:00 [accepted] PHST- 2026/08/27 17:35 [medline] PHST- 2026/03/07 01:38 [pubmed] PHST- 2026/03/06 23:26 [entrez] AID - 10.1007/s10439-026-03997-y [pii] AID - 10.1007/s10439-026-03997-y [doi] PST - ppublish SO - Ann Biomed Eng. 2026 Sep;54(9):3026-3042. doi: 10.1007/s10439-026-03997-y. Epub 2026 Mar 6. PMID- 41789741 OWN - NLM STAT- MEDLINE DCOM- 20260710 LR - 20260813 IS - 1307-7945 (Electronic) IS - 1306-696X (Print) IS - 1306-696X (Linking) VI - 32 IP - 2 DP - 2026 Feb TI - Emergency cesarean section in pregnant women with severe pulmonary hypertension: the potential role of extracorporeal life support. PG - 177-183 LID - 10.14744/tjtes.2025.33236 [doi] AB - BACKGROUND: The aim of this study was to present our institutional experience with periprocedural management of emergency cesarean section (CS) operations and maternal and fetal cardiac complications in pregnant women with pulmonary hypertension (PH). METHODS: Thirteen patients who were diagnosed with PH during pregnancy and/or prior to pregnancy according to European Society of Cardiology (ESC) criteria, and who were referred to our hospital with a decision for emergency CS from an external center, were included in the study. For patients who underwent urgent surgery, the following data were recorded: demographic characteristics, time of diagnosis, treatments for pulmonary hypertension used before pregnancy, during pregnancy, and/or after CS, arterial blood gas values, pulmonary and systemic pressure values after induction and at the 12th postoperative hour, extracorporeal membrane oxygenation (ECMO) requirements, time to extubation, length of intensive care stay, and mortality rates. RESULTS: Eight of the 13 patients were diagnosed with idiopathic pulmonary arterial hypertension (IPAH). The mean systolic systemic arterial pressure (BPs), systolic pulmonary arterial pressure (PAPs), and mean pulmonary arterial pressure were 130+-14.2 mmHg, 93+-28 mmHg, and 52+-17 mmHg, respectively. Six of the 13 patients required ECMO support. The one-month mortality rate was 46%. CONCLUSION: Pregnancy in women with PH is associated with significant maternal morbidity and mortality. If the underlying etiology is IPAH, the risk of mortality is higher than in other forms of PH. Mechanical circulatory support devices, including ECMO, may serve as a temporary bridge to lung transplantation in selected cases. Therefore, early diagnosis of IPAH, timely referral of patients to specialized centers, and planning of these operations by a multidisciplinary team consisting of cardiologists, gynecologists, and cardiac anesthesiologists are necessary. FAU - Karaca Baysal, Pinar AU - Karaca Baysal P AD - Department of Anesthesiology and Reanimation, SBU Kartal Kosuyolu Yuksek Ihtisas Training and Research Hospital, Istanbul-Turkiye. FAU - Urkut, Nur AU - Urkut N AD - Department of Anesthesiology and Reanimation, SBU Kartal Kosuyolu Yuksek Ihtisas Training and Research Hospital, Istanbul-Turkiye. FAU - Girgin Dinc, Ebru AU - Girgin Dinc E AD - Department of Anesthesiology and Reanimation, SBU Kartal Kosuyolu Yuksek Ihtisas Training and Research Hospital, Istanbul-Turkiye. FAU - Gurcu, Mustafa Emre AU - Gurcu ME AD - Department of Anesthesiology and Reanimation, SBU Kartal Kosuyolu Yuksek Ihtisas Training and Research Hospital, Istanbul-Turkiye. FAU - Erkilinc, Atakan AU - Erkilinc A AD - Department of Anesthesiology and Reanimation, SBU Kartal Kosuyolu Yuksek Ihtisas Training and Research Hospital, Istanbul-Turkiye. FAU - Kaymaz, Cihangir AU - Kaymaz C AD - Department of Cardiology SBU Kartal Kosuyolu Yuksek Ihtisas Training and Research Hospital, Istanbul-Turkiye. LA - eng PT - Journal Article TT - Ciddi pulmoner hipertansiyonlu gebelerde acil sezaryen seksiyo ameliyati - Olasi Extracorporeal yasam destegi. PL - Turkey TA - Ulus Travma Acil Cerrahi Derg JT - Ulusal travma ve acil cerrahi dergisi = Turkish journal of trauma & emergency surgery : TJTES JID - 101274231 SB - IM MH - Humans MH - Female MH - Pregnancy MH - *Cesarean Section MH - *Hypertension, Pulmonary/therapy/mortality/surgery MH - *Extracorporeal Membrane Oxygenation MH - Adult MH - *Pregnancy Complications, Cardiovascular/therapy/surgery/mortality PMC - PMC13063225 COIS- None declared. EDAT- 2026/03/06 13:44 MHDA- 2026/03/07 18:37 PMCR- 2026/02/09 CRDT- 2026/03/06 07:32 PHST- 2026/03/07 18:37 [medline] PHST- 2026/03/06 13:44 [pubmed] PHST- 2026/03/06 07:32 [entrez] PHST- 2026/02/09 00:00 [pmc-release] AID - TJTES-32-177 [pii] AID - 10.14744/tjtes.2025.33236 [doi] PST - ppublish SO - Ulus Travma Acil Cerrahi Derg. 2026 Feb;32(2):177-183. doi: 10.14744/tjtes.2025.33236. PMID- 41789303 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260306 LR - 20260813 IS - 2296-2360 (Print) IS - 2296-2360 (Electronic) IS - 2296-2360 (Linking) VI - 14 DP - 2026 TI - Bridging clinical care and lived experience: early implementation of longitudinal health-related quality of life monitoring in congenital heart disease. PG - 1701283 LID - 10.3389/fped.2026.1701283 [doi] LID - 1701283 AB - BACKGROUND: Congenital heart defects (CHD) are the most common congenital malformations, and, although survival rates now exceed 90%, children remain at risk for long-term psychomotor, cognitive, and psychosocial difficulties. Routine integration of patient-reported outcome measures (PROMs) into pediatric cardiology offers the potential to detect vulnerabilities early, guide preventive interventions, and facilitate patient- and family-centered care. However, practical implementation in routine settings remains challenging. OBJECTIVES: This pilot study describes the early feasibility and implementation experience, and process adaptations for embedding the Pediatric Quality of Life Inventory Cardiac Module (PedsQL CM) into routine pediatric cardiology care, with a focus on the development of a pragmatic implementation model, aiming to enable longitudinal health-related quality of life (HRQoL) monitoring in children with CHD following surgical or catheter-based interventions. METHODS: We are conducting a prospective, single-center, non-interventional study at the University Medical Center Freiburg, enrolling children aged 2-17 years undergoing cardiac surgery or catheterization. The PedsQL CM, available in eight languages in age-appropriate self- and parent-proxy versions, is administered at baseline (hospital admission) and at 3, 6, 9, and 12 months post-intervention. Surveys are implemented in REDCap and distributed via QR codes and automated invitations. Clinical data (diagnosis, intervention details, perioperative parameters) are extracted from the institutional research database for linkage with HRQoL trajectories. Implementation process data are collected systematically, capturing feasibility, acceptability, barriers, and facilitators. PRELIMINARY RESULTS: By mid-study, 77 families have been enrolled. Key facilitators include the visible study team presence, iterative adaptations (e.g., a user-friendly guidance document, filter questions), automation, and interdisciplinary psychosocial team involvement. Barriers comprise limited staff resources, partial IT integration, and variable clinician engagement. Early HRQoL data reflect evidence-based patterns, with generally high scores in younger children and a downward trend during adolescence. CONCLUSION: Embedding systematic, longitudinal HRQoL assessment in pediatric cardiology is feasible but requires sustained institutional commitment, robust workflows, and interdisciplinary collaboration. Disease-specific PROMs such as the PedsQL CM provide clinically meaningful insights that support proactive, individualized care. Multicenter collaboration and the extension of PROM pathways across pediatric subspecialties will be key to addressing coverage gaps, optimizing lifelong outcomes, and establishing best practice frameworks to integrate PROMs. CI - (c) 2026 Willems, Muller, Erbers, Renninger, Stricker, Konig, Kubicki, Kappler, Bobrowski, Stiller and Zurn. FAU - Willems, Jana AU - Willems J AD - Section of Health Care Research and Rehabilitation Research, Institute of Medical Biometry and Statistics, Medical Faculty and Medical Center - University of Freiburg, Freiburg, Germany. FAU - Muller, Philipp A AU - Muller PA AD - Department of Congenital Heart Defects and Pediatric Cardiology, University Heart Center Freiburg, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. FAU - Erbers, Anna AU - Erbers A AD - Department of Congenital Heart Defects and Pediatric Cardiology, University Heart Center Freiburg, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. FAU - Renninger, Franziska AU - Renninger F AD - Department of Congenital Heart Defects and Pediatric Cardiology, University Heart Center Freiburg, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. FAU - Stricker, Alina AU - Stricker A AD - Department of Congenital Heart Defects and Pediatric Cardiology, University Heart Center Freiburg, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. FAU - Konig, Vera AU - Konig V AD - Department of Congenital Heart Defects and Pediatric Cardiology, University Heart Center Freiburg, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. FAU - Kubicki, Rouven AU - Kubicki R AD - Department of Congenital Heart Defects and Pediatric Cardiology, University Heart Center Freiburg, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. FAU - Kappler, Hannah E AU - Kappler HE AD - Department of Congenital Heart Defects and Pediatric Cardiology, University Heart Center Freiburg, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. FAU - Bobrowski, Alexej AU - Bobrowski A AD - Department of Congenital Heart Defects and Pediatric Cardiology, University Heart Center Freiburg, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. FAU - Stiller, Brigitte AU - Stiller B AD - Department of Congenital Heart Defects and Pediatric Cardiology, University Heart Center Freiburg, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. FAU - Zurn, Christoph AU - Zurn C AD - Department of Congenital Heart Defects and Pediatric Cardiology, University Heart Center Freiburg, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. LA - eng PT - Journal Article DEP - 20260218 PL - Switzerland TA - Front Pediatr JT - Frontiers in pediatrics JID - 101615492 PMC - PMC12957085 OTO - NOTNLM OT - health reporting system OT - health-related quality of life OT - longitudinal quality of life data OT - patient centered care OT - patient reported outcome measure OT - targeted intervention COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/03/06 09:02 MHDA- 2026/03/06 09:03 PMCR- 2026/02/18 CRDT- 2026/03/06 04:54 PHST- 2025/09/08 00:00 [received] PHST- 2026/01/24 00:00 [revised] PHST- 2026/01/30 00:00 [accepted] PHST- 2026/03/06 09:03 [medline] PHST- 2026/03/06 09:02 [pubmed] PHST- 2026/03/06 04:54 [entrez] PHST- 2026/02/18 00:00 [pmc-release] AID - 10.3389/fped.2026.1701283 [doi] PST - epublish SO - Front Pediatr. 2026 Feb 18;14:1701283. doi: 10.3389/fped.2026.1701283. eCollection 2026. PMID- 41787485 OWN - NLM STAT- MEDLINE DCOM- 20260627 LR - 20260813 IS - 1472-6963 (Electronic) IS - 1472-6963 (Linking) VI - 26 IP - 1 DP - 2026 Mar 5 TI - Bridging communication gaps to improve adult congenital heart disease care: patient perspectives from a qualitative study. LID - 10.1186/s12913-026-14286-8 [doi] LID - 509 AB - BACKGROUND: Adults with Congenital Heart Disease (CHD) require lifelong specialist care, yet many report communication challenges that undermine health understanding, managing their condition and their overall wellbeing. Effective specialist-patient communication is associated with better outcomes, but little research has explored adult CHD (ACHD) patients' perspectives on these interactions. METHODS: This qualitative study was conducted as part of a larger investigation of ACHD care in Australia. Using purposive sampling, 43 adults aged 20-54 years with mild, moderate, or severe CHD were recruited from four hospitals. Semi-structured interviews were conducted via video conferencing, transcribed, and analysed using Framework Analysis. Rigour was maintained through double coding, iterative refinement of the thematic framework, and multidisciplinary team review. RESULTS: Four themes shaped patient experiences of communication: (1) fragmented communication between providers; (2) inadequate patient-facing communication; (3) gaps in understanding of condition; and (4) emotional impacts of suboptimal communication. Conversely, clear, respectful, and empathic communication fostered trust, confidence, and adherence. Participants recommended structured handovers, accessible records, plain-language explanations, visual and written aids, and routine psychosocial support. CONCLUSIONS: This study demonstrates that communication in ACHD care is not merely an aide to clinical management but a defining element of quality, continuity, and patient wellbeing. Participants' experiences revealed that fragmented inter-specialist communication and limited patient-facing explanations contribute to confusion, care discontinuity, and emotional distress. These findings highlight that improving communication practices is essential to strengthening patient autonomy, mitigating psychosocial burden, and sustaining engagement in lifelong specialist care. PRACTICE IMPLICATIONS: ACHD services should establish structured handover pathways, shared records, and designated care coordinators to minimise fragmentation. Specialists could engage patients more directly with age-appropriate, plain-language discussions, progressive transfer of responsibility during adolescence, and revisiting knowledge in adulthood. Incorporating visual aids, written summaries, and psychosocial screening into routine practice, alongside training specialists in empathic, patient-centred communication, could strengthen trust, improve adherence, and enhance long-term outcomes. FAU - Ruban, Sasha AU - Ruban S AD - Clinical Research Group, Heart Research Institute, Sydney, NSW, Australia. AD - Cardiology Department, Royal Prince Alfred Hospital, Sydney, NSW, 2050, Australia. AD - Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia. FAU - Lloyd, Larissa AU - Lloyd L AD - Clinical Research Group, Heart Research Institute, Sydney, NSW, Australia. AD - Cardiology Department, Royal Prince Alfred Hospital, Sydney, NSW, 2050, Australia. AD - Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia. FAU - Badal, Tanya AU - Badal T AD - Clinical Research Group, Heart Research Institute, Sydney, NSW, Australia. AD - Cardiology Department, Royal Prince Alfred Hospital, Sydney, NSW, 2050, Australia. AD - Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia. FAU - Strange, Geoff AU - Strange G AD - Clinical Research Group, Heart Research Institute, Sydney, NSW, Australia. AD - Cardiology Department, Royal Prince Alfred Hospital, Sydney, NSW, 2050, Australia. AD - Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia. FAU - Celermajer, David S AU - Celermajer DS AD - Clinical Research Group, Heart Research Institute, Sydney, NSW, Australia. AD - Cardiology Department, Royal Prince Alfred Hospital, Sydney, NSW, 2050, Australia. AD - Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia. FAU - Bonner, Carissa AU - Bonner C AD - Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia. carissa.bonner@sydney.edu.au. AD - Leeder Centre for Health Policy, Economics & Data, School of Public Health, The University of Sydney, Sydney, NSW, Australia. carissa.bonner@sydney.edu.au. AD - Sydney Health Literacy Lab, School of Public Health, The University of Sydney, Sydney, NSW, Australia. carissa.bonner@sydney.edu.au. AD - School of Public Health, The University of Sydney, Edward Ford Building (A27), Sydney, NSW, 2006, Australia. carissa.bonner@sydney.edu.au. LA - eng PT - Journal Article DEP - 20260305 PL - England TA - BMC Health Serv Res JT - BMC health services research JID - 101088677 SB - IM MH - Humans MH - Adult MH - Female MH - *Heart Defects, Congenital/therapy/psychology MH - Qualitative Research MH - Male MH - Middle Aged MH - *Communication MH - Australia MH - Young Adult MH - *Physician-Patient Relations MH - Interviews as Topic PMC - PMC13072496 OTO - NOTNLM OT - Adult Congenital Heart Disease (ACHD) OT - Continuity of care OT - Health communication OT - Patient education OT - Patient-centred care OT - Psychosocial wellbeing OT - Transition of care COIS- Declarations. Ethics approval and consent to participate: Ethical approval for this study was granted by the Human Research Ethics Committee of the Sydney Local Health District (X20-0483). Sydney Local Health District located at Royal Prince Alfred Hospital is accredited and certified by the NHMRC and the NSW Ministry of Health to approve studies under the mutual acceptance scheme and provide ethical clearance for multi-centre studies. All research conforms to the 2025 and the Australian Code for the Responsible Conduct of Research 2018. The study was conducted in accordance with the National Statement on Ethical Conduct in Human Research (2007), the CPMP/ICH Note for Guidance on Good Clinical Practice and consistent with the principles that have their origin in the Declaration of Helsinki. Compliance with these standards provides assurance that the rights, safety and well-being of trial participants are respected. Participants provided verbal and electronic written informed consent prior to their interviews. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2026/03/06 08:59 MHDA- 2026/06/27 12:36 PMCR- 2026/03/05 CRDT- 2026/03/05 23:41 PHST- 2025/12/01 00:00 [received] PHST- 2026/02/26 00:00 [accepted] PHST- 2026/06/27 12:36 [medline] PHST- 2026/03/06 08:59 [pubmed] PHST- 2026/03/05 23:41 [entrez] PHST- 2026/03/05 00:00 [pmc-release] AID - 10.1186/s12913-026-14286-8 [pii] AID - 14286 [pii] AID - 10.1186/s12913-026-14286-8 [doi] PST - epublish SO - BMC Health Serv Res. 2026 Mar 5;26(1):509. doi: 10.1186/s12913-026-14286-8. PMID- 41781336 OWN - NLM STAT- MEDLINE DCOM- 20260724 LR - 20260724 IS - 1557-8674 (Electronic) IS - 1096-2964 (Linking) VI - 27 IP - 7 DP - 2026 Sep TI - Multi-Disciplinary and Protocol-Driven Post-Operative Care Reduces Incidence of Post-Sternotomy Mediastinitis. PG - 510-516 LID - 10.1177/10962964261428654 [doi] AB - BACKGROUND: Post-sternotomy mediastinitis (PSM) is a rare but life-threatening complication of cardiac surgical procedures. This study evaluated the impact of a structured multi-disciplinary post-discharge care bundle on PSM incidence. METHODS: A single-center, retrospective cohort study compared the incidence of PSM two years before and after implementation of a care bundle led by a multi-disciplinary team. The intervention included telephonic monitoring, a specialized wound-care clinic, and a standardized two-phase wound management protocol incorporating single-use negative pressure wound therapy. Outcomes were assessed using chi-square tests and logistic regression adjusted with propensity scores and inverse probability weighting. To rule out a temporal trend in newly identified wound infections, we performed a linear regression using bimonthly incident counts as the outcome. RESULTS: A total of 1,197 patients underwent median sternotomy between May 1, 2018, and April 30, 2022. The crude incidence of PSM was 3.32% in the pre-implementation group and 1.56% in the post-implementation group (p = 0.058). After adjustment with inverse probability of treatment weighting, the care bundle was associated with a significant reduction in PSM rate (absolute risk difference 1.96%, 95% confidence interval [CI]: 0.54-3.87; p = 0.044; relative reduction 59%, 95% CI: 16.3%-116%), despite a higher baseline surgical risk in the post-implementation cohort (higher EuroSCORE II, more urgent procedures, greater need for vasoactive support). The rate of newly identified wound infections did not exhibit a significant time trend (beta = -0.43; p = 0.299). CONCLUSION: Implementation of a multi-disciplinary care bundle is significantly associated with a reduction in PSM incidence in cardiac sternotomy patients, underscoring the importance of structured outpatient wound surveillance. FAU - Fernandez-de-Velasco, David AU - Fernandez-de-Velasco D AD - Department of Internal Medicine, Hospital Universitario Alcorcon, Madrid, Spain. FAU - Carnero-Alcazar, Manuel AU - Carnero-Alcazar M AD - Department of Cardiac Surgery, Hospital Clinico Universitario San Carlos, Madrid, Spain. FAU - Reguillo-Lacruz, Fernando-Jose AU - Reguillo-Lacruz FJ AD - Department of Cardiac Surgery, Hospital Clinico Universitario San Carlos, Madrid, Spain. FAU - Torron, Juan-Miguel Miranda AU - Torron JM AD - Department of Cardiac Surgery, Hospital Clinico Universitario San Carlos, Madrid, Spain. FAU - Villamor-Jimenez, Cristina AU - Villamor-Jimenez C AD - Department of Internal Medicine, Hospital Universitario Alcorcon, Madrid, Spain. FAU - Calleja-Sanz, Jorge AU - Calleja-Sanz J AD - Department of Medicine, Division of Hospital Medicine, Hospital Universitario Clinico San Carlos, Universidad Complutense deMadrid, Madrid, Spain. FAU - Ruiz-Alvarez, Pilar AU - Ruiz-Alvarez P AD - Department of Cardiac Surgery, Hospital Clinico Universitario San Carlos, Madrid, Spain. FAU - Maroto-Castellanos, Luis AU - Maroto-Castellanos L AD - Department of Cardiac Surgery, Hospital Clinico Universitario San Carlos, Madrid, Spain. FAU - Moores, Sally AU - Moores S AUID- ORCID: 0009-0006-2469-4619 AD - Global Clinical Strategy, Smith and Nephew, Hull, UK. FAU - Alvarez-de-Arcaya, Maria Arantzazu AU - Alvarez-de-Arcaya MA AD - Department of Medicine, Division of Hospital Medicine, Hospital Universitario Clinico San Carlos, Universidad Complutense deMadrid, Madrid, Spain. LA - eng PT - Journal Article PT - Review DEP - 20260304 PL - United States TA - Surg Infect (Larchmt) JT - Surgical infections JID - 9815642 SB - IM MH - Humans MH - *Mediastinitis/epidemiology/prevention & control MH - *Sternotomy/adverse effects MH - Retrospective Studies MH - Female MH - Incidence MH - Aged MH - Male MH - *Surgical Wound Infection/prevention & control/epidemiology MH - *Postoperative Care/methods MH - Middle Aged MH - Aged, 80 and over OTO - NOTNLM OT - cardiac procedure OT - multidisciplinary care OT - negative pressure wound therapy OT - outpatient follow-up OT - post-sternotomy mediastinitis OT - sternotomy COIS- Author Disclosure StatementS.M. is an employee of Smith + Nephew, Inc, and may own shares of Smith + Nephew. The other authors have declared that no competing interests exist. EDAT- 2026/03/05 00:39 MHDA- 2026/07/24 12:37 CRDT- 2026/03/04 22:13 PHST- 2026/07/24 12:37 [medline] PHST- 2026/03/05 00:39 [pubmed] PHST- 2026/03/04 22:13 [entrez] AID - 10.1177/10962964261428654 [doi] PST - ppublish SO - Surg Infect (Larchmt). 2026 Sep;27(7):510-516. doi: 10.1177/10962964261428654. Epub 2026 Mar 4. PMID- 41780663 OWN - NLM STAT- MEDLINE DCOM- 20260710 LR - 20260710 IS - 1879-1913 (Electronic) IS - 0002-9149 (Linking) VI - 267 DP - 2026 May 15 TI - Management of Post-Myocardial Infarction Ventricular Septal Defects. PG - 145-153 LID - S0002-9149(26)00096-2 [pii] LID - 10.1016/j.amjcard.2026.02.049 [doi] AB - Post-myocardial infarction ventricular septal defect (post-MI VSD) is a rare but life-threatening complication, with an incidence of approximately 0.3% and high early mortality despite advances in reperfusion therapy. Management remains challenging and requires multidisciplinary decision-making. We conducted a narrative review of the literature through May 2024 using PubMed, Scopus, and Google Scholar, focusing on surgical, percutaneous, and mechanical circulatory support (MCS) strategies for post-MI VSD. A narrative approach was adopted due to the rarity of the condition, the heterogeneity of available evidence, and the predominance of registries and case series. Surgical repair remains the gold standard, employing approaches such as the Daggett, David, and double-patch infarct exclusion techniques. Delayed surgery (>7 days) in hemodynamically stable patients is associated with improved outcomes, whereas urgent intervention is warranted in refractory shock. Percutaneous closure, using dedicated or adapted occluder devices, offers an option for high-risk or unstable patients, either as definitive therapy or as a bridge to surgery, though residual shunts are more common. Hybrid procedures and novel beating-heart techniques have shown promise in selected cases. MCS, including intra-aortic balloon pump, veno-arterial extracorporeal membrane oxygenation, and Impella, facilitates hemodynamic stabilization, allowing myocardial recovery before repair. Overall, in-hospital mortality remains high, particularly in acute-phase interventions. In conclusion, management of post-MI VSD demands individualized strategies integrating patient stability, defect anatomy, and institutional expertise. While surgical closure offers superior long-term outcomes, percutaneous and hybrid approaches expand therapeutic options. Future studies should clarify optimal timing, refine patient selection, and evaluate the impact of advanced MCS strategies on survival and recovery. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Castiglione, Vincenzo AU - Castiglione V AD - Fondazione Toscana Gabriele Monasterio, Pisa and Massa, Italy; Interdisciplinary Center for Health Sciences, Scuola Superiore Sant'Anna, Pisa, Italy. Electronic address: vcastiglione@ftgm.it. FAU - Casula, Marta AU - Casula M AD - Clinical Experimental Cardiology, Clinical and Interventional Cardiology, University of Sassari, Sassari, Italy. FAU - Palmieri, Cataldo AU - Palmieri C AD - Fondazione Toscana Gabriele Monasterio, Pisa and Massa, Italy. FAU - Gasbarri, Tommaso AU - Gasbarri T AD - Fondazione Toscana Gabriele Monasterio, Pisa and Massa, Italy. FAU - Gimelli, Alessia AU - Gimelli A AD - Fondazione Toscana Gabriele Monasterio, Pisa and Massa, Italy. FAU - Monteleone, Angelo AU - Monteleone A AD - Fondazione Toscana Gabriele Monasterio, Pisa and Massa, Italy. FAU - Santoro, Giuseppe AU - Santoro G AD - Fondazione Toscana Gabriele Monasterio, Pisa and Massa, Italy. FAU - Solinas, Marco AU - Solinas M AD - Fondazione Toscana Gabriele Monasterio, Pisa and Massa, Italy. FAU - Berti, Sergio AU - Berti S AD - Fondazione Toscana Gabriele Monasterio, Pisa and Massa, Italy. FAU - Rizza, Antonio AU - Rizza A AD - Fondazione Toscana Gabriele Monasterio, Pisa and Massa, Italy. LA - eng PT - Journal Article PT - Review DEP - 20260302 PL - United States TA - Am J Cardiol JT - The American journal of cardiology JID - 0207277 SB - IM MH - Humans MH - *Myocardial Infarction/complications MH - *Heart Septal Defects, Ventricular/etiology/surgery/therapy MH - *Cardiac Surgical Procedures/methods MH - Extracorporeal Membrane Oxygenation MH - Heart-Assist Devices OTO - NOTNLM OT - mechanical circulatory support OT - myocardial infarction OT - ventricular septal defect COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/03/05 00:39 MHDA- 2026/04/28 00:33 CRDT- 2026/03/04 19:12 PHST- 2026/01/10 00:00 [received] PHST- 2026/02/10 00:00 [revised] PHST- 2026/02/15 00:00 [accepted] PHST- 2026/04/28 00:33 [medline] PHST- 2026/03/05 00:39 [pubmed] PHST- 2026/03/04 19:12 [entrez] AID - S0002-9149(26)00096-2 [pii] AID - 10.1016/j.amjcard.2026.02.049 [doi] PST - ppublish SO - Am J Cardiol. 2026 May 15;267:145-153. doi: 10.1016/j.amjcard.2026.02.049. Epub 2026 Mar 2. PMID- 41779486 OWN - NLM STAT- MEDLINE DCOM- 20260710 LR - 20260710 IS - 1678-4170 (Electronic) IS - 0066-782X (Linking) VI - 123 IP - 1 DP - 2026 Jan TI - Development of 3D-Printed Congenital Heart Disease Models Using Feasible Low-Cost Workflow - A Potential Tool to Improve Pediatric Cardiology Education. PG - e20250419 LID - S0066-782X2026000100603 [pii] LID - 10.36660/abc.20250419 [doi] AB - BACKGROUND: Congenital heart diseases (CHD) require an in-depth anatomopathological understanding. 3D printing is a promising educational tool for creating physical prototypes from imaging data, but costs are a major issue. OBJECTIVE: This study aimed to describe a feasible low-cost workflow for the development of 3D-printed (3DP) CHD models and create a shareable educational set. METHODS: Data from cardiac tomography images were used, following the steps of image acquisition, segmentation, digital design, slicing, 3D printing, and post-printing. Valvar structures were created from echocardiographic data using the cartographic heightmap technique and inserted into prototypes. 3DP models were evaluated by an expert team, enhanced, and applied to medical residents during an educational session. Free software, a desktop 3D printer, and low-cost materials were used. RESULTS: Twelve 3DP models were developed, including ventricular septal defect with patent ductus arteriosus, atrial septal defect, Tetralogy of Fallot, transposition of the great arteries, atrioventricular septal defect, coarctation of the Aorta, hypoplastic left heart syndrome, tricuspid atresia, pulmonary atresia, total anomalous pulmonary venous connection, Truncus arteriosus, and interrupted aortic arch. All residents (100%) agreed that prototypes were "faithful to the anatomy", "visually appealing", "motivated the study", and "allowed better spatial conceptualization". They related 3DP CHD models "are an important pedagogical resource" and can potentially benefit the education of "undergraduate students" (100%), "interdisciplinary team" (100%), "cardiologists, surgeons and residents" (100%), and "families" (93%). CONCLUSION: Development of 3DP CHD models using a low-cost workflow is feasible. Models developed are freely available for download and printing, intending to promote education to all interested in CHD. FAU - Cajueiro, Francisco Candido Monteiro AU - Cajueiro FCM AUID- ORCID: 0000-0002-6465-8798 AD - CardioPedBrasil(R) - Centro do Coracao da Crianca, Hospital da Crianca e Maternidade de Sao Jose do Rio Preto (FUNFARME/FAMERP), Sao Jose do Rio Preto, SP - Brasil. FAU - Croti, Ulisses Alexandre AU - Croti UA AUID- ORCID: 0000-0002-1127-4782 AD - CardioPedBrasil(R) - Centro do Coracao da Crianca, Hospital da Crianca e Maternidade de Sao Jose do Rio Preto (FUNFARME/FAMERP), Sao Jose do Rio Preto, SP - Brasil. FAU - Amorim Junior, Raimundo Francisco de AU - Amorim Junior RF AUID- ORCID: 0000-0003-1067-8918 AD - Instituto do Coracao de Natal (INCOR Natal), Natal, RN - Brasil. FAU - Cardoso, Mariana Ribeiro Rodero AU - Cardoso MRR AUID- ORCID: 0009-0006-8558-6953 AD - CardioPedBrasil(R) - Centro do Coracao da Crianca, Hospital da Crianca e Maternidade de Sao Jose do Rio Preto (FUNFARME/FAMERP), Sao Jose do Rio Preto, SP - Brasil. FAU - Costa, Carlos Henrique AU - Costa CH AUID- ORCID: 0000-0001-8784-4369 AD - CardioPedBrasil(R) - Centro do Coracao da Crianca, Hospital da Crianca e Maternidade de Sao Jose do Rio Preto (FUNFARME/FAMERP), Sao Jose do Rio Preto, SP - Brasil. FAU - Marchi, Carlos Henrique De AU - Marchi CH AUID- ORCID: 0000-0003-2916-7579 AD - CardioPedBrasil(R) - Centro do Coracao da Crianca, Hospital da Crianca e Maternidade de Sao Jose do Rio Preto (FUNFARME/FAMERP), Sao Jose do Rio Preto, SP - Brasil. FAU - Borim, Bruna Cury AU - Borim BC AUID- ORCID: 0000-0003-4341-0037 AD - CardioPedBrasil(R) - Centro do Coracao da Crianca, Hospital da Crianca e Maternidade de Sao Jose do Rio Preto (FUNFARME/FAMERP), Sao Jose do Rio Preto, SP - Brasil. FAU - Godoy, Moacir Fernandes de AU - Godoy MF AUID- ORCID: 0000-0001-8390-0933 AD - CardioPedBrasil(R) - Centro do Coracao da Crianca, Hospital da Crianca e Maternidade de Sao Jose do Rio Preto (FUNFARME/FAMERP), Sao Jose do Rio Preto, SP - Brasil. FAU - Freitas, Milton Benevides de AU - Freitas MB AUID- ORCID: 0000-0002-4740-5932 AD - Universidade de Pernambuco, Recife, PE - Brasil. FAU - Moscardini, Airton Camacho AU - Moscardini AC AUID- ORCID: 0009-0003-0846-9081 AD - CardioPedBrasil(R) - Centro do Coracao da Crianca, Hospital da Crianca e Maternidade de Sao Jose do Rio Preto (FUNFARME/FAMERP), Sao Jose do Rio Preto, SP - Brasil. LA - eng LA - por PT - Journal Article TT - Desenvolvimento de Modelos de Cardiopatias Congenitas em Impressao 3D utilizando Metodologia de Baixo Custo - Uma Potencial Ferramenta para Aprimorar o Ensino da Cardiologia Pediatrica. PL - Brazil TA - Arq Bras Cardiol JT - Arquivos brasileiros de cardiologia JID - 0421031 SB - IM MH - *Heart Defects, Congenital/diagnostic imaging MH - *Printing, Three-Dimensional/economics MH - Humans MH - Workflow MH - Feasibility Studies MH - *Cardiology/education MH - *Pediatrics/education MH - *Models, Anatomic EDAT- 2026/03/04 18:43 MHDA- 2026/03/07 01:38 CRDT- 2026/03/04 12:14 PHST- 2025/06/14 00:00 [received] PHST- 2025/10/01 00:00 [accepted] PHST- 2026/03/07 01:38 [medline] PHST- 2026/03/04 18:43 [pubmed] PHST- 2026/03/04 12:14 [entrez] AID - S0066-782X2026000100603 [pii] AID - 10.36660/abc.20250419 [doi] PST - ppublish SO - Arq Bras Cardiol. 2026 Jan;123(1):e20250419. doi: 10.36660/abc.20250419. PMID- 41778947 OWN - NLM STAT- MEDLINE DCOM- 20260624 LR - 20260625 IS - 1558-3597 (Electronic) IS - 0735-1097 (Linking) VI - 87 IP - 24 DP - 2026 Jun 23 TI - Real-Time Heart Team for Revascularization in Complex Coronary Artery Disease: The EHEART Randomized Trial. PG - 3467-3479 LID - S0735-1097(26)00070-7 [pii] LID - 10.1016/j.jacc.2026.01.010 [doi] AB - BACKGROUND: The routine implementation of heart teams for patients with complex coronary artery disease (CAD) is challenging due to the insufficient multidisciplinary specialist resources for face-to-face discussion. A real-time heart team during the angiography, based on an online meeting, offers the potential to efficiently integrate resources. OBJECTIVES: In this study, we sought to evaluate the implementation value and safety of a "real-time heart team" decision making approach. METHODS: This noninferiority randomized controlled trial enrolled patients with de novo left main or 3-vessel CAD at 3 cardiac centers. Patients were randomly assigned to the conventional heart team group (discussed by a face-to-face meeting after the angiography) or the real-time heart team group (discussed by an online meeting during the angiography). Implementation value outcomes included care efficiency (waiting time for treatment, recatheterization, specialist workload, and economic outcomes) and process evaluation metrics (discussion adequacy, surgeon participation, and shared decision making). The safety outcomes were a composite of 1-year major adverse cardiovascular and cerebrovascular events (MACCE) (including all-cause mortality, myocardial infarction, stroke, unplanned revascularization, and readmission due to reangina) and revascularization decision making. RESULTS: Overall, 490 complex CAD patients were included, with 245 patients in each group. Waiting time for final therapy (median: 2 days [Q1-Q3: 0-7 days] vs 5 days [Q1-Q3: 2-10 days]; P < 0.001), recatheterization rate (12.5% vs 98.9%; P < 0.001), specialist high workload rate (5.3% vs 29.0%; P < 0.001), and percutaneous coronary intervention (PCI) hospitalization cost (percentage of decrease: 18.0%; P < 0.001) were significantly reduced in the real-time group. More discussion time spent (4.0 +/- 1.8 min vs 3.4 +/- 1.6 min), better specialist satisfaction (based on NASA Task Load Index scale), more chief surgeon participation (26.5% vs 18.8%), but less multidisciplinary synchronous shared decision making (2.0% vs 11.5%) were found in the real-time group. The real-time heart team group was noninferior to the conventional group in 1-year MACCE (8.2% vs 10.6%; risk difference: -2.45%; 95% CI: -7.61%-2.71%; P for noninferiority < 0.001). The proportions of PCI, coronary artery bypass grafting, and medical therapy were similar between the 2 groups (P = 0.892). CONCLUSIONS: Compared with the conventional heart team, the real-time heart team significantly improved care efficiency and process evaluation metrics, with similar clinical outcomes and decision making. However, insufficient shared decision making and intercenter generalizability should be optimized before widespread implementation of this approach. (Feasibility and Effectiveness of a Real-Time Heart Team Approach in Complex CAD [EHEART; NCT05514210]). CI - Copyright (c) 2026 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. FAU - Lin, Shen AU - Lin S AD - National Clinical Research Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Department of Cardiovascular Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Su, Xiaoting AU - Su X AD - National Clinical Research Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Ma, Hanping AU - Ma H AD - Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Dou, Kefei AU - Dou K AD - Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Song, Lei AU - Song L AD - Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Zhao, Hanjun AU - Zhao H AD - Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Qian, Jie AU - Qian J AD - Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Liu, Sheng AU - Liu S AD - Department of Cardiovascular Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Xu, Fei AU - Xu F AD - Department of Cardiovascular Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Wang, Xianqiang AU - Wang X AD - Department of Cardiovascular Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Yang, Yan AU - Yang Y AD - Department of Cardiovascular Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Su, Pixiong AU - Su P AD - Department of Cardiac Surgery, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China. FAU - Jin, Zening AU - Jin Z AD - Department of Cardiology and Macrovascular Disease, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. FAU - Wang, Yang AU - Wang Y AD - Medical Research and Biometrics Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Zheng, Zhe AU - Zheng Z AD - National Clinical Research Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Department of Cardiovascular Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Electronic address: zhengzhe@fuwai.com. LA - eng SI - ClinicalTrials.gov/NCT05514210 PT - Equivalence Trial PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial DEP - 20260304 PL - United States TA - J Am Coll Cardiol JT - Journal of the American College of Cardiology JID - 8301365 SB - IM MH - Humans MH - *Coronary Artery Disease/surgery/diagnostic imaging MH - *Patient Care Team/organization & administration MH - Female MH - Male MH - Aged MH - Coronary Angiography/methods MH - Middle Aged MH - *Myocardial Revascularization/methods OTO - NOTNLM OT - complex coronary artery disease OT - heart team process optimization OT - revascularization decision making COIS- Funding Support and Author Disclosures The work was supported by grants from the Noncommunicable Chronic Diseases-National Science and Technology Major Project (2025ZD0546700, 2025ZD0546703, 2025ZD0546704), Capital and Funds for Health Improvement and Research (CFH; no. 2022-1-4031), Beijing High-Level Innovation and Entrepreneurship Talent Support Program Young Backbone Talent Projects (No. G202532191), and the National Natural Science Foundation of China (No. 82400409). The content is solely the responsibility of the authors and does not necessarily represent the official views of the CFH. Funding sources had no role in study design, execution, analyses, interpretation, or presentation of results. The authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2026/03/04 15:49 MHDA- 2026/06/24 18:35 CRDT- 2026/03/04 10:28 PHST- 2025/07/26 00:00 [received] PHST- 2026/01/02 00:00 [revised] PHST- 2026/01/05 00:00 [accepted] PHST- 2026/06/24 18:35 [medline] PHST- 2026/03/04 15:49 [pubmed] PHST- 2026/03/04 10:28 [entrez] AID - S0735-1097(26)00070-7 [pii] AID - 10.1016/j.jacc.2026.01.010 [doi] PST - ppublish SO - J Am Coll Cardiol. 2026 Jun 23;87(24):3467-3479. doi: 10.1016/j.jacc.2026.01.010. Epub 2026 Mar 4. PMID- 41778654 OWN - NLM STAT- In-Process LR - 20260304 IS - 1528-3976 (Electronic) IS - 1071-5754 (Linking) VI - 53 IP - 2 DP - 2026 Mar-Apr 01 TI - A Skin Team Approach to Decrease Pressure Injuries in a Cardiothoracic Intensive Care Unit: A Quality Improvement Initiative. PG - E2 LID - 10.1097/WON.0000000000001271 [doi] LA - eng PT - Journal Article DEP - 20260227 PL - United States TA - J Wound Ostomy Continence Nurs JT - Journal of wound, ostomy, and continence nursing : official publication of The Wound, Ostomy and Continence Nurses Society JID - 9435679 SB - IM EDAT- 2026/03/04 14:26 MHDA- 2026/03/04 14:26 CRDT- 2026/03/04 08:12 PHST- 2026/03/04 14:26 [medline] PHST- 2026/03/04 14:26 [pubmed] PHST- 2026/03/04 08:12 [entrez] AID - 00152192-202603000-00005 [pii] AID - 10.1097/WON.0000000000001271 [doi] PST - ppublish SO - J Wound Ostomy Continence Nurs. 2026 Mar-Apr 01;53(2):E2. doi: 10.1097/WON.0000000000001271. Epub 2026 Feb 27. PMID- 41778653 OWN - NLM STAT- MEDLINE DCOM- 20260710 LR - 20260710 IS - 1528-3976 (Electronic) IS - 1071-5754 (Linking) VI - 53 IP - 2 DP - 2026 Mar-Apr 01 TI - A Skin Team Approach to Decrease Pressure Injuries in a Cardiothoracic Intensive Care Unit: A Quality Improvement Initiative. PG - 102-107 LID - 10.1097/WON.0000000000001269 [doi] AB - PURPOSE: The primary purpose of this quality improvement initiative was to evaluate the effect of a nurse-led skin team (ST) interventions on prevalence of hospital-acquired pressure injuries (HAPIs) of stage 2 and above in our cardiothoracic intensive care unit (CTICU). PARTICIPANTS AND SETTING: Data analysis is based on patients receiving care in our CTICU from 2011 to 2024. The unit is located in the Western US (Los Angeles, CA). APPROACH: A nurse-led ST was established in 2011 to empower and engage clinical nurses in addressing the rising incidence of HAPIs in the CTICU. The team employed the Plan-Do-Study-Act framework to implement both evidence-based and innovative interventions. Project strategies included rounding, monitoring, and educating staff on best practices for pressure injury prevention. OUTCOMES: More than a decade after the team's formation, trend analysis did not demonstrate a significant downward trend in stage 2 and higher HAP prevalence. Nevertheless, our HPAI rates have consistently been below national benchmarks. IMPLICATIONS FOR PRACTICE: The ST approach has proved effective in sustaining a reduction of HAPIs within our facility. The team's interventions remain ongoing, supported by facility leadership and continued commitment to quality care. CI - Copyright (c) 2026 by the Wound, Ostomy, and Continence Nurses Society. FAU - Arenas, Aysa AU - Arenas A AD - Aysa Arenas, MSN, RN, Cardiothoracic Intensive Care Unit, Ronald Reagan UCLA Medical Center, Los Angeles, California. AD - Stephanie Sheldrick, BSN, RN, Cardiothoracic Intensive Care Unit, Ronald Reagan UCLA Medical Center, Los Angeles, California. AD - Sarah Sutton, BSN, RN, Cardiothoracic Intensive Care Unit, Ronald Reagan UCLA Medical Center, Los Angeles, California. AD - Jacqueline Gonzales, BSN, RN, CCRN, Cardiothoracic Intensive Care Unit, Ronald Reagan UCLA Medical Center, Los Angeles, California. AD - Valentina Obreja, DNP, RN, AG/AC, NP-BC, CCRN, CSC, CMC, PHN, EBP-C, ECMO-MC, Cardiothoracic Intensive Care Unit, Ronald Reagan UCLA Medical Center, Los Angeles, California. AD - Katrine Murray, MSN, RN, CCRN, NE-BC, Cardiothoracic Intensive Care Unit, Ronald Reagan UCLA Medical Center, Los Angeles, California. AD - Taline Marcarian, PhD, RN, CCRN, CSC, Cardiothoracic Intensive Care Unit, Ronald Reagan UCLA Medical Center, Los Angeles, California. FAU - Sheldrick, Stephanie AU - Sheldrick S AD - Aysa Arenas, MSN, RN, Cardiothoracic Intensive Care Unit, Ronald Reagan UCLA Medical Center, Los Angeles, California. AD - Stephanie Sheldrick, BSN, RN, Cardiothoracic Intensive Care Unit, Ronald Reagan UCLA Medical Center, Los Angeles, California. AD - Sarah Sutton, BSN, RN, Cardiothoracic Intensive Care Unit, Ronald Reagan UCLA Medical Center, Los Angeles, California. AD - Jacqueline Gonzales, BSN, RN, CCRN, Cardiothoracic Intensive Care Unit, Ronald Reagan UCLA Medical Center, Los Angeles, California. AD - Valentina Obreja, DNP, RN, AG/AC, NP-BC, CCRN, CSC, CMC, PHN, EBP-C, ECMO-MC, Cardiothoracic Intensive Care Unit, Ronald Reagan UCLA Medical Center, Los Angeles, California. AD - Katrine Murray, MSN, RN, CCRN, NE-BC, Cardiothoracic Intensive Care Unit, Ronald Reagan UCLA Medical Center, Los Angeles, California. AD - Taline Marcarian, PhD, RN, CCRN, CSC, Cardiothoracic Intensive Care Unit, Ronald Reagan UCLA Medical Center, Los Angeles, California. FAU - Sutton, Sarah AU - Sutton S AD - Aysa Arenas, MSN, RN, Cardiothoracic Intensive Care Unit, Ronald Reagan UCLA Medical Center, Los Angeles, California. AD - Stephanie Sheldrick, BSN, RN, Cardiothoracic Intensive Care Unit, Ronald Reagan UCLA Medical Center, Los Angeles, California. AD - Sarah Sutton, BSN, RN, Cardiothoracic Intensive Care Unit, Ronald Reagan UCLA Medical Center, Los Angeles, California. AD - Jacqueline Gonzales, BSN, RN, CCRN, Cardiothoracic Intensive Care Unit, Ronald Reagan UCLA Medical Center, Los Angeles, California. AD - Valentina Obreja, DNP, RN, AG/AC, NP-BC, CCRN, CSC, CMC, PHN, EBP-C, ECMO-MC, Cardiothoracic Intensive Care Unit, Ronald Reagan UCLA Medical Center, Los Angeles, California. AD - Katrine Murray, MSN, RN, CCRN, NE-BC, Cardiothoracic Intensive Care Unit, Ronald Reagan UCLA Medical Center, Los Angeles, California. AD - Taline Marcarian, PhD, RN, CCRN, CSC, Cardiothoracic Intensive Care Unit, Ronald Reagan UCLA Medical Center, Los Angeles, California. FAU - Gonzales, Jacqueline AU - Gonzales J AD - Aysa Arenas, MSN, RN, Cardiothoracic Intensive Care Unit, Ronald Reagan UCLA Medical Center, Los Angeles, California. AD - Stephanie Sheldrick, BSN, RN, Cardiothoracic Intensive Care Unit, Ronald Reagan UCLA Medical Center, Los Angeles, California. AD - Sarah Sutton, BSN, RN, Cardiothoracic Intensive Care Unit, Ronald Reagan UCLA Medical Center, Los Angeles, California. AD - Jacqueline Gonzales, BSN, RN, CCRN, Cardiothoracic Intensive Care Unit, Ronald Reagan UCLA Medical Center, Los Angeles, California. AD - Valentina Obreja, DNP, RN, AG/AC, NP-BC, CCRN, CSC, CMC, PHN, EBP-C, ECMO-MC, Cardiothoracic Intensive Care Unit, Ronald Reagan UCLA Medical Center, Los Angeles, California. AD - Katrine Murray, MSN, RN, CCRN, NE-BC, Cardiothoracic Intensive Care Unit, Ronald Reagan UCLA Medical Center, Los Angeles, California. AD - Taline Marcarian, PhD, RN, CCRN, CSC, Cardiothoracic Intensive Care Unit, Ronald Reagan UCLA Medical Center, Los Angeles, California. FAU - Obreja, Valentina AU - Obreja V AD - Aysa Arenas, MSN, RN, Cardiothoracic Intensive Care Unit, Ronald Reagan UCLA Medical Center, Los Angeles, California. AD - Stephanie Sheldrick, BSN, RN, Cardiothoracic Intensive Care Unit, Ronald Reagan UCLA Medical Center, Los Angeles, California. AD - Sarah Sutton, BSN, RN, Cardiothoracic Intensive Care Unit, Ronald Reagan UCLA Medical Center, Los Angeles, California. AD - Jacqueline Gonzales, BSN, RN, CCRN, Cardiothoracic Intensive Care Unit, Ronald Reagan UCLA Medical Center, Los Angeles, California. AD - Valentina Obreja, DNP, RN, AG/AC, NP-BC, CCRN, CSC, CMC, PHN, EBP-C, ECMO-MC, Cardiothoracic Intensive Care Unit, Ronald Reagan UCLA Medical Center, Los Angeles, California. AD - Katrine Murray, MSN, RN, CCRN, NE-BC, Cardiothoracic Intensive Care Unit, Ronald Reagan UCLA Medical Center, Los Angeles, California. AD - Taline Marcarian, PhD, RN, CCRN, CSC, Cardiothoracic Intensive Care Unit, Ronald Reagan UCLA Medical Center, Los Angeles, California. FAU - Murray, Katrine AU - Murray K AD - Aysa Arenas, MSN, RN, Cardiothoracic Intensive Care Unit, Ronald Reagan UCLA Medical Center, Los Angeles, California. AD - Stephanie Sheldrick, BSN, RN, Cardiothoracic Intensive Care Unit, Ronald Reagan UCLA Medical Center, Los Angeles, California. AD - Sarah Sutton, BSN, RN, Cardiothoracic Intensive Care Unit, Ronald Reagan UCLA Medical Center, Los Angeles, California. AD - Jacqueline Gonzales, BSN, RN, CCRN, Cardiothoracic Intensive Care Unit, Ronald Reagan UCLA Medical Center, Los Angeles, California. AD - Valentina Obreja, DNP, RN, AG/AC, NP-BC, CCRN, CSC, CMC, PHN, EBP-C, ECMO-MC, Cardiothoracic Intensive Care Unit, Ronald Reagan UCLA Medical Center, Los Angeles, California. AD - Katrine Murray, MSN, RN, CCRN, NE-BC, Cardiothoracic Intensive Care Unit, Ronald Reagan UCLA Medical Center, Los Angeles, California. AD - Taline Marcarian, PhD, RN, CCRN, CSC, Cardiothoracic Intensive Care Unit, Ronald Reagan UCLA Medical Center, Los Angeles, California. FAU - Marcarian, Taline AU - Marcarian T AD - Aysa Arenas, MSN, RN, Cardiothoracic Intensive Care Unit, Ronald Reagan UCLA Medical Center, Los Angeles, California. AD - Stephanie Sheldrick, BSN, RN, Cardiothoracic Intensive Care Unit, Ronald Reagan UCLA Medical Center, Los Angeles, California. AD - Sarah Sutton, BSN, RN, Cardiothoracic Intensive Care Unit, Ronald Reagan UCLA Medical Center, Los Angeles, California. AD - Jacqueline Gonzales, BSN, RN, CCRN, Cardiothoracic Intensive Care Unit, Ronald Reagan UCLA Medical Center, Los Angeles, California. AD - Valentina Obreja, DNP, RN, AG/AC, NP-BC, CCRN, CSC, CMC, PHN, EBP-C, ECMO-MC, Cardiothoracic Intensive Care Unit, Ronald Reagan UCLA Medical Center, Los Angeles, California. AD - Katrine Murray, MSN, RN, CCRN, NE-BC, Cardiothoracic Intensive Care Unit, Ronald Reagan UCLA Medical Center, Los Angeles, California. AD - Taline Marcarian, PhD, RN, CCRN, CSC, Cardiothoracic Intensive Care Unit, Ronald Reagan UCLA Medical Center, Los Angeles, California. LA - eng PT - Journal Article DEP - 20260227 PL - United States TA - J Wound Ostomy Continence Nurs JT - Journal of wound, ostomy, and continence nursing : official publication of The Wound, Ostomy and Continence Nurses Society JID - 9435679 SB - IM MH - Humans MH - *Pressure Ulcer/prevention & control/epidemiology/nursing MH - Quality Improvement MH - Intensive Care Units/organization & administration/statistics & numerical data MH - Patient Care Team/standards MH - Prevalence OTO - NOTNLM OT - COIS- The authors declare no conflicts of interest. EDAT- 2026/03/04 14:26 MHDA- 2026/03/07 16:11 CRDT- 2026/03/04 08:12 PHST- 2026/03/07 16:11 [medline] PHST- 2026/03/04 14:26 [pubmed] PHST- 2026/03/04 08:12 [entrez] AID - 00152192-202603000-00004 [pii] AID - 10.1097/WON.0000000000001269 [doi] PST - ppublish SO - J Wound Ostomy Continence Nurs. 2026 Mar-Apr 01;53(2):102-107. doi: 10.1097/WON.0000000000001269. Epub 2026 Feb 27. PMID- 41775291 OWN - NLM STAT- MEDLINE DCOM- 20260710 LR - 20260710 IS - 1879-1913 (Electronic) IS - 0002-9149 (Linking) VI - 266 DP - 2026 May 1 TI - Native Coronary Artery Versus Saphenous Vein Graft Percutaneous Coronary Intervention After Coronary Artery Bypass Grafting: A Contemporary Synthesis. PG - 117-123 LID - S0002-9149(26)00090-1 [pii] LID - 10.1016/j.amjcard.2026.02.048 [doi] AB - Patients with prior coronary artery bypass grafting frequently require repeat revascularization because of progressive native coronary artery disease and saphenous vein graft degeneration. Observational studies have consistently reported worse procedural and long-term outcomes with saphenous vein graft percutaneous coronary intervention (PCI) compared with native-vessel PCI. This has shaped guideline recommendations that favor native-vessel revascularization when feasible. However, these comparisons are inherently confounded, as vein graft intervention is often selected when the native vessel is not technically amenable to PCI. PROCTOR is the first randomized trial to compare native vessel versus saphenous vein graft PCI after bypass surgery, enrolling patients only after heart-team confirmation that both targets were clinically appropriate and technically feasible. The trial was terminated early after enrollment of 220 of 584 planned patients and reported only 1-year outcomes. Consequently, PROCTOR provides randomized evidence in a highly selected population characterized by favorable graft anatomy and complex native coronary disease, including a high prevalence of chronic total occlusions. In this review, we integrate the PROCTOR findings with contemporary registry data and mechanistic studies, highlighting how graft morphology and native lesion complexity modulate early procedural risk and long-term durability. We further propose an anatomy-driven framework for target-vessel selection following bypass surgery. In conclusion, PROCTOR should be interpreted as hypothesis-generating randomized evidence that refines-rather than supplants-the native-first paradigm by identifying clinical and anatomic scenarios in which carefully selected saphenous vein graft intervention may confer lower early hazard, while longer-term durability remains uncertain. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Sayaideh, Mohammad As AU - Sayaideh MA AD - Division of Cardiology, Department of Medicine, University of South Alabama, Mobile, Alabama. Electronic address: massayaideh@health.southalabama.edu. FAU - Honganur, Nagaraj Sanchitha AU - Honganur NS AD - Division of Cardiology, Department of Medicine, University of South Alabama, Mobile, Alabama. FAU - Odigwe, Celestine AU - Odigwe C AD - Division of Cardiology, Department of Medicine, University of South Alabama, Mobile, Alabama. FAU - Ruiz, Brent AU - Ruiz B AD - Division of Cardiology, Department of Medicine, University of South Alabama, Mobile, Alabama. FAU - Parks, Alexis AU - Parks A AD - Division of Cardiology, Department of Medicine, University of South Alabama, Mobile, Alabama. FAU - Elzeneini, Mohammed AU - Elzeneini M AD - Division of Cardiology, Department of Medicine, University of South Alabama, Mobile, Alabama. FAU - Omar, Bassam AU - Omar B AD - Division of Cardiology, Department of Medicine, University of South Alabama, Mobile, Alabama. FAU - DeAndrade, Kevin AU - DeAndrade K AD - Division of Cardiology, Department of Medicine, University of South Alabama, Mobile, Alabama. FAU - Lakkis, Nasser AU - Lakkis N AD - Division of Cardiology, Department of Medicine, University of South Alabama, Mobile, Alabama. LA - eng PT - Journal Article PT - Review DEP - 20260301 PL - United States TA - Am J Cardiol JT - The American journal of cardiology JID - 0207277 SB - IM MH - Humans MH - *Saphenous Vein/transplantation MH - *Percutaneous Coronary Intervention/methods MH - *Coronary Artery Bypass/methods MH - *Coronary Artery Disease/surgery MH - *Coronary Vessels/surgery MH - *Graft Occlusion, Vascular/surgery OTO - NOTNLM OT - PROCTOR trial OT - SVG degeneration OT - anatomy-driven PCI strategy OT - native coronary PCI OT - post-CABG revascularization OT - saphenous vein graft PIC COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/03/04 01:17 MHDA- 2026/04/11 00:32 CRDT- 2026/03/03 19:10 PHST- 2026/01/02 00:00 [received] PHST- 2026/02/14 00:00 [revised] PHST- 2026/02/22 00:00 [accepted] PHST- 2026/04/11 00:32 [medline] PHST- 2026/03/04 01:17 [pubmed] PHST- 2026/03/03 19:10 [entrez] AID - S0002-9149(26)00090-1 [pii] AID - 10.1016/j.amjcard.2026.02.048 [doi] PST - ppublish SO - Am J Cardiol. 2026 May 1;266:117-123. doi: 10.1016/j.amjcard.2026.02.048. Epub 2026 Mar 1. PMID- 41775220 OWN - NLM STAT- MEDLINE DCOM- 20260710 LR - 20260813 IS - 2213-2317 (Electronic) IS - 2213-2317 (Linking) VI - 92 DP - 2026 May TI - Mitochondrial permeability transition pore desensitization by a novel dispiranic derivative prevents cardiac reperfusion injury. PG - 104097 LID - S2213-2317(26)00095-9 [pii] LID - 10.1016/j.redox.2026.104097 [doi] LID - 104097 AB - Mitochondrial permeability transition pore (PTP) opening is a major determinant of cardiac ischemia/reperfusion (I/R) injury, contributing to cardiomyocyte death and impaired cardiac function following revascularization. Despite extensive research, effective pharmacological strategies targeting PTP remain limited. Here, we report the identification and characterization of a novel class of dispiranic small molecules designed to inhibit PTP opening by targeting the c subunit of F(O)-ATP synthase. Using a multidisciplinary approach combining chemical synthesis, cellular and mitochondrial assays, ex vivo cardiac models and in silico analyses, we identified compound 11d as a potent and selective PTP desensitizer. In living human cardiomyocytes, 11d inhibited PTP opening by approximately 70% at low micromolar concentrations without impairing mitochondrial bioenergetics under basal conditions. Mechanistically, 11d selectively inhibited Ca(2+)-activated F(1)F(O)-ATP synthase activity, consistent with PTP modulation, while sparing Mg(2+)-dependent ATP synthesis and succinate oxidase activity. Molecular docking and molecular dynamics simulations revealed stable binding of 11d within the canonical oligomycin-binding pocket of the ATP synthase c-ring, a finding corroborated by cellular thermal shift assays and subcellular fractionation showing preferential mitochondrial accumulation. Functionally, 11d significantly reduced cell death, mitochondrial reactive oxygen species (ROS) production and PTP opening in cardiomyocytes and endothelial cells subjected to hypoxia/reoxygenation (H/R). Importantly, in an ex vivo Langendorff rat heart model, 11d administration at reperfusion markedly improved cardiac functional recovery, reduced infarct-associated cell death and preserved myocardial architecture. Collectively, these results identify 11d as a promising lead compound for cardioprotection and support targeting the ATP synthase c subunit as a viable therapeutic strategy against reperfusion injury. CI - Copyright (c) 2026 The Authors. Published by Elsevier B.V. All rights reserved. FAU - Morciano, Giampaolo AU - Morciano G AD - Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy; Department of Medical Sciences, Laboratory for Technologies of Advanced Therapies (LTTA), University of Ferrara, Ferrara, Italy; Department of Biosciences, Biotechnology and Environment, University of Bari "Aldo Moro", Italy. Electronic address: giampaolo.morciano@uniba.it. FAU - Pedriali, Gaia AU - Pedriali G AD - Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy. FAU - Turrin, Giulia AU - Turrin G AD - Department of Environmental and Prevention Sciences, University of Ferrara, Italy. FAU - Algieri, Cristina AU - Algieri C AD - Department of Medical Veterinary Sciences, University of Bologna, Ozzano dell'Emilia, Italy. FAU - Agyapong, Esther Densu AU - Agyapong ED AD - Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy; Department of Medical Sciences, Laboratory for Technologies of Advanced Therapies (LTTA), University of Ferrara, Ferrara, Italy. FAU - Mantia, Debora La AU - Mantia D AD - Department of Medical Veterinary Sciences, University of Bologna, Ozzano dell'Emilia, Italy. FAU - Bernardini, Chiara AU - Bernardini C AD - Department of Medical Veterinary Sciences, University of Bologna, Ozzano dell'Emilia, Italy. FAU - Canini, Giorgia AU - Canini G AD - Department of Basic Biotechnological Sciences, Intensive Care and Perioperative Clinics, Universita Cattolica del Sacro Cuore, Roma, Italy. FAU - Fantinati, Anna AU - Fantinati A AD - Department of Environmental and Prevention Sciences, University of Ferrara, Italy. FAU - Colarusso, Elena Nicoletta AU - Colarusso EN AD - Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy; Department of Medical Sciences, Laboratory for Technologies of Advanced Therapies (LTTA), University of Ferrara, Ferrara, Italy. FAU - Mollica, Fabio AU - Mollica F AD - Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy. FAU - Ramaccini, Daniela AU - Ramaccini D AD - Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy. FAU - Pagliarani, Alessandra AU - Pagliarani A AD - Department of Medical Veterinary Sciences, University of Bologna, Ozzano dell'Emilia, Italy. FAU - Giorgi, Carlotta AU - Giorgi C AD - Department of Medical Sciences, Laboratory for Technologies of Advanced Therapies (LTTA), University of Ferrara, Ferrara, Italy. FAU - Tremoli, Elena AU - Tremoli E AD - Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy. FAU - Arcovito, Alessandro AU - Arcovito A AD - Department of Basic Biotechnological Sciences, Intensive Care and Perioperative Clinics, Universita Cattolica del Sacro Cuore, Roma, Italy. FAU - Nesci, Salvatore AU - Nesci S AD - Department of Medical Veterinary Sciences, University of Bologna, Ozzano dell'Emilia, Italy. FAU - Trapella, Claudio AU - Trapella C AD - Department of Chemical, Pharmaceutical and Agricultural Sciences, Laboratory for Technologies of Advanced Therapies (LTTA), University of Ferrara, Ferrara, Italy. Electronic address: claudio.trapella@unife.it. FAU - Pinton, Paolo AU - Pinton P AD - Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy; Department of Medical Sciences, Laboratory for Technologies of Advanced Therapies (LTTA), University of Ferrara, Ferrara, Italy. Electronic address: paolo.pinton@unife.it. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20260219 PL - Netherlands TA - Redox Biol JT - Redox biology JID - 101605639 RN - 0 (Mitochondrial Permeability Transition Pore) RN - 0 (Mitochondrial Membrane Transport Proteins) RN - 0 (Reactive Oxygen Species) RN - EC 3.6.3.- (Mitochondrial Proton-Translocating ATPases) SB - IM MH - *Myocardial Reperfusion Injury/metabolism/prevention & control/drug therapy/pathology MH - *Mitochondrial Permeability Transition Pore/metabolism/antagonists & inhibitors MH - Humans MH - Myocytes, Cardiac/metabolism/drug effects MH - Animals MH - Molecular Docking Simulation MH - *Mitochondrial Membrane Transport Proteins/metabolism MH - Rats MH - Reactive Oxygen Species/metabolism MH - Mitochondria, Heart/metabolism/drug effects MH - Mitochondrial Proton-Translocating ATPases/metabolism/antagonists & inhibitors/chemistry MH - Molecular Dynamics Simulation MH - Mitochondria/metabolism/drug effects PMC - PMC12968426 COIS- Declaration of competing interest All authors have nothing to disclose. EDAT- 2026/03/04 01:17 MHDA- 2026/04/21 18:34 PMCR- 2026/02/19 CRDT- 2026/03/03 18:08 PHST- 2026/02/05 00:00 [received] PHST- 2026/02/16 00:00 [revised] PHST- 2026/02/19 00:00 [accepted] PHST- 2026/04/21 18:34 [medline] PHST- 2026/03/04 01:17 [pubmed] PHST- 2026/03/03 18:08 [entrez] PHST- 2026/02/19 00:00 [pmc-release] AID - S2213-2317(26)00095-9 [pii] AID - 104097 [pii] AID - 10.1016/j.redox.2026.104097 [doi] PST - ppublish SO - Redox Biol. 2026 May;92:104097. doi: 10.1016/j.redox.2026.104097. Epub 2026 Feb 19. PMID- 41774157 OWN - NLM STAT- MEDLINE DCOM- 20260604 LR - 20261010 IS - 1615-6692 (Electronic) IS - 0340-9937 (Linking) VI - 51 IP - 3 DP - 2026 Jun TI - Contemporary insights and evolving clinical pathways in transcatheter tricuspid valve replacement. PG - 192-201 LID - 10.1007/s00059-026-05371-z [doi] AB - Transcatheter tricuspid valve replacement (TTVR) has emerged as an important therapeutic option for patients with severe tricuspid regurgitation (TR), particularly those with high surgical risk and complex anatomy. This review summarizes the current state of orthotopic TTVR, including patient selection, procedural considerations, and post-procedural care. Recent data demonstrate that TTVR provides consistent results and effective TR elimination, promotes reverse right ventricular (RV) remodeling, and improves symptoms and quality of life. In patients with massive or torrential baseline TR, TTVR has also been associated with reduced heart failure hospitalizations. Key challenges include conduction disturbances, bleeding complications, risk of afterload mismatch, and the need for long-term anticoagulation. As multiple devices become available, careful multidisciplinary evaluation, incorporating valve anatomy, RV function, pulmonary pressures, imaging quality, and comorbid conditions, remains essential for optimal therapy selection. CI - (c) 2026. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature. FAU - da Rocha E Silva, J G AU - da Rocha E Silva JG AD - Medizinische Klinik und Poliklinik I, Klinikum der Universitat Munchen, Ludwig-Maximilians-Universitat Munchen, Marchioninistr. 15, 81377, Munich, Germany. AD - Partner Site Munich Heart Alliance, German Center for Cardiovascular Research (DZHK), Munich, Germany. FAU - Stolz, L AU - Stolz L AD - Medizinische Klinik und Poliklinik I, Klinikum der Universitat Munchen, Ludwig-Maximilians-Universitat Munchen, Marchioninistr. 15, 81377, Munich, Germany. AD - Partner Site Munich Heart Alliance, German Center for Cardiovascular Research (DZHK), Munich, Germany. FAU - Kempton, H AU - Kempton H AD - Medizinische Klinik und Poliklinik I, Klinikum der Universitat Munchen, Ludwig-Maximilians-Universitat Munchen, Marchioninistr. 15, 81377, Munich, Germany. FAU - Weckbach, L T AU - Weckbach LT AD - Medizinische Klinik und Poliklinik I, Klinikum der Universitat Munchen, Ludwig-Maximilians-Universitat Munchen, Marchioninistr. 15, 81377, Munich, Germany. AD - Partner Site Munich Heart Alliance, German Center for Cardiovascular Research (DZHK), Munich, Germany. FAU - Stocker, T J AU - Stocker TJ AD - Medizinische Klinik und Poliklinik I, Klinikum der Universitat Munchen, Ludwig-Maximilians-Universitat Munchen, Marchioninistr. 15, 81377, Munich, Germany. AD - Partner Site Munich Heart Alliance, German Center for Cardiovascular Research (DZHK), Munich, Germany. FAU - Doldi, P AU - Doldi P AD - Medizinische Klinik und Poliklinik I, Klinikum der Universitat Munchen, Ludwig-Maximilians-Universitat Munchen, Marchioninistr. 15, 81377, Munich, Germany. AD - Partner Site Munich Heart Alliance, German Center for Cardiovascular Research (DZHK), Munich, Germany. FAU - Novotny, J AU - Novotny J AD - Medizinische Klinik und Poliklinik I, Klinikum der Universitat Munchen, Ludwig-Maximilians-Universitat Munchen, Marchioninistr. 15, 81377, Munich, Germany. AD - Partner Site Munich Heart Alliance, German Center for Cardiovascular Research (DZHK), Munich, Germany. FAU - Nabauer, M AU - Nabauer M AD - Medizinische Klinik und Poliklinik I, Klinikum der Universitat Munchen, Ludwig-Maximilians-Universitat Munchen, Marchioninistr. 15, 81377, Munich, Germany. AD - Partner Site Munich Heart Alliance, German Center for Cardiovascular Research (DZHK), Munich, Germany. FAU - Hausleiter, Jorg AU - Hausleiter J AD - Medizinische Klinik und Poliklinik I, Klinikum der Universitat Munchen, Ludwig-Maximilians-Universitat Munchen, Marchioninistr. 15, 81377, Munich, Germany. Joerg.Hausleiter@med.uni-muenchen.de. AD - Partner Site Munich Heart Alliance, German Center for Cardiovascular Research (DZHK), Munich, Germany. Joerg.Hausleiter@med.uni-muenchen.de. LA - eng PT - Journal Article PT - Review TT - Neue Perspektiven und klinische Ansatze mit dem Transkatheter-Trikuspidalklappenersatz. DEP - 20260303 PL - Germany TA - Herz JT - Herz JID - 7801231 SB - IM MH - Humans MH - *Tricuspid Valve Insufficiency/surgery/diagnosis MH - *Heart Valve Prosthesis Implantation/methods MH - *Cardiac Catheterization/methods MH - *Critical Pathways/trends MH - *Tricuspid Valve/surgery MH - Treatment Outcome MH - *Heart Valve Prosthesis OTO - NOTNLM OT - Multimodal imaging OT - Patient outcomes OT - Pulmonary hypertension OT - Right heart catheterization OT - Tricuspid regurgitation COIS- Declarations. Conflict of interest: J. G. da Rocha e Silva has received speaker honoraria from Edwards Lifesciences. L. Stolz has received speaker honoraria from Edwards Lifesciences. J. Hausleiter has received research support and speaker honoraria from Edwards Lifesciences. H. Kempton, L. T. Weckbach, T. J. Stocker, P. Doldi, J. Novotny and M. Nabauer declare that they have no competing interests. For this article no studies with human participants or animals were performed by any of the authors. All studies mentioned were in accordance with the ethical standards indicated in each case. EDAT- 2026/03/03 12:32 MHDA- 2026/06/04 12:42 CRDT- 2026/03/03 11:14 PHST- 2025/12/29 00:00 [received] PHST- 2026/01/27 00:00 [accepted] PHST- 2026/06/04 12:42 [medline] PHST- 2026/03/03 12:32 [pubmed] PHST- 2026/03/03 11:14 [entrez] AID - 10.1007/s00059-026-05371-z [pii] AID - 10.1007/s00059-026-05371-z [doi] PST - ppublish SO - Herz. 2026 Jun;51(3):192-201. doi: 10.1007/s00059-026-05371-z. Epub 2026 Mar 3. PMID- 41773439 OWN - NLM STAT- MEDLINE DCOM- 20260710 LR - 20260813 IS - 2532-1900 (Electronic) IS - 1128-2460 (Print) IS - 1128-2460 (Linking) VI - 44 IP - 4 DP - 2025 Dec TI - Combining traditional context and sailing in the psychological approach to patients with muscular dystrophies. A pilot study. PG - 130-134 LID - 10.36185/2532-1900-1750 [doi] AB - INTRODUCTION: Muscular diseases (MDs) are rare genetic conditions marked by progressive motor, cardiac, and respiratory decline, often accompanied by significant psychological and social challenges. Anxiety, depression and reduced quality of life (QoL) are common among individuals with MDs, highlighting the importance of integrating psychological assessment and support into multidisciplinary care. Although evidence on psychosocial interventions remains limited, emerging research suggests that nature-based therapeutic activities -particularly adapted sailing - can reduce anxiety and enhance psychological well-being in people with various disabilities. Recent studies indicate improvements in state anxiety, QoL, and respiratory perception associated with exposure to the marine environment. PATIENTS AND METHODS: Based on this evidence, the multidisciplinary team of the Naples NeMO Clinical Center developed the "Anima Libera" project, a sailing-based therapeutic program aimed at evaluating the psychological and clinical effects of an integrated intervention for individuals with muscular diseases. The project included 12 patients with different types of muscular dystrophies aged between 28 and 55 years. RESULTS: All patients showed an improvement in psychological well-being and respiratory parameters. DISCUSSION AND CONCLUSIONS: These data, although preliminary indicate that sailing could act as a complementary therapeutic tool within psychological support and rehabilitation programs for patients with muscle diseases. CI - Copyright (c) 2025 Gaetano Conte Academy - Mediterranean Society of Myology. FAU - Manzo, Raffaella AU - Manzo R AD - Department of Respiratory Pathophysiology and Rehabilitation, Monaldi Hospital, A.O.R.N. dei Colli. AD - Naples NeuroMuscular Omnicentre (NeMO), Serena Onlus, Monaldi Hospital, A.O.R.N. dei Colli. FAU - Annunziata, Anna AU - Annunziata A AD - Department of Respiratory Pathophysiology and Rehabilitation, Monaldi Hospital, A.O.R.N. dei Colli. AD - Naples NeuroMuscular Omnicentre (NeMO), Serena Onlus, Monaldi Hospital, A.O.R.N. dei Colli. FAU - Tozza, Simona AU - Tozza S AD - Department of Respiratory Pathophysiology and Rehabilitation, Monaldi Hospital, A.O.R.N. dei Colli. AD - Naples NeuroMuscular Omnicentre (NeMO), Serena Onlus, Monaldi Hospital, A.O.R.N. dei Colli. FAU - Simioli, Francesca AU - Simioli F AD - Department of Respiratory Pathophysiology and Rehabilitation, Monaldi Hospital, A.O.R.N. dei Colli. AD - Naples NeuroMuscular Omnicentre (NeMO), Serena Onlus, Monaldi Hospital, A.O.R.N. dei Colli. FAU - Coppola, Antonietta AU - Coppola A AD - Department of Respiratory Pathophysiology and Rehabilitation, Monaldi Hospital, A.O.R.N. dei Colli. AD - Naples NeuroMuscular Omnicentre (NeMO), Serena Onlus, Monaldi Hospital, A.O.R.N. dei Colli. FAU - Di Spirito, Valentina AU - Di Spirito V AD - Department of Respiratory Pathophysiology and Rehabilitation, Monaldi Hospital, A.O.R.N. dei Colli. AD - Naples NeuroMuscular Omnicentre (NeMO), Serena Onlus, Monaldi Hospital, A.O.R.N. dei Colli. FAU - Romano, Tommaso AU - Romano T AD - Department of Respiratory Pathophysiology and Rehabilitation, Monaldi Hospital, A.O.R.N. dei Colli. AD - Naples NeuroMuscular Omnicentre (NeMO), Serena Onlus, Monaldi Hospital, A.O.R.N. dei Colli. FAU - Calafiore, Gennaro AU - Calafiore G AD - Department of Respiratory Pathophysiology and Rehabilitation, Monaldi Hospital, A.O.R.N. dei Colli. AD - Naples NeuroMuscular Omnicentre (NeMO), Serena Onlus, Monaldi Hospital, A.O.R.N. dei Colli. FAU - Tsantis, Spyridon AU - Tsantis S AD - Department of Respiratory Pathophysiology and Rehabilitation, Monaldi Hospital, A.O.R.N. dei Colli. AD - Naples NeuroMuscular Omnicentre (NeMO), Serena Onlus, Monaldi Hospital, A.O.R.N. dei Colli. FAU - Fiorentino, Giuseppe AU - Fiorentino G AD - Department of Respiratory Pathophysiology and Rehabilitation, Monaldi Hospital, A.O.R.N. dei Colli. AD - Naples NeuroMuscular Omnicentre (NeMO), Serena Onlus, Monaldi Hospital, A.O.R.N. dei Colli. LA - eng PT - Journal Article PL - Italy TA - Acta Myol JT - Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology JID - 9811169 SB - IM MH - Humans MH - Pilot Projects MH - *Muscular Dystrophies/psychology/rehabilitation MH - Adult MH - *Quality of Life MH - Middle Aged MH - Female MH - Male MH - *Water Sports/psychology MH - *Anxiety/etiology/psychology/therapy MH - Depression/etiology/psychology MH - Psychological Well-Being PMC - PMC12958413 OTO - NOTNLM OT - muscular dystrophies OT - psychological intervention OT - quality of life OT - sealing COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/03/03 06:30 MHDA- 2026/03/06 09:06 PMCR- 2025/12/31 CRDT- 2026/03/03 05:13 PHST- 2025/10/16 00:00 [received] PHST- 2025/12/10 00:00 [accepted] PHST- 2026/03/06 09:06 [medline] PHST- 2026/03/03 06:30 [pubmed] PHST- 2026/03/03 05:13 [entrez] PHST- 2025/12/31 00:00 [pmc-release] AID - 10.36185/2532-1900-1750 [doi] PST - ppublish SO - Acta Myol. 2025 Dec;44(4):130-134. doi: 10.36185/2532-1900-1750. PMID- 41769673 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260302 LR - 20260813 IS - 1016-7315 (Print) IS - 2212-5043 (Electronic) IS - 1016-7315 (Linking) VI - 37 IP - 4 DP - 2025 TI - Efficacy and Safety of Transcatheter Mitral Valve Repair (MitraClip) Compared to Medical Therapy and Surgery in Patients With Secondary Mitral Regurgitation: A Systematic Review & Pairwise Meta-analysis. PG - 16 LID - 10.37616/2212-5043.1467 [doi] LID - 16 AB - BACKGROUND: Secondary mitral regurgitation (SMR) worsens outcomes in heart failure. Transcatheter mitral valve repair (MitraClip/TMVr) is an established alternative for patients who remain symptomatic on guideline-directed medical therapy (GDMT), but comparative efficacy versus GDMT and surgery has been debated. METHODS: We searched MEDLINE, Embase, and Cochrane through February 2025. To avoid double counting, quantitative syntheses used unique randomized controlled trials (RCTs) only; RCT substudies informed qualitative context. Pairwise random-effects meta-analyses compared MitraClip + GDMT vs GDMT and MitraClip vs surgery. Primary outcomes were all-cause mortality and heart-failure hospitalization (HFH). Secondary outcomes included quality of life (Kansas City Cardiomyopathy Questionnaire (KCCQ), MR 7 days) V-A ECMO support. In patients still on ECMO at day 7 (the prolonged ECMO group), a multivariable logistic regression model was developed to predict one-year mortality. Model performance was evaluated using Area Under the Receiver Operating Characteristic curve (AUROC), Brier score and calibration plot, following internal validation performed via bootstrapping. RESULTS: Out of 546 patients, 160 (29%) underwent prolonged V-A ECMO support. These patients had lower Acute Physiology And Chronic Health Evaluation (APACHE) IV scores (mean 79 [SD 29] vs. 92 [SD 36]) and differed regarding ECMO indication. One-year mortality, (1-7days: 61%, >7days: 58%), and health related QoL at one year (1-7 days: Median EQ-5D index score [IQR] 0.82 [0.71, 0.91], > 7 days: 0.82 [0.73, 0.91]) were comparable between both groups. A multivariable logistic regression model predicting one-year mortality was constructed with age, APACHE IV, pre-ECMO cardiac arrest, acute kidney injury during first week; and cumulative Sequential Organ Failure Assessment (SOFA), and pulse pressure at day 7. The internally validated model showed moderate performance, with an AUROC of 0.68 and a Brier score of 0.22. CONCLUSION: Patients with prolonged V-A ECMO differ in terms of indication and baseline risk scores. Mortality was not higher in patients who received ECMO support for longer than 7 days, and QoL at one year was good in both groups. Our developed multivariable prediction model showed moderate performance in predicting one-year mortality for those still on ECMO at day 7, and may help in multidisciplinary decision-making regarding continuation of ECMO support pending external validation. TRIAL REGISTRATION: ClinicalTrials.gov: NCT 05444764; Registration date: June 22nd, 2022. FAU - Bunge, Jeroen J H AU - Bunge JJH AD - Department of Intensive Care Adults, Erasmus MC, Rotterdam, The Netherlands. j.bunge@erasmusmc.nl. AD - Department of Cardiology, Thoraxcenter, Erasmus MC, Rotterdam, The Netherlands. j.bunge@erasmusmc.nl. FAU - Pladet, Lara C A AU - Pladet LCA AD - Department of Intensive Care Adults, Erasmus MC, Rotterdam, The Netherlands. AD - Department of Intensive Care, University Medical Center Utrecht, Utrecht, The Netherlands. FAU - Luijken, Kim AU - Luijken K AD - Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands. FAU - Van Steenwijk, Myrthe P J AU - Van Steenwijk MPJ AD - Department of Intensive Care Adults, Erasmus MC, Rotterdam, The Netherlands. FAU - Van Esch, Atreyu AU - Van Esch A AD - Department of Intensive Care Adults, Erasmus MC, Rotterdam, The Netherlands. FAU - Elzo Kraemer, Carlos V AU - Elzo Kraemer CV AD - Department of Intensive Care, Leiden University Medical Center, Leiden, The Netherlands. FAU - Maas, Jacinta J AU - Maas JJ AD - Department of Intensive Care, Leiden University Medical Center, Leiden, The Netherlands. FAU - Dos Reis Miranda, Dinis AU - Dos Reis Miranda D AD - Department of Intensive Care Adults, Erasmus MC, Rotterdam, The Netherlands. FAU - Dubois, Eric A AU - Dubois EA AD - Department of Intensive Care Adults, Erasmus MC, Rotterdam, The Netherlands. AD - Department of Cardiology, Thoraxcenter, Erasmus MC, Rotterdam, The Netherlands. FAU - Caliskan, Kadir AU - Caliskan K AD - Department of Cardiology, Thoraxcenter, Erasmus MC, Rotterdam, The Netherlands. FAU - Montenij, Leon J AU - Montenij LJ AD - Department of Intensive Care Medicine, Catharina Hospital Eindhoven, Eindhoven, The Netherlands. FAU - Otterspoor, Luuk C AU - Otterspoor LC AD - Department of Intensive Care Medicine, Catharina Hospital Eindhoven, Eindhoven, The Netherlands. FAU - Scholten, Erik AU - Scholten E AD - Department of Intensive Care, Sint Antonius Hospital, Nieuwegein, The Netherlands. FAU - Van Koppenhagen, Laurien AU - Van Koppenhagen L AD - Department of Intensive Care, Isala hospital, Zwolle, The Netherlands. FAU - Cremer, Olaf L AU - Cremer OL AD - Department of Intensive Care, University Medical Center Utrecht, Utrecht, The Netherlands. FAU - Gommers, Diederik AU - Gommers D AD - Department of Intensive Care Adults, Erasmus MC, Rotterdam, The Netherlands. FAU - Donker, Dirk W AU - Donker DW AD - Department of Intensive Care, University Medical Center Utrecht, Utrecht, The Netherlands. AD - Cardiovascular and Respiratory Physiology, TechMed Center, University of Twente, Enschede, The Netherlands. FAU - Meuwese, Christiaan L AU - Meuwese CL AD - Department of Intensive Care Adults, Erasmus MC, Rotterdam, The Netherlands. AD - Department of Cardiology, Thoraxcenter, Erasmus MC, Rotterdam, The Netherlands. LA - eng PT - Journal Article PT - Multicenter Study PT - Observational Study DEP - 20260226 PL - England TA - Crit Care JT - Critical care (London, England) JID - 9801902 SB - IM MH - Humans MH - *Extracorporeal Membrane Oxygenation/methods/mortality/standards/statistics & numerical data MH - Female MH - Cohort Studies MH - Male MH - Middle Aged MH - ROC Curve MH - Logistic Models MH - APACHE MH - Quality of Life/psychology MH - Time Factors MH - Aged PMC - PMC13040854 OTO - NOTNLM OT - Acute heart failure OT - Cardiogenic shock OT - Extra-corporeal membrane oxygenation OT - Mechanical circulatory support COIS- Declarations. Ethics approval and consent to participate: The institutional medical ethics committee of the University Medical Center Utrecht waived the need for specific informed consent (reference numbers 21-604/C). Consent for publication: Not applicable. Competing interests: The authors declare the following conflicts of interest: DD from the institutional research cooperation of the Cardiovascular and Respiratory physiology group of the University of Twente with Maquet Critical Care AB, Solna, Sweden and Sonion Nederland BV, Hoofddorp, The Netherlands (no personal honoraria received). CM has received speaker fees from AOP and Abbot and has received research funds from charity fund "Stichting Gezondheidszorg Spaarneland (SGS)" and the Dutch Heart Foundation "Hartstichting". EDAT- 2026/02/27 00:33 MHDA- 2026/06/27 10:10 PMCR- 2026/02/26 CRDT- 2026/02/26 23:49 PHST- 2025/11/10 00:00 [received] PHST- 2026/02/19 00:00 [accepted] PHST- 2026/06/27 10:10 [medline] PHST- 2026/02/27 00:33 [pubmed] PHST- 2026/02/26 23:49 [entrez] PHST- 2026/02/26 00:00 [pmc-release] AID - 10.1186/s13054-026-05919-9 [pii] AID - 5919 [pii] AID - 10.1186/s13054-026-05919-9 [doi] PST - epublish SO - Crit Care. 2026 Feb 26;30(1):140. doi: 10.1186/s13054-026-05919-9. PMID- 41745720 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260226 LR - 20260813 IS - 2035-8385 (Print) IS - 2035-8377 (Electronic) IS - 2035-8385 (Linking) VI - 18 IP - 2 DP - 2026 Feb 14 TI - Primary and Secondary Prevention of Ischemic Stroke in Elderly Patients with Cardiovascular Disease: The Role of Frailty and Care Pathways. LID - 10.3390/neurolint18020036 [doi] LID - 36 AB - Stroke is a major global health concern, particularly among the elderly, who frequently present with multiple comorbidities, most notably cardiovascular diseases. Importantly, atrial fibrillation confers a nearly fivefold increase in stroke risk and accounts for up to one-quarter of ischemic strokes in older adults. Stroke is a neurological disease characterised by a strong cardiovascular interplay, and its multifactorial nature requires an integrated preventive approach. This review focuses on primary and secondary prevention in this population, with a frailty-informed perspective. We synthesise evidence on blood pressure control, lipid-lowering (including LDL-C targets), glycemic management, and antithrombotic strategies-particularly oral anticoagulation for atrial fibrillation-as well as the role of frailty indices in guiding individualised risk-benefit decisions. We also discuss practical care pathways, including structured post-discharge programs, continuity of care, and the need for multidisciplinary collaboration involving cardiologists, neurologists, and primary care. We highlight how frailty indices refine risk-benefit assessments without justifying therapeutic nihilism, and how sex- and age-related factors shape treatment effectiveness and safety. By narrowing scope and emphasising practical, multidisciplinary prevention strategies, this review aims to support clinicians in reducing recurrent events, disability, and mortality in very old patients. Future work should prioritise pragmatic trials, including those involving the oldest old and the use of standardised frailty metrics, to inform prevention decisions. FAU - Luca, Fabiana AU - Luca F AUID- ORCID: 0000-0002-5369-5382 AD - Cardiology Department, Grande Ospedale Metropolitano of Reggio Calabria, 89124 Reggio Calabria, Italy. FAU - Ceravolo, Roberto AU - Ceravolo R AD - Cardiology Unit, Giovanni Paolo II Hospital, 88046 Lamezia Terme, Italy. FAU - Gulizia, Michele Massimo AU - Gulizia MM AD - Cardiology Department, Garibaldi Nesima Hospital, 95122 Catania, Italy. FAU - Gelsomino, Sandro AU - Gelsomino S AUID- ORCID: 0000-0002-7746-989X AD - Cardiothoracic Department, Maastricht University Hospital, 6229 Maastricht, The Netherlands. FAU - Rao, Carmelo Massimiliano AU - Rao CM AD - Cardiology Unit, Santa Maria Degli Ungheresi Hospital, Polistena, 89024 Reggio Calabria, Italy. FAU - Ingianni, Nadia AU - Ingianni N AD - Cardiologic District, Azienda Sanitaria Provinciale Trapani, 91016 Trapani, Italy. FAU - Vitale, Giuseppina AU - Vitale G AD - Neurology Department, ARNAS Garibaldi Hospital, 95124 Catania, Italy. FAU - Geraci, Giovanna AU - Geraci G AUID- ORCID: 0000-0003-0092-8717 AD - Cardiology Department, Sant'Antonio Abate Hospital, Erice, 91016 Trapani, Italy. FAU - Iacovoni, Attilio AU - Iacovoni A AD - Department of Transplant Surgery and Surgical Treatment of Heart Failure, Cardiovascular Department, ASST Papa Giovanni XXIII, 24127 Bergamo, Italy. FAU - Scicchitano, Pietro AU - Scicchitano P AUID- ORCID: 0000-0003-0471-0053 AD - Cardiology Section, Hospital "F. Perinei", Altamura, 70022 Bari, Italy. FAU - Murrone, Adriano AU - Murrone A AUID- ORCID: 0000-0003-3184-1921 AD - Cardiology, Citta di Castello Hospital, 06012 Citta di Castello, Italy. FAU - Bilato, Claudio AU - Bilato C AUID- ORCID: 0000-0003-3474-0579 AD - Cardiology Department, Ovest Vicentino Hospitals, Azienda ULSS 8 Berica, 36100 Vicenza, Italy. FAU - Guasti, Luigina AU - Guasti L AD - Department of Medicine and Surgery, University of Insubria, 21100 Varese, Italy. FAU - Colivicchi, Furio AU - Colivicchi F AD - Clinical and Rehabilitation Cardiology Department, San Filippo Neri Hospital, ASL Roma 1, 00135 Roma, Italy. FAU - Oliva, Fabrizio AU - Oliva F AD - Cardiology Unit, ASST Grande Ospedale Metropolitano Niguarda, 20162 Milano, Italy. FAU - Nardi, Federico AU - Nardi F AUID- ORCID: 0000-0002-7743-2587 AD - Cardiology Department, Santo Spirito Hospital, Casale Monferrato, 15033 Alessandria, Italy. FAU - Grimaldi, Massimo AU - Grimaldi M AUID- ORCID: 0000-0002-9347-8884 AD - Cardiology Department, General Regional Hospital "F. Miulli'', Acquaviva delle Fonti, 70021 Bari, Italy. FAU - Parrini, Iris AU - Parrini I AUID- ORCID: 0000-0002-0038-9445 AD - Cardiology Unit, Koelliker Hospital, 10134 Torino, Italy. LA - eng PT - Journal Article PT - Review DEP - 20260214 PL - Switzerland TA - Neurol Int JT - Neurology international JID - 101551564 PMC - PMC12942942 OTO - NOTNLM OT - LDL cholesterol OT - atrial fibrillation OT - cardiovascular diseases (CVD) OT - elderly patients OT - frailty OT - integrated care pathways OT - multidisciplinary approach OT - oral anticoagulation OT - secondary prevention OT - stroke COIS- The authors declare no conflict of interest. EDAT- 2026/02/26 13:40 MHDA- 2026/02/26 13:41 PMCR- 2026/02/14 CRDT- 2026/02/26 09:23 PHST- 2025/10/06 00:00 [received] PHST- 2026/01/05 00:00 [revised] PHST- 2026/01/27 00:00 [accepted] PHST- 2026/02/26 13:41 [medline] PHST- 2026/02/26 13:40 [pubmed] PHST- 2026/02/26 09:23 [entrez] PHST- 2026/02/14 00:00 [pmc-release] AID - neurolint18020036 [pii] AID - neurolint-18-00036 [pii] AID - 10.3390/neurolint18020036 [doi] PST - epublish SO - Neurol Int. 2026 Feb 14;18(2):36. doi: 10.3390/neurolint18020036. PMID- 41745344 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260226 LR - 20260813 IS - 2308-3425 (Electronic) IS - 2308-3425 (Linking) VI - 13 IP - 2 DP - 2026 Feb 16 TI - Transcatheter Paravalvular Leak Closure: A Step-by-Step Guide. LID - 10.3390/jcdd13020096 [doi] LID - 96 AB - Paravalvular leak (PVL) remains a clinically important complication after surgical or transcatheter valve implantation, presenting predominantly with heart failure (HF) and/or high-shear hemolysis. While redo surgery can be definitive, contemporary candidates frequently carry prohibitive operative risk, positioning transcatheter PVL closure as a key therapeutic alternative. However, available outcome data are largely derived from observational series and registries with heterogeneity in PVL mechanisms, prosthesis types, imaging protocols, and endpoint definitions. Standardized frameworks-such as those proposed by the PVL Academic Research Consortium-support harmonized PVL grading and clinically meaningful composite endpoints that integrate imaging/hemodynamic results with patient-centered outcomes. Across datasets, the most consistent determinant of benefit is residual PVL severity: procedural efficacy is most commonly defined as achieving 20 mm Hg preclude patients from a surgical approach. Considering the poor prognosis of advanced liver cirrhosis, futile treatments should be avoided. A multidimensional heart team approach involving surgical, cardiologic, anesthesiologic, hepatological, and medical considerations is recommended. FAU - Spadaccio, Cristiano AU - Spadaccio C AUID- ORCID: 0000-0002-1672-7576 AD - Cardiothoracic Surgery University of Cincinnati College of Medicine Cincinnati OH USA. AD - Cardiovascular Surgery Mayo Clinic Rochester MN USA. FAU - Nenna, Antonio AU - Nenna A AD - Cardiovascular Surgery Fondazione Policlinico Universitario Campus Bio-Medico Rome Italy. FAU - Mehta, Krishna AU - Mehta K AD - Lancaster University Lancaster UK. FAU - Pisani, Angelo AU - Pisani A AUID- ORCID: 0000-0002-4105-6962 AD - Cardiac Surgery Hopital Bichat - Claude-Bernard Paris France. FAU - Osho, Asishana AU - Osho A AUID- ORCID: 0000-0002-1140-097X AD - Cardiac Surgery, Massachusetts General Hospital [MGH] - Harvard Medical School Boston MA USA. FAU - Juarez-Casso, Fernando AU - Juarez-Casso F AD - Cardiovascular Surgery Mayo Clinic Rochester MN USA. FAU - Alvaro, Domenico AU - Alvaro D AUID- ORCID: 0000-0003-3771-9644 AD - Department of Translational and Precision Medicine Sapienza University of Rome Italy. AD - Lancashire Cardiac Centre Blackpool Victoria Hospital Blackpool UK. FAU - Arif, Imran AU - Arif I AD - Cardiothoracic Surgery University of Cincinnati College of Medicine Cincinnati OH USA. FAU - Panza, Antonio AU - Panza A AUID- ORCID: 0000-0002-0581-5386 AD - Cardiothoracic Surgery University of Cincinnati College of Medicine Cincinnati OH USA. FAU - Vester, Russell S AU - Vester RS AD - Cardiothoracic Surgery University of Cincinnati College of Medicine Cincinnati OH USA. FAU - Louis, Louis B AU - Louis LB AUID- ORCID: 0000-0003-3088-5164 AD - Cardiothoracic Surgery University of Cincinnati College of Medicine Cincinnati OH USA. FAU - Sundt, Thoralf M AU - Sundt TM AUID- ORCID: 0000-0002-0409-7028 AD - Cardiac Surgery, Massachusetts General Hospital [MGH] - Harvard Medical School Boston MA USA. FAU - Crestanello, Juan AU - Crestanello J AUID- ORCID: 0000-0001-5415-1478 AD - Cardiovascular Surgery Mayo Clinic Rochester MN USA. FAU - Rose, David AU - Rose D AUID- ORCID: 0000-0001-7616-6283 AD - Cardiothoracic Surgery University of Cincinnati College of Medicine Cincinnati OH USA. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20260224 PL - England TA - J Am Heart Assoc JT - Journal of the American Heart Association JID - 101580524 SB - IM MH - Humans MH - *Liver Cirrhosis/complications/therapy/diagnosis/mortality MH - *Cardiac Surgical Procedures/adverse effects/mortality MH - Risk Factors MH - Treatment Outcome MH - *Percutaneous Coronary Intervention/adverse effects/mortality PMC - PMC13055755 OTO - NOTNLM OT - cardiac surgery OT - cirrhosis OT - liver disease OT - percutaneous OT - percutaneous coronary intervention OT - transcatheter aortic valve replacement COIS- None. EDAT- 2026/02/24 18:45 MHDA- 2026/03/07 18:38 PMCR- 2026/02/24 CRDT- 2026/02/24 06:12 PHST- 2026/03/07 18:38 [medline] PHST- 2026/02/24 18:45 [pubmed] PHST- 2026/02/24 06:12 [entrez] PHST- 2026/02/24 00:00 [pmc-release] AID - JAH370274 [pii] AID - 10.1161/JAHA.125.045147 [doi] PST - ppublish SO - J Am Heart Assoc. 2026 Mar 3;15(5):e045147. doi: 10.1161/JAHA.125.045147. Epub 2026 Feb 24. PMID- 41730587 OWN - NLM STAT- MEDLINE DCOM- 20260708 LR - 20260813 IS - 2399-6641 (Electronic) IS - 2399-6641 (Linking) VI - 15 IP - 1 DP - 2026 Feb 23 TI - Rapid response teams for new leaders: a narrative review of global evidence and implementation strategies with a focus on Japan. LID - 10.1136/bmjoq-2025-003949 [doi] LID - e003949 AB - BACKGROUND: Rapid response systems (RRSs) are designed to detect and treat physiological deterioration before cardiac arrest occurs. Since 2020, Japan has seen a rapid increase in RRS adoption; however, most new team members have not received formal training in critical care. This review synthesises international and Japanese evidence supporting implementation and training for new members. METHODS: PubMed, Web of Science and Ichushi Web were searched for English or Japanese studies evaluating adult RRSs (January 2010-April 2025). We included 47 records (43 comparative and 4 systematic reviews); the national guideline was not included. RESULTS: Mature RRSs were associated with a 35% relative reduction in unexpected in-hospital cardiac arrests and a 12% decrease in all-cause hospital mortality. However, the evidence is not uniformly positive-systematic reviews and multicentre analyses reported no significant mortality benefit-and outcome heterogeneity limits comparability. Effective programmes share three key features: (1) single-parameter activation criteria augmented by early-warning scores; (2) tiered response models for advanced practice nurses and (3) audit-feedback cycles with dashboards. Crew resource management, in situ simulation and mindfulness-based self-leadership approaches may be associated with reduced decision latency. Emerging tools like deep-learning prediction algorithms, continuous wearable monitoring and tele-support systems may expand coverage but require governance. Common barriers include limited night-time staffing, cultural reluctance to escalate care and medicolegal ambiguity; targeted education and registry-driven feedback mitigate challenges. CONCLUSIONS: Well-structured RRSs improve outcomes beyond traditional code-blue models. Aligning activation thresholds, multidisciplinary competencies and data-driven quality improvement cycles with local resources may help new Japanese rapid response team members develop resilient, high-performing services. CI - (c) Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. FAU - Ogawa, Akiko AU - Ogawa A AD - Emergency Department, Fukujukai Adachi Tobu Hospital, Tokyo, Japan. FAU - Tsuchiya, Yoko AU - Tsuchiya Y AD - Emergency Department, Fukujukai Adachi Tobu Hospital, Tokyo, Japan. FAU - Sakemi, Ikue AU - Sakemi I AD - Emergency Department, Fukujukai Adachi Tobu Hospital, Tokyo, Japan. FAU - Kutsuna, Nobuo AU - Kutsuna N AUID- ORCID: 0000-0001-7044-9151 AD - Emergency Department, Fukujukai Adachi Tobu Hospital, Tokyo, Japan nobuo.kutsuna@med.toho-u.ac.jp. AD - Department of Stress and Invasiveness Control, Toho University School of Medicine, Tokyo, Japan. AD - Department of Neurosurgery, Fukujukai Adachi Tobu Hospital, Tokyo, Japan. LA - eng PT - Journal Article PT - Review DEP - 20260223 PL - England TA - BMJ Open Qual JT - BMJ open quality JID - 101710381 SB - IM MH - Humans MH - Japan MH - *Hospital Rapid Response Team/standards/statistics & numerical data/trends MH - *Leadership PMC - PMC12931532 OTO - NOTNLM OT - Continuity of Patient Care OT - Patient safety OT - Quality improvement COIS- Competing interests: None declared. EDAT- 2026/02/24 00:29 MHDA- 2026/02/24 00:30 PMCR- 2026/02/23 CRDT- 2026/02/23 20:52 PHST- 2025/10/20 00:00 [received] PHST- 2026/02/06 00:00 [accepted] PHST- 2026/02/24 00:30 [medline] PHST- 2026/02/24 00:29 [pubmed] PHST- 2026/02/23 20:52 [entrez] PHST- 2026/02/23 00:00 [pmc-release] AID - bmjoq-2025-003949 [pii] AID - 10.1136/bmjoq-2025-003949 [doi] PST - epublish SO - BMJ Open Qual. 2026 Feb 23;15(1):e003949. doi: 10.1136/bmjoq-2025-003949. PMID- 41729145 OWN - NLM STAT- MEDLINE DCOM- 20260708 LR - 20260708 IS - 1552-6259 (Electronic) IS - 0003-4975 (Linking) VI - 121 IP - 5 DP - 2026 May TI - The 2025 Accra Declaration on Upskilling and Cost-Effective Cardiac Surgery in Africa. PG - 1049-1058 LID - S0003-4975(26)00014-7 [pii] LID - 10.1016/j.athoracsur.2026.01.002 [doi] AB - The Pan-African Society for Cardiothoracic Surgery (PASCaTS) organized the 1st Pan-African Cardiothoracic Surgery Summit on 21 to 24 February 2025 in Accra, Ghana. The summit brought together leading specialists from across Africa, China, Europe, South America and the USA to address the growing burden of cardiovascular disease, to share their vision for the fight against cardiovascular disease, to raise standards in the diagnosis, treatment, and recovery of patients thereby improving procedural safety and clinical outcomes in Africa. The experts agreed on the need for cost effectiveness in cardiac surgery, simulation skills training, an African regional cardiothoracic surgery database, African heart team fellowship programs, and specialized working groups to guide cardiovascular diagnostics and treatments focusing on critical areas such as congenital heart surgery, valve surgery, and coronary artery bypass surgery (CABG) procedures, which are becoming increasingly necessary in Africa due to the rise in cardiovascular emergencies, and finally explore solutions tailored to the continent's unique healthcare challenges. The incentives generated from the summit are formulated as the "2025 Accra Declaration" to serve as roadmaps and implementable guidelines for promoting high-level cardiovascular surgery and reforms in Africa in collaboration with cardiologists and other allied cardiovascular professionals. CI - Copyright (c) 2026. Published by Elsevier Inc. FAU - Yankah, A Charles AU - Yankah AC AD - Humanitarian Cardiac Surgery, Global Heart Care, Berlin, Germany; Department of Cardiothoracic Surgery, German Heart Center Charite, Berlin, Germany. Electronic address: cyankah@web.de. FAU - Nwiloh, Jonathan AU - Nwiloh J AD - Department of Cardiothoracic Surgery, Dr. Joe Nwiloh Heart Center, Adazi Nnukwu, Nigeria. FAU - Mestres, Carlos A AU - Mestres CA AD - Department of Cardiothoracic Surgery, University of the Free State, Bloemfontein, South Africa. FAU - Bouzid, Abdelmalek AU - Bouzid A AD - Department of Cardiovascular Surgery, University of Algiers, Algiers, Algeria. FAU - Mwambu, Tom Philip AU - Mwambu TP AD - Department of Cardiothoracic Surgery, Uganda Heart Institute, Kampala, Uganda. FAU - Duncan, Andrew J AU - Duncan AJ AD - Department of Cardiothoracic Surgery, Aga Khan University, Nairobi, Kenya. FAU - Debieche, Mohamed AU - Debieche M AD - Department of Cardiovascular Surgery, University of Blida, Blida, Algeria. FAU - Omokhodion, Samuel I AU - Omokhodion SI AD - Institute of Cardiovascular Diseases, University of Ibadan, Ibadan, Nigeria. FAU - Onakpoya, Uvie U AU - Onakpoya UU AD - Department of Cardiothoracic Surgery, Obafemi Awolowo University, Ile-Ife, Nigeria. FAU - Angres, Matthias AU - Angres M AD - Aswan Heart Center, Intensive Care Unit, Aswan, Egypt. FAU - Nademo, Siyasebow M AU - Nademo SM AD - Department of Cardiothoracic Surgery, Hawassa University, Sidama, Ethiopia. FAU - Oburu, Gilbert AU - Oburu G AD - Department of Cardiothoracic Surgery, Kenyatta National University, Nairobi, Kenya. FAU - Yao, Nana-Akyaa AU - Yao NA AD - Congenital & Pediatric Cardiology, Korle Bu Teaching Hospital, National Cardiothoracic Center, Accra, Ghana. FAU - Entsua-Mensah, Kow AU - Entsua-Mensah K AD - National Cardiothoracic Center, Accra, Ghana. FAU - Reddy, Darshan AU - Reddy D AD - Lenmed Ethekwini Hospital & Heart Center, Durban, South Africa. FAU - Antunes, Manuel AU - Antunes M AD - Cardiothoracic Surgery, University of Coimbra, Portugal. FAU - Gomes, Walter J AU - Gomes WJ AD - Department of Cardiovascular Surgery, Federal University of Sa approximately o Paulo, Sa approximately o Paulo, Brazil. FAU - Akamah, Joseph A AU - Akamah JA AD - Department of Cardiology, University of Nashville, Nashville. FAU - Yigitbasi, Mustafa AU - Yigitbasi M AD - Pediatric Cardiology Clinic, Berlin, Germany. FAU - Buys, Daniel Gerhard AU - Buys DG AD - Department of Pediatric Cardiology, University of the Free State, Bloemfontein, South Africa. FAU - Bokenkamp, Regina AU - Bokenkamp R AD - Department of Pediatric Cardiology, University Medical Center Leiden, Leiden, Netherlands. FAU - Koen, Willie AU - Koen W AD - Department of Cardiothoracic Surgery, Christiaan Barnard Memorial Hospital, Cardiac, Transplant Program, Cape Town, South Africa. FAU - Smit, Francis E AU - Smit FE AD - Department of Cardiothoracic Surgery, University of the Free State, Bloemfontein, South Africa. FAU - Chikwe, Joanna AU - Chikwe J AD - Department of Cardiac Surgery, Cedars Sinai Medical Center, Smidt Heart Institute, Los Angeles. LA - eng PT - Journal Article PT - Review DEP - 20260223 PL - Netherlands TA - Ann Thorac Surg JT - The Annals of thoracic surgery JID - 15030100R SB - IM MH - Humans MH - *Cardiac Surgical Procedures/economics/education/standards MH - Africa MH - Cost-Benefit Analysis MH - *Thoracic Surgery/economics/education MH - *Cardiovascular Diseases/surgery MH - Cost-Effectiveness Analysis COIS- Disclosures The authors have no conflicts of interest to disclose. EDAT- 2026/02/23 13:05 MHDA- 2026/04/26 05:13 CRDT- 2026/02/23 10:21 PHST- 2025/09/26 00:00 [accepted] PHST- 2026/04/26 05:13 [medline] PHST- 2026/02/23 13:05 [pubmed] PHST- 2026/02/23 10:21 [entrez] AID - S0003-4975(26)00014-7 [pii] AID - 10.1016/j.athoracsur.2026.01.002 [doi] PST - ppublish SO - Ann Thorac Surg. 2026 May;121(5):1049-1058. doi: 10.1016/j.athoracsur.2026.01.002. Epub 2026 Feb 23. PMID- 41729033 OWN - NLM STAT- MEDLINE DCOM- 20260708 LR - 20260930 IS - 1897-4279 (Electronic) IS - 0022-9032 (Linking) VI - 84 IP - 4 DP - 2026 TI - The 2025 European Society of Cardiology/European Association for Cardio-Thoracic Surgery joint guidelines for the management of valvular heart disease: Revolution or evolution? PG - 459-463 LID - 10.33963/v.phj.111320 [doi] AB - The 2025 European Society of Cardiology (ESC)/European Association for Cardio-Thoracic Surgery guidelines for the management of valvular heart disease (VHD), presented at the ESC Congress in Madrid, update the 2021 document and respond to the rapid growth of evidence from randomized trials, meta-analyses, and large registries. Developed by a multidisciplinary Heart Team including patient representatives, the guidelines emphasize patient-centered "lifetime" management, shared decision-making, and treatment at high-volume expert Heart Valve Centers, especially for complex surgical and transcatheter procedures. The scope has been broadened to address cancer and radiation-associated VHD, cardiogenic shock and acute heart failure (HF), multiple and mixed VHD, and sex-specific issues. Key changes in indications for imaging, treatment, and follow-up of VHD are discussed in the perspective of evidence-based medicine. Key updates include earlier intervention in severe, high-gradient, asymptomatic aortic stenosis, refined age thresholds for transfemoral transcatheter aortic valve implantation, and its use in bicuspid aortic stenosis and aortic regurgitation in high-risk or inoperable patients. Recommendations for secondary mitral regurgitation (MR) distinguish atrial from ventricular mechanisms and upgrade mitral transcatheter edge-to-edge repair (TEER) to class I in selected cases of ventricular secondary MR. At the same time, surgery remains first line for primary MR, with defined triggers for early repair and emerging roles for TEER and TEER in high-risk patients. The document also strengthens guidance on tricuspid interventions and structured assessment of right ventricular dysfunction, and simplifies antithrombotic strategies, including restricted use of dual antiplatelet therapy after transcatheter aortic valve implantation in patients without another indication for oral anticoagulation. Implementing these recommendations should streamline care pathways and reduce the burden of VHD. FAU - Wojakowski, Wojciech AU - Wojakowski W AD - Division of Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland. wwojakowski@sum.edu.pl. FAU - Tendera, Michal AU - Tendera M AD - Division of Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland. FAU - Praz, Fabien AU - Praz F AD - Department of Cardiology, Bern University Hospital, Bern, Switzerland. LA - eng PT - Journal Article PT - Practice Guideline DEP - 20260223 PL - Poland TA - Kardiol Pol JT - Kardiologia polska JID - 0376352 SB - IM MH - Humans MH - *Heart Valve Diseases/surgery/therapy MH - Europe MH - Cardiology MH - Societies, Medical MH - *Practice Guidelines as Topic MH - Transcatheter Aortic Valve Replacement MH - Thoracic Surgery OTO - NOTNLM OT - Heart Team OT - heart valve center OT - multimodality imaging OT - valvular heart disease EDAT- 2026/02/23 13:06 MHDA- 2026/05/04 12:34 CRDT- 2026/02/23 09:23 PHST- 2026/02/23 00:00 [received] PHST- 2026/02/23 00:00 [accepted] PHST- 2026/05/04 12:34 [medline] PHST- 2026/02/23 13:06 [pubmed] PHST- 2026/02/23 09:23 [entrez] AID - VM/OJS/J/111320 [pii] AID - 10.33963/v.phj.111320 [doi] PST - ppublish SO - Kardiol Pol. 2026;84(4):459-463. doi: 10.33963/v.phj.111320. Epub 2026 Feb 23. PMID- 41728512 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260223 LR - 20260813 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 18 IP - 1 DP - 2026 Jan TI - Assessing the Impact of a Rapid Response Team on Code Blue Incidents and Hospital Mortality Rate: Evidence From a Tertiary Care Hospital in India. PG - e101923 LID - 10.7759/cureus.101923 [doi] LID - e101923 AB - BACKGROUND: Rapid Response Teams (RRTs) are designed and implemented to identify and respond to early signs of clinical deterioration, to prevent in-hospital adverse events, particularly cardiopulmonary arrests. This multidisciplinary team aims to improve patient outcomes and reduce hospital mortality. Despite their widespread adoption in high-resource settings, evidence on the efficacy of RRTs in resource-limited environments remains limited. OBJECTIVE: The objective of this study was to evaluate the impact of implementing an RRT on patient outcomes in a tertiary care hospital in South India. METHODS: This study compared data from six months before (November 2022 to April 2023) and six months after (November 2023 to April 2024) starting RRT. Event rates were analyzed using unadjusted and adjusted Poisson regression for all three outcomes. In-hospital mortality was additionally assessed using logistic regression and interrupted time series analysis to evaluate trends over time. RESULTS: Among 24,568 hospital admissions, in-hospital mortality decreased from 3.7% to 2.9% post-RRT implementation (absolute difference: 0.71%; p = 0.002). Code Blue events declined from 2.3 to 1.5 per 1,000 admissions, and unplanned MICU transfers remained stable; however, these changes were not statistically significant. Unadjusted Poisson analysis showed a significant reduction in mortality (rate ratio: 0.81; 95% CI: 0.70-0.93; p = 0.003), though adjusted models showed no significant effects. Interrupted time series analysis demonstrated a significant month-on-month decline in mortality post-intervention (OR: 0.91; 95% CI: 0.83-0.99; p = 0.021), suggesting a gradual impact over time. CONCLUSION: RRT implementation was associated with a significant reduction in in-hospital mortality, with evidence of a sustained downward trend over time. Effects on Code Blue events and MICU transfers were not statistically significant, warranting further evaluation in similar settings. CI - Copyright (c) 2026, Tom et al. FAU - Tom, Leo AU - Tom L AD - Internal Medicine, K S Hegde Medical Academy, Mangaluru, IND. AD - Internal Medicine, Malabar Medical College and Research Centre, Kozhikode, IND. FAU - Pillai, Rajeesh R AU - Pillai RR AD - Emergency Medicine, Malabar Medical College and Research Centre, Kozhikode, IND. FAU - Rajan, Gautham AU - Rajan G AD - Critical Care Medicine, Malabar Medical College and Research Centre, Kozhikode, IND. FAU - Binub, Kanniyan AU - Binub K AD - Community Medicine, Malabar Medical College and Research Centre, Kozhikode, IND. LA - eng PT - Journal Article DEP - 20260120 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC12920045 OTO - NOTNLM OT - code blue simulation OT - emergency response plan OT - in hospital cardiac arrest OT - in hospital mortality OT - medical intensive care unit (micu) OT - patient outcome research OT - quality improvement projects OT - rapid response team (rrt) COIS- Human subjects: Informed consent for treatment and open access publication was obtained or waived by all participants in this study. Malabar Medical College Hospital and Research Centre Institutional Ethics Committee issued approval MMCH&RC/IEC/2024/Aug/63. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. EDAT- 2026/02/23 13:05 MHDA- 2026/02/23 13:06 PMCR- 2026/01/20 CRDT- 2026/02/23 06:45 PHST- 2026/01/12 00:00 [accepted] PHST- 2026/02/23 13:06 [medline] PHST- 2026/02/23 13:05 [pubmed] PHST- 2026/02/23 06:45 [entrez] PHST- 2026/01/20 00:00 [pmc-release] AID - 10.7759/cureus.101923 [doi] PST - epublish SO - Cureus. 2026 Jan 20;18(1):e101923. doi: 10.7759/cureus.101923. eCollection 2026 Jan. PMID- 41725609 OWN - NLM STAT- MEDLINE DCOM- 20260708 LR - 20260708 IS - 1651-1999 (Electronic) IS - 0803-7051 (Linking) VI - 35 IP - 1 DP - 2026 Dec TI - Clinicians' time in different aspects of hypertension care: how far are we from optimal management required by guidelines? Results of an international survey of the working group of general practitioners' and team-based care of the European Society of Hypertension and the European General Practice Research Network. PG - 2635826 LID - 10.1080/08037051.2026.2635826 [doi] AB - BACKGROUND: Hypertension management guidelines provide recommendations for optimal patient care. However, the limited time available of clinicians is rarely considered. The aim of this study was to evaluate the time clinicians currently spend on different components of hypertension care during an average workday and to assess physicians' perceptions of the time required for optimal, guideline-based care. METHODS: We conducted an international, cross-sectional, anonymous questionnaire-based survey among physicians involved in hypertension care. A 37-item questionnaire assessed time spent on, and time perceived as necessary for, guideline-recommended hypertension-related activities during an average workday. The survey was distributed through the European Society of Hypertension (ESH) and the European General Practice Research Network (EGPRN) between 1 June and 15 September 2025. RESULTS: 370 responses were collected from 49 countries worldwide (91.3% from Europe). After data clarification 357 responses were analysed. Of these, 153 (42.9%) were general practitioners (GPs) and 204 (57.1%) were other specialists (internists, cardiologists, nephrologists). Across all assessed activities, clinicians consistently reported a gap between the time currently spent and the time perceived as necessary for optimal care, including office blood pressure measurement, home blood pressure measurement education, lifestyle counselling, and cardiovascular risk stratification. Differences were also observed between the practice of GPs and other specialists. CONCLUSIONS: This international survey demonstrates substantial perceived gaps between available and required time for several components of hypertension care, particularly in general practice. These findings highlight the importance of considering real-world clinician time constraints in the development and prioritisation of hypertension guideline recommendations and suggest that adequate health-system resources are needed to support their implementation. FAU - Pikkemaat, Miriam AU - Pikkemaat M AD - Center for Primary Health Care Research, Department of Clinical Sciences Malmo, Lund University, Malmo, Sweden. AD - University Clinic Primary Care, Skane University Hospital, Sweden. FAU - de Pinho, Rosa AU - de Pinho R AD - Primary Care, Sao Joao da Madeira, ULS Entre Douro e Vouga, Portugal. FAU - Rodilla, Enrique AU - Rodilla E AD - Internal Medicine Department, Hypertension and Vascular Risk Unit, Hospital Universitario de Sagunto, Sagunto, Spain. AD - Department of Medicine, Universidad Cardenal Herrera-CEU, CEU Universities, Valencia, Spain. FAU - Weber, Thomas AU - Weber T AD - Cardiology Department, Klinikum Wels-Grieskirchen, Wels, Austria. FAU - Kreutz, Reinhold AU - Kreutz R AD - Institute of Clinical Pharmacology and Toxicology, Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin. FAU - Frese, Thomas AU - Frese T AD - Medizinische Fakultat der Martin-Luther-Universitat Halle-Wittenberg Profilzentrum Gesundheitswissenschaften Institut fur Allgemeinmedizin, Halle, Germany. FAU - Johansson, Minna AU - Johansson M AD - , School of Public Health and Community Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. FAU - Jelakovic, Bojan AU - Jelakovic B AD - University Hospital Centre Zagreb, Croatia. AD - School of Medicine, University of Zagreb, Zagreb, Croatia. AD - Croatian Hypertension League, Zagreb. FAU - Bralic Lang, Valerija AU - Bralic Lang V AD - School of Medicine, University of Zagreb, Zagreb, Croatia. AD - Croatian Hypertension League, Zagreb. AD - Specialist Family Medicine Practice, Zagreb, Croatia. FAU - Dahle, Nina AU - Dahle N AD - Center for Clinical Research Dalarna, Uppsala University, Falun, Sweden. FAU - Torzsa, Peter AU - Torzsa P AD - Department of Family Medicine, Semmelweis University, Budapest, Hungary. FAU - Oostindjer, Andrew AU - Oostindjer A AD - General Practice Oostindjer, Oldenzaal, The Netherlands. FAU - Evangelidis, Nikolaos AU - Evangelidis N AD - First Propedeutic Department of Internal Medicine, AHEPA University Hospital, Hypertension Outpatient Clinic, ESH Excellence Center, Aristotle University of Thessaloniki, Thessaloniki, Greece. AD - Laboratory of Primary Health Care, General Practice and Health Services Research, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece. FAU - Triantafyllou, Areti AU - Triantafyllou A AD - First Propedeutic Department of Internal Medicine, AHEPA University Hospital, Hypertension Outpatient Clinic, ESH Excellence Center, Aristotle University of Thessaloniki, Thessaloniki, Greece. AD - Primary Health Care Research Network, Aristotle University of Thessaloniki, Thessaloniki, Greece. FAU - Doumas, Michael AU - Doumas M AD - 2nd Department of Internal Medicine, Aristotle University, Thessaloniki, Greece. FAU - Fragkoulis, Evangelos AU - Fragkoulis E AD - Hellenic Academy of General Practice/Family Medicine and Primary Health Care, Athens, Greece. FAU - Albini, Fabio AU - Albini F AD - Milano Nord-Ambulatory for Hypertension and Cardiovascular Protection, Advanced Clinical Training Academy for selected GPs, Milan, Italy. FAU - Boivin, Jean-Marc AU - Boivin JM AUID- ORCID: 0000-0002-7683-0022 AD - Department of Family Medicine, Lorraine University, Nancy, France. AD - ESH Hypertension Excellence Center Coordinator, Nancy, France. FAU - Norrman, Anders AU - Norrman A AD - Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Huddinge, Sweden. FAU - Stomby, Andreas AU - Stomby A AD - Department of Health, Medicine and Caring Sciences, Rehabilitation and Community Medicine, Unit of Clinical Medicine, Linkoping University, Linkoping, Sweden. FAU - Nemcsik, Janos AU - Nemcsik J AUID- ORCID: 0000-0002-3573-0287 AD - General Practice Oostindjer, Oldenzaal, The Netherlands. LA - eng PT - Journal Article DEP - 20260225 PL - England TA - Blood Press JT - Blood pressure JID - 9301454 SB - IM MH - Humans MH - *Hypertension/therapy/physiopathology MH - Europe MH - Cross-Sectional Studies MH - Practice Guidelines as Topic MH - Surveys and Questionnaires MH - *General Practitioners MH - Female MH - Male MH - *Practice Patterns, Physicians' MH - Guideline Adherence OAB - The time available to physicians is rarely explicitly considered in hypertension guideline recommendations.Our survey assessed time spent on, and time perceived as necessary for, guideline-recommended hypertension-related activities.Across all assessed activities, clinicians consistently reported a gap between the time currently spent and the time perceived as necessary for optimal care.Differences were also observed between the practice of general practitioners and other specialists.Our findings highlight the importance of considering real-world physician time constraints in the development and prioritisation of hypertension guideline recommendations. OABL- eng OTO - NOTNLM OT - International survey OT - general practitioner OT - guidelines OT - hypertension care OT - time needed to treat EDAT- 2026/02/23 13:06 MHDA- 2026/03/06 09:09 CRDT- 2026/02/23 06:03 PHST- 2026/03/06 09:09 [medline] PHST- 2026/02/23 13:06 [pubmed] PHST- 2026/02/23 06:03 [entrez] AID - 10.1080/08037051.2026.2635826 [doi] PST - ppublish SO - Blood Press. 2026 Dec;35(1):2635826. doi: 10.1080/08037051.2026.2635826. Epub 2026 Feb 25. PMID- 41725176 OWN - NLM STAT- MEDLINE DCOM- 20260708 LR - 20260823 IS - 1873-734X (Electronic) IS - 1010-7940 (Print) IS - 1010-7940 (Linking) VI - 68 IP - 2 DP - 2026 Feb 5 TI - The 2025 Accra Declaration on Upskilling and Cost- Effective Cardiac Surgery in Africa. LID - 10.1093/ejcts/ezag036 [doi] LID - ezag036 AB - The Pan-African Society for Cardiothoracic Surgery (PASCaTS) organized the 1st Pan-African Cardiothoracic Surgery Summit on 21 to 24 February 2025 in Accra, Ghana. The summit brought together leading specialists from across Africa, China, Europe, South America and the USA to address the growing burden of cardiovascular disease, to share their vision for the fight against cardiovascular disease, to raise standards in the diagnosis, treatment and recovery of patients thereby improving procedural safety and clinical outcomes in Africa. The experts agreed on the need for cost effectiveness in cardiac surgery, simulation skills training, an African regional cardiothoracic surgery database, African heart team fellowship programs and specialized working groups to guide cardiovascular diagnostics and treatments focusing on critical areas such as congenital heart surgery, valve surgery and coronary artery bypass surgery (CABG) procedures which are becoming increasingly necessary in Africa due to the rise in cardiovascular emergencies, and finally explore solutions tailored to the continent's unique healthcare challenges. The incentives generated from the summit are formulated as the "2025 Accra Declaration" to serve as roadmaps and implementable guidelines for promoting high-level cardiovascular surgery and reforms in Africa in collaboration with cardiologists and other allied cardiovascular professionals. CI - (c) 2026 The Author(s). Published by Elsevier Inc on behalf of The Society of Thoracic Surgeons, by SAGE Publications, by Jaypee Brothers Medical Publishers on behalf of Pan African Society for Cardiothoracic Surgery, by Oxford University Press on behalf of European Association for Cardio-Thoracic Surgery. FAU - Yankah, A Charles AU - Yankah AC AD - Humanitarian Cardiac Surgery, Global Heart Care, Berlin, Germany. AD - Department of Cardiothoracic Surgery, German Heart Center Charite Berlin, University of the Free State, Bloemfontein, Germany. FAU - Nwiloh, Jonathan AU - Nwiloh J AD - Department of Cardiothoracic Surgery, Dr. Joe Nwiloh Heart Center, Adazi Nnukwu, Nigeria. FAU - Mestres, Carlos A AU - Mestres CA AD - Department of Cardiothoracic Surgery, University of the Free State, Bloemfontein, South Africa. FAU - Bouzid, Abdelmalek AU - Bouzid A AD - Department of Cardiovascular Surgery, University of Algiers, Algiers, Algeria. FAU - Mwambu, Tom Philip AU - Mwambu TP AD - Department of Cardiothoracic Surgery, Uganda Heart Institute, Kampala, Uganda. FAU - Duncan, Andrew J AU - Duncan AJ AD - Department of Cardiothoracic Surgery, Aga Khan University, Nairobi, Kenya. FAU - Debieche, Mohamed AU - Debieche M AD - Department of Cardiovascular Surgery, University of Blida, Blida, Algeria. FAU - Omokhodion, Samuel I AU - Omokhodion SI AD - Institute of Cardiovascular Diseases, University of Ibadan, Ibadan, Nigeria. FAU - Onakpoya, Uvie U AU - Onakpoya UU AD - Department of Cardiothoracic Surgery, Obafemi Awolowo University, Ile-Ife, Nigeria. FAU - Angres, Matthias AU - Angres M AD - Aswan Heart Center, Intensive Care Unit, Aswan, Egypt. FAU - Nademo, Siyasebow M AU - Nademo SM AD - Department of Cardiothoracic Surgery, Hawassa University, Sidama, Ethiopia. FAU - Oburu, Gilbert AU - Oburu G AD - Department of Cardiothoracic Surgery, Kenyatta National University, Nairobi, Kenya. FAU - Yao, Nana-Akyaa AU - Yao NA AD - Congenital & Pediatric Cardiology, Korle Bu Teaching Hospital, National Cardiothoracic Center, Accra, Ghana. FAU - Entsua-Mensah, Kow AU - Entsua-Mensah K AD - National Cardiothoracic Center, Accra, Ghana. FAU - Reddy, Darshan AU - Reddy D AD - Lenmed Ethekwini Hospital & Heart Center, Durban, South Africa. FAU - Antunes, Manuel AU - Antunes M AD - Cardiothoracic Surgery, University of Coimbra, Portugal. FAU - Gomes, Walter J AU - Gomes WJ AD - Department of Cardiovascular Surgery, Federal University of Sao Paulo, Sao Paulo, Brazil. FAU - Akamah, Joseph A AU - Akamah JA AD - Department of Cardiology, University of Nashville, Nashville, United States. FAU - Yigitbasi, Mustafa AU - Yigitbasi M AD - Pediatric Cardiology Clinic, Berlin, Germany. FAU - Buys, Daniel Gerhard AU - Buys DG AD - Department of Pediatric Cardiology, University of the Free State, Bloemfontein, South Africa. FAU - Bokenkamp, Regina AU - Bokenkamp R AD - Department of Pediatric Cardiology, University Medical Center Leiden, Leiden, Netherlands. FAU - Koen, Willie AU - Koen W AD - Department of Cardiothoracic Surgery, Christiaan Barnard Memorial Hospital, Cardiac, Transplant Program, Cape Town, South Africa. FAU - Smit, Francis E AU - Smit FE AD - Department of Cardiothoracic Surgery, University of the Free State, Bloemfontein, South Africa. FAU - Chikwe, Joanna AU - Chikwe J AD - Department of Cardiac Surgery, Cedars Sinai Medical Center, Smidt Heart Institute, Los Angeles, United States. LA - eng PT - Journal Article PL - Germany TA - Eur J Cardiothorac Surg JT - European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery JID - 8804069 SB - IM MH - Humans MH - Africa MH - *Cardiac Surgical Procedures/economics/education MH - Cost-Benefit Analysis MH - *Thoracic Surgery/economics MH - Cost-Effectiveness Analysis PMC - PMC13016979 OTO - NOTNLM OT - Accra declaration OT - Africa OT - access to cardiac surgery OT - cost effective cardiac surgery OT - global heart forum OT - pan-African society for cardiothoracic surgery OT - structural heart disease EDAT- 2026/02/23 06:27 MHDA- 2026/02/23 06:28 PMCR- 2026/02/23 CRDT- 2026/02/23 01:13 PHST- 2026/02/23 06:28 [medline] PHST- 2026/02/23 06:27 [pubmed] PHST- 2026/02/23 01:13 [entrez] PHST- 2026/02/23 00:00 [pmc-release] AID - 8494506 [pii] AID - ezag036 [pii] AID - 10.1093/ejcts/ezag036 [doi] PST - ppublish SO - Eur J Cardiothorac Surg. 2026 Feb 5;68(2):ezag036. doi: 10.1093/ejcts/ezag036. PMID- 41719569 OWN - NLM STAT- MEDLINE DCOM- 20260708 LR - 20260824 IS - 2184-9927 (Print) IS - 2184-9927 (Linking) VI - 32 IP - 4 DP - 2026 Feb 17 TI - Management of Tricuspid Regurgitation in Patients with Rheumatic Mitral Disease. PG - 33-39 LID - 10.48729/pjctvs.604 [doi] AB - BACKGROUND: Rheumatic heart disease (RHD) remains a major cause of cardiovascular morbidity and mortality in low and middle-income countries, with tricuspid regurgitation (TR) frequently complicating rheumatic mitral pathology. While mild TR often stabilizes after mitral correction, management of moderate and severe TR in this context remains controversial due to limited evidence and applicability of guidelines largely derived from degenerative etiologies. This review synthesizes current data on diagnostic strategies, surgical decision-making, and outcomes in rheumatic TR. METHODS: A comprehensive literature search was performed across PubMed, Google Scholar, and OMNI databases (2010-2024) using the keywords "rheumatic mitral disease," "tricuspid regurgitation," and "management." Eligible studies included clinical trials, case series, reviews, and meta-analyses focusing on TR associated with rheumatic mitral disease. Data was extracted and critically appraised for study design, population, and outcome relevance. RESULTS: Evidence for managing TR in rheumatic mitral disease primarily stems from retrospective cohorts and small prospective studies, with few randomized trials. Predictors of TR progression include annular dilation (>21 mm/m(2)), right ventricular dysfunction, pulmonary hypertension, and atrial fibrillation. Mild TR generally regresses following mitral surgery and is managed conservatively. For moderate TR, concomitant repair may prevent late progression and improve hemodynamics, though risks of postoperative arrhythmia and pacemaker implantation persist. Severe TR warrants surgical correction, preferably rigid ring annuloplasty, while valve replacement is reserved for advanced calcific disease. Emerging transcatheter therapies show promise for high-risk patients but lack robust rheumatic-specific data. CONCLUSION: Optimal management of TR in rheumatic mitral disease requires individualized, Heart Team-based decision-making due to limited high-quality evidence. Future research should prioritize multicenter trials comparing repair, replacement, and transcatheter approaches, integrating advanced imaging for risk stratification and addressing access disparities in resource-limited settings. FAU - Kalasipudi, R AU - Kalasipudi R AUID- ORCID: 0009-0009-3019-7194 AD - Faculty of Medicine, St. George's University, Grenada FAU - Gupta, S AU - Gupta S AUID- ORCID: 0009-0001-3583-5580 AD - Faculty of Health Sciences, Queen's University, Kingston, Ontario, Canada FAU - Meghdadi, A AU - Meghdadi A AUID- ORCID: 0009-0000-6322-3162 AD - Faculty of Health Sciences, Queen's University, Kingston, Ontario, Canada FAU - Gupta, S AU - Gupta S AD - Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada FAU - Abu-Omar, Y AU - Abu-Omar Y AD - Cardiac Surgery Department, University Hospital Cleveland Medical Center, Cleveland, OH, USA FAU - Al-Akhtar, A AU - Al-Akhtar A AUID- ORCID: 0000-0001-8326-3719 AD - Department of Surgery, College of Medicine, Qassim University, Saudi Arabia FAU - El-Diasty, M AU - El-Diasty M AUID- ORCID: 0000-0002-1807-8397 AD - Cardiac Surgery Division, University Hospitals Cleveland Medical Centre, Cleveland, Ohio, USA; Department of Biochemical and Molecular Sciences, Queen's University, Kingston, ON, Canada LA - eng PT - Journal Article PT - Review DEP - 20260217 PL - Portugal TA - Port J Card Thorac Vasc Surg JT - Portuguese journal of cardiac thoracic and vascular surgery JID - 9918249514506676 SB - IM MH - Humans MH - *Rheumatic Heart Disease/complications/surgery MH - *Tricuspid Valve Insufficiency/surgery/etiology/diagnosis MH - *Mitral Valve Insufficiency/surgery/complications MH - Heart Valve Prosthesis Implantation EDAT- 2026/02/20 21:28 MHDA- 2026/02/20 21:29 CRDT- 2026/02/20 17:12 PHST- 2025/11/12 00:00 [received] PHST- 2026/01/08 00:00 [accepted] PHST- 2026/02/20 21:29 [medline] PHST- 2026/02/20 21:28 [pubmed] PHST- 2026/02/20 17:12 [entrez] AID - 10.48729/pjctvs.604 [doi] PST - epublish SO - Port J Card Thorac Vasc Surg. 2026 Feb 17;32(4):33-39. doi: 10.48729/pjctvs.604. PMID- 41717794 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260305 LR - 20260813 IS - 2564-6850 (Print) IS - 2564-7032 (Electronic) IS - 2564-6850 (Linking) VI - 42 IP - 1 DP - 2026 Mar 5 TI - Rare anatomical localizations of hydatid cysts (2020-2025): Narrative review of presentation, imaging, and management. PG - 13-25 LID - 10.47717/turkjsurg.2026.2025-9-22 [doi] AB - Hydatid disease, caused by Echinococcus granulosus, typically affects the liver and lungs. However, cyst development in rare anatomical sites presents unique diagnostic and therapeutic challenges. We conducted a narrative review using a structured search of PubMed, Scopus, and Google Scholar (first 200 records), with predefined eligibility criteria and dual-reviewer screening where applicable. Findings were synthesized narratively; numeric summaries reflect reporting frequency among included case-level reports rather than prevalence or comparative effectiveness. Seventeen studies (case reports/small series) were included. Among the included reports, the most commonly reported rare sites were the brain, bone, and heart. Imaging narratives most frequently supported magnetic resonance imaging triage for central nervous system/spine/cardiac disease and computed tomography for osseous/retroperitoneal involvement, while surgery was most often reported as the index treatment with context-dependent use of albendazole. Percentages in this review reflect the share of reports among included studies (i.e., reporting frequency), not population prevalence, incidence, or comparative effectiveness. Rare-site hydatid cysts require a high index of suspicion in endemic areas. Optimal outcomes are achieved through multidisciplinary evaluation, site-specific surgical planning, and tailored pharmacotherapy. Further research into minimally invasive techniques, molecular diagnostics, and vaccine development is warranted to improve diagnosis and long-term disease control. CI - Copyright(c) 2026 The Author(s). Published by Galenos Publishing House on behalf of Turkish Surgical Society. FAU - Zulfikaroglu, Baris AU - Zulfikaroglu B AUID- ORCID: 0000-0003-4782-0308 AD - Clinic of Surgery, Ankara Bilkent City Hospital, Ankara, Turkiye. FAU - Akgul, Ozgur AU - Akgul O AUID- ORCID: 0000-0002-3762-3987 AD - Clinic of Surgery, Ankara Bilkent City Hospital, Ankara, Turkiye. FAU - Dinc, Tolga AU - Dinc T AUID- ORCID: 0000-0003-3772-7468 AD - Clinic of Surgery, Ankara Bilkent City Hospital, Ankara, Turkiye. LA - eng PT - Journal Article DEP - 20260220 PL - Turkey TA - Turk J Surg JT - Turkish journal of surgery JID - 101704837 PMC - PMC12964094 OTO - NOTNLM OT - Albendazole therapy OT - diagnostic imaging OT - echinococcosis OT - extrahepatic involvement OT - general surgery OT - hydatid cyst OT - narrative review OT - rare anatomical localization COIS- No conflict of interest was declared by the authors. One of the authors of this article (O.A.) is a member of the Editorial Board of this journal. He was completely blinded to the peer review process of the article. EDAT- 2026/02/20 07:05 MHDA- 2026/02/20 07:06 PMCR- 2026/03/05 CRDT- 2026/02/20 05:50 PHST- 2026/02/20 07:06 [medline] PHST- 2026/02/20 07:05 [pubmed] PHST- 2026/02/20 05:50 [entrez] PHST- 2026/03/05 00:00 [pmc-release] AID - 10.47717/turkjsurg.2026.2025-9-22 [doi] PST - ppublish SO - Turk J Surg. 2026 Mar 5;42(1):13-25. doi: 10.47717/turkjsurg.2026.2025-9-22. Epub 2026 Feb 20. PMID- 41716933 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260220 LR - 20260813 IS - 2634-3916 (Electronic) IS - 2634-3916 (Linking) VI - 7 IP - 2 DP - 2026 Mar TI - Understanding the mechanisms of TAVI durability through computational modelling: a multidisciplinary review. PG - ztag020 LID - 10.1093/ehjdh/ztag020 [doi] LID - ztag020 AB - As transcatheter aortic valve implantation (TAVI) expands to younger populations, durability has become a concern, requiring a lifetime rather than a single-procedure perspective. While clinical trials suggest comparable mid-term performance to surgical bioprostheses, data beyond 10 years remain limited, particularly for bicuspid valves, valve-in-valve procedures, and complex anatomies. Computational modelling combines patient anatomy and device design in computer-based simulations to study valve performance under physiological loading. Applied to TAVI, these models can reproduce implantation, evaluate mechanical stresses, and simulate blood flow, providing mechanistic insights into deterioration processes, including altered leaflet loading, stent deformation, and thrombosis-prone flow. Although these simulations do not directly assess durability, they use surrogate metrics linked with these mechanisms, helping identify factors that may influence longevity and guide design and procedural refinements. Clinically, modelling could support patient-specific planning and reintervention strategies, informing decisions across the valve-replacement pathway, an important consideration as younger patients are likely to undergo multiple lifetime procedures. Integrating these tools into pre-procedural planning may help anticipate challenges such as coronary access, annular geometry, and redo feasibility. However, current studies report elements of verification and field-level validation, but none complete a pre-specified, calibrated surrogate-to-outcome validation with uncertainty/sensitivity analysis; thus, durability predictions remain exploratory. Progress needs transparent verification, field checks vs. bench or imaging, surrogate calibration to data, outcome testing in independent cohorts, and routine uncertainty/sensitivity reporting, with close clinician-engineer collaboration. This review underscores the need for a multidisciplinary approach and provides a critical analysis of the available tools and their potential to advance long-term outcomes. CI - (c) The Author(s) 2026. Published by Oxford University Press on behalf of the European Society of Cardiology. FAU - Rauseo, Elisa AU - Rauseo E AUID- ORCID: 0000-0002-7009-3447 AD - William Harvey Research Institute, NIHR Barts Biomedical Research Centre, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK. AD - Barts Heart Centre, Barts Health NHS Trust, W. Smithfield, London EC1A 7BE, UK. AD - Digital Environment Research Institute, Queen Mary University of London, 67-75 New Rd, London E1 1HH, UK. FAU - Bevis, Laura AU - Bevis L AD - Digital Environment Research Institute, Queen Mary University of London, 67-75 New Rd, London E1 1HH, UK. AD - School of Engineering and Materials Science, Queen Mary University of London, Mile End Road, London E1 4NS, UK. FAU - Chen, Xu AU - Chen X AD - Digital Environment Research Institute, Queen Mary University of London, 67-75 New Rd, London E1 1HH, UK. AD - Department of Medicine, University of Cambridge, Cambridge, UK. FAU - Petersen, Steffen E AU - Petersen SE AD - William Harvey Research Institute, NIHR Barts Biomedical Research Centre, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK. AD - Barts Heart Centre, Barts Health NHS Trust, W. Smithfield, London EC1A 7BE, UK. AD - NIHR Barts Biomedical Research Centre, Queen Mary University of London, Charterhouse Square, London, UK. FAU - Mathur, Anthony AU - Mathur A AUID- ORCID: 0000-0001-7941-9653 AD - Barts Heart Centre, Barts Health NHS Trust, W. Smithfield, London EC1A 7BE, UK. AD - NIHR Barts Biomedical Research Centre, Queen Mary University of London, Charterhouse Square, London, UK. AD - Centre for Cardiovascular Medicine and Devices, William Harvey Research Institute, Queen Mary University of London, London, UK. FAU - Slabaugh, Gregory G AU - Slabaugh GG AD - Digital Environment Research Institute, Queen Mary University of London, 67-75 New Rd, London E1 1HH, UK. FAU - Roney, Caroline H AU - Roney CH AUID- ORCID: 0000-0001-6809-0928 AD - Digital Environment Research Institute, Queen Mary University of London, 67-75 New Rd, London E1 1HH, UK. AD - School of Engineering and Materials Science, Queen Mary University of London, Mile End Road, London E1 4NS, UK. LA - eng PT - Journal Article PT - Review DEP - 20260203 PL - England TA - Eur Heart J Digit Health JT - European heart journal. Digital health JID - 101778323 PMC - PMC12912916 OTO - NOTNLM OT - Computational modelling OT - Durability OT - Simulations OT - Structural valve degeneration OT - Thrombosis OT - Transcatheter aortic valve implantation COIS- Conflict of interest: S.E.P. provides consultancy to Circle Cardiovascular Imaging, Inc., Calgary, Alberta, Canada. A.M. has received honoraria and travel bursary from Abbott and has UK Patent Application No. 2411474.6: 'Medical Support Method' describing a pipeline for TAVR digital twin simulation. G.G.S. serves on the Scientific Advisory Board to BioAI Heath, Boston, USA. The remaining authors have nothing to disclose. EDAT- 2026/02/20 07:05 MHDA- 2026/02/20 07:06 PMCR- 2026/02/03 CRDT- 2026/02/20 04:52 PHST- 2025/07/17 00:00 [received] PHST- 2025/11/19 00:00 [revised] PHST- 2026/01/07 00:00 [accepted] PHST- 2026/02/20 07:06 [medline] PHST- 2026/02/20 07:05 [pubmed] PHST- 2026/02/20 04:52 [entrez] PHST- 2026/02/03 00:00 [pmc-release] AID - ztag020 [pii] AID - 10.1093/ehjdh/ztag020 [doi] PST - epublish SO - Eur Heart J Digit Health. 2026 Feb 3;7(2):ztag020. doi: 10.1093/ehjdh/ztag020. eCollection 2026 Mar. PMID- 41716720 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260220 LR - 20260926 IS - 2352-9067 (Print) IS - 2352-9067 (Electronic) IS - 2352-9067 (Linking) VI - 63 DP - 2026 Apr TI - The impact of pullback measurement on treatment decision in significant coronary artery disease: Insights from a retrospective multicentric study. PG - 101887 LID - 10.1016/j.ijcha.2026.101887 [doi] LID - 101887 AB - BACKGROUND: Optimal management of coronary artery disease (CAD) requires tailoring treatment strategies to lesion characteristics. Intracoronary pullback enables hemodynamic mapping of coronary lesions, potentially improving therapeutic decision-making, particularly in distinguishing focal from diffuse disease. OBJECTIVES: To evaluate how pullback measurement influences overall treatment strategy-optimal medical therapy (OMT), percutaneous coronary intervention (PCI), or coronary artery bypass grafting (CABG)-in patients with significant CAD. METHODS: We conducted a retrospective, multicenter cohort study including 842 patients with stable angina, unstable angina, or non-ST-elevation myocardial infarction (NSTEMI) and functionally significant left anterior descending artery (LAD) disease. Patients were stratified into two groups: one group (PB group, n = 561) had pullback measurement, and the other (Conventional group, n = 281) not. Outcomes included treatment strategy, major adverse cardiovascular events (MACE), and all-cause mortality at 1 year. RESULTS: Pullback led to more Heart Team discussions (66.3% vs. 58.7%; p = 0.033), greater adoption of OMT (51.5% vs. 40.9%; p = 0.004), and lower PCI rates (27.1% vs. 36.3%; p = 0.007). CABG rates remained unaffected. Pullback independently increased the odds of OMT and reduced the odds of PCI (OR = 0.58, p = 0.003), while three-vessel disease strongly predicted CABG (OR = 2.51; p < 0.001). At 1 year, the PB group had higher mortality (4.3% vs. 1.1%, p = 0.013), but similar MACE compared to the Conventional group. However, clinical outcomes did not differ between treatment groups. CONCLUSIONS: Intracoronary pullback favours a conservative treatment strategy. MACE rates are not increased at 1 year. CI - (c) 2026 The Author(s). FAU - Bova, Roberto AU - Bova R AD - Department of Cardiology, Maastricht University Medical Centre+, Maastricht, The Netherlands. AD - Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands. FAU - Betti, Matteo AU - Betti M AD - Department of Cardiology, Maastricht University Medical Centre+, Maastricht, The Netherlands. AD - Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands. AD - Department of Clinical Sciences and Community Health, Cardiovascular Section, University of Milan, Milan, Italy. FAU - Heuts, Samuel AU - Heuts S AD - Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands. AD - Department of Cardiothoracic surgery, Maastricht University Medical Centre+, Maastricht, The Netherlands. FAU - Vriesendorp, Pieter A AU - Vriesendorp PA AD - Department of Cardiology, Maastricht University Medical Centre+, Maastricht, The Netherlands. AD - Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands. FAU - Ijsselmuiden, Alexander J J AU - Ijsselmuiden AJJ AD - Department of Cardiology, Maastricht University Medical Centre+, Maastricht, The Netherlands. AD - Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands. AD - Department of Cardiology, Zuyderland Medical Center, Heerlen, The Netherlands. FAU - Rasoul, Saman AU - Rasoul S AD - Department of Cardiology, Maastricht University Medical Centre+, Maastricht, The Netherlands. AD - Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands. AD - Department of Cardiology, Zuyderland Medical Center, Heerlen, The Netherlands. FAU - Ilhan, Mustafa AU - Ilhan M AD - Department of Cardiology, Maastricht University Medical Centre+, Maastricht, The Netherlands. AD - Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands. AD - Department of Cardiology, Zuyderland Medical Center, Heerlen, The Netherlands. FAU - Vainer, Jindra AU - Vainer J AD - Department of Cardiology, Maastricht University Medical Centre+, Maastricht, The Netherlands. AD - Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands. FAU - Theunissen, Ralph A L J AU - Theunissen RALJ AD - Department of Cardiology, Maastricht University Medical Centre+, Maastricht, The Netherlands. AD - Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands. FAU - Veenstra, Leo F AU - Veenstra LF AD - Department of Cardiology, Maastricht University Medical Centre+, Maastricht, The Netherlands. AD - Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands. AD - Department of Cardiology, Zuyderland Medical Center, Heerlen, The Netherlands. FAU - Winkler, Patty AU - Winkler P AD - Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands. AD - Department of Cardiology, Zuyderland Medical Center, Heerlen, The Netherlands. FAU - Stein, Mera AU - Stein M AD - Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands. AD - Department of Cardiology, Zuyderland Medical Center, Heerlen, The Netherlands. FAU - Ruiters, Alexander AU - Ruiters A AD - Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands. AD - Department of Cardiology, Zuyderland Medical Center, Heerlen, The Netherlands. FAU - Slegers, Daniek P J AU - Slegers DPJ AD - Department of Cardiology, Maastricht University Medical Centre+, Maastricht, The Netherlands. AD - Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands. FAU - van 't Hof, Arnoud W J AU - van 't Hof AWJ AD - Department of Cardiology, Maastricht University Medical Centre+, Maastricht, The Netherlands. AD - Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands. FAU - Lux, Arpad AU - Lux A AD - Department of Cardiology, Maastricht University Medical Centre+, Maastricht, The Netherlands. AD - Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands. LA - eng PT - Journal Article DEP - 20260210 PL - Ireland TA - Int J Cardiol Heart Vasc JT - International journal of cardiology. Heart & vasculature JID - 101649525 PMC - PMC12914282 OTO - NOTNLM OT - Coronary physiology OT - Optimal medical therapy OT - Pullback OT - Revascularization COIS- The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/02/20 07:04 MHDA- 2026/02/20 07:05 PMCR- 2026/02/10 CRDT- 2026/02/20 04:49 PHST- 2025/10/15 00:00 [received] PHST- 2026/01/27 00:00 [revised] PHST- 2026/02/05 00:00 [accepted] PHST- 2026/02/20 07:05 [medline] PHST- 2026/02/20 07:04 [pubmed] PHST- 2026/02/20 04:49 [entrez] PHST- 2026/02/10 00:00 [pmc-release] AID - S2352-9067(26)00021-7 [pii] AID - 101887 [pii] AID - 10.1016/j.ijcha.2026.101887 [doi] PST - epublish SO - Int J Cardiol Heart Vasc. 2026 Feb 10;63:101887. doi: 10.1016/j.ijcha.2026.101887. eCollection 2026 Apr. PMID- 41714558 OWN - NLM STAT- MEDLINE DCOM- 20260708 LR - 20260813 IS - 1534-3111 (Electronic) IS - 1522-6417 (Print) IS - 1522-6417 (Linking) VI - 28 IP - 1 DP - 2026 Feb 20 TI - Bridging the Gap in Racial/Ethnic Disparities: Perspectives from the 2025 American Heart Association/American College of Cardiology High Blood Pressure Guideline. PG - 13 LID - 10.1007/s11906-026-01367-6 [doi] LID - 13 AB - PURPOSE OF REVIEW: High blood pressure is a leading cause of cardiovascular disease (CVD) morbidity and mortality worldwide, disproportionately affecting racial/ethnic populations in the United States (US). This review summarizes racial/ethnic inequities in CVD risk, hypertension (HTN), and the social determinants or drivers of health (SDOH), highlighting the 2025 American Heart Association/American College of Cardiology (AHA/ACC) High Blood Pressure Guideline. RECENT FINDINGS: Certain US racial/ethnic populations experience disproportionate HTN burden, with Black adults demonstrating higher rates of resistant, nocturnal and masked HTN, hypertensive disorders of pregnancy, and dementia and cognitive decline. The 2025 AHA/ACC High Blood Pressure Guideline emphasizes the use of a novel race-neutral CVD risk calculator to guide initiation of pharmacotherapy, utilizing patient counseling and shared decision-making, alongside team-based, community-engaged HTN management strategies. The 2025 AHA/ACC High Blood Pressure Guideline advances health equity, integrating the SDOH into improved CVD risk assessment and management recommendations. Effective mitigation of disparities to improve blood pressure and CVD outcomes demands optimizing healthcare access, addressing systemic discrimination, incorporating social context into shared clinical-decision making, and deploying culturally-tailored, community-based interventions. CI - (c) 2026. The Author(s). FAU - Reddy, Tina K AU - Reddy TK AD - Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. FAU - Ancha, Bhavya AU - Ancha B AD - Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. FAU - Grant, Jelani K AU - Grant JK AD - Division of Cardiology, Department of Medicine, Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins School of Medicine, Baltimore, MD, USA. FAU - Ferdinand, Keith C AU - Ferdinand KC AD - Section of Cardiology, John W. Deming Department of Medicine, Tulane University School of Medicine, 1430 Tulane Ave, New Orleans, LA, 70112, USA. kferdina@tulane.edu. LA - eng PT - Journal Article PT - Review DEP - 20260220 PL - United States TA - Curr Hypertens Rep JT - Current hypertension reports JID - 100888982 SB - IM MH - Humans MH - American Heart Association MH - Cardiovascular Diseases MH - *Ethnicity MH - *Health Status Disparities MH - *Hypertension/ethnology MH - Practice Guidelines as Topic MH - Social Determinants of Health MH - United States/epidemiology MH - Black or African American PMC - PMC12920378 OTO - NOTNLM OT - AHA/ACC high blood pressure guideline OT - Blood pressure OT - Hypertension OT - Racial/ethnic disparities OT - Social determinants of health COIS- Declarations. Ethical Statement: No patient data or information was used when drafting this manuscript. Competing interests: The authors declare no competing interests. EDAT- 2026/02/20 00:32 MHDA- 2026/02/20 00:33 PMCR- 2026/02/20 CRDT- 2026/02/19 23:22 PHST- 2025/11/25 00:00 [received] PHST- 2026/02/02 00:00 [accepted] PHST- 2026/02/20 00:33 [medline] PHST- 2026/02/20 00:32 [pubmed] PHST- 2026/02/19 23:22 [entrez] PHST- 2026/02/20 00:00 [pmc-release] AID - 10.1007/s11906-026-01367-6 [pii] AID - 1367 [pii] AID - 10.1007/s11906-026-01367-6 [doi] PST - epublish SO - Curr Hypertens Rep. 2026 Feb 20;28(1):13. doi: 10.1007/s11906-026-01367-6. PMID- 41714343 OWN - NLM STAT- MEDLINE DCOM- 20260708 LR - 20260813 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 16 IP - 1 DP - 2026 Feb 19 TI - Coronary artery bypass grafting versus percutaneous coronary intervention for patients with multivessel coronary artery disease and advanced heart failure. LID - 10.1038/s41598-026-40168-4 [doi] LID - 9963 AB - Coronary artery disease (CAD) is a leading cause of heart failure (HF), including HF with severely reduced left ventricular ejection fraction (LVEF 8% predicted). CONCLUSIONS: Most contemporary patients 75years, with 2-4% presenting severe disease; nearly half of them are asymptomatic. No medical therapy halts aortic stenosis progression, and aortic valve replacement remains the only curative option. Managing asymptomatic patients is challenging because of a persistent risk of sudden death, and the potential for irreversible myocardial damage if intervention is delayed, but also because aortic valve replacement carries procedural risks and long-term prosthesis-related complications. Functional assessment, especially exercise testing, is essential as it can identify a substantial proportion of "falsely asymptomatic" patients who will benefit from timely aortic valve replacement. Accurate assessment of aortic stenosis severity is crucial, with echocardiography as the cornerstone, although additional imaging modalities may be required in selected cases. Modern risk stratification integrates markers of subclinical myocardial dysfunction, haemodynamic compromise and procedural risk. Although observational studies and randomized trials suggest that early aortic valve replacement may reduce adverse events in selected low-risk patients, results are heterogeneous and methodological concerns remain. Meta-analyses have shown reductions in unplanned hospitalizations but no clear survival benefit with early intervention. Current guidelines recommend aortic valve replacement for classical indications, such as symptom onset or reduced ejection fraction, and suggest early aortic valve replacement only in carefully selected asymptomatic patients with low procedural risk. Shared decision-making within a multidisciplinary heart valve team remains essential, taking into account patient preferences, co-morbidities, life expectancy and lifestyle. Close follow-up with regular echocardiography and functional testing is critical to optimize timing and outcomes. CI - Copyright (c) 2025 The Authors. Published by Elsevier Masson SAS.. All rights reserved. FAU - Tribouilloy, Christophe AU - Tribouilloy C AD - Department of Cardiology, Amiens University Hospital, 80054 Amiens, France; UR UPJV 7517, Jules-Verne University of Picardie, 80054 Amiens, France. Electronic address: tribouilloy.christophe@chu-amiens.fr. FAU - Bohbot, Yohann AU - Bohbot Y AD - Department of Cardiology, Amiens University Hospital, 80054 Amiens, France; UR UPJV 7517, Jules-Verne University of Picardie, 80054 Amiens, France. FAU - Rusinaru, Dan AU - Rusinaru D AD - Department of Cardiology, Amiens University Hospital, 80054 Amiens, France; UR UPJV 7517, Jules-Verne University of Picardie, 80054 Amiens, France. FAU - Leborgne, Laurent AU - Leborgne L AD - Department of Cardiology, Amiens University Hospital, 80054 Amiens, France; UR UPJV 7517, Jules-Verne University of Picardie, 80054 Amiens, France. FAU - Marechaux, Sylvestre AU - Marechaux S AD - Heart Valve Centre, Cardiology Department, GCS-Groupement des Hopitaux de l'Institut Catholique de Lille/Lille Catholic Hospitals, 59130 Lille, France; ETHICS EA 7446, DataCoeur, Lille Catholic University, 59000 Lille, France. LA - eng PT - Journal Article PT - Review DEP - 20260115 PL - Netherlands TA - Arch Cardiovasc Dis JT - Archives of cardiovascular diseases JID - 101465655 SB - IM MH - Humans MH - *Aortic Valve Stenosis/physiopathology/surgery/diagnostic imaging/mortality/therapy MH - Asymptomatic Diseases MH - Risk Factors MH - *Heart Valve Prosthesis Implantation/adverse effects/mortality/instrumentation MH - Treatment Outcome MH - Severity of Illness Index MH - *Aortic Valve/physiopathology/surgery/diagnostic imaging MH - Predictive Value of Tests MH - Risk Assessment MH - Time Factors MH - Patient Selection MH - Hemodynamics MH - Clinical Decision-Making MH - Aged OTO - NOTNLM OT - Asymptomatic severe aortic stenosis OT - Early aortic valve replacement OT - Functional testing OT - Outcomes OT - Randomized controlled trials COIS- Disclosure of interest The authors declare that they have no competing interest. EDAT- 2026/02/17 00:53 MHDA- 2026/02/17 00:54 CRDT- 2026/02/16 20:54 PHST- 2025/08/29 00:00 [received] PHST- 2025/09/26 00:00 [revised] PHST- 2025/10/14 00:00 [accepted] PHST- 2026/02/17 00:54 [medline] PHST- 2026/02/17 00:53 [pubmed] PHST- 2026/02/16 20:54 [entrez] AID - S1875-2136(25)00803-4 [pii] AID - 10.1016/j.acvd.2025.10.325 [doi] PST - ppublish SO - Arch Cardiovasc Dis. 2026 Jan;119(1):39-49. doi: 10.1016/j.acvd.2025.10.325. Epub 2026 Jan 15. PMID- 41698403 OWN - NLM STAT- Publisher LR - 20260216 IS - 1439-1902 (Electronic) IS - 0171-6425 (Linking) DP - 2026 Feb 16 TI - Endocarditis Through the Ages-What Has Changed During the Past Two Decades. LID - 10.1055/a-2797-9999 [doi] AB - Despite developments in the past 20 years in the treatment of native valve (NVE) endocarditis, including the multidisciplinary endocarditis team approach and advances in perioperative care, outcome improvements are lacking. This study compares a contemporary with a historic cohort of NVE patients.All patients undergoing first-time cardiac surgery for NVE in two periods were evaluated in a retrospective observational single-center trial. The historic period included patients from 1998 to 2003 and the contemporary cohort 2021 to 2024.Of the 359 patients who were included, 155 were in the historic cohort (years 1998-2003) and 204 in the contemporary (years 2021-2024). The annual caseload increased significantly from 25.8 to 51.0 annual cases (p < 0.01). Patient baselines changed, being nowadays older (62.6 vs. 55.5 years, p < 0.001), having higher BMI (26.9 kg/m(2) vs. 25.3 kg/m(2), p < 0.01) and higher EuroSCORE II (8.7% vs. 5.0%, p < 0.001). Accordingly, the preoperative clinical presentation also worsened with an increase in septic embolizations (33.8% vs. 22.6%, p = 0.04) and acute kidney injury (15.2% vs. 1.9%, p < 0.001). Minimally invasive procedures were newly established (41.2% vs. 0%). The contemporary group faced a higher rate of postoperative dialysis, longer intensive care unit stay, and higher perioperative mortality (14.2% vs. 6.5%, p = 0.03). Nonetheless, survival at 1 year was comparable (78.4% vs. 79.9, p = 0.52).Contemporary patients have higher risk profiles and annual caseloads. This translates into increased postoperative morbidity and mortality; however long-term outcomes have remained constant. CI - Thieme. All rights reserved. FAU - Petrov, Asen AU - Petrov A AUID- ORCID: 0000-0002-6827-2489 AD - Department of Cardiac Surgery, Heart Centre Dresden University Hospital of the University of Technology Dresden, Dresden, SN, Germany. FAU - Schone, Pascal AU - Schone P AD - Department of Cardiac Surgery, Heart Centre Dresden University Hospital of the University of Technology Dresden, Dresden, SN, Germany. FAU - Taghizadeh-Waghefi, Ali AU - Taghizadeh-Waghefi A AD - Department of Cardiac Surgery, Heart Centre Dresden University Hospital of the University of Technology Dresden, Dresden, SN, Germany. FAU - Tugtekin, Sems-Malte AU - Tugtekin SM AD - Department of Cardiac Surgery, Heart Centre Dresden University Hospital of the University of Technology Dresden, Dresden, SN, Germany. FAU - Matschke, Klaus Ehrhard AU - Matschke KE AD - Department of Cardiac Surgery, Heart Centre Dresden University Hospital of the University of Technology Dresden, Dresden, SN, Germany. FAU - Wilbring, Manuel AU - Wilbring M AD - Department of Cardiac Surgery, Heart Centre Dresden University Hospital of the University of Technology Dresden, Dresden, SN, Germany. LA - eng PT - Journal Article DEP - 20260216 PL - Germany TA - Thorac Cardiovasc Surg JT - The Thoracic and cardiovascular surgeon JID - 7903387 SB - IM COIS- The authors declare that they have no conflict of interest. EDAT- 2026/02/17 00:53 MHDA- 2026/02/17 00:53 CRDT- 2026/02/16 19:13 PHST- 2026/02/17 00:53 [medline] PHST- 2026/02/17 00:53 [pubmed] PHST- 2026/02/16 19:13 [entrez] AID - 10.1055/a-2797-9999 [doi] PST - aheadofprint SO - Thorac Cardiovasc Surg. 2026 Feb 16. doi: 10.1055/a-2797-9999. PMID- 41697012 OWN - NLM STAT- MEDLINE DCOM- 20260707 LR - 20260930 IS - 1897-4279 (Electronic) IS - 0022-9032 (Linking) VI - 84 IP - 3 DP - 2026 TI - Balancing risk and innovation: Comparative clinical outcomes of sutureless versus transcatheter aortic valve replacement in Heart Team practice. PG - 336-344 LID - 10.33963/v.phj.111015 [doi] AB - BACKGROUND: Sutureless aortic valve replacement (SU-AVR) and transcatheter aortic valve implantation (TAVI) have expanded treatment options for severe aortic stenosis, but comparative real-world data remain limited. AIMS: We aimed to compare early and up to 6-month clinical and hemodynamic outcomes of SU-AVR versus transfemoral TAVI. METHODS: All consecutive patients undergoing SU-AVR (n = 53) or TAVI (n = 245) between 2014 and 2023 were retrospectively analyzed. Propensity score matching (1:1 nearest neighbor, no replacement) generated 53 balanced pairs. RESULTS: Paravalvular leak was more frequent after TAVI and was driven by mild leaks (40.0% vs. 13.3%; P = 0.019), while moderate-to-severe paravalvular leak was low and comparable (6.7% vs. 3.3%; P = 0.646). TAVI demonstrated lower transvalvular gradients compared to SU-AVR (P = 0.004); other 6-month echocardiographic parameters, including left ventricular ejection fraction and pulmonary artery pressure, were comparable. Permanent pacemaker implantation rates were comparable. Early mortality did not differ between the SU-AVR and TAVI groups (13.5% vs. 5.7%; P = 0.173). TAVI was associated with shorter hospitalization (median 5.2, interquartile range 3.7-7.3 vs. 8.7, interquartile range 6.3-11.9 days; P <0.001). CONCLUSIONS: In selected high-risk patients, SU-AVR and TAVI showed complementary early profiles. Individualized Heart Team-based decision-making remains essential. FAU - Bayici, Bedirhan Bugra AU - Bayici BB AD - Department of Cardiovascular Surgery, Kosuyolu High Specialization Training and Research Hospital, Istanbul, Turkey. bedirhanbugra@gmail.com. FAU - Kizilyel, Fatih AU - Kizilyel F AD - Department of Cardiovascular Surgery, Kosuyolu High Specialization Training and Research Hospital, Istanbul, Turkey. FAU - Albeyoglu, Sebnem AU - Albeyoglu S AD - Department of Cardiovascular Surgery, Dr Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital, Istanbul, Turkey. LA - eng PT - Comparative Study PT - Journal Article DEP - 20260216 PL - Poland TA - Kardiol Pol JT - Kardiologia polska JID - 0376352 SB - IM MH - Humans MH - *Transcatheter Aortic Valve Replacement/methods/adverse effects MH - Female MH - Male MH - Retrospective Studies MH - Aged, 80 and over MH - *Aortic Valve Stenosis/surgery MH - Treatment Outcome MH - Aged MH - *Sutureless Surgical Procedures OTO - NOTNLM OT - aortic stenosis OT - aortic valve replacement OT - heart valve prosthesis OT - propensity score matching OT - transcatheter aortic valve replacement EDAT- 2026/02/16 12:31 MHDA- 2026/04/29 06:36 CRDT- 2026/02/16 08:53 PHST- 2026/02/02 00:00 [received] PHST- 2026/02/03 00:00 [accepted] PHST- 2026/04/29 06:36 [medline] PHST- 2026/02/16 12:31 [pubmed] PHST- 2026/02/16 08:53 [entrez] AID - VM/OJS/J/111015 [pii] AID - 10.33963/v.phj.111015 [doi] PST - ppublish SO - Kardiol Pol. 2026;84(3):336-344. doi: 10.33963/v.phj.111015. Epub 2026 Feb 16. PMID- 41694622 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260216 LR - 20260926 IS - 2090-8016 (Print) IS - 2090-0597 (Electronic) IS - 2090-0597 (Linking) VI - 2026 DP - 2026 TI - The Association of Peak Glycemia and No-Reflow Phenomenon in Patients Undergoing Primary Percutaneous Coronary Intervention. PG - 9919861 LID - 10.1155/crp/9919861 [doi] LID - 9919861 AB - OBJECTIVE: This study investigates the effect of peak glycemia on the no-reflow phenomenon in patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI) to examine the relationship between elevated blood glucose (BG) levels and no-reflow. METHOD: A total of 252 STEMI patients (81.7% male) who underwent PPCI were enrolled. BG was measured by a glucometer every 6 h for 24 h, starting at the time of patient admission. The maximum measured BG was considered the peak glycemic level. A corrected TIMI frame count (CTFC) of less than 27 was used to define the no-reflow phenomenon in this study. RESULTS: 42.4% of participants experienced no flow, with a significant association between this condition and diabetes mellitus, peak glycemia, smoking history, and elevated LDL cholesterol levels. Specifically, peak glycemia levels above 180 mg/dL independently increased the odds of no-reflow occurrence (OR = 8.16, 95% CI = 4.1-16.2, p < 0.001). CONCLUSION: The importance of monitoring BG levels in STEMI patients, as well as the critical role of a multidisciplinary approach, regardless of diabetic status, in mitigating the risk of no-reflow and improving clinical outcomes, should be highlighted. CI - Copyright (c) 2026 Golrokh Ghaffari et al. Cardiology Research and Practice published by John Wiley & Sons Ltd. FAU - Ghaffari, Golrokh AU - Ghaffari G AD - Cardiology Department, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran, tums.ac.ir. FAU - Mehrpooya, Maryam AU - Mehrpooya M AD - Cardiology Department, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran, tums.ac.ir. FAU - Faghihinia, Mohsen AU - Faghihinia M AUID- ORCID: 0009-0004-3873-5325 AD - Cardiology Department, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran, tums.ac.ir. FAU - Shahmohamadi, Elnaz AU - Shahmohamadi E AD - Center for Heart Rhythm Disorders, University of Adelaide, Adelaide, Australia, adelaide.edu.au. FAU - Larti, Farnoosh AU - Larti F AUID- ORCID: 0000-0001-7939-9306 AD - Cardiology Department, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran, tums.ac.ir. FAU - Geraiely, Babak AU - Geraiely B AUID- ORCID: 0009-0005-7466-0807 AD - Cardiology Department, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran, tums.ac.ir. LA - eng PT - Journal Article DEP - 20260213 PL - United States TA - Cardiol Res Pract JT - Cardiology research and practice JID - 101516542 PMC - PMC12905458 OTO - NOTNLM OT - ST-elevation myocardial infarction OT - SYNTAX score OT - clinical outcomes OT - no-reflow phenomenon OT - peak glycemia OT - primary percutaneous coronary intervention COIS- The authors declare no conflicts of interest. EDAT- 2026/02/16 12:30 MHDA- 2026/02/16 12:31 PMCR- 2026/02/13 CRDT- 2026/02/16 06:43 PHST- 2025/01/12 00:00 [received] PHST- 2025/12/28 00:00 [revised] PHST- 2026/01/21 00:00 [accepted] PHST- 2026/02/16 12:31 [medline] PHST- 2026/02/16 12:30 [pubmed] PHST- 2026/02/16 06:43 [entrez] PHST- 2026/02/13 00:00 [pmc-release] AID - CRP9919861 [pii] AID - 10.1155/crp/9919861 [doi] PST - epublish SO - Cardiol Res Pract. 2026 Feb 13;2026:9919861. doi: 10.1155/crp/9919861. eCollection 2026. PMID- 41692165 OWN - NLM STAT- MEDLINE DCOM- 20260707 LR - 20260707 IS - 1615-5947 (Electronic) IS - 0890-5096 (Linking) VI - 127 DP - 2026 Jun TI - Results from an Expert-Based Cross-Sectional National Survey on Antithrombotic TREATment After PEDiatric Peripheral Vascular Injuries. (The TREAT-PED-PVI Survey). PG - 187-194 LID - S0890-5096(26)00093-2 [pii] LID - 10.1016/j.avsg.2026.01.044 [doi] AB - PURPOSE: We aimed to survey the contemporary approaches on antithrombotic drugs after major pediatric peripheral vascular injuries. METHODS: Using a web-based questionnaire, we engaged physicians involved in the surgical and medical treatment of pediatric peripheral vascular injury. The survey included 24 multiple-choice questions: 7 related to the baseline demographics of panelists, 10 related to the choice of antithrombotic treatment modalities according to different clinical scenarios, 3 related to safety and hemorrhagic complications, and 4 related to follow-up considerations. RESULTS: Of the 50 physicians invited, 35 (70%) gave their availability: 27 (77.1%) were vascular surgeons, 7 (20.0%) angiologists/cardiologists, and 1 (2.9%) pediatric specialist. The vascular surgeon oversaw the drug regimen choice in 28 (80.0%) institutions. Aspirin was the most frequently used antithrombotic agent in end-to-end anastomosis (n = 25, 71.4%) and interposition vein (n = 23, 65.7%) or prosthetic (n = 25, 71.4%) grafts. Aspirin was associated with low-weight molecular heparin either in end-to-end anastomosis or interposition vein graft (28.6%, both), with anticoagulants in interposition prosthetic graft (48.6%). The most frequent (42.0%) duration of treatment was 1 to 6 months. Only a minority (n = 9, 25.7%) used an integrated monitoring coagulation protocol. Bleeding disorders were not experienced by most (n = 29, 82.9%). CONCLUSION: Aspirin and low-weight molecular heparin are the most frequently used drug regimens after major pediatric vascular traumas, most frequently used in association. A multidisciplinary team evaluation is frequently adopted, but the vascular surgeon plays a major role in selecting the antithrombotic regimen. CI - Copyright (c) 2026 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Piffaretti, Gabriele AU - Piffaretti G AD - Faculty of Medicine and Surgery, Vascular Surgery and Department of Medicine and Surgery, University of Insubria, Varese, Italy. Electronic address: gabriele.piffaretti@uninsubria.it. FAU - D'Oria, Mario AU - D'Oria M AD - Vascular and Endovascular Surgery - Department of Medical Surgical and Health Sciences, University of Trieste, Trieste, Italy. FAU - Donadini, Marco Paolo AU - Donadini MP AD - Research Center on Thromboembolic Disorders and Antithrombotic Therapies, Department of Medicine and Surgery, University of Insubria Faculty of Medicine and Surgery; Varese, Italy. FAU - Lepidi, Sandro AU - Lepidi S AD - Vascular and Endovascular Surgery - Department of Medical Surgical and Health Sciences, University of Trieste, Trieste, Italy. CN - TREAT-PED-PVI Study Group LA - eng PT - Journal Article DEP - 20260213 PL - Netherlands TA - Ann Vasc Surg JT - Annals of vascular surgery JID - 8703941 RN - 0 (Fibrinolytic Agents) RN - R16CO5Y76E (Aspirin) RN - 0 (Anticoagulants) SB - IM MH - Humans MH - *Fibrinolytic Agents/adverse effects/therapeutic use/administration & dosage MH - Cross-Sectional Studies MH - *Vascular System Injuries/surgery/diagnosis/diagnostic imaging/drug therapy MH - *Practice Patterns, Physicians'/trends MH - Health Care Surveys MH - Child MH - Treatment Outcome MH - Risk Factors MH - *Blood Vessel Prosthesis Implantation/adverse effects/trends MH - Aspirin/adverse effects MH - *Vascular Surgical Procedures/adverse effects MH - Male MH - Time Factors MH - *Anticoagulants/adverse effects FIR - Freyrie, Antonio IR - Freyrie A FIR - Angiletta, Domenico IR - Angiletta D FIR - Zaca, Sergio IR - Zaca S FIR - Kahlberg, Andrea IR - Kahlberg A FIR - Sirignano, Pasqualino IR - Sirignano P FIR - Bertoglio, Luca IR - Bertoglio L FIR - Banov, Laura IR - Banov L FIR - Spiezia, Luca IR - Spiezia L FIR - Camporese, Giuseppe IR - Camporese G FIR - Veraldi, Gian Franco IR - Veraldi GF FIR - Troisi, Nicola IR - Troisi N FIR - Ageno, Walter IR - Ageno W FIR - Tshomba, Yamume IR - Tshomba Y FIR - Mansour, Wassim IR - Mansour W FIR - Martini, Romeo IR - Martini R FIR - Pecoraro, Felice IR - Pecoraro F FIR - Antonello, Michele IR - Antonello M FIR - Piazza, Michele IR - Piazza M FIR - Marcucci, Rossella IR - Marcucci R FIR - Bellosta, Raffaello IR - Bellosta R FIR - D'Alessio, Ilenia IR - D'Alessio I FIR - Dorigo, Walter IR - Dorigo W FIR - Verzini, Fabio IR - Verzini F FIR - Gargiulo, Mauro IR - Gargiulo M FIR - Benedetto, Filippo IR - Benedetto F FIR - Gatta, Emanuele IR - Gatta E FIR - Trimarchi, Santi IR - Trimarchi S FIR - Simioni, Paolo IR - Simioni P EDAT- 2026/02/16 00:31 MHDA- 2026/04/07 00:31 CRDT- 2026/02/15 19:31 PHST- 2025/12/30 00:00 [received] PHST- 2026/01/28 00:00 [revised] PHST- 2026/01/29 00:00 [accepted] PHST- 2026/04/07 00:31 [medline] PHST- 2026/02/16 00:31 [pubmed] PHST- 2026/02/15 19:31 [entrez] AID - S0890-5096(26)00093-2 [pii] AID - 10.1016/j.avsg.2026.01.044 [doi] PST - ppublish SO - Ann Vasc Surg. 2026 Jun;127:187-194. doi: 10.1016/j.avsg.2026.01.044. Epub 2026 Feb 13. PMID- 41690665 OWN - NLM STAT- In-Process LR - 20260827 IS - 1552-6259 (Electronic) IS - 0003-4975 (Linking) VI - 122 IP - 3 DP - 2026 Sep TI - Primary Cardiac Sarcoma: A Team Approach. PG - 767-768 LID - S0003-4975(26)00122-0 [pii] LID - 10.1016/j.athoracsur.2026.01.038 [doi] FAU - Atkins, Marvin D AU - Atkins MD AD - Department of Cardiovascular and Thoracic Surgery, Houston Methodist Hospital, 6550 Fannin, Ste 1401, Houston, TX 77030. FAU - Reardon, Michael J AU - Reardon MJ AD - Department of Cardiovascular and Thoracic Surgery, Houston Methodist Hospital, 6550 Fannin, Ste 1401, Houston, TX 77030. Electronic address: mreardon@houstonmethodist.org. LA - eng PT - Journal Article DEP - 20260212 PL - Netherlands TA - Ann Thorac Surg JT - The Annals of thoracic surgery JID - 15030100R SB - IM COIS- Disclosures Michael J. Reardon reports a relationship with Medtronic Inc that includes: consulting or advisory. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/02/15 00:31 MHDA- 2026/02/15 00:31 CRDT- 2026/02/14 19:15 PHST- 2026/01/09 00:00 [received] PHST- 2026/01/11 00:00 [accepted] PHST- 2026/02/15 00:31 [pubmed] PHST- 2026/02/15 00:31 [medline] PHST- 2026/02/14 19:15 [entrez] AID - S0003-4975(26)00122-0 [pii] AID - 10.1016/j.athoracsur.2026.01.038 [doi] PST - ppublish SO - Ann Thorac Surg. 2026 Sep;122(3):767-768. doi: 10.1016/j.athoracsur.2026.01.038. Epub 2026 Feb 12. PMID- 41686115 OWN - NLM STAT- MEDLINE DCOM- 20260527 LR - 20260824 IS - 2405-5018 (Electronic) IS - 2405-500X (Linking) VI - 12 IP - 5 DP - 2026 May TI - Accuracy of Implantable Loop Recorders: Multicenter, Multidevice Comparison. PG - 1113-1127 LID - S2405-500X(26)00003-4 [pii] LID - 10.1016/j.jacep.2025.12.039 [doi] AB - BACKGROUND: Implantable loop recorders (ILRs) frequently generate false-positive alert transmissions, increasing clinical burden. OBJECTIVES: This study sought to evaluate and compare arrhythmia detection accuracy among currently used ILRs: Medtronic (MDT) LINQ II with AccuRhythm AI, Boston Scientific (BSX) LUX-Dx with a Dual-Stage Algorithm, Biotronik (BIO) Biomonitor III with RhythmCheck, and Abbott (ABT) Confirm Rx (SharpSense). METHODS: A multicenter, multivendor database of 437,351 electrocardiogram-verified episodes from 6,756 patients (January 2022 to March 2023, across 25 centers) was used. A random sample of 1,140 patients ( approximately 283 per device) was selected based on a prospectively determined power analysis. All alerts were independently adjudicated by trained physicians. RESULTS: The study cohort (median age: 69.5 years [IQR: 60.1-77.0]; 39% women) generated 25,826 total alerts, with a median of 5 alerts (IQR: 2-14) per patient. Indications for ILR implant included cryptogenic stroke (21.0%), suspected atrial fibrillation (AF) (11.3%), AF management (23.6%), syncope (23.2%), palpitations (14.9%), ventricular tachycardia (2.1%), and unknown (3.8%). Alerts for atrial tachycardia/AF were most frequent (BIO: 70.8%; MDT: 68.0%; ABT: 55.7%; BSX: 35.7%). After adjudication, BSX had the highest positive predictive values (PPVs), followed by ABT and MDT, which had similar and moderate PPVs, whereas BIO had the lowest (BSX: 0.73; MDT: 0.56; ABT: 0.51; BIO: 0.23). False-positive atrial tachycardia/AF alerts with BIO devices were due to ectopy (75.8%), combined ectopy with oversensing/noise (5.3%), isolated oversensing (5.2%), sinus arrhythmias (3.9%), indeterminate reason (3.7%), noise (3.6%), and bradycardia (2.5%). For bradycardia detection, BSX demonstrated the highest PPV (0.96), whereas MDT had the lowest PPV (0.36; primarily due to undersensing). Pause detection accuracy was lowest for ABT (PPV: 0.01; 79.8% due to undersensing) and highest for BSX (PPV: 0.70). Tachycardia alerts had moderate PPVs for BIO (0.62) and BSX (0.61), with substantially lower PPVs for MDT (0.29) and ABT (0.27). CONCLUSIONS: ILRs demonstrate variable accuracy in arrhythmia detection, with a substantial burden of false-positive alerts across all vendors despite artificial intelligence-based and other algorithmic enhancements. Further improvement of alert algorithms to reduce clinic burdens is needed. CI - Crown Copyright (c) 2026. Published by Elsevier Inc. All rights reserved. FAU - Kamsani, Suraya H AU - Kamsani SH AD - Centre for Heart Rhythm Disorders, Adelaide University and Royal Adelaide Hospital, Adelaide, South Australia, Australia; Cardiology Department, National Heart Institute, Kuala Lumpur, Malaysia. FAU - Middeldorp, Melissa E AU - Middeldorp ME AD - Centre for Heart Rhythm Disorders, Adelaide University and Royal Adelaide Hospital, Adelaide, South Australia, Australia. FAU - Evans, Shaun AU - Evans S AD - Centre for Heart Rhythm Disorders, Adelaide University and Royal Adelaide Hospital, Adelaide, South Australia, Australia. FAU - Russo, Andrea M AU - Russo AM AD - Division of Cardiology, Cooper Medical School of Rowan University, Camden, New Jersey, USA. FAU - Jayakumar, Mohanaraj AU - Jayakumar M AD - Centre for Heart Rhythm Disorders, Adelaide University and Royal Adelaide Hospital, Adelaide, South Australia, Australia. FAU - Deering, Thomas F AU - Deering TF AD - Arrhythmia Center, Piedmont Heart Institute, Atlanta, Georgia, USA. FAU - Shahmohamadi, Elnaz AU - Shahmohamadi E AD - Centre for Heart Rhythm Disorders, Adelaide University and Royal Adelaide Hospital, Adelaide, South Australia, Australia. FAU - Baykaner, Tina AU - Baykaner T AD - Department of Internal Medicine, Division of Cardiovascular Medicine and Electrophysiology, Stanford University School of Medicine, Palo Alto, California, USA. FAU - Fitzgerald, John L AU - Fitzgerald JL AD - Centre for Heart Rhythm Disorders, Adelaide University and Royal Adelaide Hospital, Adelaide, South Australia, Australia. FAU - Gopinathannair, Rakesh AU - Gopinathannair R AD - Kansas City Heart Rhythm Institute, Kansas City, Missouri, USA. FAU - Abbas, Mohamed AU - Abbas M AD - Centre for Heart Rhythm Disorders, Adelaide University and Royal Adelaide Hospital, Adelaide, South Australia, Australia. FAU - Varma, Niraj AU - Varma N AD - Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA. FAU - Freeman, James V AU - Freeman JV AD - Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA. FAU - Mittal, Suneet AU - Mittal S AD - Snyder Center for Comprehensive Atrial Fibrillation and Department of Cardiology, Valley Health System, Paramus, New Jersey, USA. FAU - Sanders, Prashanthan AU - Sanders P AD - Centre for Heart Rhythm Disorders, Adelaide University and Royal Adelaide Hospital, Adelaide, South Australia, Australia. Electronic address: prash.sanders@adelaide.edu.au. LA - eng PT - Comparative Study PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't DEP - 20260213 PL - United States TA - JACC Clin Electrophysiol JT - JACC. Clinical electrophysiology JID - 101656995 SB - IM MH - Humans MH - *Arrhythmias, Cardiac/diagnosis MH - Female MH - *Electrocardiography, Ambulatory/instrumentation/standards MH - Aged MH - Male MH - Middle Aged MH - Algorithms OTO - NOTNLM OT - arrhythmia detection OT - false-positive alerts OT - implantable loop recorder (ILR) OT - remote monitoring COIS- Funding Support and Author Disclosures This study was supported by the Centre for Heart Rhythm Disorders at the University of Adelaide. Drs Kamsani, Evans, Jayakumar, Shahmohamadi, Fitzgerald, and Abbas are supported by postgraduate scholarships from the University of Adelaide. Dr Baykaner has received research funds from the U.S. National Heart, Lung, and Blood Institute and Janssen. Dr Freeman has received by research funding from the American College of Cardiology Foundation; and grants from the U.S. National Heart, Lung, and Blood Institute. Dr Sanders is supported by an Investigator Grant from the National Health and Medical Research Council of Australia. Dr Russo has received research funding from Abbott, Boston Scientific, and Medtronic; and honoraria or consulting fees from Abbott, Biotronik, Boston Scientific, Medtronic, Orchestra BioMed, and PaceMate. Dr Deering has served on the advisory board of PaceMate. Dr Baykaner has received consulting fees from Medtronic, Biotronik, Boston Scientific, Abbott, PaceMate, Volta, iRhythm and Johnson & Johnson. Dr Varma is a consultant with Abbott, Biotronik, and Impulse Dynamics. Dr Freeman has received consulting/advisory board fees from Boston Scientific, Medtronic, Abbott, Johnson & Johnson MedTech, and PaceMate. Dr Mittal has served as a consultant to Abbott, Boston Scientific, and Medtronic. Dr Sanders has served on the advisory boards of Medtronic, Abbott Medical, Boston-Scientific, PaceMate, and CathRx. Dr Sanders reports that the University of Adelaide has received on his behalf lecture and/or consulting fees from Medtronic, Boston Scientific, and Abbott Medical. Dr Sanders reports that the University of Adelaide has received on his behalf research funding from Medtronic, Abbott Medical, Boston Scientific, and Becton Dickenson. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2026/02/13 12:50 MHDA- 2026/05/27 12:35 CRDT- 2026/02/13 10:13 PHST- 2025/08/05 00:00 [received] PHST- 2025/12/24 00:00 [revised] PHST- 2025/12/29 00:00 [accepted] PHST- 2026/05/27 12:35 [medline] PHST- 2026/02/13 12:50 [pubmed] PHST- 2026/02/13 10:13 [entrez] AID - S2405-500X(26)00003-4 [pii] AID - 10.1016/j.jacep.2025.12.039 [doi] PST - ppublish SO - JACC Clin Electrophysiol. 2026 May;12(5):1113-1127. doi: 10.1016/j.jacep.2025.12.039. Epub 2026 Feb 13. PMID- 41682984 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260213 LR - 20260216 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 15 IP - 3 DP - 2026 Feb 6 TI - The Two-Device Problem: A Comprehensive Framework for Managing Transvalvular CIED Leads in the Era of Transcatheter Tricuspid Intervention. LID - 10.3390/jcm15031303 [doi] LID - 1303 AB - Tricuspid regurgitation (TR) in patients with transvalvular cardiac implantable electronic device (CIED) leads is increasingly encountered as transcatheter tricuspid valve interventions (TTVI) expand, yet integrated guidance for managing this "two-device problem" remains limited. We performed a focused synthesis of contemporary evidence, organizing findings around mechanisms and diagnosis of TR in the setting of CIED leads, lead-device interactions across TTVI platforms, and clinical trade-offs of transvenous lead extraction (TLE) versus lead preservation or jailing. CIED-associated TR can arise from lead-leaflet impingement, leaflet injury, fibrotic adhesion, pacing-induced remodeling, or infection; true CIED-induced TR accounts for a minority of clinically significant TR, yet progression of TR after lead implantation occurs in 7-45% of patients, and moderate-to-severe TR in CIED populations is associated with 1.6- to 2.5-fold increased mortality risk. Lead conflict and lifetime consequences differ by TTVI modality: repair approaches are generally more lead-tolerant, whereas valve replacement creates obligate lead jailing with implications for lead performance, future extraction feasibility, and infection management. Management of TR with transvalvular CIED leads requires integrated Heart Team planning that anticipates downstream device needs. Standardized TR phenotyping, lead-aware TTVI selection, valve-sparing rhythm-device strategies, and structured post-procedural surveillance may improve outcomes; prospective studies are needed to define optimal extract-versus-jail pathways. FAU - Kamareddine, Mohammed Hussein AU - Kamareddine MH AD - Division of Cardiology, Lankenau Medical Center, Main Line Health, Wynnewood, PA 19096, USA. FAU - Powers, Edward M AU - Powers EM AUID- ORCID: 0000-0002-3063-1458 AD - Section of Cardiac Electrophysiology, Division of Cardiology, Johns Hopkins Hospital, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. FAU - Rahman, Faisal AU - Rahman F AD - Section of Intervention Cardiology, Division of Cardiology, Johns Hopkins Hospital, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. FAU - Keramati, Ali R AU - Keramati AR AD - Section of Cardiac Electrophysiology of Electrophysiology, Division of Cardiology, Lankenau Medical Center, Main Line Health, Wynnewood, PA 19096, USA. FAU - Aronis, Konstantinos N AU - Aronis KN AUID- ORCID: 0000-0001-7189-8434 AD - Section of Cardiac Electrophysiology, Division of Cardiology, Johns Hopkins Hospital, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. LA - eng PT - Journal Article PT - Review DEP - 20260206 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC12897658 OTO - NOTNLM OT - Heart Team OT - cardiac implantable electronic device OT - implantable cardioverter-defibrillator OT - lead jailing OT - leadless pacemaker OT - pacing strategies OT - transcatheter lead extraction OT - transcatheter tricuspid valve intervention OT - tricuspid regurgitation COIS- The authors declare no conflicts of interest. EDAT- 2026/02/13 06:33 MHDA- 2026/02/13 06:34 PMCR- 2026/02/06 CRDT- 2026/02/13 01:07 PHST- 2026/01/11 00:00 [received] PHST- 2026/01/29 00:00 [revised] PHST- 2026/02/03 00:00 [accepted] PHST- 2026/02/13 06:34 [medline] PHST- 2026/02/13 06:33 [pubmed] PHST- 2026/02/13 01:07 [entrez] PHST- 2026/02/06 00:00 [pmc-release] AID - jcm15031303 [pii] AID - jcm-15-01303 [pii] AID - 10.3390/jcm15031303 [doi] PST - epublish SO - J Clin Med. 2026 Feb 6;15(3):1303. doi: 10.3390/jcm15031303. PMID- 41682918 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260213 LR - 20260216 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 15 IP - 3 DP - 2026 Feb 4 TI - Beyond Sleep: The Cardiovascular Impact of Obstructive Sleep Apnea Syndrome. LID - 10.3390/jcm15031239 [doi] LID - 1239 AB - Background/Objectives: Obstructive Sleep Apnea Syndrome (OSAS) is a chronic disorder characterized by repeated upper airway obstruction during sleep, leading to intermittent hypoxia and elevated sympathetic activity. OSAS is strongly linked to cardiovascular comorbidities such as hypertension, arrhythmias, heart failure, and atherosclerosis, contributing to structural and functional cardiac alterations. Methods: This study enrolled 105 consecutive patients diagnosed with OSAS and a control group of 100 patients without the syndrome. All participants underwent a comprehensive echocardiographic evaluation using Doppler imaging to assess cardiac structure and function. Results: Hypertension was significantly more prevalent in the OSAS group (81%) compared to controls (74%). Left ventricular diastolic dysfunction occurred in 56.2% of OSAS patients versus 26% of controls. Left atrial enlargement and left ventricular hypertrophy were also more frequent in the OSAS group (21% and 51.4%, respectively) compared to controls (13% and 5%). Permanent atrial fibrillation was present in 17.1% of OSAS patients, significantly higher than the 7% observed in controls. These findings highlight the pronounced cardiac remodeling and arrhythmic burden associated with OSAS. Conclusions: The data confirm that OSAS is associated with increased cardiovascular abnormalities detectable by echocardiography, underscoring the need for routine cardiovascular screening in OSAS patients. Given the systemic implications of OSAS beyond sleep disturbances, a multidisciplinary approach is essential for early diagnosis and optimized management, aiming to mitigate cardiovascular risk and improve outcomes. OSAS is a significant cardiovascular risk factor requiring comprehensive clinical attention. FAU - Palmiero, Pasquale AU - Palmiero P AUID- ORCID: 0000-0001-8285-1623 AD - Cardiology Equipe, ASL Brindisi, 72100 Brindisi, Italy. AD - Medical School, University of Bari, 70122 Bari, Italy. FAU - Amati, Francesca AU - Amati F AUID- ORCID: 0009-0005-7101-7701 AD - University Cardiology Unit, Interdisciplinary Department of Medicine, Polyclinic University Hospital, 70124 Bari, Italy. FAU - Bombini, Lucrezia AU - Bombini L AD - University Cardiology Unit, Interdisciplinary Department of Medicine, Polyclinic University Hospital, 70124 Bari, Italy. FAU - Ciccone, Marco Matteo AU - Ciccone MM AD - University Cardiology Unit, Interdisciplinary Department of Medicine, Polyclinic University Hospital, 70124 Bari, Italy. FAU - Maiello, Maria AU - Maiello M AD - Cardiology Equipe, ASL Brindisi, 72100 Brindisi, Italy. LA - eng PT - Journal Article DEP - 20260204 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC12898792 OTO - NOTNLM OT - atrial fibrillation OT - cardiac remodeling OT - cardiovascular risk OT - diastolic dysfunction OT - echocardiography OT - hypertension OT - left atrial enlargement OT - left ventricular hypertrophy OT - obstructive sleep apnea syndrome COIS- The authors declare no conflicts of interest. EDAT- 2026/02/13 06:32 MHDA- 2026/02/13 06:33 PMCR- 2026/02/04 CRDT- 2026/02/13 01:07 PHST- 2026/01/14 00:00 [received] PHST- 2026/01/31 00:00 [revised] PHST- 2026/02/02 00:00 [accepted] PHST- 2026/02/13 06:33 [medline] PHST- 2026/02/13 06:32 [pubmed] PHST- 2026/02/13 01:07 [entrez] PHST- 2026/02/04 00:00 [pmc-release] AID - jcm15031239 [pii] AID - jcm-15-01239 [pii] AID - 10.3390/jcm15031239 [doi] PST - epublish SO - J Clin Med. 2026 Feb 4;15(3):1239. doi: 10.3390/jcm15031239. PMID- 41681746 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260213 LR - 20260216 IS - 2075-4418 (Print) IS - 2075-4418 (Electronic) IS - 2075-4418 (Linking) VI - 16 IP - 3 DP - 2026 Feb 1 TI - Clinical Profile of a Series of Left-Sided Prosthetic Valve Endocarditis: Revisiting Surgical Indications. LID - 10.3390/diagnostics16030426 [doi] LID - 426 AB - Background/Objectives: Prosthetic valve endocarditis (PVE) carries a high morbidity and mortality. Surgery is classically indicated for heart failure, uncontrolled infection, or prevention of embolic events; however, evidence supporting surgery for "non-classical" indications-such as Staphylococcus aureus infection, non-HACEK Gram-negative bacteria, or early PVE-remains limited. This study aimed to update the clinical and prognostic profile of PVE and assess the impact of surgery, particularly in patients with non-classical surgical indications. Methods: We prospectively included all definite left-sided PVE cases diagnosed between 2000 and 2024 at three tertiary centers. Clinical, microbiological, echocardiographic, and prognostic data were analyzed and compared. Predictors of in-hospital mortality were identified using multivariable logistic regression, and Kaplan-Meier curves were used to compare 1-year survival according to surgical indications. Results: Among 589 patients with left-sided PVE, 61% underwent surgery, and in-hospital mortality was 31%. Independent mortality predictors were chronic obstructive pulmonary disease, pulmonary hypertension, periannular complications, S. aureus infection, and poor clinical condition at admission. Non-classical surgical indications were present in 38% of patients, although only 28 (5%) of them had no other surgical indication. These patients exhibited lower mortality (14%) and no survival benefit from surgery (10% vs. 17%; p 0.999). Conclusions: PVE remains associated with high mortality. Surgery improves survival in patients with classical surgical indications but not in patients with non-classical indications, supporting individualized surgical decisions by a multidisciplinary endocarditis team. FAU - Ibanez, Adrian Lozano AU - Ibanez AL AUID- ORCID: 0009-0002-3951-129X AD - Servicio de Cardiologia, Instituto de Ciencias del Corazon (ICICOR), Hospital Clinico Universitario de Valladolid, 47003 Valladolid, Spain. FAU - Diaz, Javier Lopez AU - Diaz JL AUID- ORCID: 0000-0001-6193-629X AD - Servicio de Cardiologia, Instituto de Ciencias del Corazon (ICICOR), Hospital Clinico Universitario de Valladolid, 47003 Valladolid, Spain. AD - Centro de Investigacion Biomedica en Red de Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain. AD - Instituto de Investigacion Biosanitaria de Valladolid (IBioVALL), 47010 Valladolid, Spain. FAU - Alava, Maria de Miguel AU - Alava MM AD - Servicio de Cardiologia, Instituto de Ciencias del Corazon (ICICOR), Hospital Clinico Universitario de Valladolid, 47003 Valladolid, Spain. FAU - Cabezon Villalba, Gonzalo AU - Cabezon Villalba G AD - Servicio de Cardiologia, Instituto de Ciencias del Corazon (ICICOR), Hospital Clinico Universitario de Valladolid, 47003 Valladolid, Spain. AD - Centro de Investigacion Biomedica en Red de Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain. AD - Instituto de Investigacion Biosanitaria de Valladolid (IBioVALL), 47010 Valladolid, Spain. FAU - Ona Orive, Andrea AU - Ona Orive A AUID- ORCID: 0009-0000-9793-6718 AD - Servicio de Cardiologia, Instituto de Ciencias del Corazon (ICICOR), Hospital Clinico Universitario de Valladolid, 47003 Valladolid, Spain. FAU - Gomez-Ramirez, Daniel AU - Gomez-Ramirez D AUID- ORCID: 0009-0001-6446-7748 AD - Instituto Cardiovascular, Hospital Clinico San Carlos, Instituto de Investigacion Sanitaria del Hospital Clinico San Carlos (IdISSC), 28040 Madrid, Spain. FAU - Landin, Patricia AU - Landin P AUID- ORCID: 0009-0007-8191-4769 AD - Instituto Cardiovascular, Hospital Clinico San Carlos, Instituto de Investigacion Sanitaria del Hospital Clinico San Carlos (IdISSC), 28040 Madrid, Spain. FAU - Perez-Camargo, Daniel AU - Perez-Camargo D AD - Instituto Cardiovascular, Hospital Clinico San Carlos, Instituto de Investigacion Sanitaria del Hospital Clinico San Carlos (IdISSC), 28040 Madrid, Spain. FAU - Campillo, Sofia AU - Campillo S AD - Servicio de Cardiologia, Instituto de Ciencias del Corazon (ICICOR), Hospital Clinico Universitario de Valladolid, 47003 Valladolid, Spain. FAU - Gomez-Salvador, Itziar AU - Gomez-Salvador I AD - Servicio de Cardiologia, Instituto de Ciencias del Corazon (ICICOR), Hospital Clinico Universitario de Valladolid, 47003 Valladolid, Spain. AD - Centro de Investigacion Biomedica en Red de Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain. AD - Instituto de Investigacion Biosanitaria de Valladolid (IBioVALL), 47010 Valladolid, Spain. FAU - Saez, Carmen AU - Saez C AD - Seccion de Enfermedades Infecciosas, Servicio de Medicina Interna, Hospital Universitario de la Princesa, Instituto de Investigacion Sanitaria del H.U. Princesa (IIS-IP), 28006 Madrid, Spain. FAU - Olmos, Carmen AU - Olmos C AUID- ORCID: 0000-0001-9544-0508 AD - Instituto Cardiovascular, Hospital Clinico San Carlos, Instituto de Investigacion Sanitaria del Hospital Clinico San Carlos (IdISSC), 28040 Madrid, Spain. AD - Facultad de Medicina, Salud y Deportes, Universidad Europea de Madrid, 28670 Madrid, Spain. FAU - Vilacosta, Isidre AU - Vilacosta I AD - Centro de Investigacion Biomedica en Red de Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain. AD - Instituto Cardiovascular, Hospital Clinico San Carlos, Instituto de Investigacion Sanitaria del Hospital Clinico San Carlos (IdISSC), 28040 Madrid, Spain. AD - Department of Medicine, Universidad Complutense de Madrid, 28040 Madrid, Spain. FAU - San Roman, J Alberto AU - San Roman JA AUID- ORCID: 0000-0003-0764-0839 AD - Servicio de Cardiologia, Instituto de Ciencias del Corazon (ICICOR), Hospital Clinico Universitario de Valladolid, 47003 Valladolid, Spain. AD - Centro de Investigacion Biomedica en Red de Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain. AD - Instituto de Investigacion Biosanitaria de Valladolid (IBioVALL), 47010 Valladolid, Spain. LA - eng GR - PI22/00459/Instituto de Salud Carlos III/ PT - Journal Article DEP - 20260201 PL - Switzerland TA - Diagnostics (Basel) JT - Diagnostics (Basel, Switzerland) JID - 101658402 PMC - PMC12897040 OTO - NOTNLM OT - clinical outcomes OT - prosthetic endocarditis OT - surgical indications COIS- The authors declare no conflicts of interest. EDAT- 2026/02/13 06:33 MHDA- 2026/02/13 06:34 PMCR- 2026/02/01 CRDT- 2026/02/13 01:03 PHST- 2025/11/17 00:00 [received] PHST- 2026/01/22 00:00 [revised] PHST- 2026/01/23 00:00 [accepted] PHST- 2026/02/13 06:34 [medline] PHST- 2026/02/13 06:33 [pubmed] PHST- 2026/02/13 01:03 [entrez] PHST- 2026/02/01 00:00 [pmc-release] AID - diagnostics16030426 [pii] AID - diagnostics-16-00426 [pii] AID - 10.3390/diagnostics16030426 [doi] PST - epublish SO - Diagnostics (Basel). 2026 Feb 1;16(3):426. doi: 10.3390/diagnostics16030426. PMID- 41679540 OWN - NLM STAT- MEDLINE DCOM- 20260707 LR - 20260722 IS - 1876-2867 (Electronic) IS - 1876-2859 (Linking) VI - 26 IP - 3 DP - 2026 Apr TI - Leadership and Communication Skills Used by Pediatric Residents in the First 5 Minutes of Simulated High-Acuity Events. PG - 103244 LID - S1876-2859(26)00026-4 [pii] LID - 10.1016/j.acap.2026.103244 [doi] AB - OBJECTIVE: Effective leadership enhances clinical team performance through collaboration, resource management, and communication. Currently, most resident physicians learn leadership skills through informal apprenticeship. METHODS: This observational study quantifies the leadership and communication skills (LCS) demonstrated by pediatric residents leading interdisciplinary teams in simulated life-threatening events at a single institution using retrospective video review. Using a checklist of LCS, 3 authors each scored the occurrence of 12 LCS skills within the first 5 minutes of response, plus binary outcomes related to appropriate diagnosis, team formation, appropriate interventions, and a shared mental model. Intraclass correlation coefficients assessed interrater reliability. Wilcoxon rank-sum and Fisher's exact tests compared LCS scores to scenario types and outcomes. RESULTS: Thirty-one residents led interprofessional teams in 16 cardiogenic shock and 15 status epilepticus scenarios. Average intraclass correlation coefficients were 0.68 to 0.96. Total scores for the 12 LCS skills ranged from 7 to 26 (median 15, interquartile range 11-19). Residents performed most LCS skills less than half of the time, scoring highest in reassessment, soliciting team input, and refraining from active participation. Only 13% of residents declared themselves team leaders at any point, and core skills of resource management, anticipation, and seeking help were infrequently demonstrated. Overall, team leader behaviors resulted in 15 (48%) appropriate diagnoses, 18 (58%) team formations, 16 (52%) appropriate interventions, and 8 (26%) shared mental models. CONCLUSIONS: Pediatric residents inconsistently demonstrate LCS, regardless of familiarity with the simulated scenario, highlighting that these skills may not be effectively learned through traditional curricula. Our findings underscore the need for a targeted leadership curriculum. CI - Copyright (c) 2026 Academic Pediatric Association. Published by Elsevier Inc. All rights reserved. FAU - Han, Peggy AU - Han P AD - Department of Pediatrics (P Han and D Tawfik), Division of Pediatric Critical Care Medicine, Stanford University School of Medicine, Palo Alto, Calif. Electronic address: peggyhan@stanford.edu. FAU - Siems, Ashley AU - Siems A AD - Department of Pediatrics (A Siems and A Rake), Division of Pediatric Critical Care Medicine, Johns Hopkins-All Children's Hospital, St. Petersburg, Fla. FAU - Harvey, Helen AU - Harvey H AD - Department of Pediatrics (H Harvey), Division of Pediatric Critical Care Medicine, University of California-San Diego, Rady Children's Hospital, San Diego, Calif; Department of Pediatrics (R Blankenburg), Division of Pediatric Hospital Medicine, Stanford University School of Medicine, Center for Academic Medicine, Palo Alto, Calif. FAU - Tawfik, Daniel AU - Tawfik D AD - Department of Pediatrics (P Han and D Tawfik), Division of Pediatric Critical Care Medicine, Stanford University School of Medicine, Palo Alto, Calif. FAU - Blankenburg, Rebecca AU - Blankenburg R AD - Department of Pediatrics (H Harvey), Division of Pediatric Critical Care Medicine, University of California-San Diego, Rady Children's Hospital, San Diego, Calif; Department of Pediatrics (R Blankenburg), Division of Pediatric Hospital Medicine, Stanford University School of Medicine, Center for Academic Medicine, Palo Alto, Calif. FAU - Umoren, Rachel A AU - Umoren RA AD - Department of Pediatrics (RA Umoren), Division of Neonatology, University of Washington, Seattle, Wash. FAU - Rake, Alyssa AU - Rake A AD - Department of Pediatrics (A Siems and A Rake), Division of Pediatric Critical Care Medicine, Johns Hopkins-All Children's Hospital, St. Petersburg, Fla. LA - eng PT - Journal Article PT - Observational Study DEP - 20260210 PL - United States TA - Acad Pediatr JT - Academic pediatrics JID - 101499145 SB - IM MH - Humans MH - *Internship and Residency MH - *Leadership MH - *Pediatrics/education MH - Retrospective Studies MH - *Communication MH - *Clinical Competence MH - *Patient Care Team MH - Female OTO - NOTNLM OT - communication OT - interprofessional teams OT - leadership OT - nontechnical skills OT - resident education OT - simulation COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/02/13 01:26 MHDA- 2026/04/13 00:31 CRDT- 2026/02/12 19:13 PHST- 2025/07/31 00:00 [received] PHST- 2025/12/22 00:00 [revised] PHST- 2025/12/25 00:00 [accepted] PHST- 2026/04/13 00:31 [medline] PHST- 2026/02/13 01:26 [pubmed] PHST- 2026/02/12 19:13 [entrez] AID - S1876-2859(26)00026-4 [pii] AID - 10.1016/j.acap.2026.103244 [doi] PST - ppublish SO - Acad Pediatr. 2026 Apr;26(3):103244. doi: 10.1016/j.acap.2026.103244. Epub 2026 Feb 10. PMID- 41679408 OWN - NLM STAT- MEDLINE DCOM- 20260707 LR - 20260707 IS - 1879-1913 (Electronic) IS - 0002-9149 (Linking) VI - 266 DP - 2026 May 1 TI - Managing Obesity in Heart Failure Patients: Current Evidence and Strategies. PG - 77-85 LID - S0002-9149(26)00057-3 [pii] LID - 10.1016/j.amjcard.2026.02.016 [doi] AB - Obesity, characterized by excessive accumulation of adipose tissue, is associated with numerous health risks including diabetes mellitus, cardiovascular disease, and hypertension. Obesity affects a massive portion of the global population, with a projected increase in prevalence by 2035. It leads to various cardiovascular events, insulin resistance, and increased inflammation, all of which predispose individuals to heart failure. Addressing obesity can significantly improve these patients' functional status and quality of life. Effective management of obesity in heart failure patients requires a multidisciplinary approach. Management strategies for obesity in heart failure patients include physical therapy, nutritional therapy, pharmacotherapy, and metabolic bariatric surgery. In conclusion, this review summarizes current evidence in the management of obesity and related complications in patients with end-stage heart failure and explores candidacy for advanced therapies such as heart transplants or durable left ventricular assist devices if native heart recovery is not feasible. CI - Copyright (c) 2026. Published by Elsevier Inc. FAU - Sharma, Shriya AU - Sharma S AD - Division of Advanced Heart Failure and Transplantation, Mayo Clinic, 4500 San Pablo Road, Jacksonville, Florida. FAU - Giri, Ganesh AU - Giri G AD - Division of Quantitative Health Sciences, Mayo Clinic, 4500 San Pablo Road, Jacksonville, Florida. FAU - Desai, Aarti AU - Desai A AD - Division of Advanced Heart Failure and Transplantation, Mayo Clinic, 4500 San Pablo Road, Jacksonville, Florida. FAU - Ruiz, Jose AU - Ruiz J AD - Division of Advanced Heart Failure and Transplantation, Mayo Clinic, 4500 San Pablo Road, Jacksonville, Florida. FAU - Gomez, Victoria AU - Gomez V AD - Division of Gastroenterology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, Florida. FAU - Goswami, Rohan AU - Goswami R AD - Division of Advanced Heart Failure and Transplantation, Mayo Clinic, 4500 San Pablo Road, Jacksonville, Florida. Electronic address: goswami.rohan@mayo.edu. LA - eng PT - Journal Article PT - Review DEP - 20260210 PL - United States TA - Am J Cardiol JT - The American journal of cardiology JID - 0207277 SB - IM MH - Humans MH - *Heart Failure/complications/therapy/epidemiology MH - *Obesity/therapy/complications/epidemiology MH - Bariatric Surgery OTO - NOTNLM OT - BMI OT - GLP1 OT - LVAD OT - bariatric surgery OT - heart failure OT - impella OT - leptin OT - obesity COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/02/13 01:27 MHDA- 2026/04/11 00:32 CRDT- 2026/02/12 19:11 PHST- 2025/07/03 00:00 [received] PHST- 2026/01/28 00:00 [revised] PHST- 2026/02/07 00:00 [accepted] PHST- 2026/04/11 00:32 [medline] PHST- 2026/02/13 01:27 [pubmed] PHST- 2026/02/12 19:11 [entrez] AID - S0002-9149(26)00057-3 [pii] AID - 10.1016/j.amjcard.2026.02.016 [doi] PST - ppublish SO - Am J Cardiol. 2026 May 1;266:77-85. doi: 10.1016/j.amjcard.2026.02.016. Epub 2026 Feb 10. PMID- 41678007 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260318 LR - 20260813 IS - 1869-6953 (Print) IS - 1869-6961 (Electronic) IS - 1869-6961 (Linking) VI - 17 IP - 3 DP - 2026 Mar TI - Modern Management of CKM Syndrome: Use of GLP-1 Receptor Agonists in a Multidisciplinary Setting-Expert Group Recommendations from Kuwait. PG - 373-389 LID - 10.1007/s13300-025-01838-0 [doi] AB - Obesity, type 2 diabetes (T2D), cardiovascular disease (CVD), and chronic kidney disease (CKD) are overlapping conditions that drive premature morbidity and mortality worldwide. Care remains siloed and reactive despite shared risk factors and strong evidence for early intervention. To support integrated disease management, the American Heart Association (AHA) recently introduced the concept of cardiovascular-kidney-metabolic (CKM) syndrome, recognizing the bidirectional links between metabolic, kidney, and cardiovascular health. Kuwait faces one of the highest burdens of CKM-related diseases globally. Three-quarters of adults are overweight or have obesity, and 28% have diabetes, both of which are leading causes of mortality and health system strain. Yet multidisciplinary care remains limited, and innovative pharmacotherapies, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs), are underused. A panel of Kuwaiti endocrinologists, cardiologists, and nephrologists convened to assess barriers to optimal CKM care and define practical recommendations. Discussions focused on current gaps in screening, care coordination, provider education, and access to therapies. Evidence on GLP-1 RAs was reviewed, considering the demonstrated benefits for weight loss, glycemic control, cardiovascular outcomes, and CKD progression. The expert group agreed that multidisciplinary, risk-stratified, and patient-centered approaches are urgently needed. Recommendations include earlier screening and diagnosis, improved integration across specialties, healthcare provider upskilling, public awareness campaigns, and broader access to GLP-1 RAs. Semaglutide was highlighted as a clinically valuable option owing to its broad efficacy and safety profile. Adopting a CKM care model tailored to Kuwait's specific challenges, with appropriate use of GLP-1 RAs, can reduce disease burden, improve outcomes, and increase healthcare system efficiency. The local implementation of evidence-based, cross-specialty strategies is key to altering the trajectory of CKM syndrome in high-risk populations. CI - (c) 2026. The Author(s). FAU - Aldahi, Waleed A AU - Aldahi WA AD - Department of Endocrinology, Mubarak Alkabeer Hospital, Street 109 36, Jabriya, Hawalli, Kuwait. FAU - Alenezi, Abdullah AU - Alenezi A AD - Department of Cardiology, Chest Diseases Hospital, Shuwaikh Industrial, Kuwait City, Kuwait. FAU - Alessa, Thamer AU - Alessa T AUID- ORCID: 0000-0003-4658-9562 AD - Department of Endocrinology, Diabetes and Metabolism, Jaber Al Ahmad Hospital, King Khaled Bin Abdulaziz Road, Ministries Area-Block 1, Plot 900015, Kuwait City, Kuwait. AD - Dasman Diabetes Institute, Jasim Mohamad Al Bahar St, Kuwait City, Kuwait. FAU - Alhamdan, Rashed AU - Alhamdan R AD - Department of Cardiology, Mubarak Alkabeer Hospital, Street 109 36, Jabriya, Hawalli, Kuwait. FAU - Al-Humood, Khaldoon A AU - Al-Humood KA AD - Department of Cardiology, Alsalam International Hospital, Port Said St, 35151, Kuwait City, Kuwait. FAU - Alqallaf, Ahmed AU - Alqallaf A AD - Department of Nephrology, Jaber Al Ahmad Hospital, King Khaled Bin Abdulaziz Road, Ministries Area-Block 1, Plot 900015, Kuwait City, Kuwait. FAU - Alotaibi, Torki AU - Alotaibi T AD - Department of Nephrology, Hamed Al-Essa Organ Transplant Centre, P.O. Box 25427, 13115, Safat, Kuwait. FAU - Alrajab, Heba AU - Alrajab H AD - Department of Nephrology, Farwaniya Hospital, P.O. Box 1212, 83001, Farwaniya, Kuwait. FAU - Alshammari, Abdulmuhsen M AU - Alshammari AM AD - Department of Diabetes and Endocrinology, Mubarak Al-Kabeer Hospital, Street 109 36, Jabriya, Hawalli, Kuwait. FAU - Alyousef, Anas M AU - Alyousef AM AUID- ORCID: 0000-0002-5450-8083 AD - Department of Internal Medicine and Nephrology, Amiri Hospital, Arabian Gulf Road, Al Kuwayt, Kuwait. FAU - Alsayed Hashem, Asrar AU - Alsayed Hashem A AD - Department of Endocrinology, Metabolic Disorders and Diabetology, Amiri Hospital, Bin Misbah Street, Kuwait City, Kuwait. dr-asrar@hotmail.com. FAU - Rizzo, Manfredi AU - Rizzo M AUID- ORCID: 0000-0002-9549-8504 AD - Department of Health Promotion, Mother and Child Care, School of Medicine, Internal Medicine and Medical Specialties (Promise), University of Palermo, Via Cardinale Rampolla 1, 90100, Palermo, Italy. LA - eng PT - Journal Article PT - Review DEP - 20260212 PL - United States TA - Diabetes Ther JT - Diabetes therapy : research, treatment and education of diabetes and related disorders JID - 101539025 PMC - PMC13000071 OTO - NOTNLM OT - Cardiovascular disease OT - Cardiovascular-kidney-metabolic syndrome OT - Chronic kidney disease OT - Glucagon-like peptide-1 (GLP-1) receptor agonists OT - Kuwait OT - Obesity OT - Semaglutide OT - Type 2 diabetes COIS- Declarations. Conflict of Interest: The authors have given lectures, received honoraria and research support, and participated in conferences, advisory boards, and clinical trials sponsored by many pharmaceutical companies. However, no pharmaceutical company had any role in the scientific content of the present article, which has been written independently, and reflects only the opinion of the authors, without any role by the industry. The following conflicts of interest were reported: Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events were received by Thamer Alessa from Eli Lilly, Sanofi, Boehringer Ingelheim, Novo Nordisk, AstraZeneca, and Servier; Heba Alrajab from CSL Vifor, Bayer, Amgen, Novo Nordisk, and AstraZeneca (consulting fees were also received); Anas Alyousef from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Amgen, Bayer, and Vifor CSL. Waleed Aldahi and Asrar Alsayed Hashem received honoraria for lectures and presentations from Novo Nordisk, Eli Lilly, and Merck. Khaldoon Al-Humood has given lectures and received honorariums from Medtronic, Abbott, Boehringer Ingelheim, AstraZeneca, Pfizer, Bristol Myers Squibb (BMS), Novartis, and Servier. Dr. Alrajab has received payment for expert testimony from CSL Vifor and AstraZeneca. Dr. Alrajab received support to attend meetings and/or travel from ATC, Fresenius and Roche; and Dr. Alsayed Hashem and Dr. Aldahi received support for attending medical conferences and meetings by Novo Nordisk and Eli Lilly; and Dr Alessa by Novo Nordisk and Sanofi. Authors who participated on a Data Safety Monitoring Board or Advisory Board include Dr. Alessa for Novo Nordisk; Dr. Alrajab for CSL Vifor, Sobi - Swedish Orphan Biovitrum, and AstraZeneca; Dr. Alyousef for Sobi, and Vifor CSL; Dr. Alsayed Hashem for Algorithm. Dr. Alyousef is also President of the Kuwait Nephrology Association; he does not receive fees for this role. Dr. Alsayed Hashem is President of the Kuwait Obesity Association and Dr. Aldahi is the President of the Kuwait Diabetes Society. Both Dr. Alsayed Hashem and Dr. Aldahi have participated in public awareness campaigns for obesity and diabetes in Kuwait. Dr. Aldahi has participated in advisory boards for several companies, including Novo Nordisk. Dr. Alrajab has held a leadership or fiduciary role in other boards, societies, committees, or advocacy groups, paid or unpaid, with CSL Vifor, Sobi - Swedish Orphan Biovitrum, and AstraZeneca. Manfredi Rizzo has given lectures, received honoraria and research support, and participated in conferences, advisory boards, and clinical trials sponsored by many pharmaceutical companies, including Amgen, AstraZeneca, Biodexa, Boehringer Ingelheim, Kowa, Eli Lilly, Meda, Mylan, Merck Sharp & Dohme, Novo Nordisk, Novartis, Roche, Sanofi, and Servier. Manfredi Rizzo is an Editorial Board member of Diabetes Therapy. He was not involved in the selection of peer reviewers for the manuscript nor for any of the subsequent editorial decisions. Abdullah Alenezi, Rashed Alhamdan, Torki Alotaibi, Ahmed Alqallaf, and Abdulmuhsen Alshammari have nothing to disclose. Ethical Approval: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. EDAT- 2026/02/12 12:49 MHDA- 2026/02/12 12:50 PMCR- 2026/02/12 CRDT- 2026/02/12 11:19 PHST- 2025/11/19 00:00 [received] PHST- 2025/12/18 00:00 [accepted] PHST- 2026/02/12 12:50 [medline] PHST- 2026/02/12 12:49 [pubmed] PHST- 2026/02/12 11:19 [entrez] PHST- 2026/02/12 00:00 [pmc-release] AID - 10.1007/s13300-025-01838-0 [pii] AID - 1838 [pii] AID - 10.1007/s13300-025-01838-0 [doi] PST - ppublish SO - Diabetes Ther. 2026 Mar;17(3):373-389. doi: 10.1007/s13300-025-01838-0. Epub 2026 Feb 12. PMID- 41676015 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260212 LR - 20260214 IS - 2474-8714 (Electronic) IS - 2474-8706 (Print) IS - 2474-8706 (Linking) VI - 10 IP - 4 DP - 2026 Apr TI - Bench Testing of a New, Semirigid, Saddle-Shaped, Complete Mitral Annuloplasty Ring Designed to Circularize During Transcatheter Mitral Valve-in-Ring Procedures. PG - 100791 LID - 10.1016/j.shj.2025.100791 [doi] LID - 100791 AB - *A new mitral annuloplasty ring was purpose-built for transcatheter valve-in-ring.*Bench testing confirmed anchoring of transcatheter valves inside the ring.*Balloon filling volumes are provided for several sizes of valve-ring pairs.*Surgeons should consider future intervention when selecting an annuloplasty device.*Heart team collaboration can optimize lifetime management of mitral valve disease. CI - (c) 2025 The Author(s). FAU - Allen, Keith B AU - Allen KB AD - Division of Cardiac Surgery, St. Luke's Mid America Heart Institute, Kansas City, Missouri, USA. FAU - Romary, Daniel J AU - Romary DJ AD - Division of Cardiac Surgery, Northwestern University Feinberg School of Medicine and Bluhm Cardiovascular Institute at Northwestern Medicine, Chicago, Illinois, USA. FAU - Grier, Elizabeth A AU - Grier EA AD - Division of Cardiology, St. Luke's Mid America Heart Institute, Kansas City, Missouri, USA. FAU - Huded, Chetan P AU - Huded CP AD - Division of Cardiology, St. Luke's Mid America Heart Institute, Kansas City, Missouri, USA. FAU - Pham, Duc T AU - Pham DT AD - Division of Cardiac Surgery, Northwestern University Feinberg School of Medicine and Bluhm Cardiovascular Institute at Northwestern Medicine, Chicago, Illinois, USA. FAU - Johnston, Douglas R AU - Johnston DR AD - Division of Cardiac Surgery, Northwestern University Feinberg School of Medicine and Bluhm Cardiovascular Institute at Northwestern Medicine, Chicago, Illinois, USA. FAU - Vardas, Panos N AU - Vardas PN AD - Division of Cardiac Surgery, University of Alabama at Birmingham, Birmingham, Alabama, USA. FAU - Davis, John R AU - Davis JR AD - Division of Cardiac Surgery, St. Luke's Mid America Heart Institute, Kansas City, Missouri, USA. FAU - Chhatriwalla, Adnan K AU - Chhatriwalla AK AD - Division of Cardiology, St. Luke's Mid America Heart Institute, Kansas City, Missouri, USA. LA - eng PT - Journal Article DEP - 20251230 PL - United States TA - Struct Heart JT - Structural heart : the journal of the Heart Team JID - 101743256 PMC - PMC12887157 OTO - NOTNLM OT - Annuloplasty ring OT - Lifetime management of valvular heart disease OT - Mitral valve repair OT - Transcatheter mitral valve replacement OT - Valve-in-ring COIS- Keith B. Allen reports institutional research grants, proctoring, and consulting with Edwards Lifesciences, Medtronic, and Abbott with all payments to the institution and none to him personally. Elizabeth A. Grier is a consultant for Medtronic. Chetan P. Huded reports institutional research grants, proctoring, and consulting with Medtronic and Boston Scientific. Duc T. Pham is a consultant for Abbott, Medtronic, and AbioMed. Douglas R. Johnston is a consultant for Abbott, Artivion, Edwards Lifesciences, LivaNova, and Terumo. Panos N. Vardas is a consultant for Medtronic. Adnan K. Chhatriwalla reports institutional research grants, proctoring, and consulting with Edwards Lifesciences, Medtronic, Abbott, and Boston Scientific. The other authors had no conflicts to declare. EDAT- 2026/02/12 06:54 MHDA- 2026/02/12 06:55 PMCR- 2025/12/30 CRDT- 2026/02/12 05:47 PHST- 2025/12/02 00:00 [received] PHST- 2025/12/19 00:00 [revised] PHST- 2025/12/23 00:00 [accepted] PHST- 2026/02/12 06:55 [medline] PHST- 2026/02/12 06:54 [pubmed] PHST- 2026/02/12 05:47 [entrez] PHST- 2025/12/30 00:00 [pmc-release] AID - S2474-8706(25)00383-5 [pii] AID - 100791 [pii] AID - 10.1016/j.shj.2025.100791 [doi] PST - epublish SO - Struct Heart. 2025 Dec 30;10(4):100791. doi: 10.1016/j.shj.2025.100791. eCollection 2026 Apr. PMID- 41673828 OWN - NLM STAT- MEDLINE DCOM- 20260627 LR - 20260813 IS - 2731-4553 (Electronic) IS - 2731-4553 (Linking) VI - 27 IP - 1 DP - 2026 Feb 11 TI - Bridging the knowledge gap: assessing heart failure awareness and educational needs among clinical physicians. LID - 10.1186/s12875-026-03215-7 [doi] LID - 127 AB - INTRODUCTION: Heart failure (HF) is a life-threatening disease that affects approximately 26 million people worldwide. Meanwhile, due to the increasing rate of hypertension, diabetes, and ischemic heart diseases as heart failure's major risk factors, the incidence of HF is accordingly rising. We designed this multicenter Knowledge, Attitude, and Practice (KAP) study to assess the existing gaps in various aspects of HF management in our country. MATERIALS AND METHODS: We developed a questionnaire with 32 items. Firstly, we gathered a multidisciplinary team to conduct a literature review and an existing questionnaire review to generate items. Our questionnaire was developed concerning major heart failure aspects and consisted of 5 categories. Our target population was medical doctors such as general practitioners (GPs), cardiology and internal medicine residents (Rs), cardiologists, and cardiology subspecialists (Cs). RESULTS: Our study group consisted of 61.5% females and 38.5% males, with a total mean age of 36.16 +/- 11.27 years. We had an overall complete response rate of 76.6% (92 out of 120 distributed questionnaires), of which 27 (29.4%) were cardiology specialists and subspecialists, 21 (22.8%) were cardiology residents and internists, and 44 (47.8%) were general practitioners. The mean score of the total study population's correct responses was 68% (21.76 of 32), while the mean score of correct responses was 62% (20.02/32) in GPs, 72% (23.29/32) in Rs, and 73% (23.41/32) in Cs. CONCLUSION: Our results show suboptimal knowledge for diagnosing and managing heart failure, especially among general practitioners and internists. This highlights the importance of more extensive educational programs focusing on heart failure. FAU - Yousefi-Koma, Hannaneh AU - Yousefi-Koma H AD - Lung Transplantation Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran. FAU - Haji-Ali, Mahshid AU - Haji-Ali M AD - Lung Transplantation Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran. FAU - Parnia, Raha AU - Parnia R AD - Simon Fraser University, British Columbia, Canada. AD - Islamic Azad University of Medical Sciences, Tehran, Iran. FAU - Hajimoradi, Zahra AU - Hajimoradi Z AD - Lung Transplantation Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran. FAU - Sharif-Kashani, Babak AU - Sharif-Kashani B AD - Lung Transplantation Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran. FAU - Naghashzadeh, Farah AU - Naghashzadeh F AD - Lung Transplantation Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran. FAU - Jalalian, Rozita AU - Jalalian R AD - Department of Cardiology, Fatemeh-e-Zahra Hospital, Mazandaran University of Medical Sciences, Sari, Iran. FAU - Hajimoradi, Behzad AU - Hajimoradi B AD - Lung Transplantation Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran. FAU - Savoji, Ali Bozorg AU - Savoji AB AD - Lung Transplantation Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran. FAU - Hajimoradi, Maryam AU - Hajimoradi M AD - Lung Transplantation Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran. FAU - Avateffazeli, Masoume AU - Avateffazeli M AD - Lung Transplantation Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran. FAU - Gheydari, Mohammad-Esmail AU - Gheydari ME AD - Department of Cardiology, Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. FAU - Keshmiri, Mohammad-Sadegh AU - Keshmiri MS AD - Lung Transplantation Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran. FAU - Shafaghi, Shadi AU - Shafaghi S AD - Lung Transplantation Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran. shafaghishadi@yahoo.com. AD - Lung Transplantation Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Masih Daneshvari Hospital, Daar-Abad, Niavaran, Tehran, 19575154, Iran. shafaghishadi@yahoo.com. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20260211 PL - England TA - BMC Prim Care JT - BMC primary care JID - 9918300889006676 SB - IM MH - Humans MH - *Heart Failure/therapy/diagnosis MH - *Health Knowledge, Attitudes, Practice MH - Female MH - Male MH - Surveys and Questionnaires MH - Adult MH - *Clinical Competence MH - Cardiology/education MH - Cardiologists/education PMC - PMC13067511 OTO - NOTNLM OT - Cardiologist OT - General physician OT - Heart failure OT - KAP study OT - Physician OT - Questionnaire COIS- Declarations. Ethical approval and consent to participate: This study was conducted in full accordance with the ethical principles outlined in the Declaration of Helsinki. It was approved by the Ethics Committee of the National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran, under approval number IR.SBMU.NRITLD.REC.1402.099. All participants have given written informed consent to complete the questionnaire, participate in this study, and the publication of the study results. Consent for publication: All participants have given written informed consent to complete the questionnaire, participate in this study, and the publication of the study results. Competing interests: The authors declare no competing interests. EDAT- 2026/02/12 06:55 MHDA- 2026/06/27 18:37 PMCR- 2026/02/11 CRDT- 2026/02/12 00:09 PHST- 2025/07/26 00:00 [received] PHST- 2026/02/03 00:00 [accepted] PHST- 2026/06/27 18:37 [medline] PHST- 2026/02/12 06:55 [pubmed] PHST- 2026/02/12 00:09 [entrez] PHST- 2026/02/11 00:00 [pmc-release] AID - 10.1186/s12875-026-03215-7 [pii] AID - 3215 [pii] AID - 10.1186/s12875-026-03215-7 [doi] PST - epublish SO - BMC Prim Care. 2026 Feb 11;27(1):127. doi: 10.1186/s12875-026-03215-7. PMID- 41673593 OWN - NLM STAT- MEDLINE DCOM- 20260627 LR - 20260813 IS - 1471-2393 (Electronic) IS - 1471-2393 (Linking) VI - 26 IP - 1 DP - 2026 Feb 11 TI - Management strategies for acute type A aortic dissection during pregnancy: a single-center retrospective experience. LID - 10.1186/s12884-026-08803-0 [doi] LID - 291 AB - BACKGROUND: Acute type A aortic dissection (ATAAD) is very rare during pregnancy, it is a devastating condition, and there is no established management guideline. This study shares our center's observations and management experience to provide a practical reference for developing individualized clinical strategies. METHODS: A total of 12 pregnant patients with acute type A aortic dissection, confirmed by CTA and managed surgically, were included from Union Hospital of Fujian Medical University between January 2014 and September 2024. RESULTS: A total of 12 patients were included, with a mean age of 30.83 years and a gestational age at admission ranging from 11 weeks and 4 days to 40 weeks and 1 day. Comorbidities included Marfan syndrome (n = 4), gestational hypertension (n = 1), and diabetes mellitus (n = 2). Surgically, 7 patients underwent a Bentall procedure, 4 underwent an isolated Sun's procedure, and 1 received a combined Sun's procedure and coronary artery bypass grafting (CABG). The in-hospital mortality rate was 16.7% (2/12). There were four fetal deaths, one due to preexisting malformation and three following elective termination due to early gestational age. At the 1-year follow-up, all surviving patients and their newborns were living normally without significant complications. CONCLUSION: This single-center study demonstrates that for pregnant patients with ATAAD, timely surgical repair, when managed by a multidisciplinary team, is a feasible strategy and is associated with favorable maternal and fetal outcomes. FAU - Xu, Yu AU - Xu Y AD - Department of Cardiovascular Surgery, Fujian Medical University Union Hospital, Fuzhou, China. FAU - Xia, Yu-Hao AU - Xia YH AD - Department of Cardiovascular Surgery, Fujian Medical University Union Hospital, Fuzhou, China. FAU - Bai, Zi-Ming AU - Bai ZM AD - Department of Cardiovascular Surgery, Fujian Medical University Union Hospital, Fuzhou, China. FAU - Dai, Xiao-Fu AU - Dai XF AD - Department of Cardiovascular Surgery, Fujian Medical University Union Hospital, Fuzhou, China. 13365912195@163.com. LA - eng GR - 82070476/National Natural Science Foundation of China/ PT - Journal Article DEP - 20260211 PL - England TA - BMC Pregnancy Childbirth JT - BMC pregnancy and childbirth JID - 100967799 SB - IM MH - Humans MH - Female MH - Pregnancy MH - *Dissection, Ascending Aorta/surgery MH - *Pregnancy Complications, Cardiovascular/surgery/mortality MH - Retrospective Studies MH - Adult MH - Pregnancy Outcome MH - Hospital Mortality MH - Acute Disease MH - Marfan Syndrome MH - *Aortic Dissection/surgery PMC - PMC12998167 OTO - NOTNLM OT - Acute type a aortic dissection OT - Management strategies OT - Pregnancy COIS- Declarations. Ethics approval and consent to participate: This research was approved by the Ethics Committee of Union Hospital Affiliated to Fujian Medical University (Ethical approval number is 2025KY36). Informed consent was waived due to the retrospective nature of the study. This study complies with the relevant requirements of the Declaration of Helsinki. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2026/02/12 00:47 MHDA- 2026/06/27 06:45 PMCR- 2026/02/11 CRDT- 2026/02/11 23:55 PHST- 2026/01/04 00:00 [received] PHST- 2026/02/09 00:00 [accepted] PHST- 2026/06/27 06:45 [medline] PHST- 2026/02/12 00:47 [pubmed] PHST- 2026/02/11 23:55 [entrez] PHST- 2026/02/11 00:00 [pmc-release] AID - 10.1186/s12884-026-08803-0 [pii] AID - 8803 [pii] AID - 10.1186/s12884-026-08803-0 [doi] PST - epublish SO - BMC Pregnancy Childbirth. 2026 Feb 11;26(1):291. doi: 10.1186/s12884-026-08803-0. PMID- 41671194 OWN - NLM STAT- MEDLINE DCOM- 20260707 LR - 20260921 IS - 1664-5502 (Electronic) IS - 1664-3828 (Print) IS - 1664-5502 (Linking) VI - 16 IP - 1 DP - 2026 TI - Heart Failure and Comorbidities (Chronic Kidney Disease, Diabetes, Obesity) Management: A Multidisciplinary Approach. PG - 95-112 LID - 10.1159/000550503 [doi] AB - BACKGROUND: Heart failure (HF) frequently coexists with chronic kidney disease (CKD), type 2 diabetes (T2D), and obesity, creating a complex clinical landscape that requires integrated, multidisciplinary management. The three main HF phenotypes - HF with reduced ejection fraction (EF /=50%) - differ in their underlying pathophysiology and therapeutic approaches. Approximately 20-40% of patients with HF have T2D, 30-40% are obese (body mass index >/=30 kg/m2), and 45-63% have CKD. These comorbidities are interrelated through overlapping mechanisms such as insulin resistance, chronic inflammation, neurohormonal activation, and endothelial dysfunction, which amplify morbidity, mortality, and healthcare costs. SUMMARY: The interplay between HF, CKD, T2D, and obesity extends beyond hemodynamic compromise, influencing other frequent conditions such as anemia, sleep apnea, and atrial fibrillation. Addressing these interconnected comorbidities can yield cumulative benefits by improving both HF-specific and overall health outcomes. Data from recent clinical trials and observational studies indicate how these conditions modify risk, affect therapeutic response, and influence guideline-directed medical therapy. Optimal care involves timely recognition, evidence-based management, and coordination across specialties. Key contributors to care include cardiologists, primary care physicians, endocrinologists, nephrologists, pharmacists, dietitians, and mental health professionals. KEY MESSAGES: The coexistence of HF with CKD, T2D, and obesity constitutes a major clinical challenge with shared pathogenic pathways. Managing these comorbidities requires an integrated, multidisciplinary strategy to improve outcomes and quality of life. Barriers such as clinical inertia, polypharmacy, and socioeconomic disparities continue to impede effective therapy implementation. Enhanced collaboration and patient-centered care models are essential to optimize management in this high-risk population. CI - (c) 2026 The Author(s). Published by S. Karger AG, Basel. FAU - Abramov, Dmitry AU - Abramov D AD - Division of Cardiology, Department of Medicine, Loma Linda University Health, Loma Linda, California, USA, dabramov@llu.edu. FAU - Mathew, Roy O AU - Mathew RO AD - Division of Nephrology, Department of Medicine, Loma Linda VA Healthcare System, Loma Linda, California, USA. FAU - Fordan, Steve V AU - Fordan SV AD - University of North Texas Health Science Center, Fort Worth, Texas, USA. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20260211 PL - Switzerland TA - Cardiorenal Med JT - Cardiorenal medicine JID - 101554863 SB - IM EIN - Cardiorenal Med. 2026;16(1):311. doi: 10.1159/000552924. PMID: 42378164 MH - Humans MH - *Heart Failure/therapy/epidemiology/physiopathology/complications MH - *Diabetes Mellitus, Type 2/therapy/epidemiology/complications MH - *Obesity/therapy/epidemiology/complications MH - *Renal Insufficiency, Chronic/therapy/epidemiology/complications/physiopathology MH - Comorbidity MH - Patient Care Team MH - Stroke Volume/physiology MH - Disease Management PMC - PMC13106961 OTO - NOTNLM OT - Chronic kidney disease OT - Comorbidities OT - Guideline-directed medical therapy OT - Heart failure OT - Type 2 diabetes COIS- D.A. has received speaker fees from Bayer and AstraZeneca. S.V.F. has received research funding from Bayer and Novo Nordisk and speaker fees from Bayer, Novo Nordisk, and Eli Lilly. R.O.M. is an employee of the Veterans Health Administration (VHA) but is not speaking for the VHA in this document. EDAT- 2026/02/11 18:59 MHDA- 2026/03/24 18:42 PMCR- 2026/02/11 CRDT- 2026/02/11 13:13 PHST- 2025/08/11 00:00 [received] PHST- 2025/12/31 00:00 [accepted] PHST- 2026/03/24 18:42 [medline] PHST- 2026/02/11 18:59 [pubmed] PHST- 2026/02/11 13:13 [entrez] PHST- 2026/02/11 00:00 [pmc-release] AID - 000550503 [pii] AID - 550503 [pii] AID - 10.1159/000550503 [doi] PST - ppublish SO - Cardiorenal Med. 2026;16(1):95-112. doi: 10.1159/000550503. Epub 2026 Feb 11. PMID- 41669168 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260211 LR - 20260213 IS - 2225-319X (Print) IS - 2304-1021 (Electronic) IS - 2225-319X (Linking) VI - 15 IP - 1 DP - 2026 Jan 31 TI - Lessons learned during my 25 years as Dr. Carpentier's echocardiographer. PG - 2 LID - 10.21037/acs-2025-dmv-08 [doi] LID - 2 AB - My collaboration with Professor Carpentier began in the early 1990s and was to continue for more than 25 years. Ours was a unique relationship based on mutual respect and unwavering trust: he liked to introduce me as "the justice of the peace", a symbol of the power of partnership. The lessons I learned during my 25 years with Professor Carpentier could be summarized in four key messages: understanding the surgeon's needs based upon the pathophysiological triad and functional approach, establishing a dedicated two-dimensional (2D)/three-dimensional (3D) intra-operative echo protocol in a common language, participating in evolution and evaluation of mitral valve reconstruction and transmitting knowledge to younger generations by education: "give to be given". I owe my entire professional career to him. Beyond that, we have forged an unbreakable bond, a relationship that is not only scientific but also deeply human. This filial bond will last forever. CI - (c) AME Publishing Company. FAU - Berrebi, Alain AU - Berrebi A AD - Cardiac Surgery Department, European Georges Pompidou Hospital, AP-HP Universite Paris Cite and Institut Medico-chirurgical Montsouris, Paris, France. LA - eng PT - Journal Article PT - Review DEP - 20260129 PL - China TA - Ann Cardiothorac Surg JT - Annals of cardiothoracic surgery JID - 101605877 PMC - PMC12884184 OTO - NOTNLM OT - Heart team OT - education OT - intraoperative echo OT - mitral reconstruction COIS- Conflicts of Interest: The author has no conflicts of interest to declare. EDAT- 2026/02/11 06:30 MHDA- 2026/02/11 06:31 PMCR- 2026/01/31 CRDT- 2026/02/11 04:38 PHST- 2025/09/18 00:00 [received] PHST- 2026/01/12 00:00 [accepted] PHST- 2026/02/11 06:31 [medline] PHST- 2026/02/11 06:30 [pubmed] PHST- 2026/02/11 04:38 [entrez] PHST- 2026/01/31 00:00 [pmc-release] AID - acs-15-01-2 [pii] AID - 10.21037/acs-2025-dmv-08 [doi] PST - ppublish SO - Ann Cardiothorac Surg. 2026 Jan 31;15(1):2. doi: 10.21037/acs-2025-dmv-08. Epub 2026 Jan 29. PMID- 41664245 OWN - NLM STAT- MEDLINE DCOM- 20260627 LR - 20260627 IS - 1940-0640 (Electronic) IS - 1940-0632 (Print) IS - 1940-0632 (Linking) VI - 21 IP - 1 DP - 2026 Feb 9 TI - Improving hospital-based care for patients with injection-drug related infections: provider perspectives. PG - 25 LID - 10.1186/s13722-026-00651-9 [doi] LID - 25 AB - BACKGROUND: Injection-related severe bacterial infections (SBIs), including skin and soft tissue infections, endocarditis, and osteomyelitis, are rising in prevalence in the United States and disproportionately affect people who inject drugs (PWID). Hospitalization for SBI presents a critical opportunity to engage patients in addiction and infectious disease care, yet healthcare systems often fail to capitalize on this moment. METHODS: This qualitative study explores the perspectives of 22 clinical stakeholders, including physicians, surgeons, nurses, and social workers, on barriers and strategies to improve care for hospitalized people who inject drugs (PWID) with substance use disorders (SUDs). Participants were recruited through purposive sampling from a large urban healthcare institution and selected external sites. Semi-structured interviews were conducted and analyzed using a thematic analysis approach. RESULTS: Three core themes emerged: empowering clinical teams, enhancing patient care, and improving interdisciplinary workflows. Participants called for stronger provider education on substance use disorders, stigma reduction, and communication; expanded access to addiction consults, harm reduction tools, peer navigators, and flexible discharge options such as OPAT with coordinated follow-up. Barriers included limited staffing, inconsistent access to addiction specialists and peers, and institutional inertia around discharge and reimbursement. Stakeholders highlighted telemedicine and structured interdisciplinary communication as means to prevent care fragmentation, noting that patient-directed discharges often stem from unmanaged withdrawal, stigma, and mistrust within existing hospital systems. CONCLUSIONS: Our findings align with prior research on addiction consult models and highlight emerging support for hybrid care delivery models that integrate harm reduction, peer support, and telehealth. However, practical and structural limitations, such as policy constraints, funding gaps, and misaligned institutional incentives, remain significant obstacles. This study contributes to a growing body of literature calling for targeted, feasible interventions that can transform hospital-based care for PWID with SBIs. Future work should address patient perspectives and evaluate outcomes of proposed strategies to guide institutional investment and policy reform. FAU - Appel, Giselle AU - Appel G AD - Northwell, New Hyde Park, NY, USA. gappel@northwell.edu. FAU - Hutchings, Kayla AU - Hutchings K AD - Weill Cornell Medical College, New York, NY, USA. FAU - Chin, Cristina AU - Chin C AD - Weill Cornell Medical College, New York, NY, USA. FAU - Vien, Alexis AU - Vien A AD - University of North Carolina School of Medicine, Chapel Hill, NC, USA. FAU - Scherer, Matthew AU - Scherer M AD - Columbia University Medical Center, New York, NY, USA. FAU - Avery, Jonathan AU - Avery J AD - Weill Cornell Medical College, New York, NY, USA. FAU - Kapadia, Shashi N AU - Kapadia SN AD - Weill Cornell Medical College, New York, NY, USA. LA - eng PT - Journal Article DEP - 20260209 PL - England TA - Addict Sci Clin Pract JT - Addiction science & clinical practice JID - 101316917 SB - IM MH - Humans MH - *Substance Abuse, Intravenous/complications/therapy MH - Qualitative Research MH - Female MH - Attitude of Health Personnel MH - *Hospitalization MH - *Bacterial Infections/therapy/etiology MH - United States MH - *Quality Improvement/organization & administration MH - Male MH - Patient Care Team/organization & administration MH - *Health Personnel PMC - PMC12896020 OTO - NOTNLM OT - Addiction OT - Clinical hospital programming OT - Injection drug use OT - Severe bacterial infections OT - Stakeholders OT - Substance use disorders COIS- Declarations. Ethics approval and consent to participate: This study was conducted in accordance with the ethical standards of the institutional research committee and with the Declaration of Helsinki and its later amendments. This study was approved by the Institutional Review Board at the Biomedical Research Association of New York (BRANY, #22-08-093-380). Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2026/02/10 06:30 MHDA- 2026/06/27 06:46 PMCR- 2026/02/09 CRDT- 2026/02/10 00:21 PHST- 2025/05/27 00:00 [received] PHST- 2026/01/27 00:00 [accepted] PHST- 2026/06/27 06:46 [medline] PHST- 2026/02/10 06:30 [pubmed] PHST- 2026/02/10 00:21 [entrez] PHST- 2026/02/09 00:00 [pmc-release] AID - 10.1186/s13722-026-00651-9 [pii] AID - 651 [pii] AID - 10.1186/s13722-026-00651-9 [doi] PST - epublish SO - Addict Sci Clin Pract. 2026 Feb 9;21(1):25. doi: 10.1186/s13722-026-00651-9. PMID- 41660854 OWN - NLM STAT- MEDLINE DCOM- 20260707 LR - 20260707 IS - 1442-200X (Electronic) IS - 1328-8067 (Linking) VI - 68 IP - 1 DP - 2026 Jan-Dec TI - Cardiac involvement in pediatric patients with inherited metabolic disease. PG - e70344 LID - 10.1111/ped.70344 [doi] AB - BACKGROUND: Inherited metabolic diseases (IMDs) are genetic disorders characterized by metabolic defects leading to toxic accumulation or deficiencies in essential molecules. Cardiovascular complications, including cardiomyopathy (CM), valve dysfunction (VD), and arrhythmias, significantly contribute to morbidity and mortality in IMD patients, necessitating comprehensive cardiac evaluation. This study investigates the relationship between IMDs and cardiovascular involvement in pediatric patients to inform clinical management. METHODS: A retrospective analysis was conducted on 1215 pediatric IMD patients (2012-2021). Cardiovascular involvement was assessed through clinical records, echocardiography, and laboratory findings. Patients with congenital heart defects were excluded. RESULTS: Among 85 IMD patients with cardiovascular involvement, the median age was 85 months, with a 20-month follow-up. CM was present in 57.6%, most commonly hypertrophic CM. VD was identified in 40%, and vasculopathy in 4.7%. Rhythm abnormalities occurred in 8.2%, with two cases of clinically significant arrhythmias. Energy metabolism disorders were most associated with CM (71.8%), while VD was predominant in lipoprotein metabolism disorders (66.7%). Cardiac involvement was most frequently detected in infancy (45.9%). Disease progression occurred in 60% of intoxication-type and 41% of energy metabolism disorders. The mortality rate was 21.2%, higher in CM patients (22.4%) than in those with VD (17.6%). CONCLUSION: Cardiovascular complications impose a substantial burden on pediatric IMD patients. Early detection and a multidisciplinary approach are crucial for improving outcomes. Comprehensive cardiac assessment and tailored interventions can mitigate risks, highlighting the need for further multicenter studies to refine management strategies. CI - (c) 2026 Japan Pediatric Society. FAU - Gozen Bayramoglu, Gamzegul AU - Gozen Bayramoglu G AUID- ORCID: 0009-0007-8673-509X AD - Department of Pediatrics, Ankara University Faculty of Medicine, Ankara, Turkiye. FAU - Kose, Engin AU - Kose E AUID- ORCID: 0000-0001-7238-2894 AD - Division of Pediatric Metabolism, Department of Pediatrics, Ankara University Faculty of Medicine, Ankara, Turkiye. AD - Rare Diseases Research and Application Center, Ankara University, Ankara, Turkiye. FAU - Oncul, Ummuhan AU - Oncul U AUID- ORCID: 0000-0003-0194-9739 AD - Division of Pediatric Metabolism, Department of Pediatrics, Ankara University Faculty of Medicine, Ankara, Turkiye. FAU - Murt, Begum AU - Murt B AUID- ORCID: 0000-0003-3945-3384 AD - Division of Pediatric Cardiology, Department of Pediatrics, Ankara University Faculty of Medicine, Ankara, Turkiye. FAU - Ramoglu, Mehmet Gokhan AU - Ramoglu MG AUID- ORCID: 0000-0002-4117-0685 AD - Division of Pediatric Cardiology, Department of Pediatrics, Ankara University Faculty of Medicine, Ankara, Turkiye. FAU - Ucar, Tayfun AU - Ucar T AUID- ORCID: 0000-0003-3386-0691 AD - Division of Pediatric Cardiology, Department of Pediatrics, Ankara University Faculty of Medicine, Ankara, Turkiye. FAU - Eminoglu, Fatma Tuba AU - Eminoglu FT AUID- ORCID: 0000-0002-5880-1113 AD - Division of Pediatric Metabolism, Department of Pediatrics, Ankara University Faculty of Medicine, Ankara, Turkiye. AD - Rare Diseases Research and Application Center, Ankara University, Ankara, Turkiye. LA - eng PT - Journal Article PL - Australia TA - Pediatr Int JT - Pediatrics international : official journal of the Japan Pediatric Society JID - 100886002 SB - IM MH - Humans MH - Female MH - Retrospective Studies MH - Male MH - Child, Preschool MH - Child MH - Infant MH - Echocardiography MH - *Metabolism, Inborn Errors/complications MH - Adolescent MH - *Cardiomyopathies/etiology/epidemiology MH - Arrhythmias, Cardiac/etiology/epidemiology MH - *Metabolic Diseases/complications MH - *Heart Diseases/etiology/epidemiology OTO - NOTNLM OT - arrhythmia OT - cardiac involvement OT - cardiomyopathy OT - inherited metabolic disease OT - pediatric OT - valve dysfunction EDAT- 2026/02/09 12:53 MHDA- 2026/02/09 12:54 CRDT- 2026/02/09 08:03 PHST- 2025/11/23 00:00 [revised] PHST- 2025/09/21 00:00 [received] PHST- 2026/01/07 00:00 [accepted] PHST- 2026/02/09 12:54 [medline] PHST- 2026/02/09 12:53 [pubmed] PHST- 2026/02/09 08:03 [entrez] AID - 10.1111/ped.70344 [doi] PST - ppublish SO - Pediatr Int. 2026 Jan-Dec;68(1):e70344. doi: 10.1111/ped.70344. PMID- 41660167 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260209 LR - 20260211 IS - 2474-1949 (Electronic) IS - 2474-1949 (Linking) VI - 11 IP - 1 DP - 2026 Jan TI - Pre-Clinical Case Competition to Assess Confidence in Responding to Select Out-Of-Hospital Medical Emergencies. PG - SG29-SG58 LID - 10.5070/M5.52198 [doi] AB - AUDIENCE: This session is intended for first- and second-year medical students, or any pre-clinical medical students. INTRODUCTION: Preclinical learners build skills and confidence when they practice first responder tasks early in training, and simulation helps them to perform basic procedures better.1,2 A small group case competition uses a game format to reinforce rapid assessment, clear team roles, and closed-loop communication.3,4Out-of-hospital cardiac arrest affects hundreds of thousands of people in the United States each year, and survival to discharge is low. Bystander cardiopulmonary resuscitation (CPR) and early use of an automated external defibrillator (AED) improve outcomes.5,6 Anaphylaxis is a time-sensitive emergency seen in the community and in the emergency department (ED). Epinephrine is the first-line treatment, and delay to administration worsens outcomes.7,8 Opioid overdose remains a major cause of preventable death. Early recognition, respiratory support, and Naloxone administration are key steps.9. EDUCATIONAL OBJECTIVES: By the end of this activity, learners will be able to:Demonstrate the application of skills in real-life first responder scenarios, including suspected opioid overdose, cardiac arrest, and anaphylaxis.Apply knowledge of scene safety and the role of the first responder in various situations.Assess the challenges while applying the skills necessary for collaborative work within a medical team. EDUCATIONAL METHODS: A competition combining simulation-based and team-based learning reinforced first responder skills among first- and second-year medical students. Attending physicians evaluated simulated out-of-hospital emergency scenarios using a detailed rubric. This method was chosen to engage learners in a lower-stakes (but still simulated high-pressure) assessment of their skills where undifferentiated patients challenge recall and application in new, previously unknown scenarios.This format was chosen to keep preclinical students active and focused while they practice time-critical first responder skills. Simulation allows decision-making, hands-on actions, and immediate feedback in a safe setting. Team-based learning mirrors ED teamwork by assigning clear roles, prompting closed-loop communication, and requiring shared problem-solving. Station design supports repeated practice and brief debriefs, which builds retention and confidence for early learners. Faculty-scored rubrics provide observable, standardized performance measures and make feedback specific and actionable. RESEARCH METHODS: Pre- and post-intervention surveys assessed the effectiveness of the case competition featuring three simulation scenarios in improving students' confidence in managing emergency situations. RESULTS: The competition increased participants' confidence in responding to various scenarios, particularly opioid overdoses. Most participants expressed high likelihood of participating in future competitions. Ten preclinical students completed pre- and post-session surveys. Confidence increased across the cohort. For the opioid overdose scenario, "complete confidence" rose from 1/10 (10%) pre- to 6/10 (60%) post. Confidence in cardiac arrest and anaphylaxis also trended upward. Likelihood to respond to a public emergency changed minimally. Interest in future events was high, with 6/10 (60%) extremely likely and 4/10 (40%) somewhat likely to participate again. DISCUSSION: The competition successfully increased confidence and fostered collaboration but faced recruitment challenges due to its optional nature and scheduling. Future implementations could include more advanced learners. TOPICS: First aid, first responder, competition, pre-clinical. CI - (c) 2026 Fillmore, et al. FAU - Fillmore, Harrison AU - Fillmore H AD - Columbia University Vagelos College of Physicians and Surgeons, New York, NY. FAU - Heisler, Thomas AU - Heisler T AD - Columbia University Vagelos College of Physicians and Surgeons, New York, NY. FAU - Nadeau, Marissa AU - Nadeau M AD - Columbia University Irving Medical Center, Department of Emergency Medicine, New York, NY. FAU - Worley, Emmagene AU - Worley E AD - Columbia University Irving Medical Center, Department of Emergency Medicine, New York, NY. FAU - Titone, Lauren AU - Titone L AD - Columbia University Irving Medical Center, Department of Emergency Medicine, New York, NY. FAU - Murano, Tiffany AU - Murano T AD - Columbia University Irving Medical Center, Department of Emergency Medicine, New York, NY. FAU - Truong, Jimmy AU - Truong J AD - Columbia University Irving Medical Center, Department of Emergency Medicine, New York, NY. LA - eng PT - Journal Article DEP - 20260131 PL - United States TA - J Educ Teach Emerg Med JT - Journal of education & teaching in emergency medicine JID - 101741448 PMC - PMC12880889 EDAT- 2026/02/09 12:54 MHDA- 2026/02/09 12:55 PMCR- 2026/01/31 CRDT- 2026/02/09 06:58 PHST- 2024/09/01 00:00 [received] PHST- 2025/10/15 00:00 [accepted] PHST- 2026/02/09 12:55 [medline] PHST- 2026/02/09 12:54 [pubmed] PHST- 2026/02/09 06:58 [entrez] PHST- 2026/01/31 00:00 [pmc-release] AID - jetem-11-1-sg29 [pii] AID - 10.5070/M5.52198 [doi] PST - epublish SO - J Educ Teach Emerg Med. 2026 Jan 31;11(1):SG29-SG58. doi: 10.5070/M5.52198. eCollection 2026 Jan. PMID- 41659021 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260209 LR - 20260209 IS - 0976-5662 (Print) IS - 2213-3445 (Electronic) IS - 0976-5662 (Linking) VI - 73 DP - 2026 Feb TI - Early onset scoliosis in syndromic and neuromuscular disorders: A multidisciplinary approach. PG - 103345 LID - 10.1016/j.jcot.2026.103345 [doi] LID - 103345 AB - Children with neuromuscular and syndromic disorders are among the most medically fragile patients in pediatric spine care. Conditions such as cerebral palsy, myelomeningocele, spinal muscular atrophy, neurofibromatosis type 1, Marfan syndrome, and Prader-Willi syndrome carry a high risk of early-onset scoliosis during critical periods of thoracic and pulmonary development. In these populations, scoliosis is rarely an isolated problem; it reflects the cumulative burden of neurologic impairment, connective tissue fragility, cardiopulmonary compromise, nutritional deficiency, and systemic disease. This review highlights the clinical and surgical challenges unique to each condition while emphasizing the central role of multidisciplinary care. In cerebral palsy, scoliosis risk correlates with motor severity and is compounded by respiratory and nutritional compromise. In myelomeningocele, neurosurgical and urologic coordination is essential given the prevalence of shunt dependence, Chiari malformation, tethered cord, and neurogenic bladder. In spinal muscular atrophy, perioperative pathways center on airway clearance, noninvasive ventilation, and nutritional optimization. Neurofibromatosis type 1 is distinguished by dystrophic scoliosis and dural ectasia, requiring advanced imaging and tailored instrumentation, while families often seek broader clinic support from genetics, oncology, and ophthalmology. In Marfan syndrome, connective tissue fragility complicates fixation, and combined management with cardiology and chest wall specialists is often required. For Prader-Willi syndrome, obesity, endocrine dysfunction, and severe sleep apnea demand careful optimization. Evidence demonstrates that standardized multidisciplinary pathways shorten hospitalizations, reduce pulmonary and infectious complications, and improve consistency of care. Beyond measurable outcomes, families report greater trust and satisfaction when diverse specialties are integrated. Together, these findings reinforce that optimal management of neuromuscular and syndromic scoliosis depends not only on surgical expertise, but also on coordinated, comprehensive, and lifelong care. CI - (c) 2026 Delhi Orthopedic Association. All rights are reserved, including those for text and data mining, AI training, and similar technologies. FAU - Wey, Aaron J AU - Wey AJ AD - Shriners Children's Philadelphia, 3551 N Broad St, Philadelphia, PA, 19140, USA. FAU - Schupper, Alexander J AU - Schupper AJ AD - Shriners Children's Philadelphia, 3551 N Broad St, Philadelphia, PA, 19140, USA. FAU - CreveCoeur, Travis S AU - CreveCoeur TS AD - Shriners Children's Philadelphia, 3551 N Broad St, Philadelphia, PA, 19140, USA. FAU - Samdani, Amer F AU - Samdani AF AD - Shriners Children's Philadelphia, 3551 N Broad St, Philadelphia, PA, 19140, USA. LA - eng PT - Journal Article PT - Review DEP - 20260112 PL - India TA - J Clin Orthop Trauma JT - Journal of clinical orthopaedics and trauma JID - 101559469 PMC - PMC12873731 OTO - NOTNLM OT - Cerebral palsy OT - Early onset scoliosis OT - Marfan syndrome OT - Multidisciplinary OT - Myelomeningocele OT - Neurofibromatosis type 1 OT - Prader-Willi syndrome OT - Spinal muscular atrophy COIS- AFS: Consultant for DePuy Synthes Spine, Ethicon Endosurgery, Globus NuVasive, Highridge Medical, Medical Device Business Services, Medtronic, Mirus. Royalties from Globus NuVasive and Highridge Medical. AJW, AJS, and TAC report no competing interests. EDAT- 2026/02/09 12:53 MHDA- 2026/02/09 12:54 PMCR- 2027/01/12 CRDT- 2026/02/09 06:49 PHST- 2025/09/19 00:00 [received] PHST- 2026/01/10 00:00 [accepted] PHST- 2026/02/09 12:54 [medline] PHST- 2026/02/09 12:53 [pubmed] PHST- 2026/02/09 06:49 [entrez] PHST- 2027/01/12 00:00 [pmc-release] AID - S0976-5662(26)00011-1 [pii] AID - 103345 [pii] AID - 10.1016/j.jcot.2026.103345 [doi] PST - epublish SO - J Clin Orthop Trauma. 2026 Jan 12;73:103345. doi: 10.1016/j.jcot.2026.103345. eCollection 2026 Feb. PMID- 41658928 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260209 LR - 20260211 IS - 2666-2507 (Electronic) IS - 2666-2507 (Linking) VI - 35 DP - 2026 Feb TI - Transcatheter aortic valve replacement infective endocarditis presenting as ascending aorta false aneurysm-a new clinical entity? PG - 102160 LID - 10.1016/j.xjtc.2025.10.030 [doi] LID - 102160 AB - OBJECTIVES: Infective endocarditis (IE) after transcatheter aortic valve replacement (TAVR) is rare. We describe patients referred to a tertiary heart center endocarditis team, with post-TAVR IE complicated by infected ascending aorta false aneurysms. METHODS: Among 60 patients with post-TAVR IE who were referred to our center between January 2016 and October 2024, 7 (11.7%) patients were complicated by false aneurysm and aortitis. In all cases, self-expanding transcatheter heart valves (THVs), primarily Symetis ACURATE neo, were used. RESULTS: Infected false aneurysm formation mainly at the tip of the THV stabilization arches and aortitis were identified only on cardiac computerized tomography. Five patients underwent surgical explant of the TAVR valve with aortic valve replacement. Interposition graft replacement of the ascending aorta was performed in 4 cases whereas 1 patient underwent aorta patch repair. Mitral valve surgery and coronary artery bypass graph were performed as a concomitant procedure in 2 cases. Two patients were managed conservatively due to extreme surgical risk. One patient died perioperatively, and one patient died during follow-up. CONCLUSIONS: Unlike prosthetic valve endocarditis after surgical aortic valve replacement, TAVR-IE may involve the ascending aorta, leading to life-threatening false aneurysm formation at the tip of the THV stabilization arches, where the device was adherent to the aortic wall. This pathology often eludes detection by echocardiography, underscoring the essential role of cardiac computed tomography in diagnosis and surgical planning. Clinicians should maintain a high index of suspicion for this rare but unique life-threatening complication and consider early use of advanced imaging. CI - (c) 2025 The The Author(s). FAU - Codner, Pablo AU - Codner P AD - Department of Cardiology, Rabin Medical Center, Petach Tikva, Israel. FAU - Rubchevsky, Victor AU - Rubchevsky V AD - Infectious Disease Unit, Rabin Medical Center, Petach Tikva, Israel. FAU - Hamdan, Ashraf AU - Hamdan A AD - Department of Cardiology, Rabin Medical Center, Petach Tikva, Israel. FAU - Awesat, Janan AU - Awesat J AD - Department of Cardiology, Rabin Medical Center, Petach Tikva, Israel. FAU - Belkin, David AU - Belkin D AD - Department of Cardiology, Rabin Medical Center, Petach Tikva, Israel. FAU - Shapira, Yaron AU - Shapira Y AD - Department of Cardiology, Rabin Medical Center, Petach Tikva, Israel. FAU - Shaked, Hilla AU - Shaked H AD - Department of Nuclear Medicine, Rabin Medical Center, Petach Tikva, Israel. FAU - Bernstine, Hana AU - Bernstine H AD - Department of Cardiothoracic Surgery, Rabin Medical Center, Petach Tikva, Israel. FAU - Vaturi, Mordehay AU - Vaturi M AD - Department of Cardiology, Rabin Medical Center, Petach Tikva, Israel. FAU - Kornowski, Ran AU - Kornowski R AD - Department of Cardiology, Rabin Medical Center, Petach Tikva, Israel. FAU - Leviner, Dror B AU - Leviner DB AD - Department of Cardiothoracic Surgery, Carmel Medical Center, Haifa, Israel. FAU - Orvin, Katia AU - Orvin K AD - Department of Cardiology, Rabin Medical Center, Petach Tikva, Israel. FAU - Sharony, Ram AU - Sharony R AD - Department of Cardiothoracic Surgery, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. LA - eng PT - Journal Article DEP - 20251121 PL - United States TA - JTCVS Tech JT - JTCVS techniques JID - 101768546 PMC - PMC12881819 OTO - NOTNLM OT - aorta OT - endocarditis OT - false aneurysm OT - prosthetic valve OT - transcatheter heart valve COIS- The authors reported no conflicts of interest. The Journal policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest. EDAT- 2026/02/09 12:53 MHDA- 2026/02/09 12:54 PMCR- 2025/11/21 CRDT- 2026/02/09 06:48 PHST- 2025/09/22 00:00 [received] PHST- 2025/10/05 00:00 [accepted] PHST- 2026/02/09 12:54 [medline] PHST- 2026/02/09 12:53 [pubmed] PHST- 2026/02/09 06:48 [entrez] PHST- 2025/11/21 00:00 [pmc-release] AID - S2666-2507(25)00541-3 [pii] AID - 102160 [pii] AID - 10.1016/j.xjtc.2025.10.030 [doi] PST - epublish SO - JTCVS Tech. 2025 Nov 21;35:102160. doi: 10.1016/j.xjtc.2025.10.030. eCollection 2026 Feb. PMID- 41657216 OWN - NLM STAT- MEDLINE DCOM- 20260707 LR - 20260707 IS - 1524-4539 (Electronic) IS - 0009-7322 (Linking) VI - 153 IP - 10 DP - 2026 Mar 10 TI - Coronary Atherosclerosis in Patients With Cancer and Survivors: A Scientific Statement From the American Heart Association. PG - e916-e933 LID - 10.1161/CIR.0000000000001391 [doi] AB - There is an emerging convergence between atherosclerotic cardiovascular disease and cancer, driven by shared risk factors and overlapping pathophysiologic mechanisms. Traditional factors, such as smoking, aging, obesity, hypertension, and diabetes, alongside novel markers, such as clonal hematopoiesis of indeterminate potential, not only predispose individuals to both malignancies and coronary atherosclerosis but also amplify the risk of cardiotoxicity from cancer therapies. Inflammatory processes play a central role in atherogenesis, a process further accelerated by oncologic treatments-including chemotherapy (eg, anthracyclines, 5-fluorouracil), targeted and hormone therapies (eg, tyrosine kinase inhibitors, androgen deprivation, aromatase inhibitors), immune checkpoint inhibitors, and radiation therapy (RT)-that contribute to endothelial dysfunction and plaque instability. This scientific statement synthesizes the evidence on the interplay between cancer and coronary atherosclerosis, highlighting advances in noninvasive imaging modalities (ie, cardiac CT, nuclear imaging, cardiac magnetic resonance, echocardiography) for early detection, risk stratification, and surveillance of coronary artery disease in oncologic populations, and examines the role of invasive imaging techniques in guiding revascularization decisions. Given the elevated bleeding and thrombotic risks in these patients, individualized management of post-percutaneous coronary intervention medications and abbreviated dual antiplatelet therapy regimens is emphasized. This scientific statement also addresses knowledge gaps and reinforces the need for more evidence to improve risk stratification for atherosclerotic cardiovascular disease in patients with cancer. The shared pathobiology between coronary atherosclerosis and cancer necessitates an integrated, multidisciplinary approach to screening, diagnosis, and management. FAU - Zhang, Lili AU - Zhang L FAU - Iliescu, Cezar AU - Iliescu C FAU - Ferencik, Maros AU - Ferencik M FAU - Finamore, Victoria AU - Finamore V FAU - Beavers, Craig AU - Beavers C FAU - Patel, Amit R AU - Patel AR FAU - Ghoshhajra, Brian AU - Ghoshhajra B FAU - Milgrom, Sarah AU - Milgrom S FAU - Dent, Susan AU - Dent S FAU - Baldassarre, Lauren A AU - Baldassarre LA FAU - Jaffe, Iris Z AU - Jaffe IZ FAU - Lopez-Mattei, Juan AU - Lopez-Mattei J CN - American Heart Association Cardio-Oncology Committee of the Council on Clinical Cardiology and Council on Genomic and Precision Medicine; Council on Cardiovascular and Stroke Nursing; and Council on Lifestyle and Cardiometabolic Health LA - eng PT - Journal Article PT - Review DEP - 20260209 PL - United States TA - Circulation JT - Circulation JID - 0147763 SB - IM MH - Humans MH - *Coronary Artery Disease/therapy/epidemiology/diagnostic imaging/etiology/diagnosis MH - *Neoplasms/therapy/epidemiology/complications MH - United States/epidemiology MH - American Heart Association MH - Risk Factors MH - *Cancer Survivors OTO - NOTNLM OT - AHA Scientific Statements OT - cardiac imaging techniques OT - cardio-oncology OT - coronary artery disease OT - percutaneous coronary intervention OT - plaque, atherosclerotic EDAT- 2026/02/09 06:30 MHDA- 2026/03/09 19:00 CRDT- 2026/02/09 05:05 PHST- 2026/03/09 19:00 [medline] PHST- 2026/02/09 06:30 [pubmed] PHST- 2026/02/09 05:05 [entrez] AID - 10.1161/CIR.0000000000001391 [doi] PST - ppublish SO - Circulation. 2026 Mar 10;153(10):e916-e933. doi: 10.1161/CIR.0000000000001391. Epub 2026 Feb 9. PMID- 41653027 OWN - NLM STAT- MEDLINE DCOM- 20260707 LR - 20260707 IS - 1365-2362 (Electronic) IS - 0014-2972 (Linking) VI - 56 IP - 2 DP - 2026 Feb TI - Improving end-of-life care in the cardiac intensive care unit: Navigating the challenge of timing palliative care intervention. PG - e70174 LID - 10.1111/eci.70174 [doi] AB - BACKGROUND: Integrating end-of-life (EoL) care in cardiac intensive care units (CICUs) is particularly complex because it requires a shift from a purely curative approach to one that emphasizes symptom management, emotional and spiritual support and patient-centered care. Moreover, this transition is challenging due to the need to balance life-sustaining treatments with the goals of comfort and dignity. The concept of EoL care varies across countries and is influenced by cultural, ethical and legal factors. METHODS: This narrative review examines palliative and EoL care in critically ill cardiac patients, including those with advanced heart failure, cardiogenic shock and other acute or chronic cardiac conditions, with a focus on models of care, multidisciplinary team involvement, ethical challenges and barriers to implementation in the CICU setting. RESULTS: Key candidates for palliative care (PC) in heart disease include patients with advanced heart failure, cardiogenic shock and other acute or chronic cardiac conditions; however, its implementation remains limited compared to other disciplines, such as oncology. In EoL care, multidisciplinary teams, including cardiologists, nurses, PC specialists and social workers, play a crucial role in providing holistic care. Effective communication with patients and their families is essential for aligning treatment with individual values and goals. Ethical dilemmas, such as the withdrawal of life-sustaining treatments and the deactivation of implanted cardiac devices, require compassionate and transparent decision-making. Unlike previous reviews, this work specifically highlights the timing of palliative care integration as the main factor influencing patient outcomes and family experience. CONCLUSIONS: Timely integration of palliative care in the CICU remains a major challenge. Significant gaps persist in training, resource allocation and quality indicators for palliative and EoL care. Addressing these shortcomings through enhanced education, standardized protocols and rigorous research is essential to ensure the effective delivery of PC in the CICU setting. CI - (c) 2026 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd. FAU - Giubilato, Simona AU - Giubilato S AD - Cardiology Department, Cannizzaro Hospital, Catania, Italy. FAU - Della Bona, Roberta AU - Della Bona R AUID- ORCID: 0000-0003-4146-7099 AD - Cardiovascular Disease Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy. FAU - Gambaro, Alessia AU - Gambaro A AUID- ORCID: 0000-0001-8341-1427 AD - Division of Cardiology, Department of Medicine, University of Verona, Verona, Italy. FAU - Sorini-Dini, Carlotta AU - Sorini-Dini C AD - U.O.C. Cardiologia Clinico Chirurgica (UTIC), A.O.U. Senese Ospedale Santa Maria Alle Scotte, Siena, Italy. FAU - Valente, Serafina AU - Valente S AD - U.O.C. Cardiologia Clinico Chirurgica (UTIC), A.O.U. Senese Ospedale Santa Maria Alle Scotte, Siena, Italy. FAU - Geraci, Giovanna AU - Geraci G AD - Cardiology Unit, S. Antonio Abate Hospital, ASP, Trapani, Erice, Italy. FAU - Riccio, Carmine AU - Riccio C AD - Cardiovascular Department, Sant'anna e San Sebastiano Hospital, Caserta, Italy. FAU - Di Lenarda, Andrea AU - Di Lenarda A AD - Cardiovascular Center, University Hospital and Health Services of Trieste, Trieste, Italy. FAU - Gulizia, Michele Massimo AU - Gulizia MM AD - U.O.C. Cardiologia, Ospedale Garibaldi-Nesima, Azienda di Rilievo Nazionale e Alta Specializzazione 'Garibaldi', Catania, Italy. FAU - Grimaldi, Massimo AU - Grimaldi M AD - Department of Cardiology, General Regional Hospital 'F. Miulli', Acquaviva Delle Fonti, Bari, Italy. FAU - Rossini, Roberta AU - Rossini R AD - SC Cardiologia, Azienda Santa Croce e Carle, Cuneo, Italy. FAU - Oliva, Fabrizio AU - Oliva F AD - Cardiac Intensive Care Unit, De Gasperis Cardio Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy. FAU - Gasparetto, Nicola AU - Gasparetto N AD - Division of Cardiology, AULSS2 Marca Trevigiana, Ca' Foncello Hospital, Treviso, Italy. FAU - Sacco, Alice AU - Sacco A AUID- ORCID: 0000-0002-8150-474X AD - Cardiac Intensive Care Unit, De Gasperis Cardio Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy. LA - eng PT - Journal Article PT - Review PL - England TA - Eur J Clin Invest JT - European journal of clinical investigation JID - 0245331 SB - IM MH - Humans MH - *Palliative Care/organization & administration MH - *Terminal Care/standards/organization & administration/methods MH - Heart Failure/therapy MH - *Heart Diseases/therapy MH - Patient Care Team MH - Intensive Care Units MH - Shock, Cardiogenic/therapy MH - Withholding Treatment MH - *Coronary Care Units OTO - NOTNLM OT - cardiac intensive care OT - decision-making OT - end-of-life OT - palliative care OT - quality of life EDAT- 2026/02/07 12:44 MHDA- 2026/02/07 12:45 CRDT- 2026/02/07 06:02 PHST- 2025/08/16 00:00 [received] PHST- 2025/12/26 00:00 [accepted] PHST- 2026/02/07 12:45 [medline] PHST- 2026/02/07 12:44 [pubmed] PHST- 2026/02/07 06:02 [entrez] AID - 10.1111/eci.70174 [doi] PST - ppublish SO - Eur J Clin Invest. 2026 Feb;56(2):e70174. doi: 10.1111/eci.70174. PMID- 41652431 OWN - NLM STAT- MEDLINE DCOM- 20260627 LR - 20260813 IS - 1472-6963 (Electronic) IS - 1472-6963 (Linking) VI - 26 IP - 1 DP - 2026 Feb 7 TI - Geriatricians' perceptions on multidisciplinary heart failure care in Belgium an exploratory qualitative study. LID - 10.1186/s12913-025-13927-8 [doi] LID - 360 AB - BACKGROUND: The perceptions of general practitioners (GP), cardiologists and pharmacists on multidisciplinary heart failure (HF) care were studied before. However, geriatricians are often overlooked in HF research, despite the high prevalence of HF in the elderly. Therefore, we investigated how geriatricians perceive their role in multidisciplinary HF care. METHODS: This study is a qualitative semi-structured interview study with geriatricians, working in Flanders, Belgium. Purposive sampling was performed, and interviews were conducted until data saturation was reached. The QUAGOL method was used for data analysis. RESULTS: Thirteen geriatricians were interviewed. They reported to feel confident about HF management and see themselves as the guardians of the patient during hospitalization. Regarding care organization during the hospitalization phase, striking differences were reported in triage at the emergency department (ED). Geriatricians were satisfied with the collaboration with the cardiologists and valued their role, although they reported differences in vision about dealing with geriatric HF patients. Regarding transmural care organization, follow-up after hospitalization was valued highly to prevent rehospitalization but most geriatricians did not see this as their responsibility. They mostly passed on the follow-up to the GP and the cardiologist. Some did take this follow-up into their own hands in various forms because of the high rehospitalization rate and many suggested ways to improve the organization of multidisciplinary HF care. Advance care planning was seen as an important aspect of geriatrics, yet they expected more involvement from both the cardiologist and the GP in this matter. CONCLUSIONS: Based on these results, our study highlights three recommendations for optimizing the care of geriatric HF patients. First, the development of standardized methods to triage patients at the ED, in combination with geriatric-cardiologist co-management to ensure that each patient receives appropriate in-hospital care. Secondly, structured and closer transitional follow-up to limit readmission rates. Lastly, inclusion of advance care planning as a mandatory component in every HF program. FAU - Smeets, Miek AU - Smeets M AD - Department of Family Medicine and Population Health, Primary and interdisciplinary Care Antwerp (ELIZA), University of Antwerpen, Antwerpen, Belgium. miek.smeets@uantwerpen.be. FAU - Nys, Bram AU - Nys B AD - Department of Public Health and Primary Care, KU Leuven, Kapucijnenvoer 33, blok j bus 7001, Leuven, 3000, Belgium. FAU - Raat, Willem AU - Raat W AD - Department of Public Health and Primary Care, KU Leuven, Kapucijnenvoer 33, blok j bus 7001, Leuven, 3000, Belgium. FAU - Vaes, Bert AU - Vaes B AD - Department of Public Health and Primary Care, KU Leuven, Kapucijnenvoer 33, blok j bus 7001, Leuven, 3000, Belgium. LA - eng PT - Journal Article DEP - 20260207 PL - England TA - BMC Health Serv Res JT - BMC health services research JID - 101088677 SB - IM MH - Humans MH - Belgium MH - *Heart Failure/therapy MH - Female MH - Qualitative Research MH - *Geriatricians/psychology MH - Male MH - Interviews as Topic MH - *Attitude of Health Personnel MH - Aged MH - *Patient Care Team/organization & administration MH - Middle Aged PMC - PMC12989128 OTO - NOTNLM OT - Geriatricians OT - Health care organization OT - Heart failure OT - Qualitative research COIS- Declarations. Ethics approval and consent to participate: We received approval from the Research Ethics Committee of the UZ/KU Leuven (MP018425) on the 7th of December 2021. All participating geriatricians gave their written informed consent prior to participation. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2026/02/07 00:30 MHDA- 2026/06/27 18:39 PMCR- 2026/02/07 CRDT- 2026/02/07 00:00 PHST- 2023/12/10 00:00 [received] PHST- 2025/12/15 00:00 [accepted] PHST- 2026/06/27 18:39 [medline] PHST- 2026/02/07 00:30 [pubmed] PHST- 2026/02/07 00:00 [entrez] PHST- 2026/02/07 00:00 [pmc-release] AID - 10.1186/s12913-025-13927-8 [pii] AID - 13927 [pii] AID - 10.1186/s12913-025-13927-8 [doi] PST - epublish SO - BMC Health Serv Res. 2026 Feb 7;26(1):360. doi: 10.1186/s12913-025-13927-8. PMID- 41646023 OWN - NLM STAT- MEDLINE DCOM- 20260706 LR - 20260813 IS - 1531-4995 (Electronic) IS - 0023-852X (Print) IS - 0023-852X (Linking) VI - 136 IP - 6 DP - 2026 Jun TI - Role of Pediatric Otolaryngologist in Pediatric Tracheostomy Code Blue Cases: A New Safety Initiative. PG - 2769-2776 LID - 10.1002/lary.70422 [doi] AB - OBJECTIVE: A "Code Blue" is a term to activate an alarm for the resuscitation team for a patient who has a cardiopulmonary arrest. The role of a pediatric otolaryngologist in a tracheostomy-related code blue case is not clearly defined. We aim to describe the role of pediatric otolaryngologists in pediatric tracheostomy code blue (PTCB) cases. METHODS: This retrospective study analyzed pediatric code blue cases in a tertiary care hospital from January 2019 to December 2022, before and after the implementation of a standardized PTCB that includes a pediatric otolaryngologist in the resuscitation team. Primary outcome variables included response time and survival-to-discharge of patients. RESULTS: The most common reason for code activation was reduced oxygen saturation. The leading cause for the otolaryngology consultation was tube blockage. Tracheostomy tube change was the most common intervention performed. The mean time of otolaryngology arrival was significantly decreased from 14.0 min pre-implementation to 4.0 min post-implementation (p < 0.001). While including all 48 PTCB events, pediatric otolaryngologist involvement was significantly associated with higher survival-to-discharge (94.4% vs. 66.7%, p = 0.028). While comparing post-PTCB protocol implementation versus pre-implementation, mortality declined from 23.8% to 3.7% with increased discharge rates, although this did not reach statistical significance (p = 0.073). CONCLUSION: Inclusion of a pediatric otolaryngologist in the resuscitation team reduces time-to-arrival of the pediatric otolaryngologist to the code blue activation site. Reduced time to pediatric otolaryngologist arrival and completion of interventions by pediatric otolaryngologist are associated with reduced mortality in PTCB events. CI - (c) 2026 The Author(s). The Laryngoscope published by Wiley Periodicals LLC on behalf of The American Laryngological, Rhinological and Otological Society, Inc. FAU - Shivnani, Deepa AU - Shivnani D AUID- ORCID: 0000-0003-2772-2065 AD - Department of Otorhinolaryngology and Head & Neck Surgery, University of Iowa, Iowa City, Iowa, USA. FAU - Klimara, Miles Jonathan AU - Klimara MJ AD - Department of Otolaryngology - Head & Neck Surgery, University of Iowa, Iowa City, Iowa, USA. FAU - Shruthi, M S AU - Shruthi MS AD - Department of Otorhinolaryngology and Head & Neck Surgery, Mahadevappa Rampure Medical College, Kalaburagi, Karnataka, India. FAU - Amle, Dnyanesh Balkrishna AU - Amle DB AD - Department of Biochemistry, All India Institute of Medical Sciences (AIIMS), Nagpur, India. FAU - Lin, Matthew Ern AU - Lin ME AUID- ORCID: 0000-0001-9914-9670 AD - Department of Head and Neck Surgery, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California, USA. FAU - Kim, Ian AU - Kim I AD - Department of Pediatrics and Department of Disease Prevention, Stanford University, Palo Alto, California, USA. FAU - Ashwath Ram, R N AU - Ashwath Ram RN AD - Department of Pediatric Intensive Care Unit (PICU), Manipal Hospitals, Bangalore, Karnataka, India. FAU - Raman, Eswaran Venkat AU - Raman EV AD - Department of Otorhinolaryngology and Head & Neck Surgery, University of Iowa, Iowa City, Iowa, USA. FAU - Aram, Gnanam AU - Aram G AD - Department of Pediatric Emergency, Manipal Hospital, Bangalore, India. FAU - Kobal, Mallikarjun Ravi AU - Kobal MR AD - Department of Pediatrics, Mahadevappa Rampure Medical College, Kalaburagi, Karnataka, India. FAU - Speed, Olivia E AU - Speed OE AUID- ORCID: 0000-0002-2316-0221 AD - Department of Otorhinolaryngology- Head & Neck Surgery, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA. FAU - John, Maie A St AU - John MAS AD - Department of Head and Neck Surgery, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California, USA. FAU - Chhetri, Dinesh AU - Chhetri D AD - Department of Head & Neck Surgery, UCLA School of Medicine, Los Angeles, California, USA. LA - eng PT - Journal Article DEP - 20260206 PL - United States TA - Laryngoscope JT - The Laryngoscope JID - 8607378 SB - IM MH - Humans MH - Retrospective Studies MH - *Tracheostomy/adverse effects MH - *Heart Arrest/therapy/mortality/etiology MH - Child MH - *Otolaryngologists MH - Female MH - Male MH - Child, Preschool MH - Infant MH - *Cardiopulmonary Resuscitation MH - *Physician's Role PMC - PMC13158825 OTO - NOTNLM OT - multidisciplinary resuscitation team OT - pediatric otolaryngologist OT - pediatrics code blue OT - tracheostomy COIS- The authors declare no conflicts of interest. EDAT- 2026/02/06 13:17 MHDA- 2026/05/11 06:31 PMCR- 2026/05/11 CRDT- 2026/02/06 06:03 PHST- 2026/01/26 00:00 [revised] PHST- 2025/04/23 00:00 [received] PHST- 2026/01/29 00:00 [accepted] PHST- 2026/05/11 06:31 [medline] PHST- 2026/02/06 13:17 [pubmed] PHST- 2026/02/06 06:03 [entrez] PHST- 2026/05/11 00:00 [pmc-release] AID - LARY70422 [pii] AID - 10.1002/lary.70422 [doi] PST - ppublish SO - Laryngoscope. 2026 Jun;136(6):2769-2776. doi: 10.1002/lary.70422. Epub 2026 Feb 6. PMID- 41643743 OWN - NLM STAT- MEDLINE DCOM- 20260902 LR - 20260918 IS - 1537-6591 (Electronic) IS - 1058-4838 (Linking) VI - 83 IP - 2 DP - 2026 Sep 2 TI - Baseline Antithrombotic Therapy and Intracranial Hemorrhage Risk in Infective Endocarditis: A Multicenter Prospective Cohort Study. PG - 203-213 LID - 10.1093/cid/ciag067 [doi] AB - BACKGROUND: Infective endocarditis (IE) carries high morbidity and mortality, largely from neurological complications. The clinical significance of chronic antithrombotic therapy remains uncertain. We assessed whether baseline antithrombotic therapy influences intracranial hemorrhage (ICH) and mortality in left-sided IE. METHODS: We analyzed a prospective multicenter cohort (2008-2018) including all patients with definite left-sided IE. Patients were classified at diagnosis as receiving no therapy (NT), antiplatelet therapy (APT), anticoagulation (AC), or combined therapy (CAT). The primary outcome was 30-day ICH; secondary outcomes included ischemic stroke, embolic events, major bleeding, and all-cause mortality. Multivariable logistic and Cox regression models adjusted for confounders. RESULTS: Among 3236 patients, 182 (5.6%) developed ICH, with the highest incidence in CAT (9.5%) and AC (6.8%). Compared with NT, baseline AC was independently associated with a higher frequency of ICH (adjusted risk ratio [aRR] 1.83, 95% CI 1.16-2.91), with the highest risk observed in CAT (aRR 2.45, 95% CI 1.55-3.87). Antiplatelet therapy was not associated with ICH. Ischemic stroke rates were similar across groups. Combined anticoagulation and antiplatelet therapy independently predicted higher 1-year mortality (adjusted hazard ratio [aHR] 1.21, 95% CI 1.02-1.43). Independent factors associated with ICH were Staphylococcus aureus and Candida spp. IE, extracranial embolism, prior cerebrovascular disease, and septic shock. CONCLUSIONS: These findings highlight the value of baseline antithrombotic exposure, together with microbiologic etiology and prior cerebrovascular disease, for early neurologic risk stratification at the time of IE diagnosis, informing neuroimaging decisions and multidisciplinary discussions involving infectious diseases specialists, neurologist, and cardiac surgeons among other specialists. CI - (c) The Author(s) 2026. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com. FAU - Solera, Javier T AU - Solera JT AUID- ORCID: 0000-0001-6833-6625 AD - Unit of Infectious Diseases, Hospital Universitario 12 de Octubre, Instituto de Investigacion Biomedica imas12, Madrid, Spain. FAU - Aparicio-Minguijon, Eduardo AU - Aparicio-Minguijon E AD - Unit of Infectious Diseases, Hospital Universitario 12 de Octubre, Instituto de Investigacion Biomedica imas12, Madrid, Spain. FAU - Dominguez-Perez, Laura AU - Dominguez-Perez L AD - Cardiology Department, Hospital Universitario 12 de Octubre, Instituto de Investigacion Biomedica imas12, Madrid, Spain. FAU - Munoz, Patricia AU - Munoz P AUID- ORCID: 0000-0001-5706-5583 AD - Clinical Microbiology and Infectious Diseases Department, Hospital General Universitario Gregorio Maranon, Instituto de Investigacion Sanitaria Gregorio Maranon (IiSGM), Madrid, Spain. AD - Centro de Investigacion Biomedica en Red de Enfermedades Respiratorias-CIBERES (CB06/06/0058), Madrid, Spain. AD - Medicine Department, Universidad Complutense de Madrid, Madrid, Spain. FAU - Vazquez-Alen, Pilar AU - Vazquez-Alen P AD - Neurology Department, Hospital General Universitario Gregorio Maranon, Madrid, Spain. FAU - Miyares, Ana Alvarez-Uria AU - Miyares AA AUID- ORCID: 0000-0002-6270-7058 AD - Clinical Microbiology and Infectious Diseases Department, Hospital General Universitario Gregorio Maranon, Instituto de Investigacion Sanitaria Gregorio Maranon (IiSGM), Madrid, Spain. FAU - de Alarcon, Aristides AU - de Alarcon A AD - Clinical Unit of Infectious Diseases, Microbiology and Parasitology (UCEIMP), Hospital Universitario Virgen del Rocio, Seville, Spain. AD - Grupo de Resistencias bacterianas y antimicrobianos CIBERINFEC, Instituto de Biomedicina de Sevilla (IBiS), Seville, Spain. AD - Medicine Department, Universidad de Sevilla, Seville, Spain. FAU - Poyato-Borrego, Manuel AU - Poyato-Borrego M AD - Clinical Unit of Infectious Diseases, Microbiology and Parasitology (UCEIMP), Hospital Universitario Virgen del Rocio, Seville, Spain. AD - Grupo de Resistencias bacterianas y antimicrobianos CIBERINFEC, Instituto de Biomedicina de Sevilla (IBiS), Seville, Spain. AD - Medicine Department, Universidad de Sevilla, Seville, Spain. FAU - Farinas, M Carmen AU - Farinas MC AUID- ORCID: 0000-0002-9259-2730 AD - Infectious Diseases Department, Hospital Universitario Marques de Valdecilla-IDIVAL, Santander, Spain. AD - Centro de Investigacion Biomedica en Red de Enfermedades Infecciosas-CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain. AD - Medicine Department, University of Cantabria, Santander, Spain. FAU - Miro, Jose M AU - Miro JM AUID- ORCID: 0000-0001-8057-7755 AD - Centro de Investigacion Biomedica en Red de Enfermedades Infecciosas-CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain. AD - Infectious Diseases Department, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain. AD - Reial Academia de Medicina de Catalunya (RAMC), Barcelona, Spain. FAU - Goenaga-Sanchez, Miguel Angel AU - Goenaga-Sanchez MA AUID- ORCID: 0000-0003-3532-4681 AD - Infectious Diseases Service, Hospital Universitario Donostia, IIS Biogipuzkoa, San Sebastian, Spain. FAU - Ojeda-Burgos, Guillermo AU - Ojeda-Burgos G AD - Infectious Diseases and Preventive Medicine Unit, Hospital Universitario Virgen de la Victoria, Malaga, Spain. AD - Instituto de Investigacion Biomedica de Malaga y Plataforma en Nanomedicina (IBIMA-Plataforma BIONAND), Malaga, Spain. FAU - Lopez-Cortes, Luis Eduardo AU - Lopez-Cortes LE AD - Medicine Department, Universidad de Sevilla, Seville, Spain. AD - Centro de Investigacion Biomedica en Red de Enfermedades Infecciosas-CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain. AD - Infectious Diseases and Microbiology Clinical Unit, Hospital Universitario Virgen Macarena, Seville, Spain. AD - Instituto de Biomedicina de Sevilla (IBiS)/CSIC, Seville, Spain. FAU - Sousa-Regueiro, Dolores AU - Sousa-Regueiro D AD - Infectious Diseases Department, Complejo Hospitalario A Coruna, A Coruna, Spain. FAU - Lopez-Medrano, Francisco AU - Lopez-Medrano F AUID- ORCID: 0000-0001-5333-7529 AD - Unit of Infectious Diseases, Hospital Universitario 12 de Octubre, Instituto de Investigacion Biomedica imas12, Madrid, Spain. AD - Medicine Department, Universidad Complutense de Madrid, Madrid, Spain. AD - Centro de Investigacion Biomedica en Red de Enfermedades Infecciosas-CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain. CN - GAMES Investigators LA - eng PT - Journal Article PT - Multicenter Study PL - United States TA - Clin Infect Dis JT - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America JID - 9203213 RN - 0 (Fibrinolytic Agents) RN - 0 (Anticoagulants) RN - 0 (Platelet Aggregation Inhibitors) SB - IM MH - Humans MH - Female MH - Male MH - Prospective Studies MH - *Intracranial Hemorrhages/epidemiology/etiology/chemically induced/mortality MH - *Endocarditis/drug therapy/complications/mortality MH - Middle Aged MH - Aged MH - *Fibrinolytic Agents/adverse effects/therapeutic use MH - Risk Factors MH - Anticoagulants/adverse effects/therapeutic use MH - Platelet Aggregation Inhibitors/therapeutic use/adverse effects MH - Incidence OTO - NOTNLM OT - antithrombotic therapy OT - infective endocarditis OT - intracranial hemorrhage OT - ischemic stroke OT - mortality COIS- Potential conflicts of interest. J. T. S.: support from Pfizer and Angelini for conference attendance (ESCMID Global 2025). E. A.-M.: support from Pfizer, Gilead, and MSD for conference attendance (ECCMID 2024-2025, SEIMC 2025). P. M.: honoraria for lectures from Basilea, Gilead, MSD, Menarini, Mundipharma, Pharmamar, Pfizer, Roche, Fundacion de Ciencias de la Salud, UIMP, Future Day Foundation, and Fundacion SEIMC-GESIDA and travel support from Pfizer and Mundipharma. M. P.-B.: honoraria for lectures from Canarian Society of Intensive Care and Coronary Units, and Micellium Foundation. L. E. L.-C.: scientific advisor for Angelini and speaker for Angelini, ViiV, Gilead, and Correvio. J. M. M. has received consulting honoraria and/or research grants from Angelini, Basilea, Contrafect, Cubist, Genentech, Gilead Sciences, Jansen, Lysovant, MSD, Pfizer, and ViiV Healthcare, outside the submitted work. All other authors report no potential conflicts. EDAT- 2026/02/06 00:30 MHDA- 2026/09/03 01:13 CRDT- 2026/02/05 19:03 PHST- 2025/08/21 00:00 [received] PHST- 2026/01/11 00:00 [accepted] PHST- 2026/09/03 01:13 [medline] PHST- 2026/02/06 00:30 [pubmed] PHST- 2026/02/05 19:03 [entrez] AID - 8465468 [pii] AID - 10.1093/cid/ciag067 [doi] PST - ppublish SO - Clin Infect Dis. 2026 Sep 2;83(2):203-213. doi: 10.1093/cid/ciag067. PMID- 41643133 OWN - NLM STAT- MEDLINE DCOM- 20260707 LR - 20260707 IS - 2327-6924 (Electronic) IS - 2327-6886 (Linking) VI - 38 IP - 2 DP - 2026 Feb 1 TI - Nurse practitioner and physician assistant collaborative staffing innovations to improve a cardiovascular surgery practice. PG - 108-115 LID - 10.1097/JXX.0000000000001220 [doi] AB - BACKGROUND: Successful use of nurse practitioner (NP) and physician assistant (PA) care models is vital to delivering optimal patient care, maintaining financial stability, and reducing staff burnout and turnover. LOCAL PROBLEM: A large cardiovascular surgery practice experienced substantial growth, leading to an obsolete NP and PA care model. Consequently, workplace satisfaction scores were reduced, and the NP and PA turnover rate in 2018 was unacceptably high. METHODS: A multidisciplinary redesign team was formed to address gaps in the care model through a quality-improvement initiative. The team analyzed current workflows, collected external and internal survey data, conducted patient tracers, and observed staff. Seventeen collaborative care models were proposed by frontline staff members and presented to their peers for feedback. This feedback was used to select the best aspects of the proposed models to create a new model. INTERVENTIONS: The updated care model consisted of several key changes, which included reducing NP- and PA-to-patient ratios, eliminating redundant tasks, shifting from location-based to surgical team-based coverage, ensuring top-of-scope practice, developing specialty service lines, and separating inpatient and outpatient practices. RESULTS: After implementation of the new care model, NP and PA turnover rates decreased from baseline by an average of approximately 74% per year. Departmental work culture scores concomitantly increased from 68% to 85% after implementation of the new care model. CONCLUSIONS: Adapting care models in conjunction with departmental growth is crucial to enhancing staff satisfaction and reducing burnout. CI - Copyright (c) 2025 American Association of Nurse Practitioners. FAU - Weimer, John W AU - Weimer JW AUID- ORCID: 0009-0004-9708-2627 AD - Department of Cardiovascular Surgery, Mayo Clinic, Rochester, Minnesota. FAU - Newcome, Marci D AU - Newcome MD FAU - Ehman, Jeffrey R AU - Ehman JR FAU - Jacobson, Marcus P AU - Jacobson MP LA - eng PT - Journal Article DEP - 20260201 PL - United States TA - J Am Assoc Nurse Pract JT - Journal of the American Association of Nurse Practitioners JID - 101600770 SB - IM MH - Humans MH - *Nurse Practitioners/trends MH - *Physician Assistants/trends/statistics & numerical data MH - *Personnel Staffing and Scheduling/standards/trends MH - Quality Improvement MH - Surveys and Questionnaires MH - Job Satisfaction MH - *Workforce/standards MH - *Cooperative Behavior MH - Organizational Innovation OTO - NOTNLM OT - Burnout, professional OT - change management OT - patient care OT - quality improvement EDAT- 2026/02/05 19:05 MHDA- 2026/02/05 19:06 CRDT- 2026/02/05 15:43 PHST- 2025/09/05 00:00 [received] PHST- 2025/10/17 00:00 [accepted] PHST- 2026/02/05 19:06 [medline] PHST- 2026/02/05 19:05 [pubmed] PHST- 2026/02/05 15:43 [entrez] AID - 01741002-202602000-00009 [pii] AID - 10.1097/JXX.0000000000001220 [doi] PST - epublish SO - J Am Assoc Nurse Pract. 2026 Feb 1;38(2):108-115. doi: 10.1097/JXX.0000000000001220. PMID- 41636929 OWN - NLM STAT- MEDLINE DCOM- 20260706 LR - 20261009 IS - 1534-3170 (Electronic) IS - 1523-3782 (Linking) VI - 28 IP - 1 DP - 2026 Feb 4 TI - Cardiorenal and Metabolic Dimensions of Cardiomyopathies and Heart Failure: Focus on SGLT2i, GLP1-RA, and ns-MRA. PG - 21 LID - 10.1007/s11886-025-02340-6 [doi] AB - PURPOSE OF THE REVIEW: Metabolic disorders represent a growing epidemiological and clinical challenge, associated with worsening prognosis of cardiovascular disease. These conditions cluster in patients with heart failure and cardiomyopathies, limiting therapeutic options. Although cardiomyopathies contribute substantially to the burden of heart failure, the impact of metabolic disorders on their progression remains underexplored. This review explores the complex cardiorenal and metabolic dimensions of cardiomyopathies, focusing on pathophysiological mechanisms, therapeutic innovations, and future organizational models. RECENT FINDINGS: Metabolic disorders likely modulate genotype-phenotype expression, aggravate myocardial dysfunction, and accelerate disease progression through converging molecular mechanisms and pathways leading to energetic imbalance, inflammation and fibrosis. Novel therapies act on these pathways favouring microscopic and macroscopic reverse remodelling. A holistic and multidisciplinary approach is required to select appropriate therapies, improve disease progression and quality of life of these patients. Cardiomyopathies exemplify the complexity of heart failure, where genetic and metabolic dysfunctions coexist and act as both triggers and amplifiers of myocardial damage. DCM, HCM, HCM phenocopies and ARVC all present the burden of metabolic disorders and some of them benefit from novel therapies. SGLT2i, GLP1-RA, and non-steroidal MRA represent the forefront of a new therapeutic era, aiming at pleiotropic targets beyond neurohormonal blockade. Integrated care models will reshape disease management and improve patients' outcomes. Future research should investigate on metabolic disorders prevalence in cardiomyopathies and better characterize molecular pathways and phenotypic profiles that mostly benefit from novel therapies. CI - (c) 2026. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Indennidate, Carla AU - Indennidate C AD - Cardiothoracovascular Department, Azienda Sanitaria Giuliano-Isontina, Member of the ERN Guard-HEART, University of Trieste, Trieste, Italy. FAU - Perencin, Brigitta AU - Perencin B AD - Nephrology and Dialysis Unit of Trieste, University Hospital and Health Services of Trieste (ASUGI), Trieste, Italy. FAU - Di Maso, Vittorio AU - Di Maso V AD - Nephrology and Dialysis Unit of Trieste, University Hospital and Health Services of Trieste (ASUGI), Trieste, Italy. FAU - Buda, Iris AU - Buda I AD - Diabetes Center, University Hospital and Health Services of Trieste (ASUGI), Trieste, Italy. FAU - Candido, Riccardo AU - Candido R AD - Diabetes Center, University Hospital and Health Services of Trieste (ASUGI), Trieste, Italy. AD - Department of Medical Surgical and Health Sciences, University of Trieste, Trieste, Italy. FAU - Sinagra, Gianfranco AU - Sinagra G AD - Cardiothoracovascular Department, Azienda Sanitaria Giuliano-Isontina, Member of the ERN Guard-HEART, University of Trieste, Trieste, Italy. AD - Department of Medical Surgical and Health Sciences, University of Trieste, Trieste, Italy. FAU - Merlo, Marco AU - Merlo M AD - Cardiothoracovascular Department, Azienda Sanitaria Giuliano-Isontina, Member of the ERN Guard-HEART, University of Trieste, Trieste, Italy. marco.merlo@asugi.sanita.fvg.it. AD - Department of Medical Surgical and Health Sciences, University of Trieste, Trieste, Italy. marco.merlo@asugi.sanita.fvg.it. LA - eng PT - Journal Article PT - Review DEP - 20260204 PL - United States TA - Curr Cardiol Rep JT - Current cardiology reports JID - 100888969 RN - 0 (Sodium-Glucose Transporter 2 Inhibitors) RN - 0 (Mineralocorticoid Receptor Antagonists) RN - 0 (Glucagon-Like Peptide-1 Receptor Agonists) SB - IM MH - Humans MH - *Heart Failure/drug therapy/metabolism/physiopathology MH - *Sodium-Glucose Transporter 2 Inhibitors/therapeutic use MH - *Cardiomyopathies/drug therapy/metabolism/physiopathology MH - *Mineralocorticoid Receptor Antagonists/therapeutic use MH - *Glucagon-Like Peptide-1 Receptor Agonists MH - Disease Progression OTO - NOTNLM OT - Cardiomyopathies OT - Cardiorenal-metabolic syndrome OT - Dilated cardiomyopathy OT - GLP-1 receptor agonists OT - Heart failure OT - Hypertrophic cardiomyopathy OT - Multidisciplinary management OT - Non-steroidal mineralocorticoid receptor antagonists OT - Phenocopies OT - SGLT2 inhibitors COIS- Declarations. Human and Animal Rights and Informed Consent: This article does not contain any studies with human or animal subjects performed by any of the authors. Competing interests: The authors declare no competing interests. EDAT- 2026/02/04 15:13 MHDA- 2026/02/04 15:14 CRDT- 2026/02/04 11:17 PHST- 2025/12/03 00:00 [received] PHST- 2025/12/15 00:00 [accepted] PHST- 2026/02/04 15:14 [medline] PHST- 2026/02/04 15:13 [pubmed] PHST- 2026/02/04 11:17 [entrez] AID - 10.1007/s11886-025-02340-6 [pii] AID - 10.1007/s11886-025-02340-6 [doi] PST - epublish SO - Curr Cardiol Rep. 2026 Feb 4;28(1):21. doi: 10.1007/s11886-025-02340-6. PMID- 41636408 OWN - NLM STAT- MEDLINE DCOM- 20260707 LR - 20260707 IS - 1558-3597 (Electronic) IS - 0735-1097 (Linking) VI - 87 IP - 4 DP - 2026 Feb 3 TI - Proactive Management and Treatment of Aortic Stenosis: An International Expert Perspective. PG - 414-438 LID - S0735-1097(25)10157-5 [pii] LID - 10.1016/j.jacc.2025.10.074 [doi] AB - The 2025 European Society of Cardiology/European Association for Cardio-Thoracic Surgery guidelines mark a pivotal change, challenging the paradigm of symptom-driven watchful waiting, and supporting earlier treatment in many patients with asymptomatic severe aortic stenosis. Building on this foundation, this international expert perspective advocates a comprehensive, proactive management strategy and offers clinicians a contemporary operational framework for managing severe aortic stenosis. Key evidence-based elements include early referral to the multidisciplinary Heart Valve Team, streamlined evaluation, upstream testing, prompt aortic valve replacement in many asymptomatic patients, more urgent treatment for symptomatic patients, and structured surveillance involving close working relationships between the referring clinician and Heart Valve Team when intervention is deferred. This proactive evidence-based model aims to improve timeliness, efficiency, and equity of care, thereby reducing preventable morbidity and mortality and improving long-term outcomes. CI - Copyright (c) 2026 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. FAU - Cook, Christopher M AU - Cook CM AD - The Essexcardiothoracic Centre, Basildon University Hospital, Basildon, United Kingdom; Anglia Ruskin University, Chlemsford, United Kingdom. FAU - Pibarot, Philippe AU - Pibarot P AD - Department of Cardiology, Institut Universitaire de Cardiologie et de Pneumologie de Quebec Universite Laval/Quebec Heart & Lung Institute - Laval University, Quebec, Quebec City, Canada. FAU - Tarantini, Giuseppe AU - Tarantini G AD - Department of Cardiac, Thoracic and Vascular and Public Health, University of Padua, Padua, Italy. FAU - Genereux, Philippe AU - Genereux P AD - Gagnon Cardiovascular Institute, Morristown Medical Center, Morristown, New Jersey, USA. FAU - Delgado, Victoria AU - Delgado V AD - Heart Institute, Cardiovascular Imaging Unit, Hospital University Germans Trias i Pujol, Badalona, Spain and Centre of Comparative Medicine and Bioimaging, Research Institute Germans Trias i Pujol, Badalona, Spain. FAU - Hayashida, Kentaro AU - Hayashida K AD - Department of Cardiology, Keio University School of Medicine, Tokyo, Japan. FAU - Parma, Radoslaw AU - Parma R AD - Department of Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland. FAU - Kaneko, Tsuyoshi AU - Kaneko T AD - Division of Cardiothoracic Surgery, Washington University in St Louis, St Louis, Missouri, USA. FAU - Rudolph, Tanja K AU - Rudolph TK AD - Department of General and Interventional Cardiology/Angiology, Heart and Diabetes Center Nordrhine Westfalia, Bad Oeynhausen, Ruhr-University, Bad Oeynhausen, Germany. FAU - Cavalcante, Joao L AU - Cavalcante JL AD - Allina Health Minneapolis Heart Institute, Minneapolis, Minnesota, USA. FAU - Wood, David A AU - Wood DA AD - Dilawri Cardiovascular Institute, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Bax, Jeroen J AU - Bax JJ AD - Leiden University Medical Center, Leiden, the Netherlands. FAU - Pilgrim, Thomas AU - Pilgrim T AD - Department of Cardiology, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland. FAU - Saia, Francesco AU - Saia F AD - Interventional Cardiology Unit, IRCCS University Hospital of Bologna, Policlinico St Orsola, Bologna, Italy. FAU - Vemulapalli, Sreekanth AU - Vemulapalli S AD - Duke University School of Medicine, Duke Clinical Research Institute, Duke-Margolis Institute for Health Policy, Durham, North Carolina, USA. FAU - Pellikka, Patricia A AU - Pellikka PA AD - Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA. FAU - Iung, Bernard AU - Iung B AD - Bichat Hospital, APHP and INSERM LVTS 1148, Universite Paris Cite, Paris, France. FAU - Guibone, Kimberly AU - Guibone K AD - Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA. FAU - Dweck, Marc R AU - Dweck MR AD - BHF Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom. FAU - Eltchaninoff, Helene AU - Eltchaninoff H AD - University of Rouen Normandy, Inserm U1096, CHU Rouen, Department of Cardiology, Rouen, France. FAU - Ailawadi, Gorav AU - Ailawadi G AD - Department of Cardiac Surgery, University of Michigan, Ann Arbor, Michigan, USA. FAU - Lam, Simon Cheung-Chi AU - Lam SC AD - Division of Cardiology, Department of Medicine, Queen Mary Hospital, Hong Kong SAR, China. FAU - Poon, Karl AU - Poon K AD - University of Queensland, The Prince Charles Hospital, Brisbane, Queensland, Australia. FAU - Unbehaun, Axel AU - Unbehaun A AD - Deutsches Herzzentrum der Charite, Department of Cardiothoracic and Vascular Surgery, Berlin, Germany; Charite-Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany. FAU - Schwartz, Allan AU - Schwartz A AD - Columbia University Medical Center/NewYork-Presbyterian Hospital, New York, New York, USA. FAU - Joner, Michael AU - Joner M AD - Department of Cardiology, TUM University Hospital German Heart Center, Munich, Germany and DZHK (German Center for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany. FAU - Prendergast, Bernard AU - Prendergast B AD - Cleveland Clinic London and St Thomas' Hospital, London, United Kingdom. FAU - Mack, Michael AU - Mack M AD - Baylor Scott & White Health, Dallas, Texas, USA. FAU - Hahn, Rebecca T AU - Hahn RT AD - Columbia University Medical Center/NewYork-Presbyterian Hospital, New York, New York, USA. FAU - Windecker, Stephan AU - Windecker S AD - Department of Cardiology, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland. FAU - Leon, Martin B AU - Leon MB AD - Columbia University Medical Center/NewYork-Presbyterian Hospital, New York, New York, USA. FAU - Lindman, Brian R AU - Lindman BR AD - Structural Heart and Valve Center, Cardiovascular Division, Vanderbilt University Medical Center, Nashville, Tennessee, USA. Electronic address: brian.r.lindman@vumc.org. LA - eng PT - Journal Article PT - Review DEP - 20251114 PL - United States TA - J Am Coll Cardiol JT - Journal of the American College of Cardiology JID - 8301365 SB - IM MH - *Aortic Valve Stenosis/therapy/diagnosis MH - Humans MH - *Heart Valve Prosthesis Implantation MH - *Disease Management MH - Practice Guidelines as Topic OTO - NOTNLM OT - aortic valve replacement OT - aortic valve stenosis OT - echocardiography OT - guidelines OT - randomized clinical trials OT - valvular heart disease COIS- Funding Support and Author Disclosures Dr Cook has received consultant and speaker fees from Edwards Lifesciences, Boston Scientific, Philips, Cerebria.ai, and Viz.ai; and holds stock in Cerebria.ai and Viz.ai. Dr Pibarot has received institutional funding from Edwards Lifesciences, Medtronic, Pi-Cardia, Cardiac Success, Boston Scientific, and Novartis for echocardiography core laboratory analyses and research studies in the field of valvular heart disease, for which he received no personal compensation. Dr Tarantini has received lecture honoraria from Edwards Lifesciences. Dr Genereux is a consultant for 4C Medical, Abbott Vascular, ABIOMED, Edwards Lifesciences, Haemonetics Corporation, Medtronic, Opsens Inc, Puzzle Medical Inc., Saranas Inc., ShockWave Medical, and Teleflex Inc; is Principal Investigator and consultant for Edwards Lifesciences; and has stock options in Pi-Cardia, Puzzle Medical Inc, and Saranas Inc. Dr Delgado has received speaker fees from Abbott Structural, Edwards Lifesciences, GE Healthcare, JenaValve, Medtronic, Philips, Products & Features, and Siemens. The Heart Institute of Hospital University Germans Trias i Pujol has received research grants from WomenAsOne and Philips. Dr Hayashida is a proctor for Edwards Lifesciences, Medtronic, and Abbott. Dr Parma has received travel support from Edwards Lifesciences. Dr Kaneko serves on advisory boards for Edwards Lifesciences and Abbott; and is a consultant for Medtronic. Dr Rudolph has received speaker honoraria from Boston Scientific, Edwards Lifesciences, Medtronic, and JenaValve; institutional grants from Boston Scientific and Edwards Lifesciences; and is a proctor for Edwards Lifesciences and JenaValve. Dr Cavalcante has received honoraria or consultation fees from 4C Medical, Abbott Structural, Anteris, Boston Scientific, Braile Medical, Circle Cardiovascular Imaging, Edwards Lifesciences, JenaValve, JC Medical, Medtronic, Novo Nordisk, Pie Medical, Siemens Healthineers, Shockwave, and Zoll; and his institution has Imaging Core Lab contracts with Abbott Structural, Boston Scientific, Edwards Lifesciences, JC Medical, Medtronic, and Products & Features, for which he received no personal compensation. Dr Wood is Chief Scientific Officer for the Dilawri Cardiovascular Institute, which receives institutional funding from Edwards Lifesciences, Medtronic, Boston Scientific, Abbott, BDC Labs, Vivitro Labs, Anteris, and Corcym; he receives no direct industry compensation. Dr Bax reports that the Department of Cardiology at Leiden University Medical Center, the Netherlands, has received unrestricted research grants from Edwards Lifesciences and Abbott. Dr Pilgrim has received research grants from the Swiss National Science Foundation, the Swiss Heart Foundation, the Swiss Polar Institute, the Bangerter-Rhyner Foundation, the Mach-Gaensslen Foundation, and the Monsol Foundation; and institutional research, travel, or educational grants without personal remuneration from Biotronik, Boston Scientific, Edwards Lifesciences, and ATSens. His institution has received speaker and consultancy fees from Biotronik, Boston Scientific, Edwards Lifesciences, Abbott, Medtronic, Biosensors, and Highlife. Dr Saia is a proctor for Edwards Lifesciences, and serves on advisory boards and has received lecture fees from Abbott, Edwards Lifesciences, Medtronic, Boston Scientific, Meril, Shockwave, and Philips. Dr Vemulapalli has received grants/contracts from the National Institutes of Health (R01 and UG3/UH3), Food and Drug Administration, Abbott Vascular, Edwards Lifesciences, American College of Cardiology, American Heart Association, Cytokinetics, and Idorsia; and consulting/advisory fees from Edwards Lifesciences, Astra Zeneca, Boehringer-Ingelheim, Cytokinetics, Medtronic, Abbott Vascular, and Haymarket. Dr Pellikka has received institutional research support from Edwards Lifesciences and Ultromics, Ltd.; and receives honoraria from UpToDate. Dr Guibone is an educational consultant for Abbott Laboratories and Medtronic Inc. Dr Dweck is supported by the British Heart Foundation (FS/SCRF/21/32010) and the Sir Jules Thorn Award for Biomedical Research 2015 (15/JTA); he is Director of the Image Analysis Core Lab within the Edinburgh Clinical Research Facility, University of Edinburgh; has received speaker fees from Pfizer, Radcliffe Cardiology, Amarin, Bristol Myers Squibb, Edwards Lifesciences, and Novartis; and consultancy fees from Novartis, Jupiter Bioventures, AstraZeneca, Novonordisc, UCB Biopharma, Beren, and Silence Therapeutics. Dr Ailawadi is a consultant for Abbott, Anteris, Arthrex, Avania, Capstan, Nyra, Edwards Lifesciences, JenaValve, Johnson & Johnson, Medtronic, Philips, WL Gore, and Cultiv8 Medical. Dr Poon has received consultant and speaker fees from Edwards Lifesciences and Anteris; speaker fees from Medtronic and Abbott; and proctoring fees from Edwards Lifesciences; his institution has received research grants from Edwards Lifesciences and Abbott. Dr Unbehaun is a medical proctor for Edwards Lifesciences, JenaValve, Medtronic, and Abbott. Dr Schwartz reports that his institution receives funding from Edwards Lifesciences TAVR trials. Dr Joner has received personal fees from Abbott, Biotronik, Boston Scientific, Edwards, Integris Health Private Limited, Medtronic, Recor, TriCares, and Veryan; grants and personal fees from Boston Scientific and Edwards Lifesciences; and a grant from Cardiac Dimensions, all outside the submitted work. Dr Prendergast has received speaker fees from Edwards Lifesciences and Polaris Medical; research consultancy fees from Valvosoft; and is a partner and board member of CERC (Clinical Research Organisation). Dr Mack is a consultant for Edwards Lifesciences and serves as Trial Co-PI; and for Medtronic, he is Trial Study Chair. Dr Hahn has received speaker fees from Abbott Structural, Baylis Medical, Edwards Lifesciences, and Philips Healthcare; she has institutional consulting contracts (for which she receives no direct compensation) with Abbott Structural, Anteris, Boston Scientific, Edwards Lifesciences, Medtronic, Novartis, Philips Healthcare, and Rob'E; and she is Chief Scientific Officer for the Echocardiography Core Laboratory at the Cardiovascular Research Foundation for multiple industry-sponsored valve trials, for which she receives no direct industry compensation. Dr Windecker reports that his institution has received research, travel, and/or educational grants from Abbott, Abiomed, Alnylam, Amicus Therapeutics, Amgen, Anteris, Astra Zeneca, Bayer, B.Braun, Bioanalytica, Biotronik, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cordis Medical, CorFlow Therapeutics, CSL Behring, Daiichi Sankyo, Edwards Lifesciences, Fumedica, GE Healthcare, Guerbet, IACULIS, Inari Medical, Janssen AI, Johnson & Johnson, Medalliance, Medtronic, MSD Merck Sharp & Dohme, Neovii Pharmaceutica, Neutromedics AG, Novartis, Novo Nordisk, OM Pharma, Optimapharm, Orchestra BioMed, Pfizer, Philips AG, Sanofi-Aventis, Servier, Shockwave Medical, Siemens Healthcare, Sinomed, SMT Sahajanand Medical Technologies, Vascular Medical, and V-Wave; he serves as an advisory board member and/or steering/executive group member for trials funded by Abbott, Amgen, Anteris, Abiomed, Edwards Lifesciences, EnCarda Inc., Medtronic, Novartis, and Sinomed, with payments to the institution but no personal compensation; and serves on steering/executive committees of several investigator-initiated trials that receive industry funding, without impact on his personal remuneration. Dr Leon has received institutional grants/contracts from Abbott Fund, ABIOMED, Anora Heart Inc., Boston Scientific Corporation, Edwards Lifesciences, Medtronic, and MiRus LLC.; has served as consultant for Anteris, Croivalve, Foldax, and Laminar; he is Principal Investigator for Edwards Lifesciences; and holds stock or stock options in Pi-Cardia, SoloPace, and Xenter MD. Dr Lindman is a consultant for Edwards Lifesciences, Anteris, Medtronic, AstraZeneca, and Kardigan; and has received investigator-initiated research grants and serves as Principal Investigator of the EARLY TAVR and PROGRESS biobanks (Edwards Lifesciences). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. This international writing group unified interventional cardiologists, cardiac surgeons, cardiac imaging specialists, and general cardiologists with the aspiration of bringing a globally representative Heart Valve Team's reflection on the best contemporary management of patients suffering from severe aortic stenosis, regardless of symptoms. Edwards Lifesciences, who initiated these discussions with an advisory board, subsequently only provided administrative and logistical support to the meetings during which the coauthors of this manuscript gathered. The writing group grew at the sole discretion of its members. The company had no role in the design or content of the joint statement and had no right to approve or disapprove the final document. The present manuscript, therefore, reflects the authors' independent opinion and work. EDAT- 2026/02/04 14:12 MHDA- 2026/02/04 14:13 CRDT- 2026/02/04 08:29 PHST- 2025/08/07 00:00 [received] PHST- 2025/10/23 00:00 [revised] PHST- 2025/10/24 00:00 [accepted] PHST- 2026/02/04 14:13 [medline] PHST- 2026/02/04 14:12 [pubmed] PHST- 2026/02/04 08:29 [entrez] AID - S0735-1097(25)10157-5 [pii] AID - 10.1016/j.jacc.2025.10.074 [doi] PST - ppublish SO - J Am Coll Cardiol. 2026 Feb 3;87(4):414-438. doi: 10.1016/j.jacc.2025.10.074. Epub 2025 Nov 14. PMID- 41634805 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260627 LR - 20260920 IS - 2524-3489 (Electronic) IS - 2524-3489 (Linking) VI - 8 IP - 1 DP - 2026 Feb 3 TI - Collaborative neurocardiology board meetings for decision-making in stroke care: a real-world experience. PG - 4 LID - 10.1186/s42466-026-00464-w [doi] LID - 4 AB - BACKGROUND: Interdisciplinary collaboration between neurologists and cardiologists is needed to provide state-of-the art stroke care and individualized decisions about secondary prevention strategies. This highlights the need to establish working structures for joint decision-making between cardiologists and stroke neurologists. At present, studies describing the real-world decision-making as part of such brain-heart teams are scarce. METHODS: We established a structured heart-brain team approach with monthly virtual neurocardiology board (NCB) meetings within a neurovascular network. We conducted a retrospective analysis of the implementation phase of NCB meetings between 2021 and 2024. We describe the structure of board meetings, patient characteristics and therapeutic and diagnostic recommendations. RESULTS: During the study period, 46 board meetings were held, and 255 patients were discussed. The number of referred patients increased from 32 in 2021 to 89 in 2024. The majority of patients were evaluated for patent foramen ovale (PFO) closure (n = 189, 74.1%, median age 56 years, 59.8% female) and left atrial appendage occlusion (LAAO) (n = 32, 12.5%, median age 83 years, 50% female). Further questions centered around other individual secondary prevention strategies. Among patients referred to discuss PFO closure, closure was not recommended in 43.4% of patients (n = 82), recommended depending on additional diagnostic measures in 13.8% (n = 26), considered optional in 19.6% (n = 37) and clrearly recommended in 23.3% (n = 44). Patients for whom it was not recommended were older, had more cardiovascular risk factors and were less likely to have a large PFO shunt. The main reason for the recommendation against closure was that the PFO was not considered causal for the stroke (80.5%). Among LAAO patients, participation in a randomized controlled trial was recommended in 68.8%. CONCLUSIONS: We successfully established and steadily expanded regular NCB meetings to provide a platform for interdisciplinary exchange and personalized stroke treatment, in particular discussion of indications for interventional procedures against cardiac embolism. Our approach may serve as a blueprint for similar collaborative approaches. Future studies are needed to assess adherence to recommendations and patient outcomes as this study lacks follow-up data. FAU - Mafael, V AU - Mafael V AD - Department of Neurology with Experimental Neurology, Charite-Universitatsmedizin Berlin, Berlin, Germany. FAU - Buck, T AU - Buck T AD - Department of Neurology with Experimental Neurology, Charite-Universitatsmedizin Berlin, Berlin, Germany. FAU - Stengl, H AU - Stengl H AD - Department of Neurology with Experimental Neurology, Charite-Universitatsmedizin Berlin, Berlin, Germany. AD - Center for Stroke Research Berlin (CSB), Charite-Universitatsmedizin Berlin, Berlin, Germany. FAU - Hellwig, S AU - Hellwig S AD - Department of Neurology with Experimental Neurology, Charite-Universitatsmedizin Berlin, Berlin, Germany. AD - Center for Stroke Research Berlin (CSB), Charite-Universitatsmedizin Berlin, Berlin, Germany. FAU - Klammer, M G AU - Klammer MG AD - Department of Neurology with Experimental Neurology, Charite-Universitatsmedizin Berlin, Berlin, Germany. AD - Center for Stroke Research Berlin (CSB), Charite-Universitatsmedizin Berlin, Berlin, Germany. FAU - Endres, M AU - Endres M AD - Department of Neurology with Experimental Neurology, Charite-Universitatsmedizin Berlin, Berlin, Germany. AD - Center for Stroke Research Berlin (CSB), Charite-Universitatsmedizin Berlin, Berlin, Germany. AD - German Centre for Cardiovascular Research (DZHK), partner site Berlin, Berlin, Germany. AD - German Center for Neurodegenerative Diseases (DZNE), partner site Berlin, Berlin, Germany. AD - German Center for Mental Health (DZPG), partner site Berlin, Berlin, Germany. FAU - Reinthaler, M AU - Reinthaler M AD - Deutsches Herzzentrum der Charite, Department of Cardiology, Angiology and Intensive Care Medicine, Berlin, Germany. AD - Department of Cardiology, Angiology and Intensive Care Medicine, Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany. AD - Institute of Active Polymers and Berlin-Brandenburg, Center for Regenerative Therapies, Helmholtz-Zentrum Hereon, Teltow, Germany. FAU - Barbieri, F AU - Barbieri F AD - Deutsches Herzzentrum der Charite, Department of Cardiology, Angiology and Intensive Care Medicine, Berlin, Germany. AD - Department of Cardiology, Angiology and Intensive Care Medicine, Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany. AD - Institute of Active Polymers and Berlin-Brandenburg, Center for Regenerative Therapies, Helmholtz-Zentrum Hereon, Teltow, Germany. FAU - Audebert, H J AU - Audebert HJ AD - Department of Neurology with Experimental Neurology, Charite-Universitatsmedizin Berlin, Berlin, Germany. AD - Center for Stroke Research Berlin (CSB), Charite-Universitatsmedizin Berlin, Berlin, Germany. FAU - Leistner, D M AU - Leistner DM AD - Department of Cardiology, Universitares Herz- und Gefasszentrum Frankfurt, Universitatsmedizin Frankfurt, Frankfurt am Main, Germany. AD - German Centre for Cardiovascular Research (DZHK), partner site Rhein/Main, Frankfurt am Main, Germany. FAU - Landmesser, U AU - Landmesser U AD - German Centre for Cardiovascular Research (DZHK), partner site Berlin, Berlin, Germany. AD - Deutsches Herzzentrum der Charite, Department of Cardiology, Angiology and Intensive Care Medicine, Berlin, Germany. AD - Department of Cardiology, Angiology and Intensive Care Medicine, Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany. FAU - Doehner, W AU - Doehner W AD - Center for Stroke Research Berlin (CSB), Charite-Universitatsmedizin Berlin, Berlin, Germany. AD - Deutsches Herzzentrum der Charite, Department of Cardiology, Angiology and Intensive Care Medicine, Berlin, Germany. AD - Berlin Institute of Health at Charite (BIH), Center for Regenerative Therapies, Berlin, Germany. FAU - Skurk, C AU - Skurk C AD - Deutsches Herzzentrum der Charite, Department of Cardiology, Angiology and Intensive Care Medicine, Berlin, Germany. AD - Department of Cardiology, Angiology and Intensive Care Medicine, Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany. FAU - Scheitz, J F AU - Scheitz JF AUID- ORCID: 0000-0001-5835-4627 AD - Department of Neurology with Experimental Neurology, Charite-Universitatsmedizin Berlin, Berlin, Germany. jan.scheitz@charite.de. AD - Center for Stroke Research Berlin (CSB), Charite-Universitatsmedizin Berlin, Berlin, Germany. jan.scheitz@charite.de. AD - German Centre for Cardiovascular Research (DZHK), partner site Berlin, Berlin, Germany. jan.scheitz@charite.de. LA - eng PT - Journal Article DEP - 20260203 PL - England TA - Neurol Res Pract JT - Neurological research and practice JID - 101767802 EIN - Neurol Res Pract. 2026 Mar 17;8(1):16. doi: 10.1186/s42466-026-00472-w. PMID: 41845539 PMC - PMC12870955 OTO - NOTNLM OT - Brain‒heart teams OT - Collaboration OT - Left atrial appendage closure OT - Patent foramen ovale OT - Stroke COIS- Declarations. Ethics approval: The Berlin legislation for hospitals ( section sign 25 Berliner Krankenhausgesetz) allows the use of data derived during routine care and quality monitoring for scientific evaluations and is exempt from approval by a local review board. Consent for publication: Not applicable. Competing interests: The authors declare that they have no competing interests. Disclosures: JFS has received speaker honoraria from Bristol-Myers Squibb-Pfizer, Medtronic and AstraZeneca, outside the submitted work. FB has received speaker honoraria from Daichii Sankyo as well as grant support from Abbott Laboratories, outside of submitted work. ME reports grants from Bayer and Ipsen, and fees paid to the Charite from Amgen, AstraZeneca, Bayer Healthcare, BMS, Daiichi Sankyo, all outside the submitted work. EDAT- 2026/02/04 05:06 MHDA- 2026/02/04 05:07 PMCR- 2026/02/03 CRDT- 2026/02/03 23:58 PHST- 2025/09/16 00:00 [received] PHST- 2025/12/13 00:00 [accepted] PHST- 2026/02/04 05:07 [medline] PHST- 2026/02/04 05:06 [pubmed] PHST- 2026/02/03 23:58 [entrez] PHST- 2026/02/03 00:00 [pmc-release] AID - 10.1186/s42466-026-00464-w [pii] AID - 464 [pii] AID - 10.1186/s42466-026-00464-w [doi] PST - epublish SO - Neurol Res Pract. 2026 Feb 3;8(1):4. doi: 10.1186/s42466-026-00464-w. PMID- 41634498 OWN - NLM STAT- MEDLINE DCOM- 20260613 LR - 20261016 IS - 1556-0961 (Electronic) IS - 1541-6933 (Linking) VI - 44 IP - 3 DP - 2026 Jun TI - Neurocritical Care Experience and Attitudes Related to Organ Donation in the USA. PG - 984-997 LID - 10.1007/s12028-025-02444-5 [doi] AB - INTRODUCTION: There has been a surge in attention to ethical controversies associated with organ donation in the USA. The Neurocritical Care Society (NCS) Ethics Committee sought to understand member experiences and attitudes related to organ donation in the USA. METHODS: We designed a survey of members who practice in the USA and have interacted with an organ procurement organization (OPO)/potential donor. The survey was disseminated by NCS from 1 June 2025 to 1 September 2025. Free-text responses were reviewed to identify themes. RESULTS: Of 2204 NCS members in the USA, there were 71 respondents who completed the survey and 37 respondents who provided free-text comments. Experiences and attitudes varied, but 59% of respondents indicated that they generally think that communication between the OPO and patient surrogates about donation after brain death/death by neurologic criteria seems appropriate, and 34% indicated that they generally think that communication between the OPO and patient surrogates regarding donation after cardiac death/death by circulatory-respiratory criteria (DCD) seems appropriate. Themes included (1) the need to improve education for the treatment team about organ donation; (2) blurred boundaries between patient care and care directed toward organ donation; (3) misalignment between OPOs and treatment team priorities; (4) loss of trust between patient surrogates and the treatment team based on interactions with OPOs; (5) suboptimal timing of communication between OPOs and patient surrogates; (6) concerns regarding a potential lack of transparency, empathy, and cultural sensitivity in communication between OPOs and patient surrogates; (7) opportunities for improvement in preoperative care before donation and palliation after extubation for DCD; and (8) changes in willingness to donate organs based on interactions with OPOs. CONCLUSIONS: Although the results from this survey reflect the experience and attitudes of a small percentage of NCS members in the USA, they indicate that there are opportunities for improvement in organ donation processes. Survey results will guide the NCS Ethics Committee in supporting members navigating ethical controversies related to organ donation. CI - (c) 2026. Springer Science+Business Media, LLC, part of Springer Nature and Neurocritical Care Society. FAU - Lewis, Ariane AU - Lewis A AUID- ORCID: 0000-0002-0756-7320 AD - Division of Neurocritical Care, Departments of Neurology and Neurosurgery, New York University (NYU) Langone Medical Center, 530 First Avenue, MSB-2-206, New York, NY, 10016, USA. ariane.kansas.lewis@gmail.com. FAU - Hargis, Mitch AU - Hargis M AD - Novant Health Forsyth Medical Center, Winston-Salem, NC, USA. FAU - Durrant, Julia AU - Durrant J AD - Oregon Health Sciences University, Portland, OR, USA. FAU - Cappucci, Stefanie AU - Cappucci S AD - Yale University, New Haven, CT, USA. FAU - Choi, Richard AU - Choi R AD - Medstar Franklin Square Medical Center, Baltimore, MD, USA. FAU - Condie, Chad AU - Condie C AD - Common Spirit Health, West Valley City, UT, USA. FAU - Gandee, Richard AU - Gandee R AD - University of North Carolina (UNC) Chapel Hill, Chapel Hill, NC, USA. FAU - Lim-Hing, Krista AU - Lim-Hing K AD - Northwell Health, New Hyde Park, NY, USA. FAU - McHugh, Daryl AU - McHugh D AD - University of Rochester Medical Center, Rochester, NY, USA. FAU - Patel, Vishal AU - Patel V AD - Emory Health, Atlanta, GA, USA. FAU - Reynolds, Alexandra AU - Reynolds A AD - Hackensack University Medical Center, Hackensack, NJ, USA. FAU - Tompeck, Allison AU - Tompeck A AD - University of Arizona Phoenix/Banner Health, Phoenix, AZ, USA. FAU - Jaffa, Matthew N AU - Jaffa MN AD - Ayer Neuroscience Institute, Hartford Hospital, Hartford, CT, USA. LA - eng PT - Journal Article DEP - 20260203 PL - United States TA - Neurocrit Care JT - Neurocritical care JID - 101156086 SB - IM MH - Humans MH - *Tissue and Organ Procurement/ethics MH - United States MH - *Critical Care/ethics MH - *Attitude of Health Personnel MH - Brain Death MH - *Neurology/ethics OTO - NOTNLM OT - Brain death/death by neurologic criteria OT - Donation after cardiac death/death by circulatory-respiratory criteria OT - End-of-life OT - Normothermic regional perfusion COIS- Declarations. Conflict of interest: The authors have no financial conflicts of interest. Ariane Lewis was a lead author on the 2023 AAN/AAP/CNS/SCCM Guidelines on Brain Death/Death by Neurologic Criteria Determination and represented the American Academy of Neurology as an observer on the Determination of Death Act Drafting Committee. Julia Durrant is a neurology representative for the Cascade Life Alliance Advisory Board and the chair of the OHSU/Cascade Life Alliance committee. Krista Lim-Hing is on the Medical Advisory Board for LiveOnNY. Daryl McHugh is a member of the University of Rochester Organ Donor Steering Committee. The other authors have no relevant conflicts of interest. Ethical Approval: This study is not considered human subjects research by the NYU Langone Health Institutional Review Board and thus did not require review. It does not describe animal research. EDAT- 2026/02/04 05:06 MHDA- 2026/06/15 11:29 CRDT- 2026/02/03 23:35 PHST- 2025/09/11 00:00 [received] PHST- 2025/12/30 00:00 [accepted] PHST- 2026/06/15 11:29 [medline] PHST- 2026/02/04 05:06 [pubmed] PHST- 2026/02/03 23:35 [entrez] AID - 10.1007/s12028-025-02444-5 [pii] AID - 10.1007/s12028-025-02444-5 [doi] PST - ppublish SO - Neurocrit Care. 2026 Jun;44(3):984-997. doi: 10.1007/s12028-025-02444-5. Epub 2026 Feb 3. PMID- 41633464 OWN - NLM STAT- MEDLINE DCOM- 20260706 LR - 20260706 IS - 1873-1570 (Electronic) IS - 0300-9572 (Linking) VI - 220 DP - 2026 Mar TI - Code Blue blindspots: mapping nursing exposure to cardiac arrests. PG - 111000 LID - S0300-9572(26)00045-6 [pii] LID - 10.1016/j.resuscitation.2026.111000 [doi] AB - BACKGROUND: In-hospital cardiac arrest (IHCA) requires high-performance team responses under pressure, yet its relative rarity creates challenges for maintaining individual and team competence. Nurses often serve as first responders, but little is known about how their actual exposure to IHCA varies across time and schedule patterns. METHODS: We analyzed spatial-temporal patterns of Code Blue activations at a tertiary care hospital from January 2023 through December 2024. Using switchboard data, we identified 208 IHCA events across 17 locations and modeled nursing exposure based on nine standard 28-day work schedules and 9991 randomly generated variants (10,000 total). For each schedule, we calculated the number of Code Blue events encountered and the intervals between exposures. RESULTS: Code Blues were unevenly distributed across wards, with 30% occurring in a single cardiology step-down unit. Among the nine standard schedules, nurses would experience a median of 15 Code Blues over two years, with median gaps between exposures of 36 days (IQR 34.5-47). All nine core schedules contained at least one gap exceeding 90 days. Across 10,000 modeled schedules, the median time between exposures was 38 days (IQR 31-50.5), with 98% of schedules containing at least one gap longer than 90 days. CONCLUSIONS: Even in high-incidence wards, most nurses experience long, irregular intervals between cardiac arrest events-periods long enough for CPR and resuscitation skills to decay. These invisible gaps suggest an opportunity to target simulation-based or just-in-time training to individuals or units most at risk of skill erosion, thereby improving readiness and team performance during IHCA. CI - Copyright (c) 2026 Elsevier B.V. All rights reserved. FAU - Walker, Devin AU - Walker D AD - MD Candidate, School of Medicine, Queen's University, Kingston, Ontario, Canada. FAU - Allali, Daniah AU - Allali D AD - Department of Emergency Medicine, Queen's University, Kingston, Ontario, Canada. FAU - Szulewski, Adam AU - Szulewski A AD - Department of Emergency Medicine & Department of Psychology, Queen's University, Kingston, Ontario, Canada; Royal College of Physicians and Surgeons of Canada, Ottawa, Ontario, Canada. FAU - Howes, Daniel AU - Howes D AD - Department of Critical Care Medicine, Queen's University, Kingston, Ontario, Canada. FAU - Brennan, Erin E AU - Brennan EE AD - Department of Emergency Medicine, Queen's University, Kingston, Ontario, Canada. FAU - Chaplin, Timothy AU - Chaplin T AD - Department of Emergency Medicine, Queen's University, Kingston, Ontario, Canada. FAU - Fanning, Jeff AU - Fanning J AD - RN, Kingston Health Sciences Centre, Kingston, Ontario, Canada. FAU - Dworkis, Daniel A AU - Dworkis DA AD - Mission Critical Team Institute, Annapolis, MD, USA; Department of Emergency Medicine, Keck School of Medicine of USC, Los Angeles, CA, USA. Electronic address: dan@missioncti.com. LA - eng PT - Journal Article DEP - 20260201 PL - Ireland TA - Resuscitation JT - Resuscitation JID - 0332173 SB - IM MH - *Heart Arrest/nursing/therapy MH - Humans MH - *Cardiopulmonary Resuscitation/nursing/education MH - *Hospital Rapid Response Team/organization & administration MH - Clinical Competence MH - Personnel Staffing and Scheduling OTO - NOTNLM OT - Code Blue OT - In-hospital cardiac arrest OT - Nursing exposure OT - Resuscitation OT - Simulation training OT - Skill decay COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/02/04 05:06 MHDA- 2026/03/14 00:32 CRDT- 2026/02/03 19:10 PHST- 2025/11/14 00:00 [received] PHST- 2026/01/10 00:00 [revised] PHST- 2026/01/24 00:00 [accepted] PHST- 2026/03/14 00:32 [medline] PHST- 2026/02/04 05:06 [pubmed] PHST- 2026/02/03 19:10 [entrez] AID - S0300-9572(26)00045-6 [pii] AID - 10.1016/j.resuscitation.2026.111000 [doi] PST - ppublish SO - Resuscitation. 2026 Mar;220:111000. doi: 10.1016/j.resuscitation.2026.111000. Epub 2026 Feb 1. PMID- 41633462 OWN - NLM STAT- MEDLINE DCOM- 20260706 LR - 20260729 IS - 1552-6259 (Electronic) IS - 0003-4975 (Linking) VI - 121 IP - 6 DP - 2026 Jun TI - The Society of Thoracic Surgeons (2025) Expert Consensus Document on Interventions for Screen-Detected Lung Nodules. PG - 1283-1297 LID - S0003-4975(26)00023-8 [pii] LID - 10.1016/j.athoracsur.2026.01.004 [doi] AB - BACKGROUND: Computed tomographic (CT) lung cancer screening (LCS) reduces lung cancer-specific mortality and improves survival. We reviewed contemporary literature to develop consensus recommendations on perioperative quality standards for LCS programs to optimize outcomes. METHODS: The Society of Thoracic Surgeons (STS) Task Force on Lung Cancer Screening and STS Workforce on Evidence Based Surgery convened a multidisciplinary panel of thoracic surgeons, radiation oncologists, and interventional pulmonologists. A comprehensive literature review was conducted using the PICO (Population, Intervention, Comparisons, Outcome) framework. Consensus statements were developed through a modified Delphi process addressing: (1) preoperative biopsy and diagnostic surgical procedures, (2) acceptable rates of complications from diagnostic and therapeutic procedures, and (3) timing of intervention after a suspicious LCS finding, and the role of the multidisciplinary team in patient management. Consensus required >/=75% agreement. RESULTS: The panel developed 23 consensus statements after 3 Delphi rounds; 20 achieved consensus in the first round. Surgery without tissue diagnosis was acceptable for carefully selected patients, favoring minimally invasive, parenchymal-sparing approaches. Pneumonectomy without diagnosis was unanimously rejected. Programs should track benign resection rates. Acceptable complication benchmarks included pneumothorax <5%, hemoptysis <2%, and mortality <1% for bronchoscopic biopsy; and surgical morbidity <10% and 30-day mortality <1%, per STS database standards. Definitive resection should occur within 12 weeks of the inciting imaging study. Multidisciplinary teams should include thoracic surgery, oncology, pulmonology, and radiology. Preoperative pulmonary rehabilitation and smoking cessation were emphasized. CONCLUSIONS: This STS consensus defines perioperative quality standards for CT LCS programs, supporting shared decision-making, multidisciplinary care, and quality improvement. CI - Copyright (c) 2026 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved. FAU - Servais, Elliot L AU - Servais EL AD - Department of Thoracic Surgery, Lahey Hospital and Medical Center, Burlington, Massachusetts; Department of Surgery, UMass Chan Medical School, Worcester, Massachusetts. Electronic address: elliot.servais@lahey.org. FAU - Hayanga, J W Awori AU - Hayanga JWA AD - Department of Cardiovascular and Thoracic Surgery, Heart and Vascular Institute, West Virginia University Medicine, Morgantown, West Virginia. FAU - Linden, Philip AU - Linden P AD - Division of Thoracic and Esophageal Surgery, University Hospitals Cleveland Medical Center, Cleveland, Ohio. FAU - Sood, Pallavi AU - Sood P AD - The Society of Thoracic Surgeons, Chicago, Illinois. FAU - Raymond, Daniel P AU - Raymond DP AD - Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, Ohio. FAU - Antonoff, Mara B AU - Antonoff MB AD - Division of Surgery, Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas. FAU - Chudgar, Neel P AU - Chudgar NP AD - Department of Cardiothoracic and Vascular Surgery, Montefiore Medical Center/Albert Einstein College of Medicine, New York, New York. FAU - Keshava, Hari B AU - Keshava HB AD - Division of Thoracic Surgery, Department of Surgery, University of California, Irvine, Irvine, California. FAU - Velotta, Jeffrey B AU - Velotta JB AD - Divison of Thoracic Surgery, Kaiser Permanente, Oakland, California; Department of Surgery, University of California, San Francisco School of Medicine, San Francisco, California; Department of Clinical Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California. FAU - Crabtree, Traves AU - Crabtree T AD - Division of Cardiothoracic Surgery, Southern Illinois University Medical Center, Springfield, Illinois. FAU - Jeffrey Yang, Chi-Fu AU - Jeffrey Yang CF AD - Division of Thoracic Surgery, Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts. FAU - Raz, Dan AU - Raz D AD - Division of Thoracic Surgery, City of Hope, Duarte, California. FAU - Tong, Betty AU - Tong B AD - Division of Thoracic Surgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina. FAU - Cooke, David T AU - Cooke DT AD - Division of General Thoracic Surgery, University of California, Davis Health, Sacramento, California. FAU - Erkmen, Cherie P AU - Erkmen CP AD - Division of Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania. FAU - Shaller, Brian AU - Shaller B AD - Division of Pulmonary, Allergy and Critical Care Medicine, Stanford University School of Medicine, Stanford, California. FAU - Kent, Michael S AU - Kent MS AD - Division of Thoracic Surgery and Interventional Pulmonology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts. FAU - McKee, Andrea AU - McKee A AD - Department of Radiation Oncology, Lahey Hospital and Medical Center, Burlington, Massachusetts. FAU - Phan, Chinh T AU - Phan CT AD - Division of Pulmonary, Critical Care and Sleep Medicine, University of California, Davis Health, Sacramento, California. FAU - Daly, Megan E AU - Daly ME AD - Department of Radiation Oncology, University of California, Davis Comprehensive Cancer Center, Sacramento, California. FAU - Onaitis, Mark W AU - Onaitis MW AD - Department of Surgery, University of California, San Diego, La Jolla, California. FAU - Edwards, Janet P AU - Edwards JP AD - Section of Thoracic Surgery, Department of Surgery, University of Calgary, Calgary, Alberta, Canada. FAU - Yang, Stephen C AU - Yang SC AD - Division of Thoracic Surgery, Department of Surgery, The Johns Hopkins Medical Institutions, Baltimore, MD. FAU - Merritt, Robert E AU - Merritt RE AD - Division of Thoracic Surgery, The Ohio State Wexner Medical Center, Columbus, OH. FAU - Shrager, Joseph AU - Shrager J AD - Division of Thoracic Surgery, Department of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, California; Veterans Affairs Palo Alto Health Care Center, Palo Alto, California. LA - eng PT - Consensus Statement PT - Journal Article DEP - 20260201 PL - Netherlands TA - Ann Thorac Surg JT - The Annals of thoracic surgery JID - 15030100R SB - IM MH - Humans MH - Delphi Technique MH - *Early Detection of Cancer/standards/methods MH - *Lung Neoplasms/surgery/diagnostic imaging/diagnosis MH - *Multiple Pulmonary Nodules/diagnostic imaging/surgery/diagnosis MH - Pneumonectomy MH - Societies, Medical MH - Thoracic Surgery MH - Tomography, X-Ray Computed COIS- Disclosures Elliot L. Servais reports a relationship with Intuitive Surgical that includes: speaking and lecture fees. Daniel P. Raymond reports a relationship with Bristol-Myers Squibb Company that includes: equity or stocks. Mara B. Antonoff reports a relationship with AstraZeneca Pharmaceuticals LP that includes: consulting or advisory; with Merck & Co Inc that includes: consulting or advisory; with Ethicon Endo Surgery that includes: consulting or advisory; and with Bristol-Myers Squibb Company that includes: consulting or advisory. Neel P. Chudgar reports a relationship with AstraZeneca Pharmaceuticals LP that includes: consulting or advisory, funding grants, speaking and lecture fees, and travel reimbursement; and with LUNGevity Foundation that includes: funding grants and travel reimbursement. Jeffrey B. Velotta reports a relationship with AsparaGlue that includes: consulting or advisory. Chi-Fu Jeffrey Yang reports a relationship with AstraZeneca Pharmaceuticals LP that includes: consulting or advisory, speaking and lecture fees, and travel reimbursement; with Genentech that includes: consulting or advisory, speaking and lecture fees, and travel reimbursement; and with American Lung Cancer Screening Initiative that includes: board membership. David T. Cooke reports a relationship with Intuitive Surgical Inc that includes: travel reimbursement; with Bristol-Myers Squibb Company that includes: speaking and lecture fees; and with Oxford University Press that includes: book royalties. Cherie P. Erkmen has received funding grants from the National Institutes of Health- U54 Cancer Disparity Health Partnership and reports a relationship with Pfizer Inc that includes: funding grants; and with Merck & Co Inc that includes: funding grants. Megan E. Daly reports a relationship with AstraZeneca Pharmaceuticals LP that includes: consulting or advisory; with Novocure that includes: consulting or advisory; with BMS that includes: consulting or advisory; with Merck & Co Inc that includes: funding grants; and with Preluce that includes: consulting or advisory. Stephen Yang reports a relationship with Intuitive Surgical Inc that includes: consulting or advisory. Robert E. Merritt reports a relationship with Intuitive Surgical Inc that includes: speaking and lecture fees; with AstraZeneca Pharmaceuticals LP that includes: consulting or advisory; and with INOVA Therapeutics that includes: consulting or advisory. Joseph Shrager reports a relationship with Varian Medical Systems Finland Oy that includes: funding grants; and with Becton Dickinson and Company that includes: consulting or advisory. The other authors have no conflicts of interest to disclose. EDAT- 2026/02/04 05:06 MHDA- 2026/05/24 04:38 CRDT- 2026/02/03 19:10 PHST- 2025/11/13 00:00 [received] PHST- 2025/12/20 00:00 [revised] PHST- 2026/01/14 00:00 [accepted] PHST- 2026/05/24 04:38 [medline] PHST- 2026/02/04 05:06 [pubmed] PHST- 2026/02/03 19:10 [entrez] AID - S0003-4975(26)00023-8 [pii] AID - 10.1016/j.athoracsur.2026.01.004 [doi] PST - ppublish SO - Ann Thorac Surg. 2026 Jun;121(6):1283-1297. doi: 10.1016/j.athoracsur.2026.01.004. Epub 2026 Feb 1. PMID- 41631001 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260203 LR - 20260205 IS - 2666-6022 (Electronic) IS - 2666-6022 (Linking) VI - 63 DP - 2026 Mar TI - Cancer therapy-associated Takotsubo cardiomyopathy: A narrative review of mechanisms, drug associations, and clinical implications. PG - 100723 LID - 10.1016/j.ahjo.2026.100723 [doi] LID - 100723 AB - Anticancer therapies have been increasingly associated with Takotsubo cardiomyopathy (TTC). As prior reports remain fragmented across case studies and drug-specific reviews, this paper offers one of the most comprehensive reviews to date of cancer therapy-associated TTC. While classically triggered by emotional or physical stress, TTC has been increasingly associated with chemotherapy and other cancer-directed therapies. This literature review explores the pathophysiology, clinical features, and evolving evidence linking anticancer agents to TTC, with a focus on cytotoxic cancer therapy, hormonal therapy, targeted treatments, and immune checkpoint inhibitors. We describe the proposed mechanisms of cancer therapy-associated TTC, the diagnostic challenges, particularly in patients with cancer, and the complex management strategies, especially regarding the decision to resume oncologic treatment after TTC recovery. Given the increasing use of cardiotoxic agents, a multidisciplinary approach to cardio-oncology care among patients with suspected TTC is crucial. More research is needed to understand the role of TTC in cardiac dysfunction among patients with cancer, clarify risk stratification methods, and improve outcomes for patients at risk of TTC during cancer treatment. CI - (c) 2026 The Authors. Published by Elsevier Inc. FAU - Simeon, Michael AU - Simeon M AD - Rush Medical College, Chicago, IL, USA. FAU - Evans, Elizabeth AU - Evans E AD - Division of Cardiology, Rush University Medical Center, Chicago, IL, USA. FAU - Arif, Sally AU - Arif S AD - Department of Pharmacy, Midwestern University College of Pharmacy and Department of Cardiology, Rush University Medical Center, Chicago, IL, USA. FAU - Granado, Thomas AU - Granado T AD - Department of Internal Medicine, Rush University Medical Center, Chicago, IL, USA. FAU - Okwuosa, Tochukwu M AU - Okwuosa TM AD - Division of Cardiology, Rush University Medical Center, Chicago, IL, USA. FAU - Volgman, Annabelle Santos AU - Volgman AS AD - Division of Cardiology, Rush University Medical Center, Chicago, IL, USA. FAU - Abusin, Salaheldin AU - Abusin S AD - Division of Cardiology, Rush University Medical Center, Chicago, IL, USA. LA - eng PT - Journal Article PT - Review DEP - 20260115 PL - United States TA - Am Heart J Plus JT - American heart journal plus : cardiology research and practice JID - 101779333 PMC - PMC12860647 OTO - NOTNLM OT - Cancer-associated cardiomyopathy OT - Cardio-oncology OT - Chemotherapy-induced cardiotoxicity OT - Stress cardiomyopathy OT - Takotsubo cardiomyopathy COIS- None. EDAT- 2026/02/03 13:34 MHDA- 2026/02/03 13:35 PMCR- 2026/01/15 CRDT- 2026/02/03 04:17 PHST- 2026/01/09 00:00 [received] PHST- 2026/01/13 00:00 [accepted] PHST- 2026/02/03 13:35 [medline] PHST- 2026/02/03 13:34 [pubmed] PHST- 2026/02/03 04:17 [entrez] PHST- 2026/01/15 00:00 [pmc-release] AID - S2666-6022(26)00011-X [pii] AID - 100723 [pii] AID - 10.1016/j.ahjo.2026.100723 [doi] PST - epublish SO - Am Heart J Plus. 2026 Jan 15;63:100723. doi: 10.1016/j.ahjo.2026.100723. eCollection 2026 Mar. PMID- 41630705 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260203 LR - 20260205 IS - 2474-8714 (Electronic) IS - 2474-8706 (Print) IS - 2474-8706 (Linking) VI - 10 IP - 2 DP - 2026 Feb TI - Contemporary Life Expectancy Following Transfemoral Transcatheter Aortic Valve Replacement-Data From a National Registry Perspective. PG - 100780 LID - 10.1016/j.shj.2025.100780 [doi] LID - 100780 AB - BACKGROUND: The estimated lifespan following transcatheter aortic valve replacement (TAVR) is the key in the decision-making process of lifelong management of patients with severe symptomatic aortic stenosis (AS). We aimed to assess the contemporary lifespan and associated factors in patients with severe AS undergoing TAVR. METHODS: We performed a retrospective cohort study of patients who underwent TAVR at the 4 largest centers in Israel between July 2008 and March 2023. Mortality predictors were assessed using multivariable Cox regression analysis. RESULTS: The cohort included 6191 patients (51% females; mean age 82.7 ​+/- ​5.4 years; median follow-up 5.9 years). The overall estimated 5- and 10-year survival was 70 and 42%, respectively. To assess temporal trends, patients were stratified to early (2008-2015; n ​= ​2058) and late (2016-2023; n ​= ​4133) eras. Patients in the early TAVR era had significantly lower survival probability, compared to the late era (hazard ratio 2.0 (95% confidence interval 1.8-2.2), p ​< ​0.001], with an 8-year survival of 39 and 71%, respectively. Using an age threshold of >/=80 years, defined using spline analysis the 8-year survival in the early vs. late eras was 37 vs. 47% among older patients and 66 vs. 82% among younger patients. CONCLUSIONS: Lifespan following successful TAVR has markedly improved over the past decade across age groups. Notably, patients younger than 80 years, at the time of TAVR exhibit an estimated survival exceeding 10 ​years. These findings should be integrated into Heart Team decision-making for optimal lifelong management of AS. CI - (c) 2025 The Author(s). FAU - Zornitzki, Lior AU - Zornitzki L AD - Division of Cardiology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. AD - Grey Faculty of Medicine and Health Sciences, Tel Aviv University, Tel Aviv, Israel. FAU - Freund, Ophir AU - Freund O AD - Grey Faculty of Medicine and Health Sciences, Tel Aviv University, Tel Aviv, Israel. AD - Lung Institute, Tel Aviv Sourasky Medical Center, Affiliated with School of Medicine, Tel Aviv University, Tel Aviv, Israel. FAU - Greenberg, Inbal AU - Greenberg I AD - Division of Cardiology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. AD - Grey Faculty of Medicine and Health Sciences, Tel Aviv University, Tel Aviv, Israel. FAU - Frydman, Shir AU - Frydman S AD - Division of Cardiology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. AD - Grey Faculty of Medicine and Health Sciences, Tel Aviv University, Tel Aviv, Israel. FAU - Konigstein, Maayan AU - Konigstein M AD - Division of Cardiology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. AD - Grey Faculty of Medicine and Health Sciences, Tel Aviv University, Tel Aviv, Israel. FAU - Steinvil, Arie AU - Steinvil A AD - Division of Cardiology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. AD - Grey Faculty of Medicine and Health Sciences, Tel Aviv University, Tel Aviv, Israel. FAU - Barbash, Israel AU - Barbash I AD - Grey Faculty of Medicine and Health Sciences, Tel Aviv University, Tel Aviv, Israel. AD - Interventional Cardiology Unit, Leviev Heart and Vascular Center, Chaim Sheba Medical Center, Ramat Gan, Israel. FAU - Kornowski, Ran AU - Kornowski R AD - Grey Faculty of Medicine and Health Sciences, Tel Aviv University, Tel Aviv, Israel. AD - Cardiology Department, Rabin Medical Center, Petah Tikva, Israel. FAU - Elbaz, Gabby G AU - Elbaz GG AD - Department of Cardiology, Hadassah Medical Center, Jerusalem, Israel. AD - Department of Cardiology, Hadassah Medical Center, Jerusalem, Israel. FAU - Dvir, Danny AU - Dvir D AD - Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel. AD - Department of Cardiology, Shaare Zedek Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel. FAU - Finkelstein, Ariel AU - Finkelstein A AD - Division of Cardiology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. AD - Grey Faculty of Medicine and Health Sciences, Tel Aviv University, Tel Aviv, Israel. FAU - Topilsky, Yan AU - Topilsky Y AD - Division of Cardiology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. AD - Grey Faculty of Medicine and Health Sciences, Tel Aviv University, Tel Aviv, Israel. FAU - Halkin, Amir AU - Halkin A AD - Division of Cardiology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. AD - Grey Faculty of Medicine and Health Sciences, Tel Aviv University, Tel Aviv, Israel. FAU - Banai, Shmuel AU - Banai S AD - Division of Cardiology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. AD - Grey Faculty of Medicine and Health Sciences, Tel Aviv University, Tel Aviv, Israel. FAU - Ben-Shoshan, Jeremy AU - Ben-Shoshan J AD - Division of Cardiology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. AD - Grey Faculty of Medicine and Health Sciences, Tel Aviv University, Tel Aviv, Israel. LA - eng PT - Journal Article DEP - 20251205 PL - United States TA - Struct Heart JT - Structural heart : the journal of the Heart Team JID - 101743256 PMC - PMC12861024 OTO - NOTNLM OT - AS OT - Age OT - Frailty OT - Mortality OT - Prognosis OT - TAVR COIS- The authors report no conflict of interest. EDAT- 2026/02/03 13:34 MHDA- 2026/02/03 13:35 PMCR- 2025/12/05 CRDT- 2026/02/03 04:14 PHST- 2025/10/18 00:00 [received] PHST- 2025/11/22 00:00 [revised] PHST- 2025/11/27 00:00 [accepted] PHST- 2026/02/03 13:35 [medline] PHST- 2026/02/03 13:34 [pubmed] PHST- 2026/02/03 04:14 [entrez] PHST- 2025/12/05 00:00 [pmc-release] AID - S2474-8706(25)00372-0 [pii] AID - 100780 [pii] AID - 10.1016/j.shj.2025.100780 [doi] PST - epublish SO - Struct Heart. 2025 Dec 5;10(2):100780. doi: 10.1016/j.shj.2025.100780. eCollection 2026 Feb. PMID- 41630388 OWN - NLM STAT- MEDLINE DCOM- 20260830 LR - 20260910 IS - 0301-1526 (Print) IS - 0301-1526 (Linking) VI - 55 IP - 5 DP - 2026 Sep TI - Interdepartmental cooperation in access-site management - verifiable persistent benefit for patients. PG - 371-377 LID - 10.1024/0301-1526/a001260 [doi] AB - Background: Vascular access-site complications after catheterization remain a significant cause of morbidity and mortality. While patient- and procedure-related risk factors are well described, the impact of structured, interdisciplinary training programs is less well established. We evaluated the effect of a structured training program for cardiologists and interventional staff on access-site-related complications after transfemoral coronary interventions. Patients and methods: Over 36 months, we tracked all elective transfemoral coronary interventions at our institution. After an initial 6-month observational phase, we implemented a structured training program for cardiologists and catheter lab staff, using initial complication rates as the baseline. The training included quarterly sessions, pre-interventional angiological assessment for high-risk patients, pre-interventional assessment for all patients, and sheath removal by assistants. We prospectively assessed all access-site related complications using a standardized protocol and analysed incidence changes with a regression model, adjusting for patient-specific risk factors over time. Results: Quarterly training and pre-interventional angiological assessment for high-risk patients did not significantly impact complication rates. However, pre-interventional angiographical assessment for all patients and sheath removal training for assistants significantly reduced complication rates. The results remained consistent after adjusting for patient-specific risk factors. Conclusions: Structured angiological training for interventional staff significantly reduces access-site related complications. Interdisciplinary collaboration enhances patient safety and minimizes adverse events. FAU - Schuett, Harald AU - Schuett H AD - Department of Cardiology, Angiology and Internal Intensive Care Medicine, University Hospital Giessen and Marburg, Marburg, Germany. AD - Department of Cardiology, Angiology, and Internal Intensive Care Medicine, Faculty of Medicine, Philipps University of Marburg, Germany. FAU - Schafer, Ann-Christin AU - Schafer AC AD - Department of Cardiology, Angiology and Internal Intensive Care Medicine, University Hospital Giessen and Marburg, Marburg, Germany. AD - Department of Cardiology, Angiology, and Internal Intensive Care Medicine, Faculty of Medicine, Philipps University of Marburg, Germany. FAU - Stegemann, Berthold AU - Stegemann B AUID- ORCID: 0000-0003-2841-8022 AD - Centre for Clinical Research Kassel, Germany. FAU - Schieffer, Bernhard AU - Schieffer B AD - Department of Cardiology, Angiology and Internal Intensive Care Medicine, University Hospital Giessen and Marburg, Marburg, Germany. AD - Department of Cardiology, Angiology, and Internal Intensive Care Medicine, Faculty of Medicine, Philipps University of Marburg, Germany. FAU - Stegemann, Emilia AU - Stegemann E AUID- ORCID: 0000-0003-2407-2837 AD - Department of Cardiology, Angiology and Internal Intensive Care Medicine, University Hospital Giessen and Marburg, Marburg, Germany. AD - Clinic for General Internal Medicine, Diabetology and Angiology, Agaplesion Diakonie Clinics, Kassel, Germany. AD - Department of Cardiology, Angiology, and Internal Intensive Care Medicine, Faculty of Medicine, Philipps University of Marburg, Germany. LA - eng PT - Journal Article PT - Observational Study DEP - 20260203 PL - Switzerland TA - Vasa JT - VASA. Zeitschrift fur Gefasskrankheiten JID - 0317051 SB - IM MH - Aged MH - Female MH - Humans MH - Male MH - Middle Aged MH - *Cardiac Catheterization/adverse effects/methods MH - *Catheterization, Peripheral/adverse effects/methods MH - Clinical Competence MH - Cooperative Behavior MH - *Education, Medical, Continuing/methods MH - *Femoral Artery/diagnostic imaging MH - Interdisciplinary Communication MH - Intersectoral Collaboration MH - *Patient Care Team MH - *Percutaneous Coronary Intervention/adverse effects MH - Program Evaluation MH - Prospective Studies MH - Punctures MH - Risk Assessment MH - Risk Factors MH - Time Factors MH - Treatment Outcome OTO - NOTNLM OT - access site related vascular complication OT - interdepartmental cooperation OT - large bore vascular access OT - percutaneous coronary intervention OT - training program OT - transfemoral approach EDAT- 2026/02/03 07:40 MHDA- 2026/08/30 23:36 CRDT- 2026/02/03 01:23 PHST- 2026/08/30 23:36 [medline] PHST- 2026/02/03 07:40 [pubmed] PHST- 2026/02/03 01:23 [entrez] AID - 10.1024/0301-1526/a001260 [doi] PST - ppublish SO - Vasa. 2026 Sep;55(5):371-377. doi: 10.1024/0301-1526/a001260. Epub 2026 Feb 3. PMID- 41629122 OWN - NLM STAT- MEDLINE DCOM- 20260706 LR - 20260706 IS - 1743-498X (Electronic) IS - 1743-4971 (Linking) VI - 23 IP - 2 DP - 2026 Apr TI - Structured Team Training to Improve Resuscitation Performance and Communication in Nursing Students: A Nonrandomized Intervention Study. PG - e70352 LID - 10.1111/tct.70352 [doi] AB - AIM: This study aimed to evaluate the impact of structured team training on teamwork, communication and resuscitation performance among undergraduate nursing students in simulated cardiac arrest scenarios. DESIGN: A nonrandomized pretest-posttest intervention study with a control group. METHODS: Sixty-seven third-year nursing students from two accredited nursing programmes were assigned to either an intervention group (n = 34), which received advanced life support training integrated with five structured team training sessions based on the TeamSTEPPS framework, or a control group (n = 33), which received life support training alone. Teamwork and communication were measured before and after training using validated tools. Resuscitation performance was assessed posttraining through standardized simulation scenarios rated by trained evaluators. RESULTS: The intervention group demonstrated significant improvements in teamwork and communication scores compared to the control group. Posttraining resuscitation performance was also higher in the intervention group. These findings indicate that the integration of structured team training enhances both technical and nontechnical competencies in high-pressure clinical situations. CONCLUSION: Structured team training is an effective educational strategy to improve communication, collaboration and resuscitation performance among nursing students. CI - (c) 2026 Association for the Study of Medical Education and John Wiley & Sons Ltd. FAU - Jang, Kyeongmin AU - Jang K AUID- ORCID: 0000-0003-3599-4183 AD - Department of Nursing, College of Health Sciences, Daejin University, Pocheon-si, Gyeonggi-do, Republic of Korea. FAU - Kim, Sung Hwan AU - Kim SH AUID- ORCID: 0000-0001-9560-9115 AD - Department of Nursing, Catholic Sangji University, Andong-si, Gyeongsangbuk-do, Republic of Korea. LA - eng PT - Journal Article PL - England TA - Clin Teach JT - The clinical teacher JID - 101227511 SB - IM MH - Humans MH - *Communication MH - *Students, Nursing/psychology MH - *Patient Care Team/organization & administration MH - Clinical Competence MH - Female MH - Male MH - *Resuscitation/education MH - *Education, Nursing, Baccalaureate/methods MH - *Cardiopulmonary Resuscitation/education MH - Cooperative Behavior MH - Heart Arrest/therapy OTO - NOTNLM OT - TeamSTEPPS OT - communication skills OT - nontechnical skills OT - nursing students OT - resuscitation training OT - simulation-based education OT - teamwork EDAT- 2026/02/03 00:27 MHDA- 2026/02/03 00:28 CRDT- 2026/02/02 21:23 PHST- 2026/01/05 00:00 [revised] PHST- 2025/07/03 00:00 [received] PHST- 2026/01/08 00:00 [accepted] PHST- 2026/02/03 00:28 [medline] PHST- 2026/02/03 00:27 [pubmed] PHST- 2026/02/02 21:23 [entrez] AID - 10.1111/tct.70352 [doi] PST - ppublish SO - Clin Teach. 2026 Apr;23(2):e70352. doi: 10.1111/tct.70352. PMID- 41624889 OWN - NLM STAT- MEDLINE DCOM- 20260706 LR - 20260706 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 16 DP - 2025 TI - Hematological complications in solid organ transplant recipients with telomere biology disorders: a narrative review. PG - 1718107 LID - 10.3389/fimmu.2025.1718107 [doi] LID - 1718107 AB - Telomeres are repetitive nucleotide sequences at the ends of chromosomes that preserve genomic integrity. Defects in telomere maintenance mechanisms lead to premature telomere shortening, resulting in cellular senescence, apoptosis, and organ dysfunction, collectively termed telomere biology disorders (TBDs). Short telomere length is associated with an increased risk of end-stage fibrotic disease of the lung and/or liver, which may necessitate lung or liver transplantation. Beyond pulmonary and hepatic involvement, TBDs can also affect cardiac and renal function. Importantly, the bone marrow function is often also compromised, which can significantly influence transplant outcomes. Although evidence remains scarce, particularly in non-lung solid organ transplant recipients, post-transplant immunosuppressive therapy, typically including corticosteroids, calcineurin inhibitors, and cell cycle inhibitors, may exacerbate the underlying hematopoietic fragility in TBD patients. Hematological complications may result from both the intrinsic TBD and the additive myelotoxic effects of immunosuppressive agents (e.g., azathioprine, mycophenolate mofetil) or anti-infectious prophylaxis (e.g., trimethoprim-sulfamethoxazole, valganciclovir). Early recognition of TBDs prior to transplantation is essential. Assessment of telomere length and genetic testing should be considered in at-risk candidates, particularly those with early-onset pulmonary fibrosis, unexplained cytopenia, cryptogenic liver disease, or a family history suggestive of TBD. A multidisciplinary approach involving pulmonology, hepatology, hematology, and transplant specialists is crucial to optimize patient selection, perioperative management, and post-transplant care. This review summarizes current knowledge on hematological complications following solid organ transplantation in TBD patients and describes expert-opinion strategies for the pre-transplant evaluation and post-transplant management of these high-risk individuals. CI - Copyright (c) 2026 Carlier, Plante-Bordeneuve, Froidure, Graux, van Dievoet, van Moorsel and Hoffman. FAU - Carlier, Francois M AU - Carlier FM AD - Pole of Lung, Nose and Skin (LUNS), Institut de Recherche Experimentale et Clinique (IREC), Universite Catholique de Louvain, Brussels, Belgium. AD - Department of Pneumology, CHU Mont-Godinne UCL Namur, Yvoir, Belgium. AD - Lung Transplant Centre, CHU Mont-Godinne UCL Namur, Yvoir, Belgium. FAU - Plante-Bordeneuve, Thomas AU - Plante-Bordeneuve T AD - Pole of Lung, Nose and Skin (LUNS), Institut de Recherche Experimentale et Clinique (IREC), Universite Catholique de Louvain, Brussels, Belgium. AD - Department of Pneumology, CHU Mont-Godinne UCL Namur, Yvoir, Belgium. AD - Lung Transplant Centre, CHU Mont-Godinne UCL Namur, Yvoir, Belgium. FAU - Froidure, Antoine AU - Froidure A AD - Pole of Lung, Nose and Skin (LUNS), Institut de Recherche Experimentale et Clinique (IREC), Universite Catholique de Louvain, Brussels, Belgium. AD - Department of Pneumology, Cliniques Universitaires Saint-Luc, Brussels, Belgium. FAU - Graux, Carlos AU - Graux C AD - Department of Hematology, CHU Mont-Godinne UCL Namur, Yvoir, Belgium. FAU - van Dievoet, Marie-Astrid AU - van Dievoet MA AD - Laboratory Department, Cliniques Universitaires Saint-Luc, Brussels, Belgium. FAU - van Moorsel, Coline H M AU - van Moorsel CHM AD - ILD Center of Excellence, Sint Antonius Hospital, Nieuwegein, Netherlands. FAU - Hoffman, Thijs W AU - Hoffman TW AD - ILD Center of Excellence, Sint Antonius Hospital, Nieuwegein, Netherlands. LA - eng PT - Journal Article PT - Review DEP - 20260115 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (Immunosuppressive Agents) SB - IM MH - Humans MH - *Organ Transplantation/adverse effects MH - *Telomere/genetics MH - Transplant Recipients MH - Immunosuppressive Agents/adverse effects MH - *Hematologic Diseases/etiology/diagnosis MH - Telomere Shortening PMC - PMC12852035 OTO - NOTNLM OT - TBD OT - hematology OT - lung transplantation OT - review OT - short telomeres OT - solid organ transplantation OT - telomere biology disorders OT - telomeres COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/02/02 18:13 MHDA- 2026/02/02 18:14 PMCR- 2026/01/15 CRDT- 2026/02/02 06:48 PHST- 2025/10/03 00:00 [received] PHST- 2025/12/29 00:00 [accepted] PHST- 2026/02/02 18:14 [medline] PHST- 2026/02/02 18:13 [pubmed] PHST- 2026/02/02 06:48 [entrez] PHST- 2026/01/15 00:00 [pmc-release] AID - 10.3389/fimmu.2025.1718107 [doi] PST - epublish SO - Front Immunol. 2026 Jan 15;16:1718107. doi: 10.3389/fimmu.2025.1718107. eCollection 2025. PMID- 41623868 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260202 LR - 20260204 IS - 2297-055X (Print) IS - 2297-055X (Electronic) IS - 2297-055X (Linking) VI - 12 DP - 2025 TI - Implementation of an integrated care pathway for severe aortic stenosis: a prospective cohort study of clinical profiles, safety, and outcomes. PG - 1745204 LID - 10.3389/fcvm.2025.1745204 [doi] LID - 1745204 AB - INTRODUCTION: Severe aortic stenosis (AS) management increasingly requires multidisciplinary coordination across diagnostic, interventional, and rehabilitation stages. Integrated care pathways (ICPs) supported by structured data systems may improve safety and outcomes, but real-world evidence in AS remains limited. We aimed to characterize a contemporary cohort of patients with severe AS managed within an ICP at a tertiary hospital, comparing profiles and outcomes by treatment strategy, and to describe diagnostic procedures and the implementation of cardiac rehabilitation (CR) interventions embedded in the pathway. METHODS: Prospective observational study of all consecutive patients with AS evaluated by a multidisciplinary heart team between 2018 and 2022. Baseline characteristics and frailty, diagnostic tests, CR interventions, procedural details, and outcomes were collected via an interoperable data management platform and compared across treatment groups: surgical (SAVR) or transcatheter (TAVR) valve replacement, or conservative management. Early survival was assessed using Kaplan-Meier analysis with log-rank testing. RESULTS: Among 984 patients (median age 78 years, 42% women), 43.9% underwent SAVR, 49.8% TAVR, and 6.3% were managed conservatively. TAVR and conservative groups were older, frailer, and had higher comorbidity. Device success at 30 days was high ( approximately 91%), with periprocedural death at 2.5% for interventions, vs. 9.7% early mortality for conservative management (p < 0.001). Early survival differed significantly (log-rank p = 0.004). TAVR had higher permanent pacemaker implantation (21.7% vs. 7.4% for SAVR, p < 0.001) and major vascular complications (4.1% vs. 0.2%, p < 0.001), while SAVR had more reoperations (8.3% vs. 0.2%, p < 0.001) and atrial fibrillation (18.9% vs. 10.1%, p = 0.001). Prehabilitation was implemented in 64.6% of candidates, while postprocedural CR remained underutilized (11.3%). CONCLUSIONS: Integrated care for a cohort of patients with AS, supported by structured data management, enabled comprehensive profiling, systematic outcome monitoring, and identification of improvement areas. Both SAVR and TAVR achieved high success with low early mortality, while conservative management had poor survival. CI - (c) 2026 Gonzalez-Salvado, Sestayo Fernandez, Alonso-Vazquez, de la Fuente-Lopez, Laranjeira Correia, Lens-Bravo, Ruzo-Cedillo, Villamayor-Blanco, Gonzalez-Juanatey and Pena-Gil. FAU - Gonzalez-Salvado, Violeta AU - Gonzalez-Salvado V AD - Cardiology Department, University Clinical Hospital of Santiago de Compostela, Santiago de Compostela, Spain. AD - Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain. AD - Biomedical Research Networking Center on Cardiovascular Diseases (CIBERCV), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. FAU - Sestayo Fernandez, Manuela AU - Sestayo Fernandez M AD - Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain. AD - Biomedical Research Networking Center on Cardiovascular Diseases (CIBERCV), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. FAU - Alonso-Vazquez, Marta AU - Alonso-Vazquez M AD - Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain. AD - Biomedical Research Networking Center on Cardiovascular Diseases (CIBERCV), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. FAU - de la Fuente-Lopez, Pablo AU - de la Fuente-Lopez P AD - Cardiology Department, University Clinical Hospital of Santiago de Compostela, Santiago de Compostela, Spain. AD - Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain. AD - Biomedical Research Networking Center on Cardiovascular Diseases (CIBERCV), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. FAU - Laranjeira Correia, Joana Maria AU - Laranjeira Correia JM AD - Servico de Cardiologia, Unidade Local de Saude Tamega e Sousa, Guilhufe, Portugal. FAU - Lens-Bravo, Uxia AU - Lens-Bravo U AD - Cardiology Department, University Clinical Hospital of Santiago de Compostela, Santiago de Compostela, Spain. AD - Biomedical Research Networking Center on Cardiovascular Diseases (CIBERCV), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. FAU - Ruzo-Cedillo, Anxel AU - Ruzo-Cedillo A AD - Cardiology Department, University Clinical Hospital of Santiago de Compostela, Santiago de Compostela, Spain. AD - Biomedical Research Networking Center on Cardiovascular Diseases (CIBERCV), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. FAU - Villamayor-Blanco, Bibiana AU - Villamayor-Blanco B AD - Rehabilitation Department, University Clinical Hospital of Santiago de Compostela, Santiago de Compostela, Spain. FAU - Gonzalez-Juanatey, Jose Ramon AU - Gonzalez-Juanatey JR AD - Cardiology Department, University Clinical Hospital of Santiago de Compostela, Santiago de Compostela, Spain. AD - Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain. AD - Biomedical Research Networking Center on Cardiovascular Diseases (CIBERCV), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. FAU - Pena-Gil, Carlos AU - Pena-Gil C AD - Cardiology Department, University Clinical Hospital of Santiago de Compostela, Santiago de Compostela, Spain. AD - Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain. AD - Biomedical Research Networking Center on Cardiovascular Diseases (CIBERCV), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. LA - eng PT - Journal Article DEP - 20260116 PL - Switzerland TA - Front Cardiovasc Med JT - Frontiers in cardiovascular medicine JID - 101653388 PMC - PMC12856929 OTO - NOTNLM OT - aortic stenosis OT - aortic valve replacement OT - cardiac rehabilitation OT - health information management OT - integrated health care systems OT - postoperative complications OT - transcatheter aortic valve replacement COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/02/02 18:14 MHDA- 2026/02/02 18:15 PMCR- 2026/01/16 CRDT- 2026/02/02 06:38 PHST- 2025/11/12 00:00 [received] PHST- 2025/12/18 00:00 [revised] PHST- 2025/12/30 00:00 [accepted] PHST- 2026/02/02 18:15 [medline] PHST- 2026/02/02 18:14 [pubmed] PHST- 2026/02/02 06:38 [entrez] PHST- 2026/01/16 00:00 [pmc-release] AID - 10.3389/fcvm.2025.1745204 [doi] PST - epublish SO - Front Cardiovasc Med. 2026 Jan 16;12:1745204. doi: 10.3389/fcvm.2025.1745204. eCollection 2025. PMID- 41623372 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260202 LR - 20260926 IS - 2398-8835 (Electronic) IS - 2398-8835 (Linking) VI - 9 IP - 2 DP - 2026 Feb TI - Heyde Syndrome: A Literature Review. PG - e71778 LID - 10.1002/hsr2.71778 [doi] LID - e71778 AB - BACKGROUND AND AIMS: Heyde syndrome, a triad of anemia from gastrointestinal (GI) bleeding, aortic valve stenosis, and acquired von Willebrand syndrome, primarily affects individuals over 65. Management requires a multidisciplinary approach, including medical therapy, endoscopic intervention, and valve replacement. Despite advances, many aspects remain unclear. This review explores the epidemiology, pathophysiology, and management of Heyde syndrome while highlighting areas for future research. METHODS: A comprehensive search of PubMed and Google Scholar focused on English-language human studies, including case reports, clinical trials, reviews, and expert guidelines. Additional literature on Von Willebrand syndrome and GI angiodysplasia was reviewed. The final search was completed on April 5, 2025. RESULTS: Aortic valve replacement improves outcomes and hematologic abnormalities. Transcatheter aortic valve replacement (TAVR) showed lower rates of life-threatening bleeding, fewer perioperative complications, and reduced transfusions compared to surgical replacement. Guidelines recommend dual antiplatelet therapy (DAPT) for 3-6 months post-TAVR, with 79%-86% of patients experiencing no recurrence of GI bleeds. Management of intestinal angiodysplasia often shows high recurrence rates due to persistent lesions and vWS-2A. Surgical valve replacement also improves bleeding control, even with anticoagulation. Aortic valve replacement should be first-line therapy in severe aortic stenosis with chronic GI bleeding. CONCLUSION: Heyde syndrome remains a complex and often underrecognized condition in elderly populations. Continued research is critical to deepen understanding and improve patient outcomes, allowing for more personalized and effective care strategies. CI - (c) 2026 The Author(s). Health Science Reports published by Wiley Periodicals LLC. FAU - Gupta, Yashika AU - Gupta Y AUID- ORCID: 0009-0007-1736-2365 AD - Department of Medicine Gadag Institute of Medical Sciences Gadag India. FAU - Khan, Abdul Rehman Shahid AU - Khan ARS AUID- ORCID: 0009-0002-4885-0410 AD - Department of Medicine Lahore General hospital Lahore Pakistan. FAU - Shetty, Viraj AU - Shetty V AUID- ORCID: 0009-0000-1999-8008 AD - Department of Medicine Bangalore Medical College and Research Institute Bengaluru India. FAU - Krishna, Yeshwini Murali AU - Krishna YM AUID- ORCID: 0009-0003-7647-7286 AD - Department of Medicine Gadag Institute of Medical Sciences Gadag India. FAU - Maqsood, Ayisha AU - Maqsood A AD - Department of Internal Medicine Faisalabad Medical University Faisalabad Punjab Pakistan. FAU - Ahmad, Muhammad Husnain AU - Ahmad MH AUID- ORCID: 0009-0006-5248-0749 AD - St. Tentishev Asian Medical Institute Kant Kyrgyzstan. FAU - Ali, Masab AU - Ali M AD - Department of Internal Medicine Faisalabad Medical University Faisalabad Punjab Pakistan. FAU - Samuel, Betsy AU - Samuel B AUID- ORCID: 0009-0004-4362-5534 AD - Department of Medicine Gadag Institute of Medical Sciences Gadag India. FAU - Gohar, Ali AU - Gohar A AD - Department of Medicine Lahore General hospital Lahore Pakistan. FAU - Waheed, Abdul AU - Waheed A AUID- ORCID: 0009-0008-3121-1421 AD - Department of Medicine Lahore General hospital Lahore Pakistan. FAU - Afzal, Muhammad Bilal AU - Afzal MB AUID- ORCID: 0009-0004-1171-3644 AD - Department of Medicine Mukhtar A Sheikh Hospital Multan Pakistan. FAU - Ahmad, Rehan Naseer AU - Ahmad RN AD - KEMU Lahore Pakistan. FAU - Maqsood, Saqib AU - Maqsood S AD - Department of Internal Medicine Faisalabad Medical University Faisalabad Punjab Pakistan. LA - eng PT - Journal Article DEP - 20260128 PL - United States TA - Health Sci Rep JT - Health science reports JID - 101728855 PMC - PMC12852504 OTO - NOTNLM OT - GI angiodysplasia OT - Heyde syndrome OT - aortic stenosis OT - von Willebrand factor deficiency COIS- The authors declare no conflicts of interest. EDAT- 2026/02/02 18:14 MHDA- 2026/02/02 18:15 PMCR- 2026/01/28 CRDT- 2026/02/02 06:35 PHST- 2025/05/01 00:00 [received] PHST- 2026/01/06 00:00 [revised] PHST- 2026/01/19 00:00 [accepted] PHST- 2026/02/02 18:15 [medline] PHST- 2026/02/02 18:14 [pubmed] PHST- 2026/02/02 06:35 [entrez] PHST- 2026/01/28 00:00 [pmc-release] AID - HSR271778 [pii] AID - 10.1002/hsr2.71778 [doi] PST - epublish SO - Health Sci Rep. 2026 Jan 28;9(2):e71778. doi: 10.1002/hsr2.71778. eCollection 2026 Feb. PMID- 41622178 OWN - NLM STAT- MEDLINE DCOM- 20260706 LR - 20260813 IS - 1472-6920 (Electronic) IS - 1472-6920 (Linking) VI - 26 IP - 1 DP - 2026 Feb 2 TI - Effectiveness of integrated simulation and team-based learning in paediatric postgraduates for cardiopulmonary resuscitation training: a multiple methods study. LID - 10.1186/s12909-026-08694-x [doi] LID - 365 AB - BACKGROUND: Paediatric Cardiopulmonary resuscitation (CPR) is critical for saving children who experience cardiac arrest, but traditional teaching is often ineffective at improving clinical competence and teamwork. This study evaluates an innovative, understudied model: integrated simulation combined with Team-Based Learning (TBL) in CPR training among paediatric postgraduates. METHODS: This multi-methods observational study involved twenty-four paediatric postgraduates. The teaching method consisted of integrated simulation combined with TBL. Learning performance was measured before and after the course. Semi-structured interviews were conducted and recorded to collect data until data saturation was achieved, with the resulting data analyzed using inductive thematic analysis within a constructivist paradigm. Two researchers independently coded transcripts using NVivo 12.0, identified themes iteratively, and ensured rigour through member checking. RESULTS: The integrated simulation with TBL approach produced significant improvements in clinical operation scores: hands-on CPR (80.95 +/- 5.81 vs. 88.46 +/- 7.35), endotracheal intubation (76.03 +/- 6.51 vs. 81.89 +/- 9.72), defibrillation (79.96 +/- 4.37 vs. 89.84 +/- 3.98), and teamwork (28.33 +/- 2.46 vs. 32.99 +/- 2.85) (P < 0.05). For the qualitative component, semi-structured interviews were conducted with 11 participants, and analysis identified 10 core themes grouped into four clusters: "reflection and feedback," "highly simulated clinical scenario," "improving clinical thinking," and "teamwork and communication." CONCLUSION: The integrated simulation with TBL improves instructional effectiveness and overall clinical emergency response capabilities among paediatric postgraduates, thereby offering an innovative structured small-group learning method for paediatric CPR training. CI - (c) 2026. The Author(s). FAU - Zhang, Li-Dan AU - Zhang LD AD - Department of Paediatric Intensive Care Unit, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, Guangdong, China. FAU - Wang, Li AU - Wang L AD - Department of Paediatric Intensive Care Unit, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, Guangdong, China. FAU - Li, Ya-Ting AU - Li YT AD - Department of Paediatric Intensive Care Unit, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China. FAU - Guo, Yao-Yu AU - Guo YY AD - School of Medicine, Sun Yat-sen University, Shenzhen, Guangdong, China. FAU - Lin, Hong-Xin AU - Lin HX AD - Department of Paediatric Intensive Care Unit, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, Guangdong, China. FAU - Ye, Xiao-Ting AU - Ye XT AD - Department of Paediatric Intensive Care Unit, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, Guangdong, China. FAU - Chen, Hua-Bao AU - Chen HB AD - Department of Paediatric Intensive Care Unit, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, Guangdong, China. FAU - Tang, Yan-Lai AU - Tang YL AD - Paediatrics, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, 510080, China. tangylai@mail.sysu.edu.cn. FAU - Chen, Chun AU - Chen C AD - Paediatric Hematology Laboratory, Division of Hematology/Oncology, Department of Paediatrics, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, 518107, Guangdong, China. chenchun@mail.sysu.edu.cn. FAU - Xu, Ling-Ling AU - Xu LL AD - Paediatrics, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, 510080, China. xulingl2@mail.sysu.edu.cn. LA - eng GR - Educational Affairs of Sun Yat-sen University [2020] No. 93/application of teacher-standardized patients combined with case-guided teaching method in pediatric probation teaching of Sun Yat-sen University Undergraduate Teaching Reform and Teaching Quality Project in 2020/ GR - Sun Yat-sen University Academic Affairs Office Document No. 48 of 2025/The Second Batch of the 2024 Industry-University-Research Cooperation Education Program of Sun Yat-sen University/ GR - No. : Guangdong Education Gao Han [2020] No. 20/2020 Higher Education Teaching Reform Project of Guangdong Province/ GR - Serial number: 78/2023 Teaching Reform Project of Guangdong Province "New Medical Science" Teaching Commission/ GR - No. : Sun Yat-sen University Educational Affairs (2020) No. 93/Sun Yat-sen University 2020 Undergraduate Teaching Reform and Teaching Quality Engineering Project/ GR - No. 80000-31911130/2020 University-level undergraduate Quality Engineering and Teaching Reform research project "Application of TBL Combined with Case Teaching in Pediatric Undergraduate Clinical Practice Teaching"/ GR - No. 31911130-210409/Sun Yat-sen University School-level Education Reform Fund: The Application of Role-playing Combined with Typical Case Teaching Method in Pediatric Clinical Teaching/ PT - Journal Article PT - Observational Study DEP - 20260202 PL - England TA - BMC Med Educ JT - BMC medical education JID - 101088679 SB - IM MH - Humans MH - *Cardiopulmonary Resuscitation/education MH - *Pediatrics/education MH - Clinical Competence MH - *Patient Care Team MH - Female MH - *Simulation Training/methods MH - Male MH - *Education, Medical, Graduate/methods MH - Child PMC - PMC12954905 OTO - NOTNLM OT - Clinical teaching OT - Integrated simulation OT - Paediatrics OT - Postgraduates OT - Team-Based learning COIS- Declarations. Ethics approval and consent to participate: The ethics commission of the seventh hospital affiliated to sun yat-sen university (shenzhen) approved this study (No. KY-2024-040-02). Informed consent was obtained from all study participants. To ensure methodological rigor and ethical compliance, the following measures were implemented: (1) Participant Recruitment & Informed Consent: Study participants were independently recruited by a third-party institution, with explicit written assurance that "participation would have no bearing on clinical rotation evaluations or future employment prospects". (2) Interviews Data Collection Protocols: For in-person assessments (e.g., resuscitation group evaluations), sessions were conducted in a neutral setting (outside the teaching meeting room), with no instructors or evaluators present. (3) Ethical Oversight & Compliance: The study protocol underwent rigorous review by the institutional ethics committee and received a dedicated risk- benefit assessment from the affiliated university's Institutional Review Board (IRB); Mid-study monitoring included an anonymous student satisfaction report, which confirmed no instances of marginalization or adverse consequences due to non-participation. Consent for publication: This manuscript has not been published or presented elsewhere in part or in entirety, and is not under consideration by another journal. All participants who attended the training and all authors have read and approved the final version of the manuscript, and consent to its publication. Competing interests: The authors declare no competing interests. EDAT- 2026/02/02 00:29 MHDA- 2026/03/07 06:39 PMCR- 2026/02/02 CRDT- 2026/02/01 23:14 PHST- 2024/07/05 00:00 [received] PHST- 2026/01/23 00:00 [accepted] PHST- 2026/03/07 06:39 [medline] PHST- 2026/02/02 00:29 [pubmed] PHST- 2026/02/01 23:14 [entrez] PHST- 2026/02/02 00:00 [pmc-release] AID - 10.1186/s12909-026-08694-x [pii] AID - 8694 [pii] AID - 10.1186/s12909-026-08694-x [doi] PST - epublish SO - BMC Med Educ. 2026 Feb 2;26(1):365. doi: 10.1186/s12909-026-08694-x. PMID- 41619774 OWN - NLM STAT- MEDLINE DCOM- 20260706 LR - 20260828 IS - 1873-734X (Electronic) IS - 1010-7940 (Linking) VI - 68 IP - 2 DP - 2026 Feb 5 TI - Interdisciplinary and Cross-Sectoral Perioperative Care Model in Cardiac Surgery: ERAS Implementation in the Setting of Minimally Invasive Heart Valve Surgery (INCREASE)-Results of a Randomized Controlled Trial. LID - ezag061 [pii] LID - 10.1093/ejcts/ezag061 [doi] AB - OBJECTIVES: Enhanced recovery after surgery (ERAS) protocols are patient-centred, interprofessional perioperative care models aimed at reducing hospital stays, complications, healthcare costs, and improving patient satisfaction. Evidence for ERAS in cardiac surgery is scarce; therefore, we aimed to assess its efficacy and safety in minimally invasive heart valve surgery (MIHS). METHODS: Interdisciplinary Perioperative Care in Minimally Invasive Heart Valve Surgery (INCREASE) is a randomized-controlled trial that compares ERAS with standard care in MIHS. The intervention group (IG) received ERAS-based treatment; the control group (CG) standard care. Co-primary end-points were in-hospital stay for cardiovascular reasons within 1 year postoperatively (superiority hypothesis) and physical performance (6-minute walk test [6MWT]) at discharge (non-inferiority hypothesis). Superiority hypothesis was tested primarily in surgically treated patients (modified intention to treat population), while non-inferiority hypothesis was tested in per protocol population. RESULTS: In total, 201 patients scheduled for MIHS were randomized (IG: 101; CG: 100). Total weighted in-hospital stay within 1 year was non-significantly shorter in the IG (adjusted mean difference -2.7 days, 95% confidence interval (CI) (-6.3, 0.9), 1-sided P = .07). Sensitivity analyses favoured the IG (adjusted ratio 0.71, 95% CI, 0.6, 0.85). For 6MWT, adjusted mean difference was -14%, 95% CI (-43%, 15%) exceeding the non-inferiority margin of -15% (1-sided P = .48). Without baseline adjustment, 6MWT values revealed a mean difference between groups of -1%, 95% CI (-10%, 8%), reaching non-inferiority of the IG. Safety outcomes were comparable with the exception of an unexpected higher rate of post-operative atrial fibrillation in patients randomized to ERAS. CONCLUSIONS: ERAS is feasible and safe in MIHS. The trial did not demonstrate a reduction in length of hospital stay during the first postoperative year in the population studied. Exploratory analyses suggest that further evaluation of ERAS concepts is justified. CI - (c) The Author(s) 2026. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. FAU - Petersen, Johannes AU - Petersen J AUID- ORCID: 0000-0002-3415-3385 AD - Department of Cardiovascular Surgery, University Heart and Vascular Center, University Medical Center Hamburg-Eppendorf, Hamburg 20251, Germany. AD - DZHK (German Centre for Cardiovascular Research), partner site North, Hamburg, Germany. FAU - Stock, Sina AU - Stock S AD - Department of Cardiothoracic Surgery, University Hospital Augsburg, 86156 Augsburg, Germany. FAU - Brettschneider, Christian AU - Brettschneider C AD - Department of Health Economics and Health Services Research, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany. FAU - Dolata, Luisa AU - Dolata L AD - Department of Patient and Care Management, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany. FAU - Dumps, Christian AU - Dumps C AD - Anesthesiology and Operative Intensive Care, Faculty of Medicine, University of Augsburg, 86156 Augsburg, Germany. FAU - Lowe, Bernd AU - Lowe B AUID- ORCID: 0000-0003-4220-3378 AD - Department of Psychosomatic Medicine and Psychotherapy, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany. FAU - Nijman, Eric AU - Nijman E AD - Department of Physiotherapy and Occupational Therapy, University Hospital Augsburg, 86156 Augsburg, Germany. FAU - Ozga, Ann-Kathrin AU - Ozga AK AUID- ORCID: 0000-0002-9501-7301 AD - Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany. FAU - Reichenspurner, Hermann AU - Reichenspurner H AD - Department of Cardiovascular Surgery, University Heart and Vascular Center, University Medical Center Hamburg-Eppendorf, Hamburg 20251, Germany. AD - DZHK (German Centre for Cardiovascular Research), partner site North, Hamburg, Germany. FAU - Schmid, Mona Elisabeth AU - Schmid ME AD - Department of Cardiothoracic Surgery, University Hospital Augsburg, 86156 Augsburg, Germany. FAU - Schulte-Uentrop, Leonie AU - Schulte-Uentrop L AD - Department of Anesthesiology, Center of Anesthesiology and Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany. FAU - Vettorazzi, Eik AU - Vettorazzi E AUID- ORCID: 0000-0002-3737-6402 AD - Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany. FAU - Zapf, Antonia AU - Zapf A AUID- ORCID: 0000-0002-8467-0508 AD - Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany. FAU - Zastrow, Inke AU - Zastrow I AD - Department of Patient and Care Management, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany. FAU - Klotz, Susanne G R AU - Klotz SGR AUID- ORCID: 0000-0002-9886-9032 AD - Department of Physiotherapy, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany. FAU - Girdauskas, Evaldas AU - Girdauskas E AUID- ORCID: 0000-0003-1571-4244 AD - Department of Cardiovascular Surgery, University Heart and Vascular Center, University Medical Center Hamburg-Eppendorf, Hamburg 20251, Germany. AD - DZHK (German Centre for Cardiovascular Research), partner site North, Hamburg, Germany. AD - Department of Cardiothoracic Surgery, University Hospital Augsburg, 86156 Augsburg, Germany. LA - eng GR - 01NVF19028/Innovationsausschuss in the Gemeinsamer Bundesausschuss/ PT - Journal Article PT - Randomized Controlled Trial PL - Germany TA - Eur J Cardiothorac Surg JT - European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery JID - 8804069 SB - IM MH - Humans MH - *Minimally Invasive Surgical Procedures/methods/adverse effects MH - Female MH - *Perioperative Care/methods MH - Length of Stay/statistics & numerical data MH - Middle Aged MH - Male MH - *Cardiac Surgical Procedures/methods/adverse effects MH - Aged MH - *Enhanced Recovery After Surgery MH - *Heart Valves/surgery MH - Treatment Outcome OTO - NOTNLM OT - ERAS OT - advanced practice nurse OT - enhanced recovery after surgery OT - minimally invasive heart valve surgery OT - physiotherapy OT - psychosomatic medicine EDAT- 2026/02/01 00:43 MHDA- 2026/03/06 19:43 CRDT- 2026/01/31 19:03 PHST- 2025/09/10 00:00 [received] PHST- 2025/12/23 00:00 [revised] PHST- 2026/01/06 00:00 [accepted] PHST- 2026/03/06 19:43 [medline] PHST- 2026/02/01 00:43 [pubmed] PHST- 2026/01/31 19:03 [entrez] AID - 8450332 [pii] AID - 10.1093/ejcts/ezag061 [doi] PST - ppublish SO - Eur J Cardiothorac Surg. 2026 Feb 5;68(2):ezag061. doi: 10.1093/ejcts/ezag061. PMID- 41611313 OWN - NLM STAT- MEDLINE DCOM- 20260701 LR - 20260701 IS - 2053-3624 (Print) IS - 2053-3624 (Electronic) IS - 2053-3624 (Linking) VI - 13 IP - 1 DP - 2026 Jan 29 TI - Multidisciplinary team-guided management of severe aortic stenosis: 5-year outcomes following TAVI versus conservative treatment. LID - 10.1136/openhrt-2025-003872 [doi] LID - e003872 AB - OBJECTIVE: Multidisciplinary team (MDT) meetings are central to treatment decisions in aortic stenosis (AS), particularly for borderline or high-risk patients. This study evaluates long-term, real-world outcomes according to MDT-selected management strategy within routine clinical practice in this clinically important patient group. METHODS: We conducted a retrospective cohort study of all patients with severe AS discussed at a transcatheter aortic valve implantation (TAVI) MDT at a tertiary UK centre between January 2014 and December 2016. Patients were categorised as TAVI or non-TAVI (conservatively managed). Demographic, clinical and frailty data were collected, including Charlson Comorbidity Index, Clinical Frailty Scale (CFS) and number of prescribed medications. Survival was analysed using Kaplan-Meier estimates and Cox proportional hazards modelling adjusted for age, sex, frailty, comorbidity burden and medication count. RESULTS: A total of 373 patients were included (TAVI=178; non-TAVI=195). Patients undergoing TAVI were younger (81.3 years vs 83.5 years; p=0.01) and less frail (CFS 3.9 vs 4.9; p<0.01). Survival at 1 year, 2 years and 5 years was significantly higher following TAVI (87.6%, 74.7%, 44.9%) compared with conservative management (60.8%, 44.2%, 12.1%; p<0.001). Median survival was 53 months after TAVI versus 20 months without intervention. On multivariable analysis, TAVI was independently associated with reduced mortality (HR 0.38, 95% CI 0.28 to 0.50; p<0.001). CONCLUSIONS: In patients with severe AS discussed at MDT, TAVI was associated with a substantial and durable survival advantage compared with conservative management. These findings highlight the poor prognosis of untreated severe AS and support systematic inclusion of conservatively managed patients in interventional registries to better inform MDT deliberation and shared decision-making. CI - (c) Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. FAU - Manning, Jane AU - Manning J AD - Cutrale Perioperative and Ageing Group, Department of Bioengineering, Imperial College London, London, UK. FAU - Koizia, Louis J AU - Koizia LJ AUID- ORCID: 0000-0003-4074-6926 AD - Cutrale Perioperative and Ageing Group, Department of Bioengineering, Imperial College London, London, UK louis.koizia05@imperial.ac.uk. FAU - Dani, Melanie AU - Dani M AD - Cutrale Perioperative and Ageing Group, Department of Bioengineering, Imperial College London, London, UK. FAU - Malik, Iqbal AU - Malik I AD - Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK. FAU - Di Giovannantonio, Matteo AU - Di Giovannantonio M AD - Department of Oncology, University of Oxford, Oxford, UK. AD - Institute for Liver and Digestive Health, Division of Medicine, University College London, London, UK. FAU - Harris, Benjamin H L AU - Harris BHL AD - Cutrale Perioperative and Ageing Group, Department of Bioengineering, Imperial College London, London, UK. AD - Department of Oncology, University of Oxford, Oxford, UK. AD - Institute for Liver and Digestive Health, Division of Medicine, University College London, London, UK. AD - Department of Psychosocial Rehabilitation, Medical University of Lodz, Lodz, Poland. AD - Collaborating Centre for Values-based Practice, St Catherine's College, Oxford, UK. FAU - Fertleman, Michael B AU - Fertleman MB AD - Cutrale Perioperative and Ageing Group, Department of Bioengineering, Imperial College London, London, UK. LA - eng PT - Comparative Study PT - Journal Article DEP - 20260129 PL - England TA - Open Heart JT - Open heart JID - 101631219 SB - IM MH - Humans MH - *Aortic Valve Stenosis/mortality/therapy/surgery/physiopathology/diagnosis/diagnostic imaging MH - Female MH - Retrospective Studies MH - *Conservative Treatment/adverse effects/mortality MH - Male MH - *Patient Care Team MH - *Transcatheter Aortic Valve Replacement/adverse effects/mortality MH - Treatment Outcome MH - Aged, 80 and over MH - Time Factors MH - Severity of Illness Index MH - Risk Factors MH - Aged MH - Risk Assessment MH - Clinical Decision-Making MH - *Aortic Valve/surgery/diagnostic imaging/physiopathology PMC - PMC12863368 OTO - NOTNLM OT - Aortic Valve Stenosis OT - Quality of Health Care OT - Transcatheter Aortic Valve Replacement COIS- Competing interests: None declared. EDAT- 2026/01/30 00:54 MHDA- 2026/01/30 00:55 PMCR- 2026/01/29 CRDT- 2026/01/29 20:53 PHST- 2025/11/21 00:00 [received] PHST- 2026/01/04 00:00 [accepted] PHST- 2026/01/30 00:55 [medline] PHST- 2026/01/30 00:54 [pubmed] PHST- 2026/01/29 20:53 [entrez] PHST- 2026/01/29 00:00 [pmc-release] AID - openhrt-2025-003872 [pii] AID - 10.1136/openhrt-2025-003872 [doi] PST - epublish SO - Open Heart. 2026 Jan 29;13(1):e003872. doi: 10.1136/openhrt-2025-003872. PMID- 41610265 OWN - NLM STAT- MEDLINE DCOM- 20260721 LR - 20260721 IS - 1816-5370 (Electronic) IS - 0218-4923 (Linking) VI - 34 IP - 2 DP - 2026 Feb TI - Evidence-based guidelines for aortic stenosis: Focus on surgical aortic valve replacement versus transcatheter aortic valve implantation for young patients. PG - 136-145 LID - 10.1177/02184923251415153 [doi] AB - Transcatheter aortic valve implantation (TAVI) has revolutionized the management of aortic stenosis and is now an established alternative to surgical aortic valve replacement (SAVR) for all surgical risk categories. However, the extension of TAVI to younger, low-risk patients has raised important questions regarding the long-term outcomes, valve durability, and lifetime management strategies for these patients. This narrative review summarizes the current evidence from pivotal randomized trials and contemporary registries comparing TAVI and SAVR in young, low-risk patients, integrating the latest 2025 ESC/EACTS guidelines. While short-term outcomes and early recovery favor TAVI, SAVR remains associated with proven durability, lower rates of conduction disturbances, and a potential advantage in long-term outcomes as follow-up data extend beyond five years. Anatomical challenges such as bicuspid valves, coronary access, and patient-prosthesis mismatch further complicate the use of TAVI in this population. A "SAVR-first" lifetime management approach appears to provide greater procedural flexibility and a lower reintervention risk. Ultimately, the choice between TAVI and SAVR in young patients should be individualized through a multidisciplinary Heart Team process, balancing early procedural benefits with long-term durability and reintervention considerations. This review highlights the need for dedicated long-term data and patient-tailored strategies in the evolving management of aortic stenosis in young low-risk individuals. FAU - Alcocer, Jorge AU - Alcocer J AUID- ORCID: 0000-0003-3235-3436 AD - Department of Cardiovascular Surgery, Hospital Clinic, University of Barcelona, Barcelona, Spain. RINGGOLD: 16493 FAU - Quintana, Eduard AU - Quintana E AUID- ORCID: 0000-0002-5386-7463 AD - Department of Cardiovascular Surgery, Hospital Clinic, University of Barcelona, Barcelona, Spain. RINGGOLD: 16493 FAU - Ascaso, Maria AU - Ascaso M AUID- ORCID: 0000-0001-5944-4827 AD - Department of Cardiovascular Surgery, Hospital Clinic, University of Barcelona, Barcelona, Spain. RINGGOLD: 16493 FAU - Pruna, Robert AU - Pruna R AUID- ORCID: 0000-0003-1872-6275 AD - Department of Cardiovascular Surgery, Hospital Clinic, University of Barcelona, Barcelona, Spain. RINGGOLD: 16493 LA - eng PT - Comparative Study PT - Journal Article PT - Review DEP - 20260129 PL - England TA - Asian Cardiovasc Thorac Ann JT - Asian cardiovascular & thoracic annals JID - 9503417 SB - IM MH - *Evidence-Based Medicine/methods/standards/statistics & numerical data MH - Randomized Controlled Trials as Topic MH - *Practice Guidelines as Topic MH - *Transcatheter Aortic Valve Replacement/adverse effects/instrumentation/standards/statistics & numerical data MH - *Heart Valve Prosthesis Implantation/adverse effects/instrumentation/standards/statistics & numerical data MH - *Aortic Valve Stenosis/mortality/surgery MH - Registries/statistics & numerical data MH - Age Factors MH - Time Factors MH - Postoperative Complications/epidemiology/etiology MH - Reoperation/statistics & numerical data MH - Heart Valve Prosthesis/adverse effects/statistics & numerical data MH - Patient Selection MH - Humans MH - Middle Aged MH - Aged MH - Aged, 80 and over MH - Cardiology/standards MH - Societies, Medical/standards OTO - NOTNLM OT - Aortic stenosis OT - lifetime management OT - low-risk patients OT - surgical aortic valve replacement OT - transcatheter aortic valve implantation OT - young patients COIS- Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2026/01/29 19:11 MHDA- 2026/02/09 12:53 CRDT- 2026/01/29 14:22 PHST- 2026/02/09 12:53 [medline] PHST- 2026/01/29 19:11 [pubmed] PHST- 2026/01/29 14:22 [entrez] AID - 10.1177/02184923251415153 [doi] PST - ppublish SO - Asian Cardiovasc Thorac Ann. 2026 Feb;34(2):136-145. doi: 10.1177/02184923251415153. Epub 2026 Jan 29. PMID- 41610210 OWN - NLM STAT- MEDLINE DCOM- 20260806 LR - 20260806 IS - 2150-136X (Electronic) IS - 2150-1351 (Linking) VI - 17 IP - 5 DP - 2026 Sep TI - Cardiac Surgery Competence at a Resource-Limited Tertiary Hospital in Nigeria: From Missions to Autonomy. PG - 603-609 LID - 10.1177/21501351251408487 [doi] AB - BackgroundCardiac surgery requiring cardiopulmonary bypass began at Federal Medical Centre (FMC), Abuja, in February 2022 through visiting mission teams. Continuous collaboration between subsequent missions and local staff has led to progressive skills acquisition and increasing independence in both adult and pediatric cardiac surgery. This report outlines our path to independence and the challenges encountered.MethodsFrom February 2022 to December 2024, we reviewed 45 patients who underwent cardiac surgery with cardiopulmonary bypass. Data included the operating team (visiting vs local), case type, and outcomes.ResultsOf 45 surgeries, visiting teams performed 27 (11 adult, 16 pediatric) and local surgeons performed 18 (5 adult, 13 pediatric). Six surgical missions were conducted. The proportion of cases done independently by local surgeons increased from 14.3% in 2022 (n = 7) to 26% in 2023 (n = 23), and 73% in 2024 (n = 15). Competence was achieved first by cardiologists, followed by scrub nurses, intensive care unit nurses, anesthetists, and surgeons. The local perfusionist has yet to attain independence, representing a major program limitation. Of 45 operations, nine mortalities (20%) occurred-five in visiting-team cases and four in local-team cases. All but one were pediatric, and all occurred postoperatively.ConclusionStructured collaboration with visiting missions, deliberate skills transfer, and perseverance have enabled rapid development of cardiac surgical competence at the Federal Medical Centre, Abuja. While adult and selected pediatric cases are now managed independently, further progress requires dedicated perfusionist training and improved pediatric postoperative care. FAU - Alioke, Ikechukwuka I AU - Alioke II AUID- ORCID: 0000-0002-7846-1523 AD - Cardiothoracic Surgery Division, Federal Medical Centre, Abuja, Nigeria. RINGGOLD: 432706 FAU - Idoko, Francis L AU - Idoko FL AUID- ORCID: 0009-0001-6388-9631 AD - Cardiothoracic Surgery Division, Federal Medical Centre, Abuja, Nigeria. RINGGOLD: 432706 FAU - Igwe, Stanley N AU - Igwe SN AUID- ORCID: 0009-0005-0416-2829 AD - Department of Anaesthesia, Federal Medical Centre, Abuja, Nigeria. RINGGOLD: 432706 FAU - Apeh, Charles I AU - Apeh CI AUID- ORCID: 0009-0001-6755-7642 AD - Department of Anaesthesia, Federal Medical Centre, Abuja, Nigeria. RINGGOLD: 432706 FAU - Maduka, Ogechi C D AU - Maduka OCD AUID- ORCID: 0009-0000-6420-8829 AD - Paediatric Cardiology Unit, Federal Medical Centre, Abuja, Nigeria. RINGGOLD: 432706 FAU - Papka, Nubwa Y AU - Papka NY AUID- ORCID: 0009-0004-4427-3382 AD - Paediatric Cardiology Unit, Federal Medical Centre, Abuja, Nigeria. RINGGOLD: 432706 FAU - Abiodun, Olugbenga O AU - Abiodun OO AUID- ORCID: 0000-0001-8625-4834 AD - Adult Cardiology Unit, Federal Medical Centre, Abuja, Nigeria. RINGGOLD: 432706 FAU - Salau, Ibrahim L AU - Salau IL AUID- ORCID: 0009-0003-9502-0484 AD - Adult Cardiology Unit, Federal Medical Centre, Abuja, Nigeria. RINGGOLD: 432706 FAU - Anumenechi, Ndubuisi AU - Anumenechi N AUID- ORCID: 0000-0002-0013-3984 AD - Cardiothoracic Surgery Division, National Hospital, Abuja, Nigeria. RINGGOLD: 107690 FAU - Akanni, Bolaji AU - Akanni B AUID- ORCID: 0000-0002-9325-8048 AD - Cardiothoracic Surgery Division, Alex Ekwueme Federal University Teaching Hospital, Ebonyi, Nigeria. RINGGOLD: 107678 FAU - Afolayan, Abdul-Gafar AU - Afolayan AG AUID- ORCID: 0009-0001-3843-271X AD - Cardiothoracic Surgery Division, Federal Medical Centre, Abuja, Nigeria. RINGGOLD: 432706 LA - eng PT - Journal Article DEP - 20260129 PL - United States TA - World J Pediatr Congenit Heart Surg JT - World journal for pediatric & congenital heart surgery JID - 101518415 SB - IM MH - Humans MH - Nigeria MH - *Tertiary Care Centers MH - *Cardiac Surgical Procedures/standards MH - *Clinical Competence MH - *Medical Missions MH - Resource-Limited Settings MH - Child MH - Female MH - Male MH - Adult MH - Infant MH - Child, Preschool MH - *Heart Defects, Congenital/surgery MH - Cardiopulmonary Bypass MH - Retrospective Studies MH - Patient Care Team OTO - NOTNLM OT - Abuja OT - cardiac surgery OT - competence OT - homegrown OT - missions COIS- Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2026/01/29 19:10 MHDA- 2026/08/06 12:37 CRDT- 2026/01/29 14:13 PHST- 2026/08/06 12:37 [medline] PHST- 2026/01/29 19:10 [pubmed] PHST- 2026/01/29 14:13 [entrez] AID - 10.1177/21501351251408487 [doi] PST - ppublish SO - World J Pediatr Congenit Heart Surg. 2026 Sep;17(5):603-609. doi: 10.1177/21501351251408487. Epub 2026 Jan 29. PMID- 41609550 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260226 LR - 20260813 IS - 2772-963X (Electronic) IS - 2772-963X (Linking) VI - 5 IP - 2 DP - 2026 Feb TI - Evolution of Management and Outcomes of Infective Endocarditis After Introducing the Endocarditis Team. PG - 102579 LID - S2772-963X(25)01008-7 [pii] LID - 10.1016/j.jacadv.2025.102579 [doi] LID - 102579 AB - BACKGROUND: Current guidelines recommend discussing patients with infective endocarditis in an endocarditis team (ET). The benefits of an ET have been established, but not the evolution over time. OBJECTIVES: The objective of the study was to investigate changes in management and outcomes in infective endocarditis over time. METHODS: All patients discussed by our ET since 2016 were prospectively included and divided into 3 cohorts. Trends over time for the number of discussions, diagnostics, ET recommendations, treatment, and outcomes were assessed using Poisson, logistic, and Cox regression, respectively, adjusted for potential case mix. RESULTS: The total cohort included 1,042 patients, with 223, 364, and 455 patients in cohorts 1 (2016-2018), 2 (2019-2021), and 3 (2022-2024), respectively. The percentage of patients with a rediscussion increased with 18.2% (P < 0.001), and the number of discussions per patient increased with 3% per diagnosis-year (P = 0.006). The percentage of patients with positive blood cultures decreased with 17.5% (P < 0.001), whereas cardiac computed tomography (CT) and positron emission tomography (PET) CT usage increased with 3.1% (P = 0.028) and 12.5% (P < 0.001), respectively. Advice for additional diagnostic tests decreased by 11.6% (P < 0.001), and treatment change decreased by 18.3% (P < 0.001). Reclassification of the initial diagnosis increased with 8.3% (P = 0.045). Relapse (P = 0.82) and reinfection rates did not change (P = 0.98). One-year survival was approximately 80% and remained stable (P = 0.62). CONCLUSIONS: There were more referrals and rediscussions, but less need for additional advice, reflecting increased familiarity with and a learning effect of the ET. CT and PET-CT were used more often. Mortality did not change over time and remained high. CI - Copyright (c) 2026 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Dalebout, Eefje M AU - Dalebout EM AD - Department of Cardiology, Cardiovascular Institute, Thorax Center, Erasmus Medical Center, Rotterdam, the Netherlands; Department of Radiology and Nuclear Medicine, Erasmus Medical Center, Rotterdam, the Netherlands; Department of Cardiothoracic Surgery, Thorax Center, Erasmus Medical Center, Rotterdam, the Netherlands. FAU - Budde, Ricardo P J AU - Budde RPJ AD - Department of Cardiology, Cardiovascular Institute, Thorax Center, Erasmus Medical Center, Rotterdam, the Netherlands; Department of Radiology and Nuclear Medicine, Erasmus Medical Center, Rotterdam, the Netherlands. FAU - Galema, Tjebbe W AU - Galema TW AD - Department of Cardiology, Cardiovascular Institute, Thorax Center, Erasmus Medical Center, Rotterdam, the Netherlands. FAU - Wahadat, Ali R AU - Wahadat AR AD - Department of Cardiology, Cardiovascular Institute, Thorax Center, Erasmus Medical Center, Rotterdam, the Netherlands; Department of Radiology and Nuclear Medicine, Erasmus Medical Center, Rotterdam, the Netherlands. FAU - Swart, Laurens E AU - Swart LE AD - Department of Cardiology, Cardiovascular Institute, Thorax Center, Erasmus Medical Center, Rotterdam, the Netherlands; Department of Radiology and Nuclear Medicine, Erasmus Medical Center, Rotterdam, the Netherlands; Department of Cardiology, Spaarne Gasthuis, Haarlem, the Netherlands. FAU - Veen, Kevin M AU - Veen KM AD - Department of Cardiothoracic Surgery, Thorax Center, Erasmus Medical Center, Rotterdam, the Netherlands. FAU - Verkaik, Nelianne J AU - Verkaik NJ AD - Department of Medical Microbiology and Infectious Diseases, Erasmus MC, Rotterdam, The Netherlands. FAU - Hirsch, Alexander AU - Hirsch A AD - Department of Cardiology, Cardiovascular Institute, Thorax Center, Erasmus Medical Center, Rotterdam, the Netherlands; Department of Radiology and Nuclear Medicine, Erasmus Medical Center, Rotterdam, the Netherlands. FAU - Kluin, Jolanda AU - Kluin J AD - Department of Cardiothoracic Surgery, Thorax Center, Erasmus Medical Center, Rotterdam, the Netherlands. FAU - Roos-Hesselink, Jolien W AU - Roos-Hesselink JW AD - Department of Cardiology, Cardiovascular Institute, Thorax Center, Erasmus Medical Center, Rotterdam, the Netherlands. Electronic address: j.roos@erasmusmc.nl. LA - eng PT - Journal Article DEP - 20260129 PL - United States TA - JACC Adv JT - JACC. Advances JID - 9918419284106676 PMC - PMC12948601 OTO - NOTNLM OT - endocarditis OT - endocarditis team OT - multidisciplinary care OT - valvular heart disease COIS- Funding support and author disclosures Dr Budde received speakers fees from Bayer and Siemens and served on an advisory board for Bayer (all payments to Erasmus MC). Dr Swart has received consultancy fees from Amgen and Sanofi that are not relevant to the contents of this paper. Dr Hirsch received a research grant and consultancy fees from GE Healthcare and speaker fees from GE Healthcare, Bristol Myers Squibb, Bayer, Siemens Healthineers, and Heartflow; he is a member of the medical advisory board of Medis Medical Imaging Systems; and he was MRI corelab supervisor of Cardialysis BV until 2022. Institutional support to Erasmus MC by Siemens, Heartflow, and Bracco by research grants. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2026/01/29 14:02 MHDA- 2026/01/29 14:03 PMCR- 2026/01/29 CRDT- 2026/01/29 10:29 PHST- 2025/09/04 00:00 [received] PHST- 2025/12/22 00:00 [revised] PHST- 2025/12/22 00:00 [accepted] PHST- 2026/01/29 14:03 [medline] PHST- 2026/01/29 14:02 [pubmed] PHST- 2026/01/29 10:29 [entrez] PHST- 2026/01/29 00:00 [pmc-release] AID - S2772-963X(25)01008-7 [pii] AID - 102579 [pii] AID - 10.1016/j.jacadv.2025.102579 [doi] PST - ppublish SO - JACC Adv. 2026 Feb;5(2):102579. doi: 10.1016/j.jacadv.2025.102579. Epub 2026 Jan 29. PMID- 41602515 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260128 LR - 20260131 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 18 IP - 1 DP - 2026 Jan TI - Acute Myocardial Infarction in Pregnancy: A Multidisciplinary Approach. PG - e102240 LID - 10.7759/cureus.102240 [doi] LID - e102240 AB - Pregnancy is associated with increased hemodynamic demands on the mother's cardiovascular system. In a normal pregnancy, most women experience symptoms such as fatigue, dyspnea, lower extremity edema, and reduced exercise ability, which can be difficult to differentiate from those of cardiac malfunction. During pregnancy, very few women experience myocardial infarction (MI). With an increasing incidence of MI during pregnancy, neonatal and maternal morbidity and mortality are significant. Particular attention is required regarding the MI cause, diagnostic assessment, and treatment plan, and post-event care is essential while treating pregnant women with MI. This review article describes the epidemiology, physiological changes, risk factors, pathogenesis, clinical presentation, differential diagnosis, diagnostic modalities, treatment strategies, time and mode of delivery, anesthesia for cesarean delivery, intraoperative anesthesia monitoring techniques, postoperative analgesia, postpartum period, maternal and neonatal outcomes, future pregnancy, case studies, and outcomes for women experiencing MI during pregnancy. CI - Copyright (c) 2026, Ghafoor et al. FAU - Ghafoor, Hashaam AU - Ghafoor H AD - Department of Anesthesiology, ICU, and Perioperative Medicine, Hamad Medical Corporation, Doha, QAT. AD - Department of Anesthesia, College of Medicine, Qatar University, Doha, QAT. FAU - Haider, Farrookh AU - Haider F AD - Department of Cardiology, Hamad Medical Corporation, Doha, QAT. AD - Department of Cardiology, College of Medicine, Qatar University, Doha, QAT. FAU - Zeba, Aalami AU - Zeba A AD - Department of Obstetrics and Gynecology, Hamad Medical Corporation, Doha, QAT. FAU - Kumar, Neeraj AU - Kumar N AD - Department of Anesthesiology, ICU, and Perioperative Medicine, Hamad Medical Corporation, Doha, QAT. AD - Department of Anesthesia, College of Medicine, Qatar University, Doha, QAT. FAU - Ul Huda, Anwar AU - Ul Huda A AD - Department of Anesthesiology, ICU, and Perioperative Medicine, Hamad Medical Corporation, Doha, QAT. AD - Department of Anesthesia, College of Medicine, Qatar University, Doha, QAT. FAU - Naz, Amber AU - Naz A AD - Department of Anesthesiology, ICU, and Perioperative Medicine, Hamad Medical Corporation, Doha, QAT. FAU - Padmalayam, Pramod AU - Padmalayam P AD - Department of Anesthesiology, ICU, and Perioperative Medicine, Hamad Medical Corporation, Doha, QAT. FAU - Ashraf, Khadija AU - Ashraf K AD - Department of Obstetrics and Gynecology, Hamad Medical Corporation, Doha, QAT. FAU - Ahmed, Osman AU - Ahmed O AD - Department of Anesthesiology, ICU, and Perioperative Medicine, Hamad Medical Corporation, Doha, QAT. AD - Department of Anesthesia, College of Medicine, Qatar University, Doha, QAT. FAU - Karunakaran, Ekambaram AU - Karunakaran E AD - Department of Anesthesiology, ICU, and Perioperative Medicine, Hamad Medical Corporation, Doha, QAT. FAU - Bel Khair, Ali O Mohamed AU - Bel Khair AOM AD - Department of Anesthesiology, ICU, and Perioperative Medicine, Hamad Medical Corporation, Doha, QAT. LA - eng PT - Journal Article PT - Review DEP - 20260125 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC12834412 OTO - NOTNLM OT - acute myocardial infarction OT - diagnosis OT - maternal and neonatal outcome OT - multidisciplinary approach OT - treatment COIS- Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. EDAT- 2026/01/28 07:48 MHDA- 2026/01/28 07:49 PMCR- 2026/01/25 CRDT- 2026/01/28 05:01 PHST- 2026/01/24 00:00 [accepted] PHST- 2026/01/28 07:49 [medline] PHST- 2026/01/28 07:48 [pubmed] PHST- 2026/01/28 05:01 [entrez] PHST- 2026/01/25 00:00 [pmc-release] AID - 10.7759/cureus.102240 [doi] PST - epublish SO - Cureus. 2026 Jan 25;18(1):e102240. doi: 10.7759/cureus.102240. eCollection 2026 Jan. PMID- 41601738 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260128 LR - 20260131 IS - 2296-858X (Print) IS - 2296-858X (Electronic) IS - 2296-858X (Linking) VI - 12 DP - 2025 TI - Survival and recovery: 24-month outcomes for critically Ill COVID-19 patients receiving ECMO. PG - 1731333 LID - 10.3389/fmed.2025.1731333 [doi] LID - 1731333 AB - BACKGROUND: Veno-venous extracorporeal membrane oxygenation (V-V ECMO) was used for patients with severe COVID-19 pneumonia. The aim of our study was to assess the long-term outcomes and quality of life of the surviving patients. METHODS: This single-center observational study was performed among patients who were discharged after V-V ECMO treatment with COVID-19 pneumonia. During the 2-year follow-up period, different organ functions and quality of life parameters were evaluated three times after discharge. As a control group, SARS-CoV-2 infection positive patients were included. RESULTS: Thirty-five patients underwent V-V ECMO treatment, of whom 11 patients survived. The study population consists of 9 patients for the follow-up (2 patients did not consent to follow-up examinations). On lung CT, the occurrence of residual fibrotic banding was 22% at discharge, and increased to 89% at 24th month follow-up, while lung function tests were normal. On echocardiography, patients had a mildly elevated right ventricle end-diastolic diameter at the post discharge period, which normalized during follow-up (baseline: 37.6 +/- 2.9 mm, follow-up: 35.6 +/- 2.2 mm, p < 0.05). In the ECMO group both humoral and cellular immune responses remained elevated (Quantiferon Ag1 p = 0.005, Quantiferon Ag2 p = 0.0059, Quantiferon Ag3 p = 0.0012, IgG Roche p = 0.0037).Among the psychological factors, significant correlation was observed between ECMO duration and symptoms of depression (r = 0.727; p < 0.05), anxiety (r = 0.848; p < 0.01), and posttraumatic stress (r = 0.834; p < 0.01), furthermore, a negative correlation with positive affectivity (r = -0.868; p < 0.01) presented itself. SF-36 scores improved significantly from the 6-month to the 24-month follow-up (median 50% vs. 80%, p < 0.01). The mean body mass index increased from 29 to 35 (kg/m(2)) and physical activity decreased. The Epworth Sleepiness Scale showed higher normal daytime sleepiness values and elevated Fatigue Severity Scale scores. CONCLUSION: At the 2-year follow-up after discharge from the V-V ECMO treatment, permanent cardio muscular and structural pulmonary damage had been anticipated. However, on one hand, good cardiac and pulmonary function and robust sustained immune response were measured. On the other hand, unforeseen long-term complications arose, such as sleepiness, reduced physical activity, acute depression, and consequently, a deteriorated health related quality of life. These findings highlight the necessity of long-term, structured controlled rehabilitation programs for this patient population. CI - Copyright (c) 2026 Ulakcsai, Dohy, Szabo, Balla, Mesko, Lakatos, Fontanini Mariastefano, Fesu, Ocsovszky, Otohal, Ehrenberger, Szabo, Szabo, Nemeth, Muller, Nagy, Vago and Merkely. FAU - Ulakcsai, Zsuzsanna AU - Ulakcsai Z AD - Heart and Vascular Center, Semmelweis University, Budapest, Hungary. FAU - Dohy, Zsofia AU - Dohy Z AD - Heart and Vascular Center, Semmelweis University, Budapest, Hungary. FAU - Szabo, Liliana AU - Szabo L AD - Heart and Vascular Center, Semmelweis University, Budapest, Hungary. FAU - Balla, Dorottya AU - Balla D AD - Heart and Vascular Center, Semmelweis University, Budapest, Hungary. FAU - Mesko, Csongor AU - Mesko C AD - Heart and Vascular Center, Semmelweis University, Budapest, Hungary. FAU - Lakatos, Balint AU - Lakatos B AD - Heart and Vascular Center, Semmelweis University, Budapest, Hungary. FAU - Fontanini Mariastefano, Daniele AU - Fontanini Mariastefano D AD - Heart and Vascular Center, Semmelweis University, Budapest, Hungary. FAU - Fesu, Dorottya AU - Fesu D AD - Department of Pulmonology, Semmelweis University, Budapest, Hungary. FAU - Ocsovszky, Zsofia AU - Ocsovszky Z AD - Heart and Vascular Center, Semmelweis University, Budapest, Hungary. FAU - Otohal, Jozsef AU - Otohal J AD - Heart and Vascular Center, Semmelweis University, Budapest, Hungary. FAU - Ehrenberger, Blanka AU - Ehrenberger B AD - Heart and Vascular Center, Semmelweis University, Budapest, Hungary. FAU - Szabo, Zsofia AU - Szabo Z AD - Department of Laboratory Medicine, Semmelweis University, Budapest, Hungary. FAU - Szabo, Tamas AU - Szabo T AD - Department of Laboratory Medicine, Semmelweis University, Budapest, Hungary. FAU - Nemeth, Endre AU - Nemeth E AD - Heart and Vascular Center, Semmelweis University, Budapest, Hungary. FAU - Muller, Veronika AU - Muller V AD - Department of Pulmonology, Semmelweis University, Budapest, Hungary. FAU - Nagy, Gyorgy AU - Nagy G AD - Heart and Vascular Center, Semmelweis University, Budapest, Hungary. AD - Department of Rheumatology and Immunology, Semmelweis University, Budapest, Hungary. AD - Department of Genetics, Cell and Immunobiology, Semmelweis University, Budapest, Hungary. FAU - Vago, Hajnalka AU - Vago H AD - Heart and Vascular Center, Semmelweis University, Budapest, Hungary. AD - Department of Sports Medicine, Semmelweis University, Budapest, Hungary. FAU - Merkely, Bela AU - Merkely B AD - Heart and Vascular Center, Semmelweis University, Budapest, Hungary. AD - Department of Sports Medicine, Semmelweis University, Budapest, Hungary. LA - eng PT - Journal Article DEP - 20260112 PL - Switzerland TA - Front Med (Lausanne) JT - Frontiers in medicine JID - 101648047 PMC - PMC12833345 OTO - NOTNLM OT - COVID-19 OT - ECMO OT - SARS-CoV-2 OT - immune response OT - long-term follow-up OT - multidisciplinary approach OT - quality of life COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/01/28 07:47 MHDA- 2026/01/28 07:48 PMCR- 2026/01/12 CRDT- 2026/01/28 04:55 PHST- 2025/10/23 00:00 [received] PHST- 2025/12/03 00:00 [revised] PHST- 2025/12/05 00:00 [accepted] PHST- 2026/01/28 07:48 [medline] PHST- 2026/01/28 07:47 [pubmed] PHST- 2026/01/28 04:55 [entrez] PHST- 2026/01/12 00:00 [pmc-release] AID - 10.3389/fmed.2025.1731333 [doi] PST - epublish SO - Front Med (Lausanne). 2026 Jan 12;12:1731333. doi: 10.3389/fmed.2025.1731333. eCollection 2025. PMID- 41598751 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260128 LR - 20260131 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 15 IP - 2 DP - 2026 Jan 19 TI - Immune Checkpoint Inhibitor-Associated Myocarditis: Risk, Diagnosis, and Clinical Impact. LID - 10.3390/jcm15020814 [doi] LID - 814 AB - Background: Immune checkpoint inhibitors (ICIs), such as anti-programmed death (PD)-1 and anti-cytotoxic T-lymphocyte-associated protein (CTLA)-4 agents, have revolutionized oncology but are associated with immune-related adverse events (irAEs). Among these, ICI-associated myocarditis (ICI-M) is a rare but life-threatening complication, with mortality rates ranging from 27% to 50%. Objective: This narrative review summarizes the pathogenesis, epidemiology, clinical presentation, diagnostic methods, and management strategies for ICI-induced myocarditis, specifically highlighting emerging biomarkers and immunosuppressive therapeutic approaches. Results and Discussion: ICI-M typically presents within the first 65 days of treatment and is significantly more frequent with combination therapies. Pathologically, it is characterized by myocyte necrosis and massive infiltration of cluster of differentiation (CD)4+ and CD8+ T-cells, often overlapping with myositis (irM/M). Diagnosis relies on a multimodal approach. Management requires immediate ICI cessation and initiation of high-dose corticosteroids as first-line therapy. For steroid-refractory cases, second-line options include mycophenolate mofetil (MMF), intravenous immunoglobulin (IVIG), and emerging therapies like abatacept and ruxolitinib. Rechallenge with ICIs after high-grade ICI-M must be approached with extreme caution by the multidisciplinary team (MDT). Emerging biomarkers and omics techniques hold promise for earlier diagnosis and risk stratification. Conclusions: ICI-M is a rare yet highly lethal cardiac complication demanding high clinical vigilance and timely diagnosis. Management hinges on an aggressive multidisciplinary approach, aiming to minimize toxicity while balancing oncological efficacy. FAU - Mauriello, Alfredo AU - Mauriello A AUID- ORCID: 0000-0001-7060-6938 AD - S.C. Cardiology, Institute National Cancer, IRCCS, Foundation "G. Pascale", Via M. Semmola 52, 80131 Naples, Italy. FAU - Correra, Adriana AU - Correra A AD - Cardiology Department, Ospedali Riuniti University Hospital, Viale Pinto 1, 71122 Foggia, Italy. FAU - Maratea, Anna Chiara AU - Maratea AC AD - Department of Cardiovascular Disease, ASL Napoli 1 Centro, Via Comunale del Principe, 13/a, 80145 Napoli, Italy. FAU - Cetoretta, Valeria AU - Cetoretta V AUID- ORCID: 0000-0002-2137-0188 AD - Cardiology and Arrhythmology Clinic, Marche Polytechnic University, University Hospital "Ospedali Riuniti", Via Conca 71, 60126 Ancona, Italy. FAU - Benfari, Giovanni AU - Benfari G AUID- ORCID: 0000-0002-5660-6162 AD - Section of Cardiology, Department of Medicine, University of Verona, P.le L.A. Scuro 10, 37100 Verona, Italy. FAU - Ilardi, Federica AU - Ilardi F AUID- ORCID: 0000-0002-3885-5093 AD - Department of Advanced Biomedical Sciences, Division of Cardiology, Federico II University Hospital, Via Pansini 5, 80131 Naples, Italy. FAU - Cocchia, Rosangela AU - Cocchia R AD - Department of Advanced Biomedical Sciences, Division of Cardiology, Federico II University Hospital, Via Pansini 5, 80131 Naples, Italy. FAU - Lisi, Matteo AU - Lisi M AUID- ORCID: 0000-0003-4591-2030 AD - Department of Cardiovascular Disease-AUSL Romagna, Division of Cardiology, Ospedale "S. Maria delle Croci", Viale Randi 5, 48121 Ravenna, Italy. FAU - Malagoli, Alessandro AU - Malagoli A AUID- ORCID: 0000-0001-9119-4311 AD - Division of Cardiology, Nephro-Cardiovascular Department, "Baggiovara" Hospital, Via P. Giardini 1355, 41100 Modena, Italy. FAU - Mandoli, Giulia Elena AU - Mandoli GE AD - Department of Medical Biotechnologies, Division of Cardiology, University of Siena, Viale Bracci 16, 53100 Siena, Italy. FAU - Pastore, Maria Concetta AU - Pastore MC AD - Department of Medical Biotechnologies, Division of Cardiology, University of Siena, Viale Bracci 16, 53100 Siena, Italy. FAU - Sperlongano, Simona AU - Sperlongano S AD - Cardiology Unit, Department of Medical and Translational Sciences, University of Campania "Luigi Vanvitelli", "I Policlinico" Hospital, Piazza Luigi Miraglia 2, 80100 Naples, Italy. FAU - Russo, Vincenzo AU - Russo V AD - Cardiology Unit, Department of Medical and Translational Sciences, University of Campania "Luigi Vanvitelli", "V. Monaldi" Hospital, Via Leonardo Bianchi snc, 80131 Naples, Italy. FAU - Cameli, Matteo AU - Cameli M AUID- ORCID: 0000-0003-3872-8964 AD - Department of Medical Biotechnologies, Division of Cardiology, University of Siena, Viale Bracci 16, 53100 Siena, Italy. FAU - D'Andrea, Antonello AU - D'Andrea A AUID- ORCID: 0000-0002-9698-9145 AD - Cardiology and Intensive Care Unit, Department of Cardiology, "Umberto I" Hospital, Via Alfonso de Nicola 1, 84014 Nocera Inferiore, Italy. CN - Working Group of Echocardiography of the Italian Society of Cardiology LA - eng PT - Journal Article PT - Review DEP - 20260119 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC12841761 OTO - NOTNLM OT - cancer OT - cardiotoxicity OT - immune checkpoint inhibitors OT - myocarditis COIS- The authors declare no conflicts of interest. AI-based tools were employed for linguistic refinement, including rephrasing and orthographic correction. EDAT- 2026/01/28 07:48 MHDA- 2026/01/28 07:49 PMCR- 2026/01/19 CRDT- 2026/01/28 01:19 PHST- 2025/12/30 00:00 [received] PHST- 2026/01/15 00:00 [revised] PHST- 2026/01/16 00:00 [accepted] PHST- 2026/01/28 07:49 [medline] PHST- 2026/01/28 07:48 [pubmed] PHST- 2026/01/28 01:19 [entrez] PHST- 2026/01/19 00:00 [pmc-release] AID - jcm15020814 [pii] AID - jcm-15-00814 [pii] AID - 10.3390/jcm15020814 [doi] PST - epublish SO - J Clin Med. 2026 Jan 19;15(2):814. doi: 10.3390/jcm15020814. PMID- 41598175 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260128 LR - 20260131 IS - 2075-1729 (Print) IS - 2075-1729 (Electronic) IS - 2075-1729 (Linking) VI - 16 IP - 1 DP - 2025 Dec 22 TI - Optimising Return to Work for Cardiovascular Patients: An Interdisciplinary Approach in Occupational Medicine and Cardiology. LID - 10.3390/life16010019 [doi] LID - 19 AB - Background: This study explored facilitators and barriers to return to work (RTW) after acute cardiovascular events or elective cardiac surgery, integrating clinical, functional, and occupational factors. Methods: A prospective cohort study was conducted at the Occupational Medicine and Cardiac Rehabilitation Units of the Maggiore Hospital in Trieste, Italy. Employed adults (18-67 years) admitted for acute coronary syndrome, valve replacement, or thoracic aortic surgery between January 2024 and July 2025 were enrolled. Sociodemographic, clinical, and occupational data were collected alongside functional and psychosocial assessments, including the Work Ability Index (WAI) and EQ-5D-5L. Predictors of RTW were analyzed with Cox regression models. Results: Among 103 patients (mean age 56.8 years; 92.2% male), 77.7% returned to work after a mean of 58.9 days. Independent predictors of earlier RTW were self-employment (HR 5.08, 95% CI 2.52-10.27), occupational responsibility (HR 2.12, 95% CI 1.01-4.45), and percutaneous coronary intervention (HR 2.72, 95% CI 1.47-5.06). Higher job-related physical demands, arrhythmias, and cardiac rehabilitation participation were associated with delayed RTW. Mean WAI (37.2 +/- 5.1) and EQ-5D index (0.92 +/- 0.09; EQ-VAS 77.4 +/- 12.9) indicated preserved function and quality of life. Conclusions: RTW after cardiovascular events is multifactorial. Integrating occupational medicine into cardiac rehabilitation is key to ensuring safe, sustainable reintegration. FAU - Sansone, Donatella AU - Sansone D AUID- ORCID: 0009-0005-3427-1102 AD - UOC Unit of Occupational Medicine, Department of Medical Sciences, University of Trieste, 34129 Trieste, Italy. FAU - Cherubini, Antonella AU - Cherubini A AUID- ORCID: 0000-0001-6258-2948 AD - Cardiovascular Center, Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), 34122 Trieste, Italy. FAU - Barbiero, Fabiano AU - Barbiero F AD - Department of Medical, Surgical & Health Sciences, University of Trieste, 34129 Trieste, Italy. FAU - Bollini, Marina AU - Bollini M AD - Cardiovascular Center, Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), 34122 Trieste, Italy. FAU - Mauro, Marcella AU - Mauro M AUID- ORCID: 0000-0003-1317-3448 AD - UOC Unit of Occupational Medicine, Department of Medical Sciences, University of Trieste, 34129 Trieste, Italy. AD - Department of Medical, Surgical & Health Sciences, University of Trieste, 34129 Trieste, Italy. FAU - Di Lenarda, Andrea AU - Di Lenarda A AD - Cardiovascular Center, Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), 34122 Trieste, Italy. FAU - Rui, Francesca AU - Rui F AUID- ORCID: 0000-0002-4788-9076 AD - Department of Medical, Surgical & Health Sciences, University of Trieste, 34129 Trieste, Italy. FAU - Cegolon, Luca AU - Cegolon L AUID- ORCID: 0000-0002-6285-7355 AD - Department of Medical, Surgical & Health Sciences, University of Trieste, 34129 Trieste, Italy. FAU - Larese Filon, Francesca AU - Larese Filon F AUID- ORCID: 0000-0002-7717-0417 AD - UOC Unit of Occupational Medicine, Department of Medical Sciences, University of Trieste, 34129 Trieste, Italy. AD - Department of Medical, Surgical & Health Sciences, University of Trieste, 34129 Trieste, Italy. LA - eng PT - Journal Article DEP - 20251222 PL - Switzerland TA - Life (Basel) JT - Life (Basel, Switzerland) JID - 101580444 PMC - PMC12842632 OTO - NOTNLM OT - cardiac rehabilitation OT - cardiovascular disease OT - occupational medicine OT - quality of life OT - return to work OT - work ability COIS- The authors declare no conflicts of interest. EDAT- 2026/01/28 07:46 MHDA- 2026/01/28 07:47 PMCR- 2025/12/22 CRDT- 2026/01/28 01:17 PHST- 2025/11/25 00:00 [received] PHST- 2025/12/14 00:00 [revised] PHST- 2025/12/20 00:00 [accepted] PHST- 2026/01/28 07:47 [medline] PHST- 2026/01/28 07:46 [pubmed] PHST- 2026/01/28 01:17 [entrez] PHST- 2025/12/22 00:00 [pmc-release] AID - life16010019 [pii] AID - life-16-00019 [pii] AID - 10.3390/life16010019 [doi] PST - epublish SO - Life (Basel). 2025 Dec 22;16(1):19. doi: 10.3390/life16010019. PMID- 41594764 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260128 LR - 20260131 IS - 2076-3425 (Print) IS - 2076-3425 (Electronic) IS - 2076-3425 (Linking) VI - 16 IP - 1 DP - 2025 Dec 29 TI - Holistic Care Clinic for People with Parkinson's Disease: Outcome from a Newly Developed Service. LID - 10.3390/brainsci16010043 [doi] LID - 43 AB - Background/Objectives: Non-motor symptoms (NMS) in Parkinson's disease (PD), particularly neuropsychiatric disturbances such as anxiety, significantly impact quality of life. The Holistic Care Clinic for Parkinson's disease at St George's Hospital offers multidisciplinary assessments and personalized care to address both motor and non-motor symptoms, aiming to improve patient well-being and empower patients to manage their health and enhance their quality of life. This study evaluated the effectiveness of a holistic management approach for PD patients with prominent non-motor symptoms, particularly neuropsychiatric issues, by analyzing clinical outcomes and patient feedback. Methods: A retrospective analysis was conducted on patients referred to the clinic between June 2022 and June 2023 for non-motor symptoms. Patients received comprehensive assessments, including clinical exams and interviews focused on neuropsychiatric symptoms, followed by individualized care plans. Interventions for anxiety included online psychoeducation and cardiac biofeedback. Outcomes were assessed using the Clinical Global Impression (CGI) scale and patient feedback on interventions. Results: Thirty patients (mean age 65.7 years, mean disease duration 7.8 years) were included. Anxiety was the primary referral reason (66%). CGI scores indicated that 62% of patients experienced improvement. Medications were adjusted in 14 patients and 65% improved. For anxiety, 13 patients attended the psychoeducation session, with 91% rating it "very likely"/"likely" to recommend. Ten patients completed cardiac biofeedback training, showing a significant reduction in Parkinson's Anxiety Scale scores (p = 0.03), and 90% recommending it. Conclusions: The holistic care approach of PD patients resulted in significant improvements in clinical outcomes. Patient feedback indicates high satisfaction with the interventions, supporting their acceptability and overall satisfaction with the interventions. FAU - Ricciardi, Lucia AU - Ricciardi L AD - Neuromodulation and Motor Control Section, Department of Psychology and Neuroscience, School of Health and Medical Sciences, City St. George's, University of London, London SW17 0RE, UK. FAU - Ishihara, Bryony AU - Ishihara B AD - Neuromodulation and Motor Control Section, Department of Psychology and Neuroscience, School of Health and Medical Sciences, City St. George's, University of London, London SW17 0RE, UK. FAU - Gonzalez-Herrero, Belen AU - Gonzalez-Herrero B AD - Neuromodulation and Motor Control Section, Department of Psychology and Neuroscience, School of Health and Medical Sciences, City St. George's, University of London, London SW17 0RE, UK. AD - Departamento de Medicina, Universidad Autonoma de Barcelona (UAB), 08193 Bellaterra, Spain. AD - Queen's Hospital, Barking, Havering and Redbridge University Hospitals, Romford RM7 0AG, UK. FAU - Pradhan, Priyanka AU - Pradhan P AD - Department of Adult Psychological Professions, St. George's University Hospitals NHS Foundation Trust, London SW17 0QT, UK. FAU - Leake, Alison AU - Leake A AD - Neuromodulation and Motor Control Section, Department of Psychology and Neuroscience, School of Health and Medical Sciences, City St. George's, University of London, London SW17 0RE, UK. FAU - Trinchillo, Assunta AU - Trinchillo A AUID- ORCID: 0000-0002-9413-3394 AD - Neuromodulation and Motor Control Section, Department of Psychology and Neuroscience, School of Health and Medical Sciences, City St. George's, University of London, London SW17 0RE, UK. FAU - Bernardo, Monica AU - Bernardo M AD - Neurology Department, St. George's University Hospital, London SW17 0QT, UK. FAU - Kerogoi, Lucy AU - Kerogoi L AD - Neurology Department, St. George's University Hospital, London SW17 0QT, UK. FAU - Gallogly, Patrice AU - Gallogly P AD - Kingston Hospital, London KT2 7QB, UK. FAU - Paviour, Dominic AU - Paviour D AD - Neuromodulation and Motor Control Section, Department of Psychology and Neuroscience, School of Health and Medical Sciences, City St. George's, University of London, London SW17 0RE, UK. FAU - Makovac, Elena AU - Makovac E AD - Queen's Hospital, Barking, Havering and Redbridge University Hospitals, Romford RM7 0AG, UK. AD - Department of Neurology, Brunel University London, Uxbridge UB8 3PH, UK. AD - Centre for Neuroimaging Science, Kings College London, London SE5 9RS, UK. FAU - Morgante, Francesca AU - Morgante F AD - Neuromodulation and Motor Control Section, Department of Psychology and Neuroscience, School of Health and Medical Sciences, City St. George's, University of London, London SW17 0RE, UK. LA - eng PT - Journal Article DEP - 20251229 PL - Switzerland TA - Brain Sci JT - Brain sciences JID - 101598646 PMC - PMC12839184 OTO - NOTNLM OT - Parkinson's disease OT - anxiety OT - holistic care OT - non-motor symptoms OT - wellness COIS- LR: advisory board of Boston Scientific and Britannia, speaking Honoraria from Bial and the International Parkinson's Disease and Movement Disorders Society. Research Support: CARP/MRC. BI, BGH, PP, AL, AT, MB, LK, DP, EM: report no conflicts of interest. FM.: Consultancies fees: Boston Scientific, Medtronic; Advisory Boards: Abbvie, Boston Scientific, Merz, Medtronic, Roche; Speaking Honoraria: Abbvie, Boston Scientific, Merz, Medtronic, Teva, International Parkinson's Disease and Movement Disorders Society; Royalties: Springer; Research Support: NIHR, Innovate UK, Merz. EDAT- 2026/01/28 07:48 MHDA- 2026/01/28 07:49 PMCR- 2025/12/29 CRDT- 2026/01/28 01:04 PHST- 2025/11/06 00:00 [received] PHST- 2025/12/12 00:00 [revised] PHST- 2025/12/17 00:00 [accepted] PHST- 2026/01/28 07:49 [medline] PHST- 2026/01/28 07:48 [pubmed] PHST- 2026/01/28 01:04 [entrez] PHST- 2025/12/29 00:00 [pmc-release] AID - brainsci16010043 [pii] AID - brainsci-16-00043 [pii] AID - 10.3390/brainsci16010043 [doi] PST - epublish SO - Brain Sci. 2025 Dec 29;16(1):43. doi: 10.3390/brainsci16010043. PMID- 41591964 OWN - NLM STAT- MEDLINE DCOM- 20260630 LR - 20260813 IS - 1423-0143 (Electronic) IS - 1420-4096 (Print) IS - 1420-4096 (Linking) VI - 51 IP - 1 DP - 2026 TI - Association of Estimated Glomerular Filtration Rate Slopes with Cardiorenal Outcomes in Patients with Chronic Kidney Disease before and after Multidisciplinary Education. PG - 141-150 LID - 10.1159/000550676 [doi] AB - INTRODUCTION: Multidisciplinary education has been shown to slow the progression of chronic kidney disease (CKD) and reduce cardiovascular (CV) risk, although its effects depend partly on patient characteristics. The aim of this study was to assess how patients categorized on the basis of estimated glomerular filtration rate (eGFR) responded to multidisciplinary education in terms of cardiorenal outcomes. METHODS: In this retrospective cohort study, we included 447 CKD patients who received multidisciplinary education between January 1, 2013, and December 31, 2020, at Nara Prefecture General Medical Center. Exposure was four categories according to eGFR slopes before and after multidisciplinary education. The primary outcomes were renal events defined as the composite of dialysis initiation, transplantation, and 30% eGFR decline, and CV events defined as the composite of heart failure requiring hospitalization, coronary or leg revascularization, cardiac sudden death, and stroke. RESULTS: Multidisciplinary education decreased the median eGFR slope from -5.00 to -0.65 mL/min/1.73 m2/year. In fully adjusted models, the hazard ratios (95% confidence intervals) for total renal events relative to slow-slow eGFR decline were 1.02 (0.50-2.06) for fast-slow decline, 5.30 (2.82-9.97) for slow-fast decline, and 7.53 (4.02-14.1) for fast-fast decline. Only fast-fast eGFR decline was associated with a high risk of CV events. Subgroup analyses showed similar trends. Fast decline after education was independently associated with increased proteinuria and decreased hemoglobin levels. CONCLUSIONS: Fast eGFR decline after but not before multidisciplinary education was significantly associated with renal and CV events in CKD patients. Attention should be paid to CKD patients with limited benefit from multidisciplinary education. CI - (c) 2026 The Author(s). Published by S. Karger AG, Basel. FAU - Matsui, Masaru AU - Matsui M AD - Department of Nephrology, Nara Medical University, Nara, Japan, matsui2008420@gmail.com. AD - Department of Nephrology, Nara Prefecture General Medical Center, Nara, Japan, matsui2008420@gmail.com. FAU - Kokubu, Maiko AU - Kokubu M AD - Department of Nephrology, Nara Prefecture General Medical Center, Nara, Japan. FAU - Nishimoto, Masatoshi AU - Nishimoto M AD - Department of Nephrology, Nara Medical University, Nara, Japan. FAU - Kosugi, Takaaki AU - Kosugi T AD - Department of Nephrology, Nara Medical University, Nara, Japan. FAU - Eriguchi, Masahiro AU - Eriguchi M AD - Department of Nephrology, Nara Medical University, Nara, Japan. FAU - Samejima, Ken-Ichi AU - Samejima KI AD - Department of Nephrology, Nara Medical University, Nara, Japan. FAU - Tsuruya, Kazuhiko AU - Tsuruya K AD - Department of Nephrology, Nara Medical University, Nara, Japan. LA - eng PT - Journal Article DEP - 20260127 PL - Switzerland TA - Kidney Blood Press Res JT - Kidney & blood pressure research JID - 9610505 SB - IM MH - Humans MH - *Glomerular Filtration Rate MH - *Renal Insufficiency, Chronic/physiopathology/therapy/complications MH - Male MH - Female MH - Retrospective Studies MH - Aged MH - Middle Aged MH - *Cardiovascular Diseases/etiology MH - Disease Progression MH - *Patient Education as Topic PMC - PMC12995348 OTO - NOTNLM OT - Cardiovascular diseases OT - Chronic kidney disease OT - Estimated glomerular filtration rate slope OT - Multidisciplinary education COIS- The authors have no conflicts of interest to declare. EDAT- 2026/01/27 19:17 MHDA- 2026/03/18 04:49 PMCR- 2026/01/27 CRDT- 2026/01/27 13:23 PHST- 2025/09/01 00:00 [received] PHST- 2026/01/20 00:00 [accepted] PHST- 2026/03/18 04:49 [medline] PHST- 2026/01/27 19:17 [pubmed] PHST- 2026/01/27 13:23 [entrez] PHST- 2026/01/27 00:00 [pmc-release] AID - 000550676 [pii] AID - 550676 [pii] AID - 10.1159/000550676 [doi] PST - ppublish SO - Kidney Blood Press Res. 2026;51(1):141-150. doi: 10.1159/000550676. Epub 2026 Jan 27. PMID- 41590836 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260127 LR - 20260131 IS - 2308-3425 (Electronic) IS - 2308-3425 (Linking) VI - 13 IP - 1 DP - 2025 Dec 22 TI - Cardiogenic Shock Management in the Modern Era: A Narrative Review of Percutaneous Mechanical Circulatory Support Devices. LID - 10.3390/jcdd13010009 [doi] LID - 9 AB - Cardiogenic shock (CS) remains a significant clinical challenge with persistently high mortality rates. Defined by impaired cardiac output resulting in end-organ hypoperfusion, CS commonly arises from acute myocardial infarction (AMI-CS) or acute exacerbations of heart failure (HF-CS). The severity of CS is classified by the Society for Cardiovascular Angiography and Interventions (SCAI) into stages A (at risk) through E (extremis), which informs treatment strategies, including pharmacotherapy and mechanical circulatory support (MCS). Recent advancements in percutaneous mechanical circulatory support devices, including intra-aortic balloon pumps (IABPs), Impella devices, TandemHeart, Protek-Duo, and veno-arterial extracorporeal membrane oxygenation (VA-ECMO), have transformed management paradigms by offering targeted hemodynamic support. While DanGer-SHOCK, a pivotal randomized trial, demonstrated improved outcomes with early Impella use in anterior STEMI-associated CS, the trial's focus population and center expertise suggest that its findings should be interpreted in the context of broader AMI-CS and HF-CS presentations. Device selection is guided by shock severity, anatomical considerations, comorbidities, and institutional capabilities. This review synthesizes current evidence, evaluates the clinical utility and efficacy of existing and emerging percutaneous MCS technologies, and highlights ongoing clinical trials and future directions in optimizing CS management. Emphasis is placed on individualized patient selection, evidence-based deployment of MCS devices, and multidisciplinary team collaboration, which collectively represent a critical transition towards improving clinical outcomes in CS. FAU - Jana, Srijit AU - Jana S AD - Department of Internal Medicine, Las Vegas School of Medicine, University of Nevada, Las Vegas, NV 89102, USA. FAU - Wijesinghe, Makayla AU - Wijesinghe M AUID- ORCID: 0009-0008-8728-4785 AD - Reno School of Medicine, University of Nevada, Reno, NV 89102, USA. FAU - DiCaro, Michael V AU - DiCaro MV AUID- ORCID: 0000-0003-3376-4608 AD - Department of Cardiology, Las Vegas School of Medicine, University of Nevada, Las Vegas, NV 89102, USA. FAU - Lei, KaChon AU - Lei K AUID- ORCID: 0000-0002-3696-195X AD - Department of Cardiology, Las Vegas School of Medicine, University of Nevada, Las Vegas, NV 89102, USA. FAU - Houshmand, Nazanin AU - Houshmand N AD - Department of Cardiology, Las Vegas School of Medicine, University of Nevada, Las Vegas, NV 89102, USA. FAU - Ahsan, Chowdhury AU - Ahsan C AD - Department of Cardiology, Las Vegas School of Medicine, University of Nevada, Las Vegas, NV 89102, USA. LA - eng PT - Journal Article PT - Review DEP - 20251222 PL - Switzerland TA - J Cardiovasc Dev Dis JT - Journal of cardiovascular development and disease JID - 101651414 PMC - PMC12842289 OTO - NOTNLM OT - cardiogenic shock OT - mechanical circulatory support OT - shock COIS- The authors declare no conflict of interest. EDAT- 2026/01/27 12:59 MHDA- 2026/01/27 13:00 PMCR- 2025/12/22 CRDT- 2026/01/27 09:34 PHST- 2025/11/03 00:00 [received] PHST- 2025/12/12 00:00 [revised] PHST- 2025/12/12 00:00 [accepted] PHST- 2026/01/27 13:00 [medline] PHST- 2026/01/27 12:59 [pubmed] PHST- 2026/01/27 09:34 [entrez] PHST- 2025/12/22 00:00 [pmc-release] AID - jcdd13010009 [pii] AID - jcdd-13-00009 [pii] AID - 10.3390/jcdd13010009 [doi] PST - epublish SO - J Cardiovasc Dev Dis. 2025 Dec 22;13(1):9. doi: 10.3390/jcdd13010009. PMID- 41590833 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260127 LR - 20260131 IS - 2308-3425 (Electronic) IS - 2308-3425 (Linking) VI - 13 IP - 1 DP - 2025 Dec 22 TI - Fast-Track Extubation After Cardiac Surgery: A Narrative Review. LID - 10.3390/jcdd13010006 [doi] LID - 6 AB - Fast-track extubation has emerged as a vital component of Enhanced Recovery After Surgery pathways, designed to optimize recovery and resource utilization after cardiac surgery, contrasting with traditional prolonged ventilation. This review explores the evidence supporting fast-track extubation, detailing patient selection criteria based on preoperative risk factors and functional status and outlining perioperative management strategies. It synthesizes findings from various studies, including randomized controlled trials, retrospective studies, and meta-analyses, focusing on intraoperative techniques such as low-dose opioids, neuromuscular blockade reversal, controlled cardiopulmonary bypass duration, judicious inotrope use, and minimal transfusion, alongside structured postoperative protocols emphasizing early sedative weaning and spontaneous breathing trials. Results demonstrate that fast-track extubation decreases intensive care unit stay, reduces costs and ventilator-associated complications, with a safety comparable to conventional care. Prolonged cardiopulmonary bypass time, dependency on inotropes, and intraoperative blood transfusions are identified as critical predictors of fast-track extubation failure. In conclusion, the successful implementation of fast-track extubation protocols requires a collaborative, multidisciplinary approach, proving essential for improving patient outcomes, minimizing complications such as postoperative delirium, and enhancing hospital efficiency in cardiac surgery. Further research should aim to refine patient selection and standardize protocols across healthcare systems. FAU - Christophides, Alexa AU - Christophides A AUID- ORCID: 0000-0001-8864-0763 AD - Office of the Vice President of Medical Affairs, Northwell Mather Hospital, Port Jefferson, NY 11777, USA. FAU - DiMaria, Stephen AU - DiMaria S AD - Department of Anesthesiology, Stony Brook University Hospital, Stony Brook, NY 11794, USA. FAU - Jacob, Sophia Ann AU - Jacob SA AUID- ORCID: 0000-0001-6733-0184 AD - Department of Anesthesiology, Stony Brook University Hospital, Stony Brook, NY 11794, USA. FAU - Feit, Andrew AU - Feit A AD - Department of Anesthesiology, Stony Brook University Hospital, Stony Brook, NY 11794, USA. FAU - Oster, Jonathan AU - Oster J AD - Department of Anesthesiology, Stony Brook University Hospital, Stony Brook, NY 11794, USA. FAU - Bergese, Sergio AU - Bergese S AUID- ORCID: 0000-0001-5641-5908 AD - Department of Anesthesiology, Stony Brook University Hospital, Stony Brook, NY 11794, USA. LA - eng PT - Journal Article PT - Review DEP - 20251222 PL - Switzerland TA - J Cardiovasc Dev Dis JT - Journal of cardiovascular development and disease JID - 101651414 PMC - PMC12841624 OTO - NOTNLM OT - anesthesia management OT - early extubation OT - enhanced recovery after surgery OT - hemodynamic stability OT - intensive care unit length of stay OT - multidisciplinary protocol OT - patient selection OT - postoperative recovery OT - reintubation OT - resource utilization COIS- The authors declare no conflicts of interest. EDAT- 2026/01/27 12:59 MHDA- 2026/01/27 13:00 PMCR- 2025/12/22 CRDT- 2026/01/27 09:34 PHST- 2025/10/29 00:00 [received] PHST- 2025/12/08 00:00 [revised] PHST- 2025/12/19 00:00 [accepted] PHST- 2026/01/27 13:00 [medline] PHST- 2026/01/27 12:59 [pubmed] PHST- 2026/01/27 09:34 [entrez] PHST- 2025/12/22 00:00 [pmc-release] AID - jcdd13010006 [pii] AID - jcdd-13-00006 [pii] AID - 10.3390/jcdd13010006 [doi] PST - epublish SO - J Cardiovasc Dev Dis. 2025 Dec 22;13(1):6. doi: 10.3390/jcdd13010006. PMID- 41590537 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260127 LR - 20260131 IS - 2075-4426 (Print) IS - 2075-4426 (Electronic) IS - 2075-4426 (Linking) VI - 16 IP - 1 DP - 2026 Jan 9 TI - Outcomes of Minimally Invasive Mitral Valve Surgery Using a Multidisciplinary Team Approach: A Single-Center Experience. LID - 10.3390/jpm16010044 [doi] LID - 44 AB - Background: The advantage of employing multidisciplinary heart teams (MDHT) for the selection process of minimally invasive (MIS) mitral valve repair (MVr) and mitral valve replacement (MVR) has been previously substantiated. Here, we outline the contributions each member of the MDHT at our institution made during the intra-operative and peri-operative periods and describe their impacts on short-term outcomes. Patients and Methods: This is a single-center retrospective review of all 278 adult patients who underwent MIS MVR or MVr by a single surgeon at our institution between 2006 and 2023. The repair's efficacy was assessed intraoperatively and at 1 year post-operation. The surgical technique involved a mini-thoracotomy and valve repair or replacement. Outcomes included post-operative mortality, complications, operative time, repair success rate, hospital length of stay (LOS), and post-operative ejection fraction. There was no control group, as all patients undergoing MIS MVR/MVr were treated within an MDHT model. Results: Delivery of regional anesthesia via paravertebral catheter (PVC) was associated with a statistically significant shorter hospital LOS (6.52 vs. 7.81 days, p = 0.028). Enhanced Recovery After Surgery (ERAS) implementation by nurses was associated with a potentially clinically important, although not statistically significant, reduction in LOS (6.7 vs. 10.1 days, p = 0.168). Introduction of the COR-KNOT((R)) DEVICE for securing annuloplasty sutures was associated with a statistically significant reduction in operative time (288 vs. 326 min, p < 0.001). Percutaneous cannulation, proctored by interventional cardiology in 2019, was associated with a decrease in lymphocele rate from 6.2% before 2019 to 0% after 2019. Conclusions: Initiatives implemented by our MDHT were associated with reduced post-operative LOS, shorter operative times, and lower incidence of post-operative complications. FAU - Mourad, Nicolas AU - Mourad N AUID- ORCID: 0000-0003-4776-414X AD - Faculty of Medicine, University of British Columbia, Vancouver, BC V6T 1Z4, Canada. FAU - Al-Hakim, Durr AU - Al-Hakim D AUID- ORCID: 0009-0005-6682-7670 AD - Faculty of Medicine, University of British Columbia, Vancouver, BC V6T 1Z4, Canada. FAU - Groenewoud, Rosalind AU - Groenewoud R AD - Department of Cardiac Surgery, University of British Columbia, Vancouver, BC V6T 1Z4, Canada. FAU - Al-Zeer, Bader AU - Al-Zeer B AD - Faculty of Medicine, University of British Columbia, Vancouver, BC V6T 1Z4, Canada. FAU - Wu, Neil AU - Wu N AD - Department of Cardiac Surgery, University of British Columbia, Vancouver, BC V6T 1Z4, Canada. FAU - Myring, Amy AU - Myring A AUID- ORCID: 0009-0009-5421-3152 AD - Department of Cardiac Surgery, University of British Columbia, Vancouver, BC V6T 1Z4, Canada. FAU - Nakahara, Julie AU - Nakahara J AD - Department of Cardiac Surgery, University of British Columbia, Vancouver, BC V6T 1Z4, Canada. FAU - Wood, David AU - Wood D AD - Department of Cardiology, University of British Columbia, Vancouver, BC V6T 1Z4, Canada. FAU - Schisler, Travis AU - Schisler T AUID- ORCID: 0000-0002-6322-4314 AD - Department of Anesthesiology, University of British Columbia, Vancouver, BC V6T 1Z4, Canada. FAU - Cook, Richard C AU - Cook RC AUID- ORCID: 0000-0002-3399-5812 AD - Department of Cardiac Surgery, University of British Columbia, Vancouver, BC V6T 1Z4, Canada. LA - eng PT - Journal Article DEP - 20260109 PL - Switzerland TA - J Pers Med JT - Journal of personalized medicine JID - 101602269 PMC - PMC12842861 OTO - NOTNLM OT - COR-KNOT(R) DEVICE OT - clinical outcomes OT - enhanced recovery after surgery OT - multidisciplinary heart team OT - paravertebral catheter OT - percutaneous cannulation COIS- The authors declare no conflicts of interest. EDAT- 2026/01/27 12:59 MHDA- 2026/01/27 13:00 PMCR- 2026/01/09 CRDT- 2026/01/27 09:33 PHST- 2025/09/30 00:00 [received] PHST- 2025/12/12 00:00 [revised] PHST- 2025/12/30 00:00 [accepted] PHST- 2026/01/27 13:00 [medline] PHST- 2026/01/27 12:59 [pubmed] PHST- 2026/01/27 09:33 [entrez] PHST- 2026/01/09 00:00 [pmc-release] AID - jpm16010044 [pii] AID - jpm-16-00044 [pii] AID - 10.3390/jpm16010044 [doi] PST - epublish SO - J Pers Med. 2026 Jan 9;16(1):44. doi: 10.3390/jpm16010044. PMID- 41587105 OWN - NLM STAT- MEDLINE DCOM- 20260617 LR - 20260620 IS - 1549-8425 (Electronic) IS - 1549-8417 (Linking) VI - 22 IP - 4 DP - 2026 Jul 1 TI - Case Difficulty and Non-Routine Events by Surgical Team Members in a Large Prospective Observational Study at 5 Veterans Affairs Medical Centers. PG - 268-277 LID - 10.1097/PTS.0000000000001475 [doi] AB - BACKGROUND: Excessive workload is associated with degraded operator performance and outcomes. The construct of surgical "team workload" is poorly specified, and anesthesiologist workload has rarely been measured concurrent with that of operating room nurses and surgeons during the same cases. We sought to measure workload, operationalized as individual and team "case difficulty," as well as the occurrence of non-routine events, from all surgical team members. METHODS: This multicenter prospective observational study at 5 Veterans Affairs medical centers involved 1107 non-cardiac surgical procedures. Individual and team "case difficulty" ratings (1 "very easy" to 10 "very difficult") and the reported occurrence of non-routine events (ie, deviations from optimal care) were independently collected through facilitated survey from surgeons, anesthesia professionals, and operating room nurses before incision (pre-case) and again after skin closure (post-case). RESULTS: At least one non-routine event was reported by at least one team member in 464 (42.0%) of the cases. Overall, nurses were the most likely to report an NRE (in 57% of NRE-containing cases), whereas surgeons were the least likely (40%). Anesthesia professionals and nurses had similar ratings for both the pre-case and post-case difficulty ratings. Surgeons' pre-case and post-case difficulty ratings were at least one unit greater than either of the other two OR team members ( P <0.01). Post-case, anesthesia and nursing team difficulty ratings were at least 0.4 units higher than individual ratings ( P <0.01), whereas surgeons' pre-case and post-case ratings were similar. Only nurses' individual case difficulty ratings were significantly lower post-case versus pre-case. Individual role and team case difficulty ratings were both associated with the reporting of non-routine events. CONCLUSIONS: Capturing surgical team case difficulty ratings and non-routine events is feasible and may shed insight into factors affecting surgical performance. In particular, pre-case difficulty ratings may be a complementary predictor of surgical risk. CI - Copyright (c) 2026 Wolters Kluwer Health, Inc. All rights reserved. FAU - Weinger, Matthew B AU - Weinger MB AUID- ORCID: 0000-0001-8897-2688 AD - Geriatric Research Education and Clinical Center, VA Medical Center, VA Tennessee Valley Healthcare System. AD - Center for Research and Innovation in Systems Safety, Center for Health Services Research, Institute for Population and Public Health. AD - Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, Tennessee. FAU - Slagle, Jason S AU - Slagle JS AD - Geriatric Research Education and Clinical Center, VA Medical Center, VA Tennessee Valley Healthcare System. AD - Center for Research and Innovation in Systems Safety, Center for Health Services Research, Institute for Population and Public Health. AD - Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, Tennessee. FAU - Feinleib, Jessica AU - Feinleib J AD - Anesthesia Service, VA West Haven, Department of Anesthesiology, Yale School of Medicine, New Haven, Connecticut. FAU - Nwosu, Samuel K AU - Nwosu SK AD - Geriatric Research Education and Clinical Center, VA Medical Center, VA Tennessee Valley Healthcare System. AD - Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee. FAU - Greevy, Robert A AU - Greevy RA AD - Geriatric Research Education and Clinical Center, VA Medical Center, VA Tennessee Valley Healthcare System. AD - Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee. FAU - Schroeder, Rebecca A AU - Schroeder RA AD - Anesthesia Service, VA Durham and Department of Anesthesiology, Duke University School of Medicine, Durham, North Carolina. FAU - Shively, Martha AU - Shively M AD - Formerly Health Services Research and Development and Nursing Services, VA San Diego Healthcare System, VA Medical Center-La Jolla, La Jolla, California. FAU - Feurer, Irene D AU - Feurer ID AD - Department of Surgery, Vanderbilt University Medical Center, Nashville, Tennessee. FAU - Pousman, Robert M AU - Pousman RM AD - Department of Anesthesia, Healdsburg District Hospital, Healdsburg, California. FAU - France, Daniel J AU - France DJ AD - Center for Research and Innovation in Systems Safety, Center for Health Services Research, Institute for Population and Public Health. AD - Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, Tennessee. FAU - Speroff, Theodore AU - Speroff T AD - Geriatric Research Education and Clinical Center, VA Medical Center, VA Tennessee Valley Healthcare System. AD - Center for Research and Innovation in Systems Safety, Center for Health Services Research, Institute for Population and Public Health. LA - eng PT - Journal Article PT - Multicenter Study PT - Observational Study DEP - 20260126 PL - United States TA - J Patient Saf JT - Journal of patient safety JID - 101233393 SB - IM MH - Humans MH - Prospective Studies MH - *Patient Care Team/statistics & numerical data MH - *Hospitals, Veterans/statistics & numerical data MH - *Workload/statistics & numerical data MH - United States MH - Surgeons OTO - NOTNLM OT - non-routine event OT - quality of care OT - surgery OT - workload COIS- The authors disclose no conflict of interest. EDAT- 2026/01/26 18:28 MHDA- 2026/06/17 13:05 CRDT- 2026/01/26 12:33 PHST- 2024/02/15 00:00 [received] PHST- 2025/12/30 00:00 [accepted] PHST- 2026/06/17 13:05 [medline] PHST- 2026/01/26 18:28 [pubmed] PHST- 2026/01/26 12:33 [entrez] AID - 01209203-990000000-00442 [pii] AID - 10.1097/PTS.0000000000001475 [doi] PST - ppublish SO - J Patient Saf. 2026 Jul 1;22(4):268-277. doi: 10.1097/PTS.0000000000001475. Epub 2026 Jan 26. PMID- 41581000 OWN - NLM STAT- MEDLINE DCOM- 20260630 LR - 20260630 IS - 1531-7072 (Electronic) IS - 1070-5295 (Linking) VI - 32 IP - 2 DP - 2026 Apr 1 TI - Management of ischaemic bowel in the ICU patient. PG - 154-161 LID - 10.1097/MCC.0000000000001361 [doi] AB - PURPOSE OF REVIEW: Acute mesenteric ischaemia is an uncommon but often fatal condition frequently requiring intensive care management. This review discusses the multidisciplinary management of subtypes of acute mesenteric ischaemia, emphasizing the specific challenges of nonocclusive mesenteric ischaemia (NOMI) in the ICU. RECENT FINDINGS: While multidisciplinary approach and early revascularisation have improved outcomes in arterial occlusive acute mesenteric ischaemia, diagnostic and therapeutic strategies for NOMI remain challenging. Similarities and differences in diagnosis and management of patients with NOMI and of occlusive subtypes of acute mesenteric ischaemia are outlined. In the absence of evidence, we suggest that optimizing hemodynamic stability, with a focus on achieving euvolemia, maintaining adequate cardiac output and ensuring adequate vascular tone, may help prevent or limit nonocclusive bowel ischemia. Equally important is treating the underlying cause of hemodynamic instability (such as sepsis, cardiac dysfunction or hypovolemia). In patients admitted to ICU after revascularisation and/or bowel resection, limitation of progression of intestinal damage is the target, while addressing progression of bowel necrosis when it occurs, requires well established multidisciplinary teamwork. SUMMARY: Managing acute mesenteric ischaemia in the ICU extends beyond restoring mesenteric blood flow, it requires simultaneous correction of the systemic insult driving and/or driven by ischemia, and timely surgical intervention both when bowel viability is salvageable or already lost. Different subtypes of acute mesenteric ischaemia have some differences in diagnosis and management. CI - Copyright (c) 2026 Wolters Kluwer Health, Inc. All rights reserved. FAU - Reintam Blaser, Annika AU - Reintam Blaser A AD - Department of Anaesthesiology and Intensive Care, University of Tartu, Tartu, Estonia. AD - Department of Intensive Care Medicine, Lucerne Cantonal Hospital, Lucerne, Switzerland. FAU - Casian, Dumitru AU - Casian D AD - Department of General Surgery, University clinic of vascular surgery, "Nicolae Testemitanu" State University of Medicine and Pharmacy, Chisinau, Republic of Moldova. FAU - Lakbar, Ines AU - Lakbar I AD - Department of Anaesthesia and Intensive Care unit, Regional University Hospital of Montpellier, St-Eloi Hospital, University of Montpellier, PhyMedExp, INSERM U1046, CNRS UMR, 9214 Montpellier, CEDEX 5, France. LA - eng PT - Journal Article PT - Review DEP - 20260122 PL - United States TA - Curr Opin Crit Care JT - Current opinion in critical care JID - 9504454 SB - IM MH - Humans MH - *Mesenteric Ischemia/therapy/diagnosis/physiopathology MH - *Intensive Care Units MH - *Critical Care/methods MH - *Intestines/blood supply MH - Hemodynamics OTO - NOTNLM OT - acute mesenteric ischaemia OT - diagnosis OT - intensive care unit OT - management OT - nonocclusive mesenteric ischaemia EDAT- 2026/01/25 08:57 MHDA- 2026/03/07 18:38 CRDT- 2026/01/25 05:02 PHST- 2026/03/07 18:38 [medline] PHST- 2026/01/25 08:57 [pubmed] PHST- 2026/01/25 05:02 [entrez] AID - 00075198-990000000-00338 [pii] AID - 10.1097/MCC.0000000000001361 [doi] PST - ppublish SO - Curr Opin Crit Care. 2026 Apr 1;32(2):154-161. doi: 10.1097/MCC.0000000000001361. Epub 2026 Jan 22. PMID- 41577369 OWN - NLM STAT- MEDLINE DCOM- 20260701 LR - 20260701 IS - 2053-3624 (Print) IS - 2053-3624 (Electronic) IS - 2053-3624 (Linking) VI - 13 IP - 1 DP - 2026 Jan 23 TI - Advanced Cardiogenic-shock Team versus standard care in cardiogenic SHOCK: a single centre service evaluation project. LID - 10.1136/openhrt-2025-003794 [doi] LID - e003794 AB - BACKGROUND: Cardiogenic shock (CS) complicating acute myocardial infarction (AMI) carries high mortality. Early revascularisation improves survival, but the effect of structured multidisciplinary care on outcomes remains underexplored. METHODS AND RESULTS: ACT-SHOCK is a service evaluation at a UK tertiary cardiac centre. Between May 2023 and May 2024, 82 patients with AMI-related CS requiring emergent percutaneous coronary intervention (PCI) were identified using protocolised physiological criteria and managed by an Advanced Cardiogenic-Shock Team (ACT). The ACT comprised interventional cardiologists, intensivists, anaesthetists, critical care staff and cardiac physiologists, coordinating PCI and ongoing care. Outcomes were compared with 83 historical controls from the year preceding ACT roll-out, who received standard care without ACT activation. Primary endpoints were 30-day and 1-year all-cause mortality; secondary outcomes included predictors of 30-day mortality.Within the ACT cohort, elevated lactate, critical care admission, invasive ventilation, out-of-hospital cardiac arrest and Society for Cardiovascular Angiography and Interventions (SCAI) Shock Stage E at first medical contact predicted 1-year mortality. Adjusted analyses showed ACT management was associated with lower 1-year mortality compared with standard care (HR 0.53, 95% CI 0.30 to 0.92; p=0.026). Although 30-day mortality was lower in the ACT group, this did not reach statistical significance (HR 0.71, 95% CI 0.39 to 1.29; p=0.26). Escalation from coronary care to critical care during the recovery phase occurred more promptly in the ACT group (9.7% vs 2.4%, p=0.09). At 24 hours, a smaller proportion of ACT patients remained in SCAI stages D/E compared with standard care (42% vs 48%; p=0.003). CONCLUSIONS: Implementation of physiological criteria to identify CS and activation of a multidisciplinary ACT in a UK tertiary centre was associated with earlier detection and improved 1-year survival in AMI-related CS. These pilot data support further study across multiple UK centres to inform national policy and standardise care pathways. CI - (c) Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. FAU - Chandra Mohan, Nitin AU - Chandra Mohan N AUID- ORCID: 0000-0003-1299-0358 AD - Translation Health Sciences, University of Bristol, Bristol, UK nitin.chandramohan2@uhbw.nhs.uk. AD - Cardiology, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK. FAU - Govier, Matt AU - Govier M AD - Intensive Care, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK. FAU - Johnson, Thomas W AU - Johnson TW AD - Translation Health Sciences, University of Bristol, Bristol, UK. AD - Cardiology, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK. FAU - Felekos, Ioannis AU - Felekos I AD - Cardiology, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK. FAU - Richards, Gavin AU - Richards G AD - Cardiology, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK. FAU - Strange, Julian AU - Strange J AD - Cardiology, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK. FAU - Dastidar, Amardeep AU - Dastidar A AD - Cardiology, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK. FAU - Sidik, Novalia AU - Sidik N AD - Cardiology, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK. FAU - Dorman, Stephen AU - Dorman S AD - Cardiology, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK. FAU - Joshi, Nikhil AU - Joshi N AD - Cardiology, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK. FAU - Gurney, Stefan AU - Gurney S AD - Intensive Care, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK. FAU - Bourdeaux, Christopher AU - Bourdeaux C AD - Intensive Care, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK. FAU - Grant, Andrew AU - Grant A AD - Anaesthetics, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK. FAU - Oglesby, Kieran AU - Oglesby K AD - Intensive Care, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK. FAU - McInerney-Baker, George AU - McInerney-Baker G AD - Cardiology, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK. FAU - Yaya, Sodiq AU - Yaya S AD - Cardiology, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK. FAU - Keeble, Thomas AU - Keeble T AD - Essex Cardiothoracic Centre, Mid and South Essex NHS Foundation Trust, Basildon, UK. AD - School of Medicine and MTRC, Anglia Ruskin University Faculty of Medical Science, Chelmsford, UK. FAU - Pareek, Nilesh AU - Pareek N AD - Cardiology, King's College Hospital NHS Foundation Trust, London, UK. AD - School of Cardiovascular and Metabolic Medicine & Sciences, King's College London, London, UK. FAU - Rees, Paul AU - Rees P AD - Cardiology, Barts Health NHS Trust, London, UK. FAU - Curzen, Nick AU - Curzen N AUID- ORCID: 0000-0001-9651-7829 AD - University of Southampton Faculty of Medicine, Southampton, UK. AD - Wessex Cardiothoracic Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK. FAU - Mariathas, Mark AU - Mariathas M AD - Cardiology, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK. LA - eng PT - Comparative Study PT - Journal Article DEP - 20260123 PL - England TA - Open Heart JT - Open heart JID - 101631219 SB - IM MH - Humans MH - *Shock, Cardiogenic/therapy/mortality/etiology/diagnosis MH - Female MH - Aged MH - *Percutaneous Coronary Intervention/adverse effects MH - Male MH - *Patient Care Team/organization & administration MH - *Myocardial Infarction/complications/mortality/therapy MH - Treatment Outcome MH - Time Factors MH - Middle Aged MH - Retrospective Studies MH - United Kingdom/epidemiology PMC - PMC12853532 OTO - NOTNLM OT - Acute Coronary Syndrome OT - CARDIOGENIC SHOCK OT - Heart Failure COIS- Competing interests: NCM has received an institutional research grant from Abbott Vascular. TWJ has received consultancy & speaker fees from Abbott Vascular, Boston Scientific, Cordis, Medtronic, Shockwave and Terumo. TWJ has received institutional research grants from Abbott Vascular. MG and SG have received speaker fees from Abiomed. TK advisory board Abiomed/J&J. NC has received research grants from Boston Scientific, HeartFlow, Haemonetics, Beckman Coulter and speaker fees/consultancy from HeartFlow, Abbott, Shockwave and travel sponsorship from Abbott and HeartFlow. MM has received consultancy and speaker fees from Abiomed/J&J, Shockwave Medical, Abbott Vascular, Boston Scientific and Cordis. NP has received honoraria and educational grants from Abbott Vascular, and honoraria from NIPRO. NP serves on the Advisory Boards for Boston Scientific and Johnson & Johnson. NP has also received grants from the British Heart Foundation Centre of Research Excellence (Grant no. RE/24/130035). NP is supported by the Margaret Sail Novel Emerging Technology grant from Heart Research U.K. (RG2693). GR, JS, NJ, SD, AD, IF, NS, AG, GM-B, SY and PR have no COI to disclose. EDAT- 2026/01/24 00:32 MHDA- 2026/01/24 00:33 PMCR- 2026/01/23 CRDT- 2026/01/23 20:43 PHST- 2025/10/15 00:00 [received] PHST- 2026/01/12 00:00 [accepted] PHST- 2026/01/24 00:33 [medline] PHST- 2026/01/24 00:32 [pubmed] PHST- 2026/01/23 20:43 [entrez] PHST- 2026/01/23 00:00 [pmc-release] AID - openhrt-2025-003794 [pii] AID - 10.1136/openhrt-2025-003794 [doi] PST - epublish SO - Open Heart. 2026 Jan 23;13(1):e003794. doi: 10.1136/openhrt-2025-003794. PMID- 41573358 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260123 LR - 20260125 IS - 2055-2076 (Print) IS - 2055-2076 (Electronic) IS - 2055-2076 (Linking) VI - 12 DP - 2026 Jan-Dec TI - Development and application of a clinical nursing decision support system for pressure injury in postoperative cardiac surgery patients. PG - 20552076251411638 LID - 10.1177/20552076251411638 [doi] LID - 20552076251411638 AB - OBJECTIVE: To develop a clinical nursing decision support system for pressure injury and explore its application in managing pressure injury in postoperative cardiac surgery patients. METHODS: A multidisciplinary research team was formed to develop a clinical nursing decision support system. Key indicators, including wound assessment accuracy, wound treatment accuracy, pressure injury healing rate, pressure injury incidence, and defect rates in nursing records, were compared before and after the clinical nursing decision support system utilization. Count data were described using frequency and composition ratio (%), and comparisons were made using the chi-square test or Fisher's exact probability method. Measurement data following a normal distribution were described by mean and standard deviation, while non-normally distributed data were described by median and interquartile range. Independent sample t-tests and rank-sum tests were used for between-group comparisons. A significance level of alpha = 0.05 was set, with results considered statistically significant if P < 0.05. RESULTS: The clinical nursing decision support system implements an intelligent decision-making engine and interactive dashboard for human-computer interaction, enabling intelligent assessment and decision-making, re-evaluation reminders, interactive modules, intelligent auditing, and a three-level quality control system for pressure injury. After applying the clinical nursing decision support system, the pressure injury incidence in postoperative cardiac surgery patients decreased from 14.8% to 12.8%, with no statistically significant difference (P > 0.05). The pressure injury healing rate increased from 89.1% to 97.2%, wound assessment accuracy improved from 90.8% to 97.2%, and wound treatment accuracy increased from 88.3% to 96.5%. The defect rate in nursing records decreased from 15.3% to 7.7%, with all differences being statistically significant (P < 0.05). CONCLUSION: This study successfully developed and implemented a clinical nursing decision support system for pressure injury management in postoperative cardiac surgery patients. These results confirm the system's clinical utility in standardizing pressure injury care, optimizing nursing workflows, and elevating documentation quality. The clinical nursing decision support system provides an effective tool for enabling evidence-based, personalized interventions and strengthening closed-loop quality control in pressure injury management. CI - (c) The Author(s) 2026. FAU - Zhang, Nan AU - Zhang N AD - Department of Nursing, Tianjin Chest Hospital, Tianjin, China. RINGGOLD: 499773 FAU - Meng, Zexuan AU - Meng Z AD - Graduate School, Tianjin University of Traditional Chinese Medicine, Tianjin, China. RINGGOLD: 58301 FAU - Xu, Lina AU - Xu L AD - Cardiac Surgery, Tianjin Chest Hospital, Tianjin, China. RINGGOLD: 499773 FAU - Zhang, Yan AU - Zhang Y AUID- ORCID: 0000-0001-5047-3904 AD - Cardiac Surgery Intensive Care Unit, Tianjin Chest Hospital, Tianjin, China. RINGGOLD: 499773 FAU - Wu, Zhenhua AU - Wu Z AD - Cardiac Surgery Intensive Care Unit, Tianjin Chest Hospital, Tianjin, China. RINGGOLD: 499773 FAU - Fa, Tian'e AU - Fa T AD - Department of Nursing, Tianjin Chest Hospital, Tianjin, China. RINGGOLD: 499773 LA - eng PT - Journal Article DEP - 20260120 PL - United States TA - Digit Health JT - Digital health JID - 101690863 PMC - PMC12819986 OTO - NOTNLM OT - Clinical nursing decision support system OT - hospital information system OT - pressure injury OT - thoracic surgery COIS- The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2026/01/23 06:30 MHDA- 2026/01/23 06:31 PMCR- 2026/01/20 CRDT- 2026/01/23 04:54 PHST- 2025/03/26 00:00 [received] PHST- 2025/12/09 00:00 [accepted] PHST- 2026/01/23 06:31 [medline] PHST- 2026/01/23 06:30 [pubmed] PHST- 2026/01/23 04:54 [entrez] PHST- 2026/01/20 00:00 [pmc-release] AID - 10.1177_20552076251411638 [pii] AID - 10.1177/20552076251411638 [doi] PST - epublish SO - Digit Health. 2026 Jan 20;12:20552076251411638. doi: 10.1177/20552076251411638. eCollection 2026 Jan-Dec. PMID- 41573116 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260123 LR - 20260125 IS - 2474-8714 (Electronic) IS - 2474-8706 (Print) IS - 2474-8706 (Linking) VI - 10 IP - 1 DP - 2026 Jan TI - Impact of a Clinical Valve Coordinator on Hospital Length of Stay and Patient Outcomes: Results From the BENCHMARK Registry. PG - 100740 LID - 10.1016/j.shj.2025.100740 [doi] LID - 100740 AB - BACKGROUND: Transcatheter aortic valve implantation (TAVI) treatment pathways can be supported by a dedicated clinical valve coordinator (CVC), enhancing their efficiency. We aimed to evaluate the impact of a CVC in managing the treatment pathway of patients undergoing TAVI across Europe before and after implementing 8 Benchmark best practices. METHODS: The BENCHMARK registry (ClinicalTrials NCT04579445) was a multicenter international study of patients with severe symptomatic aortic stenosis undergoing TAVI with balloon-expandable valves across 28 European centers. Primary outcomes were hospital and intensive care length of stay (LoS). The secondary outcome was 30-day patient safety. RESULTS: Of 2323 patients, 1262 were treated at centers without a pre-existing CVC and 1061 at centers with a pre-existing CVC; propensity matching resulted in 891 matched pairs. The total procedural time was significantly reduced in both groups (p < 0.001) after implementing Benchmark best practices. Hospital LoS was lower before Benchmark when a CVC was present and was significantly shorter in both groups following implementation (p < 0.001), as was the critical care LoS (p < 0.001). The presence of a CVC did not affect safety outcomes but was associated with a reduced risk of major vascular bleeding when combined with Benchmark best practices. Patient satisfaction was higher in centers with a pre-existing CVC (p < 0.001). CONCLUSIONS: The addition of a CVC to the multidisciplinary team and their sustained contributions to processes of care align with the implementation of Benchmark practices, significantly decrease the health service requirements of TAVI patients, and are associated with improved patient-reported experiences. CI - (c) 2025 The Authors. FAU - Lauck, Sandra B AU - Lauck SB AD - Centre for Cardiovascular Innovation, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Saia, Francesco AU - Saia F AD - Department of Interventional Cardiology, IRCCS University Hospital of Bologna, Policlinico S. Orsola, Bologna, Italy. FAU - Durand, Eric AU - Durand E AD - Department of Cardiology, Univ Rouen Normandie, Rouen, France. FAU - Kirk, Bettina Hojberg AU - Kirk BH AD - Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. FAU - Kelly, Fiona AU - Kelly F AD - Cardiology Department, Royal Victoria Hospital Belfast, Belfast, Ireland. FAU - Muir, Douglas F AU - Muir DF AD - Cardiology Department, James Cook University Hospital, Middlesbrough, UK. FAU - McCalmont, Gemma AU - McCalmont G AD - Cardiology Department, James Cook University Hospital, Middlesbrough, UK. FAU - Spence, Mark S AU - Spence MS AD - Heart and Vascular, Mater Private Network and RCSI University of Medicine & Health Sciences, Dublin, Ireland. FAU - Vasa-Nicotera, Mariuca AU - Vasa-Nicotera M AD - Cardiology Department, Hospital Sindelfingen-Boblingen, Sindelfingen, Germany. FAU - Wood, David AU - Wood D AD - Centre for Cardiovascular Innovation, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Urbano Carrillo, Cristobal A AU - Urbano Carrillo CA AD - Cardiology Department, Hospital Regional Universitario de Malaga, Malaga, Spain. FAU - Bouchayer, Damien AU - Bouchayer D AD - Department of Cardiology, The Clinique de l'Infirmerie Protestante, Lyon, France. FAU - Iliescu, Vlad Anton AU - Iliescu VA AD - Department of Cardiovascular Surgery, University of Medicine and Pharmacy Carol Davila, Bucharest, Romania. FAU - Etienne, Christophe Saint AU - Etienne CS AD - Department of Cardiology, Centre Hospitalier Regional Universitaire de Tours, Hopital Trousseau, Tours, France. FAU - Faure, Nina AU - Faure N AD - Department of Cardiology, Centre Hospitalier Regional Universitaire de Tours, Hopital Trousseau, Tours, France. FAU - Hee, Celine AU - Hee C AD - Department of Cardiology, Centre Hospitalier Regional Universitaire de Tours, Hopital Trousseau, Tours, France. FAU - Leclercq, Florence AU - Leclercq F AD - Cardiology Department, Montpellier University Hospital, Montpellier University, Montpellier, France. FAU - Auffret, Vincent AU - Auffret V AD - Universite de Rennes 1, CHU Rennes Service de Cardiologie, Rennes, France. FAU - Asmarats, Lluis AU - Asmarats L AD - Cardiology Department, Hospital de la Santa Creu i Sant Pau, Instituto de Investigacion Biomedica Sant Pau, Barcelona, Spain. FAU - Di Mario, Carlo AU - Di Mario C AD - Interventional Cardiology Division, Department of Clinical & Experimental Medicine, Careggi University Hospital, Florence, Italy. FAU - Veugeois, Aurelie AU - Veugeois A AD - Department of Cardiology, Institut Mutualiste Montsouris, Paris, France. FAU - Maly, Jiri AU - Maly J AD - Cardiac Center, IKEM Prague, Prague, Czech Republic. FAU - Schober, Andreas AU - Schober A AD - Department of Cardiology, Hospital Floridsdorf and the Karl Landsteiner Institute for Cardiovascular and Critical Care Research Vienna, Vienna, Austria. FAU - Nombela-Franco, Luis AU - Nombela-Franco L AD - Instituto Cardiovascular, Hospital Clinico San Carlos, Instituto de Investigacion Sanitaria del Hospital Clinico San Carlos (IdISSC), Madrid, Spain. FAU - Werner, Nikos AU - Werner N AD - Medical Department III, Heart Center Trier, Krankenhaus der Barmherzigen Bruder, Trier, Germany. FAU - Gomez Hospital, Joan Antoni AU - Gomez Hospital JA AD - Heart Diseases Institute, Bellvitge University Hospital - IDIBELL, University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain. FAU - Mascherbauer, Julia AU - Mascherbauer J AD - Department of Internal Medicine 3 / Cardiology, University Hospital St. Polten, St. Polten, Austria. AD - Karl Landsteiner University of Health Sciences, Krems, Austria. FAU - Musumeci, Giuseppe AU - Musumeci G AD - Cardiology Division, AO Ordine Mauriziano, Torino, Italy. FAU - Meneveau, Nicolas AU - Meneveau N AD - Department of Cardiology, University Hospital Besancon, Besancon, France. AD - SINERGIES, University of Burgundy Franche-Comte, Besancon, France. FAU - Meurice, Thibaud AU - Meurice T AD - Cardiology, Polyclinique Du Bois, Lille, France. AD - Department of Cardiology, University Heart Center, University Hospital Basel, Basel, Switzerland. FAU - Mahfoud, Felix AU - Mahfoud F AD - Cardiovascular Research Institute Basel (CRIB), University Heart Center, University Hospital Basel, Basel, Switzerland. FAU - De Marco, Federico AU - De Marco F AD - Department of Interventional Cardiology, Centro Cardiologico Monzino IRCCS, Milan, Italy. FAU - Seidler, Tim AU - Seidler T AD - Cardiology and Pneumology, University Medical Center Gottingen, Gottingen, Germany. AD - Department of Cardiology, Campus Kerckhoff of the Justus-Liebig-Universitat Giessen, Kerckhoff-Clinic, Bad Nauheim, Germany. FAU - Leuschner, Florian AU - Leuschner F AD - Department of Medicine III, University of Heidelberg, German Centre for Cardiovascular Research (DZHK), Germany. FAU - Joly, Patrick AU - Joly P AD - Department of Interventional Cardiology, Hopital Saint Joseph, Marseille, France. FAU - Collet, Jean Philippe AU - Collet JP AD - Department de Cardiologie, Hopital de Pitie-Salpetriere AP-HP, Paris, France. FAU - Vogt, Ferdinand AU - Vogt F AD - Department of Cardiac Surgery, Artemed Klinikum Munchen Sud, Munchen, Germany. AD - Department of Cardiac Surgery, Paracelsus Medical University Nuremberg, Germany. FAU - Di Lorenzo, Emilio AU - Di Lorenzo E AD - UOC Cardiologia/UTIC, Monaldi Hospital, Neaples, Italy. FAU - Kuhn, Elmar AU - Kuhn E AD - Department of Cardiothoracic Surgery, Heart Center, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany. FAU - Disdier, Vicente Peral AU - Disdier VP AD - Cardiology Department, Hospital Universitari Son Espases, Palma, Spain. AD - Grupo de investigacion de Fisiopatologia y Terapeutica Cardiovascular, Institut d'Investigacio Sanitaria Illes Balears (IdISBa), Palma, Spain. FAU - Rakova, Radka AU - Rakova R AD - Department of Interventional Cardiology, Edwards Lifesciences, Prague, Czech Republic. FAU - Wesselink, Wilbert AU - Wesselink W AD - Department of Interventional Cardiology, Edwards Lifesciences, Prague, Czech Republic. FAU - Kurucova, Jana AU - Kurucova J AD - Department of Interventional Cardiology, Edwards Lifesciences, Prague, Czech Republic. FAU - Hachaturyan, Violetta AU - Hachaturyan V AD - Institute for Pharmacology and Preventive Medicine, Cloppenburg, Germany. FAU - Luske, Claudia M AU - Luske CM AD - Institute for Pharmacology and Preventive Medicine, Cloppenburg, Germany. FAU - Zielinski, Marie AU - Zielinski M AD - Institute for Pharmacology and Preventive Medicine, Cloppenburg, Germany. FAU - Bramlage, Peter AU - Bramlage P AD - Institute for Pharmacology and Preventive Medicine, Cloppenburg, Germany. FAU - Frank, Derk AU - Frank D AD - Department of Internal Medicine III (Cardiology and Critical Care Medicine), University Clinical Centre Schleswig-Holstein (UKSH), Kiel, Germany. AD - German Centre for Cardiovascular Research, Partner Site Hamburg/Kiel/Lubeck, Kiel, Germany. LA - eng PT - Journal Article DEP - 20251017 PL - United States TA - Struct Heart JT - Structural heart : the journal of the Heart Team JID - 101743256 PMC - PMC12819033 OTO - NOTNLM OT - Aortic stenosis OT - Clinical valve coordinator OT - Quality of care OT - TAVI OT - Transcatheter aortic valve implantation COIS- Sandra Lauck received speaker's fees from Edwards Lifesciences. Francesco Saia received consulting fees and payment for lectures from Edwards Lifesciences, Medtronic, Boston Scientific, and Abbott. Eric Durand received lecture fees from Edwards Lifesciences. Bettina Hojberg Kirk received consulting fees and support for the present manuscript from Edwards Lifesciences. Fiona Kelly has an ongoing contract with Edwards Lifesciences; received consulting fees and payments from Edwards Lifesciences for services relating to the Benchmark program; and received payment for presentations and support for attending meetings from Edwards Lifesciences and Medtronic. Douglas F. Muir received honoraria through the BENCHMARK process and payment for presentations and other educational events from Edwards Lifesciences. Gemma McCalmont received consulting fees from Edwards Lifesciences. Mark S. Spence received honoraria for educational activity from Edwards Lifesciences. David Wood received grants and consulting fees from Edwards Lifesciences, Medtronic, and Boston Scientific. Cristobal A. Urbano Carrillo received consulting fees from Edwards Lifesciences and payments as advisory board member from Medtronic. Vlad Anton Iliescu is a proctor for Edwards Lifesciences. Celine Hee received support for the present manuscript from Edwards Lifesciences and Medtronic. Vincent Auffret received consulting fees from Medtronic and Abbott, and payment for lectures/presentations or educational events from Edwards Lifesciences. Lluis Asmarats received consulting fees from Edwards Lifesciences. The institution of Carlo Di Mario received research funding form Edwards Lifesciences. Andreas Schober received educational/research grants, speakers fees, and meeting & travel support from Edward Lifesciences and Medtronic. Luis Nombela-Franco is a proctor for Edwards Lifesciences and received consulting fees and honoraria for lectures, presentations or educational events from Edward Lifesciences, Abbott, and Boston Scientific. Nikos Werner received honoraria for lectures/presentations and support for attending meetings from Edwards Lifesciences, Medtronic, and Meril; and participates on a Data Safety Monitoring Board or Advisory Board from Boston Scientific, Shockwave, and Meril. The institution of Nicolas Meneveau received grants or contracts from Medtronic and Boston Scientific; he himself received consulting fees from Abbott, Boston Scientific, Edwards Lifesciences, and Terumo, payment for lectures/presentations or educational events from Astra Zeneca, and support for attending meetings from Servier. Felix Mahfoud received grants from Deutsche Forschungsgemeinschaft (SFB TRR219, Project-ID 322900939) and Deutsche Herzstiftung; consulting fees and honoraria for lectures, presentations, or educational events from Ablative Solutions, Astra-Zeneca, Inari, Medtronic, Merck, Novartis, Philips, and ReCor Meidcal; and is an European Society of Cardiology Board Member. Tim Seidler received payment for lectures/presentations or educational events from Astra Zeneca, Boehringer Ingelheim, Bristol Myers Squibb, Corvia, Edwards Lifesciences, Medtronic, Myocardia, Novartis, and Pfizer; support for attending meetings from Teleflex, Corvia, Edwards Lifesciences, Abbott, Medtronic, and Bristol Myers Squibb; and participates on a Data Safety Monitoring Board or Advisory Board from Bristol Myers Squibb. Florian Leuschner received honoraria for lectures form Edwards Lifesciences and Medtronic. Elmar Kuhn received consulting fees and payment for proctoring from Medtronic and Abbott. Radka Rakova, Wilbert Wesse, and Jana Kurucova are employees of Edward Lifesciences. Peter Bramlage is representing the sponsor IPPMed who received funding form Edwards Lifesciences to his institution for the present manuscript, study related activities, consulting fees, and support for attending meetings. Violetta Hachaturyan, Claudia M. Luske, and Marie Zielinski are employees of IPPMed and received funding from Edwards Lifesciences to the institution for conducting the registry. Derk Frank received consulting fees and payment for lectures/presentations from Edwards Lifesciences; he or his personal surrounding also received support for the present manuscript. The reported conflicts of interest did not influence the analysis or interpretation of the study results. The other authors had no conflicts to declare. EDAT- 2026/01/23 06:30 MHDA- 2026/01/23 06:31 PMCR- 2025/10/17 CRDT- 2026/01/23 04:51 PHST- 2025/04/28 00:00 [received] PHST- 2025/10/09 00:00 [revised] PHST- 2025/10/10 00:00 [accepted] PHST- 2026/01/23 06:31 [medline] PHST- 2026/01/23 06:30 [pubmed] PHST- 2026/01/23 04:51 [entrez] PHST- 2025/10/17 00:00 [pmc-release] AID - S2474-8706(25)00332-X [pii] AID - 100740 [pii] AID - 10.1016/j.shj.2025.100740 [doi] PST - epublish SO - Struct Heart. 2025 Oct 17;10(1):100740. doi: 10.1016/j.shj.2025.100740. eCollection 2026 Jan. PMID- 41572759 OWN - NLM STAT- MEDLINE DCOM- 20260825 LR - 20260829 IS - 1875-6557 (Electronic) IS - 1573-403X (Print) IS - 1573-403X (Linking) VI - 22 IP - 5 DP - 2026 TI - Remote ECG-guided Cardiac Rehabilitation: An Outpatient Model Using the Accordix Platform. PG - e1573403X413907 LID - 10.2174/011573403X413907251120143344 [doi] LID - E1573403X413907 AB - Telemedicine-based cardiac rehabilitation (CR) offers a viable and accessible alternative to traditional center-based programs, leveraging remote monitoring and individualized exercise prescriptions to improve cardiovascular health in patients post-acute myocardial infarction. This overview examines the implementation of the "Accordix" system, a telemedicine platform utilized for outpatient CR. The "Accordix" system facilitates real-time ECG monitoring and communication between patients and a multidisciplinary rehabilitation team. Patients undergo an initial in-person assessment to determine individual exercise parameters, followed by home-based exercise sessions supported by the system's feedback mechanisms (e.g., heart rate alerts and Borg scale integration). The platform allows physicians to remotely monitor patient progress, adjust treatment plans, and address potential adverse events, thus enabling a hybrid CR approach that combines the benefits of in-person and remote care. Future directions include integrating video consultations to enhance guidance on exercise technique and expanding accessibility to underserved populations. The focus is on improving patient training protocols to ensure proper device use, self-monitoring skills, and adherence to exercise guidelines. Telemedicine- based CR, exemplified by the "Accordix" system, holds significant promise for improving access to cardiac rehabilitation, optimizing treatment outcomes, empowering patients through self-management, and promoting long-term adherence to lifestyle changes. Further research and implementation efforts are warranted to fully realize the potential of this approach in reducing the burden of cardiovascular disease. CI - Copyright(c) Bentham Science Publishers; For any queries, please email at epub@benthamscience.net. FAU - Mishina, Irina E AU - Mishina IE AUID- ORCID: 0000-0002-7659-8008 AD - Saint Petersburg State University, Saint Petersburg, Russia. FAU - Blinova, Ksenia A AU - Blinova KA AUID- ORCID: 0000-0002-2896-8764 AD - Faculty of Medicine, FSBEI HE, Ivanovo State Medical Academy of MOH of Russia, Ivanovo, Russia. FAU - Gudukhin, Anton A AU - Gudukhin AA AUID- ORCID: 0000-0002-6169-2421 AD - Saint Petersburg State University, Saint Petersburg, Russia. FAU - Kopysheva, Elena N AU - Kopysheva EN AUID- ORCID: 0009-0003-9067-1317 AD - Saint Petersburg State University, Saint Petersburg, Russia. LA - eng PT - Journal Article PT - Review PL - United Arab Emirates TA - Curr Cardiol Rev JT - Current cardiology reviews JID - 101261935 SB - IM MH - Humans MH - Telemedicine MH - *Cardiac Rehabilitation/methods MH - Remote Patient Monitoring MH - *Exercise Therapy/methods MH - *Electrocardiography/methods MH - Digital Health MH - *Myocardial Infarction/rehabilitation/physiopathology PMC - PMC13519553 OTO - NOTNLM OT - Cardiac rehabilitation OT - aerobic exercise OT - electrocardiographic monitoring OT - heart rate monitoring OT - heart rate selection OT - telemedicine system COIS- The authors declare no conflict of interest, financial or otherwise. EDAT- 2026/01/23 06:31 MHDA- 2026/08/25 05:34 PMCR- 2027/01/13 CRDT- 2026/01/23 02:07 PHST- 2025/06/04 00:00 [received] PHST- 2025/08/26 00:00 [revised] PHST- 2025/09/02 00:00 [accepted] PHST- 2026/08/25 05:34 [medline] PHST- 2026/01/23 06:31 [pubmed] PHST- 2026/01/23 02:07 [entrez] PHST- 2027/01/13 00:00 [pmc-release] AID - CCR-EPUB-152545 [pii] AID - CCR-22-5-E1573403X413907 [pii] AID - 10.2174/011573403X413907251120143344 [doi] PST - ppublish SO - Curr Cardiol Rev. 2026;22(5):e1573403X413907. doi: 10.2174/011573403X413907251120143344. PMID- 41571217 OWN - NLM STAT- MEDLINE DCOM- 20260630 LR - 20260630 IS - 1535-6280 (Electronic) IS - 0146-2806 (Linking) VI - 51 IP - 5 DP - 2026 May TI - Association of pre-hospital shock team implementation with outcomes in ST-segment elevation myocardial infarction patients. PG - 103274 LID - S0146-2806(26)00016-2 [pii] LID - 10.1016/j.cpcardiol.2026.103274 [doi] AB - BACKGROUND: Cardiogenic shock (CS) complicating ST-segment elevation myocardial infarction (STEMI) is associated with high mortality rates. While in-hospital shock teams have shown benefits, the impact of pre-hospital shock team activation remains underexplored. METHODS: In July 2022, our high-volume primary percutaneous coronary intervention (PPCI) center serving the entire state population implemented a pre-hospital shock team. This multidisciplinary team comprises an emergency department physician, cardiac intensivist, interventional cardiologist, cardiac anesthesiologist, and extracorporeal membrane oxygenation (ECMO) specialists. Activation criteria include hypotension, tachycardia or bradycardia, acute heart failure, significant ST-elevation, ventricular arrhythmias, or elevated lactic acid levels. We compared mortality rates 18 months before and after implementation. RESULTS: Before implementation, 1,605 STEMI patients were admitted, compared to 1,735 after implementation. Of these, 217 (12%) met shock team activation criteria. Early Hospital mortality (in ED and in Cath lab) and Overall-hospital mortality rates significantly declined following implementation (1.2% vs. 0.3%, p = 0.03; and 2.1% vs. 3.3%, p = 0.02, respectively). CONCLUSION: This study suggests that pre-hospital shock team implementation is associated with a significant reduction in STEMI mortality. CI - Copyright (c) 2026. Published by Elsevier Inc. FAU - Arabi, Abdulrahman AU - Arabi A AD - Cardiology Department, Heart Hospital, Hamad Medical Corporation, Doha, Qatar. FAU - Habib, Mhd Baraa AU - Habib MB AD - Cardiology Department, Heart Hospital, Hamad Medical Corporation, Doha, Qatar. Electronic address: br.ha.sy@gmail.com. FAU - Abdelghani, Mohamed Salah AU - Abdelghani MS AD - Cardiology Department, Heart Hospital, Hamad Medical Corporation, Doha, Qatar. FAU - AlAmeen, Osamah AU - AlAmeen O AD - Cardiology Department, Heart Hospital, Hamad Medical Corporation, Doha, Qatar. FAU - Al-Hijji, Mohammad AU - Al-Hijji M AD - Cardiology Department, Heart Hospital, Hamad Medical Corporation, Doha, Qatar. FAU - Alqahtani, Awad AU - Alqahtani A AD - Cardiology Department, Heart Hospital, Hamad Medical Corporation, Doha, Qatar. FAU - Arafa, Salah Eddin AU - Arafa SE AD - Cardiology Department, Heart Hospital, Hamad Medical Corporation, Doha, Qatar. FAU - Rafie, Ihsan AU - Rafie I AD - Cardiology Department, Heart Hospital, Hamad Medical Corporation, Doha, Qatar. FAU - Suwaidi, Jassim M S Al AU - Suwaidi JMSA AD - Cardiology Department, Heart Hospital, Hamad Medical Corporation, Doha, Qatar. LA - eng PT - Journal Article PT - Review DEP - 20260120 PL - Netherlands TA - Curr Probl Cardiol JT - Current problems in cardiology JID - 7701802 SB - IM MH - Humans MH - *ST Elevation Myocardial Infarction/complications/mortality/surgery MH - *Shock, Cardiogenic/etiology/therapy/mortality MH - Female MH - Hospital Mortality/trends MH - Male MH - *Percutaneous Coronary Intervention/methods MH - Middle Aged MH - Aged MH - *Patient Care Team/organization & administration MH - *Emergency Medical Services/methods MH - Retrospective Studies MH - Survival Rate/trends OTO - NOTNLM OT - Cardiogenic shock OT - ECMO OT - Early risk stratification OT - Emergency medical services OT - Mortality OT - Multidisciplinary care OT - Pre-hospital activation OT - Primary percutaneous coronary intervention OT - ST-elevation myocardial infarction OT - Shock team COIS- Declaration of competing interest The authors have no conflict of interest. The authors take responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation EDAT- 2026/01/23 00:26 MHDA- 2026/03/08 01:38 CRDT- 2026/01/22 19:19 PHST- 2025/12/21 00:00 [received] PHST- 2026/01/16 00:00 [revised] PHST- 2026/01/19 00:00 [accepted] PHST- 2026/03/08 01:38 [medline] PHST- 2026/01/23 00:26 [pubmed] PHST- 2026/01/22 19:19 [entrez] AID - S0146-2806(26)00016-2 [pii] AID - 10.1016/j.cpcardiol.2026.103274 [doi] PST - ppublish SO - Curr Probl Cardiol. 2026 May;51(5):103274. doi: 10.1016/j.cpcardiol.2026.103274. Epub 2026 Jan 20. PMID- 41570940 OWN - NLM STAT- MEDLINE DCOM- 20260630 LR - 20260630 IS - 2665-9867 (Electronic) IS - 1701-2163 (Linking) VI - 48 IP - 3 DP - 2026 Mar TI - Decoding Code OB: A National Survey of Obstetrical Emergency Codes. PG - 103207 LID - S1701-2163(26)00007-1 [pii] LID - 10.1016/j.jogc.2026.103207 [doi] AB - OBJECTIVES: Increasing incidence of maternal cardiac arrest, with a significant case fatality rate, highlights the urgent need for empirical protocols to inform how multiprofessional teams respond to these events. Existing international guidelines recommend a unique emergency response code for maternal cardiac arrest, without clear guidance regarding implementation. Canadian data is currently lacking, which limits our ability to compare outcomes and capture opportunities for improvement nationally and institutionally. This study maps the range of existing obstetrical emergency codes and team responses across Canada. METHODS: We extracted institutional information from publicly available documents or key informants in obstetrical units at 28 of 32 teaching hospitals across Canada with obstetrical beds (excluding Quebec), including current obstetrical code(s), practical details and evaluation procedures if specified. A composite code included many different emergencies, a combined code merged >/=2 existing codes, and a dedicated code was specific to 1 emergency. RESULTS: Overall, 50% of surveyed units use at least 1 obstetrical emergency code, most commonly for time-critical obstetrical emergencies. Only 21% (N = 6) of teaching hospitals surveyed have a either a composite (N = 3) or combined code (N = 3) that includes maternal cardiac arrest and only 1 hospital had a unique, dedicated maternal arrest code. CONCLUSIONS: Despite guidelines that support the use of a dedicated code for maternal cardiac arrest, this is rare across the sampled centres. Instead, composite or combined codes were more common, with unproven safety or efficacy. Our findings expose a national opportunity to standardize and systematically research in-hospital maternal arrest protocols to optimize relevant patient outcomes. CI - Copyright (c) 2026 The Author. Published by Elsevier Inc. All rights reserved. FAU - Reardon, Jaime AU - Reardon J AD - Department of Obstetrics and Gynaecology, Dalhousie University, Halifax, NS. FAU - Blissett, Sarah AU - Blissett S AD - Division of Cardiology, Department of Medicine, Schulich School of Medicine & Dentistry, Western University, London, ON. FAU - Jamshidi-Shahvar, Ariela AU - Jamshidi-Shahvar A AD - Schulich School of Medicine & Dentistry, Western University, London, ON. FAU - Taylor, Taryn S M AU - Taylor TSM AD - Department of Obstetrics and Gynaecology, Schulich School of Medicine & Dentistry, Western University, London, ON. Electronic address: taryn.taylor@lhsc.on.ca. LA - eng PT - Journal Article DEP - 20260120 PL - Netherlands TA - J Obstet Gynaecol Can JT - Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC JID - 101126664 SB - IM MH - Humans MH - Female MH - Pregnancy MH - *Heart Arrest/therapy/diagnosis MH - Canada MH - Hospital Rapid Response Team MH - Emergencies MH - *Pregnancy Complications, Cardiovascular/therapy MH - Hospitals, Teaching OTO - NOTNLM OT - hospital rapid response team OT - maternal mortality OT - obstetrics EDAT- 2026/01/23 00:26 MHDA- 2026/03/20 00:59 CRDT- 2026/01/22 19:12 PHST- 2025/10/08 00:00 [received] PHST- 2025/11/24 00:00 [revised] PHST- 2025/12/08 00:00 [accepted] PHST- 2026/03/20 00:59 [medline] PHST- 2026/01/23 00:26 [pubmed] PHST- 2026/01/22 19:12 [entrez] AID - S1701-2163(26)00007-1 [pii] AID - 10.1016/j.jogc.2026.103207 [doi] PST - ppublish SO - J Obstet Gynaecol Can. 2026 Mar;48(3):103207. doi: 10.1016/j.jogc.2026.103207. Epub 2026 Jan 20. PMID- 41569368 OWN - NLM STAT- MEDLINE DCOM- 20260630 LR - 20260630 IS - 1534-3170 (Electronic) IS - 1523-3782 (Print) IS - 1523-3782 (Linking) VI - 28 IP - 1 DP - 2026 Jan 22 TI - Pericardiectomy for Constrictive and Recurrent Pericarditis: State of the Art Update. PG - 14 LID - 10.1007/s11886-025-02339-z [doi] LID - 14 AB - PURPOSE OF REVIEW: This review provides a contemporary surgical view on constrictive and recurrent pericarditis. RECENT FINDINGS: Cardiac magnetic resonance imaging, echocardiography, and heart catheterization are complementary tools for diagnosis and management of patients considered for pericardiectomy. Radical pericardiectomy, unlike total/complete, represents the most extensive resection. Radical or total/complete pericardiectomy via median sternotomy is preferred over partial for both recurrent and constrictive pericarditis, to minimize the risk of symptoms and/or constriction recurrence. Utilization of cardiopulmonary bypass may facilitate the completeness and safety of the procedure. In surgical planning, attention should be paid to intraoperative challenges, especially low cardiac output syndrome, tricuspid regurgitation, and coronary injury. A multidisciplinary approach in experienced centers is essential to optimize outcomes. Radical or complete pericardiectomy is advised over partial to avoid the symptoms or constriction recurrence owing to the remaining pericardium. Further research is mandatory to identify the optimal timing and precise extent of pericardiectomy. CI - (c) 2026. The Author(s). FAU - Krzelj, Kristina AU - Krzelj K AD - Department of Thoracic and Cardiovascular Surgery, Miller Family Heart, Vascular & Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA. FAU - Bakaeen, Maria AU - Bakaeen M AD - Department of Thoracic and Cardiovascular Surgery, Miller Family Heart, Vascular & Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA. FAU - Wang, Tom Kai Ming AU - Wang TKM AD - Department of Cardiovascular Medicine, Miller Family Heart, Vascular & Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA. FAU - Klein, Allan AU - Klein A AD - Department of Cardiovascular Medicine, Miller Family Heart, Vascular & Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA. FAU - Vega, Saberio Lo Presti AU - Vega SLP AD - Department of Cardiovascular Medicine, Miller Family Heart, Vascular & Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA. FAU - Jellis, Christine AU - Jellis C AD - Department of Cardiovascular Medicine, Miller Family Heart, Vascular & Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA. FAU - Kwon, Deborah AU - Kwon D AD - Department of Cardiovascular Medicine, Miller Family Heart, Vascular & Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA. FAU - Tong, Michael AU - Tong M AD - Department of Thoracic and Cardiovascular Surgery, Miller Family Heart, Vascular & Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA. FAU - Unai, Shinya AU - Unai S AD - Department of Thoracic and Cardiovascular Surgery, Miller Family Heart, Vascular & Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA. FAU - Koprivanac, Marijan AU - Koprivanac M AD - Department of Thoracic and Cardiovascular Surgery, Miller Family Heart, Vascular & Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA. koprivm@ccf.org. LA - eng PT - Journal Article PT - Review DEP - 20260122 PL - United States TA - Curr Cardiol Rep JT - Current cardiology reports JID - 100888969 SB - IM MH - Humans MH - *Pericardiectomy/methods MH - *Pericarditis, Constrictive/surgery/diagnosis MH - Recurrence MH - Cardiac Catheterization MH - Echocardiography MH - Cardiopulmonary Bypass MH - Magnetic Resonance Imaging MH - Treatment Outcome PMC - PMC12827344 OTO - NOTNLM OT - Cardiopulmonary bypass OT - Constrictive pericarditis OT - Pericardiectomy OT - Recurrent pericarditis COIS- Declarations. Human and Animal Rights and Informed Consent: No animal or human subjects by the authors were used in this study. Competing interest: Christine Jellis reports consulting fees and payment or honoraria from Kiniksa. The other authors declare that they have no conflict of interest. EDAT- 2026/01/22 13:31 MHDA- 2026/01/22 13:32 PMCR- 2026/01/22 CRDT- 2026/01/22 11:06 PHST- 2025/10/27 00:00 [received] PHST- 2025/12/15 00:00 [accepted] PHST- 2026/01/22 13:32 [medline] PHST- 2026/01/22 13:31 [pubmed] PHST- 2026/01/22 11:06 [entrez] PHST- 2026/01/22 00:00 [pmc-release] AID - 10.1007/s11886-025-02339-z [pii] AID - 2339 [pii] AID - 10.1007/s11886-025-02339-z [doi] PST - epublish SO - Curr Cardiol Rep. 2026 Jan 22;28(1):14. doi: 10.1007/s11886-025-02339-z. PMID- 41569130 OWN - NLM STAT- Publisher LR - 20260122 IS - 1130-0108 (Print) IS - 1130-0108 (Linking) DP - 2026 Jan 22 TI - Left atrial appendage closure for atrial fibrillation patients at high risk of gastrointestinal bleeding. An evidence-based multidisciplinary review for gastroenterologists. LID - 10.17235/reed.2026.11781/2025 [doi] AB - BACKGROUND: atrial fibrillation (AF) is the most prevalent cardiac arrhythmia, constituting a significant risk factor for stroke and systemic embolism. Oral anticoagulation (OAC) remains the primary strategy for stroke prevention, however, a subset of patients must discontinue it due to adverse events. Percutaneous left atrial appendage closure (LAAC) involves the mechanical occlusion of the left atrial appendage, an embryonic remnant in the left atrium of the heart where most thrombi form in patients with AF. It offers an alternative to long-term OAC for stroke prevention. METHODS: this article provides an overview of the LAAC procedure, its indications, and the current evidence (including clinical trials, meta-analyses, and real-world practice studies) regarding gastrointestinal bleeding (GIB) secondary to OAC. RESULTS: The PROTECT-AF and PREVAIL RCTs included 1114 patients with non-valvular AF, randomized 2:1 to LAAC or warfarin. Differences in major bleeding favoured LAAC (HR 0.48; 95% CI: 0.32-0.71). In the PRAGUE-17 trial, LAAC was non-inferior to DOAC in preventing major AF-related cardiovascular, neurological and bleeding events among patients at high risk for stroke and bleeding. In the long-term follow-up, the noninferiority of LAAC was maintained after 4 years (annual rate of nonprocedural clinically relevant bleeding, including GIB, was 7.42% for DOAC vs 3.76% for LAAC). In the OPTION trial, LAAC reduced non-procedure-related major or clinically relevant nonmajor bleeding at 36 months compared to OAC in patients undergoing catheter-based AF ablation. In a real-world study about LAAC in 43 anticoagulated patients with previous GIB, hospitalization need, number of endoscopic procedures, as well as iron intravenous doses and packed red cells administered decreased after LAAC. In cirrhosis, LAAC appears to be associated with an increased risk of complications (renal failure, cardiac tamponade, GIB) and readmissions. CONCLUSIONS: LAAC offers a treatment option for stroke prevention in AF patients in whom lifelong anticoagulation is contraindicated due to recurrent GIB, chronic anaemia or high bleeding risk. In cirrhotic patients, careful selection and shared decision-making are critical due to its higher complications risk. FAU - Sanz Segura, Patricia AU - Sanz Segura P AUID- ORCID: 0000-0002-6211-1422 AD - Gastroenterology, Hospital Universitario Royo Villanova, Espana. FAU - Jimeno Sanchez, Javier AU - Jimeno Sanchez J AUID- ORCID: 0000-0003-1938-2312 AD - Interventional Cardiology Unit, Hospital Universitario Miguel Servet, Spain. FAU - Senzolo, Marco AU - Senzolo M AUID- ORCID: 0000-0002-7261-6520 AD - Surgery, Oncology and Gastroenterology, University Hospital of Padua, Italy. FAU - Grygier, Marek AU - Grygier M AUID- ORCID: 0000-0002-1134-7099 AD - Cardiology, Poznan University Hospital, Poland. FAU - Bernal-Monterde, Vanesa AU - Bernal-Monterde V AUID- ORCID: 0000-0002-4016-2165 AD - Gastroenterology , Hospital Universitario Miguel Servet, Espana. FAU - Perez de Prado, Armando AU - Perez de Prado A AUID- ORCID: 0000-0003-3283-0597 AD - Interventional Cardiology, Hospital Universitario de Leon , Spain. FAU - Lip, Gregory Y H AU - Lip GYH AUID- ORCID: 0000-0002-7566-1626 AD - Liverpool Centre for Cardiovascular Science, Liverpool John Moores University and Liverpool Heart and Chest Hospital, United Kingdom. FAU - Camm, A John AU - Camm AJ AUID- ORCID: 0000-0002-2536-2871 AD - City and St. George's University of London, United Kingdom. LA - eng PT - Journal Article DEP - 20260122 PL - Spain TA - Rev Esp Enferm Dig JT - Revista espanola de enfermedades digestivas JID - 9007566 SB - IM EDAT- 2026/01/22 13:30 MHDA- 2026/01/22 13:30 CRDT- 2026/01/22 10:13 PHST- 2026/01/22 13:30 [medline] PHST- 2026/01/22 13:30 [pubmed] PHST- 2026/01/22 10:13 [entrez] AID - 10.17235/reed.2026.11781/2025 [doi] PST - aheadofprint SO - Rev Esp Enferm Dig. 2026 Jan 22. doi: 10.17235/reed.2026.11781/2025. PMID- 41568415 OWN - NLM STAT- MEDLINE DCOM- 20260630 LR - 20260630 IS - 1744-8344 (Electronic) IS - 1477-9072 (Linking) VI - 24 IP - 2 DP - 2026 Jan-Feb TI - Alternatives to right ventricular pacing in patients with atrioventricular block: can we prevent pacing-induced cardiomyopathy? PG - 107-113 LID - 10.1080/14779072.2026.2621679 [doi] AB - INTRODUCTION: Right ventricular apical pacing (RVAP) has been a standard treatment for patients experiencing symptomatic advanced atrioventricular (AV) block. However, due to electrical and subsequent mechanical dyssynchrony, RVAP might lead to pacing-induced cardiomyopathy (PICM). Various predisposing risk factors for PICM have been identified. AREAS COVERED: This review, based on a literature search of PubMed and Scopus databases (up to April 2025), focuses on alternative pacing strategies, including conduction system pacing (CSP) and biventricular pacing (BiVP), to reduce PICM. EXPERT OPINION: Implementing pacing strategies that encourage physiological ventricular activation, like CSP and BiVP, can greatly diminish the risk of PICM in patients with AV block. Implementing alternative pacing strategies necessitates careful patient selection and consideration of individual anatomical and clinical factors. A team-based approach should be utilized to identify the most suitable pacing method for each patient, with the goal of optimizing cardiac function and reducing the risk of PICM. FAU - Dogan, Mert AU - Dogan M AD - Department of Cardiology, Cardiac Pacing Unit, Hacettepe University Faculty of Medicine, Ankara, Turkey. FAU - Canpolat, Ugur AU - Canpolat U AD - Department of Cardiology, Cardiac Pacing Unit, Hacettepe University Faculty of Medicine, Ankara, Turkey. LA - eng PT - Journal Article PT - Review DEP - 20260127 PL - England TA - Expert Rev Cardiovasc Ther JT - Expert review of cardiovascular therapy JID - 101182328 SB - IM MH - Humans MH - *Atrioventricular Block/therapy/physiopathology MH - *Cardiomyopathies/etiology/prevention & control MH - *Cardiac Pacing, Artificial/methods/adverse effects MH - Risk Factors MH - *Cardiac Resynchronization Therapy/methods/adverse effects MH - Patient Selection MH - Heart Ventricles/physiopathology OTO - NOTNLM OT - Atrioventricular block OT - biventricular pacing OT - conduction system pacing OT - pacing-induced cardiomyopathy OT - right ventricular apical pacing EDAT- 2026/01/22 07:43 MHDA- 2026/02/06 06:42 CRDT- 2026/01/22 04:52 PHST- 2026/02/06 06:42 [medline] PHST- 2026/01/22 07:43 [pubmed] PHST- 2026/01/22 04:52 [entrez] AID - 10.1080/14779072.2026.2621679 [doi] PST - ppublish SO - Expert Rev Cardiovasc Ther. 2026 Jan-Feb;24(2):107-113. doi: 10.1080/14779072.2026.2621679. Epub 2026 Jan 27. PMID- 41567648 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260122 LR - 20260124 IS - 2474-8714 (Electronic) IS - 2474-8706 (Print) IS - 2474-8706 (Linking) VI - 10 IP - 2 DP - 2026 Feb TI - Patient Selection for Transcatheter Tricuspid Valve Intervention: Not Too Early, Not Too Late. PG - 100788 LID - 10.1016/j.shj.2025.100788 [doi] LID - 100788 AB - Tricuspid regurgitation (TR) is a common but frequently underrecognized condition associated with substantial morbidity and mortality. Long regarded as a mere bystander of left-sided heart disease, TR was often left untreated, contributing to late referrals and poor surgical outcomes. The emergence of transcatheter tricuspid valve interventions has broadened therapeutic options, particularly for high-risk or inoperable patients. However, procedural success and clinical benefit critically depend on appropriate patient selection and timely intervention. This review outlines the evolving landscape of TR management, emphasizing the importance of anatomical and clinical stage-adapted device selection. Key determinants of feasibility and prognosis include right ventricular function and dimensions, TR severity, tricuspid valve leaflet and annular remodeling, and hemodynamic congestion. Advanced imaging modalities and invasive hemodynamics provide incremental value for risk stratification. While tricuspid valve transcatheter edge-to-edge repair (T-TEER) and orthotopic valve replacement are the most widely adopted techniques, direct annuloplasty, heterotopic valve replacement, and coaptation enhancement devices may be more appropriate in anatomically advanced stages. Despite symptomatic improvement and reduced heart failure hospitalizations across different treatment modalities, a survival benefit has yet to be demonstrated. Delayed referral remains a challenge, often precluding repair or even replacement strategies. Dedicated risk models may improve prognostication and guide procedural decision-making. Ultimately, a multidisciplinary approach incorporating multiparametric assessment is essential to identify optimal candidates, guide timing, and personalize therapy. Ongoing trials and long-term outcome data are needed to refine treatment algorithms and clarify the role of early intervention in altering the natural course of severe TR. CI - (c) 2025 The Author(s). FAU - von Stein, Jennifer AU - von Stein J AD - Faculty of Medicine and University Hospital Cologne, Department III of Internal Medicine, University of Cologne, Cologne, Germany. AD - Cardiovascular Research Foundation, New York, New York, USA. FAU - von Stein, Philipp AU - von Stein P AD - Faculty of Medicine and University Hospital Cologne, Department III of Internal Medicine, University of Cologne, Cologne, Germany. AD - Cardiovascular Research Foundation, New York, New York, USA. FAU - Alu, Maria C AU - Alu MC AD - Cardiovascular Research Foundation, New York, New York, USA. FAU - Scotti, Andrea AU - Scotti A AD - Montefiore-Einstein Center for Heart and Vascular Care, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA. FAU - Ho, Edwin C AU - Ho EC AD - Montefiore-Einstein Center for Heart and Vascular Care, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA. FAU - Granada, Juan F AU - Granada JF AD - Cardiovascular Research Foundation, New York, New York, USA. FAU - Latib, Azeem AU - Latib A AD - Montefiore-Einstein Center for Heart and Vascular Care, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA. LA - eng PT - Journal Article PT - Review DEP - 20251219 PL - United States TA - Struct Heart JT - Structural heart : the journal of the Heart Team JID - 101743256 PMC - PMC12818359 OTO - NOTNLM OT - T-TEER OT - Transcatheter tricuspid valve intervention OT - Transcatheter tricuspid valve replacement OT - Tricuspid regurgitation COIS- J.v.S. has received speaker honoraria and travel expenses from Edwards Lifesciences. E.C.H. is a consultant or has served on an advisory board for Abbott, Medtronic, Edwards Lifesciences, Philips, GE Healthcare, Johnson & Johnson Med Tech, Shifamed, Neochord, Nyra, Valgen, Meacor, and Trajectory. A.L. is a consultant on the advisory board of Medtronic, Abbott, Boston Scientific, Philips, Edwards Lifesciences, V-dyne, Shifamed, Trilio, Coramaze, Nyra, Tioga, and NeoChord. The other authors had no conflicts to declare. EDAT- 2026/01/22 11:58 MHDA- 2026/01/22 11:59 PMCR- 2025/12/19 CRDT- 2026/01/22 04:39 PHST- 2025/10/14 00:00 [received] PHST- 2025/12/10 00:00 [revised] PHST- 2025/12/13 00:00 [accepted] PHST- 2026/01/22 11:59 [medline] PHST- 2026/01/22 11:58 [pubmed] PHST- 2026/01/22 04:39 [entrez] PHST- 2025/12/19 00:00 [pmc-release] AID - S2474-8706(25)00380-X [pii] AID - 100788 [pii] AID - 10.1016/j.shj.2025.100788 [doi] PST - epublish SO - Struct Heart. 2025 Dec 19;10(2):100788. doi: 10.1016/j.shj.2025.100788. eCollection 2026 Feb. PMID- 41565503 OWN - NLM STAT- MEDLINE DCOM- 20260608 LR - 20260608 IS - 1535-6302 (Electronic) IS - 0363-0188 (Linking) VI - 55 IP - 4 DP - 2026 Jul-Aug TI - Beyond the breast: Mammographic manifestations of systemic disease. PG - 586-606 LID - S0363-0188(26)00003-4 [pii] LID - 10.1067/j.cpradiol.2026.01.003 [doi] AB - Mammography is traditionally regarded as a domain confined to the detection of breast malignancies; however, it can also serve as a mirror for diverse systemic, haematological, autoimmune, infectious, and metabolic diseases. Imaging manifestations may reveal distinctive pathognomonic features that directly suggest an underlying systemic disorder or provide subtle indirect clues that prompt timely multidisciplinary evaluation, thereby sparing patients from unnecessary procedures. In this comprehensive review, we present one of the most diverse compilations of extramammary and systemic disorders manifesting within the breast. Through multimodality imaging and clinico-pathological correlation, we illustrate entities ranging from tubercular mastitis, IgG4-related mastitis, breast lymphoma, breast metastases, to vasculitis, amyloidosis, diabetic mastopathy, and systemic failure states, including cardiac and renal disease. Mammography provides an underutilised opportunity to assess overall patient health, guide systemic illness workup, and aid in risk stratification for conditions such as cardiovascular disease or syndromic malignancy predisposition, in addition to cancer detection. By consolidating these entities into a single resource, this article aims to expand the interpretive lens of breast radiologists, improving diagnostic precision and enabling them to contribute decisively to multidisciplinary patient care. CI - Copyright (c) 2026. Published by Elsevier Inc. FAU - Singla, Veenu AU - Singla V AD - Department of Radiodiagnosis, PGIMER, Chandigarh 160012, India. Electronic address: veenupgi@gmail.com. FAU - Garg, Dollphy AU - Garg D AD - Department of Radiodiagnosis, PGIMER, Chandigarh 160012, India. FAU - Sri, Gopika AU - Sri G AD - Department of Radiodiagnosis, PGIMER, Chandigarh 160012, India. FAU - Sekar, Aravind AU - Sekar A AD - Department of Histopathology, PGIMER, Chandigarh 160012, India. FAU - Bal, Amanjit AU - Bal A AD - Department of Histopathology, PGIMER, Chandigarh 160012, India. FAU - Dahiya, Divya AU - Dahiya D AD - Department of Surgery, PGIMER, Chandigarh 160012, India. FAU - Basher, Rajender Kumar AU - Basher RK AD - Department of Nuclear Medicine, PGIMER, Chandigarh 160012, India. LA - eng PT - Journal Article PT - Review DEP - 20260113 PL - United States TA - Curr Probl Diagn Radiol JT - Current problems in diagnostic radiology JID - 7607123 SB - IM MH - Humans MH - Female MH - *Mammography/methods MH - *Breast Diseases/diagnostic imaging MH - Diagnosis, Differential OTO - NOTNLM OT - Breast arterial calcification OT - Breast cancer mimics OT - Breast manifestations OT - Diabetic mastopathy OT - Filariasis OT - IgG4-related disease OT - Mammography OT - Metastases OT - Neurofibromatosis OT - Radiology-pathology correlation OT - Sarcoidosis OT - Scleroderma OT - Systemic disease COIS- Declaration of competing interest None. EDAT- 2026/01/22 01:09 MHDA- 2026/06/08 06:35 CRDT- 2026/01/21 21:52 PHST- 2025/11/09 00:00 [received] PHST- 2026/01/12 00:00 [revised] PHST- 2026/01/12 00:00 [accepted] PHST- 2026/06/08 06:35 [medline] PHST- 2026/01/22 01:09 [pubmed] PHST- 2026/01/21 21:52 [entrez] AID - S0363-0188(26)00003-4 [pii] AID - 10.1067/j.cpradiol.2026.01.003 [doi] PST - ppublish SO - Curr Probl Diagn Radiol. 2026 Jul-Aug;55(4):586-606. doi: 10.1067/j.cpradiol.2026.01.003. Epub 2026 Jan 13. PMID- 41565044 OWN - NLM STAT- MEDLINE DCOM- 20260630 LR - 20260630 IS - 1535-6280 (Electronic) IS - 0146-2806 (Linking) VI - 51 IP - 4 DP - 2026 Apr TI - Ocular manifestations of transthyretin amyloidosis and their diagnostic value in cardiology: A comprehensive review. PG - 103263 LID - S0146-2806(26)00006-X [pii] LID - 10.1016/j.cpcardiol.2026.103263 [doi] AB - BACKGROUND: Transthyretin cardiac amyloidosis (ATTR-CM) is an increasingly recognized cause of heart failure with preserved ejection fraction (HFpEF); however, early diagnosis remains challenging. OBJECTIVE: From the perspective of cardiovascular physicians, this review systematically elucidates the ocular manifestations of ATTR, explores their clinical significance as early diagnostic clues, and proposes an integrated diagnostic pathway incorporating ophthalmologic assessment. CONTENT: This article focuses on the pathophysiological mechanisms and recognition criteria of characteristic ocular signs, including vitreous amyloidosis and secondary glaucoma, and constructs a multidisciplinary diagnostic workflow integrating cardiac imaging, ophthalmologic "red flags," and molecular diagnostic techniques. CONCLUSIONS: Incorporating ocular manifestations into routine cardiovascular history-taking and systematic evaluation holds significant clinical value for improving early ATTR-CM diagnosis rates and patient outcomes. Active promotion of cardiovascular-ophthalmology-neurology multidisciplinary collaboration is warranted. CI - Copyright (c) 2026 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Zhu, Yongda AU - Zhu Y AD - Department of Cardio-Thoracic Surgery, The Fourth People's Hospital of Shenyang, China Medical University, Liaoning, Shenyang 110031, China. FAU - Gao, Shun AU - Gao S AD - Department of Cardio-Thoracic Surgery, The Fourth People's Hospital of Shenyang, China Medical University, Liaoning, Shenyang 110031, China. FAU - Liu, Qingquan AU - Liu Q AD - Department of Cardio-Thoracic Surgery, The Fourth People's Hospital of Shenyang, China Medical University, Liaoning, Shenyang 110031, China. FAU - Shen, Chunjian AU - Shen C AD - Department of Cardio-Thoracic Surgery, The Fourth People's Hospital of Shenyang, China Medical University, Liaoning, Shenyang 110031, China. Electronic address: shenchunjian1976@hotmail.com. LA - eng PT - Journal Article PT - Review DEP - 20260119 PL - Netherlands TA - Curr Probl Cardiol JT - Current problems in cardiology JID - 7701802 RN - Amyloidosis, Hereditary, Transthyretin-Related SB - IM MH - Humans MH - *Amyloid Neuropathies, Familial/complications/diagnosis MH - *Eye Diseases/etiology/diagnosis MH - Early Diagnosis MH - *Heart Failure/etiology OTO - NOTNLM OT - Cardiac amyloidosis OT - Early diagnosis OT - Multidisciplinary team OT - Ocular manifestations OT - Transthyretin amyloidosis COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/01/22 01:09 MHDA- 2026/02/20 00:32 CRDT- 2026/01/21 19:12 PHST- 2026/01/03 00:00 [received] PHST- 2026/01/10 00:00 [accepted] PHST- 2026/02/20 00:32 [medline] PHST- 2026/01/22 01:09 [pubmed] PHST- 2026/01/21 19:12 [entrez] AID - S0146-2806(26)00006-X [pii] AID - 10.1016/j.cpcardiol.2026.103263 [doi] PST - ppublish SO - Curr Probl Cardiol. 2026 Apr;51(4):103263. doi: 10.1016/j.cpcardiol.2026.103263. Epub 2026 Jan 19. PMID- 41564635 OWN - NLM STAT- MEDLINE DCOM- 20260630 LR - 20260715 IS - 1361-8423 (Electronic) IS - 1361-8415 (Linking) VI - 109 DP - 2026 Mar TI - AEM: An interpretable multi-task multi-modal framework for cardiac disease prediction. PG - 103951 LID - S1361-8415(26)00020-4 [pii] LID - 10.1016/j.media.2026.103951 [doi] AB - Cardiovascular disease (CVD) is one of the leading causes of death and illness across the world. Especially, early prediction of heart failure (HF) is complicated due to the heterogeneity of its clinical presentations and symptoms. These challenges underscore the need for a multidisciplinary approach for comprehensive evaluation of cardiac state. To this end, we specifically select electrocardiogram (ECG) and 3D cardiac anatomy for their complementary coverage of cardiac electrical activities and fine-grained structural modeling. Building upon this, we present a novel pre-training framework, named Anatomy-Electrocardiogram Model (AEM), to explore their complex interactions. AEM adopts a multi-task self-supervised scheme that combines a masked reconstruction objective with a cardiac measurement (CM) regression branch to embed cardiac functional priors and structural details. Unlike image-domain models that typically localize the whole heart within the image, our 3D anatomy is background-free and continuous in 3D space. Hence, the model can naturally concentrate on finer structures at the patch level. The further integration with ECG captures functional dynamics through electrical conduction, encapsulating holistic cardiac representations. Extensive experiments are conducted on the multi-modal datasets collected from the UK Biobank, which contain paired biventricular point cloud anatomy and 12-lead ECG data. Our proposed AEM achieves an area under the receiver operating characteristic curve of 0.8192 for incident HF prediction and a concordance index of 0.6976 for survival prediction under linear evaluation, outperforming the state-of-the-art multi-modal methods. Additionally, we study the interpretability of the disease prediction by observing that our model effectively recognizes clinically plausible patterns and exhibits a high association with clinical features. CI - Copyright (c) 2026 The Author(s). Published by Elsevier B.V. All rights reserved. FAU - Peng, Jiachuan AU - Peng J AD - Department of Engineering Science, University of Oxford, Oxford, OX3 7DQ, UK. Electronic address: jiachuan.peng@seh.ox.ac.uk. FAU - Beetz, Marcel AU - Beetz M AD - Department of Engineering Science, University of Oxford, Oxford, OX3 7DQ, UK. FAU - Banerjee, Abhirup AU - Banerjee A AD - Department of Engineering Science, University of Oxford, Oxford, OX3 7DQ, UK; bDivision of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, OX3 9DU, UK. FAU - Chen, Min AU - Chen M AD - Department of Engineering Science, University of Oxford, Oxford, OX3 7DQ, UK. FAU - Grau, Vicente AU - Grau V AD - Department of Engineering Science, University of Oxford, Oxford, OX3 7DQ, UK. LA - eng GR - 40161/UK Biobank/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20260116 PL - Netherlands TA - Med Image Anal JT - Medical image analysis JID - 9713490 SB - IM MH - Humans MH - *Electrocardiography/methods MH - *Imaging, Three-Dimensional MH - *Heart Diseases/diagnostic imaging MH - Algorithms OTO - NOTNLM OT - Heart failure OT - Interpretability OT - Multi-modal transformer OT - Risk prediction OT - Self-supervised pre-training COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/01/22 01:09 MHDA- 2026/02/08 00:35 CRDT- 2026/01/21 18:06 PHST- 2024/07/12 00:00 [received] PHST- 2026/01/14 00:00 [revised] PHST- 2026/01/15 00:00 [accepted] PHST- 2026/02/08 00:35 [medline] PHST- 2026/01/22 01:09 [pubmed] PHST- 2026/01/21 18:06 [entrez] AID - S1361-8415(26)00020-4 [pii] AID - 10.1016/j.media.2026.103951 [doi] PST - ppublish SO - Med Image Anal. 2026 Mar;109:103951. doi: 10.1016/j.media.2026.103951. Epub 2026 Jan 16. PMID- 41563306 OWN - NLM STAT- Publisher LR - 20260121 IS - 1743-9159 (Electronic) IS - 1743-9159 (Linking) DP - 2026 Jan 21 TI - Mastering robotic cardiac surgery: the impact of structured milestones and technological integration on the learning curve and patient outcomes. LID - 10.1097/JS9.0000000000004908 [doi] AB - BACKGROUND: Robotic cardiac surgery represents a transformative advancement in minimally invasive surgical techniques. However, the adoption of robotic systems involves a steep learning curve, requiring systematic standardization and technological advancements to achieve proficiency and optimal patient outcomes. METHODS: This retrospective, single-center study evaluated 500 robotic cardiac surgeries performed from January 2012 to December 2024. A milestone-driven framework (technical, process, and team-based) was employed. Primary outcomes were operation time and a composite of major complications (reoperation for bleeding, stroke, renal failure requiring dialysis, reintubation, or 30-day mortality). Secondary outcomes included cross-clamp and bypass times, ICU and hospital length of stay, and New York Heart Association (NYHA) class change. We modeled learning using overall cumulative sum (CUSUM) curves for all consecutive cases with milestone timings annotated segmented regression for temporal trends. RESULTS: The learning curve exhibited three distinct phases: initial (Cases 1-50), proficiency (Cases 51-150), and mastery (Cases >150). Operation times decreased from a median of 420 minutes in the initial phase to 280 minutes in the mastery phase. Complication rates declined from 15% to 5%. Milestone interventions, including standardized port placement, suture alignment, and the introduction of the Cor-Knot system, corresponded to inflection points in the learning curve. On the single overall CUSUM plot, inflection points temporally aligned with specific milestones. Postoperative outcomes demonstrated a low complication rate (3.5% for isolated mitral valve repair) and a 30-day mortality rate of 0.2%. Most patients (60%) achieved NYHA Class I postoperatively, indicating significant functional improvement. CONCLUSION: Within a structured program, temporal improvements in efficiency and safety coincided with progressive standardization and team specialization. These results demonstrate associations still provide a replicable model for the integration and optimization of robotic surgical programs, highlighting the importance of procedural standardization, team specialization, technological innovation, and iterative refinement of robotic cardiac surgery implementation. CI - Copyright (c) 2026 The Author(s). Published by Wolters Kluwer Health, Inc. FAU - Wei, Ling-Yi AU - Wei LY AD - Division of Cardiovascular Surgery, Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan. FAU - Wang, Yi-Chia AU - Wang YC AD - Department of Anesthesiology, National Taiwan University Hospital, Taipei, Taiwan. FAU - Huang, Chi-Hsiang AU - Huang CH AD - Department of Anesthesiology, National Taiwan University Hospital, Taipei, Taiwan. FAU - Chen, Jen-Wei AU - Chen JW AD - Division of Cardiovascular Surgery, Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan. FAU - Chou, Nai-Kwan AU - Chou NK AD - Division of Cardiovascular Surgery, Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan. FAU - Yu, Hsi-Yu AU - Yu HY AD - Division of Cardiovascular Surgery, Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan. FAU - Chi, Nai-Hsin AU - Chi NH AUID- ORCID: 0000-0002-4731-1653 AD - Division of Cardiovascular Surgery, Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan. LA - eng PT - Journal Article DEP - 20260121 PL - United States TA - Int J Surg JT - International journal of surgery (London, England) JID - 101228232 SB - IM OTO - NOTNLM OT - learning curve OT - milestone-based approach OT - robotic cardiac surgery OT - surgical proficiency EDAT- 2026/01/21 12:59 MHDA- 2026/01/21 12:59 CRDT- 2026/01/21 10:34 PHST- 2025/08/20 00:00 [received] PHST- 2025/12/26 00:00 [accepted] PHST- 2026/01/21 12:59 [medline] PHST- 2026/01/21 12:59 [pubmed] PHST- 2026/01/21 10:34 [entrez] AID - 01279778-990000000-04500 [pii] AID - 10.1097/JS9.0000000000004908 [doi] PST - aheadofprint SO - Int J Surg. 2026 Jan 21. doi: 10.1097/JS9.0000000000004908. PMID- 41562659 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260121 LR - 20260125 IS - 2036-7430 (Print) IS - 2036-7449 (Electronic) IS - 2036-7430 (Linking) VI - 18 IP - 1 DP - 2025 Dec 25 TI - Infective Endocarditis in a Tertiary Hospital in Porto-Is There Anything New? LID - 10.3390/idr18010004 [doi] LID - 4 AB - BACKGROUND/OBJECTIVES: Infective endocarditis (IE) remains a severe and complex disease despite advances in diagnosis and treatment. The changing epidemiological profile, with an ageing population, has reshaped its presentation and management. This study describes the epidemiological, clinical and microbiological characteristics of IE at a Portuguese tertiary referral hospital prior to the establishment of a multidisciplinary Endocarditis Team. METHODS: A retrospective analysis was conducted including all adult patients diagnosed with definite or possible IE according to the 2015 ESC criteria, admitted to ULS Sao Joao, Porto, between January 2019 and December 2023. Data were collected from electronic medical records and included demographic characteristics, comorbidities, microbiology, imaging, surgical indications and outcomes. RESULTS: A total of 143 IE episodes were identified. Median age was 71 years, with a predominance of heterologous material-related infections (81%). Enterococcus faecalis, viridans group streptococci and coagulase-negative staphylococci were the most frequent pathogens. Surgical indication was present in 74% of cases, although surgery was not performed in 22% due to comorbidities or frailty, contributing to a high in-hospital mortality rate. CONCLUSIONS: This study provides a contemporary overview of IE in Portugal, reflecting an elderly, comorbid population and a predominance of prosthetic disease. The results highlight the need for multidisciplinary management and early surgical decisions, supporting the creation of Endocarditis Teams in tertiary centres. FAU - Gomes, Carolina AU - Gomes C AD - Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal. FAU - Abreu, Isabel Gomes AU - Abreu IG AD - Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal. AD - Infectious Diseases Department, Centro Hospitalar Universitario Sao Joao, 4200-319 Porto, Portugal. FAU - Santos, Lurdes AU - Santos L AUID- ORCID: 0000-0002-0622-6823 AD - Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal. AD - Infectious Diseases Department, Centro Hospitalar Universitario Sao Joao, 4200-319 Porto, Portugal. LA - eng PT - Journal Article DEP - 20251225 PL - Switzerland TA - Infect Dis Rep JT - Infectious disease reports JID - 101537203 PMC - PMC12821407 OTO - NOTNLM OT - Enterococcus faecalis OT - Portugal OT - epidemiology OT - infective endocarditis OT - multidisciplinary care OT - prosthetic valve endocarditis COIS- The authors declare no conflicts of interest. EDAT- 2026/01/21 13:00 MHDA- 2026/01/21 13:01 PMCR- 2025/12/25 CRDT- 2026/01/21 09:23 PHST- 2025/10/29 00:00 [received] PHST- 2025/12/17 00:00 [revised] PHST- 2025/12/22 00:00 [accepted] PHST- 2026/01/21 13:01 [medline] PHST- 2026/01/21 13:00 [pubmed] PHST- 2026/01/21 09:23 [entrez] PHST- 2025/12/25 00:00 [pmc-release] AID - idr18010004 [pii] AID - idr-18-00004 [pii] AID - 10.3390/idr18010004 [doi] PST - epublish SO - Infect Dis Rep. 2025 Dec 25;18(1):4. doi: 10.3390/idr18010004. PMID- 41561656 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260121 LR - 20260123 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 18 IP - 1 DP - 2026 Jan TI - Single-Center Experience With Minimally Invasive Approaches From Sternotomy to Thoracoscopy: Assessing the Learning Curve and Benefits. PG - e101766 LID - 10.7759/cureus.101766 [doi] LID - e101766 AB - Background Cardiac surgery is increasingly shifting from traditional full sternotomy (FS) towards minimally invasive cardiac surgery (MICS), driven by evidence of benefits like reduced trauma, faster recovery, and shorter hospital stays. However, the adoption of MICS is hindered by a significant learning curve, technical complexity, and the need for specialized team training and equipment. This study aimed to evaluate the initial outcomes and safety of a newly established MICS program by comparing its first cases with concurrent FS procedures. Results A single-center prospective cohort study was conducted from November 2024 to April 2025, including 98 patients undergoing primary, elective single-valve surgery. Patients were allocated to either the MICS group (n=30), representing the program's initial experience, or the FS group (n=68). The FS group, which had a higher preoperative risk profile and more complex procedures, served as the control. The MICS group demonstrated significantly longer operative and cardiopulmonary bypass times (6.56 vs. 4.87 hours; 122.93 vs. 92.66 minutes, p<0.001). However, MICS patients experienced substantially less blood loss (288.3 vs. 592.7 mL, p<0.001) and lower transfusion requirements. Postoperatively, the MICS group had lower pain scores, faster mobilization (1.23 vs. 2.31 days, p<0.001), shorter hospital stays (6.20 vs. 7.74 days, p=0.004), and a markedly quicker return to normal activity (2.50 vs. 10.49 weeks, p<0.001). A significant increase in phrenic nerve palsy was observed in the MICS group (16.7% vs. 0%, p=0.001). Crucially, there were no significant differences in mortality, stroke, or reoperation for bleeding. Conclusion Despite a clear learning curve, as evidenced by longer procedure times and a higher rate of procedure-specific complications such as phrenic nerve palsy, the initial implementation of a minimally invasive program was safe and conferred significant patient benefits, including enhanced recovery and superior patient-reported outcomes. Prudent patient selection and a structured team-based approach are essential for navigating the learning phase successfully. These findings support the feasibility of establishing such a program without compromising fundamental patient safety. CI - Copyright (c) 2026, Elsayed et al. FAU - Elsayed, Mohamed H AU - Elsayed MH AD - Cardiothoracic Surgery, University of Alexandria, Alexandria, EGY. FAU - Daoud, Ahmed AU - Daoud A AD - Cardiothoracic Surgery, University of Alexandria, Alexandria, EGY. FAU - Hassanein, Wael AU - Hassanein W AD - Cardiothoracic Surgery, University of Alexandria, Alexandria, EGY. FAU - Rayan, Amr A AU - Rayan AA AD - Cardiothoracic Surgery, University of Alexandria, Alexandria, EGY. LA - eng PT - Journal Article DEP - 20260118 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC12813947 OTO - NOTNLM OT - cardiopulmonary bypass OT - full sternotomy OT - surgical replacement of valve OT - transesophageal echo OT - video-assisted thoracoscopic surgery (vats) COIS- Human subjects: Informed consent for treatment and open access publication was obtained or waived by all participants in this study. The Ethics Committee of the University of Alexandria issued approval IRB 00012098. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. EDAT- 2026/01/21 06:30 MHDA- 2026/01/21 06:31 PMCR- 2026/01/18 CRDT- 2026/01/21 05:01 PHST- 2026/01/17 00:00 [accepted] PHST- 2026/01/21 06:31 [medline] PHST- 2026/01/21 06:30 [pubmed] PHST- 2026/01/21 05:01 [entrez] PHST- 2026/01/18 00:00 [pmc-release] AID - 10.7759/cureus.101766 [doi] PST - epublish SO - Cureus. 2026 Jan 18;18(1):e101766. doi: 10.7759/cureus.101766. eCollection 2026 Jan. PMID- 41561487 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260121 LR - 20260123 IS - 2949-9232 (Electronic) IS - 2949-9232 (Linking) VI - 4 DP - 2026 TI - Transition backslide: Patterns of patient reengagement with a pediatric health system after a coordinated transfer to adult care. PG - 100127 LID - 10.1016/j.hctj.2025.100127 [doi] LID - 100127 AB - BACKGROUND: Transition to adult healthcare systems is a complex process for young adults with chronic diseases and/or developmental disabilities. Our pediatric health system (PHS) created a referral-based multidisciplinary transition team (MTT) to support complex transfers, yet some patients continued to reengage post-transfer of care. We aimed to identify these patients, characterize patient-initiated reengagement trends, and assess factors associated with reengagement. METHODS: We conducted a retrospective observational study of patients referred to the MTT between July 1, 2017, and June 30, 2019, who had transitioned from pediatric to adult care providers by June 30, 2020. Data were extracted from the MTT clinical database and electronic health records. RESULTS: Of 73 eligible participants, 63 (86 %) reengaged with the PHS at large after transfer of care, accounting for 540 separate encounters. Reengagement encounters were categorized as anticipated (56 %, n = 302), unanticipated (33 %, n = 181), or specifically with the MTT (11 %, n = 57). Average time to first reengagement encounter differed significantly across groups (p < 0.0001): 28 days (MTT), 53 days (anticipated), and 99 days (unanticipated). No clinical or utilization variables were associated with time to first reengagement in unanticipated encounters or with the MTT. In anticipated encounters, reengagement was associated with prior cardiology care (HR=2.353, p = 0.0494), number of pediatric subspecialty providers (HR=1.01, p = 0.0309), and number of prescribed medications at transition (HR=1.05, p = 0.0477). CONCLUSION: Reengagement with PHS post-transfer of care was common, even among patients transitioning with structured support from our MTT. These findings underscore the need for continued PHS support even after transferring to adult healthcare systems. CI - (c) 2025 The Authors. FAU - Greenberg, Adam AU - Greenberg A AD - Children's Hospital of Philadelphia, 3401 Civic Center Boulevard, Philadelphia, PA 19104, United States. FAU - Schweig, Lorene AU - Schweig L AD - Children's Hospital of Philadelphia, 3401 Civic Center Boulevard, Philadelphia, PA 19104, United States. FAU - Faig, Walter AU - Faig W AD - Children's Hospital of Philadelphia, 3401 Civic Center Boulevard, Philadelphia, PA 19104, United States. FAU - Szalda, Dava AU - Szalda D AD - Children's Hospital of Philadelphia, 3401 Civic Center Boulevard, Philadelphia, PA 19104, United States. AD - Penn Medicine, 3400 Civic Center Boulevard, Philadelphia, PA 19104, United States. FAU - Lebet, Ruth AU - Lebet R AD - Children's Hospital of Philadelphia, 3401 Civic Center Boulevard, Philadelphia, PA 19104, United States. FAU - Froh, Elizabeth B AU - Froh EB AD - Children's Hospital of Philadelphia, 3401 Civic Center Boulevard, Philadelphia, PA 19104, United States. LA - eng PT - Journal Article DEP - 20251218 PL - United States TA - Health Care Transit JT - Health care transitions JID - 9918842988406676 PMC - PMC12813208 OTO - NOTNLM OT - Adult OT - Outcomes OT - Transition OT - Transitional care OT - Young adult COIS- The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/01/21 06:30 MHDA- 2026/01/21 06:31 PMCR- 2025/12/18 CRDT- 2026/01/21 04:59 PHST- 2025/06/30 00:00 [received] PHST- 2025/12/16 00:00 [revised] PHST- 2025/12/17 00:00 [accepted] PHST- 2026/01/21 06:31 [medline] PHST- 2026/01/21 06:30 [pubmed] PHST- 2026/01/21 04:59 [entrez] PHST- 2025/12/18 00:00 [pmc-release] AID - S2949-9232(25)00033-9 [pii] AID - 100127 [pii] AID - 10.1016/j.hctj.2025.100127 [doi] PST - epublish SO - Health Care Transit. 2025 Dec 18;4:100127. doi: 10.1016/j.hctj.2025.100127. eCollection 2026. PMID- 41560490 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260519 LR - 20260813 IS - 1738-5520 (Print) IS - 1738-5555 (Electronic) IS - 1738-5520 (Linking) VI - 56 IP - 5 DP - 2026 May TI - Shared Decision-Making in Chronic Stable Angina and Severe Aortic Stenosis. PG - 363-372 LID - 10.4070/kcj.2025.0261 [doi] AB - Shared decision-making (SDM) is the process that promotes the agreement between treatment choices based on patient values and medical knowledge. For chronic stable angina, this involves facilitating decision-making between percutaneous coronary intervention and guideline-directed medical therapy according to personalized risks and benefits associated with these 2 treatment options. In severe aortic valve stenosis, SDM again comes to play, this time to select between transcatheter aortic valve implantation and surgical aortic valve replacement. The implementation of SDM in South Korea faces challenges, including limited patient involvement and preference for physician-driven decisions. Structural improvements cover multidisciplinary heart team discussion and patient education tools which integrate SDM well into enhancing patient-centered care by addressing these barriers to improve treatment accessibility and outcome in the South Korean healthcare system. CI - Copyright (c) 2026. The Korean Society of Cardiology. FAU - Yoon, Woong Su AU - Yoon WS AUID- ORCID: 0009-0006-3364-5958 AD - Division of Cardiology, Department of Internal Medicine, Regional Cardiocerebrovascular Center, Chungbuk National University Hospital, Cheongju, Korea. FAU - Bae, Jang-Whan AU - Bae JW AUID- ORCID: 0000-0003-1362-9804 AD - Division of Cardiology, Department of Internal Medicine, Good Samsun Hospital, Busan, Korea. drcorazon@hanmail.net. LA - eng PT - Journal Article PT - Review DEP - 20251118 PL - Korea (South) TA - Korean Circ J JT - Korean circulation journal JID - 101247141 PMC - PMC13187506 OTO - NOTNLM OT - Angina, stable OT - Aortic valve stenosis OT - Decision making, shared COIS- The authors have no financial conflicts of interest. EDAT- 2026/01/21 06:31 MHDA- 2026/01/21 06:32 PMCR- 2025/11/18 CRDT- 2026/01/21 02:43 PHST- 2025/06/25 00:00 [received] PHST- 2025/09/28 00:00 [revised] PHST- 2025/10/01 00:00 [accepted] PHST- 2026/01/21 06:32 [medline] PHST- 2026/01/21 06:31 [pubmed] PHST- 2026/01/21 02:43 [entrez] PHST- 2025/11/18 00:00 [pmc-release] AID - 56.e25 [pii] AID - 10.4070/kcj.2025.0261 [doi] PST - ppublish SO - Korean Circ J. 2026 May;56(5):363-372. doi: 10.4070/kcj.2025.0261. Epub 2025 Nov 18. PMID- 41559530 OWN - NLM STAT- MEDLINE DCOM- 20260121 LR - 20260122 IS - 2639-9636 (Print) IS - 2639-9636 (Linking) VI - 41 IP - 1 DP - 2026 Jan 1 TI - Interdisciplinary Approach to Fall Risk Mitigation in an Older Adult with Atrial Fibrillation. PG - 21-33 LID - 10.4140/TCP.n.2026.21 [doi] AB - In this case study, an interdisciplinary team of clinicians, including a clinical pharmacist, cardiologist, and physical therapist, presents an approach to assessing, mitigating, and engaging in shared decision-making for fall risk reduction in an older adult through lifestyle modifications, physical activity, and medication regimen adjustments. This case explores a frequently encountered clinical dilemma: balancing the safe use of oral anticoagulants for stroke prevention in atrial fibrillation (AF) with the risks associated with recurrent falls-an area where shared decision-making is crucial. It also highlights the value of an interdisciplinary team utilizing the Age-Friendly Health Systems 4Ms framework, which focuses on aligning care with what matters most to the older adult. FAU - Pogge, Elizabeth K AU - Pogge EK AD - 1Midwestern University College of Pharmacy, Glendale, Arizona. FAU - Davis, Lindsay E AU - Davis LE AD - 1Midwestern University College of Pharmacy, Glendale, Arizona. FAU - Tuitele, John AU - Tuitele J AD - 3Banner Thunderbird Medical Center, Trauma Injury Prevention Team, Phoenix, Arizona. FAU - Bhatia, Nisha AU - Bhatia N AD - 4Cardiac Solutions, Peoria, Arizona. LA - eng PT - Journal Article PL - United States TA - Sr Care Pharm JT - The Senior care pharmacist JID - 101737969 RN - 0 (Anticoagulants) SB - IM MH - Aged MH - Aged, 80 and over MH - Humans MH - *Accidental Falls/prevention & control MH - Anticoagulants/therapeutic use/administration & dosage/adverse effects MH - *Atrial Fibrillation/drug therapy/complications MH - Decision Making, Shared MH - *Patient Care Team/organization & administration MH - Stroke/prevention & control EDAT- 2026/01/21 01:48 MHDA- 2026/01/21 06:30 CRDT- 2026/01/20 23:37 PHST- 2026/01/21 06:30 [medline] PHST- 2026/01/21 01:48 [pubmed] PHST- 2026/01/20 23:37 [entrez] AID - 10.4140/TCP.n.2026.21 [doi] PST - ppublish SO - Sr Care Pharm. 2026 Jan 1;41(1):21-33. doi: 10.4140/TCP.n.2026.21. PMID- 41558139 OWN - NLM STAT- MEDLINE DCOM- 20260630 LR - 20260630 IS - 1578-8865 (Electronic) IS - 1138-3593 (Linking) VI - 52 IP - 2 DP - 2026 Mar TI - Integrated care for COPD and cardiovascular comorbidities: A multidisciplinary approach for the cardiopulmonary patient. PG - 102678 LID - S1138-3593(25)00231-X [pii] LID - 10.1016/j.semerg.2025.102678 [doi] AB - Chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD) frequently coexist, each increasing the prevalence of the other and worsening their clinical manifestations and prognosis. The common pathophysiological mechanisms, as well as the overlap of certain symptoms and findings in complementary tests, make diagnosis and follow-up of these patients difficult. Therefore, a comprehensive approach to cardiopulmonary risk requires a multidisciplinary approach that prioritises prevention and coordinated care between the different clinical specialties involved. This document, jointly developed by several specialists in pulmonology, cardiology, internal medicine, emergency medicine, and Primary Care belonging to seven medical societies in Spain, with extensive clinical experience in the management of COPD and CVD, proposes practical recommendations and shared care pathways based on an analysis of the available scientific evidence and the clinical experience of the authors, aimed at facilitating decision-making and optimising the management of these patients. CI - Copyright (c) 2026 The Authors. Publicado por Elsevier Espana, S.L.U. All rights reserved. FAU - de Simon Gutierrez, R AU - de Simon Gutierrez R AD - Centro de Salud Luis Vives, Alcala de Henares; Grupo de Trabajo de Respiratorio de SEMERGEN, Madrid, Spain. Electronic address: rasimgu@yahoo.es. FAU - Alcazar Navarrete, B AU - Alcazar Navarrete B AD - Departamento de Medicina, Universidad de Granada; Servicio de Neumologia, Hospital Universitario Virgen de las Nieves; Instituto Biosanitario de Granada (ibs.GRANADA), Granada, Spain. FAU - Alonso Ortiz, M B AU - Alonso Ortiz MB AD - Servicio de Medicina Interna, Hospital Universitario de Gran Canaria Doctor Negrin; Departamento de Ciencias Medicas y Quirurgicas, Universidad de Las Palmas de Gran Canaria; Grupo de Trabajo EPOC de SEMI, Gran Canaria, Spain. FAU - Delgado Jimenez, J F AU - Delgado Jimenez JF AD - Servicio de Cardiologia, Hospital Universitario 12 de Octubre y Fundacion de Investigacion i+12, Madrid, Spain; Centro de Investigacion Biomedica en Red Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain. FAU - Gomez Doblas, J J AU - Gomez Doblas JJ AD - Centro de Investigacion Biomedica en Red Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain; Servicio de Cardiologia, Hospital Universitario Virgen de la Victoria, Malaga, Spain. FAU - Hurtado Garcia, R AU - Hurtado Garcia R AD - Servicio de Medicina Interna, Hospital Universitario Vega Baja de Orihuela, Alicante, Spain. FAU - Lopez Caro, J C AU - Lopez Caro JC AD - Centro de Salud Cotolino, Castro Urdiales; Grupo de Respiratorio en Atencion Primaria, Spain. FAU - Mendez Bailon, M AU - Mendez Bailon M AD - Servicio de Medicina Interna, Hospital Clinico San Carlos, Madrid, Spain. FAU - Nunez Villota, J AU - Nunez Villota J AD - Servicio de Cardiologia, Hospital Clinico Universitario de Valencia, Valencia, Spain. FAU - Pinera Salmeron, P AU - Pinera Salmeron P AD - Servicio de Urgencias, Hospital General Universitario Reina Sofia, Murcia, Spain; Grupo de trabajo de EPOC de SEMES, Spain. FAU - Pulido Herrero, E AU - Pulido Herrero E AD - Servicio de Urgencias, Hospital Galdakao-Usansolo; Instituto de Investigacion Sanitaria Bizkaia; Universidad de Deusto, Vizcaya, Spain. FAU - Rey Aldana, D AU - Rey Aldana D AD - Centro de Salud de A Estrada, Santiago de Compostela, Spain. FAU - Soler-Cataluna, J J AU - Soler-Cataluna JJ AD - Servicio de Neumologia, Hospital Arnau de Vilanova-Lliria; Departamento de Medicina, Universidad de Valencia, Valencia, Spain. FAU - Trigueros Carrero, J A AU - Trigueros Carrero JA AD - Centro de Salud Buenavista; Grupo de Respiratorio de SEMG, Toledo, Spain. FAU - Zamorano Serrano, M J AU - Zamorano Serrano MJ AD - Grupo de trabajo de EPOC de SEMES, Spain; Servicio de Urgencias, Hospital Universitario Ramon y Cajal, Madrid, Spain. FAU - de Miguel-Diez, J AU - de Miguel-Diez J AD - Servicio de Neumologia, Hospital General Universitario Gregorio Maranon; Instituto de Investigacion Sanitaria Gregorio Maranon (IiSGM); Universidad Complutense de Madrid; Grupo de Trabajo de EPOC de SEPAR, Madrid, Spain. LA - eng PT - Journal Article PT - Practice Guideline DEP - 20260119 PL - Spain TA - Semergen JT - Semergen JID - 9610769 SB - IM MH - Humans MH - *Pulmonary Disease, Chronic Obstructive/therapy/physiopathology/complications MH - *Cardiovascular Diseases/therapy/physiopathology/epidemiology/complications MH - *Patient Care Team/organization & administration MH - Delivery of Health Care, Integrated/organization & administration MH - Spain MH - Comorbidity MH - Prognosis OTO - NOTNLM OT - Atencion multidisciplinar OT - Cardiopulmonary risk OT - Cardiovascular disease OT - Chronic obstructive pulmonary disease OT - Clinical recommendations OT - Enfermedad cardiovascular OT - Enfermedad pulmonar obstructiva cronica OT - Multidisciplinary care OT - Recomendaciones clinicas OT - Riesgo cardiopulmonar EDAT- 2026/01/21 01:48 MHDA- 2026/03/08 01:38 CRDT- 2026/01/20 18:02 PHST- 2025/10/15 00:00 [received] PHST- 2025/11/14 00:00 [revised] PHST- 2025/11/22 00:00 [accepted] PHST- 2026/03/08 01:38 [medline] PHST- 2026/01/21 01:48 [pubmed] PHST- 2026/01/20 18:02 [entrez] AID - S1138-3593(25)00231-X [pii] AID - 10.1016/j.semerg.2025.102678 [doi] PST - ppublish SO - Semergen. 2026 Mar;52(2):102678. doi: 10.1016/j.semerg.2025.102678. Epub 2026 Jan 19. PMID- 41555499 OWN - NLM STAT- MEDLINE DCOM- 20260630 LR - 20260828 IS - 1873-734X (Electronic) IS - 1010-7940 (Linking) VI - 68 IP - 1 DP - 2026 Jan 6 TI - Major Vascular Complications After Percutaneous Transfemoral Approach for Transcatheter Aortic Valve Implantation in Propensity-Matched Cohort: Impact on Clinical Outcomes and Survival. LID - ezag035 [pii] LID - 10.1093/ejcts/ezag035 [doi] AB - OBJECTIVES: Transfemoral transcatheter aortic valve implantation (TAVI) has become the preferred approach for treating aortic stenosis in patients over 70 years. Despite advancements in technology and operator experience, major vascular complications (MVCs) remain a concern, potentially affecting outcomes. This study aimed to assess the incidence, risk factors, and clinical impact of MVCs following transfemoral TAVI using propensity score matching. METHODS: We retrospectively analysed patients who underwent transfemoral TAVI. Patients were divided into 2 groups: patients who developed MVCs (MVC group) and those who did not present the complication (No-MVC group). The primary end-point was the 30-day mortality. A 1:1 propensity score matching was performed, and clinical outcomes were compared at 30 days and up to 2 years. RESULTS: Between 2012 to 2023, a total of 2296 underwent a percutaneous-transfemoral approach. Major vascular complications occurred in 6.6% (n = 151) and were associated with increased transfusion requirement, major bleeding, reinterventions, and longer hospital stays. Female sex, obesity, higher STS score, use of the Manta closure device, and post-implantation balloon valvuloplasty were independently associated with MVCs. The 30-day mortality was similar between groups (P = .723). The long-term survival was lower in the MVC group (P = .016). Two-year survival after propensity score matching did not differ between groups (P = .08). CONCLUSIONS: Major vascular complications after transfemoral transcatheter valve implantation are associated with worse clinical outcomes and reduced long-term survival despite similar at 30-day mortality. Recognizing high-risk patients, optimizing procedural planning, and considering alternative access routes may help reduce vascular complications. CI - (c) The Author(s) 2026. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com. FAU - Eid, Maroua AU - Eid M AUID- ORCID: 0000-0001-5433-2607 AD - Department of Cardiothoracic and Vascular Surgery, University Hospital of Angers, 4 rue Larrey, Angers, 49933, France. AD - Mitovasc Institute INSERM U1083 UMR-CNRS 6214, University Hospital of Angers, 3 rue Roger Amsler, Angers, 49055, France. FAU - Ducroix, Antoine AU - Ducroix A AD - Department of Cardiothoracic and Vascular Surgery, University Hospital of Angers, 4 rue Larrey, Angers, 49933, France. AD - Mitovasc Institute INSERM U1083 UMR-CNRS 6214, University Hospital of Angers, 3 rue Roger Amsler, Angers, 49055, France. FAU - Dang Van, Simon AU - Dang Van S AD - Department of Cardiothoracic and Vascular Surgery, University Hospital of Angers, 4 rue Larrey, Angers, 49933, France. AD - Mitovasc Institute INSERM U1083 UMR-CNRS 6214, University Hospital of Angers, 3 rue Roger Amsler, Angers, 49055, France. AD - Department of Medico-Surgical Heart Valve Disease, University Hospital of Angers, 4 rue Larrey, Angers, 49933, France. FAU - Ammi, Myriam AU - Ammi M AD - Department of Cardiothoracic and Vascular Surgery, University Hospital of Angers, 4 rue Larrey, Angers, 49933, France. FAU - Rineau, Emmanuel AU - Rineau E AUID- ORCID: 0000-0003-1293-1120 AD - Mitovasc Institute INSERM U1083 UMR-CNRS 6214, University Hospital of Angers, 3 rue Roger Amsler, Angers, 49055, France. AD - Department of Anesthesiology, University Hospital of Angers, 4 rue Larrey, Angers, 49933, France. FAU - Binuani, Patrice AU - Binuani P AD - Department of Cardiothoracic and Vascular Surgery, University Hospital of Angers, 4 rue Larrey, Angers, 49933, France. FAU - Benard, Thomas AU - Benard T AD - Department of Medico-Surgical Heart Valve Disease, University Hospital of Angers, 4 rue Larrey, Angers, 49933, France. AD - Department of Cardiology, University Hospital of Angers, 4 rue Larrey, Angers, 49933, France. FAU - Delepine, Stephane AU - Delepine S AD - Department of Medico-Surgical Heart Valve Disease, University Hospital of Angers, 4 rue Larrey, Angers, 49933, France. AD - Department of Cardiology, University Hospital of Angers, 4 rue Larrey, Angers, 49933, France. FAU - Chausseret, Laurence AU - Chausseret L AD - Department of Anesthesiology, University Hospital of Angers, 4 rue Larrey, Angers, 49933, France. FAU - Rouleau, Frederic AU - Rouleau F AD - Department of Medico-Surgical Heart Valve Disease, University Hospital of Angers, 4 rue Larrey, Angers, 49933, France. AD - Department of Cardiology, University Hospital of Angers, 4 rue Larrey, Angers, 49933, France. FAU - Picquet, Jean AU - Picquet J AD - Department of Cardiothoracic and Vascular Surgery, University Hospital of Angers, 4 rue Larrey, Angers, 49933, France. FAU - Baufreton, Christophe AU - Baufreton C AUID- ORCID: 0000-0002-4176-3739 AD - Department of Cardiothoracic and Vascular Surgery, University Hospital of Angers, 4 rue Larrey, Angers, 49933, France. AD - Mitovasc Institute INSERM U1083 UMR-CNRS 6214, University Hospital of Angers, 3 rue Roger Amsler, Angers, 49055, France. FAU - Pinaud, Frederic AU - Pinaud F AD - Department of Cardiothoracic and Vascular Surgery, University Hospital of Angers, 4 rue Larrey, Angers, 49933, France. AD - Department of Medico-Surgical Heart Valve Disease, University Hospital of Angers, 4 rue Larrey, Angers, 49933, France. FAU - Fouquet, Olivier AU - Fouquet O AUID- ORCID: 0000-0001-9191-9095 AD - Department of Cardiothoracic and Vascular Surgery, University Hospital of Angers, 4 rue Larrey, Angers, 49933, France. AD - Mitovasc Institute INSERM U1083 UMR-CNRS 6214, University Hospital of Angers, 3 rue Roger Amsler, Angers, 49055, France. AD - Department of Medico-Surgical Heart Valve Disease, University Hospital of Angers, 4 rue Larrey, Angers, 49933, France. LA - eng PT - Journal Article PL - Germany TA - Eur J Cardiothorac Surg JT - European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery JID - 8804069 SB - IM MH - Humans MH - Female MH - *Transcatheter Aortic Valve Replacement/adverse effects/mortality/methods MH - Male MH - Retrospective Studies MH - Propensity Score MH - Aged, 80 and over MH - Femoral Artery/surgery MH - *Aortic Valve Stenosis/surgery/mortality MH - *Postoperative Complications/epidemiology/mortality MH - Treatment Outcome MH - Risk Factors MH - Aged OTO - NOTNLM OT - Heart Team OT - TAVI OT - femoral access OT - transcatheter aortic valve implantation OT - vascular complications EDAT- 2026/01/20 07:44 MHDA- 2026/01/30 00:55 CRDT- 2026/01/20 00:11 PHST- 2025/08/21 00:00 [received] PHST- 2025/11/12 00:00 [revised] PHST- 2026/01/06 00:00 [accepted] PHST- 2026/01/30 00:55 [medline] PHST- 2026/01/20 07:44 [pubmed] PHST- 2026/01/20 00:11 [entrez] AID - 8430296 [pii] AID - 10.1093/ejcts/ezag035 [doi] PST - ppublish SO - Eur J Cardiothorac Surg. 2026 Jan 6;68(1):ezag035. doi: 10.1093/ejcts/ezag035. PMID- 41555291 OWN - NLM STAT- MEDLINE DCOM- 20260627 LR - 20260926 IS - 1472-6963 (Electronic) IS - 1472-6963 (Linking) VI - 26 IP - 1 DP - 2026 Jan 19 TI - Does multidisciplinary disease management program lower hospitalization and mortality among patients with heart failure? A systematic review and meta-analysis of randomized controlled trials. PG - 226 LID - 10.1186/s12913-026-14021-3 [doi] LID - 226 AB - BACKGROUND: As the burden of Heart failure (HF) continues to rise, effective management strategies are essential. Multidisciplinary disease management programs (DMPs) have been recommended as a promising approach to improving clinical outcomes. The aim of this study was to evaluate the effectiveness of multidisciplinary DMPs in terms of HF mortality, all-cause mortality, HF admissions, and all-cause admissions, compared to usual care. METHODS: This systematic review and meta-analysis adhered to PRISMA guidelines. A comprehensive search was conducted from January 1990 to December 2025 in databases and trial registries, including ClinicalTrials.gov, the WHO International Clinical Trial Registry Platform, Web of Science, MEDLINE, Embase, and Cochrane. Randomized controlled trials comparing DMPs to usual care were included. Outcomes assessed were HF readmissions, all-cause readmissions, HF mortality, and all-cause mortality. The risk of bias was evaluated using the Cochrane Risk of Bias (ROB 2) tool. A random-effects model was used due to significant heterogeneity, and a fixed-effect model was applied in sensitivity and subgroup analyses. The GRADE framework was used to assess the certainty of the evidence. RESULTS: The analysis included 32 studies involving 9,934 participants (5,145 in the intervention group and 4,789 in the control group). DMPs may reduce HF readmissions (RR 0.76, 95% CI 0.66-0.88; I(2) = 59%; NNT = 16) and all-cause readmissions (RR 0.88, 95% CI 0.81-0.96; I(2) = 55%; NNT = 18). DMPs may also reduce all-cause mortality (RR 0.82, 95% CI 0.73-0.92; I(2) = 33%; NNT = 26) %). Limited data suggested a possible reduction in HF mortality. Certainty of evidence was rated as very low for HF readmissions, low for all-cause readmissions, very low for all-cause mortality, and low for HF mortality. Subgroup analyses revealed that clinic-based DMPs had the highest mortality benefit, although home-based and telemedicine-supported DMPs were more successful in reducing readmissions. Effects were consistent for both short-term ( 6 months) follow-up. Single-center trials produced greater impacts than multicenter trials. CONCLUSION: Multidisciplinary HF-DMPs reduce HF and all-cause readmissions while improving all-cause mortality, especially in clinic-based settings. Evidence for HF mortality reduction remains limited and should be interpreted with caution. DMP design, delivery procedure, and trial setting all impact effectiveness, emphasizing the necessity of tailored DMP implementation to the healthcare system. These findings support incorporating DMPs into standard care to enhance outcomes. Further rigorous studies are recommended to confirm and refine these results. TRIAL REGISTRATION: PROSPERO CRD42023464413. FAU - Hajaj, Ahmad AU - Hajaj A AD - QU Health, Qatar University, Doha, Qatar. FAU - Abdel-Rahman, Manar E AU - Abdel-Rahman ME AD - College of Health Sciences, QU Health, Qatar University, Doha, Qatar. FAU - Abdul Hadi, Muhammad AU - Abdul Hadi M AD - College of Pharmacy, QU Health, Qatar University, Doha, Qatar. FAU - Badr, Amr AU - Badr A AD - Heart Failure Clinics, Heart Hospital, Hamad Medical Corporation, Doha, Qatar. FAU - Turk-Adawi, Karam AU - Turk-Adawi K AUID- ORCID: 0000-0002-4162-7761 AD - College of Health Sciences, QU Health, Qatar University, Doha, Qatar. kadawi@qu.edu.qa. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20260119 PL - England TA - BMC Health Serv Res JT - BMC health services research JID - 101088677 SB - IM MH - Humans MH - *Heart Failure/mortality/therapy MH - Randomized Controlled Trials as Topic MH - *Hospitalization/statistics & numerical data MH - *Disease Management MH - Patient Readmission/statistics & numerical data MH - *Patient Care Team/organization & administration PMC - PMC12896042 OTO - NOTNLM OT - Disease management OT - Heart failure OT - Mortality OT - Patient care team OT - Patient readmission OT - Therapeutics COIS- Declarations. Ethics approval and consent to participate: Not applicable, as this study is a systematic review and meta-analysis based on previously published studies. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2026/01/20 00:37 MHDA- 2026/06/27 18:39 PMCR- 2026/01/19 CRDT- 2026/01/19 23:57 PHST- 2025/07/05 00:00 [received] PHST- 2026/01/06 00:00 [accepted] PHST- 2026/06/27 18:39 [medline] PHST- 2026/01/20 00:37 [pubmed] PHST- 2026/01/19 23:57 [entrez] PHST- 2026/01/19 00:00 [pmc-release] AID - 10.1186/s12913-026-14021-3 [pii] AID - 14021 [pii] AID - 10.1186/s12913-026-14021-3 [doi] PST - epublish SO - BMC Health Serv Res. 2026 Jan 19;26(1):226. doi: 10.1186/s12913-026-14021-3. PMID- 41550328 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260119 LR - 20260121 IS - 2048-0040 (Print) IS - 2048-0040 (Electronic) IS - 2048-0040 (Linking) VI - 15 DP - 2026 Jan-Dec TI - What work-up do we need for women with congenital heart disease in the 21st century for the preparation of pregnancy? PG - 20480040251404532 LID - 10.1177/20480040251404532 [doi] LID - 20480040251404532 AB - Pregnancy poses significant risks for women with congenital heart disease (CHD) due to major cardiovascular changes that can lead to complications which increases the morbidity and mortality rate in these patients. CHD is the leading cause of pregnancy-related deaths in the United States. In this review, we present the steps required to reduce these risks. We cover the changes to the maternal cardiovascular system that occur in pregnancy, and how they can significantly impact the cardiac patient where the disease may lead to poor adaptation in pregnancy. We discuss the epidemiology of this growing challenge and analyse the available the risk stratification models necessary to recognise and mitigate the chance of maternal cardiovascular complications arising in pregnancy. We follow on to discuss the necessity of pre-pregnancy counselling, which is often missed, but allows the potential mother to have a full conversation regarding the implication of pregnancy on her and her baby. We highlight the need to cover topics such as contraception, medication, subfertility, and maternal and fetal risk. Finally, we discuss the need of a pregnancy heart team; what specialist should be involved in the care of these high-risk women and where antenatal and delivery care should take place. CI - (c) The Author(s) 2026. FAU - Bakalis, Spyros AU - Bakalis S AUID- ORCID: 0000-0002-6285-3346 AD - Department of Obstetrics, Fetal and Maternal Medicine, St Thomas Hospital, London, UK. RINGGOLD: 8945 FAU - Douglas, Hannah AU - Douglas H AD - Department of Adult Congenital Heart Disease, St Thomas Hospital, London, UK. RINGGOLD: 8945 LA - eng PT - Journal Article PT - Review DEP - 20260116 PL - England TA - JRSM Cardiovasc Dis JT - JRSM cardiovascular disease JID - 101598607 PMC - PMC12811563 OTO - NOTNLM OT - Pregnancy OT - cardiology OT - cardiovascular (CV) surgery OT - paediatric and congenital heart disease' including cardiovascular surgery OT - pre-pregnancy counselling OT - pregnancy heart team COIS- The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2026/01/19 12:51 MHDA- 2026/01/19 12:52 PMCR- 2026/01/16 CRDT- 2026/01/19 06:06 PHST- 2025/03/07 00:00 [received] PHST- 2025/11/10 00:00 [revised] PHST- 2025/11/17 00:00 [accepted] PHST- 2026/01/19 12:52 [medline] PHST- 2026/01/19 12:51 [pubmed] PHST- 2026/01/19 06:06 [entrez] PHST- 2026/01/16 00:00 [pmc-release] AID - 10.1177_20480040251404532 [pii] AID - 10.1177/20480040251404532 [doi] PST - epublish SO - JRSM Cardiovasc Dis. 2026 Jan 16;15:20480040251404532. doi: 10.1177/20480040251404532. eCollection 2026 Jan-Dec. PMID- 41548909 OWN - NLM STAT- MEDLINE DCOM- 20260626 LR - 20260626 IS - 1349-3299 (Electronic) IS - 1349-2365 (Linking) VI - 67 IP - 1 DP - 2026 Jan 31 TI - Impact of Multidisciplinary Interventions on the Enhancement of Guideline-Directed Medical Therapy and Clinical Education in Hospitalized Heart Failure Patients. PG - 53-60 LID - 10.1536/ihj.25-490 [doi] AB - Although the efficacy of quadruple therapy-including angiotensin receptor neprilysin inhibitor-in patients with heart failure is well established, the impact of multidisciplinary interventions on its implementation in real-world clinical practice remains unclear.We retrospectively included 90 patients who received multidisciplinary intervention between April 2023 and March 2024 and 94 patients who received conventional care between April 2020 and March 2021. In the multidisciplinary care group, a standardized heart failure checklist was used to confirm the optimization of heart failure treatment. The rates of nutritional counseling, medication education, and rehabilitation introduction, as well as the implementation rate of quadruple therapy during hospitalization for heart failure, were compared between the groups.The mean age of patients was 75.7 years; 58.6% were male, and 45.3% had their first heart failure hospitalization. Background characteristics were not significantly different between the groups. The implementation rates for nutritional instruction, medication instruction, and rehabilitation were 51.2%, 72.0%, and 88.9% in the multidisciplinary intervention group, which were significantly higher than those in the conventional care group (26.3%, 49.5%, and 54.3%, respectively) (all P < 0.001). The rate of quadruple therapy implementation was higher (74.4%) compared to the conventional care group (30.6%) among the individuals with reduced ejection fraction (P < 0.001).In carefully-selected hospitalized patients with heart failure, multidisciplinary intervention was associated with increased utilization of evidence-based therapies, including quadruple therapy, highlighting its potential to enhance the quality of care in real-world clinical settings. FAU - Onoda, Hiroshi AU - Onoda H AD - Second Department of Internal Medicine, University of Toyama. FAU - Imamura, Teruhiko AU - Imamura T AD - Second Department of Internal Medicine, University of Toyama. FAU - Ushijima, Ryuichi AU - Ushijima R AD - Second Department of Internal Medicine, University of Toyama. FAU - Kinugawa, Koichiro AU - Kinugawa K AD - Second Department of Internal Medicine, University of Toyama. LA - eng PT - Journal Article DEP - 20260117 PL - Japan TA - Int Heart J JT - International heart journal JID - 101244240 RN - 0 (Angiotensin Receptor Antagonists) SB - IM MH - Humans MH - *Heart Failure/therapy/drug therapy MH - Male MH - Aged MH - Female MH - Retrospective Studies MH - Hospitalization MH - Aged, 80 and over MH - *Patient Education as Topic MH - Angiotensin Receptor Antagonists/therapeutic use MH - Practice Guidelines as Topic MH - Adherence Interventions MH - Guideline Adherence MH - Patient Care Team OTO - NOTNLM OT - Heart failure check list OT - Medication OT - Quadruple therapy EDAT- 2026/01/19 01:03 MHDA- 2026/02/02 00:29 CRDT- 2026/01/18 20:13 PHST- 2026/02/02 00:29 [medline] PHST- 2026/01/19 01:03 [pubmed] PHST- 2026/01/18 20:13 [entrez] AID - 10.1536/ihj.25-490 [doi] PST - ppublish SO - Int Heart J. 2026 Jan 31;67(1):53-60. doi: 10.1536/ihj.25-490. Epub 2026 Jan 17. PMID- 41548860 OWN - NLM STAT- MEDLINE DCOM- 20260626 LR - 20260714 IS - 1879-1913 (Electronic) IS - 0002-9149 (Linking) VI - 264 DP - 2026 Apr 1 TI - Real-World Suitability of Patients for Transcatheter Tricuspid Valve Replacement. PG - 1-6 LID - S0002-9149(26)00009-3 [pii] LID - 10.1016/j.amjcard.2026.01.002 [doi] AB - Transcatheter tricuspid valve replacement (TTVR) has shown therapeutic promise for patients with severe tricuspid regurgitation (TR). However, some patients may not be eligible due to anatomic limitations. We sought to describe the outcomes of patients who were referred for transcatheter tricuspid valve intervention (TTVI) and were ineligible for TTVR. This was a single-center, retrospective study of 251 patients referred for TTVI from February 2024 to August 2025. All patients were considered by a multidisciplinary heart team and assessed for feasibility of commercial tricuspid valve repair or replacement, with a strategy to proceed with replacement if anatomically feasible. Data on demographics, clinical characteristics, and outcomes were collected from medical records. Of 251 patients evaluated, 43 (17.1%) were unsuitable for TTVR. Compared with suitable patients, unsuitable patients were more frequently male (67.4% vs 33.2%, p <0.01) and more likely to have implanted electronic device (53.5% vs 32.2%, p = 0.01) or prior tricuspid interventions (7.9% vs 1.6%, p = 0.03). The leading reason for unsuitability was large annular dimensions (60.5%), followed by leaflet tethering (14.0%) and small annular size (11.6%). Of the unsuitable cohort, 10 patients (23.3%) underwent T-TEER and 33 (76.7%) received medical therapy alone. T-TEER resulted in significant reduction in TR severity (p = 0.034), though 80% had residual moderate or greater TR. In conclusion, this commercial experience, rates of TTVR ineligibility were lower than previously described with large annular dimensions serving as the most frequent exclusion criterion. For those ineligible, T-TEER may provide a feasible approach in appropriately selected patients. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Andrews, Tyler AU - Andrews T AD - Division of Cardiovascular Medicine, Henry Ford Hospital, Detroit, Michigan; College of Human Medicine, Michigan State University, East Lansing, Michigan. FAU - Patel, Ritik AU - Patel R AD - Department of Medicine, Wayne State University School of Medicine, Detroit, Michigan. FAU - Jaigirdar, Muhtasim AU - Jaigirdar M AD - Division of Cardiovascular Medicine, Henry Ford Hospital, Detroit, Michigan; College of Human Medicine, Michigan State University, East Lansing, Michigan. FAU - Gonzalez, PedroEngel AU - Gonzalez P AD - Division of Cardiovascular Medicine, Henry Ford Hospital, Detroit, Michigan; College of Human Medicine, Michigan State University, East Lansing, Michigan. FAU - Apostolou, Dimitrios AU - Apostolou D AD - Division of Cardiothoracic Surgery, Henry Ford Hospital, Detroit, Michigan. FAU - Lee, James AU - Lee J AD - Division of Cardiovascular Medicine, Henry Ford Hospital, Detroit, Michigan; College of Human Medicine, Michigan State University, East Lansing, Michigan. FAU - Dawdy, John AU - Dawdy J AD - Division of Cardiovascular Medicine, Henry Ford Hospital, Detroit, Michigan; College of Human Medicine, Michigan State University, East Lansing, Michigan. FAU - Zweig, Bryan AU - Zweig B AD - Division of Cardiovascular Medicine, Henry Ford Hospital, Detroit, Michigan; College of Human Medicine, Michigan State University, East Lansing, Michigan. FAU - Alnajjar, Raed AU - Alnajjar R AD - Division of Cardiothoracic Surgery, Henry Ford Hospital, Detroit, Michigan. FAU - Frisoli, Tiberio M AU - Frisoli TM AD - Division of Cardiovascular Medicine, Henry Ford Hospital, Detroit, Michigan; College of Human Medicine, Michigan State University, East Lansing, Michigan. FAU - Villablanca, Pedro AU - Villablanca P AD - Division of Cardiovascular Medicine, Henry Ford Hospital, Detroit, Michigan; College of Human Medicine, Michigan State University, East Lansing, Michigan. FAU - O'Neill, Brian P AU - O'Neill BP AD - Division of Cardiovascular Medicine, Henry Ford Hospital, Detroit, Michigan; College of Human Medicine, Michigan State University, East Lansing, Michigan. Electronic address: boneil3@hfhs.org. LA - eng PT - Journal Article DEP - 20260116 PL - United States TA - Am J Cardiol JT - The American journal of cardiology JID - 0207277 SB - IM MH - Humans MH - *Tricuspid Valve Insufficiency/surgery/diagnosis MH - Retrospective Studies MH - *Heart Valve Prosthesis Implantation/methods MH - Male MH - Female MH - *Tricuspid Valve/surgery/diagnostic imaging MH - *Cardiac Catheterization/methods MH - *Patient Selection MH - Aged MH - *Heart Valve Prosthesis MH - Aged, 80 and over OTO - NOTNLM OT - Evoque OT - TTVR OT - TriClip OT - Tricuspid regurgitation COIS- Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Brian O'Neill reports a relationship with Edwards Lifesciences Corporation that includes: consulting or advisory. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/01/19 01:03 MHDA- 2026/03/12 07:03 CRDT- 2026/01/18 19:13 PHST- 2025/10/07 00:00 [received] PHST- 2026/01/06 00:00 [revised] PHST- 2026/01/12 00:00 [accepted] PHST- 2026/03/12 07:03 [medline] PHST- 2026/01/19 01:03 [pubmed] PHST- 2026/01/18 19:13 [entrez] AID - S0002-9149(26)00009-3 [pii] AID - 10.1016/j.amjcard.2026.01.002 [doi] PST - ppublish SO - Am J Cardiol. 2026 Apr 1;264:1-6. doi: 10.1016/j.amjcard.2026.01.002. Epub 2026 Jan 16. PMID- 41544922 OWN - NLM STAT- MEDLINE DCOM- 20260623 LR - 20260707 IS - 1552-6259 (Electronic) IS - 0003-4975 (Linking) VI - 122 IP - 1 DP - 2026 Jul TI - Temporary Mechanical Circulatory Support and Shock Teams in High-Risk Cardiac Surgery: The Strategic Evolution of Protected Cardiac Surgery. PG - 22-32 LID - S0003-4975(26)00011-1 [pii] LID - 10.1016/j.athoracsur.2025.12.032 [doi] AB - BACKGROUND: Protected cardiac surgery is a proactive strategy that applies temporary mechanical circulatory support to prevent perioperative low cardiac output syndrome in high-risk cardiac surgery. Rather than escalating vasoactive agents after hemodynamic decline, the approach emphasizes early identification of physiologic vulnerability and timely initiation of support. METHODS: We conducted a structured literature review of peer-reviewed studies published from 2000 to 2024 on temporary mechanical circulatory support in adult cardiac surgery. There were 52 studies selected based on relevance to early or prophylactic support, timing of initiation, risk stratification, and systems of care. Clinical insights from multidisciplinary experts also informed the review framework. RESULTS: Inotropic escalation after hemodynamic deterioration is consistently associated with poor outcomes. High pharmacologic requirements and severe metabolic derangements predict very high mortality, whereas conventional risk scores often fail to identify vulnerable patients. In contrast, early initiation of mechanical support has been associated with lower in-hospital mortality, reduced dependence on vasoactive agents, and improved recovery. Physiologic markers, such as filling pressures and lactate levels, may provide earlier signals of circulatory decline. Effective implementation also requires institutional coordination, team-based planning, and regional referral systems. CONCLUSIONS: Protected cardiac surgery reframes success in high-risk cardiac surgery by focusing on recovery rather than survival alone. It integrates physiology-guided support with structured planning and system-level readiness to improve outcomes in vulnerable surgical populations. CI - Copyright (c) 2026. Published by Elsevier Inc. FAU - Salazar, Leonardo AU - Salazar L AD - Cardio Thoracic Surgery Department, Heart and Vascular Centre, Maastricht University Medical Centre (MUMC+), Maastricht, the Netherlands; The Cardiovascular Research Institute Maastricht (CARIM), Maastricht, the Netherlands; Fundacion Cardiovascular de Colombia, Bucaramanga, Colombia. FAU - Nersesian, Gaik AU - Nersesian G AD - Cardiac Surgery Unit, German Heart Center Charite, Berlin, Germany. FAU - Meani, Paolo AU - Meani P AD - Cardio Thoracic Surgery Department, Heart and Vascular Centre, Maastricht University Medical Centre (MUMC+), Maastricht, the Netherlands; The Cardiovascular Research Institute Maastricht (CARIM), Maastricht, the Netherlands; Intensive Care Unit, Fondazione Ca' Granda, Policlinico Hospital, University of Milan, Milan, Italy. FAU - Bari, Gabor AU - Bari G AD - Cardio Thoracic Surgery Department, Heart and Vascular Centre, Maastricht University Medical Centre (MUMC+), Maastricht, the Netherlands; The Cardiovascular Research Institute Maastricht (CARIM), Maastricht, the Netherlands; Cardiac Surgery Unit, University of Szeged, Szeged, Hungary. FAU - Mariani, Silvia AU - Mariani S AD - Cardio Thoracic Surgery Department, Heart and Vascular Centre, Maastricht University Medical Centre (MUMC+), Maastricht, the Netherlands; The Cardiovascular Research Institute Maastricht (CARIM), Maastricht, the Netherlands; Cardiac Surgery Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, S. Gerardo dei Tintori, Monza, Italy. FAU - Potapov, Evgenij AU - Potapov E AD - Cardiac Surgery Unit, German Heart Center Charite, Berlin, Germany. FAU - Di Mauro, Michele AU - Di Mauro M AD - Cardio Thoracic Surgery Department, Heart and Vascular Centre, Maastricht University Medical Centre (MUMC+), Maastricht, the Netherlands; The Cardiovascular Research Institute Maastricht (CARIM), Maastricht, the Netherlands. FAU - Gelsomino, Sandro AU - Gelsomino S AD - Cardio Thoracic Surgery Department, Heart and Vascular Centre, Maastricht University Medical Centre (MUMC+), Maastricht, the Netherlands; The Cardiovascular Research Institute Maastricht (CARIM), Maastricht, the Netherlands. FAU - Milojevic, Milan AU - Milojevic M AD - Dedinje Cardiovascular Institute, Belgrade, Serbia; Department of Cardiac Surgery, University Hospital Zurich, Switzerland. FAU - Schmack, Bastian AU - Schmack B AD - Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany. FAU - Stein, Louis AU - Stein L AD - Cardiac Surgery Department, RWJ Barnabas Health at Newark Beth Israel Medical Center, Newark, New Jersey. FAU - Zimpfer, Daniel AU - Zimpfer D AD - Cardiac Surgery Department, Medical University, Vienna, Austria. FAU - Wiedemann, Dominik AU - Wiedemann D AD - Cardiac Surgery Department, Universitatsklinikum St. Polten, St. Polten, Austria. FAU - Soltetz, Edward AU - Soltetz E AD - Thoracic and Cardiovascular Surgery Department, Cleveland Clinic, Cleveland, Ohio. FAU - Bermudez, Christian AU - Bermudez C AD - Cardiothoracic Surgery Department, University of Pennsylvania Hospital, Philadelphia, Pennsylvania. FAU - Haft, Jonathan AU - Haft J AD - Department of Cardiac Surgery, University of Michigan, Ann Arbor, Michigan. FAU - Moreno, Pedro AU - Moreno P AD - Department of Medicine/Cardiology, The Zena and Michael A. Weiner Cardiovascular Institute and the Marie-Josee and Henry R. Kravis Cardiovascular Health Center, Icahn School of Medicine at Mount Sinai, New York, New York. FAU - Tonna, Joseph AU - Tonna J AD - Cardiothoracic Critical Care, University of Utah School of Medicine, Salt Lake City, Utah. FAU - Takayama, Hiroo AU - Takayama H AD - Department of Cardiac Surgery, NewYork-Presbyterian/Columbia University Irving Medical Center, New York, New York. FAU - Lamarche, Yoan AU - Lamarche Y AD - Cardiovascular Critical Care, Hopital du Sacre-Coeur de Montreal, University of Montreal, Montreal Heart Institute, Montreal, Quebec, Canada. FAU - Rao, Vivek AU - Rao V AD - Cardiovascular Surgery Department, Toronto General Hospital, Toronto, Ontario, Canada. FAU - Faerber, Gloria AU - Faerber G AD - Cardiac Surgery Department, Universitatsklinikum, University of Saarland, Homburg, Germany. FAU - Meyns, Bart AU - Meyns B AD - Cardiac Surgery Department, Gasthuisberg University Hospital, Leuven, Belgium. FAU - Takeda, Koji AU - Takeda K AD - Department of Cardiac Surgery, NewYork-Presbyterian/Columbia University Irving Medical Center, New York, New York. FAU - Boeken, Udo AU - Boeken U AD - Cardiac Surgery Department, Uniklinik Dusseldorf, Heinrich Heine University, Dusseldorf, Germany. FAU - MacLaren, Graeme AU - MacLaren G AD - Cardiothoracic Surgery Intensive Care Unit, National University Hospital, Singapore. FAU - Whitman, Glenn AU - Whitman G AD - Cardiac Intensive Care Unit, Johns Hopkins Hospital, Baltimore, Maryland. FAU - Patel, Bhavesh AU - Patel B AD - Department of Critical Care Medicine, Mayo Clinic, Phoenix, Arizona. FAU - Silvestry, Scott AU - Silvestry S AD - Division of Cardiothoracic Surgery, University of Arizona College of Medicine, Tucson, Arizona. FAU - Goldstein, Daniel J AU - Goldstein DJ AD - Department of Cardiovascular and Thoracic Surgery, Montefiore Medical Center, New York, New York. FAU - Arora, Rakesh C AU - Arora RC AD - Harrington Heart and Vascular Institute, University Hospitals, Cleveland, Ohio. FAU - Engelman, Daniel T AU - Engelman DT AD - Heart & Vascular Program, Baystate Health, University of Massachusetts Medical School-Baystate, Springfield, Massachusetts. FAU - Lorusso, Roberto AU - Lorusso R AD - Cardio Thoracic Surgery Department, Heart and Vascular Centre, Maastricht University Medical Centre (MUMC+), Maastricht, the Netherlands; The Cardiovascular Research Institute Maastricht (CARIM), Maastricht, the Netherlands. Electronic address: roberto.lorussobs@gmail.com. LA - eng PT - Journal Article PT - Review DEP - 20260114 PL - Netherlands TA - Ann Thorac Surg JT - The Annals of thoracic surgery JID - 15030100R SB - IM MH - Humans MH - *Cardiac Surgical Procedures/methods/adverse effects MH - *Cardiac Output, Low/prevention & control/etiology MH - Risk Assessment MH - *Heart-Assist Devices COIS- Disclosures Rakesh C. Arora reports receiving consulting fees for serving on advisory boards for Alexion, Renibus Therapeutics Inc, HLS Therapeutics Inc, and Edwards LifeSciences. Rakesh C. Arora reports participation as a DSMB member on the SCOPE Trial and IDMC member on the DECIDE Trial. Rakesh C. Arora reports being an Executive Board Member on ERAS Cardiac Surgery and Past President for the Canadian Society of Cardiac Surgeons. Rakesh C. Arora reports being the Chair of the STS Workforce on Critical Care. Daniel T. Engelman reports consulting fees from Edwards Lifesciences Transcatheter Valves for sitting on the Device Safety Monitoring Board. Daniel T. Engelman reports consulting fees from Alexion, Genentech, Bayer, and RenalGuard for sitting on research trial steering committees. Daniel T. Engelman reports consulting fees from Medela, Arthrex, Atricure, and Pharmacosmos for sitting on medical advisory boards. Roberto Lorusso reports receiving research grants from Medtronic and LivaNova. Roberto Lorusso reports receiving consulting fees from Medtronic, LivaNova, and J&J MedTech Heart Recovery (payments to the institution). Roberto Lorusso reports payment for lectures from Abiomed. Roberto Lorusso reports participation on advisory boards for Eurosets, Xenios, Hemocue and ChinaBridge Medical (payments to the institution). Roberto Lorusso reports leadership roles as ELSO Research Committee Chair, EuroELSO Honorary Secretary, and ESC Cardiovascular Surgery Working Group Nucleus Chair. Roberto Lorusso reports receiving ECMO-related material for animal experiments from Medtronic. Graeme MacLaren reports being the Past President of the Extracorporeal Life Support Organisation (ELSO). Bart Meyns reports receiving an institutional research grant from Abiomed J&J. Milan Milojevic reports a leadership position as Director of the Clinical Practice Guidelines Programme at the European Association for Cardio-Thoracic Surgery. Milan Milojevic reports receiving a speaker fee from Corcym in relation to ERAS. Bhavesh Patel reports holding stock from GE Healthcare and Medtronic. Evgenij V. Potapov reports receiving grants from Abiomed, Abbott, Recovery Therapeutics, and Medtronic. Evgenij V. Potapov reports receiving consulting fees from Abiomed, Abbott, Recovery Therapeutics, and Medtronic. Evgenij V. Potapov reports receiving payment for lectures from Abiomed, Abbott, Recovery Therapeutics, and Medtronic. Evgenij V. Potapov reports receiving support for attending meetings from Abiomed, Abbott, and Medtronic. Vivek Rao reports receiving consulting fees from Abbott and Medtronic. Vivek Rao reports receiving payment for lectures from Abbott. Vivek Rao reports holding Medtronic stock. Bastian Schmack reports receiving consulting fees as a medical advisor from Adjucor GmbH, and payment or honoraria for proctoring from Johnson & Johnson MedTech, Berlin Heart GmbH, and Abbott Inc. Scott Silvestry reports receiving consulting fees from Abbott and Abiomed. Scott Silvestry reports receiving payment for lectures from Abbott and Abiomed. Scott Silvestry reports receiving payment for expert testimony from Abbott. Scott Silvestry reports participation on an advisory board for Carmat. Edward Soltetz reports receiving payment from Abiomed for speaking and training. Edward Soltetz reports being the national Co-PI for the IMPACT Trial, which is sponsored by Abiomed. Hiroo Takayama reports consulting fees from Artivion and Edwards (payments made to the institution). Joseph Tonna reports receiving grants from NIH, NHLBI, and ROI. Joseph Tonna reports being the Registry Chair of ELSO. Glenn Whitman reports receiving consulting fees from Cellphire LLC for a national RCT on cryopreserved platelets in Cardiac Surgery. Glenn Whitman reports being in the design phase of a patent, 50% owned, for a Safe Cannulation Assist Device. Dominik Wiedemann reports receiving payment for lectures from Xenios/Fresenius, Abiomed, Edwards Lifesciences, and Abbott. Dominik Wiedemann reports receiving support for attending meetings from Xenios/Fresenius, Abiomed, and Abbott. Dominik Wiedemann reports participating on an advisory board for Xenios/Fresenius as a scientific adviser. Daniel Zimpfer reports receiving grants or contracts from Edwards, Abbott, Berlin Heart, Corcym, Abiomed, Atricure. Daniel Zimpfer reports receiving consulting fees from Abiomed and Abbott. Daniel Zimpfer reports receiving payment or honoraria for lectures from Edwards, Corcym, Abbott, Abiomed, Berlin Heart, and Atricure. Daniel Zimpfer reports receiving support for attending meetings from Medtronic, Edwards, Novomed, Fa. Duschek, Biotronik, Bimed, Abbott, SJM, St. Jude Medical, Maquet, Heartware, Sorin, Janssen, Johnson, J.C General, B. Braun, Boston, Baxter, Euromed, Getinge, MIN Medical Innovation, Actelion, Cryolife, Vascutek, HSEC, Neucomed, Biomedica, Hirmann, Artivion, Takeda, C. Brady, Atricure, Cytosorbents, Covidien, Guidant, ATS, LSI Solutions, Beuroock, Nycomed, Ducest, Pfizer, Comesa, Tyco, Santec, W. L. Gore, MACs Medical, Philips, Intramed, and Roche. The other authors have no conflicts of interest to disclose. EDAT- 2026/01/17 00:36 MHDA- 2026/06/23 12:34 CRDT- 2026/01/16 19:14 PHST- 2025/05/07 00:00 [received] PHST- 2025/10/31 00:00 [revised] PHST- 2025/12/16 00:00 [accepted] PHST- 2026/06/23 12:34 [medline] PHST- 2026/01/17 00:36 [pubmed] PHST- 2026/01/16 19:14 [entrez] AID - S0003-4975(26)00011-1 [pii] AID - 10.1016/j.athoracsur.2025.12.032 [doi] PST - ppublish SO - Ann Thorac Surg. 2026 Jul;122(1):22-32. doi: 10.1016/j.athoracsur.2025.12.032. Epub 2026 Jan 14. PMID- 41543405 OWN - NLM STAT- MEDLINE DCOM- 20260626 LR - 20260813 IS - 0974-5181 (Electronic) IS - 0971-9784 (Print) IS - 0971-9784 (Linking) VI - 29 IP - 1 DP - 2026 Jan 1 TI - Impact of Introduction of Code Blue Response System in a Cardiorespiratory Center: Before-After Study. PG - 43-48 LID - 10.4103/aca.aca_102_25 [doi] AB - BACKGROUND: In-hospital cardiac arrest demands immediate response to improve survival outcomes. The Code Blue Response System (CBRS) was designed to streamline emergency interventions by reducing response times. This study aimed to evaluate the impact of a CBRS on response times and outcomes before and after its implementation. MATERIALS AND METHODS: A retrospective analysis was conducted using "Code Blue" feedback forms collected between April 2023 and March 2025. During this period, 212 patients who experienced code blue events were divided into pre-CBRS (n = 105) and post-CBRS (n = 107) groups, based on whether their code blue event occurred before or after the CBRS installation. Demographic data, response times, interventions (such as defibrillation and central venous access), and return of spontaneous circulation (ROSC) rates were analyzed. RESULTS: Post-CBRS implementation, the mean response time significantly decreased from 2.65 to 1.71 min (P < 0.001), reflecting a 35.5% reduction. Defibrillation and central venous access rates also increased significantly (P < 0.001 and P = 0.03, respectively), demonstrating the positive impact of CBRS on patient outcomes. Although the ROSC rate improved from 42.3% to 53.3%, the difference did not reach statistical significance (P = 0.78). No significant differences were noted in patient demographics, event location, or time of day. CONCLUSION: The implementation of CBRS significantly improved code blue response times and enhanced critical interventions, contributing to better immediate patient outcomes. While the ROSC rate improvement was not statistically significant, the trend suggests a positive clinical impact. CBRS stands out as an essential strategy for improving emergency response efficiency and patient survival rates in hospitals. CI - Copyright (c) 2026 Annals of Cardiac Anaesthesia. FAU - Kumar, Sandeep AU - Kumar S AD - Department of Anaesthesia and Critical Care, Armed Forces Medical College, Pune, Maharashtra, India. FAU - Kumar, Alok AU - Kumar A AD - Department of Anaesthesia and Critical Care, Armed Forces Medical College, Pune, Maharashtra, India. FAU - Ameta, Nihar AU - Ameta N AD - Department of Anaesthesia and Critical Care, Armed Forces Medical College, Pune, Maharashtra, India. FAU - Joshi, Saajan AU - Joshi S AD - Department of Anaesthesia and Critical Care, Armed Forces Medical College, Pune, Maharashtra, India. FAU - Bhargava, Devarakonda Venkata AU - Bhargava DV AD - EDAIC, Army Hospital (Research and Referral), Delhi Cantt, New Delhi, India. LA - eng PT - Journal Article DEP - 20260116 PL - India TA - Ann Card Anaesth JT - Annals of cardiac anaesthesia JID - 9815987 SB - IM MH - Humans MH - Female MH - Retrospective Studies MH - *Heart Arrest/therapy MH - Aged MH - Male MH - *Cardiopulmonary Resuscitation/methods MH - Middle Aged MH - Return of Spontaneous Circulation MH - Electric Countershock MH - *Hospital Rapid Response Team PMC - PMC12935129 OTO - NOTNLM OT - Cardiopulmonary arrest OT - code blue response system OT - return of spontaneous circulation COIS- There are no conflicts of interest. EDAT- 2026/01/16 15:03 MHDA- 2026/01/16 15:04 PMCR- 2026/01/01 CRDT- 2026/01/16 10:05 PHST- 2025/04/28 00:00 [received] PHST- 2025/06/10 00:00 [accepted] PHST- 2026/01/16 15:04 [medline] PHST- 2026/01/16 15:03 [pubmed] PHST- 2026/01/16 10:05 [entrez] PHST- 2026/01/01 00:00 [pmc-release] AID - 00660469-202601000-00006 [pii] AID - ACA-29-43 [pii] AID - 10.4103/aca.aca_102_25 [doi] PST - ppublish SO - Ann Card Anaesth. 2026 Jan 1;29(1):43-48. doi: 10.4103/aca.aca_102_25. Epub 2026 Jan 16. PMID- 41534389 OWN - NLM STAT- MEDLINE DCOM- 20260626 LR - 20260626 IS - 1578-8989 (Electronic) IS - 0025-7753 (Linking) VI - 166 IP - 1 DP - 2026 Jan TI - Prevalence of elevated lipoprotein(a) in individuals with inflammatory bowel disease: Potential implications for cardiovascular risk. PG - 107303 LID - S0025-7753(25)00531-7 [pii] LID - 10.1016/j.medcli.2025.107303 [doi] AB - BACKGROUND AND AIMS: Elevated lipoprotein(a) [Lp(a)] levels are associated with increased cardiovascular risk and have been implicated in various inflammatory conditions. However, evidence regarding the role of Lp(a) in patients with inflammatory bowel disease (IBD) remains limited. This study aimed to evaluate Lp(a) levels in a group of patients with IBD. METHODS: A cross-sectional study was conducted involving patients with IBD actively followed by a multidisciplinary team. As part of routine care, patients with cardiovascular risk factors were systematically referred for comprehensive cardiology evaluation. For comparison, a control group matched for age and sex in a 2:1 ratio was randomly selected from the hospital database. RESULTS: Seventy-eight patients with IBD and 156 controls (mean age 56.1 years; 59% male) were included. Among patients with IBD, 56.4% had ulcerative colitis and 43.6% Crohn's disease. The IBD group showed a non-significant trend toward higher Lp(a) levels compared to controls (median [IQR]: 19.1 [5.9-71.3] vs. 17.5 [7.0-39.0]mg/dL; p=0.274). A significantly greater proportion of IBD patients had high-risk Lp(a) levels (>50mg/dL) than controls (35.9% vs. 19.2%; p=0.02). Additionally, IBD patients with Lp(a)>50mg/dL exhibited a non-significant trend toward higher inflammatory marker values. CONCLUSION: A substantial proportion of IBD patients exhibited elevated Lp(a) levels. Given its inflammatory, prothrombotic, and proatherogenic properties, Lp(a) may contribute to the increased cardiovascular risk observed in this population. CI - Copyright (c) 2025 Elsevier Espana, S.L.U. All rights reserved. FAU - Masson, Walter AU - Masson W AD - Department of Cardiology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. Electronic address: walter.masson@hospitalitaliano.org.ar. FAU - Fernandez-Villar, Gonzalo AU - Fernandez-Villar G AD - Department of Cardiology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. FAU - Martinez-Elhelou, Solange AU - Martinez-Elhelou S AD - Department of Gastroenterology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. FAU - Garagoli, Fernando AU - Garagoli F AD - Department of Cardiology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. FAU - Sanchez, Maria Belen AU - Sanchez MB AD - Department of Gastroenterology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. FAU - Etchevers, Maria Josefina AU - Etchevers MJ AD - Department of Gastroenterology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. FAU - Pizarro, Rodolfo AU - Pizarro R AD - Department of Cardiology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. FAU - Sobrero, Maria Josefina AU - Sobrero MJ AD - Department of Gastroenterology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. LA - eng LA - spa PT - Journal Article DEP - 20260113 PL - Spain TA - Med Clin (Barc) JT - Medicina clinica JID - 0376377 RN - 0 (Lipoprotein(a)) RN - 0 (Biomarkers) SB - IM MH - Humans MH - Male MH - *Lipoprotein(a)/blood MH - Female MH - Middle Aged MH - Cross-Sectional Studies MH - Heart Disease Risk Factors MH - Prevalence MH - Biomarkers/blood MH - Adult MH - *Cardiovascular Diseases/etiology/blood/epidemiology MH - Case-Control Studies MH - *Colitis, Ulcerative/blood/complications MH - Aged MH - *Inflammatory Bowel Diseases/blood/complications MH - *Crohn Disease/blood/complications MH - Risk Factors OTO - NOTNLM OT - Colitis ulcerosa OT - Crohn's disease OT - Enfermedad de Crohn OT - Enfermedad inflamatoria intestinal OT - Inflammatory bowel disease OT - Lipoprotein(a) OT - Lipoproteina(a) OT - Ulcerative colitis EDAT- 2026/01/15 16:13 MHDA- 2026/02/07 00:31 CRDT- 2026/01/14 18:07 PHST- 2025/08/04 00:00 [received] PHST- 2025/10/01 00:00 [revised] PHST- 2025/10/06 00:00 [accepted] PHST- 2026/02/07 00:31 [medline] PHST- 2026/01/15 16:13 [pubmed] PHST- 2026/01/14 18:07 [entrez] AID - S0025-7753(25)00531-7 [pii] AID - 10.1016/j.medcli.2025.107303 [doi] PST - ppublish SO - Med Clin (Barc). 2026 Jan;166(1):107303. doi: 10.1016/j.medcli.2025.107303. Epub 2026 Jan 13. PMID- 41529748 OWN - NLM STAT- MEDLINE DCOM- 20260307 LR - 20260730 IS - 1535-6280 (Electronic) IS - 0146-2806 (Linking) VI - 51 IP - 5 DP - 2026 May TI - Invasive versus conservative management in infective endocarditis after transcatheter aortic valve implantation: A systematic review and meta-analysis. PG - 103264 LID - S0146-2806(26)00007-1 [pii] LID - 10.1016/j.cpcardiol.2026.103264 [doi] AB - BACKGROUND: Infective endocarditis after transcatheter aortic valve implantation (TAVI-IE) is an uncommon but severe complication associated with substantial morbidity and mortality. Therapeutic strategies vary widely, since invasive management is often precluded by prohibitive risk and conservative medical therapy may be linked to poorer outcomes. Therefore, we aimed to compare outcomes between conservative and invasive management in patients with TAVI-IE. METHODS: A systematic search of PubMed, Scopus, and Web of Science identified comparative studies evaluating conservative versus invasive treatment in TAVI-IE. The primary endpoints were all-cause in-hospital and 1-year mortality. Pooled risk ratios (RRs) with 95 % confidence intervals (CIs) were calculated using a random-effects model. Heterogeneity was quantified with I(2), publication bias was assessed with Egger's test, and sensitivity analyses (leave-one-out, GOSH plots) were performed. RESULTS: The search yielded 2,551 records; 15 studies met inclusion criteria for data extraction and meta-analysis. No significant differences were observed between conservative and invasive strategies for in-hospital mortality (RR 0.99, 95 % CI 0.80-1.24, p = 0.96; I(2) = 0 % with p = 0.67) or 1-year mortality (RR 1.03, 95 % CI 0.84-1.26; p = 0.81; I(2) = 11.4 % with p = 0.33). There was no evidence of publication bias (Egger's test: in-hospital, p = 0.07; 1-year, p = 0.54). Results were robust in sensitivity analyses. CONCLUSIONS: In patients with TAVI-IE, conservative and invasive treatments were associated with comparable in-hospital and 1-year mortality. These findings support individualized, multidisciplinary decision-making rather than presuming a uniform advantage of either approach. CI - Copyright (c) 2026. Published by Elsevier Inc. FAU - Theofilis, Panagiotis AU - Theofilis P AD - Department of Cardiology, "Hippokration" General Hospital of Athens, 11527 Athens, Greece. Electronic address: panos.theofilis@hotmail.com. FAU - Dimitriadis, Kyriakos AU - Dimitriadis K AD - Department of Cardiology, "Hippokration" General Hospital of Athens, 11527 Athens, Greece. FAU - Pyrpyris, Nikolaos AU - Pyrpyris N AD - Department of Cardiology, "Hippokration" General Hospital of Athens, 11527 Athens, Greece. FAU - Karakasis, Paschalis AU - Karakasis P AD - Department of Cardiology, Ippokrateio General Hospital of Thessaloniki, 54642 Thessaloniki, Greece. FAU - Dri, Eirini AU - Dri E AD - Department of Cardiology, "Hippokration" General Hospital of Athens, 11527 Athens, Greece. FAU - Beneki, Eirini AU - Beneki E AD - Department of Cardiology, "Hippokration" General Hospital of Athens, 11527 Athens, Greece. FAU - Vordoni, Aikaterini AU - Vordoni A AD - Department of Cardiology, "Hippokration" General Hospital of Athens, 11527 Athens, Greece. FAU - Tsioufis, Panagiotis AU - Tsioufis P AD - Department of Cardiology, "Hippokration" General Hospital of Athens, 11527 Athens, Greece. FAU - Chatzi, Maria AU - Chatzi M AD - Department of Cardiology, "Hippokration" General Hospital of Athens, 11527 Athens, Greece. FAU - Oikonomou, Evangelos AU - Oikonomou E AD - Department of Cardiology, Sotiria General Hospital, 11527 Athens, Greece. FAU - Aznaouridis, Konstantinos AU - Aznaouridis K AD - Department of Cardiology, "Hippokration" General Hospital of Athens, 11527 Athens, Greece. FAU - Tsioufis, Konstantinos AU - Tsioufis K AD - Department of Cardiology, "Hippokration" General Hospital of Athens, 11527 Athens, Greece. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20260111 PL - Netherlands TA - Curr Probl Cardiol JT - Current problems in cardiology JID - 7701802 RN - 0 (Anti-Bacterial Agents) SB - IM MH - Humans MH - *Transcatheter Aortic Valve Replacement/adverse effects MH - *Conservative Treatment/methods MH - *Endocarditis/therapy/etiology MH - Hospital Mortality/trends MH - Heart Valve Prosthesis/adverse effects MH - *Aortic Valve Stenosis/surgery MH - *Anti-Bacterial Agents/therapeutic use OTO - NOTNLM OT - infective endocarditis OT - prosthetic valve endocarditis OT - transcatheter aortic valve implantation COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/01/14 00:37 MHDA- 2026/03/08 01:38 CRDT- 2026/01/13 19:09 PHST- 2026/01/10 00:00 [received] PHST- 2026/01/10 00:00 [accepted] PHST- 2026/03/08 01:38 [medline] PHST- 2026/01/14 00:37 [pubmed] PHST- 2026/01/13 19:09 [entrez] AID - S0146-2806(26)00007-1 [pii] AID - 10.1016/j.cpcardiol.2026.103264 [doi] PST - ppublish SO - Curr Probl Cardiol. 2026 May;51(5):103264. doi: 10.1016/j.cpcardiol.2026.103264. Epub 2026 Jan 11. PMID- 41525437 OWN - NLM STAT- MEDLINE DCOM- 20260626 LR - 20260626 IS - 1524-4539 (Electronic) IS - 0009-7322 (Linking) VI - 153 IP - 2 DP - 2026 Jan 13 TI - Multivalve Involvement in Aortic Stenosis: Insights From a Narrative Review. PG - 115-131 LID - 10.1161/CIRCULATIONAHA.125.075978 [doi] AB - Many patients with severe aortic stenosis present with concomitant multivalvular heart disease. The management of this condition remains challenging and requires a multidisciplinary approach that integrates clinical, hemodynamic, and multimodality imaging data to define the most effective and durable treatment strategy. Although randomized evidence to guide treatment decisions in this setting is limited, percutaneous interventions to address additional valvular lesions are being increasingly adopted. This review provides an overview of the pathophysiology of valvular diseases commonly associated with severe aortic stenosis, highlighting their prognostic implications after surgical or transcatheter treatment and their impact on risk stratification and therapeutic management. FAU - Battistolo, Quentin AU - Battistolo Q AUID- ORCID: 0009-0001-3029-8763 AD - Quebec Heart & Lung Institute, Laval University, Quebec City, Canada (Q.B., M.A., P.Y.T., M.B., J.R.-C.). AD - Nantes University, CHU Nantes, l'Institut du Thorax, France (Q.B., P.G.). FAU - Avvedimento, Marisa AU - Avvedimento M AUID- ORCID: 0000-0002-8443-7888 AD - Quebec Heart & Lung Institute, Laval University, Quebec City, Canada (Q.B., M.A., P.Y.T., M.B., J.R.-C.). FAU - Guerin, Patrice AU - Guerin P AUID- ORCID: 0000-0002-8095-8897 AD - Nantes University, CHU Nantes, l'Institut du Thorax, France (Q.B., P.G.). FAU - Turgeon, Pierre Yves AU - Turgeon PY AUID- ORCID: 0000-0002-0656-2587 AD - Quebec Heart & Lung Institute, Laval University, Quebec City, Canada (Q.B., M.A., P.Y.T., M.B., J.R.-C.). FAU - Bernier, Mathieu AU - Bernier M AUID- ORCID: 0000-0001-9240-3816 AD - Quebec Heart & Lung Institute, Laval University, Quebec City, Canada (Q.B., M.A., P.Y.T., M.B., J.R.-C.). FAU - Mack, Michael J AU - Mack MJ AUID- ORCID: 0000-0002-3148-9158 AD - Baylor Scott & White Research Institute, Baylor Scott & White Health, Plano, TX (M.J.M.). FAU - O'Gara, Patrick AU - O'Gara P AUID- ORCID: 0000-0003-0601-1088 AD - Harvard Medical School, Brigham and Women's Hospital, Boston, MA (P.O.). FAU - Rodes-Cabau, Josep AU - Rodes-Cabau J AUID- ORCID: 0000-0001-8237-7095 AD - Quebec Heart & Lung Institute, Laval University, Quebec City, Canada (Q.B., M.A., P.Y.T., M.B., J.R.-C.). AD - Clinic Barcelona, Barcelona, Spain (J.R.-C). LA - eng PT - Journal Article PT - Review DEP - 20260112 PL - United States TA - Circulation JT - Circulation JID - 0147763 SB - IM MH - Humans MH - *Aortic Valve Stenosis/physiopathology/therapy/diagnostic imaging/surgery MH - Hemodynamics OTO - NOTNLM OT - aortic stenosis, calcific OT - aortic valve stenosis OT - mitral valve insufficiency OT - mitral valve stenosis OT - structural heart diseases OT - tricuspid valve insufficiency COIS- Dr Rodes-Cabau received institutional research grants and consultant/speaker fees from Edwards Lifesciences, Abott, and Medtronic. Dr Guerin reported institutional research grants from Edwards, Abbott, and Medtronic and receiving personal fees from Abbott. Dr Mack reported nonfinancial support from Edwards Lifesciences, Medtronic, and Abbott. The other authors report no conflicts. EDAT- 2026/01/12 19:24 MHDA- 2026/01/12 19:25 CRDT- 2026/01/12 14:12 PHST- 2026/01/12 19:25 [medline] PHST- 2026/01/12 19:24 [pubmed] PHST- 2026/01/12 14:12 [entrez] AID - 10.1161/CIRCULATIONAHA.125.075978 [doi] PST - ppublish SO - Circulation. 2026 Jan 13;153(2):115-131. doi: 10.1161/CIRCULATIONAHA.125.075978. Epub 2026 Jan 12. PMID- 41525219 OWN - NLM STAT- MEDLINE DCOM- 20260626 LR - 20260626 IS - 1938-2723 (Electronic) IS - 1076-0296 (Print) IS - 1076-0296 (Linking) VI - 32 DP - 2026 Jan-Dec TI - Narrative Review of Management Strategies and Risk Mitigation for Gastrointestinal Bleeding in Atrial Fibrillation Patients Receiving Warfarin. PG - 10760296251410932 LID - 10.1177/10760296251410932 [doi] LID - 10760296251410932 AB - A globally prevalent cardiac arrhythmia, atrial fibrillation (AF) greatly increases the risk of thromboembolic events, making effective anticoagulation necessary. The mainstay of this treatment has long been the vitamin K antagonist warfarin. However, there are significant management challenges due to its limited therapeutic index, intricate pharmacokinetics, and multiple interactions, with gastrointestinal bleeding (GIB) emerging as a serious and potentially fatal complication. The epidemiology, risk factors, mechanisms, and management approaches for GIB in AF patients taking warfarin are summarized in this review. It emphasizes how crucial it is to conduct individualized risk assessments using validated scores, monitor anticoagulation closely, and strategically combine advanced endoscopic procedures with direct oral anticoagulants (DOACs). Increased monitoring and patient education are necessary because of the high early incidence of GIB and the inherent lability of warfarin's anticoagulant effect. Furthermore, accurate clinical differentiation is necessary due to the complex risk profiles of different medications, such as fibrates versus statins. The report highlights the need for a multidisciplinary approach to care, especially in complex situations such as the resumption of post-GIB anticoagulation. It also identifies new endoscopic tools, pharmacogenomics, and artificial intelligence as promising directions for future developments in safer and more individualized patient outcomes. FAU - Soltani, Abbas Sarvari AU - Soltani AS AD - Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran. RINGGOLD: 48439 FAU - Nasab, Ali Ebrahimi AU - Nasab AE AD - Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran. RINGGOLD: 48439 FAU - Ahangar, Mehdi Hassani AU - Ahangar MH AD - Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran. RINGGOLD: 48439 FAU - Khani, Mahan AU - Khani M AD - Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran. RINGGOLD: 48439 FAU - Bi'aragh, Sina Hemmati AU - Bi'aragh SH AD - Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran. RINGGOLD: 48439 FAU - Rasouli, Kimia AU - Rasouli K AD - Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. RINGGOLD: 48432 FAU - Afsahi, Reza AU - Afsahi R AD - Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran. RINGGOLD: 48439 FAU - Pourahmad, Ramtin AU - Pourahmad R AUID- ORCID: 0000-0003-1107-047X AD - Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran. RINGGOLD: 48439 LA - eng PT - Journal Article PT - Review DEP - 20260112 PL - United States TA - Clin Appl Thromb Hemost JT - Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis JID - 9508125 RN - 5Q7ZVV76EI (Warfarin) RN - 0 (Anticoagulants) SB - IM MH - Humans MH - *Atrial Fibrillation/drug therapy/complications MH - *Warfarin/adverse effects/therapeutic use MH - *Gastrointestinal Hemorrhage/chemically induced/prevention & control/therapy MH - *Anticoagulants/therapeutic use/adverse effects MH - Risk Factors PMC - PMC12796148 OTO - NOTNLM OT - anticoagulation management OT - atrial fibrillation OT - direct oral anticoagulants (DOACs) OT - gastrointestinal bleeding OT - warfarin COIS- Declaration of Conflicting InterestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2026/01/12 19:24 MHDA- 2026/01/12 19:25 PMCR- 2026/01/12 CRDT- 2026/01/12 13:02 PHST- 2026/01/12 19:25 [medline] PHST- 2026/01/12 19:24 [pubmed] PHST- 2026/01/12 13:02 [entrez] PHST- 2026/01/12 00:00 [pmc-release] AID - 10.1177_10760296251410932 [pii] AID - 10.1177/10760296251410932 [doi] PST - ppublish SO - Clin Appl Thromb Hemost. 2026 Jan-Dec;32:10760296251410932. doi: 10.1177/10760296251410932. Epub 2026 Jan 12. PMID- 41524043 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260112 LR - 20260114 IS - 2153-8174 (Electronic) IS - 1530-6550 (Print) IS - 1530-6550 (Linking) VI - 26 IP - 12 DP - 2025 Dec TI - Utility of Cardiac Rehabilitation Following Surgical Treatment of Infective Endocarditis. PG - 45789 LID - 10.31083/RCM45789 [doi] LID - 45789 AB - Infective endocarditis (IE) is a life-threatening cardiac infection. The incidence of IE is increasing due to complex sociodemographic shifts, including increases in intravenous drug use (IVDU) attributed to opioid epidemics. Cardiac rehabilitation (CR) is a comprehensive form of secondary prevention for heart disease. Current guidelines suggest that CR may be beneficial in the recovery from IE, but supporting evidence is limited. Given the utility of CR in the recovery from other cardiac conditions and the unique characteristics of patients with IE, this narrative review summarizes the existing data on the use of CR following surgical treatment of IE. The existing literature is limited to the CopenHeart(IE) randomized clinical trial (RCT) and four case reports. Thus, to our knowledge, this represents the first review to focus specifically on CR in the context of IE. The CopenHeart(IE) RCT found that patients receiving CR showed greater improvements in levels of physical fatigue, general fatigue, maximal power, systolic blood pressure, and some questionnaire scores than the control group. The results of multiple case reports represent unique and extreme cases of IE from which support for the use of CR following IE can be drawn from the relative successes of each patient. Moreover, it is important to consider that the complex social needs of the IE population may require additional psychosocial support, which can be achieved by integrating social workers into the multidisciplinary CR team. While further research is warranted, the existing evidence supports the use of CR as part of the comprehensive recovery from IE. CI - Copyright: (c) 2025 The Author(s). Published by IMR Press. FAU - M Telles-Langdon, Sara AU - M Telles-Langdon S AUID- ORCID: 0009-0004-6392-7935 AD - Section of Cardiac Surgery, Department of Cardiac Sciences, Libin Cardiovascular Institute, Cumming School of Medicine, Calgary, AB T2N 2T9, Canada. FAU - Fatehi Hassanabad, Ali AU - Fatehi Hassanabad A AUID- ORCID: 0000-0003-0650-0260 AD - Section of Cardiac Surgery, Department of Cardiac Sciences, Libin Cardiovascular Institute, Cumming School of Medicine, Calgary, AB T2N 2T9, Canada. LA - eng PT - Journal Article PT - Review DEP - 20251223 PL - Singapore TA - Rev Cardiovasc Med JT - Reviews in cardiovascular medicine JID - 100960007 PMC - PMC12780988 OTO - NOTNLM OT - cardiac rehabilitation OT - cardiac surgery/thoracic surgery OT - infective endocarditis/endocarditis OT - social determinants of health COIS- The authors declare no conflict of interest. EDAT- 2026/01/12 06:28 MHDA- 2026/01/12 06:29 PMCR- 2025/12/23 CRDT- 2026/01/12 05:50 PHST- 2025/08/14 00:00 [received] PHST- 2025/11/03 00:00 [revised] PHST- 2025/11/11 00:00 [accepted] PHST- 2026/01/12 06:29 [medline] PHST- 2026/01/12 06:28 [pubmed] PHST- 2026/01/12 05:50 [entrez] PHST- 2025/12/23 00:00 [pmc-release] AID - S1530-6550(25)01511-0 [pii] AID - 10.31083/RCM45789 [doi] PST - epublish SO - Rev Cardiovasc Med. 2025 Dec 23;26(12):45789. doi: 10.31083/RCM45789. eCollection 2025 Dec. PMID- 41523937 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260112 LR - 20260114 IS - 2434-0790 (Electronic) IS - 2434-0790 (Linking) VI - 8 IP - 1 DP - 2026 Jan 9 TI - Effectiveness of the Shock Team on Short-Term Outcomes in Patients With Cardiogenic Shock　- Systematic Review and Meta-Analysis. PG - 13-20 LID - 10.1253/circrep.CR-25-0240 [doi] AB - BACKGROUND: Recently, shock teams have been introduced to optimize cardiogenic shock (CS) care; however, their clinical benefits remain unclear. We conducted a systematic review and meta-analysis to assess whether management by a shock team improves outcomes in patients with CS. METHODS AND RESULTS: This meta-analysis was conducted according to the PRISMA guidelines. Studies comparing adults with CS managed with or without a shock team were identified from the PubMed, Web of Science, and Cochrane Library databases. The primary outcome was short-term mortality (cardiac intensive care unit, in-hospital, or 30-day mortality); the secondary outcome was bleeding. Of the 7 retrospective cohort studies that met the inclusion criteria, 3 without a critical risk of bias were included in the analysis. Shock team management was significantly associated with lower short-term mortality (odds ratio [OR] 0.52; 95% confidence interval [CI] 0.32-0.85; P=0.010) and bleeding complications (OR 0.62; 95% CI 0.43-0.91; P=0.010). Sensitivity analysis using crude data also supported the mortality benefit (OR 0.68; 95% CI 0.54-0.85; P<0.010). However, no randomized trials were included, and the certainty of evidence was rated very low owing to the risk of bias and inconsistency. CONCLUSIONS: Shock team management may improve short-term outcomes in patients with CS; however, the level of evidence is very low. Further prospective studies are needed to evaluate optimal shock team composition and roles. CI - Copyright (c) 2026, THE JAPANESE CIRCULATION SOCIETY. FAU - Arai, Marina AU - Arai M AD - Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine Sendai Japan. FAU - Kondo, Toru AU - Kondo T AD - Department of Cardiology, Nagoya University Graduate School of Medicine Nagoya Japan. FAU - Nakashima, Takahiro AU - Nakashima T AD - Department of Cardiovascular Medicine, Kumamoto University Hospital Kumamoto Japan. FAU - Hanada, Hiroyuki AU - Hanada H AD - Emergency, Disaster and General Medicine, Hirosaki University Graduate School of Medicine Aomori Japan. FAU - Hashiba, Katsutaka AU - Hashiba K AD - Department of Cardiology, Yokosuka General Medical Center Yokohama Japan. FAU - Yamamoto, Takeshi AU - Yamamoto T AD - Division of Cardiovascular Intensive Care, Nippon Medical School Hospital Tokyo Japan. FAU - Nakayama, Naoki AU - Nakayama N AD - Department of Cardiovascular Medicine, Kumamoto University Hospital Kumamoto Japan. FAU - Kirigaya, Jin AU - Kirigaya J AD - Department of Cardiology, Yokohama City University Medical Cente Yokohama Japan. FAU - Ishizu, Tomoko AU - Ishizu T AD - Department of Cardiology, University of Tsukuba Hospital Ibaraki Japan. FAU - Hosoya, Yumiko AU - Hosoya Y AD - Department of Cardiology, Sakakibara Heart Institute Tokyo Japan. FAU - Katasako-Yabumoto, Aya AU - Katasako-Yabumoto A AD - Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center Osaka Japan. FAU - Okazaki, Yusuke AU - Okazaki Y AD - Department of Cardiology, Steel Memorial Muroran Hospital Hokkaido Japan. FAU - Yamamoto, Masahiro AU - Yamamoto M AD - Department of Cardiovascular Medicine, Kumamoto University Hospital Kumamoto Japan. FAU - Sakamoto, Kazuo AU - Sakamoto K AD - Department of Cardiology/Coronary Care Unit, Kyushu University Hospital Fukuoka Japan. FAU - Osawa, Takumi AU - Osawa T AD - Department of Cardiology, University of Tsukuba Hospital Ibaraki Japan. FAU - Tanaka, Akihito AU - Tanaka A AD - Department of Cardiology, Nagoya University Graduate School of Medicine Nagoya Japan. FAU - Matsuo, Kunihiro AU - Matsuo K AD - Department of Cardiology, Fukuoka Tokushukai Hospital Fukuoka Japan. FAU - Yamaguchi, Junichi AU - Yamaguchi J AD - Department of Cardiology, Tokyo Women's Medical University Tokyo Japan. FAU - Mano, Toshiaki AU - Mano T AD - Cardiovascular Center, Kansai Rosai Hospital Hyogo Japan. FAU - Kojima, Sunao AU - Kojima S AD - Department of Cardiovascular Medicine, Sakurajyuji Yatsushiro Rehabilitation Hospital Kumamoto Japan. FAU - Noguchi, Teruo AU - Noguchi T AD - Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center Osaka Japan. FAU - Tsujimoto, Yasushi AU - Tsujimoto Y AD - Systematic Review Workshop Peer Support Group (SRWS-PSG) Osaka Japan. AD - Oku Medical Clinic Osaka Japan. FAU - Kikuchi, Migaku AU - Kikuchi M AD - Emergency and Critical Care Center, Dokkyo Medical University Tochigi Japan. FAU - Funazaki, Toshikazu AU - Funazaki T AD - Department of Cardiovascular Medicine, Kawaguchi Cupola Rehabilitation Hospital Saitama Japan. FAU - Tahara, Yoshio AU - Tahara Y AD - Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center Osaka Japan. FAU - Nonogi, Hiroshi AU - Nonogi H AD - Pharmaceutical Sciences, University of Shizuoka Shizuoka Japan. FAU - Matoba, Tetsuya AU - Matoba T AD - Department of Cardiovascular Medicine, Kyushu University Faculty of Medical Sciences Fukuoka Japan. CN - Japan Resuscitation Council (JRC) Emergency Cardiovascular Care (ECC) Cardiogenic Shock (CS) Task Force and the Guideline Editorial Committee on behalf of the Japanese Circulation Society (JCS) Emergency and Critical Care Committee LA - eng PT - Journal Article DEP - 20251113 PL - Japan TA - Circ Rep JT - Circulation reports JID - 101746642 PMC - PMC12782905 OTO - NOTNLM OT - Acute myocardial infarction OT - Cardiogenic shock OT - Mechanical circulation support OT - Shock team COIS- T. Matoba is a member of Circulation Reports' Editorial Team. The other authors declare no conflicts of interest regarding this article. EDAT- 2026/01/12 06:29 MHDA- 2026/01/12 06:30 PMCR- 2025/11/13 CRDT- 2026/01/12 05:49 PHST- 2025/09/30 00:00 [received] PHST- 2025/09/30 00:00 [accepted] PHST- 2026/01/12 06:30 [medline] PHST- 2026/01/12 06:29 [pubmed] PHST- 2026/01/12 05:49 [entrez] PHST- 2025/11/13 00:00 [pmc-release] AID - 10.1253/circrep.CR-25-0240 [doi] PST - epublish SO - Circ Rep. 2025 Nov 13;8(1):13-20. doi: 10.1253/circrep.CR-25-0240. eCollection 2026 Jan 9. PMID- 41518590 OWN - NLM STAT- MEDLINE DCOM- 20260626 LR - 20260813 IS - 1532-2092 (Electronic) IS - 1099-5129 (Print) IS - 1099-5129 (Linking) VI - 28 IP - 2 DP - 2026 Feb 3 TI - Stereotactic radioablation for ventricular tachycardia in patients untreatable by catheter ablation: evidence of efficacy, safety, and impact on coronary arteries. LID - 10.1093/europace/euag004 [doi] LID - euag004 AB - AIMS: Ventricular tachycardia (VT) in patients with structural heart disease can be life-threatening and may persist despite anti-arrhythmic therapy and catheter ablation. When standard treatments are ineffective or contraindicated, stereotactic arrhythmia radioablation (STAR) has emerged as a non-invasive salvage option. METHODS AND RESULTS: This prospective, single-centre study included 19 patients with structural heart disease and recurrent VT unresponsive to conventional therapy and who were ineligible for ablation. Patients were selected by a multidisciplinary team and underwent cardiac CT and electroanatomic mapping for substrate characterization. STAR was delivered in a single 25 Gy fraction using volumetric modulated arc therapy. Primary endpoints included safety (adverse events within 12 months) and efficacy (reduction in VT burden, assessed by ICD-recorded anti-tachycardia pacing [ATP] and shocks). During a median follow-up of 14 months [IQR 9-15], STAR was associated with a significant reduction in ICD therapies, with an average decrease of 81%. Mean ATP interventions/month dropped from 4.5 +/- 6.5 to 0.8 +/- 2.3 (P = 0.029), and total ICD therapies/month decreased from 4.8 +/- 7.0 to 0.9 +/- 2.5 (P = 0.032). Mild pulmonary injury and pericardial effusion occurred in 22.2% of patients. Most cases were asymptomatic; one patient (5.5%) required non-urgent pericardiocentesis. No significant changes in left ventricular function, valvular status, or coronary artery disease progression (assessed by CAD-RADS and PCAT analysis) were observed. One-year mortality was 33.3%; no deaths were directly attributable to STAR. CONCLUSION: STAR shows promise as a safe, non-invasive option for patients with refractory VT and advanced cardiomyopathy. Larger multicentre studies are needed to confirm long-term outcomes and better define its clinical role. CI - (c) The Author(s) 2026. Published by Oxford University Press on behalf of the European Society of Cardiology. FAU - Carbucicchio, Corrado AU - Carbucicchio C AUID- ORCID: 0000-0001-5954-537X AD - Department of Clinical Electrophysiology & Cardiac Pacing, Centro Cardiologico Monzino IRCCS, Via Carlo Parea 4, Milan 20138, Italy. FAU - Schiavone, Marco AU - Schiavone M AUID- ORCID: 0000-0003-0720-3380 AD - Department of Clinical Electrophysiology & Cardiac Pacing, Centro Cardiologico Monzino IRCCS, Via Carlo Parea 4, Milan 20138, Italy. FAU - Piperno, Gaia AU - Piperno G AUID- ORCID: 0000-0002-5358-1297 AD - Division of Radiotherapy, IEO European Institute of Oncology IRCCS, Milan, Italy. FAU - Mancini, Maria Elisabetta AU - Mancini ME AUID- ORCID: 0000-0002-9117-8466 AD - Department of Perioperative Cardiology and Cardiovascular Imaging, Centro Cardiologico Monzino IRCCS, Milan, Italy. FAU - Cattani, Federica AU - Cattani F AUID- ORCID: 0000-0002-2488-7385 AD - Unit of Medical Physics, IEO European Institute of Oncology IRCCS, Milan, Italy. FAU - Sabatino, Mariano AU - Sabatino M AD - Department of Clinical Electrophysiology & Cardiac Pacing, Centro Cardiologico Monzino IRCCS, Via Carlo Parea 4, Milan 20138, Italy. FAU - Ferrari, Annamaria AU - Ferrari A AD - Division of Radiotherapy, IEO European Institute of Oncology IRCCS, Milan, Italy. FAU - Bonomi, Alice AU - Bonomi A AD - Biostatistics Unit, Centro Cardiologico Monzino IRCCS, Milan, Italy. FAU - Marchetti, Francesca AU - Marchetti F AUID- ORCID: 0000-0002-6626-1217 AD - Department of Perioperative Cardiology and Cardiovascular Imaging, Centro Cardiologico Monzino IRCCS, Milan, Italy. FAU - Bianchini, Lorenzo AU - Bianchini L AUID- ORCID: 0000-0001-6189-7382 AD - Department of Clinical Electrophysiology & Cardiac Pacing, Centro Cardiologico Monzino IRCCS, Via Carlo Parea 4, Milan 20138, Italy. FAU - Rondi, Elena AU - Rondi E AUID- ORCID: 0000-0003-4671-778X AD - Unit of Medical Physics, IEO European Institute of Oncology IRCCS, Milan, Italy. FAU - Ventura, Ettore AU - Ventura E AUID- ORCID: 0000-0002-7611-8641 AD - Department of Perioperative Cardiology and Cardiovascular Imaging, Centro Cardiologico Monzino IRCCS, Milan, Italy. FAU - Mushtaq, Saima AU - Mushtaq S AD - Department of Perioperative Cardiology and Cardiovascular Imaging, Centro Cardiologico Monzino IRCCS, Milan, Italy. FAU - Catto, Valentina AU - Catto V AUID- ORCID: 0000-0002-2589-6283 AD - Department of Clinical Electrophysiology & Cardiac Pacing, Centro Cardiologico Monzino IRCCS, Via Carlo Parea 4, Milan 20138, Italy. FAU - Orecchia, Roberto AU - Orecchia R AUID- ORCID: 0000-0003-3135-7152 AD - Scientific Directorate, IEO European Institute of Oncology IRCCS, Milan, Italy. FAU - Pompilio, Giulio AU - Pompilio G AUID- ORCID: 0000-0003-2581-5735 AD - Scientific Directorate, Centro Cardiologico Monzino IRCCS, Milan, Italy. AD - Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy. FAU - Tondo, Claudio AU - Tondo C AUID- ORCID: 0000-0002-8500-8313 AD - Department of Clinical Electrophysiology & Cardiac Pacing, Centro Cardiologico Monzino IRCCS, Via Carlo Parea 4, Milan 20138, Italy. AD - Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy. FAU - Pontone, Gianluca AU - Pontone G AUID- ORCID: 0000-0002-1339-6679 AD - Department of Perioperative Cardiology and Cardiovascular Imaging, Centro Cardiologico Monzino IRCCS, Milan, Italy. AD - Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy. FAU - Jereczek-Fossa, Barbara Alicja AU - Jereczek-Fossa BA AUID- ORCID: 0000-0001-8151-3673 AD - Division of Radiotherapy, IEO European Institute of Oncology IRCCS, Milan, Italy. AD - Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. LA - eng PT - Journal Article PL - England TA - Europace JT - Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology JID - 100883649 SB - IM MH - Humans MH - *Tachycardia, Ventricular/physiopathology/surgery/radiotherapy/diagnosis/diagnostic imaging MH - Female MH - Treatment Outcome MH - Male MH - Prospective Studies MH - Catheter Ablation MH - Aged MH - *Radiosurgery/adverse effects/methods MH - *Coronary Vessels/diagnostic imaging/radiation effects/physiopathology MH - Middle Aged MH - Time Factors MH - Recurrence MH - Electrophysiologic Techniques, Cardiac MH - Defibrillators, Implantable MH - Risk Factors MH - Tomography, X-Ray Computed PMC - PMC12929999 OTO - NOTNLM OT - Arrhythmogenic substrate OT - Catheter ablation OT - Computed tomography OT - Electrical storm OT - Stereotactic arrhythmia radioablation OT - Ventricular tachycardia COIS- Conflict of interest: The authors do not report relevant disclosures regarding this manuscript. MS received speaker honoraria from Boston Scientific, GE HealthCare and Haemonetics. CT is a member of Boston Scientific advisory board. EDAT- 2026/01/10 22:40 MHDA- 2026/02/24 06:32 PMCR- 2026/01/10 CRDT- 2026/01/10 11:42 PHST- 2025/08/18 00:00 [received] PHST- 2025/12/26 00:00 [accepted] PHST- 2026/02/24 06:32 [medline] PHST- 2026/01/10 22:40 [pubmed] PHST- 2026/01/10 11:42 [entrez] PHST- 2026/01/10 00:00 [pmc-release] AID - 8419763 [pii] AID - euag004 [pii] AID - 10.1093/europace/euag004 [doi] PST - ppublish SO - Europace. 2026 Feb 3;28(2):euag004. doi: 10.1093/europace/euag004. PMID- 41516051 OWN - NLM STAT- MEDLINE DCOM- 20260625 LR - 20260625 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 27 IP - 1 DP - 2025 Dec 23 TI - Adams-Oliver Syndrome: A Comprehensive Literature Review of Clinical, Nutritional, Genetic, and Molecular Aspects with Nursing Care Considerations. LID - 10.3390/ijms27010173 [doi] LID - 173 AB - The present review aims to provide a comprehensive overview of the current literature on Adams-Oliver syndrome (AOS), synthesizing information on its clinical features, genetic and molecular underpinnings, nutritional aspects, and key nursing care considerations. AOS is a rare congenital disorder. Its genetic basis is heterogeneous, involving mutations in at least six key genes (ARHGAP31, RBPJ, NOTCH1, DLL4, DOCK6, and EOGT), which primarily affect vascular development through pathways like Notch signaling and Rho GTPase regulation. The management of AOS is complex and requires a multidisciplinary approach. The clinical presentation of AOS is highly variable, ranging from mild to severe and includes a wide spectrum of clinical manifestations, most notably aplasia cutis congenita and terminal transverse limb defects. The underlying molecular mechanisms predominantly point towards vasculopathy, disrupting embryonic development. Emerging evidence also highlights the presence of nutritional issues, such as poor feeding and growth failure, which are often overlooked. Management demands an integrated, multidisciplinary management approach, requiring coordinated effort from specialists in pediatrics, genetics, molecular biology, cardiology, surgery, and nutrition. Specialized nursing care is crucial for managing complex symptoms, particularly wound care for aplasia cutis, and for providing family support. FAU - Badiu Tisa, Ioana AU - Badiu Tisa I AD - Department 1, Faculty of Nursing and Health Sciences, "Iuliu Hatieganu" University of Medicine and Pharmacy, 2-4 Campeni Street, 400217 Cluj-Napoca, Romania. FAU - Cozma-Petrut, Anamaria AU - Cozma-Petrut A AUID- ORCID: 0000-0003-4381-5544 AD - Department of Bromatology, Hygiene, Nutrition, Faculty of Pharmacy, "Iuliu Hatieganu" University of Medicine and Pharmacy, 6 Pasteur Street, 400349 Cluj-Napoca, Romania. FAU - Chiorean, Alin-Dan AU - Chiorean AD AD - Department of Cell and Molecular Biology, Faculty of Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, 6 Pasteur Street, 400349 Cluj-Napoca, Romania. FAU - Miere, Doina AU - Miere D AUID- ORCID: 0000-0001-5029-5060 AD - Department of Bromatology, Hygiene, Nutrition, Faculty of Pharmacy, "Iuliu Hatieganu" University of Medicine and Pharmacy, 6 Pasteur Street, 400349 Cluj-Napoca, Romania. FAU - Filip, Lorena AU - Filip L AUID- ORCID: 0000-0001-9469-3546 AD - Department of Bromatology, Hygiene, Nutrition, Faculty of Pharmacy, "Iuliu Hatieganu" University of Medicine and Pharmacy, 6 Pasteur Street, 400349 Cluj-Napoca, Romania. AD - Academy of Romanian Scientists (AOSR), 3 Ilfov Street, 050044 Bucharest, Romania. FAU - Banc, Roxana AU - Banc R AUID- ORCID: 0000-0001-6808-5723 AD - Department of Bromatology, Hygiene, Nutrition, Faculty of Pharmacy, "Iuliu Hatieganu" University of Medicine and Pharmacy, 6 Pasteur Street, 400349 Cluj-Napoca, Romania. FAU - Mirza, Oana AU - Mirza O AUID- ORCID: 0000-0003-3771-9003 AD - Department of Bromatology, Hygiene, Nutrition, Faculty of Pharmacy, "Iuliu Hatieganu" University of Medicine and Pharmacy, 6 Pasteur Street, 400349 Cluj-Napoca, Romania. FAU - Bordea, Madalina Adriana AU - Bordea MA AD - Department of Microbiology, Faculty of Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, 6 Pasteur Street, 400349 Cluj-Napoca, Romania. LA - eng GR - Iuliu Hatieganu University of Medicine and Pharmacy/ PT - Journal Article PT - Review DEP - 20251223 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - Adams Oliver syndrome SB - IM MH - Humans MH - *Ectodermal Dysplasia/genetics/diagnosis/therapy/nursing MH - *Scalp Dermatoses/genetics/diagnosis/therapy/congenital MH - *Limb Deformities, Congenital/genetics/diagnosis MH - Mutation PMC - PMC12786322 OTO - NOTNLM OT - Adams-Oliver syndrome OT - brain anomalies OT - genetics OT - heart defects OT - limb anomalies OT - molecular mechanisms OT - nursing care OT - nutritional issues OT - skin defects COIS- The authors declare no conflicts of interest. EDAT- 2026/01/10 06:31 MHDA- 2026/01/10 06:32 PMCR- 2025/12/23 CRDT- 2026/01/10 01:09 PHST- 2025/11/10 00:00 [received] PHST- 2025/12/08 00:00 [revised] PHST- 2025/12/20 00:00 [accepted] PHST- 2026/01/10 06:32 [medline] PHST- 2026/01/10 06:31 [pubmed] PHST- 2026/01/10 01:09 [entrez] PHST- 2025/12/23 00:00 [pmc-release] AID - ijms27010173 [pii] AID - ijms-27-00173 [pii] AID - 10.3390/ijms27010173 [doi] PST - epublish SO - Int J Mol Sci. 2025 Dec 23;27(1):173. doi: 10.3390/ijms27010173. PMID- 41514078 OWN - NLM STAT- MEDLINE DCOM- 20260625 LR - 20261009 IS - 1432-1076 (Electronic) IS - 0340-6199 (Linking) VI - 185 IP - 2 DP - 2026 Jan 10 TI - Advances in interdisciplinary care for term and preterm neonates with congenital heart disease: a narrative review. PG - 66 LID - 10.1007/s00431-025-06712-6 [doi] AB - Congenital heart disease (CHD) is the most common major birth defect, affecting nearly 1% of live-born infants. There is a high prevalence of CHD among premature neonates, with prematurity and low birth weight compounding the risks associated with CHD and leading to increased morbidity and mortality. Despite advances in diagnosis, surgery, and intensive care, outcomes for preterm infants with CHD remain guarded, particularly in the earliest gestational age groups. These infants face heightened risks of neonatal decompensation, cardiac arrest, and early mortality, but also long-term complications including neurodevelopmental impairment. The interplay between maternal-fetal factors, perinatal environment, and the complex physiology of both prematurity and CHD underscores the need for multidisciplinary care. Prenatal diagnosis, careful delivery planning, specialized postnatal management, and tailored surgical timing are critical to optimizing outcomes. Neonatal and cardiac intensivists, cardiologists, surgeons, anesthesiologists, and allied professionals must collaborate closely to address diverse challenges including hemodynamic instability, respiratory support, nutrition, neuroprotection, and social disparities. This review synthesizes current evidence on the epidemiology, pathophysiology, and management of neonates with CHD with a focus on prematurity. We highlight evolving models of interdisciplinary care and outline priorities for research. A physiology-based, team-oriented approach is essential to improve both survival and long-term quality of life for this vulnerable population. What is Known: * CHD is the most common birth defect and a leading cause of neonatal morbidity and mortality. * Prematurity and low birthweight worsen outcomes, with complications and surgical risk inversely related to gestational age. What is New: * Pregnancies with CHD carry up to a threefold higher risk of preterm delivery. * Outcomes reflect maternal-fetal and neonatal factors, highlighting the need for tailored timing, evaluation, and surgical strategies, with a key role for multidisciplinary care. CI - (c) 2026. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Lima, Giulia P AU - Lima GP AD - Department of Pediatrics, Division of Newborn Medicine, Harvard Medical School and Boston Children's Hospital, 300 Longwood Avenue, Hunnewell 436, Boston, MA, 02115, USA. FAU - Thomas, Alyssa R AU - Thomas AR AD - Department of Pediatrics, Division of Newborn Medicine, Brigham and Women's Hospital, Mass General Brigham Hospital for Children, Boston, MA, USA. FAU - Bradford, Victoria R AU - Bradford VR AD - Department of Pediatrics, Division of Newborn Medicine, Brigham and Women's Hospital, Mass General Brigham Hospital for Children, Boston, MA, USA. FAU - Morton, Sarah U AU - Morton SU AD - Department of Pediatrics, Division of Newborn Medicine, Harvard Medical School and Boston Children's Hospital, 300 Longwood Avenue, Hunnewell 436, Boston, MA, 02115, USA. FAU - Sperotto, Francesca AU - Sperotto F AD - Department of Pediatrics, Division of Newborn Medicine, Brigham and Women's Hospital, Mass General Brigham Hospital for Children, Boston, MA, USA. FAU - Levy, Philip T AU - Levy PT AUID- ORCID: 0000-0001-5103-5834 AD - Department of Pediatrics, Division of Newborn Medicine, Harvard Medical School and Boston Children's Hospital, 300 Longwood Avenue, Hunnewell 436, Boston, MA, 02115, USA. philip.levy@childrens.harvard.edu. LA - eng PT - Journal Article PT - Review DEP - 20260110 PL - Germany TA - Eur J Pediatr JT - European journal of pediatrics JID - 7603873 SB - IM MH - Humans MH - Infant, Newborn MH - *Heart Defects, Congenital/therapy/epidemiology/diagnosis/physiopathology MH - *Patient Care Team MH - Infant, Premature MH - Female MH - *Infant, Premature, Diseases/therapy OTO - NOTNLM OT - Congenital heart disease OT - Prematurity COIS- Declarations. Competing interests: The authors declare no competing interests. EDAT- 2026/01/10 00:34 MHDA- 2026/01/10 00:35 CRDT- 2026/01/09 23:35 PHST- 2025/10/01 00:00 [received] PHST- 2025/12/19 00:00 [accepted] PHST- 2025/12/12 00:00 [revised] PHST- 2026/01/10 00:35 [medline] PHST- 2026/01/10 00:34 [pubmed] PHST- 2026/01/09 23:35 [entrez] AID - 10.1007/s00431-025-06712-6 [pii] AID - 10.1007/s00431-025-06712-6 [doi] PST - epublish SO - Eur J Pediatr. 2026 Jan 10;185(2):66. doi: 10.1007/s00431-025-06712-6. PMID- 41513214 OWN - NLM STAT- MEDLINE DCOM- 20260625 LR - 20260625 IS - 1097-6868 (Electronic) IS - 0002-9378 (Linking) VI - 234 IP - 5 DP - 2026 May TI - Resuscitative cesarean delivery: prioritizing team preparedness for one of the most challenging obstetric emergencies. PG - 1560-1567 LID - S0002-9378(26)00012-8 [pii] LID - 10.1016/j.ajog.2025.12.071 [doi] AB - Resuscitative cesarean delivery, previously perimortem cesarean delivery, is one of the rarest, yet physically and emotionally demanding procedures in obstetrics. Maternal cardiac arrest occurs in approximately 1 in 12,000 delivery admissions, with frequent delays initiating interventions. Despite clear recommendations by the American Heart Association to begin resuscitative cesarean within 4 minutes of arrest and complete delivery within 1 to 2 minutes, real-world implementation remains challenging, particularly when resuscitation occurs outside of the operating room or in the absence of the obstetrical team. Effective resuscitation hinges upon the prompt availability and seamless coordination of multidisciplinary team members, clear communication, effective cardiopulmonary resuscitation, and timely resuscitative cesarean delivery. Here, we share a set of practical recommendations and lessons learned from institutional experience. We emphasize identification and removal of institutional barriers to timely intervention and highlight the value of preparation through low-cost, in-situ simulation. We propose a series of practical measures: creating standardized maternal cardiopulmonary resuscitation protocols and checklists, clearly defining obstetric team roles in resuscitation scenarios, reviewing technical aspects of both maternal and neonatal care, and conducting periodic multidisciplinary team-based simulations. These strategies are feasible even in resource-limited environments and aim to improve team performance and patient outcomes. Our proposed model highlights the leadership role of the obstetrician in the surgical aspects of care, while recognizing that advanced life support is better handled by specialized response teams. We advocate for enhanced collaboration with emergency medicine, neonatology, and support personnel to ensure a comprehensive and cohesive approach to patient care. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Nieto-Calvache, Albaro J AU - Nieto-Calvache AJ AD - Fundacion Valle del Lili, Departamento de Ginecologia y Obstetricia, Clinica de Espectro de Acretismo Placentario, Cali, Colombia. Electronic address: albaro.nieto@fvl.org.co. FAU - Palacios-Jaraquemada, Jose M AU - Palacios-Jaraquemada JM AD - Hospital Universitario CEMIC, Buenos Aires, Argentina. FAU - Shamshirsaz, Amir A AU - Shamshirsaz AA AD - Department of Obstetrics and Gynecology, Texas Children's Hospital, Houston, Houston, TX; Department of Critical Care Medicine, Baylor College of Medicine, Houston, TX. FAU - Fox, Karin A AU - Fox KA AD - University of Texas Medical Branch at Galveston, Galveston, TX. FAU - Messa-Bryon, Adriana AU - Messa-Bryon A AD - Fundacion Valle del Lili, Departamento de Ginecologia y Obstetricia, Clinica de Espectro de Acretismo Placentario, Cali, Colombia. FAU - Suarez-Revelo, Maria Alejandra AU - Suarez-Revelo MA AD - Centro de Investigaciones Clinicas, Fundacion Valle del Lili, Cali, Colombia. FAU - Echevarria, Maria Paula AU - Echevarria MP AD - Fundacion Valle del Lili, Departamento de Ginecologia y Obstetricia, Clinica de Espectro de Acretismo Placentario, Cali, Colombia. FAU - Lopez-Franco, Maria Jose AU - Lopez-Franco MJ AD - Facultad de Medicina, Universidad del Rosario, Bogota, Colombia. FAU - Ubom, Akaninyene E AU - Ubom AE AD - Department of Obstetrics and Gynaecology, Faculty of Clinical Sciences, PAMO University of Medical Sciences, Port Harcourt, Nigeria. FAU - Burgos-Luna, Juan Manuel AU - Burgos-Luna JM AD - Fundacion Valle del Lili, Departamento de Ginecologia y Obstetricia, Clinica de Espectro de Acretismo Placentario, Cali, Colombia. LA - eng PT - Journal Article DEP - 20260108 PL - United States TA - Am J Obstet Gynecol JT - American journal of obstetrics and gynecology JID - 0370476 SB - IM MH - Humans MH - Female MH - Pregnancy MH - *Cesarean Section/methods MH - *Heart Arrest/therapy MH - *Patient Care Team/organization & administration MH - *Cardiopulmonary Resuscitation/methods MH - Emergencies MH - Checklist EDAT- 2026/01/10 00:34 MHDA- 2026/04/21 17:43 CRDT- 2026/01/09 19:15 PHST- 2025/10/06 00:00 [received] PHST- 2025/12/24 00:00 [revised] PHST- 2025/12/24 00:00 [accepted] PHST- 2026/04/21 17:43 [medline] PHST- 2026/01/10 00:34 [pubmed] PHST- 2026/01/09 19:15 [entrez] AID - S0002-9378(26)00012-8 [pii] AID - 10.1016/j.ajog.2025.12.071 [doi] PST - ppublish SO - Am J Obstet Gynecol. 2026 May;234(5):1560-1567. doi: 10.1016/j.ajog.2025.12.071. Epub 2026 Jan 8. PMID- 41511846 OWN - NLM STAT- MEDLINE DCOM- 20260109 LR - 20261009 IS - 1541-8243 (Electronic) IS - 0038-4348 (Linking) VI - 119 IP - 1 DP - 2026 Jan TI - Cardiovascular Consequences of Anorexia Nervosa: QT Prolongation, Bradycardia, and Structural Cardiac Changes. PG - 44-48 LID - 10.14423/SMJ.0000000000001921 [doi] AB - Anorexia nervosa (AN) is a severe psychiatric disorder with profound cardiovascular consequences, including QT interval prolongation and bradycardia. These abnormalities contribute to an increased risk of life-threatening arrhythmias, sudden cardiac death, and long-term cardiac dysfunction. Although electrolyte imbalances and malnutrition are also recognized as key contributors, the precise mechanisms underlying these disturbances remain unclear. We conducted a comprehensive literature review using PubMed, Scopus, and Google Scholar to identify relevant studies published in the last 2 decades. Articles focusing on the cardiovascular impact of AN, particularly those addressing QT prolongation, bradycardia, structural cardiac changes, and autonomic dysfunction, were included. Corrected QT interval prolongation in AN varies widely across studies, with reported prevalence rates ranging from 0% to 40%, largely dependent on the applied threshold and patient population. Although some studies suggest that QT prolongation is not an inherent feature of AN, extrinsic factors such as hypokalemia, psychiatric medications, and refeeding complications significantly increase risk. Bradycardia in AN is driven primarily by autonomic dysfunction, metabolic adaptations, and reduced myocardial mass, with severe cases predisposing patients to syncope, hypotension, and cardiac arrest. Given the significant morbidity and mortality of these complications, a multidisciplinary approach is essential for timely diagnosis, prevention, and treatment. Further research is warranted to elucidate the underlying pathophysiological mechanisms and optimize therapeutic strategies for AN-related cardiac dysfunction. FAU - Poudel, Jigyasu AU - Poudel J AD - From the Institute of Medicine, Tribhuvan University, Kathmandu, Nepal. FAU - Rimal, Manita AU - Rimal M AD - Chitwan Medical College, Tribhuvan University, Bharatpur, Nepal. FAU - Giri, Alina AU - Giri A AD - Chitwan Medical College, Tribhuvan University, Bharatpur, Nepal. FAU - Chikatimalla, Rahul AU - Chikatimalla R AD - Kamineni Institute of Medical Sciences, Narketpally, Telangana, India. FAU - Banker, Himanshi AU - Banker H AUID- ORCID: 0009-0004-3824-1755 AD - Maulana Azad Medical College, New Delhi, India. FAU - Trivedi, Yash Vardhan AU - Trivedi YV AD - Jawaharlal Nehru Medical College, Ajmer, India. FAU - Gupta, Sarah AU - Gupta S AD - Barnard College of Columbia University, New York, New York. FAU - Jain, Rohit AU - Jain R AD - Department of Medicine, Penn State Milton S. Hershey Medical Centre, Hershey, Pennsylvania. LA - eng PT - Journal Article PT - Review PL - United States TA - South Med J JT - Southern medical journal JID - 0404522 SB - IM MH - Humans MH - *Anorexia Nervosa/complications/physiopathology MH - *Bradycardia/etiology/physiopathology MH - *Long QT Syndrome/etiology/physiopathology MH - Arrhythmias, Cardiac/etiology MH - Electrocardiography MH - Risk Factors EDAT- 2026/01/09 18:31 MHDA- 2026/01/09 18:32 CRDT- 2026/01/09 12:22 PHST- 2026/01/09 18:32 [medline] PHST- 2026/01/09 18:31 [pubmed] PHST- 2026/01/09 12:22 [entrez] AID - SMJ-25-057 [pii] AID - 10.14423/SMJ.0000000000001921 [doi] PST - ppublish SO - South Med J. 2026 Jan;119(1):44-48. doi: 10.14423/SMJ.0000000000001921. PMID- 41510219 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260109 LR - 20260926 IS - 2312-7996 (Electronic) IS - 2312-7996 (Linking) VI - 15 DP - 2025 TI - Redesigning Advanced Life Support teaching and assessment using a constructive alignment approach. PG - 48 LID - 10.12688/mep.20968.1 [doi] LID - 48 AB - Advanced Life Support (ALS) is a crucial component of medical training. Previously, a single-person OSCE-Station (Objective Structured Clinical Exam) was used to assess these skills, focusing primarily on the team leader role and emphasizing theoretical knowledge. However, students demonstrated deficiencies in key algorithm-compliant practical skills, such as cardiac massage, mask ventilation and defibrillator use, and struggled to integrate into a team-based resuscitation approach. To address this, a constructive alignment approach was used to revise the course and offer a guideline-appropriate, three-person resuscitation model. Learning outcomes and assessment targets were aligned with the course activities to increase student engagement and increase desired skill attainment. In the summer semester 2023, students and lecturers were briefed on the new structure of the course and assessment, specific skills were highlighted, and a model video was provided. The OSCE format was adjusted to assess both practical and non-technical skills. In the new setup, each student was randomly assigned one of three roles and assessed using role-specific checklists with defined criteria, focusing on non-technical and practical abilities. Course activity included training and practice in the three-person resuscitation approach. A team OSCE (tOSCE) approach for assessment was used, with one student for each role being examined. Results indicated both subjective and objective markers of satisfaction in course activities and tOSCE results. A team-based OSCE station proves effective for teaching combined practical and non-technical competencies. CI - Copyright: (c) 2025 Moll S et al. FAU - Moll, Sophie AU - Moll S AD - Department of Anaesthesiology and Intensive Care Medicine, University Hospital Essen, University Duisburg-Essen, Essen, 45147, Germany. FAU - Tannemann, Nico AU - Tannemann N AD - Department of Anaesthesiology and Intensive Care Medicine, University Hospital Essen, University Duisburg-Essen, Essen, 45147, Germany. FAU - Gestmann, Margarita AU - Gestmann M AD - Faculty of Medicine, University Duisburg-Essen, Essen, 45147, Germany. FAU - Brenner, Thorsten AU - Brenner T AD - Department of Anaesthesiology and Intensive Care Medicine, University Hospital Essen, University Duisburg-Essen, Essen, 45147, Germany. FAU - Herbstreit, Frank AU - Herbstreit F AD - Department of Anaesthesiology and Intensive Care Medicine, University Hospital Essen, University Duisburg-Essen, Essen, 45147, Germany. FAU - Szalai, Cynthia AU - Szalai C AUID- ORCID: 0000-0001-8308-3814 AD - Department of Anaesthesiology and Intensive Care Medicine, University Hospital Essen, University Duisburg-Essen, Essen, 45147, Germany. AD - Faculty of Medicine, University Duisburg-Essen, Essen, 45147, Germany. LA - eng PT - Journal Article DEP - 20250828 PL - Scotland TA - MedEdPublish (2016) JT - MedEdPublish (2016) JID - 9918418288706676 PMC - PMC12775656 OTO - NOTNLM OT - Advanced Life Support OT - Team OSCE OT - constructive alignment COIS- No competing interests were disclosed. EDAT- 2026/01/09 07:06 MHDA- 2026/01/09 07:07 PMCR- 2025/08/28 CRDT- 2026/01/09 05:09 PHST- 2025/08/21 00:00 [accepted] PHST- 2026/01/09 07:07 [medline] PHST- 2026/01/09 07:06 [pubmed] PHST- 2026/01/09 05:09 [entrez] PHST- 2025/08/28 00:00 [pmc-release] AID - 10.12688/mep.20968.1 [doi] PST - epublish SO - MedEdPublish (2016). 2025 Aug 28;15:48. doi: 10.12688/mep.20968.1. eCollection 2025. PMID- 41504945 OWN - NLM STAT- MEDLINE DCOM- 20260626 LR - 20261009 IS - 1437-2320 (Electronic) IS - 0344-5607 (Linking) VI - 49 IP - 1 DP - 2026 Jan 8 TI - Brain arteriovenous malformations (bAVMs) during pregnancy: An Italian survey and literature review. PG - 113 LID - 10.1007/s10143-025-04046-3 [doi] AB - Brain arteriovenous malformations (bAVMs) occur in approximately 0.001% to 0.5% of the general population. During pregnancy, bAVMs remain uncommon vascular lesions, with an estimated incidence of about 1 per 100,000 per year in unselected populations. Maternal physiological changes, such as the increase in cardiac output and increased estrogen levels during pregnancy make the structure of the vessels more prone to rupture. Our study investigates the management of bAVM in pregnant patients, reporting data from an Italian survey and literature review. On behalf of an ad hoc task force of the Neuro-Vascular Committee of SINch (Societa Italiana di Neurochirurgia), a survey on the treatment options and management of vascular brain lesions during pregnancy was conducted to analyze the management of pregnant patients diagnosed with bAVM between January 2011 and September 2021. We also conducted a literature search in MEDLINE (PubMed) according to PRISMA guidelines published between 1967 and 2022. A total of 18 neurosurgical centers participate in the survey. 15 pregnant women with bAVM were included in this retrospective study. Seizures occurred in 20% of cases, headache in 33.3%, hemiparesis in 13.4%. Emergency surgical intervention was required in 46.7% of cases, of which neurosurgical treatment (haematoma evacuation + bAVM exclusion) was performed in 85% of cases; endovascular treatment was required in one case. The Cesarian Section (C-section) was performed in nine cases (60%, 9/15), of which 8 (88.9%) were emergency and 1 (12.1%) elective. Conclusion The association between pregnancy and bAVM is a rare event that threatens the lives of mother and child, posing neurosurgical, obstetric and ethical challenges. A multidisciplinary approach should be pursued. In case of rupture of bAVM, the best treatment should be decided on a case-by-case basis. C-section appears to be safer than vaginal delivery. In the future, a multicenter study will hopefully provide overarching recommendations for the management of bAVM patients during pregnancy. FAU - Somma, Teresa AU - Somma T AD - Division of Neurosurgery, Department of Neurological Sciences, Universita degli Studi di Napoli Federico II, Naples, Italy. FAU - Bove, Ilaria AU - Bove I AD - Division of Neurosurgery, Department of Neurological Sciences, Universita degli Studi di Napoli Federico II, Naples, Italy. ilaria.bove@unina.it. AD - Division of Neurosurgery, Department of Neurosciences, Reproductive and Odontostomatological Sciences, Universita degli Studi di Napoli Federico II, Naples, Italy. ilaria.bove@unina.it. FAU - Ius, Tamara AU - Ius T AD - Academic Neurosurgery, Department of Neurosciences, University of Padua, Padua, Italy. FAU - Caffo, Maria AU - Caffo M AD - Unit of Neurosurgery, Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, 98125, Italy. FAU - Santi, Laura AU - Santi L AD - Neurosurgical Unit of Sondrio ASST - Valtellina e alto Lario, Sondrio, Italy. FAU - Vitulli, Francesca AU - Vitulli F AD - Division of Neurosurgery, Department of Neurological Sciences, Universita degli Studi di Napoli Federico II, Naples, Italy. FAU - Basaldella, Luca AU - Basaldella L AD - Unit of Neurosurgery, Department of Neurosciences, Angel Hospital, Mestre, VE, 30174, Italy. FAU - Montemurro, Nicola AU - Montemurro N AD - Department of Neurosurgery, Azienda Ospedaliero Universitaria Pisana, Pisa, 56100, Italy. FAU - Zoia, Cesare AU - Zoia C AD - Unit of Neurosurgery, Department of Surgical Sciences, San Matteo Hospital Foundation (IRCCS), Pavia, Italy. FAU - Spena, Giannantonio AU - Spena G AD - Unit of Neurosurgery, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. FAU - Sarrubbo, Silvio AU - Sarrubbo S AD - Division of Neurosurgery, Structural and Functional Connectivity Lab Project, Trento, Italy. FAU - Alafaci, Concetta AU - Alafaci C AD - Unit of Neurosurgery, Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, 98125, Italy. FAU - Angileri, Flavio AU - Angileri F AD - Unit of Neurosurgery, Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, 98125, Italy. FAU - Pessina, Federico AU - Pessina F AD - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy. FAU - Alviggi, Carlo AU - Alviggi C AD - Department of Public Health, University of Naples Federico II, Naples, Italy. FAU - Catapano, Giuseppe AU - Catapano G AD - UOC Neurochirurgia Ospedale del Mare, ASL Napoli 1 Centro, Naples, Italy. FAU - Cavallo, Luigi Maria AU - Cavallo LM AD - Division of Neurosurgery, Department of Neurological Sciences, Universita degli Studi di Napoli Federico II, Naples, Italy. FAU - Albanese, Alessio AU - Albanese A AD - Department of Neurosurgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, Universita Cattolica del Sacro Cuore, Rome, Italy. FAU - Bortolotti, Carlo AU - Bortolotti C AD - Division of Neurosurgery, Istituto Delle Scienze Neurologiche Di Bologna, IRCCS Bellaria Hospital, Bologna, Italy. LA - eng PT - Journal Article PT - Review DEP - 20260108 PL - Germany TA - Neurosurg Rev JT - Neurosurgical review JID - 7908181 SB - IM MH - Humans MH - Female MH - Pregnancy MH - *Intracranial Arteriovenous Malformations/surgery/epidemiology MH - Italy MH - Adult MH - Retrospective Studies MH - *Pregnancy Complications, Cardiovascular/surgery MH - Surveys and Questionnaires MH - Neurosurgical Procedures/methods OTO - NOTNLM OT - Brain arteriovenous malformations (bAVM) OT - Intracranial hemorrhage OT - Pregnancy OT - Vascular brain lesions COIS- Declarations. Human ethics and consent to participate declarations: Not applicable. Clinical trial number: Not applicable. Human and animal rights: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study, formal consent was required. Competing interests: No datasets were generated or analysed during the current study. EDAT- 2026/01/08 17:51 MHDA- 2026/06/27 00:56 CRDT- 2026/01/08 11:14 PHST- 2025/08/27 00:00 [received] PHST- 2025/12/13 00:00 [accepted] PHST- 2025/11/26 00:00 [revised] PHST- 2026/06/27 00:56 [medline] PHST- 2026/01/08 17:51 [pubmed] PHST- 2026/01/08 11:14 [entrez] AID - 10.1007/s10143-025-04046-3 [pii] AID - 10.1007/s10143-025-04046-3 [doi] PST - epublish SO - Neurosurg Rev. 2026 Jan 8;49(1):113. doi: 10.1007/s10143-025-04046-3. PMID- 41502082 OWN - NLM STAT- MEDLINE DCOM- 20260625 LR - 20260625 IS - 1365-277X (Electronic) IS - 0952-3871 (Linking) VI - 39 IP - 1 DP - 2026 Feb TI - A Qualitative Exploration of Barriers and Facilitators Influencing Nutritional Recovery in Survivors of Critical Illness After Hospital Discharge. PG - e70194 LID - 10.1111/jhn.70194 [doi] AB - INTRODUCTION: After hospital discharge, survivors of critical illness often struggle to meet their nutritional needs, which can impair long-term recovery and quality of life. However, the factors influencing nutritional recovery in the early post-discharge period remain poorly understood. This qualitative study aimed to identify and describe the barriers and facilitators influencing nutritional recovery among critical illness survivors after hospital discharge. METHODS: A qualitative health research approach was adopted using qualitative description. A convenience sample of 15 adult critical illness survivors were recruited from medical, surgical, and cardiac intensive care units (ICUs) in New York City from August 2024 to April 2025. Semi-structured interviews were conducted virtually 3 months after hospital discharge. Data were analyzed using directed content analysis. RESULTS: Reported barriers to nutritional recovery included individual-level factors (physiological, functional, and psychological) and systems-level challenges (gaps in nutrition care continuity and inadequate healthcare team communication and support). Facilitators included family support, accessible nutrition services, multidisciplinary healthcare team involvement, and improvements in recovery over time. Patients consistently expressed a desire for regular post-discharge nutrition follow-up and individualized nutrition education tailored to post-ICU recovery. CONCLUSION: Collectively, these findings revealed that survivors of critical illness encounter numerous barriers to nutritional recovery after hospital discharge, but support from family, dietitians, and healthcare teams can help overcome these challenges. Continuity of dietitian-led care and tailored nutrition education may address unmet needs and improve the nutritional recovery experience of critical illness survivors. CI - (c) 2026 The British Dietetic Association Ltd. FAU - Dudzik, Josephine AU - Dudzik J AUID- ORCID: 0000-0001-5356-1109 AD - Department of Nutrition and Food Studies, Steinhardt School of Culture, Education, and Human Development, New York University, New York City, New York, USA. FAU - Linskens, Sarah AU - Linskens S AD - Department of Nutrition and Food Studies, Steinhardt School of Culture, Education, and Human Development, New York University, New York City, New York, USA. AD - West Chester University, West Chester, Pennsylvania, USA. FAU - Balk, Ethan AU - Balk E AD - Department of Nutrition and Food Studies, Steinhardt School of Culture, Education, and Human Development, New York University, New York City, New York, USA. LA - eng GR - Academy of Nutrition and Dietetics Foundation, Dietitians in Nutrition Support Dietetic Practice Group/ PT - Journal Article PL - England TA - J Hum Nutr Diet JT - Journal of human nutrition and dietetics : the official journal of the British Dietetic Association JID - 8904840 SB - IM MH - Humans MH - *Critical Illness/rehabilitation/psychology MH - *Patient Discharge MH - *Survivors/psychology MH - Qualitative Research MH - Middle Aged MH - Male MH - Female MH - Intensive Care Units MH - *Nutritional Status MH - Aged MH - Quality of Life MH - Adult MH - New York City MH - Continuity of Patient Care MH - Patient Care Team MH - *Nutrition Therapy OTO - NOTNLM OT - critical illness OT - nutrition therapy OT - nutritional status OT - patient discharge OT - qualitative research EDAT- 2026/01/08 07:12 MHDA- 2026/01/08 07:13 CRDT- 2026/01/08 01:33 PHST- 2025/12/19 00:00 [revised] PHST- 2025/11/03 00:00 [received] PHST- 2025/12/24 00:00 [accepted] PHST- 2026/01/08 07:13 [medline] PHST- 2026/01/08 07:12 [pubmed] PHST- 2026/01/08 01:33 [entrez] AID - 10.1111/jhn.70194 [doi] PST - ppublish SO - J Hum Nutr Diet. 2026 Feb;39(1):e70194. doi: 10.1111/jhn.70194. PMID- 41497987 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260107 LR - 20260109 IS - 2772-9303 (Electronic) IS - 2772-9303 (Linking) VI - 4 IP - 12 DP - 2025 Dec TI - Contemporary Chronic Limb-Threatening Ischemia Care in the United States-Part 1: A Path Toward Multispecialty Collaboration. PG - 104013 LID - 10.1016/j.jscai.2025.104013 [doi] LID - 104013 AB - Care for patients with chronic limb-threatening ischemia (CLTI) is complex, and it is most effective when conducted with collaboration across multiple specialties. A recent upward trend in major limb amputation among patients with CLTI warrants a renewed effort to optimize care for this multifaceted condition. The Vascular InterVentional Advances (VIVA) Foundation, a not-for-profit 501(c)(3) organization, convened a Vascular Leaders Forum in 2024 to initiate an open, multispecialty discussion about the state of CLTI care in the United States and current challenges around delivery and access to such care. The forum comprised representatives from vascular surgery, interventional cardiology, interventional radiology, vascular medicine, podiatry, regulators, medical device manufacturers, patient advocacy, and the CLTI and CLTI caregiver population. This article explores the central themes of challenges in CLTI care and ways in which collaboration across specialties and care settings could improve CLTI outcomes. In summary, it was recommended that integrated CLTI care teams extend beyond vascular surgery, interventional cardiology, and interventional radiology to include vascular medicine, podiatry, wound care, diabetology, and dietetics. Meeting the increasing demand for CLTI revascularization will require these teams to span tertiary care hospitals, community hospitals, outpatient revascularization clinics, and primary care settings. CI - (c) 2025 The Author(s). FAU - Secemsky, Eric A AU - Secemsky EA AD - Division of Cardiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts. FAU - Armstrong, Ehrin J AU - Armstrong EJ AD - Department of Interventional Cardiology, Advanced Heart and Vein Center, Denver, Colorado. FAU - Chandra, Venita AU - Chandra V AD - Division of Vascular Surgery, Stanford University Medical Center, Stanford, California. FAU - Kolluri, Raghu AU - Kolluri R AD - Cardiovascular Service Line-OhioHealth Riverside Methodist Hospital, Columbus, Ohio. FAU - Patel, Parag J AU - Patel PJ AD - Division of Interventional Radiology, Department of Radiology, Medical College of Wisconsin, Milwaukee, Wisconsin. FAU - Schneider, Peter A AU - Schneider PA AD - Division of Vascular and Endovascular Surgery, University of California, San Francisco, California. FAU - Singh, Niten AU - Singh N AD - Division of Vascular Surgery, Department of Surgery, Harborview Medical Center, Seattle, Washington. LA - eng PT - Journal Article PT - Review DEP - 20251103 PL - United States TA - J Soc Cardiovasc Angiogr Interv JT - Journal of the Society for Cardiovascular Angiography & Interventions JID - 9918419271306676 PMC - PMC12766042 OTO - NOTNLM OT - chronic limb-threatening ischemia OT - cross-specialty OT - interdisciplinary OT - multispecialty OT - team-based care EDAT- 2026/01/07 06:30 MHDA- 2026/01/07 06:31 PMCR- 2025/11/03 CRDT- 2026/01/07 04:57 PHST- 2025/04/02 00:00 [received] PHST- 2025/08/21 00:00 [revised] PHST- 2025/09/09 00:00 [accepted] PHST- 2026/01/07 06:31 [medline] PHST- 2026/01/07 06:30 [pubmed] PHST- 2026/01/07 04:57 [entrez] PHST- 2025/11/03 00:00 [pmc-release] AID - S2772-9303(25)01459-0 [pii] AID - 104013 [pii] AID - 10.1016/j.jscai.2025.104013 [doi] PST - epublish SO - J Soc Cardiovasc Angiogr Interv. 2025 Nov 3;4(12):104013. doi: 10.1016/j.jscai.2025.104013. eCollection 2025 Dec. PMID- 41495683 OWN - NLM STAT- MEDLINE DCOM- 20260627 LR - 20261014 IS - 1471-2318 (Electronic) IS - 1471-2318 (Linking) VI - 26 IP - 1 DP - 2026 Jan 7 TI - Healthcare needs and priorities of older people living with heart failure and frailty: a multi-perspective study of patients, carers and clinicians. PG - 163 LID - 10.1186/s12877-025-06926-1 [doi] LID - 163 AB - BACKGROUND: Older people living with heart failure (HF) and frailty are a complex population growing in prevalence. Given the high level of comorbidity among these patients, a person-centered, holistic model of care is required to optimise outcomes in this cohort. However, there is limited knowledge on what matters to these patients and if current care pathways address their needs. We aimed to explore the healthcare needs and priorities of older people with HF and frailty from the perspective of patients, carers and clinicians. METHODS: In a step-wise, multi-method study, we conducted a qualitative survey followed by in-depth interviews among older adults (>/= 65 years) with HF and frailty (Clinical Frailty Score >/= 5), their informal carers (>/= 18 years) and healthcare professionals at a tertiary hospital in the UK. An inductive thematic analysis was performed on the data using the Framework Method. RESULTS: Between January - May 2023, 160 individuals completed the survey and 23 participated in interviews. Combined analysis of surveys and interviews revealed two major themes (i.e., healthcare needs and perceived health-related goals) and 14 subthemes. Healthcare needs identified were: (i) management of medical issues; (ii) regaining physical functioning; (iii) pharmaceutical care; (iv) nutritional care; (v) assistance with activities of daily living (ADL); (vi) environmental and social support and (vii) access to healthcare. Their health-related goals were: (i) being ADL-independent; (ii) remaining HF-symptom free; (iii); improved quality of life; (iv) being with family; (v) not a burden to family; (vi) avoiding hospitalisation and (vii) longevity. CONCLUSION: Healthcare needs of older patients living with HF and frailty are manifold; a key finding was that preserving functional capacity was given greater importance than longevity by this population. A multidisciplinary approach aligned with patients' health priorities is essential for delivery of a meaningful goal-concordant care. FAU - Krishnan, Sunanthiny AU - Krishnan S AD - NIHR Cardiovascular Research Centre and Department of Cardiovascular Sciences, University of Leicester, Glenfield Hospital, Leicester, LE3 9QP, UK. sssk2@leicester.ac.uk. FAU - Gogoi, Mayuri AU - Gogoi M AD - Department of Respiratory Sciences, University of Leicester, Leicester, LE1 7RH, UK. AD - Development Centre for Population Health, University of Leicester, Leicester, LE1 7RH, UK. FAU - Tarrant, Carolyn AU - Tarrant C AD - Department of Population Health Sciences, University of Leicester, Leicester, LE1 7RH, UK. AD - NIHR Greater Manchester Patient Safety Research Collaboration (GM PSRC), University of Manchester, Manchester, M13 9PL, UK. FAU - Conroy, Simon AU - Conroy S AD - Barts Health NHS Trust and Queen Mary University of London, London, E1 4NS, UK. FAU - Clayton, Louise AU - Clayton L AD - Department of Cardiology, Glenfield Hospital, Leicester, LE3 9QP, UK. FAU - Squire, Iain B AU - Squire IB AD - NIHR Cardiovascular Research Centre and Department of Cardiovascular Sciences, University of Leicester, Glenfield Hospital, Leicester, LE3 9QP, UK. FAU - Sze, Shirley AU - Sze S AD - NIHR Cardiovascular Research Centre and Department of Cardiovascular Sciences, University of Leicester, Glenfield Hospital, Leicester, LE3 9QP, UK. AD - Department of Population Health Sciences, University of Leicester, Leicester, LE1 7RH, UK. AD - Department of Cardiology, Glenfield Hospital, Leicester, LE3 9QP, UK. LA - eng GR - HFHF_025/BHF_/British Heart Foundation/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20260107 PL - England TA - BMC Geriatr JT - BMC geriatrics JID - 100968548 SB - IM MH - Humans MH - *Heart Failure/therapy/psychology/epidemiology MH - Female MH - Male MH - Aged MH - *Caregivers/psychology MH - *Frailty/therapy/epidemiology/psychology MH - Aged, 80 and over MH - *Frail Elderly/psychology MH - *Health Services Needs and Demand/trends MH - *Health Priorities/trends MH - *Health Personnel/psychology MH - Quality of Life MH - Activities of Daily Living PMC - PMC12870965 OTO - NOTNLM OT - Frailty OT - Health-related goals OT - Healthcare needs OT - Heart failure OT - Older people COIS- Declarations. Ethics approval and consent to participate: This study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Research Ethics Committee of Health Research Authority and Health Care Research Wales (REC Ref: 22/EM/0172). Information about the study was given to potential participants both orally and in writing at recruitment. Written informed consent was obtained from all participants prior to the survey and interview. Consent for publication: Not applicable. Competing interests: CT - Funded by the NIHR Greater Manchester Patient Safety Research Collaboration (GM PSRC); SS - Supported by the NIHR Leicester CRF and NIHR academic clinical lectureship. All other authors declare that they have no competing interests. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. EDAT- 2026/01/07 01:11 MHDA- 2026/06/27 12:38 PMCR- 2026/01/07 CRDT- 2026/01/06 23:46 PHST- 2025/08/29 00:00 [received] PHST- 2025/12/16 00:00 [accepted] PHST- 2026/06/27 12:38 [medline] PHST- 2026/01/07 01:11 [pubmed] PHST- 2026/01/06 23:46 [entrez] PHST- 2026/01/07 00:00 [pmc-release] AID - 10.1186/s12877-025-06926-1 [pii] AID - 6926 [pii] AID - 10.1186/s12877-025-06926-1 [doi] PST - epublish SO - BMC Geriatr. 2026 Jan 7;26(1):163. doi: 10.1186/s12877-025-06926-1. PMID- 41492447 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260106 LR - 20260108 IS - 2666-6022 (Electronic) IS - 2666-6022 (Linking) VI - 61 DP - 2026 Jan TI - Educational innovation in cardiovascular care: Developing a curriculum for women's cardiovascular health. PG - 100693 LID - 10.1016/j.ahjo.2025.100693 [doi] LID - 100693 AB - Cardiovascular disease (CVD) is the leading cause of death among women in the United States, with significant knowledge gaps in sex-specific care among providers. To address this, we developed and implemented a structured, multidisciplinary women's cardiovascular health (CVH) curriculum within the cardiovascular fellowship program at the University of Virginia. The curriculum focused on women-specific cardiovascular health, including cardio-obstetrics, spontaneous coronary artery dissection (SCAD) and coronary microvascular disease (CMD), and encompassed didactic lectures and unique experiential learning through clinical work, research, and community outreach. This multidisciplinary approach enhances individualized care and prepares trainees to recognize and treat the unique cardiovascular needs of women. Continued development of such curricula is crucial for reducing morbidity and mortality disparities in CVD. CI - (c) 2025 The Author(s). FAU - Borgarelli, Giorgia AU - Borgarelli G AD - Department of Family Medicine, University of Virginia Health, Charlottesville, VA, USA. FAU - Singulane, Cristiane C AU - Singulane CC AD - Department of Medicine, Cardiovascular Division, University of Virginia Health, Charlottesville, VA, USA. FAU - Montana, Paul AU - Montana P AD - Department of Medicine, Cardiovascular Division, University of Virginia Health, Charlottesville, VA, USA. FAU - Lefbom, Lucie AU - Lefbom L AD - Department of Medicine, University of Virginia Health, Charlottesville, VA, USA. FAU - Karra, Hakinya AU - Karra H AD - Department of Medicine, University of Virginia Health, Charlottesville, VA, USA. FAU - Watts, Kelsey AU - Watts K AD - Center for Public Health Genomics, University of Virginia School of Medicine, Charlottesville, VA, USA. FAU - Harrison, Kara AU - Harrison K AD - Department of Medicine, University of Virginia Health, Charlottesville, VA, USA. FAU - Choffel, Jennifer M AU - Choffel JM AD - Department of Medicine, Cardiovascular Division, University of Virginia Health, Charlottesville, VA, USA. FAU - Ennen, Christopher S AU - Ennen CS AD - Department of Obstetrics and Gynecology, University of Virginia School of Medicine, Charlottesville, VA, USA. FAU - Sharma, Aditya M AU - Sharma AM AD - Department of Medicine, Cardiovascular Division, University of Virginia Health, Charlottesville, VA, USA. FAU - Wingerter, Kelly E AU - Wingerter KE AD - Department of Medicine, Cardiovascular Division, University of Virginia Health, Charlottesville, VA, USA. FAU - Soukoulis, Victor AU - Soukoulis V AD - Department of Medicine, Cardiovascular Division, University of Virginia Health, Charlottesville, VA, USA. FAU - Rodriguez-Lozano, Patricia F AU - Rodriguez-Lozano PF AD - Department of Medicine, Cardiovascular Division, University of Virginia Health, Charlottesville, VA, USA. AD - Department of Radiology and Medical Imaging, University of Virginia Health, Charlottesville, VA, USA. LA - eng PT - Journal Article DEP - 20251209 PL - United States TA - Am Heart J Plus JT - American heart journal plus : cardiology research and practice JID - 101779333 PMC - PMC12764439 OTO - NOTNLM OT - Cardio-obstetrics OT - Health disparities OT - Innovation on education OT - Multidisciplinary Care OT - Women's Health COIS- The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2026/01/06 13:06 MHDA- 2026/01/06 13:07 PMCR- 2025/12/09 CRDT- 2026/01/06 11:56 PHST- 2024/08/15 00:00 [received] PHST- 2025/07/31 00:00 [revised] PHST- 2025/12/07 00:00 [accepted] PHST- 2026/01/06 13:07 [medline] PHST- 2026/01/06 13:06 [pubmed] PHST- 2026/01/06 11:56 [entrez] PHST- 2025/12/09 00:00 [pmc-release] AID - S2666-6022(25)00196-X [pii] AID - 100693 [pii] AID - 10.1016/j.ahjo.2025.100693 [doi] PST - epublish SO - Am Heart J Plus. 2025 Dec 9;61:100693. doi: 10.1016/j.ahjo.2025.100693. eCollection 2026 Jan. PMID- 41490934 OWN - NLM STAT- MEDLINE DCOM- 20260324 LR - 20261009 IS - 1476-5543 (Electronic) IS - 0743-8346 (Linking) VI - 46 IP - 3 DP - 2026 Mar TI - Importance of clinical practice guidelines for specialized delivery room resuscitation of newborns with prenatally diagnosed critical congenital heart disease. PG - 491-494 LID - 10.1038/s41372-025-02552-2 [doi] AB - Perinatal transition is uniquely complex in newborns with critical congenital heart disease (CCHD), whose cardiopulmonary physiology often diverges from the standard neonatal resuscitation framework. We developed lesion-specific clinical practice guidelines (CPGs) for delivery room (DR) management of six high-risk CCHD diagnoses - hypoplastic left heart syndrome, dextro- transposition of the great arteries, Ebstein anomaly, congenital complete heart block, total anomalous pulmonary venous return, and tetralogy of Fallot with absent pulmonary valve. Developed collaboratively between neonatologists, cardiologists, and cardiac intensivists, these guidelines standardize DR stabilization for high-risk, low frequency events, promote a shared mental model among multidisciplinary teams, and provide structured escalation thresholds for oxygen, respiratory support, intubation, and medication use. Beyond clinical standardization, these CPGs enhance provider education, team preparedness, and family counseling. They offer a scalable framework adaptable to centers with or without on-site cardiac care, bridging physiologic principles with practical implementation. CI - (c) 2026. The Author(s), under exclusive licence to Springer Nature America, Inc. FAU - Thomas, Alyssa R AU - Thomas AR AUID- ORCID: 0000-0002-8097-7385 AD - Division of Newborn Medicine, Department of Pediatrics, Brigham and Women's Hospital, Mass General Brigham for Children, Boston, MA, USA. Athomas20@mgb.org. AD - Department of Pediatrics, Harvard Medical School, Boston, MA, USA. Athomas20@mgb.org. FAU - Geisser, Diana AU - Geisser D AD - Department of Pediatrics, Harvard Medical School, Boston, MA, USA. AD - Department of Cardiology, Boston Children's Hospital, Boston, MA, USA. FAU - Kaza, Elisabeth AU - Kaza E AD - Division of Newborn Medicine, Department of Pediatrics, Brigham and Women's Hospital, Mass General Brigham for Children, Boston, MA, USA. AD - Department of Pediatrics, Harvard Medical School, Boston, MA, USA. FAU - Allan, Catherine AU - Allan C AD - Children's Institute Department of Heart, Vascular, and Thoracic, Division of Cardiology and Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA. FAU - Abdulhayoglu, Elisa AU - Abdulhayoglu E AD - Division of Newborn Medicine, Department of Pediatrics, Brigham and Women's Hospital, Mass General Brigham for Children, Boston, MA, USA. AD - Department of Pediatrics, Harvard Medical School, Boston, MA, USA. FAU - Flanigan, Elizabeth AU - Flanigan E AD - Division of Newborn Medicine, Department of Pediatrics, Brigham and Women's Hospital, Mass General Brigham for Children, Boston, MA, USA. AD - Department of Pediatrics, Harvard Medical School, Boston, MA, USA. FAU - Dionne, Audrey AU - Dionne A AD - Department of Pediatrics, Harvard Medical School, Boston, MA, USA. AD - Department of Cardiology, Boston Children's Hospital, Boston, MA, USA. FAU - Kerstein, Jason AU - Kerstein J AD - Department of Pediatrics, Harvard Medical School, Boston, MA, USA. AD - Department of Cardiology, Boston Children's Hospital, Boston, MA, USA. FAU - Valencia, Eleonore AU - Valencia E AD - Department of Pediatrics, Harvard Medical School, Boston, MA, USA. AD - Department of Cardiology, Boston Children's Hospital, Boston, MA, USA. FAU - Manning, Simon AU - Manning S AD - Division of Newborn Medicine, Department of Pediatrics, Brigham and Women's Hospital, Mass General Brigham for Children, Boston, MA, USA. AD - Department of Pediatrics, Harvard Medical School, Boston, MA, USA. FAU - Goldberg, Sarah AU - Goldberg S AD - Department of Pediatrics, Harvard Medical School, Boston, MA, USA. AD - Department of Cardiology, Boston Children's Hospital, Boston, MA, USA. LA - eng PT - Journal Article PT - Review DEP - 20260105 PL - United States TA - J Perinatol JT - Journal of perinatology : official journal of the California Perinatal Association JID - 8501884 SB - IM MH - Humans MH - Infant, Newborn MH - *Heart Defects, Congenital/therapy/diagnosis MH - *Delivery Rooms/standards MH - *Practice Guidelines as Topic MH - *Resuscitation/standards/methods MH - Pregnancy MH - Female MH - Prenatal Diagnosis MH - Patient Care Team COIS- Competing interests: The authors declare no competing interests. EDAT- 2026/01/06 13:06 MHDA- 2026/03/24 07:41 CRDT- 2026/01/06 10:54 PHST- 2025/10/17 00:00 [received] PHST- 2025/12/18 00:00 [accepted] PHST- 2025/12/01 00:00 [revised] PHST- 2026/03/24 07:41 [medline] PHST- 2026/01/06 13:06 [pubmed] PHST- 2026/01/06 10:54 [entrez] AID - 10.1038/s41372-025-02552-2 [pii] AID - 10.1038/s41372-025-02552-2 [doi] PST - ppublish SO - J Perinatol. 2026 Mar;46(3):491-494. doi: 10.1038/s41372-025-02552-2. Epub 2026 Jan 5. PMID- 41490144 OWN - NLM STAT- MEDLINE DCOM- 20260706 LR - 20260717 IS - 1477-111X (Electronic) IS - 0267-6591 (Linking) VI - 41 IP - 5 DP - 2026 Jul TI - Perfusionist's role in long-term ventricular assist device. PG - 576-584 LID - 10.1177/02676591251415511 [doi] AB - IntroductionVentricular assist devices (VADs) have emerged as essential tools for stage D heart failure, improving survival and quality of life by serving as a bridge to transplant, destination therapy, or bridge to decision. The successful implantation and management of VADs requires a multidisciplinary team, in which perfusionists have a critical role in ensuring proper oxygen delivery, hemodynamic support, and the smooth transition from extracorporeal support to the implanted device. The objective was to describe the institutional perfusion protocol for LVAD implantation and to characterize intraoperative perfusion parameters at a Latin American referral center.MethodsA retrospective observational cohort study was conducted including all patients who underwent LVAD implantation at a referral center in northeastern Colombia. Statistical analysis involved the use of descriptive statistics.ResultsA total of 33 patients underwent LVAD implantation, with a median age of 54 years and 51.52% of male. Ischemic cardiomyopathy was the leading etiology (27.27%). The median cardiopulmonary bypass (CPB) time was 153 min (IQR: 128-181). During cardiopulmonary bypass the median lactate levels were 1.8 mmol/L (IQR: 1.5-2.2), and the cardiac index ranged from a minimum CI of 2.3 to a maximum CI of 2.6 L/min/m(2).ConclusionsThis study highlights the vital role of cardiopulmonary perfusion in the successful implantation of long-term LVADs in advanced heart failure patients. Optimal intraoperative management, including controlled temperature, low lactate levels, and optimal cardiac index, emphasizes the need for standardized strategies and the expertise of perfusionists. FAU - Perea Bautista, Yolly Gigliola AU - Perea Bautista YG AD - Vascular Nursing and Perfusion Department, Hospital Internacional de Colombia - Instituto Cardiovascular, Floridablanca, Colombia. FAU - Estrada Garcia, Yadira AU - Estrada Garcia Y AD - Department of Cardiovascular Anesthesiology, Fundacion Cardiovascular de Colombia, Piedecuesta, Colombia. RINGGOLD: 204423 FAU - Gomez, Dafna Garcia AU - Gomez DG AD - Department of Cardiovascular Surgery, Fundacion Cardiovascular de Colombia, Santander, Colombia. RINGGOLD: 204423 FAU - Manrique-Hernandez, Edgar Fabian AU - Manrique-Hernandez EF AUID- ORCID: 0000-0002-3634-8821 AD - Department of Epidemiology, Fundacion Cardiovascular de Colombia, Piedecuesta, Colombia. RINGGOLD: 204423 FAU - Licht-Ardila, Maricel AU - Licht-Ardila M AD - Department of Epidemiology, Fundacion Cardiovascular de Colombia, Piedecuesta, Colombia. RINGGOLD: 204423 FAU - Mendoza-Monsalve, Alejandra AU - Mendoza-Monsalve A AD - Department of Epidemiology, Fundacion Cardiovascular de Colombia, Piedecuesta, Colombia. RINGGOLD: 204423 FAU - Hurtado-Ortiz, Alexandra AU - Hurtado-Ortiz A AUID- ORCID: 0000-0002-3001-2374 AD - Department of Epidemiology, Fundacion Cardiovascular de Colombia, Piedecuesta, Colombia. RINGGOLD: 204423 FAU - Prieto, Gustavo AU - Prieto G AUID- ORCID: 0000-0002-0290-1318 AD - Department of Cardiovascular Surgery, Fundacion Cardiovascular de Colombia, Santander, Colombia. RINGGOLD: 204423 FAU - Salazar, Leonardo AU - Salazar L AD - ECMO Department, Fundacion Cardiovascular de Colombia, Piedecuesta, Colombia. RINGGOLD: 204423 LA - eng PT - Journal Article PT - Observational Study DEP - 20260105 PL - England TA - Perfusion JT - Perfusion JID - 8700166 SB - IM MH - Humans MH - *Heart-Assist Devices MH - Male MH - Middle Aged MH - *Heart Failure/surgery/therapy MH - Female MH - Retrospective Studies MH - *Cardiopulmonary Bypass/methods MH - *Perfusion/methods MH - Adult OTO - NOTNLM OT - anesthesia OT - cardiac procedures OT - extracorporeal circulation OT - heart failure OT - heart-assist devices OT - perfusion COIS- Declaration of conflicting interestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2026/01/06 13:06 MHDA- 2026/07/06 12:41 CRDT- 2026/01/06 10:32 PHST- 2026/07/06 12:41 [medline] PHST- 2026/01/06 13:06 [pubmed] PHST- 2026/01/06 10:32 [entrez] AID - 10.1177/02676591251415511 [doi] PST - ppublish SO - Perfusion. 2026 Jul;41(5):576-584. doi: 10.1177/02676591251415511. Epub 2026 Jan 5. PMID- 41484225 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260106 LR - 20260108 IS - 2398-6352 (Electronic) IS - 2398-6352 (Linking) VI - 9 IP - 1 DP - 2026 Jan 3 TI - Powering responsible artificial intelligence with high-quality real-world data: the S-RACE platform for scalable, multi-specialty clinical research. PG - 6 LID - 10.1038/s41746-025-02132-w [doi] LID - 6 AB - The translation of Artificial Intelligence (AI) into clinical practice demands high-quality Real-World Data (RWD), yet unstructured healthcare information poses a significant barrier. To address this, we developed S-RACE, a secure, cloud-based platform designed to systematically transform raw hospital data into high-quality, research-grade evidence. S-RACE features an end-to-end pipeline, starting with on-premises anonymisation for data privacy, followed by Natural Language Processing (NLP) to extract and standardise clinical information into the FHIR format. This curated data foundation is essential for building robust AI models. The platform's integrated "Data Science Lab" supports responsible AI development, incorporating explainability techniques and adhering to governance standards like ISO 42001 and the EU AI Act. Currently, S-RACE is populated with data from 31,276 patients, powering 19 research projects across fields including oncology, cardiology, and diabetes. We demonstrate its utility in kidney cancer and aortic stenosis, where models trained on S-RACE's automatically processed RWE showed performance comparable to those trained on manually curated data. S-RACE provides a scalable, governed environment for RWD curation, offering a trustworthy foundation to accelerate the clinical adoption of responsible AI. CI - (c) 2025. The Author(s). FAU - Traverso, Alberto AU - Traverso A AD - S-RACE (San-Raffaele Ai CEnter), University Vita-Salute San Raffaele, Milan, Italy. traverso.alberto@hsr.it. FAU - Tiano, Donato AU - Tiano D AD - S-RACE (San-Raffaele Ai CEnter), University Vita-Salute San Raffaele, Milan, Italy. FAU - Corvaglia, Andrea AU - Corvaglia A AD - S-RACE (San-Raffaele Ai CEnter), University Vita-Salute San Raffaele, Milan, Italy. FAU - Dimonte, Alessio AU - Dimonte A AD - S-RACE (San-Raffaele Ai CEnter), University Vita-Salute San Raffaele, Milan, Italy. FAU - Draetta, Edoardo Luigi AU - Draetta EL AD - S-RACE (San-Raffaele Ai CEnter), University Vita-Salute San Raffaele, Milan, Italy. FAU - Fabiani, Bruno AU - Fabiani B AD - S-RACE (San-Raffaele Ai CEnter), University Vita-Salute San Raffaele, Milan, Italy. FAU - Scuri, Patrick AU - Scuri P AD - S-RACE (San-Raffaele Ai CEnter), University Vita-Salute San Raffaele, Milan, Italy. FAU - Barbieri, Simone AU - Barbieri S AD - S-RACE (San-Raffaele Ai CEnter), University Vita-Salute San Raffaele, Milan, Italy. FAU - Agazzi, Marcello AU - Agazzi M AD - S-RACE (San-Raffaele Ai CEnter), University Vita-Salute San Raffaele, Milan, Italy. FAU - Arslan, Muhammad AU - Arslan M AD - S-RACE (San-Raffaele Ai CEnter), University Vita-Salute San Raffaele, Milan, Italy. FAU - Celada, Daniele AU - Celada D AD - S-RACE (San-Raffaele Ai CEnter), University Vita-Salute San Raffaele, Milan, Italy. FAU - Chiabrando, Filippo AU - Chiabrando F AD - School of Medicine, University Vita-Salute San Raffaele, Milan, Italy. FAU - Cibrario, Lorenzo AU - Cibrario L AD - S-RACE (San-Raffaele Ai CEnter), University Vita-Salute San Raffaele, Milan, Italy. FAU - Cielo, Giulio AU - Cielo G AD - S-RACE (San-Raffaele Ai CEnter), University Vita-Salute San Raffaele, Milan, Italy. FAU - Colombo, Alberto AU - Colombo A AD - S-RACE (San-Raffaele Ai CEnter), University Vita-Salute San Raffaele, Milan, Italy. FAU - Contini, Stefano AU - Contini S AD - S-RACE (San-Raffaele Ai CEnter), University Vita-Salute San Raffaele, Milan, Italy. FAU - Liberotti, Marta AU - Liberotti M AD - S-RACE (San-Raffaele Ai CEnter), University Vita-Salute San Raffaele, Milan, Italy. FAU - Montagna, Marco AU - Montagna M AD - School of Medicine, University Vita-Salute San Raffaele, Milan, Italy. FAU - Ogliari, Francesca Rita AU - Ogliari FR AD - School of Medicine, University Vita-Salute San Raffaele, Milan, Italy. AD - Medical Oncology Unit, IRCCS San Raffaele Hospital, Milan, Italy. FAU - Palmisano, Anna AU - Palmisano A AD - School of Medicine, University Vita-Salute San Raffaele, Milan, Italy. AD - Experimental Imaging Center, IRCCS San Raffaele Hospital, Milan, Italy. AD - Advanced Imaging for Personalised Medicine Unit, IRCCS San Raffaele Hospital, Milan, Italy. FAU - Pisu, Francesco AU - Pisu F AD - S-RACE (San-Raffaele Ai CEnter), University Vita-Salute San Raffaele, Milan, Italy. FAU - Serra, Davide AU - Serra D AD - S-RACE (San-Raffaele Ai CEnter), University Vita-Salute San Raffaele, Milan, Italy. FAU - Varani, Diego AU - Varani D AD - S-RACE (San-Raffaele Ai CEnter), University Vita-Salute San Raffaele, Milan, Italy. FAU - Vignale, Davide AU - Vignale D AD - School of Medicine, University Vita-Salute San Raffaele, Milan, Italy. AD - Experimental Imaging Center, IRCCS San Raffaele Hospital, Milan, Italy. AD - Advanced Imaging for Personalised Medicine Unit, IRCCS San Raffaele Hospital, Milan, Italy. FAU - Vitali, Andrea Luigi AU - Vitali AL AD - S-RACE (San-Raffaele Ai CEnter), University Vita-Salute San Raffaele, Milan, Italy. FAU - Zambello, Alan AU - Zambello A AD - S-RACE (San-Raffaele Ai CEnter), University Vita-Salute San Raffaele, Milan, Italy. FAU - Chiapponi, Chiara AU - Chiapponi C AD - Microsoft Italia, Milan, Italy. FAU - Denti, Marco AU - Denti M AD - S-RACE (San-Raffaele Ai CEnter), University Vita-Salute San Raffaele, Milan, Italy. FAU - Esposito, Antonio AU - Esposito A AD - S-RACE (San-Raffaele Ai CEnter), University Vita-Salute San Raffaele, Milan, Italy. esposito.antonio@hsr.it. AD - School of Medicine, University Vita-Salute San Raffaele, Milan, Italy. esposito.antonio@hsr.it. AD - Experimental Imaging Center, IRCCS San Raffaele Hospital, Milan, Italy. esposito.antonio@hsr.it. AD - Advanced Imaging for Personalised Medicine Unit, IRCCS San Raffaele Hospital, Milan, Italy. esposito.antonio@hsr.it. FAU - Tacchetti, Carlo AU - Tacchetti C AD - S-RACE (San-Raffaele Ai CEnter), University Vita-Salute San Raffaele, Milan, Italy. AD - School of Medicine, University Vita-Salute San Raffaele, Milan, Italy. AD - Experimental Imaging Center, IRCCS San Raffaele Hospital, Milan, Italy. LA - eng PT - Journal Article DEP - 20260103 PL - England TA - NPJ Digit Med JT - NPJ digital medicine JID - 101731738 PMC - PMC12770359 COIS- Competing interests: The authors declare no competing interests. EDAT- 2026/01/04 00:31 MHDA- 2026/01/04 00:32 PMCR- 2026/01/03 CRDT- 2026/01/03 23:46 PHST- 2025/08/01 00:00 [received] PHST- 2025/10/30 00:00 [accepted] PHST- 2026/01/04 00:32 [medline] PHST- 2026/01/04 00:31 [pubmed] PHST- 2026/01/03 23:46 [entrez] PHST- 2026/01/03 00:00 [pmc-release] AID - 10.1038/s41746-025-02132-w [pii] AID - 2132 [pii] AID - 10.1038/s41746-025-02132-w [doi] PST - epublish SO - NPJ Digit Med. 2026 Jan 3;9(1):6. doi: 10.1038/s41746-025-02132-w. PMID- 41483996 OWN - NLM STAT- MEDLINE DCOM- 20260223 LR - 20260309 IS - 1471-6771 (Electronic) IS - 0007-0912 (Linking) VI - 136 IP - 3 DP - 2026 Mar TI - Management of anaesthesia for transfemoral transcatheter aortic valve implantation: an Italian interdisciplinary consensus statement. PG - 824-835 LID - S0007-0912(25)00801-3 [pii] LID - 10.1016/j.bja.2025.10.052 [doi] AB - BACKGROUND: Transfemoral transcatheter aortic valve implantation (TAVI) is a minimally invasive treatment for patients with severe aortic stenosis who are at elevated surgical risk. Despite widespread use, optimal periprocedural anaesthetic management remains highly variable, and evidence-based guidance is lacking. METHODS: An interdisciplinary panel of Italian experts in anaesthesiology, cardiology, and cardiac surgery conducted a systematic review of the literature and used the RAND/UCLA Appropriateness Method to evaluate 1032 clinical scenarios across a range of risk profiles and comorbid conditions. Ratings were conducted over three rounds, including a moderated in-person meeting to refine and discuss appropriateness scores. RESULTS: A minimally invasive approach, local anaesthesia alone, and conscious sedation were judged appropriate across most clinical scenarios. Invasive monitoring, such as placement of an additional arterial catheter or a central venous catheter, was recommended only in selected high-risk patients. Several approaches or interventions were consistently rated inappropriate across all evaluated scenarios, including nurse-administered anaesthesia, pulmonary artery catheterisation, and cardiac output monitoring using pulse wave analysis. Other approaches, such as general anaesthesia and deep sedation, were considered inappropriate in most cases but retained uncertainty in select clinical contexts. Several recommendations were rated as necessary to define a minimum standard of care. CONCLUSIONS: This Italian consensus statement provides practical, expert-driven recommendations to standardise anaesthetic care for transfemoral TAVI. While many recommendations reached strong consensus, areas of uncertainty remain, underscoring the need for further clinical research. Patient-centred, individualised decision-making remains essential, guided by institutional experience and procedural complexity. CI - Copyright (c) 2025 British Journal of Anaesthesia. Published by Elsevier Ltd. All rights reserved. FAU - Ajello, Valentina AU - Ajello V AD - Department of Cardiothoracic Anaesthesia, University Hospital Tor Vergata, Rome, Italy. FAU - Fresilli, Stefano AU - Fresilli S AD - Department of Anaesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy. FAU - D'Amico, Filippo AU - D'Amico F AD - Department of Anaesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy. Electronic address: damico.filippo@hsr.it. FAU - Franceschini, Giulia AU - Franceschini G AD - Department of Cardiothoracic Anaesthesia, University Hospital Tor Vergata, Rome, Italy. FAU - Aloisio, Tommaso AU - Aloisio T AD - Department of Cardiac Anesthesia and Intensive Care, IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy. FAU - Gottin, Leonardo AU - Gottin L AD - Unit of Cardiothoracic and Vascular Intensive Care Verona Hospital and University Trust, Department of Surgery, Dentistry and Paediatrics and Gynaecology, University of Verona, Verona, Italy. FAU - Baiocchi, Massimo AU - Baiocchi M AD - Cardiothoracic and Vascular Anaesthesia and Intensive Care, IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy. FAU - Guarracino, Fabio AU - Guarracino F AD - Department of Cardiothoracic and Vascular Anaesthesia and Intensive Care, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy. FAU - Bertini, Pietro AU - Bertini P AD - Department of Anaesthesia and Intensive Care Medicine, Casa di Cura Privata San Rossore, Pisa, Italy. FAU - Napodano, Massimo AU - Napodano M AD - Cardiologia Interventistica. Dipartimento Cardio-Toraco-Vascolare, Azienda Ospedale Universita di Padova, Padua, Italy. FAU - D'Amora, Mauro AU - D'Amora M AD - Department of Cardiac, Thoracic, and Vascular Anaesthesia, University Hospital "San Giovanni Di Dio e Ruggi D'Aragona", Salerno, Italy. FAU - Panascia, Ettore AU - Panascia E AD - Anaesthesia and Critical Care Medicine III - CAST, Policlinico University Hospital, Catania, Italy. FAU - Meani, Paolo AU - Meani P AD - Cardio-Thoracic and Vascular Anaesthesia and Intensive Care, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy. FAU - Weltert, Luca AU - Weltert L AD - Heart Surgery Department, Saint Camillus International University for Health Sciences, Rome, Italy. FAU - Monaco, Fabrizio AU - Monaco F AD - Departement of Medical and Surgical Sciences (DIMEC)Alma Mater Studiorum - University of Bologna, Italy; Cardiothoracic and Vascular Anesthesia and Intensive Care IRCCS Azienda Ospedaliero-Universitaria Sant'Orsola, BolognaVia Massarenti, Bologna, Italy. FAU - Pieri, Marina AU - Pieri M AD - Department of Anaesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy; School of Medicine, Vita-Salute San Raffaele University, Milan, Italy. FAU - Sangalli, Fabio AU - Sangalli F AD - Department of Anaesthesia and Intensive Care, ASST Brianza, University of Milano-Bicocca, Vimercate, Italy. FAU - Santonocito, Cristina AU - Santonocito C AD - Anaesthesia and Critical Care Medicine III - CAST, Policlinico University Hospital, Catania, Italy. FAU - Silvetti, Simona AU - Silvetti S AD - Department of Cardiac Anesthesia and Intensive Care, Ospedale Policlinico San Martino IRCCS- IRCCS Cardiovascular Network, Italy. FAU - Landoni, Giovanni AU - Landoni G AD - Department of Anaesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy; School of Medicine, Vita-Salute San Raffaele University, Milan, Italy. FAU - Ranucci, Marco AU - Ranucci M AD - Department of Cardiac Anesthesia and Intensive Care, IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy. FAU - Scolletta, Sabino AU - Scolletta S AD - Department of Medical Science, Surgery, and Neurosciences, Urgency-Emergency Anesthesia and Intensive Care Unit, University Hospital of Siena, Siena, Italy. FAU - Paternoster, Gianluca AU - Paternoster G AD - Department of Health Sciences, Anaesthesia and ICU, School of Medicine, University of Basilicata San Carlo Hospital, Potenza, Italy. LA - eng PT - Consensus Statement PT - Journal Article PT - Systematic Review DEP - 20260103 PL - England TA - Br J Anaesth JT - British journal of anaesthesia JID - 0372541 SB - IM MH - Humans MH - *Anesthesia/methods/standards MH - *Aortic Valve Stenosis/surgery MH - Femoral Artery MH - Italy MH - *Transcatheter Aortic Valve Replacement/methods OTO - NOTNLM OT - RAND/UCLA Appropriateness Method OT - anaesthesia OT - cardiac surgery OT - cardiology OT - expert consensus OT - transcatheter aortic valve implantation COIS- Declaration of interest The authors declare that they have no conflicts of interest. EDAT- 2026/01/04 00:32 MHDA- 2026/02/24 00:30 CRDT- 2026/01/03 22:03 PHST- 2025/06/06 00:00 [received] PHST- 2025/09/26 00:00 [revised] PHST- 2025/10/17 00:00 [accepted] PHST- 2026/02/24 00:30 [medline] PHST- 2026/01/04 00:32 [pubmed] PHST- 2026/01/03 22:03 [entrez] AID - S0007-0912(25)00801-3 [pii] AID - 10.1016/j.bja.2025.10.052 [doi] PST - ppublish SO - Br J Anaesth. 2026 Mar;136(3):824-835. doi: 10.1016/j.bja.2025.10.052. Epub 2026 Jan 3. PMID- 41482721 OWN - NLM STAT- MEDLINE DCOM- 20260103 LR - 20260607 IS - 1747-4949 (Electronic) IS - 1747-4930 (Print) IS - 1747-4930 (Linking) VI - 21 IP - 1 DP - 2026 Jan TI - Young stroke: An update on epidemiology, emerging risk factors, and future research directions. PG - 6-13 LID - 10.1177/17474930251400524 [doi] AB - The incidence of ischemic stroke among young adults (aged 18-49 years) has risen over recent decades, particularly in high-income countries, contrasting with the decline seen in older populations. This trend represents a growing public health concern, as stroke at young age often leads to long-term psychosocial consequences and loss of productive life years. The increasing incidence may partly reflect a higher prevalence of traditional vascular risk factors, as well as the identification of non-traditional risk and trigger factors such as air pollution, sleep apnea, long working hours, vigorous exercise, and illicit drug use. Diagnostic evaluation in this young population is typically more extensive than in older patients, given the broad spectrum of potential underlying causes. A structured, multidisciplinary approach integrating vascular, hematologic, and cardiac assessment is essential for accurate etiological classification. Although functional outcomes are generally favorable, many young stroke survivors experience persistent psychosocial sequelae, including cognitive impairment, depression, anxiety, and fatigue, which significantly affect quality of life. Recurrence risk varies according to stroke etiology, with the lowest rates observed in patients with a cryptogenic stroke. These findings highlight the importance of more tailored secondary prevention strategies, as antiplatelet therapy is not without risks. Further research is needed to identify novel risk and trigger factors, refine prognostic tools, optimize secondary prevention, and develop interventions addressing the psychosocial recovery of young stroke survivors. FAU - Rasing, A AU - Rasing A AUID- ORCID: 0000-0002-3681-2858 AD - Department of Neurology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Hilkens, N A AU - Hilkens NA AD - Department of Neurology, Erasmus University Medical Center, Rotterdam, The Netherlands. FAU - Leeuw, F-E de AU - Leeuw FE AD - Department of Neurology, Radboud University Medical Center, Nijmegen, The Netherlands. LA - eng PT - Journal Article PT - Review DEP - 20260102 PL - United States TA - Int J Stroke JT - International journal of stroke : official journal of the International Stroke Society JID - 101274068 SB - IM MH - Humans MH - Risk Factors MH - *Stroke/epidemiology/etiology MH - Young Adult MH - Adult MH - Adolescent MH - Middle Aged MH - Incidence PMC - PMC12764685 OTO - NOTNLM OT - Ischemic stroke in young adults OT - diagnostics OT - incidence OT - psychosocial sequelae OT - risk factors COIS- Declaration of conflicting interestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2026/01/03 06:30 MHDA- 2026/01/03 06:31 PMCR- 2026/01/04 CRDT- 2026/01/03 02:05 PHST- 2026/01/03 06:31 [medline] PHST- 2026/01/03 06:30 [pubmed] PHST- 2026/01/03 02:05 [entrez] PHST- 2026/01/04 00:00 [pmc-release] AID - 10.1177_17474930251400524 [pii] AID - 10.1177/17474930251400524 [doi] PST - ppublish SO - Int J Stroke. 2026 Jan;21(1):6-13. doi: 10.1177/17474930251400524. Epub 2026 Jan 2. PMID- 41478290 OWN - NLM STAT- MEDLINE DCOM- 20260429 LR - 20260809 IS - 1873-1953 (Electronic) IS - 1474-5151 (Linking) VI - 25 IP - 2 DP - 2026 Apr 29 TI - A multidisciplinary approach to reduce the burden of cardiovascular disease, with special reference to the allied professionals' perspective: a clinical consensus statement by the European Society of Cardiology Task Force on Allied Professionals with contributions from the Association of Cardiovascular Nursing and Allied Professions, the Association for Acute CardioVascular Care, the European Association of Percutaneous Cardiovascular Interventions, the European Association of Preventive Cardiology, the European Heart Rhythm Association, and the Heart Failure Association of the European Society of Cardiology. PG - 219-224 LID - 10.1093/eurjcn/zvaf165 [doi] AB - Management of cardiovascular disease (CVD) requires a multidisciplinary approach based on expert input from physicians, nurses, and many different allied professionals (APs). Key challenges in CVD include health inequalities, sub-optimal risk factor detection and adherence with clinical guidelines, human resourcing issues, and inadequate patient education. Allied professionals can play key roles in addressing these challenges. However, current service models will need to be transformed to better integrate APs. Appropriate strategies may include the development of shared pathways with improved definition of roles and responsibilities, creation of 'competency frameworks' to facilitate advanced practice among APs, and enhanced sharing of best practice models. CI - (c) The European Society of Cardiology 2026. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com. FAU - Back, Maria AU - Back M AUID- ORCID: 0000-0002-6031-7478 AD - Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, Gothenburg SE-405 30, Sweden. AD - Department of Physiotherapy, Sahlgrenska University Hospital, Vita Straket 13, Gothenburg SE-413 45, Sweden. AD - Department of Health, Medicine and Caring Sciences, Linkoping University, Linkoping SE-581 81, Sweden. FAU - Antoniou, Sotiris AU - Antoniou S AD - Barts Heart Centre, St Bartholomew's Hospital, London EC1A 7BE, UK. FAU - Butler, Thomas AU - Butler T AD - Faculty of Health, Social Care and Medicine, Edge Hill University, Ormskirk L39 4QP, UK. AD - Cardio Respiratory Research Centre, Edge Hill University, Ormskirk L39 4QP, UK. FAU - Dendale, Paul AU - Dendale P AD - Heart Centre Hasselt and Faculty of Medicine and Life Sciences, Hasselt University, Stadsomvaart 11, Hasselt 3500, Belgium. FAU - Greco, Andrea AU - Greco A AD - Department of Human and Social Sciences, University of Bergamo, Piazzale S. Agostino, 2, Bergamo 24129, Italy. FAU - Hansen, Dominique AU - Hansen D AD - REVAL/BIOMED, Faculty of Rehabilitation Sciences, Hasselt University, Martelarenlaan 42, Hasselt 3500, Belgium. AD - Heart Centre Hasselt, Jessa Hospital, Stadsomvaart 11, Hasselt 3500, Belgium. FAU - Hill, Loreena AU - Hill L AD - School of Nursing and Midwifery, Queen's University Belfast, 97 Lisburn Rd, Belfast BT9 7BL, UK. FAU - Neubeck, Lis AU - Neubeck L AD - School of Health and Social Care, Edinburgh Napier University, Edinburgh EH11 4BN, UK. FAU - Rand, Amanda AU - Rand A AD - School of Health and Social Care, Edinburgh Napier University, Edinburgh EH11 4BN, UK. FAU - Theuns, D A M J AU - Theuns DAMJ AD - Department of Cardiology, Erasmus MC, University Medical Center Rotterdam, Dr. Molewaterplein 40, Rotterdam 3015 GD, The Netherlands. FAU - Quinn, Thomas AU - Quinn T AD - Faculty of Health, Social Care and Education, Kingston University and St George's, University of London, Tooting, London SW17 0RE, UK. FAU - Ross, Catherine AU - Ross C AD - School of Health and Social Care, Edinburgh Napier University, Edinburgh EH11 4BN, UK. FAU - Khatib, Rani AU - Khatib R AD - Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Clarendon Way, Leeds LS2 9JT, UK. AD - Cardiology Department, Leeds Teaching Hospitals NHS Trust, Great George Street, Leeds LS1 3EX, UK. LA - eng PT - Journal Article PL - England TA - Eur J Cardiovasc Nurs JT - European journal of cardiovascular nursing JID - 101128793 SB - IM MH - Humans MH - *Cardiovascular Diseases/prevention & control/therapy MH - *Allied Health Personnel MH - Consensus MH - *Patient Care Team/organization & administration MH - Europe MH - Societies, Medical MH - *Cardiovascular Nursing MH - Cardiology MH - Practice Guidelines as Topic OTO - NOTNLM OT - Allied professionals OT - Cardiovascular OT - Holistic OT - Multidisciplinary COIS- Conflict of interest: The authors report no conflicts of interest related to this manuscript. M.B., L.H., and S.A. are Associate Editors of the European Journal of Cardiovascular Nursing. EDAT- 2026/01/02 00:33 MHDA- 2026/04/29 12:42 CRDT- 2026/01/01 19:03 PHST- 2024/12/12 00:00 [received] PHST- 2025/06/18 00:00 [revised] PHST- 2025/08/14 00:00 [accepted] PHST- 2026/04/29 12:42 [medline] PHST- 2026/01/02 00:33 [pubmed] PHST- 2026/01/01 19:03 [entrez] AID - 8406960 [pii] AID - 10.1093/eurjcn/zvaf165 [doi] PST - ppublish SO - Eur J Cardiovasc Nurs. 2026 Apr 29;25(2):219-224. doi: 10.1093/eurjcn/zvaf165. PMID- 41476913 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260101 LR - 20260103 IS - 2674-1199 (Electronic) IS - 2674-1199 (Linking) VI - 5 DP - 2025 TI - Bridging communities, prevention, and heart health: U.S. strategies for CHW cardiovascular training and integration. PG - 1597970 LID - 10.3389/fepid.2025.1597970 [doi] LID - 1597970 AB - BACKGROUND: In the United States, cardiovascular disease (CVD) disproportionately affects communities facing adverse social determinants of health (SDOH). Community Health Workers (CHWs) can bridge gaps in trust, navigation, and culturally tailored education. METHODS: We conducted a U.S.-focused narrative review (2015-2025) of PubMed, Scopus, and Google Scholar, prioritizing empirical evaluations of CHW-led CVD interventions, training models, integration strategies, and financing mechanisms. International CHW programs were used only to extract practices transferable to U.S. delivery and payment contexts. RESULTS: Multidisciplinary team-based care demonstrates that engaging CHWs in US regions improves blood pressure control and medication adherence. Economic evaluations increasingly support CHW models for CVD prevention and control. Effective programs specify CHW task bundles (e.g., self-measured BP onboarding, adherence coaching, care navigation, SDOH linkage) and align training with national core competencies. Integration pathways include clinic-embedded, payer-based, public health, and community-based partnerships. U.S. reimbursement options are emerging through Medicare Community Health Integration/Principal Illness Navigation and state Medicaid mechanisms. Faith-based collaborations can extend reach when coupled with standardized training and simple outcome tracking. CONCLUSIONS: For U.S. health systems and payers, immediate priorities are (1) competency-based CHW training with cardiac modules, (2) sustainable reimbursement tied to cardiovascular quality metrics, and (3) a minimal outcome set to demonstrate value. Global best practices should be adapted to the U.S. scope-of-practice, supervision, and documentation requirements to scale equitable CVD care. CI - (c) 2025 Asare and Echols. FAU - Asare, Akua G AU - Asare AG AD - American College of Cardiology, Washington, DC, NW, United States. FAU - Echols, Melvin R AU - Echols MR AD - American College of Cardiology, Washington, DC, NW, United States. AD - Department of Medicine, Morehouse School of Medicine, Atlanta, GA, United States. LA - eng PT - Journal Article PT - Review DEP - 20251216 PL - Switzerland TA - Front Epidemiol JT - Frontiers in epidemiology JID - 9918419158106676 PMC - PMC12748223 OTO - NOTNLM OT - cardiovascular health OT - chronic disease management OT - community health workers OT - culturally competent care OT - faith-based health initiatives OT - health equity OT - insurance navigation OT - medication adherence COIS- ME reports an advisory board relationship with Medtronic and funding from the American Heart Association (Strategically Focused Research Network) and the American College of Cardiology. The remaining author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/01/01 07:38 MHDA- 2026/01/01 07:39 PMCR- 2025/12/16 CRDT- 2026/01/01 04:41 PHST- 2025/04/19 00:00 [received] PHST- 2025/11/21 00:00 [revised] PHST- 2025/11/29 00:00 [accepted] PHST- 2026/01/01 07:39 [medline] PHST- 2026/01/01 07:38 [pubmed] PHST- 2026/01/01 04:41 [entrez] PHST- 2025/12/16 00:00 [pmc-release] AID - 10.3389/fepid.2025.1597970 [doi] PST - epublish SO - Front Epidemiol. 2025 Dec 16;5:1597970. doi: 10.3389/fepid.2025.1597970. eCollection 2025. PMID- 41474532 OWN - NLM STAT- Publisher LR - 20251231 IS - 1537-6591 (Electronic) IS - 1058-4838 (Linking) DP - 2025 Dec 31 TI - Reassessing the 2023 International Society for Cardiovascular Infectious Diseases Duke clinical criteria for infective endocarditis: Impact of excluding fever and updating diagnostic definitions. LID - ciaf737 [pii] LID - 10.1093/cid/ciaf737 [doi] AB - BACKGROUND: Fever has traditionally been included as a minor criterion in the Duke criteria for the diagnosing infective endocarditis (IE). We evaluated the diagnostic impact of excluding fever as a minor criterion within the 2023 Duke-ISCVID (International Society for Cardiovascular Infectious Diseases) framework. METHODS: : We conducted a retrospective study of suspected IE at two Swiss University Hospitals (2014-2024). The reference standard was the final diagnosis by the Endocarditis Team or expert clinicians. Each episode was classified using two versions of the 2023 ISCVID-Duke criteria: one including and one excluding fever as a minor criterion with updated definitions for definite, possible, and rejected IE. Diagnostic performance was assessed using two dichotomizations: in the first analysis, definite IE was considered positive, and possible or rejected was negative; in the second, definite or possible IE was positive, and rejected was negative. RESULTS: IE was diagnosed in 1331/3694 (36%) episodes. Fever was present in 78% of episodes, with similar prevalence in IE and non-IE episodes (78% versus 77%; P=0.484). Using the first evaluation, sensitivity increased modestly from 74% (95% CI: 71-76%) with the original criteria to 77% (74-79%) after excluding fever and updating definitions. Using the second evaluation, specificity markedly improved from 49% (47-51%) to 80% (78-82%) with these modifications. CONCLUSIONS: Exclusion of fever as a minor criterion within the updated Duke-ISCVID framework substantially improved specificity without compromising sensitivity. These findings challenge the traditional role of fever in IE diagnosis and support a broader re-evaluation of longstanding diagnostic criteria. CI - (c) The Author(s) 2025. Published by Oxford University Press on behalf of Infectious Diseases Society of America. FAU - Stavropoulou, Elisavet AU - Stavropoulou E AUID- ORCID: 0000-0002-8299-9035 AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Epprecht, Jana AU - Epprecht J AUID- ORCID: 0000-0003-3277-7044 AD - Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich and University of Zurich, Zurich, Switzerland. FAU - Siedentop, Berit AU - Siedentop B AUID- ORCID: 0000-0003-0802-7681 AD - Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich and University of Zurich, Zurich, Switzerland. FAU - Monney, Pierre AU - Monney P AUID- ORCID: 0000-0002-3083-7333 AD - Department of Cardiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Frank, Michelle AU - Frank M AD - Department of Cardiology, University Hospital Zurich and University of Zurich, Zurich, Switzerland. FAU - Tzimas, Georgios AU - Tzimas G AUID- ORCID: 0000-0002-2810-8887 AD - Department of Cardiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Fourre, Nicolas AU - Fourre N AUID- ORCID: 0009-0006-1660-9365 AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Zimmermann, Virgile AU - Zimmermann V AUID- ORCID: 0009-0005-1812-0216 AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Ianculescu, Nicoleta AU - Ianculescu N AD - Department of Cardiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Senn, Laurence AU - Senn L AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Niclauss, Lars AU - Niclauss L AUID- ORCID: 0000-0003-4453-5202 AD - Department of Cardiac Surgery, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Kirsch, Matthias AU - Kirsch M AUID- ORCID: 0000-0002-9213-7578 AD - Department of Cardiac Surgery, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Van Hemelrijck, Mathias AU - Van Hemelrijck M AUID- ORCID: 0000-0002-0191-757X AD - Department of Cardiac Surgery, University Hospital Zurich and University of Zurich, Zurich, Switzerland. FAU - Dzemali, Omer AU - Dzemali O AUID- ORCID: 0000-0001-7910-5152 AD - Department of Cardiac Surgery, University Hospital Zurich and University of Zurich, Zurich, Switzerland. AD - Department of Cardiac Surgery, City Hospital of Zurich - Triemli, Zurich, Switzerland. AD - Center for Experimental and Translational Cardiology, University of Zurich, Zurich, Switzerland. FAU - Guery, Benoit AU - Guery B AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Hasse, Barbara AU - Hasse B AUID- ORCID: 0000-0001-7196-3734 AD - Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich and University of Zurich, Zurich, Switzerland. FAU - Papadimitriou-Olivgeris, Matthaios AU - Papadimitriou-Olivgeris M AUID- ORCID: 0000-0003-0565-5105 AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. AD - Infectious Diseases Service, Hospital of Valais and Institut Central des Hopitaux, Sion, Switzerland. LA - eng PT - Journal Article DEP - 20251231 PL - United States TA - Clin Infect Dis JT - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America JID - 9203213 SB - IM OTO - NOTNLM OT - Duke criteria OT - International Society for Cardiovascular Infectious Diseases (ISCVID) OT - bacteremia OT - fever OT - infective endocarditis EDAT- 2025/12/31 12:55 MHDA- 2025/12/31 12:55 CRDT- 2025/12/31 11:52 PHST- 2025/08/30 00:00 [received] PHST- 2025/11/10 00:00 [revised] PHST- 2025/12/22 00:00 [accepted] PHST- 2025/12/31 12:55 [medline] PHST- 2025/12/31 12:55 [pubmed] PHST- 2025/12/31 11:52 [entrez] AID - 8407840 [pii] AID - 10.1093/cid/ciaf737 [doi] PST - aheadofprint SO - Clin Infect Dis. 2025 Dec 31:ciaf737. doi: 10.1093/cid/ciaf737. PMID- 41470242 OWN - NLM STAT- MEDLINE DCOM- 20251231 LR - 20260102 IS - 1648-9144 (Electronic) IS - 1010-660X (Print) IS - 1010-660X (Linking) VI - 61 IP - 12 DP - 2025 Dec 18 TI - Multimodality Imaging in Infective Endocarditis: A Clinical Approach to Diagnosis. LID - 10.3390/medicina61122241 [doi] LID - 2241 AB - Infective endocarditis (IE) is a life-threatening condition with a rising incidence, demanding rapid and precise diagnosis. While echocardiography remains the cornerstone of initial evaluation, its limitations in complex cases-such as those involving prosthetic valves or cardiac devices-are well-known. This review synthesizes current evidence and guidelines to outline a practical, multimodality imaging approach for IE. We emphasize that integrating advanced techniques like cardiac computed tomography (CT) and [18F]-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) early in the diagnostic pathway, particularly in high-risk scenarios, significantly enhances diagnostic certainty, guides therapeutic decisions, and improves patient outcomes. A tailored imaging strategy, driven by clinical presentation and integrated within a multidisciplinary endocarditis team, is paramount for modern IE management. FAU - Brugiatelli, Leonardo AU - Brugiatelli L AUID- ORCID: 0009-0000-8413-9701 AD - "G.M. Lancisi" Cardiovascular Center, 60126 Ancona, Italy. AD - San Salvatore Hospital, 61121 Pesaro, Italy. FAU - Patani, Francesca AU - Patani F AD - "G.M. Lancisi" Cardiovascular Center, 60126 Ancona, Italy. FAU - Lofiego, Carla AU - Lofiego C AD - "G.M. Lancisi" Cardiovascular Center, 60126 Ancona, Italy. FAU - Benedetti, Martina AU - Benedetti M AD - "G.M. Lancisi" Cardiovascular Center, 60126 Ancona, Italy. FAU - Capodaglio, Irene AU - Capodaglio I AD - "G.M. Lancisi" Cardiovascular Center, 60126 Ancona, Italy. FAU - Giulia, Pongetti AU - Giulia P AD - "G.M. Lancisi" Cardiovascular Center, 60126 Ancona, Italy. FAU - Matteo, Francioni AU - Matteo F AUID- ORCID: 0000-0001-7798-1351 AD - "G.M. Lancisi" Cardiovascular Center, 60126 Ancona, Italy. FAU - Enrico, Paolini AU - Enrico P AUID- ORCID: 0000-0001-6724-9001 AD - "G.M. Lancisi" Cardiovascular Center, 60126 Ancona, Italy. FAU - Marco, Nazziconi AU - Marco N AD - "G.M. Lancisi" Cardiovascular Center, 60126 Ancona, Italy. FAU - Maurizi, Kevin AU - Maurizi K AUID- ORCID: 0009-0006-2196-5540 AD - "G.M. Lancisi" Cardiovascular Center, 60126 Ancona, Italy. FAU - Giulia, Furlani AU - Giulia F AD - "G.M. Lancisi" Cardiovascular Center, 60126 Ancona, Italy. FAU - Arianna, Massari AU - Arianna M AD - "G.M. Lancisi" Cardiovascular Center, 60126 Ancona, Italy. FAU - Simone, Luciani AU - Simone L AD - "G.M. Lancisi" Cardiovascular Center, 60126 Ancona, Italy. FAU - Benedetta, Anselmi AU - Benedetta A AD - "G.M. Lancisi" Cardiovascular Center, 60126 Ancona, Italy. FAU - Chiara, Gatti AU - Chiara G AD - "G.M. Lancisi" Cardiovascular Center, 60126 Ancona, Italy. FAU - Nicolo, Schicchi AU - Nicolo S AD - Cardiovascular Radiological Diagnostics, Department of Radiological Sciences, University Hospital of Marche, 60126 Ancona, Italy. FAU - Marco, Fogante AU - Marco F AUID- ORCID: 0000-0003-2993-5718 AD - Cardiovascular Radiological Diagnostics, Department of Radiological Sciences, University Hospital of Marche, 60126 Ancona, Italy. FAU - Giovanni, Tarsi AU - Giovanni T AD - San Salvatore Hospital, 61121 Pesaro, Italy. FAU - Antonio, Dello Russo AU - Antonio DR AD - "G.M. Lancisi" Cardiovascular Center, 60126 Ancona, Italy. AD - Department of Biomedical Sciences, Faculty of Medicine and Surgery, Marche Polytechnic University, 60126 Ancona, Italy. FAU - Marco, Di Eusanio AU - Marco DE AD - "G.M. Lancisi" Cardiovascular Center, 60126 Ancona, Italy. AD - Department of Biomedical Sciences, Faculty of Medicine and Surgery, Marche Polytechnic University, 60126 Ancona, Italy. FAU - Marco, Marini AU - Marco M AUID- ORCID: 0000-0003-2165-556X AD - "G.M. Lancisi" Cardiovascular Center, 60126 Ancona, Italy. FAU - Vagnarelli, Fabio AU - Vagnarelli F AD - "G.M. Lancisi" Cardiovascular Center, 60126 Ancona, Italy. LA - eng PT - Journal Article PT - Review DEP - 20251218 PL - Switzerland TA - Medicina (Kaunas) JT - Medicina (Kaunas, Lithuania) JID - 9425208 RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18) SB - IM MH - Humans MH - *Multimodal Imaging/methods MH - *Endocarditis/diagnostic imaging/diagnosis MH - Positron Emission Tomography Computed Tomography/methods MH - Echocardiography/methods MH - Tomography, X-Ray Computed/methods MH - Fluorodeoxyglucose F18/therapeutic use PMC - PMC12735077 OTO - NOTNLM OT - cardiac CT scan OT - echocardiography OT - endocarditis team OT - infective endocarditis OT - multimodality imaging OT - nuclear imaging COIS- The authors declare no conflicts of interest. EDAT- 2025/12/31 07:37 MHDA- 2025/12/31 07:38 PMCR- 2025/12/18 CRDT- 2025/12/31 01:01 PHST- 2025/11/15 00:00 [received] PHST- 2025/12/02 00:00 [revised] PHST- 2025/12/11 00:00 [accepted] PHST- 2025/12/31 07:38 [medline] PHST- 2025/12/31 07:37 [pubmed] PHST- 2025/12/31 01:01 [entrez] PHST- 2025/12/18 00:00 [pmc-release] AID - medicina61122241 [pii] AID - medicina-61-02241 [pii] AID - 10.3390/medicina61122241 [doi] PST - epublish SO - Medicina (Kaunas). 2025 Dec 18;61(12):2241. doi: 10.3390/medicina61122241. PMID- 41466259 OWN - NLM STAT- MEDLINE DCOM- 20260627 LR - 20260627 IS - 1472-6920 (Electronic) IS - 1472-6920 (Linking) VI - 25 IP - 1 DP - 2025 Dec 29 TI - Interprofessional simulation training in acute pediatrics using rapid cycle deliberate practice (ip-star). PG - 1729 LID - 10.1186/s12909-025-08302-4 [doi] LID - 1729 AB - BACKGROUND: Undergraduate curriculums of healthcare professionals, designed as discipline-specific silos, focus more on knowledge and less on skills, and minimally on nontechnical skills and team dynamics. Lack of prior team training often results in poor team dynamics in face of the challenges of managing high stakes crisis scenarios of acute pediatrics. This study aimed to evaluate the effectiveness of Interprofessional Simulation Education (IPSE) using Rapid Cycle Deliberate Practice (RCDP) and the Team Strategies and Tools to Enhance Performance and Patient Safety (TeamSTEPPS) framework for undergraduate medical and nursing students. METHODS: A one-group pre-post study design was adopted with intervention consisting of in-situ interprofessional simulation of a pediatric cardiac arrest scenario using RCDP methodology, structured within the TeamSTEPPS framework. Assessment measures included multiple choice question (MCQ) based test, team Objectively Structured Clinical Examination (OSCE), Team Performance Observation Tool (TPOT), and self-perceived confidence surveys. Participants' feedback were collected regarding the interprofessional training experience. RESULTS: A total of 72 third-year students, comprising 46 MBBS and 26 BSc Nursing students, participated in this study conducted across 12 interprofessional simulation training sessions. The intervention led to significant improvements across all measured domains. Knowledge acquisition, assessed using MCQs, showed a marked increase, with post-test scores demonstrating significantly higher median (IQR) values compared to pre-test scores pre-test median 6 (2) vs. post-test median 8 (2), p < 0.01). Similarly, team-based clinical skills, evaluated through Team OSCE scores, improved substantially following the training pre-training median 6 (2.25) vs. post-training median 17 (2), p < 0.002). Assessment done using TPOT also demonstrated statistically significant enhancement across all 5 domains, i.e. team structure, communication, leadership, situational monitoring and mutual support. Furthermore, learners reported a notable increase in self-perceived confidence related to managing pediatric emergencies. Feedback on sessions' content, interprofessional collaboration development, skill acquisition and educational value showed high learner endorsement. CONCLUSIONS: The novel combination of RCDP methodology within the TeamSTEPPS framework in IPSE can help in development of effective individual skills and teamwork competencies among novice learners. Future studies should examine long-term retention of these skills and their transfer to clinical practice. FAU - Kumar, Manish AU - Kumar M AUID- ORCID: 0000-0002-3282-0498 AD - MAHE- FAIMER International Institute for Leadership in Interprofessional Education (M-FIILIPE), Manipal, Karantaka, India. FAU - Mittal, Mahima AU - Mittal M AUID- ORCID: 0000-0001-9199-2647 AD - AIIMS Gorakhpur, Gorakhpur, Uttar Pradesh, India. FAU - Chavan, Seema Shankarsingh AU - Chavan SS AUID- ORCID: 0000-0001-7232-095X AD - College of Nursing, AIIMS Gorakhpur, Gorakhpur, India. FAU - Krishnan S, Vimal AU - Krishnan S V AUID- ORCID: 0000-0002-0100-2396 AD - Kasturba Medical College, Manipal, Manipal Academy of Higher Education (MAHE), Manipal & Centre for Resuscitation, Acute Care and Simulation Training (CReST), MAHE, Manipal, Karnataka, India. vimal.krishnan@manipal.edu. FAU - Gilbert, John H V AU - Gilbert JHV AUID- ORCID: 0000-0001-9656-3745 AD - University of British Columbia & Dr. T.M. Pai Chair in Interprofessional Education and Care, Manipal Academy of Higher Education (MAHE), Manipal, India. FAU - Sanatombi Devi, Elsa AU - Sanatombi Devi E AUID- ORCID: 0000-0002-0738-8912 AD - Medical Surgical Nursing Department, Manipal College of Nursing, Manipal Academy of Higher Education, Manipal & Director MAHE FAIMER International Institute for Leadership in Interprofessional Education, Manipal Academy of Higher Education (MAHE), Manipal, Karnataka, India. LA - eng PT - Journal Article DEP - 20251229 PL - England TA - BMC Med Educ JT - BMC medical education JID - 101088679 SB - IM MH - Humans MH - *Pediatrics/education MH - *Simulation Training/methods MH - Clinical Competence MH - Patient Care Team/organization & administration MH - *Interprofessional Relations MH - Curriculum MH - *Education, Medical, Undergraduate/methods MH - Female MH - *Interprofessional Education MH - Male MH - Heart Arrest/therapy PMC - PMC12750579 OTO - NOTNLM OT - Interprofessional education OT - Pediatrics OT - Quality education OT - Rapid cycle deliberate practice OT - Simulation training OT - TeamSTEPPS OT - Undergraduate education COIS- Declarations. Ethics approval and consent to participate: The study protocol was approved by the Institutional Ethical Committee. All participants consented to be part of the study with an IEC-approved consent form signed by the participants. Informed consent was obtained from all participants. The study adhered to the Declaration of Helsinki. Clinical trial number: not applicable. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2025/12/30 07:40 MHDA- 2026/06/27 12:37 PMCR- 2025/12/29 CRDT- 2025/12/30 02:36 PHST- 2025/08/13 00:00 [received] PHST- 2025/11/10 00:00 [accepted] PHST- 2026/06/27 12:37 [medline] PHST- 2025/12/30 07:40 [pubmed] PHST- 2025/12/30 02:36 [entrez] PHST- 2025/12/29 00:00 [pmc-release] AID - 10.1186/s12909-025-08302-4 [pii] AID - 8302 [pii] AID - 10.1186/s12909-025-08302-4 [doi] PST - epublish SO - BMC Med Educ. 2025 Dec 29;25(1):1729. doi: 10.1186/s12909-025-08302-4. PMID- 41464833 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251230 LR - 20260926 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 14 IP - 24 DP - 2025 Dec 17 TI - Evaluation, Management and Therapeutic Approach of Cardiovascular-Kidney-Metabolic Syndrome: A Multidisciplinary Delphi Expert Consensus. LID - 10.3390/jcm14248930 [doi] LID - 8930 AB - Objective: We aimed to develop multidisciplinary recommendations for the management of cardiovascular-kidney-metabolic (CKM) syndrome in Spain. Methods: The Delphi method was used. The final questionnaire comprised 61 statements that were assessed using a 9-point Likert scale of agreement, from 1 = fully disagree to 9 = fully agree. A consensus was reached when 80% of answers in all specialties were in the range of 7-9. The overall median was used as a measure of the strength of agreement. Results: A total of 70 (97%) panelists met the selection criteria and completed two rounds, including cardiology (13), endocrinology (12), internal medicine (12), nephrology (14), and primary care (19). Among the 61 statements, a consensus was reached in 54 (89%). The consensus to be highlighted included the following: an excess and/or dysfunction of adipose tissue as the initial driver of CKM syndrome (median 8), CKM syndrome that includes both patients at risk (median 8) and those with existing CVD (median 8), coordination of patient management by the family medicine physician (median 9), the essential role of primary prevention in maintaining CKM health (median 9), the administration of drugs with demonstrated CKM benefit in both early-stage patients (median 9) and those in the advanced stages of the syndrome (median 9), and the importance of lifestyle measures (median 9), with a focus on intensive weight loss (median 9). Conclusions: This Delphi consensus offers multidisciplinary recommendations highlighting the importance of early recognition, integrated management, and the implementation of preventive and therapeutic strategies with established cardiorenal and metabolic benefits. FAU - Orozco-Beltran, Domingo AU - Orozco-Beltran D AD - Department of Clinical Medicine, School of Medicine, Miguel Hernandez University, San Juan de Alicante, 03550 Elche, Spain. FAU - Quiroga, Borja AU - Quiroga B AUID- ORCID: 0000-0001-5730-1929 AD - Service of Nephrology, University Hospital of La Princesa, 28006 Madrid, Spain. AD - RICORS2040 (Belonging to the RICORS [Redes de Investigacion Cooperativa Orientada a Resultados en Salud] Program), Instituto de Salud Carlos III, 28029 Madrid, Spain. FAU - Esteban-Fernandez, Alberto AU - Esteban-Fernandez A AUID- ORCID: 0000-0002-3839-7336 AD - Service of Cardiology, Severo Ochoa University Hospital, 28914 Leganes, Spain. AD - Facultad de Ciencias de la Salud, Universidad Alfonso X El Sabio, 28691 Villanueva de la Canada, Spain. FAU - Lorenzo Almoros, Ana AU - Lorenzo Almoros A AD - Service of Internal Medicine, Gregorio Maranon General University Hospital, Complutense University of Madrid, 28007 Madrid, Spain. FAU - Bellido, Virginia AU - Bellido V AUID- ORCID: 0000-0002-8384-043X AD - Clinical Management Unit of Endocrinology and Nutrition, Institute of Biomedicine of Sevilla (IBiS), Virgen del Rocio University Hospital, CSIC, University of Sevilla, 41013 Sevilla, Spain. FAU - Benedito Perez de Inestrosa, Teresa AU - Benedito Perez de Inestrosa T AD - Medico de Familia, Servicio Andaluz de Salud, 18013 Granada, Spain. FAU - de Haro, Ruben AU - de Haro R AD - Medical Affairs Department, Boehringer Ingelheim, 08174 Sant Cugat del Valles, Spain. FAU - Taboada, Xoana AU - Taboada X AUID- ORCID: 0009-0003-5777-9107 AD - Medical Department, Eli Lilly and Company, 28108 Alcobendas, Spain. FAU - Romero-Vigara, Juan Carlos AU - Romero-Vigara JC AUID- ORCID: 0009-0002-4944-8319 AD - Health Service of Aragon, 50017 Zaragoza, Spain. AD - IISA-Aragon Health Research Institute, 50009 Zaragoza, Spain. LA - eng GR - Not applicable/Alliance Boehringer Ingelheim-Lilly/ PT - Journal Article DEP - 20251217 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC12734211 OTO - NOTNLM OT - cardiovascular-kidney-metabolic syndrome OT - chronic kidney disease OT - consensus OT - diabetes OT - metabolic syndrome OT - obesity COIS- D.O.-B. has received funding for medical training, lectures and basic research from the following pharmaceutical companies: Boehringer Ingelheim, Lilly, MSD, Novo Nordisk, Deskcom and Sanofi. B.Q. reports honoraria for conferences, consulting fees and advisory boards from Bayer, Novo Nordisk, Genzyme-Sanofi, AstraZeneca, Boehringer and CSL-Vifor. A.E.-F. has received funding for medical training, presentations and basic research from the following pharmaceutical companies: AstraZeneca, Boehringer-Lilly, Novartis and Bayer. A.L.A. has received funding for medical training, lectures and basic research from the following pharmaceutical companies: AstraZeneca, Boehringer-Lilly, Novartis, Bayer, Abbott and Sanofi. V.B. has received funding for medical training, presentations and basic research from the following pharmaceutical companies: Abbott, AstraZeneca, Boehringer Ingelheim, Esteve, Lilly, MSD, Novo Nordisk and Sanofi. T.B.P.d.I. has received funding for medical training, presentations and basic research from the following pharmaceutical companies: FAES, AstraZeneca, Boehringer Ingelheim, Esteve, Lilly, MSD and Novo Nordisk. R.d.H. is a full-time employee of Boehringer Ingelheim. X.T. is full-time employee of Eli Lilly and Company. J.C.R.-V. has received speaking fees, consulting fees or scientific collaborations from Bayer, BMS, Boehringer, Lilly, Pfizer, Almirall, Novartis, AstraZeneca, Bial, Novo Nordisk, MSD, Organon, Daiichi Sankyo, and GlaxoSmithKline. EDAT- 2025/12/30 07:41 MHDA- 2025/12/30 07:42 PMCR- 2025/12/17 CRDT- 2025/12/30 02:03 PHST- 2025/11/07 00:00 [received] PHST- 2025/12/05 00:00 [revised] PHST- 2025/12/12 00:00 [accepted] PHST- 2025/12/30 07:42 [medline] PHST- 2025/12/30 07:41 [pubmed] PHST- 2025/12/30 02:03 [entrez] PHST- 2025/12/17 00:00 [pmc-release] AID - jcm14248930 [pii] AID - jcm-14-08930 [pii] AID - 10.3390/jcm14248930 [doi] PST - epublish SO - J Clin Med. 2025 Dec 17;14(24):8930. doi: 10.3390/jcm14248930. PMID- 41464767 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251230 LR - 20260102 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 14 IP - 24 DP - 2025 Dec 15 TI - Optimizing Interdisciplinary Referral Pathways for Chronic Obstructive Pulmonary Disease Management Across Cardiology and Pulmonology Specialties in the Kingdom of Saudi Arabia. LID - 10.3390/jcm14248865 [doi] LID - 8865 AB - Background: Chronic obstructive pulmonary disease (COPD) is a progressive respiratory condition with significant economic burden, morbidity, and mortality rates worldwide. In the Kingdom of Saudi Arabia (KSA), 4.2% of adults 40 years and older have COPD, with a higher prevalence in men and older populations. Key risk factors include smoking, air pollution, occupational exposures, and genetics. COPD coexists with cardiovascular disease (CVD) often, making diagnosis and management more difficult. This study proposes two referral algorithms to optimize care for COPD patients with coexisting CVD in the KSA. Methods: A nine-member cardiopulmonary task force reviewed pertinent literature, guidelines, and held virtual meetings from April to August 2025. Every algorithmic component was iteratively refined; consensus was reached when at least 80% of participants agreed, and items not reaching this threshold were revised until full agreement was reached. Results: According to the cardiology-to-pulmonology algorithm, patients who have unidentified respiratory symptoms or COPD risk factors undergo spirometry assessment and, if confirmed, are referred to pulmonology for diagnostic confirmation, phenotyping, and treatment, including triple fixed-dose combination therapy (TFDC) when necessary. On the other hand, the pulmonology-to-cardiology algorithm directs the evaluation of CVD risk factors and comorbidities using clinical evaluation, electrocardiogram, echocardiography, and biomarker testing, for cardiology referral. Conclusions: By establishing bidirectional referral pathways, morbidity and healthcare burden can be decreased, early detection can be improved, and multidisciplinary management can be strengthened. Future research should assess the feasibility, cost-effectiveness, and real-world impact within KSA's healthcare system. FAU - Idrees, Majdy M AU - Idrees MM AD - Division of Pulmonary Medicine, Department of Medicine, Prince Sultan Military Medical City, P.O. Box 7897, Riyadh 11159, Saudi Arabia. FAU - Habis, Yahya Z AU - Habis YZ AUID- ORCID: 0000-0002-8042-6428 AD - Pulmonology Division, Department of Internal Medicine, Faculty of Medicine, Saudi Arabia & King Abdulaziz University Hospital, King Abdulaziz University, P.O. Box 80200, Jeddah 21589, Saudi Arabia. FAU - Jelaidan, Ibrahim AU - Jelaidan I AD - King Abdullah International Medical Research Center, College of Medicine-Western Region, King Saud Bin Abdulaziz University for Health Sciences, Ministry of National Guard Health Affairs, P.O. Box 9515, Jeddah 21423, Saudi Arabia. FAU - Alsowayan, Waleed AU - Alsowayan W AUID- ORCID: 0000-0002-5719-3814 AD - Security Forces Hospital Program, Division of Pulmonary Medicine, Department of Medicine, P.O. Box 3643, Riyadh 11481, Saudi Arabia. FAU - Almogbel, Osama AU - Almogbel O AD - Cardiac Sciences Department, King Fahad Cardiac Center, King Saud University, P.O. Box 7805, Riyadh 11472, Saudi Arabia. FAU - Alasiri, Abdalla M AU - Alasiri AM AD - Respiratory and Tuberculosis Unit, Pulmonary Medicine, Ministry of Health, Abha 62522, Aseer Province, Saudi Arabia. FAU - Al-Ghamdi, Faisal AU - Al-Ghamdi F AD - King Fahad Medical City, P.O. Box 59046, Riyadh 11525, Saudi Arabia. FAU - Bakhsh, Abeer AU - Bakhsh A AD - King Abdullah Medical City, P.O. Box 57657, Makkah 21955, Saudi Arabia. FAU - Alhejaili, Faris AU - Alhejaili F AUID- ORCID: 0000-0002-0100-6063 AD - Pulmonology Division, Department of Medicine, Saudi Arabia & King Abdulaziz University Hospital, King Abdulaziz University, P.O. Box 80200, Jeddah 21589, Saudi Arabia. LA - eng GR - Unrestricted grant/AstraZeneca/ PT - Journal Article DEP - 20251215 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC12733490 OTO - NOTNLM OT - COPD OT - cardiology OT - interdisciplinary care OT - pulmonology OT - referral pathways COIS- The authors declare that they have no conflicts of interest. The funders had no role in the design of the study, the writing of the manuscript, or the decision to publish the results. EDAT- 2025/12/30 07:41 MHDA- 2025/12/30 07:42 PMCR- 2025/12/15 CRDT- 2025/12/30 02:02 PHST- 2025/10/01 00:00 [received] PHST- 2025/11/28 00:00 [revised] PHST- 2025/12/05 00:00 [accepted] PHST- 2025/12/30 07:42 [medline] PHST- 2025/12/30 07:41 [pubmed] PHST- 2025/12/30 02:02 [entrez] PHST- 2025/12/15 00:00 [pmc-release] AID - jcm14248865 [pii] AID - jcm-14-08865 [pii] AID - 10.3390/jcm14248865 [doi] PST - epublish SO - J Clin Med. 2025 Dec 15;14(24):8865. doi: 10.3390/jcm14248865. PMID- 41464728 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251230 LR - 20260102 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 14 IP - 24 DP - 2025 Dec 13 TI - Clinical and Prognostic Differences Between Mechanical Versus Biological Prosthetic Infective Endocarditis-A Nationwide Database Study. LID - 10.3390/jcm14248826 [doi] LID - 8826 AB - Objectives: Infective endocarditis (IE) is a feared and life-threatening complication, requiring a multidisciplinary approach. Prosthetic valve endocarditis (PVE) accounts for 20-30% of IE, is one of the most severe forms of IE, and is associated with high morbidity and mortality. We aim to compare and analyze baseline characteristics, microbiology, clinical presentation, complications, and prognosis between biological and mechanical PVE; we also carried out a subgroup analysis of patients aged 45-65 at the time of onset of prosthetic surgery. Methods: The present study is a post hoc analysis of a prospective multicenter cohort of patients with PVE between January 2008 and December 2023. Patients were divided into two groups regarding the type of prosthesis, mechanical vs. biological. Results: A total of 1544 patients were included. 733 (47.47%) patients with mechanical PVE (mPVE) and 811 (52.52) with biological PVE (bPVE). We found that bPVE appeared earlier than mPVE, had more healthcare-related infections and paravalvular complications. Both groups had similar clinical presentations; moreover, there was no difference in surgical indication and if surgery was performed. On the other hand, mPVE has a higher incidence of Staphylococcus aureus (SA) and Gram-negative bacteria, while bPVE has more coagulase-negative staphylococci. Multivariable logistic regression identified the following independent risk factors of mortality: EuroSCORE I, age, mPVE, SA, IE comprising two valves, and severe sepsis. mPVE had a higher mortality on admission, probably due to a higher incidence of septic shock and CNS embolism. The subgroup analysis of patients between 45 and 65 years at the time of prosthesis implantation showed similar results. Conclusions: The present analysis shows that bPVE appears earlier than mPVE, even in the subgroup of patients aged 45-65. bPVE has more healthcare-related infections and more paravalvular complications. After adjusting for baseline differences, mPVE had higher in-hospital mortality. FAU - de Villarreal-Soto, Juan Esteban AU - de Villarreal-Soto JE AUID- ORCID: 0000-0001-9019-2584 AD - Cardiac Surgery Department, Hospital Universitario Puerta de Hierro Majadahonda, 28222 Majadahonda, Spain. FAU - Parra, Jorge Calderon AU - Parra JC AUID- ORCID: 0000-0002-0369-9369 AD - Infectious Diseases Department, Hospital Universitario Puerta de Hierro Majadahonda, 28222 Majadahonda, Spain. FAU - Munoz Garcia, Patricia AU - Munoz Garcia P AUID- ORCID: 0000-0001-5706-5583 AD - Clinical Microbiology and Infectious Diseases Department, Hospital General Universitario Gregorio Maranon, 28010 Madrid, Spain. FAU - Caballero, Gregorio Cuerpo AU - Caballero GC AD - Cardiac Surgery Department, Gregorio Maranon University Hospital, 28010 Madrid, Spain. FAU - Vilchez, Marina Machado AU - Vilchez MM AD - Clinical Microbiology and Infectious Diseases Department, Hospital General Universitario Gregorio Maranon, 28010 Madrid, Spain. FAU - Rodriguez-Esteban, Maria Angeles AU - Rodriguez-Esteban MA AUID- ORCID: 0000-0001-7393-2501 AD - Intensive Care Unit, Hospital Central de Asturias, 33011 Oviedo, Spain. FAU - Rodriguez-Garcia, Raquel AU - Rodriguez-Garcia R AUID- ORCID: 0000-0002-4476-4630 AD - Intensive Care Unit, Hospital Central de Asturias, 33011 Oviedo, Spain. FAU - Tascon-Quevedo, Valentin AU - Tascon-Quevedo V AD - Cardiac Surgery Department, Hospital Universitario Marques de Valdeclla-IDIVAL, 39008 Santander, Spain. FAU - Goikoetxea-Agirre, Ane Josune AU - Goikoetxea-Agirre AJ AUID- ORCID: 0000-0003-1983-3742 AD - Infectious Diseases Department, Hospital Universitario de Cruces, 48903 Bilbao, Spain. FAU - Quintana Obrador, Eduard AU - Quintana Obrador E AUID- ORCID: 0000-0002-5386-7463 AD - Cardiovascular Surgery Department, Hospital Clinic of Barcelona, 08036 Barcelona, Spain. FAU - Goenaga-Sanchez, Miguel Angel AU - Goenaga-Sanchez MA AUID- ORCID: 0000-0003-3532-4681 AD - Infectious Diseases Department, Hospital Universitario Donosti, 20014 San Sebastian, Spain. FAU - Garcia-Vazquez, Elisa AU - Garcia-Vazquez E AD - Internal Medicine Department, Hospital Clinico Universitario Virgen de la Arrixaca, 30120 Murcia, Spain. FAU - Hernandez-Estefania, Rafael AU - Hernandez-Estefania R AD - Cardiac and Thoracic Surgery Department, Hospital Universitario Fundacion Jimenez Diaz, 28040 Madrid, Spain. FAU - Ramos Martinez, Antonio AU - Ramos Martinez A AUID- ORCID: 0000-0002-4840-9425 AD - Infectious Diseases Department, Hospital Universitario Puerta de Hierro Majadahonda, 28222 Majadahonda, Spain. FAU - Martin-Lopez, Carlos Esteban AU - Martin-Lopez CE AD - Cardiac Surgery Department, Hospital Universitario Puerta de Hierro Majadahonda, 28222 Majadahonda, Spain. LA - eng PT - Journal Article DEP - 20251213 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC12734219 OTO - NOTNLM OT - biological prosthesis OT - endocarditis OT - mechanical prosthesis OT - registry OT - valve surgery COIS- The authors have no conflicts of interest to declare. EDAT- 2025/12/30 07:40 MHDA- 2025/12/30 07:41 PMCR- 2025/12/13 CRDT- 2025/12/30 02:01 PHST- 2025/11/13 00:00 [received] PHST- 2025/12/02 00:00 [revised] PHST- 2025/12/11 00:00 [accepted] PHST- 2025/12/30 07:41 [medline] PHST- 2025/12/30 07:40 [pubmed] PHST- 2025/12/30 02:01 [entrez] PHST- 2025/12/13 00:00 [pmc-release] AID - jcm14248826 [pii] AID - jcm-14-08826 [pii] AID - 10.3390/jcm14248826 [doi] PST - epublish SO - J Clin Med. 2025 Dec 13;14(24):8826. doi: 10.3390/jcm14248826. PMID- 41463310 OWN - NLM STAT- MEDLINE DCOM- 20251230 LR - 20260327 IS - 2218-273X (Electronic) IS - 2218-273X (Linking) VI - 15 IP - 12 DP - 2025 Nov 26 TI - Embryological Divergence and Molecular Mechanisms in Thoracic and Abdominal Aortic Aneurysms: Bridging Developmental Biology and Clinical Insights. LID - 10.3390/biom15121654 [doi] LID - 1654 AB - Aortic aneurysms are complex, predominantly asymptomatic vascular diseases with distinct incidence patterns depending on anatomical localisation. The incidence of thoracic aortic aneurysms (TAAs) has moderately increased, whereas that of abdominal aortic aneurysms has declined, primarily due to public health measures. Undiagnosed or poorly managed aneurysms are at significant risk of progression to acute aortic syndrome, with high associated mortality. The embryological origins of the aorta may have a substantial impact on its structural, cellular, and functional heterogeneity. Specifically, smooth-muscle cells (SMCs) in the thoracic aorta are derived from cardiac neural crest and mesodermal cells, whereas abdominal aortic SMCs originate from the paraxial and splanchnic mesoderm. To explore these developmental and regional distinctions, we conducted a narrative review based on targeted literature retrieval and expert curation, highlighting how these distinctions might potentially influence susceptibility to aneurysms and their clinical presentation. Histological differences, such as the number of lamellar units and the presence or absence of vasa vasorum, could further explain regional vulnerability. Molecular mechanisms underlying aneurysm formation include inflammation, oxidative stress, extracellular matrix degradation, phenotypic switching, and dysregulated signalling pathways, notably transforming growth factor-beta (TGF-beta) and angiotensin II. Genetic mutations significantly contribute to TAAs, with genes involved in the elastin-contractile unit and TGF-beta signalling pathways playing pivotal roles. However, the complex interplay between genetic susceptibility and risk factors explains why some patients develop aneurysms while others do not. Clinical management strategies have evolved, emphasising early risk stratification, surveillance, and timely surgical intervention, guided increasingly by genetic profiling and segment-specific molecular understanding. Advances in genomic technologies, biomarker identification, and computational modelling promise to enhance individualised care. Bridging developmental biology, molecular genetics, and clinical practice is crucial for improving outcomes in patients with aortic aneurysms, thereby reinforcing a multidisciplinary approach to patient-centred cardiovascular medicine. FAU - Van Hemelrijck, Mathias AU - Van Hemelrijck M AUID- ORCID: 0000-0002-0191-757X AD - Department of Cardiac Surgery, Municipal Hospital Triemli, 8055 Zurich, Switzerland. AD - Department of Cardiac Surgery, University Hospital Zurich, 8091 Zurich, Switzerland. FAU - Risteski, Petar AU - Risteski P AUID- ORCID: 0000-0001-6979-5057 AD - Department of Cardiac Surgery, Municipal Hospital Triemli, 8055 Zurich, Switzerland. AD - Department of Cardiac Surgery, University Hospital Zurich, 8091 Zurich, Switzerland. FAU - Rings, Laura AU - Rings L AD - Department of Cardiac Surgery, Municipal Hospital Triemli, 8055 Zurich, Switzerland. AD - Department of Cardiac Surgery, University Hospital Zurich, 8091 Zurich, Switzerland. FAU - Milojevic, Milan AU - Milojevic M AUID- ORCID: 0000-0003-0984-9011 AD - Department of Cardiac Surgery, University Hospital Zurich, 8091 Zurich, Switzerland. AD - Department of Cardiovascular Research, Dedinje Cardiovascular Institute, 11000 Belgrade, Serbia. FAU - Rodriguez Cetina Biefer, Hector AU - Rodriguez Cetina Biefer H AUID- ORCID: 0000-0002-5855-8993 AD - Department of Cardiac Surgery, Municipal Hospital Triemli, 8055 Zurich, Switzerland. AD - Department of Cardiac Surgery, University Hospital Zurich, 8091 Zurich, Switzerland. AD - Center for Translational and Experimental Cardiology (CTEC), Department of Cardiology, University Hospital Zurich, 8952 Zurich, Switzerland. FAU - Dzemali, Omer AU - Dzemali O AUID- ORCID: 0000-0001-7910-5152 AD - Department of Cardiac Surgery, Municipal Hospital Triemli, 8055 Zurich, Switzerland. AD - Department of Cardiac Surgery, University Hospital Zurich, 8091 Zurich, Switzerland. AD - Center for Translational and Experimental Cardiology (CTEC), Department of Cardiology, University Hospital Zurich, 8952 Zurich, Switzerland. LA - eng PT - Journal Article PT - Review DEP - 20251126 PL - Switzerland TA - Biomolecules JT - Biomolecules JID - 101596414 SB - IM MH - Humans MH - *Aortic Aneurysm, Thoracic/pathology/genetics/metabolism MH - *Aortic Aneurysm, Abdominal/pathology/metabolism/genetics MH - Animals MH - Signal Transduction MH - Myocytes, Smooth Muscle/metabolism/pathology PMC - PMC12731113 OTO - NOTNLM OT - abdominal aortic disease OT - aorta OT - aortic aneurysm OT - aortopathy OT - clinical management OT - genetic variants OT - patient-centred cardiovascular medicine OT - thoracic aortic disease COIS- The authors declare no competing interests related to the content of this manuscript. EDAT- 2025/12/30 07:40 MHDA- 2025/12/30 07:41 PMCR- 2025/11/26 CRDT- 2025/12/30 01:45 PHST- 2025/07/11 00:00 [received] PHST- 2025/10/08 00:00 [revised] PHST- 2025/10/16 00:00 [accepted] PHST- 2025/12/30 07:41 [medline] PHST- 2025/12/30 07:40 [pubmed] PHST- 2025/12/30 01:45 [entrez] PHST- 2025/11/26 00:00 [pmc-release] AID - biom15121654 [pii] AID - biomolecules-15-01654 [pii] AID - 10.3390/biom15121654 [doi] PST - epublish SO - Biomolecules. 2025 Nov 26;15(12):1654. doi: 10.3390/biom15121654. PMID- 41460074 OWN - NLM STAT- MEDLINE DCOM- 20260129 LR - 20260813 IS - 1473-6543 (Electronic) IS - 1062-4821 (Print) IS - 1062-4821 (Linking) VI - 35 IP - 2 DP - 2026 Mar 1 TI - Evolution in the targets for blood pressure treatment. PG - 141-149 LID - 10.1097/MNH.0000000000001152 [doi] AB - PURPOSE OF REVIEW: This review focuses on new nonpharmacological and drug therapies for lowering blood pressure, hypertension treatment goals, and strategies to improve hypertension control. RECENT FINDINGS: Clinical trials have demonstrated salt substitutes to be effective for blood pressure lowering and cardiovascular disease prevention. Cohort studies have identified a continuous association between alcohol intake and blood pressure, indicating no safe level of alcohol consumption. Clinical trials have demonstrated significant blood pressure reduction with isometric resistance exercise and have confirmed the benefits of "weekend warrior" exercise. The 2025 American Heart Association/American College of Cardiology Blood Pressure Guideline recommends stress reduction but with less enthusiasm than for other nonpharmacological recommendations.Clinical trials support use of single pill combinations, team-based management, multilevel strategies, health coaching, electronic decision-support systems, home blood pressure monitoring, provider training, and audit and feedback strategies for improved control of hypertension. Clinical trials have also documented the benefit of systolic blood pressure targets <130 and <120 mmHg for prevention of cardiovascular disease and all-cause mortality. SUMMARY: Although recent reports have further enhanced knowledge for blood pressure lowering, hypertension remains poorly controlled, worldwide. There is an imperative to improve prevention, detection, treatment, and control of high blood pressure. CI - Copyright (c) 2025 Wolters Kluwer Health, Inc. All rights reserved. FAU - Whelton, Paul K AU - Whelton PK AD - Department of Epidemiology, Tulane University Celia Scott Weatherhead School of Public Health and Tropical Medicine. AD - Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana, USA. FAU - O'Connell, Samantha AU - O'Connell S AD - Department of Epidemiology, Tulane University Celia Scott Weatherhead School of Public Health and Tropical Medicine. FAU - Mills, Katherine AU - Mills K AD - Department of Epidemiology, Tulane University Celia Scott Weatherhead School of Public Health and Tropical Medicine. LA - eng GR - P20 GM109036/GM/NIGMS NIH HHS/United States PT - Journal Article PT - Review DEP - 20251229 PL - England TA - Curr Opin Nephrol Hypertens JT - Current opinion in nephrology and hypertension JID - 9303753 RN - 0 (Antihypertensive Agents) SB - IM MH - Humans MH - *Hypertension/physiopathology/therapy/diagnosis MH - *Antihypertensive Agents/therapeutic use/adverse effects MH - *Blood Pressure/drug effects MH - Treatment Outcome PMC - PMC13174583 MID - NIHMS2169924 OTO - NOTNLM OT - antihypertensive treatment OT - blood pressure OT - hypertension COIS- Conflicts of interest There are no conflicts of interest. EDAT- 2025/12/29 13:02 MHDA- 2026/01/29 07:34 PMCR- 2026/05/14 CRDT- 2025/12/29 09:03 PHST- 2026/01/29 07:34 [medline] PHST- 2025/12/29 13:02 [pubmed] PHST- 2025/12/29 09:03 [entrez] PHST- 2026/05/14 00:00 [pmc-release] AID - 00041552-202603000-00002 [pii] AID - 10.1097/MNH.0000000000001152 [doi] PST - ppublish SO - Curr Opin Nephrol Hypertens. 2026 Mar 1;35(2):141-149. doi: 10.1097/MNH.0000000000001152. Epub 2025 Dec 29. PMID- 41458986 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251229 LR - 20251231 IS - 2297-055X (Print) IS - 2297-055X (Electronic) IS - 2297-055X (Linking) VI - 12 DP - 2025 TI - Ethical considerations and multidisciplinary care for pediatric patients with hypoplastic left heart syndrome: a narrative review with a systematic search. PG - 1641337 LID - 10.3389/fcvm.2025.1641337 [doi] LID - 1641337 AB - BACKGROUND: Hypoplastic left heart syndrome (HLHS) was a fatal congenital heart defect (CHD) until the 1980s. Introduction of the Norwood procedure and subsequent Fontan operation significantly improved survival by creating a single-ventricle circulation. Due to the high mortality associated with the Norwood operation, neonatal orthotopic heart transplantation emerged as an alternative, despite challenges such as lifelong immunosuppressive treatment and uncertain longevity of transplanted hearts. METHODS: A narrative review with a systematic literature search was conducted in the PubMed, following PRISMA guidelines and included studies of ethical and medical considerations, decision-making, counseling and treatment planning in children with HLHS. In addition, we manually screened reference lists to identify further relevant literature. We aimed to explore: how do ethical considerations and decision-making processes influence the management and outcomes of fetuses and neonates with HLHS and their families across prenatal, postnatal, and long-term care? RESULTS: Of the 115 studies, 56 met the inclusion criteria. Early diagnosis through prenatal fetal ultrasound has markedly improved survival rates by enabling better parental awareness, counseling, and decision-making. Managing HLHS requires urgent, extensive, and costly medical interventions, with outcomes influenced by the healthcare system's expertise, the experience of cardiologists and surgeons, ethical, legal, and religious considerations of the parents and medical team. The prenatal phase is crucial for optimal management, with advanced fetal ultrasound facilitating early detection. Postnatal care involves a multidisciplinary approach, including stage palliation physiology/surgery tailored to each patient. Despite surgical advancements, HLHS patients face higher morbidity and mortality rates than other patients with CHDs, with long-term survival and quality of life remaining key concerns. Ethical considerations play a significant role in the management of HLHS, encompassing the autonomy of families, the best medical interests of the child, societal, and cultural factors. Decision-making must balance full disclosure with sensitivity to parents' values and beliefs. CONCLUSIONS: Management of HLHS involves multidisciplinary approach with complex medical and ethical considerations, but the current literature lacks high-quality studies or consensus guidelines on ethical decision-making. Therefore, the influence of ethical considerations on clinical management and patient care remains unclear, highlighting the need for further research. CI - (c) 2025 Zeleznik, Groselj and Fister. FAU - Zeleznik, Mojca AU - Zeleznik M AD - Department of Neonatology, University Children's Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia. FAU - Groselj, Urh AU - Groselj U AD - Department of Endocrinology, Diabetes and Metabolism, University Children's Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia. AD - Department of Medical Ethics, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia. AD - Department of Pediatrics, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia. AD - National Medical Ethics Committee, Minister of Health, Ljubljana, Slovenia. FAU - Fister, Petja AU - Fister P AD - Department of Pediatrics, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia. AD - National Medical Ethics Committee, Minister of Health, Ljubljana, Slovenia. AD - Department of Pediatric Critical Care, University Children's Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia. LA - eng PT - Journal Article PT - Systematic Review DEP - 20251211 PL - Switzerland TA - Front Cardiovasc Med JT - Frontiers in cardiovascular medicine JID - 101653388 PMC - PMC12738816 OTO - NOTNLM OT - congenital heart defect OT - decision making OT - hypoplastic left heart syndrome OT - medical ethic OT - multidisciplinary care OT - neonatal care OT - palliative surgery OT - prenatal diagnosis COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2025/12/29 07:08 MHDA- 2025/12/29 07:09 PMCR- 2025/12/11 CRDT- 2025/12/29 05:16 PHST- 2025/06/04 00:00 [received] PHST- 2025/11/25 00:00 [revised] PHST- 2025/11/26 00:00 [accepted] PHST- 2025/12/29 07:09 [medline] PHST- 2025/12/29 07:08 [pubmed] PHST- 2025/12/29 05:16 [entrez] PHST- 2025/12/11 00:00 [pmc-release] AID - 10.3389/fcvm.2025.1641337 [doi] PST - epublish SO - Front Cardiovasc Med. 2025 Dec 11;12:1641337. doi: 10.3389/fcvm.2025.1641337. eCollection 2025. PMID- 41457217 OWN - NLM STAT- MEDLINE DCOM- 20260131 LR - 20261014 IS - 1471-2318 (Electronic) IS - 1471-2318 (Linking) VI - 26 IP - 1 DP - 2025 Dec 28 TI - The prevalence and burden of chronic kidney disease, patterns of anticoagulation prescribing, and major bleeding risk in older adults with atrial fibrillation. PG - 138 LID - 10.1186/s12877-025-06888-4 [doi] LID - 138 AB - BACKGROUND: In older adults with atrial fibrillation (AF), the presence of comorbid chronic kidney disease (CKD) may be more challenging for optimal disease management, influence stroke prophylaxis with oral anticoagulation, and impact bleeding risk. We examined the prevalence and burden of CKD in older patients with AF, patterns of anticoagulation prescribing according to CKD stage, and major bleeding events. METHODS: Patients aged 65 years and older with AF were enrolled in a cohort study from clinics in Massachusetts and Georgia between 2016 and 2018. Kidney function was assessed with estimated glomerular filtration rate (GFR) values at study enrollment. Anticoagulation therapy with direct acting oral anticoagulation therapy (DOAC) or warfarin; and major bleeding events were ascertained from medical records. Cox proportional hazards model was used to estimate the multivariable adjusted risk of two-year major bleeding events. RESULTS: Participants' (n = 1,244) mean age was 75 years; 48% were women, and 86% were White. Overall, 25% had a normal GFR, 44%, 28%, and 3% had mild, moderate, and severe CKD/kidney failure, respectively. Patients with severe CKD/kidney failure were more likely to be the oldest participants, dependent in their instrumental activities of daily living, and had the highest burden of frailty, multimorbidity, and polypharmacy. Approximately 44% of patients with normal GFR and 39% of those with mild CKD were prescribed a DOAC, while a majority of those with severe CKD/kidney failure (69%) were prescribed warfarin. Overall, 8% (n = 105) experienced a major bleeding event over the 2-year follow-up. After adjusting for sociodemographic, psychosocial, geriatric, and clinical variables, patients with severe CKD/kidney failure (HR: 2.81 [95% CI:1.10-7.17]) had a higher bleeding risk than those with a normal GFR. CONCLUSIONS: In managing older patients with AF and comorbid CKD, healthcare providers should be increasingly aware of the increased burden of frailty, dependence for care, multimorbidity, polypharmacy, and the high risk of major bleeding especially among those with severely impaired kidney function. This finding emphasizes the need for a more holistic and multidisciplinary approach to stroke prophylaxis in older adults with AF and comorbid CKD. CI - (c) 2025. The Author(s). FAU - Abu, Hawa O AU - Abu HO AD - Division of Geriatric Medicine, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, 01605, USA. Hawa.Abu@umassmemorial.org. FAU - Del Castillo, Felipe Fernandez AU - Del Castillo FF AD - Nephrology Division, Reliant Medical Group, Worcester, MA, USA. FAU - Wang, Weijia AU - Wang W AD - Marshfield Clinic Health System, Marshfield, WI, USA. FAU - Saczynski, Jane S AU - Saczynski JS AD - Department of Pharmacy and Health Systems Sciences, School of Pharmacy, Northeastern University, Boston, MA, USA. FAU - Mehawej, Jordy AU - Mehawej J AD - Division of Cardiovascular Medicine, UMass Chan Medical School, Worcester, MA, USA. FAU - Tenes, Paul AU - Tenes P AD - Division of Cardiovascular Medicine, UMass Chan Medical School, Worcester, MA, USA. FAU - Tisminetzky, Mayra AU - Tisminetzky M AD - Division of Health Systems Science, UMass Chan Medical School, Worcester, MA, USA. FAU - Gurwitz, Jerry AU - Gurwitz J AD - Division of Geriatric Medicine, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, 01605, USA. AD - Division of Health Systems Science, UMass Chan Medical School, Worcester, MA, USA. FAU - Goldberg, Robert J AU - Goldberg RJ AD - Department of Population and Quantitative Health Sciences, UMass Chan Medical School, Worcester, MA, USA. FAU - Dosa, David AU - Dosa D AD - Division of Geriatric Medicine, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, 01605, USA. FAU - Kapoor, Alok AU - Kapoor A AD - Division of Hospital Medicine, UMass Chan Medical School, Worcester, MA, USA. FAU - McManus, David D AU - McManus DD AD - Division of Cardiovascular Medicine, UMass Chan Medical School, Worcester, MA, USA. LA - eng GR - R01 HL126911/HL/NHLBI NIH HHS/United States GR - R01 HL155343/HL/NHLBI NIH HHS/United States GR - 3R01HL155343-04S1/HL/NHLBI NIH HHS/United States GR - R01HL126911/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20251228 PL - England TA - BMC Geriatr JT - BMC geriatrics JID - 100968548 RN - 0 (Anticoagulants) RN - 5Q7ZVV76EI (Warfarin) SB - IM MH - Humans MH - *Atrial Fibrillation/drug therapy/epidemiology/complications MH - Aged MH - Female MH - Male MH - *Renal Insufficiency, Chronic/epidemiology/complications MH - *Anticoagulants/adverse effects/therapeutic use/administration & dosage MH - *Hemorrhage/chemically induced/epidemiology MH - Prevalence MH - Aged, 80 and over MH - Glomerular Filtration Rate MH - Cohort Studies MH - Stroke/prevention & control MH - Risk Factors MH - Massachusetts/epidemiology MH - *Cost of Illness MH - Warfarin/adverse effects PMC - PMC12860050 OTO - NOTNLM OT - Anticoagulation OT - Chronic kidney disease OT - Major bleeding OT - Older adults, atrial fibrillation COIS- Declarations. Ethics approval and consent to participate: The Institutional Review Boards at the participating study sites including the University of Massachusetts Medical School, Boston University, and Mercer University, provided ethical approval for conducting this study. All study participants provided written informed consent. Given our observational study design, no experiments were conducted on the study participants. Consent for publication: Not applicable. Competing interests: David McManus has received research grant support from Apple Computer, Bristol-Myers Squibb, Boeringher-Ingelheim, Pfizer, Samsung, Philips Healthcare, and Biotronik; consultancy fees from Bristol-Myers Squibb, Pfizer, Flexcon, and Boston Biomedical Associates, and has inventor equity in Mobile Sense Technologies, Inc (Farmington, CT). All other authors declare no potential conflicts of interest. EDAT- 2025/12/29 00:24 MHDA- 2026/01/31 06:31 PMCR- 2025/12/28 CRDT- 2025/12/28 23:13 PHST- 2024/12/19 00:00 [received] PHST- 2025/12/03 00:00 [accepted] PHST- 2026/01/31 06:31 [medline] PHST- 2025/12/29 00:24 [pubmed] PHST- 2025/12/28 23:13 [entrez] PHST- 2025/12/28 00:00 [pmc-release] AID - 10.1186/s12877-025-06888-4 [pii] AID - 6888 [pii] AID - 10.1186/s12877-025-06888-4 [doi] PST - epublish SO - BMC Geriatr. 2025 Dec 28;26(1):138. doi: 10.1186/s12877-025-06888-4. PMID- 41454807 OWN - NLM STAT- MEDLINE DCOM- 20251227 LR - 20260502 IS - 0971-5916 (Print) IS - 0971-5916 (Linking) VI - 162 IP - 4 DP - 2025 Oct TI - Burden of sudden death in young adults: A one-year observational study at a tertiary care centre in India. PG - 453-459 LID - 10.25259/IJMR_938_2025 [pii] AB - Background & objectives Sudden death, defined as death occurring within one hour of symptom onset in witnessed cases or within 24 h of last being seen alive in unwitnessed cases, remains a major public health concern. This study aimed to evaluate the incidence, causes, and risk factors associated with sudden death in young adults. Methods A cross-sectional study was conducted over one year at a tertiary care centre in New Delhi. Cases meeting the definition of sudden death were included, excluding trauma, suicide, homicide, and drug abuse. Each case underwent whole-body imaging, autopsy, and histopathological examination. A multidisciplinary team comprising forensic experts, pathologists, radiologists, and clinicians determined the cause of death. Comparative analysis was performed between sudden death in young adults (18-45 yr) and older adults (46-65 yr). Results Out of 2214 autopsies, 180 cases (8.1%) met the criteria for sudden death. Sudden death in young accounted for 103 (57.2%) cases. Mean age was 33.6 yr in sudden death in young (IQR=10) and 53.8 years in sudden death in old, with male predominance in both. Cardiovascular causes were most common in young (n=40, 42.6%), followed by respiratory causes (n=20, 21.3%) and sudden unexplained deaths (n=20, 21.3%), where no pathology was identified. Other causes included gastrointestinal, central nervous system, and genitourinary pathologies. Smoking and alcohol intake was equally prevalent in those who died young and at old age. Interpretation & conclusions Sudden death in young adults is a significant concern requiring targeted public health strategies. Coronary artery disease remains the leading cause. Respiratory and unexplained deaths warrant further investigation. FAU - Jain, Surabhi AU - Jain S AD - Department of Pathology, All India Institutes of Medical Sciences, New Delhi, India. FAU - Gupta, Sudhir AU - Gupta S AD - Department of Forensic Medicine, All India Institutes of Medical Sciences, New Delhi, India. FAU - Murthy, Abilash Srinivasa AU - Murthy AS AD - Department of Forensic Medicine, All India Institutes of Medical Sciences, New Delhi, India. FAU - Dagar, Shivangi AU - Dagar S AD - Department of Pathology, All India Institutes of Medical Sciences, New Delhi, India. FAU - Goswami, Ansh AU - Goswami A AD - Department of Pathology, All India Institutes of Medical Sciences, New Delhi, India. FAU - Yadav, Abhishek AU - Yadav A AD - Department of Forensic Medicine, All India Institutes of Medical Sciences, New Delhi, India. FAU - Jain, Deepali AU - Jain D AD - Department of Pathology, All India Institutes of Medical Sciences, New Delhi, India. FAU - Suri, Vaishali AU - Suri V AD - Department of Pathology, All India Institutes of Medical Sciences, New Delhi, India. FAU - Jana, Manisha AU - Jana M AD - Department of Radiology, All India Institutes of Medical Sciences, New Delhi, India. FAU - Gamanagatti, Shivanand AU - Gamanagatti S AD - Department of Radiology, All India Institutes of Medical Sciences, New Delhi, India. FAU - Ray, Ruma AU - Ray R AD - Department of Pathology, All India Institutes of Medical Sciences, New Delhi, India. FAU - Prasad, Kulbhushan AU - Prasad K AD - Department of Forensic Medicine, All India Institutes of Medical Sciences, New Delhi, India. FAU - Tabin, Millo AU - Tabin M AD - Department of Forensic Medicine, All India Institutes of Medical Sciences, New Delhi, India. FAU - Tanwar, Sachin AU - Tanwar S AD - Department of Forensic Medicine, All India Institutes of Medical Sciences, New Delhi, India. FAU - Ranjan, Amar AU - Ranjan A AD - Department of Laboratory Oncology, All India Institutes of Medical Sciences, New Delhi, India. FAU - Roy, Ambuj AU - Roy A AD - Department of Cardiology, All India Institutes of Medical Sciences, New Delhi, India. FAU - Mohan, Anant AU - Mohan A AD - Department of Pulmonary Medicine, All India Institutes of Medical Sciences, New Delhi, India. FAU - Yadav, Satyavir AU - Yadav S AD - Department of Cardiology, All India Institutes of Medical Sciences, New Delhi, India. FAU - Kumar, Sanjeev AU - Kumar S AD - Department of Cardiovascular Radiology and Endovascular Intervention, All India Institutes of Medical Sciences, New Delhi, India. FAU - Srivastava, M V Padma AU - Srivastava MVP AD - Department of Neurology, All India Institutes of Medical Sciences, New Delhi, India. FAU - Vishnu, Venugopalan Y AU - Vishnu VY AD - Department of Neurology, All India Institutes of Medical Sciences, New Delhi, India. FAU - Sebastian, Leve Joseph Devarajan AU - Sebastian LJD AD - Department of Neuroimaging and Interventional Neuroradiology, All India Institutes of Medical Sciences, New Delhi, India. FAU - Iyer, Venkateswaran K AU - Iyer VK AD - Department of Pathology, All India Institutes of Medical Sciences, New Delhi, India. FAU - Lal, Vivek AU - Lal V AD - Department of Neurology, Post Graduate Institute of Medical Education and Research, Chandigarh, India. FAU - Bahl, Ajay AU - Bahl A AD - Department of Cardiology, Post Graduate Institute of Medical Education and Research, Chandigarh, India. FAU - Sharma, Sunil Kumar AU - Sharma SK AD - Department of Forensic medicine, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India. FAU - Dhaliwal, R S AU - Dhaliwal RS AD - Division of Non-communicable Diseases, Indian Council of Medical Research, New Delhi, India. FAU - Kaur, Tanvir AU - Kaur T AD - Division of Non-communicable Diseases, Indian Council of Medical Research, New Delhi, India. FAU - Sarkar, Chitra AU - Sarkar C AD - Department of Pathology, All India Institutes of Medical Sciences, New Delhi, India. FAU - Arava, Sudheer AU - Arava S AD - Department of Pathology, All India Institutes of Medical Sciences, New Delhi, India. LA - eng PT - Journal Article PT - Observational Study PT - Research Support, Non-U.S. Gov't PL - United States TA - Indian J Med Res JT - The Indian journal of medical research JID - 0374701 SB - IM MH - Humans MH - Adult MH - Male MH - India/epidemiology MH - Female MH - Middle Aged MH - Tertiary Care Centers MH - *Death, Sudden/epidemiology/pathology MH - Adolescent MH - Cause of Death MH - Risk Factors MH - Aged MH - Autopsy MH - Young Adult MH - Cross-Sectional Studies MH - *Cardiovascular Diseases/mortality/epidemiology/pathology PMC - PMC12744565 OTO - NOTNLM OT - Arrhythmic deaths OT - coronary artery disease OT - sudden cardiac death OT - sudden death in young OT - unexplained deaths/negative autopsy COIS- None. EDAT- 2025/12/27 17:51 MHDA- 2025/12/27 17:52 PMCR- 2025/10/01 CRDT- 2025/12/27 07:49 PHST- 2025/04/17 00:00 [received] PHST- 2025/08/15 00:00 [accepted] PHST- 2025/12/27 17:52 [medline] PHST- 2025/12/27 17:51 [pubmed] PHST- 2025/12/27 07:49 [entrez] PHST- 2025/10/01 00:00 [pmc-release] AID - 10.25259/IJMR_938_2025 [pii] AID - 10.25259/IJMR_938_2025 [doi] PST - ppublish SO - Indian J Med Res. 2025 Oct;162(4):453-459. doi: 10.25259/IJMR_938_2025. PMID- 41446391 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251225 LR - 20251227 IS - 1985-207X (Print) IS - 1985-2274 (Electronic) IS - 1985-2274 (Linking) VI - 20 DP - 2025 TI - Palpitation post-vaccination: What should we do? PG - 73 LID - 10.51866/tyk.935 [doi] AB - In this clinical dilemma, we highlight the case of a previously healthy 37-year-old lady who presented to a primary care clinic with palpitations, chest discomfort and difficulty breathing within 2 hours post-mRNA COVID-19 vaccine injection. During the initial presentation to the clinic and subsequent admission to the ward, there were no significant findings except for intermittent palpitations, which were relieved by supine positioning. Serial electrocardiograms and blood investigations, including troponin-I and thyroid function tests, revealed normal findings. Given persistent symptoms, further referrals were made. She underwent a tilt table test, which demonstrated normal results. Cardiac MRI showed myocardial oedema and inflammation at the basal anteroseptal wall. Herein, we discuss several differential diagnoses, clinical features and appropriate management for this patient. This case highlights the importance of having a high clinical index of suspicion and involving a multidisciplinary team in managing a case with a diagnostic dilemma. CI - (c) Academy of Family Physicians of Malaysia. FAU - Farhani, Samat AU - Farhani S AD - MD, Master in Medicine (Fam Med), Klinik Kesihatan Tanjong Karang, Jalan Lengkungan, Tanjong Karang, Selangor, Malaysia. Email: hani5204@gmail.com. FAU - Zaharudin, Aidi AU - Zaharudin A AD - MD, MAFP/icFRACGP, Klinik Kesihatan Kalumpang Kalumpang, Kerling, Selangor, Malaysia. FAU - Rosli, Nur Athirah AU - Rosli NA AD - MBBS, Master in Medicine (Fam Med), Klinik Kesihatan Tanjong Karang Jalan Lengkungan, Tanjong Karang, Selangor, Malaysia. FAU - Ong, Jue Jing AU - Ong JJ AD - MBBS, MAFP/FRACGP, Klinik Kesihatan Kuala Selangor Jalan Klinik, Taman Malawati, Kuala Selangor, Selangor, Malaysia. FAU - Sharmilee, T Ramanathan AU - Sharmilee TR AD - MBBS, MAFP/FRACGP, Klinik Kesihatan Puchong Batu 141, Jalan PU 5, Taman Puchong Utama, Puchong, Selangor, Malaysia. FAU - Baharuddin, Siti Athirah AU - Baharuddin SA AD - MBBS, MAFP/icFRACGP, Klinik Kesihatan Tanjong Karang Jalan Lengkungan, Tanjong Karang, Selangor, Malaysia. LA - eng PT - Journal Article DEP - 20251126 PL - Malaysia TA - Malays Fam Physician JT - Malaysian family physician : the official journal of the Academy of Family Physicians of Malaysia JID - 101466855 PMC - PMC12723603 OTO - NOTNLM OT - COVID-19 OT - Myocarditis OT - Vaccines COIS- None. How does this paper make a difference in general practice? It is important to rule out vaccine-induced myocarditis in patients who present with persistent cardiac symptoms following vaccination.Primary care physicians should be able to suspect and delegate referrals to the most appropriate centres in establishing a diagnosis for patients with a diagnostic dilemma.The multidisciplinary team, which includes a primary care physician, cardiologist and neurologist, plays an important role in managing cases that require comprehensive intervention and management. EDAT- 2025/12/25 07:40 MHDA- 2025/12/25 07:41 PMCR- 2025/11/26 CRDT- 2025/12/25 05:06 PHST- 2025/12/25 07:41 [medline] PHST- 2025/12/25 07:40 [pubmed] PHST- 2025/12/25 05:06 [entrez] PHST- 2025/11/26 00:00 [pmc-release] AID - 10.51866/tyk.935 [doi] PST - epublish SO - Malays Fam Physician. 2025 Nov 26;20:73. doi: 10.51866/tyk.935. eCollection 2025. PMID- 41441205 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251224 LR - 20251226 IS - 2673-4087 (Electronic) IS - 2673-4087 (Linking) VI - 6 IP - 4 DP - 2025 Dec 15 TI - Comparison of Cardiorenal Syndrome and Heart Failure: A Preliminary Study of Clinical, Cognitive, and Emotional Aspects. LID - 10.3390/neurosci6040129 [doi] LID - 129 AB - BACKGROUND: Cardiovascular diseases (CVD) affect the heart and blood vessels. Cardiorenal syndrome (CRS) highlights the interaction between the heart and kidneys, worsening the clinical course. Assessing renal function is essential for risk stratification and guiding therapeutic decisions. Furthermore, cognitive and psychological aspects are often impaired in these patients. AIM: To compare clinical, cognitive, emotional, and quality of life parameters between patients with CRS and those with heart failure (HF) alone, and to assess the agreement between estimated glomerular filtration rate equations (Cockcroft-Gault and CKD-EPI). METHODS: This observational study was conducted at the Cardiology Unit of the IRCCS Centro Neurolesi Bonino Pulejo "Piemonte" Hospital (Messina, Italy) between June 2024 and March 2025. Thirty participants aged 45-85 years were enrolled: 15 with type 1 cardiorenal syndrome (CRS group) and 15 with heart failure without cardiorenal syndrome (HF group). All participants had a confirmed diagnosis and provided informed consent. Clinical evaluation and standardized tests (MoCA, BDI-II, BAI, and SF-12v2) were administered. Statistical analyses were performed using t-tests, chi-square tests, and Bland-Altman analysis, with significance set at p < 0.05. RESULTS: The two groups were comparable in body mass index and left ventricular ejection fraction. CRS patients had significantly higher serum creatinine and lower GFR with both equations. The two GFR equations were strongly correlated (r = 0.94; p < 0.0001). Bland-Altman analysis showed a mean difference of 5.80 mL/min (95% limits of agreement: -12.4 to +24.0 mL/min), indicating wide individual variability. No significant differences were found in cognitive performance or quality of life. However, CRS patients exhibited significantly higher depressive symptoms (BDI-II mean 11.33 +/- 8.19 vs. 5.40 +/- 6.68; p = 0.0384) and a trend toward higher anxiety (BAI mean 8.13 +/- 4.73 vs. 4.67 +/- 5.79; p = 0.0834). CONCLUSIONS: A multidisciplinary approach, including psychological support, is necessary for patients with CRS. FAU - Pagano, Maria AU - Pagano M AUID- ORCID: 0000-0002-0978-605X AD - IRCCS Centro Neurolesi Bonino-Pulejo, Via Palermo, S.S. 113, C.da Casazza, 98124 Messina, Italy. FAU - Anselmo, Anna AU - Anselmo A AD - IRCCS Centro Neurolesi Bonino-Pulejo, Via Palermo, S.S. 113, C.da Casazza, 98124 Messina, Italy. FAU - Micali, Giuseppe AU - Micali G AUID- ORCID: 0009-0007-8229-6229 AD - IRCCS Centro Neurolesi Bonino-Pulejo, Via Palermo, S.S. 113, C.da Casazza, 98124 Messina, Italy. FAU - Giambo, Fabio Mauro AU - Giambo FM AUID- ORCID: 0000-0001-6843-4153 AD - IRCCS Centro Neurolesi Bonino-Pulejo, Via Palermo, S.S. 113, C.da Casazza, 98124 Messina, Italy. FAU - Speciale, Francesco AU - Speciale F AD - IRCCS Centro Neurolesi Bonino-Pulejo, Via Palermo, S.S. 113, C.da Casazza, 98124 Messina, Italy. FAU - Costanzo, Daniela AU - Costanzo D AD - IRCCS Centro Neurolesi Bonino-Pulejo, Via Palermo, S.S. 113, C.da Casazza, 98124 Messina, Italy. FAU - D'Aleo, Piercataldo AU - D'Aleo P AD - IRCCS Centro Neurolesi Bonino-Pulejo, Via Palermo, S.S. 113, C.da Casazza, 98124 Messina, Italy. FAU - Duca, Antonio AU - Duca A AUID- ORCID: 0000-0002-0353-7482 AD - IRCCS Centro Neurolesi Bonino-Pulejo, Via Palermo, S.S. 113, C.da Casazza, 98124 Messina, Italy. FAU - Bramanti, Alessia AU - Bramanti A AUID- ORCID: 0000-0002-5247-9901 AD - Department of Medicine, Surgery and Dentistry, University of Salerno, 84081 Baronissi, Italy. FAU - Garofano, Marina AU - Garofano M AUID- ORCID: 0000-0003-1600-4682 AD - Department of Medicine, Surgery and Dentistry, University of Salerno, 84081 Baronissi, Italy. FAU - Bramanti, Placido AU - Bramanti P AD - IRCCS Centro Neurolesi Bonino-Pulejo, Via Palermo, S.S. 113, C.da Casazza, 98124 Messina, Italy. AD - Faculty of Psychology, Universita degli Studi eCampus, Via Isimbardi 10, 22060 Novedrate, Italy. FAU - Corallo, Francesco AU - Corallo F AUID- ORCID: 0000-0003-4862-3832 AD - IRCCS Centro Neurolesi Bonino-Pulejo, Via Palermo, S.S. 113, C.da Casazza, 98124 Messina, Italy. FAU - Cappadona, Irene AU - Cappadona I AUID- ORCID: 0000-0002-3984-2331 AD - IRCCS Centro Neurolesi Bonino-Pulejo, Via Palermo, S.S. 113, C.da Casazza, 98124 Messina, Italy. LA - eng PT - Journal Article DEP - 20251215 PL - Switzerland TA - NeuroSci JT - NeuroSci JID - 101772310 PMC - PMC12735993 OTO - NOTNLM OT - anxiety OT - cardiorenal syndrome OT - cognitive functioning OT - depression OT - heart failure OT - kidney failure COIS- The authors declare no conflicts of interest. EDAT- 2025/12/24 12:55 MHDA- 2025/12/24 12:56 PMCR- 2025/12/15 CRDT- 2025/12/24 09:53 PHST- 2025/08/26 00:00 [received] PHST- 2025/11/07 00:00 [revised] PHST- 2025/12/11 00:00 [accepted] PHST- 2025/12/24 12:56 [medline] PHST- 2025/12/24 12:55 [pubmed] PHST- 2025/12/24 09:53 [entrez] PHST- 2025/12/15 00:00 [pmc-release] AID - neurosci6040129 [pii] AID - neurosci-06-00129 [pii] AID - 10.3390/neurosci6040129 [doi] PST - epublish SO - NeuroSci. 2025 Dec 15;6(4):129. doi: 10.3390/neurosci6040129. PMID- 41440878 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251224 LR - 20260925 IS - 2308-3425 (Electronic) IS - 2308-3425 (Linking) VI - 12 IP - 12 DP - 2025 Dec 17 TI - Echocardiographic Assessment of Patients Undergoing Mitral Valve Repair. LID - 10.3390/jcdd12120498 [doi] LID - 498 AB - Mitral regurgitation (MR) is one of the most prevalent valvular disorders worldwide, with a growing burden driven by population aging and improved diagnostic capabilities. Understanding the mechanism of MR, whether primary, due to intrinsic valve abnormalities, or secondary, resulting from atrial or ventricular remodeling, is essential for optimal management. Echocardiography, particularly advanced modalities such as three-dimensional imaging and strain analysis, plays a central role in this process. It allows accurate quantification of MR severity, detailed characterization of valve and ventricular anatomy, and assessment of remodeling, all of which are critical for determining the optimal timing for intervention. Beyond diagnosis, echocardiography is indispensable in guiding therapy selection: it informs surgical planning by defining leaflet pathology for repair versus replacement strategies, and directs transcatheter interventions by guiding interatrial septal puncture, catheter orientation, and device deployment in real time. While surgery remains the gold standard for primary MR, transcatheter approaches including edge-to-edge repair and emerging mitral valve replacement are increasingly relevant, particularly in patients at high surgical risk or with complex anatomy. This review emphasizes the pivotal role of echocardiography in the pre-procedural assessment of MR, highlighting its ability to integrate anatomical, functional, and hemodynamic information to guide patient-tailored therapeutic strategies and optimize outcomes within a Heart Team framework. FAU - Rolando, Marco AU - Rolando M AUID- ORCID: 0000-0001-8928-8626 AD - Independent Researcher, 63100 Ascoli Piceno, Italy. FAU - Elmasry, Nadeem AU - Elmasry N AUID- ORCID: 0009-0008-3313-9611 AD - Department of Cardiology, Leiden University Medical Centre (LUMC), Albinusdreef 2, 2300 RC Leiden, The Netherlands. FAU - Gobbi, Federico AU - Gobbi F AD - Cardiology and Cardiovascular Pathophysiology, S. Maria Della Misericordia Hospital, University of Perugia, Piazzale Menghini 1, 06129 Perugia, Italy. FAU - Moreo, Antonella AU - Moreo A AUID- ORCID: 0000-0003-3150-3885 AD - Department of Cardiology, De Gasperis Cardio Center, ASST Grande Ospedale Metropolitano Niguarda, Piazza dell'Ospedale Maggiore 3, 20162 Milan, Italy. FAU - Ajmone Marsan, Nina AU - Ajmone Marsan N AUID- ORCID: 0000-0001-7208-5769 AD - Department of Cardiology, Leiden University Medical Centre (LUMC), Albinusdreef 2, 2300 RC Leiden, The Netherlands. FAU - Carluccio, Erberto AU - Carluccio E AUID- ORCID: 0000-0002-9296-4397 AD - Cardiology and Cardiovascular Pathophysiology, S. Maria Della Misericordia Hospital, University of Perugia, Piazzale Menghini 1, 06129 Perugia, Italy. FAU - Fortuni, Federico AU - Fortuni F AUID- ORCID: 0000-0001-6905-9439 AD - Cardiology and Cardiovascular Pathophysiology, S. Maria Della Misericordia Hospital, University of Perugia, Piazzale Menghini 1, 06129 Perugia, Italy. LA - eng PT - Journal Article PT - Review DEP - 20251217 PL - Switzerland TA - J Cardiovasc Dev Dis JT - Journal of cardiovascular development and disease JID - 101651414 PMC - PMC12733537 OTO - NOTNLM OT - mitral regurgitation OT - multidisciplinary approach OT - multimodality imaging OT - three-dimensional echocardiography OT - transcatheter edge-to-edge repair OT - transcatheter mitral valve intervention COIS- The Department of Cardiology of the Leiden University Medical Center received unrestricted research grants from Abbott Vascular, Alnylam, AstraZeneca, Bayer, BioVentrix, Biotronik, Boston Scientific, Edwards Lifesciences, GE Healthcare, Medtronic, Novartis, Pfizer and Pie Medical. NAM received speaker fees from GE Healthcare, Philips Ultrasound and Abbott Vascular. EDAT- 2025/12/24 12:54 MHDA- 2025/12/24 12:55 PMCR- 2025/12/17 CRDT- 2025/12/24 09:45 PHST- 2025/10/26 00:00 [received] PHST- 2025/12/12 00:00 [revised] PHST- 2025/12/12 00:00 [accepted] PHST- 2025/12/24 12:55 [medline] PHST- 2025/12/24 12:54 [pubmed] PHST- 2025/12/24 09:45 [entrez] PHST- 2025/12/17 00:00 [pmc-release] AID - jcdd12120498 [pii] AID - jcdd-12-00498 [pii] AID - 10.3390/jcdd12120498 [doi] PST - epublish SO - J Cardiovasc Dev Dis. 2025 Dec 17;12(12):498. doi: 10.3390/jcdd12120498. PMID- 41438533 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251224 LR - 20251224 IS - 0970-9134 (Print) IS - 0973-7723 (Electronic) IS - 0970-9134 (Linking) VI - 42 IP - 1 DP - 2026 Jan TI - Surgical implications of rheumatic heart disease in Indian females. PG - 59-77 LID - 10.1007/s12055-025-02068-6 [doi] AB - Rheumatic heart disease (RHD) remains a significant public health concern in India, disproportionately affecting women in the child-bearing age. Delayed diagnosis, limited awareness, and inadequate access to specialized cardiac care, contribute to advance disease presentation and poor outcome. Despite the availability of early detection tools and effective antibiotic prophylaxis, many Indian women are diagnosed at the late stages, necessitating complex surgical interventions such as balloon valvuloplasty, valve repair, or valve replacement. Surgical management presents unique challenges particularly regarding the choice between the mechanical and bioprosthetic valves, as the former requires lifelong anticoagulation therapy which poses risk during pregnancy. Socioeconomic impacts of RHD on women include not only financial constraints and loss of productivity but also significant disparities in healthcare access which further hinder timely and effective treatment. This narrative review will provide the comprehensive overview of the current state of research in a specific field and would explore the multifaceted surgical implications of RHD in Indian woman, and would also address demographic consideration, including the age of onset; clinical, reproductive, and hormonal factors; and socio-economic dimensions which influence disease progression and surgical outcomes. It also emphasizes the importance of early screening programs, tailored surgical strategies, and a multidisciplinary approach to care including preconception counselling and postoperative follow-up to improve outcomes. Addressing these gaps is essential to reduce the morbidity and mortality, and enhancing the overall quality of life for woman affected with RHD in India. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12055-025-02068-6. CI - (c) Indian Association of Cardiovascular-Thoracic Surgeons 2025. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. FAU - Chandra, Abha AU - Chandra A AUID- ORCID: 0000-0001-5575-0595 AD - Cardiovascular and Thoracic Surgery, Department of Surgery, Integral Institute of Medical Sciences and Research, Kursi Road Dasauli, 226026 Lucknow, Uttar Pradesh India. AD - Faculty of Medicine and Health Sciences, Integral University, Kursi Road Dasauli, 226026 Lucknow, Uttar Pradesh India. ROR: https://ror.org/039zd5s34. GRID: grid.411723.2. ISNI: 0000 0004 1756 4240 FAU - Gutti, Ramasubramanyam AU - Gutti R AD - Cardiothoracic Surgery, Care Hospital, Road No.1 Banjara Hills, Hyderabad, 530034 Telangana India. ROR: https://ror.org/01vka3a64. GRID: grid.413417.4. ISNI: 0000 0004 1761 1705 FAU - Sisodia, Anula AU - Sisodia A AD - Department of Cardiothoracic and Vascular Surgery, SMS Medical College and Hospital, Jaipur, 302004 Rajasthan India. ROR: https://ror.org/02x3hmg72. GRID: grid.416077.3. ISNI: 0000 0004 1767 3615 FAU - Malempati, Amaresh Rao AU - Malempati AR AD - Department of Cardiothoracic Surgery, Nizam's Institute of Medical Sciences, Punjagutta, Hyderabad, 500082 Telangana India. ROR: https://ror.org/01wjz9118. GRID: grid.416345.1. ISNI: 0000 0004 1767 2356 FAU - Davulury, Sri Satyavathi AU - Davulury SS AD - Department of Cardiovascular and Thoracic Surgery, Sri Venkateswara Institute of Medical Sciences, Alipiri, Tirupati, 517507 Andhra Pradesh India. ROR: https://ror.org/039thcs93. GRID: grid.416288.1. ISNI: 0000 0004 1767 3463 FAU - Reddy, Sailaja Vasi AU - Reddy SV AD - Care Hospital, Road No. 1, Banjara Hills, Hyderabad, 530034 Telangana India. ROR: https://ror.org/01vka3a64. GRID: grid.413417.4. ISNI: 0000 0004 1761 1705 FAU - Yadav, Amita AU - Yadav A AD - National Heart Institute, New Delhi, 110065 India. ROR: https://ror.org/00zb80875. GRID: grid.512696.f. ISNI: 0000 0004 1800 3031 LA - eng PT - Journal Article PT - Review DEP - 20251120 PL - India TA - Indian J Thorac Cardiovasc Surg JT - Indian journal of thoracic and cardiovascular surgery JID - 8700105 PMC - PMC12719373 OTO - NOTNLM OT - Acute rheumatic fever OT - Anticoagulation OT - Balloon mitral valvotomy OT - Females OT - India OT - Mitral valve OT - Pregnancy OT - Prosthetic valves OT - Rheumatic valvular disease COIS- Conflict of interestAuthors declare that there is no conflict of interest. EDAT- 2025/12/24 07:43 MHDA- 2025/12/24 07:44 PMCR- 2027/01/01 CRDT- 2025/12/24 04:52 PHST- 2025/05/07 00:00 [received] PHST- 2025/08/06 00:00 [revised] PHST- 2025/08/07 00:00 [accepted] PHST- 2025/12/24 07:44 [medline] PHST- 2025/12/24 07:43 [pubmed] PHST- 2025/12/24 04:52 [entrez] PHST- 2027/01/01 00:00 [pmc-release] AID - 2068 [pii] AID - 10.1007/s12055-025-02068-6 [doi] PST - ppublish SO - Indian J Thorac Cardiovasc Surg. 2026 Jan;42(1):59-77. doi: 10.1007/s12055-025-02068-6. Epub 2025 Nov 20. PMID- 41426930 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251222 LR - 20251224 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 17 IP - 11 DP - 2025 Nov TI - Evaluating Surgical Response Times in Category 1 Major Trauma. PG - e97139 LID - 10.7759/cureus.97139 [doi] LID - e97139 AB - Background Patients who activate a Category 1 (Cat1) trauma call have life-threatening injuries and require an immediate, coordinated response from a multidisciplinary trauma team. National guidelines emphasise prompt surgical review; however, in practice, surgical teams are not always alerted at the point of trauma activation. Delays may contribute to missed interventions, prolonged intensive care unit (ICU) stays, and increased mortality. Aim This study aims to evaluate surgical team attendance and the time interval to surgical input in Cat1 trauma cases, and to assess their association with injury severity and patient mortality. The audit also aimed to explore whether implementing a structured bleep system could improve early surgical input. Methods A retrospective audit was conducted at Royal Stoke University Hospital (a tertiary major trauma centre), including Cat1 trauma cases from October 2024 to April 2025. Thirty-seven patients were identified, of whom 30 (81%) met Cat1 criteria upon retrospective review. Data was extracted from electronic patient records and operative reports. Key measures included the time from the patient's arrival in the emergency department to surgical review, specialty attendance, ICU admission and length of stay, and 30-day mortality. Analyses were stratified by Abbreviated Injury Scale (AIS) scores and Injury Severity Score (ISS). Results Of the 30 Cat1 patients (mean age: 49.6 years, male: 77%), road traffic collisions (RTCs) were the leading mechanism of injury. The 30-day mortality rate of Cat1 trauma cases was 46.7%. Anaesthetic attendance was the highest (83%), followed by trauma and orthopaedics (T&O) (73%), cardiothoracic surgery (53%), general surgery (40%), and neurosurgery (40%). Mean arrival times varied: general surgery, 86.8 minutes; cardiothoracic surgery, 140.3 minutes; T&O, 160.4 minutes; and neurosurgery, 177.6 minutes. Damage control surgery occurred earliest in cardiothoracic cases (mean: 69 minutes) and was most delayed in T&O (mean: 231 minutes). Patients reviewed by /=2 (66.7% versus 33.3%; odds ratio (OR): 4.0, p = 0.12). Mortality patterns differed across specialities, with delayed surgical review generally associated with poorer outcomes, although most associations did not reach statistical significance due to the limited sample size. Conclusion This audit highlights variable surgical response times in Cat1 trauma, with a trend towards poorer outcomes when specialist review was delayed or limited to a single team. Although most findings did not reach statistical significance, the results suggest potential clinical benefit from earlier and broader surgical involvement. Implementing a structured bleep system for immediate activation of relevant surgical specialities may improve coordination, reduce delays, and ultimately enhance outcomes in Cat1 trauma. CI - Copyright (c) 2025, Gerard et al. FAU - Gerard, Lloyed AU - Gerard L AD - Accident and Emergency, Royal Stoke University Hospital, Stoke, GBR. LA - eng PT - Journal Article DEP - 20251118 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC12713154 OTO - NOTNLM OT - cadiothoracic surgery OT - emergency medicine OT - injury severity score (iss) OT - major trauma OT - neurosurgery OT - orthopaedics and traumatology OT - surgical response COIS- Human subjects: All authors have confirmed that this study did not involve human participants or tissue. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. EDAT- 2025/12/22 12:55 MHDA- 2025/12/22 12:56 PMCR- 2025/11/18 CRDT- 2025/12/22 06:58 PHST- 2025/11/18 00:00 [accepted] PHST- 2025/12/22 12:56 [medline] PHST- 2025/12/22 12:55 [pubmed] PHST- 2025/12/22 06:58 [entrez] PHST- 2025/11/18 00:00 [pmc-release] AID - 10.7759/cureus.97139 [doi] PST - epublish SO - Cureus. 2025 Nov 18;17(11):e97139. doi: 10.7759/cureus.97139. eCollection 2025 Nov. PMID- 41425985 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251222 LR - 20251224 IS - 2297-055X (Print) IS - 2297-055X (Electronic) IS - 2297-055X (Linking) VI - 12 DP - 2025 TI - An overview on cardiac involvement in Inborn Errors of Metabolism: from clinical clues to nutritional management strategies. PG - 1648010 LID - 10.3389/fcvm.2025.1648010 [doi] LID - 1648010 AB - Inborn Errors of Metabolism (IEMs) account for a significant proportion of cardiomyopathies presenting with a wide spectrum of cardiac involvement, from isolated manifestations to multisystem syndromes. The manuscript explores the primary forms of cardiac complications linked to various IEMs, underlining the pathophysiological mechanisms and proposing a diagnostic framework guided by specific clinical features. Early diagnosis, especially in forms not captured by newborn screening, relies on careful clinical and metabolic evaluation. Thus, a multidisciplinary approach to address IEMs is essential, with the paediatric cardiologist contributing to both differential diagnosis and treatment. In addition, this review examines nutritional strategies for managing patients affected by IEMs with cardiac involvement, providing clinicians with research-backed guidance to support cardiological care, since specific nutritional strategies have shown promise in reversing or improving cardiac function in specific IEMs. Further research is needed to clarify the long-term safety of dietary interventions, particularly in pediatric populations, and to better define the role of nutrition in managing cardiomyopathies associated with IEMs, in order to develop evidence-based clinical protocols. CI - (c) 2025 Montanari, Tagi, Tosi, Stucchi, Pisano, Raso, Fini, Fiori, Mannarino, Zuccotti and Verduci. FAU - Montanari, Chiara AU - Montanari C AD - Department of Pediatrics, Vittore Buzzi Children's Hospital, Milan, Italy. AD - Department of Biomedical and Clinical Science, University of Milan, Milan, Italy. FAU - Tagi, Veronica Maria AU - Tagi VM AD - Department of Pediatrics, Vittore Buzzi Children's Hospital, Milan, Italy. AD - Department of Biomedical and Clinical Science, University of Milan, Milan, Italy. FAU - Tosi, Martina AU - Tosi M AD - Department of Pediatrics, Vittore Buzzi Children's Hospital, Milan, Italy. AD - Department of Health Sciences, University of Milan, Milan, Italy. FAU - Stucchi, Eliana AU - Stucchi E AD - Department of Pediatrics, Vittore Buzzi Children's Hospital, Milan, Italy. FAU - Pisano, Eleonora Maria AU - Pisano EM AD - Department of Pediatrics, Vittore Buzzi Children's Hospital, Milan, Italy. FAU - Raso, Irene AU - Raso I AD - Pediatric Cardiology Unit, "Vittore Buzzi" Children's Hospital, Milan, Italy. FAU - Fini, Giulia AU - Fini G AD - Pediatric Cardiology Unit, "Vittore Buzzi" Children's Hospital, Milan, Italy. FAU - Fiori, Laura AU - Fiori L AD - Department of Pediatrics, Vittore Buzzi Children's Hospital, Milan, Italy. FAU - Mannarino, Savina AU - Mannarino S AD - Pediatric Cardiology Unit, "Vittore Buzzi" Children's Hospital, Milan, Italy. FAU - Zuccotti, Gianvincenzo AU - Zuccotti G AD - Department of Pediatrics, Vittore Buzzi Children's Hospital, Milan, Italy. AD - Department of Biomedical and Clinical Science, University of Milan, Milan, Italy. FAU - Verduci, Elvira AU - Verduci E AD - Department of Pediatrics, Vittore Buzzi Children's Hospital, Milan, Italy. AD - Department of Health Sciences, University of Milan, Milan, Italy. LA - eng PT - Journal Article PT - Review DEP - 20251204 PL - Switzerland TA - Front Cardiovasc Med JT - Frontiers in cardiovascular medicine JID - 101653388 PMC - PMC12711851 OTO - NOTNLM OT - cardiac OT - dietary treatment OT - differential diagnosis OT - metabolism OT - nutrition COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2025/12/22 18:09 MHDA- 2025/12/22 18:10 PMCR- 2025/12/04 CRDT- 2025/12/22 06:50 PHST- 2025/06/16 00:00 [received] PHST- 2025/11/11 00:00 [revised] PHST- 2025/11/17 00:00 [accepted] PHST- 2025/12/22 18:10 [medline] PHST- 2025/12/22 18:09 [pubmed] PHST- 2025/12/22 06:50 [entrez] PHST- 2025/12/04 00:00 [pmc-release] AID - 10.3389/fcvm.2025.1648010 [doi] PST - epublish SO - Front Cardiovasc Med. 2025 Dec 4;12:1648010. doi: 10.3389/fcvm.2025.1648010. eCollection 2025. PMID- 41417639 OWN - NLM STAT- MEDLINE DCOM- 20251219 LR - 20260925 IS - 1369-7625 (Electronic) IS - 1369-6513 (Print) IS - 1369-6513 (Linking) VI - 28 IP - 6 DP - 2025 Dec TI - Enhancing Post-Discharge Care for People Who Have Had an Acute Myocardial Infarction in Portugal: Insights From Patient Journey Mapping. PG - e70521 LID - 10.1111/hex.70521 [doi] LID - e70521 AB - INTRODUCTION: Cardiovascular disease is the leading cause of death and disability, with the post-discharge period being particularly vulnerable for patients due to communication issues, medication errors, and inadequate follow-up. This study explores the patient experience following acute myocardial infarction in the Portuguese healthcare system, providing insights to improve care quality, outcomes, and satisfaction. METHODS: This study used qualitative patient journey mapping through semi-structured telephone interviews with people who have had an acute myocardial infarction discharged between January and December 2023, to explore their experiences, identify areas for improvement in the Portuguese healthcare system, and develop patient-centred solutions. To complement self-reported data, data were collected from patients' electronic health records. RESULTS: While participants were generally satisfied with the care provided during hospitalisation and discharge, significant gaps were identified, such as no shared decision-making on goal setting, limited medication counselling, insufficient coordination with Primary Health Care (PHC), and delays in hospital follow-up beyond European Society of Cardiology guideline recommendations. Many patients had limited follow-up in PHC, with follow-up appointments often relying on patient initiative, and long waiting times for hospital follow-up care. By combining patient narratives with electronic health records and multidisciplinary validation, the findings underscore the need for a more integrated and patient-centred approach. CONCLUSIONS: Post-acute myocardial infarction care in Portugal shows critical gaps in discharge planning, PHC coordination, and timely follow-up. Strengthening patient-centred strategies, including structured protocols, systematic use of Patient-Reported Outcome and Experience Measures, earlier and nurse-led PHC follow-up, and stronger coordination across care levels, are essential to enhance recovery, reduce readmissions, and improve long-term outcomes. PATIENT OR PUBLIC CONTRIBUTION: Data were analysed by a multidisciplinary team, which included two patient representatives with lived experience of myocardial infarction, to ensure that the findings reflect both clinical perspectives and patient priorities. CI - (c) 2025 The Author(s). Health Expectations published by John Wiley & Sons Ltd. FAU - Homem, Filipa AU - Homem F AUID- ORCID: 0000-0003-1153-1686 AD - Coimbra University, UICISA:E/ESEnfC, ULS Coimbra, Coimbra, Portugal. FAU - Gomes, Andreia AU - Gomes A AD - ULS Coimbra, UICISA:E/ESEnfC, Coimbra, Portugal. FAU - Martins, Helena AU - Martins H AD - ULS Coimbra, UICISA:E/ESEnfC, Coimbra, Portugal. FAU - Caetano, Ana AU - Caetano A AD - ULS Coimbra, UICISA:E/ESEnfC, Coimbra, Portugal. FAU - Alves, Mauricio AU - Alves M AD - ULS Coimbra, UICISA:E/ESEnfC, Coimbra, Portugal. FAU - Rodrigues, Luis AU - Rodrigues L AD - ULS Coimbra, UICISA:E/ESEnfC, Coimbra, Portugal. FAU - Simoes, Mariana AU - Simoes M AUID- ORCID: 0000-0002-4225-1057 AD - ULS Coimbra, UICISA:E/ESEnfC, Coimbra, Portugal. FAU - Martinho, Sofia AU - Martinho S AUID- ORCID: 0000-0003-4834-8076 AD - ULS Coimbra, UICISA:E/ESEnfC, Coimbra, Portugal. FAU - Monteiro, Silvia AU - Monteiro S AD - ULS Coimbra, UICISA:E/ESEnfC, Coimbra, Portugal. FAU - Veiga, Catarina AU - Veiga C AD - ULS Coimbra, UICISA:E/ESEnfC, Coimbra, Portugal. FAU - Correia, Emilia AU - Correia E AD - Portuguese National Health Service Executive Board, UICISA:E/ESEnfC, Coimbra, Portugal. FAU - Lemos, Dario AU - Lemos D AD - UICISA:E/ESEnfC, Coimbra, Portugal. FAU - Coutinho, Veronica AU - Coutinho V AD - UICISA:E/ESEnfC, Coimbra, Portugal. FAU - Amaral, Antonio AU - Amaral A AD - UICISA:E/ESEnfC, Coimbra, Portugal. LA - eng GR - The authors received no specific funding for this work./ PT - Journal Article PL - England TA - Health Expect JT - Health expectations : an international journal of public participation in health care and health policy JID - 9815926 SB - IM MH - Humans MH - Portugal MH - *Myocardial Infarction/therapy MH - *Patient Discharge MH - Male MH - Female MH - Middle Aged MH - Aged MH - Patient Satisfaction MH - Qualitative Research MH - Interviews as Topic MH - *Continuity of Patient Care MH - Patient-Centered Care MH - *Aftercare MH - Adult MH - Primary Health Care PMC - PMC12716438 OTO - NOTNLM OT - health journey OT - myocardial infarction OT - patient experience OT - patient journey mapping COIS- The authors declare no conflicts of interest. EDAT- 2025/12/19 18:32 MHDA- 2025/12/19 18:33 PMCR- 2025/12/19 CRDT- 2025/12/19 12:53 PHST- 2025/10/16 00:00 [revised] PHST- 2025/04/19 00:00 [received] PHST- 2025/11/05 00:00 [accepted] PHST- 2025/12/19 18:33 [medline] PHST- 2025/12/19 18:32 [pubmed] PHST- 2025/12/19 12:53 [entrez] PHST- 2025/12/19 00:00 [pmc-release] AID - HEX70521 [pii] AID - 10.1111/hex.70521 [doi] PST - ppublish SO - Health Expect. 2025 Dec;28(6):e70521. doi: 10.1111/hex.70521. PMID- 41414891 OWN - NLM STAT- Publisher LR - 20251219 IS - 1545-1550 (Electronic) IS - 1526-6028 (Linking) DP - 2025 Dec 19 TI - Development of a Multidisciplinary Decision Support Instrument for Patients With a Ruptured Abdominal Aortic Aneurysm Based on Multidisciplinary Codified Peer Expertise: A Discrete Choice Experiment. PG - 15266028251397338 LID - 10.1177/15266028251397338 [doi] AB - INTRODUCTION: Treatment decisions for ruptured abdominal aortic aneurysms (rAAA) patients are made under extreme time pressure and often with limited patient information and without opportunity for multidisciplinary consultation. This study describes the development of a decision-support instrument (DSI) to predict how experts would decide in real-life emergency scenarios, based on patient characteristics including frailty, estimated life expectancy, and treatment preference. METHODS: The DSI was developed using a discrete choice experiment. A multidisciplinary group of medical specialists, including vascular/oncological surgeons, anesthesiologists, intensivists, and geriatricians, defined the relevant criteria for deciding whether to operate on an rAAA based on patient-specific factors and expert opinion. The group identified relevant levels for each criterion, with an increasing risk for worse outcomes. Criteria that would immediately exclude a patient from treatment were designated as knockout criteria. An expert panel of 21 medical specialists evaluated 30 fictional patient scenarios, which resulted in a weight for each criterion expressed as relative importance (RI); a measure of how much each criterion, compared to the sum of all criteria, contributes to the model's outcome. The finalized DSI predicts the percentage of medical specialists who would choose to operate on a specific patient, based on the input criteria for that patient. RESULTS: In 4 criteria sessions with medical experts, consensus was reached on 11 criteria that were judged to influence the decision whether to operate or not: cardiopulmonary resuscitation, patient's wish for operation, renal function, age, life expectancy, endovascular treatment options, hemoglobin blood concentration, mean arterial pressure, pulmonary burden, cardiac burden, and clinical frailty score. Nine criteria had a significant impact on the decision; the most significant were cardiac burden (RI, 15%), age (RI, 13%), life expectancy (RI, 13%), and Clinical Frailty Scale and pulmonary burden (both RI, 12%). CONCLUSION: A clinical DSI was developed, based on codified multidisciplinary peer expertise, to support real-life medical decision-making during acute treatment planning for rAAA. Three parameters that are underreported in previous scoring systems (patient's frailty, estimated life expectancy, and patient's desire to be operated) were considered most important for treatment decision.Clinical ImpactTreatment decisions for ruptured abdominal aortic aneurysm patients are time-critical and morally complex, often made with limited clinical information and without multidisciplinary consultation. This study describes the development of a transparent decision-support instrument (DSI) based on multidisciplinary peer expertise. By reflecting decision logic and criteria considered important by experts, the DSI may contribute to more consistent decision-making and help identify patients for whom palliative care might be more appropriate. Further validation is required to determine its clinical utility, although this approach may support clinicians in urgent, morally complex scenarios. FAU - Hijkoop, Lotte F AU - Hijkoop LF AUID- ORCID: 0000-0002-1519-6785 AD - Division of Vascular Surgery, Department of Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. FAU - Dijkstra, Martijn L AU - Dijkstra ML AD - Division of Vascular Surgery, Department of Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. FAU - van Leeuwen, Barbara L AU - van Leeuwen BL AD - Division of Surgical Oncology, Department of Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. FAU - Khadjeh, Sohrab AU - Khadjeh S AD - Division of Vascular Surgery, Department of Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. FAU - van Veldhuizen, Willemina A AU - van Veldhuizen WA AUID- ORCID: 0000-0002-7295-9005 AD - Division of Vascular Surgery, Department of Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. FAU - Reyntjens, Koen M E M AU - Reyntjens KMEM AUID- ORCID: 0000-0001-5375-8235 AD - Department of Anesthesiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. FAU - Fernhout, Meine H AU - Fernhout MH AD - Department of Anesthesiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. FAU - Schuurman, Simone N AU - Schuurman SN AD - Division of Vascular Surgery, Department of Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. FAU - Smit, Marije AU - Smit M AD - Department of Critical Care, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. FAU - van Munster, Barbara C AU - van Munster BC AD - Division of Geriatric Medicine, Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. FAU - Schuurmann, Richte C L AU - Schuurmann RCL AD - Division of Vascular Surgery, Department of Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. FAU - de Vries, Jean-Paul P M AU - de Vries JPM AD - Division of Vascular Surgery, Department of Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. CN - MDSI rAAA Expert Group LA - eng PT - Journal Article DEP - 20251219 PL - United States TA - J Endovasc Ther JT - Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists JID - 100896915 SB - IM OTO - NOTNLM OT - acute abdominal aneurysm OT - decision-support instrument OT - frailty OT - functional outcomes OT - peer expertise OT - ruptured abdominal aortic aneurysm EDAT- 2025/12/19 06:30 MHDA- 2025/12/19 06:30 CRDT- 2025/12/19 03:43 PHST- 2025/12/19 06:30 [medline] PHST- 2025/12/19 06:30 [pubmed] PHST- 2025/12/19 03:43 [entrez] AID - 10.1177/15266028251397338 [doi] PST - aheadofprint SO - J Endovasc Ther. 2025 Dec 19:15266028251397338. doi: 10.1177/15266028251397338. PMID- 41412895 OWN - NLM STAT- MEDLINE DCOM- 20260509 LR - 20260509 IS - 1875-2128 (Electronic) IS - 1875-2128 (Linking) VI - 119 IP - 5 DP - 2026 May TI - Contemporary management of patients with native mitral regurgitation in heart valve centres. PG - 333-340 LID - S1875-2136(25)00829-0 [pii] LID - 10.1016/j.acvd.2025.10.332 [doi] AB - BACKGROUND: Despite a key role in the latest guidelines, the screening process of patients with mitral regurgitation (MR) referred to Heart Valve Centres (HVCs) remains unexplored. AIMS: To investigate characteristics, management and outcomes of patients with native MR referred to HVCs. METHODS: Between January 2017 and May 2021, all patients with MR referred to seven French HVCs for medico-surgical evaluation were included. Individual management was left to the local interdisciplinary HVC. Patients eligible to mitral valve (MV) intervention were compared with those deemed ineligible and left on medical therapy. The primary endpoint was 2-year all-cause mortality. RESULTS: After exclusion for treatment refusal or non-MV surgery, a total of 823 patients were analysed: 662 eligible versus 161 ineligible to MV intervention. Among the 662 eligible patients, 382 (57.7%) underwent transcatheter edge-to-edge repair, 215 (32.5%) MV surgery, 40 (6.0%) transcatheter MV replacement and 25 (3.8%) were either on the waiting list at the end of follow-up (n=12) or had died before intervention (n=13). Ineligible patients had higher surgical risk scores (median EuroSCORE II 4.2% vs. 3.3%; P=0.003; median Society of Thoracic Surgeons mortality risk score 4.3% vs. 3.5%; P=0.023) and more advanced left ventricular (LV) impairment (mean LV ejection fraction 49.7% vs. 56.6%; P<0.001). At 2years, all-cause mortality was significantly higher in ineligible versus eligible patients (36.3% vs. 18.0%; P<0.0001). After multivariable adjustment, HVC-defined eligibility for MV intervention was associated with lower 2-year mortality (hazard ratio: 0.54, 95% confidence interval: 0.35-0.84; P=0.006). CONCLUSION: HVC interdisciplinary evaluation of severe native MR results in MV intervention in most cases. Eligibility for MV intervention was associated with lower risk of 2-year mortality. CI - Copyright (c) 2025 The Author(s). Published by Elsevier Masson SAS.. All rights reserved. FAU - Coisne, Augustin AU - Coisne A AD - Universite de Lille, Inserm, CHU de Lille, Institut Pasteur de Lille, U1011-EGID, 59000 Lille, France; Cardiovascular Research Foundation, New York, NY 10019, USA; Montefiore-Einstein Center for Heart and Vascular Care, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10467, USA. Electronic address: augustin.coisne@chu-lille.fr. FAU - Scotti, Andrea AU - Scotti A AD - Cardiovascular Research Foundation, New York, NY 10019, USA; Montefiore-Einstein Center for Heart and Vascular Care, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10467, USA. FAU - Bohbot, Yohann AU - Bohbot Y AD - Department of Cardiology, Amiens University Hospital, 80054 Amiens, France; UR UPJV 7517, Jules-Verne University of Picardie, 80054 Amiens, France. FAU - Dreyfus, Julien AU - Dreyfus J AD - Cardiology Department, Centre Cardiologique du Nord, 93200 Saint-Denis, France. FAU - Bernard, Anne AU - Bernard A AD - Service de Cardiologie, CHRU de Tours, 37000 Tours, France; EA4245, Loire Valley Cardiovascular Collaboration, Universite de Tours, 37000 Tours, France. FAU - Lavie Badie, Yoan AU - Lavie Badie Y AD - Heart Valve Center, Toulouse University Hospital, 31400 Toulouse, France. FAU - Rousse, Natacha AU - Rousse N AD - Universite de Lille, Inserm, CHU de Lille, Institut Pasteur de Lille, U1011-EGID, 59000 Lille, France. FAU - Sudre, Arnaud AU - Sudre A AD - Universite de Lille, Inserm, CHU de Lille, Institut Pasteur de Lille, U1011-EGID, 59000 Lille, France. FAU - Tribouilloy, Christophe AU - Tribouilloy C AD - Department of Cardiology, Amiens University Hospital, 80054 Amiens, France; UR UPJV 7517, Jules-Verne University of Picardie, 80054 Amiens, France. FAU - Peltier, Marcel AU - Peltier M AD - Department of Cardiology, Amiens University Hospital, 80054 Amiens, France; UR UPJV 7517, Jules-Verne University of Picardie, 80054 Amiens, France. FAU - Ludwig, Sebastian AU - Ludwig S AD - Cardiovascular Research Foundation, New York, NY 10019, USA; Department of Cardiology, University Heart and Vascular Center Hamburg, 52 20246 Hamburg, Germany. FAU - Marcheix, Bertrand AU - Marcheix B AD - Heart Valve Center, Toulouse University Hospital, 31400 Toulouse, France. FAU - Eyharts, Damien AU - Eyharts D AD - Heart Valve Center, Toulouse University Hospital, 31400 Toulouse, France. FAU - Steinecker, Matthieu AU - Steinecker M AD - Cardiology Department, Centre Cardiologique du Nord, 93200 Saint-Denis, France. FAU - Nejjari, Mohammed AU - Nejjari M AD - Cardiology Department, Centre Cardiologique du Nord, 93200 Saint-Denis, France. FAU - Luciani, Marie AU - Luciani M AD - Service de Cardiologie, CHRU de Tours, 37000 Tours, France. FAU - Saint Etienne, Christophe AU - Saint Etienne C AD - Service de Cardiologie, CHRU de Tours, 37000 Tours, France. FAU - Ternacle, Julien AU - Ternacle J AD - UMCV, Hopital Cardiologique Haut-Leveque, CHU de Bordeaux, 33600 Pessac, France; Quebec Heart and Lung Institute, Quebec G1V 4G5, Canada. FAU - Bonnet, Guillaume AU - Bonnet G AD - Cardiovascular Research Foundation, New York, NY 10019, USA; UMCV, Hopital Cardiologique Haut-Leveque, CHU de Bordeaux, 33600 Pessac, France. FAU - L'Official, Guillaume AU - L'Official G AD - Cardiologie, CHU de Rennes, LTSI, Inserm 1099, 35000 Rennes, France. FAU - Galli, Elena AU - Galli E AD - Cardiologie, CHU de Rennes, LTSI, Inserm 1099, 35000 Rennes, France. FAU - Lancellotti, Patrizio AU - Lancellotti P AD - University of Liege Hospital, GIGA Cardiovascular Sciences, Departments of Cardiology, Heart Valve Clinic, CHU Sart Tilman, 4000 Liege, Belgium; Gruppo Villa Maria Care and Research, Maria Cecilia Hospital, Cotignola, and Anthea Hospital, 48033 Bari, Italy. FAU - Granada, Juan AU - Granada J AD - Cardiovascular Research Foundation, New York, NY 10019, USA. FAU - Donal, Erwan AU - Donal E AD - Cardiologie, CHU de Rennes, LTSI, Inserm 1099, 35000 Rennes, France. FAU - Modine, Thomas AU - Modine T AD - UMCV, Hopital Cardiologique Haut-Leveque, CHU de Bordeaux, 33600 Pessac, France. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20251204 PL - Netherlands TA - Arch Cardiovasc Dis JT - Archives of cardiovascular diseases JID - 101465655 SB - IM MH - Humans MH - *Mitral Valve Insufficiency/mortality/physiopathology/diagnostic imaging/therapy/surgery MH - Female MH - Male MH - Aged MH - Time Factors MH - Treatment Outcome MH - *Mitral Valve/physiopathology/diagnostic imaging/surgery MH - France MH - Risk Factors MH - *Heart Valve Prosthesis Implantation/adverse effects/mortality MH - Middle Aged MH - Aged, 80 and over MH - Retrospective Studies MH - Risk Assessment MH - *Referral and Consultation MH - *Cardiac Catheterization/adverse effects/mortality MH - Clinical Decision-Making MH - Patient Selection MH - Waiting Lists/mortality OTO - NOTNLM OT - Heart team OT - Heart valve centre OT - Mitral regurgitation OT - Transcatheter edge-to-edge repair OT - Transcatheter mitral valve replacement COIS- Disclosure of interest A.C. has served as a consultant for Abbott Vascular and received speaker fees from Abbott Vascular and GE Healthcare. A.C. is also supported by grants from Federation Francaise de Cardiologie, Institut Servier, Fondation Monahan and Fulbright. A.Sc. has served as a consultant and received consulting fees from NeoChord Inc. Y.L.B. has served as consultant for Abbott Vascular and GE Healthcare. S.L. received advisory fees from Bayer and travel compensation from Edwards LifeSciences. J.T. is a consultant for Abbott Medical. A.B. has served as a consultant and proctor for Abbott and received speaker fees from Abbott Medical and GE Healthcare. The remaining authors declare that they have no competing interest. EDAT- 2025/12/19 01:45 MHDA- 2026/05/10 05:19 CRDT- 2025/12/18 22:40 PHST- 2025/04/09 00:00 [received] PHST- 2025/10/15 00:00 [revised] PHST- 2025/10/20 00:00 [accepted] PHST- 2026/05/10 05:19 [medline] PHST- 2025/12/19 01:45 [pubmed] PHST- 2025/12/18 22:40 [entrez] AID - S1875-2136(25)00829-0 [pii] AID - 10.1016/j.acvd.2025.10.332 [doi] PST - ppublish SO - Arch Cardiovasc Dis. 2026 May;119(5):333-340. doi: 10.1016/j.acvd.2025.10.332. Epub 2025 Dec 4. PMID- 41412894 OWN - NLM STAT- MEDLINE DCOM- 20260820 LR - 20260903 IS - 1878-0938 (Electronic) IS - 1878-0938 (Linking) VI - 89 DP - 2026 Aug TI - Combined strategy of transcatheter edge-to-edge repair of mitral valve and percutaneous mechanical circulatory support device to treat high-risk patients with severe mitral regurgitation and cardiogenic shock. PG - 76-84 LID - S1553-8389(25)00613-X [pii] LID - 10.1016/j.carrev.2025.12.008 [doi] AB - BACKGROUND: Acute mitral regurgitation (MR) associated with cardiogenic shock (CS) is a medical emergency with excessive in-hospital mortality. The vast majority of these patients are turned down for corrective surgery. The combined strategy of transcatheter edge-to-edge repair of mitral valves and percutaneous mechanical circulatory support devices to treat high-risk patients with severe mitral regurgitation and cardiogenic shock has not been evaluated in randomized controlled trials. AIMS: In this multicenter registry we aimed to assess the outcomes (all-cause mortality, other important secondary outcomes included freedom from 30-day cardiac death or cardiac readmission, 30-day all-cause mortality, 30-day cardiovascular mortality, and 30-day MACE events) of the combined strategy of Transcatheter Edge-to-Edge Repair of Mitral Valve and Percutaneous Mechanical Circulatory Support Device to Treat High-Risk Patients with Severe Mitral Regurgitation and Cardiogenic Shock. METHODS: This multicenter registry retrospectively evaluated all consecutive patients who presented with severe MR, had persistent cardiogenic shock (CS) despite appropriate therapy (including mechanical circulatory support [MCS]), were turned down for surgery due to operative risk from acuity at presentation, and were considered for TEER by a heart team. RESULTS: Twenty-one consecutive patients with severe acute or acute-on-chronic MR (anatomy suitable for M-TEER) and CS who were undergoing TEER after surgical turndown were included. Mean age was 63 years (SD +/- 12.4), 71 % males, mean Society of Thoracic Surgeons Score predicted risk of mortality (STS-PROM) was 20.1 +/- 19.2 % (range: 3.1 to 82), 71 % required mechanical ventilation, 52 % had pulmonary edema, 48 % had index acute myocardial infarction (AMI), 19 % required dialysis, 100 % had Impella in place. Immediate procedural outcomes included 100 % technical success, MR grade 1.2+ (mild, p < 0.001), and no events for device-device interaction were observed. The primary outcome of in-hospital all-cause mortality was 4.7 % (1 death from multiorgan failure). All-cause mortality at 30 days was 14 %, and three patients died. The procedural success rate was 81 %, with one readmission for DVT that was treated with oral anticoagulation, and none of the patients required mitral valve reintervention at 30-day follow up. Echocardiography at 30 days revealed an MR grade of 10 mm, hypertension, atrial fibrillation, and cerebral microbleeds. Advanced neuroimaging techniques (MRI, CTA, and MRA) aid in the early detection of ischemic and hemorrhagic events, while updated Duke-ISCVID (International Society of Cardiovascular Infectious Diseases) criteria improve diagnostic accuracy. Antimicrobial therapy reduces embolic risk, but the role of anticoagulants and antiplatelet agents remains controversial. Intravenous thrombolysis is contraindicated due to high hemorrhagic risk, whereas mechanical thrombectomy appears safe and effective only in carefully selected patients. The timing of cardiac surgery requires multidisciplinary decision-making: early surgery may prevent embolism but is associated with increased perioperative neurological complications, particularly in hemorrhagic stroke. Mycotic aneurysms, though uncommon, call for early diagnosis and tailored endovascular or surgical management. IE-related stroke poses complex diagnostic and therapeutic challenges that require multidisciplinary care involving the integration of cardiology, neurology, infectious disease, and surgical expertise. Advances in imaging, early antimicrobial therapy, optimized surgical timing, and cautious use of reperfusion techniques are reshaping management. Ongoing research is needed to refine risk stratification and optimize individualized care. CI - Copyright (c) 2025, Hayat et al. FAU - Hayat, Sikandar AU - Hayat S AD - General Surgery, Services Hospital Lahore, Lahore, PAK. AD - General Surgery, Chaudhary Muhammad Akram Teaching and Research Hospital, Lahore, PAK. FAU - Faisal, Affan AU - Faisal A AD - Medicine and Surgery, Mayo Hospital, Lahore, PAK. FAU - Ans, Hasaan AU - Ans H AD - Internal Medicine, Fatima Memorial Hospital (FMH) College of Medicine and Dentistry, Lahore, PAK. FAU - Rana, Ali Raza AU - Rana AR AD - Neurology, Mayo Hospital, Lahore, PAK. FAU - Ali, Mustehsan AU - Ali M AD - Medicine and Surgery, Faisalabad Medical University, Faisalabad, PAK. LA - eng PT - Journal Article PT - Review DEP - 20251114 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC12702090 OTO - NOTNLM OT - antimicrobial therapy OT - cerebral embolism OT - echocardiography OT - infective endocarditis OT - mechanical thrombectomy OT - mycotic aneurysm OT - staphylococcus aureus OT - stroke COIS- Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. EDAT- 2025/12/16 06:28 MHDA- 2025/12/16 06:29 PMCR- 2025/11/14 CRDT- 2025/12/16 04:06 PHST- 2025/11/14 00:00 [accepted] PHST- 2025/12/16 06:29 [medline] PHST- 2025/12/16 06:28 [pubmed] PHST- 2025/12/16 04:06 [entrez] PHST- 2025/11/14 00:00 [pmc-release] AID - 10.7759/cureus.96817 [doi] PST - epublish SO - Cureus. 2025 Nov 14;17(11):e96817. doi: 10.7759/cureus.96817. eCollection 2025 Nov. PMID- 41392290 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260626 LR - 20260626 IS - 2055-0464 (Print) IS - 2055-0464 (Electronic) IS - 2055-0464 (Linking) VI - 12 IP - 1 DP - 2025 Dec 15 TI - The implementation of a Cardiac Scientist Led Heart Failure diagnosis clinic for non-urgent suspected heart failure referrals. PG - 34 LID - 10.1186/s44156-025-00098-9 [doi] LID - 34 AB - BACKGROUND: NICE guidelines suggest that patients with suspected heart failure (HF) and an NT-proBNP between 400-2,000ng/l have specialist assessment and transthoracic echocardiography within 6 weeks. Typically, pathways require significant coordination of a multidisciplinary team, with upfront input from senior clinicians. In line with NHS workforce plans to develop non-medical roles, a Cardiac scientist led Heart Failure assessment clinic for non-urgent suspected HF referrals was trialled. A British Society of Echocardiography accredited physiologist with health assessment and clinical examination qualifications performed a transthoracic echocardiogram, 12 lead electrocardiogram and clinical assessment within one appointment slot. Preliminary outcome recommendations made by the physiologist were reviewed at a later point by a supervising HF consultant. The pilot aimed to ensure timely clinical assessment at the point of echocardiography and reduce delays in patient diagnosis. In a retrospective service evaluation, the clinic decision and time from scan to outcome correspondence was compared between the cardiac clinical scientist led pathway (n = 100) and the medical led pathway (n = 100). RESULTS: Both patient groups were found to have similar outcomes. In the clinical scientist led pathway 65% were discharged, 6% were found to have HF with reduced ejection fraction (HFrEF), 20% were found to have HF with preserved ejection fraction (HFpEF), 7% were referred into general cardiology, 1% were referred to the cardio-thoracic surgical team and 1% were admitted. In the medical led pathway, 61%, were discharged, 7% were found to have HFrEF, 23% were found to have HFpEF, 6% were referred into a general cardiology, 3% were referred to the cardio-thoracic surgical team and 0% were admitted. A significant reduction (30.1 days vs. 10.6 days) in time was observed from echocardiogram to outcome correspondence for patient. (p < 0.01). CONCLUSION: The scientist led pathway demonstrated improved time from diagnostic testing to outcome correspondence, ensuring timely enrolment on the relevant treatment pathway. Findings suggest that the pathway is feasible and effective, highlighting the need to utilise expertise of clinical scientists in the HF paradigm. Future work should explore long-term feasibility and sustainability of these clinics, further expansion and the feasibility of this service in a district general hospital or community diagnostic centres. FAU - Cook, Jonathan AU - Cook J AD - Royal Wolverhampton NHS Foundation Trust, New Cross Hospital, Wolverhampton Road, Wolverhampton, West Midlands, WV10 0QP, UK. jonathan.cook2@nhs.net. FAU - Jiang, Jin AU - Jiang J AD - Royal Wolverhampton NHS Foundation Trust, New Cross Hospital, Wolverhampton Road, Wolverhampton, West Midlands, WV10 0QP, UK. FAU - Khan-Kheil, Ayisha AU - Khan-Kheil A AD - Royal Wolverhampton NHS Foundation Trust, New Cross Hospital, Wolverhampton Road, Wolverhampton, West Midlands, WV10 0QP, UK. FAU - Ingram, Thomas E AU - Ingram TE AD - Royal Wolverhampton NHS Foundation Trust, New Cross Hospital, Wolverhampton Road, Wolverhampton, West Midlands, WV10 0QP, UK. LA - eng PT - Journal Article DEP - 20251215 PL - England TA - Echo Res Pract JT - Echo research and practice JID - 101664713 PMC - PMC12703911 OTO - NOTNLM OT - Echocardiography OT - Heart failure OT - Scientist led COIS- Declarations. Ethics approval and consent to participate: This project is exempt from requiring ethics approval as this study was registered as a service evaluation. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2025/12/15 00:28 MHDA- 2025/12/15 00:29 PMCR- 2025/12/15 CRDT- 2025/12/14 23:30 PHST- 2025/09/04 00:00 [received] PHST- 2025/10/17 00:00 [accepted] PHST- 2025/12/15 00:29 [medline] PHST- 2025/12/15 00:28 [pubmed] PHST- 2025/12/14 23:30 [entrez] PHST- 2025/12/15 00:00 [pmc-release] AID - 10.1186/s44156-025-00098-9 [pii] AID - 98 [pii] AID - 10.1186/s44156-025-00098-9 [doi] PST - epublish SO - Echo Res Pract. 2025 Dec 15;12(1):34. doi: 10.1186/s44156-025-00098-9. PMID- 41391909 OWN - NLM STAT- MEDLINE DCOM- 20251214 LR - 20251214 IS - 1769-664X (Electronic) IS - 0929-693X (Linking) VI - 32 IP - 7S1 DP - 2025 Dec TI - Orthopedic management in Duchenne muscular dystrophy. PG - 7S32-7S38 LID - S0929-693X(25)00251-9 [pii] LID - 10.1016/S0929-693X(25)00251-9 [doi] AB - This article provides a comprehensive overview of the orthopedic management strategies in Duchenne muscular dystrophy (DMD). DMD manifests with severe muscle wasting, respiratory insufficiency, and cardiomyopathy, with initial symptoms emerging in early childhood. By the age of 10-12 years, most patients require wheelchairs due to muscle degeneration, which often leads to spinal deformities and joint contractures. The absence of dystrophin causes the breakdown of the dystrophin glycoprotein complex, causingmuscle degeneration, necrosis, and fibrosis. Current treatments focus on symptom management, including physical therapy, corticosteroids, orthopedic surgery, ventilatory and nutritional support, and cardiac care. Long-term glucocorticoid therapy can extend mobility and life expectancy, delay the need for ventilation, and reduce the rates of scoliosis surgery. Orthopedic care focuses on prevention to preserve motor function and bone health and involves an interdisciplinary team, early use of orthotic devices, and promotion of proper posture. Common deformities include varus equinus, hip flexor retractions, scoliosis, and pelvic obliquity. Scoliosis management involves posterior fusion surgery extended to the pelvis or limited to the L5 vertebra. Preoperative evaluation should include assessing the risk of hip flexion contracture decompensation following arthrodesis. There now seems to be increasing consensus favoring lower extremity surgery only in exceptional cases. This shift is due to the limited success of surgery, with frequent recurrence of muscle retractions and minimal expected benefits. Fracture management involves bisphosphonate therapy post-fracture, with vertebral compression and lower limb fracture being the most prevalent. CI - Copyright (c) 2025 French Society of Pediatrics. Published by Elsevier Masson SAS. All rights reserved. Published by Elsevier Masson SAS. All rights reserved. FAU - Gaume, Mathilde AU - Gaume M AD - University Institute for Spine Surgery, Armand Trousseau Hospital, Sorbonne University, 75012 Paris, France. FAU - Cunin, Vincent AU - Cunin V AD - Service d'Orthopedie Pediatrique, Hopital Femme-Mere-Enfant, Hospices Civils de Lyon, 69500 Bron, France. FAU - Vuillerot, Carole AU - Vuillerot C AD - L'Escale, Service de Medecine Physique et de Readaptation Pediatrique, Hopital Femme-Mere-Enfant, Hospices Civils de Lyon, 69500 Bron, France; NeuroMyogen Institute, CNRS UMR 5310 - INSERM U1217, University of Lyon, 69008 Lyon, France. Electronic address: carole.vuillerot@chu-lyon.fr. LA - eng PT - Journal Article PT - Review PL - France TA - Arch Pediatr JT - Archives de pediatrie : organe officiel de la Societe francaise de pediatrie JID - 9421356 SB - IM MH - Humans MH - *Muscular Dystrophy, Duchenne/therapy/complications MH - Child MH - Scoliosis/etiology/therapy MH - *Orthopedic Procedures/methods OTO - NOTNLM OT - Orthopedic management OT - Orthosis OT - Physical medicine and rehabilitation OT - Spinal fusion COIS- Declaration of competing interest The authors declare no competing interest related to this article. This article is part of a supplement entitled Duchenne muscular dystrophy published with institutional support from Pfizer. EDAT- 2025/12/15 00:28 MHDA- 2025/12/15 00:29 CRDT- 2025/12/14 20:53 PHST- 2025/12/15 00:29 [medline] PHST- 2025/12/15 00:28 [pubmed] PHST- 2025/12/14 20:53 [entrez] AID - S0929-693X(25)00251-9 [pii] AID - 10.1016/S0929-693X(25)00251-9 [doi] PST - ppublish SO - Arch Pediatr. 2025 Dec;32(7S1):7S32-7S38. doi: 10.1016/S0929-693X(25)00251-9. PMID- 41391905 OWN - NLM STAT- MEDLINE DCOM- 20251214 LR - 20260102 IS - 1769-664X (Electronic) IS - 0929-693X (Linking) VI - 32 IP - 7S1 DP - 2025 Dec TI - Multidisciplinary management of Duchenne muscular dystrophy from childhood to adulthood. PG - 7S15-7S19 LID - S0929-693X(25)00248-9 [pii] LID - 10.1016/S0929-693X(25)00248-9 [doi] AB - Duchenne muscular dystrophy (DMD) is a severe, progressive neuromuscular disorder characterized by muscle degeneration and weakness, leading to significant physical disability and multisystem complications. The management of DMD requires a coordinated, multidisciplinary approach to address the evolving needs of patients from childhood through adulthood, with a focus on patient quality of life. Early diagnosis and proactive interventions are critical to optimizing outcomes and may include physical therapy, respiratory support, cardiac monitoring, and orthopedic care. In children, the focus is on preserving mobility, managing scoliosis, preventing cardiac and respiratory complications, and ensuring access to education and psychosocial support. As patients transition to adulthood, the challenges shift to maintaining independence, managing advanced respiratory and cardiac complications, and addressing vocational and social integration. Transition programs must be carefully planned to bridge pediatric and adult care systems, ensuring continuity and minimizing gaps in care. Adult care involves specialized teams to manage complex medical needs, including advanced respiratory support, cardiomyopathy, and palliative care. Anticipatory directives play a crucial role in aligningmedical interventions with patient and family preferences, particularly in advanced stages of the disease. This article outlines the principles of multidisciplinary care for DMD, emphasizing the importance of tailored interventions at each life stage, the challenges of transition, and the ethical considerations of anticipatory planning. By integrating medical, psychosocial, and rehabilitative strategies, healthcare providers can improve the quality of life and longevity of individuals with DMD. CI - Copyright (c) 2025 French Society of Pediatrics. Published by Elsevier Masson SAS. All rights reserved. Published by Elsevier Masson SAS. All rights reserved. FAU - Ropars, Juliette AU - Ropars J AD - Department of Pediatrics, CHU Brest, 29200 Brest, France; Neuromuscular center, 29200 Brest, France; Laboratoire du Traitement de l'Information Medicale, LaTIM INSERM UMR1101, 29200 Brest, France. Electronic address: ju.ropars@gmail.com. FAU - Salort-Campana, Emmanuelle AU - Salort-Campana E AD - Neuromuscular Reference Center of PACARARE, Marseille, 13005 France; Department of ALS and Neuromuscular Disorders, Pr Attarian, APHM, 13005 Marseille, France; Filnemus, APHM, 13005 Marseille, France. LA - eng PT - Journal Article PT - Review PL - France TA - Arch Pediatr JT - Archives de pediatrie : organe officiel de la Societe francaise de pediatrie JID - 9421356 SB - IM MH - Humans MH - *Muscular Dystrophy, Duchenne/therapy/diagnosis MH - Child MH - *Patient Care Team MH - *Transition to Adult Care MH - Adult MH - Adolescent MH - Quality of Life MH - Young Adult OTO - NOTNLM OT - Duchenne muscular dystrophy OT - Multidisciplinary management OT - Transition COIS- Declaration of competing interest J. Ropars declares competing interest for her involvement in clinical trials (as principal investigator, coordinator, or principal experimenter) for Biogen; for occasional advisory consultancy for Biogen, Roche, Novartis and Pfizer; for the occasional production of expert's reports for Biogen and Novartis; for invitations to congresses as a speaker by Biogen, Roche and Novartisa d Pfizer; for invitations to congresses as a participant (expenses paid) by Novartis, PTC and Genzyme. E. Salort-Campana declares competing interest for occasional advisory consultancy for Biogen, Roche, Argenx, UCB, Sanofi, Alexion; for invitations to congresses as a speaker by Biogen, Roche, Argenx, UCB, Sanofi, Amgen, Johson and Johnson. This article is part of a supplement entitled Duchenne muscular dystrophy published with institutional support from Pfizer. EDAT- 2025/12/15 00:28 MHDA- 2025/12/15 00:29 CRDT- 2025/12/14 20:53 PHST- 2025/12/15 00:29 [medline] PHST- 2025/12/15 00:28 [pubmed] PHST- 2025/12/14 20:53 [entrez] AID - S0929-693X(25)00248-9 [pii] AID - 10.1016/S0929-693X(25)00248-9 [doi] PST - ppublish SO - Arch Pediatr. 2025 Dec;32(7S1):7S15-7S19. doi: 10.1016/S0929-693X(25)00248-9. PMID- 41390092 OWN - NLM STAT- MEDLINE DCOM- 20260312 LR - 20260312 IS - 1916-7075 (Electronic) IS - 0828-282X (Linking) VI - 42 IP - 3 DP - 2026 Mar TI - Assessing Risk of Bloodstream Infections in Patients With Cardiovascular Devices: From Endocarditis to Cardiovascular Infections Team. PG - 528-542 LID - S0828-282X(25)01571-5 [pii] LID - 10.1016/j.cjca.2025.12.011 [doi] AB - Infective endocarditis (IE) was historically the predominant cardiovascular infection, but its relative burden has declined. In contrast, infections related to prosthetic valves (PVE), transcatheter aortic valve implantation (TAVI), aortic vascular grafts and endografts (VGEs), cardiac implantable electronic devices (CIED), and ventricular assist devices (VADs) are increasing. This trend reflects an ageing population with complex devices, multiple comorbidities, and greater frailty, all of which contribute to higher susceptibility to device infection and bacteremia from other sources. In cardiovascular device carriers, bacteremia must be assessed for potential device infection. Key indicators include correlation within isolated microorganism and type of device, interval between device implantation and bacteremia, periprocedural complications in early infections, persistence of bacteremia, metastatic infection, absence of alternative focus, and time-to-positivity of blood cultures as a marker of bacterial load. Patient comorbidities, procedural complexity, and device-related factors further define risk. Risk scores validated for Gram-positive bacteremia assist in stratification and guide echocardiography, although none is specific for device carriers. Echocardiography remains central but has limited sensitivity in VGE, CIED, and VAD infections. Diagnostic accuracy increases substantially when combining echocardiography, positron emission tomography/computed tomography (PET/CT), and multidetector CT angiography; in PVE, sensitivity improves from 75% to 83% to nearly 100%; in CIED, increase from 34% to 56%; and in VAD, pooled sensitivity and specificity are 95% and 91%. In daily practice, bacteremia in a device carrier should always trigger systematic risk assessment, multimodal imaging, and multidisciplinary discussion within a Cardiovascular Infection Team, expanding the traditional Endocarditis Team to address the rising burden of cardiovascular device-related bloodstream infections. CI - Copyright (c) 2025 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved. FAU - Hernandez-Meneses, Begona AU - Hernandez-Meneses B AD - Cardiology Department, Hospital Universitario Virgen Macarena, Seville, Spain. FAU - Sandoval, Elena AU - Sandoval E AD - Cardiovascular Surgery Department Hospital Clinic-FCRB IDIBAPS, University of Barcelona, Barcelona, Spain. FAU - Pena, Amelia AU - Pena A AD - Cardiology Department, Hospital Universitario Virgen Macarena, Seville, Spain. FAU - Gil-Sala, Daniel AU - Gil-Sala D AD - Vascular Surgery Department Hospital Clinic-FCRB IDIBAPS, University of Barcelona, Barcelona, Spain. FAU - Barquero, Miguel AU - Barquero M AD - Cardiovascular Surgery Department, Hospital Universitario Virgen Macarena, Seville, Spain. FAU - Yugueros, Xavier AU - Yugueros X AD - Vascular Surgery Department Hospital Clinic-FCRB IDIBAPS, University of Barcelona, Barcelona, Spain. FAU - Lopez-Cortes, Luis E AU - Lopez-Cortes LE AD - Unidad Clinica de Enfermedades Infecciosas y Microbiologia, Hospital Universitario Virgen Macarena, Departamento de Medicina, Universidad de Sevilla, Instituto de Biomedicina de Sevilla (IBiS)/CSIC, Seville, Spain, CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain. FAU - Farrero, Marta AU - Farrero M AD - Heart Failure Unit, Cardiology Department, Hospital Clinic-FCRB IDIBAPS, University of Barcelona, Barcelona, Spain. FAU - Hernandez-Meneses, Marta AU - Hernandez-Meneses M AD - Infectious Diseases Department, Hospital Clinic; FCRB-IDIBAPS, University of Barcelona, Barcelona, Spain; Instituto de Salud Carlos III, Madrid, Spain. Electronic address: mhmeneses@clinic.cat. LA - eng PT - Journal Article PT - Review DEP - 20251211 PL - England TA - Can J Cardiol JT - The Canadian journal of cardiology JID - 8510280 SB - IM MH - Humans MH - *Prosthesis-Related Infections/epidemiology/diagnosis/etiology/microbiology MH - *Bacteremia/etiology/epidemiology/diagnosis MH - Risk Assessment/methods MH - *Heart-Assist Devices/adverse effects MH - *Endocarditis/etiology/epidemiology MH - *Endocarditis, Bacterial/etiology/epidemiology/diagnosis MH - Defibrillators, Implantable/adverse effects MH - Risk Factors MH - Echocardiography MH - *Heart Valve Prosthesis/adverse effects OTO - NOTNLM OT - bloodstream infection OT - cardiac implantable electronic device OT - cardiovascular device infections OT - prosthesis infective endocarditis OT - ventricular assist device EDAT- 2025/12/14 00:39 MHDA- 2026/03/13 00:50 CRDT- 2025/12/13 19:42 PHST- 2025/09/03 00:00 [received] PHST- 2025/12/05 00:00 [revised] PHST- 2025/12/07 00:00 [accepted] PHST- 2026/03/13 00:50 [medline] PHST- 2025/12/14 00:39 [pubmed] PHST- 2025/12/13 19:42 [entrez] AID - S0828-282X(25)01571-5 [pii] AID - 10.1016/j.cjca.2025.12.011 [doi] PST - ppublish SO - Can J Cardiol. 2026 Mar;42(3):528-542. doi: 10.1016/j.cjca.2025.12.011. Epub 2025 Dec 11. PMID- 41386914 OWN - NLM STAT- MEDLINE DCOM- 20251212 LR - 20251212 IS - 1558-4518 (Electronic) IS - 0895-7967 (Linking) VI - 38 IP - 4 DP - 2025 Dec TI - Team-based approach to fibromuscular dysplasia. PG - 395-403 LID - S0895-7967(25)00070-5 [pii] LID - 10.1053/j.semvascsurg.2025.10.001 [doi] AB - The diagnosis and treatment of fibromuscular dysplasia (FMD) is challenging due to its heterogeneous clinical presentations and variable vascular involvement. Although there has been an increase in published research from large international registries to aid in the care of patients with FMD, the complexity of disease management necessitates multidisciplinary collaboration to optimize patient outcomes. Multidisciplinary teams, often including vascular medicine specialists, vascular surgeons, primary care providers, cardiologists, nephrologists, neurologists, noninvasive vascular laboratory, radiology, interventionalists, cardiovascular genetic counselors, pharmacists, and mental health care providers, collaborate using team-based models composed of coordinated visits for comprehensive and efficient evaluation, systematic imaging, and individualized management. Patient advocacy organizations also play a key role in the care of patients. Clinical care coordinators are instrumental in reinforcing individualized care plans and patient education. Vascular care centers are strongly encouraged to adopt such multidisciplinary, team-based care models using structured workflows, care coordination, and patient-centered approaches to advance FMD knowledge and care. CI - Copyright (c) 2025 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Rao, Shiavax J AU - Rao SJ AD - Cardiology, Guthrie Robert Packer Hospital, Sayre, PA. FAU - Kim, Esther S H AU - Kim ESH AD - Cardiovascular Medicine, Atrium Health, Sanger Heart & Vascular Institute, Charlotte, NC. FAU - Mitromaras, Christopher AU - Mitromaras C AD - Vascular Surgery, Atrium Health, Sanger Heart & Vascular Institute, Charlotte, NC. FAU - Guerrero, Christopher R Leon AU - Guerrero CRL AD - Neurology, Atrium Health, Charlotte, NC. FAU - Khaja, Minhaj S AU - Khaja MS AD - Vascular and Interventional Radiology, University of Michigan Health, Ann Arbor, MI. FAU - Sharma, Aditya M AU - Sharma AM AD - Vascular Medicine, Atrium Health, Sanger Heart & Vascular Institute, Charlotte, NC. Electronic address: aditya.sharma@advocatehealth.org. LA - eng PT - Journal Article PT - Review DEP - 20251017 PL - United States TA - Semin Vasc Surg JT - Seminars in vascular surgery JID - 8809602 SB - IM MH - Humans MH - *Fibromuscular Dysplasia/therapy/diagnosis/diagnostic imaging/physiopathology MH - *Patient Care Team/organization & administration MH - Interdisciplinary Communication MH - *Delivery of Health Care, Integrated/organization & administration MH - Treatment Outcome MH - Predictive Value of Tests MH - Intersectoral Collaboration MH - Cooperative Behavior OTO - NOTNLM OT - Arteriopathy OT - FMD OT - Fibromuscular dysplasia OT - Management OT - Team-based approach COIS- Declaration of competing interest Minhaj S. Khaja received institutional grant funding from Boston Scientific and is on the advisory boards of Medtronic and Boston Scientific; neither is relevant to this work. Aditya M. Sharma received consulting fees/honoraria from, and is an advisory board member of, Boston Scientific Corporation, Novartis, and EnVVeno Medical; is a data and safety monitoring board member with the QUADRA-PE study (AKURA Medical); and received research grants from Vascular Medcure, Inc and Boston Scientific Corporation. The remaining authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this article. EDAT- 2025/12/13 00:32 MHDA- 2025/12/13 00:33 CRDT- 2025/12/12 20:57 PHST- 2025/08/13 00:00 [received] PHST- 2025/10/08 00:00 [revised] PHST- 2025/10/09 00:00 [accepted] PHST- 2025/12/13 00:33 [medline] PHST- 2025/12/13 00:32 [pubmed] PHST- 2025/12/12 20:57 [entrez] AID - S0895-7967(25)00070-5 [pii] AID - 10.1053/j.semvascsurg.2025.10.001 [doi] PST - ppublish SO - Semin Vasc Surg. 2025 Dec;38(4):395-403. doi: 10.1053/j.semvascsurg.2025.10.001. Epub 2025 Oct 17. PMID- 41386909 OWN - NLM STAT- MEDLINE DCOM- 20251212 LR - 20251212 IS - 1558-4518 (Electronic) IS - 0895-7967 (Linking) VI - 38 IP - 4 DP - 2025 Dec TI - Multidisciplinary management of peripheral artery disease. PG - 360-367 LID - S0895-7967(25)00066-3 [pii] LID - 10.1053/j.semvascsurg.2025.08.003 [doi] AB - Individuals with peripheral artery disease (PAD) often have risk factors including, but not limited to, multiple comorbidities, lower extremity wounds, limb amputation, and poor quality of life. PAD has been shaped by advancements in medical technology, evolving treatment paradigms, and a growing focus on patient-reported health status and patient-centered outcomes. Collaborative care models with multidisciplinary teams including primary care physicians and vascular medicine, vascular surgery, interventional radiology, interventional cardiology, physical therapy, podiatry, infectious diseases, endocrinology, pain management, and mental health specialists continue to evolve. Because individuals with PAD have multiple comorbidities, a team-based approach has been recommended by societal guidelines to ensure optimal medical, social, and possibly interventional options. This article will review the importance of a multidisciplinary team approach for individuals with PAD. CI - Copyright (c) 2025 Elsevier Inc. All rights reserved. FAU - Ujueta, Francisco AU - Ujueta F AD - Division of Cardiovascular Medicine, Vanderbilt University Medical Center, 1211 Medical Center Drive, Nashville, TN 37232. Electronic address: francisco.ujueta@vumc.org. FAU - Henkin, Stanislav AU - Henkin S AD - Gonda Vascular Center, Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN. FAU - Biswas, Minakshi AU - Biswas M AD - Banner Health, CardioVascular Institute of North Colorado, Fort Collins, CO. FAU - Mustapha, Aishat AU - Mustapha A AD - Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA. FAU - Behrooz, Leili AU - Behrooz L AD - Department of Cardiovascular Medicine, Medical College of Wisconsin, Milwaukee, WI. FAU - Gonzalez, Andrew AU - Gonzalez A AD - Department of Surgery, Indiana University, Indianapolis, Indiana; William M. Tierney Center for Health Services Research, Regenstrief Institute, Indianapolis, Indiana; Fairbanks School of Public Health, Indiana University, Indianapolis, Indiana. FAU - Heindel, Patrick AU - Heindel P AD - Division of Vascular and Endovascular Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA. FAU - Brathwaite, Shayna AU - Brathwaite S AD - Division of Vascular Surgery, Department of Surgery, Morehouse School of Medicine, Atlanta, GA. FAU - Alabi, Olamide AU - Alabi O AD - Division of Vascular Surgery and Endovascular Therapy, Emory University School of Medicine, Atlanta, GA. LA - eng PT - Journal Article PT - Review DEP - 20250903 PL - United States TA - Semin Vasc Surg JT - Seminars in vascular surgery JID - 8809602 SB - IM MH - Humans MH - *Peripheral Arterial Disease/therapy/diagnosis/physiopathology/epidemiology MH - *Patient Care Team/organization & administration MH - Risk Factors MH - Treatment Outcome MH - Interdisciplinary Communication MH - *Vascular Surgical Procedures/adverse effects MH - *Delivery of Health Care, Integrated/organization & administration MH - Comorbidity MH - Cooperative Behavior OTO - NOTNLM OT - Critical limb-threatening ischemia OT - Multidisciplinary care OT - Peripheral artery disease OT - Revascularization OT - Wound care COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this article. EDAT- 2025/12/13 00:32 MHDA- 2025/12/13 00:33 CRDT- 2025/12/12 20:57 PHST- 2025/06/17 00:00 [received] PHST- 2025/08/05 00:00 [revised] PHST- 2025/08/29 00:00 [accepted] PHST- 2025/12/13 00:33 [medline] PHST- 2025/12/13 00:32 [pubmed] PHST- 2025/12/12 20:57 [entrez] AID - S0895-7967(25)00066-3 [pii] AID - 10.1053/j.semvascsurg.2025.08.003 [doi] PST - ppublish SO - Semin Vasc Surg. 2025 Dec;38(4):360-367. doi: 10.1053/j.semvascsurg.2025.08.003. Epub 2025 Sep 3. PMID- 41386907 OWN - NLM STAT- MEDLINE DCOM- 20251212 LR - 20251212 IS - 1558-4518 (Electronic) IS - 0895-7967 (Linking) VI - 38 IP - 4 DP - 2025 Dec TI - Institutional impact of multidisciplinary aortic team implementation on practice patterns and surgical productivity. PG - 347-354 LID - S0895-7967(25)00067-5 [pii] LID - 10.1053/j.semvascsurg.2025.09.001 [doi] AB - BACKGROUND: Multidisciplinary aortic teams (MAT) are integral to the management of aortic pathology. This study quantifies the effects of MAT implementation on aortic case volumes, practice patterns and surgical productivity at a single academic institution. METHODS: Patients receiving aortic procedures were identified using CPT codes. Three time periods were defined: 2 years prior to MAT (2018), the first year with MAT (2020), and 2 years post implementation of MAT (2022). Full MAT was defined as having aortic-focused providers from cardiothoracic surgery, vascular surgery, cardiology and genetics. RESULTS: Total aortic case volume increased over 300 over the study period. Increased volume was seen for both cardiothoracic and vascular cases with a significant increase in the proportion of ascending aortic replacements as well as thoracic endografting (P < .01). Patients receiving multiple procedures significantly increased from 2018 to 2020 (70.3% vs. 84.9%) as well as mean number of procedures per patient (1.98 vs. 2.42, both P < .05). While the number of patients receiving genetic testing and followed by the institutional cardiology team remained constant during the study period, the number of patients receiving joint cardiothoracic and vascular evaluation increased significantly (23.8% 2018 vs 41.1% 2020, P = .02). Overall procedural RVUs increased from 6.8k in 2018 to 21.1k in 2022 (310% increase). CONCLUSIONS: Implementation of MAT correlated with increased aortic case volumes for cardiothoracic and vascular surgeons as well as increased overall productivity. These data suggest that robust multidisciplinary involvement is crucial to expand complex aortic volume and develop comprehensive treatment plans for patients with thoracoabdominal pathology. CI - Copyright (c) 2025 Elsevier Inc. All rights reserved. FAU - Sorber, Rebecca AU - Sorber R AD - Division of Vascular Surgery, Washington University of St. Louis, 660 S Euclid Avenue, St. Louis MO 63110. Electronic address: rsorber@wustl.edu. FAU - Byers, Peter H AU - Byers PH AD - Division of Medical Genetics, University of Washington, 1959 NE Pacific St, Seattle WA 98195; Department of Laboratory Medicine and Pathology, University of Washington, 1959 NE Pacific St, Seattle WA 98195. FAU - Schwarze, Ulrike AU - Schwarze U AD - Department of Laboratory Medicine and Pathology, University of Washington, 1959 NE Pacific St, Seattle WA 98195. FAU - Buber, Yonatan AU - Buber Y AD - Division of Cardiology, University of Washington, 1959 NE Pacific St, Seattle WA 98195. FAU - Kirkpatrick, James N AU - Kirkpatrick JN AD - Division of Cardiology, University of Washington, 1959 NE Pacific St, Seattle WA 98195. FAU - Otto, Catherine M AU - Otto CM AD - Division of Cardiology, University of Washington, 1959 NE Pacific St, Seattle WA 98195. FAU - DeRoo, Scott C AU - DeRoo SC AD - Division of Cardiothoracic Surgery, University of Washington, 1959 NE Pacific St, Seattle WA 98195. FAU - Zettervall, Sara L AU - Zettervall SL AD - Division of Vascular Surgery, University of Washington, 1959 NE Pacific St, Seattle WA 98195. FAU - Burke, Christopher R AU - Burke CR AD - Division of Cardiothoracic Surgery, University of Washington, 1959 NE Pacific St, Seattle WA 98195. FAU - Sweet, Matthew P AU - Sweet MP AD - Division of Vascular Surgery, University of Washington, 1959 NE Pacific St, Seattle WA 98195. Electronic address: mpsweet@uw.edu. LA - eng PT - Journal Article DEP - 20250906 PL - United States TA - Semin Vasc Surg JT - Seminars in vascular surgery JID - 8809602 SB - IM MH - Humans MH - *Patient Care Team/trends/organization & administration MH - *Vascular Surgical Procedures/trends MH - *Aortic Diseases/surgery/diagnostic imaging MH - Time Factors MH - *Practice Patterns, Physicians'/trends MH - Retrospective Studies MH - Male MH - Treatment Outcome MH - Female MH - Interdisciplinary Communication MH - *Delivery of Health Care, Integrated/trends MH - Middle Aged MH - *Process Assessment, Health Care/trends OTO - NOTNLM OT - Aortic dissection OT - Genetic aortopathy OT - Multidisciplinary aortic team OT - RVU OT - Thoracoabdominal aneurysm COIS- Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests. EDAT- 2025/12/13 00:32 MHDA- 2025/12/13 00:33 CRDT- 2025/12/12 20:57 PHST- 2025/08/06 00:00 [received] PHST- 2025/09/02 00:00 [revised] PHST- 2025/09/03 00:00 [accepted] PHST- 2025/12/13 00:33 [medline] PHST- 2025/12/13 00:32 [pubmed] PHST- 2025/12/12 20:57 [entrez] AID - S0895-7967(25)00067-5 [pii] AID - 10.1053/j.semvascsurg.2025.09.001 [doi] PST - ppublish SO - Semin Vasc Surg. 2025 Dec;38(4):347-354. doi: 10.1053/j.semvascsurg.2025.09.001. Epub 2025 Sep 6. PMID- 41386363 OWN - NLM STAT- MEDLINE DCOM- 20260101 LR - 20260101 IS - 1874-1754 (Electronic) IS - 0167-5273 (Linking) VI - 446 DP - 2026 Mar 1 TI - Non-invasive hybrid functional and anatomical imaging for guiding revascularization decision-making by the heart team in patients with prior coronary artery bypass grafting. PG - 134086 LID - S0167-5273(25)01129-5 [pii] LID - 10.1016/j.ijcard.2025.134086 [doi] AB - BACKGROUND: Coronary computed tomography angiography (CCTA) and myocardial perfusion imaging (MPI) are guideline-recommended to assist in clinical decision-making in patients with prior coronary artery bypass grafting (CABG). However, the value of hybrid functional and anatomical information for guiding revascularization decision-making in post-CABG patients with recurrent ischemic symptoms remains unexplored. We compared Heart Team-defined revascularization strategies based on CCTA, MPI and hybrid CCTA/MPI imaging with strategies guided by invasive coronary angiography (ICA). METHODS: We included symptomatic patients with prior CABG who underwent CCTA, MPI (single-photon emission computed tomography, positron emission tomography or stress perfusion cardiac magnetic resonance imaging) and ICA. Simulated independent Heart Teams, composed of interventional cardiologists and either an imaging cardiologist or a cardiac radiologist, performed revascularization decision-making based on conventional CCTA, MPI and a hybrid CCTA/MPI strategy (non-invasive Heart Team) or based on ICA (invasive Heart Team). The primary outcome was the Cohen's kappa agreement (kappa) between non-invasive and invasive Heart Teams. RESULTS: A total of 115 patients (mean age 73 +/- 7 years; 86 % male) were included. Revascularization was recommended in 96 patients (84 %) by CCTA, 92 patients (80 %) by MPI, 80 patients (70 %) by hybrid CCTA/MPI and 76 patients (66 %) by ICA. The agreements were low for CCTA (kappa: 0.25 [95 % confidence interval (CI): 0.07 - 0.42]) and MPI (kappa: 0.27 [95 % CI: 0.09 - 0.48]) compared to ICA, with only a modest increase when using the hybrid non-invasive imaging strategy (kappa: 0.32 [95 % CI: 0.14 - 0.51]). CONCLUSIONS: In patients with recurrent ischemic symptoms after CABG, Heart Team revascularization strategies based on conventional CCTA and MPI showed poor agreements with those guided by ICA, with only modest improvement observed when using a hybrid non-invasive imaging approach. CI - Copyright (c) 2025 The Authors. Published by Elsevier B.V. All rights reserved. FAU - Hoek, Roel AU - Hoek R AD - Departments of Cardiology, Amsterdam University Medical Centers, Amsterdam, the Netherlands. Electronic address: roel.hoek@amsterdamumc.nl. FAU - de Winter, Ruben W AU - de Winter RW AD - Departments of Cardiology, Amsterdam University Medical Centers, Amsterdam, the Netherlands. Electronic address: r.dewinter1@amsterdamumc.nl. FAU - Planken, Nils R AU - Planken NR AD - Radiology & Nuclear Medicine, Amsterdam University Medical Centers, Amsterdam, the Netherlands; Department of Radiology, Mayo Clinic, Rochester, MN, USA. Electronic address: planken.nils@mayo.edu. FAU - Somsen, Yvemarie B O AU - Somsen YBO AD - Departments of Cardiology, Amsterdam University Medical Centers, Amsterdam, the Netherlands. Electronic address: y.somsen@amsterdamumc.nl. FAU - Jukema, Ruurt A AU - Jukema RA AD - Departments of Cardiology, Amsterdam University Medical Centers, Amsterdam, the Netherlands. Electronic address: r.jukema@amsterdamumc.nl. FAU - Raijmakers, Pieter G AU - Raijmakers PG AD - Radiology & Nuclear Medicine, Amsterdam University Medical Centers, Amsterdam, the Netherlands. Electronic address: p.raijmakers@amsterdamumc.nl. FAU - Twisk, Jos W AU - Twisk JW AD - Epidemiology & Data Science, Amsterdam University Medical Centers, Amsterdam, the Netherlands. Electronic address: jwr.twisk@amsterdamumc.nl. FAU - van Diemen, Pepijn A AU - van Diemen PA AD - Departments of Cardiology, Amsterdam University Medical Centers, Amsterdam, the Netherlands. Electronic address: p.diemen@amsterdamumc.nl. FAU - Driessen, Roel S AU - Driessen RS AD - Departments of Cardiology, Amsterdam University Medical Centers, Amsterdam, the Netherlands. Electronic address: rs.driessen@amsterdamumc.nl. FAU - Danad, Ibrahim AU - Danad I AD - Department of Cardiology, Radboud University Medical Center, Nijmegen, the Netherlands; Department of Cardiology, Northwest Clinics, Alkmaar, the Netherlands. FAU - Delewi, Ronak AU - Delewi R AD - Departments of Cardiology, Amsterdam University Medical Centers, Amsterdam, the Netherlands. Electronic address: r.delewi@amsterdamumc.nl. FAU - Knaapen, Paul AU - Knaapen P AD - Departments of Cardiology, Amsterdam University Medical Centers, Amsterdam, the Netherlands. Electronic address: p.knaapen@amsterdamumc.nl. FAU - Nap, Alexander AU - Nap A AD - Departments of Cardiology, Amsterdam University Medical Centers, Amsterdam, the Netherlands. Electronic address: a.nap@amsterdamumc.nl. LA - eng PT - Journal Article DEP - 20251210 PL - Netherlands TA - Int J Cardiol JT - International journal of cardiology JID - 8200291 SB - IM MH - Humans MH - *Coronary Artery Bypass/methods/trends MH - Male MH - Female MH - Aged MH - *Coronary Angiography/methods MH - *Myocardial Perfusion Imaging/methods MH - *Clinical Decision-Making/methods MH - *Myocardial Revascularization/methods MH - *Computed Tomography Angiography/methods MH - *Patient Care Team MH - *Coronary Artery Disease/surgery/diagnostic imaging/physiopathology MH - Middle Aged MH - Aged, 80 and over MH - Tomography, Emission-Computed, Single-Photon/methods MH - Retrospective Studies OTO - NOTNLM OT - Coronary computed tomography angiography OT - Heart team OT - Invasive coronary angiography OT - Myocardial perfusion imaging OT - Prior coronary artery bypass grafting COIS- Declaration of competing interest None declared. EDAT- 2025/12/13 00:32 MHDA- 2026/01/02 00:33 CRDT- 2025/12/12 19:32 PHST- 2025/11/05 00:00 [received] PHST- 2025/11/28 00:00 [revised] PHST- 2025/12/08 00:00 [accepted] PHST- 2026/01/02 00:33 [medline] PHST- 2025/12/13 00:32 [pubmed] PHST- 2025/12/12 19:32 [entrez] AID - S0167-5273(25)01129-5 [pii] AID - 10.1016/j.ijcard.2025.134086 [doi] PST - ppublish SO - Int J Cardiol. 2026 Mar 1;446:134086. doi: 10.1016/j.ijcard.2025.134086. Epub 2025 Dec 10. PMID- 41384417 OWN - NLM STAT- Publisher LR - 20251212 IS - 2532-5264 (Electronic) IS - 1122-0643 (Linking) DP - 2025 Dec 3 TI - Return to work and cardiovascular disease: functional capacity assessment, evidence and limits of applicability and the role of cardio-rehabilitation in occupational medicine. LID - 10.4081/monaldi.2025.3587 [doi] AB - The incidence and prevalence of cardiovascular disease are increasing progressively in the general population and workers due to higher mean age and improved prognosis and survival as a result of new therapeutic and diagnostic options. The assessment of cardiovascular risk in the workplace is complex due to the fact that it is not a specific work risk and because of the absence of a specific assessment methodology, leading to numerous limitations in the formulation of the job fitness certification, the protection of workers' expertise and health, and the applicability of regulations. The tools used in cardiology and, particularly, in cardio-rehabilitation can provide important information to both estimate the residual functional capacity and the cardiovascular load during work activity. A multidisciplinary approach and collaboration between occupational physicians, cardiologists, cardio-rehabilitators, and general practitioners are essential for managing critical cases. FAU - Milia, Simone AU - Milia S AD - Division of Occupational Medicine, Department of Medical Sciences and Public Health, University of Cagliari, Monserrato. FAU - Candura, Stefano M AU - Candura SM AD - Occupational Medicine Unit, Department of Public Health, Experimental and Forensic Sciences, University of Pavia; Occupational Medicine Unit of Pavia Institute, Istituti Clinici Scientifici Maugeri IRCCS, Pavia. LA - eng PT - Journal Article DEP - 20251203 PL - Italy TA - Monaldi Arch Chest Dis JT - Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace JID - 9307314 SB - IM EDAT- 2025/12/12 17:55 MHDA- 2025/12/12 17:55 CRDT- 2025/12/12 06:04 PHST- 2025/06/04 00:00 [received] PHST- 2025/12/12 17:55 [medline] PHST- 2025/12/12 17:55 [pubmed] PHST- 2025/12/12 06:04 [entrez] AID - 10.4081/monaldi.2025.3587 [doi] PST - aheadofprint SO - Monaldi Arch Chest Dis. 2025 Dec 3. doi: 10.4081/monaldi.2025.3587. PMID- 41384151 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251212 LR - 20251214 IS - 2532-8689 (Electronic) IS - 1124-9390 (Print) IS - 1124-9390 (Linking) VI - 33 IP - 4 DP - 2025 TI - Halfway between Cure and Care: Suppressive Therapy in Inoperable Infective Endocarditis. PG - 413-421 LID - 10.53854/liim-3304-6 [doi] AB - BACKGROUND: Infective endocarditis (IE) is a high-mortality condition that requires multidisciplinary expertise. In elderly patients with multiple comorbidities, surgery is often precluded by prohibitive risks or technical difficulties, leading to poor patient outcomes. Long-term suppressive antimicrobial therapy (SAT) is an alternative approach aimed at reducing relapse risk and maintaining clinical stability, with limited but growing evidence. METHODS: We conducted a retrospective, single-center observational study in northeastern Italy, that included 34 adult patients diagnosed with IE from January 1, 2020, to July 31, 2024. These patients were managed with SAT after completing a standard intravenous antimicrobial course and were either ineligible for curative surgery or had experienced failed surgical intervention, as determined by the Multidisciplinary Endocarditis Team (MET). The primary outcomes were all-cause mortality at the last available follow-up and documented infection relapse. Secondary outcomes included SAT characteristics (treatment duration, type of antimicrobial agent, discontinuation and its causes, and clinical course), as well as the occurrence of adverse drug events (ADEs) or tolerance issues attributable to SAT. RESULTS: The median age was 77 years (IQR 67-82), and the median Charlson Comorbidity Index was 6 (IQR 5-8). Prosthetic valve endocarditis (PVE) was the most common presentation, affecting 24 patients (70.6%). The blood culture positivity rate was 88.2%, with the main isolated microorganisms including staphylococci (13, 40.6% - mostly methicillin-susceptible Staphylococcus aureus - MSSA), streptococci (11, 34.4%), and Enterococcus faecalis (6, 18.8%). All-cause mortality during follow-up was 5/34 (14.7%), and the relapse rate was 4/34 (11.8%), all occurring during treatment. Median follow-up was 845 days (IQR 446-1488). ADEs affected 6/34 patients (17.6%), resulting in one hospitalization but without requiring treatment suspension. SAT was terminated by MET decision in 12 patients, with no subsequent relapses. CONCLUSIONS: In non-operable IE patients, SAT has proven to be a feasible long-term strategy, weighing the risks of recurrence, drug-related events, and prolonged antibiotic exposure. Careful patient selection and strict follow-up are crucial. FAU - Venturini, Sergio AU - Venturini S AD - Department of Infectious Diseases, ASFO "Santa Maria degli Angeli" Hospital of Pordenone, Pordenone, Italy. FAU - Reffo, Ingrid AU - Reffo I AD - Department of Anesthesiology, ASFO "Santa Maria dei Battuti" Hospital of San Vito al Tagliamento, Pordenone, Italy. FAU - Munaretto, Laura AU - Munaretto L AD - Department of Cardiology, ASFO "Santa Maria degli Angeli" Hospital of Pordenone, Pordenone, Italy. FAU - Mattia, Alessio Della AU - Mattia AD AD - Department of Cardiology, ASFO "Santa Maria degli Angeli" Hospital of Pordenone, Pordenone, Italy. FAU - Del Fabro, Giovanni AU - Del Fabro G AD - Department of Infectious Diseases, ASFO "Santa Maria degli Angeli" Hospital of Pordenone, Pordenone, Italy. FAU - Callegari, Astrid AU - Callegari A AD - Department of Infectious Diseases, ASFO "Santa Maria degli Angeli" Hospital of Pordenone, Pordenone, Italy. FAU - Zanus-Fortes, Agnese AU - Zanus-Fortes A AD - Department of Infectious Diseases, ASFO "Santa Maria degli Angeli" Hospital of Pordenone, Pordenone, Italy. FAU - Giovagnorio, Federico AU - Giovagnorio F AD - Department of Infectious Diseases, ASFO "Santa Maria degli Angeli" Hospital of Pordenone, Pordenone, Italy. FAU - Pavan, Daniela AU - Pavan D AD - Department of Cardiology, ASFO "Santa Maria degli Angeli" Hospital of Pordenone, Pordenone, Italy. LA - eng PT - Journal Article DEP - 20251201 PL - Italy TA - Infez Med JT - Le infezioni in medicina JID - 9613961 PMC - PMC12695164 OTO - NOTNLM OT - infective endocarditis OT - multidisciplinary endocarditis team OT - prosthetic valve endocarditis OT - suppressive antimicrobial therapy COIS- Conflicts of interest: No conflict of interest must be declared for any of the authors. EDAT- 2025/12/12 07:19 MHDA- 2025/12/12 07:20 PMCR- 2025/12/01 CRDT- 2025/12/12 04:37 PHST- 2025/09/12 00:00 [received] PHST- 2025/10/24 00:00 [accepted] PHST- 2025/12/12 07:20 [medline] PHST- 2025/12/12 07:19 [pubmed] PHST- 2025/12/12 04:37 [entrez] PHST- 2025/12/01 00:00 [pmc-release] AID - 1124-9390_33_4_2025_413-421 [pii] AID - 10.53854/liim-3304-6 [doi] PST - epublish SO - Infez Med. 2025 Dec 1;33(4):413-421. doi: 10.53854/liim-3304-6. eCollection 2025. PMID- 41378074 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251211 LR - 20260925 IS - 2150-5349 (Print) IS - 2150-5349 (Electronic) IS - 2150-5349 (Linking) VI - 16 IP - 4 DP - 2025 Dec 5 TI - Metabolic syndrome after liver transplantation: A silent threat to long-term success. PG - 111073 LID - 10.4292/wjgpt.v16.i4.111073 [doi] LID - 111073 AB - Liver transplantation (LT) has significantly improved survival for patients with end-stage liver disease, but post-transplant metabolic syndrome (MetS) has emerged as a major challenge, affecting graft function and long-term outcomes. Characterized by obesity, dyslipidemia, hypertension, and insulin resistance, MetS increases the risk of cardiovascular disease, recurrent liver disease, and reduced graft survival. We systematically examine current literature on the diagnosis, risk stratification, and management of MetS in LT recipients, with a focus on lifestyle interventions, pharmacologic strategies, and potential modifications in immunosuppressive regimens. Additionally, we discuss the role of emerging therapies, including GLP-1 receptor agonists, PCSK-9 inhibitors, and bariatric interventions, in mitigating metabolic risk in this population. With cardiovascular complications being the leading cause of post-LT mortality, proactive management of MetS is crucial. A multidisciplinary approach integrating hepatology, endocrinology, and cardiology is essential to optimize patient outcomes. Future research should focus on personalized metabolic interventions and long-term strategies to enhance post-transplant survival and quality of life. CI - (c)The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. FAU - Chan, Shu-Yen AU - Chan SY AD - Internal Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, United States. FAU - Lee, Junseo AU - Lee J AD - Department of Gastroenterology and Hepatology, University of Rochester Medical Center, Rochester, NY 14682, United States. FAU - Karki, Pratikshya AU - Karki P AD - Department of Public Health, University of Rochester Medical Center, Rochester, NY 14682, United States. FAU - Laryea, Marie AU - Laryea M AD - Department of Gastroenterology and Hepatology, University of Rochester Medical Center, Rochester, NY 14682, United States. FAU - Huang, Jonathan AU - Huang J AD - Department of Gastroenterology and Hepatology, University of Rochester Medical Center, Rochester, NY 14682, United States. FAU - Lim, Nicholas AU - Lim N AD - Department of Transplant Hepatology, University of Rochester Medical Center, Rochester, Rochester, NY 14682, United States. FAU - Twohig, Patrick AU - Twohig P AD - Department of Gastroenterology and Hepatology, University of Rochester Medical Center, Rochester, NY 14682, United States. patrick_twohig@urmc.rochester.edu. LA - eng PT - Journal Article PT - Review PL - United States TA - World J Gastrointest Pharmacol Ther JT - World journal of gastrointestinal pharmacology and therapeutics JID - 101547456 PMC - PMC12686996 OTO - NOTNLM OT - Cardiovascular disease OT - Immunosuppression OT - Liver transplantation OT - Metabolic dysfunction associated steatohepatitis OT - Metabolic syndrome OT - Post-transplant diabetes mellitus COIS- Conflict-of-interest statement: The authors report no conflicts of interest. EDAT- 2025/12/11 07:43 MHDA- 2025/12/11 07:44 PMCR- 2025/12/05 CRDT- 2025/12/11 05:29 PHST- 2025/06/23 00:00 [received] PHST- 2025/08/05 00:00 [revised] PHST- 2025/11/10 00:00 [accepted] PHST- 2025/12/11 07:44 [medline] PHST- 2025/12/11 07:43 [pubmed] PHST- 2025/12/11 05:29 [entrez] PHST- 2025/12/05 00:00 [pmc-release] AID - 10.4292/wjgpt.v16.i4.111073 [doi] PST - ppublish SO - World J Gastrointest Pharmacol Ther. 2025 Dec 5;16(4):111073. doi: 10.4292/wjgpt.v16.i4.111073. PMID- 41377913 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251211 LR - 20251213 IS - 2297-055X (Print) IS - 2297-055X (Electronic) IS - 2297-055X (Linking) VI - 12 DP - 2025 TI - Clinical outcomes of monitored anesthesia care vs. general anesthesia in transfemoral transcatheter aortic valve implantation: a single-center retrospective study. PG - 1652045 LID - 10.3389/fcvm.2025.1652045 [doi] LID - 1652045 AB - BACKGROUND: Transcatheter aortic valve implantation (TAVI) has become a preferred treatment for severe aortic stenosis in high-risk patients. In China, general anesthesia (GA) remains the standard; however, monitored anesthesia care (MAC) offers a less-invasive alternative. In this study, we compared the outcomes between MAC and GA in transfemoral TAVI. METHODS: We retrospectively analyzed the data from 106 consecutive patients (54 MAC, 52 GA) who underwent TAVI at a The Second Affiliated Hospital of Harbin Medical University from January 2021 to November 2023. MAC involved administration of a combination of local anesthesia with dexmedetomidine/remifentanil sedation, whereas GA involved endotracheal intubation. We compared procedural metrics, complications, and lengths of hospital stays. RESULTS: The baseline characteristics were comparable between the groups (mean age: 70.3 +/- 7.3 years, 46% with reduced ejection fraction). The MAC group showed shorter procedure times (102 +/- 25 vs. 145 +/- 42 min, p < 0.0001) and hospital stays (10.5 +/- 3.7 vs. 14.1 +/- 5.1 days, p < 0.0001), compared with the GA group. Safety outcomes were similar between the groups: 30-day mortality (5.8% vs. 7.4% in the MAC and GA groups, respectively, p = 0.734), stroke (1.9% in both groups), and major vascular complications (3.8% vs. 5.6%). The GA group had higher valve-in-valve rates (13% vs. 1.9%, p = 0.024) and postoperative hypotension (4 vs. 0 patients), compared with the MAC group. Pacemaker implantation was more frequent in the MAC group vs. the GA group (13% vs. 3.8%, p = 0.229). CONCLUSIONS: The use of MAC for TAVI is comparably safe to using GA, with potential advantages in recovery speed and resource utilization. A heart team approach, including cardiac anesthesiologists, is critical for optimal patient selection. CI - (c) 2025 Zhang, Chen, Yu and Zhang. FAU - Zhang, Haoran AU - Zhang H AD - Department of Cardiology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China. AD - The Key Laboratory of Myocardial Ischemia, Chinese Ministry of Education, Harbin, China. FAU - Chen, Tao AU - Chen T AD - Department of Cardiology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China. AD - The Key Laboratory of Myocardial Ischemia, Chinese Ministry of Education, Harbin, China. FAU - Yu, Bo AU - Yu B AD - Department of Cardiology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China. AD - The Key Laboratory of Myocardial Ischemia, Chinese Ministry of Education, Harbin, China. FAU - Zhang, Donghui AU - Zhang D AD - Department of Cardiology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China. AD - The Key Laboratory of Myocardial Ischemia, Chinese Ministry of Education, Harbin, China. LA - eng PT - Journal Article DEP - 20251125 PL - Switzerland TA - Front Cardiovasc Med JT - Frontiers in cardiovascular medicine JID - 101653388 PMC - PMC12687134 OTO - NOTNLM OT - aortic stenosis OT - minimalist approach OT - monitored anesthesia care OT - transcatheter aortic valve implantation OT - transfemoral COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2025/12/11 07:44 MHDA- 2025/12/11 07:45 PMCR- 2025/11/25 CRDT- 2025/12/11 05:28 PHST- 2025/06/23 00:00 [received] PHST- 2025/11/04 00:00 [revised] PHST- 2025/11/10 00:00 [accepted] PHST- 2025/12/11 07:45 [medline] PHST- 2025/12/11 07:44 [pubmed] PHST- 2025/12/11 05:28 [entrez] PHST- 2025/11/25 00:00 [pmc-release] AID - 10.3389/fcvm.2025.1652045 [doi] PST - epublish SO - Front Cardiovasc Med. 2025 Nov 25;12:1652045. doi: 10.3389/fcvm.2025.1652045. eCollection 2025. PMID- 41375895 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251211 LR - 20251214 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 14 IP - 23 DP - 2025 Dec 4 TI - Practice Patterns and Trends in Temperature Control After Cardiac Arrest: A Multi-Specialty Survey. LID - 10.3390/jcm14238592 [doi] LID - 8592 AB - Background/Objectives: Temperature control after cardiac arrest remains a recommended component of post-cardiac arrest care, yet substantial practice variability persists. Conflicting evidence regarding optimal temperature targets and mixed interpretations of recent trials, such as TTM2, may contribute to inconsistent bedside implementation. Understanding physician knowledge, attitudes, and practice patterns is essential for aligning post-cardiac arrest management with evolving evidence. This study aimed to characterize international physician perceptions of temperature control, patterns of use, understanding of neurologic injury, and the influence of emerging literature. Methods: A 39-item web-based survey was developed through iterative expert review and pilot testing and disseminated to members of critical care, neurology, and emergency medicine societies between September 2021 and January 2022. The instrument assessed demographics, temperature control practices, interpretation of new literature, and post-cardiac arrest management. Responses were analyzed using descriptive statistics in R Studio, with proportions reported for categorical variables and mode responses for ranked questions. Results: Among 501 respondents, 471 (94%) completed the survey. Most were attending-level physicians (73%), primarily practicing intensive care medicine (75%), and based in academic centers (60%). Targeted temperature management (TTM) was commonly initiated by the admitting intensivist (66%), most often because guidelines recommended it (67%). The most influential factors driving initiation were institutional protocols (21%), perceived neurologic prognosis (17%), and arrest etiology (14%). The most frequently selected temperature target was 36 degrees C (44%). Awareness of the TTM2 trial was high (70%), though only 31% reported altering their practice in response. Neurologists were more likely to individualize temperature targets and select lower temperatures, while physicians caring for higher cardiac arrest volumes also favored lower targets. Community clinicians more commonly selected lower temperature targets compared with those in academic settings. Conclusions: Substantial heterogeneity exists in the practice and rationale for temperature control after cardiac arrest. Physician specialty, cardiac arrest volume, and local practice environment influence the temperature target selection and attitudes toward emerging evidence. Despite awareness of new data, institutional protocols remain the dominant factor guiding implementation. Standardized, evidence-based institutional pathways may help reduce practice variability and promote consistent post-cardiac arrest care. FAU - Carr, Casey T AU - Carr CT AUID- ORCID: 0000-0002-6015-4998 AD - Nazih Zuhdi Transplant Institute, Specialty Critical Care and Acute Circulatory Support Service, INTERIS Baptist Medical Center, Oklahoma City, OK 73112, USA. FAU - Eckert, Melody B AU - Eckert MB AD - College of Medicine, State University of New York Downstate Health Sciences University, New York, NY 11203, USA. FAU - Bhakta, Nilan AU - Bhakta N AD - College of Medicine, University of Texas Health Science Center at Houston, Houston, TX 77030, USA. FAU - Guirgis, Faheem W AU - Guirgis FW AUID- ORCID: 0000-0002-4445-3939 AD - Department of Emergency Medicine, College of Medicine, University of Florida, Gainesville, FL 32610, USA. FAU - Hopson, Charlotte AU - Hopson C AUID- ORCID: 0009-0003-5174-0543 AD - Department of Emergency Medicine, College of Medicine, University of Florida, Gainesville, FL 32610, USA. FAU - Maciel, Carolina B AU - Maciel CB AUID- ORCID: 0000-0002-8763-5839 AD - Departments of Neurology and Neurosurgery, College of Medicine, University of Florida, Gainesville, FL 32610, USA. FAU - Becker, Torben K AU - Becker TK AUID- ORCID: 0000-0002-5287-8056 AD - Division of Critical Care Medicine, Department of Emergency Medicine, College of Medicine, University of Florida, Gainesville, FL 32610, USA. LA - eng PT - Journal Article DEP - 20251204 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC12693480 OTO - NOTNLM OT - cardiac arrest OT - post cardiac arrest syndrome OT - targeted temperature management OT - temperature control OT - therapeutic hypothermia COIS- The authors declare no conflicts of interest. EDAT- 2025/12/11 07:42 MHDA- 2025/12/11 07:43 PMCR- 2025/12/04 CRDT- 2025/12/11 01:11 PHST- 2025/11/03 00:00 [received] PHST- 2025/11/23 00:00 [revised] PHST- 2025/11/28 00:00 [accepted] PHST- 2025/12/11 07:43 [medline] PHST- 2025/12/11 07:42 [pubmed] PHST- 2025/12/11 01:11 [entrez] PHST- 2025/12/04 00:00 [pmc-release] AID - jcm14238592 [pii] AID - jcm-14-08592 [pii] AID - 10.3390/jcm14238592 [doi] PST - epublish SO - J Clin Med. 2025 Dec 4;14(23):8592. doi: 10.3390/jcm14238592. PMID- 41375607 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251211 LR - 20251214 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 14 IP - 23 DP - 2025 Nov 22 TI - AI-Automated Risk Operative Stratification for Severe Aortic Stenosis: A Proof-of-Concept Study. LID - 10.3390/jcm14238304 [doi] LID - 8304 AB - Background: Accurate operative risk stratification is essential for treatment selection in severe aortic stenosis. We developed an automated workflow using large language models (LLMs) to replicate Heart Team risk assessment. Methods: We retrospectively analyzed 231 consecutive patients with severe aortic stenosis evaluated by multidisciplinary Heart Teams (January 2022-December 2024). An automated system using GPT-4o was developed, comprising the following: (1) structured data extraction from clinical dossiers; (2) EuroSCORE II calculation via two methods (algorithmic vs. LLM-based); (3) clinical vignette generation; and (4) risk stratification comparing EuroSCORE-based thresholds versus guideline-integrated LLM approaches with/without EuroSCORE values. The primary endpoint was the risk stratification accuracy of each method compared to Heart Team decisions. Results: Mean age was 79.5 +/- 7.7 years, with 58.4% female. The automated workflow processed patients in 32.6 +/- 6.4 s. The LLM-calculated EuroSCORE II showed a lower mean difference from Heart Team values (-1.42%, 95% CI -2.32 to -0.53) versus algorithmic calculation (-1.88%, 95% CI -2.38 to -1.38). For risk stratification, the guideline-integrated LLM without EuroSCORE achieved the highest accuracy (90.0%) and AUC (0.93), outperforming both the EuroSCORE-based (accuracy 50.2% for high-risk, AUC 0.63) and guideline-integrated LLM with EuroSCORE approaches (accuracy 82.4%, AUC 0.76). However, systematic hallucinations occurred for cardiovascular risk factors when data were missing. Conclusions: LLMs accurately calculated EuroSCORE II and achieved 90% concordance with multidisciplinary Heart Team decisions. However, hallucinations, reproducibility concerns, and the absence of clinical outcome validation preclude direct clinical application. FAU - Garin, Dorian AU - Garin D AUID- ORCID: 0000-0002-3872-3496 AD - Department of Cardiology, University and Hospital Fribourg, 1708 Fribourg, Switzerland. AD - Department of Cardiology, Geneva University Hospitals, 1206 Geneve, Switzerland. FAU - Arroyo, Diego AU - Arroyo D AD - Department of Cardiology, University and Hospital Fribourg, 1708 Fribourg, Switzerland. FAU - Skalidis, Ioannis AU - Skalidis I AUID- ORCID: 0000-0002-4374-0389 AD - Department of Cardiology, University and Hospital Fribourg, 1708 Fribourg, Switzerland. FAU - Di Cicco, Philippe AU - Di Cicco P AUID- ORCID: 0009-0009-8943-393X AD - Department of Cardiology, University and Hospital Fribourg, 1708 Fribourg, Switzerland. FAU - Ferry, Charlie AU - Ferry C AUID- ORCID: 0009-0000-8997-7042 AD - Department of Cardiology, University and Hospital Fribourg, 1708 Fribourg, Switzerland. FAU - Bennar, Wesley AU - Bennar W AD - Department of Cardiology, University and Hospital Fribourg, 1708 Fribourg, Switzerland. FAU - Puricel, Serban AU - Puricel S AD - Department of Cardiology, University and Hospital Fribourg, 1708 Fribourg, Switzerland. FAU - Meier, Pascal AU - Meier P AD - Department of Cardiology, University and Hospital Fribourg, 1708 Fribourg, Switzerland. FAU - Togni, Mario AU - Togni M AD - Department of Cardiology, University and Hospital Fribourg, 1708 Fribourg, Switzerland. FAU - Cook, Stephane AU - Cook S AUID- ORCID: 0000-0003-1221-2978 AD - Department of Cardiology, University and Hospital Fribourg, 1708 Fribourg, Switzerland. LA - eng GR - NA/Fond Scientifique Cardiovasculaire/ PT - Journal Article DEP - 20251122 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC12693594 OTO - NOTNLM OT - EuroSCORE II OT - Heart Team OT - artificial intelligence OT - large language models OT - risk stratification OT - transcatheter aortic valve replacement COIS- The authors declare no conflicts of interest. EDAT- 2025/12/11 07:43 MHDA- 2025/12/11 07:44 PMCR- 2025/11/22 CRDT- 2025/12/11 01:10 PHST- 2025/10/31 00:00 [received] PHST- 2025/11/18 00:00 [revised] PHST- 2025/11/19 00:00 [accepted] PHST- 2025/12/11 07:44 [medline] PHST- 2025/12/11 07:43 [pubmed] PHST- 2025/12/11 01:10 [entrez] PHST- 2025/11/22 00:00 [pmc-release] AID - jcm14238304 [pii] AID - jcm-14-08304 [pii] AID - 10.3390/jcm14238304 [doi] PST - epublish SO - J Clin Med. 2025 Nov 22;14(23):8304. doi: 10.3390/jcm14238304. PMID- 41370459 OWN - NLM STAT- MEDLINE DCOM- 20251210 LR - 20260421 IS - 1984-0446 (Electronic) IS - 0034-7167 (Print) IS - 0034-7167 (Linking) VI - 78 IP - 5 DP - 2025 TI - Cardiopulmonary arrest in Primary Care: nursing team's theoretical, practical and soft skills interferences. PG - e20250059 LID - S0034-71672025000500163 [pii] LID - 10.1590/0034-7167-2025-0059 [doi] LID - e20250059 AB - OBJECTIVES: to identify the determining factors and soft skills that interfere with the nursing team's care for people in cardiorespiratory arrest in the Family Health Strategy. METHODS: exploratory and descriptive research, with a qualitative approach. Thirty-five nursing professionals from two Primary Health Care units in the Brazilian capital were interviewed between March and June 2023. A categorical thematic content analysis was carried out. RESULTS: three categories emerged: 1. Knowledge and experience as determining factors in assisting people in cardiorespiratory arrest; 2. Macro and micro work processes in Primary Health Care: from users' arrival to advanced life support; 3. Soft skills. FINAL CONSIDERATIONS: theoretical knowledge, experience and work processes in Primary Health Care are decisive. Soft skills include leadership and communication. Continuing education strategies adapted to Primary Health Care that value soft skills are recommended. FAU - Ferreira, Caroliny Suhet Xavier AU - Ferreira CSX AUID- ORCID: 0000-0002-8826-6182 AD - Universidade Federal do Estado do Rio de Janeiro. Rio de Janeiro, Rio de Janeiro, Brazil. FAU - Anacleto, Gabriele de Araujo AU - Anacleto GA AUID- ORCID: 0009-0005-1737-1646 AD - Universidade Federal do Estado do Rio de Janeiro. Rio de Janeiro, Rio de Janeiro, Brazil. FAU - Agonigi, Regina Cavalcante AU - Agonigi RC AUID- ORCID: 0000-0002-1499-833X AD - Secretaria Municipal de Saude do Rio de Janeiro.Rio de Janeiro, Rio de Janeiro, Brasil. FAU - Correa, Vanessa de Almeida Ferreira AU - Correa VAF AUID- ORCID: 0000-0001-7121-4493 AD - Universidade Federal do Estado do Rio de Janeiro. Rio de Janeiro, Rio de Janeiro, Brazil. FAU - Nunciaroni, Andressa Teoli AU - Nunciaroni AT AUID- ORCID: 0000-0001-6469-592X AD - Universidade Federal do Estado do Rio de Janeiro. Rio de Janeiro, Rio de Janeiro, Brazil. LA - eng LA - por PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20251208 PL - Brazil TA - Rev Bras Enferm JT - Revista brasileira de enfermagem JID - 7910105 SB - IM MH - Humans MH - Brazil MH - Primary Health Care/standards MH - *Heart Arrest/nursing/therapy MH - Qualitative Research MH - Male MH - Female MH - Adult MH - *Clinical Competence/standards/statistics & numerical data MH - Middle Aged MH - *Nursing, Team/standards/methods PMC - PMC12707765 EDAT- 2025/12/10 19:21 MHDA- 2025/12/10 19:22 PMCR- 2025/12/08 CRDT- 2025/12/10 14:13 PHST- 2025/01/30 00:00 [received] PHST- 2025/05/19 00:00 [accepted] PHST- 2025/12/10 19:22 [medline] PHST- 2025/12/10 19:21 [pubmed] PHST- 2025/12/10 14:13 [entrez] PHST- 2025/12/08 00:00 [pmc-release] AID - S0034-71672025000500163 [pii] AID - 10.1590/0034-7167-2025-0059 [doi] PST - epublish SO - Rev Bras Enferm. 2025 Dec 8;78(5):e20250059. doi: 10.1590/0034-7167-2025-0059. eCollection 2025. PMID- 41360328 OWN - NLM STAT- MEDLINE DCOM- 20260214 LR - 20260214 IS - 1097-6744 (Electronic) IS - 0002-8703 (Linking) VI - 294 DP - 2026 Apr TI - Coronary computed tomography angiography versus invasive coronary angiography for interventional triage in acute coronary syndrome: Design of the randomized TRACTION trial. PG - 107325 LID - S0002-8703(25)00387-4 [pii] LID - 10.1016/j.ahj.2025.107325 [doi] AB - PURPOSE: In patients admitted with acute coronary syndrome, invasive coronary angiography (ICA) is performed to determine which patients need revascularization. Coronary computed tomography angiography (CCTA) offers a widely available, non-invasive alternative that could reduce patient discomfort, procedural risks, and healthcare costs. The current trial aims to determine whether CCTA is noninferior to ICA in determining the interventional strategy for patients admitted with non-ST elevation acute coronary syndrome (NSTE-ACS)(Central Illustration). METHODS: TRACTION (Team-based Interventional Triage in Acute Coronary Syndrome Based on Noninvasive Coronary Computed Tomography Angiography Versus Invasive Coronary Angiography) is a multicenter, randomized, open-label, noninferiority trial enrolling 2,300 patients. Patients hospitalized with non-ST elevation myocardial infarction or unstable angina with ischemic changes on ECG will be randomized 1:1 to CCTA vs ICA (standard of care). In the CCTA group, a Coronary Team reviews the CCTA and clinical information to determine the interventional strategy. The primary composite endpoint is major adverse cardiac events at 1 year, comprised of all-cause mortality, nonfatal myocardial infarction, hospitalization due to refractory angina, or hospitalization due to heart failure. Secondary outcomes include cardiovascular death, revascularization, symptom status, procedure-related adverse events, and resource utilization. The trial is designed to demonstrate noninferiority if the 95% confidence interval excludes an absolute risk difference of the primary endpoint larger than 5%. PERSPECTIVES: If CCTA is shown to be noninferior to ICA in patients admitted with NSTE-ACS, CCTA could become the preferred management in a large group of patients. This could result in fewer patients exposed to invasive procedures and improved resource utilization. CLINICALTRIALS: gov identifier: NCT06101862. CI - Copyright (c) 2025 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Sorgaard, Mathias Holm AU - Sorgaard MH AD - Department of Cardiology, Herlev and Gentofte Hospital, Herlev, Denmark. Electronic address: mathias.holm.soergaard@regionh.dk. FAU - Kristensen, Andreas Torp AU - Kristensen AT AD - Department of Cardiology, Rigshospitalet, Copenhagen, Denmark. FAU - Eskesen, Kristian AU - Eskesen K AD - Department of Cardiology, Herlev and Gentofte Hospital, Herlev, Denmark. FAU - Kofoed, Klaus Fuglsang AU - Kofoed KF AD - Department of Cardiology, Rigshospitalet, Copenhagen, Denmark. FAU - Linde, Jesper James AU - Linde JJ AD - Department of Cardiology, Rigshospitalet, Copenhagen, Denmark. FAU - Kelbaek, Henning AU - Kelbaek H AD - Department of Cardiology, University Hospital of Zealand, Roskilde, Roskilde, Denmark. FAU - Ottesen, Michael AU - Ottesen M AD - Department of Cardiology, University Hospital of Zealand, Roskilde, Roskilde, Denmark. FAU - Neland, Keld AU - Neland K AD - Department of Cardiology, University Hospital of Zealand, Roskilde, Roskilde, Denmark. FAU - Kragelund, Charlotte AU - Kragelund C AD - Department of Cardiology, North Zealand Hospital, Hilleroed, Denmark. FAU - Bertelsen, Mette Lykke Norgaard AU - Bertelsen MLN AD - Department of Cardiology, North Zealand Hospital, Hilleroed, Denmark. FAU - Hove, Jens Dahlgaard AU - Hove JD AD - Department of Cardiology, Hvidovre Hospital, Hvidovre, Denmark. FAU - Mork, Gorm AU - Mork G AD - Department of Cardiology, Bispebjerg Hospital, Copenhagen, Denmark. FAU - Kristiansen, Ole Peter AU - Kristiansen OP AD - Department of Cardiology, Bispebjerg Hospital, Copenhagen, Denmark. FAU - Engstrom, Thomas AU - Engstrom T AD - Department of Cardiology, Rigshospitalet, Copenhagen, Denmark. FAU - Lonborg, Jacob Thomsen AU - Lonborg JT AD - Department of Cardiology, Rigshospitalet, Copenhagen, Denmark. FAU - Kuhl, Jorgen Tobias AU - Kuhl JT AD - Department of Cardiology, Rigshospitalet, Copenhagen, Denmark. FAU - Risom, Signe Stelling AU - Risom SS AD - Department of Cardiology, Herlev and Gentofte Hospital, Herlev, Denmark; Institute of Nursing and Nutrition, University College Copenhagen, Copenhagen, Denmark; Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. FAU - Blanche, Paul AU - Blanche P AD - Section of Biostatistics, Department of Public Health, Copenhagen University, Copenhagen, Denmark. FAU - Olsen, Niels Thue AU - Olsen NT AD - Department of Cardiology, Rigshospitalet, Copenhagen, Denmark. LA - eng SI - ClinicalTrials.gov/NCT06101862 PT - Clinical Trial Protocol PT - Journal Article DEP - 20251206 PL - United States TA - Am Heart J JT - American heart journal JID - 0370465 SB - IM MH - Humans MH - *Acute Coronary Syndrome/diagnostic imaging/diagnosis/surgery/therapy MH - *Coronary Angiography/methods MH - *Triage/methods MH - *Computed Tomography Angiography/methods MH - Male MH - Female MH - Non-ST Elevated Myocardial Infarction MH - Randomized Controlled Trials as Topic MH - Multicenter Studies as Topic EDAT- 2025/12/09 00:31 MHDA- 2026/02/15 00:31 CRDT- 2025/12/08 19:32 PHST- 2025/09/16 00:00 [received] PHST- 2025/11/17 00:00 [revised] PHST- 2025/12/02 00:00 [accepted] PHST- 2026/02/15 00:31 [medline] PHST- 2025/12/09 00:31 [pubmed] PHST- 2025/12/08 19:32 [entrez] AID - S0002-8703(25)00387-4 [pii] AID - 10.1016/j.ahj.2025.107325 [doi] PST - ppublish SO - Am Heart J. 2026 Apr;294:107325. doi: 10.1016/j.ahj.2025.107325. Epub 2025 Dec 6. PMID- 41359921 OWN - NLM STAT- MEDLINE DCOM- 20251208 LR - 20260925 IS - 2561-1011 (Electronic) IS - 2561-1011 (Linking) VI - 9 DP - 2025 Dec 8 TI - Outcomes of Team-Based Digital Monitoring of Patients With Multiple Chronic Conditions: Semiparametric Event Study. PG - e75170 LID - 10.2196/75170 [doi] LID - e75170 AB - BACKGROUND: Remote patient monitoring (RPM) has emerged as an effective strategy for controlling hypertension by enabling patients to collect and transmit blood pressure (BP) data outside the clinic and supporting proactive care team interventions. While its benefits for hypertension management are well established, less is known about its effectiveness in patients with multiple chronic conditions (MCC), who experience higher morbidity, mortality, and costs. OBJECTIVE: This study aimed to evaluate the impact of an electronic health record (EHR)-integrated, team-based RPM program on patients with hypertension, alone or co-occurring with ischemic heart disease, type 2 diabetes, or both. This study aimed to determine whether referral to the program was associated with reductions in systolic blood pressure (SBP) across these patient groups. METHODS: We analyzed EHR data from patients referred by their primary care physicians to the University of California San Diego Health's Digital Health Program between October 2020 and July 2022. Eligible patients had hypertension, either alone or accompanied by at least 1 coexisting condition, such as ischemic heart disease or type 2 diabetes. Participants received a Bluetooth-enabled BP cuff and ongoing support from a multidisciplinary team, including nurse care managers and a pharmacist. A semiparametric event study design was used to estimate changes in SBP over 24 months, comparing prereferral and postreferral outcomes. To understand the program's impact, outcomes were analyzed for the full cohort of all referred patients and then scaled to reflect the average change in SBP among the program participants. RESULTS: Among patients who had been referred to the program, those with hypertension only experienced an average reduction of 9.70 (SE 0.80) mm Hg in SBP by the end of the analysis horizon of 1 year. Patients with hypertension and either diabetes or ischemic heart disease experienced a reduction of 6.61 (SE 1.12) mm Hg, and those with all 3 conditions experienced a reduction of 6.60 (SE 1.72) mm Hg. The average reductions in SBP among active participants were 16.83 mm Hg, 13.22 mm Hg, and 16.01 mm Hg, respectively. CONCLUSIONS: A team-based, EHR-integrated RPM program was associated with clinically meaningful SBP reductions among patients with MCC. The program leveraged existing EHR workflows for referral and monitoring and provided technical and clinical support to patients. These findings suggest that EHR-integrated RPM services can achieve substantial improvements in BP in high-risk populations. As reimbursement for RPM expands, such models represent a promising strategy for addressing hypertension and the disproportionate burden of MCC at the population level. CI - (c) Ross Graham, Itzik Fadlon, Parag Agnihotri, Christopher A Longhurst, Ming Tai-Seale. Originally published in JMIR Cardio (https://cardio.jmir.org). FAU - Graham, Ross AU - Graham R AUID- ORCID: 0000-0003-4578-7022 AD - Department of Sociology, University of California San Diego, La Jolla, CA, United States. FAU - Fadlon, Itzik AU - Fadlon I AUID- ORCID: 0000-0003-1679-6149 AD - Department of Economics, University of California, San Diego, La Jolla, CA, United States. FAU - Agnihotri, Parag AU - Agnihotri P AUID- ORCID: 0000-0002-6798-5671 AD - Department of Medicine, University of California San Diego, La Jolla, CA, United States. FAU - Longhurst, Christopher A AU - Longhurst CA AUID- ORCID: 0000-0003-4908-6856 AD - Department of Pediatrics, University of California San Diego, La Jolla, CA, United States. AD - Department of Bioinformatics, University of California San Diego Medical Center, La Jolla, CA, United States. FAU - Tai-Seale, Ming AU - Tai-Seale M AUID- ORCID: 0000-0001-9272-066X AD - Department of Bioinformatics, University of California San Diego Medical Center, La Jolla, CA, United States. AD - Department of Family Medicine, University of California San Diego, 9500 Gilman Drive, La Jolla, CA, 92093, United States, 1 6508155485. LA - eng PT - Journal Article DEP - 20251208 PL - Canada TA - JMIR Cardio JT - JMIR cardio JID - 101718325 SB - IM MH - Humans MH - Male MH - Female MH - *Hypertension/physiopathology/therapy/diagnosis MH - Middle Aged MH - Aged MH - Electronic Health Records MH - *Blood Pressure/physiology MH - *Diabetes Mellitus, Type 2/therapy/complications MH - *Patient Care Team MH - *Multiple Chronic Conditions/therapy MH - Myocardial Ischemia MH - Telemedicine PMC - PMC12685231 OTO - NOTNLM OT - digital medicine OT - hypertension OT - multiple chronic conditions OT - remote patient monitoring OT - telemedicine COIS- Conflicts of Interest: None declared. EDAT- 2025/12/08 19:23 MHDA- 2025/12/08 19:24 PMCR- 2025/12/08 CRDT- 2025/12/08 16:14 PHST- 2025/03/29 00:00 [received] PHST- 2025/11/12 00:00 [revised] PHST- 2025/11/13 00:00 [accepted] PHST- 2025/12/08 19:24 [medline] PHST- 2025/12/08 19:23 [pubmed] PHST- 2025/12/08 16:14 [entrez] PHST- 2025/12/08 00:00 [pmc-release] AID - v9i1e75170 [pii] AID - 75170 [pii] AID - 10.2196/75170 [doi] PST - epublish SO - JMIR Cardio. 2025 Dec 8;9:e75170. doi: 10.2196/75170. PMID- 41359816 OWN - NLM STAT- MEDLINE DCOM- 20260804 LR - 20260804 IS - 1545-0066 (Electronic) IS - 1090-3127 (Linking) VI - 30 IP - 6 DP - 2026 TI - Assessing the Influence of a Statewide Dosing Reference Aid on Prehospital Pediatric Medication Dosing Errors: A Mixed-Methods Simulation-Based Investigation. PG - 848-855 LID - 10.1080/10903127.2025.2599515 [doi] AB - OBJECTIVES: Errors occur in 31% of prehospital pediatric medication administrations (PMA) in Michigan despite the implementation of the MI-MEDIC pediatric dosing reference aid. Reference aids may not effectively target the causes of dosing errors and could introduce new types of error. Our study examines the frequency, magnitude, and immediate causes of PMA dosing errors in emergency medical services (EMS) after implementation of the MI-MEDIC dosing reference aid. METHODS: We used a mixed method, mobile simulation-based approach to examine PMA dosing errors. Emergency medical services crews were recruited from a private EMS service and a fire-based EMS service in Michigan. Each crew completed three high-fidelity simulations (infant seizure, infant cardiac arrest and child burn) requiring two doses of midazolam, epinephrine, or fentanyl. Post-simulation interviews were conducted. Error rates and magnitudes were analyzed using descriptive statistics. A multidisciplinary team used a modified Delphi method, incorporating simulation observations, interview recordings, pictures of equipment that were used during the simulations, and protocols to categorize observed errors and reach consensus on their immediate causes. RESULTS: Eleven crews were recruited between both agencies, completing 33 simulations and 66 medication administrations, using the MI-MEDIC dosing reference aid. Dosing errors occurred in 19 of the 66 doses (28.8%), with 13 underdoses (68.4%) and six overdoses (31.6%). The median underdose was 0.50 (95% IQR: 0.20-0.56). The median overdose was 2.00 (95% IQR: 1.40-12.50). After two rounds, Delphi consensus categorized 13 slips (68.4%), six mistakes (31.6%), and no lapses. Immediate causes included crews obtaining the wrong weight (4/19, 21.0%), a large volume of air present in the syringe (6/19, 31.6%) and improper dilution of medications when following instructions on the MI-MEDIC reference aid (6/19, 31.6%). The remaining three involved epinephrine administration directly from the prefilled syringe system (2/19, 10.5%) and an intentional underdose (1/19, 5.3%). CONCLUSIONS: PMA dosing errors persist at a high rate with the use of the MI-MEDIC dosing reference aid. Immediate causes of error involve incorrect weight, administering air, and improper dilution, which tools like the MI-MEDIC dosing reference aid do not address. Further research is needed to develop comprehensive strategies addressing the active errors identified in our study. FAU - Harmer, Bryan M AU - Harmer BM AUID- ORCID: 0000-0003-0094-0337 AD - Department of Paramedicine, College of Nursing, Creighton University, Omaha, Nebraska. FAU - Hoyle, John D Jr AU - Hoyle JD Jr AUID- ORCID: 0000-0003-4948-2533 AD - Department of Emergency Medicine, Western Michigan University Homer Stryker School of Medicine, Kalamazoo, Michigan. FAU - Edwards, Autumn AU - Edwards A AUID- ORCID: 0000-0002-5963-197X AD - School of Communication, Western Michigan University, Kalamazoo, Michigan. FAU - Fredericks, Tycho AU - Fredericks T AD - Department of Industrial and Entrepreneurial Engineering and Engineering Management, College of Engineering and Applied Sciences, Western Michigan University, Kalamazoo, Michigan. FAU - Wells, Lee AU - Wells L AUID- ORCID: 0000-0002-0509-4769 AD - Department of Industrial and Entrepreneurial Engineering and Engineering Management, College of Engineering and Applied Sciences, Western Michigan University, Kalamazoo, Michigan. FAU - Lecznar, Adam AU - Lecznar A AUID- ORCID: 0000-0001-7496-4986 AD - Department of Industrial and Entrepreneurial Engineering and Engineering Management, College of Engineering and Applied Sciences, Western Michigan University, Kalamazoo, Michigan. FAU - Christopher, Kathryn AU - Christopher K AUID- ORCID: 0009-0009-0618-7930 AD - Department of Industrial and Entrepreneurial Engineering and Engineering Management, College of Engineering and Applied Sciences, Western Michigan University, Kalamazoo, Michigan. FAU - Dunwoody, Sue AU - Dunwoody S AUID- ORCID: 0009-0003-7214-0336 AD - Department of Emergency Medicine, Western Michigan University Homer Stryker School of Medicine, Kalamazoo, Michigan. FAU - Hong, Guan AU - Hong G AD - Department of Computer Science, College of Engineering and Applied Sciences, Western Michigan University, Kalamazoo, Michigan. FAU - Rantz, William AU - Rantz W AD - Department of Aviation Sciences, College of Aviation, Western Michigan University, Battle Creek, Michigan. FAU - Popov, Vitaliy AU - Popov V AUID- ORCID: 0000-0003-2348-5285 AD - Department of Learning Health Sciences, University of Michigan Medical School, University of Michigan, Ann Arbor, Michigan. FAU - Mahajan, Prashant AU - Mahajan P AUID- ORCID: 0000-0003-4278-3560 AD - Department of Emergency Medicine, University of Michigan Medical School, University of Michigan, Ann Arbor, Michigan. FAU - Fogarty, Kieran AU - Fogarty K AUID- ORCID: 0000-0002-1364-6076 AD - Interdisciplinary Health Sciences, College of Health and Human Services, Western Michigan University, Kalamazoo, Michigan. LA - eng PT - Journal Article DEP - 20260309 PL - England TA - Prehosp Emerg Care JT - Prehospital emergency care JID - 9703530 RN - YKH834O4BH (Epinephrine) SB - IM MH - Humans MH - *Medication Errors/prevention & control/statistics & numerical data MH - *Emergency Medical Services/standards MH - Michigan MH - Epinephrine/administration & dosage MH - Infant MH - Child EDAT- 2025/12/08 19:23 MHDA- 2026/08/09 15:03 CRDT- 2025/12/08 14:52 PHST- 2026/08/09 15:03 [medline] PHST- 2025/12/08 19:23 [pubmed] PHST- 2025/12/08 14:52 [entrez] AID - 10.1080/10903127.2025.2599515 [doi] PST - ppublish SO - Prehosp Emerg Care. 2026;30(6):848-855. doi: 10.1080/10903127.2025.2599515. Epub 2026 Mar 9. PMID- 41356306 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251208 LR - 20260925 IS - 2153-8174 (Electronic) IS - 1530-6550 (Print) IS - 1530-6550 (Linking) VI - 26 IP - 11 DP - 2025 Nov TI - Cardiovascular Complications from Tuberculosis. PG - 44092 LID - 10.31083/RCM44092 [doi] LID - 44092 AB - Tuberculosis (TB) is a contagious disease caused by Mycobacterium tuberculosis (M. tuberculosis) and is transmitted through airborne particles. Although TB usually damages the lungs, this disease can also cause complications in various organs, including the cardiovascular system. Indeed, pericarditis represents the most frequently reported cardiac manifestation of TB, and may present alongside fever, dyspnea, cough, or increased central venous pressure, hepatomegaly, and peripheral edema. Tuberculous-related pericarditis treatment is challenging due to the poor penetration of anti-tuberculous drugs into the pericardium. Myocarditis is another form of cardiac manifestation and is often associated with arrhythmias. Tuberculous aortitis typically causes dilatation leading to pseudoaneurysm formation and is usually asymptomatic; however, this manifestation can result in sepsis, aortic rupture, or even death, although rarely. Cardiac tuberculomas may present with general symptoms and can impair heart function by obstructing the outflow tracts, leading to ventricular dysfunction. Additionally, the primary treatment of TB carries cardiotoxicity risks, such as various arrhythmias. Moreover, TB significantly increases the risk of cardiovascular conditions, including myocardial infarction and coronary artery obstruction. Therefore, early recognition and a multidisciplinary approach are crucial to prevent severe outcomes such as sudden cardiac death, sepsis, or aortic rupture. Thus, this review highlights the spectrum of TB-related cardiac complications and underscores the importance of greater awareness and timely multidisciplinary care. CI - Copyright: (c) 2025 The Author(s). Published by IMR Press. FAU - Mikalajunaite, Germante AU - Mikalajunaite G AUID- ORCID: 0009-0004-8681-2575 AD - Institute of Clinical Medicine, Clinic of Cardiac and Vascular Diseases, Faculty of Medicine, Vilnius University, 03101 Vilnius, Lithuania. FAU - Rinkuniene, Egidija AU - Rinkuniene E AUID- ORCID: 0000-0002-4362-8143 AD - Institute of Clinical Medicine, Clinic of Cardiac and Vascular Diseases, Faculty of Medicine, Vilnius University, 03101 Vilnius, Lithuania. AD - Clinic of Cardiac and Vascular Diseases, Vilnius University Hospital Santaros Klinikos, 08406 Vilnius, Lithuania. AD - Center of Cardiology and Angiology, Vilnius University Hospital Santaros Klinikos, 08406 Vilnius, Lithuania. FAU - Cypiene, Alma AU - Cypiene A AUID- ORCID: 0000-0001-5697-3731 AD - Institute of Clinical Medicine, Clinic of Cardiac and Vascular Diseases, Faculty of Medicine, Vilnius University, 03101 Vilnius, Lithuania. AD - Clinic of Cardiac and Vascular Diseases, Vilnius University Hospital Santaros Klinikos, 08406 Vilnius, Lithuania. AD - Center of Cardiology and Angiology, Vilnius University Hospital Santaros Klinikos, 08406 Vilnius, Lithuania. FAU - Dzenkeviciute, Vilma AU - Dzenkeviciute V AUID- ORCID: 0000-0003-1471-9131 AD - Institute of Clinical Medicine, Clinic of Cardiac and Vascular Diseases, Faculty of Medicine, Vilnius University, 03101 Vilnius, Lithuania. AD - Clinic of Cardiac and Vascular Diseases, Vilnius University Hospital Santaros Klinikos, 08406 Vilnius, Lithuania. AD - Center of Cardiology and Angiology, Vilnius University Hospital Santaros Klinikos, 08406 Vilnius, Lithuania. FAU - Badariene, Jolita AU - Badariene J AUID- ORCID: 0000-0003-1184-9803 AD - Institute of Clinical Medicine, Clinic of Cardiac and Vascular Diseases, Faculty of Medicine, Vilnius University, 03101 Vilnius, Lithuania. AD - Clinic of Cardiac and Vascular Diseases, Vilnius University Hospital Santaros Klinikos, 08406 Vilnius, Lithuania. AD - Center of Cardiology and Angiology, Vilnius University Hospital Santaros Klinikos, 08406 Vilnius, Lithuania. LA - eng PT - Journal Article PT - Review DEP - 20251125 PL - Singapore TA - Rev Cardiovasc Med JT - Reviews in cardiovascular medicine JID - 100960007 PMC - PMC12680977 OTO - NOTNLM OT - aortitis OT - cardiovascular complications OT - myocarditis OT - pericarditis OT - tuberculosis COIS- The authors declare no conflict of interest. EDAT- 2025/12/08 13:20 MHDA- 2025/12/08 13:21 PMCR- 2025/11/25 CRDT- 2025/12/08 06:09 PHST- 2025/06/20 00:00 [received] PHST- 2025/09/17 00:00 [revised] PHST- 2025/09/25 00:00 [accepted] PHST- 2025/12/08 13:21 [medline] PHST- 2025/12/08 13:20 [pubmed] PHST- 2025/12/08 06:09 [entrez] PHST- 2025/11/25 00:00 [pmc-release] AID - S1530-6550(25)02059-9 [pii] AID - 10.31083/RCM44092 [doi] PST - epublish SO - Rev Cardiovasc Med. 2025 Nov 25;26(11):44092. doi: 10.31083/RCM44092. eCollection 2025 Nov. PMID- 41356289 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251208 LR - 20251210 IS - 2153-8174 (Electronic) IS - 1530-6550 (Print) IS - 1530-6550 (Linking) VI - 26 IP - 11 DP - 2025 Nov TI - Expert Review of the Strategies to Optimize Long-Term Outcomes After Coronary Artery Bypass Grafting. PG - 39887 LID - 10.31083/RCM39887 [doi] LID - 39887 AB - Coronary artery bypass grafting (CABG) remains a cornerstone in the treatment of advanced ischemic heart disease, offering durable and effective revascularization. Despite surgical success, long-term patient outcomes are often shaped by the progression of native coronary disease and the development of comorbid conditions. This narrative review explores seven critical domains in secondary prevention following CABG: Early recognition of postoperative complications, evidence-based pharmacotherapy, management of atrial fibrillation, lifestyle modification, psychological well-being, preservation of ventricular function, and collaboration within the multidisciplinary team. Effective secondary prevention can significantly reduce the risk of further cardiovascular events and support the longevity of the graft. Interventions such as lipid management, smoking cessation, and structured cardiac rehabilitation promote both physiological recovery and emotional resilience. Timely treatment of arrhythmias and ventricular dysfunction further reduces the risk of heart failure and recurrent ischemia. Primary care practitioners are uniquely positioned to lead the delivery of long-term secondary prevention. By integrating evidence-based strategies into routine care, these strategies can play a pivotal role in improving quality of life and long-term outcomes for post-CABG patients. CI - Copyright: (c) 2025 The Author(s). Published by IMR Press. FAU - Mokhtassi, Shiva Seyed AU - Mokhtassi SS AUID- ORCID: 0009-0004-7997-1922 AD - Department of Cardiothoracic Surgery, Harefield Hospital, Royal Brompton, and Harefield as Part of Guys and St Thomas NHS Trust, UB9 6JH London, UK. AD - Department of Cardiothoracic Surgery, St George's University Hospitals NHS Foundation Trust, SW17 0QT London, UK. FAU - Bulut, Halil Ibrahim AU - Bulut HI AD - Department of Cardiothoracic Surgery, Harefield Hospital, Royal Brompton, and Harefield as Part of Guys and St Thomas NHS Trust, UB9 6JH London, UK. FAU - Salmasi, Yousuf AU - Salmasi Y AD - Department of Cardiothoracic Surgery, Harefield Hospital, Royal Brompton, and Harefield as Part of Guys and St Thomas NHS Trust, UB9 6JH London, UK. AD - National Heart & Lung Institute, Imperial College, SW3 6LY London, UK. AD - Department of Cardiothoracic Surgery, Hammersmith Hospital as Part of Imperial College Healthcare NHS Trust, W12 0HS London, UK. FAU - Khoshbin, Espeed AU - Khoshbin E AD - Department of Cardiothoracic Surgery, Harefield Hospital, Royal Brompton, and Harefield as Part of Guys and St Thomas NHS Trust, UB9 6JH London, UK. AD - National Heart & Lung Institute, Imperial College, SW3 6LY London, UK. LA - eng PT - Journal Article PT - Review DEP - 20251127 PL - Singapore TA - Rev Cardiovasc Med JT - Reviews in cardiovascular medicine JID - 100960007 PMC - PMC12680989 OTO - NOTNLM OT - coronary artery bypass grafting OT - medical management OT - secondary prevention COIS- The authors declare no conflict of interest. EDAT- 2025/12/08 13:19 MHDA- 2025/12/08 13:20 PMCR- 2025/11/27 CRDT- 2025/12/08 06:09 PHST- 2025/04/22 00:00 [received] PHST- 2025/08/22 00:00 [revised] PHST- 2025/08/26 00:00 [accepted] PHST- 2025/12/08 13:20 [medline] PHST- 2025/12/08 13:19 [pubmed] PHST- 2025/12/08 06:09 [entrez] PHST- 2025/11/27 00:00 [pmc-release] AID - S1530-6550(25)02002-2 [pii] AID - 10.31083/RCM39887 [doi] PST - epublish SO - Rev Cardiovasc Med. 2025 Nov 27;26(11):39887. doi: 10.31083/RCM39887. eCollection 2025 Nov. PMID- 41355285 OWN - NLM STAT- MEDLINE DCOM- 20260209 LR - 20260819 IS - 2047-2412 (Electronic) IS - 2047-2404 (Linking) VI - 27 IP - 2 DP - 2026 Feb 9 TI - Current and future use of artificial intelligence in valvular heart disease imaging. PG - 319-329 LID - 10.1093/ehjci/jeaf348 [doi] AB - Valvular heart disease (VHD) remains significantly underdiagnosed and undertreated. This review examines an artificial intelligence (AI)-enhanced 'spoke-hub-node' care model designed to improve the early detection, risk stratification, and treatment of VHD. In this model, AI tools-such as automated ECG interpretation, digital stethoscopes, and point-of-care ultrasound-facilitate decentralized screening and referral for cardiac imaging at the community level. During the transition from outpatient settings to tertiary care centres, AI-integrated echocardiography, cardiac tomography, and magnetic resonance imaging facilitate advanced diagnostic evaluation and inform procedural planning. We review emerging innovations that can enhance this model of care delivery-including unsupervised machine learning to uncover novel VHD phenotypes, generative AI for automated reporting, the use of digital twins to simulate interventions, and the integration of multiple AI agents to support heart team meetings. These advances are followed by the emerging use of AI in robotic transoesophageal and intracardiac echocardiography, as well as in fusion fluoroscopy imaging, to guide valve interventions. While outlining the challenges inherent in this rapidly evolving field, the review's central contribution is its vision to connect the continuum-from AI-enabled community screening to personalized, image-guided therapies at tertiary care centres-offering a scalable and equitable model for VHD care. CI - (c) The Author(s) 2025. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com. FAU - Sengupta, Partho P AU - Sengupta PP AUID- ORCID: 0000-0003-2291-5001 AD - Division of Cardiovascular Diseases and Hypertension, Rutgers Robert Wood Johnson Medical School, 125 Patterson St, New Brunswick, NJ 08901, USA. AD - Cardiovascular Services, Robert Wood Johnson University Hospital, 1 Robert Wood Johnson Place, New Brunswick, NJ 08901, USA. FAU - Poterucha, Timothy AU - Poterucha T AD - Department of Cardiovascular Diseases, Mayo Clinic College of Medicine, Rochester, MN 55905, USA. FAU - Pezel, Theo AU - Pezel T AD - MIRACL.ai Laboratory, Multimodality Imaging for Research and Analysis Core Laboratory and Artificial Intelligence (AP-HP), Universite Paris Cite, Paris, France. AD - Department of Cardiology, University Hospital of Lariboisiere (AP-HP), Paris, France. AD - Universite Paris Cite, Inserm MASCOT-UMRS 942, 75010 Paris, France. FAU - Tsang, Teresa S M AU - Tsang TSM AD - Department of Medicine, University of British Columbia and Vancouver General Hospital Artificial Intelligence Echocardiography Core Laboratory, Vancouver, BC, Canada V5Z 1M9. AD - Division of Cardiology, University of British Columbia, Vancouver, BC, Canada V6T 1Z4. FAU - Cosyns, Bernard AU - Cosyns B AD - Department of Cardiology, Centrum Voor Hart-en Vaatziekten, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel (VUB), Laarbeeklaan 101, Brussels 1090, Belgium. LA - eng GR - National Institute of Health/ GR - 1R01HL173998-01A1/HL/NHLBI NIH HHS/United States GR - 3U01HL088942-17S/National Heart, Lung and Blood Institute/ GR - 1P50MD017356-01/National Heart, Lung and Blood Institute/ GR - National Science Foundation/ GR - Advisory Board of RCE Technologies/ GR - HeartSciences/ GR - RCE Technologies/ GR - HeartSciences/ GR - Butterfly/ GR - MindMics/ GR - US8328724B2/Mayo Clinic/ GR - US11445918B2/HeartSciences/ GR - 62/864,771; US202163152686P; WO2022182603A1; US202163211829P; WO2022266288A1/Rutgers Health/ GR - US202163212228P/Rutgers Health/ GR - Pfizer/ GR - Eidos Therapeutics/ GR - Janssen/ GR - American Heart Association/ GR - Tianqiao and Chrissy Chen Foundation/ GR - Baxter/ GR - Abbott Laboratories/ GR - AstraZeneca/ GR - Bayer/ GR - Bristol-Myers Squibb/ GR - Siemens Healthineers/ GR - General Electric/ GR - Bayer/ GR - Servier/ GR - PJT 180316; VR2-172716; VS1-175509; VS2-175578; PJT 525384/Canadian Institutes of Health/ GR - Genome BC/ GR - Genome Canada/ GR - Canadian Precision Health Initiative/ GR - Montreal Heart Institute/ GR - 02315-000/CIHR/Canada GR - Sanofi Canada/ GR - Takeda Canada/ GR - US 11,129,591 B2/University of British Columbia/ GR - US 11,367,001 B2/University of British Columbia/ GR - US 10,751,029 B2)/University of British Columbia/ PT - Journal Article PT - Review PL - England TA - Eur Heart J Cardiovasc Imaging JT - European heart journal. Cardiovascular Imaging JID - 101573788 SB - IM MH - Humans MH - *Artificial Intelligence/trends MH - *Heart Valve Diseases/diagnostic imaging MH - Forecasting MH - *Cardiac Imaging Techniques/methods/trends MH - Echocardiography/methods MH - Risk Assessment OTO - NOTNLM OT - artificial imaging OT - deep learning OT - valvular heart disease COIS- Conflict of interest: P.P.S. is supported by grants from National Institute of Health/National Heart, Lung and Blood Institute (Awards 1R01HL173998-01A1, 3U01HL088942-17S, and 1P50MD017356-01) and National Science Foundation United States [Award (#2125872)]. He has served on the Advisory Board of RCE Technologies and HeartSciences and holds stock options; received grants or contracts from RCE Technologies, HeartSciences, Butterfly, and MindMics; and hold patents with Mayo Clinic (US8328724B2), HeartSciences (US11445918B2), and Rutgers Health (62/864,771; US202163152686P; WO2022182603A1; US202163211829P; WO2022266288A1; and US202163212228P). T.J.P. has research grant funds paid to affiliated institutions by Pfizer, Eidos Therapeutics, Janssen, the American Heart Association, and the Tianqiao and Chrissy Chen Foundation, has stock ownership in Baxter and Abbott Laboratories, and is an inventor on a patent to use ECG analysis to detect structural heart disease. T.P. reports receiving consulting and lecture fees from AstraZeneca, Bayer, Bristol-Myers Squibb/Pfizer, Siemens Healthineers, General Electric, and grants from Bayer and Servier. T.S.M.T. is supported by grants from Canadian Institutes of Health (PJT 180316; VR2-172716; VS1-175509; VS2-175578; PJT 525384); Genome BC (GeneSolve Program); and Genome Canada (Canadian Precision Health Initiative, Pillar 1). She has grants or contracts with Montreal Heart Institute (CIHR Agreement number 02315-000), Sanofi Canada, Takeda Canada; and holds patents with University of British Columbia (Patent No.: US 11,129,591 B2; US 11,367,001 B2; Patent No.: US 10,751,029 B2). EDAT- 2025/12/08 06:27 MHDA- 2026/02/09 18:49 CRDT- 2025/12/08 01:57 PHST- 2025/08/07 00:00 [received] PHST- 2025/10/14 00:00 [revised] PHST- 2025/11/05 00:00 [accepted] PHST- 2026/02/09 18:49 [medline] PHST- 2025/12/08 06:27 [pubmed] PHST- 2025/12/08 01:57 [entrez] AID - 8373645 [pii] AID - 10.1093/ehjci/jeaf348 [doi] PST - ppublish SO - Eur Heart J Cardiovasc Imaging. 2026 Feb 9;27(2):319-329. doi: 10.1093/ehjci/jeaf348. PMID- 41348043 OWN - NLM STAT- MEDLINE DCOM- 20251205 LR - 20260718 IS - 1520-4383 (Electronic) IS - 1520-4391 (Print) IS - 1520-4383 (Linking) VI - 2025 IP - 1 DP - 2025 Dec 5 TI - The aging hemophilia patient. PG - 674-681 LID - 10.1182/hematology.2025000773 [doi] AB - Advances in the development of safe and effective treatments for hemophilia over the past century have significantly increased the life expectancy of persons with hemophilia (PwH). As a result, clinicians are now encountering age-related comorbidities that were previously uncommon in hemophilia care, including cardiovascular disease, malignancy, and renal disease. Managing this aging population of PwH requires addressing both the complications of hemophilia and the multifaceted effects of aging. Their care needs have become increasingly complex, requiring attention to broader aspects of health, such as liver and bone health, fall and fracture risk, and frailty. However, preventive care, including routine monitoring and treatment of these conditions, is a gap in the current care model for this population. Inadequate access to primary care physicians negatively impacts the management and prevention of chronic diseases in PwH, resulting in medical vulnerability. The focus of this review is to examine prevalent complications in the aging PwH. Case studies presented focus on identifying and reducing cardiovascular disease risk, weighing bleeding risk with stroke risk in the management of atrial fibrillation, and ensuring a multidisciplinary approach to address frailty, bone health, and orthopedic surgery in the aging PwH. As we enter a new era of therapeutics, hemophilia treatment centers will play an integral role in closing care gaps in helping PwH achieve optimal outcomes. CI - Copyright (c) 2025 by The American Society of Hematology. FAU - Lewandowska, Magdalena AU - Lewandowska M AD - Innovative Hematology/Indiana Hemophilia & Thrombosis Center, Indianapolis, IN. FAU - Lim, Ming Y AU - Lim MY AD - Department of Internal Medicine, Division of Hematology and Hematologic Malignancies, University of Utah, Salt Lake City, UT. LA - eng PT - Journal Article PT - Review PL - United States TA - Hematology Am Soc Hematol Educ Program JT - Hematology. American Society of Hematology. Education Program JID - 100890099 SB - IM MH - Aged MH - Humans MH - Male MH - *Aging MH - Atrial Fibrillation/therapy MH - Cardiovascular Diseases MH - *Hemophilia A/therapy/complications MH - Hemorrhage PMC - PMC12891591 COIS- Magdalena Lewandowska: does not accept honoraria personally and has served as a consultant for Alnylam and Roche/Genentech, advisory board member for HEMA biologics, and speaker for Pfizer and Novo Nordisk. Ming Y. Lim: has received honorarium for participation in advisory boards for Hema Biologics, BioMarin, Sanofi, Takeda, and SeraGene. EDAT- 2025/12/05 13:07 MHDA- 2025/12/05 13:08 PMCR- 2025/12/02 CRDT- 2025/12/05 10:24 PHST- 2025/12/05 13:08 [medline] PHST- 2025/12/05 13:07 [pubmed] PHST- 2025/12/05 10:24 [entrez] PHST- 2025/12/02 00:00 [pmc-release] AID - 556916 [pii] AID - 2025000773 [pii] AID - 10.1182/hematology.2025000773 [doi] PST - ppublish SO - Hematology Am Soc Hematol Educ Program. 2025 Dec 5;2025(1):674-681. doi: 10.1182/hematology.2025000773. PMID- 41346367 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260919 IS - 2640-1002 (Electronic) IS - 2640-1002 (Linking) VI - 8 IP - 3 DP - 2025 TI - A "Watchful Surgery" Approach: Timing and Valve Choice for Mildly Symptomatic Mitral and Aortic Valve Disease. PG - 460-476 LID - 10.26502/jsr.10020472 [doi] AB - The timing of surgical intervention and prosthesis selection in mildly symptomatic aortic and mitral valve disease remain an area of clinical uncertainty. Symptom-based referral often occurs after the onset of adverse ventricular remodeling, whereas earlier surgery may improve long-term outcomes but introduces procedural risk. This article synthesized contemporary evidence to delineate optimal strategies in this intermediate-risk population. In aortic stenosis, randomized trials including RECOVERY and AVATAR demonstrate that early surgical aortic valve replacement reduces heart failure events and may improve survival. In aortic and mitral regurgitation, observational data associate early intervention, triggered by mild symptoms or subclinical ventricular dysfunction, with improved survival and preservation of cardiac function. Emerging modalities such as global longitudinal strain and natriuretic peptide biomarkers enhance risk stratification in asymptomatic individuals. Prosthesis selection is primarily informed by patient age, comorbidity burden, and anticoagulation tolerance. Mechanical valves confer superior durability and lower reoperation risk in younger patients. Bioprosthetic valves are increasingly favored in older adults due to compatibility with transcatheter valve-in-valve reintervention and avoidance of lifelong anticoagulation. Comparative cohort studies and meta-analyses suggest a survival benefit for mechanical valves up to approximately 65-to-70 years of age, beyond which the benefit diminishes due to competing mortality risks. Evidence supports timely surgical referral in mildly symptomatic patients, particularly in the presence of early imaging or biomarker evidence of ventricular dysfunction. Individualized decision-making through multidisciplinary heart team evaluation remains essential. Further investigations are warranted to define long-term prosthetic durability and the role of early surgery in valvular regurgitation. FAU - Mukadam, Shaanali AU - Mukadam S AD - Department of Translational Research, College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, California 91766 USA. FAU - Kim, Chang Kon AU - Kim CK AD - Department of Translational Research, College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, California 91766 USA. FAU - Agrawal, Devendra K AU - Agrawal DK AD - Department of Translational Research, College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, California 91766 USA. LA - eng GR - R25 AI179582/AI/NIAID NIH HHS/United States PT - Journal Article DEP - 20250922 PL - United States TA - J Surg Res (Houst) JT - Journal of surgery and research JID - 101768933 PMC - PMC12674204 MID - NIHMS2117987 OTO - NOTNLM OT - Aortic valve insufficiency OT - Aortic valve stenosis OT - Early surgical intervention OT - Heart valve prosthesis OT - Mitral regurgitation OT - Mitral valve insufficiency OT - Mitral valve stenosis OT - Surgical aortic valve replacement (SAVR) OT - Transcatheter Aortic valve replacement (TAVR) OT - Valve-in-valve procedures OT - Ventricular remodeling COIS- Competing interests and declaration All authors have read the manuscript and declare no conflict of interest. The python-docx program was used to read, edit, and update the original draft of the manuscript. EDAT- 2025/12/05 06:26 MHDA- 2025/12/05 06:27 PMCR- 2025/12/04 CRDT- 2025/12/05 04:24 PHST- 2025/12/05 06:27 [medline] PHST- 2025/12/05 06:26 [pubmed] PHST- 2025/12/05 04:24 [entrez] PHST- 2025/12/04 00:00 [pmc-release] AID - 10.26502/jsr.10020472 [doi] PST - ppublish SO - J Surg Res (Houst). 2025;8(3):460-476. doi: 10.26502/jsr.10020472. Epub 2025 Sep 22. PMID- 41345995 OWN - NLM STAT- MEDLINE DCOM- 20260116 LR - 20260120 IS - 2040-0861 (Electronic) IS - 1074-4797 (Linking) VI - 45 IP - 3 DP - 2026 Jan TI - Uncovering safety risks across multispecialty: A Human Factor Analysis and Classification System (HFACS) based observational study in cardiovascular, orthopedic, trauma care, and neurosurgical environments. PG - 5-15 LID - 10.1002/jhrm.70018 [doi] AB - Despite significant progress in patient safety, human error continues to occur at high rates in surgical settings. The Human Factors Analysis and Classification System (HFACS) offers a proactive lens to understand how and where errors emerge. This study examines HFACS's utility and reliability in categorizing and comparing human error in cardiovascular, orthopedic, trauma care, and neurosurgery. Observational data from cardiovascular, orthopedic, trauma, and neurosurgery cases were coded using HFACS by trained analysts applying unanimous, majority, and reconciled consensus strategies to assess interrater reliability. Across specialties, 98.25% of disruptions occurred at the "preconditions for unsafe acts," indicating latent failures. In cardiovascular surgery, 49.20% were linked to adverse mental states (e.g., cognitive overload, stress), 26.95% to physical environment issues, and 12.69% to crew resource management. Orthopedic surgery showed 68.75% of crew resource management failures, 19.47% personal readiness issues, and 5.87% environment stressors. Trauma care involved 61.38% crew resource management, 26.71% adverse mental states, and 10.33% team availability. Neurosurgery disruptions stemmed 59.42% from technological environment/layout and 35.92% from communication, coordination, and planning. HFACS is a reliable tool for categorizing human factors in diverse surgical environments. Findings highlight distinct latent failure profiles across specialties and underscore the importance of data driven specialty-specific safety interventions. CI - (c) 2025 American Society for Health Care Risk Management. FAU - Khan, Asfand AU - Khan A AD - Department of Human Factors and Behavioral Neurobiology, Embry Riddle Aeronautical University, Project Manager at AdventHealth, Embry Riddle Aeronautical University, Daytona Beach, Florida, USA. FAU - Cohen, Tara AU - Cohen T AD - Associate Professor Surgery, Director, Simulation Research Surgery, Director, Surgical Safety and Human Factors Research, Cedar-Sinai Medical Center, Los Angeles, California, USA. FAU - Shappell, Scott A AU - Shappell SA AD - Chair Department of Human Factors and Behavioral Neurobiology, Embry Riddle Aeronautical University, Daytona Beach, Florida, USA. FAU - Boquet, Albert J AU - Boquet AJ AD - Professor of Human Factors and Behavioral Neurobiology, Embry Riddle Aeronautical University, Daytona Beach, Florida, USA. LA - eng PT - Journal Article PT - Observational Study DEP - 20251204 PL - United States TA - J Healthc Risk Manag JT - Journal of healthcare risk management : the journal of the American Society for Healthcare Risk Management JID - 9305245 SB - IM MH - Humans MH - *Patient Safety MH - *Medical Errors/classification/prevention & control/statistics & numerical data MH - Factor Analysis, Statistical MH - Orthopedics MH - Orthopedic Procedures MH - Neurosurgery MH - Reproducibility of Results MH - Neurosurgical Procedures EDAT- 2025/12/05 06:27 MHDA- 2026/01/16 15:04 CRDT- 2025/12/05 00:29 PHST- 2025/08/15 00:00 [revised] PHST- 2025/08/15 00:00 [received] PHST- 2025/11/17 00:00 [accepted] PHST- 2026/01/16 15:04 [medline] PHST- 2025/12/05 06:27 [pubmed] PHST- 2025/12/05 00:29 [entrez] AID - 10.1002/jhrm.70018 [doi] PST - ppublish SO - J Healthc Risk Manag. 2026 Jan;45(3):5-15. doi: 10.1002/jhrm.70018. Epub 2025 Dec 4. PMID- 41342904 OWN - NLM STAT- MEDLINE DCOM- 20260202 LR - 20260202 IS - 1827-1898 (Electronic) IS - 0031-0808 (Linking) VI - 67 IP - 4 DP - 2025 Dec TI - Physical activity and cardiac rehabilitation after myocardial infarction: the risk of obtaining large benefits. PG - 245-253 LID - 10.23736/S0031-0808.25.05381-9 [doi] AB - Cardiac rehabilitation (CR) is a cornerstone in the management of patients recovering from myocardial infarction (MI), significantly improving survival, functional capacity, and quality of life. Recent evidence highlights the critical importance of early initiation of rehabilitation, ideally within days to weeks following the acute event. Early cardiac rehabilitation facilitates prompt recovery of cardiovascular function, reduces complications, and enhances patient motivation and adherence to therapeutic regimens. The multidimensional nature of modern CR programs addresses not only physical reconditioning but also psychological, nutritional, and social factors, recognizing the complex interplay affecting patient outcomes. Physical exercise training, tailored to individual risk profiles and functional status, promotes myocardial perfusion, endothelial function, and autonomic balance. Concurrently, psychosocial support targets anxiety, depression, and stress, common sequelae post-MI, which are known to influence prognosis negatively. Nutritional counseling ensures optimal dietary patterns that support cardiovascular health, while smoking cessation and risk factor management are integral components. The multidisciplinary team - comprising cardiologists, physiotherapists, dietitians, psychologists, and nurses - collaborates to develop personalized care plans that maximize patient engagement and long-term adherence. Early, multidimensional cardiac rehabilitation ultimately reduces rehospitalization rates and mortality, improving comprehensive health outcomes. This review underscores the value of initiating rehabilitation promptly after MI and implementing a holistic approach to enhance recovery, prevent recurrent events, and promote sustained lifestyle changes. FAU - Tonet, Elisabetta AU - Tonet E AD - Cardiology Unit, Azienda Ospedaliero Universitaria of Ferrara, Ferrara, Italy - tonet.elisabetta@gmail.com. FAU - Sabato, Federica AU - Sabato F AD - Clinical Hildebrand Rehabilitation Center Brissago, Brissago, Switzerland. FAU - Canovi, Luca AU - Canovi L AD - Cardiology Unit, Azienda Ospedaliero Universitaria of Ferrara, Ferrara, Italy. FAU - Guidi Colombi, Gabriele AU - Guidi Colombi G AD - Cardiology Unit, Azienda Ospedaliero Universitaria of Ferrara, Ferrara, Italy. FAU - Campo, Gianluca AU - Campo G AD - Cardiology Unit, Azienda Ospedaliero Universitaria of Ferrara, Ferrara, Italy. FAU - Guardigli, Gabriele AU - Guardigli G AD - Cardiology Unit, Azienda Ospedaliero Universitaria of Ferrara, Ferrara, Italy. FAU - Perone, Francesco AU - Perone F AD - Cardiac Rehabilitation Unit, Rehabilitation Clinic 'Villa delle Magnolie', Castel Morrone, Caserta, Italy. LA - eng PT - Journal Article PT - Review DEP - 20251204 PL - Italy TA - Panminerva Med JT - Panminerva medica JID - 0421110 SB - IM MH - Humans MH - *Myocardial Infarction/rehabilitation/physiopathology/psychology/diagnosis MH - *Cardiac Rehabilitation/methods/adverse effects MH - *Exercise MH - Risk Factors MH - Treatment Outcome MH - Quality of Life MH - *Exercise Therapy MH - Recovery of Function MH - Time Factors EDAT- 2025/12/04 13:37 MHDA- 2026/02/03 00:00 CRDT- 2025/12/04 11:07 PHST- 2026/02/03 00:00 [medline] PHST- 2025/12/04 13:37 [pubmed] PHST- 2025/12/04 11:07 [entrez] AID - S0031-0808.25.05381-9 [pii] AID - 10.23736/S0031-0808.25.05381-9 [doi] PST - ppublish SO - Panminerva Med. 2025 Dec;67(4):245-253. doi: 10.23736/S0031-0808.25.05381-9. Epub 2025 Dec 4. PMID- 41341567 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251204 LR - 20260925 IS - 2050-0904 (Print) IS - 2050-0904 (Electronic) IS - 2050-0904 (Linking) VI - 13 IP - 12 DP - 2025 Dec TI - Successful Surgical Repair of Ventricular Septal Defect in a Child With Ocular Myasthenia Gravis and History of Myeloid Sarcoma Post-HSCT: A Multidisciplinary Approach. PG - e71589 LID - 10.1002/ccr3.71589 [doi] LID - e71589 AB - A 3 year-old child with ocular myasthenia gravis and a history of hematopoietic stem cell transplantation underwent successful ventricular septal defect repair through carefully coordinated multidisciplinary management. The tailored anesthetic approach and infection-control strategy enabled smooth recovery without neuromuscular or immunologic complications. This case demonstrates the feasibility of safe cardiac surgery in pediatric patients with rare, high-risk comorbidities. CI - (c) 2025 The Author(s). Clinical Case Reports published by John Wiley & Sons Ltd. FAU - Rong, Shuhan AU - Rong S AUID- ORCID: 0009-0009-2760-1408 AD - Cardiothoracic Surgery Department Children's Hospital of Soochow University, Suzhou Jiangsu Province China. FAU - Xu, Wanyu AU - Xu W AD - Cardiothoracic Surgery Department Children's Hospital of Soochow University, Suzhou Jiangsu Province China. FAU - Li, Xin AU - Li X AD - Cardiothoracic Surgery Department Children's Hospital of Soochow University, Suzhou Jiangsu Province China. LA - eng PT - Journal Article DEP - 20251201 PL - England TA - Clin Case Rep JT - Clinical case reports JID - 101620385 PMC - PMC12669070 OTO - NOTNLM OT - hematopoietic stem cell transplantation OT - multidisciplinary management OT - ocular myasthenia gravis OT - pediatric cardiac surgery OT - ventricular septal defect COIS- The authors declare no conflicts of interest. EDAT- 2025/12/04 06:27 MHDA- 2025/12/04 06:28 PMCR- 2025/12/01 CRDT- 2025/12/04 04:55 PHST- 2025/06/12 00:00 [received] PHST- 2025/11/03 00:00 [revised] PHST- 2025/11/20 00:00 [accepted] PHST- 2025/12/04 06:28 [medline] PHST- 2025/12/04 06:27 [pubmed] PHST- 2025/12/04 04:55 [entrez] PHST- 2025/12/01 00:00 [pmc-release] AID - CCR371589 [pii] AID - 10.1002/ccr3.71589 [doi] PST - epublish SO - Clin Case Rep. 2025 Dec 1;13(12):e71589. doi: 10.1002/ccr3.71589. eCollection 2025 Dec. PMID- 41340689 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251204 LR - 20251206 IS - 1731-5530 (Print) IS - 1897-4252 (Electronic) IS - 1731-5530 (Linking) VI - 22 IP - 3 DP - 2025 Sep TI - Position paper of the Polish Society of Cardiothoracic Surgeons and the Heart Rhythm Association of the Polish Society of Cardiology on atrial fibrillation hybrid management. PG - 143-157 LID - 10.5114/kitp.2025.155459 [doi] AB - This position paper, jointly authored by the Polish Society of Cardiothoracic Surgeons and the Heart Rhythm Association of the Polish Society of Cardiology, defines the role of hybrid approaches in the treatment of cardiac arrhythmias, particularly atrial fibrillation. We present a rationale for integrating epicardial and endocardial ablation strategies, summarize current evidence, and advocate for multidisciplinary planning, including arrhythmia treatment during cardiac surgery for other indications and atrial fibrillation treatment as a stand-alone procedure. The paper highlights the importance of minimally invasive approaches, the need for heart team-based planning, structured curricula, and postoperative referral pathways for comprehensive management of atrial fibrillation and non-atrial fibrillation arrhythmias. CI - Copyright: (c) 2025 Polish Society of Cardiothoracic Surgeons (Polskie Towarzystwo KardioTorakochirurgow) and the editors of the Polish Journal of Cardio-Thoracic Surgery (Kardiochirurgia i Torakochirurgia Polska). FAU - Kowalewski, Mariusz AU - Kowalewski M AD - Department of Cardiac Surgery and Transplantology, National Medical Institute of the Ministry of Interior and Administration, Warsaw, Poland. AD - Cardio-Thoracic Surgery Department, Heart and Vascular Centre, Maastricht University Medical Centre, and Cardiovascular Research Institute Maastricht (CARIM), Maastricht, the Netherlands. AD - Department for the Treatment and Study of Cardiothoracic Diseases and Cardiothoracic Transplantation, IRCCS-ISMETT, Palermo, Italy. AD - Thoracic Research Centre, Collegium Medicum Nicolaus Copernicus University, Innovative Medical Forum, Bydgoszcz, Poland. FAU - Farkowski, Michal AU - Farkowski M AD - Department of Cardiology, National Medical Institute of the Ministry of Interior and Administration, Warsaw, Poland. FAU - Batko, Jakub AU - Batko J AD - Department of Cardiac Surgery and Transplantology, National Medical Institute of the Ministry of Interior and Administration, Warsaw, Poland. AD - Thoracic Research Centre, Collegium Medicum Nicolaus Copernicus University, Innovative Medical Forum, Bydgoszcz, Poland. FAU - Ogorzelec, Natalia AU - Ogorzelec N AD - Department of Cardiac Surgery and Transplantology, National Medical Institute of the Ministry of Interior and Administration, Warsaw, Poland. FAU - Zembala, Michal AU - Zembala M AD - Department of Cardiac Surgery, Military Institute of Medicine, National Research Institute, Warsaw, Poland. FAU - Kowalski, Oskar AU - Kowalski O AD - Department of Human Nutrition, Department of Dietetics, Faculty of Health Sciences in Bytom, Medical University of Silesia in Katowice, Zabrze, Poland. AD - Silesian Center for Heart Diseases, Zabrze, Poland. FAU - Aboul-Hassan, Sebastian S AU - Aboul-Hassan SS AD - Department of Cardiac Surgery, Zbigniew Religa Heart Center "Medinet", Nowa Sol, Poland. AD - Department of Cardiac Surgery and Interventional Cardiology, Faculty of Medicine and Medical Sciences, University of Zielona Gora, Poland. FAU - Plaksej, Rafal AU - Plaksej R AD - Department of Cardiology, The Copper Health Centre Hospital (MCZ SA), Lubin, Poland. AD - Division of Cardiology at the Copper Health Center Inc. in Lubin, University of Science and Technology in Wroclaw, Poland. FAU - Buchta, Piotr AU - Buchta P AD - Silesian Center for Heart Diseases, Zabrze, Poland. FAU - Hirnle, Grzegorz AU - Hirnle G AD - Department of Cardiac, Vascular and Endovascular Surgery and Transplantology, Faculty of Medical Sciences, Medical University of Silesia, Katowice, Silesian Center for Heart Diseases, Zabrze, Poland. FAU - Jastrzebski, Marek AU - Jastrzebski M AD - First Department of Cardiology, Interventional Electrocardiology and Hypertension, Jagiellonian University Medical College, Krakow, Poland. FAU - Wojdyla-Hordynska, Agnieszka AU - Wojdyla-Hordynska A AD - Medical Sciences Institute, University of Opole, Poland. AD - Department of Cardiology, University Hospital Opole, Poland. FAU - Bartus, Krzysztof AU - Bartus K AD - Department of Cardiovascular Surgery and Transplantology, Institute of Cardiology, Jagiellonian University Medical College, St. John Paul II Hospital, Krakow, Poland. FAU - Deja, Marek A AU - Deja MA AD - Department of Cardiac Surgery, Upper-Silesian Heart Center, Medical University of Silesia, Katowice, Poland. FAU - Jasinski, Marek AU - Jasinski M AD - Department and Clinic of Cardiac Surgery, Wroclaw Medical University, Wroclaw, Poland. FAU - Hrapkowicz, Tomasz AU - Hrapkowicz T AD - Department of Cardiac, Vascular and Endovascular Surgery and Transplantology, Faculty of Medical Sciences, Medical University of Silesia, Katowice, Silesian Center for Heart Diseases, Zabrze, Poland. FAU - Maruszewski, Bohdan AU - Maruszewski B AD - Department of Pediatric Cardiothoracic Surgery, The Children's Memorial Health Institute, Warsaw, Poland. FAU - Skalski, Janusz AU - Skalski J AD - Department of Pediatric Cardiac Surgery, Collegium Medicum, Jagiellonian University, Krakow, Poland. FAU - Widenka, Kazimierz AU - Widenka K AD - Department of Surgery, Faculty of Medicine, Collegium Medicum, University of Rzeszow, Poland. FAU - Kulakowski, Piotr AU - Kulakowski P AD - Department of Cardiology, Centre of Postgraduate Medical Education, Grochowski Hospital, Warsaw, Poland. FAU - Tycinska, Agnieszka AU - Tycinska A AD - Department of Intensive Cardiac Care, Medical University of Bialystok, Poland. AD - Department of Cardiology, Medical University of Bialystok, Poland. FAU - Gil, Robert J AU - Gil RJ AD - Department of Cardiology, National Institute of Medicine of the Ministry of Interior and Administration, Warsaw, Poland. FAU - Stec, Sebastian AU - Stec S AD - Department of Cardiac Surgery and Transplantology, National Medical Institute of the Ministry of Interior and Administration, Warsaw, Poland. AD - Institute for Cardiovascular Science, CardioMedicum, Krakow, Poland. FAU - Sokal, Adam AU - Sokal A AD - Silesian Park of Medical Technology, KardioMed Silesia, Zabrze, Poland, Department of Cardiology and Angiology, Silesian Centre for Heart Diseases, Zabrze, Poland. FAU - Suwalski, Piotr AU - Suwalski P AD - Department of Cardiac Surgery and Transplantology, National Medical Institute of the Ministry of Interior and Administration, Warsaw, Poland. LA - eng PT - Journal Article DEP - 20250930 PL - Poland TA - Kardiochir Torakochirurgia Pol JT - Kardiochirurgia i torakochirurgia polska = Polish journal of cardio-thoracic surgery JID - 101279148 PMC - PMC12670236 OTO - NOTNLM OT - arrythmia OT - arrythmia treatment OT - atrial fibrillation OT - hybrid ablation COIS- Michal Farkowski received speaker and consultation fees from Abbott, Biosense, Medtronic, Zoll, Pfizer and Boehringer Ingelheim Poland. Sebastian S. Aboul-Hassan received speaking and lecture fees and travel reimbursement from Getinge.Krzysztof Bartus is a consultant to Sentreheart. Michal Zembala is a consultant for Symetis SA, Vascutek Terumo, Abbott and AtriCure. Robert J. Gil was the medical consultant of the Balton Company. Sebastian Stec is the author of several patents and a shareholder of Medicine S.A. and Tracess A.B. Piotr Suwalski serves as a consultant for AtriCure. Other authors have nothing to disclose. EDAT- 2025/12/04 06:26 MHDA- 2025/12/04 06:27 PMCR- 2025/09/30 CRDT- 2025/12/04 04:44 PHST- 2025/08/30 00:00 [received] PHST- 2025/09/30 00:00 [accepted] PHST- 2025/12/04 06:27 [medline] PHST- 2025/12/04 06:26 [pubmed] PHST- 2025/12/04 04:44 [entrez] PHST- 2025/09/30 00:00 [pmc-release] AID - 57003 [pii] AID - 10.5114/kitp.2025.155459 [doi] PST - epublish SO - Kardiochir Torakochirurgia Pol. 2025 Sep 30;22(3):143-157. doi: 10.5114/kitp.2025.155459. eCollection 2025 Sep. PMID- 41338596 OWN - NLM STAT- MEDLINE DCOM- 20251208 LR - 20260103 IS - 2052-4439 (Electronic) IS - 2052-4439 (Linking) VI - 12 IP - 1 DP - 2025 Dec 2 TI - Current practices, perceptions and future challenges in the management of moderate to severe COPD: a cross-sectional survey of respiratory consultants in the Republic of Ireland. LID - 10.1136/bmjresp-2025-003520 [doi] LID - e003520 AB - INTRODUCTION: Evidence is growing for interventions beyond inhaled therapies in chronic obstructive pulmonary disease (COPD). Clinician attitudes and access to these therapies are crucial to informing COPD care pathways. AIMS: We sought to explore current attitudes, practices, future directions and challenges in the management of moderate to severe COPD among respiratory consultants in the Republic of Ireland (ROI). METHODS: A custom online survey was disseminated by email and text messaging to respiratory consultants in the ROI through the Irish Thoracic Society contact list. RESULTS: 37 responses were received (24.5% response rate), of which 36 were eligible for inclusion. Completion rate was 97.2% (n=35). Only 9 of 30 respondents (30%) reported sufficient access to pulmonary rehabilitation (PR), and 9 of 29 (31%) to a dedicated COPD multidisciplinary team (MDT). 10 of 29 respondents (34%) infrequently or never consider long-term non-invasive ventilation (LTNIV), despite 21 of 27 (78%) rating the quality of evidence for its benefit in reducing hospitalisations as moderate or high. 16 of 27 respondents (59%) infrequently or never consider lung volume reduction (LVR), despite 22 of 25 (88%) perceiving it to be moderately or highly beneficial towards improving quality of life. There was variable uncertainty regarding the evidence for biologics in COPD, with up to 11 of 24 respondents (46%) uncertain about Tezepelumab. Perceived challenges to integrating biologics into COPD care in the ROI included the absence of national drug reimbursement agreements, lack of dedicated COPD MDTs and administrative burden. CONCLUSIONS: Our study highlights insufficient access to PR and COPD MDTs, variable attitudes towards LTNIV and LVR, and uncertainty around the role of biologics in COPD care. While the modest response rate may limit generalisability, our findings underscore the need to address infrastructural and systemic barriers to optimise care pathways for moderate to severe COPD in the ROI. CI - (c) Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. FAU - Lim, Jayleigh AU - Lim J AD - Department of Respiratory Medicine, St Vincent's University Hospital, Dublin, Ireland. FAU - O'Brien, Helen AU - O'Brien H AD - Department of Respiratory Medicine, St Vincent's University Hospital, Dublin, Ireland. AD - School of Medicine, University College Dublin, Dublin, Ireland. FAU - McCarthy, Jack AU - McCarthy J AD - Department of Respiratory Medicine, St Vincent's University Hospital, Dublin, Ireland. FAU - McCarthy, Cormac AU - McCarthy C AUID- ORCID: 0000-0003-2896-5210 AD - Department of Respiratory Medicine, St Vincent's University Hospital, Dublin, Ireland. AD - School of Medicine, University College Dublin, Dublin, Ireland. FAU - Franciosi, Alessandro Naoise AU - Franciosi AN AUID- ORCID: 0000-0002-4241-8718 AD - Department of Respiratory Medicine, St Vincent's University Hospital, Dublin, Ireland alessandro.franciosi@ucd.ie. AD - School of Medicine, University College Dublin, Dublin, Ireland. LA - eng PT - Journal Article DEP - 20251202 PL - England TA - BMJ Open Respir Res JT - BMJ open respiratory research JID - 101638061 SB - IM MH - Humans MH - Ireland MH - Cross-Sectional Studies MH - *Pulmonary Disease, Chronic Obstructive/therapy MH - Disease Management MH - *Practice Patterns, Physicians'/statistics & numerical data/trends MH - Societies, Medical MH - *Attitude of Health Personnel MH - *Respiratory Therapy/psychology/statistics & numerical data/trends MH - Thoracic Surgery/organization & administration MH - Patient Care Team MH - *Health Personnel/psychology/statistics & numerical data MH - Health Care Surveys PMC - PMC12673536 OTO - NOTNLM OT - COPD Pharmacology OT - Non invasive ventilation OT - Pulmonary Disease, Chronic Obstructive OT - Pulmonary Rehabilitation COIS- Competing interests: None declared. EDAT- 2025/12/04 02:11 MHDA- 2025/12/04 02:12 PMCR- 2025/12/02 CRDT- 2025/12/03 20:32 PHST- 2025/06/10 00:00 [received] PHST- 2025/11/03 00:00 [accepted] PHST- 2025/12/04 02:12 [medline] PHST- 2025/12/04 02:11 [pubmed] PHST- 2025/12/03 20:32 [entrez] PHST- 2025/12/02 00:00 [pmc-release] AID - 12/1/e003520 [pii] AID - bmjresp-2025-003520 [pii] AID - 10.1136/bmjresp-2025-003520 [doi] PST - epublish SO - BMJ Open Respir Res. 2025 Dec 2;12(1):e003520. doi: 10.1136/bmjresp-2025-003520. PMID- 20301632 STAT- Publisher DRDT- 20251204 CTDT- 20070418 PB - University of Washington, Seattle DP - 1993 TI - Fryns Syndrome. BTI - GeneReviews((R)) AB - CLINICAL CHARACTERISTICS: Fryns syndrome is characterized by diaphragmatic defects (diaphragmatic hernia and diaphragm eventration, hypoplasia, or agenesis); characteristic facial appearance (coarse facies, wide-set eyes, a wide and depressed nasal bridge with a broad nasal tip, long philtrum, low-set and anomalous ears, tented vermilion of the upper lip, wide mouth, and a small jaw); short distal phalanges of the fingers and toes (the nails may also be small); pulmonary hypoplasia; and associated anomalies (polyhydramnios, cloudy corneas and/or microphthalmia, orofacial clefting, renal dysplasia / renal cortical cysts, and/or malformations involving the brain, cardiovascular system, gastrointestinal system, and/or genitalia). Survival beyond the neonatal period is rare in those with severe pulmonary hypoplasia and/or multiple malformations. Data on postnatal growth and psychomotor development remain limited; however, severe developmental delays and intellectual disability are common among individuals with PIGN-related Fryns syndrome. DIAGNOSIS/TESTING: The clinical diagnosis of Fryns syndrome can be established in a proband based on clinical diagnostic criteria; the molecular diagnosis can be established in a proband with suggestive findings and biallelic loss-of-function variants in PIGN identified by molecular genetic testing. MANAGEMENT: Treatment of manifestations: For congenital diaphragmatic hernia, the neonate is immediately intubated to prevent inflation of herniated bowel; surgery and/or supportive measures performed as for the general population. Additional anomalies may require consultations and management by a craniofacial specialist, cardiologist, urologist, nephrologist, gastroenterologist, and ophthalmologist. Standardized treatment with anti-seizure medications by an experienced neurologist. Developmental services as needed, including feeding, motor, adaptive, cognitive, and speech-language therapy as well as family and social work support. Surveillance: Those with successful congenital diaphragmatic hernia repair should be followed in a specialized center with periodic evaluations by a multidisciplinary team (pediatric surgeon, nurse specialist, cardiologist, pulmonologist, nutritionist). Follow up with a craniofacial specialist, cardiologist, urologist, nephrologist, gastroenterologist, and ophthalmologist as needed. Monitor those with seizures as clinically indicated. Assess for new onset of seizures. Monitor developmental progress and educational and family needs. GENETIC COUNSELING: Fryns syndrome is inherited in an autosomal recessive manner. Assuming that both parents are heterozygous for a Fryns syndrome-causing variant, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. If a molecular diagnosis of PIGN-related Fryns syndrome has been established in an affected family member, carrier testing for at-risk relatives and prenatal/preimplantation genetic testing are possible. CI - Copyright (c) 1993-2026, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved. FED - Adam, Margaret P ED - Adam MP FED - Bick, Sarah ED - Bick S FED - Mirzaa, Ghayda M ED - Mirzaa GM FED - Wallace, Stephanie E ED - Wallace SE FED - Amemiya, Anne ED - Amemiya A FAU - Slavotinek, Anne AU - Slavotinek A AD - Professor of Human Genetics, Division of Human Genetics, Department of Pediatrics, Cincinnati Children's Hospital Medical Center LA - eng PT - Review PT - Book Chapter PL - Seattle (WA) OTO - NLM OT - GPI ethanolamine phosphate transferase 1 OT - PIGN OT - Fryns Syndrome EDAT- 2025/12/04 00:00 CRDT- 2025/12/04 00:00 AID - NBK1459 [bookaccession] PMID- 41337320 OWN - NLM STAT- MEDLINE DCOM- 20251203 LR - 20251203 IS - 2694-0604 (Electronic) IS - 2375-7477 (Linking) VI - 2025 DP - 2025 Jul TI - A New Geospatial Index for Territorial Risk Stratification of Out-of-Hospital Cardiac Arrest During Heat Days. PG - 1-6 LID - 10.1109/EMBC58623.2025.11254676 [doi] AB - Global warming is one of the most relevant effects of climate change, and poses a serious hazard for human health, in particular in relation to the cardiovascular system, leading to an increased short-term risk of Out-of-Hospital Cardiac Arrest (OHCA). This study examines this risk increase from a geospatial viewpoint, going beyond pathophysiology, and emphasizing the need for a public health-focused, multidisciplinary approach known as environmental epidemiology. While some solutions have already been proposed (in particular, risk indexing as defined by the Intergovernmental Panel on Climate Change, IPCC, and the Distributed Lag Non-linear Model, DLNM), they require complex and manifold data (thus limiting replicability), are computationally intensive, and cannot be easily interpreted. To address these gaps, this research introduces a Geospatial Heat-related Risk Index (GHRI) for territorial risk stratification, aiding in efficient Emergency Medical Services (EMS) resource planning. Focusing on Lombardy, Italy, a densely populated region with diverse climates, the study analyzes temperature data from the Regional Agency for Environmental Protection and OHCA records from the Regional Agency for Emergency/Urgency (AREU) between 2017 and 2021. Data were mapped onto 96 Base Statistical Areas (BSAs), each with approximately 100'000 residents. Using Geographic Information Systems (GIS) and Python, the study finds that heat exposure generally increases OHCA risk, though some areas showed protective or insignificant effects.. The findings highlight the importance of GIS-based environmental epidemiology in climate adaptation policies and emergency healthcare planning, providing actionable insights for public health strategies.Clinical Relevance- The proposed framework allows to identify territories that exhibit higher risk in terms of increased out-of-hospital cardiac arrest incidence during heat days, thus providing valuable information to support planning and management of Emergency Medical Services (EMS). More efficient resources allocation reduces intervention time and increases patients' survival probability, which is particularly critical for out-of-hospital cardiac arrest. FAU - Gianquintieri, Lorenzo L AU - Gianquintieri LL FAU - Gianluca E G Caiani, Enrico AU - Gianluca E G Caiani E LA - eng PT - Journal Article PL - United States TA - Annu Int Conf IEEE Eng Med Biol Soc JT - Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference JID - 101763872 SB - IM MH - *Out-of-Hospital Cardiac Arrest/epidemiology MH - Humans MH - Risk Assessment MH - *Hot Temperature/adverse effects MH - Italy/epidemiology MH - Emergency Medical Services EDAT- 2025/12/03 19:14 MHDA- 2025/12/03 19:15 CRDT- 2025/12/03 13:51 PHST- 2025/12/03 19:15 [medline] PHST- 2025/12/03 19:14 [pubmed] PHST- 2025/12/03 13:51 [entrez] AID - 10.1109/EMBC58623.2025.11254676 [doi] PST - ppublish SO - Annu Int Conf IEEE Eng Med Biol Soc. 2025 Jul;2025:1-6. doi: 10.1109/EMBC58623.2025.11254676. PMID- 41334125 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251203 LR - 20260925 IS - 2248-2997 (Print) IS - 2248-2997 (Electronic) IS - 2248-2997 (Linking) VI - 15 IP - 3 DP - 2025 Sep TI - Consensus statement: updated recommendations for the interdisciplinary management of people living with HIV in Romania. PG - 221-241 LID - 10.18683/germs.2025.1470 [doi] AB - Owing to significant advances in HIV treatment and the resultant increase in life expectancy, the number of aging individuals living with HIV and associated comorbidities continues to rise. Consequently, the management of people living with HIV is no longer solely the responsibility of infectious disease or HIV specialists, but requires an integrated and multidisciplinary approach that addresses the prevention, as well as the monitoring and treatment needs of associated conditions. The care of people living with HIV in Romania is largely aligned with international guidelines, particularly those of the European AIDS Clinical Society (EACS). However, guideline implementation requires adaptation to local clinical realities and collaboration across medical specialties. In response to this need, a team of experts in infectious diseases, cardiology, nephrology, diabetes, metabolic disorders, and clinical psychology, convened to develop a national consensus for the interdisciplinary management of people living with HIV. The consensus provides clear and practical recommendations addressed to both infectious disease specialists and healthcare providers from other specialties involved in the care of people living with HIV. Its goal is to offer a unified, up-to-date, and applicable framework to support patient-centered care, facilitate interdisciplinary collaboration, and contribute to improving the quality of life of people living with HIV in Romania. CI - GERMS. FAU - Sandulescu, Oana AU - Sandulescu O AD - MD, PhD, Carol Davila University of Medicine and Pharmacy, No. 8 Eroii Sanitari Boulevard, Bucharest, 050474, Romania, and National Institute for Infectious Diseases "Prof. Dr. Matei Bals", Bucharest, Romania, and Academy of Romanian Scientists, Bucharest, Romania, and Infection Science Forum, Bucharest, Romania. FAU - Streinu-Cercel, Anca AU - Streinu-Cercel A AD - MD, PhD, Carol Davila University of Medicine and Pharmacy, No. 8 Eroii Sanitari Boulevard, Bucharest, 050474, Romania, and National Institute for Infectious Diseases "Prof. Dr. Matei Bals", Bucharest, Romania, and Academy of Romanian Scientists, Bucharest, Romania. FAU - Mardarescu, Mariana AU - Mardarescu M AD - MD, PhD, National Institute for Infectious Diseases "Prof. Dr. Matei Bals", No. 1 Dr. Calistrat Grozovici street, Bucharest, 021105, Romania. FAU - Oprea, Cristiana AU - Oprea C AD - MD, PhD, Carol Davila University of Medicine and Pharmacy, No. 8 Eroii Sanitari Boulevard, Bucharest, 050474, Romania, and "Victor Babes" Clinical Hospital for Infectious and Tropical Diseases, Bucharest, Romania. FAU - Dorobantu, Maria AU - Dorobantu M AD - MD, PhD, Carol Davila University of Medicine and Pharmacy, No. 8 Eroii Sanitari Boulevard, Bucharest, 050474, Romania. FAU - Ismail, Gener AU - Ismail G AD - MD, PhD, Carol Davila University of Medicine and Pharmacy, No. 8 Eroii Sanitari Boulevard, Bucharest, 050474, Romania, and Clinical Institute Fundeni, Bucharest, Romania. FAU - Reghina, Aura Diana AU - Reghina AD AD - MD, PhD, Carol Davila University of Medicine and Pharmacy, No. 8 Eroii Sanitari Boulevard, Bucharest, 050474, Romania, and Elias University Emergency Hospital, Bucharest, Romania. FAU - Chirila, Odette AU - Chirila O AD - Clinical psychologist, National Institute for Infectious Diseases "Prof. Dr. Matei Bals", No. 1 Dr. Calistrat Grozovici street, Bucharest, 021105, Romania. CN - Extended Consensus Group FAU - Streinu-Cercel, Adrian AU - Streinu-Cercel A AD - MD, PhD, Carol Davila University of Medicine and Pharmacy, No. 8 Eroii Sanitari Boulevard, Bucharest, 050474, Romania, and National Institute for Infectious Diseases "Prof. Dr. Matei Bals", Bucharest, Romania, and Academy of Romanian Scientists, Bucharest, Romania. LA - eng PT - Journal Article PT - Review DEP - 20250930 PL - Switzerland TA - Germs JT - Germs JID - 101596099 PMC - PMC12642960 OTO - NOTNLM OT - HIV OT - comorbidities OT - interdisciplinary OT - people living with HIV OT - prevention OT - treatment COIS- Conflicts of interest: OS reports unrestricted grants from Gilead Sciences to her institution, speaker activities and advisory board participation for Gilead Sciences and Merck Sharp & Dohme, outside of the current work. AnSC reports unrestricted grants from Gilead Sciences to her institution, speaker activities and advisory board participation for Gilead Sciences, Merck Sharp & Dohme, and ViiV EL PHARMA, outside of the current work. CO reports speakers fee and/or advisory board participation from MSD, Gilead and ViiV, outside of the current work. GI reports speaker activities and advisory board participation for AstraZeneca, Servier, Viphor, Boehringer Ingelheim, Bayer, Gilead and STADA, outside of the current work. ADR reports speaker activities for Boehringer Ingelheim, Eli Lilly, Novartis, outside of the current work. All other authors - no conflicts of interest to declare. EDAT- 2025/12/03 07:41 MHDA- 2025/12/03 07:42 PMCR- 2025/09/30 CRDT- 2025/12/03 05:46 PHST- 2025/07/31 00:00 [received] PHST- 2025/08/29 00:00 [revised] PHST- 2025/09/12 00:00 [accepted] PHST- 2025/12/03 07:42 [medline] PHST- 2025/12/03 07:41 [pubmed] PHST- 2025/12/03 05:46 [entrez] PHST- 2025/09/30 00:00 [pmc-release] AID - germs.2025.1470 [pii] AID - 10.18683/germs.2025.1470 [doi] PST - epublish SO - Germs. 2025 Sep 30;15(3):221-241. doi: 10.18683/germs.2025.1470. eCollection 2025 Sep. PMID- 41331615 OWN - NLM STAT- MEDLINE DCOM- 20260107 LR - 20260115 IS - 1471-2482 (Electronic) IS - 1471-2482 (Linking) VI - 26 IP - 1 DP - 2025 Dec 2 TI - Atrioesophageal fistula after atrial fibrillation ablation: a single-center experience with multicenter comparisons. PG - 9 LID - 10.1186/s12893-025-03371-0 [doi] LID - 9 AB - BACKGROUND: Atrioesophageal fistula (AEF) is a rare yet highly lethal complication after radiofrequency catheter ablation (RFCA) for atrial fibrillation (AF). Efficient screening and prompt surgical intervention within a multidisciplinary framework are critical for improving survival. METHODS: We retrospectively analyzed 12 patients who developed AEF after RFCA and underwent surgical repair at Beijing Anzhen Hospital from 2020 to 2024. A rapid screening protocol was implemented, including symptom-triggered CT/CTA with 48-h repeat imaging if needed and immediate surgical treatment under multidisciplinary team (MDT) consultation. Surgical management included median sternotomy under cardiopulmonary bypass (CPB) plus left thoracotomy, with atrial and esophageal repair and omental interposition. RESULTS: The mean age was 63.5 +/- 6.4 years, with 9 males and 3 females. Symptom onset occurred at a mean of 12.4 +/- 8.1 days after ablation, most commonly fever (91.7%) and chest pain (83.3%). Diagnosis was achieved within 2 (range 1-10) days. All patients underwent emergency surgery; 11 received one-stage repair, while one required esophageal diversion due to severe mediastinitis. The in-hospital survival rate was 91.7% (11/12), with no recurrence observed during a median follow-up 12 (range 3-18) months. Postoperative complications occurred in two patients (16.7%), both developing pneumonia which resolved with antibiotic therapy. CONCLUSION: A structured rapid screening pathway combined with prompt MDT-based surgical treatment significantly improved survival in patients with AEF. Our protocol achieved a high survival rate and may offer a valuable reference for other centers. CI - (c) 2025. The Author(s). FAU - Guo, Lin AU - Guo L AD - Department of Thoracic Surgery, Beijing Anzhen Hospital, Capital Medical University, 2 Anzhen Road, Chaoyang District, Beijing, 100029, China. FAU - Ou, Songlei AU - Ou S AD - Department of Thoracic Surgery, Beijing Anzhen Hospital, Capital Medical University, 2 Anzhen Road, Chaoyang District, Beijing, 100029, China. FAU - Zhang, Shaoyan AU - Zhang S AD - Department of Thoracic Surgery, Beijing Anzhen Hospital, Capital Medical University, 2 Anzhen Road, Chaoyang District, Beijing, 100029, China. FAU - Li, Dong AU - Li D AD - Department of Thoracic Surgery, Beijing Anzhen Hospital, Capital Medical University, 2 Anzhen Road, Chaoyang District, Beijing, 100029, China. FAU - Liang, Lin AU - Liang L AD - Department of Cardiac Surgery, Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, China. FAU - You, Bin AU - You B AD - Department of Thoracic Surgery, Beijing Anzhen Hospital, Capital Medical University, 2 Anzhen Road, Chaoyang District, Beijing, 100029, China. anzhenyoubin@126.com. LA - eng GR - (2022-2Z-20611)/Capital Health Research and Development of Special Fund/ GR - (2024AZC4002)/High-level Research Discipline Construction Project of Beijing Anzhen Hospital, Capital Medical University/ PT - Comparative Study PT - Journal Article PT - Multicenter Study DEP - 20251202 PL - England TA - BMC Surg JT - BMC surgery JID - 100968567 SB - IM MH - Aged MH - Female MH - Humans MH - Male MH - Middle Aged MH - *Atrial Fibrillation/surgery MH - *Catheter Ablation/adverse effects MH - *Esophageal Fistula/etiology/surgery/diagnosis/mortality MH - *Heart Atria/surgery MH - *Heart Diseases/etiology/surgery MH - *Postoperative Complications/surgery/etiology MH - Retrospective Studies PMC - PMC12776963 OTO - NOTNLM OT - Atrial fibrillation OT - Atrioesophageal fistula OT - Multidisciplinary team OT - Radiofrequency catheter ablation OT - Rapid screening protocol OT - Surgical treatment COIS- Declarations. Ethics approval and consent to participate: This study was approved by the Institutional Review Board of Beijing Anzhen Hospital, Capital Medical University (Approval No. 2025198X). Considering the retrospective nature of the study and the use of fully anonymized patient data, the Institutional Review Board of Beijing Anzhen Hospital granted a waiver of the requirement for individual patient informed consent. This study was conducted in full compliance with the Declaration of Helsinki principles for medical research involving human subjects. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2025/12/03 01:16 MHDA- 2026/01/07 06:30 PMCR- 2025/12/02 CRDT- 2025/12/02 23:55 PHST- 2025/10/03 00:00 [received] PHST- 2025/11/18 00:00 [accepted] PHST- 2026/01/07 06:30 [medline] PHST- 2025/12/03 01:16 [pubmed] PHST- 2025/12/02 23:55 [entrez] PHST- 2025/12/02 00:00 [pmc-release] AID - 10.1186/s12893-025-03371-0 [pii] AID - 3371 [pii] AID - 10.1186/s12893-025-03371-0 [doi] PST - epublish SO - BMC Surg. 2025 Dec 2;26(1):9. doi: 10.1186/s12893-025-03371-0. PMID- 41326222 OWN - NLM STAT- MEDLINE DCOM- 20251207 LR - 20261007 IS - 2174-2030 (Electronic) IS - 0870-2551 (Linking) VI - 44 IP - 12 DP - 2025 Dec TI - Radiation protection practices in diagnostic and interventional cardiology: A position paper from the Portuguese Association of Interventional Cardiology. PG - 737-745 LID - S0870-2551(25)00318-X [pii] LID - 10.1016/j.repc.2025.07.006 [doi] AB - INTRODUCTION: Interventional cardiovascular procedures are increasingly complex, raising concerns about heightened radiation exposure for both patients and healthcare professionals. This exposure can lead to serious complications, including skin injuries, cataracts, and cancer. A range of protective tools - such as lead aprons, thyroid collars and glasses, ceiling-mounted shields, and table skirts - are available to minimize occupational exposure. Effective radiation protection relies not only on equipment but also on procedural strategies such as improved beam collimation, reduced fluoroscopic pulse rates, fluoroscopy intensity and the number of cine acquisitions, and maintaining distance from the X-ray source. Staff education, ongoing training, and routine audits are essential to ensure adherence to radiation safety protocols. While interventional cardiology teams show general awareness and use of protective measures, significant gaps remain - particularly in the consistent use of eye protection, personal dosimeters, and standardized practices across cath labs. Strengthening these areas is critical to promoting a unified national approach to radiation safety and safeguarding the long-term health of cath lab personnel. OBJECTIVES: This position paper aims to raise operator awareness and propose novel strategies for minimizing ionizing radiation doses, thus mitigating associated risks. METHODS AND RESULTS: This working group conducted a review of the scientific literature and the most recent international guidelines on radiation protection in cardiac cath labs. Based on this analysis, effective protective measures and best practices were identified and systematized, adapted to the Portuguese context. CONCLUSION: Minimizing radiation exposure in the cath lab requires a comprehensive, multidisciplinary approach that combines protective equipment, procedural adjustments, and collaborative safety protocols to safeguard both patients and healthcare providers without compromising clinical outcomes. CI - Copyright (c) 2025 Sociedade Portuguesa de Cardiologia. Publicado por Elsevier Espana, S.L.U. All rights reserved. FAU - Ribeiro, Diana AU - Ribeiro D AD - Centro Hospitalar do Porto - Hospital de Santo Antonio, Porto, Portugal. Electronic address: dianaataribeiro@gmail.com. FAU - Brochado, Bruno AU - Brochado B AD - Centro Hospitalar do Porto - Hospital de Santo Antonio, Porto, Portugal. FAU - Paulo, Graciano AU - Paulo G AD - H&TRC - Health & Technology Research Center, ESTeSC - Escola Superior de Tecnologia da Saude de Coimbra, Polytechnic University of Coimbra, Portugal. FAU - Vinhas, Hugo AU - Vinhas H AD - Hospital de Faro EPE, Faro, Portugal. FAU - Jorge, Elisabete AU - Jorge E AD - Centro Hospitalar e Universitario de Coimbra - CHC, Coimbra, Portugal. FAU - Felicio, Ana AU - Felicio A AD - Centro Hospitalar de Lisboa Ocidental - Hospital de Santa Cruz, Carnaxide, Portugal. FAU - Braga, Carlos AU - Braga C AD - Hospital de Braga, EPE, Braga, Portugal. FAU - Sousa, Pedro AU - Sousa P AD - Centro Hospitalar de Leiria, EPE - Hospital Santo Andre, Leiria, Portugal. FAU - Cale, Rita AU - Cale R AD - Hospital Garcia de Orta EPE, Almada, Portugal. LA - eng LA - por PT - Journal Article PT - Practice Guideline DEP - 20251025 PL - Portugal TA - Rev Port Cardiol JT - Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology JID - 8710716 SB - IM MH - Humans MH - *Radiation Protection/standards/methods MH - *Occupational Exposure/prevention & control MH - Cardiology MH - *Radiography, Interventional MH - *Radiation Exposure/prevention & control OTO - NOTNLM OT - Cardiologia de intervencao OT - Exposicao OT - Exposure OT - Interventional cardiology OT - Radiation OT - Radiacao OT - Radioprotection OT - Radioprotecao OT - Risco OT - Risk EDAT- 2025/12/02 01:00 MHDA- 2025/12/08 01:36 CRDT- 2025/12/01 21:43 PHST- 2025/04/29 00:00 [received] PHST- 2025/07/09 00:00 [revised] PHST- 2025/07/14 00:00 [accepted] PHST- 2025/12/08 01:36 [medline] PHST- 2025/12/02 01:00 [pubmed] PHST- 2025/12/01 21:43 [entrez] AID - S0870-2551(25)00318-X [pii] AID - 10.1016/j.repc.2025.07.006 [doi] PST - ppublish SO - Rev Port Cardiol. 2025 Dec;44(12):737-745. doi: 10.1016/j.repc.2025.07.006. Epub 2025 Oct 25. PMID- 41324852 OWN - NLM STAT- MEDLINE DCOM- 20260128 LR - 20261009 IS - 1875-8312 (Electronic) IS - 1569-5794 (Linking) VI - 42 IP - 1 DP - 2026 Jan TI - Evaluation of CT-derived aortic valve area and valve-to-annulus area ratio in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation. PG - 37-47 LID - 10.1007/s10554-025-03567-8 [doi] AB - The CT-derived aortic valve area (AVA CT) 1.2 cm(2) in 102 (29.7%). Applying a VTAAR cutoff of 1.2 cm(2), with greater sensitivity in those with left ventricular ejection fraction (LVEF) < 50%, mean aortic valve pressure gradient < 40 mmHg, and patients with body surface area (BSA) > 1.95 m(2). AVA CT Graphical abstract. FAU - Deharo, Jean-Claude AU - Deharo JC AD - Assistance Publique - Hopitaux de Marseille, Centre Hospitalier Universitaire La Timone, Service de Cardiologie, 264 Rue Saint-Pierre, 13005 Marseille, France. AD - Aix Marseille Universite, C2VN, 13005 Marseille, France, Bd Jean Moulin, 13005 Marseille, France. FAU - Dreyfus, Julien AU - Dreyfus J AD - Department of Cardiology, Centre Cardiologique du Nord, Saint-Denis, France. FAU - Bongiorni, Maria-Grazia AU - Bongiorni MG AD - Heart Rhythm Clinic, San Rossore Hospital, Pisa, Italy. FAU - Burri, Haran AU - Burri H AD - Cardiac Pacing Unit, Cardiology Departement, University Hospital of Geneva, Geneva, Switzerland. FAU - Defaye, Pascal AU - Defaye P AD - Cardiology Department, Universite de Grenoble Alpes, INSERM, CHU Grenoble Alpes, LRB, 38000 Grenoble, France. FAU - Glikson, Michael AU - Glikson M AD - Jesselson Integrated Heart Center, Shaare Zedek Medical Center and Hebrew University Faculty of Medicine, Jerusalem, Israel. FAU - Lever, Nigel AU - Lever N AD - Department of Cardiology, University of Auckland and Auckland City Hospital, Auckland, New Zealand. FAU - Mangieri, Antonio AU - Mangieri A AD - Cardio Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. FAU - Mondesert, Blandine AU - Mondesert B AD - Department of Cardiology, Montreal Heart Institute, Universite de Montreal, Montreal, Canada. FAU - Nielsen, Jens Cosedis AU - Nielsen JC AD - Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark. AD - Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. FAU - Shah, Maully AU - Shah M AD - Division of Pediatric Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA, USA. FAU - Starck, Christoph Thomas AU - Starck CT AD - Department of Cardiothoracic and Vascular Surgery, German Heart Center of Charite, Berlin, Germany. FAU - Rao, Archana AU - Rao A AD - Department of Cardiology, Liverpool Heart & Chest Hospital NHS Foundation Trust, Liverpool, UK. FAU - Leclercq, Christophe AU - Leclercq C AD - Department of Cardiology, University of Rennes, CHU Rennes, lTSI-UMR1099, Rennes F-35000, France. FAU - Praz, Fabien AU - Praz F AD - Bern University Hospital, University of Bern, Bern, Switzerland. CN - Reviewers AD - Department of Cardiology, Heart Center Dresden, University Hospital, Technische Universitat Dresden, Dresden, Germany. AD - Department of Cardiology, Institut Cardiovasculaire Paris Sud, Massy, France. AD - Senior Consultant in Electrophysiology, Head of Devices and Lead Extraction, University Heart Center, University Hospital Zurich, Raemistrasse 100, 8091 Zurich, Switzerland. AD - Department of Cardiology, Hospital Universitario y Politecnico La Fe, Valencia, Spain. AD - Department of Cardiology, Centro de Investigaciones Biomedicas en RED en Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain. AD - Cardiocenter, Third Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic. AD - London Health Sciences Centre, Western University, London, UK. AD - Electrophysiology Section, Division of Cardiology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA. AD - Cardiology Division, Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China. AD - Zentrum Bremen, Herzzentrum Bremen, Klinikum Links der Weser, Senator-Wessling-Str. 1, 28277 Bremen, Germany. AD - National Heart and Lung Institute, Imperial College London, Imperial College NHS Trust, London, UK. LA - eng PT - Journal Article PT - Practice Guideline PL - France TA - EuroIntervention JT - EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology JID - 101251040 SB - IM MH - Humans MH - *Cardiac Catheterization/methods MH - *Defibrillators, Implantable MH - *Heart Valve Prosthesis Implantation/methods/adverse effects MH - *Pacemaker, Artificial MH - *Tricuspid Valve/surgery PMC - PMC12599824 COIS- None declared. EDAT- 2025/11/17 09:07 MHDA- 2025/11/17 09:08 PMCR- 2026/11/14 CRDT- 2025/11/17 04:43 PHST- 2025/11/17 09:08 [medline] PHST- 2025/11/17 09:07 [pubmed] PHST- 2025/11/17 04:43 [entrez] PHST- 2026/11/14 00:00 [pmc-release] AID - EIJ-JAA-202501 [pii] AID - 10.4244/EIJ-JAA-202501 [doi] PST - ppublish SO - EuroIntervention. 2025 Nov 14;21(22):1317-1337. doi: 10.4244/EIJ-JAA-202501. PMID- 41243055 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251116 LR - 20251119 IS - 2090-911X (Electronic) IS - 1110-2608 (Print) IS - 1110-2608 (Linking) VI - 77 IP - 1 DP - 2025 Nov 16 TI - Peripartum aortic dissection: a rare case of Stanford type B dissection triggered by severe labor pain. PG - 105 LID - 10.1186/s43044-025-00704-5 [doi] LID - 105 AB - BACKGROUND: Peripartum aortic dissection (AD) is an uncommon yet significant complication during pregnancy and delivery, characterized by a tear in the aortic intima that can lead to severe maternal morbidity and mortality. This case report describes a rare instance of Stanford Type B aortic dissection occurring in a pregnant woman, emphasizing that acute, severe labor pain can obscure the diagnosis of AD, often leading to misattribution of symptoms to more common obstetric complications. CASE PRESENTATION: This report highlights the case of a 36-year-old primigravida who presented with acute chest pain during labor, initially misdiagnosed until imaging revealed the dissection post-delivery. The critical interplay between labor-induced hemodynamic stress and pre-existing vascular weaknesses, such as those found in connective tissue disorders, raises concerns about the cardiovascular risks faced by pregnant individuals. The importance of a multidisciplinary approach, involving obstetricians, cardiologists, and anesthesiologists, is underscored, as effective management strategies are essential to ensure maternal and fetal safety. CONCLUSION: This case underscores the necessity for healthcare providers to maintain a high index of suspicion for atypical thoracic pain in pregnant patients and advocates for enhanced screening protocols for aortic disease. The findings advocate for regular cardiovascular assessments in women of childbearing age with known risk factors to improve early diagnosis and intervention, thereby potentially reducing the associated morbidity and mortality from this rare but critical condition. Further research is needed to develop evidence-based guidelines for managing AD in the peripartum setting, aiming to refine clinical protocols and optimize patient outcomes. CI - (c) 2025. The Author(s). FAU - Lu, Yun AU - Lu Y AD - XuZhou Clinical School of Xuzhou Medical University, Xuzhou, China. FAU - Wang, Zhu AU - Wang Z AD - Affiliated Hospital of Xuzhou Medical College, Xuzhou, China. FAU - Zhang, Hu AU - Zhang H AD - Affiliated Hospital of Xuzhou Medical College, Xuzhou, China. FAU - Zhou, Zhongxin AU - Zhou Z AD - Affiliated Hospital of Xuzhou Medical College, Xuzhou, China. FAU - Wei, Jun AU - Wei J AD - Affiliated Hospital of Xuzhou Medical College, Xuzhou, China. 15365887926@163.com. FAU - Zhang, Hao AU - Zhang H AD - Affiliated Hospital of Xuzhou Medical College, Xuzhou, China. 3031324zb021@stu.xzhmu.edu.cn. LA - eng PT - Journal Article DEP - 20251116 PL - Germany TA - Egypt Heart J JT - The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology JID - 9106952 PMC - PMC12620343 OTO - NOTNLM OT - Aortic dissection OT - Connective tissue disease OT - Labor pain OT - Multidisciplinary team screening OT - Peripartum period OT - Pregnancy OT - Stanford type B COIS- Declarations. Ethics approval and consent to participate: Ethical approval for this case report was waived by the Institutional Review Board/ Ethics Committee of Affiliated Hospital of Xuzhou Medical University because the study involved no more than minimal risk, was retrospective in nature, and all patient data were de-identified. Informed consent: Written informed consent was obtained from the patient for publication of this manuscript and any accompanying images. Competing interests: The authors declare no competing interests. EDAT- 2025/11/17 00:29 MHDA- 2025/11/17 00:30 PMCR- 2025/11/16 CRDT- 2025/11/16 23:18 PHST- 2025/09/30 00:00 [received] PHST- 2025/11/08 00:00 [accepted] PHST- 2025/11/17 00:30 [medline] PHST- 2025/11/17 00:29 [pubmed] PHST- 2025/11/16 23:18 [entrez] PHST- 2025/11/16 00:00 [pmc-release] AID - 10.1186/s43044-025-00704-5 [pii] AID - 704 [pii] AID - 10.1186/s43044-025-00704-5 [doi] PST - epublish SO - Egypt Heart J. 2025 Nov 16;77(1):105. doi: 10.1186/s43044-025-00704-5. PMID- 41241633 OWN - NLM STAT- MEDLINE DCOM- 20260104 LR - 20260616 IS - 1532-8422 (Electronic) IS - 1053-0770 (Linking) VI - 40 IP - 1 DP - 2026 Jan TI - Transcatheter Tricuspid Valve Interventions for Tricuspid Regurgitation: A Review of Percutaneous Annuloplasty, Edge-to-Edge Repair, and Valve Replacement Devices. PG - 309-323 LID - S1053-0770(25)01030-4 [pii] LID - 10.1053/j.jvca.2025.10.015 [doi] AB - More than 1.6 million people in the United States are affected by tricuspid regurgitation each year; however, definitive treatment options have often been limited due to the high rates of morbidity and mortality associated with isolated tricuspid valve surgery. The year 2024 marked a milestone for percutaneous tricuspid valve interventions, with the Food and Drug Administration approving the EVOQUE valve for transcatheter tricuspid valve replacement and the TriClip for transcatheter edge-to-edge repair. The TriClip and EVOQUE valve, along with the previous Conformite Europeene-marked Cardioband and PASCAL devices, have greatly expanded our understanding of the key principles of transcatheter tricuspid interventions that will help shape the next generation of devices. As an integral member of the multidisciplinary heart valve team, the cardiac anesthesiologist plays a critical role in the perioperative care of patients undergoing transcatheter tricuspid interventions. Many patients undergoing transcatheter therapies are older or high risk, so the cardiac anesthesiologist is uniquely positioned to assist with perioperative optimization. A thorough understanding of the unique anesthetic considerations, factors influencing procedural success, and potential complications of these devices is essential to optimize patient outcomes. All four devices are reviewed in detail, including their indications, performance in clinical trials, intraprocedural imaging guidance, and current limitations in transcatheter tricuspid therapies that future investigational devices should aim to address. CI - Copyright (c) 2025 Elsevier Inc. All rights reserved. FAU - Khatib, Diana AU - Khatib D AD - Department of Anesthesiology, Weill Cornell Medicine, New York, NY. Electronic address: dik9025@med.cornell.edu. FAU - Sheu, Richard AU - Sheu R AD - Department of Anesthesiology, University of Washington, Seattle, WA. FAU - Belani, Kiran AU - Belani K AD - Department of Anesthesiology, Northwestern University, Evanston, IL. FAU - Rong, Lisa Q AU - Rong LQ AD - Department of Anesthesiology, Weill Cornell Medicine, New York, NY. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20251014 PL - United States TA - J Cardiothorac Vasc Anesth JT - Journal of cardiothoracic and vascular anesthesia JID - 9110208 SB - IM MH - Humans MH - *Tricuspid Valve Insufficiency/surgery/diagnostic imaging MH - *Heart Valve Prosthesis Implantation/methods/instrumentation MH - *Tricuspid Valve/surgery/diagnostic imaging MH - *Cardiac Valve Annuloplasty/methods/instrumentation MH - *Cardiac Catheterization/methods MH - *Heart Valve Prosthesis OTO - NOTNLM OT - Cardioband OT - EVOQUE OT - PASCAL OT - TriClip OT - transcatheter tricuspid valve repair OT - transcatheter tricuspid valve replacement COIS- Declaration of competing interest Dr. Belani is a consultant for GE Healthcare. Dr. Khatib and Dr. Sheu have no conflicts to declare. EDAT- 2025/11/16 00:28 MHDA- 2026/01/05 00:49 CRDT- 2025/11/15 21:53 PHST- 2025/06/10 00:00 [received] PHST- 2025/08/18 00:00 [revised] PHST- 2025/10/09 00:00 [accepted] PHST- 2026/01/05 00:49 [medline] PHST- 2025/11/16 00:28 [pubmed] PHST- 2025/11/15 21:53 [entrez] AID - S1053-0770(25)01030-4 [pii] AID - 10.1053/j.jvca.2025.10.015 [doi] PST - ppublish SO - J Cardiothorac Vasc Anesth. 2026 Jan;40(1):309-323. doi: 10.1053/j.jvca.2025.10.015. Epub 2025 Oct 14. PMID- 41240087 OWN - NLM STAT- MEDLINE DCOM- 20260612 LR - 20261010 IS - 1438-8359 (Electronic) IS - 0913-8668 (Linking) VI - 40 IP - 3 DP - 2026 Jun TI - An interprofessional pediatric procedural sedation service: development, pilot testing, and implementation. PG - 408-415 LID - 10.1007/s00540-025-03621-8 [doi] AB - PURPOSE: To ensure safe, effective, and timely pediatric care, a standardized procedural sedation service was developed and implemented at a tertiary pediatric hospital. METHODS: Model development was guided by working group input, literature and policy review, site benchmarking, and an environmental scan. Sedation outcomes were evaluated using the Dartmouth Operative Conditions Scale (DOCS) and the Ramsay Sedation Score (RSS) in two groups of children aged > 1 year: dental outpatients and inpatients undergoing chest tube removal after cardiac surgery. The primary outcome was the proportion achieving optimal sedation (DOCS score - 2 to 2). Pre- and post-implementation outcomes were compared using Fisher's exact and Mann-Whitney U tests. RESULTS: The new interprofessional sedation model significantly improved sedation outcomes. In dental patients, the proportion with optimal DOCS scores increased from 32% (95% confidence interval, 16-52%) to 94% (79-99%) during local anesthetic injection [difference = 62% (43-81%), OR = 32 (6-163), P < 0.001] and from 18% (6-37%) to 94% (79-99%) at tooth extraction [difference = 76% (59-92%), OR = 69 (12-388), P < 0.001]. For chest tube removal, the proportion with optimal DOCS scores increased from 22% (5-38%) to 100% (92-100%) [difference = 78% (61-95%), OR = 144 (7.5-2793), P < 0.001], with a significant improvement in Ramsay sedation scores [median (10th-90th percentiles)] from 1 (1-2) to 4 (3-4) (P < 0.001). CONCLUSION: Implementing a standardized, interprofessional sedation service that aligns with best-practice guidelines improved sedation quality and patient outcomes across pediatric outpatient and inpatient settings. CI - (c) 2025. The Author(s), under exclusive licence to Japanese Society of Anesthesiologists. FAU - Crawford, Mark W AU - Crawford MW AUID- ORCID: 0000-0003-2725-7095 AD - Department of Anesthesia and Pain Medicine, The Hospital for Sick Children, Temerty Faculty of Medicine, University of Toronto, 555 University Avenue, Toronto, ON, M5G 1X8, Canada. mark.crawford@sickkids.ca. FAU - Everett, Tobias AU - Everett T AD - Department of Anesthesia and Pain Medicine, The Hospital for Sick Children, Temerty Faculty of Medicine, University of Toronto, 555 University Avenue, Toronto, ON, M5G 1X8, Canada. FAU - Kemp, Sheelagh AU - Kemp S AD - Department of Anesthesia and Pain Medicine, The Hospital for Sick Children, Temerty Faculty of Medicine, University of Toronto, 555 University Avenue, Toronto, ON, M5G 1X8, Canada. FAU - Jarvis, Steve AU - Jarvis S AD - Department of Anesthesia and Pain Medicine, The Hospital for Sick Children, Temerty Faculty of Medicine, University of Toronto, 555 University Avenue, Toronto, ON, M5G 1X8, Canada. FAU - Pehora, Carolyne AU - Pehora C AD - Department of Anesthesia and Pain Medicine, The Hospital for Sick Children, Temerty Faculty of Medicine, University of Toronto, 555 University Avenue, Toronto, ON, M5G 1X8, Canada. FAU - Parekh, Sandhaya AU - Parekh S AD - Nursing and Interprofessional Education, Centre for Nursing, The Hospital for Sick Children, Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto, ON, Canada. FAU - Barrett, Edward AU - Barrett E AD - Department of Dentistry, Faculty of Dentistry, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada. FAU - Fleming-Carroll, Bonnie AU - Fleming-Carroll B AD - Nursing and Interprofessional Education, Centre for Nursing, The Hospital for Sick Children, Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto, ON, Canada. LA - eng PT - Journal Article DEP - 20251115 PL - Japan TA - J Anesth JT - Journal of anesthesia JID - 8905667 SB - IM MH - Humans MH - Child, Preschool MH - Pediatric Anesthesia MH - *Procedural Sedation/methods/standards MH - Infant MH - Child MH - Pilot Projects MH - Female MH - Male MH - *Patient Care Team/organization & administration MH - Hospitals, Pediatric OTO - NOTNLM OT - Anesthesia assistant OT - Interprofessional care team OT - Pediatric anesthesia OT - Procedural sedation COIS- Declarations. Conflict of interest: Mark W. Crawford, Tobias Everett, Sheelagh Kemp, Steve Jarvis, Carolyne Pehora, Sandhaya Parekh, Edward Barrett, and Bonnie Fleming-Carroll that they have no conflict of interest. EDAT- 2025/11/15 12:31 MHDA- 2026/06/12 00:38 CRDT- 2025/11/15 11:13 PHST- 2025/02/03 00:00 [received] PHST- 2025/11/02 00:00 [accepted] PHST- 2026/06/12 00:38 [medline] PHST- 2025/11/15 12:31 [pubmed] PHST- 2025/11/15 11:13 [entrez] AID - 10.1007/s00540-025-03621-8 [pii] AID - 10.1007/s00540-025-03621-8 [doi] PST - ppublish SO - J Anesth. 2026 Jun;40(3):408-415. doi: 10.1007/s00540-025-03621-8. Epub 2025 Nov 15. PMID- 41238508 OWN - NLM STAT- MEDLINE DCOM- 20260213 LR - 20260213 IS - 1876-861X (Electronic) IS - 1876-861X (Linking) VI - 20 IP - 1 DP - 2026 Jan-Feb TI - CT-derived computational modelling in the lifetime management of aortic stenosis. PG - 3-12 LID - S1934-5925(25)00478-2 [pii] LID - 10.1016/j.jcct.2025.10.014 [doi] AB - Lifetime management of aortic stenosis represents a growing procedural and clinical challenge. With recent clinical trials indicating that transcatheter aortic valve replacement (TAVR) is at least on par with surgical aortic valve replacement (SAVR) in treating lower risk patients, there has been a rise in TAVR uptake in younger, lower risk patients, leading to an increased likelihood of bioprosthetic valve degradation within a patient's lifetime. This shift in treatment has changed the landscape of interventional cardiology, incentivising the Heart Team to now plan for the initial procedure with subsequent interventions in mind. While traditional multi-slice computed tomography image-based risk assessments are sufficient for initial valve placement, they fall short in their ability to accurately predict post-procedural outcomes and future interventions. Therefore, the need to balance competing risks to optimise patient outcomes over multiple interventions requires innovation. CT-derived computational techniques are being developed to incorporate biomechanics and fluid dynamics into the risk assessment process to allow more comprehensive analysis of the risks associated with different procedures. The goal of this review is to provide an overview of computational techniques that are being developed for the purposes of optimising outcomes in both the index and valve-in-valve interventions and to give cardiologists an understanding of how they may use computational modelling as an additional tool in the lifetime management of aortic stenosis. CI - Copyright (c) 2025. Published by Elsevier Inc. FAU - Khinsoe, Georgia AU - Khinsoe G AD - Curtin Medical School, Curtin University, Perth, Western Australia, Australia; Harry Perkins Institute of Medical Research, Perth, Western Australia, Australia; T3mPLATE, Harry Perkins Institute of Medical Research, The University of Western Australia, Perth, Western Australia, Australia. FAU - Ream, Courtney AU - Ream C AD - Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA, USA; George W. Woodruff School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, GA, USA. FAU - Venkatesh, Aniket AU - Venkatesh A AD - Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA, USA; Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, USA. FAU - Sirset-Becker, Taylor AU - Sirset-Becker T AD - The Ohio State University College of Medicine, Columbus, OH, USA. FAU - De-Juan-Pardo, Elena M AU - De-Juan-Pardo EM AD - Curtin Medical School, Curtin University, Perth, Western Australia, Australia; T3mPLATE, Harry Perkins Institute of Medical Research, The University of Western Australia, Perth, Western Australia, Australia; School of Engineering, The University of Western Australia, Perth, Western Australia, Australia. FAU - Sun, Zhonghua AU - Sun Z AD - Curtin Medical School, Curtin University, Perth, Western Australia, Australia; Curtin Medical Research Institute (Curtin MRI), Curtin University, Perth, Western Australia, Australia. FAU - Sellers, Stephanie L AU - Sellers SL AD - Centre for Heart Lung Innovation, St Paul's Hospital and University of British Columbia, Vancouver, Canada. FAU - Leipsic, Jonathon AU - Leipsic J AD - Department of Radiology, St. Paul's Hospital, Vancouver, Canada. FAU - Dasi, Lakshmi Prasad AU - Dasi LP AD - Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA, USA; Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, USA. FAU - Ihdayhid, Abdul AU - Ihdayhid A AD - Curtin Medical School, Curtin University, Perth, Western Australia, Australia; Harry Perkins Institute of Medical Research, Perth, Western Australia, Australia; Department of Cardiology, Fiona Stanley Hospital, Perth, Western Australia, Australia. Electronic address: abdul.ihdayhid@perkins.org.au. LA - eng PT - Journal Article PT - Review DEP - 20251114 PL - United States TA - J Cardiovasc Comput Tomogr JT - Journal of cardiovascular computed tomography JID - 101308347 SB - IM MH - Humans MH - *Aortic Valve Stenosis/diagnostic imaging/physiopathology/surgery MH - *Aortic Valve/diagnostic imaging/physiopathology/surgery MH - *Models, Cardiovascular MH - Predictive Value of Tests MH - Risk Factors MH - Risk Assessment MH - Heart Valve Prosthesis MH - *Patient-Specific Modeling MH - Treatment Outcome MH - *Heart Valve Prosthesis Implantation/adverse effects/instrumentation MH - Hemodynamics MH - *Transcatheter Aortic Valve Replacement/adverse effects/instrumentation MH - Radiographic Image Interpretation, Computer-Assisted MH - Prosthesis Design MH - *Multidetector Computed Tomography MH - Bioprosthesis MH - Clinical Decision-Making MH - Time Factors OTO - NOTNLM OT - Aortic stenosis OT - CT-derived computational modelling OT - Lifetime management OT - Patient-specific modelling OT - Transcatheter aortic valve replacement COIS- Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: AI has received consultancy fees from Edwards Lifesciences, Abbott Medical, and Artrya (including stock options). TSB is a consultant for DASI Simulations, LLC and has patents filed on computational modelling. JL is a consultant to HeartFlow and Circle CVI, has stock options in HeartFlow, and provides institutional CT core laboratory services to Edwards Lifesciences, Abbott, Boston Scientific, and Medtronic. LPD is a stakeholder in DASI Simulations and has a patent pending as coinventor of patents related to computational predictive modeling of heart valves. SLS is a consultant to Edwards, Anteris Technologies, Excision Medical, and Medtronic; has received research support from Edwards, Medtronic, HeartFlow, Anteris Technologies, ViVitro Labs; and has stock options in Excision Medical and supported by a Michael Smith Health Research BC Scholar Award. The other authors declare no competing interests. EDAT- 2025/11/15 00:29 MHDA- 2026/02/14 05:30 CRDT- 2025/11/14 21:55 PHST- 2025/06/25 00:00 [received] PHST- 2025/09/15 00:00 [revised] PHST- 2025/10/20 00:00 [accepted] PHST- 2026/02/14 05:30 [medline] PHST- 2025/11/15 00:29 [pubmed] PHST- 2025/11/14 21:55 [entrez] AID - S1934-5925(25)00478-2 [pii] AID - 10.1016/j.jcct.2025.10.014 [doi] PST - ppublish SO - J Cardiovasc Comput Tomogr. 2026 Jan-Feb;20(1):3-12. doi: 10.1016/j.jcct.2025.10.014. Epub 2025 Nov 14. PMID- 41237705 OWN - NLM STAT- MEDLINE DCOM- 20251212 LR - 20260510 IS - 1532-8171 (Electronic) IS - 0735-6757 (Linking) VI - 99 DP - 2026 Jan TI - Airway management in emergency department thoracotomy: A narrative review. PG - 477-482 LID - S0735-6757(25)00737-5 [pii] LID - 10.1016/j.ajem.2025.11.004 [doi] AB - INTRODUCTION: Emergency department thoracotomy (EDT) is a high-risk, life-saving intervention for patients in traumatic cardiac arrest. A critical component of EDT is airway management, typically performed by emergency physicians, yet formal guidance regarding optimal strategies remains limited. Airway management in this setting is uniquely complex due to concurrent anatomic injury, physiologic instability, and the procedural demands of thoracotomy. DISCUSSION: Endotracheal intubation (ETI) during EDT presents multiple challenges. Anatomic difficulties may arise from facial or cervical trauma, restricted positioning, and the presence of cervical collars. Cognitive load is heightened by the chaotic, multidisciplinary environment, requiring strategies such as pre-briefing, checklists, and closed-loop communication. To optimize outcomes, the most experienced operator should perform ETI, preferably using video laryngoscopy, which improves visualization and confirmation of tube placement. Adjunctive measures to facilitate procedural success include preparation for airway contamination, selective mainstem intubation to facilitate surgical exposure, and orogastric tube placement to aid intra-thoracic orientation. While supraglottic devices or surgical airways may serve as temporizing options, definitive endotracheal access remains the standard. Ventilation management must be closely coordinated with the thoracotomy team, with adjustments for single-lung ventilation, reduced tidal volumes, and decompression as indicated. CONCLUSIONS: Airway management during EDT requires technical expertise, adaptability, and seamless communication between emergency physicians and surgical teams. Video laryngoscopy, selective ventilation strategies, and early orogastric tube placement can optimize procedural success. Protocolized, team-based approaches are essential to overcoming the unique airway challenges of EDT. CI - Copyright (c) 2025 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Lacy, Aaron J AU - Lacy AJ AD - Washington University School of Medicine, Department of Emergency Medicine, MSC 8072-0017-07660, S. Euclid Ave, Saint Louis, MO 63110, United States. Electronic address: aaronjlacy@gmail.com. FAU - Liebendorfer, Adam AU - Liebendorfer A AD - Washington University School of Medicine, Department of Emergency Medicine, MSC 8072-0017-07660, S. Euclid Ave, Saint Louis, MO 63110, United States. FAU - Guess, Sarah M AU - Guess SM AD - Washington University School of Medicine, Department of Emergency Medicine, MSC 8072-0017-07660, S. Euclid Ave, Saint Louis, MO 63110, United States. FAU - Al-Aref, Rami S AU - Al-Aref RS AD - Baylor College of Medicine, Department of Surgery, Division of Trauma, Bariatric, and Acute and Critical Care Surgery, One Baylor Plaza, Houston, Texas 77030, United States. FAU - Kronfli, Anthony P AU - Kronfli AP AD - Washington University School of Medicine, Department of Surgery, Section of Acute and Critical Care Surgery, 4590 Nash Way (formerly Children's Place), Suite 2300, St. Louis, MO 63110, United States. FAU - Armstrong, Rachel E AU - Armstrong RE AD - Washington University School of Medicine, Department of Emergency Medicine, MSC 8072-0017-07660, S. Euclid Ave, Saint Louis, MO 63110, United States. FAU - Maiga, Amelia W AU - Maiga AW AD - Vanderbilt University Medical Center, Department of Surgery, Division of Acute Care Surgery, 1211 Medical Center Drive, Nashville, TN 37232, United States. FAU - Bracey, Alexander AU - Bracey A AD - Albany Medical Center, Department of Emergency Medicine, 43 New Scotland Ave., D Building, Basement Level, Albany, NY 12208, United States. FAU - Barnicle, Ryan N AU - Barnicle RN AD - Warren Alpert Medical School of Brown University, Department of Emergency Medicine, Stephen Robert '62 Campus Center, 75 Waterman St, Providence, RI 02912, United States. LA - eng PT - Journal Article PT - Review DEP - 20251105 PL - United States TA - Am J Emerg Med JT - The American journal of emergency medicine JID - 8309942 SB - IM MH - Humans MH - *Thoracotomy/methods MH - *Emergency Service, Hospital MH - *Airway Management/methods MH - *Intubation, Intratracheal/methods MH - *Heart Arrest/therapy OTO - NOTNLM OT - Airway management OT - Bougie OT - Emergency department thoracotomy OT - Intubation OT - Mainstem intubation OT - Thoracotomy OT - Video laryngoscopy COIS- Declaration of competing interest All authors report no COIs. EDAT- 2025/11/15 00:29 MHDA- 2025/12/13 00:32 CRDT- 2025/11/14 18:08 PHST- 2025/09/24 00:00 [received] PHST- 2025/10/30 00:00 [revised] PHST- 2025/11/04 00:00 [accepted] PHST- 2025/12/13 00:32 [medline] PHST- 2025/11/15 00:29 [pubmed] PHST- 2025/11/14 18:08 [entrez] AID - S0735-6757(25)00737-5 [pii] AID - 10.1016/j.ajem.2025.11.004 [doi] PST - ppublish SO - Am J Emerg Med. 2026 Jan;99:477-482. doi: 10.1016/j.ajem.2025.11.004. Epub 2025 Nov 5. PMID- 41234602 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251114 LR - 20251116 IS - 1756-1485 (Electronic) IS - 1756-1477 (Print) IS - 1756-1485 (Linking) VI - 20 DP - 2025 TI - Sex Differences in Stroke Following Transcatheter Aortic Valve Replacement and the Role of Embolic Protection Devices in Women. PG - e28 LID - 10.15420/icr.2024.29 [doi] LID - e28 AB - Several historical studies reported a higher rate of complications following transcatheter aortic valve replacement (TAVR) in women compared with men, especially major bleeding, vascular complications and stroke. More recent publications have demonstrated lower stroke rates following TAVR. The growing experience of modern TAVR operators played a crucial role in the reduction of early postprocedural stroke events. In addition, the improved transcatheter heart valve technology, the emphasis on a heart team-based selection process, and the inclusion of intermediate- and low-risk patients in the latest landmark randomised trials have all contributed to the lower stroke rates in contemporary trials. It is important to note, however, that at an individual level, stroke can significantly affect both quality of life and overall prognosis. Certain factors that increase the risk of periprocedural stroke include the distribution of calcification of native aortic valves, small aortic valve annuli, left ventricular dysfunction and fibrosis, and AF. These tend to occur more frequently in women. However, the role of cerebral embolic protection devices has not been shown to reduce procedure-related strokes in men or women. The overall incidence of factors predisposing to late-onset stroke is higher in women. Currently, there are no trials that have identified sex differences in the incidence and management of stroke following TAVR. This review aims to examine potential sex differences in the pathophysiology, preventive strategies and therapeutic options for stroke following TAVR. CI - Copyright (c) The Author(s), 2025. Published by Radcliffe Group Ltd. FAU - Alasnag, Mirvat AU - Alasnag M AUID- ORCID: 0000-0002-8714-0334 AD - Cardiac Centre, King Fahd Armed Forces Hospital Jeddah, Saudi Arabia. FAU - Masiero, Giulia AU - Masiero G AUID- ORCID: 0000-0003-4209-6824 AD - Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua Medical School Padua, Italy. FAU - de Biase, Chiara AU - de Biase C AUID- ORCID: 0000-0003-2661-3246 AD - Cardiovascular Department, Clinique Pasteur Toulouse, France. FAU - Paradies, Valeria AU - Paradies V AUID- ORCID: 0000-0003-3513-7819 AD - Cardiovascular Department, Maasstad Hospital Rotterdam, the Netherlands. FAU - Kaluzna-Oleksy, Marta AU - Kaluzna-Oleksy M AUID- ORCID: 0000-0003-4048-6247 AD - 1st Department of Cardiology, University of Medical Sciences in Poznan Poznan, Poland. LA - eng PT - Journal Article PT - Review DEP - 20251103 PL - England TA - Interv Cardiol JT - Interventional cardiology (London, England) JID - 101559687 PMC - PMC12606453 OTO - NOTNLM OT - Stroke OT - embolic protection OT - sex differences OT - transcatheter aortic valve replacement COIS- Disclosure: MA is on the Interventional Cardiology Editorial Board; this did not influence peer review. All other authors have no conflicts of interest to declare. EDAT- 2025/11/14 06:28 MHDA- 2025/11/14 06:29 PMCR- 2025/11/03 CRDT- 2025/11/14 04:38 PHST- 2024/06/25 00:00 [received] PHST- 2025/09/01 00:00 [accepted] PHST- 2025/11/14 06:29 [medline] PHST- 2025/11/14 06:28 [pubmed] PHST- 2025/11/14 04:38 [entrez] PHST- 2025/11/03 00:00 [pmc-release] AID - 10.15420/icr.2024.29 [doi] PST - epublish SO - Interv Cardiol. 2025 Nov 3;20:e28. doi: 10.15420/icr.2024.29. eCollection 2025. PMID- 41233002 OWN - NLM STAT- MEDLINE DCOM- 20251113 LR - 20260701 IS - 1557-9840 (Electronic) IS - 0095-5108 (Linking) VI - 52 IP - 4 DP - 2025 Dec TI - Cardiology Overview of Pulmonary Hypertension Management in the Neonatal Intensive Care Unit. PG - 633-653 LID - S0095-5108(25)00059-4 [pii] LID - 10.1016/j.clp.2025.08.002 [doi] AB - Pulmonary hypertension (PH) in the neonatal intensive care unit represents a complex and diverse spectrum of conditions, from transient persistent pulmonary hypertension of the newborn to chronic PH associated with bronchopulmonary dysplasia, congenital heart disease, and other conditions, and can cause significant morbidity and mortality. Proper classification, timely diagnosis using echocardiography and imaging, and tailored therapy are essential. A multidisciplinary approach is critical, particularly for infants with unclear or genetic causes. This article provides a thorough overview of the current classification schema of pulmonary hypertension, underlying pathophysiology, diagnostic work-up, treatment options, and long-term prognosis. CI - Copyright (c) 2025 Elsevier Inc. All rights reserved. FAU - Kameny, Rebecca J AU - Kameny RJ AD - Department of Pediatrics, Cardiology, Stanford University, 750 Welch Road, Palo Alto, CA 94304, USA. Electronic address: rkameny@stanford.edu. FAU - Hopper, Rachel K AU - Hopper RK AD - Department of Pediatrics, Cardiology, Stanford University, 750 Welch Road, Palo Alto, CA 94304, USA. LA - eng PT - Journal Article PT - Review DEP - 20251008 PL - United States TA - Clin Perinatol JT - Clinics in perinatology JID - 7501306 SB - IM MH - Humans MH - Infant, Newborn MH - *Hypertension, Pulmonary/therapy/diagnosis/physiopathology/classification/etiology MH - *Intensive Care Units, Neonatal MH - Echocardiography MH - Prognosis MH - Bronchopulmonary Dysplasia/complications MH - Heart Defects, Congenital/complications OTO - NOTNLM OT - Bronchopulmonary dysplasia (BPD) OT - Persistent pulmonary hypertension of the newborn (PPHN) OT - Prematurity OT - Pulmonary vascular disease COIS- Disclosure The authors have nothing to disclose. EDAT- 2025/11/14 00:28 MHDA- 2025/11/14 00:29 CRDT- 2025/11/13 20:54 PHST- 2025/11/14 00:29 [medline] PHST- 2025/11/14 00:28 [pubmed] PHST- 2025/11/13 20:54 [entrez] AID - S0095-5108(25)00059-4 [pii] AID - 10.1016/j.clp.2025.08.002 [doi] PST - ppublish SO - Clin Perinatol. 2025 Dec;52(4):633-653. doi: 10.1016/j.clp.2025.08.002. Epub 2025 Oct 8. PMID- 41233001 OWN - NLM STAT- MEDLINE DCOM- 20251113 LR - 20260701 IS - 1557-9840 (Electronic) IS - 0095-5108 (Linking) VI - 52 IP - 4 DP - 2025 Dec TI - Transcatheter Closure of the Ductus Arteriosus in a Premature Neonate: A Team Effort. PG - 629-632 LID - S0095-5108(25)00058-2 [pii] LID - 10.1016/j.clp.2025.08.001 [doi] AB - New technology has ushered neonatology and cardiology providers into a new realm of transcatheter device closure of the patent ductus arteriosus within the premature neonate. Subsequently, there are lingering questions surrounding issues, such as patient candidacy, timing, procedure optimization, institutional, and referral-base practice changes, in management. Discussed here is the multidisciplinary and protocolized approach of a large volume, tertiary center with a wide referral catchment area, and it's now mid-term experience. CI - Copyright (c) 2025 Elsevier Inc. All rights reserved. FAU - Ligon, R Allen AU - Ligon RA AD - Division of Cardiology, Children's Healthcare of Atlanta, GA, USA; Emory University School of Medicine, 2835 Brandywine Road, Suite 400, Atlanta, GA 30341, USA. Electronic address: ligona@kidsheart.com. FAU - Bhombal, Shazia AU - Bhombal S AD - Division of Neonatology, Children's Healthcare of Atlanta, GA, USA; Emory University School of Medicine, 2220 North Druid Hills, Atlanta, GA 30329, USA. LA - eng PT - Journal Article PT - Review DEP - 20250913 PL - United States TA - Clin Perinatol JT - Clinics in perinatology JID - 7501306 SB - IM MH - Humans MH - *Ductus Arteriosus, Patent/therapy/surgery MH - Infant, Newborn MH - Infant, Premature MH - *Cardiac Catheterization/methods MH - *Septal Occluder Device MH - Patient Care Team OTO - NOTNLM OT - Cardiac catheterization OT - Neonatology OT - Patent ductus arteriosus COIS- Disclosure Dr Ligon is a proctor and education consultant for Abbott Vascular, Inc.; Dr Ligon is also a consultant for B. Braun Interventional Systems, Inc. No other authors have any financial relationships to disclose. No funding was associated with any of the contents covered within this work. EDAT- 2025/11/14 00:27 MHDA- 2025/11/14 00:28 CRDT- 2025/11/13 20:54 PHST- 2025/11/14 00:28 [medline] PHST- 2025/11/14 00:27 [pubmed] PHST- 2025/11/13 20:54 [entrez] AID - S0095-5108(25)00058-2 [pii] AID - 10.1016/j.clp.2025.08.001 [doi] PST - ppublish SO - Clin Perinatol. 2025 Dec;52(4):629-632. doi: 10.1016/j.clp.2025.08.001. Epub 2025 Sep 13. PMID- 41228236 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251113 LR - 20260925 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 17 IP - 21 DP - 2025 Oct 27 TI - A New Era, New Risks: The Cardio-Oncology Perspective on Immunotherapy in Non-Small Cell Lung Cancer. LID - 10.3390/cancers17213443 [doi] LID - 3443 AB - Lung cancer (LC) remains the leading cause of cancer-related mortality worldwide. In recent years, mortality rates have declined due to antismoking policies, earlier detection, and the advent of targeted therapies and immunotherapy, particularly for non-small cell lung cancer (NSCLC), which accounts for 85% of all cases. With improved survival, however, LC patients are increasingly exposed to competing causes of mortality, among which cardiovascular disease (CVD) is highly prevalent, affecting 30-50% of patients and contributing to nearly 30% of deaths. This burden reflects both shared risk factors and the cardiotoxic potential of radiotherapy, chemotherapy, and immunotherapy. Beyond acute adverse cardiovascular events during treatment, real-world data indicate that immune checkpoint inhibitors (ICIs) may also exert chronic cardiovascular effects, significantly accelerating the atherosclerotic process in multimorbid patients. These findings underscore the importance of accurate baseline assessment and aggressive management of cardiovascular risk factors in LC patients-particularly in the adjuvant and neoadjuvant settings, where longer survival is anticipated. Moreover, long-term monitoring should be implemented through a tailored, multiparametric strategy that integrates novel biomarkers and advanced artificial intelligence-assisted imaging techniques. Achieving this ambitious goal requires the close collaboration of a multidisciplinary team, with cardiologists playing a pivotal role. This review will address the complexity of LC patients, focusing on the interplay of cardio-immuno-metabolic factors, summarizing the cardiovascular impact of immunotherapy across metastatic, locally advanced, and perioperative settings, and outlining practical strategies for the management of these vulnerable patients. FAU - Tarantini, Luigi AU - Tarantini L AUID- ORCID: 0000-0003-2580-0963 AD - Cardioncology Clinic-Cardiologia Ospedaliera AUSL-IRCCS "Tecnologie Avanzate e Modelli Assistenziali in Oncologia", 42100 Reggio Emilia, Italy. FAU - Gallucci, Giuseppina AU - Gallucci G AD - Independent Researcher, 85025 Melfi, Italy. FAU - Inno, Alessandro AU - Inno A AUID- ORCID: 0000-0001-6331-6908 AD - Medical Oncology, IRCCS Ospedale Sacro Cuore Don Calabria, 37024 Negrar di Valpolicella, Italy. FAU - Camerini, Andrea AU - Camerini A AUID- ORCID: 0000-0002-1436-8397 AD - Medical Oncology, Versilia Hospital, Azienda USL Toscana Nord-Ovest, 55041 Lido di Camaiore, Italy. FAU - Canale, Maria Laura AU - Canale ML AUID- ORCID: 0000-0003-0990-6397 AD - Cardiology, Versilia Hospital, Azienda USL Toscana Nord-Ovest, 55041 Lido di Camaiore, Italy. FAU - Larocca, Mario AU - Larocca M AD - Provincial Medical Oncology, Department of Oncology and Advanced Technologies, AUSL-IRCCS in Tecnologie Avanzate e Modelli Assistenziali in Oncologia, 42100 Reggio Emilia, Italy. FAU - Zanelli, Francesca AU - Zanelli F AD - Provincial Medical Oncology, Department of Oncology and Advanced Technologies, AUSL-IRCCS in Tecnologie Avanzate e Modelli Assistenziali in Oncologia, 42100 Reggio Emilia, Italy. FAU - Pagano, Maria AU - Pagano M AD - Provincial Medical Oncology, Department of Oncology and Advanced Technologies, AUSL-IRCCS in Tecnologie Avanzate e Modelli Assistenziali in Oncologia, 42100 Reggio Emilia, Italy. FAU - Alberti, Giulia AU - Alberti G AUID- ORCID: 0000-0003-2616-7477 AD - Provincial Medical Oncology, Department of Oncology and Advanced Technologies, AUSL-IRCCS in Tecnologie Avanzate e Modelli Assistenziali in Oncologia, 42100 Reggio Emilia, Italy. FAU - Ciammella, Patrizia AU - Ciammella P AD - Radiation Oncology Unit, Azienda USL-IRCCS di Reggio Emilia, 42100 Reggio Emilia, Italy. FAU - Maurea, Nicola AU - Maurea N AD - Cardiology Division, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, 80131 Napoli, Italy. FAU - Gori, Stefania AU - Gori S AUID- ORCID: 0000-0001-6320-405X AD - Medical Oncology, IRCCS Ospedale Sacro Cuore Don Calabria, 37024 Negrar di Valpolicella, Italy. FAU - Navazio, Alessandro AU - Navazio A AUID- ORCID: 0000-0001-8417-7783 AD - Cardioncology Clinic-Cardiologia Ospedaliera AUSL-IRCCS "Tecnologie Avanzate e Modelli Assistenziali in Oncologia", 42100 Reggio Emilia, Italy. FAU - Pinto, Carmine AU - Pinto C AUID- ORCID: 0000-0002-3159-5268 AD - Provincial Medical Oncology, Department of Oncology and Advanced Technologies, AUSL-IRCCS in Tecnologie Avanzate e Modelli Assistenziali in Oncologia, 42100 Reggio Emilia, Italy. LA - eng GR - Ricerca Corrente Annual Program 2025./This study was partially funded by Italian Ministry of Health/ PT - Journal Article PT - Review DEP - 20251027 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC12609471 OTO - NOTNLM OT - cardio-immuno-metabolic risk OT - cardio-oncology OT - cardiovascular diseas OT - cardiovascular toxicity OT - immunotherapy OT - non-small cell lung cancer COIS- Alessandro Inno received honoraria for participation in speakers' bureaus from Amgen, AstraZeneca, Merck Sharp & Dohme, Novartis, and Roche; a medical writing grant from Merck Serono; and travel support from Amgen, AstraZeneca, Roche, and Sanofi. The other authors declare no conflicts of interest. EDAT- 2025/11/13 06:30 MHDA- 2025/11/13 06:31 PMCR- 2025/10/27 CRDT- 2025/11/13 01:10 PHST- 2025/09/26 00:00 [received] PHST- 2025/10/23 00:00 [revised] PHST- 2025/10/24 00:00 [accepted] PHST- 2025/11/13 06:31 [medline] PHST- 2025/11/13 06:30 [pubmed] PHST- 2025/11/13 01:10 [entrez] PHST- 2025/10/27 00:00 [pmc-release] AID - cancers17213443 [pii] AID - cancers-17-03443 [pii] AID - 10.3390/cancers17213443 [doi] PST - epublish SO - Cancers (Basel). 2025 Oct 27;17(21):3443. doi: 10.3390/cancers17213443. PMID- 41226949 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251113 LR - 20251115 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 14 IP - 21 DP - 2025 Oct 24 TI - The Introduction of Impella 5.5 in Cardiogenic Shock: A Single-Center, Retrospective Propensity Score-Matched Analysis. LID - 10.3390/jcm14217552 [doi] LID - 7552 AB - Background/Objectives: Impella 5.5 provides a higher flow rate than smaller microaxial pumps and has been increasingly adopted for cardiogenic shock (CS). This study aimed to evaluate whether its introduction into our Shock Team program in 2023 improved outcomes compared with a historical cohort supported with other mechanical circulatory support (MCS) devices. Methods: We retrospectively analyzed patients with CS treated with MCS between 2020 and 2024 at a tertiary center. The Impella 5.5 group (n = 17) included patients managed after device implementation, either as stand-alone or sequential therapy. The historical cohort comprised 40 patients treated with ECMO, Impella CP, CentriMag, or IABP prior to 2023. Propensity score matching (age, sex, etiology, lactate, SCAI stage) generated 17 matched pairs. The primary outcome was survival at discharge, 30 days, 3 months, and 6 months. Secondary outcomes included bridging to recovery, heart transplantation (HTx), durable LVAD, and major complications. Results: Impella 5.5 was associated with higher survival at discharge (94.1% vs. 58.8%, p = 0.039), 30 days (94.1% vs. 58.8%, p = 0.039), and 3 months (94.1% vs. 58.8%, p = 0.039). At 6 months, survival remained higher (88.2% vs. 58.8%) but did not reach statistical significance in point analysis (p = 0.118). Bridging occurred more frequently with Impella 5.5 (HTx 64.7% vs. 52.9% (p = 0.464), recovery 17.6% vs. 5.9% (p = 0.292)), while LVAD implantation rates were similar (11.8% vs. 17.6%, p = 1.0). Major bleeding (17.6% vs. 47.1%, p = 0.141), stroke/TIA (5.9% vs. 17.6%, p = 0.601), and the need for renal replacement therapy (5.9% vs. 23.5%, p = 0.335) were numerically lower with Impella 5.5. Conclusions: In this single-center, retrospective analysis, the introduction of Impella 5.5 was associated with higher short-term survival and favorable bridging metrics; estimates are imprecise due to small, heterogeneous samples. These hypothesis-generating findings warrant confirmation in larger, prospective multicenter cohorts. FAU - Bochenek, Maciej AU - Bochenek M AUID- ORCID: 0000-0003-0338-6482 AD - Clinical Department of Heart Transplantation and Mechanical Circulatory Support, Department of Cardiac Surgery and Heart Transplantation, Institute of Heart Diseases, Faculty of Medicine, Wroclaw Medical University, 50-556 Wroclaw, Poland. FAU - Sokolski, Mateusz AU - Sokolski M AUID- ORCID: 0000-0001-9925-3566 AD - Clinical Department of Heart Transplantation and Mechanical Circulatory Support, Department of Cardiac Surgery and Heart Transplantation, Institute of Heart Diseases, Faculty of Medicine, Wroclaw Medical University, 50-556 Wroclaw, Poland. FAU - Kedziora, Anna AU - Kedziora A AUID- ORCID: 0000-0003-1716-9374 AD - Clinical Department of Cardiac Surgery, Department of Cardiac Surgery and Heart Transplantation, Institute of Heart Diseases, Faculty of Medicine, Wroclaw Medical University, 50-556 Wroclaw, Poland. FAU - Barteczko-Grajek, Barbara AU - Barteczko-Grajek B AD - Clinical Department of Anaesthesiology and Intensive Therapy, Faculty of Medicine, Wroclaw Medical University, 50-556 Wroclaw, Poland. FAU - Bielicki, Grzegorz AU - Bielicki G AUID- ORCID: 0000-0003-0888-4229 AD - Clinical Department of Cardiac Surgery, Department of Cardiac Surgery and Heart Transplantation, Institute of Heart Diseases, Faculty of Medicine, Wroclaw Medical University, 50-556 Wroclaw, Poland. FAU - Kosiorowska, Kinga AU - Kosiorowska K AD - Clinical Department of Cardiac Surgery, Department of Cardiac Surgery and Heart Transplantation, Institute of Heart Diseases, Faculty of Medicine, Wroclaw Medical University, 50-556 Wroclaw, Poland. FAU - Rachwalik, Maciej AU - Rachwalik M AD - Clinical Department of Cardiac Surgery, Department of Cardiac Surgery and Heart Transplantation, Institute of Heart Diseases, Faculty of Medicine, Wroclaw Medical University, 50-556 Wroclaw, Poland. FAU - Nowicki, Rafal AU - Nowicki R AUID- ORCID: 0000-0002-3256-552X AD - Clinical Department of Cardiac Surgery, Department of Cardiac Surgery and Heart Transplantation, Institute of Heart Diseases, Faculty of Medicine, Wroclaw Medical University, 50-556 Wroclaw, Poland. FAU - Kosowski, Michal AU - Kosowski M AUID- ORCID: 0000-0001-8911-5303 AD - Clinical Department of Cardiology, Department of Cardiology, Institute of Heart Diseases, Faculty of Medicine, Wroclaw Medical University, 50-556 Wroclaw, Poland. FAU - Cielecka, Magdalena AU - Cielecka M AD - Clinical Department of Heart Transplantation and Mechanical Circulatory Support, Department of Cardiac Surgery and Heart Transplantation, Institute of Heart Diseases, Faculty of Medicine, Wroclaw Medical University, 50-556 Wroclaw, Poland. FAU - Zakliczynski, Michal AU - Zakliczynski M AUID- ORCID: 0000-0002-5730-019X AD - Clinical Department of Heart Transplantation and Mechanical Circulatory Support, Department of Cardiac Surgery and Heart Transplantation, Institute of Heart Diseases, Faculty of Medicine, Wroclaw Medical University, 50-556 Wroclaw, Poland. FAU - Kuliczkowski, Wiktor AU - Kuliczkowski W AD - Clinical Department of Cardiology, Department of Cardiology, Institute of Heart Diseases, Faculty of Medicine, Wroclaw Medical University, 50-556 Wroclaw, Poland. FAU - Przybylski, Roman AU - Przybylski R AD - Department of Cardiac Surgery and Heart Transplantation, Institute of Heart Diseases, Faculty of Medicine, Wroclaw Medical University, 50-556 Wroclaw, Poland. LA - eng PT - Journal Article DEP - 20251024 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC12610547 OTO - NOTNLM OT - Impella 5.5 OT - cardiogenic shock OT - mechanical circulatory support OT - survival COIS- Maciej Bochenek has received personal fees from Abiomed outside the submitted work. Barbara Barteczko-Grajek has received personal fees from Abiomed outside the submitted work. Michal Zakliczynski has received personal fees from Abiomed and Abbott outside the submitted work. Wiktor Kuliczkowski has received personal fees from Abiomed outside the submitted work. EDAT- 2025/11/13 06:29 MHDA- 2025/11/13 06:30 PMCR- 2025/10/24 CRDT- 2025/11/13 01:05 PHST- 2025/08/26 00:00 [received] PHST- 2025/09/13 00:00 [revised] PHST- 2025/10/22 00:00 [accepted] PHST- 2025/11/13 06:30 [medline] PHST- 2025/11/13 06:29 [pubmed] PHST- 2025/11/13 01:05 [entrez] PHST- 2025/10/24 00:00 [pmc-release] AID - jcm14217552 [pii] AID - jcm-14-07552 [pii] AID - 10.3390/jcm14217552 [doi] PST - epublish SO - J Clin Med. 2025 Oct 24;14(21):7552. doi: 10.3390/jcm14217552. PMID- 41226938 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251113 LR - 20251115 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 14 IP - 21 DP - 2025 Oct 24 TI - Management of Patients with Nickel Hypersensitivity Undergoing Patent Foramen Ovale Closure. LID - 10.3390/jcm14217540 [doi] LID - 7540 AB - Patent foramen ovale (PFO) is implicated in cryptogenic stroke and other clinical syndromes, with transcatheter closure demonstrating superiority over medical therapy in selected patients. Most closure devices are composed of nitinol, a nickel-titanium alloy, raising concerns in individuals with nickel hypersensitivity, one of the most prevalent contact allergies worldwide. Although typically manifesting as localized dermatitis, nickel allergy has been associated with systemic reactions after device implantation, including chest pain, palpitations, migraines, dyspnea, and cutaneous eruptions. Recent evidence indicates that nickel-sensitive patients experience a significantly higher incidence of post-procedural device-related symptoms. Nevertheless, severe reactions remain rare, and the benefits of PFO closure generally outweigh the risks. The predictive value of pre-implantation patch testing remains uncertain, and the lack of nickel-free alternatives constrains device selection. Management strategies are empirical, relying on symptomatic treatment with corticosteroids, antihistamines, or device explantation in refractory cases. Future research should focus on elucidating the pathophysiology of nickel-induced hypersensitivity in cardiovascular implants, improving diagnostic algorithms, and developing biocompatible, nickel-free devices. A multidisciplinary approach involving cardiologists, dermatologists, and allergists is essential to optimize outcomes in this complex subset of patients. FAU - Apostolos, Anastasios AU - Apostolos A AUID- ORCID: 0000-0003-2616-7952 AD - Unit of Structural Heart Diseases, First Department of Cardiology, National and Kapodistrian University of Athens, Hippocration General Hospital of Athens, 115 27 Athens, Greece. AD - First Department of Cardiology, National and Kapodistrian University of Athens, Hippocration General Hospital of Athens, 115 27 Athens, Greece. AD - Department of Cardiology, Harefield Hospital, Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London SE1 9RT, UK. FAU - Gregoriou, Stamatios AU - Gregoriou S AUID- ORCID: 0000-0002-7585-1032 AD - First Department of Dermatology and Venereology, National and Kapodistrian University of Athens, Andreas Syggros Hospital, 161 21 Athens, Greece. FAU - Drakopoulou, Maria AU - Drakopoulou M AD - Unit of Structural Heart Diseases, First Department of Cardiology, National and Kapodistrian University of Athens, Hippocration General Hospital of Athens, 115 27 Athens, Greece. AD - First Department of Cardiology, National and Kapodistrian University of Athens, Hippocration General Hospital of Athens, 115 27 Athens, Greece. FAU - Trantalis, Georgios AU - Trantalis G AUID- ORCID: 0000-0001-6193-6329 AD - Unit of Structural Heart Diseases, First Department of Cardiology, National and Kapodistrian University of Athens, Hippocration General Hospital of Athens, 115 27 Athens, Greece. AD - First Department of Cardiology, National and Kapodistrian University of Athens, Hippocration General Hospital of Athens, 115 27 Athens, Greece. FAU - Tsiogka, Aikaterini AU - Tsiogka A AD - First Department of Dermatology and Venereology, National and Kapodistrian University of Athens, Andreas Syggros Hospital, 161 21 Athens, Greece. FAU - Ktenopoulos, Nikolaos AU - Ktenopoulos N AUID- ORCID: 0000-0002-0995-7015 AD - Unit of Structural Heart Diseases, First Department of Cardiology, National and Kapodistrian University of Athens, Hippocration General Hospital of Athens, 115 27 Athens, Greece. AD - First Department of Cardiology, National and Kapodistrian University of Athens, Hippocration General Hospital of Athens, 115 27 Athens, Greece. FAU - Vlachakis, Panayotis K AU - Vlachakis PK AUID- ORCID: 0000-0003-0736-4942 AD - Unit of Structural Heart Diseases, First Department of Cardiology, National and Kapodistrian University of Athens, Hippocration General Hospital of Athens, 115 27 Athens, Greece. AD - First Department of Cardiology, National and Kapodistrian University of Athens, Hippocration General Hospital of Athens, 115 27 Athens, Greece. FAU - Karakasis, Paschalis AU - Karakasis P AUID- ORCID: 0000-0002-3561-5713 AD - Second Department of Cardiology, Medical School, Aristotle University of Thessaloniki, Hippokration General Hospital, 546 42 Thessaloniki, Greece. FAU - Synetos, Andreas AU - Synetos A AUID- ORCID: 0000-0001-8516-1177 AD - Unit of Structural Heart Diseases, First Department of Cardiology, National and Kapodistrian University of Athens, Hippocration General Hospital of Athens, 115 27 Athens, Greece. AD - First Department of Cardiology, National and Kapodistrian University of Athens, Hippocration General Hospital of Athens, 115 27 Athens, Greece. AD - Medical School, European University of Cyprus, 2404 Egkomi, Cyprus. FAU - Tsivgoulis, Georgios AU - Tsivgoulis G AUID- ORCID: 0000-0002-0640-3797 AD - Second Department of Neurology, School of Medicine, National and Kapodistrian University of Athens, "Attikon" University Hospital, 124 62 Athens, Greece. AD - Department of Neurology, University of Tennessee Health Science Center, Memphis, TN 38163, USA. FAU - Stratigos, Alexander AU - Stratigos A AD - First Department of Cardiology, National and Kapodistrian University of Athens, Hippocration General Hospital of Athens, 115 27 Athens, Greece. FAU - Tsioufis, Konstantinos AU - Tsioufis K AUID- ORCID: 0000-0002-7636-6725 AD - Unit of Structural Heart Diseases, First Department of Cardiology, National and Kapodistrian University of Athens, Hippocration General Hospital of Athens, 115 27 Athens, Greece. AD - First Department of Cardiology, National and Kapodistrian University of Athens, Hippocration General Hospital of Athens, 115 27 Athens, Greece. FAU - Toutouzas, Konstantinos AU - Toutouzas K AD - Unit of Structural Heart Diseases, First Department of Cardiology, National and Kapodistrian University of Athens, Hippocration General Hospital of Athens, 115 27 Athens, Greece. AD - First Department of Cardiology, National and Kapodistrian University of Athens, Hippocration General Hospital of Athens, 115 27 Athens, Greece. LA - eng PT - Journal Article DEP - 20251024 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC12608346 OTO - NOTNLM OT - PFO OT - allergy OT - hypersensitivity OT - metal OT - nickel OT - review COIS- The authors declare no conflicts of interest. EDAT- 2025/11/13 06:29 MHDA- 2025/11/13 06:30 PMCR- 2025/10/24 CRDT- 2025/11/13 01:05 PHST- 2025/09/17 00:00 [received] PHST- 2025/10/21 00:00 [revised] PHST- 2025/10/22 00:00 [accepted] PHST- 2025/11/13 06:30 [medline] PHST- 2025/11/13 06:29 [pubmed] PHST- 2025/11/13 01:05 [entrez] PHST- 2025/10/24 00:00 [pmc-release] AID - jcm14217540 [pii] AID - jcm-14-07540 [pii] AID - 10.3390/jcm14217540 [doi] PST - epublish SO - J Clin Med. 2025 Oct 24;14(21):7540. doi: 10.3390/jcm14217540. PMID- 41225976 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251113 LR - 20251115 IS - 2075-4418 (Print) IS - 2075-4418 (Electronic) IS - 2075-4418 (Linking) VI - 15 IP - 21 DP - 2025 Oct 23 TI - A Multi-Modality Approach to the Assessment of a Right Atrium Mass in a Female Patient with Breast Cancer Undergoing Neoadjuvant Chemotherapy. LID - 10.3390/diagnostics15212683 [doi] LID - 2683 AB - Echocardiography remains a vital part of the initial assessment and monitoring of oncological patients. It allows for proper treatment selection but can also reveal life-threatening complications, including impaired left ventricular function or thromboembolism. It can rarely detect intracardiac masses that require further investigation. In the presented case, a 51-year-old female patient with left-sided breast cancer, who had undergone neoadjuvant chemotherapy, was hospitalised due to a right atrial mass identified via routine transthoracic echocardiography (TTE). Initial anticoagulation therapy showed no clinical improvement. Follow-up TTE revealed a 12 x 19 mm hyperechogenic, mobile mass in the right atrium (RA). Computed tomography angiography (CTA) ruled out pulmonary embolism and revealed that the mass was located close to the tip of the vascular access port. Transoesophageal echocardiography showed that the lesion was not connected to the vascular port. Based on location and mobility, the lesion was most consistent with a cardiac myxoma. After the Heart Team made a decision, endovascular intervention using a vacuum-assisted device was performed without complications. Histopathological examination excluded thrombosis and myxoma, revealing a fibro-inflammatory lesion. A multimodality approach is necessary to assess RA masses. However, even an extensive evaluation could be misleading, so treatment options should always be subject to the Heart Team's decision. FAU - Chlabicz, Malgorzata AU - Chlabicz M AUID- ORCID: 0000-0002-2229-8026 AD - Department of Invasive Cardiology, Medical University of Bialystok, M. Sklodowskiej-Curie 24A, 15-276 Bialystok, Poland. FAU - Muszynski, Pawel AU - Muszynski P AUID- ORCID: 0000-0003-0974-7138 AD - Department of Invasive Cardiology, Medical University of Bialystok, M. Sklodowskiej-Curie 24A, 15-276 Bialystok, Poland. AD - Department of Cardiology, Lipidology and Internal Diseases, Medical University of Bialystok, Zurawia 14, 15-569 Bialystok, Poland. FAU - Kruszynska, Joanna AU - Kruszynska J AD - Department of Invasive Cardiology, Medical University of Bialystok, M. Sklodowskiej-Curie 24A, 15-276 Bialystok, Poland. FAU - Kazberuk, Piotr AU - Kazberuk P AD - Faculty of Medicine, Medical University of Bialystok, Kilinskiego 1, 15-089 Bialystok, Poland. FAU - Rog-Makal, Magdalena AU - Rog-Makal M AUID- ORCID: 0009-0003-9523-0334 AD - Department of Invasive Cardiology, Medical University of Bialystok, M. Sklodowskiej-Curie 24A, 15-276 Bialystok, Poland. FAU - Lipowicz, Magdalena AU - Lipowicz M AD - Department of Invasive Cardiology, Medical University of Bialystok, M. Sklodowskiej-Curie 24A, 15-276 Bialystok, Poland. FAU - Matys, Urszula AU - Matys U AD - Department of Invasive Cardiology, Medical University of Bialystok, M. Sklodowskiej-Curie 24A, 15-276 Bialystok, Poland. FAU - Tomaszuk-Kazberuk, Anna AU - Tomaszuk-Kazberuk A AUID- ORCID: 0000-0003-0153-0356 AD - Department of Cardiology, Lipidology and Internal Diseases, Medical University of Bialystok, Zurawia 14, 15-569 Bialystok, Poland. FAU - Kozuch, Marcin AU - Kozuch M AUID- ORCID: 0000-0002-1430-7455 AD - Department of Invasive Cardiology, Medical University of Bialystok, M. Sklodowskiej-Curie 24A, 15-276 Bialystok, Poland. FAU - Dobrzycki, Slawomir AU - Dobrzycki S AD - Department of Invasive Cardiology, Medical University of Bialystok, M. Sklodowskiej-Curie 24A, 15-276 Bialystok, Poland. LA - eng GR - B.SUB.25.505 B.SUB.25.295/Medical University of Bialystok/ PT - Journal Article DEP - 20251023 PL - Switzerland TA - Diagnostics (Basel) JT - Diagnostics (Basel, Switzerland) JID - 101658402 PMC - PMC12609404 OTO - NOTNLM OT - cardiac masses OT - cardio-oncology OT - echocardiography OT - multi-modality COIS- The authors declare no conflicts of interest. EDAT- 2025/11/13 06:29 MHDA- 2025/11/13 06:30 PMCR- 2025/10/23 CRDT- 2025/11/13 01:02 PHST- 2025/09/09 00:00 [received] PHST- 2025/10/20 00:00 [revised] PHST- 2025/10/21 00:00 [accepted] PHST- 2025/11/13 06:30 [medline] PHST- 2025/11/13 06:29 [pubmed] PHST- 2025/11/13 01:02 [entrez] PHST- 2025/10/23 00:00 [pmc-release] AID - diagnostics15212683 [pii] AID - diagnostics-15-02683 [pii] AID - 10.3390/diagnostics15212683 [doi] PST - epublish SO - Diagnostics (Basel). 2025 Oct 23;15(21):2683. doi: 10.3390/diagnostics15212683. PMID- 41224262 OWN - NLM STAT- MEDLINE DCOM- 20251130 LR - 20251201 IS - 1349-3299 (Electronic) IS - 1349-2365 (Linking) VI - 66 IP - 6 DP - 2025 Nov 29 TI - Clinical Implications of a Nurse-Led Heart Failure Clinic at a Rural Japanese Hospital. PG - 978-985 LID - 10.1536/ihj.25-405 [doi] AB - Clinical outcomes in patients with chronic heart failure (HF) remain suboptimal, even in the contemporary era of guideline-directed medical therapy. HF nursing clinics may offer additional benefits by enhancing self-management and improving quality of life in this population.We retrospectively analyzed prospectively collected clinical data regarding a monthly HF nursing clinic conducted between April 2023 and March 2025. The clinic was operated by certified HF nurses and certified HF educators, who consistently followed patients with chronic HF following discharge from an index HF hospitalization. All participants underwent a multidisciplinary conference prior to index discharge.A total of 47 patients (median age: 75 years; 31 [66%] men) were included, with 27 patients (57%) classified as having preserved ejection fraction. Over a median follow-up of 217 (93, 321) days, the median number of clinic visits was 5, and the median counseling duration was 25 (20, 30) minutes per visit. The most frequent counseling topics included psychological support, promotion of self-monitoring and self-management, and dietary guidance. Plasma B-type natriuretic peptide and serum albumin levels improved over the follow-up period, while the estimated glomerular filtration rate remained unchanged. The one-year freedom from HF hospitalization rate was 54%.We report our preliminary two-year experience with a HF nursing clinic led by certified HF nurses and HF educators at a rural Japanese university hospital. These findings are exploratory and may help inform future development of nurse-led multidisciplinary care models. Further studies are needed to validate this approach and better understand its potential clinical implications. FAU - Miyashita, Hiroshi AU - Miyashita H AD - Second Department of Medicine, University of Toyama. FAU - Imamura, Teruhiko AU - Imamura T AD - Second Department of Medicine, University of Toyama. FAU - Tanaka, Tomomi AU - Tanaka T AD - Second Department of Medicine, University of Toyama. FAU - Fujisaka, Aki AU - Fujisaka A AD - Second Department of Medicine, University of Toyama. FAU - Yamaguchi, Takako AU - Yamaguchi T AD - Second Department of Medicine, University of Toyama. FAU - Kinugawa, Koichiro AU - Kinugawa K AD - Second Department of Medicine, University of Toyama. LA - eng PT - Journal Article DEP - 20251111 PL - Japan TA - Int Heart J JT - International heart journal JID - 101244240 RN - Japanese people SB - IM MH - Humans MH - *Heart Failure/nursing/therapy MH - Male MH - Female MH - Aged MH - Japan/epidemiology MH - Retrospective Studies MH - *Hospitals, Rural MH - Quality of Life MH - Aged, 80 and over MH - Middle Aged MH - Hospitalization/statistics & numerical data MH - East Asian People OTO - NOTNLM OT - Adherence OT - Monitoring OT - Quality of life EDAT- 2025/11/13 00:29 MHDA- 2025/12/01 00:29 CRDT- 2025/11/12 20:32 PHST- 2025/12/01 00:29 [medline] PHST- 2025/11/13 00:29 [pubmed] PHST- 2025/11/12 20:32 [entrez] AID - 10.1536/ihj.25-405 [doi] PST - ppublish SO - Int Heart J. 2025 Nov 29;66(6):978-985. doi: 10.1536/ihj.25-405. Epub 2025 Nov 11. PMID- 41221129 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251112 LR - 20251114 IS - 2634-4793 (Electronic) IS - 2634-4793 (Linking) VI - 5 IP - 1 DP - 2025 Jan TI - A survey of UK-based screening and surveillance practices for carcinoid heart disease in patients with neuroendocrine tumours. PG - e250003 LID - 10.1530/EO-25-0003 [doi] LID - e250003 AB - Symptoms of carcinoid heart disease (CHD) can be subtle or absent even in advanced disease; therefore screening for CHD is important in the management of neuroendocrine tumours (NETs). Previous data in 2015 demonstrated variation in screening practices in the United Kingdom and Ireland; since then, consensus guidelines and European recommendations have been published on screening for CHD and surveillance in patients with NETs. We aimed to repeat the survey to compare current practice with the previous study. Eighteen NET centres caring for over 4,500 patients completed an online questionnaire on their patient population, CHD screening and surveillance practices, and the role of the multidisciplinary team. Screening occurred in all centres, including clinical examination in 56% of centres compared with 68% previously; all centres used biomarkers compared with 50% in 2015. Echocardiography was performed at varying frequency, mainly at baseline and repeated when biomarkers were abnormal (35%), compared with baseline in 21% previously. The timing of echocardiographic surveillance in established CHD remains varied: 6-monthly in 39%, annually in 17%, and according to cardiology input and individual patient context in 44%; compared with a variety of timings in 2015, ranging from less than 6-monthly to annually. The MDT included a cardiologist in 44% of centres compared with 50% previously, and 22% made cardiology referrals to a regional centre for CHD. Our findings suggest that although screening for and surveillance of CHD in the UK have improved, variation persists, which may contribute to late presentation. CI - (c) the author(s). FAU - Douglas, Sasha AU - Douglas S AUID- ORCID: 0000-0003-0384-6530 AD - Department of Cardiology, University Hospitals Birmingham (Queen Elizabeth), NHS Hospitals Foundation Trust, Birmingham, UK. AD - Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK. FAU - Shah, Tahir AU - Shah T AD - Birmingham Neuroendocrine Tumour Centre, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. FAU - Steeds, Richard P AU - Steeds RP AUID- ORCID: 0000-0001-5687-2535 AD - Department of Cardiology, University Hospitals Birmingham (Queen Elizabeth), NHS Hospitals Foundation Trust, Birmingham, UK. AD - Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK. FAU - Dobson, Rebecca AU - Dobson R AD - Department of Cardiology, Liverpool Heart and Chest NHS Foundation Trust, Liverpool, UK. LA - eng PT - Journal Article DEP - 20251105 PL - England TA - Endocr Oncol JT - Endocrine oncology (Bristol, England) JID - 9918540584106676 PMC - PMC12598728 OTO - NOTNLM OT - carcinoid heart disease OT - neuroendocrine tumour OT - screening OT - surveillance COIS- The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the work reported. EDAT- 2025/11/12 06:31 MHDA- 2025/11/12 06:32 PMCR- 2025/11/05 CRDT- 2025/11/12 04:31 PHST- 2025/01/07 00:00 [received] PHST- 2025/07/29 00:00 [revised] PHST- 2025/10/23 00:00 [accepted] PHST- 2025/11/12 06:32 [medline] PHST- 2025/11/12 06:31 [pubmed] PHST- 2025/11/12 04:31 [entrez] PHST- 2025/11/05 00:00 [pmc-release] AID - EO-25-0003 [pii] AID - 10.1530/EO-25-0003 [doi] PST - epublish SO - Endocr Oncol. 2025 Nov 5;5(1):e250003. doi: 10.1530/EO-25-0003. eCollection 2025 Jan. PMID- 41218637 OWN - NLM STAT- MEDLINE DCOM- 20251202 LR - 20260505 IS - 1439-1902 (Electronic) IS - 0171-6425 (Linking) VI - 73 IP - 8 DP - 2025 Dec TI - "End-of-Life Care" in Cardiac Surgery. PG - 649-660 LID - 10.1055/a-2686-4680 [doi] AB - Modern cardiovascular medicine and surgery enable the treatment of complex cardiovascular disease, even in elderly and multimorbid patients, through increasingly sophisticated procedures. Nevertheless, there are situations in which surgical intervention appears medically inappropriate or is explicitly declined by the patient. Similarly, it may become necessary in the postoperative course to revise the original therapeutic goals-particularly when continued survival depends upon prolonged intensive care unit treatment, or when the anticipated quality of life, from the patient's perspective, appears inadequate. While established guidelines and position papers-most notably from the German Interdisciplinary Association for Intensive and Emergency Medicine-are already available in the field of intensive care medicine, a discipline-specific framework for cardiac surgery has been lacking thus far. This inaugural position paper issued by the German Society for Thoracic and Cardiovascular Surgery seeks to contribute to the definition of clinical and ethical standards in the context of therapeutic restraint (Section A) and to the redefinition of therapeutic goals (Section B) within our specialty. The aim is to promote a structured and multiprofessional approach that transparently integrates the core pillars of goal setting in therapy-namely, medical indication and patient autonomy-into a comprehensible decision-making framework. Achieving this objective requires close collaboration among physicians and nursing staff in cardiac surgery, cardiology, intensive care, anesthesiology, ethics consultation, and palliative care. The present recommendations are intended to serve as a foundation for patient-centered, appropriate, and transparent decision-making-always with the overarching aim of preserving the dignity and self-determination of the patients concerned. CI - Thieme. All rights reserved. FAU - Lichtenberg, Artur AU - Lichtenberg A AUID- ORCID: 0000-0001-8580-6369 AD - Department of Cardiac Surgery, Faculty of Medicine, Heinrich Heine University Dusseldorf, Dusseldorf, Germany. FAU - Scherner, Max AU - Scherner M AUID- ORCID: 0009-0006-6543-5226 AD - Department of Cardiac Surgery, Faculty of Medicine, Heinrich Heine University Dusseldorf, Dusseldorf, Germany. FAU - Meier, Stefan AU - Meier S AD - Department of Anaesthesiology, Faculty of Medicine, Heinrich Heine University Dusseldorf, Dusseldorf, Germany. FAU - Blum, Moritz AU - Blum M AD - Department of Cardiac, German Heart Centre of the Charite, Thoracic and Vascular Surgery, Berlin, Germany. AD - Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany. FAU - Krane, Markus AU - Krane M AD - Department of Cardiac and Vascular Surgery, German Heart Centre Munich, Technical University of Munich, Munich, Germany. FAU - Doenst, Torsten AU - Doenst T AD - Department of Cardiac and Thoracic Surgery, University Hospital Jena, Friedrich Schiller University Jena, Jena, Germany. FAU - Beckmann, Andreas AU - Beckmann A AUID- ORCID: 0000-0003-0785-2591 AD - Department of Cardiac and Paediatric Cardiac Surgery, Evangelical Hospital Niederrhein, Heart Centre Duisburg, Duisburg, Germany. FAU - Falk, Volkmar AU - Falk V AD - Department of Cardiac, German Heart Centre of the Charite, Thoracic and Vascular Surgery, Berlin, Germany. AD - Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany. LA - eng PT - Journal Article PT - Practice Guideline PT - Review DEP - 20251111 PL - Germany TA - Thorac Cardiovasc Surg JT - The Thoracic and cardiovascular surgeon JID - 7903387 SB - IM MH - Humans MH - *Cardiac Surgical Procedures/adverse effects/standards/ethics/mortality MH - *Terminal Care/standards/ethics MH - Clinical Decision-Making MH - Treatment Outcome MH - Interdisciplinary Communication MH - Consensus MH - Patient Care Team/standards MH - Germany MH - Quality of Life COIS- None declared. EDAT- 2025/11/12 00:26 MHDA- 2025/12/03 01:16 CRDT- 2025/11/11 18:53 PHST- 2025/12/03 01:16 [medline] PHST- 2025/11/12 00:26 [pubmed] PHST- 2025/11/11 18:53 [entrez] AID - 10.1055/a-2686-4680 [doi] PST - ppublish SO - Thorac Cardiovasc Surg. 2025 Dec;73(8):649-660. doi: 10.1055/a-2686-4680. Epub 2025 Nov 11. PMID- 41218000 OWN - NLM STAT- MEDLINE DCOM- 20260413 LR - 20260413 IS - 2150-136X (Electronic) IS - 2150-1351 (Linking) VI - 17 IP - 3 DP - 2026 May TI - Development of a High-Performing Congenital Heart Program in Vietnam. PG - 310-317 LID - 10.1177/21501351251386684 [doi] AB - ObjectiveChildren's HeartLink and the University of California San Francisco (UCSF) have partnered with Vietnam National Children's Hospital (VNCH). Compared with low- and middle-income countries (LMICs) enrolled in the International Quality Improvement Collaborative for Congenital Heart Disease, VNCH is a high performing center. Our goal is to compare outcomes of VNCH with North American centers leveraging data from the Pediatric Cardiac Critical Care Consortium (PC(4)) in 2023.MethodsChildren's HeartLink established a partnership with VNCH in 2017 with a consistent senior-level medical volunteer team from UCSF (Dr Sano currently at Showa University Hospital) engaged in semiannual training visits and weekly case conferences. In-person visits have evolved to hands-off teaching. Areas of improvement are identified, and outcomes presented at the subsequent visit. International Quality Improvement Collaborative and PC(4) perform site specific audits to confirm data accuracy. Data presented are based on primary operations. Conversion from Risk Adjustment for Congenital Heart Surgery (RACHS-1) to STAT is as follows: RACHS-1 1-4 equal STAT 1-4; RACHS-1 5-6 equal STAT 5.ResultsResults represent 8 on-site visits and 109 case discussions. VNCH performed 1,056 operations, and PC(4) represents 14,506 operations in 2023. VNCH had comparable outcomes, except higher surgical mortality for infants with prematurity and noncardiac abnormalities, and a higher rate of surgical site infections. VNCH performed fewer operations on patients with noncardiac abnormalities and higher STAT scores.ConclusionsPartnership of highly resourced North American programs with underresourced LMIC centers can elevate congenital heart surgery outcomes. VNCH is a high-volume center with respectable outcomes. Future focus will be higher STAT level and neonatal surgeries. FAU - Nguyen, Chau P AU - Nguyen CP AUID- ORCID: 0009-0003-4503-6197 AD - Division of Cardiology, Department of Pediatrics, Emory University/Children's Healthcare of Atlanta, Atlanta, GA, USA. RINGGOLD: 12239 FAU - Nguyen, Huu Nhat AU - Nguyen HN AD - Department of Cardiovascular Surgery, Vietnam National Children's Hospital, Hanoi, Vietnam. RINGGOLD: 21642 FAU - Tabbutt, Sarah AU - Tabbutt S AD - Division of Critical Care Medicine, Department of Pediatrics, University of California San Francisco Benioff Children's Hospitals, San Francisco, CA, USA. FAU - Sano, Shunji AU - Sano S AD - Department of Cardiothoracic Surgery, Showa University Koto-Toyosu Hospital, Koto, Tokyo, Japan. RINGGOLD: 378609 FAU - Cocalis, Mark AU - Cocalis M AD - Division of Cardiology, Department of Pediatrics, University of California San Francisco Benioff Children's Hospitals, San Francisco, CA, USA. RINGGOLD: 21642 FAU - Nguyen, Hung AU - Nguyen H AD - Department of Anesthesia, University of California San Francisco Benioff Children's Hospitals, San Francisco, CA, USA. RINGGOLD: 21642 FAU - Busch, Helen AU - Busch H AD - Department of Nursing, University of California San Francisco Benioff Children's Hospitals, San Francisco, CA, USA. RINGGOLD: 21642 FAU - Dobrzycka, Adriana AU - Dobrzycka A AD - Children's HeartLink. RINGGOLD: 587030 FAU - Jenkins, Kathy J AU - Jenkins KJ AD - Department of Cardiology, Boston Children's Hospital, Harvard University, Cambridge, MA, USA. RINGGOLD: 1862 FAU - Gauvreau, Kimberlee AU - Gauvreau K AD - Department of Cardiology, Boston Children's Hospital, Harvard University, Cambridge, MA, USA. RINGGOLD: 1862 FAU - Nguyen Duc, Hanh Luu AU - Nguyen Duc HL AUID- ORCID: 0009-0009-4359-7154 AD - Nguyen Tat Thanh University, Ho Chi Minh City, Viet Nam. RINGGOLD: 384731 FAU - Ly Thinh, Truong N AU - Ly Thinh TN AUID- ORCID: 0000-0002-1858-1523 AD - Department of Cardiovascular Surgery, Vietnam National Children's Hospital, Hanoi, Vietnam. RINGGOLD: 21642 LA - eng PT - Journal Article DEP - 20251111 PL - United States TA - World J Pediatr Congenit Heart Surg JT - World journal for pediatric & congenital heart surgery JID - 101518415 SB - IM MH - Humans MH - *Heart Defects, Congenital/surgery MH - Vietnam/epidemiology MH - *Quality Improvement MH - Infant, Newborn MH - *Cardiac Surgical Procedures/standards MH - *Program Development MH - Infant MH - *Hospitals, Pediatric MH - Male MH - Female OTO - NOTNLM OT - Pediatric Cardiac Critical Care Consortium OT - Vietnam OT - congenital heart surgery OT - low- and middle-income countries OT - outcome COIS- Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2025/11/11 18:25 MHDA- 2026/04/13 12:37 CRDT- 2025/11/11 13:24 PHST- 2026/04/13 12:37 [medline] PHST- 2025/11/11 18:25 [pubmed] PHST- 2025/11/11 13:24 [entrez] AID - 10.1177/21501351251386684 [doi] PST - ppublish SO - World J Pediatr Congenit Heart Surg. 2026 May;17(3):310-317. doi: 10.1177/21501351251386684. Epub 2025 Nov 11. PMID- 41213660 OWN - NLM STAT- MEDLINE DCOM- 20251113 LR - 20260917 IS - 2059-7908 (Print) IS - 2059-7908 (Electronic) IS - 2059-7908 (Linking) VI - 10 IP - 11 DP - 2025 Nov 9 TI - Epidemiology of sudden cardiac arrest in the western Mediterranean area based on a prospective registry. LID - 10.1136/bmjgh-2025-020462 [doi] LID - e020462 AB - BACKGROUND: The epidemiology of sudden cardiac arrest (SCA) in the Mediterranean area remains unclear. The aim of this study is to determine the incidence, causes and characteristics of SCA in this setting. METHODS: A prospective registry of out-of-hospital cardiac arrests from multiple sources of information was carried out in the Tarragona region (western Mediterranean) with a population of 610 865 inhabitants between 2014 and 2017. The attending clinician assessed the cases on-site. SCA was defined as an unexpected out-of-hospital cardiac arrest, with a presumed cardiac cause, occurring within 1 hour of symptom onset or seen in good condition within the last 24 hours. Data were obtained from the emergency medical service, forensic autopsies, hospitals and primary care centres. RESULTS: A total of 639 SCAs were collected. The incidence was 34.8 (95% CI 32.2 to 37.6) cases per 100 000 person-years. The mean age was 66.9 (SD 15.6) years, and 70.1% were male. 20.5% did not receive a cardiopulmonary resuscitation (CPR) attempt. Investigations for the aetiology of cardiac arrest were conducted in hospitals in 20.3% of cases and through forensic autopsies in 36.4%. Of all SCAs with a presumed cardiac cause, 55.5% had a known cause, of which 85.3% were cardiovascular (69.8% cardiac, 15.5% cardiovascular non-cardiac and 14.6% non-cardiovascular). More cardiac causes were recorded in hospitalised patients than in forensic cases (76.9% vs 66.4%, p=0.042). Coronary heart disease (45.6%) was the main cause, with chronic coronary heart disease (24.5%) being the most frequent type. Cases with a non-cardiac cardiovascular cause presented similar cardiovascular risk factors compared with cases with a cardiac cause. Survival was 10.2%. Chest pain prior to collapse and the use of automatic external defibrillators were associated with survival. CONCLUSION: In this western Mediterranean region, a low incidence of SCA and a low burden of coronary heart disease were found. A comprehensive, multidisciplinary approach is needed to prevent SCA. CI - (c) Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. FAU - Azeli, Youcef AU - Azeli Y AUID- ORCID: 0000-0003-3558-124X AD - Sistema d'Emergencies Mediques de Catalunya, L'Hospitalet de Llobregat, Barcelona, Spain youcefazeli@gencat.cat. AD - Servei d'Urgencies, Hospital Universitari Sant Joan de Reus, Reus, Spain. AD - Institut d'Investigacio Sanitaria Pere i Virgili (IISPV), Reus, Spain. FAU - Barberia, Eneko AU - Barberia E AUID- ORCID: 0000-0001-5804-3597 AD - Institut de Medicina Legal i Ciencies Forenses de Catalunya, Barcelona, Spain. AD - Universitat Rovira i Virgili, Reus, Spain. FAU - Sola-Munoz, Silvia AU - Sola-Munoz S AD - Sistema d'Emergencies Mediques de Catalunya, L'Hospitalet de Llobregat, Barcelona, Spain. AD - Institut d'Investigacio Sanitaria Pere i Virgili (IISPV), Reus, Spain. FAU - Landin, Ines AU - Landin I AD - Institut de Medicina Legal i Ciencies Forenses de Catalunya, Barcelona, Spain. AD - Universitat Rovira i Virgili, Reus, Spain. FAU - Fernandez, Alberto AU - Fernandez A AUID- ORCID: 0000-0002-1241-1646 AD - Departament d'Enginyeria Quimica, Universitat Rovira i Virgili, Tarragona, Spain. FAU - Rey-Renones, Cristina AU - Rey-Renones C AUID- ORCID: 0000-0003-2017-8220 AD - Universitat Rovira i Virgili, Reus, Spain. AD - Unitat de Suport a la Recerca Tarragona-Reus, Fundacio Institut Universitari per a la recerca a l'Atencio Primaria de Salut Jordi Gol i Gurina (IDIAPJGol), Reus, Spain. FAU - Garcia-Gual, Carmen AU - Garcia-Gual C AD - Sistema d'Emergencies Mediques de Catalunya, L'Hospitalet de Llobregat, Barcelona, Spain. FAU - Gomez-Tortosa, Amanda AU - Gomez-Tortosa A AD - Sistema d'Emergencies Mediques de Catalunya, L'Hospitalet de Llobregat, Barcelona, Spain. FAU - Granado-Font, Ester AU - Granado-Font E AD - Centre d'Atencio Primaria Horts de Miro (Reus-4), Institut Catala de Salut, Reus, Spain. FAU - Fernandez-Sender, Laura AU - Fernandez-Sender L AD - Xarxa Sanitaria Social i Docent Santa Tecla, Tarragona, Spain. FAU - Garcia-Vilana, Silvia AU - Garcia-Vilana S AD - Universitat Politecnica de Catalunya, BarcelonaTech (UPC-EPSEVG), Barcelona, Spain. FAU - Bonet, Gil AU - Bonet G AD - Cardiology Department, Joan XXIII University Hospital Tarragona, Tarragona, Spain. AD - Universitat Rovira i Virgili, Tarragona, Spain. AD - Institut d'Investigacio Sanitaria Pere i Virgili (IISPV), Tarragona, Spain. FAU - Jimenez-Fabrega, Xavier AU - Jimenez-Fabrega X AD - Sistema d'Emergencies Mediques de Catalunya, L'Hospitalet de Llobregat, Barcelona, Spain. AD - Institut d'Investigacio Sanitaria Pere i Virgili (IISPV), Reus, Spain. AD - Facultat de Medicina, Universitat de Barcelona, Barcelona, Spain. FAU - Bardaji, Alfredo AU - Bardaji A AD - Cardiology Department, Joan XXIII University Hospital Tarragona, Tarragona, Spain. AD - Universitat Rovira i Virgili, Tarragona, Spain. AD - Institut d'Investigacio Sanitaria Pere i Virgili (IISPV), Tarragona, Spain. LA - eng PT - Journal Article DEP - 20251109 PL - England TA - BMJ Glob Health JT - BMJ global health JID - 101685275 SB - IM MH - Humans MH - Male MH - Female MH - Registries MH - Aged MH - Prospective Studies MH - Middle Aged MH - *Out-of-Hospital Cardiac Arrest/epidemiology/etiology MH - Incidence MH - *Death, Sudden, Cardiac/epidemiology MH - Aged, 80 and over MH - Adult MH - Spain/epidemiology MH - Cardiopulmonary Resuscitation/statistics & numerical data MH - Mediterranean Region/epidemiology MH - Risk Factors PMC - PMC12603738 OTO - NOTNLM OT - Epidemiology OT - Interdisciplinary Research OT - Public Health COIS- Competing interests: None declared. EDAT- 2025/11/11 00:27 MHDA- 2025/11/13 06:30 PMCR- 2025/11/09 CRDT- 2025/11/10 20:32 PHST- 2025/05/07 00:00 [received] PHST- 2025/10/15 00:00 [accepted] PHST- 2025/11/13 06:30 [medline] PHST- 2025/11/11 00:27 [pubmed] PHST- 2025/11/10 20:32 [entrez] PHST- 2025/11/09 00:00 [pmc-release] AID - bmjgh-2025-020462 [pii] AID - 10.1136/bmjgh-2025-020462 [doi] PST - epublish SO - BMJ Glob Health. 2025 Nov 9;10(11):e020462. doi: 10.1136/bmjgh-2025-020462. PMID- 41210341 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251112 LR - 20251112 IS - 2297-055X (Print) IS - 2297-055X (Electronic) IS - 2297-055X (Linking) VI - 12 DP - 2025 TI - Current strategies for prevention of cancer therapy-related cardiotoxicity: pharmacological, non-pharmacological and emerging approaches. PG - 1668308 LID - 10.3389/fcvm.2025.1668308 [doi] LID - 1668308 AB - BACKGROUND: Cardiotoxicity is a major concern in cancer survivors, potentially compromising treatment efficacy, quality of life and long-term survival. With increasing survival rates, the need for effective cardioprotective strategies has become paramount. OBJECTIVE: This narrative review evaluates current pharmacological, non-pharmacological, and emerging strategies for preventing cancer therapy-related cardiac dysfunction (CTR-CD), emphasizing recent advances, their clinical applicability and research gaps. METHODS: We conducted a narrative review based on a non-systematic search of PubMed/MEDLINE, Scopus, and Web of Science up to June 2025, focusing on clinical trials, meta-analyses, guideline recommendations, and key observational studies relevant to CTR-CD prevention. RESULTS: Among pharmacological approaches, renin-angiotensin-aldosterone system inhibitors (RAASi) and beta-blockers modestly preserve left ventricular ejection fraction (LVEF), though benefits on hard outcomes remain unproven. Dexrazoxane is the only FDA-approved agent and shows robust protection in anthracycline-treated patients. Statins and metformin demonstrate promising but still investigational cardioprotective effects, while sodium-glucose cotransporter-2 inhibitors (SGLT2i) show encouraging pilot data. Non-pharmacological strategies-including structured exercise, mediterranean diet, nutritional support and aggressive control of risk factors-are guideline-endorsed, although most evidence relies on surrogate endpoints. Emerging tools such as telemedicine, artificial intelligence and omics sciences offer innovative opportunities for personalized prevention but require multicenter validation. CONCLUSION: An integrated, multidisciplinary approach combining both pharmacological and non-pharmacological strategies is essential to effectively prevent cardiotoxicity in cancer patients. Current evidence supports dexrazoxane, risk factor control and selective use of RAASi or beta-blocker in high-risk patients. Exercise and nutrition provide functional and quality of life benefits, while several novel strategies remain exploratory. Future large-scale, multicenter, randomized trial are needed to harmonize international guidelines and define the most effective, sustainable prevention models across diverse patient populations. CI - (c) 2025 Migliari, Fazzini, Campana, Deidda, Dessi and Cadeddu Dessalvi. FAU - Migliari, Michele AU - Migliari M AD - Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy. FAU - Fazzini, Luca AU - Fazzini L AD - Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy. FAU - Campana, Nicola AU - Campana N AD - Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy. FAU - Deidda, Martino AU - Deidda M AD - Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy. FAU - Dessi, Mariele AU - Dessi M AD - Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy. FAU - Cadeddu Dessalvi, Christian AU - Cadeddu Dessalvi C AD - Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy. LA - eng PT - Journal Article PT - Review DEP - 20251023 PL - Switzerland TA - Front Cardiovasc Med JT - Frontiers in cardiovascular medicine JID - 101653388 PMC - PMC12589006 OTO - NOTNLM OT - artificial intelligente OT - cancer therapy-related cardiac dysfunction OT - cardio-oncology OT - cardiotoxicity OT - non-pharmacological strategies OT - pharmacological strategies OT - prevention COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2025/11/10 18:15 MHDA- 2025/11/10 18:16 PMCR- 2025/10/23 CRDT- 2025/11/10 06:07 PHST- 2025/07/17 00:00 [received] PHST- 2025/09/25 00:00 [accepted] PHST- 2025/11/10 18:16 [medline] PHST- 2025/11/10 18:15 [pubmed] PHST- 2025/11/10 06:07 [entrez] PHST- 2025/10/23 00:00 [pmc-release] AID - 10.3389/fcvm.2025.1668308 [doi] PST - epublish SO - Front Cardiovasc Med. 2025 Oct 23;12:1668308. doi: 10.3389/fcvm.2025.1668308. eCollection 2025. PMID- 41209169 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251112 LR - 20251112 IS - 2590-0595 (Electronic) IS - 2590-0595 (Linking) VI - 7 IP - 11 DP - 2025 Nov TI - Reducing Excessive Interdialytic Weight Gain in Young Hemodialysis Patients: A Quality Improvement Initiative. PG - 101109 LID - 10.1016/j.xkme.2025.101109 [doi] LID - 101109 AB - RATIONALE & OBJECTIVE: Excessive interdialytic weight gain (IDWG) is associated with increased cardiovascular risk in hemodialysis patients. We aimed to reduce excessive IDWG events by 50% over 2 years using a multi-interventional quality improvement approach. STUDY DESIGN: Prospective, single-center, multimodal quality improvement initiative using Plan-Do-Study-Act cycles. SETTING & PARTICIPANTS: All pediatric and young adult patients (<27 years old) receiving outpatient hemodialysis at a single pediatric dialysis center (n = 17; 4,166 sessions) from June 2020 to June 2022. EXPOSURES: Interventions included individualized chairside education, dialysis nurse-driven patient communication, monthly IDWG tracking in team meetings, and a reduction in dialysate sodium concentration from 140 to 137 mEq/L. OUTCOMES: The primary outcome was percent of hemodialysis sessions with excessive IDWG (>/=5%). Balancing measures included additional dialysis sessions, serum sodium levels, blood pressure trends, and dialysis nurse documentation burden. ANALYTICAL APPROACH: Statistical process control charts assessed outcome trends. t Test compared pre- and postintervention data. Statistical process control chart centerlines and control limits identified special cause variation. RESULTS: At baseline, 39% of dialysis sessions showed excessive IDWG. Following the full implementation of interventions, the mean shifted to 19%, representing a 51% reduction. The dialysate sodium change and nurse-driven communication had the greatest impact. There were no significant changes in blood pressure, serum sodium, or additional dialysis sessions. Documentation time added per session averaged <3 minutes. LIMITATIONS: We did not extract patient-level clinical data such as baseline hypertension, cardiac comorbid conditions, adherence metrics, level of engagement in psychology, or antihypertensive medication adjustments. CONCLUSIONS: A multidisciplinary, multimodal quality improvement intervention significantly reduced the frequency of excessive IDWG in pediatric dialysis patients. Lowering dialysate sodium and nurse-led counseling were particularly impactful without increasing treatment burden. Future work should focus on sustainability, behavioral health integration, and long-term cardiovascular outcomes. CI - (c) 2025 The Authors. FAU - Al Barbandi, Malek AU - Al Barbandi M AD - Holtz Children's Hospital at Jackson Memorial Hospital, Miami, FL. FAU - DeFreitas, Marissa J AU - DeFreitas MJ AD - Holtz Children's Hospital at Jackson Memorial Hospital, Miami, FL. AD - Division of Nephrology and Hypertension, University of Miami, Miami, FL. FAU - Katsoufis, Chryso P AU - Katsoufis CP AD - Holtz Children's Hospital at Jackson Memorial Hospital, Miami, FL. AD - Division of Nephrology and Hypertension, University of Miami, Miami, FL. FAU - Santos, Liz Bayes AU - Santos LB AD - Holtz Children's Hospital at Jackson Memorial Hospital, Miami, FL. AD - Department of Pediatrics, Section of Hospital Medicine, Miami, FL. FAU - Sigurjonsdottir, Vaka AU - Sigurjonsdottir V AD - Holtz Children's Hospital at Jackson Memorial Hospital, Miami, FL. AD - Division of Nephrology and Hypertension, University of Miami, Miami, FL. FAU - Ridore, Michelande AU - Ridore M AD - Holtz Children's Hospital at Jackson Memorial Hospital, Miami, FL. FAU - Jackson, Beverley AU - Jackson B AD - Pediatric Dialysis Unit, Holtz Children's Hospital at Jackson Memorial Hospital, Miami, FL. FAU - Vaccaro, Daniela Safina AU - Vaccaro DS AD - Pediatric Dialysis Unit, Holtz Children's Hospital at Jackson Memorial Hospital, Miami, FL. FAU - Weir, Janette AU - Weir J AD - Pediatric Dialysis Unit, Holtz Children's Hospital at Jackson Memorial Hospital, Miami, FL. FAU - Oliva, Melisa AU - Oliva M AD - Pediatric Behavioral Health, Jackson Memorial Hospital, Miami, FL. FAU - Ospina, Clara Lora AU - Ospina CL AD - Behavioral Health, Jackson Memorial Hospital, Miami, FL. FAU - Seeherunvong, Wacharee AU - Seeherunvong W AD - Holtz Children's Hospital at Jackson Memorial Hospital, Miami, FL. AD - Division of Nephrology and Hypertension, University of Miami, Miami, FL. FAU - Chandar, Jayanthi C AU - Chandar JC AD - Holtz Children's Hospital at Jackson Memorial Hospital, Miami, FL. AD - Division of Nephrology and Hypertension, University of Miami, Miami, FL. FAU - Abitbol, Carolyn L AU - Abitbol CL AD - Holtz Children's Hospital at Jackson Memorial Hospital, Miami, FL. AD - Division of Nephrology and Hypertension, University of Miami, Miami, FL. LA - eng PT - Journal Article DEP - 20250916 PL - United States TA - Kidney Med JT - Kidney medicine JID - 101756300 PMC - PMC12595357 OAB - This study was inspired by the importance of preventing early cardiovascular dysfunction associated with fluid overload in young children with end stage kidney disease receiving hemodialysis. We designed a quality improvement-based initiative aimed at reducing excessive fluid weight gain between dialysis sessions by leveraging a multidisciplinary team's expertise including dialysis nurses, dieticians, physicians, and psychologists. Patient-centered dialysis chairside education was provided including visual aids to measure fluid intake. A fluid balance algorithm was developed and implemented including lowering the dialysis sodium concentration. Educational reinforcement was incorporated by dialysis nurse-driven electronic health record documentation and bimonthly individualized patient assessments. The rate of excessive fluid weight gain between dialysis sessions was significantly lowered after implementation of the quality improvement project. OABL- eng OTO - NOTNLM OT - Interdialytic weight gain OT - pediatric dialysis OT - quality improvement EDAT- 2025/11/10 06:29 MHDA- 2025/11/10 06:30 PMCR- 2025/09/16 CRDT- 2025/11/10 05:57 PHST- 2025/11/10 06:30 [medline] PHST- 2025/11/10 06:29 [pubmed] PHST- 2025/11/10 05:57 [entrez] PHST- 2025/09/16 00:00 [pmc-release] AID - S2590-0595(25)00145-1 [pii] AID - 101109 [pii] AID - 10.1016/j.xkme.2025.101109 [doi] PST - epublish SO - Kidney Med. 2025 Sep 16;7(11):101109. doi: 10.1016/j.xkme.2025.101109. eCollection 2025 Nov. PMID- 41209123 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251112 LR - 20251112 IS - 2153-8174 (Electronic) IS - 1530-6550 (Print) IS - 1530-6550 (Linking) VI - 26 IP - 10 DP - 2025 Oct TI - The Effects of Surface Gastrointestinal Electrical Stimulation on Gastrointestinal Function Recovery in Patients After Acute Type A Aortic Dissection Open-Heart Surgery: A Randomized, Controlled Trial. PG - 39847 LID - 10.31083/RCM39847 [doi] LID - 39847 AB - BACKGROUND: Gastrointestinal (GI) dysfunction is a common postoperative complication in patients after acute type A aortic dissection (ATAAD) surgery. Recent evidence suggests that, in addition to early nutrition and feeding strategies, physiotherapy can help to reduce the incidence of postoperative GI dysfunction. This study aimed to investigate whether GI function after ATAAD open surgery can be recovered through surface gastrointestinal electrical stimulation (SGES). METHODS: This was a prospective, parallel-group, assessor-blind, randomized controlled trial (RCT). A total of 74 participants were included and randomly divided into a control group (CG) and an SGES intervention group (IG) in a 1:1 ratio. The CG received a standardized perioperative management program developed by a multidisciplinary team, based on the principles of enhanced recovery after surgery (ERAS). The IG implemented SGES at ST36, ST25, and two additional GI pacemakers, as well as ERAS. The primary outcome was GI-2 recovery (tolerance of oral diet and passage of stool). Secondary outcomes included the Gastrointestinal Symptom Rating Scale (GSRS), acute gastrointestinal injury ultrasonography (AGIUS), the Gastrointestinal Quality of Life Index (GIQLI), the incidence of constipation and diarrhea, length of stay in the intensive care unit (ICU), and duration of hospitalization. RESULTS: Of the 74 patients in this study, 24.32% were female, with a mean age of 49.61 years. The time to achieve GI-2 in the IG was significantly shorter, 1.9 days, than in the CG (log-rank test, p = 0.01). The GSRS scores in the IG were significantly lower than those in the CG (total scores: 1.2 vs. 1.6; p = 0.001). Moreover, the GIQLI values at all three follow-up visits were significantly higher in the IG group than in the CG group. CONCLUSIONS: To our knowledge, this is the first RCT to investigate the clinical effects of SGES on GI recovery after open-heart surgery for ATAAD. The results provide preliminary evidence supporting the feasibility and therapeutic potential of SGES in a high-risk population. SGES can promote the recovery of GI function, reduce GI-related symptoms, and improve the GI-related quality of life after open heart surgery in patients with ATAAD. CLINICAL TRIAL REGISTRATION: This trial was based on the Consolidated Standards of Reporting Trials (CONSORT) guidelines. This trial was registered in the Chinese Clinical Trial Registry (identifier ChiCTR2300075265, https://www.chictr.org.cn/showproj.html?proj=205523). CI - Copyright: (c) 2025 The Author(s). Published by IMR Press. FAU - Duan, Weitao AU - Duan W AUID- ORCID: 0009-0006-4059-8969 AD - Rehabilitation Medicine Center, Sichuan University West China Hospital, 610041 Chengdu, Sichuan, China. FAU - Luo, Zeruxin AU - Luo Z AD - Rehabilitation Medicine Center, Sichuan University West China Hospital, 610041 Chengdu, Sichuan, China. FAU - Huang, Wei AU - Huang W AD - Rehabilitation Medicine Center, Sichuan University West China Hospital, 610041 Chengdu, Sichuan, China. FAU - Zhang, Xiu AU - Zhang X AD - Rehabilitation Medicine Center, Sichuan University West China Hospital, 610041 Chengdu, Sichuan, China. FAU - Su, Jianhua AU - Su J AD - Rehabilitation Medicine Center, Sichuan University West China Hospital, 610041 Chengdu, Sichuan, China. FAU - Li, Zhi AU - Li Z AD - Department of Cardiovascular Surgery, Sichuan University West China Hospital, 610041 Chengdu, Sichuan, China. FAU - Chen, Miao AU - Chen M AD - Department of Cardiovascular Surgery, Sichuan University West China Hospital, 610041 Chengdu, Sichuan, China. FAU - Yu, Pengming AU - Yu P AUID- ORCID: 0000-0003-0727-5931 AD - Rehabilitation Medicine Center, Sichuan University West China Hospital, 610041 Chengdu, Sichuan, China. AD - Key Laboratory of Rehabilitation Medicine in Sichuan Province, 610041 Chengdu, Sichuan, China. LA - eng PT - Journal Article DEP - 20251031 PL - Singapore TA - Rev Cardiovasc Med JT - Reviews in cardiovascular medicine JID - 100960007 PMC - PMC12593729 OTO - NOTNLM OT - cardiac surgery OT - electric stimulation therapy OT - rehabilitation medicine COIS- The authors declare no conflict of interest. EDAT- 2025/11/10 06:29 MHDA- 2025/11/10 06:30 PMCR- 2025/10/31 CRDT- 2025/11/10 05:57 PHST- 2025/04/20 00:00 [received] PHST- 2025/06/19 00:00 [revised] PHST- 2025/06/30 00:00 [accepted] PHST- 2025/11/10 06:30 [medline] PHST- 2025/11/10 06:29 [pubmed] PHST- 2025/11/10 05:57 [entrez] PHST- 2025/10/31 00:00 [pmc-release] AID - S1530-6550(25)01920-9 [pii] AID - 10.31083/RCM39847 [doi] PST - epublish SO - Rev Cardiovasc Med. 2025 Oct 31;26(10):39847. doi: 10.31083/RCM39847. eCollection 2025 Oct. PMID- 41207905 OWN - NLM STAT- Publisher LR - 20251109 IS - 2193-6226 (Electronic) IS - 2193-6218 (Linking) DP - 2025 Nov 9 TI - PANDA: Development and evaluation of a nursing competence team of respiratory therapists and advanced practice nurses to optimize the weaning process : Protocol of a two-phase feasibility study. LID - 10.1007/s00063-025-01343-z [doi] AB - BACKGROUND: Weaning critically ill patients from mechanical ventilation (MV) is an important challenge of intensive care unit (ICU) management. Internationally, MV is often supported by respiratory therapists (RT) as specially trained nurses and advanced practice nurses (APN) with a master's degree, all functioning within an interdisciplinary treatment team. Currently, there is limited research focusing on the process and effectiveness of collaboration between RT and APN as a nursing competence team (NCT) in the context of the weaning process in MV. AIM: To identify factors that promote and inhibit the feasibility of an NCT team to improve the MV weaning process in ICUs and to assess the feasibility of a future confirmatory study applying patient- and nursing-sensitive outcomes. METHODS: A single-center, mixed methods, two-phase feasibility study will be carried out on two ICUs with 48 beds at the Clinic for Thoracic and Cardiovascular Surgery in a university hospital. In study phase I, six focus-group interviews (FGs) will be conducted with nurses, physicians, and physiotherapists at three measuring points (t(0): before implementation; t(1) and t(2): 6 and 12 months, respectively, after implementation of the NCT). Three separate FGs will be conducted with the NCT team at the same measuring points. Data will be analyzed using Kuckartz's content analysis method. Study phase II will be carried out as a before-and-after study over 12 months by, e.g., assessing patients' duration of MV, delirium, pain, anxiety, and mobilization. Retrospective patient data for the period 2022-2023 will be used from the hospital documentation system. In the after-study, data will be prospectively collected. EXPECTED RESULTS: Our two-phase feasibility study will generate important information on the feasibility of an NCT focusing on the implementation process and weaning outcomes in patients with MV, providing an important basis for future studies. CI - (c) 2025. The Author(s). FAU - Kruger, Lars AU - Kruger L AUID- ORCID: 0000-0003-4234-0022 AD - Project and Knowledge Management/Care Development Intensive Care, Care Directorate, Heart and Diabetes Center NRW, University Hospital of the Ruhr University Bochum, Georgstrasse 11, 32345, Bad Oeynhausen, Germany. lkrueger@hdz-nrw.de. AD - Institute of Health, Midwifery and Nursing Sciences, Medical Faculty, Martin Luther University Halle-Wittenberg, Magdeburger Strasse 8, 06112, Halle (Saale), Germany. lkrueger@hdz-nrw.de. FAU - Wefer, Franziska AU - Wefer F AUID- ORCID: 0000-0001-9405-3143 AD - Care Development, Care Directorate, Heart and Diabetes Center NRW, University Hospital of the Ruhr University Bochum, Georgstrasse 11, 32345, Bad Oeynhausen, Germany. AD - Institute for Nursing Science, Medical Faculty and University Hospital Cologne, University of Cologne, Gleueler Strasse 176-178, 50935, Cologne, Germany. FAU - Mannebach, Thomas AU - Mannebach T AUID- ORCID: 0000-0001-9217-3299 AD - Care Development, Care Directorate, Heart and Diabetes Center NRW, University Hospital of the Ruhr University Bochum, Georgstrasse 11, 32345, Bad Oeynhausen, Germany. FAU - Mertins, Esther AU - Mertins E AUID- ORCID: 0009-0006-0660-4309 AD - Care Directorate, Heart and Diabetes Center NRW, University Hospital of the Ruhr University Bochum, Georgstrasse 11, 32345, Bad Oeynhausen, Germany. FAU - Siegling, Christian AU - Siegling C AD - Care Directorate, Heart and Diabetes Center NRW, University Hospital of the Ruhr University Bochum, Georgstrasse 11, 32345, Bad Oeynhausen, Germany. FAU - Kirschning, Thomas AU - Kirschning T AD - Clinic for Thoracic and Cardiovascular Surgery, Heart and Diabetes Center NRW, University Hospital of the Ruhr University Bochum, Georgstrasse 11, 32345, Bad Oeynhausen, Germany. FAU - Weinrautner, Nicole AU - Weinrautner N AD - Clinic for Thoracic and Cardiovascular Surgery, Heart and Diabetes Center NRW, University Hospital of the Ruhr University Bochum, Georgstrasse 11, 32345, Bad Oeynhausen, Germany. FAU - Gummert, Jan AU - Gummert J AUID- ORCID: 0000-0002-6956-9110 AD - Clinic for Thoracic and Cardiovascular Surgery, Heart and Diabetes Center NRW, University Hospital of the Ruhr University Bochum, Georgstrasse 11, 32345, Bad Oeynhausen, Germany. FAU - Kopke, Sascha AU - Kopke S AUID- ORCID: 0000-0003-4106-4919 AD - Institute for Nursing Science, Medical Faculty and University Hospital Cologne, University of Cologne, Gleueler Strasse 176-178, 50935, Cologne, Germany. LA - eng PT - Journal Article TT - PANDA: Entwicklung und Evaluation eines pflegerischen Kompetenzteams aus Atmungstherapeut:innen und Advanced Practice Nurses zur Optimierung des Weaningprozesses : Protokoll einer zweiphasigen Machbarkeitsstudie. DEP - 20251109 PL - Germany TA - Med Klin Intensivmed Notfmed JT - Medizinische Klinik, Intensivmedizin und Notfallmedizin JID - 101575086 SB - IM OTO - NOTNLM OT - Delirium OT - Intensive care units OT - Mechanical ventilation OT - Nurse specialists OT - Nursing COIS- Declarations. Conflict of interest: L. Kruger, F. Wefer, T. Mannebach, E. Mertins, C. Siegling, T. Kirschning, N. Weinrautner, J. Gummert and S. Kopke declare that they have no competing interests. For this study all investigations on humans described will be carried out with the approval of the responsible ethics committee, in accordance with national law and the declaration of Helsinki in 1975 (in the current, revised version). This study is registered at the German register of clinical trials (study ID: DRKS00035320). EDAT- 2025/11/10 00:53 MHDA- 2025/11/10 00:53 CRDT- 2025/11/09 23:13 PHST- 2025/04/10 00:00 [received] PHST- 2025/10/02 00:00 [accepted] PHST- 2025/08/20 00:00 [revised] PHST- 2025/11/10 00:53 [medline] PHST- 2025/11/10 00:53 [pubmed] PHST- 2025/11/09 23:13 [entrez] AID - 10.1007/s00063-025-01343-z [pii] AID - 10.1007/s00063-025-01343-z [doi] PST - aheadofprint SO - Med Klin Intensivmed Notfmed. 2025 Nov 9. doi: 10.1007/s00063-025-01343-z. PMID- 41206262 OWN - NLM STAT- MEDLINE DCOM- 20260206 LR - 20260616 IS - 1532-8422 (Electronic) IS - 1053-0770 (Linking) VI - 40 IP - 2 DP - 2026 Feb TI - Herpes Simplex Virus Pneumonia in Immunocompetent Patients Undergoing Cardiac Surgery: Case Series. PG - 501-508 LID - S1053-0770(25)01052-3 [pii] LID - 10.1053/j.jvca.2025.10.020 [doi] AB - OBJECTIVE: To describe the frequency, diagnosis, and management, of herpes simplex virus-1 (HSV-1) pneumonia in patients without known immunodeficiency undergoing cardiac surgery with cardiopulmonary bypass. DESIGN: Retrospective observational case series. SETTING: Intensive care unit. PARTICIPANTS: Adult patients without known immunodeficiency who developed HSV-1 pneumonia after cardiac surgery. INTERVENTIONS: Baseline, perioperative, and postoperative data were collected. HSV-1 pneumonia was diagnosed by a multidisciplinary team when progressive respiratory deterioration was unresponsive to standard antibiotic therapy and quantitative HSV-1 polymerase chain reaction in a bronchoalveolar lavage (BAL) or bronchial aspirate (BAS) sample documented a viral load >10,000 copies/mL. MEASUREMENTS AND MAIN RESULTS: Among 818 patients undergoing cardiac surgery during the study period, 43 were tested for HSV. Among them, 15 (34.9%) had a positive BAL/BAS for HSV-1. In these patients (8 males [53%]; median age, 69 years [interquartile range (IQR), 63-73 years]), quantitative HSV-1 polymerase chain reaction on BAL/BAS documented a median of 3.21 x 10(6) (IQR, 5.62 x 10(5)-5.73 x 10(6)) copies/mL. Diagnosis was made at a median of 12 days (range, 7.5-19 days) after surgery. Thirteen of the 15 patients (86.7%) were mechanically ventilated, and 11 (73.3%) met criteria for acute respiratory distress syndrome. Median C-reactive protein and procalcitonin values were 108.6 (IQR, 85.7-141.4) mg/L and 1.1 (IQR, 0.4-1.4) ng/mL, respectively. All patients received antiviral therapy. The median length of stay in the intensive care unit was 54 days, and in-hospital mortality of 66.7%, higher after urgent surgery (85.7%) compared to elective surgery (50.0%). CONCLUSIONS: HSV-1 infection emerged as a relevant finding among these cardiac surgery patients with respiratory deterioration. Further studies are warranted to clarify the impact of HSV-1 on patient outcomes and to optimize treatment strategies. CI - Copyright (c) 2025 Elsevier Inc. All rights reserved. FAU - Lacalaprice, Doriana AU - Lacalaprice D AD - Section of Hygiene, Department of Life Sciences and Public Health, Catholic University of the Sacred Heart, Rome, Italy. FAU - Vitale, Pietro AU - Vitale P AD - Clinical Infectious Diseases, Department of System Medicine, Tor Vergata University, Rome, Italy. FAU - Alleva, Alessio AU - Alleva A AD - Cardio Thoracic Anesthesia Department, University Hospital Tor Vergata, Rome, Italy. FAU - Asiller, Ozgun Omer AU - Asiller OO AD - Department of Anesthesia and Intensive Care, Ankara University Faculty of Medicine, Ankara, Turkiye. FAU - Scaini, Roberto AU - Scaini R AD - Cardio Thoracic Anesthesia Department, University Hospital Tor Vergata, Rome, Italy. FAU - Franceschini, Giulia AU - Franceschini G AD - Cardio Thoracic Anesthesia Department, University Hospital Tor Vergata, Rome, Italy. FAU - Flaminio, Marzia AU - Flaminio M AD - Cardio Thoracic Anesthesia Department, University Hospital Tor Vergata, Rome, Italy. FAU - Prati, Paolo AU - Prati P AD - Cardio Thoracic Anesthesia Department, University Hospital Tor Vergata, Rome, Italy. FAU - Farinaccio, Andrea AU - Farinaccio A AD - Cardio Thoracic Anesthesia Department, University Hospital Tor Vergata, Rome, Italy. FAU - Moresco, Manuela AU - Moresco M AD - Cardio Thoracic Anesthesia Department, University Hospital Tor Vergata, Rome, Italy. FAU - Nardi, Paolo AU - Nardi P AD - Cardiac Surgery Division, Department of Surgical Sciences, Tor Vergata University, Rome, Italy. FAU - Sarmati, Loredana AU - Sarmati L AD - Clinical Infectious Diseases, Department of System Medicine, Tor Vergata University, Rome, Italy. FAU - Ajello, Valentina AU - Ajello V AD - Section of Hygiene, Department of Life Sciences and Public Health, Catholic University of the Sacred Heart, Rome, Italy; Cardio Thoracic Anesthesia Department, University Hospital Tor Vergata, Rome, Italy. Electronic address: valeajello@gmail.com. LA - eng PT - Journal Article PT - Observational Study PT - Research Support, Non-U.S. Gov't DEP - 20251017 PL - United States TA - J Cardiothorac Vasc Anesth JT - Journal of cardiothoracic and vascular anesthesia JID - 9110208 RN - 0 (Antiviral Agents) SB - IM MH - Humans MH - Male MH - Female MH - Middle Aged MH - Aged MH - Retrospective Studies MH - *Cardiac Surgical Procedures/adverse effects MH - *Herpes Simplex/diagnosis/epidemiology/immunology MH - *Immunocompetence MH - *Pneumonia, Viral/diagnosis/epidemiology/immunology MH - *Herpesvirus 1, Human MH - *Postoperative Complications/diagnosis MH - Antiviral Agents/therapeutic use OTO - NOTNLM OT - HSV-1 pneumonia OT - acyclovir OT - anesthesia OT - cardiac surgery OT - cardiopulmonary bypass OT - herpes simplex OT - intensive care COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/11/09 00:32 MHDA- 2026/02/07 00:31 CRDT- 2025/11/08 21:54 PHST- 2025/09/24 00:00 [received] PHST- 2025/10/08 00:00 [revised] PHST- 2025/10/14 00:00 [accepted] PHST- 2026/02/07 00:31 [medline] PHST- 2025/11/09 00:32 [pubmed] PHST- 2025/11/08 21:54 [entrez] AID - S1053-0770(25)01052-3 [pii] AID - 10.1053/j.jvca.2025.10.020 [doi] PST - ppublish SO - J Cardiothorac Vasc Anesth. 2026 Feb;40(2):501-508. doi: 10.1053/j.jvca.2025.10.020. Epub 2025 Oct 17. PMID- 41206173 OWN - NLM STAT- MEDLINE DCOM- 20251112 LR - 20260716 IS - 1877-9190 (Electronic) IS - 1877-9182 (Linking) VI - 17 IP - 4 DP - 2025 Dec TI - Arrhythmias in Congenital Heart Disease: Heterotaxy Syndrome. PG - 591-603 LID - S1877-9182(25)00051-6 [pii] LID - 10.1016/j.ccep.2025.07.008 [doi] AB - Arrhythmias are a major contributor to morbidity and mortality in patients with heterotaxy syndrome. This article reviews the anatomic and electrophysiological substrates that predispose to bradyarrhythmias and tachyarrhythmias. Using representative clinical cases, this article highlights key arrhythmia mechanisms, diagnostic approaches, and management strategies. Emphasis is placed on individualized long-term rhythm surveillance and multidisciplinary decision-making strategies. CI - Copyright (c) 2025 Elsevier Inc. All rights reserved. FAU - Niu, Mary C AU - Niu MC AD - Department of Pediatrics, Division of Pediatric Cardiology, University of Utah Health Sciences Center, Primary Children's Hospital, 81 N. Mario Capecchi Drive, Salt Lake, UT 84113, USA. Electronic address: Mary.Niu@hsc.utah.edu. FAU - Spentzou, Georgia AU - Spentzou G AD - Department of Pediatric Cardiology, Bristol Royal Hospital for Children, Upper Maudlin Street, Bristol, BS2 8BJ, UK. FAU - Newlon, Claire A AU - Newlon CA AD - Department of Pediatric Cardiology, UCLA Los Angeles, Mattel Children's Hospital, Medical Plaza, Suite 330, Los Angeles, CA 90024, USA. LA - eng PT - Journal Article PT - Review DEP - 20251007 PL - United States TA - Card Electrophysiol Clin JT - Cardiac electrophysiology clinics JID - 101549998 SB - IM MH - Humans MH - *Heterotaxy Syndrome/complications/physiopathology MH - *Arrhythmias, Cardiac/physiopathology/etiology/therapy/diagnosis MH - *Heart Defects, Congenital/complications/physiopathology OTO - NOTNLM OT - AV block OT - Bradyarrhythmia OT - Conduction system duplication OT - Heterotaxy OT - Isomerism OT - Sinus node dysfunction OT - Tachyarrhythmia OT - Twin AV nodes COIS- Disclosure During the preparation of this work, the authors used Gen AI. After using this tool/service, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication. EDAT- 2025/11/09 00:32 MHDA- 2025/11/12 23:30 CRDT- 2025/11/08 20:55 PHST- 2025/11/12 23:30 [medline] PHST- 2025/11/09 00:32 [pubmed] PHST- 2025/11/08 20:55 [entrez] AID - S1877-9182(25)00051-6 [pii] AID - 10.1016/j.ccep.2025.07.008 [doi] PST - ppublish SO - Card Electrophysiol Clin. 2025 Dec;17(4):591-603. doi: 10.1016/j.ccep.2025.07.008. Epub 2025 Oct 7. PMID- 41205997 OWN - NLM STAT- MEDLINE DCOM- 20260115 LR - 20260918 IS - 1538-9375 (Electronic) IS - 1525-8610 (Print) IS - 1525-8610 (Linking) VI - 27 IP - 1 DP - 2026 Jan TI - Does Cognitive Function Influence the Benefits of Multicomponent Team Interventions? PG - 105976 LID - S1525-8610(25)00493-1 [pii] LID - 10.1016/j.jamda.2025.105976 [doi] AB - OBJECTIVES: This study examined whether cognitive function influenced the benefits of multicomponent team interventions designed to improve quality of life. DESIGN: Data from 2 multisite randomized trials of multicomponent interventions were pooled. The interventions involved symptom management by a nurse, psychosocial counseling by a social worker, and collaboration among palliative care, primary care, and specialists. SETTING AND PARTICIPANTS: Patients with chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), and heart failure (HF) enrolled in 2 multisite randomized trials. METHODS: Cognitive function was assessed using the Telephone Interview for Cognitive Status (TICS) and analyzed continuously and dichotomously (<36 on TICS indicating cognitive dysfunction). Mixed-effects linear regression models assessed whether cognitive function modified the effect of the interventions on quality of life and related outcomes. We also explored whether cognitive function was associated with the number of intervention visits, intervention staff time, and completed study team recommendations (consults, tests, behavior changes). RESULTS: A total of 610 participants across both trials had a mean age of 67 years, nearly all had HF or COPD, and a small proportion had ILD; 83% of participants screened positive for cognitive dysfunction. Cognitive function did not influence the benefits of the interventions across outcomes (P > .10). In exploratory analyses, lower TICS scores were associated with fewer completed intervention visits (P = .007). Total staff time, consults, tests, and behavior change recommendations were similar across TICS scores. CONCLUSIONS AND IMPLICATIONS: Cognitive dysfunction is prevalent among patients with chronic cardiopulmonary illnesses. Intervention benefits were not affected by cognitive status. Exploratory analyses found an association between worse cognitive function and fewer intervention visits but no difference in intervention time, tests, or behavior change recommendations. Increased effort to identify cognitive dysfunction in this population and engage them in interventions to improve quality of life should be considered. CI - Published by Elsevier Inc. FAU - Lange, Allison V AU - Lange AV AD - Division of Pulmonary and Critical Care, Department of Medicine, VA Eastern Colorado Health Care System, Aurora, CO, USA. Electronic address: allison.lange@cuanschutz.edu. FAU - Glickman, Amanda AU - Glickman A AD - Department of Psychiatry, NYU Grossman School of Medicine, New York, NY, USA. FAU - Wells, Kevin AU - Wells K AD - Department of Biostatistics & Informatics, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. FAU - Mee, Thomas C AU - Mee TC AD - Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. FAU - Carey, Evan P AU - Carey EP AD - Department of Biostatistics & Informatics, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. FAU - Kavalieratos, Dio AU - Kavalieratos D AD - Department of Family and Preventive Medicine, Emory University, Atlanta, GA, USA. FAU - Bettcher, Brianne M AU - Bettcher BM AD - Department of Neurology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. FAU - Kluger, Benzi AU - Kluger B AD - Departments of Neurology and Medicine and Center for Health + Technology, University of Rochester Medical Center, Rochester, NY, USA. FAU - Bekelman, David B AU - Bekelman DB AD - Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA; Department of Medicine, VA Eastern Colorado Health Care System, Aurora, CO, USA. LA - eng GR - K24 AG070322/AG/NIA NIH HHS/United States GR - R01 NR013422/NR/NINR NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20251118 PL - United States TA - J Am Med Dir Assoc JT - Journal of the American Medical Directors Association JID - 100893243 SB - IM MH - Aged MH - Female MH - Humans MH - Male MH - Middle Aged MH - *Cognition MH - *Heart Failure/psychology/therapy MH - *Patient Care Team MH - *Pulmonary Disease, Chronic Obstructive/psychology/therapy MH - *Quality of Life MH - Randomized Controlled Trials as Topic MH - Treatment Effect Heterogeneity PMC - PMC12987410 MID - NIHMS2143033 OTO - NOTNLM OT - Cognitive dysfunction OT - chronic illness OT - intervention participation OT - quality of life COIS- Disclosure The authors declare no conflicts of interest. EDAT- 2025/11/09 00:32 MHDA- 2026/01/16 19:24 PMCR- 2026/03/13 CRDT- 2025/11/08 19:20 PHST- 2025/05/14 00:00 [received] PHST- 2025/09/30 00:00 [revised] PHST- 2025/10/02 00:00 [accepted] PHST- 2026/01/16 19:24 [medline] PHST- 2025/11/09 00:32 [pubmed] PHST- 2025/11/08 19:20 [entrez] PHST- 2026/03/13 00:00 [pmc-release] AID - S1525-8610(25)00493-1 [pii] AID - 10.1016/j.jamda.2025.105976 [doi] PST - ppublish SO - J Am Med Dir Assoc. 2026 Jan;27(1):105976. doi: 10.1016/j.jamda.2025.105976. Epub 2025 Nov 18. PMID- 41205104 OWN - NLM STAT- MEDLINE DCOM- 20260626 LR - 20260918 IS - 1546-9549 (Electronic) IS - 1546-9530 (Print) IS - 1546-9530 (Linking) VI - 22 IP - 1 DP - 2025 Nov 8 TI - Multiprofessional Interventions for Frailty in Patients with Heart Failure: A Comprehensive Review. PG - 37 LID - 10.1007/s11897-025-00727-8 [doi] LID - 37 AB - PURPOSE OF REVIEW: Frailty is a prevalent and clinically significant condition affecting up to 45% of adults with heart failure (HF). Frailty reflects a state of reduced physiologic reserve and vulnerability to stressors, which profoundly influences health outcomes including health care utilization and survival. Frailty and HF interact through multiple overlapping pathophysiologic mechanisms, including chronic inflammation, neurohormonal abnormalities, and multiorgan dysfunction. This synergy, for the patient leads to poor physical performance, reduced independence, and a greater susceptibility to complications. RECENT FINDINGS: Evidence from recent clinical trials focused on frailty in HF underscores the potential benefits of multicomponent interventions combined with medication optimisation target physical dysfunction, poor nutrition, psychological disorders, and social isolation. Multidisciplinary care teams - including cardiologists, nurses, physical therapists, dieticians, occupational therapists, and social workers - can implement tailored strategies to reverse or slow the progression of frailty to improve health outcomes of patients with HF. Interventions such as resistance and balance training, individualised nutritional supplementation, medication review, cognitive and psychological support, and caregiver education have demonstrated a range of benefits in HF, from enhanced physical capacity and reduced hospital readmissions to improved health-related quality of life. Managing frailty in patients with HF requires a personalised, holistic and multicomponent approach. Successful intervention involves addressing not only physical dysfunction but also psychological, nutritional, and social factors that collectively undermine health and independence. Integrating multicomponent care into routine practice has the potential to improve clinical outcomes, reduce health care utilisation, and enhance the overall well-being of patients. Future research should aim to identify the most effective combinations of interventions, clarify mechanisms of action, and determine cost-efficiency in health care delivery. CI - (c) 2025. The Author(s). FAU - Uchmanowicz, Izabella AU - Uchmanowicz I AD - Division of Research Methodology, Department of Nursing, Faculty of Nursing and Midwifery, Wroclaw Medical University, Wroclaw, Poland. AD - Centre for Cardiovascular Health, Edinburgh Napier University, Sighthill Campus, Edinburgh, UK. FAU - Jedrzejczyk, Maria AU - Jedrzejczyk M AD - Division of Research Methodology, Department of Nursing, Faculty of Nursing and Midwifery, Wroclaw Medical University, Wroclaw, Poland. maria.jedrzejczyk@student.umw.edu.pl. FAU - Lee, Christopher S AU - Lee CS AD - Boston College William F. Connell School of Nursing, Chestnut Hill, MA, USA. AD - Department of Emergency Medical Service, Faculty of Nursing and Midwifery, Wroclaw Medical University, Wroclaw, Poland. FAU - Hill, Loreena AU - Hill L AD - School of Nursing and Paramedic Science, Ulster University, Londonderry, UK. FAU - Vitale, Cristiana AU - Vitale C AD - San Raffaele Open University of Rome, Rome, Italy. AD - IRCCS San Raffaele, Rome, Italy. FAU - Denfeld, Quin E AU - Denfeld QE AD - School of Nursing, Oregon Health & Science University, Portland, OR, USA. FAU - Vellone, Ercole AU - Vellone E AD - Division of Research Methodology, Department of Nursing, Faculty of Nursing and Midwifery, Wroclaw Medical University, Wroclaw, Poland. AD - Department of Biomedicine and Prevention, University of Roma Tor, Vergata, Italy. FAU - Zolkowska, Bernadetta AU - Zolkowska B AD - Student Research Club of Heart Diseases, Faculty of Medicine, Wroclaw Medical University, Wroclaw, Poland. FAU - Janczak, Sara AU - Janczak S AD - General and Transplant Surgery, Students' Scientific Club of Vascular, Wroclaw Medical University, Wroclaw, Poland. FAU - Chamos, Asriel Juvenal AU - Chamos AJ AD - School of Nursing and Paramedic Science, Ulster University, Londonderry, UK. FAU - Kaluzna-Oleksy, Marta AU - Kaluzna-Oleksy M AD - 1st Department of Cardiology, University of Medical Sciences, Poznan, Poland. FAU - Wleklik, Marta AU - Wleklik M AD - Division of Research Methodology, Department of Nursing, Faculty of Nursing and Midwifery, Wroclaw Medical University, Wroclaw, Poland. FAU - Lisiak, Magdalena AU - Lisiak M AD - Division of Research Methodology, Department of Nursing, Faculty of Nursing and Midwifery, Wroclaw Medical University, Wroclaw, Poland. AD - Institute of Heart Diseases, University Hospital, Wroclaw, Poland. FAU - Lomper, Katarzyna AU - Lomper K AD - Division of Research Methodology, Department of Nursing, Faculty of Nursing and Midwifery, Wroclaw Medical University, Wroclaw, Poland. AD - University Hospital, Wroclaw, Poland. AD - School of Health & Social Care, Edinburgh Napier University, Edinburgh, UK. LA - eng PT - Journal Article PT - Review DEP - 20251108 PL - United States TA - Curr Heart Fail Rep JT - Current heart failure reports JID - 101196487 SB - IM MH - Humans MH - *Heart Failure/therapy/complications/physiopathology MH - *Frailty/therapy/rehabilitation/etiology MH - *Patient Care Team/organization & administration MH - *Quality of Life PMC - PMC12596338 OTO - NOTNLM OT - Frailty OT - Heart failure OT - Multiprofessional care OT - Nutritional support OT - Physical rehabilitation COIS- Declarations. Competing interests: The authors declare no competing interests. Human and Animal Rights and Informed Consent: This article does not contain any studies with human or animal subjects performed by any of the authors. EDAT- 2025/11/08 12:45 MHDA- 2025/11/08 12:46 PMCR- 2025/11/08 CRDT- 2025/11/08 11:27 PHST- 2025/07/03 00:00 [received] PHST- 2025/10/28 00:00 [accepted] PHST- 2025/11/08 12:46 [medline] PHST- 2025/11/08 12:45 [pubmed] PHST- 2025/11/08 11:27 [entrez] PHST- 2025/11/08 00:00 [pmc-release] AID - 10.1007/s11897-025-00727-8 [pii] AID - 727 [pii] AID - 10.1007/s11897-025-00727-8 [doi] PST - epublish SO - Curr Heart Fail Rep. 2025 Nov 8;22(1):37. doi: 10.1007/s11897-025-00727-8. PMID- 41204807 OWN - NLM STAT- MEDLINE DCOM- 20251119 LR - 20260918 IS - 1524-4563 (Electronic) IS - 0194-911X (Print) IS - 0194-911X (Linking) VI - 82 IP - 12 DP - 2025 Dec TI - Case-Based Applications of the 2025 AHA/ACC/Multispecialty High Blood Pressure Guideline. PG - 2055-2063 LID - 10.1161/HYPERTENSIONAHA.125.25913 [doi] AB - Hypertension affects nearly half of all adults in the United States and is the leading, preventable cause of cardiovascular disease worldwide. The American Heart Association, American College of Cardiology, and 11 other professional organizations recently published an updated 2025 guideline to reflect the latest advances in the prevention, detection, evaluation, and management of high blood pressure. To bridge the gap between this guideline update and individualized patient care, this Special Article presents 4 hypothetical cases of high blood pressure, focusing on management in the outpatient setting. These cases illustrate how to apply a risk-based approach to high blood pressure management that incorporates blood pressure levels, cardiovascular disease risk factors and the predicting risk of cardiovascular disease events cardiovascular disease equations. They also highlight notable updates in the 2025 guideline such as recommendations for lifestyle approaches, initiation of medications, blood pressure goals, primary aldosteronism screening, and management of high blood pressure before, during and after pregnancy. By contextualizing the 2025 guideline within these hypothetical case scenarios, this Special Article provides practical guidance to health care teams to offer the most up-to-date, evidence-based care of high blood pressure. FAU - Cameron, Natalie A AU - Cameron NA AUID- ORCID: 0000-0002-0613-7580 AD - Division of General Internal Medicine, Department of Medicine (N.A.C.), Northwestern University Feinberg School of Medicine, Chicago, IL. AD - Department of Preventive Medicine (N.A.C., S.S.K.), Northwestern University Feinberg School of Medicine, Chicago, IL. FAU - Jones, Daniel W AU - Jones DW AUID- ORCID: 0000-0003-1347-729X AD - Department of Medicine, University of Mississippi School of Medicine, Jackson (D.W.J.). FAU - Khan, Sadiya S AU - Khan SS AUID- ORCID: 0000-0003-0643-1859 AD - Department of Preventive Medicine (N.A.C., S.S.K.), Northwestern University Feinberg School of Medicine, Chicago, IL. AD - Division of Cardiology, Department of Medicine (S.S.K.), Northwestern University Feinberg School of Medicine, Chicago, IL. FAU - Lloyd-Jones, Donald M AU - Lloyd-Jones DM AUID- ORCID: 0000-0003-0847-6110 AD - Framingham Center for Population and Prevention Science and Section of Preventive Medicine and Epidemiology, Boston University Chobanian & Avedisian School of Medicine, MA (D.M.L.-J.). LA - eng GR - K23 HL175227/HL/NHLBI NIH HHS/United States PT - Journal Article DEP - 20251108 PL - United States TA - Hypertension JT - Hypertension (Dallas, Tex. : 1979) JID - 7906255 RN - 0 (Antihypertensive Agents) SB - IM MH - Humans MH - American Heart Association MH - *Antihypertensive Agents/therapeutic use MH - *Blood Pressure/physiology MH - Blood Pressure Determination/methods MH - *Hypertension/diagnosis/physiopathology/drug therapy/therapy MH - *Practice Guidelines as Topic MH - United States PMC - PMC12617343 MID - NIHMS2118140 OTO - NOTNLM OT - antihypertensive agents OT - blood pressure OT - cardiovascular diseases OT - hypertension OT - risk factors COIS- D.M. Lloyd-Jones has been an unpaid director and officer of the American Heart Association and is currently a part-time employee. The other authors report no conflicts. EDAT- 2025/11/08 06:28 MHDA- 2025/11/19 18:27 PMCR- 2026/06/24 CRDT- 2025/11/08 05:02 PHST- 2025/11/19 18:27 [medline] PHST- 2025/11/08 06:28 [pubmed] PHST- 2025/11/08 05:02 [entrez] PHST- 2026/06/24 00:00 [pmc-release] AID - 10.1161/HYPERTENSIONAHA.125.25913 [doi] PST - ppublish SO - Hypertension. 2025 Dec;82(12):2055-2063. doi: 10.1161/HYPERTENSIONAHA.125.25913. Epub 2025 Nov 8. PMID- 41204408 OWN - NLM STAT- Publisher LR - 20260813 IS - 2385-2011 (Electronic) IS - 1591-0199 (Print) IS - 1591-0199 (Linking) DP - 2025 Nov 7 TI - Misplaced central line piercing common carotid removed and stented through a multidisciplinary approach: A video description. PG - 15910199251394473 LID - 10.1177/15910199251394473 [doi] LID - 15910199251394473 AB - Central venous catheterizations, or central lines, are commonly placed in critical care situations for vasopressor support and resuscitation. However, central line placement still carries a 3% risk of major complications.(1) While rare, inadvertent placement of large-bore central venous lines into the carotid arteries can be seen in 0.1% to 0.5% of cases.(2) Utilizing a minimally invasive technique, such as a stent graft, to quickly seal the pierced artery after removal should be considered in cases needing vascular repair. We present the case of a 54-year-old female who was admitted to the intensive care unit for management of septic shock. At an outside hospital, her systolic blood pressure was 60 mmHg. She had a subclavian vein central line misplaced-inadvertently piercing the left common carotid, passing through the aortic valve, and terminating in the left ventricle. After a multidisciplinary discussion, the vascular surgery team felt surgery to be too high-risk. The patient was taken to a hybrid interventional suite with neurointerventional radiology and cardiothoracic surgery, where she underwent stenting of the left common carotid with a covered stent graft and simultaneous removal of the misplaced central line under fluoroscopy. The patient had excellent flow through the carotid stents with repeat computed tomography angiography head and neck imaging post-procedure and after three months. This case highlights the importance of considering endovascular management for iatrogenic vascular events in cases where surgical access is challenging or in critical conditions where there are increased risks of complications. FAU - Khan, Usama K AU - Khan UK AUID- ORCID: 0000-0002-4311-3692 AD - Department of Neurology, Indiana University School of Medicine, Indianapolis, IN, USA. RINGGOLD: 12250 FAU - Kumar, Arjun B AU - Kumar AB AUID- ORCID: 0009-0003-4104-5280 AD - Department of Neurology, Indiana University School of Medicine, Indianapolis, IN, USA. RINGGOLD: 12250 FAU - Chabtini, Lola AU - Chabtini L AD - Department of Cardiothoracic Surgery, Indiana University School of Medicine, Indianapolis, IN, USA. RINGGOLD: 12250 FAU - Limaye, Kaustubh AU - Limaye K AUID- ORCID: 0000-0002-7280-7407 AD - Department of Neurology, Indiana University School of Medicine, Indianapolis, IN, USA. RINGGOLD: 12250 AD - Department of Neurological Surgery, Indiana University School of Medicine, Indianapolis, IN, USA. RINGGOLD: 1772 AD - Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, USA. RINGGOLD: 12250 LA - eng PT - Journal Article DEP - 20251107 PL - United States TA - Interv Neuroradiol JT - Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences JID - 9602695 SB - IM ECI - Interv Neuroradiol. 2026 Apr 25:15910199261444853. doi: 10.1177/15910199261444853. PMID: 42033379 PMC - PMC12602278 OTO - NOTNLM OT - Stent OT - fluoroscopy OT - ultrasound COIS- The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: KL is a consultant for Medtronic, Stryker, and Scientia Vascular. All other authors have no potential conflicts of interest with respect to the research, authorship, and/or publication of this technical video. EDAT- 2025/11/08 00:28 MHDA- 2025/11/08 00:28 PMCR- 2026/11/07 CRDT- 2025/11/08 00:00 PHST- 2025/11/08 00:28 [medline] PHST- 2025/11/08 00:28 [pubmed] PHST- 2025/11/08 00:00 [entrez] PHST- 2026/11/07 00:00 [pmc-release] AID - 10.1177_15910199251394473 [pii] AID - 10.1177/15910199251394473 [doi] PST - aheadofprint SO - Interv Neuroradiol. 2025 Nov 7:15910199251394473. doi: 10.1177/15910199251394473. PMID- 41201473 OWN - NLM STAT- MEDLINE DCOM- 20260513 LR - 20260830 IS - 1873-2615 (Electronic) IS - 1050-1738 (Linking) VI - 36 IP - 4 DP - 2026 May TI - Cardiometabolic perturbations arising from treatment with novel anticancer therapies. PG - 218-228 LID - S1050-1738(25)00142-2 [pii] LID - 10.1016/j.tcm.2025.10.008 [doi] AB - Modern cancer therapies, particularly immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs), have markedly improved cancer outcomes through more selective tumor targeting. However, as survivorship increases, there is growing recognition of long-term treatment-related complications, including a range of cardiometabolic disturbances. These include hyperglycemia, dyslipidemia and accelerated atherosclerosis, thyroid dysfunction and adrenal insufficiency, which significantly elevate long-term cardiovascular and metabolic risk in cancer survivors. The cardiometabolic sequelae of ICIs and TKIs are often under-recognised and under-monitored, despite their potential to contribute to serious morbidity. The mechanisms underpinning these toxicities are diverse and agent-specific, involving immune-mediated endocrine disruption, insulin resistance, and altered lipid metabolism. Current guideline recommendations remain limited across different therapeutic classes and clinical scenarios. In this review, we synthesise available evidence regarding the prevalence, mechanisms, and clinical management of cardiometabolic complications associated with ICIs and TKIs. We highlight key gaps in monitoring and therapeutic guidance and advocate for a multidisciplinary approach to early detection and management. Greater awareness and standardised care pathways will be essential to prevent avoidable complications and optimise long-term health in cancer survivors. CI - Copyright (c) 2025. Published by Elsevier Inc. FAU - Bennetts, Joshua D AU - Bennetts JD AD - School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, NSW 2308, Australia; Hunter Medical Research Institute, New Lambton Heights, Newcastle, NSW 2305, Australia; Newcastle Centre of Excellence in Cardio-Oncology, New Lambton Heights, Newcastle, NSW 2305, Australia. FAU - Sverdlov, Aaron L AU - Sverdlov AL AD - Hunter Medical Research Institute, New Lambton Heights, Newcastle, NSW 2305, Australia; Newcastle Centre of Excellence in Cardio-Oncology, New Lambton Heights, Newcastle, NSW 2305, Australia; Hunter New England Local Health District, New Lambton Heights, NSW 2305, Australia; School of Medicine and Public Health, University of Newcastle, Callaghan, NSW 2308, Australia; Calvary Mater Newcastle, Waratah, NSW 2298, Australia. Electronic address: aaron.sverdlov@newcastle.edu.au. FAU - Ngo, Doan Tm AU - Ngo DT AD - School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, NSW 2308, Australia; Hunter Medical Research Institute, New Lambton Heights, Newcastle, NSW 2305, Australia; Newcastle Centre of Excellence in Cardio-Oncology, New Lambton Heights, Newcastle, NSW 2305, Australia. Electronic address: doan.ngo@newcastle.edu.au. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20251025 PL - United States TA - Trends Cardiovasc Med JT - Trends in cardiovascular medicine JID - 9108337 RN - 0 (Immune Checkpoint Inhibitors) RN - 0 (Protein Kinase Inhibitors) RN - 0 (Antineoplastic Agents) SB - IM MH - Humans MH - *Immune Checkpoint Inhibitors/adverse effects MH - *Cardiovascular Diseases/epidemiology/chemically induced/diagnosis/therapy MH - *Protein Kinase Inhibitors/adverse effects MH - *Neoplasms/drug therapy MH - Risk Assessment MH - Cardiometabolic Risk Factors MH - Cancer Survivors MH - Cardiotoxicity MH - *Metabolic Diseases/chemically induced/epidemiology/therapy/diagnosis MH - *Antineoplastic Agents/adverse effects OTO - NOTNLM OT - Atherosclerosis OT - Cancer OT - Cardio-oncology OT - Cardiometabolic OT - Cardiotoxicity OT - Diabetes OT - Immune checkpoint inhibitors OT - Tyrosine kinase inhibitors COIS- Declaration of competing interest The authors declare that they have no conflicts of interest. EDAT- 2025/11/07 12:47 MHDA- 2026/05/14 00:31 CRDT- 2025/11/07 11:03 PHST- 2025/08/17 00:00 [received] PHST- 2025/10/20 00:00 [revised] PHST- 2025/10/21 00:00 [accepted] PHST- 2026/05/14 00:31 [medline] PHST- 2025/11/07 12:47 [pubmed] PHST- 2025/11/07 11:03 [entrez] AID - S1050-1738(25)00142-2 [pii] AID - 10.1016/j.tcm.2025.10.008 [doi] PST - ppublish SO - Trends Cardiovasc Med. 2026 May;36(4):218-228. doi: 10.1016/j.tcm.2025.10.008. Epub 2025 Oct 25. PMID- 41200023 OWN - NLM STAT- Publisher LR - 20260813 IS - 1753-495X (Print) IS - 1753-4968 (Electronic) IS - 1753-495X (Linking) VI - 19 IP - 3 DP - 2025 Nov 4 TI - Complete heart block in pregnancy: Review of current literature and case report. PG - 1753495X251391514 LID - 10.1177/1753495X251391514 [doi] AB - Complete heart block (CHB) in pregnancy is a rare condition, with acquired cases being particularly unusual. The management of CHB is guided by the underlying aetiology, symptoms, and associated risk factors, requiring careful consideration of both maternal and fetal well-being. This review examines the causes and pathophysiological mechanisms of CHB and discusses the pregnancy-related haemodynamic and hormonal changes that may exacerbate cardiac conduction abnormalities. We present the case of a 25-year-old woman diagnosed with acquired CHB at 18 weeks and 6 days of gestation, who underwent successful dual-chamber pacemaker implantation. This case illustrates the key aspects of managing CHB in pregnancy, including comprehensive diagnostic evaluation and careful delivery planning. Given the complexity of this clinical scenario, a multidisciplinary approach, including cardiologists, obstetricians and anaesthetists, is essential for optimising maternal and fetal outcomes. Further research is required to refine clinical guidelines and develop recommendations regarding long-term patient care and the management of subsequent pregnancies. CI - (c) The Author(s) 2025. FAU - Szybka, Magdalena AU - Szybka M AUID- ORCID: 0009-0005-8222-0860 AD - Department of Obstetrics and Gynaecology, The Rosie Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. RINGGOLD: 2153 FAU - Jasper, Brittany AU - Jasper B AD - Department of Obstetrics and Gynaecology, The Rosie Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. RINGGOLD: 2153 AD - Department of Obstetrics and Gynaecology, University of Cambridge and NIHR Cambridge Biomedical Research Centre, Cambridge, UK. FAU - Bhagra, Catriona AU - Bhagra C AUID- ORCID: 0000-0002-3960-9273 AD - Department of Cardiology, Cambridge University and Royal Papworth Hospitals NHS Foundation Trust, Cambridge, UK. RINGGOLD: 2153 FAU - Aiken, Catherine E AU - Aiken CE AD - Department of Obstetrics and Gynaecology, The Rosie Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. RINGGOLD: 2153 AD - Department of Obstetrics and Gynaecology, University of Cambridge and NIHR Cambridge Biomedical Research Centre, Cambridge, UK. LA - eng PT - Journal Article PT - Review DEP - 20251104 PL - England TA - Obstet Med JT - Obstetric medicine JID - 101464191 PMC - PMC12586374 OTO - NOTNLM OT - Third-degree heart block OT - arrhythmia in pregnancy OT - cardio-obstetrics OT - complete heart block OT - pacemaker COIS- The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2025/11/07 06:28 MHDA- 2025/11/07 06:28 PMCR- 2026/11/04 CRDT- 2025/11/07 04:18 PHST- 2025/08/12 00:00 [received] PHST- 2025/10/10 00:00 [accepted] PHST- 2025/11/07 06:28 [medline] PHST- 2025/11/07 06:28 [pubmed] PHST- 2025/11/07 04:18 [entrez] PHST- 2026/11/04 00:00 [pmc-release] AID - 10.1177_1753495X251391514 [pii] AID - 10.1177/1753495X251391514 [doi] PST - aheadofprint SO - Obstet Med. 2025 Nov 4;19(3):1753495X251391514. doi: 10.1177/1753495X251391514. PMID- 41199651 OWN - NLM STAT- MEDLINE DCOM- 20251107 LR - 20260505 IS - 1399-3046 (Electronic) IS - 1397-3142 (Linking) VI - 29 IP - 8 DP - 2025 Dec TI - Post-Transplant Metabolic Syndrome in Pediatric Liver Transplant Recipients-Contributors, Screening, and Management. PG - e70218 LID - 10.1111/petr.70218 [doi] AB - Over the last decades, long-term survival after pediatric liver transplantation has improved substantially, highlighting the importance of long-term graft and recipient outcomes. About one in five pediatric liver transplant recipients will develop post-transplant metabolic syndrome (PTMS), a combination of cardiovascular risk factors increasing morbidity and mortality. In contrast to the classical metabolic syndrome (MetS), it is not always characterized by (abdominal) obesity. There are several contributing factors, among which sustained exposure to immunosuppression is a major contributor. As subclinical target organ damage is already present in childhood, cardiometabolic risk factors must be actively sought for and a structured approach including nephrological, endocrinological, and cardiological assessment is necessary. This work provides an overview of the existing literature on screening and management of post-transplant metabolic syndrome and its components. Despite consensus guidelines lacking, a patient-centered, multidisciplinary approach from the transplant team to the primary care providers is crucial to enhance long-term, meaningful survival of pediatric liver transplant recipients. CI - (c) 2025 Wiley Periodicals LLC. FAU - Buytaert, Maarten AU - Buytaert M AUID- ORCID: 0000-0002-4165-5009 AD - Hepatology Research Unit, Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium. AD - Liver Research Center Ghent, Ghent University Hospital, Ghent, Belgium. FAU - Braekman, Eline AU - Braekman E AUID- ORCID: 0009-0000-5638-0717 AD - Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium. FAU - Van Overbeke, Kaat AU - Van Overbeke K AUID- ORCID: 0000-0002-0162-2317 AD - Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium. FAU - Prytula, Agnieszka AU - Prytula A AUID- ORCID: 0000-0001-9551-8758 AD - Department of Pediatric Nephrology and Rheumatology, ERKNet Center, Ghent University Hospital, Ghent, Belgium. FAU - De Bruyne, Pauline AU - De Bruyne P AUID- ORCID: 0000-0002-3090-9755 AD - Department of Pediatric Gastroenterology, Hepatology and Nutrition, Ghent University Hospital, Ghent, Belgium. FAU - De Waele, Kathleen AU - De Waele K AD - Department of Pediatric Endocrinology, Ghent University Hospital, Ghent, Belgium. FAU - Vandekerckhove, Kristof AU - Vandekerckhove K AUID- ORCID: 0000-0002-1481-0878 AD - Department of Pediatric Cardiology, Ghent University Hospital, Ghent, Belgium. FAU - Lefere, Sander AU - Lefere S AUID- ORCID: 0000-0001-5734-3467 AD - Hepatology Research Unit, Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium. AD - Liver Research Center Ghent, Ghent University Hospital, Ghent, Belgium. FAU - De Bruyne, Ruth AU - De Bruyne R AUID- ORCID: 0000-0002-5623-3300 AD - Hepatology Research Unit, Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium. AD - Liver Research Center Ghent, Ghent University Hospital, Ghent, Belgium. AD - Department of Pediatric Gastroenterology, Hepatology and Nutrition, Ghent University Hospital, Ghent, Belgium. LA - eng GR - 1227824N/Research Foundation - Flanders (FWO)/ GR - 1843824N/Research Foundation - Flanders (FWO)/ PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review PL - Denmark TA - Pediatr Transplant JT - Pediatric transplantation JID - 9802574 SB - IM MH - Humans MH - *Liver Transplantation/adverse effects MH - *Metabolic Syndrome/diagnosis/therapy/etiology MH - Child MH - *Postoperative Complications/diagnosis/therapy/etiology MH - Risk Factors OTO - NOTNLM OT - cardiometabolic health OT - immunosuppression OT - lifestyle OT - management OT - multidisciplinary OT - pediatric liver transplantation OT - post-transplant metabolic syndrome OT - screening EDAT- 2025/11/07 06:28 MHDA- 2025/11/07 06:29 CRDT- 2025/11/07 03:42 PHST- 2025/10/08 00:00 [revised] PHST- 2025/04/10 00:00 [received] PHST- 2025/10/21 00:00 [accepted] PHST- 2025/11/07 06:29 [medline] PHST- 2025/11/07 06:28 [pubmed] PHST- 2025/11/07 03:42 [entrez] AID - 10.1111/petr.70218 [doi] PST - ppublish SO - Pediatr Transplant. 2025 Dec;29(8):e70218. doi: 10.1111/petr.70218. PMID- 41199243 OWN - NLM STAT- MEDLINE DCOM- 20251107 LR - 20251215 IS - 1472-6920 (Electronic) IS - 1472-6920 (Linking) VI - 25 IP - 1 DP - 2025 Nov 6 TI - The application and effectiveness of PBL combined with MDT and flipped classroom teaching method in acute coronary syndrome education for undergraduate medical students. PG - 1559 LID - 10.1186/s12909-025-08150-2 [doi] LID - 1559 AB - BACKGROUND: The development of medical education is rapidly evolving, with innovative teaching methods such as problem-based learning (PBL) and multidisciplinary treatment (MDT) combined with flipped classroom approaches gaining increasing attention in clinical medical education. However, the actual effectiveness of PBL combined with MDT and flipped classroom methods in the teaching of cardiovascular diseases has not been well studied. Considering that these which includedteaching methods can complement each other, this study explores the application and effectiveness of PBL combined with MDT and flipped classroom teaching method in the case-based teaching of acute coronary syndrome. METHODS: A total of 100 undergraduate clinical medicine students aged 20-21 years from Guangzhou Medical University were selected as research participants. They were randomly divided into two groups via a random number table: the experimental group (PBL combined with MDT and flipped classroom teaching), which included 50 students, and the control group (traditional teaching methods), which also included 50 students. After the clinical training, the theoretical examination scores and skill assessment results of the two groups were compared, and a questionnaire survey was conducted to evaluate teaching effectiveness. RESULTS: The theoretical examination scores and skill assessment results of the experimental group were significantly better than those of the control group (P < 0.05). The questionnaire survey revealed that the students in the experimental group outperformed those in the traditional teaching group in terms of learning motivation, theoretical learning outcomes, clinical thinking ability, literature retrieval skills, self-directed learning ability, practical ability, and classroom satisfaction, with statistically significant differences (P < 0.05). CONCLUSION: The findings of this study suggest that the integration of PBL, MDT, and the flipped classroom teaching method may have a positive impact on the theoretical knowledge and clinical skills of undergraduate medical students in the context of acute coronary syndrome (ACS). However, due to the study's limited sample size, short-term assessment period, and reliance on self-reported data, these results should be interpreted with caution. CI - (c) 2025. The Author(s). FAU - Lin, Yuhui AU - Lin Y AD - Development of Cardiovascular Medicine, Guangdong Provincial Key Laboratory of Major Obstetric Diseases, Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology, The Third Affiliated Hospital, Guangzhou Medical University, Guangzhou, China. FAU - He, Xiaoqing AU - He X AD - Development of Cardiovascular Medicine, Guangdong Provincial Key Laboratory of Major Obstetric Diseases, Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology, The Third Affiliated Hospital, Guangzhou Medical University, Guangzhou, China. FAU - Dai, Wenjun AU - Dai W AD - Development of Cardiovascular Medicine, Guangdong Provincial Key Laboratory of Major Obstetric Diseases, Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology, The Third Affiliated Hospital, Guangzhou Medical University, Guangzhou, China. FAU - Tan, Wenpeng AU - Tan W AD - Development of Cardiovascular Medicine, Guangdong Provincial Key Laboratory of Major Obstetric Diseases, Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology, The Third Affiliated Hospital, Guangzhou Medical University, Guangzhou, China. twpeng99@foxmail.com. FAU - Xu, Yunhong AU - Xu Y AD - Development of Cardiovascular Medicine, Guangdong Provincial Key Laboratory of Major Obstetric Diseases, Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology, The Third Affiliated Hospital, Guangzhou Medical University, Guangzhou, China. 451058471@qq.com. LA - eng GR - 2024312099/Tertiary Education Scientific research project of Guangzhou Municipal Education Bureau/ GR - 2024312099/Tertiary Education Scientific research project of Guangzhou Municipal Education Bureau/ GR - 2024312099/Tertiary Education Scientific research project of Guangzhou Municipal Education Bureau/ GR - GMPD [2022] 124 29/Guangzhou Medical University Undergraduate Teaching Quality Project Construction Program/ GR - GMPD [2022] 124 29/Guangzhou Medical University Undergraduate Teaching Quality Project Construction Program/ GR - GMPD [2022] 124 29/Guangzhou Medical University Undergraduate Teaching Quality Project Construction Program/ GR - 24312308/Research Projects of Higher Education Institutions of the Education Bureau of Guangzhou City/ GR - 24312308/Research Projects of Higher Education Institutions of the Education Bureau of Guangzhou City/ GR - 828/Guangdong Province Undergraduate Teaching Quality and Teaching Reform Project of Higher Education Institutions/ GR - 828/Guangdong Province Undergraduate Teaching Quality and Teaching Reform Project of Higher Education Institutions/ GR - 828/Guangdong Province Undergraduate Teaching Quality and Teaching Reform Project of Higher Education Institutions/ GR - 204/Plan on enhancing scientific research in GMU/ PT - Journal Article PT - Randomized Controlled Trial DEP - 20251106 PL - England TA - BMC Med Educ JT - BMC medical education JID - 101088679 SB - IM MH - Humans MH - *Problem-Based Learning/methods MH - *Acute Coronary Syndrome/therapy MH - *Education, Medical, Undergraduate/methods MH - Male MH - Female MH - Young Adult MH - Students, Medical MH - China MH - Clinical Competence MH - Educational Measurement MH - Teaching MH - Surveys and Questionnaires PMC - PMC12590797 OTO - NOTNLM OT - Acute coronary syndrome OT - Flipped classroom OT - MDT OT - PBL COIS- Declarations. Ethics approval and consent to participate: The study was approved by the Institutional Review Board and Ethics Committee of The Third Affiliated Hospital, Guangzhou Medical University. Written informed consent was obtained from all the participating students. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2025/11/07 00:27 MHDA- 2025/11/07 06:28 PMCR- 2025/11/06 CRDT- 2025/11/06 23:47 PHST- 2024/08/23 00:00 [received] PHST- 2025/10/10 00:00 [accepted] PHST- 2025/11/07 06:28 [medline] PHST- 2025/11/07 00:27 [pubmed] PHST- 2025/11/06 23:47 [entrez] PHST- 2025/11/06 00:00 [pmc-release] AID - 10.1186/s12909-025-08150-2 [pii] AID - 8150 [pii] AID - 10.1186/s12909-025-08150-2 [doi] PST - epublish SO - BMC Med Educ. 2025 Nov 6;25(1):1559. doi: 10.1186/s12909-025-08150-2. PMID- 41197379 OWN - NLM STAT- MEDLINE DCOM- 20251215 LR - 20260206 IS - 1878-7452 (Electronic) IS - 1878-7452 (Linking) VI - 83 IP - 1 DP - 2026 Jan TI - Enhancing Outcomes Through High-Fidelity Advanced Life Support Education: An Interdisciplinary Approach to Implementation and Quality Improvement. PG - 103764 LID - S1931-7204(25)00345-9 [pii] LID - 10.1016/j.jsurg.2025.103764 [doi] AB - OBJECTIVE: Cardiac arrest in postcardiac surgery patients presents distinct challenges that standard Advanced Cardiac Life Support (ACLS) protocols may not fully address. Cardiac advanced life support (CALS) provides specialized training to improve recognition and management of these emergencies. We developed and implemented a CALS code process to enhance postarrest outcomes in this patient population. METHODS: This study assessed the impact of an interdisciplinary CALS education program on healthcare providers' knowledge and response capabilities. The program included didactic sessions, high-fidelity simulation exercises, and pre- and post-training assessments. Participants included registered nurses (RNs), advanced practice providers, critical care physicians, pharmacists, respiratory therapists (RTs), and cardiac surgeons. Training included key CALS principles, highlighting differences from standard ACLS protocols. Simulated scenarios reinforced team-based responses, including management of emergent sternotomy. Patient outcomes following cardiac arrest were evaluated before and after implementation of the CALS code process. RESULTS: A total of 141 participants completed training (57 providers, 75 RNs/RTs, and 9 pharmacists). Confidence in the CALS response improved on a 5-point Likert scale (3.08-4.19, P < .05), when measured as a cohort. Knowledge scores improved from 85% to 95% for providers and from 80% to 90% for RNs/RTs. Postcardiac arrest patient survival showed an improvement after implementation of the CALS-focused educational program but was not statistically significant. CONCLUSIONS: A CALS-focused educational program enhanced interdisciplinary team preparedness for postcardiac surgery arrests and led to better patient survival. Additional ongoing multidisciplinary team training may be needed to further demonstrate a sustainable improvement in patient survival. CI - Copyright (c) 2025 Association of Program Directors in Surgery. Published by Elsevier Inc. All rights reserved. FAU - Peterson, Jennifer AU - Peterson J AD - Division of Cardiothoracic Surgery, Department of Surgery, University of Washington, Seattle, WA, USA. FAU - Badulak, Jenelle AU - Badulak J AD - Department of Emergency Medicine, University of Washington, Seattle, WA, USA. FAU - Surrusco, Jordan AU - Surrusco J AD - Division of Cardiothoracic Surgery, Department of Surgery, University of Washington, Seattle, WA, USA. FAU - Regan-Baggs, Janet AU - Regan-Baggs J AD - University of Washington Medical Center, Seattle, WA, USA. FAU - Robinson, Megan AU - Robinson M AD - University of Washington Medical Center, Seattle, WA, USA. FAU - Rogers, Ruth AU - Rogers R AD - University of Washington Medical Center, Seattle, WA, USA. FAU - Green, Joel AU - Green J AD - University of Washington Medical Center, Seattle, WA, USA. FAU - Garnett, Jenny AU - Garnett J AD - University of Washington, WWAMI Institute for Simulation in Healthcare, Seattle, WA, USA. FAU - Sparks, Kailey AU - Sparks K AD - University of Washington Medical Center, Seattle, WA, USA. FAU - Cullen, Melissa AU - Cullen M AD - University of Washington Medical Center, Seattle, WA, USA. FAU - Chen, Allison AU - Chen A AD - Division of Cardiothoracic Surgery, Department of Surgery, University of Washington, Seattle, WA, USA. FAU - Wong, Emeline AU - Wong E AD - Division of Cardiothoracic Surgery, Department of Surgery, University of Washington, Seattle, WA, USA. FAU - Pal, Angela D AU - Pal AD AD - University of Colorado Anschutz Medical Campus, College of Nursing, Aurora, CO, USA. FAU - Cheng, Aaron M AU - Cheng AM AD - Division of Cardiothoracic Surgery, Department of Surgery, University of Washington, Seattle, WA, USA. FAU - Pal, Jay D AU - Pal JD AD - Division of Cardiothoracic Surgery, Department of Surgery, University of Washington, Seattle, WA, USA. Electronic address: jaydpal@uw.edu. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20251105 PL - United States TA - J Surg Educ JT - Journal of surgical education JID - 101303204 SB - IM MH - Humans MH - *Advanced Cardiac Life Support/education MH - *Quality Improvement MH - *Heart Arrest/therapy MH - Female MH - Male MH - Patient Care Team/organization & administration MH - Clinical Competence MH - *High Fidelity Simulation Training MH - *Cardiac Surgical Procedures MH - Middle Aged MH - Adult OTO - NOTNLM OT - CALS OT - ECMO OT - cardiac arrest OT - cardiac surgery OT - simulation OT - team training EDAT- 2025/11/07 00:27 MHDA- 2025/12/16 00:35 CRDT- 2025/11/06 18:05 PHST- 2025/07/14 00:00 [received] PHST- 2025/09/30 00:00 [revised] PHST- 2025/10/06 00:00 [accepted] PHST- 2025/12/16 00:35 [medline] PHST- 2025/11/07 00:27 [pubmed] PHST- 2025/11/06 18:05 [entrez] AID - S1931-7204(25)00345-9 [pii] AID - 10.1016/j.jsurg.2025.103764 [doi] PST - ppublish SO - J Surg Educ. 2026 Jan;83(1):103764. doi: 10.1016/j.jsurg.2025.103764. Epub 2025 Nov 5. PMID- 41195125 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251106 LR - 20251108 IS - 2297-055X (Print) IS - 2297-055X (Electronic) IS - 2297-055X (Linking) VI - 12 DP - 2025 TI - Stent thrombosis: a contemporary guide to definitions, risk factors, and management. PG - 1622235 LID - 10.3389/fcvm.2025.1622235 [doi] LID - 1622235 AB - Stent thrombosis remains a major complication following percutaneous coronary intervention, with significant morbidity and mortality implications. Despite advancements in drug-eluting stents and optimized pharmacotherapy, real-world registry data indicate that definite or probable stent thrombosis occurs in approximately 0.5% of percutaneous coronary intervention cases, with a 30-day mortality rate approaching 25% and a long-term risk exceeding 30% at 10 years. Stent thrombosis is classified based on timing into acute, subacute, late, and very late thrombosis, with subacute and very late stent thrombosis being the most prevalent. Clinical consequences include myocardial infarction, emergent revascularization, and heightened cardiovascular risk, necessitating timely recognition and intervention. Risk factors include patient characteristics, procedural variables, and lesion complexity, with recurrent stent thrombosis remaining a notable concern. This review explores the definitions, classifications, pathophysiology, and risk factors for stent thrombosis while discussing current strategies for prevention and management. Additionally, advancements in stent technology and pharmacologic interventions are examined, underscoring the need for a multidisciplinary approach to mitigate stent thrombosis incidence and improve patient outcomes. CI - (c) 2025 Flowers, Evenhuis, Gabanic, Weiss, Eisenberg, Siddiqui, Rizwan, Riaz, Hassan Virk, Alam, Khawaja, Strauss and Krittanawong. FAU - Flowers, Ambre AU - Flowers A AD - Department of Internal Medicine, Emory University, Atlanta, GA, United States. FAU - Evenhuis, Bernard AU - Evenhuis B AD - Department of Internal Medicine, Emory University, Atlanta, GA, United States. FAU - Gabanic, Benjamin AU - Gabanic B AD - Department of Internal Medicine, Emory University, Atlanta, GA, United States. FAU - Weiss, Allison AU - Weiss A AD - Department of Internal Medicine, Emory University, Atlanta, GA, United States. FAU - Eisenberg, Scott AU - Eisenberg S AD - Department of Internal Medicine, Emory University, Atlanta, GA, United States. FAU - Siddiqui, Riyan AU - Siddiqui R AD - School of Medicine, University of Mississippi Medical Center, Jackson, MS, United States. FAU - Rizwan, Affan AU - Rizwan A AD - Departmemnt of Internal Medicine, Baylor College of Medicine, Houston, TX, United States. FAU - Riaz, Iqra AU - Riaz I AD - Department of Internal Medicine, Mobile Infirmary Medical Center, Mobile, AL, United States. FAU - Hassan Virk, Hafeez Ul AU - Hassan Virk HU AD - Harrington Heart & Vascular Institute, Case Western Reserve University, University Hospitals Cleveland Medical Center, Cleveland, OH, United States. FAU - Alam, Mahboob AU - Alam M AD - Department of Cardiology, Texas Heart Institute and Baylor College of Medicine, Houston, TX, United States. FAU - Khawaja, Muzamil AU - Khawaja M AD - Department of Cardiology, Emory University, Atlanta, GA, United States. FAU - Strauss, Markus AU - Strauss M AD - Department of Cardiology I- Coronary and Periphal Vascular Disease, Heart Failure Medicine, University Hospital Muenster, Cardiol, Muenster, Germany. FAU - Krittanawong, Chayakrit AU - Krittanawong C AD - HumanX, Delaware, DE, United States. LA - eng PT - Journal Article PT - Review DEP - 20251021 PL - Switzerland TA - Front Cardiovasc Med JT - Frontiers in cardiovascular medicine JID - 101653388 PMC - PMC12582928 OTO - NOTNLM OT - coronary artery disease OT - coronary stenting OT - ischaemic heart disease (IHD) OT - percuataneous coronary intervention OT - stent thrombosis COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2025/11/06 06:28 MHDA- 2025/11/06 06:29 PMCR- 2025/10/21 CRDT- 2025/11/06 04:07 PHST- 2025/05/02 00:00 [received] PHST- 2025/10/01 00:00 [accepted] PHST- 2025/11/06 06:29 [medline] PHST- 2025/11/06 06:28 [pubmed] PHST- 2025/11/06 04:07 [entrez] PHST- 2025/10/21 00:00 [pmc-release] AID - 10.3389/fcvm.2025.1622235 [doi] PST - epublish SO - Front Cardiovasc Med. 2025 Oct 21;12:1622235. doi: 10.3389/fcvm.2025.1622235. eCollection 2025. PMID- 41190890 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251105 LR - 20251108 IS - 2563-6316 (Electronic) IS - 2563-6316 (Linking) VI - 6 DP - 2025 Nov 3 TI - Assessing the Limitations of Large Language Models in Clinical Practice Guideline-Concordant Treatment Decision-Making on Real-World Data: Retrospective Study. PG - e74899 LID - 10.2196/74899 [doi] LID - e74899 AB - BACKGROUND: Studies have shown that large language models (LLMs) are promising in therapeutic decision-making, with findings comparable to those of medical experts, but these studies used highly curated patient data. OBJECTIVE: This study aimed to determine if LLMs can make guideline-concordant treatment decisions based on patient data as typically present in clinical practice (lengthy, unstructured medical text). METHODS: We conducted a retrospective study of 80 patients with severe aortic stenosis who were scheduled for either surgical (SAVR; n=24) or transcatheter aortic valve replacement (TAVR; n=56) by our institutional heart team in 2022. Various LLMs (BioGPT, GPT-3.5, GPT-4, GPT-4 Turbo, GPT-4o, LLaMA-2, Mistral, PaLM 2, and DeepSeek-R1) were queried using either anonymized original medical reports or manually generated case summaries to determine the most guideline-concordant treatment. We measured agreement with the heart team using Cohen kappa coefficients, reliability using intraclass correlation coefficients (ICCs), and fairness using the frequency bias index (FBI; FBI >1 indicated bias toward TAVR). RESULTS: When presented with original medical reports, LLMs showed poor performance (Cohen kappa coefficient: -0.47 to 0.22; ICC: 0.0-1.0; FBI: 0.95-1.51). The LLMs' performance improved substantially when case summaries were used as input and additional guideline knowledge was added to the prompt (Cohen kappa coefficient: -0.02 to 0.63; ICC: 0.01-1.0; FBI: 0.46-1.23). Qualitative analysis revealed instances of hallucinations in all LLMs tested. CONCLUSIONS: Even advanced LLMs require extensively curated input for informed treatment decisions. Unreliable responses, bias, and hallucinations pose significant health risks and highlight the need for caution in applying LLMs to real-world clinical decision-making. CI - (c) Tobias Roeschl, Marie Hoffmann, Djawid Hashemi, Felix Rarreck, Nils Hinrichs, Tobias Daniel Trippel, Matthias I Groschel, Axel Unbehaun, Christoph Klein, Jorg Kempfert, Henryk Dreger, Benjamin O'Brien, Gerhard Hindricks, Felix Balzer, Volkmar Falk, Alexander Meyer. Originally published in JMIRx Med (https://med.jmirx.org). FAU - Roeschl, Tobias AU - Roeschl T AUID- ORCID: 0000-0002-8376-3366 AD - Department of Cardiology, Angiology and Intensive Care Medicine, Deutsches Herzzentrum der Charite, Berlin, Germany. AD - Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Chariteplatz 1, Berlin, 10117, Germany, 49 17632864219. AD - Berlin Institute of Health at Charite - Universitatsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charite Digital Clinician Scientist Program, Berlin, Germany. AD - DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany. AD - Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charite (DHZC), Berlin, Germany. FAU - Hoffmann, Marie AU - Hoffmann M AUID- ORCID: 0000-0001-9807-8292 AD - Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Chariteplatz 1, Berlin, 10117, Germany, 49 17632864219. AD - DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany. AD - Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charite (DHZC), Berlin, Germany. FAU - Hashemi, Djawid AU - Hashemi D AUID- ORCID: 0000-0003-3933-7092 AD - Department of Cardiology, Angiology and Intensive Care Medicine, Deutsches Herzzentrum der Charite, Berlin, Germany. AD - Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Chariteplatz 1, Berlin, 10117, Germany, 49 17632864219. AD - Berlin Institute of Health at Charite - Universitatsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charite Digital Clinician Scientist Program, Berlin, Germany. AD - DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany. FAU - Rarreck, Felix AU - Rarreck F AUID- ORCID: 0000-0001-5337-977X AD - Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Chariteplatz 1, Berlin, 10117, Germany, 49 17632864219. AD - Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charite (DHZC), Berlin, Germany. FAU - Hinrichs, Nils AU - Hinrichs N AUID- ORCID: 0000-0002-1989-6156 AD - Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Chariteplatz 1, Berlin, 10117, Germany, 49 17632864219. AD - DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany. AD - Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charite (DHZC), Berlin, Germany. FAU - Trippel, Tobias Daniel AU - Trippel TD AUID- ORCID: 0000-0001-8575-0019 AD - Department of Cardiology, Angiology and Intensive Care Medicine, Deutsches Herzzentrum der Charite, Berlin, Germany. AD - Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Chariteplatz 1, Berlin, 10117, Germany, 49 17632864219. AD - DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany. FAU - Groschel, Matthias I AU - Groschel MI AUID- ORCID: 0000-0002-2509-3034 AD - Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Chariteplatz 1, Berlin, 10117, Germany, 49 17632864219. AD - Department of Infectious Diseases and Respiratory Medicine, Charite - Universitatsmedizin Berlin, Berlin, Germany. FAU - Unbehaun, Axel AU - Unbehaun A AUID- ORCID: 0000-0003-2851-695X AD - Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Chariteplatz 1, Berlin, 10117, Germany, 49 17632864219. AD - Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charite (DHZC), Berlin, Germany. FAU - Klein, Christoph AU - Klein C AUID- ORCID: 0009-0003-1016-7971 AD - Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Chariteplatz 1, Berlin, 10117, Germany, 49 17632864219. AD - Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charite (DHZC), Berlin, Germany. FAU - Kempfert, Jorg AU - Kempfert J AUID- ORCID: 0000-0002-2009-6375 AD - Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Chariteplatz 1, Berlin, 10117, Germany, 49 17632864219. AD - Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charite (DHZC), Berlin, Germany. FAU - Dreger, Henryk AU - Dreger H AUID- ORCID: 0000-0003-1909-4329 AD - Department of Cardiology, Angiology and Intensive Care Medicine, Deutsches Herzzentrum der Charite, Berlin, Germany. AD - Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Chariteplatz 1, Berlin, 10117, Germany, 49 17632864219. FAU - O'Brien, Benjamin AU - O'Brien B AUID- ORCID: 0000-0001-7024-2337 AD - Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Chariteplatz 1, Berlin, 10117, Germany, 49 17632864219. AD - Department of Cardiac Anesthesiology and Intensive Care Medicine, Deutsches Herzzentrum der Charite (DHZC), Berlin, Germany. AD - Department of Perioperative Medicine, St Bartholomew's Hospital and Barts Heart Centre, London, United Kingdom. FAU - Hindricks, Gerhard AU - Hindricks G AUID- ORCID: 0000-0002-0132-0773 AD - Department of Cardiology, Angiology and Intensive Care Medicine, Deutsches Herzzentrum der Charite, Berlin, Germany. AD - Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Chariteplatz 1, Berlin, 10117, Germany, 49 17632864219. FAU - Balzer, Felix AU - Balzer F AUID- ORCID: 0000-0003-1575-2056 AD - Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Chariteplatz 1, Berlin, 10117, Germany, 49 17632864219. AD - Charite - Universitatsmedizin Berlin, Institute of Medical Informatics, Berlin, Germany. FAU - Falk, Volkmar AU - Falk V AUID- ORCID: 0000-0002-7911-8620 AD - Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Chariteplatz 1, Berlin, 10117, Germany, 49 17632864219. AD - DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany. AD - Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charite (DHZC), Berlin, Germany. AD - Department of Health Sciences and Technology, Translational Cardiovascular Technologies, Institute of Translational Medicine, Swiss Federal Institute of Technology, Zurich, Switzerland. FAU - Meyer, Alexander AU - Meyer A AUID- ORCID: 0000-0002-6944-2478 AD - Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Chariteplatz 1, Berlin, 10117, Germany, 49 17632864219. AD - DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany. AD - Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charite (DHZC), Berlin, Germany. AD - Berlin Institute for the Foundations of Learning and Data - TU Berlin, Berlin, Germany. LA - eng PT - Journal Article DEP - 20251103 PL - Canada TA - JMIRx Med JT - JMIRx med JID - 101776650 UOF - doi: 10.2196/preprints.74899 PMC - PMC12587749 OTO - NOTNLM OT - aortic stenosis OT - clinical practice guidelines OT - foundation models OT - large language models OT - medical data processing OT - reasoning models OT - treatment decision-making COIS- Conflicts of Interest: DH reports financial engagements beyond the scope of the presented work. These activities include consultation services and speaking engagements for companies, including AstraZeneca, Bayer Vital, Boehringer Ingelheim, Coliquio, and Novartis. TDT holds shares of Microsoft, Amazon, and Palantir Technologies. AU serves as a physician proctor to Boston Scientific, Edwards Lifesciences, and Medtronic. JK reports personal fees from Edwards and personal fees from LSI outside the submitted work. BOB declares research funding from the British Heart Foundation and the National Institute for Health Science Research, and relevant financial activities outside the submitted work with Teleflex and Abiomed in relation to consultancy fees. FB reports funding from Medtronic and grants from the German Federal Ministry of Education and Research, grants from the German Federal Ministry of Health, grants from the Berlin Institute of Health, personal fees from Elsevier Publishing, grants from Hans Bockler Foundation, other funds from Robert Koch Institute, grants from Einstein Foundation, and grants from Berlin University Alliance outside the submitted work. VF declares relevant financial activities outside the submitted work with Medtronic GmbH, Biotronik SE & Co, Abbott GmbH & Co KG, Boston Scientific, Edwards Lifesciences, Berlin Heart, Novartis Pharma GmbH, JOTEC GmbH, and Zurich Heart in relation to educational grants (including travel support), fees for lectures and speeches, fees for professional consultation, and research and study funds. AM declares receiving consulting and lecturing fees from Medtronic, lecturing fees from Bayer, and consulting fees from Pfizer. AM is the founder and managing director of x-cardiac GmbH. The other authors have no conflicts of interest to disclose. EDAT- 2025/11/05 12:33 MHDA- 2025/11/05 12:34 PMCR- 2025/11/03 CRDT- 2025/11/05 09:23 PHST- 2025/03/26 00:00 [received] PHST- 2025/07/23 00:00 [revised] PHST- 2025/08/19 00:00 [accepted] PHST- 2025/11/05 12:34 [medline] PHST- 2025/11/05 12:33 [pubmed] PHST- 2025/11/05 09:23 [entrez] PHST- 2025/11/03 00:00 [pmc-release] AID - v6i1e74899 [pii] AID - 74899 [pii] AID - 10.2196/74899 [doi] PST - epublish SO - JMIRx Med. 2025 Nov 3;6:e74899. doi: 10.2196/74899. PMID- 41189091 OWN - NLM STAT- MEDLINE DCOM- 20251222 LR - 20251224 IS - 2055-5822 (Electronic) IS - 2055-5822 (Linking) VI - 12 IP - 6 DP - 2025 Dec TI - Impact of standardized team-based care on cardiogenic shock outcomes over time. PG - 4379-4390 LID - 10.1002/ehf2.70000 [doi] AB - BACKGROUND AND AIMS: Limited data exist regarding the impact of standardized care on cardiogenic shock (CS) outcomes over time. We aimed to investigate the influence of multidisciplinary management on CS outcomes following implementation of team-based protocols in 2017. METHODS: A total of 1453 consecutive patients enrolled into a single-centre CS registry were divided into two time periods, 2017-2019 versus 2020-2022. Baseline characteristics, management and outcomes were compared. The primary endpoint was adjusted in-hospital mortality. Multivariable regression analysis was performed to evaluate change in outcomes over time. RESULTS: Compared with 2017-2019, more patients with CS were treated in 2020-2022 (930 vs. 523; P < 0.01). They more often presented to the Level 1 centre (52% vs. 45%; P = 0.01), with a higher proportion of heart failure-related CS (72% vs. 58%; P < 0.01) and Society for Cardiovascular Angiography and Interventions B and C CS (64% vs. 49%; P < 0.01). They were less likely to be managed with percutaneous ventricular assist devices (11% vs. 24%; P < 0.01) but more likely to receive veno-arterial extracorporeal membrane oxygenation (14% vs. 4%; P < 0.01) and heart transplantation (9% vs. 4%; P < 0.04). No differences were noted in in-hospital mortality [adjusted odds ratio (aOR) 0.81; 95% confidence interval (CI): 0.56-1.16; P = 0.25], major adverse cardiac and cerebrovascular events (aOR 1.21; 95% CI: 0.87-1.68; P = 0.26), stroke (aOR 1.11; 95% CI: 0.65-1.91; P = 0.71) or renal replacement therapy (aOR 0.95; 95% CI: 0.66-1.37; P = 0.77). CONCLUSIONS: Standardized care for CS was associated with consistent in-hospital mortality over time despite changes in presentation and management. Further research is needed to identify the optimal care model during the vulnerable post-discharge period. CI - (c) 2025 The Author(s). ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. FAU - Tehrani, Behnam N AU - Tehrani BN AUID- ORCID: 0000-0002-8037-7021 AD - Inova Schar Heart and Vascular, Inova Fairfax Medical Campus, Falls Church, Virginia, USA. FAU - Rosner, Carolyn M AU - Rosner CM AD - Inova Schar Heart and Vascular, Inova Fairfax Medical Campus, Falls Church, Virginia, USA. AD - George Mason University, Fairfax, Virginia, USA. FAU - Fadahunsi, Adetokunbo AU - Fadahunsi A AD - George Mason University, Fairfax, Virginia, USA. FAU - Barker, Kimberly AU - Barker K AD - Inova Schar Heart and Vascular, Inova Fairfax Medical Campus, Falls Church, Virginia, USA. FAU - Batchelor, Wayne B AU - Batchelor WB AD - Inova Schar Heart and Vascular, Inova Fairfax Medical Campus, Falls Church, Virginia, USA. AD - George Mason University, Fairfax, Virginia, USA. FAU - Blumer, Vanessa AU - Blumer V AD - Inova Schar Heart and Vascular, Inova Fairfax Medical Campus, Falls Church, Virginia, USA. FAU - Clevenger, Lindsay AU - Clevenger L AD - Inova Schar Heart and Vascular, Inova Fairfax Medical Campus, Falls Church, Virginia, USA. FAU - Desai, Shashank AU - Desai S AD - Inova Schar Heart and Vascular, Inova Fairfax Medical Campus, Falls Church, Virginia, USA. FAU - Ferri, Michelle AU - Ferri M AD - Inova Schar Heart and Vascular, Inova Fairfax Medical Campus, Falls Church, Virginia, USA. FAU - Franke, Evan AU - Franke E AD - Inova Schar Heart and Vascular, Inova Fairfax Medical Campus, Falls Church, Virginia, USA. FAU - Kennedy, Jamie AU - Kennedy J AD - Inova Schar Heart and Vascular, Inova Fairfax Medical Campus, Falls Church, Virginia, USA. FAU - King, Christopher AU - King C AD - Inova Schar Heart and Vascular, Inova Fairfax Medical Campus, Falls Church, Virginia, USA. FAU - Howard, Edward AU - Howard E AD - Inova Schar Heart and Vascular, Inova Fairfax Medical Campus, Falls Church, Virginia, USA. AD - Virginia Heart, Falls Church, Virginia, USA. FAU - Isseh, Iyad AU - Isseh I AD - Inova Schar Heart and Vascular, Inova Fairfax Medical Campus, Falls Church, Virginia, USA. FAU - Lee, Seiyon Ben AU - Lee SB AD - George Mason University, Fairfax, Virginia, USA. FAU - Mehta, Aditya AU - Mehta A AD - Inova Schar Heart and Vascular, Inova Fairfax Medical Campus, Falls Church, Virginia, USA. FAU - Psotka, Mitchell AU - Psotka M AD - Inova Schar Heart and Vascular, Inova Fairfax Medical Campus, Falls Church, Virginia, USA. FAU - Singh, Ramesh AU - Singh R AD - Inova Schar Heart and Vascular, Inova Fairfax Medical Campus, Falls Church, Virginia, USA. FAU - Sinha, Shashank S AU - Sinha SS AD - Inova Schar Heart and Vascular, Inova Fairfax Medical Campus, Falls Church, Virginia, USA. FAU - Sherwood, Matthew W AU - Sherwood MW AD - Inova Schar Heart and Vascular, Inova Fairfax Medical Campus, Falls Church, Virginia, USA. FAU - Tang, Daniel AU - Tang D AD - Inova Schar Heart and Vascular, Inova Fairfax Medical Campus, Falls Church, Virginia, USA. FAU - Terek, Megan AU - Terek M AD - Inova Schar Heart and Vascular, Inova Fairfax Medical Campus, Falls Church, Virginia, USA. FAU - Truesdell, Alexander G AU - Truesdell AG AD - Inova Schar Heart and Vascular, Inova Fairfax Medical Campus, Falls Church, Virginia, USA. AD - Virginia Heart, Falls Church, Virginia, USA. FAU - Vavilin, Ilan AU - Vavilin I AD - Inova Schar Heart and Vascular, Inova Fairfax Medical Campus, Falls Church, Virginia, USA. FAU - O'Connor, Christopher M AU - O'Connor CM AD - Inova Schar Heart and Vascular, Inova Fairfax Medical Campus, Falls Church, Virginia, USA. LA - eng PT - Journal Article DEP - 20251104 PL - England TA - ESC Heart Fail JT - ESC heart failure JID - 101669191 SB - IM MH - Humans MH - *Shock, Cardiogenic/therapy/mortality MH - Male MH - Female MH - Hospital Mortality/trends MH - *Registries MH - *Patient Care Team/standards MH - Middle Aged MH - Aged MH - Time Factors MH - Retrospective Studies MH - Follow-Up Studies MH - Extracorporeal Membrane Oxygenation PMC - PMC12719795 OTO - NOTNLM OT - acute myocardial infarction OT - cardiogenic shock OT - heart failure OT - systems of care OT - team-based care OT - temporal trends COIS- Dr. Tehrani serves as a consultant for Medtronic and Recor Medical. Dr. Batchelor serves as a consultant for Boston Scientific, Abbott, Medtronic and V-Wave. Dr. Truesdell has received consulting or speaking fees from Abiomed, Getinge, Shockwave and Zoll. Dr. O'Connor serves as a consultant for Merck, Johnson & Johnson, and ZealCare. All other authors report no disclosures or conflicts of interest relevant to this manuscript. EDAT- 2025/11/05 06:29 MHDA- 2025/12/22 06:29 PMCR- 2025/11/04 CRDT- 2025/11/05 00:43 PHST- 2025/09/22 00:00 [revised] PHST- 2025/07/29 00:00 [received] PHST- 2025/09/26 00:00 [accepted] PHST- 2025/12/22 06:29 [medline] PHST- 2025/11/05 06:29 [pubmed] PHST- 2025/11/05 00:43 [entrez] PHST- 2025/11/04 00:00 [pmc-release] AID - EHF270000 [pii] AID - 10.1002/ehf2.70000 [doi] PST - ppublish SO - ESC Heart Fail. 2025 Dec;12(6):4379-4390. doi: 10.1002/ehf2.70000. Epub 2025 Nov 4. PMID- 41184831 OWN - NLM STAT- MEDLINE DCOM- 20251104 LR - 20251107 IS - 1471-2334 (Electronic) IS - 1471-2334 (Linking) VI - 25 IP - 1 DP - 2025 Nov 3 TI - Fungal endocarditis. A retrospective analysis from a high-volume surgical centre and review of the literature. PG - 1479 LID - 10.1186/s12879-025-11801-w [doi] LID - 1479 AB - PURPOSE: Fungal endocarditis (FE), a rare but severe subset of infective endocarditis (IE), accounts for 2-4% of cases, with significant morbidity and mortality despite combined clinical and surgical interventions. The incidence of FE has been rising due to an increase in patients with predisposing risk factors, such as prosthetic heart valves, indwelling central venous catheters, prolonged fungemia, and intravenous drug use, alongside advancements in diagnostic techniques. Diagnosing FE is challenging due to nonspecific symptoms and often negative or delayed blood culture results, necessitating repeated cultures and sometimes surgical specimen collection for confirmation. FE is associated with a higher incidence of extracardiac complications, such as systemic and central nervous system embolization, compared to bacterial endocarditis. METHODS: This study retrospectively analyzed 687 patients with non-device-related IE admitted to a high-volume surgical center from January 2013 to December 2023, identifying 8 cases of FE (1.2%). The diagnostic work-up followed European Society of Cardiology guidelines, including blood cultures and echocardiography. Management involved a multidisciplinary team approach, combining antifungal therapy and early surgical intervention. RESULTS: Despite advancements, the prognosis of FE remains poor, with a mortality rate exceeding 50%. Early diagnosis and timely intervention, including early surgery, are crucial for improving outcomes. CONCLUSION: This study and the review of the literature aim to enhance understanding of FE by reviewing clinical presentations, diagnostic challenges, and management strategies, emphasizing the importance of a high index of suspicion and comprehensive diagnostic evaluation in high-risk patients. CI - (c) 2025. The Author(s). FAU - Fidanzati, Antonio AU - Fidanzati A AD - Division of General Cardiology, Cardiothoracovascular Department, Careggi University Hospital, Largo Brambilla 3, Florence, 50134, Italy. FAU - Scheggi, Valentina AU - Scheggi V AUID- ORCID: 0000-0001-8182-7074 AD - Division of Cardiovascular and Perioperative Medicine, Cardiothoracovascular Department, Careggi University Hospital, Largo Brambilla 3, Florence, 50134, Italy. valentina.scheggi@gmail.com. FAU - Papi, Matilde AU - Papi M AD - Division of General Cardiology, Cardiothoracovascular Department, Careggi University Hospital, Largo Brambilla 3, Florence, 50134, Italy. FAU - Stefano, Pier Luigi AU - Stefano PL AUID- ORCID: 0000-0001-8338-3016 AD - Division of Cardiac Surgery, Cardiothoracovascular Department, Careggi University Hospital, Largo Brambilla 3, Florence, 50134, Italy. LA - eng PT - Journal Article PT - Review DEP - 20251103 PL - England TA - BMC Infect Dis JT - BMC infectious diseases JID - 100968551 RN - 0 (Antifungal Agents) SB - IM MH - Humans MH - Retrospective Studies MH - *Endocarditis/microbiology/diagnosis/therapy/epidemiology/mortality MH - Middle Aged MH - Male MH - Female MH - Aged MH - *Mycoses/diagnosis/epidemiology/microbiology/therapy/mortality MH - Antifungal Agents/therapeutic use MH - Adult MH - Risk Factors PMC - PMC12581378 OTO - NOTNLM OT - Cardiac surgery OT - Diagnostic workup OT - Fungal endocarditis OT - Prognosis COIS- Declarations. Ethics approval and consent to participate: The study was approved by the local ethics committee (Comitato Etico Regionale per la Sperimentazione Clinica della Regione Toscana), which, in accordance with statements by the Italian Regulatory Authorities for retrospective, observational studies, granted a waiver of informed consent from study participants. Registration number: 12113_oss. Registration date 13/3/2018. The study was approved in accordance with the revised Declaration of Helsinki. Data were extracted from electronic hospital records, anonymized, and secured with password protection. Consent for publication: All authors give consent to publication upon acceptance. All patients (8 patients with FE) agreed to participate in the study when contacted for follow-up and signed informed consent for publication. Competing interests: The authors declare no competing interests. EDAT- 2025/11/04 00:28 MHDA- 2025/11/04 06:29 PMCR- 2025/11/03 CRDT- 2025/11/04 00:00 PHST- 2025/01/22 00:00 [received] PHST- 2025/09/22 00:00 [accepted] PHST- 2025/11/04 06:29 [medline] PHST- 2025/11/04 00:28 [pubmed] PHST- 2025/11/04 00:00 [entrez] PHST- 2025/11/03 00:00 [pmc-release] AID - 10.1186/s12879-025-11801-w [pii] AID - 11801 [pii] AID - 10.1186/s12879-025-11801-w [doi] PST - epublish SO - BMC Infect Dis. 2025 Nov 3;25(1):1479. doi: 10.1186/s12879-025-11801-w. PMID- 41181473 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251103 LR - 20260917 IS - 2049-0801 (Print) IS - 2049-0801 (Electronic) IS - 2049-0801 (Linking) VI - 87 IP - 10 DP - 2025 Oct TI - Long-term neurodevelopmental outcomes in children with hypoplastic left heart syndrome. PG - 6533-6542 LID - 10.1097/MS9.0000000000003731 [doi] AB - BACKGROUND: Hypoplastic left heart syndrome (HLHS) is a severe congenital heart defect requiring complex surgical interventions, including the Norwood, Glenn, and Fontan procedures. This narrative review aims to explore the long-term neurodevelopmental outcomes of children with HLHS following surgical palliation with potential risk factors. OBJECTIVES: This review synthesizes current evidence on long-term ND outcomes in children with HLHS after surgical palliation and identifies key risk factors, assessment tools, and emerging neuroprotective strategies. METHODS: A comprehensive literature review was conducted, focusing on the interplay of altered fetal circulation, impaired cerebral oxygenation, and extensive medical interventions on neurodevelopment. We conducted literature search of full-text, peer-reviewed English articles published between 2000 and 2024 using PubMed, Scopus, and Google Scholar with the terms "hypoplastic left heart syndrome," "surgical palliation," "neurodevelopmental outcomes," and "children." RESULTS: Evidence indicates that children with HLHS face significant risks for cognitive, motor, behavioral, and adaptive impairments. Assessment tools such as the Bayley Scales of Infant and Toddler Development, MRI, and EEG are essential for early detection and ongoing monitoring. DISCUSSION: A multidisciplinary approach involving pediatric cardiology, neurology, and developmental therapy is crucial for managing HLHS and addressing neurodevelopmental issues. Early intervention can improve outcomes, guided by diagnostic tools like MRI, EEG, and the Bayley Scales. There is a need for more research on neuroprotective strategies and perioperative management to reduce brain injury and enhance long-term developmental outcomes in children with HLHS. CONCLUSION: Children with HLHS face significant ND challenges due to a complex interplay of physiological and medical factors. A multidisciplinary approach with early intervention is critical. Emerging strategies, such as maternal hyperoxygenation, merit further investigation regarding their feasibility, cost, and ethical considerations. CI - Copyright (c) 2025 The Author(s). Published by Wolters Kluwer Health, Inc. FAU - Al Jebawi, Kholoud AU - Al Jebawi K AD - Department of Medicine, Faculty of Medical Sciences, Lebanese University, Beirut, Lebanon. AD - Department of Life Sciences, Faculty of Sciences, Lebanese University, Beirut, Lebanon. FAU - Nasrallah, Jamil AU - Nasrallah J AD - Department of Medicine, Faculty of Medical Sciences, Lebanese University, Beirut, Lebanon. AD - Department of Life Sciences, Faculty of Sciences, Lebanese University, Beirut, Lebanon. FAU - Sajjad, Waseem AU - Sajjad W AD - Department of Medicine, King Edward Medical University, Mayo Hospital, Lahore, Pakistan. FAU - Inam, Areeba AU - Inam A AD - Department of Medicine, Ayub Medical College, Abbotabad, Pakistan. FAU - Khan, Mishaim AU - Khan M AD - Department of Medicine, FMH College of Medicine and Dentistry, Lahore, Pakistan. FAU - Kanso, Nourhan AU - Kanso N AD - Department of Medicine, Faculty of Medical Sciences, Lebanese University, Beirut, Lebanon. FAU - Al Shoufy, Mira AU - Al Shoufy M AD - Department of Medicine, Faculty of Medical Sciences, Lebanese University, Beirut, Lebanon. FAU - Eldeen, Nagham Naser AU - Eldeen NN AD - Department of Medicine, Faculty of Medical Sciences, Lebanese University, Beirut, Lebanon. FAU - Chahine, Mirna N AU - Chahine MN AD - Department of Biology, Faculty of Arts & Sciences, University of Balamand, Dekwaneh, Lebanon. AD - Foundation- Medical Research Institutes, Acharfieh, Beirut, Lebanon, Geneva, Switzerland. LA - eng PT - Journal Article PT - Review DEP - 20250814 PL - England TA - Ann Med Surg (Lond) JT - Annals of medicine and surgery (2012) JID - 101616869 PMC - PMC12578126 OTO - NOTNLM OT - cardiac surgery OT - congenital heart disease OT - hypoplastic left heart syndrome (HLHS) OT - neurodevelopment OT - pediatric cardiology COIS- Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article. There is no conflict of interest to declare. EDAT- 2025/11/03 13:42 MHDA- 2025/11/03 13:43 PMCR- 2025/08/14 CRDT- 2025/11/03 07:21 PHST- 2024/11/04 00:00 [received] PHST- 2025/08/01 00:00 [accepted] PHST- 2025/11/03 13:43 [medline] PHST- 2025/11/03 13:42 [pubmed] PHST- 2025/11/03 07:21 [entrez] PHST- 2025/08/14 00:00 [pmc-release] AID - AMSU-D-24-02343 [pii] AID - 10.1097/MS9.0000000000003731 [doi] PST - epublish SO - Ann Med Surg (Lond). 2025 Aug 14;87(10):6533-6542. doi: 10.1097/MS9.0000000000003731. eCollection 2025 Oct. PMID- 41181241 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251103 LR - 20251105 IS - 0970-9185 (Print) IS - 2231-2730 (Electronic) IS - 0970-9185 (Linking) VI - 41 IP - 4 DP - 2025 Oct-Dec TI - Anesthesia for lung transplantation: A narrative review. PG - 580-586 LID - 10.4103/joacp.joacp_259_24 [doi] AB - Lung transplantation is considered the curative treatment of end-stage lung disease. Severe chronic obstructive pulmonary disease (COPD), interstitial lung disease, cystic fibrosis, idiopathic and secondary pulmonary artery hypertension are the main indications for lung transplantation. It can either be a single lung transplant as in COPD or pulmonary fibrosis or a bilateral sequential lung transplant as in suppurative lung disease (bronchiectasis, cystic fibrosis) and severe pulmonary hypertension. If cardiac decompensation is associated with the end-stage lung disease, combined heart-lung transplantation can be considered. Anesthesiologists have a significant role to play in the multidisciplinary assessment of the recipient before fitness for listing, pretransplantation bridging by extracorporeal life support (ECLS), anesthetic management during organ retrieval and implantation, implementation of the complex perioperative protocols, and management of one-lung anesthesia. Titration of intraoperative anticoagulation, hemodynamic management, close liaison with the perfusionist during cardiopulmonary bypass or extracorporeal membrane oxygenation, and performing transesophageal echocardiography also fall under the shared responsibility of the anesthesiologist. As part of the core team, anesthesiologists also actively take part in the postoperative care protocols, ventilatory and hemodynamic management, maintaining ECLS, immunosuppressant administration, pain management, and proactive management of complications. After half a century since its inception, lung transplantation is still considered a very high-risk procedure with significant perioperative morbidity and mortality. Because of its complexity, not too many centers are doing it worldwide. Till now, in our center, we have conducted 15 bilateral sequential lung transplants. Although we did not list any recipient from pulmonary hypertension point of view, most of our patients showed very high pulmonary pressures when measured by the pulmonary artery (PA) catheter intraoperatively, some even showing >100 mmHg. The article is a culmination of our experience and knowledge gained so far on this challenging procedure. We hope that in the near future, many centers will start their lung transplantation program and our article will be helpful in formulating protocols as per the available resources in our country. CI - Copyright: (c) 2025 Journal of Anaesthesiology Clinical Pharmacology. FAU - Khanna, Sangeeta AU - Khanna S AD - Institute of Anaesthesiology and Critical Care, Medanta the Medicity, Gurugram, Haryana, India. FAU - Das, Jyotirmoy AU - Das J AD - Institute of Anaesthesiology and Critical Care, Medanta the Medicity, Gurugram, Haryana, India. FAU - Kumar, Sudhir AU - Kumar S AD - Institute of Anaesthesiology and Critical Care, Medanta the Medicity, Gurugram, Haryana, India. FAU - Mehta, Yatin AU - Mehta Y AD - Institute of Anaesthesiology and Critical Care, Medanta the Medicity, Gurugram, Haryana, India. LA - eng PT - Journal Article PT - Review DEP - 20250731 PL - India TA - J Anaesthesiol Clin Pharmacol JT - Journal of anaesthesiology, clinical pharmacology JID - 9516972 PMC - PMC12578038 OTO - NOTNLM OT - Cardiopulmonary bypass OT - chronic lung allograft dysfunction (CLAD) OT - end-stage lung disease (ESLD) OT - ex vivo lung perfusion (EVLP) OT - extracorporeal life support OT - extracorporeal membrane oxygenation OT - immunosuppression OT - interstitial lung disease OT - lung transplant OT - nitric oxide OT - primary graft dysfunction (PGD) OT - pulmonary hypertension OT - right ventricular dysfunction COIS- There are no conflicts of interest. EDAT- 2025/11/03 13:42 MHDA- 2025/11/03 13:43 PMCR- 2025/10/01 CRDT- 2025/11/03 07:18 PHST- 2024/05/29 00:00 [received] PHST- 2024/06/28 00:00 [revised] PHST- 2024/06/29 00:00 [accepted] PHST- 2025/11/03 13:43 [medline] PHST- 2025/11/03 13:42 [pubmed] PHST- 2025/11/03 07:18 [entrez] PHST- 2025/10/01 00:00 [pmc-release] AID - JOACP-41-580 [pii] AID - 10.4103/joacp.joacp_259_24 [doi] PST - ppublish SO - J Anaesthesiol Clin Pharmacol. 2025 Oct-Dec;41(4):580-586. doi: 10.4103/joacp.joacp_259_24. Epub 2025 Jul 31. PMID- 41178378 OWN - NLM STAT- MEDLINE DCOM- 20260213 LR - 20260215 IS - 1365-2516 (Electronic) IS - 1351-8216 (Print) IS - 1351-8216 (Linking) VI - 32 IP - 1 DP - 2026 Jan-Feb TI - Elucidating the Molecular Basis in a Cohort of Patients With Combined Bleeding Tendencies and Joint Hypermobility Manifestations. PG - 185-194 LID - 10.1111/hae.70160 [doi] AB - BACKGROUND: In patients with unexplained bleeding and normal haemostatic parameters, heritable disorders of connective tissue (HDCT) may be an underlying cause due to vascular fragility, as observed in Ehlers-Danlos syndrome (EDS) or Marfan syndrome (MS). This study aims to investigate the molecular profile of patients with joint hypermobility (JH) and unexplained bleeding and to establish genotype-phenotype associations. METHODS: Forty-three female patients with JH and bleeding symptoms were recruited from the haemophilia unit and rehabilitation service at Vall d'Hebron University Hospital. Whole-exome sequencing (WES) was performed to identify genetic variants. RESULTS: Candidate variants in HDCT-related genes were identified in 47% of cases, predominantly in genes associated with EDS and MS. A complete genotype-phenotype concordance was established in 37%, emphasizing the importance of assessing JH in patients presenting with unexplained bleeding. CONCLUSION: The results underscore the need for systematic assessment of JH in patients with bleeding and normal haemostatic tests, as well as for bleeding evaluation in those showing HDCT signs. WES proved valuable in identifying genetic contributors to these complex phenotypes, supporting a multidisciplinary approach to achieve accurate diagnosis and improved patient care. CI - (c) 2025 The Author(s). Haemophilia published by John Wiley & Sons Ltd. FAU - Bandini, Perla AU - Bandini P AD - Laboratori de Coagulopaties Congenites, Banc de Sang i Teixits, Barcelona, Spain. AD - Medicina Transfusional, Vall d'Hebron Institut de Recerca, Universitat Autonoma de Barcelona (VHIR-UAB), Barcelona, Spain. AD - Departament de Genetica, Microbiologia i Estadistica, Universitat de Barcelona, Barcelona, Spain. FAU - Borras, Nina AU - Borras N AD - Laboratori de Coagulopaties Congenites, Banc de Sang i Teixits, Barcelona, Spain. AD - Medicina Transfusional, Vall d'Hebron Institut de Recerca, Universitat Autonoma de Barcelona (VHIR-UAB), Barcelona, Spain. FAU - Altisent, Carme AU - Altisent C AD - Medicina Transfusional, Vall d'Hebron Institut de Recerca, Universitat Autonoma de Barcelona (VHIR-UAB), Barcelona, Spain. FAU - Sanchez-Raya, Judith AU - Sanchez-Raya J AD - Physical Medicine and Rehabilitation Service, Vall d'Hebron University Hospital, Barcelona, Spain. FAU - Martin-Fernandez, Laura AU - Martin-Fernandez L AD - Laboratori de Coagulopaties Congenites, Banc de Sang i Teixits, Barcelona, Spain. AD - Medicina Transfusional, Vall d'Hebron Institut de Recerca, Universitat Autonoma de Barcelona (VHIR-UAB), Barcelona, Spain. FAU - Garcia-Martinez, Iris AU - Garcia-Martinez I AD - Laboratori de Coagulopaties Congenites, Banc de Sang i Teixits, Barcelona, Spain. AD - Medicina Transfusional, Vall d'Hebron Institut de Recerca, Universitat Autonoma de Barcelona (VHIR-UAB), Barcelona, Spain. FAU - Comes, Natalia AU - Comes N AD - Laboratori de Coagulopaties Congenites, Banc de Sang i Teixits, Barcelona, Spain. AD - Medicina Transfusional, Vall d'Hebron Institut de Recerca, Universitat Autonoma de Barcelona (VHIR-UAB), Barcelona, Spain. FAU - Ramirez, Lorena AU - Ramirez L AD - Laboratori de Coagulopaties Congenites, Banc de Sang i Teixits, Barcelona, Spain. AD - Medicina Transfusional, Vall d'Hebron Institut de Recerca, Universitat Autonoma de Barcelona (VHIR-UAB), Barcelona, Spain. FAU - Martorell, Marta AU - Martorell M AD - Medicina Transfusional, Vall d'Hebron Institut de Recerca, Universitat Autonoma de Barcelona (VHIR-UAB), Barcelona, Spain. FAU - Hobeich, Carlos AU - Hobeich C AD - Laboratori de Coagulopaties Congenites, Banc de Sang i Teixits, Barcelona, Spain. AD - Medicina Transfusional, Vall d'Hebron Institut de Recerca, Universitat Autonoma de Barcelona (VHIR-UAB), Barcelona, Spain. FAU - Vidal, Francisco AU - Vidal F AD - Laboratori de Coagulopaties Congenites, Banc de Sang i Teixits, Barcelona, Spain. AD - Medicina Transfusional, Vall d'Hebron Institut de Recerca, Universitat Autonoma de Barcelona (VHIR-UAB), Barcelona, Spain. AD - Centro de Investigacion Biomedica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. FAU - Corrales, Irene AU - Corrales I AD - Laboratori de Coagulopaties Congenites, Banc de Sang i Teixits, Barcelona, Spain. AD - Medicina Transfusional, Vall d'Hebron Institut de Recerca, Universitat Autonoma de Barcelona (VHIR-UAB), Barcelona, Spain. AD - Centro de Investigacion Biomedica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. LA - eng GR - Spanish Ministry of the Economy and Competitiveness/ GR - PI18/01492/Instituto de Salud Carlos III/ GR - European Regional Development Fund/ GR - PI23/01672/Instituto de Salud Carlos III/ PT - Journal Article DEP - 20251103 PL - England TA - Haemophilia JT - Haemophilia : the official journal of the World Federation of Hemophilia JID - 9442916 SB - IM MH - Humans MH - Female MH - *Joint Instability/genetics/complications MH - *Hemorrhage/genetics/complications MH - Adult MH - Adolescent MH - Young Adult MH - Middle Aged MH - Phenotype MH - Ehlers-Danlos Syndrome/genetics MH - Cohort Studies MH - Child MH - Exome Sequencing MH - Marfan Syndrome/genetics MH - Genotype PMC - PMC12904184 COIS- The authors declare no competing financial interests. EDAT- 2025/11/03 06:27 MHDA- 2026/02/13 12:49 PMCR- 2026/02/13 CRDT- 2025/11/03 03:43 PHST- 2025/10/17 00:00 [revised] PHST- 2025/03/10 00:00 [received] PHST- 2025/10/20 00:00 [accepted] PHST- 2026/02/13 12:49 [medline] PHST- 2025/11/03 06:27 [pubmed] PHST- 2025/11/03 03:43 [entrez] PHST- 2026/02/13 00:00 [pmc-release] AID - HAE70160 [pii] AID - 10.1111/hae.70160 [doi] PST - ppublish SO - Haemophilia. 2026 Jan-Feb;32(1):185-194. doi: 10.1111/hae.70160. Epub 2025 Nov 3. PMID- 41177690 OWN - NLM STAT- MEDLINE DCOM- 20260206 LR - 20260616 IS - 1532-8422 (Electronic) IS - 1053-0770 (Linking) VI - 40 IP - 2 DP - 2026 Feb TI - Ethical Aspects of Organ Donation Following Extracorporeal Cardiopulmonary Resuscitation With Unfavorable Neurologic Outcomes: A Systematic Review of Literature. PG - 583-594 LID - S1053-0770(25)01011-0 [pii] LID - 10.1053/j.jvca.2025.10.003 [doi] AB - OBJECTIVE: Given the growing imbalance between the demand for solid organ transplants and the limited availability of donor organs, the potential for organ donation from patients with unfavorable neurologic outcomes following extracorporeal cardiopulmonary resuscitation (eCPR) is gaining attention. This work analysed recent studies on organ procurement following eCPR and evaluated the ethical concerns raised by the study authors. DESIGN: Systematic literature review (Scopus and PubMed, from inception to July 2024). SETTING: All study designs. PARTICIPANTS: Patients with unfavorable outcomes following eCPR. INTERVENTION: Ethical challenges raised by the authors. MEASUREMENTS AND MAIN RESULTS: Of 1,725 screened publications, 17 studies were included, comprising a total of 254 patients with unfavorable outcomes following eCPR. A total of 689 grafts were reported, and 469 organ recipients. Seven studies addressed ethical aspects, emphasizing that eCPR is primarily initiated to save patients with cardiac arrest who have a likely favorable neurologic prognosis. Organ donation is considered only secondarily, in cases where patients experience an unfavorable outcome. CONCLUSION: Organ procurement following eCPR is a sensitive issue that impacts the donor's relatives, transplant recipients, and healthcare professionals. There is a clear need for internationally coordinated, ethically grounded, and legally binding regulations governing organ procurement. These should include clearly defined criteria for the continuation or termination of eCPR, standardized consent procedures, and structured frameworks for transparent, multidisciplinary decision-making. Establishing such protocols would help ensure ethically consistent practices that balance the potential benefits of organ donation with respect for individual dignity and societal justice. CI - Copyright (c) 2025 Elsevier Inc. All rights reserved. FAU - Rajsic, Sasa AU - Rajsic S AD - Department of Anaesthesiology and Intensive Care Medicine, Medical University Innsbruck, Innsbruck, Austria. FAU - Breitkopf, Robert AU - Breitkopf R AD - Department of Anaesthesiology and Intensive Care Medicine, Medical University Innsbruck, Innsbruck, Austria. Electronic address: robert.breitkopf@i-med.ac.at. FAU - Reyer, Beatrix AU - Reyer B AD - Department of Anaesthesiology and Intensive Care Medicine, Medical University Innsbruck, Innsbruck, Austria. FAU - Berent, Felix AU - Berent F AD - Department of Anaesthesiology and Intensive Care Medicine, Medical University Innsbruck, Innsbruck, Austria. FAU - Treml, Benedikt AU - Treml B AD - Department of Anaesthesiology and Intensive Care Medicine, Medical University Innsbruck, Innsbruck, Austria. FAU - Lederer, Wolfgang AU - Lederer W AD - Department of Anaesthesiology and Intensive Care Medicine, Medical University Innsbruck, Innsbruck, Austria. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20251002 PL - United States TA - J Cardiothorac Vasc Anesth JT - Journal of cardiothoracic and vascular anesthesia JID - 9110208 SB - IM MH - Humans MH - *Tissue and Organ Procurement/ethics/methods MH - *Cardiopulmonary Resuscitation/ethics/methods/trends/adverse effects MH - *Extracorporeal Membrane Oxygenation/ethics/methods MH - *Tissue Donors/ethics MH - *Nervous System Diseases/etiology MH - *Heart Arrest/therapy MH - Treatment Outcome OTO - NOTNLM OT - ECMO OT - eCPR OT - ethics OT - extracorporeal cardiopulmonary resuscitation OT - extracorporeal membrane oxygenation OT - organ donation OT - transplantation COIS- Declaration of competing interest The authors declare that they have no conflicts of interest. EDAT- 2025/11/03 00:26 MHDA- 2026/02/07 00:31 CRDT- 2025/11/02 21:53 PHST- 2025/05/19 00:00 [received] PHST- 2025/09/04 00:00 [revised] PHST- 2025/10/01 00:00 [accepted] PHST- 2026/02/07 00:31 [medline] PHST- 2025/11/03 00:26 [pubmed] PHST- 2025/11/02 21:53 [entrez] AID - S1053-0770(25)01011-0 [pii] AID - 10.1053/j.jvca.2025.10.003 [doi] PST - ppublish SO - J Cardiothorac Vasc Anesth. 2026 Feb;40(2):583-594. doi: 10.1053/j.jvca.2025.10.003. Epub 2025 Oct 2. PMID- 41176424 OWN - NLM STAT- MEDLINE DCOM- 20260203 LR - 20260203 IS - 1879-0828 (Electronic) IS - 0953-6205 (Linking) VI - 144 DP - 2026 Feb TI - Multidisciplinary strategies and new technologies in the management of sarcoidosis. PG - 106576 LID - S0953-6205(25)00453-4 [pii] LID - 10.1016/j.ejim.2025.106576 [doi] AB - Sarcoidosis exemplifies the complexity of modern internal medicine, requiring comprehensive, system-based management. The disease is characterized by non-caseating granulomas and can affect virtually any organ, with pulmonary involvement in over 90 % of patients and extrapulmonary manifestations in up to 70 %. Its heterogeneous spectrum, variable course, and risk of organ damage make early recognition and multidisciplinary collaboration essential. This narrative review outlines the clinical manifestations of sarcoidosis, emphasizing organ-specific and systemic non-organ specific symptoms such as fatigue and small fiber neuropathy, which substantially impair quality of life (QoL). Advances in imaging, including cardiac MRI and 18F-FDG PET/CT, together with biomarkers such as soluble IL-2 receptor, have improved diagnostic accuracy, risk stratification, and monitoring. Yet, histological confirmation is almost invariably needed. Therapeutic strategies continue to evolve from the classical glucocorticoid-centered step-up approach toward more personalized regimens. Steroid-sparing agents such as methotrexate, azathioprine, and leflunomide are widely used, while biologics, particularly anti-TNF agents, and emerging small-molecule inhibitors (e.g., JAK and mTOR inhibitors) offer additional options in refractory disease. New investigational therapies, including efzofitimod, are under evaluation. Beyond pharmacology, sarcoidosis management increasingly relies on multidisciplinary teams, integration of primary and tertiary care, and attention to comorbidities and QoL. Digital health tools, telemedicine, and mindfulness-based interventions show promise in supporting patient-centered care. Artificial intelligence and multi-omics approaches may further enhance diagnostic accuracy, phenotyping, and precision medicine in the near future. In conclusion, sarcoidosis stands as a paradigm of complexity in internal medicine, underscoring the need for holistic care, innovation, and collaboration to improve long-term outcomes. CI - Copyright (c) 2025 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved. FAU - Tana, Claudio AU - Tana C AD - Internal Medicine Unit, Eastern Hospital, Manduria, ASL Taranto, Italy. Electronic address: claudio.tana@asl.taranto.it. FAU - Drent, Marjolein AU - Drent M AD - Interstitial Lung Disease (ILD) Center of Excellence, Department of Respiratory Medicine, St. Antonius Hospital, Nieuwegein, the Netherlands; Department of Pharmacology and Toxicology, Faculty of Health, Medicine and Life Sciences, Maastricht University, the Netherlands. FAU - Obi, Ogugua Ndili AU - Obi ON AD - Division of Pulmonary, Critical Care, and Sleep Medicine, Brody School of Medicine, East Carolina University, Greenville, NC, USA. FAU - Cinetto, Francesco AU - Cinetto F AD - Rare Diseases Referral Center, Internal Medicine 1, Department of Medicine (DIMED), AULSS2 Marca Trevigiana, Ca' Foncello Hospital, University of Padova, Padova, Italy. FAU - Bernardinello, Nicol AU - Bernardinello N AD - Respiratory Disease Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy. FAU - Moffa, Livia AU - Moffa L AD - Infectious Disease Clinic, University Hospital of Chieti, Italy. FAU - Tana, Marco AU - Tana M AD - Internal Medicine Unit, University Hospital of Chieti, Italy. FAU - Israel Biet, Dominique AU - Israel Biet D AD - Faculte de Medecine, Respiratory Diseases Department, Universite de Paris Cite, Paris, France. FAU - Spagnolo, Paolo AU - Spagnolo P AD - Respiratory Disease Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy. LA - eng PT - Journal Article PT - Review DEP - 20251101 PL - Netherlands TA - Eur J Intern Med JT - European journal of internal medicine JID - 9003220 SB - IM MH - Humans MH - *Sarcoidosis/therapy/diagnosis MH - Quality of Life MH - Patient Care Team OTO - NOTNLM OT - Diagnostic accuracy OT - Fatigue OT - Holistic patient management OT - Personalized medicine OT - Sarcoidosis OT - Systemic disease OT - Treatment decisions COIS- Declaration of competing interest Conflict of interest statement: Claudio Tana is Section Editor of Primary Care Section of Annals of Medicine. EDAT- 2025/11/02 00:34 MHDA- 2026/02/04 05:06 CRDT- 2025/11/01 22:52 PHST- 2025/09/24 00:00 [received] PHST- 2025/10/24 00:00 [revised] PHST- 2025/10/26 00:00 [accepted] PHST- 2026/02/04 05:06 [medline] PHST- 2025/11/02 00:34 [pubmed] PHST- 2025/11/01 22:52 [entrez] AID - S0953-6205(25)00453-4 [pii] AID - 10.1016/j.ejim.2025.106576 [doi] PST - ppublish SO - Eur J Intern Med. 2026 Feb;144:106576. doi: 10.1016/j.ejim.2025.106576. Epub 2025 Nov 1. PMID- 41176284 OWN - NLM STAT- MEDLINE DCOM- 20260215 LR - 20260418 IS - 1097-6809 (Electronic) IS - 0741-5214 (Linking) VI - 83 IP - 3 DP - 2026 Mar TI - Interdisciplinary vascular reconstructive considerations for pediatric tumors. PG - 920-932 LID - S0741-5214(25)01875-0 [pii] LID - 10.1016/j.jvs.2025.10.035 [doi] AB - Solid tumors with vascular involvement in pediatric patients are challenging to address. They are rare with limited data to guide treatment recommendations. Multidisciplinary management with a pediatric oncologist, pediatric surgeon, vascular surgeon and on occasion cardiac surgeon is paramount. Below, we review the scope of this problem in specific for treatment of Wilms tumor, hepatoblastoma, hepatocellular carcinoma, neuroblastoma, and sarcoma with involvement of the adjoining major vascular structures. Included in this manuscript is the role of vascular reconstruction principles as it applies to pediatric patients. We highlight the importance of individualized treatment plans taking into consideration the nature of the tumor, histology, and extent of disease; the role of neoadjuvant therapy in minimizing extent of resection; and discuss the variety of options that exist for vascular reconstruction. CI - Copyright (c) 2025 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved. FAU - Stetson, Alyssa AU - Stetson A AD - Department of General and Thoracic Surgery, Cincinnati Children's Medical Center, Cincinnati, OH. FAU - Gutwein, Ashley AU - Gutwein A AD - Department of Vascular Surgery, Indiana University Methodist Hospital, Indianapolis, IN. FAU - Bondoc, Alexander AU - Bondoc A AD - Department of General and Thoracic Surgery, Cincinnati Children's Medical Center, Cincinnati, OH. FAU - Dasgupta, Roshni AU - Dasgupta R AD - Department of General and Thoracic Surgery, Cincinnati Children's Medical Center, Cincinnati, OH. FAU - Maijub, John AU - Maijub J AD - Department of Vascular Surgery, Indiana University Methodist Hospital, Indianapolis, IN. FAU - Tiao, Greg AU - Tiao G AD - Department of General and Thoracic Surgery, Cincinnati Children's Medical Center, Cincinnati, OH. FAU - Motaganahalli, Raghu AU - Motaganahalli R AD - Department of Vascular Surgery, Indiana University Methodist Hospital, Indianapolis, IN. Electronic address: rmotagan@iu.edu. LA - eng PT - Journal Article PT - Review DEP - 20251030 PL - United States TA - J Vasc Surg JT - Journal of vascular surgery JID - 8407742 SB - IM MH - Humans MH - Child MH - *Vascular Surgical Procedures/adverse effects MH - *Patient Care Team MH - Treatment Outcome MH - Neoadjuvant Therapy MH - *Plastic Surgery Procedures/adverse effects MH - Neoplasm Invasiveness MH - Interdisciplinary Communication MH - Liver Neoplasms/pathology/surgery MH - Wilms Tumor/pathology/surgery MH - Neuroblastoma/pathology/surgery MH - Kidney Neoplasms/pathology/surgery OTO - NOTNLM OT - Multidisciplinary management OT - Pediatric oncology OT - Pediatric solid tumors OT - Vascular reconstruction COIS- Disclosures None. EDAT- 2025/11/02 00:33 MHDA- 2026/02/16 00:31 CRDT- 2025/11/01 20:17 PHST- 2025/08/07 00:00 [received] PHST- 2025/10/10 00:00 [revised] PHST- 2025/10/20 00:00 [accepted] PHST- 2026/02/16 00:31 [medline] PHST- 2025/11/02 00:33 [pubmed] PHST- 2025/11/01 20:17 [entrez] AID - S0741-5214(25)01875-0 [pii] AID - 10.1016/j.jvs.2025.10.035 [doi] PST - ppublish SO - J Vasc Surg. 2026 Mar;83(3):920-932. doi: 10.1016/j.jvs.2025.10.035. Epub 2025 Oct 30. PMID- 41173762 OWN - NLM STAT- MEDLINE DCOM- 20260130 LR - 20260130 IS - 1557-8194 (Electronic) IS - 0011-5029 (Linking) VI - 72 IP - 2 DP - 2026 Feb TI - Takotsubo cardiomyopathy: Advances in pathophysiology, diagnostic biomarkers, genetic insights, multisystemic involvement, treatment updates & multidisciplinary interventions. PG - 102029 LID - S0011-5029(25)00183-X [pii] LID - 10.1016/j.disamonth.2025.102029 [doi] AB - BACKGROUND: Takotsubo cardiomyopathy (TTC) is an acute, reversible cardiac syndrome triggered by physical or emotional stress, involving complex multi-system interactions, with unclear mechanisms and variable prognosis across patient subgroups. OBJECTIVES: To synthesize current evidence on comorbidities, biomarkers, genetic predispositions, prognostic factors, and management strategies in TTC, highlighting clinical implications and research gaps for improved diagnosis, prevention, and patient outcomes. METHODS: A systematic review was conducted on studies published between January 2015 and July 2025. Search was performed across Embase, PubMed, Web of Science, Scopus and Google Scholar using predefined MeSH terms and keywords. Twenty-five studies were included in this review. Quality assessment was conducted using the Newcastle-Ottawa Scale. RESULTS: TTC was associated with psychiatric disorders, malignancies, endocrine and inflammatory conditions, and neurological insults. Apical ballooning morphology predicted worse outcomes. Biomarkers (NT-proBNP/TnI) and echocardiography improved diagnostic accuracy. Adrenergic receptor polymorphisms (GRK5 L41Q, alpha2CDel322-325) increased susceptibility in select populations, though genetic findings were inconsistent. Psychological support and beta-blockers improved recovery, while machine learning models enhanced prognostic prediction. ICU-based early echocardiographic screening identified high-risk patients. Multi-disciplinary approaches integrating cardiovascular, psychological, and genetic considerations yielded better patient outcomes. Evidence was limited by heterogeneity, small genetic cohorts, and inconsistent follow-up durations, highlighting the need for standardized diagnostic criteria and prospective, multicenter studies. CONCLUSION: TTC is a multifactorial syndrome requiring integrated diagnostic, therapeutic, and preventive strategies. Early detection, comorbidity management, and personalized care improve prognosis. Standardized research is needed to refine understanding and optimize management. CI - Copyright (c) 2025. Published by Elsevier Inc. FAU - Inban, Pugazhendi AU - Inban P AD - St Mary's General Hospital and St Clare's Health, USA. Electronic address: ipugazhendi@primehealthcare.com. FAU - Thai, Andy AU - Thai A AD - Internal Medicine, Alameda Health System-Highland Hospital, Oakland, USA. FAU - Parekh, Rushin S AU - Parekh RS AD - GMERS Sola, Ahmedabad, India. FAU - Kudaiarov, Dastan AU - Kudaiarov D AD - International European University, Bishkek, Kyrgyzstan. FAU - Thalamanchi, Khyati AU - Thalamanchi K AD - Kaloji Narayana Rao University, Warangal, India. FAU - John, Jobby AU - John J AD - Internal Medicine, Dr. Somervell Memorial CSI Medical College and Hospital Karakonam, Trivandrum, India. FAU - Sharma, Renu AU - Sharma R AD - Internal Medicine, Nepalgunj Medical College, Kathmandu University, Nepal. FAU - Aravazhi, Prasanna Sakthi AU - Aravazhi PS AD - Madras Medical College, Chennai, India. LA - eng PT - Journal Article PT - Systematic Review DEP - 20251030 PL - United States TA - Dis Mon JT - Disease-a-month : DM JID - 0370657 RN - 0 (Biomarkers) SB - IM MH - Humans MH - *Takotsubo Cardiomyopathy/diagnosis/therapy/physiopathology/genetics MH - Biomarkers/blood MH - Prognosis MH - Echocardiography MH - Comorbidity OTO - NOTNLM OT - Adrenergic receptors OT - Biomarkers OT - Comorbidities OT - Echocardiography OT - Genetic predisposition OT - Machine learning OT - Prognosis OT - Takotsubo cardiomyopathy COIS- Conflict of interest The Author(s) declared that there is no conflict of interest EDAT- 2025/11/01 05:37 MHDA- 2026/01/31 00:29 CRDT- 2025/10/31 22:55 PHST- 2026/01/31 00:29 [medline] PHST- 2025/11/01 05:37 [pubmed] PHST- 2025/10/31 22:55 [entrez] AID - S0011-5029(25)00183-X [pii] AID - 10.1016/j.disamonth.2025.102029 [doi] PST - ppublish SO - Dis Mon. 2026 Feb;72(2):102029. doi: 10.1016/j.disamonth.2025.102029. Epub 2025 Oct 30. PMID- 41173449 OWN - NLM STAT- MEDLINE DCOM- 20260328 LR - 20260328 IS - 1885-5857 (Electronic) IS - 1885-5857 (Linking) VI - 79 IP - 4 DP - 2026 Apr TI - Current insights and challenges in the management of hyperkalemia. PG - 369-376 LID - S1885-5857(25)00298-1 [pii] LID - 10.1016/j.rec.2025.10.012 [doi] AB - Hyperkalemia is an electrolyte disorder characterized by elevated serum potassium levels, which can be dangerous and lead to severe cardiac complications. This condition is particularly common in patients with comorbidities such as diabetes mellitus, chronic kidney disease, heart failure, and hypertension, among others. Additionally, hyperkalemia frequently develops in patients treated concurrently with certain medications, especially renin-angiotensin-aldosterone system inhibitors, which are commonly used to manage cardiac and nephrological conditions, significantly increasing the risk of hospitalizations and mortality in these patients. This review aims to identify key challenges in the management of hyperkalemia, including improving early detection, optimizing access to appropriate therapies, ensuring continuous monitoring, and establishing effective strategies to manage complications. Furthermore, it is essential to raise awareness of its significance and promote a multidisciplinary approach to enhance health outcomes and the quality of life of patients with hyperkalemia. CI - Copyright (c) 2025 Sociedad Espanola de Cardiologia. Published by Elsevier Espana, S.L.U. All rights reserved. FAU - Ortiz-Cortes, Carolina AU - Ortiz-Cortes C AD - Servicio de Cardiologia, Hospital Universitario Fundacion Alcorcon, Alcorcon, Madrid, Spain. Electronic address: carol.ortizcortes@gmail.com. FAU - Navarro-Gonzalez, Juan Francisco AU - Navarro-Gonzalez JF AD - Servicio de Nefrologia y Unidad de Investigacion, Hospital Universitario Nuestra Senora de Candelaria, Santa Cruz de Tenerife, Spain; Instituto de Tecnologias Biomedicas, Universidad de La Laguna, Santa Cruz de Tenerife, Spain; Facultad de Ciencias de la Salud, Universidad Fernando Pessoa Canarias, Las Palmas de Gran Canaria, Spain; RICORS2040-Renal (RD24/0004/0022), Instituto de Salud Carlos III, Madrid, Spain. Electronic address: jnavgon@gobiernodecanarias.org. CN - advisory board of the Instituto de Hiperkalemia IHK LA - eng LA - spa PT - Journal Article PT - Review DEP - 20251030 PL - Spain TA - Rev Esp Cardiol (Engl Ed) JT - Revista espanola de cardiologia (English ed.) JID - 101587954 RN - RWP5GA015D (Potassium) SB - IM MH - Humans MH - *Hyperkalemia/therapy/diagnosis/blood MH - *Disease Management MH - *Potassium/blood OTO - NOTNLM OT - Chronic kidney disease OT - Enfermedad renal cronica OT - Heart failure OT - Hiperpotasemia OT - Hyperkalemia OT - Insuficiencia cardiaca EDAT- 2025/11/01 05:37 MHDA- 2026/03/29 07:35 CRDT- 2025/10/31 20:20 PHST- 2025/06/27 00:00 [received] PHST- 2025/10/21 00:00 [accepted] PHST- 2026/03/29 07:35 [medline] PHST- 2025/11/01 05:37 [pubmed] PHST- 2025/10/31 20:20 [entrez] AID - S1885-5857(25)00298-1 [pii] AID - 10.1016/j.rec.2025.10.012 [doi] PST - ppublish SO - Rev Esp Cardiol (Engl Ed). 2026 Apr;79(4):369-376. doi: 10.1016/j.rec.2025.10.012. Epub 2025 Oct 30. PMID- 41173345 OWN - NLM STAT- MEDLINE DCOM- 20260425 LR - 20260505 IS - 1552-6259 (Electronic) IS - 0003-4975 (Linking) VI - 121 IP - 5 DP - 2026 May TI - Single-Center Use of Real-Time Society of Thoracic Surgeons Congenital Heart Surgery Data to Improve Institutional Outcomes. PG - 1148-1157 LID - S0003-4975(25)01057-4 [pii] LID - 10.1016/j.athoracsur.2025.09.052 [doi] AB - BACKGROUND: Improving quality of care in pediatric cardiac surgery is complex. We describe using institutional The Society of Thoracic Surgery (STS) Congenital Heart Surgery Database (CHSD) data in real time to develop a quality framework with the aim of optimizing team performance and thus improving clinical outcomes. METHODS: A single-center retrospective study was undertaken spanning 8 quarters: 3 quarters (Q) preimplementation (Q4 2022, Q1 2023, and Q2 2023), 2 quarters during implementation (Q3 2023 and Q4 2023), and 3 quarters postimplementation (Q1 2024, Q2 2024, and Q3 2024). STS CHSD data are abstracted from medical records, input into third-party software, and are used to create visual plots for each index procedure at weekly rounds called "Collaborative Multidisciplinary Assessment of Performance Rounds" (CMAP) and to create an STS Dashboard. STS CHSD unadjusted data and Pediatric Cardiac Critical Care Consortium (PC(4)) risk-adjusted clinical outcomes were compared preimplementation and postimplementation. RESULTS: CMAP were instituted in Children's Nebraska Criss Heart Center in July 2023. CMAP attendance median is 59 (interquartile range, 48-74). The case mix preimplementation and postimplementation is similar (17.7% The Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery [STAT] Congenital Heart Surgery Mortality Categories 4 or 5 cases vs 18%). Postimplementation, 39 CMAP presented 223 index procedures. There were trends to decreased risk-adjusted PC(4) outcomes postimplementation vs preimplementation, including failure-to-rescue, major complication, cardiac arrest, seizures, infection and unplanned reintervention. CMAP discussions have resulted in "CMAP Takeaways," which have informed quality care initiatives. CONCLUSIONS: Our data demonstrate the feasibility and power of using real-time STS CHSD unadjusted data to create a quality framework based on transparent data sharing and psychological safety to enhance team performance in congenital heart surgery. CI - Copyright (c) 2025 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved. FAU - Hancock Friesen, Camille L AU - Hancock Friesen CL AD - Division of Pediatric Cardiothoracic Surgery, Children's Nebraska, Omaha, Nebraska; Department of Surgery, University of Nebraska Medical Center, Omaha, Nebraska. Electronic address: chancockfriesen@childrensnebraska.org. FAU - McGlinchey, Amanda M AU - McGlinchey AM AD - Department of Quality and Patient Safety, Children's Nebraska, Omaha, Nebraska. FAU - L'Heureux, Timothe E AU - L'Heureux TE AD - Department of Quality and Patient Safety, Children's Nebraska, Omaha, Nebraska. FAU - Ibrahimiye, Ali N AU - Ibrahimiye AN AD - Division of Pediatric Cardiothoracic Surgery, Children's Nebraska, Omaha, Nebraska; Department of Surgery, University of Nebraska Medical Center, Omaha, Nebraska. FAU - Kerns, Ellen K AU - Kerns EK AD - Department of Quality and Patient Safety, Children's Nebraska, Omaha, Nebraska. FAU - Ortmann, Laura A AU - Ortmann LA AD - Division of Pediatric Critical Care, Children's Nebraska, Omaha, Nebraska; Department of Pediatrics University of Nebraska Medical Center, Omaha, Nebraska. FAU - Kumar, Subramanyan R AU - Kumar SR AD - Division of Pediatric Cardiothoracic Surgery, Children's Nebraska, Omaha, Nebraska; Department of Surgery, University of Nebraska Medical Center, Omaha, Nebraska. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20251030 PL - Netherlands TA - Ann Thorac Surg JT - The Annals of thoracic surgery JID - 15030100R SB - IM MH - Humans MH - Retrospective Studies MH - *Heart Defects, Congenital/surgery/mortality MH - *Societies, Medical MH - *Quality Improvement MH - *Thoracic Surgery MH - *Cardiac Surgical Procedures/standards MH - Female MH - Male MH - Infant MH - Databases, Factual MH - Infant, Newborn MH - Child, Preschool COIS- Disclosures The authors have no conflicts of interest to disclose. EDAT- 2025/11/01 05:37 MHDA- 2026/04/26 05:13 CRDT- 2025/10/31 20:18 PHST- 2025/01/26 00:00 [received] PHST- 2025/08/15 00:00 [revised] PHST- 2025/09/29 00:00 [accepted] PHST- 2026/04/26 05:13 [medline] PHST- 2025/11/01 05:37 [pubmed] PHST- 2025/10/31 20:18 [entrez] AID - S0003-4975(25)01057-4 [pii] AID - 10.1016/j.athoracsur.2025.09.052 [doi] PST - ppublish SO - Ann Thorac Surg. 2026 May;121(5):1148-1157. doi: 10.1016/j.athoracsur.2025.09.052. Epub 2025 Oct 30. PMID- 41170222 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251031 LR - 20251102 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 17 IP - 9 DP - 2025 Sep TI - Outcomes of Pulmonary Arterial Hypertension in Pregnancy: A Tertiary Care Retrospective Study. PG - e93463 LID - 10.7759/cureus.93463 [doi] LID - e93463 AB - BACKGROUND AND AIMS: Pulmonary arterial hypertension (PAH) is a rare disease affecting mainly women of childbearing age. It is associated with high maternal mortality. Hence, obstetricians and cardiologists recommend against pregnancy, thereby stressing the need for effective contraception such as an intrauterine contraceptive device (IUD), and in case pregnancy occurs, early termination of pregnancy should be considered. The present study aims to retrospectively analyse 12 cases presenting with PAH in pregnancy and their maternal and fetal outcomes. METHODS: Retrospective analysis of 12 cases of PAH in pregnancy who reported to the emergency or in the cardio-obstetric clinic of Postgraduate Institution of Medical Education and Research (PGIMER), Chandigarh, India, in the last 24 years was conducted in terms of obstetric, cardiology, and neonatal parameters. PAH was diagnosed on the basis of high systolic pulmonary artery pressure (sPAP) > 20 mmHg on echocardiography. Secondary causes of pulmonary hypertension were ruled out in all patients whenever possible, depending on maternal condition. RESULTS: Out of the total 12 patients, 10 (83.33%) presented in the antepartum period, and two (16.66%) in the postpartum period. Moreover, 50% were New York Heart Association (NYHA) class 3-4 at admission. There was increased PAP, ranging from 42 to 140 mmHg. As regards obstetrical outcome in 10 patients who delivered in our institution, one (10%) delivered vaginally, five (50%) had a cesarean section, one (10%) underwent medical termination of pregnancy (MTP), one (10%) patient was lost to follow-up, and two (20%) died undelivered. Maternal mortality was 36.36% (4/11), which included two antenatal and two delivered patients. Out of seven patients who delivered, five (71.42%) had fetal growth retardation, and one (14.28%) had stillbirth. CONCLUSION: PAH has high maternal mortality despite modern treatment modalities. Patients presenting with higher NYHA class had poorer outcomes and a higher incidence of fetal growth retardation. Hence, MTP should be offered to patients with PAH who present in early pregnancy. A multidisciplinary (cardiology, anaesthesiology, neonatology, cardiac anaesthetist, along with an obstetrician experienced in managing high-risk pregnancy) team approach should be adopted while managing such patients. However, considering a very high risk in continuing the pregnancy, an ethical dilemma for continuing the pregnancy in women desirous of the same remains. CI - Copyright (c) 2025, Chopra et al. FAU - Chopra, Seema AU - Chopra S AD - Obstetrics and Gynaecology, Postgraduate Institute of Medical Education and Research, Chandigarh, Chandigarh, IND. FAU - Kaur, Amanjot AU - Kaur A AD - Obstetrics and Gynaecology, Postgraduate Institute of Medical Education and Research, Chandigarh, Chandigarh, IND. FAU - Rai, Rakhi AU - Rai R AD - Obstetrics and Gynaecology, Postgraduate Institute of Medical Education and Research, Chandigarh, Chandigarh, IND. FAU - Sikka, Pooja AU - Sikka P AD - Obstetrics and Gynaecology, Postgraduate Institute of Medical Education and Research, Chandigarh, Chandigarh, IND. FAU - Aggarwal, Neelam AU - Aggarwal N AD - Obstetrics and Gynaecology, Postgraduate Institute of Medical Education and Research, Chandigarh, Chandigarh, IND. FAU - Suri, Vanita AU - Suri V AD - Obstetrics and Gynaecology, Postgraduate Institute of Medical Education and Research, Chandigarh, Chandigarh, IND. FAU - Vijayvergiya, Rajesh AU - Vijayvergiya R AD - Cardiology, Postgraduate Institute of Medical Education and Research, Chandigarh, Chandigarh, IND. LA - eng PT - Journal Article DEP - 20250929 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC12569722 OTO - NOTNLM OT - heart disease OT - maternal mortality OT - pregnancy OT - prostacyclin OT - pulmonary arterial hypertension COIS- Human subjects: Informed consent for treatment and open access publication was obtained or waived by all participants in this study. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. EDAT- 2025/10/31 06:26 MHDA- 2025/10/31 06:27 PMCR- 2025/09/29 CRDT- 2025/10/31 04:54 PHST- 2025/09/28 00:00 [accepted] PHST- 2025/10/31 06:27 [medline] PHST- 2025/10/31 06:26 [pubmed] PHST- 2025/10/31 04:54 [entrez] PHST- 2025/09/29 00:00 [pmc-release] AID - 10.7759/cureus.93463 [doi] PST - epublish SO - Cureus. 2025 Sep 29;17(9):e93463. doi: 10.7759/cureus.93463. eCollection 2025 Sep. PMID- 41167329 OWN - NLM STAT- MEDLINE DCOM- 20251122 LR - 20261022 IS - 1095-8584 (Electronic) IS - 0022-2828 (Print) IS - 0022-2828 (Linking) VI - 209 DP - 2025 Dec TI - Molecular mechanisms of altered contraction with the beta-myosin R403Q mutation in porcine ventricular muscle and a human stem cell-derived cardiomyocyte model. PG - 143-160 LID - S0022-2828(25)00192-0 [pii] LID - 10.1016/j.yjmcc.2025.10.008 [doi] AB - The R403Q mutation in the sarcomere protein beta-myosin heavy chain (beta-MHC) is a known genetic cause of hypertrophic cardiomyopathy (HCM), associated with ventricular hypercontractility, impaired relaxation, and cardiac arrhythmias. Despite extensive research, the mutations impact on myosin contractile properties remains unclear partly due to discrepancies across different model systems. In this study, we used a multidisciplinary approach to explore mutational effects using two distinct heterozygous R403Q systems: a Yucatan minipig model and human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). X-ray diffraction of R403Q minipig ventricular muscle demonstrated reduced order of the thick filament, suggesting destabilization of the inhibited OFF (vs. ON) state of myosin in relaxed muscle, which correlated with elevated force at submaximal calcium. Super-resolution, single-molecule fluorescence microscopy indicated elevated ATPase activity in thick filament zones lacking cardiac myosin binding protein-C (cMyBP-C). Furthermore, R403Q myofibrils exhibited slower activation and relaxation kinetics, with reduced sensitivity to ADP. Molecular dynamics simulations suggested that altered interactions at the actomyosin interface contribute to these effects, rather than changes at the nucleotide binding pocket, typically associated with ADP release. Human engineered heterozygous R403Q hiPSC-CMs exhibited reduced maximal myofibril force, slowed relaxation kinetics, and hypercontraction in engineered heart tissue constructs-consistent with HCM phenotypes observed in the heterozygous porcine model. Our results demonstrate that the R403Q mutation induces contractile dysfunction within the early stages of stem cell derived cardiomyocyte development and in juvenile minipigs, and that hypercontractility and slower contractile kinetics may result from a combination of an increased population of activated (ON) myosin heads and delayed detachment during cross-bridge cycling, respectively. CI - Copyright (c) 2025 Elsevier Ltd. All rights reserved. FAU - Steczina, Sonette AU - Steczina S AD - Department of Bioengineering, University of Washington, Seattle, WA 98109, USA; Center for Translational Muscle Research, University of Washington, Seattle, WA 98109, USA; Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA 98109, USA. FAU - Mohran, Saffie AU - Mohran S AD - Department of Bioengineering, University of Washington, Seattle, WA 98109, USA; Center for Translational Muscle Research, University of Washington, Seattle, WA 98109, USA; Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA 98109, USA. FAU - Childers, Matthew C AU - Childers MC AD - Department of Bioengineering, University of Washington, Seattle, WA 98109, USA; Center for Translational Muscle Research, University of Washington, Seattle, WA 98109, USA. FAU - McMillen, Timothy S AU - McMillen TS AD - Center for Translational Muscle Research, University of Washington, Seattle, WA 98109, USA; Department of Anesthesiology and Pain Medicine, University of Washington, Seattle, WA 98109, USA. FAU - Naim, Ateeqa AU - Naim A AD - School of Natural Sciences, University of Kent, Canterbury, UK. FAU - Pilagov, Matvey AU - Pilagov M AD - School of Natural Sciences, University of Kent, Canterbury, UK. FAU - Dente, Marica AU - Dente M AD - Department of Experimental and Clinical Medicine, Division of Physiology, University of Florence, Italy. FAU - Kooiker, Kristina B AU - Kooiker KB AD - Center for Translational Muscle Research, University of Washington, Seattle, WA 98109, USA; Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA 98109, USA; Division of Cardiology, Department of Medicine, University of Washington, Seattle, WA 98109, USA; Center for Cardiovascular Biology, University of Washington, Seattle, WA, USA. FAU - Mandrycky, Christian AU - Mandrycky C AD - Department of Bioengineering, University of Washington, Seattle, WA 98109, USA; Center for Translational Muscle Research, University of Washington, Seattle, WA 98109, USA. FAU - Tawde, Khushi AU - Tawde K AD - Department of Biology, University of Washington, Seattle, WA, USA. FAU - Hesson, Jennifer AU - Hesson J AD - Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA 98109, USA. FAU - Zhao, Jing AU - Zhao J AD - College of Basic Medical Sciences, Dalian Medical University, Dalian, Liaoning, China. FAU - Mathieu, Julie AU - Mathieu J AD - Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA 98109, USA. FAU - Pioner, J Manuel AU - Pioner JM AD - Department of Biology, University of Florence, Florence, Italy. FAU - Geeves, Michael A AU - Geeves MA AD - School of Natural Sciences, University of Kent, Canterbury, UK. FAU - Ma, Weikang AU - Ma W AD - BioCAT, Department of Biology, Illinois Institute of Technology, Chicago, IL, USA; Center for Synchrotron Radiation Research and Instrumentation, Illinois Institute of Technology, Chicago, IL, USA. FAU - Moussavi-Harami, Farid AU - Moussavi-Harami F AD - Center for Translational Muscle Research, University of Washington, Seattle, WA 98109, USA; Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA 98109, USA; Division of Cardiology, Department of Medicine, University of Washington, Seattle, WA 98109, USA; Center for Cardiovascular Biology, University of Washington, Seattle, WA, USA. FAU - Kad, Neil M AU - Kad NM AD - School of Natural Sciences, University of Kent, Canterbury, UK. FAU - Regnier, Michael AU - Regnier M AD - Department of Bioengineering, University of Washington, Seattle, WA 98109, USA; Center for Translational Muscle Research, University of Washington, Seattle, WA 98109, USA; Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA 98109, USA; Center for Cardiovascular Biology, University of Washington, Seattle, WA, USA. Electronic address: mregnier@uw.edu. LA - eng GR - R01 HL157169/HL/NHLBI NIH HHS/United States GR - T32 HL007828/HL/NHLBI NIH HHS/United States GR - R01 HL128368/HL/NHLBI NIH HHS/United States GR - F31 HL164060/HL/NHLBI NIH HHS/United States GR - R01 HL171657/HL/NHLBI NIH HHS/United States GR - P30 GM138395/GM/NIGMS NIH HHS/United States GR - P30 AR074990/AR/NIAMS NIH HHS/United States GR - K99 HL173646/HL/NHLBI NIH HHS/United States PT - Journal Article DEP - 20251028 PL - England TA - J Mol Cell Cardiol JT - Journal of molecular and cellular cardiology JID - 0262322 RN - EC 3.6.4.1 (Myosin Heavy Chains) RN - EC 3.6.1.- (Cardiac Myosins) RN - SY7Q814VUP (Calcium) RN - 0 (Carrier Proteins) RN - 0 (Myosin Binding Protein C) SB - IM UOF - bioRxiv. 2025 Sep 01:2025.08.27.672708. doi: 10.1101/2025.08.27.672708. PMID: 40950005 MH - Animals MH - *Myocytes, Cardiac/metabolism/cytology MH - Humans MH - Swine MH - *Induced Pluripotent Stem Cells/metabolism/cytology MH - *Myocardial Contraction/genetics MH - *Mutation/genetics MH - *Heart Ventricles/metabolism/pathology MH - *Myosin Heavy Chains/genetics/metabolism/chemistry MH - Cardiomyopathy, Hypertrophic/genetics MH - Myofibrils/metabolism MH - Sarcomeres/metabolism MH - *Cardiac Myosins/genetics/metabolism MH - Swine, Miniature MH - Disease Models, Animal MH - Calcium/metabolism MH - Carrier Proteins MH - Myosin Binding Protein C PMC - PMC12746836 MID - NIHMS2121647 OTO - NOTNLM OT - Cardiac myosin OT - Cross-bridge cycling OT - Hypercontractility OT - Hypertrophic cardiomyopathy OT - Myosin recruitment EDAT- 2025/10/31 00:29 MHDA- 2025/11/23 00:58 PMCR- 2026/10/21 CRDT- 2025/10/30 20:12 PHST- 2025/08/21 00:00 [received] PHST- 2025/10/16 00:00 [revised] PHST- 2025/10/23 00:00 [accepted] PHST- 2025/11/23 00:58 [medline] PHST- 2025/10/31 00:29 [pubmed] PHST- 2025/10/30 20:12 [entrez] PHST- 2026/10/21 00:00 [pmc-release] AID - S0022-2828(25)00192-0 [pii] AID - 10.1016/j.yjmcc.2025.10.008 [doi] PST - ppublish SO - J Mol Cell Cardiol. 2025 Dec;209:143-160. doi: 10.1016/j.yjmcc.2025.10.008. Epub 2025 Oct 28. PMID- 41165303 OWN - NLM STAT- MEDLINE DCOM- 20251106 LR - 20251106 IS - 1531-7072 (Electronic) IS - 1070-5295 (Linking) VI - 31 IP - 6 DP - 2025 Dec 1 TI - Cardiac arrest centers improve survival. PG - 713-716 LID - 10.1097/MCC.0000000000001322 [doi] AB - PURPOSE OF REVIEW: Cardiac arrest centers (CAC) are specialized certified hospitals for patients with an out-of-hospital cardiac arrest (OHCA). The certification is gaining recognition in international guidelines, and with low survival rates in many regions, the need for specialized postresuscitation care has become increasingly urgent. RECENT FINDINGS: Current PubMed literature highlights key themes like the role of CAC in improving survival and neurological recovery after OHCA, the importance of multidisciplinary teams and evidence-based protocols. SUMMARY: The growing evidence of CAC significantly improving survival and neurological outcomes in patients with OHCA supports the need for global implementation. For clinical practice this underscores the importance of directing OHCA patients to designate CAC whenever possible, and it highlights the need to further expand CAC certifications as a main component of postresuscitation systems. CI - Copyright (c) 2025 Wolters Kluwer Health, Inc. All rights reserved. FAU - Rott, Nadine AU - Rott N AD - University of Cologne, Department of Anesthesiology and Intensive Care Medicine, Faculty of Medicine, University Hospital Cologne, Cologne. AD - German Resuscitation Council (GRC), Ulm. FAU - Reinsch, Lina AU - Reinsch L AD - German Resuscitation Council (GRC), Ulm. FAU - Bottiger, Bernd W AU - Bottiger BW AD - German Resuscitation Council (GRC), Ulm. AD - Faculty of Medicine, University of Cologne, Cologne, Germany. AD - Institute of Emergency Care, Pedagogy of Health and Nursing Science, University of Pecs, Hungary. LA - eng PT - Journal Article PT - Review DEP - 20251022 PL - United States TA - Curr Opin Crit Care JT - Current opinion in critical care JID - 9504454 SB - IM MH - Humans MH - *Out-of-Hospital Cardiac Arrest/therapy/mortality MH - *Cardiopulmonary Resuscitation/standards/methods MH - Patient Care Team/organization & administration MH - *Emergency Medical Services/organization & administration/standards MH - Survival Rate MH - Practice Guidelines as Topic OTO - NOTNLM OT - cardiac arrest center OT - out-of-hospital cardiac arrest OT - systems saving lives EDAT- 2025/10/30 12:30 MHDA- 2025/11/07 00:27 CRDT- 2025/10/30 08:53 PHST- 2025/11/07 00:27 [medline] PHST- 2025/10/30 12:30 [pubmed] PHST- 2025/10/30 08:53 [entrez] AID - 00075198-990000000-00315 [pii] AID - 10.1097/MCC.0000000000001322 [doi] PST - ppublish SO - Curr Opin Crit Care. 2025 Dec 1;31(6):713-716. doi: 10.1097/MCC.0000000000001322. Epub 2025 Oct 22. PMID- 41164785 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251030 LR - 20251101 IS - 2328-8957 (Print) IS - 2328-8957 (Electronic) IS - 2328-8957 (Linking) VI - 12 IP - 10 DP - 2025 Oct TI - Partial Oral Versus Intravenous Antibiotic Therapy for Endocarditis With Management by a Multidisciplinary Team: A Retrospective Cohort Study. PG - ofaf625 LID - 10.1093/ofid/ofaf625 [doi] LID - ofaf625 AB - BACKGROUND: Despite trial data supporting oral stepdown therapy for infective endocarditis (IE), its use remains limited, especially in North America. We evaluated outcomes of patients with IE managed by a multidisciplinary team and treated with either intravenous (IV) or partial oral antibiotics. METHODS: This was a single-center retrospective study of patients with definite IE identified from an institutional registry between 7 September 2021 and 1 March 2025. Clinical and outcomes data were analyzed using multivariable logistic regression. RESULTS: Of 236 patients, 143 received IV therapy alone and 93 were transitioned to partial oral therapy. Baseline characteristics were similar, though valve surgery was more frequent in the oral group (40.9% vs 28.0%; P = .04). There were no significant differences in 90-day relapsed infection (0.7% vs 2.2%; P = .32), 90-day all-cause mortality (2.8% vs 6.5%; P = .17), or the composite of both outcomes (3.5% vs 8.6%; P = .09). There was no difference in relapsed infection or all-cause mortality at 90 days for patients with methicillin-resistant Staphylococcus aureus transitioned to oral therapy. In multivariable analysis, oral therapy was not associated with increased 90-day mortality (odds ratio [OR], 1.72 [95% confidence interval CI .41-7.24]; P = .46). Independent predictors of mortality included older age (OR, 1.06 per year [95% CI, 1.00-1.13]; P < .001), acute heart failure (OR, 18.61), and discharge before medically advised (OR, 8.60). CONCLUSIONS: In selected patients managed by a multidisciplinary team, partial oral therapy for IE appears to be safe and effective, with outcomes comparable to exclusive IV treatment, consistent with European guidelines. CI - (c) The Author(s) 2025. Published by Oxford University Press on behalf of Infectious Diseases Society of America. FAU - El-Dalati, Sami AU - El-Dalati S AUID- ORCID: 0000-0003-2603-2951 AD - Division of Infectious Diseases, Department of Internal Medicine, University of Kentucky Medical Center, Lexington, Kentucky, USA. FAU - Collis, Bennett AU - Collis B AD - University of Kentucky College of Medicine, Lexington, Kentucky, USA. FAU - Kobayashi, Takaaki AU - Kobayashi T AUID- ORCID: 0000-0003-4751-6859 AD - Division of Infectious Diseases, Department of Internal Medicine, University of Kentucky Medical Center, Lexington, Kentucky, USA. FAU - Hall, Evan AU - Hall E AD - University of Kentucky College of Medicine, Lexington, Kentucky, USA. FAU - Alnabelsi, Talal AU - Alnabelsi T AD - Division of Cardiology, Department of Internal Medicine, University of Kentucky Medical Center, Lexington, Kentucky, USA. FAU - Cao, Chloe AU - Cao C AUID- ORCID: 0009-0000-8256-9353 AD - Department of Internal Medicine, HCA Healthcare/University of South Florida Morsani College of Medicine Graduate Medical Education/HCA Florida Trinity, Tampa, Florida, USA. FAU - Johnson, Meredith AU - Johnson M AD - Department of Surgery, University of Kentucky Medical Center, Lexington, Kentucky, USA. FAU - Gurley, John AU - Gurley J AD - Division of Cardiology, Department of Internal Medicine, University of Kentucky Medical Center, Lexington, Kentucky, USA. FAU - Strnad, Luke AU - Strnad L AUID- ORCID: 0000-0002-1583-9453 AD - Division of Infectious Diseases, Department of Internal Medicine, Oregon Health and Science University, Portland, Oregon, USA. FAU - Adams, Corey AU - Adams C AD - Department of Cardiac Sciences, Libin Cardiovascular Institute, University of Calgary, Calgary, Alberta, Canada. FAU - Weaver, Victoria AU - Weaver V AD - Division of Infectious Diseases, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Reda, Hassan AU - Reda H AD - Division of Infectious Diseases, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Sekela, Michael AU - Sekela M AD - Division of Cardiac Surgery, University of Kentucky Medical Center, Lexington, Kentucky, USA. FAU - London, Tessa AU - London T AD - Division of Infectious Diseases, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Kennedy, Kara AU - Kennedy K AUID- ORCID: 0009-0001-2428-5261 AD - Department of Neurology, University of Kentucky, Lexington, Kentucky, USA. FAU - Mansoor, Armaghan-E Rehman AU - Mansoor AR AUID- ORCID: 0000-0002-2087-187X AD - Division of Infectious Diseases, Department of Internal Medicine, University of Kentucky Medical Center, Lexington, Kentucky, USA. FAU - Olafsson, David AU - Olafsson D AD - Division of Infectious Diseases, Department of Internal Medicine, University of Kentucky Medical Center, Lexington, Kentucky, USA. FAU - Laugherty, Grant AU - Laugherty G AD - Division of Infectious Diseases, Department of Internal Medicine, University of Kentucky Medical Center, Lexington, Kentucky, USA. FAU - Tremblay, Alyssa AU - Tremblay A AD - Division of Infectious Diseases, Department of Internal Medicine, University of Kentucky Medical Center, Lexington, Kentucky, USA. FAU - Linder, Angella AU - Linder A AD - Division of Infectious Diseases, Department of Internal Medicine, University of Kentucky Medical Center, Lexington, Kentucky, USA. FAU - Gill, Deborah AU - Gill D AD - Division of Infectious Diseases, Department of Internal Medicine, University of Kentucky Medical Center, Lexington, Kentucky, USA. FAU - Van Sickels, Nicholas J AU - Van Sickels NJ AUID- ORCID: 0009-0000-1435-0720 AD - Division of Infectious Diseases, Department of Internal Medicine, University of Kentucky Medical Center, Lexington, Kentucky, USA. FAU - Pomakov, Alexander AU - Pomakov A AD - Division of Infectious Diseases, Department of Internal Medicine, University of Kentucky Medical Center, Lexington, Kentucky, USA. FAU - Harris, William AU - Harris W AUID- ORCID: 0009-0004-0979-3841 AD - University of Kentucky College of Pharmacy, Lexington, Kentucky, USA. FAU - Stoner, Bobbi Jo AU - Stoner BJ AD - University of Kentucky College of Pharmacy, Lexington, Kentucky, USA. LA - eng PT - Journal Article DEP - 20251028 PL - United States TA - Open Forum Infect Dis JT - Open forum infectious diseases JID - 101637045 PMC - PMC12560757 OTO - NOTNLM OT - endocarditis OT - multidisciplinary teams OT - oral antibiotic treatment OT - patients who inject drugs COIS- Potential conflicts of interest. All authors: No reported conflicts of interest. EDAT- 2025/10/30 12:05 MHDA- 2025/10/30 12:06 PMCR- 2025/10/28 CRDT- 2025/10/30 05:11 PHST- 2025/07/02 00:00 [received] PHST- 2025/09/26 00:00 [accepted] PHST- 2025/10/30 12:06 [medline] PHST- 2025/10/30 12:05 [pubmed] PHST- 2025/10/30 05:11 [entrez] PHST- 2025/10/28 00:00 [pmc-release] AID - ofaf625 [pii] AID - 10.1093/ofid/ofaf625 [doi] PST - epublish SO - Open Forum Infect Dis. 2025 Oct 28;12(10):ofaf625. doi: 10.1093/ofid/ofaf625. eCollection 2025 Oct. PMID- 41161878 OWN - NLM STAT- MEDLINE DCOM- 20260119 LR - 20260119 IS - 1532-6497 (Electronic) IS - 1067-991X (Linking) VI - 44 IP - 6 DP - 2025 Nov-Dec TI - Implementing In Situ Simulation of High-Risk/Low-Volume Emergency Situations for Pediatric Transport Teams. PG - 488-491 LID - S1067-991X(25)00228-7 [pii] LID - 10.1016/j.amj.2025.07.005 [doi] AB - OBJECTIVE: Cardiopulmonary resuscitation (CPR) during interfacility neonatal and pediatric transport is a rare phenomenon (0.33% and 0.18%, respectively). The ability to maintain high-quality manual CPR in a moving vehicle with limited personnel and equipment impacts its effectiveness. There are limited data about neonatal and pediatric transport teams training staff on resuscitation during transport. This study evaluated the feasibility of in situ, simulation-based CPR training for a tertiary hospital's pediatric-neonatal transport team to better replicate real-world constraints. METHODS: Critical care teams-each comprising a nurse, respiratory therapist, and paramedic-completed an in situ simulation aboard a moving ambulance. Generally, 18 participants formed 6 teams, managing a hypoxia-induced bradycardia scenario requiring CPR. Operational metrics, teamwork, and resource management were evaluated. Post-simulation, participants completed a deidentified survey. RESULTS: The mean participant age was 41.7 (standard deviation [SD] = 8.29) years with 8.9 (SD = 6.19) years of transport experience; 27% had not previously performed CPR during transport. Median time for bag-valve-mask initiation was 0.47 (SD = 0.41) minutes, CPR start was 0.62 (SD = 0.65) minutes, epinephrine administration was 1.25 (SD = 1.61) minutes, and contact with medical command was 1.40 (SD = 0.76) minutes. Post-simulation, 89% preferred in situ training over traditional simulation. Confidence improvements in prehospital care, logistics, and team resource management were negatively correlated with years of transport experience (P < .05). CONCLUSION: In situ simulation enhances training fidelity, improves provider confidence, and may be especially valuable for onboarding new transport team members, supporting safer patient care during transport. CI - Copyright (c) 2025. Published by Elsevier Inc. FAU - Qurashi, Jacob N AU - Qurashi JN AD - University of Texas Southwestern Medical Center, Dallas, TX. Electronic address: jqurashi@mcw.edu. FAU - Shelby, Jennifer AU - Shelby J AD - Children's Medical Center at Dallas, Pediatric Transport Team, Dallas, TX. FAU - Martin, Aleta Kay AU - Martin AK AD - Texas Tech University Health Sciences Center, El Paso, TX. FAU - Dhar, Archana V AU - Dhar AV AD - Division of Pediatric Critical Care, University of Texas Southwestern Medical Center, Dallas, TX. LA - eng PT - Journal Article DEP - 20250829 PL - United States TA - Air Med J JT - Air medical journal JID - 9312325 RN - YKH834O4BH (Epinephrine) SB - IM MH - *Cardiopulmonary Resuscitation/education/instrumentation/methods MH - *Simulation Training/methods MH - Humans MH - Male MH - Female MH - Infant, Newborn MH - Infant MH - Child, Preschool MH - Child MH - Emergencies MH - Tertiary Care Centers MH - *Ambulances MH - *Patient Care Team MH - Respiratory Therapists MH - Nurses MH - Paramedics MH - Bradycardia/etiology/therapy MH - Hypoxia/complications/therapy MH - Epinephrine/administration & dosage MH - Adult MH - Middle Aged MH - Feasibility Studies COIS- Declaration of competing interest The authors have no relevant disclosures. There was no grant funding or financial support for this manuscript. EDAT- 2025/10/30 00:26 MHDA- 2025/10/30 00:27 CRDT- 2025/10/29 21:53 PHST- 2025/06/03 00:00 [received] PHST- 2025/07/01 00:00 [revised] PHST- 2025/07/20 00:00 [accepted] PHST- 2025/10/30 00:27 [medline] PHST- 2025/10/30 00:26 [pubmed] PHST- 2025/10/29 21:53 [entrez] AID - S1067-991X(25)00228-7 [pii] AID - 10.1016/j.amj.2025.07.005 [doi] PST - ppublish SO - Air Med J. 2025 Nov-Dec;44(6):488-491. doi: 10.1016/j.amj.2025.07.005. Epub 2025 Aug 29. PMID- 41159978 OWN - NLM STAT- MEDLINE DCOM- 20260128 LR - 20260130 IS - 1558-3597 (Electronic) IS - 0735-1097 (Linking) VI - 87 IP - 3 DP - 2026 Jan 27 TI - PCI of Native Coronary Artery vs Saphenous Vein Graft After Prior Bypass Surgery: A Multicenter, Randomized Trial. PG - 269-282 LID - S0735-1097(25)09477-X [pii] LID - 10.1016/j.jacc.2025.09.1577 [doi] AB - BACKGROUND: In patients with prior coronary artery bypass grafting (CABG) presenting with graft failure, current guidelines recommend percutaneous coronary intervention (PCI) of the bypassed native coronary artery over PCI of the bypass graft. However, this recommendation relies solely on observational data. OBJECTIVES: This study compared clinical outcomes between a strategy of native vessel PCI with saphenous vein graft (SVG) PCI in post-CABG patients presenting with SVG failure. METHODS: The multicenter, randomized PROCTOR (Percutaneous Coronary Intervention of Native Coronary Artery versus Saphenous Vein Graft in Patients with Prior Coronary Artery Bypass Graft Surgery) trial included patients with significant SVG stenosis and a heart team-defined clinical indication for revascularization. Patients were randomly assigned (1:1) to either a strategy of native vessel PCI or SVG PCI using an interactive web-based randomization platform. The trial was conducted across 14 centers in Europe. We report the occurrence of major adverse cardiac events at 1 year following the index PCI, defined as the composite of all-cause mortality, nonfatal target coronary territory myocardial infarction (MI), or clinically driven target coronary territory revascularization, analyzed on an intention-to-treat basis. The trial is registered with ClinicalTrials.gov (NCT03805048), and long-term follow-up is ongoing. RESULTS: Between January 2019 and December 2023, 220 patients (mean age 73 +/- 7 years; 84% men [185/220 patients]) were randomized to a strategy of native vessel PCI (n = 108) or SVG PCI (n = 112). At 1 year, major adverse cardiac events occurred in 37 patients (34%) in the native vessel PCI group and 21 patients (19%) in the SVG PCI group (HR: 2.14; 95% CI: 1.25-3.65; P = 0.006). There was no significant difference in all-cause mortality (HR: 1.59; 95% CI: 0.45-5.64; P = 0.472), whereas both nonfatal target coronary territory MI (HR: 2.12; 95% CI: 1.08-4.17; P = 0.029) and clinically driven target coronary territory revascularization (HR: 2.19; 95% CI: 1.02-4.72; P = 0.044) occurred more frequently in patients assigned to native vessel PCI. The incidence of PCI-related MI was 13% in the native vessel PCI group and 1% in the SVG PCI group (HR: 14.85; 95% CI: 1.95-112.96; P = 0.009). CONCLUSIONS: In the randomized PROCTOR trial, SVG PCI was associated with improved 1-year clinical outcomes compared with native vessel PCI, primarily driven by lower rates of PCI-related MI and clinically driven target coronary territory revascularization. CI - Copyright (c) 2026. Published by Elsevier Inc. FAU - de Winter, Ruben W AU - de Winter RW AD - Department of Cardiology, Heart Center Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands. FAU - Hoek, Roel AU - Hoek R AD - Department of Cardiology, Heart Center Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands. FAU - Walsh, Simon J AU - Walsh SJ AD - Department of Cardiology, Belfast Health and Social Care Trust, Royal Victoria Hospital, Belfast, United Kingdom. FAU - Hanratty, Colm G AU - Hanratty CG AD - Heart and Vascular Centre, Mater Private Day Hospital, Dublin, Ireland. FAU - Sprengers, Ralf W AU - Sprengers RW AD - Department of Radiology and Nuclear Medicine, Amsterdam UMC, Amsterdam, the Netherlands. FAU - Twisk, Jos W R AU - Twisk JWR AD - Department of Epidemiology and Data Science, Amsterdam UMC, Amsterdam, the Netherlands. FAU - Vegting, Iris AU - Vegting I AD - Department of Cardiology, Heart Center Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands. FAU - Schumacher, Stefan P AU - Schumacher SP AD - Department of Cardiology, Heart Center Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands. FAU - Bom, Michiel J AU - Bom MJ AD - Department of Cardiology, Heart Center Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands. FAU - Verouden, Niels J AU - Verouden NJ AD - Department of Cardiology, Heart Center Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands. FAU - Henriques, Jose P AU - Henriques JP AD - Department of Cardiology, Heart Center Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands. FAU - Wilgenhof, Adriaan AU - Wilgenhof A AD - Cardiovascular Center Aalst, Onze-Lieve-Vrouwenziekenhuis, Aalst, Belgium. FAU - Viscusi, Michele M AU - Viscusi MM AD - Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy. FAU - Teeuwen, Koen AU - Teeuwen K AD - Department of Cardiology, Catharina Hospital, Eindhoven, the Netherlands. FAU - Opolski, Maksymilian P AU - Opolski MP AD - Department of Interventional Cardiology and Angiology, National Institute of Cardiology, Warsaw, Poland. FAU - Wolny, Rafal AU - Wolny R AD - Department of Interventional Cardiology and Angiology, National Institute of Cardiology, Warsaw, Poland. FAU - Agostoni, Pierfrancesco AU - Agostoni P AD - HartCentrum Ziekenhuis Aan de Stroom (ZAS) Middelheim, Antwerp, Belgium. FAU - van Kuijk, Jan-Peter AU - van Kuijk JP AD - Department of Cardiology, St Antonius Ziekenhuis, Nieuwegein, the Netherlands. FAU - Scholzel, Bas E AU - Scholzel BE AD - Department of Cardiology, Amphia Ziekenhuis, Breda, the Netherlands. FAU - Kraaijeveld, Adriaan O AU - Kraaijeveld AO AD - Department of Cardiology, University Medical Center Utrecht, Utrecht, the Netherlands. FAU - van Geuns, Robert-Jan M AU - van Geuns RM AD - Department of Cardiology, Radboud University Medical Center, Nijmegen, the Netherlands. FAU - Dirksen, Maurits T AU - Dirksen MT AD - Department of Cardiology, Noordwest Ziekenhuisgroep, Alkmaar, the Netherlands. FAU - Heestermans, Antonius A C M AU - Heestermans AACM AD - Department of Cardiology, Noordwest Ziekenhuisgroep, Alkmaar, the Netherlands. FAU - Dens, Jo AU - Dens J AD - Department of Cardiology, Ziekenhuis Oost Limburg, Genk, Belgium. FAU - Bennett, Johan AU - Bennett J AD - Department of Cardiovascular Medicine, University Hospital Leuven, Leuven, Belgium. FAU - Haine, Steven E F AU - Haine SEF AD - Department of Cardiology, Antwerp University Hospital and University of Antwerp, Antwerp, Belgium. FAU - Delewi, Ronak AU - Delewi R AD - Department of Cardiology, Heart Center Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands. FAU - Nap, Alexander AU - Nap A AD - Department of Cardiology, Heart Center Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands. FAU - Spratt, James C AU - Spratt JC AD - Department of Cardiology, St George's University Hospital NHS Trust, London, United Kingdom. FAU - Knaapen, Paul AU - Knaapen P AD - Department of Cardiology, Heart Center Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands. Electronic address: p.knaapen@amsterdamumc.nl. CN - PROCTOR Trial Investigators LA - eng SI - ClinicalTrials.gov/NCT03805048 PT - Comparative Study PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial DEP - 20251028 PL - United States TA - J Am Coll Cardiol JT - Journal of the American College of Cardiology JID - 8301365 SB - IM MH - Humans MH - *Percutaneous Coronary Intervention/methods MH - *Saphenous Vein/transplantation MH - Male MH - *Coronary Artery Bypass/adverse effects/methods MH - Female MH - Aged MH - Middle Aged MH - *Coronary Vessels/surgery MH - *Coronary Artery Disease/surgery MH - Treatment Outcome MH - Follow-Up Studies MH - *Graft Occlusion, Vascular/surgery OTO - NOTNLM OT - percutaneous coronary intervention OT - prior coronary artery bypass grafting OT - randomized controlled trial OT - saphenous vein graft failure COIS- Funding Support and Author Disclosures PROCTOR is an investigator-initiated study funded by a research grant from Abbott Vascular International BVBA and sponsored by the Amsterdam University Medical Center. The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. Dr Walsh has a consultancy agreement with Boston Scientific Corporation. Dr Hanratty has a consultancy agreement with Boston Scientific Corporation, Abbott Vascular, and Medtronic. Drs Wilgenhof and Viscusi have received a research grant from the CardioPaTh PhD Program. Dr Opolski has received a research grant from B.Braun. Dr Agostoni has received consulting fees from Abbott, Boston Scientific, iVascular, Medtronic, Shockwave, Teleflex, and Terumo. Dr Dirksen has received a speakers fee from Abbott Medical. Dr Delewi has received educational grants from Boston Scientific, ABiomed, Edwards Lifesciences, Sanofi, Meril Life Science, Novartis, and Amgen. Dr Knaapen has received research funding from Cleerly Inc and HeartFlow Inc. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. FIR - Knaapen, Paul IR - Knaapen P FIR - Scholzel, Bas E IR - Scholzel BE FIR - Teeuwen, Koen IR - Teeuwen K FIR - Kraaijeveld, Adriaan O IR - Kraaijeveld AO FIR - Dens, Jo IR - Dens J FIR - Haine, Steven E F IR - Haine SEF FIR - Spratt, James C IR - Spratt JC FIR - Murphy, Conleth IR - Murphy C FIR - Agostoni, Pierfrancesco IR - Agostoni P FIR - Opolski, Maksymilian P IR - Opolski MP FIR - Hofma, Sjoerd H IR - Hofma SH FIR - van Kuijk, Jan-Peter IR - van Kuijk JP FIR - van Geuns, Robert-Jan IR - van Geuns RJ FIR - Bennett, Johannes IR - Bennett J FIR - Nap, Alexander IR - Nap A FIR - Delewi, Ronak IR - Delewi R FIR - Simao Henriques, Jose P IR - Simao Henriques JP FIR - de Winter, Ruben W IR - de Winter RW FIR - Hoek, Roel IR - Hoek R FIR - Vegting, Iris IR - Vegting I FIR - Oemrawsingh, Rohit M IR - Oemrawsingh RM FIR - den Hollander, Jeanette IR - den Hollander J FIR - van Meel, Jeanette IR - van Meel J FIR - Steerneman-Geurts, Francine IR - Steerneman-Geurts F FIR - van Leur, Linda IR - van Leur L FIR - van Doleweerd, Marlies IR - van Doleweerd M FIR - Harasic, Maren IR - Harasic M FIR - Schogt, Jarno IR - Schogt J FIR - den Adel, Sanne IR - den Adel S FIR - Griffioen, Alexander IR - Griffioen A FIR - Swijsen, Caroline IR - Swijsen C FIR - Brosens, Nathalie IR - Brosens N FIR - Deruyter, Pieter IR - Deruyter P FIR - van Roey, Sabine IR - van Roey S FIR - Sookhoo, Vennessa IR - Sookhoo V FIR - McCart, Estelle IR - McCart E FIR - Wolny, Rafal IR - Wolny R FIR - Sprengers, Ralf W IR - Sprengers RW FIR - Walsh, Simon J IR - Walsh SJ FIR - Hanratty, Colm G IR - Hanratty CG FIR - Twisk, Jos W R IR - Twisk JWR FIR - Koch, Karel T IR - Koch KT FIR - Wykrzykowska, Joanna J IR - Wykrzykowska JJ FIR - Rahmam, Mohammed S IR - Rahmam MS FIR - Smits, Peter C IR - Smits PC FIR - Tijssen, Jan G P IR - Tijssen JGP FIR - Ten Berg, Jurrien M IR - Ten Berg JM FIR - Lemkes, Jorrit S IR - Lemkes JS FIR - Wilgenhof, Adriaan IR - Wilgenhof A FIR - Viscusi, Michele IR - Viscusi M FIR - Dirksen, Maurits T IR - Dirksen MT EDAT- 2025/10/29 12:30 MHDA- 2026/01/28 19:20 CRDT- 2025/10/29 11:27 PHST- 2025/08/01 00:00 [received] PHST- 2025/09/11 00:00 [revised] PHST- 2025/09/15 00:00 [accepted] PHST- 2026/01/28 19:20 [medline] PHST- 2025/10/29 12:30 [pubmed] PHST- 2025/10/29 11:27 [entrez] AID - S0735-1097(25)09477-X [pii] AID - 10.1016/j.jacc.2025.09.1577 [doi] PST - ppublish SO - J Am Coll Cardiol. 2026 Jan 27;87(3):269-282. doi: 10.1016/j.jacc.2025.09.1577. Epub 2025 Oct 28. PMID- 41159543 OWN - NLM STAT- MEDLINE DCOM- 20260316 LR - 20260316 IS - 2048-8734 (Electronic) IS - 2048-8726 (Linking) VI - 15 IP - 2 DP - 2026 Mar 16 TI - Rationale for and approach to establishing a multidisciplinary acute pulmonary embolism expert care team. PG - 151-161 LID - 10.1093/ehjacc/zuaf141 [doi] AB - Patients with acute pulmonary embolism (PE) may present with cardiac arrest, overt or impending cardiogenic shock and/or severe respiratory insufficiency. Immediate evaluation and management of these patients require high clinical suspicion along with (bedside) imaging to confirm the diagnosis, targeted haemodynamic and/or respiratory support, appropriate anticoagulant treatment, and in many cases reperfusion therapy. The immediate treatment decision-making is largely driven by local expertise and resources and should be guided by the individual patient's characteristics such as cardiopulmonary comorbidities, risk of bleeding and location, extent and haemodynamic impact of the clot. Over the past years, treatment options for patients with severe PE have expanded substantially. For instance, several new catheter-guided reperfusion therapies have emerged and experience with circulatory mechanical support has increased. Along with the rise of new interventional therapies has come the introduction of expert multidisciplinary pulmonary embolism (EXPERT-PE) care teams, composed of multidisciplinary specialists involved in treating severe acute PE. This model of care provides a platform for rapid decisions on individualized treatment strategies, combining expert opinion from all involved specialties, setting the quality standards for modern local and regional equity PE care, and forming the base for future research in this area. Clinical decisions should be evidence-based where possible, and incorporate the individual patient's and their carer's preferences, values, and priorities, as well as those of the managing clinicians and care team. In this review, we summarize the evidence for the introduction of EXPERT-PE care teams and provide a practical manual for their successful implementation. CI - (c) The Author(s) 2025. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com. FAU - Klok, Frederikus A AU - Klok FA AUID- ORCID: 0000-0001-9961-0754 AD - Department of Medicine-Thrombosis and Hemostasis, Leiden University Medical Center, Albinusdreef 2, 2300 RC, Leiden, the Netherlands. AD - Center for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg University, Langenbeckstrasse 1 55131 Mainz, Germany. FAU - Sharp, Andrew AU - Sharp A AD - School of Medicine, University College Dublin and The Mater Misericordiae Hospital, Dublin, Ireland. FAU - Ahrens, Ingo AU - Ahrens I AD - Augustinerinnen Hospital Cologne and Medical Faculty, University of Freiburg, Dublin, Germany. FAU - Aleksic, Milica AU - Aleksic M AUID- ORCID: 0000-0002-3955-9528 AD - Department of Cardiology, University Hospital Medical Center Bezanijska kosa, Belgrade, Serbia. FAU - Ni Ainle, Fionnuala AU - Ni Ainle F AUID- ORCID: 0000-0003-0163-792X AD - School of Medicine, University College Dublin, Belfield, Dublin 4, Ireland. FAU - Barco, Stefano AU - Barco S AUID- ORCID: 0000-0002-2618-347X AD - Center for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg University, Langenbeckstrasse 1 55131 Mainz, Germany. AD - Department of Vascular Medicine, University Hospital Zurich, Zurich, Switzerland. FAU - Bertoletti, Laurent AU - Bertoletti L AUID- ORCID: 0000-0001-8214-3010 AD - Departement of Medecine Vasculaire et Therapeutique, F-CRIN INNOVTE Network, Universite Jean Monnet Saint-Etienne, CHU Saint-Etienne, Mines Saint-Etienne, INSERM, SAINBIOSE U1059, CIC 1408, Saint-Etienne, France. FAU - Keeling, Brent AU - Keeling B AD - Professor of Surgery, Emory University School of Medicine, Atlanta, GA, USA. FAU - Fengler, Karl AU - Fengler K AUID- ORCID: 0000-0003-0611-7376 AD - Department of Cardiology, Heart Center Leipzig, Leipzig, Germany. FAU - Helms, Julie AU - Helms J AD - Strasbourg University (UNISTRA); INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM)-FHU TARGET, Strasbourg, France. AD - Medical Intensive Care Unit-NHC, Strasbourg University Hospital, Strasbourg, France. FAU - Jimenez, David AU - Jimenez D AD - Respiratory Department, Hospital Ramon y Cajal and Instituto Ramon y Cajal de Investigacion Sanitaria IRYCIS, Madrid, Spain. AD - Medicine Department, Universidad de Alcala, Madrid, Spain. AD - CIBER Enfermedades Respiratorias (CIBERES), Madrid, Spain. FAU - Lang, Irene M AU - Lang IM AD - Division of Hematology and Hemostaseology, Department of Medicine I, Universitatskliniken, Medical University of Vienna, Wien. FAU - Lauw, Mandy N AU - Lauw MN AD - Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands. FAU - Lorusso, Roberto AU - Lorusso R AUID- ORCID: 0000-0002-1777-2045 AD - Department of Cardio-Thoracic Surgery, Maastricht University Medical Centre (MUMC), Maastricht, the Netherlands. AD - Cardiovascular Research Institute Maastricht (CARIM), Maastricht, The Netherlands. FAU - Martin-Loeches, Ignacio AU - Martin-Loeches I AD - Department of Intensive Care Medicine, Multidisciplinary Intensive Care Research Organization (MICRO), St. James' Hospital, Dublin, Ireland. AD - School of Medicine, Trinity College Dublin, Dublin, Ireland. FAU - Meijboom, Lilian J AU - Meijboom LJ AD - Amsterdam Cardiovascular Sciences, Pulmonary Hypertension and Thrombosis, Amsterdam, The Netherlands. AD - Department of Radiology and Nuclear Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. FAU - Meneveau, Nicolas AU - Meneveau N AD - Department of Cardiology, University Hospital Besancon, Besancon, France. AD - SINERGIES Laboratory, University Marie & Louis Pasteur, Besancon, France. FAU - Montero-Cabezas, Jose AU - Montero-Cabezas J AD - Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands. FAU - O'Sullivan, Gerry AU - O'Sullivan G AD - Interventional Radiology, Galway University Hospital, Galway, Ireland. FAU - Pola, Roberto AU - Pola R AD - Percorso Trombosi, Dipartimento di Scienze dell'Invercchiamento, Ortopediche e Reumatologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Universita Cattolica del Sacro Cuore, Rome, Italy. FAU - Pruszczyk, Piotr AU - Pruszczyk P AUID- ORCID: 0000-0002-9768-0000 AD - Department of Internal Medicine and Cardiology with Centre for Thromboembolism, Medical University of Warsaw, Warsaw, Poland. FAU - Sanchez, Olivier AU - Sanchez O AUID- ORCID: 0000-0003-1633-8391 AD - Department of Pneumology and Intensive Care Unit, Universite Paris Cite, Hopital Europeen Georges Pompidou, AP-HP, Paris, France. AD - INSERM U970 Paris Cardiovascular Research Center, Paris, France. AD - F-CRIN INNOVTE Network, Saint-Etienne, France. FAU - Schlager, Oliver AU - Schlager O AUID- ORCID: 0000-0001-6934-5355 AD - Division of Angiology, Department of Medicine II, Medical University of Vienna, Vienna, Austria. FAU - Schultz, Jacob AU - Schultz J AD - Department of Cardiology, Aarhus Univeristy Hospital, Aarhus, Denmark. AD - Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. FAU - Sinan, Umit Yasar AU - Sinan UY AD - Department of Cardiology, Istanbul University-Cerrahpasa Cardiology Institute, Istanbul, Turkiye. FAU - Vedovati, Maria Cristina AU - Vedovati MC AD - Internal, Vascular and Emergency Medicine, Department of Medicine and Surgery, University of Perugia, Perugia, Italy. FAU - Verhamme, Peter AU - Verhamme P AUID- ORCID: 0000-0001-8698-2858 AD - Vascular Medicine and Haemostasis, Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium. FAU - Zaher, Ahmed AU - Zaher A AD - Senior Clinical Fellow in Critical Care, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom. FAU - Huisman, Menno V AU - Huisman MV AD - Department of Medicine-Thrombosis and Hemostasis, Leiden University Medical Center, Albinusdreef 2, 2300 RC, Leiden, the Netherlands. FAU - Konstantinides, Stavros V AU - Konstantinides SV AD - Center for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg University, Langenbeckstrasse 1 55131 Mainz, Germany. LA - eng PT - Journal Article PT - Review PL - England TA - Eur Heart J Acute Cardiovasc Care JT - European heart journal. Acute cardiovascular care JID - 101591369 SB - IM MH - Humans MH - *Pulmonary Embolism/therapy/diagnosis MH - *Patient Care Team/organization & administration MH - Acute Disease OTO - NOTNLM OT - Diagnosis OT - Europe OT - Interdisciplinary OT - Pulmonary embolism OT - Therapy COIS- Conflict of interest: none declared. EDAT- 2025/10/29 12:28 MHDA- 2026/03/16 21:57 CRDT- 2025/10/29 07:44 PHST- 2025/10/09 00:00 [received] PHST- 2025/10/21 00:00 [revised] PHST- 2025/10/22 00:00 [accepted] PHST- 2026/03/16 21:57 [medline] PHST- 2025/10/29 12:28 [pubmed] PHST- 2025/10/29 07:44 [entrez] AID - 8305660 [pii] AID - 10.1093/ehjacc/zuaf141 [doi] PST - ppublish SO - Eur Heart J Acute Cardiovasc Care. 2026 Mar 16;15(2):151-161. doi: 10.1093/ehjacc/zuaf141. PMID- 41157280 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251029 LR - 20251101 IS - 2075-1729 (Print) IS - 2075-1729 (Electronic) IS - 2075-1729 (Linking) VI - 15 IP - 10 DP - 2025 Oct 16 TI - Arrhythmias in Systemic Sclerosis: A Call for Interdisciplinarity Teams. LID - 10.3390/life15101608 [doi] LID - 1608 AB - BACKGROUND: Systemic sclerosis (SSc) is a rare autoimmune disease characterized by progressive fibrosis, systemic inflammation and vascular dysfunction, with manifestations that can affect multiple organs, including the heart. Cardiac involvement in SSc is often underdiagnosed, although it can have serious consequences on the prognosis, especially the occurrence of arrhythmias. These rhythm disturbances can result from direct damage to the myocardium, the conduction system, or the coronary microcirculation. Equally, the medication used can have iatrogenic consequences manifested by severe arrhythmias. METHODOLOGY: The aim of this study was to provide a synthesis of incidence, pathogenic mechanisms, diagnostic methods, and therapeutic strategies of arrhythmias associated with SSc. The potential effects of immunomodulatory therapies, such as conventional immunosuppressants and biological therapies, on cardiac electrical function were also analyzed. This narrative review could present the state of the art on arrhythmias associated with SSc, which could serve as a practical guide. In clinical practice, it is necessary to establish a team that includes cardiologists and rheumatologists as well as other specialists to contribute to a correct diagnosis followed by an optimal therapy in patients with SSc. RESULTS: Current data suggest that diffuse myocardial fibrosis, silent ischemia, and inflammatory infiltration may alter the propagation of the electrical impulse in the heart, favoring the occurrence of arrhythmias. Atrioventricular blocks, ventricular tachyarrhythmias, and atrial fibrillation are the most commonly reported rhythm abnormalities in SSc. Also, some therapies used in the treatment of the disease may influence the arrhythmic risk. CONCLUSIONS: Cardiac arrhythmias in SSc can have a significant impact on the prognosis of patients, which is why a multidisciplinary approach is essential. Collaboration between rheumatologists, cardiologists, and electrophysiologists is crucial for the early identification and appropriate management of arrhythmic risk in this patient group. FAU - Costan, Diana Elena AU - Costan DE AD - Department of Medical Sciences II, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania. AD - Department of Rheumatology, Clinic Rehabilitation Hospital, 700661 Iasi, Romania. FAU - Ungurean, Veronica AU - Ungurean V AUID- ORCID: 0009-0002-8097-2573 AD - Department of Medical Sciences II, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania. AD - Department of Rheumatology, Clinic Rehabilitation Hospital, 700661 Iasi, Romania. FAU - Dobos, Monica Claudia AU - Dobos MC AD - Department of Medical Sciences II, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania. AD - Department of Rheumatology, Clinic Rehabilitation Hospital, 700661 Iasi, Romania. FAU - Ouatu, Anca AU - Ouatu A AUID- ORCID: 0000-0001-8923-8194 AD - Department of Medical Sciences I, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania. AD - Department of Internal Medicine, Sf. Spiridon County Clinical Emergency Hospital, 700111 Iasi, Romania. FAU - Morariu, Paula Cristina AU - Morariu PC AD - Department of Medical Sciences I, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania. AD - Department of Internal Medicine, Sf. Spiridon County Clinical Emergency Hospital, 700111 Iasi, Romania. FAU - Oancea, Alexandru Florinel AU - Oancea AF AUID- ORCID: 0000-0002-5249-4562 AD - Department of Medical Sciences I, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania. AD - Department of Internal Medicine, Sf. Spiridon County Clinical Emergency Hospital, 700111 Iasi, Romania. FAU - Godun, Maria Mihaela AU - Godun MM AD - Department of Medical Sciences I, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania. AD - Department of Internal Medicine, Sf. Spiridon County Clinical Emergency Hospital, 700111 Iasi, Romania. FAU - Floria, Diana-Elena AU - Floria DE AD - Department of Medical Sciences I, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania. AD - Department of Internal Medicine, Sf. Spiridon County Clinical Emergency Hospital, 700111 Iasi, Romania. FAU - Marcu, Dragos Traian AU - Marcu DT AD - Department of Medical Sciences I, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania. FAU - Baroi, Genoveva Livia AU - Baroi GL AD - Department of Surgery, Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania. FAU - Stanciu, Silviu Marcel AU - Stanciu SM AD - Department of Internal Medicine and Gastroenterology, Carol Davila University of Medicine and Pharmacy, Central Military Emergency University Hospital, 010825 Bucharest, Romania. FAU - Knieling, Anton AU - Knieling A AD - Discipline of Forensic Medicine, Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania. FAU - Tanase, Daniela Maria AU - Tanase DM AUID- ORCID: 0000-0002-7144-2506 AD - Department of Medical Sciences I, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania. AD - Department of Internal Medicine, Sf. Spiridon County Clinical Emergency Hospital, 700111 Iasi, Romania. FAU - Ancuta, Codrina AU - Ancuta C AUID- ORCID: 0000-0002-1777-8121 AD - Department of Medical Sciences II, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania. AD - Department of Rheumatology, Clinic Rehabilitation Hospital, 700661 Iasi, Romania. FAU - Floria, Mariana AU - Floria M AUID- ORCID: 0000-0002-9465-1503 AD - Department of Medical Sciences I, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania. AD - Department of Internal Medicine, Sf. Spiridon County Clinical Emergency Hospital, 700111 Iasi, Romania. LA - eng PT - Journal Article PT - Review DEP - 20251016 PL - Switzerland TA - Life (Basel) JT - Life (Basel, Switzerland) JID - 101580444 PMC - PMC12565226 OTO - NOTNLM OT - arrhythmias OT - atrial ectopic beats OT - atrial fibrillation OT - scleroderma OT - systemic sclerosis OT - ventricular ectopic beats OT - ventricular fibrillation COIS- The authors declare no conflicts of interest. EDAT- 2025/10/29 06:28 MHDA- 2025/10/29 06:29 PMCR- 2025/10/16 CRDT- 2025/10/29 01:21 PHST- 2025/09/13 00:00 [received] PHST- 2025/10/13 00:00 [revised] PHST- 2025/10/14 00:00 [accepted] PHST- 2025/10/29 06:29 [medline] PHST- 2025/10/29 06:28 [pubmed] PHST- 2025/10/29 01:21 [entrez] PHST- 2025/10/16 00:00 [pmc-release] AID - life15101608 [pii] AID - life-15-01608 [pii] AID - 10.3390/life15101608 [doi] PST - epublish SO - Life (Basel). 2025 Oct 16;15(10):1608. doi: 10.3390/life15101608. PMID- 41157227 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251029 LR - 20251101 IS - 2075-1729 (Print) IS - 2075-1729 (Electronic) IS - 2075-1729 (Linking) VI - 15 IP - 10 DP - 2025 Oct 3 TI - Ischemia with No Obstructive Coronary Artery Disease (INOCA): A Review. LID - 10.3390/life15101554 [doi] LID - 1554 AB - BACKGROUND: Ischemia with no obstructive coronary artery disease (INOCA) is characterized by myocardial ischemia in the absence of significant coronary artery stenosis. Despite the lack of major obstructive lesions, patients often present with chest pain, making diagnosis and management a significant challenge. MATERIALS AND METHODS: A comprehensive search strategy of electronic databases (2000 to 2024) was used to identify studies assessing pathophysiology, diagnosis, surgical treatments, interventions, and outcomes in INOCA. Clinical trials, observational studies, case-control studies, and cohort studies were included. RESULTS: Emerging surgical treatments may have a role in certain subgroups of INOCA patients, particularly those with severe and persistent symptoms or underlying pathophysiological factors that do not respond adequately to pharmacological therapies. Transmyocardial revascularization (TMR) and sympathetic denervation procedures reduce coronary vasospasm in refractory angina. Trials have shown promise for coronary sinus occlusion. Autologous stem cell therapy is an innovative surgical approach that has shown promise in early trials but remains investigational. Selective surgical cardiac vein retroperfusion remains largely experimental, with limited clinical data. CONCLUSIONS: This review highlights the need for ongoing research and clinical trials to assess the effectiveness of surgical and nonsurgical options in INOCA. Although current data on surgical interventions is limited, these treatments may offer hope for patients with refractory symptoms. A personalized and multidisciplinary approach to management is essential for optimal patient outcomes. FAU - Viola, Laura AU - Viola L AUID- ORCID: 0000-0002-8394-0422 AD - Division of Cardiac Surgery, University Hospital Southampton, Southampton SO16 6YD, UK. FAU - Masters, Megan AU - Masters M AUID- ORCID: 0000-0002-3667-8492 AD - Division of Cardiac Surgery, University Hospital Southampton, Southampton SO16 6YD, UK. FAU - Shafiq, Umar AU - Shafiq U AD - Division of Cardiac Surgery, University Hospital Southampton, Southampton SO16 6YD, UK. FAU - Jujjavarapu, Krishnam Raju AU - Jujjavarapu KR AD - Division of Cardiac Surgery, University Hospital Southampton, Southampton SO16 6YD, UK. FAU - Luthra, Suvitesh AU - Luthra S AUID- ORCID: 0000-0001-7911-1894 AD - Division of Cardiac Surgery, University Hospital Southampton, Southampton SO16 6YD, UK. AD - Human Development and Health, Faculty of Medicine, University of Southampton, Southampton SO17 1BJ, UK. LA - eng PT - Journal Article PT - Review DEP - 20251003 PL - Switzerland TA - Life (Basel) JT - Life (Basel, Switzerland) JID - 101580444 PMC - PMC12565025 OTO - NOTNLM OT - INOCA OT - coronary artery disease OT - ischemia OT - myocardial ischemia OT - non-obstructive coronary artery disease OT - surgical treatment COIS- The authors declare no conflicts of interest. EDAT- 2025/10/29 06:28 MHDA- 2025/10/29 06:29 PMCR- 2025/10/03 CRDT- 2025/10/29 01:21 PHST- 2025/09/02 00:00 [received] PHST- 2025/09/24 00:00 [revised] PHST- 2025/09/30 00:00 [accepted] PHST- 2025/10/29 06:29 [medline] PHST- 2025/10/29 06:28 [pubmed] PHST- 2025/10/29 01:21 [entrez] PHST- 2025/10/03 00:00 [pmc-release] AID - life15101554 [pii] AID - life-15-01554 [pii] AID - 10.3390/life15101554 [doi] PST - epublish SO - Life (Basel). 2025 Oct 3;15(10):1554. doi: 10.3390/life15101554. PMID- 41157218 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251029 LR - 20251101 IS - 2075-1729 (Print) IS - 2075-1729 (Electronic) IS - 2075-1729 (Linking) VI - 15 IP - 10 DP - 2025 Oct 1 TI - Electrocardiographic Abnormalities in Elderly Patients Receiving Psychotropic Therapy in the Emergency Department: A Retrospective Cohort Study. LID - 10.3390/life15101545 [doi] LID - 1545 AB - BACKGROUND: Psychotropic medications are frequently prescribed to elderly patients in emergency settings, yet their potential to induce electrocardiographic (ECG) abnormalities, particularly QTc interval prolongation, raises safety concerns. Older adults may be especially vulnerable due to polypharmacy, age-related cardiac changes, and comorbidities. METHODS: We conducted a retrospective observational study on patients aged >/=65 years who underwent psychiatric evaluation in the Emergency Department (ED) of a tertiary hospital between 2015 and 2023. Data was extracted on demographics, psychiatric symptoms, psychotropic drug use, and ECG findings. The primary outcome was the prevalence of major ECG abnormalities (QTc or QRS prolongation), and secondary analyses explored associations with drug class and hospitalization. RESULTS: Seventy-seven patients were included (62.3% female, median age 74 years). Overall, 22.1% exhibited ECG abnormalities, with QTc prolongation in 16.9% and QRS widening in 5.2%. ECG alterations were more common among patients receiving psychotropic drugs (30.7% vs. 13.2%; p = 0.046). Multivariate analysis confirmed psychotropic therapy as an independent predictor of ECG abnormalities (OR 2.84; 95% CI: 1.01-7.98; p = 0.049). No significant sex-related differences were observed. CONCLUSIONS: ECG abnormalities are common in elderly patients undergoing psychiatric assessment in the ED and seem associated with psychotropic medication use. However, non-pharmacological factors also contribute significantly to risk. Integrated multidisciplinary evaluation is essential to ensure both psychiatric and cardiovascular safety in this fragile population. FAU - Mazza, Marianna AU - Mazza M AUID- ORCID: 0000-0002-3007-8162 AD - Unit of Psychiatry, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy. AD - Department of Neurosciences, Universita Cattolica del Sacro Cuore, 00168 Rome, Italy. FAU - Covino, Marcello AU - Covino M AUID- ORCID: 0000-0002-6709-2531 AD - Emergency Medicine Department, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Universita Cattolica del Sacro Cuore, 00168 Rome, Italy. FAU - Bambini, Filippo AU - Bambini F AD - Emergency Medicine Department, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Universita Cattolica del Sacro Cuore, 00168 Rome, Italy. FAU - Romagnoli, Enrico AU - Romagnoli E AUID- ORCID: 0000-0003-1611-7708 AD - Department of Cardiovascular Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy. FAU - Biondi-Zoccai, Giuseppe AU - Biondi-Zoccai G AUID- ORCID: 0000-0001-6103-8510 AD - Department of Medical Surgical Sciences and Biotechnologies, Sapienza University of Rome, 04100 Latina, Italy. AD - GVM Care & Research, Maria Cecilia Hospital, 48033 Cotignola, Italy. FAU - Fuorlo, Mariella AU - Fuorlo M AUID- ORCID: 0000-0003-2718-9360 AD - Emergency Medicine Department, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Universita Cattolica del Sacro Cuore, 00168 Rome, Italy. FAU - Barone, Fabiana AU - Barone F AD - Emergency Medicine Department, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Universita Cattolica del Sacro Cuore, 00168 Rome, Italy. FAU - Racco, Simona AU - Racco S AD - Emergency Medicine Department, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Universita Cattolica del Sacro Cuore, 00168 Rome, Italy. FAU - Simeoni, Benedetta AU - Simeoni B AD - Emergency Medicine Department, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Universita Cattolica del Sacro Cuore, 00168 Rome, Italy. FAU - Franceschi, Francesco AU - Franceschi F AD - Emergency Medicine Department, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Universita Cattolica del Sacro Cuore, 00168 Rome, Italy. FAU - Sani, Gabriele AU - Sani G AUID- ORCID: 0000-0002-9767-8752 AD - Unit of Psychiatry, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy. AD - Department of Neurosciences, Universita Cattolica del Sacro Cuore, 00168 Rome, Italy. FAU - Marano, Giuseppe AU - Marano G AUID- ORCID: 0000-0001-7058-4927 AD - Unit of Psychiatry, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy. AD - Department of Neurosciences, Universita Cattolica del Sacro Cuore, 00168 Rome, Italy. LA - eng PT - Journal Article DEP - 20251001 PL - Switzerland TA - Life (Basel) JT - Life (Basel, Switzerland) JID - 101580444 PMC - PMC12564983 OTO - NOTNLM OT - QTc prolongation OT - antidepressants OT - antipsychotics OT - cardiac safety OT - elderly OT - electrocardiography OT - emergency department OT - geriatric psychiatry OT - polypharmacy OT - psychotropic drugs COIS- The authors declare no conflict of interest. EDAT- 2025/10/29 06:27 MHDA- 2025/10/29 06:28 PMCR- 2025/10/01 CRDT- 2025/10/29 01:21 PHST- 2025/09/07 00:00 [received] PHST- 2025/09/27 00:00 [revised] PHST- 2025/09/30 00:00 [accepted] PHST- 2025/10/29 06:28 [medline] PHST- 2025/10/29 06:27 [pubmed] PHST- 2025/10/29 01:21 [entrez] PHST- 2025/10/01 00:00 [pmc-release] AID - life15101545 [pii] AID - life-15-01545 [pii] AID - 10.3390/life15101545 [doi] PST - epublish SO - Life (Basel). 2025 Oct 1;15(10):1545. doi: 10.3390/life15101545. PMID- 41156146 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251029 LR - 20251101 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 14 IP - 20 DP - 2025 Oct 15 TI - Characterization of Patients Unsuited for Transcatheter Mitral Valve Interventions. LID - 10.3390/jcm14207275 [doi] LID - 7275 AB - Background/Objectives: The objective of this study was to characterize echocardiographic characteristics comparing patients accepted or deemed unsuitable for transcatheter mitral valve interventions. Methods: We performed a retrospective analysis of 293 patients with severe mitral regurgitation evaluated for mitral transcatheter edge-to-edge repair (M-TEER) or transcatheter mitral valve replacement (TMVR), if patients were primarily identified as unsuitable candidates for M-TEER, at our institution between 2018 and 2023. All patients underwent transthoracic and transesophageal echocardiography, and mitral valve quantification (MVQ) analysis was performed. Feasibility was determined by an interdisciplinary Heart Team based on quantitative data and semi-quantitative echocardiographic parameters, including mean pressure gradient, regurgitation volumes, and morphological aspects alongside clinical assessment. Patient characteristics were evaluated using clinical records and echocardiographic data. Results: We screened 195 patients for M-TEER, 168 of which were accepted for the procedure. M-TEER-rejected patients presented with higher regurgitation volumes and higher transmitral pressure gradients than those accepted to undergo M-TEER. We then screened 104 patients for TMVR, and 27 were approved for the procedure. Patients rejected for TMVR presented with lower tenting volume, area, and height and had smaller ventricular diameters. Further, mitral valve area appears to be an important parameter in determining MR treatment strategy. Conclusions: The majority of MR patients screened for transcatheter intervention were suitable for M-TEER. However, elevated MPG and more pronounced billowing were the main factors associated with M-TEER exclusion. Conversely, the only morphological parameter associated with TMVR refusal was small left ventricular size. Importantly, the multimorbidity of patients and level of critical illness did not prohibit TMVR. FAU - Gottsche Esperanca Clara, Carolina AU - Gottsche Esperanca Clara C AD - Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW, Ruhr-Universitat Bochum, 32545 Bad Oeynhausen, Germany. AD - Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW, Medizinische Fakultat OWL der Universitat Bielefeld, 32545 Bad Oeynhausen, Germany. FAU - Eustergerling, Hannah AU - Eustergerling H AD - Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW, Ruhr-Universitat Bochum, 32545 Bad Oeynhausen, Germany. FAU - Pepping, Johanna Isabella AU - Pepping JI AD - Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW, Ruhr-Universitat Bochum, 32545 Bad Oeynhausen, Germany. FAU - Trenkpohl, Vanessa AU - Trenkpohl V AD - Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW, Ruhr-Universitat Bochum, 32545 Bad Oeynhausen, Germany. AD - Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW, Medizinische Fakultat OWL der Universitat Bielefeld, 32545 Bad Oeynhausen, Germany. FAU - Friedrichs, Kai Peter AU - Friedrichs KP AUID- ORCID: 0000-0001-9546-3048 AD - Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW, Ruhr-Universitat Bochum, 32545 Bad Oeynhausen, Germany. AD - Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW, Medizinische Fakultat OWL der Universitat Bielefeld, 32545 Bad Oeynhausen, Germany. FAU - Ivannikova, Maria AU - Ivannikova M AD - Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW, Ruhr-Universitat Bochum, 32545 Bad Oeynhausen, Germany. AD - Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW, Medizinische Fakultat OWL der Universitat Bielefeld, 32545 Bad Oeynhausen, Germany. FAU - Rudolph, Tanja Katharina AU - Rudolph TK AD - Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW, Ruhr-Universitat Bochum, 32545 Bad Oeynhausen, Germany. AD - Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW, Medizinische Fakultat OWL der Universitat Bielefeld, 32545 Bad Oeynhausen, Germany. FAU - Bormann, Johanna AU - Bormann J AUID- ORCID: 0000-0002-3854-4295 AD - Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW, Ruhr-Universitat Bochum, 32545 Bad Oeynhausen, Germany. AD - Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW, Medizinische Fakultat OWL der Universitat Bielefeld, 32545 Bad Oeynhausen, Germany. FAU - Kirchner, Johannes AU - Kirchner J AUID- ORCID: 0009-0004-8357-1323 AD - Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW, Ruhr-Universitat Bochum, 32545 Bad Oeynhausen, Germany. AD - Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW, Medizinische Fakultat OWL der Universitat Bielefeld, 32545 Bad Oeynhausen, Germany. FAU - Potratz, Max AU - Potratz M AUID- ORCID: 0000-0003-4044-7037 AD - Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW, Ruhr-Universitat Bochum, 32545 Bad Oeynhausen, Germany. AD - Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW, Medizinische Fakultat OWL der Universitat Bielefeld, 32545 Bad Oeynhausen, Germany. FAU - Rudolph, Volker AU - Rudolph V AD - Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW, Ruhr-Universitat Bochum, 32545 Bad Oeynhausen, Germany. AD - Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW, Medizinische Fakultat OWL der Universitat Bielefeld, 32545 Bad Oeynhausen, Germany. FAU - Kassar, Mohammad AU - Kassar M AD - Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW, Ruhr-Universitat Bochum, 32545 Bad Oeynhausen, Germany. AD - Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW, Medizinische Fakultat OWL der Universitat Bielefeld, 32545 Bad Oeynhausen, Germany. AD - Universitatsklinik fur Kardiologie, Inselspital, 3010 Bern, Switzerland. FAU - Gercek, Muhammed AU - Gercek M AUID- ORCID: 0000-0002-1822-936X AD - Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW, Ruhr-Universitat Bochum, 32545 Bad Oeynhausen, Germany. AD - Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW, Medizinische Fakultat OWL der Universitat Bielefeld, 32545 Bad Oeynhausen, Germany. AD - Feinberg School of Medicine, Northwestern University, Chicago, IL 60208, USA. FAU - Rudolph, Felix AU - Rudolph F AUID- ORCID: 0000-0003-4948-6438 AD - Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW, Ruhr-Universitat Bochum, 32545 Bad Oeynhausen, Germany. AD - Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW, Medizinische Fakultat OWL der Universitat Bielefeld, 32545 Bad Oeynhausen, Germany. AD - Feinberg School of Medicine, Northwestern University, Chicago, IL 60208, USA. LA - eng PT - Journal Article DEP - 20251015 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC12564858 OTO - NOTNLM OT - mitral regurgitation OT - mitral valve quantification OT - transcatheter edge-to-edge-repair OT - transcatheter mitral valve replacement COIS- Felix Rudolph has received funding from Bielefeld University (clinician scientist entry fellowship). Friedrichs is consultant for and has received speaker honoraria from Edwards Lifesciences. Ivannikova has received speaker honoraria from Edwards and AstraZeneca. Tanja Rudolph has received speaker honoraria from Edwards Lifesciences. Kassar reports research grants from the Swiss and German Heart Foundation. Volker Rudolph has received grants and speaker honoraria from Abbott and Edwards Lifesciences. Muhammed Gercek has received funding from the Ruhr University Bochum (advanced clinician scientist grant) and speaker honoraria from Edwards Lifesciences. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2025/10/29 06:28 MHDA- 2025/10/29 06:29 PMCR- 2025/10/15 CRDT- 2025/10/29 01:17 PHST- 2025/09/11 00:00 [received] PHST- 2025/10/05 00:00 [revised] PHST- 2025/10/14 00:00 [accepted] PHST- 2025/10/29 06:29 [medline] PHST- 2025/10/29 06:28 [pubmed] PHST- 2025/10/29 01:17 [entrez] PHST- 2025/10/15 00:00 [pmc-release] AID - jcm14207275 [pii] AID - jcm-14-07275 [pii] AID - 10.3390/jcm14207275 [doi] PST - epublish SO - J Clin Med. 2025 Oct 15;14(20):7275. doi: 10.3390/jcm14207275. PMID- 41155802 OWN - NLM STAT- MEDLINE DCOM- 20251029 LR - 20251101 IS - 1648-9144 (Electronic) IS - 1010-660X (Print) IS - 1010-660X (Linking) VI - 61 IP - 10 DP - 2025 Oct 10 TI - Cardiac Surgery and Postoperative Atrial Fibrillation: The Role of Cancer. LID - 10.3390/medicina61101815 [doi] LID - 1815 AB - Background: Postoperative atrial fibrillation (POAF) is the most frequent arrhythmic complication following cardiac surgery, affecting nearly 20-30% of patients. While conventional risk factors such as age, hypertension, and atrial enlargement are well known, emerging evidence suggests that cancer itself constitutes a significant, yet underrecognized, contributor to POAF risk. Objective: This review aims to systematically examine the association of cancer with POAF, explore underlying pathophysiological mechanisms, and discuss clinical implications for risk stratification and management in cardiac surgical patients with concurrent or historical malignancies. Methods: A comprehensive review of recent literature was conducted using PubMed and Scopus databases. Studies focusing on the epidemiology, mechanisms, and clinical management of POAF in patients with cancer were evaluated. AI-assisted tools (OpenAI's ChatGPT) were used for formatting the graphical abstract. Results: Lung, breast, gastrointestinal, hematologic, and prostate cancers demonstrate the strongest association with POAF. The arrhythmogenic mechanisms include systemic inflammation, hypercoagulability, direct cardiotoxicity from cancer therapies, autonomic dysregulation, and paraneoplastic syndromes. Integration of oncologic variables into perioperative cardiovascular care is essential for precision risk assessment and outcome optimization. In a recent prospective cardiac surgery cohort, active or historical cancer independently conferred ~4-fold higher odds of POAF (adjusted OR: 3.85, 95% CI: 1.54-9.66), with cancer present in 15% of POAF cases versus 4% of non-POAF patients. Conclusions: Cancer represents a pivotal and multifactorial risk factor for POAF after cardiac surgery. Recognizing its role calls for a multidisciplinary approach that aligns oncologic and cardiovascular care to mitigate arrhythmic risk and improve surgical outcomes. FAU - Georghiou, Georgios P AU - Georghiou GP AD - School of Medicine, European University Cyprus, 2404 Egkomi, Cyprus. AD - Department of Cardiothoracic Surgery, Aretaeio Hospital, 2414 Nicosia, Cyprus. AD - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel. FAU - Georghiou, Panos AU - Georghiou P AD - Barts and The London School of Medicine and Dentistry, London E1 2AD, UK. FAU - Georgiou, Amalia AU - Georgiou A AD - Department of Cardiology, Marien Hospital Dusseldorf, 40479 Dusseldorf, Germany. FAU - Triposkiadis, Filippos AU - Triposkiadis F AUID- ORCID: 0000-0001-6433-4016 AD - School of Medicine, European University Cyprus, 2404 Egkomi, Cyprus. LA - eng PT - Journal Article PT - Review DEP - 20251010 PL - Switzerland TA - Medicina (Kaunas) JT - Medicina (Kaunas, Lithuania) JID - 9425208 SB - IM MH - Humans MH - *Atrial Fibrillation/etiology/epidemiology/physiopathology MH - *Neoplasms/complications MH - *Postoperative Complications/etiology/epidemiology MH - *Cardiac Surgical Procedures/adverse effects MH - Risk Factors MH - Risk Assessment/methods PMC - PMC12566252 OTO - NOTNLM OT - arrhythmia OT - cancer OT - cardiac surgery OT - cardiotoxicity OT - hypercoagulability OT - inflammation OT - multidisciplinary care OT - postoperative atrial fibrillation OT - risk stratification COIS- The authors declare no conflicts of interest. EDAT- 2025/10/29 06:27 MHDA- 2025/10/29 06:28 PMCR- 2025/10/10 CRDT- 2025/10/29 01:16 PHST- 2025/07/30 00:00 [received] PHST- 2025/09/20 00:00 [revised] PHST- 2025/09/26 00:00 [accepted] PHST- 2025/10/29 06:28 [medline] PHST- 2025/10/29 06:27 [pubmed] PHST- 2025/10/29 01:16 [entrez] PHST- 2025/10/10 00:00 [pmc-release] AID - medicina61101815 [pii] AID - medicina-61-01815 [pii] AID - 10.3390/medicina61101815 [doi] PST - epublish SO - Medicina (Kaunas). 2025 Oct 10;61(10):1815. doi: 10.3390/medicina61101815. PMID- 41149488 OWN - NLM STAT- MEDLINE DCOM- 20251028 LR - 20251203 IS - 1718-7729 (Electronic) IS - 1198-0052 (Print) IS - 1198-0052 (Linking) VI - 32 IP - 10 DP - 2025 Oct 11 TI - Retrospective Cohort Study of Intrapericardial Cisplatin for Risk Reduction of Malignant Pericardial Effusion Recurrence. LID - 10.3390/curroncol32100568 [doi] LID - 568 AB - Malignant pericardial effusion (MPE) is a life-threatening condition in patients with cancer, with common recurrences after simple pericardiocentesis. Consequently, the intrapericardial instillation of sclerosing or cytotoxic agents has been explored, with limited evidence from small studies with different methodologies. We undertook an observational, retrospective, single-centre study, including all patients diagnosed with a solid neoplasm and clinically significant and/or recurrent, cytology-confirmed MPE, treated with Intrapericardial Instillation of Cisplatin (IPIC), between 2009 and 2022. Patients with hematological malignancies were excluded. The procedure followed a multidisciplinary approach and a standardized protocol. Variables collected included baseline patient characteristics, neoplasm details, MPE impact, adverse events (AEs) from procedures (pericardiocentesis and IPIC) and outcomes (time to MPE recurrence and survival). This study adhered to the STROBE guidelines. A total of 41 patients were included, 51% female, with a median age of 61 (51-69) years. Non-small cell lung cancer (NSCLC) was the predominant primary tumour (78%) and in 44% of the cohort, MPE was identified at cancer diagnosis. Most patients (90.2%) presented symptoms related to MPE at diagnosis, and 88% had cardiac tamponade on echocardiography. IPIC was administered a median of four times. IPIC-related AEs occurred in 10 patients (24.4%), with transient atrial fibrillation (AF) being the most frequent one. Two patients (4.9%) experienced MPE recurrence within 30 days after IPIC. The median survival time from MPE diagnosis was 161 days (5.4 months; IQR 73-455 days). IPIC appears to be a feasible, effective and safe option for reducing the risk of MPE recurrence, mainly in NSCLC. FAU - Munoz-Carrillo, Francisco Javier AU - Munoz-Carrillo FJ AUID- ORCID: 0000-0002-0162-7767 AD - Medical Oncology Department Hospital Clinic de Barcelona and Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, 08036 Barcelona, Spain. FAU - Reyes, Roxana Maribel AU - Reyes RM AD - Medical Oncology Department Hospital Clinic de Barcelona and Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, 08036 Barcelona, Spain. FAU - Pesantez, David AU - Pesantez D AD - Medical Oncology Department Hospital Clinic de Barcelona and Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, 08036 Barcelona, Spain. FAU - Carrera, Gemma AU - Carrera G AD - Medical Oncology Department Hospital Clinic de Barcelona and Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, 08036 Barcelona, Spain. FAU - Cascos, Enric AU - Cascos E AUID- ORCID: 0000-0002-9093-3642 AD - Cardiology Department, Hospital Clinic de Barcelona, 08036 Barcelona, Spain. FAU - Castro, Pedro AU - Castro P AUID- ORCID: 0000-0002-6118-8970 AD - Medical Intensive Care Unit, Internal Medicine Department, Hospital Clinic de Barcelona, 08036 Barcelona, Spain. FAU - Fernandez-Mendez, Sara AU - Fernandez-Mendez S AUID- ORCID: 0000-0003-2912-3357 AD - Medical Intensive Care Unit, Internal Medicine Department, Hospital Clinic de Barcelona, 08036 Barcelona, Spain. FAU - Font, Carme AU - Font C AD - Medical Oncology Department Hospital Clinic de Barcelona and Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, 08036 Barcelona, Spain. FAU - Gonzalez-Aguado, Laura AU - Gonzalez-Aguado L AD - Medical Oncology Department Hospital Clinic de Barcelona and Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, 08036 Barcelona, Spain. FAU - Grafia, Ignacio AU - Grafia I AD - Medical Oncology Department Hospital Clinic de Barcelona and Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, 08036 Barcelona, Spain. AD - Medical Intensive Care Unit, Internal Medicine Department, Hospital Clinic de Barcelona, 08036 Barcelona, Spain. FAU - Llavata, Lucia AU - Llavata L AD - Medical Oncology Department Hospital Clinic de Barcelona and Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, 08036 Barcelona, Spain. FAU - Monge-Escartin, Ines AU - Monge-Escartin I AD - Hospital Pharmacy Department, Hospital Clinic de Barcelona, 08036 Barcelona, Spain. FAU - Padrosa, Joan AU - Padrosa J AUID- ORCID: 0000-0002-3354-5811 AD - Medical Oncology Department Hospital Clinic de Barcelona and Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, 08036 Barcelona, Spain. AD - Medical Intensive Care Unit, Internal Medicine Department, Hospital Clinic de Barcelona, 08036 Barcelona, Spain. FAU - Reguart, Noemi AU - Reguart N AD - Medical Oncology Department Hospital Clinic de Barcelona and Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, 08036 Barcelona, Spain. FAU - Tellez, Adrian AU - Tellez A AUID- ORCID: 0000-0003-3502-5999 AD - Medical Intensive Care Unit, Internal Medicine Department, Hospital Clinic de Barcelona, 08036 Barcelona, Spain. FAU - Tuca, Albert AU - Tuca A AUID- ORCID: 0000-0002-4633-5856 AD - Medical Oncology Department Hospital Clinic de Barcelona and Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, 08036 Barcelona, Spain. AD - Chair of Palliative Care, Barcelona University, 08036 Barcelona, Spain. AD - EAPS Fundacio La Caixa, 08019 Barcelona, Spain. FAU - Viladot, Margarita AU - Viladot M AD - Medical Oncology Department Hospital Clinic de Barcelona and Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, 08036 Barcelona, Spain. FAU - Zamora-Martinez, Carles AU - Zamora-Martinez C AUID- ORCID: 0000-0002-3838-0809 AD - Medical Oncology Department Hospital Clinic de Barcelona and Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, 08036 Barcelona, Spain. AD - Medical Intensive Care Unit, Internal Medicine Department, Hospital Clinic de Barcelona, 08036 Barcelona, Spain. FAU - Amoros-Reboredo, Patricia AU - Amoros-Reboredo P AUID- ORCID: 0000-0001-9258-2623 AD - Pharmacy Department and Digital Impulse, Strategy and Transformation Area, Hospital de Sant Pau, Institut de Recerca Sant Pau (IR SANT PAU), 08041 Barcelona, Spain. FAU - Marco-Hernandez, Javier AU - Marco-Hernandez J AUID- ORCID: 0000-0001-8486-5404 AD - Medical Oncology Department Hospital Clinic de Barcelona and Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, 08036 Barcelona, Spain. AD - Medical Intensive Care Unit, Internal Medicine Department, Hospital Clinic de Barcelona, 08036 Barcelona, Spain. LA - eng PT - Journal Article PT - Observational Study DEP - 20251011 PL - Switzerland TA - Curr Oncol JT - Current oncology (Toronto, Ont.) JID - 9502503 RN - Q20Q21Q62J (Cisplatin) RN - 0 (Antineoplastic Agents) SB - IM MH - Humans MH - Female MH - Male MH - Retrospective Studies MH - Middle Aged MH - *Pericardial Effusion/drug therapy/prevention & control/etiology MH - Aged MH - *Cisplatin/therapeutic use/administration & dosage/pharmacology MH - *Antineoplastic Agents/therapeutic use/administration & dosage MH - Recurrence MH - Neoplasm Recurrence, Local PMC - PMC12564023 OTO - NOTNLM OT - cisplatin OT - intrapericardial infusion OT - malignant pericardial effusion OT - multidisciplinary approach COIS- The authors declare no conflicts of interest. EDAT- 2025/10/28 18:28 MHDA- 2025/10/28 18:29 PMCR- 2025/10/11 CRDT- 2025/10/28 12:37 PHST- 2025/06/29 00:00 [received] PHST- 2025/09/12 00:00 [revised] PHST- 2025/10/10 00:00 [accepted] PHST- 2025/10/28 18:29 [medline] PHST- 2025/10/28 18:28 [pubmed] PHST- 2025/10/28 12:37 [entrez] PHST- 2025/10/11 00:00 [pmc-release] AID - curroncol32100568 [pii] AID - curroncol-32-00568 [pii] AID - 10.3390/curroncol32100568 [doi] PST - epublish SO - Curr Oncol. 2025 Oct 11;32(10):568. doi: 10.3390/curroncol32100568. PMID- 41149285 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251028 LR - 20251030 IS - 2308-3425 (Electronic) IS - 2308-3425 (Linking) VI - 12 IP - 10 DP - 2025 Oct 21 TI - Prescription Trends and the Role of Cardiologists in the Diagnosis and Treatment of Erectile Dysfunction. LID - 10.3390/jcdd12100414 [doi] LID - 414 AB - INTRODUCTION: Erectile dysfunction (ED) is strongly associated with metabolic and cardiovascular diseases and may serve as a marker of vascular pathology. Phosphodiesterase type 5 (PDE-5) inhibitors are the mainstay of treatment. Considering this link, cardiologists and internists might be expected to play a key role in therapy initiation. PURPOSE: This study evaluated prescription patterns of PDE-5 inhibitors in Poland, focusing on physician specialization and consultation type. METHODS: We performed a retrospective analysis of electronic health records from over 300 outpatient clinics (2014-2024). Men >18 years with newly diagnosed ED were included. Data on the first prescriptions of sildenafil and tadalafil were assessed. Ethical approval was obtained. RESULTS: A total of 11,998 patients were identified (mean age 42 years; mean BMI 26.54 kg/m(2)). Common comorbidities included hypercholesterolemia (67.0%), hypertension (58.5%), obesity (31.5%), and diabetes (12.4%). PDE-5 inhibitors (predominantly tadalafil ( approximately 67%)) were prescribed in 71.5% of cases. Urologists accounted for 51.0% of prescriptions, sexologists 14.9%, internists 20.4%, and cardiologists only 0.10%. Treated patients were younger and had a lower BMI, fewer comorbidities, and more favorable metabolic profiles (all p < 0.05). CONCLUSIONS: Contrary to expectations, cardiologists and internists rarely initiate PDE-5 therapy. Prescribing is dominated by urologists despite high rates of cardiovascular comorbidities. A multidisciplinary approach incorporating metabolic and cardiovascular risk assessment is warranted. FAU - Tkaczyk, Filip AU - Tkaczyk F AUID- ORCID: 0000-0003-4847-8858 AD - Collegium Medicum, The Jan Kochanowski University in Kielce, 25-369 Kielce, Poland. FAU - Chudzik, Michal AU - Chudzik M AUID- ORCID: 0000-0001-8805-9688 AD - Department of Electrocardiology, Medical University of Lodz, 90-419 Lodz, Poland. FAU - Piotrowska, Aleksandra M AU - Piotrowska AM AUID- ORCID: 0000-0002-9799-8019 AD - Collegium Medicum, The Jan Kochanowski University in Kielce, 25-369 Kielce, Poland. FAU - Stolpe, Tim AU - Stolpe T AD - Collegium Medicum, The Jan Kochanowski University in Kielce, 25-369 Kielce, Poland. FAU - Zurawska, Julia AU - Zurawska J AD - Collegium Medicum, The Jan Kochanowski University in Kielce, 25-369 Kielce, Poland. FAU - Siudak, Zbigniew AU - Siudak Z AUID- ORCID: 0000-0002-8033-3977 AD - Collegium Medicum, The Jan Kochanowski University in Kielce, 25-369 Kielce, Poland. LA - eng PT - Journal Article DEP - 20251021 PL - Switzerland TA - J Cardiovasc Dev Dis JT - Journal of cardiovascular development and disease JID - 101651414 PMC - PMC12564340 OTO - NOTNLM OT - PDE-5 inhibitors OT - cardiovascular risk OT - erectile dysfunction OT - prescription patterns COIS- The authors declare no conflicts of interest related to this study. EDAT- 2025/10/28 18:27 MHDA- 2025/10/28 18:28 PMCR- 2025/10/21 CRDT- 2025/10/28 12:36 PHST- 2025/09/08 00:00 [received] PHST- 2025/10/15 00:00 [revised] PHST- 2025/10/19 00:00 [accepted] PHST- 2025/10/28 18:28 [medline] PHST- 2025/10/28 18:27 [pubmed] PHST- 2025/10/28 12:36 [entrez] PHST- 2025/10/21 00:00 [pmc-release] AID - jcdd12100414 [pii] AID - jcdd-12-00414 [pii] AID - 10.3390/jcdd12100414 [doi] PST - epublish SO - J Cardiovasc Dev Dis. 2025 Oct 21;12(10):414. doi: 10.3390/jcdd12100414. PMID- 41148672 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251028 LR - 20251031 IS - 2079-6382 (Print) IS - 2079-6382 (Electronic) IS - 2079-6382 (Linking) VI - 14 IP - 10 DP - 2025 Sep 29 TI - Epidemiology, Pathogenesis, Clinical Features, and Management of Non-HACEK Gram-Negative Infective Endocarditis. LID - 10.3390/antibiotics14100980 [doi] LID - 980 AB - Background/Objectives: Non-HACEK Gram-Negative Infective Endocarditis (NHGNIE) is a rare but increasingly recognized condition associated with high morbidity and mortality. Its incidence is rising among people who inject drugs (PWID), patients with prosthetic valves or cardiac devices, and those with significant healthcare exposure. We aimed to provide a comprehensive review of the epidemiology, pathogenesis, diagnosis, clinical features, and management of NHGNIE. Methods: We conducted a narrative synthesis of published cohort studies, case series, guideline documents, and recent registry data addressing NHGNIE. Evidence was extracted and critically appraised with emphasis on epidemiological patterns, microbial etiology, diagnostic frameworks, therapeutic strategies, and outcomes. Special focus was given to pathogen-specific differences and the impact of antimicrobial resistance. Results: NHGNIE accounts for approximately 1.5-10.7% of IE cases worldwide, with marked geographical variability. Pseudomonas aeruginosa, Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli are the predominant pathogens, with clinical profiles differing between younger, PWID-based populations and older, comorbidity-affected cohorts. Advances in molecular diagnostics and imaging have improved case identification, though pathogen-specific diagnostic performance remains limited. Outcomes are poor, with in-hospital mortality up to 41%. Antimicrobial therapy is complicated by biofilm formation and potential for multidrug resistance; evidence for combination therapy versus monotherapy is conflicting. Surgical intervention appears to improve outcomes when performed according to guideline-based indications, but results are heterogeneous across studies. Conclusions: NHGNIE is a clinically significant form of IE with complex epidemiology, diagnostic challenges, and limited evidence to guide treatment. Effective management requires individualized care coordinated within a multidisciplinary "endocarditis team". FAU - Monardo, Roberta AU - Monardo R AUID- ORCID: 0000-0002-1388-4322 AD - Unit of Infectious Diseases, Vita-Salute San Raffaele University, 20132 Milan, Italy. AD - Unit of Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20127 Milan, Italy. FAU - Papaioannu Borjesson, Rebecka AU - Papaioannu Borjesson R AUID- ORCID: 0009-0007-6486-2231 AD - Unit of Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20127 Milan, Italy. FAU - Ponta, Giacomo AU - Ponta G AUID- ORCID: 0000-0001-6831-2121 AD - Unit of Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20127 Milan, Italy. FAU - Castagna, Antonella AU - Castagna A AUID- ORCID: 0000-0002-8338-9714 AD - Unit of Infectious Diseases, Vita-Salute San Raffaele University, 20132 Milan, Italy. AD - Unit of Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20127 Milan, Italy. FAU - Ripa, Marco AU - Ripa M AUID- ORCID: 0000-0002-6380-0377 AD - Unit of Infectious Diseases, Vita-Salute San Raffaele University, 20132 Milan, Italy. AD - Unit of Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20127 Milan, Italy. LA - eng PT - Journal Article PT - Review DEP - 20250929 PL - Switzerland TA - Antibiotics (Basel) JT - Antibiotics (Basel, Switzerland) JID - 101637404 PMC - PMC12561054 OTO - NOTNLM OT - Escherichia coli OT - Infective Endocarditis OT - Klebsiella pneumoniae OT - Pseudomonas aeruginosa OT - Serratia marcescens OT - gram-negative COIS- The authors declare no conflicts of interest. EDAT- 2025/10/28 18:27 MHDA- 2025/10/28 18:28 PMCR- 2025/09/29 CRDT- 2025/10/28 12:33 PHST- 2025/08/27 00:00 [received] PHST- 2025/09/22 00:00 [revised] PHST- 2025/09/28 00:00 [accepted] PHST- 2025/10/28 18:28 [medline] PHST- 2025/10/28 18:27 [pubmed] PHST- 2025/10/28 12:33 [entrez] PHST- 2025/09/29 00:00 [pmc-release] AID - antibiotics14100980 [pii] AID - antibiotics-14-00980 [pii] AID - 10.3390/antibiotics14100980 [doi] PST - epublish SO - Antibiotics (Basel). 2025 Sep 29;14(10):980. doi: 10.3390/antibiotics14100980. PMID- 41148246 OWN - NLM STAT- MEDLINE DCOM- 20260811 LR - 20260828 IS - 1550-5049 (Electronic) IS - 0889-4655 (Linking) VI - 41 IP - 5 DP - 2026 Sep-Oct 01 TI - Effectiveness of a Nurse Practitioner-Led Collaborative Healthcare Model in Reducing Anxiety and Depression and Improving Quality of Life in Patients With Heart Failure: A Randomized Controlled Trial. PG - 363-370 LID - 10.1097/JCN.0000000000001264 [doi] AB - BACKGROUND: Heart failure is a common chronic illness that often leads to anxiety, depression, and poor quality of life. These psychological issues can worsen health outcomes. A nurse practitioner-led collaborative healthcare model may help address both physical and mental health needs, improving overall patient well-being. OBJECTIVE: The aim of this study was to explore the effectiveness of a nurse practitioner-led collaborative healthcare model in reducing anxiety and depression and improving quality of life in patients with heart failure. METHODS: This randomized controlled trial was conducted in the cardiology department of a regional teaching hospital in southern Taiwan. A total of 100 patients with heart failure were recruited through random sampling and randomly assigned to 2 groups. The control group (n = 50) received standard care, whereas the experimental group (n = 50) received a 12-week intervention based on the collaborative healthcare model. RESULTS: Patients in the experimental group who received a 12-week nurse practitioner-led collaborative healthcare model intervention demonstrated significant reductions in anxiety and depressive symptoms, as well as notable improvements in quality of life. Compared with the control group, the experimental group exhibited a sustained trend of improvement at weeks 12, 16, and 20. CONCLUSIONS: The nurse practitioner-led collaborative healthcare model effectively alleviates anxiety and depression in patients with heart failure while significantly improving quality of life. This multidisciplinary collaborative approach reduces disease burden, enhances physical and mental health, and demonstrates substantial clinical applicability. It is recommended to promote this model in clinical practice to optimize care outcomes. CI - Copyright (c) 2025 Wolters Kluwer Health, LLC. All rights reserved. FAU - Chen, Chih-Wen AU - Chen CW AD - Chih-Wen Chen, PhD, RN School of Nursing, National Taipei University of Nursing and Health Sciences; and Nursing Practitioner Leader, Department of Nursing, Antai Medical Care Corporation Antai Tian-Sheng Memorial Hospital, Pingtung, Taiwan. FAU - Wang, Tsae-Jyy AU - Wang TJ AD - Tsae-Jyy Wang, PhD, ARNP, RN Professor, University of Washington, Seattle; and Dean of Academic Affairs, School of Nursing, National Taipei University of Nursing and Health Sciences, Taiwan. FAU - Liu, Chieh-Yu AU - Liu CY AD - Chieh-Yu Liu, PhD Professor, Institute of Business and Management, and Director, Institute of Community Health Care, College of Nursing, National Yang Ming Chiao Tung University, Taipei, Taiwan. FAU - Chuang, Yeu-Hui AU - Chuang YH AD - Yeu-Hui Chuang, PhD, RN Professor, School of Nursing, College of Nursing, Taipei Medical University; Research Supervisor, Department of Nursing, Wan Fang Hospital, Taipei Medical University; and Research Supervisor, Research Center in Nursing Clinical Practice, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan. FAU - Su, Ching-Chuan AU - Su CC AD - Ching-Chuan Su, PhD Associate Professor, Chung Shan Medical University, Taichung; and Dean Emeritus, Antai Medical Care Corporation Antai Tian-Sheng Memorial Hospital, Pingtung, Taiwan. FAU - Vivienne Wu, Shu-Fang AU - Vivienne Wu SF AD - Shu-Fang Vivienne Wu, PhD, RN, School of Nursing, National Taipei University of Nursing and Health Sciences, Taipei, Taiwan, President. LA - eng PT - Journal Article PT - Randomized Controlled Trial DEP - 20251028 PL - United States TA - J Cardiovasc Nurs JT - The Journal of cardiovascular nursing JID - 8703516 SB - IM MH - Humans MH - *Heart Failure/psychology/nursing MH - *Quality of Life MH - Female MH - *Nurse Practitioners MH - Male MH - *Depression/prevention & control/etiology MH - *Anxiety/prevention & control/etiology MH - Aged MH - Taiwan MH - Middle Aged OTO - NOTNLM OT - anxiety OT - depression OT - heart failure OT - multidisciplinary team OT - nurse practitioner OT - quality of life OT - randomized controlled trials COIS- The authors have no funding or conflicts of interest to disclose. EDAT- 2025/10/28 18:27 MHDA- 2026/08/11 17:36 CRDT- 2025/10/28 12:13 PHST- 2026/08/11 17:36 [medline] PHST- 2025/10/28 18:27 [pubmed] PHST- 2025/10/28 12:13 [entrez] AID - 00005082-990000000-00343 [pii] AID - 10.1097/JCN.0000000000001264 [doi] PST - ppublish SO - J Cardiovasc Nurs. 2026 Sep-Oct 01;41(5):363-370. doi: 10.1097/JCN.0000000000001264. Epub 2025 Oct 28. PMID- 41146918 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251028 LR - 20251030 IS - 2772-4875 (Electronic) IS - 2772-4875 (Linking) VI - 27 DP - 2025 Dec TI - Cardiac rehabilitation for outpatients aged over 80 years with cardiovascular diseases. PG - 200516 LID - 10.1016/j.ijcrp.2025.200516 [doi] LID - 200516 AB - BACKGROUND: Japan had the highest proportion of the elderly in the world, with one in 10 individuals aged >/=80 years. Consequently, the number of patients with cardiovascular diseases is increasing. Older patients often have comorbidities such as frailty, sarcopenia, and cognitive decline that leads to a decreased quality of life (QOL). We analyzed the effects of outpatient cardiac rehabilitation (OCR) in elderly patients with cardiovascular disease. METHODS: The comprehensive OCR had been provided by a multidisciplinary team. We analyzed data from 49 patients with cardiovascular diseases, aged >/=80 years, who received cardiopulmonary exercise (CPX) tests based OCR. Frailty, physical function, QOL, exercise tolerance, and vascular endothelial function were assessed before and after OCR. RESULTS: All 49 patients had completed the OCR program. The mean patients' age was 84.1 +/- 3.6 years and 32.7 % were male. The proportion of frailty and pre-frailty participants significantly decreased from 92 % to 67 % following OCR. The QOL (KCCQ: 76.8 +/- 18.4 vs. 81.4 +/- 20.4; P = 0.0196), exercise tolerance (peak VO(2): 14.1 +/- 4.0 vs. 15.4 +/- 3.9 mL/min/kg; P = 0.0017), and vascular endothelial function (Ln-RHI: 0.48 +/- 0.39 vs. 0.57 +/- 0.3; P = 0.027) significantly improved after OCR. CONCLUSIONS: The comprehensive OCR with CPX-based exercise therapy and the multidisciplinary approach significantly improved frailty, the QOL, physical function, exercise tolerance, and vascular endothelial function in patients with cardiovascular diseases aged >/=80 years. CI - (c) 2025 The Authors. FAU - Someya, Ryoko AU - Someya R AD - Department of Rehabilitation, Yokohama City University Medical Center, Yokohama, Japan. FAU - Matsuzawa, Yasushi AU - Matsuzawa Y AD - Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan. AD - Division of Cardiology, Yokohama City University Medical Center, Yokohama, Japan. FAU - Shimizu, Yoshitaka AU - Shimizu Y AD - Department of Rehabilitation, Yokohama City University Medical Center, Yokohama, Japan. FAU - Nakahashi, Hidefumi AU - Nakahashi H AD - Division of Cardiology, Yokohama City University Medical Center, Yokohama, Japan. FAU - Konishi, Masaaki AU - Konishi M AD - Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan. FAU - Akiyama, Eiichi AU - Akiyama E AD - Kawaguchi Cardiovascular and Respiratory Hospital, Saitama, Japan. FAU - Hanajima, Yohei AU - Hanajima Y AD - Division of Cardiology, Yokohama City University Medical Center, Yokohama, Japan. FAU - Kondo, Hisaya AU - Kondo H AD - Division of Cardiology, Yokohama City University Medical Center, Yokohama, Japan. FAU - Yoshii, Tomohiro AU - Yoshii T AD - Division of Cardiology, Yokohama City University Medical Center, Yokohama, Japan. FAU - Sato, Ryosuke AU - Sato R AD - Division of Cardiology, Yokohama City University Medical Center, Yokohama, Japan. FAU - Hayashi, Kazuko AU - Hayashi K AD - Department of Rehabilitation, Yokohama City University Medical Center, Yokohama, Japan. FAU - Okada, Kozo AU - Okada K AD - Division of Cardiology, Yokohama City University Medical Center, Yokohama, Japan. FAU - Sugano, Teruyasu AU - Sugano T AD - Division of Cardiology, Yokohama City University Medical Center, Yokohama, Japan. AD - Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan. FAU - Hibi, Kiyoshi AU - Hibi K AD - Division of Cardiology, Yokohama City University Medical Center, Yokohama, Japan. AD - Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan. LA - eng PT - Journal Article DEP - 20250917 PL - Netherlands TA - Int J Cardiol Cardiovasc Risk Prev JT - International journal of cardiology. Cardiovascular risk and prevention JID - 9918282077306676 PMC - PMC12554074 OTO - NOTNLM OT - Cardiac rehabilitation OT - Cardiopulmonary exercise test OT - Cardiovascular disease OT - Elderly OT - Frailty OT - Vascular endothelial function COIS- None. EDAT- 2025/10/28 06:30 MHDA- 2025/10/28 06:31 PMCR- 2025/09/17 CRDT- 2025/10/28 04:08 PHST- 2025/06/03 00:00 [received] PHST- 2025/08/19 00:00 [revised] PHST- 2025/09/16 00:00 [accepted] PHST- 2025/10/28 06:31 [medline] PHST- 2025/10/28 06:30 [pubmed] PHST- 2025/10/28 04:08 [entrez] PHST- 2025/09/17 00:00 [pmc-release] AID - S2772-4875(25)00154-0 [pii] AID - 200516 [pii] AID - 10.1016/j.ijcrp.2025.200516 [doi] PST - epublish SO - Int J Cardiol Cardiovasc Risk Prev. 2025 Sep 17;27:200516. doi: 10.1016/j.ijcrp.2025.200516. eCollection 2025 Dec. PMID- 41146789 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251028 LR - 20251030 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 17 IP - 9 DP - 2025 Sep TI - Chronic Cardiovascular Disorders Associated With COVID-19: A Literature Review. PG - e93271 LID - 10.7759/cureus.93271 [doi] LID - e93271 AB - The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for the COVID-19 pandemic, is now widely recognized for causing several long-term effects known as post-COVID-19 syndrome (PCS) or long COVID (LC). This presents a growing challenge for healthcare systems worldwide. This narrative review summarizes original peer-reviewed studies indexed in PubMed and published between January 2020 and August 2025. It focuses on adult populations unless stated otherwise. We included studies that provided primary clinical or imaging data on chronic cardiovascular outcomes after confirmed SARS-CoV-2 infection. We excluded case reports, pediatric-only cohorts, and non-peer-reviewed sources. Among the various cardiovascular issues related to LC, we focused on heart fibrosis (HF), postural orthostatic tachycardia syndrome (POTS), new-onset hypertension (HT), and coagulopathy. These conditions consistently show up in the reports and are significant in terms of illness, potential long-term disability, and public health impact. Although these issues are distinct in their underlying causes, they share common mechanisms. These include ongoing inflammation of the endothelium, disruption of the renin-angiotensin-aldosterone system (RAAS), immune-related tissue damage, and an ongoing state that promotes blood clots. These processes can lead to measurable myocardial fibrosis that cardiac magnetic resonance imaging can detect, autonomic dysfunction often seen as POTS, a greater risk of developing hypertension shortly after infection, and a long-term rise in thromboembolic events due to increased clotting and resistant microclots. Current management is mostly focused on relief of symptoms and involves a team approach. It uses repurposed medications and tailored physical rehabilitation since no specific cure is available yet. Promising but still experimental methods, such as endothelial-protective agents like sulodexide and targeting inflammatory pathways, need thorough testing. There are significant gaps in our understanding of the long-term risk of hypertension, the natural progression of fibrosis, and the best treatment for POTS. This highlights urgent needs for future research. Beyond caring for individual patients, these ongoing cardiovascular problems raise important public health concerns. They include higher healthcare use, long-term disability, and economic costs. This situation requires increased clinical attention and proactive cardiovascular monitoring for those recovering from COVID-19. CI - Copyright (c) 2025, Dudek et al. FAU - Dudek, Adam AU - Dudek A AD - General Practice, University Hospital in Poznan, Poznan, POL. FAU - Bursy, Marcin AU - Bursy M AD - General Practice, University Hospital in Poznan, Poznan, POL. FAU - Szkudlarek, Wojciech AU - Szkudlarek W AD - Medicine, Medical Center HCP, Poznan, POL. FAU - Linkiewicz, Jan AU - Linkiewicz J AD - Medical School, Poznan University of Medical Sciences, Poznan, POL. FAU - Fabiszewski, Zbigniew AU - Fabiszewski Z AD - General Surgery, Independent Healthcare Facility in Oborniki, Oborniki, POL. FAU - Starosta, Piotr AU - Starosta P AD - General Practice, Independent Healthcare Facility in Oborniki, Oborniki, POL. LA - eng PT - Journal Article PT - Review DEP - 20250926 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC12554255 OTO - NOTNLM OT - covid-19 OT - covid-19 associated coagulopathy OT - covid-19 associated heart fibrosis OT - covid-19 associated hypertension OT - post covid syndrome COIS- Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. EDAT- 2025/10/28 06:30 MHDA- 2025/10/28 06:31 PMCR- 2025/09/26 CRDT- 2025/10/28 04:06 PHST- 2025/09/26 00:00 [accepted] PHST- 2025/10/28 06:31 [medline] PHST- 2025/10/28 06:30 [pubmed] PHST- 2025/10/28 04:06 [entrez] PHST- 2025/09/26 00:00 [pmc-release] AID - 10.7759/cureus.93271 [doi] PST - epublish SO - Cureus. 2025 Sep 26;17(9):e93271. doi: 10.7759/cureus.93271. eCollection 2025 Sep. PMID- 41146052 OWN - NLM STAT- MEDLINE DCOM- 20251028 LR - 20260423 IS - 1471-2261 (Electronic) IS - 1471-2261 (Linking) VI - 25 IP - 1 DP - 2025 Oct 27 TI - Maximum tolerated medication dose and other predictors of mortality in heart failure with reduced ejection fraction: retrospective cohort study. PG - 768 LID - 10.1186/s12872-025-05104-w [doi] LID - 768 AB - BACKGROUND: In real-world patients with Heart Failure with reduced Ejection Fraction (HFrEF), it is unclear whether up-titration of angiotensin-converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARB) and beta-blockers to maximal tolerated dose is beneficial. OBJECTIVE: To assess whether achievement of maximal tolerated heart failure therapies confers increased prognostic benefits, as compared with use of submaximal doses. DESIGN: Retrospective cohort study. PARTICIPANTS: Ambulatory HFrEF patients from two outpatient clinics in Adelaide, South Australia. MAIN MEASURES: Percentage of target dose of ACEi/ARB and beta-blocker, all-cause mortality. KEY RESULTS: Of 489 patients, with a mean age of 71 +/- 14 years, 67% male, 304 (62%) died over a mean 4.0 years of follow-up. Increasing ACEi/ARB dose from 50 to 100% target dose was independently associated with improved survival (adjusted HR 0.74 [95% CI 0.63-0.87]). Similar improvement in mortality was seen with up-titration of beta-blockers (adjusted HR 0.79 [0.65-0.93]). Significant predictors associated with improved survival included younger age, systolic blood pressure in the range 100-120 mmHg, absence of comorbidities including chronic renal failure and peripheral vascular disease, and care by a multidisciplinary specialist clinic. CONCLUSIONS: This study, whilst predating angiotensin receptor-neprilysin inhibitor and sodium-glucose cotransporter 2 inhibitor use, confirms the importance of achieving maximal tolerated doses of ACEi/ARB and beta-blocker therapy, to maximise associated prognostic benefits in a real-world population. Our findings also highlight the need for continued focus on up-titration of these therapies in the ambulatory setting, and the benefits of a multidisciplinary approach. CI - (c) 2025. The Author(s). FAU - Li, Joule J AU - Li JJ AD - Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, SA, Australia. Joule.Li@sa.gov.au. AD - Department of General Medicine, Central Adelaide Local Health Network, Adelaide, SA, Australia. Joule.Li@sa.gov.au. AD - Adelaide Institute for Sleep Health and FHMRI Sleep Health, BEDFORD PARK, Flinders University, Adelaide, SA, Australia. Joule.Li@sa.gov.au. AD - Consultant Physician, General and Acute Care Medicine, Central Adelaide Local Health Network; Clinical Lecturer,, The University of Adelaide; Adjunct Associate Lecturer, Flinders University, Adelaide, Australia. Joule.Li@sa.gov.au. FAU - Parajuli, Daya Ram AU - Parajuli DR AD - Department of Public Health, Torrens University Australia, Adelaide, SA, Australia. FAU - Brown, James AU - Brown J AD - Discipline of Paediatrics, Adelaide Medical School, Robinson Research Institute, The University of Adelaide, Adelaide, SA, Australia. FAU - Eng-Frost, Joanne AU - Eng-Frost J AD - Department of Cardiology, Flinders Medical Centre, BEDFORD PARK, Adelaide, SA, Australia. AD - College of Medicine and Public Health, BEDFORD PARK, Flinders University, Adelaide, SA, Australia. FAU - Scherer, Daniel AU - Scherer D AD - Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, SA, Australia. AD - Department of Cardiology, Central Adelaide Local Health Network, Adelaide, SA, Australia. FAU - Shakib, Sepehr AU - Shakib S AD - Department of Clinical Pharmacology, School of Biomedicine, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, Australia. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20251027 PL - England TA - BMC Cardiovasc Disord JT - BMC cardiovascular disorders JID - 100968539 RN - 0 (Angiotensin-Converting Enzyme Inhibitors) RN - 0 (Adrenergic beta-Antagonists) RN - 0 (Angiotensin Receptor Antagonists) SB - IM MH - Humans MH - Male MH - Female MH - Retrospective Studies MH - Aged MH - *Heart Failure/drug therapy/mortality/physiopathology/diagnosis MH - *Stroke Volume/drug effects MH - *Angiotensin-Converting Enzyme Inhibitors/administration & dosage/adverse effects MH - *Adrenergic beta-Antagonists/administration & dosage/adverse effects MH - *Angiotensin Receptor Antagonists/administration & dosage/adverse effects MH - Middle Aged MH - Treatment Outcome MH - Aged, 80 and over MH - Risk Factors MH - Time Factors MH - *Ventricular Function, Left/drug effects MH - Maximum Tolerated Dose MH - South Australia/epidemiology MH - Risk Assessment PMC - PMC12557942 OTO - NOTNLM OT - Angiotensin receptor blockers OT - Beta blockers OT - Heart failure OT - Maximal tolerated dose OT - Target dose COIS- Declarations. Ethics approval and consent to participate: was obtained from the Royal Adelaide Hospital Human Ethics Research Committee (R20161105). The need for informed consent to participate was waived by the Royal Adelaide Hospital Human Ethics Research Committee. Consent for publication: Not applicable. Consent to participate: declaration: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2025/10/28 06:29 MHDA- 2025/10/28 06:30 PMCR- 2025/10/27 CRDT- 2025/10/28 00:54 PHST- 2024/09/25 00:00 [received] PHST- 2025/08/04 00:00 [accepted] PHST- 2025/10/28 06:30 [medline] PHST- 2025/10/28 06:29 [pubmed] PHST- 2025/10/28 00:54 [entrez] PHST- 2025/10/27 00:00 [pmc-release] AID - 10.1186/s12872-025-05104-w [pii] AID - 5104 [pii] AID - 10.1186/s12872-025-05104-w [doi] PST - epublish SO - BMC Cardiovasc Disord. 2025 Oct 27;25(1):768. doi: 10.1186/s12872-025-05104-w. PMID- 41144096 OWN - NLM STAT- MEDLINE DCOM- 20251027 LR - 20260917 IS - 1546-9549 (Electronic) IS - 1546-9530 (Print) IS - 1546-9530 (Linking) VI - 22 IP - 1 DP - 2025 Oct 27 TI - Evaluation and Management Principles for Chronic Right Heart Failure and Tricuspid Regurgitation. PG - 32 LID - 10.1007/s11897-025-00720-1 [doi] LID - 32 AB - PURPOSE OF THE REVIEW: This review provides an updated summary of the evaluation and management principles of chronic right heart failure (RHF) and tricuspid regurgitation (TR), with a focus on evolving diagnostic approaches and the role of transcatheter tricuspid valve interventions (TTVI). RECENT FINDINGS: Chronic RHF and TR frequently coexist and are associated with significant morbidity and mortality. Their interplay is both complex and bidirectional. TR leads to right ventricular (RV) volume overload, while RV remodeling in RHF promotes TR progression, primarily through annular dilatation and leaflet tethering. Advances in imaging modalities, including 3D echocardiography and cardiac magnetic resonance, have improved the evaluation of RV function and TR severity. Additionally, a refined TR grading system, now encompassing "massive" and "torrential" categories, enables more precise severity classification, which is particularly important for evaluating treatment response in device trials. Early identification of TR and RHF is crucial, and optimal management relies on understanding the underlying mechanisms, disease progression, and available treatment options. Although medical therapy for RHF and TR remains limited, TTVI offers an emerging alternative for selected patients. However, identifying appropriate candidates and the optimal timing for intervention remain key challenges. Timely diagnosis of RHF and TR, identification of the underlying causes, and comprehensive risk stratification, along with early referral to a multidisciplinary heart team, are critical for optimizing patient outcomes. Further research is needed to better define selection criteria and timing for TTVI. CI - (c) 2025. The Author(s). FAU - Sampath-Kumar, Revathy AU - Sampath-Kumar R AD - Department of Cardiovascular Medicine, University of California, La Jolla, San Diego, CA, USA. FAU - Ruck, Andreas AU - Ruck A AD - Division of Cardiology, Department of Medicine, Karolinska Institutet, Solna, S1:02, 171 76, Stockholm, Sweden. AD - Heart and Vascular Theme, Karolinska University Hospital, Stockholm, Sweden. FAU - Manouras, Aristomenis AU - Manouras A AD - Division of Cardiology, Department of Medicine, Karolinska Institutet, Solna, S1:02, 171 76, Stockholm, Sweden. AD - Heart and Vascular Theme, Karolinska University Hospital, Stockholm, Sweden. FAU - Ben-Yehuda, Ori AU - Ben-Yehuda O AD - Department of Cardiovascular Medicine, University of California, La Jolla, San Diego, CA, USA. FAU - Lund, Lars H AU - Lund LH AD - Division of Cardiology, Department of Medicine, Karolinska Institutet, Solna, S1:02, 171 76, Stockholm, Sweden. AD - Heart and Vascular Theme, Karolinska University Hospital, Stockholm, Sweden. FAU - Shahim, Bahira AU - Shahim B AD - Division of Cardiology, Department of Medicine, Karolinska Institutet, Solna, S1:02, 171 76, Stockholm, Sweden. bahira.shahim@ki.se. AD - Heart and Vascular Theme, Karolinska University Hospital, Stockholm, Sweden. bahira.shahim@ki.se. LA - eng PT - Journal Article PT - Review DEP - 20251027 PL - United States TA - Curr Heart Fail Rep JT - Current heart failure reports JID - 101196487 SB - IM MH - Humans MH - *Tricuspid Valve Insufficiency/diagnosis/therapy/complications/physiopathology/surgery MH - *Heart Failure/diagnosis/therapy/physiopathology/complications MH - Chronic Disease MH - *Disease Management PMC - PMC12559073 OTO - NOTNLM OT - Imaging OT - Intervention OT - Management OT - Right heart failure OT - Tricuspid regurgitation COIS- Declarations. Human and Animal Rights and Informed Consent statement: This article does not contain any studies with human or animal subjects performed by any of the authors. Competing interests: The authors declare no competing interests. EDAT- 2025/10/27 18:25 MHDA- 2025/10/27 18:26 PMCR- 2025/10/27 CRDT- 2025/10/27 12:20 PHST- 2025/07/29 00:00 [received] PHST- 2025/10/08 00:00 [accepted] PHST- 2025/10/27 18:26 [medline] PHST- 2025/10/27 18:25 [pubmed] PHST- 2025/10/27 12:20 [entrez] PHST- 2025/10/27 00:00 [pmc-release] AID - 10.1007/s11897-025-00720-1 [pii] AID - 720 [pii] AID - 10.1007/s11897-025-00720-1 [doi] PST - epublish SO - Curr Heart Fail Rep. 2025 Oct 27;22(1):32. doi: 10.1007/s11897-025-00720-1. PMID- 41142716 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251027 LR - 20251029 IS - 2468-4481 (Electronic) IS - 2468-4481 (Linking) VI - 10 IP - 10 DP - 2025 Oct TI - Transcutaneous closure of an enterocutaneous fistula using a cardiac septal occluder. PG - 535-539 LID - 10.1016/j.vgie.2025.05.006 [doi] AB - BACKGROUND AND AIMS: Enterocutaneous fistula (ECF) is an abnormal connection between the gastrointestinal tract and skin, often managed surgically with a recent shift toward endoscopic closure. We are presenting a case highlighting the off-label use of a septal occluder, placed transcutaneously under fluoroscopy, for the closure of an ECF. METHODS: We are presenting a case of a 61-year-old woman with a history of metastatic colon cancer status post sigmoid resection with loop ileostomy and palliative chemotherapy. Her course was complicated by ECF with high-volume leakage. She was deemed not a surgical candidate and failed glue injections and surgical interventions. RESULTS: Endoscopy including anterograde and retrograde single balloon enteroscopy failed to reach the fistula site. The patient underwent fluoroscopic ECF closure with off-label use of a septal occluder device. CONCLUSIONS: We report a successful off-label use of a septal occluder for the closure of a refractory ECF under fluoroscopic guidance with emphasis on the importance of a multidisciplinary approach and the exploration of innovative solutions in challenging clinical scenarios. CI - (c) 2025 American Society for Gastrointestinal Endoscopy. Published by Elsevier Inc. FAU - Nimri, Faisal AU - Nimri F AD - Gastroenterology, Henry Ford Hospital, Detroit, Michigan, USA. FAU - Kadouh, Ali AU - Kadouh A AD - Gastroenterology, Henry Ford Hospital, Detroit, Michigan, USA. FAU - Jamali, Taher AU - Jamali T AD - Gastroenterology, Henry Ford Hospital, Detroit, Michigan, USA. FAU - Chavarria-Viales, Maria AU - Chavarria-Viales M AD - Gastroenterology, Henry Ford Hospital, Detroit, Michigan, USA. FAU - Piraka, Cyrus AU - Piraka C AD - Gastroenterology, Henry Ford Hospital, Detroit, Michigan, USA. FAU - Zuchelli, Tobias AU - Zuchelli T AD - Gastroenterology, Henry Ford Hospital, Detroit, Michigan, USA. LA - eng PT - Journal Article DEP - 20250602 PL - United States TA - VideoGIE JT - VideoGIE : an official video journal of the American Society for Gastrointestinal Endoscopy JID - 101719677 PMC - PMC12546728 COIS- The following authors disclosed financial relationships: T. Zuchelli: Consultant for Boston Scientific. C. Piraka: Recipient of study funding from Aries and US Endoscopy. All other authors disclosed no financial relationships. EDAT- 2025/10/27 13:29 MHDA- 2025/10/27 13:30 PMCR- 2025/06/02 CRDT- 2025/10/27 07:21 PHST- 2025/02/11 00:00 [received] PHST- 2025/05/15 00:00 [accepted] PHST- 2025/10/27 13:30 [medline] PHST- 2025/10/27 13:29 [pubmed] PHST- 2025/10/27 07:21 [entrez] PHST- 2025/06/02 00:00 [pmc-release] AID - S2468-4481(25)00136-5 [pii] AID - 10.1016/j.vgie.2025.05.006 [doi] PST - epublish SO - VideoGIE. 2025 Jun 2;10(10):535-539. doi: 10.1016/j.vgie.2025.05.006. eCollection 2025 Oct. PMID- 41141452 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251027 LR - 20251029 IS - 2328-8957 (Print) IS - 2328-8957 (Electronic) IS - 2328-8957 (Linking) VI - 12 IP - 10 DP - 2025 Oct TI - Infective Endocarditis and Antimicrobial Timing: A Case for Delay? PG - ofaf628 LID - 10.1093/ofid/ofaf628 [doi] LID - ofaf628 AB - BACKGROUND: In patients with suspected infective endocarditis (IE), current guidelines recommend prompt initiation of empiric antimicrobial treatment after obtaining blood cultures. However, the clinical benefit of immediate treatment in hemodynamically stable patients remains uncertain. This study assessed the impact of deferring antimicrobial treatment in patients with suspected IE. METHODS: We conducted a multicenter cohort study of adult patients with bacteremia and clinical suspicion of IE from 2 university hospitals (2015-24). Patients presenting with sepsis, intensive care unit admission, neutropenia, or a clearly identifiably focus other than IE were excluded. All cases were adjudicated by a dedicated Endocarditis Team as either IE or not IE. The primary outcome for all episodes was 30-day mortality; for confirmed IE cases, the composite outcome included 30-day mortality, new embolic events, or new bone and joint infection. RESULTS: Among 1230 episodes, empirical antimicrobial treatment was initiated immediately (Group I) after blood culture collection in 675 episodes (55%) and deferred until preliminary blood culture results (Group D) in 555 episodes (45%). Thirty-day mortality was 5% (59 episodes), with no difference between Groups I and D (5% vs 5%; P = .894). Of 597 confirmed IE episodes (49%) IE, 327 (55%) were in Group I and 270 (45%) in Group D. The composite primary endpoint occurred in 157 episodes (26%), with no difference between groups (28% vs 24%; P = .304). CONCLUSIONS: In clinically stable patients with suspected IE, deferring antimicrobial treatment until available blood culture results was not associated with worse clinical outcomes. CI - (c) The Author(s) 2025. Published by Oxford University Press on behalf of Infectious Diseases Society of America. FAU - Stavropoulou, Elisavet AU - Stavropoulou E AUID- ORCID: 0000-0002-8299-9035 AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Ledergerber, Bruno AU - Ledergerber B AUID- ORCID: 0000-0002-6881-4401 AD - Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich and University of Zurich, Zurich, Switzerland. FAU - Fourre, Nicolas AU - Fourre N AUID- ORCID: 0009-0006-1660-9365 AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Zimmermann, Virgile AU - Zimmermann V AUID- ORCID: 0009-0005-1812-0216 AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Epprecht, Jana AU - Epprecht J AUID- ORCID: 0000-0003-3277-7044 AD - Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich and University of Zurich, Zurich, Switzerland. FAU - Ianculescu, Nicoleta AU - Ianculescu N AD - Department of Cardiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Monney, Pierre AU - Monney P AUID- ORCID: 0000-0002-3083-7333 AD - Department of Cardiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Tzimas, Georgios AU - Tzimas G AUID- ORCID: 0000-0002-2810-8887 AD - Department of Cardiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Frank, Michelle AU - Frank M AD - Department of Cardiology, University Hospital Zurich and University of Zurich, Zurich, Switzerland. FAU - Senn, Laurence AU - Senn L AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. AD - Infection Prevention and Control Unit, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Niclauss, Lars AU - Niclauss L AD - Department of Cardiac Surgery, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Kirsch, Matthias AU - Kirsch M AD - Department of Cardiac Surgery, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Van Hemelrijck, Mathias AU - Van Hemelrijck M AUID- ORCID: 0000-0002-0191-757X AD - Department of Cardiac Surgery, University Hospital Zurich and University of Zurich, Zurich, Switzerland. FAU - Dzemali, Omer AU - Dzemali O AUID- ORCID: 0000-0001-7910-5152 AD - Department of Cardiac Surgery, University Hospital Zurich and University of Zurich, Zurich, Switzerland. AD - Department of Cardiac Surgery, City Hospital of Zurich-Triemli, Zurich, Switzerland. AD - Center for Experimental and Translational Cardiology, University of Zurich, Zurich, Switzerland. FAU - Guery, Benoit AU - Guery B AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Hasse, Barbara AU - Hasse B AUID- ORCID: 0000-0001-7196-3734 AD - Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich and University of Zurich, Zurich, Switzerland. FAU - Papadimitriou-Olivgeris, Matthaios AU - Papadimitriou-Olivgeris M AUID- ORCID: 0000-0003-0565-5105 AD - Infectious Diseases Service, Hospital of Valais and Institut Central des Hopitaux, Sion, Switzerland. LA - eng PT - Journal Article DEP - 20251007 PL - United States TA - Open Forum Infect Dis JT - Open forum infectious diseases JID - 101637045 PMC - PMC12548369 OTO - NOTNLM OT - Staphylococcus aureus OT - antimicrobial treatment OT - bloodstream infection OT - empiric treatment OT - infective endocarditis COIS- Potential conflicts of interest. All authors: No reported conflicts. EDAT- 2025/10/27 13:29 MHDA- 2025/10/27 13:30 PMCR- 2025/10/07 CRDT- 2025/10/27 07:06 PHST- 2025/07/28 00:00 [received] PHST- 2025/09/29 00:00 [accepted] PHST- 2025/10/27 13:30 [medline] PHST- 2025/10/27 13:29 [pubmed] PHST- 2025/10/27 07:06 [entrez] PHST- 2025/10/07 00:00 [pmc-release] AID - ofaf628 [pii] AID - 10.1093/ofid/ofaf628 [doi] PST - epublish SO - Open Forum Infect Dis. 2025 Oct 7;12(10):ofaf628. doi: 10.1093/ofid/ofaf628. eCollection 2025 Oct. PMID- 41141179 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251027 LR - 20251029 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 17 IP - 9 DP - 2025 Sep TI - Assessment of the Quality of Life of Saudi Patients in Pharmacist-Led Heart Failure Clinics: A Cross-Sectional Observational Study. PG - e92887 LID - 10.7759/cureus.92887 [doi] LID - e92887 AB - Objectives Heart failure (HF) is a global health challenge with high morbidity and mortality, significantly impacting patients' quality of life (QOL). The QOL of Saudi patients, who were treated in the pharmacist-led HF clinics, is unknown. This study aims to evaluate HF patients' QOL using the validated Kansas City Cardiomyopathy Questionnaire (KCCQ-12). Methods A cross-sectional observational study was conducted with 111 randomly selected HF patients. QOL was assessed using the KCCQ-12, which encompasses domains evaluating physical limitations, HF-specific symptoms (swelling, shortness of breath (SOB), and fatigue), QOL, and social impact, with a score ranging from 0 (poorest health) to 100 (best health). The interpretation of health status is based on the overall summary KCCQ score as follows: very poor to poor (0-24), poor to fair (25-49), fair to good (50-74), and good to excellent (75-100). Results Overall, the highest score was in symptom frequency (82.7), indicating a few symptoms. The score for the dimension Social Limitation was 79.4, reflecting minimal social restrictions, while that for Physical Limitation was 71.7, indicating moderate physical activity limitations. The reported QOL score was 68.9, reflecting their fair to good QOL. The summary score was 75.4, reflecting an overall positive QOL assessment. The distribution of pharmacist interventions included the following: patient counseling was performed in 111 (100%) of cases, while the guideline-directed medical therapy (GDMT) monitoring follow-up was done for 58 (52.25%) of patients, and the initiation and titration of GDMT were conducted in 52 (46.85%) and 41 (36.94%) of cases, respectively. There is a weak positive correlation (rho=0.183) between the KCCQ-12 Summary Score and the total number of interventions received by patients, with a p-value of 0.056. This suggests a trend where an increased number of interventions may be associated with a slightly higher QOL, although this correlation is not statistically significant (p>0.05). Conclusion Based on the KCCQ findings, this study demonstrates the significant influence of clinical pharmacist interventions on the HF patient's QOL, which identifies the importance of HF clinics run by a cardiology clinical pharmacist within a multidisciplinary team. CI - Copyright (c) 2025, Alsryea et al. FAU - Alsryea, Aseel A AU - Alsryea AA AD - Pharmaceutical Care Administration, Armed Forces Hospital Southern Region, Khamis Mushayt, SAU. FAU - Alhomoud, Ali M AU - Alhomoud AM AD - Pharmacy Service Department, King Faisal Hospital and Research Center, Jeddah, SAU. FAU - Abbadi, Abdu J AU - Abbadi AJ AD - Pharmaceutical Care Administration, Armed Forces Hospital Southern Region, Khamis Mushayt, SAU. FAU - Ajibi, Ahmed O AU - Ajibi AO AD - Pharmaceutical Care Administration, Najran Armed Forces Hospital, Najran, SAU. FAU - Judayba, Amjad A AU - Judayba AA AD - Pharmaceutical Care Administration, Armed Forces Hospital Southern Region, Khamis Mushayt, SAU. FAU - Harbi, Noura Y AU - Harbi NY AD - Pharmaceutical Care Administration, Najran Armed Forces Hospital, Khamis Mushayt, SAU. FAU - Almutairi, Amal A AU - Almutairi AA AD - Nursing Administration, Prince Sultan Cardiac Center, Riyadh, SAU. FAU - Ageeli, Khalid A AU - Ageeli KA AD - Pharmaceutical Care Administration, Armed Forces Hospital Southern Region, Khamis Mushayt, SAU. FAU - Alodhaib, Raneem A AU - Alodhaib RA AD - Nursing Administration, Prince Sultan Cardiac Center, Riyadh, SAU. FAU - Hakami, Ziyad E AU - Hakami ZE AD - College of Pharmacy, Jazan University, Jazan, SAU. FAU - Alasmari, Ali T AU - Alasmari AT AD - Pharmaceutical Care Administration, Armed Forces Hospital Southern Region, Khamis Mushayt, SAU. FAU - Alghubayri, Ibrahim Y AU - Alghubayri IY AD - Pharmacy Department, King Fahad Specialist Hospital, Dammam, SAU. LA - eng PT - Journal Article DEP - 20250921 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC12547608 OTO - NOTNLM OT - cross-sectional OT - heart failure OT - hf OT - qol OT - quality of life COIS- Human subjects: Informed consent for treatment and open access publication was obtained or waived by all participants in this study. Prince Sultan Military Medical City issued approval C-0005. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. EDAT- 2025/10/27 15:17 MHDA- 2025/10/27 15:18 PMCR- 2025/09/21 CRDT- 2025/10/27 07:03 PHST- 2025/09/21 00:00 [accepted] PHST- 2025/10/27 15:18 [medline] PHST- 2025/10/27 15:17 [pubmed] PHST- 2025/10/27 07:03 [entrez] PHST- 2025/09/21 00:00 [pmc-release] AID - 10.7759/cureus.92887 [doi] PST - epublish SO - Cureus. 2025 Sep 21;17(9):e92887. doi: 10.7759/cureus.92887. eCollection 2025 Sep. PMID- 41135791 OWN - NLM STAT- MEDLINE DCOM- 20251208 LR - 20251208 IS - 1879-1913 (Electronic) IS - 0002-9149 (Linking) VI - 258 DP - 2026 Jan 1 TI - Heart Failure With Preserved Ejection Fraction and Chronic Kidney Disease: From Pathophysiology to Treatment. PG - 287-301 LID - S0002-9149(25)00644-7 [pii] LID - 10.1016/j.amjcard.2025.10.013 [doi] AB - Heart failure with preserved ejection fraction (HFpEF) is an increasingly prevalent subtype of heart failure. It is characterized by a heterogeneous clinical phenotype, a less understood pathophysiology, and multifactorial etiologies. A frequent comorbidity of HFpEF is chronic kidney disease (CKD). The cardiorenal phenotype in HFpEF is growing in prevalence and represents a high-risk clinical population. HFpEF and CKD are interconnected through complex, bidirectional processes involving systemic inflammation, neurohormonal activation, hemodynamic changes, and iron deficiency. These overlapping processes, along with common risk factors, exacerbate disease presentation and progression, contributing to significantly worse outcomes, including higher rates of hospitalization, mortality, and progression to end-stage kidney disease. Historically, treatment options for HFpEF have been limited, but recent studies have identified agents with both cardiovascular and renal benefits. Emerging therapies, such as SGLT2 inhibitors, nonsteroidal MRAs, and GLP-1 receptor agonists, offer a new hope for improving outcomes in the HFpEF cardiorenal population. However, challenges related to diagnosis, volume and potassium management, and barriers such as underdiagnosis and undertreatment still remain. An integrative, multidisciplinary approach is essential for effectively managing patients with both HFpEF and CKD. CI - Copyright (c) 2025 Elsevier Inc. All rights reserved. FAU - Grilo, Rita Micaelo AU - Grilo RM AD - Faculty of Medicine, University of Lisbon, Portugal. FAU - Falcao, L Menezes AU - Falcao LM AD - Faculty of Medicine, University of Lisbon, Cardiovascular Center University of Lisbon (CCUL@RISE), Portugal. Electronic address: luizmfalcao@sapo.pt. LA - eng PT - Journal Article PT - Review DEP - 20251022 PL - United States TA - Am J Cardiol JT - The American journal of cardiology JID - 0207277 SB - IM MH - Humans MH - *Stroke Volume/physiology MH - *Renal Insufficiency, Chronic/physiopathology/complications/therapy/epidemiology MH - *Heart Failure/physiopathology/therapy/complications/epidemiology OTO - NOTNLM OT - CKD OT - HFpEF OT - cardiorenal OT - heart failure OT - preserved ejection fraction COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/10/25 00:30 MHDA- 2025/12/09 00:32 CRDT- 2025/10/24 19:39 PHST- 2025/08/06 00:00 [received] PHST- 2025/10/03 00:00 [revised] PHST- 2025/10/08 00:00 [accepted] PHST- 2025/12/09 00:32 [medline] PHST- 2025/10/25 00:30 [pubmed] PHST- 2025/10/24 19:39 [entrez] AID - S0002-9149(25)00644-7 [pii] AID - 10.1016/j.amjcard.2025.10.013 [doi] PST - ppublish SO - Am J Cardiol. 2026 Jan 1;258:287-301. doi: 10.1016/j.amjcard.2025.10.013. Epub 2025 Oct 22. PMID- 41133091 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251024 LR - 20251027 IS - 2050-3121 (Print) IS - 2050-3121 (Electronic) IS - 2050-3121 (Linking) VI - 13 DP - 2025 TI - Acute heart failure in patients with hematologic malignancies: A nationwide analysis 2016-2021. PG - 20503121251370940 LID - 10.1177/20503121251370940 [doi] LID - 20503121251370940 AB - BACKGROUND: Acute heart failure affects ~9% of patients with hematological malignancies. This study aimed to evaluate the impact of acute heart failure on in-hospital mortality among patients with hematological malignancies and to identify independent predictors of mortality in this population. METHODS: The National Inpatient Sample (2016-2021) was queried for adults (⩾18 years of age) with hematological malignancies and those who experienced in-hospital mortality. Among these, we identified patients who were hospitalized with a diagnosis of acute heart failure. Univariate analysis and multivariate regression were employed to analyze the mortality risk. A p ⩽ 0.05 was considered significant. RESULTS: Among 40,246 patients with hematological malignancies who died in the hospital, the univariate analysis showed a higher in-hospital mortality in the acute heart failure cohort compared to the non-acute heart failure group (8.08% versus 4.52%, p < 0.001). However, after adjusting for sociodemographic factors and comorbidities, acute heart failure was associated with a lower risk of in-hospital mortality (OR 0.87, 95% CI 0.84-0.9, p < 0.001). Predictors of mortality in the acute heart failure cohort were age >60 years, hematopoietic stem cell transplant, severe sepsis, arrhythmias, infective endocarditis, bleeding from any source, acute respiratory failure, hepatic dysfunction, metabolic encephalopathy, and invasive ventilation (all p < 0.01). On subgroup analysis, acute myeloid leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, and multiple myeloma had a higher in-hospital mortality in the acute heart failure cohort compared to the non-acute heart failure group (p < 0.001). CONCLUSION: Acute heart failure in patients with hematological malignancies was associated with poor outcomes in the presence of severe sepsis, organ dysfunction, and the need for mechanical ventilation. Close monitoring and a multidisciplinary team approach are recommended to optimize the treatment plan for this population. CI - (c) The Author(s) 2025. FAU - Prashanth Sivasubramanian, Barath AU - Prashanth Sivasubramanian B AD - Department of Internal Medicine, Northeast Georgia Medical Center, Gainesville, GA, USA. FAU - Ravikumar, Diviya Bharathi AU - Ravikumar DB AUID- ORCID: 0000-0002-6018-5647 AD - Department of Internal Medicine, ESIC Medical College and Postgraduate Institute of Medical Science and Research, Chennai, Tamil Nadu, India. FAU - Yarrarapu, Siva Naga S AU - Yarrarapu SNS AD - Geriatric Medicine, University of Texas Health Science Center at San Antonio, TX, USA. FAU - Saravanabavanandan, Ragavendar AU - Saravanabavanandan R AD - Department of Internal Medicine, University of Illinois College of Medicine Peoria (UICOMP), IL, USA. FAU - Sharieff, Ibthisam Ismail AU - Sharieff II AD - Department of Internal Medicine, ESIC Medical College and Postgraduate Institute of Medical Science and Research, Chennai, Tamil Nadu, India. FAU - Joshi, Shashvat AU - Joshi S AD - Department of Internal Medicine, Fudan University, Shanghai, China. FAU - Karunakar, Deepthi AU - Karunakar D AD - Department of Internal Medicine, Pondicherry Institute of Medical Sciences, India. FAU - Vairavan, Visalakshi Kannathal AU - Vairavan VK AD - Institute of Fundamental Medicine and Biology, Kazan Federal University, Republic of Tatarstan. FAU - Balamurugan, Indrajith Devandra AU - Balamurugan ID AD - School of Basic Medical Sciences, Tianjin Medical University, Heping District, P.R. China. FAU - Thirupathy, Umabalan AU - Thirupathy U AD - Department of Medicine, Saint Vincent Hospital, Keene, NH, USA. FAU - Venkata, Vikramaditya Samala AU - Venkata VS AD - Hospital Medicine Division, Cheshire Medical Center/Dartmouth-Hitchcock, Keene, NH, USA. FAU - Garg, Yash AU - Garg Y AD - Northeast Georgia Medical Center, New York, NY, USA. FAU - Ghosh, Aditya Kumar AU - Ghosh AK AD - Division of General Internal Medicine, Mayo Clinic, Rochester, MN, USA. LA - eng PT - Journal Article DEP - 20251017 PL - England TA - SAGE Open Med JT - SAGE open medicine JID - 101624744 PMC - PMC12541186 OTO - NOTNLM OT - AML OT - BCR/ABL OT - CLL OT - CML OT - heart failure OT - leukemia OT - mortality OT - multiple myeloma OT - sepsis COIS- The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2025/10/24 06:26 MHDA- 2025/10/24 06:27 PMCR- 2025/10/17 CRDT- 2025/10/24 04:56 PHST- 2025/05/02 00:00 [received] PHST- 2025/08/07 00:00 [accepted] PHST- 2025/10/24 06:27 [medline] PHST- 2025/10/24 06:26 [pubmed] PHST- 2025/10/24 04:56 [entrez] PHST- 2025/10/17 00:00 [pmc-release] AID - 10.1177_20503121251370940 [pii] AID - 10.1177/20503121251370940 [doi] PST - epublish SO - SAGE Open Med. 2025 Oct 17;13:20503121251370940. doi: 10.1177/20503121251370940. eCollection 2025. PMID- 41132758 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251024 LR - 20251027 IS - 2296-2360 (Print) IS - 2296-2360 (Electronic) IS - 2296-2360 (Linking) VI - 13 DP - 2025 TI - Artificial intelligence-driven framework for improving prenatal screening for congenital heart disease in rural Nebraska. PG - 1653305 LID - 10.3389/fped.2025.1653305 [doi] LID - 1653305 AB - PURPOSE: Congenital heart disease (CHD) is the most common birth defect and a leading cause of neonatal morbidity and mortality. Despite advances in prenatal imaging, rural communities face persistent disparities in CHD detection due to limited access to specialized diagnostics. This position paper proposes an AI-enabled framework to embed early CHD detection into routine prenatal care and reduce the rural-urban gap in Nebraska. METHOD: A review of 1,502 surgical CHD cases at Children's Nebraska (2019-2024) revealed significant geographic disparities in prenatal detection. In response, we outline a framework that leverages a secure, cloud-based platform to apply AI algorithms to standard obstetric ultrasound images. Flagged cases are referred to nearby fetal cardiology outreach centers, reducing delays associated with centralized tertiary care access. FRAMEWORK: This approach leverages existing infrastructure, including the Children's Nebraska fetal heart center, UNMC's rural residency network, and maternal-fetal medicine collaborations. Implementation will be led by an interdisciplinary team spanning cardiology, Obstetrics, rural health, imaging, and machine learning. CONCLUSION: By decentralizing diagnostics and enabling earlier triaging in community settings, this scalable, accessible framework offers a practical solution for improving prenatal CHD detection in underserved regions, with strong potential for national replication. CI - (c) 2025 Li, Foy, Christensen, Lanik, Wang, Hamill, Delaney and Kumar. FAU - Li, Ling AU - Li L AD - Criss Heart Center, Children's Nebraska, Omaha, NE, United States. AD - Department of Pediatrics, University of Nebraska College of Medicine, Omaha, NE, United States. FAU - Foy, Alex J AU - Foy AJ AD - Criss Heart Center, Children's Nebraska, Omaha, NE, United States. AD - Department of Pediatrics, University of Nebraska College of Medicine, Omaha, NE, United States. FAU - Christensen, Jason T AU - Christensen JT AD - Criss Heart Center, Children's Nebraska, Omaha, NE, United States. AD - Department of Pediatrics, University of Nebraska College of Medicine, Omaha, NE, United States. FAU - Lanik, Aaron AU - Lanik A AD - Department of Family Medicine, University of Nebraska College of Medicine, Omaha, NE, United States. FAU - Wang, Jieqiong AU - Wang J AD - Department of Neurological Sciences, University of Nebraska College of Medicine, Omaha, NE, United States. FAU - Hamill, Neil AU - Hamill N AD - Department of Obstetrics and Gynecology, University of Nebraska College of Medicine, Omaha, NE, United States. FAU - Delaney, Jeffrey W AU - Delaney JW AD - Criss Heart Center, Children's Nebraska, Omaha, NE, United States. AD - Department of Pediatrics, University of Nebraska College of Medicine, Omaha, NE, United States. FAU - Kumar, S Ram AU - Kumar SR AD - Criss Heart Center, Children's Nebraska, Omaha, NE, United States. AD - Department of Surgery, University of Nebraska College of Medicine, Omaha, NE, United States. LA - eng PT - Journal Article DEP - 20251008 PL - Switzerland TA - Front Pediatr JT - Frontiers in pediatrics JID - 101615492 PMC - PMC12541414 OTO - NOTNLM OT - artificial intelligence (AI) OT - congenital heart disease (CHD) OT - healthcare disparities OT - prenatal detection OT - rural health access COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2025/10/24 06:26 MHDA- 2025/10/24 06:27 PMCR- 2025/10/08 CRDT- 2025/10/24 04:52 PHST- 2025/06/24 00:00 [received] PHST- 2025/09/15 00:00 [accepted] PHST- 2025/10/24 06:27 [medline] PHST- 2025/10/24 06:26 [pubmed] PHST- 2025/10/24 04:52 [entrez] PHST- 2025/10/08 00:00 [pmc-release] AID - 10.3389/fped.2025.1653305 [doi] PST - epublish SO - Front Pediatr. 2025 Oct 8;13:1653305. doi: 10.3389/fped.2025.1653305. eCollection 2025. PMID- 41131880 OWN - NLM STAT- MEDLINE DCOM- 20251024 LR - 20251119 IS - 1478-5153 (Electronic) IS - 1362-1017 (Print) IS - 1362-1017 (Linking) VI - 30 IP - 6 DP - 2025 Nov TI - What Evidence is Available on Rapid Response Systems Across Europe? Findings From a Scoping Review. PG - e70217 LID - 10.1111/nicc.70217 [doi] LID - e70217 AB - BACKGROUND: Rapid Response Systems (RRS) aim to implement systematic processes for the early detection and management of emergencies in hospitals. Exploring the current characteristics and organisation of RRS in Europe and evaluating clinical outcomes may help identify areas for improvement. AIM: To provide an overview of the studies conducted in Europe, summarising the characteristics of RRS, their organisational structure and the clinical outcomes documented to date. STUDY DESIGN: A scoping review was conducted according to the framework of Levac and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) guidelines. The review protocol was registered with Open Science Framework (OSF); CINAHL, Cochrane Library, PubMed and Scopus were then searched. Quantitative primary studies about RRS conducted in Europe and published in English were included. RESULTS: Twenty-three studies were found, of which 18 (78.3%) were published in the last 10 years. Eleven (47.8%) aimed to describe the function and activities of RRS, while 12 (52.2%) analysed patient outcomes and two (8.7%) the effectiveness, feasibility and costs of RRS. Heterogeneous organisational patterns of RRS emerged, including terminologies (Medical Emergency Team [MET], Rapid Response Team [RRT], Cardiac Arrest Team [CAT], Critical Care Outreach [CCO]), team composition, availability, activation systems and activities. CONCLUSIONS: The number of RRS studies is increasing, especially to compare their organisational structure under heterogeneous terminologies. Future research should investigate the outcome variations between different RRS structures. In addition, guidelines that standardise the minimum data set in the field of RRS by also introducing registries could increase consistency between European practices and studies. RELEVANCE TO CLINICAL PRACTISE: Knowledge of the current situation of RRS in Europe can serve as a basis for policies and benchmark models to promote better patient care. STUDY REGISTRATION: This scoping review was registered on Open Science Framework (OSF) on 3 August 2024 (https://osf.io/ekb95; https://doi.org/10.17605/OSF.IO/EKB95). CI - (c) 2025 The Author(s). Nursing in Critical Care published by John Wiley & Sons Ltd on behalf of British Association of Critical Care Nurses. FAU - Zamo, Sara AU - Zamo S AUID- ORCID: 0009-0005-7004-1515 AD - Department of Medicine, University of Udine, Udine, Italy. FAU - Fonda, Federico AU - Fonda F AUID- ORCID: 0000-0002-3818-9676 AD - Department of Medicine, University of Udine, Udine, Italy. FAU - Palese, Alvisa AU - Palese A AUID- ORCID: 0000-0002-3508-844X AD - Department of Medicine, University of Udine, Udine, Italy. FAU - Galazzi, Alessandro AU - Galazzi A AUID- ORCID: 0000-0003-0085-7015 AD - Department of Medicine and Surgery, LUM University, Casamassima (Bari), Italy. LA - eng PT - Journal Article PT - Scoping Review PL - England TA - Nurs Crit Care JT - Nursing in critical care JID - 9808649 SB - IM MH - Humans MH - Europe MH - *Hospital Rapid Response Team/organization & administration PMC - PMC12550357 OTO - NOTNLM OT - cardiac arrest team OT - hospital rapid response team OT - in hospital emergency OT - scoping review COIS- The authors declare no conflicts of interest. EDAT- 2025/10/24 06:26 MHDA- 2025/10/24 06:27 PMCR- 2025/10/24 CRDT- 2025/10/24 02:13 PHST- 2025/09/10 00:00 [revised] PHST- 2025/03/21 00:00 [received] PHST- 2025/09/23 00:00 [accepted] PHST- 2025/10/24 06:27 [medline] PHST- 2025/10/24 06:26 [pubmed] PHST- 2025/10/24 02:13 [entrez] PHST- 2025/10/24 00:00 [pmc-release] AID - NICC70217 [pii] AID - 10.1111/nicc.70217 [doi] PST - ppublish SO - Nurs Crit Care. 2025 Nov;30(6):e70217. doi: 10.1111/nicc.70217. PMID- 41128890 OWN - NLM STAT- MEDLINE DCOM- 20251023 LR - 20251027 IS - 1435-2451 (Electronic) IS - 1435-2443 (Print) IS - 1435-2443 (Linking) VI - 410 IP - 1 DP - 2025 Oct 23 TI - Cut from the same cloth? investigating the personality of interventional and surgical cardiovascular specialists. PG - 309 LID - 10.1007/s00423-025-03874-7 [doi] LID - 309 AB - PURPOSE: Considering that the treatment of patients with complex vascular disease requires multidisciplinary collaboration in teams and personality traits can impact team dynamics, we investigated the personality structures of vascular surgeons, cardiothoracic surgeons, and interventional radiologists using the validated big five model. METHODS: A cross-sectional study utilizing the validated Big Five Inventory-2 (BFI-2) questionnaire. Corrected one-way analyses of variance were performed to compare personality domain scores between the specialist groups. Questionnaires were distributed among all Dutch general surgery departments and through the Dutch Societies for Interventional Radiology (NVIR) and Cardiothoracic Surgery (NVT). A total of 224 specialists participated: 78 interventional radiologists (mean age 48.2y, 20.5% female), 41 cardiothoracic surgeons (mean age 49.2y, 26.8% female), and 105 vascular surgeons (mean age 49.9y, 17.1% female). RESULTS: For the personality domains agreeableness and negative emotionality, differences were observed between the three specialist groups, while the scores for open-mindedness, conscientiousness, and extraversion were similar. In particular, cardiothoracic surgeons scored higher on agreeableness (4.13 vs. 4.00; p = .046) relative to interventional radiologists. Vascular surgeons had lower scores on negative emotionality relative to interventional radiologists (2.00 vs. 2.20, p = .007). Differences at the facet-level were present in four of the five personality domains between interventional and surgical specialists, including sub-traits such as compassion, creative imagination, and assertiveness. CONCLUSION: While vascular surgeons, cardiothoracic surgeons, and interventional radiologists are involved in shared cardiovascular care pathways, they display nuanced differences across domains and more granular facets of personality. These findings lay the foundation for studies on self-awareness and interprofessional collaboration in shared clinical pathways through joint understanding of personality in multidisciplinary teams. CI - (c) 2025. The Author(s). FAU - Sier, Vincent Q AU - Sier VQ AD - Department of Surgery, Leiden University Medical Center, Leiden, 2300 RC, the Netherlands. FAU - Verhagen, Merel J AU - Verhagen MJ AD - Department of Surgery, Leiden University Medical Center, Leiden, 2300 RC, the Netherlands. AD - Department of Surgery, Haga Hospital, The Hague, 2545 AA, the Netherlands. FAU - Zegel, Maurits AU - Zegel M AD - Department of Cardiothoracic Surgery, University Medical Center, Groningen, Groningen, 9713 GZ, the Netherlands. FAU - Schmitz, Roderick F AU - Schmitz RF AD - Department of Surgery, Groene Hart Hospital, Gouda, 2800 BB, the Netherlands. FAU - van Rijswijk, Carla S P AU - van Rijswijk CSP AD - Department of Radiology, Leiden University Medical Center, Leiden, 2300 RC, the Netherlands. FAU - van Schaik, Jan AU - van Schaik J AD - Department of Surgery, Leiden University Medical Center, Leiden, 2300 RC, the Netherlands. FAU - Schmidt, Eduard J E T AU - Schmidt EJET AD - Institute of Public Administration, Leiden University, Hague, 2501 EE, the Netherlands. FAU - Hamming, Jaap F AU - Hamming JF AD - Department of Surgery, Leiden University Medical Center, Leiden, 2300 RC, the Netherlands. FAU - Schepers, Abbey AU - Schepers A AD - Department of Surgery, Leiden University Medical Center, Leiden, 2300 RC, the Netherlands. FAU - Wijdh-den Hamer, Inez J AU - Wijdh-den Hamer IJ AD - Department of Cardiothoracic Surgery, University Medical Center, Groningen, Groningen, 9713 GZ, the Netherlands. FAU - Burgmans, Mark C AU - Burgmans MC AD - Department of Radiology, Leiden University Medical Center, Leiden, 2300 RC, the Netherlands. FAU - Hjortnaes, Jesper AU - Hjortnaes J AD - Department of Cardiothoracic Surgery, Leiden University Medical Center, Leiden, 2300 RC, the Netherlands. FAU - van der Vorst, Joost R AU - van der Vorst JR AD - Department of Surgery, Leiden University Medical Center, Leiden, 2300 RC, the Netherlands. j.r.van_der_vorst@lumc.nl. CN - SUPER Consortium LA - eng PT - Journal Article DEP - 20251023 PL - Germany TA - Langenbecks Arch Surg JT - Langenbeck's archives of surgery JID - 9808285 SB - IM MH - Humans MH - Female MH - Cross-Sectional Studies MH - Male MH - Middle Aged MH - *Personality MH - *Surgeons/psychology MH - Surveys and Questionnaires MH - Adult MH - *Thoracic Surgery MH - *Radiology, Interventional MH - *Radiologists/psychology PMC - PMC12549727 OTO - NOTNLM OT - Aortic surgery OT - Aortic team OT - Big five personality OT - Multidisciplinary team OT - Surgeon personality OT - Team dynamics COIS- Declarations. Competing interests: The authors declare no competing interests. FIR - Bobola, Aakin IR - Bobola A FIR - Beetz, I IR - Beetz I FIR - Bessems, M A IR - Bessems MA FIR - Boerma, D IR - Boerma D FIR - De Bruin, J L IR - De Bruin JL FIR - De Jonge, C IR - De Jonge C FIR - Den Hoed, P T IR - Den Hoed PT FIR - Derksen, R J IR - Derksen RJ FIR - Doornebosch, P G IR - Doornebosch PG FIR - Duijff, J W IR - Duijff JW FIR - Engelen, Mpj IR - Engelen M FIR - Evers, D J IR - Evers DJ FIR - Furnee, Ejb IR - Furnee E FIR - Gardenbroek, T J IR - Gardenbroek TJ FIR - Geelkerken, R H IR - Geelkerken RH FIR - Heemskerk, J IR - Heemskerk J FIR - Hellingman, A A IR - Hellingman AA FIR - Hissink, R J IR - Hissink RJ FIR - Hoek, Pen IR - Hoek P FIR - Hoogstins, Ces IR - Hoogstins C FIR - Houwert, R M IR - Houwert RM FIR - Iordens, Git IR - Iordens G FIR - Johannesma, P IR - Johannesma P FIR - Kelder, W IR - Kelder W FIR - Kleinveld, S IR - Kleinveld S FIR - Kruijff, Schelto IR - Kruijff S FIR - Kuipers, M M IR - Kuipers MM FIR - Lardenoije, Jhp IR - Lardenoije J FIR - Levert-Brand, L IR - Levert-Brand L FIR - Lijkwan, M A IR - Lijkwan MA FIR - Logeman, F IR - Logeman F FIR - Meesters, B IR - Meesters B FIR - Molegraaf, M J IR - Molegraaf MJ FIR - Molenkamp, B G IR - Molenkamp BG FIR - Mollers, M IR - Mollers M FIR - Naves, Cclm IR - Naves C FIR - Nijhof, H W IR - Nijhof HW FIR - Pierie, Jpen IR - Pierie J FIR - Schok, T IR - Schok T FIR - Sier, M F IR - Sier MF FIR - Sintenie, J B IR - Sintenie JB FIR - Swijnenburg, R J IR - Swijnenburg RJ FIR - Teijink, Jaw IR - Teijink J FIR - Ten Bosch, J A IR - Ten Bosch JA FIR - Tiernan, J IR - Tiernan J FIR - Van 't Sant, H P IR - Van 't Sant HP FIR - Van Beek, F J IR - Van Beek FJ FIR - Van de Luijtgaarden, K M IR - Van de Luijtgaarden KM FIR - Van den Brand, Jgh IR - Van den Brand J FIR - Van Duijvendijk, P IR - Van Duijvendijk P FIR - Van Eijck, G J IR - Van Eijck GJ FIR - Van Essen, J A IR - Van Essen JA FIR - Van Tongeren, Rbm IR - Van Tongeren R FIR - Van Weel, V IR - Van Weel V FIR - Van Workum, F IR - Van Workum F FIR - Veldman, P IR - Veldman P FIR - Veltkamp, S C IR - Veltkamp SC FIR - Verhoeven, B H IR - Verhoeven BH FIR - Wiersema, A M IR - Wiersema AM FIR - Woltz, S IR - Woltz S FIR - Zeestraten, Ecm IR - Zeestraten E EDAT- 2025/10/23 12:28 MHDA- 2025/10/23 12:29 PMCR- 2025/10/23 CRDT- 2025/10/23 11:14 PHST- 2025/08/16 00:00 [received] PHST- 2025/09/05 00:00 [accepted] PHST- 2025/10/23 12:29 [medline] PHST- 2025/10/23 12:28 [pubmed] PHST- 2025/10/23 11:14 [entrez] PHST- 2025/10/23 00:00 [pmc-release] AID - 10.1007/s00423-025-03874-7 [pii] AID - 3874 [pii] AID - 10.1007/s00423-025-03874-7 [doi] PST - epublish SO - Langenbecks Arch Surg. 2025 Oct 23;410(1):309. doi: 10.1007/s00423-025-03874-7. PMID- 41124747 OWN - NLM STAT- MEDLINE DCOM- 20251201 LR - 20251201 IS - 1878-0326 (Electronic) IS - 1872-4973 (Linking) VI - 81 DP - 2026 Feb TI - Genetic testing after sudden death with negative ancillary investigations: A French prospective study with multidisciplinary collaboration. PG - 103375 LID - S1872-4973(25)00155-3 [pii] LID - 10.1016/j.fsigen.2025.103375 [doi] AB - BACKGROUND: In case of unexplained sudden death, learned societies recommend performing genetic testing on post-mortem biological specimens to search for a potential hereditary genetic cause and implement, with a multidisciplinary team, screening and prevention measures for the deceased's relatives. The aim of this study was to assess the diagnostic contribution of a rigorous multidisciplinary approach (combining autopsy, toxicology, anatomopathology and genetics) in case of unexplained sudden death. METHODS: This was a French, prospective (2008-2020), monocentric cohort study on unexplained sudden death in young subjects (aged 2-50 years). For each case, a rigorous autopsy, and the analysis of anatomopathological, toxicological, and genetic data were performed. Fresh cardiac and brain tissue samples were systematically collected and stored at -80 degrees C. Genetic testing was performed using a targeted panel of 181 genes associated with channelopathies, cardiomyopathies and epilepsy. In negative cases, whole exome sequencing was performed. Exomes analyzed more than two years earlier were also reanalyzed. RESULTS: One or two pathogenic or likely pathogenic (P/LP) variants were identified in 23.5 % (8/34) of patients, and positive toxicology results as well as notable microscopic cardiac anomalies were identified in 25 % (2/8) of them. One or two variants of uncertain significance (VUS) were identified in 35 % (12/34) of patients, of whom 50 % (6/12) had positive toxicology results and 58.3 % (7/12) showed microscopic cardiac anomalies. In addition, 2.9 % (1/34) of patients carried both a pathogenic variant and a VUS in another gene. The identified variants were associated with cardiac, neurological or metabolic disorders, or found in a gene of uncertain significance. Two patients carried pathogenic variants in genes with an uncertain association with sudden death. A total of 20 different genes carried variants of interest (VUS, P/LP variant): KCNH2, SCN5A, RYR2, SNTA1, PRKAG2, AKAP9, GDP1L, TECRL, TRDN, HCN4, ZFHX3, DEPDC5, TANC2, CHRNA2, DCHS1, DMD, EYA4, ACADM, KLF10, SCN7A. CONCLUSION: Our study highlighted the value of extensive genetic testing in case of unexplained sudden death, reinforcing the importance of using a comprehensive, multidisciplinary approach. The presence of multiple genetic variants, minor anatomopathological changes and toxicological factors suggests the complex interplay of contributory mechanisms leading to death. Regular reanalysis of genetic data, combined with close collaboration between forensic pathologists, geneticists and clinicians, is essential to improve diagnostic yield and guide family management. CI - Copyright (c) 2025 Elsevier B.V. All rights reserved. FAU - Osouf, Julien AU - Osouf J AD - Laboratoire de Diagnostic Genetique, Hopitaux Universitaires de Strasbourg, Nouvel Hopital Civil, Strasbourg, France. FAU - Schalk, Audrey AU - Schalk A AD - Laboratoire de Diagnostic Genetique, Hopitaux Universitaires de Strasbourg, Nouvel Hopital Civil, Strasbourg, France. FAU - Schaefer, Elise AU - Schaefer E AD - Service de Genetique Medicale, Institut de Genetique Medicale D'Alsace, Hopitaux Universitaires de Strasbourg, Strasbourg, France. FAU - Calmels, Nadege AU - Calmels N AD - Laboratoire de Diagnostic Genetique, Hopitaux Universitaires de Strasbourg, Nouvel Hopital Civil, Strasbourg, France. FAU - Gonzalez, Angela AU - Gonzalez A AD - Universite de Paris, BABEL, CNRS, Paris 75012, France; Institut de Medecine Legale de Strasbourg, Federation de Medecine Translationnelle de Strasbourg (FMTS), Universite de Strasbourg, 11 Rue Humann, Strasbourg 67000, France. FAU - Tortel, Marie Claire AU - Tortel MC AD - Institut de Medecine Legale de Strasbourg, Federation de Medecine Translationnelle de Strasbourg (FMTS), Universite de Strasbourg, 11 Rue Humann, Strasbourg 67000, France. FAU - Kintz, Pascal AU - Kintz P AD - Institut de Medecine Legale de Strasbourg, Federation de Medecine Translationnelle de Strasbourg (FMTS), Universite de Strasbourg, 11 Rue Humann, Strasbourg 67000, France. FAU - Raul, Jean-Sebastien AU - Raul JS AD - Institut de Medecine Legale de Strasbourg, Federation de Medecine Translationnelle de Strasbourg (FMTS), Universite de Strasbourg, 11 Rue Humann, Strasbourg 67000, France. FAU - Schulth-Bolard, Caroline AU - Schulth-Bolard C AD - Laboratoire de Diagnostic Genetique, Hopitaux Universitaires de Strasbourg, Nouvel Hopital Civil, Strasbourg, France; Laboratoire de Genetique Medicale, Institut de Genetique Medicale d'Alsace, INSERM UMRS_1112, Universite de Strasbourg, Centre de Recherche en Biomedecine de Strasbourg, Strasbourg, France. FAU - Farrugia, Audrey AU - Farrugia A AD - Institut de Medecine Legale de Strasbourg, Federation de Medecine Translationnelle de Strasbourg (FMTS), Universite de Strasbourg, 11 Rue Humann, Strasbourg 67000, France; Institut de Genetique et de Biologie Moleculaire et Cellulaire (IGBMC), Universite de Strasbourg, Illkirch, France. Electronic address: audrey.farrugia@unistra.fr. LA - eng PT - Journal Article DEP - 20251015 PL - Netherlands TA - Forensic Sci Int Genet JT - Forensic science international. Genetics JID - 101317016 SB - IM MH - Humans MH - *Genetic Testing MH - Prospective Studies MH - France MH - Adult MH - Male MH - Middle Aged MH - Female MH - Child, Preschool MH - *Death, Sudden/etiology MH - Child MH - Adolescent MH - Young Adult MH - Exome Sequencing MH - Autopsy MH - Channelopathies/genetics MH - Brain/pathology OTO - NOTNLM OT - Ancillary investigations OT - Autopsy OT - Multidisciplinary collaboration OT - Multifactorial model of sudden death OT - Sudden unexplained death COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/10/22 18:26 MHDA- 2025/12/02 01:00 CRDT- 2025/10/22 18:01 PHST- 2025/07/01 00:00 [received] PHST- 2025/10/08 00:00 [revised] PHST- 2025/10/11 00:00 [accepted] PHST- 2025/12/02 01:00 [medline] PHST- 2025/10/22 18:26 [pubmed] PHST- 2025/10/22 18:01 [entrez] AID - S1872-4973(25)00155-3 [pii] AID - 10.1016/j.fsigen.2025.103375 [doi] PST - ppublish SO - Forensic Sci Int Genet. 2026 Feb;81:103375. doi: 10.1016/j.fsigen.2025.103375. Epub 2025 Oct 15. PMID- 41123378 OWN - NLM STAT- MEDLINE DCOM- 20251204 LR - 20260123 IS - 1529-7535 (Print) IS - 1529-7535 (Linking) VI - 26 IP - 12 DP - 2025 Dec 1 TI - Turnover and Retention of Pediatric Cardiac Critical Care Nurses in the United States: A 2022-2023 Interprofessional Qualitative Analysis. PG - e1491-e1500 LID - 10.1097/PCC.0000000000003840 [doi] AB - OBJECTIVES: Nursing turnover is a significant vulnerability in healthcare systems. Although adult critical care nurses are among the highest group of nurses leaving the workforce, we do not have information about pediatric cardiac critical care (PCCC) nurse turnover. We have, therefore, explored PCCC nursing turnover in focus groups recruited from interprofessional members of the Pediatric Cardiac Intensive Care Society (PCICS). DESIGN: Qualitative descriptive inquiry using focus groups and interviews. SETTING: Interprofessional focus group discussions in 2022-2023. SUBJECTS: Thirty-four participants (representing < 4% of the PCICS membership) were involved in focus groups and interviews. INTERVENTIONS: The transcripts of focus groups/interviews were used to explore perspectives regarding PCCC nurse turnover, its potential impact, and the potential solutions to enhance retention. Content analysis coding was used to identify themes and subcategories to support data interpretation. MEASUREMENTS AND MAIN RESULTS: Data were organized into three main themes: Nursing Turnover, Nursing Retention, and Solutions. For the themes of nursing turnover and nursing retention, there were two subcategories, meaning and impact. All participants reported that increased levels of nursing turnover impacted ICU morale. Higher turnover was also believed to increase patient vulnerability at the bedside, requiring higher levels of surveillance and support from the interprofessional team. Potential solutions to enhance retention included competitive salary and benefits packages, professional development for the multigenerational workforce, and a commitment to a healthy work environment. CONCLUSIONS: In 2022-2023, 34 PCICS members from the United States gave their perspectives and understanding of turnover in PCCC nurses. Nursing turnover and its impact on the team highlights the urgent need to collaboratively identify and implement solutions to enhance nurse retention in this area of highly specialized practice. The PCICS and other such organizations may have a role in addressing nursing shortages and continued turnover. CI - Copyright (c) 2025 by the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies. FAU - Connor, Jean A AU - Connor JA AD - Cardiovascular, Critical Care and Perioperative Services, Boston Children's Hospital, Boston, MA. AD - Department of Pediatrics, Harvard Medical School, Boston, MA. FAU - Fisk, Anna C AU - Fisk AC AD - Department of Cardiology, Boston Children's Hospital, Boston, MA. FAU - Forst, Isabella AU - Forst I AD - Cardiovascular, Critical Care and Perioperative Services, Boston Children's Hospital, Boston, MA. FAU - Engstrand, Shannon AU - Engstrand S AD - Cardiovascular, Critical Care and Perioperative Services, Boston Children's Hospital, Boston, MA. FAU - Diller, Christin AU - Diller C AD - The Heart Institute, Cincinnati Children's Hospital, Cincinnati, OH. FAU - Donnellan, Amy AU - Donnellan A AD - The Heart Institute, Cincinnati Children's Hospital, Cincinnati, OH. FAU - Justice, Lindsey AU - Justice L AD - The Heart Institute, Cincinnati Children's Hospital, Cincinnati, OH. FAU - Jones, Melissa B AU - Jones MB AD - Division of Cardiac Critical Care, Children's National Hospital, Washington, DC. LA - eng PT - Journal Article DEP - 20251021 PL - United States TA - Pediatr Crit Care Med JT - Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies JID - 100954653 SB - IM MH - Humans MH - *Personnel Turnover/statistics & numerical data MH - United States MH - Qualitative Research MH - Focus Groups MH - *Critical Care Nursing/statistics & numerical data MH - Female MH - Adult MH - Male MH - Intensive Care Units, Pediatric MH - *Nursing Staff, Hospital/psychology MH - *Pediatric Nursing MH - Interviews as Topic MH - Middle Aged MH - Attitude of Health Personnel OTO - NOTNLM OT - nurse retention OT - nurse turnover OT - pediatric cardiac critical care nurse OT - pediatric cardiac intensive care unit COIS- Dr. Connor received funding from Boston Children's Hospital. The remaining authors have disclosed that they do not have any potential conflicts of interest. EDAT- 2025/10/22 12:30 MHDA- 2025/12/04 13:38 CRDT- 2025/10/22 09:33 PHST- 2025/12/04 13:38 [medline] PHST- 2025/10/22 12:30 [pubmed] PHST- 2025/10/22 09:33 [entrez] AID - 00130478-202512000-00010 [pii] AID - 10.1097/PCC.0000000000003840 [doi] PST - ppublish SO - Pediatr Crit Care Med. 2025 Dec 1;26(12):e1491-e1500. doi: 10.1097/PCC.0000000000003840. Epub 2025 Oct 21. PMID- 41116997 OWN - NLM STAT- MEDLINE DCOM- 20260108 LR - 20260115 IS - 1600-0609 (Electronic) IS - 0902-4441 (Print) IS - 0902-4441 (Linking) VI - 116 IP - 2 DP - 2026 Feb TI - Cardiovascular Challenges in Chronic Lymphocytic Leukemia (CLL) Patients Undergoing Bruton Tyrosine Kinase (BTK) Inhibitor Therapy. PG - 104-115 LID - 10.1111/ejh.70047 [doi] AB - BACKGROUND/OBJECTIVES: Bruton tyrosine kinase inhibitors (BTKis) have revolutionized treatment for chronic lymphocytic leukemia (CLL), but cardiovascular (CV) toxicities pose significant challenges. Second-generation BTKis offer improved target specificity, yet CV risks persist. This expert opinion review evaluates current evidence and offers guidance for managing BTKi-associated CV events, particularly in patients with comorbidities. METHODS: A hematologist, specialist in CLL, and a cardiologist with specific expertise in managing cardiac complications arising from oncologic therapies conducted a systematic literature review. Subsequently, clinical findings synthesized through multidisciplinary expert discussions led to the development of practical recommendations for CV risk stratification and management in patients with CLL receiving BTKi therapy. RESULTS: Regular CV monitoring is essential for early detection of atrial fibrillation (AF), hypertension, and ventricular arrhythmias. A multidisciplinary approach between hematologists and cardiologists is recommended for comprehensive care. Identifying hematological biomarkers for predicting cardiotoxicity and exploring cardioprotective therapies for high-risk patients should be prioritized. CONCLUSIONS: It is essential to educate healthcare providers about the CV risks associated with BTKis. Additionally, clinical guidelines should be regularly updated to reflect the latest evidence, ensuring effective prevention and management strategies. In patients with a heightened risk of CV complications, the use of second-generation BTKis should be prioritized. Ongoing cardiovascular monitoring is also recommended to reduce the risk of adverse events and minimize treatment discontinuation. CI - (c) 2025 The Author(s). European Journal of Haematology published by John Wiley & Sons Ltd. FAU - Oliva, Stefano AU - Oliva S AD - Cardio-Oncology Unit, IRCCS Istituto Tumori, "Giovanni Paolo II", Bari, Italy. FAU - Molica, Stefano AU - Molica S AUID- ORCID: 0000-0003-2795-6507 AD - Department of Hematology, Hull University Teaching Hospitals NHS Trust, Hull, UK. LA - eng GR - AstraZeneca/ PT - Journal Article PT - Systematic Review DEP - 20251021 PL - England TA - Eur J Haematol JT - European journal of haematology JID - 8703985 RN - 0 (Protein Kinase Inhibitors) RN - EC 2.7.10.2 (Agammaglobulinaemia Tyrosine Kinase) RN - 0 (Antineoplastic Agents) SB - IM MH - Humans MH - *Protein Kinase Inhibitors/adverse effects/therapeutic use MH - *Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy/complications/diagnosis MH - *Agammaglobulinaemia Tyrosine Kinase/antagonists & inhibitors MH - *Cardiovascular Diseases/etiology/diagnosis/therapy MH - Cardiotoxicity/etiology/diagnosis MH - Disease Management MH - *Antineoplastic Agents/adverse effects/therapeutic use PMC - PMC12781150 OTO - NOTNLM OT - Bruton tyrosine kinase inhibitors OT - atrial fibrillation OT - cardiovascular toxicity OT - cardio-oncology OT - chronic lymphocytic leukemia OT - heart failure OT - hypertension OT - risk stratification OT - second-generation BTK inhibitors COIS- Stefano Molica received consulting honoraria from Janssen, Abbvie, and AstraZeneca. Stefano Oliva received consulting honoraria from AstraZeneca. EDAT- 2025/10/21 06:27 MHDA- 2026/01/08 17:53 PMCR- 2026/01/08 CRDT- 2025/10/21 04:12 PHST- 2025/09/24 00:00 [revised] PHST- 2025/07/18 00:00 [received] PHST- 2025/09/26 00:00 [accepted] PHST- 2026/01/08 17:53 [medline] PHST- 2025/10/21 06:27 [pubmed] PHST- 2025/10/21 04:12 [entrez] PHST- 2026/01/08 00:00 [pmc-release] AID - EJH70047 [pii] AID - 10.1111/ejh.70047 [doi] PST - ppublish SO - Eur J Haematol. 2026 Feb;116(2):104-115. doi: 10.1111/ejh.70047. Epub 2025 Oct 21. PMID- 41115284 OWN - NLM STAT- MEDLINE DCOM- 20251117 LR - 20260703 IS - 1539-3704 (Electronic) IS - 0003-4819 (Linking) VI - 178 IP - 11 DP - 2025 Nov TI - Complications Associated With Transvenous Cardiac Implantable Electronic Devices: Recognition and Management : A Narrative Review. PG - 1605-1615 LID - 10.7326/ANNALS-25-02383 [doi] AB - Cardiac implantable electronic devices (CIEDs) have increased the quality and duration of life for millions of patients. As their utilization continues to grow exponentially, clinicians need to diagnose and manage several device-associated complications that may arise during the CIED life cycle. This primer is tailored for the general internal medicine physician or hospitalist, who will inevitably take care of patients with CIEDs, to provide a contemporary update on the incidence and clinical manifestations of the 4 most common CIED complications, with the latest evidence to guide clinical management and expected outcomes. Specifically, this review focuses on: 1) generator/lead failure, which has decreased to less than 1% per year due to continuous advances in manufacturing and programming and is mostly managed conservatively with close monitoring; 2) CIED infections, which, while also rare at approximately 1% per year, carry a short-term mortality of 10% to 20%, thus requiring immediate diagnosis and often urgent treatment with lead extraction because antibiotic treatment is rarely effective; and 3) lead-related venous obstruction, which has highly variable incidence (5% to 30%) and manifestations, ranging from arm swelling to superior vena cava syndrome. Management options range from anticoagulation to balloon venoplasty, often with unsatisfying results. This review will also focus on 4) lead-related tricuspid regurgitation, which affects 20% to 30% of CIEDs and has become an area of intense interest with the development of percutaneous tricuspid treatments-where evidence is urgently needed to inform the need for lead extraction versus jailing during tricuspid interventions. The progressive adoption of leadless devices may significantly reduce many of these complications. Nonetheless, optimal management requires input from a multidisciplinary team of electrophysiologists and imaging, heart failure, and structural interventional specialists-who should be able to recognize and treat each complication promptly based on a rapidly evolving evidence base. FAU - Zimetbaum, Peter J AU - Zimetbaum PJ AD - Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston; and Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts (P.J.Z., E.G.F., E.A.S., D.B.K.). FAU - Ferro, Enrico G AU - Ferro EG AUID- ORCID: 0000-0001-9190-6331 AD - Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston; and Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts (P.J.Z., E.G.F., E.A.S., D.B.K.). FAU - Secemsky, Eric A AU - Secemsky EA AUID- ORCID: 0000-0003-3861-3163 AD - Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston; and Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts (P.J.Z., E.G.F., E.A.S., D.B.K.). FAU - Karchmer, Adolf W AU - Karchmer AW AUID- ORCID: 0000-0001-5113-6395 AD - Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, Massachusetts (A.W.K.). FAU - Kramer, Daniel B AU - Kramer DB AD - Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston; and Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts (P.J.Z., E.G.F., E.A.S., D.B.K.). LA - eng PT - Journal Article PT - Review DEP - 20251021 PL - United States TA - Ann Intern Med JT - Annals of internal medicine JID - 0372351 SB - IM MH - Humans MH - *Defibrillators, Implantable/adverse effects MH - *Pacemaker, Artificial/adverse effects MH - Prosthesis-Related Infections/therapy/diagnosis/etiology MH - Superior Vena Cava Syndrome/etiology/therapy MH - Device Removal COIS- Disclosures: Disclosure forms are available with the article online. EDAT- 2025/10/20 18:29 MHDA- 2025/11/17 18:27 CRDT- 2025/10/20 17:02 PHST- 2025/11/17 18:27 [medline] PHST- 2025/10/20 18:29 [pubmed] PHST- 2025/10/20 17:02 [entrez] AID - 10.7326/ANNALS-25-02383 [doi] PST - ppublish SO - Ann Intern Med. 2025 Nov;178(11):1605-1615. doi: 10.7326/ANNALS-25-02383. Epub 2025 Oct 21. PMID- 41114560 OWN - NLM STAT- MEDLINE DCOM- 20260811 LR - 20260811 IS - 1550-5049 (Electronic) IS - 0889-4655 (Linking) VI - 41 IP - 5 DP - 2026 Sep-Oct 01 TI - Bioelectrical Impedance Vector Analysis Identifies Body Composition Differences by Sex and Functional Class in Individuals With Heart Failure. PG - E253-E260 LID - 10.1097/JCN.0000000000001270 [doi] AB - BACKGROUND: Heart failure often leads to changes in body composition; however, conventional assessment methods struggle to differentiate body components. Bioelectrical impedance vector analysis (BIVA) offers a straightforward measurement, efficient in distinguishing fluid retention from lean mass loss. OBJECTIVE: We aimed to assess body composition and bioelectrical parameters, including BIVA, among individuals with heart failure categorized by New York Heart Association (NYHA) functional classification, and to analyze sex-related differences in BIVA's detection capacity. METHODS: This cross-sectional study included individuals with heart failure categorized according to NYHA functional class. We collected clinical data, anthropometry, bioelectrical impedance, incorporating BIVA. Statistical analysis included tests for normality and variance homogeneity, group comparisons using analysis of variance or Kruskal-Wallis with appropriate post hoc tests, Fisher's exact test for categorical data, and Hotelling's T (2) test for vector analysis. Significance was set at P < .05. RESULTS: Participants with NYHA III/IV had significantly lower values in phase angle ( P = .002) compared with the other groups. BIVA identified statistically significant vector differences between NYHA II and NYHA I groups ( P = .002). Comparison between NYHA I and NYHA II versus NYHA III/IV group ( P < .001 and P = .015, respectively) revealed greater fluid overload in those with more advanced classification. Males in all groups exhibited more pronounced fluid abnormalities, whereas females-especially those in the NYHA III/IV-exhibited with anasarca or obesity, and either reduced body cell mass or hyperhydration. CONCLUSION: BIVA effectively identified body composition variations across NYHA functional classes and between sexes. These findings emphasize the need for a multidisciplinary approach to personalized nutritional management for heart failure. CI - Copyright (c) 2025 Wolters Kluwer Health, LLC. All rights reserved. FAU - Costa da Silva, Isabelli Luara AU - Costa da Silva IL AD - Isabelli Luara Costa da Silva, MSc, RDN Graduate Program in Nutrition, Center for Health Sciences, Federal University of Rio Grande do Norte, Natal, Brazil. FAU - Sena-Evangelista, Karine Cavalcanti Mauricio AU - Sena-Evangelista KCM AD - Karine Cavalcanti Mauricio Sena-Evangelista, PhD, RDN Associate Professor, Graduate Program in Nutrition, Center for Health Sciences, Federal University of Rio Grande do Norte, Natal, Brazil; Department of Nutrition, Center for Health Sciences, Federal University of Rio Grande do Norte, Natal, Brazil; Multiprofessional Residency in Health-Cardiology, Onofre Lopes University Hospital, Federal University of Rio Grande do Norte, Natal, Brazil. FAU - Dantas-Komatsu, Raquel Costa Silva AU - Dantas-Komatsu RCS AD - Raquel Costa Silva Dantas-Komatsu, PhD, RDN Postdoctoral Fellow, Graduate Program in Pharmaceutical Sciences, Center for Health Sciences, Federal University of Rio Grande do Norte, Natal, Brazil. FAU - da Silva, Eduardo Paixao AU - da Silva EP AD - Eduardo Paixao da Silva, MSc, RDN Graduate Program in Public Health, College of Medicine, Federal University of Ceara, Fortaleza, Ceara, Brazil. FAU - Borges, Sabrina Kelly Rodrigues AU - Borges SKR AD - Sabrina Kelly Rodrigues Borges, RDN Multiprofessional Residency in Health-Cardiology, Onofre Lopes University Hospital, Federal University of Rio Grande do Norte, Natal, Brazil. FAU - Avelino, Regina Ranielly Dos Santos AU - Avelino RRDS AD - Regina Ranielly dos Santos Avelino, RDN Multiprofessional Residency in Health-Cardiology, Onofre Lopes University Hospital, Federal University of Rio Grande do Norte, Natal, Brazil. FAU - de Andrade, Fernanda Lambert AU - de Andrade FL AD - Fernanda Lambert de Andrade, MSc, RDN Graduate Program in Collective Health, Center of Biological and Health Sciences, Federal University of Maranhao, Sao Luis, Maranhao, Brazil. FAU - de Lira, Niethia Regina Dantas AU - de Lira NRD AD - Niethia Regina Dantas de Lira, MSc, RDN Dietitian, Brazilian Hospital Services Company, Onofre Lopes University Hospital, Center for Health Sciences, Federal University of Rio Grande do Norte, Natal, Brazil. FAU - Diniz, Rosiane Viana Zuza AU - Diniz RVZ AD - Rosiane Viana Zuza Diniz, PhD, MD Associate Professor, Department of Clinical Medicine, Center for Health Sciences, Federal University of Rio Grande do Norte, Natal, Brazil. FAU - Lopes, Marcia Marilia Gomes Dantas AU - Lopes MMGD AD - Marcia Marilia Gomes Dantas Lopes, PhD, RDN Associate Professor, Department of Nutrition, Center for Health Sciences, Federal University of Rio Grande do Norte, Natal, Rio Grande do Norte, Brazil; Multiprofessional Residency in Health-Cardiology, Onofre Lopes University Hospital, Federal University of Rio Grande do Norte, Natal, Rio Grande do Norte, Brazil. LA - eng PT - Journal Article DEP - 20251020 PL - United States TA - J Cardiovasc Nurs JT - The Journal of cardiovascular nursing JID - 8703516 SB - IM MH - Humans MH - *Heart Failure/physiopathology/classification MH - Male MH - Female MH - *Body Composition/physiology MH - *Electric Impedance MH - Cross-Sectional Studies MH - Sex Factors MH - Aged MH - Middle Aged OTO - NOTNLM OT - bioelectrical impedance OT - body composition OT - heart failure OT - organism hydration status COIS- The authors have no conflicts of interest to disclose. EDAT- 2025/10/20 12:30 MHDA- 2026/08/11 17:36 CRDT- 2025/10/20 08:54 PHST- 2026/08/11 17:36 [medline] PHST- 2025/10/20 12:30 [pubmed] PHST- 2025/10/20 08:54 [entrez] AID - 00005082-990000000-00341 [pii] AID - 10.1097/JCN.0000000000001270 [doi] PST - ppublish SO - J Cardiovasc Nurs. 2026 Sep-Oct 01;41(5):E253-E260. doi: 10.1097/JCN.0000000000001270. Epub 2025 Oct 20. PMID- 41109211 OWN - NLM STAT- MEDLINE DCOM- 20260804 LR - 20260804 IS - 1439-1902 (Electronic) IS - 0171-6425 (Linking) VI - 74 IP - 5 DP - 2026 Aug TI - Surgical Aortic Valve Replacement in Patients Above the Guideline-endorsed Age Cut-off: Reasons for Surgery and Clinical Outcomes. PG - 384-389 LID - 10.1055/a-2724-5108 [doi] AB - OBJECTIVES: The 2017 and 2021 ESC/EACTS guidelines for the management of valvular heart disease recommend transcatheter aortic valve implantation (TAVI) as a treatment option for severe symptomatic aortic valve stenosis (AS) in patients >/=75 years of age. However, surgical aortic valve replacement (SAVR) remains a viable option for elderly patients, particularly in specific anatomical or clinical subsets. The objective of this study was to analyze indications for SAVR and postoperative outcomes in patients >/=75 years of age. METHODS: Heart team protocols were reviewed to determine indications for SAVR. The adjudication of acute procedural and early clinical outcomes was conducted in accordance with the standardized VARC-3 definitions. Furthermore, cardiovascular mortality and rate of aortic valve re-intervention were assessed at latest follow-up with a median duration of 5.5 years (1.9-7.1 years). RESULTS: A total of 43 patients >/=75 years of age (51% male) underwent isolated SAVR at our center between 2017 and 2022. STS/EuroSCORE II was 1.7 +/- 0.6%/1.7 +/- 0.4%. The age distribution of patients was as follows: 75 to 76 years in 32.5% (14/43), 77 to 79 years in 46.5% (20/43), and 80 to 83 years in 21% (9/43) of patients. Indications for SAVR included low operative risk according to STS (1.6 +/- 0.3%) and EuroSCORE II (1.4 +/- 0.3%) in 51.2% (22/43), unicuspid/bicuspid aortic valve in 21% (9/43), patient preference in 13.9% (6/43), large aortic annulus in 9.3% (4/43), and massive calcification of the left ventricular outflow tract in 4.6% (2/43) of patients. Mean aortic cross clamp and cardiopulmonary bypass times were 67.1 +/- 18.2 minutes and 98.6 +/- 25.1 minutes. All-cause 30-day mortality was 0% (0/43). Technical success, device success, and early safety were 100% (43/43), 100% (43/43), and 81.4% (35/43). Bleeding complications and the need for permanent pacemaker implantation (PPM) were observed in 9.3% (4/43) and 4.6% (2/43) of patients. Mean ICU and hospital stay were 2.9 +/- 2.1 days and 12.5 +/- 3.6 days. Post-procedural echocardiography demonstrated absence of paravalvular leakage (PVL) in all but one patient, who exhibited moderate PVL. The mean transvalvular pressure gradient was 11.4 +/- 4.5 mmHg. Latest follow-up was at median 5.5 years (1.9-7.1 years). Aortic valve re-intervention at follow-up was 2.3% (1/43) and cardiovascular mortality was 4.6% (2/43). CONCLUSION: In the current era, SAVR is rarely performed in patients >/=75 years of age. Despite the highly selective nature of the patient cohort studied, the results are excellent, with a 30-day mortality of 0% and a low cardiovascular mortality at 5 years. SAVR should still be considered a valid option in elderly patients, evaluated by a heart team, which considers each patient's unique clinical, anatomic, and procedural characteristics. CI - Thieme. All rights reserved. FAU - Petersen, Johannes AU - Petersen J AUID- ORCID: 0000-0002-3415-3385 AD - Department of Cardiovascular Surgery, University Heart & Vascular Center Hamburg, Hamburg, Germany. FAU - Sarwari, Harun AU - Sarwari H AD - Department of Cardiovascular Surgery, University Heart & Vascular Center Hamburg, Hamburg, Germany. FAU - Demal, Till AU - Demal T AD - Department of Cardiovascular Surgery, University Heart & Vascular Center Hamburg, Hamburg, Germany. FAU - Bhadra, Oliver AU - Bhadra O AD - Department of Cardiovascular Surgery, University Heart & Vascular Center Hamburg, Hamburg, Germany. FAU - Pecha, Simon AU - Pecha S AUID- ORCID: 0000-0002-8747-166X AD - Department of Cardiovascular Surgery, University Heart & Vascular Center Hamburg, Hamburg, Germany. FAU - Reichenspurner, Hermann AU - Reichenspurner H AD - Department of Cardiovascular Surgery, University Heart & Vascular Center Hamburg, Hamburg, Germany. FAU - Schaefer, Andreas AU - Schaefer A AD - Department of Cardiovascular Surgery, University Heart & Vascular Center Hamburg, Hamburg, Germany. LA - eng PT - Journal Article DEP - 20251018 PL - Germany TA - Thorac Cardiovasc Surg JT - The Thoracic and cardiovascular surgeon JID - 7903387 SB - IM MH - Humans MH - Treatment Outcome MH - *Aortic Valve Stenosis/surgery/mortality/diagnostic imaging/physiopathology MH - *Heart Valve Prosthesis Implantation/adverse effects/mortality/instrumentation/standards MH - Time Factors MH - Risk Factors MH - Aged MH - Male MH - *Aortic Valve/surgery/physiopathology/diagnostic imaging MH - Age Factors MH - Aged, 80 and over MH - Female MH - Risk Assessment MH - Postoperative Complications/mortality MH - Retrospective Studies MH - Patient Selection MH - Heart Valve Prosthesis MH - Severity of Illness Index MH - Practice Guidelines as Topic/standards MH - Recovery of Function MH - Clinical Decision-Making COIS- The authors declare that they have no conflict of interest. EDAT- 2025/10/19 00:28 MHDA- 2026/08/05 00:44 CRDT- 2025/10/18 18:32 PHST- 2026/08/05 00:44 [medline] PHST- 2025/10/19 00:28 [pubmed] PHST- 2025/10/18 18:32 [entrez] AID - 10.1055/a-2724-5108 [doi] PST - ppublish SO - Thorac Cardiovasc Surg. 2026 Aug;74(5):384-389. doi: 10.1055/a-2724-5108. Epub 2025 Oct 18. PMID- 41107507 OWN - NLM STAT- MEDLINE DCOM- 20251215 LR - 20260715 IS - 1432-0711 (Electronic) IS - 0932-0067 (Print) IS - 0932-0067 (Linking) VI - 312 IP - 6 DP - 2025 Dec TI - Practical obstetric multi-professional training (PROMPT): the evidence for effective training. PG - 1901-1912 LID - 10.1007/s00404-025-08213-1 [doi] AB - OBJECTIVE: To test the hypothesis that Practical Obstetric Multi-Professional Training (PROMPT) is effective training. BACKGROUND: Multi-professional training in the labour ward has, in most cases, shown to be effective, in some cases not to be effective, and in some instances, it has worsened the outcome following the introduction of training. If training is to be performed, it should be adequate training. Thus, monitoring the outcomes is mandatory to determine if training is effective. Adjustments become possible to achieve improved outcomes. PROMPT Training has 14 modules: Team working, Basic life support and maternal collapse, maternal cardiac arrest and advanced life support, maternal anaesthetic emergencies, foetal monitoring in labour, pre-eclampsia and eclampsia, maternal sepsis, major obstetric haemorrhage, shoulder dystocia, cord prolapse, vaginal breech birth, twin birth, acute uterine inversion, basic newborn resuscitation. The concept involves scientifically written modules based on clinical studies, multi-professional training, central integration of teamwork and communication training and multi-professional training in the labour ward for obstetricians, midwives, neonatologists, anaesthetists and further professions involved. DESIGN: Systematic literature review. METHODOLOGY: A systematic literature search of PubMed, Embase, Medline, Scopus, and the Cochrane Library was conducted for studies published between January 2000 and November 2024. Eligible studies evaluated PROMPT training and reported clinical outcomes, training effects, or cost-effectiveness. Forty-two studies met inclusion criteria, comprising randomised controlled trials, observational cohorts, and quasi-experimental designs. Methodological quality was assessed using the Cochrane Risk of Bias tool, and sensitivity analyses explored consistency across study types. RESULTS: A total of 62 studies were identified, of which 42 met the inclusion criteria and were analysed across 14 PROMPT training modules; 20 publications were excluded. Of the eligible studies, 37/42 reported improvements in 8/14 modules, most notably in teamwork and communication, management of shoulder dystocia with reductions in brachial plexus injury, decreased rates of hypoxic-ischaemic encephalopathy and low 5-min Apgar scores, improved management of pre-eclampsia with increased magnesium sulfate use, reduced decision-to-delivery intervals for umbilical cord prolapse, and better outcomes in postpartum haemorrhage, breech and instrumental deliveries, maternal cardiac arrest, and neonatal resuscitation. Additional findings included reduced litigation costs and evidence of cost-effectiveness. Three studies demonstrated no significant improvement, one trial reported worsened 5-min Apgar scores after implementation in 12 Scottish maternity units, and one study showed mixed outcomes. At Hannover Medical School, our own data demonstrated substantially reduced adverse outcomes after 2(1/2) years of PROMPT training. CONCLUSIONS: PROMPT Training effectively reduces adverse outcomes of rare but severe obstetric complications, if training is implemented using authentic PROMPT materials, team and communication training will be implemented, and training will be repeated annually in a multi-professional way. CI - (c) 2025. The Author(s). FAU - Papageorgiou, Spyridon AU - Papageorgiou S AD - Department of Obstetrics, Gynecology and Reproductive Medicine, 1-3 at the Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. AD - Department of Obstetrics and Gynecology, Marien Hospital Witten, Marienplatz 2, 58452, Witten, Germany. FAU - Brodowski, Lars AU - Brodowski L AD - Department of Obstetrics, Gynecology and Reproductive Medicine, 1-3 at the Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. FAU - Lewinski, Halina AU - Lewinski H AD - Department of Obstetrics, Gynecology and Reproductive Medicine, 1-3 at the Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. FAU - Bohnhorst, Bettina AU - Bohnhorst B AD - Department of Pediatric Pneumology, Allergology and Neonatology, 1-3 at the Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. FAU - Flentje, Markus AU - Flentje M AD - Department of Anaesthesiology and Intensive Care, 1-3 at the Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. FAU - Schiermeier, Sven AU - Schiermeier S AD - Department of Obstetrics and Gynecology, Marien Hospital Witten, Marienplatz 2, 58452, Witten, Germany. FAU - Talbot, Steven R AU - Talbot SR AD - Institute for Laboratory Animal Science, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. FAU - von Kaisenberg, Constantin AU - von Kaisenberg C AD - Department of Obstetrics, Gynecology and Reproductive Medicine, 1-3 at the Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. vonkaisenberg.constantin@mh-hannover.de. LA - eng PT - Journal Article PT - Systematic Review DEP - 20251017 PL - Germany TA - Arch Gynecol Obstet JT - Archives of gynecology and obstetrics JID - 8710213 SB - IM MH - Humans MH - Female MH - Pregnancy MH - *Obstetrics/education MH - Patient Care Team PMC - PMC12705841 OTO - NOTNLM OT - Brachial plexus injury OT - Maternal and neonatal safety OT - Neonatal outcomes OT - PROMPT training OT - Shoulder dystocia OT - Simulation training OT - Teamwork and communication COIS- Declarations. Conflict of interest: The authors declare no competing interests. EDAT- 2025/10/18 00:30 MHDA- 2025/12/15 13:10 PMCR- 2025/10/17 CRDT- 2025/10/17 23:37 PHST- 2025/01/25 00:00 [received] PHST- 2025/09/29 00:00 [accepted] PHST- 2025/12/15 13:10 [medline] PHST- 2025/10/18 00:30 [pubmed] PHST- 2025/10/17 23:37 [entrez] PHST- 2025/10/17 00:00 [pmc-release] AID - 10.1007/s00404-025-08213-1 [pii] AID - 8213 [pii] AID - 10.1007/s00404-025-08213-1 [doi] PST - ppublish SO - Arch Gynecol Obstet. 2025 Dec;312(6):1901-1912. doi: 10.1007/s00404-025-08213-1. Epub 2025 Oct 17. PMID- 41105160 OWN - NLM STAT- MEDLINE DCOM- 20251117 LR - 20261009 IS - 2753-670X (Electronic) IS - 2753-670X (Linking) VI - 40 IP - 11 DP - 2025 Nov 6 TI - Treatment of Aorto-Oesophageal Fistula in a Tertiary German Aortic and Oesophageal Centre A Multidisciplinary Effort. LID - 10.1093/icvts/ivaf236 [doi] LID - ivaf236 AB - OBJECTIVES: Although rare, aorto-oesophageal fistula remains one of the most critical diseases in cardiovascular surgery. The lack of prospective studies or large case series leads to an absence of evidence-based therapeutic concepts. METHODS: We conducted a retrospective analysis of patients treated for aorto-oesophageal fistula between 2014 and 2023. Primary endpoints of analysis were 30-day mortality and median survival; subgroup analysis was performed for aetiology as well as treatment strategy. Additionally, a systematic search was conducted for all studies researching treatment of the disease, including >/=5 patients and published within the last 10 years. RESULTS: In the collective of 10 patients, 4 manifested as primary fistula, while in 6 patients the fistula occurred secondary to previous thoracic endovascular aortic repair. Median duration to manifestation post-TEVAR was 20.1 months (34.1). Initial treatment consisted of TEVAR or TEVAR-relining in 7 cases, followed by bovine open aortic replacement (n = 1) or partial bovine patch repair (n = 2) when viable. Treatment of the oesophagus consisted of primary suture (n = 1) or oesophagectomy (n = 5) with gastric pull-up or colon interposition. Overall 30-day mortality was 40%, and overall median survival was 7.5 months (12.8). Patients receiving surgical treatment of the oesophagus exhibited longer survival than patients who did not (12.8 months [4.7] vs 0.35 months [0.4]). Across the reviewed literature, the strongest effect on survival originates from surgical treatment of the oesophagus. Specific surgical strategies as well as patient characteristics vary widely. CONCLUSIONS: We found TEVAR effective in stabilizing the initial haemorrhage. Short-interval oesophagectomy seems to improve survival and should be considered in most patients. Open aortic replacement with bovine pericardium is a viable option. Interventional treatment options alone do not appear to be sufficient. CI - (c) The Author(s) 2025. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. FAU - Strobl, Felix AU - Strobl F AUID- ORCID: 0000-0002-7289-3448 AD - Abteilung fur Gefasschirurgie, Klinikum der Universitat Munchen, Munchen, 81377, Germany. AD - Klinik fur Gefasschirurgie, Charite Universitatsmedizin Berlin, Berlin, 12203, Germany. FAU - Stana, Jan AU - Stana J AUID- ORCID: 0000-0002-0013-7870 AD - Abteilung fur Gefasschirurgie, Klinikum der Universitat Munchen, Munchen, 81377, Germany. FAU - Bohm, Agnes Klara AU - Bohm AK AD - Klinik fur Chirurgie, Charite Universitatsmedizin Berlin, CCM|CVK, Berlin, 13353, Germany. FAU - Mehmedovic, Aldin AU - Mehmedovic A AD - Abteilung fur Gefasschirurgie, Klinikum der Universitat Munchen, Munchen, 81377, Germany. FAU - Pichlmaier, Maximilian AU - Pichlmaier M AUID- ORCID: 0000-0002-2903-2490 AD - Klinik fur Herzchirurgie, Klinikum der Universitat Munchen, Munchen, 81377, Germany. FAU - Stein, Hubert J AU - Stein HJ AD - Klinik fur Allgemein-, Viszeral- und Transplantationschirurgie, Klinikum der Universitat Munchen, Munchen, 81377, Germany. FAU - Angele, Martin AU - Angele M AD - Klinik fur Allgemein-, Viszeral- und Transplantationschirurgie, Klinikum der Universitat Munchen, Munchen, 81377, Germany. FAU - Tsilimparis, Nikolaos AU - Tsilimparis N AUID- ORCID: 0000-0002-6313-7595 AD - Abteilung fur Gefasschirurgie, Klinikum der Universitat Munchen, Munchen, 81377, Germany. LA - eng PT - Journal Article PL - England TA - Interdiscip Cardiovasc Thorac Surg JT - Interdisciplinary cardiovascular and thoracic surgery JID - 9918540787006676 SB - IM MH - Humans MH - *Esophageal Fistula/mortality/surgery/diagnostic imaging/etiology MH - Retrospective Studies MH - Male MH - *Vascular Fistula/mortality/surgery/diagnostic imaging/etiology MH - *Aortic Diseases/mortality/surgery/diagnostic imaging/etiology MH - Aged MH - Female MH - Middle Aged MH - Germany MH - Treatment Outcome MH - *Endovascular Procedures/adverse effects/mortality MH - *Tertiary Care Centers MH - *Esophagectomy/adverse effects/mortality MH - Time Factors MH - *Blood Vessel Prosthesis Implantation/adverse effects/mortality MH - Aged, 80 and over MH - Risk Factors MH - Adult PMC - PMC12622961 OTO - NOTNLM OT - TEVAR OT - aorto-oesophageal fistula OT - cardiothoracic surgery OT - endovascular surgery OT - prosthesis infection OT - upper gastrointestinal surgery COIS- All authors have read the journal's authorship agreement and policy on potential conflicts of interest. N.T. is a proctor for Cook Medical, a consultant for Medtronic, and has received institutional funding from Cook Medical and Bentley. There are no further conflicts of interest to declare. EDAT- 2025/10/17 12:31 MHDA- 2025/11/18 00:27 PMCR- 2025/10/17 CRDT- 2025/10/17 11:03 PHST- 2025/01/26 00:00 [received] PHST- 2025/08/28 00:00 [revised] PHST- 2025/09/14 00:00 [accepted] PHST- 2025/11/18 00:27 [medline] PHST- 2025/10/17 12:31 [pubmed] PHST- 2025/10/17 11:03 [entrez] PHST- 2025/10/17 00:00 [pmc-release] AID - 8292666 [pii] AID - ivaf236 [pii] AID - 10.1093/icvts/ivaf236 [doi] PST - ppublish SO - Interdiscip Cardiovasc Thorac Surg. 2025 Nov 6;40(11):ivaf236. doi: 10.1093/icvts/ivaf236. PMID- 41105058 OWN - NLM STAT- MEDLINE DCOM- 20251214 LR - 20260120 IS - 1557-3117 (Electronic) IS - 1053-2498 (Linking) VI - 45 IP - 1 DP - 2026 Jan TI - ISHLT Consensus Statement on the Perioperative use of ECLS in Lung Transplantation: Part I: Preoperative Considerations. PG - e1-e34 LID - S1053-2498(25)02201-6 [pii] LID - 10.1016/j.healun.2025.07.033 [doi] AB - The use of extracorporeal life support (ECLS) throughout the perioperative phase of lung transplantation requires nuanced planning and execution by an integrated team of multidisciplinary experts. To date, no multidisciplinary consensus document has examined the perioperative considerations of how to best manage these patients. To address this challenge, this perioperative utilization of ECLS in lung transplantation consensus statement was approved for development by the International Society for Heart and Lung Transplantation Standards and Guidelines Committee. International experts across multiple disciplines, including cardiothoracic surgery, anesthesiology, critical care, pediatric pulmonology, adult pulmonology, pharmacy, psychology, physical therapy, nursing, and perfusion, were selected based on expertise and divided into subgroups examining the preoperative, intraoperative, and postoperative periods. Following a comprehensive literature review, each subgroup developed recommendations to examine via a structured Delphi methodology. Following 2 rounds of Delphi consensus, a total of 50 recommendations regarding preoperative considerations for ECLS in lung transplantation met consensus criteria. These recommendations focus on the criteria for preoperative ECLS as well as select multidisciplinary team management considerations throughout the entire preoperative phase. CI - Copyright (c) 2025 International Society for the Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved. FAU - Reed, Anna K AU - Reed AK AD - Respiratory & Transplant Medicine, Royal Brompton and Harefield Hospitals, Part of Guy's and St Thomas' NHS Foundation Trust and Imperial College London, London, UK. FAU - Mercier, Olaf AU - Mercier O AD - Department of Thoracic Surgery and Heart-Lung Transplantation, Marie Lannelongue Hospital, Universite' Paris-Saclay, Le Plessis-Robinson, France. FAU - Behr, Juergen AU - Behr J AD - Department of Medicine V, German Center for Lung Research, LMU University Hospital, Ludwig Maximilian University of Munich, Munich, Germany. FAU - Dave, Kavita AU - Dave K AD - Department of Cardiothoracic Transplantation & Mechanical Circulatory Support, Royal Brompton & Harefield Hospitals, Part of Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK. FAU - Dellgren, Goran AU - Dellgren G AD - Department of Cardiothoracic Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden. FAU - Kotecha, Sakhee AU - Kotecha S AD - Lung Transplant Service, Alfred Hospital and Monash University, Melbourne, Australia. FAU - Kukreja, Jasleen AU - Kukreja J AD - Division of Cardiothoracic Surgery, Department of Surgery, University of California, San Francisco, California, USA. FAU - Landry, Caroline AU - Landry C AD - Division of Perfusion Services, Universite' de Montreal, Montreal, Quebec, Canada. FAU - Levvey, Bronwyn AU - Levvey B AD - Faculty of Nursing & Health Sciences, The Alfred Hospital, Monash University, Melbourne, Australia. FAU - Lyster, Haifa AU - Lyster H AD - Department of Cardiothoracic Transplantation & Mechanical Circulatory Support, Royal Brompton & Harefield Hospitals, Part of Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK. FAU - Morrissey, Orla AU - Morrissey O AD - Division of Infectious Disease, Alfred Health and Monash University, Melbourne, Australia. FAU - Saatee, Siavosh AU - Saatee S AD - Division of Cardiovascular and Thoracic Anesthesiology and Critical Care, University of Texas-Southwestern, Dallas, TX. FAU - Sanchez, Melissa AU - Sanchez M AD - Department of Clinical Health Psychology, Kensington & Chelsea, West Middlesex Hospitals, London, United Kingdom. FAU - Schecter, Marc AU - Schecter M AD - Division of Pulmonary Medicine, University of Florida - Gainesville, FL. FAU - Walsh, James AU - Walsh J AD - Department of Physiotherapy, The Prince Charles Hospital, Brisbane, Australia. FAU - Fritz, Ashley Virginia AU - Fritz AV AD - Division of Cardiovascular and Thoracic Anesthesiology, Mayo Clinic Florida, Jacksonville, FL. FAU - Gelzinis, Theresa A AU - Gelzinis TA AD - Division of Cardiovascular and Thoracic Anesthesiology, University of Pittsburgh Medical Center, Pittsburgh, PA. FAU - Hoetzenecker, Konrad AU - Hoetzenecker K AD - Department of Thoracic Surgery, Vanderbilt University Medical Center, Nashville, TN. FAU - Lindstedt, Sandra AU - Lindstedt S AD - Department of Cardiothoracic Surgery and Transplantation, Lund University, Lund, Sweden. FAU - Marczin, Nandor AU - Marczin N AD - Department of Anaesthesia and Critical Care, Royal Brompton & Harefield Hospitals, Part of Guy's and St Thomas' NHS Foundation Trust and Imperial College London, London, UK. FAU - Wilkey, Barbara J AU - Wilkey BJ AD - Department of Anesthesiology, University of Colorado, Aurora, CO. FAU - Fessler, Julien AU - Fessler J AD - Department of Anesthesiology and Pain Medicine, Hopital Foch, Universite' Versailles-Saint-Quentin-en-Yvelines, Suresnes, France. FAU - Bottiger, Brandi AU - Bottiger B AD - Division of Cardiothoracic Anesthesiology, Duke University School of Medicine, Durham, NC. FAU - Wille, Keith AU - Wille K AD - Division of Pulmonary and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL. FAU - Nasir, Basil S AU - Nasir BS AD - Division of Thoracic Surgery, Centre Hospitalier de l'Universite de Montreal (CHUM), Montreal, Quebec, Canada. FAU - Gomez-De-Antonio, David AU - Gomez-De-Antonio D AD - Department of Thoracic Surgery and Lung Transplantation, Hospital Universitario Puerta de Hierro-Majadahonda, Universidad Autonoma de Madrid, Madrid, Spain. FAU - Cypel, Marcelo AU - Cypel M AD - Toronto Lung Transplant Program, Ajmera Transplant Center, University Health Network, Toronto, Ontario, Canada. FAU - Martin, Archer Kilbourne AU - Martin AK AD - Division of Cardiovascular and Thoracic Anesthesiology, Mayo Clinic Florida, Jacksonville, FL. LA - eng PT - Consensus Statement PT - Journal Article PT - Review DEP - 20251017 PL - United States TA - J Heart Lung Transplant JT - The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation JID - 9102703 SB - IM MH - Humans MH - Delphi Technique MH - *Extracorporeal Membrane Oxygenation/methods/standards MH - *Lung Transplantation/methods MH - *Perioperative Care/methods/standards MH - *Preoperative Care/methods/standards MH - *Societies, Medical OTO - NOTNLM OT - ECLS OT - ECMO OT - End-Stage Lung Disease OT - Lung Transplantation OT - MDT EDAT- 2025/10/17 12:30 MHDA- 2025/12/15 00:28 CRDT- 2025/10/17 10:31 PHST- 2025/07/28 00:00 [received] PHST- 2025/07/29 00:00 [accepted] PHST- 2025/12/15 00:28 [medline] PHST- 2025/10/17 12:30 [pubmed] PHST- 2025/10/17 10:31 [entrez] AID - S1053-2498(25)02201-6 [pii] AID - 10.1016/j.healun.2025.07.033 [doi] PST - ppublish SO - J Heart Lung Transplant. 2026 Jan;45(1):e1-e34. doi: 10.1016/j.healun.2025.07.033. Epub 2025 Oct 17. PMID- 41098879 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251016 LR - 20251018 IS - 1178-7015 (Print) IS - 1178-7015 (Electronic) IS - 1178-7015 (Linking) VI - 18 DP - 2025 TI - Inflamed Skin, Burdened Heart: A Multidisciplinary Perspective on Atopic Dermatitis and Cardiovascular Health. PG - 2591-2604 LID - 10.2147/CCID.S552485 [doi] AB - The diseases of both skin and cardiovascular are the most significant global medical challenges for their high rates of morbidity and mortality. Although not life-threatening, skin diseases significantly impair patients' quality of life and affect a large proportion of the population due to their chronic and persistent nature. Cardiovascular diseases are characterized by both a widespread prevalence and a high risk of mortality, posing a significant public health burden. As both skin diseases and cardiovascular diseases fall under the umbrella of inflammatory disorders, a degree of pathophysiological connection exists between them. Historically, the potential interplay between these seemingly unrelated conditions was largely overlooked. However, accumulating evidence in recent years has suggested that inflammatory skin diseases-particularly Atopic Dermatitis (AD)-may be associated with an elevated risk of adverse cardiovascular outcomes. This review therefore not only examines the emerging interdisciplinary links between AD and cardiology, but also highlights ongoing controversies, the limitations of current evidence, and outlines future research directions needed to clarify their shared inflammatory pathways and clinical implications. CI - (c) 2025 Ma et al. FAU - Ma, Chenghui AU - Ma C AD - Department of Geriatrics, The Fourth People's Hospital of Shenyang, Shenyang, Liaoning, 110031, People's Republic of China. FAU - Xu, Yikang AU - Xu Y AD - Department of Cardiovascular Medicine, The Second Affiliated Hospital of Shenyang Medical College, Shenyang, 110002, People's Republic of China. FAU - Bai, Wenshuo AU - Bai W AD - Department of Cardiology, Jinzhou Central Hospital, Jinzhou, Liaoning, 121000, People's Republic of China. FAU - Zou, Yulin AU - Zou Y AUID- ORCID: 0000-0001-5747-3720 AD - Department of Dermatology, Venereology and Allergology, University Medical Center Gottingen, Gottingen, Germany. AD - Department of Dermatology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, 12100, People's Republic of China. LA - eng PT - Journal Article PT - Review DEP - 20251010 PL - New Zealand TA - Clin Cosmet Investig Dermatol JT - Clinical, cosmetic and investigational dermatology JID - 101543449 PMC - PMC12519999 OTO - NOTNLM OT - atopic dermatitis OT - cardiovascular OT - heart OT - inflammation OT - skin COIS- The authors declare that they have no competing interests. EDAT- 2025/10/16 06:29 MHDA- 2025/10/16 06:30 PMCR- 2025/10/10 CRDT- 2025/10/16 04:47 PHST- 2025/07/09 00:00 [received] PHST- 2025/10/04 00:00 [accepted] PHST- 2025/10/16 06:30 [medline] PHST- 2025/10/16 06:29 [pubmed] PHST- 2025/10/16 04:47 [entrez] PHST- 2025/10/10 00:00 [pmc-release] AID - 552485 [pii] AID - 10.2147/CCID.S552485 [doi] PST - epublish SO - Clin Cosmet Investig Dermatol. 2025 Oct 10;18:2591-2604. doi: 10.2147/CCID.S552485. eCollection 2025. PMID- 41097751 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251016 LR - 20251019 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 17 IP - 19 DP - 2025 Oct 3 TI - Cancer-Induced Cardiac Dysfunction: Mechanisms, Diagnostics, and Emerging Therapeutics in the Era of Onco-Cardiology. LID - 10.3390/cancers17193225 [doi] LID - 3225 AB - Cancer-induced cardiac dysfunction has become a major clinical challenge as advances in cancer therapies continue to extend patient survival. Once regarded as a secondary concern, cardiotoxicity is now recognized as a leading contributor to morbidity and mortality among cancer patients and survivors. Its pathophysiology is multifactorial, involving systemic inflammation (e.g., TNF-alpha, IL-6), oxidative stress driven by reactive oxygen species (ROS), neurohormonal imbalances (e.g., angiotensin II, endothelin-1), and metabolic disturbances. These mechanisms collectively promote cardiomyocyte apoptosis, atrophy, mitochondrial dysfunction, and impaired cardiac output. Cardiac complications may arise directly from cancer itself or as adverse effects of oncologic therapies such as anthracyclines, trastuzumab, and immune checkpoint inhibitors. These agents have been linked to heart failure (HF), systolic dysfunction, and cardiac atrophy, often progressing insidiously and underscoring the importance of early detection and careful monitoring. Current preventive and therapeutic strategies include pharmacological interventions such as ACE inhibitors, beta-blockers, statins, dexrazoxane, and endothelin receptor antagonists like atrasentan. Emerging compounds, particularly Withaferin A (WFA), have shown potential through their anti-inflammatory and cardiac protective properties. In addition, antioxidants and lifestyle modifications may provide supplementary cardioprotective benefits, while interventional cardiology procedures are increasingly considered in selected patients. Despite encouraging progress, standardized treatment protocols and robust long-term outcome data remain limited. Given the heterogeneity of cancer types and cardiovascular responses, a personalized and multidisciplinary approach is essential. Continued research and close collaboration between oncologists, cardiologists, and basic scientists will be the key to advancing care, reducing treatment-related morbidity, and ensuring that improvements in cancer survival are matched by preservation of cardiovascular health. FAU - Saha, Sarama AU - Saha S AD - Department of Biochemistry, All India Institute of Medical Sciences, Rishikesh 249203, India. FAU - Singh, Praveen K AU - Singh PK AD - Department of Biochemistry, Maharishi Markandeshwar Medical College & Hospital, MMU, Solan 173229, India. FAU - Roy, Partha AU - Roy P AD - Department of Biotechnology, Indian Institute of Technology Roorkee, Roorkee 247667, India. FAU - Vemuri, Vasa AU - Vemuri V AUID- ORCID: 0009-0009-5280-3212 AD - Department of Physiology, University of Louisville, Louisville, KY 40202, USA. FAU - Ratajczak, Mariusz Z AU - Ratajczak MZ AUID- ORCID: 0000-0002-0071-0198 AD - Department of Medicine, University of Louisville, Louisville, KY 40202, USA. AD - Brown Cancer Center, University of Louisville, Louisville, KY 40202, USA. FAU - Singh, Mahavir AU - Singh M AUID- ORCID: 0000-0002-2415-3314 AD - Department of Physiology, University of Louisville, Louisville, KY 40202, USA. FAU - Kakar, Sham S AU - Kakar SS AD - Department of Physiology, University of Louisville, Louisville, KY 40202, USA. AD - Brown Cancer Center, University of Louisville, Louisville, KY 40202, USA. LA - eng GR - NIH R25GM133328/GF/NIH HHS/United States PT - Journal Article PT - Review DEP - 20251003 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC12523736 OTO - NOTNLM OT - cachexia OT - cancer OT - cardiac dysfunction COIS- The authors declare no conflict of interest. EDAT- 2025/10/16 06:30 MHDA- 2025/10/16 06:31 PMCR- 2025/10/03 CRDT- 2025/10/16 01:18 PHST- 2025/09/10 00:00 [received] PHST- 2025/09/29 00:00 [revised] PHST- 2025/09/30 00:00 [accepted] PHST- 2025/10/16 06:31 [medline] PHST- 2025/10/16 06:30 [pubmed] PHST- 2025/10/16 01:18 [entrez] PHST- 2025/10/03 00:00 [pmc-release] AID - cancers17193225 [pii] AID - cancers-17-03225 [pii] AID - 10.3390/cancers17193225 [doi] PST - epublish SO - Cancers (Basel). 2025 Oct 3;17(19):3225. doi: 10.3390/cancers17193225. PMID- 41095839 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251016 LR - 20251019 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 14 IP - 19 DP - 2025 Sep 24 TI - Redefining Aortic Valve Replacement: The Transition from Open Surgery to Transcatheter Innovation. LID - 10.3390/jcm14196761 [doi] LID - 6761 AB - Aortic valve replacement (AVR) has evolved dramatically, transitioning from open surgery to minimally invasive and transcatheter approaches. This review examines the historical and technological advancements in AVR, focusing on the evolution of mechanical and bioprosthetic valves, valve-sparing techniques, and the Ross procedure. Mechanical valves offer superior durability but require lifelong anticoagulation, while bioprosthetic valves avoid this need at the expense of long-term durability. Transcatheter aortic valve replacement (TAVR), originally reserved for high-risk patients, is now used across all risk profiles due to growing evidence of safety and efficacy from major trials like PARTNER and Core Valve. Despite its benefits, TAVR presents some challenges, including paravalvular leak, pacemaker implantation, and uncertain long-term durability, especially in younger patients. Valve-in-valve techniques, novel valve designs, and anti-calcification treatments offer promising solutions. Looking forward, the integration of artificial intelligence and personalized procedural planning will play a key role in optimizing outcomes. As AVR technology advances, careful patient selection and a multidisciplinary approach remain essential to guiding individualized treatment decisions. FAU - Lodge, Frances AU - Lodge F AD - Division of Cardiothoracic Surgery, Department of Surgery, Columbia University Irving Medical Center, New York, NY 10032, USA. FAU - Soliman, Fady AU - Soliman F AUID- ORCID: 0000-0003-3555-9392 AD - Division of Cardiothoracic Surgery, Department of Surgery, Columbia University Irving Medical Center, New York, NY 10032, USA. FAU - Kandula, Viswajit AU - Kandula V AD - Division of Cardiothoracic Surgery, Department of Surgery, Columbia University Irving Medical Center, New York, NY 10032, USA. FAU - Tagliafierro, Marco AU - Tagliafierro M AUID- ORCID: 0009-0006-7585-7166 AD - Division of Cardiothoracic Surgery, Department of Surgery, Columbia University Irving Medical Center, New York, NY 10032, USA. FAU - Pirelli, Luigi AU - Pirelli L AD - Division of Cardiothoracic Surgery, Department of Surgery, Columbia University Irving Medical Center, New York, NY 10032, USA. LA - eng PT - Journal Article PT - Review DEP - 20250924 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC12525076 OTO - NOTNLM OT - Transcatheter aortic valve replacement (TAVR) OT - aortic stenosis OT - aortic valve replacement (AVR) OT - bioprosthetic valves OT - mechanical valves OT - structural valve degeneration (SVD) OT - surgical aortic valve replacement (SAVR) OT - valve-in-valve (ViV) COIS- The authors declare no conflict of interest. EDAT- 2025/10/16 06:30 MHDA- 2025/10/16 06:31 PMCR- 2025/09/24 CRDT- 2025/10/16 01:08 PHST- 2025/09/05 00:00 [received] PHST- 2025/09/18 00:00 [revised] PHST- 2025/09/21 00:00 [accepted] PHST- 2025/10/16 06:31 [medline] PHST- 2025/10/16 06:30 [pubmed] PHST- 2025/10/16 01:08 [entrez] PHST- 2025/09/24 00:00 [pmc-release] AID - jcm14196761 [pii] AID - jcm-14-06761 [pii] AID - 10.3390/jcm14196761 [doi] PST - epublish SO - J Clin Med. 2025 Sep 24;14(19):6761. doi: 10.3390/jcm14196761. PMID- 41094725 OWN - NLM STAT- MEDLINE DCOM- 20251221 LR - 20251221 IS - 1536-0237 (Electronic) IS - 0883-5993 (Linking) VI - 41 IP - 1 DP - 2026 Jan 1 TI - Evaluating the Status of Cardiac Imaging Training in Radiology Residency Programs in the United States. LID - e0856 [pii] LID - 10.1097/RTI.0000000000000856 [doi] AB - PURPOSE: Cardiac imaging is an integral part of modern diagnostic imaging and a subject heavily tested on the Radiology Core exam. Therefore, radiology residency programs should provide adequate training in this area. This study aims to investigate the current state of cardiac imaging training within radiology residency programs in the United States. MATERIALS AND METHODS: Survey questionnaires using the Research Electronic Data Capture (REDCap) platform were sent to heads of cardiac/cardiothoracic sections in all US radiology residency programs for which valid email addresses were available. RESULTS: Of 163 questionnaires sent, there were 70 responses, with 82.9% completing the entire survey. In total, 85.9% reported having a cardiac imaging rotation, with 58.8% being 4 weeks, mostly in a single block. Sixteen programs (31.4%) offered a longer cardiac experience (6 to 12 wk). In total, 90.7% reported having a designated person responsible for cardiac imaging, a radiologist in 68.5% and a combined radiologist and cardiologist in 22.2%. The responsible person for reporting cardiac CT was a radiologist in 40.7%, with a combined radiologist and cardiologist in 59.3%. For cardiac MRI studies, there was combined responsibility in 69.0%, either on alternate days of coverage or with the radiologist interpreting noncardiac findings. A total of 65.5% reported having >/=6 cardiac case conferences yearly, and 75.9% had >/=6 cardiac lectures. In total, 65.6% of programs offered cardiothoracic fellowships, with 87.2% dedicating >/=3 months to cardiac imaging. Only 18.6% had dedicated cardiovascular fellowships. CONCLUSION: Our research offers crucial insights into the current trends in cardiac imaging education and practice within radiology residency programs, so that professional societies can develop guidelines to structure a more uniform and thorough approach toward cardiac imaging education. CI - Copyright (c) 2025 Wolters Kluwer Health, Inc. All rights reserved. FAU - Bar, Nitai AU - Bar N AD - Harvard Medical School, Beth Israel Deaconess Medical Center. FAU - Eisenberg, Ronald L AU - Eisenberg RL AD - Harvard Medical School, Beth Israel Deaconess Medical Center. FAU - Liberman, Yuval AU - Liberman Y AD - Harvard Medical School, Beth Israel Deaconess Medical Center. FAU - Liubauske, Aurelija AU - Liubauske A AD - Harvard Medical School, Beth Israel Deaconess Medical Center. FAU - Queiros, Ivan D AU - Queiros ID AD - Harvard Medical School, Beth Israel Deaconess Medical Center. FAU - Cutts, Jennifer M AU - Cutts JM AD - Harvard Medical School, Beth Israel Deaconess Medical Center. FAU - Revels, Jonathan AU - Revels J AD - NYU Langone Health Long Island. FAU - Bang, Tami J AU - Bang TJ AD - National Jewish Health. FAU - Litmanovich, Diana E AU - Litmanovich DE AD - Harvard Medical School, Beth Israel Deaconess Medical Center. LA - eng PT - Journal Article DEP - 20260101 PL - United States TA - J Thorac Imaging JT - Journal of thoracic imaging JID - 8606160 SB - IM MH - *Internship and Residency/methods MH - United States MH - Humans MH - *Radiology/education MH - Surveys and Questionnaires MH - *Cardiac Imaging Techniques MH - Heart/diagnostic imaging OTO - NOTNLM OT - cardiac imaging OT - residency programs OT - survey OT - training OT - training curriculum COIS- The authors declare no conflict of interest. EDAT- 2025/10/16 06:29 MHDA- 2025/12/22 00:28 CRDT- 2025/10/16 00:23 PHST- 2024/04/30 00:00 [received] PHST- 2025/09/07 00:00 [accepted] PHST- 2025/12/22 00:28 [medline] PHST- 2025/10/16 06:29 [pubmed] PHST- 2025/10/16 00:23 [entrez] AID - 00005382-990000000-00201 [pii] AID - 10.1097/RTI.0000000000000856 [doi] PST - epublish SO - J Thorac Imaging. 2026 Jan 1;41(1):e0856. doi: 10.1097/RTI.0000000000000856. PMID- 41094192 OWN - NLM STAT- MEDLINE DCOM- 20251016 LR - 20261010 IS - 1432-1076 (Electronic) IS - 0340-6199 (Linking) VI - 184 IP - 11 DP - 2025 Oct 16 TI - Renal and cardiac involvements in children with transfusion-dependent thalassemia: A cross-sectional analysis. PG - 692 LID - 10.1007/s00431-025-06538-2 [doi] AB - Thalassemia is caused by a mutation in the globin genes of hemoglobin synthesis. Renal and cardiac complications may develop due to iron overload and chronic anemia seen in transfusion-dependent thalassemia (TDT). The aim of this study was to evaluate renal and cardiac function in pediatric TDT patients and to identify contributing risk factors. In this study, the data of 20 TDT patients aged 0-18 years who received regular transfusions at Konya City Hospital were retrospectively reviewed. The patients' demographic data, laboratory, and imaging results were obtained from their medical records. Renal function was assessed by estimating the glomerular filtration rate (eGFR) using creatinine/cystatin-C. Cardiac function was assessed by electrocardiography (ECG) and echocardiography (ECHO). Malnutrition was observed in seven (35%) of the 20 patients included in the study. The mean hemoglobin level of the patients was 9.25 g/dL, and the mean serum ferritin level was 3074.5 ng/mL. In the renal evaluation, the mean serum creatinine was 0.32 mg/dL, cystatin C was 1.00 mg/L, and eGFR was 129 mL/min/1.73 m(2). Glomerular hyperfiltration was observed in 12 (60%) of the patients, proteinuria in 5 (25%), and hypercalciuria in 3 (15%). In the cardiac evaluation, left ventricular hypertrophy was observed in 7 (35%) patients by ECHO and in 3 (15%) patients by ECG. Hypotension was observed in 3 (15%) patients, and non-dipper blood pressure patterns were observed in 2 (10%) patients. CONCLUSION: In pediatric TDT patients, hyperfiltration, tubular dysfunction, and left ventricular hypertrophy may be observed in the early stages due to anemia and iron overload. A regular and multidisciplinary approach is required for patients to reduce long-term complications. WHAT IS KNOWN: * Iron overload and chronic anemia in children with TDT lead to complications in the kidneys (hyperfiltration, tubular dysfunction) and heart (left ventricular hypertrophy). * Cardiovascular changes such as low blood pressure and non-dipper pattern associated with anemia are common. WHAT IS NEW: * A positive correlation between hemoglobin levels and kidney function (eGFR) and a negative correlation between ferritin and LVH have been identified. The relationship between growth retardation and anemia/iron overload has been emphasized. CI - (c) 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Yilmaz, Isa AU - Yilmaz I AUID- ORCID: 0000-0001-8654-9173 AD - Department of Pediatric Nephrology, Ministry of Health Konya City Hospital, Konya, Turkey. drisayilmaz@hotmail.com. FAU - Simsek, Ayse AU - Simsek A AUID- ORCID: 0000-0001-9250-078X AD - Department of Pediatric Hematology, Ministry of Health Konya City Hospital, Konya, Turkey. FAU - Yilmaz, Huseyin AU - Yilmaz H AUID- ORCID: 0000-0002-9971-9669 AD - Department of Pediatric Cardiology, Ministry of Health Konya City Hospital, Konya, Turkey. FAU - Cevizli, Derya AU - Cevizli D AUID- ORCID: 0000-0001-6333-7522 AD - Department of Pediatric Nephrology, Ministry of Health Konya City Hospital, Konya, Turkey. FAU - Leventoglu, Emre AU - Leventoglu E AUID- ORCID: 0000-0002-0504-7911 AD - Department of Pediatric Nephrology, Ministry of Health Konya City Hospital, Konya, Turkey. LA - eng PT - Journal Article DEP - 20251016 PL - Germany TA - Eur J Pediatr JT - European journal of pediatrics JID - 7603873 SB - IM MH - Humans MH - Child MH - Male MH - Female MH - Child, Preschool MH - Cross-Sectional Studies MH - Retrospective Studies MH - Adolescent MH - Infant MH - *Thalassemia/therapy/complications MH - Glomerular Filtration Rate MH - Iron Overload/etiology/complications MH - Blood Transfusion MH - *Kidney Diseases/etiology/diagnosis MH - Electrocardiography MH - *Heart Diseases/etiology/diagnosis MH - Risk Factors MH - Echocardiography OTO - NOTNLM OT - Glomerular hyperfiltration OT - Hypotension OT - Left ventricular hypertrophy OT - Left ventricular mass index OT - Transfusion-dependent thalassemia OT - Tubular dysfunction COIS- Declarations. Competing interests: The authors declare no competing interests. EDAT- 2025/10/16 05:32 MHDA- 2025/10/16 06:30 CRDT- 2025/10/15 23:38 PHST- 2025/07/24 00:00 [received] PHST- 2025/10/02 00:00 [accepted] PHST- 2025/09/16 00:00 [revised] PHST- 2025/10/16 06:30 [medline] PHST- 2025/10/16 05:32 [pubmed] PHST- 2025/10/15 23:38 [entrez] AID - 10.1007/s00431-025-06538-2 [pii] AID - 10.1007/s00431-025-06538-2 [doi] PST - epublish SO - Eur J Pediatr. 2025 Oct 16;184(11):692. doi: 10.1007/s00431-025-06538-2. PMID- 41091474 OWN - NLM STAT- MEDLINE DCOM- 20251015 LR - 20260722 IS - 2574-3805 (Electronic) IS - 2574-3805 (Linking) VI - 8 IP - 10 DP - 2025 Oct 1 TI - Multidisciplinary Treatment of Patients With Noonan Syndrome: A Consensus Statement. PG - e2537603 LID - 10.1001/jamanetworkopen.2025.37603 [doi] AB - IMPORTANCE: Noonan syndrome (NS) is a rare developmental disorder and the most common condition among the RASopathies. Diagnosis and treatment of NS can be challenging due to the wide phenotypic variability of its manifestations. A multidisciplinary approach is essential, with continuous care required from infancy through adulthood; however, there is a lack of updated and widely shared guidelines for treating this condition. OBJECTIVE: To develop consensus statements on the diagnosis of NS, patient transition from pediatric to adult care, follow-up, and treatment of short stature with recombinant human growth hormone (rhGH). EVIDENCE REVIEW: Consensus was achieved through a modified Delphi process involving a multidisciplinary steering committee comprising 3 pediatric endocrinologists, 1 pediatric cardiologist, 1 molecular geneticist, along with a 25-member expert panel who had expertise in treating NS at clinical reference centers in Italy. In December 2023, the steering committee drafted 47 statements based on published evidence and clinical experience. These statements were then submitted to the expert panel, which provided anonymous feedback on their level of agreement or disagreement between January and March 2024. FINDINGS: All 25 members of the expert panel completed the Delphi survey and consensus was achieved on all statements after the first round of voting. Full agreement (100%) was reached on several key points: importance of molecular characterization for diagnosis, prognosis, and treatment decisions; necessity of a multidisciplinary approach to NS treatment; need for improved transition from pediatric to adult care; increased risk in patients with hypertrophic cardiomyopathy (HCM); importance of monitoring adherence to rhGH therapy; acknowledgment that partial GH insensitivity should not exclude rhGH therapy; and safety concerns regarding rhGH therapy, particularly related to HCM and the risk of malignant neoplasms. CONCLUSIONS AND RELEVANCE: Effective treatment of NS requires a multidisciplinary and personalized approach from infancy through adulthood. This comprehensive set of consensus statements is intended for clinicians to implement more effective care of patients with NS. FAU - Stagi, Stefano AU - Stagi S AD - Department of Health Sciences, University of Florence, Florence, Italy. AD - Auxo-endocrinology Division, Meyer Children's Hospital, IRCSS, Florence, Italy. FAU - Cappa, Marco AU - Cappa M AD - Research Unit for Innovative Therapies in Endocrinopathies, Bambino Gesu Children's Hospital, IRCCS, Rome, Italy. FAU - Gagliardi, Maria Giulia AU - Gagliardi MG AD - Bambino Gesu Children's Hospital, IRCCS, Rome, Italy. FAU - Tartaglia, Marco AU - Tartaglia M AD - Molecular Genetics and Functional Genomics, Bambino Gesu Children's Hospital, IRCCS, Rome, Italy. FAU - Maghnie, Mohamad AU - Maghnie M AD - Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa, Italy. AD - Department of Pediatrics, Endocrinology Unit, Istituto Giannina Gaslini, IRCCS, Genoa, Italy. CN - Italian Multidisciplinary Noonan Syndrome Working Group LA - eng PT - Consensus Statement PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20251001 PL - United States TA - JAMA Netw Open JT - JAMA network open JID - 101729235 RN - 12629-01-5 (Human Growth Hormone) SB - IM MH - Humans MH - *Noonan Syndrome/therapy/diagnosis MH - Delphi Technique MH - Child MH - *Human Growth Hormone/therapeutic use MH - Adult MH - Transition to Adult Care MH - Italy FIR - Antoniazzi, Franco IR - Antoniazzi F FIR - Brambilla, Ilaria IR - Brambilla I FIR - Cappa, Marco IR - Cappa M FIR - Cattoni, Alessandro IR - Cattoni A FIR - Cherubini, Valentino IR - Cherubini V FIR - De Luca, Alessandro IR - De Luca A FIR - Faienza, Maria Felicia IR - Faienza MF FIR - Favilli, Silvia IR - Favilli S FIR - Formigari, Roberto IR - Formigari R FIR - Franceschi, Roberto IR - Franceschi R FIR - Giacomozzi, Claudio IR - Giacomozzi C FIR - Grandone, Anna IR - Grandone A FIR - Guazzarotti, Laura IR - Guazzarotti L FIR - Ibba, Anastasia IR - Ibba A FIR - Iughetti, Lorenzo IR - Iughetti L FIR - Limongelli, Giuseppe IR - Limongelli G FIR - Longhi, Silvia IR - Longhi S FIR - Maghnie, Mohamad IR - Maghnie M FIR - Mazzanti, Laura IR - Mazzanti L FIR - Pozzobon, Gabriella IR - Pozzobon G FIR - Salerno, Mariacarolina IR - Salerno M FIR - Scarano, Emanuela IR - Scarano E FIR - Stagi, Stefano IR - Stagi S FIR - Street, Maria Elisabeth IR - Street ME FIR - Tornese, Gianluca IR - Tornese G FIR - Tyutyusheva, Nina IR - Tyutyusheva N FIR - Vannelli, Silvia IR - Vannelli S FIR - Wasniewska, Malgorzata Gabriella IR - Wasniewska MG EDAT- 2025/10/15 12:30 MHDA- 2025/10/15 18:28 CRDT- 2025/10/15 11:33 PHST- 2025/10/15 18:28 [medline] PHST- 2025/10/15 12:30 [pubmed] PHST- 2025/10/15 11:33 [entrez] AID - 2840145 [pii] AID - 10.1001/jamanetworkopen.2025.37603 [doi] PST - epublish SO - JAMA Netw Open. 2025 Oct 1;8(10):e2537603. doi: 10.1001/jamanetworkopen.2025.37603. PMID- 41090802 OWN - NLM STAT- MEDLINE DCOM- 20260521 LR - 20260522 IS - 1554-558X (Electronic) IS - 0894-1912 (Linking) VI - 46 IP - 2 DP - 2026 Spring 01 TI - From Training to Reality: System-Level Barriers and Behavioral Gaps in Prehospital Cardiopulmonary Resuscitation Among Emergency Medical Technicians in Taiwan. PG - 95-102 LID - 10.1097/CEH.0000000000000625 [doi] AB - INTRODUCTION: Despite regular cardiopulmonary resuscitation (CPR) training, emergency medical technicians (EMTs) often struggle to transfer learned skills into real-world performance. This study explores how system-level and contextual factors affect learning transfer in Taiwan, using the Systems Engineering Initiative for Patient Safety and Kirkpatrick frameworks. METHODS: We employed a mixed-methods design involving 123 EMTs. Data sources included quality cardiopulmonary resuscitation simulation scores, 125 video-recorded out-of-hospital cardiac arrest events, and EMTs' open-ended reflections. Quantitative analyses examined associations between CPR performance and training or demographic variables. Qualitative data were analyzed thematically, guided by Systems Engineering Initiative for Patient Safety domains and Kirkpatrick levels 2 to 3. RESULTS: Automated external defibrillator voice prompts were significantly associated with improved compression rates ( P = .03 in regression analysis), whereas no demographic factor predicted compression depth or recoil, and the regression model explained only a small fraction of performance variance (adjusted R2 = 0.04). Video data revealed frequent field errors such as equipment misplacement, delayed automated external defibrillator use, and poor team coordination. Reflections highlighted environmental barriers and lack of structured debriefing. DISCUSSION: Findings suggest that real-world CPR performance is more influenced by systemic and contextual obstacles than by individual competencies. Enhancing psychological realism, team-based simulations, and debriefing practices may improve learning transfer from training to field performance. The integration of simulation, field video, and EMT reflections underscores that training-performance gaps must be addressed through system-level reforms rather than isolated technical retraining. CI - Copyright (c) 2025 The Alliance for Continuing Education in the Health Professions, the Association for Hospital Medical Education, and the Society for Academic Continuing Medical Education. FAU - Huang, Wei-Hsiang AU - Huang WH AUID- ORCID: 0000-0002-5219-7920 AD - Dr. Huang: Firefighter (EMT-Paramedic), New Taipei City Government Fire Department, New Taipei City, Taiwan, and Adjunct Assistant Professor, Department of Early Childhood Care and Education, University of Kang Ning, Taipei City, Taiwan. LA - eng PT - Journal Article DEP - 20251016 PL - United States TA - J Contin Educ Health Prof JT - The Journal of continuing education in the health professions JID - 8805847 SB - IM MH - Humans MH - Taiwan MH - *Cardiopulmonary Resuscitation/education/methods/standards MH - *Emergency Medical Technicians/education/psychology/statistics & numerical data MH - Female MH - Male MH - Adult MH - Middle Aged MH - Clinical Competence/standards/statistics & numerical data MH - Qualitative Research MH - Emergency Medical Services/methods/standards MH - Out-of-Hospital Cardiac Arrest/therapy OTO - NOTNLM OT - EMTs OT - SEIPS framework OT - behavioral transfer OT - continuing professional development OT - simulation-based training COIS- Disclosures: The author declares no conflict of interest. EDAT- 2025/10/15 12:30 MHDA- 2026/05/22 00:33 CRDT- 2025/10/15 08:53 PHST- 2026/05/22 00:33 [medline] PHST- 2025/10/15 12:30 [pubmed] PHST- 2025/10/15 08:53 [entrez] AID - 00005141-202606000-00005 [pii] AID - 10.1097/CEH.0000000000000625 [doi] PST - ppublish SO - J Contin Educ Health Prof. 2026 Spring 01;46(2):95-102. doi: 10.1097/CEH.0000000000000625. Epub 2025 Oct 16. PMID- 41089805 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251015 LR - 20251017 IS - 2153-8174 (Electronic) IS - 1530-6550 (Print) IS - 1530-6550 (Linking) VI - 26 IP - 9 DP - 2025 Sep TI - Multidisciplinary Atrial Fibrillation Clinics: A Model for Comprehensive Management. PG - 38739 LID - 10.31083/RCM38739 [doi] LID - 38739 AB - Atrial fibrillation (AF) is the most common cardiac arrhythmia and is associated with increased morbidity, mortality, and healthcare expenses. Meanwhile, effective management of AF requires a comprehensive, patient-centered approach that includes risk factor modification, rate and rhythm control strategies, and prevention of thromboembolic events. Multidisciplinary AF clinics have emerged as a model for comprehensive management to improve patient outcomes and reduce healthcare burden. This review discusses the rationale, structure, benefits, challenges, and future directions of multidisciplinary AF clinics, emphasizing their role in optimizing AF management. CI - Copyright: (c) 2025 The Author(s). Published by IMR Press. FAU - Abdelnabi, Mahmoud AU - Abdelnabi M AUID- ORCID: 0000-0001-8016-9049 AD - Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ 85054, USA. FAU - Ashour, Firas AU - Ashour F AD - Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA. FAU - Rodriguez, Cristian AU - Rodriguez C AD - Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA. FAU - Puchongmart, Chanokporn AU - Puchongmart C AD - Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA. FAU - Thiravetyan, Ben AU - Thiravetyan B AD - Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA. FAU - Cruz, Diego AU - Cruz D AD - Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA. FAU - Ibrahim, Ramzi AU - Ibrahim R AD - Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ 85054, USA. FAU - Pham, Hoang Nhat AU - Pham HN AD - Department of Medicine, University of Arizona, Tucson, AZ 85719, USA. FAU - Habib, Eiad AU - Habib E AD - Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ 85054, USA. FAU - Kanaan, Christopher AU - Kanaan C AD - Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ 85054, USA. FAU - Arsanjani, Reza AU - Arsanjani R AD - Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ 85054, USA. FAU - Sorajja, Dan AU - Sorajja D AD - Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ 85054, USA. LA - eng PT - Journal Article PT - Review DEP - 20250924 PL - Singapore TA - Rev Cardiovasc Med JT - Reviews in cardiovascular medicine JID - 100960007 PMC - PMC12516757 OTO - NOTNLM OT - atrial fibrillation OT - cerebrovascular stroke OT - clinics OT - multidisciplinary clinics OT - prevention OT - risk factors OT - thromboembolic events COIS- The authors declare no conflict of interest. EDAT- 2025/10/15 06:30 MHDA- 2025/10/15 06:31 PMCR- 2025/09/24 CRDT- 2025/10/15 04:54 PHST- 2025/03/02 00:00 [received] PHST- 2025/06/15 00:00 [revised] PHST- 2025/07/15 00:00 [accepted] PHST- 2025/10/15 06:31 [medline] PHST- 2025/10/15 06:30 [pubmed] PHST- 2025/10/15 04:54 [entrez] PHST- 2025/09/24 00:00 [pmc-release] AID - S1530-6550(25)01937-4 [pii] AID - 10.31083/RCM38739 [doi] PST - epublish SO - Rev Cardiovasc Med. 2025 Sep 24;26(9):38739. doi: 10.31083/RCM38739. eCollection 2025 Sep. PMID- 41089790 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251015 LR - 20251017 IS - 2153-8174 (Electronic) IS - 1530-6550 (Print) IS - 1530-6550 (Linking) VI - 26 IP - 9 DP - 2025 Sep TI - Four-Step Framework for Valve-in-Valve Transcatheter Aortic Valve Replacement for Failed Surgical and Transcatheter Aortic Bioprostheses. PG - 43142 LID - 10.31083/RCM43142 [doi] LID - 43142 AB - Transcatheter aortic valve replacement (TAVR), originally developed to treat native aortic valve disease, has become increasingly adopted in the valve-in-valve (ViV) setting to manage bioprosthetic valve dysfunction of both surgically implanted bioprostheses (TAV-in-SAV) and prior transcatheter valves (TAV-in-TAV). Recent advances have significantly refined the ViV technique to address procedural challenges, including suboptimal hemodynamic outcomes and the risk of coronary obstruction. This review summarizes the current clinical data supporting the use of TAVR in a ViV setting and outlines a structured, four-step framework that encompasses procedural planning, including determining the perioperative risk for a patient, identifying the mode of valve failure, recognizing valve-specific implantation strategies, and assessing concomitant structural lesions. This review also aims to synthesize current evidence into a clinically actionable format, helping to guide heart team discussions, pre-procedural planning, and patient counseling. CI - Copyright: (c) 2025 The Author(s). Published by IMR Press. FAU - Brankovic, Milos AU - Brankovic M AUID- ORCID: 0000-0002-4730-957X AD - Cardiovascular Division, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA. FAU - Akram, Hassan AU - Akram H AD - Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA. FAU - Shabbir, Aisha AU - Shabbir A AD - Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA. FAU - Alhuneafat, Laith AU - Alhuneafat L AD - Cardiovascular Division, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA. FAU - Sharma, Abhishek AU - Sharma A AD - Division of Cardiology, Department of Medicine, Rutgers New Jersey Medical School, Newark, NJ 07103, USA. LA - eng PT - Journal Article PT - Review DEP - 20250929 PL - Singapore TA - Rev Cardiovasc Med JT - Reviews in cardiovascular medicine JID - 100960007 PMC - PMC12516776 OTO - NOTNLM OT - bioprosthetic valve failure OT - structural valve deterioration OT - transcatheter aortic valve implantation, TAVI OT - transcatheter aortic valve replacement, TAVR OT - transcatheter aortic valve-in-surigical aortic valve OT - transcatheter aortic valve-in-transcatheter aortic valve OT - valve-in-valve, ViV COIS- The authors declare no conflict of interest. EDAT- 2025/10/15 06:29 MHDA- 2025/10/15 06:30 PMCR- 2025/09/29 CRDT- 2025/10/15 04:54 PHST- 2025/06/07 00:00 [received] PHST- 2025/08/01 00:00 [revised] PHST- 2025/08/12 00:00 [accepted] PHST- 2025/10/15 06:30 [medline] PHST- 2025/10/15 06:29 [pubmed] PHST- 2025/10/15 04:54 [entrez] PHST- 2025/09/29 00:00 [pmc-release] AID - S1530-6550(25)01973-8 [pii] AID - 10.31083/RCM43142 [doi] PST - epublish SO - Rev Cardiovasc Med. 2025 Sep 29;26(9):43142. doi: 10.31083/RCM43142. eCollection 2025 Sep. PMID- 41089501 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251015 LR - 20260925 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 15 DP - 2025 TI - An interdisciplinary approach to ensure adherence to exercise and potentially reduce adverse cardiac events in cancer patients: primers in cardio-oncology. PG - 1649742 LID - 10.3389/fonc.2025.1649742 [doi] LID - 1649742 AB - Exercise training can improve mortality, quality of life, exercise capacity and morbidity in cancer patients. Although current cardio-oncological guidelines recommend exercise intervention in cancer patients, a structured, interdisciplinary approach from diagnosis to maintenance of therapy including repetitive sports cardiological assessment to guide exercise intervention has not been established. Currently, exercise prescriptions are based on assessment of peak oxygen consumption, which does not differentiate between central (stroke volume and heart rate reserve) and peripheral (peripheral oxygen difference) limitations. Knowledge of these mechanisms could facilitate more effective exercise prescriptions because cancer subtypes may respond differently to exercise stimuli requiring individualized and cancer-specific exercise intervention. Our approach uses simultaneous cardiopulmonary exercise testing and stress echocardiography to analyze the entire oxygen cascade in one exam. Based on these findings, we propose individualized assessment of treatment and cardiovascular risk as well as exercise prescriptions. As cardiopulmonary limitations indicative of cancer therapy-related cardiac dysfunction or cardiotoxicity may first be detected during exercise, our approach may help to address cancer therapy-related adverse events earlier. Our approach contains repetitive exercise testing which should serve to re-assess efficacy of exercise intervention. Results of each sports cardio-oncological assessment is fed back to the treating oncologists as it may provide valuable insights to adapt treatment regimens. In addition, we propose a transition from supervised on-site and home-based to self-directed training, which may achieve better long-term training adherence from prehabilitation to post-treatment. In the advent of precision medicine and oncology we provide a concept for precision sports cardio-oncological care to tailor individual exercise prescriptions based on pathophysiological findings during exercise testing. CI - Copyright (c) 2025 Wernhart, Fiorentini, Madl, Kuehberger, Glowka, Murr, Grill, Kiechle, Alguel, Bassermann, Combs, Gschwend, Haykowsky and Halle. FAU - Wernhart, Simon AU - Wernhart S AD - Department for Preventive Sports Medicine and Sports Cardiology, TUM School of Medicine and Health, TUM University Hospital, Technical University of Munich (TUM), Munich, Germany. AD - DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany. FAU - Fiorentini, Caterina AU - Fiorentini C AD - Department for Preventive Sports Medicine and Sports Cardiology, TUM School of Medicine and Health, TUM University Hospital, Technical University of Munich (TUM), Munich, Germany. FAU - Madl, Bernadine AU - Madl B AD - Department for Preventive Sports Medicine and Sports Cardiology, TUM School of Medicine and Health, TUM University Hospital, Technical University of Munich (TUM), Munich, Germany. FAU - Kuehberger, Louisa AU - Kuehberger L AD - Department for Preventive Sports Medicine and Sports Cardiology, TUM School of Medicine and Health, TUM University Hospital, Technical University of Munich (TUM), Munich, Germany. FAU - Glowka, Simon AU - Glowka S AD - Department for Preventive Sports Medicine and Sports Cardiology, TUM School of Medicine and Health, TUM University Hospital, Technical University of Munich (TUM), Munich, Germany. FAU - Murr, Elena AU - Murr E AD - Department for Preventive Sports Medicine and Sports Cardiology, TUM School of Medicine and Health, TUM University Hospital, Technical University of Munich (TUM), Munich, Germany. FAU - Grill, Sabine AU - Grill S AD - Department of Gynecology and Obstetrics, Technical University Munich (TUM), Munich, Germany. FAU - Kiechle, Marion AU - Kiechle M AD - Department of Gynecology and Obstetrics, Technical University Munich (TUM), Munich, Germany. FAU - Alguel, Hana AU - Alguel H AD - Comprehensive Cancer Center, Technical University Munich (TUM), Munich, Germany. FAU - Bassermann, Florian AU - Bassermann F AD - Department of Hematology and Oncology, Technical University Munich (TUM), Munich, Germany. FAU - Combs, Stephanie E AU - Combs SE AD - Department of Radio Oncology and Radiation Therapy, Technical University Munich (TUM), Munich, Germany. FAU - Gschwend, Juergen E AU - Gschwend JE AD - Department of Urology, Technical University Munich (TUM), Munich, Germany. FAU - Haykowsky, Mark J AU - Haykowsky MJ AD - Integrated Cardiovascular Exercise Physiology and Rehabilitation Lab, College of Health Sciences, University of Alberta, Edmonton, AB, Canada. AD - Hochgebirgsklinik, Davos, Switzerland. FAU - Halle, Martin AU - Halle M AD - Department for Preventive Sports Medicine and Sports Cardiology, TUM School of Medicine and Health, TUM University Hospital, Technical University of Munich (TUM), Munich, Germany. AD - DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany. LA - eng PT - Journal Article DEP - 20250929 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC12516702 OTO - NOTNLM OT - cancer therapy-related cardiac dysfunction OT - cardio-oncology OT - cardiotoxicity OT - exercise testing OT - long-term adherence COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2025/10/15 12:10 MHDA- 2025/10/15 12:11 PMCR- 2025/09/29 CRDT- 2025/10/15 04:50 PHST- 2025/06/18 00:00 [received] PHST- 2025/09/11 00:00 [accepted] PHST- 2025/10/15 12:11 [medline] PHST- 2025/10/15 12:10 [pubmed] PHST- 2025/10/15 04:50 [entrez] PHST- 2025/09/29 00:00 [pmc-release] AID - 10.3389/fonc.2025.1649742 [doi] PST - epublish SO - Front Oncol. 2025 Sep 29;15:1649742. doi: 10.3389/fonc.2025.1649742. eCollection 2025. PMID- 41088689 OWN - NLM STAT- MEDLINE DCOM- 20251015 LR - 20260114 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 104 IP - 41 DP - 2025 Oct 10 TI - Evaluating the efficacy of perioperative bundle care in reducing postoperative complications among patients undergoing coronary artery interventions. PG - e43830 LID - 10.1097/MD.0000000000043830 [doi] LID - e43830 AB - This study sought to assess whether implementing a perioperative bundle care strategy could enhance recovery and minimize adverse events in patients undergoing percutaneous coronary intervention (PCI). A retrospective cohort analysis was conducted on 134 PCI patients treated between February 2023 and February 2024. Participants were categorized into 2 groups: an experimental group (n = 51) receiving structured bundle care and a control group (n = 83) managed with conventional protocols. Following propensity score matching, 50 patients from each cohort were included for comparative evaluation. Key metrics analyzed included baseline demographics, perioperative management, and postoperative outcomes, such as complication incidence, recovery progression, and patient-reported satisfaction. The bundle care intervention significantly lowered the occurrence of postoperative adverse events, including bleeding, hematoma, and pseudoaneurysm formation (P < .05). Additionally, this approach accelerated clinical recovery, evidenced by quicker stabilization of hemodynamic parameters (e.g., blood pressure and heart rate) and improved adherence to postoperative guidelines. Patients receiving bundle care also reported higher satisfaction levels and better health-related quality of life (HRQoL), alongside notable reductions in anxiety and depression scores compared to the control group. Perioperative bundle care demonstrates substantial benefits in PCI patients, including fewer complications, expedited recovery, and greater patient satisfaction. These findings suggest that this systematic, multidisciplinary approach holds significant potential for optimizing perioperative management in coronary interventions. Further prospective research is recommended to validate these results and investigate the long-term impact of bundle care in this clinical setting. CI - Copyright (c) 2025 the Author(s). Published by Wolters Kluwer Health, Inc. FAU - Li, Gaoya AU - Li G AD - Department of Cardiovascular Medicine Center, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, Hubei Province, China. FAU - Tan, Piaopiao AU - Tan P AD - Department of Cardiovascular Medicine Center, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, Hubei Province, China. FAU - Li, Lu AU - Li L AD - Department of Cardiovascular Medicine Center, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, Hubei Province, China. FAU - Tan, Huarong AU - Tan H AUID- ORCID: 0009-0002-2899-9795 AD - Department of Radiology, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, Hubei Province, China. LA - eng PT - Journal Article PT - Observational Study PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R SB - IM MH - Humans MH - Male MH - Female MH - Retrospective Studies MH - *Postoperative Complications/prevention & control/epidemiology MH - *Percutaneous Coronary Intervention/adverse effects/methods MH - Middle Aged MH - Aged MH - *Patient Care Bundles/methods MH - Quality of Life MH - Patient Satisfaction MH - *Perioperative Care/methods MH - Propensity Score PMC - PMC12517853 OTO - NOTNLM OT - bundled care OT - patient satisfaction OT - percutaneous coronary intervention (PCI) OT - postoperative complications OT - rehabilitation OT - retrospective study COIS- The authors have no funding and conflicts of interest to disclose. EDAT- 2025/10/15 06:29 MHDA- 2025/10/15 06:30 PMCR- 2025/10/10 CRDT- 2025/10/15 01:03 PHST- 2025/05/25 00:00 [received] PHST- 2025/07/22 00:00 [accepted] PHST- 2025/10/15 06:30 [medline] PHST- 2025/10/15 06:29 [pubmed] PHST- 2025/10/15 01:03 [entrez] PHST- 2025/10/10 00:00 [pmc-release] AID - 00005792-202510100-00118 [pii] AID - MD-D-25-06325 [pii] AID - 10.1097/MD.0000000000043830 [doi] PST - ppublish SO - Medicine (Baltimore). 2025 Oct 10;104(41):e43830. doi: 10.1097/MD.0000000000043830. PMID- 41085952 OWN - NLM STAT- MEDLINE DCOM- 20251126 LR - 20261009 IS - 1179-1985 (Electronic) IS - 1120-9879 (Linking) VI - 32 IP - 6 DP - 2025 Nov TI - Cardiovascular Pre-participation Evaluation of Athletes with an Impairment Recruited for Paris 2024 Paralympic Games. PG - 617-628 LID - 10.1007/s40292-025-00740-x [doi] AB - INTRODUCTION: Paralympic athletes (PA) represent a special part of the athletic population and deserve a specialized functional and medical care. In view of the 2024 Paris Paralympic Games, a comprehensive sport medical screening was carried out in Italy. This pre-participation medical assessment included clinical, laboratory and instrumental tests including cardiopulmonary exercise test (CPET) and trans thoracic echocardiography (TTE). AIM: To assess prevalence and type of cardiovascular abnormalities in PA candidate to compete in 2024 Paralympic Games. METHODS: We enrolled 167 PA, 80 female and 87 male PA. All of them underwent a comprehensive, multidisciplinary evaluation, including a full panel of blood tests, resting ECG, TTE and CPET. RESULTS: 74 PA (44%) showed one or more cardiovascular abnormalities. In details, 12 PA showed abnormal basal ECG findings, 7 abnormal TTE results, 1 uncontrolled hypertension, 30 exercise induced arrhythmias, 8 abnormal basal ECG findings in combination with exercise induced arrhythmias and 7 abnormal basal ECG finding and abnormal echocardiographic findings. Furthermore, 9 PA showed exercise test induced arrhythmias with abnormal echocardiographic findings. CONCLUSIONS: PA, despite their attitude high levels of performance, are not exempt from cardiovascular and metabolic abnormalities, including a small proportion of cardiac conditions at potential risk of sudden cardiac death. Comprehensive diagnostic tools, including CPET, echocardiography and full blood tests are important to identify hidden cardiovascular abnormalities potentially harmful to the athlete's health. CI - (c) 2025. The Author(s). FAU - Squeo, Maria Rosaria AU - Squeo MR AD - Institute of Sports Medicine and Science, National Italian Olympic Committee, Largo Piero Gabrielli, 1, 00197, Rome, Italy. mariarosaria.squeo@coni.it. FAU - Ferrera, Armando AU - Ferrera A AD - Institute of Sports Medicine and Science, National Italian Olympic Committee, Largo Piero Gabrielli, 1, 00197, Rome, Italy. FAU - Di Gioia, Giuseppe AU - Di Gioia G AD - Institute of Sports Medicine and Science, National Italian Olympic Committee, Largo Piero Gabrielli, 1, 00197, Rome, Italy. AD - Department of Movement, Human and Health Sciences, University of Rome "Foro Italico", Piazza Lauro De Bosis, 15, 00135, Rome, Italy. FAU - Triolo, Cristian AU - Triolo C AD - Department of Biomedical, Dental Sciences and Morphological and Functional Images, University of Messina, 98125, Messina, Italy. FAU - Serdoz, Andrea AU - Serdoz A AD - Institute of Sports Medicine and Science, National Italian Olympic Committee, Largo Piero Gabrielli, 1, 00197, Rome, Italy. FAU - Mango, Federica AU - Mango F AD - Institute of Sports Medicine and Science, National Italian Olympic Committee, Largo Piero Gabrielli, 1, 00197, Rome, Italy. FAU - Maestrini, Viviana AU - Maestrini V AD - Institute of Sports Medicine and Science, National Italian Olympic Committee, Largo Piero Gabrielli, 1, 00197, Rome, Italy. AD - Department of Clinical, Internal, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, Piazzale Aldo Moro, 5, 00185, Rome, Italy. FAU - Monosilio, Sara AU - Monosilio S AD - Institute of Sports Medicine and Science, National Italian Olympic Committee, Largo Piero Gabrielli, 1, 00197, Rome, Italy. AD - Department of Clinical, Internal, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, Piazzale Aldo Moro, 5, 00185, Rome, Italy. FAU - Dutti, Giovanni Marco AU - Dutti GM AD - IRCCS San Raffaele Roma, 00166, Rome, Italy. FAU - Spinelli, Alessandro AU - Spinelli A AD - Institute of Sports Medicine and Science, National Italian Olympic Committee, Largo Piero Gabrielli, 1, 00197, Rome, Italy. FAU - Fiore, Roberto AU - Fiore R AD - Institute of Sports Medicine and Science, National Italian Olympic Committee, Largo Piero Gabrielli, 1, 00197, Rome, Italy. FAU - Zampaglione, Domenico AU - Zampaglione D AD - Institute of Sports Medicine and Science, National Italian Olympic Committee, Largo Piero Gabrielli, 1, 00197, Rome, Italy. FAU - Paoletti, Giulia AU - Paoletti G AD - Institute of Sports Medicine and Science, National Italian Olympic Committee, Largo Piero Gabrielli, 1, 00197, Rome, Italy. FAU - Crotta, Simone AU - Crotta S AD - Institute of Sports Medicine and Science, National Italian Olympic Committee, Largo Piero Gabrielli, 1, 00197, Rome, Italy. FAU - Santoro, Giuseppe AU - Santoro G AD - Department of Biomedical, Dental Sciences and Morphological and Functional Images, University of Messina, 98125, Messina, Italy. FAU - Volpe, Massimo AU - Volpe M AD - IRCCS San Raffaele Roma, 00166, Rome, Italy. FAU - Pelliccia, Antonio AU - Pelliccia A AD - Institute of Sports Medicine and Science, National Italian Olympic Committee, Largo Piero Gabrielli, 1, 00197, Rome, Italy. FAU - Bernardi, Marco AU - Bernardi M AD - Department of Physiology and Pharmacology "V. Erspamer", Sapienza University of Rome, Rome, Italy. LA - eng PT - Journal Article DEP - 20251014 PL - New Zealand TA - High Blood Press Cardiovasc Prev JT - High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension JID - 9421087 SB - IM MH - Humans MH - Male MH - Female MH - Adult MH - *Cardiovascular Diseases/epidemiology/diagnosis/physiopathology MH - Prevalence MH - *Para-Athletes MH - Young Adult MH - Electrocardiography MH - Predictive Value of Tests MH - Exercise Test MH - Echocardiography MH - *Sports for Persons with Disabilities MH - Risk Assessment MH - Middle Aged MH - Risk Factors MH - Heart Disease Risk Factors MH - Italy/epidemiology MH - Paris/epidemiology OTO - NOTNLM OT - Cardiovascular prevention OT - Cardiovascular screening OT - Disability OT - Oxygen uptake peak OT - Pre-participation evaluation OT - Sport cardiology OT - Sports medicine COIS- Declarations. Conflict of interest: The authors delcares that they have no conflict of interest. Ethical Approval: The study design of the present investigation was evaluated and approved by the Ethical Committee (CET - Comitato Etico Territoriale Lazio Area 1, date of approval 06\03\2024 IRB number 0208/2024). All athletes included in this study were fully informed of the types and nature of the evaluation and signed the consent form, according to Italian Law and Institute policy. All clinical data assembled from the study population are maintained in an institutional database. De-identified participant data are available upon reasonable request from the corresponding author. EDAT- 2025/10/14 12:30 MHDA- 2025/11/26 06:29 CRDT- 2025/10/14 11:24 PHST- 2025/07/22 00:00 [received] PHST- 2025/08/27 00:00 [accepted] PHST- 2025/11/26 06:29 [medline] PHST- 2025/10/14 12:30 [pubmed] PHST- 2025/10/14 11:24 [entrez] AID - 10.1007/s40292-025-00740-x [pii] AID - 10.1007/s40292-025-00740-x [doi] PST - ppublish SO - High Blood Press Cardiovasc Prev. 2025 Nov;32(6):617-628. doi: 10.1007/s40292-025-00740-x. Epub 2025 Oct 14. PMID- 41085415 OWN - NLM STAT- MEDLINE DCOM- 20260403 LR - 20260918 IS - 2149-2271 (Electronic) IS - 2149-2263 (Print) IS - 2149-2263 (Linking) VI - 29 IP - 11 DP - 2025 Oct 14 TI - Screening for Pulmonary Hypertension in Connective Tissue Diseases: Literature Review and Multidisciplinary Consensus Statement. PG - 599-607 LID - 10.14744/AnatolJCardiol.2025.5301 [doi] AB - Patients with connective tissue diseases (CTDs) are at increased risk for the development of pulmonary hypertension (PH) and pulmonary arterial hypertension (PAH), which is a specific subtype of PH characterized by progressive remodeling of precapillary pulmonary arterioles. Evidence suggests that early detection of PH through screening in this patient group may be associated with better outcomes. Various methods, including cardiac and thoracic imaging, blood biomarkers, pulmonary function tests, and composite algorithms, have been employed for screening of PH. Here, a multidisciplinary consensus group composed of 10 rheumatologists, 4 cardiologists, and 3 pulmonologists was formed with the objective of developing recommendations and a screening algorithm for PH in patients with CTD. A systematic literature review in the PubMed database focusing on the studies evaluating the performance of different screening methods on detecting PH in CTDs was conducted. The literature review identified 33 relevant articles after title, abstract, and full-text evaluation. The included studies had considerable heterogeneity regarding hemodynamic definitions of PH and PAH, the diagnostic cutoff values of screening methods utilized, and the symptom status of the patients. With the exception of 2 studies, the populations in included studies consisted of only patients with systemic sclerosis (SSc). Consensus-based recommendations and an algorithm prioritizing echocardiography for screening and early detection of PH in patients with SSc and patients with CTD exhibiting overlap features of SSc were developed based on literature data and incorporating the perspectives of group members. No recommendations could be made for asymptomatic patients with CTDs without overlap features of SSc due to limited data. FAU - Sari, Alper AU - Sari A AD - Department of Rheumatology, Etlik City Hospital, Ankara, Turkiye. FAU - Temiz Karadag, Duygu AU - Temiz Karadag D AD - Department of Rheumatology, Kocaeli University Faculty of Medicine, Kocaeli, Turkiye. FAU - Erdogan, Mustafa AU - Erdogan M AD - Department of Rheumatology, Marmara University Pendik Training and Research Hospital, Istanbul, Turkiye. FAU - Yayla, Mucteba Enes AU - Yayla ME AD - Department of Rheumatology, Ankara University Faculty of Medicine, Ankara, Turkiye. FAU - Firlatan Yazgan, Busra AU - Firlatan Yazgan B AD - Department of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkiye. FAU - Dikkanoglu Demirok, Betul AU - Dikkanoglu Demirok B AD - Department of Rheumatology, Kocaeli University Faculty of Medicine, Kocaeli, Turkiye. FAU - Amikishiyev, Shirkhan AU - Amikishiyev S AD - Department of Rheumatology, Istanbul University Faculty of Medicine, Istanbul, Turkiye. FAU - Yalcinkaya, Yasemin AU - Yalcinkaya Y AD - Department of Rheumatology, Istanbul University Faculty of Medicine, Istanbul, Turkiye. FAU - Inanc, Murat AU - Inanc M AD - Department of Rheumatology, Istanbul University Faculty of Medicine, Istanbul, Turkiye. FAU - Karcioglu, Oguz AU - Karcioglu O AD - Department of Chest Diseases, Hacettepe University Faculty of Medicine, Ankara, Turkiye. FAU - Karakulak, Ugur Nadir AU - Karakulak UN AD - Department of Cardiology, Hacettepe University Faculty of Medicine, Ankara, Turkiye. FAU - Onen, Zeynep Pinar AU - Onen ZP AD - Department of Chest Diseases, Ankara University Faculty of Medicine, Ankara, Turkiye. FAU - Akdeniz, Bahri AU - Akdeniz B AD - Department of Cardiology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkiye. FAU - Okumus, Gulfer AU - Okumus G AD - Department of Chest Diseases, Istanbul University Faculty of Medicine, Istanbul, Turkiye. FAU - Mutlu, Bulent AU - Mutlu B AD - Department of Cardiology, Marmara University Faculty of Medicine, Istanbul, Turkiye. FAU - Kucukoglu, Serdar AU - Kucukoglu S AD - Department of Cardiology, Istanbul University Cerrahpasa Faculty of Medicine, Istanbul, Turkiye. FAU - Akdogan, Ali AU - Akdogan A AD - Department of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkiye. LA - eng PT - Consensus Statement PT - Journal Article PT - Systematic Review PL - Turkey TA - Anatol J Cardiol JT - Anatolian journal of cardiology JID - 101652981 SB - IM MH - Humans MH - *Connective Tissue Diseases/complications MH - *Hypertension, Pulmonary/diagnosis/etiology/diagnostic imaging MH - Algorithms PMC - PMC12588305 COIS- Declaration of Interests: The authors have no conflicts of interest to declare. EDAT- 2025/10/14 12:29 MHDA- 2026/04/03 18:35 PMCR- 2025/10/13 CRDT- 2025/10/14 10:03 PHST- 2026/04/03 18:35 [medline] PHST- 2025/10/14 12:29 [pubmed] PHST- 2025/10/14 10:03 [entrez] PHST- 2025/10/13 00:00 [pmc-release] AID - ajc-29-11-599 [pii] AID - 10.14744/AnatolJCardiol.2025.5301 [doi] PST - ppublish SO - Anatol J Cardiol. 2025 Oct 14;29(11):599-607. doi: 10.14744/AnatolJCardiol.2025.5301. PMID- 41084877 OWN - NLM STAT- MEDLINE DCOM- 20251120 LR - 20260828 IS - 1945-1474 (Electronic) IS - 1062-2551 (Linking) VI - 47 IP - 4 DP - 2025 Oct-Dec 01 TI - Reducing Heart Failure Readmission Through Collaboration: An Acute Care and Post-Acute Success Story. LID - e0495 [pii] LID - 10.1097/JHQ.0000000000000495 [doi] AB - INTRODUCTION: Heart failure (HF) is one of the most common diagnoses in the United States during hospitalization. The incidence of HF is expected to increase in the future, coinciding with the expected increase in the utilization of post-acute care facilities. Recent studies have demonstrated that the implementation of an original Heart Failure Disease Management Program (HFDMP) has a significant potential to decrease readmissions. The Department of Internal Medicine at two acute care hospitals coordinated with a post-acute facility for the implementation of an HFDMP quality improvement project. METHODS: The interdisciplinary team developed the HFDMP, which included formalized training for the entire resident care staff, redesigning the post-acute facility's dietary manual, strengthening the postdischarge appointments workflow, creating a dedicated HF unit, identifying additional patient care supplies needed to care for residents with HF, and identifying metrics to monitor after implementation to determine success. RESULTS: Before the implementation of the program, the 30-day readmission rate of the HF hospital was 20%. After implementation, only one resident was readmitted for non-HF-related conditions, corresponding to a 30-day readmission rate of 2.78%. CONCLUSIONS: The implementation of similar HFDMPs at post-acute care facilities across the country represents a significant opportunity to decrease 30-day readmissions and improve resource utilization. CI - Copyright (c) 2025 National Association for Healthcare Quality. FAU - Ramic, Meghan M AU - Ramic MM AUID- ORCID: 0000-0002-0213-8295 FAU - Comiskey, Karen M AU - Comiskey KM FAU - Dorow, Lisa J AU - Dorow LJ FAU - Keller, Elizabeth R AU - Keller ER FAU - Abbasi, Ahmed M AU - Abbasi AM FAU - Baker, Kathleen M AU - Baker KM FAU - Mathews, Krista AU - Mathews K FAU - Okapal, Kevin M AU - Okapal KM FAU - Yousif, Omer A AU - Yousif OA FAU - Varga, Jacob J AU - Varga JJ FAU - Miniaci, Anthony M AU - Miniaci AM LA - eng PT - Journal Article DEP - 20251021 PL - United States TA - J Healthc Qual JT - Journal for healthcare quality : official publication of the National Association for Healthcare Quality JID - 9202994 SB - IM MH - *Patient Readmission/statistics & numerical data MH - Humans MH - *Heart Failure/therapy MH - *Quality Improvement/organization & administration MH - United States MH - Disease Management MH - *Cooperative Behavior OTO - NOTNLM OT - disease management program OT - heart failure OT - interdisciplinary OT - post-acute facility OT - readmission COIS- The authors declare no conflicts of interest. EDAT- 2025/10/14 12:30 MHDA- 2025/11/20 13:38 CRDT- 2025/10/14 06:32 PHST- 2025/11/20 13:38 [medline] PHST- 2025/10/14 12:30 [pubmed] PHST- 2025/10/14 06:32 [entrez] AID - 01445442-990000000-00115 [pii] AID - 10.1097/JHQ.0000000000000495 [doi] PST - ppublish SO - J Healthc Qual. 2025 Oct-Dec 01;47(4):e0495. doi: 10.1097/JHQ.0000000000000495. Epub 2025 Oct 21. PMID- 41081261 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251013 LR - 20251015 IS - 2434-0790 (Electronic) IS - 2434-0790 (Linking) VI - 7 IP - 10 DP - 2025 Oct 10 TI - Cardiac Rehabilitation and Heart Failure With Preserved Ejection Fraction. PG - 837-841 LID - 10.1253/circrep.CR-25-0130 [doi] AB - Heart failure with preserved ejection fraction (HFpEF) is becoming increasingly prevalent in aging societies. A recent multicenter cohort study in Japan demonstrated that cardiac rehabilitation (CR) significantly improves the prognosis of patients with HFpEF and frailty. The 2025 Japanese Heart Failure Guidelines recommend pharmacologic therapies for HFpEF. Recent international trials have led to the adoption of sodium-glucose transporter 2 inhibitors and angiotensin-receptor-neprilysin inhibitors in Japan, supported by evidence showing reduced rates of heart failure readmission. However, it should be noted that the majority of patients enrolled in those trials were in their early 70s. In real-world clinical practice, the number of patients in their 80s and 90s receiving treatment is increasing. This older population is more susceptible to adverse effects such as orthostatic hypotension, hyperkalemia, and urinary tract infections. Polypharmacy further complicates medication management. In such cases, CR plays a vital role in maintaining quality of life and supporting long-term prognosis. Furthermore, HFpEF is frequently accompanied by comorbidities such as atrial fibrillation, hypertension, and ischemic heart disease. It is important to note that elderly patients are also susceptible to additional conditions, including cerebrovascular disease, musculoskeletal disorders and malignancies. A multidisciplinary approach to CR, tailored to these complex health profiles, is essential to prevent the progression of functional decline and frailty. CI - Copyright (c) 2025, THE JAPANESE CIRCULATION SOCIETY. FAU - Hirashiki, Akihiro AU - Hirashiki A AD - Department of Cardiology, National Center for Geriatrics and Gerontology Aichi Japan. FAU - Shimizu, Atsuya AU - Shimizu A AD - Department of Cardiology, National Center for Geriatrics and Gerontology Aichi Japan. LA - eng PT - Journal Article DEP - 20250902 PL - Japan TA - Circ Rep JT - Circulation reports JID - 101746642 PMC - PMC12510967 OTO - NOTNLM OT - Cardiac rehabilitation OT - Heart failure OT - Preserved ejection fraction COIS- None. EDAT- 2025/10/13 12:31 MHDA- 2025/10/13 12:32 PMCR- 2025/09/02 CRDT- 2025/10/13 07:43 PHST- 2025/06/19 00:00 [received] PHST- 2025/06/19 00:00 [revised] PHST- 2025/06/20 00:00 [accepted] PHST- 2025/10/13 12:32 [medline] PHST- 2025/10/13 12:31 [pubmed] PHST- 2025/10/13 07:43 [entrez] PHST- 2025/09/02 00:00 [pmc-release] AID - 10.1253/circrep.CR-25-0130 [doi] PST - epublish SO - Circ Rep. 2025 Sep 2;7(10):837-841. doi: 10.1253/circrep.CR-25-0130. eCollection 2025 Oct 10. PMID- 41079596 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251013 LR - 20251015 IS - 2297-055X (Print) IS - 2297-055X (Electronic) IS - 2297-055X (Linking) VI - 12 DP - 2025 TI - Unveiling the spectrum of sudden cardiac death: a multidisciplinary analysis from the Friuli Venezia Giulia registry. PG - 1651235 LID - 10.3389/fcvm.2025.1651235 [doi] LID - 1651235 AB - INTRODUCTION: Sudden cardiac death in individuals aged 35 years. Toxicological analyses revealed polysubstance use in most positive cases, with ethanol, benzodiazepines, and methadone most detected. Genetic testing was performed in 14 cases identified pathogenic or likely pathogenic variants in five individuals, mainly involving hypertrophic cardiomyopathy, highlighting the utility of molecular autopsy for familial risk assessment. The registry uncovered a higher burden of substance-related mortality than official statistics, emphasizing underreporting in death certificates. Post-mortem cardiac MRI contributed to detecting myocardial abnormalities, aiding pathological examination. DISCUSSION: The study underscores the importance of a comprehensive, multidisciplinary registry model for accurate SCD cause determination, improved family screening, and targeted prevention strategies. These findings provide valuable epidemiological and genetic insights relevant to public health interventions, particularly in regions with unique genetic backgrounds such as Friuli Venezia Giulia. CI - (c) 2025 Radaelli, Moreschi, Bussani, Basciu, Di Loreto, Concato, Addobbati, Franzin, Cova, Pagnan, Girotto, Lenarduzzi, Spedicati, Dal Ferro, Sinagra and D'Errico. FAU - Radaelli, D AU - Radaelli D AD - Department of Medical Surgical and Health Sciences, University of Trieste, Trieste, Italy. AD - Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), University of Trieste, Trieste, Italy. FAU - Moreschi, C AU - Moreschi C AD - Departmental Section of Forensic Medicine, University of Udine, Udine, Italy. AD - Department of Medical and Biological Sciences, University of Udine, Udine, Italy. FAU - Bussani, R AU - Bussani R AD - Department of Medical Surgical and Health Sciences, University of Trieste, Trieste, Italy. AD - Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), University of Trieste, Trieste, Italy. FAU - Basciu, M AU - Basciu M AD - Department of Anatomy and Histopathology, ASFO, Pordenone, Italy. FAU - Di Loreto, C AU - Di Loreto C AD - Institute of Anatomic Pathology, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy. AD - Department of Medicine (DMED), University of Udine, Udine, Italy. FAU - Concato, M AU - Concato M AD - Department of Medical Surgical and Health Sciences, University of Trieste, Trieste, Italy. AD - Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), University of Trieste, Trieste, Italy. FAU - Addobbati, R AU - Addobbati R AD - Institute for Maternal and Child Health, IRCCS "Burlo Garofolo", Trieste, Italy. FAU - Franzin, M AU - Franzin M AD - Institute for Maternal and Child Health, IRCCS "Burlo Garofolo", Trieste, Italy. FAU - Cova, M A AU - Cova MA AD - Department of Medical Surgical and Health Sciences, University of Trieste, Trieste, Italy. AD - Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), University of Trieste, Trieste, Italy. FAU - Pagnan, L AU - Pagnan L AD - Department of Medical Surgical and Health Sciences, University of Trieste, Trieste, Italy. AD - Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), University of Trieste, Trieste, Italy. FAU - Girotto, G AU - Girotto G AD - Institute for Maternal and Child Health, IRCCS "Burlo Garofolo", Trieste, Italy. FAU - Lenarduzzi, S AU - Lenarduzzi S AD - Institute for Maternal and Child Health, IRCCS "Burlo Garofolo", Trieste, Italy. FAU - Spedicati, B AU - Spedicati B AD - Institute for Maternal and Child Health, IRCCS "Burlo Garofolo", Trieste, Italy. FAU - Dal Ferro, M AU - Dal Ferro M AD - Department of Medical Surgical and Health Sciences, University of Trieste, Trieste, Italy. AD - Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), University of Trieste, Trieste, Italy. FAU - Sinagra, G AU - Sinagra G AD - Department of Medical Surgical and Health Sciences, University of Trieste, Trieste, Italy. AD - Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), University of Trieste, Trieste, Italy. FAU - D'Errico, S AU - D'Errico S AD - Department of Medical Surgical and Health Sciences, University of Trieste, Trieste, Italy. AD - Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), University of Trieste, Trieste, Italy. LA - eng PT - Journal Article DEP - 20250926 PL - Switzerland TA - Front Cardiovasc Med JT - Frontiers in cardiovascular medicine JID - 101653388 PMC - PMC12510988 OTO - NOTNLM OT - autopsy OT - cardiomyopathy OT - multidisciplinary approach OT - prevention OT - sudden cardiac death COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer RD declared a past co-authorship with the author GS to the handling editor. EDAT- 2025/10/13 12:30 MHDA- 2025/10/13 12:31 PMCR- 2025/09/26 CRDT- 2025/10/13 07:28 PHST- 2025/06/21 00:00 [received] PHST- 2025/08/28 00:00 [accepted] PHST- 2025/10/13 12:31 [medline] PHST- 2025/10/13 12:30 [pubmed] PHST- 2025/10/13 07:28 [entrez] PHST- 2025/09/26 00:00 [pmc-release] AID - 10.3389/fcvm.2025.1651235 [doi] PST - epublish SO - Front Cardiovasc Med. 2025 Sep 26;12:1651235. doi: 10.3389/fcvm.2025.1651235. eCollection 2025. PMID- 41077369 OWN - NLM STAT- MEDLINE DCOM- 20260925 LR - 20261011 IS - 1556-3871 (Electronic) IS - 1547-5271 (Print) IS - 1547-5271 (Linking) VI - 23 IP - 10 DP - 2026 Oct TI - Alternative pacing strategies after transcatheter tricuspid valve interventions: Procedural challenges and lessons learned. PG - 2098-2106 LID - S1547-5271(25)02966-2 [pii] LID - 10.1016/j.hrthm.2025.10.013 [doi] AB - BACKGROUND: Decision making regarding new pacemaker implantation after transcatheter tricuspid valve intervention (TTVI), including transcatheter edge-to-edge repair (TEER) or transcatheter tricuspid valve replacement (TTVR), is complex owing to anatomic and TTVI-related challenges. OBJECTIVE: This study aimed to evaluate the feasibility of nontransvalvular pacing strategies, including coronary sinus (CS) or leadless pacemaker (LP) placement, after TTVI. METHODS: Consecutive patients undergoing TTVI at a single institution were retrospectively studied for new pacemaker indications and pacing strategy. Procedural challenges and outcomes associated with nontransvalvular pacemaker implantation were assessed. RESULTS: Among 137 patients who underwent TTVI (69 TTVR; 68 TEER) at a single center, 34 patients (25%) were excluded for preexisting pacemaker, and 15 of 103 patients (15%) subsequently developed an indication for pacing after TEER (n = 5 of 53; 9%) or TTVR (n = 10 of 50; 20%). An alternative pacing strategy was attempted after TEER and TTVR. After TEER (n = 5), CS lead placement was 50% successful (2 of 4) and 1 LP attempt was unsuccessful (0 of 1). After TTVR (n = 10), CS lead placement was 75% successful (6 of 8) and LP placement was 100% successful (2 of 2) on the initial attempt. CS lead placement was limited by CS anatomy, whereas LP placement was limited by TTVR interaction. A transvenous pacemaker was successfully placed if needed. No pacemaker device-related adverse event occurred in any patient peri-procedurally or at 1-year follow-up. CONCLUSION: Alternative nontransvalvular pacing strategies may be feasible and safe in patients who require pacing after TTVI. Preprocedural planning with a multidisciplinary approach can help optimize procedural success. Further studies and longer-term follow-up are warranted. CI - Copyright (c) 2025 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved. FAU - Tat, Emily AU - Tat E AD - Department of Medicine, Columbia University Irving Medical Center/NewYork-Presbyterian Hospital, New York, New York. FAU - Nazif, Tamim AU - Nazif T AD - Department of Medicine, Columbia University Irving Medical Center/NewYork-Presbyterian Hospital, New York, New York. FAU - George, Isaac AU - George I AD - Department of Medicine, Columbia University Irving Medical Center/NewYork-Presbyterian Hospital, New York, New York. FAU - Le Ruz, Robin AU - Le Ruz R AD - Interventional Cardiology Department, l'institut du thorax, Nantes Universite, CHU Nantes, Nantes, France. FAU - Hahn, Rebecca T AU - Hahn RT AD - Department of Medicine, Columbia University Irving Medical Center/NewYork-Presbyterian Hospital, New York, New York. FAU - Biviano, Angelo AU - Biviano A AD - Department of Medicine, Columbia University Irving Medical Center/NewYork-Presbyterian Hospital, New York, New York. FAU - Wan, Elaine Y AU - Wan EY AD - Department of Medicine, Columbia University Irving Medical Center/NewYork-Presbyterian Hospital, New York, New York. FAU - Kodali, Susheel K AU - Kodali SK AD - Department of Medicine, Columbia University Irving Medical Center/NewYork-Presbyterian Hospital, New York, New York. FAU - Yarmohammadi, Hirad AU - Yarmohammadi H AD - Department of Medicine, Columbia University Irving Medical Center/NewYork-Presbyterian Hospital, New York, New York. FAU - Saluja, Deepak AU - Saluja D AD - Department of Medicine, Columbia University Irving Medical Center/NewYork-Presbyterian Hospital, New York, New York. Electronic address: a.saluja@columbia.edu. LA - eng GR - R01 HL152236/HL/NHLBI NIH HHS/United States GR - R01 HL170606/HL/NHLBI NIH HHS/United States PT - Journal Article DEP - 20251010 PL - United States TA - Heart Rhythm JT - Heart rhythm JID - 101200317 SB - IM MH - Humans MH - Retrospective Studies MH - Female MH - *Cardiac Pacing, Artificial/methods MH - Male MH - *Cardiac Catheterization/methods MH - *Pacemaker, Artificial MH - *Tricuspid Valve/surgery MH - *Heart Valve Prosthesis Implantation/methods MH - Aged MH - Feasibility Studies MH - Treatment Outcome MH - Aged, 80 and over MH - Follow-Up Studies PMC - PMC12861325 MID - NIHMS2121902 OTO - NOTNLM OT - Alternative pacing OT - Coronary sinus lead OT - Leadless pacemaker OT - Transcatheter tricuspid valve repair OT - Transcatheter tricuspid valve replacement COIS- Disclosures Dr Nazif has received consulting fees or honoraria from Medtronic, Boston Scientific, Teleflex, Encompass Technologies, and OpSens Medical and received institutional research grants from Edwards Lifesciences, Boston Scientific, Medtronic, and Abbott. Dr George has received consulting fees from Cardiomech, Mitre Medical, AtriCure, VDyne, Valcare Medical, DurVena, MITRx, and Johnson & Johnson. Dr Wan is funded by National Institutes of Health National Heart, Lung, and Blood Institute R01HL152236 and National Institutes of Health National Heart, Lung, and Blood Institute R01HL170606 and has consulted for Boston Scientific, Medtronic, Cardiologs, and Sanofi. Dr Hahn reports speaker fees from Abbott Structural, Baylis Medical, Edwards Lifesciences, and Philips Healthcare; has institutional consulting contracts for which she receives no direct compensation with Abbott Structural, Anteris, Boston Scientific, Edwards Lifesciences, Medtronic, Novartis, and Philips Healthcare; and is the chief scientific officer for the Echocardiography Core Laboratory at the Cardiovascular Research Foundation for industry-sponsored valve trials, for which she receives no direct industry compensation. Dr Biviano is on the medical advisory board for AltaThera Pharmaceuticals. Dr Kodali received grant support, paid to his institution, from Medtronic, Boston Scientific, and Abbott Vascular; received consulting fees from Abbott Vascular, Claret Medical, Admedus, and Meril Life Sciences; and holds equity options in BioTrace Medical, Dura Biotech, and Thubrikar Aortic Valve. All other authors have no relationships relevant to the contents of this paper to disclose. EDAT- 2025/10/13 00:27 MHDA- 2026/09/25 23:47 PMCR- 2026/10/10 CRDT- 2025/10/12 19:34 PHST- 2025/08/05 00:00 [received] PHST- 2025/09/20 00:00 [revised] PHST- 2025/10/07 00:00 [accepted] PHST- 2026/09/25 23:47 [medline] PHST- 2025/10/13 00:27 [pubmed] PHST- 2025/10/12 19:34 [entrez] PHST- 2026/10/10 00:00 [pmc-release] AID - S1547-5271(25)02966-2 [pii] AID - 10.1016/j.hrthm.2025.10.013 [doi] PST - ppublish SO - Heart Rhythm. 2026 Oct;23(10):2098-2106. doi: 10.1016/j.hrthm.2025.10.013. Epub 2025 Oct 10. PMID- 41077359 OWN - NLM STAT- MEDLINE DCOM- 20251231 LR - 20260105 IS - 1873-6513 (Electronic) IS - 0885-3924 (Linking) VI - 71 IP - 2 DP - 2026 Feb TI - Improving Compassionate Extubation Practices in the Pediatric Intensive Care Unit. PG - 234-242 LID - S0885-3924(25)00872-3 [pii] LID - 10.1016/j.jpainsymman.2025.09.029 [doi] AB - BACKGROUND: This study was conducted in a free-standing pediatric academic institution in the pediatric intensive care unit (PICU) and cardiothoracic intensive care unit (CTICU), focusing on children with planned compassionate extubation (CE). Prior to the study, variability in CE practices led to inconsistencies in care and communication. OBJECTIVES: Implement and assess the efficacy of a protocol to ensure consistent symptom management, enhance documentation, and promote communication among providers during CE events. METHODS: Pre and post quality improvement project with implementation of a CE protocol in February 2022, including (1) a checklist to standardize orders, documentation, medical management, and provider availability around the time of CE and (2) a postextubation staff debriefing tool. The study was carried out by a multidisciplinary team composed of providers, nurses, respiratory therapists, palliative care specialists, and a child life specialist. The improvement team evaluated CE events for a 12 month period before (January-December 2020) and for 12 months after (February 2022-January 2023) the intervention roll-out date via manual chart review and Research Electronic Data Capture surveys of staff members who participated in the CE. The primary outcome was the compliance with best practices surrounding documentation and clinical interventions at the time of CE. Secondary outcomes included staff satisfaction with the CE process and rate of debriefings. RESULTS: There were 18 preintervention events and 26 postintervention CE events that underwent chart review. 53 surveys were reviewed, 20 preintervention and 33 postintervention. There was a significant increase in the appropriate placement of extubation orders (6% prior to protocol, 69% at study conclusion), improvement in timely advance care plan documentation (89% prior to protocol, 100% at study conclusion), and increase in cessation of vasoactive infusions at the time of extubation (78% prior to protocol, 100% at study conclusion). The rates of debriefs remained similar before and after protocol implementation (65% and 67% respectively). Overall, the protocol was well received by ICU staff, over 90% of staff surveys showed positive feedback on patient and provider comfort during CE. CONCLUSIONS: A CE protocol improved documentation and communication around pediatric end-of-life care. Future improvements should focus on exploring the barriers to postextubation debriefings. CI - Copyright (c) 2025 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved. FAU - Rinaldi, Elizabeth AU - Rinaldi E AD - Department of Anesthesiology Critical Care Medicine, Children's Hospital Los Angeles (E.R., R.V.K., M.C.W.), Los Angeles, California, US. Electronic address: elrinaldi@chla.usc.edu. FAU - Brostoff, Debbie AU - Brostoff D AD - Pediatric Intensive Care Unit, Children's Hospital Los Angeles (D.B.), Los Angeles, California, US. FAU - Klein, Robin V AU - Klein RV AD - Department of Anesthesiology Critical Care Medicine, Children's Hospital Los Angeles (E.R., R.V.K., M.C.W.), Los Angeles, California, US; Keck School of Medicine, University of Southern California (R.V.K., M.C.W.), Los Angeles, California, US. FAU - Winter, Meredith C AU - Winter MC AD - Department of Anesthesiology Critical Care Medicine, Children's Hospital Los Angeles (E.R., R.V.K., M.C.W.), Los Angeles, California, US; Keck School of Medicine, University of Southern California (R.V.K., M.C.W.), Los Angeles, California, US. LA - eng PT - Journal Article DEP - 20251010 PL - United States TA - J Pain Symptom Manage JT - Journal of pain and symptom management JID - 8605836 SB - IM MH - Humans MH - *Airway Extubation/methods/standards MH - *Intensive Care Units, Pediatric MH - *Quality Improvement MH - Child MH - Female MH - Male MH - Child, Preschool MH - Documentation OTO - NOTNLM OT - Intensive care units OT - airway extubation OT - checklist OT - pediatric OT - quality improvement OT - terminal care COIS- Disclosures and Acknowledgments The authors declare no conflicts of interest. We would like to thank the entire interdisciplinary quality improvement team at Children's Hospital Los Angeles for their expertise and commitment to implementing this intervention, including Sabrina Derrington, MD, MA, HECC for providing the debriefing tool, Patrick Ross, MD, and Debra Lotstein, MD, MPH. This work was supported by the Department of Anesthesiology Critical Care Medicine, Children's Hospital Los Angeles, George Donnell Society for Pediatric Scientists. EDAT- 2025/10/13 00:27 MHDA- 2026/01/01 00:35 CRDT- 2025/10/12 19:34 PHST- 2025/03/21 00:00 [received] PHST- 2025/09/30 00:00 [revised] PHST- 2025/09/30 00:00 [accepted] PHST- 2026/01/01 00:35 [medline] PHST- 2025/10/13 00:27 [pubmed] PHST- 2025/10/12 19:34 [entrez] AID - S0885-3924(25)00872-3 [pii] AID - 10.1016/j.jpainsymman.2025.09.029 [doi] PST - ppublish SO - J Pain Symptom Manage. 2026 Feb;71(2):234-242. doi: 10.1016/j.jpainsymman.2025.09.029. Epub 2025 Oct 10. PMID- 41077108 OWN - NLM STAT- MEDLINE DCOM- 20251101 LR - 20251121 IS - 1535-6280 (Electronic) IS - 0146-2806 (Linking) VI - 50 IP - 12 DP - 2025 Dec TI - Impact of cardio-obstetrics care on maternal outcomes in pregnant women with heart disease: A systematic review and meta-analysis. PG - 103190 LID - S0146-2806(25)00209-9 [pii] LID - 10.1016/j.cpcardiol.2025.103190 [doi] AB - BACKGROUND: Maternal mortality is at an all-time high in the U.S., with maternal cardiac disease being the leading cause of death. Cardio-obstetrics is a collaborative, multidisciplinary approach to maternal care, bringing together experts from maternal-fetal medicine, cardiology, and other specialties. This study investigates the impact of cardio-obstetrics team care on maternal outcomes, focusing on how this integrated model can improve the health and well-being of pregnant women with cardiovascular disease (CVD). METHODS: We conducted a systematic review by searching MEDLINE, Web of Science, Scopus, and Cochrane up to March 5, 2025. Statistical analysis was performed using RevMan 5.4, with an inverse variance random effects model to calculate risk ratios (RR) for dichotomous outcomes. Heterogeneity was assessed using the Higgins I(2) test. The study protocol is registered in PROSPERO (CRD420251010149). RESULTS: We identified six observational studies evaluating cardio-obstetrics team care, including a total of 1,109 pregnant women with CVD, with a mean age of 30.8 years. Most participants had a CARPREG II score > 2, indicating high risk for adverse maternal cardiovascular outcomes. The average gestational age at delivery was 38 weeks, with arrhythmias being the most common cardiovascular condition, followed by congenital and valvular heart disease. Pooled analysis revealed a statistically significant reduction in the 30-day postpartum readmission rate for pregnant women with CVD receiving cardio-obstetrics care compared to standard care (RR 0.29, 95 % CI: 0.13-0.64, p = 0.002, I(2) = 0 %) with no observed heterogeneity. There was also a significant decrease in postpartum arrhythmias (RR 0.07, 95 % CI: 0.04-0.12, p < 0.001, I(2) = 0 %). However, no significant difference in maternal mortality was found between the two groups (RR 0.74, 95 % CI: 0.14-3.93, p = 0.72, I(2) = 0 %). CONCLUSION: Maternal outcomes with cardio-obstetrics team care in pregnant women with CVD were promising, indicating the potential of this integrated care model when compared with standard care. These results emphasize the need for further research to explore its long-term benefits. Standard care data were approximated using national averages due to the lack of direct comparison data, which should be considered when interpreting the results. LAY SUMMARY: Heart disease is the leading cause of death during pregnancy in the U.S. This study looked at whether having a specialized cardio-obstetrics team made up of doctors from different specialties working together improves outcomes for pregnant women with heart disease. Six studies with >1,100 women found that women cared for by these cardio-obstetrics teams had fewer hospital readmissions and fewer heart rhythm problems after delivery, though death rates were not different. CI - Copyright (c) 2025 Elsevier Inc. All rights reserved. FAU - Sebastian, Sneha Annie AU - Sebastian SA AD - Department of Internal Medicine, Augusta Health, Fishersville, VA, USA. Electronic address: sasebastian@augustahealth.com. FAU - Atwal, Harshan AU - Atwal H AD - Department of Internal Medicine, Saint James School of Medicine, Illinois, USA. FAU - Ayyalu, Tanesh AU - Ayyalu T AD - Department of Cardiology, Saint Vincent Hospital, Worcester, MA, USA. FAU - Gulati, Martha AU - Gulati M AD - Barbra Streisand Women's Heart Center, Smidt Heart Institute, Cedars Sinai Medical Center, Los Angeles, CA, USA. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20251010 PL - Netherlands TA - Curr Probl Cardiol JT - Current problems in cardiology JID - 7701802 SB - IM MH - Female MH - Humans MH - Pregnancy MH - *Heart Diseases/therapy MH - Maternal Mortality MH - *Obstetrics/methods MH - *Pregnancy Complications, Cardiovascular/therapy MH - Pregnancy Outcome OTO - NOTNLM OT - Cardio-obstetrics OT - Heart disease OT - Maternal mortality OT - Maternal outcomes OT - Pregnancy COIS- Declaration of competing interest None. EDAT- 2025/10/13 00:27 MHDA- 2025/11/02 00:34 CRDT- 2025/10/12 19:30 PHST- 2025/10/04 00:00 [received] PHST- 2025/10/09 00:00 [accepted] PHST- 2025/11/02 00:34 [medline] PHST- 2025/10/13 00:27 [pubmed] PHST- 2025/10/12 19:30 [entrez] AID - S0146-2806(25)00209-9 [pii] AID - 10.1016/j.cpcardiol.2025.103190 [doi] PST - ppublish SO - Curr Probl Cardiol. 2025 Dec;50(12):103190. doi: 10.1016/j.cpcardiol.2025.103190. Epub 2025 Oct 10. PMID- 41074810 OWN - NLM STAT- MEDLINE DCOM- 20251011 LR - 20251011 IS - 2755-0079 (Electronic) IS - 2755-0060 (Linking) VI - 13 IP - 37 DP - 2025 Oct TI - Strategies to manage emergency ambulance telephone callers with sustained high needs: the STRETCHED mixed-methods evaluation with linked data. PG - 1-76 LID - 10.3310/PWGF6008 [doi] AB - BACKGROUND: Emergency ambulance services aim to respond to patients calling with urgent healthcare needs, prioritising the sickest. A small minority make high use of the service, which raises clinical and operational concerns. Multidisciplinary 'case management' approaches combining emergency, primary and social care have been introduced in some areas but evidence about effectiveness is lacking. AIM: To evaluate effectiveness, safety and costs of case management for people frequently calling emergency ambulance services. DESIGN: A mixed-methods 'natural experiment', evaluating anonymised linked routine outcomes for intervention ('case management') and control ('usual care') patient cohorts within participating ambulance services, and qualitative data. Cohorts met criteria for 'Frequent Callers' designation; we assessed effects of case management within 6 months on processes, outcomes, safety and costs. The primary outcome combined indicators on mortality, emergency hospital admission, emergency department attendance and emergency ambulance call. Focus groups and interviews elicited views of service providers on acceptability, successes and challenges of case management; interviews with service users examined their experiences. SETTING: Four United Kingdom ambulance services each with one intervention and one control area. PARTICIPANTS: Natural experiment: adults meeting criteria for 'frequent caller' classification by ambulance services during 2018. Service providers: service commissioners; emergency and non-acute health and social care providers. Service users: adults with experience of calling emergency ambulance services frequently. INTERVENTIONS: Usual care comprised within-service management, typically involving: patient and general practitioner letters; call centre flags invoking care plans; escalation to other services, including police. Intervention care comprised usual care with optional 'case management' referral to cross-service multidisciplinary team to review and plan care for selected patients. RESULTS: We found no differences in intervention (n = 550) and control (n = 633) patients in the primary outcome (adjusted odds ratio: 1.159; 95% confidence interval: 0.595 to 2.255) or its components. Nearly all patients recorded at least one outcome (95.6% intervention; 94.9% control). Mortality was high (10.5% intervention; 14.1% control). Less than 25% of calls resulted in conveyance (24.3% intervention; 22.3% control). The most common reasons for calling were 'fall' (6.5%), 'sick person' (5.2%) and acute coronary syndrome (4.7%). Case management models varied highly in provision, resourcing, leadership and implementation costs. We found no differences in costs per patient of healthcare resource utilisation (adjusted difference: pound243.57; 95% confidence interval: - pound1972.93 to pound1485.79). Service providers (n = 31) recognised a range of drivers for frequent calling, with some categories of need more amenable to case management than others. Some service users (n = 15) reported deep-seated and complex needs for which appropriate support may not have been available when needed. CONCLUSIONS: People who called frequently had a high risk of death and emergency healthcare utilisation at 6 months and were a heterogeneous group. Case management may work for some, but we did not find effects on emergency healthcare utilisation or mortality across the population. LIMITATIONS: This retrospective study provided limited options in selecting control areas, or in meeting recruitment targets. Data quality was variable. Arranging patient interviews proved challenging. FUTURE RESEARCH: This should prospectively evaluate different forms of case management; improve data collection; and include patients fully in qualitative components. STUDY REGISTRATION: This study is registered as research registry (www.researchregistry.com/) researchregistry7895. FUNDING STATEMENT: This award was funded by the National Institute for Health and Care Research (NIHR) Health and Social Care Delivery Research programme (NIHR award ref: 18/03/02) and is published in full in Health and Social Care Delivery Research; Vol. 13, No. 37. See the NIHR Funding and Awards website for further award information. FAU - Watkins, Alan AU - Watkins A AUID- ORCID: 0000-0003-3804-1943 AD - Faculty of Medicine, Health and Life Science, Swansea University, Swansea, UK. FAU - Aslam, Rabeea'h AU - Aslam R AUID- ORCID: 0000-0002-0916-9641 AD - School of Social Sciences, Cardiff University, Cardiff, UK. FAU - Dearden, Alex AU - Dearden A AUID- ORCID: 0009-0002-8529-0192 AD - Faculty of Medicine, Health and Life Science, Swansea University, Swansea, UK. FAU - Driscoll, Timothy AU - Driscoll T AUID- ORCID: 0000-0001-9879-2509 AD - Faculty of Medicine, Health and Life Science, Swansea University, Swansea, UK. FAU - Edwards, Adrian AU - Edwards A AUID- ORCID: 0000-0002-6228-4446 AD - Division of Population Medicine, Cardiff University, Cardiff, UK. FAU - Edwards, Bethan AU - Edwards B AUID- ORCID: 0000-0001-7413-056X AD - Independent Research Consultant. FAU - Evans, Bridie Angela AU - Evans BA AUID- ORCID: 0000-0003-0293-0888 AD - Faculty of Medicine, Health and Life Science, Swansea University, Swansea, UK. FAU - Farr, Angela AU - Farr A AUID- ORCID: 0000-0002-2087-9310 AD - Faculty of Medicine, Health and Life Science, Swansea University, Swansea, UK. FAU - Foster, Theresa AU - Foster T AUID- ORCID: 0000-0002-6395-0885 AD - East of England Ambulance Service NHS Trust, Melbourn, UK. FAU - Fothergill, Rachael AU - Fothergill R AUID- ORCID: 0000-0003-1341-6200 AD - London Ambulance Service NHS Trust, London, UK. FAU - Gripper, Penny AU - Gripper P AUID- ORCID: 0009-0002-5957-7843 AD - Public Contributor. FAU - Gunson, Imogen M AU - Gunson IM AUID- ORCID: 0000-0001-8335-3335 AD - West Midlands Ambulance Service University NHS Foundation Trust, Brierley Hill, UK. FAU - John, Ann AU - John A AUID- ORCID: 0000-0002-5657-6995 AD - Faculty of Medicine, Health and Life Science, Swansea University, Swansea, UK. FAU - Khanom, Ashrafunnesa AU - Khanom A AUID- ORCID: 0000-0002-5735-6601 AD - Faculty of Medicine, Health and Life Science, Swansea University, Swansea, UK. FAU - Noakes, Tessa AU - Noakes T AUID- ORCID: 0000-0001-5245-3835 AD - East of England Ambulance Service NHS Trust, Melbourn, UK. FAU - Petterson, Robin AU - Petterson R AUID- ORCID: 0009-0002-3448-9214 AD - Welsh Ambulance Services NHS Trust, Cardiff, UK. FAU - Porter, Alison AU - Porter A AUID- ORCID: 0000-0002-3408-7007 AD - Faculty of Medicine, Health and Life Science, Swansea University, Swansea, UK. FAU - Rees, Nigel AU - Rees N AUID- ORCID: 0000-0001-8799-5335 AD - Welsh Ambulance Services NHS Trust, Cardiff, UK. FAU - Rosser, Andy AU - Rosser A AUID- ORCID: 0000-0002-5477-4269 AD - West Midlands Ambulance Service University NHS Foundation Trust, Brierley Hill, UK. FAU - Scott, Jason AU - Scott J AUID- ORCID: 0000-0002-6566-8007 AD - Department of Social Work, Education & Community Wellbeing, Northumbria University, Newcastle, UK. FAU - Sewell, Bernadette AU - Sewell B AUID- ORCID: 0000-0001-5471-922X AD - Faculty of Medicine, Health and Life Science, Swansea University, Swansea, UK. FAU - Tee, Anna AU - Tee A AUID- ORCID: 0009-0009-9564-2391 AD - Independent Research Consultant. FAU - Snooks, Helen AU - Snooks H AUID- ORCID: 0000-0003-0173-8843 AD - Faculty of Medicine, Health and Life Science, Swansea University, Swansea, UK. LA - eng PT - Journal Article PL - England TA - Health Soc Care Deliv Res JT - Health and social care delivery research JID - 9918470788706676 SB - IM MH - Humans MH - *Ambulances/statistics & numerical data MH - Female MH - Male MH - Middle Aged MH - United Kingdom MH - *Case Management/organization & administration/economics MH - Adult MH - Aged MH - *Emergency Medical Services/statistics & numerical data/organization & administration MH - *Telephone MH - Focus Groups MH - Emergency Service, Hospital/statistics & numerical data MH - Health Services Needs and Demand MH - Qualitative Research OAB - Ambulance services respond to patients calling with urgent healthcare needs. A small minority of people make very high use of this emergency service. This is of concern to ambulance service staff and commissioners, patients and the wider National Health Service. Some ambulance services have introduced, in collaboration with other emergency, primary and social care services, in some areas a multidisciplinary approach to the care of people who call the emergency ambulance service frequently. We assessed the effectiveness, safety and costs of this approach in four United Kingdom ambulance services. Using a nationally agreed definition, we included patients who made 5 or more calls in a month (or 12 or more in 3 months) and compared their outcomes between case management (intervention) and usual care (control) sites within each service. We discussed the acceptability, successes and challenges of case management with ambulance service managers and other health and social care staff. We spoke to a range of people who had made high use of the emergency ambulance service. We found no differences in key outcomes for patients between intervention and control sites. Most patients (95.6% of intervention patients; 94.9% of control patients) contacted an emergency healthcare service at least once within a 6-month follow-up period. Mortality within this period was high (10.5% intervention; 14.1% control). We found variations in approaches to and costs of case management across the four ambulance services, but no systematic differences in emergency treatment costs between intervention and control sites. Staff recognised a range of possible reasons for calling frequently, with some more suitable to case management than others. Some patients reported deep-seated and complex needs for which other forms of support may not have been available when needed. Patients who call the emergency ambulance service frequently have high but varied needs. Provision of case management did not reduce further calls to the emergency ambulance service, other emergency healthcare contacts or deaths. OABL- eng OTO - NOTNLM OT - AMBULANCE SERVICE OT - CASE MANAGEMENT OT - COST-CONSEQUENCES ANALYSIS OT - EMERGENCY AMBULANCE SERVICE CALL OT - FREQUENT CALLER OT - MIXED-METHODS STUDY OT - MULTIDISCIPLINARY TEAM OT - ROUTINE LINKED ANONYMISED DATA EDAT- 2025/10/11 12:31 MHDA- 2025/10/11 12:32 CRDT- 2025/10/11 09:13 PHST- 2025/10/11 12:32 [medline] PHST- 2025/10/11 12:31 [pubmed] PHST- 2025/10/11 09:13 [entrez] AID - 10.3310/PWGF6008 [doi] PST - ppublish SO - Health Soc Care Deliv Res. 2025 Oct;13(37):1-76. doi: 10.3310/PWGF6008. PMID- 41068531 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251010 LR - 20260917 IS - 1319-0164 (Print) IS - 2213-7475 (Electronic) IS - 1319-0164 (Linking) VI - 33 IP - 5 DP - 2025 Oct 9 TI - Myocarditis induced by durvalumab in a patient with hepatocellular carcinoma: A case report. PG - 40 LID - 10.1007/s44446-025-00041-3 [doi] LID - 40 AB - Durvalumab is an immune checkpoint inhibitor that targets PD-L1 and is used for malignancies such as hepatocellular carcinoma. Although effective, it may cause immune-related adverse events, including rare cases of myocarditis (0.06% to 1%), which usually appear early. This complication results from immune response-induced damage to the myocardium, highlighting the importance of prompt detection and management to prevent potentially fatal outcomes. This report describes a 70-year-old woman with advanced hepatocellular carcinoma who developed myocarditis after receiving a single dose of durvalumab. The patient presented with atypical chest pain, shortness of breath, and gastrointestinal symptoms. Initial investigations revealed elevated cardiac biomarkers, including Troponin I and CK-MB, and an ECG showing sinus tachycardia and right bundle branch block. A cardiac MRI confirmed non-ischemic myocardial injury, leading to a diagnosis of ICI-induced myocarditis. The patient was treated with high-dose corticosteroids, resulting in rapid clinical improvement and stabilization of cardiac function. A multidisciplinary approach involving cardiology, oncology, and clinical pharmacy was crucial in managing this complex case. This case highlights the importance of heightened vigilance among healthcare providers when administering ICIs, particularly durvalumab, due to the risk of myocarditis. Early detection and prompt intervention are essential to manage ICI-related adverse events and prevent severe outcomes. The successful treatment of this patient demonstrates the importance of a multidisciplinary approach in tackling the complexities of ICI-induced myocarditis. Further research is necessary to optimize management strategies and follow-up protocols for patients experiencing this rare but serious adverse event. CI - (c) 2025. The Author(s). FAU - Alfehaid, Lama AU - Alfehaid L AUID- ORCID: 0000-0002-1549-0941 AD - Department of Pharmacy Practice, College of Pharmacy, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Kingdom of Saudi Arabia. lamaalfehaid@yahoo.com. AD - Department of Pharmaceutical Care Services, King Abdulaziz Medical City, Ministry of National Guard-Health Affairs, Riyadh, Saudi Arabia. lamaalfehaid@yahoo.com. AD - King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia. lamaalfehaid@yahoo.com. FAU - Alsuhebany, Nada AU - Alsuhebany N AD - Department of Pharmacy Practice, College of Pharmacy, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Kingdom of Saudi Arabia. AD - Department of Pharmaceutical Care Services, King Abdulaziz Medical City, Ministry of National Guard-Health Affairs, Riyadh, Saudi Arabia. AD - King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia. FAU - Aldoughaim, Maha AU - Aldoughaim M AD - Department of Pharmacy Practice, College of Pharmacy, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Kingdom of Saudi Arabia. AD - Department of Pharmaceutical Care Services, King Abdulaziz Medical City, Ministry of National Guard-Health Affairs, Riyadh, Saudi Arabia. AD - King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia. FAU - Bukhari, Rawan AU - Bukhari R AD - Department of Pharmaceutical Care Services, King Abdulaziz Medical City, Ministry of National Guard-Health Affairs, Riyadh, Saudi Arabia. FAU - Sait, Walaa AU - Sait W AD - International Medical Center, Jeddah, Kingdom of Saudi Arabia. FAU - Alshammari, Kanan AU - Alshammari K AD - Adult Medical Oncology Department, King Abdulaziz Medical City, Ministry of National Guard-Health Affairs, Riyadh, Saudi Arabia. AD - College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Kingdom of Saudi Arabia. FAU - Aziz, Mohammed AU - Aziz M AD - Adult Cardiology Department, King Abdulaziz Medical City, Ministry of National Guard-Health Affairs, Riyadh, Saudi Arabia. LA - eng PT - Journal Article DEP - 20251009 PL - Netherlands TA - Saudi Pharm J JT - Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society JID - 9705695 PMC - PMC12511464 OTO - NOTNLM OT - Durvalumab OT - Immune Checkpoint Inhibitor OT - Myocarditis COIS- Declarations. Ethics approval: The study protocol received approval from the Institutional Review Board (IRB) of King Abdullah International Medical Research Center (KAIMRC) at the Ministry of National Guard Health Affairs (IRB Approval No.: 0000074824). KIMARC IRB waived patient consent due to the retrospective nature of the study. This project was conducted in accordance with the Declaration of Helsinki. Competing interests: The authors declare that they have no competing interests. EDAT- 2025/10/10 00:29 MHDA- 2025/10/10 00:30 PMCR- 2025/10/09 CRDT- 2025/10/09 23:47 PHST- 2025/02/10 00:00 [received] PHST- 2025/08/21 00:00 [accepted] PHST- 2025/10/10 00:30 [medline] PHST- 2025/10/10 00:29 [pubmed] PHST- 2025/10/09 23:47 [entrez] PHST- 2025/10/09 00:00 [pmc-release] AID - 10.1007/s44446-025-00041-3 [pii] AID - 41 [pii] AID - 10.1007/s44446-025-00041-3 [doi] PST - epublish SO - Saudi Pharm J. 2025 Oct 9;33(5):40. doi: 10.1007/s44446-025-00041-3. PMID- 41068030 OWN - NLM STAT- MEDLINE DCOM- 20251031 LR - 20260312 IS - 2013-2514 (Electronic) IS - 2013-2514 (Linking) VI - 45 IP - 8 DP - 2025 Oct TI - Cardiorenal unit in advanced cardiorenal disease: Clinical impact and reduction of hospital costs. PG - 501350 LID - S2013-2514(25)00129-4 [pii] LID - 10.1016/j.nefroe.2025.501350 [doi] AB - BACKGROUND AND OBJECTIVE: Cardiorenal syndrome (CRS) reflects a bidirectional interaction between heart failure (HF) and chronic kidney disease (CKD), with high associated healthcare costs. Hospitalizations due to cardiovascular (CV) events, particularly for decompensated HF, represent most CKD-related costs. Cardiorenal units (CRU) emerge as an innovative strategy to address this complexity through a multidisciplinary approach. This study analyses the effectiveness and efficiency of CRUs. MATERIAL AND METHODS: Observational, longitudinal, prospective, and single-centre study using an adapted interrupted time-series design. Patients with advanced CKD (eGFR < 30 ml/min/1.73 m(2)) and HF with reduced left ventricular ejection fraction (LVEF) were included. Clinical, demographic, and care-related data were analysed during the year before and the year after enrollment. Economic costs were derived from healthcare resource consumption associated with hospital care activities. RESULTS: In 55 patients (mean age 73.9 +/- 8.6 years; 78% male), a 65% reduction in emergency department visits (p = 0.0001) and a 60.5% reduction in hospitalizations (p = 0.0015) were observed. The economic analysis revealed cost savings of approximately ;700,000, with an average reduction of almost ;13,000 per patient/year. After inclusion in the CRU, there was an increased prescription of prognostic drugs, with no significant changes in serum potassium concentration (p = 0.26) and no evidence of renal function deterioration (pre-vs. post-eGFR: 23.36 +/- 7.6 mg/dl vs. 22.44 +/- 8.5 mg/dl; p = 0.17). A significant differential impact was observed in all healthcare outcomes, particularly among patients receiving quadruple therapy. CONCLUSION: CRUs emerge as effective and efficient models for the management of cardiorenal syndrome. Randomized controlled studies are needed to validate these findings and optimize healthcare policies. CI - Copyright (c) 2025 Sociedad Espanola de Nefrologia. Published by Elsevier Espana, S.L.U. All rights reserved. FAU - Soriano Paya, Eliecer AU - Soriano Paya E AD - Servicio de Nefrologia, Hospital Universitario Virgen de las Nieves, Granada, Spain; Programa de Doctorado en Medicina Clinica y Salud Publica, Escuela Internacional de Posgrado, Universidad de Granada, Granada, Spain. FAU - Arco Adamuz, Ismael AU - Arco Adamuz I AD - Servicio de Cardiologia, Hospital Universitario Virgen de las Nieves, Granada, Spain. FAU - Garcia Giron, Ana Maria AU - Garcia Giron AM AD - Servicio de Nefrologia, Hospital Universitario Virgen de las Nieves, Granada, Spain. FAU - Bermudez Jimenez, Francisco Jose AU - Bermudez Jimenez FJ AD - Servicio de Cardiologia, Hospital Universitario Virgen de las Nieves, Granada, Spain; Instituto de Investigacion Biosanitaria ibs.GRANADA, Granada, Spain. Electronic address: fco.bermudezj@ugr.es. FAU - Pereira Perez, Elisa Berta AU - Pereira Perez EB AD - Servicio de Nefrologia, Hospital Universitario Virgen de las Nieves, Granada, Spain. FAU - Jordan Martinez, Laura AU - Jordan Martinez L AD - Servicio de Cardiologia, Hospital Universitario Virgen de las Nieves, Granada, Spain; Instituto de Investigacion Biosanitaria ibs.GRANADA, Granada, Spain. FAU - Olvera-Porcel, Maria Carmen AU - Olvera-Porcel MC AD - Unidad de Gestion y Apoyo a la Investigacion (UGAI), Hospital Universitario Virgen de las Nieves, Granada, Spain. FAU - Garcia Mochon, Leticia AU - Garcia Mochon L AD - Instituto de Investigacion Biosanitaria ibs.GRANADA, Granada, Spain; Departamento de Economia Aplicada, Universidad de Granada, Granada, Spain. FAU - Lopez Fernandez, Silvia AU - Lopez Fernandez S AD - Servicio de Cardiologia, Hospital Universitario Virgen de las Nieves, Granada, Spain; Instituto de Investigacion Biosanitaria ibs.GRANADA, Granada, Spain. FAU - Espigares Huete, Maria Jose AU - Espigares Huete MJ AD - Servicio de Nefrologia, Hospital Universitario Virgen de las Nieves, Granada, Spain; Instituto de Investigacion Biosanitaria ibs.GRANADA, Granada, Spain. LA - eng PT - Journal Article PT - Observational Study DEP - 20251008 PL - Spain TA - Nefrologia (Engl Ed) JT - Nefrologia JID - 101778581 SB - IM MH - Humans MH - Male MH - *Cardio-Renal Syndrome/economics/therapy MH - Aged MH - Female MH - Prospective Studies MH - *Hospital Costs/statistics & numerical data MH - Longitudinal Studies MH - Aged, 80 and over MH - Hospitalization/economics/statistics & numerical data MH - Cost Savings MH - Middle Aged OTO - NOTNLM OT - Analisis economico OT - Cardiorenal disease OT - Cardiorenal unit OT - Chronic kidney disease OT - Economic analysis OT - Enfermedad cardiorrenal OT - Enfermedad renal cronica OT - Heart failure OT - Insuficiencia cardiaca OT - Unidad cardiorrenal COIS- Declaration of competing interest None. EDAT- 2025/10/10 00:30 MHDA- 2025/11/01 05:37 CRDT- 2025/10/09 22:00 PHST- 2025/01/31 00:00 [received] PHST- 2025/05/06 00:00 [revised] PHST- 2025/05/10 00:00 [accepted] PHST- 2025/11/01 05:37 [medline] PHST- 2025/10/10 00:30 [pubmed] PHST- 2025/10/09 22:00 [entrez] AID - S2013-2514(25)00129-4 [pii] AID - 10.1016/j.nefroe.2025.501350 [doi] PST - ppublish SO - Nefrologia (Engl Ed). 2025 Oct;45(8):501350. doi: 10.1016/j.nefroe.2025.501350. Epub 2025 Oct 8. PMID- 41064604 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251009 LR - 20260925 IS - 2050-0904 (Print) IS - 2050-0904 (Electronic) IS - 2050-0904 (Linking) VI - 13 IP - 10 DP - 2025 Oct TI - Navigating Diagnostic Dilemmas in Cardiology: A Rare Case Report of Tuberculosis Presenting as a Cardiac Abscess. PG - e70949 LID - 10.1002/ccr3.70949 [doi] LID - e70949 AB - Cardiac tuberculosis (TB) is a rare but important extrapulmonary form of TB that often presents diagnostic challenges due to nonspecific symptoms and its ability to mimic other cardiac conditions. We report the case of a 45-year-old woman with end-stage renal disease secondary to granulomatosis with polyangiitis (GPA) who presented with fever and a seizure-like episode. Initial investigations identified a cardiac mass located in the mitral-aortic intervalvular fibrosa and a cavitary lung lesion. Although sputum PCR tests for Mycobacterium tuberculosis were negative, histopathological examination and PCR analysis of the surgically resected cardiac mass confirmed necrotizing granulomatous inflammation consistent with TB. This case highlights the difficulty of diagnosing cardiac TB, particularly in patients with overlapping conditions such as GPA, as the similar granulomatous histopathology can complicate differentiation. The initial false-negative PCR results further emphasize limitations in current diagnostic tests, especially in immunocompromised hosts or atypical presentations. Given the complex interplay between cardiac TB and GPA, a multidisciplinary approach is essential for accurate diagnosis and management, with early recognition and tissue sampling critical to improving patient outcomes. CI - (c) 2025 The Author(s). Clinical Case Reports published by John Wiley & Sons Ltd. FAU - Bayat, Fariba AU - Bayat F AD - Shahid Beheshti University of Medical Sciences Tehran, Tehran Iran. FAU - Jame Bozorgi, Sepideh AU - Jame Bozorgi S AUID- ORCID: 0009-0005-4900-5931 AD - Cardiology Shahid Beheshti University of Medical Sciences Tehran, Tehran Iran. FAU - Khani, Mohammad AU - Khani M AD - Cardiovascular Research Center Shahid Beheshti University of Medical Sciences Tehran Iran. FAU - Jafari Fesharaki, Mehrdad AU - Jafari Fesharaki M AUID- ORCID: 0000-0002-4866-2623 AD - Department of Cardiology, School of Medicine Shahid Beheshti University of Medical Sciences Tehran Iran. FAU - Bagheri, Abdoulhamid AU - Bagheri A AD - Shahid Beheshti University of Medical Sciences Tehran, Tehran Iran. FAU - Farahani, Elham AU - Farahani E AD - Cardiology Shahid Beheshti University of Medical Sciences Tehran, Tehran Iran. LA - eng PT - Journal Article DEP - 20251006 PL - England TA - Clin Case Rep JT - Clinical case reports JID - 101620385 PMC - PMC12500525 OTO - NOTNLM OT - cardiac tuberculosis OT - extrapulmonary tuberculosis OT - granulomatosis with polyangiitis OT - immunocompromised patients OT - mitral-aortic intervalvular abscess OT - necrotizing granulomatous inflammation COIS- The authors declare no conflicts of interest. EDAT- 2025/10/09 12:12 MHDA- 2025/10/09 12:13 PMCR- 2025/10/06 CRDT- 2025/10/09 05:06 PHST- 2025/01/04 00:00 [received] PHST- 2025/04/11 00:00 [revised] PHST- 2025/09/09 00:00 [accepted] PHST- 2025/10/09 12:13 [medline] PHST- 2025/10/09 12:12 [pubmed] PHST- 2025/10/09 05:06 [entrez] PHST- 2025/10/06 00:00 [pmc-release] AID - CCR370949 [pii] AID - 10.1002/ccr3.70949 [doi] PST - epublish SO - Clin Case Rep. 2025 Oct 6;13(10):e70949. doi: 10.1002/ccr3.70949. eCollection 2025 Oct. PMID- 41063414 OWN - NLM STAT- MEDLINE DCOM- 20260312 LR - 20260828 IS - 1873-734X (Electronic) IS - 1010-7940 (Linking) VI - 68 IP - 3 DP - 2026 Mar 10 TI - EACTS Expert Consensus Document on protected cardiac surgery: pre-emptive use of temporary mechanical circulatory support in adult cardiac surgery patients at high risk for perioperative low cardiac output syndrome. LID - ezaf296 [pii] LID - 10.1093/ejcts/ezaf296 [doi] AB - Perioperative low cardiac output syndrome (LCOS) remains a significant complication in adult cardiac surgery, contributing to substantial morbidity, prolonged intensive care, and increased mortality. Its incidence is expected to rise further due to the evolving complexity of referred surgical patients, often characterised by advanced age, multiple comorbidities, challenging anatomy, and impaired haemodynamics. Despite advances in pharmacological and perioperative care, outcomes for high-risk patients have not shown significant improvement, prompting interest in temporary mechanical circulatory support (tMCS) as a proactive strategy. This Expert Consensus Document from the European Association for Cardio-Thoracic Surgery (EACTS) presents the first dedicated guidance on the pre-emptive use of tMCS in high-risk adult cardiac surgical patients. Developed by a multidisciplinary task force, it emphasises structured risk stratification, early initiation, and individualised device management informed by interdisciplinary Heart Team discussions. The document proposes clinical pathways for patient selection, defines criteria for tMCS initiation, and provides practical algorithms for various scenarios, including advanced heart failure, cardiogenic shock, and post-cardiotomy LCOS. It reviews the current evidence on available tMCS devices, such as intra-aortic balloon pumps, microaxial flow pumps, veno-arterial extracorporeal life support and hybrid strategies, and addresses perioperative care, intensive care unit protocols, ethical considerations, as well as informed consent and support withdrawal. Despite promising results, substantial knowledge gaps remain, including long-term outcome data, device selection criteria, and cost-effectiveness analyses. This consensus aims to support clinical decision-making, standardise practice, and stimulate research to improve outcomes in a growing population of high-risk surgical patients. CI - (c) European Association for Cardio-Throracic Surgery 2025. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com. FAU - Lorusso, Roberto AU - Lorusso R AUID- ORCID: 0000-0002-1777-2045 AD - Cardio-Thoracic Surgery Department, Heart and Vascular Centre, Maastricht University Medical Centre (MUMC+), Cardiovascular Research Institute Maastricht (CARIM), Maastricht, The Netherlands. FAU - Salazar, Leonardo AU - Salazar L AD - Cardio-Thoracic Surgery Department, Heart and Vascular Centre, Maastricht University Medical Centre (MUMC+), Cardiovascular Research Institute Maastricht (CARIM), Maastricht, The Netherlands. AD - ECMO and Mechanical Circulatory Support Program, Instituto Cardiovascular, Hospital Internacional de Colombia, Bucaramanga, Colombia. FAU - Nersesian, Gaik AU - Nersesian G AUID- ORCID: 0000-0002-9524-7705 AD - Deutsches Herzzentrum der Charite, Department of Cardiothoracic and Vascular Surgery, Berlin, Germany. AD - Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany. AD - DZHK German Centre for Cardiovascular Research, Partner Site Berlin, Berlin, Germany. FAU - Milojevic, Milan AU - Milojevic M AUID- ORCID: 0000-0003-0984-9011 AD - Department of Cardiac Surgery and Cardiovascular Research, Dedinje Cardiovascular Institute, Belgrade, Serbia. AD - Department of Cardiac Surgery, University Hospital Zurich, University of Zurich, Zurich, Switzerland. FAU - Schmack, Bastian AU - Schmack B AD - Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany. FAU - Engelman, Daniel T AU - Engelman DT AD - Department of Surgery, Baystate Medical Center, University of Massachusetts Chan Medical School-Baystate, Springfield, MA, USA. FAU - Stein, Louis AU - Stein L AD - Department of Cardiac Surgery, RWJ Barnabas Health at Newark Beth Israel Medical Center, Newark, NJ, USA. FAU - Silvestry, Scott AU - Silvestry S AD - Division of Cardiothoracic Surgery, Department of Surgery, University of Arizona College of Medicine, Tucson, AZ, USA. FAU - Zimpfer, Daniel AU - Zimpfer D AUID- ORCID: 0000-0002-2185-4895 AD - Department of Cardiac and Thoracic Aortic Surgery, Medical University of Vienna, Vienna, Austria. FAU - Wiedemann, Dominik AU - Wiedemann D AUID- ORCID: 0000-0002-2055-8293 AD - Department of Cardiac Surgery, University Hospital St. Polten, Austria. AD - Karl Landsteiner University of Health Sciences, Krems, Austria. FAU - Goldstein, Daniel AU - Goldstein D AD - Department of Cardiovascular and Thoracic Surgery, Montefiore Medical Center, New York, NY, USA. FAU - Soltesz, Edward AU - Soltesz E AD - Thoracic and Cardiovascular Surgery Department, The Cleveland Clinic, Cleveland, OH, USA. FAU - Bermudez, Christian AU - Bermudez C AD - Division of Cardiac Surgery, University of Pennsylvania Hospital, Philadelphia, PA, USA. FAU - Haft, Jonathan AU - Haft J AD - Department of Cardiac Surgery, University of Michigan, Ann Arbor, MI, USA. FAU - Patel, Bhavesh AU - Patel B AD - Department of Critical Care Medicine, Mayo Clinic, Phoenix, AZ, USA. FAU - Moreno, Pedro AU - Moreno P AD - Department of Medicine/Cardiology, The Zena and Michael A. Weiner Cardiovascular Institute and the Marie-Josee and Henry R. Kravis Cardiovascular Health Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - MacLaren, Graeme AU - MacLaren G AD - Cardiothoracic ICU, National University Hospital, Singapore. FAU - Tonna, Joseph AU - Tonna J AD - Division of Cardiothoracic Surgery, Department of Surgery, University of Utah School of Medicine, Salt Lake City, UT, USA. FAU - Takayama, Hiroo AU - Takayama H AUID- ORCID: 0000-0002-7840-801X AD - Division of Cardiothoracic and Vascular Surgery, New York Presbyterian Hospital/Columbia University Medical Center, NY, USA. FAU - Lamarche, Yoan AU - Lamarche Y AD - Cardiac Surgery Department and Cardiac Surgical Critical Care Service, Montreal Heart Institute, University of Montreal, Montreal, Quebec, Canada. FAU - Rao, Vivek AU - Rao V AUID- ORCID: 0000-0003-1920-0937 AD - Cardiovascular Surgery Department, Toronto General Hospital, Toronto, Ontario, Canada. FAU - Faerber, Gloria AU - Faerber G AD - Department of Thoracic and Cardiovascular Surgery, University Hospital Wurzburg, Wurzburg, Germany. FAU - Meyns, Bart AU - Meyns B AUID- ORCID: 0000-0002-8110-4009 AD - Cardiac Surgery Department, Gasthuisberg University Hospital, Leuven, Belgium. FAU - Takeda, Koji AU - Takeda K AD - Division of Cardiothoracic and Vascular Surgery, New York Presbyterian Hospital/Columbia University Medical Center, NY, USA. FAU - Boeken, Udo AU - Boeken U AD - Cardiac Surgery Department, Uniklinik Dusseldorf, Heinrich Heine University, Dusseldorf, Germany. FAU - Arora, Rakesh C AU - Arora RC AD - Department of Surgery Northwestern University, Feinberg School of Medicine, Chicago, Ohio, USA. AD - Harrington Heart and Vascular Institute, University Hospitals, Cleveland, Ohio, USA. FAU - Whitman, Glenn AU - Whitman G AD - Division of Cardiothoracic Surgery, Department of Surgery, Johns Hopkins School of Medicine, Baltimore, MD, USA. FAU - Potapov, Evgenij AU - Potapov E AUID- ORCID: 0000-0002-9720-3175 AD - Deutsches Herzzentrum der Charite, Department of Cardiothoracic and Vascular Surgery, Berlin, Germany. AD - Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany. AD - DZHK German Centre for Cardiovascular Research, Partner Site Berlin, Berlin, Germany. CN - EACTS Scientific Document Group LA - eng GR - European Association of Cardio-Thoracic Surgery/ PT - Consensus Statement PT - Journal Article PT - Practice Guideline PT - Review PL - Germany TA - Eur J Cardiothorac Surg JT - European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery JID - 8804069 SB - IM MH - Humans MH - *Cardiac Output, Low/prevention & control/etiology MH - *Cardiac Surgical Procedures/adverse effects/methods MH - Adult MH - *Postoperative Complications/prevention & control MH - *Heart-Assist Devices MH - Perioperative Care/methods MH - Risk Assessment OTO - NOTNLM OT - haemodynamic stabilisation OT - high-risk cardiac surgery OT - interdisciplinary Heart Team OT - low cardiac output syndrome OT - pre-emptive support OT - protected cardiac surgery OT - tMCS strategy OT - temporary mechanical circulatory support FIR - Sartipy, Ulrik IR - Sartipy U FIR - Fux, Thomas IR - Fux T FIR - Russo, Claudio Francesco IR - Russo CF FIR - Turina, Marko Ivan IR - Turina MI FIR - Morshuis, Michiel IR - Morshuis M FIR - Meineri, Massimiliano IR - Meineri M FIR - Knosalla, Christoph IR - Knosalla C FIR - Paparella, Domenico IR - Paparella D EDAT- 2025/10/09 06:28 MHDA- 2026/03/13 00:50 CRDT- 2025/10/09 01:03 PHST- 2024/10/07 00:00 [received] PHST- 2025/04/14 00:00 [revised] PHST- 2026/03/13 00:50 [medline] PHST- 2025/10/09 06:28 [pubmed] PHST- 2025/10/09 01:03 [entrez] AID - 8277356 [pii] AID - 10.1093/ejcts/ezaf296 [doi] PST - ppublish SO - Eur J Cardiothorac Surg. 2026 Mar 10;68(3):ezaf296. doi: 10.1093/ejcts/ezaf296. PMID- 41062843 OWN - NLM STAT- MEDLINE DCOM- 20260115 LR - 20260118 IS - 1437-1596 (Electronic) IS - 0937-9827 (Print) IS - 0937-9827 (Linking) VI - 140 IP - 1 DP - 2026 Jan TI - Update on the similarities between SADS, SIDS, and SUDEP: Three sides of the same pyramid? PG - 1-12 LID - 10.1007/s00414-025-03612-0 [doi] AB - Sudden Arrhythmic Death Syndrome (SADS), Sudden Unexpected Death In Epilepsy (SUDEP) and Sudden Infant Death Syndrome (SIDS) present some overlaps and similarities in terms of molecular autopsy and pathophysiological mechanism. Genes associated with cardiac arrhythmias represent promising biomarkers, in light of the growing evidence of neurocardiac interconnections and phenotypic similarities between SUDEP, SADS and also SIDS. The interactions between these different forms of sudden death are reciprocal and could help to understand the mechanism of death that in some cases remains unexplained. In this review of the literature we analyse the overlaps and the common aspects between these different conditions of sudden death, we discuss the clinical, social and medico-legal implications. SIDS, SADS and SUDEP still represent a huge challenge for the Forensic Pathologist and their diagnostic interpretation contains some ambiguities and evaluation difficulties. All cases of sudden death require a thorough cardio-pathological and neuropathological evaluation. A thorough anamnesis and molecular analysis of the major channel protein genes (such as SCN5A, RYR2, KCHN2, and KCNQ1) should be performed in these cases, in addition to histological and toxicological analyses. Only a thorough and multidisciplinary evaluation can help to better define the cases of sudden death, avoid improper classifications and clarify the pathological mechanism more precisely. CI - (c) 2025. The Author(s). FAU - Barranco, Rosario AU - Barranco R AUID- ORCID: 0000-0002-2838-7716 AD - Department of Legal and Forensic Medicine, Health Science Department (DISSAL), University of Genova, via De Toni 12, Genova, 16132, Italy. rosario.barranco@libero.it. AD - IRCCS-Ospedale Policlinico San Martino Teaching Hospital, Largo Rosanna Benzi 10, Genova, 16132, Italy. rosario.barranco@libero.it. FAU - Caristo, Isabella AU - Caristo I AD - Department of Legal and Forensic Medicine, Health Science Department (DISSAL), University of Genova, via De Toni 12, Genova, 16132, Italy. FAU - Molinelli, Andrea AU - Molinelli A AD - Department of Legal and Forensic Medicine, Health Science Department (DISSAL), University of Genova, via De Toni 12, Genova, 16132, Italy. AD - IRCCS-Ospedale Policlinico San Martino Teaching Hospital, Largo Rosanna Benzi 10, Genova, 16132, Italy. FAU - Rocca, Gabriele AU - Rocca G AD - Department of Legal and Forensic Medicine, Health Science Department (DISSAL), University of Genova, via De Toni 12, Genova, 16132, Italy. AD - IRCCS-Ospedale Policlinico San Martino Teaching Hospital, Largo Rosanna Benzi 10, Genova, 16132, Italy. FAU - Vernazza, Nicolo AU - Vernazza N AD - Department of Legal and Forensic Medicine, Health Science Department (DISSAL), University of Genova, via De Toni 12, Genova, 16132, Italy. FAU - Ventura, Francesco AU - Ventura F AD - Department of Legal and Forensic Medicine, Health Science Department (DISSAL), University of Genova, via De Toni 12, Genova, 16132, Italy. AD - IRCCS-Ospedale Policlinico San Martino Teaching Hospital, Largo Rosanna Benzi 10, Genova, 16132, Italy. LA - eng PT - Journal Article PT - Review DEP - 20251009 PL - Germany TA - Int J Legal Med JT - International journal of legal medicine JID - 9101456 SB - IM MH - Humans MH - *Sudden Infant Death/pathology/diagnosis/genetics MH - *Sudden Unexpected Death in Epilepsy/pathology MH - Infant MH - *Death, Sudden/etiology MH - *Arrhythmias, Cardiac/genetics PMC - PMC12808204 OTO - NOTNLM OT - Forensic pathology OT - Molecular autopsy OT - Pathophysiological overlaps OT - SADS OT - SIDS OT - SUDEP COIS- Declarations. Conflict of interest: Authors declare that there is no conflict of interest. EDAT- 2025/10/09 00:30 MHDA- 2026/01/15 18:47 PMCR- 2025/10/09 CRDT- 2025/10/08 23:39 PHST- 2025/02/04 00:00 [received] PHST- 2025/09/04 00:00 [accepted] PHST- 2026/01/15 18:47 [medline] PHST- 2025/10/09 00:30 [pubmed] PHST- 2025/10/08 23:39 [entrez] PHST- 2025/10/09 00:00 [pmc-release] AID - 10.1007/s00414-025-03612-0 [pii] AID - 3612 [pii] AID - 10.1007/s00414-025-03612-0 [doi] PST - ppublish SO - Int J Legal Med. 2026 Jan;140(1):1-12. doi: 10.1007/s00414-025-03612-0. Epub 2025 Oct 9. PMID- 41062402 OWN - NLM STAT- MEDLINE DCOM- 20260206 LR - 20260616 IS - 1532-8422 (Electronic) IS - 1053-0770 (Linking) VI - 40 IP - 2 DP - 2026 Feb TI - Perceptions, Definitions, and Preparedness Regarding Low-Performing and Impaired Colleagues in Cardiothoracic and Vascular Anesthesia: An International Survey. PG - 522-538 LID - S1053-0770(25)00734-7 [pii] LID - 10.1053/j.jvca.2025.08.055 [doi] AB - OBJECTIVE: To define low-performing colleagues in cardiothoracic and vascular anesthesia (LPC-CTVA), evaluate institutional preparedness to identify and manage such individuals, and identify predictors of recognition, reporting, and response behaviors. DESIGN: International cross-sectional survey. SETTING: Web-based data collection from June to September 2024. PARTICIPANTS: Of 878 responses, 537 (61.2%) were complete and analyzed, representing 57 countries. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: A 43-item questionnaire was developed by a multidisciplinary team and distributed via professional societies, social media, and email. It assessed definitions of LPC-CTVA, institutional protocols, and preparedness to address underperformance. Consensus was defined as >/=70% agreement. Thirteen of the 18 statements met consensus. Common indicators included non-compliance with infection control (80.0%), outdated knowledge (80.3%), repeated procedural failures (80.0%), and persistent negligence (79.1%). Institutional support was limited: among 464 respondents, 22.2% reported active supervision for underperformance, 15.3% reported the presence of identification mechanisms, and 11.7% indicated the existence of formal management processes. Although 39.9% of 434 had encountered a low-performing colleague, only 23.1% of 447 had reported one. Preparedness to manage impaired colleagues was reported by 46.2% of 418 respondents, and preparedness to manage underperforming colleagues by 44.1% of 416 respondents. Key barriers included the belief that others would act (33.7% of 265), perceived ineffectiveness (28.3%), and fear of retaliation (21.9%). Preparedness was more prevalent among older, more experienced clinicians, those in leadership roles, and those with prior experience in reporting. CONCLUSIONS: A consensus-based definition of LPC-CTVA has been established. However, institutional readiness and clinician confidence remain limited. Experience and structured systems enhance response capability. CI - Copyright (c) 2025 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Samara, Evangelia AU - Samara E AD - Department of Anesthesiology and Postoperative Intensive Care, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece. Electronic address: gelysamara@uoi.gr. FAU - Momeni, Mona AU - Momeni M AD - Department of Anesthesiology, Cliniques Universitaires Saint-Luc, Universite Catholique de Louvain, Institut de Recherche Experimentale et Clinique, Brussels, Belgium. FAU - Karakosta, Agathi AU - Karakosta A AD - Department of Anesthesiology and Postoperative Intensive Care, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece. FAU - Smyrli, Anna AU - Smyrli A AD - Department of Anaesthesiology, Onassis Cardiac Surgery Center, Kallithea, Greece. FAU - Kolonia, Konstantina AU - Kolonia K AD - Department of Anaesthesiology, Onassis Cardiac Surgery Center, Kallithea, Greece. FAU - Tzimas, Petros AU - Tzimas P AD - Department of Anesthesiology and Postoperative Intensive Care, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece. FAU - Huang, Jiapeng AU - Huang J AD - Department of Anesthesiology and Perioperative Medicine, University of Louisville, Louisville, KY. FAU - Neskovic, Vojislava AU - Neskovic V AD - Anesthesia and Intensive Care, Clinic for Anesthesia and Critical Care, Military Medical Academy, Faculty of Medicine MMA, Belgrade, Serbia. FAU - Gil, Manuel Granell AU - Gil MG AD - Anesthesiology Section, Consorcio Hospital General Universitario of Valencia, Spain; Surgery Department, Faculty of Medicine, University of Valencia, Spain. FAU - Paternoster, Gianluca AU - Paternoster G AD - Department of Health Science, School of Medicine, Anesthesia and ICU, University of Basilicata, San Carlo Hospital, Potenza, Italy. FAU - Eldawlatly, Abdelazeem AU - Eldawlatly A AD - Department of Anesthesia, College of Medicine, Assiut University, Egypt; formerly Department of Anesthesia, College of Medicine, King Saud University, Riyadh, Saudi Arabia. FAU - Kirov, Mikhail AU - Kirov M AD - Department of Anesthesiology and Intensive Care Medicine, Northern State Medical University, Arkhangelsk, Russia; Secretary of the Russian Federation of Anesthesiologists and Reanimatologists (FAR). FAU - Grigoryev, Evgeny AU - Grigoryev E AD - Department of Anesthesiology and Intensive Care Medicine, Kemerovo State Medical University, Kemerovo, Russia. FAU - Ao, Hushan AU - Ao H AD - Department of Anesthesiology, The National Cardiovascular Institute & Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing, China, and The Society of Chinese Cardiothoracic and Vascular Anesthesiology (CSCTVA). FAU - Cheng, Davy AU - Cheng D AD - Chinese University of Hong Kong, Shenzhen, Guangdong, China; Western University, London, Canada. FAU - Aboulfetouh, Fawzia AU - Aboulfetouh F AD - College of Medicine, Misr University for Science and Technology; Egyptian Cardiothoracic Anaesthesia Society (ECTAS); Cardiothoracic and Liver Transplantation Anaesthesia, College of Medicine, Cairo University. FAU - Lineburger, Eric Benedet AU - Lineburger EB AD - Department of Anesthesia and Pain Management, Hospital Sao Jose, Criciuma, SC, Brazil; University of the Extreme South of Santa Catarina (UNESC); Brazilian Journal of Anesthesiology (BJAN); Core Group for Intraoperative Transthoracic and Transesophageal Echocardiography, Brazilian Society of Anesthesiology (NETTISBA), Brazil. FAU - Wittenstein, Jakob AU - Wittenstein J AD - Department of Anaesthesiology and Intensive Care Medicine, Pulmonary Engineering Group, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany. FAU - Senturk, Mert AU - Senturk M AD - Cardiothoracic Anaesthesia, EACTAIC Thoracic Subspecialty Committee, Istanbul, Acibadem University, School of Medicine, Department of Anesthesiology and Reanimation. FAU - Sungur, Zerrin AU - Sungur Z AD - Istanbul University, Istanbul Faculty of Medicine, Dept of Anesthesiology and Reanimation. FAU - Ahmad, Abdulaziz AU - Ahmad A AD - Anesthesia, College of Medicine, King Saud University, Riyadh, Saudi Arabia. FAU - Liu, Xiaojie AU - Liu X AD - Department of Anesthesiology, Affiliated Hospital of Qingdao University, Shandong Province, China. FAU - Ferreira, Carolina Baeta Neves Duarte AU - Ferreira CBND AD - Sao Paulo State Society of Anesthesiology (SAESP), Perioperative Echocardiography Group of the Brazilian Society of Anesthesiology (SBA), Anesthesiology Residency Program, Hospital Moriah, Sao Paulo, Brazil. FAU - Guarracino, Fabio AU - Guarracino F AD - Department of Cardiothoracic and Vascular Anesthesia and Intensive Care, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy. FAU - Kenichi, Ueda AU - Kenichi U AD - P3L 129 Department of Anesthesiology, Kameda Medical Center, Japan; Department of Anesthesia, University of Iowa Hospitals and Clinics, USA. FAU - Szegedi, Laszlo L AU - Szegedi LL AD - Universite Libre de Bruxelles, H.U.B. Hopital Erasme, Department of Anesthesiology, Brussels, Belgium. FAU - Beshara, Mina Tharwat Fouad AU - Beshara MTF AD - Egyptian Fellowship of Anesthesia, Anesthesiology Department, King Fahd Hospital of Imam Abdulrahman Bin Faisal University, Al Khobar, Saudi Arabia. FAU - Vives, Marc AU - Vives M AD - Anesthesiology & Critical Care, Cinica Universidad de Navarra, Pamplona, Spain; EACTAIC CPB, ECMO and MCS Subspecialty Committee; EACTAIC Representative Council for Spain; Instituto de Investigation Sanitaria de Navarra (idiSNA). FAU - Menon, Priya Ramachandran AU - Menon PR AD - Madinat Zayed Hospital, Al Dhafra, SEHA, Abu Dhabi. FAU - El Tahan, Mohamed R AU - El Tahan MR AD - Cardiothoracic Anesthesia, Anesthesiology Department, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia; Cardiothoracic Anesthesia Unit, Department of Anesthesia, Surgical Intensive Care and Pain Medicine, College of Medicine, Mansoura University, Mansoura, Egypt, Egyptian Cardiothoracic Anaesthesia Society (ECTAS). LA - eng PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't DEP - 20250901 PL - United States TA - J Cardiothorac Vasc Anesth JT - Journal of cardiothoracic and vascular anesthesia JID - 9110208 SB - IM MH - Humans MH - Cross-Sectional Studies MH - Surveys and Questionnaires MH - *Clinical Competence/standards MH - Male MH - Internationality MH - Female MH - *Anesthesia, Cardiac Procedures/standards MH - *Anesthesiologists/standards/psychology MH - *Perception MH - Attitude of Health Personnel OTO - NOTNLM OT - Anesthesiology OT - Cardiothoracic Anesthesia OT - Ethics OT - Performance Appraisal OT - Physician Impairment OT - Physician Performance OT - Professional Competence OT - Supervision OT - Vascular Anesthesia COIS- Declaration of competing interest All authors reviewed the final version of the manuscript and have declared that they have no conflicts of interest to disclose. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Preliminary results from this survey were briefly mentioned during a lecture by Dr. Evangelia Samara at the 26(th) National Greek Congress of Anesthesiology, 9 May 2025, Athens, Greece. No slides or formal abstracts were submitted or published, and the session was not recorded. EDAT- 2025/10/09 00:30 MHDA- 2026/02/07 00:31 CRDT- 2025/10/08 21:59 PHST- 2025/06/09 00:00 [received] PHST- 2025/08/21 00:00 [revised] PHST- 2025/08/25 00:00 [accepted] PHST- 2026/02/07 00:31 [medline] PHST- 2025/10/09 00:30 [pubmed] PHST- 2025/10/08 21:59 [entrez] AID - S1053-0770(25)00734-7 [pii] AID - 10.1053/j.jvca.2025.08.055 [doi] PST - ppublish SO - J Cardiothorac Vasc Anesth. 2026 Feb;40(2):522-538. doi: 10.1053/j.jvca.2025.08.055. Epub 2025 Sep 1. PMID- 41062385 OWN - NLM STAT- MEDLINE DCOM- 20260309 LR - 20260309 IS - 1460-9584 (Electronic) IS - 1268-7731 (Linking) VI - 32 IP - 3 DP - 2026 Apr TI - Time critical charcot foot reconstructions can be safely performed in the absence of optimal preoperative glycaemic control when delivered by MDT. PG - 269-274 LID - S1268-7731(25)00223-1 [pii] LID - 10.1016/j.fas.2025.10.001 [doi] AB - AIM: Established guidelines recommend a pre-operative HbA1c target of 8.5 % for elective surgeries. Patients waiting for Charcot foot reconstructions often have impaired mobility and fail to achieve this target, and risk getting their surgeries delayed or cancelled. In our unit, the multidisciplinary team (MDT) recommends proceeding with surgery even if the target HbA1c levels are not achieved. Our aim is to review the patient outcomes among patients with diabetes and variable pre-operative glycaemic control undergoing Charcot foot reconstructions. MATERIALS AND METHODS: We reviewed the clinical outcomes and glycaemic control of consecutive patients that had undergone elective Charcot foot reconstructions over a 22-month period with a minimum follow-up of 12 months. RESULTS / DISCUSSION: 18 diabetic patients were operated on between October 2020 and August 2022, including 8 midfoot, 2 hindfoot and 8 combined hindfoot and midfoot reconstructions. There were 11 males, the mean age was 56.7 years, the mean preoperative HbA1c was 7.9 %. In 7 patients, the preoperative recommended HbA1c target of 8.5 % was not achieved (non-target group). There were 4 post-operative complications, all resolved with conservative management. There were no renal or cardiac complications. After one year, 61 % (n = 11) of patients were mobilising in shoes. There was no outcome difference between the groups with or without the targeted glycaemic control. CONCLUSION: Although preoperative glycaemic optimization should be aimed for, the time critical Charcot foot reconstructions can still be performed in the absence of targeted glycaemic control if delivered by MDT. CI - Copyright (c) 2025 European Foot and Ankle Society. Published by Elsevier Ltd. All rights reserved. FAU - Ahmed, Shuaib AU - Ahmed S AD - Department of Trauma & Orthopaedics, King's College Hospital, London SE5 9RS, United Kingdom. Electronic address: shuaib.ahmed8@nhs.net. FAU - Vainieri, Erika AU - Vainieri E AD - Department of Diabetic Foot Medicine, King's College Hospital, London SE5 9RS, United Kingdom. FAU - Manu, Chris AU - Manu C AD - Department of Diabetic Foot Medicine, King's College Hospital, London SE5 9RS, United Kingdom. FAU - Hester, Thomas AU - Hester T AD - Department of Trauma & Orthopaedics, King's College Hospital, London SE5 9RS, United Kingdom. FAU - Kavarthapu, Venu AU - Kavarthapu V AD - Department of Trauma & Orthopaedics, King's College Hospital, London SE5 9RS, United Kingdom. LA - eng PT - Journal Article DEP - 20251006 PL - France TA - Foot Ankle Surg JT - Foot and ankle surgery : official journal of the European Society of Foot and Ankle Surgeons JID - 9609647 RN - 0 (Glycated Hemoglobin) SB - IM MH - Humans MH - Middle Aged MH - Male MH - Female MH - *Arthropathy, Neurogenic/surgery/etiology/blood MH - Glycated Hemoglobin/analysis/metabolism MH - *Diabetic Foot/surgery/blood MH - *Glycemic Control MH - Aged MH - *Patient Care Team MH - Retrospective Studies MH - Preoperative Care MH - *Plastic Surgery Procedures/methods MH - Adult MH - Time Factors OTO - NOTNLM OT - Charcot OT - Glycaemic OT - Multidisciplinary OT - Reconstructions COIS- Declaration of Competing Interest The authors declare that they have no conflict of interest EDAT- 2025/10/09 00:31 MHDA- 2026/03/09 07:42 CRDT- 2025/10/08 21:59 PHST- 2025/06/02 00:00 [received] PHST- 2025/08/17 00:00 [revised] PHST- 2025/10/03 00:00 [accepted] PHST- 2026/03/09 07:42 [medline] PHST- 2025/10/09 00:31 [pubmed] PHST- 2025/10/08 21:59 [entrez] AID - S1268-7731(25)00223-1 [pii] AID - 10.1016/j.fas.2025.10.001 [doi] PST - ppublish SO - Foot Ankle Surg. 2026 Apr;32(3):269-274. doi: 10.1016/j.fas.2025.10.001. Epub 2025 Oct 6. PMID- 41057819 OWN - NLM STAT- MEDLINE DCOM- 20251008 LR - 20251010 IS - 1472-6963 (Electronic) IS - 1472-6963 (Linking) VI - 25 IP - 1 DP - 2025 Oct 7 TI - Management capacity for stable coronary heart disease in Shanghai community medical institutions: a cross-sectional study. PG - 1318 LID - 10.1186/s12913-025-13486-y [doi] LID - 1318 AB - BACKGROUND: Coronary heart disease (CHD) remains one of the leading causes of death worldwide. However, systematic evaluations of CHD management quality at the community level remain limited, thereby constraining improvements in primary medical capacity. This study aims to evaluate community-based CHD management using Donabedian's model to optimise resource allocation, standardise clinical pathways, and improve chronic disease management. METHODS: Guided by Donabedian's model, this study assessed the quality of CHD diagnosis and management within Shanghai's primary healthcare system across three dimensions-structure, process, and outcome-from the dual perspectives of community healthcare institutions and general practitioners (GPs). A cross-sectional survey was conducted between April and May 2024, involving 247 primary healthcare institutions selected through census sampling. Within each administrative district, 50% of institutions were randomly selected using cluster sampling. Subsequently, stratified sampling based on professional titles was employed to survey 50% of GPs within these institutions. In total, 247 institutional questionnaires and 2,093 GPs' responses were deemed valid and included in the final analysis. RESULTS: Structural analysis indicated adequate CHD-specialised clinics (74.8% with integrated care teams) and essential equipment availability (> 97%), but significant gaps in rehabilitation resources (personnel: 14.6%; equipment: 8.5%). Process evaluation showed high referral rates (91.5%) yet poor patient self-management (18.6%) and limited health record completeness (27.1%). Only 26.7% of institutions adopted CHD-specific information systems. GPs demonstrated strong acute care capacity but had knowledge gaps in advanced concepts (53.6%) and test interpretation (45.4%). Key barriers included equipment shortages (75.5%) and protocol adherence issues (73.1%), with prioritised solutions emphasising medical consortium collaboration (89.4%) and multidisciplinary team development (88.3%). CONCLUSION: CHD management in Shanghai's community settings is marked by adequate provision of essential resources but notable deficiencies in rehabilitation services and digital infrastructure. Strengthening rehabilitation services, enhancing information system development, and providing targeted training to improve diagnostic and management capacities are recommended. These findings may provide valuable insights for informing similar efforts in other regions. CI - (c) 2025. The Author(s). FAU - Yang, Sen AU - Yang S AD - Daqiao Community Healthcare Centre, Yangpu District, Shanghai, 200090, PR China. AD - Department of General Practice, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, 200090, China. FAU - He, Liuhua AU - He L AD - School of Medicine, Tongji University, Shanghai, 200331, China. AD - Huayang Street Community Health Service Centre, Changning District, Shanghai, 200042, China. FAU - Wang, Jiaojiao AU - Wang J AD - Daqiao Community Healthcare Centre, Yangpu District, Shanghai, 200090, PR China. FAU - Ma, Le AU - Ma L AD - Department of General Practice, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, 200090, China. AD - Shanghai General Practice Clinical Quality Control Centre, Shanghai, 200090, China. FAU - Li, Wanyu AU - Li W AD - Xiayang Street Community Health Service Centre, Qingpu District, Shanghai, 201703, China. FAU - Wang, Yang AU - Wang Y AD - Department of General Practice, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, 200090, China. AD - Shanghai General Practice and Community Health Development Research Centre, Shanghai, 200090, China. FAU - Mei, Bosheng AU - Mei B AD - Department of Emergency Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. FAU - Zhang, Hanzhi AU - Zhang H AD - Department of General Practice, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, 200090, China. AD - Shanghai General Practice and Community Health Development Research Centre, Shanghai, 200090, China. FAU - Pan, Ying AU - Pan Y AD - Department of General Practice, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, 200090, China. AD - Shanghai General Practice and Community Health Development Research Centre, Shanghai, 200090, China. FAU - Yu, Dehua AU - Yu D AUID- ORCID: 0000-0001-7652-938X AD - Department of General Practice, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, 200090, China. ydh1404@sina.com. AD - Shanghai General Practice Clinical Quality Control Centre, Shanghai, 200090, China. ydh1404@sina.com. FAU - Jin, Hua AU - Jin H AUID- ORCID: 0000-0002-9735-0335 AD - Department of General Practice, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, 200090, China. drjinhua@tongji.edu.cn. AD - Shanghai General Practice and Community Health Development Research Centre, Shanghai, 200090, China. drjinhua@tongji.edu.cn. LA - eng GR - 20234Y0057/Shanghai Municipal Health Commission/ GR - 2023HP28/Shanghai Municipal Health Commission Health Policy Research Project/ GR - 2023HP71/Shanghai Municipal Health Commission Health Policy Research Project/ GR - 72104183/National Natural Science Foundation of China/ PT - Journal Article DEP - 20251007 PL - England TA - BMC Health Serv Res JT - BMC health services research JID - 101088677 SB - IM MH - Humans MH - Cross-Sectional Studies MH - China MH - *Coronary Disease/therapy/diagnosis MH - Male MH - Female MH - *Primary Health Care/organization & administration MH - *Community Health Services/organization & administration MH - Surveys and Questionnaires MH - General Practitioners MH - Middle Aged PMC - PMC12506379 OTO - NOTNLM OT - Coronary heart disease OT - Diagnostic quality OT - Health services evaluation OT - Management capacity OT - Primary healthcare OT - Quality assessment OT - Therapeutic quality COIS- Declarations. Ethical approval: This study was conducted in accordance with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Yangpu Hospital affiliated to Tongji University (Approval No.: LL-2025-LW-001). Consent to participate: All participants gave written informed consent before participation. Competing interests: The authors declare no competing interests. EDAT- 2025/10/08 00:29 MHDA- 2025/10/08 06:29 PMCR- 2025/10/07 CRDT- 2025/10/07 23:51 PHST- 2025/05/20 00:00 [received] PHST- 2025/09/08 00:00 [accepted] PHST- 2025/10/08 06:29 [medline] PHST- 2025/10/08 00:29 [pubmed] PHST- 2025/10/07 23:51 [entrez] PHST- 2025/10/07 00:00 [pmc-release] AID - 10.1186/s12913-025-13486-y [pii] AID - 13486 [pii] AID - 10.1186/s12913-025-13486-y [doi] PST - epublish SO - BMC Health Serv Res. 2025 Oct 7;25(1):1318. doi: 10.1186/s12913-025-13486-y. PMID- 41057729 OWN - NLM STAT- MEDLINE DCOM- 20260821 LR - 20261008 IS - 1432-1971 (Electronic) IS - 0172-0643 (Linking) VI - 47 IP - 6 DP - 2026 Aug TI - The Trauma Informed Family Meeting: A New Model of Information Sharing and Family Support During Cardiac Admission. PG - 2512-2515 LID - 10.1007/s00246-025-04054-6 [doi] AB - While best practice guidelines for family meetings in pediatric CICU settings emphasize empathic listening, deliberation, and a focus on family experiences and values, recent research reveals that cardiac care teams face barriers when putting these guidelines into practice. Exposure to traumatic medical experiences impacts the degree to which both family members and cardiac clinicians are able to engage in collaborative conversations during family meetings. Instead, these meetings often become lengthy summaries of the patient's medical history, bringing us no closer to the goal of family centered partnership, an essential component of care for children with complex cardiac conditions. We propose the Trauma Informed Family Meeting (TIFM), which draws upon relational ethics, trauma informed care principles, and the most current empirical research on teamwork and family centered care in CICUs. Central to an effective TIFM are structured, pre-family meeting huddles, which provide opportunities for critical care teams to support one another, establish a shared understanding of medical facts and treatment recommendations, and develop an effective communication strategy. We propose guidelines for TIFMs, including those to be used before and during a TIFM. By shifting our perspective on the purpose of family meetings, a TIFM has the potential to set families on a trajectory to be fully engaged in treatment planning and medical decision-making, to ensure clinicians receive necessary supports, and for teams and families to emerge as strong partners in a child's cardiac care. CI - (c) 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Gramszlo, Colette AU - Gramszlo C AD - Department of Child and Adolescent Psychiatry and Behavioral Sciences, Children's Hospital of Philadelphia, 3500 Civic Center Blvd, Philadelphia, PA, 19104, USA. gramszloc@chop.edu. FAU - DeWitt, Aaron AU - DeWitt A AD - Division of Cardiac Critical Care Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, USA. FAU - Walter, Jennifer K AU - Walter JK AD - Department of Medical Ethics, Children's Hospital of Philadelphia, Philadelphia, PA, USA. AD - Justin Michael Ingerman Center for Palliative Care, Children's Hospital of Philadelphia, Philadelphia, PA, USA. LA - eng PT - Journal Article PT - Review DEP - 20251008 PL - United States TA - Pediatr Cardiol JT - Pediatric cardiology JID - 8003849 SB - IM MH - Humans MH - *Professional-Family Relations MH - Family Support MH - *Information Dissemination MH - Child MH - Patient Care Team MH - Communication MH - *Family/psychology MH - *Heart Diseases/therapy MH - Patient Admission OTO - NOTNLM OT - Cardiac intensive care unit OT - Family centered care OT - Family meetings OT - Trauma informed care COIS- Declarations. Conflict of interest: I declare that the authors have no competing interests as defined by Springer, or other interests that might be perceived to influence the results and/or discussion reported in this paper. EDAT- 2025/10/08 00:29 MHDA- 2026/08/22 05:37 CRDT- 2025/10/07 23:47 PHST- 2025/08/14 00:00 [received] PHST- 2025/09/29 00:00 [accepted] PHST- 2026/08/22 05:37 [medline] PHST- 2025/10/08 00:29 [pubmed] PHST- 2025/10/07 23:47 [entrez] AID - 10.1007/s00246-025-04054-6 [pii] AID - 10.1007/s00246-025-04054-6 [doi] PST - ppublish SO - Pediatr Cardiol. 2026 Aug;47(6):2512-2515. doi: 10.1007/s00246-025-04054-6. Epub 2025 Oct 8. PMID- 41055081 OWN - NLM STAT- MEDLINE DCOM- 20251007 LR - 20260905 IS - 2291-9694 (Electronic) IS - 2291-9694 (Linking) VI - 13 DP - 2025 Aug 14 TI - Application of Large Language Models in Complex Clinical Cases: Cross-Sectional Evaluation Study. PG - e73941 LID - 10.2196/73941 [doi] LID - e73941 AB - BACKGROUND: Large language models (LLMs) have made significant advancements in natural language processing (NLP) and are gradually showing potential for application in the medical field. However, LLMs still face challenges in medicine. OBJECTIVE: This study aims to evaluate the efficiency, accuracy, and cost of LLMs in handling complex medical cases and to assess their potential and applicability as tools for clinical decision support. METHODS: We selected cases from the database of the Department of Cardiothoracic Surgery, the Third Affiliated Hospital of Sun Yat-sen University (2021-2024), and conducted a multidimensional preliminary evaluation of the latest LLMs in clinical decision-making for complex cases. The evaluation included measuring the time taken for the LLMs to generate decision recommendations, Likert scores, and calculating decision costs to assess the execution efficiency, accuracy, and cost-effectiveness of the models. RESULTS: A total of 80 complex cases were included in this study, and the performance of multiple LLMs in clinical decision-making was evaluated. Experts required 33.60 minutes on average (95% CI 32.57-34.63), far longer than any LLM. GPTo1 (0.71, 95% CI 0.67-0.74), GPT4o (0.88, 95% CI 0.83-0.92), and Deepseek (0.94, 95% CI 0.90-0.96) all finished under a minute without statistical differences. Although Kimi, Gemini, LLaMa3-8B, and LLaMa3-70B took 1.02-3.20 minutes, they were still faster than experts. In terms of decision accuracy, Deepseek-R1 had the highest accuracy (mean Likert score=4.19), with no significant difference compared to GPTo1 (P=.699), and both performed significantly better than GPT4o, Kimi, Gemini, LLaMa3-70B, and LLaMa3-8B (P<.001). Deepseek-R1 and GPTo1 demonstrated the lowest hallucination rates-6/80 (8%) and 5/80 (6%), respectively-significantly outperforming GPT-4o (7/80, 9%), Kimi (10/80, 12%), and the Gemini and LLaMa3 models, which exhibited substantially higher rates ranging from 13/80 (16%) to 25/80 (31%). Regarding decision costs, all LLMs showed significantly lower costs than the Multidisciplinary Team, with open-source models such as Deepseek-R1 offering a zero direct cost advantage. CONCLUSIONS: GPTo1 and Deepseek-R1 show strong clinical potential, boosting efficiency, maintaining accuracy, and reducing costs. GPT4o and Kimi performed moderately, indicating suitability for broader clinical tasks. Further research is needed to validate LLaMa3 series and Gemini in clinical decision. CI - (c) Yuanheng Huang, Guozhen Yang, Yahui Shen, Huiguo Chen, Weibin Wu, Xiaojun Li, Yonghui Wu, Kai Zhang, Jiannan Xu, Jian Zhang. Originally published in JMIR Medical Informatics (https://medinform.jmir.org). FAU - Huang, Yuanheng AU - Huang Y AUID- ORCID: 0000-0003-3357-8645 AD - Department of Cardiothoracic Surgery, Third Affiliated Hospital of Sun Yat-sen University, 2693 Kaichuang Avenue, Huangpu District, Guangzhou, 510000, China, 86 13922192727, 86 82179042. FAU - Yang, Guozhen AU - Yang G AUID- ORCID: 0009-0003-0919-5780 AD - Department of Cardiothoracic Surgery, Third Affiliated Hospital of Sun Yat-sen University, 2693 Kaichuang Avenue, Huangpu District, Guangzhou, 510000, China, 86 13922192727, 86 82179042. FAU - Shen, Yahui AU - Shen Y AUID- ORCID: 0009-0009-0953-0976 AD - Department of Gynecologic Oncology, Shaanxi Provincial Cancer Hospital, Xi'an, China. FAU - Chen, Huiguo AU - Chen H AUID- ORCID: 0000-0003-3905-5095 AD - Department of Cardiothoracic Surgery, Third Affiliated Hospital of Sun Yat-sen University, 2693 Kaichuang Avenue, Huangpu District, Guangzhou, 510000, China, 86 13922192727, 86 82179042. FAU - Wu, Weibin AU - Wu W AUID- ORCID: 0000-0002-2272-8735 AD - Department of Cardiothoracic Surgery, Third Affiliated Hospital of Sun Yat-sen University, 2693 Kaichuang Avenue, Huangpu District, Guangzhou, 510000, China, 86 13922192727, 86 82179042. FAU - Li, Xiaojun AU - Li X AUID- ORCID: 0000-0001-7078-8241 AD - Department of Cardiothoracic Surgery, Third Affiliated Hospital of Sun Yat-sen University, 2693 Kaichuang Avenue, Huangpu District, Guangzhou, 510000, China, 86 13922192727, 86 82179042. FAU - Wu, Yonghui AU - Wu Y AUID- ORCID: 0000-0003-2392-1382 AD - Department of Cardiothoracic Surgery, Third Affiliated Hospital of Sun Yat-sen University, 2693 Kaichuang Avenue, Huangpu District, Guangzhou, 510000, China, 86 13922192727, 86 82179042. FAU - Zhang, Kai AU - Zhang K AUID- ORCID: 0000-0002-7877-4538 AD - Department of Cardiothoracic Surgery, Third Affiliated Hospital of Sun Yat-sen University, 2693 Kaichuang Avenue, Huangpu District, Guangzhou, 510000, China, 86 13922192727, 86 82179042. FAU - Xu, Jiannan AU - Xu J AUID- ORCID: 0000-0003-0586-6703 AD - Department of Cardiothoracic Surgery, Third Affiliated Hospital of Sun Yat-sen University, 2693 Kaichuang Avenue, Huangpu District, Guangzhou, 510000, China, 86 13922192727, 86 82179042. FAU - Zhang, Jian AU - Zhang J AUID- ORCID: 0000-0001-5000-6142 AD - Department of Cardiothoracic Surgery, Third Affiliated Hospital of Sun Yat-sen University, 2693 Kaichuang Avenue, Huangpu District, Guangzhou, 510000, China, 86 13922192727, 86 82179042. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20250814 PL - Canada TA - JMIR Med Inform JT - JMIR medical informatics JID - 101645109 SB - IM MH - Humans MH - *Natural Language Processing MH - Cross-Sectional Studies MH - *Decision Support Systems, Clinical MH - *Clinical Decision-Making/methods MH - Large Language Models PMC - PMC12501899 OTO - NOTNLM OT - artificial intelligence OT - clinical decision support OT - complex medical cases OT - cross-sectional studies OT - large language models COIS- Conflicts of Interest: None declared. EDAT- 2025/10/07 12:31 MHDA- 2025/10/07 12:32 PMCR- 2025/08/14 CRDT- 2025/10/07 06:35 PHST- 2025/03/14 00:00 [received] PHST- 2025/05/30 00:00 [revised] PHST- 2025/06/10 00:00 [accepted] PHST- 2025/10/07 12:32 [medline] PHST- 2025/10/07 12:31 [pubmed] PHST- 2025/10/07 06:35 [entrez] PHST- 2025/08/14 00:00 [pmc-release] AID - v13i1e73941 [pii] AID - 73941 [pii] AID - 10.2196/73941 [doi] PST - epublish SO - JMIR Med Inform. 2025 Aug 14;13:e73941. doi: 10.2196/73941. PMID- 41051335 OWN - NLM STAT- MEDLINE DCOM- 20251006 LR - 20251006 IS - 1543-0790 (Print) IS - 1543-0790 (Linking) VI - 23 IP - 7 DP - 2025 Oct TI - Cancer and cardiovascular health: a multidisciplinary approach. PG - 446-452 AB - Early detection and improved cancer therapies have led to increases in cancer survivorship. There were 18.1 million cancer survivors in the United States alone in 2022, and this number will grow to 21.6 million by 2030. Cancer survivors are at increased risk for non-cancer-related morbidity and mortality, including cardiovascular disease. Cardio-oncology has emerged as a new subspecialty of medicine, dedicated to improving the cardiovascular health of patients with cancer and facilitating the administration of the best cancer therapy while optimizing cardiovascular health. Contemporary cancer treatments are associated with multiple types of cancer treatment-related cardiac dysfunction (CTRCD), including heart failure, vascular toxicities, arrhythmias/corrected QT prolongation, hypertension, and myocarditis. In 2022, the European Society of Cardiology published comprehensive guidelines that endorsed the Heart Failure Association/International Cardio-Oncology Society baseline risk stratification tool for assessing all patients with cancer before cancer therapy is started. Primary prevention strategies can be considered for patients at high risk and very high risk for CTRCD, with the goal of facilitating the delivery of cancer therapy while minimizing the risk of cardiovascular toxicity. Dedicated multidisciplinary cardio-oncology clinics have emerged across North America, Europe, South America, Asia, South Africa, and Australia to enhance cancer care while optimizing cardiovascular health. FAU - Dent, Susan AU - Dent S AD - Wilmot Cancer Institute, Department of Medicine, University of Rochester, New York. LA - eng PT - Journal Article PT - Review PL - United States TA - Clin Adv Hematol Oncol JT - Clinical advances in hematology & oncology : H&O JID - 101167661 SB - IM MH - Humans MH - *Neoplasms/therapy/complications MH - *Cardiovascular Diseases/etiology/prevention & control/epidemiology MH - Cancer Survivors EDAT- 2025/10/06 12:31 MHDA- 2025/10/06 12:32 CRDT- 2025/10/06 10:13 PHST- 2025/10/06 12:32 [medline] PHST- 2025/10/06 12:31 [pubmed] PHST- 2025/10/06 10:13 [entrez] PST - ppublish SO - Clin Adv Hematol Oncol. 2025 Oct;23(7):446-452. PMID- 41049899 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251006 LR - 20251008 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 17 IP - 9 DP - 2025 Sep TI - Postoperative Clinical Outcomes of Transurethral Resection of the Prostate (TURP) Combined With Otis Urethrotomy in High-Risk Patients With Coronary Artery Disease (Post-Angioplasty): Insights From a Prospective Observational Cohort. PG - e91439 LID - 10.7759/cureus.91439 [doi] LID - e91439 AB - Background Transurethral resection of the prostate (TURP) is widely used for treating benign prostatic hyperplasia (BPH) but is associated with postoperative urethral strictures, especially in patients with narrow urethral anatomy. The risk is further complicated in patients with coronary artery disease (CAD) on dual antiplatelet therapy, where surgical bleeding and cardiac events are significant concerns. Otis urethrotomy may help reduce stricture risk, but its safety and effectiveness in high-risk cardiac patients undergoing TURP remain underexplored. Materials and methods In this prospective observational study, 80 male CAD patients with prior angioplasty underwent TURP with prophylactic Otis urethrotomy. All patients were assessed and optimized preoperatively through a multidisciplinary approach. Follow-up evaluations at one, three, and six months included assessments of urinary flow (Qmax), post-void residual (PVR) urine, International Prostatic Symptom Score (IPSS), quality of life (QOL) score, and perioperative complications. Results Urethral stricture occurred in only two patients (2.5%), notably lower than typical post-TURP rates. Qmax improved from 7.1 to 12.3 mL/s, and PVR declined from 165.5 to 52.7 mL. IPSS decreased from 23.5 to 14.3, and QOL scores improved from 4.5 to 2.0. Cardiac complications were limited to minor events (angina 2.5%, arrhythmia 1.2%), with no reinfarctions. Urological complications were mild and self-limiting. Conclusion The combination of Otis urethrotomy with TURP in CAD patients is safe and effective, yielding strong functional outcomes and low complication rates. It offers a promising surgical option in high-risk individuals when managed through a structured, multidisciplinary framework. CI - Copyright (c) 2025, Sharma et al. FAU - Sharma, A Yagneshwar AU - Sharma AY AD - Department of Urology, Chhattisgarh Institute of Medical Sciences, Bilaspur, IND. FAU - Tiwari, Bhrigudutt AU - Tiwari B AD - Department of General Surgery, Chhattisgarh Institute of Medical Sciences, Bilaspur, IND. FAU - Ekka, Shubha AU - Ekka S AD - Department of General Surgery, Chhattisgarh Institute of Medical Sciences, Bilaspur, IND. FAU - Kumar, Abhishek AU - Kumar A AD - Department of Cardiology, Chhattisgarh Institute of Medical Sciences, Bilaspur, IND. FAU - Jangir, Murlidhar AU - Jangir M AD - Department of Urology, Chhattisgarh Institute of Medical Sciences, Bilaspur, IND. FAU - Peswani, Mamta AU - Peswani M AD - Department of Urology, Chhattisgarh Institute of Medical Sciences, Bilaspur, IND. FAU - Agrawal, Siddharth AU - Agrawal S AD - Department of Urology, Chhattisgarh Institute of Medical Sciences, Bilaspur, IND. LA - eng PT - Journal Article DEP - 20250901 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC12491640 OTO - NOTNLM OT - benign prostatic hyperplasia OT - coronary artery disease OT - dual antiplatelet therapy OT - otis urethrotomy OT - transurethral resection of the prostate OT - urethral stricture COIS- Human subjects: Informed consent for treatment and open access publication was obtained or waived by all participants in this study. Institutional Ethical Committee issued approval Roc.No.AS/11/IEC/SVIMS/2017. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. EDAT- 2025/10/06 12:31 MHDA- 2025/10/06 12:32 PMCR- 2025/09/01 CRDT- 2025/10/06 07:28 PHST- 2025/09/01 00:00 [accepted] PHST- 2025/10/06 12:32 [medline] PHST- 2025/10/06 12:31 [pubmed] PHST- 2025/10/06 07:28 [entrez] PHST- 2025/09/01 00:00 [pmc-release] AID - 10.7759/cureus.91439 [doi] PST - epublish SO - Cureus. 2025 Sep 1;17(9):e91439. doi: 10.7759/cureus.91439. eCollection 2025 Sep. PMID- 41044732 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251210 LR - 20251217 IS - 1738-5520 (Print) IS - 1738-5555 (Electronic) IS - 1738-5520 (Linking) VI - 55 IP - 12 DP - 2025 Dec TI - Management of Coronary Artery Disease in Patients With Severe Aortic Stenosis. PG - 1055-1076 LID - 10.4070/kcj.2025.0268 [doi] AB - The coexistence of severe aortic stenosis (AS) and coronary artery disease (CAD) presents complex diagnostic and therapeutic challenges, particularly as transcatheter aortic valve replacement (TAVR) expands to younger, lower-risk populations. CAD prevalence in AS patients ranges from 27.7% in low-risk cohorts to 74.9% in high-risk populations, synergistically worsening ventricular function and prognosis. Diagnostic evaluation remains challenging due to overlapping symptomatology and altered coronary physiology in severe AS. While invasive coronary angiography remains the gold standard, coronary computed tomography (CT) angiography with CT-derived fractional flow reserve (FFR) shows promise as a non-invasive alternative. Standard FFR thresholds may not be reliable in AS patients, with emerging evidence suggesting AS-specific cutoffs may be needed. Treatment strategies must balance the complexity of CAD with patient risk profiles. Current guidelines recommend bypass surgery with surgical aortic valve replacement for complex multivessel disease, while percutaneous coronary intervention (PCI) with TAVR is preferred for less complex lesions or high-risk patients. The optimal timing of PCI relative to TAVR remains debated, with recent data favoring a "TAVR-first" approach for non-critical lesions. As TAVR extends to younger patients, lifetime management considerations become paramount, including valve durability, future coronary access, and planning for potential re-interventions. Commissural alignment techniques during TAVR are crucial for preserving future coronary access. A multidisciplinary Heart Team approach with robust shared decision-making is essential for optimizing individualized care in this evolving field. CI - Copyright (c) 2025. The Korean Society of Cardiology. FAU - Kim, Ju Hyeon AU - Kim JH AUID- ORCID: 0000-0002-4193-0891 AD - Division of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. FAU - Kang, Do-Yoon AU - Kang DY AUID- ORCID: 0000-0002-6307-0562 AD - Division of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. FAU - Ahn, Jung-Min AU - Ahn JM AUID- ORCID: 0000-0003-4031-391X AD - Division of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. FAU - Seo, Kyeong-Won AU - Seo KW AUID- ORCID: 0009-0001-7307-0830 AD - Division of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. FAU - Lee, Seung Han AU - Lee SH AUID- ORCID: 0009-0008-6849-1658 AD - Division of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. FAU - Wee, Seong-Bong AU - Wee SB AUID- ORCID: 0009-0009-5779-5266 AD - Division of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. FAU - An, Soo Yeon AU - An SY AUID- ORCID: 0000-0002-4313-1700 AD - Division of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. FAU - Park, Hansu AU - Park H AUID- ORCID: 0000-0001-5123-8383 AD - Division of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. FAU - Park, Duk-Woo AU - Park DW AUID- ORCID: 0000-0001-6643-0239 AD - Division of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. dwpark@amc.seoul.kr. FAU - Park, Seung-Jung AU - Park SJ AUID- ORCID: 0000-0002-9187-5405 AD - Division of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. LA - eng PT - Journal Article PT - Review DEP - 20250814 PL - Korea (South) TA - Korean Circ J JT - Korean circulation journal JID - 101247141 PMC - PMC12705249 OTO - NOTNLM OT - Aortic stenosis OT - Coronary artery disease OT - Transcatheter aortic valve replacement COIS- The authors have no financial conflicts of interest. EDAT- 2025/10/04 06:32 MHDA- 2025/10/04 06:33 PMCR- 2025/08/14 CRDT- 2025/10/04 00:12 PHST- 2025/06/29 00:00 [received] PHST- 2025/07/21 00:00 [revised] PHST- 2025/07/23 00:00 [accepted] PHST- 2025/10/04 06:33 [medline] PHST- 2025/10/04 06:32 [pubmed] PHST- 2025/10/04 00:12 [entrez] PHST- 2025/08/14 00:00 [pmc-release] AID - 55.e127 [pii] AID - 10.4070/kcj.2025.0268 [doi] PST - ppublish SO - Korean Circ J. 2025 Dec;55(12):1055-1076. doi: 10.4070/kcj.2025.0268. Epub 2025 Aug 14. PMID- 41044191 OWN - NLM STAT- MEDLINE DCOM- 20251003 LR - 20251118 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 15 IP - 1 DP - 2025 Oct 3 TI - Sutureless versus transcatheter valves for the treatment of aortic valve stenosis: a systematic review and meta-analysis. PG - 34540 LID - 10.1038/s41598-025-17857-7 [doi] LID - 34540 AB - An important limitation of the pivotal randomized controlled trials that compared transcatheter aortic valve replacement (TAVR) to surgical aortic valve replacement (SAVR) is that the SAVR arm scarcely included sutureless bioprosthetic valves. We identified 13 retrospective propensity-matched studies in low (n = 2), intermediate (n = 8), and high-risk (n = 3) patients, using EuroSCORE and STS score to assess perioperative risk. One large registry drove the outcome in low-risk patients, showing better early survival with TAVR, lower rates of stroke and acute kidney injury. Intermediate-risk patients showed improved early and medium-term survival with SU-AVR, whilst in high-risk patients, no significant differences were seen between treatment options. Overall, across all risk categories, the rates of moderate and severe aortic regurgitation and permanent pacemaker implantation were significantly lower with SU-AVR, while transprosthetic gradients and duration of hospital stay were higher compared to TAVR. The differences in survival in the intermediate risk group are not in line with conclusions of pivotal randomized trials comparing TAVR with SAVR. Specific features of SU-AVR may account for these survival differences, positioning SU-AVR as a valid and safe alternative for patients at intermediate risk. Awaiting confirmation in randomized trials, careful patient selection and consideration of either of the AVR options in the heart team remain crucial. CI - (c) 2025. The Author(s). FAU - Minten, Lennert AU - Minten L AD - Department of Cardiovascular Sciences, KU Leuven, Herestraat 49, Leuven, 3000, Belgium. AD - Department of Cardiovascular Medicine, University Hospitals Leuven (UZ Leuven), Leuven, Belgium. FAU - Lamberigts, Marie AU - Lamberigts M AD - Department of Cardiovascular Sciences, KU Leuven, Herestraat 49, Leuven, 3000, Belgium. AD - Department of Cardiac Surgery, University Hospitals Leuven (UZ Leuven), Leuven, Belgium. FAU - Van Langenhoven, Leen AU - Van Langenhoven L AD - I-BioStat, KU Leuven & University of Hasselt, Leuven, Belgium. FAU - Verbrugghe, Peter AU - Verbrugghe P AD - Department of Cardiovascular Sciences, KU Leuven, Herestraat 49, Leuven, 3000, Belgium. AD - Department of Cardiac Surgery, University Hospitals Leuven (UZ Leuven), Leuven, Belgium. FAU - Bennett, Johan AU - Bennett J AD - Department of Cardiovascular Sciences, KU Leuven, Herestraat 49, Leuven, 3000, Belgium. AD - Department of Cardiovascular Medicine, University Hospitals Leuven (UZ Leuven), Leuven, Belgium. FAU - Dubois, Christophe AU - Dubois C AD - Department of Cardiovascular Sciences, KU Leuven, Herestraat 49, Leuven, 3000, Belgium. AD - Department of Cardiovascular Medicine, University Hospitals Leuven (UZ Leuven), Leuven, Belgium. FAU - Meuris, Bart AU - Meuris B AD - Department of Cardiovascular Sciences, KU Leuven, Herestraat 49, Leuven, 3000, Belgium. bart.meuris@uzleuven.be. AD - Department of Cardiac Surgery, University Hospitals Leuven (UZ Leuven), Leuven, Belgium. bart.meuris@uzleuven.be. LA - eng PT - Comparative Study PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20251003 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 SB - IM MH - Humans MH - *Aortic Valve Stenosis/surgery/mortality MH - *Transcatheter Aortic Valve Replacement/methods/adverse effects MH - *Heart Valve Prosthesis MH - Treatment Outcome MH - *Aortic Valve/surgery MH - *Sutureless Surgical Procedures/methods MH - Bioprosthesis PMC - PMC12494754 OTO - NOTNLM OT - Aortic valve stenosis, transcatheter aortic valve replacement OT - Meta-analysis OT - Sutureless aortic valve replacement OT - Systematic review COIS- Declarations. Competing Interests: BM & PV are consultants to Corcym srl. CD receives speaker fees from Corcym srl. CD is transcatheter heart valve (THV) proctor for Edwards Lifesciences. The Research Foundation Flanders (FWO) supported L. Minten with a personal research grant (1194521-23N). Corcym supported M. Lamberigts by a research grant. EDAT- 2025/10/04 00:30 MHDA- 2025/10/04 00:31 PMCR- 2025/10/03 CRDT- 2025/10/03 23:32 PHST- 2024/06/20 00:00 [received] PHST- 2025/08/26 00:00 [accepted] PHST- 2025/10/04 00:31 [medline] PHST- 2025/10/04 00:30 [pubmed] PHST- 2025/10/03 23:32 [entrez] PHST- 2025/10/03 00:00 [pmc-release] AID - 10.1038/s41598-025-17857-7 [pii] AID - 17857 [pii] AID - 10.1038/s41598-025-17857-7 [doi] PST - epublish SO - Sci Rep. 2025 Oct 3;15(1):34540. doi: 10.1038/s41598-025-17857-7. PMID- 41042176 OWN - NLM STAT- In-Process LR - 20251121 IS - 1522-9645 (Electronic) IS - 0195-668X (Linking) VI - 46 IP - 44 DP - 2025 Nov 21 TI - The European Society of Cardiology Council on Stroke: building the future of the multidisciplinary study of stroke. PG - 4632-4634 LID - 10.1093/eurheartj/ehaf719 [doi] FAU - Lip, Gregory Y H AU - Lip GYH AUID- ORCID: 0000-0002-7566-1626 AD - Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart and Chest Hospital, Liverpool, UK. AD - Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. AD - Department of Cardiology, Lipidology and Internal Medicine with Intensive Coronary Care Unit, Medical University of Bialystok, Bialystok, Poland. FAU - Romiti, Giulio Francesco AU - Romiti GF AUID- ORCID: 0000-0002-3788-8942 AD - Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart and Chest Hospital, Liverpool, UK. AD - Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy. FAU - Proietti, Marco AU - Proietti M AUID- ORCID: 0000-0003-1452-2478 AD - Department of Clinical Sciences and Community Health, University of Milan, Via della Commenda 19, Milan 20122, Italy. AD - Division of Cardiogeriatric Subacute Care, IRCCS Istituti Clinici Scientifici Maugeri, Via Camaldoli 64, Milan 20138, Italy. CN - ESC Council on Stroke Nucleus LA - eng PT - Journal Article PL - England TA - Eur Heart J JT - European heart journal JID - 8006263 SB - IM FIR - Lip, Gregory IR - Lip G FIR - Schnabel, Renate IR - Schnabel R FIR - Halliday, Alison IR - Halliday A FIR - Proietti, Marco IR - Proietti M FIR - Taborsky, Milos IR - Taborsky M FIR - Nikas, Dimitrios IR - Nikas D FIR - Romiti, Giulio Francesco IR - Romiti GF FIR - Imberti, Jacopo Francesco IR - Imberti JF FIR - Widimsky, Petr IR - Widimsky P EDAT- 2025/10/03 12:34 MHDA- 2025/10/03 12:34 CRDT- 2025/10/03 10:22 PHST- 2025/10/03 12:34 [pubmed] PHST- 2025/10/03 12:34 [medline] PHST- 2025/10/03 10:22 [entrez] AID - 8272626 [pii] AID - 10.1093/eurheartj/ehaf719 [doi] PST - ppublish SO - Eur Heart J. 2025 Nov 21;46(44):4632-4634. doi: 10.1093/eurheartj/ehaf719. PMID- 41040440 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251003 LR - 20251005 IS - 2772-9303 (Electronic) IS - 2772-9303 (Linking) VI - 4 IP - 9 DP - 2025 Sep TI - SCAI Position Statement on Transcatheter Occlusion of Patent Ductus Arteriosus in Premature Infants. PG - 103866 LID - 10.1016/j.jscai.2025.103866 [doi] LID - 103866 AB - Historically, pharmacotherapy and surgical ligation have been the primary treatments for occlusion of patent ductus arteriosus (PDA), but recent advancements have led to the US Food and Drug Administration approval of the first transcatheter PDA occlusion device for low birth weight infants in 2019. Although short-term outcomes have been encouraging, successful outcomes are highly dependent on proper patient selection, awareness of key procedural considerations, appropriately trained operators, and institutions meeting a standard of required infrastructural requirements. A multidisciplinary approach involving neonatologists and cardiologists is beneficial, as well as shared decision-making with the patient's family. This position statement from the Society for Cardiovascular Angiography & Interventions provides comprehensive suggestions to optimize the safety and efficacy of transcatheter PDA occlusion in premature infants, aiming to improve long-term outcomes in this vulnerable population. CI - (c) 2025 The Author(s). FAU - Batlivala, Sarosh P AU - Batlivala SP AD - Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, Ohio. FAU - Boucek, Dana AU - Boucek D AD - The University of Utah and Primary Children's Hospital, Salt Lake City, Utah. FAU - Downing, Tacy AU - Downing T AD - Children's National Medical Center, Washington, District of Columbia. FAU - Head, Timothy AU - Head T AD - Cook Children's Hospital, Fort Worth, Texas. FAU - Herbert, Carrie AU - Herbert C AD - Medical City Children's, Dallas, Texas. FAU - Levy, Philip AU - Levy P AD - Boston Children's Hospital, Boston, Massachusetts. FAU - Ligon, R Allen AU - Ligon RA AD - Children's Healthcare of Atlanta, Atlanta, Georgia. FAU - Mitra, Souvik AU - Mitra S AD - Dalhousie University, Halifax, Nova Scotia, Canada. FAU - Salavitabar, Arash AU - Salavitabar A AD - Nationwide Children's Hospital, Columbus, Ohio. FAU - Sathanandam, Shyam AU - Sathanandam S AD - The University of Tennessee Health Science Center, Memphis, Tennessee. FAU - Taggart, Nathaniel AU - Taggart N AD - Mayo Clinic, Rochester, Minnesota. FAU - Zablah, Jenny AU - Zablah J AD - Children's Hospital Colorado Anschutz Medical Campus, Aurora, Colorado. FAU - Zahn, Evan AU - Zahn E AD - Cedars-Sinai Medical Center, Los Angeles, California. FAU - Gordon, Brent M AU - Gordon BM AD - Rady Children's Hospital/University of California, San Diego, California. LA - eng PT - Journal Article DEP - 20250818 PL - United States TA - J Soc Cardiovasc Angiogr Interv JT - Journal of the Society for Cardiovascular Angiography & Interventions JID - 9918419271306676 PMC - PMC12485563 OTO - NOTNLM OT - congenital interventional cardiology OT - premature patent ductus arteriosus occlusion COIS- Tacy Downing is a site principal investigator for the COMPASS Trial. Allen Ligon is a proctor for Abbott. Shyam Sathanandam is a consultant, advisor, and speaker for Abbott and is a principal investigator for the US PDA Registry, which is funded by Abbott. He is also a principal investigator for a preclinical trial sponsored by Medtronic. Nathaniel Taggart is a coinvestigator on the Harmony TPV trial sponsored by Medtronic. Jenny Zablah is a consultant for Medtronic and a principal investigator for a clinical trial on OCT in pulmonary vein stenosis sponsored by Abbott. Brent M. Gordon is a proctor and consultant for Abbott and Merit Medical. The other authors reported no financial interests. EDAT- 2025/10/03 06:31 MHDA- 2025/10/03 06:32 PMCR- 2025/08/18 CRDT- 2025/10/03 05:20 PHST- 2025/10/03 06:32 [medline] PHST- 2025/10/03 06:31 [pubmed] PHST- 2025/10/03 05:20 [entrez] PHST- 2025/08/18 00:00 [pmc-release] AID - S2772-9303(25)01308-0 [pii] AID - 103866 [pii] AID - 10.1016/j.jscai.2025.103866 [doi] PST - epublish SO - J Soc Cardiovasc Angiogr Interv. 2025 Aug 18;4(9):103866. doi: 10.1016/j.jscai.2025.103866. eCollection 2025 Sep. PMID- 41036153 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251002 LR - 20260925 IS - 2050-0904 (Print) IS - 2050-0904 (Electronic) IS - 2050-0904 (Linking) VI - 13 IP - 10 DP - 2025 Oct TI - An Unusual Presentation of Metastatic Soft Tissue Sarcoma to the Left Atrium and Pulmonary Veins: A Case Report and Comprehensive Literature Review. PG - e70991 LID - 10.1002/ccr3.70991 [doi] LID - e70991 AB - Metastatic soft tissue sarcoma (STS) is a rare and aggressive malignancy arising from connective tissues. It is characterized by its ability to metastasize to distant sites, with the lungs being the most common location. Despite advances in diagnosis and treatment, the prognosis remains poor, particularly in cases with advanced metastasis. Management often involves a multidisciplinary approach, combining surgery, radiotherapy, chemotherapy, and newer targeted therapies. This report highlights an unusual case of STS metastasizing to the left atrium (LA) and pulmonary veins, which presented with complex clinical and therapeutic challenges. We report the case of a 74-year-old male with a history of synovial cell sarcoma of the left elbow, initially treated with wide resection surgery and adjuvant radiotherapy. Eight months post-treatment, bone metastasis to the ipsilateral humerus bone was detected and managed surgically. The patient later presented with sudden-onset numbness and weakness on the left side, along with sudden-onset aphasia, raising suspicion of neurologic or embolic complications. Diagnostic evaluation, including transthoracic echocardiogram (TEE) and chest computed tomography, revealed a large mass in the LA and pulmonary vein, consistent with metastatic sarcoma. Open-heart surgery was performed to resect the tumor palliatively. Adjuvant chemotherapy and radiotherapy were initiated. Follow-up demonstrated stability of the disease for up to 1 year under the treatment protocol. CI - (c) 2025 The Author(s). Clinical Case Reports published by John Wiley & Sons Ltd. FAU - Bagheri, Abdulhamid AU - Bagheri A AD - Cardiovascular Research Center Shahid Beheshti University of Medical Sciences Tehran Iran. FAU - Khani, Mohammad AU - Khani M AD - Cardiovascular Research Center Shahid Beheshti University of Medical Sciences Tehran Iran. FAU - Fesharaki, Mehrdad Jafari AU - Fesharaki MJ AUID- ORCID: 0000-0002-4866-2623 AD - Cardiovascular Research Center Shahid Beheshti University of Medical Sciences Tehran Iran. FAU - Bayat, Fariba AU - Bayat F AD - Cardiovascular Research Center Shahid Beheshti University of Medical Sciences Tehran Iran. FAU - Langroudi, Taraneh Faghihi AU - Langroudi TF AD - Cardiovascular Research Center Shahid Beheshti University of Medical Sciences Tehran Iran. FAU - Kazeminejad, Behrang AU - Kazeminejad B AD - Cardiovascular Research Center Shahid Beheshti University of Medical Sciences Tehran Iran. FAU - Shahmohammadi, Amirreza AU - Shahmohammadi A AUID- ORCID: 0009-0007-3042-5578 AD - Tehran Heart Center, Cardiovascular Diseases Research Institute Tehran University of Medical Sciences Tehran Iran. FAU - Farahani, Elham AU - Farahani E AD - Cardiovascular Research Center Shahid Beheshti University of Medical Sciences Tehran Iran. LA - eng PT - Journal Article DEP - 20250929 PL - England TA - Clin Case Rep JT - Clinical case reports JID - 101620385 PMC - PMC12479212 OTO - NOTNLM OT - cardiac surgery OT - case report OT - echocardiogram OT - metastasis OT - oncology OT - sarcoma COIS- The authors declare no conflicts of interest. EDAT- 2025/10/02 06:28 MHDA- 2025/10/02 06:29 PMCR- 2025/09/29 CRDT- 2025/10/02 04:54 PHST- 2025/02/21 00:00 [received] PHST- 2025/08/21 00:00 [revised] PHST- 2025/09/17 00:00 [accepted] PHST- 2025/10/02 06:29 [medline] PHST- 2025/10/02 06:28 [pubmed] PHST- 2025/10/02 04:54 [entrez] PHST- 2025/09/29 00:00 [pmc-release] AID - CCR370991 [pii] AID - 10.1002/ccr3.70991 [doi] PST - epublish SO - Clin Case Rep. 2025 Sep 29;13(10):e70991. doi: 10.1002/ccr3.70991. eCollection 2025 Oct. PMID- 41033710 OWN - NLM STAT- MEDLINE DCOM- 20251001 LR - 20260925 IS - 2053-3624 (Print) IS - 2053-3624 (Electronic) IS - 2053-3624 (Linking) VI - 12 IP - 2 DP - 2025 Sep 30 TI - Clarification of embolic source in ischaemic stroke by non-obstructive general angioscopy. LID - 10.1136/openhrt-2025-003590 [doi] LID - e003590 AB - BACKGROUND: Aortogenic stroke is an important subtype of embolic strokes, yet lacks a diagnostic method for proactive identification. Non-obstructive general angioscopy (NOGA) is a catheter-based technique to observe spontaneously ruptured aortic plaques (SRAPs), a potential embolic source of ischaemic stroke. OBJECTIVES: This study aimed to identify the embolic source of ischaemic stroke using NOGA. METHODS: From June 2022 to January 2024, 321 consecutive patients with acute ischaemic stroke were hospitalised. 25 underwent emergent mechanical thrombectomy and NOGA. The aortic arch was screened using NOGA, and atherosclerotic materials from the SRAPs were sampled and pathologically analysed. Transoesophageal echocardiography (TEE) was performed the day after catheterisation to investigate intracardiac thrombus, patent foramen ovale and aortic plaques. The primary outcome was the diagnosis of aortogenic stroke. RESULTS: NOGA identified seven SRAPs in the aortic arch as potential embolic sources. Of those, one patient with atrial fibrillation and cardiac chamber thrombus was diagnosed as having a cardiogenic stroke. The findings of the six remaining cases included aortic arch plaque (also observed via TEE) (n=2), thrombus in an artificial aortic graft wall (n=1), and cholesterol crystals in sampled materials indicating plaque rupture (n=3). The Brain-Heart team finally diagnosed these 6 cases (24%) as aortogenic stroke. 16 patients were diagnosed with cardiogenic stroke. One was diagnosed with paradoxical embolism. The remaining two cases (8%) with unidentified embolic sources were diagnosed with cryptogenic stroke. CONCLUSIONS: Using a systematic diagnostic protocol for embolic source detection, the Brain-Heart team could proactively diagnose aortogenic stroke and clarify embolic source. CI - (c) Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. FAU - Shiba, Mikio AU - Shiba M AUID- ORCID: 0000-0003-4418-7834 AD - Cardiovascular Division, Osaka Keisatsu Hospital, Osaka, Japan. FAU - Higuchi, Yoshiharu AU - Higuchi Y AUID- ORCID: 0000-0002-1665-3407 AD - Cardiovascular Division, Osaka Keisatsu Hospital, Osaka, Japan yhiguchi.ja@gmail.com. FAU - Fukutome, Kenji AU - Fukutome K AD - Department of Neurosurgery, Osaka keisatsu Hospital, Osaka, Japan. FAU - Hamanaka, Yuma AU - Hamanaka Y AD - Cardiovascular Division, Osaka Keisatsu Hospital, Osaka, Japan. FAU - Murakami, Yasutaka AU - Murakami Y AD - Department of Neurology, Osaka keisatsu Hospital, Osaka, Japan. FAU - Minami, Shinya AU - Minami S AD - Cardiovascular Division, Osaka Keisatsu Hospital, Osaka, Japan. FAU - Hayami, Hiromichi AU - Hayami H AD - Department of Neurosurgery, Osaka keisatsu Hospital, Osaka, Japan. FAU - Mitsui, Takaaki AU - Mitsui T AD - Department of Neurosurgery, Osaka keisatsu Hospital, Osaka, Japan. FAU - Matsuoka, Ryuta AU - Matsuoka R AD - Department of Neurosurgery, Osaka keisatsu Hospital, Osaka, Japan. FAU - Shiraishi, Yuki AU - Shiraishi Y AD - Department of Neurosurgery, Osaka keisatsu Hospital, Osaka, Japan. FAU - Fukumori, Junji AU - Fukumori J AD - Department of Neurosurgery, Osaka keisatsu Hospital, Osaka, Japan. FAU - Tsuji, Hiromi AU - Tsuji H AD - Department of Pathology, Osaka Keisatsu Hospital, Osaka, Japan. FAU - Iida, Osamu AU - Iida O AD - Cardiovascular Division, Osaka Keisatsu Hospital, Osaka, Japan. FAU - Aketa, Shuta AU - Aketa S AD - Department of Neurosurgery, Osaka keisatsu Hospital, Osaka, Japan. FAU - Motoyama, Yasushi AU - Motoyama Y AD - Department of Neurosurgery, Osaka keisatsu Hospital, Osaka, Japan. FAU - Hirayama, Atsushi AU - Hirayama A AD - Cardiovascular Division, Osaka Keisatsu Hospital, Osaka, Japan. LA - eng PT - Journal Article DEP - 20250930 PL - England TA - Open Heart JT - Open heart JID - 101631219 SB - IM MH - Humans MH - Male MH - Female MH - Aged MH - *Angioscopy/methods MH - *Ischemic Stroke/etiology/diagnosis MH - Middle Aged MH - *Embolic Stroke/etiology/diagnosis MH - Echocardiography, Transesophageal MH - *Aorta, Thoracic/diagnostic imaging MH - *Plaque, Atherosclerotic/complications/diagnosis MH - Retrospective Studies MH - Aged, 80 and over MH - *Aortic Diseases/complications/diagnosis PMC - PMC12496066 OTO - NOTNLM OT - Aortic Diseases OT - Cardiac Imaging Techniques OT - STROKE COIS- Competing interests: None declared. EDAT- 2025/10/02 00:28 MHDA- 2025/10/02 00:29 PMCR- 2025/09/30 CRDT- 2025/10/01 20:53 PHST- 2025/07/21 00:00 [received] PHST- 2025/09/16 00:00 [accepted] PHST- 2025/10/02 00:29 [medline] PHST- 2025/10/02 00:28 [pubmed] PHST- 2025/10/01 20:53 [entrez] PHST- 2025/09/30 00:00 [pmc-release] AID - openhrt-2025-003590 [pii] AID - 10.1136/openhrt-2025-003590 [doi] PST - epublish SO - Open Heart. 2025 Sep 30;12(2):e003590. doi: 10.1136/openhrt-2025-003590. PMID- 41032461 OWN - NLM STAT- MEDLINE DCOM- 20260213 LR - 20260623 IS - 1526-7598 (Electronic) IS - 0003-2999 (Linking) VI - 142 IP - 3 DP - 2026 Mar 1 TI - The Association Between Surgeon-Anesthesiologist Dyad Familiarity and Operative Mortality: A Retrospective Study at a Large Academic Cardiac Surgery Program. PG - 561-569 LID - 10.1213/ANE.0000000000007759 [doi] AB - BACKGROUND: Effective teamwork is essential in high-stakes environments such as cardiac surgery, where complex procedures require coordinated efforts, particularly between surgeons and anesthesiologists. While team dynamics have been shown to affect surgical outcomes, the impact of surgeon-anesthesiologist familiarity on operative mortality in cardiac surgery remains underexplored. We aimed to assess whether increased familiarity within this dyad was associated with reduced operative mortality and improved patient outcomes. METHODS: We conducted a retrospective, single-center cohort study using data from a large academic medical center, covering cases from July 2011 to January 2024. Surgeon-anesthesiologist dyads were defined by unique pairings who worked together in each case. Familiarity was measured by the frequency of collaboration over the previous 365 days and divided into quintiles. The primary outcome was operative mortality, defined as death before discharge or within 30 days post-procedure. Secondary outcomes included operative length, hospital and intensive care length of stay, reoperation, readmission, and reported organ system complications. A logistic mixed-effects model adjusted for patient demographics, comorbidities, and procedure type, was used to examine associations. RESULTS: We identified 481 unique surgeon-anesthesiologist pairs from 16,811 cases. Higher dyad familiarity was associated with significantly lower operative mortality when analyzing the entire cohort ( P < .001). Patients cared for by higher-familiarity dyads also had reduced rates of several adverse outcomes, although deep sternal wound infection showed no association with dyad familiarity. After adjusting for confounders, the odds of operative mortality were significantly higher for the lowest-familiarity dyads compared to the highest-familiarity dyads (odds ratio [OR], 1.90, 95% confidence interval [CI], 1.29-2.81, P = .001). CONCLUSIONS: Increased surgeon-anesthesiologist familiarity was associated with lower operative mortality and improved outcomes in cardiac surgery, highlighting the importance of consistent team collaboration. Multi-center studies are warranted to validate these findings and explore familiarity's effects across diverse clinical settings. CI - Copyright (c) 2025 International Anesthesia Research Society. FAU - Lakha, Sameer AU - Lakha S AD - From the Departments of Anesthesiology, Perioperative and Pain Medicine. FAU - Huang, Sharon G AU - Huang SG AD - Medical Education. FAU - Wang, Cindy AU - Wang C AD - Medical Education. FAU - Rome, Eric AU - Rome E AD - From the Departments of Anesthesiology, Perioperative and Pain Medicine. FAU - Egorova, Natalia AU - Egorova N AD - Population Health Science and Policy. FAU - Ouyang, Yuxia AU - Ouyang Y AD - From the Departments of Anesthesiology, Perioperative and Pain Medicine. FAU - Levin, Matthew A AU - Levin MA AD - From the Departments of Anesthesiology, Perioperative and Pain Medicine. AD - Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York. FAU - DeMaria, Samuel Jr AU - DeMaria S Jr AD - From the Departments of Anesthesiology, Perioperative and Pain Medicine. LA - eng PT - Journal Article DEP - 20251001 PL - United States TA - Anesth Analg JT - Anesthesia and analgesia JID - 1310650 SB - IM MH - Humans MH - Retrospective Studies MH - Female MH - Male MH - *Cardiac Surgical Procedures/mortality/adverse effects MH - *Surgeons/psychology MH - Aged MH - Middle Aged MH - *Academic Medical Centers MH - *Anesthesiologists/psychology MH - *Patient Care Team MH - Clinical Competence MH - Treatment Outcome MH - *Recognition, Psychology MH - Postoperative Complications/mortality MH - Hospital Mortality MH - Risk Factors COIS- Conflicts of Interest, Funding : Please see DISCLOSURES at the end of this article. EDAT- 2025/10/01 18:28 MHDA- 2026/02/14 05:30 CRDT- 2025/10/01 13:03 PHST- 2026/02/14 05:30 [medline] PHST- 2025/10/01 18:28 [pubmed] PHST- 2025/10/01 13:03 [entrez] AID - 00000539-990000000-01495 [pii] AID - 10.1213/ANE.0000000000007759 [doi] PST - ppublish SO - Anesth Analg. 2026 Mar 1;142(3):561-569. doi: 10.1213/ANE.0000000000007759. Epub 2025 Oct 1. PMID- 41030729 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251001 LR - 20251003 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 17 IP - 8 DP - 2025 Aug TI - Infective Endocarditis in Patients With a History of Intravenous Drug Abuse. PG - e91270 LID - 10.7759/cureus.91270 [doi] LID - e91270 AB - Infective endocarditis (IE) in people who inject drugs (PWID) has emerged as a growing public health concern. It entails two main issues future medicine will have to face: an increase in patients with substance abuse and the evolution of new microbial threats. The analysis of characteristics of the disease in this group of patients enables us to draw differentiating points. IE in PWID predominantly involves the right side of the heart, mainly the tricuspid valve. The prevalence of the disease is high in developed countries, in regions with a strong impact of drug abuse, particularly in the younger part of populations facing socioeconomic difficulties linked to changing life conditions in postindustrial economic systems. Staphylococcus aureus is by far the most frequent pathogen responsible for the infection in these patients, proportionally outnumbering the prevalence of this species in non-drug users. Also, higher rates of Gram-negative and fungal infections are posing a serious challenge in the treatment process. The Duke Criteria remain the common diagnostic methodology in all cases of IE, with echocardiography - both transthoracic echocardiography (TTE) and transoesophageal echocardiography (TEE) - being staples for imaging. The identification of the pathogen includes both standard microbiologic blood culture tests and the use of advanced biomolecular methods. Management in an optimal therapeutic process requires targeted antimicrobial therapy, which in many cases has to be supported by invasive surgical or percutaneous interventions. The widening spectrum of surgical procedures, such as percutaneous vegetation debulking, transcatheter valve-in-valve implantation, or minimally invasive cardiac surgery, represents a positive change for patients in poor clinical condition who are not suitable for standard cardiothoracic procedures.. While short-term survival seems promising at first, the long-term results are still dissatisfying. The main area for improvement is the need for a multidisciplinary approach that integrates infection management and prevention with addiction treatment. An innovative approach combining these factors could lead to a better prognosis in PWID with IE in the future. CI - Copyright (c) 2025, Bursy et al. FAU - Bursy, Marcin AU - Bursy M AD - General Practice, University Hospital in Poznan, Poznan, POL. FAU - Dudek, Adam AU - Dudek A AD - General Practice, University Hospital in Poznan, Poznan, POL. FAU - Szkudlarek, Wojciech AU - Szkudlarek W AD - Hospital-Based Medicine, Medical Center HCP, Poznan, POL. FAU - Linkiewicz, Jan AU - Linkiewicz J AD - Medical School, Poznan University of Medical Sciences, Poznan, POL. FAU - Lizurej, Wojciech AU - Lizurej W AD - Hospital-Based Medicine, University Hospital in Poznan, Poznan, POL. FAU - Buda, Aleksandra AU - Buda A AD - Hospital-Based Medicine, Poznan University of Medical Sciences, Poznan, POL. FAU - Kubik, Marta AU - Kubik M AD - Research, Poznan University of Medical Sciences, Poznan, POL. FAU - Bogdanski, Aleksander AU - Bogdanski A AD - Hospital-Based Medicine, Charite Universitatsmedizin Berlin, Berlin, DEU. FAU - Bogdanska, Kalina AU - Bogdanska K AD - Medical Education, Wroclaw Medical University, Wroclaw, POL. FAU - Mazur, Maksym AU - Mazur M AD - Medical Education, Wroclaw Medical University, Wroclaw, POL. LA - eng PT - Journal Article PT - Review DEP - 20250830 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC12477519 OTO - NOTNLM OT - angiovac and infective enocarditis OT - echocardiography findings OT - right sided infective endocarditis OT - valvular endocarditis OT - drug abuse COIS- Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. EDAT- 2025/10/01 12:01 MHDA- 2025/10/01 12:02 PMCR- 2025/08/30 CRDT- 2025/10/01 04:59 PHST- 2025/08/29 00:00 [accepted] PHST- 2025/10/01 12:02 [medline] PHST- 2025/10/01 12:01 [pubmed] PHST- 2025/10/01 04:59 [entrez] PHST- 2025/08/30 00:00 [pmc-release] AID - 10.7759/cureus.91270 [doi] PST - epublish SO - Cureus. 2025 Aug 30;17(8):e91270. doi: 10.7759/cureus.91270. eCollection 2025 Aug. PMID- 41024656 OWN - NLM STAT- Publisher LR - 20251101 IS - 1969-6213 (Electronic) IS - 1774-024X (Print) IS - 1774-024X (Linking) VI - 21 IP - 21 DP - 2025 Sep 30 TI - Mechanical circulatory support in high-risk elective PCI: rationale and design of the PROTECT IV trial. PG - e1244-58 LID - EIJ-D-25-00486 [pii] LID - 10.4244/EIJ-D-25-00486 [doi] AB - Coronary artery disease (CAD) is the leading cause of heart failure with reduced ejection fraction (HFrEF). Coronary artery bypass grafting (CABG) improves long-term mortality in HFrEF. Percutaneous coronary intervention (PCI) is often performed as an alternative to CABG in patients at high surgical risk. However, in patients with HFrEF and limited myocardial reserve, PCI may result in haemodynamic instability, increasing risk and precluding optimal revascularisation. Mechanical circulatory support (MCS) during high-risk PCI may enhance haemodynamic stability during the procedure and enable complete revascularisation. We thus performed the PROTECT IV trial to determine whether PCI with routine use of the Impella CP microaxial flow pump improves early and late outcomes in patients with HFrEF and complex CAD compared with PCI with or without use of an intra-aortic balloon pump (IABP). PROTECT IV is a prospective, multicentre, randomised, parallel-controlled, open-label, superiority trial with an adaptive design. Patients with complex CAD and left ventricular ejection fraction /= 75 years with AF or atrial flutter, followed in the geriatric departments (via outpatient consultation or hospitalization; > 98% were hospitalized). Participants were followed for 6 months or until death. The primary exposure was a hospital multidisciplinary team meeting within 45 days of inclusion, involving geriatricians, cardiologists, neurovascular specialists, and hemostasis experts. Cumulative incidences were estimated using the reverse Kaplan-Meier method. RESULTS: The study included 818 patients, 138 (16.9%) in the hospital multidisciplinary-team meeting arm (median age 89 (Q1Q3 84-93), 57% female). The 6-month cumulative incidence of the primary composite outcome was 35.3% (95% CI, 29.6 to 41.8) in the multidisciplinary-team meeting arm and 36.2% (95% CI, 32.2 to 40.1) in the control arm (risk difference - 0.9 (95% CI, - 7.5 to 6.0); p = .79). The 2 arms did not differ in individual events within the composite measure. CONCLUSIONS: A hospital multidisciplinary team meeting dedicated to antithrombotics management in older adults with AF was not associated with a reduction in all-cause death, major thromboembolic events, or major or clinically relevant bleeding within 6 months. These findings should be interpreted with caution due to the observational design and potential for residual confounding. TRIAL REGISTRATION: ClinicalTrials.gov registration: NCT04932603. CI - (c) 2025. The Author(s). FAU - Prunel, Maiwenn AU - Prunel M AD - Institut Pierre Louis d'Epidemiologie Et de Sante Publique (IPLESP), Sorbonne Universite, INSERM, Paris, 75013, France. FAU - Cochard, Alexis AU - Cochard A AD - Institut Pierre Louis d'Epidemiologie Et de Sante Publique (IPLESP), Sorbonne Universite, INSERM, Paris, 75013, France. AD - Biostatistics and Epidemiology Office, Gustave Roussy, INSERM, University Paris-Saclay, Labeled Ligue Contre Le Cancer, Oncostat U1018, Villejuif, France. FAU - Abbas, Leila AU - Abbas L AD - Institut Pierre Louis d'Epidemiologie Et de Sante Publique (IPLESP), Sorbonne Universite, INSERM, Paris, 75013, France. FAU - Baudry, Elodie AU - Baudry E AD - Department of Geriatrics, Assistance Publique - Hopitaux de Paris, Bicetre Hospital, Paris-Saclay University, Le Kremlin-Bicetre, France. FAU - Pautas, Eric AU - Pautas E AD - Sorbonne Universite, Paris, France. AD - Department of Geriatrics, Assistance Publique - Hopitaux de Paris, Sorbonne Universite, Charles Foix Hospital, Ivry-Sur-Seine, France. AD - Therapeutic Innovations in Hemostasis, Paris-Cite University, Inserm UMR-S 1140, Paris, France. FAU - Legris, Nicolas AU - Legris N AD - Stroke Unit and Department of Neurology, Assistance Publique - Hopitaux de Paris, Bicetre Hospital, Paris-Saclay University, Le Kremlin-Bicetre, France. FAU - Assayag, Patrick AU - Assayag P AD - Department of Cardiology, Assistance Publique - Hopitaux de Paris, Bicetre Hospital, Paris-Saclay University, Le Kremlin-Bicetre, France. AD - Universite Paris-Saclay, Le Kremlin-Bicetre, France. FAU - Frere, Corinne AU - Frere C AD - UMRS-1166, Institute of Cardiometabolism and Nutrition, Sorbonne Universite, INSERM, GRC 27 GRECO, Paris, France. AD - Department of Hematology, Assistance Publique - Hopitaux de Paris, Sorbonne Universite, Pitie-Salpetriere Hospital, Paris, France. FAU - Verny, Marc AU - Verny M AD - Department of Geriatrics, Assistance Publique - Hopitaux de Paris, Sorbonne Universite, Pitie-Salpetriere Hospital, Paris, France. AD - UMR8256 (CNRS), Team Neuronal Cell Biology & Pathology, Sorbonne Universite, Paris, France. FAU - Simon-Tillaux, Noemie AU - Simon-Tillaux N AD - Biostatistics and Epidemiology Office, Gustave Roussy, INSERM, University Paris-Saclay, Labeled Ligue Contre Le Cancer, Oncostat U1018, Villejuif, France. FAU - Zerah, Lorene AU - Zerah L AD - Institut Pierre Louis d'Epidemiologie Et de Sante Publique (IPLESP), Sorbonne Universite, INSERM, Paris, 75013, France. lorene.zerah@aphp.fr. AD - Department of Geriatrics, Assistance Publique - Hopitaux de Paris, Sorbonne Universite, Pitie-Salpetriere Hospital, Paris, France. lorene.zerah@aphp.fr. LA - eng SI - ClinicalTrials.gov/NCT04932603 PT - Journal Article PT - Multicenter Study PT - Observational Study DEP - 20250929 PL - England TA - BMC Med JT - BMC medicine JID - 101190723 RN - 0 (Anticoagulants) RN - 0 (Fibrinolytic Agents) SB - IM MH - Aged MH - Aged, 80 and over MH - Female MH - Humans MH - Male MH - Anticoagulants/therapeutic use MH - *Atrial Fibrillation/drug therapy/complications/mortality MH - *Fibrinolytic Agents/therapeutic use/adverse effects MH - Hemorrhage/chemically induced MH - *Patient Care Team MH - Prospective Studies MH - Treatment Outcome PMC - PMC12482002 OTO - NOTNLM OT - Antithrombotics OT - Atrial fibrillation OT - Multidisciplinary team OT - Patient-centered approach COIS- Declarations. Ethics approval and consent to participate: This study was approved by the Institutional Ethics Committee on May 25, 2021 (no. CER-2021-026). All enrolled patients or their legal representative gave their non-opposition for the use of their medical data. Consent for publication: Not applicable. Competing interests: o EP received honoraria for participation in expert meetings on low-molecular-weight Heparin (Leo Pharma), vitamin K antagonist (Merck) and direct oral anticoagulant (Boehringer Ingelheim, Bayer Healthcare AG, and Bristol Myers Squibb-Pfizer) o MV received honoraria for a lecture at a scientific meeting in 2021 (Bayer) o NST received support for attending meeting in 2025 (Sanofi) o LZ received honoraria for a lecture at a scientific meeting in 2023 and for participation in 2 expert meetings in 2024 (Bristol Myers Squibb) o The remaining authors declare no competing interests. EDAT- 2025/09/30 06:38 MHDA- 2025/09/30 06:39 PMCR- 2025/09/29 CRDT- 2025/09/30 00:39 PHST- 2025/03/26 00:00 [received] PHST- 2025/07/22 00:00 [accepted] PHST- 2025/09/30 06:39 [medline] PHST- 2025/09/30 06:38 [pubmed] PHST- 2025/09/30 00:39 [entrez] PHST- 2025/09/29 00:00 [pmc-release] AID - 10.1186/s12916-025-04291-9 [pii] AID - 4291 [pii] AID - 10.1186/s12916-025-04291-9 [doi] PST - epublish SO - BMC Med. 2025 Sep 29;23(1):521. doi: 10.1186/s12916-025-04291-9. PMID- 41022171 OWN - NLM STAT- In-Process LR - 20260323 IS - 1532-6551 (Electronic) IS - 1071-3581 (Linking) VI - 57 DP - 2026 Mar TI - How to manage patients receiving long-term suppressive antibiotic treatment for infective endocarditis: The role of [18F]-FDGCT/CT imaging-An international multidisciplinary survey. PG - 102505 LID - S1071-3581(25)00379-4 [pii] LID - 10.1016/j.nuclcard.2025.102505 [doi] FAU - Pascale, Renato AU - Pascale R AD - Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy; Department of Medical and Surgical Sciences, University of Bologna, Italy. Electronic address: renato.pascale2@unibo.it. FAU - Fernandez-Hidalgo, Nuria AU - Fernandez-Hidalgo N AD - Servei de Malalties Infeccioses, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Campus Hospitalari. Passeig de la Vall d'Hebron 119-129, 08035, Barcelona, Spain; Departament de Medicina. Universitat Autonoma de Barcelona, Barcelona, Spain; CIBERINFEC, ISCIII-CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain. FAU - Tazza, Beatrice AU - Tazza B AD - Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy. FAU - Bartoletti, Michele AU - Bartoletti M AD - Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20090 Milan, Italy; Infectious Diseases Unit, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy. FAU - Bertolino, Lorenzo AU - Bertolino L AD - Department of Precision Medicine, University of Campania 'L. Vanvitelli', and Unit of Internal Medicine and Transplants, AORN Ospedali dei Colli-Monaldi Hospital, Naples, Italy. FAU - Durante-Mangoni, Emanuele AU - Durante-Mangoni E AD - Department of Precision Medicine, University of Campania 'L. Vanvitelli', and Unit of Internal Medicine and Transplants, AORN Ospedali dei Colli-Monaldi Hospital, Naples, Italy. FAU - Roque Perez, Albert AU - Roque Perez A AD - Departament de Medicina. Universitat Autonoma de Barcelona, Barcelona, Spain; Departments of Radiology and Nuclear Medicine, Hospital Universitary Val d'Hebron. Barcelona, Spain; Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. FAU - Pizzi, Maria Nazarena AU - Pizzi MN AD - Departament de Medicina. Universitat Autonoma de Barcelona, Barcelona, Spain; Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain; Department of Cardiology and Nuclear Medicine, Hospital Universitari Vall d'Hebron, Barcelona, Spain; Centro de Investigacion Biomedica en Red en Enfermedades Cardiovasculares (CIBER-CV), Madrid, Spain. FAU - Viale, Pierluigi AU - Viale P AD - Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy; Department of Medical and Surgical Sciences, University of Bologna, Italy. FAU - Giannella, Maddalena AU - Giannella M AD - Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy; Department of Medical and Surgical Sciences, University of Bologna, Italy. CN - European Society of Clinical Microbiology and Infectious Diseases Study Group on Implant Associated Infections (ESGIAI) CN - European Society of Clinical Microbiology and Infectious Diseases Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES) LA - eng PT - Journal Article DEP - 20250927 PL - United States TA - J Nucl Cardiol JT - Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology JID - 9423534 SB - IM OTO - NOTNLM OT - Antibiotic treatment duration OT - Imaging monitoring OT - Infective endocarditis OT - PET-FDG OT - Suppressive antibiotic treatment EDAT- 2025/09/30 05:17 MHDA- 2025/09/30 05:17 CRDT- 2025/09/29 19:26 PHST- 2025/06/28 00:00 [received] PHST- 2025/09/02 00:00 [revised] PHST- 2025/09/20 00:00 [accepted] PHST- 2025/09/30 05:17 [pubmed] PHST- 2025/09/30 05:17 [medline] PHST- 2025/09/29 19:26 [entrez] AID - S1071-3581(25)00379-4 [pii] AID - 10.1016/j.nuclcard.2025.102505 [doi] PST - ppublish SO - J Nucl Cardiol. 2026 Mar;57:102505. doi: 10.1016/j.nuclcard.2025.102505. Epub 2025 Sep 27. PMID- 41019439 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250929 LR - 20251001 IS - 2297-055X (Print) IS - 2297-055X (Electronic) IS - 2297-055X (Linking) VI - 12 DP - 2025 TI - Sudden cardiac death in the young: single-center study of Bari autopsy cases. PG - 1630511 LID - 10.3389/fcvm.2025.1630511 [doi] LID - 1630511 AB - INTRODUCTION: Sudden Cardiac Death (SCD) is one of the main causes of death in the world, with a significant impact especially on young people. Sudden Cardiac Death in the Young (SCDY) is characterized by multifactorial etiology, which includes cardiomyopathies, myocarditis, channelopathies, aortopathies and coronary artery diseases. Despite progress in prevention, a significant percentage of these deaths remain unexplained without a thorough autopsy. This study aims to SCDY cases registered between 2016 and 2024, exploring the association between type of autopsy, age, sex, causes of death and temporal changes. METHODS: Data relating to subjects who died for suspected SCDY, who underwent forensic, or hospital autopsy were retrospectively analysed. Investigations included type of autopsy (diagnostic or judicial), age (in years), sex, available clinical data, gross and histological findings, and cause of death. The data were divided by age groups (0-10, 11-20, 21-30, 31-40 years), sex and cause of death (arrhythmias, congenital heart defects, myocarditis, vascular dissections and cardiomyopathies). The temporal distribution of cases was also evaluated. RESULTS: A total of 62 cases were analysed, with a prevalence of male subjects (70%). Forensic autopsies (65%) were more frequent than diagnostic findings (35%). The most represented age groups were 11-20 years (30%) and 21-30 years (25%). Unknown arrhythmias were the main cause (40%), followed by congenital heart disease (20%) and cardiomyopathy (15%). Congenital heart defects prevailed in newborns and children, while hypertrophic or arrhythmogenic cardiomyopathies were more frequently observed in young adults. Temporally, there has been a progressive increase in molecular autopsies and genetic diagnoses, in particular after the introduction of the AECVP (2017) and SCVP (2023) guidelines. DISCUSSION: The findings highlight the need for a multidisciplinary approach to diagnosis of SCDY, with particular emphasis on molecular autopsy to identify genetic causes. The male predominance and age-related etiological differences underline the importance of specific preventive strategies, such as genetic screening in newborns and victims' relatives. The increase in diagnoses over time reflects the effectiveness of updated guidelines, but it remains crucial to expand the mandatory nature of autopsies to improve understanding of the causes of SCDY and reduce the incidence of these tragic events. CI - (c) 2025 Salzillo, Ciccone, Introna, Santobuono, Solarino and Marzullo. FAU - Salzillo, Cecilia AU - Salzillo C AD - Pathology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro", Bari, Italy. AD - PhD Course in Public Health, Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy. FAU - Ciccone, Marco Matteo AU - Ciccone MM AD - Cardiology Unit, Interdisciplinary Department of Medicine, University of Bari "Aldo Moro", Bari, Italy. FAU - Introna, Francesco AU - Introna F AD - Legal Medicine Unit, Interdisciplinary Department of Medicine, University of Bari "Aldo Moro", Bari, Italy. FAU - Santobuono, Vincenzo Ezio AU - Santobuono VE AD - Cardiology Unit, Interdisciplinary Department of Medicine, University of Bari "Aldo Moro", Bari, Italy. FAU - Solarino, Biagio AU - Solarino B AD - Legal Medicine Unit, Interdisciplinary Department of Medicine, University of Bari "Aldo Moro", Bari, Italy. FAU - Marzullo, Andrea AU - Marzullo A AD - Pathology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro", Bari, Italy. LA - eng PT - Journal Article DEP - 20250911 PL - Switzerland TA - Front Cardiovasc Med JT - Frontiers in cardiovascular medicine JID - 101653388 PMC - PMC12460248 OTO - NOTNLM OT - autopsy guidelines OT - epidemiology OT - genetic screening OT - molecular autopsy OT - prevention OT - sudden cardiac death OT - young COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision. EDAT- 2025/09/29 13:20 MHDA- 2025/09/29 13:21 PMCR- 2025/09/11 CRDT- 2025/09/29 06:55 PHST- 2025/05/17 00:00 [received] PHST- 2025/08/22 00:00 [accepted] PHST- 2025/09/29 13:21 [medline] PHST- 2025/09/29 13:20 [pubmed] PHST- 2025/09/29 06:55 [entrez] PHST- 2025/09/11 00:00 [pmc-release] AID - 10.3389/fcvm.2025.1630511 [doi] PST - epublish SO - Front Cardiovasc Med. 2025 Sep 11;12:1630511. doi: 10.3389/fcvm.2025.1630511. eCollection 2025. PMID- 41018547 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250929 LR - 20260916 IS - 2474-8714 (Electronic) IS - 2474-8706 (Print) IS - 2474-8706 (Linking) VI - 9 IP - 10 DP - 2025 Oct TI - Managing Bradycardia in Patients After Transcatheter Tricuspid Valve Replacement. PG - 100710 LID - 10.1016/j.shj.2025.100710 [doi] LID - 100710 AB - The recent development and approval of a transcatheter tricuspid valve represent a significant breakthrough in the management of patients with tricuspid regurgitation who are not suitable for existing invasive or interventional therapies. Despite promising outcomes, pacemaker dependency is a common consequence of transcatheter tricuspid valve replacement (TTVR). In the pivotal TRISCEND II randomized trial, conduction disorders requiring pacemaker implantation were the most frequent major adverse event at 30 days. Managing bradycardia following valve implantation in the tricuspid position requires specialized knowledge and tailored approaches for both temporary and permanent pacing. This necessity is driven by the specific design features of the valves and the evolving choices of valve-sparing pacing strategies. Our aim is to summarize these unique challenges to support both heart team members and nonelectrophysiology health care professionals performing TTVR, as well as intensive care unit and bradycardia specialists who may be unfamiliar with the distinctive characteristics of TTVR. Bradycardia due to atrioventricular (AV) conduction delay, requiring new pacemaker implantation, affects approximately 1 in 4 patients receiving the bioprosthetic EVOQUE valve and is also common with other TTVR devices. This review summarizes current knowledge on TTVR-associated bradycardia and a management algorithm for both acute and long-term settings, highlighting specialized considerations for patients undergoing TTVR. CI - (c) 2025 The Authors. FAU - Hain, Andreas AU - Hain A AD - Department of Cardiology, Kerckhoff-Clinic, Campus of the Justus-Liebig University of Giessen, Bad Nauheim, Germany. FAU - Schmermund, Ben N AU - Schmermund BN AD - Department of Cardiology, Kerckhoff-Clinic, Campus of the Justus-Liebig University of Giessen, Bad Nauheim, Germany. FAU - Kriechbaum, Steffen D AU - Kriechbaum SD AD - Department of Cardiology, Kerckhoff-Clinic, Campus of the Justus-Liebig University of Giessen, Bad Nauheim, Germany. FAU - Unbehaun, Claudia AU - Unbehaun C AD - Department of Cardiology, Kerckhoff-Clinic, Campus of the Justus-Liebig University of Giessen, Bad Nauheim, Germany. FAU - Lampert, Theresa AU - Lampert T AD - Department of Cardiology, Kerckhoff-Clinic, Campus of the Justus-Liebig University of Giessen, Bad Nauheim, Germany. FAU - Sossalla, Samuel T AU - Sossalla ST AD - Department of Cardiology, Kerckhoff-Clinic, Campus of the Justus-Liebig University of Giessen, Bad Nauheim, Germany. AD - Department of Cardiology, Justus-Liebig University of Giessen, Giessen, Germany. FAU - Seidler, Tim AU - Seidler T AD - Department of Cardiology, Kerckhoff-Clinic, Campus of the Justus-Liebig University of Giessen, Bad Nauheim, Germany. LA - eng PT - Journal Article PT - Review DEP - 20250805 PL - United States TA - Struct Heart JT - Structural heart : the journal of the Heart Team JID - 101743256 PMC - PMC12476106 OTO - NOTNLM OT - AV-block OT - Bradycardia treatment algorithm OT - EVOQUE OT - Leadless pacemaker OT - Pacemaker OT - Transcatheter tricuspid valve replacement OT - Tricuspid regurgitation COIS- The authors report no conflict of interest. EDAT- 2025/09/29 13:19 MHDA- 2025/09/29 13:20 PMCR- 2025/08/05 CRDT- 2025/09/29 06:44 PHST- 2025/04/13 00:00 [received] PHST- 2025/07/22 00:00 [revised] PHST- 2025/07/23 00:00 [accepted] PHST- 2025/09/29 13:20 [medline] PHST- 2025/09/29 13:19 [pubmed] PHST- 2025/09/29 06:44 [entrez] PHST- 2025/08/05 00:00 [pmc-release] AID - S2474-8706(25)00302-1 [pii] AID - 100710 [pii] AID - 10.1016/j.shj.2025.100710 [doi] PST - epublish SO - Struct Heart. 2025 Aug 5;9(10):100710. doi: 10.1016/j.shj.2025.100710. eCollection 2025 Oct. PMID- 41016532 OWN - NLM STAT- MEDLINE DCOM- 20251228 LR - 20251228 IS - 1879-1913 (Electronic) IS - 0002-9149 (Linking) VI - 259 DP - 2026 Jan 15 TI - What is the Diagnostic Utility of Cardiac Magnetic Resonance Imaging in Unselected Patients With Premature Ventricular Contractions and Nonsustained Ventricular Tachycardia? PG - 110-115 LID - S0002-9149(25)00596-X [pii] LID - 10.1016/j.amjcard.2025.09.040 [doi] AB - Premature ventricular contractions (PVCs) and nonsustained ventricular tachycardia (NSVT) are common arrhythmias that may signal underlying structural heart disease (SHD). Cardiac magnetic resonance imaging (CMR) has emerged as a valuable tool for detecting myocardial abnormalities in this population. This study aimed to evaluate the diagnostic utility of CMR in patients with PVCs/NSVT and identify clinical predictors of pathologic late gadolinium enhancement (LGE). We retrospectively reviewed patients who underwent CMR for PVCs or NSVT between 2012 and 2023 at a single health system. The primary outcome was the presence of pathologic LGE. Clinical data were extracted using ICD-10 codes, and cardiac sarcoidosis (CS) was adjudicated by a multidisciplinary team using WASOG criteria. Among 553 patients (mean age 61.1 +/- 14.6 years; 40.7% female), pathologic LGE was identified in 214 (38.6%). Patients with LGE were older and had a greater burden of comorbidities. On multivariable analysis, independent risk factors for LGE included age (aOR 1.04, p = 0.001), male sex (aOR 2.37, p < 0.001), heart failure (aOR 2.53, p < 0.001), and polymorphic PVCs (aOR 1.94, p = 0.015). Among patients with LGE, 12.6% had highly probable CS. Other diagnoses included nonischemic cardiomyopathy (53.7%), ischemic cardiomyopathy (11.7%), and idiopathic (34.6%). CMR frequently detects clinically significant myocardial abnormalities in patients with PVCs or NSVT, particularly in those with high-risk features. In this real-world study, nearly 40% of patients had LGE on CMR. An etiology was identified in one-third of these cases. These findings can inform patient selection for CMR in clinical practice to guide diagnosis, risk stratification, and management. CI - Copyright (c) 2025 Elsevier Inc. All rights reserved. FAU - Obeidat, Liyan AU - Obeidat L AD - Henry Ford Hospital, Cardiovascular Medicine department, Detroit, Michigan. Electronic address: Lobeida1@hfhs.org. FAU - Fadel, Raef AU - Fadel R AD - Henry Ford Hospital, Cardiovascular Medicine department, Detroit, Michigan. FAU - Gupta, Kartik AU - Gupta K AD - Henry Ford Hospital, Cardiovascular Medicine department, Detroit, Michigan. FAU - Naimi, Alyssa AU - Naimi A AD - Henry Ford Hospital, Internal Medicine department, Detroit, Michigan. FAU - Ronchetto, Elizabeth AU - Ronchetto E AD - Henry Ford Hospital, Internal Medicine department, Detroit, Michigan. FAU - Ama, Sara AU - Ama S AD - Henry Ford Hospital, Internal Medicine department, Detroit, Michigan. FAU - Helaly, Mayar AU - Helaly M AD - Henry Ford Hospital, Internal Medicine department, Detroit, Michigan. FAU - Malick, Allison AU - Malick A AD - Henry Ford Hospital, Internal Medicine department, Detroit, Michigan. FAU - Jamil, Dawood AU - Jamil D AD - Henry Ford Hospital, Internal Medicine department, Detroit, Michigan. FAU - Ananthasubramaniam, Karthikeyan AU - Ananthasubramaniam K AD - Henry Ford Hospital, Cardiovascular Medicine department, Detroit, Michigan. FAU - Azzo, Zain AU - Azzo Z AD - Henry Ford Hospital, Cardiovascular Medicine department, Detroit, Michigan. LA - eng PT - Journal Article DEP - 20250926 PL - United States TA - Am J Cardiol JT - The American journal of cardiology JID - 0207277 SB - IM MH - Humans MH - Male MH - Female MH - Middle Aged MH - *Tachycardia, Ventricular/diagnostic imaging/diagnosis MH - *Ventricular Premature Complexes/diagnostic imaging/diagnosis MH - Retrospective Studies MH - *Magnetic Resonance Imaging, Cine/methods MH - Aged MH - *Cardiomyopathies/complications/diagnostic imaging MH - Sarcoidosis/complications/diagnostic imaging MH - Risk Factors OTO - NOTNLM OT - cardiac magnetic resonance OT - cardiac sarcoidosis OT - late gadolinium enhancement OT - premature ventricular contractions COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have influenced the work reported in this paper. EDAT- 2025/09/29 00:31 MHDA- 2025/12/29 00:24 CRDT- 2025/09/28 19:37 PHST- 2025/08/16 00:00 [received] PHST- 2025/09/19 00:00 [revised] PHST- 2025/09/22 00:00 [accepted] PHST- 2025/12/29 00:24 [medline] PHST- 2025/09/29 00:31 [pubmed] PHST- 2025/09/28 19:37 [entrez] AID - S0002-9149(25)00596-X [pii] AID - 10.1016/j.amjcard.2025.09.040 [doi] PST - ppublish SO - Am J Cardiol. 2026 Jan 15;259:110-115. doi: 10.1016/j.amjcard.2025.09.040. Epub 2025 Sep 26. PMID- 41015724 OWN - NLM STAT- MEDLINE DCOM- 20251207 LR - 20251207 IS - 1444-2892 (Electronic) IS - 1443-9506 (Linking) VI - 34 IP - 11 DP - 2025 Nov TI - Diabetes is an Increasingly Common Issue After Heart Transplantation: A Case for Integrated Diabetes Care. PG - 1290-1294 LID - S1443-9506(25)00321-X [pii] LID - 10.1016/j.hlc.2025.04.081 [doi] AB - BACKGROUND: Orthotopic heart transplantation (OHT) survival rates have improved with advances in immunosuppression over the last 20 years. With these improvements, there has been a greater focus on post-transplant care. Diabetes is common after transplantation and may be pre-existing (type 2 diabetes mellitus [T2DM]) or develop after transplant (post-transplant diabetes mellitus [PTDM]). The aim of this study was to compare the incidence and prevalence of diabetes in OHT recipients in two cohorts separated by 20 years. METHODS: Retrospective audit comparing the prevalence of T2DM and cumulative 2-year incidence of PTDM in 88 consecutive OHT recipients in 1996-1998 and 141 consecutive OHT recipients in 2015-2018 at the same tertiary referral teaching hospital. RESULTS: The prevalence of pre-transplant T2DM at the time of OHT increased three-fold between 1998 and 2018, from 6% (n=5) to 18% (n=25) respectively (p=0.009). Similarly, the incidence of PTDM increased from 16% (n=13) in 1998 to 36% (n=42) in 2018 (p=0.001). OHT recipients who developed PTDM were older in 2018 vs 1998 (mean age 52 [+/-11] vs 44 [+/-9] years; p=0.03). The mean age was not different between individuals with T2DM between the 1998 and 2018 eras. Body mass index was not different between the 1998 and 2018 eras in any of the diabetes status subgroups. CONCLUSIONS: The incidence and prevalence of diabetes after OHT at our Australian institution has increased over 20 years. With improved OHT survival and rates of diabetes, endocrinologists should be incorporated into the care teams of heart transplant recipients. Further studies of glucose-lowering therapies in patients with diabetes after transplantation are warranted. CI - Copyright (c) 2025 The Author(s). Published by Elsevier B.V. All rights reserved. FAU - Raven, Lisa M AU - Raven LM AD - Department of Diabetes and Endocrinology, St Vincent's Hospital, Sydney, NSW, Australia; Clinical Diabetes, Appetite and Metabolism Laboratory, Garvan Institute of Medical Research, Sydney, NSW, Australia; School of Clinical Medicine, St Vincent's Campus, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW, Australia. Electronic address: lisa.raven@svha.org.au. FAU - Jabbour, Andrew AU - Jabbour A AD - School of Clinical Medicine, St Vincent's Campus, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW, Australia; Victor Chang Cardiac Research Institute, Sydney, NSW, Australia; Department of Heart and Lung Transplantation, St Vincent's Hospital, Sydney, NSW, Australia. FAU - Macdonald, Peter S AU - Macdonald PS AD - School of Clinical Medicine, St Vincent's Campus, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW, Australia; Victor Chang Cardiac Research Institute, Sydney, NSW, Australia; Department of Heart and Lung Transplantation, St Vincent's Hospital, Sydney, NSW, Australia. FAU - Greenfield, Jerry R AU - Greenfield JR AD - Department of Diabetes and Endocrinology, St Vincent's Hospital, Sydney, NSW, Australia; Clinical Diabetes, Appetite and Metabolism Laboratory, Garvan Institute of Medical Research, Sydney, NSW, Australia; School of Clinical Medicine, St Vincent's Campus, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW, Australia. FAU - Muir, Christopher A AU - Muir CA AD - Department of Diabetes and Endocrinology, St Vincent's Hospital, Sydney, NSW, Australia; School of Clinical Medicine, St Vincent's Campus, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW, Australia. LA - eng PT - Comparative Study PT - Journal Article DEP - 20250926 PL - Australia TA - Heart Lung Circ JT - Heart, lung & circulation JID - 100963739 RN - 0 (Blood Glucose) SB - IM MH - *Heart Transplantation/adverse effects/methods/statistics & numerical data MH - Incidence MH - Prevalence MH - Australia MH - *Diabetes Mellitus, Type 2/diagnosis/epidemiology/etiology/therapy MH - Retrospective Studies MH - Patient Care Team/organization & administration MH - *Postoperative Complications/diagnosis/epidemiology/etiology/therapy MH - Endocrinologists/organization & administration MH - Blood Glucose/analysis MH - Humans MH - Male MH - Female MH - Adult MH - Middle Aged MH - Aged OTO - NOTNLM OT - Diabetes OT - Heart transplant OT - Post-transplant diabetes COIS- Declaration of Competing Interests There are no conflicts of interest to disclose. EDAT- 2025/09/28 01:03 MHDA- 2025/11/13 06:29 CRDT- 2025/09/27 23:17 PHST- 2024/11/18 00:00 [received] PHST- 2025/04/03 00:00 [revised] PHST- 2025/04/12 00:00 [accepted] PHST- 2025/11/13 06:29 [medline] PHST- 2025/09/28 01:03 [pubmed] PHST- 2025/09/27 23:17 [entrez] AID - S1443-9506(25)00321-X [pii] AID - 10.1016/j.hlc.2025.04.081 [doi] PST - ppublish SO - Heart Lung Circ. 2025 Nov;34(11):1290-1294. doi: 10.1016/j.hlc.2025.04.081. Epub 2025 Sep 26. PMID- 41014602 OWN - NLM STAT- MEDLINE DCOM- 20260311 LR - 20260316 IS - 2048-8734 (Electronic) IS - 2048-8726 (Linking) VI - 15 IP - 1 DP - 2026 Mar 10 TI - Haemodynamic monitoring and management of the hypotensive out-of-hospital cardiac arrest patient in the adult intensive care unit: a clinical consensus statement of the Association for Acute CardioVascular Care of the ESC. PG - 63-71 LID - 10.1093/ehjacc/zuaf125 [doi] AB - AIMS: Out-of-hospital cardiac arrest (OHCA) represents a major public health challenge, with high mortality and significant neurological impairments among survivors. Haemodynamic instability, particularly hypotension (a mean arterial blood pressure <65 mmHg), may be a key contributor to post-resuscitation morbidity and mortality. METHODS AND RESULTS: After return of spontaneous circulation, hypotension can result from various causes, including arrhythmias, mechanical complications, thromboembolism, or different types of shock, as well as sedation, temperature control and positive pressure ventilation. Differentiating between hypotension with vs. without hypoperfusion is critical to avoid unnecessary interventions while ensuring adequate cerebral and myocardial perfusion. Clinical assessment and repeated echocardiography should be routine in all patients. Therapeutic targets should include evidence of preserved end-organ function, including urine output, and normal or decreasing lactate. In selected cases, advanced haemodynamic monitoring with pulmonary artery catheters may be necessary to diagnose the shock-type and monitor treatment effects. Causal treatment of the precipitating cause of hypotension is crucial as well as symptomatic treatment with fluids, vasopressors and inotropes if needed. Mechanical circulatory support may be employed for refractory shock unresponsive to other treatment. CONCLUSION: This clinical consensus statement by the Association for Acute CardioVascular Care (ACVC) of the European Society of Cardiology (ESC) provides clinical guidance for the haemodynamic monitoring and management of hypotension in OHCA patients in intensive care. The document advocates for a multidisciplinary approach that integrates clinical assessment, imaging, and haemodynamic parameters to guide treatment, with the overarching goal of improving survival rates and neurological outcomes. CI - (c) The Author(s) 2025. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com. FAU - Grand, Johannes AU - Grand J AUID- ORCID: 0000-0002-5511-4668 AD - Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9b, 2100 Copenhagen, Denmark. AD - Copenhagen University Hospital, Amager-Hvidovre, Kettegards Alle 36, 2650 Hvidovre, Denmark. FAU - Sionis, Alessandro AU - Sionis A AUID- ORCID: 0000-0003-0843-9512 AD - Hospital de la Santa Creu I Sant Pau, Carrer de Sant Quinti 89, 08041 Barcelona, Spain. FAU - Hassager, Christian AU - Hassager C AUID- ORCID: 0000-0002-1199-0981 AD - Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9b, 2100 Copenhagen, Denmark. FAU - Perez, Pablo Jorge AU - Perez PJ AD - University Hospital of the Canaries, Ctra. Ofra s/n, 38320 La Cuesta, Santa Cruz de Tenerife, Spain. FAU - Poess, Janine AU - Poess J AD - Heart Center of Leipzig, Strumpellstrasse 39, 04289 Leipzig, Germany. FAU - Schaubroeck, Hannah AU - Schaubroeck H AUID- ORCID: 0000-0002-5219-4834 AD - University Hospital Ghent, C. Heymanslaan 10, 9000 Gent, Belgium. FAU - Desch, Steffen AU - Desch S AUID- ORCID: 0000-0002-9416-8044 AD - Heart Center Leipzig, Strumpellstrasse 39, 04289 Leipzig, Germany. FAU - Krychtiuk, Konstantin A AU - Krychtiuk KA AUID- ORCID: 0000-0001-7792-2837 AD - Department of Internal Medicine II-Division of Cardiology, Medical University of Vienna, WahringerGurtel 18-20, 1090 Vienna, Austria. FAU - Belohlavek, Jan AU - Belohlavek J AD - Charles University of Prague, Karlovo namesti 40, 120 00 Praha 2, Czechia. FAU - Mebazaa, Alexandre AU - Mebazaa A AUID- ORCID: 0000-0001-8715-7753 AD - Hospital Lariboisiere, 2 RueAmbroise Pare, 75010 Paris, France. FAU - Huber, Kurt AU - Huber K AUID- ORCID: 0000-0002-7934-5524 AD - Sigmund Freud University Vienna, Faculty of Medicine, Freudplatz 1, 1020 Vienna, Austria. FAU - van Diepen, Sean AU - van Diepen S AUID- ORCID: 0000-0002-6688-828X AD - University of Alberta, 116 St & 85 Ave, Edmonton AB T6G 2R3, Canada. FAU - Vandenbriele, Christophe AU - Vandenbriele C AUID- ORCID: 0000-0003-2338-8346 AD - Royal Brompton and Harefield Hospitals, Guy's & St. Thomas' NHS Foundation Trust, Sydney Street, London SW3 6NP, UK. AD - Heart Centre Aalst, OLV Hospitals, Moorselbaan 164, 9300 Aalst, Belgium. AD - Department of Cancer and Surgery, Imperial College, Du Cane Road, London W12 0HS, UK. FAU - Morrow, David AU - Morrow D AUID- ORCID: 0000-0002-9589-5382 AD - Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA. FAU - Tavazzi, Guido AU - Tavazzi G AUID- ORCID: 0000-0002-9560-5138 AD - University of Pavia, Corso Strada Nuova 65, 27100 Pavia, Italy. LA - eng PT - Consensus Statement PT - Journal Article PL - England TA - Eur Heart J Acute Cardiovasc Care JT - European heart journal. Acute cardiovascular care JID - 101591369 SB - IM MH - Adult MH - Humans MH - Cardiopulmonary Resuscitation/methods MH - *Critical Care/methods MH - *Disease Management MH - *Hemodynamic Monitoring/methods MH - Hemodynamics MH - *Hypotension/therapy/etiology/physiopathology/diagnosis MH - *Intensive Care Units MH - *Out-of-Hospital Cardiac Arrest/therapy/complications/physiopathology MH - Societies, Medical OTO - NOTNLM OT - Blood pressure OT - Cardiac Arrest OT - Haemodynamic OT - Hypotension COIS- Conflict of interest: Dr M.W. is a member of the TIMI Study Group which has received institutional research grant support through Brigham and Women's Hospital from: Abbott, Abiomed, Amgen, Anthos Therapeutics, AstraZeneca, Daiichi-Sankyo, Intarcia, Merck, Novartis, Pfizer, Quark Pharmaceuticals, Regeneron, Roche, Siemens Healthcare Diagnostics, Inc., and Zora Biosciences. He has received consulting fees from Abbott Laboratories, 4TEEN4, InCarda, Merck & Co, Novartis, Regeneron, Roche. K.A.K.: related to the contents of this manuscript: Speaker Fees Zoll Medical (past). Unrelated to the contents of this manuscript: Speaker fees: Daiichi Sankyo, Amarin; Consulting Fees: Amarin, Novartis, Sanofi; Travel Support: Amgen, Sanofi, Daiichi Sankyo, Christophe Vandenbriele: speaking, consultancy and research fees from Abiomed. EDAT- 2025/09/27 18:31 MHDA- 2026/03/12 01:10 CRDT- 2025/09/27 14:03 PHST- 2025/02/19 00:00 [received] PHST- 2025/07/12 00:00 [revised] PHST- 2025/09/15 00:00 [accepted] PHST- 2026/03/12 01:10 [medline] PHST- 2025/09/27 18:31 [pubmed] PHST- 2025/09/27 14:03 [entrez] AID - 8266910 [pii] AID - 10.1093/ehjacc/zuaf125 [doi] PST - ppublish SO - Eur Heart J Acute Cardiovasc Care. 2026 Mar 10;15(1):63-71. doi: 10.1093/ehjacc/zuaf125. PMID- 41014021 OWN - NLM STAT- MEDLINE DCOM- 20260930 LR - 20261005 IS - 1464-3677 (Electronic) IS - 1353-4505 (Linking) VI - 37 IP - 4 DP - 2025 Oct 6 TI - Characteristics of paediatric patients requiring rapid response system activations. LID - mzaf103 [pii] LID - 10.1093/intqhc/mzaf103 [doi] AB - BACKGROUND: Although paediatric rapid response system implementation is gradually increasing worldwide, the characteristics of paediatric rapid response systems and factors associated with adverse outcomes remain underexplored. In this study, we aimed to investigate the characteristics of paediatric rapid response systems and factors associated with adverse outcomes by analysing data from a multicentre rapid response system registry in Japan. METHODS: This retrospective observational study included patients aged <18 years who required rapid response system activation across 35 hospitals between November 2017 and June 2022. We analysed demographic data, clinical triggers, interventions, and outcomes, including a primary composite outcome defined as intensive care unit transfer, cardiac arrest, or death following rapid response system activation. Logistic regression was used to explore associations between clinical outcomes and various predictors. RESULTS: Data of 213 paediatric patients (median age, 47 months) were analysed. Most rapid response system activations, primarily initiated by nurses, were for respiratory issues and clinical concerns. Approximately 60% of activations involved interventions. Cardiac arrest, intensive care unit admission, and mortality following rapid response system activation occurred in 4.7%, 24.9%, and 1.9% of cases, respectively, resulting in a composite outcome rate of 28.6%. A decreased SpO2, lower blood pressure, increased body temperature, and altered consciousness at the time of rapid response system activation were significantly associated with adverse outcomes. Furthermore, multiple violations of the criteria for rapid response system activation and multiple interventions were significantly associated with these outcomes. CONCLUSION: This study provides valuable insights into the characteristics of paediatric patients requiring rapid response system activation and factors associated with adverse outcomes, which can optimize paediatric rapid response system protocols, potentially improving paediatric patient safety. CI - (c) The Author(s) 2025. Published by Oxford University Press on behalf of International Society for Quality in Health Care. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com . FAU - Haga, Taiki AU - Haga T AUID- ORCID: 0000-0001-5401-6479 AD - Department of Critical Care Medicine, Osaka City General Hospital, Osaka City, Osaka, Japan. FAU - Sakaguchi, Takaaki AU - Sakaguchi T AD - Department of Critical Care Medicine, Osaka City General Hospital, Osaka City, Osaka, Japan. FAU - Matsuda, Takuya AU - Matsuda T AD - Department of Critical Care Medicine, Osaka City General Hospital, Osaka City, Osaka, Japan. FAU - Yamane, Masahiro AU - Yamane M AD - Nursing Department, Intensive Care Centre, Osaka City General Hospital, Osaka City, Osaka, Japan. FAU - Maruyama, Junji AU - Maruyama J AD - Nursing Department, Intensive Care Centre, Osaka City General Hospital, Osaka City, Osaka, Japan. FAU - Mori, Hitomi AU - Mori H AD - Nursing Department, Intensive Care Centre, Osaka City General Hospital, Osaka City, Osaka, Japan. FAU - Nishimine, Ikue AU - Nishimine I AD - Nursing Department, Emergency and Critical Care Medical Centre, Osaka City General Hospital, Osaka City, Osaka, Japan. FAU - Hidari, Tadako AU - Hidari T AD - Nursing Department, Intensive Care Centre, Osaka City General Hospital, Osaka City, Osaka, Japan. FAU - Morooka, Takaya AU - Morooka T AD - Department of Emergency and Critical Care Medical Centre, Osaka City General Hospital, Osaka City, Osaka, Japan. FAU - Rinka, Hiroshi AU - Rinka H AD - Department of Emergency and Critical Care Medical Centre, Osaka City General Hospital, Osaka City, Osaka, Japan. LA - eng GR - JP24592755, JP18K16548/Japan Society for the Promotion of Science KAKENHI/ GR - Japanese Society of Intensive Care Medicine; and the Japanese Society of Emergency Medicine/ PT - Journal Article PT - Multicenter Study PT - Observational Study PL - England TA - Int J Qual Health Care JT - International journal for quality in health care : journal of the International Society for Quality in Health Care JID - 9434628 SB - IM MH - Humans MH - *Hospital Rapid Response Team/statistics & numerical data/organization & administration MH - Retrospective Studies MH - Female MH - Japan MH - Child MH - Infant MH - Heart Arrest/epidemiology MH - Male MH - Child, Preschool MH - Adolescent MH - Registries OTO - NOTNLM OT - Japan OT - child OT - clinical deterioration OT - hospital rapid response team OT - patient care team EDAT- 2025/09/27 06:33 MHDA- 2026/09/30 17:32 CRDT- 2025/09/27 03:53 PHST- 2025/02/16 00:00 [received] PHST- 2025/04/30 00:00 [revised] PHST- 2025/09/08 00:00 [accepted] PHST- 2026/09/30 17:32 [medline] PHST- 2025/09/27 06:33 [pubmed] PHST- 2025/09/27 03:53 [entrez] AID - 8266704 [pii] AID - 10.1093/intqhc/mzaf103 [doi] PST - ppublish SO - Int J Qual Health Care. 2025 Oct 6;37(4):mzaf103. doi: 10.1093/intqhc/mzaf103. PMID- 41011033 OWN - NLM STAT- MEDLINE DCOM- 20250927 LR - 20251216 IS - 1648-9144 (Electronic) IS - 1010-660X (Print) IS - 1010-660X (Linking) VI - 61 IP - 9 DP - 2025 Sep 10 TI - How Does Turner Syndrome Affect Quality of Life? A Systematic Review. LID - 10.3390/medicina61091643 [doi] LID - 1643 AB - Background and Objectives: Turner Syndrome (ORPHA:881) is a rare genetic disorder characterized by complete or partial loss of one of the X chromosomes (monosomy X). In addition to specific somatic features and hormonal imbalances, affected individuals often face challenges related to quality of life (QoL). The aim of this review is to analyze the available scientific literature on the QoL in patients with Turner Syndrome. Materials and Methods: A systematic literature review was conducted using the databases Scopus, PubMed, and Web of Science, using specific key words. The search was performed from the date of inception of each database through July 2025. Only full-text articles in English assessing the QoL in individuals with Turner Syndrome were included. Results: The search identified 843 records, of which 12 studies met the eligibility criteria and were included in the final analysis. These studies consistently reported significant differences in the QoL between patients with Turner Syndrome and healthy controls. Factors such as hormone replacement therapy, social support, and comorbid conditions were highlighted as key determinants of QoL. Conclusions: Assessing the QoL in patients with Turner Syndrome is essential for understanding their overall adaptation and the need for a multidisciplinary approach to care. The findings highlight the necessity of additional long-term studies to better understand the impact of various therapeutic strategies on the QoL. The systematic review of the literature underscores the importance of a multidisciplinary approach in the care of patients with Turner Syndrome and the need for individualized therapeutic strategies aimed at improving their health-related quality of life. FAU - Stoynova, Hristina AU - Stoynova H AD - Department of Organisation and Economics of Pharmacy, Faculty of Pharmacy, Medical University of Plovdiv, 4002 Plovdiv, Bulgaria. FAU - Staynova, Radiana AU - Staynova R AUID- ORCID: 0000-0002-8466-3236 AD - Department of Organisation and Economics of Pharmacy, Faculty of Pharmacy, Medical University of Plovdiv, 4002 Plovdiv, Bulgaria. FAU - Kafalova, Daniela AU - Kafalova D AUID- ORCID: 0000-0002-4105-9485 AD - Department of Organisation and Economics of Pharmacy, Faculty of Pharmacy, Medical University of Plovdiv, 4002 Plovdiv, Bulgaria. LA - eng PT - Journal Article PT - Systematic Review DEP - 20250910 PL - Switzerland TA - Medicina (Kaunas) JT - Medicina (Kaunas, Lithuania) JID - 9425208 SB - IM MH - Humans MH - *Turner Syndrome/psychology/complications MH - *Quality of Life/psychology MH - Female PMC - PMC12471895 OTO - NOTNLM OT - Turner Syndrome OT - female patients OT - hormone replacement therapy OT - monosomy X OT - psychosocial adaptation OT - quality of life COIS- The authors declare no conflicts of interest. EDAT- 2025/09/27 06:33 MHDA- 2025/09/27 06:34 PMCR- 2025/09/10 CRDT- 2025/09/27 01:21 PHST- 2025/08/19 00:00 [received] PHST- 2025/09/05 00:00 [revised] PHST- 2025/09/08 00:00 [accepted] PHST- 2025/09/27 06:34 [medline] PHST- 2025/09/27 06:33 [pubmed] PHST- 2025/09/27 01:21 [entrez] PHST- 2025/09/10 00:00 [pmc-release] AID - medicina61091643 [pii] AID - medicina-61-01643 [pii] AID - 10.3390/medicina61091643 [doi] PST - epublish SO - Medicina (Kaunas). 2025 Sep 10;61(9):1643. doi: 10.3390/medicina61091643. PMID- 41010554 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250927 LR - 20250930 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 14 IP - 18 DP - 2025 Sep 9 TI - The Role of Minimally Invasive Surgery in Mitral Valve Repair: Through the Female Gaze. LID - 10.3390/jcm14186349 [doi] LID - 6349 AB - Purpose of review: Numerous studies have investigated sex-specific differences in mitral regurgitation (MR) and mitral valve (MV) surgery. However, less is known about the possibility of sex-related outcomes in minimally invasive cardiac surgery, particularly in the case of minimally invasive MV repair. This review seeks to highlight existing evidence and identify gaps in the literature. Findings: Female patients with MR tend to present later, more symptomatically, and more comorbidly. This sex bias extends to pre-operative investigation, with females underrepresented in multidisciplinary evaluation and having longer intervals to surgery, often only receiving investigations as inpatients, and suffering from excess post-operative mortality compared to male patients. Very few studies directly investigate how these factors are related to female patients who undergo minimally invasive MV surgery, and fewer still interrogate sex-specific outcomes in minimally invasive MV repair. Summary: As cardiac surgery continues to evolve, it is of utmost importance to fully characterise the importance of sex as a factor in patient care for MR, and further research is necessary to reconcile its role in the advancement of minimally invasive MV surgery. FAU - Ho, Minji AU - Ho M AD - Faculty of Life Sciences and Medicine, King's College London, London SE1 1UL, UK. AD - Department of Cardiac Surgery, St. Thomas' Hospital, London SE1 7EH, UK. FAU - Long, Edouard AU - Long E AUID- ORCID: 0009-0002-1008-7966 AD - Faculty of Life Sciences and Medicine, King's College London, London SE1 1UL, UK. FAU - Bosco, Paolo AU - Bosco P AD - Department of Cardiac Surgery, St. Thomas' Hospital, London SE1 7EH, UK. LA - eng PT - Journal Article PT - Review DEP - 20250909 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC12471095 OTO - NOTNLM OT - cardiac surgery OT - female sex OT - minimally invasive cardiac surgery OT - mitral regurgitation OT - mitral valve repair COIS- The authors declare no conflicts of interest. EDAT- 2025/09/27 06:33 MHDA- 2025/09/27 06:34 PMCR- 2025/09/09 CRDT- 2025/09/27 01:18 PHST- 2025/05/21 00:00 [received] PHST- 2025/08/14 00:00 [revised] PHST- 2025/08/28 00:00 [accepted] PHST- 2025/09/27 06:34 [medline] PHST- 2025/09/27 06:33 [pubmed] PHST- 2025/09/27 01:18 [entrez] PHST- 2025/09/09 00:00 [pmc-release] AID - jcm14186349 [pii] AID - jcm-14-06349 [pii] AID - 10.3390/jcm14186349 [doi] PST - epublish SO - J Clin Med. 2025 Sep 9;14(18):6349. doi: 10.3390/jcm14186349. PMID- 41010368 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250927 LR - 20250930 IS - 2075-1729 (Print) IS - 2075-1729 (Electronic) IS - 2075-1729 (Linking) VI - 15 IP - 9 DP - 2025 Sep 11 TI - Arrhythmias in Rheumatoid Arthritis: A Call for a Multidisciplinary Team. LID - 10.3390/life15091426 [doi] LID - 1426 AB - BACKGROUND: Rheumatoid arthritis is the most prevalent systemic inflammatory disease, mainly affecting the synovial tissue of small and large joints, also associated with significant extra-articular manifestations. Throughout the progression of the disease, cardiac structures may be affected, including the conducting system, myocardium, endocardium, coronary arteries, and valves, potentially resulting in a higher incidence of cardiac arrhythmias. METHODS: We performed a narrative review of the most recent studies that highlight the epidemiology, pathophysiology, diagnosis, and management of arrhythmias occurring in patients with rheumatoid arthritis. Furthermore, we examined the impact of disease-modifying antirheumatic drugs (DMARDs)-including conventional synthetic (csDMARDs), biologic (bDMARDs), and targeted synthetic agents (tsDMARDs)-on cardiac electrophysiology. RESULTS: Cardiac immune cells may influence arrhythmogenesis through non-canonical and inflammatory mechanisms by modifying myocardial tissue architecture or by interacting with cardiomyocytes, potentially altering their electrical function. CONCLUSIONS: This review emphasizes the essential role of a multidisciplinary approach integrating rheumatology and cardiology expertise in the screening and management of arrhythmias in patients with rheumatoid arthritis. FAU - Ungurean, Veronica AU - Ungurean V AUID- ORCID: 0009-0002-8097-2573 AD - Department of Medical Sciences II, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania. AD - Department of Rheumatology, Clinic Rehabilitation Hospital, 700661 Iasi, Romania. FAU - Costan, Diana Elena AU - Costan DE AD - Department of Medical Sciences II, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania. AD - Department of Rheumatology, Clinic Rehabilitation Hospital, 700661 Iasi, Romania. FAU - Dobos, Monica Claudia AU - Dobos MC AD - Department of Medical Sciences II, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania. AD - Department of Rheumatology, Clinic Rehabilitation Hospital, 700661 Iasi, Romania. FAU - Ouatu, Anca AU - Ouatu A AUID- ORCID: 0000-0001-8923-8194 AD - Department of Medical Sciences I, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania. AD - Department of Internal Medicine, Sf. Spiridon County Clinical Emergency Hospital, 700111 Iasi, Romania. FAU - Morariu, Paula Cristina AU - Morariu PC AUID- ORCID: 0009-0006-5066-0690 AD - Department of Medical Sciences I, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania. AD - Department of Internal Medicine, Sf. Spiridon County Clinical Emergency Hospital, 700111 Iasi, Romania. FAU - Oancea, Alexandru Florinel AU - Oancea AF AUID- ORCID: 0000-0002-5249-4562 AD - Department of Medical Sciences I, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania. AD - Department of Internal Medicine, Sf. Spiridon County Clinical Emergency Hospital, 700111 Iasi, Romania. FAU - Godun, Maria Mihaela AU - Godun MM AD - Department of Medical Sciences I, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania. AD - Department of Internal Medicine, Sf. Spiridon County Clinical Emergency Hospital, 700111 Iasi, Romania. FAU - Floria, Diana-Elena AU - Floria DE AD - Department of Medical Sciences I, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania. AD - Department of Internal Medicine, Sf. Spiridon County Clinical Emergency Hospital, 700111 Iasi, Romania. FAU - Marcu, Dragos Traian AU - Marcu DT AD - Department of Medical Sciences I, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania. FAU - Baroi, Genoveva Livia AU - Baroi GL AD - Department of Surgery, Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania. FAU - Stanciu, Silviu Marcel AU - Stanciu SM AD - Department of Internal Medicine and Gastroenterology, Carol Davila University of Medicine and Pharmacy, Central Military Emergency University Hospital, 010825 Bucharest, Romania. FAU - Knieling, Anton AU - Knieling A AD - Discipline of Forensic Medicine, Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy Iasi, 16 Universitatii Street, 700115 Iasi, Romania. FAU - Tanase, Daniela Maria AU - Tanase DM AUID- ORCID: 0000-0002-7144-2506 AD - Department of Medical Sciences I, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania. AD - Department of Internal Medicine, Sf. Spiridon County Clinical Emergency Hospital, 700111 Iasi, Romania. FAU - Ancuta, Codrina AU - Ancuta C AUID- ORCID: 0000-0002-1777-8121 AD - Department of Medical Sciences II, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania. AD - Department of Rheumatology, Clinic Rehabilitation Hospital, 700661 Iasi, Romania. FAU - Floria, Mariana AU - Floria M AUID- ORCID: 0000-0002-9465-1503 AD - Department of Medical Sciences I, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania. AD - Department of Internal Medicine, Sf. Spiridon County Clinical Emergency Hospital, 700111 Iasi, Romania. LA - eng PT - Journal Article PT - Review DEP - 20250911 PL - Switzerland TA - Life (Basel) JT - Life (Basel, Switzerland) JID - 101580444 PMC - PMC12471337 OTO - NOTNLM OT - arrhythmias OT - atrial fibrillation OT - bDMARDs OT - csDMARDs OT - epidemiology OT - rheumatoid arthritis OT - tsDMARDs OT - ventricular ectopic beats COIS- The authors declare no conflicts of interest. EDAT- 2025/09/27 06:33 MHDA- 2025/09/27 06:34 PMCR- 2025/09/11 CRDT- 2025/09/27 01:17 PHST- 2025/08/06 00:00 [received] PHST- 2025/09/08 00:00 [revised] PHST- 2025/09/10 00:00 [accepted] PHST- 2025/09/27 06:34 [medline] PHST- 2025/09/27 06:33 [pubmed] PHST- 2025/09/27 01:17 [entrez] PHST- 2025/09/11 00:00 [pmc-release] AID - life15091426 [pii] AID - life-15-01426 [pii] AID - 10.3390/life15091426 [doi] PST - epublish SO - Life (Basel). 2025 Sep 11;15(9):1426. doi: 10.3390/life15091426. PMID- 41005782 OWN - NLM STAT- MEDLINE DCOM- 20250926 LR - 20251002 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 15 IP - 9 DP - 2025 Sep 26 TI - Rapid response teams and recommended ward-based management of acute deterioration: a single-centre retrospective cohort study in an inner-city London (UK) teaching hospital. PG - e102016 LID - 10.1136/bmjopen-2025-102016 [doi] LID - e102016 AB - OBJECTIVES : To describe the associations between Rapid Response Team (RRT) patient review and other predefined clinical management actions, with risk of in-hospital cardiac arrest and in-hospital mortality in the first unplanned admission (UPA) to the adult intensive care unit (ICU) from the ward environment for each patient.To describe a novel RRT assessment tool for ward-based care for patients who were deteriorating. DESIGN: A retrospective cohort study. SETTING: A large multispecialty, tertiary referral and teaching hospital in England, UK. PARTICIPANTS: The study included 3175 consecutive adult ICU UPAs from hospital wards over a 6-year period (2014-2019). OUTCOME MEASURES: Ward-based management of deterioration prior to ICU admission was assessed by the RRT, using a scored checklist-the UPA score. Admissions were compared in two groups according to their exposure to an RRT review in the 72 hours before ICU admission. Associations with in-hospital cardiac arrest within 24 hours before ICU admission and all-cause in-hospital mortality were estimated, using unadjusted and adjusted odds ratios (aORs) with 95%CI. RESULTS: RRT review occurred in 1413 (44.5%) admissions and was associated with reduced odds of in-hospital cardiac arrest (aOR 0.51; 95% CI 0.36 to 0.78; p<0.001), but similar odds of in-hospital mortality (OR 0.97; 95% CI 0.83 to 1.12; p=0.65). The median (IQR) UPA score was 1 (0 to 2), and each point increase was associated with increased odds of in-hospital cardiac arrest (aOR 1.13; 95% CI 1.06 to 1.23; p<0.001) and in-hospital mortality (aOR 1.10; 95% CI 1.05 to 1.15; p<0.001). Among individual UPA score items, Nursing Escalation Failure, Blood Gas Omission and Laboratory Blood Omission were associated with increased odds of in-hospital cardiac arrest, whereas Delayed Vital Signs and Failure to Recognise Deterioration were associated with increased odds of in-hospital mortality. CONCLUSIONS AND RELEVANCE: An RRT review in the 72 hours prior to ICU admission was associated with reduced odds of in-hospital cardiac arrest but did not impact in-hospital mortality. Higher UPA scores were associated with increased incidence of both in-hospital cardiac arrest and in-hospital mortality. In addition, this study describes a novel and adaptable RRT scoring tool (the UPA score) for safety monitoring and quality improvement. CI - (c) Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. FAU - Hadfield, Sophie AU - Hadfield S AD - Department of Critical Care, King's College Hospital NHS Foundation Trust, London, UK. FAU - Zentar, Marc AU - Zentar M AD - Department of Critical Care, King's College Hospital NHS Foundation Trust, London, UK. AD - Department of Critical Care, Guy's and St Thomas' Hospitals NHS Trust, London, UK. FAU - McPhail, Mark AU - McPhail M AD - School of Immunology and Microbial Sciences, King's College London, London, UK. AD - Liver Intensive Therapy Unit, Institute of Liver Studies, King's College Hospital NHS Foundation Trust, London, UK. FAU - Helme, Eloise AU - Helme E AD - Department of Critical Care, King's College Hospital NHS Foundation Trust, London, UK. AD - Department of Anaesthesia, Royal Surrey County Hospital NHS Foundation Trust, Guildford, UK. FAU - Broderick, Rebecca AU - Broderick R AD - Department of Critical Care, King's College Hospital NHS Foundation Trust, London, UK. FAU - Logan, Francesca AU - Logan F AD - Department of Critical Care, King's College Hospital NHS Foundation Trust, London, UK. FAU - Loveridge, Robert AU - Loveridge R AD - Department of Critical Care, King's College Hospital NHS Foundation Trust, London, UK. AD - Liver Intensive Therapy Unit, Institute of Liver Studies, King's College Hospital NHS Foundation Trust, London, UK. FAU - Madine, Emma AU - Madine E AD - Department of Critical Care, King's College Hospital NHS Foundation Trust, London, UK. FAU - Vining, Imogen AU - Vining I AD - King's College Hospital NHS Foundation Trust, London, UK. FAU - Wendon, Julia AU - Wendon J AD - Liver Intensive Therapy Unit, Institute of Liver Studies, King's College Hospital NHS Foundation Trust, London, UK. FAU - Metaxa, Victoria AU - Metaxa V AUID- ORCID: 0000-0003-4232-6845 AD - Department of Critical Care, King's College Hospital NHS Foundation Trust, London, UK. AD - Centre for Education, Faculty of Life Sciences and Medicine, King's College London, London, UK. FAU - Hadfield, Daniel AU - Hadfield D AUID- ORCID: 0000-0003-0334-7221 AD - Department of Critical Care, King's College Hospital NHS Foundation Trust, London, UK daniel.hadfield@nhs.net. AD - Centre for Human and Applied Physiological Science, King's College London, London, UK. AD - Florence Nightingale Faculty of Nursing, Midwifery and Palliative Care, King's College London, London, UK. LA - eng PT - Journal Article DEP - 20250926 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 SB - IM MH - Humans MH - Retrospective Studies MH - *Hospital Rapid Response Team MH - Hospitals, Teaching MH - Hospital Mortality MH - Male MH - Female MH - Aged MH - Middle Aged MH - *Clinical Deterioration MH - London/epidemiology MH - Intensive Care Units MH - *Heart Arrest/epidemiology MH - Aged, 80 and over PMC - PMC12481366 OTO - NOTNLM OT - INTENSIVE & CRITICAL CARE OT - Inpatients OT - Observational Study OT - Patient Care Management OT - Retrospective Studies OT - Safety COIS- Competing interests: None declared. EDAT- 2025/09/27 00:30 MHDA- 2025/09/27 00:31 PMCR- 2025/09/26 CRDT- 2025/09/26 20:43 PHST- 2025/09/27 00:31 [medline] PHST- 2025/09/27 00:30 [pubmed] PHST- 2025/09/26 20:43 [entrez] PHST- 2025/09/26 00:00 [pmc-release] AID - bmjopen-2025-102016 [pii] AID - 10.1136/bmjopen-2025-102016 [doi] PST - epublish SO - BMJ Open. 2025 Sep 26;15(9):e102016. doi: 10.1136/bmjopen-2025-102016. PMID- 41005459 OWN - NLM STAT- MEDLINE DCOM- 20251105 LR - 20260428 IS - 2174-2030 (Electronic) IS - 0870-2551 (Linking) VI - 44 IP - 11 DP - 2025 Nov TI - Etiology of sudden cardiac arrest: Literature review and proposal for an intensive care unit study protocol. PG - 691-698 LID - S0870-2551(25)00292-6 [pii] LID - 10.1016/j.repc.2025.04.007 [doi] AB - Sudden cardiac arrest (SCA) affects individuals across all age groups and is defined as the sudden cessation of normal cardiac activity, leading to hemodynamic collapse. Determining the etiology of SCA is challenging due to its wide range of cardiac and noncardiac causes. Structural heart disease, mainly coronary artery disease, is predominant in older adults, while cardiomyopathies and primary electrical diseases are more common in younger individuals. Noncardiac causes, such as intracranial hemorrhage and pulmonary embolism, account for 15-25% of cases. This review examines the epidemiology, etiology, and investigation of SCA and proposes a diagnostic approach for SCA patients admitted to the emergency department and intensive care unit. The study protocol is divided into four main stages: (1) initial evaluation, identification of reversible causes, and exclusion of ischemic heart disease and extracardiac disease; (2) assessment of nonischemic cardiac causes; (3) neuroprognostication; and (4) clinical autopsy and/or genetic testing, if appropriate. We emphasize the importance of a multidisciplinary approach, involving an intensivist, cardiologist, neurologist, geneticist, and pathologist, as well as early genetic testing to identify potential heritable diseases and facilitate early referral of patient relatives. By providing this structured diagnostic algorithm, we aim to improve the management and outcomes of SCA patients. CI - Copyright (c) 2025 Sociedade Portuguesa de Cardiologia. Publicado por Elsevier Espana, S.L.U. All rights reserved. FAU - Cravo, Joao AU - Cravo J AD - Servico de Cardiologia, Centro Hospitalar Universitario Lisboa Norte, CAML (CCUL@RISE), Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal. FAU - Inacio Cazeiro, Daniel AU - Inacio Cazeiro D AD - Servico de Cardiologia, Centro Hospitalar Universitario Lisboa Norte, CAML (CCUL@RISE), Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal. Electronic address: danielcazeiro@gmail.com. FAU - Moldovan, Oana AU - Moldovan O AD - Servico de Genetica Medica, Centro Hospitalar Universitario Lisboa Norte, CAML, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal. FAU - Cortez-Dias, Nuno AU - Cortez-Dias N AD - Servico de Cardiologia, Centro Hospitalar Universitario Lisboa Norte, CAML (CCUL@RISE), Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal. FAU - Silva, Doroteia AU - Silva D AD - Servico de Cardiologia, Centro Hospitalar Universitario Lisboa Norte, CAML (CCUL@RISE), Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal; Servico de Medicina Intensiva, Centro Hospitalar Universitario Lisboa Norte, CAML, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal. LA - eng LA - por PT - Journal Article PT - Review DEP - 20250924 PL - Portugal TA - Rev Port Cardiol JT - Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology JID - 8710716 SB - IM MH - Humans MH - *Death, Sudden, Cardiac/etiology MH - *Intensive Care Units MH - Clinical Trial Protocols as Topic OTO - NOTNLM OT - Epidemiologia OT - Epidemiology OT - Etiology review OT - Morte subita cardiaca OT - Protocolo de estudo OT - Revisao etiologica OT - Study protocol OT - Sudden cardiac arrest EDAT- 2025/09/27 00:30 MHDA- 2025/11/06 00:27 CRDT- 2025/09/26 19:36 PHST- 2024/11/26 00:00 [received] PHST- 2025/04/28 00:00 [accepted] PHST- 2025/11/06 00:27 [medline] PHST- 2025/09/27 00:30 [pubmed] PHST- 2025/09/26 19:36 [entrez] AID - S0870-2551(25)00292-6 [pii] AID - 10.1016/j.repc.2025.04.007 [doi] PST - ppublish SO - Rev Port Cardiol. 2025 Nov;44(11):691-698. doi: 10.1016/j.repc.2025.04.007. Epub 2025 Sep 24. PMID- 41003463 OWN - NLM STAT- In-Process LR - 20260311 IS - 1558-3597 (Electronic) IS - 0735-1097 (Linking) VI - 87 IP - 9 DP - 2026 Mar 10 TI - 2025 ACC/AHA Clinical Practice Guidelines Core Principles and Development Process: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. PG - 1165-1176 LID - S0735-1097(25)06838-X [pii] LID - 10.1016/j.jacc.2025.06.013 [doi] FAU - Otto, Catherine M AU - Otto CM FAU - Abdullah, Abdul R AU - Abdullah AR FAU - Davis, Leslie L AU - Davis LL FAU - Ferrari, Victor A AU - Ferrari VA FAU - Fremes, Stephen AU - Fremes S FAU - Mukherjee, Debabrata AU - Mukherjee D FAU - Prestera, Lauren AU - Prestera L FAU - Ziaeian, Boback AU - Ziaeian B LA - eng PT - Journal Article PT - Practice Guideline DEP - 20250925 PL - United States TA - J Am Coll Cardiol JT - Journal of the American College of Cardiology JID - 8301365 SB - IM OTO - NOTNLM OT - ACC/AHA clinical practice guidelines OT - evidence-based medicine OT - medical history taking OT - multidisciplinary care team OT - patient education OT - patient reported outcomes OT - physical examination OT - risk factors for cardiovascular disease OT - shared decision-making OT - social determinants of health EDAT- 2025/09/26 12:33 MHDA- 2025/09/26 12:33 CRDT- 2025/09/26 10:31 PHST- 2025/09/26 12:33 [pubmed] PHST- 2025/09/26 12:33 [medline] PHST- 2025/09/26 10:31 [entrez] AID - S0735-1097(25)06838-X [pii] AID - 10.1016/j.jacc.2025.06.013 [doi] PST - ppublish SO - J Am Coll Cardiol. 2026 Mar 10;87(9):1165-1176. doi: 10.1016/j.jacc.2025.06.013. Epub 2025 Sep 25. PMID- 41002604 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250926 LR - 20250928 IS - 2308-3425 (Electronic) IS - 2308-3425 (Linking) VI - 12 IP - 9 DP - 2025 Aug 25 TI - From Acute Carditis, Rheumatic Carditis, and Morphologic Cardiac Reactions to Allergic Angina, Allergic Myocardial Infarction, and Kounis Syndrome: A Multidisciplinary and Multisystem Disease. LID - 10.3390/jcdd12090325 [doi] LID - 325 AB - This narrative review explains the history of anaphylactic or hypersensitivity reactions, their connection to the cardiovascular system, and Kounis syndrome, which is linked to hypersensitivity. Additional subjects discussed include immunoglobulin E and serum tryptase, common pathways of allergic and nonallergic cardiovascular events, current perspectives on Kounis syndrome, allergic myocardial infarction, allergic angina, and the impact of COVID-19 and its vaccination on Kounis syndrome. Kounis syndrome is a distinct kind of acute vascular disease that affects the coronary, cerebral, mesenteric, peripheral, and venous systems. Kounis syndrome is currently used to describe coronary symptoms linked to disorders involving mast cell activation and inflammatory cell interactions, such as those involving T-lymphocytes and macrophages, which further induce allergic, hypersensitive, anaphylactic, or anaphylactic insults. Platelet activating factor, histamine, neutral proteases like tryptase and chymase, arachidonic acid products, and a range of cytokines and chemokines released during the activation process are among the inflammatory mediators that cause it. Proinflammatory cytokines are primarily produced by mast cells in COVID-19 infections. Mast cell-derived proteases and eosinophil-associated mediators are also more prevalent in the lung tissues and sera of COVID-19 patients. As a modern global threat to civilization, COVID-19 is linked to chemical patterns that can activate mast cells; therefore, allergic stimuli are usually the reason. Virus-associated molecular patterns can activate mast cells, but allergic triggers are typically the cause. By activating SARS-CoV-2 and other toll-like receptors, a variety of proinflammatory mediators, including IL-6 and IL-1beta, are released, potentially contributing to the pathology of COVID-19. FAU - Kounis, Nicholas G AU - Kounis NG AUID- ORCID: 0000-0002-9751-6710 AD - Department of Medicine, Division of Cardiology, University Hospital of Patras, 26500 Patras, Greece. FAU - Stefanidis, Alexandros AU - Stefanidis A AUID- ORCID: 0000-0001-5814-1859 AD - First Cardiology Department, General Hospital of Nikea, Agios Panteleimon Piraeus, 3 D Mantouvalou Street, 18454 Piraeus, Greece. FAU - Hung, Ming-Yow AU - Hung MY AUID- ORCID: 0000-0002-6912-7523 AD - Division of Cardiology, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, 18 No. 291, Zhongzheng Rd., Zhonghe District, New Taipei City 23561, Taiwan. AD - Taipei Heart Institute, Taipei Medical University, Taipei City 110301, Taiwan. AD - Division of Cardiology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei City 110301, Taiwan. FAU - Ozkan, Ugur AU - Ozkan U AUID- ORCID: 0000-0002-7552-7654 AD - Department of Cardiology, School of Medicine, Trakya University, 22030 Edirne, Turkey. FAU - de Gregorio, Cesare AU - de Gregorio C AUID- ORCID: 0000-0003-3022-266X AD - Department of Clinical and Experimental Medicine, University of Messina Medical School, 98122 Messina, Italy. FAU - Ceasovschih, Alexandr AU - Ceasovschih A AUID- ORCID: 0000-0002-0043-9051 AD - Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania. AD - Second Internal Medicine Department, "Sf. Spiridon" Clinical Emergency Hospital, 700111 Iasi, Romania. FAU - Mplani, Virginia AU - Mplani V AUID- ORCID: 0000-0003-1610-0156 AD - Intensive Care Unit, Patras University Hospital, 26504 Patras, Greece. FAU - Gogos, Christos AU - Gogos C AUID- ORCID: 0000-0002-9598-6954 AD - Department of Cardiology, Mamatseio, General Hospital of Kozani, 50100 Kozani, Greece. AD - First University Cardiology Department, AHEPA General Hospital, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece. FAU - Assimakopoulos, Stelios F AU - Assimakopoulos SF AUID- ORCID: 0000-0002-6901-3681 AD - Division of Infectious Diseases, Department of Internal Medicine, Medical School, University of Patras, University Hospital of Patras, 26504 Patras, Greece. FAU - Chatzigrigoriadis, Christodoulos AU - Chatzigrigoriadis C AUID- ORCID: 0009-0004-5449-0911 AD - School of Medicine, University of Patras, 26504 Patras, Greece. FAU - Plotas, Panagiotis AU - Plotas P AUID- ORCID: 0000-0001-5514-7083 AD - Department of Speech Therapy, University of Patras, 26504 Patras, Greece. FAU - Dousdampanis, Periklis AU - Dousdampanis P AD - Department of Nephrology, Saint Andrews State General Hospital, 26221 Patras, Greece. FAU - Kouni, Sophia N AU - Kouni SN AUID- ORCID: 0009-0008-2544-1044 AD - Speech Therapy Practice, Queen Olgas Square, 26221 Patras, Greece. FAU - Tsigkas, Grigorios AU - Tsigkas G AUID- ORCID: 0000-0002-2779-0765 AD - Department of Medicine, Division of Cardiology, University Hospital of Patras, 26500 Patras, Greece. FAU - Patsouras, Nicholas AU - Patsouras N AD - Department of Medicine, Division of Cardiology, University Hospital of Patras, 26500 Patras, Greece. FAU - Calogiuri, Gianfranco AU - Calogiuri G AD - Department of Internal Medicine, Immunology and Infectious Diseases, Section of Allergology and Clinical Immunology, University of Bari Medical School, 70121 Bari, Italy. FAU - Pourmasumi, Soheila AU - Pourmasumi S AD - Clinical Research Development Unit, Ali-Ibn Abi-Talib Hospital, Rafsanjan University of Medical Sciences, Rafsanjan 7717933777, Iran. FAU - Koniari, Ioanna AU - Koniari I AD - Department of Medicine, Division of Cardiology, University Hospital of Patras, 26500 Patras, Greece. LA - eng PT - Journal Article PT - Review DEP - 20250825 PL - Switzerland TA - J Cardiovasc Dev Dis JT - Journal of cardiovascular development and disease JID - 101651414 PMC - PMC12470948 OTO - NOTNLM OT - COVID-19 OT - Kounis syndrome OT - allergic angina OT - allergic myocardial infarction OT - degranulation OT - immunoglobulin E OT - mast cell OT - tryptase COIS- The authors declare no conflicts of interest. EDAT- 2025/09/26 12:31 MHDA- 2025/09/26 12:32 PMCR- 2025/08/25 CRDT- 2025/09/26 10:15 PHST- 2025/04/14 00:00 [received] PHST- 2025/07/15 00:00 [revised] PHST- 2025/08/06 00:00 [accepted] PHST- 2025/09/26 12:32 [medline] PHST- 2025/09/26 12:31 [pubmed] PHST- 2025/09/26 10:15 [entrez] PHST- 2025/08/25 00:00 [pmc-release] AID - jcdd12090325 [pii] AID - jcdd-12-00325 [pii] AID - 10.3390/jcdd12090325 [doi] PST - epublish SO - J Cardiovasc Dev Dis. 2025 Aug 25;12(9):325. doi: 10.3390/jcdd12090325. PMID- 41001682 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250926 LR - 20260925 IS - 2637-3726 (Electronic) IS - 2637-3726 (Linking) VI - 13 IP - 2 DP - 2025 Jul-Dec TI - Anaesthetic management of colorectal surgery in a patient with chronic pericardial effusion. PG - e70031 LID - 10.1002/anr3.70031 [doi] LID - e70031 AB - Chronic pericardial effusions are a peri-operative challenge as anaesthesia and surgery can precipitate haemodynamic compromise. Guidance for managing patients requiring time-sensitive non-cardiac surgery in this setting is limited. We report the case of a 43-year-old woman with a moderate chronic, asymptomatic pericardial effusion scheduled for robotic anterior resection of rectal cancer. The principal challenge was balancing the need for time-sensitive oncological surgery against the risk of haemodynamic compromise in the context of suboptimal pre-operative cardiology assessment. Surgery proceeded after multidisciplinary discussion, with pre-emptive vasopressor support and intra-operative transoesophageal echocardiography monitoring to guide management. The peri-operative course was stable, and the patient was discharged on postoperative day 4. Two months later, she required pericardial window formation for a persistent effusion which had become symptomatic. This case illustrates that non-cardiac surgery in chronic, asymptomatic pericardial effusion can be performed safely when guided by physiological reasoning, real-time echocardiography and multidisciplinary planning. CI - (c) 2025 Association of Anaesthetists. FAU - Ahmad, E AU - Ahmad E AD - Shrewsbury and Telford Hospitals NHS Trust Shrewsbury UK. FAU - Liu, H S AU - Liu HS AD - Shrewsbury and Telford Hospitals NHS Trust Shrewsbury UK. FAU - Miller, A AU - Miller A AUID- ORCID: 0000-0002-6665-1514 AD - Shrewsbury and Telford Hospitals NHS Trust Shrewsbury UK. LA - eng PT - Journal Article DEP - 20250924 PL - England TA - Anaesth Rep JT - Anaesthesia reports JID - 101759073 PMC - PMC12460003 OTO - NOTNLM OT - colorectal surgery OT - echocardiography, transoesophageal OT - haemodynamics OT - pericardial effusion EDAT- 2025/09/26 06:31 MHDA- 2025/09/26 06:32 PMCR- 2026/09/24 CRDT- 2025/09/26 05:48 PHST- 2025/09/18 00:00 [accepted] PHST- 2025/09/26 06:32 [medline] PHST- 2025/09/26 06:31 [pubmed] PHST- 2025/09/26 05:48 [entrez] PHST- 2026/09/24 00:00 [pmc-release] AID - ANR370031 [pii] AID - 10.1002/anr3.70031 [doi] PST - epublish SO - Anaesth Rep. 2025 Sep 24;13(2):e70031. doi: 10.1002/anr3.70031. eCollection 2025 Jul-Dec. PMID- 41000413 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250926 LR - 20250928 IS - 1178-7074 (Print) IS - 1178-7074 (Electronic) IS - 1178-7074 (Linking) VI - 18 DP - 2025 TI - Impact of an Infective Endocarditis Team on Management and Outcomes: A Retrospective Cohort Study. PG - 5743-5754 LID - 10.2147/IJGM.S542511 [doi] AB - PURPOSE: Multidisciplinary team approaches have been reported to improve the management of infective endocarditis (IE). This study evaluated changes in management and outcomes after the establishment of an IE team at a tertiary care facility in Japan. PATIENTS AND METHODS: A retrospective study was conducted on inpatients aged >/=18 years with definite IE between November 2015 and October 2023. The primary outcome was 90-day all-cause mortality. Secondary outcomes included in-hospital mortality, unplanned cardiac surgery, new cerebral embolism, bacteremia relapse within 90 days of admission, and duration of antibiotic therapy. Outcomes were compared between patients admitted before (control period) and after (intervention period) the implementation of the IE team in November 2019. RESULTS: Characteristics were comparable between the two periods. No significant differences were found in 90-day mortality (15.2% vs 17.0%, P > 0.99), in-hospital mortality (19.6% vs 12.8%, P = 0.54), or new cerebral embolism (8.7% vs 2.1%, P = 0.20). The rate of unplanned cardiac surgery was lower in the intervention period (17.4% vs 2.1%, P = 0.02), while the duration of antibiotic therapy was longer (6.0 weeks vs 7.5 weeks, P = 0.02). No bacteremia relapse occurred. CONCLUSION: Although no significant differences were observed in 90-day mortality, the rate of unplanned surgery was significantly lower in the intervention period, supporting the usefulness of an IE team. The longer duration of antibiotic therapy in the intervention period may reflect a higher prevalence of complicated infections including muscle abscesses. CI - (c) 2025 Sakamoto et al. FAU - Sakamoto, Tetsu AU - Sakamoto T AUID- ORCID: 0000-0001-9104-8891 AD - Department of Diagnostic and Generalist Medicine, Dokkyo Medical University, Mibu, Tochigi, Japan. FAU - Hirosawa, Takanobu AU - Hirosawa T AUID- ORCID: 0000-0002-3573-8203 AD - Department of Diagnostic and Generalist Medicine, Dokkyo Medical University, Mibu, Tochigi, Japan. FAU - Harada, Yukinori AU - Harada Y AUID- ORCID: 0000-0001-6042-7397 AD - Department of Diagnostic and Generalist Medicine, Dokkyo Medical University, Mibu, Tochigi, Japan. FAU - Shibasaki, Ikuko AU - Shibasaki I AD - Department of Cardiac and Vascular Surgery, Dokkyo Medical University, Mibu, Tochigi, Japan. FAU - Sairenchi, Toshimi AU - Sairenchi T AD - Department of Medical Science of Nursing, Dokkyo Medical University School of Nursing, Mibu, Tochigi, Japan. FAU - Nishikawa, Riichi AU - Nishikawa R AD - Department of Cardiovascular Medicine, Dokkyo Medical University, Mibu, Tochigi, Japan. FAU - Sakikawa, Haruka AU - Sakikawa H AD - Department of Cardiovascular Medicine, Dokkyo Medical University, Mibu, Tochigi, Japan. FAU - Shimizu, Taro AU - Shimizu T AD - Department of Diagnostic and Generalist Medicine, Dokkyo Medical University, Mibu, Tochigi, Japan. LA - eng PT - Journal Article DEP - 20250920 PL - New Zealand TA - Int J Gen Med JT - International journal of general medicine JID - 101515487 PMC - PMC12459389 OTO - NOTNLM OT - IE team OT - cardiac surgery OT - endocarditis team OT - infective endocarditis OT - multidisciplinary management COIS- The authors report no conflicts of interest in this work. EDAT- 2025/09/26 06:31 MHDA- 2025/09/26 06:32 PMCR- 2025/09/20 CRDT- 2025/09/26 05:29 PHST- 2025/05/24 00:00 [received] PHST- 2025/09/16 00:00 [accepted] PHST- 2025/09/26 06:32 [medline] PHST- 2025/09/26 06:31 [pubmed] PHST- 2025/09/26 05:29 [entrez] PHST- 2025/09/20 00:00 [pmc-release] AID - 542511 [pii] AID - 10.2147/IJGM.S542511 [doi] PST - epublish SO - Int J Gen Med. 2025 Sep 20;18:5743-5754. doi: 10.2147/IJGM.S542511. eCollection 2025. PMID- 40997854 OWN - NLM STAT- MEDLINE DCOM- 20250925 LR - 20250928 IS - 1473-2300 (Electronic) IS - 0300-0605 (Print) IS - 0300-0605 (Linking) VI - 53 IP - 9 DP - 2025 Sep TI - Emerging evidence on transcatheter edge-to-edge repair for secondary mitral regurgitation. PG - 3000605251378694 LID - 10.1177/03000605251378694 [doi] LID - 03000605251378694 AB - The surgical management of mitral valve disease is undergoing rapid development, with various treatment options available. Increasing evidence has emerged on the optimal strategy for the management of secondary mitral regurgitation, a condition characterised by ventricular pathology. This review discusses surgical treatments for secondary mitral regurgitation. Currently, there is no consensus on the optimal strategy for the treatment of patients with secondary mitral regurgitation. Management of this condition requires a dedicated heart team to ensure the most favourable outcome by tailoring interventions to individual patients. The aim of this narrative review is to compare available interventions for secondary mitral regurgitation. FAU - Nappi, Francesco AU - Nappi F AUID- ORCID: 0000-0002-9705-5360 AD - Department of Cardiac Surgery, Centre Cardiologique du Nord, France. RINGGOLD: 56509 LA - eng PT - Journal Article PT - Review DEP - 20250925 PL - England TA - J Int Med Res JT - The Journal of international medical research JID - 0346411 SB - IM MH - Humans MH - *Mitral Valve Insufficiency/surgery/etiology MH - *Mitral Valve/surgery MH - *Heart Valve Prosthesis Implantation/methods MH - *Cardiac Catheterization/methods MH - Treatment Outcome PMC - PMC12464391 OTO - NOTNLM OT - Secondary ischaemic mitral regurgitation OT - subvalvular repair OT - transcatheter edge-to-edge repair OT - undersized mitral annuloplasty COIS- Declaration of conflicting interestThe author declares that there are no conflicts of interest. EDAT- 2025/09/26 00:30 MHDA- 2025/09/26 00:31 PMCR- 2025/09/25 CRDT- 2025/09/25 18:53 PHST- 2025/09/26 00:31 [medline] PHST- 2025/09/26 00:30 [pubmed] PHST- 2025/09/25 18:53 [entrez] PHST- 2025/09/25 00:00 [pmc-release] AID - 10.1177_03000605251378694 [pii] AID - 10.1177/03000605251378694 [doi] PST - ppublish SO - J Int Med Res. 2025 Sep;53(9):3000605251378694. doi: 10.1177/03000605251378694. Epub 2025 Sep 25. PMID- 40997146 OWN - NLM STAT- In-Process LR - 20251103 IS - 1524-4539 (Electronic) IS - 0009-7322 (Linking) VI - 152 IP - 18 DP - 2025 Nov 4 TI - 2025 ACC/AHA Clinical Practice Guidelines Core Principles and Development Process: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. PG - e359-e370 LID - 10.1161/CIR.0000000000001383 [doi] CN - Writing Committee Members FAU - Otto, Catherine M AU - Otto CM FAU - Abdullah, Abdul R AU - Abdullah AR FAU - Davis, Leslie L AU - Davis LL FAU - Ferrari, Victor A AU - Ferrari VA FAU - Fremes, Stephen AU - Fremes S FAU - Mukherjee, Debabrata AU - Mukherjee D FAU - Prestera, Lauren AU - Prestera L FAU - Ziaeian, Boback AU - Ziaeian B LA - eng PT - Journal Article PT - Review DEP - 20250925 PL - United States TA - Circulation JT - Circulation JID - 0147763 SB - IM OTO - NOTNLM OT - AHA Scientific Statements OT - evidence-based medicine OT - medical history taking OT - multidisciplinary care team OT - patient education OT - patient reported outcomes OT - physical examination OT - risk factors for cardiovascular disease OT - shared decision making OT - social determinants of health EDAT- 2025/09/25 18:31 MHDA- 2025/09/25 18:31 CRDT- 2025/09/25 14:05 PHST- 2025/09/25 18:31 [pubmed] PHST- 2025/09/25 18:31 [medline] PHST- 2025/09/25 14:05 [entrez] AID - 10.1161/CIR.0000000000001383 [doi] PST - ppublish SO - Circulation. 2025 Nov 4;152(18):e359-e370. doi: 10.1161/CIR.0000000000001383. Epub 2025 Sep 25. PMID- 40994242 OWN - NLM STAT- MEDLINE DCOM- 20251030 LR - 20251030 IS - 1467-1107 (Electronic) IS - 1047-9511 (Linking) VI - 35 IP - 10 DP - 2025 Oct TI - Creating and implementing a novel international interprofessional bootcamp in paediatric cardiac critical care. PG - 1999-2004 LID - 10.1017/S1047951125109529 [doi] AB - OBJECTIVE: To determine the feasibility of developing and implementing a multidisciplinary bootcamp for early-career Paediatric Cardiac Critical Care practitioners. SETTING: A one-day pre-conference bootcamp at the Pediatric Cardiac Intensive Care Society Annual Meeting in December 2022. SUBJECTS: Physicians, fellows, nurses, advanced practice registered nurses, and respiratory therapists who work primarily in paediatric cardiac critical care units. METHODS: A modified Delphi needs assessment with interprofessional content experts for the development of a mixed didactic and simulation-based bootcamp at the Pediatric Cardiac Intensive Care Society Annual Meeting in December 2022, with pre- and post-testing to evaluate knowledge gain and additional surveys to assess perceived value. RESULTS: Eighty-three course participants came from a variety of professions and represented institutions nationally and internationally. Most participants (77%) had two or more years of professional experience, aligning with the bootcamp's focus on advanced learners. The bootcamp received strong participant evaluations: 84.1% (37/44) strongly agreed that the bootcamp improved their clinical knowledge. Ninety-seven percent (43/44) reported increased confidence in the ability to care for paediatric cardiac critical care patients. The bootcamp demonstrated a significant improvement in participant knowledge, with pre-test scores averaging 54.9% (95% CI: 49.9-59.9) compared to post-test scores of 64.5% (95% CI: 59.7-69.2), achieving statistical significance (p < 0.05). CONCLUSIONS: Our pilot bootcamp has shown an improvement in immediate knowledge retention with valuable insights gathered to enhance future bootcamps. The results of this advanced interprofessional bootcamp evaluation will inform future iterations for providers in paediatric cardiac critical care. FAU - Mannarino, Candace AU - Mannarino C AUID- ORCID: 0000-0002-8329-6016 AD - Divisions of Cardiology and Critical Care Medicine, Department of Pediatrics, Ann & Robert H Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. FAU - Beke, Dorothy AU - Beke D AD - Department of Nursing, Boston Children's Hospital, Boston, MA, USA. FAU - Callow, Louise AU - Callow L AD - Pediatric Cardiac Surgery Nurse Practitioner, Congenital Heart Center, CS Mott Children's Hospital Michigan Medicine, Ann Arbor, MI, USA. FAU - Chlebowski, Meghan Marie AU - Chlebowski MM AUID- ORCID: 0000-0002-9763-9200 AD - The Heart Institute, Cincinnati Children's Hospital Medical Center, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA. FAU - Fortkiewicz, Justine M AU - Fortkiewicz JM AD - Division of Cardiac Critical Care, Children's National Hospital, Washington, DC, USA. FAU - Jones, Melissa AU - Jones M AUID- ORCID: 0000-0001-9526-6992 AD - Division of Cardiac Critical Care, Children's National Hospital, Washington, DC, USA. FAU - Matiasek, Megan AU - Matiasek M AD - Division of Cardiology, Ann & Robert H Lurie Children's Hospital of Chicago, Chicago, IL, USA. FAU - McBride, Mary E AU - McBride ME AD - Divisions of Cardiology and Critical Care Medicine, Department of Pediatrics, Ann & Robert H Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. FAU - Mille, Felina AU - Mille F AD - Division of Cardiac Critical Care, Department of Anesthesiology and Critical Care Medicine, The Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA, USA. FAU - Pareja, Jennifer Christine Munoz AU - Pareja JCM AD - Division of Critical Care, Department of Pediatrics, Holtz Children's Hospital, University of Miami, Miami, FL, USA. FAU - Riley, Christine AU - Riley C AD - Division of Cardiac Critical Care, Children's National Hospital, Washington, DC, USA. FAU - Rodriguez, Zahidee AU - Rodriguez Z AD - Division of Cardiology, Department of Pediatrics, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, GA, USA. FAU - Justice, Lindsey AU - Justice L AUID- ORCID: 0000-0002-6554-8881 AD - The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. LA - eng PT - Journal Article DEP - 20250925 PL - England TA - Cardiol Young JT - Cardiology in the young JID - 9200019 SB - IM MH - Humans MH - *Critical Care MH - Child MH - *Clinical Competence MH - Delphi Technique MH - *Pediatrics/education MH - Intensive Care Units, Pediatric MH - *Interprofessional Relations MH - Feasibility Studies MH - *Cardiology/education MH - Patient Care Team OTO - NOTNLM OT - Congenital heart disease OT - bootcamp OT - education OT - paediatric cardiac intensive care unit OT - paediatrics EDAT- 2025/09/25 06:28 MHDA- 2025/10/30 12:29 CRDT- 2025/09/25 03:24 PHST- 2025/10/30 12:29 [medline] PHST- 2025/09/25 06:28 [pubmed] PHST- 2025/09/25 03:24 [entrez] AID - S1047951125109529 [pii] AID - 10.1017/S1047951125109529 [doi] PST - ppublish SO - Cardiol Young. 2025 Oct;35(10):1999-2004. doi: 10.1017/S1047951125109529. Epub 2025 Sep 25. PMID- 40989898 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250924 LR - 20250926 IS - 2632-1823 (Electronic) IS - 2632-1823 (Linking) VI - 7 IP - 5 DP - 2025 Oct TI - Antibiotic treatment duration for isolated methicillin-susceptible Staphylococcus aureus native tricuspid valve endocarditis: a standardized multidisciplinary approach. PG - dlaf171 LID - 10.1093/jacamr/dlaf171 [doi] LID - dlaf171 AB - BACKGROUND: MSSA tricuspid valve infective endocarditis (TVIE) is associated with significant morbidity and there is not consensus surrounding the optimal duration of antibiotic therapy. We report the outcomes of treating MSSA TVIE endocarditis using a multidisciplinary team and cardiovascular infectious diseases consult service. METHODS: Patients were identified from the multidisciplinary endocarditis team registry in a single-centre retrospective study. RESULTS: Between 7 September 2021 and 7 September 2024, 34 patients, including 27 who inject drugs, with isolated native MSSA TVIE were identified. Patients received a median of 28 days (IQR 11-41) of antibiotics and 50% transitioned to oral antibiotics for a median of 14 days. There was one relapsed infection (2.9%) and one death at 90 days (2.9%). There was no difference in relapsed infection or mortality at 90 days for patients transitioned to oral therapy compared with IV (P = 0.52). CONCLUSIONS: With a standardized approach to patient care, including a cardiovascular infectious diseases consult service and multidisciplinary team, patients with MSSA isolated TVIE without metastatic osteoarticular or spinal infections were successfully treated with antibiotic courses of  10 mm). CONCLUSION: Although all patients accepted for percutaneous PFO closure were individually assessed by a dedicated HST, 20% had a PFO without risk-enhancing features but were still accepted for closure due to other reasons. This highlights the importance of careful individual assessment of young stroke patients with a PFO. Future studies are needed to identify the characteristics that contribute to stroke in these patients. CI - (c) 2025. The Author(s). FAU - Immens, Maikel H M AU - Immens MHM AUID- ORCID: 0000-0003-3359-4645 AD - Department of Neurology, Radboudumc, Donders Institute for Brain, Cognition and Behaviour, Nijmegen, The Netherlands. FAU - Witte, Lars S AU - Witte LS AD - Department of Cardiology, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands. FAU - El Bouziani, Abdelhak AU - El Bouziani A AD - Department of Cardiology, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands. FAU - Duijnhouwer, Anthonie AU - Duijnhouwer A AD - Department of Cardiology, Radboudumc, Radboud Institute for research and medical innovation, Nijmegen, The Netherlands. FAU - Bouma, Berto J AU - Bouma BJ AD - Department of Cardiology, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands. FAU - Tijssen, Jan G P AU - Tijssen JGP AD - Department of Cardiology, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands. FAU - de Leeuw, Frank-Erik AU - de Leeuw FE AD - Department of Neurology, Radboudumc, Donders Institute for Brain, Cognition and Behaviour, Nijmegen, The Netherlands. FAU - de Winter, Rob J AU - de Winter RJ AD - Department of Cardiology, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands. FAU - Ten Cate, Tim J F AU - Ten Cate TJF AD - Department of Cardiology, Radboudumc, Radboud Institute for research and medical innovation, Nijmegen, The Netherlands. tim.tencate@radboudumc.nl. LA - eng PT - Journal Article DEP - 20250915 PL - Netherlands TA - Neth Heart J JT - Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation JID - 101095458 PMC - PMC12454762 OTO - NOTNLM OT - Anatomical features OT - Patent Foramen Ovale OT - Percutaneous closure OT - Stroke COIS- Conflict of interest: M.H.M. Immens, L.S. Witte, A. el Bouziani, A. Duijnhouwer, B.J. Bouma, J.G.P. Tijssen, F.-E. de Leeuw, R.J. de Winter and T.J.F. ten Cate declare that they have no competing interests. Dr. Tim ten Cate and dr. Berto Bouma are associate editors of Netherlands Heart Journal. EDAT- 2025/09/15 12:35 MHDA- 2025/09/15 12:36 PMCR- 2025/09/15 CRDT- 2025/09/15 11:23 PHST- 2025/07/28 00:00 [accepted] PHST- 2025/09/15 12:36 [medline] PHST- 2025/09/15 12:35 [pubmed] PHST- 2025/09/15 11:23 [entrez] PHST- 2025/09/15 00:00 [pmc-release] AID - 10.1007/s12471-025-01983-y [pii] AID - 1983 [pii] AID - 10.1007/s12471-025-01983-y [doi] PST - ppublish SO - Neth Heart J. 2025 Oct;33(10):313-318. doi: 10.1007/s12471-025-01983-y. Epub 2025 Sep 15. PMID- 40952628 OWN - NLM STAT- MEDLINE DCOM- 20250916 LR - 20261010 IS - 1534-6242 (Electronic) IS - 1523-3804 (Linking) VI - 27 IP - 1 DP - 2025 Sep 15 TI - Tackling the Cardio-Kidney-Metabolic Burden in Cancer. PG - 92 LID - 10.1007/s11883-025-01336-5 [doi] AB - PURPOSE OF THE REVIEW: This review aims to examine the clinical relevance of cardio-kidney-metabolic syndrome (CKMS) in oncology, highlighting its role as both a preexisting comorbidity and a consequence of cancer treatment. It aims to integrating CKMS staging into personalized cancer care. RECENT FINDINGS: CKMS is a progressive syndrome marked by dysfunction across cardiovascular, renal, and metabolic systems. Cancer therapies-particularly hormonal agents, immune checkpoint inhibitors, and chemotherapeutics-can accelerate or reveal underlying CKMS through inflammatory and metabolic pathways. Early risk stratification based on CKMS stage enables more effective monitoring, referral, and therapeutic strategies. A stage-based, multidisciplinary approach tailored to cancer type and comorbidity burden is essential for optimizing outcomes. With rising multimorbidity among cancer patients, recognizing and addressing CKMS is increasingly critical. Routine CKMS assessment in oncology offers a pathway for earlier intervention and potentially altering its course. A comprehensive, individualized care model based on CKS stage is necessary to mitigate CKMS-related complications and deliver high-quality, integrated cancer care. CI - (c) 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Nahle, Tarek AU - Nahle T AD - Division of Cardiology, Department of Medicine, Medical College of Georgia at Augusta University, Augusta, GA, 30912, USA. tnahle@augusta.edu. AD - Cardio-Oncology Program, Medical College of Georgia at Augusta University, Augusta, GA, 30912, USA. tnahle@augusta.edu. FAU - Shah, Viraj AU - Shah V AD - Division of Cardiology, Department of Medicine, Medical College of Georgia at Augusta University, Augusta, GA, 30912, USA. AD - Cardio-Oncology Program, Medical College of Georgia at Augusta University, Augusta, GA, 30912, USA. FAU - Kunhiraman, Harikrishnan Hyma AU - Kunhiraman HH AD - Division of Cardiology, Department of Medicine, Medical College of Georgia at Augusta University, Augusta, GA, 30912, USA. AD - Cardio-Oncology Program, Medical College of Georgia at Augusta University, Augusta, GA, 30912, USA. FAU - Makram, Omar M AU - Makram OM AD - Division of Cardiology, Department of Medicine, Medical College of Georgia at Augusta University, Augusta, GA, 30912, USA. AD - Cardio-Oncology Program, Medical College of Georgia at Augusta University, Augusta, GA, 30912, USA. AD - Department of Medicine, Medical College of Georgia at Augusta University, Augusta, GA, USA. FAU - Ahmed, Ola AU - Ahmed O AD - Division of Cardiology, Department of Medicine, Medical College of Georgia at Augusta University, Augusta, GA, 30912, USA. FAU - Yerraguntla, Sandeep AU - Yerraguntla S AD - Division of Cardiology, Department of Medicine, Medical College of Georgia at Augusta University, Augusta, GA, 30912, USA. FAU - Gopu, Gaurav AU - Gopu G AD - Division of Cardiology, Department of Medicine, Medical College of Georgia at Augusta University, Augusta, GA, 30912, USA. FAU - Vy, Jenny AU - Vy J AD - Division of Cardiology, Department of Medicine, Medical College of Georgia at Augusta University, Augusta, GA, 30912, USA. FAU - Singh, Shivam AU - Singh S AD - Depart of Internal Medicine, Reading Tower, Tower Health, West Reading, PA, USA. FAU - Borse, Tanvi AU - Borse T AD - Department of Internal Medicine, Parkview Health, Fort Wayne, IN, USA. FAU - Kalinsky, Kevin AU - Kalinsky K AD - Winship Cancer Institute at Emory University, Atlanta, GA, USA. FAU - Deswal, Anita AU - Deswal A AD - Department of Cardiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Sadler, Diego AU - Sadler D AD - Cardio Oncology Section, Department of Cardiovascular Medicine, Heart Vascular and Thoracic Institute, Cleveland Clinic Florida, Weston, FL, USA. FAU - Chitalia, Vipul AU - Chitalia V AD - Renal Section, Department of Medicine, Boston University School of Medicine, Boston, MA, USA. AD - Veterans Affairs Boston Healthcare System, Boston, MA, 02118, USA. AD - Institute of Medical Engineering and Sciences, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA. FAU - Weintraub, Neal L AU - Weintraub NL AD - Division of Cardiology, Department of Medicine, Medical College of Georgia at Augusta University, Augusta, GA, 30912, USA. FAU - Guha, Avirup AU - Guha A AD - Division of Cardiology, Department of Medicine, Medical College of Georgia at Augusta University, Augusta, GA, 30912, USA. AD - Cardio-Oncology Program, Medical College of Georgia at Augusta University, Augusta, GA, 30912, USA. LA - eng GR - R01 DK141016/DK/NIDDK NIH HHS/United States GR - R01 HL132325/HL/NHLBI NIH HHS/United States GR - #HT94252310158/U.S. Department of Defense/ GR - #847740/Strategically Focused Research Network/ PT - Journal Article PT - Review DEP - 20250915 PL - United States TA - Curr Atheroscler Rep JT - Current atherosclerosis reports JID - 100897685 RN - 0 (Antineoplastic Agents) SB - IM MH - Humans MH - *Neoplasms/complications/therapy/metabolism/drug therapy MH - *Metabolic Syndrome/epidemiology/therapy MH - *Cardio-Renal Syndrome/epidemiology/etiology/therapy MH - Antineoplastic Agents/adverse effects MH - Comorbidity OTO - NOTNLM OT - Cancer OT - Cancer therapy OT - Cardio-kidney-metabolic syndrome OT - Cardio-oncology OT - Metabolic syndrome COIS- Declarations. Competing Interests: K.K.: Spouse: Employee of and Stockholder in ADC Therapeutics. Consultant for Genentech/Roche, Immunomedics, Seattle Genetics, AstraZeneca, Daiichi Sankyo, Puma Biotechnology, Mersana, Menarini Silicon Biosystems, Myovant Sciences, Takeda, MerckA.G. is supported by American Heart Association-Strategically Focused Research Network Grant in Disparities in Cardio-Oncology (#847740, #863620) and Department of Defense Prostate Cancer Research Program's Physician Research Award (#HT94252310158). Human and Animal Rights and Informed Consent: This article does not contain any studies with human or animal subjects performed by any of the authors. EDAT- 2025/09/15 12:33 MHDA- 2025/09/16 18:31 CRDT- 2025/09/15 11:23 PHST- 2025/05/09 00:00 [received] PHST- 2025/08/11 00:00 [accepted] PHST- 2025/09/16 18:31 [medline] PHST- 2025/09/15 12:33 [pubmed] PHST- 2025/09/15 11:23 [entrez] AID - 10.1007/s11883-025-01336-5 [pii] AID - 10.1007/s11883-025-01336-5 [doi] PST - epublish SO - Curr Atheroscler Rep. 2025 Sep 15;27(1):92. doi: 10.1007/s11883-025-01336-5. PMID- 40952357 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260117 LR - 20260118 IS - 2666-0873 (Electronic) IS - 2666-0873 (Linking) VI - 7 IP - 7 DP - 2025 Dec TI - Cardiovascular and Oncologic Considerations in Adult Hodgkin Lymphoma: JACC: CardioOncology State-of the-Art Review. PG - 781-799 LID - S2666-0873(25)00293-5 [pii] LID - 10.1016/j.jaccao.2025.07.011 [doi] AB - Classic Hodgkin lymphoma is a highly curable lymphoma that affects primarily younger patients. The therapeutic landscape has evolved and generally consists of varying combinations of chemotherapy and immunotherapy as well as radiation in selected cases. Although most patients are cured of their lymphoma, there is a risk for late treatment-related cardiotoxicity that affects long-term survival and quality of life in this population. Careful consideration of baseline cardiac function and risk factors should be undertaken prior to proceeding with anthracycline-based therapies or thoracic radiation, as adjuvant cardiac-focused efforts may serve to mitigate the risk for cardiovascular dysfunction in this population. This review outlines the evidence supporting current recommendations for assessing baseline cardiotoxicity risk, implementing risk reduction strategies and treatment modifications, the role of multidisciplinary evaluation in high-risk patients, and strategies for long-term cardiac monitoring to minimize treatment-related cardiac morbidity and mortality. CI - Copyright (c) 2025 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Raman, Hari S AU - Raman HS AD - Harvard Medical School, Boston, Massachusetts, USA; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. FAU - Mitchell, Joshua AU - Mitchell J AD - Cardio-Oncology Center of Excellence, Washington University, St. Louis, Missouri, USA; Alvin J. Siteman Center, Washington University, St. Louis, Missouri, USA; Division of Cardiology, Department of Medicine, Washington University, St. Louis, Missouri, USA. FAU - Nohria, Anju AU - Nohria A AD - Harvard Medical School, Boston, Massachusetts, USA; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA. FAU - Upshaw, Jenica N AU - Upshaw JN AD - Harvard Medical School, Boston, Massachusetts, USA; Richard A. and Susan F. Smith Center for Outcomes Research, Division of Cardiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA. FAU - LaCasce, Ann S AU - LaCasce AS AD - Harvard Medical School, Boston, Massachusetts, USA; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. Electronic address: ann_lacasce@dfci.harvard.edu. LA - eng PT - Journal Article PT - Review DEP - 20250915 PL - United States TA - JACC CardioOncol JT - JACC. CardioOncology JID - 101761697 PMC - PMC12805397 OTO - NOTNLM OT - Hodgkin OT - anthracycline OT - heart failure OT - immune checkpoint inhibitor OT - lymphoma OT - radiation COIS- Funding Support and Author Disclosures Dr Mitchell has received research support from Abbott Laboratories and Myocardial Solutions, unrelated to this work; and has served as a consultant or an advisor to Alnylam, AstraZeneca, BridgeBio, and Pfizer, unrelated to this work. Dr Nohria has received research support from Bristol Myers Squibb, unrelated to this work; and has served as a consultant to AstraZeneca and Takeda Oncology, unrelated to this work. Dr LaCasce has received consulting fees from Genmab, Kite Pharma, and Pierre Fabre, unrelated to this work. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2025/09/15 12:32 MHDA- 2025/09/15 12:33 PMCR- 2025/09/15 CRDT- 2025/09/15 10:27 PHST- 2025/06/06 00:00 [received] PHST- 2025/07/15 00:00 [accepted] PHST- 2025/09/15 12:33 [medline] PHST- 2025/09/15 12:32 [pubmed] PHST- 2025/09/15 10:27 [entrez] PHST- 2025/09/15 00:00 [pmc-release] AID - S2666-0873(25)00293-5 [pii] AID - 10.1016/j.jaccao.2025.07.011 [doi] PST - ppublish SO - JACC CardioOncol. 2025 Dec;7(7):781-799. doi: 10.1016/j.jaccao.2025.07.011. Epub 2025 Sep 15. PMID- 40948719 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250915 LR - 20260521 IS - 2223-3652 (Print) IS - 2223-3660 (Electronic) IS - 2223-3652 (Linking) VI - 15 IP - 4 DP - 2025 Aug 30 TI - Digital clinical teaching of cardiovascular surgery supported by precision imaging and 3D printing technology: a randomized parallel-controlled trial. PG - 714-725 LID - 10.21037/cdt-2025-98 [doi] AB - BACKGROUND: Cardiovascular surgery demands deep knowledge of the heart's intricate three-dimensional (3D) anatomy, but current teaching methods do not adequately develop students' spatial skills. Advances in precise imaging and 3D printing offer transformative potential for clinical education. In this study, taking the teaching of cardiovascular surgery as an example, we aimed to integrate precision imaging and 3D printing technologies with case-based learning (CBL), problem-based learning (PBL), and team-based learning (TBL). Our objective was to explore digital teaching approaches in clinical surgery and address the limitations of current learning models in spatial visualization training. METHODS: This study employed a parallel design randomized controlled trial (RCT) methodology. A total of 80 clinical medicine students from the 2020 cohort, currently undertaking their practicum in the Department of Cardiac Great Vascular Surgery at The Second Hospital of Hebei Medical University, were randomly assigned into two groups: a digital teaching group and a case-, problem-, and team-based learning (C-P-TBL) teaching group, each comprising 40 students. The digital teaching group utilized an innovative digital teaching approach, enhanced by precision imaging and 3D printing technology. In contrast, the C-P-TBL teaching group employed an integrated teaching model combining CBL, PBL, and TBL. The two groups were compared via theoretical and skills assessment, along with the analysis of teaching quality questionnaires and teaching satisfaction metrics, so as to evaluate the incremental benefits conferred by digital tools within the existing teaching framework. RESULTS: The digital teaching group demonstrated superior performance compared to the C-P-TBL teaching group, as evidenced by higher scores in theoretical knowledge (86.28+/-10.756 vs. 80.25+/-9.440), clinical skills (87.90+/-7.530 vs. 83.05+/-7.473), and overall assessment (86.93+/-8.131 vs. 81.37+/-7.716). Based on the results of the teaching quality questionnaires, the digital teaching group demonstrated a statistically significant superiority over the C-P-TBL teaching group in several areas: self-learning ability, comprehension and application of theoretical knowledge, problem discovery and analysis skills, spatial imagination capability, and overall self-comprehensive ability. CONCLUSIONS: The integration of digital technologies, exemplified by precision imaging and 3D printing, with CBL, PBL, and TBL methodologies, has been shown to significantly enhance the spatial visualization skills of medical students. This approach not only improves their theoretical understanding and technical proficiency, but also leads to higher self-assessment of abilities and increased satisfaction with the teaching process. Consequently, this pedagogical strategy merits consideration for widespread implementation in the clinical education of cardiovascular surgery. CI - Copyright (c) 2025 AME Publishing Company. All rights reserved. FAU - Zhao, Tengyue AU - Zhao T AD - Department of Cardiovascular Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang, China. AD - Department of Physiology, Hebei Medical University, Shijiazhuang, China. FAU - Wang, Yuanyuan AU - Wang Y AD - Office of Postgraduate Education, The Second Hospital of Hebei Medical University, Shijiazhuang, China. FAU - Wang, Bingjie AU - Wang B AD - Department of Anesthesiology, The Third Hospital of Hebei Medical University, Shijiazhuang, China. FAU - Liu, Yu AU - Liu Y AD - Department of Cardiovascular Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang, China. FAU - Chen, Ziying AU - Chen Z AD - Department of Cardiovascular Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang, China. FAU - Wu, Yuming AU - Wu Y AD - Department of Physiology, Hebei Medical University, Shijiazhuang, China. LA - eng PT - Journal Article DEP - 20250828 PL - China TA - Cardiovasc Diagn Ther JT - Cardiovascular diagnosis and therapy JID - 101601613 CIN - Cardiovasc Diagn Ther. 2026 Apr 24;16(2):14. doi: 10.21037/cdt-2025-aw-546. PMID: 42164745 PMC - PMC12432650 OTO - NOTNLM OT - Precision imaging three-dimensional printing (precision imaging 3D printing) OT - cardiovascular surgery OT - clinical teaching OT - digitalization COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://cdt.amegroups.com/article/view/10.21037/cdt-2025-98/coif). The authors have no conflicts of interest to declare. EDAT- 2025/09/15 12:33 MHDA- 2025/09/15 12:34 PMCR- 2025/08/30 CRDT- 2025/09/15 07:36 PHST- 2025/02/22 00:00 [received] PHST- 2025/05/26 00:00 [accepted] PHST- 2025/09/15 12:34 [medline] PHST- 2025/09/15 12:33 [pubmed] PHST- 2025/09/15 07:36 [entrez] PHST- 2025/08/30 00:00 [pmc-release] AID - cdt-15-04-714 [pii] AID - 10.21037/cdt-2025-98 [doi] PST - ppublish SO - Cardiovasc Diagn Ther. 2025 Aug 30;15(4):714-725. doi: 10.21037/cdt-2025-98. Epub 2025 Aug 28. PMID- 40947800 OWN - NLM STAT- MEDLINE DCOM- 20260504 LR - 20260504 IS - 0301-1526 (Print) IS - 0301-1526 (Linking) VI - 55 IP - 3 DP - 2026 May TI - The Future of Vascular Medicine in Europe - Insights from the ESVM Survey on Training Experiences and Career Perspectives. PG - 220-228 LID - 10.1024/0301-1526/a001221 [doi] AB - Background: Vascular medicine/angiology plays a crucial role in managing vascular diseases, yet its recognition, training, and practice vary across Europe. To understand these disparities, the European Society for Vascular Medicine (ESVM) conducted a survey among young trainees to assess their attitudes and perception towards vascular medicine training. Methods: A cross-sectional survey was distributed among trainees and young specialists from European countries, including nations with and without vascular medicine as a recognized specialty. The survey was published on the ESVM website and shared through national vascular medicine societies. Participants provided insights into their training experiences, opinions of the specialty, and priorities for improvement. Statistical analysis compared responses based on specialty recognition. Findings: Among 210 respondents, 36.2% (n=76) were from countries without formal specialty recognition. Training was more structured in countries with a recognized specialty (p<.001). Multidisciplinary team meetings were deemed critical by 98.1% but were more common in countries with a recognized specialty (p=.003). Overall, 80.5% (n=169) expressed interest in training abroad. Core vascular domains were well-covered, while areas like lymphatic and microvascular diseases lacked sufficient training both in countries where the specialty was recognized and where it was not. Respondents from countries with a recognized specialty rated their training significantly higher (p=.001). Despite challenges, 85.2% (n=179) would choose the specialty again, and 90.4% (n=190) supported a unified European certification. Interpretation: These findings highlight the need for a harmonized training framework in Europe ensuring a shared foundational curriculum in vascular medicine while enhancing professional mobility and improving patient care across the whole spectrum of vascular diseases. FAU - Buso, Giacomo AU - Buso G AUID- ORCID: 0000-0002-5645-9553 AD - Department of Clinical and Experimental Sciences, Division of Internal Medicine, ASST Spedali Civili Brescia, University of Brescia, Italy. AD - University of Lausanne, Switzerland. FAU - Hersant, Jeanne AU - Hersant J AUID- ORCID: 0000-0002-7126-0534 AD - Department of Vascular Medicine, University Hospital of Angers, France. FAU - Keller, Sanjiv AU - Keller S AUID- ORCID: 0009-0000-5567-9290 AD - Angiology Division, Heart and Vessel Department, Lausanne University Hospital, University of Lausanne, Switzerland. FAU - Kalaja, Igli AU - Kalaja I AUID- ORCID: 0000-0003-1082-5578 AD - Department for Cardiology III - Angiology, University Medical Centre of the Johannes Gutenberg-University, Mainz, Germany. FAU - Bigolin, Paola AU - Bigolin P AUID- ORCID: 0000-0002-2582-5119 AD - UOC Angiologia, Azienda ULSS 2 Marca Trevigiana, Italy. FAU - Dzupina, Andrej AU - Dzupina A AD - Department of Angiology, Comenius University and National Institute of Cardiovascular Diseases, Bratislava, Slovakia. FAU - Gary, Thomas AU - Gary T AD - Division of Angiology, Department of Internal Medicine, Medical University of Graz, Austria. FAU - Boc, Vinko AU - Boc V AUID- ORCID: 0000-0002-2171-7794 AD - Department of Vascular Diseases, University Medical Centre Ljubljana, Slovenia. AD - Department of Internal Medicine, Faculty of Medicine, University of Ljubljana, Slovenia. FAU - Brodmann, Marianne AU - Brodmann M AD - Division of Angiology, Department of Internal Medicine, Medical University of Graz, Austria. FAU - Heiss, Christian AU - Heiss C AUID- ORCID: 0000-0002-3212-8995 AD - Vascular Medicine Department, Surrey and Sussex Healthcare NHS Trust, Redhill, UK. AD - Discipline of Clinical Sciences, Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK. FAU - Madaric, Juraj AU - Madaric J AUID- ORCID: 0000-0003-1326-2336 AD - Department of Angiology, Comenius University and National Institute of Cardiovascular Diseases, Bratislava, Slovakia. FAU - Visona, Adriana AU - Visona A AD - ORAS Ospedale Riabilitativo di Alta Specializzazione, Treviso, Italy. FAU - Mazzolai, Lucia AU - Mazzolai L AD - Angiology Division, Heart and Vessel Department, Lausanne University Hospital, University of Lausanne, Switzerland. CN - ESVM-European Society of Vascular Medicine Board, and Presidents of European National Societies of Vascular Medicine/Angiology LA - eng PT - Journal Article DEP - 20250915 PL - Switzerland TA - Vasa JT - VASA. Zeitschrift fur Gefasskrankheiten JID - 0317051 SB - IM MH - Humans MH - Europe MH - Cross-Sectional Studies MH - *Attitude of Health Personnel MH - *Career Choice MH - *Education, Medical, Graduate/trends MH - Curriculum MH - *Vascular Diseases/therapy/diagnosis MH - Health Knowledge, Attitudes, Practice MH - Male MH - Forecasting MH - Female MH - Surveys and Questionnaires MH - *Cardiology/education/trends MH - Adult OTO - NOTNLM OT - European survey OT - Vascular medicine OT - medical education OT - specialty recognition EDAT- 2025/09/15 06:32 MHDA- 2026/05/04 06:33 CRDT- 2025/09/15 02:44 PHST- 2026/05/04 06:33 [medline] PHST- 2025/09/15 06:32 [pubmed] PHST- 2025/09/15 02:44 [entrez] AID - 10.1024/0301-1526/a001221 [doi] PST - ppublish SO - Vasa. 2026 May;55(3):220-228. doi: 10.1024/0301-1526/a001221. Epub 2025 Sep 15. PMID- 40947357 OWN - NLM STAT- MEDLINE DCOM- 20251102 LR - 20251102 IS - 1873-2623 (Electronic) IS - 0041-1345 (Linking) VI - 57 IP - 9 DP - 2025 Nov TI - Living Donor Liver Transplantation in Patients With Portal Vein Thrombosis: A Single-Center Experience. PG - 1808-1811 LID - S0041-1345(25)00382-3 [pii] LID - 10.1016/j.transproceed.2025.08.011 [doi] AB - BACKGROUND: Portal vein thrombosis (PVT) is a significant vascular complication in liver transplant candidates, necessitating modifications in surgical techniques and increasing the risk of postoperative complications. This study aimed to evaluate postoperative thrombotic complications, the need for reoperation, survival, and mortality rates after living donor liver transplantation (LDLT) in patients with preoperative PVT. METHODS: Forty-nine patients diagnosed with preoperative PVT undergoing LDLT between July 2021 and August 2024 at our center were retrospectively reviewed. Patients were classified according to the Yerdel classification. Surgical techniques, portal vein reconstruction, associated diseases, MELD/PELD scores, postoperative PVT occurrence, the need for reoperation, and survival data were analyzed. RESULTS: Postoperative PVT developed in 6 patients (12.2%); 3 of these patients (6.1%) required reoperation. Overall, mortality occurred in 13 patients (26.5%); 3 cases were due to non-PVT-related reasons (sepsis following ERCP/PTC or sudden cardiac arrest). The PVT-related mortality rate was 20.4% (10 patients). Mortality was observed in 4 (66.7%) patients with postoperative PVT. Among 8 patients with Yerdel Grade 3-4 PVT, postoperative PVT occurred in 2 patients (25%). Thrombosis occurred in 2 of 6 patients (33.3%) who underwent graft reconstruction; 1 required reoperation. Portal flow was successfully restored in 83.3% of reconstructed cases. Patients developing postoperative PVT had a higher mean MELD/PELD score (22.5 vs. 19.2), an average age of 48.8 years, and equal gender distribution. The mean follow-up period was 14.2 months overall and 7.7 months in patients with postoperative PVT. Comorbidities (diabetes, hypertension, cardiac, or pulmonary pathology) were present in approximately 50% of patients with postoperative PVT and 62% of those who died. The most common preoperative diagnoses were cryptogenic cirrhosis (22.4%), NASH (18.3%), and HBV infection (16.3%). CONCLUSION: Preoperative PVT significantly correlates with postoperative PVT development and mortality following LDLT. Advanced Yerdel stages, high MELD/PELD scores, and the necessity for portal vein reconstruction increase this risk. Early diagnosis, close imaging follow-up, and proper anticoagulation management postoperatively are crucial. Our findings highlight the importance of a multidisciplinary approach in surgical planning and lay the groundwork for prospective, multi-center studies. CI - Copyright (c) 2025 Elsevier Inc. All rights reserved. FAU - Sahin, Emrah AU - Sahin E AD - Department of General Surgery, Istanbul Aydin University, Istanbul, Turkiye. FAU - Tuncer, Adem AU - Tuncer A AD - Department of General Surgery, Istanbul Aydin University, Istanbul, Turkiye. Electronic address: ademtuncer89@hotmail.com. FAU - Topcu, Feyza Sonmez AU - Topcu FS AD - Radiology Department, Istanbul Aydin University, Istanbul, Turkiye. FAU - Ersan, Veysel AU - Ersan V AD - Department of General Surgery, Istanbul Aydin University, Istanbul, Turkiye. FAU - Civan, Hasret Ayyildiz AU - Civan HA AD - Department of Pediatric Gastroenterology, Istanbul Aydin University, Istanbul, Turkiye. FAU - Dirican, Abuzer AU - Dirican A AD - Department of General Surgery, Istanbul Aydin University, Istanbul, Turkiye. FAU - Unal, Bulent AU - Unal B AD - Department of General Surgery, Istanbul Aydin University, Istanbul, Turkiye. LA - eng PT - Journal Article DEP - 20250914 PL - United States TA - Transplant Proc JT - Transplantation proceedings JID - 0243532 SB - IM MH - Humans MH - *Liver Transplantation/adverse effects/methods/mortality MH - *Portal Vein/surgery MH - Male MH - Female MH - *Living Donors MH - Middle Aged MH - *Venous Thrombosis/surgery/mortality/etiology MH - Retrospective Studies MH - Adult MH - *Postoperative Complications/etiology/mortality MH - Reoperation/statistics & numerical data MH - Treatment Outcome COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/09/15 00:32 MHDA- 2025/11/03 00:26 CRDT- 2025/09/14 21:53 PHST- 2025/04/01 00:00 [received] PHST- 2025/08/21 00:00 [accepted] PHST- 2025/11/03 00:26 [medline] PHST- 2025/09/15 00:32 [pubmed] PHST- 2025/09/14 21:53 [entrez] AID - S0041-1345(25)00382-3 [pii] AID - 10.1016/j.transproceed.2025.08.011 [doi] PST - ppublish SO - Transplant Proc. 2025 Nov;57(9):1808-1811. doi: 10.1016/j.transproceed.2025.08.011. Epub 2025 Sep 14. PMID- 40945713 OWN - NLM STAT- MEDLINE DCOM- 20260211 LR - 20260211 IS - 1931-3543 (Electronic) IS - 0012-3692 (Linking) VI - 169 IP - 2 DP - 2026 Feb TI - In Situ Cardiac Arrest Simulation. PG - 478-485 LID - S0012-3692(25)05194-3 [pii] LID - 10.1016/j.chest.2025.09.003 [doi] AB - Over 300,000 patients experience in-hospital cardiac arrest in the United States each year, resulting in substantial morbidity, mortality, and loss of disability-adjusted life years. Although survival after in-hospital cardiac arrest has improved over the past 2 decades, outcomes remain poor and many initial survivors of in-hospital cardiac arrest are discharged with substantial disability. Across the United States, risk-standardized survival after in-hospital cardiac arrest varies significantly, reflecting potential for process improvement. Improving processes of care and outcomes after in-hospital cardiac arrest is a priority of national organizations such as the Joint Commission, the American Hospital Association, and other professional bodies. Nevertheless, best approaches to improving in-hospital cardiac arrest care have not been well defined. Performance of regular multidisciplinary in situ cardiac arrest simulations has been identified as a trait common to best performing hospitals with respect to in-hospital cardiac arrest outcomes. However, no clear approach to establishing an in situ cardiac arrest program has been established. In this How I Do It installment, we describe the creation of a robust and sustainable in situ cardiac program including securing sponsorship and assembling a multidisciplinary team, acquiring and maintaining equipment and resources, execution of realistic simulations, and facilitating structured debriefings and continuous quality improvement. Our framework and ready-to-use tools will enable hospitals to implement sustainable in situ in-hospital cardiac arrest simulation programs and drive measurable improvements in care and outcomes. CI - Copyright (c) 2025 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved. FAU - Moskowitz, Ari AU - Moskowitz A AD - Division of Critical Care Medicine, Montefiore Medical Center, the Bronx, NY. Electronic address: Amoskowitz@montefiore.org. FAU - Paul, Anil AU - Paul A AD - Departments of Nursing Education, Montefiore Medical Center, the Bronx, NY. FAU - Ferguson, Nadia AU - Ferguson N AD - Departments of Pharmacy, Montefiore Medical Center, the Bronx, NY. FAU - Dormer, Leighton AU - Dormer L AD - Departments of Respiratory Therapy, Montefiore Medical Center, the Bronx, NY. FAU - Bangar, Maneesha AU - Bangar M AD - Division of Critical Care Medicine, Montefiore Medical Center, the Bronx, NY. LA - eng PT - Journal Article PT - Review DEP - 20250911 PL - United States TA - Chest JT - Chest JID - 0231335 SB - IM MH - Humans MH - *Heart Arrest/therapy/mortality MH - *Cardiopulmonary Resuscitation/education/methods MH - United States/epidemiology MH - Quality Improvement MH - *Simulation Training/methods OTO - NOTNLM OT - cardiac arrest OT - in situ simulation OT - latent safety threat OT - simulation COIS- Financial/Nonfinancial Disclosures The authors have reported to CHEST the following: A. M. is a volunteer member of the International Liaison Committee on Resuscitation (ILCOR) Advanced Life Support Task Force and the American Heart Association Post-Cardiac Arrest Care Guideline Writing Committee. None declared (A. P., N. F., L. D., M. B.). EDAT- 2025/09/14 00:29 MHDA- 2026/02/12 00:47 CRDT- 2025/09/13 19:15 PHST- 2025/06/23 00:00 [received] PHST- 2025/08/22 00:00 [revised] PHST- 2025/09/03 00:00 [accepted] PHST- 2026/02/12 00:47 [medline] PHST- 2025/09/14 00:29 [pubmed] PHST- 2025/09/13 19:15 [entrez] AID - S0012-3692(25)05194-3 [pii] AID - 10.1016/j.chest.2025.09.003 [doi] PST - ppublish SO - Chest. 2026 Feb;169(2):478-485. doi: 10.1016/j.chest.2025.09.003. Epub 2025 Sep 11. PMID- 40945276 OWN - NLM STAT- MEDLINE DCOM- 20251020 LR - 20260206 IS - 1878-7452 (Electronic) IS - 1878-7452 (Linking) VI - 82 IP - 11 DP - 2025 Nov TI - The Effect of Surgeon Workload on Intraoperative Communication Qualities: An Observational Study Using Physiologically Assessed Workload During Cardiac Surgery. PG - 103697 LID - S1931-7204(25)00278-8 [pii] LID - 10.1016/j.jsurg.2025.103697 [doi] AB - OBJECTIVES: To examine how intraoperative communication qualities differ during periods of high and low workload to identify possible gaps in surgical training. DESIGN: A prospective observational study. Over 100 hours of surgical procedures were recorded and all communication between the surgeon, anaesthesia team and perfusionist transcribed. Surgeons' heart rate variability was measured to determine periods of high and low workload. Communication quality standards were assessed across workload conditions, including exchange loop-types, substantive responses, directed exchanges and communication errors. SETTING: A cardio-thoracic surgery department at a university medical centre in the Netherlands. PARTICIPANTS: Twenty four operating room teams during elective adult open-heart cardiac surgeries. RESULTS: Compared to periods of low workload, surgeons were significantly less likely to respond in open loop (i.e. no verbal response) (IRR = 0.75, 95% CI: 0.63-0.88) and more likely to respond in call-back during periods of high workload (IRR = 1.14, 95% CI: 1.01-1.29). Surgeons were also less likely to give a substantive response during high workload (IRR = 1.23, 95% CI: 1.04-1.46) and less likely to address others by their name (IRR = 0.84, 95% CI: 0.71-0.99). Other team members addressed the surgeon less frequently when the surgeon was experiencing high workload (IRR = 0.64, 95% CI: 0.53-0.79). They were also more likely to address the surgeon by name (IRR = 0.74, 95% CI: 0.56-0.99) and reply substantively during high workload (IRR = 1.50, 95% CI: 1.12-2.02). CONCLUSIONS: Intraoperative communication qualities varied across workload levels, with less directed and less substantive communication exchanges from the surgeon during high workload. Other team members appeared to adapt their communication behaviours accordingly, which contribute to the resilience in OR teams during high stress situations. These results highlight the importance of online measurements of workload for the assessment and training non-technical skills in the OR. CI - Copyright (c) 2025 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Wietzorrek, Liam AU - Wietzorrek L AD - Department of Cardiothoracic Surgery, Heart Centre, University of Groningen, University Medical Centre Groningen, Groningen, 9700 RB, the Netherlands; Department of Artificial Intelligence, Bernoulli Institute of Mathematics, Computer Science and Artificial Intelligence, University of Groningen, Groningen, 9747 AG, the Netherlands. Electronic address: L.K.Wietzorrek@umcg.nl. FAU - Craenen, Eugenie AU - Craenen E AD - Department of Anaesthesiology, University of Groningen, University Medical Centre Groningen, Groningen, 9700 RB, the Netherlands. FAU - van Boven, Indy AU - van Boven I AD - Department of Artificial Intelligence, Bernoulli Institute of Mathematics, Computer Science and Artificial Intelligence, University of Groningen, Groningen, 9747 AG, the Netherlands. FAU - Mariani, Massimo A AU - Mariani MA AD - Department of Cardiothoracic Surgery, Heart Centre, University of Groningen, University Medical Centre Groningen, Groningen, 9700 RB, the Netherlands. FAU - Cnossen, Fokie AU - Cnossen F AD - Department of Artificial Intelligence, Bernoulli Institute of Mathematics, Computer Science and Artificial Intelligence, University of Groningen, Groningen, 9747 AG, the Netherlands. LA - eng PT - Journal Article PT - Observational Study DEP - 20250911 PL - United States TA - J Surg Educ JT - Journal of surgical education JID - 101303204 SB - IM MH - *Workload MH - Humans MH - Prospective Studies MH - *Cardiac Surgical Procedures/education MH - *Communication MH - Male MH - Netherlands MH - Female MH - *Surgeons MH - Adult MH - Operating Rooms MH - Patient Care Team OTO - NOTNLM OT - cardiac surgery OT - cognitive workload OT - heart-rate variability OT - intraoperative communication quality OT - stress OT - teamwork EDAT- 2025/09/14 00:29 MHDA- 2025/10/21 00:28 CRDT- 2025/09/13 18:07 PHST- 2025/06/18 00:00 [received] PHST- 2025/08/13 00:00 [accepted] PHST- 2025/10/21 00:28 [medline] PHST- 2025/09/14 00:29 [pubmed] PHST- 2025/09/13 18:07 [entrez] AID - S1931-7204(25)00278-8 [pii] AID - 10.1016/j.jsurg.2025.103697 [doi] PST - ppublish SO - J Surg Educ. 2025 Nov;82(11):103697. doi: 10.1016/j.jsurg.2025.103697. Epub 2025 Sep 11. PMID- 40944089 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250915 LR - 20260925 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 14 IP - 17 DP - 2025 Sep 8 TI - The Importance of Dental Treatment in Patients Before Radiotherapy, Chemotherapy, and Cardiac Surgeries: A Narrative Review. LID - 10.3390/jcm14176330 [doi] LID - 6330 AB - Oncological patients or the individuals scheduled for cardiovascular surgeries are at risk of both oral and systemic complications when existing dental pathologies are not addressed before these therapies. This narrative review explores the current literature on the role of pre-treatment dental care in reducing unfavorable outcomes and promoting treatment efficacy in medically compromised patients. The data show that early dental intervention, particularly prior to head and neck radiotherapy, considerably reduces the risk of osteoradionecrosis, rampant radiation caries, and xerostomia. Chemotherapy-associated mucositis, infections, and microbial imbalance are similarly worsened by untreated oral disease but may be managed through early sanitation and hygiene reinforcement. In cardiac patients, conditions such as apical periodontitis and periodontitis may lead to bacteremia, infective endocarditis, or prosthetic valve infections, highlighting the systemic relevance of oral health. Tooth extractions, restorative treatment of carious lesions, and control of active oral infections performed before systemic therapy can reduce complication rates, improve treatment continuity, and enhance patients' quality of life. Integrating comprehensive dental assessment into routine pre-treatment planning allows early identification of oral health risks and supports a multidisciplinary approach that optimizes overall clinical outcomes. FAU - Mostafavi, Seyedamirreza AU - Mostafavi S AD - Division of Medical Sciences in Zabrze, Doctoral's School, Medical University of Silesia in Katowice, 15 Poniatowskiego Street, 40-055 Katowice, Poland. FAU - Wyszynska, Magdalena AU - Wyszynska M AUID- ORCID: 0000-0003-0483-4902 AD - Department of Dental Materials, Division of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, 15 Poniatowskiego Street, 40-055 Katowice, Poland. FAU - Skucha-Nowak, Malgorzata AU - Skucha-Nowak M AUID- ORCID: 0000-0003-0584-968X AD - Department of Dental Propedeutics, Division of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, 15 Poniatowskiego Street, 40-055 Katowice, Poland. LA - eng GR - no number/Medical University of Silesia/ PT - Journal Article PT - Review DEP - 20250908 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC12429391 OTO - NOTNLM OT - cardiac surgical procedures OT - chemotherapy OT - chemotherapy adverse effects OT - dental care OT - oral manifestation OT - radiotherapy OT - radiotherapy adverse effects COIS- The authors declare no conflicts of interest. EDAT- 2025/09/13 06:31 MHDA- 2025/09/13 06:32 PMCR- 2025/09/08 CRDT- 2025/09/13 01:19 PHST- 2025/07/02 00:00 [received] PHST- 2025/08/20 00:00 [revised] PHST- 2025/08/29 00:00 [accepted] PHST- 2025/09/13 06:32 [medline] PHST- 2025/09/13 06:31 [pubmed] PHST- 2025/09/13 01:19 [entrez] PHST- 2025/09/08 00:00 [pmc-release] AID - jcm14176330 [pii] AID - jcm-14-06330 [pii] AID - 10.3390/jcm14176330 [doi] PST - epublish SO - J Clin Med. 2025 Sep 8;14(17):6330. doi: 10.3390/jcm14176330. PMID- 40941741 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250915 LR - 20250916 IS - 2075-4418 (Print) IS - 2075-4418 (Electronic) IS - 2075-4418 (Linking) VI - 15 IP - 17 DP - 2025 Sep 5 TI - A Patient Presenting with Joint Deformities and ST-Elevation Myocardial Infarction. LID - 10.3390/diagnostics15172254 [doi] LID - 2254 AB - A 62-year-old man presented with ST-elevation myocardial infarction and advanced tophaceous gout, despite long-term urate-lowering therapy. His history included chronic kidney disease, hypertension, heart failure, and atrial fibrillation. Examination revealed severe joint deformities with multiple tophi. Coronary angiography showed multivessel disease with critical right coronary artery stenosis, treated with primary percutaneous coronary intervention. Following a Heart Team consultation, the patient was bridged with cangrelor and underwent urgent hybrid coronary artery bypass grafting and left atrial appendage occlusion. This case highlights the systemic burden of treatment-refractory gout, with progressive cardiovascular and renal complications. Tophaceous gout represents a distinct, high-risk phenotype associated with increased mortality and reduced quality of life. Despite standard therapies, this patient experienced continued disease progression, prompting referral for advanced treatment with pegloticase and canakinumab. Multidisciplinary care and personalized strategies are essential in managing severe, refractory gout with multi-organ involvement. FAU - Dabrowski, Emil J AU - Dabrowski EJ AUID- ORCID: 0000-0001-7598-1913 AD - Department of Invasive Cardiology, Medical University of Bialystok, 15-089 Bialystok, Poland. FAU - Kozlowska, Wiktoria U AU - Kozlowska WU AD - Department of Invasive Cardiology, Medical University of Bialystok, 15-089 Bialystok, Poland. FAU - Lipska, Patrycja O AU - Lipska PO AD - Department of Invasive Cardiology, Medical University of Bialystok, 15-089 Bialystok, Poland. FAU - Kozuch, Marcin AU - Kozuch M AUID- ORCID: 0000-0002-1430-7455 AD - Department of Invasive Cardiology, Medical University of Bialystok, 15-089 Bialystok, Poland. FAU - Dobrzycki, Slawomir AU - Dobrzycki S AD - Department of Invasive Cardiology, Medical University of Bialystok, 15-089 Bialystok, Poland. LA - eng GR - B.SUB.25.535/Medical University of Bialystok/ GR - B.SUB.25.504/Medical University of Bialystok/ PT - Journal Article DEP - 20250905 PL - Switzerland TA - Diagnostics (Basel) JT - Diagnostics (Basel, Switzerland) JID - 101658402 PMC - PMC12427831 OTO - NOTNLM OT - coronary artery disease OT - gout OT - myocardial infarction COIS- The authors declare no conflict of interest. EDAT- 2025/09/13 06:34 MHDA- 2025/09/13 06:35 PMCR- 2025/09/05 CRDT- 2025/09/13 01:06 PHST- 2025/07/22 00:00 [received] PHST- 2025/08/21 00:00 [revised] PHST- 2025/09/03 00:00 [accepted] PHST- 2025/09/13 06:35 [medline] PHST- 2025/09/13 06:34 [pubmed] PHST- 2025/09/13 01:06 [entrez] PHST- 2025/09/05 00:00 [pmc-release] AID - diagnostics15172254 [pii] AID - diagnostics-15-02254 [pii] AID - 10.3390/diagnostics15172254 [doi] PST - epublish SO - Diagnostics (Basel). 2025 Sep 5;15(17):2254. doi: 10.3390/diagnostics15172254. PMID- 40940874 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250915 LR - 20250916 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 17 IP - 17 DP - 2025 Aug 26 TI - Determining Risk Factors Associated with Cardiovascular Complications in Patients with Acute Leukemia: A Systematic Review. LID - 10.3390/cancers17172777 [doi] LID - 2777 AB - BACKGROUND: Patients with acute leukemia (AL) are at heightened risk of cardiovascular complications due to both disease-related and treatment-related factors. These complications include heart failure, arrhythmias, myocardial infarction, and thromboembolic events which may significantly impact morbidity and mortality. OBJECTIVE: To identify the risk factors contributing to cardiovascular complications in patients with acute leukemia. METHODS: This systematic review was conducted according to the PRISMA reporting guideline. Multiple databases including PubMed, Scopus, IEEE Xplore, the Cochrane Library, Web of Science, ProQuest, and Google Scholar were searched for studies published between 2020 and 2024. Eligible studies included those analyzing cardiovascular risk factors in AL patients across various subtypes and treatment stages. A total of 75 studies were included following rigorous screening and critical appraisal using tools appropriate for different study designs. RESULTS: The results showed that cardiovascular complications in AL patients are multifactorial including demographic factors (e.g., age, sex, BMI), comorbidities (e.g., hypertension, diabetes, dyslipidemia), treatment exposures (e.g., anthracyclines, tyrosine kinase inhibitors, hematopoietic stem cell transplantation, radiation), and genetic predispositions (e.g., somatic and germline variants). Cardiac biomarkers (e.g., troponins, BNP), imaging (strain echocardiography), and electrocardiogram (ECG) abnormalities were key factors in detecting early or subclinical damage. Complications occurred both during and years after treatment, especially in childhood and long-term survivors. CONCLUSIONS: Cardiovascular complications are prevalent, and serious consequences in AL patients necessitate a personalized, multidisciplinary approach to risk stratification and monitoring. Considering clinical, genetic, and biomarker data can improve early detection and preventive strategies, ultimately enhancing patient outcomes. FAU - Abasi, Arezoo AU - Abasi A AD - Student Research Committee, Iran University of Medical Sciences, Tehran 14496-14535, Iran. FAU - Ayatollahi, Haleh AU - Ayatollahi H AD - Health Management and Economics Research Center, Health Management Research Institute, Iran University of Medical Sciences, Tehran 19967-13883, Iran. FAU - Rad, Soroush AU - Rad S AD - Hematology, Oncology and Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology, and Cell Therapy, Tehran University of Medical Sciences, Tehran 14117-13135, Iran. FAU - Hajahmadipoor Rafsanjani, Marjan AU - Hajahmadipoor Rafsanjani M AD - Cardiovascular Department, Rasoul Akram General Hospital Iran University of Medical Sciences, Tehran 14456-13131, Iran. LA - eng PT - Journal Article PT - Review DEP - 20250826 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC12427311 OTO - NOTNLM OT - acute leukemia OT - cardio-oncology OT - cardiotoxicity OT - cardiovascular complications COIS- The authors declare no conflicts of interest. EDAT- 2025/09/13 06:34 MHDA- 2025/09/13 06:35 PMCR- 2025/08/26 CRDT- 2025/09/13 01:02 PHST- 2025/07/09 00:00 [received] PHST- 2025/08/18 00:00 [revised] PHST- 2025/08/22 00:00 [accepted] PHST- 2025/09/13 06:35 [medline] PHST- 2025/09/13 06:34 [pubmed] PHST- 2025/09/13 01:02 [entrez] PHST- 2025/08/26 00:00 [pmc-release] AID - cancers17172777 [pii] AID - cancers-17-02777 [pii] AID - 10.3390/cancers17172777 [doi] PST - epublish SO - Cancers (Basel). 2025 Aug 26;17(17):2777. doi: 10.3390/cancers17172777. PMID- 40938219 OWN - NLM STAT- MEDLINE DCOM- 20251126 LR - 20251216 IS - 1827-1928 (Electronic) IS - 0022-4707 (Linking) VI - 65 IP - 12 DP - 2025 Dec TI - Wearable technology in rehabilitation: assessing the impact of the Apple watch on physical activity and cardiovascular health: a scoping review. PG - 1660-1669 LID - 10.23736/S0022-4707.25.16874-6 [doi] AB - INTRODUCTION: The Apple Watch is increasingly used in rehabilitation to monitor physical activity, cardiovascular health, and other physiological parameters. This review evaluates its effectiveness and accuracy in various rehabilitation settings, examining its potential to enhance patient adherence and clinical outcomes. EVIDENCE ACQUISITION: A comprehensive search was conducted across databases including MEDLINE, Cochrane Central, Scopus, PEDro, and Web of Science, alongside grey literature. Studies were included based on the PCC criteria (Population, Concept, Context), focusing on the use of the Apple Watch in rehabilitation programs. Bias risk was assessed using RoB 2 for RCTs and ROBINS-I for non-randomized studies. EVIDENCE SYNTHESIS: Five studies were reviewed. The Apple Watch showed potential in improving physical activity levels and functional outcomes, particularly when combined with behavioral interventions. It demonstrated effectiveness in detecting atrial fibrillation in large-scale screening but presented variability in heart rate and energy expenditure accuracy, especially during high-intensity activities. The studies highlighted that integrating cognitive support with the device enhances adherence and health outcomes. However, limitations in measurement accuracy and the need for hybrid monitoring approaches were noted. CONCLUSIONS: The Apple Watch is a valuable tool in rehabilitation when used alongside behavioral support and validated clinical methods. Its effectiveness is enhanced when integrated into a multidisciplinary approach, but its limitations in accuracy necessitate further calibration and hybrid use with traditional tools. Future research should focus on long-term impacts and algorithm improvements to optimize its clinical utility in diverse rehabilitation contexts. FAU - Tedeschi, Roberto AU - Tedeschi R AD - Private Practitioner, Bologna, Italy - roberto.tedeschi2@unibo.it. FAU - Giorgi, Federica AU - Giorgi F AD - Unit of Pediatric Physical Medicine and Rehabilitation, IRCCS Institute of Neurological Sciences, Bologna, Italy. FAU - Ricci, Vincenzo AU - Ricci V AD - Unit of Physical and Rehabilitation Medicine, ASST Fatebenefratelli-Sacco, Luigi Sacco University Hospital, Milan, Italy. FAU - Vita, Fabio AU - Vita F AD - IRCCS Rizzoli Orthopedic Institute, First Orthopedics and Traumatology Clinic, Bologna, Italy. FAU - Donati, Danilo AU - Donati D AD - Unit of Physical Therapy and Rehabilitation, Policlinico di Modena, Modena, Italy. AD - Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy. LA - eng PT - Journal Article PT - Scoping Review DEP - 20250912 PL - Italy TA - J Sports Med Phys Fitness JT - The Journal of sports medicine and physical fitness JID - 0376337 SB - IM MH - Humans MH - *Exercise/physiology MH - *Wearable Electronic Devices MH - Heart Rate MH - Atrial Fibrillation/diagnosis MH - *Fitness Trackers MH - Energy Metabolism MH - Patient Compliance EDAT- 2025/09/12 12:30 MHDA- 2025/11/26 06:29 CRDT- 2025/09/12 10:24 PHST- 2025/11/26 06:29 [medline] PHST- 2025/09/12 12:30 [pubmed] PHST- 2025/09/12 10:24 [entrez] AID - S0022-4707.25.16874-6 [pii] AID - 10.23736/S0022-4707.25.16874-6 [doi] PST - ppublish SO - J Sports Med Phys Fitness. 2025 Dec;65(12):1660-1669. doi: 10.23736/S0022-4707.25.16874-6. Epub 2025 Sep 12. PMID- 40933723 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250915 LR - 20250915 IS - 2444-8672 (Electronic) IS - 2444-8664 (Print) IS - 2444-8664 (Linking) VI - 10 IP - 5 DP - 2025 Sep-Oct TI - Potential impact of aortic stenosis diagnosis on mortality and other in-hospital complications in patients with pancreatic cancer undergoing pancreaticoduodenectomy. PG - e302 LID - 10.1097/j.pbj.0000000000000302 [doi] LID - e302 AB - BACKGROUND: Patients with aortic stenosis undergoing noncardiac surgery pose a dilemma to physicians as they are at an increased risk for complications. This study aims to investigate the effect of aortic stenosis on mortality and other complications in patients with pancreatic cancer undergoing pancreaticoduodenectomy. METHODS: We investigated patients with pancreatic cancer undergoing pancreaticoduodenectomy between 2016 and 2019 using the National Inpatient Sample database. The study population was divided based on the presence or absence of aortic stenosis. Multivariate logistic regression analyses were performed to determine factors associated with in-hospital mortality and other complications. RESULTS: Of the 16,150 patients with pancreatic cancer who underwent pancreaticoduodenectomy, 165 patients were diagnosed with aortic stenosis. The mean age of patients with aortic stenosis was significantly higher. Patients with aortic stenosis had a significantly higher in-hospital mortality, occurrence of cardiac arrest, and ICU admission compared with patients without aortic stenosis. There was no difference in mechanical ventilation, hospital charges, and length of stay between the two groups. CONCLUSIONS: Aortic stenosis was found to be associated with higher in-hospital mortality and worse outcomes in patients with pancreatic cancer undergoing pancreaticoduodenectomy. Preoperative risk stratification and a multidisciplinary approach to perioperative management, among other measures, should be considered to improve outcomes. CI - Copyright (c) 2025 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of PBJ-Associacao Porto Biomedical/Porto Biomedical Society. FAU - Obeidat, Adham E AU - Obeidat AE AD - Department of Internal Medicine, Presbyterian Healthcare System, Albuquerque, NM 87106. FAU - Mahfouz, Ratib T AU - Mahfouz RT AD - Department of Nephrology, Henry Ford Hospital, Detroit, MI 48202. FAU - Shah, Parthav K AU - Shah PK AD - Department of Cardiology, University of Hawaii, Honolulu, HI 96813. FAU - Kozai, Landon A AU - Kozai LA AD - Department of Internal Medicine, University of Hawaii, Honolulu, HI 96813. FAU - Darweesh, Mohammad R AU - Darweesh MR AD - Department of Gastroenterology, East Tennessee State University, Johnson City, TN 37614. FAU - Mansour, Mahmoud M AU - Mansour MM AD - Department of Gastroenterology, University of Missouri/Columbia, Columbia, MO 65212. FAU - Yassine, Ahmad A AU - Yassine AA AD - Department of Gastroenterology and Hepatology, University of New Mexico, Albuquerque, NM 87106. FAU - Kuwada, Scott K AU - Kuwada SK AD - Department of Gastroenterology, University of Hawaii, Honolulu, HI 96813. FAU - Chang, Christopher H AU - Chang CH AD - Department of Gastroenterology and Hepatology, University of New Mexico, Albuquerque, NM 87106. LA - eng PT - Journal Article DEP - 20250910 PL - United States TA - Porto Biomed J JT - Porto biomedical journal JID - 101707479 PMC - PMC12419423 OTO - NOTNLM OT - aortic stenosis OT - mortality OT - pancreas OT - pancreatic cancer OT - pancreaticoduodenectomy EDAT- 2025/09/11 18:30 MHDA- 2025/09/11 18:31 PMCR- 2025/09/10 CRDT- 2025/09/11 12:41 PHST- 2025/07/23 00:00 [received] PHST- 2025/08/07 00:00 [revised] PHST- 2025/08/08 00:00 [accepted] PHST- 2025/09/11 18:31 [medline] PHST- 2025/09/11 18:30 [pubmed] PHST- 2025/09/11 12:41 [entrez] PHST- 2025/09/10 00:00 [pmc-release] AID - PBJ-D-25-00038 [pii] AID - 10.1097/j.pbj.0000000000000302 [doi] PST - epublish SO - Porto Biomed J. 2025 Sep 10;10(5):e302. doi: 10.1097/j.pbj.0000000000000302. eCollection 2025 Sep-Oct. PMID- 20301736 STAT- Publisher DRDT- 20250911 CTDT- 20081009 PB - University of Washington, Seattle DP - 1993 TI - FLNB-Related Disorders. BTI - GeneReviews((R)) AB - CLINICAL CHARACTERISTICS: The FLNB-related disorders can be divided into two groups of conditions caused by loss of function or gain of function of filamin-B. Biallelic loss-of-function pathogenic variants in FLNB cause spondylocarpotarsal synostosis syndrome (FLNB-SCT). Monoallelic gain-of-function pathogenic variants in FLNB cause a spectrum of phenotypic severity ranging from apparently isolated clubfoot to Larsen syndrome (FLNB-LS), atelosteogenesis type 3 (FLNB-AO3), and atelosteogenesis type 1 (FLNB-AO1), which is perinatal lethal. For the purposes of this GeneReview, the previously described entities Piepkorn dysplasia and boomerang dysplasia are subsumed under the FLNB-AO1 spectrum. FLNB-SCT is characterized by postnatal disproportionate short stature; scoliosis and lordosis due to vertebral fusions; carpal and tarsal synostosis; and, variably, clubfeet, hearing loss, and dental enamel hypoplasia. FLNB-LS is characterized by combinations of congenital dislocations of the hip, knee, and elbow; clubfeet (equinovarus or equinovalgus foot deformities); scoliosis and cervical kyphosis (which can be associated with a cervical myelopathy); short, broad, spatulate distal phalanges; distinctive craniofacial features (prominent forehead, depressed nasal bridge, malar flattening, and widely spaced eyes); vertebral anomalies; and supernumerary carpal and tarsal ossification centers. Individuals with FLNB-LS may also present with midline cleft palate and hearing loss. FLNB-AO1 and FLNB-AO3 are characterized by severe short-limbed dwarfism; dislocated hips, knees, and elbows; and clubfeet. FLNB-AO1 is lethal in the perinatal period. At its most severe, the spectrum of phenotypes assigned FLNB-AO1 can present with perinatal-lethal micromelic dwarfism characterized by flipper-like limbs (polysyndactyly with complete syndactyly of all fingers and toes, hypoplastic or absent first digits, and duplicated intermediate and distal phalanges); macrobrachycephaly; prominent forehead; hypertelorism; and proptosis. Occasional features include cleft palate, omphalocele, and cardiac and genitourinary anomalies. In individuals with FLNB-AO3, survival beyond the neonatal period is possible with intensive and invasive respiratory support. DIAGNOSIS/TESTING: The diagnosis of FLNB-SCT is established in a proband by identification of biallelic loss-of-function pathogenic variants in FLNB by molecular genetic testing. The diagnosis of other FLNB-related disorders (LS, AO1, AO3) is established in a proband by identification of a heterozygous gain-of-function pathogenic variant in FLNB by molecular genetic testing. MANAGEMENT: Treatment of manifestations: Cervical spine instability in asymptomatic infants can be successfully managed with posterior arthrodesis. Function can be stabilized (if not improved) in infants with myelopathic signs by a combination of anterior decompression and circumferential arthrodesis. Hip dislocation in individuals with FLNB-LS usually requires operative reduction. Scoliosis and clubfeet are managed in a routine manner. Anesthetic agents that allow more rapid induction and recovery are preferred in those with laryngotracheomalacia. When possible, cleft palate and hearing loss are best managed by multidisciplinary teams. Surveillance: Annual orthopedic evaluation for progressive scoliosis; feeding and growth assessment for those with cleft palate by a multidisciplinary team; annual audiologic and dental evaluations. Pregnancy management: Delivery of an affected infant has the potential to be complicated by extended breech presentation due to dislocation of the hips and knees. GENETIC COUNSELING: FLNB-SCT is inherited in an autosomal recessive manner. If both parents are known to be heterozygous for an FLNB pathogenic variant, each sib of an affected individual has at conception a 25% chance of inheriting biallelic pathogenic variants and being affected, a 50% chance of inheriting one pathogenic variant and being heterozygous, and a 25% chance of inheriting neither of the familial FLNB pathogenic variants. Heterozygous sibs of a proband with FLNB-SCT can exhibit mild reductions in stature but no other medically significant phenotypic manifestations. Once the FLNB pathogenic variant(s) have been identified in an affected family member, heterozygote testing for at-risk relatives and prenatal/preimplantation genetic testing are possible. FLNB-LS, FLNB-AO1, FLNB-AO3, and FLNB-related apparently isolated clubfoot are inherited in an autosomal dominant manner. Comparatively mild (e.g., FLNB-LS) and severe (e.g., FLNB-AO3) forms of the autosomal dominant FLNB-related disorders can occur in the same family. Some individuals diagnosed with an autosomal dominant FLNB-related disorder have the disorder as the result of a pathogenic variant inherited from a heterozygous or mosaic parent. Some individuals have the disorder as the result of a de novo pathogenic variant (the vast majority of lethal FLNB conditions are the result of de novo pathogenic variants). Each child of a proband who is heterozygous for an FLNB pathogenic variant has a 50% chance of inheriting the pathogenic variant. Each child of a proband with somatic mosaicism for an FLNB pathogenic variant has up to a 50% chance of inheriting the pathogenic variant. Offspring who inherit an FLNB pathogenic variant from a proband with somatic mosaicism may be more severely affected than the proband. Once the FLNB pathogenic variant has been identified in an affected family member, prenatal/preimplantation genetic testing are possible. CI - Copyright (c) 1993-2026, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved. FED - Adam, Margaret P ED - Adam MP FED - Bick, Sarah ED - Bick S FED - Mirzaa, Ghayda M ED - Mirzaa GM FED - Wallace, Stephanie E ED - Wallace SE FED - Amemiya, Anne ED - Amemiya A FAU - Robertson, Stephen AU - Robertson S AD - Professor of Paediatric Genetics, Department of Paediatrics and Child Health, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand FAU - Meira, Joanna AU - Meira J AD - Professor, State University of Bahia (UNEB), Salvador, Bahia, Brazil LA - eng PT - Review PT - Book Chapter PL - Seattle (WA) OTO - NLM OT - Atelosteogenesis Type 1 (FLNB-AO1) OT - Atelosteogenesis Type 3 (FLNB-AO3) OT - Larsen syndrome (FLNB-LS) OT - Spondylocarpotarsal Synostosis Syndrome (FLNB-SCT) OT - FLNB-Related Apparently Isolated Clubfoot OT - Filamin-B OT - FLNB OT - FLNB-Related Disorders EDAT- 2025/09/11 00:00 CRDT- 2025/09/11 00:00 AID - NBK2534 [bookaccession] PMID- 40928994 OWN - NLM STAT- MEDLINE DCOM- 20260819 LR - 20260819 IS - 1557-7740 (Electronic) IS - 1557-7740 (Linking) VI - 29 IP - 9 DP - 2026 Sep TI - Top Ten Tips Palliative Care Clinicians Should Know About Intentionally Interprofessional Collaboration. PG - 1303-1311 LID - 10.1177/10966218251374425 [doi] AB - Although high-quality and holistic specialty palliative care is delivered by an interprofessional team, little guidance is available to optimize approaches to and sustainment of such teamwork. This article supports individuals to practice at the top of their education, clinical training, and scope of practice while maximizing the functionality of the palliative care team as a whole. We intentionally use the term interprofessional rather than interdisciplinary to clarify that we are focused on collaboration of team members who represent multiple professions or occupations that require specialized training and meet ethical standards (e.g., nursing, chaplaincy, social work, medicine, and pharmacy) rather than interactions among specific fields of study (e.g., cardiology, nephrology, and oncology). Synthesized from current data and best practices elicited from an interprofessional author team of palliative specialists, these ten tips aim to bolster collaboration, integration, and communication among palliative care team members, community providers, and referral sources. Topics are relevant for all teams across practice settings to promote and advance integrated teamwork, patient care, leadership, and research. FAU - Milic, Michelle M AU - Milic MM AD - Division of Pulmonary, Critical Care and Sleep Medicine, and Division of Palliative Care Medicine, MedStar Georgetown University Hospital, Washington, District of Columbia, USA. FAU - Donesky, DorAnne AU - Donesky D AD - Emeritus, University of California, San Francisco, California, USA. FAU - Saks, Naomi Tzril AU - Saks NT AD - Division of Palliative Medicine, University of California San Francisco, California, USA. FAU - Cammy, Rebecca AU - Cammy R AD - Division of Supportive Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA. FAU - Dahlin, Constance AU - Dahlin C AD - Graduate Studies in Palliative Care, Center to Advance Palliative Care, University of Maryland Baltimore, Baltimore, Maryland, USA. FAU - DeSanto-Madeya, Susan AU - DeSanto-Madeya S AD - University of Rhode Island, College of Nursing, Kingston, Rhode Island, USA. FAU - Fasolino, Tracy AU - Fasolino T AD - Distinguished Palliative Care Leader, Clemson University School of Nursing, Salem, South Carolina, USA. FAU - Izumi, Seiko AU - Izumi S AUID- ORCID: 0000-0002-9488-9458 AD - School of Nursing, Oregon Health & Science University, Portland, Oregon, USA. FAU - Kirkpatrick, Amanda AU - Kirkpatrick A AUID- ORCID: 0000-0002-5275-2322 AD - Creighton University College of Nursing, Omaha, Nebraska, USA. FAU - Lakin, Joshua R AU - Lakin JR AD - Palliative Care, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. FAU - Leff, Vickie AU - Leff V AD - Carolina School of Social Work, University of North, Cary, North Carolina, USA. FAU - Lockman, Kashelle AU - Lockman K AUID- ORCID: 0000-0001-8017-8084 AD - Office of Consultation and Research in Medical Education, Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA. FAU - Walter, Jennifer AU - Walter J AD - Justin Michael Ingerman Center for Palliative Care and Department of Medical Ethics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. FAU - Rosa, William E AU - Rosa WE AUID- ORCID: 0000-0002-0680-8911 AD - Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York, USA. FAU - Wallace, Cara L AU - Wallace CL AUID- ORCID: 0000-0002-6739-1910 AD - Trudy Busch Valentine School of Nursing, Saint Louis University, Saint Louis, Missouri, USA. LA - eng PT - Journal Article DEP - 20250909 PL - United States TA - J Palliat Med JT - Journal of palliative medicine JID - 9808462 SB - IM MH - Humans MH - *Palliative Care/standards/organization & administration MH - *Interprofessional Relations MH - *Cooperative Behavior MH - *Patient Care Team/organization & administration/standards MH - Male MH - Female OTO - NOTNLM OT - clinical experts OT - complementary strengths OT - interprofessional team members OT - palliative care COIS- Author Disclosure StatementNo competing financial interests exist. EDAT- 2025/09/10 18:30 MHDA- 2026/08/19 14:48 CRDT- 2025/09/10 13:13 PHST- 2026/08/19 14:48 [medline] PHST- 2025/09/10 18:30 [pubmed] PHST- 2025/09/10 13:13 [entrez] AID - 10.1177/10966218251374425 [doi] PST - ppublish SO - J Palliat Med. 2026 Sep;29(9):1303-1311. doi: 10.1177/10966218251374425. Epub 2025 Sep 9. PMID- 40927463 OWN - NLM STAT- In-Process LR - 20250912 IS - 1179-7258 (Print) IS - 1179-7258 (Electronic) IS - 1179-7258 (Linking) VI - 16 DP - 2025 TI - Enhancing Pediatric Residency Training Through Peer-Education Based Gamified Simulation. PG - 1621-1626 LID - 10.2147/AMEP.S518814 [doi] AB - The reduction in clinical rotation hours, particularly in high-demand pediatric subspecialties such as Neonatal Intensive Care Units (NICU) and Pediatric Emergency Rooms (ER), has highlighted the need for innovative approaches to enhance pediatric residency education. A 2019 survey of Italian pediatric residency programs revealed that most residents receive fewer than five hours of simulation-based training annually, with 66% participating in no simulation activities. Additionally, pediatric ER rotation hours have seen significant reductions-daytime rotations decreased by 29%, while nighttime rotations were reduced by 60% over the past four years at the University of Genoa. These challenges emphasize the importance of simulation-based curricula to address gaps in clinical exposure.This study presents a gamified simulation-based curriculum developed at the University of Genoa, designed to improve both technical and non-technical competencies among pediatric residents while compensating for reduced clinical exposure. The curriculum spans five years, with Year 1 focusing on foundational skills such as airway management, vascular access, and diagnostic techniques. Year 2 introduces more advanced scenarios like neonatal resuscitation, shock management, and cardiac arrest, while Years 3-5 culminate in high-fidelity simulations involving complex trauma and crisis resource management.Throughout the program, gamification elements such as badges, leaderboards, and team-based rewards enhance engagement, motivation, and participation. These elements provide feedback and foster progression, reinforcing residents' commitment to mastering technical skills and non-technical competencies like teamwork, leadership, and decision-making. By combining simulation-based training with gamification, this curriculum offers an innovative approach to residency education, preparing pediatric residents for real-world challenges and developing essential skills for high-stakes pediatric care. CI - (c) 2025 Scaglione et al. FAU - Scaglione, Marco AU - Scaglione M AUID- ORCID: 0000-0002-6411-7983 AD - Department of Neuroscience, Rehabilitation, Ophtalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa, 16132, Italy. FAU - Calandrino, Andrea AU - Calandrino A AUID- ORCID: 0000-0002-2710-1798 AD - Department of Neuroscience, Rehabilitation, Ophtalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa, 16132, Italy. AD - Department of Maternal and Neonatal Health, Neonatal Intensive Care Unit, IRCCS Giannina Gaslini Institute, Genoa, 16147, Italy. FAU - Puzone, Laura AU - Puzone L AD - Department of Neuroscience, Rehabilitation, Ophtalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa, 16132, Italy. FAU - Bottino, Giovanni AU - Bottino G AD - Department of Neuroscience, Rehabilitation, Ophtalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa, 16132, Italy. AD - Department of Maternal and Neonatal Health, Pediatric and Neonatology Spoke Unit of Savona, IRCCS Giannina Gaslini Institute, San Paolo Hospital, Savona, 17100, Italy. FAU - Conte, Alessio AU - Conte A AUID- ORCID: 0009-0006-5781-3178 AD - Department of Neuroscience, Rehabilitation, Ophtalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa, 16132, Italy. FAU - Striano, Pasquale AU - Striano P AUID- ORCID: 0000-0002-6065-1476 AD - Department of Neuroscience, Rehabilitation, Ophtalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa, 16132, Italy. AD - Department of Pediatrics, Pediatric Neurology and Muscular Diseases Unit, IRCCS Giannina Gaslini Institute, Genoa, 16147, Italy. FAU - Maghnie, Mohamad AU - Maghnie M AUID- ORCID: 0000-0002-7183-5238 AD - Department of Neuroscience, Rehabilitation, Ophtalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa, 16132, Italy. AD - Department of Pediatrics, Pediatric Endocrinology Unit, IRCCS Giannina Gaslini Institute, Genoa, 16147, Italy. LA - eng PT - Journal Article DEP - 20250903 PL - New Zealand TA - Adv Med Educ Pract JT - Advances in medical education and practice JID - 101562700 PMC - PMC12416069 OTO - NOTNLM OT - Simulation OT - gamification OT - non-technical skills OT - peer-education OT - residents OT - technical skills OT - training COIS- The authors have no competing interest to declare for this work. EDAT- 2025/09/10 06:29 MHDA- 2025/09/10 06:29 PMCR- 2025/09/03 CRDT- 2025/09/10 05:01 PHST- 2025/01/31 00:00 [received] PHST- 2025/04/20 00:00 [accepted] PHST- 2025/09/10 06:29 [medline] PHST- 2025/09/10 06:29 [pubmed] PHST- 2025/09/10 05:01 [entrez] PHST- 2025/09/03 00:00 [pmc-release] AID - 518814 [pii] AID - 10.2147/AMEP.S518814 [doi] PST - epublish SO - Adv Med Educ Pract. 2025 Sep 3;16:1621-1626. doi: 10.2147/AMEP.S518814. eCollection 2025. PMID- 40927103 OWN - NLM STAT- In-Process LR - 20250912 IS - 2153-8174 (Electronic) IS - 1530-6550 (Print) IS - 1530-6550 (Linking) VI - 26 IP - 8 DP - 2025 Aug TI - Artificial Intelligence in Cardiac Treatment Decision-Making: An Evaluation of the Performance of ChatGPT Versus the Heart Team in Coronary Revascularization. PG - 38705 LID - 10.31083/RCM38705 [doi] LID - 38705 AB - BACKGROUND: This study aimed to investigate the performance of two versions of ChatGPT (o1 and 4o) in making decisions about coronary revascularization and to compare the recommendations of these versions with those of a multidisciplinary Heart Team. Moreover, the study aimed to assess whether the decisions generated by ChatGPT, based on the internal knowledge base of the system and clinical guidelines, align with expert recommendations in real-world coronary artery disease management. Given the increasing prevalence and processing capabilities of large language models, such as ChatGPT, this comparison offers insights into the potential applicability of these systems in complex clinical decision-making. METHODS: We conducted a retrospective study at a single center, which included 128 patients who underwent coronary angiography between August and September 2024. The demographics, medical history, current medications, echocardiographic findings, and angiographic findings for each patient were provided to the two ChatGPT versions. The two models were then asked to choose one of three treatment options: coronary artery bypass grafting (CABG), percutaneous coronary intervention (PCI), or medical therapy, and to justify their choice. Performance was assessed using metrics such as accuracy, sensitivity, specificity, precision, F1 score, Cohen's kappa, and Shannon's entropy. RESULTS: The Heart Team recommended CABG for 78.1% of the patients, PCI for 12.5%, and medical therapy for 9.4%. ChatGPT o1 demonstrated higher sensitivity in identifying patients who needed CABG (82%) but lower sensitivity for PCI (43.7%), whereas ChatGPT 4o performed better in recognizing PCI candidates (68.7%) but was less accurate for CABG cases (43%). Both models struggled to identify patients suitable for medical therapy, with no correct predictions in this category. Agreement with the Heart Team was low (Cohen's kappa: 0.17 for o1 and 0.03 for 4o). Notably, these errors were often attributed to the limited understanding of the model in a clinical context and the inability to analyze angiographic images directly. CONCLUSION: While ChatGPT-based artificial intelligence (AI) models show promise in assisting with cardiac care decisions, the current limitations of these models emphasize the need for further development. Incorporating imaging data and enhancing comprehension of clinical context is essential to improve the reliability of these AI models in real-world medical settings. CI - Copyright: (c) 2025 The Author(s). Published by IMR Press. FAU - Mola, Serkan AU - Mola S AUID- ORCID: 0000-0002-5526-5298 AD - Cardiovascular Surgery Department, Ankara Bilkent City Hospital, 06800 Ankara, Turkey. FAU - Yildirim, Alp AU - Yildirim A AUID- ORCID: 0000-0002-6547-2450 AD - Cardiovascular Surgery Department, Ankara Ataturk Sanatoryum Training and Research Hospital, 06290 Ankara, Turkey. FAU - Gul, Enis Burak AU - Gul EB AUID- ORCID: 0009-0005-8038-145X AD - Cardiovascular Surgery Department, Ankara Bilkent City Hospital, 06800 Ankara, Turkey. LA - eng PT - Journal Article DEP - 20250819 PL - Singapore TA - Rev Cardiovasc Med JT - Reviews in cardiovascular medicine JID - 100960007 PMC - PMC12415735 OTO - NOTNLM OT - ChatGPT OT - artificial intelligence OT - coronary revascularization OT - heart team COIS- The authors declare no conflict of interest. EDAT- 2025/09/10 06:29 MHDA- 2025/09/10 06:29 PMCR- 2025/08/19 CRDT- 2025/09/10 04:56 PHST- 2025/02/28 00:00 [received] PHST- 2025/06/21 00:00 [revised] PHST- 2025/06/26 00:00 [accepted] PHST- 2025/09/10 06:29 [medline] PHST- 2025/09/10 06:29 [pubmed] PHST- 2025/09/10 04:56 [entrez] PHST- 2025/08/19 00:00 [pmc-release] AID - S1530-6550(25)01917-9 [pii] AID - 10.31083/RCM38705 [doi] PST - epublish SO - Rev Cardiovasc Med. 2025 Aug 19;26(8):38705. doi: 10.31083/RCM38705. eCollection 2025 Aug. PMID- 40922291 OWN - NLM STAT- MEDLINE DCOM- 20250909 LR - 20251030 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 104 IP - 36 DP - 2025 Sep 5 TI - Cardiac rehabilitation for workers with ischemic heart disease: Benefits for cardiovascular health and quality of life. PG - e44019 LID - 10.1097/MD.0000000000044019 [doi] LID - e44019 AB - Cardiac rehabilitation programs (CRPs) are multifactorial interventions defined by the World Health Organization as essential strategies to improve patients' health-related quality of life (HRQoL) by enhancing their physical, psychological, social, and occupational well-being. These programs are a cornerstone in the comprehensive treatment of heart disease, facilitating the recovery of functional capacity and reintegration into the workforce through a multidisciplinary approach. The objective of this study was to assess the efficacy of CRPs in enhancing functional capacity (cardiac and psychological) and HRQoL in workers with ischemic heart disease. An observational pre-post study without a control group was conducted, focusing on actively employed individuals with ischemic heart disease. A total of 214 patients were included, selected according to specific inclusion criteria after excluding those not suitable for longitudinal follow-up. Participants were active workers aged 18 to 65 years who were prescribed a CRP between January 2020 and December 2021. Sociodemographic, occupational, cardiovascular risk, and clinical-therapeutic data were collected to evaluate changes following completion of the program. Health-related quality of life (HRQoL) was also assessed. A total of 214 patients were included, 83.9% male, with a mean age of 54.21 years. Most had a history of hypertension, dyslipidemia, smoking, low physical activity, overweight or obesity, and a family history of ischemic heart disease. Among those who started the program (94.4%), the most common diagnosis was acute myocardial infarction involving a single coronary vessel. Additionally, 77.1% underwent stent angioplasty, and 47.2% participated in a moderate-risk CRP. After completion, the SF-36 score improved significantly (46.92 vs 70.21), and depressive symptoms decreased (55.10% vs 38.22%). Significant benefits were observed in most modifiable cardiovascular risk factors, along with an increase in the proportion of patients with preserved left ventricular ejection fraction (65.4% vs 72%) and in metabolic equivalent (MET) levels. In 157 participants (73.4%), MET gain was quantified, with a mean increase of 2.67 +/- 1.64 METs. These findings suggest that cardiac rehabilitation, as a secondary prevention strategy, effectively improves cardiac function and HRQoL in working-age patients with ischemic heart disease. CI - Copyright (c) 2025 the Author(s). Published by Wolters Kluwer Health, Inc. FAU - Delgado-Calderon, Manuel AU - Delgado-Calderon M AD - Occupational Health Service, Hospital Universitario Virgen Macarena, Sevilla, Spain. FAU - Jimenez-Ortega, Lara Estefania AU - Jimenez-Ortega LE AD - Occupational Health Service, Hospital Universitario Virgen Macarena, Sevilla, Spain. FAU - Ladisa, Maria AU - Ladisa M AUID- ORCID: 0000-0003-3885-1639 AD - Department of Preventive Medicine, Hospital Universitario Virgen Macarena, Sevilla, Spain. FAU - Camacho-Vega, Juan Carlos AU - Camacho-Vega JC AUID- ORCID: 0000-0003-3140-9039 AD - Department of Building Construction II, Higher Technical School of Building Engineering, University of Seville, Sevilla, Spain. AD - Occupational Risk Prevention Unit, Hospital Universitario Virgen Macarena, Sevilla, Spain. FAU - Vilches-Arenas, Angel AU - Vilches-Arenas A AUID- ORCID: 0000-0003-2197-3760 AD - Department of Preventive Medicine, Hospital Universitario Virgen Macarena, Sevilla, Spain. AD - Department of Preventive Medicine and Public Health, University of Seville, Sevilla, Spain. FAU - Luque-Romero, Luis Gabriel AU - Luque-Romero LG AUID- ORCID: 0000-0002-7818-2380 AD - Department of Preventive Medicine and Public Health, University of Seville, Sevilla, Spain. AD - Investigation Unit, Distrito Sanitario Aljarafe-Sevilla Norte, Sevilla, Spain. AD - Institute of Biomedicine of Sevilla, IBiS/Hospital Universitario Virgen del Rocio/CSIC, University of Seville, Sevilla, Spain. FAU - Palomo-Gomez, Rocio AU - Palomo-Gomez R AUID- ORCID: 0009-0002-4729-7078 AD - Department of Obstetrics, Hospital of La Linea de la Concepcion, Cadiz, Spain. FAU - Martin-Pereira, Jorge AU - Martin-Pereira J AUID- ORCID: 0000-0002-9544-1532 AD - School of Doctorate, University of Huelva, Huelva, Spain. FAU - Gomez-Salgado, Juan AU - Gomez-Salgado J AUID- ORCID: 0000-0001-9053-7730 AD - Department of Sociology, Social Work and Public Health, Faculty of Labour Sciences, University of Huelva, Huelva, Spain. AD - Safety and Health Postgraduate Programme, Universidad Espiritu Santo, Guayaquil, Ecuador. LA - eng PT - Journal Article PT - Observational Study PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R SB - IM MH - Humans MH - *Quality of Life MH - Male MH - Middle Aged MH - Female MH - *Myocardial Ischemia/rehabilitation/psychology MH - *Cardiac Rehabilitation/methods MH - Adult MH - Aged PMC - PMC12419251 OTO - NOTNLM OT - cardiac rehabilitation OT - cardiovascular risk management OT - functional capacity OT - health-related quality of life OT - ischemic heart disease OT - preventive cardiology OT - psychosocial determinants OT - tertiary prevention COIS- The authors have no funding and conflicts of interest to disclose. EDAT- 2025/09/09 06:35 MHDA- 2025/09/09 06:36 PMCR- 2025/09/05 CRDT- 2025/09/09 01:07 PHST- 2025/03/27 00:00 [received] PHST- 2025/07/31 00:00 [accepted] PHST- 2025/09/09 06:36 [medline] PHST- 2025/09/09 06:35 [pubmed] PHST- 2025/09/09 01:07 [entrez] PHST- 2025/09/05 00:00 [pmc-release] AID - 00005792-202509050-00056 [pii] AID - MD-D-25-03569 [pii] AID - 10.1097/MD.0000000000044019 [doi] PST - ppublish SO - Medicine (Baltimore). 2025 Sep 5;104(36):e44019. doi: 10.1097/MD.0000000000044019. PMID- 40921499 OWN - NLM STAT- MEDLINE DCOM- 20250908 LR - 20260711 IS - 2399-6641 (Electronic) IS - 2399-6641 (Linking) VI - 14 IP - 3 DP - 2025 Sep 8 TI - Impact of a 24/7 on-site percutaneous coronary intervention team strategy on door-to-wire time. LID - 10.1136/bmjoq-2025-003386 [doi] LID - e003386 AB - BACKGROUND: Current guidelines recommend that the door-to-wire (D2W) time should be <90 min in patients undergoing primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI). This study evaluated the effect of a 24/7 on-site PCI team strategy on the D2W time. METHODS: In this single-centre, retrospective study, patients with STEMI undergoing primary PCI within 1 year before (control group, n=143) and 1 year after (intervention group, n=96) implementing a 24/7 on-site PCI team strategy were enrolled. This strategy required that the PCI team was always available in hospital to minimise the time required to make the catheterisation laboratory ready for PCI. The primary endpoint was the D2W time, and the secondary endpoints were the rate of delayed PCI (D2W time >/=90 min) and the on-site time of the PCI team members. Multivariate analysis was conducted to determine the independent predictors of delayed PCI in the intervention group. RESULTS: The D2W time was shorter (52 vs 97 min, p<0.001), the rate of delayed PCI was lower (19.8% vs 55.2%, p<0.001), but the on-site time of the PCI team members (35 040 vs 9960 hours) was longer in the intervention group than in the control group. Time-to-obtain electrocardiogram >10 min (p=0.027) and time-to-make STEMI diagnosis >9 min (p=0.001) were independent predictors of delayed PCI after implementing the strategy. CONCLUSIONS: Implementing a 24/7 on-site PCI team strategy was associated with reductions in the D2W time and the rate of delayed PCI but an increase in the on-site time of the PCI team members. CI - (c) Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. FAU - Wang, Liang AU - Wang L AD - Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. FAU - Yang, Xinglin AU - Yang X AUID- ORCID: 0000-0002-9743-4053 AD - Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. FAU - Wu, Wei AU - Wu W AD - Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. FAU - Tian, Ran AU - Tian R AD - Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. FAU - Yang, Ming AU - Yang M AD - Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. FAU - Han, Yechen AU - Han Y AD - Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. FAU - Shen, Jianzhong AU - Shen J AD - Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. FAU - Qian, Hao AU - Qian H AD - Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. FAU - Guo, Fan AU - Guo F AD - Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. FAU - Zhang, Tengyue AU - Zhang T AD - Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. FAU - Zhu, Xueqing AU - Zhu X AD - Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. FAU - Jin, Xiaofeng AU - Jin X AD - Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. FAU - Wang, Chonghui AU - Wang C AD - Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. FAU - Xie, Hongzhi AU - Xie H AD - Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. FAU - Fan, Zhongjie AU - Fan Z AD - Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. FAU - Shen, Zhujun AU - Shen Z AD - Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. FAU - Liu, Jihai AU - Liu J AD - Emergency Department, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. FAU - Zhang, Zhanjie AU - Zhang Z AD - Department of Medical Affairs, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. FAU - Ma, Xiaojun AU - Ma X AD - Department of Medical Affairs, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. FAU - Liu, Zhenyu AU - Liu Z AD - Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China pumch_lzy1@163.com. FAU - Zhu, Huadong AU - Zhu H AD - Emergency Department, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. LA - eng PT - Journal Article DEP - 20250908 PL - England TA - BMJ Open Qual JT - BMJ open quality JID - 101710381 SB - IM MH - Humans MH - *Percutaneous Coronary Intervention/methods/statistics & numerical data/standards MH - Female MH - Retrospective Studies MH - Male MH - Middle Aged MH - Aged MH - *Time-to-Treatment/statistics & numerical data/standards MH - Time Factors MH - ST Elevation Myocardial Infarction/surgery MH - *Patient Care Team/standards/statistics & numerical data PMC - PMC12421147 OTO - NOTNLM OT - Duty Hours/Work hours OT - Health services research OT - Teams COIS- Competing interests: None declared. EDAT- 2025/09/09 00:33 MHDA- 2025/09/09 00:34 PMCR- 2025/09/08 CRDT- 2025/09/08 20:53 PHST- 2025/02/25 00:00 [received] PHST- 2025/08/13 00:00 [accepted] PHST- 2025/09/09 00:34 [medline] PHST- 2025/09/09 00:33 [pubmed] PHST- 2025/09/08 20:53 [entrez] PHST- 2025/09/08 00:00 [pmc-release] AID - bmjoq-2025-003386 [pii] AID - 10.1136/bmjoq-2025-003386 [doi] PST - epublish SO - BMJ Open Qual. 2025 Sep 8;14(3):e003386. doi: 10.1136/bmjoq-2025-003386. PMID- 40920492 OWN - NLM STAT- MEDLINE DCOM- 20251222 LR - 20251224 IS - 2055-5822 (Electronic) IS - 2055-5822 (Linking) VI - 12 IP - 6 DP - 2025 Dec TI - Nurse-coordinated multidisciplinary comprehensive heart failure management programme: A propensity-matched trial. PG - 4160-4170 LID - 10.1002/ehf2.15418 [doi] AB - AIMS: Despite therapeutic advancements, the prognosis of heart failure (HF) remains poor, with high rates of mortality and readmission, particularly following a HF exacerbation. This study aimed to evaluate the effects of a nurse-coordinated multidisciplinary comprehensive HF management programme on HF patients. METHODS AND RESULTS: This retrospective cohort study involved patients admitted for acute HF exacerbation at a regional hospital in Hong Kong. We established two patient cohorts: the control cohort, recruited between January and December 2021, received standard care, while the programme cohort, recruited from October 2022 to December 2023, participated in a comprehensive programme. This programme included multidisciplinary ward rounds, early initiation of guideline-directed medical therapy (GDMT), discharge education, post-discharge transitional care and cardiac rehabilitation. The primary outcome was the composite endpoint of all-cause mortality and HF-related readmission at 6 months. Secondary endpoints included HF-related readmission and all-cause mortality. We also assessed patient satisfaction and health-related quality of life (HRQoL) in the programme cohort. The study included 732 patients, 24.0% female, 81.6% with HFrEF, mean age of 67.9 +/- 13.2 years. After matching for age, sex and type of HF, 366 patients were allocated to each cohort. The programme cohort demonstrated significantly lower rates of the composite endpoint [12.0% vs. 38.0%, adjusted hazard ratio (aHR) = 0.26, 95% confidence interval (CI) = 0.19-0.37, P < 0.001]) and HF-related readmissions (10.1% vs. 25.4%, aHR = 0.36, 95% CI = 0.24-0.52, P < 0.001) compared with the control cohort. All-cause mortality was also significantly reduced (4.4% vs. 18.3%, aHR = 0.22, 95% CI = 0.13-0.38, P < 0.001). Improvements in HRQoL and high patient satisfaction were noted in the programme cohort. CONCLUSIONS: The nurse-coordinated comprehensive HF management programme significantly reduced readmissions and mortality, with consistent benefits across different subgroups. Further research is needed to confirm these benefits and explore mechanisms. CI - (c) 2025 The Author(s). ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. FAU - Chan, Cecilia Miu-Ching AU - Chan CM AD - Department of Medicine, Division of Cardiology, Queen Elizabeth Hospital, Hong Kong, Hong Kong. FAU - Li, Polly Wai-Chi AU - Li PW AUID- ORCID: 0000-0001-6309-5906 AD - School of Nursing, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong. FAU - Lee, Derek Pok-Him AU - Lee DP AD - Department of Medicine, Division of Cardiology, Queen Elizabeth Hospital, Hong Kong, Hong Kong. FAU - Fong, Esmond Yan-Hang AU - Fong EY AD - Department of Medicine, Division of Cardiology, Queen Elizabeth Hospital, Hong Kong, Hong Kong. FAU - Ng, Ivy Sin-Yee AU - Ng IS AD - Department of Medicine, Division of Cardiology, Queen Elizabeth Hospital, Hong Kong, Hong Kong. FAU - Chiu, Samantha Ki-Man AU - Chiu SK AD - Department of Medicine, Division of Cardiology, Queen Elizabeth Hospital, Hong Kong, Hong Kong. FAU - Fok, Clara Woon-Shan AU - Fok CW AD - Department of Medicine, Division of Cardiology, Queen Elizabeth Hospital, Hong Kong, Hong Kong. FAU - Li, Frederick Kin-Wa AU - Li FK AD - Physiotherapy Department, Queen Elizabeth Hospital, Hong Kong, Hong Kong. FAU - Lee, Shirley Ka-Wai AU - Lee SK AD - Physiotherapy Department, Queen Elizabeth Hospital, Hong Kong, Hong Kong. FAU - Ho, Karen K Y AU - Ho KKY AD - Department of Pharmacy, Queen Elizabeth Hospital, Hong Kong, Hong Kong. FAU - Leung, Wilson Y S AU - Leung WYS AD - Department of Pharmacy, Queen Elizabeth Hospital, Hong Kong, Hong Kong. FAU - Chan, Cathy Cheuk-Sum AU - Chan CC AD - Department of Occupational Therapy, Queen Elizabeth Hospital, Hong Kong, Hong Kong. FAU - Tsang, Cindy Yiu-Ning AU - Tsang CY AD - Department of Occupational Therapy, Queen Elizabeth Hospital, Hong Kong, Hong Kong. FAU - Lee, Michael Kang-Yin AU - Lee MK AUID- ORCID: 0000-0002-7074-2347 AD - Department of Medicine, Division of Cardiology, Queen Elizabeth Hospital, Hong Kong, Hong Kong. LA - eng PT - Journal Article DEP - 20250908 PL - England TA - ESC Heart Fail JT - ESC heart failure JID - 101669191 SB - IM MH - Humans MH - *Heart Failure/nursing/therapy/mortality MH - Female MH - Male MH - Retrospective Studies MH - Aged MH - Hong Kong/epidemiology MH - *Quality of Life MH - *Propensity Score MH - Patient Readmission MH - Middle Aged MH - *Patient Care Team MH - *Disease Management MH - Follow-Up Studies PMC - PMC12719847 OTO - NOTNLM OT - Guideline-directed medical therapy OT - Heart failure OT - Mortality OT - Multidisciplinary care OT - Readmission OT - Transitional care COIS- None declared. EDAT- 2025/09/08 18:34 MHDA- 2025/12/22 06:29 PMCR- 2025/09/08 CRDT- 2025/09/08 12:22 PHST- 2025/07/15 00:00 [revised] PHST- 2025/03/12 00:00 [received] PHST- 2025/08/19 00:00 [accepted] PHST- 2025/12/22 06:29 [medline] PHST- 2025/09/08 18:34 [pubmed] PHST- 2025/09/08 12:22 [entrez] PHST- 2025/09/08 00:00 [pmc-release] AID - EHF215418 [pii] AID - 10.1002/ehf2.15418 [doi] PST - ppublish SO - ESC Heart Fail. 2025 Dec;12(6):4160-4170. doi: 10.1002/ehf2.15418. Epub 2025 Sep 8. PMID- 40918928 OWN - NLM STAT- In-Process LR - 20250910 IS - 2666-6677 (Electronic) IS - 2666-6677 (Linking) VI - 23 DP - 2025 Sep TI - Impact of mode of delivery on maternal and fetal outcomes in pregnant patients with heart failure or pulmonary hypertension. PG - 101263 LID - 10.1016/j.ajpc.2025.101263 [doi] LID - 101263 AB - BACKGROUND: Data on outcomes associated with various modes of delivery in pregnant patients with heart failure (HF) or pulmonary hypertension (pHTN) are limited. OBJECTIVE: We aim to investigate the association between mode of delivery on maternal and fetal outcomes in pregnant patients with HF or pHTN by conducting a multicenter, large scale and nationwide retrospective cohort study. METHODS: This retrospective population-based cohort study used the Nationwide Readmission Database to identify all hospitalized pregnant patients who were primarily admitted for vaginal or cesarean delivery from 2011 to 2019. Pregnant patients with HF or pHTN were identified. The primary outcomes were in-hospital maternal and fetal mortality. RESULTS: 23,359 hospitalized pregnant patients with HF or pHTN were identified: 7885 (33.8 %) underwent vaginal delivery, and 15,474 (66.2 %) underwent cesarean delivery. Patients undergoing cesarean delivery had lower odds of fetal mortality than vaginal delivery (OR: 0.18, 95 % CI: 0.07-0.45; p < 0.001). However, the odds of in-hospital maternal mortality (OR: 2.0, 95 % CI: 1.07-3.77; p = 0.03) were higher in the cesarean group than vaginal delivery group. When considering vaginal delivery as a control group, 167 pregnant women would have to undergo cesarean delivery to have one in-hospital maternal mortality and 164 pregnant women would have to undergo cesarean delivery to reduce one fetal mortality. CONCLUSIONS: In this multicentric cohort study, cesarean delivery was associated with lower fetal mortality but higher in-hospital maternal mortality. Thus, the unique features of each patient case should be considered via a multidisciplinary team before determining the optimal delivery method for patients with HF or pHTN. CI - (c) 2025 The Author(s). FAU - Majmundar, Monil AU - Majmundar M AD - Department of Cardiovascular Medicine, University of Kansas Medical Center, Kansas City, KS, USA. FAU - Patel, Kunal N AU - Patel KN AD - Department of Cardiovascular Medicine, University of Kansas Medical Center, Kansas City, KS, USA. FAU - Khawaja, Tasveer AU - Khawaja T AD - Department of Cardiovascular Medicine, Case Western Reserve University, University Hospitals, Cleveland, OH, USA. FAU - Doshi, Rajkumar AU - Doshi R AD - Department of Cardiology, Atlantic Medical Group Cardiology, Hackettstown, NJ, USA. FAU - Zala, Harshvardhan AU - Zala H AD - Department of Medicine, SUNY Upstate Medical University, Syracuse, NY, USA. FAU - Kalra, Ankur AU - Kalra A AD - Department of Cardiology, State University of New York, Upstate Medical University, Syracuse, NY, USA. FAU - Thomas, Megan McKee AU - Thomas MM AD - Department of Gynecology and Obstetrics, University of Kansas Medical Center, Kansas City, KS, USA. FAU - Lippmann, Matthew AU - Lippmann M AD - Department of Cardiology, Zucker School of Medicine at Hofstra/Northwell, Bay Shore, NY, USA. FAU - Gulati, Martha AU - Gulati M AD - Department of Cardiology, Cedars-Sinai Smidt Heart Institute, Los Angeles, CA, USA. LA - eng PT - Journal Article DEP - 20250822 PL - Netherlands TA - Am J Prev Cardiol JT - American journal of preventive cardiology JID - 101769122 PMC - PMC12410395 OTO - NOTNLM OT - Acute coronary syndrome OT - Cesarean delivery OT - Fetal mortality OT - Heart failure OT - In-hospital mortality OT - Pregnancy OT - Readmission OT - Vaginal delivery COIS- The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Martha Gulati reports a relationship with Novartis, Esperion and Boehringer Ingelheim that includes: consulting or advisory. Dr. Martha Gulati serves on a DSMB for Merck Inc. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/09/08 12:42 MHDA- 2025/09/08 12:42 PMCR- 2025/08/22 CRDT- 2025/09/08 07:16 PHST- 2024/08/25 00:00 [received] PHST- 2025/07/13 00:00 [revised] PHST- 2025/08/21 00:00 [accepted] PHST- 2025/09/08 12:42 [medline] PHST- 2025/09/08 12:42 [pubmed] PHST- 2025/09/08 07:16 [entrez] PHST- 2025/08/22 00:00 [pmc-release] AID - S2666-6677(25)00338-1 [pii] AID - 101263 [pii] AID - 10.1016/j.ajpc.2025.101263 [doi] PST - epublish SO - Am J Prev Cardiol. 2025 Aug 22;23:101263. doi: 10.1016/j.ajpc.2025.101263. eCollection 2025 Sep. PMID- 40918745 OWN - NLM STAT- In-Process LR - 20250910 IS - 2474-8714 (Electronic) IS - 2474-8706 (Print) IS - 2474-8706 (Linking) VI - 9 IP - 9 DP - 2025 Sep TI - Cardiac Implantable Electronic Devices and Transcatheter Tricuspid Valve Replacement With the EVOQUE System: A Case-Review Series Highlighting Procedural and Management Considerations. PG - 100707 LID - 10.1016/j.shj.2025.100707 [doi] LID - 100707 AB - Severe, untreated tricuspid regurgitation is associated with worse clinical outcomes. While isolated tricuspid valve (TV) surgery has been linked to poor long-term outcomes, transcatheter TV therapies, including edge-to-edge repair and transcatheter tricuspid valve replacement (TTVR), have emerged as effective alternatives and have been shown to improve outcomes, leading to their regulatory approval in the United States. Conduction system abnormalities are commonly seen among patients undergoing TTVR due to the close proximity of the atrioventricular node and the His bundle to the TV annulus. In the TRISCEND II (Transcatheter Tricuspid Valve Replacement: Pivotal Clinical Investigation of Safety and Clinical Efficacy Using a Novel Device) trial, 38% of the patients had prior cardiac implantable electronic devices (CIEDs), while 25% of patients developed new conduction abnormalities necessitating implantation of new CIEDs. Concerns exist regarding trapping existing CIED leads during TTVR. Similarly, transvenous permanent pacemaker implantation post-TTVR has been reported to be associated with valve dysfunction. In this case-based narrative review, we describe case examples of patients with prior CIEDs undergoing TTVR and conduction abnormalities post-TTVR needing a new permanent pacemaker and discuss potential periprocedural strategies for optimal outcomes. Electrophysiologists specializing in periprocedural management of CIEDs, including lead extraction and post-TTVR device management, play a crucial role and should be part of a comprehensive heart team approach for optimal outcomes. CI - (c) 2025 The Author(s). FAU - Guddeti, Raviteja R AU - Guddeti RR AD - The Carl and Edyth Lindner Research Center at the Christ Hospital, Cincinnati, Ohio, USA. FAU - Seshiah, Puvi AU - Seshiah P AD - The Carl and Edyth Lindner Research Center at the Christ Hospital, Cincinnati, Ohio, USA. FAU - Bae, Richard AU - Bae R AD - The Carl and Edyth Lindner Research Center at the Christ Hospital, Cincinnati, Ohio, USA. FAU - El-Hangouche, Nadia AU - El-Hangouche N AD - The Carl and Edyth Lindner Research Center at the Christ Hospital, Cincinnati, Ohio, USA. FAU - Costea, Alex AU - Costea A AD - The Carl and Edyth Lindner Research Center at the Christ Hospital, Cincinnati, Ohio, USA. FAU - Schloss, Edward AU - Schloss E AD - The Carl and Edyth Lindner Research Center at the Christ Hospital, Cincinnati, Ohio, USA. FAU - Yildiz, Mehmet AU - Yildiz M AD - The Carl and Edyth Lindner Research Center at the Christ Hospital, Cincinnati, Ohio, USA. FAU - Garcia, Santiago AU - Garcia S AD - The Carl and Edyth Lindner Research Center at the Christ Hospital, Cincinnati, Ohio, USA. LA - eng PT - Journal Article PT - Review DEP - 20250726 PL - United States TA - Struct Heart JT - Structural heart : the journal of the Heart Team JID - 101743256 PMC - PMC12410443 OTO - NOTNLM OT - Cardiac implantable electronic devices OT - Implantable cardiac defibrillator OT - Pacemaker OT - Transcatheter tricuspid valve replacement OT - Tricuspid regurgitation COIS- S. Garcia is a consultant for Edwards Lifesciences, Medtronic, Abbott Vascular, Boston Scientific, Anteris, Capstan Medical, and B. Braun; a proctor for Edwards Lifesciences and Abbott Vascular; an advisory board member for Medtronic and Boston Scientific; and has stock options in Capstan Medical. The other authors had no conflicts to declare. EDAT- 2025/09/08 12:43 MHDA- 2025/09/08 12:43 PMCR- 2025/07/26 CRDT- 2025/09/08 07:15 PHST- 2025/04/28 00:00 [received] PHST- 2025/07/12 00:00 [revised] PHST- 2025/07/22 00:00 [accepted] PHST- 2025/09/08 12:43 [medline] PHST- 2025/09/08 12:43 [pubmed] PHST- 2025/09/08 07:15 [entrez] PHST- 2025/07/26 00:00 [pmc-release] AID - S2474-8706(25)00299-4 [pii] AID - 100707 [pii] AID - 10.1016/j.shj.2025.100707 [doi] PST - epublish SO - Struct Heart. 2025 Jul 26;9(9):100707. doi: 10.1016/j.shj.2025.100707. eCollection 2025 Sep. PMID- 40918237 OWN - NLM STAT- In-Process LR - 20250910 IS - 2432-0935 (Electronic) IS - 2432-0935 (Linking) VI - 10 DP - 2025 TI - Latest Trend of Endovascular Treatment for Lower Extremity Artery Disease and Recommendations from Interventional Radiologist: To Continue Engaging in This Field Moving Forward. PG - e20240052 LID - 10.22575/interventionalradiology.2024-0052 [doi] AB - Lower extremity artery disease affects more than 230 million people worldwide, leading to significant cardiovascular and limb-related complications. Recent advancements in endovascular treatment, driven by technological innovations and increasing patient prevalence due to aging populations and lifestyle diseases, has contributed to a growing demand for endovascular treatment. In Japan, the number of endovascular treatment procedures has increased specifically among cardiologists, whereas the involvement of interventional radiology physicians remains limited. This review explores the latest trends and clinical outcomes of endovascular treatment, and the importance of multidisciplinary collaboration, including the role of interventional radiology physicians. The findings encourage greater involvement of interventional radiology physicians in endovascular treatment. CI - (c) 2025 Japanese Society of Interventional Radiology. FAU - Endo, Masayuki AU - Endo M AD - Division of Radiology, Department of Multidisciplinary Internal Medicine, Tottori University, Japan. FAU - Yata, Shinsaku AU - Yata S AD - Division of Radiology, Department of Multidisciplinary Internal Medicine, Tottori University, Japan. FAU - Takasugi, Shohei AU - Takasugi S AD - Division of Radiology, Department of Multidisciplinary Internal Medicine, Tottori University, Japan. FAU - Yamamoto, Shuichi AU - Yamamoto S AD - Division of Radiology, Department of Multidisciplinary Internal Medicine, Tottori University, Japan. FAU - Kamata, Yuji AU - Kamata Y AD - Division of Radiology, Department of Multidisciplinary Internal Medicine, Tottori University, Japan. FAU - Makishima, Jun AU - Makishima J AD - Department of Radiology, Matsue City Hospital, Japan. FAU - Kishimoto, Misato AU - Kishimoto M AD - Division of Radiology, Department of Multidisciplinary Internal Medicine, Tottori University, Japan. FAU - Shinano, Kentaro AU - Shinano K AD - Division of Radiology, Department of Multidisciplinary Internal Medicine, Tottori University, Japan. FAU - Fujii, Shinya AU - Fujii S AD - Division of Radiology, Department of Multidisciplinary Internal Medicine, Tottori University, Japan. LA - eng PT - Journal Article PT - Review DEP - 20250630 PL - Japan TA - Interv Radiol (Higashimatsuyama) JT - Interventional radiology (Higashimatsuyama-shi (Japan) JID - 101745449 PMC - PMC12408231 OTO - NOTNLM OT - chronic limb-threatening ischemia OT - endovascular treatment OT - lower extremity artery disease OT - multidisciplinary team COIS- None EDAT- 2025/09/08 12:43 MHDA- 2025/09/08 12:43 PMCR- 2025/06/30 CRDT- 2025/09/08 07:09 PHST- 2024/12/07 00:00 [received] PHST- 2025/01/31 00:00 [accepted] PHST- 2025/09/08 12:43 [medline] PHST- 2025/09/08 12:43 [pubmed] PHST- 2025/09/08 07:09 [entrez] PHST- 2025/06/30 00:00 [pmc-release] AID - 10.22575/interventionalradiology.2024-0052 [doi] PST - epublish SO - Interv Radiol (Higashimatsuyama). 2025 Jun 30;10:e20240052. doi: 10.22575/interventionalradiology.2024-0052. eCollection 2025. PMID- 40917916 OWN - NLM STAT- In-Process LR - 20250910 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 17 IP - 9 DP - 2025 Sep TI - Genetics of Congenital Heart Disease: A Narrative Review of Challenges and Strategies in Identifying Novel Genes. PG - e91674 LID - 10.7759/cureus.91674 [doi] LID - e91674 AB - Congenital heart disease (CHD) is the most common congenital anomaly. While surgical and interventional advancements have improved survival, the management of associated complications and comorbidities remains complex and would benefit from a personalised approach that more accurately predicts individualised risks and prognoses. Recently, next-generation sequencing has uncovered diverse genetic factors, including epigenetic modifications, somatic mosaicism and regulatory non-coding variants. Despite these advances, challenges persist in translating genomic data into clinical risk prediction and therapeutic guidance. Experimental approaches, such as patient-derived induced pluripotent stem cells (iPSCs) and single-cell sequencing, offer promising preclinical models for interpreting novel variants. Integrating genomic insights into clinical practice requires multidisciplinary team collaboration. The clinicians need to keep themselves abreast with current genomic advancements to optimise customised, individualised care to improve future outcomes for patients with CHD. We aim to provide an overview of the advances in genomic technologies linking the genetics of cardiac development with the pathogenesis of CHD for a better understanding of molecular-morphological correlation. CI - Copyright (c) 2025, Rao et al. FAU - Rao, Eteesha AU - Rao E AD - Department of Medical Education, Newcastle University, Newcastle, GBR. FAU - Annavarapu, Srinivas AU - Annavarapu S AD - Department of Paediatric Histopathology, Alder Hey Children's Hospital, Liverpool, GBR. LA - eng PT - Journal Article PT - Review DEP - 20250905 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC12412710 OTO - NOTNLM OT - congenital heart disease OT - gene regulation OT - genetics OT - genomics OT - signalling pathways OT - transcription factors COIS- Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. EDAT- 2025/09/08 12:45 MHDA- 2025/09/08 12:45 PMCR- 2025/09/05 CRDT- 2025/09/08 07:06 PHST- 2025/09/05 00:00 [accepted] PHST- 2025/09/08 12:45 [medline] PHST- 2025/09/08 12:45 [pubmed] PHST- 2025/09/08 07:06 [entrez] PHST- 2025/09/05 00:00 [pmc-release] AID - 10.7759/cureus.91674 [doi] PST - epublish SO - Cureus. 2025 Sep 5;17(9):e91674. doi: 10.7759/cureus.91674. eCollection 2025 Sep. PMID- 40916648 OWN - NLM STAT- Publisher LR - 20250908 IS - 1522-726X (Electronic) IS - 1522-1946 (Linking) DP - 2025 Sep 8 TI - Inducible Ischemia in Asymptomatic Patients With Coronary Chronic Total Occlusions: A Stress CMR Study. LID - 10.1002/ccd.70161 [doi] AB - BACKGROUND: Given the divergence in recommendations regarding the relevance of inducible ischemia regarding the indication to revascularize chronic total occlusions (CTOs) among European and North American guidelines, we aim at investigating the prevalence and the prognostic impact of significant inducible ischemia in an unselected cohort of asymptomatic CTO patients, integrating collateralization status and viability assessment with stress cardiac magnetic resonance (CMR). METHODS: From a cohort of 749 patients referred to our center with a diagnosis of CTO, we retrospectively analyzed 111 asymptomatic individuals who underwent an adenosine stress CMR. The amount of inducible ischemia subtended by the CTO was calculated, as well as the presence of viable myocardium and the collateralization status. The decision to revascularize the CTO was based on a multiparametric assessment conducted by the Heart Team, taking into consideration the vessels' anatomy and the amount of inducible ischemia. A composite endpoint of cardiovascular mortality and non-fatal myocardial infarction was considered. RESULTS: Thirty-seven patients out of 111 (33%) showed a significant amount of inducible ischemia, indicated by an ischemic burden of at least 10% of the left ventricular (LV) mass. The risk of cardiovascular adverse events was similar among patients who received or not revascularization of the CTO. CONCLUSIONS: Among asymptomatic patients with CTO undergoing stress CMR, one out of three patients exhibited a substantial amount of inducible ischemia. Considering the possible benefit of revascularization in patients with a significant amount of inducible ischemia, these observations may suggest a possible broader role of stress-CMR within asymptomatic CTO patients. CI - (c) 2025 Wiley Periodicals LLC. FAU - Pinto, Giuseppe AU - Pinto G AUID- ORCID: 0000-0003-2213-2955 AD - IRCCS Humanitas Research Hospital, Rozzano-Milan, Italy. AD - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele-Milan, Italy. FAU - Chiarito, Mauro AU - Chiarito M AUID- ORCID: 0000-0002-9333-2658 AD - IRCCS Humanitas Research Hospital, Rozzano-Milan, Italy. AD - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele-Milan, Italy. FAU - Liccardo, Gaetano AU - Liccardo G AUID- ORCID: 0000-0002-3883-1622 AD - IRCCS Humanitas Research Hospital, Rozzano-Milan, Italy. AD - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele-Milan, Italy. FAU - Baggio, Sara AU - Baggio S AD - IRCCS Humanitas Research Hospital, Rozzano-Milan, Italy. AD - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele-Milan, Italy. FAU - Bacci, Elodi AU - Bacci E AD - IRCCS Humanitas Research Hospital, Rozzano-Milan, Italy. FAU - Del Monaco, Guido AU - Del Monaco G AD - IRCCS Humanitas Research Hospital, Rozzano-Milan, Italy. AD - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele-Milan, Italy. FAU - Catapano, Federica AU - Catapano F AD - IRCCS Humanitas Research Hospital, Rozzano-Milan, Italy. FAU - Gasparini, Gabriele L AU - Gasparini GL AUID- ORCID: 0000-0003-3653-9553 AD - IRCCS Humanitas Research Hospital, Rozzano-Milan, Italy. FAU - Stefanini, Giulio G AU - Stefanini GG AUID- ORCID: 0000-0002-3558-6967 AD - IRCCS Humanitas Research Hospital, Rozzano-Milan, Italy. AD - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele-Milan, Italy. FAU - Condorelli, Gianluigi AU - Condorelli G AD - IRCCS Humanitas Research Hospital, Rozzano-Milan, Italy. AD - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele-Milan, Italy. FAU - Francone, Marco AU - Francone M AD - IRCCS Humanitas Research Hospital, Rozzano-Milan, Italy. AD - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele-Milan, Italy. FAU - Monti, Lorenzo AU - Monti L AD - IRCCS Humanitas Research Hospital, Rozzano-Milan, Italy. AD - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele-Milan, Italy. LA - eng GR - The authors received no specific funding for this work./ PT - Journal Article DEP - 20250908 PL - United States TA - Catheter Cardiovasc Interv JT - Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions JID - 100884139 SB - IM OTO - NOTNLM OT - cardiac magnetic resonance OT - chronic total occlusion OT - coronary collaterals OT - inducible ischemia OT - myocardial viability EDAT- 2025/09/08 06:32 MHDA- 2025/09/08 06:32 CRDT- 2025/09/08 03:43 PHST- 2025/08/17 00:00 [revised] PHST- 2025/07/04 00:00 [received] PHST- 2025/09/01 00:00 [accepted] PHST- 2025/09/08 06:32 [medline] PHST- 2025/09/08 06:32 [pubmed] PHST- 2025/09/08 03:43 [entrez] AID - 10.1002/ccd.70161 [doi] PST - aheadofprint SO - Catheter Cardiovasc Interv. 2025 Sep 8. doi: 10.1002/ccd.70161. PMID- 40912227 OWN - NLM STAT- MEDLINE DCOM- 20251113 LR - 20260425 IS - 1878-5883 (Electronic) IS - 0022-510X (Linking) VI - 478 DP - 2025 Nov 15 TI - The expanding clinical utility of blood neurofilament light chain (bNfL): a multi-disciplinary diagnostic tool. PG - 123669 LID - S0022-510X(25)00289-8 [pii] LID - 10.1016/j.jns.2025.123669 [doi] AB - BACKGROUND: The protein neurofilament light chain in blood (bNfL) has become a valuable biomarker in the diagnosis, monitoring, and prognosis of neurological diseases. However, its potential use beyond neurology in routine clinical practice remains unexplored. This study aimed to examine the clinical utility of bNfL by investigating its expanding use (i) assessing its integration into in- and outpatient routine practice, (ii) both within and outside of academic hospitals, and (iii) across different medical disciplines and various departments. METHODS: This study examined data from two large clinical chemistry laboratories that provide bNfL measurements for the clinical routine: Labor Berlin, Germany, and the Clinical Neurochemistry Laboratory at Sahlgrenska University Hospital, Sweden. Together, this large-scale retrospective study acquired data on bNfL measurements from n = 22,122 individuals during the years 2021 to 2023. RESULTS: Our findings revealed that (i) outpatient clinics and (ii) non-academic healthcare settings are gradually integrating bNfL into their routine practice and (iii) its use has expanded across an increasing number of medical disciplines over time, indicating its growing importance as a diagnostic tool, beyond neurology. Notably, departments such as cardiology, hematology/oncology and intensive care units increasingly incorporated bNfL into their clinical repertoire. DISCUSSION: This study underscores the developing impact of easily accessible bNfL on clinical routine, not only enhancing neurologists' diagnostic tools but also offering valuable insights into diverse medical fields, in- and outside the academic environment. CI - Copyright (c) 2025. Published by Elsevier B.V. FAU - Kortvelyessy, Peter AU - Kortvelyessy P AD - Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Department of Neurology, Berlin, Germany; Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, MVZ Neurology, Berlin, Germany; Labor Berlin GmbH, Immunology and Neurodegeneration, Germany; German Center for Neurodegenerative Diseases (DZNE), partner site Magdeburg, Germany. Electronic address: peter.koertvelyessy@charite.de. FAU - Arslan, Burak AU - Arslan B AD - Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Molndal, Sweden. FAU - Nietiet, Jonah AU - Nietiet J AD - Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Department of Neurology, Berlin, Germany. FAU - Leithner, Christoph AU - Leithner C AD - Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Department of Neurology, Berlin, Germany. FAU - Huhnchen, Petra AU - Huhnchen P AD - Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Department of Neurology, Berlin, Germany. FAU - Bohmerle, Wolfgang AU - Bohmerle W AD - Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Department of Neurology, Berlin, Germany. FAU - Endres, Matthias AU - Endres M AD - Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Department of Neurology, Berlin, Germany; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Molndal, Sweden; German Center for Neurodegenerative Diseases (DZNE), partner site Berlin, Germany; Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Center for Stroke Research Berlin, Berlin, Germany; German Centre for Cardiovascular Research (DZHK), partner site Berlin, Germany. FAU - Ploner, Christoph J AU - Ploner CJ AD - Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Department of Neurology, Berlin, Germany. FAU - Audebert, Heiner AU - Audebert H AD - Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Department of Neurology, Berlin, Germany. FAU - Hahn, Katrin AU - Hahn K AD - Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Department of Neurology, Berlin, Germany. FAU - Meyer, Thomas AU - Meyer T AD - Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Department of Neurology, Berlin, Germany. FAU - Luschow, Andreas AU - Luschow A AD - Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, MVZ Neurology, Berlin, Germany. FAU - Weiss, Claudia AU - Weiss C AD - Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Department of Neuropediatrics, Berlin, Germany. FAU - Biztan, Lisa-Valerie AU - Biztan LV AD - Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Department of Neuropediatrics, Berlin, Germany. FAU - Spethmann, Sebastian AU - Spethmann S AD - Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Center for Stroke Research Berlin, Berlin, Germany; Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Deutsches Herzzentrum der Charite, Department of Cardiology, Angiology and Intensive Care Medicine, Berlin, Germany. FAU - Graw, Adriaan J AU - Graw AJ AD - Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Department of Anaesthesiology, Intensive care medicine, Angiology, Berlin, Germany; Department of Intensive Care, University Ulm, Germany. FAU - Unterwalder, Nadine AU - Unterwalder N AD - Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, MVZ Neurology, Berlin, Germany; Labor Berlin GmbH, Immunology and Neurodegeneration, Germany. FAU - Meisel, Christian AU - Meisel C AD - Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, MVZ Neurology, Berlin, Germany; Labor Berlin GmbH, Immunology and Neurodegeneration, Germany. FAU - Ashton, Nicholas J AU - Ashton NJ AD - Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Molndal, Sweden. FAU - Blennow, Kaj AU - Blennow K AD - Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Molndal, Sweden. FAU - Zetterberg, Henrik AU - Zetterberg H AD - Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Molndal, Sweden; Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Molndal, Sweden; Dementia Research Institute, University College London, UK; Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK; Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53792, USA. FAU - Goschel, Laura AU - Goschel L AD - Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Department of Neurology, Berlin, Germany. LA - eng PT - Journal Article DEP - 20250823 PL - Netherlands TA - J Neurol Sci JT - Journal of the neurological sciences JID - 0375403 RN - 0 (Neurofilament Proteins) RN - 0 (neurofilament protein L) RN - 0 (Biomarkers) SB - IM MH - Humans MH - *Neurofilament Proteins/blood MH - Biomarkers/blood MH - Retrospective Studies MH - Female MH - Male MH - *Nervous System Diseases/blood/diagnosis MH - Middle Aged MH - Adult MH - Aged MH - Sweden OTO - NOTNLM OT - Neurofilament light chain OT - Neurology OT - Real world data OT - Serum COIS- Declaration of competing interest PK served on advisory boards received travel and accommodation reimbursement and speaker honoraria from Novartis, Alector, Roche Diagnostics, Biogen, Eli Lilly, EISAI, Biogen, and Schering Consultation. HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZpath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures sponsored by Alzecure, BioArctic, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, Roche, and WebMD, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). ME reports grants from Bayer and fees paid to the Charite from Amgen, AstraZeneca, Bayer, BMS, and Daiichi Sankyo, all outside the submitted work. PH and WB have received lecture fees from NOGGO e.V. (Nord-Ostdeutsche Gesellschaft fur Gynakologische Onkologie). None of the other authors have reported any declaration of interest. EDAT- 2025/09/06 00:34 MHDA- 2025/11/13 18:30 CRDT- 2025/09/05 18:11 PHST- 2025/03/25 00:00 [received] PHST- 2025/07/27 00:00 [revised] PHST- 2025/08/21 00:00 [accepted] PHST- 2025/11/13 18:30 [medline] PHST- 2025/09/06 00:34 [pubmed] PHST- 2025/09/05 18:11 [entrez] AID - S0022-510X(25)00289-8 [pii] AID - 10.1016/j.jns.2025.123669 [doi] PST - ppublish SO - J Neurol Sci. 2025 Nov 15;478:123669. doi: 10.1016/j.jns.2025.123669. Epub 2025 Aug 23. PMID- 40910961 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251106 LR - 20251206 IS - 2772-3747 (Electronic) IS - 2772-3747 (Linking) VI - 5 IP - 11 DP - 2025 Nov TI - Addressing Frailty in Cardiology: Identifying Barriers Faced by Cardiologists and Health Care Professionals in Asia. PG - 1457-1471 LID - S2772-3747(25)00373-4 [pii] LID - 10.1016/j.jacasi.2025.07.002 [doi] AB - BACKGROUND: Preventing frailty is crucial for improving outcomes in aging populations at heightened cardiovascular risk, yet implementation in real-world practice remains challenging. The authors previously reported low use of frailty strategies among cardiologists in Asia. OBJECTIVES: The aim of this study was to explore the barriers to frailty implementation among cardiologists, other physicians, and nurses. METHODS: A multinational web-based survey was conducted targeting health care communities across Asia. RESULTS: Among 238 respondents (median age 34.0 years; IQR: 12 years; 63.4% women), 172 were doctors, 57 nurses, and 8 allied health professionals. Among doctors, 59 were cardiologists representing various subspecialties, including critical care cardiology, interventional cardiology, and general cardiology. Among all respondents, one-quarter lacked confidence in identifying (22.7%) or treating (28.2%) frailty, and many were uncertain of the screening tools (34.9%) and subsequent steps (37.8%). Other barriers include inadequate multidisciplinary support (21%), communication difficulties (45.8%), resource limitations (52.9%), patient and caregiver unreceptiveness (21.8%), and insufficient community care collaborations (39.5%). Compared with other physicians, cardiologists reported being too busy (P = 0.041) and having less awareness of screening selection (P = 0.018) and appropriate assessment tools (P = 0.008). Nurses experienced fewer interdisciplinary communication difficulties (P = 0.003) than cardiologists. There were no significant differences in understanding, support received, and patients' and caregivers' receptiveness toward frailty interventions between nurses and cardiologists. CONCLUSIONS: Distinct barriers to frailty implementation exist at multiple levels, including gaps in provider expertise, insufficient support, and resource constraints that limit adequate frailty care provision. To address the diverse needs of stakeholders, a comprehensive implementation strategy leveraging interdisciplinary cardiogeriatric team resources and involving nurses could improve frailty care in cardiology. CI - Copyright (c) 2025 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Wong, Jie Jun AU - Wong JJ AD - Department of Cardiology, National Heart Center Singapore, Singapore, Singapore. FAU - Hong, Rilong AU - Hong R AD - Department of Cardiology, National Heart Center Singapore, Singapore, Singapore. FAU - Ong, Terence Ing Wei AU - Ong TIW AD - Department of Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia. FAU - Lim, Jae-Young AU - Lim JY AD - Department of Rehabilitation Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea. FAU - Yan, Tingting AU - Yan T AD - Nursing Department, Liaocheng Vocational and Technical College, Liaocheng City, China. FAU - Park, Duk-Woo AU - Park DW AD - Division of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. FAU - Tan, Gabrielle H N AU - Tan GHN AD - Department of Cardiology, National Heart Center Singapore, Singapore, Singapore. FAU - Zhang, Hongzhou AU - Zhang H AD - Department of Cardiology, First Affiliated Hospital of Gannan Medical University, Ganzhou, China. FAU - Nguyen, Thu Thi Hoai AU - Nguyen TTH AD - Department of Geriatrics, Hanoi Medical University, Hanoi, Vietnam; Scientific Research Department, National Geriatric Hospital, Hanoi, Vietnam. FAU - Nguyen, Huong Thi Thu AU - Nguyen HTT AD - Department of Geriatrics, Hanoi Medical University, Hanoi, Vietnam; Scientific Research Department, National Geriatric Hospital, Hanoi, Vietnam. FAU - Dong, Yanhong AU - Dong Y AD - Alice Lee Centre for Nursing Studies, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. FAU - Kong, William K F AU - Kong WKF AD - Department of Cardiology, National University Heart Centre, Singapore, Singapore; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. FAU - Li, Shang AU - Li S AD - Duke-National University of Singapore Medical School, Singapore, Singapore. FAU - Tan, Jack W C AU - Tan JWC AD - Department of Cardiology, National Heart Center Singapore, Singapore, Singapore; Duke-National University of Singapore Medical School, Singapore, Singapore. FAU - Vu, Huyen Thi Thanh AU - Vu HTT AD - Department of Geriatrics, Hanoi Medical University, Hanoi, Vietnam; Scientific Research Department, National Geriatric Hospital, Hanoi, Vietnam. FAU - Koh, Angela S AU - Koh AS AD - Department of Cardiology, National Heart Center Singapore, Singapore, Singapore; Duke-National University of Singapore Medical School, Singapore, Singapore. Electronic address: angela.koh.s.m@singhealth.com.sg. LA - eng PT - Journal Article DEP - 20250905 PL - United States TA - JACC Asia JT - JACC. Asia JID - 9918452380106676 PMC - PMC12673825 OTO - NOTNLM OT - barriers OT - cardiology OT - frailty OT - implementation OT - policy COIS- Funding Support and Author Disclosures This study has received funding support from National Medical Research Council of Singapore (grant MOH-001200). The funder had no role in the design and conduct of the study; the collection, management, analysis, and interpretation of the data; and the preparation, review, and approval of the manuscript. The authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2025/09/05 12:40 MHDA- 2025/09/05 12:41 PMCR- 2025/09/05 CRDT- 2025/09/05 10:29 PHST- 2025/04/14 00:00 [received] PHST- 2025/07/07 00:00 [revised] PHST- 2025/07/08 00:00 [accepted] PHST- 2025/09/05 12:41 [medline] PHST- 2025/09/05 12:40 [pubmed] PHST- 2025/09/05 10:29 [entrez] PHST- 2025/09/05 00:00 [pmc-release] AID - S2772-3747(25)00373-4 [pii] AID - 10.1016/j.jacasi.2025.07.002 [doi] PST - ppublish SO - JACC Asia. 2025 Nov;5(11):1457-1471. doi: 10.1016/j.jacasi.2025.07.002. Epub 2025 Sep 5. PMID- 40908974 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250915 LR - 20250929 IS - 2328-8957 (Print) IS - 2328-8957 (Electronic) IS - 2328-8957 (Linking) VI - 12 IP - 9 DP - 2025 Sep TI - Performance of Different Versions of Duke Criteria in Diagnosing Infective Endocarditis in Patients With Intracardiac Prosthetic Materials. PG - ofaf507 LID - 10.1093/ofid/ofaf507 [doi] LID - ofaf507 AB - BACKGROUND: Diagnosing infective endocarditis (IE) is a significant challenge. This study aimed to compare the diagnostic performance of the 2015 and 2023 European Society of Cardiology (ESC) and the 2023 International Society for Cardiovascular Infectious Diseases (ISCVID) Duke clinical criteria in a cohort of patients with suspected IE and intracardiac prosthetic material. METHODS: This retrospective study was conducted at 2 Swiss University Hospitals (2014-2024). The reference standard was the diagnosis of the Endocarditis Team or expert clinicians. Patients with IE (reference standard) classified as definite IE by the Duke criteria were considered true positives, while those without IE classified as rejected IE were considered true negatives. RESULTS: Of the 1025 episodes with suspected IE and intracardiac prosthetic material, 537 (61%) had IE. Using the 2015 ESC, 2023 ESC, and 2023 ISCVID clinical criteria, 324 (32%), 367 (36%), and 430 (42%) episodes were classified as definite IE, respectively. The sensitivity for the 2015 Duke-ESC, 2023 Duke-ESC, and 2023 Duke-ISCVID the clinical criteria was calculated to be 56% (95% CI: 52-60%), 61% (57-65%), and 71% (67-74%), respectively, while the specificity 67% (63-71%), 56% (51-61%), and 34% (29-38%), respectively. CONCLUSIONS: The 2023 ISCVID Duke clinical criteria demonstrated the highest sensitivity for diagnosing IE compared to the 2015 and 2023 ESC Duke criteria in patients with intracardiac prosthetic material. However, this was at the expense of specificity. CI - (c) The Author(s) 2025. Published by Oxford University Press on behalf of Infectious Diseases Society of America. FAU - Papadimitriou-Olivgeris, Matthaios AU - Papadimitriou-Olivgeris M AUID- ORCID: 0000-0003-0565-5105 AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. AD - Infectious Diseases Service, Hospital of Valais and Institut Central des Hopitaux, Sion, Switzerland. FAU - Ledergerber, Bruno AU - Ledergerber B AUID- ORCID: 0000-0002-6881-4401 AD - Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich and University of Zurich, Zurich, Switzerland. FAU - Epprecht, Jana AU - Epprecht J AUID- ORCID: 0000-0003-3277-7044 AD - Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich and University of Zurich, Zurich, Switzerland. FAU - Siedentop, Berit AU - Siedentop B AUID- ORCID: 0000-0003-0802-7681 AD - Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich and University of Zurich, Zurich, Switzerland. FAU - Monney, Pierre AU - Monney P AUID- ORCID: 0000-0002-3083-7333 AD - Department of Cardiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Frank, Michelle AU - Frank M AD - Department of Cardiology, University Hospital Zurich and University of Zurich, Zurich, Switzerland. FAU - Tzimas, Georgios AU - Tzimas G AUID- ORCID: 0000-0002-2810-8887 AD - Department of Cardiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Fourre, Nicolas AU - Fourre N AUID- ORCID: 0009-0006-1660-9365 AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Zimmermann, Virgile AU - Zimmermann V AUID- ORCID: 0009-0005-1812-0216 AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Domenichini, Giulia AU - Domenichini G AD - Department of Cardiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Niclauss, Lars AU - Niclauss L AUID- ORCID: 0000-0003-4453-5202 AD - Department of Cardiac Surgery, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Kirsch, Matthias AU - Kirsch M AUID- ORCID: 0000-0002-9213-7578 AD - Department of Cardiac Surgery, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Van Hemelrijck, Mathias AU - Van Hemelrijck M AUID- ORCID: 0000-0002-0191-757X AD - Department of Cardiac Surgery, University Hospital Zurich and University of Zurich, Zurich, Switzerland. FAU - Dzemali, Omer AU - Dzemali O AUID- ORCID: 0000-0001-7910-5152 AD - Department of Cardiac Surgery, University Hospital Zurich and University of Zurich, Zurich, Switzerland. AD - Department of Cardiac Surgery, City Hospital of Zurich - Triemli, Zurich, Switzerland. AD - Center for Experimental and Translational Cardiology, University of Zurich, Zurich, Switzerland. FAU - Guery, Benoit AU - Guery B AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Hasse, Barbara AU - Hasse B AUID- ORCID: 0000-0001-7196-3734 AD - Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich and University of Zurich, Zurich, Switzerland. LA - eng PT - Journal Article DEP - 20250819 PL - United States TA - Open Forum Infect Dis JT - Open forum infectious diseases JID - 101637045 PMC - PMC12404897 OTO - NOTNLM OT - Duke criteria OT - European society of cardiology (ESC) OT - infective endocarditis OT - international society for cardiovascular infectious diseases (ISCVID) OT - prosthetic valve COIS- Potential conflicts of interest. All authors: No reported conflicts. EDAT- 2025/09/05 06:34 MHDA- 2025/09/05 06:35 PMCR- 2025/08/19 CRDT- 2025/09/05 04:55 PHST- 2025/06/04 00:00 [received] PHST- 2025/08/16 00:00 [accepted] PHST- 2025/09/05 06:35 [medline] PHST- 2025/09/05 06:34 [pubmed] PHST- 2025/09/05 04:55 [entrez] PHST- 2025/08/19 00:00 [pmc-release] AID - ofaf507 [pii] AID - 10.1093/ofid/ofaf507 [doi] PST - epublish SO - Open Forum Infect Dis. 2025 Aug 19;12(9):ofaf507. doi: 10.1093/ofid/ofaf507. eCollection 2025 Sep. PMID- 40908972 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250915 LR - 20261024 IS - 2328-8957 (Print) IS - 2328-8957 (Electronic) IS - 2328-8957 (Linking) VI - 12 IP - 9 DP - 2025 Sep TI - Evaluating Blood Culture Parameters to Identify Patients at Low Risk of Infective Endocarditis Among Those With Bacteremia by Gram-positive Cocci. PG - ofaf518 LID - 10.1093/ofid/ofaf518 [doi] LID - ofaf518 AB - BACKGROUND: Identifying patients at low risk for infective endocarditis (IE) among those with bacteremia by Gram-positive cocci is critical to optimize cardiac imaging use. The aim was to assess the diagnostic performance of blood culture parameters in identifying patients at low risk for IE. METHODS: Adult patients with bacteremia due to Staphylococcus aureus, streptococci, or Enterococcus faecalis at the Lausanne University Hospital were included. Low-risk criteria were defined as: only one positive out of four initial blood culture bottles and bacteremia clearance within 48 hours. The primary outcome was the diagnosis of IE, determined by the Endocarditis Team. Negative likelihood ratios (NLRs) were calculated. RESULTS: Among 2165 episodes of bacteremia, 1165 (54%) were due to S. aureus, 726 (34%) to streptococci, and 326 (15%) to E. faecalis. IE was diagnosed in 561 (26%) episodes. Among all episodes, 1767 (82%) had >1 positive out of the initial 4 blood culture bottles collected, and 1783 (82%) had either >1 positive out of the initial 4 blood culture bottles or persistent bacteremia for >/=48 hours. Having only 1 positive out of 4 initial blood culture bottles was associated with a NLR of 0.10 (95% CI, .06-.18). When combining both criteria, 1 positive out of 4 blood culture bottles and bacteremia clearance before 48 hours, the NLR was 0.08 (0.05-0.15). CONCLUSIONS: Simple blood culture parameters may help identify patients at low risk for IE. However, the approach classifies most patients as high-risk and may have limited impact on reducing echocardiography use. CI - (c) The Author(s) 2025. Published by Oxford University Press on behalf of Infectious Diseases Society of America. FAU - Fourre, Nicolas AU - Fourre N AUID- ORCID: 0009-0006-1660-9365 AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Zimmermann, Virgile AU - Zimmermann V AUID- ORCID: 0009-0005-1812-0216 AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Ianculescu, Nicoleta AU - Ianculescu N AD - Department of Cardiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Brahier, Thomas AU - Brahier T AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Dennebouy, Zelie AU - Dennebouy Z AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Teixeira-Antunes, Andre AU - Teixeira-Antunes A AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Monney, Pierre AU - Monney P AUID- ORCID: 0000-0002-3083-7333 AD - Department of Cardiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Tzimas, Georgios AU - Tzimas G AUID- ORCID: 0000-0002-2810-8887 AD - Department of Cardiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Senn, Laurence AU - Senn L AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. AD - Infection Prevention and Control Unit, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Niclauss, Lars AU - Niclauss L AUID- ORCID: 0000-0003-4453-5202 AD - Department of Cardiac Surgery, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Kirsch, Matthias AU - Kirsch M AUID- ORCID: 0000-0002-9213-7578 AD - Department of Cardiac Surgery, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Guery, Benoit AU - Guery B AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Papadimitriou-Olivgeris, Matthaios AU - Papadimitriou-Olivgeris M AUID- ORCID: 0000-0003-0565-5105 AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. AD - Infectious Diseases Service, Hospital of Valais and Institut Central des Hopitaux, Sion, Switzerland. LA - eng PT - Journal Article DEP - 20250822 PL - United States TA - Open Forum Infect Dis JT - Open forum infectious diseases JID - 101637045 EIN - Open Forum Infect Dis. 2026 Oct 22;13(10):ofag618. doi: 10.1093/ofid/ofag618. PMID: 42924266 PMC - PMC12405998 OTO - NOTNLM OT - Enterococcus faecalis OT - Staphylococcus aureus OT - bacteremia OT - infective endocarditis OT - streptococci COIS- Potential conflicts of interest. The authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. EDAT- 2025/09/05 06:34 MHDA- 2025/09/05 06:35 PMCR- 2025/08/22 CRDT- 2025/09/05 04:55 PHST- 2025/07/30 00:00 [received] PHST- 2025/08/20 00:00 [accepted] PHST- 2025/09/05 06:35 [medline] PHST- 2025/09/05 06:34 [pubmed] PHST- 2025/09/05 04:55 [entrez] PHST- 2025/08/22 00:00 [pmc-release] AID - ofaf518 [pii] AID - 10.1093/ofid/ofaf518 [doi] PST - epublish SO - Open Forum Infect Dis. 2025 Aug 22;12(9):ofaf518. doi: 10.1093/ofid/ofaf518. eCollection 2025 Sep. PMID- 40908174 OWN - NLM STAT- MEDLINE DCOM- 20260426 LR - 20260522 IS - 1878-0938 (Electronic) IS - 1878-0938 (Linking) VI - 85 DP - 2026 Apr TI - Decision-making in valve reintervention: Redo-Transcatheter aortic valve replacement vs. explant surgery. PG - 28-32 LID - S1553-8389(25)00456-7 [pii] LID - 10.1016/j.carrev.2025.08.018 [doi] AB - OBJECTIVE: Data remain limited on factors influencing the selection of redo-transcatheter aortic valve replacement (TAVR) versus surgical explant in patients with failing transcatheter heart valves. This study aimed to identify clinical and procedural factors guiding treatment decisions. METHODS: This single-center, retrospective study included all patients who underwent aortic valve reintervention following prior TAVR at a U.S. tertiary referral center between January 2015 and June 2024. Clinical records, imaging, and Heart Team notes were reviewed to determine rationale for treatment selection. Procedural details and major adverse cardiac events (MACE: death, rehospitalization, or stroke) were collected. RESULTS: Among 47 patients, 24 (51 %) underwent surgical explant and 23 (49 %) redo-TAVR. The explant group was significantly younger (75 vs. 79 years; p = 0.018), with similar gender distribution (31.9 % female). Time to reintervention was comparable (27.8 vs. 34.2 months; p = 0.75). Common indications for explant included endocarditis (33.3 %), patient-prosthesis mismatch (16.7 %), prior valve-in-valve (16.7 %), annular rupture risk (12.5 %), need for concomitant surgery (8.3 %), and coronary obstruction risk (8.3 %). Thirty-day and one-year MACE rates were significantly higher with explant (30.4 % vs. 0 %, p = 0.029; 59.1 % vs. 21.4 %, p = 0.041). Mortality was numerically higher but not statistically significant. Patients undergoing explant often had more comorbidities and required complex procedures. CONCLUSION: Among patients undergoing reintervention after TAVR, treatment was evenly split between redo-TAVR and explant, underscoring the importance of lifetime planning at initial TAVR. This analysis shows the two groups represent inherently different patient populations and highlights the need for randomized trials to define optimal treatment pathways. CI - Copyright (c) 2025 Elsevier Inc. All rights reserved. FAU - Lupu, Lior AU - Lupu L AD - Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA. FAU - Reddy, Pavan AU - Reddy P AD - Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA. FAU - Haberman, Dan AU - Haberman D AD - Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA. FAU - Cellamare, Matteo AU - Cellamare M AD - Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA. FAU - Zhang, Cheng AU - Zhang C AD - Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA. FAU - Sawant, Vaishnavi AU - Sawant V AD - Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA. FAU - Rappaport, Hank AU - Rappaport H AD - Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA. FAU - Chitturi, Kalyan R AU - Chitturi KR AD - Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA. FAU - Chaturvedi, Abhishek AU - Chaturvedi A AD - Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA. FAU - Abusnina, Waiel AU - Abusnina W AD - Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA. FAU - Cohen, Jeffrey E AU - Cohen JE AD - Department of Cardiac Surgery, MedStar Washington Hospital Center, Washington, DC, USA. FAU - Shults, Christian C AU - Shults CC AD - Department of Cardiac Surgery, MedStar Washington Hospital Center, Washington, DC, USA. FAU - MacGillivray, Thomas E AU - MacGillivray TE AD - Department of Cardiac Surgery, MedStar Washington Hospital Center, Washington, DC, USA. FAU - Satler, Lowell F AU - Satler LF AD - Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA. FAU - Ben-Dor, Itsik AU - Ben-Dor I AD - Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA. FAU - Waksman, Ron AU - Waksman R AD - Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA. FAU - Rogers, Toby AU - Rogers T AD - Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA; Cardiovascular Branch, Division of Intramural Research, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address: toby.rogers@medstar.net. LA - eng PT - Comparative Study PT - Journal Article DEP - 20250822 PL - United States TA - Cardiovasc Revasc Med JT - Cardiovascular revascularization medicine : including molecular interventions JID - 101238551 SB - IM MH - Humans MH - Female MH - Male MH - *Transcatheter Aortic Valve Replacement/adverse effects/mortality/instrumentation MH - Retrospective Studies MH - Aged MH - *Clinical Decision-Making MH - *Aortic Valve/surgery/diagnostic imaging/physiopathology MH - Treatment Outcome MH - Risk Factors MH - Aged, 80 and over MH - Time Factors MH - *Reoperation/adverse effects/mortality MH - Heart Valve Prosthesis MH - Risk Assessment MH - *Aortic Valve Stenosis/diagnostic imaging/surgery/physiopathology/mortality MH - *Device Removal/adverse effects/mortality MH - Patient Selection OTO - NOTNLM OT - Aortic valve reintervention OT - Bioprosthetic valve failure OT - Decision-making OT - Heart team OT - Transcatheter aortic valve replacement (TAVR) OT - Valve explant surgery COIS- Declaration of competing interest Relationships with Industry Kalyan R. Chitturi - Consultant: Glass Health. Toby Rogers - Consultant: Edwards Lifesciences, Medtronic, Boston Scientific, Abbott, Anteris; Advisory board: Medtronic, Boston Scientific; Equity: Transmural Systems; Intellectual property: co-inventor on patents for transcatheter electrosurgery devices, assigned to NIH. Ron Waksman - Advisory Board: Abbott Vascular, Boston Scientific, Medtronic, Philips IGT, Pi-Cardia Ltd.; Consultant: Abbott Vascular, Append Medical, Biotronik, Boston Scientific, JC Medical, MedAlliance/Cordis, Medtronic, Philips IGT, Pi-Cardia Ltd., Swiss Interventional/SIS Medical AG, Transmural Systems Inc.; Institutional Grant Support: Biotronik, Medtronic, Philips IGT; Investor: Append Medical, Pi-Cardia Ltd., Transmural Systems Inc. All other authors - None. EDAT- 2025/09/05 00:36 MHDA- 2026/04/27 00:30 CRDT- 2025/09/04 21:52 PHST- 2025/08/08 00:00 [received] PHST- 2025/08/21 00:00 [accepted] PHST- 2026/04/27 00:30 [medline] PHST- 2025/09/05 00:36 [pubmed] PHST- 2025/09/04 21:52 [entrez] AID - S1553-8389(25)00456-7 [pii] AID - 10.1016/j.carrev.2025.08.018 [doi] PST - ppublish SO - Cardiovasc Revasc Med. 2026 Apr;85:28-32. doi: 10.1016/j.carrev.2025.08.018. Epub 2025 Aug 22. PMID- 40905971 OWN - NLM STAT- MEDLINE DCOM- 20260317 LR - 20260813 IS - 1613-7671 (Electronic) IS - 0043-5325 (Print) IS - 0043-5325 (Linking) VI - 138 IP - 5-6 DP - 2026 Mar TI - Effectiveness of controlled-expansion transjugular intrahepatic portosystemic shunt (CX-TIPS) in an interdisciplinary setting at a large tertiary center. PG - 144-153 LID - 10.1007/s00508-025-02606-7 [doi] AB - INTRODUCTION: The use of controlled-expansion transjugular intrahepatic portosystemic shunt (CX-TIPS) effectively controls portal hypertension (PH)-related complications while reducing risks related to fully expanded stents. We evaluated the effectiveness of CX-TIPS in a large Viennese patient cohort. METHOD: We assessed the number of patients evaluated for CX-TIPS placement by interdisciplinary discussion at the Medical University of Vienna and included all patients from the prospective AUTIPS registry undergoing CX-TIPS placement between June 2018 - December 2024. After clinical and laboratory characterization at baseline, patients were followed up for clinical events. RESULTS: Overall, 200 patients underwent interdisciplinary evaluation for CX-TIPS. In 62.5% CX-TIPS was recommended and 82.4% of these patients underwent CX-TIPS placement. Among 103 patients with CX-TIPS placement between June 2018 - December 2024 (median age 57 years, 67.0% male, median MELD 11), the primary indication for CX-TIPS implantation was ascites (65.0%). The median portal pressure gradient decreased from 18 mm Hg to 8 mm Hg after CX-TIPS. Underdilated CX-TIPS placement was performed in 13.6% (n = 14) of patients and portal vein recanalization (PVR-TIPS) was performed in 4 patients. During a median follow-up time of 13.5 months, 30.1% of patients experienced hepatic encephalopathy and 5.8% cardiac decompensation. Kaplan-Meier survival analyses revealed 1‑year and 3‑year transplant-free survival rates of 78.0% and 74.7%, respectively. CONCLUSION: Implementation of interdisciplinary case discussions and the use of CX-TIPS enable personalized medicine in patients with cirrhosis. Underdilation of CX-TIPS should be considered in patients at high risk for complications. CI - (c) 2025. The Author(s). FAU - Hintersteininger, Marlene AU - Hintersteininger M AD - Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria. AD - Vienna Hepatic Hemodynamic Lab, Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria. AD - Clinical Research Group MOTION, Medical University of Vienna, Vienna, Austria. FAU - Kappel, Julia AU - Kappel J AD - Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria. AD - Clinical Research Group MOTION, Medical University of Vienna, Vienna, Austria. FAU - Mullner-Buscics, Theresa AU - Mullner-Buscics T AD - Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria. AD - Vienna Hepatic Hemodynamic Lab, Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria. AD - Clinical Research Group MOTION, Medical University of Vienna, Vienna, Austria. FAU - Riegler, Susanna AU - Riegler S AD - Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria. FAU - Dominik, Nina AU - Dominik N AD - Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria. AD - Vienna Hepatic Hemodynamic Lab, Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria. AD - Clinical Research Group MOTION, Medical University of Vienna, Vienna, Austria. FAU - Kramer, Georg AU - Kramer G AD - Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria. AD - Vienna Hepatic Hemodynamic Lab, Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria. AD - Clinical Research Group MOTION, Medical University of Vienna, Vienna, Austria. AD - Christian Doppler Lab for Portal Hypertension and Liver Fibrosis, Medical University of Vienna, Vienna, Austria. FAU - Sebesta, Christian AU - Sebesta C AD - Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria. AD - Vienna Hepatic Hemodynamic Lab, Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria. AD - Clinical Research Group MOTION, Medical University of Vienna, Vienna, Austria. FAU - Thone, Paul AU - Thone P AD - Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria. AD - Vienna Hepatic Hemodynamic Lab, Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria. AD - Clinical Research Group MOTION, Medical University of Vienna, Vienna, Austria. FAU - Stattermayer, Albert Friedrich AU - Stattermayer AF AD - Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria. FAU - Reider, Lukas AU - Reider L AD - Division of Cardiovascular and Interventional Radiology, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria. FAU - Schoder, Maria AU - Schoder M AD - Division of Cardiovascular and Interventional Radiology, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria. FAU - Klausenitz, Catharina AU - Klausenitz C AD - Division of Cardiovascular and Interventional Radiology, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria. FAU - Varga, Raoul AU - Varga R AD - Division of Cardiovascular and Interventional Radiology, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria. FAU - Waneck, Fredrik AU - Waneck F AD - Division of Cardiovascular and Interventional Radiology, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria. FAU - Trauner, Michael AU - Trauner M AD - Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria. AD - Clinical Research Group MOTION, Medical University of Vienna, Vienna, Austria. FAU - Mandorfer, Mattias AU - Mandorfer M AD - Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria. AD - Vienna Hepatic Hemodynamic Lab, Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria. AD - Clinical Research Group MOTION, Medical University of Vienna, Vienna, Austria. FAU - Reiberger, Thomas AU - Reiberger T AUID- ORCID: 0000-0002-4590-3583 AD - Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria. thomas.reiberger@meduniwien.ac.at. AD - Vienna Hepatic Hemodynamic Lab, Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria. thomas.reiberger@meduniwien.ac.at. AD - Clinical Research Group MOTION, Medical University of Vienna, Vienna, Austria. thomas.reiberger@meduniwien.ac.at. AD - Christian Doppler Lab for Portal Hypertension and Liver Fibrosis, Medical University of Vienna, Vienna, Austria. thomas.reiberger@meduniwien.ac.at. FAU - Hartl, Lukas AU - Hartl L AD - Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria. AD - Vienna Hepatic Hemodynamic Lab, Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria. AD - Clinical Research Group MOTION, Medical University of Vienna, Vienna, Austria. LA - eng GR - LBG_KFG_22_32/Ludwig Boltzmann Gesellschaft/ PT - Journal Article DEP - 20250904 PL - Austria TA - Wien Klin Wochenschr JT - Wiener klinische Wochenschrift JID - 21620870R SB - IM MH - Humans MH - *Portasystemic Shunt, Transjugular Intrahepatic/methods/statistics & numerical data/mortality MH - Male MH - Female MH - Middle Aged MH - *Hypertension, Portal/surgery/mortality MH - Austria/epidemiology MH - Treatment Outcome MH - Tertiary Care Centers MH - Aged MH - Adult MH - Prospective Studies MH - *Liver Cirrhosis/surgery PMC - PMC12992416 OTO - NOTNLM OT - Ascites OT - Collaterals OT - Interdisciplinary board OT - Portal hypertension OT - Survival OT - Variceal bleeding COIS- Conflict of interest: J. Kappel, T. Mullner-Buscics, S. Riegler, N. Dominik, G. Kramer, C. Sebesta, P. Thone, A.F. Stattermayer, L. Reider, M. Schoder, C. Klausenitz, R. Varga and F. Waneck declare that they have no competing interests. M. Hintersteininger received travel support from Roche. M. Trauner served as a speaker and/or consultant and/or advisory board member for Agomab, Albireo, BiomX, Chemomab, Falk, Boehringer Ingelheim, Bristol-Myers Squibb, Genfit, Gilead, Intercept, Ipsen, Janssen, Madrigal, Mirum, MSD, Novartis, Phenex, Pliant, ProQR Therapeuics, Regulus, and Shire, and received travel support from AbbVie, Falk Foundation, Gilead, and Intercept, as well as grants/research support from Albireo, Alnylam, Cymabay, Falk, Genfit, Gilead, Intercept, MSD, Takeda, and UltraGenyx. He is also co-inventor of patents on the medical use of 24-norursodeoxycholic acid filed by the Medical Universities of Graz and Vienna. M. Mandorfer served as a speaker and/or consultant and/or advisory board member for AbbVie, Collective Acumen, Gilead, Takeda, and W. L. Gore & Associates and received travel support from AbbVie and Gilead. T. Reiberger served as a speaker and/or consultant and/or advisory board member for AbbVie, Bayer, Boehringer Ingelheim, Gilead, Intercept, MSD, Siemens, and W. L. Gore & Associates and received grants/research support from AbbVie, Boehringer Ingelheim, Gilead, Intercept, MSD, Myr Pharmaceuticals, Pliant, Philips, Siemens, and W. L. Gore & Associates as well as travel support from AbbVie, Boehringer Ingelheim, Gilead and Roche. L. Hartl received travel support from Abbvie. EDAT- 2025/09/04 12:37 MHDA- 2026/03/17 06:47 PMCR- 2025/09/04 CRDT- 2025/09/04 11:03 PHST- 2025/06/12 00:00 [received] PHST- 2025/08/07 00:00 [accepted] PHST- 2026/03/17 06:47 [medline] PHST- 2025/09/04 12:37 [pubmed] PHST- 2025/09/04 11:03 [entrez] PHST- 2025/09/04 00:00 [pmc-release] AID - 10.1007/s00508-025-02606-7 [pii] AID - 2606 [pii] AID - 10.1007/s00508-025-02606-7 [doi] PST - ppublish SO - Wien Klin Wochenschr. 2026 Mar;138(5-6):144-153. doi: 10.1007/s00508-025-02606-7. Epub 2025 Sep 4. PMID- 40905683 OWN - NLM STAT- MEDLINE DCOM- 20260427 LR - 20260427 IS - 1531-1937 (Electronic) IS - 0897-1900 (Linking) VI - 39 IP - 3 DP - 2026 Jun TI - Beyond the Bedside: Utilization of an On-Call Pharmacist to Bridge Gaps in Clinical Coverage for Select Critically ill Populations. PG - 211-218 LID - 10.1177/08971900251376800 [doi] AB - PurposeTo describe the utilization of an on-call critical care pharmacist to bridge gaps in clinical coverage for subspecialized critically ill populations.MethodsIn October 2022, a 24/7 on-call team of medical and cardiac ICU pharmacists was established to field questions regarding patients with mechanical circulatory support and pulmonary hypertension. On-call pharmacists were available via centralized telephone number Monday through Friday from 4:00 p.m. to 8:00 a.m., and at all hours on weekends. Information characterizing calls received was collected in an electronic database. A review of all database entries through March 2025 was conducted and descriptive statistics were used to quantify calls received, time spent, multidisciplinary team member engagement, and types of interventions.ResultsOn-call pharmacists received 207 calls and documented 218 interventions. Calls were most often received between the hours of 4:00 p.m. and 8:00 a.m., and the median time spent per call was 10 minutes (IQR 5-20 minutes). On-call critical care pharmacists received the most calls for ECMO patients (38.2%), followed by pulmonary hypertension (26.1%) and Impella(R) patients (20.8%). The majority of inquiries were from pharmacists (35.7%), followed by advanced practice providers (33.3%) and physicians (21.3%). Anticoagulation and hemostasis was the most commonly cited intervention category (56.4%).ConclusionIn the absence of an onsite critical care pharmacist, a 24/7 on-call critical care pharmacist was utilized by members of the multidisciplinary team to bridge gaps in clinical coverage. Further research is needed to determine the pharmacoeconomic and clinical impacts of on-call critical care pharmacists when onsite resources are unavailable. FAU - Meester, Alyssa S AU - Meester AS AUID- ORCID: 0000-0002-8071-0226 AD - Ohio Health Riverside Methodist Hospital, Columbus, OH, USA. RINGGOLD: 24601 FAU - Caffarini, Erica AU - Caffarini E AUID- ORCID: 0000-0002-8530-6329 AD - Ohio Health Riverside Methodist Hospital, Columbus, OH, USA. RINGGOLD: 24601 FAU - Cardona Gonzalez, Mariela AU - Cardona Gonzalez M AUID- ORCID: 0009-0002-2035-0449 AD - Ohio Health Riverside Methodist Hospital, Columbus, OH, USA. RINGGOLD: 24601 FAU - Young, Michael AU - Young M AD - Ohio Health Riverside Methodist Hospital, Columbus, OH, USA. RINGGOLD: 24601 FAU - DeWitt, Jordan AU - DeWitt J AUID- ORCID: 0000-0002-3254-7938 AD - Ohio Health Riverside Methodist Hospital, Columbus, OH, USA. RINGGOLD: 24601 LA - eng PT - Journal Article DEP - 20250904 PL - United States TA - J Pharm Pract JT - Journal of pharmacy practice JID - 8900945 SB - IM MH - Humans MH - *Pharmacists/trends MH - *Critical Illness/therapy MH - *Critical Care/methods MH - Professional Role MH - Patient Care Team/organization & administration MH - *Pharmacy Service, Hospital/organization & administration MH - Intensive Care Units/organization & administration OTO - NOTNLM OT - anticoagulation OT - cardiology OT - critical care OT - medication safety COIS- Declaration of Conflicting InterestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2025/09/04 12:38 MHDA- 2026/04/27 06:31 CRDT- 2025/09/04 09:04 PHST- 2026/04/27 06:31 [medline] PHST- 2025/09/04 12:38 [pubmed] PHST- 2025/09/04 09:04 [entrez] AID - 10.1177/08971900251376800 [doi] PST - ppublish SO - J Pharm Pract. 2026 Jun;39(3):211-218. doi: 10.1177/08971900251376800. Epub 2025 Sep 4. PMID- 40900855 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250915 LR - 20251221 IS - 2222-0682 (Print) IS - 2222-0682 (Electronic) IS - 2222-0682 (Linking) VI - 15 IP - 4 DP - 2025 Dec 20 TI - Challenges and solutions in the treatment of spinal disorders in patients with skeletal dysplasia: A comprehensive review. PG - 102401 LID - 10.5662/wjm.v15.i4.102401 [doi] LID - 102401 AB - Skeletal dysplasia includes numerous genetic disorders marked by abnormal bone and cartilage growth, causing various spinal issues. The 2023 nosology identifies 771 distinct dysplasias involving 552 genes, with achondroplasia being the most common and significantly affecting the spine. Other disorders include type II collagenopathies, sulphation defects, Filamin B disorders, and osteogenesis imperfecta, presenting with short stature, limb deformities, joint contractures, and spinal abnormalities. Spinal pathology often impacts physeal growth areas, leading to conditions like foramen magnum stenosis, atlantoaxial instability, spinal stenosis, kyphosis, and scoliosis. Non-orthopaedic symptoms can include hearing and vision loss, neurological issues like hydrocephalus, and cardiac abnormalities. The incidence is around 1 in 4000 to 5000 births, with achondroplasia at about 1 in 30000 live births. Advances in genetics and imaging enable prenatal diagnosis, though milder cases may go undetected. Effective management requires a multidisciplinary approach involving various specialists. This review emphasises early diagnosis, continuous monitoring, and comprehensive management of spinal pathology in skeletal dysplasia. In the current article, the authors present a thorough review on spinal conditions associated with skeletal dysplasia, their pathophysiology and management options. CI - (c)The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. FAU - Tsirikos, Athanasios I AU - Tsirikos AI AD - Scottish National Spine Deformity Centre, Royal Hospital for Sick Children, Edinburgh EH91LF, United Kingdom. atsirikos@hotmail.com. FAU - Jain, Akash AU - Jain A AD - Department of Orthopaedics, All India Institute of Medical Sciences, Rishikesh 249203, Uttarakhand, India. FAU - Ahuja, Kaustubh AU - Ahuja K AD - Department of Orthopaedics, All India Institute of Medical Sciences, Rishikesh 249203, Uttarakhand, India. LA - eng PT - Journal Article PT - Review DEP - 20251220 PL - United States TA - World J Methodol JT - World journal of methodology JID - 101628739 PMC - PMC12400334 OTO - NOTNLM OT - Achondroplasia OT - Mucopolysccharidosis OT - Osteogenesis imperfecta OT - Skeletal dysplasia OT - Spinal disorders OT - Spondyloepiphyseal dysplasia COIS- Conflict-of-interest statement: None of the authors have any potential conflict of interest pertaining to the manuscript. EDAT- 2025/09/03 18:35 MHDA- 2025/09/03 18:36 PMCR- 2025/12/20 CRDT- 2025/09/03 12:07 PHST- 2024/10/17 00:00 [received] PHST- 2025/03/09 00:00 [revised] PHST- 2025/03/13 00:00 [accepted] PHST- 2025/09/03 18:36 [medline] PHST- 2025/09/03 18:35 [pubmed] PHST- 2025/09/03 12:07 [entrez] PHST- 2025/12/20 00:00 [pmc-release] AID - 10.5662/wjm.v15.i4.102401 [doi] PST - epublish SO - World J Methodol. 2025 Dec 20;15(4):102401. doi: 10.5662/wjm.v15.i4.102401. eCollection 2025 Dec 20. PMID- 40900620 OWN - NLM STAT- MEDLINE DCOM- 20250930 LR - 20250930 IS - 1531-7080 (Electronic) IS - 0268-4705 (Linking) VI - 40 IP - 6 DP - 2025 Nov 1 TI - Invasive treatment strategies in the ESC guidelines developed in collaboration with EACTS for the management of chronic coronary syndrome: implications for contemporary clinical practice. PG - 382-389 LID - 10.1097/HCO.0000000000001253 [doi] AB - PURPOSE OF REVIEW: To critically appraise the 2024 ESC Guidelines for chronic coronary syndrome (CCS), developed in collaboration with EACTS, emphasizing invasive-treatment recommendations, their underlying rationale and key areas requiring further clarification for clinical implementation. RECENT FINDINGS: The document formally incorporates indications for myocardial revascularization and the criteria for choosing between percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) into the single CCS guideline framework. It calls for Heart-Team decisions whenever CABG and PCI are equally recommended and introduces modality-specific criteria based on anatomical complexity, SYNTAX score, and clinically relevant comorbidities. CABG remains the preferred strategy for anatomically complex disease, including left main and multivessel involvement, especially when PCI cannot achieve equivalent completeness of revascularization or in patients with comorbidities associated with a favorable prognosis (e.g., diabetes mellitus, heart failure). PCI is recommended for less complex lesions in which comparable completeness is feasible for patients whose primary goal is symptom relief or those at high surgical risk. Apart from patient selection, the document provides limited procedural detail, offers limited guidance on secondary prevention measures, and lacks explicit recommendations on the optimal timing of intervention. SUMMARY: The 2024 guideline re-establishes a unified, multidisciplinary European approach to the management of CCS, reaffirming the prognostic value of guideline-directed revascularization and the central role of the Heart Team in selecting the optimal strategy. Supplementary documents are required to fill procedural, secondary prevention and implementation gaps. CI - Copyright (c) 2025 Wolters Kluwer Health, Inc. All rights reserved. FAU - Milojevic, Milan AU - Milojevic M AD - Department of Cardiac Surgery and Cardiovascular Research. FAU - Micovic, Slobodan AU - Micovic S AD - Department of Cardiac Surgery and Cardiovascular Research. AD - School of Medicine, University of Belgrade, Belgrade, Serbia. FAU - Otasevic, Petar AU - Otasevic P AD - Department of Cardiology and Cardiovascular Research, Dedinje Cardiovascular Institute. AD - School of Medicine, University of Belgrade, Belgrade, Serbia. LA - eng PT - Journal Article PT - Review DEP - 20250903 PL - United States TA - Curr Opin Cardiol JT - Current opinion in cardiology JID - 8608087 SB - IM MH - Humans MH - *Percutaneous Coronary Intervention/methods/standards MH - *Practice Guidelines as Topic MH - Chronic Disease MH - *Coronary Artery Bypass/methods/standards MH - Europe MH - *Coronary Artery Disease/surgery MH - Myocardial Revascularization/methods OTO - NOTNLM OT - chronic coronary syndrome OT - clinical practice guidelines OT - coronary artery bypass grafting OT - heart team OT - percutaneous coronary intervention EDAT- 2025/09/03 12:35 MHDA- 2025/09/30 14:17 CRDT- 2025/09/03 11:52 PHST- 2025/09/30 14:17 [medline] PHST- 2025/09/03 12:35 [pubmed] PHST- 2025/09/03 11:52 [entrez] AID - 00001573-202511000-00003 [pii] AID - 10.1097/HCO.0000000000001253 [doi] PST - ppublish SO - Curr Opin Cardiol. 2025 Nov 1;40(6):382-389. doi: 10.1097/HCO.0000000000001253. Epub 2025 Sep 3. PMID- 40899690 OWN - NLM STAT- MEDLINE DCOM- 20250903 LR - 20250905 IS - 1572-0241 (Electronic) IS - 0002-9270 (Linking) VI - 120 IP - 9 DP - 2025 Sep 3 TI - ACG Clinical Guideline: Perioperative Risk Assessment and Management in Patients With Cirrhosis. PG - 1968-1984 LID - 10.14309/ajg.0000000000003616 [doi] AB - This guideline presents a comprehensive approach to perioperative risk assessment and management in patients with cirrhosis. Recognizing the unique surgical risks in this population, the guideline emphasizes a multidisciplinary approach to preoperative evaluation, perioperative care, and postoperative follow-up. Key considerations include the severity of liver disease, nonhepatic comorbidities, and surgery-specific factors, with an emphasis on the use of validated cirrhosis-specific risk calculators, such as the VOCAL-Penn Score, for individualized risk stratification. Recommendations highlight preoperative optimization strategies, including nutritional support, management of portal hypertension, correction of hemostatic abnormalities, and addressing frailty and sarcopenia. For patients with decompensated cirrhosis, interventions such as transjugular intrahepatic portosystemic shunt may reduce portal pressure and surgical risks when indicated. Elective surgeries, including cholecystectomy and hernia repair, are advised for select patients with compensated cirrhosis, whereas alternatives to surgery are explored for high-risk patients. The guideline underscores the importance of performing surgeries at high-volume centers with expertise in managing patients with cirrhosis and emphasizes shared decision-making informed by objective risk assessments. Furthermore, it addresses procedure-specific considerations, including the role of bariatric and cardiac surgeries in cirrhotic patients. Through evidence-based recommendations and expert insights, this guideline aims to enhance surgical outcomes and inform clinical decision-making in a growing population of patients with cirrhosis undergoing surgery. CI - Copyright (c) 2025 by The American College of Gastroenterology. FAU - Mahmud, Nadim AU - Mahmud N AUID- ORCID: 0000-0003-1889-3954 AD - Division of Gastroenterology and Hepatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. AD - Department of Medicine, Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania, USA. AD - Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, Pennsylvania, USA. AD - Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics, Epidemiology & Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. FAU - Fricker, Zachary P AU - Fricker ZP AD - Division of Gastroenterology, Hepatology, and Nutrition, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA. AD - Harvard Medical School, Boston, Massachusetts, USA. FAU - McElroy, Lisa M AU - McElroy LM AD - Division of Abdominal Transplant, Department of Surgery, Duke University, Durham, North Carolina, USA. FAU - Qayed, Emad AU - Qayed E AD - Division of Digestive Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA. FAU - Wong, Robert J AU - Wong RJ AD - Gastroenterology Section, VA Palo Alto Health Care System, Palo Alto, California, USA. AD - Division of Gastroenterology and Hepatology, Stanford University, Palo Alto, California, USA. FAU - Ioannou, George N AU - Ioannou GN AD - Division of Gastroenterology, Department of Medicine, Veterans Affairs Puget Sound Health Care System, Seattle, Washington, USA. AD - Division of Gastroenterology, Department of Medicine, University of Washington, Seattle, Washington, USA. LA - eng PT - Journal Article PT - Practice Guideline DEP - 20250903 PL - United States TA - Am J Gastroenterol JT - The American journal of gastroenterology JID - 0421030 SB - IM MH - Humans MH - *Liver Cirrhosis/complications/surgery/therapy MH - Risk Assessment/methods MH - *Perioperative Care/standards/methods MH - *Postoperative Complications/prevention & control MH - Elective Surgical Procedures MH - Hypertension, Portal/therapy/etiology OTO - NOTNLM OT - VOCAL-Penn Score OT - cirrhosis surgical risk OT - multidisciplinary surgical evaluation OT - perioperative management in liver disease OT - portal hypertension and surgery EDAT- 2025/09/03 11:16 MHDA- 2025/09/03 18:35 CRDT- 2025/09/03 08:13 PHST- 2024/12/04 00:00 [received] PHST- 2025/05/14 00:00 [accepted] PHST- 2025/09/03 18:35 [medline] PHST- 2025/09/03 11:16 [pubmed] PHST- 2025/09/03 08:13 [entrez] AID - 00000434-202509000-00016 [pii] AID - 10.14309/ajg.0000000000003616 [doi] PST - epublish SO - Am J Gastroenterol. 2025 Sep 3;120(9):1968-1984. doi: 10.14309/ajg.0000000000003616. PMID- 40898534 OWN - NLM STAT- MEDLINE DCOM- 20250903 LR - 20251028 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 104 IP - 35 DP - 2025 Aug 29 TI - Effect of continuity of care on self-management, quality of life, and clinical outcomes in patients with chronic heart failure. PG - e43972 LID - 10.1097/MD.0000000000043972 [doi] LID - e43972 AB - This research aims to investigate the impact of continuity of care on individuals diagnosed with chronic heart failure (CHF), specifically examining its effects on their self-care capabilities, life quality, mental well-being, and physical condition. A total of 90 patients diagnosed with CHF and treated at our hospital between January and September 2023 were included in this retrospective controlled study. Propensity score matching was used to assign patients into 2 comparable groups: an intervention group and a control group (CG), each consisting of 45 individuals. The intervention group received a comprehensive continuity of care program in addition to standard nursing care, while the CG received standard care alone. The continuity of care model included components such as a collaborative multidisciplinary team, tailored patient education, emotional support, guidance on medication adherence, and consistent follow-up monitoring. The study assessed various outcomes, including patients' self-care performance, quality of life scores, psychological assessments via the Hamilton Depression and Anxiety Scales, physical health indicators, and the frequency of adverse cardiovascular events. Following the continuity of care intervention, patients in the intervention group demonstrated a significant improvement in their self-care scores, increasing from 73.39 +/- 4.02 pre-intervention to 89.41 +/- 5.38 post-intervention (P < .05). In terms of quality of life, post-intervention scores were significantly better than those in the CG, indicating a positive shift. Physical capacity, measured by average walking distance, rose from 337.76 +/- 23.87 m to 462.53 +/- 26.28 m in the intervention group (P < .05). Regarding complication rates, there were no cases of myocardial infarction or sudden cardiac death in the intervention group, with only one case of arrhythmia, reflecting a notably lower complication rate compared to the CG (P < .05). These results suggest that continuity of care may play a key role in reducing adverse outcomes. The implementation of a continuity of care model for patients with CHF significantly improves their ability to manage their condition, enhances their overall quality of life, and contributes to better clinical outcomes. These findings emphasize the necessity of incorporating continuous care strategies into the standard management of CHF, offering important guidance for nursing professionals. CI - Copyright (c) 2025 the Author(s). Published by Wolters Kluwer Health, Inc. FAU - Wang, Pengjun AU - Wang P AD - Department of General Practice, Huanggang Central Hospital, Huanggang, Hubei Province, China. FAU - Zhou, Yanwen AU - Zhou Y AD - Department of Urology Surgery, Huanggang Central Hospital, Huanggang, Hubei Province, China. FAU - Wang, Li AU - Wang L AD - Department of General Practice, Huanggang Central Hospital, Huanggang, Hubei Province, China. FAU - Liu, Rong AU - Liu R AD - Department of Urology Surgery, Huanggang Central Hospital, Huanggang, Hubei Province, China. FAU - Qian, Fei AU - Qian F AD - Department of General Practice, Huanggang Central Hospital, Huanggang, Hubei Province, China. FAU - Lin, Mei AU - Lin M AUID- ORCID: 0009-0001-3992-0678 AD - Department of Urology Surgery, Huanggang Central Hospital, Huanggang, Hubei Province, China. LA - eng GR - Study on the Impact of Continuous Nursing Measures on Patients with Chronic Heart Failure and Its Therapeutic Effect/ PT - Journal Article PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R SB - IM MH - Humans MH - *Quality of Life MH - *Heart Failure/therapy/psychology MH - Male MH - Female MH - *Continuity of Patient Care MH - Retrospective Studies MH - Aged MH - Middle Aged MH - *Self-Management/psychology/methods MH - Chronic Disease MH - Propensity Score PMC - PMC12401313 OTO - NOTNLM OT - chronic heart failure OT - continuity of care OT - physiological health OT - psychological state OT - quality of life OT - self-management COIS- The authors have no conflicts of interest to disclose. EDAT- 2025/09/03 06:37 MHDA- 2025/09/04 00:35 PMCR- 2025/08/29 CRDT- 2025/09/03 01:02 PHST- 2025/05/31 00:00 [received] PHST- 2025/07/29 00:00 [accepted] PHST- 2025/09/04 00:35 [medline] PHST- 2025/09/03 06:37 [pubmed] PHST- 2025/09/03 01:02 [entrez] PHST- 2025/08/29 00:00 [pmc-release] AID - 00005792-202508290-00083 [pii] AID - MD-D-25-06632 [pii] AID - 10.1097/MD.0000000000043972 [doi] PST - ppublish SO - Medicine (Baltimore). 2025 Aug 29;104(35):e43972. doi: 10.1097/MD.0000000000043972. PMID- 40897609 OWN - NLM STAT- MEDLINE DCOM- 20251115 LR - 20251115 IS - 1590-3729 (Electronic) IS - 0939-4753 (Linking) VI - 35 IP - 12 DP - 2025 Dec TI - Translational biomarkers for integrated cardiovascular disease risk assessment: A multidisciplinary review with applications in precision medicine. PG - 104215 LID - S0939-4753(25)00369-2 [pii] LID - 10.1016/j.numecd.2025.104215 [doi] AB - AIMS: Cardiovascular disease (CVD) continues to be a leading cause of morbidity and mortality, significantly impacting healthcare systems and individual lives. This pragmatic review focuses on the assessment of CVD utilizing traditional and emerging risk factors that provide a basis for personalized medicine and precision nutrition, highlighting the knowledge and application of these insights for accurate risk diagnosis, individualized interventions, and precise outcome/evaluation prognosis. DATA SYNTHESIS: Critical biochemical markers such as lipid metabolism signatures, inflammatory molecules, endocrine mediators, homeostatic signals (including omics data), and lifestyle factors such as unhealthy dietary habits, physical inactivity, smoking, alcohol abuse, along with anthropometric variables and body composition measurements, play a pivotal role in assessing and managing CVD. This progression starts with early vascular and cardiac dysfunctions, advancing to atherosclerosis, and ultimately leading to cardiovascular events. Major adverse cardiovascular events, including myocardial infarction, stroke, and heart failure, highlight the need for effective and accurate risk stratification and objective assessment. Various CVD risk scores, such as the Framingham Risk Score, SCORE, and the Atherosclerotic Cardiovascular Disease Risk Calculator, provide valuable global frameworks for predicting individual risk based on recognized conventional factors. Additionally, omics markers-which encompass genomic, transcriptomic, epigenomic, proteomic, metabolomic, and metagenomic data-offer deeper insights into the molecular mechanisms underlying CVD, alongside novel lipidomic and immunomic determinants. CONCLUSIONS: Integrating these various determinants and risk factors through a comprehensive approach is essential for advancing and implementing precision medicine and nutrition in the management of CVD. CI - Copyright (c) 2025 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved. FAU - Visioli, Francesco AU - Visioli F AD - Department of Molecular Medicine, University of Padova, 35121, Padova, Italy. FAU - Urbistondo, Diego Martinez AU - Urbistondo DM AD - Grupo de Riesgo Vascular, Sociedad Espanola de Medicina Interna (SEMI), 28016, Madrid, Spain; Area de Medicina Vascular, Departamento de Medicina Interna, Clinica Universidad de Navarra, Spain; Biomedical Research Centre for Obesity Physiopathology and Nutrition Network (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28029, Madrid, Spain. FAU - Gkipalis, Sokratis AU - Gkipalis S AD - Department of Nutrition and Dietetics, School of Health Sciences and Education, Harokopio University, El. Venizelou Ave.,70, Kallithea, 176 76, Athens, Greece. FAU - Vidal-Ostos De Lara, Fernando AU - Vidal-Ostos De Lara F AD - Department of Endocrinology and Nutrition. Hospital Universitario Principe de Asturias, Alcala de Henares, Madrid, Spain. FAU - Ruiz-Saavedra, Antonio AU - Ruiz-Saavedra A AD - Escuela Internacional de Doctorado de la Universidad Nacional de Educacion a Distancia (UNED), Programa en Ciencias Biomedicas y Salud Publica, Madrid, Spain. FAU - Leon, Marta AU - Leon M AD - Hospital Universitario Santa Barbara, Soria, Spain; Universidad de Valladolid, Campus de Soria, Spain. FAU - Beddar Chaib, F AU - Beddar Chaib F AD - Soria Primary Care Management, Soria, Spain; Soria Campus, University of Valladolid, Spain. FAU - Hernandez, Aitor Hernandez AU - Hernandez AH AD - Departamento de Medicina Preventiva y Salud Publica, Universidad de Navarra, Instituto de Investigacion Sanitaria de Navarra (IdiSNA), Pamplona, Spain; Departamento de Cardiologia, Clinica Universidad de Navarra, Madrid, Spain. FAU - Landecho Acha, Manuel Fortun AU - Landecho Acha MF AD - Internal Medicine Dpt. Clinica, Universidad de Navarra, 31008, Pamplona, Spain. FAU - Laparra, Moises AU - Laparra M AD - Molecular Immunonutrition Group, IMDEA-Nutricion, Campus of International Excellence (CEI) UAM+CSIC, 28049, Madrid, Spain. FAU - Vizmanos, Barbara AU - Vizmanos B AD - Centro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara (UdeG), Guadalajara, 44340, Mexico; Centre of Medicine and Endocrinology, University of Valladolid, Valladolid, 47002, Spain. FAU - Ramos-Lopez, Omar AU - Ramos-Lopez O AD - Medicine and Psychology School, Autonomous University of Baja California, Tijuana, 22390, Baja California, Mexico. Electronic address: oscar.omar.ramos.lopez@uabc.edu.mx. FAU - Yannakoulia, Mary AU - Yannakoulia M AD - Department of Nutrition and Dietetics, School of Health Sciences and Education, Harokopio University, El. Venizelou Ave.,70, Kallithea, 176 76, Athens, Greece. FAU - Martinez, J Alfredo AU - Martinez JA AD - Precision Nutrition and Cardiometabolic Health, IMDEA-Nutrition, Campus of International Excellence (CEI) UAM+CSIC, 28049, Madrid, Spain; Biomedical Research Centre for Obesity Physiopathology and Nutrition Network (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28029, Madrid, Spain; Centre of Medicine and Endocrinology, University of Valladolid, Valladolid, 47002, Spain. LA - eng PT - Journal Article PT - Review DEP - 20250702 PL - Netherlands TA - Nutr Metab Cardiovasc Dis JT - Nutrition, metabolism, and cardiovascular diseases : NMCD JID - 9111474 RN - 0 (Biomarkers) SB - IM MH - Humans MH - *Precision Medicine MH - Risk Assessment MH - *Cardiovascular Diseases/diagnosis/blood/epidemiology/therapy/genetics MH - Biomarkers/blood MH - Predictive Value of Tests MH - Prognosis MH - Heart Disease Risk Factors MH - *Translational Research, Biomedical OTO - NOTNLM OT - Cardiovascular disease markers OT - Cardiovascular omics markers OT - Cardiovascular risk OT - Risk calculators OT - Scores EDAT- 2025/09/03 00:42 MHDA- 2025/11/16 00:27 CRDT- 2025/09/02 21:53 PHST- 2025/02/12 00:00 [received] PHST- 2025/06/20 00:00 [revised] PHST- 2025/06/30 00:00 [accepted] PHST- 2025/11/16 00:27 [medline] PHST- 2025/09/03 00:42 [pubmed] PHST- 2025/09/02 21:53 [entrez] AID - S0939-4753(25)00369-2 [pii] AID - 10.1016/j.numecd.2025.104215 [doi] PST - ppublish SO - Nutr Metab Cardiovasc Dis. 2025 Dec;35(12):104215. doi: 10.1016/j.numecd.2025.104215. Epub 2025 Jul 2. PMID- 40897479 OWN - NLM STAT- MEDLINE DCOM- 20250903 LR - 20250916 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 15 IP - 9 DP - 2025 Sep 2 TI - Nurse-led cardiac rehabilitation programme on physical capacity and mental health for heart valve patients: study protocol of a quasi-experimental study. PG - e096823 LID - 10.1136/bmjopen-2024-096823 [doi] LID - e096823 AB - INTRODUCTION: Evidence-based early rehabilitation intervention after heart valve surgery has been proven to have many benefits, but the experience of implementing nurse-led early rehabilitation combining exercise and psychology is still lacking. It is urgent to find a more acceptable and cost-effective method to provide exercise intervention and psychological support. The aim of this study is to design a nurse-led cardiac rehabilitation programme to increase the physical capacity and mental health for heart valve patient based on broaden-and-build theory. METHODS AND ANALYSIS: A non-blinded randomised controlled trial will be conducted. A total of 86 adults diagnosed with heart valve disease will be recruited and randomly assigned to the control group and intervention group. The recovery for valvular heart disease intervention, based on the broaden-and-build theory, will be guided one-on-one by a multidisciplinary team and will consist of two main components: physical intervention and psychological intervention. The baseline assessment will be conducted 1 to 2 days after admission, and sequent evaluations will be implemented at post-intervention, 3 months after intervention and 6 months after intervention. The primary outcome is the finding of six-min walk test and mental state. Other outcomes include quality of life, 36-item short-form health survey, Short Physical Performance Battery, stress, coping modes and social support. ETHICS AND DISSEMINATION: This study was conducted following the Helsinki Declaration and was approved by the ethics committee of the Zhong Da Hospital, Southeast University (2024ZDSYLL098-P01). The results of this study are scheduled to be published in relevant peer-reviewed journals. TRIAL REGISTRATION NUMBER: Registered at the Chinese Clinical Trials.gov (ChiCTR2400090853). CI - (c) Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. FAU - Zhou, Juan AU - Zhou J AD - Department of cardiac surgery, Southeast University Zhongda Hospital, Nanjing, Jiangsu, China. FAU - Zhou, Yufeng AU - Zhou Y AD - Department of cardiac surgery, Southeast University Zhongda Hospital, Nanjing, Jiangsu, China. FAU - Huang, Yurong AU - Huang Y AD - Department of cardiac surgery, Southeast University Zhongda Hospital, Nanjing, Jiangsu, China. FAU - Wang, Pan AU - Wang P AUID- ORCID: 0000-0002-7299-0627 AD - Department of cardiac surgery, Southeast University Zhongda Hospital, Nanjing, Jiangsu, China 1183180315@qq.com. LA - eng PT - Clinical Trial Protocol PT - Journal Article DEP - 20250902 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 SB - IM MH - Humans MH - *Cardiac Rehabilitation/nursing/methods MH - *Mental Health MH - Quality of Life MH - *Heart Valve Diseases/rehabilitation/nursing/surgery/psychology MH - Adult MH - Female MH - Male MH - Middle Aged MH - Walk Test MH - Randomized Controlled Trials as Topic MH - Exercise Therapy MH - Non-Randomized Controlled Trials as Topic PMC - PMC12406905 OTO - NOTNLM OT - Cardiothoracic surgery OT - Nursing Care OT - Valvular heart disease COIS- Competing interests: None declared. EDAT- 2025/09/03 00:43 MHDA- 2025/09/04 02:12 PMCR- 2025/09/02 CRDT- 2025/09/02 21:14 PHST- 2025/09/04 02:12 [medline] PHST- 2025/09/03 00:43 [pubmed] PHST- 2025/09/02 21:14 [entrez] PHST- 2025/09/02 00:00 [pmc-release] AID - bmjopen-2024-096823 [pii] AID - 10.1136/bmjopen-2024-096823 [doi] PST - epublish SO - BMJ Open. 2025 Sep 2;15(9):e096823. doi: 10.1136/bmjopen-2024-096823. PMID- 40897425 OWN - NLM STAT- MEDLINE DCOM- 20250903 LR - 20250919 IS - 1658-3175 (Electronic) IS - 0379-5284 (Print) IS - 0379-5284 (Linking) VI - 46 IP - 9 DP - 2025 Sep TI - Clinical outcomes of tetralogy canal repair: A multidisciplinary perspective. PG - 1039-1045 LID - 10.15537/smj.2025.46.9.20250398 [doi] AB - OBJECTIVES: To assess the surgical outcomes of atrioventricular septal defect associated with Tetralogy of Fallot (AVSD)-TOF repair performed at 2 specialized cardiac centers. METHODS: From May 2012 to December 2024, 20 patients diagnosed with AVSD-TOF who underwent surgical repair were included. RESULTS: The median age at the time of surgical repair was 13 months, with a median weight of 8.2 kg (IQR: 6.2-11.5 kg). Biventricular repair was successfully performed in 18 patients (90%), while one and half ventricular repair was required in 2 patients (10%). Before definitive repair, palliative procedures, including bidirectional Glenn shunts, were carried out in 2 patients (10%), and right ventricular outflow tract (RVOT) stenting in another 2 patients (10%). Postoperative complications included a third-degree heart block requiring pacemaker implantation in 10% and chylothorax in 15%. The median duration of chest drains was 10 days. In 40% of patients, reintervention was required, involving catheter-based procedures and redo surgeries for residual lesions. Despite these complexities, overall survival was 90%, with all patients surviving to hospital discharge. CONCLUSION: Biventricular repair of AVSD-TOF is feasible and offers favorable early survival. However, the complexity of the condition, frequent reinterventions, and residual lesions highlight the need for individualized surgical/interventional planning and long-term follow-up. CI - Copyright: (c) Saudi Medical Journal. FAU - Mashali, Mohamed H AU - Mashali MH AD - From the Pediatric Cardiology Division (Mashali, Abdelmohsen, Baamer, Elhudairy, Alkhushi, Bahaidarah, Abdelsalam, Elakaby, Maghrabi, Azhar, Zaher, Al Ata, Dohain, Baamer), Department of Pediatrics, King Abdulaziz University, Jeddah, Saudi Arabia, From the Department of Cardiac Surgery (Al-Radi, Jamjoom, Shihata, Elmahrouk), King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia, From the Department of Pediatrics (Dohain), King Fahd Armed Forces Hospital, Jeddah, Saudi Arabia, From the Department of Cardiology (Abdelsalam), Banaha University, Banha, Egypt, From the Department of Pediatric (Elakaby) Al Azhar University, Cairo, Egypt and from the Division of Pediatric Cardiology (Mashali, Abdelmohsen, Dohain, Bekheet), Department of Pediatrics, Cairo University, Cairo, Egypt. FAU - Abdelmohsen, Gaser A AU - Abdelmohsen GA AUID- ORCID: 0000-0002-0361-2921 AD - From the Pediatric Cardiology Division (Mashali, Abdelmohsen, Baamer, Elhudairy, Alkhushi, Bahaidarah, Abdelsalam, Elakaby, Maghrabi, Azhar, Zaher, Al Ata, Dohain, Baamer), Department of Pediatrics, King Abdulaziz University, Jeddah, Saudi Arabia, From the Department of Cardiac Surgery (Al-Radi, Jamjoom, Shihata, Elmahrouk), King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia, From the Department of Pediatrics (Dohain), King Fahd Armed Forces Hospital, Jeddah, Saudi Arabia, From the Department of Cardiology (Abdelsalam), Banaha University, Banha, Egypt, From the Department of Pediatric (Elakaby) Al Azhar University, Cairo, Egypt and from the Division of Pediatric Cardiology (Mashali, Abdelmohsen, Dohain, Bekheet), Department of Pediatrics, Cairo University, Cairo, Egypt. FAU - Baamer, Ahmed S AU - Baamer AS AD - From the Pediatric Cardiology Division (Mashali, Abdelmohsen, Baamer, Elhudairy, Alkhushi, Bahaidarah, Abdelsalam, Elakaby, Maghrabi, Azhar, Zaher, Al Ata, Dohain, Baamer), Department of Pediatrics, King Abdulaziz University, Jeddah, Saudi Arabia, From the Department of Cardiac Surgery (Al-Radi, Jamjoom, Shihata, Elmahrouk), King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia, From the Department of Pediatrics (Dohain), King Fahd Armed Forces Hospital, Jeddah, Saudi Arabia, From the Department of Cardiology (Abdelsalam), Banaha University, Banha, Egypt, From the Department of Pediatric (Elakaby) Al Azhar University, Cairo, Egypt and from the Division of Pediatric Cardiology (Mashali, Abdelmohsen, Dohain, Bekheet), Department of Pediatrics, Cairo University, Cairo, Egypt. FAU - Elhudairy, Mohamed S AU - Elhudairy MS AD - From the Pediatric Cardiology Division (Mashali, Abdelmohsen, Baamer, Elhudairy, Alkhushi, Bahaidarah, Abdelsalam, Elakaby, Maghrabi, Azhar, Zaher, Al Ata, Dohain, Baamer), Department of Pediatrics, King Abdulaziz University, Jeddah, Saudi Arabia, From the Department of Cardiac Surgery (Al-Radi, Jamjoom, Shihata, Elmahrouk), King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia, From the Department of Pediatrics (Dohain), King Fahd Armed Forces Hospital, Jeddah, Saudi Arabia, From the Department of Cardiology (Abdelsalam), Banaha University, Banha, Egypt, From the Department of Pediatric (Elakaby) Al Azhar University, Cairo, Egypt and from the Division of Pediatric Cardiology (Mashali, Abdelmohsen, Dohain, Bekheet), Department of Pediatrics, Cairo University, Cairo, Egypt. FAU - Alkhushi, Naif A AU - Alkhushi NA AD - From the Pediatric Cardiology Division (Mashali, Abdelmohsen, Baamer, Elhudairy, Alkhushi, Bahaidarah, Abdelsalam, Elakaby, Maghrabi, Azhar, Zaher, Al Ata, Dohain, Baamer), Department of Pediatrics, King Abdulaziz University, Jeddah, Saudi Arabia, From the Department of Cardiac Surgery (Al-Radi, Jamjoom, Shihata, Elmahrouk), King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia, From the Department of Pediatrics (Dohain), King Fahd Armed Forces Hospital, Jeddah, Saudi Arabia, From the Department of Cardiology (Abdelsalam), Banaha University, Banha, Egypt, From the Department of Pediatric (Elakaby) Al Azhar University, Cairo, Egypt and from the Division of Pediatric Cardiology (Mashali, Abdelmohsen, Dohain, Bekheet), Department of Pediatrics, Cairo University, Cairo, Egypt. FAU - Bahaidarah, Saud A AU - Bahaidarah SA AD - From the Pediatric Cardiology Division (Mashali, Abdelmohsen, Baamer, Elhudairy, Alkhushi, Bahaidarah, Abdelsalam, Elakaby, Maghrabi, Azhar, Zaher, Al Ata, Dohain, Baamer), Department of Pediatrics, King Abdulaziz University, Jeddah, Saudi Arabia, From the Department of Cardiac Surgery (Al-Radi, Jamjoom, Shihata, Elmahrouk), King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia, From the Department of Pediatrics (Dohain), King Fahd Armed Forces Hospital, Jeddah, Saudi Arabia, From the Department of Cardiology (Abdelsalam), Banaha University, Banha, Egypt, From the Department of Pediatric (Elakaby) Al Azhar University, Cairo, Egypt and from the Division of Pediatric Cardiology (Mashali, Abdelmohsen, Dohain, Bekheet), Department of Pediatrics, Cairo University, Cairo, Egypt. FAU - Abdelsalam, Mohamed H AU - Abdelsalam MH AD - From the Pediatric Cardiology Division (Mashali, Abdelmohsen, Baamer, Elhudairy, Alkhushi, Bahaidarah, Abdelsalam, Elakaby, Maghrabi, Azhar, Zaher, Al Ata, Dohain, Baamer), Department of Pediatrics, King Abdulaziz University, Jeddah, Saudi Arabia, From the Department of Cardiac Surgery (Al-Radi, Jamjoom, Shihata, Elmahrouk), King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia, From the Department of Pediatrics (Dohain), King Fahd Armed Forces Hospital, Jeddah, Saudi Arabia, From the Department of Cardiology (Abdelsalam), Banaha University, Banha, Egypt, From the Department of Pediatric (Elakaby) Al Azhar University, Cairo, Egypt and from the Division of Pediatric Cardiology (Mashali, Abdelmohsen, Dohain, Bekheet), Department of Pediatrics, Cairo University, Cairo, Egypt. FAU - Elakaby, Ahmed R AU - Elakaby AR AD - From the Pediatric Cardiology Division (Mashali, Abdelmohsen, Baamer, Elhudairy, Alkhushi, Bahaidarah, Abdelsalam, Elakaby, Maghrabi, Azhar, Zaher, Al Ata, Dohain, Baamer), Department of Pediatrics, King Abdulaziz University, Jeddah, Saudi Arabia, From the Department of Cardiac Surgery (Al-Radi, Jamjoom, Shihata, Elmahrouk), King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia, From the Department of Pediatrics (Dohain), King Fahd Armed Forces Hospital, Jeddah, Saudi Arabia, From the Department of Cardiology (Abdelsalam), Banaha University, Banha, Egypt, From the Department of Pediatric (Elakaby) Al Azhar University, Cairo, Egypt and from the Division of Pediatric Cardiology (Mashali, Abdelmohsen, Dohain, Bekheet), Department of Pediatrics, Cairo University, Cairo, Egypt. FAU - Maghrabi, Khadijah A AU - Maghrabi KA AD - From the Pediatric Cardiology Division (Mashali, Abdelmohsen, Baamer, Elhudairy, Alkhushi, Bahaidarah, Abdelsalam, Elakaby, Maghrabi, Azhar, Zaher, Al Ata, Dohain, Baamer), Department of Pediatrics, King Abdulaziz University, Jeddah, Saudi Arabia, From the Department of Cardiac Surgery (Al-Radi, Jamjoom, Shihata, Elmahrouk), King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia, From the Department of Pediatrics (Dohain), King Fahd Armed Forces Hospital, Jeddah, Saudi Arabia, From the Department of Cardiology (Abdelsalam), Banaha University, Banha, Egypt, From the Department of Pediatric (Elakaby) Al Azhar University, Cairo, Egypt and from the Division of Pediatric Cardiology (Mashali, Abdelmohsen, Dohain, Bekheet), Department of Pediatrics, Cairo University, Cairo, Egypt. FAU - Azhar, Ahmed S AU - Azhar AS AD - From the Pediatric Cardiology Division (Mashali, Abdelmohsen, Baamer, Elhudairy, Alkhushi, Bahaidarah, Abdelsalam, Elakaby, Maghrabi, Azhar, Zaher, Al Ata, Dohain, Baamer), Department of Pediatrics, King Abdulaziz University, Jeddah, Saudi Arabia, From the Department of Cardiac Surgery (Al-Radi, Jamjoom, Shihata, Elmahrouk), King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia, From the Department of Pediatrics (Dohain), King Fahd Armed Forces Hospital, Jeddah, Saudi Arabia, From the Department of Cardiology (Abdelsalam), Banaha University, Banha, Egypt, From the Department of Pediatric (Elakaby) Al Azhar University, Cairo, Egypt and from the Division of Pediatric Cardiology (Mashali, Abdelmohsen, Dohain, Bekheet), Department of Pediatrics, Cairo University, Cairo, Egypt. FAU - Zaher, Zaher F AU - Zaher ZF AD - From the Pediatric Cardiology Division (Mashali, Abdelmohsen, Baamer, Elhudairy, Alkhushi, Bahaidarah, Abdelsalam, Elakaby, Maghrabi, Azhar, Zaher, Al Ata, Dohain, Baamer), Department of Pediatrics, King Abdulaziz University, Jeddah, Saudi Arabia, From the Department of Cardiac Surgery (Al-Radi, Jamjoom, Shihata, Elmahrouk), King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia, From the Department of Pediatrics (Dohain), King Fahd Armed Forces Hospital, Jeddah, Saudi Arabia, From the Department of Cardiology (Abdelsalam), Banaha University, Banha, Egypt, From the Department of Pediatric (Elakaby) Al Azhar University, Cairo, Egypt and from the Division of Pediatric Cardiology (Mashali, Abdelmohsen, Dohain, Bekheet), Department of Pediatrics, Cairo University, Cairo, Egypt. FAU - Al Ata, Jameel A AU - Al Ata JA AD - From the Pediatric Cardiology Division (Mashali, Abdelmohsen, Baamer, Elhudairy, Alkhushi, Bahaidarah, Abdelsalam, Elakaby, Maghrabi, Azhar, Zaher, Al Ata, Dohain, Baamer), Department of Pediatrics, King Abdulaziz University, Jeddah, Saudi Arabia, From the Department of Cardiac Surgery (Al-Radi, Jamjoom, Shihata, Elmahrouk), King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia, From the Department of Pediatrics (Dohain), King Fahd Armed Forces Hospital, Jeddah, Saudi Arabia, From the Department of Cardiology (Abdelsalam), Banaha University, Banha, Egypt, From the Department of Pediatric (Elakaby) Al Azhar University, Cairo, Egypt and from the Division of Pediatric Cardiology (Mashali, Abdelmohsen, Dohain, Bekheet), Department of Pediatrics, Cairo University, Cairo, Egypt. FAU - Al-Radi, Osman O AU - Al-Radi OO AD - From the Pediatric Cardiology Division (Mashali, Abdelmohsen, Baamer, Elhudairy, Alkhushi, Bahaidarah, Abdelsalam, Elakaby, Maghrabi, Azhar, Zaher, Al Ata, Dohain, Baamer), Department of Pediatrics, King Abdulaziz University, Jeddah, Saudi Arabia, From the Department of Cardiac Surgery (Al-Radi, Jamjoom, Shihata, Elmahrouk), King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia, From the Department of Pediatrics (Dohain), King Fahd Armed Forces Hospital, Jeddah, Saudi Arabia, From the Department of Cardiology (Abdelsalam), Banaha University, Banha, Egypt, From the Department of Pediatric (Elakaby) Al Azhar University, Cairo, Egypt and from the Division of Pediatric Cardiology (Mashali, Abdelmohsen, Dohain, Bekheet), Department of Pediatrics, Cairo University, Cairo, Egypt. FAU - Jamjoom, Ahmed A AU - Jamjoom AA AD - From the Pediatric Cardiology Division (Mashali, Abdelmohsen, Baamer, Elhudairy, Alkhushi, Bahaidarah, Abdelsalam, Elakaby, Maghrabi, Azhar, Zaher, Al Ata, Dohain, Baamer), Department of Pediatrics, King Abdulaziz University, Jeddah, Saudi Arabia, From the Department of Cardiac Surgery (Al-Radi, Jamjoom, Shihata, Elmahrouk), King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia, From the Department of Pediatrics (Dohain), King Fahd Armed Forces Hospital, Jeddah, Saudi Arabia, From the Department of Cardiology (Abdelsalam), Banaha University, Banha, Egypt, From the Department of Pediatric (Elakaby) Al Azhar University, Cairo, Egypt and from the Division of Pediatric Cardiology (Mashali, Abdelmohsen, Dohain, Bekheet), Department of Pediatrics, Cairo University, Cairo, Egypt. FAU - Shihata, Mohammad S AU - Shihata MS AD - From the Pediatric Cardiology Division (Mashali, Abdelmohsen, Baamer, Elhudairy, Alkhushi, Bahaidarah, Abdelsalam, Elakaby, Maghrabi, Azhar, Zaher, Al Ata, Dohain, Baamer), Department of Pediatrics, King Abdulaziz University, Jeddah, Saudi Arabia, From the Department of Cardiac Surgery (Al-Radi, Jamjoom, Shihata, Elmahrouk), King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia, From the Department of Pediatrics (Dohain), King Fahd Armed Forces Hospital, Jeddah, Saudi Arabia, From the Department of Cardiology (Abdelsalam), Banaha University, Banha, Egypt, From the Department of Pediatric (Elakaby) Al Azhar University, Cairo, Egypt and from the Division of Pediatric Cardiology (Mashali, Abdelmohsen, Dohain, Bekheet), Department of Pediatrics, Cairo University, Cairo, Egypt. FAU - Elmahrouk, Ahmed F AU - Elmahrouk AF AD - From the Pediatric Cardiology Division (Mashali, Abdelmohsen, Baamer, Elhudairy, Alkhushi, Bahaidarah, Abdelsalam, Elakaby, Maghrabi, Azhar, Zaher, Al Ata, Dohain, Baamer), Department of Pediatrics, King Abdulaziz University, Jeddah, Saudi Arabia, From the Department of Cardiac Surgery (Al-Radi, Jamjoom, Shihata, Elmahrouk), King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia, From the Department of Pediatrics (Dohain), King Fahd Armed Forces Hospital, Jeddah, Saudi Arabia, From the Department of Cardiology (Abdelsalam), Banaha University, Banha, Egypt, From the Department of Pediatric (Elakaby) Al Azhar University, Cairo, Egypt and from the Division of Pediatric Cardiology (Mashali, Abdelmohsen, Dohain, Bekheet), Department of Pediatrics, Cairo University, Cairo, Egypt. FAU - Dohain, Ahmed M AU - Dohain AM AD - From the Pediatric Cardiology Division (Mashali, Abdelmohsen, Baamer, Elhudairy, Alkhushi, Bahaidarah, Abdelsalam, Elakaby, Maghrabi, Azhar, Zaher, Al Ata, Dohain, Baamer), Department of Pediatrics, King Abdulaziz University, Jeddah, Saudi Arabia, From the Department of Cardiac Surgery (Al-Radi, Jamjoom, Shihata, Elmahrouk), King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia, From the Department of Pediatrics (Dohain), King Fahd Armed Forces Hospital, Jeddah, Saudi Arabia, From the Department of Cardiology (Abdelsalam), Banaha University, Banha, Egypt, From the Department of Pediatric (Elakaby) Al Azhar University, Cairo, Egypt and from the Division of Pediatric Cardiology (Mashali, Abdelmohsen, Dohain, Bekheet), Department of Pediatrics, Cairo University, Cairo, Egypt. FAU - Baamer, Faris A AU - Baamer FA AD - From the Pediatric Cardiology Division (Mashali, Abdelmohsen, Baamer, Elhudairy, Alkhushi, Bahaidarah, Abdelsalam, Elakaby, Maghrabi, Azhar, Zaher, Al Ata, Dohain, Baamer), Department of Pediatrics, King Abdulaziz University, Jeddah, Saudi Arabia, From the Department of Cardiac Surgery (Al-Radi, Jamjoom, Shihata, Elmahrouk), King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia, From the Department of Pediatrics (Dohain), King Fahd Armed Forces Hospital, Jeddah, Saudi Arabia, From the Department of Cardiology (Abdelsalam), Banaha University, Banha, Egypt, From the Department of Pediatric (Elakaby) Al Azhar University, Cairo, Egypt and from the Division of Pediatric Cardiology (Mashali, Abdelmohsen, Dohain, Bekheet), Department of Pediatrics, Cairo University, Cairo, Egypt. FAU - Bekheet, Samia A AU - Bekheet SA AD - From the Pediatric Cardiology Division (Mashali, Abdelmohsen, Baamer, Elhudairy, Alkhushi, Bahaidarah, Abdelsalam, Elakaby, Maghrabi, Azhar, Zaher, Al Ata, Dohain, Baamer), Department of Pediatrics, King Abdulaziz University, Jeddah, Saudi Arabia, From the Department of Cardiac Surgery (Al-Radi, Jamjoom, Shihata, Elmahrouk), King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia, From the Department of Pediatrics (Dohain), King Fahd Armed Forces Hospital, Jeddah, Saudi Arabia, From the Department of Cardiology (Abdelsalam), Banaha University, Banha, Egypt, From the Department of Pediatric (Elakaby) Al Azhar University, Cairo, Egypt and from the Division of Pediatric Cardiology (Mashali, Abdelmohsen, Dohain, Bekheet), Department of Pediatrics, Cairo University, Cairo, Egypt. LA - eng PT - Journal Article PL - Saudi Arabia TA - Saudi Med J JT - Saudi medical journal JID - 7909441 SB - IM MH - Humans MH - *Tetralogy of Fallot/surgery/mortality MH - Infant MH - Female MH - Male MH - Treatment Outcome MH - Postoperative Complications/epidemiology MH - *Cardiac Surgical Procedures/methods MH - Retrospective Studies MH - Child, Preschool PMC - PMC12441897 OTO - NOTNLM OT - Atrioventricular septal defect OT - Multidisciplinary Care OT - Outcome OT - Pediatrics OT - Tetralogy of Fallot EDAT- 2025/09/02 22:41 MHDA- 2025/09/03 12:34 PMCR- 2025/09/01 CRDT- 2025/09/02 20:43 PHST- 2025/04/30 00:00 [received] PHST- 2025/06/30 00:00 [accepted] PHST- 2025/09/03 12:34 [medline] PHST- 2025/09/02 22:41 [pubmed] PHST- 2025/09/02 20:43 [entrez] PHST- 2025/09/01 00:00 [pmc-release] AID - 46/9/1039 [pii] AID - SaudiMedJ-46-9-1039 [pii] AID - 10.15537/smj.2025.46.9.20250398 [doi] PST - ppublish SO - Saudi Med J. 2025 Sep;46(9):1039-1045. doi: 10.15537/smj.2025.46.9.20250398. PMID- 40896709 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250905 IS - 2375-1916 (Print) IS - 2375-1924 (Electronic) IS - 2375-1916 (Linking) VI - 12 IP - 12 DP - 2024 Dec TI - A Personalized Medicine Approach is Best for Patients with Homozygous Familial Hypercholesterolemia. LID - 10.18103/mra.v12i12.6160 [doi] AB - Homozygous familial hypercholesterolemia (HoFH) is an autosomal semi-dominant condition characterized by biallelic pathogenic variants impacting low-density lipoprotein receptor (LDLR) function. Affected individuals have severely elevated LDL cholesterol, early onset atherosclerotic heart disease and/or aortic stenosis, and characteristic clinical findings. While the cause is known and diagnosis is relatively simple, real-world HoFH care presents many complexities, including genetic heterogeneity and the diverse personal and social circumstances that influence care. Genetics-informed treatment involves a trial-and-error approach that warrants specific considerations during pregnancy. Thus, HoFH care requires a deep understanding of personal factors, social determinants of health, and a flexible, adaptable approach to treatment, all of which justify the need for personalized care. Framed by complexity theory, this review offers strategies for personalizing HoFH care, including a reconceptualization of the definition of health and implementing a multidisciplinary team approach. We also recommend integrating complexity theory and systems thinking into clinical care. By doing so, we illustrate the advantages of classifying knowledge complexity to inform clinical decision-making. We also demonstrate how openness to relationship-building and time investment is critical to materializing personalized care to HoFH. FAU - Morales, Ana AU - Morales A AD - Department of Genomic Health, Geisinger, Danville, PA, USA. FAU - Jamison, Allison AU - Jamison A AD - Family Heart Foundation, Pasadena, CA, USA. FAU - Hegele, Robert A AU - Hegele RA AD - Schulich School of Medicine and Dentistry, Western University, London, Ontario, CA. FAU - Hemphill, Linda AU - Hemphill L AD - Corrigan Minehan Heart Center, Massachusetts General Hospital, Boston, MA. USA. FAU - Gidding, Samuel S AU - Gidding SS AD - Department of Genomic Health, Geisinger, Danville, PA, USA. LA - eng GR - R33 HL161775/HL/NHLBI NIH HHS/United States PT - Journal Article DEP - 20241224 PL - United States TA - Med Res Arch JT - Medical research archives JID - 101668511 PMC - PMC12393222 MID - NIHMS2076868 EDAT- 2025/09/02 22:31 MHDA- 2025/09/02 22:32 PMCR- 2025/08/29 CRDT- 2025/09/02 17:39 PHST- 2025/09/02 22:32 [medline] PHST- 2025/09/02 22:31 [pubmed] PHST- 2025/09/02 17:39 [entrez] PHST- 2025/08/29 00:00 [pmc-release] AID - 10.18103/mra.v12i12.6160 [doi] PST - ppublish SO - Med Res Arch. 2024 Dec;12(12):10.18103/mra.v12i12.6160. doi: 10.18103/mra.v12i12.6160. Epub 2024 Dec 24. PMID- 40896567 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250915 LR - 20250915 IS - 1671-5411 (Print) IS - 1671-5411 (Linking) VI - 22 IP - 7 DP - 2025 Jul 28 TI - Patient reported experience measures in TAVI procedures: VALVEX study. PG - 638-647 LID - 10.26599/1671-5411.2025.07.009 [doi] AB - BACKGROUND: Transcatheter Aortic Valve Implantation (TAVI) has changed the treatment paradigm of the aortic stenosis (AS). It has become the treatment of choice in patients with symptomatic AS and surgical high risk, and a valid alternative to surgical aortic valve replacement in patients with low and medium surgical risk. Despite numerous evidence on clinical results, indications and benefits, only a few studies analyse it from patient's perspective and the impact of TAVI on them. The objective of this study is to evaluate the experience of patients undergoing TAVI. METHODS: Cross-sectional, descriptive observational study in two Spanish hospitals, with a establish Nurse TAVI program, with 100 patients undergoing TAVI. A specific questionnaire was designed (VALVEX questionnaire) and a pilot study was conducted by a multidisciplinary team of doctors, nurses and patients. The questionnaire was given to patients at 30 days after TAVI procedure during the follow up at the TAVI nurse clinic. RESULTS: The study demonstrated a mean satisfaction of 9 for the TAVI program, with 96% of patients that would recommend TAVI to other patients. Patients scored a high satisfaction on the information received prior to the procedure. During the procedure and admission, the satisfaction was high in relation to the care received. During the follow up, satisfaction was high in relation to the role of the TAVI nurse, for the information and continuation of care during the procedure, in reducing anxiety, organising their admission and understanding the process. However, questions with less scores were related to hospital catering, delay between diagnosed and treatment, and patient decision-making process. CONCLUSION: The evaluation of patient experience allows us to improve the information given to the patient during their TAVI process and it can also allow patients to be more relax, aware and prepared for the procedure. Continuous follow up enables monitoring of patient recovery and helps to discuss any doubts improving patient's satisfaction. The use of PREMs and PROMs associated to TAVI pathway combined with an active participation of the patient on the design of the questionnaire is essential for keeping the patient in the centre of the TAVI pathway. CI - (c) 2025 JGC All rights reserved; www.jgc301.com. FAU - Gonzalez-Cebrian, Miryam AU - Gonzalez-Cebrian M AD - Cardiology Department, University Hospital of Salamanca, Salamanca, Spain. AD - CIBER-CV Instituto de Salud Carlos III (ISCIII), Madrid, Spain. AD - IBSAL, Instituto de Investigacion Biomedico de Salamanca, Salamanca, Spain. AD - USAL, University of Salamanca, Salamanca, Spain. FAU - Garcia, Jose Luis Mendoza AU - Garcia JLM AD - Servicio de Medicina Preventiva, University Hospital of Torrevieja, Alicante, Spain. FAU - Cruz-Gonzalez, Ignacio AU - Cruz-Gonzalez I AD - Cardiology Department, University Hospital of Salamanca, Salamanca, Spain. AD - CIBER-CV Instituto de Salud Carlos III (ISCIII), Madrid, Spain. AD - IBSAL, Instituto de Investigacion Biomedico de Salamanca, Salamanca, Spain. FAU - Melendez, Sara Alonso AU - Melendez SA AD - Cardiology Department, University Hospital of Salamanca, Salamanca, Spain. AD - IBSAL, Instituto de Investigacion Biomedico de Salamanca, Salamanca, Spain. FAU - Poyo, Rocio Castillo AU - Poyo RC AD - Cardiology Department, University Hospital of Bellvitge, Barcelona, Spain. FAU - Nieto, Raquel Zafrilla AU - Nieto RZ AD - Cardiology Department, University Hospital of Bellvitge, Barcelona, Spain. FAU - Sanchez, Pedro L AU - Sanchez PL AD - Cardiology Department, University Hospital of Salamanca, Salamanca, Spain. AD - CIBER-CV Instituto de Salud Carlos III (ISCIII), Madrid, Spain. AD - IBSAL, Instituto de Investigacion Biomedico de Salamanca, Salamanca, Spain. FAU - Segria, Cristina Ruiz AU - Segria CR AD - GRIN-IDIBELL, Instituto de Investigacion Biomedica de Bellvitge, L'Hospitalet de Llobregat, Spain. FAU - Barriuso, Elena Calvo AU - Barriuso EC AD - CIBER-CV Instituto de Salud Carlos III (ISCIII), Madrid, Spain. AD - Cardiology Department, University Hospital of Bellvitge, Barcelona, Spain. AD - Cardiothoracics Department, South Tees-James Cook University Hospital, Middlesbrough, United Kingdom. LA - eng PT - Journal Article PL - China TA - J Geriatr Cardiol JT - Journal of geriatric cardiology : JGC JID - 101237881 PMC - PMC12394955 COIS- ICG is proctor and consultant for Medtronic, Abbott, Boston Scientific and Biosensors. The rest of the authors have no conflicts of interest to declare. EDAT- 2025/09/02 22:31 MHDA- 2025/09/02 22:32 PMCR- 2025/07/28 CRDT- 2025/09/02 17:37 PHST- 2025/09/02 22:32 [medline] PHST- 2025/09/02 22:31 [pubmed] PHST- 2025/09/02 17:37 [entrez] PHST- 2025/07/28 00:00 [pmc-release] AID - jgc-22-7-638 [pii] AID - 10.26599/1671-5411.2025.07.009 [doi] PST - ppublish SO - J Geriatr Cardiol. 2025 Jul 28;22(7):638-647. doi: 10.26599/1671-5411.2025.07.009. PMID- 40895901 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250915 LR - 20250915 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 17 IP - 7 DP - 2025 Jul TI - Global Insights Into Spondylodiscitis: A Bibliometric Analysis of Four Decades of Research. PG - e89001 LID - 10.7759/cureus.89001 [doi] LID - e89001 AB - The diagnosis and management of spondylodiscitis (SD) remain challenging for clinicians due to its insidious onset and nonspecific clinical presentation. Patients often have multiple comorbidities, requiring a multidisciplinary approach that may involve both nonsurgical and surgical interventions. This bibliometric study aims to analyze global research output on SD, exploring publication trends, citation patterns, contributing countries and journals, and commonly associated keywords. Data were collected from the Clarivate Analytics Web of Science (WoS) database on July 22, 2024, using the search terms "Spondylodiscitis" OR "Spondylodiskitis" OR "vertebral osteomyelitis" OR "spine osteomyelitis" OR "spinal osteomyelitis" OR "osteodiscitis" OR "osteodiskitis" OR "discitis" OR "diskitis". A total of 4,363 relevant publications were identified, spanning the years 1982 to 2023. Descriptive and quantitative analyses were conducted, including keyword network visualizations. There was an almost 15-fold increase in publication volume, from 18 publications in 1982 to 269 in 2023. Citation frequency followed a similar trajectory, rising from a single citation in 1982 to 7,148 in 2023. The United States, Germany, and France accounted for over 50% of the total research output, with Spine identified as the most prolific journal. Commonly co-occurring keywords included "endocarditis" and "staphylococcus aureus," as revealed by network visualization analysis. In conclusion, SD is a complex condition requiring multidisciplinary care. This bibliometric review demonstrates significant growth in both research volume and citation impact, particularly from high-income countries. Notably, keyword mapping revealed an underrepresentation of comorbidity-related terms in recent literature, indicating a potential gap in current academic discourse. CI - Copyright (c) 2025, Gerstmeyer et al. FAU - Gerstmeyer, Julius AU - Gerstmeyer J AD - Orthopedics and Trauma Surgery, BG University Hospital Bergmannsheil, Ruhr University, Bochum, DEU. FAU - Gorbacheva, Anna AU - Gorbacheva A AD - Neurosurgery, Seattle Science Foundation, Seattle, USA. FAU - Pierre, Clifford AU - Pierre C AD - Neurosurgery, Swedish Neuroscience Institute, Seattle, USA. FAU - Jouppi, Luke AU - Jouppi L AD - Neurosurgery, Seattle Science Foundation, Seattle, USA. FAU - Kraemer, Mark AU - Kraemer M AD - Complex Spine Surgery, Swedish Neuroscience Institute, Seattle, USA. FAU - Minissale, Nicholas AU - Minissale N AD - Complex Spine Surgery, Swedish Neuroscience Institute, Seattle, USA. FAU - Hogsett, Cameron AU - Hogsett C AD - Complex Spine Surgery, Swedish Neuroscience Institute, Seattle, USA. FAU - Gold, Colin AU - Gold C AD - Complex Spine Surgery, Swedish Neuroscience Institute, Seattle, USA. FAU - Lockey, Stephen D AU - Lockey SD AD - Orthopedic Surgery, University of Virginia, Charlottesville, USA. FAU - Schildhauer, Thomas A AU - Schildhauer TA AD - Orthopedics and Trauma Surgery, BG University Hospital Bergmannsheil, Ruhr University, Bochum, DEU. FAU - Abdul-Jabbar, Amir AU - Abdul-Jabbar A AD - Orthopedics and Spine Surgery, Swedish Neuroscience Institute, Seattle, USA. FAU - Oskouian, Rod J AU - Oskouian RJ AD - Neurosurgery, Swedish Neuroscience Institute, Seattle, USA. FAU - Chapman, Jens AU - Chapman J AD - Neurosurgery, Swedish Neuroscience Institute, Seattle, USA. LA - eng PT - Journal Article PT - Review DEP - 20250729 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC12395117 OTO - NOTNLM OT - bibliometric OT - spinal infection OT - spinal osteomyelitis OT - spine surgery OT - spondylodiscitis COIS- Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. EDAT- 2025/09/02 22:33 MHDA- 2025/09/02 22:34 PMCR- 2025/07/29 CRDT- 2025/09/02 17:23 PHST- 2025/07/29 00:00 [accepted] PHST- 2025/09/02 22:34 [medline] PHST- 2025/09/02 22:33 [pubmed] PHST- 2025/09/02 17:23 [entrez] PHST- 2025/07/29 00:00 [pmc-release] AID - 10.7759/cureus.89001 [doi] PST - epublish SO - Cureus. 2025 Jul 29;17(7):e89001. doi: 10.7759/cureus.89001. eCollection 2025 Jul. PMID- 40894231 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250915 LR - 20250915 IS - 1663-9812 (Print) IS - 1663-9812 (Electronic) IS - 1663-9812 (Linking) VI - 16 DP - 2025 TI - Clinicians' view on non-adherence: sharing expert opinion. PG - 1636806 LID - 10.3389/fphar.2025.1636806 [doi] LID - 1636806 AB - INTRODUCTION: Medication non-adherence (NA) remains a persistent challenge across all medical specialties, contributing to adverse patient outcomes and increased healthcare burdens. While numerous studies have explored patient-related factors influencing adherence, the perspectives of healthcare professionals remain underrepresented in literature. This study aims to document the individual experiences of seven international physicians across diverse medical fields, highlighting barriers, detection methods, and strategies employed to address NA in their daily practice. METHODOLOGY: A structured qualitative approach was employed, incorporating semi-structured interviews and written questionnaires to capture expert insights. Seven physicians from specialties including family medicine, gastroenterology, otolaryngology, otology and neurotology, obstetrics and gynecology, endocrinology and cardiology participated in the study. Data were analyzed thematically to identify recurring patterns, specialty-specific challenges, and practical solutions implemented by clinicians. RESULTS: Clinicians reported that NA detection primarily relied on patient self-reporting, clinical markers, and medication reconciliation. Barriers to adherence varied by specialty but commonly included polypharmacy, treatment complexity, patient skepticism, socioeconomic constraints, and asymptomatic conditions. Strategies to enhance adherence encompassed patient education, shared decision-making, therapeutic simplification, digital tools, and team-based care models. Despite proactive efforts, clinicians cited systemic limitations such as time constraints, fragmented healthcare records, and inadequate adherence-tracking mechanisms. CONCLUSION: Addressing NA requires a patient-centered, interdisciplinary approach integrating education, digital innovations, and structured follow-up strategies. The study underscores the necessity for larger-scale research to validate adherence interventions and refine multidisciplinary frameworks. Given the study's qualitative nature and small sample size, future research should incorporate broader datasets and diverse healthcare perspectives to develop more comprehensive adherence solutions. CI - Copyright (c) 2025 Tan, Joshi, De-Madaria, Mostafa, Ozgirgin, Simoncini and Tokgozoglu. FAU - Tan, Ngiap Chuan AU - Tan NC AD - SingHealth Polyclinics, Singapore, Singapore. FAU - Joshi, Shashank R AU - Joshi SR AD - Joshi Clinic, Mumbai, India. FAU - De-Madaria, Enrique AU - De-Madaria E AD - Department of Gastroenterology, Dr. Balmis General University Hospital and Department of Clinical Medicine, Miguel Hernandez University, Alicante, Spain. AD - Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain. FAU - Mostafa, Badr Eldin AU - Mostafa BE AD - Faculty of Medicine, Ain Shams University, Heliopolis-Cairo, Egypt. FAU - Ozgirgin, O Nuri AU - Ozgirgin ON AD - Bayindir Sogutozu Hospital, Ankara, Turkiye. FAU - Simoncini, Tommaso AU - Simoncini T AD - Division of Obstetrics and Gynecology, Department of Experimental and Clinical Medicine, University of Pisa, Pisa, Italy. FAU - Tokgozoglu, Lale AU - Tokgozoglu L AD - Department of Cardiology, Hacettepe University Medical Faculty, Ankara, Turkiye. LA - eng PT - Journal Article DEP - 20250815 PL - Switzerland TA - Front Pharmacol JT - Frontiers in pharmacology JID - 101548923 PMC - PMC12396120 OTO - NOTNLM OT - adherence strategies OT - expert opinion OT - medication adherence OT - non-adherence OT - patient compliance COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2025/09/02 22:33 MHDA- 2025/09/02 22:34 PMCR- 2025/08/15 CRDT- 2025/09/02 16:44 PHST- 2025/05/28 00:00 [received] PHST- 2025/07/18 00:00 [accepted] PHST- 2025/09/02 22:34 [medline] PHST- 2025/09/02 22:33 [pubmed] PHST- 2025/09/02 16:44 [entrez] PHST- 2025/08/15 00:00 [pmc-release] AID - 1636806 [pii] AID - 10.3389/fphar.2025.1636806 [doi] PST - epublish SO - Front Pharmacol. 2025 Aug 15;16:1636806. doi: 10.3389/fphar.2025.1636806. eCollection 2025. PMID- 40891128 OWN - NLM STAT- MEDLINE DCOM- 20250902 LR - 20250916 IS - 1478-5153 (Electronic) IS - 1362-1017 (Linking) VI - 30 IP - 5 DP - 2025 Sep TI - Patient Handover From the Cardiac Surgery Operating Room to the Critical Care Unit: A Prospective Observational Study. PG - e70154 LID - 10.1111/nicc.70154 [doi] AB - BACKGROUND: Incomplete and inaccurate information transfer during the patient handover process has many risks, such as disruption of postoperative care and complications. Therefore, effective patient handover is essential. AIM: This study aimed to evaluate the handover of patients from the cardiac surgery operating room to the critical care unit by examining the type of information transferred, healthcare workers' roles during handover, handover time and frequency of interruptions. STUDY DESIGN: This is a prospective observational study. The sample of this study consisted of the handover process of 85 cardiac surgery patients at a university hospital, Izmir, Turkey, between January and June 2023. RESULTS: In this study, it was found that the cardiac surgery team gave more information about systolic/mean arterial blood pressure goals/limits (95.3%), cross-clamp time (95.3%) and surgical procedure (94.1%). The anaesthesia team provided more information about arterial blood gas results (96.5%), and recently administered antibiotics (95.3%). While the surgical residents performed 100% of the patient handovers of the cardiac surgery team, 80% of the patients were only received by the critical care physician. In the anaesthesia team, 97.6% of the patient handovers were performed by the anaesthesia residents, while 81.2% of the patients were received by the critical care physician alone. CONCLUSIONS: This study found that the cardiac surgery team provided more information about the surgical and intraoperative procedures. The anaesthesia team provided more information about the monitoring of the patient's condition and the drugs administered. The most striking finding of the study was that few nurses were involved in most patient handovers. In line with the results of this study, it is recommended to conduct intervention studies to increase nurse participation in patient handover processes and to comparatively examine the effectiveness of handover models involving different disciplines. RELEVANCE TO CLINICAL PRACTICE: This study provided a comprehensive evaluation of the handover process of cardiac surgery patients. The findings emphasise the need to establish protocols to overcome knowledge deficiencies in the patient handover process and to ensure the active participation of nurses in this process. CI - (c) 2025 British Association of Critical Care Nurses. FAU - Celikturk Doruker, Nihal AU - Celikturk Doruker N AUID- ORCID: 0000-0002-9004-0502 AD - Ege University, Faculty of Nursing, Department of Surgical Nursing, Izmir, Turkey, Izmir, Turkey. FAU - Demir Korkmaz, Fatma AU - Demir Korkmaz F AUID- ORCID: 0000-0003-3810-297X AD - Ege University, Faculty of Nursing, Department of Surgical Nursing, Izmir, Turkey, Izmir, Turkey. FAU - Sarp, Asli AU - Sarp A AUID- ORCID: 0009-0007-1254-4901 AD - Ege University, Faculty of Medicine Hospital, Department of Cardiovascular Surgery, Izmir, Turkey. LA - eng PT - Journal Article PT - Observational Study PL - England TA - Nurs Crit Care JT - Nursing in critical care JID - 9808649 SB - IM MH - Humans MH - *Patient Handoff/standards/statistics & numerical data MH - Prospective Studies MH - Turkey MH - *Operating Rooms/organization & administration MH - Female MH - Male MH - *Cardiac Surgical Procedures MH - *Intensive Care Units/organization & administration MH - Middle Aged MH - Aged MH - Patient Care Team OTO - NOTNLM OT - cardiac surgery OT - critical care unit OT - operating room OT - patient handover EDAT- 2025/09/02 08:44 MHDA- 2025/09/02 08:45 CRDT- 2025/09/02 02:43 PHST- 2025/07/30 00:00 [revised] PHST- 2024/12/06 00:00 [received] PHST- 2025/08/06 00:00 [accepted] PHST- 2025/09/02 08:45 [medline] PHST- 2025/09/02 08:44 [pubmed] PHST- 2025/09/02 02:43 [entrez] AID - 10.1111/nicc.70154 [doi] PST - ppublish SO - Nurs Crit Care. 2025 Sep;30(5):e70154. doi: 10.1111/nicc.70154. PMID- 40890837 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250915 LR - 20250915 IS - 2055-0294 (Print) IS - 2055-0294 (Electronic) IS - 2055-0294 (Linking) VI - 11 IP - 1 DP - 2025 Sep 1 TI - Severe symptomatic cardiac dysfunction in a patient with BRAF V600E-mutated metastatic colorectal cancer treated with encorafenib, binimetinib, and cetuximab: a case report. PG - 80 LID - 10.1186/s40780-025-00480-z [doi] LID - 80 AB - BACKGROUND: V-Raf murine sarcoma viral oncogene homolog B1 (BRAF) mutations are present in approximately 5% of Japanese patients with colorectal cancer (CRC) who receive BRAF-targeted triplet therapy, consisting of encorafenib (a BRAF inhibitor), binimetinib (a mitogen-activated protein kinase inhibitor [MEKi]), and cetuximab. This combination therapy is associated with an increased risk of cardiac dysfunction (CD), primarily attributed to MEKi. However, the detailed clinical course of this adverse event remains unclear. Here, we report a case of severe symptomatic CD that developed during this triplet therapy. CASE PRESENTATION: The patient was a 70-year-old Japanese man diagnosed with BRAF-mutated CRC with multiple metastases. BRAF-targeted triplet therapy was initiated as a third-line treatment. His baseline left ventricular ejection fraction (LVEF) was 66% and he had no history of heart disease. On Day 106, a pharmacist conducting the patient's consultation suspected CD associated with binimetinib because of symptoms such as deterioration of general condition and dyspnea. The pharmacist immediately recommended an echocardiography that revealed a significant decline in LVEF to 33%. The patient was referred to a cardiologist and treatment with enalapril, followed by bisoprolol, was initiated while triplet therapy was discontinued. Within 1 week of treatment interruption, the patient's general condition improved rapidly and his symptoms resolved. Therefore, cancer treatment was resumed as doublet therapy without binimetinib. Under close multidisciplinary monitoring, no recurrence of CD symptoms was observed. Doublet therapy was continued until Day 168, when disease progression occurred. This exceeded the median progression-free survival reported in the phase III BEACON-CRC trial. CONCLUSIONS: This case highlights two crucial insights into BRAF/MEK inhibitor-associated CD. First, even severe symptomatic CD can be effectively managed and reversed upon immediate discontinuation of binimetinib and initiation of cardiotropic medications. Second, in such a severe case, rapid recovery is observed. Once stabilized, BRAF-targeted treatment could be continued as doublet therapy without binimetinib to ensure safety and disease control. However, regular echocardiographic surveillance is essential, with an interval shorter than 4 months, based on the clinical course of this case. Additionally, early recognition of CD may be improved by closely monitoring patients' symptoms and complaints through a multidisciplinary approach. CI - (c) 2025. The Author(s). FAU - Kondo, Masahiro AU - Kondo M AD - Department of Clinical Pharmaceutics, Nagoya City University Graduate School of Medical Sciences, 1-Kawasumi, Mizuho-Cho, Mizuho-Ku, Nagoya, Aichi, 467-8601, Japan. phkondou@med.nagoya-cu.ac.jp. AD - Department of Pharmacy, Nagoya City University East Medical Center, 1-2-23 Wakamizu, Chikusa-Ku, Nagoya, Aichi, 464-8547, Japan. phkondou@med.nagoya-cu.ac.jp. FAU - Nagao, Yukiko AU - Nagao Y AD - Department of Pharmacy, Nagoya City University East Medical Center, 1-2-23 Wakamizu, Chikusa-Ku, Nagoya, Aichi, 464-8547, Japan. FAU - Hayashi, Shohei AU - Hayashi S AD - Department of Gastroenterological Surgery, Nagoya City University Graduate School of Medical Sciences, 1-Kawasumi, Mizuho-Cho, Mizuho-Ku, Nagoya City, Aichi, 467-8601, Japan. FAU - Wakita, Eri AU - Wakita E AD - Department of Pharmacy, Nagoya City University East Medical Center, 1-2-23 Wakamizu, Chikusa-Ku, Nagoya, Aichi, 464-8547, Japan. FAU - Noda, Masato AU - Noda M AD - Department of Clinical Pharmaceutics, Nagoya City University Graduate School of Medical Sciences, 1-Kawasumi, Mizuho-Cho, Mizuho-Ku, Nagoya, Aichi, 467-8601, Japan. AD - Department of Pharmacy, Nagoya City University East Medical Center, 1-2-23 Wakamizu, Chikusa-Ku, Nagoya, Aichi, 464-8547, Japan. FAU - Okada, Itsuki AU - Okada I AD - Department of Clinical Pharmaceutics, Nagoya City University Graduate School of Medical Sciences, 1-Kawasumi, Mizuho-Cho, Mizuho-Ku, Nagoya, Aichi, 467-8601, Japan. AD - Department of Pharmacy, Nagoya City University East Medical Center, 1-2-23 Wakamizu, Chikusa-Ku, Nagoya, Aichi, 464-8547, Japan. FAU - Wachino, Chiharu AU - Wachino C AD - Department of Clinical Pharmaceutics, Nagoya City University Graduate School of Medical Sciences, 1-Kawasumi, Mizuho-Cho, Mizuho-Ku, Nagoya, Aichi, 467-8601, Japan. AD - Department of Pharmacy, Nagoya City University East Medical Center, 1-2-23 Wakamizu, Chikusa-Ku, Nagoya, Aichi, 464-8547, Japan. FAU - Yamada-Nishide, Keiko AU - Yamada-Nishide K AD - Department of Clinical Pharmaceutics, Nagoya City University Graduate School of Medical Sciences, 1-Kawasumi, Mizuho-Cho, Mizuho-Ku, Nagoya, Aichi, 467-8601, Japan. AD - Department of Pharmacy, Nagoya City University East Medical Center, 1-2-23 Wakamizu, Chikusa-Ku, Nagoya, Aichi, 464-8547, Japan. FAU - Hori, Masayuki AU - Hori M AD - Department of Pharmacy, Nagoya City University Hospital, 1-Kawasumi, Mizuho-Cho, Mizuho-Ku, Nagoya, Aichi, 467-8602, Japan. FAU - Hotta, Yuji AU - Hotta Y AD - Department of Clinical Pharmaceutics, Nagoya City University Graduate School of Medical Sciences, 1-Kawasumi, Mizuho-Cho, Mizuho-Ku, Nagoya, Aichi, 467-8601, Japan. AD - Department of Pharmacy, Nagoya City University Hospital, 1-Kawasumi, Mizuho-Cho, Mizuho-Ku, Nagoya, Aichi, 467-8602, Japan. FAU - Matsuo, Yoichi AU - Matsuo Y AD - Department of Gastroenterological Surgery, Nagoya City University Graduate School of Medical Sciences, 1-Kawasumi, Mizuho-Cho, Mizuho-Ku, Nagoya City, Aichi, 467-8601, Japan. FAU - Furukawa-Hibi, Yoko AU - Furukawa-Hibi Y AD - Department of Clinical Pharmaceutics, Nagoya City University Graduate School of Medical Sciences, 1-Kawasumi, Mizuho-Cho, Mizuho-Ku, Nagoya, Aichi, 467-8601, Japan. AD - Department of Pharmacy, Nagoya City University Hospital, 1-Kawasumi, Mizuho-Cho, Mizuho-Ku, Nagoya, Aichi, 467-8602, Japan. LA - eng GR - non/MOKUTEKITSUMITATEKIN/ PT - Journal Article DEP - 20250901 PL - England TA - J Pharm Health Care Sci JT - Journal of pharmaceutical health care and sciences JID - 101672177 PMC - PMC12400612 OTO - NOTNLM OT - BRAF gene mutation OT - Binimetinib OT - Cardiac dysfunction OT - Cetuximab OT - Colorectal cancer OT - Encorafenib COIS- Declarations. Ethics approval and consent to participate: This study was approved by the Ethical Review Board of Nagoya City University Graduate School of Medical Sciences (60-25-0001). Consent was obtained from the patient's wife as a representative because the participant had died at the time of preparation of this case report. Consent for publication: Consent for the publication of this case report was obtained from the patient's wife as a representative because the patient had died at the time of submission to this journal. A copy of the consent document is available for review by the Editor-in-Chief. Competing interests: The authors declare no competing interests. EDAT- 2025/09/02 08:44 MHDA- 2025/09/02 08:45 PMCR- 2025/09/01 CRDT- 2025/09/02 00:05 PHST- 2025/05/08 00:00 [received] PHST- 2025/08/01 00:00 [accepted] PHST- 2025/09/02 08:45 [medline] PHST- 2025/09/02 08:44 [pubmed] PHST- 2025/09/02 00:05 [entrez] PHST- 2025/09/01 00:00 [pmc-release] AID - 10.1186/s40780-025-00480-z [pii] AID - 480 [pii] AID - 10.1186/s40780-025-00480-z [doi] PST - epublish SO - J Pharm Health Care Sci. 2025 Sep 1;11(1):80. doi: 10.1186/s40780-025-00480-z. PMID- 40890370 OWN - NLM STAT- MEDLINE DCOM- 20260505 LR - 20260813 IS - 1432-1971 (Electronic) IS - 0172-0643 (Print) IS - 0172-0643 (Linking) VI - 47 IP - 5 DP - 2026 Jun TI - Current Status of Fetal Echocardiography Imaging and Fetal Counseling Fellow Training in 29 European Countries. PG - 2138-2146 LID - 10.1007/s00246-025-04006-0 [doi] AB - Limited data exist on the implementation of current fetal cardiology training and practice guidelines, how trainees are assessed, and how trained fetal cardiologists maintain their skills among countries affiliated with the Association of European Paediatric and Congenital Cardiology (AEPC). A structured questionnaire was sent to fetal cardiologists or national delegates from 44 centers in 33 European countries. Responses were obtained from 37 centers in 29 European countries with 31 responses from fetal cardiologists. Fetal echocardiography was equally performed in maternal (18) and pediatric (16) hospitals with median 3 (range 0-6) fetal cardiologists per center and > 4 fetal cardiologists in 13 centers. Core and advanced fetal cardiology training was offered in 17 (46%) and 21 (57%) centers. Advanced training was provided in higher volume centers (19/21). Assessment methods included direct trainee observation, case-based discussions, and participation in multidisciplinary team meetings, with mostly verbal feedback provided. Criteria for independent fetal echocardiography and counseling were based on training duration (range 2-24 months), number of assessments (range 100-1500), and number of counseling abnormal cases (range 40-200) performed under expert supervision, as well as on expert evaluations of trainees based on direct observation and fetal cardiac diagnostic accuracy. Formal certification in fetal cardiology was reported in three centers. Research activity among trained experts was reported among 25 (68%) respondents overall with 19 respondents involved with collaborative research. Trainee research was encouraged but not mandatory in clinical training. Maintenance of expert skills included sufficient clinical activity volume, teaching, and different forms of national and international networking. Fetal cardiology service quality assessments included missed cases discussion in 20 (54%) centers. There is substantial variation in advanced fetal cardiology training practice in Europe suggesting a need for further clarification of training criteria and structure. Trainee assessment is mainly verbal and based on direct observation. There seems to be a need to strengthen the fetal cardiology module in core pediatric cardiology training and to improve quality assessment of the clinical service provided. CI - (c) 2025. The Author(s). FAU - Sarkola, Taisto AU - Sarkola T AD - Children's Hospital, University of Helsinki and Helsinki University Hospital, Stenbackinkatu 9, PO box 281, 00029, Helsinki, Finland. taisto.sarkola@helsinki.fi. AD - Minerva Foundation Institute for Medical Research, Helsinki, Finland. taisto.sarkola@helsinki.fi. FAU - Seale, Anna N AU - Seale AN AD - Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK. AD - Heart Unit, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK. FAU - Tulzer, Andreas AU - Tulzer A AD - Department of Pediatric Cardiology, Children's Heart Center Linz, Kepler University Hospital, Linz, Austria. AD - Medical Faculty, Johannes Kepler University Linz, Linz, Austria. FAU - Duignan, Sophie M AU - Duignan SM AD - Department of Paediatric Cardiology, Children's Health Ireland at Crumlin, Dublin, Ireland. AD - School of Medicine, University College Dublin, Belfield, Dublin, Ireland. FAU - Grzyb, Agnieszka AU - Grzyb A AD - Department of Perinatal Cardiology and Congenital Anomalies, Centre of Postgraduate Medical Education, Warsaw, Poland. AD - Department of Cardiac Surgery, The Children's Memorial Health Institute, Warsaw, Poland. FAU - Tuo, Giulia AU - Tuo G AD - Pediatric Cardiology and Cardiac Surgery Unit, Surgery Department, IRCCS Instituto Giannina Gaslini, Genoa, Italy. FAU - Vanhie, Ellen AU - Vanhie E AD - Pediatric Cardiology, Paola Children's Hospital, Antwerp, Belgium. AD - Fetal Cardiology Department, University Hospital Ghent, Ghent, Belgium. FAU - McMahon, Colin J AU - McMahon CJ AD - Department of Paediatric Cardiology, Children's Health Ireland at Crumlin, Dublin, Ireland. AD - School of Medicine, University College Dublin, Belfield, Dublin, Ireland. CN - Fetal Cardiology Working Group of the AEPC LA - eng PT - Journal Article PT - Multicenter Study DEP - 20250901 PL - United States TA - Pediatr Cardiol JT - Pediatric cardiology JID - 8003849 SB - IM MH - Humans MH - *Echocardiography MH - Europe MH - *Ultrasonography, Prenatal MH - Pregnancy MH - Surveys and Questionnaires MH - Female MH - Clinical Competence MH - *Heart Defects, Congenital/diagnostic imaging MH - *Cardiology/education MH - *Counseling MH - *Fetal Heart/diagnostic imaging PMC - PMC13144209 OTO - NOTNLM OT - Fetal counseling OT - Fetal echocardiography OT - Training COIS- Declarations. Conflict of interest: The authors declare no competing interests. Ethical Approval: The requirement for a full review by the Children's Health Ireland Research ethics committee was waived. FIR - Bhat, Misha IR - Bhat M FIR - Bonnet, Damien IR - Bonnet D FIR - Clur, Sally-Ann IR - Clur SA FIR - Escobar-Diaz, Maria C IR - Escobar-Diaz MC FIR - De Groote, Katya IR - De Groote K FIR - Dinarevic, Senka IR - Dinarevic S FIR - Kruse, Charlotte Duhn IR - Kruse CD FIR - Dumitrascu-Biris, Ioana IR - Dumitrascu-Biris I FIR - Diab, Simone Goa IR - Diab SG FIR - Herberg, Ulrike IR - Herberg U FIR - Jossif, Antonis IR - Jossif A FIR - Kavga, Maria IR - Kavga M FIR - Ladanyi, Aniko IR - Ladanyi A FIR - Lubaua, Inguna IR - Lubaua I FIR - McMahon, Colin IR - McMahon C FIR - Meyer-Szary, Jaroslaw IR - Meyer-Szary J FIR - Miranda, Joana O IR - Miranda JO FIR - Olejnik, Peter IR - Olejnik P FIR - Oskarsson, Gylfi IR - Oskarsson G FIR - Parezanovic, Vojislav IR - Parezanovic V FIR - Seale, Anna IR - Seale A FIR - Seidl-Mlczoch, Lila IR - Seidl-Mlczoch L FIR - Sendzikaite, Skaiste IR - Sendzikaite S FIR - Steinhard, Johannes IR - Steinhard J FIR - Suuden, Eva-Liina IR - Suuden EL FIR - Tomek, Viktor IR - Tomek V FIR - Tulzer, Gerald IR - Tulzer G FIR - Turi, Alexandra IR - Turi A FIR - Tzifa, Aphrodite IR - Tzifa A FIR - Vassileva, Zornitsa IR - Vassileva Z FIR - Weber, Roland IR - Weber R EDAT- 2025/09/02 00:44 MHDA- 2026/05/06 00:35 PMCR- 2025/09/01 CRDT- 2025/09/01 23:35 PHST- 2025/05/15 00:00 [received] PHST- 2025/08/19 00:00 [accepted] PHST- 2026/05/06 00:35 [medline] PHST- 2025/09/02 00:44 [pubmed] PHST- 2025/09/01 23:35 [entrez] PHST- 2025/09/01 00:00 [pmc-release] AID - 10.1007/s00246-025-04006-0 [pii] AID - 4006 [pii] AID - 10.1007/s00246-025-04006-0 [doi] PST - ppublish SO - Pediatr Cardiol. 2026 Jun;47(5):2138-2146. doi: 10.1007/s00246-025-04006-0. Epub 2025 Sep 1. PMID- 40889957 OWN - NLM STAT- MEDLINE DCOM- 20250901 LR - 20251110 IS - 2053-3624 (Print) IS - 2053-3624 (Electronic) IS - 2053-3624 (Linking) VI - 12 IP - 2 DP - 2025 Aug 31 TI - MAGGIC risk score-based risk stratification for selecting patients with heart failure who will benefit from multidisciplinary care. LID - 10.1136/openhrt-2025-003496 [doi] LID - e003496 AB - OBJECTIVE: Guidelines worldwide recommend specialist outpatient clinics staffed by a multidisciplinary team for management of patients with heart failure (HF). However, there is limited information on how best to select these patients for efficient use of resources. This study aimed to determine the effectiveness of team-based care for patients with HF after discharge from hospital according to duration of intervention and stratification of patients according to risk. METHODS: We retrospectively identified 185 eligible patients who were hospitalised with acute decompensated HF at our institution between January 2021 and June 2023. Multidisciplinary team care was defined as outpatient follow-up by both cardiologists and nurses postdischarge. The primary outcome was a composite of cardiovascular-related death and readmission with HF within 1 year, which was compared between patients receiving HF team care and those receiving standard follow-up. RESULTS: HF team care was provided for 53.0% of patients, who were younger than those receiving standard follow-up and required more oral inotropes, tolvaptan and amiodarone. Among those receiving HF team care, the majority (58.2%) had an intervention duration of 30 days or less after discharge. After adjusting for background differences by inverse probability of treatment weighting, HF team care was associated with favourable 180-day outcomes, but there was no significant between-group difference in the 1-year primary outcomes. In subgroup analysis, patients with a higher Meta-Analysis Global Group in Chronic Heart Failure score (>/=28), indicating a higher risk of exacerbation of HF, had significantly lower 1-year event rates with HF team care (p value for interaction <0.05). CONCLUSIONS: Multidisciplinary HF team care is most effective for patients at higher risk of exacerbation of HF. A risk score model may optimise patient selection for specialised care. CI - (c) Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. FAU - Kinugasa, Yoshiharu AU - Kinugasa Y AUID- ORCID: 0000-0001-5310-2017 AD - Department of Cardiovascular Medicine and Endocrinology and Metabolism, Faculty of Medicine, Tottori University, Yonago, Japan ykinugasa-circ@tottori-u.ac.jp. FAU - Nakamura, Kensuke AU - Nakamura K AD - Department of Cardiovascular Medicine and Endocrinology and Metabolism, Faculty of Medicine, Tottori University, Yonago, Japan. FAU - Hirai, Masayuki AU - Hirai M AD - Department of Cardiovascular Medicine and Endocrinology and Metabolism, Faculty of Medicine, Tottori University, Yonago, Japan. FAU - Manba, Midori AU - Manba M AD - Tottori University Hospital, Yonago, Tottori Prefecture, Japan. FAU - Ishiga, Natsuko AU - Ishiga N AD - Tottori University Hospital, Yonago, Tottori Prefecture, Japan. FAU - Sota, Takeshi AU - Sota T AD - Tottori University Hospital, Yonago, Tottori Prefecture, Japan. FAU - Nakayama, Natsuko AU - Nakayama N AD - Tottori University Hospital, Yonago, Tottori Prefecture, Japan. FAU - Ota, Tomoki AU - Ota T AD - Tottori University Hospital, Yonago, Tottori Prefecture, Japan. FAU - Kato, Masahiko AU - Kato M AD - Department of Pathobiological Science and Technology, School of Health Science, Faculty of Medicine, Tottori University, Yonago, Japan. FAU - Kato, Masaru AU - Kato M AD - Department of Cardiovascular Medicine and Endocrinology and Metabolism, Faculty of Medicine, Tottori University, Yonago, Japan. LA - eng PT - Journal Article DEP - 20250831 PL - England TA - Open Heart JT - Open heart JID - 101631219 SB - IM MH - Humans MH - *Heart Failure/therapy/mortality/diagnosis MH - Male MH - Female MH - Retrospective Studies MH - Risk Assessment/methods MH - Aged MH - *Patient Care Team MH - Middle Aged MH - Risk Factors MH - *Patient Selection MH - Follow-Up Studies PMC - PMC12406894 OTO - NOTNLM OT - Health Care Economics and Organizations OT - Heart Failure OT - Quality of Health Care COIS- Competing interests: YK has received lecture fees from AstraZeneca and Boehringer Ingelheim. MasarK has received research grants from Abbott, Otsuka Pharmaceutical, Biotronik Japan, Japan Lifeline, Fukuda Denshi, Medtronic Japan and Boston Scientific. EDAT- 2025/09/02 00:44 MHDA- 2025/09/02 00:45 PMCR- 2025/08/31 CRDT- 2025/09/01 21:43 PHST- 2025/06/20 00:00 [received] PHST- 2025/08/20 00:00 [accepted] PHST- 2025/09/02 00:45 [medline] PHST- 2025/09/02 00:44 [pubmed] PHST- 2025/09/01 21:43 [entrez] PHST- 2025/08/31 00:00 [pmc-release] AID - openhrt-2025-003496 [pii] AID - 10.1136/openhrt-2025-003496 [doi] PST - epublish SO - Open Heart. 2025 Aug 31;12(2):e003496. doi: 10.1136/openhrt-2025-003496. PMID- 40889687 OWN - NLM STAT- MEDLINE DCOM- 20251004 LR - 20251004 IS - 1553-6467 (Electronic) IS - 0002-9459 (Linking) VI - 89 IP - 10 DP - 2025 Oct TI - Evaluating Instructional Efficiency in a Flipped Classroom: A Pilot Study in a Pharmacotherapy Course. PG - 101500 LID - S0002-9459(25)00145-7 [pii] LID - 10.1016/j.ajpe.2025.101500 [doi] AB - OBJECTIVE: This study aims to evaluate the instructional efficiency of preclass learning materials in an integrated pharmacotherapy course, using mental effort and assessment performance as metrics. METHODS: This pilot study was conducted in a required pharmacotherapy course that uses a flipped classroom approach. Third-year PharmD students completed preclass learning activities across 6 different modules and 2 sections during the Fall 2024 semester. Preclass materials primarily consisted of readings and guided learning questions. Mental effort, measured using the Paas scale, and performance on individual readiness assurance tests were standardized and used to calculate the instructional efficiency of preclass materials for each module. Data were used to inform decision-making related to course quality improvement. RESULTS: A total of 129 students participated, with a response rate greater than 90% for the mental effort survey. Assessment performance data were available for all students. Instructional efficiency scores identified less efficient topics, such as atrial fibrillation and acute coronary syndrome, as areas for quality improvement. Efficiency graphs compared instructional efficiency across modules and sections, highlighting specific areas in need of refinement. CONCLUSION: Preclass learning is essential but challenging in flipped classrooms. Instructional efficiency measures can support quality improvement by identifying inefficient learning tasks. Efficiency data can guide decision-making and allow for year-over-year comparisons of course topics. Strategies informed by cognitive load theory and motivational theory can improve instructional efficiency and promote student success. CI - Copyright (c) 2025 American Association of Colleges of Pharmacy. Published by Elsevier Inc. All rights reserved. FAU - Noel, Zachary R AU - Noel ZR AD - University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC, USA. Electronic address: znoel@unc.edu. FAU - Ong, Emily AU - Ong E AD - University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC, USA; El Camino Health, Mountain View, CA, USA. Electronic address: emily_ong@elcaminohealth.org. FAU - Womack-Adams, Kelly AU - Womack-Adams K AD - University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC, USA; Appalachian State University, Boone, NC, USA. Electronic address: womackadamska@appstate.edu. LA - eng PT - Journal Article DEP - 20250830 PL - United States TA - Am J Pharm Educ JT - American journal of pharmaceutical education JID - 0372650 SB - IM MH - Pilot Projects MH - Humans MH - *Education, Pharmacy/methods MH - *Students, Pharmacy MH - Curriculum MH - Educational Measurement/methods MH - *Problem-Based Learning/methods MH - Quality Improvement OTO - NOTNLM OT - Flipped classroom OT - Preclass learning OT - Readiness assurance OT - Team-based learning COIS- Declaration of Competing Interest None declared. EDAT- 2025/09/02 00:44 MHDA- 2025/10/05 00:33 CRDT- 2025/09/01 19:13 PHST- 2025/04/02 00:00 [received] PHST- 2025/08/08 00:00 [revised] PHST- 2025/08/22 00:00 [accepted] PHST- 2025/10/05 00:33 [medline] PHST- 2025/09/02 00:44 [pubmed] PHST- 2025/09/01 19:13 [entrez] AID - S0002-9459(25)00145-7 [pii] AID - 10.1016/j.ajpe.2025.101500 [doi] PST - ppublish SO - Am J Pharm Educ. 2025 Oct;89(10):101500. doi: 10.1016/j.ajpe.2025.101500. Epub 2025 Aug 30. PMID- 40883780 OWN - NLM STAT- MEDLINE DCOM- 20250830 LR - 20260925 IS - 1756-0500 (Electronic) IS - 1756-0500 (Linking) VI - 18 IP - 1 DP - 2025 Aug 29 TI - Task sharing and teamwork: clinician preferences for alcohol screening and brief interventions in cardiology. PG - 373 LID - 10.1186/s13104-025-07452-4 [doi] LID - 373 AB - OBJECTIVE: To investigate clinicians' preferences for alcohol screening and brief interventions in clinical cardiology settings. RESULTS: A total of 664 cardiology clinicians responded to a cross-sectional survey (30.9% response rate), including 55.1% nurses, 21.4% assistant nurses, 18.8% doctors, and 4.7% other clinical staff. Among these participants, 87.5% indicated that patients should be screened for alcohol use on cardiology wards, 79.8% in outpatient clinics, 49.1% in emergency departments, and 45.9% on coronary care units. Doctors and nurses were the preferred professions to be responsible for screening across all clinical contexts, while fewer respondents indicated that assistant nurses or physiotherapists should be responsible for screening (p < .001). Most participants (85.2%) indicated that patients should be screened in more than one clinical context and 84.6% indicated that more than one profession should be responsible for alcohol screening. Clinicians' preferred modality for assessing alcohol use was verbal screening (92% of participants), followed by questionnaires (53.5%), digital tools (28.5%), and alcohol biomarkers (22.1%, p < .001). Just over half of participants (58%) indicated that they would like to attend training on brief interventions. Findings suggest that task sharing, teamwork, and training may be effective strategies for implementation of alcohol screening and brief interventions in clinical cardiology. CI - (c) 2025. The Author(s). FAU - Welfordsson, Paul AU - Welfordsson P AD - Department of Global Public Health, Karolinska Institutet, Solna, Sweden. paul.welfordsson@ki.se. FAU - Danielsson, Anna-Karin AU - Danielsson AK AD - Department of Global Public Health, Karolinska Institutet, Solna, Sweden. FAU - Bjorck, Caroline AU - Bjorck C AD - Department of Women's and Children's Health, Uppsala University, Akademiska sjukhuset, Uppsala, Sweden. AD - Centre for Research and Development, Region Gavleborg, Gavle, Sweden. FAU - Grzymala-Lubanski, Bartosz AU - Grzymala-Lubanski B AD - Centre for Research and Development, Region Gavleborg, Gavle, Sweden. AD - Department of Public Health and Clinical Medicine, Umea University, Umea, Sweden. FAU - Hambraeus, Kristina AU - Hambraeus K AD - Department of Cardiology, Falun Hospital, Falun, Dalarna, Sweden. FAU - Lofman, Ida Haugen AU - Lofman IH AD - Department of Medicine, Unit of Cardiology, Karolinska Institutet, Stockholm, Sweden. AD - Department of Cardiology, Heart and Vascular Center, Karolinska University Hospital, Stockholm, Sweden. FAU - Braunschweig, Frieder AU - Braunschweig F AD - Department of Medicine, Unit of Cardiology, Karolinska Institutet, Stockholm, Sweden. AD - Department of Cardiology, Heart and Vascular Center, Karolinska University Hospital, Stockholm, Sweden. FAU - Lidin, Matthias AU - Lidin M AD - Department of Medicine, Unit of Cardiology, Karolinska Institutet, Stockholm, Sweden. AD - Department of Cardiology, Heart and Vascular Center, Karolinska University Hospital, Stockholm, Sweden. FAU - Wallhed Finn, Sara AU - Wallhed Finn S AD - Department of Global Public Health, Karolinska Institutet, Solna, Sweden. AD - Unit of Clinical Alcohol Research, Institute of Clinical Research, University of Southern Denmark, Odense, Denmark. AD - Centre for Dependency Disorders, Stockholm, Sweden. LA - eng PT - Journal Article DEP - 20250829 PL - England TA - BMC Res Notes JT - BMC research notes JID - 101462768 SB - IM MH - Humans MH - Cross-Sectional Studies MH - Female MH - Male MH - *Cardiology MH - Adult MH - *Attitude of Health Personnel MH - Middle Aged MH - *Mass Screening MH - *Patient Care Team MH - Surveys and Questionnaires MH - *Alcoholism/diagnosis MH - *Alcohol Drinking MH - Physicians PMC - PMC12398004 OTO - NOTNLM OT - Alcohol OT - Brief interventions OT - Cardiology OT - Cross-sectional survey OT - Implementation OT - Preferences OT - Screening COIS- Declarations. Ethical approval: This study obtained approval from the Swedish Ethical Review Authority (Dn: 2022-02059-01) and was conducted in accordance with the principles stated in the Declaration of Helsinki. Consent to participate: All participants provided informed consent. Consent for publication: Not applicable. Competing interests: FB is a member of the adverse event adjudication committee for Medtronic and Biotronic. FB has collaborated with industry through service contracts signed with his employer - Karolinska University Hospital - but no payment has been directly transferred to FB as a result of these activities. SWF receives book royalties for "Ater till kontrollerat drickande - en handbok for kliniker" [Controlled drinking - a handbook for clinicians] from Studentlitteratur and "Missbrukspsykologi" [Addiction Psychology] from Liber. EDAT- 2025/09/01 16:45 MHDA- 2025/09/01 16:46 PMCR- 2025/08/29 CRDT- 2025/08/29 23:45 PHST- 2025/06/17 00:00 [received] PHST- 2025/08/18 00:00 [accepted] PHST- 2025/09/01 16:46 [medline] PHST- 2025/09/01 16:45 [pubmed] PHST- 2025/08/29 23:45 [entrez] PHST- 2025/08/29 00:00 [pmc-release] AID - 10.1186/s13104-025-07452-4 [pii] AID - 7452 [pii] AID - 10.1186/s13104-025-07452-4 [doi] PST - epublish SO - BMC Res Notes. 2025 Aug 29;18(1):373. doi: 10.1186/s13104-025-07452-4. PMID- 40885461 OWN - NLM STAT- MEDLINE DCOM- 20260118 LR - 20260916 IS - 1097-6809 (Electronic) IS - 0741-5214 (Print) IS - 0741-5214 (Linking) VI - 83 IP - 2 DP - 2026 Feb TI - Characteristics of multidisciplinary limb preservation teams and their impact on outcomes in the BEST-CLI trial. PG - 528-538 LID - S0741-5214(25)01660-X [pii] LID - 10.1016/j.jvs.2025.08.028 [doi] AB - OBJECTIVE: Multidisciplinary care of chronic limb-threatening ischemia (CLTI) through specialized CLTI teams has been associated with improved outcomes, including decreased major amputations. Our goal was to characterize CLTI teams and examine their association with outcomes in the Best Endovascular vs Best Surgical Therapy in Patients with CLTI (BEST-CLI) trial. METHODS: Responses from a previously described post-trial electronic survey were used to describe CLTI care providers and characterize centers based on the presence of a "formally defined team dedicated to the care of patients with CLTI." Patient-level data were analyzed to determine the association of CLTI teams with outcomes. Primary outcomes were: (1) major (above-ankle) amputation and (2) major adverse limb events (MALE) or death from any cause. A secondary outcome was the high-low amputation ratio (ratio of major amputations to minor amputations). Cox multivariable models were used to control for patient demographics, limb stage, and revascularization type. RESULTS: The overall survey response rate was 20.2% with at least one response from 75% of enrolling sites. Among survey respondents, specialties identified most frequently as being among those primarily responsible for CLTI care at centers with CLTI teams were revascularization (vascular surgery, interventional cardiology, or interventional radiology, 92%), podiatry (32%), and wound care (22%). Compared with centers without CLTI teams, podiatrists at CLTI team centers were more likely to have a primary role (32% vs 11%) and less likely to be unavailable (4% vs 22%) (P < .001). Similarly, at centers with CLTI teams, wound care specialists were more likely to have a primary role (22% vs 8%) and less likely to be unavailable (4% vs 11%) (P = .02). Effectiveness of teamwork among CLTI providers was described as "highly effective" in 71% of respondents with a CLTI team vs 29% without a team (P < .001). In the BEST-CLI trial, 110 centers (73%) could be classified based on the availability of a CLTI team (31% team vs 69% no team), representing 83% of all enrolled patients (n = 1520). Patients treated at centers with a CLTI team had similar rates of unadjusted 1-year above-ankle amputation (7.9% team [95% confidence interval (CI), 5.7%-10.7%] vs 12.1% no team [95% CI, 10.1%-14.4%]; P = .07) and MALE or death (29% team [95% CI, 25.1%-33.3%] vs 33% no team [95% CI, 30.1%-36.2%]; P = .07). On multivariable analysis, the presence of a CLTI team was found to be independently associated with decreased major amputation (hazard ratio, 0.60 [95% CI, 0.42-0.86]; P = .005) but no significant difference in MALE or death (hazard ratio, 0.89 [95% CI, 0.74-1.06]; P = .2). The high-low amputation ratio was lower at centers with CLTI teams (0.20 [95% CI, 0.14-0.28]) compared with centers with no team (0.31 [95% CI, 0.25-0.38]) (P = .03). CONCLUSIONS: In the BEST-CLI trial, formally defined CLTI teams were associated with a decreased risk of major amputation. This may be partially attributable to more effective communication and closer involvement between vascular specialists, podiatrists, and wound care providers. CI - Copyright (c) 2025 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved. FAU - Jones, Douglas W AU - Jones DW AD - Division of Vascular and Endovascular Surgery, University of Massachusetts Medical Center, University of Massachusetts Chan Medical School, Worcester, MA. Electronic address: douglas.jones@umassmemorial.org. FAU - Farber, Alik AU - Farber A AD - Department of Surgery, Boston University Chobanian & Avedisian School of Medicine, Boston Medical Center, Boston, MA. FAU - Armstrong, David G AU - Armstrong DG AD - Southwestern Academic Limb Salvage Alliance (SALSA), Department of Surgery, Keck Medical Center of USC, Los Angeles, CA. FAU - Azene, Ezana AU - Azene E AD - Department of Interventional Radiology, Gundersen Health System, La Crosse, WI. FAU - Duncan, Audra AU - Duncan A AD - Division of Vascular Surgery, London Health Sciences Center, University of Western Ontario, London, Ontario, Canada. FAU - Todoran, Thomas M AU - Todoran TM AD - Division of Cardiology, Department of Medicine, Medical University of South Carolina, Charleston, SC. FAU - Doros, Gheorghe AU - Doros G AD - Boston University School of Public Health, Department of Biostatistics, Boston, MA. FAU - Strong, Michael B AU - Strong MB AD - Division of Vascular and Endovascular Surgery, Brigham and Women's Hospital, Boston, MA. FAU - Rosenfield, Kenneth AU - Rosenfield K AD - Section of Vascular Medicine and Intervention, Massachusetts General Hospital, Boston, MA. FAU - Conte, Michael S AU - Conte MS AD - Division of Vascular and Endovascular Surgery, University of California, San Francisco, San Francisco, CA. FAU - Menard, Matthew T AU - Menard MT AD - Division of Vascular and Endovascular Surgery, Brigham and Women's Hospital, Boston, MA. LA - eng SI - ClinicalTrials.gov/NCT02060630 GR - U01 HL107352/HL/NHLBI NIH HHS/United States GR - U01 HL107407/HL/NHLBI NIH HHS/United States GR - U01 HL115662/HL/NHLBI NIH HHS/United States PT - Comparative Study PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20250828 PL - United States TA - J Vasc Surg JT - Journal of vascular surgery JID - 8407742 SB - IM MH - Aged MH - Female MH - Humans MH - Male MH - Middle Aged MH - Amputation, Surgical MH - *Chronic Limb-Threatening Ischemia/mortality/therapy MH - *Endovascular Procedures/adverse effects/mortality MH - Health Care Surveys MH - *Ischemia/diagnosis/mortality/physiopathology/surgery MH - *Limb Salvage MH - *Patient Care Team/organization & administration MH - *Peripheral Arterial Disease/mortality/therapy/diagnosis/physiopathology MH - Risk Factors MH - Time Factors MH - Treatment Outcome MH - United States MH - *Vascular Surgical Procedures/adverse effects/mortality PMC - PMC12416768 MID - NIHMS2107862 OTO - NOTNLM OT - Amputation OT - Endovascular OT - Limb preservation OT - Lower extremity bypass OT - Multidisciplinary team COIS- Disclosures A.F. received a grant from the Novo Nordisk Foundation and is a consultant or member of a scientific advisory board for BioGenCell, Dialysis-X, Ithera Medical, LeMaitre, and Sanifit. D.G.A. received research support from the National Institutes of Health and National Science Foundation Center to Stream Healthcare in Place. E.A. is a consultant at Philips. K.R. is a consultant or member of a scientific advisory board for Abbott Vascular, Angiodynamics, Boston Scientific, Contego, Innova Vascular, InspireMD, Janssen/Johnson and Johnson, MedAlliance, Medtronic, Neptune Medical, Philips, Thrombolex, Vasorum, and Vumedi; has equity or stock options in the following entities: Access Vascular, Contego, Endospan, Imperative Care/Truvic, Innova Vascular, InspireMD, Jana Care, Magneto, MedAlliance, Neptune Medical, Orchestra, Skydance, Summa Therapeutics, Thrombolex, Vasorum, and Vumedi; received a research grant from Boston Scientific, the Novo Nordisk Foundation, and Penumbra; and serves on the Board of Directors for the National PERT Consortium. M.S.C. is a member of a scientific advisory board for Abbott Vascular. M.T.M. is a member of a scientific advisory board for Janssen. The remaining authors report no conflicts. EDAT- 2025/08/31 04:44 MHDA- 2026/01/19 01:03 PMCR- 2026/08/28 CRDT- 2025/08/30 19:15 PHST- 2025/06/13 00:00 [received] PHST- 2025/08/14 00:00 [revised] PHST- 2025/08/19 00:00 [accepted] PHST- 2026/01/19 01:03 [medline] PHST- 2025/08/31 04:44 [pubmed] PHST- 2025/08/30 19:15 [entrez] PHST- 2026/08/28 00:00 [pmc-release] AID - S0741-5214(25)01660-X [pii] AID - 10.1016/j.jvs.2025.08.028 [doi] PST - ppublish SO - J Vasc Surg. 2026 Feb;83(2):528-538. doi: 10.1016/j.jvs.2025.08.028. Epub 2025 Aug 28. PMID- 40881854 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250915 LR - 20250915 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 15 DP - 2025 TI - Multidisciplinary strategies to reduce radiotherapy-induced cardiotoxicity in breast cancer: surgical and technological innovations. PG - 1647080 LID - 10.3389/fonc.2025.1647080 [doi] LID - 1647080 AB - Radiotherapy remains essential in breast cancer management, yet its long-term cardiotoxicity, driven primarily by radiation-induced myocardial fibrosis, threatens survivorship, particularly in left-sided tumors. Surgical refinements, including breast-conserving surgery with sentinel lymph node biopsy and total mastectomy, effectively reduce radiation fields and cardiac exposure. Intraoperative radiotherapy with lead shielding markedly lowers left anterior descending artery dose from 5.2 Gy to 0.07 Gy. Technological advances-such as deep-inhalation breath-hold, proton therapy exploiting the Bragg peak, and intensity-modulated radiotherapy, further optimize cardiac sparing while preserving oncologic efficacy. Integrating intraoperative image guidance, pharmacological cardioprotection, and AI-assisted planning facilitates precise dose delivery tailored to individual anatomy and risk. This review synthesizes multidisciplinary strategies to mitigate cardiac injury through surgical and technological innovation, underscoring a paradigm shift toward organ-sparing precision radiotherapy. Future directions include the application of degradable shielding materials, senescence-targeted therapies, and predictive modeling to balance therapeutic efficacy with long-term cardiovascular safety in breast cancer care. CI - Copyright (c) 2025 Lu, Sun and Yi. FAU - Lu, Kai AU - Lu K AD - Department of Thyroid and Breast Surgery, Affiliated Hospital of Jiangsu University, Zhenjiang, China. FAU - Sun, Zhenhua AU - Sun Z AD - Department of Thyroid and Breast Surgery, Affiliated Hospital of Jiangsu University, Zhenjiang, China. FAU - Yi, Yide AU - Yi Y AD - Institute of Medical Imaging and Artificial Intelligence of Jiangsu University, Affiliated Hospital of Jiangsu University, Zhenjiang, China. LA - eng PT - Journal Article PT - Review DEP - 20250813 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC12380825 OTO - NOTNLM OT - breast cancer OT - cardiac protection OT - cardiotoxicity OT - radiotherapy OT - radiotherapy-induced cardiotoxicity COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2025/08/31 22:22 MHDA- 2025/08/31 22:23 PMCR- 2025/08/13 CRDT- 2025/08/29 14:34 PHST- 2025/06/14 00:00 [received] PHST- 2025/07/28 00:00 [accepted] PHST- 2025/08/31 22:23 [medline] PHST- 2025/08/31 22:22 [pubmed] PHST- 2025/08/29 14:34 [entrez] PHST- 2025/08/13 00:00 [pmc-release] AID - 10.3389/fonc.2025.1647080 [doi] PST - epublish SO - Front Oncol. 2025 Aug 13;15:1647080. doi: 10.3389/fonc.2025.1647080. eCollection 2025. PMID- 40870496 OWN - NLM STAT- MEDLINE DCOM- 20250828 LR - 20250831 IS - 1648-9144 (Electronic) IS - 1010-660X (Print) IS - 1010-660X (Linking) VI - 61 IP - 8 DP - 2025 Aug 12 TI - The Role of Myocardial Revascularization in Ischemic Heart Failure in the Era of Modern Optimal Medical Therapy. LID - 10.3390/medicina61081451 [doi] LID - 1451 AB - Background/Objectives: Heart failure (HF) with reduced ejection fraction (EF) has, in more than 50% of cases, an ischemic etiology and continues to be associated with increased mortality and morbidity despite all the progress registered in the field of medical therapy and interventional revascularization. Myocardial revascularization is extensively used in clinical practice based on the traditional concept that it can improve myocardial function and outcome in ischemic HF. This review is aimed at presenting current knowledge regarding revascularization in patients with chronic ischemic HF and reduced EF. Methods: The impact of revascularization on symptomatology, left ventricle reverse remodeling, major adverse cardiac events (MACEs), and the role of complete revascularization and of percutaneous interventional revascularization in chronic total occlusion (PCI-CTO) were analyzed. The best therapeutic strategies, revascularization and/or optimal medical therapy (OMT), are debated in different categories of patients, in order to identify who will benefit more from revascularization strategies. Results: Based on the long-term results of the STICH trial incorporated in the guidelines with a class I-b recommendation, coronary artery bypass graft (CABG) remains the main modality of revascularization for prognostic improvement in ischemic HF with multivessel disease. But real-life patients are usually old with multiple comorbidities and high surgical risk. In this category, the Heart Team opinion is required to evaluate the probability of complete revascularization and to choose between percutaneous coronary intervention (PCI) and CABG according to clinical status and coronary anatomy. Conclusions: However, until further studies are available, the results of the REVIVED-BCIS2 trial encourage OMT over PCI in patients with ischemic cardiomyopathy. The available randomized controlled trials (RCTs) showed improved angina and quality of life in PCI-CTO versus OMT, but the effect on MACEs was not demonstrated. FAU - Blaj-Tunduc, Ioana-Paula AU - Blaj-Tunduc IP AUID- ORCID: 0009-0006-0375-6278 AD - Doctoral School of Biomedical Sciences, Faculty of Medicine and Pharmacy, University of Oradea, 410087 Oradea, Romania. FAU - Brisc, Ciprian Marcel Ioan AU - Brisc CMI AD - Doctoral School of Biomedical Sciences, Faculty of Medicine and Pharmacy, University of Oradea, 410087 Oradea, Romania. AD - Department of Medical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania. FAU - Brisc, Cristina Mihaela AU - Brisc CM AD - Doctoral School of Biomedical Sciences, Faculty of Medicine and Pharmacy, University of Oradea, 410087 Oradea, Romania. AD - Department of Medical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania. FAU - Zaha, Dana-Carmen AU - Zaha DC AUID- ORCID: 0000-0003-4021-4989 AD - Doctoral School of Biomedical Sciences, Faculty of Medicine and Pharmacy, University of Oradea, 410087 Oradea, Romania. AD - Department of Preclinical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania. FAU - Bustea, Cristiana-Magdalena AU - Bustea CM AUID- ORCID: 0000-0003-1252-0057 AD - Doctoral School of Biomedical Sciences, Faculty of Medicine and Pharmacy, University of Oradea, 410087 Oradea, Romania. AD - Department of Preclinical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania. FAU - Babes, Vlad-Victor AU - Babes VV AD - Department of Medical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania. FAU - Sirca-Tirla, Teodora AU - Sirca-Tirla T AUID- ORCID: 0009-0007-3214-688X AD - Doctoral School of Biomedical Sciences, Faculty of Medicine and Pharmacy, University of Oradea, 410087 Oradea, Romania. FAU - Muste, Francesca-Andreea AU - Muste FA AD - Doctoral School of Biomedical Sciences, Faculty of Medicine and Pharmacy, University of Oradea, 410087 Oradea, Romania. FAU - Babes, Elena-Emilia AU - Babes EE AD - Doctoral School of Biomedical Sciences, Faculty of Medicine and Pharmacy, University of Oradea, 410087 Oradea, Romania. AD - Department of Medical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania. LA - eng GR - no grant number assigned/University of Oradea/ PT - Journal Article PT - Review DEP - 20250812 PL - Switzerland TA - Medicina (Kaunas) JT - Medicina (Kaunas, Lithuania) JID - 9425208 SB - IM MH - Humans MH - *Heart Failure/surgery/physiopathology MH - *Myocardial Revascularization/methods/standards MH - *Myocardial Ischemia/surgery/complications MH - Percutaneous Coronary Intervention/methods MH - Coronary Artery Bypass/methods PMC - PMC12388460 OTO - NOTNLM OT - chronic coronary syndrome OT - complete revascularization OT - depressed ejection fraction OT - ischemic heart failure OT - percutaneous coronary intervention COIS- The authors declare no conflicts of interest. EDAT- 2025/08/30 04:50 MHDA- 2025/08/30 04:51 PMCR- 2025/08/12 CRDT- 2025/08/28 01:15 PHST- 2025/07/19 00:00 [received] PHST- 2025/08/06 00:00 [revised] PHST- 2025/08/08 00:00 [accepted] PHST- 2025/08/30 04:51 [medline] PHST- 2025/08/30 04:50 [pubmed] PHST- 2025/08/28 01:15 [entrez] PHST- 2025/08/12 00:00 [pmc-release] AID - medicina61081451 [pii] AID - medicina-61-01451 [pii] AID - 10.3390/medicina61081451 [doi] PST - epublish SO - Medicina (Kaunas). 2025 Aug 12;61(8):1451. doi: 10.3390/medicina61081451. PMID- 40869571 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250914 LR - 20250914 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 14 IP - 16 DP - 2025 Aug 14 TI - Coronary Artery Bypass Grafting Versus Percutaneous Coronary Intervention for Left Main Coronary Artery Disease-Long-Term Outcomes. LID - 10.3390/jcm14165747 [doi] LID - 5747 AB - Background: The optimal revascularization strategy for patients with left main coronary artery (LMCA) disease has been repeatedly addressed in randomized controlled trials (RCTs), although outcomes from real-life clinical studies are still poorly investigated. Objectives: This retrospective study aimed to assess the complete 5-year outcomes for individuals with multivessel coronary artery disease (MVD) involving LMCA disease treated with coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) as recommended by a local HT. Methods: From 2016 to 2019, 176 Heart Team (HT) meetings were held. Primary and secondary endpoints of 267 patients with MVD involving LMCA disease qualified either for CABG or PCI (109 and 158 patients, respectively) with subsequent optimal medical therapy (OMT) were assessed. The primary endpoint of the study was as an overall mortality, while secondary endpoints contained major adverse cardiac and cerebrovascular events (MACCE)-specifically, stroke, myocardial infarction (MI), repeat revascularization (RR), and the individual components of MACCE. Results: At 5 years, we found no significant difference in overall mortality between the both cohorts (22.9%-CABG vs. 24.7%-PCI, p = 0.74). The rate of MI was higher in patients treated percutaneously (7.3% vs. 15.8% for PCI, p = 0.04), while the incidence of stroke was higher in patients who underwent CABG (3.8% vs. 11.0% for CABG, p = 0.02). A MACCE occurrence was higher in PCI cohort (77.2% vs. 55.0%, p < 0.001), mainly driven by higher rates of RR was higher in patients treated percutaneously (32.9% vs. 13.8%, p < 0.001). Conclusions: For patients with LMCA disease, neither CABG nor PCI following HT decisions showed overwhelming superiority in real-life clinical practice: occurrence of all-cause death was similar, rates of MACCE, MI, and repeat revascularization advocated CABG, while incidence of strokes favored PCI. FAU - Jonik, Szymon AU - Jonik S AD - 1st Department of Cardiology, Medical University of Warsaw, Banacha 1a Str., 01-267 Warsaw, Poland. FAU - Gumiezna, Karolina AU - Gumiezna K AD - 1st Department of Cardiology, Medical University of Warsaw, Banacha 1a Str., 01-267 Warsaw, Poland. FAU - Barus, Piotr AU - Barus P AD - 1st Department of Cardiology, Medical University of Warsaw, Banacha 1a Str., 01-267 Warsaw, Poland. FAU - Wilimski, Radoslaw AU - Wilimski R AD - Department of Heart, Thorax Surgery and Transplantology, Medical University of Warsaw, Banacha 1a Str., 01-267 Warsaw, Poland. FAU - Kusmierczyk, Mariusz AU - Kusmierczyk M AUID- ORCID: 0009-0003-9665-7129 AD - Department of Heart, Thorax Surgery and Transplantology, Medical University of Warsaw, Banacha 1a Str., 01-267 Warsaw, Poland. FAU - Opolski, Grzegorz AU - Opolski G AD - 1st Department of Cardiology, Medical University of Warsaw, Banacha 1a Str., 01-267 Warsaw, Poland. FAU - Grabowski, Marcin AU - Grabowski M AD - 1st Department of Cardiology, Medical University of Warsaw, Banacha 1a Str., 01-267 Warsaw, Poland. FAU - Kochman, Janusz AU - Kochman J AD - 1st Department of Cardiology, Medical University of Warsaw, Banacha 1a Str., 01-267 Warsaw, Poland. FAU - Huczek, Zenon AU - Huczek Z AD - 1st Department of Cardiology, Medical University of Warsaw, Banacha 1a Str., 01-267 Warsaw, Poland. FAU - Mazurek, Tomasz AU - Mazurek T AD - 1st Department of Cardiology, Medical University of Warsaw, Banacha 1a Str., 01-267 Warsaw, Poland. LA - eng PT - Journal Article DEP - 20250814 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC12387798 OTO - NOTNLM OT - Heart Team OT - coronary artery disease OT - left main coronary artery disease OT - multivessel coronary artery disease OT - percutaneous coronary intervention COIS- The authors declare no conflicts of interest. EDAT- 2025/08/30 04:48 MHDA- 2025/08/30 04:49 PMCR- 2025/08/14 CRDT- 2025/08/28 01:12 PHST- 2025/06/20 00:00 [received] PHST- 2025/08/11 00:00 [revised] PHST- 2025/08/11 00:00 [accepted] PHST- 2025/08/30 04:49 [medline] PHST- 2025/08/30 04:48 [pubmed] PHST- 2025/08/28 01:12 [entrez] PHST- 2025/08/14 00:00 [pmc-release] AID - jcm14165747 [pii] AID - jcm-14-05747 [pii] AID - 10.3390/jcm14165747 [doi] PST - epublish SO - J Clin Med. 2025 Aug 14;14(16):5747. doi: 10.3390/jcm14165747. PMID- 40864894 OWN - NLM STAT- MEDLINE DCOM- 20250828 LR - 20250831 IS - 1438-8871 (Electronic) IS - 1439-4456 (Print) IS - 1438-8871 (Linking) VI - 27 DP - 2025 Aug 27 TI - The Effectiveness of Nurse-Led Multidimensional Digital Cardiac Rehabilitation in Patients With Unstable Angina Undergoing Percutaneous Coronary Intervention: Emulated Target Trial. PG - e75325 LID - 10.2196/75325 [doi] LID - e75325 AB - BACKGROUND: Cardiac rehabilitation (CR) interventions for patients with coronary heart disease are increasingly adopted. However, research on the integration of digital health technologies into CR for patients with unstable angina (UA) undergoing percutaneous coronary intervention (PCI) remains limited. OBJECTIVE: This study assessed the effectiveness of a multidimensional digital CR program for patients with UA undergoing PCI. METHODS: This prospective study enrolled 164 patients with UA who underwent PCI between April and June 2022. Patients were assigned to either the usual care group (April-May 2022) or the multidimensional digital CR intervention group (May-June 2022). The intervention group received rehabilitation through a nurse-led, multidisciplinary team, using a customized digital CR program. This program encompassed 7 key rehabilitation components: exercise, medication management, nutritional guidance, psychological support, sleep management, health education, and smoking cessation assistance. The usual care group received standardized treatment and routine nursing care. To minimize selection bias, propensity score matching was applied between the 2 groups. The primary outcomes included changes in the 6-minute walk test (6MWT), 12-item Short Form Health Survey (SF-12) scores, and frailty phenotype scores at 3 months. Secondary outcomes assessed differences in gait speed, 30-second chair stand test (30-s CST), grip strength, waist circumference (WC), BMI, and lipid profiles at 3 months. RESULTS: A total of 136 patients were included in the final analysis. At 3 months, the intervention group demonstrated significant improvements in frailty status compared to the control group. The proportion of prefrail patients decreased from 100% (68 patients) to 75% (51 patients), while nonfrail patients increased from 0% to 25% (17 patients; P<.001). Regarding physical fitness, the intervention group exhibited improvements in 6MWT: from 347.06 (SD 32.43) to 375.22 (SD 29.71) m (P<.001); gait speed: from 0.87 (SD 0.17) to 1.05 (SD 0.14) m/s (P<.001); and 30-s CST: from 10.0 (SD 1.89) to 12.71 (SD 1.97; P<.001). Grip strength, BMI, and WC improved significantly in the intervention group. Grip strength increased from 16.64 (SD 6.57) to 20.74 (SD 5.37; P<.001). BMI decreased from 25.74 (SD 3.05) to 23.88 (SD 2.14; P<.001), and WC decreased from 94.98 (SD 7.87) to 89.91 (SD 7.50) cm (P<.001). The intervention group achieved greater improvements in lipid profiles, with significant reductions in total cholesterol (P<.001), triglycerides (P<.001), and low-density lipoprotein cholesterol (P<.001), while high-density lipoprotein cholesterol remained stable (P=.45). CONCLUSIONS: This study demonstrates that a novel multidimensional digital CR program is acceptable and effective in improving functional status and health-related quality of life in patients with UA undergoing PCI within a short timeframe. CI - (c) Tong Zhou, Yijun Wang, Jun Wang, Jinjun Liu, Nana Zhang, Xiaoling Zhang, Shengnan Yao, Mingming Tang, Guixia Xu, Yongxia Chen. Originally published in the Journal of Medical Internet Research (https://www.jmir.org). FAU - Zhou, Tong AU - Zhou T AUID- ORCID: 0000-0002-7139-5594 AD - Department of Cardiology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China. FAU - Wang, Yijun AU - Wang Y AUID- ORCID: 0009-0001-2972-8367 AD - Department of Cardiology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China. AD - West China Hospital, Sichuan University, Chengdu, China. FAU - Wang, Jun AU - Wang J AUID- ORCID: 0009-0007-1477-9093 AD - Department of Cardiology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China. AD - Joint Research Center for Regional Diseases of IHM, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China. FAU - Liu, Jinjun AU - Liu J AUID- ORCID: 0009-0009-1799-2708 AD - Department of Cardiology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China. AD - Joint Research Center for Regional Diseases of IHM, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China. FAU - Zhang, Nana AU - Zhang N AUID- ORCID: 0009-0000-4739-3612 AD - Department of Cardiology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China. FAU - Zhang, Xiaoling AU - Zhang X AUID- ORCID: 0009-0007-9120-1949 AD - Department of Cardiology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China. FAU - Yao, Shengnan AU - Yao S AUID- ORCID: 0009-0004-2115-8031 AD - Department of Cardiology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China. FAU - Tang, Mingming AU - Tang M AUID- ORCID: 0009-0000-5101-0645 AD - Department of Cardiology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China. FAU - Xu, Guixia AU - Xu G AUID- ORCID: 0009-0002-9919-6826 AD - Department of Nursing, The First Affiliated Hospital of Bengbu Medical University, No. 287, Changhuai Road, Longzihu District, Bengbu, 233000, China, 86 05523086107. FAU - Chen, Yongxia AU - Chen Y AUID- ORCID: 0009-0003-0744-8721 AD - Department of Nursing, The First Affiliated Hospital of Bengbu Medical University, No. 287, Changhuai Road, Longzihu District, Bengbu, 233000, China, 86 05523086107. LA - eng PT - Journal Article DEP - 20250827 PL - Canada TA - J Med Internet Res JT - Journal of medical Internet research JID - 100959882 SB - IM MH - Humans MH - *Angina, Unstable/rehabilitation/nursing/surgery MH - Male MH - Female MH - Middle Aged MH - *Cardiac Rehabilitation/methods/nursing MH - *Percutaneous Coronary Intervention MH - Prospective Studies MH - Aged PMC - PMC12384693 OTO - NOTNLM OT - Baduanjin OT - cardiac rehabilitation OT - digital health technologies OT - mHealth OT - multicomponent intervention OT - multidimensional intervention OT - percutaneous coronary intervention OT - unstable angina COIS- Conflicts of Interest: None declared. EDAT- 2025/08/30 04:49 MHDA- 2025/08/30 04:50 PMCR- 2025/08/27 CRDT- 2025/08/27 15:02 PHST- 2025/04/01 00:00 [received] PHST- 2025/06/23 00:00 [revised] PHST- 2025/07/09 00:00 [accepted] PHST- 2025/08/30 04:50 [medline] PHST- 2025/08/30 04:49 [pubmed] PHST- 2025/08/27 15:02 [entrez] PHST- 2025/08/27 00:00 [pmc-release] AID - v27i1e75325 [pii] AID - 75325 [pii] AID - 10.2196/75325 [doi] PST - epublish SO - J Med Internet Res. 2025 Aug 27;27:e75325. doi: 10.2196/75325. PMID- 40862426 OWN - NLM STAT- MEDLINE DCOM- 20250914 LR - 20250915 IS - 1518-8787 (Electronic) IS - 0034-8910 (Print) IS - 0034-8910 (Linking) VI - 59 DP - 2025 TI - Dysphagia in frail elderly: self-reported mealtime symptoms and risk. PG - e23 LID - S0034-89102025000100221 [pii] LID - 10.11606/s1518-8787.2025059006440 [doi] LID - e23 AB - OBJECTIVE: This study aimed to characterize swallowing and investigate the association between self-reported coughing and/or choking during meals and the risk of dysphagia in frail elderly individuals receiving healthcare at a specialized center in Sao Paulo, Brazil. METHODS: This cross-sectional observational study included elderly individuals attending an Elderly Health Reference Unit (URSI) from July 2017 to December 2023. Data from all patients referred to the URSI were collected, excluding only those with incomplete medical records. The study proceeded in two phases: the first phase involved physical, functional, and social assessments, while the second phase included speech and swallowing evaluations. Participants were categorized into groups based on self-reported mealtime symptoms. Descriptive and inferential analyses compared these groups using the Mann-Whitney U test for quantitative data and Pearson's chi2 test for qualitative data. Risk analysis employed multiple logistic regression with forward stepwise selection. RESULTS: The study comprised 1,027 elderly individuals (mean age 78 years; 68.2% women; 64.2% self-identified as white). Approximately half reported frequent choking during meals. Sex, Multidimensional Assessment of the Elderly in Primary Care classification and score, polypharmacy, chronic diseases, falls, urinary incontinence, osteoporosis, cardiac disease, last dental visit, speech difficulty, change in food consistency, hearing loss, and hearing aid use were associated with mealtime symptoms. Speech alterations increased bronchoaspiration risk by 16%, memory complaints by 11%, and xerostomia and food consistency changes by 8%. CONCLUSION: Speech alterations, changes in food consistency, memory complaints, and xerostomia were identified as factors increasing the risk of bronchoaspiration. Early identification and a multidisciplinary approach to swallowing disorders in frail elderly individuals are crucial for preventing aspiration pneumonia and maintaining quality of life. These findings underscore the significance of proactive management strategies in clinical practice. FAU - Valente Junior, Cirley Novais AU - Valente Junior CN AUID- ORCID: 0000-0002-0237-1185 AD - Universidade de Sao Paulo. Faculdade de Medicina. Departamento de Fisioterapia, Fonoaudiologia e Terapia Ocupacional. Sao Paulo, SP, Brasil. FAU - Sassi, Fernanda Chiarion AU - Sassi FC AUID- ORCID: 0000-0002-7958-6280 AD - Universidade de Sao Paulo. Faculdade de Medicina. Departamento de Fisioterapia, Fonoaudiologia e Terapia Ocupacional. Sao Paulo, SP, Brasil. FAU - Ritto, Ana Paula AU - Ritto AP AUID- ORCID: 0000-0002-7509-0528 AD - Universidade de Sao Paulo. Faculdade de Medicina. Departamento de Fisioterapia, Fonoaudiologia e Terapia Ocupacional. Sao Paulo, SP, Brasil. FAU - Pecenin, Isadora Cardoso Salles Fila AU - Pecenin ICSF AUID- ORCID: 0009-0003-7705-6870 AD - Universidade de Sao Paulo. Escola de Enfermagem. Sao Paulo, SP, Brasil. FAU - Andrade, Claudia Regina Furquim de AU - Andrade CRF AUID- ORCID: 0000-0001-9639-6377 AD - Universidade de Sao Paulo. Faculdade de Medicina. Departamento de Fisioterapia, Fonoaudiologia e Terapia Ocupacional. Sao Paulo, SP, Brasil. LA - eng PT - Journal Article PT - Observational Study DEP - 20250825 PL - Brazil TA - Rev Saude Publica JT - Revista de saude publica JID - 0135043 SB - IM MH - Humans MH - *Deglutition Disorders/physiopathology/etiology/epidemiology MH - Female MH - Male MH - Aged MH - Cross-Sectional Studies MH - *Frail Elderly/statistics & numerical data MH - Self Report MH - Aged, 80 and over MH - Brazil/epidemiology MH - Risk Factors MH - *Meals MH - Cough/complications MH - Airway Obstruction PMC - PMC12377804 COIS- Conflict of Interests: The authors declare no conflict of interests. EDAT- 2025/08/30 04:48 MHDA- 2025/09/14 18:31 PMCR- 2025/08/25 CRDT- 2025/08/27 07:43 PHST- 2024/07/03 00:00 [received] PHST- 2024/12/12 00:00 [accepted] PHST- 2025/09/14 18:31 [medline] PHST- 2025/08/30 04:48 [pubmed] PHST- 2025/08/27 07:43 [entrez] PHST- 2025/08/25 00:00 [pmc-release] AID - S0034-89102025000100221 [pii] AID - 10.11606/s1518-8787.2025059006440 [doi] PST - epublish SO - Rev Saude Publica. 2025 Aug 25;59:e23. doi: 10.11606/s1518-8787.2025059006440. eCollection 2025. PMID- 40881865 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250915 LR - 20250915 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 15 DP - 2025 TI - Cardiovascular toxicity in testicular germ cell tumor survivors. PG - 1654063 LID - 10.3389/fonc.2025.1654063 [doi] LID - 1654063 AB - INTRODUCTION: Testicular germ cell tumors (TGCT) are highly curable malignancies, with excellent survival rates largely attributable to advances in cancer treatment. Consequently, there is a growing population of long-term TGCT survivors whose life expectancy approaches that of the general population. However, these survivors may experience acute and late adverse effects of cancer treatment, with cardiovascular toxicity being among the most serious and potentially life-threatening. METHODS: This narrative review synthesizes current evidence on cardiovascular toxicity in testicular cancer survivors, including clinical manifestations, pathophysiology of cisplatin-induced cardiovascular damage, additional adverse effects of radiotherapy, and prevalence of traditional cardiovascular risk factors. Key clinical guidelines, observational studies, and experimental findings were analyzed to identify trends, knowledge gaps, and opportunities for improving survivorship care. RESULTS: Multiple studies consistently demonstrate an increased risk of cardiovascular disease (CVD) among TGCT survivors, particularly following cisplatin-based chemotherapy. Common clinical manifestations include myocardial infarction, angina pectoris, cerebrovascular events, thromboembolism, and heart failure. The highest risk occurs within the first year post-treatment but may persist or recur even after a decade. Cisplatin-induced cardiovascular toxicity involves vascular injury - characterized by endothelial dysfunction, oxidative stress, and prothrombotic state - and myocardial damage driven by oxidative stress, inflammation, and apoptosis. Furthermore, TGCT survivors exhibit a higher prevalence of traditional cardiovascular risk factors, such as smoking, hypertension, dyslipidemia, diabetes, and obesity, contributing to the overall elevated CVD risk. DISCUSSION: There is an urgent need for a structured, long-term survivorship care model for TGCT survivors. Cardiovascular risk assessment and prevention should be central components, especially in survivors treated with cisplatin-based chemotherapy. Early detection of treatment-related toxicities, combined with lifestyle interventions and regular monitoring, is essential. Future research should focus on elucidating molecular mechanisms of cardiovascular toxicity, validating TGCT survivor-specific screening tools, identifying early biomarkers of cardiac injury, and exploring pharmacologic and behavioral interventions. CONCLUSION: Protecting cardiovascular health in TGCT survivors requires a proactive, personalized, and multidisciplinary approach. Integrating cardiometabolic monitoring, risk factor modification, and tailored follow-up strategies into survivorship care is vital. Focused research and clinical attention are needed to ensure that the long-term success of cancer treatment is not compromised by preventable cardiovascular disease. CI - Copyright (c) 2025 Orszaghova, Mladosievicova, Mego and Chovanec. FAU - Orszaghova, Zuzana AU - Orszaghova Z AD - 2ndDepartment of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute, Bratislava, Slovakia. FAU - Mladosievicova, Beata AU - Mladosievicova B AD - Department of Clinical Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovakia. FAU - Mego, Michal AU - Mego M AD - 2ndDepartment of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute, Bratislava, Slovakia. FAU - Chovanec, Michal AU - Chovanec M AD - 2ndDepartment of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute, Bratislava, Slovakia. LA - eng PT - Journal Article PT - Review DEP - 20250813 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC12380584 OTO - NOTNLM OT - cancer treatment OT - cardiotoxicity OT - germ cell tumor OT - late toxicity OT - survivorship OT - testicular cancer COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2025/08/29 20:45 MHDA- 2025/08/29 20:46 PMCR- 2025/08/13 CRDT- 2025/08/29 14:34 PHST- 2025/06/25 00:00 [received] PHST- 2025/07/27 00:00 [accepted] PHST- 2025/08/29 20:46 [medline] PHST- 2025/08/29 20:45 [pubmed] PHST- 2025/08/29 14:34 [entrez] PHST- 2025/08/13 00:00 [pmc-release] AID - 10.3389/fonc.2025.1654063 [doi] PST - epublish SO - Front Oncol. 2025 Aug 13;15:1654063. doi: 10.3389/fonc.2025.1654063. eCollection 2025. PMID- 40881156 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250915 LR - 20250915 IS - 2633-5565 (Electronic) IS - 2633-5565 (Linking) VI - 15 DP - 2025 Jan-Dec TI - Network of doctors for multimorbidity and diabetes: Development of the NOMAD intervention - a multidisciplinary team for patients with diabetes and multimorbidity. PG - 26335565251366466 LID - 10.1177/26335565251366466 [doi] LID - 26335565251366466 AB - PURPOSE: This article reports the development of the NOMAD intervention, a model of multidisciplinary team conferences designed to improve care coordination and treatment for patients with multimorbidity and diabetes. Managing multiple chronic conditions increases care complexity, and multidisciplinary approaches may enhance care coherence, optimise treatment, and improve quality of life. METHOD: Guided by the Medical Research Council framework for developing complex interventions, we established a working group, formulated a programme theory, and conducted a preliminary test with qualitative interviews of patients and physicians. The intervention targets patients with diabetes and concurrent chronic conditions affecting the heart, lungs, or kidneys. RESULTS: The NOMAD intervention was developed as a structured model of regular, in-person multidisciplinary team conferences involving specialists in endocrinology, cardiology, respiratory medicine, nephrology, and pharmacology. A key component was the integration of patient-reported outcomes to enhance patient-centred care, highlighting the aspect of quality of life. CONCLUSION: This development process provides a foundation for feasibility testing and future evaluation of NOMAD's impact in a randomised trial. Our experiences may also inform researchers and healthcare providers developing similar multidisciplinary interventions for complex patient populations. CI - (c) The Author(s) 2025. FAU - Bugge, Stine Jorstad AU - Bugge SJ AUID- ORCID: 0000-0002-8618-2938 AD - Steno Diabetes Centre Odense, Odense University Hospital, Odense, Denmark. RINGGOLD: 11286 AD - Department of Clinical Research, University of Southern Denmark, Odense, Denmark. AD - Pharmacology, Odense University Hospital, Odense, Denmark. RINGGOLD: 11286 FAU - Hangaard, Jorgen AU - Hangaard J AD - Steno Diabetes Centre Odense, Odense University Hospital, Odense, Denmark. RINGGOLD: 11286 FAU - Damkier, Per AU - Damkier P AD - Department of Clinical Research, University of Southern Denmark, Odense, Denmark. AD - Pharmacology, Odense University Hospital, Odense, Denmark. RINGGOLD: 11286 FAU - Jensen, Per Bruno AU - Jensen PB AD - Department of Nephrology, Odense University Hospital, Odense, Denmark. RINGGOLD: 11286 FAU - Johansson, Sofie Lock AU - Johansson SL AD - Department of Respiratory Medicine, Odense University Hospital, Odense, Denmark. RINGGOLD: 11286 AD - Odense Respiratory Research Unit (ODIN), Department of Clinical Research, University of Southern Denmark, Odense, Denmark. FAU - Nagarajah, Subagini AU - Nagarajah S AD - Department of Nephrology, Odense University Hospital, Odense, Denmark. RINGGOLD: 11286 FAU - Panou, Vasiliki AU - Panou V AUID- ORCID: 0000-0002-3607-5640 AD - Department of Respiratory Medicine, Odense University Hospital, Odense, Denmark. RINGGOLD: 11286 AD - Odense Respiratory Research Unit (ODIN), Department of Clinical Research, University of Southern Denmark, Odense, Denmark. FAU - Poulsen, Marianne Kjaer AU - Poulsen MK AD - Steno Diabetes Centre Odense, Odense University Hospital, Odense, Denmark. RINGGOLD: 11286 FAU - Rahbek, Martin Torp AU - Rahbek MT AD - Department of Clinical Research, University of Southern Denmark, Odense, Denmark. AD - Pharmacology, Odense University Hospital, Odense, Denmark. RINGGOLD: 11286 FAU - Horup, Mette Bog AU - Horup MB AD - Department of Clinical Development, Odense University Hospital, Odense, Denmark. RINGGOLD: 11286 FAU - Rothmann, Mette Juel AU - Rothmann MJ AUID- ORCID: 0000-0001-6505-4163 AD - Steno Diabetes Centre Odense, Odense University Hospital, Odense, Denmark. RINGGOLD: 11286 AD - Department of Clinical Research, University of Southern Denmark, Odense, Denmark. FAU - Schousboe, Karoline AU - Schousboe K AD - Steno Diabetes Centre Odense, Odense University Hospital, Odense, Denmark. RINGGOLD: 11286 AD - Department of Clinical Research, University of Southern Denmark, Odense, Denmark. FAU - Schneider, Ida Ransby AU - Schneider IR AD - Department of Cardiology, Odense University Hospital, Odense, Denmark. RINGGOLD: 11286 FAU - Henriksen, Daniel Pilsgaard AU - Henriksen DP AUID- ORCID: 0000-0003-1303-6195 AD - Steno Diabetes Centre Odense, Odense University Hospital, Odense, Denmark. RINGGOLD: 11286 AD - Department of Clinical Research, University of Southern Denmark, Odense, Denmark. AD - Pharmacology, Odense University Hospital, Odense, Denmark. RINGGOLD: 11286 FAU - Olsen Zwisler, Ann-Dorthe AU - Olsen Zwisler AD AD - Steno Diabetes Centre Odense, Odense University Hospital, Odense, Denmark. RINGGOLD: 11286 AD - Department of Palliative Care, Rigshospitalet, Copenhagen, Denmark. RINGGOLD: 53146 LA - eng PT - Journal Article DEP - 20250826 PL - England TA - J Multimorb Comorb JT - Journal of multimorbidity and comorbidity JID - 9918333280706676 PMC - PMC12381452 OTO - NOTNLM OT - care coordination OT - complex intervention development OT - diabetes OT - multidisciplinary teamwork OT - multimorbidity OT - patient-centred care OT - patient-reported outcome OT - quality of life COIS- The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2025/08/29 20:45 MHDA- 2025/08/29 20:46 PMCR- 2025/08/26 CRDT- 2025/08/29 14:23 PHST- 2025/05/15 00:00 [received] PHST- 2025/07/04 00:00 [revised] PHST- 2025/07/24 00:00 [accepted] PHST- 2025/08/29 20:46 [medline] PHST- 2025/08/29 20:45 [pubmed] PHST- 2025/08/29 14:23 [entrez] PHST- 2025/08/26 00:00 [pmc-release] AID - 10.1177_26335565251366466 [pii] AID - 10.1177/26335565251366466 [doi] PST - epublish SO - J Multimorb Comorb. 2025 Aug 26;15:26335565251366466. doi: 10.1177/26335565251366466. eCollection 2025 Jan-Dec. PMID- 40880698 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250915 LR - 20250915 IS - 1841-9038 (Print) IS - 2069-6116 (Electronic) IS - 1841-9038 (Linking) VI - 20 IP - 2 DP - 2025 Jun TI - Multidisciplinary Insights into Perioperative Cardiac Events in Non-Cardiac Surgery: an ECG Holter Monitoring Study. PG - 182-191 LID - 10.26574/maedica.2025.20.2.182 [doi] AB - BACKGROUND: Cardiovascular complications after non-cardiac surgery have a major impact on perioperative morbidity and mortality. Despite several scales and scores for assessing the preoperative cardiovascular status, an individualized assessment focused on each patient is mandatory. AIM: To identify the new cardiac events that occur after non-cardiac surgery. METHODS: In 100 patients hospitalized in the general surgery department with acute and chronic surgical pathologies, the perioperative cardiac events were assessed using Holter monitoring along with clinical and biochemical markers, including C reactive protein (CRP) and high-sensitive troponin (hscTnI). RESULTS: Out of the 100 participants with a mean age of 54.5 (43-77.9) years, 54% were men. Ten patients developed paroxysmal postoperative atrial fibrillation (AF), which was related with longer surgery time 165 (150-180) vs 120 (90-150) minutes (p=0.002) and postoperative anaemia [haemoglobin (Hg) 10.4 (9.37-12.6) vs 12.1 (11-13.2) g/dL, (p=0.041)]. Higher CRP levels were also correlated with paroxysmal AF. The AF group correlated with higher values of presurgical CRP: 81 (46.5-186.75) vs 27 (6-102.5) mg/dL, (p=0.041). Higher postsurgical CRP values were also found in the AF group: 76 (47.75-110.75) vs 40.5 (12-82.5) mg/dL (p=0.045). Sinus pauses were present in nine patients and there was a strong association between sinus pauses and age (p = 0.011), history of high blood pressure (HBP) (p = 0.031), intraoperative HBP (p = 0.026) and the preexisting AF (p = 0.028). Postsurgical ST changes were present in 30 patients and ST depression was correlated with age (p < 0.001), prolonged surgery time [150 (120-180) vs 120 (90-150) minutes (p < 0.001)], history of HBP [(33.3% vs 12.2%) (p=0.017)] and intraoperative maximum values of BP (p = 0.007). CONCLUSIONS: There is an increased risk of cardiovascular events during the postoperative period of non-cardiac surgery in patients with advanced age, pre-existing diseases (hypertension, preexisting atrial fibrillation, diabetes mellitus), the level of inflammation and longer intraoperative stress. Holter monitoring revealed rhythm and conduction disorders as well as ST segment changes that were associated with the inflammatory status and slightly elevated cardiac enzyme levels. Future studies are needed to see the impact of cardiac complications in the long term. FAU - Palcau, Alexandru Cosmin AU - Palcau AC AD - "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania. AD - General Surgery Department, University Emergency Hospital of Bucharest, 050098 Bucharest, Romania. FAU - Paduraru, Livia Florentina AU - Paduraru LF AD - "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania. AD - Department of Cardiology, Elias Emergency University Hospital, 011461Bucharest, Romania. FAU - Dinulescu, Alexandru AU - Dinulescu A AD - "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania. AD - Departament of Pediatrics, "Grigore Alexandrescu" Emergency Hospital for Children, 011743 Bucharest, Romania. FAU - Musat, Florentina AU - Musat F AD - "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania. AD - General Surgery Department, University Emergency Hospital of Bucharest, 050098 Bucharest, Romania. FAU - Ion, Daniel AU - Ion D AD - "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania. AD - General Surgery Department, University Emergency Hospital of Bucharest, 050098 Bucharest, Romania. FAU - Paduraru, Dan Nicolae AU - Paduraru DN AD - "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania. AD - General Surgery Department, University Emergency Hospital of Bucharest, 050098 Bucharest, Romania. FAU - Iliesiu, Adriana Mihaela AU - Iliesiu AM AD - "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania. AD - Department of Cardiology, "Prof. Dr. Theodor Burghele" Clinical Hospital, 050659 Bucharest, Romania. LA - eng PT - Journal Article PL - Romania TA - Maedica (Bucur) JT - Maedica JID - 101526930 PMC - PMC12347042 COIS- None declared. EDAT- 2025/08/29 20:45 MHDA- 2025/08/29 20:46 PMCR- 2025/06/01 CRDT- 2025/08/29 14:16 PHST- 2025/03/18 00:00 [received] PHST- 2025/04/25 00:00 [accepted] PHST- 2025/08/29 20:46 [medline] PHST- 2025/08/29 20:45 [pubmed] PHST- 2025/08/29 14:16 [entrez] PHST- 2025/06/01 00:00 [pmc-release] AID - 10.26574/maedica.2025.20.2.182 [doi] PST - ppublish SO - Maedica (Bucur). 2025 Jun;20(2):182-191. doi: 10.26574/maedica.2025.20.2.182. PMID- 40879970 OWN - NLM STAT- MEDLINE DCOM- 20251202 LR - 20261010 IS - 1970-9366 (Electronic) IS - 1828-0447 (Linking) VI - 20 IP - 8 DP - 2025 Nov TI - Fostering interconnected care in heart failure: a call to action for a comprehensive assessment and management of the patient's journey. PG - 2307-2318 LID - 10.1007/s11739-025-04102-2 [doi] AB - A growing body of evidence underscores the importance of investigating the patient journey in managing systemic disorders. This is particularly relevant in heart failure (HF), a condition in which achieving long-term outcomes requires advancements in the early detection, accurate diagnosis, and comprehensive treatment of HF throughout the patient's care experience. Addressing this challenge necessitates tackling critical barriers, including workforce shortages, insufficient funding, and limited awareness of HF care among both healthcare providers and patients. Cardiac rehabilitation (CR) plays a pivotal role within the continuum of care, serving as a cornerstone for engaging and motivating patients and caregivers. Despite its recognized value, gaps persist in the integration of CR into interconnected care networks and the broader healthcare system. This paper seeks to highlight the essential role of CR as a "bridging tool" to promote patient stabilization, emphasizing the implementation of guideline-directed medical therapy, as well as fostering patient education and empowerment. Achieving this integration requires embedding CR as a central component within the comprehensive management pathway for patients with HF. CI - (c) 2025. The Author(s), under exclusive licence to Societa Italiana di Medicina Interna (SIMI). FAU - Cusmano, Ignazio AU - Cusmano I AD - Cardiac Rehabilitation Unit, IRCCS S. Maria Nascente-Fondazione Don Carlo Gnocchi ONLUS, Via Alfonso Capecelatro 66, 20149, Milan, Italy. FAU - Loguercio, Monica AU - Loguercio M AD - Cardiovascular Rehabilitation Unit, ASST Crema, Santa Marta Hospital, Rivolta D'Adda, Italy. FAU - Di Salvo, Francesca AU - Di Salvo F AD - Cardiac Rehabilitation Unit, IRCCS S. Maria Nascente-Fondazione Don Carlo Gnocchi ONLUS, Via Alfonso Capecelatro 66, 20149, Milan, Italy. FAU - Gonella, Stefano AU - Gonella S AD - Cardiac Rehabilitation Unit, IRCCS S. Maria Nascente-Fondazione Don Carlo Gnocchi ONLUS, Via Alfonso Capecelatro 66, 20149, Milan, Italy. FAU - Ambrosetti, Marco AU - Ambrosetti M AD - Cardiovascular Rehabilitation Unit, ASST Crema, Santa Marta Hospital, Rivolta D'Adda, Italy. FAU - Morici, Nuccia AU - Morici N AUID- ORCID: 0000-0003-1070-8857 AD - Cardiac Rehabilitation Unit, IRCCS S. Maria Nascente-Fondazione Don Carlo Gnocchi ONLUS, Via Alfonso Capecelatro 66, 20149, Milan, Italy. nmorici@dongnocchi.it. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20250829 PL - Italy TA - Intern Emerg Med JT - Internal and emergency medicine JID - 101263418 SB - IM MH - Humans MH - *Heart Failure/therapy/diagnosis OTO - NOTNLM OT - Cardiac rehabilitation OT - Heart failure OT - Interconnected care OT - Multidisciplinary team COIS- Declarations. Conflict of interest: The authors declare no competing interests. EDAT- 2025/08/29 12:47 MHDA- 2025/12/02 12:56 CRDT- 2025/08/29 11:26 PHST- 2025/04/28 00:00 [received] PHST- 2025/08/16 00:00 [accepted] PHST- 2025/12/02 12:56 [medline] PHST- 2025/08/29 12:47 [pubmed] PHST- 2025/08/29 11:26 [entrez] AID - 10.1007/s11739-025-04102-2 [pii] AID - 10.1007/s11739-025-04102-2 [doi] PST - ppublish SO - Intern Emerg Med. 2025 Nov;20(8):2307-2318. doi: 10.1007/s11739-025-04102-2. Epub 2025 Aug 29. PMID- 40879673 OWN - NLM STAT- MEDLINE DCOM- 20260505 LR - 20260813 IS - 1432-1971 (Electronic) IS - 0172-0643 (Print) IS - 0172-0643 (Linking) VI - 47 IP - 5 DP - 2026 Jun TI - Practice Patterns in Pediatric Cardiothoracic Presurgical Conferences: A Multicenter Survey Study. PG - 2160-2169 LID - 10.1007/s00246-025-04008-y [doi] AB - Pediatric cardiothoracic surgeries are high-stakes, complex procedures, typically undergoing prior review at multidisciplinary conferences. This study evaluates practice patterns of conferences throughout the United States (US). Surveys were distributed to fellowship program directors or division directors in 124 US pediatric cardiology centers seeking information on conference logistics, fellow roles, quality improvement (QI), and satisfaction. All 47 responding centers (response rate 38%) conduct presurgical conferences, mostly on a weekly basis (92%) lasting 60-120 min (79%). The conferences are solely virtual (19%) or hybrid (81%). High-volume centers (> 300 surgical cases/year) are more likely to hold multiple conferences (13/20 vs 7/27, p < 0.01) and less likely to designate a moderator (11/20 vs 22/26, p = 0.027). Categorical pediatric cardiology fellows at 33 centers present clinical data (97%), echocardiograms (85%), catheterizations (82%), and cross-sectional imaging (39%), typically beginning in their first year. Most centers report that minor (98%) or major changes (51%) are made to patient management at least "sometimes." Responders rate conferences as very important (median 10/10 on a 10-point Likert scale, IQR 9-10), but satisfaction is more modest (median 7/10, IQR 7-9). Only 17% of centers have a formal QI process. Comments from 42 centers reveal positive themes of collaboration (68%) but also concerns about lengthy (30%) or inefficient (36%) discussion. Conclusions: This survey highlights common practices for pediatric cardiothoracic presurgical conferences. Conferences are collaborative and seen as highly impactful. However, satisfaction varies, and QI efforts are infrequent. These findings highlight opportunities for process improvement and standardization. CI - (c) 2025. The Author(s). FAU - Reed, Britney AU - Reed B AD - IU School of Medicine, Indianapolis IN, Indianapolis, USA. bklotzsc@iu.edu. FAU - Puranik, Poonam AU - Puranik P AD - Pediatric Cardiology, Riley Hospital for Children, Indianapolis IN, Indianapolis, USA. FAU - Rodenbarger, Andrew AU - Rodenbarger A AD - Pediatric Cardiology, Riley Hospital for Children, Indianapolis IN, Indianapolis, USA. FAU - Trivedi, Mira AU - Trivedi M AD - Pediatric Cardiology, Riley Hospital for Children, Indianapolis IN, Indianapolis, USA. FAU - Adebo, Dilachew A AU - Adebo DA AD - Children's Heart Institute, University of Texas Health Science Center at Houston, Houston, TX, USA. FAU - Beasley, Gary AU - Beasley G AD - Department of Pediatrics, Division of Pediatric Cardiology, University of Iowa Carver College of Medicine, Iowa City, IA, USA. FAU - Bezold, Louis AU - Bezold L AD - Department of Pediatrics, Joint Pediatric Heart Program, University of Kentucky College of Medicine, Lexington, KY, USA. FAU - Campbell, M Jay AU - Campbell MJ AD - Duke University School of Medicine, Durham, NC, USA. FAU - Carr, Michael R AU - Carr MR AD - Ann & Robert H.Lurie Children's Hospital Chicago, Chicago, IL, USA. FAU - Daily, Joshua AU - Daily J AD - Arkansas Children's Hospital, Little Rock, AR, USA. FAU - DeBrunner, Mark AU - DeBrunner M AD - Pediatric Cardiology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, USA. FAU - Del Grippo, Erica AU - Del Grippo E AD - Nemours Cardiac Center, Wilmington, DE, USA. FAU - Fifer, Carlen G AU - Fifer CG AD - Michigan Congenital Heart Center, University of Michigan, Ann Arbor, MI, USA. FAU - Hoffman, Timothy M AU - Hoffman TM AD - University of North Carolina, Chapel Hill, NC, USA. FAU - Hupp, Susan R AU - Hupp SR AD - Duke Children's Hospital, Duke University, Durham, NC, USA. FAU - Kurtz, Joshua D AU - Kurtz JD AD - Division of Pediatric Cardiology, University of Louisville, Louisville, KY, USA. FAU - Morchi, Gira AU - Morchi G AD - Pediatric Cardiology, Children's Hospital of Orange County, Orange, CA, USA. FAU - Owada, Carl AU - Owada C AD - Department of Cardiology and Cardiothoracic Surgery, Valley Children's Hospital, Madera, CA, USA. FAU - Peterson, Renuka AU - Peterson R AD - Department of Pediatrics, Saint Louis University School of Medicine, Saint Louis, MO, USA. FAU - Puchalski, Michael D AU - Puchalski MD AD - Johns Hopkins All Children's Hospital, St. Petersburg, FL, USA. FAU - Romans, Ryan A AU - Romans RA AD - Ward Family Heart Center, Children's Mercy Kansas City, Kansas City, MO, USA. FAU - Saidi, Arwa AU - Saidi A AD - Congenital Heart Center, University of Florida, Gainesville, FL, USA. FAU - Shenoy, Rajesh U AU - Shenoy RU AD - Wolfson Children's Hospital, Jacksonville, FL, USA. FAU - Singh, Anoop K AU - Singh AK AD - Medical College of Wisconsin, Children's Wisconsin, Milwaukee, WI, USA. FAU - Tunks, Robert D AU - Tunks RD AD - Department of Pediatrics, Penn State Health, Hershey, PA, USA. FAU - Yohannan, Thomas M AU - Yohannan TM AD - University of Tennessee Health Science Center, Memphis, TN, USA. FAU - Wilhelm, Carolyn M AU - Wilhelm CM AD - Case Western Reserve University, University Hospitals Rainbow Babies & Children's Hospital, Cleveland, OH, USA. FAU - Patel, Jyoti K AU - Patel JK AD - Pediatric Cardiology, Riley Hospital for Children, Indianapolis IN, Indianapolis, USA. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20250829 PL - United States TA - Pediatr Cardiol JT - Pediatric cardiology JID - 8003849 SB - IM MH - Humans MH - United States MH - *Congresses as Topic MH - *Practice Patterns, Physicians'/statistics & numerical data MH - Surveys and Questionnaires MH - *Pediatrics MH - *Cardiology MH - Quality Improvement MH - Child MH - *Cardiac Surgical Procedures MH - *Preoperative Care PMC - PMC13144215 OTO - NOTNLM OT - Cardiac surgery OT - Congenital heart disease OT - Multidisciplinary conference OT - Pediatric cardiology COIS- Declarations. Conflict of interest: The authors declare no competing interests. EDAT- 2025/08/29 12:48 MHDA- 2026/05/06 00:35 PMCR- 2025/08/29 CRDT- 2025/08/29 11:03 PHST- 2025/07/23 00:00 [received] PHST- 2025/08/21 00:00 [accepted] PHST- 2026/05/06 00:35 [medline] PHST- 2025/08/29 12:48 [pubmed] PHST- 2025/08/29 11:03 [entrez] PHST- 2025/08/29 00:00 [pmc-release] AID - 10.1007/s00246-025-04008-y [pii] AID - 4008 [pii] AID - 10.1007/s00246-025-04008-y [doi] PST - ppublish SO - Pediatr Cardiol. 2026 Jun;47(5):2160-2169. doi: 10.1007/s00246-025-04008-y. Epub 2025 Aug 29. PMID- 40878775 OWN - NLM STAT- MEDLINE DCOM- 20260209 LR - 20260209 IS - 1878-4429 (Electronic) IS - 1878-4429 (Linking) VI - 19 IP - 2 DP - 2026 Mar TI - Deceptive appearances: Congenital infections simulating genetic syndromes in fetal Pathology. PG - 134-146 LID - 10.1177/19345798251372555 [doi] AB - Transplacental infections such as cytomegalovirus, Zika virus, toxoplasmosis, and rubella, especially if acquired in the perinatal period, are well-known causes of congenital anomalies. However, their phenotypic overlap with certain genetic syndromes can pose significant diagnostic challenges during fetal autopsy and prenatal counseling. With an objective to review and highlight the clinical and pathological similarities between congenital infections and genetic syndromes, and emphasizing diagnostic pitfalls in fetal autopsy and the importance of integrated approaches, a comprehensive literature review was performed of articles that discussed congenital infections, fetal autopsy findings, and differential diagnosis with genetic syndromes. We found that several transplacental infections mimic the phenotype of genetic syndromes through features such as microcephaly, intracranial calcifications, cardiac anomalies, and hydrops fetalis. Placental pathology, maternal serology, and targeted molecular testing are essential to delineate the cause. An awareness of overlapping features between congenital infections and genetic syndromes is crucial to avoid misdiagnosis. A multidisciplinary approach combining clinical, histopathological, and molecular insights is necessary to reach an accurate diagnosis, guide recurrence risk counseling, and inform management in future pregnancies. FAU - Mangla, Mishu AU - Mangla M AUID- ORCID: 0000-0003-0708-1037 AD - Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, Bibinagar, Hyderabad. FAU - Palo, Seetu AU - Palo S AUID- ORCID: 0000-0001-9956-2246 AD - Department of Pathology and Laboratory Medicine, All India Institute of Medical Sciences, Bibinagar, Hyderabad. LA - eng PT - Journal Article PT - Review DEP - 20250829 PL - United States TA - J Neonatal Perinatal Med JT - Journal of neonatal-perinatal medicine JID - 101468335 SB - IM MH - Humans MH - Pregnancy MH - Female MH - Diagnosis, Differential MH - Zika Virus Infection/diagnosis/congenital/pathology MH - *Pregnancy Complications, Infectious/pathology/diagnosis MH - Infectious Disease Transmission, Vertical MH - Autopsy MH - Toxoplasmosis, Congenital/diagnosis/pathology MH - Microcephaly/pathology MH - Fetus/pathology MH - *Genetic Diseases, Inborn/diagnosis/pathology MH - Rubella/diagnosis/congenital/pathology MH - Cytomegalovirus Infections/congenital/diagnosis/pathology MH - Hydrops Fetalis/pathology/diagnosis OTO - NOTNLM OT - TORCH OT - Zika virus OT - congenital anomalies OT - cytomegalovirus OT - fetal autopsy OT - genetic syndromes OT - mimicry OT - placental pathology OT - transplacental infections COIS- Declaration of conflicting interestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2025/08/29 08:45 MHDA- 2026/02/09 06:29 CRDT- 2025/08/29 05:53 PHST- 2026/02/09 06:29 [medline] PHST- 2025/08/29 08:45 [pubmed] PHST- 2025/08/29 05:53 [entrez] AID - 10.1177/19345798251372555 [doi] PST - ppublish SO - J Neonatal Perinatal Med. 2026 Mar;19(2):134-146. doi: 10.1177/19345798251372555. Epub 2025 Aug 29. PMID- 40877031 OWN - NLM STAT- MEDLINE DCOM- 20260312 LR - 20260831 IS - 1468-201X (Electronic) IS - 1355-6037 (Print) IS - 1355-6037 (Linking) VI - 112 IP - 7 DP - 2026 Mar 12 TI - Analysis and prediction of cardiovascular research hotspots, trends and interdisciplinarity. PG - 399-408 LID - 10.1136/heartjnl-2025-325877 [doi] LID - e325877 AB - OBJECTIVE: Comprehensive data and analyses on cardiovascular research could clarify recent research trends for the academic community and facilitate policy development. We examined publications and reference data to identify research topics, trends and interdisciplinarity for cardiovascular disease (CVD). METHODS: We extracted and clustered text fragments from the titles and abstracts of 2 512 445 publications using artificial intelligence techniques, including natural language processing (NLP) for semantic analysis. Cardiovascular experts identified topics and document clusters based on the output of those semiautomatic methods. We also applied machine learning algorithms to predict the trends over the next 5 years in each field. We examined the crossover between the two cluster groups using citation relationships in the documents. RESULTS: Research in clinical studies showed the most notable increase; that was followed by research in population and basic studies. The research hotspots were minimally invasive treatments for valve disease, circulatory haemodynamics, and prevention and control of hypertension. The fastest-growing topics were health monitoring, evidence-based medicine and immunotherapy. We found extensive crossover relationships among document clusters for the periods of 2017-2018 and 2020-2021. CONCLUSIONS: This study provides valuable insights into the research hotspots for cardiovascular research, including an increasing emphasis on early disease detection and prevention, exploration of minimally invasive treatments and assessment of risk factors. The research landscape demonstrates signs of interdisciplinarity and integration as reflected in citation relationships. These findings suggest practical implications for optimising resource allocation in healthcare systems, guiding clinical guideline updates and informing policy-making to prioritise high-impact research areas aligned with evolving CVD challenges. Given the evolving global burden of CVD, continuous research and innovation are imperative, with interdisciplinary collaboration assuming a pivotal role in advancing scientific knowledge. CI - (c) Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY. Published by BMJ Group. FAU - Liu, Zeye AU - Liu Z AD - Department of Cardiac Surgery, Peking University People's Hospital, Peking University, Beijing, China. FAU - Li, Ziping AU - Li Z AD - Department of Structural Heart Disease, National Center for Cardiovascular Disease, China & Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. FAU - Jiang, Hong AU - Jiang H AD - Department of Structural Heart Disease, National Center for Cardiovascular Disease, China & Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. FAU - Pan, Guangyu AU - Pan G AD - Department of Cardiac Surgery, Peking University People's Hospital, Peking University, Beijing, China. FAU - Li, Wenchao AU - Li W AD - Zhengzhou University People's Hospital, Zhengzhou, Henan, China. FAU - Zhang, Fengwen AU - Zhang F AD - Department of Structural Heart Disease, National Center for Cardiovascular Disease, China & Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. FAU - Ou-Yang, Wen-Bin AU - Ou-Yang WB AD - Department of Structural Heart Disease, National Center for Cardiovascular Disease, China & Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. FAU - Wang, Shouzheng AU - Wang S AD - Department of Structural Heart Disease, National Center for Cardiovascular Disease, China & Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. FAU - Wang, Cheng AU - Wang C AD - Department of Structural Heart Disease, National Center for Cardiovascular Disease, China & Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. FAU - An, Xuanqi AU - An X AD - Department of Structural Heart Disease, National Center for Cardiovascular Disease, China & Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. FAU - Dai, Anlin AU - Dai A AD - National Engineering Research Center for Medical Big Data Application Technology, Chinese PLA General Hospital, Beijing, China. FAU - Xia, Ruibing AU - Xia R AD - University Hospital Munich Department of Cardiology - Medical Clinic and Polyclinic I, Munich, Germany. FAU - Li, Yakun AU - Li Y AD - Academic Medical Centre, Amsterdam, The Netherlands. FAU - Sun, Xiaochun AU - Sun X AD - National Engineering Research Center for Medical Big Data Application Technology, Chinese PLA General Hospital, Beijing, China chengliangyin@163.com panxiangbin@fuwaihospital.org shiyi1088@126.com sunxc20@163.com. AD - Medical Innovation Research Department, Chinese PLA General Hospital, Beijing, China. FAU - Shi, Yi AU - Shi Y AD - Department of Cardiac Surgery, Peking University People's Hospital, Peking University, Beijing, China chengliangyin@163.com panxiangbin@fuwaihospital.org shiyi1088@126.com sunxc20@163.com. FAU - Yin, Chengliang AU - Yin C AUID- ORCID: 0000-0001-8262-5749 AD - National Engineering Research Center for Medical Big Data Application Technology, Chinese PLA General Hospital, Beijing, China chengliangyin@163.com panxiangbin@fuwaihospital.org shiyi1088@126.com sunxc20@163.com. AD - Medical Innovation Research Department, Chinese PLA General Hospital, Beijing, China. FAU - Pan, Xiang-Bin AU - Pan XB AUID- ORCID: 0000-0003-2746-4481 AD - Department of Structural Heart Disease, National Center for Cardiovascular Disease, China & Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China chengliangyin@163.com panxiangbin@fuwaihospital.org shiyi1088@126.com sunxc20@163.com. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20260312 PL - England TA - Heart JT - Heart (British Cardiac Society) JID - 9602087 SB - IM MH - Humans MH - *Cardiovascular Diseases/therapy/diagnosis MH - *Biomedical Research/trends MH - *Cardiology/trends MH - *Interdisciplinary Research/trends MH - Natural Language Processing MH - Interdisciplinary Communication PMC - PMC13018832 OTO - NOTNLM OT - Cardiovascular Diseases OT - Education, Medical OT - Research Design COIS- Competing interests: None declared. EDAT- 2025/08/29 00:45 MHDA- 2026/03/13 00:49 PMCR- 2026/03/26 CRDT- 2025/08/28 21:32 PHST- 2025/02/07 00:00 [received] PHST- 2025/08/09 00:00 [accepted] PHST- 2026/03/13 00:49 [medline] PHST- 2025/08/29 00:45 [pubmed] PHST- 2025/08/28 21:32 [entrez] PHST- 2026/03/26 00:00 [pmc-release] AID - heartjnl-2025-325877 [pii] AID - 10.1136/heartjnl-2025-325877 [doi] PST - epublish SO - Heart. 2026 Mar 12;112(7):399-408. doi: 10.1136/heartjnl-2025-325877. PMID- 40875033 OWN - NLM STAT- MEDLINE DCOM- 20251002 LR - 20261010 IS - 1615-6692 (Electronic) IS - 0340-9937 (Linking) VI - 50 IP - 5 DP - 2025 Oct TI - The multidisciplinary Heart Team in mitral valve transcatheter edge-to-edge repair. PG - 319-325 LID - 10.1007/s00059-025-05328-8 [doi] AB - Treatment options for mitral regurgitation (MR) have markedly evolved over the past few decades, with mitral valve transcatheter edge-to-edge repair (M-TEER) expanding the clinical armamentarium of guideline-directed medical therapy and surgical techniques. However, the variety of mitral valve anatomies, the presence of heart failure (HF), and consideration of the individual patient risk require a multidisciplinary Heart Team approach to identify the optimal treatment for MR for each patient. Despite the growing field of transcatheter mitral interventions and the longstanding availability of surgical mitral valve repair and replacement, evidence from randomized clinical trials comparing intervention with surgery remains scarce. In the meantime, the increasing safety and experience of surgical and interventional procedures have shifted the perspective on mitral valve disease in terms of when and how to treat it. Therefore, the multidisciplinary Heart Team discussion has become of paramount importance in the evaluation and treatment decisions for patients with mitral valve disease. CI - (c) 2025. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature. FAU - Mueller, Christoph S AU - Mueller CS AD - Herzchirurgische Klinik und Poliklinik, LMU Klinikum, LMU Munchen, Marchioninistrasse 15, 81377, Munich, Germany. christoph.mueller@med.uni-muenchen.de. FAU - Hagl, Christian AU - Hagl C AD - Herzchirurgische Klinik und Poliklinik, LMU Klinikum, LMU Munchen, Marchioninistrasse 15, 81377, Munich, Germany. AD - German Center for Cardiovascular Research (DZHK), Partner Site Munich, Heart Alliance, Munich, Germany. FAU - Hausleiter, Jorg AU - Hausleiter J AD - Medizinische Klinik und Poliklinik I, LMU Klinikum, LMU Munchen, Munich, Germany. AD - German Center for Cardiovascular Research (DZHK), Partner Site Munich, Heart Alliance, Munich, Germany. FAU - Stocker, Thomas J AU - Stocker TJ AD - Medizinische Klinik und Poliklinik I, LMU Klinikum, LMU Munchen, Munich, Germany. AD - German Center for Cardiovascular Research (DZHK), Partner Site Munich, Heart Alliance, Munich, Germany. LA - eng PT - Journal Article PT - Review TT - Das multidisziplinare Herzteam bei "Edge-to-edge-Reparatur" der Mitralklappe. DEP - 20250828 PL - Germany TA - Herz JT - Herz JID - 7801231 SB - IM MH - Humans MH - *Mitral Valve Insufficiency/surgery/diagnosis MH - *Patient Care Team/organization & administration MH - *Heart Valve Prosthesis Implantation/methods MH - *Cardiac Catheterization/methods MH - *Mitral Valve/surgery MH - *Mitral Valve Annuloplasty/methods MH - Treatment Outcome OTO - NOTNLM OT - Heart failure OT - Mitral regurgitation OT - Mitral valve disease OT - Mitral valve surgery OT - M‑TEER COIS- Declarations. Conflict of interest: C.S. Mueller, C. Hagl, J. Hausleiter, and T.J. Stocker declare that they have no competing interests. For this article no studies with human participants or animals were performed by any of the authors. All studies mentioned were in accordance with the ethical standards indicated in each case. EDAT- 2025/08/28 20:45 MHDA- 2025/10/02 12:32 CRDT- 2025/08/28 11:14 PHST- 2025/07/23 00:00 [accepted] PHST- 2025/10/02 12:32 [medline] PHST- 2025/08/28 20:45 [pubmed] PHST- 2025/08/28 11:14 [entrez] AID - 10.1007/s00059-025-05328-8 [pii] AID - 10.1007/s00059-025-05328-8 [doi] PST - ppublish SO - Herz. 2025 Oct;50(5):319-325. doi: 10.1007/s00059-025-05328-8. Epub 2025 Aug 28. PMID- 40863402 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250914 LR - 20250914 IS - 2075-4426 (Print) IS - 2075-4426 (Electronic) IS - 2075-4426 (Linking) VI - 15 IP - 8 DP - 2025 Aug 1 TI - Fetal Supraventricular Tachycardia: What Do We Know up to This Day? LID - 10.3390/jpm15080341 [doi] LID - 341 AB - Fetal tachyarrhythmias, particularly supraventricular tachycardia (SVT) and atrial flutter (AFL), pose significant clinical challenges, especially when complicated by hydrops fetalis. This article provides a comprehensive review of the tachyarrhythmia types, the diagnostic modalities applied, and the therapeutic strategies followed in fetal tachyarrhythmias. Diagnostic techniques such as M-mode echocardiography and fetal magnetocardiography (fMCG) are highlighted for their capacity to provide real-time, high-quality assessments of fetal cardiac rhythms. The review, also, focuses on pharmacologic management via transplacental therapy, discussing the safety and efficacy of the key agents including digoxin, flecainide, and sotalol, under different clinical scenarios, such as hydropic fetus and renal impairment. In addition to transplacental administration, alternative approaches such as direct fetal intramuscular or intravascular injections are examined. These direct methods, while potentially more effective in refractory cases, carry risks that necessitate specialized expertise and careful consideration of maternal and fetal safety. The limitations of current evidence, largely based on small case studies and retrospective analyses, underscore the need for larger, prospective multicenter observational studies and randomized control trials to establish standardized protocols for fetal tachyarrhythmia management. Overall, this review advocates for a personalized, multidisciplinary approach, emphasizing early fetal tachyarrhythmias diagnosis, tailored treatment regimens that balances efficacy with safety, and rigorous monitoring to optimize outcomes for both the fetus and the mother. FAU - Tsokkou, Sophia AU - Tsokkou S AUID- ORCID: 0009-0000-1703-6980 AD - 1st Department of Cardiology, AHEPA Hospital, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece. AD - Laboratory of Histology-Embryology, Department of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece. FAU - Konstantinidis, Ioannis AU - Konstantinidis I AUID- ORCID: 0009-0000-1632-821X AD - Laboratory of Histology-Embryology, Department of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece. FAU - Anastasiou, Vasileios AU - Anastasiou V AD - 1st Department of Cardiology, AHEPA Hospital, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece. FAU - Matsas, Alkis AU - Matsas A AUID- ORCID: 0000-0002-9758-8079 AD - Laboratory of Experimental Surgery and Surgical Research 'N.S. Christeas', Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece. FAU - Stamoula, Eleni AU - Stamoula E AUID- ORCID: 0000-0002-8952-821X AD - Department of Clinical Pharmacology, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece. FAU - Peteinidou, Emmanuela AU - Peteinidou E AD - 1st Department of Cardiology, AHEPA Hospital, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece. FAU - Sioga, Antonia AU - Sioga A AD - Laboratory of Histology-Embryology, Department of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece. FAU - Papamitsou, Theodora AU - Papamitsou T AUID- ORCID: 0000-0002-0709-5407 AD - Laboratory of Histology-Embryology, Department of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece. FAU - Ziakas, Antonios AU - Ziakas A AD - 1st Department of Cardiology, AHEPA Hospital, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece. FAU - Kamperidis, Vasileios AU - Kamperidis V AUID- ORCID: 0000-0001-8424-6718 AD - 1st Department of Cardiology, AHEPA Hospital, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece. LA - eng PT - Journal Article PT - Review DEP - 20250801 PL - Switzerland TA - J Pers Med JT - Journal of personalized medicine JID - 101602269 PMC - PMC12387273 OTO - NOTNLM OT - amiodarone OT - digoxin OT - direct fetal intramuscular injection OT - fetal magnetocardiography (fMCG) OT - fetal supraventricular tachycardia (SVT) OT - fetal tachyarrhythmias OT - flecainide OT - repeated intravascular injection OT - sotalol OT - transplacental administration COIS- The authors declare no conflict of interest. EDAT- 2025/08/28 20:51 MHDA- 2025/08/28 20:52 PMCR- 2025/08/01 CRDT- 2025/08/27 10:15 PHST- 2025/05/06 00:00 [received] PHST- 2025/07/14 00:00 [revised] PHST- 2025/07/21 00:00 [accepted] PHST- 2025/08/28 20:52 [medline] PHST- 2025/08/28 20:51 [pubmed] PHST- 2025/08/27 10:15 [entrez] PHST- 2025/08/01 00:00 [pmc-release] AID - jpm15080341 [pii] AID - jpm-15-00341 [pii] AID - 10.3390/jpm15080341 [doi] PST - epublish SO - J Pers Med. 2025 Aug 1;15(8):341. doi: 10.3390/jpm15080341. PMID- 40863399 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250914 LR - 20250914 IS - 2075-4426 (Print) IS - 2075-4426 (Electronic) IS - 2075-4426 (Linking) VI - 15 IP - 8 DP - 2025 Aug 1 TI - Individualized Selection of Valve Intervention Strategies in Aortic Disease Is Key for Better Outcomes. LID - 10.3390/jpm15080337 [doi] LID - 337 AB - Aortic valve diseases affect a significant percentage of the population, and with the extension of survival expectancy, they are expected to increase furthermore. Surgical treatment of aortic valve diseases mainly includes valve replacement and, rarely, its repair. The technology of both surgical and transcatheter valves is evolving, and new prosthetic valves with improved characteristics are available, e.g., longer lifespan, faster implantation, better hemodynamic performance with better effective orifice area, suitable for small aortic annuli, etc. Minimally invasive surgical techniques are constantly evolving and spreading. New access sites are used for transcatheter valve implantation. The Heart Team determines the most appropriate intervention for each patient based on their anatomical and clinical profiles, aiming to optimize long-term outcomes. FAU - Androutsopoulou, Vasiliki AU - Androutsopoulou V AUID- ORCID: 0009-0005-2445-0879 AD - Department of Cardiothoracic Surgery, University Hospital of Larissa, 41110 Larissa, Greece. FAU - Zotos, Prokopis-Andreas AU - Zotos PA AD - Department of Cardiothoracic Surgery, University Hospital of Larissa, 41110 Larissa, Greece. FAU - Xanthopoulos, Andrew AU - Xanthopoulos A AUID- ORCID: 0000-0002-9439-3946 AD - Department of Cardiology, University Hospital of Larissa, 41110 Larissa, Greece. FAU - Boultadakis, Evangelos AU - Boultadakis E AUID- ORCID: 0000-0002-2227-4657 AD - Department of Cardiothoracic Surgery, University Hospital of Larissa, 41110 Larissa, Greece. FAU - Magouliotis, Dimitrios AU - Magouliotis D AUID- ORCID: 0000-0001-5417-6392 AD - Department of Cardiac Surgery Research, Lankenau Institute for Medical Research, Wynnewood, PA 19096, USA. FAU - Schizas, Nikolaos AU - Schizas N AUID- ORCID: 0000-0002-3523-4881 AD - 4th Cardiac Surgery Department, Hygeia Hospital, 15123 Athens, Greece. FAU - Iliopoulos, Dimitrios C AU - Iliopoulos DC AD - 4th Cardiac Surgery Department, Hygeia Hospital, 15123 Athens, Greece. FAU - Skoularigis, John AU - Skoularigis J AUID- ORCID: 0000-0001-7159-2478 AD - Department of Cardiology, University Hospital of Larissa, 41110 Larissa, Greece. FAU - Athanasiou, Thanos AU - Athanasiou T AD - Department of Cardiothoracic Surgery, University Hospital of Larissa, 41110 Larissa, Greece. LA - eng PT - Journal Article PT - Review DEP - 20250801 PL - Switzerland TA - J Pers Med JT - Journal of personalized medicine JID - 101602269 PMC - PMC12387331 OTO - NOTNLM OT - aortic valve disease OT - aortic valve replacement OT - bio prosthesis OT - mechanical prosthesis OT - transcatheter valve OT - valve intervention COIS- The authors declare no conflicts of interest. EDAT- 2025/08/28 20:50 MHDA- 2025/08/28 20:51 PMCR- 2025/08/01 CRDT- 2025/08/27 10:15 PHST- 2025/06/08 00:00 [received] PHST- 2025/07/16 00:00 [revised] PHST- 2025/07/29 00:00 [accepted] PHST- 2025/08/28 20:51 [medline] PHST- 2025/08/28 20:50 [pubmed] PHST- 2025/08/27 10:15 [entrez] PHST- 2025/08/01 00:00 [pmc-release] AID - jpm15080337 [pii] AID - jpm-15-00337 [pii] AID - 10.3390/jpm15080337 [doi] PST - epublish SO - J Pers Med. 2025 Aug 1;15(8):337. doi: 10.3390/jpm15080337. PMID- 40863383 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250914 LR - 20250914 IS - 2308-3425 (Electronic) IS - 2308-3425 (Linking) VI - 12 IP - 8 DP - 2025 Aug 19 TI - Blood Pressure Variability in Hypertension: A Rehabilitation Perspective. LID - 10.3390/jcdd12080317 [doi] LID - 317 AB - The role of blood pressure variability (BPV) as an important marker of cardiovascular (CV) health, specifically its relationship with arterial stiffness and left ventricular remodeling in patients with hypertension, was investigated. This review aimed to elucidate the intricate relationship between BPV, arterial stiffness, and cardiac remodeling. BPV, as both a risk factor and a target of treatment, was also evaluated. The results point to the pivotal role of BPV in cardiovascular events, serving as an independent factor contributing to arterial stiffness and adverse left ventricular remodeling. The article concludes that BPV is a modifiable risk factor and that there is a need for an intervention in specific regions. BPV is a therapy target that is significant in the treatment of hypertension. The optimization of risk and prevention needs a multidisciplinary approach involving rehabilitation therapy, which will improve cardiovascular conditions and patient outcomes. FAU - Raju, Manikandan AU - Raju M AUID- ORCID: 0000-0002-0679-6789 AD - Department of Neurorehabilitation Sciences, Casa-di-Cura Igea, 20144 Milan, Italy. AD - Department of Human Neuroscience, Sapienza University of Rome, 00185 Rome, Italy. FAU - Perrone, Marco Alfonso AU - Perrone MA AUID- ORCID: 0000-0002-0511-2621 AD - Department of Clinical Sciences and Translational Medicine, University of Rome Tor Vergata, 00133 Rome, Italy. FAU - Alashram, Anas R AU - Alashram AR AUID- ORCID: 0000-0002-3066-3943 AD - Department of Physiotherapy, Middle East University, Amman 11831, Jordan. FAU - Iellamo, Ferdinando AU - Iellamo F AUID- ORCID: 0000-0001-8421-5065 AD - Department of Clinical Sciences and Translational Medicine, University of Rome Tor Vergata, 00133 Rome, Italy. LA - eng PT - Journal Article PT - Review DEP - 20250819 PL - Switzerland TA - J Cardiovasc Dev Dis JT - Journal of cardiovascular development and disease JID - 101651414 PMC - PMC12386972 OTO - NOTNLM OT - blood pressure variability OT - hypertension OT - rehabilitation COIS- The authors declare no conflicts of interest. EDAT- 2025/08/28 20:47 MHDA- 2025/08/28 20:48 PMCR- 2025/08/19 CRDT- 2025/08/27 10:15 PHST- 2025/06/24 00:00 [received] PHST- 2025/08/08 00:00 [revised] PHST- 2025/08/12 00:00 [accepted] PHST- 2025/08/28 20:48 [medline] PHST- 2025/08/28 20:47 [pubmed] PHST- 2025/08/27 10:15 [entrez] PHST- 2025/08/19 00:00 [pmc-release] AID - jcdd12080317 [pii] AID - jcdd-12-00317 [pii] AID - 10.3390/jcdd12080317 [doi] PST - epublish SO - J Cardiovasc Dev Dis. 2025 Aug 19;12(8):317. doi: 10.3390/jcdd12080317. PMID- 40863355 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250914 LR - 20250914 IS - 2308-3425 (Electronic) IS - 2308-3425 (Linking) VI - 12 IP - 8 DP - 2025 Jul 29 TI - Minimally Invasive Surgical Strategies for the Treatment of Atrial Fibrillation: An Evolving Role in Contemporary Cardiac Surgery. LID - 10.3390/jcdd12080289 [doi] LID - 289 AB - Atrial fibrillation remains the most frequent sustained arrhythmia, particularly in the elderly population, and is associated with increased risks of stroke, heart failure, and reduced quality of life. While catheter ablation is widely used for rhythm control, its efficacy is limited in persistent and long-standing atrial fibrillation. Over the past two decades, minimally invasive surgical strategies have emerged as effective alternatives, aiming to replicate the success of the Cox-Maze procedure while reducing surgical trauma. This overview critically summarizes the current minimally invasive techniques available for atrial fibrillation treatment, including mini-thoracotomy ablation, thoracoscopic ablation, and hybrid procedures such as the convergent approach. These methods offer the potential for durable sinus rhythm restoration by enabling direct visualization, transmural lesion creation, and left atrial appendage exclusion, with lower perioperative morbidity compared to traditional open surgery. The choice of energy source plays a key role in lesion efficacy and safety. Particular attention is given to the technical steps of each procedure, patient selection criteria, and the role of left atrial appendage closure in stroke prevention. Hybrid strategies, which combine epicardial surgical ablation with endocardial catheter-based procedures, have shown encouraging outcomes in patients with refractory or long-standing atrial fibrillation. Despite the steep learning curve, minimally invasive techniques provide significant benefits in terms of recovery time, reduced hospital stay, and fewer complications. As evidence continues to evolve, these approaches represent a key advancement in the surgical management of atrial fibrillation, deserving integration into contemporary treatment algorithms and multidisciplinary heart team planning. FAU - Benvegnu, Luciana AU - Benvegnu L AD - Cardiac Surgery Unit, Ospedale Santa Chiara di Trento, 38122 Trento, Italy. FAU - Cibin, Giorgia AU - Cibin G AUID- ORCID: 0000-0002-2584-2613 AD - Cardiac Surgery Unit, Azienda Ospedale, Universita di Padova, 35122 Padova, Italy. FAU - Perrone, Fabiola AU - Perrone F AUID- ORCID: 0009-0005-8290-9406 AD - Cardiac Surgery Unit, Azienda Ospedaliera Integrata Verona, 37126 Verona, Italy. FAU - Tarzia, Vincenzo AU - Tarzia V AD - Cardiac Surgery Unit, Azienda Ospedale, Universita di Padova, 35122 Padova, Italy. FAU - D'Onofrio, Augusto AU - D'Onofrio A AUID- ORCID: 0000-0002-9835-9091 AD - Cardiac Surgery Unit, University of Rome "Tor Vergata", 00133 Rome, Italy. FAU - Luciani, Giovanni Battista AU - Luciani GB AUID- ORCID: 0000-0003-0931-018X AD - Cardiac Surgery Unit, Azienda Ospedaliera Integrata Verona, 37126 Verona, Italy. FAU - Gerosa, Gino AU - Gerosa G AUID- ORCID: 0000-0002-6261-699X AD - Cardiac Surgery Unit, Azienda Ospedale, Universita di Padova, 35122 Padova, Italy. FAU - Onorati, Francesco AU - Onorati F AUID- ORCID: 0000-0002-0879-3557 AD - Cardiac Surgery Unit, Ospedale Santa Chiara di Trento, 38122 Trento, Italy. LA - eng PT - Journal Article PT - Review DEP - 20250729 PL - Switzerland TA - J Cardiovasc Dev Dis JT - Journal of cardiovascular development and disease JID - 101651414 PMC - PMC12386810 OTO - NOTNLM OT - atrial fibrillation ablation OT - minimally invasive surgery OT - surgical rhythm control COIS- The authors declare no conflicts of interest. EDAT- 2025/08/28 20:50 MHDA- 2025/08/28 20:51 PMCR- 2025/07/29 CRDT- 2025/08/27 10:15 PHST- 2025/05/31 00:00 [received] PHST- 2025/07/17 00:00 [revised] PHST- 2025/07/28 00:00 [accepted] PHST- 2025/08/28 20:51 [medline] PHST- 2025/08/28 20:50 [pubmed] PHST- 2025/08/27 10:15 [entrez] PHST- 2025/07/29 00:00 [pmc-release] AID - jcdd12080289 [pii] AID - jcdd-12-00289 [pii] AID - 10.3390/jcdd12080289 [doi] PST - epublish SO - J Cardiovasc Dev Dis. 2025 Jul 29;12(8):289. doi: 10.3390/jcdd12080289. PMID- 40863098 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250914 LR - 20250914 IS - 2039-7275 (Print) IS - 2039-7283 (Electronic) IS - 2039-7275 (Linking) VI - 15 IP - 8 DP - 2025 Aug 6 TI - Minimally Invasive Off-Pump Coronary Artery Bypass as Palliative Revascularization in High-Risk Patients. LID - 10.3390/clinpract15080147 [doi] LID - 147 AB - Background: In high-risk and frail patients with multivessel coronary artery disease (MV CAD), guidelines indicated complete revascularization with or without the use of cardiopulmonary bypass (CPB) bears a high morbidity and mortality risk. In cases where catheter interventions were deemed unsuitable and conventional coronary artery bypass grafting (CABG) posed an unacceptable perioperative risk, patients were scheduled for minimally invasive direct coronary artery bypass (MIDCAB) grafting or minimally invasive multivessel coronary artery bypass grafting (MICS-CABG). We called this approach "palliative revascularization." This study assesses the safety and impact of palliative revascularization on clinical outcomes and overall survival. Methods: A consecutive series of 57 patients undergoing MIDCAB or MICS-CABG as a palliative surgery between 2008 and 2018 was included. The decision for palliative surgery was met in heart team after carefully assessing each case. The patients underwent single or double-vessel revascularization using the left internal thoracic artery and rarely radial artery/saphenous vein segments, both endoscopically harvested. Inpatient data could be completed for all 57 patients. The mean follow-up interval was 4.2 +/- 3.7 years, with a follow-up rate of 91.2%. Results: Mean patient age was 79.7 +/- 7.4 years. Overall, 46 patients (80.7%) were male, 26 (45.6%) had a history of atrial fibrillation and 25 (43.9%) of chronic kidney disease. In total, 13 patients exhibited a moderate EuroSCORE II, while 27 were classified as high risk, with a EuroSCORE II exceeding 5%. Additionally, 40 patients (70.2%) presented with three-vessel disease, 17 (29.8%) suffered an acute myocardial infarction within three weeks prior to surgery and 50.9% presented an impaired ejection fraction. There were 48 MIDCAB and nine MICS CABG with no conversions either to sternotomy or to CPB. Eight cases were planned as hybrid procedures and only 15 patients (26.3%) were completely revascularized. During the first 30 days, four patients (7%) died. A myocardial infarction occurred in only one case, no patient necessitated immediate reoperation. The one-, three- and five-year survival rates were 83%, 67% and 61%, respectively. Conclusions: MIDCAB and MICS CABG can be successfully conducted as less invasive palliative surgery in high-risk multimorbid patients with MV CAD. The early and mid-term results were better than predicted. A higher rate of hybrid procedures could improve long-term outcome in selected cases. FAU - Rufa, Magdalena AU - Rufa M AUID- ORCID: 0000-0003-0395-9834 AD - Department of Cardiovascular Surgery, Robert Bosch Hospital, 70376 Stuttgart, Germany. FAU - Ursulescu, Adrian AU - Ursulescu A AD - Department of Cardiovascular Surgery, Robert Bosch Hospital, 70376 Stuttgart, Germany. FAU - Ahad, Samir AU - Ahad S AD - Department of Cardiovascular Surgery, Robert Bosch Hospital, 70376 Stuttgart, Germany. FAU - Nagib, Ragi AU - Nagib R AD - Department of Cardiovascular Surgery, Robert Bosch Hospital, 70376 Stuttgart, Germany. FAU - Albert, Marc AU - Albert M AD - Department of Cardiovascular Surgery, Robert Bosch Hospital, 70376 Stuttgart, Germany. FAU - Ayala, Rafael AU - Ayala R AUID- ORCID: 0000-0002-3104-6816 AD - Department of Cardiovascular Surgery, Robert Bosch Hospital, 70376 Stuttgart, Germany. FAU - Gobel, Nora AU - Gobel N AUID- ORCID: 0000-0002-7692-3480 AD - Department of Cardiovascular Surgery, Robert Bosch Hospital, 70376 Stuttgart, Germany. FAU - Shavahatli, Tunjay AU - Shavahatli T AD - Department of Cardiovascular Surgery, Robert Bosch Hospital, 70376 Stuttgart, Germany. FAU - Ghinescu, Mihnea AU - Ghinescu M AD - Department of Cardiovascular Surgery, Robert Bosch Hospital, 70376 Stuttgart, Germany. FAU - Franke, Ulrich AU - Franke U AD - Department of Cardiovascular Surgery, University Heart Centre Freiburg Bad Krozingen, 79189 Freiburg, Germany. FAU - Rylski, Bartosz AU - Rylski B AUID- ORCID: 0000-0001-6890-2172 AD - Department of Cardiovascular Surgery, Robert Bosch Hospital, 70376 Stuttgart, Germany. LA - eng PT - Journal Article DEP - 20250806 PL - Switzerland TA - Clin Pract JT - Clinics and practice JID - 101563282 PMC - PMC12384423 OTO - NOTNLM OT - coronary artery bypass grafting (CABG) OT - coronary artery disease (CAD) OT - minimally invasive direct coronary artery bypass (MIDCAB) OT - minimally invasive multivessel coronary artery bypass grafting (MICS CABG) OT - multivessel coronary artery disease (MV CAD) OT - palliative therapy COIS- The authors declare no conflicts of interest. EDAT- 2025/08/28 04:51 MHDA- 2025/08/28 04:52 PMCR- 2025/08/06 CRDT- 2025/08/27 10:05 PHST- 2025/05/08 00:00 [received] PHST- 2025/06/19 00:00 [revised] PHST- 2025/08/03 00:00 [accepted] PHST- 2025/08/28 04:52 [medline] PHST- 2025/08/28 04:51 [pubmed] PHST- 2025/08/27 10:05 [entrez] PHST- 2025/08/06 00:00 [pmc-release] AID - clinpract15080147 [pii] AID - clinpract-15-00147 [pii] AID - 10.3390/clinpract15080147 [doi] PST - epublish SO - Clin Pract. 2025 Aug 6;15(8):147. doi: 10.3390/clinpract15080147. PMID- 40855573 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250914 LR - 20250914 IS - 2586-7296 (Electronic) IS - 2586-7210 (Print) VI - 33 IP - 1 DP - 2025 Aug 25 TI - Atrial fibrillation and thromboembolic risk in hypertrophic cardiomyopathy. PG - 12 LID - 10.1186/s44348-025-00057-2 [doi] LID - 12 AB - Atrial fibrillation (AF) is the most common sustained arrhythmia in patients with hypertrophic cardiomyopathy (HCM), conferring a markedly increased risk of thromboembolic events. Conventional risk stratification tools such as the CHA(2)DS(2)-VASc (congestive heart failure, hypertension, age >/= 75 years [doubled], diabetes mellitus, prior stroke or transient ischemic attack [doubled], vascular disease, age 65-74 years, female sex) score are often insufficient to predict thromboembolic events in patients with HCM and AF, as thromboembolic risk in HCM is driven by disease-specific structural, functional, and prothrombotic substrates. This review synthesizes current evidence on the epidemiology, pathophysiological mechanisms, and clinical impact of AF and thromboembolism in HCM. We discuss variable imaging modalities-including strain echocardiography, cardiac magnetic resonance, and cardiac computed tomography-that offer enhanced characterization of atrial remodeling and thromboembolic risk in patients with HCM. Furthermore, we outline current guideline-based anticoagulation strategies, the evolving role of direct oral anticoagulants, and adjunctive therapies such as left atrial appendage occlusion and catheter ablation. A comprehensive, multidisciplinary approach that incorporates advanced imaging, molecular profiling, and individualized management is ideal to optimize outcomes and reduce stroke burden in patients with HCM and AF. CI - (c) 2025. The Author(s). FAU - Choi, You-Jung AU - Choi YJ AD - Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea. flyiing48@gmail.com. AD - Department of Genetics, Harvard Medical School, Boston, MA, USA. flyiing48@gmail.com. FAU - Lakdawala, Neal K AU - Lakdawala NK AD - Department of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. LA - eng PT - Journal Article PT - Review DEP - 20250825 PL - England TA - J Cardiovasc Imaging JT - Journal of cardiovascular imaging JID - 101728106 PMC - PMC12376757 OTO - NOTNLM OT - Arrhythmias OT - Cardiac OT - Cardiomyopathies OT - Ischemic stroke COIS- Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2025/08/28 04:47 MHDA- 2025/08/28 04:48 PMCR- 2025/08/25 CRDT- 2025/08/26 00:45 PHST- 2025/06/20 00:00 [received] PHST- 2025/07/23 00:00 [accepted] PHST- 2025/08/28 04:48 [medline] PHST- 2025/08/28 04:47 [pubmed] PHST- 2025/08/26 00:45 [entrez] PHST- 2025/08/25 00:00 [pmc-release] AID - 10.1186/s44348-025-00057-2 [pii] AID - 57 [pii] AID - 10.1186/s44348-025-00057-2 [doi] PST - epublish SO - J Cardiovasc Imaging. 2025 Aug 25;33(1):12. doi: 10.1186/s44348-025-00057-2. PMID- 40860752 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250914 LR - 20250914 IS - 1179-1535 (Print) IS - 1179-1535 (Electronic) IS - 1179-1535 (Linking) VI - 17 DP - 2025 TI - MAFLD: A Comprehensive Review of the Link Between Metabolic Dysfunction and Cardiovascular Risk. PG - 75-90 LID - 10.2147/HMER.S506402 [doi] AB - Metabolic dysfunction-associated fatty liver disease (MAFLD) affects over 30% of the global population. It is a multisystem condition with a strong association with cardiovascular disease (CVD), the leading cause of mortality worldwide. Key shared mechanisms, including insulin resistance, systemic inflammation, oxidative stress, and genetic predisposition, couple MAFLD with increased risks of coronary artery disease, ischemic heart disease, and heart failure. Early detection via non-invasive imaging and biomarkers is crucial for effective risk stratification. Management strategies emphasize lifestyle modifications and the development of targeted pharmacotherapies addressing metabolic and inflammatory pathways. Understanding the interconnected pathogenic mechanisms facilitates personalized interventions to reduce morbidity and improve long-term outcomes. A multidisciplinary approach remains essential to prevent and manage the cardiovascular implications of MAFLD. CI - (c) 2025 Mostafa et al. FAU - Mostafa, Alaa M AU - Mostafa AM AD - Department of Gastroenterology, Hepatology and Endemic Medicine, Faculty of Medicine, Minia University, Minia, Egypt. FAU - Pan, Ziyan AU - Pan Z AD - Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Sydney, NSW, Australia. FAU - Yu, Ming-Lung AU - Yu ML AUID- ORCID: 0000-0001-8145-1900 AD - School of Medicine, College of Medicine and Center of Excellence for Metabolic Associated Fatty Liver Disease, National Sun Yat-sen University, Kaohsiung, Taiwan. AD - Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital; College of Medicine and Center of Metabolic Disorders and Obesity, Kaohsiung Medical University, Kaohsiung, Taiwan. FAU - Ormeci, Necati AU - Ormeci N AD - Department of Internal Medicine, Istanbul Health and Technology University, Istanbul, Turkiye. FAU - Fouad, Yasser AU - Fouad Y AD - Department of Gastroenterology, Hepatology and Endemic Medicine, Faculty of Medicine, Minia University, Minia, Egypt. FAU - Eslam, Mohammed AU - Eslam M AUID- ORCID: 0000-0002-4315-4144 AD - Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Sydney, NSW, Australia. LA - eng PT - Journal Article PT - Review DEP - 20250819 PL - New Zealand TA - Hepat Med JT - Hepatic medicine : evidence and research JID - 101544801 PMC - PMC12374717 OTO - NOTNLM OT - cardiometabolic risk OT - fatty liver OT - metabolic dysfunction OT - pharmacotherapy COIS- Professor Ming-Lung Yu reports grants from Abbvie, Abbott Diagnostic, BMS, Gilead, Merck, Novo Nordisc and Roche diagnostics, other from Abbvie, Abbott Diagnostic, BMS, Gilead, Novo Nordisc, Roche and Roche diagnostics, other from Abbvie, BMS, Eisai, Gilead, Roche and Roche diagnostics, outside the submitted work. The authors report no other conflicts of interest. EDAT- 2025/08/27 20:46 MHDA- 2025/08/27 20:47 PMCR- 2025/08/19 CRDT- 2025/08/27 06:32 PHST- 2025/06/03 00:00 [received] PHST- 2025/08/12 00:00 [accepted] PHST- 2025/08/27 20:47 [medline] PHST- 2025/08/27 20:46 [pubmed] PHST- 2025/08/27 06:32 [entrez] PHST- 2025/08/19 00:00 [pmc-release] AID - 506402 [pii] AID - 10.2147/HMER.S506402 [doi] PST - epublish SO - Hepat Med. 2025 Aug 19;17:75-90. doi: 10.2147/HMER.S506402. eCollection 2025. PMID- 40860394 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250914 LR - 20260902 IS - 0970-9134 (Print) IS - 0973-7723 (Electronic) IS - 0970-9134 (Linking) VI - 41 IP - 9 DP - 2025 Sep TI - Surgical management of coronary stent infections: an institutional experience with 18 patients and analysis of long-term outcomes. PG - 1153-1164 LID - 10.1007/s12055-025-01897-9 [doi] AB - Coronary stent infection (CSI) is a rare but serious complication following percutaneous coronary intervention, and is associated with significant morbidity and mortality. This report presents a 6-year institutional experience involving 18 patients who underwent surgical management for CSI. The patients, predominantly male (94.12%), ranged from 31 to 80 years old, with the majority presenting with fever, chest pain, and other symptoms, often leading to delayed diagnosis. Infections were primarily caused by Pseudomonas aeruginosa, Staphylococcus aureus, and non-tuberculous mycobacteria, with six cases yielding no pathogen on blood/tissue cultures. Surgical intervention involved stent removal, coronary artery ligation, and revascularization, when feasible. Sixteen patients underwent complete revascularization using on-pump techniques. Despite the complexity of these cases, there was no mortality during the minimum 6-month follow-up, and patients remained in New York Heart Association (NYHA) class I/II. This report underscores the critical importance of early- and late-onset recognition and multidisciplinary approach to managing CSI, emphasizing the need for high clinical suspicion in patients presenting with unexplained fever following stent placement. Strict adherence to sterilization practices in catheterization laboratories is crucial for preventing these infections. Successful outcomes can be achieved with timely surgical intervention and comprehensive perioperative care, highlighting the necessity of coordinated effort among cardiothoracic surgeons, cardiologists, infectious disease specialists, microbiologists, and radiologists. CI - (c) Indian Association of Cardiovascular-Thoracic Surgeons 2025, corrected publication 2025. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. FAU - Shah, Dhiren AU - Shah D AD - Department of Cardiac Surgery, Marengo CIMS Hospital, Ahmedabad, India. ROR: https://ror.org/00yqqsx19. GRID: grid.488743.4. ISNI: 0000 0004 8340 2274 FAU - Gupta, Kishore AU - Gupta K AUID- ORCID: 0000-0002-5596-8102 AD - Department of Cardiac Surgery, Marengo CIMS Hospital, Ahmedabad, India. ROR: https://ror.org/00yqqsx19. GRID: grid.488743.4. ISNI: 0000 0004 8340 2274 AD - Marengo CIMS Hospital, Science City Road, Ahmedabad, 380060 India. ROR: https://ror.org/00yqqsx19. GRID: grid.488743.4. ISNI: 0000 0004 8340 2274 FAU - Madan, Surabhi AU - Madan S AD - Department of Medicine, Marengo CIMS Hospital, Ahmedabad, India. ROR: https://ror.org/00yqqsx19. GRID: grid.488743.4. ISNI: 0000 0004 8340 2274 FAU - Gupta, Satya AU - Gupta S AD - Department of Intervention Cardiology, Marengo CIMS Hospital, Ahmedabad, India. ROR: https://ror.org/00yqqsx19. GRID: grid.488743.4. ISNI: 0000 0004 8340 2274 FAU - Naik, Dhaval AU - Naik D AD - Department of Cardiac Surgery, Marengo CIMS Hospital, Ahmedabad, India. ROR: https://ror.org/00yqqsx19. GRID: grid.488743.4. ISNI: 0000 0004 8340 2274 FAU - Shah, Deepa AU - Shah D AD - Department of Radiology, Marengo CIMS Hospital, Ahmedabad, India. ROR: https://ror.org/00yqqsx19. GRID: grid.488743.4. ISNI: 0000 0004 8340 2274 FAU - Sheth, Chintan AU - Sheth C AD - Department of Cardiac Anaesthesia, Marengo CIMS Hospital, Ahmedabad, India. ROR: https://ror.org/00yqqsx19. GRID: grid.488743.4. ISNI: 0000 0004 8340 2274 FAU - Bhavsar, Niren AU - Bhavsar N AD - Department of Cardiac Anaesthesia, Marengo CIMS Hospital, Ahmedabad, India. ROR: https://ror.org/00yqqsx19. GRID: grid.488743.4. ISNI: 0000 0004 8340 2274 LA - eng PT - Journal Article DEP - 20250215 PL - India TA - Indian J Thorac Cardiovasc Surg JT - Indian journal of thoracic and cardiovascular surgery JID - 8700105 EIN - Indian J Thorac Cardiovasc Surg. 2025 Sep;41(9):1268-1269. doi: 10.1007/s12055-025-02047-x. PMID: 40860412 PMC - PMC12373583 OTO - NOTNLM OT - Coronary stent infection OT - Percutaneous coronary intervention OT - Surgical intervention COIS- Conflict of interestNot applicable. EDAT- 2025/08/27 20:46 MHDA- 2025/08/27 20:47 PMCR- 2026/09/01 CRDT- 2025/08/27 06:29 PHST- 2024/09/19 00:00 [received] PHST- 2025/01/02 00:00 [revised] PHST- 2025/01/02 00:00 [accepted] PHST- 2025/08/27 20:47 [medline] PHST- 2025/08/27 20:46 [pubmed] PHST- 2025/08/27 06:29 [entrez] PHST- 2026/09/01 00:00 [pmc-release] AID - 1897 [pii] AID - 10.1007/s12055-025-01897-9 [doi] PST - ppublish SO - Indian J Thorac Cardiovasc Surg. 2025 Sep;41(9):1153-1164. doi: 10.1007/s12055-025-01897-9. Epub 2025 Feb 15. PMID- 40859740 OWN - NLM STAT- MEDLINE DCOM- 20250909 LR - 20250909 IS - 1467-1107 (Electronic) IS - 1047-9511 (Linking) VI - 35 IP - 8 DP - 2025 Aug TI - Revived role of reverse Potts shunt in management of paediatric severe pulmonary hypertension. PG - 1567-1576 LID - 10.1017/S1047951125101352 [doi] AB - Pulmonary artery hypertension in children is a progressive, fatal disease secondary to a variety of causes leading to right ventricular dysfunction. Traditional treatments include lung transplantation (LTx) and targeted therapy. However, due to the shortage of donor sources, heavy medical economic burden, immune rejection, and other problems, many patients are discouraged. In the past 20 years, the Potts palliative shunt, which was initially used for the treatment of cyanotic heart disease, has been gradually revived. Studies have shown that reverse Potts shunt can improve postoperative cardiac function, delay lung transplantation, and improve long-term quality of life in children with severe pulmonary arterial hypertension, which is a feasible and effective alternative to LTx. The surgical procedure is relatively less complex, so it is worth promoting in resource-poor countries, and limited medical expertise. In the future, with refinements of the reverse Potts shunt (unidirectional-valved shunt and transcatheter Potts shunt) and formulation of guidelines (shunt sizes, involvement of multidisciplinary team), there is expected to be further expansion of indications. This article reviews the physiological mechanisms, past and present status of reverse Potts shunt indications and contraindications, surgical procedures, benefits, future application prospects, and key unsolved problems of reverse Potts shunt in the treatment of severe pulmonary arterial hypertension in children. FAU - Wang, Zhangwei AU - Wang Z AUID- ORCID: 0000-0002-1256-3981 AD - Department of Cardiovascular Surgery, Chinese Academy of Medical Sciences and Peking Union Medical College, National Center for Cardiovascular Diseases, Fuwai Hospital, Beijing, China. FAU - Fu, Honghao AU - Fu H AD - Department of Cardiovascular Surgery, Chinese Academy of Medical Sciences and Peking Union Medical College, National Center for Cardiovascular Diseases, Fuwai Hospital, Beijing, China. FAU - Li, Shoujun AU - Li S AD - Department of Cardiovascular Surgery, Chinese Academy of Medical Sciences and Peking Union Medical College, National Center for Cardiovascular Diseases, Fuwai Hospital, Beijing, China. LA - eng PT - Journal Article PT - Review DEP - 20250827 PL - England TA - Cardiol Young JT - Cardiology in the young JID - 9200019 SB - IM MH - Humans MH - Child MH - *Hypertension, Pulmonary/surgery/physiopathology MH - *Pulmonary Artery/surgery MH - Quality of Life OTO - NOTNLM OT - prognosis OT - pulmonary artery hypertension OT - reverse Potts shunt OT - right heart failure EDAT- 2025/08/27 08:45 MHDA- 2025/09/10 00:28 CRDT- 2025/08/27 03:33 PHST- 2025/09/10 00:28 [medline] PHST- 2025/08/27 08:45 [pubmed] PHST- 2025/08/27 03:33 [entrez] AID - S1047951125101352 [pii] AID - 10.1017/S1047951125101352 [doi] PST - ppublish SO - Cardiol Young. 2025 Aug;35(8):1567-1576. doi: 10.1017/S1047951125101352. Epub 2025 Aug 27. PMID- 40859438 OWN - NLM STAT- MEDLINE DCOM- 20250827 LR - 20250827 IS - 0386-300X (Print) IS - 0386-300X (Linking) VI - 79 IP - 4 DP - 2025 Aug TI - Organ Donation after Extracorporeal Cardiopulmonary Resuscitation: Clinical and Ethical Perspectives. PG - 221-229 LID - 10.18926/AMO/69147 [doi] AB - Extracorporeal cardiopulmonary resuscitation (ECPR) has evolved into a life-saving therapy for select cardiac arrest patients, yet a growing body of evidence suggests it also holds promise as a bridge to organ donation in non-survivors. This review explores the clinical outcomes, ethical complexities, and evolving policies surrounding organ donation after ECPR. We summarize recent international and Japanese data demonstrating favorable graft function from ECPR donors, with the exception of lung transplantation. The ethical challenges - particularly those involving brain death determination on extracorporeal membrane oxygenation and adherence to the dead donor rule - are discussed in the context of Japan's recent regulatory reforms. Additionally, we highlight the importance of structured end-of-life communication through multidisciplinary team meetings in facilitating ethically sound transitions from rescue efforts to donation pathways. Moving forward, improvements in donor management, standardized legal frameworks, and public and professional education are essential to optimizing the life-saving and life-giving potential of ECPR. FAU - Yumoto, Tetsuya AU - Yumoto T AD - Department of Emergency, Critical Care and Disaster Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University. FAU - Naito, Hiromichi AU - Naito H AD - Department of Emergency, Critical Care and Disaster Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University. FAU - Hongo, Takashi AU - Hongo T AD - Department of Emergency, Critical Care and Disaster Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University. FAU - Obara, Takafumi AU - Obara T AD - Department of Emergency, Critical Care and Disaster Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University. FAU - Kosaki, Yoshinori AU - Kosaki Y AD - Department of Emergency, Critical Care and Disaster Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University. FAU - Ageta, Kohei AU - Ageta K AD - Department of Emergency, Critical Care and Disaster Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University. FAU - Nojima, Tsuyoshi AU - Nojima T AD - Department of Emergency, Critical Care and Disaster Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University. FAU - Tsukahara, Kohei AU - Tsukahara K AD - Department of Emergency, Critical Care and Disaster Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University. FAU - Nakao, Atsunori AU - Nakao A AD - Department of Emergency, Critical Care and Disaster Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University. LA - eng PT - Journal Article PT - Review PL - Japan TA - Acta Med Okayama JT - Acta medica Okayama JID - 0417611 SB - IM MH - Humans MH - *Tissue and Organ Procurement/ethics/legislation & jurisprudence MH - *Extracorporeal Membrane Oxygenation/ethics MH - *Cardiopulmonary Resuscitation/ethics MH - Brain Death MH - Tissue Donors/ethics OTO - NOTNLM OT - brain death OT - end-of-life care OT - ethical dilemmas OT - extracorporeal cardiopulmonary resuscitation COIS- No potential conflict of interest relevant to this article was reported. EDAT- 2025/08/27 08:45 MHDA- 2025/08/27 08:46 CRDT- 2025/08/27 00:32 PHST- 2025/08/27 08:46 [medline] PHST- 2025/08/27 08:45 [pubmed] PHST- 2025/08/27 00:32 [entrez] AID - 10.18926/AMO/69147 [doi] PST - ppublish SO - Acta Med Okayama. 2025 Aug;79(4):221-229. doi: 10.18926/AMO/69147. PMID- 40843857 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250914 LR - 20250914 IS - 2305-6320 (Print) IS - 2305-6320 (Electronic) IS - 2305-6320 (Linking) VI - 12 IP - 3 DP - 2025 Jul 28 TI - Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies. LID - 10.3390/medicines12030019 [doi] LID - 19 AB - Obesity is a growing global health concern with widespread impacts on physical, psychological, and social well-being. Clinically, it is a major driver of type 2 diabetes (T2D), cardiovascular disease (CVD), non-alcoholic fatty liver disease (NAFLD), and cancer, reducing life expectancy by 5-20 years and imposing a staggering economic burden of USD 2 trillion annually (2.8% of global GDP). Despite its significant health and socioeconomic impact, earlier obesity medications, such as fenfluramine, sibutramine, and orlistat, fell short of expectations due to limited effectiveness, serious side effects including valvular heart disease and gastrointestinal issues, and high rates of treatment discontinuation. The advent of glucagon-like peptide-1 (GLP-1) receptor agonists (e.g., semaglutide, tirzepatide) has revolutionized obesity management. These agents demonstrate unprecedented efficacy, achieving 15-25% mean weight loss in clinical trials, alongside reducing major adverse cardiovascular events by 20% and T2D incidence by 72%. Emerging therapies, including oral GLP-1 agonists and triple-receptor agonists (e.g., retatrutide), promise enhanced tolerability and muscle preservation, potentially bridging the efficacy gap with bariatric surgery. However, challenges persist. High costs, supply shortages, and unequal access pose significant barriers to the widespread implementation of obesity treatment, particularly in low-resource settings. Gastrointestinal side effects and long-term safety concerns require close monitoring, while weight regain after medication discontinuation emphasizes the need for ongoing adherence and lifestyle support. This review highlights the transformative potential of incretin-based therapies while advocating for policy reforms to address cost barriers, equitable access, and preventive strategies. Future research must prioritize long-term cardiovascular outcome trials and mitigate emerging risks, such as sarcopenia and joint degeneration. A multidisciplinary approach combining pharmacotherapy, behavioral interventions, and systemic policy changes is critical to curbing the obesity epidemic and its downstream consequences. FAU - Ullah, Mohammad Iftekhar AU - Ullah MI AD - Department of Medicine, University of Mississippi Medical Center, 2500 N State St., Jackson, MS 39216, USA. FAU - Tamanna, Sadeka AU - Tamanna S AD - Department of Medicine, University of Mississippi Medical Center, 2500 N State St., Jackson, MS 39216, USA. AD - G. V. (Sonny) Montgomery VA Medical Center, 1500 E Woodrow Wilson Ave., Jackson, MS 39216, USA. LA - eng PT - Journal Article PT - Review DEP - 20250728 PL - Switzerland TA - Medicines (Basel) JT - Medicines (Basel, Switzerland) JID - 101671069 PMC - PMC12372088 OTO - NOTNLM OT - Dual GIP/GLP-1 agonists OT - GLP-1 receptor agonists OT - emerging therapies OT - metabolic syndrome OT - obesity OT - pharmacotherapy OT - weight management COIS- The authors declare no conflicts of interest. EDAT- 2025/08/26 04:44 MHDA- 2025/08/26 04:45 PMCR- 2025/07/28 CRDT- 2025/08/22 06:45 PHST- 2025/06/02 00:00 [received] PHST- 2025/07/06 00:00 [revised] PHST- 2025/07/22 00:00 [accepted] PHST- 2025/08/26 04:45 [medline] PHST- 2025/08/26 04:44 [pubmed] PHST- 2025/08/22 06:45 [entrez] PHST- 2025/07/28 00:00 [pmc-release] AID - medicines12030019 [pii] AID - medicines-12-00019 [pii] AID - 10.3390/medicines12030019 [doi] PST - epublish SO - Medicines (Basel). 2025 Jul 28;12(3):19. doi: 10.3390/medicines12030019. PMID- 40853147 OWN - NLM STAT- Publisher LR - 20250825 IS - 1538-4683 (Electronic) IS - 1061-5377 (Linking) DP - 2025 Aug 25 TI - Stage A Cardiogenic Shock in the SCAI Classification: Limitations and Prospects for Diagnostic Improvement. LID - 10.1097/CRD.0000000000001027 [doi] AB - Cardiogenic shock (CS) remains one of the most critical challenges in emergency cardiology, associated with high mortality rates. Early recognition and prevention of its progression are pivotal, as preventing shock not only improves prognosis but also significantly reduces treatment costs compared with managing established shock. Stage A of the Society for Cardiovascular Angiography and Interventions classification demonstrates substantial clinical and prognostic heterogeneity in real-world practice. The criteria for stage A remain ambiguous: studies vary in defining "extensive myocardial infarction," overlook the impact of infarct localization, and fail to account for microvascular dysfunction and systemic inflammation in disease progression. This results in the inclusion of patients with diametrically opposed risks-from minimal to critical-limiting opportunities for preventive intervention. A key issue is the lack of specific biomarkers to identify patients at genuine risk of shock progression. Emerging evidence highlights the underappreciated roles of microcirculatory disturbances and inflammatory responses. Integrating imaging techniques and inflammatory biomarkers into CS diagnostic algorithms, as supported by recent studies, represents a promising direction. Dynamic reassessment of patient status, including continuous monitoring of lactate, hemodynamics, and organ perfusion markers, is another critical aspect. Early application of mechanical circulatory support in stages A-B reduces mortality but requires precise identification of the target population. Only a multidisciplinary approach incorporating dynamic risk stratification and precision methods can minimize inappropriate use of aggressive therapies or ensure their timely application, thereby improving outcomes in patients at risk of CS. CI - Copyright (c) 2025 Wolters Kluwer Health, Inc. All rights reserved. FAU - Dil, Stanislav AU - Dil S AD - From the Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia. FAU - Kercheva, Maria AU - Kercheva M AD - From the Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia. FAU - Belich, Nina AU - Belich N AD - From the Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia. FAU - Rumyantseva, Anastasia AU - Rumyantseva A AD - From the Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia. FAU - Krivosheev, Dmitry AU - Krivosheev D AD - From the Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia. FAU - Ryabov, Vyacheslav AU - Ryabov V AD - From the Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia. AD - Siberian State Medical University, Tomsk, Russia. LA - eng PT - Journal Article DEP - 20250825 PL - United States TA - Cardiol Rev JT - Cardiology in review JID - 9304686 SB - IM OTO - NOTNLM OT - SCAI classification OT - myocardial infarction-associated shock OT - risk prediction OT - stage A shock COIS- Disclosures: The authors have no conflicts of interest to report. EDAT- 2025/08/25 12:45 MHDA- 2025/08/25 12:45 CRDT- 2025/08/25 09:13 PHST- 2025/08/25 12:45 [medline] PHST- 2025/08/25 12:45 [pubmed] PHST- 2025/08/25 09:13 [entrez] AID - 00045415-990000000-00583 [pii] AID - 10.1097/CRD.0000000000001027 [doi] PST - aheadofprint SO - Cardiol Rev. 2025 Aug 25. doi: 10.1097/CRD.0000000000001027. PMID- 40848468 OWN - NLM STAT- MEDLINE DCOM- 20251124 LR - 20251124 IS - 2590-0412 (Electronic) IS - 2590-0412 (Linking) VI - 88 DP - 2025 Nov TI - Assessment of cardiopulmonary risk in COPD patients: Expert opinion formalized using the Delphi method. PG - 101187 LID - S2590-0412(25)00034-0 [pii] LID - 10.1016/j.resmer.2025.101187 [doi] AB - BACKGROUND: Cardiovascular (CV) comorbidities are frequent in patients with chronic obstructive pulmonary disease (COPD), increasing individual morbidity and mortality. This observation has given rise to the concept of cardiopulmonary risk. However, assessment and management of CV risk in COPD patients is highly variable in practice. Cardiologists' and pulmonologists' knowledge and understanding of cardiopulmonary risk and its assessment in COPD patients, along with the management of special situations, were analyzed using the Delphi consensus methodology. STUDY DESIGN AND METHODS: A Steering Committee of ten experts (five cardiologists and five pulmonologists) developed a questionnaire covering 73 clinical situations grouped into 31 statements. This Steering Committee recommended a panel of expert respondents with clinical experience. The Delphi consensus methodology was applied in two rounds, with 74 respondents in the first round and 68 in the second. Consensus was defined as agreement or disagreement by >75 % of respondents. RESULTS: The panel agreed that COPD patients face elevated CV risk independently of other risk factors. Consensus was reached on systematically assessing CV risk factors in COPD patients and the necessity for cardiological consultation and arterial imaging (coronary, supra-aortic trunks) if CV risk scores are high. The panel opposed routine Holter EKG use, but recommended both cardiological and pneumological investigations in cases of disproportionate dyspnea. Minor disagreements emerged between pulmonologists and cardiologists about abdominal aortic aneurysm screening, glycated hemoglobin testing, and specific CV assessments post COPD exacerbation. INTERPRETATION: This Delphi report summarizes expert cardiologist and pulmonologist perspectives on CV risk assessment in COPD patients, emphasizing the need for integrated management of respiratory and CV conditions. These findings demonstrate the importance of a multidisciplinary approach and suggest that while some practical aspects of CV assessment in COPD patients are the subject of clear consensus, other areas require further research to develop precise protocols. CI - Copyright (c) 2025. Published by Elsevier Masson SAS. FAU - Roche, Nicolas AU - Roche N AD - Service de Pneumologie, Hopital Cochin, APHP Centre and UMR 1016 Institut Cochin, Universite Paris Cite, Paris, France. Electronic address: nicolas.roche@aphp.fr. FAU - Zysman, Maeva AU - Zysman M AD - Services des Maladies Respiratoires, CHU Haut Leveque, Pessac, France / Centre de Recherche cardio-thoracique de Bordeaux, UMR 1045, Universite de Bordeaux, Pessac, France. FAU - Aboyans, Victor AU - Aboyans V AD - Service de cardiologie, CHU de Limoges / EpiMaCT, Inserm1094/IRD270, Universite de Limoges, Limoges, France. FAU - Deslee, Gaetan AU - Deslee G AD - Universite de Reims Champagne-Ardenne, INSERM, UMRS1250, Reims, France / CHU Reims, Hopital Maison Blanche, Service de Pneumologie, Reims, France. FAU - Fauchier, Laurent AU - Fauchier L AD - Service de Cardiologie, Pole Coeur Thorax Vasculaire, CHU Trousseau / Faculte de Medecine, Universite Francois Rabelais, Tours, France. FAU - Kownator, Serge AU - Kownator S AD - Centre Cardiologique et Vasculaire << coeur de Lorraine >> Thionville, France. FAU - Montalescot, Gilles AU - Montalescot G AD - ACTION Study Group, Sorbonne Universite, Institut de Cardiologie, Pitie-Salpetriere Hospital AP-HP, Paris, France. FAU - Pinet, Christophe AU - Pinet C AD - Hopital Prive de Provence, Aix en Provence, France. FAU - Lamia, Bouchra AU - Lamia B AD - Departement de Pneumologie, Groupe Hospitalier du Havre, Le Havre, France / Universite de Rouen Normandie, UNIROUEN, UR3830- GRHVN, IRIB, Rouen, France. FAU - Cohen-Solal, Alain AU - Cohen-Solal A AD - Universite Paris Cite. INSERM U942. Service de Cardiologie, Hopital Lariboisiere, AP-HP, Paris, France. CN - Respondents' group LA - eng PT - Journal Article DEP - 20250806 PL - France TA - Respir Med Res JT - Respiratory medicine and research JID - 101746324 SB - IM MH - Humans MH - *Pulmonary Disease, Chronic Obstructive/epidemiology/diagnosis/complications MH - *Delphi Technique MH - *Cardiovascular Diseases/epidemiology/diagnosis/etiology MH - Risk Assessment/methods MH - Surveys and Questionnaires MH - Consensus MH - Male MH - Female MH - Risk Factors OTO - NOTNLM OT - COPD OT - Cardiopulmonary risk OT - Cardiovascular disease OT - Delphi method OT - Multimorbidity COIS- Declaration of competing interest NR: Pfizer, GSK, Austral, Biosency, AstraZeneca, Chiesi, Menarini, MSD, Nuvaira, Roche, Sanofi, Zambon. MZ: CSL Behring, Chiesi, GSK, Boeringer Ingelheim, AstraZeneca, Menarini, Sanofi. VA: AstraZeneca, Boehringer-Ingelheim, NovoNordisk. BL: AstraZeneca, Bayer, Chiesi, GSK, Lowenstein, MSD, Philips Ultrasons, Sanofi, SOS Oxygene. GD: Boehringer Ingelheim, GSK, AstraZeneca, Chiesi, Sanofi. LF: AstraZeneca, Bayer, BMS/Pfizer, Boehringer Ingelheim, Novo, Boston Scientific, Medtronic, Zoll. SK: Amgen, Astra Zeneca, Bayer, BMS, Boehringer Ingelheim, Lilly, NovoNordisk, Organon, Pfizer, Philips Healthcare, Sanofi, Servier. GM: Abbott, Amgen, AstraZeneca, Bayer, BMS, Boehringer-Ingelheim, Celecor, CSL Behring, Hexacath, Idorsia, Lilly, Novo Nordisk, Pfizer, SMT, Terumo. CP: AstraZeneca, Boeringer Ingelheim, GSK, Menarini, Novartis. ACS: Astra Zeneca, Bayer, Boehringer Ingelheim, Sanofi, Novartis, Vifor. EDAT- 2025/08/24 00:46 MHDA- 2025/11/25 00:28 CRDT- 2025/08/23 18:06 PHST- 2024/11/22 00:00 [received] PHST- 2025/06/16 00:00 [revised] PHST- 2025/06/16 00:00 [accepted] PHST- 2025/11/25 00:28 [medline] PHST- 2025/08/24 00:46 [pubmed] PHST- 2025/08/23 18:06 [entrez] AID - S2590-0412(25)00034-0 [pii] AID - 10.1016/j.resmer.2025.101187 [doi] PST - ppublish SO - Respir Med Res. 2025 Nov;88:101187. doi: 10.1016/j.resmer.2025.101187. Epub 2025 Aug 6. PMID- 40846216 OWN - NLM STAT- MEDLINE DCOM- 20251114 LR - 20251211 IS - 1879-1913 (Electronic) IS - 0002-9149 (Linking) VI - 256 DP - 2025 Dec 1 TI - Long-Term Healthcare Utilization and Outcomes in Patients Hospitalized for Heart Failure With and Without Atrial Fibrillation. PG - 115-124 LID - S0002-9149(25)00479-5 [pii] LID - 10.1016/j.amjcard.2025.08.022 [doi] AB - The long-term association between AF and clinical outcomes, healthcare resource utilization, and healthcare costs among patients with HF remains underexplored. We conducted an exploratory analysis of 5-year outcomes among patients enrolled in the patient-centered care transitions in HF (PACT-HF) stepped-wedge cluster randomized trial who were hospitalized for HF and discharged alive between February 2015 and March 2016. Patients were stratified by baseline AF status. Administrative health databases were linked to assess mortality, rehospitalizations, emergency department visits, healthcare utilization, and costs. Mortality was analyzed using Cox proportional hazards models adjusted for baseline comorbidities. Healthcare utilization and cost differences were assessed using Wilcoxon and generalized linear models. Among 4,441 patients, 2,151 patients (48.4%) had AF at baseline. Patients with AF were older and had a higher prevalence of hypertension, stroke, and vascular disease. Patients with AF had a shorter life span (mean [SD] days alive 957.9 [697.8] vs 1,119.6 [698.2], p <0.01) and a higher 5-year all-cause mortality (adjusted HR 1.09 95% CI 1.01 to 1.17; p = 0.03) relative to those without AF. Patients with AF experienced more all-cause rehospitalizations (mean [SD] 3.2 [8.3] vs 2.6 [7.9], p = 0.03) and longer hospital length of stays (mean [SD] days 29.6 [48.6] vs 24.8 [46.9], p <0.01), but no difference in HF rehospitalizations (mean [SD] 0.9 [4.5] vs 0.8 [3.6], p = 0.24) than those without AF. Annual healthcare costs were greater in the AF cohort (mean [SD] $83,748 [114,398] vs $77,792 [114,874]) CAD. In conclusion, despite only modestly increased mortality, patients with AF experienced substantially greater healthcare utilization and cost, largely unrelated to HF-specific care. These exploratory findings underscore the need for a multidisciplinary approach to reduce morbidity and optimize care delivery for patients with HF and comorbid AF. CI - Copyright (c) 2025 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Verelst, Faro R AU - Verelst FR AD - Research Group Cardiovascular Diseases, GENCOR Department, University of Antwerp, Antwerp, Belgium; Department of Cardiology, Antwerp University Hospital, Edegem, Belgium. FAU - Zagorski, Brandon AU - Zagorski B AD - Institute of Clinical Evaluative Sciences, Toronto, Ontario, Canada. FAU - Averbuch, Tauben AU - Averbuch T AD - Department of Cardiology, University of Calgary, Calgary, Alberta, Canada. FAU - Bagur, Rodrigo AU - Bagur R AD - Division of Cardiology, Department of Medicine, Western University, London, Ontario, Canada. FAU - Granger, Christopher AU - Granger C AD - Division of Cardiovascular Medicine, Duke University, Durham, North Carolina. FAU - Gevaert, Andreas B AU - Gevaert AB AD - Research Group Cardiovascular Diseases, GENCOR Department, University of Antwerp, Antwerp, Belgium; Department of Cardiology, Antwerp University Hospital, Edegem, Belgium. FAU - Van Spall, Harriette G C AU - Van Spall HGC AD - Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada; Population Health Research Institute, Ontario, Canada; Department of Medicine, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada. Electronic address: Harriette.VanSpall@phri.ca. LA - eng PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial DEP - 20250820 PL - United States TA - Am J Cardiol JT - The American journal of cardiology JID - 0207277 SB - IM MH - Humans MH - Male MH - Female MH - *Atrial Fibrillation/complications/therapy/epidemiology/economics MH - *Heart Failure/therapy/complications/economics/mortality/epidemiology MH - Aged MH - *Patient Acceptance of Health Care/statistics & numerical data MH - *Hospitalization/statistics & numerical data MH - *Health Care Costs MH - Patient Readmission/statistics & numerical data MH - Middle Aged MH - United States/epidemiology MH - Aged, 80 and over MH - Survival Rate/trends MH - Time Factors OTO - NOTNLM OT - all-cause mortality OT - atrial fibrillation OT - heart failure OT - hospitalization COIS- Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Harriette Van Spall reports financial support was provided by Canadian Institutes of Health Research. Faro Verelst reports financial support was provided by EHRA-PATHS. Harriette Van Spall reports financial support was provided by Ontario Ministry of Health and Long-Term Care Population and Public Health Division. Andreas Gevaert reports a relationship with Abbott that includes: funding grants. Andreas Gevaert reports a relationship with Boehringer Ingelheim that includes: funding grants. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. This document used data adapted from the Statistics Canada Postal CodeOM Conversion File, which is based on data licensed from Canada Post Corporation, and/or data adapted from the Ontario Ministry of Health Postal Code Conversion File, which contains data copied under license from (c)Canada Post Corporation and Statistics Canada. Parts of this material are based on data and/or information compiled and provided by CIHI and the Ontario Ministry of Health. The analyses, conclusions, opinions and statements expressed herein are solely those of the authors and do not reflect those of the funding or data sources; no endorsement is intended or should be inferred. We thank IQVIA Solutions Canada Inc. for use of their Drug Information File. ABG reports lecture/advisory fees paid to his institution by Abbott, AstraZeneca, Boehringer Ingelheim, Johnson and Johnson, Novartis, and Menarini, all unrelated to this work. HV reports clinical trial consulting services to Medtronic, Novo Nordisk, and Bayer. EDAT- 2025/08/23 00:44 MHDA- 2025/11/15 00:29 CRDT- 2025/08/22 19:19 PHST- 2025/07/09 00:00 [received] PHST- 2025/08/01 00:00 [revised] PHST- 2025/08/09 00:00 [accepted] PHST- 2025/11/15 00:29 [medline] PHST- 2025/08/23 00:44 [pubmed] PHST- 2025/08/22 19:19 [entrez] AID - S0002-9149(25)00479-5 [pii] AID - 10.1016/j.amjcard.2025.08.022 [doi] PST - ppublish SO - Am J Cardiol. 2025 Dec 1;256:115-124. doi: 10.1016/j.amjcard.2025.08.022. Epub 2025 Aug 20. PMID- 40845629 OWN - NLM STAT- MEDLINE DCOM- 20251202 LR - 20251222 IS - 1532-8449 (Electronic) IS - 0882-5963 (Linking) VI - 85 DP - 2025 Nov-Dec TI - Examination of the implementation determinants of skin-to-skin care in the pediatric cardiac Intensive Care Unit. PG - 321-331 LID - S0882-5963(25)00289-1 [pii] LID - 10.1016/j.pedn.2025.08.008 [doi] AB - INTRODUCTION: Skin-to-skin care (SSC), where parents hold their unclothed baby directly on their bare chest, is regarded as best practice for hospitalized infants. SSC is not routine for infants with complex congenital heart disease (cCHD) in the Pediatric Cardiac Intensive Care Unit (PCICU). SSC is understudied and the contextual factors influencing its implementation in the PCICU are unknown. This multisite, multi-methods study using the Tailored Implementation for Chronic Diseases implementation determinants framework aimed to identify the contextual factors influencing the implementation of SSC in the PCICU. METHODS: We interviewed stakeholders across two US PCICUs, one with previous implementation experience of SSC and one with little to no implementation experience. We used purposive snowball sampling, representing the interdisciplinary team of clinicians (n = 25) and parents (n = 21) at each site, until we reached thematic saturation. Clinicians completed a suite of valid and reliable surveys of acceptability, feasibility, and appropriateness. Descriptive statistics were calculated for the acceptability, feasibility, and appropriateness measures, with comparative analysis across clinician characteristics. Cross-cutting key themes were generated from a combined inductive and deductive approach to content analysis. RESULTS: On a five-point Likert scale, clinicians rated their acceptability (mean = 4.7, SD = 0.4), feasibility (mean = 4.2, SD = 0.7), and appropriateness (mean = 4.5, SD = 0.5) of SSC in the PCICU within the agree/completely agree range. Cross-cutting themes included knowledge, communication, role clarity, resources, and safety. CONCLUSIONS: Findings will be the foundation for implementation mapping, where identified barriers and facilitators are linked with evidence-based implementation strategies that can be tested to enhance the implementation of SSC in the PCICU. CI - Copyright (c) 2025 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Lisanti, Amy Jo AU - Lisanti AJ AD - Department of Family and Community Health, School of Nursing, University of Pennsylvania, 418 Curie Boulevard, Philadelphia, PA 19104, United States of America; Research Institute, Children's Hospital of Philadelphia, 734 Schuylkill Ave, Office 11292, Philadelphia, PA 19146, United States of America. Electronic address: lisanti@upenn.edu. FAU - Demianczyk, Abigail C AU - Demianczyk AC AD - Division of Pediatric Psychology, Department of Pediatric Behavioral Health & Neurosciences and Division of Cardiology & Cardiovascular Medicine, Department of Heart, Vascular & Thoracic Children's Institute, Cleveland Clinic, 8950 Euclid Avenue, Cleveland, OH 44106, United States of America. FAU - Whittaker, Jennifer AU - Whittaker J AD - Qualitative Research Core, Research Institute, Children's Hospital of Philadelphia, 734 Schuylkill Ave, Philadelphia, PA 19146, United States of America. FAU - Nag, Diya AU - Nag D AD - Qualitative Research Core, Research Institute, Children's Hospital of Philadelphia, 734 Schuylkill Ave, Philadelphia, PA 19146, United States of America. FAU - Kellom, Katherine AU - Kellom K AD - Qualitative Research Core, Research Institute, Children's Hospital of Philadelphia, 734 Schuylkill Ave, Philadelphia, PA 19146, United States of America. FAU - Brennan, Claire AU - Brennan C AD - Cardiology Clinical Research, Division of Cardiology, Children's Hospital of Philadelphia, Colket Translational Research Building, 2nd Floor, 3501 Civic Center Blvd., Philadelphia, PA 19105, United States of America. FAU - Hayden-Rush, Christina AU - Hayden-Rush C AD - Cardiology Clinical Research, Division of Cardiology, Children's Hospital of Philadelphia, Colket Translational Research Building, 2nd Floor, 3501 Civic Center Blvd., Philadelphia, PA 19105, United States of America. FAU - Herrup, Elizabeth A AU - Herrup EA AD - Department of Anesthesiology and Critical Care Medicine, Children's Hospital of Philadelphia, 3401 Civic Center Blvd, Philadelphia, PA 19104, United States of America. FAU - Grabill, Megan AU - Grabill M AD - Department of Anthropology, University of California, 375 Portola Plaza, Rm 341 Haines Hall, Los Angeles, CA 90095, United States of America. FAU - O'Brien, Caroline AU - O'Brien C AD - Department of Family Medicine and Communnity Health, University of Pennsylvania, Penn Presbyterian Medical Center, 7th Floor, 51 N 39th St. Andrew Mutch Building, Philadelphia, PA 19104, United States of America. FAU - Min, Jungwon AU - Min J AD - Department of Family and Community Health, School of Nursing, University of Pennsylvania, 418 Curie Boulevard, Philadelphia, PA 19104, United States of America. FAU - Bettencourt, Amanda P AU - Bettencourt AP AD - Department of Family and Community Health, School of Nursing, University of Pennsylvania, 418 Curie Boulevard, Philadelphia, PA 19104, United States of America. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20250821 PL - United States TA - J Pediatr Nurs JT - Journal of pediatric nursing JID - 8607529 SB - IM MH - Humans MH - *Intensive Care Units, Pediatric MH - Female MH - Male MH - Infant MH - *Heart Defects, Congenital/therapy/nursing MH - *Kangaroo-Mother Care Method/methods MH - Infant, Newborn MH - Parents/psychology MH - United States OTO - NOTNLM OT - Congenital heart disease OT - Implementation science OT - Intensive care OT - Kangaroo care OT - Skin-to-skin care COIS- Declaration of competing interest The authors have no competing interests to declare. EDAT- 2025/08/23 00:45 MHDA- 2025/12/02 07:36 CRDT- 2025/08/22 18:11 PHST- 2025/03/21 00:00 [received] PHST- 2025/07/01 00:00 [revised] PHST- 2025/08/08 00:00 [accepted] PHST- 2025/12/02 07:36 [medline] PHST- 2025/08/23 00:45 [pubmed] PHST- 2025/08/22 18:11 [entrez] AID - S0882-5963(25)00289-1 [pii] AID - 10.1016/j.pedn.2025.08.008 [doi] PST - ppublish SO - J Pediatr Nurs. 2025 Nov-Dec;85:321-331. doi: 10.1016/j.pedn.2025.08.008. Epub 2025 Aug 21. PMID- 40842186 OWN - NLM STAT- MEDLINE DCOM- 20251007 LR - 20260803 IS - 1522-726X (Electronic) IS - 1522-1946 (Linking) VI - 106 IP - 4 DP - 2025 Oct TI - Long-Term Outcomes of Patients Undergoing Extracorporeal Membrane Oxygenator-Assisted High-Risk Percutaneous Coronary Intervention. PG - 2637-2644 LID - 10.1002/ccd.70098 [doi] AB - BACKGROUND: Data regarding the long-term outcomes of patients undergoing venoarterial extracorporeal membrane oxygenator (VA-ECMO) assisted high-risk percutaneous coronary intervention (PCI) and the impact of the operator experience is limited. AIMS: We aimed to investigate the long-term outcomes of patients undergoing VA-ECMO-assisted PCI and the effect of the operator experience. METHODS: The study was a retrospective cohort study that consecutively enrolled patients who were declined by the Heart Team for coronary artery bypass grafting (CABG) due to high surgical risk and treated with VA-ECMO-assisted PCI from November 1, 2016, to March 1, 2024, in Xijing Hospital, China. The primary endpoint was all-cause death at 1 year. RESULTS: A total of 220 patients were included. The mean age +/- SD was 65.6 +/- 11.4 years and the median LVEF% (IQR) was 36.0 (30.0-40.0). The mean +/- SD of the SYNTAX score was 34.7 +/- 6.9. The median (IQR) follow-up was 1.9 (1.3-4.9) years, and the vital status of all patients was available at 1 year. The all-cause death occurred in 56 (25.5%) of patients at 1 year. Utilizing the restricted cubic spline, the threshold to categorize an experienced operator was performing > 10 cases of VA-ECMO-assisted PCI. Compared to the 10 cases group was associated with a 44% decrease in risk of all-cause death (19.8% vs. 31.5%, HR adjusted: 0.56, 95% CI: 0.33-0.97, p = 0.039). CONCLUSION: VA-ECMO-assisted PCI appeared to be a feasible option for patients unsuitable for CABG. Performing > 10 cases could be a threshold to categorize an experienced operator. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT06713876. CI - (c) 2025 Wiley Periodicals LLC. FAU - Cheng, Aiyuan AU - Cheng A AUID- ORCID: 0009-0001-7359-5338 AD - Department of Cardiology, Xijing Hospital, Xi'an, China. FAU - Wang, Bo AU - Wang B AD - Department of Cardiology, Xijing Hospital, Xi'an, China. FAU - Fu, Guotao AU - Fu G AD - Department of Cardiology, Xijing Hospital, Xi'an, China. FAU - Li, Chengxiang AU - Li C AD - Department of Cardiology, Xijing Hospital, Xi'an, China. FAU - Liu, Yi AU - Liu Y AD - Department of Cardiology, Xijing Hospital, Xi'an, China. FAU - Li, Fei AU - Li F AUID- ORCID: 0000-0003-1081-7105 AD - Department of Cardiology, Xijing Hospital, Xi'an, China. FAU - Wang, Qiong AU - Wang Q AD - Department of Cardiology, Xijing Hospital, Xi'an, China. FAU - Yin, Zhiyong AU - Yin Z AD - Department of Cardiology, Xijing Hospital, Xi'an, China. FAU - Gao, Haokao AU - Gao H AUID- ORCID: 0000-0001-7750-4491 AD - Department of Cardiology, Xijing Hospital, Xi'an, China. FAU - Gao, Chao AU - Gao C AD - Department of Cardiology, Xijing Hospital, Xi'an, China. AD - Department of Cardiology, The First Affiliated Hospital of USTC, Hefei, China. FAU - Tao, Ling AU - Tao L AD - Department of Cardiology, Xijing Hospital, Xi'an, China. LA - eng SI - ClinicalTrials.gov/NCT06713876 GR - The study has been supported by Xijing Hospital (Grant Number: XJZT24LY36) and Fourth Military Medical University (2023LC2313)./ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20250821 PL - United States TA - Catheter Cardiovasc Interv JT - Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions JID - 100884139 SB - IM MH - Humans MH - *Extracorporeal Membrane Oxygenation/adverse effects/mortality/instrumentation MH - Male MH - Female MH - *Percutaneous Coronary Intervention/adverse effects/mortality MH - Retrospective Studies MH - Time Factors MH - Aged MH - Treatment Outcome MH - Middle Aged MH - Risk Factors MH - Risk Assessment MH - *Coronary Artery Disease/mortality/therapy/diagnostic imaging/physiopathology MH - China OTO - NOTNLM OT - extracorporeal membrane oxygenator support high-risk PCI OT - learning curve OT - percutaneous coronary intervention EDAT- 2025/08/22 08:45 MHDA- 2025/10/07 12:30 CRDT- 2025/08/22 02:03 PHST- 2025/07/29 00:00 [revised] PHST- 2025/06/08 00:00 [received] PHST- 2025/08/09 00:00 [accepted] PHST- 2025/10/07 12:30 [medline] PHST- 2025/08/22 08:45 [pubmed] PHST- 2025/08/22 02:03 [entrez] AID - 10.1002/ccd.70098 [doi] PST - ppublish SO - Catheter Cardiovasc Interv. 2025 Oct;106(4):2637-2644. doi: 10.1002/ccd.70098. Epub 2025 Aug 21. PMID- 40841307 OWN - NLM STAT- MEDLINE DCOM- 20250821 LR - 20250821 IS - 1476-4954 (Electronic) IS - 1476-4954 (Linking) VI - 38 IP - 1 DP - 2025 Dec TI - Pre-pregnancy cardiac status impacts risk of postpartum mood and anxiety disorders. PG - 2547400 LID - 10.1080/14767058.2025.2547400 [doi] AB - OBJECTIVE: Our study aimed to assess whether maternal cardiac disease is an independent risk factor for postpartum mood and anxiety disorders (PPMADs) and whether higher cardiac risk scores are associated with higher risk of PPMAD. METHODS: This was a retrospective matched cohort study of patients who delivered between June 2019 and February 2024 and completed PPMAD screening at a tertiary care institution. The cardiac cohort was managed by a multidisciplinary cardio-obstetrics team, and the non-cardiac cohort was identified through matching on important demographic factors. The primary outcome was a positive PPMAD screen, defined as Patient Health Questionnaire-9 (PHQ-9) or General Anxiety Disorder-7 (GAD-7) score >/=10. Relative risks (RRs) for positive PPMAD screen were obtained using binomial regression. RESULTS: The prevalence of positive PPMAD screening was 18.2% (27/148) in the cardiac cohort and 16.2% (24/148) in the non-cardiac cohort. Cardiac disease alone did not increase risk of positive PPMAD screening (RR 1.13, 95% confidence interval (CI) 0.68-1.86). New York Heart Association class >/= II (RR 3.12, 95% CI 1.80-5.41) and pre-pregnancy diuretic use (RR 2.98, 95% CI 1.08-8.20) were associated with increased PPMAD. Other factors that increased PPMAD risk included being from a neighborhood with greater socioeconomic disadvantage (RR 1.18, 95% CI 1.03-1.34), unplanned pregnancy (RR 2.42, 95% CI 1.46-4.0), history of antidepressant use (RR 2.19, 95% CI 1.33-3.61), and history of interpersonal violence (RR 3.05, 95% CI 1.72-5.4). Adverse pregnancy outcomes, such as hypertensive disorders of pregnancy (RR 2.60, 95% CI 1.59-4.27), peripartum transfusion (RR 2.61, 95% CI 1.39-4.9), and preterm birth (RR 2.00, 95% CI 1.09-5.43) were also associated with positive PPMAD screening. CONCLUSIONS: Cardiac disease alone was not independently associated with positive PPMAD screening, while poorly optimized cardiac status, social history, and adverse pregnancy outcomes were. Our findings stress the importance of optimizing early cardiac status and providing full-scope prenatal care to patients with cardiac disease to reduce PPMAD risk. FAU - Shao, Shirley J AU - Shao SJ AD - School of Medicine, University of California San Francisco, San Francisco, CA, USA. FAU - Fu, Lucy J AU - Fu LJ AD - Division of Pediatric Hematology/Oncology, University of California, San Francisco, CA, USA. FAU - Boscardin, John AU - Boscardin J AD - Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA. FAU - Yeaton-Massey, Amanda AU - Yeaton-Massey A AD - Department of Obstetrics, Gynecology, and Reproductive Sciences, Division of Maternal-Fetal Medicine, University of California, San Francisco, CA, USA. FAU - Agarwal, Anushree AU - Agarwal A AD - Department of Medicine, Division of Cardiology, University of California, San Francisco, CA, USA. FAU - Sobhani, Nasim C AU - Sobhani NC AD - Department of Obstetrics, Gynecology, and Reproductive Sciences, Division of Maternal-Fetal Medicine, University of California, San Francisco, CA, USA. LA - eng PT - Journal Article DEP - 20250821 PL - England TA - J Matern Fetal Neonatal Med JT - The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians JID - 101136916 SB - IM MH - Humans MH - Female MH - Pregnancy MH - Adult MH - Retrospective Studies MH - *Anxiety Disorders/epidemiology/etiology MH - Risk Factors MH - *Heart Diseases/complications/epidemiology MH - *Mood Disorders/epidemiology/etiology MH - *Depression, Postpartum/epidemiology/etiology MH - Postpartum Period/psychology MH - *Puerperal Disorders/epidemiology/etiology OTO - NOTNLM OT - Cardiac disease in pregnancy OT - maternal cardiac disease OT - perinatal mood disorders OT - postpartum anxiety OT - postpartum depression EDAT- 2025/08/22 00:44 MHDA- 2025/08/22 00:45 CRDT- 2025/08/21 22:09 PHST- 2025/08/22 00:45 [medline] PHST- 2025/08/22 00:44 [pubmed] PHST- 2025/08/21 22:09 [entrez] AID - 10.1080/14767058.2025.2547400 [doi] PST - ppublish SO - J Matern Fetal Neonatal Med. 2025 Dec;38(1):2547400. doi: 10.1080/14767058.2025.2547400. Epub 2025 Aug 21. PMID- 40828781 OWN - NLM STAT- MEDLINE DCOM- 20250914 LR - 20261028 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 20 IP - 8 DP - 2025 TI - A real-world pharmacovigilance analysis of ALK inhibitor-associated pleural and pericardial effusion using the FDA Adverse Events Reporting System (FAERS) database from 2013 to 2024. PG - e0330630 LID - 10.1371/journal.pone.0330630 [doi] LID - e0330630 AB - INTRODUCTION: The advent of anaplastic lymphoma kinase (ALK) inhibitors has revolutionized the treatment of ALK-rearranged malignancies, establishing these agents as vital components of precision oncology. Despite their proven efficacy in prolonging progression-free and overall survival, ALK inhibitors are associated with notable adverse events, particularly cardiopulmonary complications such as pleural and pericardial effusions. METHODS: This study investigates the real-world prevalence and risk of these effusions associated with five ALK inhibitors, crizotinib, ceritinib, alectinib, brigatinib, and lorlatinib, through disproportionality analysis using the FAERS pharmacovigilance database. RESULTS: The data revealed elevated reporting odds ratios (RORs) for pleural and pericardial effusions, with notable variability among the agents. Crizotinib exhibited RORs of 7.76 (95% CI: 6.60-9.12) and 9.00 (95% CI: 7.10-11.41) for pleural and pericardial effusions, respectively. Ceritinib demonstrated RORs of 7.36 (95% CI: 5.16-10.50) and 10.80 (95% CI: 6.79-17.19), respectively. Alectinib showed lower RORs of 4.76 (95% CI: 3.80-5.97) and 6.67 (95% CI: 4.92-9.04). Brigatinib displayed elevated RORs of 8.70 (95% CI: 6.58-11.52) and 7.87 (95% CI: 4.95-12.51). Lorlatinib presented the highest risk, with RORs of 8.61 (95% CI: 6.72-11.02) and 12.57 (95% CI: 9.08-17.38). CONCLUSIONS: This study highlights the critical need for vigilant pharmacovigilance and a multidisciplinary approach to balance the oncologic benefits of ALK inhibitors against their cardiopulmonary risks. By enhancing awareness and fostering proactive management, these findings aim to support the safe and effective use of ALK inhibitors in treating ALK-rearranged malignancies. CI - Copyright: (c) 2025 Connor Frey. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. FAU - Frey, Connor AU - Frey C AUID- ORCID: 0000-0002-4080-3030 AD - Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20250819 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - EC 2.7.10.1 (Anaplastic Lymphoma Kinase) RN - 0 (Protein Kinase Inhibitors) RN - LIJ4CT1Z3Y (alectinib) RN - 0 (Piperidines) RN - K418KG2GET (ceritinib) RN - 53AH36668S (Crizotinib) RN - 0 (Pyrimidines) RN - 0 (Carbazoles) RN - OSP71S83EU (lorlatinib) RN - EC 2.7.10.1 (ALK protein, human) RN - 0 (Sulfones) RN - 0 (Lactams, Macrocyclic) RN - 0 (Organophosphorus Compounds) RN - HYW8DB273J (brigatinib) RN - 0 (Lactams) RN - 0 (Pyrroles) RN - 0 (Pyrazoles) RN - 0 (Aminopyridines) SB - IM MH - Humans MH - Pharmacovigilance MH - *Anaplastic Lymphoma Kinase/antagonists & inhibitors MH - Adverse Drug Reaction Reporting Systems MH - *Protein Kinase Inhibitors/adverse effects MH - United States/epidemiology MH - Piperidines/adverse effects MH - *Pericardial Effusion/chemically induced/epidemiology MH - United States Food and Drug Administration MH - Crizotinib/adverse effects MH - Pyrimidines/adverse effects MH - *Pleural Effusion/chemically induced/epidemiology MH - Carbazoles/adverse effects MH - Sulfones/adverse effects MH - Databases, Factual MH - Female MH - Male MH - Lactams, Macrocyclic/adverse effects MH - Organophosphorus Compounds/adverse effects MH - Middle Aged MH - Lactams/adverse effects MH - Pyrroles/adverse effects MH - Adult MH - Pyrazoles/adverse effects MH - Aminopyridines PMC - PMC12364337 COIS- The authors have declared that no competing interests exist. EDAT- 2025/08/19 18:29 MHDA- 2025/09/14 13:08 PMCR- 2025/08/19 CRDT- 2025/08/19 13:33 PHST- 2025/05/19 00:00 [received] PHST- 2025/08/05 00:00 [accepted] PHST- 2025/09/14 13:08 [medline] PHST- 2025/08/19 18:29 [pubmed] PHST- 2025/08/19 13:33 [entrez] PHST- 2025/08/19 00:00 [pmc-release] AID - PONE-D-25-25904 [pii] AID - 10.1371/journal.pone.0330630 [doi] PST - epublish SO - PLoS One. 2025 Aug 19;20(8):e0330630. doi: 10.1371/journal.pone.0330630. eCollection 2025. PMID- 40822943 OWN - NLM STAT- MEDLINE DCOM- 20250826 LR - 20260219 IS - 1664-2392 (Print) IS - 1664-2392 (Electronic) IS - 1664-2392 (Linking) VI - 16 DP - 2025 TI - Understanding obesity in children with 22q11.2 deletion syndrome. PG - 1628796 LID - 10.3389/fendo.2025.1628796 [doi] LID - 1628796 AB - BACKGROUND: 22q11.2 deletion syndrome (22q11.2DS) is a complex and heterogeneous genetic disorder. While short stature is well-documented, data on weight excess in pediatric patients remain sparse and conflicting. OBJECTIVE: To evaluate the prevalence of overweight and obesity in children and adolescents with 22q11.2DS when compared to the general Italian pediatric population and identify risk factors and periods of critical weight gain. METHODS: In this single-center, retrospective study, 61 children with molecularly confirmed 22q11.2DS were followed up for 441 patient-years. Anthropometric data were evaluated and compared to national surveillance databases ("OKKio alla Salute" and "HBSC"). Risk factors for overweight and obesity were identified by univariate and multivariate analyses. RESULTS: While overweight prevalence in 22q11.2DS patients did not differ significantly from that in the general population, obesity had a bimodal age distribution with peaks at 11 and 17 years. Both neuropsychiatric comorbidities and the use of psychoactive medication were significantly associated with an increased risk of overweight and obesity. In multivariate analysis, the use of psychoactive medication was the only independent risk factor. CONCLUSIONS: Obesity in 22q11.2DS may not be syndrome-intrinsic but is heavily influenced by pharmacological treatment. Identification of vulnerable periods and modifiable risk factors is crucial. A preventive, multidisciplinary approach with metabolic screening and cautious use of psychotropic medication is warranted to avoid obesity risk in this population. CI - Copyright (c) 2025 Sarli, Cerutti, Pontone, Guarnieri, Soldovieri, Giotta, Ricci, Azzari and Stagi. FAU - Sarli, Walter Maria AU - Sarli WM AD - Immunology Unit, Meyer Children's Hospital IRCCS, Florence, Italy. AD - Department of Health Sciences, University of Florence, Florence, Italy. FAU - Cerutti, Matteo AU - Cerutti M AD - Department of Health Sciences, University of Florence, Florence, Italy. FAU - Pontone, Matteo AU - Pontone M AD - Department of Health Sciences, University of Florence, Florence, Italy. FAU - Guarnieri, Valentina AU - Guarnieri V AD - Immunology Unit, Meyer Children's Hospital IRCCS, Florence, Italy. AD - Department of Health Sciences, University of Florence, Florence, Italy. FAU - Soldovieri, Sara AU - Soldovieri S AD - Department of Health Sciences, University of Florence, Florence, Italy. FAU - Giotta, Massimo AU - Giotta M AD - PhD School in Public Health, Clinical Medicine and Oncology, Department of Precision and Regenerative Medicine and Ionian Area, School of Medicine, University of Bari Aldo Moro, Bari, Italy. FAU - Ricci, Silvia AU - Ricci S AD - Immunology Unit, Meyer Children's Hospital IRCCS, Florence, Italy. AD - Department of Health Sciences, University of Florence, Florence, Italy. FAU - Azzari, Chiara AU - Azzari C AD - Immunology Unit, Meyer Children's Hospital IRCCS, Florence, Italy. AD - Department of Health Sciences, University of Florence, Florence, Italy. FAU - Stagi, Stefano AU - Stagi S AD - Department of Health Sciences, University of Florence, Florence, Italy. AD - Diabetology and Endocrinology Unit, Meyer Children's Hospital IRCCS, Florence, Italy. LA - eng PT - Journal Article DEP - 20250731 PL - Switzerland TA - Front Endocrinol (Lausanne) JT - Frontiers in endocrinology JID - 101555782 SB - IM MH - Humans MH - Child MH - Female MH - Male MH - Adolescent MH - *DiGeorge Syndrome/complications/epidemiology MH - Retrospective Studies MH - Risk Factors MH - *Pediatric Obesity/epidemiology/etiology MH - Prevalence MH - Child, Preschool MH - Italy/epidemiology MH - Follow-Up Studies MH - Overweight/epidemiology MH - Body Mass Index PMC - PMC12350139 OTO - NOTNLM OT - 22q11 deletion syndrome OT - DiGeorge OT - children OT - neuropsychiatric disease OT - obesity OT - overweight OT - prevention OT - thyroid COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision. EDAT- 2025/08/18 12:33 MHDA- 2025/08/31 20:08 PMCR- 2025/07/31 CRDT- 2025/08/18 07:09 PHST- 2025/05/14 00:00 [received] PHST- 2025/07/10 00:00 [accepted] PHST- 2025/08/31 20:08 [medline] PHST- 2025/08/18 12:33 [pubmed] PHST- 2025/08/18 07:09 [entrez] PHST- 2025/07/31 00:00 [pmc-release] AID - 10.3389/fendo.2025.1628796 [doi] PST - epublish SO - Front Endocrinol (Lausanne). 2025 Jul 31;16:1628796. doi: 10.3389/fendo.2025.1628796. eCollection 2025. PMID- 40821687 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250914 LR - 20250914 IS - 3005-7590 (Electronic) IS - 3005-7590 (Linking) VI - 2 IP - 8 DP - 2025 Aug TI - Tuberculous endocarditis: a case-based proposal for new diagnostic criteria. PG - 486-492 LID - 10.5588/ijtldopen.25.0042 [doi] AB - BACKGROUND: Tuberculous endocarditis (TBE) is a rare but often fatal manifestation of Mycobacterium tuberculosis. Although diagnosis is now possible with advanced techniques, the lack of standardized diagnostic criteria complicates timely recognition and management. METHODS: A 79-year-old man with a history of the Bentall procedure for annuloaortic ectasia, presented with fever and chest pain. Imaging revealed infective endocarditis with an aortic root abscess and vegetations. Histopathology identified granulation tissue with multinucleated giant cells, and M. tuberculosis was confirmed via PCR and culture. A literature review of TBE cases was performed to develop systematic diagnostic criteria. RESULTS: The diagnosis of TBE was established through histopathology and molecular methods. Based on this case and prior reports, diagnostic criteria for TBE were developed and categorized as 'Definitive', 'Probable', and 'Possible'. These criteria incorporate clinical, microbiological, histological, and imaging findings to aid in diagnosis. The patient's treatment included surgical intervention combined with antimicrobial therapy, aligning with strategies designed to improve outcomes. CONCLUSION: This case underscores the importance of considering TBE in infective endocarditis cases, especially those with atypical features. The proposed diagnostic criteria aim to improve the recognition and guide the management of TBE, emphasizing a multidisciplinary approach for better patient outcomes. CI - (c) 2025 The Authors. FAU - Higa, M AU - Higa M AD - Dept. of Respiratory Medicine, Okinawa Prefectural Nanbu Medical Center & Children's Medical Center, Haebaru, Japan. AD - Dept. of Respiratory Medicine, National Hospital Organization (NHO) Okinawa Hospital, Ginowan, Japan. FAU - Munakata, H AU - Munakata H AD - Dept. of Cardiovascular Surgery, Okinawa Kyodo Hospital, Okinawa, Japan. FAU - Yamazato, T AU - Yamazato T AD - Dept. of Cardiovascular Surgery, Okinawa Prefectural Nanbu Medical Center & Children's Medical Center, Haebaru, Japan. FAU - Abe, N AU - Abe N AD - Dept. of Cardiovascular Surgery, Okinawa Prefectural Nanbu Medical Center & Children's Medical Center, Haebaru, Japan. FAU - Ohyama, N AU - Ohyama N AD - Dept. of Cardiovascular Surgery, Okinawa Prefectural Nanbu Medical Center & Children's Medical Center, Haebaru, Japan. FAU - Fujii, T AU - Fujii T AD - Dept. of Cardiovascular Surgery, Okinawa Prefectural Nanbu Medical Center & Children's Medical Center, Haebaru, Japan. FAU - Nambu, J AU - Nambu J AD - Dept. of Diagnostic Pathology, Okinawa Prefectural Nanbu Medical Center & Children's Medical Center, Haebaru, Japan. FAU - Nakazato, I AU - Nakazato I AD - Dept. of Diagnostic Pathology, Okinawa Prefectural Nanbu Medical Center & Children's Medical Center, Haebaru, Japan. FAU - Cho, Y AU - Cho Y AD - Dept. of Pediatric Infectious Diseases, Okinawa Prefectural Nanbu Medical Center & Children's Medical Center, Haebaru, Japan. FAU - Inamine, M AU - Inamine M AD - Dept. of Respiratory Medicine, Okinawa Prefectural Nanbu Medical Center & Children's Medical Center, Haebaru, Japan. FAU - Takahashi, K AU - Takahashi K AD - Dept. of Pathology, National Institute of Infectious Diseases, Tokyo, Japan. FAU - Katano, H AU - Katano H AD - Dept. of Pathology, National Institute of Infectious Diseases, Tokyo, Japan. FAU - Narita, M AU - Narita M AD - Division of Infectious Diseases, Dept. of Internal Medicine, Okinawa Prefectural Nanbu Medical Center & Children's Medical Center, Haebaru, Japan. AD - Division of Infectious Diseases, Dept. of Internal Medicine, Okinawa Prefectural Chubu Hospital, Uruma, Japan. LA - eng PT - Journal Article DEP - 20250813 PL - France TA - IJTLD Open JT - IJTLD open JID - 9918803487706676 PMC - PMC12352953 OTO - NOTNLM OT - Bentall procedure OT - TBE OT - case report OT - gram staining of Mycobacterium tuberculosis COIS- Conflicts of interest: none declared. EDAT- 2025/08/18 12:33 MHDA- 2025/08/18 12:34 PMCR- 2025/08/13 CRDT- 2025/08/18 06:50 PHST- 2025/03/10 00:00 [received] PHST- 2025/04/12 00:00 [accepted] PHST- 2025/08/18 12:34 [medline] PHST- 2025/08/18 12:33 [pubmed] PHST- 2025/08/18 06:50 [entrez] PHST- 2025/08/13 00:00 [pmc-release] AID - 25-0042 [pii] AID - 10.5588/ijtldopen.25.0042 [doi] PST - epublish SO - IJTLD Open. 2025 Aug 13;2(8):486-492. doi: 10.5588/ijtldopen.25.0042. eCollection 2025 Aug. PMID- 40821489 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250914 LR - 20250914 IS - 0899-8280 (Print) IS - 1525-3252 (Electronic) IS - 0899-8280 (Linking) VI - 38 IP - 5 DP - 2025 TI - Long-term survival after multidisciplinary heart team-guided management of complex coronary artery disease. PG - 589-597 LID - 10.1080/08998280.2025.2516981 [doi] AB - OBJECTIVE: Guidelines recommend a multidisciplinary heart team approach for managing complex coronary artery disease (CAD), yet its impact on clinical outcomes and adherence to recommendations is rarely reported. METHODS: Between June 2021 and August 2022, 210 high-risk patients with isolated, complex CAD were evaluated at our institution's weekly heart team conference for consideration of coronary artery bypass grafting (CABG), percutaneous coronary intervention (PCI), hybrid PCI/CABG, or optimal medical therapy (OMT). Adherence to recommendations and clinical outcomes, including 30-day, 1-year, and 2-year mortality, were assessed. RESULTS: Overall adherence to heart team recommendations was 92%, with 96% adherence for CABG, 90% for PCI, 87% for OMT, and 75% for hybrid PCI/CABG. CABG was the most frequently recommended treatment (53%) and demonstrated the lowest mortality at 1 year (4%) and 2 years (6%) compared with PCI (1 year, 28%; 2 year, 40%) and OMT (1 year, 10%; 2 year, 20%). CABG patients had a lower-than-expected mortality (observed-to-expected ratio 0.9), while PCI was associated with significantly higher mortality (observed-to-expected ratio 3.0). CONCLUSION: This single-center multidisciplinary heart team approach for complex CAD offers a collaborative, patient-centered model that facilitates high adherence rates and favorable patient outcomes. These findings highlight the potential benefits of integrating multidisciplinary evaluation and support its implementation into standard practice for high-risk CAD patients. CI - Copyright (c) 2025 Baylor University Medical Center. FAU - Pickering, Taylor AU - Pickering T AUID- ORCID: 0009-0001-6369-3807 AD - Baylor Scott & White Research Institute, Plano, Texas, USA. FAU - Kluis, Austin AU - Kluis A AD - Baylor Scott & White Research Institute, Plano, Texas, USA. AD - Department of Cardiothoracic Surgery, Baylor Scott & White The Heart Hospital - Plano, Plano, Texas, USA. FAU - Shih, Emily AU - Shih E AD - Baylor Scott & White Research Institute, Plano, Texas, USA. AD - Department of Cardiothoracic Surgery, Baylor Scott & White The Heart Hospital - Plano, Plano, Texas, USA. FAU - Squiers, John J AU - Squiers JJ AD - Baylor Scott & White Research Institute, Plano, Texas, USA. AD - Department of Cardiothoracic Surgery, Baylor Scott & White The Heart Hospital - Plano, Plano, Texas, USA. FAU - McCullough, Kyle AU - McCullough K AD - Baylor Scott & White Research Institute, Plano, Texas, USA. FAU - Dorton, Cody AU - Dorton C AD - Baylor Scott & White Research Institute, Plano, Texas, USA. FAU - Moore, David O AU - Moore DO AD - Department of Cardiothoracic Surgery, Baylor Scott & White The Heart Hospital - Plano, Plano, Texas, USA. FAU - Potluri, Srinivasa P AU - Potluri SP AD - Department of Cardiology, Baylor Scott & White The Heart Hospital - Plano, Plano, Texas, USA. FAU - Szerlip, Molly AU - Szerlip M AD - Department of Cardiology, Baylor Scott & White The Heart Hospital - Plano, Plano, Texas, USA. FAU - Al-Azizi, Karim AU - Al-Azizi K AD - Department of Cardiology, Baylor Scott & White The Heart Hospital - Plano, Plano, Texas, USA. FAU - Moubarak, Ghadi AU - Moubarak G AD - Baylor Scott & White Research Institute, Plano, Texas, USA. FAU - Ladner, Jonathan AU - Ladner J AD - Baylor Scott & White Research Institute, Plano, Texas, USA. FAU - Vaishnav, Radhika AU - Vaishnav R AD - Baylor Scott & White Research Institute, Plano, Texas, USA. FAU - McCoy, Shelby AU - McCoy S AD - Baylor Scott & White Research Institute, Plano, Texas, USA. FAU - Ejiofor, Julius AU - Ejiofor J AD - Department of Cardiothoracic Surgery, Baylor Scott & White The Heart Hospital - Plano, Plano, Texas, USA. FAU - Sawhney, Rahul AU - Sawhney R AD - Department of Cardiology, Baylor Scott & White The Heart Hospital - Plano, Plano, Texas, USA. FAU - Hale, Sarah AU - Hale S AD - Baylor Scott & White Research Institute, Plano, Texas, USA. FAU - Schaffer, Justin M AU - Schaffer JM AD - Department of Cardiothoracic Surgery, Baylor Scott & White The Heart Hospital - Plano, Plano, Texas, USA. FAU - Banwait, Jasjit AU - Banwait J AD - Baylor Scott & White Research Institute, Plano, Texas, USA. FAU - Harrington, Katherine B AU - Harrington KB AD - Department of Cardiothoracic Surgery, Baylor Scott & White The Heart Hospital - Plano, Plano, Texas, USA. FAU - Brinkman, William T AU - Brinkman WT AD - Department of Cardiothoracic Surgery, Baylor Scott & White The Heart Hospital - Plano, Plano, Texas, USA. FAU - Hafen, Lee R AU - Hafen LR AD - Department of Cardiothoracic Surgery, Baylor Scott & White The Heart Hospital - Plano, Plano, Texas, USA. FAU - Smith, Robert L AU - Smith RL AD - Department of Cardiothoracic Surgery, Baylor Scott & White The Heart Hospital - Plano, Plano, Texas, USA. FAU - George, Timothy J AU - George TJ AD - Department of Cardiothoracic Surgery, Baylor Scott & White The Heart Hospital - Plano, Plano, Texas, USA. FAU - DiMaio, J Michael AU - DiMaio JM AD - Baylor Scott & White Research Institute, Plano, Texas, USA. AD - Department of Cardiothoracic Surgery, Baylor Scott & White The Heart Hospital - Plano, Plano, Texas, USA. AD - Department of Biomedical Engineering, Texas A&M University, College Station, Texas, USA. FAU - Ryan, William H AU - Ryan WH AD - Department of Cardiothoracic Surgery, Baylor Scott & White The Heart Hospital - Plano, Plano, Texas, USA. FAU - Hutcheson, Kelley A AU - Hutcheson KA AD - Department of Cardiothoracic Surgery, Baylor Scott & White The Heart Hospital - Plano, Plano, Texas, USA. LA - eng PT - Journal Article DEP - 20250620 PL - United States TA - Proc (Bayl Univ Med Cent) JT - Proceedings (Baylor University. Medical Center) JID - 9302033 PMC - PMC12351742 OTO - NOTNLM OT - Coronary artery bypass grafting OT - coronary artery disease OT - long-term outcomes OT - multidisciplinary heart team OT - percutaneous coronary intervention COIS- Dr. Potluri: Advisory board member, proctor, and speaker for Medtronic, Boston Scientific, Abbott, and Cordis; proctor and speaker for Edwards Lifesciences, Terumo, and AstraZeneca. Dr. Szerlip: Proctor, speaker, and consultant for Edwards Lifesciences; advisory board member, consultant, and proctor for Abbott Vascular; steering committee member for Medtronic; speaker for Boston Scientific. Dr. Al-Azizi: Proctor and consultant for Edwards Lifesciences; consultant and advisory board member for Medtronic; consultant for Boston Scientific; speaker bureau member. Dr. Harrington: Consultant for Abbott Laboratories and Maquet Cardiovascular; speaker for Artivion, Inc. and Medtronic, Inc.; speaker and advisory board member for Boston Scientific Corporation; speaker and proctor for Edwards Lifesciences Corporation. Dr. Brinkman: Teaching and travel support from Artivion; consultant for Bolton Medical, Inc., Maquet Cardiovascular, Medtronic, Terumo Medical Corporation, and W.L. Gore; advisory board member for Medtronic. Dr. Smith: Grant support recipient from Edwards Lifesciences; speaker honoraria recipient from Edwards Lifesciences, Abbott, and CryoLife. Dr. George: Speaker for Abiomed. Dr. DiMaio: Investment and ownership interests in HeartFlow, Inc. and Spectral MD. The remaining authors have no competing interests to declare. EDAT- 2025/08/18 12:32 MHDA- 2025/08/18 12:33 PMCR- 2025/06/20 CRDT- 2025/08/18 06:49 PHST- 2025/08/18 12:33 [medline] PHST- 2025/08/18 12:32 [pubmed] PHST- 2025/08/18 06:49 [entrez] PHST- 2025/06/20 00:00 [pmc-release] AID - 2516981 [pii] AID - 10.1080/08998280.2025.2516981 [doi] PST - epublish SO - Proc (Bayl Univ Med Cent). 2025 Jun 20;38(5):589-597. doi: 10.1080/08998280.2025.2516981. eCollection 2025. PMID- 40820703 OWN - NLM STAT- MEDLINE DCOM- 20250826 LR - 20260925 IS - 2046-4924 (Electronic) IS - 1366-5278 (Print) IS - 1366-5278 (Linking) VI - 29 IP - 39 DP - 2025 Aug TI - Optimising cardiac surgery outcomes in people with diabetes: the OCTOPuS pilot feasibility study. PG - 1-31 LID - 10.3310/POYW3311 [doi] AB - BACKGROUND: Surgical outcomes are worse in people with diabetes, in part, because of the effects of hyperglycaemia, obesity and other comorbidities. Two important uncertainties in the management of people with diabetes undergoing major surgery exist: (1) how to improve diabetes management prior to an elective procedure and (2) whether that improved management leads to better post-operative outcomes. OBJECTIVE: The Optimising Cardiac Surgery ouTcOmes in People with diabeteS project aimed to assess whether a pre-operative outpatient intervention delivered by a multidisciplinary specialist diabetes team could improve diabetes management and cardiac surgical outcomes for people with diabetes. Although the intervention could be applied to any surgical discipline, cardiothoracic surgery was chosen because 30-40% of those undergoing elective cardiac revascularisation have diabetes. METHODS: The project had three phases: (1) designing the intervention, (2) a pilot study of the intervention and (3) a multicentre randomised controlled study in United Kingdom cardiothoracic centres to assess whether the intervention could improve surgical outcomes. The first two phases were completed, but the COVID-19 pandemic and its subsequent effects on cardiothoracic services and research capacity in the United Kingdom meant that the randomised controlled study could not be undertaken. INTERVENTION DEVELOPMENT: Two rapid literature reviews were undertaken to understand what factors influence surgical outcomes in people with diabetes and what interventions have previously been tested. The Optimising Cardiac Surgery ouTcOmes in People with diabeteS intervention was based on an existing nurse-led outpatient intervention, delivered in the 3 months before elective orthopaedic surgery. This intervention reduced pre-operative glycated haemoglobin and reduced length of stay. We undertook a survey of United Kingdom cardiothoracic surgeons, which found limited and inconsistent pre-operative management of people with diabetes awaiting cardiothoracic surgery. A prototype intervention was developed following discussions with relevant stakeholders. PILOT STUDY: The pilot feasibility study recruited 17 people with diabetes and was undertaken by the diabetes and cardiothoracic surgery departments at University Hospital Southampton NHS Foundation Trust. Biomedical data were collected at baseline and prior to surgery. We assessed how the intervention was used. In-depth qualitative interviews with participants and healthcare professionals explored perceptions and experiences of the intervention and how it might be improved. Thirteen people completed the study and underwent cardiothoracic surgery. All components of the Optimising Cardiac Surgery ouTcOmes in People with diabeteS intervention were used, but not all parts were used for all participants. Minor changes were made to the intervention following feedback from the participants and healthcare professionals. Median (interquartile range) glycated haemoglobin fell 10 mmol/mol (3-13) prior to surgery. The median duration of admission for surgery was 7 (interquartile range 6-9) days. MULTICENTRE RANDOMISED CONTROLLED STUDY OF THE UNITED KINGDOM CARDIOTHORACIC CENTRES: We could not proceed to the multicentre randomised controlled study because of the impact of COVID-19 on the delivery of cardiothoracic surgical services and research capacity. CONCLUSION: There remains an urgent need to improve the surgical outcomes for people with diabetes. This project demonstrated that it is possible to develop a clinical pathway to improve diabetes management prior to admission. LIMITATIONS: We could not test the effectiveness of the intervention in a multicentre randomised controlled trial because of the COVID-19 pandemic. FUTURE WORK: The intervention is available for future research or clinical implementation. FUNDING: This synopsis presents independent research funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programmme as award number 16/25/12. FAU - Holt, Richard Ig AU - Holt RI AUID- ORCID: 0000-0001-8911-6744 AD - School of Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UK. AD - National Institute for Health and Care Research Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK. FAU - Barnard-Kelly, Katharine AU - Barnard-Kelly K AUID- ORCID: 0000-0002-3888-3123 AD - Barnard Health - Health Psychology Research, Fareham, UK. FAU - Patel, Mayank AU - Patel M AUID- ORCID: 0000-0002-6609-5394 AD - Diabetes Department, University Hospital Southampton NHS Foundation Trust, Southampton, UK. FAU - Newland-Jones, Philip AU - Newland-Jones P AUID- ORCID: 0000-0001-6056-0008 AD - Diabetes Department, University Hospital Southampton NHS Foundation Trust, Southampton, UK. FAU - Luthra, Suvitesh AU - Luthra S AUID- ORCID: 0000-0001-7911-1894 AD - Cardiothoracic Surgery Department, University Hospital Southampton NHS Foundation Trust, Southampton, UK. FAU - Picot, Jo AU - Picot J AUID- ORCID: 0000-0001-5987-996X AD - Southampton Health Technology Assessments Centre, University of Southampton, Southampton, UK. FAU - Partridge, Helen AU - Partridge H AUID- ORCID: 0009-0001-0454-7148 AD - Diabetes Department, University Hospitals Dorset NHS Foundation Trust, Bournemouth, UK. FAU - Cook, Andrew AU - Cook A AUID- ORCID: 0000-0002-6680-439X AD - Clinical Trials Unit, Faculty of Medicine, University of Southampton, Southampton, UK. CN - OCTOPuS Study Group LA - eng PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't PL - England TA - Health Technol Assess JT - Health technology assessment (Winchester, England) JID - 9706284 SB - IM MH - Humans MH - Pilot Projects MH - Feasibility Studies MH - *Cardiac Surgical Procedures MH - United Kingdom MH - *Diabetes Mellitus/therapy MH - COVID-19/epidemiology MH - Female MH - Male MH - Aged MH - Middle Aged MH - Preoperative Care/methods PMC - PMC12376008 OAB - People with diabetes whose blood sugar levels are too high tend to have a slower recovery after surgery. They are more likely to get infections (both chest infections and in their surgical wounds). They cannot go home as quickly after surgery as those without diabetes or those with diabetes whose sugar levels are closer to normal. Their risk of dying after surgery is also higher. Several years ago, a hospital in Bournemouth developed an outpatient-based approach to improve blood glucose levels in the weeks before surgery. They have shown that in patients receiving joint replacements, this approach reduced the time they had to stay in hospital. In this project, we adapted the approach from Bournemouth so that it could be used for people undergoing heart surgery. We tested it in Southampton and showed that it was well received by patients and healthcare professionals and reduced blood sugar levels. We originally planned to test this approach in up to 15 hospitals across the United Kingdom in a large trial, but we were unable to perform this study because of the effects of the COVID-19 pandemic. Nevertheless, we have made the intervention available for use, and this could form the basis for future research or use in clinical practice. OABL- eng OTO - NOTNLM OT - CARDIOVASCULAR DISEASE OT - COVID-19 OT - DIABETES MELLITUS OT - FEASIBILITY STUDIES OT - HYPERGLYCAEMIA OT - LENGTH OF STAY OT - MORBIDITY OT - NURSE'S ROLE OT - OBESITY OT - OUTPATIENTS OT - SURGEONS OT - TREATMENT OUTCOME EDAT- 2025/08/18 06:28 MHDA- 2025/08/31 20:08 PMCR- 2025/08/25 CRDT- 2025/08/18 04:43 PHST- 2025/08/31 20:08 [medline] PHST- 2025/08/18 06:28 [pubmed] PHST- 2025/08/18 04:43 [entrez] PHST- 2025/08/25 00:00 [pmc-release] AID - 10.3310/POYW3311 [doi] PST - ppublish SO - Health Technol Assess. 2025 Aug;29(39):1-31. doi: 10.3310/POYW3311. PMID- 40819359 OWN - NLM STAT- MEDLINE DCOM- 20250828 LR - 20250828 IS - 1066-2936 (Print) IS - 1066-2936 (Linking) VI - 52 IP - 2 DP - 2025 Second Quarter TI - Technical Suitability of Implantable Cardiac Devices for Recreational Diving. PG - 169-177 AB - BACKGROUND: Diving is a diffused recreational activity, and the number of divers carrying cardiac implanted devices is similarly growing. Due to the lack of guidelines or technical indications, the suitability of such devices for diving or the fitness to dive for these patients still needs to be determined. OBJECTIVE: This work summarizes implantable cardiac devices' suitability for recreational diving, technical vulnerability factors, and recommendations to improve implanted divers' safety. METHODS: Between May 1, 2021, and March 20, 2022, three interventional cardiologists retrieved the technical documentation of selected implantable cardiac devices. In particular, any suitability and tests conducted in hyperbaric environments were tracked. RESULTS: Technical documentation was recovered for four companies. Most devices were tested in hyperbaric conditions in single, prolonged, or repeated exposures to pressurized air; underwater tests were not mentioned. No company expressly disclosed the suitability of the devices for underwater activities. CONCLUSION: In the absence of technical indications or guidelines, a multidisciplinary evaluation between cardiology, diving medicine, and sports medicine is essential to establish the suitability for underwater sports in implanted patients. Before each diving trip, device control is advisable, and underwater physiological adaptations should be considered, especially in the cardiovascular domain. Stressors other than water and pressure must be considered during diving, such as lead strain caused by arm movements and pressure exerted by suits or buoyancy control devices on the chest. Future directions point towards a follow-up of implanted, active divers and developing leadless devices and underwater telemonitoring. CI - Copyright(c) Undersea and Hyperbaric Medical Society. FAU - Paganini, Matteo AU - Paganini M AD - Department of Biomedical Sciences, University of Padova, Padova, Italy. FAU - Tarsia, Luigi AU - Tarsia L AD - Department of Medical and Surgical Sciences, DIMEC, University of Bologna, Bologna, Italy. AD - Cardiology Division, IRCCS Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola-Malpighi, Bologna, Italy. FAU - Bosco, Gerardo AU - Bosco G AD - Department of Biomedical Sciences, University of Padova, Padova, Italy. FAU - Camporesi, Enrico M AU - Camporesi EM AD - TEAMHealth Research Institute, Tampa General Hospital, Tampa, Florida, USA. FAU - Biffi, Mauro AU - Biffi M AD - Cardiology Division, IRCCS Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola-Malpighi, Bologna, Italy. FAU - Martignani, Cristian AU - Martignani C AD - Cardiology Division, IRCCS Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola-Malpighi, Bologna, Italy. FAU - Ziacchi, Matteo AU - Ziacchi M AD - Cardiology Division, IRCCS Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola-Malpighi, Bologna, Italy. FAU - Boriani, Giuseppe AU - Boriani G AD - Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy. FAU - Vitolo, Marco AU - Vitolo M AD - Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy. AD - Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy. FAU - Diemberger, Igor AU - Diemberger I AD - Department of Medical and Surgical Sciences, DIMEC, University of Bologna, Bologna, Italy. AD - Cardiology Division, IRCCS Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola-Malpighi, Bologna, Italy. LA - eng PT - Journal Article PL - United States TA - Undersea Hyperb Med JT - Undersea & hyperbaric medicine : journal of the Undersea and Hyperbaric Medical Society, Inc JID - 9312954 SB - IM MH - Humans MH - Cardiology/standards MH - Cardiorespiratory Fitness MH - *Defibrillators, Implantable/standards MH - *Diving/adverse effects/standards MH - Guidelines as Topic MH - *Pacemaker, Artificial/standards MH - Pressure/adverse effects MH - Diving and Hyperbaric Medicine/standards OTO - NOTNLM OT - cardiac arrest OT - diving OT - drowning OT - electrophysiology OT - implantable cardiac device OT - pacemaker COIS- The authors of this paper declare no conflicts of interest exist with this submission. EDAT- 2025/08/17 12:41 MHDA- 2025/08/31 20:08 CRDT- 2025/08/17 11:52 PHST- 2025/08/31 20:08 [medline] PHST- 2025/08/17 12:41 [pubmed] PHST- 2025/08/17 11:52 [entrez] PST - ppublish SO - Undersea Hyperb Med. 2025 Second Quarter;52(2):169-177. PMID- 40817750 OWN - NLM STAT- MEDLINE DCOM- 20251223 LR - 20260817 IS - 1744-8298 (Electronic) IS - 1479-6678 (Print) IS - 1479-6678 (Linking) VI - 21 IP - 12 DP - 2025 Dec TI - Pregnancy with prosthetic heart valves: navigating risks, anticoagulation, and valve function in a growing population. PG - 1091-1096 LID - 10.1080/14796678.2025.2548152 [doi] AB - Pregnancy in patients with prosthetic heart valves presents complex challenges requiring multidisciplinary care and individualized decision-making. While bioprosthetic valves are often preferred in women of childbearing age to avoid anticoagulation-related fetal risks, these valves are susceptible to structural degeneration potentially accelerated by the physiologic demands of pregnancy. Conversely, mechanical valves offer durability but necessitate lifelong anticoagulation, posing substantial risks of valve thrombosis, fetal hemorrhage, and warfarin embryopathy. The Ross operation, which can be considered for individuals with advanced aortic valve disease, is an appealing option yet is offered only in highly specialized centers. In this review, we present contemporary data on maternal and fetal outcomes, valve function, and anticoagulation strategies in pregnant patients with mechanical and bioprosthetic heart valves. We highlight geographical and knowledge gaps regarding type of valve utilization, optimal anticoagulation in pregnancy, durability of modern valve designs, and long-term reoperation risk. Future research priorities include uniform global approach with improved access to contemporary surgical and medical solutions in low- and middle-income countries, safety of direct oral anticoagulants, improved surveillance of valve function during pregnancy, and comparative studies of bioprosthetic valve models. By consolidating evolving evidence, we aim to support informed decision-making and multidisciplinary management for this high-risk patient population. FAU - Joshi, Ishani AU - Joshi I AD - Department of Medicine, University of Washington, Seattle, WA, USA. FAU - Buber, Jonathan AU - Buber J AD - Department of Cardiology, University of Washington, Seattle, WA, USA. LA - eng PT - Journal Article PT - Review DEP - 20250816 PL - England TA - Future Cardiol JT - Future cardiology JID - 101239345 RN - 0 (Anticoagulants) SB - IM MH - Humans MH - Pregnancy MH - Female MH - *Heart Valve Prosthesis/adverse effects MH - *Anticoagulants/therapeutic use MH - *Pregnancy Complications, Cardiovascular MH - *Heart Valve Diseases/surgery MH - Bioprosthesis MH - Risk Factors MH - Pregnancy Outcome MH - Prosthesis Design PMC - PMC12758166 OAB - Many women with heart valve replacements (also called prosthetic valves) are now living long, healthy lives and may wish to become pregnant. However, pregnancy puts extra strain on the heart and creates special challenges for women with these valves. This is because the heart needs to pump more blood, and some valves - especially mechanical ones - require blood-thinning medications that can affect both the mother and the baby.In this review, we summarize what is currently known about how different types of prosthetic valves behave during pregnancy. We discuss the changes that happen in a woman's body during pregnancy and how these may impact valve function. We also review the risks and benefits of the two main types of valves - mechanical and bioprosthetic - and how they influence pregnancy planning, care during delivery, and long-term outcomes.We highlight the importance of a team-based approach to care, including heart doctors, pregnancy specialists, and others, to help ensure the best outcomes for both mother and baby. We also emphasize how important it is for women with prosthetic valves to meet with their care team before becoming pregnant, so they can receive advice that is tailored to their specific needs. OABL- eng OTO - NOTNLM OT - Thrombosis OT - Valvular heart disease OT - cardiac imaging OT - comparative effectiveness OT - mitral stenosis OT - personalized medicine COIS- The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties EDAT- 2025/08/16 06:28 MHDA- 2025/12/23 12:48 PMCR- 2026/08/16 CRDT- 2025/08/16 05:02 PHST- 2025/12/23 12:48 [medline] PHST- 2025/08/16 06:28 [pubmed] PHST- 2025/08/16 05:02 [entrez] PHST- 2026/08/16 00:00 [pmc-release] AID - 2548152 [pii] AID - 10.1080/14796678.2025.2548152 [doi] PST - ppublish SO - Future Cardiol. 2025 Dec;21(12):1091-1096. doi: 10.1080/14796678.2025.2548152. Epub 2025 Aug 16. PMID- 40816333 OWN - NLM STAT- MEDLINE DCOM- 20251103 LR - 20260411 IS - 1531-5053 (Electronic) IS - 0278-2391 (Linking) VI - 83 IP - 11 DP - 2025 Nov TI - Is Procedural Anesthesia Safety Similar Between Residents and Attending Surgeons? PG - 1314-1320 LID - S0278-2391(25)00647-0 [pii] LID - 10.1016/j.joms.2025.07.004 [doi] AB - BACKGROUND: The safety of the single-provider anesthesia model in oral and maxillofacial surgery (OMS) is well established. While previous studies have shown operative outcomes similar between attending surgeons and resident trainees, it remains unclear if the same is true for procedural (deep sedation to general) anesthesia. PURPOSE: The study purpose was to estimate and compare the frequencies of anesthesia-related adverse events between residents and attendings. STUDY DESIGN, SETTING, SAMPLE: This was a retrospective cohort study. Subjects who received procedural sedation between 2012 and 2020 at the University of Alabama at Birmingham outpatient clinics were identified through review of electronic medical records and paper charts. Exclusion criteria included incomplete documentation of demographics, periprocedural events, or sedation medications, and procedures not performed by providers within the University of Alabama at Birmingham Department of OMS. The sedation model adheres to the American Association of Oral and Maxillofacial Surgeons team-based approach, emphasizing structured roles and monitoring. PREDICTOR VARIABLE: The predictor variable was the type of surgeon performing the procedural sedation: attending versus resident. OUTCOME VARIABLE: The outcome variables were adverse events (respiratory, cardiac, neurological, allergy, aspiration, and medication errors). COVARIATES: Subject demographics (age, sex), smoking status, American Society of Anesthesiologists physical status, medications (identity, dose, and route), and procedure duration. ANALYSES: Descriptive statistics were reported as counts and frequencies for categorical variables and means, standard deviations, ranges, and interquartile ranges for continuous variables. chi(2) and Fisher exact test was used for bivariate analysis. P value <.05 was considered statistically significant. All analyses were conducted using SAS 9.4. RESULTS: The sample was composed of 3,940 subjects with a mean age of 37.05 +/- 21.41 years, and n = 1,595 (41.52%) were male (P =< .001). There were n = 985 (25.1%) and n = 2,951 (74.9%) subjects in the resident and attending samples, respectively. One adverse event (0.1%) occurred in the resident clinic (apnea), while 2 events (0.07%) occurred in the attending clinic (bradycardia; postoperative nausea and vomiting), with no statistically significant difference between groups (P = 1.0). CONCLUSIONS AND RELEVANCE: Procedural sedation administered by both OMS residents and attendings in an academic outpatient setting demonstrated a similarly low rate of adverse events (0.08%), with no permanent sequelae. These findings support the safety of supervised resident-delivered sedation and validate current OMS training protocols. CI - Copyright (c) 2025 American Association of Oral and Maxillofacial Surgeons. Published by Elsevier Inc. All rights reserved. FAU - Hofheins, John AU - Hofheins J AD - Resident, Department of Oral and Maxillofacial Surgery, University of Alabama at Birmingham, Birmingham, AL. Electronic address: hofheins@uab.edu. FAU - Provenzano, Carl AU - Provenzano C AD - Resident, Department of Oral and Maxillofacial Surgery, University of Alabama at Birmingham, Birmingham, AL. FAU - Ma, Boyu AU - Ma B AD - Resident, Department of Oral and Maxillofacial Surgery, University of Alabama at Birmingham, Birmingham, AL. FAU - Le, John M AU - Le JM AD - Fellow, Department of Oral and Maxillofacial Surgery, University of Florida Health Science Center Jacksonville. FAU - Powell, Kathlyn AU - Powell K AD - Associate Professor/Program Director, Department of Oral and Maxillofacial Surgery, University of Alabama at Birmingham, Birmingham, AL. FAU - Morlandt, Anthony AU - Morlandt A AD - Professor/Vice Chair, Department of Oral and Maxillofacial Surgery, University of Alabama at Birmingham, Birmingham, AL. LA - eng PT - Comparative Study PT - Journal Article DEP - 20250723 PL - United States TA - J Oral Maxillofac Surg JT - Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons JID - 8206428 SB - IM MH - Humans MH - Retrospective Studies MH - *Internship and Residency MH - Male MH - Female MH - Middle Aged MH - Adult MH - *Surgery, Oral/education MH - *Anesthesia, Dental/adverse effects MH - *Patient Safety MH - *Anesthesia, General/adverse effects MH - *Deep Sedation/adverse effects MH - *Oral Surgical Procedures MH - Alabama EDAT- 2025/08/16 00:30 MHDA- 2025/11/04 00:28 CRDT- 2025/08/15 19:21 PHST- 2025/03/02 00:00 [received] PHST- 2025/07/05 00:00 [revised] PHST- 2025/07/17 00:00 [accepted] PHST- 2025/11/04 00:28 [medline] PHST- 2025/08/16 00:30 [pubmed] PHST- 2025/08/15 19:21 [entrez] AID - S0278-2391(25)00647-0 [pii] AID - 10.1016/j.joms.2025.07.004 [doi] PST - ppublish SO - J Oral Maxillofac Surg. 2025 Nov;83(11):1314-1320. doi: 10.1016/j.joms.2025.07.004. Epub 2025 Jul 23. PMID- 40812624 OWN - NLM STAT- MEDLINE DCOM- 20250910 LR - 20260821 IS - 1874-1754 (Electronic) IS - 0167-5273 (Linking) VI - 441 DP - 2025 Dec 15 TI - Pregnancy outcomes in women with the highest cardiovascular risk (mWHO class IV): A single-centre study. PG - 133774 LID - S0167-5273(25)00817-4 [pii] LID - 10.1016/j.ijcard.2025.133774 [doi] AB - INTRODUCTION: The modified World Health Organization (mWHO) classification of maternal risk is used to estimate morbidity and mortality in pregnant women with cardiovascular disease. Despite guidelines advising against pregnancy in the highest risk category (mWHO Class IV), successful outcomes have been achieved in select managed cases with specialised multidisciplinary care. This single-centre study examines pregnancy outcomes in this high-risk group. METHODS: We conducted a retrospective cohort study of 32 pregnancies in 30 women classified as mWHO Class IV between 2008 and 2022. Maternal demographics, cardiac and obstetric complications, delivery details, neonatal outcomes, and long-term follow-up data were collected and analysed. RESULTS: The mean maternal age at delivery was 29.6 +/- 5.1 years. Pulmonary arterial hypertension (PAH) and systemic ventricular dysfunction were the most prevalent conditions. Cardiovascular events occurred in 65.6 % of pregnancies, with PAH accounting for the majority. All women delivered via Caesarean section, with 93.7 % under general anaesthesia. Preterm birth occurred in 75 % of cases, and 87 % of neonates required NICU admission. One maternal death occurred in the late postpartum period. At one year, the major adverse cardiovascular event (MACE) rate was 9.3 %. Long-term follow-up revealed three additional maternal deaths. CONCLUSIONS: Although pregnancy in women with mWHO Class IV disease carries substantial risk, favourable outcomes are achievable in a tertiary centre with a specialised Pregnancy Heart Team. However, the burden of morbidity remains high, reinforcing the need for early counselling, close surveillance, and long-term follow-up in this vulnerable population. CI - Copyright (c) 2025 Elsevier B.V. All rights reserved. FAU - Nashat, Heba AU - Nashat H AD - Adult Congenital Heart Centre and Centre for Pulmonary Hypertension, Royal Brompton Hospital, London, United Kingdom; Heart and Lung Institute, Imperial College London, United Kingdom. FAU - Masding, Abigail AU - Masding A AD - Adult Congenital Heart Centre and Centre for Pulmonary Hypertension, Royal Brompton Hospital, London, United Kingdom. FAU - Krishnathasan, Kaushiga AU - Krishnathasan K AD - Adult Congenital Heart Centre and Centre for Pulmonary Hypertension, Royal Brompton Hospital, London, United Kingdom; Heart and Lung Institute, Imperial College London, United Kingdom. FAU - Guglielmi, Giulia AU - Guglielmi G AD - Adult Congenital Heart Centre and Centre for Pulmonary Hypertension, Royal Brompton Hospital, London, United Kingdom. FAU - Ferrara, Laura AU - Ferrara L AD - Department of Obstetrics and Gynaecology, Chelsea and Westminster Hospital, London, United Kingdom. FAU - Swan, Lorna AU - Swan L AD - Adult Congenital Heart Centre and Centre for Pulmonary Hypertension, Royal Brompton Hospital, London, United Kingdom. FAU - Alexander, David AU - Alexander D AD - Adult Congenital Heart Centre and Centre for Pulmonary Hypertension, Royal Brompton Hospital, London, United Kingdom. FAU - Price, Susana AU - Price S AD - Adult Congenital Heart Centre and Centre for Pulmonary Hypertension, Royal Brompton Hospital, London, United Kingdom. FAU - Pires, Ana AU - Pires A AD - Adult Congenital Heart Centre and Centre for Pulmonary Hypertension, Royal Brompton Hospital, London, United Kingdom. FAU - Patel, Roshni AU - Patel R AD - Department of Obstetrics and Gynaecology, Chelsea and Westminster Hospital, London, United Kingdom. FAU - Price, Laura C AU - Price LC AD - Adult Congenital Heart Centre and Centre for Pulmonary Hypertension, Royal Brompton Hospital, London, United Kingdom; Heart and Lung Institute, Imperial College London, United Kingdom. FAU - Wort, Stephen J AU - Wort SJ AD - Adult Congenital Heart Centre and Centre for Pulmonary Hypertension, Royal Brompton Hospital, London, United Kingdom; Heart and Lung Institute, Imperial College London, United Kingdom. FAU - Wander, Gurleen AU - Wander G AD - Department of Obstetrics and Gynaecology, Chelsea and Westminster Hospital, London, United Kingdom. FAU - Steer, Philip AU - Steer P AD - Department of Obstetrics and Gynaecology, Chelsea and Westminster Hospital, London, United Kingdom; Faculty of medicine, Imperial College London, United Kingdom. FAU - Gatzoulis, Michael AU - Gatzoulis M AD - Adult Congenital Heart Centre and Centre for Pulmonary Hypertension, Royal Brompton Hospital, London, United Kingdom; Heart and Lung Institute, Imperial College London, United Kingdom. FAU - Dimopoulos, Konstantinos AU - Dimopoulos K AD - Adult Congenital Heart Centre and Centre for Pulmonary Hypertension, Royal Brompton Hospital, London, United Kingdom; Heart and Lung Institute, Imperial College London, United Kingdom. FAU - Johnson, Mark AU - Johnson M AD - Department of Obstetrics and Gynaecology, Chelsea and Westminster Hospital, London, United Kingdom; Faculty of medicine, Imperial College London, United Kingdom. FAU - Rafiq, Isma AU - Rafiq I AD - Adult Congenital Heart Centre and Centre for Pulmonary Hypertension, Royal Brompton Hospital, London, United Kingdom; Heart and Lung Institute, Imperial College London, United Kingdom. Electronic address: i.rafiq@rbht.nhs.uk. LA - eng PT - Journal Article DEP - 20250812 PL - Netherlands TA - Int J Cardiol JT - International journal of cardiology JID - 8200291 SB - IM MH - Humans MH - Female MH - Pregnancy MH - Retrospective Studies MH - *Pregnancy Outcome/epidemiology MH - Adult MH - *Pregnancy Complications, Cardiovascular/epidemiology/diagnosis MH - Follow-Up Studies MH - Young Adult MH - Cohort Studies MH - *Cardiovascular Diseases/diagnosis/epidemiology MH - Infant, Newborn MH - Risk Factors OTO - NOTNLM OT - Maternal cardiology OT - Maternal counselling OT - Pregnancy heart team EDAT- 2025/08/14 22:50 MHDA- 2025/09/11 00:28 CRDT- 2025/08/14 19:45 PHST- 2025/05/14 00:00 [received] PHST- 2025/07/07 00:00 [revised] PHST- 2025/08/11 00:00 [accepted] PHST- 2025/09/11 00:28 [medline] PHST- 2025/08/14 22:50 [pubmed] PHST- 2025/08/14 19:45 [entrez] AID - S0167-5273(25)00817-4 [pii] AID - 10.1016/j.ijcard.2025.133774 [doi] PST - ppublish SO - Int J Cardiol. 2025 Dec 15;441:133774. doi: 10.1016/j.ijcard.2025.133774. Epub 2025 Aug 12. PMID- 40811142 OWN - NLM STAT- MEDLINE DCOM- 20251112 LR - 20260918 IS - 2753-670X (Electronic) IS - 2753-670X (Linking) VI - 40 IP - 11 DP - 2025 Nov 6 TI - Interdisciplinary Periprocedural Management of Patients Undergoing Transapical TMVI with the Tendyne System: A Narrative Review and Institutional Experience. LID - 10.1093/icvts/ivaf181 [doi] LID - ivaf181 AB - OBJECTIVES: Mitral regurgitation (MR) represents the most common valvular heart disease (VHD) in the Western world. While transcatheter mitral valve repair (M-TEER) is the leading interventional treatment for surgically high-risk patients, transcatheter mitral valve implantation (TMVI) is reserved for selected patients with unsuitable anatomy for M-TEER. This review aims to summarize our institutional experience with transapical TMVI using the Tendyne valve (Abbott Vascular, CA, USA), focusing on interdisciplinary preoperative, intraoperative, and postoperative management strategies. METHODS: We conducted a narrative review of current literature on TMVI with the Tendyne system and integrated it with a comprehensive analysis of our interdisciplinary clinical experience. Data were collected regarding patient selection, imaging protocols, procedural techniques, and postoperative care. RESULTS: Utilizing the Tendyne valve, TMVI addresses symptomatic moderate-to-severe or severe MR in patients unsuitable for conventional surgery or M-TEER. Successful outcomes require thorough patient selection, including assessment of mitral annular calcification, absence of intracardiac thrombus, low left ventricular outflow tract (LVOT) obstruction risk, and optimal annular sizing. Multimodal imaging, particularly transoesophageal echocardiography and cardiac computed tomography, is essential for procedural planning and execution. TMVI is performed under general anaesthesia with intraoperative transoesophageal guidance and haemodynamic monitoring to minimize complications such as LVOT obstruction, bleeding, and valve malposition. Postoperative management emphasizes haemodynamic stabilization, bleeding control, and surveillance for paravalvular leaks or device dysfunction. CONCLUSIONS: TMVI with the Tendyne valve provides a viable and effective treatment for selected patients with symptomatic relevant MR. Optimal outcomes are dependent on meticulous interdisciplinary collaboration, advanced imaging protocols, and comprehensive perioperative management. CI - (c) The Author(s) 2025. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. FAU - Ferro, Cyril D AU - Ferro CD AUID- ORCID: 0009-0007-2554-2593 AD - Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland. FAU - Praz, Fabien AU - Praz F AUID- ORCID: 0000-0001-5416-165X AD - Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland. FAU - Brugger, Nicolas AU - Brugger N AUID- ORCID: 0000-0002-8778-8421 AD - Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland. FAU - Reineke, David AU - Reineke D AD - Department of Cardiac Surgery, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland. FAU - Terbeck, Sandra AU - Terbeck S AD - Department of Anesthesiology and Pain Medicine, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland. FAU - Setzer, Florian AU - Setzer F AD - Department of Cardiac Surgery, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland. FAU - Windecker, Stephan AU - Windecker S AUID- ORCID: 0000-0003-2653-6762 AD - Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland. FAU - Erdoes, Gabor AU - Erdoes G AUID- ORCID: 0000-0002-6742-1016 AD - Department of Anesthesiology and Pain Medicine, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland. LA - eng PT - Journal Article PT - Review PL - England TA - Interdiscip Cardiovasc Thorac Surg JT - Interdisciplinary cardiovascular and thoracic surgery JID - 9918540787006676 SB - IM MH - Humans MH - *Heart Valve Prosthesis Implantation/instrumentation/adverse effects/methods MH - *Mitral Valve Insufficiency/surgery/physiopathology/diagnostic imaging MH - *Heart Valve Prosthesis MH - *Cardiac Catheterization/adverse effects/instrumentation/methods MH - *Mitral Valve/surgery/diagnostic imaging/physiopathology MH - *Patient Care Team MH - Prosthesis Design MH - Treatment Outcome MH - Patient Selection MH - Perioperative Care MH - Echocardiography, Transesophageal MH - Risk Factors PMC - PMC12597874 OTO - NOTNLM OT - mitral regurgitation OT - mitral stenosis OT - transcatheter edge-to-edge repair OT - transcatheter mitral valve implantation OT - transcatheter mitral valve replacement COIS- Dr Ferro reports no conflicts of interest. Dr Praz has received travel expenses from Edwards Lifesciences, Abbott Vascular, Medira, Siemens Healthineers and InQB8 Medical Technologies, as well as a research grant to the institution from Abbott Vascular. Dr Brugger reports travel expenses from Abbott. Dr Reineke reports travel expenses from Abbott, Edwards Lifesciences and Medtronic and has proctor and consulting contracts with Abbott and Medtronic. Dr Terbeck reports no conflicts of interest. Dr Setzer reports no conflicts of interest. Dr Windecker reports research, travel or educational grants to the institution from Abbott, Abiomed, Amgen, Astra Zeneca, Bayer, Bbraun, Biotronik, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cardinal Health, CardioValve, Cleerly Inc., Cordis Medical, Corflow Therapeutics, CSL Behring, Daiichi Sankyo, Edwards Lifesciences, Farapulse Inc. Fumedica, GE Medical Systems, Gebro Pharma, Guerbet, Idorsia, Inari Medical, InfraRedx, Janssen-Cilag, Johnson & Johnson, Medalliance, Medicure, Medtronic, Merck Sharp & Dohm, Miracor Medical, Neucomed, Novartis, Novo Nordisk, Organon, OrPha Suisse, Pharming Tech, Pfizer, Philips AG, Polares, Regeneron, Sanofi-Aventis, Servier, Siemens Healthcare, Sinomed, SMT Sahajanand Medical Technologies, Terumo, Vifor, V-Wave, Zoll Medical. Dr Windecker serves as advisory board member and/or member of the steering/executive group of trials funded by Abbott, Abiomed, Amgen, Astra Zeneca, Bayer, Boston Scientific, Biotronik, Bristol Myers Squibb, Edwards Lifesciences, MedAlliance, Medtronic, Novartis, Polares, Recardio, Sinomed, Terumo, and V-Wave with payments to the institution but no personal payments. He is also member of the steering/executive committee group of several investigator-initiated trials that receive funding by industry without impact on his personal remuneration. Dr Erdoes reports no conflicts of interest. EDAT- 2025/08/14 22:52 MHDA- 2025/11/12 23:30 PMCR- 2025/08/14 CRDT- 2025/08/14 13:23 PHST- 2025/05/25 00:00 [received] PHST- 2025/08/05 00:00 [accepted] PHST- 2025/11/12 23:30 [medline] PHST- 2025/08/14 22:52 [pubmed] PHST- 2025/08/14 13:23 [entrez] PHST- 2025/08/14 00:00 [pmc-release] AID - 8234525 [pii] AID - ivaf181 [pii] AID - 10.1093/icvts/ivaf181 [doi] PST - ppublish SO - Interdiscip Cardiovasc Thorac Surg. 2025 Nov 6;40(11):ivaf181. doi: 10.1093/icvts/ivaf181. PMID- 40810888 OWN - NLM STAT- MEDLINE DCOM- 20250826 LR - 20261010 IS - 1534-6293 (Electronic) IS - 1528-4042 (Linking) VI - 25 IP - 1 DP - 2025 Aug 14 TI - On Neurocardiology Updates: an Interdisciplinary Field at the Intersection of Neurology and Cardiology. PG - 59 LID - 10.1007/s11910-025-01447-1 [doi] AB - PURPOSE OF REVIEW: This review examines the evolving field of neurocardiology, tracing its development from early homeostatic theories to modern understandings of the bidirectional neural networks that link the heart and brain. We propose an integrative framework to explain neuro-cardiac interactions in health and disease, with a focus on clinical applications and emerging therapies. RECENT FINDINGS: The neuro-cardiac axis comprises hierarchical neural networks, from the intrinsic cardiac nervous system to subcortical and cortical brain regions. This structure underlies a range of clinical syndromes. Acute brain injuries can induce cardiac dysfunction via autonomic dysregulation, as seen in neurogenic stunned myocardium (NSM), while cardiac disease contributes to cerebral small vessel disease (CSVD) and cognitive decline. Cardioception-the brain's processing of cardiac signals-is increasingly recognized as a key mediator of autonomic control and emotional experience. Clinical trials highlight the value of targeted interventions, including extended cardiac monitoring to detect occult atrial fibrillation, improved risk stratification for managing patent foramen ovale, and intensive vascular risk control for cerebrovascular protection. Growing awareness of neuro-cardiac pathways is reshaping clinical care. Understanding how brain insults provoke cardiac dysfunction via disrupted autonomic outflow is critical, particularly in NSM. Meanwhile, cardioception is gaining relevance as a therapeutic target in the regulation of emotions and the autonomic nervous system. Conversely, cardiac pathology promotes stroke, CSVD, and cognitive impairment not only through embolism but also through altered perfusion and autonomic imbalance. Comprehensive management of modifiable vascular risks confers dual protection for the heart and brain. Interdisciplinary collaboration is increasingly vital for managing disorders along the heart-brain continuum. Translating insights from neurocardiac mechanisms into precision therapies marks a new frontier. Advances in neuroimaging, artificial intelligence, and neuromodulation offer opportunities for personalized care. The ongoing development of cross-specialty training and integrated research platforms will be essential for translating scientific progress into improved outcomes in neurocardiac disorders. CI - (c) 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Bhatti, Muhammad Qasim AU - Bhatti MQ AD - Department of Neurology, University of Mississippi Medical Center, Jackson, MS, USA. FAU - Chapman, Ryan AU - Chapman R AD - Department of Neurology, University of Mississippi Medical Center, Jackson, MS, USA. FAU - Kulik, Tobias AU - Kulik T AD - Marion Bloch Neuroscience Institute, Saint Luke's Hospital, Kansas City, MO, USA. AD - Department of Neurology, University of Missouri, Kansas City, MO, USA. FAU - Di Napoli, Mario AU - Di Napoli M AD - Neurological Service, dell'Annunziata Hospital, Sulmona, L'Aquila, Italy. FAU - Bhatia, Kunal AU - Bhatia K AD - Department of Neurology, University of Mississippi Medical Center, Jackson, MS, USA. FAU - Elkind, Mitchell S V AU - Elkind MSV AD - Department of Neurology, Vagelos College of Physicians and Surgeons, and Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA. FAU - Selim, Magdy AU - Selim M AD - Stroke Division, Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. FAU - McCullough, Louise D AU - McCullough LD AD - Department of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA. FAU - Caceres, Eder AU - Caceres E AD - Unisabana Center for Translational Science, School of Medicine, Universidad de La Sabana, Chia, Colombia. AD - Department of Critical Care, Clinica Universidad de La Sabana, Chia, Colombia. FAU - Flaherty, James D AU - Flaherty JD AD - Bluhm Cardiovascular Institute, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. FAU - Zoghi, Mehdi AU - Zoghi M AD - Department of Cardiology, Ege University, Izmir, Turkiye. FAU - Al Qassab, Omar AU - Al Qassab O AD - Department of Medicine, Beth Israel Lahey Health, Burlington, MA, USA. FAU - Divani, Afshin A AU - Divani AA AD - Department of Neurology, UNM Neurology MSC10 5620 1 University of New Mexico, Albuquerque, NM, 87131, USA. adivani@gmail.com. LA - eng GR - R35 NS132265/NS/NINDS NIH HHS/United States PT - Journal Article PT - Review DEP - 20250814 PL - United States TA - Curr Neurol Neurosci Rep JT - Current neurology and neuroscience reports JID - 100931790 SB - IM MH - Humans MH - *Neurology/trends MH - *Cardiology/trends MH - *Heart Diseases/physiopathology/therapy MH - Autonomic Nervous System/physiopathology MH - *Brain/physiopathology OTO - NOTNLM OT - Atrial cardiopathy OT - Autonomic regulation OT - Cardioception OT - Heart-brain axis OT - Integrated care models OT - Neuro-cardiac axis OT - Neurocardiology OT - Neurogenic stunned myocardium OT - Patent foramen ovale OT - Stroke prevention OT - Vascular cognitive impairment COIS- Declarations. Competing Interests: Dr. Elkind is a full-time employee of American Heart Association. Other authors declare no competing interests. EDAT- 2025/08/14 22:51 MHDA- 2025/08/31 20:07 CRDT- 2025/08/14 11:21 PHST- 2025/08/05 00:00 [received] PHST- 2025/08/07 00:00 [accepted] PHST- 2025/08/31 20:07 [medline] PHST- 2025/08/14 22:51 [pubmed] PHST- 2025/08/14 11:21 [entrez] AID - 10.1007/s11910-025-01447-1 [pii] AID - 10.1007/s11910-025-01447-1 [doi] PST - epublish SO - Curr Neurol Neurosci Rep. 2025 Aug 14;25(1):59. doi: 10.1007/s11910-025-01447-1. PMID- 40810441 OWN - NLM STAT- MEDLINE DCOM- 20250826 LR - 20260727 IS - 1929-0748 (Electronic) IS - 1929-0748 (Linking) VI - 14 DP - 2025 Aug 14 TI - An Interdisciplinary Ecosystem for the Prevention of Cardiotoxicity in Older Patients With Breast Cancer: Protocol for a Prospective and Multicentric Study. PG - e63455 LID - 10.2196/63455 [doi] LID - e63455 AB - BACKGROUND: Over 50% of newly diagnosed patients with breast cancer are aged >/=65 years. Due to age-related factors and the presence of comorbidities, these patients are particularly vulnerable to developing cardiac toxicity associated with cancer treatments, which may lead to suboptimal interventions and undertreatment, resulting in poorer health outcomes, quality of life (QoL) deterioration, and increased health care costs. Given the underrepresentation of older patients with breast cancer in clinical trials and the increasing recognition of the impact of psychosocial and behavioral factors on cardiovascular disease onset, broader and interdisciplinary studies are required to develop new and innovative best practices for this clinical population. OBJECTIVE: Using an innovative eHealth approach combining the CARDIOCARE (An Interdisciplinary Approach for the Management of the Elderly Multimorbid Patient with Breast Cancer Therapy Induced Cardiac Toxicity-grant agreement 945175) mobile app and technologically advanced wearable devices (ie, the Garmin Venu SQ watch and Polar H10 sensor), the CARDIOCARE prospective study pursues a twofold aim: (1) testing the effectiveness of the CARDIOCARE mobile app to monitor and assess the intrinsic capacity and QoL of older patients with breast cancer and evaluating the CARDIOCARE eHealth interventions' effectiveness on these parameters and (2) developing a holistic, patient-centered risk prediction model specific for the detection of cardiotoxicity before it clinically emerges. METHODS: This prospective and multicentric study involves 6 clinical and 5 technical partners across Europe. In total, 750 older patients with breast cancer (aged >/=60 years) are assigned to either the standard practice or enhanced monitoring group, with only patients in the latter receiving access to eHealth psychological, behavioral, and functional interventions implemented on the CARDIOCARE eHealtHeart app. Patients will be recruited in 6 clinical centers and will undergo clinical procedures to collect multimodal data, including clinical data, cardiac imaging, biochemical and psychological biomarkers and omics, intrinsic capacity, and QoL indicators measured at baseline (T0) and every 3 months up to 12 months (T5). RESULTS: CARDIOCARE is a project funded by Horizon 2020, and enrollment started in May 2023. As of October 17, 2024, a total of 50% (375/750) of the target number of patients had been recruited. CONCLUSIONS: The CARDIOCARE prospective study will contribute to developing new best practice guidelines for managing older patients with breast cancer and multimorbidity while preserving their intrinsic capacity and improving their QoL. Furthermore, the CARDIOCARE mobile app and the wearable devices will allow clinicians to identify trajectories across the cardiotoxicity disease continuum and thus intervene in a preventative way among patients at higher risk. Such a health care approach will also benefit the health care system, which currently spends almost 40% of its resources on patients aged >60 years, with long-term care and hospital admissions being the primary cost drivers. TRIAL REGISTRATION: ClinicalTrials.gov NCT06334445; https://clinicaltrials.gov/study/NCT06334445. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/63455. CI - (c)Gaia Giulia Angela Sacco, Ketti Mazzocco, Anastasia Constantinidou, Andri Papakonstantinou, Davide Mauri, Grigorios Kalliatakis, Manolis Tsiknakis, Domen Ribnikar, Dorothea Tsekoura, Valantis Aidarinis, Kalliopi Keramida, Panagiotis Oikonomopoulos, Athos Antoniades, Cameron Brown, Federica Rizzi, Anca Bucur, Elsa Pacella, Georgia Karanasiou, Daniela Cardinale, Carlo Cipolla, Elisabetta Munzone, Dimitrios Fotiadis, Giuseppe Curigliano, Gabriella Pravettoni. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 14.08.2025. FAU - Sacco, Gaia Giulia Angela AU - Sacco GGA AUID- ORCID: 0000-0002-5450-5317 AD - European Institute of Oncology, IRCCS, Milan, Italy. FAU - Mazzocco, Ketti AU - Mazzocco K AUID- ORCID: 0000-0003-1382-6779 AD - European Institute of Oncology, IRCCS, Milan, Italy. AD - Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy. FAU - Constantinidou, Anastasia AU - Constantinidou A AUID- ORCID: 0000-0001-5316-7574 AD - Medical Oncology Department, Bank of Cyprus Oncology Centre, Nicosia, Cyprus. FAU - Papakonstantinou, Andri AU - Papakonstantinou A AUID- ORCID: 0000-0002-4232-4658 AD - Oncology-Pathology Dept., Karolinska Institutet - Cancer Center Karolinska (CCK), Solna, Sweden. FAU - Mauri, Davide AU - Mauri D AUID- ORCID: 0000-0002-8501-5986 AD - Medical Oncology Department, General Hospital of Lamia, Lamia, Greece. FAU - Kalliatakis, Grigorios AU - Kalliatakis G AUID- ORCID: 0000-0002-2194-7709 AD - Computation, Computational BioMedicine Laboratory (CBML), Foundation for Research and Technology-Hellas (FORTH), Heraklion, Greece. FAU - Tsiknakis, Manolis AU - Tsiknakis M AUID- ORCID: 0000-0001-8454-1450 AD - Department of Electrical & Computer Engineering, Hellenic Mediterranean University (HMU), Chania, Greece. FAU - Ribnikar, Domen AU - Ribnikar D AUID- ORCID: 0000-0001-5146-4524 AD - Medical Oncology Department, Institute of Oncology Ljubljana, Ljubljana, Slovenia. FAU - Tsekoura, Dorothea AU - Tsekoura D AUID- ORCID: 0000-0002-9896-964X AD - 2nd Department of Surgery, Aretaieio University Hospital, National and Kapodistrian University of Athens, Athens, Greece. FAU - Aidarinis, Valantis AU - Aidarinis V AUID- ORCID: 0009-0004-7405-3217 AD - 2nd Department of Surgery, Aretaieio University Hospital, National and Kapodistrian University of Athens, Athens, Greece. FAU - Keramida, Kalliopi AU - Keramida K AUID- ORCID: 0000-0002-9533-6951 AD - 2nd Department of Cardiology, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece. FAU - Oikonomopoulos, Panagiotis AU - Oikonomopoulos P AUID- ORCID: 0000-0002-6417-8241 AD - 2nd Department of Cardiology, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece. FAU - Antoniades, Athos AU - Antoniades A AUID- ORCID: 0000-0002-5789-5103 AD - Stremble Ventures LTD, Limassol, Cyprus. FAU - Brown, Cameron AU - Brown C AUID- ORCID: 0000-0002-6736-0620 AD - Stremble Ventures LTD, Limassol, Cyprus. FAU - Rizzi, Federica AU - Rizzi F AUID- ORCID: 0000-0002-4606-6553 AD - IMS - Istituto di Management Sanitario, Bresso, Italy. FAU - Bucur, Anca AU - Bucur A AUID- ORCID: 0000-0002-1940-5652 AD - Philips Research Europe, Eindhoven, The Netherlands. FAU - Pacella, Elsa AU - Pacella E AUID- ORCID: 0009-0007-1141-8583 AD - ESC, European Society of Cardiology, Sophia Antipolis, France. FAU - Karanasiou, Georgia AU - Karanasiou G AUID- ORCID: 0000-0001-9478-0375 AD - Department of Materials Science and Engineering, UOI - University of Ioannina, Ioannina, Greece. FAU - Cardinale, Daniela AU - Cardinale D AUID- ORCID: 0000-0002-4038-8033 AD - European Institute of Oncology, IRCCS, Milan, Italy. FAU - Cipolla, Carlo AU - Cipolla C AUID- ORCID: 0000-0003-4168-1474 AD - European Institute of Oncology, IRCCS, Milan, Italy. FAU - Munzone, Elisabetta AU - Munzone E AUID- ORCID: 0000-0003-3371-3878 AD - European Institute of Oncology, IRCCS, Milan, Italy. FAU - Fotiadis, Dimitrios AU - Fotiadis D AUID- ORCID: 0000-0002-7362-5082 AD - Department of Materials Science and Engineering, UOI - University of Ioannina, Ioannina, Greece. FAU - Curigliano, Giuseppe AU - Curigliano G AUID- ORCID: 0000-0003-1781-2518 AD - European Institute of Oncology, IRCCS, Milan, Italy. AD - Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy. FAU - Pravettoni, Gabriella AU - Pravettoni G AUID- ORCID: 0000-0002-4843-4663 AD - European Institute of Oncology, IRCCS, Milan, Italy. AD - Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy. LA - eng SI - ClinicalTrials.gov/NCT06334445 PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20250814 PL - Canada TA - JMIR Res Protoc JT - JMIR research protocols JID - 101599504 RN - 0 (Antineoplastic Agents) SB - IM MH - Aged MH - Aged, 80 and over MH - Female MH - Humans MH - *Antineoplastic Agents/adverse effects MH - *Breast Neoplasms/drug therapy/complications MH - *Cardiotoxicity/prevention & control/etiology MH - Mobile Applications MH - Multicenter Studies as Topic MH - Prospective Studies MH - Quality of Life MH - Telemedicine MH - Observational Studies as Topic PMC - PMC12395101 OTO - NOTNLM OT - breast cancer OT - cardiotoxicity OT - eHealth OT - mobile app OT - older adult OT - prospective study OT - risk prediction model COIS- Conflicts of Interest: GC is on the advisory board for Roche, Pfizer, AstraZeneca, Daichii Sankyo, Lilly, Novartis, Menarini, Gilead, and Exact Sciences. All other authors declare no conflicts of interest. EDAT- 2025/08/14 22:51 MHDA- 2025/09/01 16:45 PMCR- 2025/08/14 CRDT- 2025/08/14 08:22 PHST- 2024/06/20 00:00 [received] PHST- 2025/02/26 00:00 [accepted] PHST- 2025/01/09 00:00 [revised] PHST- 2025/09/01 16:45 [medline] PHST- 2025/08/14 22:51 [pubmed] PHST- 2025/08/14 08:22 [entrez] PHST- 2025/08/14 00:00 [pmc-release] AID - v14i1e63455 [pii] AID - 10.2196/63455 [doi] PST - epublish SO - JMIR Res Protoc. 2025 Aug 14;14:e63455. doi: 10.2196/63455. PMID- 40807025 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250817 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 14 IP - 15 DP - 2025 Jul 31 TI - Transcatheter Aortic Valve Implantation in Cardiogenic Shock: Current Evidence, Clinical Challenges, and Future Directions. LID - 10.3390/jcm14155398 [doi] LID - 5398 AB - Cardiogenic shock (CS) in the setting of severe aortic stenosis (AS) presents a critical and high-risk scenario with limited therapeutic options and poor prognosis. Transcatheter aortic valve implantation (TAVI), initially reserved for inoperable or high-risk surgical candidates, is increasingly being considered in patients with CS due to improvements in device technology, operator experience, and supportive care. This review synthesizes current evidence from large registries, observational studies, and meta-analyses that support the feasibility, safety, and potential survival benefit of urgent or emergent TAVI in selected CS patients. Procedural success is high, and early intervention appears to confer improved short-term and mid-term outcomes compared to balloon aortic valvuloplasty or medical therapy alone. Critical factors influencing prognosis include lactate levels, left ventricular ejection fraction, renal function, and timing of intervention. The absence of formal guidelines, logistical constraints, and ethical concerns complicate decision-making in this unstable population. A multidisciplinary Heart Team/Shock Team approach is essential to identify appropriate candidates, manage procedural risk, and guide post-intervention care. Further studies and the development of TAVI-specific risk models in CS are anticipated to refine patient selection and therapeutic strategies. TAVI may represent a transformative option for stabilizing hemodynamics and improving outcomes in this otherwise high-mortality group. FAU - Karamasis, Grigoris V AU - Karamasis GV AUID- ORCID: 0000-0002-4560-7629 AD - Cardiology Department, Attikon University Hospital, National and Kapodistrian University of Athens Medical School, Rimini 1, Chaidari, 12462 Athens, Greece. FAU - Kourek, Christos AU - Kourek C AUID- ORCID: 0000-0003-4348-2153 AD - Cardiology Department, Attikon University Hospital, National and Kapodistrian University of Athens Medical School, Rimini 1, Chaidari, 12462 Athens, Greece. FAU - Alexopoulos, Dimitrios AU - Alexopoulos D AUID- ORCID: 0000-0001-5210-9807 AD - 7th Department of Cardiology, Hygeia Hospital, 15123 Athens, Greece. FAU - Parissis, John AU - Parissis J AD - Heart Failure Unit and University Clinic of Emergency Medicine, Attikon University Hospital, National and Kapodistrian University of Athens Medical School, Rimini 1, Chaidari, 12462 Athens, Greece. LA - eng PT - Journal Article PT - Review DEP - 20250731 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC12348004 OTO - NOTNLM OT - aortic stenosis OT - cardiogenic shock OT - heart failure OT - transcatheter aortic valve implantation (TAVI) COIS- The authors declare no conflict of interest. EDAT- 2025/08/14 06:28 MHDA- 2025/08/14 06:29 PMCR- 2025/07/31 CRDT- 2025/08/14 01:15 PHST- 2025/06/22 00:00 [received] PHST- 2025/07/24 00:00 [revised] PHST- 2025/07/30 00:00 [accepted] PHST- 2025/08/14 06:29 [medline] PHST- 2025/08/14 06:28 [pubmed] PHST- 2025/08/14 01:15 [entrez] PHST- 2025/07/31 00:00 [pmc-release] AID - jcm14155398 [pii] AID - jcm-14-05398 [pii] AID - 10.3390/jcm14155398 [doi] PST - epublish SO - J Clin Med. 2025 Jul 31;14(15):5398. doi: 10.3390/jcm14155398. PMID- 40804935 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250817 IS - 2075-4418 (Print) IS - 2075-4418 (Electronic) IS - 2075-4418 (Linking) VI - 15 IP - 15 DP - 2025 Aug 6 TI - "Single Coronary Artery" from Right Sinus-Uncommon Causes of Ischemia with Non-Obstructive Coronary Arteries. LID - 10.3390/diagnostics15151971 [doi] LID - 1971 AB - Anomalies of coronary artery origins are rare but significant conditions that can range from benign to life-threatening. Early detection through imaging is crucial in preventing adverse outcomes. The treatment strategy varies depending on the type and severity of the anomaly, ranging from pharmacological treatment to surgery. A 22-year-old male patient, after syncope, after excluding other causes, had an exercise drill test, which was clinically negative and ECG-positive. Angio-CT revealed an undeveloped left main coronary artery (LMCA), and the circulation was supplied through the right coronary artery (RCA). The RCA provides the left anterior descending artery (LAD), and the LAD retrogradely supplies the left circumflex artery (LCX). The myocardial perfusion scintigraphy showed a slight lack of perfusion in the anterior wall (6% of total perfusion). The patient was qualified for further observation. A 77-year-old female underwent cardiac CT due to stenocardia. CT showed a lack of LMCA. The initial segment of the RCA gave rise to the left coronary artery (LCA), which encircled the aortic bulb posteriorly and bifurcated into branches resembling the LCX and LAD. After the Heart Team consultation, the patient was deemed eligible for conservative treatment. Angio-CT is a valuable tool for detecting coronary artery anomalies. FAU - Muszynski, Pawel AU - Muszynski P AUID- ORCID: 0000-0003-0974-7138 AD - Department of Cardiology, Lipidology and Internal Diseases, Medical University of Bialystok, Zurawia 14, 15-569 Bialystok, Poland. FAU - Swiecicka, Marlena AU - Swiecicka M AD - Department of Cardiology, Lipidology and Internal Diseases, Medical University of Bialystok, Zurawia 14, 15-569 Bialystok, Poland. FAU - Musialowska, Dominika AU - Musialowska D AD - Department of Cardiology, Lipidology and Internal Diseases, Medical University of Bialystok, Zurawia 14, 15-569 Bialystok, Poland. FAU - Pura, Dorota AU - Pura D AD - Department of Cardiology, Lipidology and Internal Diseases, Medical University of Bialystok, Zurawia 14, 15-569 Bialystok, Poland. FAU - Kazberuk, Malgorzata AU - Kazberuk M AUID- ORCID: 0000-0002-2229-8026 AD - Faculty of Medicine, Medical University of Bialystok, Kilinskiego 1, 15-089 Bialystok, Poland. FAU - Kozuchowska-Eljasiewicz, Anna AU - Kozuchowska-Eljasiewicz A AUID- ORCID: 0009-0005-4481-9143 AD - Faculty of Medicine, Medical University of Bialystok, Kilinskiego 1, 15-089 Bialystok, Poland. FAU - Sasinowski, Caroline AU - Sasinowski C AD - Department of Cardiology, Lipidology and Internal Diseases, Medical University of Bialystok, Zurawia 14, 15-569 Bialystok, Poland. FAU - Bajda, Urszula AU - Bajda U AD - Department of Cardiology, Lipidology and Internal Diseases, Medical University of Bialystok, Zurawia 14, 15-569 Bialystok, Poland. FAU - Gradzka-Matys, Wiktoria AU - Gradzka-Matys W AD - Department of Cardiology, Lipidology and Internal Diseases, Medical University of Bialystok, Zurawia 14, 15-569 Bialystok, Poland. FAU - Tomaszuk-Kazberuk, Anna AU - Tomaszuk-Kazberuk A AUID- ORCID: 0000-0003-0153-0356 AD - Department of Cardiology, Lipidology and Internal Diseases, Medical University of Bialystok, Zurawia 14, 15-569 Bialystok, Poland. LA - eng GR - B.SUB.25.505/Medical University of Bialystok/ PT - Journal Article DEP - 20250806 PL - Switzerland TA - Diagnostics (Basel) JT - Diagnostics (Basel, Switzerland) JID - 101658402 PMC - PMC12345700 OTO - NOTNLM OT - computer tomography OT - coronary artery OT - coronary artery anomalies COIS- The authors declare no conflicts of interest. EDAT- 2025/08/14 06:27 MHDA- 2025/08/14 06:28 PMCR- 2025/08/06 CRDT- 2025/08/14 01:02 PHST- 2025/07/11 00:00 [received] PHST- 2025/07/31 00:00 [revised] PHST- 2025/08/04 00:00 [accepted] PHST- 2025/08/14 06:28 [medline] PHST- 2025/08/14 06:27 [pubmed] PHST- 2025/08/14 01:02 [entrez] PHST- 2025/08/06 00:00 [pmc-release] AID - diagnostics15151971 [pii] AID - diagnostics-15-01971 [pii] AID - 10.3390/diagnostics15151971 [doi] PST - epublish SO - Diagnostics (Basel). 2025 Aug 6;15(15):1971. doi: 10.3390/diagnostics15151971. PMID- 40804916 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250817 IS - 2075-4418 (Print) IS - 2075-4418 (Electronic) IS - 2075-4418 (Linking) VI - 15 IP - 15 DP - 2025 Aug 4 TI - Fatal Congenital Heart Disease in a Postpartum Woman. LID - 10.3390/diagnostics15151952 [doi] LID - 1952 AB - The image represents the post-mortem heart of a 28-year-old female patient, diagnosed in childhood with complete common atrioventricular canal defect. At time of diagnosis, the family refused surgery, as did the patient during her adulthood. Despite being advised against pregnancy, she became pregnant. On presentation to hospital, she was cyanotic, with clubbed fingers, and hemodynamically unstable, in sinus rhythm, with Eisenmenger syndrome and respiratory failure partially responsive to oxygen. During pregnancy, owing to systemic vasodilatation, the right-to-left shunt is increased, with more severe cyanosis and low cardiac output. Echocardiography revealed the complete common atrioventricular canal defect, with a single atrioventricular valve with severe regurgitation, right ventricular hypertrophy, pulmonary artery dilatation, severe pulmonary hypertension and a hypoplastic left ventricle. The gestational age at delivery was 38 weeks. She gave birth to a healthy boy, with an Apgar score of 10. The vaginal delivery was chosen by an interdisciplinary team. The cesarean delivery and the anesthesia were considered too risky compared to vaginal delivery. Three days later, the patient died. The autopsy revealed hepatomegaly, a greatly hypertrophied right ventricle with a purplish clot ascending the dilated pulmonary arteries and a hypoplastic left ventricle with a narrowed chamber. A single valve was observed between the atria and ventricles, making all four heart chambers communicate, also insufficiently developed interventricular septum and its congenital absence in the cranial third. These morphological changes indicate the complete common atrioventricular canal defect, with right ventricular dominance, which is a rare and impressive malformation that requires mandatory treatment in early childhood in order for the condition to be solved. FAU - Cinezan, Corina AU - Cinezan C AUID- ORCID: 0009-0009-0855-938X AD - Department of Medical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania. AD - Clinical County Emergency Hospital Bihor, 410169 Oradea, Romania. FAU - Rus, Camelia Bianca AU - Rus CB AUID- ORCID: 0009-0009-9229-2656 AD - Department of Medical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania. AD - Clinical County Emergency Hospital Bihor, 410169 Oradea, Romania. AD - Doctoral School of Biological and Biomedical Sciences, University of Oradea, 410087 Oradea, Romania. FAU - Muresan, Mihaela Mirela AU - Muresan MM AD - Clinical County Emergency Hospital Bihor, 410169 Oradea, Romania. AD - Doctoral School of Biological and Biomedical Sciences, University of Oradea, 410087 Oradea, Romania. AD - Department of Morphological Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania. FAU - Pop, Ovidiu Laurean AU - Pop OL AD - Clinical County Emergency Hospital Bihor, 410169 Oradea, Romania. AD - Doctoral School of Biological and Biomedical Sciences, University of Oradea, 410087 Oradea, Romania. AD - Department of Morphological Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania. LA - eng PT - Journal Article DEP - 20250804 PL - Switzerland TA - Diagnostics (Basel) JT - Diagnostics (Basel, Switzerland) JID - 101658402 PMC - PMC12346633 OTO - NOTNLM OT - Eisenmenger syndrome OT - atrioventricular defect OT - clubbed fingers OT - right-to-left shunt OT - single atrioventricular valve COIS- The authors declare no conflicts of interest. EDAT- 2025/08/14 06:27 MHDA- 2025/08/14 06:28 PMCR- 2025/08/04 CRDT- 2025/08/14 01:02 PHST- 2025/06/12 00:00 [received] PHST- 2025/07/30 00:00 [revised] PHST- 2025/08/02 00:00 [accepted] PHST- 2025/08/14 06:28 [medline] PHST- 2025/08/14 06:27 [pubmed] PHST- 2025/08/14 01:02 [entrez] PHST- 2025/08/04 00:00 [pmc-release] AID - diagnostics15151952 [pii] AID - diagnostics-15-01952 [pii] AID - 10.3390/diagnostics15151952 [doi] PST - epublish SO - Diagnostics (Basel). 2025 Aug 4;15(15):1952. doi: 10.3390/diagnostics15151952. PMID- 40803723 OWN - NLM STAT- MEDLINE DCOM- 20250825 LR - 20250825 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 15 IP - 8 DP - 2025 Aug 12 TI - Convergent parallel mixed-methods study to understand the impact of decision-making for congenital cardiac surgery patients at a tertiary paediatric hospital: a study protocol. PG - e099080 LID - 10.1136/bmjopen-2025-099080 [doi] LID - e099080 AB - INTRODUCTION: Congenital heart disease (CHD) is the most common congenital condition, often necessitating complex heart surgeries that require careful planning by multidisciplinary teams. Multidisciplinary meetings (MDMs) in CHD care aim to integrate diverse expertise to optimise surgical planning. However, the lack of standardised protocols for conducting these meetings introduces undesirable variability in decision-making processes, potentially impacting patient outcomes. This study addresses the critical gap in understanding which aspects of MDMs should be standardised to ensure consistent, high-quality decision-making while also identifying areas where flexibility is essential to accommodate individual patient needs. The objective is to characterise current MDM practices in CHD care, identify factors contributing to variability and provide insights into how a balance between standardisation and flexibility can improve decision-making and patient outcomes. METHODS AND ANALYSIS: A convergent parallel mixed-methods study design will be used to collect, analyse and interpret quantitative and qualitative data. Data collection will include a blend of naturalistic observations and chart reviews to track patient journeys from surgical planning through to postoperative outcomes. To complement these findings, interviews with healthcare providers will capture subjective perspectives on multidisciplinary decision-making. Additionally, departmental metrics will be collected to contextualise the broader clinical environment. Closed-ended observational and chart review data will be analysed using summary statistics and descriptive analysis (eg, percentages, means) to characterise MDM decision-making. Qualitative data (eg, reflections and learnings) from weekly post-surgical debriefs (called Performance Rounds) and clinician interviews on MDM decision-making will be analysed using a modified Framework Method. ETHICS AND DISSEMINATION: Institutional research ethics approval has been acquired (REB #1000080464). To engage key stakeholders and foster collaborative improvement, study results will be shared in research rounds, where staff attending medical surgical conferences, team huddles, morbidity and mortality reviews, and Performance Rounds will be invited to participate. Targeted meetings with individual clinician groups will further allow for in-depth discussion and valuable feedback on the findings. Finally, the findings from this study are anticipated to make a meaningful contribution to the literature; a manuscript is planned for submission to a peer-reviewed journal. CI - (c) Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. FAU - Yin, Leyi AU - Yin L AUID- ORCID: 0009-0004-6064-2221 AD - Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada bellinda.yin@mail.utoronto.ca. FAU - Pinkney, Sonia AU - Pinkney S AD - Dalla Lana School of Public Health, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada. FAU - Assadi, Azadeh AU - Assadi A AD - Department of Critical Care Medicine, The Hospital for Sick Children, Toronto, Ontario, Canada. AD - Lawrence Bloomberg Faculty of Nursing, University of Toronto, Toronto, Ontario, Canada. FAU - Fan, Mark AU - Fan M AD - Research and Innovation, North York General Hospital, Toronto, Ontario, Canada. FAU - Zahiri, Yasmin AU - Zahiri Y AD - Division of Cardiovascular Surgery, The Hospital for Sick Children, Toronto, Ontario, Canada. FAU - Mazwi, Mjaye AU - Mazwi M AD - Department of Critical Care Medicine, The Hospital for Sick Children, Toronto, Ontario, Canada. AD - Division of Critical Care Medicine, Seattle Children's Hospital, Seattle, Washington, USA. FAU - Honjo, Osami AU - Honjo O AD - Division of Cardiovascular Surgery, The Hospital for Sick Children, Toronto, Ontario, Canada. AD - Department of Surgery, University of Toronto, Toronto, Ontario, Canada. FAU - Trbovich, Patricia AU - Trbovich P AUID- ORCID: 0000-0002-8120-5926 AD - Dalla Lana School of Public Health, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada. AD - Research and Innovation, North York General Hospital, Toronto, Ontario, Canada. LA - eng PT - Journal Article DEP - 20250812 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 SB - IM MH - Humans MH - *Heart Defects, Congenital/surgery MH - Tertiary Care Centers MH - *Patient Care Team MH - Hospitals, Pediatric MH - *Cardiac Surgical Procedures MH - *Clinical Decision-Making/methods MH - Research Design MH - *Decision Making MH - Qualitative Research PMC - PMC12352240 OTO - NOTNLM OT - Cardiac surgery OT - Clinical Decision-Making OT - Congenital heart disease OT - Paediatric cardiac surgery OT - Paediatric cardiology OT - Paediatric intensive & critical care COIS- Competing interests: None declared. EDAT- 2025/08/14 00:28 MHDA- 2025/08/31 20:07 PMCR- 2025/08/12 CRDT- 2025/08/13 20:44 PHST- 2025/08/31 20:07 [medline] PHST- 2025/08/14 00:28 [pubmed] PHST- 2025/08/13 20:44 [entrez] PHST- 2025/08/12 00:00 [pmc-release] AID - bmjopen-2025-099080 [pii] AID - 10.1136/bmjopen-2025-099080 [doi] PST - epublish SO - BMJ Open. 2025 Aug 12;15(8):e099080. doi: 10.1136/bmjopen-2025-099080. PMID- 40801278 OWN - NLM STAT- MEDLINE DCOM- 20250901 LR - 20250901 IS - 1559-0879 (Electronic) IS - 1556-9845 (Linking) VI - 20 IP - 4 DP - 2025 Jul-Aug TI - State-of-the-Art Review: Operating Room Extubation. PG - 341-349 LID - 10.1177/15569845251363231 [doi] AB - Enhancing recovery protocols seek to optimize multiple aspects of care throughout the patient's perioperative cardiac surgery journey. Fast-track recovery protocols, specifically those involving earlier extubation, have been among the early methods to enhance a patient's recovery. However, how early these protocols should be implemented after surgery remains a source of ongoing controversy. Strong opinions exist on whether it is appropriate to extubate patients after cardiac surgery in the operating room (OR). Although OR extubation may offer benefits such as reduced intensive care unit length of stay and resource utilization, there are concerns regarding safety, patient selection, and inconsistent outcomes, which have raised significant controversy. This review aims to discuss the reasons why a team may consider exploring extubation in the OR and provide a practical approach for the interdisciplinary team seeking to implement this practice in appropriately selected patients. FAU - Arora, Rakesh C AU - Arora RC AUID- ORCID: 0000-0002-5799-3619 AD - Harrington Heart and Vascular Institute, University Hospitals, Cleveland, OH, USA. AD - Department of Surgery, Division of Cardiac Surgery, Case Western Reserve University, Cleveland, OH, USA. FAU - Teman, Nicholas AU - Teman N AUID- ORCID: 0000-0001-7711-6966 AD - Department of Surgery, Division of Cardiothoracic Surgery, University of Colorado, Aurora, CO, USA. FAU - Gregory, Alexander J AU - Gregory AJ AUID- ORCID: 0000-0003-3483-7952 AD - Department of Anesthesiology, Perioperative and Pain Medicine, Libin Cardiovascular Institute, University of Calgary, AB, Canada. LA - eng PT - Journal Article PT - Review DEP - 20250813 PL - United States TA - Innovations (Phila) JT - Innovations (Philadelphia, Pa.) JID - 101257528 SB - IM MH - Humans MH - *Airway Extubation/methods MH - *Operating Rooms MH - *Cardiac Surgical Procedures/methods MH - Length of Stay OTO - NOTNLM OT - cardiac surgery OT - operating room extubation OT - ultra-fast track COIS- Declaration of Conflicting InterestsThe authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: R.C.A. has received honoraria from Edwards Lifesciences, Medtronic, Serb Pharmaceuticals, HLS Therapeutics, and Bioporto. R.C.A. has also served on the Advisory Board for Alexion and Renibus Therapeutics Inc. EDAT- 2025/08/13 12:31 MHDA- 2025/09/01 08:44 CRDT- 2025/08/13 07:24 PHST- 2025/09/01 08:44 [medline] PHST- 2025/08/13 12:31 [pubmed] PHST- 2025/08/13 07:24 [entrez] AID - 10.1177/15569845251363231 [doi] PST - ppublish SO - Innovations (Phila). 2025 Jul-Aug;20(4):341-349. doi: 10.1177/15569845251363231. Epub 2025 Aug 13. PMID- 40799791 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250816 IS - 2328-8957 (Print) IS - 2328-8957 (Electronic) IS - 2328-8957 (Linking) VI - 12 IP - 8 DP - 2025 Aug TI - Hepatitis C Treatment Outcomes for Patients With Infective Endocarditis Treated by an Interdisciplinary Team. PG - ofaf431 LID - 10.1093/ofid/ofaf431 [doi] LID - ofaf431 AB - BACKGROUND: Patients with endocarditis often have comorbid injection substance use and are at risk for hepatitis C virus (HCV) infection. This population may encounter several significant barriers to treatment. To improve access to treatment, we developed an interdisciplinary collaboration between specialty pharmacy and the University of Kentucky endocarditis team and conducted a retrospective study evaluating treatment outcomes. METHODS: Beginning in September 2021, the endocarditis team worked with specialty pharmacy to connect inpatients with endocarditis and HCV to expedited treatment and coordinated outpatient follow-up. Study investigators then retrospectively reviewed data consisting of patient demographics and treatment outcomes. RESULTS: Between September 2021 and April 2024, 64 patients with infective endocarditis and HCV were identified (median age, 37 years; 41% female, 97% with a history of injection drug use). Upon discharge, 75% (48 of 64) initiated treatment. Treatment was completed in 69% (33 of 48) of these patients. The main reasons for discontinuation included loss to follow-up (n = 10) and medication side effects (n = 3). Sustained virologic response at 12 weeks was achieved in 42% (n = 20) of patients who initiated treatment and 31% of all patients. Among 22 patients with available laboratory results at 12 weeks posttreatment, 91% (n = 20) were HCV RNA negative. CONCLUSIONS: Despite efforts promoting expedited treatment and interdisciplinary coordination of care, sustained virologic response rates for patients with endocarditis and HCV infection remained <40%. More research is required to determine if interventions such as starting therapy during inpatient stay or immediately upon discharge and dispensing the entire course of medication at once can improve treatment outcomes. CI - (c) The Author(s) 2025. Published by Oxford University Press on behalf of Infectious Diseases Society of America. FAU - McQuaide, Lauren AU - McQuaide L AD - College of Pharmacy, University of Kentucky, Lexington, Kentucky, USA. FAU - El-Dalati, Sami AU - El-Dalati S AUID- ORCID: 0000-0003-2603-2951 AD - Division of Infectious Diseases, Department of Internal Medicine, University of Kentucky Medical Center, Lexington, Kentucky, USA. FAU - Gill, Deborah AU - Gill D AD - Division of Infectious Diseases, Department of Internal Medicine, University of Kentucky Medical Center, Lexington, Kentucky, USA. FAU - Stoner, Bobbi Jo AU - Stoner BJ AD - College of Pharmacy, University of Kentucky, Lexington, Kentucky, USA. LA - eng PT - Journal Article DEP - 20250721 PL - United States TA - Open Forum Infect Dis JT - Open forum infectious diseases JID - 101637045 PMC - PMC12341923 OTO - NOTNLM OT - hepatitis C OT - infective endocarditis OT - multidisciplinary teams EDAT- 2025/08/13 06:30 MHDA- 2025/08/13 06:31 PMCR- 2025/07/21 CRDT- 2025/08/13 05:54 PHST- 2025/02/05 00:00 [received] PHST- 2025/07/17 00:00 [accepted] PHST- 2025/08/13 06:31 [medline] PHST- 2025/08/13 06:30 [pubmed] PHST- 2025/08/13 05:54 [entrez] PHST- 2025/07/21 00:00 [pmc-release] AID - ofaf431 [pii] AID - 10.1093/ofid/ofaf431 [doi] PST - epublish SO - Open Forum Infect Dis. 2025 Jul 21;12(8):ofaf431. doi: 10.1093/ofid/ofaf431. eCollection 2025 Aug. PMID- 40799423 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250816 IS - 2218-6751 (Print) IS - 2226-4477 (Electronic) IS - 2218-6751 (Linking) VI - 14 IP - 7 DP - 2025 Jul 31 TI - Surgical consensus for screening, diagnosis, staging, multimodal management and surveillance of early-stage resectable non-small cell lung cancer (NSCLC) in Malaysia. PG - 2403-2426 LID - 10.21037/tlcr-2025-296 [doi] AB - BACKGROUND: Lung cancer is the most frequently diagnosed cancer globally. In Malaysia, it ranks as the second most common cancer among men and third among women. Presently, no local clinical practice guidelines exist for lung cancer care in Malaysia. Given the lack of consensus regarding the perioperative management of early-stage non-small cell lung cancer (NSCLC), this article seeks to harmonise surgical practices among thoracic physicians and surgeons in Malaysia by recommending best practices for screening, diagnosis and staging, as well as multimodal management and surveillance in early-stage disease (stages I to IIIB-N2). METHODS: A local expert committee comprising nine high-volume actively practicing cardiothoracic or general thoracic surgeons gathered between February to July 2024 to deliberate existing evidence and formulate recommendations. A modified Delphi method comprising systematic review of published evidence and expert opinion based on local experience was utilised. The document was subsequently independently reviewed by two senior oncologists and two senior respiratory physicians, before incorporating their feedback into the final version. RESULTS: This document comprises a surgical consensus of evidence-based guidelines to provide local recommendations on contemporary real-world best practices. The consensus statements were grouped into five domains of early-stage resectable NSCLC: (I) screening (3 statements); (II) diagnosis and staging (6 statements); (III) neoadjuvant/perioperative immunotherapy (3 statements); (IV) adjuvant therapy with tyrosine kinase inhibitors (TKIs) or immunotherapy (4 statements); and (V) operative metrics and post-operative surveillance (5 statements). CONCLUSIONS: These consensus statement guidelines will elevate and standardise the perioperative management of early-stage NSCLC in Malaysia, serve as a valuable educational and training tool for relevant medical professionals, and promote an inclusive, comprehensive multidisciplinary approach to integrated holistic patient care, aimed at improving both clinical outcomes and patients' quality of life with the best available evidence. CI - Copyright (c) 2025 AME Publishing Company. All rights reserved. FAU - Sachithanandan, Anand AU - Sachithanandan A AD - Division of Cardiothoracic Surgery, Sunway Medical Centre, Selangor, Malaysia. AD - School of Medical & Life Sciences, Sunway University, Selangor, Malaysia. FAU - Mohammad Razi, Adli Azam AU - Mohammad Razi AA AD - Department of Cardiovascular and Thoracic Surgery, Faculty of Medicine, Universiti Teknologi MARA (UiTM), Selangor, Malaysia. AD - Department of Cardiothoracic Surgery, Gleneagles Hospital Johor, Johor, Malaysia. FAU - Krishnasamy, Sivakumar AU - Krishnasamy S AD - Cardiothoracic Division, University Malaya, Kuala Lumpur, Malaysia. FAU - Chan, Kok Meng John AU - Chan KMJ AD - Department of Cardiothoracic Surgery, CVSKL Hospital Kuala Lumpur, Kuala Lumpur, Malaysia. FAU - Lam, Hong Yoong AU - Lam HY AD - Lam Wah Ee Hospital, Pulau Pinang, Malaysia. FAU - Diong, Nguk Chai AU - Diong NC AD - Department of Surgery, Hospital Sultan Ismail, Johor, Malaysia. FAU - Sathiamurthy, Narasimman AU - Sathiamurthy N AD - Thoracic Unit, Department of Surgery, Hospital Kuala Lumpur, Kuala Lumpur, Malaysia. FAU - Ooi, Adrian Seng Wae AU - Ooi ASW AD - Department of Cardiothoracic Surgery, Oriental Melaka Straits Medical Centre, Melaka, Malaysia. FAU - Soon, Sing Yang AU - Soon SY AD - Department of Cardiothoracic Surgery, Sarawak Heart Centre, Sarawak, Malaysia. LA - eng PT - Journal Article PT - Review DEP - 20250728 PL - China TA - Transl Lung Cancer Res JT - Translational lung cancer research JID - 101646875 PMC - PMC12337061 OTO - NOTNLM OT - Malaysia OT - Non-small cell lung cancer (NSCLC) OT - perioperative OT - surgical consensus COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-2025-296/coif). All authors report that they received medical writing support from Mediconnexions Consulting Sdn. Bhd. for the present manuscript funded by AstraZeneca Malaysia. The authors have no other conflicts of interest to declare. EDAT- 2025/08/13 06:30 MHDA- 2025/08/13 06:31 PMCR- 2025/07/31 CRDT- 2025/08/13 05:49 PHST- 2025/03/14 00:00 [received] PHST- 2025/06/12 00:00 [accepted] PHST- 2025/08/13 06:31 [medline] PHST- 2025/08/13 06:30 [pubmed] PHST- 2025/08/13 05:49 [entrez] PHST- 2025/07/31 00:00 [pmc-release] AID - tlcr-14-07-2403 [pii] AID - 10.21037/tlcr-2025-296 [doi] PST - ppublish SO - Transl Lung Cancer Res. 2025 Jul 31;14(7):2403-2426. doi: 10.21037/tlcr-2025-296. Epub 2025 Jul 28. PMID- 40795923 OWN - NLM STAT- MEDLINE DCOM- 20251007 LR - 20260505 IS - 1439-1902 (Electronic) IS - 0171-6425 (Linking) VI - 73 IP - 7 DP - 2025 Oct TI - Diagnosis-Driven, Cross-Disciplinary QA System for Coronary Artery Disease-Study Protocol. PG - 554-559 LID - 10.1055/a-2680-6089 [doi] AB - Percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) are invasive treatment options for coronary artery disease (CAD), aiming to improve quality of life and reduce cardiovascular morbidity and mortality. Guidelines-based revascularization decisions should consider anatomical complexity, comorbidities, and patient preferences, with procedural risk assessed through validated scoring systems. However, the current legal quality assurance (QA) programs in Germany remain procedure specific and therefore lack a patient-centered, diagnosis-oriented approach. This study proposes a paradigm shift toward diagnosis-based QA to optimize individualized treatment selection, improve outcome attribution, and ensure transparent quality assessment. By integrating guideline recommendations with enhanced data linkage, this framework aims to standardize and improve CAD care quality while addressing limitations of existing QA schemes.This mixed-methods study aims to develop a cross-disciplinary QA framework for CAD patients undergoing elective PCI or CABG. Qualitative methods will be employed to formulate preliminary evidence-based quality indicators (QI), while secondary data analyses will provide empirical support for QI prioritization, modeling, and future evaluation. Findings from both approaches will undergo a structured consensus process to establish validated QI as basis of a redesigned QA scheme.The resulting framework seeks to standardize and improve QA procedures across CAD care pathways, integrating clinical expertise with real-world data to enhance patient outcome.The study proposes a patient-centered, diagnosis-based quality assurance framework for coronary artery disease care, aiming to improve treatment decisions and outcomes. By integrating guideline, expert input, and real-world data, it seeks to enhance transparency and standardization in quality assessment across CAD treatment pathways. CI - Thieme. All rights reserved. FAU - Iqbal, Fakhrah Maryam AU - Iqbal FM AD - Institute for Health Services Research and Clinical Epidemiology, Marburg University (UMR), Marburg, Germany. FAU - Geraedts, Max AU - Geraedts M AD - Institute for Health Services Research and Clinical Epidemiology, Marburg University (UMR), Marburg, Germany. FAU - Ji, Limei AU - Ji L AD - Institute for Health Services Research and Clinical Epidemiology, Marburg University (UMR), Marburg, Germany. FAU - Falk, Volkmar AU - Falk V AD - German Society for Thoracic and Cardiovascular Surgery (DGTHG), Berlin, Germany. FAU - Doenst, Torsten AU - Doenst T AD - German Society for Thoracic and Cardiovascular Surgery (DGTHG), Berlin, Germany. FAU - Blankenberg, Stefan AU - Blankenberg S AD - German Society for Cardiology, Heart and Circulation Research (DGK), Dusseldorf, Germany. FAU - Diemert, Patrick AU - Diemert P AD - Association of Senior Cardiological Hospital Physicians (ALKK), Dusseldorf, Germany. FAU - Dobler, Klaus AU - Dobler K AD - Competence Center for Quality Assurance (KCQ), Stuttgart, Germany. FAU - Gunster, Christian AU - Gunster C AD - The AOK Research Institute (WIdO), Berlin, Germany. FAU - Beckmann, Andreas AU - Beckmann A AUID- ORCID: 0000-0003-0785-2591 AD - German Society for Thoracic and Cardiovascular Surgery (DGTHG), Berlin, Germany. LA - eng GR - 01VSF24056/Innovation Fund of the Federal Joint Committee/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20250812 PL - Germany TA - Thorac Cardiovasc Surg JT - The Thoracic and cardiovascular surgeon JID - 7903387 SB - IM MH - Humans MH - *Coronary Artery Disease/therapy/diagnosis/diagnostic imaging/surgery/mortality MH - *Quality Indicators, Health Care/standards MH - *Percutaneous Coronary Intervention/standards/adverse effects/mortality MH - *Coronary Artery Bypass/standards/adverse effects/mortality MH - Treatment Outcome MH - Germany MH - *Quality Improvement/standards MH - Predictive Value of Tests MH - Research Design MH - Interdisciplinary Communication MH - Consensus MH - Practice Guidelines as Topic/standards MH - *Patient Care Team/standards MH - *Process Assessment, Health Care/standards MH - Clinical Decision-Making MH - *Outcome and Process Assessment, Health Care/standards MH - Cooperative Behavior COIS- None declared. EDAT- 2025/08/13 00:28 MHDA- 2025/10/08 00:29 CRDT- 2025/08/12 19:02 PHST- 2025/10/08 00:29 [medline] PHST- 2025/08/13 00:28 [pubmed] PHST- 2025/08/12 19:02 [entrez] AID - 10.1055/a-2680-6089 [doi] PST - ppublish SO - Thorac Cardiovasc Surg. 2025 Oct;73(7):554-559. doi: 10.1055/a-2680-6089. Epub 2025 Aug 12. PMID- 40795291 OWN - NLM STAT- MEDLINE DCOM- 20250826 LR - 20260523 IS - 1873-734X (Electronic) IS - 1010-7940 (Print) IS - 1010-7940 (Linking) VI - 67 IP - 8 DP - 2025 Aug 2 TI - Beyond the Heart: The Significance of Depression in Cardiac Surgery. LID - 10.1093/ejcts/ezaf277 [doi] LID - ezaf277 AB - OBJECTIVES: Preoperative depression is common among patients with cardiovascular disease and a significant risk factor for worse outcomes after cardiac surgery. This review summarizes the current evidence on depression as a risk factor and possible treatment options in patients undergoing cardiac surgery, and highlights future perspectives for clinical research. METHODS: This narrative review was based on a selection of key papers, identified through collegial expert discussions rather than a systematic literature search. RESULTS: Depression is often underdiagnosed and undertreated in patients undergoing cardiac surgery, significantly affecting recovery and increasing the risk of adverse outcomes. Implementing systematic psychological screening for depression and anxiety preoperatively and during follow-up is crucial for identifying at-risk patients. Psychological interventions, especially cognitive behavioral therapy have been shown to offer substantial benefits. Adopting a multidisciplinary approach integrating cardiovascular and psychological care is essential for improving recovery and long-term outcomes. Incorporating psychological screening and interventions into standard care can enhance postoperative outcomes, reduce complications, and provide comprehensive support for cardiac surgery patients. CONCLUSIONS: Depression is often overlooked in cardiac surgery patients, despite its significant impact on recovery and long-term outcomes. Systematic psychological screening before and after surgery together with a multidisciplinary approach integrating cardiovascular and psychological care can improve patient outcomes. Future research should clarify how depression and cardiovascular disease are linked, assess treatment effectiveness, and identify appropriate intervention strategies. CI - (c) The Author(s) 2025. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. FAU - Stenman, Malin AU - Stenman M AUID- ORCID: 0000-0002-6782-0586 AD - Department of Molecular Medicine and Surgery, Karolinska Institutet, 17177, Stockholm, Sweden. AD - Perioperative Medicine and Intensive Care Function, Karolinska University Hospital, 17176, Stockholm, Sweden. FAU - Jackson, Veronica AU - Jackson V AUID- ORCID: 0000-0002-1301-8440 AD - Department of Molecular Medicine and Surgery, Karolinska Institutet, 17177, Stockholm, Sweden. AD - Stockholm Healthcare Services, Region Stockholm, 10431, Stockholm, Sweden. FAU - Sarnholm, Josefin AU - Sarnholm J AUID- ORCID: 0000-0002-9872-4781 AD - Department of Clinical Neuroscience, Division of Psychology, Karolinska Institutet, 17177, Stockholm, Sweden. AD - Center for Behavioral Cardiovascular Health, Columbia University Irving Medical Center, New York, NY, 10027-6907, United States. FAU - Falk, Anna AU - Falk A AUID- ORCID: 0000-0003-4829-0943 AD - Perioperative Medicine and Intensive Care Function, Karolinska University Hospital, 17176, Stockholm, Sweden. AD - Department of Physiology and Pharmacology, Karolinska Institutet, 17177, Stockholm, Sweden. FAU - J Nielsen, Susanne AU - J Nielsen S AD - Department of Molecular and Clinical Medicine, Sahlgrenska Academy, Gothenburg University, 40530, Gothenburg, Sweden. AD - Department of Cardiothoracic Surgery, Sahlgrenska University Hospital, 41345, Gothenburg, Sweden. FAU - Sartipy, Ulrik AU - Sartipy U AUID- ORCID: 0000-0003-2707-0263 AD - Department of Molecular Medicine and Surgery, Karolinska Institutet, 17177, Stockholm, Sweden. AD - Department of Cardiothoracic Surgery, Karolinska University Hospital, 17176, Stockholm, Sweden. LA - eng GR - 20220151/Swedish Heart-Lung Foundation/ GR - 2024-02499/Karolinska Institutet Foundations and Funds/ PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review PL - Germany TA - Eur J Cardiothorac Surg JT - European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery JID - 8804069 SB - IM MH - Humans MH - *Cardiac Surgical Procedures/psychology/adverse effects MH - *Depression/therapy/diagnosis/epidemiology/etiology/psychology MH - Risk Factors MH - *Cardiovascular Diseases/surgery/psychology MH - Postoperative Complications/psychology PMC - PMC12377910 OTO - NOTNLM OT - cardiac psychiatry OT - cardiac surgery OT - cardiovascular disease OT - cognitive behavioral therapy OT - depression COIS- None declared. EDAT- 2025/08/12 18:33 MHDA- 2025/08/31 20:07 PMCR- 2025/08/08 CRDT- 2025/08/12 16:42 PHST- 2025/04/09 00:00 [received] PHST- 2025/07/10 00:00 [revised] PHST- 2025/08/06 00:00 [accepted] PHST- 2025/08/31 20:07 [medline] PHST- 2025/08/12 18:33 [pubmed] PHST- 2025/08/12 16:42 [entrez] PHST- 2025/08/08 00:00 [pmc-release] AID - 8226741 [pii] AID - ezaf277 [pii] AID - 10.1093/ejcts/ezaf277 [doi] PST - ppublish SO - Eur J Cardiothorac Surg. 2025 Aug 2;67(8):ezaf277. doi: 10.1093/ejcts/ezaf277. PMID- 40793956 OWN - NLM STAT- MEDLINE DCOM- 20251212 LR - 20260130 IS - 1743-9159 (Electronic) IS - 1743-9191 (Print) IS - 1743-9159 (Linking) VI - 111 IP - 12 DP - 2025 Dec 1 TI - Treatment strategies for patients with ischemic mitral regurgitation: a systematic review and meta-analysis. PG - 9669-9685 LID - 10.1097/JS9.0000000000003170 [doi] AB - BACKGROUND: Treatments for ischemic mitral regurgitation (IMR) include coronary artery bypass grafting combined with mitral valve replacement (CABG + MVR), percutaneous coronary intervention (PCI) alone, and PCI combined with transcatheter edge-to-edge repair (TEER), but comparative evidence remains limited. We aimed to systematically evaluate perioperative characteristics, in-hospital and long-term outcomes of these strategies. MATERIALS AND METHODS: This PRISMA 2020-compliant systematic review and meta-analysis searched PubMed, EMBASE, Web of Science, Cochrane Library, and ClinicalTrials.gov through 12 November 2024. We included studies reporting outcomes for CABG + MVR, PCI alone, or PCI + TEER in IMR, excluding non-human studies, reviews, case reports, editorials, etc. The endpoints included in-hospital/30-day mortality, long-term mortality, cardiovascular mortality, procedural metrics (cardiopulmonary bypass and cross-clamp time), hospital stay, ICU stay, reoperation, readmission, cerebrovascular events, atrial fibrillation, and low cardiac output syndrome (LCOS). Data were pooled using random-effects models. RESULTS: Thirty-three studies (1 randomized controlled trial, 32 cohorts; n = 3001 patients: 1355 CABG + MVR, 1617 PCI, and 29 PCI + TEER) were analyzed. In-hospital/30-day mortality was 13.8% (95% CI 3.9%-31.7%) for PCI + TEER, 11.8% (95% CI 8.4%-16.5%) for CABG + MVR, and 9.4% (95% CI 7.7%-11.5%) for PCI. Five-year mortality was 37.5% for CABG + MVR vs. 41.8% for PCI. The pooled cardiopulmonary bypass and cross-clamp time for CABG + MVR was 140.2 minutes and 101.0 minutes, respectively. PCI + TEER had shorter hospital stays (17.3 days) than CABG + MVR (22.4 days). Hospital/30-day intra-aortic balloon pump rate was lower in CABG + MVR (7.9%) than PCI + TEER (24.1%). 30-day/in-hospital complications included cerebrovascular events (CABG + MVR: 4.1%, PCI: 0.7%), atrial fibrillation (CABG + MVR: 22.9%), and LCOS (CABG + MVR: 19.6%). One-year readmission and 10-year reoperation rates post-CABG + MVR were 7.4% and 31.1%, respectively. CONCLUSIONS: CABG + MVR demonstrated superior long-term survival and lower cardiovascular mortality than PCI but carried higher perioperative risks and complication rates. PCI + TEER showed shorter hospital stays but insufficient data to assess long-term efficacy. Treatment selection requires balancing comorbidities, surgical risk, and MR severity through multidisciplinary decision-making. Robust comparative trials are needed to optimize IMR management. CI - Copyright (c) 2025 The Author(s). Published by Wolters Kluwer Health, Inc. FAU - Li, Qi AU - Li Q AD - Department of Cardiology, Fuwai Shenzhen Hospital, Chinese Academy of Medical Sciences, Shenzhen, Guangdong, P.R. China. AD - Medical Research and Biometrics Center, National Clinical Research Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College/National Center for Cardiovascular Diseases, Beijing, P.R. China. FAU - Liang, Meiling AU - Liang M AD - Department of Cardiology, Fuwai Shenzhen Hospital, Chinese Academy of Medical Sciences, Shenzhen, Guangdong, P.R. China. FAU - Gao, Mingyou AU - Gao M AD - Department of Nutrition, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P.R. China. FAU - Liu, Weida AU - Liu W AD - State Key Laboratory for Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P.R. China. FAU - Bie, Dongyun AU - Bie D AD - Department of Anaesthesiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P.R. China. FAU - Luo, Xinlin AU - Luo X AD - Department of Cardiology, Fuwai Shenzhen Hospital, Chinese Academy of Medical Sciences, Shenzhen, Guangdong, P.R. China. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20250812 PL - United States TA - Int J Surg JT - International journal of surgery (London, England) JID - 101228232 SB - IM MH - Humans MH - *Mitral Valve Insufficiency/surgery/mortality/etiology MH - *Coronary Artery Bypass/methods MH - *Percutaneous Coronary Intervention/methods MH - *Myocardial Ischemia/complications/surgery MH - *Heart Valve Prosthesis Implantation/methods MH - Treatment Outcome PMC - PMC12695253 OTO - NOTNLM OT - coronary artery bypass OT - ischemic mitral regurgitation OT - mitral valve replacement OT - percutaneous coronary intervention OT - prognosis OT - transcatheter edge-to-edge repair COIS- Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article. All authors declared no competing interests. EDAT- 2025/08/12 12:29 MHDA- 2025/12/12 07:20 PMCR- 2025/12/10 CRDT- 2025/08/12 10:03 PHST- 2025/05/05 00:00 [received] PHST- 2025/07/22 00:00 [accepted] PHST- 2025/12/12 07:20 [medline] PHST- 2025/08/12 12:29 [pubmed] PHST- 2025/08/12 10:03 [entrez] PHST- 2025/12/10 00:00 [pmc-release] AID - 01279778-202512000-00070 [pii] AID - IJS-D-25-02146 [pii] AID - 10.1097/JS9.0000000000003170 [doi] PST - ppublish SO - Int J Surg. 2025 Dec 1;111(12):9669-9685. doi: 10.1097/JS9.0000000000003170. Epub 2025 Aug 12. PMID- 40792594 OWN - NLM STAT- MEDLINE DCOM- 20251008 LR - 20260823 IS - 2047-9980 (Electronic) IS - 2047-9980 (Linking) VI - 14 IP - 19 DP - 2025 Oct 7 TI - Prehospital Prediction of Cardiogenic Shock Among Patients With ST-Segment-Elevation Myocardial Infarction: The EARLY SHOCK Score. PG - e040681 LID - 10.1161/JAHA.124.040681 [doi] LID - e040681 AB - BACKGROUND: Cardiogenic shock (CS) develops in up to 10% of patients with ST-segment-elevation myocardial infarction and is associated with high mortality and morbidity rates. The objective of the current study was to generate a clinical scoring system that can be easily applied in the prehospital setting to predict the development of in-hospital CS among patients undergoing primary percutaneous coronary intervention for ST-segment-elevation myocardial infarction. METHODS: The authors conducted a retrospective cohort study using prospective data from a dual hub-and-spoke health system. Logistic regression was used to assess the relationship between prespecified clinical predictors and the occurrence of in-hospital CS. Internal validation was conducted to assess the C statistic and calibration curve of the prediction model. The prediction model was converted to a risk score by scaling of the regression coefficients. RESULTS: From April 1, 2012, to December 31, 2020, there were 2736 consecutive patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Of these, 415 (15.2%) developed CS. Eight strong predictors were independently associated with CS by multivariable analysis and used to develop a prediction model. The model achieved a C statistic of 0.87. The EARLY SHOCK risk scoring algorithm incorporates Emergency Medical Services Heart Rate and Systolic Blood Pressure, Age, Renal Replacement, Location of Infarction, Sugar (diabetes), Heart Failure, and Cardiac Arrest. CONCLUSIONS: The authors identified 8 clinical variables that strongly predict CS among patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention. This has been developed into the EARLY SHOCK score, which can be easily applied in the prehospital setting to rapidly identify CS and enable shock team activation. External validation for the scoring system is pending for broader application. FAU - Yang, Cathevine AU - Yang C AUID- ORCID: 0000-0002-1641-1002 AD - Division of Cardiology, Department of Medicine University of British Columbia Vancouver British Columbia Canada. AD - Interventional Cardiology Section, Division of Cardiovascular Medicine, Department of Medicine Stanford Health Care Palo Alto California USA. FAU - Lee, Terry AU - Lee T AUID- ORCID: 0000-0003-2582-2337 AD - Centre for Advancing Health Outcomes Providence Health Care Research Institute, University of British Columbia Vancouver British Columbia Canada. FAU - Kochan, Andrew AU - Kochan A AUID- ORCID: 0000-0001-7961-642X AD - Division of Cardiology, Department of Medicine University of British Columbia Vancouver British Columbia Canada. AD - Interdepartmental Division of Critical Care Medicine University of Toronto Toronto Ontario Canada. FAU - Barker, Madeleine AU - Barker M AUID- ORCID: 0000-0002-1334-5943 AD - Division of Cardiology, Department of Medicine University of British Columbia Vancouver British Columbia Canada. AD - Centre for Cardiovascular Innovation University of British Columbia Vancouver British Columbia Canada. AD - Division of Cardiology Emory School of Medicine Atlanta Georgia USA. FAU - Roston, Thomas M AU - Roston TM AUID- ORCID: 0000-0001-5663-4377 AD - Division of Cardiology, Department of Medicine University of British Columbia Vancouver British Columbia Canada. AD - Centre for Cardiovascular Innovation University of British Columbia Vancouver British Columbia Canada. FAU - Cairns, John A AU - Cairns JA AUID- ORCID: 0000-0001-8875-8841 AD - Division of Cardiology, Department of Medicine University of British Columbia Vancouver British Columbia Canada. FAU - Singer, Joel AU - Singer J AUID- ORCID: 0000-0002-7220-4382 AD - Centre for Advancing Health Outcomes Providence Health Care Research Institute, University of British Columbia Vancouver British Columbia Canada. FAU - Grunau, Brian AU - Grunau B AUID- ORCID: 0000-0003-4103-1383 AD - Centre for Cardiovascular Innovation University of British Columbia Vancouver British Columbia Canada. AD - Division of Cardiology Emory School of Medicine Atlanta Georgia USA. AD - Department of Emergency Medicine University of British Columbia Vancouver British Columbia Canada. FAU - Helmer, Jennie AU - Helmer J AUID- ORCID: 0000-0002-3513-9307 AD - Department of Emergency Medicine University of British Columbia Vancouver British Columbia Canada. AD - BC Emergency Health Services Victoria British Columbia Canada. FAU - Berg, David D AU - Berg DD AUID- ORCID: 0000-0002-0366-5492 AD - Division of Cardiovascular Medicine Brigham and Women's Hospital, Harvard Medical School Boston Massachusetts USA. FAU - Wong, Graham C AU - Wong GC AD - Division of Cardiology, Department of Medicine University of British Columbia Vancouver British Columbia Canada. AD - Centre for Cardiovascular Innovation University of British Columbia Vancouver British Columbia Canada. FAU - Fordyce, Christopher B AU - Fordyce CB AUID- ORCID: 0000-0002-4050-1518 AD - Division of Cardiology, Department of Medicine University of British Columbia Vancouver British Columbia Canada. AD - Centre for Advancing Health Outcomes Providence Health Care Research Institute, University of British Columbia Vancouver British Columbia Canada. AD - Centre for Cardiovascular Innovation University of British Columbia Vancouver British Columbia Canada. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20250812 PL - England TA - J Am Heart Assoc JT - Journal of the American Heart Association JID - 101580524 SB - IM MH - Humans MH - *Shock, Cardiogenic/etiology/diagnosis/epidemiology MH - *ST Elevation Myocardial Infarction/complications/surgery/diagnosis MH - Male MH - Female MH - Retrospective Studies MH - Middle Aged MH - *Emergency Medical Services/methods MH - Risk Assessment/methods MH - *Percutaneous Coronary Intervention/adverse effects MH - Aged MH - Risk Factors MH - Predictive Value of Tests MH - Time Factors PMC - PMC12684621 OTO - NOTNLM OT - STEMI OT - cardiogenic shock OT - prehospital OT - shock team COIS- None. EDAT- 2025/08/12 12:29 MHDA- 2025/10/08 17:33 PMCR- 2025/08/12 CRDT- 2025/08/12 07:36 PHST- 2025/10/08 17:33 [medline] PHST- 2025/08/12 12:29 [pubmed] PHST- 2025/08/12 07:36 [entrez] PHST- 2025/08/12 00:00 [pmc-release] AID - JAH310952 [pii] AID - 10.1161/JAHA.124.040681 [doi] PST - ppublish SO - J Am Heart Assoc. 2025 Oct 7;14(19):e040681. doi: 10.1161/JAHA.124.040681. Epub 2025 Aug 12. PMID- 40787232 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250813 IS - 2297-055X (Print) IS - 2297-055X (Electronic) IS - 2297-055X (Linking) VI - 12 DP - 2025 TI - Open-source customizable website to follow-up physical rehabilitation of cardiovascular patients at home. PG - 1633106 LID - 10.3389/fcvm.2025.1633106 [doi] LID - 1633106 AB - BACKGROUND: Telemedicine home monitoring of physical rehabilitation in cardiovascular patients, which may substantially improve adherence and, thus, prognosis and quality of life, is an underused practice. Indeed, the Apps and websites available are generic and cannot be easily adapted to each specific rehabilitation protocol. We thus aimed at developing a flexible, low-cost, and open-source telemedicine tool that can be customized and operated by any healthcare professional with just user-level internet knowledge. METHODS: The website was co-designed by an interdisciplinary team, including website developers and clinical experts in physical rehabilitation programs for patients with cardiovascular diseases. The operability and robustness of the website were tested on simulated patients and health professionals, and the suitability of the tutorial for website customization was assessed. RESULTS: The website asks the patient to complete a periodic diary of physical activities (e.g., intensity, type, duration, warm-up, cool-down, subjective effort). At any time, the patient can see graphs of the different types of exercise performed during a selected period. The website allows healthcare professionals to browse patients' data, send feedback messages, and export data in a conventional spreadsheet format. The tutorial for website customization was prepared as a learning by doing tool. CONCLUSIONS: The website developed can interest cardiovascular physical rehabilitation professionals aiming at quickly and cheaply setting up an approach for home monitoring programs. This telemedicine tool can also be customized to different clinical applications and is particularly well suited for low-resource settings. CI - (c) 2025 Sabala, Mcbrearty, Salama, Farre, Loughnane, Otero and Farre. FAU - Sabala, Ariadna AU - Sabala A AD - Unit of Biophysics and Bioengineering, School of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain. FAU - Mcbrearty, Donough AU - Mcbrearty D AD - Discipline of Cardiology, Saolta University Healthcare Group, Galway, Ireland. FAU - Salama, Raffaella AU - Salama R AD - Unit of Biophysics and Bioengineering, School of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain. FAU - Farre, Ramon AU - Farre R AD - Unit of Biophysics and Bioengineering, School of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain. AD - CIBER de Enfermedades Respiratorias, Barcelona, Spain. AD - Institut d'Investigacions Biomediques August Pi Sunyer, Barcelona, Spain. FAU - Loughnane, Ailis AU - Loughnane A AD - Discipline of Cardiology, Saolta University Healthcare Group, Galway, Ireland. FAU - Otero, Jorge AU - Otero J AD - Unit of Biophysics and Bioengineering, School of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain. AD - CIBER de Enfermedades Respiratorias, Barcelona, Spain. FAU - Farre, Nuria AU - Farre N AD - Discipline of Cardiology, Saolta University Healthcare Group, Galway, Ireland. AD - School of Medicine, University of Galway, Galway, Ireland. LA - eng PT - Journal Article DEP - 20250725 PL - Switzerland TA - Front Cardiovasc Med JT - Frontiers in cardiovascular medicine JID - 101653388 PMC - PMC12331590 OTO - NOTNLM OT - cardiac rehabilitation OT - healthcare followup OT - home monitoring OT - low-cost OT - open-source website OT - telemedicine COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2025/08/11 12:32 MHDA- 2025/08/11 12:33 PMCR- 2025/07/25 CRDT- 2025/08/11 06:28 PHST- 2025/05/22 00:00 [received] PHST- 2025/07/11 00:00 [accepted] PHST- 2025/08/11 12:33 [medline] PHST- 2025/08/11 12:32 [pubmed] PHST- 2025/08/11 06:28 [entrez] PHST- 2025/07/25 00:00 [pmc-release] AID - 10.3389/fcvm.2025.1633106 [doi] PST - epublish SO - Front Cardiovasc Med. 2025 Jul 25;12:1633106. doi: 10.3389/fcvm.2025.1633106. eCollection 2025. PMID- 40783746 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250813 IS - 2057-3804 (Electronic) IS - 2057-3804 (Linking) VI - 11 IP - 1 DP - 2025 Aug 9 TI - Challenges and opportunities for improving cardiovascular health in women with breast cancer: a review. PG - 72 LID - 10.1186/s40959-025-00362-1 [doi] LID - 72 AB - BACKGROUND: Breast cancer survivors are at a high risk of developing cardiovascular disease (CVD) owing to cancer treatment. Breast cancer and CVD share common risk factors, necessitating CVD risk assessment along with cancer screening. This review aimed to explore the challenges and opportunities associated with promoting cardiovascular health in women with breast cancer. MAIN TEXT: Cardio-oncology is a rapidly developing discipline that focuses on identifying, monitoring, and managing CVD in cancer patients. Preventing and managing CVD in patients with breast cancer involves evaluating risk factors, initiating cardioprotective medications, and implementing cardio-oncology rehabilitation. Major barriers to cardio-oncology prevention and management include inadequate programs, sex/gender-specific issues, financial constraints, underutilization of cardiac rehabilitation (CR), determination of the appropriate time to begin CR, physical limitations, psychological issues, and social and racial disparities. CONCLUSION: A preventive cardio-oncology approach; early identification of cardiotoxicity, CVD risk factors, anxiety, and depression; individualized CR programs; early CR referrals; home/community and virtual CR models; dedicated funding, resources, and personnel; a multidisciplinary team approach; and culturally tailored cardio-oncology care can be beneficial for addressing CVD health challenges and disparities in women with breast cancer. CI - (c) 2025. The Author(s). FAU - Ali, Sana AU - Ali S AD - Department of Medicine, The Ottawa Hospital, 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada. sanali@toh.ca. AD - The Ottawa Hospital, Ottawa Hospital Research Institute, 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada. sanali@toh.ca. FAU - Mullen, Kerri A AU - Mullen KA AD - School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, 40 Ruskin St, Ottawa, ON, K1Y4W7, Canada. AD - Division of Cardiac Prevention and Rehabilitation, University of Ottawa Heart Institute, 40 Ruskin St, Ottawa, ON, K1Y4W7, Canada. LA - eng PT - Journal Article PT - Review DEP - 20250809 PL - England TA - Cardiooncology JT - Cardio-oncology (London, England) JID - 101689938 PMC - PMC12335184 OTO - NOTNLM OT - Breast cancer OT - CVD risk factors OT - Cardiac rehabilitation OT - Cardio-oncology OT - Cardiotoxicity OT - Cardiovascular health OT - Challenges OT - Prevention COIS- Declarations. Ethics approval and consent to participate: The authors confirm that ethical approval and patient consent are not applicable to this study. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2025/08/10 07:31 MHDA- 2025/08/10 07:32 PMCR- 2025/08/09 CRDT- 2025/08/10 00:14 PHST- 2024/09/30 00:00 [received] PHST- 2025/06/18 00:00 [accepted] PHST- 2025/08/10 07:32 [medline] PHST- 2025/08/10 07:31 [pubmed] PHST- 2025/08/10 00:14 [entrez] PHST- 2025/08/09 00:00 [pmc-release] AID - 10.1186/s40959-025-00362-1 [pii] AID - 362 [pii] AID - 10.1186/s40959-025-00362-1 [doi] PST - epublish SO - Cardiooncology. 2025 Aug 9;11(1):72. doi: 10.1186/s40959-025-00362-1. PMID- 40782497 OWN - NLM STAT- MEDLINE DCOM- 20251002 LR - 20260415 IS - 1095-8673 (Electronic) IS - 0022-4804 (Linking) VI - 314 DP - 2025 Oct TI - Same-Day Discharge Sleeve Gastrectomy at a Military Treatment Facility: Protocol and Initial Outcomes. PG - 284-290 LID - S0022-4804(25)00443-3 [pii] LID - 10.1016/j.jss.2025.07.013 [doi] AB - INTRODUCTION: The laparoscopic sleeve gastrectomy (LSG) has become the most common bariatric surgery. Due to its relative safety and low complication rate, it has been more commonly performed as an ambulatory surgery. "Outpatient" or discharge from postanesthesia care unit within 23 h has been well studied in the civilian sector and has been shown to result in reduced costs, hospital-acquired infections, and improved patient satisfaction. Although there are numerous benefits to outpatient LSG, the military health system has been slow to adopt this practice. This study represents the first and only series on same day (SD)-LSG within the military and demonstrates our protocol, experience, and initial outcomes at Madigan Army Medical Center. METHODS: Twenty-eight patients underwent SD-LSG between April 28, 2021, and May 22, 2023. Before initiation of the SD-LSG, a multidisciplinary protocol to include all phases of care (surgical clinic, operating room, and the postanesthesia care unit) was created. Data were prospectively collected. Exclusion criteria included patients with BMI >50 kg/m(2), expected operative time >2 h, nonambulatory, intermediate or high cardiac risk, severe obstructive sleep apnea, immunocompromised, or dialysis dependent. The primary outcomes included mortality, complications, and readmission rates. The secondary outcomes included patient satisfaction, operating room and postanesthesia care unit times, pIV patency rates, and percent excess body weight loss. RESULTS: Our patient demographics were similar to national demographics for all LSG in the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program reported for the same period, with the exception of being slightly younger. During the study period in our institution, 76 LSG were performed in total, 46 of which were performed by participating surgeons and therefore included in the study. Of those included, 28 (61%) were same-day LSG, and 18 (39%) were inpatient LSG, as they did not qualify for the same-day protocol. Of the same-day group, none required unplanned postoperative admission. We had no mortality, reoperations, or readmissions. Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program data for the same time frame showed 2.4% readmissions, 0.4% reoperations, and 0.1% mortality. We had one Clavien-Dindo class 2 complication of postoperative hematoma requiring transfusion (3.6%, n = 1/28), which is comparable to reported minor complication rates for LSG, ranging from 2.5% to 5.8% in the literature. CONCLUSIONS: SD-LSG can be a safe and feasible practice in the military health system, helping to offload the inpatient census. Initiating this protocol requires careful patient selection, a multidisciplinary approach, and appropriate coordination with all phases of patient care. SD-LSG has comparable risks to inpatient LSG while reducing inpatient hospital care burden and improving patient satisfaction. CI - Published by Elsevier Inc. FAU - Palmerton, Hannah AU - Palmerton H AD - Madigan Army Medical Center, Joint Base Lewis-McChord, Tacoma, Washington. Electronic address: hmpalmerton@gmail.com. FAU - Pak, Grace AU - Pak G AD - Madigan Army Medical Center, Joint Base Lewis-McChord, Tacoma, Washington. FAU - Zhang, Bobby AU - Zhang B AD - Madigan Army Medical Center, Joint Base Lewis-McChord, Tacoma, Washington. FAU - Shawhan, Robert AU - Shawhan R AD - Madigan Army Medical Center, Joint Base Lewis-McChord, Tacoma, Washington. FAU - Porta, C Rees AU - Porta CR AD - Madigan Army Medical Center, Joint Base Lewis-McChord, Tacoma, Washington. LA - eng PT - Journal Article DEP - 20250808 PL - United States TA - J Surg Res JT - The Journal of surgical research JID - 0376340 SB - IM MH - Humans MH - Male MH - Female MH - Adult MH - *Gastrectomy/methods/adverse effects/statistics & numerical data MH - Middle Aged MH - *Ambulatory Surgical Procedures/adverse effects/methods/statistics & numerical data MH - *Obesity, Morbid/surgery MH - Hospitals, Military/statistics & numerical data MH - Patient Discharge/statistics & numerical data MH - *Laparoscopy/adverse effects/methods MH - Treatment Outcome MH - Postoperative Complications/epidemiology/etiology MH - Patient Readmission/statistics & numerical data MH - Clinical Protocols MH - *Bariatric Surgery/methods/adverse effects MH - Patient Satisfaction/statistics & numerical data MH - Length of Stay/statistics & numerical data OTO - NOTNLM OT - Ambulatory surgery OT - Bariatric surgery OT - Same-day discharge OT - Sleeve gastrectomy EDAT- 2025/08/10 06:16 MHDA- 2025/10/03 00:29 CRDT- 2025/08/09 18:04 PHST- 2025/02/25 00:00 [received] PHST- 2025/06/24 00:00 [revised] PHST- 2025/07/03 00:00 [accepted] PHST- 2025/10/03 00:29 [medline] PHST- 2025/08/10 06:16 [pubmed] PHST- 2025/08/09 18:04 [entrez] AID - S0022-4804(25)00443-3 [pii] AID - 10.1016/j.jss.2025.07.013 [doi] PST - ppublish SO - J Surg Res. 2025 Oct;314:284-290. doi: 10.1016/j.jss.2025.07.013. Epub 2025 Aug 8. PMID- 40780989 OWN - NLM STAT- MEDLINE DCOM- 20251215 LR - 20251215 IS - 1875-2128 (Electronic) IS - 1875-2128 (Linking) VI - 118 IP - 12 DP - 2025 Dec TI - Single-centre retrospective series on neonatal intracardiac, aortic and arterial thrombosis: Clinical presentation, therapeutic strategies and outcomes. PG - 652-660 LID - S1875-2136(25)00406-1 [pii] LID - 10.1016/j.acvd.2025.06.074 [doi] AB - BACKGROUND: Neonatal arterial thrombosis is a rare but extremely severe condition with a variable death rate. AIM: To evaluate treatment options and outcomes in a series of hyperacute presentations of intracardiac, aortic or arterial thrombosis in neonates. METHODS: All neonates with proven aortic or arterial thrombus without iatrogenic aetiology were reviewed retrospectively in a single-centre series from January 1990 to September 2023. Clinical presentation was reviewed, as well as diagnostic tools used. Treatment, outcomes and potential aetiologies were analysed. RESULTS: Seventeen neonates (six females) were identified from our database. Twelve were diagnosed between day 0 and day 1, and the rest in first week. The modes of presentation were antenatal ventricular asymmetry (n=3), cardiogenic shock (n=6), limb ischaemia (n=4), seizure (n=2) and pulmonary hypertension (n=2). The thrombus locations were thoracic aorta (n=4), abdominal aorta (n=5), coronary arteries (n=2), left atrial appendage (n=2), foramen ovale (n=1) and limb arteries (n=3). Five patients had surgical removal, four had percutaneous treatment (including thromboaspiration, thrombolysis and stent implantation) and seven had heparin infusion only. Two patients received parenteral thrombolysis. Two patients with coronary thrombosis ultimately died, one patient had limb amputation and the other patients had a complete cardiac recovery. Only one patient had a heterozygous factor V Leiden mutation as a potential thrombophilia. CONCLUSIONS: All therapeutic strategies should be discussed in multidisciplinary team, ranging from heparin infusion to surgical resection. Endovascular therapy is a valid option in a substantial number of patients. CI - Copyright (c) 2025. Published by Elsevier Masson SAS. FAU - Jaber, Mohamed AU - Jaber M AD - M3C-Necker, Hopital Universitaire Necker-Enfants-Malades, AP-HP, 75015 Paris, France. Electronic address: jaber.mohamed@hotmail.fr. FAU - Bajolle, Fanny AU - Bajolle F AD - M3C-Necker, Hopital Universitaire Necker-Enfants-Malades, AP-HP, 75015 Paris, France. FAU - Garcelon, Nicolas AU - Garcelon N AD - Inserm UMR1163, Data Science Platform, Imagine Institute, Universite de Paris, 75006 Paris, France; Inserm UMR1163, Clinical Bioinformatics Group, Imagine Institute, Universite Paris-Cite, 75015 Paris, France. FAU - Bonnet, Damien AU - Bonnet D AD - M3C-Necker, Hopital Universitaire Necker-Enfants-Malades, AP-HP, 75015 Paris, France; Universite Paris-Cite, 75006 Paris, France. FAU - Malekzadeh-Milani, Sophie AU - Malekzadeh-Milani S AD - M3C-Necker, Hopital Universitaire Necker-Enfants-Malades, AP-HP, 75015 Paris, France. LA - eng PT - Journal Article DEP - 20250805 PL - Netherlands TA - Arch Cardiovasc Dis JT - Archives of cardiovascular diseases JID - 101465655 RN - 0 (Anticoagulants) RN - 9005-49-6 (Heparin) SB - IM MH - Humans MH - Retrospective Studies MH - Infant, Newborn MH - Female MH - Male MH - Treatment Outcome MH - *Thrombosis/therapy/diagnostic imaging/mortality MH - *Aortic Diseases/therapy/diagnostic imaging/mortality MH - *Heart Diseases/therapy/mortality/diagnostic imaging MH - Time Factors MH - *Anticoagulants/administration & dosage/adverse effects MH - *Thrombolytic Therapy/adverse effects/mortality MH - Risk Factors MH - *Arterial Occlusive Diseases/therapy/diagnostic imaging/mortality MH - *Thrombectomy/adverse effects/mortality MH - *Endovascular Procedures/adverse effects/instrumentation/mortality MH - Databases, Factual MH - Heparin/administration & dosage OTO - NOTNLM OT - Aortic thrombosis OT - Arterial thrombosis OT - Endovascular thrombectomy OT - Neonatal thrombosis COIS- Disclosure of interest The authors declare that they have no competing interest. EDAT- 2025/08/09 13:49 MHDA- 2025/12/16 00:35 CRDT- 2025/08/08 22:01 PHST- 2025/03/08 00:00 [received] PHST- 2025/06/02 00:00 [revised] PHST- 2025/06/17 00:00 [accepted] PHST- 2025/12/16 00:35 [medline] PHST- 2025/08/09 13:49 [pubmed] PHST- 2025/08/08 22:01 [entrez] AID - S1875-2136(25)00406-1 [pii] AID - 10.1016/j.acvd.2025.06.074 [doi] PST - ppublish SO - Arch Cardiovasc Dis. 2025 Dec;118(12):652-660. doi: 10.1016/j.acvd.2025.06.074. Epub 2025 Aug 5. PMID- 40780539 OWN - NLM STAT- MEDLINE DCOM- 20251221 LR - 20251221 IS - 2772-803X (Electronic) IS - 0003-4509 (Linking) VI - 84 IP - 1 DP - 2026 Jan TI - A multidisciplinary intervention to improve postoperative antithrombotic therapy after urgent coronary artery bypass-grafts. PG - 114-123 LID - S0003-4509(25)00121-X [pii] LID - 10.1016/j.pharma.2025.08.005 [doi] AB - OBJECTIVES: The objective of this study was to assess whether implementing a protocol could improve adherence to European guidelines on postoperative antithrombotic therapy prescription in patients undergoing coronary artery bypass-grafts surgery (CABG) after acute coronary syndrome (ACS). METHODS: We included patients who underwent cardiac surgery between January 2018 and December 2022. The population was divided in two groups, one before (group 1) and one after (group 2) the dissemination of a protocol on postoperative antithrombotic therapy issued by a multidisciplinary collaboration (January 2021) and its subsequent implementation during ward rounds. We analysed the protocol's impact on adherence to European guidelines in terms of antithrombotic therapy at discharge. RESULTS: We included 259 patients, 83.8% were men and the median age was 67 [58; 74] years. At baseline, group 1 (n=152) and group 2 (n=107) had similar demographic characteristics except for smoking status and ACS events. Patients in group 2 had a higher rate of guideline adherence in terms of postoperative antithrombotic therapy (group 1=58.6% vs. group 2=82.2%, P<0.001). Using logistic regression accounting for demographic and temporal factors, the effect of the intervention was positive but not statistically significant. Adherence increased significantly over time, suggesting that the intervention contributed to an overall trend of improved adherence as apart of ongoing quality improvement efforts. CONCLUSION: Implementing the protocol was associated with a positive effect on guideline adherence for postoperative antithrombotic therapy in ACS patients undergoing CABG. Although the intervention's independent effect was not statistically significant after adjustment, the findings support its role in achieving sustained improvement in adherence over time. CI - Copyright (c) 2025 Academie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved. FAU - Feka, Alma AU - Feka A AD - Pharmacy Department, Lausanne University Hospital, University of Lausanne, 1011 Lausanne, Switzerland. FAU - Verdugo-Marchese, Mario AU - Verdugo-Marchese M AD - Cardiac Surgery Department, Lausanne University Hospital, University of Lausanne, 1011 Lausanne, Switzerland. FAU - Hugelshofer, Sarah AU - Hugelshofer S AD - Cardiology Department, Lausanne University Hospital, University of Lausanne, 1011 Lausanne, Switzerland. FAU - Guerrier, Stephane AU - Guerrier S AD - School of Pharmaceutical Sciences, University of Geneva, 1206 Geneva, Switzerland; Department of Earth Sciences, University of Geneva, 1206 Geneva, Switzerland. FAU - Perrottet, Nancy AU - Perrottet N AD - Pharmacy Department, Lausanne University Hospital, University of Lausanne, 1011 Lausanne, Switzerland; School of Pharmaceutical Sciences, University of Geneva, 1206 Geneva, Switzerland; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, University of Lausanne, Lausanne, Switzerland. FAU - Kirsch, Matthias AU - Kirsch M AD - Cardiac Surgery Department, Lausanne University Hospital, University of Lausanne, 1011 Lausanne, Switzerland. FAU - Sadeghipour, Farshid AU - Sadeghipour F AD - Pharmacy Department, Lausanne University Hospital, University of Lausanne, 1011 Lausanne, Switzerland; School of Pharmaceutical Sciences, University of Geneva, 1206 Geneva, Switzerland; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, University of Lausanne, Lausanne, Switzerland. Electronic address: farshid.sadeghipour@unil.ch. FAU - Gunga, Ziyad AU - Gunga Z AD - Cardiac Surgery Department, Lausanne University Hospital, University of Lausanne, 1011 Lausanne, Switzerland. LA - eng PT - Journal Article DEP - 20250806 PL - France TA - Ann Pharm Fr JT - Annales pharmaceutiques francaises JID - 2985176R RN - 0 (Fibrinolytic Agents) SB - IM MH - Humans MH - Male MH - Female MH - Middle Aged MH - Aged MH - *Coronary Artery Bypass MH - *Fibrinolytic Agents/therapeutic use MH - Guideline Adherence MH - Acute Coronary Syndrome/surgery/drug therapy MH - *Postoperative Care/methods MH - Postoperative Complications/prevention & control MH - Patient Care Team OTO - NOTNLM OT - Acute coronary syndrome OT - Cardiac surgery OT - Chirurgie cardiaque OT - Coronary artery bypass-grafts OT - Double anti-agregation antiplaquettaire OT - Pontages aorto-coronariens OT - STEMI OT - Suisse OT - Switzerland OT - Syndrome coronarien aigu COIS- Disclosure of interest The authors declare that they have no competing interest. EDAT- 2025/08/09 13:49 MHDA- 2025/12/22 00:28 CRDT- 2025/08/08 19:52 PHST- 2025/04/23 00:00 [received] PHST- 2025/08/04 00:00 [revised] PHST- 2025/08/04 00:00 [accepted] PHST- 2025/12/22 00:28 [medline] PHST- 2025/08/09 13:49 [pubmed] PHST- 2025/08/08 19:52 [entrez] AID - S0003-4509(25)00121-X [pii] AID - 10.1016/j.pharma.2025.08.005 [doi] PST - ppublish SO - Ann Pharm Fr. 2026 Jan;84(1):114-123. doi: 10.1016/j.pharma.2025.08.005. Epub 2025 Aug 6. PMID- 40778399 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250810 IS - 2048-0040 (Print) IS - 2048-0040 (Electronic) IS - 2048-0040 (Linking) VI - 14 DP - 2025 Jan-Dec TI - Mechanical heart valves and pregnancy. PG - 20480040251365987 LID - 10.1177/20480040251365987 [doi] LID - 20480040251365987 AB - Pregnancy is an exciting time, with great anticipation of the future for the woman and her baby. However, for women with mechanical heart valves (MHVs) pregnancy is a challenging undertaking fraught with risk to them and their baby. This article considers the issues for the woman, highlighting pre-surgical opportunities, pre-pregnancy counselling, the issues to consider with fertility treatment, the options during pregnancy for anti-coagulation management and the recognition and management of complications. This update stresses the complex challenges in the management of women with MHV during pregnancy and the need for specialist multi-disciplinary team involvement. CI - (c) The Author(s) 2025. FAU - Kelly, Bronagh AU - Kelly B AD - Scottish Adult Congenital Cardiac Service, Golden Jubilee National Hospital, Clydebank, G81 4DY, UK. RINGGOLD: 41444 FAU - Walker, Niki AU - Walker N AUID- ORCID: 0000-0001-6676-1097 AD - Scottish Adult Congenital Cardiac Service, Golden Jubilee National Hospital, Clydebank, G81 4DY, UK. RINGGOLD: 41444 LA - eng PT - Journal Article PT - Review DEP - 20250806 PL - England TA - JRSM Cardiovasc Dis JT - JRSM cardiovascular disease JID - 101598607 PMC - PMC12329187 OTO - NOTNLM OT - CV surgery: valvular disease OT - Valvular heart disease OT - anti-coagulants OT - cardiology OT - cardiovascular (CV) surgery OT - cardiovascular pharmacology OT - coagulation OT - compliance/adherence OT - coumarins OT - hypertension OT - thrombosis OT - treatment COIS- The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: NW received payment for a talk from Bayer UK in 2023. EDAT- 2025/08/08 06:29 MHDA- 2025/08/08 06:30 PMCR- 2025/08/06 CRDT- 2025/08/08 05:34 PHST- 2024/11/13 00:00 [received] PHST- 2025/07/04 00:00 [revised] PHST- 2025/07/06 00:00 [accepted] PHST- 2025/08/08 06:30 [medline] PHST- 2025/08/08 06:29 [pubmed] PHST- 2025/08/08 05:34 [entrez] PHST- 2025/08/06 00:00 [pmc-release] AID - 10.1177_20480040251365987 [pii] AID - 10.1177/20480040251365987 [doi] PST - epublish SO - JRSM Cardiovasc Dis. 2025 Aug 6;14:20480040251365987. doi: 10.1177/20480040251365987. eCollection 2025 Jan-Dec. PMID- 40778095 OWN - NLM STAT- MEDLINE DCOM- 20250808 LR - 20260520 IS - 2214-9996 (Electronic) IS - 2214-9996 (Linking) VI - 91 IP - 1 DP - 2025 TI - Implementation Outcomes of an Intervention to Improve Myocardial Infarction Care in Tanzania. PG - 43 LID - 10.5334/aogh.4651 [doi] LID - 43 AB - Background: Uptake of evidence-based care for acute myocardial infarction (AMI) is limited in Tanzania. To address this, a tailored intervention, the Multicomponent Intervention to Improve Acute Myocardial Infarction Care (MIMIC), was co-designed by an interdisciplinary team. Objectives: To determine implementation outcomes from a pilot trial of the MIMIC intervention in a Tanzanian emergency department (ED). Methods: The MIMIC intervention was implemented by the ED staff for one year. Fidelity, penetration, and costs were observed for each of the intervention components: designated champions to audit care, an online training module for staff, a triage card for nurses to flag patients with AMI symptoms, pocket cards summarizing AMI management for physicians, and an educational pamphlet for patients. Thirty days following enrollment, patient participants were contacted via telephone to inquire whether they had read the pamphlet. Results: Physician champions and nurse champions were actively engaged in the intervention across the twelve-month study period. Fidelity to the pocket card was excellent, with all 22 (100%) physicians observed to have ever brought their pocket cards to work, and penetration across physician-shifts was 96.1% (1835/1910). The training module was started by 20 out of the 22 (91%) physicians and 25 of the 32 (78%) nurses observed. Penetration, measured by module completion, was the same for physicians (20 of 22, 91%) but lower among nurses (21 of 32, 65.6%). Triage cards were used for 453 out of the 577 (78.5%) patients with chest pain or dyspnea. Fidelity to patients with AMI receiving the educational pamphlet was 37.6% (53 of 141). Only 22 of the 39 (56%) surviving AMI patients who received the pamphlet reported reading it, with most of the rest reporting being unaware that they had received it. The total annual cost of the MIMIC intervention was USD 1324.24. Conclusions: There was high variability in fidelity and penetration of the individual intervention components. Future studies should explore reasons for incomplete penetration and analyze cost-effectiveness for scale-up efforts across Tanzania. CI - Copyright: (c) 2025 The Author(s). FAU - Hertz, Julian T AU - Hertz JT AD - Department of Emergency Medicine, Duke University, Durham, North Carolina, USA. AD - Duke Global Health Institute, Durham, North Carolina, USA. FAU - Sakita, Francis M AU - Sakita FM AD - Kilimanjaro Christian Medical Centre, Moshi, Tanzania. AD - Kilimanjaro Christian Medical University College, Moshi, Tanzania. FAU - Munshi, Zaheer Rik AU - Munshi ZR AD - The College, University of Chicago, Chicago, Illinois, USA. FAU - Rahim, Faraan O AU - Rahim FO AD - Harvard Medical School, Harvard University, Cambridge, Massachusetts, USA. FAU - Mganga, Daniel AU - Mganga D AD - Kibosho Hospital, Kibosho, Tanzania. FAU - Kachenje, Arafa AU - Kachenje A AD - Tanga Regional Hospital, Tanga, Tanzania. FAU - Munisi, James J AU - Munisi JJ AD - Tanga Regional Hospital, Tanga, Tanzania. FAU - Pyne, Abigail S AU - Pyne AS AD - Department of Emergency Medicine, Duke University, Durham, North Carolina, USA. FAU - Bashaka, Prosper AU - Bashaka P AD - Mbeya Zonal Referral Hospital, Mbeya, Tanzania. FAU - Kilungu, Adamu AU - Kilungu A AD - Mbeya Zonal Referral Hospital, Mbeya, Tanzania. FAU - Aboud, Ayshat Mussa AU - Aboud AM AD - Mnazi Mmoja Hospital, Zanzibar, Tanzania. FAU - Bosworth, Hayden B AU - Bosworth HB AD - Department of Population Health Sciences, Duke University, Durham, North Carolina, USA. FAU - Bettger, Janet Prvu AU - Bettger JP AD - Duke Global Health Institute, Durham, North Carolina, USA. AD - Department of Physical Medicine & Rehabilitation, University of North Carolina School of Medicine, North Carolina, USA. LA - eng SI - ClinicalTrials.gov/NCT04563546 GR - K23 HL155500/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20250805 PL - United States TA - Ann Glob Health JT - Annals of global health JID - 101620864 SB - IM MH - Humans MH - Tanzania MH - *Myocardial Infarction/therapy/diagnosis MH - *Emergency Service, Hospital/standards/organization & administration MH - Pilot Projects MH - Male MH - Female MH - *Quality Improvement MH - Middle Aged MH - Triage MH - Adult PMC - PMC12330802 OTO - NOTNLM OT - Sub-Saharan Africa OT - emergency department OT - fidelity OT - implementation science OT - myocardial infarction OT - penetration COIS- The authors have no competing interests to declare. EDAT- 2025/08/08 06:29 MHDA- 2025/08/08 06:30 PMCR- 2025/08/05 CRDT- 2025/08/08 05:30 PHST- 2025/01/03 00:00 [received] PHST- 2025/07/12 00:00 [accepted] PHST- 2025/08/08 06:30 [medline] PHST- 2025/08/08 06:29 [pubmed] PHST- 2025/08/08 05:30 [entrez] PHST- 2025/08/05 00:00 [pmc-release] AID - 10.5334/aogh.4651 [doi] PST - epublish SO - Ann Glob Health. 2025 Aug 5;91(1):43. doi: 10.5334/aogh.4651. eCollection 2025. PMID- 40771558 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260924 IS - 2050-0904 (Print) IS - 2050-0904 (Electronic) IS - 2050-0904 (Linking) VI - 13 IP - 8 DP - 2025 Aug TI - ECMO-Assisted Da Vinci Robotic Surgery for Pheochromocytoma-Induced Acute Catecholamine Cardiomyopathy: A Case Report. PG - e70712 LID - 10.1002/ccr3.70712 [doi] LID - e70712 AB - Pheochromocytoma, an uncommon neuroendocrine neoplasm, has the potential to precipitate acute catecholamine cardiomyopathy (ACIC), a perilous condition characterized by cardiogenic shock and the failure of multiple organ systems. The significance of early diagnosis and the implementation of a multidisciplinary approach are paramount for patient survival. A 40-year-old female patient presented with a 6-day history of an adrenal mass, labile hypertension range of 180-120/80-90 mmHg, hyperglycemia at 19 mmol/L, and respiratory distress that progressed to cardiogenic shock with a left ventricular ejection fraction (LVEF) of 18%. Imaging studies unveiled a right adrenal mass; biochemical analyses substantiated elevated levels of plasma metanephrines. The employment of venoarterial extracorporeal membrane oxygenation (ECMO) served to stabilize hemodynamic parameters, whereas continuous renal replacement therapy (CRRT) was instrumental in managing the multiorgan dysfunction. Preoperative alpha-blockade with phenoxybenzamine was administered to alleviate catecholamine toxicity. The definitive therapeutic intervention comprised a da Vinci robot-assisted adrenalectomy conducted with the support of ECMO. Following the surgical procedure, the patient's vital signs reverted to normal, and the LVEF improved to 55% at the 6-month follow-up. The patient was able to resume her daily activities without any residual functional impairment. This case underscores the efficacy of the synergistic application of ECMO with robotic surgery in the management of pheochromocytoma-induced ACIC. This approach accentuates the importance of rapid diagnostic procedures, mechanical support systems, and minimally invasive surgical techniques in critical care scenarios. Further research is warranted to establish standardized protocols for such combined therapeutic interventions. CI - (c) 2025 The Author(s). Clinical Case Reports published by John Wiley & Sons Ltd. FAU - Wang, Qi AU - Wang Q AD - Department of Urology The Third Central Hospital of Tianjin Tianjin China. AD - Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases Tianjin China. AD - Artificial Cell Engineering Technology Research Center Tianjin China. FAU - Xin, Jiayan AU - Xin J AUID- ORCID: 0000-0001-9939-4609 AD - Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases Tianjin China. AD - Artificial Cell Engineering Technology Research Center Tianjin China. AD - Tianjin Institute of Hepatobiliary Disease Tianjin China. AD - Department of Cardiology The Third Central Hospital of Tianjin Tianjin China. FAU - Cui, Xiaoqiong AU - Cui X AD - Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases Tianjin China. FAU - Hu, Liya AU - Hu L AD - Department of Intensive Care Unit The Third Central Hospital of Tianjin Tianjin China. FAU - Ning, Meng AU - Ning M AUID- ORCID: 0000-0003-0686-6457 AD - Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases Tianjin China. FAU - Gao, Wenqing AU - Gao W AD - Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases Tianjin China. AD - Artificial Cell Engineering Technology Research Center Tianjin China. FAU - Liu, Yingwu AU - Liu Y AD - Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases Tianjin China. AD - Artificial Cell Engineering Technology Research Center Tianjin China. AD - Tianjin Institute of Hepatobiliary Disease Tianjin China. AD - Department of Cardiology The Third Central Hospital of Tianjin Tianjin China. LA - eng PT - Journal Article DEP - 20250805 PL - England TA - Clin Case Rep JT - Clinical case reports JID - 101620385 PMC - PMC12325086 OTO - NOTNLM OT - acute catecholamine cardiomyopathy OT - da Vinci robot OT - extracorporeal membrane oxygenation OT - pheochromocytoma COIS- The authors declare no conflicts of interest. EDAT- 2025/08/07 11:42 MHDA- 2025/08/07 11:43 PMCR- 2025/08/05 CRDT- 2025/08/07 05:02 PHST- 2025/01/16 00:00 [received] PHST- 2025/05/07 00:00 [revised] PHST- 2025/07/11 00:00 [accepted] PHST- 2025/08/07 11:43 [medline] PHST- 2025/08/07 11:42 [pubmed] PHST- 2025/08/07 05:02 [entrez] PHST- 2025/08/05 00:00 [pmc-release] AID - CCR370712 [pii] AID - 10.1002/ccr3.70712 [doi] PST - epublish SO - Clin Case Rep. 2025 Aug 5;13(8):e70712. doi: 10.1002/ccr3.70712. eCollection 2025 Aug. PMID- 40769665 OWN - NLM STAT- MEDLINE DCOM- 20250806 LR - 20260127 IS - 1558-0474 (Electronic) IS - 0889-8545 (Linking) VI - 52 IP - 3 DP - 2025 Sep TI - Systemic Lupus and Other Autoimmune Disorders During Pregnancy. PG - 581-597 LID - S0889-8545(25)00024-5 [pii] LID - 10.1016/j.ogc.2025.05.007 [doi] AB - Rheumatologic conditions occur in reproductive aged women, requiring a multidisciplinary approach to care. Patients require coordinated care with obstetrics, maternal fetal medicine, and rheumatology. Many drugs used for the care of rheumatologic conditions are safe in pregnancy, but detailed review should occur, ideally preconception, so the patient can be on the safest regimen while maintaining disease control. Anti-Ro/SSA and anti-La/SSB antibodies particularly pose unique risks of neonatal lupus syndrome, including cardiac manifestations. Medical management is unique to each disease and includes ultrasounds and antenatal testing to optimize both maternal and fetal well-being and minimize perinatal risks. CI - Copyright (c) 2025 Elsevier Inc. All rights reserved. FAU - Patton, Kathryn A AU - Patton KA AD - Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Loyola University Medical Center, 2160 S 1st Avenue, Maywood, IL 60153, USA. FAU - Siddique, Faizah AU - Siddique F AD - Division of Rheumatology, Department of Internal Medicine, Loyola University Medical Center, 2160 S 1st Avenue, Maywood, IL 60153, USA. FAU - Lal, Ann K AU - Lal AK AD - Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Loyola University Medical Center, 2160 S 1st Avenue, Maywood, IL 60153, USA. Electronic address: ann.lal@lumc.edu. LA - eng PT - Journal Article PT - Review DEP - 20250617 PL - United States TA - Obstet Gynecol Clin North Am JT - Obstetrics and gynecology clinics of North America JID - 8709551 RN - Neonatal Systemic lupus erythematosus SB - IM MH - Humans MH - Pregnancy MH - Female MH - *Lupus Erythematosus, Systemic/therapy/diagnosis/drug therapy/immunology/congenital MH - *Pregnancy Complications/therapy/immunology/diagnosis/drug therapy MH - *Autoimmune Diseases/therapy/diagnosis/drug therapy MH - Infant, Newborn OTO - NOTNLM OT - Anti-La/SSB OT - Anti-Ro/SSA OT - Complete heart block OT - Lupus OT - Rheumatoid arthritis OT - Rheumatology pregnancy COIS- Disclosure The authors have no disclosures. EDAT- 2025/08/07 00:27 MHDA- 2025/08/07 00:28 CRDT- 2025/08/06 20:56 PHST- 2025/08/07 00:28 [medline] PHST- 2025/08/07 00:27 [pubmed] PHST- 2025/08/06 20:56 [entrez] AID - S0889-8545(25)00024-5 [pii] AID - 10.1016/j.ogc.2025.05.007 [doi] PST - ppublish SO - Obstet Gynecol Clin North Am. 2025 Sep;52(3):581-597. doi: 10.1016/j.ogc.2025.05.007. Epub 2025 Jun 17. PMID- 40769656 OWN - NLM STAT- MEDLINE DCOM- 20250806 LR - 20250806 IS - 1558-0474 (Electronic) IS - 0889-8545 (Linking) VI - 52 IP - 3 DP - 2025 Sep TI - Cardiac Considerations in Pregnancy: A Spotlight on Peripartum Cardiomyopathy and Pregnancy-Associated Spontaneous Coronary Dissection. PG - 445-456 LID - S0889-8545(25)00030-0 [pii] LID - 10.1016/j.ogc.2025.06.001 [doi] AB - Cardiovascular diseases complicating pregnancies are major causes of peripartum morbidity and mortality. The field of Cardio-Obstetrics has evolved to treat women with acquired and metabolic-related cardiovascular diseases in addition to congenital heart disease. Peripartum cardiomyopathy (PPCM) is a heart failure etiology specific to pregnant and post-partum women. Pregnancy-associated spontaneous coronary dissection (p-SCAD) is the most common cause of acute myocardial infarction in the pregnant and post-partum population, highlighting the importance of evaluating chest discomfort. Adequate therapy for both PPCM and p-SCAD requires expertise from multiple medical subspecialities, which underscores the necessity of the Cardio-Obstetric team approach. CI - Copyright (c) 2025 Elsevier Inc. All rights reserved. FAU - Thordsen, Sarah AU - Thordsen S AD - Division of Cardiovascular Medicine, University of Wisconsin Madison, Madison, WI 53792, USA. FAU - Briller, Joan AU - Briller J AD - Division of Cardiology, Department of Medicine, Department of Obstetrics and Gynecology, University of Illinois, Chicago, IL 60612, USA. FAU - Cruz, Meredith O AU - Cruz MO AD - Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI 53226, USA. Electronic address: Mocruz@mcw.edu. LA - eng PT - Journal Article PT - Review DEP - 20250712 PL - United States TA - Obstet Gynecol Clin North Am JT - Obstetrics and gynecology clinics of North America JID - 8709551 RN - Coronary Artery Dissection, Spontaneous SB - IM MH - Humans MH - Female MH - Pregnancy MH - *Pregnancy Complications, Cardiovascular/therapy/diagnosis MH - Peripartum Period MH - *Cardiomyopathies/therapy/diagnosis MH - *Coronary Vessel Anomalies/therapy/diagnosis/complications MH - *Vascular Diseases/congenital/therapy/diagnosis/complications MH - Myocardial Infarction/etiology/therapy MH - Peripartum Cardiomyopathy OTO - NOTNLM OT - Acute myocardial infarction OT - Cardio-obstetrics team OT - Heart failure OT - Peripartum cardiomyopathy OT - Pregnancy-associated spontaneous coronary dissection COIS- Disclosure Sarah Thordsen is a site investigator for REBIRTH trial of bromocriptine for peripartum cardiomyopathy. She has received funding for the National Institutes of Health, United States funded REBIRTH trial (of bromocriptine in peripartum cardiomyopathy) from the pass-through entity federal award to the University of Pittsburgh(1UG3HL153847-01A1). Joan Briller is an unpaid consultant for the Illinois Maternal Mortality Committee (IL MMRC) and serves on the steering committee and is a site investigator REBIRTH trial of bromocriptine for peripartum cardiomyopathy. She has received honoraria from the American Heart Association for academic lectures and for lectures at academic cardio-obstetric lectures. She has received funding for the National Institutes of Health funded REBIRTH trial (of bromocriptine in peripartum cardiomyopathy) from the pass-through entity (PTE) federal award to the University of Pittsburgh(1UG3HL153847-01A1) and from subaward UIC AWD00004314 (137,168-1) and from NIH, United States/NINR funded EASE trial for effects of Acupuncture on Symptoms of Stable Angina: a randomized controlled trial (NR02037600). She has received consulting fees from Medtronic inc. Meredith Cruz, MD: None. EDAT- 2025/08/07 00:27 MHDA- 2025/08/07 00:28 CRDT- 2025/08/06 20:56 PHST- 2025/08/07 00:28 [medline] PHST- 2025/08/07 00:27 [pubmed] PHST- 2025/08/06 20:56 [entrez] AID - S0889-8545(25)00030-0 [pii] AID - 10.1016/j.ogc.2025.06.001 [doi] PST - ppublish SO - Obstet Gynecol Clin North Am. 2025 Sep;52(3):445-456. doi: 10.1016/j.ogc.2025.06.001. Epub 2025 Jul 12. PMID- 40769655 OWN - NLM STAT- MEDLINE DCOM- 20250806 LR - 20250806 IS - 1558-0474 (Electronic) IS - 0889-8545 (Linking) VI - 52 IP - 3 DP - 2025 Sep TI - Intensive Care Considerations for the Critically Ill Pregnant Patient. PG - 431-444 LID - S0889-8545(25)00019-1 [pii] LID - 10.1016/j.ogc.2025.05.002 [doi] AB - Critical care of the pregnant patient requires a multidisciplinary approach. These patients can present a significant diagnostic and therapeutic challenge. Sepsis and acute respiratory distress syndrome should be readily recognized and treated on obstetric units. In cases of cardiopulmonary arrest, advanced life support care remains largely unchanged with only a few pregnancy-specific modifications. The maternal status should be prioritized as maternal well-being is a pre-requisite to ensure optimal neonatal outcomes. Stabilizing the mother will improve the fetal status in many cases. Critical, life-saving interventions should not be withheld from patients solely because of their pregnant status. CI - Copyright (c) 2025 Elsevier Inc. All rights reserved. FAU - Hensel, Drew AU - Hensel D AD - Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Washington University, MSC 8064-37-1005, 660 S. Euclid Avenue, St Louis, MO 63110, USA. Electronic address: dhensel@wustl.edu. FAU - Dombrowski, Michael AU - Dombrowski M AD - Division of Criticial Care, John T. Milliken Department of Medicine, MSC 8052-43-14, 660 South Euclid Avenue, St Louis, MO 63110, USA. LA - eng PT - Journal Article PT - Review DEP - 20250609 PL - United States TA - Obstet Gynecol Clin North Am JT - Obstetrics and gynecology clinics of North America JID - 8709551 SB - IM MH - Humans MH - Pregnancy MH - Female MH - *Critical Care/methods MH - *Critical Illness/therapy MH - *Pregnancy Complications/therapy/diagnosis MH - Sepsis/therapy/diagnosis MH - Respiratory Distress Syndrome/therapy/diagnosis OTO - NOTNLM OT - Acute respiratory distress syndrome OT - Cardiac arrest OT - Critical care OT - Pregnancy OT - Sepsis COIS- Disclosures The authors have nothing to disclose. EDAT- 2025/08/07 00:27 MHDA- 2025/08/07 00:28 CRDT- 2025/08/06 20:56 PHST- 2025/08/07 00:28 [medline] PHST- 2025/08/07 00:27 [pubmed] PHST- 2025/08/06 20:56 [entrez] AID - S0889-8545(25)00019-1 [pii] AID - 10.1016/j.ogc.2025.05.002 [doi] PST - ppublish SO - Obstet Gynecol Clin North Am. 2025 Sep;52(3):431-444. doi: 10.1016/j.ogc.2025.05.002. Epub 2025 Jun 9. PMID- 40768737 OWN - NLM STAT- MEDLINE DCOM- 20260206 LR - 20260225 IS - 1550-5049 (Electronic) IS - 0889-4655 (Linking) VI - 41 IP - 2 DP - 2026 Mar-Apr 01 TI - Multidisciplinary Management and the Role of Heart Failure Nurses in the Recognition and Treatment of Cardiac Amyloidosis. PG - E41-E46 LID - 10.1097/JCN.0000000000001251 [doi] AB - BACKGROUND: Cardiac amyloidosis is a life-limiting disease with poor prognosis if not identified and treated early. Heart failure related to amyloidosis carries high mortality, necessitating timely intervention. PURPOSE: This review provides an overview of recent American College of Cardiology guidelines regarding the multidisciplinary approach to diagnosing and managing cardiac amyloidosis, highlighting the essential role of nurses in early recognition and differentiation from other heart failure types. CLINICAL IMPLICATIONS: Heart failure nurses-whether formally designated as navigators or not-effectively connect patients with specialized amyloid centers and advanced therapies. By coordinating appointments, treatments, genetic testing, insurance, and education, nurses enhance care delivery and outcomes. CONCLUSIONS: Early diagnosis and referral to specialized amyloidosis centers is crucial. Heart failure nurses or nurse navigators facilitate evaluation, make appropriate referrals, and coordinate care to improve treatment and reduce outcome disparities. CI - Copyright (c) 2025 Wolters Kluwer Health, Inc. All rights reserved. FAU - Gast, Sarah AU - Gast S AUID- ORCID: 0000-0003-2677-5173 AD - Sarah Gast, DNP, AGACNP, FNP, Cardiac Intensive Care Unit APP, TriStar Centennial Medical Center, Nashville, Tennessee. FAU - Enstrom, Cate AU - Enstrom C AD - Cate Enstrom, DNP, AGACNP, Cardiac Intensive Care Unit APP and Director of APP CICU Research and Quality, TriStar Centennial Medical Center, Nashville, Tennessee. FAU - Roberts, Austin AU - Roberts A AD - Austin Roberts, PharmD, MBA, BCCCP, BCPS, Critical Care Pharmacist, TriStar Centennial Medical Center, Nashville, Tennessee. FAU - Knipper, Elaine AU - Knipper E AD - Elaine Knipper, BSN, RN, Amyloid Nurse Navigator, University of Kansas Health Systems, Kansas City. FAU - Yacovino, Jennifer AU - Yacovino J AD - Jennifer Yacovino, BSN, RN, Advanced Heart Failure Nurse, Centennial Heart, TriStar Centennial Medical Center, Nashville, Tennessee. FAU - Brooksbank, Jeremy AU - Brooksbank J AD - Jeremy Brooksbank, MD, FACC, Advanced Heart Failure and Transplant Cardiologist, Centennial Heart Cardiovascular Consultants, TriStar Centennial Medical Center, Nashville, Tennessee. LA - eng PT - Journal Article PT - Review DEP - 20250807 PL - United States TA - J Cardiovasc Nurs JT - The Journal of cardiovascular nursing JID - 8703516 SB - IM MH - Humans MH - *Heart Failure/nursing/diagnosis/etiology/therapy MH - *Nurse's Role MH - *Amyloidosis/diagnosis/nursing/therapy MH - *Patient Care Team MH - Practice Guidelines as Topic MH - *Cardiovascular Nursing MH - *Cardiomyopathies/nursing/diagnosis/therapy OTO - NOTNLM OT - amyloid OT - cardiac amyloidosis OT - heart failure COIS- The authors have no funding or conflicts of interest to disclose. EDAT- 2025/08/06 18:28 MHDA- 2026/02/06 18:30 CRDT- 2025/08/06 16:24 PHST- 2026/02/06 18:30 [medline] PHST- 2025/08/06 18:28 [pubmed] PHST- 2025/08/06 16:24 [entrez] AID - 00005082-202603000-00012 [pii] AID - 10.1097/JCN.0000000000001251 [doi] PST - ppublish SO - J Cardiovasc Nurs. 2026 Mar-Apr 01;41(2):E41-E46. doi: 10.1097/JCN.0000000000001251. Epub 2025 Aug 7. PMID- 40765108 OWN - NLM STAT- MEDLINE DCOM- 20250806 LR - 20250809 IS - 1466-7657 (Electronic) IS - 0020-8132 (Print) IS - 0020-8132 (Linking) VI - 72 IP - 3 DP - 2025 Sep TI - Cohesion Challenges in a Multicultural Nursing Team. PG - e70089 LID - 10.1111/inr.70089 [doi] LID - e70089 AB - AIM: This study aimed to explore and describe the cohesion challenges that the multicultural nursing team of a cardiac centre in a designated hospital in Saudi Arabia experienced. BACKGROUND: The World Health Organization predicts a huge global shortage of nurses by 2030. Healthcare services will have to recruit nurses from other countries. Internationally recruited nurses' poor understanding of their colleagues' and patients' cultural backgrounds may lead to cohesive challenges in teams to the detriment of quality patient care. METHODS: A descriptive qualitative design was applied. Face-to-face interviews were done with 15 participants (five nurse managers and ten nurses), their ages ranging between 30 and 50 years. They were from different countries and cultural backgrounds. One open-ended question was used 'What cohesion challenges does the multicultural nursing team of the cardiac centre experience, and what support should they get from management to overcome these challenges?' A thematic data analysis was done. RESULTS: Cohesion challenges were experienced due to poor communication, the exclusion of members in decision making, a lack of meaningful team-building events and limited introduction of newly appointed members. The diversity of the team led to the alienation of some members, and the internationally recruited nurses felt that they were expected to conform to the expectations of the Saudi members. CONCLUSIONS: The participants did not appreciate the benefits of multicultural teams and only focussed on the challenges that they experienced to function as a cohesive unit. The participants wanted to be respected, acknowledged and valued as team members. IMPLICATIONS FOR NURSING AND HEALTH POLICY: Managers should invest in cultural competence training, the enhancement of communication practices and the encouragement of trust among members to ultimately improve team cohesion. CI - (c) 2025 The Author(s). International Nursing Review published by John Wiley & Sons Ltd on behalf of International Council of Nurses. FAU - Govender, Kaminie AU - Govender K AD - Department of Nursing Science, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa. FAU - van Wyk, Neltjie AU - van Wyk N AUID- ORCID: 0000-0002-9456-2121 AD - Department of Nursing Science, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa. FAU - du Plessis, Moselene AU - du Plessis M AD - Department of Nursing Science, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa. LA - eng PT - Journal Article PL - England TA - Int Nurs Rev JT - International nursing review JID - 7808754 SB - IM MH - Humans MH - Saudi Arabia MH - Middle Aged MH - Adult MH - Female MH - Male MH - *Cultural Diversity MH - Qualitative Research MH - *Interprofessional Relations MH - *Nursing Staff, Hospital/psychology MH - *Nursing, Team/organization & administration PMC - PMC12326109 OTO - NOTNLM OT - cohesion OT - multicultural OT - nurse managers OT - nurses OT - nursing teams COIS- The authors declare that they have no financial or personal relationships that may have inappropriately influenced them in writing this article. EDAT- 2025/08/06 06:28 MHDA- 2025/08/06 06:29 PMCR- 2025/08/06 CRDT- 2025/08/06 01:22 PHST- 2025/03/14 00:00 [received] PHST- 2025/07/15 00:00 [accepted] PHST- 2025/08/06 06:29 [medline] PHST- 2025/08/06 06:28 [pubmed] PHST- 2025/08/06 01:22 [entrez] PHST- 2025/08/06 00:00 [pmc-release] AID - INR70089 [pii] AID - 10.1111/inr.70089 [doi] PST - ppublish SO - Int Nurs Rev. 2025 Sep;72(3):e70089. doi: 10.1111/inr.70089. PMID- 40763128 OWN - NLM STAT- MEDLINE DCOM- 20250805 LR - 20261028 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 20 IP - 8 DP - 2025 TI - Registered nurse effect on long length of stay in the heart failure hospitalizations of African Americans. PG - e0329602 LID - 10.1371/journal.pone.0329602 [doi] LID - e0329602 AB - African Americans experience approximately 2.5 times more heart failure hospitalizations than Caucasians and the complexity of heart failure requires registered nurses to work in collaboration with other types of healthcare professionals. The purpose of this study was to identify care team configurations associated with long lengths of hospital stay in African Americans with heart failure hospitalizations and the related effect of the presence of registered nurses on their length of hospital stay. This study analyzed electronic health record data on the heart failure hospitalizations of 2,274 African American patients. Binomial logistic regression identified the association between specific care team configurations and length of stay among subgroups of African American patients. Of the significant team configurations, a Kruskal-Wallis H test and linear regression further assessed the team composition and the specific change in days associated with a one-unit change in the number of registered nurses on a patient's care team. Six team configurations were associated with a long length of stay among all African Americans regardless of age, sex, rurality, heart failure severity, and overall health severity. The configurations only differed significantly in the proportion of registered nurses with respect to other care team roles. An increase in one additional registered nurse on a care delivery team was associated with an increase in length of stay of 8.4 hours (i.e., 504 minutes). Identifying the full range of social and technical care delivery tasks performed by RNs, and controlling for their effect on length of stay, may be a key strategy for reducing length of stay and explaining why these six configurations and RNs are associated with long LOS. The identification of these models can be used to support decision-making that optimizes the availability of patient access to high-quality care (e.g., clinical staffing and supplies). CI - Copyright: (c) 2025 Williams et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. FAU - Williams, Tremaine B AU - Williams TB AUID- ORCID: 0000-0003-4902-3038 AD - Department of Biomedical Informatics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America. FAU - Parker, Pearman AU - Parker P AD - College of Nursing, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America. FAU - Bimali, Milan AU - Bimali M AD - Department of Biostatistics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America. FAU - Garza, Maryam Y AU - Garza MY AD - Department of Population Health Sciences, University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States of America. FAU - Crump, Alisha AU - Crump A AD - Department of Biomedical Informatics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America. FAU - Robins, Taiquitha AU - Robins T AUID- ORCID: 0000-0003-4828-325X AD - Department of Biomedical Informatics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America. FAU - Seker, Emel AU - Seker E AD - Department of Biomedical Informatics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America. FAU - Storey, Ava AU - Storey A AD - Department of Biomedical Informatics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America. FAU - Purvis, Allison AU - Purvis A AD - Department of Biomedical Informatics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America. FAU - Tolbert, Mya AU - Tolbert M AD - Department of Biomedical Informatics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America. FAU - Drake, Anthony AU - Drake A AD - Division of Academic Pathways and Workforce Partnerships, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America. FAU - Swindle, Taren Massey AU - Swindle TM AD - Department of Pediatrics, University of Arkansas for Medical Sciences, Arkansas Children's Research Institute, Arkansas Children's Nutrition Center, Little Rock, Arkansas, United States of America. FAU - Sexton, Kevin Wayne AU - Sexton KW AUID- ORCID: 0000-0002-1460-9867 AD - Department of Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America. AD - Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America. LA - eng GR - R21 NR021063/NR/NINR NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20250805 PL - United States TA - PLoS One JT - PloS one JID - 101285081 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Female MH - Humans MH - Male MH - Middle Aged MH - *Black or African American/statistics & numerical data MH - *Heart Failure/nursing/therapy MH - *Hospitalization/statistics & numerical data MH - *Length of Stay/statistics & numerical data MH - *Nurses MH - Patient Care Team PMC - PMC12324096 COIS- The authors declare the following commercial and/or financial relationships: KWS has equity in HoopCare, Inc; hDrop Technologies, Inc; Decisio Healthcare, Inc; and Datafy, LLC. KWS has licensed intellectual property owned by Vanderbilt University and the University of Arkansas for Medical Sciences. For the remaining authors none were declared. EDAT- 2025/08/05 18:28 MHDA- 2025/08/05 18:29 PMCR- 2025/08/05 CRDT- 2025/08/05 13:32 PHST- 2025/02/04 00:00 [received] PHST- 2025/07/19 00:00 [accepted] PHST- 2025/08/05 18:29 [medline] PHST- 2025/08/05 18:28 [pubmed] PHST- 2025/08/05 13:32 [entrez] PHST- 2025/08/05 00:00 [pmc-release] AID - PONE-D-25-05816 [pii] AID - 10.1371/journal.pone.0329602 [doi] PST - epublish SO - PLoS One. 2025 Aug 5;20(8):e0329602. doi: 10.1371/journal.pone.0329602. eCollection 2025. PMID- 40761680 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260924 IS - 2050-0904 (Print) IS - 2050-0904 (Electronic) IS - 2050-0904 (Linking) VI - 13 IP - 8 DP - 2025 Aug TI - Extremely Rare Neonatal Case With Pyloric Atresia, Heart Defects, Hypotonia, Jaundice, and Acidosis. PG - e70727 LID - 10.1002/ccr3.70727 [doi] LID - e70727 AB - Pyloric atresia (PA) is an exceptionally rare congenital cause of gastric outlet obstruction, often associated with syndromic conditions such as epidermolysis bullosa (EB). This case highlights a diagnostically challenging presentation of *non-syndromic pyloric atresia* in a neonate, complicated by a moderate mid-muscular ventricular septal defect (VSD), metabolic acidosis, and physiologic hydronephrosis, without any cutaneous manifestations. Initial hypotonia and respiratory irregularities diverted suspicion toward neurological or septic etiologies, delaying definitive diagnosis. Imaging, including upper gastrointestinal contrast study and echocardiography, confirmed the diagnosis of complete gastric outlet obstruction due to PA and coexisting VSD. The patient underwent successful gastro-duodenostomy with resolution of symptoms and stable postoperative recovery. This case underscores the importance of maintaining a high index of suspicion for gastrointestinal obstruction in neonates with polyhydramnios and early feeding intolerance, even in the absence of classic syndromic features. Comprehensive, multidisciplinary evaluation-incorporating pediatric surgery, neonatology, and cardiology-is essential to address overlapping congenital anomalies and optimize outcomes. This report contributes to the limited literature on non-syndromic PA with multisystem involvement. CI - (c) 2025 The Author(s). Clinical Case Reports published by John Wiley & Sons Ltd. FAU - Abouodeh, Saja AU - Abouodeh S AD - Faculty of Medicine Palestine Polytechnic University Bethlehem Palestine. FAU - Alshami, Yasmeen AU - Alshami Y AD - Faculty of Medicine Palestine Polytechnic University Bethlehem Palestine. FAU - Hroub, Osama AU - Hroub O AUID- ORCID: 0009-0006-6889-2932 AD - Faculty of Medicine Palestine Polytechnic University Hebron Palestine. FAU - Hroub, Mohammad AU - Hroub M AD - Faculty of Medicine Palestine Polytechnic University Hebron Palestine. FAU - Hammouri, Ahmad G AU - Hammouri AG AUID- ORCID: 0000-0003-2919-4980 AD - Radiology Department Al-Ahli Hospital Hebron Palestine. FAU - Shaltaf, Ahmad AU - Shaltaf A AD - Ped Surgeon Ramallah Palestine. FAU - Shihadeh, Wafa AU - Shihadeh W AD - Ped Surgery Fellow Ramallah Palestine. FAU - Dawod, Nimatee AU - Dawod N AD - General Surgery Resident Ramallah Palestine. LA - eng PT - Journal Article DEP - 20250803 PL - England TA - Clin Case Rep JT - Clinical case reports JID - 101620385 PMC - PMC12318670 OTO - NOTNLM OT - congenital ventricular septal defect OT - gastro-duodenostomy in newborns OT - isolated pyloric atresia OT - metabolic acidosis in neonates OT - non-syndromic neonatal intestinal obstruction OT - surgical management of pyloric atresia COIS- The authors declare no conflicts of interest. EDAT- 2025/08/05 11:12 MHDA- 2025/08/05 11:13 PMCR- 2025/08/03 CRDT- 2025/08/05 04:52 PHST- 2025/04/19 00:00 [received] PHST- 2025/06/20 00:00 [revised] PHST- 2025/07/24 00:00 [accepted] PHST- 2025/08/05 11:13 [medline] PHST- 2025/08/05 11:12 [pubmed] PHST- 2025/08/05 04:52 [entrez] PHST- 2025/08/03 00:00 [pmc-release] AID - CCR370727 [pii] AID - 10.1002/ccr3.70727 [doi] PST - epublish SO - Clin Case Rep. 2025 Aug 3;13(8):e70727. doi: 10.1002/ccr3.70727. eCollection 2025 Aug. PMID- 40756296 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250806 IS - 1302-7123 (Print) IS - 1308-5123 (Electronic) IS - 1302-7123 (Linking) VI - 59 IP - 2 DP - 2025 TI - The Role of Cold Agglutinins Screening in Cardiac Surgery: Necessity or Redundancy? PG - 173-177 LID - 10.14744/SEMB.2025.60863 [doi] AB - OBJECTIVES: This study aims to determine the prevalence of cold agglutinins (CA) in patients undergoing cardiac surgery in the Turkish population, to draw attention to the importance of preoperative diagnosis, and to increase clinicians' awareness of cold hemagglutinin disease (CHD). METHODS: 4273 patients who underwent elective cardiac surgery between 2012-2022 were examined. All patients were routinely screened for CA. Patients were divided into two groups: 18-49 years old (Group 1) and over 50 years old (Group 2). Prevalence analysis was performed by comparing these age groups and genders. RESULTS: Among all patients, CA was positive in 390 (9.12%). There was no difference between group 1 and group 2 in all patient groups and women. However, CA was found to be higher in group 2 in men compared to group 1 (n=154 (8.9%) and n=65 (6.6%), respectively), p=0.47). CA was found to be higher in women compared to men (n=171 (10.9%), n=219 (8.07%), respectively), p=0.015). CONCLUSION: We found that CAs were considerably high in patients undergoing cardiac surgery in the Turkish population. CA is important for cardiac surgery where hypothermia is used, and we believe that this pathology should be routinely screened in the preoperative period. Due to these rates that cannot be ignored, the clinical awareness of the heart team about CHD should be increased. CI - (c) Copyright 2025 by The Medical Bulletin of Sisli Etfal Hospital. FAU - Beyazal, Osman Fehmi AU - Beyazal OF AD - Department of Cardiovascular Surgery, Basaksehir Cam and Sakura City Hospital, Istanbul, Turkiye. FAU - Yilmaz, Bilge Ecemis AU - Yilmaz BE AD - Department of Cardiovascular Surgery, Istanbul Medipol University Hospital, Istanbul, Turkiye. FAU - Erkanli, Korhan AU - Erkanli K AD - Department of Cardiovascular Surgery, Istanbul Medipol University Hospital, Istanbul, Turkiye. LA - eng PT - Journal Article DEP - 20250207 PL - Turkey TA - Sisli Etfal Hastan Tip Bul JT - Sisli Etfal Hastanesi tip bulteni JID - 9424130 PMC - PMC12314445 OTO - NOTNLM OT - Autoimmune disease OT - cardiac surgery OT - cold agglutinin OT - cold agglutinin disease OT - hypothermia COIS- None declared. EDAT- 2025/08/04 12:27 MHDA- 2025/08/04 12:28 PMCR- 2025/02/07 CRDT- 2025/08/04 06:11 PHST- 2024/12/16 00:00 [received] PHST- 2025/01/23 00:00 [revised] PHST- 2025/04/01 00:00 [accepted] PHST- 2025/08/04 12:28 [medline] PHST- 2025/08/04 12:27 [pubmed] PHST- 2025/08/04 06:11 [entrez] PHST- 2025/02/07 00:00 [pmc-release] AID - SEMB-59-173 [pii] AID - 10.14744/SEMB.2025.60863 [doi] PST - epublish SO - Sisli Etfal Hastan Tip Bul. 2025 Feb 7;59(2):173-177. doi: 10.14744/SEMB.2025.60863. eCollection 2025. PMID- 28613530 STAT- Publisher CTDT- 20250803 PB - StatPearls Publishing DP - 2025 Jan TI - Atorvastatin. BTI - StatPearls AB - HMG-CoA reductase inhibitors (statins) are lipid-lowering medications used in the primary, secondary, and tertiary prevention of coronary heart disease. Atorvastatin is a medication primarily used to manage and treat dyslipidemias and prevent cardiovascular disease. This activity focuses on the indications, mechanism of action, and contraindications of atorvastatin as a valuable agent in managing these conditions. The activity reviews the warnings, adverse event profile, toxicity, and key considerations, including monitoring and relevant drug interactions. Understanding the intricate pharmacology of atorvastatin enables healthcare professionals to tailor treatment plans to individual patient needs. Notably, the emphasis lies on empowering healthcare professionals, highlighting the essential role of the interprofessional healthcare team in managing atorvastatin therapy for hyperlipidemia and reducing cardiovascular risk. CI - Copyright (c) 2025, StatPearls Publishing LLC. FAU - McIver, Lindsey A AU - McIver LA AD - The Brooklyn Hospital Center FAU - Siddique, Momin S AU - Siddique MS AD - SIU LA - eng PT - Study Guide PT - Book Chapter PL - Treasure Island (FL) COIS- Disclosure: Lindsey A McIver declares no relevant financial relationships with ineligible companies. Disclosure: Momin S Siddique declares no relevant financial relationships with ineligible companies. EDAT- 2025/08/03 00:00 CRDT- 2025/08/03 00:00 AID - NBK430779 [bookaccession] PMID- 40748923 OWN - NLM STAT- MEDLINE DCOM- 20250801 LR - 20250801 IS - 1940-8250 (Electronic) IS - 0279-5442 (Linking) VI - 45 IP - 4 DP - 2025 Aug 1 TI - Integration of Rapid Response Teams and Early Warning Systems to Reduce Cardiac Arrests and Intensive Care Unit Readmissions. PG - 49-56 LID - 10.4037/ccn2025131 [doi] AB - BACKGROUND: Early identification and treatment of clinical deterioration is crucial for improving outcomes among hospital patients. A high-acuity response team (HART) program can integrate early warning systems and proactive rounding by critical care nurses to prevent unplanned escalations in care. LOCAL PROBLEM: During the COVID-19 pandemic, a HART program was inconsistently implemented because of intensive care unit staffing shortages. Barriers to optimizing the HART nurse role included inconsistent practices, lack of clear role expectations, and frequent reassignment of HART nurses to compensate for staffing shortages. METHODS: Postpilot implementation of the HART program began in October 2019. Critical care nurses were designated as HART nurses, responsible for monitoring the Rothman Index, and assisted bedside nurses with high-acuity patients. Data were collected from 2019 to 2023 and were analyzed using IBM SPSS Statistics, version 29, with statistical significance defined as P 89%, Agatston values of the full coronary tree >170 allow for a sensitivity of 90% (AUC 0.76, NPV 0.93). The sum Agatston score of the proximal segments >117 enables a sensitivity of 90% (AUC 0.74, NPV 0.93) and >47 a sensitivity of 98% (NPV 0.98). On the segmental level, Agatston values of >22 in the proximal RCA and >30 in the proximal LAD and CX allow for a sensitivity of 90% (AUC RCA 0.74, NPV 0.98; LAD 0.71, NPV 0.94; CX 0.75, NPV 0.99). Aiming for 98% sensitivity or higher, Agatston values of >2 for the RCA, >3 for the LAD and >27 for the CX apply (RCA NPV 1; LAD NPV 0.97; CX NPV 1). Coronary artery Agatston scoring on TAVI evaluation CT scans can serve as a predictor for the need of coronary interventions in the workup leading up to TAVI and it provides valuable information for identification of patients without significant coronary artery disease and may aid in allowing for the avoidance of invasive coronary artery diagnostics. CI - (c) 2025. The Author(s). FAU - Mostafa, Karim AU - Mostafa K AD - Department of Radiology and Neuroradiology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany. karim.mostafa@uksh.de. AD - Department of Radiology and Neuroradiology, UKSH Kiel, Arnold-Heller-Strasse 3, 24015, Kiel, Germany. karim.mostafa@uksh.de. FAU - Voran, Jakob Christoph AU - Voran JC AD - Department of Internal Medicine III, Cardiology and critical care, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany. AD - DZHK (German Centre for Cardiovascular Research), partner site Hamburg/Kiel/Lubeck, Kiel, Germany. FAU - Muller, Markus AU - Muller M AD - Department of Internal Medicine III, Cardiology and critical care, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany. FAU - Pohlmeyer, Anka AU - Pohlmeyer A AD - Department of Internal Medicine III, Cardiology and critical care, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany. FAU - Noormalal, Marie AU - Noormalal M AD - Department of Internal Medicine III, Cardiology and critical care, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany. AD - DZHK (German Centre for Cardiovascular Research), partner site Hamburg/Kiel/Lubeck, Kiel, Germany. FAU - Salem, Mostafa AU - Salem M AD - Department of Internal Medicine III, Cardiology and critical care, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany. FAU - Saad, Mohammed AU - Saad M AD - Department of Internal Medicine III, Cardiology and critical care, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany. FAU - Langguth, Patrick AU - Langguth P AD - Department of Radiology and Neuroradiology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany. FAU - Frank, Derk AU - Frank D AD - Department of Internal Medicine III, Cardiology and critical care, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany. AD - DZHK (German Centre for Cardiovascular Research), partner site Hamburg/Kiel/Lubeck, Kiel, Germany. FAU - Wolf, Carmen AU - Wolf C AD - Department of Radiology and Neuroradiology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany. FAU - Seoudy, Hatim AU - Seoudy H AD - Department of Internal Medicine III, Cardiology and critical care, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany. AD - DZHK (German Centre for Cardiovascular Research), partner site Hamburg/Kiel/Lubeck, Kiel, Germany. LA - eng PT - Journal Article DEP - 20250801 PL - United States TA - Int J Cardiovasc Imaging JT - The international journal of cardiovascular imaging JID - 100969716 SB - IM MH - Humans MH - Predictive Value of Tests MH - Male MH - *Coronary Angiography/methods MH - Female MH - *Coronary Artery Disease/diagnostic imaging/therapy/complications MH - *Computed Tomography Angiography MH - Aged, 80 and over MH - Aged MH - Severity of Illness Index MH - *Transcatheter Aortic Valve Replacement/adverse effects MH - *Aortic Valve Stenosis/diagnostic imaging/surgery/complications/physiopathology MH - ROC Curve MH - Percutaneous Coronary Intervention/instrumentation MH - Treatment Outcome MH - Area Under Curve MH - *Multidetector Computed Tomography MH - Reproducibility of Results MH - Stents MH - *Coronary Vessels/diagnostic imaging MH - Risk Factors MH - Retrospective Studies MH - *Aortic Valve/surgery/diagnostic imaging/physiopathology MH - Observer Variation MH - *Cardiac Catheterization/instrumentation/adverse effects PMC - PMC12405386 COIS- Declarations. Ethics approval and consent to participate: The study was approved by the ethics committee of the Christian-Albrechts-University in Kiel (Votum No. AZ D 506/22). All patients consented to participating in this retrospective study. The datasets used and analysed during the current study are available from the corresponding author on reasonable request. Consent for publication: Written informed consent for publication was obtained from all participants in this study for publication of their personal and clinical details. Competing interests: The authors declare no competing interests. EDAT- 2025/08/01 12:35 MHDA- 2025/09/04 02:12 PMCR- 2025/08/01 CRDT- 2025/08/01 11:16 PHST- 2025/02/01 00:00 [received] PHST- 2025/07/21 00:00 [accepted] PHST- 2025/09/04 02:12 [medline] PHST- 2025/08/01 12:35 [pubmed] PHST- 2025/08/01 11:16 [entrez] PHST- 2025/08/01 00:00 [pmc-release] AID - 10.1007/s10554-025-03471-1 [pii] AID - 3471 [pii] AID - 10.1007/s10554-025-03471-1 [doi] PST - ppublish SO - Int J Cardiovasc Imaging. 2025 Sep;41(9):1729-1738. doi: 10.1007/s10554-025-03471-1. Epub 2025 Aug 1. PMID- 40748298 OWN - NLM STAT- Publisher LR - 20250801 IS - 2724-5772 (Electronic) IS - 2724-5683 (Linking) DP - 2025 Aug 1 TI - Cardiac rehabilitation in patients with atrial fibrillation. LID - 10.23736/S2724-5683.25.06885-1 [doi] AB - Cardiovascular diseases (CVD) remain the leading cause of morbidity and mortality worldwide, accounting for significant public health and economic burdens. Cardiac rehabilitation (CR) is a comprehensive, multidisciplinary program designed to aid patients in recovering from cardiac events and to prevent further complications. The aim of CR is to improve their quality of life and prognosis. It involves continued prognostic stratification, clinical stabilization, optimization of pharmacological and non-pharmacological therapy, management of comorbidities, treatment of disabilities, reinforcement of secondary prevention interventions, and maintenance of adherence to therapy. The most recent European Society of Cardiology guidelines for the diagnosis and management of atrial fibrillation (AF) emphasize the importance of cardiorespiratory fitness, recommending that patients engage in moderate-intensity exercise and remain physically active to prevent AF incidence or recurrence. Through this symbiotic relationship, CR addresses all aspect of cardiac fitness in AF management. The program's structured exercise regimens are specifically tailored to address the challenges associated with AF, promoting overall cardiovascular health and reducing the risk for cardiac death. CR is also crucial for emotional well-being, offering support and coping mechanisms for the psychological impact of AF, beyond the physical training program. CR programs involve a multidisciplinary approach that is carried out collaboratively by a team of healthcare professionals, including nurses, physiotherapists, psychologists, and dietitians. Moreover, CR in AF patients aims to carry out comprehensive patient support through clinical stabilization and therapy optimization interventions, prescription and implementation of physical activity, educational support on lifestyle risk factors and social-emotional distress, and periodic assessment of outcomes. This narrative review aims to elucidate the role of CR in AF patients, shedding light on the potential benefits and challenges associated with integrating rehabilitation programs into the care of individuals with AF. FAU - Cersosimo, Angelica AU - Cersosimo A AD - Division of Cardiology and Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, ASST Spedali Civili di Brescia, University of Brescia, Brescia, Italy. FAU - Longo Elia, Raffaele AU - Longo Elia R AD - Unit of Rehabilitation, ASP Catanzaro, Catanzaro, Italy. FAU - Condello, Francesco AU - Condello F AD - IRCCS Multimedica, Sesto San Giovanni, Milan, Italy. FAU - Colombo, Flavia AU - Colombo F AD - Department of Geriatric and Orthopedic Sciences, Sacred Heart Catholic University, Rome, Italy. FAU - Pierucci, Nicola AU - Pierucci N AD - Department of Cardiovascular, Respiratory, Nephrological, Anesthesiological and Geriatric Sciences, Sapienza University, Rome, Italy. FAU - Arabia, Gianmarco AU - Arabia G AD - Division of Cardiology and Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, ASST Spedali Civili di Brescia, University of Brescia, Brescia, Italy. FAU - Matteucci, Andrea AU - Matteucci A AD - Department of Experimental Medicine, Tor Vergata University, Rome, Italy. FAU - Metra, Marco AU - Metra M AD - Division of Cardiology and Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, ASST Spedali Civili di Brescia, University of Brescia, Brescia, Italy. FAU - Adamo, Marianna AU - Adamo M AD - Division of Cardiology and Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, ASST Spedali Civili di Brescia, University of Brescia, Brescia, Italy. FAU - Vizzardi, Enrico AU - Vizzardi E AD - Division of Cardiology and Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, ASST Spedali Civili di Brescia, University of Brescia, Brescia, Italy. FAU - LA Fazia, Vincenzo M AU - LA Fazia VM AD - Department of Experimental Medicine, Tor Vergata University, Rome, Italy - vmirco.lafazia@gmail.com. AD - Texas Cardiac Arrhythmia Institute, St David's Medical Center, Austin, TX, USA. LA - eng PT - Journal Article DEP - 20250801 PL - Italy TA - Minerva Cardiol Angiol JT - Minerva cardiology and angiology JID - 101776555 SB - IM EDAT- 2025/08/01 12:34 MHDA- 2025/08/01 12:34 CRDT- 2025/08/01 10:29 PHST- 2025/08/01 12:34 [medline] PHST- 2025/08/01 12:34 [pubmed] PHST- 2025/08/01 10:29 [entrez] AID - S2724-5683.25.06885-1 [pii] AID - 10.23736/S2724-5683.25.06885-1 [doi] PST - aheadofprint SO - Minerva Cardiol Angiol. 2025 Aug 1. doi: 10.23736/S2724-5683.25.06885-1. PMID- 40747626 OWN - NLM STAT- MEDLINE DCOM- 20250901 LR - 20250901 IS - 1467-1107 (Electronic) IS - 1047-9511 (Linking) VI - 35 IP - 7 DP - 2025 Jul TI - Paediatric coronary artery bypass grafting in a middle-income country: a case series and literature review. PG - 1415-1420 LID - 10.1017/S1047951125101285 [doi] AB - BACKGROUND: Coronary artery abnormalities in children that require bypass grafting are infrequent but represent a well-recognised entity with a broad spectrum of indications beyond Kawasaki disease. Although myocardial revascularisation in children is uncommon, studies have shown that it can yield favourable short- and long-term outcomes, allowing affected children to regain health and grow up to live normal lives.Myocardial revascularisation in children is an extremely rare intervention in Western countries, accounting for less than 1% of all paediatric cardiac surgeries in this region. It is a highly technically demanding procedure that opens a new arena in cardiac surgery, for which cardiovascular surgeons need to be trained to achieve outcomes as good as those shown in the literature.We present the experience of paediatric coronary artery bypass grafting in a middle-income country, with a wide range of indications. METHODS: A retrospective descriptive study was conducted on paediatric patients (under 18 years of age) who underwent coronary artery bypass grafting between 2004 and 2023 at a cardiovascular centre in Bogota, Colombia. Data were collected from electronic medical records, including demographics, preoperative diagnoses, surgical details, and outcomes. Follow-up included clinical assessment and imaging with echocardiography. Ethical approval was obtained, and confidentiality was ensured. RESULTS: Nine paediatric patients (ages 6-17) underwent coronary artery bypass grafting between 2004 and 2023. Kawasaki disease was the most common indication, but there are other aetiologies, including post-arterial switch coronary occlusion, anomalous origin of the LCA from the pulmonary artery, anomalous origin of coronary arteries from the aorta, Takayasu disease, and iatrogenic injury. The internal mammary artery was used in most cases, with successful completion of the planned revascularisation in all patients. There were no perioperative deaths or reinterventions. At a mean follow-up of 5.5 years, all patients showed clinical and biventricular improvement, and all grafts evaluated showed graft patency.Paediatric coronary artery bypass grafting is a safe and effective treatment for selected congenital and acquired coronary pathologies, even in complex cases. Outcomes are optimised with the use of internal mammary arteries and a multidisciplinary heart team approach. In middle-income settings, favourable short- and mid-term results can be achieved despite follow-up challenges. Paediatric coronary artery bypass grafting should be considered a key component of congenital cardiac surgery training. FAU - Roa-Bastidas, Isabella AU - Roa-Bastidas I AUID- ORCID: 0000-0002-2486-9646 AD - Cardiovascular Surgery Resident. Universidad del Rosario. School of Medicine and Health Sciences, Bogota, Colombia. FAU - Chalela, Tomas AU - Chalela T AD - Cardiovascular Surgery, Fundacion Cardioinfantil - La Cardio, Bogota, Colombia. FAU - Rivera, Aura M AU - Rivera AM AD - Cardiovascular Surgery, Fundacion Cardioinfantil - La Cardio, Bogota, Colombia. FAU - Guerrero, Albert F AU - Guerrero AF AD - Cardiovascular Surgery, Fundacion Cardioinfantil - La Cardio, Bogota, Colombia. FAU - Obando, Carlos E AU - Obando CE AD - Cardiovascular Surgery, Fundacion Cardioinfantil - La Cardio, Bogota, Colombia. FAU - Camacho, Jaime AU - Camacho J AD - Cardiovascular Surgery, Fundacion Cardioinfantil - La Cardio, Bogota, Colombia. FAU - Villa, Carlos A AU - Villa CA AD - Cardiovascular Surgery, Fundacion Cardioinfantil - La Cardio, Bogota, Colombia. FAU - Jimenez, Andres F AU - Jimenez AF AD - Cardiovascular Surgery, Fundacion Cardioinfantil - La Cardio, Bogota, Colombia. FAU - Sandoval, Nestor AU - Sandoval N AUID- ORCID: 0000-0002-9020-0422 AD - Cardiovascular Surgery, Fundacion Cardioinfantil - La Cardio, Bogota, Colombia. LA - eng PT - Journal Article PT - Review DEP - 20250801 PL - England TA - Cardiol Young JT - Cardiology in the young JID - 9200019 SB - IM MH - Humans MH - *Coronary Artery Bypass/methods MH - Male MH - Child MH - Female MH - Retrospective Studies MH - Adolescent MH - Colombia/epidemiology MH - *Coronary Vessel Anomalies/surgery MH - Treatment Outcome MH - Echocardiography MH - *Coronary Artery Disease/surgery MH - Developing Countries OTO - NOTNLM OT - Coronary artery bypass OT - Kawasaki disease OT - paediatric OT - revascularization EDAT- 2025/08/01 06:27 MHDA- 2025/09/02 00:44 CRDT- 2025/08/01 05:53 PHST- 2025/09/02 00:44 [medline] PHST- 2025/08/01 06:27 [pubmed] PHST- 2025/08/01 05:53 [entrez] AID - S1047951125101285 [pii] AID - 10.1017/S1047951125101285 [doi] PST - ppublish SO - Cardiol Young. 2025 Jul;35(7):1415-1420. doi: 10.1017/S1047951125101285. Epub 2025 Aug 1. PMID- 40746156 OWN - NLM STAT- MEDLINE DCOM- 20250821 LR - 20250821 IS - 1744-8344 (Electronic) IS - 1477-9072 (Linking) VI - 23 IP - 8 DP - 2025 Aug TI - How can clinicians reduce the risk of and manage severe aortic valve regurgitation manifesting as cardiogenic shock? PG - 405-413 LID - 10.1080/14779072.2025.2542838 [doi] AB - INTRODUCTION: Severe aortic regurgitation is a progressive condition that can lead to cardiogenic shock, a life-threatening emergency associated with high morbidity and mortality. AREAS COVERED: This article provides an updated review on how clinicians can diagnose, prevent, and manage aortic regurgitation presenting as cardiogenic shock, as well as discusses emerging technologies that have transformed the management of this condition. EXPERT OPINION: Clinicians can reduce the risk of aortic regurgitation manifesting as cardiogenic shock through a combination of early diagnosis, vigilant monitoring, optimized medical management, and timely intervention. Advanced imaging modalities, such as echocardiography and computed cardiac tomography, are essential for assessing valve function and identifying high-risk patients before decompensation occurs. For patients at risk, early referral to a multidisciplinary Heart Team is crucial for determining the optimal intervention, whether surgical or transcatheter. Future advancements in transcatheter therapies, including dedicated devices for aortic valve replacement, hold promise for expanding treatment options for high-risk patients. FAU - Tagliari, Ana Paula AU - Tagliari AP AD - Institute of Basic Health Sciences, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil. AD - Cardiac Surgery Department, Hospital Mae de Deus, Porto Alegre, Brazil. FAU - Nunes Kochi, Adriano AU - Nunes Kochi A AD - Electrophysiology Department, Hospital Mae de Deus, Porto Alegre, Brazil. LA - eng PT - Journal Article PT - Review DEP - 20250804 PL - England TA - Expert Rev Cardiovasc Ther JT - Expert review of cardiovascular therapy JID - 101182328 SB - IM MH - Humans MH - *Shock, Cardiogenic/etiology/prevention & control MH - *Aortic Valve Insufficiency/diagnosis/therapy/complications/physiopathology MH - Severity of Illness Index MH - Echocardiography/methods MH - Early Diagnosis MH - Patient Care Team/organization & administration MH - Heart Valve Prosthesis Implantation/methods MH - Transcatheter Aortic Valve Replacement/methods MH - Referral and Consultation OTO - NOTNLM OT - Aortic regurgitation OT - cardiogenic shock OT - mechanical circulatory support OT - surgical aortic valve replacement OT - transcatheter aortic valve replacement EDAT- 2025/08/01 06:27 MHDA- 2025/09/08 08:06 CRDT- 2025/08/01 03:42 PHST- 2025/09/08 08:06 [medline] PHST- 2025/08/01 06:27 [pubmed] PHST- 2025/08/01 03:42 [entrez] AID - 10.1080/14779072.2025.2542838 [doi] PST - ppublish SO - Expert Rev Cardiovasc Ther. 2025 Aug;23(8):405-413. doi: 10.1080/14779072.2025.2542838. Epub 2025 Aug 4. PMID- 40744353 OWN - NLM STAT- MEDLINE DCOM- 20260311 LR - 20260811 IS - 1532-2165 (Electronic) IS - 1078-5884 (Linking) VI - 71 IP - 3 DP - 2026 Mar TI - Vascular Graft and Endograft Infections: A Delphi Consensus Document on Terminology, Definitions, Treatment, Outcomes, Follow Up, and Reporting Standards. PG - 497-507 LID - S1078-5884(25)00707-5 [pii] LID - 10.1016/j.ejvs.2025.07.044 [doi] AB - OBJECTIVE: There is a lack of consensus on certain terminology and definitions related to vascular graft and endograft infections (VGEIs) and secondary aorto-enteric erosion and or fistula and their treatment, outcome reporting, follow up, and reporting standards. The objective of this study was to complete a Delphi consensus study on these VGEI related issues. METHODS: The Delphi methodology was used with a panel of 43 international experts (specialists in vascular or cardiovascular surgery, infectious diseases, nuclear medicine, and radiology). Four Delphi rounds were planned using an online questionnaire initially with 31 statements. Panellists rated the statements on a five point Likert scale. Comments on statements were analysed, statements were revised, added, or deleted, and the results were presented in iterative rounds. Consensus was defined as >/= 75% of the panel rating a statement as strongly agree or agree on the Likert scale, and consensus on the final assessment was defined as Cronbach's alpha > 0.80. Reporting was performed according to the ACcurate COnsensus Reporting Document (ACCORD) guideline. RESULTS: All 43 panellists fulfilled all four rounds, resulting in 100% participation. Cronbach's alpha increased through the rounds: round 1, 0.88; round 2, 0.89; round 3, 0.90; and round 4, 0.90. A final fifth round was performed among all surgeons (n = 27) defining secondary aorto-enteric erosion and or fistula, with 100% participation. Agreement was reached for 29 final statements: two on need for consensus, two on definition of multidisciplinary team, three on microbiology diagnosis, six on treatment, three on secondary graft-enteric partial erosion, secondary graft-enteric fistula, and secondary aorto-enteric fistula, three on treatment outcomes, nine on follow up, and one on reporting standards including 11 items. CONCLUSION: Consensus was achieved for 29 statements, which were developed to establish a common perception of VGEI and secondary aorto-enteric erosion and or fistula, with the potential to improve research in this field and ultimately patient care. CI - Copyright (c) 2025 European Society for Vascular Surgery. Published by Elsevier B.V. All rights reserved. FAU - Sorelius, Karl AU - Sorelius K AD - Department of Vascular Surgery, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. Electronic address: karlsorelius@hotmail.com. FAU - Verhoek, Robin AU - Verhoek R AD - Department of Vascular Surgery, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; Department of Interventional Radiology and Vascular Surgery, Kantonsspital Winterthur, Winterthur, Switzerland. FAU - Berard, Xavier AU - Berard X AD - Vascular Surgery Department, Bordeaux University Hospital, Bordeaux, France. FAU - Lyons, Oliver T A AU - Lyons OTA AD - Department of Surgery, University of Otago, Christchurch, New Zealand; Vascular, Endovascular and Transplant Surgery, Christchurch Public Hospital, Canterbury, New Zealand. FAU - Puges, Mathilde AU - Puges M AD - Infectious and Tropical Diseases Department, Bordeaux University Hospital, Bordeaux, France. FAU - Wyss, Thomas R AU - Wyss TR AD - Department of Vascular Surgery, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; Department of Interventional Radiology and Vascular Surgery, Kantonsspital Winterthur, Winterthur, Switzerland. CN - International Expert Panel on Vascular Graft and Endograft Infections CN - European Society for Vascular Surgery Clinical Practice Guidelines on the Management of Vascular Graft and Endograft Infections Writing Committee LA - eng PT - Consensus Statement PT - Journal Article DEP - 20250729 PL - England TA - Eur J Vasc Endovasc Surg JT - European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery JID - 9512728 SB - IM MH - Humans MH - Delphi Technique MH - *Prosthesis-Related Infections/therapy/diagnosis/classification/microbiology MH - *Blood Vessel Prosthesis/adverse effects MH - *Terminology as Topic MH - *Blood Vessel Prosthesis Implantation/adverse effects/instrumentation MH - *Endovascular Procedures/adverse effects/instrumentation MH - Treatment Outcome MH - Intestinal Fistula/therapy/etiology OTO - NOTNLM OT - Definitions OT - Delphi study OT - Outcome OT - Reporting standards OT - Vascular graft and endograft infection EDAT- 2025/08/01 00:29 MHDA- 2026/03/12 01:09 CRDT- 2025/07/31 19:42 PHST- 2025/04/02 00:00 [received] PHST- 2025/07/02 00:00 [revised] PHST- 2025/07/21 00:00 [accepted] PHST- 2026/03/12 01:09 [medline] PHST- 2025/08/01 00:29 [pubmed] PHST- 2025/07/31 19:42 [entrez] AID - S1078-5884(25)00707-5 [pii] AID - 10.1016/j.ejvs.2025.07.044 [doi] PST - ppublish SO - Eur J Vasc Endovasc Surg. 2026 Mar;71(3):497-507. doi: 10.1016/j.ejvs.2025.07.044. Epub 2025 Jul 29. PMID- 40744275 OWN - NLM STAT- MEDLINE DCOM- 20251025 LR - 20260304 IS - 1469-0691 (Electronic) IS - 1198-743X (Linking) VI - 31 IP - 11 DP - 2025 Nov TI - Treatment and follow-up of vascular graft and endograft infection: Delphi consensus document. PG - 1828-1838 LID - S1198-743X(25)00361-1 [pii] LID - 10.1016/j.cmi.2025.07.020 [doi] AB - SCOPE: Vascular graft or endograft infection (VGEI) is a severe complication requiring a multidisciplinary approach combining surgery and antimicrobial therapy. This study aimed to develop expert consensus on the management and follow-up of VGEI, with a focus on antimicrobial strategies. METHODS: A modified Delphi method was conducted to reach consensus on key aspects of VGEI care, including antimicrobial treatment, surgical management, and follow-up. An expert panel representing infectious diseases, vascular and cardiothoracic surgery, microbiology, and nuclear medicine participated in four rounds of surveys. Ten general and 35 specific statements were rated using a five-point Likert scale. Statements with >/=75% agreement (agree/strongly agree) were considered to have achieved consensus. Internal consistency across rounds was assessed using Cronbach's alpha (>0.80). QUESTIONS ADDRESSED BY THE DELPHI METHOD AND RECOMMENDATIONS: The panel agreed that empirical antimicrobial therapy should be initiated only in patients with complications (e.g. sepsis and bleeding) or when diagnostic intervention is delayed. Empirical therapy must be individualized based on graft location and risk factors. For abdominal VGEI without aorto-enteric fistula and unknown pathogens, initial coverage should target gram-positive cocci, gram-negative bacilli, and anaerobes, with consideration for Methicillin-Resistant Staphylococcus aureus (MRSA)/Methicillin-Resistant Staphylococcus epidermidis (MRSE) based on risk. For thoracic VGEI without fistula, gram-positive coverage is prioritized, with optional MRSA coverage. Postoperative treatment duration should be individualized. In cases of complete graft removal and replacement with autologous veins, a 6-week antibiotic course is recommended, with early oral switch if bioavailable options are available. If prosthetic material remains, at least 4 to 6 weeks of intravenous therapy followed by oral treatment for a total of 12 weeks is advised. Prolonged therapy should be considered in cases with virulent pathogens, incomplete source control, or persistent inflammatory markers. The study provides practical, expert-based antimicrobial guidance for VGEI management and emphasizes the importance of individualized, microbiologically informed therapy within a multidisciplinary care framework. CI - Copyright (c) 2025 The Author(s). Published by Elsevier Ltd.. All rights reserved. FAU - Kouijzer, Ilse J E AU - Kouijzer IJE AD - Department of Internal Medicine and Radboud Community of Infectious Diseases, Radboud university medical center, Nijmegen, the Netherlands. Electronic address: Ilse.Kouijzer@radboudumc.nl. FAU - Hernandez-Meneses, Marta AU - Hernandez-Meneses M AD - Department of Infectious Diseases, Hospital Clinic Barcelona, University of Barcelona, Barcelona, Spain. FAU - Aarntzen, Erik H J G AU - Aarntzen EHJG AD - Department of Medical Imaging, Radboud university medical center, and Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen. FAU - Ahl, Jonas AU - Ahl J AD - Clinical Infection Medicine, Department of Translational Medicine, Faculty of Medicine, Lund University, Malmo, Sweden. FAU - Baddour, Larry M AU - Baddour LM AD - Division of Public Health, Infectious Diseases and Occupational Medicine, Departments of Medicine and Cardiovascular Medicine, Mayo Clinic College of Medicine and Science, Mayo Clinic, Rochester, MN USA. FAU - DeSimone, Daniel C AU - DeSimone DC AD - Division of Public Health, Infectious Diseases and Occupational Medicine, Departments of Medicine and Cardiovascular Medicine, Mayo Clinic College of Medicine and Science, Mayo Clinic, Rochester, MN USA. FAU - Mangoni, Emanuele Durante AU - Mangoni ED AD - Department of Precision Medicine, University of Campania 'L. Vanvitelli', Monaldi Hospital, Naples, Italy. FAU - Fernandez-Hidalgo, Nuria AU - Fernandez-Hidalgo N AD - Servei de Malalties Infeccioses, Hospital Universitari Vall d'Hebron, Barcelona, Spain, Departament de Medicina, Universitat Autonoma de Barcelona, Barcelona, Spain, CIBERINFEC, ISCIII-CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain. FAU - Geuzebroek, Guillaume S C AU - Geuzebroek GSC AD - Department of Cardio-Thoracic Surgery, Radboud university medical centre, Nijmegen, The Netherlands. FAU - Giannitsioti, Efthymia AU - Giannitsioti E AD - 1(st) Department of Propaedeutic and Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece. FAU - Glaudemans, Andor W J M AU - Glaudemans AWJM AD - Department of Medical Imaging, Radboud university medical center, and Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen. FAU - Husmann, Lars AU - Husmann L AD - Department of Nuclear Medicine, University Hospital Zurich/ University of Zurich, Zurich, Switzerland. FAU - Merli, Marco AU - Merli M AD - Infectious Diseases Clinic, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy. FAU - Mestres, Carlos A AU - Mestres CA AD - Department of Cardiothoracic Surgery and The Robert WM Frater Cardiovascular Research Centre, The University of the Free State, Bloemfontein, South Africa. FAU - Olearo, Flaminia AU - Olearo F AD - Center for Diagnostics, Institute of Medical Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Papadimitriou-Olivgeris, Matthaios AU - Papadimitriou-Olivgeris M AD - Hospital of Valais and Institut Central des Hopitaux, Sion, Switzerland. FAU - Jorgensen, Nis Pedersen AU - Jorgensen NP AD - Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark. FAU - Perissinotti, Andres AU - Perissinotti A AD - Department of Nuclear Medicine, Hospital Clinic-IDIBAPS, Barcelona, Spain. Biomedical Research Networking Center of Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN) ISCIII Barcelona, Spain. FAU - Raglio, Annibale AU - Raglio A AD - Department of Microbiology and Virology, Bergamo, Italy. FAU - Rancic, Zoran AU - Rancic Z AD - Department of Surgery, Lachen Hospital, Lachen, Medical Faculty University of Zurich, Switzerland. FAU - Ravindra, Akshatha AU - Ravindra A AD - Department of Infectious Diseases, Kasturba Medical College Manipal, Manipal Academy of Higher Education, Manipal, India. FAU - Reutersberg, Benedikt AU - Reutersberg B AD - Department of Vascular Surgery, University Hospital Zurich, Zurich, Switzerland. FAU - Rezzonico, Leonardo Francesco AU - Rezzonico LF AD - Clinic of Infectious Diseases and Tropical Medicine, Department of Health Sciences, San Paolo Hospital / University of Milan, Milan, Italy. FAU - Ripa, Marco AU - Ripa M AD - Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Department of Infectious Diseases, Milan, Italy. FAU - Risteski, Petar AU - Risteski P AD - Department of Cardiac Surgery, University Hospital Zurich, Zurich, Switzerland. FAU - Russo, Alessandro AU - Russo A AD - Infectious and Tropical Diseases Unit, Department of Medical and Surgical Sciences, 'Magna Graecia' University of Catanzaro, Italy. FAU - Saleem, Ben R AU - Saleem BR AD - Department of Surgery (Division of Vascular Surgery), University Medical Center Groningen, University of Groningen. FAU - Sorelius, Karl AU - Sorelius K AD - Department of Vascular Surgery, Rigshospitalet, Copenhagen, and Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. FAU - Sousa, Dolores AU - Sousa D AD - Department of Infectious Diseases, Complejo Hospitalario Universitario A Coruna (CHUAC), and Faculty of Medicine, University of Santiago de Compostela, Spain. FAU - Tattevin, Pierre AU - Tattevin P AD - Infectious Diseases and Intensive Care Unit, Pontchaillou University Hospital, Rennes, France. FAU - Wouthuyzen-Bakker, Marjan AU - Wouthuyzen-Bakker M AD - Department of Medical Microbiology and Infection Prevention, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. FAU - Wyss, Thomas R AU - Wyss TR AD - Department of Interventional Radiology and Vascular Surgery, Kantonsspital Winterthur, Winterthur, Switzerland. FAU - Yugueros, Xavier AU - Yugueros X AD - Department of Vascular Surgery, Hospital Clinic de Barcelona, Barcelona, Spain. FAU - Zimmermann, Alexander AU - Zimmermann A AD - Department of Vascular Surgery, University Hospital Zurich, Zurich, Switzerland. FAU - Hasse, Barbara AU - Hasse B AD - Department of Infectious Diseases and Hospital epidemiology, University Hospital Zurich/ University of Zurich, Zurich, Switzerland. CN - ESCMID Study Group of Implant Associated Infections (ESGIAI) LA - eng PT - Consensus Statement PT - Journal Article DEP - 20250729 PL - England TA - Clin Microbiol Infect JT - Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases JID - 9516420 RN - 0 (Anti-Bacterial Agents) SB - IM MH - Humans MH - Delphi Technique MH - *Prosthesis-Related Infections/drug therapy/therapy/microbiology/diagnosis MH - *Blood Vessel Prosthesis/adverse effects/microbiology MH - *Anti-Bacterial Agents/therapeutic use OTO - NOTNLM OT - Antimicrobial therapy OT - Delphi survey OT - Follow-up OT - Surgery OT - Vascular (endo)graft infection EDAT- 2025/08/01 00:29 MHDA- 2025/10/26 00:31 CRDT- 2025/07/31 19:35 PHST- 2025/04/08 00:00 [received] PHST- 2025/07/22 00:00 [revised] PHST- 2025/07/23 00:00 [accepted] PHST- 2025/10/26 00:31 [medline] PHST- 2025/08/01 00:29 [pubmed] PHST- 2025/07/31 19:35 [entrez] AID - S1198-743X(25)00361-1 [pii] AID - 10.1016/j.cmi.2025.07.020 [doi] PST - ppublish SO - Clin Microbiol Infect. 2025 Nov;31(11):1828-1838. doi: 10.1016/j.cmi.2025.07.020. Epub 2025 Jul 29. PMID- 40744194 OWN - NLM STAT- MEDLINE DCOM- 20251009 LR - 20260722 IS - 1097-6744 (Electronic) IS - 0002-8703 (Linking) VI - 291 DP - 2026 Jan TI - The low-risk TAVR trials-A critical appraisal of the current landscape. PG - 10-13 LID - S0002-8703(25)00288-1 [pii] LID - 10.1016/j.ahj.2025.07.070 [doi] AB - The low-risk TAVR vs SAVR RCTs - PARTNER-3, Evolut Low-Risk, DEDICATE, and NOTION-2 - demonstrate that TAVR is at least as effective as SAVR in terms of early mortality and disabling stroke, although outcomes varied across studies. The excellent outcomes observed in the PARTNER-3 trial reflect the highly selected patient population, while the NOTION-2 trial highlights the challenges posed by anatomical variations, such as bicuspid aortic valves (AV). These findings highlight the importance of a personalized approach guided by a multidisciplinary Heart Team, taking into account both clinical and anatomical aspects when choosing between TAVR and SAVR. Trial registration number: ClinicalTrials.gov NCT02825134. CI - Copyright (c) 2025 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Jorgensen, Troels Hojsgaard AU - Jorgensen TH AD - Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. FAU - Thyregod, Hans Gustav Horsted AU - Thyregod HGH AD - Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. FAU - Blankenberg, Stefan AU - Blankenberg S AD - Department of Cardiology, UKE, Hamburg, Germany. FAU - Leon, Martin AU - Leon M AD - Clinical Research Foundation and Columbia University Hospital, New York, NY. FAU - Sondergaard, Lars AU - Sondergaard L AD - Abbott, Santa Clara, CA. FAU - Prendergast, Bernard AU - Prendergast B AD - St Thomas' Hospital and Cleveland Clinic London, London, UK. FAU - De Backer, Ole AU - De Backer O AD - Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. Electronic address: ole.de.backer@regionh.dk. LA - eng SI - ClinicalTrials.gov/NCT02825134 PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20250729 PL - United States TA - Am Heart J JT - American heart journal JID - 0370465 SB - IM MH - Humans MH - *Transcatheter Aortic Valve Replacement/methods MH - *Aortic Valve Stenosis/surgery MH - *Aortic Valve/surgery/abnormalities MH - Randomized Controlled Trials as Topic MH - Risk Assessment MH - *Stroke/epidemiology/etiology COIS- Declaration of competing interest Predergast, B is member of the Anteris Technologies Advisory Board, Medtronic Trial Steering Committee and Valvosoft Data Safety Monitoring Committee. Leon, M has received grants from Edwards Lifesciences, Abbott Vascular and Medtronic, consultant fees from Foldax and Anteris Technologies, is a member of the Medtronic Data Safety Monitoring Board, has a leadership role in the Heart Valve Collaboratory and stock equity in Pi-Cardia; Sondergaard, L. is an employee at Abbott. De Baclker, O. received institutional research grants and consulting fees from Abbott, Boston Scientific, and Medtronic. EDAT- 2025/08/01 00:29 MHDA- 2025/10/10 00:30 CRDT- 2025/07/31 19:34 PHST- 2025/03/30 00:00 [received] PHST- 2025/07/10 00:00 [revised] PHST- 2025/07/26 00:00 [accepted] PHST- 2025/10/10 00:30 [medline] PHST- 2025/08/01 00:29 [pubmed] PHST- 2025/07/31 19:34 [entrez] AID - S0002-8703(25)00288-1 [pii] AID - 10.1016/j.ahj.2025.07.070 [doi] PST - ppublish SO - Am Heart J. 2026 Jan;291:10-13. doi: 10.1016/j.ahj.2025.07.070. Epub 2025 Jul 29. PMID- 40741970 OWN - NLM STAT- MEDLINE DCOM- 20250908 LR - 20260523 IS - 1873-734X (Electronic) IS - 1010-7940 (Linking) VI - 67 IP - 8 DP - 2025 Aug 2 TI - The Role of Surgery in Contemporary Infective Endocarditis. LID - ezaf259 [pii] LID - 10.1093/ejcts/ezaf259 [doi] AB - OBJECTIVES: Infective endocarditis (IE) is a multifaceted disease and its treatment can often be challenging. Furthermore, along with a rising incidence, the clinical manifestation of IE has changed over the years. This study analyses the interdisciplinary endocarditis team management of IE in a tertiary care hospital. METHODS: We reviewed the patients who were admitted for IE at our institution between January 2012 and December 2021. Risk estimation was performed by calculating the EuroSCORE II and the EndoSCORE. RESULTS: A total of 812 consecutive patients were admitted to our centre for IE. Among these patients, 249 patients (30.7%) underwent conservative treatment for IE (Group C) and 563 patients (69.3%) underwent surgery (Group S). The EuroSCORE II was 5.5 (2.6-10.1) in Group C and 5.1 (2.5-10.7) in group S, whereas the EndoSCORE was 7.6 (6.9-19.6) in Group C and 12.3 (6.9-19.5) in Group S. The Duke criteria were not met in 297 patients (36.6%) and patients not meeting the Duke criteria were more often treated conservatively. A higher number of patients suffering from TAVR-endocarditis and tricuspid valve endocarditis were treated conservatively. Whereas patients with aortic valve endocarditis were treated surgically more often. CONCLUSIONS: Infective endocarditis is a multifaceted disease, which requires a specialized interdisciplinary approach. Decisions on treatment modalities should be made on a case-to-case basis in an endocarditis team setting. In addition to treatment modality, adequate consideration should be given to the pathogen causing IE and the extent of IE. CI - (c) The Author(s) 2025. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com. FAU - Saha, Shekhar AU - Saha S AUID- ORCID: 0000-0002-9903-3237 AD - Department of Cardiac Surgery, Ludwig Maximillian University of Munich, Marchioninistrasse 15, Munich 81377, Germany. FAU - Zauner, Benjamin AU - Zauner B AD - Department of Cardiac Surgery, Ludwig Maximillian University of Munich, Marchioninistrasse 15, Munich 81377, Germany. FAU - Schnackenburg, Philipp AU - Schnackenburg P AD - Department of Cardiac Surgery, Ludwig Maximillian University of Munich, Marchioninistrasse 15, Munich 81377, Germany. AD - German Centre for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Biedersteiner Str. 29, Munich 80802, Germany. FAU - Rizas, Konstantinos AU - Rizas K AUID- ORCID: 0000-0002-5993-0339 AD - German Centre for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Biedersteiner Str. 29, Munich 80802, Germany. AD - Department of Cardiology, Ludwig Maximillian University of Munich, Munich, Marchioninistrasse 15, Munich 81377, Germany. FAU - Orban, Martin AU - Orban M AD - German Centre for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Biedersteiner Str. 29, Munich 80802, Germany. AD - Department of Cardiology, Ludwig Maximillian University of Munich, Munich, Marchioninistrasse 15, Munich 81377, Germany. FAU - Massberg, Steffen AU - Massberg S AUID- ORCID: 0000-0001-7387-3986 AD - German Centre for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Biedersteiner Str. 29, Munich 80802, Germany. AD - Department of Cardiology, Ludwig Maximillian University of Munich, Munich, Marchioninistrasse 15, Munich 81377, Germany. FAU - Hagl, Christian AU - Hagl C AD - Department of Cardiac Surgery, Ludwig Maximillian University of Munich, Marchioninistrasse 15, Munich 81377, Germany. AD - German Centre for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Biedersteiner Str. 29, Munich 80802, Germany. FAU - Joskowiak, Dominik AU - Joskowiak D AUID- ORCID: 0000-0003-3995-8737 AD - Department of Cardiac Surgery, Ludwig Maximillian University of Munich, Marchioninistrasse 15, Munich 81377, Germany. AD - German Centre for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Biedersteiner Str. 29, Munich 80802, Germany. LA - eng PT - Journal Article PL - Germany TA - Eur J Cardiothorac Surg JT - European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery JID - 8804069 RN - 0 (Anti-Bacterial Agents) RN - 0 (Antifungal Agents) SB - IM MH - *Endocarditis/diagnosis/microbiology/therapy MH - Tertiary Care Centers/statistics & numerical data MH - Conservative Treatment/statistics & numerical data MH - Transcatheter Aortic Valve Replacement/adverse effects MH - *Postoperative Complications/diagnosis/microbiology/therapy MH - Tricuspid Valve/microbiology/surgery MH - Aortic Valve/microbiology/surgery MH - Severity of Illness Index MH - Patient Care Team MH - Retrospective Studies MH - Humans MH - Male MH - Female MH - Middle Aged MH - Aged MH - *Cardiac Surgical Procedures/statistics & numerical data MH - Anti-Bacterial Agents/therapeutic use MH - Antifungal Agents/therapeutic use OTO - NOTNLM OT - Endocarditis OT - Valve Disease EDAT- 2025/07/31 12:34 MHDA- 2025/09/08 08:06 CRDT- 2025/07/31 08:13 PHST- 2025/01/09 00:00 [received] PHST- 2025/06/20 00:00 [revised] PHST- 2025/07/30 00:00 [accepted] PHST- 2025/09/08 08:06 [medline] PHST- 2025/07/31 12:34 [pubmed] PHST- 2025/07/31 08:13 [entrez] AID - 8219941 [pii] AID - 10.1093/ejcts/ezaf259 [doi] PST - ppublish SO - Eur J Cardiothorac Surg. 2025 Aug 2;67(8):ezaf259. doi: 10.1093/ejcts/ezaf259. PMID- 40741568 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250802 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 17 IP - 6 DP - 2025 Jun TI - Venous Thromboembolism in Dermatological, Pulmonary, and Cardiac Disorders: A Systematic Review of Emergency Presentations and Interdisciplinary Management Strategies. PG - e87008 LID - 10.7759/cureus.87008 [doi] LID - e87008 AB - Venous thromboembolism (VTE), encompassing deep vein thrombosis (DVT) and pulmonary embolism (PE), is a significant clinical challenge due to its multifaceted presentation and high morbidity and mortality. While commonly linked with surgical and oncological settings, VTE also emerges in association with dermatological, pulmonary, and cardiac disorders, often complicating their clinical course and management. This systematic review aims to elucidate the emergency presentations and interdisciplinary management strategies of VTE within dermatological, pulmonary, and cardiac conditions, emphasizing early detection and coordinated care. A comprehensive literature search was conducted across multiple databases, including PubMed, Scopus, and Web of Science, up to January 2025. Studies were screened and selected based on predefined inclusion criteria focusing on VTE occurrences in patients with dermatologic, pulmonary, or cardiac pathologies. Data on clinical presentation, diagnostic modalities, treatment strategies, and outcomes were extracted and synthesized. The review highlights diverse VTE manifestations across the three disciplines. Dermatological conditions, such as pyoderma gangrenosum and systemic vasculitides, exhibit prothrombotic states, while pulmonary disorders, notably chronic obstructive pulmonary disease (COPD) and interstitial lung disease, show increased VTE risk due to hypoxia and immobility. Cardiac conditions, including atrial fibrillation and heart failure, frequently precipitate thromboembolic events. Management involves a combination of anticoagulation, targeted therapy for underlying conditions, and collaborative care between dermatologists, pulmonologists, cardiologists, and emergency physicians. VTE in dermatological, pulmonary, and cardiac contexts necessitates heightened clinical awareness and interdisciplinary collaboration for optimal outcomes. Early recognition and tailored management strategies can significantly reduce VTE-associated complications, underscoring the need for integrated emergency protocols and continued research in these intersecting domains. CI - Copyright (c) 2025, Ullah et al. FAU - Ullah, Hamid AU - Ullah H AD - Internal Medicine, Russells Hall Hospital, Dudley Group NHS Foundation Trust, Dudley, USA. FAU - Khan, Nisar Ahmad AU - Khan NA AD - Medicine, St. Luke's Hospital, Kilkenny, IRL. AD - Internal Medicine, Lady Reading Hospital, Peshawar, PAK. FAU - Iqbal, Zahid AU - Iqbal Z AD - Internal Medicine, Midland Regional Hospital Mullingar, Mullingar, IRL. FAU - Alam, Fakhre AU - Alam F AD - General Medicine, Regional Hospital Mullingar, Mullingar, IRL. FAU - Khan, Muhammad S AU - Khan MS AD - General Practice, Islamabad Diagnostic Center, Islamabad, PAK. FAU - Ullah, Saddam AU - Ullah S AD - Internal Medicine, Midland Regional Hospital Mullingar, Mullingar, IRL. FAU - Amjad, Hira AU - Amjad H AD - Surgery, Sandeman Provincial Hospital, Quetta, PAK. FAU - Qureshi, Zarak AU - Qureshi Z AD - Acute Internal Medicine, Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool, GBR. FAU - Rehman, Hidayat U AU - Rehman HU AD - Internal Medicine, Hayatabad Medical Complex Peshawar, Peshawar, PAK. FAU - Hanfi, Hanifullah AU - Hanfi H AD - Medical A unit, Mardan Medical Complex, Mardan, PAK. FAU - Ahmad, Zubair AU - Ahmad Z AD - Internal Medicine, Hayatabad Medical Complex Peshawar, Peshawar, PAK. FAU - Ullah, Naqeeb AU - Ullah N AD - Internal Medicine, Lady Reading Hospital Peshawar, Peshawar, PAK. FAU - Iqbal, Sheema AU - Iqbal S AD - Public Health, BHU (Basic Health Unit) Chakdara, Chakdara, PAK. LA - eng PT - Journal Article PT - Review DEP - 20250629 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC12308166 OTO - NOTNLM OT - deep vein thrombosis OT - dermatological disorders OT - emergency care OT - interdisciplinary management OT - pulmonary embolism OT - venous thromboembolism COIS- Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. EDAT- 2025/07/31 12:11 MHDA- 2025/07/31 12:12 PMCR- 2025/06/29 CRDT- 2025/07/31 05:42 PHST- 2025/06/29 00:00 [accepted] PHST- 2025/07/31 12:12 [medline] PHST- 2025/07/31 12:11 [pubmed] PHST- 2025/07/31 05:42 [entrez] PHST- 2025/06/29 00:00 [pmc-release] AID - 10.7759/cureus.87008 [doi] PST - epublish SO - Cureus. 2025 Jun 29;17(6):e87008. doi: 10.7759/cureus.87008. eCollection 2025 Jun. PMID- 40741106 OWN - NLM STAT- MEDLINE DCOM- 20250731 LR - 20250802 IS - 2219-2840 (Electronic) IS - 1007-9327 (Print) IS - 1007-9327 (Linking) VI - 31 IP - 27 DP - 2025 Jul 21 TI - Cardiovascular risk assessment and predictors of cardiac decompensation after transjugular intrahepatic portosystemic shunt in patients with cirrhosis. PG - 107740 LID - 10.3748/wjg.v31.i27.107740 [doi] LID - 107740 AB - BACKGROUND: Portal hypertension (PH) is a major complication of chronic liver disease and a leading cause of mortality and morbidity in patients with cirrhosis. Transjugular intrahepatic portosystemic shunt (TIPS) is an established treatment for PH-related complications, including refractory ascites, variceal bleeding, hepatic hydrothorax and Budd-Chiari syndrome. However, post-TIPS cardiac decompensation has been reported in up to 25% of patients, often due to haemodynamic shifts revealing occult cardiac dysfunction. Current approaches to pre-procedural cardiac assessment and risk stratification remain inconsistent. This systematic review examines current recommendations and emerging strategies for cardiovascular evaluation in patients with cirrhosis prior to a TIPS. AIM: To identify the key predictive factors for cardiac decompensation following a TIPS in patients with cirrhosis. METHODS: A systematic review of available literature, using PubMed (including MEDLINE), Embase and Cochrane databases. Results were searched comprehensively, without exclusion criteria, from inception to May 2025. Given the predominance of retrospective cohort studies, risk of bias assessment was primarily performed using the ROBINS-E tool. RESULTS: Thirteen studies were included (n = 1674 patients), with a pulled mean decompensation rate of 8.8%. Due to the variability in TIPS timing, study quality and heterogeneity, a meta-analysis was not feasible, therefore results were synthesised narratively. Multiple diastolic dysfunction parameters independently and integrated through the American Society of Echocardiography guidelines demonstrated predictive value. Newly validated risk score, heart failure with preserved ejection fraction, and biomarkers such as N-terminal pro-B-type natriuretic peptide >/= 125 pg/mL consistently highlight cardiac dysfunction amongst the literature. Our review also explored left-atrial strain imaging as well as recent advances in cardiac magnetic resonance imaging and potential genetic contributors. CONCLUSION: Multiple predictors of cardiac decompensation following TIPS exist, however studies are of limited quality. Implementing reliable markers may enable early risk stratification, candidate selection and guide pre-procedural optimisation. CI - (c)The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. FAU - Tomassoni, Davide R AU - Tomassoni DR AD - Department of General Medicine, Eastern Health, Melbourne 3128, Victoria, Australia. FAU - Schildkraut, Tamar AU - Schildkraut T AD - Department of Gastroenterology, Eastern Health, Melbourne 3128, Victoria, Australia. FAU - Ramachandran, Vivekananda AU - Ramachandran V AD - Department of Radiology, Eastern Health, Melbourne 3128, Victoria, Australia. FAU - Cooke, Jennifer C AU - Cooke JC AD - Department of Cardiology, Eastern Health, Melbourne 3128, Victoria, Australia. AD - Eastern Health Clinical School, Monash University, Melbourne 3128, Victoria, Australia. FAU - Sawhney, Rohit AU - Sawhney R AD - Department of Gastroenterology, Eastern Health, Melbourne 3128, Victoria, Australia. AD - Eastern Health Clinical School, Monash University, Melbourne 3128, Victoria, Australia. rohit.sawhney@easternhealth.org.au. LA - eng PT - Journal Article PT - Systematic Review PL - United States TA - World J Gastroenterol JT - World journal of gastroenterology JID - 100883448 SB - IM MH - Humans MH - *Portasystemic Shunt, Transjugular Intrahepatic/adverse effects MH - *Liver Cirrhosis/complications/surgery MH - *Hypertension, Portal/etiology/surgery MH - Risk Assessment/methods MH - *Heart Failure/etiology/diagnosis/epidemiology/blood MH - *Postoperative Complications/etiology/epidemiology/diagnosis MH - Risk Factors PMC - PMC12305093 OTO - NOTNLM OT - Diastolic dysfunction OT - Echocardiography OT - Heart failure OT - Left atrial strain OT - Multidisciplinary team OT - N-terminal pro-B-type natriuretic peptide OT - Portal hypertension OT - Pre-emptive transjugular intrahepatic portosystemic shunt OT - Risk stratification OT - Transjugular intrahepatic portosystemic shunt COIS- Conflict-of-interest statement: The authors declare that they have no conflict of interest. EDAT- 2025/07/31 12:10 MHDA- 2025/07/31 12:11 PMCR- 2025/07/21 CRDT- 2025/07/31 05:36 PHST- 2025/03/30 00:00 [received] PHST- 2025/05/16 00:00 [revised] PHST- 2025/07/01 00:00 [accepted] PHST- 2025/07/31 12:11 [medline] PHST- 2025/07/31 12:10 [pubmed] PHST- 2025/07/31 05:36 [entrez] PHST- 2025/07/21 00:00 [pmc-release] AID - 10.3748/wjg.v31.i27.107740 [doi] PST - ppublish SO - World J Gastroenterol. 2025 Jul 21;31(27):107740. doi: 10.3748/wjg.v31.i27.107740. PMID- 40738637 OWN - NLM STAT- MEDLINE DCOM- 20250730 LR - 20250823 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 15 IP - 7 DP - 2025 Jul 30 TI - Identification of novel genetic, neurobiological and radio-anatomical biomarkers for risk stratification of sudden unexpected death in infancy and early childhood: the BIOMINRISK study protocol. PG - e101811 LID - 10.1136/bmjopen-2025-101811 [doi] LID - e101811 AB - INTRODUCTION: The BIOMINRISK project is a national French study aimed at identifying novel biomarkers associated with sudden unexpected death in infancy (SUDI) through a multidisciplinary approach encompassing three key components of intrinsic vulnerability to SUDI: genetic, neurobiological and radio-anatomical. A better understanding of the pathophysiological mechanisms underlying SUDI may enhance the personalisation of prevention strategies and contribute to reducing its incidence. METHODS AND ANALYSIS: We will analyse data from 250 children under the age of 2 included in the national SUDI registry (the OMIN registry) since 2020 for which biological samples and medical imaging data will have been collected from 15 participating French hospitals. Our investigations will focus on three axes: (1) genetic: we will conduct whole genome sequencing family trio analyses to identify novel variants and genes associated with sudden infant death syndrome (SIDS) by examining SIDS cases along with their two parents; (2) neurobiological: a case-control study will be performed to investigate the roles of various neuromodulators-including serum serotonin, blood butyrylcholinesterase and cerebrospinal fluid orexin-in the arousal regulation in children who have died from SUDI. We will recruit 250 living age-matched and sex-matched controls who will undergo blood tests and lumbar punctures as part of their routine care and (3) radio-anatomical: a case-control study will explore the potential anatomical predisposition to SUDI by assessing upper airway narrowness. We will compare the osseous structures of the upper airways (nasal fossae, hard palate) using geometric morphometrics on CT images. Recruitment of 250 living age-matched and sex-matched controls who have undergone brain CT scans, including facial bones, will be conducted. ETHICS AND DISSEMINATION: The study has received ethics approval for all three axes. Results will be published in international peer-reviewed journals and presented at national and international conferences. TRIAL REGISTRATION NUMBER: NCT06244433. CI - (c) Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. FAU - Ducloyer, Mathilde AU - Ducloyer M AUID- ORCID: 0000-0003-1116-4943 AD - CHU Nantes, Forensic Department, Nantes University, Nantes, France mathilde.ducloyer@chu-nantes.fr. AD - Centre for Anthropobiology and Genomics of Toulouse, UMR 5288 (CNRS/UT3), Toulouse III University-Paul Sabatier, Toulouse, France. FAU - Baruteau, Alban-Elouen AU - Baruteau AE AUID- ORCID: 0000-0003-2548-7858 AD - CHU Nantes, Department of Pediatric Cardiology and Pediatric Cardiac Surgery, FHU PreciCare, CIC1413, Nantes Universite, Nantes, France. AD - CNRS, INSERM, l'institut du thorax, Nantes University, Nantes, France. FAU - Franco, Patricia AU - Franco P AD - Pediatric Sleep Unit, Hopital Femme-Mere Enfant, Hospices Civils de Lyon, INSERM U1028/CNRS UMR 5292, Lyon Neuroscience Research Center, Lyon, France. FAU - Guyon, Aurore AU - Guyon A AD - Pediatric Sleep Unit, Hopital Femme-Mere Enfant, Hospices Civils de Lyon, INSERM U1028/CNRS UMR 5292, Lyon Neuroscience Research Center, Lyon, France. FAU - Sapin, Vincent AU - Sapin V AD - Biochemistry and Molecular Genetics Department, University Hospital of Clermont-Ferrand, Clermont-Ferrand, France. FAU - Karakachoff, Matilde AU - Karakachoff M AD - Clinique des donnees, CIC 1413, INSERM, Pole Hospitalo-Universitaire 11: Sante Publique, Centre Hospitalier Universitaire Nantes, Nantes University, Nantes, France. FAU - Savall, Frederic AU - Savall F AD - Centre for Anthropobiology and Genomics of Toulouse, UMR 5288 (CNRS/UT3), Toulouse III University-Paul Sabatier, Toulouse, France. AD - CHU Toulouse, Forensic Department, Rangueil Hospital, Toulouse III University-Paul Sabatier, Toulouse, France. FAU - Schott, Jean-Jacques AU - Schott JJ AD - CHU Nantes, CNRS, INSERM, l'institut du thorax, Nantes University, Nantes, France. FAU - de Pontual, Loic AU - de Pontual L AD - Department of Pediatrics, Assistance Publique - Hopitaux de Paris, Paris, France. FAU - De Visme, Sophie AU - De Visme S AD - CHU Nantes, INSERM, UIC Femme-Enfant-Adolescent, CIC 1413, Nantes University, Nantes, France. FAU - Ferrand, Lea AU - Ferrand L AD - CHU Nantes, INSERM, UIC Femme-Enfant-Adolescent, CIC 1413, Nantes University, Nantes, France. FAU - Jarry, Berengere AU - Jarry B AD - CHU Nantes, INSERM, UIC Femme-Enfant-Adolescent, CIC 1413, Nantes University, Nantes, France. FAU - Beudin, Didier AU - Beudin D AD - CHU Nantes, Research and Innovation Department, Promotion Department, INSERM, UIC Femme-Enfant-Adolescent, CIC 1413, Nantes University, Nantes, France. FAU - Scherdel, Pauline AU - Scherdel P AUID- ORCID: 0000-0003-4517-9430 AD - CHU Nantes, INSERM, UIC Femme-Enfant-Adolescent, CIC 1413, Nantes University, Nantes, France. FAU - Lorton, Fleur AU - Lorton F AUID- ORCID: 0000-0003-0921-4622 AD - CHU Nantes, INSERM, Paediatric Emergency Department, CIC 1413, Nantes University, Nantes, France. LA - eng SI - ClinicalTrials.gov/NCT06244433 PT - Journal Article PT - Multicenter Study PT - Observational Study DEP - 20250730 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 RN - 0 (Biomarkers) RN - 0 (Orexins) SB - IM MH - Child, Preschool MH - Female MH - Humans MH - Infant MH - Infant, Newborn MH - Male MH - Biomarkers/blood MH - Case-Control Studies MH - France/epidemiology MH - Orexins/cerebrospinal fluid MH - Registries MH - Research Design MH - Risk Assessment MH - *Sudden Infant Death/genetics/epidemiology MH - Whole Genome Sequencing PMC - PMC12314952 OTO - NOTNLM OT - Cot death OT - Death, Sudden, Cardiac OT - GENETICS OT - Neurobiology OT - PUBLIC HEALTH OT - Paediatric radiology COIS- Competing interests: None declared. EDAT- 2025/07/31 00:28 MHDA- 2025/07/31 00:29 PMCR- 2025/07/30 CRDT- 2025/07/30 21:12 PHST- 2025/07/31 00:29 [medline] PHST- 2025/07/31 00:28 [pubmed] PHST- 2025/07/30 21:12 [entrez] PHST- 2025/07/30 00:00 [pmc-release] AID - bmjopen-2025-101811 [pii] AID - 10.1136/bmjopen-2025-101811 [doi] PST - epublish SO - BMJ Open. 2025 Jul 30;15(7):e101811. doi: 10.1136/bmjopen-2025-101811. PMID- 40738574 OWN - NLM STAT- MEDLINE DCOM- 20250730 LR - 20260719 IS - 1876-7605 (Electronic) IS - 1936-8798 (Linking) VI - 18 IP - 14 DP - 2025 Jul 28 TI - Outcomes of Entrapped Right Ventricular Pacing or Defibrillator Leads Following Transcatheter Tricuspid Valve Replacement. PG - 1762-1772 LID - S1936-8798(25)01642-5 [pii] LID - 10.1016/j.jcin.2025.05.042 [doi] AB - BACKGROUND: In patients with a cardiac implantable electronic device (CIED) using a transvenous right ventricular (RV) lead, transcatheter tricuspid valve replacement (TTVR) results in RV lead entrapment. OBJECTIVES: The authors sought to evaluate outcomes of patients with pre-existing transvenous RV leads undergoing EVOQUE TTVR. METHODS: Patients with a CIED referred for TTVR at 3 centers were evaluated preoperatively by the heart team. Lead and clinical assessments were performed at baseline and in follow-up per local clinical practice. The primary outcome was the nature and incidence of major lead-related complications after TTVR. Secondary outcomes included changes in lead parameters after entrapment. RESULTS: Of 146 EVOQUE TTVR, 52 consecutive patients with entrapped RV leads (age 81 [77-85] years; 33 female patients (63.5%), lead dwell time 8.9 [3.3-13.6] years) were evaluated. Paravalvular leak was mild or less in 47 of 48 patients (98%) 30 days post-TTVR. Four patients had procedure-related lead complications: 1 intraprocedural RV lead dislodgement; 2 implantable cardioverter-defibrillator lead fractures 6- and 8-weeks post-TTVR; and 1 methicillin-resistant Staphylococcus aureus endocarditis 1 month post-TTVR. Among 46 complication-free patients with follow-up >30 days (356 [196-965] days), there were no other lead-related adverse events. Of the 33 patients without complications who had >/=1 CIED interrogation >30 days (424 [182-1,006] days) following TTVR, there was a significant decrease in lead impedance and increase in capture threshold on the final lead assessment, but no additional patients required lead revision. CONCLUSIONS: Following TTVR, most with entrapped RV leads remain free of lead-related complications. The need for urgent CIED revision due to RV lead dislodgment or failure is uncommon but may occur. CI - Copyright (c) 2025 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Peigh, Graham AU - Peigh G AD - Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA. Electronic address: https://twitter.com/GrahamPeigh. FAU - Al-Kazaz, Mohamed AU - Al-Kazaz M AD - Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA. FAU - Davidson, Laura J AU - Davidson LJ AD - Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA. FAU - Gercek, Muhammed AU - Gercek M AD - Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA; Herz- und Diabeteszentrum Nordrhein-Westfalen, Universitatsklinik der Ruhr-Universitat Bochum, Bad Oeynhausen, Germany. FAU - Potratz, Max AU - Potratz M AD - Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA; University of Cologne, Faculty of Medicine and University Hospital, Clinic III for Internal Medicine, Cologne, Germany. FAU - Malaisrie, S Christopher AU - Malaisrie SC AD - Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA. FAU - Finke, Rachel AU - Finke R AD - Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA. FAU - Meng, Zhiying AU - Meng Z AD - Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA. FAU - Baldridge, Abigail S AU - Baldridge AS AD - Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA. FAU - Gao, Jing AU - Gao J AD - Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA. FAU - Magod, Benjamin AU - Magod B AD - Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA. FAU - Attinoto, Alexis AU - Attinoto A AD - Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA. FAU - Narang, Akhil AU - Narang A AD - Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA. FAU - Puthumana, Jyothy J AU - Puthumana JJ AD - Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA. FAU - Lee, Linda AU - Lee L AD - Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA. FAU - Adam, Matti AU - Adam M AD - University of Cologne, Faculty of Medicine and University Hospital, Clinic III for Internal Medicine, Cologne, Germany. FAU - Althoff, Jan AU - Althoff J AD - University of Cologne, Faculty of Medicine and University Hospital, Clinic III for Internal Medicine, Cologne, Germany. FAU - Cremer, Paul AU - Cremer P AD - Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA. FAU - Passman, Rod S AU - Passman RS AD - Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA. FAU - Korber, Maria Isabel AU - Korber MI AD - Herz- und Diabeteszentrum Nordrhein-Westfalen, Universitatsklinik der Ruhr-Universitat Bochum, Bad Oeynhausen, Germany. FAU - Knight, Bradley P AU - Knight BP AD - Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA. FAU - Lin, Albert C AU - Lin AC AD - Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA. FAU - Rudolph, Volker AU - Rudolph V AD - University of Cologne, Faculty of Medicine and University Hospital, Clinic III for Internal Medicine, Cologne, Germany. FAU - Davidson, Charles J AU - Davidson CJ AD - Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA. Electronic address: cdavidson@nm.org. LA - eng PT - Journal Article PT - Multicenter Study PT - Research Support, N.I.H., Extramural PL - United States TA - JACC Cardiovasc Interv JT - JACC. Cardiovascular interventions JID - 101467004 SB - IM MH - Humans MH - Female MH - Male MH - Aged MH - *Defibrillators, Implantable/adverse effects MH - Treatment Outcome MH - Aged, 80 and over MH - *Pacemaker, Artificial/adverse effects MH - *Tricuspid Valve/surgery/physiopathology/diagnostic imaging MH - *Heart Valve Prosthesis Implantation/adverse effects/instrumentation/methods MH - Time Factors MH - Risk Factors MH - *Cardiac Catheterization/adverse effects/instrumentation/mortality MH - *Cardiac Pacing, Artificial/adverse effects MH - *Electric Countershock/instrumentation/adverse effects MH - Retrospective Studies MH - *Tricuspid Valve Insufficiency/physiopathology/surgery/diagnostic imaging OTO - NOTNLM OT - cardiac implantable electronic device OT - defibrillation OT - lead revision OT - pacemaker OT - transcatheter tricuspid valve replacement OT - tricuspid regurgitation COIS- Funding Support and Author Disclosures Dr Al-Kazaz has received research grant and speaking honoraria from Kiniksa Pharmaceuticals; and has received consulting fees from Edwards Lifesciences. Dr Gercek has received funding from the Ruhr University Bochum (Advanced Clinician Scientist); and has served as a consultant for Edwards Lifesciences. Dr Passman has received research support from the American Heart Association grant #18SFRN34250013, National Institutes of Health grant UG3HL165065, Abbott, and Medtronic; speaker fees from Medtronic; and royalties from UpToDate. Dr Korber has received travel support and consultant honoraria from Edwards Lifesciences, Abbott Medical. and JenaValve. Dr Knight has received research grants or consulting fees from Abbott, Biotronik, Boston Scientific, Edwards Lifesciences, and Medtronic. Dr Rudolph has received research grants or consulting fees from Abbott Vascular and Edwards Lifesciences. Dr Davidson receives institutional grant support from and is an uncompensated advisor for Edwards Lifesciences. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2025/07/31 00:29 MHDA- 2025/07/31 00:30 CRDT- 2025/07/30 20:54 PHST- 2025/05/08 00:00 [received] PHST- 2025/05/09 00:00 [revised] PHST- 2025/05/20 00:00 [accepted] PHST- 2025/07/31 00:30 [medline] PHST- 2025/07/31 00:29 [pubmed] PHST- 2025/07/30 20:54 [entrez] AID - S1936-8798(25)01642-5 [pii] AID - 10.1016/j.jcin.2025.05.042 [doi] PST - ppublish SO - JACC Cardiovasc Interv. 2025 Jul 28;18(14):1762-1772. doi: 10.1016/j.jcin.2025.05.042. PMID- 40738569 OWN - NLM STAT- MEDLINE DCOM- 20250819 LR - 20260719 IS - 1876-7605 (Electronic) IS - 1936-8798 (Linking) VI - 18 IP - 14 DP - 2025 Jul 28 TI - Atrioventricular Conduction Disturbances in Patients Undergoing Transcatheter Tricuspid Valve Intervention: A Multidisciplinary Consensus. PG - 1721-1736 LID - S1936-8798(25)01736-4 [pii] LID - 10.1016/j.jcin.2025.06.026 [doi] AB - Tricuspid regurgitation (TR) is a highly prevalent valve disease, and cardiac surgery has been used in patients with severe symptomatic TR undergoing surgery for other cardiac lesions or less frequently for isolated TR. More recently, transcatheter therapies, particularly transcatheter edge-to-edge repair and valve replacement, have emerged as therapeutic alternatives in those considered at high to extreme risk for surgery. Because of the anatomical proximity of the tricuspid valve (TV) and the atrioventricular conduction system, the risk for high-degree atrioventricular block and permanent pacemaker implantation remains important, as they are common adverse events after transcatheter valve replacement. Furthermore, a significant number of these patients have cardiac implantable electronic devices with leads that may either worsen TR or complicate the treatment procedure. The aim of this review is to provide an overview of different TV interventions, focusing on the risk for atrioventricular conduction disturbances in patients without previous cardiac implantable electronic devices as well as the risk for pacemaker lead-related adverse events following transcatheter TV interventions. Finally, the authors propose a management algorithm for patients with conduction disturbances following TV intervention and for those with permanent leads undergoing transcatheter interventions. CI - Copyright (c) 2025 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. FAU - Fischer, Quentin AU - Fischer Q AD - Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada. FAU - Ellenbogen, Kenneth A AU - Ellenbogen KA AD - Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA. FAU - Mittal, Suneet AU - Mittal S AD - Valley Hospital and the Snyder Center for Comprehensive Atrial Fibrillation, Paramus, New Jersey, USA. FAU - Hausleiter, Jorg AU - Hausleiter J AD - Medizinische Klinik und Poliklinik I, Klinikum der Universitat Munchen, Munich, Germany; German Center for Cardiovascular Research, Partner Site Munich Heart Alliance, Munich, Germany. FAU - Nuche, Jorge AU - Nuche J AD - Servicio de Cardiologia, Hospital Universitario 12 de Octubre, Instituto de Investigacion Sanitaria 12 de Octubre (imas12), Madrid, Spain; Consorcio de Investigacion Biomedica en Red - Cardiovascular (CIBER-CV), Madrid, Spain. FAU - Sorajja, Paul AU - Sorajja P AD - Abbott Northwestern Hospital, Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, USA. FAU - Taramasso, Maurizio AU - Taramasso M AD - Cardiac Surgery Department, University Heart Center of Zurich, Zurich, Switzerland. FAU - Thourani, Vinod H AU - Thourani VH AD - Department of Cardiovascular Surgery, Marcus Valve Center, Piedmont Heart Institute, Atlanta, Georgia, USA. FAU - Windecker, Stephan AU - Windecker S AD - Bern University Hospital, Inselspital University of Bern, Bern, Switzerland. FAU - Labbe, Benoit AU - Labbe B AD - Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada. FAU - Philippon, Francois AU - Philippon F AD - Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada. FAU - Rodes-Cabau, Josep AU - Rodes-Cabau J AD - Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada. Electronic address: josep.rodes@criucpq.ulaval.ca. LA - eng PT - Consensus Statement PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review PL - United States TA - JACC Cardiovasc Interv JT - JACC. Cardiovascular interventions JID - 101467004 SB - IM MH - Humans MH - *Tricuspid Valve Insufficiency/surgery MH - *Tricuspid Valve/surgery MH - *Heart Conduction System/surgery MH - *Cardiac Surgical Procedures/adverse effects/instrumentation/methods MH - *Cardiac Catheterization/adverse effects/instrumentation/methods MH - Treatment Outcome MH - Risk Factors MH - Pacemaker, Artificial/adverse effects MH - Cardiac Pacing, Artificial/adverse effects MH - Heart Valve Prosthesis MH - Heart Valve Prosthesis Implantation/adverse effects/instrumentation/methods MH - Interdisciplinary Research OTO - NOTNLM OT - cardiac implantable electronic device OT - transcatheter tricuspid valve replacement OT - tricuspid regurgitation COIS- Funding Support and Author Disclosures Dr Ellenbogen has received consulting fees from Medtronic, Boston Scientific, Abbott, and Biotronik; and has received honoraria from Medtronic, Boston Scientific, and Biotronik. Dr Mittal is a consultant to Medtronic. Dr Hausleiter has received speaker honoraria and research support from and serves as a consultant for Edwards Lifesciences. Dr Sorajja has received consulting fees from 4C Medical, Abbott Structural, Boston Scientific, Edwards Lifesciences, Foldax, GE Healthcare, Medtronic, Phillips, Siemens, Vdyne, and W.L. Gore. Dr Taramasso has served as a consultant for Abbott Vascular, Edwards Lifesciences, Boston Scientific, Shenqi Medical, MEDIRA, CoreMedic, Simulands, MTEX, Occlufit, Ventrimend, and Hi-D Imaging. Dr Thourani has received consulting fees from Abbott Vascular, Artivion, Boston Scientific, CroiValve, Edwards Lifesciences, Articure, and Egnite Medical; and has received equity from Dasi Simulations and Trisol. Dr Windecker has received research, travel, and educational grants to the institution from Abbott, Abiomed, Amgen, AstraZeneca, Bayer, Biotronik, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cardinal Health, CardioValve, Corflow Therapeutics, CSL Behring, Daiichi-Sankyo, Edwards Lifesciences, Guerbet, InfraRedx, Janssen-Cilag, Johnson and Johnson, Medicure, Medtronic, Merck Sharp & Dohme, Miracor Medical, Novartis, Novo Nordisk, Organon, OrPha Suisse, Pfizer, Polares, Regeneron, Sanofi, Servier, Sinomed, Terumo, Vifor, and V-Wave; has served as an advisory board member and/or member of the steering and executive groups of trials funded by Abbott, Abiomed, Amgen, AstraZeneca, Bayer, Boston Scientific, Biotronik, Bristol Myers Squibb, Edwards Lifesciences, Janssen, MedAlliance, Medtronic, Novartis, Polares, Recardio, Sinomed, Terumo, V-Wave, and Xeltis, with payments to the institution but no personal payments; and has been a member of the steering and executive committee groups of several investigator-initiated trials that receive funding from industry without impact on his personal remuneration. Dr Rodes-Cabau has received institutional research grants and consultant and speaker fees from Edwards Lifesciences and Medtronic, and holds the Research Chair "Fondation Famille Jacques Lariviere" for the Development of Structural Heart Interventions (Laval University, Quebec City, Canada). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2025/07/31 00:29 MHDA- 2025/07/31 00:30 CRDT- 2025/07/30 20:54 PHST- 2025/05/16 00:00 [received] PHST- 2025/06/12 00:00 [revised] PHST- 2025/06/17 00:00 [accepted] PHST- 2025/07/31 00:30 [medline] PHST- 2025/07/31 00:29 [pubmed] PHST- 2025/07/30 20:54 [entrez] AID - S1936-8798(25)01736-4 [pii] AID - 10.1016/j.jcin.2025.06.026 [doi] PST - ppublish SO - JACC Cardiovasc Interv. 2025 Jul 28;18(14):1721-1736. doi: 10.1016/j.jcin.2025.06.026. PMID- 40738513 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260718 IS - 2452-302X (Electronic) IS - 2452-302X (Linking) VI - 10 IP - 7 DP - 2025 Jul TI - The Cardiohepatic Axis in Cirrhosis. PG - 101314 LID - S2452-302X(25)00263-3 [pii] LID - 10.1016/j.jacbts.2025.101314 [doi] LID - 101314 AB - Cardiac dysfunction in the setting of cirrhosis is often overlooked despite its impact on contractility, diastolic dysfunction, and electrophysiological abnormalities. This review examines the complex interactions of the cardiohepatic axis, with a particular focus on how liver disease impacts heart function. We highlight the roles of portal hypertension, systemic inflammation, hemodynamic changes, and neurohormonal signaling to shed light on this important connection. The underlying mechanisms for impaired cardiac performance involve both molecular and structural changes. Diagnosis remains challenging because it is frequently subclinical; however, advanced imaging, biomarkers, and electrocardiographic changes have improved early detection. Clinically, this syndrome has significant implications, particularly in decompensated cirrhosis and periods of increased myocardial stress. Although no standardized treatment guidelines exist, orthotopic liver transplantation remains the most effective intervention and often results in cardiovascular recovery. A multidisciplinary approach between cardiologists, hepatologists, and transplant surgeons is crucial to improving patient outcomes and optimizing long-term management. CI - Copyright (c) 2025 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Ali, Saad A AU - Ali SA AD - Division of Cardiovascular Medicine, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA. FAU - Frick, Kyle AU - Frick K AD - Division of Cardiovascular Medicine, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA. Electronic address: kafrick@iu.edu. LA - eng PT - Journal Article PT - Review PL - United States TA - JACC Basic Transl Sci JT - JACC. Basic to translational science JID - 101677259 PMC - PMC12434259 OTO - NOTNLM OT - advanced cardiac imaging OT - cardiohepatic axis OT - cirrhotic cardiomyopathy OT - coronary artery disease OT - end stage liver disease OT - orthotopic liver transplantation COIS- Funding support and author disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2025/07/31 00:28 MHDA- 2025/07/31 00:29 PMCR- 2025/07/28 CRDT- 2025/07/30 20:53 PHST- 2025/03/03 00:00 [received] PHST- 2025/05/28 00:00 [revised] PHST- 2025/05/28 00:00 [accepted] PHST- 2025/07/31 00:29 [medline] PHST- 2025/07/31 00:28 [pubmed] PHST- 2025/07/30 20:53 [entrez] PHST- 2025/07/28 00:00 [pmc-release] AID - S2452-302X(25)00263-3 [pii] AID - 101314 [pii] AID - 10.1016/j.jacbts.2025.101314 [doi] PST - ppublish SO - JACC Basic Transl Sci. 2025 Jul;10(7):101314. doi: 10.1016/j.jacbts.2025.101314. PMID- 20301290 STAT- Publisher DRDT- 20250731 CTDT- 20040720 PB - University of Washington, Seattle DP - 1993 TI - Holt-Oram Syndrome. BTI - GeneReviews((R)) AB - CLINICAL CHARACTERISTICS: Holt-Oram syndrome (HOS) is characterized by the association of upper-limb defects, congenital heart malformations, and cardiac conduction disease. Upper-limb malformations are usually bilateral/asymmetric, rarely unilateral or bilateral/symmetric, and affect the radial ray. They can range from thenar hypoplasia, triphalangeal thumb(s), or absent thumb(s) to radial agenesis/hypoplasia to phocomelia. Deformities of the carpal and thenar bones, abnormalities of the shoulders and/or elbows, and vertebral defects can occur. A congenital heart malformation is present in 90% of individuals with HOS and most commonly involves the septum. Atrial septal defect and ventricular septal defect can vary in number, size, and location. Complex congenital heart malformations can also occur in individuals with HOS. Individuals with HOS with or without a congenital heart malformation are at risk for cardiac conduction disease (30%). While individuals may present at birth with sinus bradycardia and first-degree atrioventricular (AV) block, AV block can progress unpredictably to a higher grade including complete heart block with and without atrial fibrillation. DIAGNOSIS/TESTING: The clinical diagnosis of HOS is established by the presence in a proband of a preaxial radial ray anomaly and a personal or family history of cardiac septation and/or conduction defects. More than 70% of individuals who meet strict clinical diagnostic criteria have an identifiable heterozygous pathogenic variant in TBX5. MANAGEMENT: Treatment of manifestations: Management involves a multidisciplinary team of specialists in medical genetics, cardiology, orthopedics, and hand surgery. Treatment of upper-limb malformations per orthopedist can include surgery, physical therapy, occupational therapy, and/or prostheses in those with severe limb shortening. Social and psychological support for affected individuals and families; standard treatment for congenital heart malformation per cardiologist and cardiac surgeon; anticoagulants and antibiotic prophylaxis for bacterial endocarditis if recommended by cardiologist; treatment for arrhythmias may require medication, surgery, and/or pacemaker implantation; pharmacologic treatment for individuals with pulmonary hypertension per cardiologist and/or intensivist. Surveillance: Assess limb function and activities of daily living per orthopedist, physical therapist, and/or occupational therapist; annual EKG in those at risk of developing a conduction defect; annual EKG combined with Holter monitor for individuals with known conduction disease; echocardiogram according to the absence/presence of congenital heart defect and history of heart surgery, every five years in the absence of congenital heart defects to assess for rare cardiomyopathy; surveillance in those with pulmonary hypertension per cardiologist and/or intensivist. Agents/circumstances to avoid: Certain medications may be contraindicated in individuals with arrhythmias, cardiomyopathy, and/or pulmonary hypertension. Evaluation of relatives at risk: Presymptomatic diagnosis and treatment is warranted in relatives at risk to identify those who would benefit from appropriate cardiac management. Pregnancy management: Affected women who have not undergone cardiac evaluation should do so prior to pregnancy or as soon as the pregnancy is recognized; those with a known history of a structural cardiac defect or cardiac conduction abnormality should be followed by a cardiologist during pregnancy. GENETIC COUNSELING: HOS is inherited in an autosomal dominant manner. Some individuals diagnosed with HOS have an affected parent; up to 60% of affected individuals represent simplex cases. Significant intrafamilial variability in limb and heart defect severity is observed among affected family members. Offspring of an individual with HOS have a 50% risk for HOS. If the TBX5 pathogenic variant has been identified in an affected family member, prenatal and preimplantation genetic testing are possible. If the pathogenic variant in the family is not known, prenatal ultrasound (US) examination evaluating for characteristic limb and cardiac manifestations is recommended (a normal US examination does not eliminate the possibility of HOS in the fetus). CI - Copyright (c) 1993-2026, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved. FED - Adam, Margaret P ED - Adam MP FED - Bick, Sarah ED - Bick S FED - Mirzaa, Ghayda M ED - Mirzaa GM FED - Wallace, Stephanie E ED - Wallace SE FED - Amemiya, Anne ED - Amemiya A FAU - Vanlerberghe, Clemence AU - Vanlerberghe C AD - Clinique de Genetique "Guy Fontaine", CHU de Lille, Lille, France FAU - Petit, Florence AU - Petit F AD - Clinique de Genetique "Guy Fontaine", CHU de Lille, Lille, France LA - eng PT - Review PT - Book Chapter PL - Seattle (WA) OTO - NLM OT - Heart-Hand Syndrome OT - T-box transcription factor TBX5 OT - TBX5 OT - Holt-Oram Syndrome OT - Heart-Hand Syndrome EDAT- 2025/07/31 00:00 CRDT- 2025/07/31 00:00 AID - NBK1111 [bookaccession] PMID- 40737507 OWN - NLM STAT- MEDLINE DCOM- 20250910 LR - 20260917 IS - 1549-490X (Electronic) IS - 1083-7159 (Print) IS - 1083-7159 (Linking) VI - 30 IP - 9 DP - 2025 Sep 1 TI - Considerations for the practical management of cardiovascular risk with Bruton's tyrosine kinase inhibitors for patients with chronic lymphocytic leukemia. LID - 10.1093/oncolo/oyaf237 [doi] LID - oyaf237 AB - BACKGROUND: Bruton's tyrosine kinase inhibitors (BTKis) are central to the medical management of chronic lymphocytic leukemia. However, accumulating data suggest an important association with cardiovascular (CV) adverse events (AEs), including arrhythmias, hypertension, and bleeding, in patients with chronic lymphocytic leukemia and other hematological malignancies treated with this therapeutic class. Data from comparative trials with BTKis suggest second-generation agents, for example, acalabrutinib and zanubrutinib, may be associated with fewer CV AEs than first-in-class BTKi ibrutinib. METHODS: PubMed and the proceedings of key hematology congresses were searched for relevant information using broad search terms, including chronic lymphocytic leukemia, BTKi, and toxicity. RESULTS: When managing patients with chronic lymphocytic leukemia, screening before and during treatment to assess CV risk is suggested to guide decision-making. Due to the increased toxicity with ibrutinib, the second-generation BTKis are now preferred (per the NCCN Clinical Practice Guidelines in Oncology [NCCN Guidelines]). For patients with a high CV risk, the decision between second-generation BTKi or a time-limited alternative, like venetoclax plus an anti-CD20 monoclonal antibody, should be made on an individual basis after patient consultation and consideration of the presenting characteristics of chronic lymphocytic leukemia in any given patient. The management of anticoagulant/antiplatelet medication during BTKi treatment requires specific attention, with coexistent medications being carefully assessed before starting a BTKi to reduce the risk of bleeding. For patients with a new-onset or worsening CV events during BTKi therapy, management may involve temporarily stopping the BTKi or switching to another class of therapy. To ensure the best outcomes, a collaborative care approach is essential, and some patients may need to be referred to a cardiologist/cardio-oncologist for specialist management. CONCLUSION: Baseline and ongoing CV risk assessment, careful monitoring, management, and a multidisciplinary team approach are all critical to ensure optimal oncologic and CV outcomes for patients with chronic lymphocytic leukemia receiving BTKis. CI - (c) The Author(s) 2025. Published by Oxford University Press. FAU - Lenihan, Daniel AU - Lenihan D AUID- ORCID: 0000-0001-9458-0154 AD - Cardio-Oncology Center of Excellence, Cardiac Rehabilitation, and Heart Failure Clinic, Saint Francis Healthcare System, MO 63703, United States. FAU - Bloom, Michelle AU - Bloom M AD - Cardio-oncology program, NYU Langone Health, New York, NY 11501, United States. FAU - Copeland-Halperin, Robert AU - Copeland-Halperin R AD - Cardiology, Northwell Health, New York, NY 11040, United States. FAU - Fleming, Matthew R AU - Fleming MR AD - Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, United States. FAU - Fradley, Michael AU - Fradley M AD - Cardio-oncology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, United States. FAU - O'Quinn, Rupal AU - O'Quinn R AD - Cardiovascular Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 43210, United States. FAU - Bhat, Seema A AU - Bhat SA AD - Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, United States. LA - eng GR - K12 CA090625/CA/NCI NIH HHS/United States GR - AstraZeneca/ PT - Journal Article PT - Review PL - England TA - Oncologist JT - The oncologist JID - 9607837 RN - 0 (Protein Kinase Inhibitors) RN - EC 2.7.10.2 (Agammaglobulinaemia Tyrosine Kinase) RN - 0 (Piperidines) RN - JAC85A2161 (Adenine) RN - 1X70OSD4VX (ibrutinib) RN - 0 (Pyrazoles) RN - EC 2.7.10.2 (BTK protein, human) RN - I42748ELQW (acalabrutinib) RN - 0 (Pyrimidines) RN - 0 (Tyrosine Kinase Inhibitors) RN - 0 (Benzamides) RN - 0 (Pyrazines) SB - IM MH - Humans MH - *Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy/complications/pathology MH - *Protein Kinase Inhibitors/adverse effects/therapeutic use MH - *Cardiovascular Diseases/chemically induced/pathology MH - *Agammaglobulinaemia Tyrosine Kinase/antagonists & inhibitors MH - Piperidines MH - Adenine/analogs & derivatives MH - Pyrazoles/adverse effects/therapeutic use MH - Pyrimidines/adverse effects/therapeutic use MH - Tyrosine Kinase Inhibitors MH - Benzamides MH - Pyrazines PMC - PMC12548057 OTO - NOTNLM OT - Bruton's tyrosine kinase inhibitor OT - arrhythmia OT - cardiovascular OT - chronic lymphocytic leukemia OT - hemorrhage OT - hypertension COIS- Daniel Lenihan: consulting/advisory role: AstraZeneca, Myocardial Solutions, and Intellia; scientific advisory board: AstraZeneca. Michelle Bloom: consulting/advisory role: AstraZeneca and Bayer Pharmaceuticals; scientific advisory board: AstraZeneca. Robert Copeland-Halperin: consulting/advisory role: Doximity Inc; research funding: Bristol Myers Squibb and Medtronic; employment: ProviderLoop; ownership interests: Citrus Oncology; scientific advisory board: AstraZeneca. Matthew R. Fleming: consulting/advisory role: AstraZeneca; scientific advisory board: AstraZeneca. Michael Fradley: consulting/advisory role: Abbvie, AstraZeneca, Janssen, Johnson and Johnson, Pfizer, and Zoll Medical Devices and Technology Solutions; research funding: AstraZeneca and Medtronic; scientific advisory board: AstraZeneca. Rupal O'Quinn: consulting/advisory role: AstraZeneca and ICON imaging core lab; honoraria: Belgium Hematology Society, Zoll Medical Devices, and Technology Solutions; scientific advisory board: AstraZeneca. Seema A Bhat: consulting/advisory role: AstraZeneca, AbbVie, and Pharmacyclics; research funding: AstraZeneca; scientific advisory board: AstraZeneca. EDAT- 2025/07/30 18:28 MHDA- 2025/09/10 18:30 PMCR- 2025/07/30 CRDT- 2025/07/30 14:24 PHST- 2025/03/25 00:00 [received] PHST- 2025/07/29 00:00 [accepted] PHST- 2025/09/10 18:30 [medline] PHST- 2025/07/30 18:28 [pubmed] PHST- 2025/07/30 14:24 [entrez] PHST- 2025/07/30 00:00 [pmc-release] AID - 8219469 [pii] AID - oyaf237 [pii] AID - 10.1093/oncolo/oyaf237 [doi] PST - ppublish SO - Oncologist. 2025 Sep 1;30(9):oyaf237. doi: 10.1093/oncolo/oyaf237. PMID- 40736534 OWN - NLM STAT- MEDLINE DCOM- 20260305 LR - 20260610 IS - 1460-2385 (Electronic) IS - 0931-0509 (Linking) VI - 41 IP - 3 DP - 2026 Feb 27 TI - Myocardial ischaemic syndromes in chronic kidney disease: risky pathways from non-acute to acute events. PG - 411-417 LID - 10.1093/ndt/gfaf142 [doi] AB - Chronic kidney disease (CKD) has emerged as a critical global public health concern. This condition is strongly associated with an increased risk of atherosclerotic cardiovascular disease and acute coronary syndromes (ACSs), which have been recently renamed as acute myocardial ischaemic syndromes (AMIS). In CKD patients, the atypical presentation of symptoms complicates the diagnosis and management of angina, a condition that can, if not promptly addressed, rapidly progress to myocardial infarction (MI). Traditional diagnostic tools, such as the electrocardiogram and cardiac biomarkers, are less reliable in this population due to CKD-related baseline alterations, necessitating advanced imaging techniques for accurate assessment. Management strategies for transient myocardial ischaemia in CKD must also carefully balance the risk related to myocardial ischaemia against potential complications from invasive procedures, such as further renal impairment and bleeding. Tailored therapeutic approaches, including adjusted medication regimens and innovative revascularization techniques, are crucial to improve outcomes in this high-risk population. Additionally, asymptomatic MI is notably prevalent in CKD, often remaining undetected and posing significant prognostic implications. The interplay of traditional and non-traditional risk factors, such as uraemia-induced toxicity and chronic inflammation, further exacerbates the risk for plaque instability in CKD patients. This review highlights the necessity of a multidisciplinary approach in managing myocardial ischaemia in CKD, incorporating meticulous risk stratification and personalized treatment plans. CI - (c) The Author(s) 2025. Published by Oxford University Press on behalf of the ERA. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com. FAU - Zoccali, Carmine AU - Zoccali C AUID- ORCID: 0000-0002-6616-1996 AD - Renal Research Institute, New York, NY, USA. AD - Institute of Molecular Biology and Genetics (Biogem), Ariano Irpino, Italy. AD - Associazione Ipertensione Nefrologia Trapianto (IPNET), c/o Nefrologia, Grande Ospedale Metropolitano, Reggio Calabria, Italy. FAU - Chinnappa, Shanmugakumar AU - Chinnappa S AD - Department of Nephrology, Doncaster and Bassetlaw Teaching Hospitals NHS Trust, Doncaster, UK. AD - Leeds Institute of Cardiovascular and Metabolic Medicine (LICAMM), University of Leeds, Leeds, UK. FAU - Fernandez-Fernandez, Beatriz AU - Fernandez-Fernandez B AD - 2IIS-Fundacion Jimenez Diaz UAM, Madrid, Spain. AD - Department of Medicine, School of Medicine, Universidad Autonoma de Madrid, Madrid, Spain. AD - RICORS2040, Madrid, Spain. FAU - Iatridi, Fotini AU - Iatridi F AD - First Department of Nephrology, Hippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece. FAU - Mallamaci, Francesca AU - Mallamaci F AD - Associazione Ipertensione Nefrologia Trapianto (IPNET), c/o Nefrologia, Grande Ospedale Metropolitano, Reggio Calabria, Italy. FAU - Mark, Patrick B AU - Mark PB AD - School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK. FAU - Ntounousi, Evangelia AU - Ntounousi E AD - Department of Nephrology, University Hospital of Ioannina, Ioannina, Greece. FAU - Piko, Nejc AU - Piko N AD - Department of Dialysis, Clinic for Internal Medicine, University Medical Centre Maribor, Maribor, Slovenia. FAU - Stegbauer, Joannes AU - Stegbauer J AD - Department of Nephrology, Medical Faculty, University Hospital Dusseldorf, Heinrich Heine University Dusseldorf, Dusseldorf, Germany. AD - Cardiovascular Research Institute Dusseldorf, Medical Faculty, Heinrich Heine University Dusseldorf, Dusseldorf, Germany. FAU - Torino, Claudia AU - Torino C AD - National Research Council of Italy (CNR) Institute of Clinical Physiology, Reggio Calabria, Italy. FAU - Valdivielso, Jose Manuel AU - Valdivielso JM AD - Nephrology Department, Arnau de Vilanova University Hospital, Lleida, Spain. AD - Biomedical Research Institute August Pi I Sunyer, Lleida, Spain. FAU - Van Craenenbroeck, Amaryllis AU - Van Craenenbroeck A AD - Division of Nephrology, University Hospitals Leuven, Leuven, Belgium. AD - Department of Microbiology, Immunology and Transplantation, Nephrology and Renal Transplantation Research Group, KU Leuven, Leuven, Belgium. FAU - Vogt, Liffert AU - Vogt L AD - Department of Internal Medicine, Section of Nephrology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands. FAU - De Caterina, Raffaele AU - De Caterina R AD - Cardiology Chair and Postgraduate School of Cardiology and the Invasive Cardiology Unit, Pisa University Hospital, University of Pisa, Pisa, Italy. LA - eng GR - European Renal Association/ PT - Journal Article PT - Review PL - England TA - Nephrol Dial Transplant JT - Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association JID - 8706402 SB - IM EIN - Nephrol Dial Transplant. 2026 Jul 31;41(8):1583. doi: 10.1093/ndt/gfag123. PMID: 42267493 MH - Humans MH - *Renal Insufficiency, Chronic/complications MH - *Myocardial Ischemia/etiology/diagnosis MH - Risk Factors MH - Prognosis OTO - NOTNLM OT - asymptomatic coronary artery disease OT - chronic kidney disease OT - myocardial infarction OT - myocardial ischaemia OT - unstable angina EDAT- 2025/07/30 12:31 MHDA- 2026/03/06 09:03 CRDT- 2025/07/30 11:07 PHST- 2025/06/23 00:00 [received] PHST- 2026/03/06 09:03 [medline] PHST- 2025/07/30 12:31 [pubmed] PHST- 2025/07/30 11:07 [entrez] AID - 8219168 [pii] AID - 10.1093/ndt/gfaf142 [doi] PST - ppublish SO - Nephrol Dial Transplant. 2026 Feb 27;41(3):411-417. doi: 10.1093/ndt/gfaf142. PMID- 40736241 OWN - NLM STAT- Publisher LR - 20250730 IS - 1538-4683 (Electronic) IS - 1061-5377 (Linking) DP - 2025 Jul 30 TI - Pregnancy and Ischemic Heart Disease: A Review of Risks and Therapeutic Approaches. LID - 10.1097/CRD.0000000000001013 [doi] AB - Ischemic heart disease (IHD) in pregnancy presents significant risks to both mother and fetus, especially as cardiovascular risk factors become more prevalent in women of reproductive age. This literature review examines the epidemiology, pathophysiology, clinical impact, and multidisciplinary management of IHD during pregnancy. Maternal complications include acute coronary syndrome, heart failure, and arrhythmias, with fetal risks such as preterm birth, intrauterine growth restriction, and neonatal death. Physiological and hematologic adaptations of pregnancy exacerbate ischemic risk, particularly in women with underlying atherosclerosis. Evidence-based pharmacologic and interventional strategies are discussed, alongside delivery planning and postpartum care. A coordinated, multidisciplinary approach remains essential to improving outcomes in this high-risk population. CI - Copyright (c) 2025 Wolters Kluwer Health, Inc. All rights reserved. FAU - Huhulea, Ellen N AU - Huhulea EN AD - From the Department of Medicine, New York Medical College, Valhalla, NY. FAU - Huang, Lillian AU - Huang L AD - From the Department of Medicine, New York Medical College, Valhalla, NY. FAU - Aifuwa, Esewi AU - Aifuwa E AD - Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY. FAU - Frishman, William H AU - Frishman WH AD - Department of Medicine, Westchester Medical Center, Valhalla, NY. FAU - Aronow, Wilbert S AU - Aronow WS AD - Departments of Cardiology and Medicine, Westchester Medicine and New York Medical College, Valhalla, NY. LA - eng PT - Journal Article DEP - 20250730 PL - United States TA - Cardiol Rev JT - Cardiology in review JID - 9304686 SB - IM OTO - NOTNLM OT - cardiovascular disease OT - ischemic heart disease OT - maternal mortality OT - myocardial infarction OT - pregnancy COIS- Disclosures: The authors have no conflicts of interest to report. EDAT- 2025/07/30 12:31 MHDA- 2025/07/30 12:31 CRDT- 2025/07/30 09:02 PHST- 2025/07/30 12:31 [medline] PHST- 2025/07/30 12:31 [pubmed] PHST- 2025/07/30 09:02 [entrez] AID - 00045415-990000000-00557 [pii] AID - 10.1097/CRD.0000000000001013 [doi] PST - aheadofprint SO - Cardiol Rev. 2025 Jul 30. doi: 10.1097/CRD.0000000000001013. PMID- 40735719 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260925 IS - 2050-0904 (Print) IS - 2050-0904 (Electronic) IS - 2050-0904 (Linking) VI - 13 IP - 8 DP - 2025 Aug TI - Percutaneous Closure of Perivalvular Leakage After Aortic Valve Replacement Using Preoperative 3D Printing Technology Guidance: A Case Report. PG - e70640 LID - 10.1002/ccr3.70640 [doi] LID - e70640 AB - We report a case of transcatheter paravalvular leak (PVL) closure assisted by three-dimensional (3D) printing and intracardiac echocardiography (ICE) in a patient with complex valvular history. A 70-year-old male manifested acute exacerbation of dyspnea, accompanied by orthopnea and nocturnal paroxysmal respiratory distress. Echocardiographic evaluation revealed severe aortic PVL. After multidisciplinary heart team evaluation, transcatheter aortic PVL closure was selected as the preferred therapeutic strategy. The preoperative assessment of PVL location, size, and morphology using 3D printing technology accurately guided the interventional position and the selection of the occluder size and the successful completion of closed treatment under local anesthesia, which was assisted by intracardiac echocardiography to ensure the safety and smoothness of the procedure. CI - (c) 2025 The Author(s). Clinical Case Reports published by John Wiley & Sons Ltd. FAU - Xu, Zewei AU - Xu Z AUID- ORCID: 0009-0000-9320-5010 AD - Department of Cardiology The Second Hospital of Jilin University Changchun China. FAU - Zhang, Chunpeng AU - Zhang C AD - Department of Cardiology The Second Hospital of Jilin University Changchun China. FAU - Xu, Chenhao AU - Xu C AD - Department of Pulmonary and Critical Care Medicine The Second Hospital of Jilin University Changchun China. FAU - Wang, Guan AU - Wang G AD - Department of Cardiology The Second Hospital of Jilin University Changchun China. FAU - Zhao, Lei AU - Zhao L AD - Department of Cardiology The Second Hospital of Jilin University Changchun China. LA - eng PT - Journal Article DEP - 20250727 PL - England TA - Clin Case Rep JT - Clinical case reports JID - 101620385 PMC - PMC12301155 OTO - NOTNLM OT - 3D printing technology OT - case report OT - intra-cardiac echography OT - percutaneous closure OT - perivalvular leakage COIS- The authors declare no conflicts of interest. EDAT- 2025/07/30 06:29 MHDA- 2025/07/30 06:30 PMCR- 2025/07/27 CRDT- 2025/07/30 05:11 PHST- 2025/01/16 00:00 [received] PHST- 2025/05/15 00:00 [revised] PHST- 2025/05/21 00:00 [accepted] PHST- 2025/07/30 06:30 [medline] PHST- 2025/07/30 06:29 [pubmed] PHST- 2025/07/30 05:11 [entrez] PHST- 2025/07/27 00:00 [pmc-release] AID - CCR370640 [pii] AID - 10.1002/ccr3.70640 [doi] PST - epublish SO - Clin Case Rep. 2025 Jul 27;13(8):e70640. doi: 10.1002/ccr3.70640. eCollection 2025 Aug. PMID- 40731025 OWN - NLM STAT- MEDLINE DCOM- 20250730 LR - 20250801 IS - 1466-609X (Electronic) IS - 1364-8535 (Print) IS - 1364-8535 (Linking) VI - 29 IP - 1 DP - 2025 Jul 29 TI - Use of extracorporeal membrane oxygenation in adult trauma patients with refractory acute cardiopulmonary failure: guideline from the Chinese society of extracorporeal life support 2025. PG - 334 LID - 10.1186/s13054-025-05504-6 [doi] LID - 334 AB - BACKGROUND: Adult trauma patients with refractory acute cardiopulmonary failure suffer from high morbidity and mortality. In the past decade, a growing body of researches has shown survival benefits of extracorporeal membrane oxygenation (ECMO) in trauma patients who fail to respond to optimal damage control resuscitation (DCR), and there is an opportunity to formulate clinical practice guidelines to guide clinicians in implementing trauma ECMO at the bedside. METHODS: The Chinese Society of Extracorporeal Life Support (CSECLS) convened a domestic panel of interdisciplinary experts to develop this guideline, adhering to the principles of the World Health Organization (WHO) Manual for Guideline Development and the policy of conflict of interest. Clinical key questions pertaining to trauma ECMO use were informed from expert interviews and literature reviews, and formulated as PICO (Population/Intervention/Comparison/Outcome) format for literature retrieval of original studies supporting the question. Then, panelists were assigned to address specific clinical questions, synthesize evidence, formulate recommendations and determine their strength, following the Recommendations Assessment, Development and Evaluation (GRADE) framework. The guideline steering committee and stakeholders approved the final document. RESULTS: Eleven recommendations regarding trauma ECMO use in adult patients were formulated, focusing on the following topics: (1) indications; (2) patient screening; (3) timing of initiation; (4) multidisciplinary approach; (5) trauma ECMO management; and (6) complication prevention. Supporting evidences are elaborated in detail, and expert opinions on clinical application and future research provided. CONCLUSION: Although the quality of the body of evidence is low to very-low, most researches have shown that ECMO improves the survival of adult trauma patients with varied injury mechanisms. However, decision-making should consider the individual characteristics, benefits and potential harms, patients' values and preferences, and long-term outcomes. CI - (c) 2025. The Author(s). FAU - Wang, Hua AU - Wang H AD - Department of Critical Care Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, China. FAU - Cen, Zhongran AU - Cen Z AD - Department of Critical Care Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, China. FAU - Liu, Xingxing AU - Liu X AD - Department of Critical Care Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, China. FAU - Liu, Zhanguo AU - Liu Z AD - Department of Critical Care Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, China. zhguoliu@163.com. FAU - Hou, Xiaotong AU - Hou X AD - Department of Critical Care Medicine, Beijing Anzhen Hospital, Capital Medical University, Beijing, China. xt.hou@ccmu.edu.cn. FAU - Guan, Xiangdong AU - Guan X AD - Department of Critical Care Medicine, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. FAU - Wu, Jianfeng AU - Wu J AD - Department of Critical Care Medicine, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. FAU - Li, Yimin AU - Li Y AD - Department of Critical Care Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. FAU - Xu, Yonghao AU - Xu Y AD - Department of Critical Care Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. FAU - Zhou, Chengbin AU - Zhou C AD - Department of anesthesiology, Guangdong Provincial People's Hospital, Guangzhou, China. FAU - Peng, Zhiyong AU - Peng Z AD - Department of Critical Care Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China. FAU - Zhou, Fachun AU - Zhou F AD - Department of Critical Care Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. FAU - Sun, Tongwen AU - Sun T AD - Department of Critical Care Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. FAU - Qin, Bingyu AU - Qin B AD - Department of Critical Care Medicine, Henan Provincial People's Hospital, Zhengzhou, China. FAU - Lin, Jiandong AU - Lin J AD - Department of Critical Care Medicine, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China. FAU - Zhang, Lina AU - Zhang L AD - Department of Critical Care Medicine, Xiangya Hospital of Central South University, Changsha, China. FAU - Li, Jinghui AU - Li J AD - Department of Critical Care Medicine, Haikou People's Hospital, Haikou, China. FAU - Shang, You AU - Shang Y AD - Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Liu, Songqiao AU - Liu S AD - Department of Critical Care Medicine, Zhongda Hospital Southeast University, Nanjing, China. FAU - Zeng, Zhenhua AU - Zeng Z AD - Department of Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China. FAU - Wang, Xiaowu AU - Wang X AD - Cardiovascular Surgery, Zhujiang Hospital of Southern Medical University, Guangzhou, China. FAU - Chen, Qunqing AU - Chen Q AD - Thoracic Surgery, Zhujiang Hospital of Southern Medical University, Guangzhou, China. FAU - Guo, Yanwu AU - Guo Y AD - Department of Neurosurgery, Zhujiang Hospital of Southern Medical University, Guangzhou, China. FAU - Peng, Changbiao AU - Peng C AD - Department of Medical Administration, Zhujiang Hospital of Southern Medical University, Guangzhou, China. FAU - Wang, Yang AU - Wang Y AD - Department of Radiology, Zhujiang Hospital of Southern Medical University, Guangzhou, China. FAU - Li, Songjian AU - Li S AD - Orthopedic Department, Zhujiang Hospital of Southern Medical University, Guangzhou, China. FAU - Wang, Chunyao AU - Wang C AD - Department of Critical Care Medicine, Peking Union Medical College Hospital, Beijing, China. FAU - Xiang, Shulin AU - Xiang S AD - Department of Critical Care Medicine, The People's Hospital of Guangxi Zhuang Autonomous Region, Guangxi, China. FAU - Cheng, Zhou AU - Cheng Z AD - Department of anesthesiology, Zhongshan City People's Hospital, Guangdong, China. FAU - Cao, Peihua AU - Cao P AD - Department of Biostatistics, School of Public Health, Southern Medical University, Guangzhou, China. FAU - Jiang, Jie AU - Jiang J AD - Department of Critical Care Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, China. FAU - Chen, Yihao AU - Chen Y AD - Department of Critical Care Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, China. FAU - Yu, Duoduo AU - Yu D AD - Department of Critical Care Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, China. FAU - Liao, Wenzhan AU - Liao W AD - Department of Critical Care Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, China. FAU - Liao, Ye AU - Liao Y AD - Department of Critical Care Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, China. FAU - Cheng, Xiaoqin AU - Cheng X AD - Department of Critical Care Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, China. FAU - Chen, Limei AU - Chen L AD - Department of Critical Care Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, China. FAU - He, Yuxuan AU - He Y AD - Department of Critical Care Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, China. FAU - He, Jie AU - He J AD - Department of Critical Care Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, China. FAU - Guo, Qingling AU - Guo Q AD - Department of Critical Care Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, China. FAU - Yue, Zenghui AU - Yue Z AD - Department of Critical Care Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, China. FAU - Deng, Ke AU - Deng K AD - Department of Critical Care Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, China. FAU - Tang, Ying AU - Tang Y AD - Department of Critical Care Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, China. FAU - Huang, Bo AU - Huang B AD - Department of Critical Care Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, China. FAU - Liu, Cuiping AU - Liu C AD - Department of Critical Care Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, China. FAU - Peng, Sheng AU - Peng S AD - Department of Critical Care Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, China. FAU - Cai, Jing AU - Cai J AD - Department of Critical Care Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, China. FAU - Zhu, Yaru AU - Zhu Y AD - Department of Critical Care Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, China. FAU - Wang, Kai AU - Wang K AD - Department of Critical Care Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, China. FAU - Wang, Yangyang AU - Wang Y AD - Department of Critical Care Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, China. FAU - Wang, Qianwen AU - Wang Q AD - Department of Critical Care Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, China. FAU - Yang, Jingjing AU - Yang J AD - Department of Critical Care Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, China. FAU - Shichen, Maoyou AU - Shichen M AD - Department of Critical Care Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, China. FAU - Li, Zhuo AU - Li Z AD - Department of Critical Care Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, China. FAU - Guo, Manli AU - Guo M AD - Department of Critical Care Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, China. FAU - Luo, Xueshan AU - Luo X AD - Department of Critical Care Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, China. CN - Chinese Society of Extracorporeal Life Support (CSECLS) CN - Guangdong Province Restrictive Techniques (ECMO) Clinical Application Training Base LA - eng GR - 82472176/National Natural Science Foundation of China/ PT - Journal Article PT - Practice Guideline DEP - 20250729 PL - England TA - Crit Care JT - Critical care (London, England) JID - 9801902 SB - IM MH - Adult MH - Humans MH - China MH - *Extracorporeal Membrane Oxygenation/methods/standards/trends MH - *Heart Failure/therapy MH - *Wounds and Injuries/therapy/complications MH - Review Literature as Topic PMC - PMC12308958 OTO - NOTNLM OT - Adult OT - Evidence-based medicine OT - Extracorporeal membrane oxygenation OT - Wounds and injuries COIS- Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: All authors critically read and revised the manuscript, approved the final manuscript and agreed to be submitted it to the scientific journals for publication. Competing interests: The authors declare no competing interests. EDAT- 2025/07/30 00:31 MHDA- 2025/07/30 06:29 PMCR- 2025/07/29 CRDT- 2025/07/29 23:46 PHST- 2025/06/10 00:00 [received] PHST- 2025/06/14 00:00 [accepted] PHST- 2025/07/30 06:29 [medline] PHST- 2025/07/30 00:31 [pubmed] PHST- 2025/07/29 23:46 [entrez] PHST- 2025/07/29 00:00 [pmc-release] AID - 10.1186/s13054-025-05504-6 [pii] AID - 5504 [pii] AID - 10.1186/s13054-025-05504-6 [doi] PST - epublish SO - Crit Care. 2025 Jul 29;29(1):334. doi: 10.1186/s13054-025-05504-6. PMID- 40729660 OWN - NLM STAT- MEDLINE DCOM- 20250730 LR - 20260918 IS - 2369-3762 (Electronic) IS - 2369-3762 (Linking) VI - 11 DP - 2025 Jul 29 TI - Cardiac Implantable Electronic Device Educational Application for Cardiac Anesthesiology Trainees: Tutorial on App Development. PG - e60087 LID - 10.2196/60087 [doi] LID - e60087 AB - Despite the exposure of cardiothoracic anesthesiology trainees to patients with cardiac implantable electronic devices (CIEDs), there is a paucity of formal curricula on this subject. Major impediments to educating cardiothoracic anesthesiology trainees on CIEDs include busy clinical schedules, short staffing, inconsistent trainees' exposure to CIEDs, multiplicity of vendors, and a "millennial" mentality of the new generation of learners. As a result, cardiothoracic anesthesiology trainees graduating from their residency and fellowship programs may lack the competency to manage patients with CIEDs. Herein, we report our systematic approach to designing, validating, mapping, evaluating, and delivering a CIED curriculum on the first mobile app of its kind on this subject. Development of the CIED curriculum proceeded through the Kern 6-step approach of problem identification, determining and prioritizing content, writing goals and objectives, selecting instructional strategies, implementation of the material, and evaluation and applications of lessons learned. This was followed by the delivery of the curriculum in the form of a user-study app and administrator-type app with functionalities in the assessment of the learners' gains, experience, and satisfaction as well as the administrator's capability to update the educational content based on the feedback of the learners and the emerging technology. As such, the CIED app allows asynchronous learning at the pace of the learners and allows, through a multiplicity of educational materials, the ability to digest this complex and understudied subject. We report on the pilot phase of the project. We benefit from the experience of a multidisciplinary team of anesthesiologists, computer scientists, and educators in accomplishing this project. CI - (c) Ahmed Zaky, Aisha Waheed, Brittany Hatter, Srilakshmi Malempati, Sai Hemanth Maremalla, Ragib Hasan, Yuliang Zheng, Scott Snyder. Originally published in JMIR Medical Education (https://mededu.jmir.org). FAU - Zaky, Ahmed AU - Zaky A AUID- ORCID: 0000-0002-0548-6906 AD - Department of Anesthesiology and Perioperative Medicine, University of Alabama at Birmingham, 619 South 19th Street, JT 804, Birmingham, AL, 35249-6810, United States, 1 3522176319. FAU - Waheed, Aisha AU - Waheed A AUID- ORCID: 0009-0002-6212-3332 AD - Department of Internal Medicine, Princeton Baptist Health System, Birmingham, AL, United States. FAU - Hatter, Brittany AU - Hatter B AUID- ORCID: 0009-0000-4295-5049 AD - Department of Anesthesiology and Perioperative Medicine, University of Alabama at Birmingham, 619 South 19th Street, JT 804, Birmingham, AL, 35249-6810, United States, 1 3522176319. FAU - Malempati, Srilakshmi AU - Malempati S AUID- ORCID: 0009-0009-7909-6327 AD - Department of Computer Sciences, University of Alabama at Birmingham, Birmingham, AL, United States. FAU - Maremalla, Sai Hemanth AU - Maremalla SH AUID- ORCID: 0009-0002-0410-4133 AD - Department of Computer Sciences, University of Alabama at Birmingham, Birmingham, AL, United States. FAU - Hasan, Ragib AU - Hasan R AUID- ORCID: 0000-0001-5248-8341 AD - Department of Computer Sciences, University of Alabama at Birmingham, Birmingham, AL, United States. FAU - Zheng, Yuliang AU - Zheng Y AUID- ORCID: 0000-0002-9815-9727 AD - Department of Computer Sciences, University of Alabama at Birmingham, Birmingham, AL, United States. FAU - Snyder, Scott AU - Snyder S AUID- ORCID: 0000-0002-3903-9792 AD - Department of Education, University of Alabama at Birmingham, Birmingham, AL, United States. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20250729 PL - Canada TA - JMIR Med Educ JT - JMIR medical education JID - 101684518 SB - IM MH - Humans MH - *Mobile Applications MH - *Anesthesiology/education MH - Curriculum MH - Internship and Residency MH - *Defibrillators, Implantable MH - *Pacemaker, Artificial MH - Clinical Competence PMC - PMC12306915 OTO - NOTNLM OT - anesthesiology OT - anesthesiology trainees OT - app OT - application OT - assessment OT - cardiac OT - cardiac implantable OT - cardiothoracic anesthesiology OT - curriculum OT - education OT - electronic device OT - medical education OT - mobile OT - pacemakers OT - rhythm devices OT - technology OT - trainee COIS- Conflicts of Interest: None declared. EDAT- 2025/07/29 18:30 MHDA- 2025/07/30 06:29 PMCR- 2025/07/29 CRDT- 2025/07/29 16:33 PHST- 2024/05/04 00:00 [received] PHST- 2025/02/17 00:00 [revised] PHST- 2025/04/19 00:00 [accepted] PHST- 2025/07/30 06:29 [medline] PHST- 2025/07/29 18:30 [pubmed] PHST- 2025/07/29 16:33 [entrez] PHST- 2025/07/29 00:00 [pmc-release] AID - v11i1e60087 [pii] AID - 60087 [pii] AID - 10.2196/60087 [doi] PST - epublish SO - JMIR Med Educ. 2025 Jul 29;11:e60087. doi: 10.2196/60087. PMID- 40728215 OWN - NLM STAT- MEDLINE DCOM- 20260624 LR - 20260624 IS - 1538-943X (Electronic) IS - 1058-2916 (Linking) VI - 72 IP - 7 DP - 2026 Jul 1 TI - Global Survey of Extracorporeal Membrane Oxygenation Transport Programs: Variability in Team Composition, Training, and Capabilities. PG - 570-576 LID - 10.1097/MAT.0000000000002515 [doi] AB - Extracorporeal membrane oxygenation (ECMO) is a form of cardiopulmonary support associated with improved survival in severe respiratory failure and refractory cardiac arrest. Extracorporeal membrane oxygenation is highly specialized and resource-intensive; high-volume ECMO centers demonstrate improved outcomes, supporting the creation of regionalized care models. As such, the role of critical care transport medicine (CCTM) is vital. Given limited prior analysis, we aimed to descriptively review ECMO transport processes globally. A 27 item survey addressing team composition, training, and transport capabilities was distributed to 16 transport organizations in eight countries. If available, ECMO transport protocols were reviewed. Fourteen ECMO programs responded from six countries (87.5% response rate). Most programs (78.6%) offer ground, 71.4% offer rotary-wing, and 50% offer fixed-wing transport. A minority (28.6%) provided all transport modes. Nearly half (42.9%) of programs did not require a separate ECMO team. A physician was present in 57.1% and a perfusionist/ECMO specialists in 71.4% of transport teams, respectively. All programs required initial team ECMO training. Critical care transport medicine teams are essential for enabling ECMO access. There is significant variability in team composition, capabilities, and transport modality, but training requirements are seen across programs. Further study should align best practices for interfacility transport of ECMO patients. CI - Copyright (c) ASAIO 2025. FAU - Gottula, Adam L AU - Gottula AL AD - From the Center for Resuscitation Medicine, University of Minnesota, Minneapolis, Minnesota. AD - Division of Critical Care, Department of Anesthesiology, University of Minnesota, Minneapolis, Minnesota. AD - Department of Emergency Medicine, University of Minnesota, Minneapolis, Minnesota. AD - Department of Emergency Medicine, University of Michigan, Ann Arbor, Michigan. AD - Institute for Extracorporeal Life Support, San Antonio, Texas. AD - The Weil Institute for Critical Care Research and Innovation, Ann Arbor, Michigan. FAU - Gillespie, Lauren AU - Gillespie L AD - Department of Emergency Medicine, University of Michigan, Ann Arbor, Michigan. AD - Department of Emergency Medicine, University of Cincinnati, Cincinnati, Ohio. AD - Air Care & Mobile Care, UC Health, Cincinnati, Ohio. FAU - Lauria, Michael AU - Lauria M AD - Sections of Critical Care and EMS, Resuscitation Engineering Science Unit (RESCU) Research Center, Department of Emergency Medicine, University of Washington, Seattle, Washington. AD - USAF Reserve, 624th Aeromedical Staging Squadron, Critical Care Air Transport Team, Joint Base Pearl Harbor Hickam, Hawaii. FAU - Shaw, Christopher R AU - Shaw CR AD - Division of Critical Care, Department of Emergency Medicine, Oregon Health and Science University, Portland, Oregon. FAU - Purington, Ella AU - Purington E AD - Department of Emergency Medicine, University of Michigan, Ann Arbor, Michigan. FAU - Bernardoni, Brittney AU - Bernardoni B AD - Division of Critical Care and Pre-hospital Medicine, Department of Emergency Medicine, University of Wisconsin, Madison, Wisconsin. AD - UW Med Flight, Madison, Wisconsin. AD - Division of Critical Care, Department of Anesthesiology, University of Wisconsin, Madison, Wisconsin. FAU - Cathers, Andrew AU - Cathers A AD - Division of Critical Care and Pre-hospital Medicine, Department of Emergency Medicine, University of Wisconsin, Madison, Wisconsin. AD - UW Med Flight, Madison, Wisconsin. FAU - Kolbet, Kolby AU - Kolbet K AD - Life Link III, Minneapolis, Minnesota. FAU - Rudolph, Marcus AU - Rudolph M AD - DRF Stiftung Luftrettung, Filderstadt, Germany. FAU - Lucchini, Alberto AU - Lucchini A AD - Fondazione IRCCS San Gerardo Hospital, Monza, Italy. FAU - Bredmose, Per AU - Bredmose P AD - Oslo HEMS, Oslo, Norway. FAU - Frakes, Michael AU - Frakes M AD - Boston MedFlight, Boston, Massachusetts. FAU - Badulak, Jenelle AU - Badulak J AD - Airlift Northwest, University of Washington, Seattle, Washington. FAU - Danielson, Kyle AU - Danielson K AD - Airlift Northwest, University of Washington, Seattle, Washington. FAU - Vogelsong, Melissa Ann AU - Vogelsong MA AD - Department of Anesthesiology, Stanford Life Flight, Stanford University, Stanford, California. FAU - Miranda, Dinis Reis AU - Miranda DR AD - HEMS, Amsterdam, the Netherlands. FAU - Imbriaco, Guglielmo AU - Imbriaco G AD - Emilia Est Emergency Medical Communication Center, Maggiore Hospital, Bologna, Italy. FAU - DellaVolpe, Jeffrey D AU - DellaVolpe JD AD - Institute for Extracorporeal Life Support, San Antonio, Texas. FAU - Hinckley, William R AU - Hinckley WR AD - Department of Emergency Medicine, University of Cincinnati, Cincinnati, Ohio. AD - Air Care & Mobile Care, UC Health, Cincinnati, Ohio. FAU - Burns, Brian AU - Burns B AD - Aeromedical Operations, NSW Ambulance, Sydney, New South Wales, Australia. AD - Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia. FAU - Bartos, Jason A AU - Bartos JA AD - From the Center for Resuscitation Medicine, University of Minnesota, Minneapolis, Minnesota. AD - Division of Cardiology, Department of Medicine, University of Minnesota, Minneapolis, Minnesota. FAU - Hsu, Cindy H AU - Hsu CH AD - Department of Emergency Medicine, University of Michigan, Ann Arbor, Michigan. AD - The Weil Institute for Critical Care Research and Innovation, Ann Arbor, Michigan. FAU - Brent, Christine AU - Brent C AD - Department of Emergency Medicine, University of Michigan, Ann Arbor, Michigan. AD - The Weil Institute for Critical Care Research and Innovation, Ann Arbor, Michigan. FAU - Lane, Bennett H AU - Lane BH AD - Department of Emergency Medicine, University of Cincinnati, Cincinnati, Ohio. AD - Air Care & Mobile Care, UC Health, Cincinnati, Ohio. LA - eng PT - Journal Article DEP - 20250729 PL - United States TA - ASAIO J JT - ASAIO journal (American Society for Artificial Internal Organs : 1992) JID - 9204109 SB - IM MH - *Extracorporeal Membrane Oxygenation/education/statistics & numerical data MH - Humans MH - *Transportation of Patients MH - *Patient Care Team MH - Critical Care MH - Surveys and Questionnaires OTO - NOTNLM OT - air ambulance OT - critical care transport medicine OT - extracorporeal membrane oxygenation OT - patient transfer COIS- Disclosure: A.L.G. and M.L. report receiving consulting fees from Abiomed. B.B. reports receiving consulting fees from Flight Bridge ED. B.H.L. reports receiving consulting fees, holding equity interest in TriAxia Health. The other authors have no conflicts of interest to report. EDAT- 2025/07/29 12:31 MHDA- 2026/06/24 18:35 CRDT- 2025/07/29 08:05 PHST- 2026/06/24 18:35 [medline] PHST- 2025/07/29 12:31 [pubmed] PHST- 2025/07/29 08:05 [entrez] AID - 00002480-990000000-00759 [pii] AID - 10.1097/MAT.0000000000002515 [doi] PST - ppublish SO - ASAIO J. 2026 Jul 1;72(7):570-576. doi: 10.1097/MAT.0000000000002515. Epub 2025 Jul 29. PMID- 40725701 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250801 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 14 IP - 14 DP - 2025 Jul 15 TI - Tricuspid Regurgitation in the Era of Transcatheter Interventions: The Pivotal Role of Multimodality Imaging. LID - 10.3390/jcm14145011 [doi] LID - 5011 AB - Over the last ten years, transcatheter tricuspid valve interventions (TTVIs) have emerged as effective options for symptomatic patients with moderate-to-severe tricuspid regurgitation (TR) who are at prohibitive surgical risk. Successful application of these therapies depends on a patient-tailored, multimodal imaging workflow. Transthoracic and transesophageal echocardiography remain the first-line diagnostic tools, rapidly stratifying TR severity, mechanism, and right ventricular function, and identifying cases requiring further evaluation. Cardiac computed tomography (CT) then provides anatomical detail-quantifying tricuspid annular dimension, leaflet tethering, coronary artery course, and venous access anatomy-to refine candidacy and simulate optimal device sizing and implantation angles. In patients with suboptimal echocardiographic windows or equivocal functional data, cardiovascular magnetic resonance (CMR) offers gold-standard quantification of RV volumes, ejection fraction, regurgitant volume, and tissue characterization to detect fibrosis. Integration of echo-derived parameters, CT anatomical notes, and CMR functional assessment enables the heart team to better select patients, plan procedures, and determine the optimal timing, thereby maximizing procedural success and minimizing complications. This review describes the current strengths, limitations, and future directions of multimodality imaging in comprehensive evaluations of TTVI candidates. FAU - De Luca, Valeria Maria AU - De Luca VM AUID- ORCID: 0009-0005-3276-3373 AD - GVM Care & Research, Maria Cecilia Hospital, 48033 Cotignola, Italy. AD - Department of Cardiology, University Medical Center Mainz, 55131 Mainz, Germany. FAU - Censi, Stefano AU - Censi S AUID- ORCID: 0000-0002-9893-3508 AD - GVM Care & Research, Maria Cecilia Hospital, 48033 Cotignola, Italy. FAU - Conti, Rita AU - Conti R AD - GVM Care & Research, Maria Cecilia Hospital, 48033 Cotignola, Italy. FAU - Nerla, Roberto AU - Nerla R AD - GVM Care & Research, Maria Cecilia Hospital, 48033 Cotignola, Italy. FAU - Bombace, Sara AU - Bombace S AD - Department of Cardiology, University Medical Center Mainz, 55131 Mainz, Germany. FAU - Ruf, Tobias Friedrich AU - Ruf TF AUID- ORCID: 0000-0003-4540-6621 AD - Department of Cardiology, University Medical Center Mainz, 55131 Mainz, Germany. FAU - von Bardeleben, Ralph Stephan AU - von Bardeleben RS AUID- ORCID: 0000-0002-1356-0037 AD - Department of Cardiology, University Medical Center Mainz, 55131 Mainz, Germany. FAU - Lurz, Philipp AU - Lurz P AD - Department of Cardiology, University Medical Center Mainz, 55131 Mainz, Germany. FAU - Castriota, Fausto AU - Castriota F AD - GVM Care & Research, Maria Cecilia Hospital, 48033 Cotignola, Italy. FAU - Squeri, Angelo AU - Squeri A AUID- ORCID: 0000-0001-9115-5443 AD - GVM Care & Research, Maria Cecilia Hospital, 48033 Cotignola, Italy. LA - eng PT - Journal Article PT - Review DEP - 20250715 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC12295391 OTO - NOTNLM OT - multimodality imaging OT - transcatheter tricuspid valve interventions OT - tricuspid regurgitation OT - tricuspid valve disease COIS- The authors declare no conflicts of interest. EDAT- 2025/07/29 06:30 MHDA- 2025/07/29 06:31 PMCR- 2025/07/15 CRDT- 2025/07/29 01:17 PHST- 2025/05/30 00:00 [received] PHST- 2025/07/02 00:00 [revised] PHST- 2025/07/11 00:00 [accepted] PHST- 2025/07/29 06:31 [medline] PHST- 2025/07/29 06:30 [pubmed] PHST- 2025/07/29 01:17 [entrez] PHST- 2025/07/15 00:00 [pmc-release] AID - jcm14145011 [pii] AID - jcm-14-05011 [pii] AID - 10.3390/jcm14145011 [doi] PST - epublish SO - J Clin Med. 2025 Jul 15;14(14):5011. doi: 10.3390/jcm14145011. PMID- 40725670 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250801 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 14 IP - 14 DP - 2025 Jul 14 TI - Sailing Across Contraception, Pregnancy, and Breastfeeding: The Complex Journey of Women with Cardiomyopathies. LID - 10.3390/jcm14144977 [doi] LID - 4977 AB - Gender-specific cardiology has gained increasing recognition in recent years, emphasizing the need for tailored management strategies for women with cardiovascular disease. Among these, cardiomyopathies-dilated, arrhythmogenic, hypertrophic, and restrictive-pose unique challenges throughout a woman's reproductive life, affecting contraception choices, pregnancy outcomes, and breastfeeding feasibility. Despite significant advances in cardiovascular care, there is still limited guidance on balancing maternal safety and neonatal well-being in this complex setting. This review provides a comprehensive overview of the current evidence on reproductive counseling, pregnancy management, and postpartum considerations in women with cardiomyopathies. We discuss the cardiovascular risks associated with each cardiomyopathy subtype during pregnancy, highlighting risk stratification tools and emerging therapeutic strategies. Additionally, we address the safety and implications of breastfeeding, an often overlooked but increasingly relevant aspect of postpartum care. A multidisciplinary approach involving cardiologists, gynecologists, obstetricians, and anesthesiologists is crucial to optimizing maternal and fetal outcomes. Improved risk assessment, tailored patient counseling, and careful management strategies are essential to ensuring safer reproductive choices for women with cardiomyopathy. From now on, greater attention is expected to be given to bridging existing knowledge gaps, promoting a more personalized and evidence-based approach to managing these patients throughout different stages of reproductive life. FAU - Carella, Maria Cristina AU - Carella MC AUID- ORCID: 0000-0002-5094-2237 AD - Cardiology Unit, Department of Interdisciplinary Medicine (DIM), University of Bari "Aldo Moro", University Hospital Consortium Polyclinic of Bari, 70124 Bari, Italy. AD - Internal Medicine Section, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari "Aldo Moro", University Hospital Consortium Polyclinic of Bari, 70124 Bari, Italy. FAU - Santobuono, Vincenzo Ezio AU - Santobuono VE AUID- ORCID: 0000-0002-8746-729X AD - Cardiology Unit, Department of Interdisciplinary Medicine (DIM), University of Bari "Aldo Moro", University Hospital Consortium Polyclinic of Bari, 70124 Bari, Italy. FAU - Grosso, Francesca Maria AU - Grosso FM AD - Internal Medicine Section, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari "Aldo Moro", University Hospital Consortium Polyclinic of Bari, 70124 Bari, Italy. AD - Functional Department of Prevention, ASST Fatebenefratelli Sacco, 20133 Milan, Italy. FAU - Dicorato, Marco Maria AU - Dicorato MM AUID- ORCID: 0009-0008-4865-2522 AD - Cardiology Unit, Department of Interdisciplinary Medicine (DIM), University of Bari "Aldo Moro", University Hospital Consortium Polyclinic of Bari, 70124 Bari, Italy. FAU - Basile, Paolo AU - Basile P AUID- ORCID: 0000-0002-2327-7585 AD - Cardiology Unit, Department of Interdisciplinary Medicine (DIM), University of Bari "Aldo Moro", University Hospital Consortium Polyclinic of Bari, 70124 Bari, Italy. AD - Internal Medicine Section, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari "Aldo Moro", University Hospital Consortium Polyclinic of Bari, 70124 Bari, Italy. FAU - Dentamaro, Ilaria AU - Dentamaro I AD - Cardiology Unit, Department of Interdisciplinary Medicine (DIM), University of Bari "Aldo Moro", University Hospital Consortium Polyclinic of Bari, 70124 Bari, Italy. FAU - Naccarati, Maria Ludovica AU - Naccarati ML AD - Cardiology Unit, Department of Interdisciplinary Medicine (DIM), University of Bari "Aldo Moro", University Hospital Consortium Polyclinic of Bari, 70124 Bari, Italy. FAU - Santoro, Daniela AU - Santoro D AUID- ORCID: 0000-0002-0506-560X AD - Cardiology Unit, Department of Interdisciplinary Medicine (DIM), University of Bari "Aldo Moro", University Hospital Consortium Polyclinic of Bari, 70124 Bari, Italy. FAU - Monitillo, Francesco AU - Monitillo F AUID- ORCID: 0000-0002-8327-1468 AD - Cardiology Unit, Department of Interdisciplinary Medicine (DIM), University of Bari "Aldo Moro", University Hospital Consortium Polyclinic of Bari, 70124 Bari, Italy. FAU - Valecce, Rosanna AU - Valecce R AD - UOC Cardiologia, Ospedale Di Venere, Asl Bari, 70124 Bari, Italy. FAU - Ruggieri, Roberta AU - Ruggieri R AD - UOC Cardiologia, Ospedale Di Venere, Asl Bari, 70124 Bari, Italy. FAU - Agea, Aldo AU - Agea A AD - Cardiology Unit, Department of Interdisciplinary Medicine (DIM), University of Bari "Aldo Moro", University Hospital Consortium Polyclinic of Bari, 70124 Bari, Italy. FAU - Pepe, Martino AU - Pepe M AD - Cardiology Unit, Department of Interdisciplinary Medicine (DIM), University of Bari "Aldo Moro", University Hospital Consortium Polyclinic of Bari, 70124 Bari, Italy. FAU - Pontone, Gianluca AU - Pontone G AD - Department of Perioperative Cardiology and Cardiovascular Imaging, Centro Cardiologico Monzino IRCCS, 20133 Milan, Italy. AD - Department of Biomedical, Surgical and Dental Sciences, University of Milan, 20133 Milan, Italy. FAU - Vimercati, Antonella AU - Vimercati A AUID- ORCID: 0000-0002-9862-1619 AD - Unit of Obstetrics and Gynecology, Department of Interdisciplinary Medicine (DIM), University of Bari "Aldo Moro", University Hospital Consortium Polyclinic of Bari, 70124 Bari, Italy. FAU - Cicinelli, Ettore AU - Cicinelli E AUID- ORCID: 0000-0003-2390-4582 AD - Unit of Obstetrics and Gynecology, Department of Interdisciplinary Medicine (DIM), University of Bari "Aldo Moro", University Hospital Consortium Polyclinic of Bari, 70124 Bari, Italy. FAU - Laforgia, Nicola AU - Laforgia N AUID- ORCID: 0000-0002-4610-1216 AD - Neonatology and Neonatal Intensive Care Unit, Department of Interdisciplinary Medicine (DIM), University of Bari "Aldo Moro", University Hospital Consortium Polyclinic of Bari, 70124 Bari, Italy. FAU - Resta, Nicoletta AU - Resta N AUID- ORCID: 0000-0001-8640-5532 AD - Medical Genetics Unit, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari "Aldo Moro", University Hospital Consortium Polyclinic of Bari, 70124 Bari, Italy. FAU - Guaricci, Andrea Igoren AU - Guaricci AI AUID- ORCID: 0000-0001-7133-4401 AD - Cardiology Unit, Department of Interdisciplinary Medicine (DIM), University of Bari "Aldo Moro", University Hospital Consortium Polyclinic of Bari, 70124 Bari, Italy. FAU - Ciccone, Marco Matteo AU - Ciccone MM AD - Cardiology Unit, Department of Interdisciplinary Medicine (DIM), University of Bari "Aldo Moro", University Hospital Consortium Polyclinic of Bari, 70124 Bari, Italy. FAU - Forleo, Cinzia AU - Forleo C AUID- ORCID: 0000-0002-9452-4037 AD - Cardiology Unit, Department of Interdisciplinary Medicine (DIM), University of Bari "Aldo Moro", University Hospital Consortium Polyclinic of Bari, 70124 Bari, Italy. LA - eng PT - Journal Article PT - Review DEP - 20250714 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC12295082 OTO - NOTNLM OT - breastfeeding OT - cardiomyopathy OT - gender differences OT - gynecology OT - lactation OT - neonatology OT - obstetrics OT - pregnancy OT - reproductive health OT - sexual health OT - women's health COIS- The authors declare no conflicts of interest. EDAT- 2025/07/29 06:30 MHDA- 2025/07/29 06:31 PMCR- 2025/07/14 CRDT- 2025/07/29 01:17 PHST- 2025/06/01 00:00 [received] PHST- 2025/07/04 00:00 [revised] PHST- 2025/07/08 00:00 [accepted] PHST- 2025/07/29 06:31 [medline] PHST- 2025/07/29 06:30 [pubmed] PHST- 2025/07/29 01:17 [entrez] PHST- 2025/07/14 00:00 [pmc-release] AID - jcm14144977 [pii] AID - jcm-14-04977 [pii] AID - 10.3390/jcm14144977 [doi] PST - epublish SO - J Clin Med. 2025 Jul 14;14(14):4977. doi: 10.3390/jcm14144977. PMID- 40725641 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250801 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 14 IP - 14 DP - 2025 Jul 12 TI - Aortic Stenosis: Diagnosis, Molecular Mechanisms and Therapeutic Strategies-A Comprehensive Review. LID - 10.3390/jcm14144949 [doi] LID - 4949 AB - Aortic stenosis (AS) is a progressive valvular heart disease marked by a restriction of blood flow through the aortic valve, resulting in considerable morbidity and mortality if not addressed. AS has historically been managed through surgical aortic valve replacement (SAVR), but there is a growing trend towards the use of transcatheter aortic valve replacement (TAVR). TAVR has transformed the management of symptomatic severe AS and is currently authorized for patients with varying levels of surgical risk. The rising application of TAVR in patients under 65 years presents a challenge for heart valve teams (HVTs) managing younger individuals whose life expectancy may surpass the durability of the valve. Patients over 65 years are typically treated with bioprosthetic tissue valves; however, there remains significant uncertainty regarding the selection between TAVR and SAVR. FAU - Banceu, Cosmin Marian AU - Banceu CM AUID- ORCID: 0000-0002-4415-4357 AD - Department ME 2, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540139 Targu Mures, Romania. AD - Emergency Institute for Cardiovascular Diseases and Transplantation Targu Mures, 540136 Targu Mures, Romania. FAU - Cristutiu, Daiana AU - Cristutiu D AD - Emergency Institute for Cardiovascular Diseases and Transplantation Targu Mures, 540136 Targu Mures, Romania. FAU - Gurzu, Simona AU - Gurzu S AUID- ORCID: 0000-0003-3968-5118 AD - Department of Pathology, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540139 Targu Mures, Romania. AD - Research Center for Oncopathology and Translational Medicine (CCOMT), George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540142 Targu Mures, Romania. FAU - Harpa, Marius Mihai AU - Harpa MM AUID- ORCID: 0000-0002-9044-8866 AD - Emergency Institute for Cardiovascular Diseases and Transplantation Targu Mures, 540136 Targu Mures, Romania. AD - Department M 3, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540139 Targu Mures, Romania. FAU - Banceu, Diana AU - Banceu D AD - Organizing Institution for Doctoral University Studies, West University of Timisoara, 300223 Timisoara, Romania. FAU - Suciu, Horatiu AU - Suciu H AD - Department ME 2, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540139 Targu Mures, Romania. AD - Department M 3, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540139 Targu Mures, Romania. LA - eng PT - Journal Article PT - Review DEP - 20250712 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC12295745 OTO - NOTNLM OT - SAVR OT - TAVR OT - aortic stenosis OT - heart team strategy OT - individual risk profiles COIS- The authors declare no conflicts of interest. EDAT- 2025/07/29 06:29 MHDA- 2025/07/29 06:30 PMCR- 2025/07/12 CRDT- 2025/07/29 01:17 PHST- 2025/05/25 00:00 [received] PHST- 2025/07/04 00:00 [revised] PHST- 2025/07/10 00:00 [accepted] PHST- 2025/07/29 06:30 [medline] PHST- 2025/07/29 06:29 [pubmed] PHST- 2025/07/29 01:17 [entrez] PHST- 2025/07/12 00:00 [pmc-release] AID - jcm14144949 [pii] AID - jcm-14-04949 [pii] AID - 10.3390/jcm14144949 [doi] PST - epublish SO - J Clin Med. 2025 Jul 12;14(14):4949. doi: 10.3390/jcm14144949. PMID- 40725634 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250801 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 14 IP - 14 DP - 2025 Jul 12 TI - Prevalence of Healthcare-Associated Infections in Patients with Cardiovascular Diseases: A Literature Review. LID - 10.3390/jcm14144941 [doi] LID - 4941 AB - This review aims to summarize the global prevalence of healthcare-associated infections in patients with acute heart failure who have been admitted to coronary care units, highlighting the underrepresented burden of infection in this high-risk population. Coronary care units (CCUs) play a pivotal role in the care of patients experiencing acute or decompensated heart failure, offering a highly monitored environment with immediate access to advanced cardiac interventions. The management of heart failure in CCUs involves a multidisciplinary approach that includes hemodynamic monitoring, pharmacologic therapy, respiratory support, and, in selected cases, mechanical circulatory assistance. The early identification of deterioration, rapid therapeutic escalation, and close monitoring of cardiac function are hallmarks of CCU care. However, the complexity and severity of illness in this population are compounded by a high risk of infections, including hospital-acquired pneumonia, bloodstream infections, and device-related infections. These infections not only increase morbidity and prolong hospitalization but also significantly impact mortality and healthcare costs. The immunocompromised state of many heart failure patients-due to poor perfusion, malnutrition, and the use of invasive devices-further elevates their vulnerability. Effective infection prevention, early diagnosis, and targeted antimicrobial therapy are, therefore, critical components of heart failure management within CCUs. This intersection of advanced cardiac care and infection control highlights the need for integrated, multidisciplinary strategies to improve outcomes in this high-risk population. FAU - Virtosu, Daniela-Mirela AU - Virtosu DM AD - Doctoral School, "Victor Babes" University of Medicine and Pharmacy, 300041 Timisoara, Romania. AD - Institute of Cardiovascular Diseases Timisoara, 13A Gheorghe Adam Street, 300310 Timisoara, Romania. AD - Research Center of the Institute of Cardiovascular Diseases Timisoara, 13A Gheorghe Adam Street, 300310 Timisoara, Romania. FAU - Munteanu Dragomir, Angela AU - Munteanu Dragomir A AD - Institute of Cardiovascular Diseases Timisoara, 13A Gheorghe Adam Street, 300310 Timisoara, Romania. FAU - Crisan, Simina AU - Crisan S AD - Institute of Cardiovascular Diseases Timisoara, 13A Gheorghe Adam Street, 300310 Timisoara, Romania. AD - Research Center of the Institute of Cardiovascular Diseases Timisoara, 13A Gheorghe Adam Street, 300310 Timisoara, Romania. AD - Cardiology Department, "Victor Babes" University of Medicine and Pharmacy, 2 Eftimie Murgu Sq., 300041 Timisoara, Romania. FAU - Luca, Silvia AU - Luca S AD - Doctoral School, "Victor Babes" University of Medicine and Pharmacy, 300041 Timisoara, Romania. AD - Institute of Cardiovascular Diseases Timisoara, 13A Gheorghe Adam Street, 300310 Timisoara, Romania. AD - Research Center of the Institute of Cardiovascular Diseases Timisoara, 13A Gheorghe Adam Street, 300310 Timisoara, Romania. AD - Cardiology Department, "Victor Babes" University of Medicine and Pharmacy, 2 Eftimie Murgu Sq., 300041 Timisoara, Romania. FAU - Patru, Oana AU - Patru O AD - Doctoral School, "Victor Babes" University of Medicine and Pharmacy, 300041 Timisoara, Romania. AD - Research Center of the Institute of Cardiovascular Diseases Timisoara, 13A Gheorghe Adam Street, 300310 Timisoara, Romania. AD - Cardiology Department, "Victor Babes" University of Medicine and Pharmacy, 2 Eftimie Murgu Sq., 300041 Timisoara, Romania. FAU - Baghina, Ruxandra-Maria AU - Baghina RM AUID- ORCID: 0009-0000-7681-4308 AD - Doctoral School, "Victor Babes" University of Medicine and Pharmacy, 300041 Timisoara, Romania. AD - Institute of Cardiovascular Diseases Timisoara, 13A Gheorghe Adam Street, 300310 Timisoara, Romania. AD - Research Center of the Institute of Cardiovascular Diseases Timisoara, 13A Gheorghe Adam Street, 300310 Timisoara, Romania. FAU - Lazar, Mihai-Andrei AU - Lazar MA AD - Institute of Cardiovascular Diseases Timisoara, 13A Gheorghe Adam Street, 300310 Timisoara, Romania. AD - Research Center of the Institute of Cardiovascular Diseases Timisoara, 13A Gheorghe Adam Street, 300310 Timisoara, Romania. AD - Cardiology Department, "Victor Babes" University of Medicine and Pharmacy, 2 Eftimie Murgu Sq., 300041 Timisoara, Romania. FAU - Cozlac, Alina-Ramona AU - Cozlac AR AD - Institute of Cardiovascular Diseases Timisoara, 13A Gheorghe Adam Street, 300310 Timisoara, Romania. FAU - Iurciuc, Stela AU - Iurciuc S AD - Cardiology Department, "Victor Babes" University of Medicine and Pharmacy, 2 Eftimie Murgu Sq., 300041 Timisoara, Romania. FAU - Luca, Constantin-Tudor AU - Luca CT AD - Institute of Cardiovascular Diseases Timisoara, 13A Gheorghe Adam Street, 300310 Timisoara, Romania. AD - Research Center of the Institute of Cardiovascular Diseases Timisoara, 13A Gheorghe Adam Street, 300310 Timisoara, Romania. AD - Cardiology Department, "Victor Babes" University of Medicine and Pharmacy, 2 Eftimie Murgu Sq., 300041 Timisoara, Romania. LA - eng PT - Journal Article PT - Review DEP - 20250712 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC12294981 OTO - NOTNLM OT - coronary care units OT - heart failure OT - infection COIS- The authors declare no conflicts of interest. EDAT- 2025/07/29 06:30 MHDA- 2025/07/29 06:31 PMCR- 2025/07/12 CRDT- 2025/07/29 01:17 PHST- 2025/05/26 00:00 [received] PHST- 2025/07/03 00:00 [revised] PHST- 2025/07/09 00:00 [accepted] PHST- 2025/07/29 06:31 [medline] PHST- 2025/07/29 06:30 [pubmed] PHST- 2025/07/29 01:17 [entrez] PHST- 2025/07/12 00:00 [pmc-release] AID - jcm14144941 [pii] AID - jcm-14-04941 [pii] AID - 10.3390/jcm14144941 [doi] PST - epublish SO - J Clin Med. 2025 Jul 12;14(14):4941. doi: 10.3390/jcm14144941. PMID- 40725594 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250801 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 14 IP - 14 DP - 2025 Jul 10 TI - Screening and Procedural Guidance for Mitral Transcatheter Edge-to-Edge Repair (M-TEER). LID - 10.3390/jcm14144902 [doi] LID - 4902 AB - Mitral regurgitation (MR) is a common valvular heart disease associated with significant morbidity and mortality. For patients at high or prohibitive surgical risk, mitral transcatheter edge-to-edge repair (M-TEER) offers a less invasive alternative to surgery. This review outlines key aspects of patient selection and procedural planning for M-TEER, with a focus on clinical and echocardiographic criteria essential for success. Comprehensive imaging-especially 2D and 3D transesophageal echocardiography-is critical to assess leaflet anatomy, coaptation geometry, and mitral valve area. Selection criteria differ between primary and secondary MR and are guided by trials such as COAPT and MITRA-FR. Optimal outcomes rely on careful screening, anatomical suitability, and multidisciplinary evaluation. With growing experience and advancing technology, M-TEER has become a transformative option for treating severe MR in non-surgical candidates. FAU - Zygouri, Andromahi AU - Zygouri A AUID- ORCID: 0000-0002-6424-0287 AD - Cardiology Department, Universite of Rennes, CHU Rennes, Inserm, LTSI-UMR 1099, F-35000 Rennes, France. FAU - Rasmeehirun, Prayuth AU - Rasmeehirun P AUID- ORCID: 0009-0004-5478-4610 AD - Cardiology Department, Universite of Rennes, CHU Rennes, Inserm, LTSI-UMR 1099, F-35000 Rennes, France. FAU - L'Official, Guillaume AU - L'Official G AUID- ORCID: 0000-0002-6379-0156 AD - Cardiology Department, Universite of Rennes, CHU Rennes, Inserm, LTSI-UMR 1099, F-35000 Rennes, France. FAU - Papadopoulos, Konstantinos AU - Papadopoulos K AUID- ORCID: 0000-0001-7356-2379 AD - Echocardiography Laboratory, European Interbalkan Medical Center, 57001 Thessaloniki, Greece. FAU - Ikonomidis, Ignatios AU - Ikonomidis I AUID- ORCID: 0000-0001-8241-7886 AD - Echocardiography Laboratory, 2nd Cardiology Department, Medical School, National and Kapodistrian University of Athens, Attikon University Hospital, 12462 Athens, Greece. FAU - Donal, Erwan AU - Donal E AUID- ORCID: 0000-0003-2677-3389 AD - Cardiology Department, Universite of Rennes, CHU Rennes, Inserm, LTSI-UMR 1099, F-35000 Rennes, France. LA - eng PT - Journal Article PT - Review DEP - 20250710 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC12295293 OTO - NOTNLM OT - MitraClip OT - TEER OT - mitral regurgitation OT - structural heart diseases OT - transcatheter edge-to-edge repair OT - transcatheter interventions OT - valvulopathies COIS- The authors declare no conflicts of interest. EDAT- 2025/07/29 06:30 MHDA- 2025/07/29 06:31 PMCR- 2025/07/10 CRDT- 2025/07/29 01:17 PHST- 2025/05/26 00:00 [received] PHST- 2025/07/04 00:00 [revised] PHST- 2025/07/06 00:00 [accepted] PHST- 2025/07/29 06:31 [medline] PHST- 2025/07/29 06:30 [pubmed] PHST- 2025/07/29 01:17 [entrez] PHST- 2025/07/10 00:00 [pmc-release] AID - jcm14144902 [pii] AID - jcm-14-04902 [pii] AID - 10.3390/jcm14144902 [doi] PST - epublish SO - J Clin Med. 2025 Jul 10;14(14):4902. doi: 10.3390/jcm14144902. PMID- 40723990 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250801 IS - 2079-6382 (Print) IS - 2079-6382 (Electronic) IS - 2079-6382 (Linking) VI - 14 IP - 7 DP - 2025 Jul 7 TI - Should Microhematuria Be Incorporated into the 2023 Duke-International Society for Cardiovascular Infectious Diseases Minor Immunological Criteria? LID - 10.3390/antibiotics14070687 [doi] LID - 687 AB - Background/Objectives: Microhematuria is common in patients with infective endocarditis (IE). The present study aims to assess whether the addition of microhematuria in the 2023 Duke-International Society for Cardiovascular Infectious Diseases (ISCVID) minor immunological criteria could enhance its diagnostic performance. Methods: This retrospective study was conducted at the Lausanne University Hospital, Switzerland (2014-2024). All patients with suspected IE and urinalysis within 24 h from presentation were included. The Endocarditis Team classified episodes as IE or non-IE. Microhematuria was defined as >5 red blood cells per high power field (HPF). Results: Among 801 episodes with suspected IE, 263 (33%) were diagnosed with IE. Microhematuria (>5/HPF) was present in 462 (58%) episodes, with no difference between episodes with and without confirmed IE (61% versus 56%; p = 0.223). Based on the 2023 ISCVID-Duke, minor immunological criteria were present in 42 episodes (5%). By adding microhematuria, 473 (59%) episodes met the minor immunological criteria. Sensitivity of the clinical criteria of the 2023 ISCVID-Duke version without and with hematuria was calculated at 75% (69-80%) and 86% (81-90%), respectively. Specificity was at 52% (48-57%) and 40% (36-45%), respectively. Among episodes with suspected IE, microhematuria was associated with female sex, enterococcal bacteremia, sepsis or septic shock, acute kidney injury, non-cerebral embolic events, and bone and joint infection. Conclusions: Microhematuria was frequent among patients with suspected IE, but it was not associated with the diagnosis of IE. The addition of microhematuria in the 2023 ISCVID-Duke minor immunological criteria did not enhance the overall performance of the criteria. FAU - Regina, Jean AU - Regina J AUID- ORCID: 0000-0003-2219-9834 AD - Department of Internal Medicine, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland. FAU - Stavart, Louis AU - Stavart L AUID- ORCID: 0009-0005-4072-0736 AD - Transplantation Center, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland. FAU - Guery, Benoit AU - Guery B AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland. FAU - Tzimas, Georgios AU - Tzimas G AUID- ORCID: 0000-0002-2810-8887 AD - Department of Cardiology, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland. FAU - Monney, Pierre AU - Monney P AUID- ORCID: 0000-0002-3083-7333 AD - Department of Cardiology, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland. FAU - Niclauss, Lars AU - Niclauss L AUID- ORCID: 0000-0003-4453-5202 AD - Department of Cardiac Surgery, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland. FAU - Kirsch, Matthias AU - Kirsch M AUID- ORCID: 0000-0002-9213-7578 AD - Department of Cardiac Surgery, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland. FAU - Golshayan, Dela AU - Golshayan D AUID- ORCID: 0000-0001-5631-6096 AD - Transplantation Center, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland. FAU - Papadimitriou-Olivgeris, Matthaios AU - Papadimitriou-Olivgeris M AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland. AD - Infectious Diseases Service, Institut Central des Hopitaux, Hospital of Valais, 1951 Sion, Switzerland. LA - eng GR - #32003B_219351/1/SNSF_/Swiss National Science Foundation/Switzerland GR - #FF24013/Swiss Heart Foundation/ PT - Journal Article DEP - 20250707 PL - Switzerland TA - Antibiotics (Basel) JT - Antibiotics (Basel, Switzerland) JID - 101637404 PMC - PMC12291632 OTO - NOTNLM OT - Duke criteria OT - acute kidney injury OT - bacteremia OT - embolic events OT - infective endocarditis OT - microhematuria OT - sepsis OT - urinalysis COIS- The authors declare no conflicts of interest. EDAT- 2025/07/29 06:29 MHDA- 2025/07/29 06:30 PMCR- 2025/07/07 CRDT- 2025/07/29 01:10 PHST- 2025/06/10 00:00 [received] PHST- 2025/07/01 00:00 [revised] PHST- 2025/07/04 00:00 [accepted] PHST- 2025/07/29 06:30 [medline] PHST- 2025/07/29 06:29 [pubmed] PHST- 2025/07/29 01:10 [entrez] PHST- 2025/07/07 00:00 [pmc-release] AID - antibiotics14070687 [pii] AID - antibiotics-14-00687 [pii] AID - 10.3390/antibiotics14070687 [doi] PST - epublish SO - Antibiotics (Basel). 2025 Jul 7;14(7):687. doi: 10.3390/antibiotics14070687. PMID- 40722822 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250801 IS - 2227-9059 (Print) IS - 2227-9059 (Electronic) IS - 2227-9059 (Linking) VI - 13 IP - 7 DP - 2025 Jul 17 TI - A Mid-Term Follow-Up in Patients with Symptomatic Moderate to Severe and Severe Degenerative Mitral Valve Regurgitation After Transapical NeoChord Implantation. LID - 10.3390/biomedicines13071751 [doi] LID - 1751 AB - Background: The transapical off-pump NeoChord procedure is a recognized minimally invasive surgical approach for the treatment of severe degenerative mitral regurgitation. This study aims to report the initial Greek experience with the NeoChord procedure, presenting mid-term clinical and echocardiographic outcomes from a single cardiothoracic surgical center, with a median follow-up duration of 20 months. Methods: In this study, 42 symptomatic patients with moderate to severe and severe primary mitral regurgitation underwent mitral valve repair with the Neochord procedure between March 2018 and December 2024. All patients were evaluated clinically and echocardiographically by the Heart team preoperatively, after 1 month, and at the last follow-up (end of 2024). The primary endpoint was established as the presence of a major clinical event (all-cause mortality, reintervention due to deterioration of MR, and cardiac-related rehospitalization). Results: The median age of patients was 69 [61.75-79.25] years, and 69% of patients were men. The median EuroScore II was 1.79 [1.32-2.48], and the STS-PROM MV repair score was 3.18 [2.28-4.66]. Regarding the preprocedural mitral valve anatomical evaluation, 35 patients had type A (83.3%),4 had type B(9.5%), whereas only two patients had type C and 1 with type D anatomy. The median of LAI was 1.2 [1.15-1.25], whereas the CI was 4 [2.15-5]. More than two neochordae were implanted in 34 patients (81%). MR severity improved at 1-month (/=2% used to define higher risk. The primary endpoint was a composite of major adverse cardiovascular events (MACE), including myocardial infarction, stroke, and all-cause mortality. Associations were assessed using Cox proportional hazards models, ROC analysis, and Kaplan-Meier survival estimates. Overall, 546 patients were included (mean age 67 years, 17% female sex) with a median EuroSCORE II of 1.19% (IQR 0.78-2.03) Final treatment strategies were CABG (65.2%), PCI (12.6%), or medical therapy (19.6%). Over a median follow-up of 3.2 years, 79 patients (14.5%) experienced MACE. EuroSCORE II >/=2% was significantly associated with higher risk of MACE (HR 2.58, 95% CI 1.65-4.05, p < 0.001). Predictive accuracy was limited (AUC 0.66), with an AUC of 0.59, 0.72 and 0.66 for CABG, PCI and medical therapy, respectively. In conclusion, in a contemporary Heart Team setting, EuroSCORE II >/=2% was independently associated with long-term MACE and mortality across treatment strategies. These findings suggest that EuroSCORE II may serve as a pragmatic adjunct to guide risk stratification and treatment planning beyond its traditional surgical context. CI - Copyright (c) 2025 Elsevier Inc. All rights reserved. FAU - Bradbury, Jack Lewis AU - Bradbury JL AD - Department of Cardiology, Austin Health, Heidelberg, Victoria 3084, Australia. FAU - Rodrigues, Thalys Sampaio AU - Rodrigues TS AD - Department of Cardiology, Austin Health, Heidelberg, Victoria 3084, Australia; Department of Medicine, The University of Melbourne, Parkville, Victoria 3010, Australia. FAU - Kumarasiri, Manasha AU - Kumarasiri M AD - Department of General Medicine, Austin Health, Heidelberg, Victoria 3084, Australia. FAU - Nilsen, Oliver Joshua AU - Nilsen OJ AD - Department of General Medicine, Austin Health, Heidelberg, Victoria 3084, Australia. FAU - Luc, Michael AU - Luc M AD - Department of General Medicine, Austin Health, Heidelberg, Victoria 3084, Australia. FAU - Yudi, Matias Benjamin AU - Yudi MB AD - Department of Cardiology, Austin Health, Heidelberg, Victoria 3084, Australia. FAU - Yeoh, Julian AU - Yeoh J AD - Department of Cardiology, Austin Health, Heidelberg, Victoria 3084, Australia. FAU - Clark, David John AU - Clark DJ AD - Department of Cardiology, Austin Health, Heidelberg, Victoria 3084, Australia. FAU - Theuerle, James AU - Theuerle J AD - Department of Cardiology, Austin Health, Heidelberg, Victoria 3084, Australia. FAU - Koshy, Anoop Ninan AU - Koshy AN AD - Department of Cardiology, Austin Health, Heidelberg, Victoria 3084, Australia; Department of Medicine, The University of Melbourne, Parkville, Victoria 3010, Australia; Department of Cardiology, The Royal Melbourne Hospital, Parkville, Victoria 3050, Australia. Electronic address: ankoshy@gmail.com. LA - eng PT - Journal Article DEP - 20250715 PL - United States TA - Am J Cardiol JT - The American journal of cardiology JID - 0207277 SB - IM MH - Humans MH - Female MH - Male MH - *Coronary Artery Disease/surgery/mortality/therapy MH - Aged MH - Retrospective Studies MH - Risk Assessment/methods MH - Australia/epidemiology MH - Middle Aged MH - Percutaneous Coronary Intervention MH - Prognosis MH - Coronary Artery Bypass MH - Survival Rate/trends OTO - NOTNLM OT - coronary artery disease OT - euroscore II OT - major adverse cardiovascular events COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/07/18 01:40 MHDA- 2025/11/15 00:29 CRDT- 2025/07/17 19:43 PHST- 2025/06/04 00:00 [received] PHST- 2025/06/30 00:00 [revised] PHST- 2025/07/09 00:00 [accepted] PHST- 2025/11/15 00:29 [medline] PHST- 2025/07/18 01:40 [pubmed] PHST- 2025/07/17 19:43 [entrez] AID - S0002-9149(25)00410-2 [pii] AID - 10.1016/j.amjcard.2025.07.014 [doi] PST - ppublish SO - Am J Cardiol. 2025 Dec 1;256:18-22. doi: 10.1016/j.amjcard.2025.07.014. Epub 2025 Jul 15. PMID- 40674777 OWN - NLM STAT- MEDLINE DCOM- 20250910 LR - 20260913 IS - 1873-7714 (Electronic) IS - 0163-8343 (Linking) VI - 96 DP - 2025 Sep-Oct TI - A retrospective study of deceased veterans with serious mental illness and heart failure: Analysis of palliative care and mental health collaboration on hospice utilization. PG - 151-155 LID - S0163-8343(25)00145-8 [pii] LID - 10.1016/j.genhosppsych.2025.07.009 [doi] AB - INTRODUCTION: Serious Mental Illness (SMI) adds complexity to end of life care including medical decision making. For complex patients, enrollment in team-based hospice care providescoordinated services and supports. This retrospective study evaluated if the combinations of mental health care or palliative care increased hospice enrollment in the last 6 months of life. METHODS: We identified deceased Veterans with diagnoses of heart failure (HF) and SMI. SMI was defined as schizophrenia spectrum or bipolar spectrum disorder. We categorized the SMI population into 4 groups: those with mental health and palliative care (n = 2973), only mental health (n = 4333), only palliative care (n = 892), or neither (n = 1171). The outcome of hospice use in the 6-months before death was measured with VA and Medicare records. Logistic regression compared the mental health and palliative care groups to the reference group and included adjustment for demographics and comorbidities. RESULTS: The cohort included 9369 Veterans with HF and SMI who died between 2011 and 2020. Relative to the reference group (23.9 % hospice), those with mental health engagement had lower odds of receiving hospice (adjusted Odds Ratio (aOR) = 0.74; 95 % confidence interval (CI) 0.62,0.87). Exposure to palliative care increased the adjusted odds of hospice in those with mental health services (aOR = 6.67, 95 % CI 5.61, 7.92) and with only palliative care (aOR = 5.96, 95 % CI 4.86, 7.32). CONCLUSION: This study demonstrates a gap in hospice enrollment for people with SMI. Palliative care improves the gap. Increased collaboration between mental health and palliative providers and cross-training may improve the experience of people with SMI. CI - Copyright (c) 2024. Published by Elsevier Inc. FAU - Boozalis, Jaclyn AU - Boozalis J AD - Division of Geriatrics and Palliative Medicine, Department of Medicine, The Warren Alpert Medical School of Brown University, Physicians Office Building 438, 593 Eddy Street, Providence, RI 02903, United States of America. Electronic address: Jboozalis@brownhealth.org. FAU - Perreault, Jaclyn AU - Perreault J AD - Division of Geriatrics and Palliative Medicine, Department of Medicine, The Warren Alpert Medical School of Brown University, Physicians Office Building 438, 593 Eddy Street, Providence, RI 02903, United States of America. Electronic address: Jperreault1@brownhealth.org. FAU - Turner, Helen I AU - Turner HI AD - Division of Geriatrics and Palliative Medicine, Department of Medicine, The Warren Alpert Medical School of Brown University, Physicians Office Building 438, 593 Eddy Street, Providence, RI 02903, United States of America. Electronic address: Hturner@brownhealth.org. FAU - Wu, Wen-Chih AU - Wu WC AD - Center of Innovation on Transformative Health Systems Research to Improve Veteran Equity and Independence (THRIVE COIN), Providence VA Healthcare System, 830 Chalkstone Ave, Providence, RI 02908, United States of America; Division of Cardiology, Department of Medicine, The Warren Alpert Medical School of Brown University, 593 Eddy Street, Providence, RI 02903, United States of America. Electronic address: Wen-chih.wu@va.gov. FAU - Browne, Julia AU - Browne J AD - Center of Innovation on Transformative Health Systems Research to Improve Veteran Equity and Independence (THRIVE COIN), Providence VA Healthcare System, 830 Chalkstone Ave, Providence, RI 02908, United States of America; Department of Psychiatry and Human Behavior, The Warren Alpert Medical School of Brown University, Providence, RI 02912, United States of America. Electronic address: Julia_browne@brown.edu. FAU - Jiang, Lan AU - Jiang L AD - Center of Innovation on Transformative Health Systems Research to Improve Veteran Equity and Independence (THRIVE COIN), Providence VA Healthcare System, 830 Chalkstone Ave, Providence, RI 02908, United States of America. Electronic address: Lan.jiang@va.gov. FAU - Wice, Mitchell AU - Wice M AD - Division of Geriatrics and Palliative Medicine, Department of Medicine, The Warren Alpert Medical School of Brown University, Physicians Office Building 438, 593 Eddy Street, Providence, RI 02903, United States of America. Electronic address: Mitchell_wice@brown.edu. FAU - Rudolph, James L AU - Rudolph JL AD - Center of Innovation on Transformative Health Systems Research to Improve Veteran Equity and Independence (THRIVE COIN), Providence VA Healthcare System, 830 Chalkstone Ave, Providence, RI 02908, United States of America; Center for Gerontology and Healthcare Research, Brown University School of Public Health, 121 S Main Street, Providence, RI 02903, United States of America. Electronic address: James.Rudolph@va.gov. FAU - Stafford, Jensy P AU - Stafford JP AD - Division of Geriatrics and Palliative Medicine, Department of Medicine, The Warren Alpert Medical School of Brown University, Physicians Office Building 438, 593 Eddy Street, Providence, RI 02903, United States of America. Electronic address: Jstafford@hopehealthco.org. LA - eng GR - IK2 RX005010/RX/RRD VA/United States GR - CIN-13-419/HX/HSRD VA/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20250713 PL - United States TA - Gen Hosp Psychiatry JT - General hospital psychiatry JID - 7905527 SB - IM MH - Humans MH - Male MH - *Heart Failure/therapy/epidemiology MH - Retrospective Studies MH - Female MH - *Palliative Care/statistics & numerical data MH - Aged MH - *Veterans/statistics & numerical data MH - *Hospice Care/statistics & numerical data MH - United States/epidemiology MH - Middle Aged MH - United States Department of Veterans Affairs/statistics & numerical data MH - *Schizophrenia/therapy/epidemiology MH - *Bipolar Disorder/therapy/epidemiology MH - *Patient Acceptance of Health Care/statistics & numerical data MH - Comorbidity MH - Aged, 80 and over OTO - NOTNLM OT - Bipolar disorder OT - Heart failure OT - Hospice care OT - Mental health OT - Palliative care OT - Schizophrenia OT - Veterans EDAT- 2025/07/17 18:25 MHDA- 2025/09/11 00:28 CRDT- 2025/07/17 17:59 PHST- 2025/03/19 00:00 [received] PHST- 2025/07/08 00:00 [revised] PHST- 2025/07/08 00:00 [accepted] PHST- 2025/09/11 00:28 [medline] PHST- 2025/07/17 18:25 [pubmed] PHST- 2025/07/17 17:59 [entrez] AID - S0163-8343(25)00145-8 [pii] AID - 10.1016/j.genhosppsych.2025.07.009 [doi] PST - ppublish SO - Gen Hosp Psychiatry. 2025 Sep-Oct;96:151-155. doi: 10.1016/j.genhosppsych.2025.07.009. Epub 2025 Jul 13. PMID- 40672900 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250719 IS - 2048-0040 (Print) IS - 2048-0040 (Electronic) IS - 2048-0040 (Linking) VI - 14 DP - 2025 Jan-Dec TI - Pregnancy and breastfeeding in the mother with cardiomyopathy. PG - 20480040251352901 LID - 10.1177/20480040251352901 [doi] LID - 20480040251352901 AB - Cardiomyopathies are diseases of the heart muscle, characterised by structural and functional abnormalities of the myocardium that are not caused by ischemia, valvular problems or congenital heart disease. They are responsible for one-third of pregnancy-related cardiovascular deaths. A woman may enter pregnancy with a pre-existing diagnosis, or the cardiomyopathy may emerge or develop de novo during pregnancy. The most common cardiomyopathies encountered in pregnancy are dilated cardiomyopathy, hypertrophic cardiomyopathy and peripartum cardiomyopathy. All cardiomyopathies can be complicated by clinical heart failure, arrhythmia and thromboembolic events. Pregnancy may be poorly tolerated in women with dilated cardiomyopathy. New York Heart Association Class (NYHA) III/IV symptoms, and severe left ventricular dysfunction are the main determinants of adverse maternal outcomes. Peripartum cardiomyopathy is a diagnosis of exclusion with symptom onset towards the end of pregnancy, or within a few months following delivery. The management of heart failure and arrhythmias is based upon established guidelines, tailored for the unique considerations of pregnancy. Contemporary data suggests that recovery in cardiac function by 12 months is approximately 60-70% for the peripartum group. Maternal cardiovascular risk can be determined using specific risk-predictive scores. All patients with cardiomyopathy who wish to consider pregnancy should be offered individualized pre-conception and contraceptive counselling by a multidisciplinary team. This article reviews the management of women with cardiomyopathy during pregnancy and breastfeeding, focusing on the essential role of the multidisciplinary team at every stage of pregnancy and postpartum period to improve the maternal, fetal, and neonatal outcomes. CI - (c) The Author(s) 2025. FAU - Coldea, Bianca Maria AU - Coldea BM AUID- ORCID: 0009-0009-8193-8693 AD - Department of Cardiology, Addenbrooke's Hospital, Cambridge, UK. RINGGOLD: 89744 FAU - Middleton, Lucille AU - Middleton L AUID- ORCID: 0009-0002-8483-2535 AD - University of Nottingham, Nottingham, UK. FAU - Aiken, Catherine AU - Aiken C AUID- ORCID: 0000-0002-6510-5626 AD - Department of Obstetrics and Gynaecology, The Rosie Hospital, Cambridge, UK. FAU - Bhagra, Catriona J AU - Bhagra CJ AUID- ORCID: 0000-0002-3960-9273 AD - Department of Cardiology, Addenbrooke's Hospital, Cambridge, UK. RINGGOLD: 89744 LA - eng PT - Journal Article PT - Review DEP - 20250714 PL - England TA - JRSM Cardiovasc Dis JT - JRSM cardiovascular disease JID - 101598607 PMC - PMC12264410 OTO - NOTNLM OT - Cardiomyopathy OT - heart failure in pregnancy OT - pre-conception counselling OT - pregnancy and heart conditions COIS- The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2025/07/17 06:27 MHDA- 2025/07/17 06:28 PMCR- 2025/07/14 CRDT- 2025/07/17 05:41 PHST- 2024/11/19 00:00 [received] PHST- 2025/05/08 00:00 [revised] PHST- 2025/05/29 00:00 [accepted] PHST- 2025/07/17 06:28 [medline] PHST- 2025/07/17 06:27 [pubmed] PHST- 2025/07/17 05:41 [entrez] PHST- 2025/07/14 00:00 [pmc-release] AID - 10.1177_20480040251352901 [pii] AID - 10.1177/20480040251352901 [doi] PST - epublish SO - JRSM Cardiovasc Dis. 2025 Jul 14;14:20480040251352901. doi: 10.1177/20480040251352901. eCollection 2025 Jan-Dec. PMID- 40670036 OWN - NLM STAT- MEDLINE DCOM- 20250716 LR - 20250716 IS - 1557-8224 (Electronic) IS - 1089-3261 (Linking) VI - 29 IP - 3 DP - 2025 Aug TI - The Liver in Heart Failure and Adults with Congenital Heart Disease. PG - 527-544 LID - S1089-3261(25)00021-2 [pii] LID - 10.1016/j.cld.2025.03.005 [doi] AB - Liver disease is common in patients with heart failure, often resulting from hepatic congestion and decreased perfusion due to reduced cardiac output. Patients with congenital heart disease (CHD) are particularly susceptible to hepatic injury due to their complex physiology, both before and following surgical interventions. Individuals with single-ventricle CHD who have undergone the Fontan procedure are especially prone to developing Fontan-associated liver disease (FALD). Screening and managing FALD remains challenging, necessitating a multidisciplinary approach to guide patient-care and to deepen the understanding of liver disease in the context of CHD. CI - Copyright (c) 2025 Elsevier Inc. All rights reserved. FAU - Millo, Lorena AU - Millo L AD - Department of Internal Medicine, Duke University Medical Center, Durham, NC, USA. FAU - Kappus, Matthew AU - Kappus M AD - Division of Gastroenterology and Hepatology, Duke University Medical Center, 2301 Erwin Road, Durham, NC 27710, USA. Electronic address: matthew.kappus@duke.edu. LA - eng PT - Journal Article PT - Review DEP - 20250513 PL - United States TA - Clin Liver Dis JT - Clinics in liver disease JID - 9710002 SB - IM MH - Humans MH - *Heart Defects, Congenital/surgery/complications MH - *Heart Failure/complications/surgery/physiopathology MH - *Liver Diseases/etiology/therapy/diagnosis MH - *Fontan Procedure/adverse effects MH - Adult OTO - NOTNLM OT - Cirrhosis OT - Congenital heart disease OT - Fontan OT - Heart failure OT - Liver disease COIS- Disclosures No commercial or financial conflicts of interest. EDAT- 2025/07/17 04:41 MHDA- 2025/07/17 04:42 CRDT- 2025/07/16 20:57 PHST- 2025/07/17 04:42 [medline] PHST- 2025/07/17 04:41 [pubmed] PHST- 2025/07/16 20:57 [entrez] AID - S1089-3261(25)00021-2 [pii] AID - 10.1016/j.cld.2025.03.005 [doi] PST - ppublish SO - Clin Liver Dis. 2025 Aug;29(3):527-544. doi: 10.1016/j.cld.2025.03.005. Epub 2025 May 13. PMID- 40669044 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250725 IS - 2291-9279 (Print) IS - 2291-9279 (Electronic) VI - 13 DP - 2025 Jul 16 TI - Exergaming System for Exercise-Based Cardiac Rehabilitation in Patients With Heart Failure: Development and Usability Assessment Study of a Device Prototype. PG - e71385 LID - 10.2196/71385 [doi] LID - e71385 AB - BACKGROUND: Heart failure (HF) is a growing global health concern, and adherence to early cardiac rehabilitation (CR) remains suboptimal. Exergaming is a promising alternative to conventional exercise programs for patients with HF. However, existing research has limitations, and the integration of exergaming into clinical practice remains challenging. Most notably, current studies often rely on commercially available systems that are not tailored to needs specific to patients with HF, lack long-term adherence strategies, and have limited evaluation in the initial phases of cardiac rehabilitation. OBJECTIVE: This study aimed to design, develop, and assess the usability of a novel exergaming prototype (ie, HEFMOB), integrating immersive virtual reality (VR), real-time biometric monitoring, and autonomous session management to support early-phase, exercise-based CR in patients with HF. METHODS: A multidisciplinary team developed HEFMOB through iterative prototyping. The final system included a pedal-based VR cycling game and an upper-limb mobilization minigame, with real-time monitoring of heart rate, blood pressure, and peripheral capillary oxygen saturation. Usability was assessed in two phases: (1) an expert evaluation and refinement phase and (2) a single-session usability phase involving 10 patients with HF (4 female). The sessions were recorded and individually evaluated by 2 researchers using the Serious Game Usability Evaluator tool. After each session, the participants completed the System Usability Scale (SUS) and a subscale of Intrinsic Motivation Inventory (IMI) to rate the usability of the exergaming prototype and enjoyment, respectively. Descriptive statistics were reported. RESULTS: The participants had a mean age of 64.8 (SD 8.4) years, BMI of 26.7 (SD 4.6) kg/m2, and left ventricular ejection fraction of 40.5% (SD 7.4%). All participants completed the session without adverse events. The SUS score averaged 71.5, SD 17.8 (indicating good usability) and IMI scores indicated very high enjoyment (mean 25.1, SD 3.5). A total of 136 gameplay-related events were recorded: negative (n=76, mostly confusion), neutral (n=49), and positive (n=11). Interface-related issues (n=61) were most common, followed by design (n=52) and hardware (n=23). CONCLUSIONS: HEFMOB appears to be a promising, engaging, and well-tolerated tool for delivering tailored exergaming interventions in patients with HF. High usability and enjoyment ratings support its acceptability, while structured user experience analysis provided valuable insights for system refinement. This study marks a critical step toward integrating personalized, gamified exercise in inpatient settings, especially where early mobilization is lacking. Building on these findings, future research will assess long-term usability and clinical impact through a multicenter randomized controlled trial. CI - (c) Carles Blasco-Peris, Juan Pedro Alcolea Garrido, Barbara Segui, Rocio Zaragoza, Vicente Climent-Paya, Laura Fuertes-Kenneally, Agustin Manresa-Rocamora, Ana Sanz-Rocher, Sabina Baladzhaeva, Jose M Sarabia. Originally published in JMIR Serious Games (https://games.jmir.org). FAU - Blasco-Peris, Carles AU - Blasco-Peris C AUID- ORCID: 0000-0002-8257-1231 AD - Instituto de investigacion sanitaria y biomedica de Alicante, Alicante, Spain. AD - Department of Physical Education and Sport, Universitat de Valencia, Valencia, Spain. FAU - Alcolea Garrido, Juan Pedro AU - Alcolea Garrido JP AUID- ORCID: 0009-0007-3560-0419 AD - Aiju, Ibi, Spain. FAU - Segui, Barbara AU - Segui B AUID- ORCID: 0009-0009-1489-9890 AD - Aiju, Ibi, Spain. FAU - Zaragoza, Rocio AU - Zaragoza R AUID- ORCID: 0009-0008-2403-317X AD - Aiju, Ibi, Spain. FAU - Climent-Paya, Vicente AU - Climent-Paya V AUID- ORCID: 0000-0001-7362-1922 AD - Department of Cardiology, Dr Balmis General University Hospital (HGUA), Instituto de investigacion sanitaria y biomedica de Alicante, Av. Pintor Baeza, 12, Alicante, 03010, Spain, 34 965913941. FAU - Fuertes-Kenneally, Laura AU - Fuertes-Kenneally L AUID- ORCID: 0000-0003-1361-8806 AD - Department of Cardiology, Dr Balmis General University Hospital (HGUA), Instituto de investigacion sanitaria y biomedica de Alicante, Av. Pintor Baeza, 12, Alicante, 03010, Spain, 34 965913941. FAU - Manresa-Rocamora, Agustin AU - Manresa-Rocamora A AUID- ORCID: 0000-0002-1399-2411 AD - Instituto de investigacion sanitaria y biomedica de Alicante, Alicante, Spain. AD - Department of Sport Sciences, Sports Research Centre, Universitat de Miguel Hernandez d'Elx, Elche, Spain. FAU - Sanz-Rocher, Ana AU - Sanz-Rocher A AUID- ORCID: 0009-0007-1476-9776 AD - Instituto de investigacion sanitaria y biomedica de Alicante, Alicante, Spain. AD - Department of Sport Sciences, Sports Research Centre, Universitat de Miguel Hernandez d'Elx, Elche, Spain. FAU - Baladzhaeva, Sabina AU - Baladzhaeva S AUID- ORCID: 0009-0009-8730-5600 AD - Instituto de investigacion sanitaria y biomedica de Alicante, Alicante, Spain. AD - Department of Sport Sciences, Sports Research Centre, Universitat de Miguel Hernandez d'Elx, Elche, Spain. FAU - Sarabia, Jose M AU - Sarabia JM AUID- ORCID: 0000-0002-1917-6634 AD - Instituto de investigacion sanitaria y biomedica de Alicante, Alicante, Spain. AD - Department of Sport Sciences, Sports Research Centre, Universitat de Miguel Hernandez d'Elx, Elche, Spain. LA - eng PT - Journal Article DEP - 20250716 PL - Canada TA - JMIR Serious Games JT - JMIR serious games JID - 101645255 PMC - PMC12286565 OTO - NOTNLM OT - HEFMOB OT - early mobilization OT - early rehabilitation OT - exercise OT - game-based rehabilitation OT - personalized intervention OT - virtual reality COIS- Conflicts of Interest: None declared. EDAT- 2025/07/16 18:27 MHDA- 2025/07/16 18:28 PMCR- 2025/07/16 CRDT- 2025/07/16 16:12 PHST- 2025/01/25 00:00 [received] PHST- 2025/06/03 00:00 [revised] PHST- 2025/06/04 00:00 [accepted] PHST- 2025/07/16 18:28 [medline] PHST- 2025/07/16 18:27 [pubmed] PHST- 2025/07/16 16:12 [entrez] PHST- 2025/07/16 00:00 [pmc-release] AID - v13i1e71385 [pii] AID - 71385 [pii] AID - 10.2196/71385 [doi] PST - epublish SO - JMIR Serious Games. 2025 Jul 16;13:e71385. doi: 10.2196/71385. PMID- 40660099 OWN - NLM STAT- MEDLINE DCOM- 20250715 LR - 20250717 IS - 1471-227X (Electronic) IS - 1471-227X (Linking) VI - 25 IP - 1 DP - 2025 Jul 15 TI - Performance improvers in cardio-pulmonary resuscitation: a qualitative study. PG - 122 LID - 10.1186/s12873-025-01281-1 [doi] LID - 122 AB - INTRODUCTION: In-hospital cardiac arrest is a critical event, and while cardiopulmonary resuscitation (CPR) is the primary intervention, human factors significantly influence its quality. Traditional quantitative studies often fail to capture the impact of resuscitation team members' operational and emotional experiences. To address this gap, this qualitative study uses a pragmatist approach to explore the factors that improve the performance of resuscitation team members in emergency departments. METHODS: A qualitative content analysis was conducted in Western Iran from January /2024 to July /2024, to explore factors improving the performance of resuscitation team members. Participants included 25 nurses and physicians from in-hospital resuscitation teams, selected through purposive sampling. Data was collected through in-depth, semi-structured interviews. Graneheim and Lundman's systematic approach was employed to analyze the data and uncover latent and manifest content. RESULTS: The mean age of participants was 34 years (range 24-51 years), and most held a bachelor's degree in nursing (48%). The collected data were categorized into a theme titled " latent enhancers " and three main categories with ten subcategories. These categories and subcategories included Perceived beliefs influencing resuscitation (Positive spiritual feedback, mental simulation, and compassion), organizational catalysts (effective leadership, responsive physical space, fertility of motivation, and fruitful education), and psychological improvers (euphoria, pride in competence, and Hope in the shadow of a surprising successful resuscitation). CONCLUSION: Rescuers' positive beliefs, effective organizational factors, and Psychological improvers were themes extracted from the experiences of rescuers in our study. Holding psychoanalysis sessions with the to create a positive attitude in rescuers towards the outcomes of resuscitation, as well as empowering resuscitation leaders through training leadership skills, considering organizational incentives for resuscitation team members, suitable physical space, and the use of operational training will be an effective and helpful measure in this regard. CLINICAL TRIAL NUMBER: Not applicable. CI - (c) 2025. The Author(s). FAU - Babaei, Keivan AU - Babaei K AUID- ORCID: 0000-0001-9837-7401 AD - School of Nursing and Midwifery, Kermanshah University of Medical Sciences, Kermanshah, Iran. FAU - Ghesmati, Faezeh AU - Ghesmati F AUID- ORCID: 0009-0000-7108-238X AD - Department of Nursing, Kermanshah Branch, Islamic Azad University, Kermanshah, Iran. FAU - Nowzari, Amir Hossein AU - Nowzari AH AUID- ORCID: 0009-0009-1179-9456 AD - Student Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran. FAU - Goodarzi, Afshin AU - Goodarzi A AUID- ORCID: 0000-0001-5641-9028 AD - Department of Pre-Hospital Emergency Care, School of Paramedicine, Kermanshah University of Medical Sciences, Kermanshah, Iran. afshingoodarzy@yahoo.com. LA - eng GR - 4020912/Kermanshah University of Medical Sciences/ GR - 4020912/Kermanshah University of Medical Sciences/ GR - 4020912/Kermanshah University of Medical Sciences/ GR - 4020912/Kermanshah University of Medical Sciences/ PT - Journal Article DEP - 20250715 PL - England TA - BMC Emerg Med JT - BMC emergency medicine JID - 100968543 SB - IM MH - Humans MH - Qualitative Research MH - *Cardiopulmonary Resuscitation/standards MH - Adult MH - Female MH - Middle Aged MH - Male MH - Iran MH - Emergency Service, Hospital MH - Young Adult MH - *Heart Arrest/therapy MH - Leadership MH - Attitude of Health Personnel MH - *Patient Care Team MH - Interviews as Topic PMC - PMC12261817 OTO - NOTNLM OT - Cardiac arrest OT - Cardiopulmonary resuscitation OT - Emergency department OT - Qualitative research COIS- Declarations. Ethics approval and consent to participate: The Institutional Review Board of Kermanshah University of Medical Sciences and Iran National Committee for Ethics in Biomedical Research approved this study (Project Code: 4020912 and Ethics Code: IR.KUMS.REC.1402.604). Informed consent was obtained from all participants and all information (including participant names, interview files, and writings) was kept confidential, and the confidentiality principles were strictly followed. Participants' withdrawal right from the study was described at the start of the interview and reserved at any time. In the present study, all methods were performed in accordance with the relevant guidelines and regulations, including the Declaration of Helsinki. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2025/07/15 00:30 MHDA- 2025/07/15 06:27 PMCR- 2025/07/15 CRDT- 2025/07/14 23:37 PHST- 2025/02/14 00:00 [received] PHST- 2025/07/02 00:00 [accepted] PHST- 2025/07/15 06:27 [medline] PHST- 2025/07/15 00:30 [pubmed] PHST- 2025/07/14 23:37 [entrez] PHST- 2025/07/15 00:00 [pmc-release] AID - 10.1186/s12873-025-01281-1 [pii] AID - 1281 [pii] AID - 10.1186/s12873-025-01281-1 [doi] PST - epublish SO - BMC Emerg Med. 2025 Jul 15;25(1):122. doi: 10.1186/s12873-025-01281-1. PMID- 40652730 OWN - NLM STAT- MEDLINE DCOM- 20250903 LR - 20260415 IS - 1095-8673 (Electronic) IS - 0022-4804 (Linking) VI - 313 DP - 2025 Sep TI - Evaluating the Performance of Large Language Models on Multispecialty FRCS Section 1 Questions. PG - 66-77 LID - S0022-4804(25)00360-9 [pii] LID - 10.1016/j.jss.2025.06.026 [doi] AB - INTRODUCTION: Large language models (LLMs) have increasingly demonstrated utility in medical education and professional examinations. However, their reliability, accuracy, and consistency in answering complex surgical questions remain unclear. This study aims to assess the accuracy, consistency, and intermodel reliability of four widely used LLMs, ChatGPT 4o, Google Gemini, Perplexity AI, and Microsoft Copilot, in answering Fellowship of the Royal Colleges of Surgeons Section 1 single best answer questions. METHODS: A total of 50 single best answer-type questions from the official Joint Committee on Intercollegiate Examinations sample set, covering ten surgical specialties, were presented to each LLM three times in independent sessions to prevent memory effects. Accuracy (correct versus incorrect responses), response consistency across repeated trials, and intermodel reliability were evaluated. RESULTS: ChatGPT had the highest accuracy (81.33%, 122/150, P < 0.0001), followed by Gemini (69.33%), Perplexity (64%), and Copilot (59.33%). ChatGPT achieved 100% accuracy in cardiothoracic Surgery and neurosurgery, whereas Gemini performed poorly in neurosurgery (40%) and urology (20%). Otolaryngology and plastic surgery had lower accuracy across all models. Gemini and Perplexity showed the highest consistency (90%). Intermodel reliability was low (Fleiss' Kappa = 0.127, P < 0.0001), with cardiothoracic surgery having the highest agreement (0.401) and oral and maxillofacial surgery the lowest (-0.0992). CONCLUSIONS: ChatGPT performed best overall, whereas other models showed variable accuracies and lower agreement. Although Gemini and Perplexity demonstrated high internal consistency, intermodel reliability was limited. The study findings suggest that, although promising, these tools should be used with care in Fellowship of the Royal Colleges of Surgeons surgical assessments. CI - Copyright (c) 2025 Elsevier Inc. All rights reserved. FAU - Ahmed, H Shafeeq AU - Ahmed HS AD - Department of Medicine, Bangalore Medical College and Research Institute, Bangalore, Karnataka, India. Electronic address: shafeeqahmed2002@gmail.com. LA - eng PT - Evaluation Study PT - Journal Article DEP - 20250712 PL - United States TA - J Surg Res JT - The Journal of surgical research JID - 0376340 SB - IM MH - Humans MH - Reproducibility of Results MH - *Language MH - *Specialties, Surgical/education MH - *Educational Measurement/methods MH - Large Language Models OTO - NOTNLM OT - Artificial intelligence OT - Education OT - Examination OT - Fellowship OT - Royal College of Surgeons EDAT- 2025/07/14 00:28 MHDA- 2025/09/04 00:37 CRDT- 2025/07/13 18:05 PHST- 2025/02/03 00:00 [received] PHST- 2025/05/12 00:00 [revised] PHST- 2025/06/16 00:00 [accepted] PHST- 2025/09/04 00:37 [medline] PHST- 2025/07/14 00:28 [pubmed] PHST- 2025/07/13 18:05 [entrez] AID - S0022-4804(25)00360-9 [pii] AID - 10.1016/j.jss.2025.06.026 [doi] PST - ppublish SO - J Surg Res. 2025 Sep;313:66-77. doi: 10.1016/j.jss.2025.06.026. Epub 2025 Jul 12. PMID- 40652443 OWN - NLM STAT- MEDLINE DCOM- 20250730 LR - 20260811 IS - 1559-0259 (Electronic) IS - 1530-7905 (Linking) VI - 25 IP - 9 DP - 2025 Sep TI - Immunotherapy-Induced Cardiotoxicity: A Narrative Review of Real-World Case Reports, Recent Information and Clinical Evidence. PG - 1381-1410 LID - 10.1007/s12012-025-10038-y [doi] AB - Immunotherapy is revolutionizing the treatment of cancer and other conditions. However, it also precipitates a loss of self-tolerance and causes immune-related adverse events (irAEs). We provide a narrative synthesis of the scopes and methods of immunotherapy and mechanisms, clinical presentation, and diagnostic considerations of cardiovascular irAEs while providing real-world examples and perspectives. Recent real-world cases and emerging evidence suggest myocarditis is the most common and potentially fatal cardiovascular irAE, often presenting with symptoms such as shortness of breath or chest pain within weeks of therapy initiation. Other cardiotoxic effects include arrhythmias such as tachyarrhythmias or conduction blocks, heart failure, takotsubo cardiomyopathy, and pericardial disease, sometimes with pericardial effusion. These events can be severe, requiring prompt recognition and intervention to avoid deterioration. Diagnosis typically involves surveillance, a high index of suspicion, biomarker elevations, imaging modalities, cardiac magnetic resonance, and in select cases, endomyocardial biopsy. Early cessation of immunotherapy and high-dose corticosteroids frequently help stabilize acutely ill patients with additional immunomodulators such as intravenous immunoglobulin or abatacept considered in steroid-refractory cases. Clinicians are urged to adopt a multidisciplinary approach involving close cardiology collaboration for baseline risk evaluation, structured surveillance, and cautious rechallenge decisions. Despite these challenges, immunotherapy remains vital for the management of many malignancies. Ongoing research into targeted immunomodulation, refined imaging protocols, and genetic profiling may enhance clinical outcomes by enabling prevention, earlier detection and safer management of cardiovascular irAEs. CI - (c) 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Ogunniyi, Kayode E AU - Ogunniyi KE AD - Richmond University Medical Center/Mount Sinai, Staten Island, NY, USA. AD - Royal College of Physicians, London, UK. FAU - Djunadi, Trie Arni AU - Djunadi TA AD - Richmond University Medical Center/Mount Sinai, Staten Island, NY, USA. FAU - Adewara, Oluwadabira AU - Adewara O AD - Faculty of Clinical Sciences, College of Medicine, University of Ibadan, Ibadan, Nigeria. FAU - Babawale, Isaac AU - Babawale I AD - Faculty of Clinical Sciences, College of Medicine, University of Ibadan, Ibadan, Nigeria. FAU - Akinmoju, Olumide Damilola AU - Akinmoju OD AD - Montefiore St. Luke's Cornwall Hospital, Newburgh, NY, USA. FAU - Olaiya, Victor Olamiposi AU - Olaiya VO AD - Department of Internal Medicine, Izhevsk State Medical Academy, Izhevsk, Russia. FAU - Nwatamole, Bright AU - Nwatamole B AD - Vassar Brothers Medical Center/Nuvance Health, Poughkeepsie, NY, USA. FAU - Shazad, Salar AU - Shazad S AD - Richmond University Medical Center/Mount Sinai, Staten Island, NY, USA. FAU - Patel, Dhruvesh AU - Patel D AD - American University of Antigua College of Medicine, Osbourn, Antigua and Barbuda. FAU - Popoola, Hakeem Adegboyega AU - Popoola HA AD - Henry Ford Jackson Hospital, Jackson, MI, USA. FAU - Onaolapo, David AU - Onaolapo D AD - First Cardiology Consultants Hospital, Ikoyi, Lagos, Nigeria. FAU - Gold-Olufadi, Shakirat AU - Gold-Olufadi S AD - Brookdale University Hospital and Medical Center, Brooklyn, NY, USA. FAU - Ogieuhi, Ikponmwosa Jude AU - Ogieuhi IJ AD - Siberian State Medical University, Tomsk, Russia. Jude.ogieuhi@gmail.com. FAU - Nfonoyim, Jay AU - Nfonoyim J AD - Richmond University Medical Center/Mount Sinai, Staten Island, NY, USA. LA - eng PT - Journal Article PT - Review DEP - 20250713 PL - United States TA - Cardiovasc Toxicol JT - Cardiovascular toxicology JID - 101135818 RN - 0 (Immune Checkpoint Inhibitors) RN - 0 (Antineoplastic Agents, Immunological) SB - IM MH - Humans MH - Cardiotoxicity MH - *Immunotherapy/adverse effects MH - Risk Assessment MH - *Heart Diseases/chemically induced/therapy/physiopathology/diagnostic imaging/diagnosis MH - Risk Factors MH - *Immune Checkpoint Inhibitors/adverse effects MH - Male MH - Treatment Outcome MH - Female MH - *Neoplasms/immunology/drug therapy MH - Middle Aged MH - Heart Disease Risk Factors MH - *Antineoplastic Agents, Immunological/adverse effects OTO - NOTNLM OT - CAR-T cells OT - Cardio-oncology OT - Immune checkpoint inhibitors OT - Immunotherapy-induced cardiotoxicity OT - Literature review COIS- Declarations. Conflict of interests: The authors declare that they have no competing interests. Ethics Approval and Consent to Participate: Not applicable. Clinical Trial Number: Not applicable. Consent for Publication: Not applicable. EDAT- 2025/07/13 13:18 MHDA- 2025/07/30 18:29 CRDT- 2025/07/13 11:04 PHST- 2025/03/14 00:00 [received] PHST- 2025/06/19 00:00 [accepted] PHST- 2025/07/30 18:29 [medline] PHST- 2025/07/13 13:18 [pubmed] PHST- 2025/07/13 11:04 [entrez] AID - 10.1007/s12012-025-10038-y [pii] AID - 10.1007/s12012-025-10038-y [doi] PST - ppublish SO - Cardiovasc Toxicol. 2025 Sep;25(9):1381-1410. doi: 10.1007/s12012-025-10038-y. Epub 2025 Jul 13. PMID- 40649115 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250714 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 14 IP - 13 DP - 2025 Jul 4 TI - Insights into Pulmonary Arterial Hypertension in Connective Tissue Diseases. LID - 10.3390/jcm14134742 [doi] LID - 4742 AB - Pulmonary arterial hypertension (PAH) is a severe complication associated with connective tissue diseases (CTDs), which is characterized by a significant influence on the patient's prognosis and mortality. The prevalence of PAH varies depending on the type of CTD. Still, it is highly prevalent in patients with systemic sclerosis (SSc), systemic lupus erythematosus (SLE), mixed connective tissue disease (MCTD), and primary Sjogren's syndrome (pSS). Identifying rheumatic disease-specific risk factors is crucial for early diagnosis and intervention. Risk factors for PAH development include specific sociological factors (related to race, gender, and age), clinical features (particularly severe Raynaud's phenomenon and multiple telangiectasias), cardiological factors (pericarditis and left heart disease), biochemical factors (elevated NT-proBNP and decreased HDL-cholesterol), serological factors (presence of ANA, e.g., anti-U1-RNP or SSA, and antiphospholipid antibodies), and pulmonary factors (interstitial lung disease and decreased DLCO or DLCO/alveolar volume ratio < 70%, FVC/DLCO > 1.6). The analysis of risk factors can be the most useful during the selection of patients at high risk of PAH development. The initial diagnosis of PAH is usually based on transthoracic echocardiography (TTE) and is finally confirmed by right heart catheterization (RHC). Targeted therapies can improve outcomes and include endothelin receptor antagonists, prostacyclin analogs, phosphodiesterase inhibitors, and tailored immunosuppressive treatments. Effective management strategies require a multidisciplinary approach involving rheumatologists, cardiologists, and pulmonologists. The risk stratification and individualized treatment strategies can enhance survival and quality of life in patients with PAH-CTD. FAU - Grygiel-Gorniak, Bogna AU - Grygiel-Gorniak B AUID- ORCID: 0000-0002-3438-0764 AD - Department of Rheumatology, Rehabilitation and Internal Diseases, Poznan University of Medical Sciences, 61-701 Poznan, Poland. FAU - Lucki, Mateusz AU - Lucki M AD - Department and Clinic of Cardiology, University of Medical Sciences, 60-545 Poznan, Poland. FAU - Daroszewski, Przemyslaw AU - Daroszewski P AD - Department of Organization and Management in Healthcare, Poznan University of Medical Sciences, 60-545 Poznan, Poland. FAU - Lucka, Ewa AU - Lucka E AUID- ORCID: 0000-0002-8248-2247 AD - Clinical Rehabilitation Laboratory, Department of Rehabilitation and Physiotherapy, University of Medical Sciences, 60-545 Poznan, Poland. LA - eng PT - Journal Article PT - Review DEP - 20250704 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC12250367 OTO - NOTNLM OT - connective tissue diseases OT - pulmonary arterial hypertension OT - risk factors OT - treatment strategies COIS- The authors declare that they have no financial or non-financial interests that could influence the outcomes of this study. There are no competing interests to report. None of the authors has any conflicts of interest to disclose. EDAT- 2025/07/13 03:32 MHDA- 2025/07/13 03:33 PMCR- 2025/07/04 CRDT- 2025/07/12 01:16 PHST- 2025/04/25 00:00 [received] PHST- 2025/06/12 00:00 [revised] PHST- 2025/07/02 00:00 [accepted] PHST- 2025/07/13 03:33 [medline] PHST- 2025/07/13 03:32 [pubmed] PHST- 2025/07/12 01:16 [entrez] PHST- 2025/07/04 00:00 [pmc-release] AID - jcm14134742 [pii] AID - jcm-14-04742 [pii] AID - 10.3390/jcm14134742 [doi] PST - epublish SO - J Clin Med. 2025 Jul 4;14(13):4742. doi: 10.3390/jcm14134742. PMID- 40649068 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260925 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 14 IP - 13 DP - 2025 Jul 2 TI - Chronic Total Occlusions: Current Approaches, Evidence and Outcomes. LID - 10.3390/jcm14134695 [doi] LID - 4695 AB - Chronic total occlusions (CTOs), defined as complete coronary artery blockages persisting for over three months, are frequently encountered in up to 25% of coronary angiograms. Although percutaneous coronary intervention (PCI) for CTO remains technically challenging, advancements in guidewires, microcatheters, re-entry devices, and intravascular imaging, along with the expertise of specialized operators, have significantly improved procedural success rates, now exceeding 90% in expert centers. While recent evidence, such as the SYNTAX II study, emphasizes the importance of complete revascularization, over half of CTO cases continue to be managed conservatively with optimal medical therapy (OMT), partly due to the limited high-quality randomized evidence supporting revascularization. Observational studies have demonstrated that successful CTO-PCI is associated with improved angina relief, quality of life, left ventricular function, and possibly long-term survival. Extended observational follow-up, such as the Korean and Canadian registries, suggests long-term reductions in cardiac and all-cause mortality with CTO revascularization. However, randomized controlled trials (RCTs) have primarily shown symptomatic benefit, with no consistent reduction in major adverse cardiac events (MACE) or mortality, likely due to limited sample sizes, short follow-up, and treatment crossovers. Various strategies, including the hybrid algorithm, guide CTO interventions by balancing antegrade and retrograde techniques based on lesion complexity. Imaging modalities such as coronary CT angiography and intravascular ultrasound play a pivotal role in planning and optimizing these procedures. Future innovations, such as real-time fusion imaging of CCTA with coronary angiography, may enhance lesion visualization and guidewire navigation. While current guidelines recommend CTO-PCI in selected symptomatic patients with demonstrable ischemia or viable myocardium, the decision should be individualized, incorporating anatomical feasibility, comorbidities, patient preferences, and input from a multidisciplinary Heart Team. Looking ahead, adequately powered RCTs with extended follow-up are essential to determine the long-term clinical impact of CTO-PCI on hard outcomes such as mortality and myocardial infarction. FAU - Arnold, Remi AU - Arnold R AUID- ORCID: 0009-0002-3216-6817 AD - Department of Cardiology, Arnaud de Villeneuve Hospital, 34295 Montpellier, France. FAU - Gervasoni, Richard AU - Gervasoni R AD - Department of Cardiology, Arnaud de Villeneuve Hospital, 34295 Montpellier, France. FAU - Leclercq, Florence AU - Leclercq F AUID- ORCID: 0000-0001-5936-5184 AD - Department of Cardiology, Arnaud de Villeneuve Hospital, 34295 Montpellier, France. LA - eng PT - Journal Article PT - Review DEP - 20250702 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC12251027 OTO - NOTNLM OT - coronary chronic total occlusion OT - major coronary events OT - percutaneous coronary intervention OT - procedure success COIS- The authors declare no conflicts of interest. EDAT- 2025/07/13 03:33 MHDA- 2025/07/13 03:34 PMCR- 2025/07/02 CRDT- 2025/07/12 01:16 PHST- 2025/04/26 00:00 [received] PHST- 2025/06/19 00:00 [revised] PHST- 2025/06/26 00:00 [accepted] PHST- 2025/07/13 03:34 [medline] PHST- 2025/07/13 03:33 [pubmed] PHST- 2025/07/12 01:16 [entrez] PHST- 2025/07/02 00:00 [pmc-release] AID - jcm14134695 [pii] AID - jcm-14-04695 [pii] AID - 10.3390/jcm14134695 [doi] PST - epublish SO - J Clin Med. 2025 Jul 2;14(13):4695. doi: 10.3390/jcm14134695. PMID- 40648908 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250714 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 14 IP - 13 DP - 2025 Jun 26 TI - Nursing Care Across the Clinical Continuum of TAVI: A Systematic Review of Multidisciplinary Roles. LID - 10.3390/jcm14134535 [doi] LID - 4535 AB - Background/Objectives: Aortic stenosis is a common heart disease, particularly among elderly patients. Transcatheter aortic valve implantation (TAVI) offers a minimally invasive alternative method to surgical valve replacement for high-risk patients. Although clinical guidelines for TAVI are well established, standardized nursing care pathways are lacking. This systematic review aims to clarify the nursing role in the pre-, peri-, and postoperative phases of TAVI. Methods: This review was conducted in accordance with the PRISMA guidelines. After applying the eligibility criteria, ten studies were selected from five databases: PubMed, Scopus, CINAHL, Web of Science, and the Cochrane Library. The work was registered in the PROSPERO database with the ID number CRD420251061863. Results: The analysis revealed the following: (1) a strong emphasis on preoperative patient education, often led by nurse coordinators; (2) perioperative nursing roles in conscious sedation protocols and early mobilization; (3) a lack of standardized rehabilitative protocols, especially in the preoperative phase; and (4) an emerging but insufficiently evaluated role of the TAVI nurse coordinator in multidisciplinary care. Most studies concentrated on postoperative care, outcomes, follow-up, and rehabilitation, but the small sample sizes limited the strength of the conclusions. Conclusions: Nurses play a vital role in multidisciplinary TAVI teams. There is an urgent need for evidence-based nursing guidelines to standardize care, improve clinical outcomes, and address the needs of TAVI patients. This review highlights the pivotal contribution of nursing to the success of TAVI. FAU - Jendrzejczak, Anna AU - Jendrzejczak A AD - Chair of Nursing Management and Clinical Nursing, Institute of Clinical Sciences, Faculty of Health Sciences, Academy of Zamosc, 22-400 Zamosc, Poland. FAU - Klukow, Jadwiga AU - Klukow J AD - Chair of Nursing Management and Clinical Nursing, Institute of Clinical Sciences, Faculty of Health Sciences, Academy of Zamosc, 22-400 Zamosc, Poland. FAU - Czerwik-Marcinkowska, Joanna AU - Czerwik-Marcinkowska J AUID- ORCID: 0000-0003-2019-7819 AD - Institute of Biology, Jan Kochanowski University, 25-369 Kielce, Poland. FAU - Styk, Wojciech AU - Styk W AUID- ORCID: 0000-0003-0186-3118 AD - Academic Laboratory of Psychological Tests, Medical University, 20-059 Lublin, Poland. FAU - Zmorzynski, Szymon AU - Zmorzynski S AUID- ORCID: 0000-0002-2039-2908 AD - Institute of Human Sciences, Faculty of Health Sciences, Academy of Zamosc, Pereca Street 2, 22-400 Zamosc, Poland. LA - eng GR - KONF/SP/0031/2023/01/Ministry of Science and Higher Education in Poland/ GR - SUPB.RN.21.234/Ministry of Science and Higher Education in Poland/ PT - Journal Article PT - Review DEP - 20250626 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC12250256 OTO - NOTNLM OT - aortic stenosis OT - cardiac surgery OT - nursing care OT - patient education OT - perioperative period OT - postoperative period OT - preoperative period COIS- The authors declare no conflicts of interest. EDAT- 2025/07/13 03:38 MHDA- 2025/07/13 03:39 PMCR- 2025/06/26 CRDT- 2025/07/12 01:15 PHST- 2025/05/31 00:00 [received] PHST- 2025/06/19 00:00 [revised] PHST- 2025/06/24 00:00 [accepted] PHST- 2025/07/13 03:39 [medline] PHST- 2025/07/13 03:38 [pubmed] PHST- 2025/07/12 01:15 [entrez] PHST- 2025/06/26 00:00 [pmc-release] AID - jcm14134535 [pii] AID - jcm-14-04535 [pii] AID - 10.3390/jcm14134535 [doi] PST - epublish SO - J Clin Med. 2025 Jun 26;14(13):4535. doi: 10.3390/jcm14134535. PMID- 40648826 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250714 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 14 IP - 13 DP - 2025 Jun 23 TI - Comparing AI-Driven and Heart Team Decision-Making in Multivessel Coronary Artery Disease. LID - 10.3390/jcm14134452 [doi] LID - 4452 AB - Background/Objectives: Multivessel coronary artery disease (CAD) remains a challenging condition requiring multidisciplinary decision-making, particularly when determining between percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG). Recent advancements in artificial intelligence (AI), particularly generative language models like ChatGPT, present an opportunity to assist in the decision-making process. However, their ability to replicate human clinical judgment in complex scenarios, such as multivessel CAD, remains untested. Methods: The aim of this study was to evaluate the concordance between recommendations from AI (ChatGPT) and those from heart team (HT) in the management of multivessel CAD, with a focus on comparing treatment strategies such as PCI and CABG. A retrospective observational study was conducted on 137 patients with multivessel CAD, discussed at multidisciplinary HT meetings in 2024. Standardized clinical vignettes, including clinical and anatomical data, were presented to ChatGPT for treatment recommendations. The AI's responses were compared with the HT's decisions regarding PCI or CABG. Statistical analysis was performed to assess the level of agreement and predictive value of ChatGPT's recommendations. Results: ChatGPT achieved an overall accuracy of 65% in its recommendations. The agreement rate was higher for CABG (82.4%) than for PCI (44.4%). Discordance was identified in 48 patients, with a notable bias towards recommending CABG. Factors such as age, diabetes, and chronic kidney disease were predictors of discordance, although no significant factors emerged for the PCI or CABG subgroups. Conclusions: AI, particularly ChatGPT, demonstrated modest concordance with HT decisions in the management of multivessel CAD, especially favoring CABG. While AI offers potential as a decision-support tool, its current limitations highlight the continued need for human clinical judgment in complex cases. Further research is required to optimize AI integration into clinical decision-making frameworks. FAU - Migliaro, Stefano AU - Migliaro S AD - Department of Cardiovascular Sciences, European Hospital and Aurelia Hospital, 00165 Rome, Italy. FAU - Celotto, Roberto AU - Celotto R AUID- ORCID: 0000-0003-1837-5997 AD - Department of Cardiovascular Sciences, European Hospital and Aurelia Hospital, 00165 Rome, Italy. FAU - Teliti, Romina AU - Teliti R AD - Department of Cardiovascular Sciences, European Hospital and Aurelia Hospital, 00165 Rome, Italy. FAU - Mariani, Simona AU - Mariani S AD - Department of Cardiovascular Sciences, European Hospital and Aurelia Hospital, 00165 Rome, Italy. FAU - Altamura, Luca AU - Altamura L AD - Department of Cardiovascular Sciences, European Hospital and Aurelia Hospital, 00165 Rome, Italy. FAU - Tomai, Fabrizio AU - Tomai F AUID- ORCID: 0000-0002-2196-2941 AD - Department of Cardiovascular Sciences, European Hospital and Aurelia Hospital, 00165 Rome, Italy. LA - eng PT - Journal Article DEP - 20250623 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC12250507 OTO - NOTNLM OT - artificial intelligence (AI) OT - coronary artery bypass grafting (CABG) OT - heart team (HT) OT - multivessel coronary artery disease (CAD) OT - percutaneous coronary intervention (PCI) COIS- The authors declare no conflict of interest. EDAT- 2025/07/13 03:32 MHDA- 2025/07/13 03:33 PMCR- 2025/06/23 CRDT- 2025/07/12 01:14 PHST- 2025/05/28 00:00 [received] PHST- 2025/06/19 00:00 [revised] PHST- 2025/06/21 00:00 [accepted] PHST- 2025/07/13 03:33 [medline] PHST- 2025/07/13 03:32 [pubmed] PHST- 2025/07/12 01:14 [entrez] PHST- 2025/06/23 00:00 [pmc-release] AID - jcm14134452 [pii] AID - jcm-14-04452 [pii] AID - 10.3390/jcm14134452 [doi] PST - epublish SO - J Clin Med. 2025 Jun 23;14(13):4452. doi: 10.3390/jcm14134452. PMID- 40643001 OWN - NLM STAT- MEDLINE DCOM- 20251105 LR - 20251211 IS - 2058-1742 (Electronic) IS - 2058-1742 (Linking) VI - 11 IP - 7 DP - 2025 Nov 4 TI - Current management of transition and multidisciplinary care of patients with inherited and rare cardiomyopathies in Europe: results of the European Reference Network for rare and low prevalence complex diseases of the heart. PG - 1155-1163 LID - 10.1093/ehjqcco/qcaf055 [doi] AB - AIMS: Cardiomyopathies are a heterogeneous group of genetic disorders requiring specialised, multidisciplinary management to optimize patient outcomes. A critical aspect of care is the transition of paediatric patients to adult services, which varies significantly across healthcare systems.This study assessed current practices in care transition and multidisciplinary management of inherited and rare cardiomyopathies across specialised European centres within the European Reference Network for rare and low prevalence complex diseases of the heart network. METHODS AND RESULTS: A 21-question survey was distributed to healthcare providers within the network. A single participant (i.e. cardiologist with expertise in the diagnosis and management of inherited and rare cardiomyopathies) from each centre was approached. Responses from 26 centres across 12 European countries were analysed using descriptive statistics to evaluate institutional characteristics, transition protocols, and multidisciplinary team involvement. While 81% of centres reported having a transition plan, only 42% implemented it for all patients, and 19% had no formal protocol. Multidisciplinary care was well integrated, with regular team discussions, though key professionals such as psychologists and nurses were often absent. The lack of structured transition programmes, inconsistent use of standardized protocols, and a shortage of specialists in cardiogenetics emerged as major unmet needs. CONCLUSION: Significant variability exists in the transition and multidisciplinary care of patients with inherited and rare cardiomyopathies. Standardized transition protocols, greater involvement of multiple healthcare professionals, and enhanced training in cardiogenetics are needed to ensure continuity of care and improve patient care across Europe. CI - (c) The Author(s) 2025. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com. FAU - Monda, Emanuele AU - Monda E AD - Department of Translational Medical Sciences, Inherited and Rare Cardiovascular Diseases, University of Campania 'Luigi Vanvitelli', Monaldi Hospital, Via Leonardo Bianchi Naples 80131, Italy. AD - Member of the European Reference Network for Rare, low-Prevalence, or complex Diseases of the Heart (ERN GUARD-Heart). FAU - Biagini, Elena AU - Biagini E AUID- ORCID: 0000-0003-0295-0440 AD - Member of the European Reference Network for Rare, low-Prevalence, or complex Diseases of the Heart (ERN GUARD-Heart). AD - Cardiology Unit, IRCSS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. FAU - Blom, Nico AU - Blom N AD - Member of the European Reference Network for Rare, low-Prevalence, or complex Diseases of the Heart (ERN GUARD-Heart). AD - Department of Pediatrics, Division of Pediatric Cardiology, Leiden University Medical Center, Leiden, the Netherlands. FAU - Drago, Fabrizio AU - Drago F AUID- ORCID: 0000-0003-1888-373X AD - Member of the European Reference Network for Rare, low-Prevalence, or complex Diseases of the Heart (ERN GUARD-Heart). AD - Pediatric Cardiology and Cardiac Arrhythmia/Syncope Unit, Bambino Gesu Children's Hospital IRCCS, Rome, Italy. FAU - Krapels, Ingrid AU - Krapels I AD - Member of the European Reference Network for Rare, low-Prevalence, or complex Diseases of the Heart (ERN GUARD-Heart). AD - Department of Clinical Genetics, Maastricht University Medical Center, the Netherlands. FAU - Krebsova, Alice AU - Krebsova A AUID- ORCID: 0000-0001-8319-1460 AD - Member of the European Reference Network for Rare, low-Prevalence, or complex Diseases of the Heart (ERN GUARD-Heart). AD - Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. FAU - Koubsky, Karel AU - Koubsky K AD - Member of the European Reference Network for Rare, low-Prevalence, or complex Diseases of the Heart (ERN GUARD-Heart). AD - Children's Heart Centre, Second Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic. FAU - Khraiche, Diala AU - Khraiche D AD - Member of the European Reference Network for Rare, low-Prevalence, or complex Diseases of the Heart (ERN GUARD-Heart). AD - Pediatric and Congenital Cardiology Unit, Hopital Necker Enfants Malades, M3C-Necker, Paris, France. FAU - Martins, Elisabete AU - Martins E AD - Member of the European Reference Network for Rare, low-Prevalence, or complex Diseases of the Heart (ERN GUARD-Heart). AD - Department of Medicine, Faculty of Medicine, University of Porto, Porto, Portugal. FAU - Merlo, Marco AU - Merlo M AD - Member of the European Reference Network for Rare, low-Prevalence, or complex Diseases of the Heart (ERN GUARD-Heart). AD - Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), University of Trieste, Italy. FAU - Michels, Michelle AU - Michels M AUID- ORCID: 0000-0001-6432-0431 AD - Member of the European Reference Network for Rare, low-Prevalence, or complex Diseases of the Heart (ERN GUARD-Heart). AD - Department of Cardiology, Thorax Center, Cardiovascular Institute, Erasmus Medical Center, Rotterdam, the Netherlands. FAU - Mizia-Stec, Katarzyna AU - Mizia-Stec K AUID- ORCID: 0000-0001-6907-2799 AD - Member of the European Reference Network for Rare, low-Prevalence, or complex Diseases of the Heart (ERN GUARD-Heart). AD - First Department of Cardiology, Medical University of Silesia School of Medicine in Katowice, Katowice, Poland. FAU - Morner, Stellan AU - Morner S AD - Member of the European Reference Network for Rare, low-Prevalence, or complex Diseases of the Heart (ERN GUARD-Heart). AD - Department of Clinical Sciences, Pediatrics, Umea University, Umea, Sweden. FAU - Pena Pena, Maria Luisa AU - Pena Pena ML AD - Member of the European Reference Network for Rare, low-Prevalence, or complex Diseases of the Heart (ERN GUARD-Heart). AD - Cardiology, Virgen del Rocio University Hospital Cardiology and Cardiovascular Surgery Service, Sevilla, Spain. FAU - Planinc, Ivo AU - Planinc I AD - Member of the European Reference Network for Rare, low-Prevalence, or complex Diseases of the Heart (ERN GUARD-Heart). AD - Department of Cardiovascular Diseases, University of Zagreb School of Medicine and Univerisity Hospital Centre Zagreb, Zagreb, Croatia. FAU - Robyns, Tomas AU - Robyns T AUID- ORCID: 0000-0002-8676-4874 AD - Member of the European Reference Network for Rare, low-Prevalence, or complex Diseases of the Heart (ERN GUARD-Heart). AD - Department of Cardiovascular Sciences, KU Leuven, Leuven, Belgium. FAU - Rydberg, Annika AU - Rydberg A AUID- ORCID: 0000-0001-9655-7783 AD - Member of the European Reference Network for Rare, low-Prevalence, or complex Diseases of the Heart (ERN GUARD-Heart). AD - Department of Clinical Sciences, Pediatrics, Umea University, Umea, Sweden. FAU - Saenen, Johan AU - Saenen J AUID- ORCID: 0000-0002-0049-4632 AD - Member of the European Reference Network for Rare, low-Prevalence, or complex Diseases of the Heart (ERN GUARD-Heart). AD - Antwerp University Hospital, Antwerp, Belgium. FAU - Rodriguez Palomares, Jose Fernando AU - Rodriguez Palomares JF AD - Member of the European Reference Network for Rare, low-Prevalence, or complex Diseases of the Heart (ERN GUARD-Heart). AD - Centro de Investigacion Biomedica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain. FAU - Rutger, Hassink AU - Rutger H AD - Member of the European Reference Network for Rare, low-Prevalence, or complex Diseases of the Heart (ERN GUARD-Heart). AD - Department of Cardiology, University Medical Centre Utrecht, Utrecht, The Netherlands. FAU - Sarquella Brugada, Georgia AU - Sarquella Brugada G AD - Member of the European Reference Network for Rare, low-Prevalence, or complex Diseases of the Heart (ERN GUARD-Heart). AD - Pediatric Arrhythmias, Inherited Cardiac Diseases and Sudden Death Unit, Hospital Sant Joan de Deu Esplugues de Llobregat 08950, Spain. FAU - Scheirlynck, Esther AU - Scheirlynck E AD - Member of the European Reference Network for Rare, low-Prevalence, or complex Diseases of the Heart (ERN GUARD-Heart). AD - Centrum Voor Hart-en Vaatziekten, Universitair Ziekenhuis Brussel-Vrije Universiteit Brussel, Brussels, Belgium. FAU - Schulze-Bahr, Eric AU - Schulze-Bahr E AUID- ORCID: 0000-0001-6884-2501 AD - Member of the European Reference Network for Rare, low-Prevalence, or complex Diseases of the Heart (ERN GUARD-Heart). AD - Institute for Genetics of Heart Diseases, University Hospital Munster, Munster, Germany. FAU - Tfelt-Hansen, Jacob AU - Tfelt-Hansen J AUID- ORCID: 0000-0003-3895-9316 AD - Member of the European Reference Network for Rare, low-Prevalence, or complex Diseases of the Heart (ERN GUARD-Heart). AD - Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark. FAU - Wolf, Cordula M AU - Wolf CM AD - Member of the European Reference Network for Rare, low-Prevalence, or complex Diseases of the Heart (ERN GUARD-Heart). AD - Department of Congenital Heart Defects and Pediatric Cardiology, TUM University Hospital German Heart Center, Munich, Germany. FAU - Hofman, Nynke AU - Hofman N AD - Member of the European Reference Network for Rare, low-Prevalence, or complex Diseases of the Heart (ERN GUARD-Heart). AD - Department of Cardiology, Amsterdam UMC Location University of Amsterdam, Amsterdam Cardiovascular Science, Heart Failure and Arrhythmias, the Netherlands. FAU - Amin, Ahmad S AU - Amin AS AD - Member of the European Reference Network for Rare, low-Prevalence, or complex Diseases of the Heart (ERN GUARD-Heart). AD - Department of Cardiology, Amsterdam UMC Location University of Amsterdam, Amsterdam Cardiovascular Science, Heart Failure and Arrhythmias, the Netherlands. FAU - Wilde, Arthur AU - Wilde A AD - Member of the European Reference Network for Rare, low-Prevalence, or complex Diseases of the Heart (ERN GUARD-Heart). AD - Department of Cardiology, Amsterdam UMC Location University of Amsterdam, Amsterdam Cardiovascular Science, Heart Failure and Arrhythmias, the Netherlands. FAU - Charron, Philippe AU - Charron P AUID- ORCID: 0000-0003-1018-1231 AD - Member of the European Reference Network for Rare, low-Prevalence, or complex Diseases of the Heart (ERN GUARD-Heart). AD - Departement de Cardiologie et Departement de Genetique, Sorbonne Universite, AP-HP, Hopital Universitaire Pitie-Salpetriere, Paris, France. FAU - Limongelli, Giuseppe AU - Limongelli G AUID- ORCID: 0000-0002-8291-9517 AD - Department of Translational Medical Sciences, Inherited and Rare Cardiovascular Diseases, University of Campania 'Luigi Vanvitelli', Monaldi Hospital, Via Leonardo Bianchi Naples 80131, Italy. AD - Member of the European Reference Network for Rare, low-Prevalence, or complex Diseases of the Heart (ERN GUARD-Heart). LA - eng PT - Journal Article PT - Multicenter Study PL - England TA - Eur Heart J Qual Care Clin Outcomes JT - European heart journal. Quality of care & clinical outcomes JID - 101677796 SB - IM MH - Humans MH - Europe/epidemiology MH - *Patient Care Team/organization & administration MH - *Cardiomyopathies/therapy/epidemiology/genetics MH - *Rare Diseases/therapy/epidemiology MH - Prevalence MH - Surveys and Questionnaires MH - *Disease Management MH - *Transition to Adult Care/organization & administration MH - Male OTO - NOTNLM OT - Cardiomyopathy OT - Multidisciplinary care OT - Transition COIS- Conflict of interest: none declared. EDAT- 2025/07/11 12:31 MHDA- 2025/11/05 12:32 CRDT- 2025/07/11 07:03 PHST- 2025/05/21 00:00 [received] PHST- 2025/06/03 00:00 [revised] PHST- 2025/06/24 00:00 [accepted] PHST- 2025/11/05 12:32 [medline] PHST- 2025/07/11 12:31 [pubmed] PHST- 2025/07/11 07:03 [entrez] AID - 8196530 [pii] AID - 10.1093/ehjqcco/qcaf055 [doi] PST - ppublish SO - Eur Heart J Qual Care Clin Outcomes. 2025 Nov 4;11(7):1155-1163. doi: 10.1093/ehjqcco/qcaf055. PMID- 40641530 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250712 IS - 1392-0138 (Print) IS - 2029-4174 (Electronic) IS - 1392-0138 (Linking) VI - 32 IP - 1 DP - 2025 TI - Antidepressant Prescription to Children/Adolescents and Its Effects on the Cardiovascular System, Comprising the Actual Questions of Periodicity of the Checkups, Cooperation among Pediatricians, Family Doctors, Cardiologists and Children-Adolescent Psychiatrists. PG - 52-63 LID - 10.15388/Amed.2025.32.1.15 [doi] AB - BACKGROUND: Pharmacological treatment is one of the most effective ways to help psychiatric patients with depressive disorders. However, prescription of antidepressants to children and adolescents creates controversial thoughts due to possible negative effects on the cardiovascular system. Despite being beneficial in controlling serious illnesses, there is less research done on the side effects of antidepressants which would require periodical checkups and cooperation among medical specialists. This literature review was completed to evaluate effects of antidepressants on the cardiovascular system and the necessity of regular assessment while treating children and adolescents. AIM: To review the cardiovascular effects of antidepressants prescribed to children and adolescents; to discuss the need for regular patient checkups with a multidisciplinary team: pediatricians, family doctors, cardiologists and children-adolescent psychiatrists. METHODOLOGY: Literature sources were selected from the Pubmed, Google Scholar, Clinical Key, and Research Gate databases by following dates from 2013 to 2024 while using the following keywords and their combinations: antidepressant, cardiovascular, side effects, cardiovascular risk, children and adolescents, selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), psychotropic medication, antidepressants in pediatrics, atypical antidepressants, benzodiazepines, lipid metabolism. RESULTS: Antidepressants, including SSRIs, SNRIs, TCAs, atypical antidepressants and benzodiazepines, are associated with significant cardiovascular risks in children and adolescents. SSRIs, like citalopram and escitalopram, can disturb the heart rhythm by prolonging the QT interval, or increasing the risk of serious arrhythmias. SNRIs have been linked to an elevated blood pressure and heart rate. TCAs are known for their proarrhythmic effects, particularly in overdose situations, posing a high risk of sudden cardiac events. Atypical antidepressants like bupropion can cause cardiovascular disturbances, especially when overdosed. Additionally, less commonly prescribed benzodiazepines contribute to cardiovascular risks when combined with SSRIs during pregnancy, due to increasing the likelihood of congenital heart defects. These risks underscore the importance of careful monitoring, dosage management and thorough cardiovascular assessment when prescribing these medications to children, adolescents, and pregnant women. A team consisting of professional specialists - children-adolescent psychiatrists, cardiologists, pediatricians and family doctors - should detect long-term effects of pharmacotherapy by checking up the young patients regularly. CONCLUSIONS: The use of antidepressants in children and adolescents, though crucial for managing severe psychiatric disorders, raises significant cardiovascular safety concerns. SSRIs, SNRIs, TCAs, atypical antidepressants, and benzodiazepines have varying cardiovascular risks, especially in vulnerable youth populations and during the prenatal period. Given these risks, careful prescribing, close monitoring, creating guidelines and collaboration among healthcare providers are essential to ensure safe and effective treatment. Additionally, more research is needed to fully understand the long-term cardiovascular impacts of these medications in the pediatric population. CI - Copyright (c) 2025 Reda Montvilaite. Published by Vilnius University Press. FAU - Montvilaite, Reda AU - Montvilaite R AUID- ORCID: 0009-0001-3735-5492 AD - Faculty of Medicine, Vilnius University, Vilnius, Lithuania. LA - eng PT - Journal Article DEP - 20250218 PL - Lithuania TA - Acta Med Litu JT - Acta medica Lituanica JID - 9442465 PMC - PMC12239188 OTO - NOTNLM OT - Antidepressants OT - antidepressants in pediatrics OT - atypical antidepressants OT - benzodiazepines OT - cardiovascular OT - cardiovascular risk OT - children and adolescents OT - lipid metabolism OT - psychotropic medication OT - selective serotonin reuptake inhibitors (SSRIs) OT - serotonin-norepinephrine reuptake inhibitors (SNRIs) OT - side effects OT - tricyclic antidepressants EDAT- 2025/07/11 06:27 MHDA- 2025/07/11 06:28 PMCR- 2025/01/01 CRDT- 2025/07/11 05:04 PHST- 2024/09/03 00:00 [received] PHST- 2025/03/19 00:00 [revised] PHST- 2025/03/24 00:00 [accepted] PHST- 2025/07/11 06:28 [medline] PHST- 2025/07/11 06:27 [pubmed] PHST- 2025/07/11 05:04 [entrez] PHST- 2025/01/01 00:00 [pmc-release] AID - amed-32-052 [pii] AID - 10.15388/Amed.2025.32.1.15 [doi] PST - ppublish SO - Acta Med Litu. 2025;32(1):52-63. doi: 10.15388/Amed.2025.32.1.15. Epub 2025 Feb 18. PMID- 40636951 OWN - NLM STAT- MEDLINE DCOM- 20250710 LR - 20251208 IS - 1735-3688 (Electronic) IS - 0253-0716 (Print) IS - 0253-0716 (Linking) VI - 50 IP - 6 DP - 2025 Jun TI - Targeted Temperature Management in Pregnant Patients after Cardiac Arrest: A Systematic Review. PG - 363-375 LID - 10.30476/ijms.2024.104167.3767 [doi] AB - BACKGROUND: Targeted temperature management (TTM) is a standard care intervention following resuscitation, known to improve neurological outcomes in patients. However, there is a lack of comprehensive studies on the application of TTM, specifically therapeutic hypothermia, in pregnant patients. Considering the critical importance of maternal and fetal health, this study aimed to investigate the use of TTM in pregnant women following cardiac arrest. METHODS: This systematic review was conducted by searching multiple databases, including Web of Science, PubMed Central, MEDLINE, Scopus, EMBASE, and Cochrane, up to October 2024. The search was conducted with no restrictions on time, place, or language. Articles were selected based on predefined inclusion criteria, which included case reports detailing the use of TTM in pregnant women after cardiac arrest. The quality of the included studies was assessed using the Jonna Briggs Institute (JBI) checklist for case reports. RESULTS: A total of nine articles met the inclusion criteria. Among the reported cases, there was 1 (11.1%) case of maternal death and 2 (22.2%) cases of fetal death, neither of which appeared to be directly attributable to the use of hypothermia. Neurological outcomes were favorable for all surviving mothers and fetuses following the application of TTM. The most common maternal complications during hypothermia for mothers were decreased blood pressure and heart rate, occurring in 2 (22.2%) cases. For the fetuses, bradycardia was the most frequently reported complication, occurring in 5 (55.5%) cases. CONCLUSION: The use of TTM in pregnant patients following cardiac arrest might be considered on a case-by-case basis with the involvement of a multidisciplinary team. Pregnancy does not appear to be an absolute contraindication for TTM. However, close fetal monitoring is essential to ensure fetal well-being during the procedure. CI - Copyright: (c) Iranian Journal of Medical Sciences. FAU - Azadikhah Jahromi, Sina AU - Azadikhah Jahromi S AD - Research Center for Noncommunicable Diseases, Jahrom University of Medical Sciences, Jahrom, Iran. FAU - Ostovan, Mina AU - Ostovan M AD - Research Center for Noncommunicable Diseases, Jahrom University of Medical Sciences, Jahrom, Iran. FAU - Zahedi, Razieh AU - Zahedi R AD - Research Center for Noncommunicable Diseases, Jahrom University of Medical Sciences, Jahrom, Iran. FAU - Rahmanian, Zhila AU - Rahmanian Z AD - Research Center for Noncommunicable Diseases, Jahrom University of Medical Sciences, Jahrom, Iran. FAU - Abdollahzadeh, Pegah AU - Abdollahzadeh P AD - Research Center for Noncommunicable Diseases, Jahrom University of Medical Sciences, Jahrom, Iran. LA - eng PT - Journal Article PT - Systematic Review DEP - 20250601 PL - Iran TA - Iran J Med Sci JT - Iranian journal of medical sciences JID - 8104374 SB - IM MH - Humans MH - Pregnancy MH - Female MH - *Heart Arrest/therapy MH - *Hypothermia, Induced/methods/adverse effects MH - *Pregnancy Complications, Cardiovascular/therapy PMC - PMC12235274 OTO - NOTNLM OT - Cardiac arrest OT - Cardiopulmonary resuscitation OT - Hypothermia OT - Hypothermia, induced OT - Pregnancy COIS- None declared. EDAT- 2025/07/10 06:27 MHDA- 2025/07/10 06:28 PMCR- 2025/06/01 CRDT- 2025/07/10 05:11 PHST- 2024/09/22 00:00 [received] PHST- 2024/11/06 00:00 [revised] PHST- 2024/11/30 00:00 [accepted] PHST- 2025/07/10 06:28 [medline] PHST- 2025/07/10 06:27 [pubmed] PHST- 2025/07/10 05:11 [entrez] PHST- 2025/06/01 00:00 [pmc-release] AID - IJMS-50-6 [pii] AID - 10.30476/ijms.2024.104167.3767 [doi] PST - epublish SO - Iran J Med Sci. 2025 Jun 1;50(6):363-375. doi: 10.30476/ijms.2024.104167.3767. eCollection 2025 Jun. PMID- 40636563 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250711 IS - 2052-3211 (Print) IS - 2052-3211 (Electronic) IS - 2052-3211 (Linking) VI - 18 IP - 1 DP - 2025 TI - Optimisation of lipid-lowering therapy post-Acute Coronary Syndromes: a multidisciplinary, cross-interface novel pharmacy care model within a local cardiac rehabilitation centre. PG - 2523934 LID - 10.1080/20523211.2025.2523934 [doi] LID - 2523934 AB - BACKGROUND: Acute coronary syndromes (ACS) are a spectrum of diseases that diminish blood flow to the heart and are a major cause of global death. They can be prevented with lipid-lowering therapies (LLTs) but these are often sub-optimally managed in practice. A potential solution could include implementing independent prescribing (IP) pharmacists to optimise LLTs within cardiac rehabilitation services. Aim: To explore the impact of a novel pharmacy service within a cardiac rehabilitation centre (CRC) at a local hospital in the West Midlands UK, on post-ACS patients' ability to achieve targets of non-HDL-C. METHODS: A retrospective analysis was undertaken at a rehabilitation centre to evaluate pharmacist interventions in lipid management. Inclusion criteria: Post-ACS patients not attaining target levels of non-HDL-C < 2.5 mmol/L, 3 months after discharge. Non-HDL-C levels were also measured 2 months after the pharmacist interventions. RESULTS: 169 post-ACS patients were eligible for treatment. 54% of patients achieved their <2.5 mmol/L of non-HDL-C levels. 25% of these were combination therapy of high-intensity statin and ezetimibe. 36% of patients achieved a 40% reduction of baseline non-HDL levels. 38% did not achieve either target. CONCLUSION: This innovative pharmacy role in CR could address the suboptimal LLT management that is common in the post-ACS population. It fosters collaborative care across healthcare sectors, improving patient outcomes and augmenting the probability of reducing ACS risk. CI - (c) 2025 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. FAU - Gul, Idil Z AU - Gul IZ AD - School of Pharmacy, School of Health Sciences, College of Medicine and Health, University of Birmingham, Birmingham, UK. FAU - Baig, Sarah AU - Baig S AD - School of Pharmacy, School of Health Sciences, College of Medicine and Health, University of Birmingham, Birmingham, UK. FAU - Glover, Maria AU - Glover M AD - Royal Wolverhampton NHS Trust, Wolverhampton, UK. FAU - Virdee, Mandeep AU - Virdee M AD - Royal Wolverhampton NHS Trust, Wolverhampton, UK. FAU - Osman, Samira AU - Osman S AD - School of Pharmacy, School of Health Sciences, College of Medicine and Health, University of Birmingham, Birmingham, UK. FAU - Jenkins, Duncan AU - Jenkins D AD - Dudley Integrated Health and Care NHS Trust Health and Social Care Centre, Brierley Hill, UK. FAU - Jalal, Zahraa AU - Jalal Z AUID- ORCID: 0000-0002-6126-3379 AD - School of Pharmacy, School of Health Sciences, College of Medicine and Health, University of Birmingham, Birmingham, UK. LA - eng PT - Journal Article DEP - 20250708 PL - England TA - J Pharm Policy Pract JT - Journal of pharmaceutical policy and practice JID - 101627192 PMC - PMC12239226 OTO - NOTNLM OT - Acute coronary syndromes OT - cardiac rehabilitation OT - lipid-lowering therapies OT - non-HDL-C reduction OT - pharmacist-led interventions OT - secondary prevention COIS- No potential conflict of interest was reported by the author(s). EDAT- 2025/07/10 06:27 MHDA- 2025/07/10 06:28 PMCR- 2025/07/08 CRDT- 2025/07/10 05:05 PHST- 2025/07/10 06:28 [medline] PHST- 2025/07/10 06:27 [pubmed] PHST- 2025/07/10 05:05 [entrez] PHST- 2025/07/08 00:00 [pmc-release] AID - 2523934 [pii] AID - 10.1080/20523211.2025.2523934 [doi] PST - epublish SO - J Pharm Policy Pract. 2025 Jul 8;18(1):2523934. doi: 10.1080/20523211.2025.2523934. eCollection 2025. PMID- 40633862 OWN - NLM STAT- MEDLINE DCOM- 20250809 LR - 20260617 IS - 1096-3650 (Electronic) IS - 1044-579X (Linking) VI - 114 DP - 2025 Sep TI - From awareness to action: Revolutionizing cardio-oncology in China. PG - 195-202 LID - S1044-579X(25)00092-6 [pii] LID - 10.1016/j.semcancer.2025.06.011 [doi] AB - Cardio-oncology is an emerging interdisciplinary field focused on the intersection of cancer and cardiovascular disease. With the rising incidence of both cancer and cardiovascular disease in China, establishing a strong cardio-oncology framework has become essential. This review examines the historical development, clinical practices, and key milestones of cardio-oncology in China, emphasizing the importance of multidisciplinary teams, specialized guidelines, and international collaborations. Additionally, it discusses the current challenges and future opportunities for advancing cardio-oncology within China's healthcare landscape. CI - Copyright (c) 2025. Published by Elsevier Ltd. FAU - Wang, Aman AU - Wang A AD - Department of Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian, China. FAU - Liu, Jiwei AU - Liu J AD - Department of Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian, China. Electronic address: liujiwei@dmu.edu.cn. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20250707 PL - England TA - Semin Cancer Biol JT - Seminars in cancer biology JID - 9010218 SB - IM MH - Humans MH - China/epidemiology MH - *Neoplasms/epidemiology/therapy/complications MH - *Medical Oncology/methods/trends MH - *Cardiovascular Diseases/epidemiology/therapy MH - *Cardiology MH - Cardio-Oncology OTO - NOTNLM OT - Cardio-oncology OT - China OT - Future directions OT - Guidelines OT - Multidisciplinary team COIS- Declaration of Competing Interest The authors declare that there is no conflict of interest regarding the publication of this paper. No financial, personal, or professional affiliations influenced the research, analysis, or interpretation of the findings presented in this work. All authors have reviewed and approved the final manuscript, and there are no competing interests that could inappropriately influence, or be perceived to influence, this research. EDAT- 2025/07/10 00:36 MHDA- 2025/08/10 06:16 CRDT- 2025/07/09 19:36 PHST- 2024/10/30 00:00 [received] PHST- 2025/06/21 00:00 [revised] PHST- 2025/06/29 00:00 [accepted] PHST- 2025/08/10 06:16 [medline] PHST- 2025/07/10 00:36 [pubmed] PHST- 2025/07/09 19:36 [entrez] AID - S1044-579X(25)00092-6 [pii] AID - 10.1016/j.semcancer.2025.06.011 [doi] PST - ppublish SO - Semin Cancer Biol. 2025 Sep;114:195-202. doi: 10.1016/j.semcancer.2025.06.011. Epub 2025 Jul 7. PMID- 40630234 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250710 IS - 2772-9303 (Electronic) IS - 2772-9303 (Linking) VI - 4 IP - 6 DP - 2025 Jun TI - First-in-human TAVR With Navitor Self-expanding Intra-annular Valve in LVAD-Associated Aortic Regurgitation. PG - 102620 LID - 10.1016/j.jscai.2025.102620 [doi] LID - 102620 AB - BACKGROUND: Aortic regurgitation (AR) is commonly reported in patients with left ventricular assist device (LVAD) and is associated with poor outcomes. Surgical management of AR in these patients carries high operative mortality. Dedicated transcatheter options for AR are limited to research trials and are not commercially available. Transcatheter aortic valve replacement (TAVR) in patients with LVAD and AR is challenging due to a lack of adequate annular calcium to anchor the valve with a high risk of embolization. METHODS: Two patients with severe LVAD-associated AR and heart failure were referred for consideration for TAVR. Evaluation of the aortic valve revealed no significant valve calcification. They were attempted to be enrolled in trials of the JenaValve and J-valve but failed screening due to the presence of LVAD. Compassionate use of these AR-dedicated TAVR valves was closed due to registries that are going to begin later in 2025. Hence, after heart team approach, we proceeded with commercially available Navitor self-expanding intra-annular valve (Abbott) that has the largest aortic diameter. RESULTS: We were able to successfully treat AR due to LVAD using the Navitor valve without valve migration at the recommended depth. CONCLUSIONS: Commercial TAVR devices for LVAD-associated AR carry high risk of embolization in the absence of valve calcification. Abbott Navitor valve with its unique frame design can be used safely to treat AR associated with LVAD. CI - (c) 2025 The Author(s). FAU - Guddeti, Raviteja R AU - Guddeti RR AD - The Christ Hospital Heart and Vascular Institute, Cincinnati, Ohio. FAU - Garcia, Santiago AU - Garcia S AD - The Christ Hospital Heart and Vascular Institute, Cincinnati, Ohio. FAU - Egnaczyk, Gregory F AU - Egnaczyk GF AD - The Christ Hospital Heart and Vascular Institute, Cincinnati, Ohio. FAU - Chung, Eugene AU - Chung E AD - The Christ Hospital Heart and Vascular Institute, Cincinnati, Ohio. FAU - Bae, Richard AU - Bae R AD - The Christ Hospital Heart and Vascular Institute, Cincinnati, Ohio. FAU - Answini, Geoffrey AU - Answini G AD - The Christ Hospital Heart and Vascular Institute, Cincinnati, Ohio. FAU - Seshiah, Puvi AU - Seshiah P AD - The Christ Hospital Heart and Vascular Institute, Cincinnati, Ohio. LA - eng PT - Journal Article DEP - 20250617 PL - United States TA - J Soc Cardiovasc Angiogr Interv JT - Journal of the Society for Cardiovascular Angiography & Interventions JID - 9918419271306676 PMC - PMC12230469 OTO - NOTNLM OT - aortic regurgitation OT - left ventricular assist device EDAT- 2025/07/09 06:26 MHDA- 2025/07/09 06:27 PMCR- 2025/06/17 CRDT- 2025/07/09 04:57 PHST- 2024/09/19 00:00 [received] PHST- 2025/01/26 00:00 [revised] PHST- 2025/01/28 00:00 [accepted] PHST- 2025/07/09 06:27 [medline] PHST- 2025/07/09 06:26 [pubmed] PHST- 2025/07/09 04:57 [entrez] PHST- 2025/06/17 00:00 [pmc-release] AID - S2772-9303(25)00061-4 [pii] AID - 102620 [pii] AID - 10.1016/j.jscai.2025.102620 [doi] PST - epublish SO - J Soc Cardiovasc Angiogr Interv. 2025 Jun 17;4(6):102620. doi: 10.1016/j.jscai.2025.102620. eCollection 2025 Jun. PMID- 34033395 STAT- Publisher CTDT- 20250707 PB - StatPearls Publishing DP - 2025 Jan TI - Extracorporeal Membrane Oxygenation Anticoagulation (Archived). BTI - StatPearls AB - Extracorporeal membrane oxygenation (ECMO) has become an increasingly utilized modality in the treatment of critically ill patients experiencing severe cardiac or respiratory failure. As access to ECMO continues to expand globally, clinicians across multiple specialties are encountering this life-sustaining intervention in various settings. The primary goal of ECMO is to maintain systemic perfusion and gas exchange in patients with cardiopulmonary failure, serving as a bridge to recovery, transplantation, or prolonged mechanical support. ECMO is typically categorized into 2 configurations: venovenous (VV), which supports pulmonary function, and venoarterial (VA), which supports both pulmonary and circulatory function. Although ECMO can be lifesaving, it carries substantial risk, particularly related to bleeding and thromboembolic complications. Thromboembolism remains a leading cause of morbidity and circuit failure, reinforcing the necessity of precise anticoagulation. A clear understanding of ECMO circuit physiology and coagulation disturbances during support is essential for reducing complications and improving outcomes. Mastery of pharmacologic approaches, monitoring methods, and interprofessional coordination enhances the safety and efficacy of anticoagulation. This educational activity provides a detailed review of anticoagulation in ECMO, promotes evidence-based practices, and advances team-based competence in treating patients supported with ECMO. CI - Copyright (c) 2025, StatPearls Publishing LLC. FAU - Szymanski, Michael W AU - Szymanski MW AD - Boston Medical Center FAU - Wang, Cecily F AU - Wang CF AD - Straub Benioff Medical Center, University of Hawaii John A. Burns School of Medicine, OptimumAir Hawaii FAU - Hafzalah, Mina AU - Hafzalah M AD - Children's Hospital of Michigan LA - eng PT - Study Guide PT - Book Chapter PL - Treasure Island (FL) COIS- Disclosure: Michael W Szymanski declares no relevant financial relationships with ineligible companies. Disclosure: Cecily F Wang declares no relevant financial relationships with ineligible companies. Disclosure: Mina Hafzalah declares no relevant financial relationships with ineligible companies. EDAT- 2025/07/07 00:00 CRDT- 2025/07/07 00:00 AID - NBK570633 [bookaccession] PMID- 40617580 OWN - NLM STAT- MEDLINE DCOM- 20250904 LR - 20250904 IS - 2666-9919 (Electronic) IS - 2666-9919 (Linking) VI - 55 IP - 6 DP - 2025 Sep TI - Treatment of left-sided prosthetic valve endocarditis by suppressive antibiotic therapy: A retrospective monocentric real-world study. PG - 105112 LID - S2666-9919(25)00091-0 [pii] LID - 10.1016/j.idnow.2025.105112 [doi] AB - OBJECTIVES: Prosthetic valve endocarditis has a poor prognosis, with high risks of relapse complicating management. Suppressive antibiotic therapy is increasingly considered as a means of treatment for infected devices that cannot be removed. We compared i) early mortality and ii) one-year overall and relapse-free survival between different strategies in real-world management of prosthetic valve endocarditis, one of them being suppressive antibiotic therapy. PATIENTS AND METHODS: This single-center retrospective study included patients with aortic or mitral prosthetic valve endocarditis managed between 2019 and 2021. Each strategy was patient-centered and decided on by a multidisciplinary team. At first, we divided the population between surgically and conservatively managed patients. Initial intravenous antibiotic therapy lasted at least six weeks, and we compared early mortality having occurred prior to its completion. At a later stage, we divided the conservatively managed survivors between those who received suppressive antibiotic therapy and those who did not, and we compared survival and relapse rates during the first year subsequent to adaptation of each strategy. RESULTS: Seventy-five patients were included. Biological prostheses (33 %) for aortic valve replacement (95 %) predominated. The 17 (22.3 %) surgically managed patients were younger. Among the 58 conservatively managed patients, 42 had a theoretical indication for surgery. Eleven (14.6 %) patients died before having completed their course of intravenous antibiotic therapy, with no difference between surgical and conservative strategies (17.6 % vs. 13.8 %, p = 0.7043). Out of the 50 conservatively managed survivors, 35 received suppressive antibiotic therapy. Overall one-year survival was 73.9 % [64.1-85.2] and did not differ from one strategy to the next. Only six relapses occurred within the first year, including one (7.1 %) in surgically managed survivors and two (5.6 %) among the conservatively managed survivors receiving suppressive antibiotic therapy (5.6 %). CONCLUSIONS: While surgery remains the gold standard for prosthetic valve endocarditis, especially in complicated cases, suppressive antibiotic therapy appeared suitable for selected patients for whom the surgical option seemed excessively risky. CI - Copyright (c) 2025 Elsevier Masson SAS. All rights reserved. FAU - Sebestyen, A AU - Sebestyen A AD - Cardiac Surgery Department, University Hospital of Grenoble-Alpes, Grenoble, France. Electronic address: asebestyen@chu-grenoble.fr. FAU - Boisson, M AU - Boisson M AD - Cardiac Surgery Department, University Hospital of Grenoble-Alpes, Grenoble, France. FAU - Rhem, D AU - Rhem D AD - Perioperative Medicine Department, Cardiothoracic Anesthesiology and Intensive Care, University Hospital of Grenoble-Alpes, Grenoble, France. FAU - Korabi, M AU - Korabi M AD - Cardiology Department, University Hospital of Grenoble-Alpes, Grenoble, France. FAU - Behouche, A AU - Behouche A AD - Perioperative Medicine Department, Cardiothoracic Anesthesiology and Intensive Care, University Hospital of Grenoble-Alpes, Grenoble, France. FAU - Blanc, M AU - Blanc M AD - Tropical and Infectious Disease Department, University Hospital of Grenoble-Alpes, Grenoble, France. FAU - Chavanon, O AU - Chavanon O AD - Cardiac Surgery Department, University Hospital of Grenoble-Alpes, Grenoble, France. LA - eng PT - Journal Article DEP - 20250703 PL - France TA - Infect Dis Now JT - Infectious diseases now JID - 101775152 RN - 0 (Anti-Bacterial Agents) SB - IM MH - Humans MH - Retrospective Studies MH - Male MH - Female MH - *Anti-Bacterial Agents/therapeutic use/administration & dosage MH - Middle Aged MH - *Prosthesis-Related Infections/drug therapy/mortality MH - Aged MH - *Heart Valve Prosthesis/adverse effects/microbiology MH - *Endocarditis, Bacterial/drug therapy/mortality MH - Recurrence MH - *Endocarditis/drug therapy MH - Treatment Outcome MH - Adult OTO - NOTNLM OT - Prosthetic valve endocarditis OT - Suppressive antibiotic therapy OT - Survival COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/07/06 06:18 MHDA- 2025/09/05 00:35 CRDT- 2025/07/05 19:42 PHST- 2025/02/12 00:00 [received] PHST- 2025/06/29 00:00 [revised] PHST- 2025/07/02 00:00 [accepted] PHST- 2025/09/05 00:35 [medline] PHST- 2025/07/06 06:18 [pubmed] PHST- 2025/07/05 19:42 [entrez] AID - S2666-9919(25)00091-0 [pii] AID - 10.1016/j.idnow.2025.105112 [doi] PST - ppublish SO - Infect Dis Now. 2025 Sep;55(6):105112. doi: 10.1016/j.idnow.2025.105112. Epub 2025 Jul 3. PMID- 40613952 OWN - NLM STAT- MEDLINE DCOM- 20250704 LR - 20260226 IS - 1534-3170 (Electronic) IS - 1523-3782 (Print) IS - 1523-3782 (Linking) VI - 27 IP - 1 DP - 2025 Jul 4 TI - Insomnia in Heart Failure Patients in a Hospital Setting: Causes, Consequences, and Interventions. PG - 108 LID - 10.1007/s11886-025-02256-1 [doi] LID - 108 AB - PURPOSE OF REVIEW: This review explores the causes, consequences, and management approaches of hospital-acquired insomnia in patients with heart failure (HF). It examines the key factors contributing to insomnia in hospitalized HF patients, its impact on health outcomes, and effective management strategies to address the issue. RECENT FINDINGS: Recent research highlights that environmental factors (such as noise, lighting, and medical interventions) and clinical symptoms (including dyspnea and nocturia) significantly contribute to insomnia in hospitalized HF patients. Insomnia exacerbates HF symptoms, increasing hospitalization rates, healthcare costs, and the risk of cardiovascular complications. Non-pharmacological interventions have improved sleep quality and overall well-being, including Cognitive Behavioral Therapy for Insomnia (CBT-I), sleep hygiene education, and supervised exercise programs. Hospital-acquired insomnia negatively affects both the physical and psychosocial health of HF patients. Effective management requires a multidisciplinary approach, incorporating both pharmacological and non-pharmacological strategies. Nurses play a crucial role in implementing sleep-promoting interventions. Creating a hospital environment that supports sleep, raising healthcare professionals' awareness, and integrating evidence-based interventions can enhance recovery outcomes. Future research should focus on long-term studies evaluating the efficacy of insomnia management strategies in HF patients. CI - (c) 2025. The Author(s). FAU - Atay, Mehmet Emin AU - Atay ME AUID- ORCID: 0000-0002-5373-9031 AD - Agri Ibrahim Cecen University, Agri, Turkiye. FAU - Ciftci, Bahar AU - Ciftci B AUID- ORCID: 0000-0001-6221-3042 AD - Ataturk University, Erzurum, Turkiye. bahar.ciftci@atauni.edu.tr. LA - eng PT - Journal Article PT - Review DEP - 20250704 PL - United States TA - Curr Cardiol Rep JT - Current cardiology reports JID - 100888969 SB - IM MH - Humans MH - *Sleep Initiation and Maintenance Disorders/therapy/etiology MH - *Heart Failure/complications/therapy MH - Cognitive Behavioral Therapy MH - Hospitalization MH - Risk Factors PMC - PMC12227457 OTO - NOTNLM OT - Heart failure OT - Hospital environment OT - Insomnia OT - Quality of life OT - Sleep management COIS- Compliance with Ethical Standards. Ethical Approval: None. Conflict of interest: The authors declare no competing interests. Human and Animal Rights and Informed Consent: None. EDAT- 2025/07/04 12:41 MHDA- 2025/07/04 12:42 PMCR- 2025/07/04 CRDT- 2025/07/04 11:18 PHST- 2025/06/17 00:00 [accepted] PHST- 2025/07/04 12:42 [medline] PHST- 2025/07/04 12:41 [pubmed] PHST- 2025/07/04 11:18 [entrez] PHST- 2025/07/04 00:00 [pmc-release] AID - 10.1007/s11886-025-02256-1 [pii] AID - 2256 [pii] AID - 10.1007/s11886-025-02256-1 [doi] PST - epublish SO - Curr Cardiol Rep. 2025 Jul 4;27(1):108. doi: 10.1007/s11886-025-02256-1. PMID- 40611441 OWN - NLM STAT- MEDLINE DCOM- 20251204 LR - 20251204 IS - 1537-1921 (Electronic) IS - 0898-4921 (Linking) VI - 38 IP - 1 DP - 2026 Jan 1 TI - Perioperative Management of Anticoagulant and Antiplatelet Therapy in Elective Neurosurgery Patients: A Narrative Review. PG - 10-22 LID - 10.1097/ANA.0000000000001047 [doi] AB - Antiplatelet and anticoagulant medications are widely prescribed to the general population for therapeutic and prophylactic purposes in a wide range of diseases, mainly of cardiovascular interest, spanning from acute events such as acute coronary syndromes (ACS), strokes, and thromboembolic disorders to chronic conditions like atrial fibrillation (AF) and peripheral vascular diseases. The management of such therapies is expected to escalate over time due to the aging population, which has a growing need for these medications, and the rising demand for surgical procedures. The management of anticoagulants and antiplatelets still represents a tough challenge for clinicians in elective neurosurgical procedures, where the balance between preventing thromboembolic events and an increased bleeding risk plays a crucial role in all phases of the perioperative setting. Managing antiplatelet and anticoagulant drugs in elective neurosurgery is complex and requires a tailored and multidisciplinary approach. Careful assessment of patient factors, surgery type, and potential risks and benefits is essential. POC testing can be valuable in optimizing therapy management and bleeding risk assessment. This narrative review for clinicians aims to provide an updated overview of the management of these drugs in the perioperative setting of elective neurosurgical procedures. We explored coagulation abnormalities commonly found in neurosurgical patients, the pharmacological profile of each class of drugs, the appropriate management according to the type of procedure (brain or spinal), and the available diagnostic tests, focusing on the application of point-of-care (POC) coagulation testing. CI - Copyright (c) 2025 Wolters Kluwer Health, Inc. All rights reserved. FAU - Iaquaniello, Carolina AU - Iaquaniello C AUID- ORCID: 0000-0002-9105-8253 AD - Department of Neurosurgery, Neuroanesthesia and Intensive Care, Fondazione IRCCS Istituto Neurologico Carlo Besta. FAU - Scordo, Emanuela AU - Scordo E AD - Department of Anesthesia, Critical Care and Emergency, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico. AD - Department of Pathophysiology and Transplantation, University of Milan, MI. FAU - Gemma, Marco AU - Gemma M AD - Department of Neurosurgery, Neuroanesthesia and Intensive Care, Fondazione IRCCS Istituto Neurologico Carlo Besta. FAU - Agostini, Vanessa AU - Agostini V AD - IRCCS Policlinico San Martino. FAU - Bertuccio, Alessandro AU - Bertuccio A AD - Department of Surgical, Diagnostic and Integrated Sciences, University of Genoa, Genova. FAU - Robba, Chiara AU - Robba C AD - IRCCS Policlinico San Martino. AD - Department of Neurosurgery, S Cesare Arrigo Antonio Biagio, Alessandria, Italy. LA - eng PT - Journal Article PT - Review DEP - 20250704 PL - United States TA - J Neurosurg Anesthesiol JT - Journal of neurosurgical anesthesiology JID - 8910749 RN - 0 (Platelet Aggregation Inhibitors) RN - 0 (Anticoagulants) SB - IM MH - Humans MH - *Platelet Aggregation Inhibitors/therapeutic use MH - *Anticoagulants/therapeutic use MH - *Perioperative Care/methods MH - *Elective Surgical Procedures/methods MH - *Neurosurgical Procedures/methods OTO - NOTNLM OT - anticoagulants OT - antiplatelets OT - brain surgery OT - point of care coagulation testing OT - spinal surgery COIS- The authors have no conflicts of interest to declare. EDAT- 2025/07/04 06:26 MHDA- 2025/12/04 13:38 CRDT- 2025/07/04 00:35 PHST- 2024/10/28 00:00 [received] PHST- 2025/06/02 00:00 [accepted] PHST- 2025/12/04 13:38 [medline] PHST- 2025/07/04 06:26 [pubmed] PHST- 2025/07/04 00:35 [entrez] AID - 00008506-990000000-00165 [pii] AID - 10.1097/ANA.0000000000001047 [doi] PST - ppublish SO - J Neurosurg Anesthesiol. 2026 Jan 1;38(1):10-22. doi: 10.1097/ANA.0000000000001047. Epub 2025 Jul 4. PMID- 40610274 OWN - NLM STAT- MEDLINE DCOM- 20250905 LR - 20250905 IS - 1875-2128 (Electronic) IS - 1875-2128 (Linking) VI - 118 IP - 8-9 DP - 2025 Sep TI - Redo surgical aortic valve replacement: An outdated technique in the era of valve-in-valve procedures? PG - 429-435 LID - S1875-2136(25)00330-4 [pii] LID - 10.1016/j.acvd.2025.05.007 [doi] AB - BACKGROUND: The treatment of degenerative prosthetic aortic valves is increasingly important. However, redo surgical aortic valve replacement (Re-SAVR) carries higher perioperative risks than primary surgical aortic valve replacement. AIM: This study aims to identify predictors of early morbidity and death after Re-SAVR. METHODS: A retrospective analysis of 220 patients scheduled for elective Re-SAVR between 2009 and 2017 was conducted. Patients were divided into isolated (n=87) and combined (n=133) redo procedures. The primary endpoint was in-hospital death, and secondary endpoints were postoperative complications, such as stroke, dialysis and pacemaker implantation. Regression analysis identified independent predictors of death. RESULTS: Among the patients undergoing Re-SAVR (mean age, 62.6+/-13.2years; 71% male; mean EuroSCORE II, 12.6+/-11.1%), 86.4% received biological prostheses and 13.6% received mechanical prostheses. The in-hospital death rate was 5.7% for isolated Re-SAVR and 18.0% for combined procedures (P=0.003). Excluding patients with endocarditis, the in-hospital death rate was 0% for isolated Re-SAVR and 19.7% for combined procedures (P=0.002). The incidence of postoperative complications after an isolated procedure was similar to that after a combined procedure. Independent predictors of 30-day death were previous coronary artery bypass grafting (odds ratio: 14.12, 95% confidence interval: 4.40-51.35; P<0.001), a combined procedure (odds ratio: 7.01, 95% confidence interval: 2.09-31.54; P=0.004) and New York Heart Association functional class III/IV (odds ratio: 3.73, 95% confidence interval: 1.31-12.58; P=0.020). CONCLUSIONS: The perioperative risk of death after isolated Re-SAVR in patients without endocarditis was 0%. Independent predictors of in-hospital death included previous coronary artery bypass grafting, combined procedures and New York Heart Association class III/IV. These findings may inform the decision-making process of the heart team regarding the optimal approach (surgical or transcatheter) for redo aortic valve replacement. CI - Copyright (c) 2025 Elsevier Masson SAS. All rights reserved. FAU - Petersen, Johannes AU - Petersen J AD - Department of Cardiovascular Surgery, University Heart & Vascular Centre, 20251 Hamburg, Germany; DZHK (German Centre for Cardiovascular Research), partner site Hamburg/Kiel/Lubeck, Hamburg, Germany. Electronic address: joh.petersen@uke.de. FAU - Stiefel, Roman AU - Stiefel R AD - Department of Cardiovascular Surgery, University Heart & Vascular Centre, 20251 Hamburg, Germany. FAU - Westhofen, Sumi AU - Westhofen S AD - Department of Cardiovascular Surgery, University Heart & Vascular Centre, 20251 Hamburg, Germany. FAU - Vettorazzi, Eik AU - Vettorazzi E AD - Department of Medical Biometry and Epidemiology, University Medical Centre Hamburg-Eppendorf, 20251 Hamburg, Germany. FAU - Demal, Till AU - Demal T AD - Department of Cardiovascular Surgery, University Heart & Vascular Centre, 20251 Hamburg, Germany. FAU - Reiter, Beate AU - Reiter B AD - Department of Cardiovascular Surgery, University Heart & Vascular Centre, 20251 Hamburg, Germany. FAU - Sill, Bjorn AU - Sill B AD - Department of Cardiovascular Surgery, University Heart & Vascular Centre, 20251 Hamburg, Germany. FAU - Conradi, Lenard AU - Conradi L AD - Department of Cardiovascular Surgery, University Heart & Vascular Centre, 20251 Hamburg, Germany. FAU - Al Assar, Yousuf AU - Al Assar Y AD - Department of Cardiovascular Surgery, University Heart & Vascular Centre, 20251 Hamburg, Germany. FAU - Reichenspurner, Hermann AU - Reichenspurner H AD - Department of Cardiovascular Surgery, University Heart & Vascular Centre, 20251 Hamburg, Germany; DZHK (German Centre for Cardiovascular Research), partner site Hamburg/Kiel/Lubeck, Hamburg, Germany. FAU - Detter, Christian AU - Detter C AD - Department of Cardiovascular Surgery, University Heart & Vascular Centre, 20251 Hamburg, Germany. LA - eng PT - Journal Article DEP - 20250619 PL - Netherlands TA - Arch Cardiovasc Dis JT - Archives of cardiovascular diseases JID - 101465655 SB - IM MH - Humans MH - Male MH - Female MH - Retrospective Studies MH - Middle Aged MH - *Heart Valve Prosthesis Implantation/adverse effects/mortality/instrumentation MH - *Aortic Valve/surgery/physiopathology/diagnostic imaging MH - Aged MH - Risk Factors MH - Treatment Outcome MH - Reoperation/adverse effects/mortality MH - *Heart Valve Prosthesis MH - Hospital Mortality MH - Postoperative Complications/mortality/surgery/etiology MH - Time Factors MH - Risk Assessment MH - Prosthesis Design MH - *Aortic Valve Stenosis/surgery/mortality/diagnostic imaging/physiopathology OTO - NOTNLM OT - Aortic valve surgery OT - Redo surgery OT - Valve-in-valve procedure COIS- Disclosure of interest The authors declare that they have no competing interest. EDAT- 2025/07/04 00:28 MHDA- 2025/09/06 00:35 CRDT- 2025/07/03 21:52 PHST- 2024/10/07 00:00 [received] PHST- 2025/05/18 00:00 [revised] PHST- 2025/05/27 00:00 [accepted] PHST- 2025/09/06 00:35 [medline] PHST- 2025/07/04 00:28 [pubmed] PHST- 2025/07/03 21:52 [entrez] AID - S1875-2136(25)00330-4 [pii] AID - 10.1016/j.acvd.2025.05.007 [doi] PST - ppublish SO - Arch Cardiovasc Dis. 2025 Sep;118(8-9):429-435. doi: 10.1016/j.acvd.2025.05.007. Epub 2025 Jun 19. PMID- 40608489 OWN - NLM STAT- MEDLINE DCOM- 20250723 LR - 20260524 IS - 1873-734X (Electronic) IS - 1010-7940 (Linking) VI - 67 IP - 7 DP - 2025 Jul 1 TI - Surgical Implications of the 2023 ESC Endocarditis Guidelines Endorsed by EACTS: Bridging Guidelines and Practice. LID - ezaf225 [pii] LID - 10.1093/ejcts/ezaf225 [doi] AB - Infective endocarditis (IE) remains a challenging condition with high morbidity and mortality despite advances in diagnosis and management. The 2023 European Society of Cardiology guidelines, endorsed by the European Association of Cardio-Thoracic Surgery, introduce significant updates, including several new recommendations with regard to surgical intervention. This review synthesizes current evidence on the surgical management of IE, emphasizing indications, timing, and outcomes. The multidisciplinary Endocarditis Team approach is highlighted as a key factor in improving patient prognosis by optimizing diagnosis and treatment strategies. Advanced imaging techniques, such as positron emission tomography-CT, have enhanced diagnostic accuracy, particularly for prosthetic valve endocarditis. Despite the clear survival benefits associated with surgery, only a minority of eligible patients undergo surgical treatment, underscoring the need for better patient selection and timely intervention. Furthermore, the worse prognosis is found in patients with indications for surgery who do not undergo surgical intervention. The updated IE guidelines provide detailed timing recommendations for surgery based on the clinical scenario, including new considerations for patients with stroke. Additionally, novel recommendations regarding partial oral antibiotic therapy following surgery have been introduced. Finally, important measures for the prevention of IE recurrence are discussed. In conclusion, timely surgical intervention, based on defined recommendations guided by multidisciplinary collaboration and enhanced diagnostic tools, is crucial in improving outcomes for IE patients. Surgical essentials: key principles for clinical practiceRole of the multidisciplinary "Endocarditis Team": All patients with complicated infective endocarditis (IE) should be managed by a specialized Endocarditis Team to improve diagnosis, optimize treatment, and enhance outcomes (Figure 1).Indications for surgery: The main surgical indications for IE include heart failure, uncontrolled infection, and prevention of embolic events. Surgery is one of the most important protective factors against mortality in IE patients.Timing of surgery: The updated guidelines define surgical timing as emergency (within 24 h), urgent (within 3-5 days), and non-urgent (within the same hospital stay). Delayed intervention increases the risk of complications.Post-stroke patients: Once an indication for surgery has been identified, embolic (ischaemic) stroke should not delay surgery. In the case of haemorrhagic stroke, surgery might be delayed up to 4 weeks according to the patient's clinical condition.Positron emission CT (PET-CT) in diagnosis: PET-CT has been incorporated into the diagnostic criteria for prosthetic valve endocarditis (PVE), significantly improving detection and treatment planning.Right-sided IE management: Surgery is required in select cases of right-sided IE, particularly in the presence of large vegetations, persistent bactaeremia, or septic pulmonary embolism.PVE: Early PVE (within 6 months post-surgery) requires urgent surgical intervention. PVE caused by Staphylococcus aureus or non-HACEK Gram-negative bacteria is also an indication for surgery.Cardiac implantable electronic device (CIED) IE: Complete system extraction remains the gold standard for patients with confirmed CIED-associated IE, significantly improving survival.Partial oral antibiotic therapy: Select post-surgical IE patients treated with adequate intravenous antibiotic therapy >7 days after surgery may transition to oral antibiotic therapy, based on strict clinical criteria.Long-term follow-up and prevention: Structured post-surgical follow-up, patient education, and antibiotic prophylaxis (especially for dental procedures) are crucial for preventing IE recurrence. CI - (c) The Author(s) 2025. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com. FAU - de la Cuesta, Manuela AU - de la Cuesta M AUID- ORCID: 0000-0003-4159-8523 AD - University Department of Cardiac Surgery, Leipzig Heart Center, 04289 Leipzig, Germany. FAU - Marin-Cuartas, Mateo AU - Marin-Cuartas M AUID- ORCID: 0000-0003-1000-4710 AD - University Department of Cardiac Surgery, Leipzig Heart Center, 04289 Leipzig, Germany. FAU - de Waha, Suzanne AU - de Waha S AD - University Department of Cardiac Surgery, Leipzig Heart Center, 04289 Leipzig, Germany. AD - Department of Electrophysiology, University Hospital Schleswig-Holstein, 23562 Lubeck, Germany. FAU - Milojevic, Milan AU - Milojevic M AUID- ORCID: 0000-0003-0984-9011 AD - Department of Cardiac Surgery and Cardiovascular Research, Dedinje Cardiovascular Institute, 11040 Belgrade, Serbia. FAU - Myers, Patrick O AU - Myers PO AUID- ORCID: 0000-0002-1768-8433 AD - Department of Cardiac Surgery, Lausanne University Hospital, 1005 Lausanne, Switzerland. AD - La Tour Hospital, Geneva University Medical School, 1217 Geneva, Switzerland. FAU - Misfeld, Martin AU - Misfeld M AD - Department of Cardiothoracic Surgery, Royal Prince Alfred Hospital, NSW 2050 Sydney, Australia. AD - Department of Cardiothoracic Surgery, Sydney Adventist Hospital, NSW 2076 Sydney, Australia. AD - Department of Cardiothoracic Surgery, Macquarie University Hospital, NSW 2113 Sydney, Australia. AD - Sydney Medical School, University of Sydney, NSW 2050 Sydney, Australia. FAU - Quintana, Eduard AU - Quintana E AD - Hospital Clinic Barcelona, University of Barcelona, 08036 Barcelona, Spain. FAU - Bonaros, Nikolaos AU - Bonaros N AD - Department of Cardiac Surgery, Medical University of Innsbruck, 6020 Innsbruck, Austria. FAU - Mestres, Carlos A AU - Mestres CA AD - Department of Cardiothoracic Surgery and The Robert WM Frater Cardiovascular Research Centre, The University of the Free State, 9301 Bloemfontein, South Africa. FAU - Doenst, Torsten AU - Doenst T AUID- ORCID: 0000-0002-6411-909X AD - Department of Cardiothoracic Surgery, Friedrich-Schiller-University of Jena, Jena University Hospital, 07747 Jena, Germany. FAU - Dashkevich, Alexey AU - Dashkevich A AD - University Department of Cardiac Surgery, Leipzig Heart Center, 04289 Leipzig, Germany. FAU - Kiefer, Philipp AU - Kiefer P AD - University Department of Cardiac Surgery, Leipzig Heart Center, 04289 Leipzig, Germany. FAU - Holzhey, David AU - Holzhey D AD - University Department of Cardiac Surgery, Leipzig Heart Center, 04289 Leipzig, Germany. FAU - Borger, Michael A AU - Borger MA AD - University Department of Cardiac Surgery, Leipzig Heart Center, 04289 Leipzig, Germany. LA - eng PT - Journal Article PT - Review PL - Germany TA - Eur J Cardiothorac Surg JT - European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery JID - 8804069 SB - IM MH - Humans MH - *Endocarditis/surgery/diagnosis MH - *Practice Guidelines as Topic MH - Europe MH - Societies, Medical MH - *Cardiac Surgical Procedures/standards OTO - NOTNLM OT - Cardiac surgery OT - Infective endocarditis EDAT- 2025/07/03 18:26 MHDA- 2025/07/24 00:25 CRDT- 2025/07/03 12:33 PHST- 2025/03/13 00:00 [received] PHST- 2025/06/11 00:00 [revised] PHST- 2025/07/02 00:00 [accepted] PHST- 2025/07/24 00:25 [medline] PHST- 2025/07/03 18:26 [pubmed] PHST- 2025/07/03 12:33 [entrez] AID - 8185406 [pii] AID - 10.1093/ejcts/ezaf225 [doi] PST - ppublish SO - Eur J Cardiothorac Surg. 2025 Jul 1;67(7):ezaf225. doi: 10.1093/ejcts/ezaf225. PMID- 40608156 OWN - NLM STAT- MEDLINE DCOM- 20250703 LR - 20250708 IS - 1590-9999 (Electronic) IS - 1590-9921 (Print) IS - 1590-9921 (Linking) VI - 26 IP - 1 DP - 2025 Jul 3 TI - Intensive care needs after hip and knee replacement: understanding risk profiles for severe postoperative complications. PG - 42 LID - 10.1186/s10195-025-00862-x [doi] LID - 42 AB - BACKGROUND: The etiology of serious life-threatening events after total joint arthroplasty (TJA) is poorly elaborated and understood in literature. The purpose of this study was to identify independent predictors of postoperative intensive care following total hip arthroplasty (THA) and total knee arthroplasty (TKA) and to clarify the circumstances leading to these transfers. MATERIAL AND METHODS: A total of 142 patients suffering from postoperative intensive care-dependent serious adverse events (Clavien-Dindo classification Grade IV, CD degrees IV) after THA or TKA were matched 1:1 with non-CD degrees IV patients using propensity score matching for age, sex, comorbidity (Charlson Comorbidity Index, CCI), and year of treatment. Possible predictive factors for the need of postoperative intensive care were initially evaluated using univariate tests, followed by multivariate regression analyses to identify independent predictors. RESULTS: CD degrees IV transfers correlate with higher Hospitality Frailty Risk Score levels (HFRS) [mean 4.4 (standard deviation, SD 3.8) versus mean 3.0 (SD 3.0); p < 0.001], higher American Society of Anesthesiologists Physical Status Classification System (ASA) Scores [mean 2.5 (SD 0.6) versus mean 2.3 (SD 0.7); p = 0.02], a greater proportion of octogenarians [35.9% (n = 51) versus 23.9% (n = 34); p = 0.028] and a higher incidence of medical complications [97.9% (n = 139) versus 60.6% (n = 86); p < 0.001] compared with an adjusted control group after total joint arthroplasty (TJA). Multivariate regression analysis confirmed "Frailty" (odds ratio, OR 1.14, 95% confidence intervals, CI 1.05-1.23, p = .002), preexisting cardiological (odds ratio, OR 2.0, 95% confidence intervals, CI 1.004-4.1, p = 0.049) and gastrointestinal secondary diagnoses (OR 3.0, 95% CI 1.3-6.9, p = 0.01), and intake of anticoagulants (OR 2.7, 95% CI 1.6-4.6, p < 0.001) as independent risk factors for CD degrees IV intensive care unit (ICU) transfers after TJA. CONCLUSIONS: Patients with CD degrees IV events after THA and TKA represent a complex, vulnerable, and multimorbid patient population. There is a need for a multidisciplinary approach that integrates prehabilitation and perioperative risk assessments to reduce the occurrence of severe, life-threatening events requiring ICU care. LEVEL OF EVIDENCE: Level III-retrospective cohort study. TRIAL REGISTRATION: Retrospectively registered. CI - (c) 2025. The Author(s). FAU - Holzapfel, Dominik Emanuel AU - Holzapfel DE AUID- ORCID: 0000-0002-0236-695X AD - Department of Orthopaedic Surgery, Regensburg University Medical Center, Kaiser-Karl V.-Allee 3, 93077, Bad Abbach, Germany. dominik.holzapfel@ukr.de. FAU - Kappenschneider, Tobias AU - Kappenschneider T AD - Department of Orthopaedic Surgery, Regensburg University Medical Center, Kaiser-Karl V.-Allee 3, 93077, Bad Abbach, Germany. FAU - Holzapfel, Sabrina AU - Holzapfel S AD - Department of Neonatology, University Children's Hospital Regensburg, Hospital St. Hedwig of the Order of St John, University of Regensburg, Steinmetzstrasse 1-3, 93049, Regensburg, Germany. FAU - Schuster, Marie Farina AU - Schuster MF AD - Department of Orthopaedic Surgery, Regensburg University Medical Center, Kaiser-Karl V.-Allee 3, 93077, Bad Abbach, Germany. FAU - Michalk, Katrin AU - Michalk K AD - Department of Orthopaedic Surgery, Regensburg University Medical Center, Kaiser-Karl V.-Allee 3, 93077, Bad Abbach, Germany. FAU - Auer, Patrick AU - Auer P AD - Department of Anaesthesiology, Regensburg University Medical Center, Asklepios Klinikum Bad Abbach, Kaiser-Karl V.-Allee 3, 93077, Bad Abbach, Germany. FAU - Schwarz, Timo AU - Schwarz T AD - Department of Orthopaedic Surgery, Regensburg University Medical Center, Kaiser-Karl V.-Allee 3, 93077, Bad Abbach, Germany. LA - eng PT - Journal Article DEP - 20250703 PL - Italy TA - J Orthop Traumatol JT - Journal of orthopaedics and traumatology : official journal of the Italian Society of Orthopaedics and Traumatology JID - 101090931 SB - IM MH - Humans MH - *Arthroplasty, Replacement, Hip/adverse effects MH - Male MH - Female MH - *Arthroplasty, Replacement, Knee/adverse effects MH - Aged MH - *Postoperative Complications/therapy/epidemiology/etiology MH - Risk Factors MH - Middle Aged MH - *Critical Care MH - Retrospective Studies MH - Risk Assessment MH - Propensity Score MH - Aged, 80 and over PMC - PMC12229386 OTO - NOTNLM OT - Arthroplasty OT - Clavien-Dindo classification OT - Frailty OT - ICU OT - Intensive care OT - Severe complications OT - THA OT - TJA OT - TKA COIS- Declarations. Ethics approval and consent to participate: This study was approved by the Ethics Committee of the University of Regensburg, Germany (24-3941-104). It was performed in line with the principles of the Declaration of Helsinki. Human ethics and consent to participate : For this type of study, human ethics and consent to participate were not applicable or required. Consent for publication: For this type of study, consent for publication was not required. Competing interests: There are no competing of interest among the authors. EDAT- 2025/07/03 12:33 MHDA- 2025/07/03 12:34 PMCR- 2025/07/03 CRDT- 2025/07/03 11:16 PHST- 2025/01/08 00:00 [received] PHST- 2025/06/15 00:00 [accepted] PHST- 2025/07/03 12:34 [medline] PHST- 2025/07/03 12:33 [pubmed] PHST- 2025/07/03 11:16 [entrez] PHST- 2025/07/03 00:00 [pmc-release] AID - 10.1186/s10195-025-00862-x [pii] AID - 862 [pii] AID - 10.1186/s10195-025-00862-x [doi] PST - epublish SO - J Orthop Traumatol. 2025 Jul 3;26(1):42. doi: 10.1186/s10195-025-00862-x. PMID- 40598991 OWN - NLM STAT- Publisher LR - 20250702 IS - 2724-5780 (Electronic) IS - 2724-5780 (Linking) DP - 2025 Jul 2 TI - Pediatric tracheal surgery: indications, complications and results. LID - 10.23736/S2724-5276.25.07753-5 [doi] AB - BACKGROUND: Pediatric tracheal surgery includes several complex and rare procedures. We report the surgical experience at our center. METHODS: Our center has multidisciplinary team manages laryngotracheal malformations. We retrospectively analyzed all tracheal surgeries from January 2009 to September 2023, excluding endoscopic cases and tracheostomy insertion, revision, or closure not related to reconstructive tracheal surgery. We evaluated diagnosis, comorbidities, type of surgery, need for tracheostomy, complications, death, outcome in terms of decannulation and adequate caliber airway. RESULTS: A total of 122 patients with a median age of 2.61 years (0-25.4 years) were operated for congenital (59.8%) or acquired (40.2%) tracheal pathology. The procedures performed were: cricothyroid resection (N.=18; 14.8%), laryngotracheal reconstruction with rib cartilage graft (N.=33; 27%), tracheal resection-anastomosis (N.=20; 16.4%), laryngotracheal cleft closure (N.=5; 4.1%), "slide tracheoplasty" (N.=15; 12.3%), posterior tracheopexy (N.=14; 11.5%); isolated tracheoesophageal fistula closure (N.=17; 13.9%). Depending on the type of operation, cardiac surgeons and otolaryngologists were involved. Preoperative tracheotomy was required in 54 patients and postoperative in 51 patients. We reported a mortality of 6.1%, or seven patients, four of whom died in the immediate postoperative period, but only one death was due to surgical causes. Other intraoperative complications were reported in two patients (1.6%) and postoperative complications in 34 patients (27.9%). Ninety-two patients (75.4%) were alive with adequate airway caliber and no need for tracheostomy. CONCLUSIONS: There are many indications for tracheal surgery and a multidisciplinary approach has been essential. Tracheal surgery is complex and potentially associated with major complications, but outcomes are generally satisfactory. FAU - Monti, Martina AU - Monti M AD - Pediatric Surgery Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy - martinamonti3194@gmail.com. AD - Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics and Mother-Child Sciences (DINOGMI), University of Genoa, Genoa, Italy - martinamonti3194@gmail.com. FAU - Guerriero, Vittorio AU - Guerriero V AD - Pediatric Surgery Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy. FAU - D'Agostino, Roberto AU - D'Agostino R AD - Otorhinolaryngology Unit, Gaslini Children's Hospital, Genoa, Italy. FAU - Sacco, Oliviero AU - Sacco O AD - Pulmonary Diseases Unit, Gaslini Children's Hospital, Genoa, Italy. FAU - Moscatelli, Andrea AU - Moscatelli A AD - Anesthesia and Intensive Care Unit, Gaslini Children's Hospital, Genoa, Italy. FAU - Della Rocca, Mirta AU - Della Rocca M AD - Anesthesia and Intensive Care Unit, Gaslini Children's Hospital, Genoa, Italy. FAU - Stagnaro, Nicola AU - Stagnaro N AD - Service of Radiology, Gaslini Children's Hospital, Genoa, Italy. FAU - Rizzo, Francesca AU - Rizzo F AD - Service of Radiology, Gaslini Children's Hospital, Genoa, Italy. FAU - Mattioli, Girolamo AU - Mattioli G AD - Pediatric Surgery Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy. AD - Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics and Mother-Child Sciences (DINOGMI), University of Genoa, Genoa, Italy. FAU - Torre, Michele AU - Torre M AD - Pediatric Surgery Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy. AD - Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics and Mother-Child Sciences (DINOGMI), University of Genoa, Genoa, Italy. LA - eng PT - Journal Article DEP - 20250702 PL - Italy TA - Minerva Pediatr (Torino) JT - Minerva pediatrics JID - 101777303 SB - IM EDAT- 2025/07/02 06:28 MHDA- 2025/07/02 06:28 CRDT- 2025/07/02 05:06 PHST- 2025/07/02 06:28 [medline] PHST- 2025/07/02 06:28 [pubmed] PHST- 2025/07/02 05:06 [entrez] AID - S2724-5276.25.07753-5 [pii] AID - 10.23736/S2724-5276.25.07753-5 [doi] PST - aheadofprint SO - Minerva Pediatr (Torino). 2025 Jul 2. doi: 10.23736/S2724-5276.25.07753-5. PMID- 40597136 OWN - NLM STAT- MEDLINE DCOM- 20250702 LR - 20250704 IS - 1472-6963 (Electronic) IS - 1472-6963 (Linking) VI - 25 IP - 1 DP - 2025 Jul 1 TI - Economic impact of TAVI pathway optimisation: the experience of the University Hospital of Parma. PG - 835 LID - 10.1186/s12913-025-13021-z [doi] LID - 835 AB - BACKGROUND: Transcatheter Aortic Valve Implantation (TAVI) has emerged as a standard of care for patients suffering from symptomatic severe aortic stenosis. However, organisational analyses and investigations of this intervention's economic impact are lacking. This study aims to assess the potential impact of implementing a process designed to optimise the TAVI pathway regarding organisational, human, material, and economic resources. METHODS: The research is conducted through a case study. The methodology consisted of three stages: (1) mapping of the current TAVI pathway; (2) identification of the organisational changes necessary to optimise it and implementation of the identified action with a multidisciplinary teamwork; (3) simulations of the organisational and economic impact of the optimisation process. Data related to costs, revenues, and activities were provided by the hospital's Management Control office. The data analysed refer to a 12-month period. The TAVI pathway optimisation presented in this analysis is aligned with the best practices described in the BENCHMARK study. RESULTS: The analysis of the current TAVI pathway in the studied hospital highlighted several critical points during the three phases of the course (pre-procedure, peri-procedure, and post-procedure). The working groups identified five areas for TAVI pathway improvement: patient and family education, coronary risk stratification, conduction disorders management, fast-track discharge eligibility, nurse-led rapid mobilisation and early discharge. The organisational solutions highlighted by the working groups outline a new TAVI pathway capable of generating a significant impact not only from an organisational point of view, but also from an economic point of view. We estimated that in our cohort TAVI optimisation would have saved approximately 112 ICCU bed-days and have led to an average cost reduction of about euro3,900 per patient. CONCLUSIONS: This study showed a process of optimisation of the TAVI pathway highlighting the positive impacts for patients, caregivers, healthcare workers, and the hospital. A Clinical Valve Coordinator may help to manage the procedural programme for individual patients while maintaining seamless communication with the Heart Team throughout the patient care journey, making the process even more streamlined. The case study analysed can be useful to all hospitals wishing to undertake processes aimed at improving the TAVI pathway. CI - (c) 2025. The Author(s). FAU - Fanelli, Simone AU - Fanelli S AD - Department of Economics and Management, University of Parma, Parma, 43125, Italy. simone.fanelli@unipr.it. FAU - Lanza, Gianluca AU - Lanza G AD - Department of Economics and Management, University of Parma, Parma, 43125, Italy. FAU - Pratici, Lorenzo AU - Pratici L AD - Department of Economics and Management, University of Parma, Parma, 43125, Italy. FAU - Benatti, Giorgio AU - Benatti G AD - Division of Cardiology, Parma University Hospital, Parma, 43126, Italy. FAU - Vignali, Luigi AU - Vignali L AD - Division of Cardiology, Parma University Hospital, Parma, 43126, Italy. LA - eng PT - Journal Article DEP - 20250701 PL - England TA - BMC Health Serv Res JT - BMC health services research JID - 101088677 SB - IM MH - Humans MH - *Transcatheter Aortic Valve Replacement/economics MH - *Hospitals, University/economics/organization & administration MH - *Aortic Valve Stenosis/surgery/economics MH - *Critical Pathways/economics MH - Italy MH - Organizational Case Studies PMC - PMC12211903 OTO - NOTNLM OT - Capacity enhancing innovation OT - Clinical valve coordinator OT - Economic impact OT - Healthcare management OT - Management control OT - Organisational process OT - Transfemoral TAVI COIS- Declarations. Ethics approval and consent to participate: The AVEN Territorial Ethics Committee, with prot. n. 43459 of 10/31/202, approved this study. The General Director of the Parma Hospital, with resolution DELI0000896_2023, authorised this study. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2025/07/02 06:27 MHDA- 2025/07/02 06:28 PMCR- 2025/07/01 CRDT- 2025/07/02 03:54 PHST- 2024/07/15 00:00 [received] PHST- 2025/06/06 00:00 [accepted] PHST- 2025/07/02 06:28 [medline] PHST- 2025/07/02 06:27 [pubmed] PHST- 2025/07/02 03:54 [entrez] PHST- 2025/07/01 00:00 [pmc-release] AID - 10.1186/s12913-025-13021-z [pii] AID - 13021 [pii] AID - 10.1186/s12913-025-13021-z [doi] PST - epublish SO - BMC Health Serv Res. 2025 Jul 1;25(1):835. doi: 10.1186/s12913-025-13021-z. PMID- 40591239 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250704 IS - 2090-911X (Electronic) IS - 1110-2608 (Print) IS - 1110-2608 (Linking) VI - 77 IP - 1 DP - 2025 Jul 1 TI - Every great story seems to begin with a snake: a case report of large right atrial thrombus encountered during MitraClip procedure. PG - 67 LID - 10.1186/s43044-025-00661-z [doi] LID - 67 AB - BACKGROUND: TEER has revolutionized mitral regurgitation treatment, addressing clinical burden in aging patients. However, thrombotic complications may still occur. CASE PRESENTATION: An 83-year-old man with severe mitral regurgitation underwent a MitraClip procedure. A large molding thrombus was observed during the procedure, despite a targeted ACT. To prevent cerebral embolization, two carotid filters were placed. The procedure was successfully completed, and mitral regurgitation was reduced. The patient was stable during the procedure, with no evidence of pulmonary or cerebral embolism. CONCLUSIONS: The case highlights the importance of close observation and multidisciplinary decision-making in managing acute thrombus during TEER. Further research is needed to establish the potential role of cerebral protection devices and the effect of anticoagulation procedures on thrombus formation. CI - (c) 2025. The Author(s). FAU - Totaro, Antonio AU - Totaro A AD - Department of Medicine and Health Sciences "V. Tiberio", University of Molise, Campobasso, Italy. antonio.totaro@unimol.it. AD - Interventional cardiology Unit, Responsible Research Hospital, Campobasso, Italy. antonio.totaro@unimol.it. FAU - Ienco, Vincenzo AU - Ienco V AD - Interventional cardiology Unit, Responsible Research Hospital, Campobasso, Italy. FAU - Galluccio, Chiara AU - Galluccio C AD - Interventional cardiology Unit, Responsible Research Hospital, Campobasso, Italy. FAU - Sacra, Vincenzo AU - Sacra V AD - Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy. FAU - Pierro, Antonio AU - Pierro A AD - Radiology Department, S. Timoteo Hospital, Termoli, Italy. FAU - Testa, Nicola AU - Testa N AD - Agostino Gemelli University Polyclinic, Rome, Italy. FAU - Testa, Gianluca AU - Testa G AD - Department of Medicine and Health Sciences "V. Tiberio", University of Molise, Campobasso, Italy. FAU - Sacra, Cosimo AU - Sacra C AD - Interventional cardiology Unit, Responsible Research Hospital, Campobasso, Italy. LA - eng GR - PE00000015-CUP H13C22000560006/NextGenerationEU/ PT - Journal Article DEP - 20250701 PL - Germany TA - Egypt Heart J JT - The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology JID - 9106952 PMC - PMC12214111 OTO - NOTNLM OT - Atrial thrombus OT - Carotid filter OT - MitraClip OT - TEER COIS- Declarations. Ethics approval and consent to participate: This study does not require institutional review board approval. Consent for publication: Informed consent was obtained for the case report to be published. Competing interests: The authors declare no competing interests. EDAT- 2025/07/01 21:14 MHDA- 2025/07/01 21:15 PMCR- 2025/07/01 CRDT- 2025/07/01 11:27 PHST- 2025/03/15 00:00 [received] PHST- 2025/06/10 00:00 [accepted] PHST- 2025/07/01 21:15 [medline] PHST- 2025/07/01 21:14 [pubmed] PHST- 2025/07/01 11:27 [entrez] PHST- 2025/07/01 00:00 [pmc-release] AID - 10.1186/s43044-025-00661-z [pii] AID - 661 [pii] AID - 10.1186/s43044-025-00661-z [doi] PST - epublish SO - Egypt Heart J. 2025 Jul 1;77(1):67. doi: 10.1186/s43044-025-00661-z. PMID- 40590724 OWN - NLM STAT- MEDLINE DCOM- 20250701 LR - 20260310 IS - 1558-2035 (Electronic) IS - 1558-2027 (Linking) VI - 26 IP - 7 DP - 2025 Jul 1 TI - Comprehensive insights into peripheral artery disease: an overview from the working groups of pathogenesis of atherosclerosis and thrombosis of the Italian Society of Cardiology. PG - 325-338 LID - 10.2459/JCM.0000000000001740 [doi] AB - Peripheral artery disease (PAD) is a global health burden due to its high prevalence, morbidity, and mortality. It affects more than 200 million people worldwide. PAD is a manifestation of systemic atherosclerosis that is often associated with coronary and cerebrovascular disease, underscoring its crucial role as an indicator of advanced vascular pathology. Despite its strong association with cardiovascular morbidity, PAD remains underdiagnosed and undertreated compared with coronary artery disease (CAD), highlighting a significant gap in care. Patients with PAD are at increased risk of myocardial infarction (MI), stroke, and limb amputation, so a multidisciplinary approach is required to reduce adverse outcomes. Identifying at-risk patients through early screening and implementing evidence-based therapeutic strategies is crucial in treating PAD. Modern lipid-lowering agents, dual antithrombotic therapies, and aggressive risk factor control are essential treatment components. Recent advances, including PCSK9 inhibitors and novel antiplatelet agents, have shown promise for improving cardiovascular and limb-related outcomes, although further validation is needed. Given the systemic nature of atherosclerosis, managing PAD should be a cornerstone of cardiovascular care, requiring individualised treatment plans. Increasing awareness and understanding of PAD is critical to bridging gaps in diagnosis and treatment to improve the overall prognosis and quality of life of patients with this debilitating disease. This work aims to enhance practical approaches to PAD by providing comprehensive insights into its management and offering a foundation for exploring innovative future treatment options. CI - Copyright (c) 2025 Italian Federation of Cardiology - I.F.C. All rights reserved. FAU - Muscoli, Saverio AU - Muscoli S AD - Division of Cardiology, Policlinico Tor Vergata, Rome. FAU - Cimmino, Giovanni AU - Cimmino G AD - Department of Translational Medical Sciences, Section of Cardiology, University of Campania 'Luigi Vanvitelli'. AD - UOSD Cardiologia, Azienda Ospedaliera Universitaria Luigi Vanvitelli, Naples, Italy. FAU - Canonico, Mario Enrico AU - Canonico ME AD - CPC Clinical Research, Aurora, Colorado, USA; University of Colorado School of Medicine, Aurora, Colorado, USA. FAU - Cesaro, Arturo AU - Cesaro A AD - Department of Translational Medical Sciences, Section of Cardiology, University of Campania 'Luigi Vanvitelli'. AD - Division of Cardiology, A.O.R.N. 'Sant'Anna e San Sebastiano', Caserta. FAU - De Rosa, Gennaro AU - De Rosa G AD - Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples. FAU - De Rosa, Salvatore AU - De Rosa S AD - Department of Medical and Surgical Sciences, University Magna Graecia of Catanzaro. FAU - Coronelli, Maurizio Maria AU - Coronelli MM AD - Department of Internal Medicine and Medical Therapy, University of Pavia. FAU - Natale, Francesco AU - Natale F AD - Department of Translational Medical Sciences, Section of Cardiology, University of Campania 'Luigi Vanvitelli'. AD - Department of Life Science, Health, and Health Professions, Link Campus University. FAU - Perrone, Marco Alfonso AU - Perrone MA AD - Division of Cardiology and CardioLab, Department of Clinical Sciences and Translational Medicine, University of Rome Tor Vergata, Rome. FAU - Sticchi, Alessandro AU - Sticchi A AD - University of Pisa, 56126 Pisa. FAU - Sorrentino, Sabato AU - Sorrentino S AD - Department of Medical and Surgical Sciences, University Magna Graecia of Catanzaro. FAU - Sucato, Vincenzo AU - Sucato V AD - Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE) 'G. D'Alessandro', University of Palermo, Palermo. FAU - Renda, Giulia AU - Renda G AD - Department of Neuroscience, Imaging and Clinical Sciences, 'G. d'Annunzio' University of Chieti-Pescara, Chieti 66100, Italy; Heart Department, SS. Annunziata Hospital, University Cardiology Division, Chieti. FAU - Paolillo, Stefania AU - Paolillo S AD - Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples. FAU - Indolfi, Ciro AU - Indolfi C AD - Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy. FAU - Calabro, Paolo AU - Calabro P AD - Department of Translational Medical Sciences, Section of Cardiology, University of Campania 'Luigi Vanvitelli'. AD - Division of Cardiology, A.O.R.N. 'Sant'Anna e San Sebastiano', Caserta. FAU - Perrone Filardi, Pasquale AU - Perrone Filardi P AD - Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples. FAU - Cirillo, Plinio AU - Cirillo P AD - Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples. LA - eng PT - Journal Article PT - Review DEP - 20250530 PL - United States TA - J Cardiovasc Med (Hagerstown) JT - Journal of cardiovascular medicine (Hagerstown, Md.) JID - 101259752 RN - 0 (Fibrinolytic Agents) RN - 0 (Platelet Aggregation Inhibitors) RN - 0 (Hypolipidemic Agents) SB - IM MH - Humans MH - *Peripheral Arterial Disease/epidemiology/therapy/diagnosis/physiopathology MH - Risk Factors MH - Fibrinolytic Agents/therapeutic use MH - Cardiology MH - Italy/epidemiology MH - Risk Assessment MH - Platelet Aggregation Inhibitors/therapeutic use MH - Hypolipidemic Agents/therapeutic use OTO - NOTNLM OT - antithrombotic therapy OT - atherosclerosis OT - cardiovascular risk factors OT - lipid-lowering treatments OT - peripheral artery disease EDAT- 2025/07/01 21:14 MHDA- 2025/07/01 21:15 CRDT- 2025/07/01 10:03 PHST- 2025/02/20 00:00 [received] PHST- 2025/04/28 00:00 [accepted] PHST- 2025/07/01 21:15 [medline] PHST- 2025/07/01 21:14 [pubmed] PHST- 2025/07/01 10:03 [entrez] AID - 01244665-202507000-00001 [pii] AID - 10.2459/JCM.0000000000001740 [doi] PST - ppublish SO - J Cardiovasc Med (Hagerstown). 2025 Jul 1;26(7):325-338. doi: 10.2459/JCM.0000000000001740. Epub 2025 May 30. PMID- 40590516 OWN - NLM STAT- MEDLINE DCOM- 20251006 LR - 20260303 IS - 1522-9645 (Electronic) IS - 0195-668X (Print) IS - 0195-668X (Linking) VI - 46 IP - 38 DP - 2025 Oct 7 TI - Refractory angina: mechanisms and stratified treatment in obstructive and non-obstructive chronic myocardial ischaemic syndromes. PG - 3738-3757 LID - 10.1093/eurheartj/ehaf284 [doi] AB - The diagnosis of refractory angina has conventionally been limited to patients with angina and ischaemia secondary to obstructive atherosclerotic epicardial coronary disease who experience persistent symptoms despite optimal pharmacological and revascularization therapies. It is now well-established that angina may also be caused by ischaemia resulting from coronary microcirculatory disorders, coronary vasospasm, and bridging in the absence of obstructive epicardial coronary disease or after "successful" revascularization. This increasingly prevalent and symptomatic group of patients, with both angina and demonstrable ischaemia, have been excluded from the conventional definition of refractory angina. In patients with obstructive epicardial coronary disease, disturbed microcirculatory and vasomotor function, amongst other ischaemic mechanisms, may account for continuing symptoms despite revascularization. Under-recognition of these mechanisms results in inadequate treatment and symptom persistence. In this review, a redefinition of refractory angina is proposed to include the full spectrum of patients experiencing persistent angina despite current maximal guideline-directed medical and revascularization therapies. Systematic approaches for comprehensive investigation are suggested to identify underlying mechanisms of ischaemia and stratify treatments accordingly. The complex needs of patients with refractory angina are likely best addressed by an inter-disciplinary Angina Heart Team with the aim of improving patient symptoms, quality of life, and clinical outcomes. CI - (c) The Author(s) 2025. Published by Oxford University Press on behalf of the European Society of Cardiology. FAU - de Silva, Ranil AU - de Silva R AUID- ORCID: 0000-0003-1107-2117 AD - National Heart and Lung Institute, Imperial College London, Brompton Campus, Level 2 Chelsea Wing, Sydney Street, London SW3 6NP, UK. AD - Specialist Angina Service, Royal Brompton and Harefield Hospitals part of Guy's and St Thomas' NHS Foundation Trust, Level 2 Chelsea Wing, Sydney Street, London SW3 6NP, UK. FAU - Cheng, Kevin AU - Cheng K AUID- ORCID: 0000-0003-1262-9474 AD - National Heart and Lung Institute, Imperial College London, Brompton Campus, Level 2 Chelsea Wing, Sydney Street, London SW3 6NP, UK. AD - Specialist Angina Service, Royal Brompton and Harefield Hospitals part of Guy's and St Thomas' NHS Foundation Trust, Level 2 Chelsea Wing, Sydney Street, London SW3 6NP, UK. FAU - Henry, Timothy D AU - Henry TD AUID- ORCID: 0000-0003-1123-0533 AD - The Carl and Edith Lindner Center of Research and Education, The Christ Hospital, 2123 Auburn Avenue, Suite 424, Cincinnati, OH 45219, USA. FAU - Perera, Divaka AU - Perera D AUID- ORCID: 0000-0001-6362-1291 AD - British Heart Foundation Centre of Research Excellence at the School of Cardiovascular and Metabolic Medicine & Sciences, King's College London, Westminster Bridge Road, London SE1 7EH, UK. AD - Guy's and St Thomas' NHS Foundation Trust, Westminster Bridge Road, London SE1 7EH, UK. FAU - Taqueti, Viviany R AU - Taqueti VR AUID- ORCID: 0000-0002-0136-3781 AD - Cardiovascular Imaging Program, Departments of Radiology and Medicine, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA. FAU - Abreu, Ana AU - Abreu A AUID- ORCID: 0000-0003-0786-7830 AD - Cardiovascular Rehabilitation Centre, Department of Cardiology, ULS Santa Maria and Faculdade Medicina de Universidade Lisboa (CAML), ISAMB, IMPSP, CCUL, Av. Professor Egas Moniz, 1649-028, Lisboa, Portugal. FAU - Vervaat, Fabienne AU - Vervaat F AUID- ORCID: 0000-0001-6693-7355 AD - Department of Cardiology, Catharina Hospital, Michelangelolaan 2, Eindhoven 5623 EJ, the Netherlands. FAU - Gulati, Martha AU - Gulati M AUID- ORCID: 0000-0003-0735-9756 AD - Barbra Streisand Women's Heart Center, Smidt Heart Institute, Cedars-Sinai Medical Center, 8700 Beverly Blvd., Los Angeles, CA 90048, USA. FAU - Shimokawa, Hiroaki AU - Shimokawa H AUID- ORCID: 0000-0001-7534-4826 AD - Graduate School, International University of Health and Welfare, Kozunomori 4-3, Narita 286-8686, Japan. AD - Department of Cardiovascular Medicine, Tohoku University, Seiryo-machi 1-1, Sendai 980-8574, Japan. FAU - Andreotti, Felicita AU - Andreotti F AUID- ORCID: 0000-0002-1456-6430 AD - Cardiovascular Science Department, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Gemelli 8, 00168 Rome, Italy. AD - CardioThoracic Department, Catholic University Medical School, Rome, Italy. FAU - Kaski, Juan-Carlos AU - Kaski JC AUID- ORCID: 0000-0001-8068-0189 AD - Molecular and Clinical Sciences Research Institute, St. George's University of London, Cranmer Terrace, London SW17 0RE, UK. LA - eng GR - K23 HL135438/HL/NHLBI NIH HHS/United States GR - BHF_/British Heart Foundation/United Kingdom PT - Journal Article PT - Review PL - England TA - Eur Heart J JT - European heart journal JID - 8006263 SB - IM MH - Humans MH - *Angina Pectoris/etiology/therapy/physiopathology MH - *Myocardial Ischemia/therapy/etiology/complications MH - Myocardial Revascularization/methods MH - Coronary Vasospasm/complications MH - Chronic Disease MH - Microcirculation/physiology PMC - PMC12500330 OTO - NOTNLM OT - ANOCA OT - Chronic coronary syndromes OT - INOCA OT - Non-acute myocardial ischaemic syndromes OT - Refractory angina pectoris EDAT- 2025/07/01 21:15 MHDA- 2025/10/07 06:01 PMCR- 2025/07/01 CRDT- 2025/07/01 08:43 PHST- 2024/07/03 00:00 [received] PHST- 2024/10/24 00:00 [revised] PHST- 2025/04/09 00:00 [accepted] PHST- 2025/10/07 06:01 [medline] PHST- 2025/07/01 21:15 [pubmed] PHST- 2025/07/01 08:43 [entrez] PHST- 2025/07/01 00:00 [pmc-release] AID - 8180268 [pii] AID - ehaf284 [pii] AID - 10.1093/eurheartj/ehaf284 [doi] PST - ppublish SO - Eur Heart J. 2025 Oct 7;46(38):3738-3757. doi: 10.1093/eurheartj/ehaf284. PMID- 40586017 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250702 IS - 2589-790X (Electronic) IS - 2589-790X (Linking) VI - 7 IP - 6 DP - 2025 Jun TI - A Digital Tool to Improve Family Engagement in Acute Care: The NGAGE Randomized Pilot Feasibility Trial. PG - 743-749 LID - 10.1016/j.cjco.2025.03.007 [doi] AB - BACKGROUND: Engaging families in care is an important aspect of healthcare delivery. Our interdisciplinary team designed the NGAGE (for "family eNGAGEment") tool to empower family members to increase their engagement in patient care. The objective of this study was to assess the feasibility of use of the NGAGE tool. METHODS: We conducted a single-centre, pilot, feasibility randomized controlled trial in the acute cardiac unit of a tertiary-care academic hospital. Family members of admitted patients were randomized in a 1:1 manner to the intervention (use of the NGAGE tool) or usual-care group. Intervention group participants could request engagement activities using the NGAGE tool and this request was transmitted to the treating healthcare team. At enrollment, demographics and family engagement scores were captured. At discharge, data on care satisfaction, mental health, and engagement were collected. Recruitment rate, intervention uptake, tool use, requests fulfilled, and follow-up rate were used to assess feasibility outcomes. RESULTS: A total of 88 participants (45 intervention, 43 control) were included in the analysis. The mean recruitment rate was 2.9 participants per week. In the intervention group, 69% of participants used the NGAGE tool (1.5 +/- 0.9 uses per participant). Most engagement requests (39 of 47; 83.0%) were fulfilled. Follow-up data were available for 76% of participants (67 of 88). Family members who used the NGAGE tool improved their family engagement score. No between-group differences occurred in mental health or satisfaction at follow-up (all P > 0.05). CONCLUSIONS: We found evidence to suggest that implementation of the NGAGE tool was feasible. The results will inform the design of a multicentre effectiveness trial of use of the NGAGE tool. CLINICAL TRIAL REGISTRATION: NCT05528185. CI - (c) 2025 The Authors. FAU - Abdallah, Jean Pierre AU - Abdallah JP AD - Division of Experimental Medicine, Department of Medicine, McGill University, Montreal, Quebec, Canada. FAU - Morel, Sara B A AU - Morel SBA AD - Faculty of Medicine and Health Sciences, McGill University, Montreal, Quebec, Canada. FAU - Soboleva, Nataliya AU - Soboleva N AD - Department of Nursing, Jewish General Hospital, McGill University, Montreal, Quebec, Canada. FAU - Quan, Jessica AU - Quan J AD - Department of Nursing, Jewish General Hospital, McGill University, Montreal, Quebec, Canada. FAU - Price, Chella AU - Price C AD - Faculty of Medicine and Health Sciences, McGill University, Montreal, Quebec, Canada. AD - Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, Quebec, Canada. FAU - Goldfarb, Michael AU - Goldfarb M AD - Division of Experimental Medicine, Department of Medicine, McGill University, Montreal, Quebec, Canada. AD - Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, Quebec, Canada. AD - Division of Cardiology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada. LA - eng SI - ClinicalTrials.gov/NCT05528185 PT - Journal Article DEP - 20250311 PL - United States TA - CJC Open JT - CJC open JID - 101763635 PMC - PMC12198593 EDAT- 2025/07/01 04:06 MHDA- 2025/07/01 04:07 PMCR- 2025/03/11 CRDT- 2025/06/30 06:30 PHST- 2024/12/24 00:00 [received] PHST- 2025/03/02 00:00 [accepted] PHST- 2025/07/01 04:07 [medline] PHST- 2025/07/01 04:06 [pubmed] PHST- 2025/06/30 06:30 [entrez] PHST- 2025/03/11 00:00 [pmc-release] AID - S2589-790X(25)00123-4 [pii] AID - 10.1016/j.cjco.2025.03.007 [doi] PST - epublish SO - CJC Open. 2025 Mar 11;7(6):743-749. doi: 10.1016/j.cjco.2025.03.007. eCollection 2025 Jun. PMID- 40578894 OWN - NLM STAT- MEDLINE DCOM- 20250627 LR - 20250710 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 15 IP - 6 DP - 2025 Jun 27 TI - Process evaluation of a randomised trial of a triple low-dose combination pill strategy to improve hypertension control: a qualitative study. PG - e101689 LID - 10.1136/bmjopen-2025-101689 [doi] LID - e101689 AB - BACKGROUND: High blood pressure (BP) is a significant global health issue, with many treated patients failing to achieve BP control. The Triple Pill vs Usual Care Management for Patients with Mild-to-Moderate Hypertension (TRIUMPH) trial evaluated the effectiveness, cost-effectiveness and acceptability of early use of low-dose triple fixed-dose combination of BP-lowering drugs ('triple pill') compared with usual care in the management of hypertension. The TRIUMPH trial showed superior BP control with the triple pill strategy compared with usual care. This process evaluation of the TRIUMPH trial aimed to explore the contextual factors that influenced the trial outcomes, implementation of the triple pill strategy, mechanisms of its effects and potential barriers and facilitators for implementing the triple pill strategy in routine practice. METHODS: Guided by the UK Medical Research Council's framework, semistructured interviews were conducted with 23 patients and 13 healthcare providers involved in the TRIUMPH trial. Data were analysed using the framework analysis method in NVivo. RESULTS: Hypertension care in Sri Lanka was hindered by the absence of systematic screening and overcrowded public clinics. Despite free medication provision at public clinics, long waiting times and occasional stock-outs posed challenges. In the TRIUMPH trial, both intervention and usual care were delivered in the context of 'better than usual' care, including team-based management, reduced waiting times, monetary assistance for travel, routine adherence monitoring and intensive follow-up. The triple pill strategy provided a simplified regimen, better access to BP-lowering medications and better BP-lowering efficacy. Key barriers to implementation in routine practice included the triple pill's large size, therapeutic inertia and restrictive regulatory policies regarding fixed-dose combinations. CONCLUSIONS: Implementation of the triple pill strategy into routine practice requires health system strengthening, provider training and supportive policy measures to replicate its effectiveness seen in the trial. TRIAL REGISTRATION NUMBER: ACTRN12612001120864, SLCTR/2015/020. CI - (c) Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY. Published by BMJ Group. FAU - Salam, Abdul AU - Salam A AUID- ORCID: 0000-0002-5870-7936 AD - The George Institute for Global Health India, New Delhi, India asalam@georgeinstitute.org.in. AD - University of New South Wales, Sydney, New South Wales, Australia. AD - Manipal Academy of Higher Education, Manipal, India. FAU - Laba, Tracey AU - Laba T AD - The University of Sydney, Sydney, New South Wales, Australia. FAU - Dhurjati, Rupasvi AU - Dhurjati R AUID- ORCID: 0000-0002-8579-3972 AD - The George Institute for Global Health India, Telangana, Hyderabad, India. FAU - Josyula, Lakshmi K AU - Josyula LK AD - Indian Institute of Public Health, Hyderabad, Telangana, India. FAU - de Silva, Asita AU - de Silva A AD - University of Kelaniya Faculty of Medicine, Ragama, Western, Sri Lanka. FAU - Godamunne, Pavithra AU - Godamunne P AD - Department of Medical Education, Faculty of Medicine, University of Kelaniya, Colombo, Sri Lanka. FAU - Guggilla, Rama AU - Guggilla R AUID- ORCID: 0000-0002-7486-5977 AD - Uppsala University, Uppsala, Sweden. FAU - Jan, Stephen AU - Jan S AD - University of New South Wales, Sydney, New South Wales, Australia. FAU - Maulik, Pallab Kumar AU - Maulik PK AUID- ORCID: 0000-0001-6835-6175 AD - The George Institute for Global Health India, New Delhi, India. FAU - Naik, Nitish AU - Naik N AD - All India Institute of Medical Sciences, New Delhi, India. FAU - Patel, Anushka AU - Patel A AD - University of New South Wales, Sydney, New South Wales, Australia. FAU - Pathmeswaran, Arunasalam AU - Pathmeswaran A AD - Department of Public Health, Faculty of Medicine, University of Kelaniya, Kelaniya, Sri Lanka. FAU - Prabhakaran, Dorairaj AU - Prabhakaran D AUID- ORCID: 0000-0002-3172-834X AD - Centre for Chronic Disease Control, New Delhi, India. AD - Public Health Foundation of India, New Delhi, India. FAU - Rodgers, Anthony AU - Rodgers A AD - University of New South Wales, Sydney, New South Wales, Australia. FAU - Selak, Vanessa AU - Selak V AUID- ORCID: 0000-0002-9824-8674 AD - Epidemiology & Biostatistics, University of Auckland, Auckland, New Zealand. FAU - Webster Griffiths, Ruth AU - Webster Griffiths R AD - The George Institute for Global Health, Sydney, New South Wales, Australia. AD - University of Technology Sydney Centre for Health Economics Research and Evaluation, Broadway, New South Wales, Australia. LA - eng PT - Journal Article PT - Randomized Controlled Trial DEP - 20250627 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 RN - 0 (Antihypertensive Agents) RN - 0 (Drug Combinations) SB - IM MH - Humans MH - *Hypertension/drug therapy MH - *Antihypertensive Agents/administration & dosage/therapeutic use/economics MH - Female MH - Male MH - Qualitative Research MH - Middle Aged MH - Drug Combinations MH - Sri Lanka MH - Aged MH - Cost-Benefit Analysis MH - Drug Therapy, Combination MH - Adult PMC - PMC12207132 OTO - NOTNLM OT - Blood Pressure OT - CARDIOLOGY OT - Hypertension OT - Meta-Analysis OT - Systematic Review COIS- Competing interests: AR is employed by The George Institute for Global Health (TGI) and Imperial College London. TGI has submitted patent applications for low-dose combination products for hypertension, and AR is listed as an inventor. George Medicines Pty (GM) is a subsidiary of TGI, holds a licence for these patents and has received investment to develop these combination therapies. AR is seconded part-time to GM. AR has no financial interest in these patents or in GM. All other authors have no completing interest to declare. EDAT- 2025/06/28 00:39 MHDA- 2025/06/28 00:40 PMCR- 2025/06/27 CRDT- 2025/06/27 20:33 PHST- 2025/06/28 00:40 [medline] PHST- 2025/06/28 00:39 [pubmed] PHST- 2025/06/27 20:33 [entrez] PHST- 2025/06/27 00:00 [pmc-release] AID - bmjopen-2025-101689 [pii] AID - 10.1136/bmjopen-2025-101689 [doi] PST - epublish SO - BMJ Open. 2025 Jun 27;15(6):e101689. doi: 10.1136/bmjopen-2025-101689. PMID- 40578158 OWN - NLM STAT- MEDLINE DCOM- 20250705 LR - 20250705 IS - 1879-0534 (Electronic) IS - 0010-4825 (Linking) VI - 195 DP - 2025 Sep TI - Computational study of halbach-array-driven magnetic targeting for aortic tumor using Non-Newtonian blood flow models. PG - 110580 LID - S0010-4825(25)00931-X [pii] LID - 10.1016/j.compbiomed.2025.110580 [doi] AB - Aortic tumors are uncommon but aggressive and require thoughtful, focused treatment modalities. In this study, a novel computational study into magnetic drug targeting (MDT) for aortic tumors using a Halbach array to produce a non-uniform magnetic field was performed. Additionally, non-Newtonian blood flow properties, using Power-law and Carreau models were used in simulations. A case-specific aortic geometry was reconstructed from a CT image, and finite element simulations were conducted to evaluate the capture efficiency (CE) of the magnetic nanoparticles in different scenarios. Nanoparticles of varying diameters between 250 and 1000 nm and magnetic field intensities of 0.5 T, 0.78 T, and 1.2 T were used. The results showed a significant dependence of CE on particle size and the magnetic field. For example, at 1.2 T, particles of 1000 nm produced a CE of 55 % by the third cardiac cycle, while 500 nm particles produced a CE of 36 % based on Newtonian flow assumptions. Non-Newtonian models produced slightly higher CE at initial periods for larger particles: Carreau would yield 44.5 % and Power-law would yield 43.9 % for initial CE in the first cycle, compared to 42.4 % for the Newtonian model. These results demonstrate the important roles of particle size, the intensity of magnetic fields, and rheological blood behavior in optimizing MDT. The present study improves the computational design of MDT systems for vascular tumors and highlights the importance of considering realistic hemodynamics when planning treatment. CI - Copyright (c) 2025. Published by Elsevier Ltd. FAU - Aminian, Saman AU - Aminian S AD - Department of Mechanical and Aerospace Engineering, SR.C., Islamic Azad University, Tehran, Iran. FAU - Najafi, Mohammad AU - Najafi M AD - Department of Mechanical and Aerospace Engineering, SR.C., Islamic Azad University, Tehran, Iran. Electronic address: m.njafi36@gmail.com. FAU - Saadat, Habibollah AU - Saadat H AD - Cardiovascular Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. FAU - Ashjaee, Mehdi AU - Ashjaee M AD - School of Mechanical Engineering, College of Engineering, University of Tehran, Tehran, Iran. LA - eng PT - Journal Article DEP - 20250626 PL - United States TA - Comput Biol Med JT - Computers in biology and medicine JID - 1250250 RN - 0 (Magnetite Nanoparticles) SB - IM MH - Humans MH - *Models, Cardiovascular MH - *Aorta/diagnostic imaging/physiopathology MH - *Magnetite Nanoparticles/therapeutic use MH - Computer Simulation MH - Magnetic Fields MH - *Drug Delivery Systems/methods MH - Hemodynamics OTO - NOTNLM OT - Aortic tumors OT - Halbach array OT - MDT OT - Nanoparticles OT - Wall shear stress COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. We confirm that the manuscript has been read and approved by all named authors and that there are no other persons who satisfied the criteria for authorship but are not listed. We further confirm that the order of authors listed in the manuscript has been approved by all of us. EDAT- 2025/06/28 00:39 MHDA- 2025/07/06 06:18 CRDT- 2025/06/27 18:11 PHST- 2024/12/28 00:00 [received] PHST- 2025/05/21 00:00 [revised] PHST- 2025/06/12 00:00 [accepted] PHST- 2025/07/06 06:18 [medline] PHST- 2025/06/28 00:39 [pubmed] PHST- 2025/06/27 18:11 [entrez] AID - S0010-4825(25)00931-X [pii] AID - 10.1016/j.compbiomed.2025.110580 [doi] PST - ppublish SO - Comput Biol Med. 2025 Sep;195:110580. doi: 10.1016/j.compbiomed.2025.110580. Epub 2025 Jun 26. PMID- 40577535 OWN - NLM STAT- MEDLINE DCOM- 20251216 LR - 20260513 IS - 1535-2900 (Electronic) IS - 1079-2082 (Linking) VI - 83 IP - 1 DP - 2025 Dec 16 TI - Cost analysis of a clinical pharmacist-led multidisciplinary iron deficiency treatment clinic for patients with heart failure or pulmonary hypertension. PG - e46-e52 LID - 10.1093/ajhp/zxaf113 [doi] AB - PURPOSE: To conduct a data-driven cost analysis comparing a clinical pharmacist-led iron deficiency treatment clinic to usual care for patients with heart failure (HF) or pulmonary hypertension (PH). METHODS: Direct medical costs for providing services and associated reimbursements over a 19-month period were estimated from the hospital perspective for a group of patients who received iron deficiency treatment in a pharmacist-led clinic and a group that received usual care. The frequency of various services within each group were derived from clinical data of a published cohort study. Unit costs for services were obtained from the literature. The net cost per patient was calculated and compared between groups, with one-way sensitivity analysis conducted on hospitalization and clinical pharmacist personnel costs. All costs were inflated to 2024 US dollar value. RESULTS: A total of 81 patients received clinical pharmacist-led services, and the cost for the services provided was $3,089 per patient, while 42 received usual care, with a cost of $5,547 per patient. The reimbursement per patient was $1,852 in the clinical pharmacist group and $1,798 in the usual care group. The net cost per patient was lower in the clinical pharmacist group by $2,512 than in the usual care group. One-way sensitivity analyses indicated that varying hospitalization costs significantly impacted the net cost in both groups. CONCLUSION: This study demonstrated that a clinical pharmacist-led service incurred lower net cost per patient than usual care, leading to cost savings for the hospital. Economic analyses can complement clinical studies in demonstrating the sustainability of clinical services. CI - (c) American Society of Health-System Pharmacists 2025. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com. FAU - Pathan, Maryam AU - Pathan M AD - Department of Pharmaceutical Systems and Policy, West Virginia University School of Pharmacy, Morgantown, WV, USA. FAU - Kido, Kazuhiko AU - Kido K AD - Department of Clinical Pharmacy, West Virginia University School of Pharmacy, Morgantown, WV, USA. FAU - Kamal, Khalid M AU - Kamal KM AD - Department of Pharmaceutical Systems and Policy, West Virginia University School of Pharmacy, Morgantown, WV, USA. LA - eng PT - Journal Article PL - England TA - Am J Health Syst Pharm JT - American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists JID - 9503023 SB - IM MH - Humans MH - *Heart Failure/economics/complications/therapy MH - *Pharmacists/economics/organization & administration MH - *Hypertension, Pulmonary/economics/complications/therapy MH - *Pharmacy Service, Hospital/economics MH - Costs and Cost Analysis MH - Male MH - Female MH - *Anemia, Iron-Deficiency/economics/drug therapy/therapy MH - Aged MH - Professional Role MH - Middle Aged MH - Hospitalization/economics MH - Health Care Costs MH - Cohort Studies OTO - NOTNLM OT - clinical pharmacist OT - cost analysis OT - cost savings OT - heart failure OT - iron deficiency OT - pulmonary hypertension EDAT- 2025/06/27 18:28 MHDA- 2025/12/16 06:28 CRDT- 2025/06/27 14:22 PHST- 2025/12/16 06:28 [medline] PHST- 2025/06/27 18:28 [pubmed] PHST- 2025/06/27 14:22 [entrez] AID - 8168975 [pii] AID - 10.1093/ajhp/zxaf113 [doi] PST - ppublish SO - Am J Health Syst Pharm. 2025 Dec 16;83(1):e46-e52. doi: 10.1093/ajhp/zxaf113. PMID- 40575426 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250628 IS - 1949-8462 (Print) IS - 1949-8462 (Electronic) VI - 17 IP - 6 DP - 2025 Jun 26 TI - Navigating women with congenital heart disease during pregnancy: Management strategies and future directions. PG - 106295 LID - 10.4330/wjc.v17.i6.106295 [doi] LID - 106295 AB - Women with adult congenital heart disease (CHD) face unique challenges during pregnancy, as gestational cardiovascular (CV) and hemodynamic changes can exacerbate underlying cardiac conditions. While these adaptations are well tolerated in women with structurally and functionally normal hearts, they pose significant risks for those with adult CHD (ACHD), whether repaired, palliated, or with residual defects. Maternal CHD is associated with an increased risk of adverse CV events, including stroke, heart failure, arrhythmias, and thromboembolic complications during pregnancy and the peripartum period. Effective management requires a multidisciplinary team, including cardiologists, perinatologists, anesthesiologists, and other skilled care providers. Risk stratification tools such as the modified World Health Organization classification, CARPREG II, and ZAHARA scores are useful for predicting maternal and fetal outcomes and guiding clinical decision-making. Preconception counseling plays a critical role in assessing individual risks, optimizing cardiac function, and educating patients about potential complications. Future research should prioritize innovative therapies, including targeted pharmacological agents and minimally invasive interventions, alongside improved screening methods to identify high-risk patients before symptomatic disease manifests. This review synthesizes current literature on managing pregnant women with ACHD, highlights gaps in clinical practice, and explores future directions to enhance care. Addressing these challenges is essential to improving maternal and fetal outcomes and ensuring comprehensive, patient-centered care throughout the reproductive journey. CI - (c)The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. FAU - Das, Bibhuti B AU - Das BB AD - Congenital Heart Institute, Methodist Children's Hospital, San Antonio, TX 78229, United States. bbdas001@gmail.com. FAU - Aggarwal, Varun AU - Aggarwal V AD - Department of Pediatrics, University of Minnesota Medical School, University of Minnesota Medical School, Minneapolis, MN 55454, United States. FAU - Deshpande, Shriprasad R AU - Deshpande SR AD - Department of Pediatric Cardiology, Children's National Hospital, The George Washington University, Washington, DC 20010, United States. LA - eng PT - Journal Article PT - Review PL - United States TA - World J Cardiol JT - World journal of cardiology JID - 101537090 PMC - PMC12186142 OTO - NOTNLM OT - Congenital heart disease OT - Contraception OT - Maternal & fetal outcomes OT - Postpartum care OT - Pregnancy OT - Women with congenital heart disease COIS- Conflict-of-interest statement: There is no conflict of interest associated with any of the senior author or other coauthors contributed their efforts in this manuscript. EDAT- 2025/06/27 06:27 MHDA- 2025/06/27 06:28 PMCR- 2025/06/26 CRDT- 2025/06/27 04:53 PHST- 2025/02/24 00:00 [received] PHST- 2025/04/08 00:00 [revised] PHST- 2025/05/21 00:00 [accepted] PHST- 2025/06/27 06:28 [medline] PHST- 2025/06/27 06:27 [pubmed] PHST- 2025/06/27 04:53 [entrez] PHST- 2025/06/26 00:00 [pmc-release] AID - 10.4330/wjc.v17.i6.106295 [doi] PST - ppublish SO - World J Cardiol. 2025 Jun 26;17(6):106295. doi: 10.4330/wjc.v17.i6.106295. PMID- 40575425 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250628 IS - 1949-8462 (Print) IS - 1949-8462 (Electronic) VI - 17 IP - 6 DP - 2025 Jun 26 TI - Metabolic-dysfunction associated steatotic liver disease and atrial fibrillation: A review of pathogenesis. PG - 106147 LID - 10.4330/wjc.v17.i6.106147 [doi] LID - 106147 AB - Metabolic dysfunction-associated steatotic liver disease (MASLD) significantly contributes to cardiovascular morbidity, with cardiovascular disease being the leading cause of mortality among affected individuals. Atrial fibrillation (AF), the most common cardiac arrhythmia, is frequently observed in patients with MASLD. While shared metabolic risk factors such as obesity, diabetes, dyslipidemia, and hypertension are implicated, underlying pathophysiological mechanisms that include systemic inflammation, oxidative stress, insulin resistance, endothelial dysfunction, and activation of the renin-angiotensin-aldosterone system (RAAS) are proposed to play significant part in the increased risk of AF in MASLD. The aim is to review the pathogenesis linking MASLD and AF. A comprehensive literature review was conducted, focusing on studies that explore the epidemiology, pathogenesis, and clinical implications of MASLD and AF. Databases searched included PubMed, Scopus, and Web of Science, with keywords such as "metabolic associated steatotic liver disease", "non fibrotic metabolic associated steatohepatitis", "Nonalcoholic fatty liver disease", "metabolic syndrome", "atrial fibrillation", "antifibrotic therapies", "pathogenesis", and "cardiovascular risk". Chronic low-grade inflammation and oxidative stress in MASLD contribute to atrial structural and electrical remodeling, fostering an arrhythmogenic substrate. Insulin resistance, a hallmark of MASLD, exacerbates metabolic dysfunction and promotes atrial fibrosis. Dysregulated lipid metabolism and gut microbiota alterations further compound cardiovascular risk. Aldosterone dysregulation and systemic inflammation stemming from RAAS activation contributes to the shared pathophysiology. The severity of MASLD does not seem to directly influence the risk of AF, suggesting that even early stages of liver disease can increase susceptibility to this arrhythmia. Effective management of MASLD requires targeted risk-factor modification strategies, including weight management, glycemic control, and pharmacological interventions. A multidisciplinary approach is essential for comprehensive assessment and management of MASLD patients, with a focus on cardiovascular risk assessment and arrhythmia prevention. Future research should explore the impact of emerging MASLD therapeutic agents on the incidence and recurrence of cardiac arrhythmias. Early detection and comprehensive management of MASLD and AF are crucial to mitigate the dual burden of these conditions. CI - (c)The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. FAU - Bharaj, Inderjeet Singh AU - Bharaj IS AD - Department of Internal Medicine, Abrazo Health Network, Glendale, AZ 85308, United States. FAU - Brar, Ajit Singh AU - Brar AS AD - Department of Internal Medicine, Michigan State University at Hurley Medical Center, Flint, MI 48503, United States. FAU - Kahlon, Jasraj AU - Kahlon J AD - Department of Internal Medicine, Abrazo Health Network, Glendale, AZ 85308, United States. FAU - Singh, Anmol AU - Singh A AD - Department of Medicine, Tristar Centennial Medical Center, Nashville, TN 37203, United States. FAU - Hotwani, Priya AU - Hotwani P AD - Department of Internal Medicine, Parkview Health Internal Medicine Residency, Fort Wayne, IN 46845, United States. FAU - Kumar, Vikash AU - Kumar V AD - Department of Gastroenterology and Hepatology, Creighton University School of Medicine, Phoenix, AZ 85012, United States. FAU - Sohal, Aalam AU - Sohal A AD - Department of Gastroenterology and Hepatology, Creighton University School of Medicine, Phoenix, AZ 85012, United States. aalamsohal@gmail.com. FAU - Batta, Akash AU - Batta A AD - Department of Cardiology, Dayanand Medical College and Hospital, Ludhiana 141001, Punjab, India. LA - eng PT - Journal Article PT - Review PL - United States TA - World J Cardiol JT - World journal of cardiology JID - 101537090 PMC - PMC12186170 OTO - NOTNLM OT - Atrial fibrillation OT - Dyslipidemia OT - Insulin resistance OT - Metabolic-dysfunction associated steatotic liver disease OT - Non-alcoholic fatty liver disease OT - Non-alcoholic steatohepatitis OT - Obesity OT - Oxidative stress COIS- Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article. EDAT- 2025/06/27 06:27 MHDA- 2025/06/27 06:28 PMCR- 2025/06/26 CRDT- 2025/06/27 04:53 PHST- 2025/02/17 00:00 [received] PHST- 2025/04/09 00:00 [revised] PHST- 2025/05/21 00:00 [accepted] PHST- 2025/06/27 06:28 [medline] PHST- 2025/06/27 06:27 [pubmed] PHST- 2025/06/27 04:53 [entrez] PHST- 2025/06/26 00:00 [pmc-release] AID - 10.4330/wjc.v17.i6.106147 [doi] PST - ppublish SO - World J Cardiol. 2025 Jun 26;17(6):106147. doi: 10.4330/wjc.v17.i6.106147. PMID- 40574909 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250628 IS - 2048-0040 (Print) IS - 2048-0040 (Electronic) IS - 2048-0040 (Linking) VI - 14 DP - 2025 Jan-Dec TI - The pearls for optimal intrapartum care in women with cardiac disease. PG - 20480040251349579 LID - 10.1177/20480040251349579 [doi] LID - 20480040251349579 AB - Cardiac disease during pregnancy is one of the leading causes of maternal mortality and morbidity in both the UK and the USA. Labour, delivery, and the initial postpartum phase are characterised by significant haemodynamic alterations that play a significant role in the clinical deterioration observed in women with heart disease. Heart failure, arrhythmia, and myocardial ischaemia can occur in women with high-risk cardiac lesions during labour. The cardio-obstetric multidisciplinary team, after risk stratification, should establish an individualised cardiac care plan that incorporates patients' preferences. This care plan should address the location, mode, timing of delivery, monitoring, analgesia, and anaesthetic options for operative intervention, uterotonics that may be administered, emergency contact numbers for relevant personnel along with appropriate postpartum care. High-risk patients need to be delivered in tertiary units. Clear haemodynamic objectives should be established along with a postpartum contraception plan with information cascaded to community midwifery teams and primary care providers to ensure surveillance and continuity of care. Co-ordinated multidisciplinary care can enhance preparedness for obstetric and cardiac emergencies, thereby decreasing morbidity and mortality associated with heart disease in pregnancy during childbirth. CI - (c) The Author(s) 2025. FAU - Thompson, Caroline AU - Thompson C AUID- ORCID: 0009-0003-4725-8180 AD - Health Education England, North-West, UK. FAU - Ormesher, Laura AU - Ormesher L AUID- ORCID: 0000-0002-1820-5800 AD - Maternal and Fetal Health Research Centre, University of Manchester and Saint Mary's Hospital, Manchester, UK. FAU - Bhatia, Kailash AU - Bhatia K AUID- ORCID: 0000-0001-8108-1196 AD - Department of Anaesthesia, University of Manchester, Saint Mary's Hospital, Manchester, UK. LA - eng PT - Journal Article PT - Review DEP - 20250625 PL - England TA - JRSM Cardiovasc Dis JT - JRSM cardiovascular disease JID - 101598607 PMC - PMC12198545 OTO - NOTNLM OT - Anaesthesia OT - analgesia OT - cardiac disease OT - labour OT - morbidity OT - mortality OT - pregnancy COIS- The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2025/06/27 10:33 MHDA- 2025/06/27 10:34 PMCR- 2025/06/25 CRDT- 2025/06/27 04:46 PHST- 2024/11/06 00:00 [received] PHST- 2025/04/09 00:00 [revised] PHST- 2025/05/28 00:00 [accepted] PHST- 2025/06/27 10:34 [medline] PHST- 2025/06/27 10:33 [pubmed] PHST- 2025/06/27 04:46 [entrez] PHST- 2025/06/25 00:00 [pmc-release] AID - 10.1177_20480040251349579 [pii] AID - 10.1177/20480040251349579 [doi] PST - epublish SO - JRSM Cardiovasc Dis. 2025 Jun 25;14:20480040251349579. doi: 10.1177/20480040251349579. eCollection 2025 Jan-Dec. PMID- 40572770 OWN - NLM STAT- MEDLINE DCOM- 20250627 LR - 20250628 IS - 1648-9144 (Electronic) IS - 1010-660X (Print) IS - 1010-660X (Linking) VI - 61 IP - 6 DP - 2025 Jun 12 TI - Early Phase I Cardiac Rehabilitation Integrated with Multidisciplinary Post-Acute Care in Decompensated Heart Failure: Insights from Serial Cardiopulmonary Exercise Testing. LID - 10.3390/medicina61061080 [doi] LID - 1080 AB - Background and Objectives: Acute decompensated heart failure (ADHF) leads to significant impairments in exercise capacity and functional outcomes. This study aimed to evaluate the feasibility and effectiveness of integrating early phase I cardiac rehabilitation with a multidisciplinary heart failure post-acute care (HF-PAC) program to improve functional capacity in patients hospitalized for ADHF, assessed by serial cardiopulmonary exercise testing (CPET). Materials and Methods: We conducted a prospective cohort study at a medical center in Taiwan. Patients hospitalized for ADHF between February 2017 and March 2023 who completed inpatient and six-month follow-up CPET were enrolled. The rehabilitation protocol included supervised aerobic and resistance training during hospitalization, followed by outpatient multidisciplinary care. The primary outcome was the change in peak oxygen uptake (peak VO(2)) over six months. Results: A total of 90 patients were included (74.4% male, mean age 58.4 +/- 14.7 years). Peak VO(2) significantly improved from 11.57 +/- 3.33 to 13.99 +/- 4.2 mL/kg/min (p < 0.001). Significant improvements were also observed in 6 min walk distance, anaerobic threshold, heart rate recovery, oxygen uptake efficiency slope, and left ventricular ejection fraction. Conclusions: Early integration of phase I cardiac rehabilitation with multidisciplinary HF-PAC is feasible and enhances exercise capacity in patients with ADHF. Serial CPET provides an objective evaluation of functional recovery and may guide rehabilitation strategies in this high-risk population. FAU - Ding, Ruei-Sian AU - Ding RS AUID- ORCID: 0000-0003-2813-8610 AD - Department of Physical Medicine and Rehabilitation, Kaohsiung Veterans General Hospital, Kaohsiung 813, Taiwan. FAU - Lin, Ko-Long AU - Lin KL AD - Department of Physical Medicine and Rehabilitation, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan. AD - Department of Physical Medicine and Rehabilitation, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan. FAU - Wang, Wen-Hwa AU - Wang WH AD - Cardiovascular Center, Kaohsiung Veterans General Hospital, Kaohsiung 813, Taiwan. FAU - Huang, Ming-Hsuan AU - Huang MH AD - Department of Physical Medicine and Rehabilitation, Kaohsiung Veterans General Hospital, Kaohsiung 813, Taiwan. FAU - Liou, I-Hsiu AU - Liou IH AD - Department of Physical Medicine and Rehabilitation, Kaohsiung Veterans General Hospital, Kaohsiung 813, Taiwan. AD - Department of Physical Therapy, School of Medical and Health Science, Fooyin University, Kaohsiung 831, Taiwan. LA - eng PT - Journal Article DEP - 20250612 PL - Switzerland TA - Medicina (Kaunas) JT - Medicina (Kaunas, Lithuania) JID - 9425208 SB - IM MH - Humans MH - Male MH - Female MH - *Heart Failure/rehabilitation/physiopathology/therapy MH - Middle Aged MH - *Cardiac Rehabilitation/methods/standards MH - *Exercise Test/methods/statistics & numerical data MH - Aged MH - Prospective Studies MH - Taiwan MH - Cohort Studies MH - *Subacute Care/methods MH - Oxygen Consumption/physiology MH - Exercise Tolerance/physiology PMC - PMC12195422 OTO - NOTNLM OT - acute decompensated heart failure OT - cardiac rehabilitation OT - cardiopulmonary exercise testing OT - heart failure OT - multidisciplinary team OT - peak oxygen uptake OT - post-acute care COIS- The authors declare no conflicts of interest. EDAT- 2025/06/27 06:26 MHDA- 2025/06/27 06:27 PMCR- 2025/06/12 CRDT- 2025/06/27 01:05 PHST- 2025/04/21 00:00 [received] PHST- 2025/06/01 00:00 [revised] PHST- 2025/06/09 00:00 [accepted] PHST- 2025/06/27 06:27 [medline] PHST- 2025/06/27 06:26 [pubmed] PHST- 2025/06/27 01:05 [entrez] PHST- 2025/06/12 00:00 [pmc-release] AID - medicina61061080 [pii] AID - medicina-61-01080 [pii] AID - 10.3390/medicina61061080 [doi] PST - epublish SO - Medicina (Kaunas). 2025 Jun 12;61(6):1080. doi: 10.3390/medicina61061080. PMID- 40571458 OWN - NLM STAT- MEDLINE DCOM- 20250905 LR - 20250908 IS - 1875-2128 (Electronic) IS - 1875-2128 (Linking) VI - 118 IP - 8-9 DP - 2025 Sep TI - Safety and efficacy of transcatheter correction of sinus venosus defect using 70-100mm-long partially covered Optimus-CVS(R) XXL stents compared with surgery: The OPTIVENOSUS study design. PG - 497-507 LID - S1875-2136(25)00321-3 [pii] LID - 10.1016/j.acvd.2025.05.003 [doi] AB - BACKGROUND: Transcatheter correction of sinus venosus defect provides a less invasive alternative to open-heart surgery. AIM: To evaluate the safety and efficacy of 70-100mm-long partially covered balloon-expandable Optimus-CVS(R) XXL stents (AndraTec, Koblenz, Germany), specifically designed for sinus venosus defect repair, compared with surgical intervention. METHODS: OPTIVENOSUS is a French nationwide multicentre prospective comparative cohort study of patients with indications for sinus venosus defect correction (May 2023 to February 2031). The study comprises two parts, with a comprehensive shift in patient assignment to the catheter group. Part 1 will enrol 30 adult patients (aged>18years) deemed ineligible for surgery by a multidisciplinary team, who will undergo feasibility assessment for catheter correction, including virtual simulations and three-dimensional-printed bench testing. Part 2 will add 30 adult patients with favourable anatomy, considered directly for stent therapy, whereas three-dimensional-printed bench testing will be reserved for complex cases. Surgical patients (aged >/=12years) will be enrolled continuously throughout the study, with no enrolment cap. All patients will receive standardized follow-up for up to 5years. RESULTS: The primary endpoint is a 6-month composite measure of safety and efficacy, defined by trivial or absent residual shunt and the absence of major adverse events (death or surgical conversion). If no significant difference is found, efficacy (end-diastolic right ventricular volume reduction) and safety (absence of reintervention, stroke, pacemaker implantation or severe arrhythmia) will be further evaluated using hierarchical analysis. CONCLUSION: The OPTIVENOSUS study evaluates the safety and effectiveness of transcatheter sinus venosus defect correction with Optimus-CVS(R) XXL stents versus surgery (NCT05865119). CI - Copyright (c) 2025. Published by Elsevier Masson SAS. FAU - Batteux, Clement AU - Batteux C AD - Filiere des Cardiopathies Congenitales Enfant Adultes, Centre Constitutif du Reseau Maladies Rares Malformations Cardiaques Congenitales Complexes (M3C), Hopital Marie-Lannelongue, 92350 Le-Plessis-Robinson, France; Faculte de Medecine Bicetre, Universite Paris-Saclay, 94270 Le Kremlin-Bicetre, France; INSERM UMR-S 999 "Hypertension Pulmonaire : Physiopathologie and Innovation Therapeutique (HPPIT)", Hopital Marie-Lannelongue, Universite Paris-Saclay, ERN-LUNG, 92350 Le-Plessis-Robinson, France. FAU - Ciobotaru, Vlad AU - Ciobotaru V AD - Faculte de Medecine Bicetre, Universite Paris-Saclay, 94270 Le Kremlin-Bicetre, France; INSERM UMR-S 999 "Hypertension Pulmonaire : Physiopathologie and Innovation Therapeutique (HPPIT)", Hopital Marie-Lannelongue, Universite Paris-Saclay, ERN-LUNG, 92350 Le-Plessis-Robinson, France; Cardiologie, Clinique Les Franciscaines, 3DHeartModeling, 30000 Nimes, France. FAU - Haddad, Raymond N AU - Haddad RN AD - Filiere des Cardiopathies Congenitales Enfant Adultes, Centre Constitutif du Reseau Maladies Rares Malformations Cardiaques Congenitales Complexes (M3C), Hopital Marie-Lannelongue, 92350 Le-Plessis-Robinson, France; Faculte de Medecine Bicetre, Universite Paris-Saclay, 94270 Le Kremlin-Bicetre, France; INSERM UMR-S 999 "Hypertension Pulmonaire : Physiopathologie and Innovation Therapeutique (HPPIT)", Hopital Marie-Lannelongue, Universite Paris-Saclay, ERN-LUNG, 92350 Le-Plessis-Robinson, France; Direction de la Recherche et de l'Innovation Medicale, MALIC, Hopital Marie-Lannelongue, 92350 Le-Plessis-Robinson, France. FAU - Houeijeh, Ali AU - Houeijeh A AD - Service de Cardiologie Pediatrique, Centre de competence du Reseau Maladies Rares Malformations Cardiaques Congenitales Complexes (M3C), Centre Hospitalier Universitaire de Lille, 59000 Lille, France. FAU - Karsenty, Clement AU - Karsenty C AD - Service de Cardiologie Pediatrique, Centre de competence du Reseau Maladies Rares Malformations Cardiaques Congenitales Complexes (M3C), Hopital des Enfants, CHU Toulouse, 31300 Toulouse, France. FAU - Bouzguenda, Ivan AU - Bouzguenda I AD - Cabinet Intercard, Hopital Prive de la Louviere, 59800 Lille, France. FAU - Roussin, Regine AU - Roussin R AD - Filiere des Cardiopathies Congenitales Enfant Adultes, Centre Constitutif du Reseau Maladies Rares Malformations Cardiaques Congenitales Complexes (M3C), Hopital Marie-Lannelongue, 92350 Le-Plessis-Robinson, France. FAU - Combes, Nicolas AU - Combes N AD - Filiere des Cardiopathies Congenitales Enfant Adultes, Centre Constitutif du Reseau Maladies Rares Malformations Cardiaques Congenitales Complexes (M3C), Hopital Marie-Lannelongue, 92350 Le-Plessis-Robinson, France; Service de Cardiologie, Clinique Pasteur, 31000 Toulouse, France. FAU - Bakloul, Mohamed AU - Bakloul M AD - Departement Medico-Chirurgical de Cardiologie Congenitale du Foetus, de l'Enfant et de l'Adulte, Centre de competence du Reseau Maladies Rares Malformations Cardiaques Congenitales Complexes (M3C), Hopital Louis Pradel, Hospices Civils de Lyon, 69500 Bron, France. FAU - Aldebert, Philippe AU - Aldebert P AD - Service de Cardiologie Pediatrique, Centre Constitutif du Reseau Maladies Rares Malformations Cardiaques Congenitales Complexes (M3C), Hopital Timone, AP-HM, 13385 Marseille, France. FAU - Dion, Fanny AU - Dion F AD - Service de Cardiologie Pediatrique, Centre de competence du Reseau Maladies Rares Malformations Cardiaques Congenitales Complexes (M3C), CHRU de Tours, 37000 Tours, France. FAU - Lefort, Bruno AU - Lefort B AD - Service de Cardiologie Pediatrique, Centre de competence du Reseau Maladies Rares Malformations Cardiaques Congenitales Complexes (M3C), CHRU de Tours, 37000 Tours, France. FAU - Bosser, Gilles AU - Bosser G AD - Service de Cardiologie Congenitale et Pediatrique, Centre Constitutif du Reseau Maladies Rares Malformations Cardiaques Congenitales Complexes (M3C), CHRU de Nancy, 54511 Vandoeuvre-les-Nancy, France. FAU - Bonnet, Damien AU - Bonnet D AD - Centre de Reference coordinateur du reseau Malformations Cardiaques Congenitales Complexes (M3C), Hopital Universitaire Necker-Enfants Malades, AP-HP, 75015 Paris, France. FAU - Fraisse, Alain AU - Fraisse A AD - Royal Brompton & Harefield Hospitals, Guys & St Thomas's NHS Trust and National Heart and Lung Institute, Imperial College, Sydney Street, London, SW3 6NP, United Kingdom. FAU - Bouvaist, Helene AU - Bouvaist H AD - Service de Cardiologie, Centre de competence du Reseau Maladies Rares Malformations Cardiaques Congenitales Complexes (M3C), CHU Grenoble Alpes, 38043 Grenoble, France. FAU - Hoerer, Jurgen AU - Hoerer J AD - Department of Congenital Heart Disease and Paediatric Cardiology, German Heart Centre Munich, Technical University of Munich, 80636 Munich, Germany. FAU - Moceri, Pamela AU - Moceri P AD - Service de Cardiologie, Centre de competence du Reseau Maladies Rares Malformations Cardiaques Congenitales Complexes (M3C), CHU Nice, 06001 Nice, France. FAU - Godart, Francois AU - Godart F AD - Service de Cardiologie Pediatrique, Centre de competence du Reseau Maladies Rares Malformations Cardiaques Congenitales Complexes (M3C), Centre Hospitalier Universitaire de Lille, 59000 Lille, France. FAU - Lenoir, Marien AU - Lenoir M AD - Service de Cardiologie Pediatrique, Centre Constitutif du Reseau Maladies Rares Malformations Cardiaques Congenitales Complexes (M3C), Hopital Timone, AP-HM, 13385 Marseille, France. FAU - Dauphin, Claire AU - Dauphin C AD - Service de Cardiologie Pediatrique, Centre de Competence du Reseau Maladies Rares Malformations Cardiaques Congenitales Complexes (M3C), CHU Clermont-Ferrand, 63000 Clermont-Ferrand, France. FAU - Radojevic, Jelena AU - Radojevic J AD - Filiere des Cardiopathies Congenitales Enfant Adultes, Centre Constitutif du Reseau Maladies Rares Malformations Cardiaques Congenitales Complexes (M3C), Hopital Marie-Lannelongue, 92350 Le-Plessis-Robinson, France; Cabinet de Cardiologie Foetale Pediatrique et Congenitale, Maison Medicale des 2 Rives, Clinique Rhena, 67000 Strasbourg, France. FAU - Thambo, Jean-Benoit AU - Thambo JB AD - Service de Cardiologie Pediatrique, Centre de competence du Reseau Maladies Rares Malformations Cardiaques Congenitales Complexes (M3C), CHU de Bordeaux, Electrophysiology and Heart Modelling Institute, IHU LIRYC, CRCTB, INSERM U1045, 33600 Pessac, France. FAU - Lecerf, Florence AU - Lecerf F AD - Direction de la Recherche et de l'Innovation Medicale, MALIC, Hopital Marie-Lannelongue, 92350 Le-Plessis-Robinson, France. FAU - Hache, Oceane AU - Hache O AD - Direction de la Recherche et de l'Innovation Medicale, MALIC, Hopital Marie-Lannelongue, 92350 Le-Plessis-Robinson, France. FAU - Chevalier, Delphine AU - Chevalier D AD - Direction de la Recherche et de l'Innovation Medicale, MALIC, Hopital Marie-Lannelongue, 92350 Le-Plessis-Robinson, France. FAU - Beaussier, Helene AU - Beaussier H AD - Direction de la Recherche et de l'Innovation Medicale, MALIC, Hopital Marie-Lannelongue, 92350 Le-Plessis-Robinson, France. FAU - Aubrege, Laure AU - Aubrege L AD - Direction de la Recherche et de l'Innovation Medicale, MALIC, Hopital Marie-Lannelongue, 92350 Le-Plessis-Robinson, France. FAU - Azarine, Arshid AU - Azarine A AD - INSERM UMR-S 999 "Hypertension Pulmonaire : Physiopathologie and Innovation Therapeutique (HPPIT)", Hopital Marie-Lannelongue, Universite Paris-Saclay, ERN-LUNG, 92350 Le-Plessis-Robinson, France; Service de Radiologie, Hopital Marie-Lannelongue (Groupe Hospitalier Paris Saint-Joseph), 92350 Le-Plessis-Robinson, France. FAU - Decante, Benoit AU - Decante B AD - INSERM UMR-S 999 "Hypertension Pulmonaire : Physiopathologie and Innovation Therapeutique (HPPIT)", Hopital Marie-Lannelongue, Universite Paris-Saclay, ERN-LUNG, 92350 Le-Plessis-Robinson, France; Direction de la Recherche et de l'Innovation Medicale, MALIC, Hopital Marie-Lannelongue, 92350 Le-Plessis-Robinson, France. FAU - Chatellier, Gilles AU - Chatellier G AD - Direction de la Recherche et de l'Innovation Medicale, MALIC, Hopital Marie-Lannelongue, 92350 Le-Plessis-Robinson, France. FAU - Ladouceur, Magalie AU - Ladouceur M AD - Filiere des Cardiopathies Congenitales Enfant Adultes, Centre Constitutif du Reseau Maladies Rares Malformations Cardiaques Congenitales Complexes (M3C), Hopital Marie-Lannelongue, 92350 Le-Plessis-Robinson, France; Service de Radiologie, Hopital Marie-Lannelongue (Groupe Hospitalier Paris Saint-Joseph), 92350 Le-Plessis-Robinson, France; Service de Cardiologie, Hopitaux Universitaires de Geneve, 1205 Geneve, Switzerland. FAU - Baruteau, Alban-Elouen AU - Baruteau AE AD - Service de Cardiologie Pediatrique, Centre de competence du Reseau Maladies Rares Malformations Cardiaques Congenitales Complexes (M3C), Centre Hospitalier Universitaire de Nantes, 44093 Nantes, France. FAU - Henaine, Roland AU - Henaine R AD - Departement Medico-Chirurgical de Cardiologie Congenitale du Foetus, de l'Enfant et de l'Adulte, Centre de competence du Reseau Maladies Rares Malformations Cardiaques Congenitales Complexes (M3C), Hopital Louis Pradel, Hospices Civils de Lyon, 69500 Bron, France. FAU - Albenque, Gregoire AU - Albenque G AD - Filiere des Cardiopathies Congenitales Enfant Adultes, Centre Constitutif du Reseau Maladies Rares Malformations Cardiaques Congenitales Complexes (M3C), Hopital Marie-Lannelongue, 92350 Le-Plessis-Robinson, France; Faculte de Medecine Bicetre, Universite Paris-Saclay, 94270 Le Kremlin-Bicetre, France; INSERM UMR-S 999 "Hypertension Pulmonaire : Physiopathologie and Innovation Therapeutique (HPPIT)", Hopital Marie-Lannelongue, Universite Paris-Saclay, ERN-LUNG, 92350 Le-Plessis-Robinson, France. FAU - Hascoet, Sebastien AU - Hascoet S AD - Filiere des Cardiopathies Congenitales Enfant Adultes, Centre Constitutif du Reseau Maladies Rares Malformations Cardiaques Congenitales Complexes (M3C), Hopital Marie-Lannelongue, 92350 Le-Plessis-Robinson, France; Faculte de Medecine Bicetre, Universite Paris-Saclay, 94270 Le Kremlin-Bicetre, France; INSERM UMR-S 999 "Hypertension Pulmonaire : Physiopathologie and Innovation Therapeutique (HPPIT)", Hopital Marie-Lannelongue, Universite Paris-Saclay, ERN-LUNG, 92350 Le-Plessis-Robinson, France; Direction de la Recherche et de l'Innovation Medicale, MALIC, Hopital Marie-Lannelongue, 92350 Le-Plessis-Robinson, France. Electronic address: s.hascoet@ghpsj.fr. LA - eng SI - ClinicalTrials.gov/NCT05865119 PT - Clinical Trial Protocol PT - Journal Article DEP - 20250529 PL - Netherlands TA - Arch Cardiovasc Dis JT - Archives of cardiovascular diseases JID - 101465655 RN - Atrial Septal Defect Sinus Venosus SB - IM MH - Humans MH - Treatment Outcome MH - Prospective Studies MH - Prosthesis Design MH - *Cardiac Catheterization/adverse effects/instrumentation MH - France MH - Time Factors MH - *Stents MH - Multicenter Studies as Topic MH - *Heart Septal Defects, Atrial/diagnostic imaging/physiopathology/therapy/surgery MH - *Cardiac Surgical Procedures/adverse effects/instrumentation MH - Female MH - Male MH - Adult MH - Feasibility Studies MH - Middle Aged OTO - NOTNLM OT - Catheterization OT - Congenital heart disease OT - Covered stent OT - Sinus venosus defect COIS- Disclosure of interest The authors declare that they have no competing interest. EDAT- 2025/06/27 00:28 MHDA- 2025/09/06 00:34 CRDT- 2025/06/26 21:52 PHST- 2025/03/21 00:00 [received] PHST- 2025/05/02 00:00 [revised] PHST- 2025/05/05 00:00 [accepted] PHST- 2025/09/06 00:34 [medline] PHST- 2025/06/27 00:28 [pubmed] PHST- 2025/06/26 21:52 [entrez] AID - S1875-2136(25)00321-3 [pii] AID - 10.1016/j.acvd.2025.05.003 [doi] PST - ppublish SO - Arch Cardiovasc Dis. 2025 Sep;118(8-9):497-507. doi: 10.1016/j.acvd.2025.05.003. Epub 2025 May 29. PMID- 40567349 OWN - NLM STAT- MEDLINE DCOM- 20250626 LR - 20250627 IS - 1734-154X (Electronic) IS - 0001-527X (Print) IS - 0001-527X (Linking) VI - 72 DP - 2025 TI - Monitoring and optimization of POCT devices in a multi-specialty hospital in Poland: usage trends, quality assurance, and clinical impact (2017-2024). PG - 14299 LID - 10.3389/abp.2025.14299 [doi] LID - 14299 AB - Rapid access to blood laboratory test results is crucial for diagnosing and treating patients in life-threatening conditions. Oxygenation status and acid-base balance are determined on arterial blood gasometry and are vital components of modern treatment algorithms for critically ill patients, similar to capillary blood glucose level measurement. The aim of this study is to present a modern method of reporting the work of critical parameter analyzers and glucometers in a multi-speciality hospital. The material for the analysis consisted of data obtained during the supervision of POCT devices in the clinics/departments/institutes of MIM-NRI from 2017 to 2024. Analyzing the use of glucometers in MIM-NRI from 2017 to 2024, it was noted that their usage significantly increased during the COVID-19 pandemic compared to the previous period. Currently, 112 devices are continuously used in both locations. All of them are subject to international and national quality testing, as well as daily internal calibration checking at their workplaces. There are currently 13 analyzers of critical parameter in the clinics and departments of MIM-NRI. All operate within the AQURE system, which allows for monitoring the correct operation of these devices and helps in quickly identifying analytical problems and reporting in real-time about the device's operational status. In the first half of 2024, 40,082 blood sample tests were performed on patients. Analysis of correctly performed gasometric tests conducted in clinics and laboratories shows similar values, ranging from 84.17% to 86.38%. In addition to external control, critical parameter devices must necessarily undergo daily internal laboratory control and calibration. The highest number of correctly performed calibrations, 9,239, was recorded in the Cardiac Surgery Clinic's Intensive Therapy Unit, accounting for 29% of all correctly performed calibrations for these devices. In the analyzed period of 2024, the rate of correctly performed quality checking's was 82.26%. The highest number of correct analyses, 636, was conducted in the Intensive Therapy Unit of the hospital in Legionowo, accounting for 10.32% of all controls performed. The demand for POCT tests in Polish hospitals is steadily growing due to their enormous potential and the time savings associated with performing tests directly at the patient's bedside. The greatest advantage of POCT is that by providing quick access to test results, diagnosis can be accelerated, and treatment initiated more rapidly. Additionally, POCT tests conducted in emergency rooms or hospital emergency departments can help to reduce the number of unnecessary hospitalizations or costly imaging tests. Having an appropriate POCT data management system in a multi-specialty hospital and ensuring IT communication is currently indispensable for proper patient care. CI - Copyright (c) 2025 Wozniak-Kosek and Drazek. FAU - Wozniak-Kosek, Agnieszka AU - Wozniak-Kosek A AD - Department of Laboratory Diagnostics, Military Institute of Medicine - National Research Institute in Warsaw, Warsaw, Poland. FAU - Drazek, Lucyna AU - Drazek L AD - Department of Laboratory Diagnostics, Laboratory of Medical Analytics in Legionowo, Military Institute of Medicine-National Research Institute in Warsaw, Warsaw, Poland. LA - eng PT - Journal Article DEP - 20250611 PL - Switzerland TA - Acta Biochim Pol JT - Acta biochimica Polonica JID - 14520300R RN - 0 (Blood Glucose) SB - IM MH - Humans MH - Poland/epidemiology MH - *COVID-19/epidemiology/diagnosis MH - *Quality Assurance, Health Care MH - SARS-CoV-2/isolation & purification MH - *Point-of-Care Testing/standards/trends MH - *Point-of-Care Systems/standards/trends MH - Blood Glucose/analysis MH - *Hospitals, Special MH - Blood Gas Analysis/instrumentation PMC - PMC12187598 OTO - NOTNLM OT - critical parameter analyzers OT - glucometers OT - laboratory management OT - point-of-care testing (POCT) OT - quality management COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2025/06/26 06:26 MHDA- 2025/06/26 06:27 PMCR- 2025/06/11 CRDT- 2025/06/26 05:15 PHST- 2025/01/04 00:00 [received] PHST- 2025/05/01 00:00 [accepted] PHST- 2025/06/26 06:27 [medline] PHST- 2025/06/26 06:26 [pubmed] PHST- 2025/06/26 05:15 [entrez] PHST- 2025/06/11 00:00 [pmc-release] AID - 14299 [pii] AID - 10.3389/abp.2025.14299 [doi] PST - epublish SO - Acta Biochim Pol. 2025 Jun 11;72:14299. doi: 10.3389/abp.2025.14299. eCollection 2025. PMID- 40566650 OWN - NLM STAT- MEDLINE DCOM- 20250626 LR - 20250703 IS - 1643-3750 (Electronic) IS - 1234-1010 (Print) IS - 1234-1010 (Linking) VI - 31 DP - 2025 Jun 26 TI - Six-Year Outcomes of CABG vs PCI in Diabetic Patients with Multivessel Coronary Disease. PG - e948348 LID - 10.12659/MSM.948348 [doi] LID - e948348 AB - BACKGROUND Many randomized controlled trials have explored the optimal revascularization strategy for patients with diabetes, but real-life outcomes are still poorly investigated. We assessed the complete 6-year outcomes of diabetic individuals with multivessel coronary artery disease (MVD) treated either with coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI). MATERIAL AND METHODS We reviewed data of all patients from 176 local Heart Team meetings and their treatment recommendations and assessed primary and secondary endpoints of 317 MVD patients with diabetes qualified either for CABG or PCI (98 and 219 patients, respectively) with subsequent optimal medical therapy. RESULTS At 6 years, no significant difference in overall mortality was observed (16.3% vs 20.5% for PCI, P=0.38). The incidence of myocardial infarction (MI) was higher in patients treated percutaneously (4.1% vs 12.3% for PCI, P=0.02), while those undergoing CABG had significantly longer postprocedural hospital stay (10.7 vs 4.4 days for PCI, P<0.01). The occurrence of major adverse cardiac and cerebrovascular events (MACCE), mainly driven by the increased rate of repeat revascularization (RR), was higher in the PCI group (83.6% vs 44.9%, P<0.01 and 47.0% vs 17.3%, P<0.01, respectively). The rates of stroke and in-hospital mortality were similar between the 2 groups. CONCLUSIONS For MVD patients with diabetes, CABG was superior in real-life clinical practice in terms of rates of MI, RR, and MACCE, while postprocedural hospital stays were shorted with PCI. The rates of all-cause death, stroke, and in-hospital mortality were comparable between groups. FAU - Jonik, Szymon AU - Jonik S AUID- ORCID: 0000-0002-9230-5455 AD - 1st Department of Cardiology, Medical University of Warsaw, Warsaw, Poland. FAU - Piasecki, Adam AU - Piasecki A AUID- ORCID: 0009-0002-5614-6415 AD - 1st Department of Cardiology, Medical University of Warsaw, Warsaw, Poland. FAU - Jastrzebska, Anna AU - Jastrzebska A AD - 1st Department of Cardiology, Medical University of Warsaw, Warsaw, Poland. FAU - Opolski, Grzegorz AU - Opolski G AUID- ORCID: 0000-0003-4744-2554 AD - 1st Department of Cardiology, Medical University of Warsaw, Warsaw, Poland. FAU - Grabowski, Marcin AU - Grabowski M AUID- ORCID: 0000-0003-3306-0301 AD - 1st Department of Cardiology, Medical University of Warsaw, Warsaw, Poland. FAU - Huczek, Zenon AU - Huczek Z AUID- ORCID: 0000-0002-5912-2649 AD - 1st Department of Cardiology, Medical University of Warsaw, Warsaw, Poland. FAU - Kochman, Janusz AU - Kochman J AUID- ORCID: 0000-0001-8239-8726 AD - 1st Department of Cardiology, Medical University of Warsaw, Warsaw, Poland. LA - eng PT - Journal Article DEP - 20250626 PL - United States TA - Med Sci Monit JT - Medical science monitor : international medical journal of experimental and clinical research JID - 9609063 SB - IM MH - Humans MH - *Coronary Artery Bypass/methods/adverse effects MH - *Percutaneous Coronary Intervention/methods/adverse effects MH - Female MH - Male MH - *Coronary Artery Disease/surgery MH - Treatment Outcome MH - Middle Aged MH - Aged MH - *Diabetes Mellitus/surgery MH - Myocardial Infarction PMC - PMC12211400 COIS- Conflict of interest: None declared EDAT- 2025/06/26 06:26 MHDA- 2025/06/26 06:27 PMCR- 2025/06/26 CRDT- 2025/06/26 01:22 PHST- 2025/06/26 06:27 [medline] PHST- 2025/06/26 06:26 [pubmed] PHST- 2025/06/26 01:22 [entrez] PHST- 2025/06/26 00:00 [pmc-release] AID - 948348 [pii] AID - 10.12659/MSM.948348 [doi] PST - epublish SO - Med Sci Monit. 2025 Jun 26;31:e948348. doi: 10.12659/MSM.948348. PMID- 40565875 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250628 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 14 IP - 12 DP - 2025 Jun 11 TI - Coronary Revascularization in Patients with Hemophilia and Acute Coronary Syndrome: Case Report and Brief Literature Review. LID - 10.3390/jcm14124130 [doi] LID - 4130 AB - The current management of patients with acute coronary syndrome (ACS) and bleeding disorders, such as hemophilia, is supported by small retrospective studies or expert consensus documents. Moreover, people with hemophilia are less likely to receive invasive treatments like percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) for ACS compared to those without hemophilia, which could affect their cardiovascular outcomes. A multidisciplinary team with an expert hematologist is essential to properly define the therapeutic strategy, which should balance both the thrombotic and bleeding risks. We report a clinical case that illustrates an alternative revascularization strategy for hemophilic patients presenting with ACS and with a pattern of diffuse coronary atherosclerotic disease (CAD), encompassing drug-coated balloons (DCBs) in combination with spot stenting. The proposed approach might avoid a full-length drug-eluting stent (DES) implantation and also allow a short dual antiplatelet therapy (DAPT) regimen that is desirable in patients at a very high bleeding risk (HBR) like hemophiliacs. Furthermore, we have provided a review of the available literature on this topic and a focus on the main recommendations for managing ACS, in response to the presented clinical case. Finally, this article aims to share information and develop more confidence in the current guidelines on the treatment of hemophiliacs who need myocardial revascularization. FAU - Vadala, Giuseppe AU - Vadala G AUID- ORCID: 0000-0003-0869-4855 AD - Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University Hospital "Paolo Giaccone", University of Palermo, 90133 Palermo, Italy. AD - Cardiology Department, University Hospital "Paolo Giaccone", University of Palermo, 90133 Palermo, Italy. FAU - Mingoia, Giulia AU - Mingoia G AD - Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University Hospital "Paolo Giaccone", University of Palermo, 90133 Palermo, Italy. FAU - Astuti, Giuseppe AU - Astuti G AUID- ORCID: 0009-0004-6084-4755 AD - Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University Hospital "Paolo Giaccone", University of Palermo, 90133 Palermo, Italy. FAU - Madaudo, Cristina AU - Madaudo C AUID- ORCID: 0000-0002-9151-4335 AD - Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University Hospital "Paolo Giaccone", University of Palermo, 90133 Palermo, Italy. AD - Cardiology Department, University Hospital "Paolo Giaccone", University of Palermo, 90133 Palermo, Italy. FAU - Sucato, Vincenzo AU - Sucato V AUID- ORCID: 0000-0001-9514-1575 AD - Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University Hospital "Paolo Giaccone", University of Palermo, 90133 Palermo, Italy. FAU - Adorno, Daniele AU - Adorno D AD - Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University Hospital "Paolo Giaccone", University of Palermo, 90133 Palermo, Italy. FAU - D'Agostino, Alessandro AU - D'Agostino A AUID- ORCID: 0000-0003-3330-7466 AD - Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University Hospital "Paolo Giaccone", University of Palermo, 90133 Palermo, Italy. FAU - Novo, Giuseppina AU - Novo G AUID- ORCID: 0000-0003-2127-7351 AD - Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University Hospital "Paolo Giaccone", University of Palermo, 90133 Palermo, Italy. FAU - Corrado, Egle AU - Corrado E AD - Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University Hospital "Paolo Giaccone", University of Palermo, 90133 Palermo, Italy. FAU - Galassi, Alfredo Ruggero AU - Galassi AR AUID- ORCID: 0000-0002-9366-2251 AD - Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University Hospital "Paolo Giaccone", University of Palermo, 90133 Palermo, Italy. LA - eng PT - Journal Article PT - Review DEP - 20250611 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC12194593 OTO - NOTNLM OT - ACS OT - DAPT OT - HBR OT - PCI OT - antithrombotic therapy OT - factor VIII OT - hemophilia A COIS- The authors declare no conflicts of interest. EDAT- 2025/06/26 06:26 MHDA- 2025/06/26 06:27 PMCR- 2025/06/11 CRDT- 2025/06/26 01:16 PHST- 2025/04/17 00:00 [received] PHST- 2025/06/02 00:00 [revised] PHST- 2025/06/07 00:00 [accepted] PHST- 2025/06/26 06:27 [medline] PHST- 2025/06/26 06:26 [pubmed] PHST- 2025/06/26 01:16 [entrez] PHST- 2025/06/11 00:00 [pmc-release] AID - jcm14124130 [pii] AID - jcm-14-04130 [pii] AID - 10.3390/jcm14124130 [doi] PST - epublish SO - J Clin Med. 2025 Jun 11;14(12):4130. doi: 10.3390/jcm14124130. PMID- 40564779 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250628 IS - 2075-4418 (Print) IS - 2075-4418 (Electronic) IS - 2075-4418 (Linking) VI - 15 IP - 12 DP - 2025 Jun 8 TI - Endometriosis and Cardiovascular Disease: Exploring Pathophysiological Interconnections and Risk Mechanisms. LID - 10.3390/diagnostics15121458 [doi] LID - 1458 AB - Endometriosis, traditionally viewed as a gynecological disorder, is increasingly recognized as a systemic disease with significant cardiovascular implications. Recent studies suggest that women with endometriosis are at higher risk for developing atherosclerosis and other cardiovascular diseases (CVDs), due to chronic systemic inflammation, endothelial dysfunction, oxidative stress, and metabolic disturbances. This review aimed to summarize current evidence on the vascular implications of endometriosis. A literature search was conducted in PubMed and Google Scholar, focusing on studies exploring the relationship between endometriosis and cardiovascular risk. In rare cases, endometriosis can affect extrapelvic locations such as the diaphragm or pericardium, presenting with cyclical chest pain or dyspnea and mimicking cardiopulmonary conditions. These atypical manifestations often delay diagnosis and highlight the need for heightened clinical awareness. Advances in imaging and minimally invasive techniques, including robotic surgery, have improved the detection and management of such presentations. Shared molecular pathways between endometriosis and CVDs, including pro-inflammatory cytokines and metabolic dysregulation, provide a rationale for exploring novel therapeutic approaches. Emerging pharmacologic options such as statins, metformin, or antiplatelet agents may offer dual benefits for both reproductive and cardiovascular health. Given the multifactorial nature of endometriosis, a multidisciplinary approach involving gynecologists, cardiologists, and primary care providers is essential. These findings highlight the need for early cardiovascular risk assessment and tailored preventive strategies in this population. FAU - Szpila, Gabriela AU - Szpila G AUID- ORCID: 0009-0008-5105-1189 AD - 4. Military Clinical Hospital with Polyclinic SP ZOZ in Wroclaw, 53-114 Wroclaw, Poland. FAU - Szczotka, Julia AU - Szczotka J AUID- ORCID: 0009-0009-7619-9259 AD - 4. Military Clinical Hospital with Polyclinic SP ZOZ in Wroclaw, 53-114 Wroclaw, Poland. FAU - Suchodolski, Alexander AU - Suchodolski A AD - Doctoral School, Medical University of Silesia in Katowice, 40-055 Katowice, Poland. AD - Department of Cardiology and Electrotherapy, Silesian Center for Heart Diseases, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, 40-055 Katowice, Poland. FAU - Szulik, Mariola AU - Szulik M AUID- ORCID: 0000-0002-8229-7279 AD - Department of Cardiology and Electrotherapy, Silesian Center for Heart Diseases, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, 40-055 Katowice, Poland. AD - Collegium Medicum-Faculty of Medicine and Faculty of Applied Sciences, Department of Medical and Health Sciences, WSB University, 41-300 Dabrowa Gornicza, Poland. LA - eng PT - Journal Article PT - Review DEP - 20250608 PL - Switzerland TA - Diagnostics (Basel) JT - Diagnostics (Basel, Switzerland) JID - 101658402 PMC - PMC12192228 OTO - NOTNLM OT - atherosclerosis OT - cardiovascular disease OT - endometriosis OT - inflammation COIS- The authors declare no conflicts of interest. EDAT- 2025/06/26 06:27 MHDA- 2025/06/26 06:28 PMCR- 2025/06/08 CRDT- 2025/06/26 01:09 PHST- 2025/04/12 00:00 [received] PHST- 2025/06/04 00:00 [revised] PHST- 2025/06/06 00:00 [accepted] PHST- 2025/06/26 06:28 [medline] PHST- 2025/06/26 06:27 [pubmed] PHST- 2025/06/26 01:09 [entrez] PHST- 2025/06/08 00:00 [pmc-release] AID - diagnostics15121458 [pii] AID - diagnostics-15-01458 [pii] AID - 10.3390/diagnostics15121458 [doi] PST - epublish SO - Diagnostics (Basel). 2025 Jun 8;15(12):1458. doi: 10.3390/diagnostics15121458. PMID- 40558670 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250627 IS - 2308-3425 (Electronic) IS - 2308-3425 (Linking) VI - 12 IP - 6 DP - 2025 Jun 19 TI - Navigating the Complexities of Cancer Treatment-Induced Hypertension. LID - 10.3390/jcdd12060235 [doi] LID - 235 AB - Cancer therapy-induced hypertension (HTN) is an increasingly recognized complication associated with a wide range of anticancer agents, including vascular endothelial growth factor (VEGF) inhibitors, proteasome inhibitors, tyrosine kinase inhibitors, and alkylating agents. The pathogenesis of HTN in this setting is multifactorial, involving mechanisms such as endothelial dysfunction, nitric oxide (NO) suppression, sympathetic nervous system activation, and vascular remodeling. Additional factors, including paraneoplastic syndromes, poorly controlled pain, mood disturbances, and overlapping cardiovascular risk factors like obesity and diabetes, further contribute to the complexity of diagnosis and management. Despite its prevalence and clinical implications, cancer therapy-induced HTN is often addressed using general population guidelines, with limited oncology-specific protocols available. Accurate blood pressure measurement and individualized treatment plans are critical to optimize outcomes and avoid interruptions to cancer therapy. Antihypertensive agents such as angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARB), and calcium channel blockers have shown efficacy in both blood pressure control and, in some cases, oncologic outcomes. A multidisciplinary approach involving oncologists, cardiologists, and primary care providers is essential to navigate the interplay between cancer treatment and cardiovascular health. Ongoing research is needed to develop targeted guidelines and improve the long-term care of cancer patients affected by treatment-induced HTN. FAU - Arriola-Montenegro, Jose AU - Arriola-Montenegro J AD - Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN 55905, USA. FAU - Roth, John AU - Roth J AUID- ORCID: 0009-0000-0954-2947 AD - Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA. FAU - Gonzalez Suarez, Maria L AU - Gonzalez Suarez ML AUID- ORCID: 0000-0002-8930-4611 AD - Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN 55905, USA. LA - eng PT - Journal Article PT - Review DEP - 20250619 PL - Switzerland TA - J Cardiovasc Dev Dis JT - Journal of cardiovascular development and disease JID - 101651414 PMC - PMC12194795 OTO - NOTNLM OT - VEGF OT - cancer OT - hypertension OT - onconephrology COIS- The authors declare no conflicts of interest. EDAT- 2025/06/25 12:28 MHDA- 2025/06/25 12:29 PMCR- 2025/06/19 CRDT- 2025/06/25 09:33 PHST- 2025/04/23 00:00 [received] PHST- 2025/06/11 00:00 [revised] PHST- 2025/06/13 00:00 [accepted] PHST- 2025/06/25 12:29 [medline] PHST- 2025/06/25 12:28 [pubmed] PHST- 2025/06/25 09:33 [entrez] PHST- 2025/06/19 00:00 [pmc-release] AID - jcdd12060235 [pii] AID - jcdd-12-00235 [pii] AID - 10.3390/jcdd12060235 [doi] PST - epublish SO - J Cardiovasc Dev Dis. 2025 Jun 19;12(6):235. doi: 10.3390/jcdd12060235. PMID- 40558654 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250627 IS - 2308-3425 (Electronic) IS - 2308-3425 (Linking) VI - 12 IP - 6 DP - 2025 Jun 11 TI - Cardiovascular Nursing in Rehabilitative Cardiology: A Review. LID - 10.3390/jcdd12060219 [doi] LID - 219 AB - Cardiovascular diseases (CVDs) remain the leading cause of mortality worldwide, necessitating comprehensive management and prevention strategies. Rehabilitative cardiology, also known as cardiac rehabilitation (CR), is a multidisciplinary approach aimed at enhancing recovery, reducing the risk of recurrent cardiac events, and improving patients' quality of life. This review explores the critical role of cardiovascular nursing in CR, highlighting its contributions to patient education, psychosocial support, and care coordination. Through an analysis of current evidence, we outline the core components of CR, including exercise training, risk factor modification, and behavioral interventions. Cardiovascular nurses play a pivotal role in optimizing patient outcomes by conducting assessments, providing tailored education, and addressing psychological challenges such as depression and anxiety, which often accompany CVDs. Despite the well-documented benefits of CR, participation rates remain low due to barriers such as inadequate referral systems, accessibility challenges, and socioeconomic disparities. Emerging solutions, including telemedicine and home-based CR, offer promising alternatives to improve adherence and accessibility. The review underscores the need for expanded nursing roles, interdisciplinary collaboration, and policy advancements to bridge existing gaps in CR utilization. By integrating innovative care models, cardiovascular nursing can further enhance the effectiveness of rehabilitative cardiology and contribute to improved long-term patient outcomes. FAU - Izzo, Carmine AU - Izzo C AUID- ORCID: 0000-0001-8499-5428 AD - Department of Medicine, Surgery and Dentistry, University of Salerno, 84081 Salerno, Italy. FAU - Visco, Valeria AU - Visco V AUID- ORCID: 0000-0002-2197-5355 AD - Department of Medicine, Surgery and Dentistry, University of Salerno, 84081 Salerno, Italy. FAU - Loria, Francesco AU - Loria F AD - Department of Medicine, Surgery and Dentistry, University of Salerno, 84081 Salerno, Italy. FAU - Squillante, Antonio AU - Squillante A AD - Department of Medicine, Surgery and Dentistry, University of Salerno, 84081 Salerno, Italy. FAU - Iannarella, Chiara AU - Iannarella C AD - Department of Medicine, Surgery and Dentistry, University of Salerno, 84081 Salerno, Italy. FAU - Guerriero, Antonio AU - Guerriero A AD - Department of Medicine, Surgery and Dentistry, University of Salerno, 84081 Salerno, Italy. FAU - Cirillo, Alessandra AU - Cirillo A AD - Department of Medicine, Surgery and Dentistry, University of Salerno, 84081 Salerno, Italy. FAU - Barbato, Maria Grazia AU - Barbato MG AD - Department of Medicine, Surgery and Dentistry, University of Salerno, 84081 Salerno, Italy. FAU - Ferrigno, Ornella AU - Ferrigno O AD - Cardiology Unit, University Hospital "San Giovanni di Dio e Ruggi d'Aragona", 84081 Salerno, Italy. FAU - Augusto, Annamaria AU - Augusto A AD - Cardiology Unit, University Hospital "San Giovanni di Dio e Ruggi d'Aragona", 84081 Salerno, Italy. FAU - Rusciano, Maria Rosaria AU - Rusciano MR AD - Department of Medicine, Surgery and Dentistry, University of Salerno, 84081 Salerno, Italy. FAU - Virtuoso, Nicola AU - Virtuoso N AD - Cardiology Unit, University Hospital "San Giovanni di Dio e Ruggi d'Aragona", 84081 Salerno, Italy. FAU - Venturini, Eleonora AU - Venturini E AD - Vascular Physiopathology Unit, IRCCS Neuromed Mediterranean Neurological Institute, 86077 Pozzilli, Italy. FAU - Di Pietro, Paola AU - Di Pietro P AUID- ORCID: 0000-0003-1327-1961 AD - Department of Medicine, Surgery and Dentistry, University of Salerno, 84081 Salerno, Italy. FAU - Carrizzo, Albino AU - Carrizzo A AUID- ORCID: 0000-0003-2689-0008 AD - Department of Medicine, Surgery and Dentistry, University of Salerno, 84081 Salerno, Italy. AD - Vascular Physiopathology Unit, IRCCS Neuromed Mediterranean Neurological Institute, 86077 Pozzilli, Italy. FAU - Vecchione, Carmine AU - Vecchione C AD - Department of Medicine, Surgery and Dentistry, University of Salerno, 84081 Salerno, Italy. AD - Vascular Physiopathology Unit, IRCCS Neuromed Mediterranean Neurological Institute, 86077 Pozzilli, Italy. FAU - Ciccarelli, Michele AU - Ciccarelli M AUID- ORCID: 0000-0003-2379-1960 AD - Department of Medicine, Surgery and Dentistry, University of Salerno, 84081 Salerno, Italy. LA - eng PT - Journal Article PT - Review DEP - 20250611 PL - Switzerland TA - J Cardiovasc Dev Dis JT - Journal of cardiovascular development and disease JID - 101651414 PMC - PMC12193484 OTO - NOTNLM OT - cardiac rehabilitation OT - cardiovascular diseases OT - cardiovascular nursing OT - multidisciplinary care OT - patient education OT - psychosocial support OT - risk factor modification OT - secondary prevention OT - telemedicine COIS- The authors declare no conflicts of interest. EDAT- 2025/06/25 12:28 MHDA- 2025/06/25 12:29 PMCR- 2025/06/11 CRDT- 2025/06/25 09:33 PHST- 2025/03/23 00:00 [received] PHST- 2025/05/29 00:00 [revised] PHST- 2025/06/10 00:00 [accepted] PHST- 2025/06/25 12:29 [medline] PHST- 2025/06/25 12:28 [pubmed] PHST- 2025/06/25 09:33 [entrez] PHST- 2025/06/11 00:00 [pmc-release] AID - jcdd12060219 [pii] AID - jcdd-12-00219 [pii] AID - 10.3390/jcdd12060219 [doi] PST - epublish SO - J Cardiovasc Dev Dis. 2025 Jun 11;12(6):219. doi: 10.3390/jcdd12060219. PMID- 40554782 OWN - NLM STAT- MEDLINE DCOM- 20250624 LR - 20260925 IS - 1929-0748 (Electronic) IS - 1929-0748 (Linking) VI - 14 DP - 2025 Jun 24 TI - The First 6 Years' Experiences of a National Centralized Offspring Surveillance Setting for Dutch Children Prenatally Exposed to Maternal Cancer to Inform Future International Practice: Protocol for a Demographic Review of Referred Families and Key Lessons Learned. PG - e71612 LID - 10.2196/71612 [doi] LID - e71612 AB - BACKGROUND: Cancer during pregnancy is a rare and significant life-changing event affecting approximately 1 in 1000-2000 pregnancies. With increasing maternal age and broader application of prenatal screening programs such as the Dutch Non-Invasive Prenatal Testing, incidental detection of maternal cancer is becoming more frequent. Advancements in safe treatment options during pregnancy, supported by the International Network on Cancer Infertility and Pregnancy (INCIP), have led to fewer pregnancy terminations. Consequently, more children are exposed to chemotherapy and other cancer treatments in utero. While short-term safety has been demonstrated for many oncological agents, long-term side effects including physical, neuromotor, neurocognitive, and psychosocial impacts on offspring and their families after delivery are still being assessed. Standard settings for surveillance and care of offspring and their families have, however, never been described. OBJECTIVE: Given the importance of expertise in assessing the long-term outcomes of children, the Netherlands established the national centralized Cancer in Pregnancy (CIP) offspring outpatient clinic in 2018, which functions as a standard-of-care surveillance clinic and contributes data to the INCIP registry. Here we provide a demographic overview of referred families and to share (logistic) experiences with the national, centralized, multidisciplinary, and standardized long-term surveillance program for all Dutch children with in utero exposure to maternal cancer and its treatment. METHODS: The CIP offspring outpatient clinic is located at the Princess Maxima Center for Pediatric Oncology and provides surveillance from infancy until 18 years of age. The, relatively small dedicated team, comprising pediatric oncologists, physiotherapists, and a psychological expert, offers a 1-day, multidisciplinary assessment, including physical examinations, neuromotor tests, cardiac monitoring (for anthracycline exposure), renal and auditory screening (for platinum agents), neurocognitive testing, and psychosocial evaluation. Surveillance is aligned with international INCIP guidelines. RESULTS: From May 2018 to 2024, a total of 226 children (from 221 mothers) have been referred to the CIP offspring outpatient clinic, with 465 follow-up visits completed. The most common maternal cancer types were breast, gynecological, and hematological malignancies. Most women (58%) received chemotherapy during pregnancy; 11% of them had surgery only, 3% underwent radiotherapy, 3% underwent immunotherapy, 16% received a combination of treatment modalities, and 8% did not undergo treatment during pregnancy. Anthracyclines were the most commonly used agents. Median gestational age at delivery was 37.3 weeks. Fourteen percent of the mothers died shortly after delivery, underscoring the emotional and logistical challenges for families. CONCLUSIONS: The CIP offspring outpatient clinic provides a unique, structured approach to long-term surveillance for in utero-exposed children, which enables early detection of potential late effects and provides comprehensive family support. By sharing knowledge and experiences from the unique setting of this national centralized CIP offspring outpatient clinic, this initiative may inspire other countries in developing similar translational facilities to support affected families and improve care worldwide. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/71612. CI - (c)Evangeline A Huis in 't Veld, Anouk M Kruse, Emma J Verwaaijen, Sterre C Huizer, Elisabeth M van Dijk-Lokkart, Christianne Lok, Maaike Kuethe, Frederic Amant, Mathilde M A van Gerwen, Martine van Grotel, Marry M van den Heuvel-Eibrink. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 24.06.2025. FAU - Huis In 't Veld, Evangeline A AU - Huis In 't Veld EA AUID- ORCID: 0000-0002-6891-2255 AD - Center for Gynecological Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. AD - Princess Maxima Center, Utrecht, The Netherlands. AD - Research Program, Cancer Center Amsterdam, Amsterdam, The Netherlands. FAU - Kruse, Anouk M AU - Kruse AM AUID- ORCID: 0009-0001-3980-8619 AD - Princess Maxima Center, Utrecht, The Netherlands. FAU - Verwaaijen, Emma J AU - Verwaaijen EJ AUID- ORCID: 0000-0003-1350-3363 AD - Princess Maxima Center, Utrecht, The Netherlands. FAU - Huizer, Sterre C AU - Huizer SC AUID- ORCID: 0009-0003-6695-8334 AD - Center for Gynecological Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. AD - Princess Maxima Center, Utrecht, The Netherlands. FAU - van Dijk-Lokkart, Elisabeth M AU - van Dijk-Lokkart EM AUID- ORCID: 0000-0003-3441-5135 AD - Department of Child & Adolescent Psychiatry and Psychosocial Care, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. AD - Child Development, Amsterdam Reproduction and Development, Amsterdam, The Netherlands. FAU - Lok, Christianne AU - Lok C AUID- ORCID: 0000-0001-8693-7299 AD - Center for Gynecological Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. FAU - Kuethe, Maaike AU - Kuethe M AUID- ORCID: 0009-0004-3966-1073 AD - Stichting Ster(k), Den Haag, The Netherlands. FAU - Amant, Frederic AU - Amant F AUID- ORCID: 0000-0002-5452-4905 AD - Center for Gynecological Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. AD - Child Development, Amsterdam Reproduction and Development, Amsterdam, The Netherlands. AD - Department of Oncology, Unit of Gynaecological Oncology, KU Leuven, Leuven, Belgium. AD - Department of Obstetrics and Gynaecology, Division of Gynaecological Oncology, UZ Leuven, Leuven, Belgium. FAU - van Gerwen, Mathilde M A AU - van Gerwen MMA AUID- ORCID: 0000-0001-5564-8873 AD - Center for Gynecological Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. AD - Princess Maxima Center, Utrecht, The Netherlands. AD - Department of Child & Adolescent Psychiatry and Psychosocial Care, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. FAU - van Grotel, Martine AU - van Grotel M AUID- ORCID: 0000-0002-8849-8573 AD - Princess Maxima Center, Utrecht, The Netherlands. FAU - van den Heuvel-Eibrink, Marry M AU - van den Heuvel-Eibrink MM AUID- ORCID: 0000-0002-7760-879X AD - Princess Maxima Center, Utrecht, The Netherlands. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20250624 PL - Canada TA - JMIR Res Protoc JT - JMIR research protocols JID - 101599504 SB - IM MH - Humans MH - Female MH - Netherlands/epidemiology MH - Pregnancy MH - Child MH - *Pregnancy Complications, Neoplastic/therapy/epidemiology MH - Child, Preschool MH - *Prenatal Exposure Delayed Effects/epidemiology/diagnosis MH - Infant MH - Male MH - *Neoplasms/therapy MH - Adolescent MH - Infant, Newborn MH - Adult PMC - PMC12238779 OTO - NOTNLM OT - cancer OT - exposure in utero, toxic effects OT - offspring OT - outpatient clinic OT - surveillance OT - treatment COIS- Conflicts of Interest: None declared. EDAT- 2025/06/24 18:30 MHDA- 2025/06/24 18:31 PMCR- 2025/06/24 CRDT- 2025/06/24 16:53 PHST- 2025/01/27 00:00 [received] PHST- 2025/05/29 00:00 [accepted] PHST- 2025/05/13 00:00 [revised] PHST- 2025/06/24 18:31 [medline] PHST- 2025/06/24 18:30 [pubmed] PHST- 2025/06/24 16:53 [entrez] PHST- 2025/06/24 00:00 [pmc-release] AID - v14i1e71612 [pii] AID - 10.2196/71612 [doi] PST - epublish SO - JMIR Res Protoc. 2025 Jun 24;14:e71612. doi: 10.2196/71612. PMID- 40552838 OWN - NLM STAT- MEDLINE DCOM- 20250714 LR - 20250819 IS - 1531-7072 (Electronic) IS - 1070-5295 (Linking) VI - 31 IP - 4 DP - 2025 Aug 1 TI - Diagnosis and management of cardiogenic shock. PG - 428-436 LID - 10.1097/MCC.0000000000001288 [doi] AB - PURPOSE OF REVIEW: Cardiogenic shock continues to portend a poor prognosis. Despite ongoing efforts over the past few decades to help improve mortality, little progress has been made in improving the short-term and long-term outcomes of patients presenting with cardiogenic shock. This is especially true of those presenting with acute myocardial infarct related cardiogenic shock. RECENT FINDINGS: Cardiogenic shock should be understood as a continuum. Patients can move from one stage of shock to another and hence should be assessed on an ongoing basis. Cardiogenic shock should be assessed based on the severity, the phenotypic presentation and the concomitant processes that influence prognosis. Right ventricular cardiogenic shock and mixed cardiogenic shock have been recognized as predictors of worse overall prognosis. Incorporating detailed classification of cause of cardiogenic shock into routine clinical practice and will help with standardizing nomenclature and aid in understanding of the disease process and assist in refining interventions. SUMMARY: Early identification, risk stratification and understanding the nuances of presentation may help with selecting appropriate treatment strategies. Aggressive management should include multidisciplinary team-based approaches to help escalate care as needed. CI - Copyright (c) 2025 Wolters Kluwer Health, Inc. All rights reserved. FAU - Bellumkonda, Lavanya AU - Bellumkonda L AD - Section of Cardiovascular Medicine, Department of Medicine, Yale School of Medicine New Haven, Connecticut, USA. LA - eng PT - Journal Article PT - Review DEP - 20250623 PL - United States TA - Curr Opin Crit Care JT - Current opinion in critical care JID - 9504454 SB - IM MH - Humans MH - *Shock, Cardiogenic/diagnosis/therapy/etiology/physiopathology MH - Prognosis MH - *Myocardial Infarction/complications MH - Risk Assessment MH - Severity of Illness Index OTO - NOTNLM OT - cardiogenic shock OT - diagnosis OT - management EDAT- 2025/06/24 13:08 MHDA- 2025/07/14 12:28 CRDT- 2025/06/24 09:12 PHST- 2025/07/14 12:28 [medline] PHST- 2025/06/24 13:08 [pubmed] PHST- 2025/06/24 09:12 [entrez] AID - 00075198-202508000-00011 [pii] AID - 10.1097/MCC.0000000000001288 [doi] PST - ppublish SO - Curr Opin Crit Care. 2025 Aug 1;31(4):428-436. doi: 10.1097/MCC.0000000000001288. Epub 2025 Jun 23. PMID- 40549031 OWN - NLM STAT- MEDLINE DCOM- 20251021 LR - 20251024 IS - 1861-0692 (Electronic) IS - 1861-0684 (Print) IS - 1861-0684 (Linking) VI - 114 IP - 11 DP - 2025 Nov TI - Fighting time: the critical importance of pre-TAVR mortality risk prediction. PG - 1565-1573 LID - 10.1007/s00392-025-02698-1 [doi] AB - BACKGROUND: Symptomatic severe aortic valve stenosis (AS) is a life-threatening condition requiring prompt medical attention. While transcatheter aortic valve replacement (TAVR) is an effective treatment, current scheduling practices often do not account for individual patient risk profiles due to limited data on mortality rates during the waiting period and a lack of viable risk assessment. Consequently, non-prioritized wait times may be unacceptably long for high-risk patient populations. OBJECTIVE: This study aimed to evaluate the mortality rate of patients with symptomatic severe AS awaiting TAVR and identify pragmatic clinical risk predictors during this period. METHODS: Between January 2019 and December 2023, 2,454 patients with symptomatic severe AS, were scheduled for TAVR after an interdisciplinary Heart Team discussion at the Heart Center Bonn. Mortality during the waiting period was assessed, and the characteristics of survivors (patients who underwent TAVR) were compared to non-survivors (patients who died before the procedure). RESULTS: The median waiting time for TAVR was 41 days. A total of 105 (4.3%) patients died during the waiting period, with a median time to death of 29 days. By comparison, 30 day post-TAVR mortality, including the intervention, was 1.7%. Multivariate regression analysis identified independent predictors of pre-TAVR mortality including reduced left ventricular ejection fraction, decreased estimated glomerular filtration rate, mitral regurgitation, tricuspid regurgitation, and advanced heart failure symptoms. An IMPACT score, incorporating these parameters, strongly predicted outcome with a hazard ratio for mortality of 2.1 greatly outperforming both EuroSCORE II and STS-PROM. The IMPACT score of >/= 5 identified high-risk patients with a pre-TAVR mortality rate of 12.6%. CONCLUSION: The mortality rate for patients with symptomatic severe AS awaiting TAVR is unacceptably high. Utilizing the IMPACT score could enable precise risk stratification, identifying patients who require urgent or prioritized intervention to improve outcomes. CI - (c) 2025. The Author(s). FAU - Shamekhi, Jasmin AU - Shamekhi J AUID- ORCID: 0000-0002-5724-9814 AD - Heart Center Bonn, Department of Medicine II, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany. jasmin.shamekhi@ukbonn.de. FAU - Ebert, Marius AU - Ebert M AD - Heart Center Bonn, Department of Medicine II, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany. FAU - Lorek, Angelina AU - Lorek A AD - Heart Center Bonn, Department of Medicine II, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany. FAU - Eckardt, Irina AU - Eckardt I AD - Heart Center Bonn, Department of Medicine II, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany. FAU - Al-Kassou, Baravan AU - Al-Kassou B AD - Heart Center Bonn, Department of Medicine II, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany. FAU - Basha, Mustafa Mousa AU - Basha MM AD - Heart Center Bonn, Department of Medicine II, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany. FAU - Weber, Marcel AU - Weber M AD - Heart Center Bonn, Department of Medicine II, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany. FAU - Silaschi, Miriam AU - Silaschi M AD - Heart Center Bonn, Cardiac Surgery, University Hospital Bonn, Bonn, Germany. FAU - Bakhtiary, Farhad AU - Bakhtiary F AD - Heart Center Bonn, Cardiac Surgery, University Hospital Bonn, Bonn, Germany. FAU - Nickenig, Georg AU - Nickenig G AD - Heart Center Bonn, Department of Medicine II, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany. FAU - Zimmer, Sebastian AU - Zimmer S AD - Heart Center Bonn, Department of Medicine II, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany. LA - eng PT - Journal Article DEP - 20250623 PL - Germany TA - Clin Res Cardiol JT - Clinical research in cardiology : official journal of the German Cardiac Society JID - 101264123 SB - IM MH - Humans MH - Male MH - Female MH - *Transcatheter Aortic Valve Replacement/mortality MH - *Aortic Valve Stenosis/surgery/mortality/diagnosis MH - Risk Assessment/methods MH - Aged, 80 and over MH - Aged MH - Severity of Illness Index MH - Risk Factors MH - Time Factors MH - *Waiting Lists/mortality MH - Retrospective Studies MH - Survival Rate/trends MH - *Time-to-Treatment MH - Germany/epidemiology PMC - PMC12540598 OTO - NOTNLM OT - Aortic valve stenosis OT - IMPACT score OT - Mortality rate OT - Risk stratification OT - TAVR OT - Transcatheter aortic valve replacement OT - Waiting time for TAVR COIS- Declarations. Conflict of interest: Drs. G. Nickenig and S. Zimmer have received speaker honoraria from Abbott, Abiomed, AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi, Novartis, Pfizer, Medtronic, Boston Scientific, and Edwards Lifesciences. Dr. M. Silaschi received research grants from Medtronic, LSI solutions and Artivion. The other authors report no conflicts of interest. Informed consent: Patients with severe aortic stenosis awaiting TAVR face high mortality, highlighting the need for timely intervention. The newly established IMPACT score predicts adverse outcomes, enabling risk stratification and prioritization of high-risk individuals. This tool aids in clinical decision-making, optimizing perioperative care and guiding resource allocation. Its implementation may reduce wait list mortality by improving triage and early intervention strategies. Further validation and research are needed to refine its predictive accuracy. EDAT- 2025/06/24 10:52 MHDA- 2025/10/21 12:35 PMCR- 2025/06/23 CRDT- 2025/06/23 11:04 PHST- 2025/03/10 00:00 [received] PHST- 2025/06/08 00:00 [accepted] PHST- 2025/10/21 12:35 [medline] PHST- 2025/06/24 10:52 [pubmed] PHST- 2025/06/23 11:04 [entrez] PHST- 2025/06/23 00:00 [pmc-release] AID - 10.1007/s00392-025-02698-1 [pii] AID - 2698 [pii] AID - 10.1007/s00392-025-02698-1 [doi] PST - ppublish SO - Clin Res Cardiol. 2025 Nov;114(11):1565-1573. doi: 10.1007/s00392-025-02698-1. Epub 2025 Jun 23. PMID- 40548370 OWN - NLM STAT- MEDLINE DCOM- 20260409 LR - 20260915 IS - 1559-6834 (Electronic) IS - 0899-823X (Linking) VI - 46 IP - 8 DP - 2025 Aug TI - Candida auris outbreak in a cardiothoracic transplant intensive care unit: implications for infection prevention practices and keeping pace with an evolving landscape. PG - 789-796 LID - 10.1017/ice.2025.10217 [doi] AB - OBJECTIVE: To describe the mitigation strategies for a Candida auris outbreak in a cardiothoracic transplant intensive care unit (CTICU) and its implications for infection prevention practices. DESIGN: Retrospective cohort study from July 2023 to February 2024. SETTING: A large academic medical center. METHODS: A multidisciplinary team convened to conduct the outbreak investigation and develop mitigation strategies in the CTICU. RESULTS: From July 2023 to February 2024, 34 possible hospital-onset cases of C. auris were identified in our CTICU. Whole-genome sequencing and phylogenetic analysis based on pairwise single nucleotide polymorphism (WG-SNP) distance revealed two distinct outbreak clusters. Of the 34 patients, 11 (32.3%) were solid organ transplant recipients and 12 (35.3%) had a mechanical circulatory support device. Of the cohort, only 11/34 (32.3%) had prior exposure to high-risk healthcare facilities within six months prior to admission, as follows: acute inpatient rehabilitation facilities (AIRs) (n = 5, 14.7%), skilled nursing facilities (SNFs) (n = 3, 8.8%), and long-term acute care hospitals (LTACHs) (n = 3, 8.8%). The cohort had a median of 22.0 antibiotic-days prior to their positive results. Five (14.7%) patients had C. auris candidemia, three of whom expired likely due to infection. Infection Prevention (IP) interventions addressed several modes of transmission, including healthcare personnel hands, shared patient equipment, and the environment. CONCLUSION: Our experience suggests that the epidemiology of C. auris may be changing, pointing towards a rising prevalence in acute care settings. IP interventions targeting hand hygiene behavior and promoting centralizing cleaning and disinfection of shared patient equipment may have contributed to outbreak resolution. FAU - Rathod, Shardul N AU - Rathod SN AUID- ORCID: 0000-0002-9768-4095 AD - Department of Healthcare Epidemiology and Infection Prevention, Northwestern Memorial Hospital, Chicago, IL, USA. FAU - Barajas, Grace AU - Barajas G AD - Department of Healthcare Epidemiology and Infection Prevention, Northwestern Memorial Hospital, Chicago, IL, USA. FAU - Mitchell, Brooks I AU - Mitchell BI AD - Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. AD - Clinical Microbiology Laboratory, Northwestern Memorial Hospital, Chicago, IL, USA. FAU - Malczynski, Michael AU - Malczynski M AD - Clinical Microbiology Laboratory, Northwestern Memorial Hospital, Chicago, IL, USA. FAU - Moore, W Justin AU - Moore WJ AUID- ORCID: 0000-0001-5385-354X AD - Department of Pharmacy, Northwestern Medicine, Chicago, IL, USA. FAU - Weslander, Erin AU - Weslander E AD - Department of Pharmacy, Northwestern Medicine, Chicago, IL, USA. FAU - Bulger, Christine AU - Bulger C AD - Department of Environmental Services and Patient Escort, Northwestern Memorial Hospital, Chicago, IL, USA. FAU - Stone, Andrea AU - Stone A AD - Inpatient Cardiology Nursing Administration, Northwestern Memorial Hospital, Chicago, IL, USA. FAU - Al-Qamari, Abbas AU - Al-Qamari A AD - Division of Cardiac Surgery, Department of Surgery, Bluhm Cardiovascular Institute, Northwestern University Feinberg School of Medicine and Northwestern Medicine, Chicago, IL, USA. AD - Department of Anesthesiology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. FAU - Bertram, Christie M AU - Bertram CM AD - Department of Pharmacy, Northwestern Medicine, Chicago, IL, USA. FAU - Sutton, Sarah H AU - Sutton SH AD - Department of Healthcare Epidemiology and Infection Prevention, Northwestern Memorial Hospital, Chicago, IL, USA. AD - Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. FAU - Stosor, Valentina AU - Stosor V AD - Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. AD - Division of Organ Transplantation, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. FAU - Qi, Chao AU - Qi C AD - Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. AD - Clinical Microbiology Laboratory, Northwestern Memorial Hospital, Chicago, IL, USA. FAU - Zembower, Teresa R AU - Zembower TR AD - Department of Healthcare Epidemiology and Infection Prevention, Northwestern Memorial Hospital, Chicago, IL, USA. AD - Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. AD - Clinical Microbiology Laboratory, Northwestern Memorial Hospital, Chicago, IL, USA. AD - Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. FAU - Bolon, Maureen K AU - Bolon MK AD - Department of Healthcare Epidemiology and Infection Prevention, Northwestern Memorial Hospital, Chicago, IL, USA. AD - Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. LA - eng PT - Journal Article DEP - 20250623 PL - United States TA - Infect Control Hosp Epidemiol JT - Infection control and hospital epidemiology JID - 8804099 SB - IM MH - Humans MH - *Disease Outbreaks/prevention & control MH - Retrospective Studies MH - Male MH - Middle Aged MH - Female MH - *Cross Infection/epidemiology/prevention & control/microbiology MH - *Candida auris/isolation & purification/genetics MH - *Candidiasis/epidemiology/prevention & control MH - Intensive Care Units MH - *Infection Control/methods MH - Aged MH - Academic Medical Centers MH - Adult MH - Heart Transplantation EDAT- 2025/06/24 10:48 MHDA- 2026/04/09 12:46 CRDT- 2025/06/23 06:24 PHST- 2026/04/09 12:46 [medline] PHST- 2025/06/24 10:48 [pubmed] PHST- 2025/06/23 06:24 [entrez] AID - S0899823X25102171 [pii] AID - 10.1017/ice.2025.10217 [doi] PST - ppublish SO - Infect Control Hosp Epidemiol. 2025 Aug;46(8):789-796. doi: 10.1017/ice.2025.10217. Epub 2025 Jun 23. PMID- 40546647 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250624 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 17 IP - 5 DP - 2025 May TI - The Role of N-terminal Pro-B-Type Natriuretic Peptide, Troponins, and D-dimer in Acute Cardio-Respiratory Syndromes: A Multi-specialty Systematic Review. PG - e84460 LID - 10.7759/cureus.84460 [doi] LID - e84460 AB - This systematic review evaluates the diagnostic and prognostic utility of N-terminal pro-B-type natriuretic peptide (NT-proBNP), cardiac troponins, and D-dimer in acute cardio-respiratory syndromes, including heart failure (HF), acute coronary syndrome (ACS), pulmonary embolism (PE), acute respiratory distress syndrome (ARDS), and coronavirus disease 2019 (COVID-19)-related complications. These biomarkers play critical roles in assessing myocardial stress, injury, and thrombosis risk, offering a rapid and cost-effective alternative to traditional diagnostic tools. A comprehensive literature search from 2015 to 2024 identified 14 high-quality studies, demonstrating NT-proBNP's strong correlation with HF severity and mortality risk in severe COVID-19, while cardiac troponins were associated with myocardial injury in ARDS and ACS. D-dimer emerged as a predictor of thrombotic complications and poor outcomes in interstitial lung disease (ILD) and PE. The combined use of these biomarkers significantly improved risk stratification, enabling early intervention and reducing unnecessary imaging and invasive testing. A multi-marker approach provided superior predictive accuracy for mortality and recurrence risk in PE compared to single biomarker assessments. Despite some methodological limitations, including heterogeneity in biomarker thresholds, the findings support the integration of these markers into routine clinical practice to enhance early diagnosis and patient management. Future research should focus on standardizing biomarker cut-off values, conducting large-scale multi-center trials, and incorporating biomarker data into artificial intelligence (AI)-driven decision systems. This study highlights the potential of biomarker-driven risk assessment in cardio-respiratory medicine, paving the way for more precise, early, and effective intervention strategies to optimize patient outcomes and advance precision medicine in critical care settings. CI - Copyright (c) 2025, Ibrahim et al. FAU - Ibrahim, Muhammad AU - Ibrahim M AD - Acute Internal Medicine (AIM), University Hospitals Birmingham NHS Foundation Trust, Birmingham, GBR. FAU - Ahmad, Jawad AU - Ahmad J AD - Neurology, Lady Reading Hospital Peshawar, Peshawar, PAK. FAU - Abbas, Muhammad AU - Abbas M AD - Respiratory Medicine, Hayatabad Medical Complex Peshawar, Peshawar, PAK. FAU - Zainullah AU - Zainullah AD - Psychiatry, Bolan Medical Complex Hospital Quetta, Quetta, PAK. FAU - Umar, Zeeshan AU - Umar Z AD - Emergency Medicine, Pak Emirates Military Hospital (PEMH), Rawalpindi, PAK. FAU - Nasir, Momal AU - Nasir M AD - General Practice, Ziauddin University, Karachi, PAK. FAU - Zain, Kabsha AU - Zain K AD - Internal Medicine, Khyber Girls Medical College, Hayatabad Medical Complex Peshawar, Peshawar, PAK. FAU - Ahmad, Jamil AU - Ahmad J AD - Internal Medicine, Lady Reading Hospital Peshawar, Peshawar, PAK. FAU - Arshad, Seemab AU - Arshad S AD - Medicine, Independent Medical College, Faisalabad, PAK. FAU - Bashir, Atif AU - Bashir A AD - Internal Medicine, Lady Reading Hospital Peshawar, Peshawar, PAK. FAU - Ullah, Sami AU - Ullah S AD - Internal Medicine, Lady Reading Hospital Peshawar, Peshawar, PAK. FAU - Ahmad, Zubair AU - Ahmad Z AD - Internal Medicine, Hayatabad Medical Complex Peshawar, Peshawar, PAK. FAU - Safdar, Sundas AU - Safdar S AD - Diagnostic Radiology, Lady Reading Hospital Peshawar, Peshawar, PAK. LA - eng PT - Journal Article PT - Review DEP - 20250520 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC12180772 OTO - NOTNLM OT - biomarkers OT - cardio-respiratory syndromes OT - d-dimer OT - nt-probnp OT - troponins COIS- Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. EDAT- 2025/06/23 08:42 MHDA- 2025/06/23 08:43 PMCR- 2025/05/20 CRDT- 2025/06/23 05:59 PHST- 2025/05/20 00:00 [accepted] PHST- 2025/06/23 08:43 [medline] PHST- 2025/06/23 08:42 [pubmed] PHST- 2025/06/23 05:59 [entrez] PHST- 2025/05/20 00:00 [pmc-release] AID - 10.7759/cureus.84460 [doi] PST - epublish SO - Cureus. 2025 May 20;17(5):e84460. doi: 10.7759/cureus.84460. eCollection 2025 May. PMID- 40537224 OWN - NLM STAT- MEDLINE DCOM- 20250624 LR - 20250703 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 15 IP - 6 DP - 2025 Jun 19 TI - Clinical characteristics, treatment patterns and healthcare resource utilisation for portopulmonary hypertension patients in the USA: a real-world study. PG - e089223 LID - 10.1136/bmjopen-2024-089223 [doi] LID - e089223 AB - OBJECTIVES: To investigate demographic, clinical characteristics, treatment patterns and healthcare resource utilisation (HCRU) among patients with portopulmonary hypertension (PoPH). DESIGN: Retrospective analysis of a real-world cross-sectional survey, the pulmonary arterial hypertension (PAH) Disease Specific Programme. SETTING: Secondary care settings in the USA. PARTICIPANTS: Pulmonologists (n=22), cardiologists (n=17) and internists (n=7) who saw >/=2 patients with PAH/month provided data on 90 PoPH patients. Mean age of patients was 56.8 years, 51.1% were male, 76.7% were white/Caucasian. PRIMARY AND SECONDARY OUTCOME MEASURES: Demographic characteristics, initial presentation/diagnosis, disease trajectory, symptoms, comorbidities, treatment patterns and HCRU. RESULTS: The most common diagnostic tests were echocardiogram (62.2%), right heart catheterisation (56.7%) and electrocardiogram (48.9%). Dyspnea on exertion (64.4%), dyspnea following exertion (51.1%) and fatigue (48.9%) were the most common symptoms prior to PAH diagnosis as well as the most bothersome. Overall, 13.3% patients had mild disease before treatment vs 42.2% at time of survey. Most (60.0%) had stable disease (21.1% were improving and 18.8% were deteriorating at the time of the survey). Most common recent symptoms were dyspnea on exertion (51.1%), fatigue (37.8%) and dyspnea following exertion (32.2%). Patients had a mean of 1.8 comorbidities. In total, 80.0% of PoPH patients were receiving PAH-specific treatment; 41.7%, 22.2% and 12.5% received monotherapy, dual therapy and triple therapy, respectively. Patients had seen their physician 4.1 times in the past 12 months (3.5 visits specifically for PAH), while 31.1% had been hospitalised for PAH. Most (70.0%) patients were managed in a multidisciplinary team, and 8.9% of patients relied on a caregiver. CONCLUSIONS: This study highlights the high symptomatic burden coupled with mostly moderate-to-severe disease status and a high hospitalisation rate despite the majority of PoPH patients being on therapy. Therefore, new treatment options in PoPH are in great need. CI - (c) Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. FAU - DuBrock, Hilary AU - DuBrock H AD - Mayo Clinic, Rochester, Minnesota, USA. FAU - Small, Mark AU - Small M AD - Adelphi Real World, Bollington, UK. FAU - Scott, Megan AU - Scott M AD - Adelphi Real World, Bollington, UK megan.scott@adelphigroup.com. FAU - Harley, Julia AU - Harley J AUID- ORCID: 0000-0002-0497-6719 AD - Adelphi Real World, Bollington, UK. FAU - Agron, Peter AU - Agron P AD - Janssen Pharmaceutical Companies of Johnson and Johnson, Titusville, New Jersey, USA. FAU - Tsang, Yuen AU - Tsang Y AD - Janssen Pharmaceutical Companies of Johnson and Johnson, Titusville, New Jersey, USA. FAU - Panjabi, Sumeet AU - Panjabi S AD - Janssen Pharmaceutical Companies of Johnson and Johnson, Titusville, New Jersey, USA. LA - eng PT - Journal Article DEP - 20250619 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 SB - IM MH - Humans MH - Male MH - Female MH - Middle Aged MH - Retrospective Studies MH - Cross-Sectional Studies MH - United States/epidemiology MH - *Hypertension, Pulmonary/therapy/diagnosis MH - *Patient Acceptance of Health Care/statistics & numerical data MH - Aged MH - Adult MH - *Health Resources/statistics & numerical data MH - *Hypertension, Portal/therapy/diagnosis MH - *Practice Patterns, Physicians'/statistics & numerical data MH - Echocardiography MH - Dyspnea/etiology PMC - PMC12182033 OTO - NOTNLM OT - Patient Care Management OT - Patients OT - Pulmonary Disease COIS- Competing interests: HD received consulting fees from Janssen; MSm, MSc and JH are employees of Adelphi Real World, an agency that received funding from Janssen to undertake this study; PA, YT and SP are former employees of Janssen. EDAT- 2025/06/20 00:25 MHDA- 2025/06/24 11:10 PMCR- 2025/06/19 CRDT- 2025/06/19 21:03 PHST- 2025/06/24 11:10 [medline] PHST- 2025/06/20 00:25 [pubmed] PHST- 2025/06/19 21:03 [entrez] PHST- 2025/06/19 00:00 [pmc-release] AID - bmjopen-2024-089223 [pii] AID - 10.1136/bmjopen-2024-089223 [doi] PST - epublish SO - BMJ Open. 2025 Jun 19;15(6):e089223. doi: 10.1136/bmjopen-2024-089223. PMID- 40533731 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260626 LR - 20260626 IS - 1865-1372 (Print) IS - 1865-1380 (Electronic) IS - 1865-1372 (Linking) VI - 18 IP - 1 DP - 2025 Jun 18 TI - Ventricular double rupture following myocardial infarction: a case report and literature review. PG - 105 LID - 10.1186/s12245-025-00907-2 [doi] LID - 105 AB - BACKGROUND: The frequency of mechanical complications related to transmural myocardial infarction (MI) has decreased due to the widespread implementation of reperfusion therapies. However, mortality related to these complications remains high, requiring prompt intervention by a Heart Team. Ventricular double rupture (VDR) is a particularly rare and fatal MI complication. CASE PRESENTATION: A 58-year-old female patient presenting with 3 days of chest pain was diagnosed with ST-elevation MI. She underwent primary percutaneous coronary intervention of the left anterior descending artery. Transthoracic echocardiogram revealed an apical ventricular septum rupture and a mild pericardial effusion suggestive of free wall rupture. Emergent surgical repair included ventricular septal defect closure with a heterologous pericardial patch and repair of the free wall rupture with Dacron patch placement. Perioperative intraaortic balloon pump support was utilized. The patient had a favorable clinical course and was asymptomatic at her cardiology follow-up. CONCLUSIONS: VDR is the combination of two types of mechanical complications of MI. High clinical suspicion is necessary in hemodynamically unstable patients and those with risk factors for myocardial rupture, warranting echocardiographic evaluation for its diagnosis and characterization. Treatment of VDR is primarily surgical and may involve mechanical circulatory support (MCS). Despite advances in reperfusion therapies and surgical techniques, the prognosis of VDR remains poor. Our patient had a favorable outcome highlighting the importance of a multidisciplinary approach. FAU - Calderon-Miranda, Camilo Andres AU - Calderon-Miranda CA AD - Departamento de Cardiologia, Fundacion Valle del Lili, Carrera 98 No. 18 - 49, Cali, 760032, Colombia. camilo.calderon@fvl.org.co. AD - Facultad de Ciencias de la Salud, Universidad Icesi, Calle 18 No. 122-135, Cali, 760031, Colombia. camilo.calderon@fvl.org.co. FAU - Vesga-Reyes, Carlos Enrique AU - Vesga-Reyes CE AD - Departamento de Cardiologia, Fundacion Valle del Lili, Carrera 98 No. 18 - 49, Cali, 760032, Colombia. AD - Facultad de Ciencias de la Salud, Universidad Icesi, Calle 18 No. 122-135, Cali, 760031, Colombia. FAU - Olaya, Pastor AU - Olaya P AD - Departamento de Cardiologia, Fundacion Valle del Lili, Carrera 98 No. 18 - 49, Cali, 760032, Colombia. AD - Facultad de Ciencias de la Salud, Universidad Icesi, Calle 18 No. 122-135, Cali, 760031, Colombia. FAU - Reyes-Cardona, Maria Juliana AU - Reyes-Cardona MJ AD - Facultad de Ciencias de la Salud, Universidad Icesi, Calle 18 No. 122-135, Cali, 760031, Colombia. AD - Centro de Investigaciones Clinicas, Fundacion Valle del Lili, Carrera 98 No. 18 - 49, Cali, 760032, Colombia. FAU - Sanchez-Blanco, Jairo AU - Sanchez-Blanco J AD - Departamento de Cardiologia, Fundacion Valle del Lili, Carrera 98 No. 18 - 49, Cali, 760032, Colombia. AD - Facultad de Ciencias de la Salud, Universidad Icesi, Calle 18 No. 122-135, Cali, 760031, Colombia. FAU - Zambrano-Franco, Jorge Alexander AU - Zambrano-Franco JA AD - Departamento de Cardiologia, Fundacion Valle del Lili, Carrera 98 No. 18 - 49, Cali, 760032, Colombia. AD - Facultad de Ciencias de la Salud, Universidad Icesi, Calle 18 No. 122-135, Cali, 760031, Colombia. FAU - Cruz-Suarez, Gustavo Adolfo AU - Cruz-Suarez GA AD - Facultad de Ciencias de la Salud, Universidad Icesi, Calle 18 No. 122-135, Cali, 760031, Colombia. AD - Departamento de Anestesiologia, Fundacion Valle del Lili, Carrera 98 No. 18 - 49, Cali, 760032, Colombia. FAU - Pena-Gonzalez, Alvaro Diego AU - Pena-Gonzalez AD AD - Facultad de Ciencias de la Salud, Universidad Icesi, Calle 18 No. 122-135, Cali, 760031, Colombia. AD - Departamento de Cirugia Cardiovascular, Fundacion Valle del Lili, Carrera 98 No. 18 - 49, Cali, 760032, Colombia. LA - eng PT - Journal Article DEP - 20250618 PL - England TA - Int J Emerg Med JT - International journal of emergency medicine JID - 101469435 PMC - PMC12175461 OTO - NOTNLM OT - Acute myocardial infarction OT - Echocardiography OT - Mechanical complications OT - Surgical treatment OT - Ventricular rupture COIS- Declarations. Ethics approval and consent to participate: This case report was reviewed and approved by the Institutional Review Board (IRB) of Fundacion Valle del Lili, Cali, Colombia. The patient provided informed consent for the use and publication of their medical information, and all identifying details have been anonymized to ensure confidentiality. Consent for publication: Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal. Competing interests: The authors declare no competing interests. EDAT- 2025/06/19 00:25 MHDA- 2025/06/19 00:26 PMCR- 2025/06/18 CRDT- 2025/06/18 23:33 PHST- 2025/01/23 00:00 [received] PHST- 2025/06/05 00:00 [accepted] PHST- 2025/06/19 00:26 [medline] PHST- 2025/06/19 00:25 [pubmed] PHST- 2025/06/18 23:33 [entrez] PHST- 2025/06/18 00:00 [pmc-release] AID - 10.1186/s12245-025-00907-2 [pii] AID - 907 [pii] AID - 10.1186/s12245-025-00907-2 [doi] PST - epublish SO - Int J Emerg Med. 2025 Jun 18;18(1):105. doi: 10.1186/s12245-025-00907-2. PMID- 40532844 OWN - NLM STAT- MEDLINE DCOM- 20260715 LR - 20260805 IS - 1532-8414 (Electronic) IS - 1071-9164 (Linking) VI - 32 IP - 7 DP - 2026 Jul TI - Consolidating Concepts From Recent International Expert Consensus on Sarcopenia: Implications for Heart Failure Management. PG - 1257-1266 LID - S1071-9164(25)00249-0 [pii] LID - 10.1016/j.cardfail.2025.03.021 [doi] AB - Heart failure (HF) is a clinical syndrome associated with a range of pathophysiological disorders, including secondary sarcopenia that reduces patients' quality of life, mobility, physical fitness, and capacity to undergo rehabilitation and recovery from acute decompensation. Although international expert writing groups have convened and developed consensus documents for sarcopenia, the vast majority of the content has focused on the disorder from the aging perspective. HF is rarely or never considered in the available consensus statements and recommendations. Moreover, there are differences in the sarcopenia diagnostic criteria pertaining to race/ethnicity (translating into differences in body composition and anthropometry), investigative methodologies, practice patterns, and variations in access to health care resources across nations that are not discussed in the current HF-management guidelines. Here, we review the key contents of the recent major international consensus documents concerning sarcopenia that were published between 2019 and 2024. We highlight the gaps in knowledge (eg, sarcopenic obesity, cardiac atrophy/wasting) and recent developments in HF treatment (eg sodium glucose co-transporter 2 inhibitors) and interventions (eg, rehabilitation, inspiratory muscle training) that may benefit sarcopenia; and we reformulate the 4-step pathway of early screening, investigation, diagnosis and severity determination (Find-Assess-Confirm-Severity) for sarcopenia as a vital part of HF management under a multidisciplinary care team. CI - Copyright (c) 2025 Elsevier Inc. All rights reserved. FAU - Lau, Gloria H W AU - Lau GHW AD - Gerald Choa Cardiac Research Centre and Laboratory for Heart Failure + Circulation Research, Li Ka Shing Institute of Health Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China; Centre for Cardiovascular Genomics & Medicine and HK HOPE, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China. FAU - Auyeung, Tung Wai AU - Auyeung TW AD - CUHK Jockey Club Institute of Ageing, The Chinese University of Hong Kong, Hong Kong, China. FAU - Joyce, Emer AU - Joyce E AD - Mater University Hospital and University College Dublin, Dublin, Ireland. FAU - McDonagh, Julee AU - McDonagh J AD - Faculty of Science, Medicine and Health, School of Nursing, University of Wollongong, Wollongong, New South Wales, Australia. FAU - Yu, Ka Man AU - Yu KM AD - Gerald Choa Cardiac Research Centre and Laboratory for Heart Failure + Circulation Research, Li Ka Shing Institute of Health Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China; Centre for Cardiovascular Genomics & Medicine and HK HOPE, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China. FAU - Woo, Jean AU - Woo J AD - CUHK Jockey Club Institute of Ageing, The Chinese University of Hong Kong, Hong Kong, China. FAU - Lee, Jenny S W AU - Lee JSW AD - CUHK Jockey Club Institute of Ageing, The Chinese University of Hong Kong, Hong Kong, China; Department of Medicine & Geriatrics, Alice Ho Miu Ling Nethersole Hospital and Tai Po Hospital, Hong Kong, China. FAU - Jha, Sunita AU - Jha S AD - School of Medicine, University of Notre Dame, Sydney, New South Wales, Australia; Heart Transplant Unit, St. Vincent's Hospital, Darlinghurst, Sydney, New South Wales, Australia. FAU - Macdonald, Peter S AU - Macdonald PS AD - Heart Transplant Unit, St. Vincent's Hospital, Darlinghurst, Sydney, New South Wales, Australia; St. Vincent's Clinical School, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia; Victor Chang Cardiac Research Institute, Darlinghurst, Sydney, New South Wales, Australia. FAU - Fung, Erik AU - Fung E AD - Gerald Choa Cardiac Research Centre and Laboratory for Heart Failure + Circulation Research, Li Ka Shing Institute of Health Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China; Centre for Cardiovascular Genomics & Medicine and HK HOPE, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China; CUHK Medical Centre, Hong Kong, China; School of Public Health, Faculty of Medicine, Imperial College London, London, UK; Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong, China. Electronic address: erikfung@ust.hk. LA - eng PT - Journal Article PT - Review DEP - 20250616 PL - United States TA - J Card Fail JT - Journal of cardiac failure JID - 9442138 SB - IM MH - Humans MH - *Consensus MH - *Disease Management MH - *Heart Failure/therapy/complications/physiopathology/diagnosis/epidemiology MH - *Quality of Life MH - *Sarcopenia/therapy/diagnosis/epidemiology/physiopathology OTO - NOTNLM OT - Sarcopenia OT - heart failure OT - multidisciplinary care team OT - nutrition OT - rehabilitation COIS- Disclosures The authors declare no relevant conflicts of interest. EDAT- 2025/06/19 00:25 MHDA- 2026/07/15 12:37 CRDT- 2025/06/18 19:13 PHST- 2024/09/12 00:00 [received] PHST- 2025/03/18 00:00 [revised] PHST- 2025/03/29 00:00 [accepted] PHST- 2026/07/15 12:37 [medline] PHST- 2025/06/19 00:25 [pubmed] PHST- 2025/06/18 19:13 [entrez] AID - S1071-9164(25)00249-0 [pii] AID - 10.1016/j.cardfail.2025.03.021 [doi] PST - ppublish SO - J Card Fail. 2026 Jul;32(7):1257-1266. doi: 10.1016/j.cardfail.2025.03.021. Epub 2025 Jun 16. PMID- 40532825 OWN - NLM STAT- Publisher LR - 20250618 IS - 1097-6787 (Electronic) IS - 0190-9622 (Linking) DP - 2025 Jun 16 TI - RASopathies. Part II: Cutaneous and extracutaneous manifestations. LID - S0190-9622(25)02340-0 [pii] LID - 10.1016/j.jaad.2025.01.106 [doi] AB - Many RASopathies can be clinically diagnosed based on their cutaneous findings, thus it is essential for dermatologists to be comfortable differentiating RASopathies for accurate diagnosis and appropriate management. Employing the same framework to categorize as in Part I, the most common RASopathies include those principally caused by genetic variants in tumor suppressor genes (neurofibromatosis type 1, Noonan syndrome with multiple lentigines, Legius syndrome, capillary malformation-arteriovenous malformation syndrome), those principally due to variants in oncogenes (Noonan syndrome, Costello syndrome, cardiofaciocutaneous syndrome), and mosaic conditions such as sebaceous nevus syndrome, neurocutaneous melanosis, McCune-Albright syndrome, phakomatosis pigmentokeratotica, epidermal nevus syndrome, and encephalocraniocutaneous lipomatosis. Germline variants cause systemic disease and must be managed in conjunction with a multidisciplinary team of specialists for holistic care. Common extracutaneous manifestations affect the neurologic, psychiatric, cardiac, ocular, musculoskeletal, genitourinary, and hematologic systems. The genetic basis of disease necessitates family counseling with a geneticist and patient support groups. It is also important to recognize risk of cancer in RASopathy patients for appropriate surveillance. Thus, dermatologists play a critical role in patients' healthcare through familiarity with and prompt diagnosis of RASopathies. CI - Copyright (c) 2025. Published by Elsevier Inc. FAU - Jaeger, Zachary J AU - Jaeger ZJ AD - Washington University School of Medicine, St. Louis, Missouri; Veterans' Affairs Caribbean Healthcare System, San Juan, Puerto Rico; University of California San Diego Department of Dermatology, San Diego, California. FAU - Maverakis Ramirez, Natalia K A AU - Maverakis Ramirez NKA AD - San Juan Bautista School of Medicine, Caguas, Puerto Rico; The Lundquist Institute at Harbor-University of California Los Angeles Medical Center, Torrance, California. FAU - Osborne, Ashley D AU - Osborne AD AD - Washington University School of Medicine, St. Louis, Missouri; Shawn Jenkins Children's Hospital, Medical University of South Carolina, Charleston, South Carolina. FAU - Staser, Karl W AU - Staser KW AD - Washington University School of Medicine, St. Louis, Missouri; Meramec Dermatology, Missouri. FAU - King, Katherine A AU - King KA AD - Washington University School of Medicine, St. Louis, Missouri. FAU - Bayliss, Susan J AU - Bayliss SJ AD - Washington University School of Medicine, St. Louis, Missouri. FAU - Mann, Caroline AU - Mann C AD - Washington University School of Medicine, St. Louis, Missouri. Electronic address: mannc@wustl.edu. LA - eng PT - Journal Article PT - Review DEP - 20250616 PL - United States TA - J Am Acad Dermatol JT - Journal of the American Academy of Dermatology JID - 7907132 SB - IM OTO - NOTNLM OT - CM-AVM OT - Costello OT - ECCL OT - HRAS OT - KRAS OT - LEOPARD OT - Legius OT - NF1 OT - NRAS OT - Noonan OT - Noonan syndrome with multiple lentigines OT - RAS OT - RASopathies OT - RASopathy OT - Schimmelpenning OT - cancer OT - capillary malformation-arteriovenous malformation OT - cardiofaciocutaneous OT - encephalocraniocutaneous lipomatosis OT - epidermal nevus OT - genetics OT - malignancy OT - multidisciplinary OT - neurofibromatosis OT - oncogene OT - phakomatosis pigmentokeratotica OT - sebaceous nevus OT - tumor suppressor EDAT- 2025/06/19 00:25 MHDA- 2025/06/19 00:25 CRDT- 2025/06/18 19:13 PHST- 2024/08/17 00:00 [received] PHST- 2024/12/03 00:00 [revised] PHST- 2025/01/10 00:00 [accepted] PHST- 2025/06/19 00:25 [medline] PHST- 2025/06/19 00:25 [pubmed] PHST- 2025/06/18 19:13 [entrez] AID - S0190-9622(25)02340-0 [pii] AID - 10.1016/j.jaad.2025.01.106 [doi] PST - aheadofprint SO - J Am Acad Dermatol. 2025 Jun 16:S0190-9622(25)02340-0. doi: 10.1016/j.jaad.2025.01.106. PMID- 40532228 OWN - NLM STAT- MEDLINE DCOM- 20250826 LR - 20260429 IS - 1536-3708 (Electronic) IS - 0148-7043 (Linking) VI - 95 IP - 3 DP - 2025 Sep 1 TI - Pectoralis Major Flaps for Sternal Reconstruction: Multidisciplinary Considerations and Patient Outcomes. PG - 301-307 LID - 10.1097/SAP.0000000000004409 [doi] AB - BACKGROUND: Sternal wounds following cardiothoracic surgery are a challenging surgical problem, and pectoralis muscle flaps are a mainstay for reconstruction. Multiple variations of this strategy exist, and this study seeks to characterize key decision factors and patient outcomes to increase accessibility of this technique to surgeons. MATERIALS AND METHODS: This is a retrospective cohort study of adult sternal wound patients at a tertiary referral center between 2010-2020. Patient demographics, comorbidities, wound characteristics, and perioperative data were collected. Multinomial logistic regression determined factors significantly associated with reconstructive technique. Binomial logistic regression was used to analyze 90-day readmission and reoperation for sternal wounds. RESULTS: In total, 114 patients underwent reconstruction with pectoralis flaps. Bilateral advancement flaps were the most common strategy (64%) followed by bilateral advancement/turnover (15%), unilateral advancement (11%), unilateral turnover (8%), and bilateral turnover (2%). The absence of the internal mammary artery was significantly associated with bilateral vs unilateral pectoralis flap reconstruction ( P < 0.01). Deep space sternal wounds were most likely to be treated with a turnover flap component ( P < 0.001). Type of flap reconstruction was associated with sternal wound recurrence ( P < 0.03). However, multivariable logistic regression modeling identified coronary artery disease [odds ratio (OR) = 8.18, P < 0.02], prior cardiothoracic surgeries (OR = 2.95, P < 0.01), and discharge before plastic surgery consultation (OR = 3.73, P < 0.04) as significant predictors of 90-day readmission or reoperations for sternal wound recurrence. CONCLUSIONS: Multiple configurations of the pectoralis major can be utilized for treating sternal wounds. The absence of the internal mammary artery is an important factor given its association with bilateral flap reconstruction, while the turnover pectoralis is more frequently used for deep space wounds. Internal mammary artery patency should be clearly communicated to improve multidisciplinary management of these challenging problems. CI - Copyright (c) 2025 Wolters Kluwer Health, Inc. All rights reserved. FAU - Chi, David AU - Chi D AD - From the Division of Plastic and Reconstructive Surgery, Department of Surgery Washington University Medical Center, Saint Louis, MO. FAU - Skladman, Rachel AU - Skladman R AD - From the Division of Plastic and Reconstructive Surgery, Department of Surgery Washington University Medical Center, Saint Louis, MO. FAU - Arhewoh, Reme E AU - Arhewoh RE AD - From the Division of Plastic and Reconstructive Surgery, Department of Surgery Washington University Medical Center, Saint Louis, MO. FAU - Chiang, Sarah N AU - Chiang SN AD - From the Division of Plastic and Reconstructive Surgery, Department of Surgery Washington University Medical Center, Saint Louis, MO. FAU - Vuong, Linh AU - Vuong L AD - From the Division of Plastic and Reconstructive Surgery, Department of Surgery Washington University Medical Center, Saint Louis, MO. FAU - Sachar, Ryan J AU - Sachar RJ AD - From the Division of Plastic and Reconstructive Surgery, Department of Surgery Washington University Medical Center, Saint Louis, MO. FAU - Masood, Muhammad F AU - Masood MF AD - Division of Cardiothoracic Surgery, Washington University Medical Center, Saint Louis, MO. FAU - Fox, Ida K AU - Fox IK AD - From the Division of Plastic and Reconstructive Surgery, Department of Surgery Washington University Medical Center, Saint Louis, MO. LA - eng GR - W81XWH-22-1-0909/Department of Defense office of the Congressionally Directed Medical Research Programs (CDMRP) Fiscal Year 2021 Spinal Cord Injury Research Program (SCIRP) Expansion Award-Early-Career Partnering PI Option/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20250605 PL - United States TA - Ann Plast Surg JT - Annals of plastic surgery JID - 7805336 SB - IM MH - Humans MH - *Pectoralis Muscles/transplantation MH - Retrospective Studies MH - Male MH - Female MH - *Sternum/surgery MH - *Plastic Surgery Procedures/methods MH - *Surgical Flaps/transplantation MH - Middle Aged MH - Aged MH - Reoperation/statistics & numerical data MH - Treatment Outcome MH - Patient Readmission/statistics & numerical data MH - Adult MH - *Cardiac Surgical Procedures/adverse effects OTO - NOTNLM OT - cardiothoracic surgery OT - coronary artery disease OT - pectoralis major OT - plastic surgery OT - reconstruction OT - sternal wound COIS- Conflicts of interest and sources of funding: Ida K Fox, MD, has grant funding as PI for "Expanding Knowledge and Information Delivery Around Improving Upper Extremity Function After Cervical Spinal Cord Injury" Department of Defense office of the Congressionally Directed Medical Research Programs (CDMRP) Fiscal Year 2021 Spinal Cord Injury Research Program (SCIRP) Expansion Award-Early-Career Partnering PI Option. W81XWH-22-1-0909. The other authors have no other disclosures. EDAT- 2025/06/18 18:27 MHDA- 2025/08/31 20:01 CRDT- 2025/06/18 17:33 PHST- 2024/09/07 00:00 [received] PHST- 2025/04/24 00:00 [accepted] PHST- 2025/08/31 20:01 [medline] PHST- 2025/06/18 18:27 [pubmed] PHST- 2025/06/18 17:33 [entrez] AID - 00000637-990000000-00836 [pii] AID - 10.1097/SAP.0000000000004409 [doi] PST - ppublish SO - Ann Plast Surg. 2025 Sep 1;95(3):301-307. doi: 10.1097/SAP.0000000000004409. Epub 2025 Jun 5. PMID- 40529206 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250710 IS - 2633-4402 (Electronic) IS - 2633-4402 (Linking) VI - 5 DP - 2025 TI - Affordable Cardiac Rehabilitation An Outreach Inter-Disciplinary Strategic Study (ACROSS) - Research Programme Protocol. PG - 41 LID - 10.3310/nihropenres.13957.1 [doi] LID - 41 AB - BACKGROUND: The evidence and infrastructure needed to access and deliver cardiac rehabilitation (CR) services are absent or lacking in low and middle-income countries (LMICs), resulting in a substantial loss of potential health and socio-economic benefits. Home-based programmes provide an affordable model of delivery that can leverage a scalable increase in CR access in LMICs. ACROSS (Affordable Cardiac Rehabilitation: An Outreach Inter-disciplinary Strategic Study) seeks to co-develop (with patients, caregivers, clinicians, and service commissioners) a culturally and contextually applicable and affordable home-based programme for people with the multimorbidity of coronary heart disease and/or heart failure with co-existing depression and/or anxiety and evaluate the acceptability, clinical effectiveness, and cost-effectiveness of its implementation in Bangladesh, India, and Pakistan and to determine its scalability and sustainability. METHODS: Four linked work packages (WPs). WP1 (cultural adaptation/refinement of home-based rehabilitation): examine rehabilitation implementation barriers/enablers from multiple stakeholder perspectives and co-develop a feasible and acceptable culturally & contextually adapted home-based programme, extended to take account of co-existing depression and/or anxiety; WP2 (external pilot): assess feasibility/acceptability of the co-developed rehabilitation intervention and study design and processes necessary for a full-scale trial; WP3: (multicentre/multi-country hybrid effectiveness and implementation randomised trial) determine the clinical and cost-effectiveness of a culturally adapted home-based rehabilitation intervention for people with coronary heart disease and/or heart failure and depression and/or anxiety; WP4 (capacity building): build research and rehabilitation delivery capacity. CONCLUSIONS: The ACROSS programme overarching goal is to develop a clinically and cost-effective CR model in low-resource settings for people in Bangladesh, India, and Pakistan with a multimorbidity of heart disease and depression and/or anxiety with the potential for substantial health and socio-economic benefits. CI - Copyright: (c) 2025 Taylor RS et al. FAU - Taylor, Rod S AU - Taylor RS AUID- ORCID: 0000-0002-3043-6011 AD - School of Health and Wellbeing, University of Glasgow College of Medical Veterinary and Life Sciences, Glasgow, Scotland, G12 8TA, UK. FAU - Chaudhry, Imran Bashir AU - Chaudhry IB AD - Pakistan Institute of Living and Learning, Karachi, Sindh, Pakistan. AD - The University of Manchester, Division of Psychology and Mental Health, Manchester, England, UK. AD - University of Karachi, Karachi, Sindh, Pakistan. FAU - Faraque, Mithila AU - Faraque M AD - Bangladesh University of Health Sciences, Dhaka, Dhaka Division, Bangladesh. FAU - Jeemon, Panniyammakal AU - Jeemon P AD - Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, Kerala, India. FAU - Blakemore, Amy AU - Blakemore A AD - The University of Manchester, Division of Psychology and Mental Health, Manchester, England, UK. FAU - Lovell, Karina AU - Lovell K AD - The University of Manchester, Division of Psychology and Mental Health, Manchester, England, UK. FAU - Husain, Nusrat AU - Husain N AD - The University of Manchester, Division of Psychology and Mental Health, Manchester, England, UK. FAU - Saghir, Tahir AU - Saghir T AD - National Institute of Cardiovascular Diseases, National Institute of Cardiovascular Diseases, Karachi, Sindh, Pakistan. FAU - Mashreky, Saidur Rahman AU - Mashreky SR AUID- ORCID: 0000-0001-7892-798X AD - Department of Public Health, North South University, Dhaka, Dhaka Division, Bangladesh. FAU - Harikrishnan, Sivadasanpillai AU - Harikrishnan S AD - Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, Kerala, India. FAU - Ahmed, Chaudhury Meshkat AU - Ahmed CM AD - Bangabandhu Sheikh Mujib Medical University, Dhaka, Dhaka Division, Bangladesh. FAU - Babu, Abraham Samuel AU - Babu AS AD - Department of Physiotherapy, Manipal College of Health Professions, Manipal, Karnataka, India. FAU - McConnachie, Alex AU - McConnachie A AUID- ORCID: 0000-0002-7262-7000 AD - School of Health and Wellbeing, University of Glasgow College of Medical Veterinary and Life Sciences, Glasgow, Scotland, G12 8TA, UK. FAU - McIntosh, Emma AU - McIntosh E AUID- ORCID: 0000-0001-6340-3083 AD - School of Health and Wellbeing, University of Glasgow College of Medical Veterinary and Life Sciences, Glasgow, Scotland, G12 8TA, UK. FAU - Memon, Rakhshi AU - Memon R AD - University College London, Faculty of Population Health Sciences, London, England, UK. FAU - Singh, Sally AU - Singh S AD - Respiratory Sciences, University of Leicester, Leicester, England, UK. AD - University Hospitals of Leicester NHS Trust, Leicester, England, UK. FAU - Leyland, Alastair AU - Leyland A AD - School of Health and Wellbeing, University of Glasgow College of Medical Veterinary and Life Sciences, Glasgow, Scotland, G12 8TA, UK. FAU - Jani, Bhautesh AU - Jani B AD - School of Health and Wellbeing, University of Glasgow College of Medical Veterinary and Life Sciences, Glasgow, Scotland, G12 8TA, UK. FAU - Flores, Walter AU - Flores W AD - Accountability Research Center, American University Washington College of Law, Washington, District of Columbia, USA. CN - ACROSS Collaborative Group LA - eng PT - Journal Article DEP - 20250506 PL - England TA - NIHR Open Res JT - NIHR open research JID - 9918333281906676 PMC - PMC12171719 OAB - The combination of heart disease alongside depression and anxiety is a common and profound unmet need for global health systems, especially in low and middle-income country settings. It affects people of working age, causing them ill-health and major financial loss. Cardiac rehabilitation is recommended as a core component of health services and includes exercise, education, and psychological support. It has been shown to reduce death rate and hospital admissions and improve the quality of life. However, cardiac rehabilitation services in low- and middle-income countries are virtually absent. Working with partners in Bangladesh, Pakistan, and India, the 'Affordable Cardiac Rehabilitation: An Outreach Interdisciplinary Strategic Study' (ACROSS) programme seeks to develop and evaluate the implementation of a clinically effective, affordable, and culturally and contextually appropriate model of home-based rehabilitation. ACROSS has four work packages: (1) Engagement events with those with lived-disease experience, their families, healthcare staff, and service providers to co-develop a culturally and contextually adapted home-based rehabilitation ('ACROSS') programme and training materials for providers; (2) A pilot study to understand if the ACROSS programme is acceptable and practical for patients and staff and whether a full-scale trial is doable; (3) A trial in 3000 patients with multiple long-term conditions that include heart disease and depression and anxiety across several sites in each country to tell us whether the programme improves health outcomes at 12-months and what its affordability is; and (4) Develop a sustainable model of workforce training and implementation to enable long-term programme delivery as well as build partner research capacity. People with lived-disease experience, clinicians, community leaders, and healthcare policymakers have been extensively involved in the planning of ACROSS. Our stakeholder meetings have consistently emphasised the importance of this research and supported the development of our research plans. Patients and stakeholders in each partner country will provide ongoing advice. OABL- eng OTO - NOTNLM OT - cardiac rehabilitation OT - coronary artery disease OT - heart failure OT - low and middle income country. OT - mental health OT - randomised controlled trial COIS- Competing interests: RST is currently co-Chair of the NIHR Research on Interventions for Global Health Transformation (RIGHT) Funding Committee. NH has been a past Trustee of the Pakistan Institute of Living and Learning (PILL), Abaseen Foundation UK, Lancashire Mind UK and Manchester Global Foundation (MGF). He is a member of the Academic Faculty at the Royal College of Psychiatrists (RCPsych), London. He is a National Institute for Health and Care Research (NIHR) Senior Investigator. He has attended educational events organised by various pharmaceutical industries. RM is CEO of Manchester Global Foundation (UK Charity Number 116841) and trustee of UK Association for Medical Aid to Pakistan (UK Charity Number 1123929). IBC has given lectures or advice to Eli Lilly, Bristol Myers Squibb, Lundbeck, Astra Zeneca, and Janssen pharmaceuticals for which he or his employing institution have been reimbursed, outside the submitted work. Prof Chaudhry was previously a trustee of the Pakistan Institute of Living and Learning (PILL). Other authors declare no conflicts of interest. FIR - Karim, Rezaul IR - Karim R FIR - Ul Haq, Zia IR - Ul Haq Z FIR - Soomro, Nabila IR - Soomro N FIR - Zadeh, Zainab B IR - Zadeh ZB FIR - Khoso, Ameer IR - Khoso A FIR - Tofique, Sehrish IR - Tofique S FIR - Jafri, Farhat IR - Jafri F FIR - Sultana, Riffat IR - Sultana R FIR - Naeem, Huma IR - Naeem H FIR - Chandra Banik, Palash IR - Chandra Banik P FIR - Choudhury, Sohel IR - Choudhury S FIR - Taylor, Louise IR - Taylor L FIR - Uddin, Jamal IR - Uddin J FIR - Copping, Claire IR - Copping C FIR - Innes, David IR - Innes D FIR - Roy Tn, Sunil IR - Roy Tn S FIR - Joseph, Stigi IR - Joseph S FIR - Ganesan, Vijayan IR - Ganesan V FIR - Prabhu, Mukund A IR - Prabhu MA FIR - Vijay Ms, Jyothi IR - Vijay Ms J FIR - Das Nk, Ramya IR - Das Nk R EDAT- 2025/06/18 06:25 MHDA- 2025/06/18 06:26 PMCR- 2025/05/06 CRDT- 2025/06/18 05:28 PHST- 2025/04/25 00:00 [accepted] PHST- 2025/06/18 06:25 [pubmed] PHST- 2025/06/18 06:26 [medline] PHST- 2025/06/18 05:28 [entrez] PHST- 2025/05/06 00:00 [pmc-release] AID - 10.3310/nihropenres.13957.1 [doi] PST - epublish SO - NIHR Open Res. 2025 May 6;5:41. doi: 10.3310/nihropenres.13957.1. eCollection 2025. PMID- 40527298 OWN - NLM STAT- MEDLINE DCOM- 20250806 LR - 20260813 IS - 1476-1645 (Electronic) IS - 0002-9637 (Print) IS - 0002-9637 (Linking) VI - 113 IP - 2 DP - 2025 Aug 6 TI - Intrathoracic Echinococcosis: A 5-Year, Single-Center Experience. PG - 298-302 LID - 10.4269/ajtmh.24-0094 [doi] AB - Human cystic echinococcosis (CE) is caused by the larval forms of Echinococcus granulosus s.l. species complex that mainly affect the liver, with lung as the second most frequent location. We describe our experience with surgical treatment of lung CE, emphasizing the need for the least invasive approach when possible. Patients with intrathoracic CE who accessed our center from January 2019 to November 2023 were reviewed. Twenty-two patients, 12 males (54.5%), mean age 35 years, range 9-60, were treated. Eight patients (36.4%) had only lung involvement, seven (31.8%) had both liver and lung involvement, and seven (31.8%) had other locations. Thoracic surgery was required for large dimensions or pain (six each), hemoptysis (four each), skin fistulization and pericardial involvement (two each), and infection and emission of parasitic material by cough (one). A minimally invasive video-assisted thoracic surgery approach was used for 12 (54.5%) patients, whereas 10 underwent anterior thoracotomy. Three patients underwent sequential lung and hepatic surgery in a single session, one with myocardial wall involvement underwent thoracic and cardiac surgery in a single session. All patients received albendazole before and during surgery. There was no operative and postoperative mortality. The mean follow-up was 11.5 months (range 1-30). Patients with intrathoracic CE may present with acute and even life-threatening symptoms and should be managed preferably with tissue-sparing surgery by a multidisciplinary team in a referral center. FAU - Lissandrin, Raffaella AU - Lissandrin R AD - Division of Infectious Diseases I, IRCCS San Matteo Hospital Foundation, Pavia, Italy. AD - WHO Collaborating Centre for Clinical Management of Cystic Echinococcosis, University of Pavia, Pavia, Italy. FAU - Vola, Ambra AU - Vola A AD - Microbiology and Virology Unit, IRCCS San Matteo Hospital Foundation, Pavia, Italy. FAU - Pelizzola, Matilde AU - Pelizzola M AD - Department of Clinical, Surgical Diagnostic, and Pediatric Sciences, University of Pavia, Pavia, Italy. FAU - Scopis, Federico AU - Scopis F AD - Division of Thoracic Surgery, AOU San Luigi Gonzaga, Torino, Italy. FAU - Meda, Stefano AU - Meda S AD - Division of Thoracic Surgery, SS Antonio, Biagio and Cesare Arrigo Hospital, Alessandria, Italy. FAU - Primiceri, Cristiano AU - Primiceri C AD - Division of Thoracic Surgery, SS Antonio, Biagio and Cesare Arrigo Hospital, Alessandria, Italy. FAU - D'Alessandro, Gianluca AU - D'Alessandro G AD - Department of Clinical, Surgical Diagnostic, and Pediatric Sciences, University of Pavia, Pavia, Italy. FAU - Manciulli, Tommaso AU - Manciulli T AD - Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. FAU - Maestri, Marcello AU - Maestri M AD - Department of General Surgery 1, IRCCS San Matteo Hospital Foundation, Pavia, Italy. FAU - Brunetti, Enrico AU - Brunetti E AD - Division of Infectious Diseases I, IRCCS San Matteo Hospital Foundation, Pavia, Italy. AD - WHO Collaborating Centre for Clinical Management of Cystic Echinococcosis, University of Pavia, Pavia, Italy. AD - Department of Clinical, Surgical Diagnostic, and Pediatric Sciences, University of Pavia, Pavia, Italy. FAU - Rinaldi, Pietro AU - Rinaldi P AD - Division of Thoracic Surgery, SS Antonio, Biagio and Cesare Arrigo Hospital, Alessandria, Italy. AD - Department of Molecular Medicine, University of Pavia, Pavia, Italy. LA - eng PT - Journal Article DEP - 20250617 PL - United States TA - Am J Trop Med Hyg JT - The American journal of tropical medicine and hygiene JID - 0370507 RN - F4216019LN (Albendazole) SB - IM MH - Humans MH - Male MH - Adult MH - Female MH - Adolescent MH - Middle Aged MH - Young Adult MH - Child MH - *Echinococcosis, Pulmonary/surgery MH - Animals MH - Retrospective Studies MH - Thoracic Surgery, Video-Assisted MH - Thoracotomy MH - Echinococcus granulosus MH - *Echinococcosis/surgery MH - Albendazole/therapeutic use MH - Lung/parasitology/surgery PMC - PMC12360070 EDAT- 2025/06/18 00:29 MHDA- 2025/08/07 00:27 PMCR- 2026/08/01 CRDT- 2025/06/17 18:23 PHST- 2024/03/06 00:00 [received] PHST- 2025/03/20 00:00 [accepted] PHST- 2025/08/07 00:27 [medline] PHST- 2025/06/18 00:29 [pubmed] PHST- 2025/06/17 18:23 [entrez] PHST- 2026/08/01 00:00 [pmc-release] AID - tpmd240094 [pii] AID - 10.4269/ajtmh.24-0094 [doi] PST - epublish SO - Am J Trop Med Hyg. 2025 Jun 17;113(2):298-302. doi: 10.4269/ajtmh.24-0094. Print 2025 Aug 6. PMID- 40526671 OWN - NLM STAT- MEDLINE DCOM- 20250617 LR - 20250617 IS - 0043-5147 (Print) IS - 0043-5147 (Linking) VI - 78 IP - 5 DP - 2025 TI - Transformation of pharmaceutical care during the matrial state in Ukraine: doctors' perception of interprofessional communication. PG - 1143-1153 LID - 10.36740/WLek/205386 [doi] AB - OBJECTIVE: Aim: To investigate the perception of general practitioners of family medicine of the implementation of Good Pharmacy Practice (GPP) standards by pharmacists to determine approaches to interprofessional communication and further integration of pharmacists into primary health care. PATIENTS AND METHODS: Materials and Methods: The study was conducted at the Department of Cardiology of the Shupyk National Healthcare University of Ukraine from March to December 2024 by means of an anonymous online survey using Google Forms. The methods of analysis, deduction, induction, comparison, systematization, generalization, forecasting, statistics and bibliography were used. RESULTS: Results: The functions of pharmacists in integrated care teams were determined: monitoring and compatibility of medicines, monitoring the effectiveness of pharmacotherapy, dispensing prescription medicines "only on prescription" (72.5% [CI 95% 72.5 +/- 0.02, p<0.0001]); joint training in the process of continuous professional development (4.8% [CI 95% 4.8 +/- 0.01, p<0.0001]). It was found that the level of clinical competencies of pharmacists (65.3% [CI 95% 65.3 +/- 0.03, p<0.0001]) and safe use of medicines (60.7% [CI 95% 60.7, +/- 0.03, p<0.0001]) is mediocre. CONCLUSION: Conclusions: The high interest of doctors of therapeutic specialties in interprofessional communication with pharmacists as part of integrated care teams was determined (72.5% [CI 95% 72.5 +/- 0.02, p<0.0001]). The need for additional training of pharmacists in the process of continuous professional development for work as part of integrated care teams in order to obtain and deepen clinical competencies was substantiated. We see the development of clinical recommendations for community pharmacists in accordance with the ESC/AHA recommendations and taking into account the compatibility of medicines when providing pharmaceutical care to patients with ischemic heart disease with comorbid conditions as a prospect for further research. FAU - Bilousova, Natalia A AU - Bilousova NA AD - SHUPYK NATIONAL HEALTHCARE UNIVERSITY OF UKRAINE, KYIV, UKRAINE. FAU - Mykhalchuk, Vasyl M AU - Mykhalchuk VM AD - SHUPYK NATIONAL HEALTHCARE UNIVERSITY OF UKRAINE, KYIV, UKRAINE. FAU - Tkachenko, Natalia O AU - Tkachenko NO AD - ZHAPORIZHZHIA STATE MEDICAL AND PHARMACEUTICAL UNIVERSITY, ZHAPORIZHZHIA, UKRAINE. FAU - Yakovenko, Liudmyla I AU - Yakovenko LI AD - SHUPYK NATIONAL HEALTHCARE UNIVERSITY OF UKRAINE, KYIV, UKRAINE. FAU - Dolzhenko, Maryna M AU - Dolzhenko MM AD - SHUPYK NATIONAL HEALTHCARE UNIVERSITY OF UKRAINE, KYIV, UKRAINE. LA - eng PT - Journal Article PL - Poland TA - Wiad Lek JT - Wiadomosci lekarskie (Warsaw, Poland : 1960) JID - 9705467 SB - IM MH - Humans MH - Ukraine MH - *Interprofessional Relations MH - *Pharmacists MH - *Attitude of Health Personnel MH - Male MH - Female MH - Surveys and Questionnaires MH - Patient Care Team MH - Primary Health Care MH - *Physicians/psychology MH - Adult MH - *Communication MH - *Pharmaceutical Services/organization & administration OTO - NOTNLM OT - interprofessional communication OT - medication monitoring OT - pharmaceutical care OT - community pharmacist OT - ischemic heart disease OT - pharmacotherapy management OT - integrated care team EDAT- 2025/06/17 18:26 MHDA- 2025/06/17 18:27 CRDT- 2025/06/17 13:43 PHST- 2025/06/17 18:27 [medline] PHST- 2025/06/17 18:26 [pubmed] PHST- 2025/06/17 13:43 [entrez] AID - 10.36740/WLek/205386 [doi] PST - ppublish SO - Wiad Lek. 2025;78(5):1143-1153. doi: 10.36740/WLek/205386. PMID- 40523024 OWN - NLM STAT- MEDLINE DCOM- 20250709 LR - 20250819 IS - 1473-6500 (Electronic) IS - 0952-7907 (Linking) VI - 38 IP - 4 DP - 2025 Aug 1 TI - Perioperative cardiovascular assessment and management of liver transplant patients. PG - 498-502 LID - 10.1097/ACO.0000000000001509 [doi] AB - PURPOSE OF REVIEW: Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in patients with end-stage liver disease (ESLD), particularly in the perioperative and posttransplant periods. Despite its critical impact, cardiovascular risk assessment and management strategies remain inconsistent across institutions. This review provides a timely synthesis of recent findings, highlighting the need for standardized cardiovascular evaluation and optimization in ESLD patients undergoing liver transplantation (LT). RECENT FINDINGS: Emerging data emphasize the interplay between cirrhosis, portal hypertension, systemic inflammation, and cardiovascular dysfunction, contributing to cirrhotic cardiomyopathy, coronary artery disease, arrhythmias, and heart failure. Advances in pretransplant screening suggest a shift toward risk-stratified approaches, integrating noninvasive imaging and selective coronary angiography. Intraoperative and postoperative cardiovascular complications remain prevalent, with immunosuppressive therapy exacerbating long-term CVD risk. SUMMARY: A multidisciplinary approach to cardiovascular management in ESLD patients is essential to improving LT outcomes. Standardized preoperative protocols, refined risk stratification, and evidence-based postoperative monitoring are critical to reducing CVD-related complications. Future research should focus on optimizing cardiovascular interventions, developing consensus guidelines, and improving long-term cardiovascular care in LT recipients. CI - Copyright (c) 2025 Wolters Kluwer Health, Inc. All rights reserved. FAU - Ibrahim, Ali O AU - Ibrahim AO AD - Department of Cardiovascular Medicine, Allegheny General Hospital, Pittsburgh, Pennsylvania, USA. FAU - Mohamed, Mohamed Salah AU - Mohamed MS FAU - Ivanova, Valentyna AU - Ivanova V LA - eng PT - Journal Article PT - Review DEP - 20250616 PL - United States TA - Curr Opin Anaesthesiol JT - Current opinion in anaesthesiology JID - 8813436 SB - IM MH - Humans MH - *Liver Transplantation/adverse effects/methods MH - *Cardiovascular Diseases/diagnosis/etiology/therapy/prevention & control MH - *Perioperative Care/methods/standards MH - *End Stage Liver Disease/surgery/complications MH - *Postoperative Complications/prevention & control/etiology/diagnosis MH - Risk Assessment/methods OTO - NOTNLM OT - cardiovascular risk OT - end-stage liver disease OT - liver transplantation OT - preoperative assessment EDAT- 2025/06/16 18:26 MHDA- 2025/07/09 12:28 CRDT- 2025/06/16 13:44 PHST- 2025/07/09 12:28 [medline] PHST- 2025/06/16 18:26 [pubmed] PHST- 2025/06/16 13:44 [entrez] AID - 00001503-202508000-00028 [pii] AID - 10.1097/ACO.0000000000001509 [doi] PST - ppublish SO - Curr Opin Anaesthesiol. 2025 Aug 1;38(4):498-502. doi: 10.1097/ACO.0000000000001509. Epub 2025 Jun 16. PMID- 40519055 OWN - NLM STAT- MEDLINE DCOM- 20250709 LR - 20250709 IS - 1744-8344 (Electronic) IS - 1477-9072 (Linking) VI - 23 IP - 5 DP - 2025 Apr-May TI - Understanding gastrointestinal bleeding in patients with cardiac disease: an interdisciplinary approach. PG - 197-207 LID - 10.1080/14779072.2025.2520831 [doi] AB - INTRODUCTION: Cardiovascular disease remains the leading cause of global mortality and a significant contributor to disability. The incidence of gastrointestinal bleeding (GIB) varies across cardiac conditions, with notable risks observed in patients undergoing complex antiplatelet or anticoagulant therapy, acute coronary syndrome, hypertrophic cardiomyopathy, percutaneous coronary interventions, mechanical cardiac support, acute decompensated heart failure, and post-cardiac surgery. AREAS COVERED: A comprehensive search of the PubMed/Medline database was conducted to retrieve articles related to GIB and cardiovascular disease from 2014 to 2024. The authors then synthesized a narrative review that endorses an interdisciplinary approach to this challenging paradigm, drawing from cardiology and gastroenterology perspectives to provide a comprehensive overview of the current understanding of the risk of GIB in cardiac patients. EXPERT OPINION: In acute coronary syndrome, upper GIB significantly increases mortality risk, with early endoscopic intervention proving beneficial. Post-coronary revascularization presents a low GIB incidence but a high mortality rate when it occurs. Decompensated heart failure patients frequently experience GIB due to concomitant conditions. Cardiogenic shock and mechanical cardiac support also show notable GIB risks, with mechanical support patients facing higher mortality. Following transcatheter aortic valve implantation, GIB incidence is low, but hospitalization rates are significant. FAU - Gries, Jacob J AU - Gries JJ AD - Department of Internal Medicine, Geisinger Medical Center, Danville, PA, USA. FAU - Virk, Hafeez Ul Hassan AU - Virk HUH AD - Harrington Heart & Vascular Institute, Case Western Reserve University, University Hospitals Cleveland Medical Center, Cleveland, OH, USA. FAU - Birnbaum, Yochai AU - Birnbaum Y AD - Section of Cardiology, Baylor College of Medicine, Houston, TX, USA. FAU - Jneid, Hani AU - Jneid H AD - Section of Cardiology, Baylor College of Medicine, Houston, TX, USA. AD - Division of Cardiology, University of Texas Medical Branch, Houston, TX, USA. FAU - Virani, Salim S AU - Virani SS AD - Office of the Vice Provost (Research), The Aga Khan University, Karachi, Pakistan. AD - Section of Cardiology and Cardiovascular Research, Department of Medicine, Baylor College of Medicine, Houston, TX, USA. FAU - Sharma, Samin AU - Sharma S AD - Cardiac Catheterization Laboratory of the Cardiovascular Institute, Mount Sinai Hospital, New York, NY, USA. FAU - Krittanawong, Chayakrit AU - Krittanawong C AD - HumanX, Delaware, DE, USA. LA - eng PT - Journal Article PT - Review DEP - 20250702 PL - England TA - Expert Rev Cardiovasc Ther JT - Expert review of cardiovascular therapy JID - 101182328 SB - IM MH - Humans MH - *Gastrointestinal Hemorrhage/epidemiology/etiology/therapy MH - *Heart Diseases/complications/therapy/physiopathology MH - Incidence MH - *Cardiovascular Diseases/therapy/complications/physiopathology MH - Risk Factors MH - Hospitalization/statistics & numerical data MH - Patient Care Team/organization & administration OTO - NOTNLM OT - Cardiovascular disease OT - acute coronary syndrome (ACS) OT - aortic valve implantation OT - dual antiplatelet therapy (DAPT) OT - gastrointestinal bleeding (GIB) OT - heart failure OT - left ventricular assist device (LVAD) OT - post-coronary revascularization EDAT- 2025/06/16 11:10 MHDA- 2025/07/09 12:28 CRDT- 2025/06/16 05:13 PHST- 2025/07/09 12:28 [medline] PHST- 2025/06/16 11:10 [pubmed] PHST- 2025/06/16 05:13 [entrez] AID - 10.1080/14779072.2025.2520831 [doi] PST - ppublish SO - Expert Rev Cardiovasc Ther. 2025 Apr-May;23(5):197-207. doi: 10.1080/14779072.2025.2520831. Epub 2025 Jul 2. PMID- 40518172 OWN - NLM STAT- MEDLINE DCOM- 20260223 LR - 20260608 IS - 2047-9956 (Print) IS - 2047-9956 (Linking) VI - 33 IP - 2 DP - 2026 Feb 23 TI - Nine years' experience of an educational programme for patients treated with oral anticoagulants in a cardiology department. PG - 117-125 LID - 10.1136/ejhpharm-2024-004372 [doi] AB - OBJECTIVES: Oral anticoagulants present significant risks of iatrogenic complications. An educational programme dedicated to patients treated with vitamin-K antagonists (VKAs) or direct oral anticoagulants (DOACs) was set up in our cardiology department in 2013. The aim of this study is to describe and assess our programme's effectiveness, through evaluation of patients' skills and adherence, and to identify associated factors. METHODS: Skills were assessed through a questionnaire designed by our multidisciplinary team, targeting different items, and a global score was rated from 0 to 1. Adherence was assessed using a validated tool. Data from patients educated between January 2013 and December 2021 were collected retrospectively. R software was used for statistical analysis, performing Student or chi(2) tests for comparison of variables and univariate linear regression analysis for identification of variability factors. A value of p<0.05 was considered significant. RESULTS: Since 2013, 934 patients were educated, representing 14.7% of patients with oral anticoagulants in cardiology units. Mean+/-SD age was 68.7+/-16.4 years and the proportion of men was 58.9%. After hospital discharge, skills were assessed for 334 patients: mean score was 0.80+/-0.17 (minimum 0.1 to maximum 1). Younger patients presented higher scores than older ones (p<0.001). Adherence was assessed for 331 patients: levels were high, medium and low for 58%, 31.4% and 10.6% of them, respectively. Women presented higher adherence than men (p=0.01). Neither oral anticoagulant type (VKA or DOAC) nor characteristics of educational sessions presented significant association with skills or adherence. CONCLUSIONS: Our programme educated a large number of patients and seems to fit with VKAs and DOACs. Improvement areas could be to increase patient assessment and to reinforce education of elderly patients. CI - (c) European Association of Hospital Pharmacists 2026. No commercial re-use. See rights and permissions. Published by BMJ Group. FAU - Leclerc, Elisabeth AU - Leclerc E AUID- ORCID: 0000-0003-2963-2127 AD - Pharmacie a Usage Interieur (PUI), Pitie-Salpetriere University Hospital, AP-HP, Paris, Ile-de-France, France lec.elisabeth@gmail.com. FAU - Cavagna, Pauline AU - Cavagna P AD - Pharmacie a Usage Interieur (PUI), Pitie-Salpetriere University Hospital, AP-HP, Paris, Ile-de-France, France. AD - Universite Paris Cite, Inserm, PARCC, F-75015 Paris, France, Team integrative epidemiology of cardiovascular diseases, Paris, France. FAU - Cuquel, Anne-Claire AU - Cuquel AC AD - Pharmacie a Usage Interieur (PUI), Hopital Saint-Antoine, AP-HP, Paris, Ile-de-France, France. FAU - Chung, Cecile AU - Chung C AD - Pharmacie a Usage Interieur (PUI), Hopital Saint-Antoine, AP-HP, Paris, Ile-de-France, France. FAU - Gauthier, Victoria AU - Gauthier V AD - Pharmacie a Usage Interieur (PUI), Hopital Saint-Antoine, AP-HP, Paris, Ile-de-France, France. FAU - Lastennet, Diane AU - Lastennet D AD - Pharmacie a Usage Interieur (PUI), Hopital Saint-Antoine, AP-HP, Paris, Ile-de-France, France. FAU - Fernandez, Christine AU - Fernandez C AD - Pharmacie a Usage Interieur (PUI), Hopital Saint-Antoine, AP-HP, Paris, Ile-de-France, France. FAU - Brito, Ernesto AU - Brito E AD - Hopital Saint-Antoine Service Cardiologie, Paris, Ile-de-France, France. FAU - Cohen, Ariel AU - Cohen A AD - Hopital Saint-Antoine Service Cardiologie, Paris, Ile-de-France, France. AD - Unite INSERM UMRS 1166 Unite de recherche sur les maladies cardiovasculaires et metaboliques, Institut Hospitalo-Universitaire, Institut de Cardiometabolisme et Nutrition (ICAN), Sorbonne Universite, F-75013, Paris, France, Paris, France. FAU - Antignac, Marie AU - Antignac M AD - Pharmacie a Usage Interieur (PUI), Pitie-Salpetriere University Hospital, AP-HP, Paris, Ile-de-France, France. AD - Universite Paris Cite, Inserm, PARCC, F-75015 Paris, France, Team integrative epidemiology of cardiovascular diseases, Paris, France. LA - eng PT - Journal Article DEP - 20260223 PL - England TA - Eur J Hosp Pharm JT - European journal of hospital pharmacy : science and practice JID - 101578294 RN - 0 (Anticoagulants) SB - IM MH - Humans MH - *Anticoagulants/administration & dosage MH - Male MH - Female MH - Aged MH - Middle Aged MH - Retrospective Studies MH - Administration, Oral MH - *Patient Education as Topic/methods MH - *Cardiology Service, Hospital/trends MH - Aged, 80 and over MH - Surveys and Questionnaires MH - Medication Adherence OTO - NOTNLM OT - Anticoagulants OT - CARDIOLOGY OT - EDUCATION, PHARMACY OT - PHARMACY SERVICE, HOSPITAL OT - PUBLIC HEALTH COIS- Competing interests: None declared. EDAT- 2025/06/16 00:26 MHDA- 2026/02/24 00:29 CRDT- 2025/06/15 20:43 PHST- 2024/10/02 00:00 [received] PHST- 2025/06/02 00:00 [accepted] PHST- 2026/02/24 00:29 [medline] PHST- 2025/06/16 00:26 [pubmed] PHST- 2025/06/15 20:43 [entrez] AID - ejhpharm-2024-004372 [pii] AID - 10.1136/ejhpharm-2024-004372 [doi] PST - epublish SO - Eur J Hosp Pharm. 2026 Feb 23;33(2):117-125. doi: 10.1136/ejhpharm-2024-004372. PMID- 40517346 OWN - NLM STAT- MEDLINE DCOM- 20260306 LR - 20260813 IS - 1432-1971 (Electronic) IS - 0172-0643 (Print) IS - 0172-0643 (Linking) VI - 47 IP - 4 DP - 2026 Apr TI - Evaluating Vocal Cord Dysfunction in Infants Following the Norwood Operation: A National Pediatric Cardiology Quality Improvement Collaborative Analysis. PG - 1451-1458 LID - 10.1007/s00246-025-03919-0 [doi] AB - The Norwood operation is associated with postoperative complications including vocal cord dysfunction (VCD). This multicenter study evaluates VCD prevalence, risk factors, and diagnostic practices in a high-risk population. We performed a retrospective review of data from the National Pediatric Cardiology Quality Improvement Collaborative registry, examining infants who underwent the Norwood operation (S1P) with a surgical shunt and either completed stage 2 palliation or died after S1P discharge. The primary outcome was the endoscopic diagnosis of VCD after Norwood operation. Analysis of patient characteristics, operative details, and postoperative outcomes was performed to identify associations with VCD. Center variation in VCD was also assessed. Among the 2342 infants, VCD was diagnosed in 21.7%. Aortic arch reintervention (AAR) occurred in 19% and was associated with higher odds of VCD (OR 1.525, p = 0.001). Infants with VCD had higher rates of G-tube placement (42% vs. 22%, p < 0.001), though tracheostomy was uncommon (3.3%). Center analysis revealed lower rates of VCD at higher volume centers. Over time, AAR rates declined while VCD diagnoses increased. Our findings suggest that the Norwood operation plays a significant role in the development of VCD. The link between AAR and VCD is complex but may be influenced by institutional differences in evaluation practices. Given its impact on feeding and potential for persistence, VCD represents an important postoperative complication. Comprehensive postoperative care, low threshold to screen for VCD, and a multidisciplinary approach to management is needed to continually improve outcomes in infants undergoing the Norwood operation. CI - (c) 2025. The Author(s). FAU - Hashim, Liza AU - Hashim L AD - Division of Cardiology, Department of Pediatrics, University of Virginia Health Systems, Charlottesville, VA, USA. liza.hashim2510@gmail.com. AD - Pediatric Cardiology, UVA Medical Center, 1215 Lee Street, Charlottesville, VA, 22903, USA. liza.hashim2510@gmail.com. FAU - Chaves, Alicia AU - Chaves A AD - Division of Cardiology, Department of Pediatrics, University of Maryland School of Medicine, Baltimore, MD, USA. FAU - Conaway, Mark AU - Conaway M AD - Department of Public Health Sciences, University of Virginia, Charlottesville, VA, USA. FAU - Vergales, Jeffrey AU - Vergales J AD - Division of Cardiology, Department of Pediatrics, University of Virginia Health Systems, Charlottesville, VA, USA. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20250615 PL - United States TA - Pediatr Cardiol JT - Pediatric cardiology JID - 8003849 SB - IM MH - Humans MH - *Norwood Procedures/adverse effects MH - Retrospective Studies MH - Male MH - *Quality Improvement MH - Female MH - *Postoperative Complications/epidemiology/diagnosis MH - Infant, Newborn MH - Infant MH - *Vocal Cord Dysfunction/epidemiology/etiology/diagnosis MH - Risk Factors MH - Registries MH - United States/epidemiology MH - *Hypoplastic Left Heart Syndrome/surgery MH - Prevalence PMC - PMC12946325 OTO - NOTNLM OT - Norwood OT - Single ventricle OT - Vocal cord dysfunction COIS- Declarations. Competing interests: The authors declare no competing interests. EDAT- 2025/06/15 16:41 MHDA- 2026/03/06 13:43 PMCR- 2025/06/15 CRDT- 2025/06/15 11:03 PHST- 2025/04/10 00:00 [received] PHST- 2025/05/30 00:00 [accepted] PHST- 2026/03/06 13:43 [medline] PHST- 2025/06/15 16:41 [pubmed] PHST- 2025/06/15 11:03 [entrez] PHST- 2025/06/15 00:00 [pmc-release] AID - 10.1007/s00246-025-03919-0 [pii] AID - 3919 [pii] AID - 10.1007/s00246-025-03919-0 [doi] PST - ppublish SO - Pediatr Cardiol. 2026 Apr;47(4):1451-1458. doi: 10.1007/s00246-025-03919-0. Epub 2025 Jun 15. PMID- 40514338 OWN - NLM STAT- MEDLINE DCOM- 20250801 LR - 20250801 IS - 1444-2892 (Electronic) IS - 1443-9506 (Linking) VI - 34 IP - 8 DP - 2025 Aug TI - Requirements for the Delivery of an Australian Rapid Access Chest Pain Clinic. PG - 812-820 LID - S1443-9506(25)00172-6 [pii] LID - 10.1016/j.hlc.2025.02.108 [doi] AB - BACKGROUND: Rapid access chest pain clinics (RACPCs) are outpatient cardiac services designed to promptly assess and manage patients experiencing chest pain. Despite the establishment of 25 RACPCs across Australia, a standardised implementation framework has yet to be developed. This study aimed to identify the core components of successful delivery of an existing RACPC. METHOD: A qualitative process assessment study was conducted at an RACPC in a metropolitan, tertiary hospital in Tasmania, Australia from November 2022 to July 2023. Clinical observations and semi-structured interviews were conducted with seven RACPC clinicians. Deductive data analysis was undertaken according to a Context-Mechanism-Outcome framework. RESULTS: Core components of successful RACPC delivery included (1) a multidisciplinary team-based approach to care with discreet clinical roles, (2) timely patient review by RACPC clinicians within 30 days of referral, (3) embedded patient education, (4) ongoing clinical team training and education, and (5) a shared understanding of the RACPC service's identity and purpose. Challenges to RACPC delivery were also identified and included resource constraints and administrative burdens. CONCLUSIONS: Successful delivery of an RACPC model of care relies on a range of interrelated factors. These findings align with the broader theme of ongoing health service assessment as a driver for continuous quality improvement and care standards within RACPCs. Further research aimed at developing and implementing effective strategies to enhance service delivery is needed to determine a national model of care. CI - Copyright (c) 2025 The Authors. Published by Elsevier B.V. All rights reserved. FAU - Wilson, Annika AU - Wilson A AD - Menzies Institute for Medical Research, University of Tasmania, Hobart, Tas, Australia. FAU - Sutton, Laura AU - Sutton L AD - Menzies Institute for Medical Research, University of Tasmania, Hobart, Tas, Australia. FAU - Nash, Rose AU - Nash R AD - Tasmanian School of Medicine, College of Health and Medicine, University of Tasmania, Hobart, Tas, Australia. FAU - Jayasinghe, Senali AU - Jayasinghe S AD - Menzies Institute for Medical Research, University of Tasmania, Hobart, Tas, Australia. FAU - Sharman, James E AU - Sharman JE AD - Menzies Institute for Medical Research, University of Tasmania, Hobart, Tas, Australia. FAU - Black, J Andrew AU - Black JA AD - Menzies Institute for Medical Research, University of Tasmania, Hobart, Tas, Australia; Royal Hobart Hospital, Tasmanian Department of Health, Hobart, Tas, Australia. FAU - Chapman, Niamh AU - Chapman N AD - School of Health Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia. Electronic address: niamh.chapman@sydney.edu.au. LA - eng PT - Journal Article DEP - 20250612 PL - Australia TA - Heart Lung Circ JT - Heart, lung & circulation JID - 100963739 SB - IM MH - Humans MH - *Chest Pain/therapy/epidemiology/diagnosis MH - Australia MH - Male MH - Female MH - *Delivery of Health Care/organization & administration MH - *Pain Clinics/organization & administration OTO - NOTNLM OT - Cardiovascular diseases OT - Health services research OT - Multidisciplinary care OT - Patient care OT - Qualitative research COIS- Declaration of Competing Interests A.J.B. is an employee of the Royal Hobart Hospital Cardiology Department, Tasmania, Australia but was not involved in the analysis of the study. The remaining authors have no relevant financial or non-financial interests to disclose. EDAT- 2025/06/14 16:45 MHDA- 2025/08/02 10:43 CRDT- 2025/06/13 22:01 PHST- 2024/08/06 00:00 [received] PHST- 2025/02/20 00:00 [revised] PHST- 2025/02/26 00:00 [accepted] PHST- 2025/08/02 10:43 [medline] PHST- 2025/06/14 16:45 [pubmed] PHST- 2025/06/13 22:01 [entrez] AID - S1443-9506(25)00172-6 [pii] AID - 10.1016/j.hlc.2025.02.108 [doi] PST - ppublish SO - Heart Lung Circ. 2025 Aug;34(8):812-820. doi: 10.1016/j.hlc.2025.02.108. Epub 2025 Jun 12. PMID- 40513676 OWN - NLM STAT- MEDLINE DCOM- 20250705 LR - 20260821 IS - 1874-1754 (Electronic) IS - 0167-5273 (Linking) VI - 437 DP - 2025 Oct 15 TI - Assessing palliative care needs in worsening heart failure patients: Insights from OPPORTUNITIES registry. PG - 133491 LID - S0167-5273(25)00534-0 [pii] LID - 10.1016/j.ijcard.2025.133491 [doi] AB - BACKGROUND: Worsening heart failure (WHF) patients experience frequent hospitalizations and reduced quality of life (QoL). Palliative care (PC) is recognized as essential for HF management, but its integration represent an unmet need. OBJECTIVE: This study aimed to assess PC needs in WHF patients using the Palliative Care Needs Assessment Tool (PCNAT), and correlate the findings with biomarkers, clinical outcomes and prognostic scores. METHODS: 144 WHF patients were prospectively evaluated at the dedicated facility in Papa Giovanni XXIII Hospital in Bergamo, Northern Italy. Patients were stratified by the highest tertile of PCNAT, identifying two groups with PCNAT>/=10 or < 10. The primary outcome was the composite of all-cause mortality, HF hospitalization (HHF), emergency room (ER) visits or urgent clinical evaluation and referral to PC specialist. RESULTS: The median follow-up was 91 days. Thirty-three percent of patients (47/144) had a PCNAT score >/= 10. These patients had lower body mass index, worse NYHA class and more comorbidities, including chronic kidney disease, diabetes, and atrial fibrillation. They also showed worse biomarkers and lower guideline directed medical therapy use, with higher diuretic doses. Prognostic scores and QoL were significantly correlated with PCNAT score. Kaplan-Meier analysis confirmed higher clinical event rates in patients with higher PCNAT scores. Univariate and multivariate Cox regression analysis showed that PCNAT score was a significant independent predictor of clinical outcomes. CONCLUSION: PCNAT effectively stratifies WHF patients by PC needs, correlating with poorer clinical outcomes. Early integration of PC could improve patient-centred care, highlighting the need for systematic referral pathways. CI - Copyright (c) 2025 Elsevier B.V. All rights reserved. FAU - D'Elia, Emilia AU - D'Elia E AD - Cardiovascular Department, Papa Giovanni XXIII Hospital, Bergamo, Italy; Department of Medicine and Surgery, Milano Bicocca University, Milan, Italy. Electronic address: edelia@asst-pg23.it. FAU - Zucchetti, Ottavio AU - Zucchetti O AD - Cardiovascular Department, Papa Giovanni XXIII Hospital, Bergamo, Italy. FAU - Pedrazzoli, Francesco AU - Pedrazzoli F AD - Cardiovascular Department, Papa Giovanni XXIII Hospital, Bergamo, Italy. FAU - Cereda, Alberto AU - Cereda A AD - Cardiovascular Department, Papa Giovanni XXIII Hospital, Bergamo, Italy. FAU - Giaccherini, Cinzia AU - Giaccherini C AD - FROM Research Foundation E.T.S., Papa Giovanni XXIII Hospital, Bergamo, Italy. FAU - Sciatti, Edoardo AU - Sciatti E AD - Cardiovascular Department, Papa Giovanni XXIII Hospital, Bergamo, Italy. FAU - D'Isa, Salvatore AU - D'Isa S AD - Cardiovascular Department, Papa Giovanni XXIII Hospital, Bergamo, Italy. FAU - Di Odoardo, Luca AU - Di Odoardo L AD - Cardiovascular Department, Papa Giovanni XXIII Hospital, Bergamo, Italy. FAU - Tomasoni, Laura AU - Tomasoni L AD - Direzione Socio Sanitaria, Papa Giovanni XXIII Hospital, Bergamo, Italy. FAU - Gavazzi, Antonello AU - Gavazzi A AD - FROM Research Foundation E.T.S., Papa Giovanni XXIII Hospital, Bergamo, Italy. FAU - Gori, Mauro AU - Gori M AD - Cardiovascular Department, Papa Giovanni XXIII Hospital, Bergamo, Italy; Department of Medicine and Surgery, Milano Bicocca University, Milan, Italy. FAU - Marchesi, Roberta AU - Marchesi R AD - Palliative Care Department, Papa Giovanni XXIII Hospital, Bergamo, Italy. FAU - Cesa, Simonetta AU - Cesa S AD - Direzione Socio Sanitaria, Papa Giovanni XXIII Hospital, Bergamo, Italy. FAU - Senni, Michele AU - Senni M AD - Cardiovascular Department, Papa Giovanni XXIII Hospital, Bergamo, Italy; Department of Medicine and Surgery, Milano Bicocca University, Milan, Italy. LA - eng PT - Journal Article DEP - 20250611 PL - Netherlands TA - Int J Cardiol JT - International journal of cardiology JID - 8200291 SB - IM MH - Humans MH - Male MH - Female MH - *Heart Failure/therapy/diagnosis/mortality/psychology/epidemiology MH - *Palliative Care/methods/trends MH - Aged MH - *Registries MH - Prospective Studies MH - Italy/epidemiology MH - Middle Aged MH - *Needs Assessment MH - Aged, 80 and over MH - Follow-Up Studies MH - *Disease Progression MH - *Quality of Life/psychology MH - Hospitalization/trends OTO - NOTNLM OT - Multidisciplinary approach OT - Outcome OT - Palliative care OT - Risk stratification OT - Worsening heart failure EDAT- 2025/06/14 16:45 MHDA- 2025/07/06 06:18 CRDT- 2025/06/13 19:13 PHST- 2025/02/04 00:00 [received] PHST- 2025/05/20 00:00 [revised] PHST- 2025/06/06 00:00 [accepted] PHST- 2025/07/06 06:18 [medline] PHST- 2025/06/14 16:45 [pubmed] PHST- 2025/06/13 19:13 [entrez] AID - S0167-5273(25)00534-0 [pii] AID - 10.1016/j.ijcard.2025.133491 [doi] PST - ppublish SO - Int J Cardiol. 2025 Oct 15;437:133491. doi: 10.1016/j.ijcard.2025.133491. Epub 2025 Jun 11. PMID- 40511913 OWN - NLM STAT- MEDLINE DCOM- 20250911 LR - 20260813 IS - 1098-6618 (Electronic) IS - 0893-8512 (Print) IS - 0893-8512 (Linking) VI - 38 IP - 3 DP - 2025 Sep 11 TI - Bacterial and fungal infections in persons who inject drugs. PG - e0016223 LID - 10.1128/cmr.00162-23 [doi] LID - e00162-23 AB - SUMMARYPersons who inject drugs are at increased risk of bacterial and fungal injecting-related infections due to many physiological, societal, and structural factors. An estimated 15 million persons inject drugs worldwide, with recent increases in the burden of injecting-related infections. Acquisition of these infections has distinct pathophysiology and microbiology related to drug supply, drug composition, and the process of injecting. Clinical management of these infections is complicated by usual factors such as the need for source control and effective antibiotics, as well as the complex challenges faced by persons who inject drugs while in hospital. These challenges include drug withdrawal, difficult pain control related to opioid tolerance, stigma, discrimination, and lack of access to outpatient parenteral antibiotic therapy, which can lead to high rates of patient-directed discharge and non-completion of treatment with subsequent poor outcomes. This review seeks to provide an evidence-based summary of what is known about the risks, epidemiology, microbiology, and presentation of injecting-related bacterial and fungal infections, as well as provide recommendations for treatment, including pharmacological considerations, opportunistic screening, multidisciplinary team care, and approaches to outpatient therapy. It also provides insight into the medicolegal and ethical considerations of care for persons who inject drugs and a first-person perspective of someone with lived experience. FAU - Masters, Jeffrey AU - Masters J AUID- ORCID: 0009-0009-7339-9685 AD - Kirby Institute UNSW, Kensington, New South Wales, Australia. RINGGOLD: 2786 AD - Department of Infectious Diseases, Royal Prince Alfred Hospital, Sydney, Australia. ROR: https://ror.org/05gpvde20 FAU - Goodman-Meza, David AU - Goodman-Meza D AD - Kirby Institute UNSW, Kensington, New South Wales, Australia. RINGGOLD: 2786 FAU - Russell, Danielle AU - Russell D AD - Kirby Institute UNSW, Kensington, New South Wales, Australia. RINGGOLD: 2786 FAU - Marks, Laura AU - Marks L AD - Washington University in St Louis School of Medicine, St. Louis, Missouri, USA. RINGGOLD: 12275 FAU - McCreary, Erin AU - McCreary E AUID- ORCID: 0000-0001-6705-2225 AD - Department of Medicine, Division of Infectious Diseases, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA. ROR: https://ror.org/01an3r305 FAU - Jacka, Brendan AU - Jacka B AD - Kirby Institute UNSW, Kensington, New South Wales, Australia. RINGGOLD: 2786 FAU - Seear, Kate AU - Seear K AD - School of Law, Deakin University, Melbourne, Victoria, Australia. ROR: https://ror.org/02czsnj07 FAU - Davis, Joshua S AU - Davis JS AUID- ORCID: 0000-0001-9864-5699 AD - School of Medicine and Public Health, University of Newcastle, Newcastle, New South Wales, Australia. ROR: https://ror.org/00eae9z71 AD - Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia. RINGGOLD: 10095. ROR: https://ror.org/048zcaj52 AD - Department of Infectious Diseases, John Hunter Hospital, Newcastle, New South Wales, Australia. ROR: https://ror.org/0187t0j49 FAU - Matthews, Gail AU - Matthews G AD - Kirby Institute UNSW, Kensington, New South Wales, Australia. RINGGOLD: 2786 AD - Department of Infectious Diseases, St Vincent's Hospital, Darlinghurst, New South Wales, Australia. RINGGOLD: 60078 FAU - Martinello, Marianne AU - Martinello M AD - Kirby Institute UNSW, Kensington, New South Wales, Australia. RINGGOLD: 2786 AD - Department of Infectious Diseases, Prince of Wales Hospital, Sydney, Australia. ROR: https://ror.org/022arq532 FAU - Tong, Steven Y C AU - Tong SYC AUID- ORCID: 0000-0002-1368-8356 AD - Department of Infectious Diseases, The University of Melbourne Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia. ROR: https://ror.org/01ej9dk98 AD - Victorian Infectious Diseases Service, Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia. RINGGOLD: 534133 FAU - Dore, Gregory J AU - Dore GJ AUID- ORCID: 0000-0002-4741-2622 AD - Kirby Institute UNSW, Kensington, New South Wales, Australia. RINGGOLD: 2786 AD - Department of Infectious Diseases, St Vincent's Hospital, Darlinghurst, New South Wales, Australia. RINGGOLD: 60078 LA - eng GR - 2008276/National Health and Medical Research Council/ GR - 2016698/National Health and Medical Research Council/ PT - Journal Article PT - Review DEP - 20250613 PL - United States TA - Clin Microbiol Rev JT - Clinical microbiology reviews JID - 8807282 SB - IM MH - Humans MH - *Mycoses/epidemiology/drug therapy/etiology/microbiology/diagnosis MH - *Substance Abuse, Intravenous/complications/microbiology MH - *Bacterial Infections/epidemiology/drug therapy/microbiology/etiology/diagnosis PMC - PMC12424395 OTO - NOTNLM OT - bacteremia OT - infective endocarditis OT - injecting-related infections OT - intravenous drug use OT - outpatient parenteral antibiotic therapy OT - persons who inject drugs COIS- The authors declare no conflict of interest. EDAT- 2025/06/13 12:30 MHDA- 2025/09/11 12:30 PMCR- 2026/06/13 CRDT- 2025/06/13 09:02 PHST- 2025/09/11 12:30 [medline] PHST- 2025/06/13 12:30 [pubmed] PHST- 2025/06/13 09:02 [entrez] PHST- 2026/06/13 00:00 [pmc-release] AID - cmr00162-23 [pii] AID - cmr.00162-23 [pii] AID - 10.1128/cmr.00162-23 [doi] PST - ppublish SO - Clin Microbiol Rev. 2025 Sep 11;38(3):e0016223. doi: 10.1128/cmr.00162-23. Epub 2025 Jun 13. PMID- 40510395 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250614 IS - 2042-8812 (Print) IS - 2042-8812 (Electronic) IS - 2042-8812 (Linking) VI - 2025 IP - 6 DP - 2025 Jun TI - Hepatic rupture as a life-threatening emergency and rare complication of CPR with the CORPULS device. PG - rjaf409 LID - 10.1093/jscr/rjaf409 [doi] LID - rjaf409 AB - Cardiopulmonary resuscitation (CPR) is a life-saving intervention to restore circulation in cardiac arrest patients, with chest compressions being its cornerstone. However, CPR is associated with complications, predominantly chest wall injuries such as rib and sternum fractures. Rarely, intra-abdominal injuries, including liver rupture, can occur, posing life-threatening bleeding risks that require emergent intervention. Recognition of these less common complications can lead to significant improvements in post-CPR protocols and patient outcomes. Raising awareness of visceral injuries after resuscitation highlights the critical need for systematic evaluation and timely intervention. Here, we present a case of a patient with hepatic laceration following CPR with a CORPULS system, successfully identified and managed through a multidisciplinary approach. We propose the adoption of a structured post-CPR abdominal assessment protocol in high-risk patients who have undergone resuscitation. CI - Published by Oxford University Press and JSCR Publishing Ltd 2025. FAU - Marin-Cuartas, Tomas AU - Marin-Cuartas T AD - Department of General and Visceral Surgery, Helios Clinics Schwerin, University Campus Medical School Hamburg, Wismarsche Str. 393397, 19055 Schwerin, Germany. FAU - Ponitz, Steffen AU - Ponitz S AD - Department of General and Visceral Surgery, Helios Clinics Schwerin, University Campus Medical School Hamburg, Wismarsche Str. 393397, 19055 Schwerin, Germany. FAU - Scholz, Steffi AU - Scholz S AD - Department of General and Visceral Surgery, Helios Clinics Schwerin, University Campus Medical School Hamburg, Wismarsche Str. 393397, 19055 Schwerin, Germany. FAU - Ritz, Jorg-Peter AU - Ritz JP AD - Department of General and Visceral Surgery, Helios Clinics Schwerin, University Campus Medical School Hamburg, Wismarsche Str. 393397, 19055 Schwerin, Germany. FAU - Sporn, Judith AU - Sporn J AD - Department of General and Visceral Surgery, Helios Clinics Schwerin, University Campus Medical School Hamburg, Wismarsche Str. 393397, 19055 Schwerin, Germany. FAU - Protzel, Jana AU - Protzel J AD - Department of Intensive Care Medicine, Helios Clinics Schwerin, Wismarsche Str. 393-397, 19055 Schwerin, Germany. LA - eng PT - Journal Article DEP - 20250612 PL - England TA - J Surg Case Rep JT - Journal of surgical case reports JID - 101560169 PMC - PMC12161492 OTO - NOTNLM OT - CORPULS system OT - CPR-related injury OT - hepatic rupture OT - nonskeletal injuries OT - visceral injuries COIS- None declared. EDAT- 2025/06/13 06:34 MHDA- 2025/06/13 06:35 PMCR- 2025/06/12 CRDT- 2025/06/13 05:08 PHST- 2025/03/29 00:00 [received] PHST- 2025/05/14 00:00 [accepted] PHST- 2025/06/13 06:35 [medline] PHST- 2025/06/13 06:34 [pubmed] PHST- 2025/06/13 05:08 [entrez] PHST- 2025/06/12 00:00 [pmc-release] AID - rjaf409 [pii] AID - 10.1093/jscr/rjaf409 [doi] PST - epublish SO - J Surg Case Rep. 2025 Jun 12;2025(6):rjaf409. doi: 10.1093/jscr/rjaf409. eCollection 2025 Jun. PMID- 40506689 OWN - NLM STAT- MEDLINE DCOM- 20261019 LR - 20261019 IS - 1467-1107 (Electronic) IS - 1047-9511 (Linking) VI - 35 IP - 6 DP - 2025 Jun TI - Standardising discharge post-surgical pain control: a quality improvement project. PG - 1178-1183 LID - 10.1017/S1047951125100474 [doi] AB - Healthcare-prescribed opioids are a known contributor to the opioid epidemic. Locally, there was an identified opportunity to improve opioid prescribing practices in cardiac surgical patients. The cardiac surgical team sought to standardise prescribing practices in postoperative patients and reduce opioid prescriptions at discharge. The improvement was undertaken at a large midwestern freestanding children's hospital with over 400 beds and 120 cardiac surgeries annually. A multidisciplinary team was formed, using the model for Improvement to guide the improvement work. The key improvement interventions included standardised evidence-based prescribing guidelines based patient age and surgical approach, enhanced pain management with non-opioid medications, and integration of prescribing guidelines into the electronic health record. The primary outcome measure was rate of compliance with the prescribing guidelines and secondary measures included morphine equivalent dosing at discharge, opioid-free discharge, and length of stay. A balancing measure of opioid re-prescriptions was tracked. There were 289 patients included in the primary study period (January 2019 through December 2021). Sustainability of key outcomes was tracked though December 2022. The guideline compliance increased from 24% to 100%. The morphine equivalent dosing decreased to 22.5 in 2021 then 0 in 2022, from baseline of 36.25 in 2019. Opioid-free discharges decreased from 8% (2019) to 1.5% (2021) and 0% in 2022. Establishment and compliance with standardised guidelines for post-operative cardiac surgical pain management yielded a reduction in morphine equivalent dosing, an increase opioid-free discharges, and no increase in length of stay or opioid re-prescriptions. FAU - Wheller, Kathyrn M AU - Wheller KM AUID- ORCID: 0009-0005-3641-7347 AD - Department of Surgical Services, Akron Children's Hospital, Akron, OH, USA. FAU - Stewart, Robert D AU - Stewart RD AD - Department of Surgical Services, Akron Children's Hospital, Akron, OH, USA. FAU - Breedlove, Kristen L AU - Breedlove KL AD - Department of Surgical Services, Akron Children's Hospital, Akron, OH, USA. FAU - Feesler, Frances AU - Feesler F AD - Department of Surgical Services, Akron Children's Hospital, Akron, OH, USA. FAU - Padrutt, Gregory C AU - Padrutt GC AD - Department of Surgical Services, Akron Children's Hospital, Akron, OH, USA. FAU - Bigham, Michael T AU - Bigham MT AD - Department of Pediatrics, Akron Children's Hospital, Akron, OH, USA. LA - eng PT - Journal Article DEP - 20250613 PL - England TA - Cardiol Young JT - Cardiology in the young JID - 9200019 RN - 0 (Analgesics, Opioid) SB - IM MH - Humans MH - *Postoperative Pain/drug therapy MH - *Quality Improvement MH - *Patient Discharge/standards MH - *Analgesics, Opioid/therapeutic use MH - *Pain Management/methods/standards MH - *Cardiac Surgical Procedures/adverse effects MH - Guideline Adherence MH - Female MH - Male MH - Child MH - *Practice Patterns, Physicians'/standards MH - Practice Guidelines as Topic OTO - NOTNLM OT - Opioids OT - care standardisation OT - pain management OT - postoperative pain EDAT- 2025/06/13 00:27 MHDA- 2026/10/19 11:35 CRDT- 2025/06/12 23:23 PHST- 2026/10/19 11:35 [medline] PHST- 2025/06/13 00:27 [pubmed] PHST- 2025/06/12 23:23 [entrez] AID - S1047951125100474 [pii] AID - 10.1017/S1047951125100474 [doi] PST - ppublish SO - Cardiol Young. 2025 Jun;35(6):1178-1183. doi: 10.1017/S1047951125100474. Epub 2025 Jun 13. PMID- 40506157 OWN - NLM STAT- MEDLINE DCOM- 20250612 LR - 20250612 IS - 1551-7136 (Print) IS - 1551-7136 (Linking) VI - 21 IP - 3 DP - 2025 Jul TI - Radionuclide Imaging of Infective Endocarditis. PG - 443-459 LID - S1551-7136(25)00008-X [pii] LID - 10.1016/j.hfc.2025.01.008 [doi] AB - Infective endocarditis (IE) is associated with high morbidity and mortality. Early diagnosis is crucial for adequate patient management. Due to difficulties in the diagnosis, a multidisciplinary discussion in addition to the integration of clinical signs, microbiology data, and imaging data is used. Imaging, including echocardiography, molecular imaging techniques, and coronary CT angiography (CTA) is central to detect infections involving heart valves and implanted cardiovascular devices, also allowing for early detection of septic emboli and metastatic. This article describes the main clinical application of white blood cell SPECT/CT and [(18)F]FDG-PET/CT and CTA in IE and infections associated with cardiovascular implantable electronic devices. CI - Copyright (c) 2025 Elsevier Inc. All rights reserved. FAU - Ferro, Paola AU - Ferro P AD - Nuclear Medicine Department ASST Ospedale Papa Giovanni XXIII Bergamo (Italy), Piazza OMS 1, Bergamo 24127, Italy. FAU - Boni, Roberto AU - Boni R AD - Nuclear Medicine Department ASST Ospedale Papa Giovanni XXIII Bergamo (Italy), Piazza OMS 1, Bergamo 24127, Italy. FAU - Bartoli, Francesco AU - Bartoli F AD - Department of Translational Research and Advanced Technologies in Medicine and Surgery, Regional Center of Nuclear Medicine, University of Pisa, Via Roma 57, Pisa I-56126, Italy. FAU - Lazzeri, Francesca AU - Lazzeri F AD - Department of Translational Research and Advanced Technologies in Medicine and Surgery, Regional Center of Nuclear Medicine, University of Pisa, Via Roma 57, Pisa I-56126, Italy. FAU - Slart, Riemer H J A AU - Slart RHJA AD - Medical Imaging Center, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, the Netherlands. FAU - Erba, Paola A AU - Erba PA AD - Department of Medicine and Surgery, University of Milan Bicocca and Nuclear Medicine Unit ASST Ospedale Papa Giovanni XXIII Bergamo (Italy), Piazza OMS 1, Bergamo 24127, Italy. Electronic address: paolaanna.erba@unimib.it. LA - eng PT - Journal Article PT - Review PL - United States TA - Heart Fail Clin JT - Heart failure clinics JID - 101231934 RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18) SB - IM MH - Humans MH - *Endocarditis/diagnostic imaging MH - Positron Emission Tomography Computed Tomography/methods MH - Fluorodeoxyglucose F18 MH - Coronary Angiography/methods MH - Echocardiography OTO - NOTNLM OT - Duke/ESC criteria OT - Echocardiography OT - Infections associated with cardiovascular implantable electronic devices (CIED) OT - Infectious endocarditis (IE) OT - Labeled leukocyte (WBC) imaging OT - PET/CT imaging OT - SPECT/CT imaging OT - diagnosis EDAT- 2025/06/13 00:27 MHDA- 2025/06/13 00:28 CRDT- 2025/06/12 20:56 PHST- 2025/06/13 00:28 [medline] PHST- 2025/06/13 00:27 [pubmed] PHST- 2025/06/12 20:56 [entrez] AID - S1551-7136(25)00008-X [pii] AID - 10.1016/j.hfc.2025.01.008 [doi] PST - ppublish SO - Heart Fail Clin. 2025 Jul;21(3):443-459. doi: 10.1016/j.hfc.2025.01.008. PMID- 40497123 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250826 IS - 2434-0790 (Electronic) IS - 2434-0790 (Linking) VI - 7 IP - 6 DP - 2025 Jun 10 TI - Impact of Tailored Multidisciplinary Cardiac Rehabilitation on Patients With Cardiovascular Diseases and Multimorbidity in Convalescent Rehabilitation Hospitals in Japan　- A Multicenter, Prospective Observational Study. PG - 403-410 LID - 10.1253/circrep.CR-24-0137 [doi] AB - BACKGROUND: Data on cardiac rehabilitation (CR) outcomes in patients with cardiovascular disease (CVD), frailty, and multimorbidity in post-acute settings are limited. This study aimed to evaluate the feasibility and efficacy of individualized, multidisciplinary CR in convalescent rehabilitation hospitals (cRHs). METHODS AND RESULTS: This multicenter, prospective, observational study included 72 consecutive patients transferred from acute care hospitals. Personalized CR programs were implemented in cRHs. Primary outcomes were changes in the Barthel Index (BI) and functional independence measure (FIM) scores. Secondary outcomes included assessments of physical and cognitive function, and nutritional status. Mean participant age was 78.6+/-11.8 years. Prior to admission, 51.4% experienced acute decompensated heart failure (ADHF). The average length of stay was 59.5+/-39.2 days. BI and FIM scores improved from admission to discharge. The following parameters improved: Short Physical Performance Battery, knee extensor strength, comfortable gait speed, 6-min walk distance, New York Heart Association classification, and cognitive function (Mini-Mental State Examination). Discharge dispositions included 53 (73.6%) home discharges, and 19 (26.4%) outpatient CR post-discharges. Patients with post-ADHF and patients with other conditions both showed functional improvements, but ∆BI and ∆FIM were lower in the post-ADHF group. CONCLUSIONS: Tailored multidisciplinary CR in cRHs effectively improves daily living activities and physical and cognitive outcomes in patients with CVD with complex conditions. Expanded use of these hospitals may help address clinical challenges. CI - Copyright (c) 2025, THE JAPANESE CIRCULATION SOCIETY. FAU - Miyazawa, Ryo AU - Miyazawa R AD - Cardiac Rehabilitation Unit, Showa Medical University Fujigaoka Rehabilitation Hospital Yokohama Japan. AD - School of Nursing and Rehabilitation Sciences, Showa Medical University Yokohama Japan. FAU - Iso, Yoshitaka AU - Iso Y AD - Cardiac Rehabilitation Unit, Showa Medical University Fujigaoka Rehabilitation Hospital Yokohama Japan. AD - Division of Cardiology, Department of Internal Medicine, Showa Medical University Fujigaoka Hospital Yokohama Japan. FAU - Yamamoto, Satoshi AU - Yamamoto S AD - Department of Rehabilitation, IMS Itabashi Rehabilitation Hospital Tokyo Japan. FAU - Matsuo, Tomohiro AU - Matsuo T AD - Department of Rehabilitation, Nishi Memorial Port-island Rehabilitation Hospital Kobe Japan. FAU - Morisawa, Tomoyuki AU - Morisawa T AD - Department of Physical Therapy, Faculty of Health Sciences, Juntendo University Tokyo Japan. FAU - Takahashi, Tetsuya AU - Takahashi T AD - Department of Physical Therapy, Faculty of Health Sciences, Juntendo University Tokyo Japan. FAU - Makita, Shigeru AU - Makita S AD - Department of Rehabilitation Medicine, Saitama Medical University International Medical Center Saitama Japan. AD - Department of Rehabilitation Medicine, Kawaguchi Cupola Rehabilitation Hospital Saitama Japan. FAU - Fujimoto, Shigeru AU - Fujimoto S AD - Division of Neurology, Department of Medicine, Jichi Medical University Tochigi Japan. LA - eng PT - Journal Article DEP - 20250422 PL - Japan TA - Circ Rep JT - Circulation reports JID - 101746642 PMC - PMC12148360 OTO - NOTNLM OT - Cardiac rehabilitation OT - Convalescent rehabilitation hospitals OT - Heart failure OT - Multimorbidity COIS- T.T. is an Editorial Team member of Circulation Reports. EDAT- 2025/06/11 11:29 MHDA- 2025/06/11 11:30 PMCR- 2025/04/22 CRDT- 2025/06/11 05:30 PHST- 2024/10/31 00:00 [received] PHST- 2025/02/09 00:00 [revised] PHST- 2025/02/24 00:00 [accepted] PHST- 2025/06/11 11:30 [medline] PHST- 2025/06/11 11:29 [pubmed] PHST- 2025/06/11 05:30 [entrez] PHST- 2025/04/22 00:00 [pmc-release] AID - 10.1253/circrep.CR-24-0137 [doi] PST - epublish SO - Circ Rep. 2025 Apr 22;7(6):403-410. doi: 10.1253/circrep.CR-24-0137. eCollection 2025 Jun 10. PMID- 40488688 OWN - NLM STAT- MEDLINE DCOM- 20251215 LR - 20260619 IS - 1536-3732 (Electronic) IS - 1049-2275 (Print) IS - 1049-2275 (Linking) VI - 36 IP - 8 DP - 2025 Nov-Dec 01 TI - Impact of SMAD6 Variants on Neurodevelopment in Craniosynostosis. PG - 3059-3064 LID - 10.1097/SCS.0000000000011461 [doi] AB - BACKGROUND: Some pathogenic variants in Smad6 are implicated in midline craniosynostosis, particularly in metopic synostosis. These variants increase the risk of both nonsyndromic and syndromic presentations. Craniosynostosis, whether treated surgically or not, can be associated with developmental delays. METHODS: The authors aimed to assess developmental outcomes in children with craniosynostosis carrying a Smad6 variant. A cohort of children who underwent craniosynostosis surgery at the national reference center for craniosynostosis at Lyon University Hospital (2018-2023) was studied. Children with Smad6 variants were followed postsurgery to evaluate their neuropsychological development. Evaluations were conducted by a multidisciplinary team comprising neurosurgeons, clinical geneticists, and neuropsychologists. RESULTS: Among 249 patients with craniosynostosis, 11 were identified with Smad6 variants. Of these, 7 presented with trigonocephaly, 2 with scaphocephaly, and 2 with oxycephaly. Patients with SMAD6 gene variants followed by the department were between 18 and 121 months, with a sex ratio of 6 girls to 5 boys. None of these children exhibited cardiac abnormalities. Mild walking and/or language acquisition delays are observed in 8 children, 5 of them benefit from ambulatory-specific care, and only one cannot benefit from a normal schooling. CONCLUSION: Neuropsychological follow-up is crucial for children with craniosynostosis. Most patients with SMAD6 variants show mild to moderate effects, with developmental scores normalizing with appropriate therapies. However, the impact of Smad6, especially in cases with additional variants, requires further study. Early intervention remains key to optimizing cognitive and behavioral outcomes. CI - Copyright (c) 2025 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of Mutaz B. Habal, MD. FAU - Verlut, Isabelle AU - Verlut I AD - Department of Pediatric Neurosurgery, French Referral Center for Craniosynostosis, Hopital Femme Mere-Enfant Hospices Civils de Lyon, University of Lyon 1, INSERM. FAU - Guernouche, Sofia AU - Guernouche S AUID- ORCID: 0000-0001-6978-3179 AD - Department of Pediatric Neurosurgery, French Referral Center for Craniosynostosis, Hopital Femme Mere-Enfant Hospices Civils de Lyon, University of Lyon 1, INSERM. FAU - Rossi, Massimiliano AU - Rossi M AD - Department of Genetics, Lyon University Hospitals, INSERM U1028, CNRS UMR5292, Centre de Recherche en Neurosciences. FAU - Szathmari, Alexandru AU - Szathmari A AD - Department of Pediatric Neurosurgery, French Referral Center for Craniosynostosis, Hopital Femme Mere-Enfant Hospices Civils de Lyon, University of Lyon 1, INSERM. FAU - Beuriat, Pierre A AU - Beuriat PA AD - Department of Pediatric Neurosurgery, French Referral Center for Craniosynostosis, Hopital Femme Mere-Enfant Hospices Civils de Lyon, University of Lyon 1, INSERM. FAU - Chatron, Nicolas AU - Chatron N AD - Department of Genetics, Lyon University Hospitals, INSERM U1028, CNRS UMR5292, Centre de Recherche en Neurosciences. FAU - Chauvel-Picard, Julie AU - Chauvel-Picard J AD - Department of Pediatric Cranio-Maxillo-Facial Surgery, Hopital Femme Mere Enfant, Universite Claude Bernard, Lyon. FAU - Mottolese, Carmine AU - Mottolese C AD - Department of Pediatric Neurosurgery, French Referral Center for Craniosynostosis, Hopital Femme Mere-Enfant Hospices Civils de Lyon, University of Lyon 1, INSERM. FAU - Monin, Pauline AU - Monin P AD - Department of Genetics, Lyon University Hospitals, INSERM U1028, CNRS UMR5292, Centre de Recherche en Neurosciences. FAU - Vinchon, Matthieu AU - Vinchon M AD - Department of Pediatric Neurosurgery, French Referral Center for Craniosynostosis, Hopital Femme Mere-Enfant Hospices Civils de Lyon, University of Lyon 1, INSERM. FAU - Collet, Corinne AU - Collet C AD - Department of Genetics, Robert Debre Hospital, Inserm, Paris, France. FAU - Di Rocco, Federico AU - Di Rocco F AD - Department of Pediatric Neurosurgery, French Referral Center for Craniosynostosis, Hopital Femme Mere-Enfant Hospices Civils de Lyon, University of Lyon 1, INSERM. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20250609 PL - United States TA - J Craniofac Surg JT - The Journal of craniofacial surgery JID - 9010410 RN - 0 (Smad6 Protein) RN - 0 (SMAD6 protein, human) SB - IM MH - Humans MH - *Craniosynostoses/genetics/surgery MH - Female MH - Male MH - *Smad6 Protein/genetics MH - Infant MH - Child, Preschool MH - *Developmental Disabilities/genetics/etiology PMC - PMC12537030 OTO - NOTNLM OT - Craniosynostosis OT - SMAD6 OT - genetic OT - neurodevelopment COIS- The authors report no conflicts of interest. EDAT- 2025/06/09 12:29 MHDA- 2025/12/15 13:10 PMCR- 2025/10/20 CRDT- 2025/06/09 10:32 PHST- 2025/04/01 00:00 [received] PHST- 2025/04/01 00:00 [accepted] PHST- 2025/12/15 13:10 [medline] PHST- 2025/06/09 12:29 [pubmed] PHST- 2025/06/09 10:32 [entrez] PHST- 2025/10/20 00:00 [pmc-release] AID - 00001665-202511000-00083 [pii] AID - SCS-25-0450 [pii] AID - 10.1097/SCS.0000000000011461 [doi] PST - ppublish SO - J Craniofac Surg. 2025 Nov-Dec 01;36(8):3059-3064. doi: 10.1097/SCS.0000000000011461. Epub 2025 Jun 9. PMID- 40488258 OWN - NLM STAT- MEDLINE DCOM- 20251121 LR - 20251123 IS - 1475-6773 (Electronic) IS - 0017-9124 (Print) IS - 0017-9124 (Linking) VI - 60 IP - 6 DP - 2025 Dec TI - Staff Experiences With Implementation of the Referral Coordination Initiative. PG - e14654 LID - 10.1111/1475-6773.14654 [doi] LID - e14654 AB - OBJECTIVE: To understand VHA staff experiences with the referral coordination initiative (RCI) following nationwide dissemination. STUDY SETTING AND DESIGN: RCI uses a team-based approach to improve the timeliness, efficiency, and patient-centeredness of specialty care referrals, while redistributing the time-intensive triage tasks from specialist providers to nurses. To assess frontline experiences with RCI, we purposively sampled four VHA sites for qualitative interviews, ensuring variability around the use of nurses in triage and the organization of scheduling staff within three high-volume specialties: cardiology, gastroenterology, and pulmonary. From May to December 2023, we conducted semi-structured interviews with 68 VHA staff members who engaged in various aspects of referral coordination, including interviews with nurses, schedulers, specialists, and referring providers. DATA SOURCES AND ANALYTIC SAMPLE: We asked staff about challenges and facilitators to RCI implementation and maintenance. If certain RCI elements (e.g., nurse triage) were not implemented, we asked about anticipated challenges and facilitators. We analyzed qualitative data concurrently with data collection using a rapid matrix analysis approach. PRINCIPAL FINDINGS: Staff expressed varying perceptions around the effects of RCI and its impacts on specialist burden and clinic staffing. We identified challenges to RCI, including (1) inconsistent staff perceptions around program goals, (2) mixed perceptions around the appropriateness of nurse triage, (3) lack of clear specialty-specific triage guidelines, and (4) limited coordination with schedulers. Key facilitators of RCI included (1) leveraging existing relationships and nurses with existing specialty-specific expertise, and (2) building relationships and clear triage guidelines with specialties. CONCLUSIONS: To streamline patient-centered referrals, health systems should foster working relationships between referral management teams and specialties. While nurse-led triage can improve efficiency, concerted efforts are necessary to train nurses and develop clear triage criteria. CI - Published 2025. This article is a U.S. Government work and is in the public domain in the USA. FAU - Mog, Ashley C AU - Mog AC AUID- ORCID: 0000-0001-7622-3217 AD - VA Collaborative Evaluation Center (VACE), Veterans Health Administration, Seattle, Washington, USA. AD - VA Collaborative Evaluation Center (VACE), Veterans Health Administration, Denver, Colorado, USA. AD - Seattle-Denver Center of Innovation for Veteran-Centered and Value-Driven Care (COIN), Veterans Health Administration, Seattle, Washington, USA. FAU - Woolery, Anna AU - Woolery A AD - VA Collaborative Evaluation Center (VACE), Veterans Health Administration, Seattle, Washington, USA. AD - VA Collaborative Evaluation Center (VACE), Veterans Health Administration, Denver, Colorado, USA. AD - Seattle-Denver Center of Innovation for Veteran-Centered and Value-Driven Care (COIN), Veterans Health Administration, Denver, Colorado, USA. FAU - Fehling, Kelty AU - Fehling K AD - VA Collaborative Evaluation Center (VACE), Veterans Health Administration, Seattle, Washington, USA. AD - VA Collaborative Evaluation Center (VACE), Veterans Health Administration, Denver, Colorado, USA. AD - Seattle-Denver Center of Innovation for Veteran-Centered and Value-Driven Care (COIN), Veterans Health Administration, Denver, Colorado, USA. FAU - Makkawi, Makkawi AU - Makkawi M AD - VA Collaborative Evaluation Center (VACE), Veterans Health Administration, Seattle, Washington, USA. AD - VA Collaborative Evaluation Center (VACE), Veterans Health Administration, Denver, Colorado, USA. AD - Seattle-Denver Center of Innovation for Veteran-Centered and Value-Driven Care (COIN), Veterans Health Administration, Denver, Colorado, USA. FAU - O'Donnell, Colin I AU - O'Donnell CI AD - VA Collaborative Evaluation Center (VACE), Veterans Health Administration, Seattle, Washington, USA. AD - VA Collaborative Evaluation Center (VACE), Veterans Health Administration, Denver, Colorado, USA. AD - Seattle-Denver Center of Innovation for Veteran-Centered and Value-Driven Care (COIN), Veterans Health Administration, Denver, Colorado, USA. FAU - O'Brien, Edward AU - O'Brien E AD - VA Collaborative Evaluation Center (VACE), Veterans Health Administration, Seattle, Washington, USA. AD - VA Collaborative Evaluation Center (VACE), Veterans Health Administration, Denver, Colorado, USA. AD - Seattle-Denver Center of Innovation for Veteran-Centered and Value-Driven Care (COIN), Veterans Health Administration, Seattle, Washington, USA. FAU - Hebert, Paul L AU - Hebert PL AUID- ORCID: 0000-0002-5886-7964 AD - VA Collaborative Evaluation Center (VACE), Veterans Health Administration, Seattle, Washington, USA. AD - VA Collaborative Evaluation Center (VACE), Veterans Health Administration, Denver, Colorado, USA. AD - Seattle-Denver Center of Innovation for Veteran-Centered and Value-Driven Care (COIN), Veterans Health Administration, Seattle, Washington, USA. FAU - Palen, Brian N AU - Palen BN AD - Department of Veterans Affairs, Center for Care and Payment Innovation, Washington, District of Columbia, USA. FAU - Au, David H AU - Au DH AD - Seattle-Denver Center of Innovation for Veteran-Centered and Value-Driven Care (COIN), Veterans Health Administration, Seattle, Washington, USA. AD - Department of Veterans Affairs, Center for Care and Payment Innovation, Washington, District of Columbia, USA. FAU - Arfons, Lisa M AU - Arfons LM AD - U.S. Department of Veterans Affairs, Office of Integrated Veteran Care, Washington, District of Columbia, USA. FAU - Winchester, David AU - Winchester D AD - U.S. Department of Veterans Affairs, Office of Integrated Veteran Care, Washington, District of Columbia, USA. FAU - Donovan, Lucas M AU - Donovan LM AUID- ORCID: 0000-0001-8187-2641 AD - VA Collaborative Evaluation Center (VACE), Veterans Health Administration, Seattle, Washington, USA. AD - VA Collaborative Evaluation Center (VACE), Veterans Health Administration, Denver, Colorado, USA. AD - Seattle-Denver Center of Innovation for Veteran-Centered and Value-Driven Care (COIN), Veterans Health Administration, Seattle, Washington, USA. LA - eng GR - IK2 HX002816/HX/HSRD VA/United States GR - CDA 18-187/VA Health Systems Research/ GR - United States (U.S.) Department of Veterans Affairs, Office of Integrated Veteran Care/ PT - Journal Article DEP - 20250609 PL - United States TA - Health Serv Res JT - Health services research JID - 0053006 SB - IM MH - Humans MH - *Referral and Consultation/organization & administration MH - *Triage/organization & administration MH - Qualitative Research MH - United States MH - United States Department of Veterans Affairs/organization & administration MH - Interviews as Topic MH - *Attitude of Health Personnel MH - Patient-Centered Care/organization & administration PMC - PMC12636254 OTO - NOTNLM OT - VA healthcare system OT - program evaluation OT - referrals OT - specialty care OT - triage COIS- The authors declare no conflicts of interest. EDAT- 2025/06/09 12:30 MHDA- 2025/11/21 12:50 PMCR- 2026/12/01 CRDT- 2025/06/09 07:05 PHST- 2025/03/31 00:00 [revised] PHST- 2024/08/20 00:00 [received] PHST- 2025/05/16 00:00 [accepted] PHST- 2025/11/21 12:50 [medline] PHST- 2025/06/09 12:30 [pubmed] PHST- 2025/06/09 07:05 [entrez] PHST- 2026/12/01 00:00 [pmc-release] AID - HESR14654 [pii] AID - 10.1111/1475-6773.14654 [doi] PST - ppublish SO - Health Serv Res. 2025 Dec;60(6):e14654. doi: 10.1111/1475-6773.14654. Epub 2025 Jun 9. PMID- 40485340 OWN - NLM STAT- MEDLINE DCOM- 20251008 LR - 20251008 IS - 2150-136X (Electronic) IS - 2150-1351 (Linking) VI - 16 IP - 6 DP - 2025 Nov TI - Report of Facing Heterotaxy Together 2024: A Virtual, Multidisciplinary Scientific Conference. PG - 839-844 LID - 10.1177/21501351251345795 [doi] AB - Heterotaxy is a rare condition involving abnormal arrangement of organs across the left-right axis of the body. It is associated with variable morphological and functional impairments of multiple organ systems and significant morbidity and mortality. Optimal patient care and innovative research require consistent definitions, standardized multidisciplinary practice guidelines, local clinical champions, and a centralized national registry. The Heterotaxy Research and Clinical Care Collaborative and Heterotaxy Connection conducted a virtual scientific conference for expert clinicians, scientists, patients, and families, to discuss state-of-the-art knowledge and establish networks to promote and improve heterotaxy research and clinical care. FAU - Saba, Thomas G AU - Saba TG AUID- ORCID: 0000-0003-4753-9233 AD - Department of Pediatrics, Pulmonary Division, University of Michigan Medical School, Ann Arbor, MI, USA. RINGGOLD: 1259 FAU - Schidlow, David N AU - Schidlow DN AD - Department of Cardiology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA. FAU - Sabin, Necia AU - Sabin N AD - Heterotaxy Connection, Eagle Mountain, UT, USA. FAU - Ware, Stephanie M AU - Ware SM AD - Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA. RINGGOLD: 1772 LA - eng PT - Journal Article PT - Review DEP - 20250609 PL - United States TA - World J Pediatr Congenit Heart Surg JT - World journal for pediatric & congenital heart surgery JID - 101518415 SB - IM MH - Humans MH - *Heterotaxy Syndrome/therapy/diagnosis MH - *Congresses as Topic OTO - NOTNLM OT - embryology OT - heterotaxy OT - pediatrics OT - practice guideline COIS- Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2025/06/09 06:26 MHDA- 2025/10/08 17:33 CRDT- 2025/06/09 04:03 PHST- 2025/10/08 17:33 [medline] PHST- 2025/06/09 06:26 [pubmed] PHST- 2025/06/09 04:03 [entrez] AID - 10.1177/21501351251345795 [doi] PST - ppublish SO - World J Pediatr Congenit Heart Surg. 2025 Nov;16(6):839-844. doi: 10.1177/21501351251345795. Epub 2025 Jun 9. PMID- 40484501 OWN - NLM STAT- MEDLINE DCOM- 20250608 LR - 20250608 IS - 1557-8216 (Electronic) IS - 0272-5231 (Linking) VI - 46 IP - 2 DP - 2025 Jun TI - Management of Recurrent Transudative Effusions in Congestive Heart Failure and Hepatic Hydrothorax. PG - 261-269 LID - S0272-5231(25)00007-3 [pii] LID - 10.1016/j.ccm.2025.02.005 [doi] AB - Pleural effusions are commonly present in the setting of decompensated heart failure (up to 87%) and liver failure (5%-16%). Notably, patients with decompensated congestive heart failure-induced pleural effusions have a significant 1 year mortality rate from 46% to 50%, while decompensated liver failure accompanied by hepatic hydrothorax demonstrates even higher mortality, particularly when complicated by spontaneous bacterial empyema (51% compared to 19% with refractory ascites). Diagnosis typically involves comprehensive clinical assessment alongside pleural fluid analysis. However, the management of recurrent transudative pleural effusions lacks standardized guidelines, often necessitating a multidisciplinary approach due to the nuanced nature of these cases. CI - Copyright (c) 2025 Elsevier Inc. All rights reserved. FAU - Low, See-Wei AU - Low SW AD - Department of Medicine, Cleveland Clinic Lerner School of Medicine, Case Western Reserve University, Division of Pulmonary Medicine, Cleveland Clinic, Cleveland, OH 44195, USA. FAU - Boyle, Taryn AU - Boyle T AD - Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA. FAU - Shojaee, Samira AU - Shojaee S AD - Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA. Electronic address: samira.shojaee@vumc.org. LA - eng PT - Journal Article PT - Review DEP - 20250324 PL - United States TA - Clin Chest Med JT - Clinics in chest medicine JID - 7907612 SB - IM MH - Humans MH - *Heart Failure/complications MH - *Hydrothorax/therapy/etiology/complications MH - *Pleural Effusion/therapy/etiology/diagnosis MH - Recurrence MH - *Liver Failure/complications OTO - NOTNLM OT - Congestive heart failure OT - Hepatic hydrothorax OT - Transudative effusion EDAT- 2025/06/09 00:28 MHDA- 2025/06/09 00:29 CRDT- 2025/06/08 20:55 PHST- 2025/06/09 00:29 [medline] PHST- 2025/06/09 00:28 [pubmed] PHST- 2025/06/08 20:55 [entrez] AID - S0272-5231(25)00007-3 [pii] AID - 10.1016/j.ccm.2025.02.005 [doi] PST - ppublish SO - Clin Chest Med. 2025 Jun;46(2):261-269. doi: 10.1016/j.ccm.2025.02.005. Epub 2025 Mar 24. PMID- 40483640 OWN - NLM STAT- MEDLINE DCOM- 20250608 LR - 20261010 IS - 1437-9813 (Electronic) IS - 0179-0358 (Linking) VI - 41 IP - 1 DP - 2025 Jun 8 TI - Cloacal exstrophy management in a low- and middle-income country (LMIC): comparative outcomes of direct versus staged closure and a multidisciplinary risk-stratified protocol. PG - 160 LID - 10.1007/s00383-025-06061-3 [doi] AB - PURPOSE: Cloacal exstrophy represents a significant challenge for pediatric surgeons. A critical component of treatment involves bladder closure and reconstruction of the urethra, genitalia and pubic symphysis. The objective of this study is to describe and compare outcomes of patients with cloacal exstrophy based on the type of closure employed and to propose a multidisciplinary management protocol. METHODS: A retrospective descriptive study was conducted on patients with cloacal exstrophy treated between 2008 and 2024. Demographic, clinical, surgical, and immediate post-operative (< 30 days) variables were recorded. The analysis was stratified into two groups based on the surgical approach: staged closure (SC) versus direct closure (DC). RESULTS: Twelve patients were evaluated. In the DC group (n = 5), three (60%) were male, with a mean birth weight of 2401 (+/- 488) g. The median age at the time of surgery was 9 days [interquartile range (IQR): 5526 days]. Cecal plate rescue was successfully achieved in 80% of cases, and the mean pubic diastasis was 4.65 (+/- 2.84) cm. The most frequent complication observed was surgical wound infection. In the SC group (n = 7), five (71.4%) were female, with a mean birth weight of 2046.67 (+/- 489.8) g. The median age at surgery was 62.5 days (IQR: 1116 days). Cecal plate rescue was successful in six (85.7%) patients, and the mean pubic diastasis was 5.16 (+/- 2.74) cm. The most common complication was surgical wound infection associated with external fixation. No statistically significant differences were observed. CONCLUSION: The outcomes of both techniques were comparable. In the DC group, males predominated, as this technique achieves greater phalloplasty length and was performed at an earlier age. The staged group included patients with higher risks of bladder closure dehiscence: lower birth weight, larger pubic diastasis, and associated cardiac comorbidities. This approach necessitates a specialized team of orthopedic surgeons for modern closure techniques, involving osteotomies and external fixators, which entail higher costs. Individualizing the surgical technique for bladder closure is critical. We recommend single stage closure for male neonates. A staged approach is advised for patients referred later in life with low birth weight, pubic diastasis > 5 cm, or hemodynamically significant cardiac comorbidities. CI - (c) 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Costa-Roig, Adria AU - Costa-Roig A AD - Department of Paediatric Colorectal Surgery, Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico. adriacostaroig@gmail.com. FAU - Fernandez-Portilla, Emilio AU - Fernandez-Portilla E AD - Department of Paediatric Colorectal Surgery, Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico. FAU - Dominguez-Munoz, Alfredo AU - Dominguez-Munoz A AD - Department of Paediatric Colorectal Surgery, Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico. FAU - Gonzalez-Ledon, Fernando AU - Gonzalez-Ledon F AD - Department of Paediatric Urology, Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico. FAU - Ramirez-Velazquez, Elias AU - Ramirez-Velazquez E AD - Department of Paediatric Urology, Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico. FAU - Menjivar-Rivera, Andres AU - Menjivar-Rivera A AD - Department of Paediatric Urology, Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico. FAU - Briseno-Chavarria, Norma AU - Briseno-Chavarria N AD - Department of Paediatric Colorectal Surgery, Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico. FAU - Lopez-Rodriguez, Rosalinda AU - Lopez-Rodriguez R AD - Department of Paediatric Colorectal Surgery, Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico. FAU - Davila-Perez, Roberto AU - Davila-Perez R AD - Department of Paediatric Colorectal Surgery, Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico. LA - eng PT - Comparative Study PT - Journal Article DEP - 20250608 PL - Germany TA - Pediatr Surg Int JT - Pediatric surgery international JID - 8609169 SB - IM MH - Humans MH - Retrospective Studies MH - Male MH - Female MH - Infant, Newborn MH - Treatment Outcome MH - *Bladder Exstrophy/surgery MH - Developing Countries MH - *Urologic Surgical Procedures/methods MH - Infant MH - *Plastic Surgery Procedures/methods MH - *Anus, Imperforate/surgery MH - Cloacal Exstrophy OTO - NOTNLM OT - Cloacal exstrophy OT - Developing countries OT - Patient care team OT - Reconstructive surgical procedures OT - Surgical wound infection OT - Treatment outcome COIS- Declarations. Conflict of interest: All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript EDAT- 2025/06/08 13:02 MHDA- 2025/06/08 13:03 CRDT- 2025/06/08 11:04 PHST- 2025/05/22 00:00 [accepted] PHST- 2025/06/08 13:03 [medline] PHST- 2025/06/08 13:02 [pubmed] PHST- 2025/06/08 11:04 [entrez] AID - 10.1007/s00383-025-06061-3 [pii] AID - 10.1007/s00383-025-06061-3 [doi] PST - epublish SO - Pediatr Surg Int. 2025 Jun 8;41(1):160. doi: 10.1007/s00383-025-06061-3. PMID- 40475350 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250607 IS - 2050-0904 (Print) IS - 2050-0904 (Electronic) IS - 2050-0904 (Linking) VI - 13 IP - 6 DP - 2025 Jun TI - Massive Acute Thrombosis of a Mechanical Mitral Valve in a Young Patient on Acenocoumarin: A Case Report Comparing Surgical and Thrombolytic Approaches. PG - e70561 LID - 10.1002/ccr3.70561 [doi] LID - e70561 AB - Obstructive mechanical mitral valve thrombosis is a life-threatening emergency requiring urgent intervention. Surgery is often first-line; thrombolysis may be considered in high-risk cases. A multidisciplinary approach is essential to balance thromboembolic and bleeding risks, emphasizing early recognition, optimized anticoagulation, and improved strategies for prevention and postoperative management. CI - (c) 2025 The Author(s). Clinical Case Reports published by John Wiley & Sons Ltd. FAU - Khallikane, Said AU - Khallikane S AUID- ORCID: 0009-0009-0279-6026 AD - Anesthesiology-ICU-Emergency Department Avicenna Military Hospital, Faculty of Medicine and Pharmacy, Cadi Ayyad University Marrakech Morocco. FAU - Bencharfa, Bassam AU - Bencharfa B AD - Avicenna Military Hospital, Faculty of Medicine and Pharmacy, Cadi Ayyad University Marrakech Morocco. FAU - Atmani, Noureddine AU - Atmani N AD - Avicenna Military Hospital, Faculty of Medicine and Pharmacy, Cadi Ayyad University Marrakech Morocco. AD - Faculty of Medicine and Pharmacy of Fes, Sidi Mohamed Beni Abdellah University Fes Morocco. FAU - Abdou, Abdessamad AU - Abdou A AD - Avicenna Military Hospital, Faculty of Medicine and Pharmacy, Cadi Ayyad University Marrakech Morocco. FAU - Belhadj, Ayoub AU - Belhadj A AD - Avicenna Military Hospital, Faculty of Medicine and Pharmacy, Cadi Ayyad University Marrakech Morocco. FAU - Aissaoui, Younes AU - Aissaoui Y AD - Avicenna Military Hospital, Faculty of Medicine and Pharmacy, Cadi Ayyad University Marrakech Morocco. LA - eng PT - Journal Article DEP - 20250604 PL - England TA - Clin Case Rep JT - Clinical case reports JID - 101620385 PMC - PMC12137188 OTO - NOTNLM OT - acenocoumarin OT - hemodynamic instability OT - mechanical mitral valve thrombosis OT - thrombectomy OT - thrombolysis COIS- The authors declare no conflicts of interest. EDAT- 2025/06/06 06:32 MHDA- 2025/06/06 06:33 PMCR- 2025/06/04 CRDT- 2025/06/06 05:12 PHST- 2025/01/29 00:00 [received] PHST- 2025/05/01 00:00 [revised] PHST- 2025/05/18 00:00 [accepted] PHST- 2025/06/06 06:33 [medline] PHST- 2025/06/06 06:32 [pubmed] PHST- 2025/06/06 05:12 [entrez] PHST- 2025/06/04 00:00 [pmc-release] AID - CCR370561 [pii] AID - 10.1002/ccr3.70561 [doi] PST - epublish SO - Clin Case Rep. 2025 Jun 4;13(6):e70561. doi: 10.1002/ccr3.70561. eCollection 2025 Jun. PMID- 40473890 OWN - NLM STAT- MEDLINE DCOM- 20250606 LR - 20250609 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 15 IP - 1 DP - 2025 Jun 5 TI - Brain lateralization for perceiving direction of motion is reversed in Williams syndrome and related to BUD23. PG - 19772 LID - 10.1038/s41598-025-94742-3 [doi] LID - 19772 AB - Lateralized nervous system function is phylogenetically old but fundamentally important for human brain function. Although altered in developmental and psychiatric disorders, we know little about its genetics. To understand the genetic origins of hemispheric specialization, we investigated laterality in a genetic disorder, Williams Syndrome (WS), caused by ~ 27 deleted genes on 7q11.2. Using a multidisciplinary approach combining individuals' molecular genetic, electrophysiological, and behavioral data, we identify reversed lateralization, from right to left hemisphere for perceiving direction of motion in WS and show hemispheric strengths are inversely correlated. Moreover, we correlate decreased transcript levels of the deleted gene BUD23, with strength of the reversed lateralization and with decreased performance in mental rotation, another right hemisphere lateralized function. The results implicate dosed BUD23, an 18S ribosomal RNA methyltransferase, in human brain laterality, support an evolutionary origin and provide altered lateralization as a novel mechanism for impaired cognition in genetic and behavioral disorders. CI - (c) 2025. The Author(s). FAU - Mills, Debra L AU - Mills DL AD - School of Psychology and Sport Science, Bangor University, Bangor, UK. d.l.mills@bangor.ac.uk. FAU - Dai, Li AU - Dai L AD - Department of Pediatrics, University of Utah, Salt Lake City, UT, USA. AD - Aliri Bioanalysis, Salt Lake City, UT, USA. FAU - Korenberg, Julie R AU - Korenberg JR AD - Department of Pediatrics, University of Utah, Salt Lake City, UT, USA. julie.korenberg@hsc.utah.edu. AD - Department of Neurology, University of Utah, Salt Lake City, UT, USA. julie.korenberg@hsc.utah.edu. LA - eng GR - P01 HD033113/HD/NICHD NIH HHS/United States GR - IAF-2018-014/Leverhulme Trust/ GR - 3P01HD033113-12S1A1/National Institute of Child Health and Human Development/ PT - Journal Article DEP - 20250605 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - EC 2.1.1.- (Methyltransferases) SB - IM MH - Humans MH - *Williams Syndrome/genetics/physiopathology MH - Male MH - *Functional Laterality/genetics/physiology MH - Female MH - *Brain/physiopathology MH - Adult MH - *Methyltransferases/genetics/metabolism MH - *Motion Perception/physiology MH - Young Adult MH - Adolescent PMC - PMC12141689 COIS- Declarations. Competing interests: The authors declare no competing interests. EDAT- 2025/06/06 00:27 MHDA- 2025/06/06 06:30 PMCR- 2025/06/05 CRDT- 2025/06/05 23:30 PHST- 2024/12/11 00:00 [received] PHST- 2025/03/17 00:00 [accepted] PHST- 2025/06/06 06:30 [medline] PHST- 2025/06/06 00:27 [pubmed] PHST- 2025/06/05 23:30 [entrez] PHST- 2025/06/05 00:00 [pmc-release] AID - 10.1038/s41598-025-94742-3 [pii] AID - 94742 [pii] AID - 10.1038/s41598-025-94742-3 [doi] PST - epublish SO - Sci Rep. 2025 Jun 5;15(1):19772. doi: 10.1038/s41598-025-94742-3. PMID- 40473283 OWN - NLM STAT- MEDLINE DCOM- 20250605 LR - 20250703 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 15 IP - 6 DP - 2025 Jun 5 TI - Prenatal detection of congenital heart defects using the deep learning-based image and video analysis: protocol for Clinical Artificial Intelligence in Fetal Echocardiography (CAIFE), an international multicentre multidisciplinary study. PG - e101263 LID - 10.1136/bmjopen-2025-101263 [doi] LID - e101263 AB - INTRODUCTION: Congenital heart defect (CHD) is a significant, rapidly emerging global problem in child health and a leading cause of neonatal and childhood death. Prenatal detection of CHDs with the help of ultrasound allows better perinatal management of such pregnancies, leading to reduced neonatal mortality, morbidity and developmental complications. However, there is a wide variation in reported fetal heart problem detection rates from 34% to 85%, with some low- and middle-income countries detecting as low as 9.3% of cases before birth. Research has shown that deep learning-based or more general artificial intelligence (AI) models can support the detection of fetal CHDs more rapidly than humans performing ultrasound scan. Progress in this AI-based research depends on the availability of large, well-curated and diverse data of ultrasound images and videos of normal and abnormal fetal hearts. Currently, CHD detection based on AI models is not accurate enough for practical clinical use, in part due to the lack of ultrasound data available for machine learning as CHDs are rare and heterogeneous, the retrospective nature of published studies, the lack of multicentre and multidisciplinary collaboration, and utilisation of mostly standard planes still images of the fetal heart for AI models. Our aim is to develop AI models that could support clinicians in detecting fetal CHDs in real time, particularly in nonspecialist or low-resource settings where fetal echocardiography expertise is not readily available. METHODS AND ANALYSIS: We have designed the Clinical Artificial Intelligence Fetal Echocardiography (CAIFE) study as an international multicentre multidisciplinary collaboration led by a clinical and an engineering team at the University of Oxford. This study involves five multicountry hospital sites for data collection (Oxford, UK (n=1), London, UK (n=3) and Southport, Australia (n=1)). We plan to curate 14 000 retrospective ultrasound scans of fetuses with normal hearts (n=13 000) and fetuses with CHDs (n=1000), as well as 2400 prospective ultrasound cardiac scans, including the proposed research-specific CAIFE 10 s video sweeps, from fetuses with normal hearts (n=2000) and fetuses diagnosed with major CHDs (n=400). This gives a total of 16 400 retrospective and prospective ultrasound scans from the participating hospital sites. We will build, train and validate computational models capable of differentiating between normal fetal hearts and those diagnosed with CHDs and recognise specific types of CHDs. Data will be analysed using statistical metrics, namely, sensitivity, specificity and accuracy, which include calculating positive and negative predictive values for each outcome, compared with manual assessment. ETHICS AND DISSEMINATION: We will disseminate the findings through regional, national and international conferences and through peer-reviewed journals. The study was approved by the Health Research Authority, Care Research Wales and the Research Ethics Committee (Ref: 23/EM/0023; IRAS Project ID: 317510) on 8 March 2023. All collaborating hospitals have obtained the local trust research and development approvals. CI - (c) Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY. Published by BMJ Group. FAU - Patey, Olga AU - Patey O AUID- ORCID: 0000-0001-8008-5144 AD - Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford, England, UK olga.patey@wrh.ox.ac.uk. AD - Brompton Fetal Centre, Paediatric Cardiology, Royal Brompton Hospital, London, England, UK. AD - Fetal Medicine Unit, St George's University Hospitals NHS Foundation Trust, London, England, UK. FAU - Hernandez-Cruz, Netzahualcoyotl AU - Hernandez-Cruz N AD - Institute of Biomedical Engineering (IBME), University of Oxford, Oxford, England, UK. FAU - D'Alberti, Elena AU - D'Alberti E AD - Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford, England, UK. FAU - Salovic, Bojana AU - Salovic B AD - Fetal Medicine Unit, St George's University Hospitals NHS Foundation Trust, London, England, UK. FAU - Noble, J Alison AU - Noble JA AD - Institute of Biomedical Engineering (IBME), University of Oxford, Oxford, England, UK. FAU - Papageorghiou, Aris T AU - Papageorghiou AT AD - Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford, England, UK. AD - St George's University Hospitals NHS Foundation Trust, London, England, UK. CN - CAIFE Research Group LA - eng PT - Journal Article PT - Multicenter Study DEP - 20250605 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 SB - IM MH - Humans MH - *Heart Defects, Congenital/diagnostic imaging MH - *Deep Learning MH - *Echocardiography/methods MH - *Ultrasonography, Prenatal/methods MH - Pregnancy MH - Female MH - Artificial Intelligence MH - *Fetal Heart/diagnostic imaging MH - Multicenter Studies as Topic MH - Video Recording PMC - PMC12142171 OTO - NOTNLM OT - Artificial Intelligence OT - Congenital heart disease OT - Diagnostic Imaging OT - Echocardiography OT - Pregnant Women OT - Prenatal diagnosis COIS- Competing interests: None declared. FIR - Adu-Bredu, Theophilus IR - Adu-Bredu T FIR - Ahuja, Rahul IR - Ahuja R FIR - Aye, Christina IR - Aye C FIR - Black, David IR - Black D FIR - Bo, Ilaria IR - Bo I FIR - Brent, Bernadette IR - Brent B FIR - Carvalho, Julene IR - Carvalho J FIR - Craik, Rachel IR - Craik R FIR - Cavallaro, Angelo IR - Cavallaro A FIR - SivaCosta, FabricioDa IR - SivaCosta F FIR - D'Alberti, Elena IR - D'Alberti E FIR - Eccleston, Emma IR - Eccleston E FIR - Everingham, Joanne IR - Everingham J FIR - FreitasPaganoti, CristianeDe IR - FreitasPaganoti C FIR - Farmer, Jessica IR - Farmer J FIR - Fotaki, Eleni IR - Fotaki E FIR - Hernandez-Cruz, Netzahualcoyotl IR - Hernandez-Cruz N FIR - Impey, Lawrence IR - Impey L FIR - Ioannou, Christos IR - Ioannou C FIR - Hatch, Tyrrell IR - Hatch T FIR - Kellett, Joanna IR - Kellett J FIR - Lopes, Karina IR - Lopes K FIR - Mahler, Sally IR - Mahler S FIR - Sankar, Risa Miyazaki IR - Sankar RM FIR - Mishra, Divyanshu IR - Mishra D FIR - Nair, Anupama IR - Nair A FIR - Noble, Alison IR - Noble A FIR - Norville, Jennifer IR - Norville J FIR - Nunn, Olivia IR - Nunn O FIR - Oshodi, Lola IR - Oshodi L FIR - Papageorghiou, Aris IR - Papageorghiou A FIR - Patey, Olga IR - Patey O FIR - Polyviou, Stavros IR - Polyviou S FIR - Rajah, Lorjah IR - Rajah L FIR - Roman, Kevin IR - Roman K FIR - LaCruz, Daifenir Rodriguezde IR - LaCruz DR FIR - Savvidou, Makrina IR - Savvidou M FIR - Shipp, Katja IR - Shipp K FIR - Shobbrook, Bethany IR - Shobbrook B FIR - Tooth, Sophie IR - Tooth S FIR - Tsai-Goodman, Beverly IR - Tsai-Goodman B FIR - Weerasuriya, Dimuthu IR - Weerasuriya D FIR - Yang, Qianye IR - Yang Q FIR - Yang, Yingyu IR - Yang Y FIR - Salovic, Bojana IR - Salovic B EDAT- 2025/06/06 00:27 MHDA- 2025/06/06 00:28 PMCR- 2025/06/05 CRDT- 2025/06/05 20:52 PHST- 2025/06/06 00:28 [medline] PHST- 2025/06/06 00:27 [pubmed] PHST- 2025/06/05 20:52 [entrez] PHST- 2025/06/05 00:00 [pmc-release] AID - bmjopen-2025-101263 [pii] AID - 10.1136/bmjopen-2025-101263 [doi] PST - epublish SO - BMJ Open. 2025 Jun 5;15(6):e101263. doi: 10.1136/bmjopen-2025-101263. PMID- 40472173 OWN - NLM STAT- MEDLINE DCOM- 20250605 LR - 20260311 IS - 1558-2035 (Electronic) IS - 1558-2027 (Linking) VI - 26 IP - 6 DP - 2025 Jun 1 TI - Multidisciplinary approach and combination pharmacotherapy for the management of cardiometabolic patients. PG - 297-302 LID - 10.2459/JCM.0000000000001734 [doi] AB - Cardiometabolic disorders such as hypertension, coronary artery disease, dyslipidaemia, heart failure, and diabetes often cluster together, resulting in patients affected by multiple, related disorders. Therefore, there is a clear need for a multidisciplinary approach when managing these complex patients. Also, therapeutic measures targeting cardiometabolic disorders are expected to influence their common pathogenic mechanisms, such as inflammation and oxidative stress. These were key highlights from a recent forum on cardiometabolic health including various experts across cardiology, endocrinology, and primary care. This consensus document highlights the importance of a combined treatment approach rather than siloed specialties. CI - Copyright (c) 2025 Italian Federation of Cardiology - I.F.C. All rights reserved. FAU - Rosano, Giuseppe M C AU - Rosano GMC AD - Department of Human Sciences and Promotion of Quality of Life, San Raffaele Open University of Rome, Rome, Italy. AD - Department of Cardiology, San Raffaele Cassino Hospital, Cassino, Italy. FAU - Vitale, Cristiana AU - Vitale C AD - Department of Cardiology, St George's University Medical School of London, London, UK. FAU - Spoletini, Ilaria AU - Spoletini I AD - Department of Cardiology, IRCCS San Raffaele Roma, Rome, Italy. FAU - Khunti, Kamlesh AU - Khunti K AD - Department of Cardiology, University of Leicester, UK. FAU - Tsioufis, Kostantinos AU - Tsioufis K AD - Department of Cardiology, National and Kapodistrian University of Athens, Medical School, Greece. FAU - Onida, Sarah AU - Onida S AD - Department of Cardiology, Imperial College London, London, UK. FAU - Papaluca, Marisa AU - Papaluca M AD - Department of Cardiology, Imperial College London, London, UK. FAU - Zambon, Alberto AU - Zambon A AD - Department of Cardiology, University of Padua School of Medicine, Padova, Italy. LA - eng PT - Journal Article PT - Review DEP - 20250521 PL - United States TA - J Cardiovasc Med (Hagerstown) JT - Journal of cardiovascular medicine (Hagerstown, Md.) JID - 101259752 RN - 0 (Cardiovascular Agents) SB - IM MH - Humans MH - *Patient Care Team MH - *Cardiovascular Diseases/drug therapy/therapy/diagnosis MH - Drug Therapy, Combination MH - Consensus MH - *Cardiovascular Agents/therapeutic use/adverse effects OTO - NOTNLM OT - cardiometabolic disorders OT - coronary artery disease OT - diabetes OT - dyslipidaemia OT - heart failure OT - hypertension OT - multidisciplinary approach EDAT- 2025/06/05 18:29 MHDA- 2025/06/05 18:30 CRDT- 2025/06/05 14:33 PHST- 2024/03/30 00:00 [received] PHST- 2025/03/17 00:00 [accepted] PHST- 2025/06/05 18:30 [medline] PHST- 2025/06/05 18:29 [pubmed] PHST- 2025/06/05 14:33 [entrez] AID - 01244665-202506000-00007 [pii] AID - 10.2459/JCM.0000000000001734 [doi] PST - ppublish SO - J Cardiovasc Med (Hagerstown). 2025 Jun 1;26(6):297-302. doi: 10.2459/JCM.0000000000001734. Epub 2025 May 21. PMID- 40471673 OWN - NLM STAT- In-Process LR - 20250911 IS - 1522-9645 (Electronic) IS - 0195-668X (Linking) VI - 46 IP - 32 DP - 2025 Aug 21 TI - Great debate: transcatheter aortic valve implantation should also be performed in non-surgical centres. PG - 3154-3166 LID - 10.1093/eurheartj/ehaf363 [doi] FAU - Compagnone, Miriam AU - Compagnone M AD - Interventional and Structural Cardiovascular Unit, Forli-Cesena, AUSL Romagna, Forli, Italy. FAU - Windecker, Stephan AU - Windecker S AUID- ORCID: 0000-0003-2653-6762 AD - Department of Cardiology, Cardiovascular Center, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland. FAU - Dall'Ara, Gianni AU - Dall'Ara G AD - Interventional and Structural Cardiovascular Unit, Forli-Cesena, AUSL Romagna, Forli, Italy. AD - Department of Medical and Surgical Sciences-DIMEC-Alma Mater Studiorum, University of Bologna, Bologna, Italy. FAU - Galvani, Marcello AU - Galvani M AD - Cardiovascular Research Unit, Fondazione Cardiologica Sacco, Forli, Italy. FAU - Grotti, Simone AU - Grotti S AD - Interventional and Structural Cardiovascular Unit, Forli-Cesena, AUSL Romagna, Forli, Italy. FAU - Siepe, Matthias AU - Siepe M AUID- ORCID: 0000-0003-3305-9343 AD - Department of Cardiac Surgery, Cardiovascular Center, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland. FAU - Tarantino, Fabio Felice AU - Tarantino FF AD - Interventional and Structural Cardiovascular Unit, Forli-Cesena, AUSL Romagna, Forli, Italy. FAU - Tomii, Daijiro AU - Tomii D AUID- ORCID: 0000-0002-4488-1335 AD - Department of Cardiology, Cardiovascular Center, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland. FAU - Urena, Marina AU - Urena M AUID- ORCID: 0000-0002-4150-290X AD - Department of Cardiology, Bichat Claude Bernard Hospital, Assistance Publique Hopitaux de Paris, Paris, France. FAU - Baumgartner, Helmut AU - Baumgartner H AUID- ORCID: 0000-0002-9542-8821 AD - Dept. of Cardiology III-Adult Congenital and Valvular Heart Disease, University Hospital, Muenster, Albert-Schweitzer-Campus 1, Building A1 Muenster 48149, Germany. LA - eng PT - Journal Article PL - England TA - Eur Heart J JT - European heart journal JID - 8006263 SB - IM OTO - NOTNLM OT - Aortic stenosis OT - Emergent cardiac surgery OT - Heart team OT - Heart valve centre OT - Surgical aortic valve replacement OT - Transcatheter aortic valve implantation EDAT- 2025/06/05 12:31 MHDA- 2025/06/05 12:31 CRDT- 2025/06/05 11:54 PHST- 2024/12/17 00:00 [received] PHST- 2025/02/12 00:00 [revised] PHST- 2025/05/12 00:00 [accepted] PHST- 2025/06/05 12:31 [pubmed] PHST- 2025/06/05 12:31 [medline] PHST- 2025/06/05 11:54 [entrez] AID - 8157275 [pii] AID - 10.1093/eurheartj/ehaf363 [doi] PST - ppublish SO - Eur Heart J. 2025 Aug 21;46(32):3154-3166. doi: 10.1093/eurheartj/ehaf363. PMID- 40462648 OWN - NLM STAT- MEDLINE DCOM- 20250710 LR - 20260507 IS - 1365-2788 (Electronic) IS - 0964-2633 (Linking) VI - 69 IP - 8 DP - 2025 Aug TI - Co-Occurring Medical Conditions in Over 2300 Children With Down Syndrome at a Down Syndrome Multispecialty Clinic. PG - 711-720 LID - 10.1111/jir.13257 [doi] AB - BACKGROUND: Children with Down syndrome (DS) have an increased frequency of co-occurring medical complications compared to the typically developing population; however, incidence rates of co-occurring medical conditions in a large paediatric population-based study are limited. The goal of this study was to further investigate the frequencies of concomitant medical conditions, as well as newborn complications in children with DS. METHODS: This is a retrospective, large cohort review of children with DS (n = 2321) receiving care at a referral centre specialising in DS to identify common patterns of co-occurring conditions in children and young adults with DS. Participants from birth to 24 years of age received care from the Anna and John J. Sie Center for Down Syndrome at Children's Hopsital Colorado, which serves 88% of the State of Colorado's paediatric population with DS. Records reviewed included demographics, birth history, and medical conditions of each patient. RESULTS: Neonatal complications requiring admission to the neonatal intensive care unit (NICU) were present in 80.0% of the population. Complications leading to these admissions include oxygen requirement (53.7%), feeding problems (49.7%), respiratory distress syndrome (14.7%), and persistent pulmonary hypertension of the newborn (12.6%). Incidence of medical complications for children and young adults with DS includes obstructive sleep apnea (56.8%), cardiac defect requiring surgical repair (48.9%), feeding problems (42.3%), and dysphagia (26.2%). Recently identified co-occurring conditions lacking in the literature, such as keratoconus (3.6%) and Wolff-Parkinson-White syndrome (3.4%), are also reported. Testing, labs and procedures were also common amongst children to meet American Academy of Pediatrics (AAP) DS Guidelines. CONCLUSION: Children with DS have unique phenotypic clinical patterns of co-occurring conditions and medical complications. Some conditions present clinically in the neonatal period and require close monitoring and anticipation for a higher level of care for newborns with DS. Our results, using a large sample of over 2300 patients, provide information to improve evidence-based early identification and timely intervention for children and young adults with DS. CI - (c) 2025 MENCAP and John Wiley & Sons Ltd. FAU - Hickey, Francis AU - Hickey F AD - Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, United States. AD - Anna and John J. Sie Center for Down Syndrome, Children's Hospital Colorado, Aurora, Colorado, United States. FAU - Maastricht, Liz AU - Maastricht L AUID- ORCID: 0009-0005-0427-8813 AD - Anna and John J. Sie Center for Down Syndrome, Children's Hospital Colorado, Aurora, Colorado, United States. FAU - Wolter-Warmerdam, Kristine AU - Wolter-Warmerdam K AD - Anna and John J. Sie Center for Down Syndrome, Children's Hospital Colorado, Aurora, Colorado, United States. FAU - Daniels, Dee AU - Daniels D AD - Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, United States. AD - Anna and John J. Sie Center for Down Syndrome, Children's Hospital Colorado, Aurora, Colorado, United States. FAU - Herfindahl, Bailey AU - Herfindahl B AD - Anna and John J. Sie Center for Down Syndrome, Children's Hospital Colorado, Aurora, Colorado, United States. FAU - Kelminson, Karen AU - Kelminson K AD - Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, United States. AD - Anna and John J. Sie Center for Down Syndrome, Children's Hospital Colorado, Aurora, Colorado, United States. LA - eng PT - Journal Article DEP - 20250604 PL - England TA - J Intellect Disabil Res JT - Journal of intellectual disability research : JIDR JID - 9206090 SB - IM MH - Humans MH - *Down Syndrome/epidemiology MH - Child MH - Adolescent MH - Female MH - Child, Preschool MH - Male MH - Infant MH - Colorado/epidemiology MH - Retrospective Studies MH - Infant, Newborn MH - Young Adult MH - Comorbidity MH - Adult OTO - NOTNLM OT - American Academy of Pediatrics Down Syndrome Guidelines OT - Down syndrome OT - paediatrics OT - trisomy 21 EDAT- 2025/06/04 06:27 MHDA- 2025/07/11 00:26 CRDT- 2025/06/04 03:52 PHST- 2025/05/19 00:00 [revised] PHST- 2024/12/05 00:00 [received] PHST- 2025/05/20 00:00 [accepted] PHST- 2025/07/11 00:26 [medline] PHST- 2025/06/04 06:27 [pubmed] PHST- 2025/06/04 03:52 [entrez] AID - 10.1111/jir.13257 [doi] PST - ppublish SO - J Intellect Disabil Res. 2025 Aug;69(8):711-720. doi: 10.1111/jir.13257. Epub 2025 Jun 4. PMID- 40457696 OWN - NLM STAT- MEDLINE DCOM- 20250916 LR - 20260821 IS - 1365-2044 (Electronic) IS - 0003-2409 (Linking) VI - 80 IP - 10 DP - 2025 Oct TI - Anaesthesia support for transcatheter heart valve interventions: a narrative review. PG - 1254-1268 LID - 10.1111/anae.16635 [doi] AB - INTRODUCTION: There have been few other areas of medical practice in the last two decades that have evolved at the same pace as transcatheter heart valve interventions. As well as providing peri-operative care, anaesthetists are core members of 'Heart Teams', who plan the care of and manage patients with valvular heart disease. This review aims to summarise core information on these procedures for anaesthetists. METHODS: We conducted a literature review to identify highly cited or high Altmetric scoring articles published in the last five years on the peri-operative management of patients undergoing transcatheter aortic, mitral, pulmonary and tricuspid valve interventions. RESULTS: There was little contemporary published evidence comparing or recommending anaesthetic techniques and describing their effect on peri-operative outcomes. Instead, there is a wealth of evidence on outcomes in specific patient risk groups undergoing transcatheter procedures. However, these trials focussed mainly on mortality and complications, received substantial industry funding and pooled adverse outcomes as a composite using frequentist non-inferiority methods. Most real-world patients would likely be excluded from these trials and clinicians therefore should apply evidence, expertise and local experience to make risk/benefit judgements for individual patients referred to the Heart Team. Knowledge of the issues around diagnosis, patient selection, procedural steps and device design characteristics are arguably of more importance to the anaesthetist than the specifics of techniques for local anaesthesia infiltration, conscious sedation and general anaesthesia, which are transferrable skills for all adult anaesthetists. DISCUSSION: There is a need for new peri-operative research with a focus on patient-centred metrics, rather than complication composites and mortality outcomes. Clinically, there is increasing focus on patient-centred treatment, timing of interventions and a team-based approach with greater emphasis placed on comorbidities and their aggressive management. CI - (c) 2025 Association of Anaesthetists. FAU - Charlesworth, Mike AU - Charlesworth M AUID- ORCID: 0000-0001-7389-4955 AD - Department of Cardiothoracic Anaesthesia, Critical Care and ECMO, Wythenshawe Hospital, Manchester, UK. FAU - Hayes, Tim AU - Hayes T AD - Department of Cardiothoracic Anaesthesia, Critical Care and ECMO, Wythenshawe Hospital, Manchester, UK. FAU - Buch, Mamta H AU - Buch MH AD - Department of Interventional Cardiology, Wythenshawe Hospital, Manchester, UK. FAU - Davies, Eryl A AU - Davies EA AD - Department of Cardiothoracic Anaesthesia, Critical Care and ECMO, Wythenshawe Hospital, Manchester, UK. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20250602 PL - England TA - Anaesthesia JT - Anaesthesia JID - 0370524 SB - IM MH - Humans MH - *Anesthesia/methods MH - *Heart Valve Diseases/surgery MH - *Heart Valve Prosthesis Implantation/methods MH - *Cardiac Catheterization/methods OTO - NOTNLM OT - anaesthesia OT - aortic OT - mitral OT - transcatheter interventions OT - tricuspid EDAT- 2025/06/03 06:27 MHDA- 2025/09/16 13:03 CRDT- 2025/06/03 02:03 PHST- 2025/04/08 00:00 [accepted] PHST- 2025/09/16 13:03 [medline] PHST- 2025/06/03 06:27 [pubmed] PHST- 2025/06/03 02:03 [entrez] AID - 10.1111/anae.16635 [doi] PST - ppublish SO - Anaesthesia. 2025 Oct;80(10):1254-1268. doi: 10.1111/anae.16635. Epub 2025 Jun 2. PMID- 40456311 OWN - NLM STAT- MEDLINE DCOM- 20250705 LR - 20260428 IS - 2174-2030 (Electronic) IS - 0870-2551 (Linking) VI - 44 IP - 7 DP - 2025 Jul TI - Surgical revascularization of chronic coronary total occlusions - A systematic review and meta-analysis. PG - 427-439 LID - S0870-2551(25)00159-3 [pii] LID - 10.1016/j.repc.2025.01.006 [doi] AB - INTRODUCTION AND OBJECTIVES: Chronic coronary total occlusion (CTO) optimal therapeutic management remains a topic of debate despite its association with adverse clinical outcomes. This study aimed to compare clinical outcomes of patients with CTOs treated with coronary artery bypass graft (CABG) versus medical therapy (MT), assessing the effect of CTO revascularization in patients with multivessel disease undergoing CABG. METHODS: In July 2023, PubMed, Embase, Cochrane, and Web of Science databases were systematically searched for studies comparing CTOs treated with CABG versus MT. A sub-analysis of CABG patients, comparing complete surgical revascularization, including CTO bypass, to CABG without CTO bypass, was performed. A pooled odds ratio meta-analysis assessed four main outcomes: mortality, myocardial infarction (MI), stroke, and major adverse cardiovascular events (MACE). The primary outcome was all-cause mortality. RESULTS: Ten observational studies (6458 patients) comparing CABG-CTO with MT-CTO showed lower all-cause mortality in the CABG group (OR 0.31, 95% CI 0.24-0.40, p<0.001, I(2)=36%). Despite heterogeneity, CABG exhibited reduced CV mortality and MACE (OR 0.37, 95% CI 0.24-0.57, p<0.001, I(2)=59%; OR 0.37, 95% CI 0.15-0.92, p=0.03, I(2)=80%, respectively). The MI rate was lower in the CABG group (OR 0.41, 95% CI 0.30-0.56, p<0.001, I(2)=0%). Comparing bypassed to non-bypassed CTO groups (5 studies, 1949 patients), the bypassed-CTO group had considerably lower MACE (OR 0.49, 95% CI 0.30-0.81, p=0.005, I(2)=44%). CONCLUSION: This study suggests a clinical benefit of bypassing a CTO in multivessel disease patients during CABG, with significantly lower MACE. The improved outcomes of CABG over MT further underscore these findings, warranting careful consideration by the Heart Team during their decision-making process. CI - Copyright (c) 2025 Sociedade Portuguesa de Cardiologia. Publicado por Elsevier Espana, S.L.U. All rights reserved. FAU - Silva, Ana Luisa AU - Silva AL AD - Cardiology Department, Unidade Local de Saude de Coimbra, Coimbra, Portugal. Electronic address: ana1ferreira.silva@gmail.com. FAU - Costa, Goncalo Ferraz AU - Costa GF AD - Cardiology Department, Unidade Local de Saude de Coimbra, Coimbra, Portugal; Faculty of Medicine of the University of Coimbra, Coimbra, Portugal; ICBR, Coimbra Institute for Clinical and Biomedical Research, Coimbra, Portugal. FAU - Martins, Jose Luis AU - Martins JL AD - Cardiology Department, Unidade Local de Saude de Coimbra, Coimbra, Portugal. FAU - Leite, Luis AU - Leite L AD - Cardiology Department, Unidade Local de Saude de Coimbra, Coimbra, Portugal; Faculty of Medicine of the University of Coimbra, Coimbra, Portugal; ICBR, Coimbra Institute for Clinical and Biomedical Research, Coimbra, Portugal. FAU - Goncalves, Lino AU - Goncalves L AD - Cardiology Department, Unidade Local de Saude de Coimbra, Coimbra, Portugal; Faculty of Medicine of the University of Coimbra, Coimbra, Portugal; ICBR, Coimbra Institute for Clinical and Biomedical Research, Coimbra, Portugal. LA - eng LA - por PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20250531 PL - Portugal TA - Rev Port Cardiol JT - Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology JID - 8710716 SB - IM MH - Humans MH - *Coronary Occlusion/surgery/mortality MH - *Coronary Artery Bypass MH - Chronic Disease MH - Treatment Outcome OTO - NOTNLM OT - Chronic coronary total occlusion OT - Cirurgia de revascularizacao miocardica OT - Complete revascularization OT - Coronary artery bypass grafting OT - Oclusoes coronarias cronicas OT - Revascularizacao completa EDAT- 2025/06/03 00:29 MHDA- 2025/07/06 06:18 CRDT- 2025/06/02 19:36 PHST- 2024/06/14 00:00 [received] PHST- 2025/01/15 00:00 [revised] PHST- 2025/01/25 00:00 [accepted] PHST- 2025/07/06 06:18 [medline] PHST- 2025/06/03 00:29 [pubmed] PHST- 2025/06/02 19:36 [entrez] AID - S0870-2551(25)00159-3 [pii] AID - 10.1016/j.repc.2025.01.006 [doi] PST - ppublish SO - Rev Port Cardiol. 2025 Jul;44(7):427-439. doi: 10.1016/j.repc.2025.01.006. Epub 2025 May 31. PMID- 40465811 STAT- Publisher CTDT- 20250602 PB - StatPearls Publishing DP - 2025 Jan TI - Single-Anastomosis Duodeno-Ileal Bypass. BTI - StatPearls AB - Worldwide, approximately 650 million adults and 340 million children are designated as obese. Environmental and genetic factors influence obesity, which is associated with comorbidities including diabetes, dyslipidemia, obstructive sleep apnea, nonalcoholic fatty liver disease, and coronary artery disease. Truncal obesity is associated with an increased risk of hypertension, heart disease, diabetes, and metabolic syndrome, which is defined by triglyceride levels greater than 150 mg/dL, fasting glucose levels of 100 to 125 mg/dL, or an elevated hemoglobin A1c level. Recently, the World Health Organization noted that over 60% of people in Europe are overweight or obese, which represents a tripling of obesity in the last 50 years, mainly due to decreased activity and diet. In the United States, obesity, morbid, and super morbid obesity continue to increase in both children and adults, predominantly impacting those with the highest genetic predisposition. Genetic influences include single genes associated with hyperphagia. Obesity has the most significant impact on Black women, Hispanic adults, and indigenous peoples. Treating obesity, its physiological and psychological sequelae, and comorbidities is costly and requires a comprehensive interdisciplinary approach for the most effective management. A recent surge in medications targeting energy expenditure and appetite-regulating mechanisms has occurred; these are most effective when implemented in conjunction with behavioral changes. National and global increases in obesity place a sizeable burden on health systems and economies and necessitate a multidisciplinary approach to management. Conventional weight management often fails in severe obesity, and surgery is the most effective intervention in such cases by offering persistent weight loss and improving obesity-related comorbidities. A body mass index (BMI) of 40 kg/m(2) or higher, or a BMI of 35 kg/m(2) or higher with severe comorbidities, is most effectively treated with surgical intervention to achieve a BMI between 18.5 and 24.9. The primary mechanism by which obesity surgery impacts weight loss is through restriction and malabsorption. Still, multiple complex hormonal and neuroregulatory factors influence the regulation of metabolism and food intake, which can aid in weight loss. Sustained weight loss following bariatric surgery also depends on patient compliance with diet and exercise. Bariatric surgery can resolve comorbid conditions such as hypertension, diabetes, and sleep apnea. The American Society of Metabolic and Bariatric Surgery in conjunction with the International Federation for the Surgery of Obesity and Metabolic Disorders has updated their indications for bariatric surgery to include persons with a BMI of 35 kg/m(2) or higher with or without comorbidities, and persons with a BMI between 30 to 34.9 kg/m(2) with related conditions. Additionally, the recent implementation of obesity surgery-specific quality improvement and enhanced recovery after surgery programs has standardized and improved the quality of care for these patients. According to the ASMBS, the most commonly performed bariatric surgery procedure in the United States is sleeve gastrectomy, followed by Roux-en-Y gastric bypass. Additional bariatric surgery options include biliopancreatic diversion with or without duodenal switch, 1 anastomosis gastric bypass, and SADI, all of which are typically performed laparoscopically or robotically. The SADI bypass, in conjunction with sleeve gastrectomy, is a relatively recent modification that exhibits physiology comparable to that of the duodenal switch and biliopancreatic diversion, with similar weight loss and improvements in comorbidities. In early studies, patients who had undergone SADI experienced resolution of diabetes and hypertension within months of surgery. The restrictive component of SADI with sleeve gastrectomy is created through resection of the stomach, and the malabsorptive aspect is generated through bypassing the small bowel. The distal small bowel becomes the common channel that receives ingested items from the esophagus and stomach, as well as secretions from the biliopancreatic limb, thereby reducing the absorption of nutrients. SADI has become more common due to its relative simplicity, with comparable efficacy compared to more complex surgeries like gastric bypass. First described by Sanchez-Pernaute and colleagues, this intervention offers the combined benefits of restriction and malabsorption, aiming to optimize weight loss and metabolic outcomes with fewer complications. The metabolic outcomes of SADI eliminate diabetes, hypertension, dyslipidemia, and obstructive sleep apnea. The single anastomosis technique reduces the number of potential failure points, thereby lowering the incidence of internal hernias and anastomotic leaks, which are more common in multianastomosis procedures. Additionally, the incidence of dumping syndrome is reduced with SADI compared to gastric bypass through preservation of the pylorus, which maintains a more natural gastric emptying process. However, SADI is not without potential complications. Nutritional deficiencies are common and require lifelong monitoring. Furthermore, while fewer steps reduce operative time and immediate postoperative risks, long-term data are still emerging, necessitating ongoing research to understand durability and long-term safety. CI - Copyright (c) 2025, StatPearls Publishing LLC. FAU - Ali, Afaque AU - Ali A AD - College of Physician and Surgeon Pakistan FAU - Marietta, Mia AU - Marietta M AD - University of Colorado Health Sciences LA - eng PT - Study Guide PT - Book Chapter PL - Treasure Island (FL) COIS- Disclosure: Afaque Ali declares no relevant financial relationships with ineligible companies. Disclosure: Mia Marietta declares no relevant financial relationships with ineligible companies. EDAT- 2025/06/02 00:00 CRDT- 2025/06/02 00:00 AID - NBK615300 [bookaccession] PMID- 40455186 OWN - NLM STAT- MEDLINE DCOM- 20251214 LR - 20260304 IS - 1557-3117 (Electronic) IS - 1053-2498 (Linking) VI - 45 IP - 1 DP - 2026 Jan TI - ISHLT Consensus Statement on the Perioperative use of ECLS in Lung Transplantation: Part III: Postoperative Considerations. PG - e63-e81 LID - S1053-2498(25)01838-8 [pii] LID - 10.1016/j.healun.2025.03.004 [doi] AB - The use of extracorporeal life support (ECLS) throughout the perioperative phase of lung transplantation requires nuanced planning and execution by an integrated team of multidisciplinary experts. To date, no multidisciplinary consensus document has examined the perioperative considerations of how to best manage these patients. To address this challenge, this perioperative utilization of ECLS in lung transplantation consensus statement was approved for development by the International Society for Heart and Lung Transplantation Standards and Guidelines Committee. International experts across multiple disciplines, including cardiothoracic surgery, anesthesiology, critical care, pediatric pulmonology, adult pulmonology, pharmacy, psychology, physical therapy, nursing, and perfusion, were selected based on expertise and divided into subgroups examining the preoperative, intraoperative, and postoperative periods. Following a comprehensive literature review, each subgroup developed recommendations to examine via a structured Delphi methodology. Following 2 rounds of Delphi consensus, a total of 22 recommendations regarding postoperative considerations for ECLS in lung transplantation met consensus criteria. These recommendations focus on the criteria for postoperative ECLS as well as select multidisciplinary team management considerations throughout the entire postoperative spectrum. CI - Copyright (c) 2025 International Society for the Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved. FAU - Martin, Archer Kilbourne AU - Martin AK AD - Division of Cardiovascular and Thoracic Anesthesiology, Mayo Clinic Florida, Jacksonville, Florida. Electronic address: martin.archer@mayo.edu. FAU - Mercier, Olaf AU - Mercier O AD - Department of Thoracic Surgery and Heart-Lung Transplantation, Marie Lannelongue Hospital, Universite' Paris-Saclay, Le Plessis-Robinson, France. FAU - Bottiger, Brandi AU - Bottiger B AD - Division of Cardiothoracic Anesthesiology, Duke University School of Medicine, Durham, North Carolina. FAU - Cypel, Marcelo AU - Cypel M AD - Toronto Lung Transplant Program, Ajmera Transplant Center, University Health Network, Toronto, Ontario, Canada. FAU - Fessler, Julien AU - Fessler J AD - Department of Anesthesiology and Pain Medicine, Hospital Foch, Universite' Versailles-Saint-Quentin-en-Yvelines, Suresnes, France. FAU - Gomez-De-Antonio, David AU - Gomez-De-Antonio D AD - Department of Thoracic Surgery and Lung Transplantation, Hospital Universitario Puerta de Hierro-Majadahonda, Universidad Autonoma de Madrid, Madrid, Spain. FAU - Levvey, Bronwyn AU - Levvey B AD - Faculty of Nursing and Health Sciences, The Alfred Hospital, Monash University, Melbourne, Victoria, Australia. FAU - Lyster, Haifa AU - Lyster H AD - Department of Cardiothoracic Transplantation and Mechanical Circulatory Support, Royal Brompton and Harefield Hospitals, Part of Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK. FAU - Nasir, Basil AU - Nasir B AD - Division of Thoracic Surgery, Centre Hospitalier de l'Universite de Montreal (CHUM), Montreal, Quebec, Canada. FAU - Sanchez, Melissa AU - Sanchez M AD - Department of Clinical Health Psychology, Kensington and Chelsea, West Middlesex Hospitals, London, UK. FAU - Wille, Keith AU - Wille K AD - Division of Pulmonary and Critical Care Medicine, University of Alabama, Birmingham, Alabama. FAU - Fritz, Ashley Virginia AU - Fritz AV AD - Division of Cardiovascular and Thoracic Anesthesiology, Mayo Clinic Florida, Jacksonville, Florida. FAU - Gelzinis, Theresa AU - Gelzinis T AD - Division of Cardiovascular and Thoracic Anesthesiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. FAU - Hoetzenecker, Konrad AU - Hoetzenecker K AD - Department of Thoracic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee. FAU - Dave, Kavita AU - Dave K AD - Department of Cardiothoracic Transplantation and Mechanical Circulatory Support, Royal Brompton and Harefield Hospitals, Part of Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK. FAU - Lindstedt, Sandra AU - Lindstedt S AD - Department of Cardiothoracic Surgery and Transplantation, Lund University, Lund, Sweden. FAU - Marczin, Nandor AU - Marczin N AD - Department of Anaesthesia and Critical Care, Royal Brompton and Harefield Hospitals, Part of Guy's and St Thomas' NHS Foundation Trust and Imperial College London, London, UK. FAU - Wilkey, Barbara AU - Wilkey B AD - Department of Anesthesiology, University of Colorado, Aurora, Colorado. FAU - Schecter, Marc AU - Schecter M AD - Division of Pulmonary Medicine, University of Florida, Gainesville, Florida. FAU - Walsh, James AU - Walsh J AD - Department of Physiotherapy, The Prince Charles Hospital, Brisbane, Queensland, Australia. FAU - Morrissey, Orla AU - Morrissey O AD - Division of Infectious Disease, Alfred Health and Monash University, Melbourne, Victoria, Australia. FAU - Landry, Caroline AU - Landry C AD - Division of Perfusion Services, Universite' de Montreal, Montreal, Quebec, Canada. FAU - Saatee, Siavosh AU - Saatee S AD - Division of Cardiovascular and Thoracic Anesthesiology and Critical Care, University of Texas-Southwestern, Dallas, Texas. FAU - Kotecha, Sakhee AU - Kotecha S AD - Lung Transplant Service, Alfred Hospital and Monash University, Melbourne, Victoria, Australia. FAU - Behr, Juergen AU - Behr J AD - Department of Medicine V, German Center for Lung Research, LMU University Hospital, Ludwig Maximilian University of Munich, Munich, Germany. FAU - Kukreja, Jasleen AU - Kukreja J AD - Division of Cardiothoracic Surgery, Department of Surgery, University of California, San Francisco, California. FAU - Dellgren, Goran AU - Dellgren G AD - Department of Cardiothoracic Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden. FAU - Reed, Anna K AU - Reed AK AD - Respiratory and Transplant Medicine, Royal Brompton and Harefield Hospitals, Part of Guy's and St Thomas' NHS Foundation Trust and Imperial College London, London, UK. LA - eng PT - Consensus Statement PT - Journal Article PT - Practice Guideline PT - Review DEP - 20250602 PL - United States TA - J Heart Lung Transplant JT - The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation JID - 9102703 SB - IM MH - Humans MH - Delphi Technique MH - *Extracorporeal Membrane Oxygenation/methods/standards MH - *Lung Transplantation/methods MH - *Perioperative Care/methods/standards MH - *Postoperative Care/methods MH - *Societies, Medical OTO - NOTNLM OT - extracorporeal circulatory life support (ECLS) OT - extracorporeal membrane oxygenation (ECMO) OT - intensive care unit OT - lung transplant OT - multidisciplinary EDAT- 2025/06/02 12:30 MHDA- 2025/12/15 00:28 CRDT- 2025/06/02 11:09 PHST- 2025/03/01 00:00 [received] PHST- 2025/03/03 00:00 [accepted] PHST- 2025/12/15 00:28 [medline] PHST- 2025/06/02 12:30 [pubmed] PHST- 2025/06/02 11:09 [entrez] AID - S1053-2498(25)01838-8 [pii] AID - 10.1016/j.healun.2025.03.004 [doi] PST - ppublish SO - J Heart Lung Transplant. 2026 Jan;45(1):e63-e81. doi: 10.1016/j.healun.2025.03.004. Epub 2025 Jun 2. PMID- 40452615 OWN - NLM STAT- MEDLINE DCOM- 20250909 LR - 20250911 IS - 1440-0960 (Electronic) IS - 0004-8380 (Print) IS - 0004-8380 (Linking) VI - 66 IP - 6 DP - 2025 Sep TI - Improving Cardiovascular Outcomes in the Psoriasis Cohort. Psoriasis and Cardiovascular Disease-Patient Knowledge, Perspectives and Practice. PG - 338-343 LID - 10.1111/ajd.14528 [doi] AB - BACKGROUND AND STUDY AIMS: Patient perspectives on psoriasis as a systemic disease, with its heightened risk of cardiovascular disease (CVD), are unclear. Approaches to cardiovascular risk factor screening and management vary in this cohort. This study aimed to ascertain knowledge, practice and perceptions of patients with respect to psoriasis and CVD, CV risk factor screening and management. METHODS: This cross-sectional study consisted of a self-administered questionnaire capturing demographic characteristics, knowledge of the association between psoriasis and CVD, and perspectives on cardiovascular risk factor screening and management. This was distributed to psoriasis patients in public and private clinic settings. The survey data was assessed with the use of descriptive statistics. RESULTS: A total of 102 patients with psoriasis were surveyed. The majority of respondents were male 52%, (53/102), 46-60 years old 30.4% (31/102), with longstanding psoriasis (> 20 years), 42.2.% (43/102). Most patients nominated a dermatologist in a public hospital setting as the primary clinician responsible for their psoriasis management 71.6% (73/102). A total of 20.6% (21/102) psoriasis patients surveyed indicated knowledge of the association between CVD and psoriasis, and 22.5% (23/102) agreed that psoriasis was associated with worse CVD outcomes compared to the general population. 63.7% (65/102) indicated they had undergone CV risk factor screening in the last year, with most nominating general practitioners (GPs) 38.4% (38/99), followed by cardiologists 14.1% (14/99), then dermatologists 9.1% (9/99), as the clinician who performed this CV RF screening. A total of 68.6% (70/102) responded they did not currently have a treating cardiologist, while 34.3% (35/102) nominated a Cardiologist as their preferred clinician to facilitate CVD risk factor screening/management, 23.5% (24/102) indicated a preference for a multidisciplinary team, 17.6% (18/102) nominated GPs and 6.9% (7/102) nominated the dermatologist. CONCLUSION: There is a need for improved patient education regarding the relationship between psoriasis and CVD. Heightened awareness around cardiovascular risk may serve as an impetus for patients to seek relevant cardiovascular risk factor screening, management and pursue healthy lifestyle behaviours. CI - (c) 2025 The Author(s). Australasian Journal of Dermatology published by John Wiley & Sons Australia, Ltd on behalf of Australasian College of Dermatologists. FAU - Smith, Annika AU - Smith A AUID- ORCID: 0000-0001-9520-920X AD - Westmead Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia. AD - Department of Dermatology, Westmead Hospital, Westmead, New South Wales, Australia. AD - St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia. AD - Department of Dermatology, School of Clinical Medicine, UNSW Medicine and Health, St Vincent's Clinical Campus, Darlinghurst, New South, UK. AD - Westmead Applied Research Centre, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia. FAU - Lai, Belinda AU - Lai B AD - Westmead Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia. AD - Department of Dermatology, Westmead Hospital, Westmead, New South Wales, Australia. AD - St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia. AD - Department of Dermatology, School of Clinical Medicine, UNSW Medicine and Health, St Vincent's Clinical Campus, Darlinghurst, New South, UK. FAU - Chow, Clara K AU - Chow CK AD - Westmead Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia. AD - Westmead Applied Research Centre, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia. AD - Department of Cardiology, Westmead Hospital, Westmead, New South Wales, Australia. FAU - Zaman, Sarah AU - Zaman S AD - Westmead Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia. AD - Westmead Applied Research Centre, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia. AD - Department of Cardiology, Westmead Hospital, Westmead, New South Wales, Australia. LA - eng PT - Journal Article DEP - 20250602 PL - Australia TA - Australas J Dermatol JT - The Australasian journal of dermatology JID - 0135232 SB - IM MH - Humans MH - *Psoriasis/complications/therapy MH - Male MH - Female MH - Middle Aged MH - *Cardiovascular Diseases/diagnosis/etiology/prevention & control/therapy MH - Cross-Sectional Studies MH - *Health Knowledge, Attitudes, Practice MH - Adult MH - Heart Disease Risk Factors MH - Surveys and Questionnaires MH - Aged PMC - PMC12418152 OTO - NOTNLM OT - cardiovascular disease OT - patients OT - psoriasis OT - survey COIS- The authors declare no conflicts of interest. EDAT- 2025/06/02 06:28 MHDA- 2025/09/09 06:35 PMCR- 2025/09/09 CRDT- 2025/06/02 05:13 PHST- 2025/05/05 00:00 [revised] PHST- 2025/02/27 00:00 [received] PHST- 2025/05/09 00:00 [accepted] PHST- 2025/09/09 06:35 [medline] PHST- 2025/06/02 06:28 [pubmed] PHST- 2025/06/02 05:13 [entrez] PHST- 2025/09/09 00:00 [pmc-release] AID - AJD14528 [pii] AID - 10.1111/ajd.14528 [doi] PST - ppublish SO - Australas J Dermatol. 2025 Sep;66(6):338-343. doi: 10.1111/ajd.14528. Epub 2025 Jun 2. PMID- 40452212 OWN - NLM STAT- MEDLINE DCOM- 20260527 LR - 20260813 IS - 1472-1465 (Electronic) IS - 0007-1250 (Print) IS - 0007-1250 (Linking) VI - 228 IP - 4 DP - 2026 Apr TI - Multidisciplinary consensus on prevention, screening and monitoring of clozapine-associated myocarditis and clozapine rechallenge after myocarditis. PG - 348-356 LID - 10.1192/bjp.2025.89 [doi] AB - BACKGROUND: Clozapine is the antipsychotic of choice for people with treatment-resistant schizophrenia (TRS) but is associated with the uncommon but potentially life-threatening adverse effect of myocarditis. However, there are no criteria for diagnosing clozapine-associated myocarditis (CAM) or global guidelines on detection and risk reduction, or for restarting clozapine after CAM. AIMS: To develop criteria for CAM and algorithms for clozapine initiation and clozapine rechallenge after CAM in a multiprofessional consensus process. METHOD: We conducted a systematic literature search for cases of clozapine rechallenge following CAM using the PubMed, EMBASE, CINAHL and PsycINFO databases, followed by a multidisciplinary international two-step Delphi consensus process in July and October 2024. The Delphi panel comprised psychiatrists, cardiologists, pharmacists, psychopharmacologists and nurses with expertise on clozapine or myocarditis. RESULTS: Ninety-three clinicians and academics with experience in prescribing clozapine from six continents participated in the Delphi process. A consensus was reached on a definition of CAM according to modified clinical criteria from the European Society of Cardiology for myocarditis associated with immune checkpoint inhibitors. Titration schemes slower than those given in the Summary of Product Characteristics for clozapine were recommended to minimise CAM risk. Minimum and enhanced requirements for screening and monitoring were developed to account for global perspectives and limited resources in certain healthcare systems, and an approach to clozapine rechallenge was elaborated. CONCLUSIONS: This multidisciplinary project represents the first guidance for CAM and will inform clinicians, other caregivers and patients, as well as facilitating the development of national guidelines on CAM prevention, screening and monitoring and rechallenge after an index episode of myocarditis in individuals taking clozapine. FAU - Wagner, Elias AU - Wagner E AUID- ORCID: 0000-0002-7147-6167 AD - Evidence-based Psychiatry and Psychotherapy, Faculty of Medicine, University of Augsburg, Augsburg, Germany. AD - Department of Psychiatry, Psychotherapy and Psychosomatics, Medical Faculty, University of Augsburg, BKH Augsburg, Augsburg, Germany. FAU - Korman, Nicole AU - Korman N AD - Queensland Centre for Mental Health Research, Brisbane, Australia. AD - Metro South Addiction and Mental Health Service, Metro South Health, Brisbane, Australia. AD - University of Queensland School of Clinical Medicine, Brisbane, Australia. FAU - Solmi, Marco AU - Solmi M AUID- ORCID: 0000-0003-4877-7233 AD - Department of Psychiatry and Ottawa Hospital Research Institute Clinical Epidemiology Program, University of Ottawa, Ottawa, Canada. FAU - Mortazavi, Matin AU - Mortazavi M AD - Evidence-based Psychiatry and Psychotherapy, Faculty of Medicine, University of Augsburg, Augsburg, Germany. AD - Department of Psychiatry, Psychotherapy and Psychosomatics, Medical Faculty, University of Augsburg, BKH Augsburg, Augsburg, Germany. FAU - Aminifarsani, Zahra AU - Aminifarsani Z AD - Evidence-based Psychiatry and Psychotherapy, Faculty of Medicine, University of Augsburg, Augsburg, Germany. AD - Department of Psychiatry, Psychotherapy and Psychosomatics, Medical Faculty, University of Augsburg, BKH Augsburg, Augsburg, Germany. FAU - Dubrovin Leao, Douglas AU - Dubrovin Leao D AD - Department of Psychiatry, Psychotherapy and Psychosomatics, Medical Faculty, University of Augsburg, BKH Augsburg, Augsburg, Germany. FAU - Burrage, Matthew K AU - Burrage MK AD - Regional Centre for the Treatment of Eating Disorders and On Track: The Champlain First Episode Psychosis Program, Department of Mental Health, The Ottawa Hospital, Ottawa, Canada. AD - Department of Child and Adolescent Psychiatry, Charite Universitatsmedizin, Berlin, Germany. FAU - Siskind, Dan AU - Siskind D AUID- ORCID: 0000-0002-2072-9216 AD - Queensland Centre for Mental Health Research, Brisbane, Australia. AD - Metro South Addiction and Mental Health Service, Metro South Health, Brisbane, Australia. AD - University of Queensland School of Clinical Medicine, Brisbane, Australia. AD - Faculty of Medicine, University of Queensland, Brisbane, Australia. FAU - McMahon, Laura AU - McMahon L AD - Department of Psychiatry and Ottawa Hospital Research Institute Clinical Epidemiology Program, University of Ottawa, Ottawa, Canada. AD - Department of Cardiology, Ipswich Hospital, Ipswich, Australia. FAU - Howes, Oliver D AU - Howes OD AUID- ORCID: 0000-0002-2928-1972 AD - Queensland Brain Institute, University of Queensland, Brisbane, Australia. FAU - Correll, Christoph U AU - Correll CU AD - Mental Health Service, Darling Downs Health District, Toowoomba, Australia. AD - Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. AD - Department of Psychiatry, Zucker Hillside Hospital, Glen Oaks, NY, USA. CN - CAM Expert Group FAU - Hasan, Alkomiet AU - Hasan A AD - Department of Psychiatry, Psychotherapy and Psychosomatics, Medical Faculty, University of Augsburg, BKH Augsburg, Augsburg, Germany. AD - Departments of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA. AD - DZPG (German Center for Mental Health), Partner Site Munchen/Augsburg, Augsburg, Germany. LA - eng PT - Consensus Statement PT - Journal Article PT - Systematic Review DEP - 20250602 PL - England TA - Br J Psychiatry JT - The British journal of psychiatry : the journal of mental science JID - 0342367 RN - 0 (Antipsychotic Agents) RN - J60AR2IKIC (Clozapine) SB - IM EIN - Br J Psychiatry. 2025 Aug 15;228(4):387. doi: 10.1192/bjp.2025.10372. PMID: 40814826 MH - Humans MH - *Antipsychotic Agents/adverse effects MH - *Clozapine/adverse effects MH - Delphi Technique MH - *Myocarditis/chemically induced/prevention & control/diagnosis MH - Schizophrenia/drug therapy MH - *Schizophrenia, Treatment-Resistant/drug therapy PMC - PMC13051212 OTO - NOTNLM OT - Clozapine OT - cardiotoxicity OT - myocarditis OT - schizophrenia OT - treatment resistance COIS- The authors declare that there are no conflicts of interest in relation to the subject of this study. E.W. has been invited to advisory boards for Recordati, Teva and Boehringer Ingelheim. C.U.C. has been a consultant and/or advisor to or has received honoraria from: AbbVie, Acadia, Adock Ingram, Alkermes, Allergan, Angelini, Aristo, Biogen, Boehringer-Ingelheim, Bristol Myers Squibb, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Delpor, Denovo, Eli Lilly, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Jamjoom Pharma, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedInCell, Merck, Mindpax, Mitsubishi Tanabe Pharma, Maplight, Mylan, Neumora Therapeutics, Neurocrine, Neurelis, Newron, Noven, Novo Nordisk, Otsuka, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Sage, Saladax, Sanofi, Seqirus, SK Life Science, Sumitomo Pharma America, Sunovion, Sun Pharma, Supernus, Tabuk, Takeda, Teva, Tolmar, Vertex, Viatris and Xenon Pharmaceuticals. He has also provided expert testimony for Janssen, Lundbeck and Otsuka; has served on Data Safety Monitoring Boards for Compass Pathways, Denovo, IntraCellular Therapies, Lundbeck, Relmada, Reviva, Rovi, Supernus and Teva; has received grant support from Boehringer-Ingelheim, Janssen and Takeda; has received royalties from UpToDate and is a stock option holder of Cardio Diagnostics, Kuleon Biosciences, LB Pharma, Medlink, Mindpax and Quantic. O.D.H. reports investigator-initiated research funding from and/or participation in advisory/speaker meetings organised by Abbvie, Angellini, Autifony, Biogen, Boehringer-Ingelheim, Delix, Eli Lilly, Elysium, Heptares, Global Medical Education, Invicro, Jansenn, Karuna, Lilly, Lundbeck, Merck, Neumora, Neurocrine, Ontrack/ Pangea, Otsuka, Sunovion, Teva, Recordati, Roche, Rovi and Viatris/ Mylan. He was previously a part-time employee of Lundbeck A/v. D.S. is funded in part by an NHMRC EL2 Investigator Grant (GNT 1194635) and declares that as associate editor of the British Journal of Psychiatry, he did not take part in the review or decision-making process for this paper. M.S. received honoraria from and/or has been a consultant for Angelini, AbbVie, Boehringer Ingelheim, Lundbeck and Otsuka. A.H. has been a member of advisory boards of Boehringer Ingelheim, Lundbeck, Janssen, Otsuka, Rovi and Recordati and has received paid speakerships from these companies, as well as from AbbVie and Advanz. He is the editor of the German schizophrenia guideline. Declarations of interest from CAM expert group are provided in the Supplementary Material. EDAT- 2025/06/02 06:28 MHDA- 2026/05/27 12:34 PMCR- 2026/04/06 CRDT- 2025/06/02 01:53 PHST- 2026/05/27 12:34 [medline] PHST- 2025/06/02 06:28 [pubmed] PHST- 2025/06/02 01:53 [entrez] PHST- 2026/04/06 00:00 [pmc-release] AID - S0007125025000893 [pii] AID - 10.1192/bjp.2025.89 [doi] PST - ppublish SO - Br J Psychiatry. 2026 Apr;228(4):348-356. doi: 10.1192/bjp.2025.89. Epub 2025 Jun 2. PMID- 40452087 OWN - NLM STAT- MEDLINE DCOM- 20250601 LR - 20250601 IS - 1812-2078 (Electronic) IS - 1812-2027 (Linking) VI - 22 IP - 87 DP - 2024 Jul-Sep TI - Development of a Model One Stop Approach to Post-COVID-19 and other Rehabilitation Conditions. PG - 271-276 AB - Background Post-COVID-19 cases can cause severe disabling symptoms and functional disabilities. WHO recognizes the severity of the condition and publishes a standardised Case Report Form to inform clinical management and public health response. Objective To determine the post-COVID-19 case load. A multidisciplinary team including a diverse team were composed and priority intervention areas were identified through a transdisciplinary approach eventually developing a Model One Stop Approach to post-COVID-19 and other Rehabilitation Conditions. Method The COVID-19 cases recorded at Dhulikhel Hospital were monitored through phone calls to post-COVID-19 complications. Patients were then invited for additional clinical assessments. A diverse team conducted these assessments to identify the needs for expanding a post-COVID-19 clinic and devised rehabilitation services based on predefined criteria. Result A total of 550 respondents were included in the study. The proportion of males (51.7%) was slightly higher than females (48.3%) with the majority of them being Brahmin/Chettri. The primary comorbidities identified were diabetes (10.55%) and hypertension (11.4%). Of the participants, about 50.73% experienced persistent symptoms. About 17.8% reported lasting muscle-related problems, 12.1% had persistent joint pain, and 33% faced temporary cardiac issues. Less than 10% experienced enduring health problems related to vision, hearing, and sleep patterns. Conclusion After COVID-19, patients experienced cardiac and muscle-related issues, increasing morbidity, financial burdens, and pressure on healthcare systems. With the need of sustainable rehabilitation training package, Dhulikhel Hospital serves as a model for a One-Stop Approach to post-COVID-19 and other rehabilitation conditions. FAU - Adhikari, P AU - Adhikari P AD - Research and Development Division, Dhulikhel Hospital, Kathmandu University Hospital, Dhulikhel, Kavre, Nepal. FAU - Tamrakar, D AU - Tamrakar D AD - Research and Development Division, Dhulikhel Hospital, Kathmandu University Hospital, Dhulikhel, Kavre, Nepal. FAU - Thakur, C AU - Thakur C AD - Research and Development Division, Dhulikhel Hospital, Kathmandu University Hospital, Dhulikhel, Kavre, Nepal. FAU - Shakya, R AU - Shakya R AD - Department of Physiotherapy, Dhulikhel Hospital, Kathmandu University Hospital, Dhulikhel, Kavre, Nepal. FAU - Vaidya, N AU - Vaidya N AD - Department of Internal Medicine, Dhulikhel Hospital, Kathmandu University Hospital, Dhulikhel, Kavre, Nepal. FAU - Acharya, R AU - Acharya R AD - Department of Nursing, Dhulikhel Hospital, Kathmandu University Hospital, Dhulikhel, Kavre, Nepal. FAU - Shrestha, J AU - Shrestha J AD - Department of Nursing, Dhulikhel Hospital, Kathmandu University Hospital, Dhulikhel, Kavre, Nepal. FAU - Byanju Shrestha, I AU - Byanju Shrestha I AD - Research and Development Division, Dhulikhel Hospital, Kathmandu University Hospital, Dhulikhel, Kavre, Nepal. LA - eng PT - Journal Article PL - Nepal TA - Kathmandu Univ Med J (KUMJ) JT - Kathmandu University medical journal (KUMJ) JID - 101215359 SB - IM MH - Humans MH - *COVID-19/rehabilitation/complications/epidemiology MH - Female MH - Male MH - Middle Aged MH - Adult MH - SARS-CoV-2 MH - Nepal/epidemiology MH - Aged MH - Comorbidity EDAT- 2025/06/02 03:18 MHDA- 2025/06/02 03:19 CRDT- 2025/06/01 23:42 PHST- 2025/06/02 03:19 [medline] PHST- 2025/06/02 03:18 [pubmed] PHST- 2025/06/01 23:42 [entrez] PST - ppublish SO - Kathmandu Univ Med J (KUMJ). 2024 Jul-Sep;22(87):271-276. PMID- 40451807 OWN - NLM STAT- MEDLINE DCOM- 20250601 LR - 20250601 IS - 1349-3299 (Electronic) IS - 1349-2365 (Linking) VI - 66 IP - 3 DP - 2025 TI - Clinical Courses of Elderly Patients with Heart Failure Managed by Local Partnership Clinical Pathway and Multidisciplinary Care. PG - 352-362 LID - 10.1536/ihj.24-467 [doi] AB - Heart failure (HF) is the most critical issue in the medical and long-term care for the elderly because HF is an economic and social burden due to its high prevalence and poor prognosis. General practitioners (GPs) have recently managed patients with chronic HF (CHF) in collaboration with hospital cardiologists. However, little is known about how to collaborate and its outcomes.We have operated a local partnership program using clinical pathway (LPCP) for CHF to facilitate medical and nursing care teamwork in the local community since June 2009. The hospital's multidisciplinary teams evaluate and share patient information periodically. Among 500 patients with available follow-up data as of December 2020, we defined patients who withdrew from the LPCP for reasons other than death as path-dropout (n = 164) and the remaining as path-continue patients (n = 336). The Kaplan-Meier method considering time co-variability of path-dropout, showed a significantly higher hazard ratio of all-cause death in the path-dropout group than in the path-continue group (HR: 5.09; 95% CI: 3.54-7.30, P < 0.001).LPCP provides integrated disease management for CHF by cardiologists and multidisciplinary professionals in the hospital collaborating with local GPs and home care teams. A multivariate analysis identified LPCP as the most important independent predictor of clinical outcome. LPCP may work as an observational tool to distinguish HF patient clinical outcomes. FAU - Yamamoto, Yuki AU - Yamamoto Y AD - Division of Cardiovascular Medicine, Hokushin General Hospital. FAU - Watanabe, Noboru AU - Watanabe N AD - Division of Cardiovascular Medicine, Hokushin General Hospital. AD - Division of Internal and Cardiovascular Medicine, Marunouchi Hospital. FAU - Hasegawa, Satoru AU - Hasegawa S AD - Hasegawa Clinic, Chuko Medical Association. FAU - Tanaka, Chieko AU - Tanaka C AD - Nursing Department, Hokushin General Hospital. FAU - Takano, Chie AU - Takano C AD - Nursing Department, Hokushin General Hospital. FAU - Shimizu, Takahiro AU - Shimizu T AD - Division of Cardiovascular Medicine, Hokushin General Hospital. FAU - Motoki, Hirohiko AU - Motoki H AD - Department of Cardiovascular Medicine, Shinshu University School of Medicine. FAU - Isobe, Mitsuaki AU - Isobe M AD - Sakakibara Heart Institute. FAU - Kuwahara, Koichiro AU - Kuwahara K AD - Department of Cardiovascular Medicine, Shinshu University School of Medicine. LA - eng PT - Journal Article PL - Japan TA - Int Heart J JT - International heart journal JID - 101244240 SB - IM MH - Humans MH - *Heart Failure/therapy/mortality MH - Male MH - Female MH - Aged MH - *Patient Care Team/organization & administration MH - *Critical Pathways/organization & administration MH - Aged, 80 and over OTO - NOTNLM OT - Clinical pathway OT - Disease management OT - Local community OT - Long-term care EDAT- 2025/06/02 03:18 MHDA- 2025/06/02 03:19 CRDT- 2025/06/01 23:04 PHST- 2025/06/02 03:19 [medline] PHST- 2025/06/02 03:18 [pubmed] PHST- 2025/06/01 23:04 [entrez] AID - 10.1536/ihj.24-467 [doi] PST - ppublish SO - Int Heart J. 2025;66(3):352-362. doi: 10.1536/ihj.24-467. PMID- 40451445 OWN - NLM STAT- MEDLINE DCOM- 20250910 LR - 20250910 IS - 1879-1913 (Electronic) IS - 0002-9149 (Linking) VI - 252 DP - 2025 Oct 1 TI - Association of Mechanical Circulatory Support and Cardiac Catheterization Laboratory Procedural Volumes With Outcomes of Cardiogenic Shock. PG - 49-55 LID - S0002-9149(25)00343-1 [pii] LID - 10.1016/j.amjcard.2025.05.031 [doi] AB - Despite advancements in cardiogenic shock (CS) management, mortality remains high. While hospital volume has been linked to reduced mortality across myriad complex procedures, the cross-volume effects of mechanical circulatory support (MCS) and cardiac catheterization laboratory (CCL) procedures on CS patients not receiving these interventions remain unexplored. Using the 2016 to 2022 Nationwide Readmissions Database, we analyzed nonelective adult CS admissions at MCS- and CCL-capable hospitals. Hospitals were stratified into quartiles by annual volumes of MCS (intra-aortic balloon pump, percutaneous ventricular assist device, extracorporeal membrane oxygenation) and CCL procedures (coronary angiography, percutaneous coronary intervention), with the top quartile classified as high-volume (HVH-MCS or HVHCCL). Multivariable logistic and linear regression models were constructed to evaluate the independent association of high-volume status with mortality, complications, and resource utilization. Among 130,822 CS hospitalizations, 48.2% were treated at HVH-MCS and 46.1% at HVHCCL. Unadjusted mortality was lower at HVH-MCS (24.8% vs 30.7%, p <0.001) and HVHCCL (26.6% vs 29.0%, p <0.001). Following adjustment, HVH-MCS remained associated with reduced mortality (Adjusted odds ratio [AOR] 0.87, 95% confidence interval [CI] 0.82 to 0.93), while HVHCCL showed no significant benefit (p = 0.10). HVH-MCS also had lower respiratory (AOR 0.82, 95% CI 0.78 to 0.86) and infectious (AOR 0.85, 95% CI 0.80 to 0.90) complications, but longer hospital stays (beta +1.75 days, 95% CI 1.48 to 2.01) and higher costs (+$8,600, 95% CI 7,100 to 10,100). Increasing MCS volume appears independently correlated with improved CS outcomes, highlighting the cross-volume effect of institutional expertise. Contrastingly, CCL volume was not associated with in-hospital mortality, supporting centralization of CS care at high-volume MCS centers. CI - Copyright (c) 2025 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Tabibian, Kevin AU - Tabibian K AD - Cardiovascular Outcomes Research Laboratories (CORELAB), David Geffen School of Medicine at UCLA, Los Angeles, California. FAU - Vadlakonda, Amulya AU - Vadlakonda A AD - Cardiovascular Outcomes Research Laboratories (CORELAB), David Geffen School of Medicine at UCLA, Los Angeles, California. FAU - Coaston, Troy AU - Coaston T AD - Cardiovascular Outcomes Research Laboratories (CORELAB), David Geffen School of Medicine at UCLA, Los Angeles, California. FAU - Sakowitz, Sara AU - Sakowitz S AD - Cardiovascular Outcomes Research Laboratories (CORELAB), David Geffen School of Medicine at UCLA, Los Angeles, California. FAU - Ebrahimian, Shayan AU - Ebrahimian S AD - Cardiovascular Outcomes Research Laboratories (CORELAB), David Geffen School of Medicine at UCLA, Los Angeles, California; Department of Medicine, Division of Cardiology, David Geffen School of Medicine at UCLA, Los Angeles, California. FAU - Srivastava, Pratyaksh K AU - Srivastava PK AD - Department of Medicine, Division of Cardiology, David Geffen School of Medicine at UCLA, Los Angeles, California. FAU - Benharash, Peyman AU - Benharash P AD - Cardiovascular Outcomes Research Laboratories (CORELAB), David Geffen School of Medicine at UCLA, Los Angeles, California; Department of Surgery, Division of Cardiac Surgery, David Geffen School of Medicine at UCLA, Los Angeles, California. Electronic address: PBenharash@mednet.ucla.edu. LA - eng PT - Journal Article DEP - 20250530 PL - United States TA - Am J Cardiol JT - The American journal of cardiology JID - 0207277 SB - IM MH - Humans MH - *Shock, Cardiogenic/therapy/mortality MH - Male MH - Female MH - *Extracorporeal Membrane Oxygenation/statistics & numerical data MH - *Heart-Assist Devices/statistics & numerical data MH - *Cardiac Catheterization/statistics & numerical data MH - Middle Aged MH - *Intra-Aortic Balloon Pumping/statistics & numerical data MH - Hospital Mortality/trends MH - Aged MH - *Hospitals, High-Volume/statistics & numerical data MH - United States/epidemiology MH - Retrospective Studies MH - Percutaneous Coronary Intervention/statistics & numerical data MH - Coronary Angiography/statistics & numerical data MH - Survival Rate/trends OTO - NOTNLM OT - cardiac catheterization laboratory OT - cardiogenic shock OT - cross-volume OT - mechanical circulatory support OT - shock team OT - volume-outcome COIS- Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Peyman Benharash reports a relationship with AtriCure Inc that includes: consulting or advisory. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/06/02 03:18 MHDA- 2025/09/11 00:28 CRDT- 2025/06/01 21:16 PHST- 2025/04/19 00:00 [received] PHST- 2025/05/18 00:00 [revised] PHST- 2025/05/27 00:00 [accepted] PHST- 2025/09/11 00:28 [medline] PHST- 2025/06/02 03:18 [pubmed] PHST- 2025/06/01 21:16 [entrez] AID - S0002-9149(25)00343-1 [pii] AID - 10.1016/j.amjcard.2025.05.031 [doi] PST - ppublish SO - Am J Cardiol. 2025 Oct 1;252:49-55. doi: 10.1016/j.amjcard.2025.05.031. Epub 2025 May 30. PMID- 40449934 OWN - NLM STAT- MEDLINE DCOM- 20250531 LR - 20260813 IS - 1940-8250 (Electronic) IS - 0279-5442 (Linking) VI - 45 IP - 3 DP - 2025 Jun 1 TI - Interprofessional Approach to Reducing Central Line-Associated Bloodstream Infections in a Cardiac Surgical Intensive Care Unit. PG - 11-22 LID - 10.4037/ccn2025723 [doi] AB - BACKGROUND: Central line [catheter]-associated bloodstream infection (CLABSI) is associated with longer stays and increased cost, morbidity, and mortality. LOCAL PROBLEM: An academic cardiothoracic intensive care unit had a high CLABSI incidence (standardized infection ratio of 2.3 at baseline). The hospital's executive leadership team (chief nursing officer, chief medical officer, and chief of quality and performance improvement) directed intensive care unit leaders to reduce the standardized infection ratio. METHODS: Interprofessional CLABSI reduction efforts were formulated using A3 methods based on the plan-do-check-act cycle. Unit leaders (nurses, physicians, advanced practice providers, and allied health professionals) met every 2 weeks for 2 years to formulate CLABSI reduction efforts. Efficacy of CLABSI reduction was evaluated with the standardized infection ratio. INTERVENTIONS: Quality improvement activities included improved hand hygiene compliance, optimization of central venous catheter insertion, improved chlorhexidine dressing adherence, daily assessment of high-risk catheters for removal, use of an electronic intensive care unit bundle checklist to highlight central venous catheter duration for clinicians, and promotion of a blood culturing stewardship program with guidance on when to obtain blood samples for culture. RESULTS: Interprofessional CLABSI reduction efforts reduced the standardized infection ratio from 2.3 to 0.8 over 3 years. The standardized utilization ratio, reflecting observed to expected central venous catheter days, decreased from 1.0 to 0.89. CONCLUSION: Interprofessional CLABSI reduction efforts can be effective in a cardiac surgical intensive care unit and improve patient safety. Keys to success include teamwork, accountability, acceptance from intensive care unit staff, and support from hospital executive leaders. CI - (c)2025 American Association of Critical-Care Nurses. FAU - Mazzeffi, Michael AU - Mazzeffi M AD - Michael Mazzeffi is an anesthesiologist and critical care physician, Department of Anesthesiology, University of Virginia School of Medicine, Charlottesville, Virginia. FAU - White, Marcia P AU - White MP AD - Marcia P. White is a director of nursing, inpatient heart and vascular, University of Virginia Health, Charlottesville. FAU - Wade, Ashley AU - Wade A AD - Ashley Wade is the nurse manager for the thoracic and cardiovascular intensive care unit (ICU), University of Virginia Health. FAU - Jordan, Jacob AU - Jordan J AD - Jacob Jordan is an assistant nurse manager for the thoracic and cardiovascular intensive care unit, University of Virginia Health. FAU - Zaaqoq, Akram AU - Zaaqoq A AD - Akram Zaaqoq is medical director of the thoracic and cardiovascular ICU, Department of Anesthesiology, University of Virginia School of Medicine. FAU - Schneiderman, Emily AU - Schneiderman E AD - Emily Schneiderman is the lead advanced practice provider for the thoracic and cardiovascular ICU, Department of Anesthesiology, University of Virginia School of Medicine. FAU - Phillips, Tiffany AU - Phillips T AD - Tiffany Phillips is an assistant nurse manager for the thoracic and cardiovascular ICU, University of Virginia Health. FAU - Davis, Claire AU - Davis C AD - Claire Davis is a critical care physician, Department of Chest and Critical Care Medicine, Scripps Green Hospital, Scripps Clinic Medical Group, San Diego, California. FAU - Dahl, Jolian AU - Dahl J AD - Jolian Dahl is a cardiothoracic surgeon, Department of Cardiothoracic Surgery, Kaiser Permanente, Los Angeles, California. FAU - McNeil, John AU - McNeil J AD - John McNeil is division chief for cardiothoracic anesthesiology, Department of Anesthesiology, University of Virginia School of Medicine. FAU - Singh, Karen AU - Singh K AD - Karen Singh is a cardiothoracic anesthesiologist, Department of Anesthesiology, University of Virginia School of Medicine. FAU - Buckner, Joan AU - Buckner J AD - Joan Buckner is a hospital epidemiologist, University of Virginia Health. FAU - Sifri, Costi D AU - Sifri CD AD - Costi D. Sifri is an infectious disease physician, Department of Medicine, University of Virginia School of Medicine, and director of hospital epidemiology, Division of Infectious Diseases, Hospital Infection Prevention and Control and Epidemiology, University of Virginia Health. LA - eng PT - Journal Article PL - United States TA - Crit Care Nurse JT - Critical care nurse JID - 8207799 SB - IM EIN - Crit Care Nurse. 2025 Oct 1;45(5):7. doi: 10.4037/ccn2025750. PMID: 41027647 MH - Humans MH - *Catheter-Related Infections/prevention & control MH - *Intensive Care Units MH - *Catheterization, Central Venous/adverse effects MH - *Infection Control/standards/methods MH - Quality Improvement MH - Male MH - Critical Care Nursing/standards MH - Female MH - *Cardiac Surgical Procedures MH - *Cross Infection/prevention & control MH - *Interprofessional Relations MH - Patient Care Team MH - Middle Aged MH - Practice Guidelines as Topic EDAT- 2025/06/01 00:45 MHDA- 2025/06/01 00:46 CRDT- 2025/05/31 20:15 PHST- 2025/06/01 00:46 [medline] PHST- 2025/06/01 00:45 [pubmed] PHST- 2025/05/31 20:15 [entrez] AID - 32750 [pii] AID - 10.4037/ccn2025723 [doi] PST - ppublish SO - Crit Care Nurse. 2025 Jun 1;45(3):11-22. doi: 10.4037/ccn2025723. PMID- 40444359 OWN - NLM STAT- MEDLINE DCOM- 20250826 LR - 20260531 IS - 1524-4628 (Electronic) IS - 0039-2499 (Print) IS - 0039-2499 (Linking) VI - 56 IP - 9 DP - 2025 Sep TI - Perioperative Stroke: Mechanisms, Risk Stratification, and Management. PG - 2798-2809 LID - 10.1161/STROKEAHA.125.051673 [doi] AB - Perioperative stroke, defined as a cerebrovascular event occurring during surgery or within 30 days postoperatively, remains a devastating complication associated with substantial morbidity, disability, mortality, and increased healthcare utilization. Although overall incidence is relatively low-up to 1% in most surgical populations-it is significantly elevated in cardiac, major vascular, and neurosurgical procedures, often exceeding 5%. The rising prevalence of perioperative stroke, primarily driven by an aging surgical population burdened by multiple chronic vascular conditions and increasingly eligible for high-risk surgical interventions, underscores the urgency of optimizing preventive and management strategies. This review synthesizes insights into patient- and procedure-related risk factors, highlighting the intricate interplay of embolic, thrombotic, and hypoperfusion mechanisms underpinning perioperative ischemic strokes. Key patient-specific risks include advanced age, recent cerebrovascular events, atrial fibrillation, carotid stenosis, and chronic cardiovascular comorbidities. Procedural factors, such as the type and complexity of surgery, intraoperative hypotension, and vascular manipulations, further modulate stroke risk. Emphasizing an evidence-based approach to risk mitigation, this review examines preoperative risk stratification, intraoperative techniques designed to minimize cerebral embolization and preserve adequate perfusion, and structured postoperative protocols aimed at rapid stroke detection. Acute management complexities are also discussed, with careful consideration of intravenous thrombolysis and mechanical thrombectomy in the postoperative setting. Finally, gaps in current guidelines and promising areas for future research are identified, advocating a multidisciplinary approach involving neurology, surgery, anesthesiology, and allied specialties to enhance patient outcomes and reduce the perioperative stroke burden. FAU - Shu, Liqi AU - Shu L AUID- ORCID: 0000-0002-9784-8475 AD - Department of Neurology, The Alpert Medical School of Brown University, Providence, RI (L.S., S.Y.). FAU - Aziz, Yasmin N AU - Aziz YN AUID- ORCID: 0000-0002-3515-4005 AD - Department of Neurology and Rehabilitation Medicine, University of Cincinnati, OH (Y.N.A.). FAU - de Havenon, Adam AU - de Havenon A AUID- ORCID: 0000-0001-8178-8597 AD - Department of Neurology, Yale University, New Haven, CT (A.d.H.). FAU - Messe, Steven R AU - Messe SR AUID- ORCID: 0000-0003-3108-5441 AD - Department of Neurology, Hospital of the University of Pennsylvania, Philadelphia (S.R.M.). FAU - Nguyen, Thanh N AU - Nguyen TN AUID- ORCID: 0000-0002-2810-1685 AD - Departments of Neurology and Radiology, Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, MA (T.N.N.). FAU - Sur, Nicole B AU - Sur NB AUID- ORCID: 0000-0002-3541-3599 AD - Department of Neurology, University of Miami Miller School of Medicine, FL (N.B.S.). FAU - Xiong, Lize AU - Xiong L AUID- ORCID: 0000-0002-9204-8129 AD - Shanghai Key Laboratory of Anesthesiology and Brain Functional Modulation, Department of Anaesthesiology and Perioperative Medicine, Shanghai Fourth People's Hospital Affiliated to Tongji University, Tongji University, China (L.X.). FAU - Yaghi, Shadi AU - Yaghi S AUID- ORCID: 0000-0003-0031-1004 AD - Department of Neurology, The Alpert Medical School of Brown University, Providence, RI (L.S., S.Y.). LA - eng GR - U24 NS107215/NS/NINDS NIH HHS/United States PT - Journal Article PT - Review DEP - 20250530 PL - United States TA - Stroke JT - Stroke JID - 0235266 SB - IM MH - Humans MH - *Stroke/therapy/etiology/epidemiology/diagnosis MH - *Postoperative Complications/therapy/epidemiology MH - Risk Factors MH - Risk Assessment MH - *Intraoperative Complications/therapy PMC - PMC12354081 MID - NIHMS2084029 OTO - NOTNLM OT - intraoperative complications OT - ischemic stroke OT - perioperative care OT - postoperative complications OT - risk factors COIS- Dr Sur receives research funding from the Evelyn F. McKnight Brain Institute and serves on the editorial boards for Stroke, JACC: Advances, and Journal of Clinical and Translational Science. Dr Nguyen discloses being Associate Editor of Stroke; part of the advisory board at Brainomix and Aruna Bio; speaker for Genentech and Kaneka. Dr de Havenon reports consulting fees from Novo Nordisk, equity in Titin KM and Certus, and fees from UptoDate. The other authors report no conflicts. EDAT- 2025/05/30 08:30 MHDA- 2025/08/31 19:59 PMCR- 2026/05/30 CRDT- 2025/05/30 05:03 PHST- 2025/08/31 19:59 [medline] PHST- 2025/05/30 08:30 [pubmed] PHST- 2025/05/30 05:03 [entrez] PHST- 2026/05/30 00:00 [pmc-release] AID - 10.1161/STROKEAHA.125.051673 [doi] PST - ppublish SO - Stroke. 2025 Sep;56(9):2798-2809. doi: 10.1161/STROKEAHA.125.051673. Epub 2025 May 30. PMID- 40443129 OWN - NLM STAT- Publisher LR - 20250530 IS - 1545-1550 (Electronic) IS - 1526-6028 (Linking) DP - 2025 May 29 TI - The Curated Treatment of a Young Woman With Marfan Syndrome: Elective Open Ascending Repair to Emergent Thoracoabdominal Endovascular Repair. PG - 15266028251344802 LID - 10.1177/15266028251344802 [doi] AB - BACKGROUND: Hereditary aortopathies traditionally require open repair when significant pathologies arise. Open provides the most durable outcome for nominally a younger patient population that can tolerate larger procedures well. In certain situations, literature has described proceeding with endovascular repair in patients with known hereditary aortopathies. CASE REPORT: This case report describes the treatment of a 29-year-old female with a history of type A dissection previously treated with a valve sparing aortic root repair and a type B dissection with a thoracic endovascular aortic repair (TEVAR) 2 years prior. Genetic testing then confirmed Marfan's syndrome, and she was followed by vascular medicine specialists and optimized medically. Several other family members also tested positive and imaging revealed aortic abnormalities. She arrived at our institution endorsing severe nausea, vomiting, back, flank, and abdominal pain. She was found on imaging to have a rapidly degenerating type II thoracoabdominal aortic aneurysm (TAAA) with dissection. A multidisciplinary team evaluated the patient and working with cardiothoracic (CT) surgery, our initial plan was an open repair. Following admission to the ICU, her symptoms improved with tight blood pressure control; however, she rapidly clinically decompensated with worsening pain and hypotension the day prior to her planned open repair. A massive transfusion protocol was initiated and CT scan revealed more than a 1 cm growth and evolution of her dissection. At the time, the CT surgery group were in cases and could not free an attending, and therefore recommended that we temporize the situation with balloon control and a fenestrated repair. We emergently proceeded to the operating room and obtained balloon control prior to induction of anesthesia while the 4-vessel fenestrated/branched endograft (F/BEVAR) was constructed. Repair was carried out with a bifurcated graft into the bilateral iliac arteries. However, following the endovascular repair, the patient did not want to proceed with a large open surgery and was managed definitively with endovascular means and ultimately required reintervention for a type 3 endoleak (EL) (bridging TEVAR) and type 1B EL requiring hypogastric preservation to minimize spinal cord ischemia. CT scan prior to discharge revealed only a type 2 EL, and she was discharged home with full motor and sensory function. Approximately 1 year later, a CT scan revealed regression of the aneurysm near her visceral segment, but growth near the aortic bifurcation and a type 2 EL. This was treated with a trans-caval approach and embolization of several segmental branches and the aneurysm sac with thrombin and gelfoam. Subsequent CT scans over the next 2 years have shown continued sac regression. CONCLUSION: This case serves as an example that an endovascular repair may play a role in the emergent treatment of complex anatomies in patients with Marfan syndrome especially when refusing open surgery. This repair has to date shown mid-term success with near-complete aneurysm sac regression and no endoleak, but to achieve this the patient has required strict surveillance and 2 reinterventions in the first year following the index case. Ultimately, this represents one of the first ruptured TAAA in a Marfan patient treated with a F/BEVAR.Clinical ImpactPatients with genetic aortopathies are at risk for aneurysmal degeneration and disease progression. It is important to manage patients with genetic aortopathies expeditiously and in emergency settings a total endovascular approach can be used. Each case requires a multidisciplinary approach and thoughtful planning. FAU - Patel, Rohini J AU - Patel RJ AUID- ORCID: 0000-0002-9812-6992 AD - Division of Vascular and Endovascular Surgery, Department of Surgery, University of California San Diego, San Diego, CA, USA. FAU - Golts, Eugene AU - Golts E AD - Division of Cardiac and Thoracic Surgery, Department of Surgery, University of California San Diego, San Diego, CA, USA. FAU - Barleben, Andrew R AU - Barleben AR AUID- ORCID: 0000-0003-1586-084X AD - Division of Vascular and Endovascular Surgery, Department of Surgery, University of California San Diego, San Diego, CA, USA. LA - eng PT - Journal Article DEP - 20250529 PL - United States TA - J Endovasc Ther JT - Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists JID - 100896915 SB - IM OTO - NOTNLM OT - Marfan syndrome OT - aortic dissection OT - endovascular aneurysm repair OT - fenestrated EVAR OT - hereditary aortopathy OT - thoracoabdominal aortic aneurysm EDAT- 2025/05/30 07:50 MHDA- 2025/05/30 07:50 CRDT- 2025/05/30 02:43 PHST- 2025/05/30 07:50 [medline] PHST- 2025/05/30 07:50 [pubmed] PHST- 2025/05/30 02:43 [entrez] AID - 10.1177/15266028251344802 [doi] PST - aheadofprint SO - J Endovasc Ther. 2025 May 29:15266028251344802. doi: 10.1177/15266028251344802. PMID- 40442583 OWN - NLM STAT- MEDLINE DCOM- 20250530 LR - 20250601 IS - 1471-227X (Electronic) IS - 1471-227X (Linking) VI - 25 IP - 1 DP - 2025 May 30 TI - Barriers to the success of cardiopulmonary resuscitation teams in emergency departments: A perspective from nurses. PG - 85 LID - 10.1186/s12873-025-01245-5 [doi] LID - 85 AB - BACKGROUND: Cardiopulmonary arrest is one of the most important emergency situations in hospitals. Although cardiopulmonary resuscitation has long been the first step in these conditions, the low success rate of this process is still a major concern in treatment systems. Therefore, identifying the barriers and causes of failure of the cardiopulmonary resuscitation team has become an important factor in improving the results. The present study was conducted to identify the barriers to the success of cardiopulmonary resuscitation teams in emergency departments. METHODS: A descriptive-analytical study was conducted in the emergency department of teaching hospitals in Qazvin, Iran 2023-2024. Using available sampling, 198 emergency department nurses were included in the study. Nurses were included in the study if they had at least 6 months of work experience in the emergency department, had at least a bachelor's degree, and experienced at least one cardiopulmonary resuscitation operation. The exclusion criteria were incomplete completion of the questionnaires and withdrawal from the study for any reason. The data was collected using the demographic characteristics checklist and the questionnaire on barriers to the success of the cardiopulmonary resuscitation team. Data analysis was performed using SPSS-24 software and descriptive and inferential statistics. The significance level of all tests was considered less than p < 0.05. RESULTS: The mean age of the participants was 30.96 +/- 5.15. Out of 198 nurses participating in the study, 125 were female (63.1%) and the rest were male. According to the results, the main barriers to the success of the cardiopulmonary resuscitation team in the emergency department are related to the individual and professional characteristics of the resuscitation team members with a score of 2.50 +/- 0.38 and the least reason is related to the program and educational facilities dimension with a score of 2.32 +/- 0.50. In the patient characteristics dimension, the initial rhythm (2.70 +/- 0.58) and in the individual and professional characteristics of the resuscitation team members, the lack of skilled and experienced people (2.62 +/- 1.51) were the main barriers to the success of the cardiopulmonary resuscitation team. From the nurses' point of view, in the dimension of resuscitation team management, the absence of an effective leader in the team (2.41 +/- 0.64), in the dimension of equipment and devices needed for resuscitation, the absence and unpreparedness of resuscitation equipment and devices in the department (2.53 +/- 0.55), and in the dimension of program and educational facilities related to resuscitation, the lack of adequate and appropriate educational facilities and equipment (2.40 +/- 0.64) were the main barriers to the success of the cardiopulmonary resuscitation team. The results of the t-test showed that there is no significant relationship between age, gender, and educational qualification with the average score of the whole questionnaire (P > 0.05). CONCLUSIONS: The results of this study showed that the individual and professional characteristics of cardiopulmonary resuscitation team members are the weak points and the most important barriers to the success of this team in the emergency department. Therefore, it is possible to reduce the barriers to the success of cardiopulmonary resuscitation and increase the survival rate of cardiopulmonary resuscitation by using experienced, skilled, and highly knowledgeable staff. Reducing or eliminating these barriers requires a detailed policy of managers and planners in individual, equipment, and training dimensions. CI - (c) 2025. The Author(s). FAU - Sadeghi, Alireza AU - Sadeghi A AD - Student Research Committee, Qazvin University of Medical Sciences, Qazvin, Iran. FAU - Jahani, Hosein AU - Jahani H AD - Student Research Committee, Social Determinants of Health Research Center, Research Institute for Prevention of Non-Communicable Diseases, Qazvin University of Medical Sciences, Qazvin, Iran. FAU - Senmar, Mojtaba AU - Senmar M AUID- ORCID: 0000-0002-6011-4267 AD - Student Research Committee, Social Determinants of Health Research Center, Research Institute for Prevention of Non-Communicable Diseases, Qazvin University of Medical Sciences, Qazvin, Iran. senmarmojtaba@gmail.com. FAU - Mehdipour, Farzaneh AU - Mehdipour F AD - Non-Communicable Diseases Research Center, Research Institute for Prevention of Non-Communicable Diseases, Qazvin University of Medical Sciences, Qazvin, Iran. FAU - Mirzaei, Amir Reza AU - Mirzaei AR AD - Student Research Committee, Qazvin University of Medical Sciences, Qazvin, Iran. FAU - Poorshivaee, Ali AU - Poorshivaee A AD - Student Research Committee, Qazvin University of Medical Sciences, Qazvin, Iran. FAU - Hosseini, Faranak Sadat AU - Hosseini FS AD - Student Research Committee, Qazvin University of Medical Sciences, Qazvin, Iran. LA - eng PT - Journal Article DEP - 20250530 PL - England TA - BMC Emerg Med JT - BMC emergency medicine JID - 100968543 SB - IM MH - Humans MH - *Emergency Service, Hospital/organization & administration MH - *Cardiopulmonary Resuscitation/nursing MH - Female MH - Male MH - Iran MH - Adult MH - Middle Aged MH - Surveys and Questionnaires MH - *Patient Care Team MH - *Heart Arrest/therapy MH - *Nursing Staff, Hospital/psychology MH - *Attitude of Health Personnel MH - Hospitals, Teaching PMC - PMC12123817 OTO - NOTNLM OT - Cardiopulmonary resuscitation OT - Code team OT - Emergency OT - Nurse COIS- Declarations. Ethics approval and consent to participate: The present study is approved by the Ethics Committee of Qazvin University of Medical Sciences (IR.QUMS.REC.1401.220). The participants were given information about the purpose and method of conducting the study, the confidentiality of the information, and the optional participation in the study. Written informed consent was obtained from the nurses. All the steps of the research were done according to the Declaration of Helsinki. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2025/05/30 02:00 MHDA- 2025/05/30 02:01 PMCR- 2025/05/30 CRDT- 2025/05/29 23:38 PHST- 2025/02/04 00:00 [received] PHST- 2025/05/20 00:00 [accepted] PHST- 2025/05/30 02:01 [medline] PHST- 2025/05/30 02:00 [pubmed] PHST- 2025/05/29 23:38 [entrez] PHST- 2025/05/30 00:00 [pmc-release] AID - 10.1186/s12873-025-01245-5 [pii] AID - 1245 [pii] AID - 10.1186/s12873-025-01245-5 [doi] PST - epublish SO - BMC Emerg Med. 2025 May 30;25(1):85. doi: 10.1186/s12873-025-01245-5. PMID- 40439952 OWN - NLM STAT- MEDLINE DCOM- 20250624 LR - 20250624 IS - 1865-8652 (Electronic) IS - 0741-238X (Print) IS - 0741-238X (Linking) VI - 42 IP - 7 DP - 2025 Jul TI - Economic Burden and Provider Referral Patterns Among Patients with Unresectable Stage III EGFR-Mutated NSCLC Receiving Chemoradiotherapy in the United States. PG - 3505-3527 LID - 10.1007/s12325-025-03239-y [doi] AB - INTRODUCTION: Among patients with unresectable stage III non-small cell lung cancer (NSCLC), those whose tumors harbor epidermal growth factor receptor mutations (EGFRm) are associated with comparatively fewer treatment options and worse prognosis. With the recent approval of targeted treatment, characterizing the economic burden and EGFRm testing and provider referral patterns is crucial to understanding the unmet needs of these patients. METHODS: This was a retrospective analysis of Optum's Market Clarity Dataset from January 1, 2018 to June 30, 2023. Eligibility criteria included diagnosis with unresectable stage III EGFRm NSCLC and chemoradiotherapy (CRT) initiation (index date) within 90 days. Primary outcomes were per patient per month (PPPM) all-cause and NSCLC-related health care resource utilization (HCRU) and costs, and EGFRm testing and provider referral patterns. RESULTS: A total of 144 patients were followed for a median of 15.5 months; 56.3% of patients underwent EGFRm testing before CRT initiation. All-cause and NSCLC-related costs during follow-up were $28,020 and $22,816 PPPM, respectively. Ambulatory utilization was the major driver of this economic burden. Pharmacy costs accounted for $4244 (15.1%) and $3736 (16.4%) of the total all-cause and NSCLC-related costs, respectively. Between diagnosis and CRT initiation, the most common specialties visited were oncology/hematology (seen by 67.4% of patients), radiology (26.4%), pulmonology (22.2%), and cardiology (21.5%). Patients who visited three or more specialties on separate days before CRT initiation had a median time to CRT initiation of 33.0 days versus 22.0 days when patients visited multiple specialties on the same day (suggestive of a multidisciplinary care team, MDT). CONCLUSION: Patients with unresectable stage III EGFRm NSCLC incur substantial economic burden, especially in ambulatory HCRU and costs. With the recent approval of targeted treatment for these patients, reflex EGFRm testing in all early-stage NSCLC at diagnosis is encouraged. Our results also suggest MDT involvement may improve completeness in diagnosis and staging, resulting in acceleration of treatment planning and management. CI - (c) 2025. The Author(s). FAU - Kim, YongJin AU - Kim Y AUID- ORCID: 0000-0002-3055-9943 AD - AstraZeneca, Mississauga, ON, Canada. FAU - Zhu, Yong AU - Zhu Y AUID- ORCID: 0009-0006-1090-0979 AD - Optum, 1 Optum Circle, Eden Prairie, MN, 55344, USA. yong_zhu@optum.com. FAU - Moore, Kristin J AU - Moore KJ AUID- ORCID: 0000-0003-2179-6565 AD - Optum, 1 Optum Circle, Eden Prairie, MN, 55344, USA. FAU - DuCharme, Mary AU - DuCharme M AUID- ORCID: 0009-0000-1372-8525 AD - Optum, 1 Optum Circle, Eden Prairie, MN, 55344, USA. FAU - James, Dan AU - James D AD - Polaris Biostatistics, Edinburgh, UK. FAU - Shehu, Arber AU - Shehu A AUID- ORCID: 0000-0002-0196-2960 AD - US Oncology Medical Affairs, AstraZeneca, Gaithersburg, MD, USA. FAU - Rattigan-Brown, Yanique AU - Rattigan-Brown Y AD - US Oncology Medical Affairs, AstraZeneca, Gaithersburg, MD, USA. FAU - Ohaegbulam, Kim AU - Ohaegbulam K AUID- ORCID: 0000-0002-0498-3708 AD - Department of Radiation Medicine, Oregon Health & Science University, Portland, OR, USA. LA - eng PT - Journal Article DEP - 20250529 PL - United States TA - Adv Ther JT - Advances in therapy JID - 8611864 RN - EC 2.7.10.1 (ErbB Receptors) RN - EC 2.7.10.1 (EGFR protein, human) SB - IM MH - Humans MH - *Carcinoma, Non-Small-Cell Lung/therapy/genetics/economics/pathology MH - *Lung Neoplasms/therapy/genetics/economics/pathology MH - Retrospective Studies MH - Male MH - Female MH - *Chemoradiotherapy/economics MH - Middle Aged MH - United States MH - *Referral and Consultation/economics/statistics & numerical data MH - ErbB Receptors/genetics MH - Aged MH - Mutation MH - Cost of Illness MH - Neoplasm Staging MH - Health Care Costs MH - Adult PMC - PMC12182491 OAB - Chemotherapy followed by radiotherapy, known as chemoradiotherapy (CRT), is recommended as the most appropriate treatment for patients with unresectable (inoperable) stage III non-small cell lung cancer (NSCLC). In the USA, 10-15% of patients with unresectable stage III NSCLC have tumors that contain a mutation in the epidermal growth factor receptor gene (known as EGFRm NSCLC). EGFR is a protein that controls cell growth and division. Osimertinib has emerged as a promising new treatment for patients with EGFRm, but little is known about their needs and course of treatment. Our study assessed the economic burden, provider referral patterns, and mutation testing patterns associated with treatment in the era prior to osimertinib's approval.We used insurance claims and electronic health records to identify 144 patients with EGFRm and unresectable stage III NSCLC. After initiating CRT, costs averaged $28,020 per patient per month, mostly attributable to ambulatory (office/outpatient) visits (49.0% of total costs) and medications (15.1%). Between NSCLC diagnosis and CRT initiation, patients most frequently visited oncology/hematology specialists (seen by 67.4% of patients). Suggestive of a multidisciplinary team of providers, 13 patients (9.0%) had same-day consultations with multiple specialties before CRT initiation. The median time to CRT initiation from diagnosis was 11 days earlier than patients who saw three or more specialists in sequential order. Although all patients had EGFRm, only 76.4% of testing claims occurred before CRT initiation. To improve patient care and treatment access, multidisciplinary provider consultations and EGFR testing prior to CRT initiation are encouraged. OABL- eng OTO - NOTNLM OT - EGFR mutation OT - Chemoradiotherapy OT - Health care resource utilization OT - Non-small cell lung cancer OT - Referral and consultation COIS- Declarations. Conflict of Interest: YongJin Kim, Arber Shehu, and Yanique Rattigan-Brown are employees and stockholders of AstraZeneca, PLC. Yong Zhu and Mary DuCharme are employees of Optum, a business unit of UnitedHealth Group, and stockholders of UnitedHealth Group. Kristin J. Moore is a current employee and stockholder of Jazz Pharmaceuticals, PLC. At the time of the study, she was an employee of Optum, a business unit of UnitedHealth Group. She is also a stockholder of UnitedHealth Group. Dan James is an employee of Polaris Biostatistics, Ltd., and received payment from AstraZeneca, PLC, for consultancy work. Kim Ohaegbulam has nothing to disclose. Ethical Approval: Institutional review board approval or waiver of approval was not required for this study because the study data were secondary and de-identified in accordance with the US Department of Health and Human Services Privacy Rule's requirements for de-identification codified at 45 CFR section sign 164.514(b). EDAT- 2025/05/29 12:59 MHDA- 2025/06/24 13:13 PMCR- 2025/05/29 CRDT- 2025/05/29 11:15 PHST- 2025/02/13 00:00 [received] PHST- 2025/05/09 00:00 [accepted] PHST- 2025/06/24 13:13 [medline] PHST- 2025/05/29 12:59 [pubmed] PHST- 2025/05/29 11:15 [entrez] PHST- 2025/05/29 00:00 [pmc-release] AID - 10.1007/s12325-025-03239-y [pii] AID - 3239 [pii] AID - 10.1007/s12325-025-03239-y [doi] PST - ppublish SO - Adv Ther. 2025 Jul;42(7):3505-3527. doi: 10.1007/s12325-025-03239-y. Epub 2025 May 29. PMID- 40439162 OWN - NLM STAT- MEDLINE DCOM- 20250609 LR - 20260622 IS - 1873-734X (Electronic) IS - 1010-7940 (Print) IS - 1010-7940 (Linking) VI - 67 IP - 6 DP - 2025 Jun 3 TI - Outcomes of conservative treatment for thoracic vascular graft infections. LID - 10.1093/ejcts/ezaf171 [doi] LID - ezaf171 AB - OBJECTIVES: Thoracic vascular graft infections are devastating complications after aortic surgery, entailing high mortality. The gold standard treatment combines excisional surgery and antimicrobial therapy, but patients deemed inoperable might benefit from a conservative approach. Outcomes of patients treated only with antimicrobial agents without reoperative surgery are scanty. We aim to describe patients' characteristics and outcomes using an antibiotic-only strategy without thorough debridement. METHODS: Retrospectively collected data from a prospective cohort in a tertiary centre. Descriptive analysis for baseline characteristics and Kaplan-Meier estimates for survival were performed. RESULTS: From November 2012 to December 2022, 66 patients were identified with aortic root, ascending aortic and aortic arch graft infections. Of these, 44 received an antibiotic-only strategy or in combination with selective debridement after achieving multidisciplinary consensus. Median follow-up was 4.8 years [interquartile range (IQR) 1.7-6.1], and cumulative survival was 82.9% (CI 95%, 69.7-96.1). Streptococcus spp were the most common isolated microorganisms. CONCLUSIONS: In selected cases, a conservative approach with antibiotics only or in combination with selective debridement showed acceptable results at follow-up, suggesting a valuable therapy option for this cohort of patients. CI - (c) The Author(s) 2025. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. FAU - Van Hemelrijck, Mathias AU - Van Hemelrijck M AUID- ORCID: 0000-0002-0191-757X AD - Department of Cardiac Surgery, University Hospital Zurich, Zurich, Switzerland. FAU - Sromicki, Juri AU - Sromicki J AUID- ORCID: 0000-0001-9964-7733 AD - Department of Cardiac Surgery, University Hospital Zurich, Zurich, Switzerland. FAU - Risteski, Petar AU - Risteski P AUID- ORCID: 0000-0001-6979-5057 AD - Department of Cardiac Surgery, University Hospital Zurich, Zurich, Switzerland. FAU - Boulos, Rasha AU - Boulos R AD - Department of Cardiac Surgery, University Hospital Zurich, Zurich, Switzerland. FAU - Buechel, Ronny R AU - Buechel RR AUID- ORCID: 0000-0001-8064-8904 AD - Department of Nuclear Medicine, Cardiac Imaging, University Hospital Zurich, Zurich, Switzerland. FAU - Frank, Michelle AU - Frank M AD - Department of Cardiology, University Hospital Zurich, Zurich, Switzerland. FAU - Hasse, Barbara AU - Hasse B AUID- ORCID: 0000-0001-7196-3734 AD - Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland. FAU - Rodriguez Cetina Biefer, Hector AU - Rodriguez Cetina Biefer H AUID- ORCID: 0000-0002-5855-8993 AD - Department of Cardiac Surgery, University Hospital Zurich, Zurich, Switzerland. AD - Center for Translational and Experimental Cardiology (CTEC), University of Zurich, Zurich, Switzerland. FAU - Dzemali, Omer AU - Dzemali O AUID- ORCID: 0000-0001-7910-5152 AD - Department of Cardiac Surgery, University Hospital Zurich, Zurich, Switzerland. AD - Center for Translational and Experimental Cardiology (CTEC), University of Zurich, Zurich, Switzerland. CN - VASGRA Cohort LA - eng GR - #32003B_219351/1/SNSF_/Swiss National Science Foundation/Switzerland PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Germany TA - Eur J Cardiothorac Surg JT - European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery JID - 8804069 RN - 0 (Anti-Bacterial Agents) SB - IM MH - Humans MH - Male MH - Female MH - Retrospective Studies MH - *Conservative Treatment/methods MH - *Prosthesis-Related Infections/therapy/mortality/microbiology MH - Aged MH - *Anti-Bacterial Agents/therapeutic use MH - Middle Aged MH - *Blood Vessel Prosthesis/adverse effects MH - Debridement/methods MH - *Aorta, Thoracic/surgery MH - Treatment Outcome MH - *Blood Vessel Prosthesis Implantation/adverse effects PMC - PMC12148214 OTO - NOTNLM OT - Antimicrobial treatment OT - Endocarditis team OT - Thoracic vascular graft infection FIR - Hasse, Barbara IR - Hasse B FIR - Ledergerber, Bruno IR - Ledergerber B FIR - Reutersberg, Benedikt IR - Reutersberg B FIR - Zinkernagel, Annelies S IR - Zinkernagel AS FIR - Zimmermann, Alexander IR - Zimmermann A EDAT- 2025/05/29 13:06 MHDA- 2025/06/09 18:28 PMCR- 2025/05/29 CRDT- 2025/05/29 07:13 PHST- 2024/11/14 00:00 [received] PHST- 2025/02/24 00:00 [revised] PHST- 2025/05/23 00:00 [accepted] PHST- 2025/06/09 18:28 [medline] PHST- 2025/05/29 13:06 [pubmed] PHST- 2025/05/29 07:13 [entrez] PHST- 2025/05/29 00:00 [pmc-release] AID - 8152695 [pii] AID - ezaf171 [pii] AID - 10.1093/ejcts/ezaf171 [doi] PST - ppublish SO - Eur J Cardiothorac Surg. 2025 Jun 3;67(6):ezaf171. doi: 10.1093/ejcts/ezaf171. PMID- 40439013 OWN - NLM STAT- MEDLINE DCOM- 20261008 LR - 20261008 IS - 2532-5264 (Electronic) IS - 1122-0643 (Linking) VI - 96 IP - 3 DP - 2026 Sep 7 TI - Infective endocarditis and oral health: a long-known threat, still a challenge. LID - 10.4081/monaldi.2025.3497 [doi] AB - Infective endocarditis (IE) remains a life-threatening condition associated with high morbidity and mortality, often influenced by the complex interplay between systemic and oral health. The increasing recognition of oral health as a risk modifier has led to greater focus on the oral microbiome, dental procedures, and periodontal disease as potential contributors to bacteremia and IE. This review critically examines the relationship between oral health and IE, exploring pathophysiological mechanisms, risk factors, and the evolving epidemiology of the disease. The discussion includes diagnostic challenges, particularly in culture-negative cases, and the emerging role of advanced imaging and molecular diagnostics in improving early detection. A central focus is placed on preventive strategies, highlighting the debate surrounding antibiotic prophylaxis (AP) in high-risk individuals and the potential role of periodontal therapy in reducing systemic inflammation and transient bacteremia. The review also addresses the growing concern of antimicrobial resistance and the necessity of balancing AP recommendations with antimicrobial stewardship. Additionally, this review identifies critical research gaps, including the need for longitudinal studies on the impact of oral health interventions on IE incidence and the importance of interdisciplinary collaboration between dental and medical professionals in optimizing patient care. By synthesizing current guidelines and emerging evidence, this review underscores the necessity of an integrated, multidisciplinary approach to mitigate the burden of IE and establish oral health as a key pillar of infection prevention. FAU - Alsergani, Mohamed AU - Alsergani M AUID- ORCID: 0009-0006-6071-8796 AD - Riyadh Elm University, Riyadh. FAU - Zaini, Renad Hatim AU - Zaini RH AD - Princess Nourah Bint Abdulrahman University, Riyadh. FAU - Al Kholaif, Naji AU - Al Kholaif N AUID- ORCID: 0009-0003-6914-0730 AD - Heart Center of Excellence, King Faisal Specialist Hospital and Research Center, Riyadh; College of Medicine, Alfaisal University, Riyadh. FAU - Al Admawi, Mohammed AU - Al Admawi M AD - Heart Center of Excellence, King Faisal Specialist Hospital and Research Center, Riyadh. FAU - Savo, Maria Teresa AU - Savo MT AUID- ORCID: 0000-0003-1877-8550 AD - Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua. FAU - Cozac, Dan Alexandru AU - Cozac DA AUID- ORCID: 0000-0002-9390-7263 AD - Physiology Department, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures. FAU - Tansella, Donatella AU - Tansella D AUID- ORCID: 0009-0005-9684-6426 AD - Division of Cardiology, Ospedale Mater Dei, Bari. FAU - Aladani, Basil Ali AU - Aladani BA AUID- ORCID: 0009-0009-5319-0948 AD - Heart Center of Excellence, King Faisal Specialist Hospital and Research Center, Riyadh. FAU - Di Michele, Sara AU - Di Michele S AD - Division of Cardiology, San Filippo Neri Hospital, Rome. FAU - Pergola, Valeria AU - Pergola V AD - Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua. LA - eng PT - Journal Article PT - Review DEP - 20250527 PL - Italy TA - Monaldi Arch Chest Dis JT - Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace JID - 9307314 RN - 0 (Anti-Bacterial Agents) SB - IM MH - Humans MH - *Oral Health/standards MH - Antibiotic Prophylaxis/methods MH - Risk Factors MH - *Endocarditis/epidemiology/prevention & control/etiology/diagnosis MH - Bacteremia/prevention & control/etiology MH - *Periodontal Diseases/complications/epidemiology MH - Anti-Bacterial Agents/therapeutic use MH - Microbiota OTO - NOTNLM OT - Infective endocarditis OT - antibiotic prophylaxis OT - oral health OT - oral microbiome EDAT- 2025/05/29 13:00 MHDA- 2026/10/08 05:31 CRDT- 2025/05/29 06:03 PHST- 2025/04/02 00:00 [received] PHST- 2025/04/12 00:00 [accepted] PHST- 2026/10/08 05:31 [medline] PHST- 2025/05/29 13:00 [pubmed] PHST- 2025/05/29 06:03 [entrez] AID - 10.4081/monaldi.2025.3497 [doi] PST - ppublish SO - Monaldi Arch Chest Dis. 2026 Sep 7;96(3). doi: 10.4081/monaldi.2025.3497. Epub 2025 May 27. PMID- 40436948 OWN - NLM STAT- MEDLINE DCOM- 20250528 LR - 20250531 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 15 IP - 1 DP - 2025 May 28 TI - Historical trends in histological composition and cause specific mortality of small intestine tumors based on SEER database analysis. PG - 18628 LID - 10.1038/s41598-025-03046-z [doi] LID - 18628 AB - Small intestine tumors, though rare, have shown a concerning increase in incidence and mortality in recent years. This study aimed to investigate the historical trends in histological composition and causes of death among patients with small intestine tumors using the SEER database. A total of 18,234 patients diagnosed with primary small intestine cancer from 1992 to 2018 were included in this study. Demographic details, tumor characteristics, treatment modalities, and outcomes were collected. Cause-specific mortality was analyzed using Fine and Gray regression, with non-small intestine-specific deaths considered as competing risks. Small intestine-specific deaths were the leading cause of mortality, with adenocarcinoma and carcinoid tumors being the most common histological types. Heart disease emerged as a significant cause of death following diagnosis, surpassing small intestine-specific deaths after 5-6 years. The study revealed variations in mortality causes across histological subtypes and identified risk factors for small intestine-specific mortality, including age, tumor site, grade, and treatment modalities. The findings highlight the substantial impact of heart disease on the long-term survival of patients with small intestine tumors. This underscores the potential benefits of adopting comprehensive management strategies that integrate oncological and cardiological care to improve survival rates and quality of life. A multidisciplinary approach in oncocardiology may help address the complex needs of these patients and optimize clinical outcomes. CI - (c) 2025. The Author(s). FAU - Ma, Tianheng AU - Ma T AD - Department of Gastroenterology, The Affiliated Huai'an No 1 People's Hospital of Nanjing Medical University, No.1 Huanghe West Road, Huai'an, 223300, Jiangsu, China. FAU - Wang, Honggang AU - Wang H AD - Department of Gastroenterology, The Affiliated Huai'an No 1 People's Hospital of Nanjing Medical University, No.1 Huanghe West Road, Huai'an, 223300, Jiangsu, China. FAU - Dai, Weijie AU - Dai W AD - Department of Gastroenterology, The Affiliated Huai'an No 1 People's Hospital of Nanjing Medical University, No.1 Huanghe West Road, Huai'an, 223300, Jiangsu, China. FAU - Shen, Peng AU - Shen P AD - Department of Gastroenterology, The Affiliated Huai'an No 1 People's Hospital of Nanjing Medical University, No.1 Huanghe West Road, Huai'an, 223300, Jiangsu, China. FAU - Zhang, Jialing AU - Zhang J AD - Department of Gastroenterology, The Affiliated Huai'an No 1 People's Hospital of Nanjing Medical University, No.1 Huanghe West Road, Huai'an, 223300, Jiangsu, China. zhangjialingone@163.com. FAU - Xie, Rui AU - Xie R AD - Department of Gastroenterology, The Affiliated Huai'an No 1 People's Hospital of Nanjing Medical University, No.1 Huanghe West Road, Huai'an, 223300, Jiangsu, China. kxpt_03@163.com. LA - eng GR - ID: SLKYQN20240126/Natural Science Research Cultivation Project of Northern Jiangsu Clinical Medicine Research Institute, Nanjing Medical University/ PT - Journal Article DEP - 20250528 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 SB - IM MH - Humans MH - *Intestinal Neoplasms/mortality/pathology MH - Male MH - *Intestine, Small/pathology MH - Female MH - Middle Aged MH - SEER Program MH - Aged MH - Cause of Death/trends MH - Adult MH - Risk Factors MH - Aged, 80 and over MH - Survival Rate MH - Adenocarcinoma/mortality/pathology PMC - PMC12120026 OTO - NOTNLM OT - Cause of death OT - Competing risk OT - Small intestine COIS- Declarations. Competing interests: The authors declare no competing interests. EDAT- 2025/05/29 00:27 MHDA- 2025/05/29 00:28 PMCR- 2025/05/28 CRDT- 2025/05/28 23:20 PHST- 2024/07/07 00:00 [received] PHST- 2025/05/19 00:00 [accepted] PHST- 2025/05/29 00:28 [medline] PHST- 2025/05/29 00:27 [pubmed] PHST- 2025/05/28 23:20 [entrez] PHST- 2025/05/28 00:00 [pmc-release] AID - 10.1038/s41598-025-03046-z [pii] AID - 3046 [pii] AID - 10.1038/s41598-025-03046-z [doi] PST - epublish SO - Sci Rep. 2025 May 28;15(1):18628. doi: 10.1038/s41598-025-03046-z. PMID- 40435875 OWN - NLM STAT- MEDLINE DCOM- 20250627 LR - 20260830 IS - 1527-3288 (Electronic) IS - 0147-9563 (Linking) VI - 73 DP - 2025 Sep-Oct TI - A novel nurse-led, multidisciplinary, and guideline-directed disease intensive management program improves long-term survival of pulmonary hypertension patients. PG - 190-196 LID - S0147-9563(25)00120-7 [pii] LID - 10.1016/j.hrtlng.2025.05.011 [doi] AB - BACKGROUND: Although the overall survival of pulmonary hypertension (PH) patients improved in the current era, better management strategy for PH patients still needs further exploration. OBJECTIVES: Here, we proposed a novel nurse-led, multidisciplinary, and guideline-directed disease intensive management program and hypothesized this strategy would improve the overall survival of PH patients. METHODS: Patients were prospectively enrolled and divided into the intensive management group (IDM) and the conventional disease care (CDC) group voluntarily. Intensive management was nurse-led and delivered by multidisciplinary teams, including patient education, symptoms monitoring, and patient adherence improvement with careful outpatient or inpatient assessment every 3 months and medicine prescription whenever needed. Patients with conventional care were treated by primary cardiologists' consultants and telephone follow-ups every year. RESULTS: Overall, 413 PH patients were finally included. Both total survival (p<0.001) and event-free survival (p=0.008) of the IDM group were significantly higher than the CDC group. After adjustment of age and sex, intensive management was also an independent protective predictor for both primary [all-cause mortality, HR 0.378, 95% CI (0.214-0.668), p<0.001] and composite endpoints [all-cause mortality and re-hospitalization, HR 0.648, 95% CI (0.454-0.927), p=0.017]. In subgroup analysis, IDM was beneficial in prolonging the overall survival of patients in high-risk situations (HR 0.283, 95% CI 0.125-0.641, p=0.002) and with advanced RV dysfunction (HR 0.250, 95% CI 0.123-0.510, p<0.001). CONCLUSION: Nurse-led, multidisciplinary, and guideline-directed disease intensive management program represented an ideal method to strengthen the overall and event-free survival of PH patients, especially for those in advanced stages of PH. CI - Copyright (c) 2025. Published by Elsevier Inc. FAU - Guo, Jiajun AU - Guo J AD - Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China. FAU - He, Juan AU - He J AD - Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China. FAU - Wang, Jiaqi AU - Wang J AD - Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China. FAU - Liang, Yaodan AU - Liang Y AD - Department of Pulmonary and Critical Care Medicine, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, China. FAU - Li, Yangjie AU - Li Y AD - Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China. FAU - Chen, Chen AU - Chen C AD - Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China. FAU - Wen, Bi AU - Wen B AD - Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China. FAU - Yin, Lidan AU - Yin L AD - Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China. FAU - Pu, Shoufang AU - Pu S AD - Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China. FAU - Wan, Ke AU - Wan K AD - Department of Geriatrics, West China Hospital, Sichuan University, Chengdu, China. FAU - Wang, Jie AU - Wang J AD - Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China. FAU - Li, Weihao AU - Li W AD - Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China. FAU - Xu, Yuanwei AU - Xu Y AD - Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China. FAU - Han, Yuchi AU - Han Y AD - Cardiovascular Medicine, Wexner Medical Center, College of Medicine, The Ohio State University, 460 W. 12th Avenue, Columbus. FAU - Chen, Yucheng AU - Chen Y AD - Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China. Electronic address: chenyucheng2003@126.com. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20250527 PL - United States TA - Heart Lung JT - Heart & lung : the journal of critical care JID - 0330057 SB - IM MH - Humans MH - *Hypertension, Pulmonary/mortality/nursing/therapy MH - Male MH - Female MH - Middle Aged MH - Prospective Studies MH - *Patient Care Team/organization & administration MH - Aged MH - *Disease Management MH - *Practice Guidelines as Topic MH - Survival Rate/trends OTO - NOTNLM OT - Disease management OT - Multidisciplinary OT - Nurse-led OT - Prognosis OT - Pulmonary hypertension COIS- Declaration of competing interest The authors report no relationships that could be construed as a conflict of interest. EDAT- 2025/05/29 00:27 MHDA- 2025/06/28 00:39 CRDT- 2025/05/28 18:10 PHST- 2024/10/11 00:00 [received] PHST- 2025/01/02 00:00 [revised] PHST- 2025/05/20 00:00 [accepted] PHST- 2025/06/28 00:39 [medline] PHST- 2025/05/29 00:27 [pubmed] PHST- 2025/05/28 18:10 [entrez] AID - S0147-9563(25)00120-7 [pii] AID - 10.1016/j.hrtlng.2025.05.011 [doi] PST - ppublish SO - Heart Lung. 2025 Sep-Oct;73:190-196. doi: 10.1016/j.hrtlng.2025.05.011. Epub 2025 May 27. PMID- 40434908 OWN - NLM STAT- MEDLINE DCOM- 20250610 LR - 20260822 IS - 1873-734X (Electronic) IS - 1010-7940 (Linking) VI - 67 IP - 5 DP - 2025 May 6 TI - Review of minimally invasive coronary artery bypass grafting. LID - ezaf160 [pii] LID - 10.1093/ejcts/ezaf160 [doi] AB - OBJECTIVES: Minimally invasive coronary artery bypass grafting (CABG), defined broadly as surgical revascularization via any sternotomy-sparing approach. Here, we provide an overview of minimally invasive CABG targeted to cardiologists, cardiac surgeons and other clinicians involved in the care of patients with coronary artery disease (CAD). METHODS: A narrative review of the literature on minimally invasive CABG was performed. RESULTS: Minimally invasive CABG was first described over 20 years ago, yet uptake has been slow and available data are limited. The most common iteration of minimally invasive CABG is a single-vessel CABG (left internal mammary artery to the left anterior descending artery) performed without the cardiopulmonary bypass machine via mini-thoracotomy. However, in patients with multivessel CAD, other options include minimally invasive multivessel CABG and hybrid revascularization (minimally invasive CABG with percutaneous coronary intervention). Patient selection and preoperative planning are paramount. Observational studies and small randomized controlled trials demonstrate that minimally invasive CABG is associated with reduced rates of blood transfusion, surgical site infections, lengths of intensive care unit and hospital stays, and time to return to full activity with promising late outcomes. Finally, we describe future areas for growth, including ongoing clinical trials, gaps in evidence and pragmatic considerations for surgeons interested in starting a minimally invasive CABG programme. CONCLUSIONS: Minimally invasive CABG can expand the armamentarium of revascularization techniques available for the ageing and increasingly complex population of patients with CAD. CI - (c) The Author(s) 2025. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com. FAU - Walton, Allison J AU - Walton AJ AD - Division of Cardiothoracic Surgery, Department of Surgery, Duke University Medical Center, Durham, NC, USA. FAU - Pineda, Andres M AU - Pineda AM AD - Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC, USA. FAU - Rogers, Luke AU - Rogers L AD - Division of Cardiovascular Surgery, Peter Munk Cardiac Centre, Toronto General Hospital, University Health Network, Toronto, ON, Canada. AD - Department of Surgery, University of Toronto, Toronto, ON, Canada. FAU - Davierwala, Piroze M AU - Davierwala PM AD - Division of Cardiovascular Surgery, Peter Munk Cardiac Centre, Toronto General Hospital, University Health Network, Toronto, ON, Canada. AD - Department of Surgery, University of Toronto, Toronto, ON, Canada. FAU - Zwischenberger, Brittany A AU - Zwischenberger BA AUID- ORCID: 0000-0002-0675-0983 AD - Division of Cardiothoracic Surgery, Department of Surgery, Duke University Medical Center, Durham, NC, USA. LA - eng PT - Journal Article PT - Review PL - Germany TA - Eur J Cardiothorac Surg JT - European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery JID - 8804069 SB - IM EIN - Eur J Cardiothorac Surg. 2026 Feb 5;68(2):ezag080. doi: 10.1093/ejcts/ezag080. PMID: 41656894 MH - Humans MH - *Coronary Artery Bypass/methods/adverse effects MH - *Minimally Invasive Surgical Procedures/methods MH - *Coronary Artery Disease/surgery OTO - NOTNLM OT - Frailty OT - Heart team OT - Hybrid revascularization OT - Minimally invasive coronary artery bypass grafting OT - Off-pump coronary artery bypass grafting OT - Robotic cardiac surgery EDAT- 2025/05/28 18:27 MHDA- 2025/06/10 06:28 CRDT- 2025/05/28 12:53 PHST- 2024/11/21 00:00 [received] PHST- 2025/04/15 00:00 [revised] PHST- 2025/06/10 06:28 [medline] PHST- 2025/05/28 18:27 [pubmed] PHST- 2025/05/28 12:53 [entrez] AID - 8152305 [pii] AID - 10.1093/ejcts/ezaf160 [doi] PST - ppublish SO - Eur J Cardiothorac Surg. 2025 May 6;67(5):ezaf160. doi: 10.1093/ejcts/ezaf160. PMID- 40434753 OWN - NLM STAT- MEDLINE DCOM- 20250709 LR - 20260529 IS - 2168-6262 (Electronic) IS - 2168-6254 (Print) IS - 2168-6254 (Linking) VI - 160 IP - 7 DP - 2025 Jul 1 TI - Familiarity of the Surgeon-Anesthesiologist Dyad and Major Morbidity After High-Risk Elective Surgery. PG - 772-781 LID - 10.1001/jamasurg.2025.1386 [doi] AB - IMPORTANCE: The surgeon-anesthesiologist teamwork is a core component of performance in the operating room, which can influence patient outcomes. OBJECTIVE: To examine the association between surgeon-anesthesiologist dyad familiarity (as dyad volume, the number of procedures done together) with 90-day postoperative major morbidity for high-risk elective surgery. DESIGN, SETTING, AND PARTICIPANTS: This population-based retrospective cohort study used administrative health care data from Ontario, Canada. Participants included high-risk elective operations (cardiac, low- and high- risk gastrointestinal [GI], genitourinary, gynecology oncology, neurosurgery, orthopedic, spine, vascular, and head and neck) from 2009 through 2019. Data were analyzed from January 2009 to March 2020. EXPOSURE: Dyad familiarity, as the annual volume of procedures done by the surgeon-anesthesiologist dyad in 4 years prior to index surgery. MAIN OUTCOMES AND MEASURES: 90-day major morbidity (any Clavien-Dindo grade 3 to 5). The association between exposure and outcome was examined using multivariable logistic regression, stratified by type of procedure. RESULTS: Among 711 006 index procedures, the median dyad volume and rate of 90-day major morbidity varied by type of procedure. There was higher median volume and dyad consistency for cardiac, orthopedic, and lung surgery. For other procedures, the median dyad volume was low (3 or less procedures per dyad per year). An independent association was observed between dyad volume and 90-day major morbidity for high-risk GI surgery (odds ratio [OR], 0.92; 95% CI, 0.88-0.96), low-risk GI surgery (OR, 0.96; 95% CI, 0.95-0.98), gynecology oncology surgery (OR, 0.97; 95% CI, 0.94-0.99), and spine surgery (OR, 0.97; 95% CI, 0.96-0.99), after adjusting for hospital setting, hospital, surgeon and anesthesiologist volume, and patient age, sex, and comorbidity burden. The adjusted associations were not significant for other types of procedures. CONCLUSIONS AND RELEVANCE: In this study, increasing familiarity of the surgeon-anesthesiologist dyad was associated with improved postoperative outcomes for patients undergoing low- and high-risk GI surgery, gynecology oncology surgery, and spine surgery. For each additional time that a unique surgeon-anesthesiologist dyad worked together, the odds of 90-day major morbidity decreased by 4% for low-risk GI surgery, 8% for high-risk GI surgery, 3% for gynecology oncology surgery, and 3% for spine surgery. Additional research is needed to determine the most effective care structures that harness the benefits of surgeon-anesthesiologist familiarity to potentially improve patient outcomes. FAU - Hallet, Julie AU - Hallet J AD - Department of Surgery, University of Toronto, Toronto, Ontario, Canada. AD - Division of Surgical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. FAU - Jerath, Angela AU - Jerath A AD - Clinical Evaluative Sciences, Sunnybrook Research Institute, Toronto, Ontario, Canada. AD - ICES, Toronto, Ontario, Canada. AD - Department of Anesthesiology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. AD - Department of Anesthesiology and Pain Medicine, University of Toronto, Toronto, Ontario, Canada. FAU - d'Empaire, Pablo Perez AU - d'Empaire PP AD - Department of Anesthesiology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. AD - Department of Anesthesiology and Pain Medicine, University of Toronto, Toronto, Ontario, Canada. FAU - Carrier, Francois Martin AU - Carrier FM AD - Carrefour de l'innovation et sante des populations, Centre de recherche du CHUM, and Department of Anesthesiology and Division of Critical Care, Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada. AD - Department of Anesthesiology and Pain Medicine, Universite de Montreal, Montreal, Quebec, Canada. FAU - Turgeon, Alexis F AU - Turgeon AF AD - Department of Anesthesiology and Critical Care Medicine, Division of Critical Care Medicine, Universite Laval, Quebec City, Quebec, Canada. AD - CHU de Quebec-Universite Laval Research Centre, Population Health and Optimal Health Practices Research Unit, Trauma-Emergency-Critical Care Medicine, Universite Laval, Quebec City, Quebec, Canada. FAU - McIsaac, Daniel I AU - McIsaac DI AD - Departments of Anesthesiology & Pain Medicine, University of Ottawa and The Ottawa Hospital, Ottawa, Ontario, Canada. FAU - Idestrup, Chris AU - Idestrup C AD - Department of Anesthesiology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. AD - Department of Anesthesiology and Pain Medicine, University of Toronto, Toronto, Ontario, Canada. FAU - Lorello, Gianni AU - Lorello G AD - Department of Anesthesiology and Pain Medicine, University of Toronto, Toronto, Ontario, Canada. AD - Department of Anesthesiology and The Wilson Centre, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada. AD - Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada. FAU - Flexman, Alana AU - Flexman A AD - Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada. AD - Department of Anesthesiology, St Paul's Hospital/Providence Health Care, Vancouver, British Columbia, Canada. FAU - Kidane, Biniam AU - Kidane B AD - Section of Thoracic Surgery, Departments of Surgery and of Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada. FAU - Chan, Wing C AU - Chan WC AD - ICES, Toronto, Ontario, Canada. FAU - Gombay, Anna AU - Gombay A AD - Clinical Evaluative Sciences, Sunnybrook Research Institute, Toronto, Ontario, Canada. FAU - Coburn, Natalie AU - Coburn N AD - Department of Surgery, University of Toronto, Toronto, Ontario, Canada. AD - Division of Surgical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. AD - Clinical Evaluative Sciences, Sunnybrook Research Institute, Toronto, Ontario, Canada. AD - ICES, Toronto, Ontario, Canada. FAU - Eskander, Antoine AU - Eskander A AD - Division of Surgical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. AD - Clinical Evaluative Sciences, Sunnybrook Research Institute, Toronto, Ontario, Canada. AD - ICES, Toronto, Ontario, Canada. AD - Department of Otolaryngology-Head & Neck Surgery, University of Toronto, Toronto, Ontario, Canada. FAU - Sutradhar, Rinku AU - Sutradhar R AD - ICES, Toronto, Ontario, Canada. AD - Division of Biostatistics, Dalla Lana School of Public Health, University of Toronto, Ontario, Canada. LA - eng PT - Journal Article PL - United States TA - JAMA Surg JT - JAMA surgery JID - 101589553 SB - IM CIN - JAMA Surg. 2025 Jul 1;160(7):781-782. doi: 10.1001/jamasurg.2025.1376. PMID: 40434788 MH - Humans MH - *Elective Surgical Procedures/adverse effects MH - Female MH - Retrospective Studies MH - Male MH - *Postoperative Complications/epidemiology MH - *Surgeons MH - Middle Aged MH - Aged MH - Ontario/epidemiology MH - *Anesthesiologists MH - *Clinical Competence MH - *Patient Care Team PMC - PMC12120681 COIS- Conflict of Interest Disclosures: Dr Flexman reported grants from Michael Smith Health Research BC during the conduct of the study; personal fees from Wolters Kluwer, Canadian Anesthesiologists' Society, the University of Manitoba, the University of Ottawa, the Mayo Clinic, and the Neuroanesthesia and Critical Care Society of the United Kingdom and grants from Eisai Co and the Society for Cardiovascular Anesthesiology outside the submitted work. Dr Kidane reported consultant fees from Olympus, J & J, Medtronic outside the submitted work. No other disclosures were reported. EDAT- 2025/05/28 12:29 MHDA- 2025/07/09 12:29 PMCR- 2026/05/28 CRDT- 2025/05/28 11:33 PHST- 2025/07/09 12:29 [medline] PHST- 2025/05/28 12:29 [pubmed] PHST- 2025/05/28 11:33 [entrez] PHST- 2026/05/28 00:00 [pmc-release] AID - 2834597 [pii] AID - soi250024 [pii] AID - 10.1001/jamasurg.2025.1386 [doi] PST - ppublish SO - JAMA Surg. 2025 Jul 1;160(7):772-781. doi: 10.1001/jamasurg.2025.1386. PMID- 40429602 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250531 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 14 IP - 10 DP - 2025 May 21 TI - Optimizing Imaging Techniques for Left Atrial Appendage Closure: Insights and Emerging Directions. LID - 10.3390/jcm14103607 [doi] LID - 3607 AB - Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in adults and is associated with significant morbidity and mortality, including an increased risk of stroke, heart failure, dementia, and recurrent hospitalizations. As life expectancy rises, both the incidence and prevalence of AF continue to grow. Stroke prevention remains a cornerstone of AF management, with oral anticoagulation being the primary strategy to reduce thromboembolic risk. However, despite their advantages, direct oral anticoagulants do not completely eliminate the risk of bleeding complications. For patients in whom anticoagulation is contraindicated, poorly tolerated, or ineffective at preventing AF-related stroke, interventional alternatives have gained traction. The left atrial appendage (LAA), a primary site of thrombus formation in AF, can be occluded through a catheter-based procedure known as left atrial appendage closure (LAAC) or left atrial appendage occlusion (LAAO). This review aims to provide imaging specialists with a comprehensive understanding of their role in LAAC, underscoring the importance of a multidisciplinary approach to enhance patient selection, procedural success, and long-term efficacy. FAU - Barletta, Valentina AU - Barletta V AUID- ORCID: 0000-0002-4231-7781 AD - Department of Cardiac-Thoracic and Vascular, Second Division of Cardiology, Pisa University Hospital, 56100 Pisa, Italy. FAU - Alberti, Mattia AU - Alberti M AUID- ORCID: 0009-0004-5589-6059 AD - Department of Surgical, Medical and Molecular Pathology and Critical Area, Cardiology Division, University of Pisa, 56126 Pisa, Italy. FAU - Agostini, Riccardo AU - Agostini R AD - Department of Cardiac, Thoracic, and Vascular Medicine, Azienda Ospedaliero Universitaria Careggi, 50134 Florence, Italy. FAU - Pizzino, Fausto AU - Pizzino F AUID- ORCID: 0000-0003-1053-8325 AD - Fondazione Toscana G. Monasterio, Ospedale del Cuore, 54100 Massa, Italy. FAU - Trimarchi, Giancarlo AU - Trimarchi G AUID- ORCID: 0009-0008-9165-7732 AD - Fondazione Toscana G. Monasterio, Ospedale del Cuore, 54100 Massa, Italy. FAU - D'Alfonso, Maria Grazia AU - D'Alfonso MG AD - Department of Cardiac, Thoracic, and Vascular Medicine, Azienda Ospedaliero Universitaria Careggi, 50134 Florence, Italy. FAU - Solari, Marco AU - Solari M AUID- ORCID: 0000-0001-6195-4228 AD - Department of Cardiology, S. Giuseppe Hospital, 50053 Empoli, Italy. FAU - Zucchelli, Giulio AU - Zucchelli G AD - Department of Cardiac-Thoracic and Vascular, Second Division of Cardiology, Pisa University Hospital, 56100 Pisa, Italy. FAU - Cresti, Alberto AU - Cresti A AUID- ORCID: 0000-0003-2328-8943 AD - Cardiology Department, Misericordia Hospital, Azienda Sanitaria Toscana SudEst, 58100 Grosseto, Italy. LA - eng PT - Journal Article PT - Review DEP - 20250521 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC12112684 OTO - NOTNLM OT - echocardiography OT - left atrial appendage OT - multi-imaging OT - oral anticoagulants OT - thrombus COIS- The authors declare no conflict of interest. EDAT- 2025/05/28 06:28 MHDA- 2025/05/28 06:29 PMCR- 2025/05/21 CRDT- 2025/05/28 01:23 PHST- 2025/03/26 00:00 [received] PHST- 2025/05/13 00:00 [revised] PHST- 2025/05/16 00:00 [accepted] PHST- 2025/05/28 06:29 [medline] PHST- 2025/05/28 06:28 [pubmed] PHST- 2025/05/28 01:23 [entrez] PHST- 2025/05/21 00:00 [pmc-release] AID - jcm14103607 [pii] AID - jcm-14-03607 [pii] AID - 10.3390/jcm14103607 [doi] PST - epublish SO - J Clin Med. 2025 May 21;14(10):3607. doi: 10.3390/jcm14103607. PMID- 40427120 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260924 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 17 IP - 10 DP - 2025 May 10 TI - Brain Metastases from Primary Cardiac Tumors: A Systematic Review of Diagnosis, Treatment, and Prognosis. LID - 10.3390/cancers17101621 [doi] LID - 1621 AB - Background: Primary cardiac tumors (PCTs) are rare entities, with only a minority being malignant and capable of distant dissemination. Among the rarest and most challenging metastatic events are brain metastases originating from cardiac tumors. Due to the heart's direct access to systemic circulation, even benign tumors such as atrial myxomas may cause cerebral embolic phenomena. Understanding the distinct biological behavior, diagnostic pathways, therapeutic strategies, and prognostic implications of these cases remains limited by the scarcity of the available literature. Methods: A systematic review was conducted following PRISMA guidelines. PubMed, Scopus, Embase, and other major databases were systematically searched using specific MeSH terms and keywords related to cardiac tumors and brain metastases. After applying strict inclusion and exclusion criteria, nineteen studies were included, comprising sixteen single-patient case reports and three multi-patient series. Extracted data included tumor histology, cardiac and brain imaging findings, neurological presentation, treatment approaches, and patient outcomes. Results: A total of 320 patients were analyzed. Atrial myxomas represented the predominant benign tumors causing embolic cerebral events, while angiosarcomas and other cardiac sarcomas were responsible for true hematogenous brain metastases. Brain involvement was frequently hemorrhagic and manifested with seizures, focal deficits, or signs of intracranial hypertension. Cardiac echocardiography and cardiac magnetic resonance imaging (CMR) were essential for tumor detection, while brain MRI, including SWI and DWI sequences, and CT scanning were critical for cerebral lesion characterization. Treatment strategies varied according to tumor type and included surgery, radiotherapy, and systemic therapies. Malignant cardiac tumors correlated with a poor prognosis, with median survival post-CNS involvement ranging from 12 to 14 months. Conclusions: Brain metastases from PCTs, though rare, represent a distinct and serious clinical phenomenon. Benign tumors like myxomas mainly cause embolic cerebral events, whereas malignant tumors, particularly sarcomas, lead to true metastatic brain lesions. Recognizing this biological distinction is crucial for diagnosis, prognostication, and therapeutic planning. An integrated multidisciplinary approach combining advanced cardiac and neuroimaging techniques is vital for early detection and appropriate management. Despite multimodal treatment, survival remains limited, underscoring the urgent need for novel targeted therapies and improved surveillance strategies. FAU - Marrone, Salvatore AU - Marrone S AD - Department of Neurosurgery, Sant'Elia Hospital, 93100 Caltanissetta, Italy. FAU - Gueli, Ignazio Alessio AU - Gueli IA AUID- ORCID: 0009-0001-2407-5942 AD - Cardiology Division, Fondazione Toscana Gabriele Monasterio, 56124 Pisa, Italy. FAU - Lo Coco, Roberta AU - Lo Coco R AD - Unit of Pathology, Sant'Elia Hospital, 93100 Caltanissetta, Italy. FAU - Scalia, Lorenzo AU - Scalia L AUID- ORCID: 0009-0006-8429-1619 AD - Division of Cardiology, Umberto I Hospital, 94100 Enna, Italy. FAU - Rizzica, Salvatore AU - Rizzica S AD - Department of Internal Medicine, Sant'Elia Hospital, 93100 Caltanissetta, Italy. FAU - Baiamonte, Giuliana AU - Baiamonte G AUID- ORCID: 0009-0004-7620-9625 AD - Electric, Electronics and Computer Engineering Department, University of Catania, 95125 Catania, Italy. FAU - Costanzo, Roberta AU - Costanzo R AUID- ORCID: 0000-0003-3215-7179 AD - Department of Neurosurgery, Villa Sofia Hospital, 90146 Palermo, Italy. FAU - Rubino, Antonino Salvatore AU - Rubino AS AUID- ORCID: 0000-0002-9399-7422 AD - Department of Medicine and Surgery, University of Enna Kore, 94100 Enna, Italy. AD - Cardiac Surgery Unit, C.C.D. "G.B. Morgagni", Heart Center, 95030 Pedara, Italy. FAU - Ferini, Gianluca AU - Ferini G AUID- ORCID: 0000-0002-2305-5544 AD - Department of Medicine and Surgery, University of Enna Kore, 94100 Enna, Italy. AD - Department of Radiation Oncology, REM Radioterapia Srl, 95126 Viagrande, Italy. FAU - Umana, Giuseppe Emmanuele AU - Umana GE AUID- ORCID: 0000-0002-1573-431X AD - Department of Medicine and Surgery, University of Enna Kore, 94100 Enna, Italy. AD - Department of Neurosurgery, Trauma and Gamma Knife Center, Cannizzaro Hospital, 95126 Catania, Italy. FAU - Scalia, Gianluca AU - Scalia G AUID- ORCID: 0000-0002-9465-2506 AD - Department of Medicine and Surgery, University of Enna Kore, 94100 Enna, Italy. AD - Neurosurgery Unit, Department of Head and Neck Surgery, Highly Specialized Hospital of National Importance "Garibaldi", 95124 Catania, Italy. LA - eng PT - Journal Article PT - Review DEP - 20250510 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC12110033 OTO - NOTNLM OT - brain metastases OT - cardiac myxoma OT - cardiac sarcoma OT - cardiac tumors OT - multimodal imaging COIS- The authors declare no conflicts of interest. EDAT- 2025/05/28 06:28 MHDA- 2025/05/28 06:29 PMCR- 2025/05/10 CRDT- 2025/05/28 01:07 PHST- 2025/04/07 00:00 [received] PHST- 2025/05/06 00:00 [revised] PHST- 2025/05/09 00:00 [accepted] PHST- 2025/05/28 06:29 [medline] PHST- 2025/05/28 06:28 [pubmed] PHST- 2025/05/28 01:07 [entrez] PHST- 2025/05/10 00:00 [pmc-release] AID - cancers17101621 [pii] AID - cancers-17-01621 [pii] AID - 10.3390/cancers17101621 [doi] PST - epublish SO - Cancers (Basel). 2025 May 10;17(10):1621. doi: 10.3390/cancers17101621. PMID- 40423004 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250531 IS - 2313-433X (Electronic) IS - 2313-433X (Linking) VI - 11 IP - 5 DP - 2025 May 7 TI - Towards the Performance Characterization of a Robotic Multimodal Diagnostic Imaging System. LID - 10.3390/jimaging11050147 [doi] LID - 147 AB - Characterizing imaging performance requires a multidisciplinary approach that evaluates various interconnected parameters, including dosage optimization and dynamic accuracy. Radiation dose and dynamic accuracy are challenged by patient motion that results in poor image quality. These challenges are more prevalent in the brain/cardiac pediatric patient imaging, as they relate to excess radiation dose that may be associated with various complications. Scanning vulnerable pediatric patients ought to eliminate anesthesia due to critical risks associated in some cases with intracranial hemorrhages, brain strokes, and congenital heart disease. Some pediatric imaging, however, requires prolonged scanning under anesthesia. It can often be a laborious, suboptimal process, with limited field of view and considerable dose. High dynamic accuracy is also necessary to diagnose tissue's dynamic behavior beyond its static structural morphology. This study presents several performance characterization experiments from a new robotic multimodal imaging system using specially designed calibration methods at different system configurations. Additional musculoskeletal imaging and imaging from a pediatric brain stroke patient without anesthesia are presented for comparisons. The findings suggest that the system's large dynamically controlled gantry enables scanning at full patient movement and with important improvements in scan times, accuracy, radiation dose, and the ability to image brain structures without anesthesia. This could position the system as a potential transformative tool in the pediatric interventional imaging landscape. FAU - Papaioannou, George AU - Papaioannou G AUID- ORCID: 0009-0003-2580-7759 AD - New Bedford Research & Robotics, Downtown New Bedford, New Bedford, MA 02740, USA. FAU - Mitrogiannis, Christos AU - Mitrogiannis C AD - New Bedford Research & Robotics, Downtown New Bedford, New Bedford, MA 02740, USA. FAU - Schweitzer, Mark AU - Schweitzer M AD - Office of the Vice President of Health Affairs, School of Medicine, Wayne State University, 1241 Scott Hall, 540 E. Canfield, Detroit, MI 48201, USA. FAU - Michailidis, Nikolaos AU - Michailidis N AUID- ORCID: 0000-0002-4291-5327 AD - School of Mechanical Engineering, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece. FAU - Pappa, Maria AU - Pappa M AUID- ORCID: 0000-0003-2991-7456 AD - School of Mechanical Engineering, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece. FAU - Khosravi, Pegah AU - Khosravi P AUID- ORCID: 0000-0003-3497-2820 AD - Biomedical AI, New York City College of Technology, Graduate Center, CUNY, 285 Jay Street, Brooklyn, NY 11201, USA. FAU - Karantanas, Apostolos AU - Karantanas A AUID- ORCID: 0000-0002-0927-2403 AD - Department of Medical Imaging, University Hospital, 71500 Heraklion, Greece. FAU - Starling, Sean AU - Starling S AD - Level 1, Meat and Livestock Australia, 40 Mount Street, P.O. Box 1961, North Sydney, NSW 2059, Australia. FAU - Ruberg, Christian AU - Ruberg C AD - Level 1, Meat and Livestock Australia, 40 Mount Street, P.O. Box 1961, North Sydney, NSW 2059, Australia. LA - eng GR - W81XWH-07-2-0113/US Army Medical Research and Material Command, DoD-TATRC Contract/ GR - #P.PSH.0914 and #P.PSH.0915/MLA Australian Government Meat and Livestock Australia Ltd 2019 Grants/ GR - # 07-2-01/US Army Medical Research and Material Command, MOVE Center Award/ GR - R44 HD068150/HD/NICHD NIH HHS/United States GR - #R44 HD068150-01/Department of Health and Human Services National Institutes of Health EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT-SBIR Award/ PT - Journal Article DEP - 20250507 PL - Switzerland TA - J Imaging JT - Journal of imaging JID - 101698819 PMC - PMC12112859 OTO - NOTNLM OT - X-ray CT OT - calibration OT - dynamic accuracy OT - multimodal OT - pediatric imaging OT - radiation dose OT - robotics-driven imaging device OT - stereovideoradiography OT - tomosynthesis COIS- The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. EDAT- 2025/05/27 12:43 MHDA- 2025/05/27 12:44 PMCR- 2025/05/07 CRDT- 2025/05/27 09:16 PHST- 2025/02/25 00:00 [received] PHST- 2025/03/19 00:00 [revised] PHST- 2025/04/04 00:00 [accepted] PHST- 2025/05/27 12:44 [medline] PHST- 2025/05/27 12:43 [pubmed] PHST- 2025/05/27 09:16 [entrez] PHST- 2025/05/07 00:00 [pmc-release] AID - jimaging11050147 [pii] AID - jimaging-11-00147 [pii] AID - 10.3390/jimaging11050147 [doi] PST - epublish SO - J Imaging. 2025 May 7;11(5):147. doi: 10.3390/jimaging11050147. PMID- 40420795 OWN - NLM STAT- MEDLINE DCOM- 20260519 LR - 20260519 IS - 1827-1855 (Electronic) IS - 0390-5616 (Linking) VI - 70 IP - 3 DP - 2026 Jun TI - Ventriculo-atrial shunt and European regulations: a delicate balance. PG - 179-185 LID - 10.23736/S0390-5616.25.06465-3 [doi] AB - BACKGROUND: European regulations on medical devices have been introduced to improve medical standards. However, these changes are leading to the transient lack of medical tools with possible disadvantages. Herein, the problem is addressed for the first time in neurosurgery with regards to ventriculo-atrial shunt (VAS). METHODS: Children undergoing VAS in the 2020-2022 period at a single Institution were enrolled. Patients receiving VAS with Pudenz cardiac catheter (distal slit "valves") were assigned to group A (2020-2021) while those with VAS harboring proximal adjustable valve to group B (2021-2022, Pudenz no more available). The complications leading to shunt malfunction within 2 years from VAS were analyzed. RESULTS: Twenty-four children belonged to group A (M/F ratio: 2.4; mean age: 42.5 months) and 18 to group B (MF/ratio: 1.8, mean age: 48.1 months). Statistically significant differences were found about: 1) patients needing shunt revision: 7 cases (29%) in group A vs. 11 cases (61%) in group B; 2) number of shunt revisions: 8 in group A vs. 16 in group B; 3) number of children with mechanical complications: 2 (8.3%) in group A vs. 7 (39%) in group B; 4) number of mechanical complications: 2 (group A) vs. 9 (group B). No differences in other complications or placement-to-revision time were detected. CONCLUSIONS: The lack of simple surgical tools (Pudenz catheter) may make VAS more prone to mechanical complications. Prospective and multicenter trials are needed to produce scientific evidence. In the meantime, a multidisciplinary discussion on the European regulation (including Doctors and Manufacturers) is welcome. FAU - Massimi, Luca AU - Massimi L AD - Department of Pediatric Neurosurgery, IRCCS A. Gemelli University Polyclinic Foundation, Rome, Italy - luca.massimi@policlinicogemelli.it. AD - Department of Neuroscience, Sacred Heart Catholic University, Rome, Italy - luca.massimi@policlinicogemelli.it. FAU - Obersnel, Marco AU - Obersnel M AD - Department of Pediatric Neurosurgery, IRCCS A. Gemelli University Polyclinic Foundation, Rome, Italy. FAU - Frassanito, Paolo AU - Frassanito P AD - Department of Pediatric Neurosurgery, IRCCS A. Gemelli University Polyclinic Foundation, Rome, Italy. FAU - Bianchi, Federico AU - Bianchi F AD - Department of Pediatric Neurosurgery, IRCCS A. Gemelli University Polyclinic Foundation, Rome, Italy. FAU - Tamburrini, Gianpiero AU - Tamburrini G AD - Department of Pediatric Neurosurgery, IRCCS A. Gemelli University Polyclinic Foundation, Rome, Italy. AD - Department of Neuroscience, Sacred Heart Catholic University, Rome, Italy. LA - eng PT - Journal Article DEP - 20250527 PL - Italy TA - J Neurosurg Sci JT - Journal of neurosurgical sciences JID - 0432557 SB - IM MH - Humans MH - Female MH - Male MH - Child, Preschool MH - Infant MH - *Hydrocephalus/surgery MH - *Cerebrospinal Fluid Shunts MH - Child MH - Europe MH - Reoperation EDAT- 2025/05/27 06:27 MHDA- 2026/05/19 12:37 CRDT- 2025/05/27 04:00 PHST- 2026/05/19 12:37 [medline] PHST- 2025/05/27 06:27 [pubmed] PHST- 2025/05/27 04:00 [entrez] AID - S0390-5616.25.06465-3 [pii] AID - 10.23736/S0390-5616.25.06465-3 [doi] PST - ppublish SO - J Neurosurg Sci. 2026 Jun;70(3):179-185. doi: 10.23736/S0390-5616.25.06465-3. Epub 2025 May 27. PMID- 40417346 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260421 LR - 20260522 IS - 2604-7276 (Electronic) IS - 2604-7306 (Print) IS - 2604-7306 (Linking) VI - 6 IP - 4 DP - 2024 Oct-Dec TI - Edge-to-edge therapy in acute mitral regurgitation. Proposal for a management protocol of the Ischemic Heart Disease and Acute Cardiac Care, Interventional Cardiology, and Cardiovascular Imaging Associations of the Spanish Society of Cardiology. PG - 313-320 LID - 10.24875/RECICE.M24000464 [doi] AB - The approach to patients with acute mitral regurgitation poses a therapeutic challenge. These patients have a very high morbidity and mortality rate, thus requiring a multidisciplinary approach. This document presents the position of 3 associations involved in the management of these patients: the Ischemic Heart Disease and Acute Cardiovascular Care Association, the Interventional Cardiology Association, and the Cardiac Imaging Association. The document discusses aspects related to patient selection and care, technical features of the edge-to-edge procedure from both the interventional and imaging unit perspectives, and the outcomes of this process. The results of mitral repair and/or replacement surgery, which is the first-line treatment option to consider in these patients, have not been included as they exceed the scope of the aims of the document. CI - Copyright: (c) 2024 Sociedad Espanola de Cardiologia. FAU - Viana-Tejedor, Ana AU - Viana-Tejedor A AD - Servicio de Cardiologia, Hospital Universitario Clinico San Carlos, Instituto de Investigacion Sanitaria del Hospital Clinico San Carlos (IdISSC), Madrid, Espana Servicio de Cardiologia Hospital Universitario Clinico San Carlos Instituto de Investigacion Sanitaria del Hospital Clinico San Carlos (IdISSC) Madrid Espana. FAU - Ferrera, Carlos AU - Ferrera C AD - Servicio de Cardiologia, Hospital Universitario Clinico San Carlos, Instituto de Investigacion Sanitaria del Hospital Clinico San Carlos (IdISSC), Madrid, Espana Servicio de Cardiologia Hospital Universitario Clinico San Carlos Instituto de Investigacion Sanitaria del Hospital Clinico San Carlos (IdISSC) Madrid Espana. FAU - Estevez-Loureiro, Rodrigo AU - Estevez-Loureiro R AD - Servicio de Cardiologia, Hospital Universitario Alvaro Cunqueiro, Instituto de Investigacion Sanitaria Galicia Sur (IISGS), Vigo, Pontevedra, Espana Servicio de Cardiologia Hospital Universitario Alvaro Cunqueiro Instituto de Investigacion Sanitaria Galicia Sur (IISGS) Vigo Espana. FAU - Barreiro-Perez, Manuel AU - Barreiro-Perez M AD - Servicio de Cardiologia, Hospital Universitario Alvaro Cunqueiro, Instituto de Investigacion Sanitaria Galicia Sur (IISGS), Vigo, Pontevedra, Espana Servicio de Cardiologia Hospital Universitario Alvaro Cunqueiro Instituto de Investigacion Sanitaria Galicia Sur (IISGS) Vigo Espana. FAU - Jimenez Quevedo, Pilar AU - Jimenez Quevedo P AD - Servicio de Cardiologia, Hospital Universitario Clinico San Carlos, Instituto de Investigacion Sanitaria del Hospital Clinico San Carlos (IdISSC), Madrid, Espana Servicio de Cardiologia Hospital Universitario Clinico San Carlos Instituto de Investigacion Sanitaria del Hospital Clinico San Carlos (IdISSC) Madrid Espana. FAU - Nombela-Franco, Luis AU - Nombela-Franco L AD - Servicio de Cardiologia, Hospital Universitario Clinico San Carlos, Instituto de Investigacion Sanitaria del Hospital Clinico San Carlos (IdISSC), Madrid, Espana Servicio de Cardiologia Hospital Universitario Clinico San Carlos Instituto de Investigacion Sanitaria del Hospital Clinico San Carlos (IdISSC) Madrid Espana. FAU - Jorge-Perez, Pablo AU - Jorge-Perez P AD - Servicio de Cardiologia, Hospital Universitario de Canarias, La Laguna, Santa Cruz de Tenerife, Espana Servicio de Cardiologia Hospital Universitario de Canarias La Laguna Espana. FAU - Pascual, Isaac AU - Pascual I AD - Servicio de Cardiologia, Hospital Universitario Central de Asturias, Oviedo, Asturias, Espana Servicio de Cardiologia Hospital Universitario Central de Asturias Oviedo Espana. AD - Departamento de Medicina, Universidad de Oviedo, Oviedo, Asturias, Espana Departamento de Medicina Universidad de Oviedo Oviedo Espana. FAU - Martinez Monzonis, Amparo AU - Martinez Monzonis A AD - Servicio de Cardiologia, Hospital Clinico Universitario de Santiago de Compostela, Instituto de Investigacion Sanitaria de Santiago (IDIS), Santiago de Compostela, A Coruna, Espana Servicio de Cardiologia Hospital Clinico Universitario de Santiago de Compostela Instituto de Investigacion Sanitaria de Santiago (IDIS) Santiago de Compostela Espana. AD - Centro de Investigacion Biomedica en Red de Enfermedades Cardiovasculares (CIBERCV), Espana Centro de Investigacion Biomedica en Red de Enfermedades Cardiovasculares (CIBERCV) Centro de Investigacion Biomedica en Red de Enfermedades Cardiovasculares (CIBERCV) Espana. FAU - Cid Alvarez, Ana Belen AU - Cid Alvarez AB AD - Servicio de Cardiologia, Hospital Clinico Universitario de Santiago de Compostela, Instituto de Investigacion Sanitaria de Santiago (IDIS), Santiago de Compostela, A Coruna, Espana Servicio de Cardiologia Hospital Clinico Universitario de Santiago de Compostela Instituto de Investigacion Sanitaria de Santiago (IDIS) Santiago de Compostela Espana. AD - Centro de Investigacion Biomedica en Red de Enfermedades Cardiovasculares (CIBERCV), Espana Centro de Investigacion Biomedica en Red de Enfermedades Cardiovasculares (CIBERCV) Centro de Investigacion Biomedica en Red de Enfermedades Cardiovasculares (CIBERCV) Espana. LA - eng PT - Journal Article DEP - 20240610 PL - Spain TA - REC Interv Cardiol JT - REC, interventional cardiology JID - 9919033203206676 PMC - PMC12097375 OTO - NOTNLM OT - Acute myocardial infarction OT - Left ventricular ejection fraction OT - Mitral regurgitation OT - Papillary muscle rupture OT - Transcatheter edge-to-edge mitral valve repair COIS- CONFLICTO DE INTERESES: No existe ningun conflicto de intereses. EDAT- 2025/05/26 12:37 MHDA- 2025/05/26 12:38 PMCR- 2024/06/10 CRDT- 2025/05/26 06:13 PHST- 2024/03/03 00:00 [received] PHST- 2024/04/24 00:00 [accepted] PHST- 2025/05/26 12:37 [pubmed] PHST- 2025/05/26 12:38 [medline] PHST- 2025/05/26 06:13 [entrez] PHST- 2024/06/10 00:00 [pmc-release] AID - 2604-7306-recic-6-4-313 [pii] AID - 10.24875/RECICE.M24000464 [doi] PST - epublish SO - REC Interv Cardiol. 2024 Jun 10;6(4):313-320. doi: 10.24875/RECICE.M24000464. eCollection 2024 Oct-Dec. PMID- 40415922 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260902 IS - 0973-6883 (Print) IS - 2213-3453 (Electronic) IS - 0973-6883 (Linking) VI - 15 IP - 5 DP - 2025 Sep-Oct TI - Cardiac Evaluation in Liver Transplant Candidates. PG - 102554 LID - 10.1016/j.jceh.2025.102554 [doi] LID - 102554 AB - Liver transplantation (LT) is the only cure for patients with end-stage liver disease. With an increase in the prevalence of obesity and associated metabolic risk factors cardiovascular disease, in particular coronary artery disease is increasingly recognised in patients with liver cirrhosis. Identification and management of these cardiovascular risk factors may influence post-transplant clinical outcomes. A detailed assessment of patients' cardiovascular status is therefore crucial in the decision-making of patients for LT. Identification of patients with CAD requires risk stratification around perioperative and long term post-operative period. Advanced age, male sex, smoking diabetes mellitus, hypertension, obesity and metabolic-associated steatohepatitis (MASH) cirrhosis significantly increase the risk of coronary artery disease (CAD). Patients with these high-risk factors should undergo cardiac investigations with higher sensitivity to identify CAD. Patients with low-risk factors for CAD may undergo cardiac investigations with high specificity. Patients with cirrhosis may also suffer from conditions directly related to liver disease such as cirrhotic cardiomyopathy and porto-pulmonary hypertension, and conditions unrelated to liver disease such as arrhythmias. Rarely, valvular heart disease may be identified during transplant evaluation. Clinicians managing patients for liver transplantation should carefully evaluate cardiovascular risk and treat it appropriately prior to the surgery, to minimise post-transplant complication. A multidisciplinary approach involving transplant physicians, anaesthetists, cardiologists and transplant surgeons is strongly recommended. CI - (c) 2025 Indian National Association for Study of the Liver. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies. FAU - Jothimani, Dinesh AU - Jothimani D AD - Institute of Liver Disease and Transplantation, Dr Rela Institute and Medical Centre, Chennai, India. FAU - Kumar Marannan, Navin AU - Kumar Marannan N AD - Institute of Liver Disease and Transplantation, Dr Rela Institute and Medical Centre, Chennai, India. FAU - Jain, Karan AU - Jain K AD - Institute of Liver Disease and Transplantation, Dr Rela Institute and Medical Centre, Chennai, India. FAU - Krishna, Aswin AU - Krishna A AD - Institute of Liver Disease and Transplantation, Dr Rela Institute and Medical Centre, Chennai, India. FAU - Rela, Mohamed AU - Rela M AD - Institute of Liver Disease and Transplantation, Dr Rela Institute and Medical Centre, Chennai, India. LA - eng PT - Journal Article PT - Review DEP - 20250327 PL - India TA - J Clin Exp Hepatol JT - Journal of clinical and experimental hepatology JID - 101574137 PMC - PMC12099453 OTO - NOTNLM OT - cirrhotic cardiomyopathy OT - coronary angiography OT - coronary artery disease OT - liver transplantation OT - portopulmonary hypertension COIS- The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this article. EDAT- 2025/05/26 06:27 MHDA- 2025/05/26 06:28 PMCR- 2026/09/01 CRDT- 2025/05/26 05:55 PHST- 2023/03/08 00:00 [received] PHST- 2025/03/18 00:00 [accepted] PHST- 2025/05/26 06:28 [medline] PHST- 2025/05/26 06:27 [pubmed] PHST- 2025/05/26 05:55 [entrez] PHST- 2026/09/01 00:00 [pmc-release] AID - S0973-6883(25)00054-4 [pii] AID - 102554 [pii] AID - 10.1016/j.jceh.2025.102554 [doi] PST - ppublish SO - J Clin Exp Hepatol. 2025 Sep-Oct;15(5):102554. doi: 10.1016/j.jceh.2025.102554. Epub 2025 Mar 27. PMID- 40415771 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260421 LR - 20260522 IS - 2604-7276 (Electronic) IS - 2604-7306 (Print) IS - 2604-7306 (Linking) VI - 6 IP - 3 DP - 2024 Jul-Sep TI - Left ventricular remodeling following transcatheter versus surgical aortic valve replacement: a speckle tracking study. PG - 191-200 LID - 10.24875/RECICE.M24000459 [doi] AB - INTRODUCTION AND OBJECTIVES: Transcatheter aortic valve implantation (TAVI) has emerged as an alternative and less invasive treatment to surgical aortic valve replacement (SAVR). Left ventricular global longitudinal strain (LV-GLS) can reveal changes in left ventricular performance before involvement of ejection fraction. Our aim was to present and evaluate our center's experience regarding short- and long-term reverse left ventricular remodeling using two-dimensional-speckle tracking echocardiography-derived LV-GLS after TAVI compared with SAVR. METHODS: Our multidisciplinary cardiac team carefully evaluated 65 patients for SAVR who presented with severe symptomatic aortic stenosis and who had high, intermediate, or low surgical risk. The patients underwent either TAVI with an Evolut-R self-expanding valve or SAVR. Echocardiographic evaluation was performed before, 1 month, and 1 year after the procedure. RESULTS: TAVI was performed in 31 patients and SAVR in 34 patients. The incidence of valvular and paravalvular leak was higher in the TAVI group despite early favorable LV remodeling with a significant decrease in left ventricular mass index and E/e' shortly after the procedure and an early detectable improvement in LV-GLS from -8.18 +/- 1.81 to -14.52 +/- 2.52, reaching -16.12 +/- 2.69 at 1 year (P < .001). This early improvement was not observed in the SAVR group. TAVI preserved right ventricular function without affecting tricuspid annular plane systolic excursion or increasing estimated pulmonary artery pressure. CONCLUSIONS: Patients who underwent TAVI had earlier and significantly better LV remodeling with early reduction in left ventricular mass index, E/e' ratio, and significant early improvement in LV-GLS without concomitant impairment of left ventricular ejection fraction percentage or deterioration of right ventricular function. CI - Copyright: (c) 2024 Sociedad Espanola de Cardiologia. FAU - El-Saied, Shaimaa B AU - El-Saied SB AD - Cardiovascular Department, Faculty of Medicine, Tanta University, Tanta, Egipto Cardiovascular Department Faculty of Medicine Tanta University Tanta Egipto. FAU - Atlm, Ramy AU - Atlm R AD - Cardiovascular Department, Faculty of Medicine, Tanta University, Tanta, Egipto Cardiovascular Department Faculty of Medicine Tanta University Tanta Egipto. FAU - Ghoneim, Ahmed AU - Ghoneim A AD - Cardiothoracic Surgery Department, Faculty of Medicine, Tanta University, Tanta, Egipto Cardiothoracic Surgery Department Faculty of Medicine Tanta University Tanta Egipto. FAU - Sherif, Mohammed H AU - Sherif MH AD - Cardiovascular Department, Faculty of Medicine, Tanta University, Tanta, Egipto Cardiovascular Department Faculty of Medicine Tanta University Tanta Egipto. FAU - Elbarbary, Mohammed AU - Elbarbary M AD - Cardiovascular Department, Faculty of Medicine, Tanta University, Tanta, Egipto Cardiovascular Department Faculty of Medicine Tanta University Tanta Egipto. LA - eng PT - Journal Article DEP - 20240709 PL - Spain TA - REC Interv Cardiol JT - REC, interventional cardiology JID - 9919033203206676 PMC - PMC12097341 OTO - NOTNLM OT - Left ventricular remodeling OT - SAVR OT - Surgical aortic valve replacement OT - TAVI OT - Transcatheter aortic valve implantation OT - Two-dimensional speckle tracking COIS- CONFLICTO DE INTERESES: Ninguno. EDAT- 2025/05/26 06:27 MHDA- 2025/05/26 06:28 PMCR- 2024/07/09 CRDT- 2025/05/26 05:54 PHST- 2023/12/21 00:00 [received] PHST- 2024/03/20 00:00 [accepted] PHST- 2025/05/26 06:27 [pubmed] PHST- 2025/05/26 06:28 [medline] PHST- 2025/05/26 05:54 [entrez] PHST- 2024/07/09 00:00 [pmc-release] AID - 2604-7306-recic-6-3-191 [pii] AID - 10.24875/RECICE.M24000459 [doi] PST - epublish SO - REC Interv Cardiol. 2024 Jul 9;6(3):191-200. doi: 10.24875/RECICE.M24000459. eCollection 2024 Jul-Sep. PMID- 40414218 OWN - NLM STAT- MEDLINE DCOM- 20251006 LR - 20260701 IS - 1423-0348 (Electronic) IS - 0033-3190 (Print) IS - 0033-3190 (Linking) VI - 94 IP - 5 DP - 2025 TI - Efficacy of Team-Based Collaborative Care for Distressed Patients in Secondary Prevention of Chronic Coronary Heart Disease: Results from the Multicenter, Randomized Controlled TEACH Trial. PG - 324-342 LID - 10.1159/000545865 [doi] AB -

Introduction: Coronary heart disease (CHD) has serious implications for patients' quality of life (QoL). Psychological distress affects 15-40% of patients with CHD and is robustly associated with poorer prognosis. Blended collaborative care (BCC), a telephone-delivered intervention involving non-physician care managers that addresses both psychological and medical factors, can be applied for secondary prevention of CHD. METHODS: We conducted the multicenter, randomized controlled TEACH trial that investigated the efficacy of a BCC intervention (TeamCare) in distressed CHD patients. The primary aim was to examine the treatment response rate of TeamCare, defined as >/=50% improvements in health-related QoL (HRQoL, assessed by HeartQoL) after 12 months compared to usual care (UC). Secondary endpoints were changes in HRQoL, psychological and medical factors, and satisfaction with care. RESULTS: In total, 457 patients (mean age 62.9 +/- 9.5 years, 23% females) were randomized to TeamCare (n = 230) or UC (n = 227). At 12 months, TeamCare patients showed a significantly higher proportion of treatment response to HeartQoL compared to UC (19% vs. 10%, respectively). TeamCare yielded significantly greater improvements in HeartQoL scores: global (d = 0.338), physical (d = 0.270), and emotional (d = 0.382). Further, TeamCare led to a significantly greater decrease in depression (d = -0.329), anxiety (d = -0.300), perceived stress (d = -0.233), and medical risk score (d = -0.235). Finally, BCC patients showed a higher satisfaction with overall treatment and psychosocial care. CONCLUSION: The TEACH study is the first ever performed BCC trial in distressed CHD patients in Europe. The BCC intervention has the potential to significantly improve secondary prevention in distressed CHD patients.

. CI - (c) 2025 The Author(s). Published by S. Karger AG, Basel. FAU - Sadlonova, Monika AU - Sadlonova M AD - Department of Psychosomatic Medicine and Psychotherapy, University Medical Center Gottingen, Gottingen, Germany. AD - Department of Cardiothoracic and Vascular Surgery, University Medical Center Gottingen, Gottingen, Germany. AD - Department of Geriatrics, University Medical Center Gottingen, Gottingen, Germany. AD - Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts, USA. AD - German Center for Cardiovascular Research (DZHK), partner site Lower Saxony, Gottingen, Germany. FAU - Herbeck Belnap, Birgit AU - Herbeck Belnap B AD - Department of Psychosomatic Medicine and Psychotherapy, University Medical Center Gottingen, Gottingen, Germany. AD - Centre for Behavioral Health and Smart Technology, University of Pittsburgh Medical School, Pittsburgh, Pennsylvania, USA. FAU - Becker, Ingrid AU - Becker I AD - Institute of Medical Statistics and Computational Biology, Faculty of Medicine, University Hospital of Cologne, Cologne, Germany. FAU - Bersch, Kristina AU - Bersch K AD - Clinical Trials Unit, University Medical Center Gottingen, Gottingen, Germany. FAU - Geiser, Franziska AU - Geiser F AD - Department of Psychosomatic Medicine and Psychotherapy, University Hospital of Bonn, University of Bonn, Bonn, Germany. FAU - Adenauer, Viktoria AU - Adenauer V AD - Department of Internal Medicine II - Cardiology, Angiology and Internal Intensive Medicine, University Hospital of Bonn, University of Bonn, Bonn, Germany. FAU - Hellmich, Martin AU - Hellmich M AD - Institute of Medical Statistics and Computational Biology, Faculty of Medicine, University Hospital of Cologne, Cologne, Germany. AD - Department of Medical Statistics, University Medical Center Gottingen, Gottingen, Germany. FAU - Kindermann, Ingrid AU - Kindermann I AD - Department of Internal Medicine III - Cardiology, Angiology and Internal Intensive Medicine, University Hospital of Homburg, Homburg, Germany. FAU - Zimmer, Angela AU - Zimmer A AD - Department of Internal Medicine III - Cardiology, Angiology and Internal Intensive Medicine, University Hospital of Homburg, Homburg, Germany. FAU - Michal, Matthias AU - Michal M AD - Department of Psychosomatic Medicine and Psychotherapy, University Medical Center Mainz, Mainz, Germany. FAU - Ghaemi Kerahrodi, Jasmin AU - Ghaemi Kerahrodi J AD - Department of Psychosomatic Medicine and Psychotherapy, University Medical Center Mainz, Mainz, Germany. FAU - Nohre, Mariel AU - Nohre M AD - Department of Psychosomatic Medicine and Psychotherapy, Hannover Medical School, Hannover, Germany. FAU - de Zwaan, Martina AU - de Zwaan M AD - Department of Psychosomatic Medicine and Psychotherapy, Hannover Medical School, Hannover, Germany. FAU - Petersmann, Astrid AU - Petersmann A AD - Department of Clinical Chemistry and Laboratory Medicine, University of Oldenburg, Oldenburg, Germany. FAU - Muller-Kozarez, Irina AU - Muller-Kozarez I AD - Department of Cardiology, University Hospital of Leipzig, Leipzig, Germany. FAU - Ehlers, Maja AU - Ehlers M AD - Department of Psychosomatic Medicine and Psychotherapy, University Hospital of Cologne, Cologne, Germany. FAU - Wachter, Rolf AU - Wachter R AD - German Center for Cardiovascular Research (DZHK), partner site Lower Saxony, Gottingen, Germany. AD - Department of Cardiology, University Hospital of Leipzig, Leipzig, Germany. FAU - Albus, Christian AU - Albus C AD - Department of Psychosomatic Medicine and Psychotherapy, University Hospital of Cologne, Cologne, Germany. FAU - Herrmann-Lingen, Christoph AU - Herrmann-Lingen C AD - Department of Psychosomatic Medicine and Psychotherapy, University Medical Center Gottingen, Gottingen, Germany. AD - German Center for Cardiovascular Research (DZHK), partner site Lower Saxony, Gottingen, Germany. CN - TEACH investigators LA - eng PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20250523 PL - Switzerland TA - Psychother Psychosom JT - Psychotherapy and psychosomatics JID - 0024046 SB - IM MH - Aged MH - Female MH - Humans MH - Male MH - Middle Aged MH - *Coronary Disease/prevention & control/psychology MH - *Patient Care Team MH - *Psychological Distress MH - Quality of Life/psychology MH - *Secondary Prevention/methods MH - *Stress, Psychological/therapy MH - Treatment Outcome PMC - PMC12215170 OTO - NOTNLM OT - Blended collaborative care OT - Cardiovascular risk factors OT - Coronary heart disease OT - Psychological distress OT - Randomized controlled trial OT - Secondary prevention COIS- R.W. reports receiving personal fees from AstraZeneca, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, CVRx, Daiichi Sankyo, Medtronic, Novartis, Pfizer, Pharmacosmos, and Servier and research support from Boehringer Ingelheim, German Ministry of Education and Research, the German Research Foundation, the European Union and Medtronic, outside the submitted work. C.A. received lecture honoraria from Bayer Vital and research funding from the German Ministry of Education and Research and the Commission of the European Union. C.H.-L. reports that he is receiving royalties from Hogrefe Huber Publishers for the German version of the HADS. During the last 3 years, he has received a lecture honorarium from Pfizer and research support from the German Ministry of Education and Research, the German Research Foundation and the European Commission, all unrelated to this research. Others declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2025/05/26 00:28 MHDA- 2025/10/06 18:31 PMCR- 2025/05/23 CRDT- 2025/05/25 18:24 PHST- 2025/01/31 00:00 [received] PHST- 2025/04/03 00:00 [accepted] PHST- 2025/10/06 18:31 [medline] PHST- 2025/05/26 00:28 [pubmed] PHST- 2025/05/25 18:24 [entrez] PHST- 2025/05/23 00:00 [pmc-release] AID - 000545865 [pii] AID - 545865 [pii] AID - 10.1159/000545865 [doi] PST - ppublish SO - Psychother Psychosom. 2025;94(5):324-342. doi: 10.1159/000545865. Epub 2025 May 23. PMID- 40403850 OWN - NLM STAT- MEDLINE DCOM- 20250609 LR - 20260918 IS - 1874-1754 (Electronic) IS - 0167-5273 (Linking) VI - 436 DP - 2025 Oct 1 TI - Percutaneous or surgical revascularization in patients with severe left main coronary artery disease in Latin America: A GRADE clinical practice guideline. PG - 133401 LID - S0167-5273(25)00444-9 [pii] LID - 10.1016/j.ijcard.2025.133401 [doi] AB - BACKGROUND: Severe left main coronary artery disease (LMD) poses a major treatment challenge in Latin America, where both percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) are used. METHODS: This guideline was developed de novo using the GRADE approach. A multidisciplinary panel reviewed evidence from a systematic review of randomized trials comparing PCI and CABG, incorporating a comprehensive literature search of patient values and preferences and outcome utilities. Thresholds were assigned for each clinical outcome, from small to large effect. RESULTS: Five randomized trials enrolling 4612 patients were included. At 30 days, PCI resulted in a large reduction in major bleeding and a small reduction in strokes. At 5 years, PCI was associated with a small to moderate increase of spontaneous myocardial infarction and a moderate to large increase in repeat revascularization. No important differences in short- or long-term mortality were observed between PCI and CABG. The overall certainty of evidence was rated low. There was a notable variability in patient values and a close call on the balance of effects. CONCLUSIONS: For patients in Latin America with severe left main coronary artery disease, the guideline panel suggests either PCI or CABG. This is a conditional recommendation, based on low certainty in the evidence (⨁⨁ large circle large circle). It applies when both procedures are clinically and anatomically appropriate and can be performed at centers meeting acceptable standards. The decision should be made through a shared decision-making process involving the patient and the multidisciplinary care team. CI - Copyright (c) 2025 The Authors. Published by Elsevier B.V. All rights reserved. FAU - Lamelas, Pablo AU - Lamelas P AD - Fundacion Favaloro, Buenos Aires, Argentina; Health Research Methods, Evidence, and Impact, McMaster University, Canada. Electronic address: plamelas@ffavaloro.org. FAU - Pompeu Sa, Michel AU - Pompeu Sa M AD - Department of Cardiovascular Surgery, Pronto Socorro Cardiologico de Pernambuco (PROCAPE), University of Pernambuco (UPE), Brazil. FAU - Izcovich, Ariel AU - Izcovich A AD - Hospital Aleman, Buenos Aires, Argentina. FAU - Bottaro, Federico AU - Bottaro F AD - Department of Internal Medicine, Hospital Britanico, Buenos Aires, Argentina. FAU - Tisi Bana, Matias AU - Tisi Bana M AD - Department of Medicine, Hospital Universitario Austral, Pilar, Buenos Aires, Argentina. FAU - Sosa Liprandi, Maria Ines AU - Sosa Liprandi MI AD - Sanatorio Guemes, Buenos Aires, Argentina. FAU - Lanas, Fernando AU - Lanas F AD - Universidad de la Frontera, Temuco, Chile. FAU - Vilca Mejia, Omar Asdrubal AU - Vilca Mejia OA AD - Department of Cardiovascular Surgery, Instuto de Coracao, Universidade de Sao Paulo, Brazil. FAU - Zuniga Luna, Mauricio AU - Zuniga Luna M AD - Department of Interventional Cardiology, Angiografia de Occidente, Cali, Colombia. FAU - Aubanel, Patricia AU - Aubanel P AD - Hospital del Prado, Tijuana, Mexico. FAU - Munera, Ana AU - Munera A AD - Clinica Rosario Tesoro, Cardioestudio, Medellin, Colombia. FAU - Contreras Reyes, Juan AU - Contreras Reyes J AD - Department of Cardiac Surgery, Universidad de la Frontera, Temuco, Chile. FAU - Bagur, Rodrigo AU - Bagur R AD - Western University, London, Ontario, Canada. FAU - Whitlock, Richard AU - Whitlock R AD - Health Research Methods, Evidence, and Impact, McMaster University, Canada; Department of Surgery, McMaster University, Hamilton, Ontario, Canada. FAU - Garcia Garcia, Hector AU - Garcia Garcia H AD - Washington Hospital Center, Washington, USA. FAU - Mamas, Mamas AU - Mamas M AD - Keele Cardiovascular Research Group, Keele University, Staffordshire, UK. FAU - Cohen, Mauricio G AU - Cohen MG AD - Cleveland Clinic Florida, Weston, Florida, USA. FAU - Ricalde, Alejando AU - Ricalde A AD - Hospital ABC, Ciudad de Mexico, Mexico. FAU - Abizaid, Alexandre AU - Abizaid A AD - Instituto do Coracao, Sao Paulo, Brazil. FAU - Mendiz, Oscar AU - Mendiz O AD - Fundacion Favaloro, Buenos Aires, Argentina. FAU - Araya, Mario AU - Araya M AD - Clinica Alemana, Universidad del Desarrollo, Santiago de Chile, Chile. FAU - Costa, Ricardo AU - Costa R AD - Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil. FAU - Santaera, Omar AU - Santaera O AD - Clinica privada provincial de Merlo, Buenos Aires, Argentina. FAU - Hidalgo, Pedro AU - Hidalgo P AD - Policlinica Amado, Maracaibo, Venezuela. FAU - Caldonazo, Tulio AU - Caldonazo T AD - Department of Cardiothoracic Surgery, Jena University Hospital, Jena, Germany; Department of Cardiothoracic Surgery, Weil Cornell Medicine, New York, USA. FAU - Baranchuk, Adrian AU - Baranchuk A AD - Queens University, Kingston, Ontario, Canada. FAU - Ragusa, Martin Alberto AU - Ragusa MA AD - Division Clinica Medica, Hospital Fernandez, Buenos Aires, Argentina. CN - Endorsed by the Sociedad Latino Americana de Cardiologia Intervencionista (SOLACI) CN - Sociedad Interamericana de Cardiologia (SIAC) LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20250520 PL - Netherlands TA - Int J Cardiol JT - International journal of cardiology JID - 8200291 SB - IM EIN - Int J Cardiol. 2025 Nov 1;438:133520. doi: 10.1016/j.ijcard.2025.133520. PMID: 40633476 MH - Humans MH - Latin America/epidemiology MH - *Coronary Artery Disease/surgery/epidemiology/diagnosis MH - *Percutaneous Coronary Intervention/standards/methods MH - *Coronary Artery Bypass/standards/methods MH - Randomized Controlled Trials as Topic/methods MH - *Severity of Illness Index MH - *Practice Guidelines as Topic/standards OTO - NOTNLM OT - CABG OT - CAD OT - PCI COIS- Declaration of competing interest PL consulting and transcatheter aortic valve implant proctoring for Boston Scientific, Medtronic, Meril, and Microport. EDAT- 2025/05/23 00:27 MHDA- 2025/06/10 00:30 CRDT- 2025/05/22 19:36 PHST- 2025/03/25 00:00 [received] PHST- 2025/05/16 00:00 [revised] PHST- 2025/05/16 00:00 [accepted] PHST- 2025/06/10 00:30 [medline] PHST- 2025/05/23 00:27 [pubmed] PHST- 2025/05/22 19:36 [entrez] AID - S0167-5273(25)00444-9 [pii] AID - 10.1016/j.ijcard.2025.133401 [doi] PST - ppublish SO - Int J Cardiol. 2025 Oct 1;436:133401. doi: 10.1016/j.ijcard.2025.133401. Epub 2025 May 20. PMID- 40402378 OWN - NLM STAT- MEDLINE DCOM- 20250624 LR - 20250624 IS - 1865-8652 (Electronic) IS - 0741-238X (Print) IS - 0741-238X (Linking) VI - 42 IP - 7 DP - 2025 Jul TI - Shared Decision-Making for Restoring Trust in the Management of Atherosclerotic Cardiovascular Disease in the Post-pandemic Era. PG - 3002-3010 LID - 10.1007/s12325-025-03182-y [doi] AB - Real-world data indicate that the management of low-density lipoprotein cholesterol (LDL-C) is suboptimal in clinical practice and that many patients fail to reach guideline-recommended LDL-C goals. This may be due in part to physician inertia with regard to prescribing appropriate lipid-lowering therapies or poor adherence to such therapies in real-world practice. Shared decision-making is a collaborative process in which patients and healthcare professionals work together to develop treatment plans and management strategies that consider an individual's values and preferences, as well as clinical evidence. In this commentary, two preventive cardiologists and a nurse practitioner working in US practice discuss their real-world experiences of shared decision-making as well as key benefits such as helping to tackle the negative impacts of medical misinformation to restore patients' trust in healthcare professionals. Other potential benefits of shared decision-making include increased adherence to therapy and greater trust between patients and healthcare professionals. Finally, the authors discuss proposed solutions for potential barriers to the implementation of shared decision-making, including the support of a multidisciplinary team, the provision of learning materials from trustworthy sources, and tailoring of discussions to the individual patient. CI - (c) 2025. The Author(s). FAU - Wexelman, Warren J AU - Wexelman WJ AD - Maimonides Medical Center, 4802 Tenth Avenue, Brooklyn, NY, USA. wexelmanmd@aol.com. AD - NYU Langone Brooklyn Health, Brooklyn, NY, USA. wexelmanmd@aol.com. FAU - Ciffone, Nicole AU - Ciffone N AD - Arizona Center for Advanced Lipidology, Tucson, AZ, USA. FAU - Shah, Nishant P AU - Shah NP AD - Division of Cardiology, Department of Medicine, Duke University Hospital, Durham, NC, USA. LA - eng PT - Journal Article DEP - 20250522 PL - United States TA - Adv Ther JT - Advances in therapy JID - 8611864 SB - IM MH - Humans MH - *Decision Making, Shared MH - *Trust MH - *Atherosclerosis/therapy MH - *COVID-19/epidemiology MH - Physician-Patient Relations MH - *Cardiovascular Diseases/therapy MH - *Patient Participation MH - Pandemics PMC - PMC12182467 OTO - NOTNLM OT - Atherosclerotic cardiovascular disease OT - Cardiovascular OT - Lipid-lowering therapy OT - Shared decision-making COIS- Declarations. Conflict of Interest: Warren J. Wexelman serves as a speaker/advisor for Amgen, Astra Zeneca, Merck, and Novartis. Nishant P. Shah received research grant support from Amgen, Janssen, National Institutes of Health, and Novartis, and serves as a speaker/advisor for Amgen, Esperion, and Novartis. Nicole Ciffone serves as a consultant for Novartis. Ethical Approval: This article does not include any studies with human participants or animals performed by any of the authors. EDAT- 2025/05/22 12:31 MHDA- 2025/06/24 11:11 PMCR- 2025/05/22 CRDT- 2025/05/22 11:20 PHST- 2024/12/19 00:00 [received] PHST- 2025/03/13 00:00 [accepted] PHST- 2025/06/24 11:11 [medline] PHST- 2025/05/22 12:31 [pubmed] PHST- 2025/05/22 11:20 [entrez] PHST- 2025/05/22 00:00 [pmc-release] AID - 10.1007/s12325-025-03182-y [pii] AID - 3182 [pii] AID - 10.1007/s12325-025-03182-y [doi] PST - ppublish SO - Adv Ther. 2025 Jul;42(7):3002-3010. doi: 10.1007/s12325-025-03182-y. Epub 2025 May 22. PMID- 40401916 OWN - NLM STAT- Publisher LR - 20250522 IS - 1538-4683 (Electronic) IS - 1061-5377 (Linking) DP - 2025 May 22 TI - Antiplatelet and Anticoagulation Therapy for Peripheral Arterial Disease: Risks Versus Benefits. LID - 10.1097/CRD.0000000000000956 [doi] AB - Peripheral arterial disease (PAD) affects millions of people worldwide. It is a progressive atherosclerotic condition that ranges from asymptomatic disease to severe manifestations such as chronic limb-threatening ischemia and acute limb ischemia. Major risk factors-diabetes mellitus, smoking, hypertension, and hypercholesterolemia-contribute to its pathogenesis by promoting oxidative stress, endothelial dysfunction, and platelet activation. Optimizing antiplatelet and anticoagulant therapy is essential to reducing major adverse cardiovascular events and major adverse limb events. Aspirin and clopidogrel remain standard therapies, but recent trials such as COMPASS and VOYAGER PAD highlight the benefits of combination therapy with low-dose rivaroxaban and aspirin, particularly postrevascularization. Dual antiplatelet therapy is beneficial in select patients, but bleeding risks necessitate individualized treatment approaches. Emerging therapies and procedural advancements offer promising options for high-risk populations, such as those with diabetes, chronic kidney disease, and frailty. This review presents a multidisciplinary approach to PAD management, emphasizing risk stratification and personalized pharmacologic strategies that balance ischemic event prevention with bleeding risk mitigation. CI - Copyright (c) 2025 The Author(s). Published by Wolters Kluwer Health, Inc. FAU - Kim, Daniel AU - Kim D AD - From the Department of Medicine, New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, NY. FAU - Shah, Samir K AU - Shah SK AD - From the Department of Medicine, New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, NY. FAU - Trivedi, Dhaval B AU - Trivedi DB AD - From the Department of Medicine, New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, NY. FAU - Parikh, Manish A AU - Parikh MA AD - From the Department of Medicine, New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, NY. AD - Weill Department of Medicine, Weill Cornell Medicine, New York, NY. FAU - Jackson, Kaedrea A AU - Jackson KA AD - Department of Emergency Medicine, Weill Cornell Medicine, New York, NY. FAU - Frishman, William H AU - Frishman WH AD - Department of Medicine, New York Medical College, Valhalla, NY. FAU - Peterson, Stephen J AU - Peterson SJ AD - From the Department of Medicine, New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, NY. AD - Weill Department of Medicine, Weill Cornell Medicine, New York, NY. LA - eng PT - Journal Article DEP - 20250522 PL - United States TA - Cardiol Rev JT - Cardiology in review JID - 9304686 SB - IM OTO - NOTNLM OT - anticoagulation OT - atherosclerosis OT - bleeding risk OT - coronary artery disease OT - coronary plaque OT - myocardial infarction OT - peripheral arterial disease COIS- Disclosure: The authors have no conflicts of interest to report. EDAT- 2025/05/22 12:30 MHDA- 2025/05/22 12:30 CRDT- 2025/05/22 09:03 PHST- 2025/05/22 12:30 [medline] PHST- 2025/05/22 12:30 [pubmed] PHST- 2025/05/22 09:03 [entrez] AID - 00045415-990000000-00507 [pii] AID - 10.1097/CRD.0000000000000956 [doi] PST - aheadofprint SO - Cardiol Rev. 2025 May 22. doi: 10.1097/CRD.0000000000000956. PMID- 40398599 OWN - NLM STAT- MEDLINE DCOM- 20250606 LR - 20260623 IS - 1559-2030 (Electronic) IS - 1551-7144 (Linking) VI - 154 DP - 2025 Jul TI - Comparing primary-tertiary multidisciplinary collaborative care with usual care in community patients with atrial fibrillation: The protocol for a cluster randomized controlled trial. PG - 107957 LID - S1551-7144(25)00151-X [pii] LID - 10.1016/j.cct.2025.107957 [doi] AB - BACKGROUND: The community health service centers (CHCs) are becoming the major undertakers in China in the prevention and treatment of chronic cardiovascular and cerebrovascular diseases such as atrial fibrillation (AF). The objective of this study was to evaluate the effect of a standardized model of primary-tertiary multidisciplinary collaborative care (PTCC) compared to usual care on AF patients in the community settings. METHODS: This study is a two-arm, prospective, multicenter, cluster randomized controlled, non-inferiority trial. A total of 220 AF patients aged 65 years or more will be recruited from 16 CHCs in the Yuexiu District of Guangzhou, China. The 16 CHCs will be randomly assigned to the PTCC intervention group and usual care control groups (1:1). The interventions will last for two years, and the survey will be conducted at baseline, 3-month, 6-month, 12-month, and 24-month. The baseline information from AF patients will be collected through face-to-face interviews with a standardized questionnaire or retrieval of health records and medical treatment records, and the following-up data will be collected by regular telephone calls or outpatient face-to-face interviews at each follow-up. The primary endpoint is the anticoagulation rate and the secondary outcomes include AF-related adverse events (cardiovascular mortality, cardiovascular and non-cardiovascular hospitalizations, major adverse cardiovascular events, stroke, major bleeding, clinically relevant non-major bleeding), health-related quality of life, and cost-effectiveness. DISCUSSION: The implementation of the PTCC program in AF patients may provide evidence for the management of AF patients and promote their prognosis in community. TRIAL REGISTRATION NUMBER: This study is registered at the Chinese Clinical Trial Registry (ChiCTR2200057242). CI - Copyright (c) 2025 Elsevier Inc. All rights reserved. FAU - Wang, Yongqi AU - Wang Y AD - School of Public Health, Guangdong Pharmaceutical University, Guangzhou 510310, China. FAU - Huang, Jun AU - Huang J AD - Department of Geriatrics, Institute of Geriatrics, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Science, Southern Medical University, Guangzhou 510080, China. FAU - Zhang, Dexing AU - Zhang D AD - School of Nursing, The Hong Kong Polytechnic University, Hong Kong, SAR, China; JC School of Public Health and Primary Care, The Chinese University of Hong Kong, HKSAR, China. FAU - Jiang, Junrong AU - Jiang J AD - Guangdong Provincial Key Laboratory of Clinical Pharmacology, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China. FAU - Xue, Yumei AU - Xue Y AD - Guangdong Provincial Geriatrics Institute, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China. Electronic address: xymgdci@163.com. FAU - Zhao, Wenjing AU - Zhao W AD - School of Public Health and Emergency Management, Southern University of Science and Technology, Shenzhen 518055, China. FAU - Deng, Hai AU - Deng H AD - Guangdong Provincial Key Laboratory of Clinical Pharmacology, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China. FAU - Wu, Shulin AU - Wu S AD - Guangdong Provincial Key Laboratory of Clinical Pharmacology, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China. FAU - Liu, Xudong AU - Liu X AD - School of Public Health, Guangdong Pharmaceutical University, Guangzhou 510310, China. Electronic address: xdliu.cn@hotmail.com. LA - eng SI - ChiCTR/ChiCTR2200057242 PT - Clinical Trial Protocol PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20250519 PL - United States TA - Contemp Clin Trials JT - Contemporary clinical trials JID - 101242342 RN - 0 (Anticoagulants) SB - IM MH - Humans MH - *Atrial Fibrillation/therapy/complications MH - China MH - Prospective Studies MH - Aged MH - Multicenter Studies as Topic MH - Male MH - Female MH - Quality of Life MH - *Patient Care Team/organization & administration MH - Randomized Controlled Trials as Topic MH - *Primary Health Care/organization & administration MH - Anticoagulants/therapeutic use MH - Stroke/prevention & control MH - *Community Health Centers/organization & administration MH - *Community Health Services/organization & administration MH - Hemorrhage/chemically induced/epidemiology MH - Equivalence Trials as Topic OTO - NOTNLM OT - Atrial fibrillation OT - Cluster-randomized control trial OT - Community health OT - Primary-tertiary collaborative care OT - Usual care COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/05/22 00:28 MHDA- 2025/06/07 16:44 CRDT- 2025/05/21 19:34 PHST- 2024/10/27 00:00 [received] PHST- 2025/04/04 00:00 [revised] PHST- 2025/05/16 00:00 [accepted] PHST- 2025/06/07 16:44 [medline] PHST- 2025/05/22 00:28 [pubmed] PHST- 2025/05/21 19:34 [entrez] AID - S1551-7144(25)00151-X [pii] AID - 10.1016/j.cct.2025.107957 [doi] PST - ppublish SO - Contemp Clin Trials. 2025 Jul;154:107957. doi: 10.1016/j.cct.2025.107957. Epub 2025 May 19. PMID- 40385976 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250520 IS - 2049-9361 (Print) IS - 2049-937X (Electronic) IS - 2049-9361 (Linking) VI - 12 DP - 2025 Jan-Dec TI - Use of whole body PET scan in patients with infective endocarditis may impact care of those with intravascular devices: results from a comparative retrospective cohort study. PG - 20499361251336849 LID - 10.1177/20499361251336849 [doi] LID - 20499361251336849 AB - BACKGROUND: Whole body 18F-fluorodeoxyglucose positron emission tomography/CT (WBP) may be an important tool for the management of infective endocarditis (IE) by identifying areas of occult primary or metastatic infection. However, the optimal use of this study in patients with IE is unknown. OBJECTIVES: Compare clinical characteristics and outcomes in patients who did and did not have WBP as part of their endocarditis management, and describe the impact that WBP has on the management of IE. DESIGN: Retrospective cohort study. METHODS: We performed a protocolized chart review of hospitalized patients with suspected IE who were discussed by a multidisciplinary endocarditis team at a tertiary care center between June 2018 and January 2022. RESULTS: Among 427 patients, there were 114 patients (26.7%) in the WBP group and 313 patients (73.3%) in the non-WBP group. The WBP group was significantly more likely to have end-stage renal disease, intracardiac prostheses, and cardiac devices, while the non-WBP group was more likely to have flail leaflet or paravalvular abscesses. There were no statistically significant differences in mortality, hospital readmission, or length of stay between the two cohorts. The WBP group was more likely to receive longer antibiotic courses and had higher rates of suppressive antibiotics following treatment courses (p < 0.001). The use of WBP directly affected management in 44.6% of those patients, especially when performed to evaluate intravascular prostheses and grafts. Changes in management included further workup, performance of a source control procedure, or a change in the antibiotic regimen. CONCLUSION: WBP plays an important role in identifying metastatic foci of infection and directly impacting the management of patients with confirmed or suspected endocarditis. Infected intravascular prostheses were effectively identified via WBP, and as a result, these patients were prescribed longer courses of antibiotics and suppressive antibiotics. CI - (c) The Author(s), 2025. FAU - Park, Jason AU - Park J AUID- ORCID: 0000-0001-5234-5965 AD - University of Pittsburgh Medical Center, Falk Medical Building, 3601 Fifth Avenue, Pittsburgh, PA 15213-2582, USA. FAU - Simpson, Kaitlyn AU - Simpson K AD - Case Western Reserve University Hospital, Cleveland, OH, USA. FAU - Neils, Megan AU - Neils M AD - University of Pittsburgh Medical Center, Pittsburgh, PA, USA. FAU - Riddell, James 4th AU - Riddell J 4th AD - University of Michigan, Ann Arbor, MI, USA. LA - eng PT - Journal Article DEP - 20250516 PL - England TA - Ther Adv Infect Dis JT - Therapeutic advances in infectious disease JID - 101606715 PMC - PMC12084698 OTO - NOTNLM OT - bacteremia OT - device infection OT - endocarditis OT - infective endocarditis OT - injection drug use-associated infections EDAT- 2025/05/19 12:30 MHDA- 2025/05/19 12:31 PMCR- 2025/05/16 CRDT- 2025/05/19 06:18 PHST- 2024/08/19 00:00 [received] PHST- 2025/04/07 00:00 [accepted] PHST- 2025/05/19 12:31 [medline] PHST- 2025/05/19 12:30 [pubmed] PHST- 2025/05/19 06:18 [entrez] PHST- 2025/05/16 00:00 [pmc-release] AID - 10.1177_20499361251336849 [pii] AID - 10.1177/20499361251336849 [doi] PST - epublish SO - Ther Adv Infect Dis. 2025 May 16;12:20499361251336849. doi: 10.1177/20499361251336849. eCollection 2025 Jan-Dec. PMID- 40384737 OWN - NLM STAT- MEDLINE DCOM- 20250519 LR - 20250520 IS - 1947-6108 (Electronic) IS - 1947-6094 (Print) IS - 1947-6108 (Linking) VI - 21 IP - 3 DP - 2025 TI - Multi-Organ Transplantation in Adult Congenital Heart Disease: Navigating the Unique Challenges of a Distinct Patient Population. PG - 72-82 LID - 10.14797/mdcvj.1576 [doi] AB - The prevalence of adult congenital heart disease (ACHD) is increasing, with heart failure being the leading cause of death. For many ACHD patients, heart transplantation is the only treatment option for advanced heart failure, though significant extracardiac involvement may require multi-organ transplantation. Despite the rising number of ACHD transplants, multi-organ transplants in this population remain challenging, and a substantial gap remains between those in need and those who receive a transplant. While short-term outcomes may be worse for ACHD patients, long-term outcomes are comparable and even superior to other cardiomyopathies. Extracardiac organ dysfunction is common in ACHD patients, often precluding heart-alone transplantation. Fontan-associated liver disease, pulmonary vascular and restrictive lung disease, and renal dysfunction frequently necessitate multi-organ transplantation. ACHD patients have a unique immunological and sensitization profile, increasing their risk for infection, rejection, and malignancies, requiring specialized pretransplant desensitization and post-transplant immunosuppression strategies. ACHD transplantation presents unique surgical challenges, including chest reentry, vascular access issues, bleeding risks, extensive anatomical reconstruction, the need for longer vascular segments from donors, and prolonged ischemic times. Decisions regarding heart-alone versus heart-liver, heart-lung, or heart-kidney transplantation demand careful evaluation. These complex surgical plans require extensive multimodal imaging and collaboration with ACHD cardiac imaging specialists and abdominal transplant teams. Comprehensive coordination and psychosocial support are crucial for ACHD patients throughout the transplant process. A dedicated multidisciplinary team and an established and separate pathway for pre-, peri-, and postoperative care in centers with ACHD and multi-organ transplant expertise are essential. There is need for a revised organ allocation system to ensure timely access to transplantation for ACHD patients. CI - Copyright: (c) 2025 The Author(s). FAU - Duarte, Valeria E AU - Duarte VE AUID- ORCID: 0000-0001-6616-5412 AD - Houston Methodist DeBakey Heart & Vascular Center, Houston Methodist, Houston, Texas, US. FAU - Urey, Marcus A AU - Urey MA AUID- ORCID: 0000-0001-8311-5003 AD - University of California, San Diego, California, US. FAU - Adler, Eric D AU - Adler ED AUID- ORCID: 0000-0002-4765-0188 AD - University of California, San Diego, California, US. FAU - Merkelz, Brenda AU - Merkelz B AD - J.C. Walter Jr. Transplant Center, Houston Methodist, Houston, Texas, US. FAU - Hobeika, Mark J AU - Hobeika MJ AUID- ORCID: 0000-0002-7444-7097 AD - Houston Methodist Hospital, Houston, Texas, US. FAU - Suarez, Erik E AU - Suarez EE AD - Houston Methodist, Houston, Texas, US. FAU - Quarti, Andrea G AU - Quarti AG AUID- ORCID: 0000-0002-0040-7084 AD - Houston Methodist, Houston, Texas, US. FAU - Yousefzai, Rayan AU - Yousefzai R AUID- ORCID: 0000-0002-1759-8892 AD - Houston Methodist DeBakey Heart & Vascular Center, Houston Methodist, Houston, Texas, US. LA - eng PT - Journal Article PT - Review DEP - 20250515 PL - United States TA - Methodist Debakey Cardiovasc J JT - Methodist DeBakey cardiovascular journal JID - 101508600 SB - IM MH - Humans MH - *Heart Defects, Congenital/surgery/physiopathology/mortality/diagnosis MH - Adult MH - Risk Factors MH - Treatment Outcome MH - Patient Selection MH - *Heart Transplantation/adverse effects MH - Clinical Decision-Making MH - Risk Assessment MH - Heart-Lung Transplantation/adverse effects MH - *Liver Transplantation/adverse effects/mortality MH - *Kidney Transplantation/adverse effects PMC - PMC12082638 OTO - NOTNLM OT - adult congenital heart disease OT - complication associated with adult congenital heart disease OT - heart transplant OT - multi-organ transplant COIS- The authors have no competing interests to declare. EDAT- 2025/05/19 12:30 MHDA- 2025/05/19 12:31 PMCR- 2025/05/15 CRDT- 2025/05/19 06:04 PHST- 2025/01/31 00:00 [received] PHST- 2025/04/09 00:00 [accepted] PHST- 2025/05/19 12:31 [medline] PHST- 2025/05/19 12:30 [pubmed] PHST- 2025/05/19 06:04 [entrez] PHST- 2025/05/15 00:00 [pmc-release] AID - 10.14797/mdcvj.1576 [doi] PST - epublish SO - Methodist Debakey Cardiovasc J. 2025 May 15;21(3):72-82. doi: 10.14797/mdcvj.1576. eCollection 2025. PMID- 40382115 OWN - NLM STAT- MEDLINE DCOM- 20250517 LR - 20250517 IS - 1092-9126 (Print) IS - 1092-9126 (Linking) VI - 28 DP - 2025 TI - Addressing Complexities in Fontan Combined Heart-Liver Transplantation: A Collaborative Perspective. PG - 117-123 LID - S1092-9126(25)00007-9 [pii] LID - 10.1053/j.pcsu.2025.02.004 [doi] AB - In Fontan circulatory failure, heart or combined heart-liver transplantation (CHLT) is considered a final therapeutic option. Fontan patients present unique challenges for the cardiac and liver transplant teams. Improving outcomes of CHLT in Fontan patients requires a multidisciplinary team approach to patient selection, meticulous surgical planning, intraoperative and postoperative management, and continuous learning. CI - Copyright (c) 2025 Elsevier Inc. All rights reserved. FAU - Lin, Jeannette AU - Lin J AD - Ahmanson/UCLA Adult Congenital Heart Disease Center, Division of Adult Cardiology, Los Angeles, California. FAU - Lubin, Lorraine AU - Lubin L AD - UCLA Department of Anesthesiology and Perioperative Medicine, Los Angeles, California. FAU - Reardon, Leigh AU - Reardon L AD - Ahmanson/UCLA Adult Congenital Heart Disease Center, Division of Adult Cardiology, Los Angeles, California. FAU - Lluri, Gentian AU - Lluri G AD - Ahmanson/UCLA Adult Congenital Heart Disease Center, Division of Adult Cardiology, Los Angeles, California. FAU - Aboulhosn, Jamil AU - Aboulhosn J AD - Ahmanson/UCLA Adult Congenital Heart Disease Center, Division of Adult Cardiology, Los Angeles, California. FAU - Cruz, Daniel AU - Cruz D AD - Ahmanson/UCLA Cardiomyopathy Center, Los Angeles, California. FAU - Vucicevic, Darko AU - Vucicevic D AD - Ahmanson/UCLA Cardiomyopathy Center, Los Angeles, California. FAU - Wray, Christopher AU - Wray C AD - UCLA Department of Anesthesiology and Perioperative Medicine, Los Angeles, California. FAU - Saab, Sammy AU - Saab S AD - UCLA Department of Medicine, Pfleger Liver Institute, Los Angeles, California. FAU - Venick, Robert AU - Venick R AD - Department of Pediatric Gastroenterology, Los Angeles, California. FAU - Kaldas, Fady AU - Kaldas F AD - UCLA Department of Surgery, Pfleger Liver Institute, Los Angeles, California. FAU - Si, Ming-Sing AU - Si MS AD - UCLA Department of Surgery, Cardiothoracic Surgery, Los Angeles, California. FAU - Biniwale, Reshma AU - Biniwale R AD - UCLA Department of Surgery, Cardiothoracic Surgery, Los Angeles, California. FAU - Van Arsdell, Glen AU - Van Arsdell G AD - UCLA Department of Surgery, Cardiothoracic Surgery, Los Angeles, California. Electronic address: gvanarsdell@mednet.ucla.edu. LA - eng PT - Journal Article PT - Review DEP - 20250217 PL - United States TA - Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu JT - Seminars in thoracic and cardiovascular surgery. Pediatric cardiac surgery annual JID - 9815944 SB - IM MH - Humans MH - *Fontan Procedure/adverse effects/methods MH - *Liver Transplantation/methods MH - *Heart Transplantation/methods MH - *Heart Defects, Congenital/surgery MH - Patient Selection MH - Patient Care Team OTO - NOTNLM OT - Fontan OT - combined heart-liver transplantation OT - failing Fontan COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/05/18 17:01 MHDA- 2025/05/18 17:02 CRDT- 2025/05/17 20:55 PHST- 2024/11/08 00:00 [received] PHST- 2025/01/28 00:00 [revised] PHST- 2025/02/02 00:00 [accepted] PHST- 2025/05/18 17:02 [medline] PHST- 2025/05/18 17:01 [pubmed] PHST- 2025/05/17 20:55 [entrez] AID - S1092-9126(25)00007-9 [pii] AID - 10.1053/j.pcsu.2025.02.004 [doi] PST - ppublish SO - Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu. 2025;28:117-123. doi: 10.1053/j.pcsu.2025.02.004. Epub 2025 Feb 17. PMID- 40381954 OWN - NLM STAT- MEDLINE DCOM- 20250604 LR - 20250613 IS - 1473-4893 (Electronic) IS - 1470-2118 (Print) IS - 1470-2118 (Linking) VI - 25 IP - 3 DP - 2025 May TI - Sarcoidosis: Key disease aspects and update on management. PG - 100326 LID - S1470-2118(25)00044-2 [pii] LID - 10.1016/j.clinme.2025.100326 [doi] LID - 100326 AB - Sarcoidosis is a complex disease of unknown origin, primarily affecting the lungs but capable of involving almost any organ. Diagnosis is challenging due to the lack of specific markers and requires assessment of clinical features, careful imaging, exclusion of other conditions and, ideally, a tissue biopsy demonstrating non-necrotising granulomas. Over 90% of patients have pulmonary involvement, presenting with symptoms like dry cough and breathlessness, along with systemic signs such as fever and weight loss. Extrapulmonary manifestations occur in about 30% of cases and can affect any organ, including the heart, nervous system and eyes. Management involves a multidisciplinary approach with some patients requiring immunosuppressive and antifibrotic therapies. Despite generally good outcomes, sarcoidosis can lead to significant morbidity and mortality, particularly from pulmonary and cardiac complications. Emerging treatments like infliximab and nintedanib offer hope for refractory cases, although they carry risks of serious infections and other side effects. CI - Crown Copyright (c) 2025. Published by Elsevier Ltd. All rights reserved. FAU - Coker, Robina K AU - Coker RK AD - Respiratory Medicine, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London W12 0HS, United Kingdom. Electronic address: r.coker@nhs.net. FAU - Cullen, Kathy M AU - Cullen KM AD - Consultant Respiratory Physician, Belfast Trust, Interim Director of Centre for Medical Education, Queens University, Belfast BT7 1NN, United Kingdom. LA - eng PT - Journal Article PT - Review DEP - 20250515 PL - England TA - Clin Med (Lond) JT - Clinical medicine (London, England) JID - 101092853 SB - IM MH - Humans MH - *Sarcoidosis/diagnosis/therapy MH - Disease Management PMC - PMC12151669 OTO - NOTNLM OT - Antifibrotic OT - Arrhythmia OT - Granuloma OT - Hypercalcaemia OT - Uveitis COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/05/18 17:00 MHDA- 2025/06/05 00:28 PMCR- 2025/05/15 CRDT- 2025/05/17 19:37 PHST- 2025/03/03 00:00 [received] PHST- 2025/05/02 00:00 [revised] PHST- 2025/05/06 00:00 [accepted] PHST- 2025/06/05 00:28 [medline] PHST- 2025/05/18 17:00 [pubmed] PHST- 2025/05/17 19:37 [entrez] PHST- 2025/05/15 00:00 [pmc-release] AID - S1470-2118(25)00044-2 [pii] AID - 100326 [pii] AID - 10.1016/j.clinme.2025.100326 [doi] PST - ppublish SO - Clin Med (Lond). 2025 May;25(3):100326. doi: 10.1016/j.clinme.2025.100326. Epub 2025 May 15. PMID- 40379497 OWN - NLM STAT- MEDLINE DCOM- 20250822 LR - 20250822 IS - 2152-2669 (Electronic) IS - 2152-2669 (Linking) VI - 25 IP - 9 DP - 2025 Sep TI - Role of a Multidisciplinary Program (Amyloidosis Program of Calgary) on Recognition and Intervention for AL and ATTR Amyloidosis. PG - e619-e627 LID - S2152-2650(25)00140-5 [pii] LID - 10.1016/j.clml.2025.04.009 [doi] AB - BACKGROUND: The diagnosis and management of amyloidosis requires strong coordination among various teams and a multidisciplinary approach which is essential for providing the diagnostic tools needed for patients with organ amyloid deposition. METHODS: In this study, we reviewed the referral patterns to the cardiac and hematology amyloid clinics since the inception of the Amyloidosis Program of Calgary (APC) in 2019. The APC was established to facilitate the diagnosis and treatment of amyloidosis. Additionally, a central referral system was created to expedite the triage of cases with potential amyloid-related symptoms. RESULTS: The cardiac amyloid clinic saw an increase in referrals from 41 in 2018 to 105 in 2022, although there was a temporary decrease from 67 in 2019 to 56 in 2020 during the first year of the pandemic. Most referrals came from nonamyloid cardiology clinics, followed by hematology referrals. Fifty percent of the cases referred were patients with ATTR and 18% represented AL cases. Moreover, amyloid clinic at our cancer center also began receiving referrals via the central triage system in 2019, with AL amyloidosis cases increasing from 16 to 25 between 2018 and 2023. Therefore, we report here the significant impact of the APC on increasing referrals for patients with ATTR, with the program facilitating diagnostic pathways for these rare conditions. IN SUMMARY: Since 2022, the establishment of an amyloid screening clinic has furthered these efforts, aiming to enhance early recognition and improve clinical outcomes. CI - Copyright (c) 2025 Elsevier Inc. All rights reserved. FAU - Burande, Aksha AU - Burande A AD - Department of Medical Oncology and Hematology, Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada. FAU - Fine, Nowell AU - Fine N AD - Department of Cardiac Sciences, Division of Cardiology, Libin Cardiovascular Institute, Calgary, Alberta, Canada. FAU - Miller, Robert Jh AU - Miller RJ AD - Department of Cardiac Sciences, Division of Cardiology, Libin Cardiovascular Institute, Calgary, Alberta, Canada. FAU - Hahn, Christopher AU - Hahn C AD - Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada. FAU - Mahe, Etienne AU - Mahe E AD - Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada. FAU - Bosley, Debra AU - Bosley D AD - Department of Cardiac Sciences, Division of Cardiology, Libin Cardiovascular Institute, Calgary, Alberta, Canada. FAU - Litwin, Lyndsay AU - Litwin L AD - Department of Cardiac Sciences, Division of Cardiology, Libin Cardiovascular Institute, Calgary, Alberta, Canada. FAU - Jimenez-Zepeda, Victor H AU - Jimenez-Zepeda VH AD - Department of Medical Oncology and Hematology, Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada; Arnie Charbonneau Research Institute, University of Calgary, Calgary, AB, Canada. Electronic address: Victor.Zepeda@albertahealthservices.ca. LA - eng PT - Journal Article DEP - 20250417 PL - United States TA - Clin Lymphoma Myeloma Leuk JT - Clinical lymphoma, myeloma & leukemia JID - 101525386 RN - Amyloidosis, Hereditary, Transthyretin-Related SB - IM MH - Humans MH - *Immunoglobulin Light-chain Amyloidosis/diagnosis/therapy MH - Female MH - Male MH - Referral and Consultation/statistics & numerical data MH - Alberta/epidemiology MH - Aged MH - Middle Aged MH - Patient Care Team MH - *Amyloid Neuropathies, Familial/diagnosis/therapy OTO - NOTNLM OT - AL amyloidosis OT - Amyloidosis Program of Calgary OT - Cardiac amyloidosis OT - MGUS OT - Multidisciplinary team approach COIS- Disclosure Victor Jimenez-Zepeda has received honoraria from Janssen, Prothena, Pfizer, Alnylam, and Myeloma Canada. Robert Miller has received research support and consulting fees from Pfizer. EDAT- 2025/05/17 17:03 MHDA- 2025/08/31 19:58 CRDT- 2025/05/16 21:56 PHST- 2024/09/18 00:00 [received] PHST- 2025/04/05 00:00 [revised] PHST- 2025/04/08 00:00 [accepted] PHST- 2025/08/31 19:58 [medline] PHST- 2025/05/17 17:03 [pubmed] PHST- 2025/05/16 21:56 [entrez] AID - S2152-2650(25)00140-5 [pii] AID - 10.1016/j.clml.2025.04.009 [doi] PST - ppublish SO - Clin Lymphoma Myeloma Leuk. 2025 Sep;25(9):e619-e627. doi: 10.1016/j.clml.2025.04.009. Epub 2025 Apr 17. PMID- 40377321 OWN - NLM STAT- Publisher LR - 20250516 IS - 1538-4683 (Electronic) IS - 1061-5377 (Linking) DP - 2025 May 16 TI - Percutaneous Coronary Intervention in Pregnancy: A Contemporary Review. LID - 10.1097/CRD.0000000000000945 [doi] AB - Percutaneous coronary intervention (PCI) during pregnancy presents unique challenges due to physiological cardiovascular adaptations and concerns regarding maternal and fetal safety. This comprehensive review examines the current understanding of PCI in pregnancy, including pathophysiology, indications, technical considerations, outcomes, and management approaches. Despite being rare, cardiovascular disease remains the leading cause of maternal mortality in developed countries, with acute coronary syndrome increasing in frequency among pregnant women. The management of acute coronary syndrome in pregnancy requires a multidisciplinary approach focusing on maternal safety while minimizing fetal risks. Current evidence supports the use of PCI as the preferred revascularization strategy for appropriate indications during pregnancy, with specific procedural modifications to minimize radiation exposure and optimize medication selection. This review synthesizes contemporary literature to provide evidence-based recommendations for the management of pregnant patients requiring coronary intervention. CI - Copyright (c) 2025 Wolters Kluwer Health, Inc. All rights reserved. FAU - Bolaji, Olayiwola Akeem AU - Bolaji OA AD - From the Department of Medicine, Cardiology Division, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Bahar, Yasemin AU - Bahar Y AD - Department of Medicine, Wayne State University/Detroit Medical Center, Detroit, MI. FAU - Bahar, Abdul Rasheed AU - Bahar AR AD - Department of Medicine, Wayne State University/Detroit Medical Center, Detroit, MI. FAU - Adabale, Olanrewaju AU - Adabale O AD - Department of Medicine, ECU Health Medical Center, Greenville, NC. FAU - Anuforo, Anderson AU - Anuforo A AD - Department of Medicine, SUNY Upstate Medical University, Syracuse, NY. FAU - Echari, Blanche AU - Echari B AD - Department of Internal Medicine, The Brooklyn Hospital Center, Brooklyn, NY. FAU - Bob-Manuel, Tamunoinemi AU - Bob-Manuel T AD - Department of Interventional Cardiology, Interventional and Endovascular Cardiology, University of Tennessee Health Science Center, Memphis, TN. FAU - Nebuwa, Chikodili Nora AU - Nebuwa CN AD - Department of Medicine, Vassar Brothers Medical Center, Poughkeepsie, NY. FAU - Alraies, M Chadi AU - Alraies MC AD - Department of Interventional Cardiology, Cardiovascular Institute, Detroit Medical Center, DMC Heart Hospital, Detroit, MI. LA - eng PT - Journal Article DEP - 20250516 PL - United States TA - Cardiol Rev JT - Cardiology in review JID - 9304686 SB - IM OTO - NOTNLM OT - acute coronary syndrome OT - coronary artery disease OT - percutaneous coronary intervention OT - pregnancy OT - radiation safety COIS- Disclosure: The authors declare no conflict of interest. EDAT- 2025/05/16 13:02 MHDA- 2025/05/16 13:02 CRDT- 2025/05/16 09:03 PHST- 2025/05/16 13:02 [medline] PHST- 2025/05/16 13:02 [pubmed] PHST- 2025/05/16 09:03 [entrez] AID - 00045415-990000000-00499 [pii] AID - 10.1097/CRD.0000000000000945 [doi] PST - aheadofprint SO - Cardiol Rev. 2025 May 16. doi: 10.1097/CRD.0000000000000945. PMID- 40371621 OWN - NLM STAT- MEDLINE DCOM- 20250520 LR - 20260817 IS - 2047-9980 (Electronic) IS - 2047-9980 (Linking) VI - 14 IP - 10 DP - 2025 May 20 TI - Nomogram for Predicting 1-, 3-, and 5-Year Survival in Hemodynamically Significant Aortic Regurgitation: The ARISE Score. PG - e039169 LID - 10.1161/JAHA.124.039169 [doi] LID - e039169 AB - BACKGROUND: A user-friendly tool that integrates key clinical variables to estimate prognosis in aortic regurgitation is lacking. We aimed to develop and validate a nomogram-based score to predict survival and identify high-risk patients for timely aortic valve surgery referral. METHODS AND RESULTS: From 2008 to 2022, 1229 patients (derivation data set: 764 Taiwanese; validation data set: 465 Japanese; age: 64+/-17 years) with isolated chronic moderately severe to severe aortic regurgitation from 3 centers were included. All echocardiograms were reviewed de novo. At a median follow-up of 5.0 (interquartile range, 2.2-8.2) years, 204 all-cause deaths occurred and 247 underwent aortic valve surgery within 3 months. In multivariable analysis, age (P<0.001), Charlson Comorbidity Index (P<0.001), New York Heart Association functional class IV (P<0.001), left ventricular ejection fraction (P<0.001), left ventricular end-systolic dimension index (P=0.03), and aortic valve surgery in 3 months (P=0.03) were associated with all-cause death. These variables, along with sex and maximal aorta diameter index, were incorporated into the combined left ventricular ejection fraction and left ventricular end-systolic dimension index nomogram to estimate 1-, 3-, and 5-year survival and to calculate the Aortic Regurgitation/Insufficiency Survival Estimation (ARISE) score. Calibration plots demonstrated good performance, with the area under the receiver operating characteristic curve reaching 0.79 in the validation data set. The left ventricular end-systolic dimension index-based nomogram showed similar performance. By using the tertiles of the ARISE score to risk stratify individuals, Kaplan-Meier curves demonstrated significant survival differences among 3 risk groups in both the derivation and validation cohorts (P<0.001). CONCLUSIONS: The ARISE score (https://arise-score.vercel.app/), which includes guideline-recommended parameters, effectively predicts survival in patients with aortic regurgitation. It may facilitate shared decision-making between the heart team and patients. FAU - Liu, Kang AU - Liu K AD - Department of Internal Medicine and Cardiovascular Center National Taiwan University Hospital Taipei Taiwan. FAU - Tsai, Meng-Han AU - Tsai MH AUID- ORCID: 0000-0001-8188-6437 AD - Department of Internal Medicine and Cardiovascular Center National Taiwan University Hospital Taipei Taiwan. FAU - Wang, Wei-Jyun AU - Wang WJ AUID- ORCID: 0009-0000-6172-5636 AD - Department of Internal Medicine and Cardiovascular Center National Taiwan University Hospital Taipei Taiwan. FAU - Wang, Jui AU - Wang J AUID- ORCID: 0000-0003-4800-5276 AD - Institute of Epidemiology and Prevention Medicine National Taiwan University Taipei Taiwan. AD - Health Data Research Center National Taiwan University Taipei Taiwan. FAU - Ju, Seanson Chance AU - Ju SC AUID- ORCID: 0009-0003-5170-0947 AD - Department of Internal Medicine and Cardiovascular Center National Taiwan University Hospital Taipei Taiwan. FAU - Amano, Masashi AU - Amano M AD - Department of Heart Failure and Transplantation National Cerebral and Cardiovascular Center Osaka Japan. FAU - Izumi, Chisato AU - Izumi C AUID- ORCID: 0000-0002-3282-1327 AD - Department of Heart Failure and Transplantation National Cerebral and Cardiovascular Center Osaka Japan. FAU - Ho, Yi-Lwun AU - Ho YL AUID- ORCID: 0000-0002-8936-9570 AD - Department of Internal Medicine and Cardiovascular Center National Taiwan University Hospital Taipei Taiwan. AD - Telehealth Center, National Taiwan University Hospital Taipei Taiwan. FAU - Takeuchi, Masaaki AU - Takeuchi M AUID- ORCID: 0000-0001-7606-1537 AD - Department of Laboratory and Transfusion Medicine Hospital of University of Occupational and Environmental Health, School of Medicine Kitakyushu Japan. FAU - Yang, Li-Tan AU - Yang LT AUID- ORCID: 0000-0002-6341-5735 AD - Department of Internal Medicine and Cardiovascular Center National Taiwan University Hospital Taipei Taiwan. AD - Telehealth Center, National Taiwan University Hospital Taipei Taiwan. LA - eng PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't PT - Validation Study DEP - 20250515 PL - England TA - J Am Heart Assoc JT - Journal of the American Heart Association JID - 101580524 SB - IM MH - Humans MH - *Aortic Valve Insufficiency/mortality/physiopathology/surgery/diagnosis/diagnostic imaging MH - *Nomograms MH - Female MH - Male MH - Middle Aged MH - Aged MH - Risk Assessment MH - Severity of Illness Index MH - Time Factors MH - *Hemodynamics/physiology MH - Retrospective Studies MH - Risk Factors MH - Taiwan/epidemiology MH - Survival Rate/trends MH - Prognosis MH - Predictive Value of Tests MH - Echocardiography MH - *Aortic Valve/surgery/physiopathology/diagnostic imaging MH - Stroke Volume PMC - PMC12184561 OTO - NOTNLM OT - ARISE score OT - all-cause mortality OT - aortic regurgitation OT - clinical decision support system OT - nomogram COIS- None. EDAT- 2025/05/15 06:33 MHDA- 2025/05/20 17:06 PMCR- 2025/05/15 CRDT- 2025/05/15 05:53 PHST- 2025/05/20 17:06 [medline] PHST- 2025/05/15 06:33 [pubmed] PHST- 2025/05/15 05:53 [entrez] PHST- 2025/05/15 00:00 [pmc-release] AID - JAH310967 [pii] AID - 10.1161/JAHA.124.039169 [doi] PST - ppublish SO - J Am Heart Assoc. 2025 May 20;14(10):e039169. doi: 10.1161/JAHA.124.039169. Epub 2025 May 15. PMID- 40371586 OWN - NLM STAT- MEDLINE DCOM- 20250520 LR - 20260813 IS - 2047-9980 (Electronic) IS - 2047-9980 (Linking) VI - 14 IP - 10 DP - 2025 May 20 TI - Sustained Improvements After Intervention to Prevent Contrast-Associated Acute Kidney Injury: A Randomized Controlled Trial. PG - e038920 LID - 10.1161/JAHA.124.038920 [doi] LID - e038920 AB - BACKGROUND: In the IMPROVE AKI (A Cluster-Randomized Trial of Team-Based Coaching Interventions to Improve Acute Kidney Injury) trial, a combination of team-based coaching and data-driven surveillance dashboards reduced the odds of AKI following cardiac catheterization by 46%. The objective of this study was to determine if improvements in AKI outcomes would be sustained after completion of the active intervention. METHODS AND RESULTS: A 2x2 factorial cluster-randomized trial with an 18-month active intervention phase (October 2019-March 2021) and an 18-month sustainability phase (April 2021-September 2022) conducted among cardiac catheterization laboratories in 20 Veterans Affairs sites. Interventions included team-based coaching in a virtual learning collaborative or technical assistance, with and without access to an automated surveillance reporting dashboard. Data were collected on procedures involving adult patients undergoing diagnostic coronary angiography or percutaneous coronary interventions and not receiving chronic dialysis. The main outcome was AKI within 7 days of cardiac catheterization among all participants and those with preexisting chronic kidney disease. In addition, survey and focused interview data were collected to understand barriers and facilitators to sustaining AKI improvements. In this phase, 440 of 4160 patients experienced AKI, including 216 of 1260 patients with chronic kidney disease. Compared with technical assistance alone, we observed a reduction in AKI among virtual learning collaborative + automated surveillance reporting sites (adjusted odds ratio, 0.60 [95% CI, 0.42-0.86]). Sites had implemented standardized orders (11), oral and intravenous hydration standing orders (13), and contrast limiting protocols (10). CONCLUSIONS: Team-based coaching coupled with data-driven surveillance dashboards reduced AKI by 40% during the 18 months after active participation in the trial. Process improvement education, care process standardization, and automated outcome feedback may be effective and durable methods for reducing AKI. REGISTRATION: URL: https://clinicaltrials.gov/; Unique Identifier: NCT03556293. FAU - Matheny, Michael E AU - Matheny ME AUID- ORCID: 0000-0003-3217-4147 AD - Department of Biomedical Informatics Vanderbilt University Medical Center Nashville TN USA. AD - Geriatric Research Education and Clinical Care Center Tennessee Valley Healthcare System VA Nashville TN USA. FAU - Carpenter-Song, Elizabeth AU - Carpenter-Song E AD - Department of Anthropology Dartmouth College Hanover NH USA. FAU - Ricket, Iben M AU - Ricket IM AD - Department of Epidemiology Geisel School of Medicine at Dartmouth Hanover NH USA. AD - The Dartmouth Institute for Health Policy and Clinical Practice Lebanon NH USA. FAU - Solomon, Richard J AU - Solomon RJ AD - University of Vermont Larner College of Medicine Burlington VT USA. FAU - Stabler, Meagan E AU - Stabler ME AD - Department of Community and Family Medicine Dartmouth-Hitchcock Medical Center Lebanon NH USA. FAU - Davis, Sharon E AU - Davis SE AUID- ORCID: 0000-0003-0792-8867 AD - Department of Biomedical Informatics Vanderbilt University Medical Center Nashville TN USA. FAU - Zubkoff, Lisa AU - Zubkoff L AUID- ORCID: 0000-0002-0728-2237 AD - University of Alabama at Birmingham and VA Birmingham Health Care Birmingham AL USA. FAU - Westerman, Dax M AU - Westerman DM AUID- ORCID: 0000-0002-9547-7789 AD - Department of Biomedical Informatics Vanderbilt University Medical Center Nashville TN USA. FAU - Dorn, Chad AU - Dorn C AUID- ORCID: 0000-0002-4886-6159 AD - Department of Biomedical Informatics Vanderbilt University Medical Center Nashville TN USA. FAU - Cox, Kevin C AU - Cox KC AD - Department of Anthropology Dartmouth College Hanover NH USA. FAU - Minter, Freneka F AU - Minter FF AUID- ORCID: 0000-0003-4513-2704 AD - Department of Biomedical Informatics Vanderbilt University Medical Center Nashville TN USA. FAU - Jneid, Hani AU - Jneid H AUID- ORCID: 0000-0002-8754-358X AD - Division of Cardiovascular Medicine University of Texas Medical Branch Galveston TX USA. FAU - Currier, Jesse W AU - Currier JW AD - Division of Cardiology, Department of Medicine Veteran Affairs Greater Los Angeles Healthcare System Los Angeles CA USA. AD - Division of Cardiology, Department of Medicine University of California Los Angeles Healthcare System Los Angeles CA USA. FAU - Athar, S Ahmed AU - Athar SA AUID- ORCID: 0000-0002-8993-1367 AD - Cardiology Section Loma Linda VA Medical Center Loma Linda CA USA. AD - Department of Medicine, Division of Cardiology Loma Linda University School of Medicine Loma Linda CA USA. FAU - Girotra, Saket AU - Girotra S AUID- ORCID: 0000-0002-4784-4513 AD - Division of Cardiology, Department of Internal Medicine University of Texas Southwestern Medical Center Dallas TX USA. FAU - Leung, Calvin AU - Leung C AUID- ORCID: 0009-0001-8905-4448 AD - Department of Medicine, Section of Cardiology Orlando VA Medical Center Orlando FL USA. FAU - Helton, Thomas J AU - Helton TJ AUID- ORCID: 0009-0001-5651-4401 AD - East Tennessee State University Johnson City TN USA. FAU - Agarwal, Ajay AU - Agarwal A AD - Wright State University Dayton VA Medical Center Dayton OH USA. FAU - Vidovich, Mladen I AU - Vidovich MI AD - Section of Cardiology, Jesse Brown VA Medical Center and Department of Medicine University of Illinois at Chicago IL USA. FAU - Plomondon, Mary E AU - Plomondon ME AUID- ORCID: 0000-0002-8616-4916 AD - CART Program VHA Office of Quality and Safety Washington DC USA. FAU - Waldo, Stephen W AU - Waldo SW AUID- ORCID: 0000-0003-0678-4873 AD - CART Program VHA Office of Quality and Safety Washington DC USA. AD - Department of Medicine, Cardiology Section Rocky Mountain Regional VA Medical Center Aurora CO USA. AD - Department of Medicine, Division of Cardiology University of Colorado School of Medicine Aurora CO USA. FAU - Aschbrenner, Kelly A AU - Aschbrenner KA AD - Department of Anthropology Dartmouth College Hanover NH USA. FAU - McKay, Virginia AU - McKay V AUID- ORCID: 0000-0002-9299-3294 AD - Washington University in St. Louis, MO (V.M.). FAU - O'Malley, A James AU - O'Malley AJ AUID- ORCID: 0000-0001-8389-6217 AD - The Dartmouth Institute for Health Policy and Clinical Practice Lebanon NH USA. FAU - Brown, Jeremiah R AU - Brown JR AUID- ORCID: 0000-0003-4512-9716 AD - Department of Epidemiology Geisel School of Medicine at Dartmouth Hanover NH USA. AD - The Dartmouth Institute for Health Policy and Clinical Practice Lebanon NH USA. AD - Dartmouth Center for Implementation Science, Biomedical Data Science Geisel School of Medicine at Dartmouth Hanover NH USA. LA - eng SI - ClinicalTrials.gov/NCT03556293 GR - R01 DK113201/DK/NIDDK NIH HHS/United States GR - R01 HL160734/HL/NHLBI NIH HHS/United States GR - R56 HL158803/HL/NHLBI NIH HHS/United States GR - R01 HL166305/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial PT - Research Support, N.I.H., Extramural DEP - 20250515 PL - England TA - J Am Heart Assoc JT - Journal of the American Heart Association JID - 101580524 RN - 0 (Contrast Media) SB - IM MH - Humans MH - *Acute Kidney Injury/prevention & control/chemically induced/epidemiology/diagnosis MH - Male MH - *Contrast Media/adverse effects MH - Female MH - Aged MH - Middle Aged MH - *Cardiac Catheterization/adverse effects MH - *Percutaneous Coronary Intervention/adverse effects MH - *Coronary Angiography/adverse effects MH - United States MH - *Patient Care Team MH - Time Factors MH - Quality Improvement PMC - PMC12184551 OTO - NOTNLM OT - acute kidney injury OT - chronic kidney disease OT - contrast nephropathy OT - prevention COIS- Agarwal reports employment with VA Medical Center, Wright State University, and an advisory or leadership role for the American College of Cardiology Board of Trustees-Ohio Chapter (an unpaid position). S.A. Athar reports employment with Loma Linda VA Medical Center. E. Carpenter-Song served as a consultant for Westat during 2022 to support the use of qualitative methods in 2 studies: (1) a study examining an employment program for veterans transitioning to civilian life and (2) a study examining evidence-based supported employment for young adults with serious mental illnesses. E. Carpenter-Song was part of a research team that received funding in 2020 from the Bristol Meyers Squibb Foundation to conduct research examining the impact of COVID-19 on rural health systems and communities. S. Girotra reports research funding from National Heart, Lung, and Blood Institute (R01HL160734, R56HL158803, and R01HL166305). T.J. Helton reports employment with James H. Quillen VA Medical Center and ownership interest in Apple, AirBNB, ASML holding, Confluent, Crowdstrike, Microsoft, Shopify, and Upstart. C. Leung reports employment with Orlando Veterans Affairs Medical Center. M.E. Matheny reports employment with Department of Veterans Affairs and consultancy agreements with NIH-VA-DoD Pain Management Grant Consortium (PMC3), and membership in Informatics & Methods Section, SMRB Study Section, VA HSR&D; Steering Committee-Indianapolis VA HSR&D COIN Center; and Steering Committee-VA HSR&D VIREC. A.J. O'Malley reports consultancy agreements with JB Associates and an advisory or leadership role for Statistics in Medicine and Observational Studies. M.E. Plomondon reports employment with Veterans Health Administration, Washington, DC. R. Solomon reports consultancy agreements with MediBeacon, Inc., PLC Inc., and Sonogenix, Inc.; research funding from REATA and Vera Pharmaceuticals; and advisory or leadership roles for MediBeacon, PLC Med, Inc., and Sonogenix. M.I. Vidovich reports consultancy agreements with Boston Scientific, research funding from Boston Scientific, patents or royalties from Merit Medical, and an advisory or leadership role for Intersocietal Accreditation Commission. S.W. Waldo reports employment with Rocky Mountain Regional VA Medical Center and research funding from Cardiovascular Systems Incorporated and Janssen Pharmaceuticals. L. Zubkoff reports employment with Birmingham VA Healthcare System. All remaining authors have nothing to disclose. EDAT- 2025/05/15 06:34 MHDA- 2025/05/20 17:07 PMCR- 2025/05/15 CRDT- 2025/05/15 05:42 PHST- 2025/05/20 17:07 [medline] PHST- 2025/05/15 06:34 [pubmed] PHST- 2025/05/15 05:42 [entrez] PHST- 2025/05/15 00:00 [pmc-release] AID - JAH310879 [pii] AID - 10.1161/JAHA.124.038920 [doi] PST - ppublish SO - J Am Heart Assoc. 2025 May 20;14(10):e038920. doi: 10.1161/JAHA.124.038920. Epub 2025 May 15. PMID- 40370972 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260924 IS - 2296-2360 (Print) IS - 2296-2360 (Electronic) IS - 2296-2360 (Linking) VI - 13 DP - 2025 TI - Advancing multidisciplinary management of pediatric hyperinflammatory disorders. PG - 1553861 LID - 10.3389/fped.2025.1553861 [doi] LID - 1553861 AB - Pediatric hyperinflammatory diseases, including Still's disease, Kawasaki disease (KD), multisystem inflammatory syndrome in children (MIS-C), and recurrent pericarditis (RP), represent a spectrum of conditions characterized by immune dysregulation and systemic inflammation. Each disorder exhibits distinct pathophysiological mechanisms and clinical features, yet their overlapping presentations often pose diagnostic challenges. Early and accurate differentiation is critical to mitigate complications such as macrophage activation syndrome (MAS), coronary artery aneurysms, and myocardial dysfunction. This narrative review explores the pathophysiology, diagnostic criteria, and management of these conditions, emphasizing the utility of advanced biomarkers, imaging modalities, and genetic testing. For Still's disease, the review highlights the transformative role of biologic therapies targeting IL-1 and IL-6 in reducing systemic inflammation and improving outcomes. In KD, timely administration of intravenous immunoglobulin (IVIG) and combination with high-dose steroids in high-risk patients is pivotal for preventing coronary complications. MIS-C, associated with SARS-CoV-2 infection, requires tailored immunomodulatory approaches, including corticosteroids and biologics, to address severe hyperinflammation and multiorgan involvement. RP management prioritizes NSAIDs, colchicine, and IL-1 inhibitors to reduce recurrence and corticosteroid dependence. The review advocates for a multidisciplinary approach, integrating standardized diagnostic algorithms and disease-specific expertise to optimize patient care. Future research directions include the identification of predictive biomarkers, exploration of novel therapeutic targets, and development of evidence-based treatment protocols to enhance long-term outcomes in pediatric inflammatory diseases. CI - (c) 2025 La Torre, Meliota, Civino, Campanozzi, Cecinati, Rosati, Sacco, Santoro, Vairo and Cardinale. FAU - La Torre, Francesco AU - La Torre F AD - Department of Pediatrics, Giovanni XXIII Pediatric Hospital, University of Bari, Bari, Italy. FAU - Meliota, Giovanni AU - Meliota G AD - Pediatric Cardiology, Giovanni XXIII Pediatric Hospital, Bari, Italy. FAU - Civino, Adele AU - Civino A AD - Pediatric Rheumatology and Immunology Unit, "Vito Fazzi" Hospital, Lecce, Italy. FAU - Campanozzi, Angelo AU - Campanozzi A AD - Pediatric Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy. FAU - Cecinati, Valerio AU - Cecinati V AD - Pediatric and Pediatric Oncohematology Unit, Santissima Annunziata Hospital, Taranto, Italy. FAU - Rosati, Enrico AU - Rosati E AD - Neonatology and Intensive Care Unit, "Vito Fazzi" Hospital, Lecce, Italy. FAU - Sacco, Emanuela AU - Sacco E AD - Pediatric Unit, Fondazione IRCCS Casa Sollievo della Sofferenza, Foggia, Italy. FAU - Santoro, Nicola AU - Santoro N AD - Pediatric and Oncohematology Unit, Azienda Ospedaliero Universitaria "Policlinico Consorziale", Bari, Italy. FAU - Vairo, Ugo AU - Vairo U AD - Pediatric Cardiology, Giovanni XXIII Pediatric Hospital, Bari, Italy. FAU - Cardinale, Fabio AU - Cardinale F AD - Department of Pediatrics, Giovanni XXIII Pediatric Hospital, University of Bari, Bari, Italy. LA - eng PT - Journal Article PT - Review DEP - 20250430 PL - Switzerland TA - Front Pediatr JT - Frontiers in pediatrics JID - 101615492 PMC - PMC12075326 OTO - NOTNLM OT - IL-1 OT - IL-6 OT - Kawasaki disease OT - MIS-C multisystem inflammatory syndrome OT - biologics OT - hyperinflammation OT - recurrent pericarditis OT - still disease COIS- FL has received speakers' fees from Sobi and Novartis. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2025/05/15 11:20 MHDA- 2025/05/15 11:21 PMCR- 2025/04/30 CRDT- 2025/05/15 04:53 PHST- 2024/12/31 00:00 [received] PHST- 2025/04/03 00:00 [accepted] PHST- 2025/05/15 11:21 [medline] PHST- 2025/05/15 11:20 [pubmed] PHST- 2025/05/15 04:53 [entrez] PHST- 2025/04/30 00:00 [pmc-release] AID - 10.3389/fped.2025.1553861 [doi] PST - epublish SO - Front Pediatr. 2025 Apr 30;13:1553861. doi: 10.3389/fped.2025.1553861. eCollection 2025. PMID- 40368775 OWN - NLM STAT- MEDLINE DCOM- 20250601 LR - 20250601 IS - 1349-3299 (Electronic) IS - 1349-2365 (Linking) VI - 66 IP - 3 DP - 2025 May 31 TI - Real-World Data on Post-Discharge Prognosis of Elderly and Frail Hospitalized Patients with Heart Failure Reflecting the Latest Guideline-Directed Medical Therapy in Japan. PG - 404-412 LID - 10.1536/ihj.24-752 [doi] AB - The West Tokyo Heart Failure (WET-HF) registry has recently reported that the post-discharge prognosis for hospitalized patients with heart failure (HF) between 2011 and 2021 has been improving over time and that there has been an upward trend in the use of guideline-directed medical therapy (GDMT). However, there are few post-discharge prognostic data for elderly and frail hospitalized patients with HF. A total of 738 consecutive patients with HF hospitalized at the Konan Medical Center between April 2020 and March 2024 were retrospectively studied. The primary endpoint was cardiovascular death or HF hospitalization. The mean age and clinical frailty scale were 83.4 +/- 11.0 years and 4.8 +/- 2.3, respectively. The average prescription rates of GDMT at discharge over the 4-year period were 71.0% for beta-blockers, 23.4% for angiotensin-converting enzyme inhibitors (ACE-I) or angiotensin receptor blockers (ARB), 42.7% for angiotensin receptor neprilysin inhibitor (ARNI), 56.1% for mineralocorticoid receptor antagonists (MRA), and 23.2% for sodium-glucose cotransporter 2 (SGLT2) inhibitors. Although, there has been an upward trend in the use of GDMT, the Kaplan-Meier curve showed no improvement in prognosis over time. Multivariate analyses showed that none of the beta-blockers, ACE-I, ARB, ARNI, MRA, or SGLT2-inhibitors at discharge reduced the primary endpoint for hospitalized patients with HF. GDMT alone may not be sufficient to improve the prognosis of elderly and frail hospitalized patients with HF. In addition to GDMT, comprehensive management by a multidisciplinary team may be vital, since currently there seems to be no one-size-fits-all approach for these patients. FAU - Odajima, Susumu AU - Odajima S AD - Department of Cardiology, Konan Medical Center. FAU - Fujimoto, Keisuke AU - Fujimoto K AD - Department of Cardiology, Konan Medical Center. FAU - Kadoi, Akihiro AU - Kadoi A AD - Department of Cardiology, Konan Medical Center. FAU - Tsuboi, Takafumi AU - Tsuboi T AD - Department of Cardiology, Konan Medical Center. FAU - Nagasawa, Yoshinori AU - Nagasawa Y AD - Department of Cardiology, Konan Medical Center. FAU - Hyogo, Kiyohiro AU - Hyogo K AD - Department of Cardiology, Konan Medical Center. FAU - Uzu, Kenzo AU - Uzu K AD - Department of Cardiology, Konan Medical Center. FAU - Fukuoka, Yoko AU - Fukuoka Y AD - Department of Cardiology, Konan Medical Center. FAU - Shimokawa, Yasushi AU - Shimokawa Y AD - Department of Cardiology, Konan Medical Center. FAU - Okubo, Hideaki AU - Okubo H AD - Department of Cardiology, Konan Medical Center. FAU - Mizutani, Kazuo AU - Mizutani K AD - Department of Cardiology, Rokko Island Konan Hospital. FAU - Shimizu, Hiroki AU - Shimizu H AD - Department of Cardiology, Rokko Island Konan Hospital. LA - eng PT - Journal Article DEP - 20250515 PL - Japan TA - Int Heart J JT - International heart journal JID - 101244240 RN - 0 (Angiotensin-Converting Enzyme Inhibitors) RN - 0 (Angiotensin Receptor Antagonists) RN - 0 (Mineralocorticoid Receptor Antagonists) RN - 0 (Adrenergic beta-Antagonists) SB - IM MH - Humans MH - *Heart Failure/drug therapy/mortality/epidemiology MH - Male MH - Japan/epidemiology MH - Female MH - Aged, 80 and over MH - Retrospective Studies MH - Prognosis MH - Aged MH - *Frail Elderly/statistics & numerical data MH - *Patient Discharge MH - Practice Guidelines as Topic MH - Angiotensin-Converting Enzyme Inhibitors/therapeutic use MH - Hospitalization/statistics & numerical data MH - Angiotensin Receptor Antagonists/therapeutic use MH - Registries MH - Mineralocorticoid Receptor Antagonists/therapeutic use MH - Adrenergic beta-Antagonists/therapeutic use OTO - NOTNLM OT - Frailty OT - Hospitalized heart failure patient OT - Multidisciplinary team OT - Prognosis EDAT- 2025/05/15 00:35 MHDA- 2025/06/02 03:18 CRDT- 2025/05/14 22:03 PHST- 2025/06/02 03:18 [medline] PHST- 2025/05/15 00:35 [pubmed] PHST- 2025/05/14 22:03 [entrez] AID - 10.1536/ihj.24-752 [doi] PST - ppublish SO - Int Heart J. 2025 May 31;66(3):404-412. doi: 10.1536/ihj.24-752. Epub 2025 May 15. PMID- 40367472 OWN - NLM STAT- MEDLINE DCOM- 20250515 LR - 20250514 IS - 0043-5147 (Print) IS - 0043-5147 (Linking) VI - 78 IP - 4 DP - 2025 TI - Study of the influence of medication properties and lifestyle of patients with coronary heart disease on adherence to treatment. PG - 860-875 LID - 10.36740/WLek/203897 [doi] AB - OBJECTIVE: Aim: To investigate how lifestyle factors of patients with CHD and comorbid conditions, along with medicines properties, influence treatment adherence. PATIENTS AND METHODS: Materials and Methods: include the results of a survey conducted among patients with CHD and comorbid conditions at the Department of Cardiology of the P.L. Shupyk National Healthcare University of Ukraine from June to September 2024 (n = 101). The study employed methods of analysis, synthesis, deduction, induction, comparison, statistical and bibliographic research. RESULTS: Results: The study revealed a significantly low adherence rate of 13.9% [CI 95% 13.9 +/- 0.002; p<0.0001] to risk factor modification and prescribed pharmacotherapy in secondary prevention of CHD. It confirmed a statistically significant influence of patient preferences with CHD and comorbid conditions on effective pharmacotherapy (chi2 = 3.350,232, p = 0.067). Patients receiving consultations from both doctors and pharmacists were 22 times more likely (OR = 22.67) to adhere to pharmacotherapy compared to those consulting only doctors. The study found that only 7.8% [CI 95% 7.8 +/- 0.05; p<0.0001] of surveyed patients with CHD and comorbid conditions such as hypertension, diabetes mellitus and chronic kidney disease utilized the "Affordable Medicines" program. CONCLUSION: Conclusions: The decline in the socioeconomic status of the population during the war in Ukraine negatively affects adherence to clinical guidelines for risk factor modification and secondary prevention of CHD, as evidenced by observational studies EUROASPIRE IV and V. The study identified that 42.8% of respondents prefer original medicines when selecting medications, but financial constraints prevent prolonged use as part of prescribed pharmacotherapy, adversely affecting treatment adherence. The effectiveness of a multidisciplinary approach in enhancing treatment adherence among patients with CHD and comorbid conditions was confirmed, demonstrating a 22-fold higher adherence rate compared to consultations with doctors alone. FAU - Dolzhenko, Maryna M AU - Dolzhenko MM AD - SHUPYK NATIONAL HEALTHCARE UNIVERSITY OF UKRAINE, KYIV, UKRAINE. FAU - Bilousova, Natalia A AU - Bilousova NA AD - SHUPYK NATIONAL HEALTHCARE UNIVERSITY OF UKRAINE, KYIV, UKRAINE. FAU - Mykhalchuk, Vasyl M AU - Mykhalchuk VM AD - SHUPYK NATIONAL HEALTHCARE UNIVERSITY OF UKRAINE, KYIV, UKRAINE. FAU - Tkachenko, Natalia O AU - Tkachenko NO AD - ZAPORIZHZHIA STATE MEDICAL AND PHARMACEUTICAL UNIVERSITY, ZAPORIZHZHIA, UKRAINE. FAU - Luchinskaya, Yuliya O AU - Luchinskaya YO AD - SHUPYK NATIONAL HEALTHCARE UNIVERSITY OF UKRAINE, KYIV, UKRAINE. LA - eng PT - Journal Article PL - Poland TA - Wiad Lek JT - Wiadomosci lekarskie (Warsaw, Poland : 1960) JID - 9705467 SB - IM MH - Humans MH - Male MH - Female MH - *Coronary Disease/drug therapy MH - Ukraine MH - Middle Aged MH - *Life Style MH - Aged MH - *Medication Adherence/psychology MH - Secondary Prevention MH - Surveys and Questionnaires MH - Comorbidity MH - Adult OTO - NOTNLM OT - pharmaceutical care OT - generic medicines OT - multidisciplinary team OT - original medicines OT - Coronary heart disease OT - treatment adherence EDAT- 2025/05/14 19:17 MHDA- 2025/05/15 06:33 CRDT- 2025/05/14 16:32 PHST- 2025/05/15 06:33 [medline] PHST- 2025/05/14 19:17 [pubmed] PHST- 2025/05/14 16:32 [entrez] AID - 10.36740/WLek/203897 [doi] PST - ppublish SO - Wiad Lek. 2025;78(4):860-875. doi: 10.36740/WLek/203897. PMID- 40365885 OWN - NLM STAT- MEDLINE DCOM- 20250908 LR - 20260504 IS - 1897-4279 (Electronic) IS - 0022-9032 (Linking) VI - 83 IP - 7-8 DP - 2025 TI - First SHOCK TEAM in Poland: Single-hub-center experience with multidisciplinary care for cardiogenic shock. PG - 823-831 LID - 10.33963/v.phj.105827 [doi] AB - BACKGROUND: Cardiogenic shock (CS) remains a complex syndrome with alarmingly high mortality despite treatment advances. AIMS: This study aimed to describe the experience of the management of patients with CS according to a standardized multidisciplinary team-based protocols. MATERIAL AND METHODS: This is a retrospective analysis of patients with a diagnosis of CS admitted to a large academic tertiary hospital between 2021 and 2023. Patients were managed according to the CS protocols developed at our institution by a dedicated multidisciplinary shock team. We report patients' clinical characteristics, mechanical circulatory support (MCS) utilization, and in-hospital outcomes. RESULTS: Over the three-year period, we identified 257 patients (median age: 69 years, 69% males). In this cohort, acute coronary syndrome was the most common cause of CS (55% of patients), 17% presented with out-of-hospital cardiac arrest, 18% experienced in-hospital cardiac arrest, and 20% of patients were transferred from remote centers. An MCS system was used in 39% of all patients. In-hospital mortality was 62% with significant improvement in consecutive 1-year periods: 75% in 2021 vs. 69% in 2022 vs. 44% in 2023, respectively, P = 0.004 for trend. This improvement was particularly evident in the group supported with MCS: all-cause mortality: 75% in 2021, 50% in 2022, and 29% in 2023 (P = 0.005). The use of MCS was a significant independent predictor of improved survival in 2022 and 2023 (odds ratio, 0.38; confidence interval, 0.149-0.996; P = 0.04). CONCLUSIONS: Our results suggest that a standardized multidisciplinary approach incorporating the availability of MCS therapies and heart transplantation may be associated with improved outcomes in patients with CS. FAU - Kuliczkowski, Wiktor AU - Kuliczkowski W AD - Institute of Heart Diseases, Faculty of Medicine, Wroclaw Medical University, Wroclaw, Poland. AD - University Hospital in Wroclaw, Wroclaw, Poland. FAU - Blaziak, Mikolaj AU - Blaziak M AD - Institute of Heart Diseases, Faculty of Medicine, Wroclaw Medical University, Wroclaw, Poland. blaziak.mikolaj@gmail.com. AD - University Hospital in Wroclaw, Wroclaw, Poland. blaziak.mikolaj@gmail.com. FAU - Przybylski, Roman AU - Przybylski R AD - Institute of Heart Diseases, Faculty of Medicine, Wroclaw Medical University, Wroclaw, Poland. AD - University Hospital in Wroclaw, Wroclaw, Poland. FAU - Gozdzik, Waldemar AU - Gozdzik W AD - Clinical Department of Anesthesiology and Intensive Therapy, Faculty of Medicine, Wroclaw Medical University, Wroclaw, Poland. AD - University Hospital in Wroclaw, Wroclaw, Poland. FAU - Zakliczynski, Michal AU - Zakliczynski M AD - Institute of Heart Diseases, Faculty of Medicine, Wroclaw Medical University, Wroclaw, Poland. AD - University Hospital in Wroclaw, Wroclaw, Poland. FAU - Barteczko-Grajek, Barbara AU - Barteczko-Grajek B AD - Clinical Department of Anesthesiology and Intensive Therapy, Faculty of Medicine, Wroclaw Medical University, Wroclaw, Poland. AD - University Hospital in Wroclaw, Wroclaw, Poland. FAU - Kupiec, Anna AU - Kupiec A AD - Clinical Department of Anesthesiology and Intensive Therapy, Faculty of Medicine, Wroclaw Medical University, Wroclaw, Poland. AD - University Hospital in Wroclaw, Wroclaw, Poland. FAU - Bochenek, Maciej AU - Bochenek M AD - Institute of Heart Diseases, Faculty of Medicine, Wroclaw Medical University, Wroclaw, Poland. AD - University Hospital in Wroclaw, Wroclaw, Poland. FAU - Bielicki, Grzegorz AU - Bielicki G AD - Institute of Heart Diseases, Faculty of Medicine, Wroclaw Medical University, Wroclaw, Poland. AD - University Hospital in Wroclaw, Wroclaw, Poland. FAU - Gajewski, Piotr AU - Gajewski P AD - Institute of Heart Diseases, Faculty of Medicine, Wroclaw Medical University, Wroclaw, Poland. AD - University Hospital in Wroclaw, Wroclaw, Poland. FAU - Garus, Mateusz AU - Garus M AD - Institute of Heart Diseases, Faculty of Medicine, Wroclaw Medical University, Wroclaw, Poland. AD - University Hospital in Wroclaw, Wroclaw, Poland. FAU - Sokolski, Mateusz AU - Sokolski M AD - Institute of Heart Diseases, Faculty of Medicine, Wroclaw Medical University, Wroclaw, Poland. AD - University Hospital in Wroclaw, Wroclaw, Poland. FAU - Zymlinski, Robert AU - Zymlinski R AD - Institute of Heart Diseases, Faculty of Medicine, Wroclaw Medical University, Wroclaw, Poland. AD - University Hospital in Wroclaw, Wroclaw, Poland. FAU - Zimoch, Wojciech AU - Zimoch W AD - Institute of Heart Diseases, Faculty of Medicine, Wroclaw Medical University, Wroclaw, Poland. AD - University Hospital in Wroclaw, Wroclaw, Poland. FAU - Biegus, Jan AU - Biegus J AD - Institute of Heart Diseases, Faculty of Medicine, Wroclaw Medical University, Wroclaw, Poland. AD - University Hospital in Wroclaw, Wroclaw, Poland. FAU - Kosowski, Michal AU - Kosowski M AD - Institute of Heart Diseases, Faculty of Medicine, Wroclaw Medical University, Wroclaw, Poland. AD - University Hospital in Wroclaw, Wroclaw, Poland. FAU - Protasiewicz, Marcin AU - Protasiewicz M AD - Institute of Heart Diseases, Faculty of Medicine, Wroclaw Medical University, Wroclaw, Poland. AD - University Hospital in Wroclaw, Wroclaw, Poland. FAU - Kubler, Piotr AU - Kubler P AD - Institute of Heart Diseases, Faculty of Medicine, Wroclaw Medical University, Wroclaw, Poland. AD - University Hospital in Wroclaw, Wroclaw, Poland. FAU - Tomasiewicz, Brunon AU - Tomasiewicz B AD - Institute of Heart Diseases, Faculty of Medicine, Wroclaw Medical University, Wroclaw, Poland. AD - University Hospital in Wroclaw, Wroclaw, Poland. FAU - Sroka, Michal AU - Sroka M AD - Institute of Heart Diseases, Faculty of Medicine, Wroclaw Medical University, Wroclaw, Poland. AD - Department of Nephrology, Research and Development Center, Provincial Specialist Hospital, Wroclaw, Poland. FAU - Balcer, Bartosz AU - Balcer B AD - University Hospital in Wroclaw, Wroclaw, Poland. FAU - Wietrzyk, Weronika AU - Wietrzyk W AD - University Hospital in Wroclaw, Wroclaw, Poland. FAU - Dolata, Natalia AU - Dolata N AD - University Hospital in Wroclaw, Wroclaw, Poland. FAU - Reczuch, Krzysztof AU - Reczuch K AD - Institute of Heart Diseases, Faculty of Medicine, Wroclaw Medical University, Wroclaw, Poland. AD - University Hospital in Wroclaw, Wroclaw, Poland. FAU - Ponikowski, Piotr AU - Ponikowski P AD - Institute of Heart Diseases, Faculty of Medicine, Wroclaw Medical University, Wroclaw, Poland. AD - University Hospital in Wroclaw, Wroclaw, Poland. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20250514 PL - Poland TA - Kardiol Pol JT - Kardiologia polska JID - 0376352 SB - IM MH - Humans MH - *Shock, Cardiogenic/therapy/mortality MH - Male MH - Female MH - Retrospective Studies MH - Aged MH - Poland MH - Middle Aged MH - *Patient Care Team MH - Hospital Mortality MH - Aged, 80 and over MH - Treatment Outcome OTO - NOTNLM OT - Shock Team OT - cardiogenic shock OT - mechanical circulatory support EDAT- 2025/05/14 12:41 MHDA- 2025/09/08 12:44 CRDT- 2025/05/14 06:53 PHST- 2025/04/15 00:00 [received] PHST- 2025/04/15 00:00 [accepted] PHST- 2025/09/08 12:44 [medline] PHST- 2025/05/14 12:41 [pubmed] PHST- 2025/05/14 06:53 [entrez] AID - VM/OJS/J/105827 [pii] AID - 10.33963/v.phj.105827 [doi] PST - ppublish SO - Kardiol Pol. 2025;83(7-8):823-831. doi: 10.33963/v.phj.105827. Epub 2025 May 14. PMID- 40364123 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250517 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 14 IP - 9 DP - 2025 Apr 29 TI - Can Thrombosed Abdominal Aortic Dissecting Aneurysm Cause Mesenteric Artery Thrombosis and Ischemic Colitis?-A Case Report and a Review of Literature. LID - 10.3390/jcm14093092 [doi] LID - 3092 AB - Background/Objectives: Ischemic colitis, typically caused by thrombosis or reduced blood flow in the inferior mesenteric artery, is the most common ischemic lesion at the colorectal level. This case contributes to existing knowledge by highlighting the rare co-occurrence of a thrombosed aortic aneurysm and ischemic colitis, pointing to a direct vascular etiology rather than a multifactorial or idiopathic cause. Methods: A thorough electronic search was conducted on PubMed to identify risk factors and etiological determinants of ischemic colitis. Results: We present the case of a 70-year-old male with diffuse abdominal pain and multiple cardiac comorbidities. A CT scan revealed aeroenteritis, aerocolia, fusiform aneurysmal dilation of the abdominal aorta (18 cm long, 7.3 cm in diameter, from below the renal arteries to the bifurcation), parietal thrombosis, a circulating lumen of 2.7 cm, and inferior mesenteric artery thrombosis. Intraoperatively, necrosis was found in the upper rectum, sigmoid colon, descending colon, and the middle third of the left transverse colon, with clear demarcation between healthy and necrotic tissue. A subtotal proctocolectomy with transverse colostomy was performed. Conclusions: This case highlights ischemic colitis as a vascular disorder, urging broader differential diagnosis when common causes are unclear. Timely imaging, a multidisciplinary approach, and attention to vascular risks are key to identifying rare causes like aneurysmal thrombosis. While thrombosed abdominal aortic aneurysms can cause mesenteric ischemia, their link to ischemic and ulcerative colitis is unique, emphasizing the importance of accurate risk assessment in treatment planning. FAU - Barbu, Laurentiu Augustus AU - Barbu LA AUID- ORCID: 0009-0008-5822-8805 AD - Department of Surgery, Railway Clinical Hospital Craiova, University of Medicine and Pharmacy of Craiova, 2 Petru Rares Street, 200349 Craiova, Romania. FAU - Margaritescu, Nicolae-Dragos AU - Margaritescu ND AD - Department of Surgery, Emergency County Hospital, University of Medicine and Pharmacy of Craiova, 2 Petru Rares Street, 200349 Craiova, Romania. FAU - Cercelaru, Liliana AU - Cercelaru L AUID- ORCID: 0000-0002-8232-3457 AD - Department of Pathology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania. FAU - Caragea, Daniel-Cosmin AU - Caragea DC AD - Departament of Internal Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania. FAU - Vilcea, Ionica-Daniel AU - Vilcea ID AD - Department of Surgery, Emergency County Hospital, University of Medicine and Pharmacy of Craiova, 2 Petru Rares Street, 200349 Craiova, Romania. FAU - Surlin, Valeriu AU - Surlin V AUID- ORCID: 0000-0003-2648-5408 AD - Department of Surgery, Emergency County Hospital, University of Medicine and Pharmacy of Craiova, 2 Petru Rares Street, 200349 Craiova, Romania. FAU - Mogoanta, Stelian-Stefanita AU - Mogoanta SS AD - Department of Surgery, Emergency County Hospital, University of Medicine and Pharmacy of Craiova, 2 Petru Rares Street, 200349 Craiova, Romania. FAU - Mogos, Gabriel Florin Razvan AU - Mogos GFR AD - Department of Surgery, Railway Clinical Hospital Craiova, University of Medicine and Pharmacy of Craiova, 2 Petru Rares Street, 200349 Craiova, Romania. FAU - Vasile, Liviu AU - Vasile L AUID- ORCID: 0000-0002-7018-5675 AD - Department of Surgery, Emergency County Hospital, University of Medicine and Pharmacy of Craiova, 2 Petru Rares Street, 200349 Craiova, Romania. FAU - Tenea Cojan, Tiberiu Stefanita AU - Tenea Cojan TS AD - Department of Surgery, Railway Clinical Hospital Craiova, University of Medicine and Pharmacy of Craiova, 2 Petru Rares Street, 200349 Craiova, Romania. LA - eng PT - Journal Article PT - Review DEP - 20250429 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC12072285 OTO - NOTNLM OT - abdominal aortic aneurysms OT - inferior mesenteric artery thrombosis OT - ischemic colitis COIS- The authors declare that there are no conflicts of interest. EDAT- 2025/05/14 11:41 MHDA- 2025/05/14 11:42 PMCR- 2025/04/29 CRDT- 2025/05/14 01:21 PHST- 2025/03/21 00:00 [received] PHST- 2025/04/27 00:00 [revised] PHST- 2025/04/28 00:00 [accepted] PHST- 2025/05/14 11:42 [medline] PHST- 2025/05/14 11:41 [pubmed] PHST- 2025/05/14 01:21 [entrez] PHST- 2025/04/29 00:00 [pmc-release] AID - jcm14093092 [pii] AID - jcm-14-03092 [pii] AID - 10.3390/jcm14093092 [doi] PST - epublish SO - J Clin Med. 2025 Apr 29;14(9):3092. doi: 10.3390/jcm14093092. PMID- 40362262 OWN - NLM STAT- MEDLINE DCOM- 20250514 LR - 20250516 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 26 IP - 9 DP - 2025 Apr 24 TI - Morphometric and Molecular Interplay in Hypertension-Induced Cardiac Remodeling with an Emphasis on the Potential Therapeutic Implications. LID - 10.3390/ijms26094022 [doi] LID - 4022 AB - Hypertension-induced cardiac remodeling is a complex process driven by interconnected molecular and cellular mechanisms that culminate in hypertensive myocardium, characterized by ventricular hypertrophy, fibrosis, impaired angiogenesis, and myocardial dysfunction. This review discusses the histomorphometric changes in capillary density, fibrosis, and mast cells in the hypertensive myocardium and delves into the roles of key regulatory systems, including the apelinergic system, vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR) pathways, and nitric oxide (NO)/nitric oxide synthase (NOS) signaling in the pathogenesis of hypertensive heart disease (HHD). Capillary rarefaction, a hallmark of HHD, contributes to myocardial ischemia and fibrosis, underscoring the importance of maintaining vascular integrity. Targeting capillary density (CD) through antihypertensive therapy or angiogenic interventions could significantly improve cardiac outcomes. Myocardial fibrosis, mediated by excessive collagen deposition and influenced by fibroblast growth factor-2 (FGF-2) and transforming growth factor-beta (TGF-beta), plays a pivotal role in the structural remodeling of hypertensive myocardium. While renin-angiotensin-aldosterone system (RAAS) inhibitors show anti-fibrotic effects, more targeted therapies are needed to address fibrosis directly. Mast cells, though less studied in humans, emerge as critical regulators of cardiac remodeling through their release of pro-fibrotic mediators such as histamine, tryptase, and FGF-2. The apelinergic system emerges as a promising therapeutic target due to its vasodilatory, anti-fibrotic, and cardioprotective properties. The system counteracts the deleterious effects of the RAAS and has demonstrated efficacy in preclinical models of hypertension-induced cardiac damage. Despite its potential, human studies on apelin analogs remain limited, warranting further exploration to evaluate their clinical utility. VEGF signaling plays a dual role, facilitating angiogenesis and compensatory remodeling during the early stages of arterial hypertension (AH) but contributing to maladaptive changes when dysregulated. Modulating VEGF signaling through exercise or pharmacological interventions has shown promise in improving CD and mitigating hypertensive cardiac damage. However, VEGF inhibitors, commonly used in oncology, can exacerbate AH and endothelial dysfunction, highlighting the need for therapeutic caution. The NO/NOS pathway is essential for vascular homeostasis and the prevention of oxidative stress. Dysregulation of this pathway, particularly endothelial NOS (eNOS) uncoupling and inducible NOS (iNOS) overexpression, leads to endothelial dysfunction and nitrosative stress in hypertensive myocardium. Strategies to restore NO bioavailability, such as tetrahydrobiopterin (BH(4)) supplementation and antioxidants, hold potential for therapeutic application but require further validation. Future studies should adopt a multidisciplinary approach to integrate molecular insights with clinical applications, paving the way for more personalized and effective treatments for HHD. Addressing these challenges will not only enhance the understanding of hypertensive myocardium but also improve patient outcomes and quality of life. FAU - Gaydarski, Lyubomir AU - Gaydarski L AUID- ORCID: 0000-0003-4774-6507 AD - Department of Anatomy, Histology and Embryology, Medical University of Sofia, 1431 Sofia, Bulgaria. FAU - Petrova, Kristina AU - Petrova K AUID- ORCID: 0009-0008-4093-7945 AD - Department of Anatomy, Histology and Embryology, Medical University of Sofia, 1431 Sofia, Bulgaria. FAU - Stanchev, Stancho AU - Stanchev S AD - Department of Anatomy, Histology and Embryology, Medical University of Sofia, 1431 Sofia, Bulgaria. FAU - Pelinkov, Dimitar AU - Pelinkov D AD - Department of Anatomy, Histology and Embryology, Medical University of Sofia, 1431 Sofia, Bulgaria. FAU - Iliev, Alexandar AU - Iliev A AUID- ORCID: 0000-0001-6971-8086 AD - Department of Anatomy, Histology and Embryology, Medical University of Sofia, 1431 Sofia, Bulgaria. FAU - Dimitrova, Iva N AU - Dimitrova IN AD - Department of Cardiology, University Hospital "St. Ekaterina", Medical University of Sofia, 1431 Sofia, Bulgaria. FAU - Kirkov, Vidin AU - Kirkov V AD - Department of Health Policy and Management, Faculty of Public Health 'Prof. Dr. Tzekomir Vodenicharov', Medical University of Sofia, 1527 Sofia, Bulgaria. FAU - Landzhov, Boycho AU - Landzhov B AD - Department of Anatomy, Histology and Embryology, Medical University of Sofia, 1431 Sofia, Bulgaria. FAU - Stamenov, Nikola AU - Stamenov N AD - Department of Anatomy, Histology and Embryology, Medical University of Sofia, 1431 Sofia, Bulgaria. LA - eng PT - Journal Article PT - Review DEP - 20250424 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 SB - IM MH - Humans MH - *Ventricular Remodeling MH - *Hypertension/metabolism/complications/pathology/physiopathology MH - Animals MH - Fibrosis MH - Myocardium/pathology/metabolism MH - Signal Transduction MH - Mast Cells/metabolism/pathology PMC - PMC12071960 OTO - NOTNLM OT - apelin OT - apelin receptor OT - capillary density OT - fibrosis OT - hypertensive myocardium OT - mast cells OT - nitric oxide synthase OT - therapeutic implications OT - vascular endothelial growth factor COIS- The authors declare no conflicts of interest. EDAT- 2025/05/14 11:42 MHDA- 2025/05/14 12:41 PMCR- 2025/04/24 CRDT- 2025/05/14 01:09 PHST- 2025/01/30 00:00 [received] PHST- 2025/04/16 00:00 [revised] PHST- 2025/04/19 00:00 [accepted] PHST- 2025/05/14 12:41 [medline] PHST- 2025/05/14 11:42 [pubmed] PHST- 2025/05/14 01:09 [entrez] PHST- 2025/04/24 00:00 [pmc-release] AID - ijms26094022 [pii] AID - ijms-26-04022 [pii] AID - 10.3390/ijms26094022 [doi] PST - epublish SO - Int J Mol Sci. 2025 Apr 24;26(9):4022. doi: 10.3390/ijms26094022. PMID- 40361980 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260924 IS - 2075-4418 (Print) IS - 2075-4418 (Electronic) IS - 2075-4418 (Linking) VI - 15 IP - 9 DP - 2025 May 2 TI - Development of a Pulmonary Nodule Service and Clinical Pathway: A Pragmatic Approach Addressing an Unmet Need. LID - 10.3390/diagnostics15091162 [doi] LID - 1162 AB - Background/Objectives: The surveillance of patients with incidental pulmonary nodules overloads existing respiratory and lung cancer clinics, as well as multidisciplinary team meetings. In our clinical setting, until 2018, we had numerous patients with incidental pulmonary nodules inundating our outpatient clinics; therefore, the need to develop a novel service and dedicated clinical pathway arose. The aims of this study are to 1. provide (a) a model of setting up a novel pulmonary nodule service, and (b) a pragmatic clinical pathway to address the increasing need for surveillance of patients with incidental pulmonary nodules. 2. share real-world data from a dedicated pulmonary nodule service running in a tertiary setting with existing resources. Methods: A retrospective review of established processes and referral mechanisms to our tertiary pulmonary nodule service was conducted. We have also performed a retrospective collection and review of data for patients reviewed and discussed in our tertiary pulmonary nodule service between April 2018 and April 2024. Results: Our tertiary pulmonary nodule service (PNS) comprises a dedicated pulmonary nodule clinic, a nodule multidisciplinary team (MDT) meeting and a dedicated proforma referral system. Due to the current national health system legislation and relevant processes, patients are required to physically attend clinic appointments. There are various sources of referral, including other departments within the hospital, other hospitals, various specialties in primary care and self-referrals. Between 15 April 2018 and 15 April 2024, 2203 patients were reviewed in the pulmonary nodule clinic (903 females, 1300 males, mean age 64 +/- 19 years). Of those patients, 65% (1432/2203) were current smokers. A total of 1365 new patients and 838 follow-up patients were reviewed in total. Emphysema was radiologically present in 72% of patients, and 75% of those (1189/1586) already had a confirmed diagnosis of chronic obstructive pulmonary disease (COPD). Coronary calcification was identified in 32% (705/2203), and 78% of those (550/705) were already known to cardiology services. Interestingly, 27% (368/1365) of the new patients were discharged following their first MDT meeting discussion, and 67% of these were discharged as the reason for their referral was an intrapulmonary lymph node which did not warrant any further action. Among all patients, 11% (246/2203) were referred to the multidisciplinary thoracic oncology service (MTOS) due to suspicious appearances/changes in their nodules that warranted further investigation, and from those, 37% were discharged (92/246) from the MTOS. The lung cancer diagnosis rate was 7% (154/2203). Conclusions: The applied pathway offers a pragmatic approach in setting up a service that addresses an increasing patient need. Its application is feasible in a tertiary care setting, and admin support is of vital importance to ensure patients are appropriately tracked and not lost to follow-up. Real-world data from pulmonary nodules services provide a clear overview and contribute to understanding patients' characteristics and improving service provision. FAU - Hardavella, Georgia AU - Hardavella G AD - 6th Department of Respiratory Medicine, "Sotiria" Athens' Chest Diseases Hospital, 11527 Athens, Greece. FAU - Karampinis, Ioannis AU - Karampinis I AD - Department of Thoracic Surgery, "Sotiria" Athens' Chest Diseases Hospital, 11527 Athens, Greece. FAU - Anastasiou, Nikolaos AU - Anastasiou N AD - Department of Thoracic Surgery, General Oncology Hospital, "Agioi Anargyroi", 14564 Kifisia, Greece. FAU - Stefanidis, Konstantinos AU - Stefanidis K AD - Department of Radiology, "Metaxa" Cancer Hospital, 18537 Piraeus, Greece. AD - Department of Nuclear Medicine, "Metaxa" Cancer Hospital, 18537 Piraeus, Greece. FAU - Tavernaraki, Kyriaki AU - Tavernaraki K AD - Imaging and Interventional Radiology Department, "Sotiria" Athens' Chest Diseases Hospital, 11527 Athens, Greece. FAU - Arapostathi, Styliani AU - Arapostathi S AD - Imaging and Interventional Radiology Department, "Sotiria" Athens' Chest Diseases Hospital, 11527 Athens, Greece. FAU - Sidiropoulou, Nektaria AU - Sidiropoulou N AD - Imaging and Interventional Radiology Department, "Sotiria" Athens' Chest Diseases Hospital, 11527 Athens, Greece. FAU - Filippousis, Petros AU - Filippousis P AD - Imaging and Interventional Radiology Department, "Sotiria" Athens' Chest Diseases Hospital, 11527 Athens, Greece. FAU - Patirelis, Alexandro AU - Patirelis A AUID- ORCID: 0009-0009-7409-8470 AD - Department of Thoracic Surgery, Tor Vergata University Hospital, 00133 Rome, Italy. FAU - Pompeo, Eugenio AU - Pompeo E AUID- ORCID: 0000-0002-5958-1423 AD - Department of Thoracic Surgery, Tor Vergata University Hospital, 00133 Rome, Italy. FAU - Demertzis, Panagiotis AU - Demertzis P AD - 9th Department of Respiratory Medicine, "Sotiria" Athens' Chest Diseases Hospital, 11527 Athens, Greece. FAU - Elia, Stefano AU - Elia S AUID- ORCID: 0000-0001-8914-8711 AD - Department of Thoracic Surgery, Tor Vergata University Hospital, 00133 Rome, Italy. AD - Department of Medicine and Health Sciences "V.Tiberio", University of Molise, 86100 Campobasso, Italy. LA - eng PT - Journal Article DEP - 20250502 PL - Switzerland TA - Diagnostics (Basel) JT - Diagnostics (Basel, Switzerland) JID - 101658402 PMC - PMC12071812 OTO - NOTNLM OT - clinical pathway OT - lung nodules OT - pulmonary nodule service OT - pulmonary nodules COIS- The authors declare no conflicts of interest. EDAT- 2025/05/14 11:41 MHDA- 2025/05/14 11:42 PMCR- 2025/05/02 CRDT- 2025/05/14 01:07 PHST- 2025/03/17 00:00 [received] PHST- 2025/04/25 00:00 [revised] PHST- 2025/04/28 00:00 [accepted] PHST- 2025/05/14 11:42 [medline] PHST- 2025/05/14 11:41 [pubmed] PHST- 2025/05/14 01:07 [entrez] PHST- 2025/05/02 00:00 [pmc-release] AID - diagnostics15091162 [pii] AID - diagnostics-15-01162 [pii] AID - 10.3390/diagnostics15091162 [doi] PST - epublish SO - Diagnostics (Basel). 2025 May 2;15(9):1162. doi: 10.3390/diagnostics15091162. PMID- 40361837 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250517 IS - 2227-9032 (Print) IS - 2227-9032 (Electronic) IS - 2227-9032 (Linking) VI - 13 IP - 9 DP - 2025 May 4 TI - Perception of Social Support and Disease Acceptance Among Patients Undergoing Cardiac Rehabilitation-Cross-Sectional Study. LID - 10.3390/healthcare13091059 [doi] LID - 1059 AB - BACKGROUND: Cardiovascular diseases (CVD), the leading cause of mortality worldwide, require a multidisciplinary approach, with cardiac rehabilitation being a recommended component. The rehabilitation process may be directly influenced by social support, which enhances motivation to cope with the disease and fosters its acceptance. AIMS: This study aims to assess the level of social support among patients undergoing cardiac rehabilitation and its impact on disease acceptance. METHODS: The study included a sample of 150 patients currently participating in cardiac rehabilitation. Data were collected through direct contact using the validated, anonymous Acceptance of Illness Scale questionnaire, supplemented with a demographic section addressing social support. RESULTS: The majority of respondents reported receiving strong family support (51.3%) and good institutional support (47.3%) during treatment. The mean score for illness acceptance was 29.6 +/- 6.9, indicating a high acceptance level observed in most patients (57.3%). The p-values for the association between illness acceptance and support from family and institutions were p = 0.43 and p = 0.82, respectively, suggesting no statistically significant relationship. CONCLUSIONS: Patients undergoing cardiac rehabilitation generally experience strong family support, good institutional support, and a high level of disease acceptance. No statistically significant relationship was observed between family or institutional support and the level of disease acceptance. FAU - Szlacheta, Patryk AU - Szlacheta P AD - Department of Basic Medical Sciences, Faculty of Public Health in Bytom, Medical University of Silesia in Katowice, 41902 Bytom, Poland. FAU - Wlazlo, Marika AU - Wlazlo M AD - Department of Cardiovascular Disease Prevention, Faculty of Public Health in Bytom, Medical University of Silesia in Katowice, 41902 Bytom, Poland. FAU - Grajek, Mateusz AU - Grajek M AUID- ORCID: 0000-0001-6588-8598 AD - Department of Public Health, Faculty of Public Health in Bytom, Medical University of Silesia in Katowice, 41902 Bytom, Poland. FAU - Kloda-Suchon, Magdalena AU - Kloda-Suchon M AD - Silesian Center for Rehabilitation and Prevention, 43450 Ustron, Poland. FAU - Choromanska-Matera, Beata AU - Choromanska-Matera B AD - Silesian Center for Rehabilitation and Prevention, 43450 Ustron, Poland. FAU - Yanakieva, Antoniya AU - Yanakieva A AUID- ORCID: 0000-0001-6418-2788 AD - Department of Health Technology Assessment, Faculty of Public Health, Medical University of Sofia, 1000 Sofia, Bulgaria. FAU - Korzonek-Szlacheta, Ilona AU - Korzonek-Szlacheta I AD - Department of Cardiovascular Disease Prevention, Faculty of Public Health in Bytom, Medical University of Silesia in Katowice, 41902 Bytom, Poland. LA - eng PT - Journal Article DEP - 20250504 PL - Switzerland TA - Healthcare (Basel) JT - Healthcare (Basel, Switzerland) JID - 101666525 PMC - PMC12071769 OTO - NOTNLM OT - cardiac rehabilitation OT - cardiovascular diseases OT - disease acceptance OT - social support COIS- The authors declare no conflicts of interest. EDAT- 2025/05/14 11:41 MHDA- 2025/05/14 11:42 PMCR- 2025/05/04 CRDT- 2025/05/14 01:07 PHST- 2025/04/10 00:00 [received] PHST- 2025/04/30 00:00 [revised] PHST- 2025/05/03 00:00 [accepted] PHST- 2025/05/14 11:42 [medline] PHST- 2025/05/14 11:41 [pubmed] PHST- 2025/05/14 01:07 [entrez] PHST- 2025/05/04 00:00 [pmc-release] AID - healthcare13091059 [pii] AID - healthcare-13-01059 [pii] AID - 10.3390/healthcare13091059 [doi] PST - epublish SO - Healthcare (Basel). 2025 May 4;13(9):1059. doi: 10.3390/healthcare13091059. PMID- 40352700 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250513 IS - 2284-2594 (Electronic) IS - 2284-2594 (Linking) VI - 12 IP - 5 DP - 2025 TI - When Two Chambers Collide: A Rare Case of an Acquired Gerbode Defect in Infective Endocarditis. PG - 005357 LID - 10.12890/2025_005357 [doi] LID - 005357 AB - INTRODUCTION: The Gerbode defect is a rare cardiac anomaly characterised by abnormal communication between the left ventricle and right atrium. Although primarily congenital, it can also be acquired, typically as a complication of myocardial infarction or infective endocarditis. This report examines a unique case of multivalvular infective endocarditis caused by group B Streptococcal bacteraemia, which led to the development of an acquired Gerbode defect. CASE DESCRIPTION: A 64-year-old male patient presented with symptoms of fever and dyspnoea and was diagnosed with group B Streptococcal bacteraemia. Transoesophageal echocardiography (TOE) and cardiac magnetic resonance were used to assess the extent of valvular involvement and detect any underlying structural abnormalities. Comprehensive clinical, microbiological and imaging evaluations were performed to confirm the diagnosis. DISCUSSION: A transthoracic echocardiography revealed multivalvular vegetations and a newly detected left ventricle-to-right atrium shunt, consistent with a Gerbode defect. Cardiovascular magnetic resonance imaging confirmed the acquired defect. Surgery was considered but deemed too high a risk due to the likelihood of postoperative dialysis and a greater than 50% morality risk. After discussing these risks, the patient and family opted for conservative management, and palliative care was initiated. CONCLUSION: This case highlights the rare development of an acquired Gerbode defect in the context of multivalvular infective endocarditis due to group B Streptococcus. Early diagnosis using advanced imaging techniques is critical for proper management. Surgical intervention remains a key therapeutic option, and a multidisciplinary approach is essential for optimising patient outcomes in such complex cases. LEARNING POINTS: An acquired Gerbode defect (left ventricular to right atrial shunt) is a rare but critical complication of infective endocarditis.Infective endocarditis caused by group B Streptococcus in adults, though uncommon, carries a high risk of complications and mortality, especially in prosthetic valve patients.Early transoesophageal echocardiography is essential for identifying structural complications of infective endocarditis. CI - (c) EFIM 2025. FAU - Rimsky, Elizabeth R AU - Rimsky ER AD - Department of Medicine, Northwell at Staten Island University Hospital, Staten Island, USA. FAU - Sattarzadeh, Aysan AU - Sattarzadeh A AD - Department of Medicine, Northwell at Staten Island University Hospital, Staten Island, USA. FAU - Jia, Kaiyu AU - Jia K AD - Department of Medicine, Northwell at Staten Island University Hospital, Staten Island, USA. FAU - Khan, Shahkar AU - Khan S AD - Department of Cardiology, Northwell at Staten Island University Hospital, Staten Island, USA. FAU - Khan, Danyal AU - Khan D AD - Department of Cardiology, Northwell at Staten Island University Hospital, Staten Island, USA. FAU - Amor, Martin AU - Amor M AD - Department of Cardiology, Northwell at Staten Island University Hospital, Staten Island, USA. FAU - Spagnola, Jonathan AU - Spagnola J AD - Department of Cardiology, Northwell at Staten Island University Hospital, Staten Island, USA. LA - eng PT - Journal Article DEP - 20250423 PL - Italy TA - Eur J Case Rep Intern Med JT - European journal of case reports in internal medicine JID - 101648453 PMC - PMC12061214 OTO - NOTNLM OT - Gerbode defect OT - group B Streptococcus OT - infective endocarditis COIS- Conflicts of Interests: The Authors declare that there are no competing interests. EDAT- 2025/05/12 12:34 MHDA- 2025/05/12 12:35 PMCR- 2025/04/23 CRDT- 2025/05/12 06:10 PHST- 2025/03/18 00:00 [received] PHST- 2025/03/24 00:00 [accepted] PHST- 2025/05/12 12:35 [medline] PHST- 2025/05/12 12:34 [pubmed] PHST- 2025/05/12 06:10 [entrez] PHST- 2025/04/23 00:00 [pmc-release] AID - 5357 [pii] AID - 10.12890/2025_005357 [doi] PST - epublish SO - Eur J Case Rep Intern Med. 2025 Apr 23;12(5):005357. doi: 10.12890/2025_005357. eCollection 2025. PMID- 40351671 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250513 IS - 2153-8174 (Electronic) IS - 1530-6550 (Print) IS - 1530-6550 (Linking) VI - 26 IP - 4 DP - 2025 Apr TI - Mitral Transcatheter Edge-to-Edge Repair in Acute Ischemic Mitral Regurgitation: Current Evidence and Future Perspectives. PG - 33396 LID - 10.31083/RCM33396 [doi] LID - 33396 AB - Acute ischemic mitral regurgitation is a rare but potentially catastrophic complication following acute myocardial infarction (AMI), characterized by severe clinical presentation and high mortality. Meanwhile, advancements in primary percutaneous coronary intervention (PCI) have reduced the incidence of acute mitral regurgitation (AMR). The surgical approach remains the standard treatment but is associated with high rates of complications and in-hospital mortality, particularly in patients with cardiogenic shock or mechanical complications, such as papillary muscle rupture. Mitral transcatheter edge-to-edge repair (M-TEER) has emerged as a minimally invasive treatment. Current evidence demonstrates the feasibility and safety of M-TEER in reducing mitral regurgitation, stabilizing hemodynamics, and improving in-hospital and short-term survival. The procedural success rate is high, with notable symptoms and functional status improvements. Mortality rates remain significant, reflecting the severity of AMR, but are lower compared to medical management alone. Challenges remain regarding the optimal timing of M-TEER, long-term device durability, and patient selection criteria. Ongoing iterations in device technology and procedural techniques are expected to enhance outcomes. This review highlights the role of M-TEER in AMR management, emphasizing the need for multidisciplinary decision-making and further research to refine M-TEER application and improve outcomes in this high-risk AMR population. CI - Copyright: (c) 2025 The Author(s). Published by IMR Press. FAU - Frazzetto, Marco AU - Frazzetto M AUID- ORCID: 0000-0002-6543-7567 AD - Harrington Heart & Vascular Institute, University Hospitals, School of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA. FAU - Sanfilippo, Claudio AU - Sanfilippo C AUID- ORCID: 0000-0002-1508-4927 AD - De Gasperis Cardio Center, Interventional Cardiology Unit, Niguarda Hospital, 20162 Milan, Italy. AD - Division of Cardiology, A.O.U. Policlinico "G. Rodolico - San Marco", 95123 Catania, Italy. FAU - Briguglio, Francesco AU - Briguglio F AD - Division of Cardiology, A.O.U. Policlinico "G. Rodolico - San Marco", 95123 Catania, Italy. FAU - Giacalone, Chiara AU - Giacalone C AD - Division of Cardiology, A.O.U. Policlinico "G. Rodolico - San Marco", 95123 Catania, Italy. FAU - Contrafatto, Claudia AU - Contrafatto C AD - Division of Cardiology, A.O.U. Policlinico "G. Rodolico - San Marco", 95123 Catania, Italy. FAU - Munafo, Andrea AU - Munafo A AD - De Gasperis Cardio Center, Interventional Cardiology Unit, Niguarda Hospital, 20162 Milan, Italy. FAU - Bonanni, Michela AU - Bonanni M AD - Department of Cardiology, Policlinico Tor Vergata, University of Rome, 00133 Rome, Italy. FAU - Oreglia, Jacopo AU - Oreglia J AD - De Gasperis Cardio Center, Interventional Cardiology Unit, Niguarda Hospital, 20162 Milan, Italy. FAU - Costa, Giuliano AU - Costa G AD - Division of Cardiology, A.O.U. Policlinico "G. Rodolico - San Marco", 95123 Catania, Italy. FAU - Attizzani, Guilherme AU - Attizzani G AD - Harrington Heart & Vascular Institute, University Hospitals, School of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA. FAU - Capodanno, Davide AU - Capodanno D AUID- ORCID: 0000-0002-5156-7723 AD - Division of Cardiology, A.O.U. Policlinico "G. Rodolico - San Marco", 95123 Catania, Italy. FAU - Grasso, Carmelo AU - Grasso C AD - Division of Cardiology, A.O.U. Policlinico "G. Rodolico - San Marco", 95123 Catania, Italy. LA - eng PT - Journal Article PT - Review DEP - 20250421 PL - Singapore TA - Rev Cardiovasc Med JT - Reviews in cardiovascular medicine JID - 100960007 PMC - PMC12059755 OTO - NOTNLM OT - Mitraclip OT - acute mitral regurgitation OT - mitral transcatheter edge-to-edge repair COIS- The authors declare no conflict of interest. EDAT- 2025/05/12 06:33 MHDA- 2025/05/12 06:34 PMCR- 2025/04/21 CRDT- 2025/05/12 05:58 PHST- 2024/11/29 00:00 [received] PHST- 2025/02/15 00:00 [revised] PHST- 2025/03/07 00:00 [accepted] PHST- 2025/05/12 06:34 [medline] PHST- 2025/05/12 06:33 [pubmed] PHST- 2025/05/12 05:58 [entrez] PHST- 2025/04/21 00:00 [pmc-release] AID - S1530-6550(25)01805-8 [pii] AID - 10.31083/RCM33396 [doi] PST - epublish SO - Rev Cardiovasc Med. 2025 Apr 21;26(4):33396. doi: 10.31083/RCM33396. eCollection 2025 Apr. PMID- 40342976 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250511 IS - 2297-055X (Print) IS - 2297-055X (Electronic) IS - 2297-055X (Linking) VI - 12 DP - 2025 TI - Glucagon-like peptide-1 receptor agonists: a review from a cardiovascular perspective. PG - 1535134 LID - 10.3389/fcvm.2025.1535134 [doi] LID - 1535134 AB - INTRODUCTION: Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are novel agents with proven cardiovascular (CV) benefits. GLP-1 RAs have been used for diabetes and found to improve CV outcomes in diabetic and nondiabetic patients. They are authorized for treating obesity. Our narrative review discussed the CV benefits of GLP-1 RAs in terms of controlling CV risk factors and improving CV outcomes in diabetic and nondiabetic patients regardless of their CV history, and the CV perspectives related to their use in clinical practice. AREAS COVERED: Literature was searched with no limits on date or language, using various combinations of keywords. Data on the CV benefits of GLP-1 RAs and their use in clinical practice were summarized. RESULTS: Several studies have discussed the CV beneficial effects of GLP-1 RAs in terms of reducing blood pressure, lipid levels, body weight, risk for arrhythmias, reducing the risk of major adverse CV events, and hospital admission for heart failure. CONCLUSION: The cardioprotective effects and low risk of hypoglycemia of GLP-1 RAs make them preferred agents in any multidisciplinary approach aiming to reduce CV disease burden and improve prognosis. Cardiologists are encouraged to strongly consider the CV benefits of GLP-1 RAs in their risk-reduction strategies. CI - (c) 2025 Turkistani. FAU - Turkistani, Yosra AU - Turkistani Y AD - Department of Medicine, College of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia. LA - eng PT - Journal Article PT - Review DEP - 20250424 PL - Switzerland TA - Front Cardiovasc Med JT - Frontiers in cardiovascular medicine JID - 101653388 PMC - PMC12060260 OTO - NOTNLM OT - cardiovascular disease OT - cardiovascular outcome OT - glucagon-like peptide-1 receptor agonists OT - heart failure OT - obesity COIS- The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2025/05/09 18:32 MHDA- 2025/05/09 18:33 PMCR- 2025/01/01 CRDT- 2025/05/09 12:42 PHST- 2024/11/26 00:00 [received] PHST- 2025/03/28 00:00 [accepted] PHST- 2025/05/09 18:33 [medline] PHST- 2025/05/09 18:32 [pubmed] PHST- 2025/05/09 12:42 [entrez] PHST- 2025/01/01 00:00 [pmc-release] AID - 10.3389/fcvm.2025.1535134 [doi] PST - epublish SO - Front Cardiovasc Med. 2025 Apr 24;12:1535134. doi: 10.3389/fcvm.2025.1535134. eCollection 2025. PMID- 40336691 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250509 IS - 2474-1949 (Electronic) IS - 2474-1949 (Linking) VI - 10 IP - 2 DP - 2025 Apr TI - Stabilization of Cardiogenic Shock for Critical Care Transport, a Simulation. PG - S31-S57 LID - 10.21980/J82354 [doi] AB - AUDIENCE: This simulation is designed for critical care transport providers but can be easily adapted for the inpatient setting. It is applicable to an interdisciplinary team including nurses, respiratory therapists, medical students, emergency medicine residents, and emergency medicine attendings. INTRODUCTION: Cardiogenic shock carries an incredibly high burden of morbidity and mortality. Acute myocardial infarction accounts for 81% of cardiogenic shock patients and is a common indication for transfer to a tertiary care facility.1 Hypotension due to cardiogenic shock is often refractory to volume resuscitation and often requires pharmacologic intervention. Additionally, the resultant end organ dysfunction frequently requires advanced ventilatory support.1-6 This simulation aims to educate critical care transport providers on the best practices for management of the cardiogenic shock patients requiring resuscitation and intubation prior to transport. EDUCATIONAL OBJECTIVES: By the end of this simulation session, learners will be able to: 1) recognize the need for intubation in an unstable patient in cardiogenic shock who requires transport, 2) appropriately titrate bi-Level non-invasive ventilatory support (BiPAP) to optimize oxygenation and ventilation in preparation for intubation, 3) choose appropriate vasoactive medications to support the hemodynamics of a patient in cardiogenic shock, 4) perform rapid sequence intubation using appropriate induction and paralytic agents and dosing for a patient in cardiogenic shock, 5) choose appropriate initial lung-protective ventilator settings, and 6) implement an adequate analgesia and sedation plan for transport of an intubated patient in cardiogenic shock. EDUCATIONAL METHODS: This session was conducted using high-fidelity simulation, allowing learners to manage a patient in cardiogenic shock and respiratory distress requiring intubation. Each session was followed by a debriefing and discussion. RESEARCH METHODS: Qualitative feedback provided by participants during the discussion session was utilized to adjust the simulation between each session. In addition, participants were surveyed using a five-point Likert scale (strongly disagree to strongly agree) on if the simulation met their professional and educational needs, its efficacy and appropriateness for Level, and whether it would change future practice. RESULTS: A total of 36 learners, including 20 physicians and 16 nurses, participated in the simulation over a total of nine sessions. Twenty out of the thirty-six participants completed the survey (both RNs and MDs) and 100% responded "strongly agree" to all four prompts (top response out of a five Likert scale). Feedback provided by participants was used after each session to adjust the simulation. Changes implemented included the addition of a nurse confederate, greater emphasis on management and titration of non-invasive ventilation for optimal preoxygenation, and initiation of post intubation sedation and analgesia. DISCUSSION: Cardiogenic shock is a common cause of mortality, often requires transport, and is particularly challenging to manage. This simulation was overall effective at educating learners on the resuscitation of cardiogenic shock, including appropriate use of vasopressors and ventilatory support. TOPICS: Cardiogenic shock, hypoxic respiratory failure, vasopressor management, airway management, intubation, non-invasive positive pressure ventilation management, ventilatory management, emergency medicine, critical care transport medicine. CI - (c) 2025 Heffernan, et al. FAU - Heffernan, Matthew AU - Heffernan M AD - University of Wisconsin-Madison School of Medicine and Public Health, Department of Emergency Medicine, Madison, WI. AD - UW Med Flight, Madison, WI. FAU - Quinn, Jennifer AU - Quinn J AD - University of Wisconsin-Madison School of Medicine and Public Health, Department of Emergency Medicine, Madison, WI. AD - UW Med Flight, Madison, WI. FAU - Tschautscher, Craig AU - Tschautscher C AD - University of Wisconsin-Madison School of Medicine and Public Health, Department of Emergency Medicine, Madison, WI. AD - UW Med Flight, Madison, WI. FAU - Newberry, Ryan AU - Newberry R AD - University of Wisconsin-Madison School of Medicine and Public Health, Department of Emergency Medicine, Madison, WI. AD - UW Med Flight, Madison, WI. FAU - Cathers, Andrew AU - Cathers A AD - University of Wisconsin-Madison School of Medicine and Public Health, Department of Emergency Medicine, Madison, WI. AD - UW Med Flight, Madison, WI. FAU - Bernardoni, Brittney AU - Bernardoni B AD - University of Wisconsin-Madison School of Medicine and Public Health, Department of Emergency Medicine, Madison, WI. AD - UW Med Flight, Madison, WI. LA - eng PT - Journal Article DEP - 20250430 PL - United States TA - J Educ Teach Emerg Med JT - Journal of education & teaching in emergency medicine JID - 101741448 PMC - PMC12054092 EDAT- 2025/05/08 11:13 MHDA- 2025/05/08 11:14 PMCR- 2025/04/30 CRDT- 2025/05/08 05:06 PHST- 2024/04/22 00:00 [received] PHST- 2025/02/26 00:00 [accepted] PHST- 2025/05/08 11:14 [medline] PHST- 2025/05/08 11:13 [pubmed] PHST- 2025/05/08 05:06 [entrez] PHST- 2025/04/30 00:00 [pmc-release] AID - jetem-10-2-s31 [pii] AID - 10.21980/J82354 [doi] PST - epublish SO - J Educ Teach Emerg Med. 2025 Apr 30;10(2):S31-S57. doi: 10.21980/J82354. eCollection 2025 Apr. PMID- 40334977 OWN - NLM STAT- MEDLINE DCOM- 20250808 LR - 20260120 IS - 1615-5947 (Electronic) IS - 0890-5096 (Linking) VI - 119 DP - 2025 Oct TI - PRE-oPerative Assessment for Patients with Chronic Limb ThReatening IschEmia (PREPARE): A Multinational Delphi Consensus. PG - 79-90 LID - S0890-5096(25)00316-4 [pii] LID - 10.1016/j.avsg.2025.04.122 [doi] AB - BACKGROUND: Chronic limb-threatening ischemia (CLTI) presents significant challenges in both diagnosis and management, with a lack of standardized preoperative assessment and optimization frameworks. This study aimed to establish a contemporary consensus among vascular specialists on the perioperative care of CLTI patients across diverse health-care systems. METHODS: A modified Delphi methodology was used, involving iterative rounds of consultation with 42 expert vascular surgeons from the United Kingdom, Ireland, Australia, and New Zealand. Four broad domains were explored: availability of services, preoperative assessment, perioperative optimization, and the role of multidisciplinary teams (MDTs). Consensus was defined as >/=70% agreement RESULTS: A total of 59 consensus statements were established, covering key areas such as rapid access clinics, the value of preoperative investigations and anemia. Unanimous agreement was reached regarding the necessity of clear referral pathways, and a strong majority supported the importance of MDTs in complex cases. However, significant uncertainty remained about the utility of existing risk prediction models, with only 53% endorsing tools like the American College of Surgeons Risk Calculator. Notably, 81% agreed that if preoperative investigations could change the type of intervention a patient received, this investigation should be performed prior to surgery even at the expense of delayed intervention. CONCLUSION: This Delphi consensus study highlights the complexity in managing patients with CLTI and the necessity of a multifaceted, interdisciplinary approach to preoperative care. The findings advocate for improved primary care management, selective use of preoperative investigations and emphasizes the importance of interdisciplinary care. While consensus was reached on several key aspects of care, the study highlights ongoing uncertainties around risk prediction and cardiac stress testing therefore highlighting the need for further research to validate current tools and practices. These results lay the groundwork for future clinical guidelines aimed at reducing practice variability and improving patient outcomes. CI - Copyright (c) 2025 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Hodge, Stacie AU - Hodge S AD - Division of Cardiovascular Sciences, School of Medical Sciences, University of Manchester, Manchester, UK; Manchester Academic Vascular Research and Innovation Centre (MAVRIC), Manchester University NHS Foundation Trust, Manchester, UK. Electronic address: stacie.hodge@postgrad.manchester.ac.uk. FAU - Lowery, Jane AU - Lowery J AD - Manchester University NHS Foundation Trust, Department of Anaesthesia, Manchester, UK. FAU - Bowling, Frank AU - Bowling F AD - Manchester Academic Vascular Research and Innovation Centre (MAVRIC), Manchester University NHS Foundation Trust, Manchester, UK; Faculty of Biology, Medicine and Health, School of Medical Sciences, University of Manchester, Manchester, UK. FAU - Haque, Adam AU - Haque A AD - Division of Cardiovascular Sciences, School of Medical Sciences, University of Manchester, Manchester, UK; Manchester Academic Vascular Research and Innovation Centre (MAVRIC), Manchester University NHS Foundation Trust, Manchester, UK. FAU - Riding, David AU - Riding D AD - Manchester Academic Vascular Research and Innovation Centre (MAVRIC), Manchester University NHS Foundation Trust, Manchester, UK. FAU - Ghosh, Jonathan AU - Ghosh J AD - Division of Cardiovascular Sciences, School of Medical Sciences, University of Manchester, Manchester, UK; Manchester Academic Vascular Research and Innovation Centre (MAVRIC), Manchester University NHS Foundation Trust, Manchester, UK. CN - PREPARE Collaborative LA - eng PT - Consensus Statement PT - Journal Article PT - Multicenter Study DEP - 20250505 PL - Netherlands TA - Ann Vasc Surg JT - Annals of vascular surgery JID - 8703941 SB - IM MH - Humans MH - Delphi Technique MH - *Ischemia/diagnosis/surgery/physiopathology/therapy MH - Predictive Value of Tests MH - Risk Factors MH - Chronic Disease MH - *Peripheral Arterial Disease/diagnosis/surgery/physiopathology/therapy MH - Risk Assessment MH - *Preoperative Care/standards MH - Patient Care Team MH - *Vascular Surgical Procedures/adverse effects/standards MH - Treatment Outcome MH - *Chronic Limb-Threatening Ischemia/diagnosis/surgery MH - Clinical Decision-Making EDAT- 2025/05/08 00:25 MHDA- 2025/08/09 13:46 CRDT- 2025/05/07 19:37 PHST- 2025/03/03 00:00 [received] PHST- 2025/04/09 00:00 [revised] PHST- 2025/04/09 00:00 [accepted] PHST- 2025/08/09 13:46 [medline] PHST- 2025/05/08 00:25 [pubmed] PHST- 2025/05/07 19:37 [entrez] AID - S0890-5096(25)00316-4 [pii] AID - 10.1016/j.avsg.2025.04.122 [doi] PST - ppublish SO - Ann Vasc Surg. 2025 Oct;119:79-90. doi: 10.1016/j.avsg.2025.04.122. Epub 2025 May 5. PMID- 40334731 OWN - NLM STAT- MEDLINE DCOM- 20250729 LR - 20250729 IS - 1556-5653 (Electronic) IS - 0015-0282 (Linking) VI - 124 IP - 2 DP - 2025 Aug TI - Special considerations in assisted reproductive technology for patients with medically complex disease. PG - 186-187 LID - S0015-0282(25)00252-3 [pii] LID - 10.1016/j.fertnstert.2025.04.038 [doi] AB - This Views and Reviews is a series of articles on special considerations for assisted reproductive technology in patients with medically complex disease. Each piece combines a review of the literature with expert opinion on the provision of safe fertility care in the settings of cardiac disease, pulmonary disease, obesity, and hematologic disease. These articles highlight the importance of a multidisciplinary approach in caring for medically complex patients. CI - Copyright (c) 2025 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved. FAU - Boots, Christina E AU - Boots CE AD - Division of Reproductive Endocrinology, Department of Obstetrics and Gynecology, Northwestern University Feinberg School of Medicine, Chicago, Illinois. FAU - Feinberg, Eve C AU - Feinberg EC AD - Division of Reproductive Endocrinology, Department of Obstetrics and Gynecology, Northwestern University Feinberg School of Medicine, Chicago, Illinois. Electronic address: eve.feinberg@nm.org. LA - eng PT - Journal Article PT - Review DEP - 20250505 PL - United States TA - Fertil Steril JT - Fertility and sterility JID - 0372772 SB - IM MH - Humans MH - *Reproductive Techniques, Assisted/trends/adverse effects MH - Female MH - Pregnancy MH - *Infertility/therapy/physiopathology/diagnosis/epidemiology MH - Fertility MH - Comorbidity MH - Obesity/therapy/epidemiology MH - Chronic Disease/therapy OTO - NOTNLM OT - Pulmonary disease OT - cardiac disease OT - hematologic disease OT - obesity COIS- Declaration of Interests C.E.B. has nothing to disclose. E.C.F. has nothing to disclose. EDAT- 2025/05/08 00:24 MHDA- 2025/07/29 18:32 CRDT- 2025/05/07 19:33 PHST- 2025/04/23 00:00 [received] PHST- 2025/04/24 00:00 [accepted] PHST- 2025/07/29 18:32 [medline] PHST- 2025/05/08 00:24 [pubmed] PHST- 2025/05/07 19:33 [entrez] AID - S0015-0282(25)00252-3 [pii] AID - 10.1016/j.fertnstert.2025.04.038 [doi] PST - ppublish SO - Fertil Steril. 2025 Aug;124(2):186-187. doi: 10.1016/j.fertnstert.2025.04.038. Epub 2025 May 5. PMID- 40332986 OWN - NLM STAT- MEDLINE DCOM- 20250613 LR - 20250613 IS - 1941-9260 (Electronic) IS - 0032-5481 (Linking) VI - 137 IP - 5 DP - 2025 Jun TI - A comprehensive review of inpatient heart failure management for the hospitalist. PG - 327-337 LID - 10.1080/00325481.2025.2503696 [doi] AB - Acute decompensated heart failure (ADHF) is a leading cause of hospital admissions and is associated with significant increases in morbidity and mortality, as well as marked impacts on quality of life. This review aims to guide hospital medicine providers in the management of ADHF from hospital admission to safe discharge. Hospitalists commonly care for HF patients in the acute phase, and a clear understanding of HF classification and etiologies is vital for guiding the evaluation and treatment of HF decompensation. Medical management of HF is centered around guideline-directed medical therapy (GDMT), agents which have been shown in large-scale studies to improve morbidity and mortality, while diuretics are used in adjunct to alleviate symptoms and improve volume status. As patients approach discharge, a multidisciplinary approach centering on patient education, counseling, and coordination of transitional care services can help to improve outcomes and reduce readmission risk. FAU - Rajesh, Athul AU - Rajesh A AUID- ORCID: 0009-0001-8562-882X AD - Department of Internal Medicine, Lankenau Medical Center, Wynnewood, PA, USA. FAU - Kovacik, Ryan AU - Kovacik R AUID- ORCID: 0000-0002-7134-5933 AD - Department of Internal Medicine, Lankenau Medical Center, Wynnewood, PA, USA. FAU - Wasef, Beman AU - Wasef B AUID- ORCID: 0009-0002-2969-4432 AD - Department of Internal Medicine, Lankenau Medical Center, Wynnewood, PA, USA. FAU - Lohr, Kristin AU - Lohr K AUID- ORCID: 0009-0000-0580-8496 AD - Department of Hospital Medicine, Lankenau Medical Center, Wynnewood, PA, USA. FAU - Kasprowicz, Eric AU - Kasprowicz E AUID- ORCID: 0009-0005-2084-1004 AD - Department of Hospital Medicine, Lankenau Medical Center, Wynnewood, PA, USA. LA - eng PT - Journal Article PT - Review DEP - 20250514 PL - England TA - Postgrad Med JT - Postgraduate medicine JID - 0401147 RN - 0 (Diuretics) SB - IM MH - Humans MH - *Heart Failure/therapy/diagnosis/drug therapy MH - *Hospitalists MH - Diuretics/therapeutic use MH - Hospitalization MH - Inpatients MH - Patient Discharge MH - Practice Guidelines as Topic OTO - NOTNLM OT - CHF OT - Congestive heart failure OT - GDMT OT - HFmrEF OT - HFpEF OT - HFrEF OT - discharge planning OT - hospital medicine OT - hospitalist OT - transitions of care EDAT- 2025/05/07 12:31 MHDA- 2025/06/13 12:30 CRDT- 2025/05/07 11:44 PHST- 2025/06/13 12:30 [medline] PHST- 2025/05/07 12:31 [pubmed] PHST- 2025/05/07 11:44 [entrez] AID - 10.1080/00325481.2025.2503696 [doi] PST - ppublish SO - Postgrad Med. 2025 Jun;137(5):327-337. doi: 10.1080/00325481.2025.2503696. Epub 2025 May 14. PMID- 40329251 OWN - NLM STAT- MEDLINE DCOM- 20250507 LR - 20250509 IS - 1472-684X (Electronic) IS - 1472-684X (Linking) VI - 24 IP - 1 DP - 2025 May 6 TI - Development of a complex palliative care intervention for patients with heart failure and their family carers: a theory of change approach. PG - 129 LID - 10.1186/s12904-025-01776-5 [doi] LID - 129 AB - BACKGROUND: Patients with heart failure have significant palliative care needs but few receive palliative care. Guidance is lacking on how to integrate palliative care into standard heart failure care. Palliative care interventions often lack an underpinning theory and details on how key components interact to achieve an impact. Understanding how and why an intervention works enhances implementation. This study aimed to develop and refine a theory-based, complex palliative care intervention for patients with heart failure and their family carers. METHODS: A preliminary theory that underlies the intervention and delineates its key components was co-designed, based upon a literature review, in three Theory of Change workshops with stakeholders from a hospital heart failure multidisciplinary team. The workshop discussions and analysis were informed by Normalisation Process Theory. Subsequently, analysis of secondary data on patient and carer experiences with palliative care services was presented to stakeholders to refine the proposed theory. Service users were consulted to provide feedback on the intervention components. RESULTS: The agreed impact of the intervention was to meet the holistic palliative care needs of patients with heart failure and their families. Three long-term outcomes were identified: reduced unnecessary hospitalisations, symptom burden, and caregiving burden. Twelve preconditions on the patient, family, and healthcare professional levels and contextual assumptions were determined to achieve these outcomes. Proposed intervention activities include educating patients and heart failure teams on palliative care, completing a needs-assessment tool (NAT: PD-HF), addressing primary palliative care needs, sharing a summary of the tool with healthcare staff, and sharing experiences of using NAT: PD-HF in practice. CONCLUSIONS: The study provided novel insights into complex intervention development and the potential mechanism of integrating palliative care in heart failure. It outlined how the complex intervention could work and identified the active ingredients necessary for replication. The developed Theory of Change serves as a model for researchers and policymakers to use in heart failure, but also as an example of how to develop interventions embedded in and co-produced from practice. CI - (c) 2025. The Author(s). FAU - Remawi, Bader Nael AU - Remawi BN AD - Lancaster Medical School, Lancaster University, Lancaster, LA1 4AT, UK. bremawi@birzeit.edu. AD - Doctor of Pharmacy Department, Birzeit University, Birzeit, Palestine. bremawi@birzeit.edu. FAU - Preston, Nancy AU - Preston N AD - Division of Health Research, Lancaster University, Lancaster, LA1 4AT, UK. FAU - Gadoud, Amy AU - Gadoud A AD - Lancaster Medical School, Lancaster University, Lancaster, LA1 4AT, UK. LA - eng PT - Journal Article DEP - 20250506 PL - England TA - BMC Palliat Care JT - BMC palliative care JID - 101088685 SB - IM MH - Humans MH - *Heart Failure/therapy/psychology/complications MH - *Palliative Care/methods/standards MH - *Caregivers/psychology MH - Male MH - Female MH - Qualitative Research PMC - PMC12057136 OTO - NOTNLM OT - Co-design OT - Complex intervention OT - Heart failure OT - Normalisation process theory OT - Palliative care OT - Theory of change COIS- Declarations. Ethics approval and consent to participate: Ethics approval for the group workshops was obtained from the Research Ethics Committee in the Faculty of Health and Medicine at Lancaster University on 9th August 2019 (reference number: FHMREC18098). Ethics approval for the follow-up meetings with service providers was obtained from the same committee on 20th July 2021 (reference number: FHMREC20170). Study participants were asked to sign an informed consent form before enrolment in the study. Ethics approval was not required by the same Research Ethics Committee for the consultation with service users as this was a PPI group consultation that aimed to get feedback from service users on the intervention. Consent for publication: Not applicable. Competing interests: One author (NP) was a section editor at BMC Palliative Care. She has previously published with the other authors (BR and AG) and shares the same institution with AG (Faculty of Health and Medicine, Lancaster University). Declarations: All methods were performed in accordance with the relevant guidelines and regulations. EDAT- 2025/05/07 00:28 MHDA- 2025/05/07 12:32 PMCR- 2025/05/06 CRDT- 2025/05/06 23:37 PHST- 2024/08/03 00:00 [received] PHST- 2025/04/28 00:00 [accepted] PHST- 2025/05/07 12:32 [medline] PHST- 2025/05/07 00:28 [pubmed] PHST- 2025/05/06 23:37 [entrez] PHST- 2025/05/06 00:00 [pmc-release] AID - 10.1186/s12904-025-01776-5 [pii] AID - 1776 [pii] AID - 10.1186/s12904-025-01776-5 [doi] PST - epublish SO - BMC Palliat Care. 2025 May 6;24(1):129. doi: 10.1186/s12904-025-01776-5. PMID- 40326781 OWN - NLM STAT- MEDLINE DCOM- 20250904 LR - 20260304 IS - 1873-1953 (Electronic) IS - 1474-5151 (Linking) VI - 24 IP - 6 DP - 2025 Sep 5 TI - A multidisciplinary team approach in the 2024 ESC guidelines for the management of patients with Atrial Fibrillation-what is the role of nurses and allied professionals? A Clinical Consensus Statement of the Association of Cardiovascular Nursing and Allied Professions (ACNAP) and the European Heart Rhythm Association (EHRA) of the ESC. PG - 828-840 LID - 10.1093/eurjcn/zvaf083 [doi] AB - The complexity of atrial fibrillation (AF) requires an integrated, multifaceted, multidisciplinary, and holistic team approach to optimize the management of AF patients. Active engagement of patients and involvement of nurses and various allied professionals (AP) and a strong collaboration with physicians is crucial in this respect as indicated by the 2024 European Society of Cardiology Guidelines on the management of AF. This is also reflected in these latest guidelines by the concept of AF-CARE, which emphasizes the importance of including the patient, carers, and various healthcare professionals. In this Clinical Consensus Statement, the role of nurses and APs is highlighted and includes optimal approaches on their involvement in the implementation and execution for these guideline recommendations in daily clinical practice. Moreover, additional detail will be provided to the key components and their requirements to allow this integrated multidisciplinary care to be implemented alongside the perspective of the patient. This Statement also examines the challenges and opportunities in relation to their application to clinical practice and how optimal multidisciplinary care can be implemented. CI - (c) The Author(s) 2025. Published by Oxford University Press on behalf of the European Society of Cardiology. FAU - Desteghe, Lien AU - Desteghe L AUID- ORCID: 0000-0001-8641-4658 AD - Centre for Research and Innovation in Care (CRIC), Department of Nursing and Midwifery Sciences, University of Antwerp, Prinsstraat 13, Antwerp 2000, Belgium. AD - Department of Cardiology, Antwerp University Hospital, Drie Eikenstraat 655, Edegem 2650, Belgium. AD - Faculty of Medicine and Life Sciences, Hasselt University, Martelarenlaan 42, Hasselt 3500, Belgium. AD - Heart Center Hasselt, Jessa Hospital, Stadsomvaart 11, Hasselt 3500, Belgium. FAU - Lee, Geraldine AU - Lee G AUID- ORCID: 0000-0001-6385-8600 AD - School of Nursing and Midwifery, University College Cork, Cork, Ireland. FAU - Antoniou, Sotiris AU - Antoniou S AUID- ORCID: 0000-0002-9149-1372 AD - St Bartholomew's Hospital, Barts Health NHS Trust, London, UK. FAU - Merino, Jose L AU - Merino JL AUID- ORCID: 0000-0002-1737-1903 AD - Arrhythmia-Robotic Electrophysiology Unit, La Paz University Hospital, IdiPAZ, Universidad Autonoma, Madrid, Spain. FAU - Neubeck, Lis AU - Neubeck L AUID- ORCID: 0000-0001-5852-1034 AD - School of Health and Social Care, Edinburgh Napier University, Edinburgh, UK. AD - Department of Nursing, Faculty of Nursing and Midwifery, Wroclaw Medical University, 51-618 Wroclaw, Poland. FAU - Ross, Catherine AU - Ross C AUID- ORCID: 0000-0001-6311-9701 AD - School of Health and Social Care, Edinburgh Napier University, Edinburgh, UK. FAU - Svennberg, Emma AU - Svennberg E AUID- ORCID: 0000-0002-6413-0870 AD - Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. FAU - Hendriks, Jeroen M AU - Hendriks JM AUID- ORCID: 0000-0003-4326-9256 AD - Department of Nursing, Maastricht University Medical Centre, P. Debyelaan 25, PO Box 5800, HX Maastricht 6229, The Netherlands. AD - Department of Health Services Research, Care and Public Health Research Institute, Maastricht University, PO Box 616, MD Maastricht 6200, The Netherlands. AD - Centre for Heart Rhythm Disorders, University of Adelaide, Adelaide, SA 5001, Australia. LA - eng PT - Consensus Statement PT - Journal Article PL - England TA - Eur J Cardiovasc Nurs JT - European journal of cardiovascular nursing JID - 101128793 SB - IM MH - Humans MH - *Allied Health Personnel MH - *Atrial Fibrillation/therapy/nursing MH - *Cardiovascular Nursing/standards MH - Europe MH - *Nurse's Role MH - *Patient Care Team/standards/organization & administration OTO - NOTNLM OT - Atrial fibrillation OT - Clinical Practice Guidelines OT - Models of care OT - Multidisciplinary teams OT - Nurses Allied Professionals COIS- Conflict of interest: J.M.H. has received speaker fees from Biotronik and Medtronic. L.D. has nothing to declare. E.S. is supported by the Stockholm County Council (Clinical researcher appointment), the Swedish Research Council (DNR 2022-01466), the Swedish Heart and Lung foundation, CIMED, and has received lecture fees from Abbott, Bayer, Bristol-Myers Squibb-Pfizer, Boehringer- Ingelheim, Johnson & Johnson, Merck Sharp & Dohme. L.N. has received investigator-initiated grants from Pfizer BMS and Daiichi Sankyo, and speaker fees from Sanofi and Novartis. J.L.M. has received speaker fees from and honoraria for lectures and scientific advice from Biotronik, Medtronic, Microport, Milestone Pharmaceutical, Sanofi, and Zoll. S.A. has received speaker fees from and honoraria for lectures and scientific advice from Bayer AG, Bristol Myers Squibb, Daiichi Sankyo, Pfizer, and Johnson and Johnson. G.L., L.D., E.S., and J.L.M. are investigators on the H2020 EHRA-PATHS study (grant agreement No 945260). C.R. has nothing to declare. EDAT- 2025/05/06 12:42 MHDA- 2025/09/05 00:36 CRDT- 2025/05/06 09:03 PHST- 2025/04/08 00:00 [received] PHST- 2025/04/28 00:00 [revised] PHST- 2025/04/29 00:00 [accepted] PHST- 2025/09/05 00:36 [medline] PHST- 2025/05/06 12:42 [pubmed] PHST- 2025/05/06 09:03 [entrez] AID - 8125700 [pii] AID - 10.1093/eurjcn/zvaf083 [doi] PST - ppublish SO - Eur J Cardiovasc Nurs. 2025 Sep 5;24(6):828-840. doi: 10.1093/eurjcn/zvaf083. PMID- 40322185 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250507 IS - 1301-5680 (Print) IS - 2149-8156 (Electronic) IS - 1301-5680 (Linking) VI - 32 IP - 4 Suppl 2 DP - 2024 Nov TI - [MSB-61] Open Heart Surgery in Patients with A Lung Mass: A Single-Center Experience. PG - 085-85 LID - 10.5606/tgkdc.dergisi.2024.msb-61 [doi] AB - OBJECTIVE: This study aimed to share our experience with patients with heart disease requiring open heart surgery who also had a concomitant lung mass. METHODS: This retrospective study included 22 patients (20 males, 2 females; mean age: 63.6 years; range, 43 to 79 years) who required open heart surgery and had a detected lung mass during preoperative evaluation. All the patients were discussed between cardiac and thoracic surgery teams, and different approaches according to patient and mass characters were chosen. Thoracic computed tomography and positron emission tomography scans and, when needed, biopsies were used to determine mass characters. RESULTS: Seven patients were deemed to have small benign nodules, and it was decided not to intervene on the mass. A biopsy before surgery was performed in two patients, and an intervention was not deemed necessary in these patients. One patient was evaluated as having late-stage lung cancer, and no cardiac surgical intervention was performed. Ten patients underwent cardiac surgery and lung resections or lobectomies in a simultaneous operation. Two of the patients subsequently underwent a separate thoracic surgery after the cardiac surgery. There was no perioperative mortality or myocardial infarction. CONCLUSION: Managing patients with both cardiac disease requiring surgery and a lung mass is complex and necessitates a multidisciplinary approach. The decision to perform combined surgery or staged procedures should be individualized based on patient-specific factors, the nature of the lung mass, and the urgency of the cardiac condition. While outcomes for combined procedures are generally favorable in well-selected patients, they require meticulous perioperative planning and long-term follow-up. CI - Copyright (c) 2024, Turkish Society of Cardiovascular Surgery. FAU - Asaroglu, Abdussamet AU - Asaroglu A AD - Department of Cardiovascular Surgery, Basaksehir Cam and Sakura City Hospital, Istanbul, Turkiye. FAU - Temizturk, Zeki AU - Temizturk Z AD - Department of Cardiovascular Surgery, Basaksehir Cam and Sakura City Hospital, Istanbul, Turkiye. FAU - Gunes, Gokhan AU - Gunes G AD - Department of Cardiovascular Surgery, Basaksehir Cam and Sakura City Hospital, Istanbul, Turkiye. FAU - Yanartas, Mehmed AU - Yanartas M AD - Department of Cardiovascular Surgery, Basaksehir Cam and Sakura City Hospital, Istanbul, Turkiye. LA - eng PT - Journal Article DEP - 20241231 PL - Turkey TA - Turk Gogus Kalp Damar Cerrahisi Derg JT - Turk gogus kalp damar cerrahisi dergisi JID - 100887967 PMC - PMC12045203 OTO - NOTNLM OT - Cardiac surgical procedures OT - lung neoplasms OT - thoracic surgery. EDAT- 2025/05/05 06:27 MHDA- 2025/05/05 06:28 PMCR- 2024/12/31 CRDT- 2025/05/05 05:35 PHST- 2024/09/13 00:00 [received] PHST- 2024/09/29 00:00 [accepted] PHST- 2025/05/05 06:28 [medline] PHST- 2025/05/05 06:27 [pubmed] PHST- 2025/05/05 05:35 [entrez] PHST- 2024/12/31 00:00 [pmc-release] AID - 10.5606/tgkdc.dergisi.2024.msb-61 [doi] PST - epublish SO - Turk Gogus Kalp Damar Cerrahisi Derg. 2024 Dec 31;32(4 Suppl 2):085-85. doi: 10.5606/tgkdc.dergisi.2024.msb-61. eCollection 2024 Nov. PMID- 40322130 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250613 IS - 1301-5680 (Print) IS - 2149-8156 (Electronic) IS - 1301-5680 (Linking) VI - 32 IP - 4 Suppl 2 DP - 2024 Nov TI - [MEP-48] Perioperative Management Strategies in Cardiac Surgery for Patients with Ankylosing Spondylitis. PG - 148 LID - 10.5606/tgkdc.dergisi.2024.mep-48 [doi] AB - OBJECTIVE: This study aimed to discuss preoperative, intraoperative, and postoperative management strategies in patients with ankylosing spondylitis undergoing cardiac surgery. METHODS: A retrospective analysis was performed with patients who underwent cardiac surgery between 2009 and 2024. Fourteen patients diagnosed with ankylosing spondylitis and followed by relevant clinics were identified. These patients were compared with 15 randomly selected patients who had similar profiles in terms of age, sex, and type of cardiac surgery. Age, sex, mode of intubation, length of hospital stay, duration of intubation, postoperative pulmonary complications, transfusion requirements, mobilization time, and the incidence of postoperative venous thromboembolism were evaluated. RESULTS: Of the patients, 78.6% were male, with a mean age of 55+/-8 years. The postoperative intubation duration was significantly longer in the ankylosing spondylitis group (14+/-8 h vs. 6+/-5 h). Due to intubation difficulty, the need for fiberoptic intubation was higher in the ankylosing spondylitis group (16.6% vs. 0%). There were no significant differences between the groups in terms of hospital stay, postoperative exploration rates, transfusion requirements, or venous thromboembolism incidence. No postoperative sternal dehiscence was observed in either group. The need for rehabilitation due to postoperative pulmonary complications was higher in the ankylosing spondylitis group (33.3% vs. 13.3%). Cardiovascular mortality rates were similar in both groups. CONCLUSION: The management of cardiac surgery in patients with ankylosing spondylitis requires a multidisciplinary approach. Appropriate perioperative management, including preoperative patient planning as well as intraoperative and postoperative follow-up and care, is essential. CI - Copyright (c) 2024, Turkish Society of Cardiovascular Surgery. FAU - Yucel, Murat AU - Yucel M AD - Department of Cardiovascular Surgery, Ankara Bilkent City Hospital, Ankara, Turkiye. LA - eng PT - Journal Article DEP - 20241231 PL - Turkey TA - Turk Gogus Kalp Damar Cerrahisi Derg JT - Turk gogus kalp damar cerrahisi dergisi JID - 100887967 PMC - PMC12045164 OTO - NOTNLM OT - Ankylosing spondylitis OT - cardiac surgical procedures OT - postoperative complications. EDAT- 2025/05/05 06:27 MHDA- 2025/05/05 06:28 PMCR- 2024/12/31 CRDT- 2025/05/05 05:35 PHST- 2024/09/13 00:00 [received] PHST- 2024/09/29 00:00 [accepted] PHST- 2025/05/05 06:28 [medline] PHST- 2025/05/05 06:27 [pubmed] PHST- 2025/05/05 05:35 [entrez] PHST- 2024/12/31 00:00 [pmc-release] AID - 10.5606/tgkdc.dergisi.2024.mep-48 [doi] PST - epublish SO - Turk Gogus Kalp Damar Cerrahisi Derg. 2024 Dec 31;32(4 Suppl 2):148. doi: 10.5606/tgkdc.dergisi.2024.mep-48. eCollection 2024 Nov. PMID- 40319163 OWN - NLM STAT- MEDLINE DCOM- 20260212 LR - 20261009 IS - 1432-1971 (Electronic) IS - 0172-0643 (Linking) VI - 47 IP - 3 DP - 2026 Mar TI - Adult-Trained Cardiac Sonographers: Essential Team Members in the Evaluation and Management of Unexpected Neonatal Critical Congenital Heart Disease. PG - 1018-1025 LID - 10.1007/s00246-025-03872-y [doi] AB - Early identification of critical congenital heart disease (CCHD) is essential in the management of neonates without a prenatal diagnosis. Adult-trained cardiac sonographers often perform initial neonatal transthoracic echocardiograms for outside interpretation. We sought to critically evaluate the accuracy and quality of these echocardiograms. Neonates treated at our center for postnatally diagnosed CCHD, who had an initial echocardiogram performed by an adult-trained sonographer at an outside birthing center were included. Each initial echocardiogram was evaluated using a 4-point Likert scale for diagnostic accuracy and quality, and a 3-point Likert scale assessing 5 standard echocardiogram views. Six paired graders independently assessed an equal distribution of echocardiograms. 52 echocardiograms from 4 states met all inclusion criteria. The most common diagnoses were aortic arch abnormalities (37%), followed by dTGA (19%), and TAPVR (17%). Ninety-eight percent of the original interpretations provided the correct primary diagnosis or high enough suspicion of the primary diagnosis to warrant appropriate escalation in care. Average scores of the echocardiograms were 3.13 +/- 0.66 for diagnostic accuracy and 3.09 +/- 0.54 for overall image quality. Average scores were highest for parasternal long-axis view (2.74 +/- 0.31) and lowest for suprasternal notch (2.18 +/- 0.46) and subcostal (2.07 +/- 0.34) views. The average intraclass correlation between raters was > 0.9. Postnatal CCHD is discoverable by adult-trained sonographers with remote interpretation by pediatric cardiologists. Suprasternal notch and subcostal views are areas of educational opportunity. With appropriate support systems, adult-trained sonographers can be an invaluable asset in the early diagnosis and management of unexpected CCHD. CI - (c) 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - McRae, Robert AU - McRae R AUID- ORCID: 0000-0002-4303-2534 AD - University of Washington School of Medicine, 1959 NE Pacific St., Seattle, WA, 98195, USA. Robert.McRae@SeattleChildrens.org. AD - Seattle Children's Hospital, 4800 Sand Point Way NE, Seattle, WA, 98105, USA. Robert.McRae@SeattleChildrens.org. FAU - Brown, Nicholas AU - Brown N AD - University of Washington School of Medicine, 1959 NE Pacific St., Seattle, WA, 98195, USA. AD - Seattle Children's Hospital, 4800 Sand Point Way NE, Seattle, WA, 98105, USA. FAU - Pinto, Nelangi AU - Pinto N AD - University of Washington School of Medicine, 1959 NE Pacific St., Seattle, WA, 98195, USA. AD - Seattle Children's Hospital, 4800 Sand Point Way NE, Seattle, WA, 98105, USA. FAU - Bhat, Aarti AU - Bhat A AD - University of Washington School of Medicine, 1959 NE Pacific St., Seattle, WA, 98195, USA. AD - Seattle Children's Hospital, 4800 Sand Point Way NE, Seattle, WA, 98105, USA. FAU - Perez-Kersey, Plicy AU - Perez-Kersey P AD - University of Washington School of Medicine, 1959 NE Pacific St., Seattle, WA, 98195, USA. AD - Seattle Children's Hospital, 4800 Sand Point Way NE, Seattle, WA, 98105, USA. FAU - Olson, Briana AU - Olson B AD - Seattle Children's Hospital, 4800 Sand Point Way NE, Seattle, WA, 98105, USA. FAU - Hobbs, Cheyenne AU - Hobbs C AD - Seattle Children's Hospital, 4800 Sand Point Way NE, Seattle, WA, 98105, USA. FAU - Kelly, Amber AU - Kelly A AD - Seattle Children's Hospital, 4800 Sand Point Way NE, Seattle, WA, 98105, USA. FAU - Schultz, Amy AU - Schultz A AD - Perelman School of Medicine at the University of Pennsylvania, 3400 Civic Center Blvd, Philadelphia, PA, 19104, USA. AD - Children's Hospital of Philadelphia, 3401 Civic Center Blvd, Philadelphia, PA, 19104, USA. FAU - Soriano, Brian AU - Soriano B AD - University of Washington School of Medicine, 1959 NE Pacific St., Seattle, WA, 98195, USA. AD - Seattle Children's Hospital, 4800 Sand Point Way NE, Seattle, WA, 98105, USA. FAU - Studer, Matthew AU - Studer M AD - University of Washington School of Medicine, 1959 NE Pacific St., Seattle, WA, 98195, USA. AD - Seattle Children's Hospital, 4800 Sand Point Way NE, Seattle, WA, 98105, USA. LA - eng PT - Journal Article DEP - 20250504 PL - United States TA - Pediatr Cardiol JT - Pediatric cardiology JID - 8003849 SB - IM MH - Humans MH - *Heart Defects, Congenital/diagnostic imaging MH - Infant, Newborn MH - *Echocardiography/methods/standards MH - Female MH - *Clinical Competence MH - Male MH - Adult MH - *Patient Care Team MH - Retrospective Studies OTO - NOTNLM OT - Congenital heart disease OT - Echocardiogram education OT - Neonatal echocardiography OT - Remote interpretation OT - Telehealth COIS- Declarations. Conflict of interest: The authors declare no competing interests. EDAT- 2025/05/04 00:45 MHDA- 2026/02/12 12:50 CRDT- 2025/05/03 23:21 PHST- 2025/03/06 00:00 [received] PHST- 2025/04/16 00:00 [accepted] PHST- 2026/02/12 12:50 [medline] PHST- 2025/05/04 00:45 [pubmed] PHST- 2025/05/03 23:21 [entrez] AID - 10.1007/s00246-025-03872-y [pii] AID - 10.1007/s00246-025-03872-y [doi] PST - ppublish SO - Pediatr Cardiol. 2026 Mar;47(3):1018-1025. doi: 10.1007/s00246-025-03872-y. Epub 2025 May 4. PMID- 40318243 OWN - NLM STAT- MEDLINE DCOM- 20250517 LR - 20250606 IS - 1532-1983 (Electronic) IS - 0261-5614 (Linking) VI - 49 DP - 2025 Jun TI - Nutritional characteristics and the potential impact of dietetic intervention on patients assessed for heart transplant. PG - 157-164 LID - S0261-5614(25)00110-4 [pii] LID - 10.1016/j.clnu.2025.04.016 [doi] AB - BACKGROUND & AIMS: Heart transplant (HT) is the gold standard treatment for people with end stage heart failure (HF). Up to 46 % of patients with chronic HF are malnourished and increasing rates of obesity have also been identified. Therefore, at time of HT assessment, patients are required to meet eligibility criteria, including nutrition targets. It is recommended that patients being considered for HT receive comprehensive assessment by a multidisciplinary team (MDT) to assist in meeting HT criteria. This study aimed to describe the baseline nutritional characteristics of patients undergoing HT assessment and to explore the impact of dietetic intervention on key nutritional parameters including BMI and malnutrition status pre-transplant. METHODS: This study was a single-centre combined retrospective and prospective observational cohort study. Adults who underwent HT assessment and met inclusion criteria between January 1, 2015 and June 30, 2021 were included. Key nutrition-related parameters assessed were weight, Body Mass Index (BMI), and nutritional status using the Subjective Global Assessment (SGA): A well-nourished, B and C moderately and severely malnourished, collected at HT assessment, listing and HT. The impact of dietetic intervention on nutrition-related parameters was also assessed. RESULTS: 255 patients were included, with 2.7 % (n = 7) underweight, 32.2 % healthy weight, 38.8 % overweight and 26.3 % obese. Of 161 patients assessed using the SGA 22.4 % (n = 36) were moderately or severely malnourished. 26 patients had a relative nutrition contraindication for HT listing (BMI>35 kg/m(2) and/or HbA1c >7.5 %) and n = 39 had suboptimal nutritional status including BMI <18.5 kg/m(2) and/or presence of malnutrition.Dietetic intervention did not result in statistically significant changes in weight, BMI or nutritional status. 25.5 % of patients had relative nutritional contraindications to HT or suboptimal nutritional parameters and 9 had a decline in nutritional status, defined as developing malnutrition or worsened malnutrition. CONCLUSIONS: This study showed a quarter of HT patients had suboptimal nutrition-related parameters including malnutrition, underweight, overweight or obesity at time of HT assessment, indicating opportunity for improved nutrition support prior to HT. The results also indicated that nutritional status can deteriorate in patients waiting for HT. Routine nutrition assessment and regular monitoring by a dietitian has the potential to support patients in their HT journey through optimising BMI and preventing nutritional decline. CI - Crown Copyright (c) 2025. Published by Elsevier Ltd. All rights reserved. FAU - Chalmers, Grace AU - Chalmers G AD - School of Exercise and Nutrition Science, Queensland University of Technology, 149 Victoria Park Rd, Kelvin Grove, Brisbane, QLD, 4059, Australia. FAU - Whitmore, Emma AU - Whitmore E AD - Department of Nutrition & Dietetics, The Prince Charles Hospital, 627 Rode Rd, Chermside, Brisbane, QLD, 4032, Australia. FAU - Silburn, Kelsey A AU - Silburn KA AD - School of Exercise and Nutrition Science, Queensland University of Technology, 149 Victoria Park Rd, Kelvin Grove, Brisbane, QLD, 4059, Australia. FAU - Chan, Wandy AU - Chan W AD - Advanced Heart Failure & Cardiac Transplant Unit, The Prince Charles Hospital, 627 Rode Rd, Chermside, Brisbane, QLD, 4032, Australia; Northside Clinical School, The University of Queensland, 280-284 Sir Fred Schonell Dr, St Lucia, Brisbane, QLD, 4067, Australia. FAU - Ross, Lynda J AU - Ross LJ AD - School of Exercise and Nutrition Science, Queensland University of Technology, 149 Victoria Park Rd, Kelvin Grove, Brisbane, QLD, 4059, Australia. FAU - Cheung, Ho Ching AU - Cheung HC AD - School of Exercise and Nutrition Science, Queensland University of Technology, 149 Victoria Park Rd, Kelvin Grove, Brisbane, QLD, 4059, Australia. FAU - Elmas, Kai AU - Elmas K AD - Department of Nutrition & Dietetics, The Prince Charles Hospital, 627 Rode Rd, Chermside, Brisbane, QLD, 4032, Australia. FAU - Hickling, Donna F AU - Hickling DF AD - Department of Nutrition & Dietetics, The Prince Charles Hospital, 627 Rode Rd, Chermside, Brisbane, QLD, 4032, Australia. Electronic address: Donna.Hickling@health.qld.gov.au. LA - eng PT - Journal Article PT - Observational Study DEP - 20250417 PL - England TA - Clin Nutr JT - Clinical nutrition (Edinburgh, Scotland) JID - 8309603 SB - IM MH - Humans MH - Male MH - Female MH - *Heart Transplantation MH - Middle Aged MH - *Nutritional Status MH - *Malnutrition/diagnosis/diet therapy MH - *Heart Failure/surgery/complications MH - Retrospective Studies MH - Prospective Studies MH - Nutrition Assessment MH - Body Mass Index MH - Aged MH - *Dietetics/methods MH - Adult OTO - NOTNLM OT - BMI OT - Heart failure OT - Heart transplant OT - Malnutrition OT - Obese OT - Underweight COIS- Conflict of Interest There are no conflicts of interest to declare. EDAT- 2025/05/03 22:26 MHDA- 2025/05/18 17:01 CRDT- 2025/05/03 18:00 PHST- 2024/12/04 00:00 [received] PHST- 2025/03/30 00:00 [revised] PHST- 2025/04/13 00:00 [accepted] PHST- 2025/05/18 17:01 [medline] PHST- 2025/05/03 22:26 [pubmed] PHST- 2025/05/03 18:00 [entrez] AID - S0261-5614(25)00110-4 [pii] AID - 10.1016/j.clnu.2025.04.016 [doi] PST - ppublish SO - Clin Nutr. 2025 Jun;49:157-164. doi: 10.1016/j.clnu.2025.04.016. Epub 2025 Apr 17. PMID- 40317546 OWN - NLM STAT- MEDLINE DCOM- 20250503 LR - 20250505 IS - 1932-8737 (Electronic) IS - 0160-9289 (Print) IS - 0160-9289 (Linking) VI - 48 IP - 5 DP - 2025 May TI - Prognostic Impact of Implementation of Heart Team Approach on Cardiovascular Outcomes in Patients With Complex Coronary Artery Disease. PG - e70141 LID - 10.1002/clc.70141 [doi] LID - e70141 AB - BACKGROUND: In patients with stable coronary artery disease (CAD), treatment options include medical therapy, percutaneous coronary intervention (PCI), and coronary artery bypass grafting (CABG). The decision between PCI and CABG depends on disease severity and revascularization risk. Guidelines promote a heart team approach (HTA) with shared decision-making, yet PCI remains prevalent. METHODS AND RESULTS: We conducted a retrospective analysis of 753 patients with complex CAD (left main or multivessel disease and SYNTAX score >/= 33) between January 2019 and April 2022. We evaluated a quality improvement program featuring a clinical decision flow map, a support system for risk score calculations, and a standard operating procedure for HTA. We compared HTA activation, revascularization strategy choices, and long-term cardiovascular outcomes (composite endpoint: death, myocardial infarction, or unplanned revascularization) between patients treated with HTA (HTA group, n = 448) and without HTA (non-HTA group, n = 304). The program significantly increased HTA activation (from 26.4% to 61.7%) and CABG selection (from 11.1% to 20.4%). The HTA group had better CABG recommendations and choices (75.5% vs. 37.2%, and 26.8% vs. 7.2%, respectively), with a lower incidence of the primary composite endpoint (18.1% vs. 42.4%). CONCLUSION: A quality improvement program enhances HTA activation and revascularization strategies, leading to improved cardiovascular outcomes in complex CAD patients. CI - (c) 2025 The Author(s). Clinical Cardiology published by Wiley Periodicals LLC. FAU - Su, Po-Hsueh AU - Su PH AUID- ORCID: 0000-0002-1589-4057 AD - Department of Internal Medicine, Division of Cardiology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. AD - Department of Internal Medicine, Division of Cardiology, Madou Sin-Lau Hospital, Tainan, Taiwan. FAU - Huang, Ya-Lin AU - Huang YL AD - Department of Internal Medicine, Division of Cardiology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. FAU - Chen, Po-Wei AU - Chen PW AD - Department of Internal Medicine, Division of Cardiology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. FAU - Chang, Hsien-Yuan AU - Chang HY AD - Department of Internal Medicine, Division of Cardiology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. FAU - Roan, Jun-Neng AU - Roan JN AD - Department of Surgery, Division of Cardiovascular Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. AD - School of Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan. FAU - Chao, Ting-Hsing AU - Chao TH AD - Department of Internal Medicine, Division of Cardiology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. AD - Department of Internal Medicine, Division of Cardiology, Chung-Shan Medical University Hospital and School of Medicine, Chung Shan Medical University, Taichung, Taiwan. LA - eng GR - This study is supported by the grant from the National Science and Technology Council under the grant number NSC 111-2314-B-006-019-MY3 and Chung Shan Medical University Hospital under the grant number CSH-2-25-D-002./ PT - Journal Article PL - United States TA - Clin Cardiol JT - Clinical cardiology JID - 7903272 SB - IM MH - Humans MH - *Coronary Artery Disease/surgery/diagnosis/therapy/mortality MH - Retrospective Studies MH - Female MH - Male MH - *Patient Care Team MH - *Percutaneous Coronary Intervention/methods MH - *Coronary Artery Bypass MH - Aged MH - Middle Aged MH - Prognosis MH - Risk Assessment MH - Quality Improvement MH - Risk Factors MH - Treatment Outcome PMC - PMC12046974 OTO - NOTNLM OT - coronary artery bypass grafting OT - coronary artery disease OT - percutaneous coronary intervention OT - quality improvement COIS- The authors declare no conflicts of interest. EDAT- 2025/05/03 22:26 MHDA- 2025/05/03 22:27 PMCR- 2025/05/02 CRDT- 2025/05/03 12:26 PHST- 2025/04/17 00:00 [revised] PHST- 2025/02/28 00:00 [received] PHST- 2025/04/22 00:00 [accepted] PHST- 2025/05/03 22:27 [medline] PHST- 2025/05/03 22:26 [pubmed] PHST- 2025/05/03 12:26 [entrez] PHST- 2025/05/02 00:00 [pmc-release] AID - CLC70141 [pii] AID - 10.1002/clc.70141 [doi] PST - ppublish SO - Clin Cardiol. 2025 May;48(5):e70141. doi: 10.1002/clc.70141. PMID- 40317284 OWN - NLM STAT- MEDLINE DCOM- 20250624 LR - 20260325 IS - 1097-685X (Electronic) IS - 0022-5223 (Linking) VI - 170 IP - 1 DP - 2025 Jul TI - The American Association for Thoracic Surgery (AATS) 2025 Expert Consensus Document: Management of Ebstein anomaly in children and adults. PG - 1-16 LID - S0022-5223(25)00212-0 [pii] LID - 10.1016/j.jtcvs.2025.03.014 [doi] AB - OBJECTIVES: Patients with Ebstein anomaly (EA) require complex management. A group of experts was commissioned by the American Association for Thoracic Surgery to provide a framework on this topic, focusing on preoperative assessment, indications for intervention, and medical management before and after surgical intervention in older children and adults. This is a companion document to a recently issued document regarding management of EA in neonates and infants. This document addresses children older than 1 year of age and adults. METHODS: The EA Writing Group of the Congenital Clinical Practice Standards Committee is a multinational and multidisciplinary group of surgeons and cardiologists with expertise in EA. A citation search in PubMed, Embase, Scopus, and Web of Science was conducted using key words related to EA. The search was restricted to the English language and the year 2000 or later and yielded 455 results. Expert consensus statements with class of recommendation and level of evidence were developed using a modified Delphi method, requiring 80% of members' votes with at least 75% agreement on each statement. RESULTS: In patients with EA, the presence of congestive heart failure, cyanosis, significant left ventricular dysfunction, severe cardiomegaly, and persistent arrhythmia increases the risk for morbidity and mortality. Asymptomatic patients with EA should undergo exercise stress testing with measurement of oxygen consumption to unmask occult exercise intolerance. Cardiac magnetic resonance imaging is recommended for comprehensive imaging of EA for reliable volume assessment of both ventricles, evaluation of tricuspid regurgitation fraction, and right ventricle stroke volume. Surgery is recommended for symptoms that include fatigue, decreased objective exercise tolerance, decreased arterial oxygen saturation (cyanosis), and exertional dyspnea. Surgery can be beneficial in asymptomatic patients with severe tricuspid regurgitation, moderate right ventricular enlargement, and valve anatomy favorable for repair. Bidirectional cavopulmonary shunt is reasonable when there is severe right ventricular dilation, severe right ventricular systolic dysfunction, right atrial pressure: left atrial pressure ratio >1.5, or failure to separate from cardiopulmonary bypass after repair. Concomitant maze procedure at the time of surgery is reasonable when there is paroxysmal or continuous atrial fibrillation. In EA patients with evidence of systolic left ventricular dysfunction, concomitant acquired disease should be excluded, and goal-directed medical therapies is recommended. CONCLUSIONS: Management of EA requires a tailored and multidisciplinary approach. The introduction of the cone procedure has revolutionized surgical management, providing excellent outcomes and durability across a wide range of anatomical variations. The timing of intervention, especially in asymptomatic patients, remains a topic of ongoing research and debate. Comprehensive preoperative evaluations, including exercise testing and arrhythmia assessment, are critical for optimizing surgical outcomes. In complex cases, adjunct procedures like bidirectional cavopulmonary shunt or the maze procedure offer additional therapeutic benefits. CI - Copyright (c) 2025 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved. CN - Expert Consensus Panel FAU - Chai, Paul AU - Chai P AD - Division of Cardiothoracic Surgery, Children's Healthcare of Atlanta, Emory University, Atlanta, Ga. Electronic address: paul.chai@choa.org. FAU - Konstantinov, Igor E AU - Konstantinov IE AD - Department of Cardiothoracic Surgery, Royal Children's Hospital, Department of Paediatrics, University of Melbourne, Heart Research Group, Murdoch Children's Research Institute, Melbourne, Australia. FAU - da Fonseca da Silva, Luciana AU - da Fonseca da Silva L AD - Division of Cardiothoracic Surgery, UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pa. FAU - Qureshi, Muhammad AU - Qureshi M AD - Department of Pediatrics, Mayo Clinic, Rochester, Minn. FAU - Wackel, Philip AU - Wackel P AD - Department of Pediatrics, Mayo Clinic, Rochester, Minn. FAU - Knott-Craig, Christopher AU - Knott-Craig C AD - Division of Cardiothoracic Surgery, Le Bonheur Children's Hospital, University of Tennessee Health Science Center, Memphis, Tenn. FAU - Connolly, Heidi AU - Connolly H AD - Department of Medicine, Mayo Clinic, Rochester, Minn. FAU - Walsh, Ed AU - Walsh E AD - Department of Pediatrics, Boston Children's Hospital, Boston, Mass. FAU - Singh, Harsimran AU - Singh H AD - Department of Medicine, Weill-Cornell Medical Center, New York, NY. FAU - Nelson, Jennifer AU - Nelson J AD - Department of Surgery, Nemours Children's Hospital, Orlando, Fla. FAU - Yoo, Shi-Joon AU - Yoo SJ AD - Department of Radiology, The Hospital for Sick Children, Toronto, Ontario, Canada. FAU - Brizard, Christian AU - Brizard C AD - Department of Cardiothoracic Surgery, Royal Children's Hospital, Department of Paediatrics, University of Melbourne, Heart Research Group, Murdoch Children's Research Institute, Melbourne, Australia. FAU - Bacha, Emile AU - Bacha E AD - Division of Cardiothoracic Surgery, Columbia University Medical Center, New York, NY. FAU - Nido, Pedro Del AU - Nido PD AD - Department of Cardiac Surgery, Boston Children's Hospital, Boston, Mass. FAU - Starnes, Vaughn AU - Starnes V AD - Department of Surgery, Keck School of Medicine, University of Southern California, Los Angeles, Calif. FAU - Pedro da Silva, Jose AU - Pedro da Silva J AD - Division of Cardiothoracic Surgery, UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pa. FAU - Dearani, Joseph AU - Dearani J AD - Department of Cardiovascular Surgery, Mayo Clinic, Rochester, Minn. LA - eng PT - Consensus Statement PT - Journal Article PT - Practice Guideline DEP - 20250503 PL - United States TA - J Thorac Cardiovasc Surg JT - The Journal of thoracic and cardiovascular surgery JID - 0376343 SB - IM MH - Humans MH - *Ebstein Anomaly/surgery/physiopathology/diagnosis/therapy MH - Child MH - Adult MH - *Cardiac Surgical Procedures/standards/adverse effects MH - Treatment Outcome MH - Infant MH - Age Factors MH - Adolescent OTO - NOTNLM OT - Ebstein anomaly OT - cone procedure OT - tricuspid valve COIS- Conflict of Interest Statement The authors reported no conflicts of interest. The Journal policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest. EDAT- 2025/05/03 22:25 MHDA- 2025/06/24 11:11 CRDT- 2025/05/03 10:31 PHST- 2025/02/03 00:00 [received] PHST- 2025/03/17 00:00 [revised] PHST- 2025/03/17 00:00 [accepted] PHST- 2025/06/24 11:11 [medline] PHST- 2025/05/03 22:25 [pubmed] PHST- 2025/05/03 10:31 [entrez] AID - S0022-5223(25)00212-0 [pii] AID - 10.1016/j.jtcvs.2025.03.014 [doi] PST - ppublish SO - J Thorac Cardiovasc Surg. 2025 Jul;170(1):1-16. doi: 10.1016/j.jtcvs.2025.03.014. Epub 2025 May 3. PMID- 40314370 OWN - NLM STAT- MEDLINE DCOM- 20250507 LR - 20260822 IS - 2047-9980 (Electronic) IS - 2047-9980 (Linking) VI - 14 IP - 9 DP - 2025 May 6 TI - Cardiac Conduction Disorders Due to Acquired or Genetic Causes in Young Adults: A Review of the Current Literature. PG - e040274 LID - 10.1161/JAHA.124.040274 [doi] LID - e040274 AB - Cardiac conduction disorders can manifest in young adults in isolated forms, associated with myocardial diseases or as part of a multiorgan disorder. Underlying causes of cardiac conduction disorders may be genetically determined or acquired. Cardiac conduction disorder in young adults is a complex and often underestimated and underrecognized disease that may need of a multidisciplinary team for the diagnosis, treatment, and long-term management of these patients. Therefore, it is crucial to raise clinicians' awareness of this condition. In this review, we provide a comprehensive update on the cause, diagnosis, and treatment of young adults with cardiac conduction disorders, also suggesting potential strategies to improve the current clinical management of these patients. FAU - Balla, Cristina AU - Balla C AUID- ORCID: 0000-0003-2110-8961 AD - Cardiology Unit Azienda Ospedaliero-Universitaria di Ferrara Cona FE Italy. FAU - Canovi, Luca AU - Canovi L AD - Cardiology Unit Azienda Ospedaliero-Universitaria di Ferrara Cona FE Italy. FAU - Zuin, Marco AU - Zuin M AUID- ORCID: 0000-0002-4559-1292 AD - Cardiology Unit Azienda Ospedaliero-Universitaria di Ferrara Cona FE Italy. FAU - Di Lenno, Luca AU - Di Lenno L AD - Pediatric Cardiology and Adult Congenital Heart Disease Program, Department of Cardio-Thoracic and Vascular Medicine IRCCS Azienda Ospedaliero-Universitaria di Bologna Bologna Italy. FAU - Berloni, Maria L AU - Berloni ML AUID- ORCID: 0009-0002-2774-0853 AD - Cardiology Unit Azienda Ospedaliero-Universitaria di Ferrara Cona FE Italy. FAU - de Carolis, Beatrice AU - de Carolis B AUID- ORCID: 0009-0009-9397-5977 AD - Cardiology Unit Azienda Ospedaliero-Universitaria di Ferrara Cona FE Italy. FAU - Di Domenico, Assunta AU - Di Domenico A AUID- ORCID: 0009-0000-3768-3181 AD - Cardiology Unit Azienda Ospedaliero-Universitaria di Ferrara Cona FE Italy. FAU - Tonet, Elisabetta AU - Tonet E AUID- ORCID: 0000-0003-0257-1272 AD - Cardiology Unit Azienda Ospedaliero-Universitaria di Ferrara Cona FE Italy. FAU - Vitali, Francesco AU - Vitali F AUID- ORCID: 0000-0002-0667-7616 AD - Cardiology Unit Azienda Ospedaliero-Universitaria di Ferrara Cona FE Italy. FAU - Malagu, Michele AU - Malagu M AUID- ORCID: 0000-0002-1972-9665 AD - Cardiology Unit Azienda Ospedaliero-Universitaria di Ferrara Cona FE Italy. FAU - Boriani, Giuseppe AU - Boriani G AUID- ORCID: 0000-0002-9820-4815 AD - Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences University of Modena and Reggio Emilia, Policlinico di Modena Modena Italy. FAU - Bertini, Matteo AU - Bertini M AUID- ORCID: 0000-0002-5285-7140 AD - Cardiology Unit Azienda Ospedaliero-Universitaria di Ferrara Cona FE Italy. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20250502 PL - England TA - J Am Heart Assoc JT - Journal of the American Heart Association JID - 101580524 SB - IM MH - Humans MH - Young Adult MH - *Heart Conduction System/physiopathology MH - *Cardiac Conduction System Disease/therapy/genetics/diagnosis/etiology/physiopathology MH - Genetic Predisposition to Disease MH - *Arrhythmias, Cardiac/therapy/genetics/diagnosis/physiopathology/etiology MH - Electrocardiography MH - Adult MH - Risk Factors PMC - PMC12184228 OTO - NOTNLM OT - atrioventricular block OT - cardiac conduction disorders OT - genetic OT - myocardial disease OT - young adults COIS- None. EDAT- 2025/05/02 12:32 MHDA- 2025/05/07 12:32 PMCR- 2025/05/02 CRDT- 2025/05/02 08:04 PHST- 2025/05/07 12:32 [medline] PHST- 2025/05/02 12:32 [pubmed] PHST- 2025/05/02 08:04 [entrez] PHST- 2025/05/02 00:00 [pmc-release] AID - JAH310844 [pii] AID - 10.1161/JAHA.124.040274 [doi] PST - ppublish SO - J Am Heart Assoc. 2025 May 6;14(9):e040274. doi: 10.1161/JAHA.124.040274. Epub 2025 May 2. PMID- 40311710 OWN - NLM STAT- MEDLINE DCOM- 20250714 LR - 20250721 IS - 1872-7913 (Electronic) IS - 0924-8579 (Linking) VI - 66 IP - 3 DP - 2025 Sep TI - Antimicrobial suppressive therapy in prosthetic valve endocarditis rejected from surgery despite indication. PG - 107526 LID - S0924-8579(25)00083-4 [pii] LID - 10.1016/j.ijantimicag.2025.107526 [doi] AB - BACKGROUND: Prosthetic valve endocarditis (PVE) incidence is rising in older patients, often rejected for surgery, leading them to a poor prognosis. Optimal antibiotic management is unknown for these patients. We compared the efficacy and safety of suppressive (SAT) versus conventional antimicrobial therapy (CAT) in this setting. METHODS: We conducted a prospective, multicentric, cohort study in southwest France including patients with PVE rejected from surgery despite indication, and surviving the initial 6 weeks of intravenous therapy. Beyond this period, patients could or not receive SAT, according to endocarditis team decision. Primary outcome was a composite endpoint of one-year all-cause mortality and PVE-related hospitalization. Secondary outcome was the incidence and nature of SAT-related adverse events. RESULTS: Between 2012 and 2022, 88 patients were included in the study, 42 receiving SAT and 46 CAT. Mean age was 69.4 +/- 16.4 years and patients were highly comorbid (mean Charlson Comorbidity Index 5.6 +/- 2.7). Main organisms included Streptococcus spp. (26/88, 29.5%) and Staphylococcus aureus (25/88, 28.4%). The primary composite outcome occurred in 7/42 (16.7%) patients in the SAT group, and 16/46 (34.8%) in the CAT group. Using a Cox model, SAT was significantly and independently associated with a lower incidence of one-year primary outcome (Hazard ratio 0.23, 95% CI 0.08-0.67, P = 0.007). Adverse effects in the SAT group were reported for 6/42 patients (14.3%). These effects were limited, causing only one treatment discontinuation. CONCLUSION: In patients with PVE rejected from surgery despite indication, SAT may be safe and associated with better outcomes than CAT. CI - Copyright (c) 2025 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved. FAU - Tillement, Jeremie AU - Tillement J AD - Cardiology and Cardiac Surgery Departments, Bordeaux University Hospital-Haut-Leveque, Pessac, France. Electronic address: jeremie.tillement@chu-bordeaux.fr. FAU - Issa, Nahema AU - Issa N AD - Internal Medicine and Infectious Disease Unit, Groupe Saint-Andre, University Hospital, Bordeaux, France. FAU - Ternacle, Julien AU - Ternacle J AD - Cardiology and Cardiac Surgery Departments, Bordeaux University Hospital-Haut-Leveque, Pessac, France. FAU - Hemar, Victor AU - Hemar V AD - Internal Medicine and Infectious Disease Unit, Groupe Saint-Andre, University Hospital, Bordeaux, France. FAU - Beurton, Antoine AU - Beurton A AD - Department of Cardiovascular Anesthesia and Critical Care, Hopital Cardiologique de Haut-Leveque, Bordeaux University Hospital, Pessac, France; UMR INSERM 1034 University of Bordeaux, Bordeaux, France. FAU - Busuttil, Olivier AU - Busuttil O AD - Cardiology and Cardiac Surgery Departments, Bordeaux University Hospital-Haut-Leveque, Pessac, France. FAU - Chaussade, Helene AU - Chaussade H AD - Internal Medicine and Infectious Disease Unit, Groupe Saint-Andre, University Hospital, Bordeaux, France. FAU - Dijos, Marina AU - Dijos M AD - Cardiology and Cardiac Surgery Departments, Bordeaux University Hospital-Haut-Leveque, Pessac, France. FAU - Greib, Carine AU - Greib C AD - Bacteriology Department, Bordeaux University Hospital-Pellegrin, Bordeaux, France. FAU - Labrousse, Louis AU - Labrousse L AD - Cardiology and Cardiac Surgery Departments, Bordeaux University Hospital-Haut-Leveque, Pessac, France. FAU - Peltan, Julien AU - Peltan J AD - Cardiology and Cardiac Surgery Departments, Bordeaux University Hospital-Haut-Leveque, Pessac, France. FAU - Peuchant, Olivia AU - Peuchant O AD - Bacteriology Department, Bordeaux University Hospital-Pellegrin, Bordeaux, France. FAU - Wirth, Gaetane AU - Wirth G AD - Infectious Diseases Department, Bordeaux University Hospital-Pellegrin, Bordeaux, France. FAU - Roubaud-Baudron, Claire AU - Roubaud-Baudron C AD - CHU Bordeaux, Pole de Gerontologie Clinique, Bordeaux, France; Univ. Bordeaux, INSERM UMR 1312 BRIC, Bordeaux, France. FAU - Camou, Fabrice AU - Camou F AD - Internal Medicine and Infectious Diseases Department, Bordeaux University Hospital-Haut-Leveque, Pessac, France. FAU - Boulestreau, Romain AU - Boulestreau R AD - UMR INSERM 1034 University of Bordeaux, Bordeaux, France; Coronary and vascular diseases department, Bordeaux University Hospital-Haut-Leveque; INI-CRCT Network. LA - eng PT - Journal Article PT - Multicenter Study PT - Observational Study DEP - 20250429 PL - Netherlands TA - Int J Antimicrob Agents JT - International journal of antimicrobial agents JID - 9111860 RN - 0 (Anti-Bacterial Agents) SB - IM MH - Aged MH - Aged, 80 and over MH - Female MH - Humans MH - Male MH - Middle Aged MH - *Anti-Bacterial Agents/therapeutic use/adverse effects MH - *Endocarditis, Bacterial/drug therapy/microbiology MH - France MH - *Heart Valve Prosthesis/adverse effects/microbiology MH - Prospective Studies MH - *Prosthesis-Related Infections/drug therapy/microbiology MH - Staphylococcal Infections/drug therapy MH - Treatment Outcome OTO - NOTNLM OT - Frailty OT - Management OT - Medical therapy OT - Observational study OT - Prognosis COIS- Declaration of competing interest None declared. EDAT- 2025/05/02 00:28 MHDA- 2025/07/15 00:30 CRDT- 2025/05/01 19:31 PHST- 2025/01/07 00:00 [received] PHST- 2025/04/05 00:00 [revised] PHST- 2025/04/23 00:00 [accepted] PHST- 2025/07/15 00:30 [medline] PHST- 2025/05/02 00:28 [pubmed] PHST- 2025/05/01 19:31 [entrez] AID - S0924-8579(25)00083-4 [pii] AID - 10.1016/j.ijantimicag.2025.107526 [doi] PST - ppublish SO - Int J Antimicrob Agents. 2025 Sep;66(3):107526. doi: 10.1016/j.ijantimicag.2025.107526. Epub 2025 Apr 29. PMID- 40310872 OWN - NLM STAT- Publisher LR - 20250501 IS - 1539-2031 (Electronic) IS - 0192-0790 (Linking) DP - 2025 Apr 30 TI - Percutaneous Coronary Intervention in Cancer Patients: Assessing 30-Day Readmissions for Gastrointestinal Bleeding. LID - 10.1097/MCG.0000000000002194 [doi] AB - BACKGROUND: Percutaneous coronary intervention (PCI) is a procedure used to treat coronary artery disease. Cancer patients frequently present with comorbidities, including cardiovascular disease, which may necessitate PCI. However, oncologic treatments can increase the risk of complications during and after PCI. One such complication is upper gastrointestinal (GI) bleeding, which can occur due to concomitant use of anticoagulant and antiplatelet medications during PCI, as well as underlying cancer-related factors such as tumor invasion, mucosal damage, or coagulopathy. This study examined the readmission rates for nonvariceal UGI bleeding post-PCI. METHODS: This retrospective cohort study analyzed cancer patients who underwent PCI and were readmitted within 30 days for GI bleed. Data were acquired from the Nationwide Readmission Database (NRD) from 2016 to 2020 and analyzed using multivariable logistic regression. RESULTS: A total of 2,705,049 patients were included in the analysis. Eight thousand eight hundred ninty (0.3%) patients were readmitted for GI bleeding within 30 days post-PCI (P<0.001). Over the study period, there was a slight uptick in the trend of readmissions for bleeding, rising from 0.3% to 0.4%. Those readmitted were more likely to be male (P<0.001), aged more than 61 years (P<0.001), and covered by Medicare insurance (P<0.001). Notably, patients readmitted for GI bleeding within 30 days post-PCI had a significantly higher incidence of cancer diagnosis (58% with cancer vs. 29% without, P<0.001). Furthermore, the likelihood of 30-day readmission for bleeding after PCI was notably elevated in patients with active cancer compared with those without (0.66% vs. 0.19%) (P<0.001). Among cancer types, breast cancer exhibited the highest readmission rates (0.78% vs. 0.33%), followed by lung cancer (0.55% vs. 0.33%), prostate cancer (0.46% vs. 0.33%), and colorectal cancer (0.34% vs. 0.33%) (P<0.001). The average time to GI bleeding readmission ranged from 9.4 days for colorectal cancer to 13.3 days for breast cancer, with an overall average of 12.7 days across all cancer types. CONCLUSION: PCI in cancer patients presents a complex clinical scenario with a multidisciplinary approach, integrating cardiology, oncology, and gastroenterology expertise. Post-PCI, individuals with cancer face heightened susceptibility to readmissions due to bleeding events, with the degree of risk influenced by cancer type, sex, age, and active cancer. CI - Copyright (c) 2025 Wolters Kluwer Health, Inc. All rights reserved. FAU - Choday, Silpa AU - Choday S AUID- ORCID: 0000-0002-6171-7609 AD - Department of Internal Medicine, Creighton University School of Health Science. FAU - Zahdeh, Tamer AU - Zahdeh T AD - Department of Internal Medicine, Montefiore Medical Center, NY. FAU - Reddymasu, Savio AU - Reddymasu S AD - Department of Gastroenterology and Hepatology, St. Joseph Medical Center, AZ. LA - eng PT - Journal Article DEP - 20250430 PL - United States TA - J Clin Gastroenterol JT - Journal of clinical gastroenterology JID - 7910017 SB - IM OTO - NOTNLM OT - GI bleeding OT - PCI OT - cancer OT - readmissions OT - trends EDAT- 2025/05/01 18:30 MHDA- 2025/05/01 18:30 CRDT- 2025/05/01 13:33 PHST- 2024/12/17 00:00 [received] PHST- 2025/04/03 00:00 [accepted] PHST- 2025/05/01 18:30 [medline] PHST- 2025/05/01 18:30 [pubmed] PHST- 2025/05/01 13:33 [entrez] AID - 00004836-990000000-00443 [pii] AID - 10.1097/MCG.0000000000002194 [doi] PST - aheadofprint SO - J Clin Gastroenterol. 2025 Apr 30. doi: 10.1097/MCG.0000000000002194. PMID- 40310329 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251205 LR - 20260122 IS - 2772-963X (Electronic) IS - 2772-963X (Linking) VI - 4 IP - 11 Pt 2 DP - 2025 Nov TI - Moving Beyond the Perfect Donor: An Interdisciplinary Approach to Optimizing Donor Utilization. PG - 101712 LID - S2772-963X(25)00129-2 [pii] LID - 10.1016/j.jacadv.2025.101712 [doi] LID - 101712 AB - BACKGROUND: Despite a growing demand for donor hearts, more than two-thirds of viable hearts are discarded in North America. Our initiative sought to improve donor heart utilization by reviewing institutional donor acceptance practices and implementing targeted interventions. OBJECTIVES: Our aim was to increase donor heart utilization rate to 20% and reduce the rate of missed viable opportunities to 50%, age <45 years, ischemic time <4 hours, and /= 65 years undergoing non-cardiac surgery with intermediate or high surgical risk and preoperative N-terminal pro-brain natriuretic peptide levels >/= 450 pg/mL, will reduce postoperative morbidity. The preoperative evaluation includes clinical evaluations by anaesthesiologists and cardiologists, electrocardiography and echocardiography, as well as a discussion of these findings by a perioperative management team, where all involved specialities, including the speciality surgeon, will decide the perioperative treatment strategy for each patient. Intraoperative strategies include individualised haemodynamic optimisation. The interdisciplinary team and specialised HF nurses will screen patients for HF-related postoperative complications. The primary end point will be a composite morbidity end point, comprising any rehospitalisation, acute kidney injury, suspected or proven bacterial infection requiring treatment and acute decompensated HF at postoperative day 90. CONCLUSION: The new treatment form can potentially reduce the morbidity burden after major non-cardiac surgery in patients with known or unknown HF. If the PeriOP-CARE HF trial yields positive results, the treatment of patients with HF undergoing major non-cardiac surgery could be considerably improved. TRIAL REGISTRATION: clinicaltrials.gov: NCT06381427, registered April 24, 2024. CI - (c) 2025. The Author(s). CN - PeriOP-CARE HF study group LA - eng SI - ClinicalTrials.gov/NCT06381427 GR - 01NVF22109/Gemeinsame Bundesausschuss/ PT - Clinical Trial Protocol PT - Journal Article DEP - 20250429 PL - Germany TA - Clin Res Cardiol JT - Clinical research in cardiology : official journal of the German Cardiac Society JID - 101264123 SB - IM MH - Aged MH - Female MH - Humans MH - Male MH - Germany/epidemiology MH - *Heart Failure/therapy/complications/physiopathology/diagnosis MH - Multicenter Studies as Topic MH - *Patient Care Team MH - *Perioperative Care/methods MH - *Postoperative Complications/prevention & control/epidemiology MH - Prospective Studies MH - Randomized Controlled Trials as Topic MH - Risk Assessment MH - Risk Factors MH - *Surgical Procedures, Operative/adverse effects PMC - PMC12058920 OTO - NOTNLM OT - Acute decompensated heart failure OT - Acute kidney injury OT - Brain natriuretic peptide OT - Infection OT - Preoperative OT - Rehospitalisation COIS- Declarations. Conflict of interest: All authors certify that they have no affiliations with or involvement in any organisation or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript. Ethical approval: The study was approved by the local ethics committee of the medical faculty of the Justus-Liebig-University, Giessen, Germany (AZ 73/22). FIR - Schmidt, Gotz Friedrich IR - Schmidt GF FIR - Habicher, Marit IR - Habicher M FIR - Herrmann, Ester Judith IR - Herrmann EJ FIR - Kenz, Manuel IR - Kenz M FIR - Reichert, Martin IR - Reichert M FIR - Koch, Christian IR - Koch C FIR - Markmann, Melanie IR - Markmann M FIR - Schneck, Emmanuel IR - Schneck E FIR - Assmus, Birgit IR - Assmus B FIR - Sander, Michael IR - Sander M FIR - Frey, Ulrich IR - Frey U FIR - Guder, Gulmisal IR - Guder G FIR - Meybohm, Patrick IR - Meybohm P FIR - Reuter, Daniel IR - Reuter D FIR - Saugel, Bernd IR - Saugel B FIR - Treskatsch, Sascha IR - Treskatsch S FIR - Heuschmann, Peter Ulrich IR - Heuschmann PU FIR - Nuernberger, Carolin IR - Nuernberger C FIR - Reese, Jens Peter IR - Reese JP FIR - Widmann, Jonas IR - Widmann J FIR - Rucker, Viktoria IR - Rucker V FIR - Asgarpur, Golschan IR - Asgarpur G FIR - Aldarwish, Saeed IR - Aldarwish S FIR - Beyer, Katharina IR - Beyer K FIR - Buchmann, Nikolaus IR - Buchmann N FIR - Flemming, Sven IR - Flemming S FIR - Germer, Christoph-Thomas IR - Germer CT FIR - Greiner, Andreas IR - Greiner A FIR - Grundmann, Carla Davina IR - Grundmann CD FIR - Hackert, Thilo IR - Hackert T FIR - Hecker, Andreas IR - Hecker A FIR - Kouz, Karim IR - Kouz K FIR - Landmesser, Ulf IR - Landmesser U FIR - Loser, Benjamin L IR - Loser BL FIR - Lehmacher, Jonas IR - Lehmacher J FIR - Mardian, Sven IR - Mardian S FIR - Neumann, Johannes Tobias IR - Neumann JT FIR - Oner, Alper IR - Oner A FIR - Riese, Thorsten IR - Riese T FIR - Sasko, Benjamin IR - Sasko B FIR - Stork, Stefan IR - Stork S FIR - Ukena, Christian IR - Ukena C FIR - Welsch, Thilo IR - Welsch T FIR - Willis, Franziska IR - Willis F FIR - Zitzmann, Amelie IR - Zitzmann A EDAT- 2025/04/29 12:41 MHDA- 2025/05/08 11:14 PMCR- 2025/04/29 CRDT- 2025/04/29 11:15 PHST- 2024/07/24 00:00 [received] PHST- 2025/02/23 00:00 [accepted] PHST- 2025/05/08 11:14 [medline] PHST- 2025/04/29 12:41 [pubmed] PHST- 2025/04/29 11:15 [entrez] PHST- 2025/04/29 00:00 [pmc-release] AID - 10.1007/s00392-025-02626-3 [pii] AID - 2626 [pii] AID - 10.1007/s00392-025-02626-3 [doi] PST - ppublish SO - Clin Res Cardiol. 2025 May;114(5):523-531. doi: 10.1007/s00392-025-02626-3. Epub 2025 Apr 29. PMID- 40295083 OWN - NLM STAT- MEDLINE DCOM- 20250429 LR - 20250428 IS - 1539-2880 (Electronic) IS - 0730-0832 (Linking) VI - 44 IP - 2 DP - 2025 Apr 1 TI - A Comprehensive and Collaborative Approach to Improving Small Baby Care and Outcomes. PG - 94-106 LID - 10.1891/NN-2024-0050 [doi] AB - Extremely preterm infants (EPIs) require complex management because of structural and functional organ immaturity leading to unique medical needs and evolving approaches throughout their NICU course because of changes in physiology. A comprehensive approach to care for these small babies is essential, as changes in management of one organ system can have downstream effects on others. This care plan ideally begins before delivery and involves a multidisciplinary team developing the initial plan of care based on individual patient factors and continues to evolve. Because of the complexity of these fragile patients, multidisciplinary guidelines developed by a team with expertise in caring for EPIs can lead to improved care and outcomes. Additionally, multicenter collaboration to share knowledge and experience, work together on research and quality improvement initiatives, and discuss complicated cases is essential because of the relatively small numbers of these tiniest patients at each individual site. CI - (c) 2025 Springer Publishing Company. FAU - Pavlek, Leeann R AU - Pavlek LR FAU - Lopata, Susan M AU - Lopata SM FAU - Halling, Cecilie AU - Halling C FAU - Armbruster, Debra AU - Armbruster D FAU - Jebbia, Maria R AU - Jebbia MR LA - eng PT - Journal Article PL - United States TA - Neonatal Netw JT - Neonatal network : NN JID - 8503921 SB - IM MH - Humans MH - Infant, Newborn MH - *Neonatal Nursing/standards/organization & administration MH - *Quality Improvement MH - *Patient Care Team/organization & administration MH - *Intensive Care, Neonatal/standards/organization & administration/methods MH - *Infant, Extremely Premature MH - Intensive Care Units, Neonatal/organization & administration MH - Female MH - Cooperative Behavior OTO - NOTNLM OT - NICU care OT - cardiac OT - evidence-based practice OT - family OT - fetal/maternal OT - physiology/pathophysiology OT - respiratory/ventilation OT - resuscitation/stabilization EDAT- 2025/04/29 00:28 MHDA- 2025/04/29 06:26 CRDT- 2025/04/28 20:53 PHST- 2025/04/29 06:26 [medline] PHST- 2025/04/29 00:28 [pubmed] PHST- 2025/04/28 20:53 [entrez] AID - 44/2/94 [pii] AID - 10.1891/NN-2024-0050 [doi] PST - ppublish SO - Neonatal Netw. 2025 Apr 1;44(2):94-106. doi: 10.1891/NN-2024-0050. PMID- 40291586 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250429 IS - 2157-6998 (Print) IS - 2157-7005 (Electronic) IS - 2157-7005 (Linking) VI - 15 IP - 2 DP - 2025 Apr TI - Adverse Pregnancy Outcomes in Sjogren's Disease Compared to Controls: An Interdisciplinary Approach with Maternal-Fetal Medicine. PG - e47-e52 LID - 10.1055/a-2562-1643 [doi] AB - OBJECTIVES: Outside of the association of SS-A antibody with congenital heart block, little is known about adverse maternal and neonatal outcomes, in patients with Sjogren's disease (SjD). Our study involved collaboration with maternal-fetal medicine (MFM). METHODS: A retrospective cohort study of pregnant patients: SjD patients were matched 1:3 with non-SjD controls. SjD patients were included by meeting the 2016 ACR/EULAR Criteria or by a rheumatologist diagnosis. Exclusion criteria were concurrent autoimmune disease or related antibodies. A composite of grouped outcomes was utilized and verified by MFM specialists. The primary outcome was adverse pregnancy outcome (APO) between the two groups. Statistical analysis was performed using a two-sample t -test and Fisher's exact test. RESULTS: 48 patients were included: 12 SjD patients and 36 controls. APO was significantly increased in SjD with one preterm birth, one fetal growth restriction, and one limb anomaly; non-SjD had one cardiac anomaly. There were no cases of CHB. SjD patients were more likely to be delivered by cesarean delivery. CONCLUSION: There was an increased risk of APO in SjD patients compared with controls. No significant difference in neonatal outcomes was found. We speculate that placental pathology may play a role in pathophysiology and future studies should be performed. KEY POINTS: There was an increased risk of APO in SjD patients compared with controls.No significant difference in neonatal outcomes was found.We speculate that placental pathology may play a role in pathophysiology, prompting future studies. CI - The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. ( https://creativecommons.org/licenses/by/4.0/ ). FAU - Tesoriero, Lauren AU - Tesoriero L AD - Division of Rheumatology, Department of Internal Medicine, NYU Langone Hospital, Long Island, Mineola, New York. AD - NYU Long Island School of Medicine, Mineola, New York. FAU - Kidd, Jennifer AU - Kidd J AD - Northwell Health New Hyde Park, New York. AD - Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Uniondale, Uniondale, New York. AD - Department of Obstetrics and Gynecology, Long Island Jewish Medical Center, New Hyde Park, New York. FAU - Piccione, Julie AU - Piccione J AD - Division of Rheumatology, Department of Internal Medicine, NYU Langone Hospital, Long Island, Mineola, New York. AD - NYU Long Island School of Medicine, Mineola, New York. FAU - Izmirly, Peter AU - Izmirly P AD - Division of Rheumatology, NYU Langone Health, New York, New York. AD - NYU Grossman School of Medicine New York, New York. FAU - Akerman, Meredith AU - Akerman M AD - NYU Long Island School of Medicine, Mineola, New York. FAU - Carsons, Steven AU - Carsons S AD - Division of Rheumatology, Department of Internal Medicine, NYU Langone Hospital, Long Island, Mineola, New York. AD - NYU Long Island School of Medicine, Mineola, New York. FAU - Rekawek, Patricia AU - Rekawek P AUID- ORCID: 0000-0003-4648-0583 AD - NYU Long Island School of Medicine, Mineola, New York. AD - Department of Maternal Fetal Medicine, NYU Langone Hospital, Long Island, Mineola, New York. FAU - Nusbaum, Julie AU - Nusbaum J AD - Division of Rheumatology, Department of Internal Medicine, NYU Langone Hospital, Long Island, Mineola, New York. AD - NYU Long Island School of Medicine, Mineola, New York. LA - eng PT - Journal Article DEP - 20250408 PL - United States TA - AJP Rep JT - AJP reports JID - 101569862 PMC - PMC12020534 OTO - NOTNLM OT - SS-A OT - SS-B antibodies OT - Sjogren's disease OT - adverse pregnancy outcomes OT - autoimmune disease COIS- Conflict of Interest None declared. EDAT- 2025/04/28 17:04 MHDA- 2025/04/28 17:05 PMCR- 2025/04/01 CRDT- 2025/04/28 06:33 PHST- 2025/01/07 00:00 [received] PHST- 2025/02/27 00:00 [accepted] PHST- 2025/04/28 17:05 [medline] PHST- 2025/04/28 17:04 [pubmed] PHST- 2025/04/28 06:33 [entrez] PHST- 2025/04/01 00:00 [pmc-release] AID - AJPR-25-Jan-0004 [pii] AID - 10.1055/a-2562-1643 [doi] PST - epublish SO - AJP Rep. 2025 Apr 8;15(2):e47-e52. doi: 10.1055/a-2562-1643. eCollection 2025 Apr. PMID- 40288730 OWN - NLM STAT- MEDLINE DCOM- 20250729 LR - 20260505 IS - 1552-6259 (Electronic) IS - 0003-4975 (Linking) VI - 120 IP - 2 DP - 2025 Aug TI - Engaging the Next Generation: Evaluating the Long-term Success of a Premedical Program in Cardiothoracic Surgery. PG - 393-400 LID - S0003-4975(25)00341-8 [pii] LID - 10.1016/j.athoracsur.2025.04.007 [doi] AB - BACKGROUND: Early exposure to surgical specialties positively influences students' perceptions of and interest in surgical careers, particularly at the preclinical and premedical stages. This study sought to evaluate the long-term academic and career impacts of a structured, short-term undergraduate elective in cardiothoracic (CT) surgery. METHODS: A retrospective study of participants who completed the Cardiothoracic Surgery Intersession (CTIS) program from 2003 to 2019 was conducted. Former participants were surveyed to assess perceptions of program impact on academic and career pursuits. Medical school matriculation and residency specialty data were obtained through the Association of American Medical Colleges database and an online search. Qualitative data were manually coded, and quantitative data were analyzed using descriptive statistics. RESULTS: Sixty-eight undergraduates participated in the CTIS program; 66 (97%) subsequently matriculated to medical school. Of 61 participants who have entered residency, 24 (39%) pursued surgical specialties, and 5 (8%) pursued CT surgery specifically. Survey completion rate was 49% (33 of 68). Most respondents found operating room shadowing (97%), cardiac case conferences (73%), and suturing workshops (58%) particularly valuable program components. Additionally, 94% of respondents indicated the CTIS program was moderately, very, or extremely important in influencing their decision to pursue their long-term academic and career paths. CONCLUSIONS: Structured, intensive early exposure programs in CT surgery meaningfully influence undergraduate students' long-term academic and career trajectories. Programs that integrate students into the day-to-day life of CT surgeons effectively attract talented students to CT surgery and medicine broadly, thereby addressing anticipated workforce challenges within the specialty. CI - Copyright (c) 2025 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved. FAU - Rizaldi, Alexandra A AU - Rizaldi AA AD - Division of Cardiac Surgery, Department of Surgery, Johns Hopkins Hospital, Baltimore, Maryland. FAU - Larson, Emily L AU - Larson EL AD - Division of Cardiac Surgery, Department of Surgery, Johns Hopkins Hospital, Baltimore, Maryland. FAU - Zhou, Alice L AU - Zhou AL AD - Division of Cardiac Surgery, Department of Surgery, Johns Hopkins Hospital, Baltimore, Maryland. FAU - Alejo, Diane E AU - Alejo DE AD - Division of Cardiac Surgery, Department of Surgery, Johns Hopkins Hospital, Baltimore, Maryland. FAU - Wang, Hanghang AU - Wang H AD - Division of Cardiac Surgery, Department of Surgery, Johns Hopkins Hospital, Baltimore, Maryland. FAU - Baumgartner, William A AU - Baumgartner WA AD - Division of Cardiac Surgery, Department of Surgery, Johns Hopkins Hospital, Baltimore, Maryland. FAU - Sussman, Marc S AU - Sussman MS AD - Division of Cardiac Surgery, Department of Surgery, Johns Hopkins Hospital, Baltimore, Maryland. Electronic address: msussma1@jhmi.edu. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20250425 PL - Netherlands TA - Ann Thorac Surg JT - The Annals of thoracic surgery JID - 15030100R SB - IM MH - Humans MH - Retrospective Studies MH - *Career Choice MH - *Thoracic Surgery/education MH - Female MH - Male MH - *Education, Medical, Undergraduate/methods MH - *Education, Premedical/methods MH - Internship and Residency MH - Adult MH - Time Factors MH - United States COIS- Disclosures The authors have no conflicts of interest to disclose. EDAT- 2025/04/28 00:27 MHDA- 2025/07/29 18:32 CRDT- 2025/04/27 19:35 PHST- 2024/11/19 00:00 [received] PHST- 2025/03/21 00:00 [revised] PHST- 2025/04/17 00:00 [accepted] PHST- 2025/07/29 18:32 [medline] PHST- 2025/04/28 00:27 [pubmed] PHST- 2025/04/27 19:35 [entrez] AID - S0003-4975(25)00341-8 [pii] AID - 10.1016/j.athoracsur.2025.04.007 [doi] PST - ppublish SO - Ann Thorac Surg. 2025 Aug;120(2):393-400. doi: 10.1016/j.athoracsur.2025.04.007. Epub 2025 Apr 25. PMID- 40283183 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250428 IS - 2075-1729 (Print) IS - 2075-1729 (Electronic) IS - 2075-1729 (Linking) VI - 15 IP - 4 DP - 2025 Apr 9 TI - From Joints to the Heart: An Integrated Perspective on Systemic Inflammation. LID - 10.3390/life15040629 [doi] LID - 629 AB - BACKGROUND: Rheumatoid arthritis (RA) is an autoimmune inflammatory disease which predominantly affects joints, but it can also lead to significant extra-articular complications, particularly cardiovascular disease (CVD). Chronic systemic inflammation promotes endothelial dysfunction and accelerates atherosclerosis, increasing cardiovascular risk. METHODS: Current data were analyzed to explore the mechanisms between RA and CVD, focusing on systemic inflammation, pro-inflammatory cytokine patways (IL-1, IL-6, TNF, and JAK-STAT), and their interactions with traditional cardiovascular risk factors. Recent studies and clinical guidelines were reviewed to highlight gaps and advances in risk assessment and management. RESULTS: Persistent disease activity and the presence of autoantibodies significantly increase cardiovascular risk in RA contributing to atherosclerosis and major cardiovascular events. Data also suggest that anti-inflammatory treatments, including methotrexate and biologic agents, may lower this risk. CONCLUSION: This review highlights the pathophysiological mechanisms between RA and CVD, and the need for early diagnosis and active monitoring to identify and assess cardiovascular risk. A multidisciplinary approach, involving rheumatologists and cardiologists is essential for optimizing cardiovascular risk management and improving patient outcomes. Optimization of cardiovascular risk management strategies in patients with RA should be an essential component of current medical practice, with the main goal of reducing morbidity and mortality from cardiovascular complications. FAU - Cosau, Diana Elena AU - Cosau DE AD - Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania. AD - Clinical Rehabilitation Hospital, 700661 Iasi, Romania. FAU - Costache Enache, Irina Iuliana AU - Costache Enache II AD - Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania. AD - "St. Spiridon" Emergency County Hospital, 700111 Iasi, Romania. FAU - Costache, Alexandru Dan AU - Costache AD AUID- ORCID: 0000-0001-8544-9904 AD - Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania. AD - Clinical Rehabilitation Hospital, 700661 Iasi, Romania. FAU - Tudorancea, Ionut AU - Tudorancea I AUID- ORCID: 0000-0002-4956-2595 AD - Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania. AD - "St. Spiridon" Emergency County Hospital, 700111 Iasi, Romania. FAU - Ancuta, Codrina AU - Ancuta C AUID- ORCID: 0000-0002-1777-8121 AD - Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania. AD - Clinical Rehabilitation Hospital, 700661 Iasi, Romania. FAU - Serban, Dragomir Nicolae AU - Serban DN AD - Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania. FAU - Badescu, Codruta Minerva AU - Badescu CM AUID- ORCID: 0000-0001-8942-1909 AD - Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania. AD - "St. Spiridon" Emergency County Hospital, 700111 Iasi, Romania. FAU - Loghin, Catalin AU - Loghin C AD - Department of Internal Medicine, Cardiology Division, University of Texas Health Science Center, Houston, TX 77030, USA. FAU - Serban, Ionela Lacramioara AU - Serban IL AD - Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania. LA - eng PT - Journal Article PT - Review DEP - 20250409 PL - Switzerland TA - Life (Basel) JT - Life (Basel, Switzerland) JID - 101580444 PMC - PMC12028888 OTO - NOTNLM OT - atherosclerosis OT - autoantibodies multidisciplinary approach OT - cardiovascular disease OT - endothelial dysfunction OT - pro-inflammatory cytokines OT - rheumatoid arthritis OT - systemic inflammation COIS- The authors declare no conflicts of interest. EDAT- 2025/04/26 16:06 MHDA- 2025/04/26 16:07 PMCR- 2025/04/09 CRDT- 2025/04/26 01:11 PHST- 2025/02/27 00:00 [received] PHST- 2025/03/31 00:00 [revised] PHST- 2025/04/07 00:00 [accepted] PHST- 2025/04/26 16:07 [medline] PHST- 2025/04/26 16:06 [pubmed] PHST- 2025/04/26 01:11 [entrez] PHST- 2025/04/09 00:00 [pmc-release] AID - life15040629 [pii] AID - life-15-00629 [pii] AID - 10.3390/life15040629 [doi] PST - epublish SO - Life (Basel). 2025 Apr 9;15(4):629. doi: 10.3390/life15040629. PMID- 40283129 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250428 IS - 2075-1729 (Print) IS - 2075-1729 (Electronic) IS - 2075-1729 (Linking) VI - 15 IP - 4 DP - 2025 Apr 1 TI - Optimizing Revascularization in Ischemic Cardiomyopathy: Comparative Evidence on the Benefits and Indications of CABG and PCI. LID - 10.3390/life15040575 [doi] LID - 575 AB - Ischemic cardiomyopathy remains a leading cause of heart failure, yet the optimal revascularization approach for patients with reduced left ventricular function remains uncertain. This review synthesizes current evidence on coronary revascularization strategies, emphasizing real-world applicability and individualized treatment. It critically evaluates the benefits and limitations of coronary artery bypass grafting [CABG] and percutaneous coronary intervention [PCI], highlighting key knowledge gaps. Findings from the STICH trial demonstrate that CABG improves long-term survival despite an elevated early procedural risk, particularly in patients with extensive multivessel disease. In contrast, the REVIVED-BCIS2 trial suggests that PCI enhances quality of life but does not significantly reduce mortality compared to optimal medical therapy, making it a viable alternative for high-risk patients ineligible for surgery. This review underscores the role of advanced imaging techniques in myocardial viability assessment and emphasizes the importance of comprehensive risk stratification in guiding revascularization decisions. Special attention is given to managing high-risk patients unsuitable for CABG and the potential benefits of PCI in symptom relief despite uncertain survival benefits. A stepwise algorithm is proposed to assist clinicians in tailoring revascularization strategies, reinforcing the need for a multidisciplinary Heart Team approach to optimize outcomes. FAU - Prunea, Dan M AU - Prunea DM AUID- ORCID: 0000-0003-3843-6670 AD - Medical Clinic No. 1, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400006 Cluj-Napoca, Romania. FAU - Homorodean, Calin AU - Homorodean C AD - Medical Clinic No. 1, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400006 Cluj-Napoca, Romania. AD - Cluj County Emergency Clinical Hospital, 3-5, Clinicilor Street, 400006 Cluj-Napoca, Romania. FAU - Olinic, Maria AU - Olinic M AD - Medical Clinic No. 1, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400006 Cluj-Napoca, Romania. AD - Cluj County Emergency Clinical Hospital, 3-5, Clinicilor Street, 400006 Cluj-Napoca, Romania. FAU - Achim, Alexandru AU - Achim A AUID- ORCID: 0000-0002-5540-3478 AD - "Niculae Stancioiu" Heart Institute, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400001 Cluj-Napoca, Romania. FAU - Olinic, Dan-Mircea AU - Olinic DM AUID- ORCID: 0000-0002-1886-9375 AD - Medical Clinic No. 1, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400006 Cluj-Napoca, Romania. AD - Cluj County Emergency Clinical Hospital, 3-5, Clinicilor Street, 400006 Cluj-Napoca, Romania. LA - eng PT - Journal Article PT - Review DEP - 20250401 PL - Switzerland TA - Life (Basel) JT - Life (Basel, Switzerland) JID - 101580444 PMC - PMC12028861 OTO - NOTNLM OT - REVIVED OT - STICH OT - coronary artery bypass grafting OT - heart failure OT - ischemic cardiomyopathy OT - left ventricular dysfunction OT - myocardial revascularization OT - myocardial viability OT - percutaneous coronary intervention COIS- The authors declare no conflicts of interest. EDAT- 2025/04/26 16:09 MHDA- 2025/04/26 16:10 PMCR- 2025/04/01 CRDT- 2025/04/26 01:11 PHST- 2025/02/28 00:00 [received] PHST- 2025/03/23 00:00 [revised] PHST- 2025/03/29 00:00 [accepted] PHST- 2025/04/26 16:10 [medline] PHST- 2025/04/26 16:09 [pubmed] PHST- 2025/04/26 01:11 [entrez] PHST- 2025/04/01 00:00 [pmc-release] AID - life15040575 [pii] AID - life-15-00575 [pii] AID - 10.3390/life15040575 [doi] PST - epublish SO - Life (Basel). 2025 Apr 1;15(4):575. doi: 10.3390/life15040575. PMID- 40278215 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260924 IS - 2308-3425 (Electronic) IS - 2308-3425 (Linking) VI - 12 IP - 4 DP - 2025 Apr 14 TI - The Prenatal Diagnosis and Perinatal Management of Congenital Long QT Syndrome: A Comprehensive Literature Review and Recent Updates. LID - 10.3390/jcdd12040156 [doi] LID - 156 AB - Congenital long QT syndrome (LQTS) is a group of heritable conditions that are associated with cardiac repolarization abnormalities characterized by QT prolongation on electrocardiogram and the risk of life-threatening arrhythmias. The prenatal detection of LQTS presents significant challenges for clinicians, and a multidisciplinary approach is required for optimal prenatal and postnatal management. In this comprehensive literature review, we describe strategies for the fetal diagnosis of LQTS with variable initial presentation, genetic testing in suspected fetal LQTS, the utility of fetal magnetocardiography as an additional diagnostic tool, prenatal management, and postnatal treatment. We focus on a multidisciplinary team approach including fetal cardiology, adult and pediatric electrophysiology, neonatology, maternal-fetal medicine, and genetic counselors, all playing vital roles in the comprehensive prenatal management and orchestration of postnatal treatment to optimize neonatal outcomes. FAU - Samples, Stefani AU - Samples S AUID- ORCID: 0000-0002-2906-0651 AD - Division of Pediatric Cardiology, Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. FAU - Cherny, Sara AU - Cherny S AD - Division of Pediatric Cardiology, Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. FAU - Madan, Nitin AU - Madan N AD - Division of Pediatric Cardiology, Children's Mercy Kansas City, Ward Family Heart Center, UMKC School of Medicine, Kansas City, MO 64108, USA. FAU - Hong, Jeff AU - Hong J AD - Division of Pediatric Cardiology, Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. FAU - Mansukhani, Sheena A AU - Mansukhani SA AD - Division of Pediatric Cardiology, Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. FAU - Strasburger, Janette F AU - Strasburger JF AUID- ORCID: 0000-0002-6986-2544 AD - Division of Cardiology, Department of Pediatrics and Biomedical Engineering, Children's Wisconsin, Herma Heart Institute, Medical College of Wisconsin, Milwaukee, WI 26509, USA. FAU - Carr, Michael R AU - Carr MR AUID- ORCID: 0000-0003-0345-0341 AD - Division of Pediatric Cardiology, Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. FAU - Patel, Sheetal R AU - Patel SR AUID- ORCID: 0000-0003-4257-1103 AD - Division of Pediatric Cardiology, Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. LA - eng PT - Journal Article PT - Review DEP - 20250414 PL - Switzerland TA - J Cardiovasc Dev Dis JT - Journal of cardiovascular development and disease JID - 101651414 PMC - PMC12027825 OTO - NOTNLM OT - arrhythmia OT - electrophysiology OT - fetal echocardiography OT - fetal magnetocardiography OT - genetics OT - inherited arrhythmia syndrome COIS- The authors declare no conflicts of interest. Strasburger would like to acknowledge three grants not directly related to this review: NIH R01HL143485, NIH R01HL063174, NIH R44HL160257. EDAT- 2025/04/25 13:47 MHDA- 2025/04/25 13:48 PMCR- 2025/04/14 CRDT- 2025/04/25 10:04 PHST- 2025/03/19 00:00 [received] PHST- 2025/04/07 00:00 [revised] PHST- 2025/04/10 00:00 [accepted] PHST- 2025/04/25 13:48 [medline] PHST- 2025/04/25 13:47 [pubmed] PHST- 2025/04/25 10:04 [entrez] PHST- 2025/04/14 00:00 [pmc-release] AID - jcdd12040156 [pii] AID - jcdd-12-00156 [pii] AID - 10.3390/jcdd12040156 [doi] PST - epublish SO - J Cardiovasc Dev Dis. 2025 Apr 14;12(4):156. doi: 10.3390/jcdd12040156. PMID- 40278186 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250427 IS - 2308-3425 (Electronic) IS - 2308-3425 (Linking) VI - 12 IP - 4 DP - 2025 Mar 31 TI - Frailty in Cardiac Surgery-Assessment Tools, Impact on Outcomes, and Optimisation Strategies: A Narrative Review. LID - 10.3390/jcdd12040127 [doi] LID - 127 AB - BACKGROUND: Advancements in surgical care have made it possible to offer cardiac surgery to an older and frailer patient cohort. Frailty has been recognised as a prognostic indicator that impacts post-operative recovery and patient outcomes. The aim of this study is to identify frailty assessment tools, evaluate the impact of frailty on post-operative outcomes, and explore strategies to optimise care for frail patients undergoing cardiac surgery. METHODS: A comprehensive literature search was performed across PubMed, MEDLINE, and SCOPUS to identify articles reporting post-operative outcomes related to frail patients undergoing cardiac surgery. RESULTS: Measurement tools such as gait speed, the Clinical Frailty Scale, Fried frailty phenotype, deficit accumulation frailty index and the Short Physical Performance Battery can be used to assess frailty. Frailty has been reported to increase the risk of post-operative morbidity and mortality. Multiple studies have also reported the association between frailty and an increased length of intensive care unit and hospital stays, as well as an increased risk of post-operative delirium. It is important to perform a comprehensive frailty assessment and implement perioperative optimisation strategies to improve outcomes in this patient population. Pre-operative strategies that can be considered include adequate nutritional support, cardiac prehabilitation, and assessing patients using a multidisciplinary team approach with geriatric involvement. Post-operatively, interventions such as early recognition and treatment of post-operative delirium, nutrition optimisation, early planning for cardiac rehabilitation, and occupational therapy can support patients' recovery and reintegration into daily activities. CONCLUSIONS: The early identification of frail patients during the perioperative period is essential for risk stratification and tailored management strategies to minimise the impact of frailty on outcomes following cardiac surgery. FAU - Chandiramani, Ashwini AU - Chandiramani A AD - Department of Cardiology, Royal Papworth Hospital, Cambridge, CB2 0AY, UK. FAU - Ali, Jason M AU - Ali JM AUID- ORCID: 0000-0003-2146-0711 AD - Department of Cardiac Surgery, Royal Papworth Hospital, Cambridge, CB2 0AY, UK. LA - eng PT - Journal Article PT - Review DEP - 20250331 PL - Switzerland TA - J Cardiovasc Dev Dis JT - Journal of cardiovascular development and disease JID - 101651414 PMC - PMC12028191 OTO - NOTNLM OT - cardiac surgery OT - frailty OT - optimisation OT - perioperative interventions COIS- The authors declare no conflicts of interest. EDAT- 2025/04/25 13:46 MHDA- 2025/04/25 13:47 PMCR- 2025/03/31 CRDT- 2025/04/25 10:04 PHST- 2025/01/21 00:00 [received] PHST- 2025/03/08 00:00 [revised] PHST- 2025/03/17 00:00 [accepted] PHST- 2025/04/25 13:47 [medline] PHST- 2025/04/25 13:46 [pubmed] PHST- 2025/04/25 10:04 [entrez] PHST- 2025/03/31 00:00 [pmc-release] AID - jcdd12040127 [pii] AID - jcdd-12-00127 [pii] AID - 10.3390/jcdd12040127 [doi] PST - epublish SO - J Cardiovasc Dev Dis. 2025 Mar 31;12(4):127. doi: 10.3390/jcdd12040127. PMID- 40276444 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250426 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 17 IP - 3 DP - 2025 Mar TI - Virtual Reality Simulation in Interprofessional Pediatric Cardiology Education. PG - e81181 LID - 10.7759/cureus.81181 [doi] LID - e81181 AB - Introduction In acute care settings, pediatric congenital heart patients require comprehensive team-based care. Physicians and advanced practice providers (APPs) co-manage these patients in the same manner. However, there may be few opportunities to train together. Virtual reality (VR) simulation in the pediatric cardiology setting offers a portable, immersive experience and can be a cost-saving alternative to traditional manikin-based simulation. We sought to study the effectiveness of VR as a tool for providing interprofessional education to physicians and APPs working with cardiology patients in both the cardiac intensive care unit (CICU) and the emergency department (ED). Methods Physicians and APP pairs who clinically manage pediatric cardiology patients in the emergency department, cardiology acute care, and CICUs were identified to participate in two of eight VR simulations developed by a stand-alone pediatric hospital. The APP specialty was used to determine the appropriate selection of simulations for each provider pair. Four scenarios were designed in a virtual CICU, and four were in a virtual ED. Each physician-APP pair met for one hour, during which a 10-minute orientation, a five- to 10-minute simulation, a 10-minute debrief, and a second simulation were conducted. Each simulation was based on actual clinical situations, including five priority objectives for patient management to be met in five minutes or less, and whether a physician or APP initiated each objective was recorded. Following the VR simulations, participants completed a debrief and exit questionnaire. Results Seventeen physician-APP pairs participated in 33 simulations. An average of 3.4 objectives were met across all scenarios. Of the objectives met, 41% were initiated by an APP. Thirty-one participants completed post-simulation surveys. All agreed or strongly agreed that the VR environment enhanced their simulation experience and believed VR-based simulation could be useful for education in various pediatric settings. Conclusion Virtual reality simulation offers an immersive educational experience for providers across different professions within a pediatric cardiology setting. Further endeavors include evaluating bedside nurses' use of VR and comparing the use of VR with manikin-based approaches. CI - Copyright (c) 2025, Ring et al. FAU - Ring, Lisa M AU - Ring LM AD - Advanced Practice Providers, Children's National Hospital, Washington, DC, USA. AD - Pediatrics, George Washington University School of Medicine and Health Sciences, Washington, DC, USA. FAU - DeBitetto, Juliana AU - DeBitetto J AD - Pediatrics, George Washington University School of Medicine and Health Sciences, Washington, DC, USA. FAU - Cheng, Jenhao J AU - Cheng JJ AD - Quality and Patient Safety, Children's National Hospital, Washington, DC, USA. FAU - Yurasek, Gregory K AU - Yurasek GK AD - Cardiac Critical Care, Children's National Hospital, Washington, DC, USA. AD - Pediatrics, George Washington University School of Medicine and Health Sciences, Washington, DC, USA. LA - eng PT - Journal Article DEP - 20250325 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC12021375 OTO - NOTNLM OT - advanced practice providers OT - pediatric cardiology OT - simulation-based continuing education (sbce) OT - virtual reality simulation OT - 
pediatric COIS- Human subjects: Consent for treatment and open access publication was obtained or waived by all participants in this study. Childrens National Hospital's Institutional Review Board (IRB) issued approval (PR000015161). Based on the information submitted, this is a project undertaken as a Quality Improvement Initiative at Children's National Hospital and does not constitute human subjects research. As such, the project does not require oversight by the IRB. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: We have a contract with SimX(c) at the hospital level. No one on the team has a financial interest in or is employed by SimX(c). EDAT- 2025/04/25 06:27 MHDA- 2025/04/25 06:28 PMCR- 2025/03/25 CRDT- 2025/04/25 04:42 PHST- 2025/03/19 00:00 [accepted] PHST- 2025/04/25 06:28 [medline] PHST- 2025/04/25 06:27 [pubmed] PHST- 2025/04/25 04:42 [entrez] PHST- 2025/03/25 00:00 [pmc-release] AID - 10.7759/cureus.81181 [doi] PST - epublish SO - Cureus. 2025 Mar 25;17(3):e81181. doi: 10.7759/cureus.81181. eCollection 2025 Mar. PMID- 40274291 OWN - NLM STAT- MEDLINE DCOM- 20250724 LR - 20250728 IS - 2055-5822 (Electronic) IS - 2055-5822 (Linking) VI - 12 IP - 4 DP - 2025 Aug TI - Microaxial pump-supported coronary surgery without CPB to optimize outcome in severely impaired left ventricles. PG - 2749-2758 LID - 10.1002/ehf2.15261 [doi] AB - AIMS: Cardiopulmonary bypass (CPB) is the standard approach for coronary artery bypass grafting (CABG) in advanced ischaemic cardiomyopathy. Microaxial pump support has been envisioned to allow for beating-heart CABG without CPB (MPCAB), thereby avoiding CPB-inherent complications. This study aims to compare the in-hospital and follow-up outcome of MPCAB versus CPB-CABG in patients with severely impaired left ventricular function. METHODS AND RESULTS: Eleven patients suffering from three-vessel coronary artery disease with median ejection fraction of 27% and deemed appropriate for CABG according to a heart team decision underwent MPCAB (support up to 5.5 L/min). Propensity score matching generated a CPB-CABG control group (n = 33). The primary endpoint was defined as death from any cause by the end of the follow-up (up to 4 years). MPCAB enabled continuous intraoperative and postoperative haemodynamic stabilization and complete myocardial revascularization. After CPB-CABG, additional mechanical circulatory support was required in 45.5% (vs. 9.1% in MPCAB; P = 0.0363). The follow-up all-cause mortality after MPCAB amounted to 0% (vs. 33.3% after CPB-CABG; P = 0.0414; NNT = 3). MPCAB patients showed a significantly decreased occurrence of major adverse cardiovascular events (MACE: 0% vs. 39.4%; P = 0.0189). CONCLUSIONS: MPCAB allows for complete surgical revascularization without the necessity of extracorporeal circulation in spite of severely impaired left ventricular function. This first comparative study on the outcome after MPCAB versus CPB-CABG demonstrates a significantly decreased risk of death as well as MACE in MPCAB patients. The MPCAB concept expands the spectrum of patients eligible for CABG without CPB towards patients with severely impaired left ventricular function. CI - (c) 2025 The Author(s). ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. FAU - Assmann, Anna Kathrin AU - Assmann AK AD - Department of Cardiac Surgery, Medical Faculty, Heinrich Heine University, Duesseldorf, Germany. FAU - Arik-Doganay, Merve AU - Arik-Doganay M AD - Department of Cardiac Surgery, Medical Faculty, Heinrich Heine University, Duesseldorf, Germany. FAU - Wassenberg, Sebastian AU - Wassenberg S AD - punkt05 Statistics Consultants, Life Science Centre, Duesseldorf, Germany. FAU - Akhyari, Payam AU - Akhyari P AD - Department of Cardiac Surgery, Medical Faculty, Heinrich Heine University, Duesseldorf, Germany. AD - Department for Thoracic and Cardiovascular Surgery, University Hospital Essen, Essen, Germany. FAU - Lichtenberg, Artur AU - Lichtenberg A AD - Department of Cardiac Surgery, Medical Faculty, Heinrich Heine University, Duesseldorf, Germany. FAU - Assmann, Alexander AU - Assmann A AUID- ORCID: 0000-0003-3777-7772 AD - Department of Cardiac Surgery, Medical Faculty, Heinrich Heine University, Duesseldorf, Germany. LA - eng PT - Journal Article DEP - 20250424 PL - England TA - ESC Heart Fail JT - ESC heart failure JID - 101669191 SB - IM MH - Humans MH - Male MH - Female MH - Middle Aged MH - *Ventricular Dysfunction, Left/physiopathology/surgery MH - Follow-Up Studies MH - *Coronary Artery Bypass/methods MH - Retrospective Studies MH - Aged MH - Treatment Outcome MH - *Coronary Artery Disease/surgery/complications MH - *Ventricular Function, Left/physiology MH - *Cardiopulmonary Bypass/methods MH - *Stroke Volume/physiology MH - *Heart-Assist Devices MH - *Heart Ventricles/physiopathology/diagnostic imaging PMC - PMC12287806 OTO - NOTNLM OT - Ischaemic cardiomyopathy OT - Mechanical circulatory support OT - Microaxial pump (Impella 5) OT - Off-pump coronary artery bypass grafting OT - Severely impaired left ventricular function COIS- P.A. is PI of IMpella-Protected cArdiaC Surgery Trial and consultant for Abiomed and Medtronic. EDAT- 2025/04/25 01:21 MHDA- 2025/07/24 12:27 PMCR- 2025/04/24 CRDT- 2025/04/24 20:43 PHST- 2025/01/03 00:00 [revised] PHST- 2024/07/04 00:00 [received] PHST- 2025/02/23 00:00 [accepted] PHST- 2025/07/24 12:27 [medline] PHST- 2025/04/25 01:21 [pubmed] PHST- 2025/04/24 20:43 [entrez] PHST- 2025/04/24 00:00 [pmc-release] AID - EHF215261 [pii] AID - 10.1002/ehf2.15261 [doi] PST - ppublish SO - ESC Heart Fail. 2025 Aug;12(4):2749-2758. doi: 10.1002/ehf2.15261. Epub 2025 Apr 24. PMID- 40270852 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250425 IS - 2225-319X (Print) IS - 2304-1021 (Electronic) IS - 2225-319X (Linking) VI - 14 IP - 2 DP - 2025 Mar 31 TI - Surgical management is associated with improved survival for endocarditis after transcatheter aortic valve replacement. PG - 141-150 LID - 10.21037/acs-2024-etavr-0103 [doi] AB - BACKGROUND: Prosthetic valve endocarditis is a rare yet devastating complication following transcatheter aortic valve replacement (TAVR). This study aims to investigate the outcomes of surgical versus medical management of post-TAVR endocarditis. METHODS: Between 2011 and 2024, 67 patients with post-TAVR endocarditis were identified, comprising 24 (35.8%) patients managed surgically and 43 (64.2%) managed medically. All cases were reviewed by our multidisciplinary endocarditis team to determine the optimal treatment strategy. RESULTS: The overall incidence of post-TAVR endocarditis was 1.4%. The number of endocarditis cases increased over time from 1-2 in 2015-2018 to 18 in 2023. The most frequent source of endocarditis was unknown (32.8%), and the predominant causative organism was enterococcus species (25.4%). Notably, among the 43 medically managed patients, 19 (44.2%) exhibited surgical indications, predominantly due to large vegetations with or without embolic complications (n=11; 57.9%). The medical management group had a higher proportion of females and more frequent use of self-expandable valves compared to the surgical group. The time interval between TAVR and endocarditis diagnosis was similar across both groups. In the surgically managed cohort, isolated aortic valve replacement was uncommon, with most patients undergoing complex TAVR explantations coupled with concomitant procedures, most frequently aortic root repair (n=11; 45.8%). The 30-day and 1-year mortality rates for the three groups (surgical, medical without surgical indications, and medical with surgical indications) were 0%, 4.2%, and 31.6% (P=0.002), and 4.2%, 20.8%, and 73.7% (P<0.001), respectively. CONCLUSIONS: Surgical management was associated with significantly improved survival compared to medical management for post-TAVR endocarditis. The poor clinical outcomes in the medically managed group were primarily due to patients who did not undergo surgery despite having surgical indications. Prudent clinical judgment and timely surgical intervention when indicated are critical to enhancing the overall clinical outcomes of this challenging condition. CI - Copyright (c) 2025 AME Publishing Company. All rights reserved. FAU - Fukuhara, Shinichi AU - Fukuhara S AD - Department of Cardiac Surgery, University of Michigan, Ann Arbor, MI, USA. FAU - Suzuki, Taichi AU - Suzuki T AD - Department of Cardiac Surgery, University of Michigan, Ann Arbor, MI, USA. FAU - Deeb, G Michael AU - Deeb GM AD - Department of Cardiac Surgery, University of Michigan, Ann Arbor, MI, USA. FAU - Ailawadi, Gorav AU - Ailawadi G AD - Department of Cardiac Surgery, University of Michigan, Ann Arbor, MI, USA. FAU - Patel, Himanshu J AU - Patel HJ AD - Department of Cardiac Surgery, University of Michigan, Ann Arbor, MI, USA. FAU - Yang, Bo AU - Yang B AD - Department of Cardiac Surgery, University of Michigan, Ann Arbor, MI, USA. FAU - El-Dalati, Sami AU - El-Dalati S AD - Division of Infectious Diseases, Department of Internal Medicine, University of Kentucky College of Medicine, Lexington, KY, USA. LA - eng PT - Journal Article DEP - 20241112 PL - China TA - Ann Cardiothorac Surg JT - Annals of cardiothoracic surgery JID - 101605877 PMC - PMC12013770 OTO - NOTNLM OT - Transcatheter aortic valve replacement (TAVR) OT - aortic root abscess OT - prosthetic valve endocarditis OT - surgical aortic valve replacement (SAVR) COIS- Conflicts of Interest: S.F. serves as a consultant for Terumo Aortic, Medtronic. Edwards Lifesciences and Artivion. G.M.D. is a consultant and investigator for Medtronic. H.J.P. serves as a consultant for Medtronic Inc. G.A. serves as a consultant/advisory board member for Medtronic, Abbott, Edwards Lifesciences, and Cephea. The other authors have no conflicts of interest to declare. EDAT- 2025/04/24 12:30 MHDA- 2025/04/24 12:31 PMCR- 2025/03/31 CRDT- 2025/04/24 06:19 PHST- 2024/07/18 00:00 [received] PHST- 2024/10/01 00:00 [accepted] PHST- 2025/04/24 12:31 [medline] PHST- 2025/04/24 12:30 [pubmed] PHST- 2025/04/24 06:19 [entrez] PHST- 2025/03/31 00:00 [pmc-release] AID - acs-14-02-141 [pii] AID - 10.21037/acs-2024-etavr-0103 [doi] PST - ppublish SO - Ann Cardiothorac Surg. 2025 Mar 31;14(2):141-150. doi: 10.21037/acs-2024-etavr-0103. Epub 2024 Nov 12. PMID- 40270850 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250425 IS - 2225-319X (Print) IS - 2304-1021 (Electronic) IS - 2225-319X (Linking) VI - 14 IP - 2 DP - 2025 Mar 31 TI - The current state of redo transcatheter aortic valve replacement (TAVR) and limitations: why TAVR explant is important as the valve reintervention strategy. PG - 98-111 LID - 10.21037/acs-2024-etavr-0149 [doi] AB - The rise of transcatheter aortic valve replacement (TAVR) over the past two decades has substantially changed the lifetime management of patients with aortic valve disease. As the indications for TAVR expand to include younger and lower-risk patients, the proportion of patients who subsequently require reintervention for failed transcatheter heart valves (THVs) will increase. The two primary options for reintervention are redo TAVR and TAVR explant followed by surgical aortic valve replacement (SAVR). The indications for redo TAVR in the short term include emergency "bailout" procedures due to malpositioning, embolization, or long-term device failure due to paravalvular leak (PVL) or valvular degeneration. However, redo TAVR is not suitable for all patients. Those with prohibitive coronary anatomy, multivalvular involvement, severe patient-prosthetic mismatch, or endocarditis should be referred for TAVR explant, which is a comparatively higher-risk procedure. Redo TAVR has generally been associated with low mortality and complication rates, with key procedural considerations being valve selection [e.g., sizing, balloon-expandable valve (BEV) vs. self-expandable valve (SEV)], access, and coronary protection. TAVR explant poses numerous technical challenges, including concomitant ascending aorta or aortic root replacement, mitral valve involvement, or adhesions to the coronary ostia. Compared to redo TAVR, TAVR explant is associated with higher rates of short-term mortality and periprocedural complications. The 30-day mortality rates of TAVR explant approach 20%, and 1-year mortality rates range from 20% to 30%, with significantly greater risk associated with concomitant procedures. The data on both redo TAVR and TAVR explant are limited to observational cohorts without long-term follow-up. Given that patient populations and indications for redo TAVR and TAVR explant are vastly different, direct comparisons of outcomes between these two groups should be avoided. Nonetheless, multidisciplinary Heart Team collaboration remains imperative to advancing our knowledge of redo TAVR or TAVR explant procedures and the careful lifetime management of patients with aortic valve disease. CI - Copyright (c) 2025 AME Publishing Company. All rights reserved. FAU - Lee, Grace S AU - Lee GS AD - Division of Cardiac Surgery, University of Toronto, Toronto, ON, Canada. FAU - Tang, Gilbert AU - Tang G AD - Mount Sinai Health System, Department of Cardiovascular Surgery, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Zaid, Syed AU - Zaid S AD - Division of Cardiology, Baylor College of Medicine, Michael E. DeBakey VA Medical Center, Houston, TX, USA. FAU - Tam, Derrick Y AU - Tam DY AD - Department of Cardiac Surgery, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. LA - eng PT - Journal Article PT - Review DEP - 20250304 PL - China TA - Ann Cardiothorac Surg JT - Annals of cardiothoracic surgery JID - 101605877 PMC - PMC12013764 OTO - NOTNLM OT - Redo transcatheter aortic valve replacement (redo TAVR) OT - TAVR OT - TAVR explant OT - aortic valve replacement OT - transcatheter COIS- Conflicts of Interest: G.T. has received speaker's honoraria and served as a physician proctor, consultant, advisory board member, TAVR publications committee member, RESTORE study steering committee member, APOLLO trial screening committee member and IMPACT MR steering committee member for Medtronic; has received speaker's honoraria and served as a physician proctor, consultant, advisory board member and TRILUMINATE trial anatomic eligibility and publications committee member for Abbott Structural Heart, has served as an advisory board member for Boston Scientific and JenaValve, a consultant and physician screening committee member for Shockwave Medical, a consultant for NeoChord, Peija Medical and Shenqi Medical Technology; and has received speaker's honoraria from Siemens Healthineers. The other authors have no conflicts of interest to declare. EDAT- 2025/04/24 12:28 MHDA- 2025/04/24 12:29 PMCR- 2025/03/31 CRDT- 2025/04/24 06:19 PHST- 2024/10/01 00:00 [received] PHST- 2024/12/13 00:00 [accepted] PHST- 2025/04/24 12:29 [medline] PHST- 2025/04/24 12:28 [pubmed] PHST- 2025/04/24 06:19 [entrez] PHST- 2025/03/31 00:00 [pmc-release] AID - acs-14-02-98 [pii] AID - 10.21037/acs-2024-etavr-0149 [doi] PST - ppublish SO - Ann Cardiothorac Surg. 2025 Mar 31;14(2):98-111. doi: 10.21037/acs-2024-etavr-0149. Epub 2025 Mar 4. PMID- 40269372 OWN - NLM STAT- MEDLINE DCOM- 20250424 LR - 20250424 IS - 0030-9982 (Print) IS - 0030-9982 (Linking) VI - 75 IP - 4 DP - 2025 Apr TI - Systemic and local associated disorders in children with congenital cataracts-a retrospective analysis. PG - 621-626 LID - 10.47391/JPMA.21257 [doi] AB - OBJECTIVE: To assess the systemic and local disorders associated with congenital cataracts in children in a tertiary care setting. METHODS: The retrospective study was conducted at the Department of Ophthalmology and Visual Sciences, Aga Khan University Hospital, Karachi, and comprised data from January 2014 to December 2019 of patients aged <12 months who underwent lens aspiration. Data on demographics, family history, maternal illness, and associated systemic and local disorders were collected through chart reviews. Unilateral and bilateral cataracts were stratified. Data was analysed using RStudio. RESULTS: Of the 84 cases evaluated, 81(96.4%) were analysed after excluding incomplete records; 41(50.6%) boys and 40 (49.4%) girls. The median age at presentation was 6 months (interquartile range: 4-11 months). Bilateral cataracts were more common (n=50, 61.7%) than unilateral cataracts (n=31, 38.3%). Only 2 (2.5%) cases had a family history of congenital cataracts. Systemic associations included cardiac abnormalities (n=4, 4.9%), central nervous system anomalies (n=3, 3.7%), hearing impairment (n=1, 1.2%), and genitourinary malformations (n=1, 1.2%). Chromosomal anomalies (n=3, 3.7%) and inborn errors of metabolism (n=3, 3.7%) were also noted. CONCLUSIONS: The burden of congenital cataracts was significant and its aetiology was multifactorial, emphasising the need for early detection and a multidisciplinary approach to management. FAU - Baig, Rashid AU - Baig R AD - Department of Ophthalmology and Visual Sciences, Aga Khan University and Hospital, Karachi, Pakistan. FAU - Rahman, Asma AU - Rahman A AD - Department of Ophthalmology and Visual Sciences, Aga Khan University and Hospital, Karachi, Pakistan. FAU - Jehanzeb, Hamzah AU - Jehanzeb H AD - Department of Ophthalmology and Visual Sciences, Aga Khan University and Hospital, Karachi, Pakistan. FAU - Abid, Khadijah AU - Abid K AD - Department of Ophthalmology and Visual Sciences, Aga Khan University and Hospital, Karachi, Pakistan. LA - eng PT - Journal Article PL - Pakistan TA - J Pak Med Assoc JT - JPMA. The Journal of the Pakistan Medical Association JID - 7501162 SB - IM MH - Humans MH - *Cataract/congenital/epidemiology MH - Female MH - Male MH - Retrospective Studies MH - Infant MH - Pakistan/epidemiology MH - Heart Defects, Congenital/epidemiology MH - Hearing Loss/epidemiology OTO - NOTNLM OT - Blindness, Children, Congenital cataracts, Local disorders, Systemic disorders. EDAT- 2025/04/24 06:27 MHDA- 2025/04/24 12:29 CRDT- 2025/04/24 00:15 PHST- 2025/04/24 12:29 [medline] PHST- 2025/04/24 06:27 [pubmed] PHST- 2025/04/24 00:15 [entrez] AID - 10.47391/JPMA.21257 [doi] PST - ppublish SO - J Pak Med Assoc. 2025 Apr;75(4):621-626. doi: 10.47391/JPMA.21257. PMID- 40264904 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250424 IS - 2045-8932 (Print) IS - 2045-8940 (Electronic) IS - 2045-8932 (Linking) VI - 15 IP - 2 DP - 2025 Apr TI - Outcomes of Multidisciplinary Care at a Chronic Thromboembolic Pulmonary Hypertension Center. PG - e70085 LID - 10.1002/pul2.70085 [doi] LID - e70085 AB - Recent international guidelines recommend a multidisciplinary evaluation and care model for patients with chronic thromboembolic pulmonary hypertension (CTEPH), but there is a paucity of supporting data. The aim of this study was to describe the outcomes of a multidisciplinary team approach to the comprehensive care of CTEPH patients. This single-center cohort study enrolled 166 consecutive adult patients undergoing CTEPH treatment evaluation from 2016 to 2022 at a tertiary care, academic regional referral and comprehensive CTEPH center with pulmonary thromboendarterectomy (PTE) and balloon pulmonary angioplasty (BPA) capabilities. Patients underwent PTE, BPA, or medical management after consensus evaluation by a multidisciplinary team including pulmonary hypertension physicians, surgeons, interventional cardiologists, and radiologists. 86% (142/166) of patients underwent interventional therapies; 100 (60%) underwent PTE and 42 (25%) BPA. Of the 24 (14%) medically treated patients, 13 patients were offered but deferred intervention; 11 patients had non-intervenable disease. 30-day mortality in both PTE and BPA was 0%. 1- and 3-year survival was 99% and 96% for PTE, 100% and 93% for BPA, 79% and 79% for medical management. Patients who underwent PTE had the best hemodynamic response (∆PVR: PTE -278.8 +/- 366.9 dyne/sec/cm(5); BPA -15.9 +/- 171.8 dyne/sec/cm(5); medical -60.2 +/- 233.1 dyne/sec/cm(5); p = 0.001), largest improvement in Borg Dyspnea Scale; [PTE -1.0 (-2.8 to 0.0), BPA + 0.5 (-0.8 to 5.0), medical +1.0 (0.75 to 3.0), p = 0.01], and most improvement in NYHA functional class [% improving at least 1 functional class: PTE 64% (47/73), BPA 18% (5/28), medical 21% (4/19), p = 0.0004]. CI - (c) 2025 The Author(s). Pulmonary Circulation published by John Wiley & Sons Ltd on behalf of Pulmonary Vascular Research Institute. FAU - Christopher Malaisrie, S AU - Christopher Malaisrie S AD - Division of Cardiac Surgery, Department of Surgery Northwestern University Feinberg School of Medicine Chicago Illinois. FAU - Chiu, Stephen AU - Chiu S AUID- ORCID: 0000-0003-2759-9394 AD - Division of Cardiac Surgery, Department of Surgery Northwestern University Feinberg School of Medicine Chicago Illinois. FAU - Schimmel, Daniel AU - Schimmel D AD - Division of Cardiology, Department of Medicine Northwestern University Feinberg School of Medicine Chicago Illinois. FAU - Samant, Maanasi AU - Samant M AD - Division of Pulmonary and Critical Care Medicine, Department of Medicine Northwestern University Feinberg School of Medicine Chicago Illinois. FAU - Avery, Ryan AU - Avery R AD - Department of Radiology Northwestern University Feinberg School of Medicine Chicago Illinois. FAU - Rahsepar, Amir AU - Rahsepar A AD - Department of Radiology Northwestern University Feinberg School of Medicine Chicago Illinois. FAU - Allen, Bradley AU - Allen B AD - Department of Radiology Northwestern University Feinberg School of Medicine Chicago Illinois. FAU - Raza, Yasmin AU - Raza Y AD - Division of Cardiology, Department of Medicine Northwestern University Feinberg School of Medicine Chicago Illinois. FAU - Freed, Benjamin AU - Freed B AD - Division of Cardiology, Department of Medicine Northwestern University Feinberg School of Medicine Chicago Illinois. FAU - Mylvaganam, Ruben AU - Mylvaganam R AD - Division of Pulmonary and Critical Care Medicine, Department of Medicine Northwestern University Feinberg School of Medicine Chicago Illinois. FAU - Cuttica, Michael J AU - Cuttica MJ AD - Division of Pulmonary and Critical Care Medicine, Department of Medicine Northwestern University Feinberg School of Medicine Chicago Illinois. LA - eng PT - Journal Article DEP - 20250421 PL - United States TA - Pulm Circ JT - Pulmonary circulation JID - 101557243 PMC - PMC12011997 OTO - NOTNLM OT - balloon pulmonary angioplasty OT - multimodal therapy OT - pulmonary thromboendarterectomy OT - team-based care COIS- The authors declare no conflicts of interest. EDAT- 2025/04/23 11:18 MHDA- 2025/04/23 11:19 PMCR- 2025/04/21 CRDT- 2025/04/23 04:19 PHST- 2025/02/24 00:00 [received] PHST- 2025/04/03 00:00 [revised] PHST- 2025/04/08 00:00 [accepted] PHST- 2025/04/23 11:19 [medline] PHST- 2025/04/23 11:18 [pubmed] PHST- 2025/04/23 04:19 [entrez] PHST- 2025/04/21 00:00 [pmc-release] AID - PUL270085 [pii] AID - 10.1002/pul2.70085 [doi] PST - epublish SO - Pulm Circ. 2025 Apr 21;15(2):e70085. doi: 10.1002/pul2.70085. eCollection 2025 Apr. PMID- 40261198 OWN - NLM STAT- MEDLINE DCOM- 20250612 LR - 20260624 IS - 1934-1563 (Electronic) IS - 1934-1482 (Print) IS - 1934-1482 (Linking) VI - 17 IP - 6 DP - 2025 Jun TI - Multidisciplinary collaborative guidance on the assessment and treatment of patients with Long COVID: A compendium statement. PG - 684-708 LID - 10.1002/pmrj.13397 [doi] AB - BACKGROUND: In 2021, the American Academy of Physical Medicine and Rehabilitation established the Multi-Disciplinary Post-Acute Sequelae of SARS-CoV-2 Infection Collaborative to provide guidance from established Long COVID clinics for the evaluation and management of Long COVID. The collaborative previously published eight Long COVID consensus guidance statements using a primarily symptom-based approach. However, Long COVID symptoms most often do not occur in isolation. AIMS: This compendium aims to equip clinicians with an efficient, up-to-date clinical resource for evaluating and managing adults experiencing Long COVID symptoms. The primary intended audience includes physiatrists, primary care physicians, and other clinicians who provide first-line assessment and management of Long COVID symptoms, especially in settings where subspecialty care is not readily available. This compendium provides a holistic framework for assessment and management, symptom-specific considerations, and updates on prevalence, health equity, disability considerations, pathophysiology, and emerging evidence regarding treatments under investigation. Because Long COVID closely resembles other infection-associated chronic conditions (IACCs) such as myalgic encephalomyelitis/chronic fatigue syndrome, the guidance in this compendium may also be helpful for clinicians managing these related conditions. METHODS: Guidance in this compendium was developed by the collaborative's established modified Delphi approach. The collaborative is a multidisciplinary group whose members include physiatrists, primary care physicians, pulmonologists, cardiologists, psychiatrists, neuropsychologists, neurologists, occupational therapists, physical therapists, speech and language pathologists, patients, and government representatives. Over 40 Long COVID centers are represented in the collaborative. RESULTS: Long COVID is defined by the National Academies of Sciences, Engineering, and Medicine as "an IACC that occurs after SARS-CoV-2 infection and is present for at least 3 months as a continuous, relapsing and remitting, or progressive disease state that affects one or more organ systems." The current global prevalence of Long COVID is estimated to be 6%. Higher prevalence has been identified among female gender, certain racial and ethnic groups, and individuals who live in nonurban areas. However, anyone can develop Long COVID after being infected with the SARS-CoV-2 virus. Long COVID can present as a wide variety of symptom clusters. The most common symptoms include exaggerated fatigue and diminished energy windows, postexertional malaise (PEM)/postexertional symptom exacerbation (PESE), cognitive impairment (brain fog), dysautonomia, pain/myalgias, and smell and taste alterations. Holistic assessment should include a traditional history, physical examination, and additional diagnostic testing, as indicated. A positive COVID-19 test during acute SARS-CoV-2 infection is not required to diagnose Long COVID, and currently, there is no single laboratory finding that is definitively diagnostic for confirming or ruling out the diagnosis of Long COVID. A basic laboratory assessment is recommended for all patients with possible Long COVID, and consideration for additional labs and diagnostic procedures is guided by the patient's specific symptoms. Current management strategies focus on symptom-based supportive care. Critical considerations include energy conservation strategies and addressing comorbidities and modifiable risk factors. Additionally, (1) it is essential to validate the patient's experience and provide reassurance that their symptoms are being taken seriously because many patients have had their symptoms dismissed by loved ones and clinicians; (2) physical activity recommendations must be carefully tailored to the patient's current activity tolerance because overly intense activity can trigger PEM/PESE and worsened muscle damage; and (3) treatment recommendations should be delivered with humility because there are many persistent unknowns related to Long COVID. To date, there are limited data to guide medication management specifically in the context of Long COVID. As such, medication use generally follows standard practice regarding indications and dosing, with extra attention to prioritize (1) patient preference via shared decision-making and (2) cautious use of medications that may improve some symptoms (eg, cognitive/attention impairment) but may worsen other symptoms (eg, PEM/PESE). Numerous clinical trials are investigating additional treatments. The return-to-work process for individuals with Long COVID can be challenging because symptoms can fluctuate, vary in nature, affect multiple functional areas (eg, physical and cognitive), and often manifest as an "invisible disability" that may not be readily acknowledged by employers or coworkers. Clinicians can help patients return to work by identifying suitable workplace accommodations and resources, providing necessary documentation, and recommending occupational or vocational therapy when needed. If these efforts are unsuccessful and work significantly worsens Long COVID symptoms or impedes recovery, applying for disability may be warranted. Long COVID is recognized as a potential disability under the Americans with Disabilities Act. CONCLUSION: To contribute to the overall health and well-being for all patients, Long COVID care should be delivered in a holistic manner that acknowledges challenges faced by the patient and uncertainties in the field. For more detailed information on assessment and management of specific Long COVID symptoms, readers can reference the collaborative's symptom-specific consensus guidance statements. CI - (c) 2025 American Academy of Physical Medicine and Rehabilitation. FAU - Cheng, Abby L AU - Cheng AL AUID- ORCID: 0000-0002-8166-0806 AD - Division of Musculoskeletal Physical Medicine and Rehabilitation, Department of Orthopaedic Surgery, Washington University in St. Louis, St. Louis, Missouri, USA. FAU - Herman, Eric AU - Herman E AD - Department of Family Medicine, Oregon Health & Sciences University, Portland, Oregon, USA. FAU - Abramoff, Benjamin AU - Abramoff B AD - Department of Physical Medicine and Rehabilitation, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA. FAU - Anderson, Jordan R AU - Anderson JR AD - Department of Psychiatry and Neurology, Oregon Health and Science University, Portland, Oregon, USA. FAU - Azola, Alba AU - Azola A AD - Department of Pediatrics, Division of Adolescent Medicine, Department of Physical Medicine and Rehabilitation, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. FAU - Baratta, John M AU - Baratta JM AUID- ORCID: 0000-0002-1124-7928 AD - Department of Physical Medicine and Rehabilitation, UNC-Chapel Hill, Chapel Hill, North Carolina, USA. FAU - Bartels, Matthew N AU - Bartels MN AD - Department of Rehabilitation Medicine, Albert Einstein College of Medicine/Montefiore Health System, Bronx, New York, USA. FAU - Bhavaraju-Sanka, Ratna AU - Bhavaraju-Sanka R AD - Department of Neurology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA. FAU - Blitshteyn, Svetlana AU - Blitshteyn S AD - Department of Neurology, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, New York, USA. AD - Dysautonomia Clinic, Williamsville, New York, USA. FAU - Fine, Jeffrey S AU - Fine JS AD - Associate Professor, Rehabilitation Medicine, Grossman NYU School of Medicine, Rusk Rehabilitation Medicine, Grossman NYU School of Medicine, New York, New York, USA. FAU - Fleming, Talya K AU - Fleming TK AUID- ORCID: 0000-0002-2034-8253 AD - Department of Physical Medicine and Rehabilitation, JFK Johnson Rehabilitation Institute at Hackensack Meridian Health, Rutgers Robert Wood Johnson Medical School, Hackensack Meridian School of Medicine, Edison, New Jersey, USA. FAU - Verduzco-Gutierrez, Monica AU - Verduzco-Gutierrez M AUID- ORCID: 0000-0003-0964-5908 AD - Department of Rehabilitation Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA. FAU - Herrera, Joseph E AU - Herrera JE AD - Department of Rehabilitation and Human Performance, Icahn School of Medicine at Mount Sinai, New York, New York, USA. FAU - Karnik, Rasika AU - Karnik R AD - Department of General Internal Medicine, University of Chicago, Chicago, Illinois, USA. FAU - Kurylo, Monica AU - Kurylo M AD - Department of Psychiatry & Behavioral Sciences, Department of Physical Medicine & Rehabilitation, University of Kansas Medical Center and Health System, Kansas City, Kansas, USA. FAU - Longo, Michele T AU - Longo MT AD - Tulane Department of Clinical Neurosciences, New Orleans, Louisiana, USA. FAU - McCauley, Mark D AU - McCauley MD AD - Division of Cardiology, Department of Medicine, College of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA. AD - Jesse Brown VA Medical Center, Chicago, Illinois, USA. AD - Department of Physiology and Biophysics and the Center for Cardiovascular Research, College of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA. FAU - Melamed, Esther AU - Melamed E AD - Department of Neurology, Dell Medical School, UT, Austin, Texas, USA. FAU - Miglis, Mitchell G AU - Miglis MG AD - Department of Neurology and Neurological Sciences, Stanford University, Palo Alto, California, USA. FAU - Neal, Jacqueline D AU - Neal JD AD - Physical Medicine and Rehabilitation, Jesse Brown VA, Chicago, Illinois, USA. AD - Physical Medicine and Rehabilitation, Northwestern Feinberg School of Medicine, Chicago, Illinois, USA. FAU - Oleson, Christina V AU - Oleson CV AD - Department of Physical Medicine and Rehabilitation, Case Western Reserve University, MetroHealth Rehabilitation Institute, Cleveland, Ohio, USA. FAU - Putrino, David AU - Putrino D AD - Department of Rehabilitation and Human Performance, Icahn School of Medicine at Mount Sinai, New York, New York, USA. FAU - Rydberg, Leslie AU - Rydberg L AUID- ORCID: 0000-0001-5817-4861 AD - Department of Physical Medicine and Rehabilitation, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. FAU - Silver, Julie K AU - Silver JK AUID- ORCID: 0000-0001-9711-0713 AD - Senior Associate Dean for Faculty Experience and Success, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA. FAU - Terzic, Carmen M AU - Terzic CM AD - Professor of Physical Medicine and Rehabilitation, Mayo Clinic, Rochester, Minnesota, USA. AD - Medical Director Cardiovascular Rehabilitation Program, Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA. FAU - Whiteson, Jonathan H AU - Whiteson JH AD - Department of Physical Medicine and Rehabilitation, and Medicine, NYU Grossman School of Medicine, New York, New York, USA. FAU - Niehaus, William N AU - Niehaus WN AD - Department of Physical Medicine & Rehabilitation, University of Colorado School of Medicine, Denver, Colorado, USA. LA - eng GR - U18 HS029911/HS/AHRQ HHS/United States GR - R01 HL151508/HL/NHLBI NIH HHS/United States GR - RM1 DA055437/DA/NIDA NIH HHS/United States GR - R01 MH110623/MH/NIMH NIH HHS/United States GR - U18 HS029947/HS/AHRQ HHS/United States GR - I01 BX004918/BX/BLRD VA/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, U.S. Gov't, Non-P.H.S. PT - Research Support, U.S. Gov't, P.H.S. DEP - 20250422 PL - United States TA - PM R JT - PM & R : the journal of injury, function, and rehabilitation JID - 101491319 SB - IM MH - Humans MH - *COVID-19/complications/epidemiology/therapy MH - SARS-CoV-2 MH - Post-Acute COVID-19 Syndrome MH - Physical and Rehabilitation Medicine MH - *Practice Guidelines as Topic MH - Consensus MH - *Patient Care Team PMC - PMC12162235 MID - NIHMS2067016 EDAT- 2025/04/22 16:26 MHDA- 2025/06/12 12:31 PMCR- 2026/06/01 CRDT- 2025/04/22 10:13 PHST- 2025/03/03 00:00 [revised] PHST- 2024/09/23 00:00 [received] PHST- 2025/03/04 00:00 [accepted] PHST- 2025/06/12 12:31 [medline] PHST- 2025/04/22 16:26 [pubmed] PHST- 2025/04/22 10:13 [entrez] PHST- 2026/06/01 00:00 [pmc-release] AID - 10.1002/pmrj.13397 [doi] PST - ppublish SO - PM R. 2025 Jun;17(6):684-708. doi: 10.1002/pmrj.13397. Epub 2025 Apr 22. PMID- 40250545 OWN - NLM STAT- MEDLINE DCOM- 20250518 LR - 20260813 IS - 1873-1570 (Electronic) IS - 0300-9572 (Print) IS - 0300-9572 (Linking) VI - 211 DP - 2025 Jun TI - Race is not associated with medical emergency team evaluation prior to in-hospital cardiac arrest. PG - 110609 LID - S0300-9572(25)00121-2 [pii] LID - 10.1016/j.resuscitation.2025.110609 [doi] AB - BACKGROUND: Black patients have worse outcomes after in-hospital cardiac arrest (IHCA). Whether these racial disparities are associated with medical emergency team (MET) evaluation prior to IHCA remains unknown. METHODS: A retrospective cohort study of adults age >/= 18 years from the American Heart Association Get With The Guidelines(R) Resuscitation registry who had an IHCA between 2000 and 2021 with acute physiologic decline (modified early warning score [MEWS] >/= 3) during the 24 h prior to IHCA. A propensity-weighted cohort was constructed to balance confounders between Black and White patients. The association between race and MET evaluation was quantified with weighted multivariable logistic regression. RESULTS: Among 354,480 patients, 88,507 met the initial inclusion criteria, of which 29,714 patients (median age 69 [IQR 58-79] years, 42.5% female, and 26.9% Black) had acute physiologic decline during the 24 h prior to IHCA. Among patients with acute physiologic decline, 4102 (13.8%) patients had a preceding MET evaluation before IHCA. Rates of MET evaluation prior to cardiac arrest did not differ significantly between Black and White patients with acute physiologic decline (aOR 1.02, 95% CI 0.94-1.11, p = 0.62). CONCLUSIONS: Though racial disparities in IHCA outcomes exist, this study did not detect a difference in rates of MET evaluation prior to IHCA among patients with acute physiologic decline as a potential mechanism for these disparities. CI - Copyright (c) 2025 Elsevier B.V. All rights reserved. FAU - Gathers, Cody-Aaron L AU - Gathers CL AD - Department of Anesthesiology and Critical Care, University of Pennsylvania, Philadelphia, PA, United States. Electronic address: gathersc@chop.edu. FAU - Morgan, Ryan W AU - Morgan RW AD - Department of Anesthesiology & Critical Care Medicine, Children's Hospital of Philadelphia and Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States. FAU - Alvey, Jessica S AU - Alvey JS AD - Department of Pediatrics, University of Utah, Salt Lake City, UT, United States. FAU - Reeder, Ron AU - Reeder R AD - Department of Pediatrics, University of Utah, Salt Lake City, UT, United States. FAU - Goldberger, Zachary D AU - Goldberger ZD AD - Department of Medicine, Division of Cardiovascular Medicine, University of Wisconsin, Madison, WI, United States. FAU - Fowler, Jessica AU - Fowler J AD - Department of Anesthesiology & Critical Care Medicine, Children's Hospital of Philadelphia and Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States. FAU - Naim, Maryam Y AU - Naim MY AD - Department of Anesthesiology & Critical Care Medicine, Children's Hospital of Philadelphia and Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States. FAU - O'Halloran, Amanda AU - O'Halloran A AD - Department of Anesthesiology & Critical Care Medicine, Children's Hospital of Philadelphia and Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States. FAU - Merchant, Raina M AU - Merchant RM AD - Department of Emergency Medicine, University of Pennsylvania, Philadelphia, PA, United States. FAU - Kienzle, Martha AU - Kienzle M AD - Department of Anesthesiology & Critical Care Medicine, Children's Hospital of Philadelphia and Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States. FAU - Nadkarni, Vinay AU - Nadkarni V AD - Department of Anesthesiology & Critical Care Medicine, Children's Hospital of Philadelphia and Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States. FAU - Berg, Robert A AU - Berg RA AD - Department of Anesthesiology & Critical Care Medicine, Children's Hospital of Philadelphia and Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States. FAU - Sutton, Robert M AU - Sutton RM AD - Department of Anesthesiology & Critical Care Medicine, Children's Hospital of Philadelphia and Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States. CN - American Heart Association's Get With The Guidelines(R)-Resuscitation Investigators LA - eng GR - R01 HL141844/HL/NHLBI NIH HHS/United States GR - K23 HL148541/HL/NHLBI NIH HHS/United States GR - T32 HL098054/HL/NHLBI NIH HHS/United States GR - R01 MH127686/MH/NIMH NIH HHS/United States GR - K24 HL157621/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20250416 PL - Ireland TA - Resuscitation JT - Resuscitation JID - 0332173 SB - IM MH - Aged MH - Female MH - Humans MH - Male MH - Middle Aged MH - *Black or African American/statistics & numerical data MH - Cardiopulmonary Resuscitation MH - Early Warning Score MH - *Heart Arrest/therapy/ethnology/mortality MH - *Hospital Rapid Response Team/statistics & numerical data MH - Registries MH - Retrospective Studies MH - United States/epidemiology MH - *White/statistics & numerical data PMC - PMC13123872 MID - NIHMS2165574 OTO - NOTNLM OT - Cardiac arrest OT - Health equity OT - Medical emergency team COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/04/19 00:56 MHDA- 2025/05/19 00:37 PMCR- 2026/04/28 CRDT- 2025/04/18 19:38 PHST- 2025/01/26 00:00 [received] PHST- 2025/04/06 00:00 [revised] PHST- 2025/04/07 00:00 [accepted] PHST- 2025/05/19 00:37 [medline] PHST- 2025/04/19 00:56 [pubmed] PHST- 2025/04/18 19:38 [entrez] PHST- 2026/04/28 00:00 [pmc-release] AID - S0300-9572(25)00121-2 [pii] AID - 10.1016/j.resuscitation.2025.110609 [doi] PST - ppublish SO - Resuscitation. 2025 Jun;211:110609. doi: 10.1016/j.resuscitation.2025.110609. Epub 2025 Apr 16. PMID- 40248303 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250419 IS - 1520-765X (Print) IS - 1554-2815 (Electronic) IS - 1520-765X (Linking) VI - 27 IP - Suppl 3 DP - 2025 Mar TI - Aortic and mitral structural interventions in the absence of cardiac surgery. PG - iii64-iii68 LID - 10.1093/eurheartjsupp/suaf038 [doi] AB - Traditionally, structural heart interventions have been performed at heart valve centres with on-site heart surgery to maximize expertise and deal with complications requiring emergent cardiac surgery (ECS). However, at present, only transcatheter aortic-valve implantation (TAVI) must be performed at centres with on-site heart surgery according to current guidelines, while mitral transcatheter edge-to-edge repair, or left appendage atrial occlusion could be performed also in centres without on-site cardiac surgery. Today, ageing of the population and improved results of TAVI have increased the need for such procedures posing strong pressure to traditional heart valve centres, prolonging waiting times for TAVI and increasing access disparities. Fortunately, TAVI procedures have a very low rate of complications, including those necessitating ECS, and observational data suggest that TAVI can be safely performed in centres without on-site cardiac surgery. However, guideline recommendations need randomized clinical trials like the TRanscatheter Aortic-Valve Implantation with or without on-site Cardiac Surgery (TRACS) trial to be updated. The TRACS trial randomizes high-risk symptomatic aortic stenosis patients to treatment by the same operators either at centres with or without on-site cardiac surgery and compares 1-year follow-up. Key issues for structural interventions, in particular TAVI, at centres without on-site surgery are shared indications through heart team evaluation, consistent experiences and competences of non-surgical centres, and strong networking with the Hub centre. The increasing demand for structural heart interventions highlights the need for innovative care models and the careful introduction of a 'Hub-and-Spoke' approach for high-volume heart valve networks could be a study option. CI - (c) The Author(s) 2025. Published by Oxford University Press on behalf of the European Society of Cardiology. FAU - Iannopollo, Gianmarco AU - Iannopollo G AD - Cardiology Unit, Ospedale Maggiore, Largo Nigrisoli 2, Bologna 40133, Italy. FAU - Capecchi, Alessandro AU - Capecchi A AD - Cardiology Unit, Ospedale Maggiore, Largo Nigrisoli 2, Bologna 40133, Italy. FAU - Verardi, Roberto AU - Verardi R AD - Cardiology Unit, Ospedale Maggiore, Largo Nigrisoli 2, Bologna 40133, Italy. FAU - Biasco, Luigi AU - Biasco L AD - Department of Biomedical Sciences, University of Italian Switzerland, Lugano, Switzerland. AD - Azienda Sanitaria Locale Torino 4, Department of Cardiology, Cirie, Turin, Italy. FAU - Pedone, Chiara AU - Pedone C AD - Cardiology Unit, Ospedale Maggiore, Largo Nigrisoli 2, Bologna 40133, Italy. FAU - Lanzilotti, Valerio AU - Lanzilotti V AD - Cardiology Unit, Ospedale Maggiore, Largo Nigrisoli 2, Bologna 40133, Italy. FAU - Bruno, Matteo AU - Bruno M AD - Cardiology Unit, Ospedale Maggiore, Largo Nigrisoli 2, Bologna 40133, Italy. FAU - Nobile, Giampiero AU - Nobile G AD - Cardiology Unit, Ospedale Maggiore, Largo Nigrisoli 2, Bologna 40133, Italy. FAU - Casella, Gianni AU - Casella G AD - Cardiology Unit, Ospedale Maggiore, Largo Nigrisoli 2, Bologna 40133, Italy. LA - eng PT - Journal Article DEP - 20250416 PL - England TA - Eur Heart J Suppl JT - European heart journal supplements : journal of the European Society of Cardiology JID - 100886647 PMC - PMC12001765 OTO - NOTNLM OT - Heart surgery OT - TAVI OT - TEER COIS- Conflict of interest: none declared. EDAT- 2025/04/18 11:02 MHDA- 2025/04/18 11:03 PMCR- 2025/04/16 CRDT- 2025/04/18 04:40 PHST- 2025/04/18 11:03 [medline] PHST- 2025/04/18 11:02 [pubmed] PHST- 2025/04/18 04:40 [entrez] PHST- 2025/04/16 00:00 [pmc-release] AID - suaf038 [pii] AID - 10.1093/eurheartjsupp/suaf038 [doi] PST - epublish SO - Eur Heart J Suppl. 2025 Apr 16;27(Suppl 3):iii64-iii68. doi: 10.1093/eurheartjsupp/suaf038. eCollection 2025 Mar. PMID- 40248292 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250419 IS - 1520-765X (Print) IS - 1554-2815 (Electronic) IS - 1520-765X (Linking) VI - 27 IP - Suppl 3 DP - 2025 Mar TI - Transcatheter edge-to-edge repair in functional tricuspid regurgitation. PG - iii162-iii168 LID - 10.1093/eurheartjsupp/suaf040 [doi] AB - Tricuspid edge-to-edge repair (T-TEER) has emerged as a promising treatment option for severe functional tricuspid regurgitation (TR) in patients unsuitable for surgery. Recent findings from randomized clinical trials consistently demonstrated a reduction in TR severity and significant symptomatic improvement with T-TEER, particularly in terms of quality of life and functional status. However, no significant differences in mortality or hospitalizations were observed compared to guideline-directed medical therapy. In this complex scenario, careful patient selection and a comprehensive evaluation of the tricuspid valve remain critical for optimizing outcomes. Patients with preserved right ventricular (RV) function, absence of pulmonary hypertension (PH), and no significant organ dysfunction are more likely to benefit from T-TEER. Conversely, in patients with severe RV dysfunction, lack of contractile reserve, pre-capillary or severe combined post-capillary PH, end-stage organ failure, and significant impairment in daily activities and self-care, the procedure may be futile. Patients in the grey zone should be evaluated by a dedicated heart team, with a tailored decision-making approach. CI - (c) The Author(s) 2025. Published by Oxford University Press on behalf of the European Society of Cardiology. FAU - Bacigalupi, Elena AU - Bacigalupi E AD - Department of Neuroscience, Imaging and Clinical Sciences, 'G. D'Annunzio' University of Chieti-Pescara, Chieti 66100, Italy. AD - Cardiology Department, SS. Annunziata Hospital, Chieti-ASL 2 Abruzzo, Via dei Vestini, Chieti 66013, Italy. FAU - Scorpiglione, Luca AU - Scorpiglione L AD - Department of Neuroscience, Imaging and Clinical Sciences, 'G. D'Annunzio' University of Chieti-Pescara, Chieti 66100, Italy. AD - Cardiology Department, SS. Annunziata Hospital, Chieti-ASL 2 Abruzzo, Via dei Vestini, Chieti 66013, Italy. FAU - Perfetti, Matteo AU - Perfetti M AD - Cardiology Department, SS. Annunziata Hospital, Chieti-ASL 2 Abruzzo, Via dei Vestini, Chieti 66013, Italy. FAU - Appignani, Marianna AU - Appignani M AD - Cardiology Department, SS. Annunziata Hospital, Chieti-ASL 2 Abruzzo, Via dei Vestini, Chieti 66013, Italy. FAU - Rende, Greta AU - Rende G AD - Department of Neuroscience, Imaging and Clinical Sciences, 'G. D'Annunzio' University of Chieti-Pescara, Chieti 66100, Italy. AD - Cardiology Department, SS. Annunziata Hospital, Chieti-ASL 2 Abruzzo, Via dei Vestini, Chieti 66013, Italy. FAU - Duronio, Gino AU - Duronio G AD - Cardiology Department, SS. Annunziata Hospital, Chieti-ASL 2 Abruzzo, Via dei Vestini, Chieti 66013, Italy. FAU - Di Fulvio, Maria AU - Di Fulvio M AD - Cardiology Department, SS. Annunziata Hospital, Chieti-ASL 2 Abruzzo, Via dei Vestini, Chieti 66013, Italy. FAU - Zimarino, Marco AU - Zimarino M AD - Department of Neuroscience, Imaging and Clinical Sciences, 'G. D'Annunzio' University of Chieti-Pescara, Chieti 66100, Italy. AD - Cardiology Department, SS. Annunziata Hospital, Chieti-ASL 2 Abruzzo, Via dei Vestini, Chieti 66013, Italy. LA - eng PT - Journal Article DEP - 20250416 PL - England TA - Eur Heart J Suppl JT - European heart journal supplements : journal of the European Society of Cardiology JID - 100886647 PMC - PMC12001761 OTO - NOTNLM OT - TRI fr OT - Transcatheter edge-to-edge tricuspid repair OT - Tricuspid regurgitation COIS- Conflict of interest: none declared. EDAT- 2025/04/18 11:02 MHDA- 2025/04/18 11:03 PMCR- 2025/04/16 CRDT- 2025/04/18 04:40 PHST- 2025/04/18 11:03 [medline] PHST- 2025/04/18 11:02 [pubmed] PHST- 2025/04/18 04:40 [entrez] PHST- 2025/04/16 00:00 [pmc-release] AID - suaf040 [pii] AID - 10.1093/eurheartjsupp/suaf040 [doi] PST - epublish SO - Eur Heart J Suppl. 2025 Apr 16;27(Suppl 3):iii162-iii168. doi: 10.1093/eurheartjsupp/suaf040. eCollection 2025 Mar. PMID- 40248284 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250419 IS - 1520-765X (Print) IS - 1554-2815 (Electronic) IS - 1520-765X (Linking) VI - 27 IP - Suppl 3 DP - 2025 Mar TI - MitraClip and repair surgery: comparable results? PG - iii36-iii39 LID - 10.1093/eurheartjsupp/suaf013 [doi] AB - Mitral regurgitation (MR) is the most common valvular disease in industrialized countries, with a significant impact on patient quality of life and survival, especially in an increasingly elderly and comorbid population. Repair surgery is considered the treatment of choice for primary MR, offering excellent long-term outcomes. However, the MitraClip system, a less invasive percutaneous option based on the edge-to-edge principle, has proved to be a valid alternative for patients at high surgical risk, showing initial benefits in terms of fewer post-operative complications. Surgery remains superior in terms of durability and prevention of residual regurgitation, but the MitraClip system offers advantages in selected patients, with improvements in quality of life and reductions in hospitalizations for heart failure. A multidisciplinary approach and careful patient selection are essential to optimize outcomes. CI - (c) The Author(s) 2025. Published by Oxford University Press on behalf of the European Society of Cardiology. FAU - Bianchini, Francesco AU - Bianchini F AD - Department of Cardiovascular and Pulmonary Sciences, Universita Cattolica del Sacro Cuore, Rome, Italy. AD - Department of Cardiovascular Sciences, CUORE, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. FAU - Aurigemma, Cristina AU - Aurigemma C AD - Department of Cardiovascular Sciences, CUORE, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. FAU - Trani, Carlo AU - Trani C AD - Department of Cardiovascular and Pulmonary Sciences, Universita Cattolica del Sacro Cuore, Rome, Italy. AD - Department of Cardiovascular Sciences, CUORE, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. FAU - Burzotta, Francesco AU - Burzotta F AD - Department of Cardiovascular and Pulmonary Sciences, Universita Cattolica del Sacro Cuore, Rome, Italy. AD - Department of Cardiovascular Sciences, CUORE, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. LA - eng PT - Journal Article DEP - 20250416 PL - England TA - Eur Heart J Suppl JT - European heart journal supplements : journal of the European Society of Cardiology JID - 100886647 PMC - PMC12001788 OTO - NOTNLM OT - Heart failure OT - Left ventricular dysfunction OT - MitraClip OT - Mitral insufficiency COIS- Conflict of interest: F.Bi. has received a research grant from Abbott. C.A. has received speaking fees from Abbott Vascular, Abiomed, Medtronic, Terumo, and Daiichi Sankyo. C.T. has received speaking fees from Abbott Vascular, Abiomed, Medtronic, and Terumo. F.Bu. has received speaking fees from Abbott Vascular, Abiomed, Medtronic, and Terumo. EDAT- 2025/04/18 11:02 MHDA- 2025/04/18 11:03 PMCR- 2025/04/16 CRDT- 2025/04/18 04:40 PHST- 2025/04/18 11:03 [medline] PHST- 2025/04/18 11:02 [pubmed] PHST- 2025/04/18 04:40 [entrez] PHST- 2025/04/16 00:00 [pmc-release] AID - suaf013 [pii] AID - 10.1093/eurheartjsupp/suaf013 [doi] PST - epublish SO - Eur Heart J Suppl. 2025 Apr 16;27(Suppl 3):iii36-iii39. doi: 10.1093/eurheartjsupp/suaf013. eCollection 2025 Mar. PMID- 40243722 OWN - NLM STAT- MEDLINE DCOM- 20250417 LR - 20260127 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 26 IP - 7 DP - 2025 Mar 27 TI - Analysis of FBN1, TGFbeta2, TGFbetaR1 and TGFbetaR2 mRNA as Key Molecular Mechanisms in the Damage of Aortic Aneurysm and Dissection in Marfan Syndrome. LID - 10.3390/ijms26073067 [doi] LID - 3067 AB - Marfan syndrome (MFS) is an inherited connective tissue disorder, with aortic root aneurysm and/or dissection being the most severe and life-threatening complication. These conditions have been linked to pathogenic variants in the FBN1 gene and dysregulated TGFbeta signaling. Our objective was to evaluate the mRNA expression of FBN1, TGFBR1, TGFBR2, and TGFB2 in aortic tissue from MFS patients undergoing surgery for aortic dilation. This prospective study (2014-2023) included 20 MFS patients diagnosed according to the 2010 Ghent criteria, who underwent surgery for aneurysm or dissection based on Heart Team recommendations, along with 20 non-MFS controls. RNA was extracted, and mRNA levels were quantified using RT-qPCR. Patients with dissection showed significantly higher FBN1 mRNA levels [79 (48.1-110.1)] compared to controls [37.2 (25.1-79)] (p = 0.03). Conversely, TGFB2 expression was significantly lower in MFS patients [12.17 (6.54-24.70)] than in controls [44.29 (25.85-85.36)] (p = 0.029). A positive correlation was observed between higher FBN1 expression and a larger sinotubular junction diameter (r = 0.42, p = 0.07), while increased FBN1 expression was particularly evident in MFS patients with dissection. Additionally, TGFB2 expression showed an inverse correlation with ascending aortic diameter (r = 0.53, p = 0.01). In aortic tissue, we found decreased TGFB2 and receptor levels alongside increased FBN1 mRNA levels. These molecular alterations may reflect compensatory mechanisms in response to tissue damage caused by mechanical stress, leading to dysregulation of physiological signaling pathways and ultimately contributing to aortic dilation in MFS. FAU - Soto, Maria Elena AU - Soto ME AUID- ORCID: 0000-0003-1332-2888 AD - Research Direction, Instituto Nacional de Cardiologia Ignacio Chavez, Juan Badiano No. 1, Col. Seccion XVI, Mexico City 14080, Mexico. AD - Cardiovascular Line in American British Cowdray (ABC) Medical Center, PAI ABC Sur 136 No. 16, Col. Las Americas, Mexico City 01120, Mexico. FAU - Rodriguez-Brito, Myrlene AU - Rodriguez-Brito M AD - Cardiothoracic Surgery Department, Instituto Nacional de Cardiologia Ignacio Chavez, Juan Badiano No. 1, Col. 4 Seccion XVI, Mexico City 14080, Mexico. FAU - Perez-Torres, Israel AU - Perez-Torres I AUID- ORCID: 0000-0001-6510-2954 AD - Cardiovascular Biomedicine Department, Instituto Nacional de Cardiologia Ignacio Chavez, Juan Badiano No. 1, Col. Seccion XVI, Mexico City 14080, Mexico. FAU - Herrera-Alarcon, Valentin AU - Herrera-Alarcon V AD - Cardiothoracic Surgery Department, Instituto Nacional de Cardiologia Ignacio Chavez, Juan Badiano No. 1, Col. 4 Seccion XVI, Mexico City 14080, Mexico. FAU - Martinez-Hernandez, Humberto AU - Martinez-Hernandez H AD - Cardiothoracic Surgery Department, Instituto Nacional de Cardiologia Ignacio Chavez, Juan Badiano No. 1, Col. 4 Seccion XVI, Mexico City 14080, Mexico. FAU - Hernandez, Ivan AU - Hernandez I AD - Cardiothoracic Surgery Department, Instituto Nacional de Cardiologia Ignacio Chavez, Juan Badiano No. 1, Col. 4 Seccion XVI, Mexico City 14080, Mexico. FAU - Castrejon-Tellez, Vicente AU - Castrejon-Tellez V AUID- ORCID: 0000-0002-8518-6961 AD - Physiology Department, Instituto Nacional de Cardiologia Ignacio Chavez, Juan Badiano No. 1, Col. 4 Seccion XVI, Mexico City 14080, Mexico. FAU - Pena-Ocana, Betsy Anaid AU - Pena-Ocana BA AD - Biochemistry Department, Instituto Nacional de Cardiologia Ignacio Chavez, Juan Badiano No. 1, Col. Seccion XVI, Mexico City 14080, Mexico. AD - Tecnologico Nacional de Mexico, Instituto Tecnologico de Tuxtla Gutierrez, Tuxtla Gutierrez 29050, Mexico. FAU - Alvarez-Leon, Edith AU - Alvarez-Leon E AD - Sub-Directorate of Basic Research, Instituto Nacional de Cardiologia Ignacio Chavez, Juan Badiano No. 1, Col. Seccion XVI, Mexico City 14080, Mexico. FAU - Manzano-Pech, Linaloe AU - Manzano-Pech L AD - Cardiovascular Biomedicine Department, Instituto Nacional de Cardiologia Ignacio Chavez, Juan Badiano No. 1, Col. Seccion XVI, Mexico City 14080, Mexico. FAU - Gamboa, Ricardo AU - Gamboa R AUID- ORCID: 0000-0001-9102-4240 AD - Physiology Department, Instituto Nacional de Cardiologia Ignacio Chavez, Juan Badiano No. 1, Col. 4 Seccion XVI, Mexico City 14080, Mexico. FAU - Fuentevilla-Alvarez, Giovanny AU - Fuentevilla-Alvarez G AUID- ORCID: 0000-0002-1819-8444 AD - Endocrinology Department, Instituto Nacional de Cardiologia Ignacio Chavez, Juan Badiano No. 1, Col. 4 Seccion XVI, Mexico City 14080, Mexico. FAU - Huesca-Gomez, Claudia AU - Huesca-Gomez C AUID- ORCID: 0000-0002-6806-3484 AD - Physiology Department, Instituto Nacional de Cardiologia Ignacio Chavez, Juan Badiano No. 1, Col. 4 Seccion XVI, Mexico City 14080, Mexico. LA - eng PT - Journal Article DEP - 20250327 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (Fibrillin-1) RN - 0 (Transforming Growth Factor beta2) RN - 0 (FBN1 protein, human) RN - EC 2.7.11.30 (Receptor, Transforming Growth Factor-beta Type II) RN - EC 2.7.11.30 (Receptor, Transforming Growth Factor-beta Type I) RN - EC 2.7.11.30 (TGFBR2 protein, human) RN - 0 (RNA, Messenger) RN - 0 (TGFB2 protein, human) RN - EC 2.7.11.30 (TGFBR1 protein, human) RN - 0 (Adipokines) SB - IM MH - Humans MH - *Marfan Syndrome/genetics/complications/metabolism/pathology MH - *Fibrillin-1/genetics/metabolism MH - *Transforming Growth Factor beta2/genetics/metabolism MH - Male MH - Female MH - *Receptor, Transforming Growth Factor-beta Type II/genetics/metabolism MH - *Receptor, Transforming Growth Factor-beta Type I/genetics/metabolism MH - Adult MH - *Aortic Aneurysm/genetics/etiology/pathology/metabolism MH - *Aortic Dissection/genetics/etiology/pathology/metabolism MH - RNA, Messenger/genetics/metabolism MH - Middle Aged MH - Prospective Studies MH - Adipokines PMC - PMC11989073 OTO - NOTNLM OT - FBN1 OT - Marfan syndrome OT - TGFbeta2 OT - TGFbetaR1 OT - TGFbetaR2 OT - aortic dissection COIS- The authors declare no conflicts of interest. EDAT- 2025/04/17 12:26 MHDA- 2025/04/17 12:27 PMCR- 2025/03/27 CRDT- 2025/04/17 10:13 PHST- 2025/02/12 00:00 [received] PHST- 2025/03/20 00:00 [revised] PHST- 2025/03/25 00:00 [accepted] PHST- 2025/04/17 12:27 [medline] PHST- 2025/04/17 12:26 [pubmed] PHST- 2025/04/17 10:13 [entrez] PHST- 2025/03/27 00:00 [pmc-release] AID - ijms26073067 [pii] AID - ijms-26-03067 [pii] AID - 10.3390/ijms26073067 [doi] PST - epublish SO - Int J Mol Sci. 2025 Mar 27;26(7):3067. doi: 10.3390/ijms26073067. PMID- 40241434 OWN - NLM STAT- MEDLINE DCOM- 20260410 LR - 20260813 IS - 1550-5049 (Electronic) IS - 0889-4655 (Print) IS - 0889-4655 (Linking) VI - 41 IP - 3 DP - 2026 May-Jun 01 TI - Impact of Routine Postoperative Care Versus Nurse-Led Lifestyle Interventions on Patient Outcomes After Radiofrequency Ablation: A Randomized Controlled Trial. PG - E105-E111 LID - 10.1097/JCN.0000000000001219 [doi] AB - BACKGROUND: Paroxysmal atrial fibrillation (AF) is a common arrhythmia associated with significant morbidity. Radiofrequency ablation (RFA) is a widely used treatment, but postoperative complications and recurrence remain concerns. Nurse-led lifestyle interventions have been proposed as a strategy to improve patient outcomes after RFA. OBJECTIVE: The objective of this randomized controlled trial was to compare the effects of routine (usual) care versus a nurse-led lifestyle intervention on postoperative outcomes in patients undergoing RFA for paroxysmal AF. METHODS: A total of 160 patients undergoing RFA for paroxysmal AF were randomly assigned in a 1:1 ratio to either the intervention group or the usual-care group. The intervention group received tailored lifestyle interventions managed by a nurse-led multidisciplinary team, focusing on exercise, diet, medication adherence, and psychological support. The usual-care group received standard postoperative care. The primary outcomes were quality of life (Short Form-36 scores) and recurrence of AF. Data were collected at baseline, 6 months, and 12 months. RESULTS: The nurse-led lifestyle intervention group showed significant improvements in Short Form-36 scores for Physical Functioning, Role Limitations, Vitality, General Health, and Social Functioning compared with the usual-care group at 6 months ( P < .05). The recurrence rate of AF at 12 months was significantly lower in the nurse-led lifestyle intervention group (12.5%) compared with the usual-care group (26.3%, P = .021). The incidence of postoperative complications was also reduced in the nurse-led lifestyle intervention group. CONCLUSION: These findings suggest that nurse-led care models may provide a valuable approach to optimizing postoperative outcomes for AF patients, emphasizing the need for structured, personalized interventions in clinical practice. CI - Copyright (c) 2025 The Authors. Published by Wolters Kluwer Health, Inc. FAU - Yang, Fan AU - Yang F AD - Fan Yang, BM, Nurse Practitioner, Department of Cardiology, West China Hospital, Sichuan University Sichuan University, Chengdu, China. FAU - Wu, Yao AU - Wu Y AD - Yao Wu, BM, Nurse Practitioner, Department of Emergency Medicine, West China Hospital, Sichuan University, Chengdu, China. LA - eng PT - Comparative Study PT - Journal Article PT - Randomized Controlled Trial DEP - 20250417 PL - United States TA - J Cardiovasc Nurs JT - The Journal of cardiovascular nursing JID - 8703516 SB - IM MH - Humans MH - Male MH - Female MH - Middle Aged MH - *Postoperative Care/nursing/methods MH - *Atrial Fibrillation/surgery/nursing MH - Aged MH - Quality of Life MH - *Life Style MH - *Catheter Ablation/nursing MH - Treatment Outcome MH - *Radiofrequency Ablation MH - Recurrence PMC - PMC13064824 OTO - NOTNLM OT - nurse-led interventions OT - paroxysmal atrial fibrillation OT - postoperative complications OT - quality of life OT - radiofrequency ablation OT - recurrence EDAT- 2025/04/17 06:23 MHDA- 2026/04/10 13:00 PMCR- 2026/04/09 CRDT- 2025/04/17 03:03 PHST- 2026/04/10 13:00 [medline] PHST- 2025/04/17 06:23 [pubmed] PHST- 2025/04/17 03:03 [entrez] PHST- 2026/04/09 00:00 [pmc-release] AID - 00005082-990000000-00296 [pii] AID - JCN-D-24-00423 [pii] AID - 10.1097/JCN.0000000000001219 [doi] PST - ppublish SO - J Cardiovasc Nurs. 2026 May-Jun 01;41(3):E105-E111. doi: 10.1097/JCN.0000000000001219. Epub 2025 Apr 17. PMID- 40240181 OWN - NLM STAT- MEDLINE DCOM- 20250510 LR - 20250521 IS - 1875-2128 (Electronic) IS - 1875-2128 (Linking) VI - 118 IP - 5 DP - 2025 May TI - Management of diabetes in patients hospitalized for acute cardiac events: Joint position paper from the French Society of Cardiology and the French-speaking Diabetes Society. PG - 330-343 LID - S1875-2136(25)00214-1 [pii] LID - 10.1016/j.acvd.2025.02.012 [doi] AB - Patients with type 2 diabetes, but also older patients with type 1 diabetes, are at major risk of cardiovascular morbidity and death. After an acute cardiac event, the prognosis of patients with diabetes is impaired, with clear increases in in-hospital and long-term morbidity and deaths. Both hyper- and hypoglycaemia are deleterious after an acute cardiac event, and the decision to start intravenous insulin is often challenging. Moreover, some antidiabetic treatments have cardioprotective effects, and the onset of an acute cardiac event provides an opportunity to shift to these treatments. The objective of this position statement is to offer practical tools to cardiologists seeking to improve the care of patients with diabetes hospitalized for an acute cardiac event, and to optimize collaboration between cardiologists and diabetologists. After a summary of the evidence for antidiabetic treatments in patients with acute cardiac events, we propose an algorithm to start and adapt intravenous insulin in the most severe patients, and conclude with standard insulin protocols or oral treatments at discharge. We also discuss appropriate antidiabetic treatment of these patients at discharge, based on the main cardiological diagnosis, kidney function and antidiabetic strategies. Finally, situations in which the diabetologist must be consulted are discussed. CI - Copyright (c) 2025 The Authors. Published by Elsevier Masson SAS.. All rights reserved. FAU - Henry, Patrick AU - Henry P AD - Department of Cardiology, Lariboisiere Hospital, AP-HP, INSERM U942, Universite Paris Cite, 75010 Paris, France. Electronic address: Patrick.henry@aphp.fr. FAU - Jacqueminet, Sophie AU - Jacqueminet S AD - Diabetology Department, La Pitie Salpetriere-Charles Foix University Hospitals, 75013 Paris, France; Sorbonne Universite, 75005 Paris, France; Institute of Cardiometabolism and Nutrition (ICAN), 75013 Paris, France. FAU - Lemesle, Gilles AU - Lemesle G AD - Heart and Lung Institute, CHU de Lille, 59000 Lille, France; Lille University, 59000 Lille, France; INSERM U1011-EGID, Institut Pasteur de Lille, 59000 Lille, France; FACT (French Alliance for Cardiovascular Trials), 75000 Paris, France. FAU - Prevost, Gaetan AU - Prevost G AD - INSERM U1239, University of Rouen Normandy, 76821 Mont-Saint-Aignan, France; Department of Endocrinology, Diabetes and Metabolic Diseases, CHU de Rouen, 76000 Rouen, France; INSERM CIC-CRB 1404, 76000 Rouen, France. FAU - Boccara AU - Boccara AD - Department of Cardiology, Hopital Saint-Antoine, AP-HP, 75012 Paris, France; GRC no 2, C2MV (Complications Cardiovasculaires et Metaboliques chez les patients vivant avec le Virus de l'immunodeficience humaine), INSERM UMR_S 938, Centre de Recherche Saint-Antoine, Sorbonne Universite, 75012 Paris, France; Institute of Cardiometabolism and Nutrition (ICAN), 75013 Paris, France. FAU - Cosson, Emmanuel AU - Cosson E AD - Department of Endocrinology, Diabetology and Nutrition, Avicenne Hospital, AP-HP, Universite Paris 13, Sorbonne-Paris-Cite, CRNH-IdF, CINFO, 93000 Bobigny, France; Nutritional Epidemiology Research Team (EREN), Centre of Research in Epidemiology and StatisticS (CRESS), Universite Sorbonne Paris Nord and Universite Paris Cite, INSERM, INRAE, CNAM, 93017 Bobigny, France. FAU - Puymirat, Etienne AU - Puymirat E AD - Department of Cardiology, Hopital Europeen Georges-Pompidou, AP-HP, 75015 Paris, France. FAU - Angoulvant, Denis AU - Angoulvant D AD - Department of Cardiology, Hopital Trousseau, CHRU de Tours, 37170 Chambray-les-Tours, France; INSERM UMR 1327 (ISCHEMIA "Membrane Signalling and Inflammation in Reperfusion Injuries"), Universite de Tours, 37032 Tours, France. FAU - Roubille, Francois AU - Roubille F AD - PhyMedExp, Cardiology Department, CHU de Montpellier, University of Montpellier, INSERM, CNRS, INI-CRCT, 34295 Montpellier, France. FAU - Kownator, Serge AU - Kownator S AD - Centre Cardiologique et Vasculaire "Coeur de Lorraine", 57100 Thionville, France. FAU - Valensi, Paul AU - Valensi P AD - Polyclinique d'Aubervilliers, 93300 Aubervilliers, France; Universite Paris 13, Sorbonne Paris Cite, 93000 Bobigny, France. FAU - Aboyans, Victor AU - Aboyans V AD - Department of Cardiology, CHU de Limoges, 87000 Limoges, France; EpiMaCT, INSERM 1094/IRD 270, Limoges University, 87025 Limoges, France. FAU - Verges, Bruno AU - Verges B AD - Department of Endocrinology and Diabetology, CHU de Dijon, 21000 Dijon, France; INSERM UMR 1231, 21000 Dijon, France. LA - eng PT - Journal Article PT - Practice Guideline PT - Review DEP - 20250415 PL - Netherlands TA - Arch Cardiovasc Dis JT - Archives of cardiovascular diseases JID - 101465655 RN - 0 (Blood Glucose) RN - 0 (Hypoglycemic Agents) RN - 0 (Insulin) SB - IM MH - Humans MH - Acute Disease MH - *Blood Glucose/metabolism/drug effects MH - *Cardiology/standards MH - Clinical Decision-Making MH - Consensus MH - *Diabetes Mellitus, Type 1/drug therapy/diagnosis/mortality/complications/blood MH - *Diabetes Mellitus, Type 2/drug therapy/diagnosis/mortality/complications/blood MH - France MH - *Glycemic Control/adverse effects/standards MH - *Heart Diseases/diagnosis/therapy/mortality MH - Hospitalization MH - Hypoglycemia/chemically induced MH - *Hypoglycemic Agents/adverse effects/administration & dosage/therapeutic use MH - Insulin/administration & dosage/adverse effects MH - Interdisciplinary Communication MH - Patient Care Team MH - Risk Factors MH - Treatment Outcome OTO - NOTNLM OT - Antidiabetic agents OT - Diabetes OT - Intensive cardiac care unit EDAT- 2025/04/17 00:24 MHDA- 2025/05/11 00:44 CRDT- 2025/04/16 21:57 PHST- 2024/06/03 00:00 [received] PHST- 2025/02/19 00:00 [revised] PHST- 2025/02/21 00:00 [accepted] PHST- 2025/05/11 00:44 [medline] PHST- 2025/04/17 00:24 [pubmed] PHST- 2025/04/16 21:57 [entrez] AID - S1875-2136(25)00214-1 [pii] AID - 10.1016/j.acvd.2025.02.012 [doi] PST - ppublish SO - Arch Cardiovasc Dis. 2025 May;118(5):330-343. doi: 10.1016/j.acvd.2025.02.012. Epub 2025 Apr 15. PMID- 40235047 OWN - NLM STAT- MEDLINE DCOM- 20250910 LR - 20260513 IS - 1445-5994 (Electronic) IS - 1444-0903 (Linking) VI - 55 IP - 9 DP - 2025 Sep TI - Individual and shared situational awareness in in-hospital cardiac arrest: insights from a real-world observational study. PG - 1452-1462 LID - 10.1111/imj.70064 [doi] AB - BACKGROUND: Individual and shared situational awareness (SA) are crucial for team performance in high-pressure emergencies like cardiopulmonary resuscitation (CPR). While SA has been extensively studied in simulations, little research has examined its role in real-world in-hospital cardiac arrest (IHCA) settings. This study assessed individual and shared SA among medical emergency team (MET) members during CPR and explored its influence on team structure, communication and outcomes. METHODS: A cross-sectional observational study was conducted in real-world clinical settings, involving seven METs (n = 40). Individual SA was measured using the Situation Awareness Global Assessment Technique (SAGAT), while shared SA was assessed via a similarity index reflecting the alignment of team members' responses. Associations between SA, team structure, stress levels and clinical performance were analysed. RESULTS: Findings showed substantial variability in individual SA, with only 25% achieving full SA. Shared SA scores ranged from 0.95 +/- 0.046 to 0.78 +/- 0.144, with higher scores significantly associated with improved team structure (P = 0.034) and resuscitation success (P = 0.048). Mental work stress during CPR was linked to lower individual SA (P = 0.004), highlighting cognitive overload's impact on SA. CONCLUSIONS: This study identifies critical SA gaps, affecting both individual performance and team coordination. Shared SA is a key predictor of resuscitation success and should be enhanced through structured SA training, high-frequency simulations and algorithm-driven protocols to improve team synchronisation, decision-making and patient outcomes in IHCA settings. CI - (c) 2025 Royal Australasian College of Physicians. FAU - Alnadwi, Bashaer Salem AU - Alnadwi BS AD - Emergency department, Security Forces Hospital, Makah Region, Saudi Arabia. FAU - Al-Moteri, Modi AU - Al-Moteri M AUID- ORCID: 0000-0002-5703-1057 AD - Medical Surgical Nursing Department, College of Nursing, Taif University, Taif, Saudi Arabia. LA - eng GR - TU-DSPP-2024-282/Taif University/ PT - Journal Article PT - Observational Study DEP - 20250415 PL - Australia TA - Intern Med J JT - Internal medicine journal JID - 101092952 SB - IM MH - Humans MH - Cross-Sectional Studies MH - *Heart Arrest/therapy/psychology MH - *Cardiopulmonary Resuscitation/methods/psychology MH - Male MH - Female MH - *Awareness MH - Middle Aged MH - *Patient Care Team MH - Adult OTO - NOTNLM OT - cardiopulmonary resuscitation OT - emergency OT - observation OT - share OT - situation awareness EDAT- 2025/04/16 06:19 MHDA- 2025/09/10 18:30 CRDT- 2025/04/16 00:23 PHST- 2024/12/19 00:00 [received] PHST- 2025/03/25 00:00 [accepted] PHST- 2025/09/10 18:30 [medline] PHST- 2025/04/16 06:19 [pubmed] PHST- 2025/04/16 00:23 [entrez] AID - 10.1111/imj.70064 [doi] PST - ppublish SO - Intern Med J. 2025 Sep;55(9):1452-1462. doi: 10.1111/imj.70064. Epub 2025 Apr 15. PMID- 40230667 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250416 IS - 2772-9303 (Electronic) IS - 2772-9303 (Linking) VI - 4 IP - 3Part B DP - 2025 Mar TI - Artificial Intelligence in Cardiology: Insights From a Multidisciplinary Perspective. PG - 102612 LID - 10.1016/j.jscai.2025.102612 [doi] LID - 102612 FAU - Niroda, Kalynn AU - Niroda K AD - University of Maryland Medical Center, Baltimore, Maryland. FAU - Drudi, Cristian AU - Drudi C AD - Department of Electronics, Information and Bioengineering, Politecnico di Milano, Milan, Italy. AD - Picower Institute of Learning and Memory, Massachusetts Institute of Technology, Cambridge, Massachusetts. FAU - Byers, Joseph AU - Byers J AD - Beth Israel Deaconess Medical Center, Boston, Massachusetts. FAU - Johnson, Jasmine AU - Johnson J AD - University of Maryland Medical Center, Baltimore, Maryland. FAU - Cozzi, Gabrielle AU - Cozzi G AD - Beth Israel Deaconess Medical Center, Boston, Massachusetts. FAU - Celi, Leo Anthony AU - Celi LA AD - Beth Israel Deaconess Medical Center, Boston, Massachusetts. AD - Laboratory for Computational Physiology, Massachusetts Institute of Technology, Cambridge, Massachusetts. FAU - Khraishah, Haitham AU - Khraishah H AD - Harrington Heart and Vascular Institute, University Hospitals at Case Western Reserve University, Cleveland, Ohio. LA - eng PT - Journal Article DEP - 20250318 PL - United States TA - J Soc Cardiovasc Angiogr Interv JT - Journal of the Society for Cardiovascular Angiography & Interventions JID - 9918419271306676 PMC - PMC11993857 OTO - NOTNLM OT - artificial intelligence OT - equity OT - health care integration EDAT- 2025/04/15 06:24 MHDA- 2025/04/15 06:25 PMCR- 2025/03/18 CRDT- 2025/04/15 04:38 PHST- 2024/11/22 00:00 [received] PHST- 2025/01/22 00:00 [revised] PHST- 2025/01/23 00:00 [accepted] PHST- 2025/04/15 06:25 [medline] PHST- 2025/04/15 06:24 [pubmed] PHST- 2025/04/15 04:38 [entrez] PHST- 2025/03/18 00:00 [pmc-release] AID - S2772-9303(25)00053-5 [pii] AID - 102612 [pii] AID - 10.1016/j.jscai.2025.102612 [doi] PST - epublish SO - J Soc Cardiovasc Angiogr Interv. 2025 Mar 18;4(3Part B):102612. doi: 10.1016/j.jscai.2025.102612. eCollection 2025 Mar. PMID- 40227522 OWN - NLM STAT- MEDLINE DCOM- 20250414 LR - 20260813 IS - 1934-6638 (Electronic) IS - 1934-662X (Print) IS - 1934-662X (Linking) VI - 133 IP - 5 DP - 2025 May TI - Clinicopathological and molecular characterization of non-small cell lung cancer with pericardial effusions. PG - e70015 LID - 10.1002/cncy.70015 [doi] AB - BACKGROUND: Cytological evaluation is essential for assessing pericardial effusions (PEs) in non-small cell lung cancer (NSCLC). This study retrospectively examined the clinicopathological, molecular, and prognostic characteristics of patients with NSCLC with PE. METHODS: Clinical data from 80 patients with NSCLC with PE treated at an academic center over the course of 15 years were reviewed. PE specimens were categorized according to the International System for Reporting Serous Fluid Cytopathology (ISRSFC). The analysis included patient demographics, molecular alterations, cytopathology, histology, and survival outcomes. RESULTS: Of the 80 patients, 36 (45%) were female and 90% had stage IV disease. A smoking history was noted in 58 patients (72.5%), and 22 patients (27.5%) presented with tamponade. Lung adenocarcinoma predominated (87.5%). The ISRSFC categorized 25% of the specimens as negative for malignancy (NFM), 7.5% as atypia of undetermined significance (AUS), 3.75% as suspicious for malignancy (SFM), and 63.75% as malignant (MAL). Immunohistochemistry in 57 specimens identified thyroid transcription factor 1 (65%) as the most frequently positive marker. Molecular analysis revealed p53 mutations (59.1%) as the most prevalent, followed by KRAS (34.1%) and EGFR (15.9%). Kaplan-Meier analysis showed significantly better survival for NFM patients than non-NFM patients (MAL, SFM, and AUS; p = .0036). Bloody PEs and tamponade were associated with worse outcomes. The immunotherapy group achieved the most prolonged survival among stage IV patients (9.07 months; p = .017). Cox regression confirmed cytology-negative status as an independent prognostic factor. CONCLUSIONS: Cytological evaluation and ISRSFC classification are crucial for NSCLC-associated PEs. A multidisciplinary approach integrating cytology, immunohistochemistry, and molecular profiling is essential for optimal management and prognosis. CI - (c) 2025 American Cancer Society. FAU - Ma, Weijie AU - Ma W AUID- ORCID: 0000-0002-4434-1371 AD - Department of Pathology and Laboratory Medicine, Dartmouth Hitchcock Medical Center, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, USA. FAU - Rodrigues Simoes, Nathalie J AU - Rodrigues Simoes NJ AD - Department of Pathology and Laboratory Medicine, Dartmouth Hitchcock Medical Center, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, USA. FAU - Seery, Peter P AU - Seery PP AD - Department of Pathology and Laboratory Medicine, Dartmouth Hitchcock Medical Center, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, USA. FAU - Li, Tianhong AU - Li T AUID- ORCID: 0000-0001-7422-3520 AD - Division of Hematology/Oncology, Department of Internal Medicine, University of California Davis Comprehensive Cancer Center, University of California Davis School of Medicine, Sacramento, California, USA. FAU - Tafe, Laura J AU - Tafe LJ AUID- ORCID: 0000-0001-9613-641X AD - Department of Pathology and Laboratory Medicine, Dartmouth Hitchcock Medical Center, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, USA. FAU - Kerr, Darcy A AU - Kerr DA AUID- ORCID: 0000-0002-3228-2044 AD - Department of Pathology and Laboratory Medicine, Dartmouth Hitchcock Medical Center, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, USA. FAU - Liu, Xiaoying AU - Liu X AUID- ORCID: 0000-0002-0597-685X AD - Department of Pathology and Laboratory Medicine, Dartmouth Hitchcock Medical Center, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, USA. LA - eng GR - I01 BX003895/BX/BLRD VA/United States GR - P30 CA023108/CA/NCI NIH HHS/United States GR - 5P30 CA023108-37/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PL - United States TA - Cancer Cytopathol JT - Cancer cytopathology JID - 101499453 RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - Female MH - *Carcinoma, Non-Small-Cell Lung/pathology/genetics/complications/mortality MH - Male MH - Middle Aged MH - *Lung Neoplasms/pathology/genetics/complications/mortality MH - Aged MH - *Pericardial Effusion/pathology/etiology MH - Retrospective Studies MH - Prognosis MH - Adult MH - Aged, 80 and over MH - Biomarkers, Tumor/genetics MH - Mutation MH - Neoplasm Staging PMC - PMC12991063 MID - NIHMS2137524 OTO - NOTNLM OT - International System for Reporting Serous Fluid Cytopathology (ISRSFC) OT - biomarker OT - molecular characterization OT - non-small cell lung cancer OT - pericardial effusions OT - prognosis COIS- CONFLICT OF INTEREST STATEMENT The authors declare no conflicts of interest. EDAT- 2025/04/14 12:25 MHDA- 2025/04/14 12:26 PMCR- 2026/03/16 CRDT- 2025/04/14 11:18 PHST- 2025/03/09 00:00 [revised] PHST- 2024/12/15 00:00 [received] PHST- 2025/03/27 00:00 [accepted] PHST- 2025/04/14 12:26 [medline] PHST- 2025/04/14 12:25 [pubmed] PHST- 2025/04/14 11:18 [entrez] PHST- 2026/03/16 00:00 [pmc-release] AID - 10.1002/cncy.70015 [doi] PST - ppublish SO - Cancer Cytopathol. 2025 May;133(5):e70015. doi: 10.1002/cncy.70015. PMID- 40224148 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250415 IS - 1664-042X (Print) IS - 1664-042X (Electronic) IS - 1664-042X (Linking) VI - 16 DP - 2025 TI - Feasibility and safety of upper limb extremity ergometer exercise in the cardiac intensive care unit in critically ill patients with cardiac disease: a prospective observational study. PG - 1448647 LID - 10.3389/fphys.2025.1448647 [doi] LID - 1448647 AB - BACKGROUND: There is no established method for early bed rehabilitation of patients after cardiogenic shock (CS) who require mechanical circulatory support (MCS). This study aimed to evaluate the safety of early upper limb extremity ergometer exercise in critically ill patients with CS or at risk for CS. METHODS: The study was conducted as a prospective, single-center feasibility and observational study. Patients with CS or at risk for CS in the cardiac intensive care unit were enrolled. Upper limb extremity ergometer exercise was performed with alternating intervals of exercise and rest, in parallel with the rehabilitation program focused on early mobilization. A multidisciplinary team was established to determine the criteria for exercise initiation and cessation. Endpoint measures included exercise-related adverse events (circulatory or respiratory failure requiring new medical intervention, inability to continue device support, bleeding requiring hemostatic treatment at the insertion site, and exercise-related skeletal pain), vital signs, and subjective symptoms. RESULTS: Forty-seven sessions in 28 patients (71 +/- 15 years, 75% male) were included in the analysis. MCS was used in 86% of the patients, and rehabilitation was initiated within 3 +/- 1 day. Two patients had temporary dyspnea, and none discontinued exercise. There was a significant increase in heart rate (p < 0.05) and respiratory rate (p < 0.001) during exercise compared with pre-excercise, but not in systolic or diastolic blood pressure and oxygen saturation. CONCLUSION: Early upper limb extremity ergometer exercises for critically ill patients with CS or at risk for CS resulted in changes in heart rate and respiratory rate during exercise. However, no exercise-related adverse events occurred. Upper limb extremity ergometer exercise can be a new tool of physical therapy in the acute phase of patients after CS or at risk for CS. CI - Copyright (c) 2025 Hirakawa, Nakayama, Arimitsu, Kon, Ueki, Hori, Ishimoto, Ogawa, Higuchi, Hosoya, Nanasato and Isobe. FAU - Hirakawa, Kotaro AU - Hirakawa K AD - Department of Rehabilitation, Sakakibara Heart Institute, Tokyo, Japan. FAU - Nakayama, Atsuko AU - Nakayama A AD - Department of Cardiology, Sakakibara Heart Institute, Tokyo, Japan. FAU - Arimitsu, Takeshi AU - Arimitsu T AD - Department of Rehabilitation, Sakakibara Heart Institute, Tokyo, Japan. FAU - Kon, Kazuki AU - Kon K AD - Department of Rehabilitation, Sakakibara Heart Institute, Tokyo, Japan. FAU - Ueki, Hiromichi AU - Ueki H AD - Department of Rehabilitation, Sakakibara Heart Institute, Tokyo, Japan. FAU - Hori, Kentaro AU - Hori K AD - Department of Rehabilitation, Sakakibara Heart Institute, Tokyo, Japan. FAU - Ishimoto, Yuki AU - Ishimoto Y AD - Division of Nurse, Sakakibara Heart Institute, Tokyo, Japan. FAU - Ogawa, Ayaka AU - Ogawa A AD - Division of Nurse, Sakakibara Heart Institute, Tokyo, Japan. FAU - Higuchi, Ryosuke AU - Higuchi R AD - Department of Cardiology, Sakakibara Heart Institute, Tokyo, Japan. FAU - Hosoya, Yumiko AU - Hosoya Y AD - Department of Cardiology, Sakakibara Heart Institute, Tokyo, Japan. FAU - Nanasato, Mamoru AU - Nanasato M AD - Department of Cardiology, Sakakibara Heart Institute, Tokyo, Japan. FAU - Isobe, Mitsuaki AU - Isobe M AD - Sakakibara Heart Institute, Tokyo, Japan. LA - eng PT - Journal Article DEP - 20250328 PL - Switzerland TA - Front Physiol JT - Frontiers in physiology JID - 101549006 PMC - PMC11985777 OTO - NOTNLM OT - cardiac disease OT - cardiac intensive care unit OT - cardiac rehabilitation OT - cardiogenic shock OT - upper limb extremity ergometer COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2025/04/14 17:28 MHDA- 2025/04/14 17:29 PMCR- 2025/03/28 CRDT- 2025/04/14 06:56 PHST- 2024/06/29 00:00 [received] PHST- 2025/03/06 00:00 [accepted] PHST- 2025/04/14 17:29 [medline] PHST- 2025/04/14 17:28 [pubmed] PHST- 2025/04/14 06:56 [entrez] PHST- 2025/03/28 00:00 [pmc-release] AID - 1448647 [pii] AID - 10.3389/fphys.2025.1448647 [doi] PST - epublish SO - Front Physiol. 2025 Mar 28;16:1448647. doi: 10.3389/fphys.2025.1448647. eCollection 2025. PMID- 40334032 STAT- Publisher CTDT- 20250412 PB - StatPearls Publishing DP - 2025 Jan TI - Jacobsen Syndrome (11q Terminal Deletion Syndrome). BTI - StatPearls AB - Jacobsen syndrome, also known as 11q terminal deletion syndrome or 11q syndrome, is a rare genetic disorder caused by a partial deletion of the long (q) arm of chromosome 11. The syndrome was first described in 1973 by Petra Jacobsen, who reported multiple children with an inherited unbalanced 11:21 translocation from a balanced translocation carrier parent. The presentation varies and is often related to the length and location of the chromosomal terminal deletion. However, all patients develop platelet disorders, specifically Paris-Trousseau syndrome, and more than 50% of patients have congenital cardiac defects requiring medical treatment, hospitalization, or cardiac surgery. Patients with Jacobsen syndrome often have distinct facial features, including skull malformations; small, low-set ears; hypertelorism; coloboma; epicanthal folds (monolid eyes); and down-slanting palpebral fissures. Other common findings include growth and developmental delays, skeletal abnormalities, immunodeficiencies, and gastrointestinal or genitourinary malformations. Diagnosing this condition can be challenging due to incomplete penetrance and unpredictable genotype-to-phenotype correlation. Prognosis is variable and often depends on the severity of cardiac disease, with approximately 20% of infants dying in the first year of life. Although there is no cure, management focuses on surgical repair of cardiac disorders, monitoring and treating coagulopathy and immunodeficiencies, and providing supportive care for developmental delays and other comorbidities. A multidisciplinary team of healthcare professionals is essential to ensure optimal care for affected patients. CI - Copyright (c) 2025, StatPearls Publishing LLC. FAU - OBrien, Matthew P AU - OBrien MP AD - Yale University School of Medicine FAU - Corado, Andres AU - Corado A AD - Columbia University LA - eng PT - Study Guide PT - Book Chapter PL - Treasure Island (FL) COIS- Disclosure: Matthew P OBrien declares no relevant financial relationships with ineligible companies. Disclosure: Andres Corado declares no relevant financial relationships with ineligible companies. EDAT- 2025/04/12 00:00 CRDT- 2025/04/12 00:00 AID - NBK614164 [bookaccession] PMID- 40217961 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250415 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 14 IP - 7 DP - 2025 Apr 7 TI - Biomarkers of Inflammation and Association with Cardiovascular Magnetic Resonance Imaging for Risk Stratification and Outcome in Patients with Severe Aortic Stenosis. LID - 10.3390/jcm14072512 [doi] LID - 2512 AB - Background: Inflammatory indices have been proposed as simple and routinely obtainable markers of systemic inflammation in cardiac disease. This study investigated whether the neutrophil-to-lymphocyte ratio (NLR), the monocyte-to-lymphocyte ratio (MLR), and the pan-immune inflammation value (PIV) serve as biomarkers for risk stratification and outcomes measures in patients with severe aortic stenosis (AS) following valve replacement (AVR). Methods: In this retrospective analysis (January 2017-June 2022), patients with AS underwent pre-procedural cardiovascular magnetic resonance (CMR) imaging and were assigned a treatment strategy by a multidisciplinary Heart Team: (1) transcatheter AVR, (2) surgical AVR, or (3) no valvular intervention. Kaplan-Meier estimates and regression analyses were used to demonstrate associations between the NLR, MLR, and PIV with myocardial fibrosis-assessed by late gadolinium enhancement (LGE) and extracellular volume (ECV) on CMR-and a combined endpoint of heart failure hospitalizations and all-cause mortality. Results: A total of 356 patients (median age: 80 years, 50% male) were followed for a median of 40 months, during which 162 (46%) reached the combined endpoint. Linear regression identified C-reactive protein, but not the presence of LGE or elevated ECV, as the only independent predictor of all three inflammatory indices (p for all <0.001). After multivariable adjustment for clinical (EuroSCORE II), laboratory (baseline N-terminal prohormone of brain natriuretic peptide [NT-proBNP] and C-reactive protein), and imaging parameters (AV mean pressure gradient, right ventricular ejection fraction, and ECV), the above-the-upper-quartile NLR (adjusted hazard ratio [aHR]: 1.45, 95%-confidence interval [CI]: 1.01-1.92, p = 0.042), MLR (aHR: 1.48, 95%-CI: 1.05-2.09, p = 0.025), and PIV (aHR: 1.56, 95%-CI: 1.11-2.21, p = 0.011) remained significantly associated with adverse outcomes. Following AVR, the median NLR (3.5 to 3.4) and PIV (460 to 376) showed a significant post-procedural decline compared to baseline (p /= 75 years hospitalized for acute HF were included. In the UC group, patients discharged between January 2018 and December 2019 received standard follow-up with referrals to a cardiologist and general practitioner. In the CG group, patients discharged between January 2020 and July 2022 attended CG ambulatory care within three weeks of discharge. Primary outcomes were one-year all-cause mortality, HF readmissions, and DOAH. The impact of CG follow-up was assessed using a 1:1 propensity score matched (PSM) analysis. RESULTS: A total of 652 patients (mean age 86 years, 56% female) were included in the study, with 477 receiving UC and 175 referred to CG follow-up. Following a 1:1 PSM of 350 patients (50% CG), we observed a significant reduction in 1-year rehospitalizations (36.5% vs. 50.8%, p < 0.001) and mortality (20.0% vs. 40.0%, p < 0.001) in the CG group. CG patients also had nearly double median DAOH compared to UC patients (300 [IQR: 100] vs. 162 [145] days, p < 0.001). Cox regression analysis confirmed that the CG integrated approach was independently associated with a lower risk of mortality [HR 0.34, 95% CI: 0.24-0.47]. Respiratory diseases, neurological conditions, and infections were common causes of readmission. CONCLUSIONS: Early referral to a CG outpatients service post-discharge for acute HF significantly improves outcomes, highlighting the value of integrated care for older adults with complex needs. CI - (c) 2025. The Author(s). FAU - Okoye, Chukwuma AU - Okoye C AD - School of Medicine and Surgery, University of Milano-Bicocca, Via Cadore 48, Monza, 20900, Italy. chukwuma.okoye@unimib.it. AD - Fondazione IRCCS San Gerardo Dei Tintori, Monza, Italy. chukwuma.okoye@unimib.it. AD - Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm University, Stockholm, Sweden. chukwuma.okoye@unimib.it. FAU - Mazzarone, Tessa AU - Mazzarone T AD - Geriatrics Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. FAU - Finazzi, Alberto AU - Finazzi A AD - School of Medicine and Surgery, University of Milano-Bicocca, Via Cadore 48, Monza, 20900, Italy. FAU - Daniela, Guarino AU - Daniela G AD - Geriatrics Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. FAU - Bruni, Adriana Antonella AU - Bruni AA AD - Fondazione IRCCS San Gerardo Dei Tintori, Monza, Italy. FAU - Maccioni, Lorenzo AU - Maccioni L AD - Geriatrics Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. FAU - Pescatore, Giulia AU - Pescatore G AD - Geriatrics Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. FAU - Bianco, Maria Giovanna AU - Bianco MG AD - Geriatrics Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. FAU - Guerrini, Cinzia AU - Guerrini C AD - Geriatrics Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. FAU - Giusti, Andrea AU - Giusti A AD - Geriatrics Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. FAU - Bellelli, Giuseppe AU - Bellelli G AD - School of Medicine and Surgery, University of Milano-Bicocca, Via Cadore 48, Monza, 20900, Italy. giuseppe.bellelli@unimib.it. AD - Fondazione IRCCS San Gerardo Dei Tintori, Monza, Italy. giuseppe.bellelli@unimib.it. FAU - Virdis, Agostino AU - Virdis A AD - Geriatrics Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. LA - eng PT - Journal Article DEP - 20250409 PL - England TA - BMC Geriatr JT - BMC geriatrics JID - 100968548 SB - IM MH - Humans MH - Female MH - Male MH - *Heart Failure/therapy/mortality MH - Aged, 80 and over MH - Aged MH - *Patient Discharge/trends MH - Patient Readmission/statistics & numerical data MH - *Frail Elderly MH - Acute Disease MH - Ambulatory Care MH - Follow-Up Studies PMC - PMC11983887 OTO - NOTNLM OT - Cardiogeriatrics OT - Follow-up OT - Heart failure OT - Outcomes OT - Outpatients COIS- Declarations. Ethics approval and consent to participate: The study adhered to the Declaration of Helsinki and received approval from the Institutional Review Board (IRB, Tuscany Regional Ethics Committee for Clinical Experimentation: FUN-sc 23956). The IRB waived the need for informed consent for the retrospective phase, while written informed consent was obtained from all participants or their next of kin for the prospective phase. Competing interests: The authors declare no competing interests. EDAT- 2025/04/10 00:20 MHDA- 2025/04/10 06:25 PMCR- 2025/04/09 CRDT- 2025/04/09 23:47 PHST- 2024/10/16 00:00 [received] PHST- 2025/03/25 00:00 [accepted] PHST- 2025/04/10 06:25 [medline] PHST- 2025/04/10 00:20 [pubmed] PHST- 2025/04/09 23:47 [entrez] PHST- 2025/04/09 00:00 [pmc-release] AID - 10.1186/s12877-025-05883-z [pii] AID - 5883 [pii] AID - 10.1186/s12877-025-05883-z [doi] PST - epublish SO - BMC Geriatr. 2025 Apr 9;25(1):236. doi: 10.1186/s12877-025-05883-z. PMID- 40202473 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250518 IS - 2772-3747 (Electronic) IS - 2772-3747 (Linking) VI - 5 IP - 5 DP - 2025 May TI - A New Benchmark for Modern Management of Valvular Heart Disease: The Whole-Life Cycle Management System. PG - 609-632 LID - S2772-3747(25)00177-2 [pii] LID - 10.1016/j.jacasi.2025.01.017 [doi] AB - Valvular heart disease (VHD) is rapidly increasing in prevalence worldwide, affecting millions and significantly impacting global health care systems. Despite notable advancements in understanding VHD progression, perioperative management, imaging techniques, and transcatheter therapies over the past 2 decades, the condition has not received the attention it deserves from the public and policymakers. Many patients with VHD in low- and middle-income countries continue to experience low detection, intervention, and follow-up rates. Systematic care for elderly patients and those with severe comorbidities, as well as postoperative patients, remains insufficient, leading to higher mortality and morbidity rates. This review focuses on the deficiencies in VHD treatment within the Chinese health care system and discusses the modern management program, known as the whole-life cycle management system, that has been implemented to enhance the survival prognosis of VHD patients. CI - Copyright (c) 2025 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Wang, Yuqiang AU - Wang Y AD - Department of Cardiovascular Surgery and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China; Cardiovascular Surgery Research Laboratory, West China Hospital, Sichuan University, Chengdu, China. FAU - Cao, Tingqian AU - Cao T AD - Cardiovascular Surgery Research Laboratory, West China Hospital, Sichuan University, Chengdu, China; Department of Integrated Care Management Center, West China Hospital, Sichuan University, Chengdu, China. FAU - Liu, Xiang AU - Liu X AD - Cardiovascular Surgery Research Laboratory, West China Hospital, Sichuan University, Chengdu, China; Information Technology Center, West China Hospital, Sichuan University, Chengdu, China. FAU - He, Siyu AU - He S AD - Department of Cardiovascular Surgery and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China; Cardiovascular Surgery Research Laboratory, West China Hospital, Sichuan University, Chengdu, China. FAU - Ran, Zechao AU - Ran Z AD - Department of Cardiovascular Surgery and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China; Cardiovascular Surgery Research Laboratory, West China Hospital, Sichuan University, Chengdu, China. FAU - Du, Chunlin AU - Du C AD - Department of Integrated Care Management Center, West China Hospital, Sichuan University, Chengdu, China. FAU - Lu, Beiyao AU - Lu B AD - Department of Cardiovascular Surgery, West China Hospital, Sichuan University, Chengdu, China. FAU - Liu, Yahui AU - Liu Y AD - Department of Cardiovascular Surgery, West China Hospital, Sichuan University, Chengdu, China. FAU - Shi, Jun AU - Shi J AD - Department of Cardiovascular Surgery and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China; Cardiovascular Surgery Research Laboratory, West China Hospital, Sichuan University, Chengdu, China. FAU - Liu, Lulu AU - Liu L AD - Department of Cardiovascular Surgery and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China; Cardiovascular Surgery Research Laboratory, West China Hospital, Sichuan University, Chengdu, China. FAU - Zhou, Yongzhao AU - Zhou Y AD - Department of Integrated Care Management Center, West China Hospital, Sichuan University, Chengdu, China. FAU - Guo, Yingqiang AU - Guo Y AD - Department of Cardiovascular Surgery and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China; Cardiovascular Surgery Research Laboratory, West China Hospital, Sichuan University, Chengdu, China. Electronic address: drguoyq@wchscu.cn. LA - eng PT - Journal Article PT - Review DEP - 20250408 PL - United States TA - JACC Asia JT - JACC. Asia JID - 9918452380106676 PMC - PMC12081237 OTO - NOTNLM OT - heart valve clinic OT - integrated OT - multidisciplinary team OT - valvular heart disease OT - whole-life cycle COIS- Funding Support and Author Disclosures This study was supported by National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University (No. Z2024YY001). The authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2025/04/09 12:29 MHDA- 2025/04/09 12:30 PMCR- 2025/04/08 CRDT- 2025/04/09 10:30 PHST- 2024/09/23 00:00 [received] PHST- 2025/01/02 00:00 [revised] PHST- 2025/01/22 00:00 [accepted] PHST- 2025/04/09 12:30 [medline] PHST- 2025/04/09 12:29 [pubmed] PHST- 2025/04/09 10:30 [entrez] PHST- 2025/04/08 00:00 [pmc-release] AID - S2772-3747(25)00177-2 [pii] AID - 10.1016/j.jacasi.2025.01.017 [doi] PST - ppublish SO - JACC Asia. 2025 May;5(5):609-632. doi: 10.1016/j.jacasi.2025.01.017. Epub 2025 Apr 8. PMID- 40202395 OWN - NLM STAT- MEDLINE DCOM- 20250526 LR - 20250526 IS - 1744-8344 (Electronic) IS - 1477-9072 (Linking) VI - 23 IP - 4 DP - 2025 Apr TI - What is the impact of dynamic score reassessment for stroke and bleeding risk outcome prediction in atrial fibrillation patients? PG - 107-112 LID - 10.1080/14779072.2025.2489725 [doi] AB - INTRODUCTION: Dynamic reassessment of stroke and bleeding risks is a cornerstone of patient-centered care in atrial fibrillation (AF) management. Unlike traditional approaches that evaluate these risks only at diagnosis or at initiation of oral anticoagulation, current evidence emphasizes periodic reassessment due to the evolving nature of risks. AREAS COVERED: Stroke and bleeding risks in AF patients are influenced by aging, new comorbidities, and worsening health conditions, requiring updates to management plans to optimize outcomes. Dynamic increases in CHA(2)DS(2)-VASc (or the sex-less CHA(2)DS(2)-VA) and HAS-BLED scores are associated with heightened risks of stroke and bleeding, underscoring the need for regular reassessment. Addressing modifiable risk factors such as hypertension, renal dysfunction, and concurrent medications is key to improving outcomes. Although several guidelines now recommend risk reassessment at least annually, optimal timing remains unclear. Evidence supports more frequent reassessments for low-risk stroke patients (every 4 months) and high-risk bleeding patients (within 4-6 weeks) to promptly identify changes requiring intervention. EXPERT OPINION: Despite its benefits, challenges remain regarding risk reassessment, including the lack of universally applicable intervals and the complexity of multidisciplinary evaluations. Future advancements in artificial intelligence tools are expected to enhance risk reassessment by enabling more precise, personalized, and dynamic patient management. FAU - Soler-Espejo, Eva AU - Soler-Espejo E AD - Department of Hematology, Hospital Clinico Universitario Virgen de la Arrixaca, University of Murcia, Instituto Murciano de Investigacion Biosanitaria (IMIB-Arrixaca), Murcia, Spain. FAU - Marin, Francisco AU - Marin F AD - Department of Cardiology, Hospital Clinico Universitario Virgen de la Arrixaca, University of Murcia, Instituto Murciano de Investigacion Biosanitaria (IMIB-Arrixaca), CIBERCV, Murcia, Spain. FAU - Roldan, Vanessa AU - Roldan V AD - Department of Hematology, Hospital Clinico Universitario Virgen de la Arrixaca, University of Murcia, Instituto Murciano de Investigacion Biosanitaria (IMIB-Arrixaca), Murcia, Spain. FAU - Rivera-Caravaca, Jose Miguel AU - Rivera-Caravaca JM AD - Faculty of Nursing, University of Murcia, Instituto Murciano de Investigacion Biosanitaria (IMIB-Arrixaca), CIBERCV, Murcia, Spain. LA - eng PT - Journal Article PT - Review DEP - 20250410 PL - England TA - Expert Rev Cardiovasc Ther JT - Expert review of cardiovascular therapy JID - 101182328 RN - 0 (Anticoagulants) SB - IM MH - Humans MH - *Atrial Fibrillation/complications/drug therapy MH - *Hemorrhage/chemically induced/epidemiology/etiology/prevention & control MH - *Stroke/etiology/prevention & control/epidemiology MH - Risk Assessment/methods MH - *Anticoagulants/administration & dosage/adverse effects MH - Risk Factors MH - Patient-Centered Care MH - Practice Guidelines as Topic MH - Time Factors OTO - NOTNLM OT - Atrial fibrillation OT - bleeding OT - dynamic risk reassessment OT - risk prediction OT - stroke EDAT- 2025/04/09 12:28 MHDA- 2025/05/26 06:26 CRDT- 2025/04/09 09:42 PHST- 2025/05/26 06:26 [medline] PHST- 2025/04/09 12:28 [pubmed] PHST- 2025/04/09 09:42 [entrez] AID - 10.1080/14779072.2025.2489725 [doi] PST - ppublish SO - Expert Rev Cardiovasc Ther. 2025 Apr;23(4):107-112. doi: 10.1080/14779072.2025.2489725. Epub 2025 Apr 10. PMID- 40201304 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250410 IS - 1758-3896 (Electronic) IS - 1758-3896 (Print) IS - 1758-3896 (Linking) VI - 19 DP - 2025 TI - Cardio-obstetrics in the Cardiac Intensive Care Unit: An Introductory Guide. PG - e07 LID - 10.15420/usc.2024.20 [doi] LID - e07 AB - The care of the cardio-obstetric population in the cardiac intensive care unit is challenging due to limited data in this patient population. Optimal care requires a broad multidisciplinary team of experts such that both maternal and fetal health are fully supported. A deep understanding of the interplay between the hemodynamics of pregnancy and the clinical manifestations of varied cardiac disease states is essential. The assessment, diagnostic testing, and treatment of patients who are pregnant require special consideration, especially as teams consider pharmacological and invasive therapies. Complex ethical decisions often arise and therapies may be limited by federal and state policy, which adds an additional layer of complexity. This review serves as an introductory guide to cardio-obstetric care in the cardiac intensive care unit. CI - Copyright (c) The Author(s), 2025. Published by Radcliffe Group Ltd. FAU - Skowronski, Jenna AU - Skowronski J AD - Department of Cardiology, Vanderbilt University Medical Center Nashville, TN. FAU - Christenson, Eleanor AU - Christenson E AD - Heart and Vascular Institute, University of Pittsburgh Medical Center Pittsburgh, PA. FAU - Shapero, Kayle AU - Shapero K AD - Lifespan, Cardiovascular Institute, Warren Alpert Medical School, Brown University Providence, RI. FAU - Hausvater, Anais AU - Hausvater A AD - Sarah Ross Soter Center for Women's Cardiovascular Research, Leon H Charney Division of Cardiology, New York University Grossman School of Medicine New York, NY. FAU - Gage, Ann AU - Gage A AD - Department of Cardiology, Centennial Heart, Centennial Medical Center Nashville, TN. FAU - Jeyabalan, Arun AU - Jeyabalan A AD - Department of Obstetrics, Gynecology and Reproductive Sciences, Magee-Womens Hospital, University of Pittsburgh School of Medicine Pittsburgh, PA. FAU - Berlacher, Kathryn AU - Berlacher K AD - Heart and Vascular Institute, University of Pittsburgh Medical Center Pittsburgh, PA. LA - eng PT - Journal Article PT - Review DEP - 20250325 PL - England TA - US Cardiol JT - US cardiology JID - 101574791 PMC - PMC11976738 OTO - NOTNLM OT - Cardio-obstetrics OT - cardiac critical care OT - ethics OT - mechanical circulatory support OT - multidisciplinary care OT - pregnancy COIS- Disclosure: AG has received honoraria from Zoll for Fellows' Education, is Treasurer for the Society of Critical Care Cardiology, is PI for QUADRA-PE and Site PI for Empower-CAD. All other authors have no conflicts of interest to declare. EDAT- 2025/04/09 10:13 MHDA- 2025/04/09 10:14 PMCR- 2025/03/25 CRDT- 2025/04/09 04:39 PHST- 2024/03/20 00:00 [received] PHST- 2025/01/13 00:00 [accepted] PHST- 2025/04/09 10:14 [medline] PHST- 2025/04/09 10:13 [pubmed] PHST- 2025/04/09 04:39 [entrez] PHST- 2025/03/25 00:00 [pmc-release] AID - 10.15420/usc.2024.20 [doi] PST - epublish SO - US Cardiol. 2025 Mar 25;19:e07. doi: 10.15420/usc.2024.20. eCollection 2025. PMID- 40200470 OWN - NLM STAT- MEDLINE DCOM- 20250409 LR - 20250514 IS - 1879-8365 (Electronic) IS - 0926-9630 (Linking) VI - 323 DP - 2025 Apr 8 TI - Implementing PyautoGUI for Enhanced Heart Team Protocol Creation: Improving Efficiency in Cardiovascular Patient Management. PG - 179-183 LID - 10.3233/SHTI250073 [doi] AB - INTRODUCTION: The integration of the "heart team" (HT) concept has become essential in managing complex cardiovascular diseases,. Initially, decisions on CAD treatment were predominantly made by cardiologists or cardiac surgeons. However, the increasing complexity of patient data and the publication of milestone studies underscored the need for an interdisciplinary approach. The HT approach, which first gained traction in Dutch hospitals in the late 1990s, has since been endorsed by European guidelines, highlighting its importance in patient management. Conversely, managing the increasing number of multimorbid patients and the complexity of cardiovascular diagnostics has become challenging. METHODS: We have designed a standardized protocol including all necessary data for risk assessment and social medicine considerations. This protocol, while comprehensive, has become increasingly cumbersome, prompting the need for automation. We have implemented an automated script using PyautoGUI, a Python library for GUI automation, to enhance efficiency. We conducted a timed comparison of data entry efficiency between this automated software program and an experienced human operator. Each participant entered all required data elements, and the total completion times were recorded. Comparative analysis of the two methods was performed using a two-sample Student's t-test, under the assumption of normally distributed means. Statistical analyses were conducted using SPSS software, version 30.0.0. RESULTS: This script automates data entry from referring departments into our standardized heart team protocol operating via screen coordinates. The automated data entry script demonstrated a statistically significant improvement in data collection efficiency compared to manual entry, with a p-value of 0.049. This suggests that the automated approach may provide meaningful time savings in standardized protocol completion. DISCUSSION: Our automation means a crucial step in managing the increasing number of multimorbid patients and the complex therapeutic approaches. Although not fully integrated into the KIS, our approach adheres to ethical standards and provides a foundation for future advancements. CONCLUSION: This automated script allows physicians to focus on quality control and decision-making, without the burden of manual data entry. Continuous validation and optimization are essential to fully realize the benefits of automation in clinical practice, enhancing patient care and outcomes while maintaining data protection. FAU - Fernandes Branco, Roberto AU - Fernandes Branco R AD - Deutsches Herzzentrum der Charite, Department of Cardiology, Angiology and Intensive Care Medicine, Chariteplatz1, 10117 Berlin, Germany. FAU - Fernandes Branco, Diego AU - Fernandes Branco D AD - Manfred von Ardenne Gymnasium, Berlin, Germany. FAU - Mattig, Isabel AU - Mattig I AD - Deutsches Herzzentrum der Charite, Department of Cardiology, Angiology and Intensive Care Medicine, Chariteplatz1, 10117 Berlin, Germany. FAU - Lueg, Julia AU - Lueg J AD - Deutsches Herzzentrum der Charite, Department of Cardiology, Angiology and Intensive Care Medicine, Chariteplatz1, 10117 Berlin, Germany. FAU - Barzen, Gina AU - Barzen G AD - Deutsches Herzzentrum der Charite, Department of Cardiology, Angiology and Intensive Care Medicine, Chariteplatz1, 10117 Berlin, Germany. FAU - Buhring, Nanike AU - Buhring N AD - Deutsches Herzzentrum der Charite, Department of Cardiology, Angiology and Intensive Care Medicine, Chariteplatz1, 10117 Berlin, Germany. FAU - Bischoff, Sven AU - Bischoff S AD - Deutsches Herzzentrum der Charite, Department of Cardiology, Angiology and Intensive Care Medicine, Chariteplatz1, 10117 Berlin, Germany. FAU - Hegselmann, Stefan AU - Hegselmann S AD - Deutsches Herzzentrum der Charite, Department of Cardiology, Angiology and Intensive Care Medicine, Chariteplatz1, 10117 Berlin, Germany. FAU - Sundermann, Simon AU - Sundermann S AD - Deutsches Herzzentrum der Charite, Department of Cardiothoracic and Vascular Surgery, Augustenburger Platz 1, 13353 Berlin Germany. FAU - Brand, Anna AU - Brand A AD - Deutsches Herzzentrum der Charite, Department of Cardiology, Angiology and Intensive Care Medicine, Chariteplatz1, 10117 Berlin, Germany. FAU - Hindricks, Gerhard AU - Hindricks G AD - Deutsches Herzzentrum der Charite, Department of Cardiology, Angiology and Intensive Care Medicine, Chariteplatz1, 10117 Berlin, Germany. FAU - Dreger, Henryk AU - Dreger H AD - Deutsches Herzzentrum der Charite, Department of Cardiology, Angiology and Intensive Care Medicine, Augustenburger Platz 1, 13353 Berlin Germany. FAU - Spethmann, Sebastian AU - Spethmann S AD - Deutsches Herzzentrum der Charite, Department of Cardiology, Angiology and Intensive Care Medicine, Chariteplatz1, 10117 Berlin, Germany. LA - eng PT - Journal Article PL - Netherlands TA - Stud Health Technol Inform JT - Studies in health technology and informatics JID - 9214582 SB - IM MH - Humans MH - *Patient Care Team/organization & administration MH - *Cardiovascular Diseases/therapy/diagnosis MH - *Software MH - Netherlands MH - Efficiency, Organizational OTO - NOTNLM OT - Automated script OT - data entry in healthcare OT - e-health OT - heart team EDAT- 2025/04/09 10:14 MHDA- 2025/04/09 10:15 CRDT- 2025/04/09 01:00 PHST- 2025/04/09 10:15 [medline] PHST- 2025/04/09 10:14 [pubmed] PHST- 2025/04/09 01:00 [entrez] AID - SHTI250073 [pii] AID - 10.3233/SHTI250073 [doi] PST - ppublish SO - Stud Health Technol Inform. 2025 Apr 8;323:179-183. doi: 10.3233/SHTI250073. PMID- 40198815 OWN - NLM STAT- MEDLINE DCOM- 20250812 LR - 20250812 IS - 2048-8734 (Electronic) IS - 2048-8726 (Linking) VI - 14 IP - 7 DP - 2025 Aug 6 TI - Clinical management of acute myocarditis in daily practice: an expert practical view. PG - 420-431 LID - 10.1093/ehjacc/zuaf057 [doi] AB - Acute Myocarditis (AM) encompasses a broad spectrum of clinical presentations and causes. Despite the recent advances in cardiovascular imaging, pathology, virology, and genetics, specific therapies are still lacking. This collaborative review aims to analyse the current evidence to answer practical questions that physicians may face during the early management of patients presenting with an acute form of the disease, complicated or not. This review analyses current evidence to address practical questions posed by acute cardiovascular physicians during the early management of acute, or potentially, myocarditis. Based on the current literature, this review provides a step-by-step approach to treat AM patients from their admission in the cardiac intensive care unit (CICU) to discharge, by answering 10 clinical questions: Might this patient be suffering from an AM? Should I hospitalize this patient and, if so, where? Which cardiac imaging exam should I perform and what can I learn from it? Is this patient requiring an EMB? What should the non-invasive aetiological work-up be? Is her/his episode of AM of viral, toxic, or other origin? Does this patient need specific treatments or mechanical circulatory support? Is there an indication for guideline-directed medical heart failure treatment? When can the patient be discharged and resume physical activity? Notably, this review highlights the need to build a multidisciplinary response team to address the many diagnostic and therapeutic challenges of AM patients. It also points out the lack of evidence to guide the treatment of these patients. CI - (c) The Author(s) 2025. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com. FAU - Kerneis, Mathieu AU - Kerneis M AUID- ORCID: 0000-0002-7141-5209 AD - Allies in Cardiovascular Trials Initiatives and Organized Networks (ACTION) Study Group, Sorbonne Universite, INSERM UMRS1166, Hopital Pitie-Salpetriere (AP-HP), Paris, France. FAU - Ammirati, Enrico AU - Ammirati E AUID- ORCID: 0000-0002-1676-5257 AD - De Gasperis Cardio Center, Transplant Center, Niguarda Hospital, Milano, Italy. AD - Department of Health Sciences, University of Milano-Bicocca, Monza, Italy. FAU - Delmas, Clement AU - Delmas C AD - Intensive Cardiac Care Unit, Rangueil University Hospital, Toulouse 31059, France. AD - Universite Paul Sabatier Toulouse III, 118 route de Narbonne, 31062 Toulouse cedex 9, France. AD - Institute of Metabolic and Cardiovascular Diseases (I2MC), UMR-1048, National Institute of Health and Medical Research (INSERM), Toulouse, France. FAU - Heggermont, Ward AU - Heggermont W AD - Cardiovascular Research Center, Cardiology Department, AZORG Clinic Aalst, Moorselbaan 164, Aalst 9300, Belgium. FAU - Heymans, Stephane AU - Heymans S AUID- ORCID: 0000-0001-9477-7803 AD - Department of Cardiology, Centre for Heart Failure Research, Maastricht University, Maastricht, The Netherlands. AD - Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium. FAU - Lenz, Max AU - Lenz M AUID- ORCID: 0000-0003-3539-994X AD - Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna 1090, Austria. AD - Division of Cardiology, Ludwig Boltzmann Institute for Cardiovascular Research, Waehringer Guertel 18-20, Vienna 1090, Austria. FAU - Madonna, Rosalinda AU - Madonna R AD - University Cardiology Division, Pisa University Hospital and University of Pisa, Via Paradisa, 2, Pisa 56124, Italy. FAU - Morosin, Marco AU - Morosin M AD - Adult Intensive Care Unit, Royal Brompton Hospital, Royal Brompton & Harefield Hospitals, part of Guy's and St Thomas' NHS Foundation Trust, London, UK. FAU - Schaubroeck, Hannah AU - Schaubroeck H AUID- ORCID: 0000-0002-5219-4834 AD - Intensive Care Department, Ghent University Hospital, Ghent, Belgium. FAU - Sionis, Alessandro AU - Sionis A AUID- ORCID: 0000-0003-0843-9512 AD - Department of Cardiology, Hospital de la Santa Creu I Sant Pau, IIB-SantPau, Universidad Autonoma de Barcelona, Barcelona, Spain. AD - Department of Cardiology, Centro de Investigacion Biomedica en Red Enfermedades Cardiovasculares (CIBER-CV), Madrid, Spain. FAU - Tsaban, Gal AU - Tsaban G AUID- ORCID: 0000-0003-4234-6504 AD - Department of Cardiology, Soroka University Medical Center, Beersheva, Israel. AD - Faculty of Health Sciences, Ben Gurion University of the Negev, Beersheva, Israel. AD - Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA. FAU - Uzokov, Jamol AU - Uzokov J AUID- ORCID: 0000-0003-4452-3391 AD - Department of Cardiology, Republican Specialized Scientific Practical Medical Center of Therapy and Medical Rehabilitation, 4 Osiyo, Tashkent 100084, Uzbekistan. FAU - Vardanyan, Katarine AU - Vardanyan K AD - Department of Cardiology, Nork Marash Medical Center, Yerevan, Armenia. FAU - Vandenbriele, Christophe AU - Vandenbriele C AUID- ORCID: 0000-0001-5151-6400 AD - Cardiovascular Research Center, Cardiology Department, AZORG Clinic Aalst, Moorselbaan 164, Aalst 9300, Belgium. AD - Department of Critical Care, Royal Brompton & Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, UK. AD - Division of Anaesthetics, Pain Medicine and Intensive Care, Faculty of Medicine, Imperial College, London, UK. FAU - Roubille, Francois AU - Roubille F AUID- ORCID: 0000-0002-5288-9687 AD - Universite Paul Sabatier Toulouse III, 118 route de Narbonne, 31062 Toulouse cedex 9, France. AD - Department of Cardiology, PhyMedExp, Universite de Montpellier, INSERM, CNRS, CHU de Montpellier, 371 Avenue du doyen GIRAUD, 34295 Montpellier, France. LA - eng PT - Journal Article PT - Review PL - England TA - Eur Heart J Acute Cardiovasc Care JT - European heart journal. Acute cardiovascular care JID - 101591369 SB - IM MH - Humans MH - *Myocarditis/therapy/diagnosis MH - Acute Disease MH - *Disease Management OTO - NOTNLM OT - Acute cardiovascular care OT - Arrhythmias OT - Heart failure OT - Inflammation OT - Myocarditis COIS- Conflict of interest: M.K. received a grant from the French Ministry of Health (principal investigator of the investigator-driven ARAMIS Trial and the ARGO trial, a grand from the French Society of Cardiology and received consultation fees for Kiniksa, Sanofi, and Novonordisk. F.R. has received honoraria for lectures of consulting from Astra Zeneca, Servier, Boehringer, Astra Zeneca, Vifor, Bayer, Pfizer, Novartis, Servier, Novonordisk, Air liquid, Abbott, QuidelOrtho, Newcard, MSD, BMS, Sanofi, Alnylam. E.A. received a grant from the Italian Ministry of Health (GR-2019-12368506; principal investigator of the investigator-driven MYTHS [Myocarditis Therapy with Steroids] trial) and a grant from Italian Ministry of Health and NextGenerationEU (PNRR-MAD-2022-12376225) and received consultation fees for Kiniksa, Cytokinetics, and AstraZeneca. C.D. received consultation fees from Abiomed. M.L. has nothing to declare. H.S. has nothing to declare. S.H. receives funding from the IMI2-CARDIATEAM, from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement N degrees 821508; The JU receives support from the European Union's Horizon 2020 Research and Innovation Programme and EFPIA; the support from the Netherlands Cardiovascular Research Initiative, an initiative with the support of the Dutch Heart Foundation, Dutch Cardiovascular Alliance Double Dosis, 2020-B005; ZonMW-Metacor. S.H. receives personal fees for independent scientific advice on early development in the field of heart failure for AstraZeneca, Ribocure, and CSL Behring, and receives research support from AstraZeneca and CSL Behring. W.H. reports that Cardiac Research Institute Aalst receives consultancy fees on his behalf of Astra Zeneca, Boston Scientific, Biotronik, Medtronic, Microport, St Jude Medical. W.H. also reports being the local PI of the MYTHS trial and affiliated substudies. R.M. received grants from Italian Ministry of University and Research and NextGeneration EU (PNRR-M4C2-I1.3 Project PE_00000019 "Heal Italia", CUP I53C22001440006; PNRR-MR1-2022-12376879, CUP I53C22003230007; PRIN-PNRR 2022S74XWB, CUP 153D23005240006). J.U. received a grant from the World Bank Group and the Government of the Republic of Uzbekistan under the MUNIS (Modernizing Uzbekistan's National Innovation System) project (PRIM-01-28). EDAT- 2025/04/09 10:11 MHDA- 2025/08/12 18:34 CRDT- 2025/04/08 15:22 PHST- 2024/10/13 00:00 [received] PHST- 2025/02/26 00:00 [revised] PHST- 2025/04/01 00:00 [accepted] PHST- 2025/08/12 18:34 [medline] PHST- 2025/04/09 10:11 [pubmed] PHST- 2025/04/08 15:22 [entrez] AID - 8108456 [pii] AID - 10.1093/ehjacc/zuaf057 [doi] PST - ppublish SO - Eur Heart J Acute Cardiovasc Care. 2025 Aug 6;14(7):420-431. doi: 10.1093/ehjacc/zuaf057. PMID- 40197947 OWN - NLM STAT- MEDLINE DCOM- 20250409 LR - 20260506 IS - 1678-4170 (Electronic) IS - 0066-782X (Print) IS - 0066-782X (Linking) VI - 122 IP - 1 DP - 2025 Mar TI - The Complex Puzzle of Hypertrophic Phenotype: A Practical Approach for the Clinician. PG - e20240529 LID - S0066-782X2025000100401 [pii] LID - 10.36660/abc.20240529 [doi] LID - e20240529 AB - Left ventricular hypertrophy (LVH) represents a frequent observation in clinical practice. Nonetheless, the hypertrophic phenotype emerges as a common manifestation of diverse conditions, thereby presenting a diagnostic conundrum for clinicians. Differentiation among the etiologies of LVH is imperative for therapy decision-making, as different approaches must be implemented for distinct conditions, such as LVH secondary to loading changes, hypertrophic cardiomyopathy (HCM), or HCM mimics. In some instances, an erroneous or late diagnosis may lead to a progression of the underlying disease with worsening functional capacity, high morbidity and mortality. The rational use of cardiovascular multimodality imaging is of great importance when carried out in addition to a thorough clinical assessment and correlated with electrocardiographic findings, providing clues to fill the gaps, being, most of the time, the missing piece to solve this challenging puzzle. An integrative approach is of paramount importance for the evaluation of these patients, as they are often followed by several specialties, with varied systemic manifestations. Although a multidisciplinary team is needed for an optimized follow-up of these patients, the most important player in this journey is the clinician, whose mission is to bring together all the red flags and coordinate all the data for an assertive diagnosis. The objective of this review is to provide a pragmatic methodology, highlighting important clues for discriminating among the diverse conditions that result in LVH. FAU - Felix, Alex Dos Santos AU - Felix ADS AUID- ORCID: 0000-0001-7046-8707 AD - Instituto Nacional de Cardiologia, Rio de Janeiro, RJ - Brasil. AD - DASA - Diagnosticos da America SA, Rio de Janeiro, RJ - Brasil. AD - Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ - Brasil. AD - Complexo Hospitalar Americas - Vitoria / Samaritano Barra, Rio de Janeiro, RJ - Brasil. FAU - Barberato, Silvio Henrique AU - Barberato SH AUID- ORCID: 0000-0002-0711-7995 AD - CardioEco Centro de Diagnostico Cardiovascular, Curitiba, PR - Brasil. AD - Quanta Diagnostico - Ecocardiografia, Curitiba, PR - Brasil. FAU - Melo, Marcelo Dantas Tavares de AU - Melo MDT AUID- ORCID: 0000-0001-8809-8783 AD - Universidade Federal da Paraiba, Joao Pessoa, PB - Brasil. FAU - Rosa, Silvia Aguiar AU - Rosa SA AUID- ORCID: 0000-0002-8812-2330 AD - Hospital of Santa Marta, Lisboa - Portugal. AD - NOVA Medical School, Lisboa - Portugal. FAU - Cardim, Nuno AU - Cardim N AUID- ORCID: 0000-0002-3812-4872 AD - NOVA Medical School, Lisboa - Portugal. AD - Hospital CUF Descobertas, Lisboa - Portugal. LA - eng LA - por PT - Journal Article PT - Review TT - O Complexo Quebra-Cabeca do Fenotipo Hipertrofico: Uma Abordagem Pratica para o Clinico. PL - Brazil TA - Arq Bras Cardiol JT - Arquivos brasileiros de cardiologia JID - 0421031 SB - IM MH - Humans MH - Phenotype MH - *Cardiomyopathy, Hypertrophic/diagnosis/diagnostic imaging MH - *Hypertrophy, Left Ventricular/diagnosis/etiology/diagnostic imaging/physiopathology MH - Electrocardiography MH - Diagnosis, Differential PMC - PMC12013738 OAB - OABL- eng OAB - Left ventricular hypertrophy (LVH) represents a frequent observation in clinical practice. Nonetheless, the hypertrophic phenotype emerges as a common manifestation of diverse conditions, thereby presenting a diagnostic conundrum for clinicians. Differentiation among the etiologies of LVH is imperative for therapy decision-making, as different approaches must be implemented for distinct conditions, such as LVH secondary to loading changes, hypertrophic cardiomyopathy (HCM), or HCM mimics. In some instances, an erroneous or late diagnosis may lead to a progression of the underlying disease with worsening functional capacity, high morbidity and mortality. The rational use of cardiovascular multimodality imaging is of great importance when carried out in addition to a thorough clinical assessment and correlated with electrocardiographic findings, providing clues to fill the gaps, being, most of the time, the missing piece to solve this challenging puzzle. An integrative approach is of paramount importance for the evaluation of these patients, as they are often followed by several specialties, with varied systemic manifestations. Although a multidisciplinary team is needed for an optimized follow-up of these patients, the most important player in this journey is the clinician, whose mission is to bring together all the red flags and coordinate all the data for an assertive diagnosis. The objective of this review is to provide a pragmatic methodology, highlighting important clues for discriminating among the diverse conditions that result in LVH. OABL- eng COIS- Potencial conflito de interesse: Nao ha conflito com o presente artigo EDAT- 2025/04/08 13:56 MHDA- 2025/04/08 13:57 PMCR- 2025/03/18 CRDT- 2025/04/08 11:12 PHST- 2024/08/06 00:00 [received] PHST- 2024/11/26 00:00 [accepted] PHST- 2025/04/08 13:57 [medline] PHST- 2025/04/08 13:56 [pubmed] PHST- 2025/04/08 11:12 [entrez] PHST- 2025/03/18 00:00 [pmc-release] AID - S0066-782X2025000100401 [pii] AID - 10.36660/abc.20240529 [doi] PST - ppublish SO - Arq Bras Cardiol. 2025 Mar;122(1):e20240529. doi: 10.36660/abc.20240529. PMID- 40196891 OWN - NLM STAT- MEDLINE DCOM- 20250616 LR - 20250618 IS - 1522-9645 (Electronic) IS - 0195-668X (Print) IS - 0195-668X (Linking) VI - 46 IP - 23 DP - 2025 Jun 16 TI - Cardiovascular disease in chronic kidney disease. PG - 2148-2160 LID - 10.1093/eurheartj/ehaf167 [doi] AB - Individuals with chronic kidney disease (CKD) exhibit an increased risk for the development of cardiovascular disease (CVD) with its manifestations coronary artery disease, stroke, heart failure, arrhythmias, and sudden cardiac death. The presence of both, CVD and CKD has a major impact on the prognosis of patients. This association likely reflects the involvement of several pathophysiological mechanisms, including shared risk factors (e.g. diabetes and hypertension), as well as other factors such as inflammation, anaemia, volume overload, and the presence of uraemic toxins. Identifying and characterizing CKD is crucial for appropriate CVD risk prediction. Mitigating CVD risk in patients with CKD mandates a multidisciplinary approach involving cardiologists, nephrologists, and other health care professionals. The present State-of-the-Art Review addresses the current understanding on the pathophysiological link between CVD and CKD, clinical implications and challenges in the treatment of these patients. CI - (c) The Author(s) 2025. Published by Oxford University Press on behalf of the European Society of Cardiology. FAU - Marx-Schutt, Katharina AU - Marx-Schutt K AUID- ORCID: 0000-0002-0162-5219 AD - Department of Internal Medicine I, University Hospital Aachen, RWTH Aachen, Pauwelsstrasse 30, Aachen D-52074, Aachen, Germany. FAU - Cherney, David Z I AU - Cherney DZI AD - Department of Medicine, Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada. FAU - Jankowski, Joachim AU - Jankowski J AUID- ORCID: 0000-0002-4528-2967 AD - Institute for Molecular Cardiovascular Research, University Hospital, RWTH Aachen, Pauwelsstrasse 30, Aachen 52074, Germany. FAU - Matsushita, Kunihiro AU - Matsushita K AUID- ORCID: 0000-0002-7179-718X AD - Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. FAU - Nardone, Massimo AU - Nardone M AUID- ORCID: 0000-0002-1990-6481 AD - Department of Medicine, Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada. FAU - Marx, Nikolaus AU - Marx N AUID- ORCID: 0000-0001-6141-634X AD - Department of Internal Medicine I, University Hospital Aachen, RWTH Aachen, Pauwelsstrasse 30, Aachen D-52074, Aachen, Germany. LA - eng GR - TRR 219/German Research Foundation/ GR - University of Toronto/ GR - University of Toronto Merit Award/ GR - CAPMC/CIHR/Canada GR - Diabetes Canada/ GR - Heart & Stroke/Richard Lewar Centre of Excellence in Cardiovascular Research/ GR - Canadian Institutes of Health Research-Kidney Foundation of Canada Team Grant/ GR - CAPMC/CIHR/Canada PT - Journal Article PT - Review PL - England TA - Eur Heart J JT - European heart journal JID - 8006263 SB - IM MH - Humans MH - *Renal Insufficiency, Chronic/complications/physiopathology/therapy MH - *Cardiovascular Diseases/etiology/physiopathology MH - Risk Factors MH - Prognosis PMC - PMC12167664 OTO - NOTNLM OT - CV risk OT - Cardiovascular disease OT - Chronic kidney disease OT - GLP-1 receptor agonists OT - Non-steroidal MRAs OT - SGLT2 inhibitors EDAT- 2025/04/08 06:25 MHDA- 2025/06/16 11:11 PMCR- 2025/04/08 CRDT- 2025/04/08 05:00 PHST- 2024/10/10 00:00 [received] PHST- 2025/01/07 00:00 [revised] PHST- 2025/03/05 00:00 [accepted] PHST- 2025/06/16 11:11 [medline] PHST- 2025/04/08 06:25 [pubmed] PHST- 2025/04/08 05:00 [entrez] PHST- 2025/04/08 00:00 [pmc-release] AID - 8107983 [pii] AID - ehaf167 [pii] AID - 10.1093/eurheartj/ehaf167 [doi] PST - ppublish SO - Eur Heart J. 2025 Jun 16;46(23):2148-2160. doi: 10.1093/eurheartj/ehaf167. PMID- 40196049 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250409 IS - 2050-0904 (Print) IS - 2050-0904 (Electronic) IS - 2050-0904 (Linking) VI - 13 IP - 4 DP - 2025 Apr TI - Infective Endocarditis Caused by Abiotrophia defectiva: A Unique Case Complicated by Mitral Valve Perforation. PG - e70400 LID - 10.1002/ccr3.70400 [doi] LID - e70400 AB - Abiotrophia defectiva, a nutritionally variant streptococcus, represents a rare yet serious cause of infective endocarditis (IE), accounting for 1%-2% of the total IE cases. It affects native valves in 10% of patients, and it is implicated in catastrophic complications. A 33-year-old medically free male presented with a persistent nonproductive cough for 4 months. It was associated with unintentional weight loss (10 kg); however, he denied any other symptoms. His symptoms started after he had a dental implant. Physical examination was unremarkable except for a systolic murmur. Upon further investigations, a blood culture showed Abiotrophia defectiva, and echocardiography demonstrated severe mitral regurgitation originating from the perforation site located on the posterior leaflet measuring 10 x 4 mm, in addition to 2 masses suggestive of vegetations, the largest measuring 10 x 6 mm. The patient was hospitalized as a case of IE and acute mitral valve regurgitation. In light of mitral valve perforation, large vegetation, and bacteremia, an urgent multidisciplinary decision to proceed with mitral valve replacement was made, and the patient received a total of 6 weeks of antibiotics. Physicians should remain highly vigilant for IE, its rare causes, and associated complications. In addition, managing complex cases of IE necessitates a multidisciplinary team approach between cardiology, infectious diseases, and cardiac surgery teams. CI - (c) 2025 The Author(s). Clinical Case Reports published by John Wiley & Sons Ltd. FAU - Ababneh, Ra'ed AU - Ababneh R AUID- ORCID: 0009-0001-2073-6619 AD - Internal Medicine Hamad Medical Corporation Doha Qatar. FAU - Rhabneh, Laith AU - Rhabneh L AD - Internal Medicine HMH Ocean University Medical Center USA. FAU - Qaddour, Shahd AU - Qaddour S AD - Diagnostic Radiology King Abdullah University Hospital Irbid Jordan. FAU - Algorani, Emad AU - Algorani E AD - Internal Medicine Hamad Medical Corporation Doha Qatar. FAU - Aloqaily, Mohammed AU - Aloqaily M AD - University of Maryland Medical Center Midtown Campus Baltimore Maryland USA. FAU - Abool Maaly, Cheikh Ahmed AU - Abool Maaly CA AD - Cardiology Hamad Medical Corporation Doha Qatar. LA - eng PT - Journal Article DEP - 20250406 PL - England TA - Clin Case Rep JT - Clinical case reports JID - 101620385 PMC - PMC11972973 OTO - NOTNLM OT - Abiotrophia defectiva OT - cardiovascular OT - dental procedure-related infections OT - endocarditis complications OT - infective endocarditis COIS- The authors declare no conflicts of interest. EDAT- 2025/04/08 06:25 MHDA- 2025/04/08 06:26 PMCR- 2025/04/06 CRDT- 2025/04/08 04:27 PHST- 2025/01/07 00:00 [received] PHST- 2025/03/21 00:00 [revised] PHST- 2025/03/26 00:00 [accepted] PHST- 2025/04/08 06:26 [medline] PHST- 2025/04/08 06:25 [pubmed] PHST- 2025/04/08 04:27 [entrez] PHST- 2025/04/06 00:00 [pmc-release] AID - CCR370400 [pii] AID - 10.1002/ccr3.70400 [doi] PST - epublish SO - Clin Case Rep. 2025 Apr 6;13(4):e70400. doi: 10.1002/ccr3.70400. eCollection 2025 Apr. PMID- 40195614 OWN - NLM STAT- MEDLINE DCOM- 20250704 LR - 20260826 IS - 1522-726X (Electronic) IS - 1522-1946 (Print) IS - 1522-1946 (Linking) VI - 106 IP - 1 DP - 2025 Jul TI - Emergent Cardiac Surgery After Transcatheter Structural Heart Procedures: Narrative Review. PG - 136-143 LID - 10.1002/ccd.31519 [doi] AB - Transcatheter structural heart procedures have become standard therapy for elderly patients with high surgical risk. Over time, these procedures have significantly increased worldwide, accompanied by a concomitant reduction of major complications, including those requiring emergent cardiac surgery (ECS). This marked decline in ECS is due to technological advancements, improved patient selection and procedural techniques, and increased institutional and operators expertize. Moreover, most major structural complications after transcatheter structural heart procedures are now managed percutaneously, with only a small proportion requiring ECS. It is important to note that outcomes for patients requiring ECS remain unfavorable, even in the optimal setting. Currently, ECS after percutaneous structural interventions is very rare, less than 0.5%, as reported in multicenter available studies. However, fragmented data exist in the literature on the need of ECS. Indeed, low incidence, different definitions, and lack of recent reports make it difficult to have a precise and up-to-date overview of bailout surgery for treatment of procedural complications. This is the first comprehensive analysis focusing on ECS following the major frequent percutaneous structural procedures, that is, transcatheter aortic valve replacement, mitral valve repair/replacement, and left atrial appendage occlusion. More in general, a collaborative approach among Heart Team members, along with thorough procedural planning guided by advanced imaging techniques, is essential for ensuring high-quality interventions thus minimizing the risk of adverse events. CI - (c) 2025 The Author(s). Catheterization and Cardiovascular Interventions published by Wiley Periodicals LLC. FAU - Compagnone, Miriam AU - Compagnone M AUID- ORCID: 0000-0002-3458-8717 AD - Interventional and Structural Cardiovascular Unit, Forli-Cesena, AUSL Romagna, Italy. FAU - Dall'Ara, Gianni AU - Dall'Ara G AUID- ORCID: 0000-0003-1394-402X AD - Interventional and Structural Cardiovascular Unit, Forli-Cesena, AUSL Romagna, Italy. AD - Department of Medical and Surgical Sciences-DIMEC-Alma Mater Studiorum, University of Bologna, Bologna, Italy. FAU - Grotti, Simone AU - Grotti S AD - Interventional and Structural Cardiovascular Unit, Forli-Cesena, AUSL Romagna, Italy. FAU - Sparta, Daniela AU - Sparta D AD - Interventional and Structural Cardiovascular Unit, Forli-Cesena, AUSL Romagna, Italy. FAU - Guerrieri, Giuseppe AU - Guerrieri G AD - Cardiology Unit, Bufalini Hospital Cesena, Cesena, Italy. FAU - Pizzi, Carmine AU - Pizzi C AD - Department of Medical and Surgical Sciences-DIMEC-Alma Mater Studiorum, University of Bologna, Bologna, Italy. AD - Cardiology Unit, Morgagni Pierantoni Hospital Forli, Forli, Italy. FAU - Tarantino, Fabio Felice AU - Tarantino FF AD - Interventional and Structural Cardiovascular Unit, Forli-Cesena, AUSL Romagna, Italy. FAU - Galvani, Marcello AU - Galvani M AD - Cardiovascular Research Unit, Fondazione Cardiologica Sacco, Forli, Italy. LA - eng PT - Journal Article PT - Review DEP - 20250407 PL - United States TA - Catheter Cardiovasc Interv JT - Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions JID - 100884139 SB - IM MH - Humans MH - *Cardiac Catheterization/adverse effects/mortality/instrumentation MH - Risk Factors MH - Treatment Outcome MH - *Heart Valve Prosthesis Implantation/adverse effects/mortality/instrumentation MH - Emergencies MH - Risk Assessment MH - *Transcatheter Aortic Valve Replacement/adverse effects MH - *Postoperative Complications/surgery/diagnostic imaging/etiology/mortality MH - *Cardiac Surgical Procedures/adverse effects/mortality MH - Aged PMC - PMC12231157 OTO - NOTNLM OT - emergent cardiac surgery OT - left atrial appendage occlusion OT - transcatheter aortic valve replacement OT - transcatheter edge-to-edge repair COIS- The authors declare no conflicts of interest. EDAT- 2025/04/08 06:24 MHDA- 2025/07/04 12:41 PMCR- 2025/07/07 CRDT- 2025/04/08 02:44 PHST- 2025/03/06 00:00 [revised] PHST- 2024/10/19 00:00 [received] PHST- 2025/03/23 00:00 [accepted] PHST- 2025/07/04 12:41 [medline] PHST- 2025/04/08 06:24 [pubmed] PHST- 2025/04/08 02:44 [entrez] PHST- 2025/07/07 00:00 [pmc-release] AID - CCD31519 [pii] AID - 10.1002/ccd.31519 [doi] PST - ppublish SO - Catheter Cardiovasc Interv. 2025 Jul;106(1):136-143. doi: 10.1002/ccd.31519. Epub 2025 Apr 7. PMID- 40194269 OWN - NLM STAT- MEDLINE DCOM- 20250407 LR - 20260909 IS - 1438-8871 (Electronic) IS - 1439-4456 (Print) IS - 1438-8871 (Linking) VI - 27 DP - 2025 Apr 7 TI - Psychological eHealth Interventions for Patients With Cardiovascular Diseases: Systematic Review and Meta-Analysis. PG - e57368 LID - 10.2196/57368 [doi] LID - e57368 AB - BACKGROUND: Psychological distress is recognized as an independent risk factor for cardiovascular diseases (CVDs), contributing to increased morbidity and mortality. While eHealth is increasingly used to deliver psychological interventions, their effectiveness for patients with CVDs remains unclear. OBJECTIVE: This meta-analysis aimed to evaluate the effects of eHealth psychological interventions for patients with CVDs. METHODS: Eligible studies were retrieved from 5 databases (Embase, Medline, PubMed, CINAHL, and Cochrane Library), covering the period from database inception to December 2024. Randomized controlled trials (RCTs) investigating the effect of evidence-based psychological eHealth interventions to improve psychosocial well-being and cardiovascular outcomes for people with CVDs were included. The Cochrane Risk of Bias tool (version 2) was used to judge the methodological quality of reviewed studies. RevMan (version 5.3) was used for meta-analysis. RESULTS: A total of 12 RCTs, comprising 2319 participants from 10 countries, were included in the review. The results demonstrated significant alleviation of depressive symptoms for patients receiving psychological eHealth intervention compared to controls (number of paper included in that particular analysis, n=7; standardized mean difference=-0.30, 95% CI -0.47 to -0.14; I(2)=57%; P<.001). More specifically, in 6 trials where internet-based cognitive behavioral therapy was delivered, a significant alleviation of depressive symptoms was achieved (standardized mean difference=-0.39, 95% CI -0.56 to -0.21; I(2)=53%; P<.001). There was no significant change in anxiety or quality of life. Synthesis without meta-analysis regarding stress, adverse events, and cardiovascular events showed inconclusive findings. CONCLUSIONS: Psychological eHealth interventions, particularly internet-based cognitive behavioral therapy, can significantly reduce depressive symptoms among patients with CVDs. A multidisciplinary approach is crucial for comprehensively improving psychological and cardiovascular outcomes. Future studies should explore integrating persuasive design features into eHealth and involving mental health professionals for intervention delivery. TRIAL REGISTRATION: PROSPERO CRD42023452276; https://www.crd.york.ac.uk/PROSPERO/view/CRD42023452276. CI - (c)Jing Jing Su, Rose Lin, Ladislav Batalik, Arkers Kwan Ching Wong, Sherry L Grace. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 07.04.2025. FAU - Su, Jing Jing AU - Su JJ AUID- ORCID: 0000-0002-8242-811X AD - School of Nursing, Tung Wah College, Hong Kong, China (Hong Kong). AD - Translational Research Center for Digital Mental Health, Tung Wah College, Hong Kong, China (Hong Kong). FAU - Lin, Rose AU - Lin R AUID- ORCID: 0000-0002-7670-1247 AD - Elaine C. Hubbard Center for Nursing Research on Aging, School of Nursing, University of Rochester, Rochester, NY, United States. FAU - Batalik, Ladislav AU - Batalik L AUID- ORCID: 0000-0003-2147-1541 AD - Department of Physiotherapy and Rehabilitation, Faculty of Medicine, Masaryk University, Brno, Czech Republic. AD - Department of Rehabilitation, University Hospital Brno, Brno, Czech Republic. FAU - Wong, Arkers Kwan Ching AU - Wong AKC AUID- ORCID: 0000-0001-6708-3099 AD - School of Nursing, Hong Kong Polytechnic University, Hong Kong, China (Hong Kong). FAU - Grace, Sherry L AU - Grace SL AUID- ORCID: 0000-0001-7063-3610 AD - Faculty of Health, York University, Toronto, ON, Canada. AD - KITE-Toronto Rehabilitation Institute, University Health Network, University of Toronto, Toronto, ON, Canada. AD - Peter Munk Cardiac Centre, University Health Network, University of Toronto, Toronto, ON, Canada. LA - eng PT - Journal Article PT - Meta-Analysis PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20250407 PL - Canada TA - J Med Internet Res JT - Journal of medical Internet research JID - 100959882 SB - IM MH - Humans MH - *Cardiovascular Diseases/psychology/therapy MH - *Telemedicine MH - Randomized Controlled Trials as Topic MH - Depression/therapy MH - Cognitive Behavioral Therapy PMC - PMC12012401 OTO - NOTNLM OT - CBT OT - CVD OT - Cochrane Risk of Bias Tool OT - GRADE approach OT - anxiety OT - cardiology OT - cardiovascular diseases OT - cognitive behavioral therapy OT - depression OT - digital health OT - eHealth OT - evidence-based OT - heart OT - high-risk OT - iCBT OT - internet-based OT - mental health OT - meta-analysis OT - psychological OT - psychological intervention OT - psychological therapy OT - psychosocial OT - psychotherapy OT - systematic review COIS- Conflicts of Interest: None declared. EDAT- 2025/04/07 18:24 MHDA- 2025/04/07 18:25 PMCR- 2025/04/07 CRDT- 2025/04/07 16:52 PHST- 2024/02/14 00:00 [received] PHST- 2025/03/14 00:00 [accepted] PHST- 2025/02/10 00:00 [revised] PHST- 2025/04/07 18:25 [medline] PHST- 2025/04/07 18:24 [pubmed] PHST- 2025/04/07 16:52 [entrez] PHST- 2025/04/07 00:00 [pmc-release] AID - v27i1e57368 [pii] AID - 10.2196/57368 [doi] PST - epublish SO - J Med Internet Res. 2025 Apr 7;27:e57368. doi: 10.2196/57368. PMID- 40193655 OWN - NLM STAT- MEDLINE DCOM- 20250407 LR - 20250530 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 104 IP - 14 DP - 2025 Apr 4 TI - Impact of multidisciplinary collaborative jejunal nutrition care on nutritional status and quality of life in severely burned patients. PG - e41965 LID - 10.1097/MD.0000000000041965 [doi] LID - e41965 AB - To access the impact of multidisciplinary collaborative jejunal nutrition care on the nutritional status, pain level, wound healing, and quality of life in severely burned cases. A total of 120 cases with severe burns who visited our hospital from January 2021 to May 2023 were enrolled. Inclusion criteria: 1 in circle severe burn diagnosis; 2 in circle admission within 18 hours; 3 in circle normal heart, liver, kidney, and cognitive function; 4 in circle informed consent signed. Exclusion criteria: 1 in circle consumptive/metabolic diseases; 2 in circle malignant tumors; 3 in circle midway death; 4 in circle pregnant or lactating women. Patients were divided into 2 groups: control (n = 60) receiving parenteral nutrition and observation (n = 60) receiving multidisciplinary collaborative jejunal nutrition care. The latter included a multidisciplinary team (burns, endocrinology, cardiology, nephrology) and professionally trained caregivers. The jejunal nutrition care included the placement of a nasojejunal tube, individualized nutrition infusion protocols, close monitoring of vital signs, psychological counseling, and regular consultations with the multidisciplinary team. Outcomes assessed included hemoglobin, transferrin, albumin levels, pain (Visual Analogue Scale), wound healing, complications, SF-36 quality of life, and nursing satisfaction. After management, the observation group indicated significantly higher levels of hemoglobin (mean difference: 16.28 g/L, 95% CI: 12.5-20.1; Cohen d: 2.0, 95% CI: 1.7-2.3), transferrin (mean difference: 0.67 g/L, 95% CI: 0.5-0.9; Cohen d: 2.5, 95% CI: 2.1-3.0), and albumin (mean difference: 5.26 g/L, 95% CI: 4.2-6.3; Cohen d: 3.5, 95% CI: 3.0-4.0) compared to the control group (P < .05). The Visual Analogue Scale scores in the observation group were significantly lower (mean difference: 3.18 points, 95% CI: 2.8-3.5; Cohen d: 6.5, 95% CI: 5.9-7.2), and the wound healing time was significantly shorter (mean difference: 7.41 days, 95% CI: 4.5-10.3; Cohen d: 0.8, 95% CI: 0.6-1.0, P < .05). The observation group showed a lower complication rate (P = .02). Additionally, the observation group demonstrated significant improvements in SF-36 quality of life scores and higher nursing satisfaction (96.67% vs 80.00%, P = .0001). Multidisciplinary collaborative jejunal nutrition care effectively improves nutritional status, reduces pain, accelerates wound healing, and enhances quality of life and satisfaction in severely burned patients. CI - Copyright (c) 2025 the Author(s). Published by Wolters Kluwer Health, Inc. FAU - Zou, Fang AU - Zou F AD - Burn Intensive Care Unit, The Affiliated Hospital of Jiangnan University, Jiangsu, Wuxi, China. FAU - Sun, Dan AU - Sun D AD - Department of Burns and Plastic Surgery, The Affiliated Hospital of Jiangnan University, Jiangsu, Wuxi, China. FAU - Chang, Jiang AU - Chang J AD - Department of Burns and Plastic Surgery, The Affiliated Hospital of Jiangnan University, Jiangsu, Wuxi, China. FAU - Huang, Chonggen AU - Huang C AD - Burn Intensive Care Unit, The Affiliated Hospital of Jiangnan University, Jiangsu, Wuxi, China. FAU - Zhou, Qing AU - Zhou Q AD - Burn Intensive Care Unit, The Affiliated Hospital of Jiangnan University, Jiangsu, Wuxi, China. FAU - Ding, Lingtao AU - Ding L AUID- ORCID: 0009-0006-5083-8778 AD - Burn Intensive Care Unit, The Affiliated Hospital of Jiangnan University, Jiangsu, Wuxi, China. LA - eng PT - Journal Article PT - Observational Study PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R SB - IM MH - Humans MH - *Quality of Life MH - Female MH - *Nutritional Status MH - Male MH - Adult MH - *Burns/therapy/complications MH - Middle Aged MH - *Patient Care Team MH - Wound Healing MH - *Enteral Nutrition/methods MH - Jejunum PMC - PMC11977715 OTO - NOTNLM OT - multidisciplinary collaborative based jejunal nutrition care OT - nutritional status OT - quality of life OT - severe burns COIS- The authors have no funding and conflicts of interest to disclose. EDAT- 2025/04/07 18:24 MHDA- 2025/04/07 18:25 PMCR- 2025/04/04 CRDT- 2025/04/07 15:22 PHST- 2025/04/07 18:25 [medline] PHST- 2025/04/07 18:24 [pubmed] PHST- 2025/04/07 15:22 [entrez] PHST- 2025/04/04 00:00 [pmc-release] AID - 00005792-202504040-00025 [pii] AID - MD-D-24-11720 [pii] AID - 10.1097/MD.0000000000041965 [doi] PST - ppublish SO - Medicine (Baltimore). 2025 Apr 4;104(14):e41965. doi: 10.1097/MD.0000000000041965. PMID- 40192959 OWN - NLM STAT- MEDLINE DCOM- 20250924 LR - 20260925 IS - 1439-0973 (Electronic) IS - 0300-8126 (Print) IS - 0300-8126 (Linking) VI - 53 IP - 5 DP - 2025 Oct TI - Factors associated with persistent bacteraemia among patients with suspected infective endocarditis. PG - 2015-2024 LID - 10.1007/s15010-025-02537-5 [doi] AB - PURPOSE: To ascertain the predictors of persistent bacteraemia among patients with suspected infective endocarditis (IE) and those with IE. METHODS: Retrospective study. SETTING: This study conducted at a Swiss university hospital (2015-2023) included adult patients with bacteraemia and suspected IE. Persistent bacteraemia was defined as continued positive blood cultures with the same microorganism for at least 48 h from antibiotic treatment initiation. Endocarditis Team classified cases as IE or not IE. RESULTS: Among 2312 episodes of suspected IE, S. aureus was the most common pathogen (1045 episodes; 45%). IE (644; 28%) was the most prevalent infection type. Persistent bacteraemia was observed in 480 (21%) episodes and was independently associated with S. aureus, >/= 2 positive sets of index blood cultures, resistant bacterium, sepsis, IE, central venous catheter-associated bacteraemia, and acute native bone and joint infections (BJIs), while, streptococcal bacteraemia, appropriate initial antimicrobial treatment and, performance of source control interventions within 48 h were associated with rapid blood culture clearance. Of the 644 IE episodes, persistent bacteraemia was observed in 196 (30%) and was associated with obesity, S. aureus, >/= 2 positive sets of index blood cultures, resistant bacterium, acute native BJIs, immunologic phenomena, thoracic embolic events, while streptococcal bacteraemia and performance of source control interventions within 48 h were associated with rapid clearance of blood cultures. CONCLUSIONS: Persistent bacteraemia was associated with S. aureus and BJI. Delaying source control interventions may increase the risk of persistent bacteraemia. No specific intracardiac lesion was associated with persistent bacteraemia in IE episodes. CI - (c) 2025. The Author(s). FAU - Teixeira-Antunes, Andre AU - Teixeira-Antunes A AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Zimmermann, Virgile AU - Zimmermann V AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Fourre, Nicolas AU - Fourre N AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Ianculescu, Nicoleta AU - Ianculescu N AD - Department of Cardiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Monney, Pierre AU - Monney P AD - Department of Cardiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Tzimas, Georgios AU - Tzimas G AD - Department of Cardiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Senn, Laurence AU - Senn L AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. AD - Infection Prevention and Control Unit, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Tozzi, Piergiorgio AU - Tozzi P AD - Department of Cardiac Surgery, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Kirsch, Matthias AU - Kirsch M AD - Department of Cardiac Surgery, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Guery, Benoit AU - Guery B AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Papadimitriou-Olivgeris, Matthaios AU - Papadimitriou-Olivgeris M AUID- ORCID: 0000-0003-0565-5105 AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. Matthaios.Papadimitriou-Olivgeris@hopitalvs.ch. AD - Infectious Diseases Service, Hospital of Valais and Institut Central des Hopitaux, Sion, 1951, Switzerland. Matthaios.Papadimitriou-Olivgeris@hopitalvs.ch. LA - eng PT - Journal Article DEP - 20250407 PL - Germany TA - Infection JT - Infection JID - 0365307 RN - 0 (Anti-Bacterial Agents) SB - IM MH - Humans MH - *Bacteremia/epidemiology/microbiology MH - Male MH - Female MH - Retrospective Studies MH - Middle Aged MH - Aged MH - Risk Factors MH - *Endocarditis/microbiology/epidemiology/complications MH - Adult MH - Anti-Bacterial Agents/therapeutic use MH - Switzerland/epidemiology MH - Blood Culture MH - Staphylococcus aureus/isolation & purification MH - Staphylococcal Infections/epidemiology MH - Aged, 80 and over MH - *Endocarditis, Bacterial/microbiology/epidemiology PMC - PMC12460498 OTO - NOTNLM OT - Bone and joint infection OT - Follow-up blood cultures OT - Infective endocarditis OT - Persistent bacteraemia OT - Sepsis COIS- Declarations. Ethics approval: The study adhered to the Declaration of Helsinki and was approved by the ethics committee of the Canton of Vaud (CER-VD 2021-02516, CER-VD 2017-02137). Consent to participate: Due to the retrospective nature of the study, the ethic committee waived the need of informed consent to participate. However, patients were excluded if they had previously refused to permit the use of their data for research purposes. Consent to publish: Due to the retrospective nature of the study, the ethic committee waived the need of informed consent to publish. However, patients were excluded if they had previously refused to permit the use of their data for research purposes. Competing interests: The authors declare no competing interests. EDAT- 2025/04/07 13:16 MHDA- 2025/09/24 13:02 PMCR- 2025/04/07 CRDT- 2025/04/07 11:21 PHST- 2025/02/04 00:00 [received] PHST- 2025/03/31 00:00 [accepted] PHST- 2025/09/24 13:02 [medline] PHST- 2025/04/07 13:16 [pubmed] PHST- 2025/04/07 11:21 [entrez] PHST- 2025/04/07 00:00 [pmc-release] AID - 10.1007/s15010-025-02537-5 [pii] AID - 2537 [pii] AID - 10.1007/s15010-025-02537-5 [doi] PST - ppublish SO - Infection. 2025 Oct;53(5):2015-2024. doi: 10.1007/s15010-025-02537-5. Epub 2025 Apr 7. PMID- 40188904 OWN - NLM STAT- MEDLINE DCOM- 20250625 LR - 20260505 IS - 1552-6259 (Electronic) IS - 0003-4975 (Linking) VI - 120 IP - 1 DP - 2025 Jul TI - Lessons from 19 Years of a Pediatric Heart Surgery Volunteer Program in Jamaica: Partnership, Teamwork, and Sustainability. PG - 157-166 LID - S0003-4975(25)00294-2 [pii] LID - 10.1016/j.athoracsur.2025.03.030 [doi] AB - BACKGROUND: The purpose of this analysis was to review our 19-year experience (2006-2024) of a pediatric cardiac surgery volunteer program in Jamaica and to examine the transition of surgical responsibility to the local team, case complexity, and Operative Mortality. METHODS: This was a retrospective study with a prospectively maintained database. Data points included diagnosis, procedure, surgeon, assistant, patient age, weight, sex, postoperative complications, and Operative Mortality. RESULTS: A total of 142 index pediatric cardiac operations were performed on 137 patients. The mean age was 5.2 years (SD +/- 5.1 years), with a range from 0 days to 16.9 years. The mean patient weight was 17.5 kg (SD +/- 14.6 kg), with a range of 2.2 to 62 kg; 47.7% (n = 52) of patients were male and 52.3% (n = 57) were female. Operative complexity varied during the course of the 14 mission trips. There was a 5-year pause in mission trips (2018-2022), largely due to COVID-19. During the course of 13 operative mission trips in 18 years (2007-2024), the primary surgeon transitioned from the visiting surgeon to the local surgeon. In 2007 and 2008, 100% of cases were performed by visiting surgeons, whereas in 2024, only 33% of cases were performed by the visiting surgeons; 5.6% (n = 8/142) of patients had postoperative mediastinal reexplorations, with 1 patient having 2 reexplorations. Operative Mortality was 5 of 142 (3.5%). CONCLUSIONS: A 19-year collaboration between the local Jamaican team and the visiting team, based on partnership, teamwork, and sustainability, allowed gradual and safe transition of surgical leadership to the local Jamaican team. CI - Copyright (c) 2025 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved. FAU - Ramdeen, Sanjhai L AU - Ramdeen SL AD - Departments of Surgery and Pediatrics, Congenital Heart Center, University of Florida, Gainesville, Florida; Cardiac Kids Foundation of Florida, St Petersburg, Florida; Department of Cardiac Surgery, Frankel Cardiovascular Center, University of Michigan, Ann Arbor, Michigan. FAU - Little, Sherard G H AU - Little SGH AD - Bustamante Hospital for Children, Kingston, Jamaica, West Indies. FAU - Forrester, Sharonne AU - Forrester S AD - Bustamante Hospital for Children, Kingston, Jamaica, West Indies. FAU - Patterson, Cleopatra AU - Patterson C AD - Bustamante Hospital for Children, Kingston, Jamaica, West Indies. FAU - Morris, Tamra Tomlinson AU - Morris TT AD - Bustamante Hospital for Children, Kingston, Jamaica, West Indies. FAU - Cooper, David S AU - Cooper DS AD - Cardiac Kids Foundation of Florida, St Petersburg, Florida; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio; Cincinnati Children's Hospital Medical Center (CCHMC), Cincinnati, Ohio. FAU - Vener, David F AU - Vener DF AD - Cardiac Kids Foundation of Florida, St Petersburg, Florida; Division of Pediatric Cardiovascular Anesthesiology, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas. FAU - Justice, Lindsey B AU - Justice LB AD - Cardiac Kids Foundation of Florida, St Petersburg, Florida; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio; Cincinnati Children's Hospital Medical Center (CCHMC), Cincinnati, Ohio. FAU - Redmer, Wendy E AU - Redmer WE AD - Departments of Surgery and Pediatrics, Congenital Heart Center, University of Florida, Gainesville, Florida; Cardiac Kids Foundation of Florida, St Petersburg, Florida. FAU - Hoag, Katie AU - Hoag K AD - Cardiac Kids Foundation of Florida, St Petersburg, Florida. FAU - Lucas, Kayla V AU - Lucas KV AD - Departments of Surgery and Pediatrics, Congenital Heart Center, University of Florida, Gainesville, Florida; Cardiac Kids Foundation of Florida, St Petersburg, Florida. FAU - Walker, Douglas J AU - Walker DJ AD - Departments of Surgery and Pediatrics, Congenital Heart Center, University of Florida, Gainesville, Florida; Cardiac Kids Foundation of Florida, St Petersburg, Florida. FAU - McDonald, Donna E AU - McDonald DE AD - Cardiac Kids Foundation of Florida, St Petersburg, Florida; The Society of Thoracic Surgeons, Chicago, Illinois. FAU - Hewitt, LeeAnn AU - Hewitt L AD - Departments of Surgery and Pediatrics, Congenital Heart Center, University of Florida, Gainesville, Florida; Cardiac Kids Foundation of Florida, St Petersburg, Florida. FAU - Sukumar, Sarah AU - Sukumar S AD - Departments of Surgery and Pediatrics, Congenital Heart Center, University of Florida, Gainesville, Florida; Cardiac Kids Foundation of Florida, St Petersburg, Florida. FAU - Carapellucci, Jennifer AU - Carapellucci J AD - Cardiac Kids Foundation of Florida, St Petersburg, Florida; Heart Institute, Johns Hopkins All Children's Hospital, St Petersburg, Florida. FAU - John, J Blaine AU - John JB AD - Cardiac Kids Foundation of Florida, St Petersburg, Florida; Pediatric Cardiology Associates, St Joseph's Children's Hospital of Tampa, Tampa, Florida. FAU - Scholl, Frank G AU - Scholl FG AD - Cardiac Kids Foundation of Florida, St Petersburg, Florida; Department of Cardiovascular and Thoracic Surgery, Joe DiMaggio Children's Hospital, Hollywood, Florida. FAU - Badhwar, Vinay AU - Badhwar V AD - Cardiac Kids Foundation of Florida, St Petersburg, Florida; Department of Cardiovascular and Thoracic Surgery, West Virginia University, Morgantown, West Virginia. FAU - Edwards, Melanie A AU - Edwards MA AD - Cardiac Kids Foundation of Florida, St Petersburg, Florida; Cardiovascular & Thoracic Surgery, Trinity Health IHA Medical Group, Ypsilanti, Michigan. FAU - Jacobs, Jeffrey Phillip AU - Jacobs JP AD - Departments of Surgery and Pediatrics, Congenital Heart Center, University of Florida, Gainesville, Florida; Cardiac Kids Foundation of Florida, St Petersburg, Florida. Electronic address: jeffjacobs@msn.com. LA - eng GR - T32 HL166113/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20250404 PL - Netherlands TA - Ann Thorac Surg JT - The Annals of thoracic surgery JID - 15030100R SB - IM MH - Humans MH - Jamaica/epidemiology MH - Female MH - Child MH - Male MH - Retrospective Studies MH - Child, Preschool MH - Adolescent MH - Infant MH - *Cardiac Surgical Procedures MH - *Patient Care Team/organization & administration MH - Infant, Newborn MH - *Medical Missions/organization & administration MH - *Volunteers MH - Program Evaluation MH - *Thoracic Surgery MH - *Heart Defects, Congenital/surgery COIS- Disclosures The authors have no conflicts of interest to disclose. EDAT- 2025/04/07 02:02 MHDA- 2025/06/26 00:27 CRDT- 2025/04/06 19:33 PHST- 2024/11/12 00:00 [received] PHST- 2025/03/25 00:00 [revised] PHST- 2025/03/26 00:00 [accepted] PHST- 2025/06/26 00:27 [medline] PHST- 2025/04/07 02:02 [pubmed] PHST- 2025/04/06 19:33 [entrez] AID - S0003-4975(25)00294-2 [pii] AID - 10.1016/j.athoracsur.2025.03.030 [doi] PST - ppublish SO - Ann Thorac Surg. 2025 Jul;120(1):157-166. doi: 10.1016/j.athoracsur.2025.03.030. Epub 2025 Apr 4. PMID- 40188253 OWN - NLM STAT- MEDLINE DCOM- 20250516 LR - 20250516 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 15 IP - 1 DP - 2025 Apr 5 TI - Sex-specific aspects in a population of patients undergoing evaluation for interstitial lung disease with transbronchial cryobiopsy. PG - 11730 LID - 10.1038/s41598-025-94575-0 [doi] LID - 11730 AB - There are well-documented differences in idiopathic pulmonary fibrosis (IPF) between sexes. The sex-specific prevalence of interstitial lung disease (ILD) subtypes in patients who require a full diagnostic work-up, including transbronchial cryobiopsy (TCB), after initial multidisciplinary discussion (MDD) is still unknown. Retrospective analysis of sex dispareties in patients with ILD who received an interdisciplinary indication for lung biopsy and underwent bronchoalveolar lavage, TCB and, if necessary, surgical lung biopsy at our ILD centre in Heidelberg between 11/17 and 12/21. The analysis included clinical parameters, visual assessment of computed tomography (CT), automated histogram analyses of lung density by validated software and final MDD-ILD classifications. A total of 402 patients (248 men, 154 women; mean age 68 +/- 12 years) were analysed. Smoking behaviour was similar between the sexes, but women were more exposed to environmental factors, whereas men were more exposed to occupational factors. Women had higher rates of thyroid disease (29.9% vs. 12.5%; p < 0.001) and extrathoracic malignancies (16.2% vs. 9.3%; p = 0.041), but lower rates of coronary heart disease (7.1% vs. 19.8%; p < 0.001), stroke (1.3% vs. 6.5%; p = 0.014) and sleep apnoea (5.8% vs. 17.7%; p < 0.001). There were no sex differences regarding CT lung density. On visual inspection, women were less likely to have reticular opacities (65% vs. 76%; p = 0.017) and features of usual interstitial pneumonia (17% vs. 34%; p < 0.001). Among final diagnoses, hypersensitivity pneumonitis was more common in women (34.4%) compared to men (21.8%; p = 0.007). In contrast, IPF was more common in men (22.6%) than in women (7.1%; p < 0.001), and unclassifiable interstitial lung disease was also more frequent in men (21.8%) compared to women (6.5%; p < 0.001). This study highlights significant sex-based differences in the prevalence and characteristics of ILD requiring comprehensive diagnostic work-up. These findings underscore the importance of considering sex-specific factors in the diagnosis and management of ILD. CI - (c) 2025. The Author(s). FAU - Reinhard, Janna AU - Reinhard J AD - Department of Pneumology and Critical Care Medicine, Center for Interstitial and Rare Lung Diseases, Translational Lung Research Center Heidelberg (TLRC-H), German Center for Lung Research (DZL), Thoraxklinik University of Heidelberg, Heidelberg, Germany. AD - Translational Lung Research Center Heidelberg (TLRC-H), German Center for Lung Research (DZL), Heidelberg, Germany. FAU - Polke, Markus AU - Polke M AD - Department of Pneumology and Critical Care Medicine, Center for Interstitial and Rare Lung Diseases, Translational Lung Research Center Heidelberg (TLRC-H), German Center for Lung Research (DZL), Thoraxklinik University of Heidelberg, Heidelberg, Germany. AD - Translational Lung Research Center Heidelberg (TLRC-H), German Center for Lung Research (DZL), Heidelberg, Germany. FAU - Buschulte, Katharina AU - Buschulte K AD - Department of Pneumology and Critical Care Medicine, Center for Interstitial and Rare Lung Diseases, Translational Lung Research Center Heidelberg (TLRC-H), German Center for Lung Research (DZL), Thoraxklinik University of Heidelberg, Heidelberg, Germany. AD - Translational Lung Research Center Heidelberg (TLRC-H), German Center for Lung Research (DZL), Heidelberg, Germany. FAU - Eichinger, Monika AU - Eichinger M AD - Translational Lung Research Center Heidelberg (TLRC-H), German Center for Lung Research (DZL), Heidelberg, Germany. AD - Department of Diagnostic and Interventional Radiology with Nuclear Medicine, Thoraxklinik, University Medical Center Heidelberg, Heidelberg, Germany. AD - Department of Diagnostic & Interventional Radiology, University Hospital of Heidelberg, Heidelberg, Germany. FAU - Heussel, Claus Peter AU - Heussel CP AD - Translational Lung Research Center Heidelberg (TLRC-H), German Center for Lung Research (DZL), Heidelberg, Germany. AD - Department of Diagnostic and Interventional Radiology with Nuclear Medicine, Thoraxklinik, University Medical Center Heidelberg, Heidelberg, Germany. FAU - Guttlein, Maximilian AU - Guttlein M AD - Translational Lung Research Center Heidelberg (TLRC-H), German Center for Lung Research (DZL), Heidelberg, Germany. AD - Department of Diagnostic & Interventional Radiology, University Hospital of Heidelberg, Heidelberg, Germany. FAU - Michels-Zetsche, Julia D AU - Michels-Zetsche JD AD - Department of Pneumology and Critical Care Medicine, Center for Interstitial and Rare Lung Diseases, Translational Lung Research Center Heidelberg (TLRC-H), German Center for Lung Research (DZL), Thoraxklinik University of Heidelberg, Heidelberg, Germany. AD - Translational Lung Research Center Heidelberg (TLRC-H), German Center for Lung Research (DZL), Heidelberg, Germany. FAU - Wielputz, Mark Oliver AU - Wielputz MO AD - Translational Lung Research Center Heidelberg (TLRC-H), German Center for Lung Research (DZL), Heidelberg, Germany. AD - Department of Diagnostic & Interventional Radiology, University Hospital of Heidelberg, Heidelberg, Germany. FAU - Kahnert, Kathrin AU - Kahnert K AD - MediCenterGermering, Germering, Germany. AD - Department of Medicine V, LMU University Hospital, LMU Munich, Comprehensive Pneumology Center, Member of the German Center for Lung Research (DZL), Munich, Germany. FAU - Kontogianni, Konstantina AU - Kontogianni K AD - Department of Pneumology and Critical Care Medicine, Center for Interstitial and Rare Lung Diseases, Translational Lung Research Center Heidelberg (TLRC-H), German Center for Lung Research (DZL), Thoraxklinik University of Heidelberg, Heidelberg, Germany. AD - Translational Lung Research Center Heidelberg (TLRC-H), German Center for Lung Research (DZL), Heidelberg, Germany. FAU - Klotz, Laura V AU - Klotz LV AD - Translational Lung Research Center Heidelberg (TLRC-H), German Center for Lung Research (DZL), Heidelberg, Germany. AD - Department of Thoracic Surgery, Thoraxklinik at Heidelberg University Hospital, Heidelberg, Germany. FAU - Allgauer, Michael AU - Allgauer M AD - Department of Pathology, University of Heidelberg, Heidelberg, Germany. FAU - Herth, Felix J AU - Herth FJ AD - Department of Pneumology and Critical Care Medicine, Center for Interstitial and Rare Lung Diseases, Translational Lung Research Center Heidelberg (TLRC-H), German Center for Lung Research (DZL), Thoraxklinik University of Heidelberg, Heidelberg, Germany. AD - Translational Lung Research Center Heidelberg (TLRC-H), German Center for Lung Research (DZL), Heidelberg, Germany. FAU - Eberhardt, Ralf AU - Eberhardt R AD - Department of Pneumology and Intensive Care Medicine, Asklepios Klinik Barmbek, Hamburg, Germany. FAU - Kreuter, Michael AU - Kreuter M AD - Departments of Pneumology, Mainz Center for Pulmonary Medicine, Mainz University Medical Center and of Pulmonary, Critical Care & Sleep Medicine, Marienhaus Clinic Mainz, Mainz, Germany. FAU - Trudzinski, Franziska C AU - Trudzinski FC AD - Department of Pneumology and Critical Care Medicine, Center for Interstitial and Rare Lung Diseases, Translational Lung Research Center Heidelberg (TLRC-H), German Center for Lung Research (DZL), Thoraxklinik University of Heidelberg, Heidelberg, Germany. franziska.trudzinski@med.uni-heidelberg.de. AD - Translational Lung Research Center Heidelberg (TLRC-H), German Center for Lung Research (DZL), Heidelberg, Germany. franziska.trudzinski@med.uni-heidelberg.de. LA - eng PT - Journal Article DEP - 20250405 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 SB - IM MH - Humans MH - Male MH - Female MH - Aged MH - *Lung Diseases, Interstitial/diagnosis/pathology/epidemiology MH - Middle Aged MH - Biopsy/methods MH - Retrospective Studies MH - Sex Factors MH - Lung/pathology/diagnostic imaging MH - Bronchoscopy/methods MH - Tomography, X-Ray Computed MH - Idiopathic Pulmonary Fibrosis/pathology MH - Aged, 80 and over MH - Cryosurgery/methods PMC - PMC11972388 OTO - NOTNLM OT - Computed tomography OT - Gender OT - Idiopathic pulmonary fibrosis OT - Interstitial lung disease OT - Quantitative CT analysis OT - Sex OT - Transbronchial lung cryobiopsy COIS- Competing interests: MP received lecture fees from AstraZeneca, Boehringer Ingelheim and Novartis. FCT received payment lectures, or reimbursement of travel expenses from Novartis AG, GlaxoSmithKline, Chiesi, Boehringer Ingelheim GmbH, Grifols and AstraZeneca, CSL Behring and Grifols Deutschland GmbH. MOW reports study grants by Vertex Pharmaceuticals, and advisory board membership at Boehringer Ingelheim and Vertex Pharmaceuticals, KK received lecture fees from AstraZeneca, Boehringer Ingelheim, GSK, Insmed, GlaxoSmithKLine and Chiesi. JDMZ is a board member of the E&H Knorr Stiftung and reports funding by the innovation fund of the G-BA as well as payment or honoraria for lectures from AstraZeneca and reimbursement of travel expenses from CSL Behring. FJH received lecture fees from CSL Behring and Grifols Deutschland GmbH. KKo has received honoraria for lectures from Berlin-Chemie, Astra Zeneca and Boston Scientific, outside the submitted work. MA received lecture fees from Boehringer Ingelheim. KB reports on financial support from the Sarcoidosis Network e.V., consultancy fees from Boehringer-Ingelheim and Astra Zeneca as well as fees for lectures from Boehringer-Ingelheim, Astra Zeneca and Chiesi. CPH has stock ownership in GSK and is a co-inventor of a patent for a method and device for representing the microstructure of the lungs.Dr. Heussel has received consultation and fees from Boehringer Ingelheim, Pfizer, and Exscientia. His research has been funded by Boehringer Ingelheim and Exscientia. He has also received lecture fees from Boehringer Ingelheim and Pfizer. All the remaining authors declare no conflict of interest. Ethics approval and consent to participate: The study was approved by the Institutional Review Board Ethics Committee of the Medical Faculty of Heidelberg University (S-382/2023). Informed consent was waived by the Ethics Committee due to the retrospective nature of the study. The study was conducted in accordance with the principles of the Declaration of Helsinki. EDAT- 2025/04/06 04:44 MHDA- 2025/04/06 04:45 PMCR- 2025/04/05 CRDT- 2025/04/05 23:26 PHST- 2024/09/20 00:00 [received] PHST- 2025/03/14 00:00 [accepted] PHST- 2025/04/06 04:45 [medline] PHST- 2025/04/06 04:44 [pubmed] PHST- 2025/04/05 23:26 [entrez] PHST- 2025/04/05 00:00 [pmc-release] AID - 10.1038/s41598-025-94575-0 [pii] AID - 94575 [pii] AID - 10.1038/s41598-025-94575-0 [doi] PST - epublish SO - Sci Rep. 2025 Apr 5;15(1):11730. doi: 10.1038/s41598-025-94575-0. PMID- 40187984 OWN - NLM STAT- MEDLINE DCOM- 20251122 LR - 20251122 IS - 0013-7006 (Print) IS - 0013-7006 (Linking) VI - 51 IP - 6 DP - 2025 Dec TI - New cross-disciplinary sleep medicine residency in France: Results after five years. PG - 660-667 LID - S0013-7006(25)00061-2 [pii] LID - 10.1016/j.encep.2025.01.006 [doi] AB - The new cross-disciplinary sleep medicine residency program (SMR) was created in 2017 in France and effectively implemented beginning in 2019. This first French specific sleep medicine residency program aims to train specialists in sleep medicine by complementing the knowledge from their original Specialized Studies Diplomas (SSD). The SMR lasts one year, offering comprehensive theoretical cross-disciplinary training and two practical internships of six months each. This study, based on a standardized questionnaire, aims to provide an initial assessment of this training and its impact on the professional careers of physicians who completed the SMR, five years after its implementation. The 42 participants in this study, with an average age of 30.3 years, primarily came from Paris (21.4%) and Strasbourg (16.7%), followed by Bordeaux, Dijon, Lille, and Marseille (7.1%), Besancon, Caen, and Toulouse (4.8%), and Angers, Grenoble, Lyon, Martinique, Montpellier, Nancy, Poitiers, and Reims (2.4%). Psychiatry and pulmonology were the most represented specialties among nine specialties, with the other seven being general medicine, neurology, geriatrics, otolaryngology, cardiology, occupational medicine, and public health. Regarding practical training, combined internships (paired with SSD internship) and internships outside the subdivision were popular, highlighting the importance of diversified training. The majority of participants (76.2%) had defended their medical thesis, with 66.7% of them related to sleep medicine. Additionally, 52.4% worked in a sleep center, and 81% had activities related to sleep medicine. For participants who did not have a permanent position (residents, junior doctors, chief residents, assistants), 72.5% considered a hospital career, and 45% considered an academic career. Regarding research trajectories, 69% of participants had already published at least one scientific article, and 38.1% held or were enrolled in a master's degree in research. The survey revealed a high level of satisfaction among participants (97.6%). In conclusion, the SMR is perceived as enriching and has a direct impact on the academic and professional career paths of its participants. These results highlight the significant role of this new innovating transversal training in the development of sleep medicine in France. CI - Copyright (c) 2025 L'Encephale, Paris. Published by Elsevier Masson SAS. All rights reserved. FAU - Garrivet, Julie AU - Garrivet J AD - Departement de Psychiatrie et Addictologie, CHU d'Angers, Angers, France; Service de Medecine Respiratoire et du Sommeil, CHU d'Angers, Angers, France; Inserm, CNRS, MITOVASC, Universite d'Angers, Angers, France. FAU - Romier, Alix AU - Romier A AD - Departement de Psychiatrie et Addictologie, Hopital Bichat - Claude-Bernard, AP-HP, Paris, France; Centre ChronoS, GHU Paris Nord, DMU Neurosciences, Secteur G22, Hopital Bichat - Claude Bernard, Paris, France. FAU - Arnulf, Isabelle AU - Arnulf I AD - Clinique des troubles du sommeil, Service R3S, Hopital de la Pitie-Salpetriere, AP-HP-Sorbonne, Paris, France; Universite de la Sorbonne, Paris, France; Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, Paris, France. FAU - Bequignon, Emilie AU - Bequignon E AD - Service d'ORL et chirurgie cervico-faciale, Centre Hospitalier Intercommunal de Creteil, Creteil, France; CNRS EMR 7000, Creteil, France; Inserm, IMRB, Faculte de Sante, Universite Paris Est Creteil, Creteil, France. FAU - Bettega, Georges AU - Bettega G AD - Service de chirurgie maxillo-faciale, Hopital Annecy Genevois, Annecy, France. FAU - Bokov, Plamen AU - Bokov P AD - Service de Physiologie Pediatrique-Centre du Sommeil, Universite de Paris-Cite, Hopital Robert-Debre, AP-HP, CRMR Maladies respiratoires rares - Hypoventilations alveolaires rares - Syndrome d'Ondine, Paris, France. FAU - Bonin-Guillaume, Sylvie AU - Bonin-Guillaume S AD - Service de medecine interne geriatrie, Hopitaux Universitaires de Marseille, Marseille, France. FAU - Bourgin, Patrice AU - Bourgin P AD - Service de medecine interne geriatrie, Hopitaux Universitaires de Marseille, Marseille, France; CNRS UPR 3212, Institut des Neurosciences Cellulaires et Integratives, 67000 Strasbourg, France. FAU - Dufour, Xavier AU - Dufour X AD - Service d'ORL, de Chirurgie Cervico-Faciale et d'Audiophonologie - CHU de Poitiers - Laboratoire Inflammation, Tissus Epitheliaux et Cytokines, LITEC UR 15560 - Universite de Poitiers, Poitiers, France. FAU - Esquirol, Yolande AU - Esquirol Y AD - UMR1295, Universite Paul Sabatier III - INSERM CERPOP : Centre d'epidemiologie et de recherche sur la sante des populations, Toulouse, Service de sante au travail, CHU de Toulouse, Toulouse, France. FAU - Franco, Patricia AU - Franco P AD - Service d'Epileptologie Clinique, des Troubles du Sommeil et de Neurologie Fonctionnelle de l'Enfant, Hopital Femme Mere Enfant, Hospices Civils de Lyon, Bron, France; U1028, CNRL, Universite de Lyon 1, Lyon, France. FAU - Garcia, Rodrigue AU - Garcia R AD - Service de cardiologie, Hopital Universitaire de Poitiers, Poitiers, France. FAU - Kinugawa, Kiyoka AU - Kinugawa K AD - Sorbonne Universite, CNRS-SU, UMR Adaptation biologique et vieillissement, 75252 Paris, France; Unite d'exploration fonctionnelle du sujet age, AP-HP, Hopital Charles-Foix, 94200 Ivry-sur-Seine, France. FAU - Launois, Claire AU - Launois C AD - Service des maladies respiratoires, CHU de Reims, Reims, France Universite de Reims Champagne-Ardenne (URCA), Inserm UMR-S 1250, SFR Cap-Sante, Reims, France. FAU - Leger, Damien AU - Leger D AD - Universite Paris Cite, VIFASOM (Vigilance, Fatigue, Sleep and Public Health), ERC 7330, AP-HP, Hotel-Dieu, Centre du Sommeil et de la Vigilance, 1, place Parvis-Notre-Dame, 75004 Paris, France. FAU - Lequeux, Benoit AU - Lequeux B AD - Service de cardiologie, Hopital Universitaire de Poitiers, Poitiers, France. FAU - Meurice, Jean-Claude AU - Meurice JC AD - Service de pneumologie, CHU de Poitiers, Faculte de medecine et de pharmacie, Universite de Poitiers, Poitiers, France. FAU - Micoulaud-Franchi, Jean-Arthur AU - Micoulaud-Franchi JA AD - Unite de medecine du sommeil, UMR CNRS 6033 SANPSY, CHU de Bordeaux, 33076 Bordeaux, France. FAU - Philip, Pierre AU - Philip P AD - Unite de medecine du sommeil, UMR CNRS 6033 SANPSY, CHU de Bordeaux, 33076 Bordeaux, France. FAU - d'Ortho, Marie Pia AU - d'Ortho MP AD - Departement de Physiologie-Explorations fonctionnelles-Centre du Sommeil, Hopital Bichat-Claude-Bernard, AP-HP, 75018, Paris, France; Universite Paris Cite, NeuroDiderot, Inserm, 75019 Paris, France. FAU - Schouman, Thomas AU - Schouman T AD - Sorbonne Universite, AP-HP, Hopital Pitie-Salpetriere, Service de chirurgie maxillo-faciale et stomatologie, Paris, France; Arts et Metiers - Institute of Technology, Paris, France. FAU - Schroder, Carmen AU - Schroder C AD - Centre des troubles du sommeil - CIRCOM (Centre international de recherche en chrono-somnologie), CHRU Strasbourg - Hopital Civil, Strasbourg, France; CNRS UPR 3212, Institut des Neurosciences Cellulaires et Integratives, 67000 Strasbourg, France; Departement de psychiatrie de l'enfant et de l'adolescent, Hopitaux universitaires de Strasbourg, Strasbourg, France. FAU - Trzepizur, Wojciech AU - Trzepizur W AD - Service de Medecine Respiratoire et du Sommeil, CHU d'Angers, Angers, France; Inserm, CNRS, MITOVASC, Universite d'Angers, Angers, France. FAU - Geoffroy, Pierre A AU - Geoffroy PA AD - Departement de Psychiatrie et Addictologie, Hopital Bichat - Claude-Bernard, AP-HP, Paris, France; CNRS UPR 3212, Institut des Neurosciences Cellulaires et Integratives, 67000 Strasbourg, France; Universite Paris Cite, NeuroDiderot, Inserm, 75019 Paris, France; Centre ChronoS, GHU Paris Nord, DMU Neurosciences, Secteur G22, Hopital Bichat - Claude Bernard, Paris, France. Electronic address: pierrealexis.geoffroy@aphp.fr. LA - eng PT - Journal Article DEP - 20250404 PL - France TA - Encephale JT - L'Encephale JID - 7505643 SB - IM MH - Humans MH - France MH - *Internship and Residency/organization & administration/statistics & numerical data MH - *Sleep Medicine Specialty/education/organization & administration MH - Adult MH - Male MH - Female MH - Surveys and Questionnaires MH - *Interdisciplinary Communication MH - Curriculum MH - Career Choice OTO - NOTNLM OT - Fellowship in sleep medicine OT - Formation en medecine du sommeil OT - Formation specialisee transversale OT - Internat en medecine du sommeil OT - Residency program OT - Sleep medicine training COIS- Disclosure of interest The authors declare that they have no competing interest. EDAT- 2025/04/06 04:44 MHDA- 2025/11/23 00:58 CRDT- 2025/04/05 22:00 PHST- 2024/10/16 00:00 [received] PHST- 2024/12/22 00:00 [revised] PHST- 2025/01/16 00:00 [accepted] PHST- 2025/11/23 00:58 [medline] PHST- 2025/04/06 04:44 [pubmed] PHST- 2025/04/05 22:00 [entrez] AID - S0013-7006(25)00061-2 [pii] AID - 10.1016/j.encep.2025.01.006 [doi] PST - ppublish SO - Encephale. 2025 Dec;51(6):660-667. doi: 10.1016/j.encep.2025.01.006. Epub 2025 Apr 4. PMID- 40187587 OWN - NLM STAT- MEDLINE DCOM- 20250729 LR - 20260518 IS - 1552-6259 (Electronic) IS - 0003-4975 (Linking) VI - 120 IP - 2 DP - 2025 Aug TI - Best Management Practices on Temporary Mechanical Circulatory Support: Joint Consensus Report of the PeriOperative Quality Initiative and the Enhanced Recovery After Surgery Cardiac Society. PG - 225-243 LID - S0003-4975(25)00287-5 [pii] LID - 10.1016/j.athoracsur.2025.01.039 [doi] AB - BACKGROUND: Effective use of temporary mechanical circulatory support (tMCS) mandates a multifaceted understanding of patient physiology, device technology, procedural techniques, patient-device interactions, and interdisciplinary collaboration. The consensus statement presented here endeavors to provide clinicians with a practical roadmap incorporating evidence-based best practices in several key areas that delineate the initial priorities in mechanical ventilation, anticoagulation, sedation, and monitoring for patients requiring tMCS. METHODS: With an interdisciplinary, international group of clinicians and through a structured literature review, a modified Delphi method was used to achieve consensus on best practices in tMCS. RESULTS: Nine key questions were developed with accompanying statements to direct areas that institutions and providers should prioritize to optimize care. These questions included: What expertise is required within the interdisciplinary team to optimize patient care? How should medical centers facilitate escalation of care when indicated? What is the optimal ventilation management strategy? What are the recommended gas exchange targets to preserve end-organ function? What is the recommended timing to start or resume anticoagulation? What anticoagulation agent and monitoring approach should be used routinely? What is the optimal strategy for patient comfort and device interactions? Can a patient on tMCS be mobilized? What routine monitoring needs to be performed? CONCLUSIONS: A comprehensive review is provided of key management strategies incorporating interdisciplinary team and evidence-based medical knowledge to improve patient outcomes while using tMCS. CI - Copyright (c) 2025 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Deschamps, Jean AU - Deschamps J AD - Department of Intensive Care and Resuscitation, Integrated Hospital Institute, Cleveland Clinic, Cleveland, Ohio. Electronic address: deschamps.jd@gmail.com. FAU - Obanor, Osamudiamen AU - Obanor O AD - Department of Anesthesiology, Critical Care Medicine & Pain Management, McGovern Medical School, University of Texas Health Science Center at Houston (UT Health), Houston, Texas. FAU - Clarizia, Nadia AU - Clarizia N AD - Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, Ohio. FAU - Singh, Gurmeet AU - Singh G AD - Division of Cardiac Surgery, Departments of Critical Care Medicine and Surgery, Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta, Canada. FAU - Lobdell, Kevin AU - Lobdell K AD - Sanger Heart & Vascular Institute, Wake Forest University School of Medicine, Charlotte, North Carolina. FAU - Bailey, Dwight AU - Bailey D AD - Division of Pediatric Critical Care Medicine, Levine Children's Hospital at Atrium Health, Charlotte, North Carolina. FAU - Barnett, Christopher F AU - Barnett CF AD - Division of Cardiology, University of California, San Francisco, San Francisco, California. FAU - Shaw, Andrew D AU - Shaw AD AD - Department of Intensive Care and Resuscitation, Integrated Hospital Institute, Cleveland Clinic, Cleveland, Ohio. FAU - Engelman, Daniel T AU - Engelman DT AD - Heart & Vascular Program, Baystate Health, University of Massachusetts Chan Medical, School-Baystate, Springfield, Massachusetts. FAU - Arora, Rakesh C AU - Arora RC AD - Division of Cardiac Surgery, Harrington Heart and Vascular Institute, University Hospitals, Cleveland, Ohio. CN - PeriOperative Quality Initiative (POQI) and the Enhanced Recovery After Surgery (ERAS) Cardiac Society workgroup LA - eng PT - Consensus Statement PT - Journal Article PT - Practice Guideline PT - Research Support, Non-U.S. Gov't DEP - 20250403 PL - Netherlands TA - Ann Thorac Surg JT - The Annals of thoracic surgery JID - 15030100R SB - IM MH - Humans MH - *Cardiac Surgical Procedures MH - Delphi Technique MH - *Enhanced Recovery After Surgery MH - *Heart-Assist Devices MH - *Perioperative Care/standards MH - Societies, Medical MH - Review Literature as Topic COIS- Disclosures Rakesh C. Arora reports a relationship with Edwards Lifesciences Corp that includes: speaking and lecture fees; with HLS Therapeutics Inc that includes: speaking and lecture fees; and with Renibus Therapeutics, Inc that includes: board membership. Daniel T. Engelman reports a relationship with Edwards Lifesciences Corp that includes: board membership; with Renibus Therapeutics, Inc that includes: board membership; with Alexion that includes: board membership; with Genentech Inc that includes: board membership; with CardioRenal Systems that includes: board membership; with Medela AG that includes: board membership; with Arthrex Inc that includes: board membership; with AtriCure Inc that includes: board membership; with Pharmacosmos AS that includes: board membership; and with BioPorto Diagnostics Inc that includes: board membership. Andrew D. Shaw reports a relationship with Alexion that includes: board membership; with Chugai Pharmaceutical Co Ltd that includes: board membership; with Retia that includes: board membership; with Renibus Therapeutics, Inc that includes: board membership; with Novartis that includes: board membership; with RenalGuard Solutions Inc that includes: board membership; with CalciMedica Inc that includes: board membership; and with Fresenius Medical Care AG that includes: board membership. Kevin W. Lobdell reports a relationship with Abiomed Inc that includes: consulting or advisory; with Alexion that includes: consulting or advisory; with Medela AG that includes: consulting or advisory; with Medtronic that includes: board membership; and with Renibus Therapeutics, Inc that includes: consulting or advisory. Gurmeet Singh reports a relationship with Abbott that includes: speaking and lecture fees. Rakesh C Arora reports a relationship with BioPorto Diagnostics Inc that includes: speaking and lecture fees. The other authors have no conflicts of interest to disclose. FIR - Shaw, Andrew D IR - Shaw AD IRAD- Cleveland Clinic, Cleveland, Ohio. FIR - Engelman, Daniel T IR - Engelman DT IRAD- University of Massachusetts Chan Medical School-Baystate, Springfield, Massachusetts. FIR - Grant, Michael C IR - Grant MC IRAD- Johns Hopkins University School of Medicine, Baltimore, Maryland. FIR - Brudney, Charles Scott IR - Brudney CS IRAD- University of Manitoba, Winnipeg, Manitoba, Canada. FIR - Hernandez-Montfort, Jaime IR - Hernandez-Montfort J IRAD- Baylor Scott and White Health, Temple, Texas. FIR - Ibekwe, Stephanie O IR - Ibekwe SO IRAD- Baylor College of Medicine, Houston, Texas. FIR - Rae, Amanda IR - Rae A IRAD- University of Maryland Saint Joseph's Medical Center, Baltimore, Maryland. FIR - Stoppe, Christian IR - Stoppe C IRAD- University Hospital Wuerzburg, Wuerzburg, Germany. FIR - Zarbock, Alexander IR - Zarbock A IRAD- University Hospital, Munster, Munster, Germany. FIR - Kanwar, Manreet K IR - Kanwar MK IRAD- Cardiovascular Institute at Allegheny Health Network, Pittsburgh, Pennsylvania. FIR - Chatterjee, Subhasis IR - Chatterjee S IRAD- Baylor College of Medicine, Houston, Texas. FIR - Spelde, Audrey E IR - Spelde AE IRAD- University of Pennsylvania, Philadelphia, Pennsylvania. FIR - Barron, Lauren M IR - Barron LM IRAD- Baylor College of Medicine, Houston, Texas. FIR - Cangut, Busra IR - Cangut B IRAD- Mount Sinai School of Medicine, New York, New York. FIR - Hickey, Gavin W IR - Hickey GW IRAD- University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. FIR - Lorusso, Roberto IR - Lorusso R IRAD- Maastricht University Medical Centre, Cardiovascular Research Institute Maastricht, Maastricht, the Netherlands. FIR - Silvestry, Scott C IR - Silvestry SC IRAD- University of Arizona School of Medicine, Phoenix, Arizona. FIR - Tong, Michael Z IR - Tong MZ IRAD- Cleveland Clinic, Cleveland, Ohio. EDAT- 2025/04/06 04:44 MHDA- 2025/07/30 00:29 CRDT- 2025/04/05 19:35 PHST- 2024/07/31 00:00 [received] PHST- 2024/12/05 00:00 [revised] PHST- 2025/01/19 00:00 [accepted] PHST- 2025/07/30 00:29 [medline] PHST- 2025/04/06 04:44 [pubmed] PHST- 2025/04/05 19:35 [entrez] AID - S0003-4975(25)00287-5 [pii] AID - 10.1016/j.athoracsur.2025.01.039 [doi] PST - ppublish SO - Ann Thorac Surg. 2025 Aug;120(2):225-243. doi: 10.1016/j.athoracsur.2025.01.039. Epub 2025 Apr 3. PMID- 40187586 OWN - NLM STAT- MEDLINE DCOM- 20250729 LR - 20260518 IS - 1552-6259 (Electronic) IS - 0003-4975 (Linking) VI - 120 IP - 2 DP - 2025 Aug TI - Escalation and De-escalation of Temporary Mechanical Circulatory Support: Joint Consensus Report of the PeriOperative Quality Initiative and the Enhanced Recovery After Surgery Cardiac Society. PG - 213-224 LID - S0003-4975(25)00286-3 [pii] LID - 10.1016/j.athoracsur.2025.01.038 [doi] AB - BACKGROUND: Temporary mechanical circulatory support (tMCS) for cardiogenic shock (CS) is increasing despite knowledge gaps and variations in management practices. This document was created to provide clinicians with guidance regarding initiation, escalation, and de-escalation of tMCS in patients with CS. METHODS: An interdisciplinary, international expert panel using a structured literature appraisal and modified Delphi method derived consensus statements regarding triggers for prompt patient assessment and initiating tMCS in CS, assessing adequacy of support, readiness for tMCS weaning, and next steps in nonrecovery. Individual statements were graded on the basis of the quality of available evidence. RESULTS: The panel addressed 4 main questions aimed at initiation, escalation, and de-escalation of tMCS. On the basis of available literature review and expert consensus, 11 recommendations were formulated. Key principles included recognition of the need for patients with CS who have ongoing hemodynamic compromise, tissue hypoperfusion, and metabolic derangements to be considered for early tMCS initiation. An interdisciplinary shock team should be involved in management, with early referral when patient conditions require care beyond center capabilities. Discussions providing anticipatory guidance should be performed with patients and decision makers before initiating tMCS. Management of tMCS involves frequent, timely hemodynamic and tissue perfusion reassessments to determine the need for escalation or weaning. For patients unable to be weaned from tMCS, evaluation should include interdisciplinary assessment for advanced therapies, with palliation included as a consideration in care discussions. CONCLUSIONS: A practical guide to initiation, escalation, and de-escalation of tMCS is provided. Center-specific approaches that are based on local capabilities should be implemented. CI - Copyright (c) 2025 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved. FAU - Spelde, Audrey E AU - Spelde AE AD - Department of Anesthesiology & Critical Care, University of Pennsylvania, Philadelphia, Pennsylvania. FAU - Barron, Lauren M AU - Barron LM AD - Division of Cardiothoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas; Department of Cardiovascular Surgery, Texas Heart Institute, Houston, Texas. FAU - Cangut, Busra AU - Cangut B AD - Department of Cardiovascular Surgery, Mount Sinai School of Medicine, New York, New York. FAU - Hickey, Gavin W AU - Hickey GW AD - Division of Cardiology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. FAU - Lorusso, Roberto AU - Lorusso R AD - Department of Cardio-Thoracic Surgery, Maastricht University Medical Centre, Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands. FAU - Silvestry, Scott C AU - Silvestry SC AD - Division of Cardiothoracic Surgery, Department of Surgery, University of Arizona School of Medicine, Phoenix, Arizona. FAU - Tong, Michael Z AU - Tong MZ AD - Department of Thoracic and Cardiovascular Surgery, Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio. FAU - Engelman, Daniel T AU - Engelman DT AD - Heart and Vascular Program, Baystate Health, University of Massachusetts Chan Medical School-Baystate, Springfield, Massachusetts. FAU - Shaw, Andrew D AU - Shaw AD AD - Department of Intensive Care and Resuscitation, Cleveland Clinic, Cleveland, Ohio. FAU - Chatterjee, Subhasis AU - Chatterjee S AD - Division of Cardiothoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas; Department of Cardiovascular Surgery, Texas Heart Institute, Houston, Texas; Division of Acute Care Surgery/Trauma, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas. Electronic address: subhasis.chatterjee@bcm.edu. CN - PeriOperative Quality Initiative (POQI) and the Enhanced Recovery After Surgery (ERAS) Cardiac Society Workgroup LA - eng GR - Medtronic/ GR - LivaNova/ PT - Consensus Statement PT - Journal Article PT - Practice Guideline PT - Research Support, Non-U.S. Gov't DEP - 20250403 PL - Netherlands TA - Ann Thorac Surg JT - The Annals of thoracic surgery JID - 15030100R SB - IM MH - Humans MH - *Shock, Cardiogenic/therapy/surgery MH - *Heart-Assist Devices MH - *Societies, Medical MH - *Enhanced Recovery After Surgery MH - *Perioperative Care/standards MH - *Cardiac Surgical Procedures MH - Delphi Technique MH - *Extracorporeal Membrane Oxygenation/methods COIS- Disclosures Lauren M. Barron reports a relationship with Abiomed that includes: speaking and lecture fees. Roberto Lorusso reports a relationship with Xenios that includes: consulting or advisory; and with Abiomed that includes: speaking and lecture fees. Scott C. Silvestry reports a relationship with Abiomed that includes: consulting or advisory; with Abbott Vascular that includes: consulting or advisory; and with Medtronic that includes: consulting or advisory. Michael Z. Tong reports a relationship with Abiomed that includes: consulting or advisory; with Abbott Vascular that includes: consulting or advisory; and with LifeNet Health that includes: consulting or advisory. Daniel T. Engelman reports a relationship with Edwards Lifesciences that includes: consulting or advisory; with Renibus Therapeutics that includes: consulting or advisory; with Alexion Pharmaceuticals that includes: consulting or advisory; with Medela AG that includes: consulting or advisory; with Arthrex that includes: consulting or advisory; with AtriCure that includes: consulting or advisory; and with Pharmacosmos AS that includes: consulting or advisory. Andrew D. Shaw reports a relationship with Alexion Pharmaceuticals that includes: consulting or advisory; with Chugai Pharmaceutical Co that includes: consulting or advisory; with Alexion Pharmaceuticals includes: consulting or advisory; with Retia Medical that includes: consulting or advisory; with Renibus Therapeutics that includes: consulting or advisory; with Novartis Pharmaceuticals that includes: consulting or advisory; with RenalGuard Solutions that includes: consulting or advisory; and with Fresenius Medical Care that includes: consulting or advisory. Subhasis Chatterjee reports a relationship with Edwards Lifesciences that includes: consulting or advisory; with La Jolla Pharmaceutical Company that includes: consulting or advisory; with Eagle Pharmaceutical that includes: consulting or advisory; and with Baxter Pharmaceutical Products that includes: consulting or advisory. All other authors declare that they have no conflicts of interest. FIR - Grant, Michael C IR - Grant MC IRAD- Johns Hopkins School of Medicine, Baltimore, Maryland. FIR - Brudney, Charles S IR - Brudney CS IRAD- University of Manitoba, Winnipeg, Manitoba, Canada. FIR - Hernandez-Montfort, Jaime IR - Hernandez-Montfort J IRAD- Baylor Scott and White, Temple, Texas. FIR - Ibekwe, Stephanie O IR - Ibekwe SO IRAD- Baylor College of Medicine, Houston, Texas. FIR - Rae, Amanda IR - Rae A IRAD- University Maryland Saint Joseph's Medical Center, Baltimore, Maryland. FIR - Stoppe, Christian IR - Stoppe C IRAD- University Hospital Wuerzburg, Wuerzburg, Germany. FIR - Zarbock, Alexander IR - Zarbock A IRAD- University Hospital, Munster, Germany. FIR - Kanwar, Manreet K IR - Kanwar MK IRAD- Cardiovascular Institute Allegheny Health, Pittsburgh, Pennsylvania. FIR - Arora, Rakesh C IR - Arora RC IRAD- Harrington Heart and Vascular, University Hospitals, Cleveland, Ohio. FIR - Bailey, Dwight IR - Bailey D IRAD- Levine Children's Hospital Atrium Health, Charlotte, North Carolina. FIR - Barnett, Christopher IR - Barnett C IRAD- University of California San Francisco, San Francisco, California. FIR - Clarizia, Nadia IR - Clarizia N IRAD- Cleveland Clinic, Cleveland, Ohio. FIR - Deschamps, Jean IR - Deschamps J IRAD- Cleveland Clinic, Cleveland, Ohio. FIR - Lobdell, Kevin IR - Lobdell K IRAD- Sanger Heart & Vascular Institute, Charlotte, North Carolina. FIR - Obanor, Osamudosamudiamen IR - Obanor O IRAD- McGovern Medical School-University of Texas HSC at Houston (UT Health), Houston, Texas. FIR - Singh, Gurmeet IR - Singh G IRAD- University of Alberta, Edmonton, Alberta, Canada. EDAT- 2025/04/06 04:44 MHDA- 2025/07/29 18:31 CRDT- 2025/04/05 19:35 PHST- 2024/08/23 00:00 [received] PHST- 2025/01/08 00:00 [revised] PHST- 2025/01/19 00:00 [accepted] PHST- 2025/07/29 18:31 [medline] PHST- 2025/04/06 04:44 [pubmed] PHST- 2025/04/05 19:35 [entrez] AID - S0003-4975(25)00286-3 [pii] AID - 10.1016/j.athoracsur.2025.01.038 [doi] PST - ppublish SO - Ann Thorac Surg. 2025 Aug;120(2):213-224. doi: 10.1016/j.athoracsur.2025.01.038. Epub 2025 Apr 3. PMID- 40187229 OWN - NLM STAT- MEDLINE DCOM- 20250526 LR - 20250526 IS - 1873-5134 (Electronic) IS - 0738-3991 (Linking) VI - 136 DP - 2025 Jul TI - Co-design and feasibility testing of the heart failure carer support programme (HELP): A convergent, mixed-method study. PG - 108760 LID - S0738-3991(25)00127-2 [pii] LID - 10.1016/j.pec.2025.108760 [doi] AB - OBJECTIVES: This study co-designed and feasibility tested a novel psychoeducational intervention delivered online to carers of patients with heart failure (HF) and examined the potential impact on carer-related outcomes. METHODS: The HEart faiLure carer support Programme (HELP) was co-designed with carers and healthcare professionals at a large University hospital. This intervention comprises an information booklet and six psychoeducational support group sessions delivered online by a multidisciplinary team. A convergent mixed-method design examined the feasibility, acceptability, and potential impact of HELP. Carers of patients with HF were recruited in the United Kingdom (UK) via clinical teams along with printed and online advertisements. Quantitative measurements included carer-related outcomes (carer burden, carer preparedness, quality of life, anxiety, depression, stress, and social support) and feasibility assessments (recruitment rates, attrition, and intervention usefulness). Focus groups conducted post-intervention qualitatively investigated the acceptability of HELP. Data was collected at baseline, 6 weeks post-intervention, and 3 months post-intervention. Quantitative and qualitative data were analyzed with descriptive and thematic analysis, respectively. The results were integrated to generate a holistic understanding of the findings. RESULTS: 51 carers were eligible and 22 (43 %) provided consent. Of those 22, 18 (89 %) participated and 12 (67 %) completed all intervention sessions. Participants highly rated the usefulness of the intervention via a feedback questionnaire (4.7 +/- 0.59 out of 5, overall) and positive changes were found across the following carer-related outcomes: anxiety, depression, caregiver burden, stress, preparedness, and social support. Data integration generated three key findings: (1) Improved carer preparedness and knowledge, (2) Support from group environment, and (3) Emotional support and personal wellbeing. CONCLUSIONS: HELP delivery to carers of patients with HF is feasible and potentially provides emotional support and empowerment in their caring role. PRACTICE IMPLICATIONS: HELP will advance to implementation testing across the UK to inform large-scale adoption in routine clinical practice. CI - Copyright (c) 2025 The Authors. Published by Elsevier B.V. All rights reserved. FAU - Cassidy, Lorna AU - Cassidy L AD - School of Nursing and Midwifery, Queen's University Belfast, Belfast, United Kingdom. Electronic address: lcassidy14@qub.ac.uk. FAU - Thompson, Gareth AU - Thompson G AD - School of Nursing and Midwifery, Queen's University Belfast, Belfast, United Kingdom. Electronic address: gareth.thompson@qub.ac.uk. FAU - Hill, Loreena AU - Hill L AD - School of Nursing and Paramedic Science, Ulster University, Derry/Londonderry, United Kingdom. Electronic address: l.hill@ulster.ac.uk. FAU - McGaughey, Jennifer AU - McGaughey J AD - School of Nursing and Midwifery, Queen's University Belfast, Belfast, United Kingdom. Electronic address: j.mcgaughey01@gmail.com. FAU - Dempster, Martin AU - Dempster M AD - School of Psychology, Queen's University Belfast, Belfast, United Kingdom. Electronic address: m.dempster@qub.ac.uk. FAU - Greene, Eunice AU - Greene E AD - School of Nursing and Midwifery, Queen's University Belfast, Belfast, United Kingdom. Electronic address: e.greene@qub.ac.uk. FAU - Donnelly, Patrick AU - Donnelly P AD - Ulster Hospital, South Eastern Health and Social Care Trust, Belfast, United Kingdom. Electronic address: patrick.donnelly@setrust.hscni.net. FAU - Dixon, Lana AU - Dixon L AD - Royal Victoria Hospital, Belfast Health and Social Care Trust, Belfast, United Kingdom. Electronic address: lana.dixon@belfasttrust.hscni.net. FAU - Campbell, Patricia AU - Campbell P AD - Craigavon Area Hospital, Southern Health and Social Care Trust, Portadown, United Kingdom. Electronic address: PatriciaM.Campbell@southerntrust.hscni.net. FAU - Fitzsimons, Donna AU - Fitzsimons D AD - School of Nursing and Midwifery, Queen's University Belfast, Belfast, United Kingdom. Electronic address: d.fitzsimons@qub.ac.uk. LA - eng PT - Journal Article DEP - 20250320 PL - Ireland TA - Patient Educ Couns JT - Patient education and counseling JID - 8406280 SB - IM MH - Humans MH - *Caregivers/psychology/education MH - *Heart Failure/nursing/therapy/psychology MH - Female MH - *Social Support MH - Male MH - Feasibility Studies MH - Middle Aged MH - Quality of Life/psychology MH - Aged MH - United Kingdom MH - Focus Groups MH - Stress, Psychological MH - Adult MH - Depression/psychology MH - Anxiety/psychology MH - Qualitative Research OTO - NOTNLM OT - Carers OT - Feasibility OT - Heart failure OT - Psychoeducation OT - Virtual intervention COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/04/06 04:44 MHDA- 2025/05/27 00:28 CRDT- 2025/04/05 18:10 PHST- 2024/11/05 00:00 [received] PHST- 2025/02/25 00:00 [revised] PHST- 2025/03/16 00:00 [accepted] PHST- 2025/05/27 00:28 [medline] PHST- 2025/04/06 04:44 [pubmed] PHST- 2025/04/05 18:10 [entrez] AID - S0738-3991(25)00127-2 [pii] AID - 10.1016/j.pec.2025.108760 [doi] PST - ppublish SO - Patient Educ Couns. 2025 Jul;136:108760. doi: 10.1016/j.pec.2025.108760. Epub 2025 Mar 20. PMID- 40187122 OWN - NLM STAT- MEDLINE DCOM- 20250608 LR - 20250925 IS - 1036-7314 (Print) IS - 1036-7314 (Linking) VI - 38 IP - 4 DP - 2025 Jul TI - Long-term outcomes following a rapid response team attendance. PG - 101221 LID - S1036-7314(25)00051-7 [pii] LID - 10.1016/j.aucc.2025.101221 [doi] AB - OBJECTIVE: The aim of this study was to describe the long-term results of patients needing a rapid response team (RRT) call at a university-affiliated Australian hospital that accepts quaternary referrals. METHODS: An observational study to evaluate the database of RRT for inpatients aged >/=16 years was linked to a population registry of deaths (July 2013-July 2021). Outcomes were 96-month cumulative survival, RRT call, hospital and posthospital (the period beyond hospital stay associated with RRT call) mortality, and trend over time. RESULTS: There were 31 447 calls to 17 349 inpatients, of whom 9274 (53.5%) were males, with a median age of 72 (interquartile range: 57-83) years. At the 96-month census point, 9317 (53.7%) patients were alive. Of the 8032 who died, 204 (2.5%) died at RRT call, 2262 (28.1%) at hospital discharge, and 5570 (69.3%) died following hospital discharge. A total of 5470 (68.1%) patients had died within 12 months of RRT call. Compared with general population deaths, RRT patients died younger (median age: 79 vs 88 years), were more likely to die in a hospital (54.6% vs 41.7%), and were less likely to die in a private location (11.9% vs 18.8%). DISCUSSION: Survival duration varied by RRT trigger, with the least duration observed for cardiac arrest, followed by oxygen desaturation and tachypnoea. Lesser survival duration was also observed for male patients, medical admissions, patients with multiple calls, and those with a not-for-resuscitation order. Mortality decreased over the study period, whilst the RRT dose increased. CONCLUSIONS: Most deaths occur within 12 months of an index RRT call and following hospital discharge. RRT patients die at a younger age than the general population. Cumulative survival varied by RRT trigger and improved over time. CI - Copyright (c) 2025 The Author(s). Published by Elsevier Ltd.. All rights reserved. FAU - Sundararajan, Krishnaswamy AU - Sundararajan K AD - Intensive Care Medicine, Royal Adelaide Hospital, Central Adelaide Local Health Network, South Australia, Australia; Faculty of Health and Medical Sciences, The University of Adelaide, South Australia, Australia. Electronic address: krishnaswamy.sundararajan@adelaide.edu.au. FAU - Gilbert, Toby AU - Gilbert T AD - Division of Medicine, Northern Adelaide Local Health Network, South Australia, Australia; Faculty of Health and Medical Sciences, The University of Adelaide, South Australia, Australia. FAU - O'Connell, Alice AU - O'Connell A AD - General Medicine Service, Royal Adelaide Hospital, Central Adelaide Local Health Network, South Australia, Australia; Faculty of Health and Medical Sciences, The University of Adelaide, South Australia, Australia. FAU - Flabouris, Arthas AU - Flabouris A AD - Intensive Care Medicine, Royal Adelaide Hospital, Central Adelaide Local Health Network, South Australia, Australia; Faculty of Health and Medical Sciences, The University of Adelaide, South Australia, Australia. LA - eng PT - Journal Article PT - Observational Study DEP - 20250404 PL - Australia TA - Aust Crit Care JT - Australian critical care : official journal of the Confederation of Australian Critical Care Nurses JID - 9207852 SB - IM MH - Humans MH - Male MH - Female MH - *Hospital Rapid Response Team/statistics & numerical data MH - Aged MH - Middle Aged MH - Aged, 80 and over MH - Australia/epidemiology MH - Hospital Mortality MH - Hospitals, University OTO - NOTNLM OT - General population OT - Medical emergency response OT - Medical emergency teams OT - Patient discharge OT - RRT OT - Rapid response systems OT - Rapid response teams OT - Registry COIS- Declaration of competing interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this manuscript. EDAT- 2025/04/06 04:44 MHDA- 2025/06/09 00:28 CRDT- 2025/04/05 18:07 PHST- 2024/11/21 00:00 [received] PHST- 2025/02/10 00:00 [revised] PHST- 2025/02/18 00:00 [accepted] PHST- 2025/06/09 00:28 [medline] PHST- 2025/04/06 04:44 [pubmed] PHST- 2025/04/05 18:07 [entrez] AID - S1036-7314(25)00051-7 [pii] AID - 10.1016/j.aucc.2025.101221 [doi] PST - ppublish SO - Aust Crit Care. 2025 Jul;38(4):101221. doi: 10.1016/j.aucc.2025.101221. Epub 2025 Apr 4. PMID- 40184150 OWN - NLM STAT- MEDLINE DCOM- 20250521 LR - 20250625 IS - 1941-7705 (Electronic) IS - 1941-7713 (Print) IS - 1941-7713 (Linking) VI - 18 IP - 5 DP - 2025 May TI - Impact of In-Hospital Quality of Care Improvement Initiative on Secondary Prevention of Acute Coronary Syndrome in Six Months After Patient Discharge: A Large Stepped Wedge- and Cluster-Randomized Controlled Trial. PG - e011441 LID - 10.1161/CIRCOUTCOMES.124.011441 [doi] AB - BACKGROUND: Patients discharged after acute coronary syndrome experience a high risk of major adverse cardiovascular events (MACE) within the first 6 months. We examined whether a quality of care improvement initiative implemented in hospitals affects clinical preventive management and outcomes after discharge. METHODS: We used data from the third phase of the CPACS-3 study (Clinical Pathways for Acute Coronary Syndromes in China), a large stepped wedge- and cluster-randomized trial conducted from 2011 to 2015, to evaluate the effectiveness of an in-hospital quality of care improvement program on the composite score of preventive medication use and the risk of MACE in 6 months after discharge among acute coronary syndrome survivors. The intervention included establishing a quality of care improvement team, training clinical staff, implementing acute coronary syndrome clinical pathways, performance assessment and feedback, online technical support, and patient education. A total of 101 hospitals were randomized into 4 wedges, and the intervention was initiated randomly by wedge and step. Participants recruited before (control) and after (intervention) the intervention initiation were compared with generalized estimating equations, adjusting for clustering and time trend. RESULTS: A total of 23 258 patients (11 224 in the intervention group and 12 034 in the control group), with a mean age of 63.6+/-11.6 years and 39% women, had available follow-up data on MACE and 14 826 patients (6813 in the intervention group and 8013 in the control group) had available data on preventive medication use at 6 months were analyzed. Compared with the control period, the mean preventive medication use score during the intervention period was higher at 6 months (65.8 versus 60.4 for intervention and control periods, adjusted mean difference, 3.7 [95% CI, 0.3-7.0]), but the 6-month incidence of MACE showed no difference (5.8% versus 6.6%, adjusted odds ratio, 1.04 [95% CI, 0.83-1.29]). CONCLUSIONS: The in-hospital multifaceted quality of care improvement intervention in resource-constrained Chinese hospitals increased preventive medication use among acute coronary syndrome survivors in the 6 months after discharge, but this did not translate into a reduction in MACE. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01398228. FAU - Xie, Gaoqiang AU - Xie G AUID- ORCID: 0000-0002-4123-3535 AD - Clinical Research Institute, Institute of Advanced Clinical Medicine (G.X., Y.W.), Peking University, Beijing, China. AD - Key Laboratory of Epidemiology of Major Diseases (Peking University), Ministry of Education (G.X., Y.W.), Peking University, Beijing, China. AD - Peking University First Hospital (G.X., Y.W.), Peking University, Beijing, China. AD - State Key Laboratory of Vascular Homeostasis and Remodeling (G.X., Y.W.), Peking University, Beijing, China. FAU - Patel, Anushka AU - Patel A AUID- ORCID: 0000-0003-3825-4092 AD - The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia (A.P.). FAU - Du, Xin AU - Du X AUID- ORCID: 0000-0002-7463-8707 AD - Anzhen hospital, Beijing, China (X.D., Y.S.). FAU - Sun, Yihong AU - Sun Y AUID- ORCID: 0000-0001-7812-9793 AD - Anzhen hospital, Beijing, China (X.D., Y.S.). FAU - Li, Xian AU - Li X AUID- ORCID: 0000-0001-5445-4022 AD - The George Institute for Global Health Beijing, China (X.L., T.W., Z.H.). FAU - Wu, Tao AU - Wu T AD - The George Institute for Global Health Beijing, China (X.L., T.W., Z.H.). FAU - Hao, Zhixin AU - Hao Z AD - The George Institute for Global Health Beijing, China (X.L., T.W., Z.H.). FAU - Gao, Runlin AU - Gao R AUID- ORCID: 0000-0002-2425-2005 AD - The Department of Cardiology, Cardiovascular Institute and Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China (R.G.). FAU - Wu, Yangfeng AU - Wu Y AUID- ORCID: 0000-0002-4451-1932 AD - Clinical Research Institute, Institute of Advanced Clinical Medicine (G.X., Y.W.), Peking University, Beijing, China. AD - Key Laboratory of Epidemiology of Major Diseases (Peking University), Ministry of Education (G.X., Y.W.), Peking University, Beijing, China. AD - Peking University First Hospital (G.X., Y.W.), Peking University, Beijing, China. AD - State Key Laboratory of Vascular Homeostasis and Remodeling (G.X., Y.W.), Peking University, Beijing, China. AD - Department of Epidemiology and Biostatistics, Peking University School of Public Health, Beijing, China (Y.W.). LA - eng SI - ClinicalTrials.gov/NCT01398228 PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial DEP - 20250404 PL - United States TA - Circ Cardiovasc Qual Outcomes JT - Circulation. Cardiovascular quality and outcomes JID - 101489148 RN - 0 (Cardiovascular Agents) SB - IM MH - Aged MH - Female MH - Humans MH - Male MH - Middle Aged MH - *Acute Coronary Syndrome/diagnosis/mortality/prevention & control/therapy MH - *Cardiovascular Agents/therapeutic use MH - China/epidemiology MH - Critical Pathways/standards MH - *Outcome and Process Assessment, Health Care/standards MH - Patient Care Team/standards MH - *Patient Discharge/standards MH - Patient Education as Topic MH - *Quality Improvement/standards MH - *Quality Indicators, Health Care/standards MH - Risk Assessment MH - Risk Factors MH - *Secondary Prevention/standards MH - Time Factors MH - Treatment Outcome PMC - PMC12084016 OTO - NOTNLM OT - acute coronary syndrome OT - clinical trial OT - quality improvement OT - secondary prevention COIS- None. EDAT- 2025/04/04 12:29 MHDA- 2025/05/21 18:30 PMCR- 2025/05/16 CRDT- 2025/04/04 11:33 PHST- 2025/05/21 18:30 [medline] PHST- 2025/04/04 12:29 [pubmed] PHST- 2025/04/04 11:33 [entrez] PHST- 2025/05/16 00:00 [pmc-release] AID - CIRCCQO-2024-011441 [pii] AID - 10.1161/CIRCOUTCOMES.124.011441 [doi] PST - ppublish SO - Circ Cardiovasc Qual Outcomes. 2025 May;18(5):e011441. doi: 10.1161/CIRCOUTCOMES.124.011441. Epub 2025 Apr 4. PMID- 40177965 OWN - NLM STAT- MEDLINE DCOM- 20250526 LR - 20250526 IS - 1744-8344 (Electronic) IS - 1477-9072 (Linking) VI - 23 IP - 4 DP - 2025 Apr TI - Optimizing the management of tricuspid regurgitation: an update on current treatment strategies and perspectives. PG - 131-139 LID - 10.1080/14779072.2025.2488869 [doi] AB - INTRODUCTION: Tricuspid regurgitation (TR) is a prevalent condition and is independently associated with high morbidity and mortality rates. Despite its prognostic impact, TR remains undertreated, with patients often referred at late stages when medical therapy is ineffective and surgical intervention high risk. Emerging transcatheter therapies offer a promising alternative for safer and effective management of this elderly patient population with numerous comorbidities. AREAS COVERED: This review highlights recent advances in treatment strategies and future directions for addressing significant TR. The literature search was conducted across the PubMed, Embase, Scopus, and Google Scholar databases. A structured search strategy was developed using 'tricuspid regurgitation' and 'management' or 'treatment' or 'therapy' and 'surgery' or 'tricuspid valve repair' or 'tricuspid valve replacement' or 'transcatheter tricuspid intervention' as MeSH terms and keywords. Selected articles from 2017 to present were critically analyzed for strengths, limitations, and gaps in evidence. EXPERT OPINION: Enhancing disease awareness, the involvement of multidisciplinary Heart Team and intervening earlier are critical priorities for TR therapies to prevent treatment futility. Improved device designs, more performant imaging techniques, and dedicated research endpoints will help optimizing the management of TR. FAU - Angellotti, Domenico AU - Angellotti D AUID- ORCID: 0000-0002-7941-0779 AD - Department of Cardiology, Bern University Hospital, Bern, Switzerland. AD - Department of Advanced Biomedical Science, University of Naples Federico II, Naples, Italy. FAU - Franzone, Anna AU - Franzone A AD - Department of Advanced Biomedical Science, University of Naples Federico II, Naples, Italy. FAU - Brugger, Nicolas AU - Brugger N AD - Department of Cardiology, Bern University Hospital, Bern, Switzerland. FAU - Reineke, David AU - Reineke D AD - Department of Cardiology, Bern University Hospital, Bern, Switzerland. FAU - Esposito, Giovanni AU - Esposito G AD - Department of Advanced Biomedical Science, University of Naples Federico II, Naples, Italy. FAU - Praz, Fabien AU - Praz F AD - Department of Cardiology, Bern University Hospital, Bern, Switzerland. LA - eng PT - Journal Article PT - Review DEP - 20250406 PL - England TA - Expert Rev Cardiovasc Ther JT - Expert review of cardiovascular therapy JID - 101182328 SB - IM MH - Humans MH - *Tricuspid Valve Insufficiency/physiopathology/therapy/surgery MH - *Heart Valve Prosthesis Implantation/methods MH - *Cardiac Catheterization/methods MH - Aged MH - Prognosis MH - Tricuspid Valve/surgery OTO - NOTNLM OT - Tricuspid regurgitation OT - management OT - medical therapy OT - surgery OT - transcatheter interventions EDAT- 2025/04/03 12:24 MHDA- 2025/05/26 06:26 CRDT- 2025/04/03 07:13 PHST- 2025/05/26 06:26 [medline] PHST- 2025/04/03 12:24 [pubmed] PHST- 2025/04/03 07:13 [entrez] AID - 10.1080/14779072.2025.2488869 [doi] PST - ppublish SO - Expert Rev Cardiovasc Ther. 2025 Apr;23(4):131-139. doi: 10.1080/14779072.2025.2488869. Epub 2025 Apr 6. PMID- 40177743 OWN - NLM STAT- MEDLINE DCOM- 20250421 LR - 20250421 IS - 1524-4539 (Electronic) IS - 0009-7322 (Linking) VI - 151 IP - 16 DP - 2025 Apr 22 TI - Outcomes of Transcatheter Aortic Valve Replacement in Low-Risk Patients in the United States: A Report From the STS/ACC TVT Registry. PG - 1134-1146 LID - 10.1161/CIRCULATIONAHA.124.071838 [doi] AB - BACKGROUND: Real-world low-risk transcatheter aortic valve replacement (TAVR) outcomes in the United States have not been assessed comprehensively versus pivotal trials, which is a key component of measuring the quality of clinical technology adoption. METHODS: We identified heart team-designated low-risk patients undergoing TAVR for trileaflet severe, symptomatic aortic stenosis in the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Registry, as well as a subset of patients who met low-risk trial inclusion and exclusion criteria, from January 2020 to March 2024. Outcomes (mortality, stroke, new pacemaker, and "alive and well," defined as alive at 1 year with Kansas City Cardiomyopathy Questionnaire score >/=60 and /=90% as 'very strong'. RESULTS: A total of 34 consensus statements were generated in seven domains: (1) challenges in the system approach to HFpEF; (2) enhancing referral for specialist review including echocardiography; (3) confidence in using a summary statement in an echo report; (4) identifying HFpEF and its underlying aetiology; (5) HF awareness, training and education; (6) refining multidisciplinary team roles in decision-making; (7) optimising patient experience.135 UK specialists experienced in managing HF participated in the survey, including physiologists/clinical scientists (n=43), HF specialist nurses (n=35), cardiologists (n=34), general practitioners (n=12), pharmacists (n=4) and others (n=7). 20 of 34 (59%) statements achieved very strong agreement, 10 of 34 (29%) achieved strong agreement and 4 of 34 (12%) did not meet the consensus threshold. CONCLUSIONS: Diagnosis of HFpEF requires access to essential diagnostic tools. Establishing standardised pathways for specialist assessment and referral, including TTE reporting of HFpEF, may help eliminate diagnostic delays and geographical disparities. Further education and awareness are crucial for improving detection rates, prompt referral and patient experience. CI - (c) Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. FAU - Paton, Maria F AU - Paton MF AUID- ORCID: 0000-0001-8517-4621 AD - Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK. AD - Leeds Teaching Hospitals NHS Trust, Leeds, UK. FAU - Barton, Carys AU - Barton C AD - Imperial College Healthcare NHS Trust, London, UK. FAU - Baruah, Resham AU - Baruah R AUID- ORCID: 0000-0001-7883-3633 AD - AstraZeneca UK Limited, London, UK. FAU - Hartshorne-Evans, Nick AU - Hartshorne-Evans N AD - Pumping Marvellous Foundation, Preston, UK. FAU - Jenkins, Geraint H AU - Jenkins GH AD - Regional Cardiac Centre, Morriston Cardiac Centre, Swansea Bay University Health Board, Swansea, UK. FAU - Potter, Andrew AU - Potter A AD - Whaddon Medical Centre, Milton Keynes, UK. FAU - Robinson, Shaun AU - Robinson S AD - Imperial College Healthcare NHS Trust, London, UK. FAU - Thakkar, Raj AU - Thakkar R AD - AstraZeneca UK Limited, London, UK. AD - Primary Care Cardiovascular Society, London, UK. FAU - Zakeri, Rosita AU - Zakeri R AD - School of Cardiovascular Medicine & Metabolic Sciences, King's College London, London, UK. FAU - Taylor, Clare J AU - Taylor CJ AUID- ORCID: 0000-0001-8926-2581 AD - Department of Applied Health Sciences, School of Health Sciences, College of Medicine and Health, University of Birmingham, Birmingham, UK c.j.taylor.1@bham.ac.uk. LA - eng PT - Consensus Statement PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20250328 PL - England TA - Open Heart JT - Open heart JID - 101631219 SB - IM MH - Humans MH - *Heart Failure/physiopathology/diagnostic imaging/diagnosis MH - *Stroke Volume/physiology MH - *Delphi Technique MH - *Echocardiography/methods/standards MH - *Ventricular Function, Left/physiology MH - United Kingdom PMC - PMC11956303 OTO - NOTNLM OT - Cardiac Imaging Techniques OT - Echocardiography OT - HEART FAILURE OT - Health Services COIS- Competing interests: CB has received speaker and consultancy fees from AstraZeneca, Pharmacosmos, Medtronic, Pfizer. CJJT has received occasional consultancy and speaker fees from AstraZeneca, Roche and Bayer. GHJ has received consultancy, speaker fees or sponsored attendance at meetings from AstraZeneca, Boerrhinger-Ingelheim, Amarin, Novartis, Novo-Nordisk, Pfizer, Janssen, Vifor Pharma, Pharmacosmos, Relyspa, Amicus. MFP is a Trustee of the British Society of Echocardiography and has received consultancy or speaker fees from Medtronic, Abbott, AstraZeneca and GE Healthcare. NH-E has received consultancy, speaker fees or sponsored attendance at meetings Roche, Pharmacosmos, Novartis, Medtronic, AstraZeneca. RB was employed by AstraZeneca UK during the study and is currently affiliated with Novo Nordisk. RT has been employed by AstraZeneca UK during the study. RZ is supported by a National Institute for Healthcare Research (NIHR) Advanced Fellowship award (NIHR302961) and has received consultancy and speaker fees from AstraZeneca. SR has received speaker and consultancy fees from AstraZeneca. EDAT- 2025/03/29 16:13 MHDA- 2025/03/29 16:14 PMCR- 2025/03/28 CRDT- 2025/03/28 20:52 PHST- 2024/11/11 00:00 [received] PHST- 2025/03/19 00:00 [accepted] PHST- 2025/03/29 16:14 [medline] PHST- 2025/03/29 16:13 [pubmed] PHST- 2025/03/28 20:52 [entrez] PHST- 2025/03/28 00:00 [pmc-release] AID - openhrt-2024-003063 [pii] AID - 10.1136/openhrt-2024-003063 [doi] PST - epublish SO - Open Heart. 2025 Mar 28;12(1):e003063. doi: 10.1136/openhrt-2024-003063. PMID- 40153788 OWN - NLM STAT- MEDLINE DCOM- 20250515 LR - 20250515 IS - 2561-1011 (Electronic) IS - 2561-1011 (Linking) VI - 9 DP - 2025 Mar 28 TI - Pharmacist-Initiated Team-Based Intervention for Optimizing Guideline-Directed Lipid Therapy of Hospitalized Patients With Acute Coronary Syndrome: Pilot Study Using a Stepped-Wedge Cluster Design. PG - e58837 LID - 10.2196/58837 [doi] LID - e58837 AB - BACKGROUND: Clinical guidelines recommend high-intensity statin therapy for patients with acute coronary syndrome (ACS). However, high-intensity statins have been underused in this population. OBJECTIVE: The objective of this study was to evaluate the feasibility of a pharmacist-initiated, team-based intervention for the delivery of individualized, guideline-directed, lipid-lowering therapy for patients with ACS. METHODS: Patients admitted with ACS to cardiology hospital services at Mayo Clinic from August 1, 2021, to June 19, 2022, were assigned to a pharmacist-initiated, team-based intervention group or control group using a stepped wedge cluster study design. For the intervention group, pharmacists reviewed electronic health records and provided recommendations for lipid lowering therapy in hospital and at follow-up. In the control group, patients received usual care. Neither care team, nor study team were blinded to study assignments. The primary outcome was the proportion of patients with ACS discharged on high-intensity statins in the intervention group compared to controls. Secondary outcomes were (1) proportion of patients in the intervention group with a specific templated pharmacist intervention note in their electronic health records, (2) frequency of low-density lipoprotein (LDL) measurements in hospital, (3) proportion of patients with information related to lipid follow-up in their discharge summary, and (4) proportion of patients that received LDL monitoring at the outpatient follow-up 4 to 12 weeks post discharge. RESULTS: There were 410 patients included in this study (median age 68, IQR 60-78 years) of whom 285 (69.5%) were male. Of the 402 patients alive at discharge, 355 (88.3%) were discharged taking a high-intensity statin, with no significant difference (P=.89) observed between groups. Lipid levels were measured in the hospital for 176/210 (83.8%) patients in the intervention group and 155/200 (77.5%) patients in the control group (P=.14). Fifty-four of 205 (26.3%) intervention patients alive at discharge had lipid-related recommendations in their discharge summary compared to 27/197 (13.7%) controls (P=.002). Forty-seven of 81 (58%) patients with lipid management recommendations provided in the discharge summary had LDL measured in the follow-up period compared with only 119/321 (37.1%) patients without these recommendations (P=.001). Of the 402 patients who survived to discharge, 166 (41.3%) had LDL measured at follow-up; the median LDL level was 63.5 (IQR 49-79) mg/dL, and distributions were similar by group (P=.95). Only 101/166 (60.8%) patients had follow-up LDL values below the target of 70 mg/dL. CONCLUSIONS: During hospitalization, there was no group difference in the primary outcome of high-intensity statin therapy. Feasibility of an effective pharmacist-initiated intervention for improvement of lipid management was demonstrated by entry of recommendations in the discharge summary and related adjustment in outpatient statin therapy. The main opportunity for future improvement in lipid management of patients with ACS is in longitudinal patient follow-up. CI - (c) Gayle L Flo, Mateo Alzate Aguirre, Benjamin R Gochanour, Kristin J Hynes, Christopher G Scott, Angela L Fink, Adelaide M Arruda-Olson. Originally published in JMIR Cardio (https://cardio.jmir.org). FAU - Flo, Gayle L AU - Flo GL AUID- ORCID: 0009-0001-8808-6261 AD - Department of Cardiovascular Medicine, Mayo Clinic, 200 First Street Southwest, Rochester, MN, 55905, United States, 1 507-284-2511. FAU - Alzate Aguirre, Mateo AU - Alzate Aguirre M AUID- ORCID: 0000-0003-1129-238X AD - Ascension St. John Hospital, Detroit, MI, United States. AD - Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, United States. FAU - Gochanour, Benjamin R AU - Gochanour BR AUID- ORCID: 0000-0002-0950-1739 AD - Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, United States. FAU - Hynes, Kristin J AU - Hynes KJ AUID- ORCID: 0009-0009-4395-5361 AD - Department of Cardiovascular Medicine, Mayo Clinic, 200 First Street Southwest, Rochester, MN, 55905, United States, 1 507-284-2511. AD - Pharmacy Services, Mayo Clinic, Rochester, MN, United States. FAU - Scott, Christopher G AU - Scott CG AUID- ORCID: 0000-0003-1340-0647 AD - Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, United States. FAU - Fink, Angela L AU - Fink AL AUID- ORCID: 0000-0001-8817-6155 AD - Department of Nursing, Mayo Clinic, Rochester, MN, United States. FAU - M Arruda-Olson, Adelaide AU - M Arruda-Olson A AUID- ORCID: 0000-0001-9541-9899 AD - Department of Cardiovascular Medicine, Mayo Clinic, 200 First Street Southwest, Rochester, MN, 55905, United States, 1 507-284-2511. LA - eng GR - UL1 TR002377/TR/NCATS NIH HHS/United States PT - Journal Article DEP - 20250328 PL - Canada TA - JMIR Cardio JT - JMIR cardio JID - 101718325 RN - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors) RN - 0 (Lipids) SB - IM MH - Humans MH - *Acute Coronary Syndrome/drug therapy/blood MH - Male MH - Female MH - Pilot Projects MH - *Pharmacists MH - Aged MH - Middle Aged MH - *Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use/administration & dosage MH - *Patient Care Team MH - Hospitalization MH - Practice Guidelines as Topic MH - *Lipids/blood PMC - PMC11970799 OTO - NOTNLM OT - coronary disease OT - follow-up studies OT - lipids OT - myocardial infarction OT - statins COIS- Conflicts of Interest: None declared. EDAT- 2025/03/28 18:25 MHDA- 2025/03/28 18:26 PMCR- 2025/03/28 CRDT- 2025/03/28 16:53 PHST- 2024/03/26 00:00 [received] PHST- 2025/02/08 00:00 [revised] PHST- 2025/02/11 00:00 [accepted] PHST- 2025/03/28 18:26 [medline] PHST- 2025/03/28 18:25 [pubmed] PHST- 2025/03/28 16:53 [entrez] PHST- 2025/03/28 00:00 [pmc-release] AID - v9i1e58837 [pii] AID - 58837 [pii] AID - 10.2196/58837 [doi] PST - epublish SO - JMIR Cardio. 2025 Mar 28;9:e58837. doi: 10.2196/58837. PMID- 40152032 OWN - NLM STAT- MEDLINE DCOM- 20250725 LR - 20250728 IS - 2724-5772 (Electronic) IS - 2724-5683 (Linking) VI - 73 IP - 4 DP - 2025 Aug TI - Clinical implications of Body Mass Index and sarcopenic obesity in patients with severe aortic stenosis. PG - 471-478 LID - 10.23736/S2724-5683.24.06577-3 [doi] AB - BACKGROUND: Aortic valve stenosis (AS) often coexists with various comorbidities and concurrent cardiovascular risk factors. However, the clinical impact of obesity, considering sarcopenia, remains unexplored in patients with severe symptomatic AS evaluated by a Heart Team. This study evaluates Body Mass Index (BMI)'s discriminative power and clinical implications regarding adverse clinical events in severe symptomatic AS patients assessed by a Heart Team, while considering sarcopenia. METHODS: This retrospective single-center cohort study included severe symptomatic AS patients evaluated by a Heart Team, analyzing baseline characteristics, anatomo-functional data, biochemical parameters, and adverse clinical events during a 2-year follow-up. The cohort was stratified by BMI and the presence of sarcopenia, determined using the validated SARC-F Questionnaire. RESULTS: The mean age of the study cohort (N.=278) was 83.25+/-6.88 years (51.1% female), with a median follow-up of 13.05 months (IQR 5.96-24.50). The AUC for the primary outcome related to BMI was 0.623 ([95% CI 0.543-0.704]; P=0.004), with the optimal BMI threshold at 24.95 kg/m(2). Patients with a BMI>24.95 kg/m(2) exhibited improved survival (HR 0.508 [95% CI 0.303-0.853]; P=0.010). Conditional dependence regarding the presence of sarcopenia was observed in the relationship between BMI and adverse clinical events (sarcopenic patients, P=0.015 vs. non-sarcopenic, P=0.618; Cochran-Mantel-Haenszel test P=0.171). CONCLUSIONS: Among severe symptomatic AS patients evaluated by a Heart Team, BMI predicts adverse clinical outcomes. Remarkably, normal-weight patients have higher mortality rates than obese patients. This association was only evident in the absence of sarcopenic obesity. FAU - Garmendia, Cristian M AU - Garmendia CM AD - Department of Interventional Cardiology, Italian Hospital of Buenos Aires, Buenos Aires, Argentina - cristian.garmendia@hospitalitaliano.org.ar. FAU - Seropian, Ignacio M AU - Seropian IM AD - Department of Interventional Cardiology, Italian Hospital of Buenos Aires, Buenos Aires, Argentina. FAU - Damonte, Juan I AU - Damonte JI AD - Department of Interventional Cardiology, Italian Hospital of Buenos Aires, Buenos Aires, Argentina. FAU - Medina Del Chazal, Horacio AU - Medina Del Chazal H AD - Department of Interventional Cardiology, Italian Hospital of Buenos Aires, Buenos Aires, Argentina. FAU - Kotowicz, Vadim AU - Kotowicz V AD - Department of Cardiovascular Surgery, Italian Hospital of Buenos Aires, Buenos Aires, Argentina. FAU - Cal, Mariela AU - Cal M AD - Department of Internal Medicine, Geriatrics Division, Italian Hospital of Buenos Aires, Buenos Aires, Argentina. FAU - Smietniansky, Maximiliano AU - Smietniansky M AD - Department of Internal Medicine, Geriatrics Division, Italian Hospital of Buenos Aires, Buenos Aires, Argentina. FAU - Falconi, Mariano AU - Falconi M AD - Department of Cardiology and Advanced Cardiac Imaging, Italian Hospital of Buenos Aires, Buenos Aires, Argentina. FAU - Agatiello, Carla R AU - Agatiello CR AD - Department of Interventional Cardiology, Italian Hospital of Buenos Aires, Buenos Aires, Argentina. LA - eng PT - Journal Article DEP - 20250328 PL - Italy TA - Minerva Cardiol Angiol JT - Minerva cardiology and angiology JID - 101776555 SB - IM CIN - Minerva Cardiol Angiol. 2025 Aug;73(4):467-470. doi: 10.23736/S2724-5683.25.06844-9. PMID: 40052278 MH - Humans MH - *Sarcopenia/complications/epidemiology MH - Female MH - *Body Mass Index MH - Male MH - Retrospective Studies MH - *Obesity/complications/epidemiology MH - *Aortic Valve Stenosis/complications/physiopathology/mortality MH - Aged, 80 and over MH - Aged MH - Severity of Illness Index MH - Follow-Up Studies MH - Cohort Studies MH - Risk Factors EDAT- 2025/03/28 06:24 MHDA- 2025/07/25 12:32 CRDT- 2025/03/28 05:54 PHST- 2025/07/25 12:32 [medline] PHST- 2025/03/28 06:24 [pubmed] PHST- 2025/03/28 05:54 [entrez] AID - S2724-5683.24.06577-3 [pii] AID - 10.23736/S2724-5683.24.06577-3 [doi] PST - ppublish SO - Minerva Cardiol Angiol. 2025 Aug;73(4):471-478. doi: 10.23736/S2724-5683.24.06577-3. Epub 2025 Mar 28. PMID- 40151941 OWN - NLM STAT- MEDLINE DCOM- 20250521 LR - 20250521 IS - 1941-3297 (Electronic) IS - 1941-3289 (Linking) VI - 18 IP - 5 DP - 2025 May TI - Cardiogenic Shock Teams: Past, Present, and Future Directions. PG - e011630 LID - 10.1161/CIRCHEARTFAILURE.124.011630 [doi] AB - Cardiogenic shock (CS) remains a significant challenge in cardiovascular medicine, characterized by substantial morbidity and mortality. Historically, patient outcomes in CS have been varied, highly dependent on the timeliness of interventions and the expertise available at treating centers. Emerging evidence indicates that structured, team-based approaches significantly improve survival rates and diminish complications linked to CS. However, several challenges for implementing a team-based approach persist, including optimizing team composition and resource distribution. This article delves into the evolution, current implementations, and future directions of CS teams, emphasizing their crucial role in enhancing patient outcomes. We advocate for the adoption of standardized protocols to ensure uniformity of care across institutions, highlighting the critical need for prompt recognition and management strategies that integrate invasive hemodynamic monitoring and early mechanical circulatory support. Looking ahead, we propose the extension of CS team models into regional networks, broadening their impact through education, telemedicine and collaborative protocols. We also emphasize the importance of continuous research and data sharing via national registries to refine CS team strategies and substantiate their effects on patient outcomes. Ultimately, this review highlights the imperative for ongoing innovation and standardization in CS team operations to improve care delivery and enhance survival rates in CS scenarios. FAU - Blumer, Vanessa AU - Blumer V AUID- ORCID: 0000-0001-5062-5015 AD - Inova Schar Heart and Vascular, Falls Church, VA (V.B.). FAU - Hanff, Thomas C AU - Hanff TC AUID- ORCID: 0000-0003-3096-1227 AD - Division of Cardiology, University of Utah, Salt Lake City (T.C.H.). FAU - Gage, Ann AU - Gage A AUID- ORCID: 0000-0001-5735-5011 AD - Department of Cardiology, Centennial Medical Center, Nashville, TN (A.G.). FAU - Schrage, Benedikt AU - Schrage B AUID- ORCID: 0000-0001-9041-3922 AD - Department of Cardiology, University Heart and Vascular Center Hamburg, Germany (B.S.). FAU - Kanwar, Manreet K AU - Kanwar MK AUID- ORCID: 0000-0002-7280-5268 AD - Department of Cardiology, University of Chicago, IL (M.K.K.). LA - eng PT - Journal Article PT - Review DEP - 20250328 PL - United States TA - Circ Heart Fail JT - Circulation. Heart failure JID - 101479941 SB - IM MH - Humans MH - *Shock, Cardiogenic/therapy/mortality/physiopathology/diagnosis MH - *Patient Care Team/trends OTO - NOTNLM OT - cardiovascular agents OT - hemodynamic monitoring OT - information dissemination OT - survival rate OT - telemedicine COIS- Dr Gage received honorarium from Zoll Fellows' Education and was a former member of Abiomed Speaker's Bureau. Dr Hanff received a research grant funded by Abiomed and National Institutes of Health/National Heart, Lung, and Blood Institute (1L30HL170339-01). Dr Schrage received honoraria from Abbott, Abiomed, AstraZeneca, and Inari, as well as research funding from Abiomed. The other authors report no conflicts. EDAT- 2025/03/28 06:25 MHDA- 2025/05/21 18:30 CRDT- 2025/03/28 05:03 PHST- 2025/05/21 18:30 [medline] PHST- 2025/03/28 06:25 [pubmed] PHST- 2025/03/28 05:03 [entrez] AID - 10.1161/CIRCHEARTFAILURE.124.011630 [doi] PST - ppublish SO - Circ Heart Fail. 2025 May;18(5):e011630. doi: 10.1161/CIRCHEARTFAILURE.124.011630. Epub 2025 Mar 28. PMID- 40150110 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250330 IS - 2075-4418 (Print) IS - 2075-4418 (Electronic) IS - 2075-4418 (Linking) VI - 15 IP - 6 DP - 2025 Mar 19 TI - Ultrasound Screening in the First and Second Trimester of Pregnancy for the Detection of Fetal Cardiac Anomalies in a Low-Risk Population. LID - 10.3390/diagnostics15060769 [doi] LID - 769 AB - Background/Objectives: Congenital heart disease (CHD) is the most common birth defect, an important cause of morbidity and mortality, with a reported prevalence of 5-12 per 1000 live births. The aim of our study was to identify the role of fetal morphological ultrasound examination in the first and second trimester of pregnancy in the detection of fetal congenital cardiac anomalies in a low-risk population. Methods: We performed a retrospective study in a tertiary fetal medicine center in Emergency Hospital Craiova, Romania. The longitudinal analysis combined first- and second-trimester screening using improved ultrasound protocols. Our study evaluated 8944 pregnant women with singleton pregnancies in a 6-year period between January 2018 and December 2023. All ultrasound examinations were performed using a standard extended protocol according to the main guidelines' recommendations for the detection of fetal anomalies. Results: In the first trimester of pregnancy, 37 cases with cardiac anomalies were diagnosed. Thirteen of these cases were associated with genetic anomalies (Down syndrome-eight cases, Edwards syndrome-four cases, Turner syndrome-one case). Some of these pregnancies were associated with at least one of the minor ultrasound markers (inverted ductus venosus, abnormal flow in the tricuspid valve, presence of choroid plexus cysts, absent/hypoplastic nasal bone). In the second trimester of pregnancy, 17 cases of cardiac anomalies were diagnosed. From these cases, one was associated with genetic anomalies (DiGeorge Syndrome), and one case developed hydrops and delivered prematurely in the early third trimester. Conclusions: Ultrasound screening for the detection of congenital heart disease is feasible early in pregnancy, but some anomalies would be obvious later in pregnancy. An early diagnosis using an extended ultrasound protocol, genetic testing, and a multidisciplinary evaluation would improve the prognosis and the overall survival rate by delivering in a tertiary center that allows for rapid cardiac surgery in dedicated cases. FAU - Popa, Aura Iuliana AU - Popa AI AD - Doctoral School, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania. FAU - Cernea, Nicolae AU - Cernea N AD - Department of Obstetrics and Gynecology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania. FAU - Marinas, Marius Cristian AU - Marinas MC AD - Department of Human Anatomy, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania. FAU - Comanescu, Maria Cristina AU - Comanescu MC AD - Department of Human Anatomy, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania. FAU - Sirbu, Ovidiu Costinel AU - Sirbu OC AD - Department of Obstetrics and Gynecology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania. FAU - Popa, Dragos George AU - Popa DG AD - Department of Plastic Surgery, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania. FAU - Patru, Larisa AU - Patru L AD - Department 9, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania. FAU - Padureanu, Vlad AU - Padureanu V AUID- ORCID: 0000-0001-7398-5689 AD - Department of Internal Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania. FAU - Patru, Ciprian Laurentiu AU - Patru CL AD - Department of Obstetrics and Gynecology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania. LA - eng PT - Journal Article DEP - 20250319 PL - Switzerland TA - Diagnostics (Basel) JT - Diagnostics (Basel, Switzerland) JID - 101658402 PMC - PMC11941630 OTO - NOTNLM OT - congenital heart disease OT - echocardiography OT - fetus OT - prenatal diagnosis COIS- All authors declare that they have no conflicts of interest. EDAT- 2025/03/28 06:24 MHDA- 2025/03/28 06:25 PMCR- 2025/03/19 CRDT- 2025/03/28 01:09 PHST- 2025/01/19 00:00 [received] PHST- 2025/03/13 00:00 [revised] PHST- 2025/03/15 00:00 [accepted] PHST- 2025/03/28 06:25 [medline] PHST- 2025/03/28 06:24 [pubmed] PHST- 2025/03/28 01:09 [entrez] PHST- 2025/03/19 00:00 [pmc-release] AID - diagnostics15060769 [pii] AID - diagnostics-15-00769 [pii] AID - 10.3390/diagnostics15060769 [doi] PST - epublish SO - Diagnostics (Basel). 2025 Mar 19;15(6):769. doi: 10.3390/diagnostics15060769. PMID- 40147631 OWN - NLM STAT- MEDLINE DCOM- 20260120 LR - 20260120 IS - 2341-1929 (Electronic) IS - 2341-1929 (Linking) VI - 72 IP - 8 DP - 2025 Oct TI - Anaesthesia evaluation and perioperative strategies in liver disease patients with cardiohepatic syndrome. PG - 501735 LID - S2341-1929(25)00120-9 [pii] LID - 10.1016/j.redare.2025.501735 [doi] AB - Cardiohepatic syndrome (CHS) presents a significant challenge in perioperative management due to the complex interaction between liver and heart dysfunction. CHS, analogous to cardiorenal syndrome, encompasses various conditions where hepatic and cardiovascular pathologies exacerbate one another. Patients with chronic liver disease, cirrhosis, or heart failure often exhibit increased perioperative morbidity and mortality, necessitating tailored anesthetic strategies. A comprehensive understanding of CHS pathophysiology is crucial, as it informs risk assessment and guides perioperative management. Risk stratification tools such as the Child-Pugh and MELD scores are commonly used, but they have limitations in fully capturing perioperative risks. The updated STS 2024 model includes liver-specific parameters, improving risk prediction in cardiac surgeries. Additionally, the VOCAL-Penn score addresses gaps in traditional risk models, providing a more accurate assessment for patients with advanced liver disease. Perioperative management focuses on minimizing hemodynamic stress and avoiding drugs metabolized by the liver. Agents like Remifentanil, Atracurium, and Esmolol are preferred for their minimal hepatic metabolism. Vasopressors such as terlipressin and vasopressin, which target the splanchnic circulation, improve hemodynamics in these patients. Within the Enhanced Recovery After Surgery (ERAS) framework, optimizing nutrition and fluid management is essential for reducing perioperative complications. Effective management of patients with CHS requires a multidisciplinary approach that integrates comprehensive risk assessment and individualized anesthetic strategies. This approach improves outcomes by reducing perioperative complications and mortality in this high-risk population. CI - Copyright (c) 2025 Sociedad Espanola de Anestesiologia, Reanimacion y Terapeutica del Dolor. Publicado por Elsevier Espana, S.L.U. All rights reserved. FAU - Espinosa, A AU - Espinosa A AD - Department of Anesthesia, King Salman Specialist Hospital, Hail City, Kingdom of Saudi Arabia. Electronic address: drangelespinosa@gmail.com. FAU - Ripolles Melchor, J AU - Ripolles Melchor J AD - Anesthesia Department, Hospital Universitario Infanta Leonor, Madrid, Spain; Universidad Complutense de Madrid, Madrid, Spain. FAU - Jain, M AU - Jain M AD - Department of Critical Care, Royal Brompton Hospital, London, United Kingdom. FAU - Navarro-Perez, R AU - Navarro-Perez R AD - Department of Anaesthesia, Hospital Clinico San Carlos, Madrid, Spain. FAU - Shadad, Y A AU - Shadad YA AD - Department of Perfusion Sciences, Mohammed Bin Khalifa Specialist Cardiac Centre, Awali, Kingdom of Bahrain. FAU - Malvido, A AU - Malvido A AD - Department of Gastroenterology University Hospital Carlos B. Udaondo, Buenos Aires, Argentina. FAU - Abad Gurumeta, A AU - Abad Gurumeta A AD - Anesthesia Department, Hospital Universitario Infanta Leonor, Madrid, Spain; Universidad Complutense de Madrid, Madrid, Spain. FAU - Alharbi, R AU - Alharbi R AD - Department of Anesthesia, King Salman Specialist Hospital, Hail City, Kingdom of Saudi Arabia. LA - eng PT - Journal Article PT - Review DEP - 20250325 PL - Spain TA - Rev Esp Anestesiol Reanim (Engl Ed) JT - Revista espanola de anestesiologia y reanimacion JID - 101778594 SB - IM MH - *Anesthesia/methods MH - *Perioperative Care/methods MH - *Liver Diseases/complications/pathology/surgery MH - *Cardiovascular Diseases/complications/pathology/surgery MH - Syndrome MH - Liver Function Tests MH - *Risk Assessment/methods MH - Hemodynamics MH - Enhanced Recovery After Surgery MH - Postoperative Complications/etiology/prevention & control MH - Humans OTO - NOTNLM OT - Albumin gap OT - Brecha de albumina OT - Calificacion de riesgo OT - Cardiac surgery OT - Cardiohepatic OT - Cardiohepatico OT - Cirugia cardiaca OT - Clevidipina OT - Clevidipine OT - ERAS OT - Esterasas OT - Esterases OT - Insuficiencia hepatica OT - Liver failure OT - Perioperative OT - Perioperatorio OT - Remimazolam OT - Risk scoring OT - VOCAL-Penn OT - Vocal-Penn COIS- Declaration of competing interest None of the authors report a conflict of interest. EDAT- 2025/03/28 00:24 MHDA- 2025/10/04 00:30 CRDT- 2025/03/27 20:32 PHST- 2024/10/01 00:00 [received] PHST- 2024/11/29 00:00 [revised] PHST- 2024/12/06 00:00 [accepted] PHST- 2025/10/04 00:30 [medline] PHST- 2025/03/28 00:24 [pubmed] PHST- 2025/03/27 20:32 [entrez] AID - S2341-1929(25)00120-9 [pii] AID - 10.1016/j.redare.2025.501735 [doi] PST - ppublish SO - Rev Esp Anestesiol Reanim (Engl Ed). 2025 Oct;72(8):501735. doi: 10.1016/j.redare.2025.501735. Epub 2025 Mar 25. PMID- 40147620 OWN - NLM STAT- MEDLINE DCOM- 20250729 LR - 20250729 IS - 1556-5653 (Electronic) IS - 0015-0282 (Linking) VI - 124 IP - 2 DP - 2025 Aug TI - Special considerations in assisted reproductive technology for patients with cardiovascular disease. PG - 188-199 LID - S0015-0282(25)00169-4 [pii] LID - 10.1016/j.fertnstert.2025.03.021 [doi] AB - Many individuals with cardiovascular disease can benefit from the availability of assisted reproductive technologies (ARTs) for family building. Its use for this population may be because of underlying infertility, a need for fertility preservation before disease worsening or heart transplant, a genetic cardiac condition they believe to avoid passing to offspring, or the need to use a gestational surrogate in the setting of cardiovascular contraindications to pregnancy. Cardiovascular disease exists on a spectrum, from mild and common diseases that pose minimal threat to maternal health during pregnancy to severe and rare diseases with a high risk of morbidity and maternal mortality if ART or pregnancy is pursued. In this review, we characterize the varying cardiovascular diseases from the lens of the reproductive-aged patient undergoing ART. We classify the necessary steps in the pre-ART evaluation from the multidisciplinary team, discuss risk stratification before ART treatment and possible subsequent pregnancy, and offer specific evidence-based guidance on the care of these patients during the in vitro fertilization and embryo transfer cycles. CI - Copyright (c) 2025 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved. FAU - Cromack, Sarah C AU - Cromack SC AD - Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Northwestern University Feinberg School of Medicine, Chicago, Illinois. Electronic address: sarah.capelouto@nm.org. FAU - Kalinowska, Vanessa AU - Kalinowska V AD - Department of Obstetrics and Gynecology, Northwestern University Feinberg School of Medicine, Chicago, Illinois. FAU - Boots, Christina E AU - Boots CE AD - Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Northwestern University Feinberg School of Medicine, Chicago, Illinois. FAU - Mendelson, Marla A AU - Mendelson MA AD - Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois. LA - eng PT - Journal Article PT - Review DEP - 20250325 PL - United States TA - Fertil Steril JT - Fertility and sterility JID - 0372772 SB - IM MH - Humans MH - Female MH - *Reproductive Techniques, Assisted/adverse effects MH - Pregnancy MH - *Cardiovascular Diseases/diagnosis/therapy/physiopathology/epidemiology/complications MH - *Infertility/therapy/physiopathology/diagnosis MH - Risk Assessment MH - Risk Factors MH - *Pregnancy Complications, Cardiovascular/therapy/diagnosis/physiopathology MH - Treatment Outcome OTO - NOTNLM OT - Cardiovascular OT - anticoagulation OT - congenital OT - heart disease OT - in vitro fertilization COIS- Declaration of Interests S.C.C. has nothing to disclose. V.K. has nothing to disclose. C.E.B. has nothing to disclose. M.A.M. has nothing to disclose. EDAT- 2025/03/28 00:24 MHDA- 2025/07/29 18:31 CRDT- 2025/03/27 20:32 PHST- 2025/03/05 00:00 [received] PHST- 2025/03/20 00:00 [revised] PHST- 2025/03/21 00:00 [accepted] PHST- 2025/07/29 18:31 [medline] PHST- 2025/03/28 00:24 [pubmed] PHST- 2025/03/27 20:32 [entrez] AID - S0015-0282(25)00169-4 [pii] AID - 10.1016/j.fertnstert.2025.03.021 [doi] PST - ppublish SO - Fertil Steril. 2025 Aug;124(2):188-199. doi: 10.1016/j.fertnstert.2025.03.021. Epub 2025 Mar 25. PMID- 31082134 STAT- Publisher CTDT- 20250328 PB - StatPearls Publishing DP - 2025 Jan TI - Anesthesia Inhalation Agents and Their Cardiovascular Effects. BTI - StatPearls AB - Over the past several decades, multiple studies and clinical practice have demonstrated the cardiovascular effects of inhalation anesthetic agents. Early anesthetics included diethyl ether and nitrous oxide, whereas more recent halogenated agents include isoflurane, desflurane, and sevoflurane. Halogenated agents produce similar circulatory effects in young, healthy individuals during maintenance anesthesia. However, comorbidities, extremes of age, concurrent medications, and additional factors can alter the expected effects. The development of the anesthetic care team approach underscores the importance of effective communication to improve outcomes. A significant cardiovascular effect of inhalation anesthetic agents is their impact on components of cardiac output, which can lead to reductions in blood pressure. Lowering blood pressure may benefit certain patients, such as those with hypertension, but it may also pose risks for individuals with hypotension or those predisposed to hemodynamic instability. To counteract these effects, anesthesiologists may administer medications to support blood pressure or cardiac output while closely monitoring the patient throughout the procedure. Inhalation anesthetics can alter heart rate and rhythm. These changes may result from the direct effects of the anesthetic on the heart and contributing factors such as cardiac output fluctuations. Inhalation anesthetic agents likewise influence the respiratory system by altering breathing rate and depth. These changes can affect oxygen and carbon dioxide levels in the blood, potentially impacting cardiovascular function. The cardioprotective effects of volatile anesthetics and certain intravenous anesthetics have been well-documented in preclinical studies, but their clinical efficacy remains uncertain. Translating these insights into clinical practice presents ongoing challenges due to the complexity of underlying mechanisms and variability in patient response. Several recent clinical trials have investigated the cardioprotective effects of anesthetics over the past 5 years. Studies have produced mixed findings regarding the clinical relevance of volatile anesthetics for cardioprotection. Guidelines have evolved, with some endorsing the use of volatile anesthetics for cardioprotection in noncardiac surgeries or coronary artery bypass graft surgery, whereas others do not support their use. Clinical trials have evaluated multiple anesthetic techniques, including volatile, intravenous, and xenon gas anesthetics. Some studies have found no differences in clinical outcomes between volatile and intravenous anesthetics, whereas others have reported biomarker improvements that did not translate into clinical benefits. Meta-analyses have consistently shown reductions in morbidity or mortality with volatile anesthetics compared to total intravenous anesthesia. Xenon gas has also been explored as a cardioprotective agent, but its clinical advantages over other anesthetics remain uncertain. CI - Copyright (c) 2025, StatPearls Publishing LLC. FAU - Hendrix, Joseph Maxwell AU - Hendrix JM AD - Texas Health Resources FAU - Kramer, Jeremy AU - Kramer J AD - Michigan State University LA - eng PT - Study Guide PT - Book Chapter PL - Treasure Island (FL) COIS- Disclosure: Joseph Maxwell Hendrix declares no relevant financial relationships with ineligible companies. Disclosure: Jeremy Kramer declares no relevant financial relationships with ineligible companies. EDAT- 2025/03/28 00:00 CRDT- 2025/03/28 00:00 AID - NBK541090 [bookaccession] PMID- 40145170 OWN - NLM STAT- MEDLINE DCOM- 20250327 LR - 20250515 IS - 0300-5283 (Print) IS - 0300-5283 (Linking) VI - 80 IP - 2 DP - 2025 Mar TI - Non-statin therapy in patients with elevated LDL-C and high platelet reactivity: a narrative review. PG - 258-265 AB - INTRODUCTION: Evidence of an association between elevated LDL-C levels and HRPR - which are highly prevalent separately and both lead to rapid progression of atherosclerosis on ineffective hypolipidaemic therapy - is scarce. MATERIALS AND METHODS: We searched electronic databases. All available randomized controlled trials (RCTs) were included, and we considered the scientific novelty of the study, the reliability of the reported study results; the high methodological level of the study of non-statin therapy in patients with dyslipidemia and high residual platelet reactivity, with no language or date restrictions. We did separate random-effects meta-analyses for LDL-capital ES, Cyrillic, HRRP on their effects on LDL-capital ES, Cyrillic levels and outcomes, taking into account the reliability of the reported study results and the high methodological level of the study. The challenge of achieving target LDL-capital ES, Cyrillic levels, their impact on high residual platelet reactivity, and the choice of optimal antiplatelet and lipid-lowering therapy remains unresolved. RESULTS: The integration of newer therapies, such as inclisiran and PCSK9 inhibitors, may play a critical role in achieving optimal outcomes for patients at high cardiovascular risk. CONCLUSION: The necessity of applying an individual multidisciplinary approach in order to determine the best regimen of antiplatelet and lipid-lowering therapy in patients with coronary heart disease, including after revascularization, is shown. This approach will reduce the risk of recurrent cardiovascular events. Few studies on the relationship between LDL-capital ES, Cyrillic and HRPR dictate the need for more detailed research in this area. FAU - Nurmukhammad, F N AU - Nurmukhammad FN AD - H.A. Yasawi International Kazakh-Turkish University, Turkestan, Republic of Kazakhstan. FAU - Zhangelova Sh, B AU - Zhangelova Sh B AD - Universiti Malaysia Sarawak, Faculty of Medicine and Health Sciences, Kota Samarahan, Sarawak, Malaysia. Zhangelova.s@kaznmu.kz. FAU - capital KA, Cyrillicapsultanova, D A AU - capital KA, Cyrillicapsultanova DA AD - Scientific research institute of cardiology and internal diseases, Almaty, Republic of Kazakhstan. FAU - Musagaliyeva, A T AU - Musagaliyeva AT AD - Scientific research institute of cardiology and internal diseases, Almaty, Republic of Kazakhstan. FAU - Danyarova, L B AU - Danyarova LB AD - Scientific research institute of cardiology and internal diseases, Almaty, Republic of Kazakhstan. FAU - Rustamova, F E AU - Rustamova FE AD - Scientific research institute of cardiology and internal diseases, Almaty, Republic of Kazakhstan. FAU - Sugraliyev, A B AU - Sugraliyev AB AD - Asfendiyarov Kazakh National Medical University, Almaty, Republic of Kazakhstan. FAU - Ospanova, G E AU - Ospanova GE AD - Scientific research institute of cardiology and internal diseases, Almaty, Republic of Kazakhstan. LA - eng PT - Journal Article PT - Review PL - Malaysia TA - Med J Malaysia JT - The Medical journal of Malaysia JID - 0361547 RN - 0 (Cholesterol, LDL) RN - 0 (Platelet Aggregation Inhibitors) SB - IM MH - Humans MH - *Cholesterol, LDL/blood MH - *Platelet Aggregation Inhibitors/therapeutic use MH - *Blood Platelets/drug effects/physiology MH - Randomized Controlled Trials as Topic MH - *Dyslipidemias/drug therapy EDAT- 2025/03/27 06:29 MHDA- 2025/03/27 13:18 CRDT- 2025/03/27 05:23 PHST- 2025/03/27 13:18 [medline] PHST- 2025/03/27 06:29 [pubmed] PHST- 2025/03/27 05:23 [entrez] PST - ppublish SO - Med J Malaysia. 2025 Mar;80(2):258-265. PMID- 40144249 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250328 IS - 2950-1334 (Electronic) IS - 2950-1334 (Linking) VI - 4 DP - 2024 May TI - Phase-of-care mortality assessment in cardiogenic shock due to end-stage heart failure. PG - 100077 LID - 10.1016/j.jhlto.2024.100077 [doi] LID - 100077 AB - End-stage heart failure-related cardiogenic shock (HF-CS) is associated with high risk of short-term mortality, but the causes and mode of death in HF-CS have not been described. This study aimed to (i) describe the causes/modes of death in patients with HF-CS based on the phases-of-care (Rescue-Optimization-Stabilization-Exit therapy), analogous to the phase-of-care mortality analysis, and (ii) assess the impact of the introduction of a standardized team-based care. We included 120 consecutive patients with HF-CS who underwent temporary mechanical circulatory support. The introduction of standardized team-based care reduced mortality at 6 months (36/63 (57%) vs 17/57 (30%), p = 0.003), but did not alter the distribution of phase-of-care mortality. There were fewer deaths following heart transplantation/left ventricular assist device therapy with standardized team-based care (6% vs 28%, p = 0.067) may be clinically relevant. CI - (c) 2024 International Society for Heart and Lung Transplantation. FAU - Lim, Hoong Sern AU - Lim HS AD - Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK. AD - Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Edgbaston, Birmingham, UK. FAU - Mascaro, Jorge AU - Mascaro J AD - Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK. AD - Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Edgbaston, Birmingham, UK. LA - eng PT - Journal Article DEP - 20240302 PL - United States TA - JHLT Open JT - JHLT open JID - 9918716187806676 PMC - PMC11935383 OTO - NOTNLM OT - cardiogenic shock OT - heart failure OT - heart transplantation OT - mechanical circulatory support OT - multi-organ failure COIS- H.S.L. has received honoraria from Abiomed. Funding and Acknowledgments: None. EDAT- 2025/03/27 06:29 MHDA- 2025/03/27 06:30 PMCR- 2024/03/02 CRDT- 2025/03/27 05:08 PHST- 2025/03/27 06:30 [medline] PHST- 2025/03/27 06:29 [pubmed] PHST- 2025/03/27 05:08 [entrez] PHST- 2024/03/02 00:00 [pmc-release] AID - S2950-1334(24)00026-0 [pii] AID - 100077 [pii] AID - 10.1016/j.jhlto.2024.100077 [doi] PST - epublish SO - JHLT Open. 2024 Mar 2;4:100077. doi: 10.1016/j.jhlto.2024.100077. eCollection 2024 May. PMID- 40142910 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250329 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 14 IP - 6 DP - 2025 Mar 19 TI - Mission and One-Year Experience of a Kidney-Heart Outpatient Service: A Patient-Centered Management Model. LID - 10.3390/jcm14062102 [doi] LID - 2102 AB - Background: Cardiorenal Syndrome (CRS) represents a growing global health challenge due to the increasing prevalence of coexisting kidney and heart disease. The complex pathophysiology of CRS demands an integrated, multidisciplinary approach involving both nephrology and cardiology. However, specialized care models remain limited, leading to fragmented management and suboptimal outcomes. Methods: A Kidney-Heart Outpatient Service was established at "Paolo Giaccone" University Hospital in Palermo in May 2023 to provide coordinated, multidisciplinary care for non-hospitalized patients with CRS. The service involves structured patient assessments, including medical history, physical examinations, laboratory tests, imaging, and a collaborative therapeutic plan formulated by nephrologists and cardiologists. Preliminary patient data were collected and analysed to assess demographic characteristics, comorbidities, and clinical outcomes. Results: Among the first 115 patients evaluated, most were male and over 70 years old. Hypertension (91%) and diabetes were the leading comorbidities, with CKD stage G3b being the most prevalent. Cardiovascular conditions such as atrial fibrillation (18%), prior myocardial infarction (17%), and heart failure (15%) were frequently observed. Three patient deaths occurred, and one progressed to hemodialysis. Conclusions: The Kidney-Heart Outpatient Service represents a novel, patient-centered model for CRS management, aiming to improve clinical outcomes and reduce hospital admissions through multidisciplinary collaboration. Longitudinal follow-up and expanded data collection are essential to validate the long-term efficacy of this approach and refine management strategies for CRS patients. Ongoing research efforts will focus on tracking patient outcomes over extended periods, optimizing therapeutic strategies, and further integrating nephrology and cardiology training. The goal is to establish a sustainable and scalable framework for CRS management that enhances patient care and reduces the healthcare burden. FAU - Carollo, Caterina AU - Carollo C AUID- ORCID: 0000-0002-6767-8823 AD - Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE) "G. D'Alessandro", University of Palermo, 90133 Palermo, Italy. FAU - Evola, Salvatore AU - Evola S AD - Catheterization Laboratory, Department of Medicine and Cardiology, Azienda Ospedaliera Universitaria Policlinico "P. Giaccone", 90127 Palermo, Italy. FAU - Sorce, Alessandra AU - Sorce A AD - Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE) "G. D'Alessandro", University of Palermo, 90133 Palermo, Italy. FAU - Cirafici, Emanuele AU - Cirafici E AUID- ORCID: 0009-0002-4934-0818 AD - Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE) "G. D'Alessandro", University of Palermo, 90133 Palermo, Italy. FAU - Bennici, Miriam AU - Bennici M AUID- ORCID: 0009-0005-0786-5976 AD - Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE) "G. D'Alessandro", University of Palermo, 90133 Palermo, Italy. FAU - Mule, Giuseppe AU - Mule G AD - Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE) "G. D'Alessandro", University of Palermo, 90133 Palermo, Italy. FAU - Geraci, Giulio AU - Geraci G AUID- ORCID: 0000-0003-3806-1151 AD - Department of Medicine and Surgery, "Kore" University of Enna, 94100 Enna, Italy. LA - eng PT - Journal Article DEP - 20250319 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC11942838 OTO - NOTNLM OT - cardiorenal OT - clinical nephrology OT - consultation OT - referral COIS- The authors declare no conflicts of interest. EDAT- 2025/03/27 06:28 MHDA- 2025/03/27 06:29 PMCR- 2025/03/19 CRDT- 2025/03/27 01:15 PHST- 2025/01/10 00:00 [received] PHST- 2025/03/10 00:00 [revised] PHST- 2025/03/14 00:00 [accepted] PHST- 2025/03/27 06:29 [medline] PHST- 2025/03/27 06:28 [pubmed] PHST- 2025/03/27 01:15 [entrez] PHST- 2025/03/19 00:00 [pmc-release] AID - jcm14062102 [pii] AID - jcm-14-02102 [pii] AID - 10.3390/jcm14062102 [doi] PST - epublish SO - J Clin Med. 2025 Mar 19;14(6):2102. doi: 10.3390/jcm14062102. PMID- 40137102 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260924 IS - 2308-3425 (Electronic) IS - 2308-3425 (Linking) VI - 12 IP - 3 DP - 2025 Mar 17 TI - Transition to Advanced Heart Failure: From Identification to Improving Prognosis. LID - 10.3390/jcdd12030104 [doi] LID - 104 AB - Advanced heart failure (AHF) represents the terminal stage of heart failure (HF), characterized by persistent symptoms and functional limitations despite optimal guideline-directed medical therapy (GDMT). This review explores the clinical definition, pathophysiology, and therapeutic approaches for AHF. Characterized by severe symptoms, New York Heart Association (NYHA) class III-IV, significant cardiac dysfunction, and frequent hospitalizations, AHF presents substantial challenges in prognosis and management. Pathophysiological mechanisms include neurohormonal activation, ventricular remodeling, and systemic inflammation, leading to reduced cardiac output and organ dysfunction. Therapeutic strategies for AHF involve a multidisciplinary approach, including pharmacological treatments, device-based interventions like ventricular assisted devices, and advanced options such as heart transplantation. Despite progress, AHF management faces limitations, including disparities in access to care and the need for personalized approaches. Novel therapies, artificial intelligence, and remote monitoring technologies offer future opportunities to improve outcomes. Palliative care, which focuses on symptom relief and quality of life, remains crucial for patients ineligible for invasive interventions. Early identification and timely intervention are pivotal for enhancing survival and functional outcomes in this vulnerable population. This review underscores the necessity of integrating innovative technologies, personalized medicine, and robust palliative strategies into AHF management to address its high morbidity and mortality. FAU - Tepetes, Nikolaos-Iason AU - Tepetes NI AUID- ORCID: 0009-0003-0972-3002 AD - Department of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece. FAU - Kourek, Christos AU - Kourek C AUID- ORCID: 0000-0003-4348-2153 AD - Department of Cardiology, 417 Army Share Fund Hospital of Athens (NIMTS), 11521 Athens, Greece. FAU - Papamichail, Adamantia AU - Papamichail A AD - Medical School of Athens, National and Kapodistrian University of Athens, 15772 Athens, Greece. FAU - Xanthopoulos, Andrew AU - Xanthopoulos A AUID- ORCID: 0000-0002-9439-3946 AD - Department of Cardiology, University Hospital of Larissa, 41110 Larissa, Greece. FAU - Kostakou, Peggy AU - Kostakou P AUID- ORCID: 0000-0002-3821-224X AD - Department of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece. FAU - Paraskevaidis, Ioannis AU - Paraskevaidis I AUID- ORCID: 0000-0002-7764-6411 AD - Department of Cardiology, Hygeia Hospital, 15123 Athens, Greece. FAU - Briasoulis, Alexandros AU - Briasoulis A AUID- ORCID: 0000-0002-5740-9670 AD - Department of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece. LA - eng PT - Journal Article PT - Review DEP - 20250317 PL - Switzerland TA - J Cardiovasc Dev Dis JT - Journal of cardiovascular development and disease JID - 101651414 PMC - PMC11943400 OTO - NOTNLM OT - advanced heart failure OT - cardiopulmonary exercise testing OT - devices OT - guideline-directed therapy OT - palliative care OT - therapeutic strategy COIS- The authors declare no conflicts of interest. EDAT- 2025/03/26 12:29 MHDA- 2025/03/26 12:30 PMCR- 2025/03/17 CRDT- 2025/03/26 11:53 PHST- 2024/12/22 00:00 [received] PHST- 2025/02/15 00:00 [revised] PHST- 2025/03/13 00:00 [accepted] PHST- 2025/03/26 12:30 [medline] PHST- 2025/03/26 12:29 [pubmed] PHST- 2025/03/26 11:53 [entrez] PHST- 2025/03/17 00:00 [pmc-release] AID - jcdd12030104 [pii] AID - jcdd-12-00104 [pii] AID - 10.3390/jcdd12030104 [doi] PST - epublish SO - J Cardiovasc Dev Dis. 2025 Mar 17;12(3):104. doi: 10.3390/jcdd12030104. PMID- 40135918 OWN - NLM STAT- Publisher LR - 20250326 IS - 1538-4683 (Electronic) IS - 1061-5377 (Linking) DP - 2025 Mar 26 TI - A Comprehensive Review of Effusive-Constrictive Pericarditis, Diagnosis, and Management. LID - 10.1097/CRD.0000000000000900 [doi] AB - Effusive-constrictive pericarditis (ECP) is characterized by fluid accumulation in the pericardial space and a rigid, fibrotic pericardium that restricts heart filling. Its diverse causes include infectious agents, systemic inflammatory conditions, malignancies, and iatrogenic factors. ECP is more prevalent in areas burdened by contagious diseases, such as tuberculous pericardial effusion, and it is found in about 6.7% of patients with tuberculous pericardial effusion. The diagnosis of ECP has improved with advanced imaging techniques, yet challenges persist. Although Doppler echocardiography is sensitive, it lacks specificity, and cardiac catheterization remains the gold standard. Emerging biomarkers such as interleukin-10 may enhance diagnosis, but further validation is needed. Techniques such as cardiac magnetic resonance imaging and computed tomography are used to identify structural abnormalities, but their routine application is still developing. Management of ECP is based on its underlying cause and severity, often starting with pericardiocentesis followed by anti-inflammatory treatments. For severe cases with significant fibrosis, pericardiectomy is the definitive solution. Prognosis varies, with malignancy-related cases typically yielding poorer outcomes than infectious origins. This review explores ECP's pathophysiology, diagnostic challenges, and treatment strategies. It highlights knowledge gaps and suggests future research directions. A multidisciplinary approach is crucial for understanding and improving patient care for this complex condition. CI - Copyright (c) 2025 Wolters Kluwer Health, Inc. All rights reserved. FAU - Jamaleddin Ahmad, Fadi Ali AU - Jamaleddin Ahmad FA AD - From the American University of The Caribbean Medical School, Cupecoy, Sint Maarten. FAU - Ali Abdi, Syed Imran AU - Ali Abdi SI AD - Thumbay University Hospital, Ajman, United Arab Emirates. FAU - Verma, Tarun AU - Verma T AD - Indira Gandhi Medical College, Shimla, India. FAU - Barsinge, Tanvi AU - Barsinge T AD - Seth GS Medical College and King Edward Memorial Hospital, Mumbai, India. FAU - Banderas Echeverry, Waldyr M AU - Banderas Echeverry WM AD - Universidad Libre, Cali, Colombia. FAU - Sampath, Neha AU - Sampath N AD - Sri Ramachandra Medical College, Chennai, India. FAU - Fathima, Alia AU - Fathima A AD - Sri Ramachandra Medical College, Chennai, India. FAU - Khelifi, Abdulrahman AU - Khelifi A AD - University of Jordan, Amman, Jordan. FAU - Ashraf Sanour, Omar AU - Ashraf Sanour O AD - Hawler Medical University, Erbil, Iraq. FAU - Zerin, Annu AU - Zerin A AD - All India Institute of Medical Sciences, Bhubaneswar, India; and. FAU - Mowo-Wale, Adetola AU - Mowo-Wale A AD - Obafemi Awolowo College of Health Sciences/Olabisi Onabanjo University, Ago-Iwoye, Nigeria. FAU - Khan, Shaymaa AU - Khan S AD - Thumbay University Hospital, Ajman, United Arab Emirates. LA - eng PT - Journal Article DEP - 20250326 PL - United States TA - Cardiol Rev JT - Cardiology in review JID - 9304686 SB - IM COIS- Disclosures: The authors have no conflicts of interest to report. EDAT- 2025/03/26 12:30 MHDA- 2025/03/26 12:30 CRDT- 2025/03/26 09:04 PHST- 2025/03/26 12:30 [medline] PHST- 2025/03/26 12:30 [pubmed] PHST- 2025/03/26 09:04 [entrez] AID - 00045415-990000000-00452 [pii] AID - 10.1097/CRD.0000000000000900 [doi] PST - aheadofprint SO - Cardiol Rev. 2025 Mar 26. doi: 10.1097/CRD.0000000000000900. PMID- 40135105 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260813 IS - 0973-6883 (Print) IS - 2213-3453 (Electronic) IS - 0973-6883 (Linking) VI - 15 IP - 4 DP - 2025 Jul-Aug TI - Combined Living Donor Liver Transplantation With Coronary Artery Bypass Grafting: Possible but not Without a Struggle. PG - 102515 LID - 10.1016/j.jceh.2025.102515 [doi] LID - 102515 AB - BACKGROUND: A combined liver transplant (LT) and coronary artery bypass grafting (CABG) may sometimes be needed for patients with decompensated cirrhosis who also have significant coronary artery disease (CAD). However, such a procedure is associated with significant morbidity and mortality. METHODS: From May 2012 to August 2020, eight patients with significant coronary artery disease (CAD) underwent combined off pump CABG (OPCAB) and living donor liver transplantation (LDLT) at our center. We analyzed patient demographics, preoperative clinical findings, operative details, and postoperative outcomes. RESULTS: Mean recipient age and body mass index were 59 +/- 6 years and 26 +/- 3kg/m(2), respectively. The model for end-stage liver disease (MELD) score was 20. Four patients each had hypertension and diabetes. Mean total duration of the surgery was 982 +/- 117 min, with 598 +/- 89 min for living donor liver transplantation (LDLT). The mean volume of packed red blood cell transfusion was 2500ml. The duration of the ventilatory support (median 49 h post-surgery), and the median intensive care unit and hospital stay (8 and 18 days, respectively). Two patients died during the postoperative period due to sepsis with multiorgan failure No recipient had evidence of acute coronary syndrome, stress cardiomyopathy; none required interventional hemodynamic support. Four patients developed atrial arrhythmia's in the post-operative period, all were managed successfully with medical management. CONCLUSION: Combined CABG and LDLT is feasible but poses significant challenges. Careful preprocedure planning, and meticulous intra- and post-operative management involving a multidisciplinary team of LT Surgeons and anesthetists, hepatologists, cardiologists, and cardiac surgeons is required to ensure optimal outcomes in these patients. CI - (c) 2025 Indian National Association for Study of the Liver. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies. FAU - Vohra, Vijay AU - Vohra V AD - Department of Liver Transplant and GI Anaesthesia, Medanta - The Medicity, Sector 38, Gurgaon, 122001, India. FAU - Bhangui, Pooja AU - Bhangui P AD - Department of Liver Transplant and GI Anaesthesia, Medanta - The Medicity, Sector 38, Gurgaon, 122001, India. FAU - Bhangui, Prashant AU - Bhangui P AD - Medanta Institute of Liver Transplantation and Regenerative Medicine, Medanta - The Medicity, Sector 38, Gurgaon, 122001, India. FAU - Sharma, Nishant AU - Sharma N AD - Department of Liver Transplant and GI Anaesthesia, Medanta - The Medicity, Sector 38, Gurgaon, 122001, India. FAU - Gupta, Nikunj AU - Gupta N AD - Department of Liver Transplant and GI Anaesthesia, Medanta - The Medicity, Sector 38, Gurgaon, 122001, India. FAU - Bansal, Manish AU - Bansal M AD - Clinical & Preventive Cardiology, Medanta - The Medicity, Sector 38, Gurgaon, 122001, India. FAU - Soin, Arvinder Singh AU - Soin AS AD - Medanta Institute of Liver Transplantation and Regenerative Medicine, Medanta - The Medicity, Sector 38, Gurgaon, 122001, India. LA - eng PT - Journal Article DEP - 20250214 PL - India TA - J Clin Exp Hepatol JT - Journal of clinical and experimental hepatology JID - 101574137 PMC - PMC11930670 OTO - NOTNLM OT - Cardiac evaluation OT - End stage liver disease OT - Off pump coronary artery bypass graft OT - Outcomes COIS- Authors have no competing interests to declare. EDAT- 2025/03/26 13:06 MHDA- 2025/03/26 13:07 PMCR- 2026/07/01 CRDT- 2025/03/26 04:34 PHST- 2024/11/24 00:00 [received] PHST- 2025/02/11 00:00 [accepted] PHST- 2025/03/26 13:07 [medline] PHST- 2025/03/26 13:06 [pubmed] PHST- 2025/03/26 04:34 [entrez] PHST- 2026/07/01 00:00 [pmc-release] AID - S0973-6883(25)00015-5 [pii] AID - 102515 [pii] AID - 10.1016/j.jceh.2025.102515 [doi] PST - ppublish SO - J Clin Exp Hepatol. 2025 Jul-Aug;15(4):102515. doi: 10.1016/j.jceh.2025.102515. Epub 2025 Feb 14. PMID- 40135093 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250327 IS - 1301-5680 (Print) IS - 2149-8156 (Electronic) IS - 1301-5680 (Linking) VI - 33 IP - 1 DP - 2025 Jan TI - Enhanced recovery after cardiac surgery and developments in perioperative care: A comprehensive review. PG - 121-131 LID - 10.5606/tgkdc.dergisi.2024.26770 [doi] AB - Enhanced Recovery After Cardiac Surgery (ERAS Cardiac) protocols offer a comprehensive, multidisciplinary approach to improve patient outcomes and reduce postoperative complications. By incorporating evidence-based practices, ERAS Cardiac aims to reduce hospital stays, enhance patient satisfaction, and optimize resource utilization. Key components include patient education, prehabilitation, nutritional optimization, and personalized medicine. The protocol's success relies on interdisciplinary collaboration among healthcare professionals, as well as active patient and family engagement. Despite challenges in implementation, such as resource constraints and patient variability, ongoing research and adaptive strategies continue to refine ERAS Cardiac programs, promising significant advancements in cardiac surgical care and recovery. CI - Copyright (c) 2025, Turkish Society of Cardiovascular Surgery. FAU - Gunaydin, Serdar AU - Gunaydin S AUID- ORCID: 0000-0002-9717-9793 AD - Department of Cardiovascular Surgery, University of Health Sciences, Ankara City Hospital (ERAS Turkey Society), Ankara, Turkiye. FAU - Simsek, Erdal AU - Simsek E AUID- ORCID: 0000-0002-2484-4676 AD - Department of Cardiovascular Surgery, University of Health Sciences, Ankara City Hospital (ERAS Turkey Society), Ankara, Turkiye. FAU - Engelman, Daniel AU - Engelman D AUID- ORCID: 0000-0003-4346-5492 AD - University of Massachusetts Chan Medical School; President ERAS(R) Cardiac Society, Cardiac Surgical Critical Care & Inpatient Services, Baystate, USA. LA - eng PT - Journal Article PT - Review DEP - 20241022 PL - Turkey TA - Turk Gogus Kalp Damar Cerrahisi Derg JT - Turk gogus kalp damar cerrahisi dergisi JID - 100887967 PMC - PMC11931364 OTO - NOTNLM OT - Enhanced recovery after cardiac surgery OT - perioperative care OT - prehabilitation. COIS- Conflict of Interest: The authors declared no conflicts of interest with respect to the authorship and/or publication of this article. EDAT- 2025/03/26 13:06 MHDA- 2025/03/26 13:07 PMCR- 2024/10/22 CRDT- 2025/03/26 04:34 PHST- 2024/08/04 00:00 [received] PHST- 2024/08/18 00:00 [accepted] PHST- 2025/03/26 13:07 [medline] PHST- 2025/03/26 13:06 [pubmed] PHST- 2025/03/26 04:34 [entrez] PHST- 2024/10/22 00:00 [pmc-release] AID - 10.5606/tgkdc.dergisi.2024.26770 [doi] PST - epublish SO - Turk Gogus Kalp Damar Cerrahisi Derg. 2024 Oct 22;33(1):121-131. doi: 10.5606/tgkdc.dergisi.2024.26770. eCollection 2025 Jan. PMID- 40126737 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260329 IS - 2110-5820 (Print) IS - 2110-5820 (Electronic) IS - 2110-5820 (Linking) VI - 15 IP - 1 DP - 2025 Mar 24 TI - Effect of manual decongestive therapy on cardiac preload in critically ill patients: a randomized controlled trial. PG - 39 LID - 10.1186/s13613-025-01453-z [doi] LID - 39 AB - BACKGROUND: Capillary leakage is common in critical illness and can lead to intravascular hypovolemia and edema. Fluid balance, however, is crucial to optimize cardiac preload, vascular filling and tissue perfusion. Intravenously administered fluids are rapidly distributed to the extravascular spaces and further increase edema with consecutive harm for impeded wound healing, weakness, distribution of pharmaceutics to the third space and patient discomfort. We hypothesized that manual decongestive therapy (MDT) followed by elastic bandaging increases cardiac preload and reduces interstitial edema and thus, offers a promising approach to restore the imbalance in fluid distribution between the interstitium and the intravascular space in critically ill patients. METHODS: From November 2021 to May 2023, 34 critical ill requiring advanced hemodynamic monitoring with thermodilution-calibrated pulse contour analysis were randomized to either standard care or MDT followed by elastic bandaging for 24 h. Global end-diastolic volume index (GEDI) as a marker of the cardiac preload was measured 15, 30, 60 min and 24 h after MDT. Wrist and ankle circumferences were measured as markers of the extent of local interstitial edema. RESULTS: In the intervention group, a significant increase in Delta GEDI was observed 15 min [median 48 (IQR 82) to median -19 (IQR 39)], 60 min [median 75 (IQR 106.5) to median -11 (IQR80)] and 24 h [median 107 (IQR 153) to median -16 (IQR 114)] after the study intervention compared to the control group. After 24 h ankle [median 23.5 (IQR 5) cm to median 24 (IQR 6) cm, p < 0.0001] and wrist] median 18 (IQR 2) cm to median 19 (IQR 2) cm, p < 0.0001] circumferences were increased significantly in the control group. In the intervention group a significant reduction in the ankle circumference [median 24.5 (IQR 5) cm to median 24 (IQR 4.5) cm, p < 0.0001] and a significant reduction in the wrist circumference [median 20 (IQR 3.8) cm to median 18 (IQR 3.5) cm, p < 0.0001], was observed after 24 h. CONCLUSIONS: MDT increases cardiac preload and helps to reduce interstitial fluid overload and edema in critically ill patients. TRIAL REGISTRATION: This prospective randomized controlled trial was registered at the German Clinical Trials Register DRKS00026226 on 17/09/2021. CI - (c) 2025. The Author(s). FAU - Posch, Matthias J AU - Posch MJ AD - Department of Anesthesiology and Critical Care, Faculty of Medicine, Medical Center - University of Freiburg, University of Freiburg, Freiburg I.Br., Germany. FAU - Schwer, Christian I AU - Schwer CI AD - Department of Anesthesiology and Critical Care, Faculty of Medicine, Medical Center - University of Freiburg, University of Freiburg, Freiburg I.Br., Germany. FAU - Kalbhenn, Johannes AU - Kalbhenn J AD - Department of Anesthesiology and Critical Care, Faculty of Medicine, Medical Center - University of Freiburg, University of Freiburg, Freiburg I.Br., Germany. FAU - Bansbach, Joachim AU - Bansbach J AUID- ORCID: 0000-0001-9769-5547 AD - Department of Anesthesiology and Critical Care, Faculty of Medicine, Medical Center - University of Freiburg, University of Freiburg, Freiburg I.Br., Germany. joachim.bansbach@uniklinik-freiburg.de. LA - eng PT - Journal Article DEP - 20250324 PL - France TA - Ann Intensive Care JT - Annals of intensive care JID - 101562873 PMC - PMC11933644 OTO - NOTNLM OT - Capillary leak OT - Cardiac preload OT - Critical care OT - Fluid balance OT - Lymphatic drainage OT - Manual decongestive therapy COIS- Declarations. Ethics approval and consent to participate: The study was approved by the local ethics committee with the registration number EK 21-1256. The trial was conducted in accordance with the declaration of Helsinki. Written informed consent was obtained from all included patients. Consent for publication: Written informed consent for publication was obtained. Competing interests: The authors declare that they have no competing interests. EDAT- 2025/03/24 18:31 MHDA- 2025/03/24 18:32 PMCR- 2025/03/24 CRDT- 2025/03/24 12:18 PHST- 2024/07/12 00:00 [received] PHST- 2025/03/03 00:00 [accepted] PHST- 2025/03/24 18:32 [medline] PHST- 2025/03/24 18:31 [pubmed] PHST- 2025/03/24 12:18 [entrez] PHST- 2025/03/24 00:00 [pmc-release] AID - S2110-5820(25)00043-3 [pii] AID - 1453 [pii] AID - 10.1186/s13613-025-01453-z [doi] PST - epublish SO - Ann Intensive Care. 2025 Mar 24;15(1):39. doi: 10.1186/s13613-025-01453-z. PMID- 40126020 OWN - NLM STAT- Publisher LR - 20250324 IS - 1538-4683 (Electronic) IS - 1061-5377 (Linking) DP - 2025 Mar 24 TI - Management of Valvular Heart Disease in Pregnancy: Challenges, Risk Stratification, and Multidisciplinary Approaches. LID - 10.1097/CRD.0000000000000905 [doi] AB - Advancements in medicine and surgery have led to an increasing number of women with valvular heart disease (VHD) reaching reproductive age and pursuing pregnancy. VHD, which may be congenital or acquired, accounts for a significant proportion of heart diseases in pregnant women, with rheumatic heart disease being the predominant cause globally, especially in developing countries. Pregnancy-induced hemodynamic changes can exacerbate preexisting valvular conditions, leading to complications such as heart failure, arrhythmia, and adverse fetal outcomes. Management of pregnant women with VHD requires a comprehensive, multidisciplinary approach involving preconceptional counseling, risk stratification, and careful monitoring throughout pregnancy. Risk assessment models, including CARPREG II, ZAHARA II, mWHO, and the DEVI score, help identify high-risk patients and guide management strategies. Specific challenges arise in patients with mechanical prosthetic valves due to the need for anticoagulation therapy, which must be carefully managed to minimize risks to both mother and fetus. The delivery plan should be tailored to the severity of the valvular disease, with careful consideration of the mode of delivery and the need for anticoagulation management during labor and postpartum. Preconception counseling is crucial in informing women of the potential risks and helping guide family planning decisions. This paper highlights the importance of early diagnosis, tailored treatment, and a multidisciplinary approach to reduce maternal and fetal morbidity and mortality in pregnant women with valvular heart disease. CI - Copyright (c) 2025 Wolters Kluwer Health, Inc. All rights reserved. FAU - Thukral, Jatin AU - Thukral J AD - From the Department of Internal Medicine, New York Medical College/Landmark Medical Center, Woonsocket, RI. FAU - Maheta, Darshilkumar AU - Maheta D AD - Department of Public Health, New York Medical College, Valhalla, NY. FAU - Khangurra, Sehajnoor Kaur AU - Khangurra SK AD - Gian Sagar Medical College, Ramnagar, India. FAU - Agrawal, Siddharth Pravin AU - Agrawal SP AD - From the Department of Internal Medicine, New York Medical College/Landmark Medical Center, Woonsocket, RI. FAU - Kaur, Harbir AU - Kaur H AD - Hamilton Medical Center, Dalton, GA. FAU - Thukral, Nikhil AU - Thukral N AD - Pt. Deendayal Upadhyay National Institute for Persons with Physical Disabilities, New Delhi, India. FAU - Frishman, William H AU - Frishman WH AD - Department of Medicine, New York Medical College, Valhalla, NY. FAU - Aronow, Wilbert S AU - Aronow WS AD - Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY. AD - Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY. LA - eng PT - Journal Article DEP - 20250324 PL - United States TA - Cardiol Rev JT - Cardiology in review JID - 9304686 SB - IM COIS- Disclosures: The authors have no conflicts of interest to report. EDAT- 2025/03/24 12:46 MHDA- 2025/03/24 12:46 CRDT- 2025/03/24 09:03 PHST- 2025/03/24 12:46 [medline] PHST- 2025/03/24 12:46 [pubmed] PHST- 2025/03/24 09:03 [entrez] AID - 00045415-990000000-00450 [pii] AID - 10.1097/CRD.0000000000000905 [doi] PST - aheadofprint SO - Cardiol Rev. 2025 Mar 24. doi: 10.1097/CRD.0000000000000905. PMID- 40124985 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260319 LR - 20260319 IS - 2397-1991 (Electronic) IS - 2397-1983 (Print) IS - 2397-1983 (Linking) VI - 10 IP - 3 DP - 2025 Oct TI - International expert agreement on World Scleroderma Foundation/Heart Failure Association consensus-based definition and guidance on screening, diagnosis, and follow-up assessment of systemic sclerosis-associated primary heart involvement. PG - 175-181 LID - 10.1177/23971983251321691 [doi] AB - OBJECTIVE: The aim of this study was to evaluate the level of agreement among international experts on the World Scleroderma Foundation/Heart Failure Association consensus-based definition of systemic sclerosis-associated primary heart involvement (SSc-pHI) and on the guidance for its screening, diagnosis, and follow-up assessment, including feasibility and applicability assessments. METHODS: An online survey was conducted to assess the level of agreement and feasibility/applicability using a 10-point scale (0 = not at all, 10 = completely agree or completely feasible/applicable). The weblink to the survey was shared with 1199 participants worldwide. A high level of agreement was defined by an average score over 7/10. RESULTS: In total, 161 external experts completed the survey. Most of them were rheumatologists (80.7%), working in Europe (81.4%), and had > 10 years of clinical experience in managing SSc patients (59%). Overall agreement among external experts was high (mean 8.27, SD 1.86). The highest scores regarded items emphasizing the involvement of a multidisciplinary team, personalization of patient management, and initial evaluation techniques. A lower level of agreement was obtained in questions related to cardiac magnetic resonance imaging and endomyocardial biopsy. No factors associated with low level of agreement and feasibility/applicability were identified. CONCLUSION: The consensus-based definition and guidance on screening, diagnosis, and follow-up assessment of SSc-pHI provides a basis for application by the wider community. A lower level of agreement on the use of advanced or more invasive diagnostic techniques likely reflects regional differences in access and the need for more evidence on its use. This emphasizes the importance of involving a multidisciplinary team. CI - (c) The Author(s) 2025. FAU - Dubas, Vitalii AU - Dubas V AD - Department of Noncoronary Heart Diseases, Rheumatology and Therapy, State Institution, National Scientific Center, The M.D. Strazhesko Institute of Cardiology, Clinical and Regenerative Medicine of the National academy of Medical Sciences of Ukraine, Kyiv, Ukraine. FAU - Buch, Maya H AU - Buch MH AD - Centre for Musculoskeletal Research, Division of Musculoskeletal & Dermatological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK. AD - NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK. FAU - Seferovic, Petar AU - Seferovic P AD - Faculty of Medicine, University of Belgrade, Belgrade, Serbia. AD - Serbian Academy of Sciences and Arts, Belgrade, Serbia. FAU - Matucci-Cerinic, Marco AU - Matucci-Cerinic M AD - Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UNIRAR) & Inflammation, Fibrosis and Ageing Initiative (INFLAGE), IRCCS San Raffaele Hospital, Milan, Italy. AD - School of Medicine, Vita-Salute San Raffaele University, Milan, Italy. FAU - Bruni, Cosimo AU - Bruni C AUID- ORCID: 0000-0003-2813-2083 AD - Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. LA - eng GR - WT_/Wellcome Trust/United Kingdom PT - Journal Article DEP - 20250319 PL - England TA - J Scleroderma Relat Disord JT - Journal of scleroderma and related disorders JID - 101685427 PMC - PMC11924048 OTO - NOTNLM OT - Systemic sclerosis OT - level of agreement OT - overarching principle OT - primary heart involvement OT - statement OT - survey COIS- The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: V.D. reported no conflict of interests to declare relevant to the topic of the article. M.H.B. is a Consultant for Boehringer Ingelheim (funds paid to host institution). P.S. is the past president of the Heart Failure Association of the European society of Cardiology. M.M.C. is the President of the World Scleroderma Foundation. The Editor/ Editorial Board Member of JSRD is an author of this article; therefore, the peer review process was managed by alternative members of the Board and the submitting Editor/Board member had no involvement in the decision-making process. C.B. is a Consultant for Boehringer Ingelheim; received grant/research support from Gruppo Italiano Lotta alla Sclerodermia (GILS), European Scleroderma Trials and Research Group (EUSTAR), Foundation for research in Rheumatology (FOREUM), Scleroderma Clinical Trials Consortium (SCTC), Scleroderma Research Foundation (SRF), Novartis Foundation for Bio-Medical Research, EMDO Foundation; Educational grants from AbbVie and Wellcome Trust; and Congress Support from Boehringer Ingelheim. All outside of the submitted work. EDAT- 2025/03/24 12:46 MHDA- 2025/03/24 12:47 PMCR- 2026/03/19 CRDT- 2025/03/24 06:13 PHST- 2024/12/05 00:00 [received] PHST- 2025/02/01 00:00 [accepted] PHST- 2025/03/24 12:47 [medline] PHST- 2025/03/24 12:46 [pubmed] PHST- 2025/03/24 06:13 [entrez] PHST- 2026/03/19 00:00 [pmc-release] AID - 10.1177_23971983251321691 [pii] AID - 10.1177/23971983251321691 [doi] PST - epublish SO - J Scleroderma Relat Disord. 2025 Mar 19;10(3):175-181. doi: 10.1177/23971983251321691. eCollection 2025 Oct. PMID- 40116171 OWN - NLM STAT- MEDLINE DCOM- 20250624 LR - 20250624 IS - 2724-6116 (Electronic) IS - 2724-6116 (Linking) VI - 50 IP - 2 DP - 2025 Jun TI - Endocrinologist's crucial role in metabolic dysfunction-associated steatotic liver disease: a comprehensive review. PG - 209-226 LID - 10.23736/S2724-6507.24.04314-8 [doi] AB - Metabolic dysfunction-associated steatotic liver disease (MASLD) is a widespread disorder strongly associated with metabolic conditions such as obesity, insulin resistance, and type 2 diabetes (T2D). The progression of MASLD, which can lead to severe complications like hepatic fibrosis and cirrhosis, is closely tied to cardiometabolic risks, including cardiovascular disease, and to liver-related cancers associated with metabolic dysfunction. Endocrinologists are uniquely positioned to detect MASLD early, particularly in individuals with metabolic risk factors such as T2D, polycystic ovary syndrome (PCOS), and thyroid dysfunction. While they may not routinely perform advanced diagnostic procedures, they play a critical role in identifying at-risk patients and collaborating with specialists for further evaluation, including the use of transient elastography to assess liver stiffness and fibrosis. By doing so, they help reduce the need for invasive procedures. Beyond screening and diagnosis, endocrinologists collaborate with hepatologists, cardiologists, and nutritionists to ensure a comprehensive, multidisciplinary treatment approach. Managing MASLD requires addressing both liver-specific conditions and broader metabolic dysfunctions through lifestyle interventions and pharmacological therapies. Recent studies highlight the potential benefits of medications, such as farnesoid X receptor (FXR) agonists and peroxisome proliferator-activated receptor (PPAR) agonists, when combined with lifestyle interventions such as modifying diet and engaging in more physical activity. This review highlights the pivotal role of endocrinologists in managing MASLD, focusing on their contributions to screening, diagnosis, and integrated care. It examines the complex interplay between hormonal regulation and both pharmacological and non-non-pharmacological treatment strategies, providing insights for enhancing clinical practice and improving patient outcomes through a comprehensive, multidisciplinary approach. FAU - Reytor-Gonzalez, Claudia AU - Reytor-Gonzalez C AD - Universidad UTE, Facultad de Ciencias de la Salud Eugenio Espejo, Centro de Investigacion en Salud Publica y Epidemiologia Clinica (CISPEC), Quito, Ecuador. FAU - Annunziata, Giuseppe AU - Annunziata G AD - Facolty of Human Sciences, Education and Sports, Universita Telematica Pegaso, Naples, Italy. FAU - Campuzano-Donoso, Martin AU - Campuzano-Donoso M AD - Universidad UTE, Facultad de Ciencias de la Salud Eugenio Espejo, Centro de Investigacion en Salud Publica y Epidemiologia Clinica (CISPEC), Quito, Ecuador. FAU - Morales-Lopez, Tania AU - Morales-Lopez T AD - Universidad UTE, Facultad de Ciencias de la Salud Eugenio Espejo, Quito, Ecuador. FAU - Basantes-Tituana, Carmen AU - Basantes-Tituana C AD - Universidad UTE, Facultad de Ciencias de la Salud Eugenio Espejo, Quito, Ecuador. FAU - Fasci-Spurio, Federica AU - Fasci-Spurio F AD - Unit of Gastroenterology, dell'Angelo Hospital, Venice, Italy. FAU - Verde, Ludovica AU - Verde L AD - Department of Public Health, University of Naples Federico II, Naples, Italy. FAU - Muscogiuri, Giovanna AU - Muscogiuri G AD - Unit of Endocrinology, Diabetology and Andrology, Department of Clinical and Surgical Medicine, University of Naples Federico II, Naples, Italy. AD - Centro Italiano per la Cura e il Benessere del Paziente con Obesita (C.I.B.O.), Unit of Endocrinology, Diabetology and Andrology, Department of Clinical and Surgical Medicine, University of Naples Federico II, Naples, Italy. AD - Cattedra Unesco "Educazione alla Salute e allo Sviluppo Sostenibile", University of Naples Federico II, Naples, Italy. FAU - Barrea, Luigi AU - Barrea L AD - Department of Wellness, Nutrition and Sports, Universita Telematica Pegaso, Centro Direzionale, Naples, Italy. FAU - Frias-Toral, Evelyn AU - Frias-Toral E AD - Holy Spirit University, School of Medicine, Samborondon, Ecuador. FAU - Simancas-Racines, Daniel AU - Simancas-Racines D AD - Universidad UTE, Facultad de Ciencias de la Salud Eugenio Espejo, Centro de Investigacion en Salud Publica y Epidemiologia Clinica (CISPEC), Quito, Ecuador - dsimancas@ute.edu.ec. LA - eng PT - Journal Article PT - Review DEP - 20250321 PL - Italy TA - Minerva Endocrinol (Torino) JT - Minerva endocrinology JID - 101777342 SB - IM MH - Humans MH - *Fatty Liver/therapy/diagnosis/etiology MH - *Physician's Role MH - Diabetes Mellitus, Type 2/complications MH - *Endocrinologists MH - *Metabolic Diseases/complications MH - Female MH - Polycystic Ovary Syndrome/complications EDAT- 2025/03/21 20:04 MHDA- 2025/06/24 13:13 CRDT- 2025/03/21 06:11 PHST- 2025/06/24 13:13 [medline] PHST- 2025/03/21 20:04 [pubmed] PHST- 2025/03/21 06:11 [entrez] AID - S2724-6507.24.04314-8 [pii] AID - 10.23736/S2724-6507.24.04314-8 [doi] PST - ppublish SO - Minerva Endocrinol (Torino). 2025 Jun;50(2):209-226. doi: 10.23736/S2724-6507.24.04314-8. Epub 2025 Mar 21. PMID- 40114122 OWN - NLM STAT- MEDLINE DCOM- 20250321 LR - 20250704 IS - 1472-6963 (Electronic) IS - 1472-6963 (Linking) VI - 25 IP - 1 DP - 2025 Mar 21 TI - Integrated specialty care for amyloidosis: a scoping review using the Consolidated Framework for Implementation Research. PG - 415 LID - 10.1186/s12913-025-12520-3 [doi] LID - 415 AB - BACKGROUND: Amyloidosis is a complex and rare disease requiring specialized, multidisciplinary care to effectively manage its diverse manifestations. Existing evidence underscores the benefits of such care, linked to improved patient outcomes and clinician satisfaction. With the rising incidence of amyloidosis diagnoses and rapid advancements in treatment, the need for coordinated, expert-led care is increasing. However, implementing these centers is challenging due to resource allocation and inter-specialty collaboration. While resource allocation is a known hurdle, there has not been a comprehensive review of all the barriers and facilitators to establishing these clinics. This scoping review aims to identify the barriers and facilitators related to the implementation of coordinated, multidisciplinary specialty care clinics in amyloidosis management. METHODS: An electronic search was conducted in Medline, Embase, and CINAHL for studies published in English from 2013 to 2023, supplemented by a grey literature search. The inclusion criteria focused on studies discussing multidisciplinary clinical environments for amyloidosis care, particularly light-chain (AL) and transthyretin amyloidosis (TTR). Exclusion criteria included books, opinion pieces, dissertations, and conference abstracts. Data were analyzed and synthesized using a narrative synthesis approach, guided by the Consolidated Framework for Implementation Research (CFIR), and reported according to PRISMA-ScR guidelines. RESULTS: The search resulted in 1547 findings. After screening with Covidence, 7 papers were included in the final review. Independent reviewers screened and extracted the papers. Key facilitators identified include access to experts, adequate staffing, secure funding, partnerships with patient advocacy groups, and robust processes for multidisciplinary communication. Barriers primarily relate to the complexity of care, a lack of standardized protocols, difficulties in communication and coordination between providers, and challenges in training and maintaining knowledgeable care providers. The review also revealed significant gaps in existing research. CONCLUSIONS: This review enhances understanding of the barriers and facilitators in establishing amyloidosis specialty clinics. Addressing these barriers and leveraging facilitators are crucial for shaping the future of amyloidosis care. These insights support a model for implementing integrated care for this growing patient population and highlight the need for further research to support policy development and effective implementation of these specialized clinics. CI - (c) 2025. The Author(s). FAU - O'Sullivan, Mary AU - O'Sullivan M AD - Lawrence Bloomberg Faculty of Nursing, University of Toronto, 155 College St, Toronto, ON, M5T 1P8, Canada. mary.osullivan@mail.utoronto.ca. FAU - Osman, Wahab AU - Osman W AD - Lawrence Bloomberg Faculty of Nursing, University of Toronto, 155 College St, Toronto, ON, M5T 1P8, Canada. AD - Department of Advanced Nursing Practice, School of Nursing and Midwifery, University for Development Studies, Tamale, Ghana. FAU - Krisnagopal, Archanaa AU - Krisnagopal A AD - Lawrence Bloomberg Faculty of Nursing, University of Toronto, 155 College St, Toronto, ON, M5T 1P8, Canada. FAU - Parry, Monica AU - Parry M AD - Lawrence Bloomberg Faculty of Nursing, University of Toronto, 155 College St, Toronto, ON, M5T 1P8, Canada. FAU - Davis, Margot AU - Davis M AD - UBC Cardiology, Advanced Heart Failure and Transplant Cardiology, St. Paul's Hospital, 1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada. AD - UBC Cardio-Oncology Program and Cardiac Amyloidosis Clinic, Vancouver, Canada. FAU - Chu, Charlene H AU - Chu CH AD - Lawrence Bloomberg Faculty of Nursing, University of Toronto, 155 College St, Toronto, ON, M5T 1P8, Canada. AD - University of Toronto, 155 College St, Toronto, ON, M5T 1P8, Canada. AD - Institute for Life Course and Aging, University of Toronto, 155 College St, Toronto, ON, M5T 1P8, Canada. LA - eng PT - Journal Article PT - Scoping Review DEP - 20250321 PL - England TA - BMC Health Serv Res JT - BMC health services research JID - 101088677 SB - IM MH - Humans MH - *Amyloidosis/therapy MH - *Delivery of Health Care, Integrated/organization & administration PMC - PMC11927205 OTO - NOTNLM OT - AL amyloidosis OT - Cardiac amyloidosis OT - Centre of excellence OT - Clinical pathway OT - Comprehensive care OT - Integrated care OT - Light chain amyloidosis OT - Multidisciplinary team approach OT - Transthyretin OT - Transthyretin amyloidosis COIS- Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2025/03/21 11:17 MHDA- 2025/03/21 11:18 PMCR- 2025/03/21 CRDT- 2025/03/21 00:41 PHST- 2024/06/17 00:00 [received] PHST- 2025/03/05 00:00 [accepted] PHST- 2025/03/21 11:18 [medline] PHST- 2025/03/21 11:17 [pubmed] PHST- 2025/03/21 00:41 [entrez] PHST- 2025/03/21 00:00 [pmc-release] AID - 10.1186/s12913-025-12520-3 [pii] AID - 12520 [pii] AID - 10.1186/s12913-025-12520-3 [doi] PST - epublish SO - BMC Health Serv Res. 2025 Mar 21;25(1):415. doi: 10.1186/s12913-025-12520-3. PMID- 40113346 OWN - NLM STAT- MEDLINE DCOM- 20250320 LR - 20260512 IS - 1557-3117 (Electronic) IS - 1053-2498 (Linking) VI - 44 IP - 4 DP - 2025 Apr TI - A consensus-based framework for the psychosocial evaluation of pediatric candidates for cardiothoracic transplant and ventricular assist devices. PG - 487-502 LID - S1053-2498(24)01973-9 [pii] LID - 10.1016/j.healun.2024.11.028 [doi] AB - The psychosocial evaluation plays an essential role in the multidisciplinary assessment of pediatric patients for thoracic organ transplantation or ventricular assist device (VAD) placement. However, there is considerable practice variation with regard to the content and process of the evaluation, with no known recent published guidelines. Furthermore, the pediatric evaluation necessarily differs from the adult evaluation in a number of substantive ways, including caregiver roles and decision-making. A writing committee of 25 multidisciplinary experts in pediatric cardiothoracic transplantation/VAD was established, who conducted a comprehensive literature review which resulted in the development of this consensus-based framework. This framework, which is a collaborative effort of the International Society for Heart and Lung Transplantation (ISHLT), the International Pediatric Transplant Association (IPTA), the Pediatric Heart Transplant Society (PHTS), the Advancing Cardiac Therapies Improving Outcomes Network (ACTION), and Transplant Families, represents the first known framework specific to both the content and process of the psychosocial evaluation for pediatric cardiothoracic transplantation/VAD. Attention was paid to relevant ethical, cultural and health equity considerations inherent in the pediatric evaluation process. Rather than provide a proscriptive evaluation process, the goal was to create a flexible framework to encourage consistency across centers, while also acknowledging the complexities inherent in evaluating children and their families for cardiothoracic transplant and VAD. CI - Copyright (c) 2025 International Society for the Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved. FAU - Lefkowitz, Debra S AU - Lefkowitz DS AD - Children's Hospital of Philadelphia, Philadelphia, PA; Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA. Electronic address: lefkowitz@chop.edu. FAU - Triplett, Kelli AU - Triplett K AD - Children's Medical Center; University of Texas Southwestern Medical Center, Dallas, TX. FAU - Schneider, Lauren AU - Schneider L AD - Stanford University School of Medicine, Palo Alto, CA. FAU - West, Kara AU - West K AD - Children's Hospital of Philadelphia, Philadelphia, PA. FAU - Anton, Corinne AU - Anton C AD - Children's Medical Center; University of Texas Southwestern Medical Center, Dallas, TX. FAU - Rea, Kelly E AU - Rea KE AD - C.S. Mott Children's Hospital, University of Michigan School of Medicine, Ann Arbor, MI. FAU - Brosbe, Micah AU - Brosbe M AD - Johns Hopkins Medicine, Baltimore, MD. FAU - Christofferson, Elizabeth S AU - Christofferson ES AD - Children's Hospital Colorado; University of Colorado School of Medicine, Denver, CO. FAU - Christon, Lillian AU - Christon L AD - Medical University of South Carolina, Charleston, SC. FAU - Kasparian, Nadine AU - Kasparian N AD - Cincinnati Children's Hospital, University of Cincinnati School of Medicine, Cincinnati, OH. FAU - Lamari-Fisher, Alexandra AU - Lamari-Fisher A AD - Dell Medical School, Austin, TX. FAU - McIntyre, Katie AU - McIntyre K AD - Pittsburgh Children's Hospital, University of Pittsburgh School of Medicine, Pittsburgh, PA. FAU - Plevinsky, Jill AU - Plevinsky J AD - Children's Hospital of Philadelphia, Philadelphia, PA; Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA. FAU - Auerbach, Scott AU - Auerbach S AD - Children's Hospital Colorado; University of Colorado School of Medicine, Denver, CO. FAU - Bansal, Neha AU - Bansal N AD - Icahn School of Medicine at Mount Sinai, New York, NY. FAU - Benden, Christian AU - Benden C AD - Boston Children's Hospital/Harvard Medical School, Boston, MA. FAU - Dugan, Molly AU - Dugan M AD - Children's Hospital of Atlanta, Atlanta, GA. FAU - Edelson, Jonathan AU - Edelson J AD - Children's Hospital of Philadelphia, Philadelphia, PA; Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA. FAU - Gross-Toalson, Jami AU - Gross-Toalson J AD - University of Missouri-Kansas City School of Medicine, Kansas City, MO. FAU - Mayersohn, Gillian AU - Mayersohn G AD - SSM Health Cardinal Glennon Children's Hospital, St. Louis, MO. FAU - Prufe, Jenny AU - Prufe J AD - Hannover Medical School, Hannover, Niedersachsen, Germany. FAU - White, Rachel M AU - White RM AD - Children's Hospital of Philadelphia, Philadelphia, PA. FAU - Wichart, Jenny AU - Wichart J AD - Alberta Health Services, Alberta, CA. FAU - Wray, Jo AU - Wray J AD - Great Ormond Street Hospital for Children, London, UK. FAU - Cousino, Melissa K AU - Cousino MK AD - C.S. Mott Children's Hospital, University of Michigan School of Medicine, Ann Arbor, MI. LA - eng PT - Journal Article PT - Practice Guideline PT - Review PL - United States TA - J Heart Lung Transplant JT - The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation JID - 9102703 SB - IM MH - Child MH - Humans MH - Consensus MH - *Heart Failure/psychology/surgery MH - *Heart Transplantation/psychology MH - *Heart-Assist Devices/psychology OTO - NOTNLM OT - Heart transplant OT - Lung transplant OT - Pediatric OT - Psychosocial evaluation OT - VAD EDAT- 2025/03/21 00:22 MHDA- 2025/03/21 00:23 CRDT- 2025/03/20 21:55 PHST- 2024/11/09 00:00 [received] PHST- 2024/11/17 00:00 [accepted] PHST- 2025/03/21 00:23 [medline] PHST- 2025/03/21 00:22 [pubmed] PHST- 2025/03/20 21:55 [entrez] AID - S1053-2498(24)01973-9 [pii] AID - 10.1016/j.healun.2024.11.028 [doi] PST - ppublish SO - J Heart Lung Transplant. 2025 Apr;44(4):487-502. doi: 10.1016/j.healun.2024.11.028. PMID- 40112791 OWN - NLM STAT- MEDLINE DCOM- 20250425 LR - 20260720 IS - 1664-5502 (Electronic) IS - 1664-5502 (Linking) VI - 15 IP - 1 DP - 2025 TI - Risk of Hospital Admissions and Death in Patients with Heart Failure and Chronic Kidney Disease: Findings from a Novel Multidisciplinary Clinic. PG - 249-260 LID - 10.1159/000541806 [doi] AB - INTRODUCTION: Patients with heart failure (HF) and chronic kidney disease (CKD) are often suboptimally treated due to concerns of hyperkalaemia, declining kidney function, and hypotension. They commonly suffer from fluid overload which can lead to frequent hospitalisations and death. This research aims to determine the characteristics associated with hospital admissions and death in patients with CKD and HF. METHODS: Consecutive patients with CKD stage 3-5 and HF (regardless of ejection fraction) attending a large, specialised CKD-HF clinic between 12/Sept/2019 and 11/Nov/2021 were identified and data were collected on demographic factors, renal and heart function, medications, hospitalisations, and death. Multinomial and Cox regressions determined the characteristics of patients requiring hospitalisation and their risk of death, respectively. RESULTS: A total of 667 admissions were attributable to 318 patients, 201 admissions were for HF. Men were less likely than women to have been admitted to hospital for HF (risk ratio [RR] 0.43, 95% CI 0.20, 0.94) and non-HF causes (RR 0.21, 95% CI 0.10, 0.47). A serum haemoglobin level greater than 100 g/L was associated with fewer HF and non-HF admissions compared to a serum haemoglobin less than 100 g/L (RR 0.26, 95% CI 0.09, 0.74; RR 0.17, 95% CI 0.06, 0.47). Compared to CKD stage 3, CKD stage 4 was associated with an increased risk of HF and non-HF admissions (RR 4.01, 95% CI 1.04, 15.5; RR 4.33, 95% CI 1.13, 16.5). Having a HF admission (HR 2.41, 95% CI 1.27, 4.60), HFrEF (HR 2.18, 95% CI 1.30, 3.63), CKD stage 4 (HR 1.91, 95% CI 1.16, 3.16), and loop diuretic use (HR 2.24, 95% CI 1.14, 4.40) were associated with a significantly increased risk of death compared to people with no admissions, with HF with reduced preserved ejection fraction, CKD stage 3, and no diuretic use, respectively. The use of RAAS inhibitors halved the risk of death compared to non-prescribed patients (HR 0.44, 95% CI 0.27, 0.72). CONCLUSION: Hospital admissions among CKD-HF patients were common, particularly in those with lower serum haemoglobin levels and advanced CKD stage. The risk of death was higher in those with HF admissions, the presence of HFrEF, advanced CKD stage, loop diuretic use, and those not prescribed RAAS inhibitors. CI - (c) 2025 The Author(s). Published by S. Karger AG, Basel. FAU - Parmar, Simran AU - Parmar S AD - Renal and Transplantation Unit, St Georges University Hospitals NHS Foundation Trust, London, UK. AD - Institute of Medical and Biomedical Allied Health Education, St Georges University of London, London, UK. FAU - Lopez, Tony AU - Lopez T AD - Renal and Transplantation Unit, St Georges University Hospitals NHS Foundation Trust, London, UK. AD - Institute of Medical and Biomedical Allied Health Education, St Georges University of London, London, UK. FAU - Shah, Ronak AU - Shah R AD - Renal and Transplantation Unit, St Georges University Hospitals NHS Foundation Trust, London, UK. FAU - Murphy, Daniel AU - Murphy D AD - Department of Acute Medicine, Royal Free Hospital, London, UK. FAU - Warrens, Hilary AU - Warrens H AD - Renal and Transplantation Unit, St Georges University Hospitals NHS Foundation Trust, London, UK. AD - Institute of Medical and Biomedical Allied Health Education, St Georges University of London, London, UK. FAU - Khairallah, Marwa AU - Khairallah M AD - Nephrology Division, Internal Medicine Department, Faculty of Medicine, Assiut University Hospital, Assiut, Egypt. FAU - Anderson, Lisa AU - Anderson L AD - Institute of Medical and Biomedical Allied Health Education, St Georges University of London, London, UK. FAU - Rosano, Giuseppe AU - Rosano G AD - Institute of Medical and Biomedical Allied Health Education, St Georges University of London, London, UK. FAU - Chis Ster, Irina AU - Chis Ster I AD - Infection and Immunity Institute, St George's School of Health and Medical Sciences, City St Georges University of London, London, UK. FAU - Banerjee, Debasish AU - Banerjee D AD - Renal and Transplantation Unit, St Georges University Hospitals NHS Foundation Trust, London, UK. AD - Institute of Medical and Biomedical Allied Health Education, St Georges University of London, London, UK. LA - eng PT - Journal Article DEP - 20250320 PL - Switzerland TA - Cardiorenal Med JT - Cardiorenal medicine JID - 101554863 SB - IM MH - Humans MH - *Heart Failure/mortality/complications/physiopathology/therapy MH - Male MH - Female MH - *Renal Insufficiency, Chronic/mortality/complications/physiopathology/therapy MH - Aged MH - *Hospitalization/statistics & numerical data MH - Middle Aged MH - Risk Factors MH - Stroke Volume/physiology MH - Aged, 80 and over MH - Retrospective Studies MH - Risk Assessment OTO - NOTNLM OT - Chronic kidney disease OT - Heart failure OT - Hospitalisations OT - Risk of death EDAT- 2025/03/21 00:22 MHDA- 2025/04/25 06:28 CRDT- 2025/03/20 19:25 PHST- 2024/06/13 00:00 [received] PHST- 2024/09/30 00:00 [accepted] PHST- 2025/04/25 06:28 [medline] PHST- 2025/03/21 00:22 [pubmed] PHST- 2025/03/20 19:25 [entrez] AID - 000541806 [pii] AID - 10.1159/000541806 [doi] PST - ppublish SO - Cardiorenal Med. 2025;15(1):249-260. doi: 10.1159/000541806. Epub 2025 Mar 20. PMID- 40109295 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250321 IS - 2297-055X (Print) IS - 2297-055X (Electronic) IS - 2297-055X (Linking) VI - 12 DP - 2025 TI - Framing anticoagulation control according to clinical practice for patients with atrial fibrillation in Spain: a multidisciplinary vision trough AMFA Project. PG - 1426072 LID - 10.3389/fcvm.2025.1426072 [doi] LID - 1426072 AB - INTRODUCTION AND OBJECTIVES: The use of vitamin K antagonists (VKA) in patients with atrial fibrillation (AF) in Spain remains high, even though the available data on anticoagulation control (TRT, time in therapeutic range) shows suboptimal results. The objective of the AMFA project, an atlas of the management of anticoagulation in patients with AF, was to describe oral anticoagulation management in Spanish patients. MATERIALS AND METHODS: The AMFA Project is a descriptive, multicenter study. It included information from 60 healthcare areas from each of the 17 Spanish regions. Consensus methodologies were used to analyze qualitative information obtained from the physicians' experience and perception and quantitative data collected through a specialized study questionnaire. In this questionnaire, experts were asked to include data of the last 10 consecutive patients attended with AF on anticoagulation treatment. RESULTS: Records from 1,580 patients were obtained from 176 experts. Of them, 34.7% were cardiologists, 32.9% general practitioners (GPs), and 32.4% hematologists. The utilization rates of Direct Oral Anticoagulants (DOACs) and VKAs in clinical practice was 55.8% and 43.3%, respectively, which was not correlated with experts' perception. Clinical practice data revealed that 30.3% of the patients included did not have international normalized ratio (INR) or TTR data available, while only 3.8% of the experts reported that INR/TTR information was not available according to their perception. Considering only patients who had INR and TTR available, clinical practice showed that 59.0% of the patients had their coagulation in range, while the remaining 41.0% were uncontrolled. This result matches with the general perception reported by the experts, 62.6% of patients in range. Additionally, up to 22.2% of patients received DOAC treatment at suboptimal doses. CONCLUSIONS: These data highlight the suboptimal control of the INR of patients, as well as the difficulties in DOACs access in Spain. The study uncovers the need to implement actions to improve INR control, facilitate access to DOACs treatment, and standardize AF patients' management. Establishing protocols that facilitate intervention may optimize the management of the patients with AF. CI - (c) 2025 Cosin-Sales, Polo-Garcia, Gavin Sebastian, Rubio Cabezas and Lloret Avella. FAU - Cosin-Sales, Juan AU - Cosin-Sales J AD - Department of Cardiology, Hospital Arnau de Vilanova, Valencia, Spain. FAU - Polo-Garcia, Jose AU - Polo-Garcia J AD - Primary Care, Centro de Salud de Casar de Caceres, Caceres, Spain. FAU - Gavin Sebastian, Olga AU - Gavin Sebastian O AD - Department of Hemathology, Hospital Clinico Universitario Lozano Blesa, Zaragoza, Spain. FAU - Rubio Cabezas, Marta AU - Rubio Cabezas M AD - Real World Evidence (RWE), IQVIA S.A, Madrid, Spain. FAU - Lloret Avella, Maria AU - Lloret Avella M AD - Real World Evidence (RWE), IQVIA S.A, Madrid, Spain. LA - eng PT - Journal Article DEP - 20250305 PL - Switzerland TA - Front Cardiovasc Med JT - Frontiers in cardiovascular medicine JID - 101653388 PMC - PMC11919873 OTO - NOTNLM OT - anticoagulation OT - atrial fibrillation OT - direct oral anticoagulants (DOAC) OT - international normalized ratio (INR) OT - time in therapeutic range (TTR) OT - vitamin k antagonists (VKA) COIS- JC-S has received lecturing and consulting honoraria from Bayer, Boehringer Ingelheim, Daiichi Sankyo, Bristol Myers Squibb and Pfizer. OG has received lecturing and consulting honoraria from Bayer, Boehringer Ingelheim, Daiichi Sankyo, Bristol Myers Squibb, Pfizer, Rovi, Sanofi and LEO. JP-G has received lecturing and consulting honoraria from Bayer, Boehringer Ingelheim, Daiichi Sankyo, Bristol Myers Squibb, ROVI. Marta Rubio and Maria Lloret were employed by IQVIA S.A. EDAT- 2025/03/20 11:14 MHDA- 2025/03/20 11:15 PMCR- 2025/01/01 CRDT- 2025/03/20 05:04 PHST- 2024/04/30 00:00 [received] PHST- 2025/02/14 00:00 [accepted] PHST- 2025/03/20 11:15 [medline] PHST- 2025/03/20 11:14 [pubmed] PHST- 2025/03/20 05:04 [entrez] PHST- 2025/01/01 00:00 [pmc-release] AID - 10.3389/fcvm.2025.1426072 [doi] PST - epublish SO - Front Cardiovasc Med. 2025 Mar 5;12:1426072. doi: 10.3389/fcvm.2025.1426072. eCollection 2025. PMID- 40100445 OWN - NLM STAT- MEDLINE DCOM- 20250513 LR - 20250513 IS - 1432-1076 (Electronic) IS - 0340-6199 (Print) IS - 0340-6199 (Linking) VI - 184 IP - 4 DP - 2025 Mar 18 TI - When should a neonatologist consult a rheumatologist? PG - 256 LID - 10.1007/s00431-025-06086-9 [doi] LID - 256 AB - Pediatric rheumatologic diseases are complex conditions that can present with various clinical manifestations, including fever, rash, joint involvement, and diarrhea, impacting more than one organ system and affecting all pediatric age groups from 0 to 18 years. This review focuses on rheumatologic diseases in neonates, encompassing both primary neonatal-onset conditions and those influenced by maternal autoimmune diseases and treatments during pregnancy. Diagnosing rheumatologic diseases in neonates is challenging due to their nonspecific symptoms, which can overlap with other conditions. While primary neonatal-onset diseases such as cryopyrin-associated periodic syndromes (CAPS), deficiency of IL-1 receptor antagonist (DIRA), and neonatal-onset juvenile idiopathic arthritis (JIA) are rare, maternal autoimmune diseases and their treatments can also impact neonatal health. Conditions like systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) may increase neonatal risks, leading to complications such as thrombosis or pregnancy loss. Identifying these conditions early and providing the proper care is crucial to reduce morbidity and mortality in this vulnerable group. CONCLUSION: Persistent fever, rash, or unexplained joint involvement warrants early referral to a pediatric rheumatologist. A multidisciplinary approach involving obstetricians, rheumatologists, and neonatologists is essential for timely diagnosis and optimal neonatal outcomes. WHAT IS KNOWN: * Diagnosis of neonatal rheumatologic diseases is difficult because their symptoms are nonspecific and may overlap with other neonatal diseases. * Maternal autoantibodies transmitted through the placenta may lead to neonatal complications (e.g. congenital heart block, thrombosis). WHAT IS NEW: * Long-term follow-up of autoinflammatory diseases is essential, as the absence of neonatal-specific damage indices limits the ability to assess disease progression and treatment outcomes, underscoring the need for validated scoring systems tailored to neonates. * Novel biomarkers, such as elevated levels of cord C-reactive protein, NT-proBNP, MMP-2, uPA, uPAR, and plasminogen, have been identified, offering new insights into potential diagnostic tools for cardiac neonatal lupus. CI - (c) 2025. The Author(s). FAU - Oksel, Ali AU - Oksel A AD - Medicalpark Hospital, Pediatrics, Kocaeli, Turkey. oksel.ali@gmail.com. FAU - Sahin, Nihal AU - Sahin N AD - Department of Pediatric Rheumatology, Kocaeli University, Kocaeli, Turkey. FAU - Gunlemez, Ayla AU - Gunlemez A AD - Department of Neoanatology, Kocaeli University, Kocaeli, Turkey. LA - eng PT - Journal Article PT - Review DEP - 20250318 PL - Germany TA - Eur J Pediatr JT - European journal of pediatrics JID - 7603873 SB - IM MH - Humans MH - Infant, Newborn MH - *Referral and Consultation MH - *Rheumatic Diseases/diagnosis/therapy MH - Pregnancy MH - Female MH - Pregnancy Complications/diagnosis MH - Rheumatologists MH - *Infant, Newborn, Diseases/diagnosis/therapy PMC - PMC11920313 OTO - NOTNLM OT - Autoinflammatory diseases OT - Maternal OT - Medication on pregnancy OT - Neonates OT - Rheumatic diseases COIS- Declarations. Competing interests: The authors declare no competing interests. EDAT- 2025/03/18 18:22 MHDA- 2025/03/18 18:23 PMCR- 2025/03/18 CRDT- 2025/03/18 12:16 PHST- 2024/09/12 00:00 [received] PHST- 2025/03/06 00:00 [accepted] PHST- 2025/02/28 00:00 [revised] PHST- 2025/03/18 18:23 [medline] PHST- 2025/03/18 18:22 [pubmed] PHST- 2025/03/18 12:16 [entrez] PHST- 2025/03/18 00:00 [pmc-release] AID - 10.1007/s00431-025-06086-9 [pii] AID - 6086 [pii] AID - 10.1007/s00431-025-06086-9 [doi] PST - epublish SO - Eur J Pediatr. 2025 Mar 18;184(4):256. doi: 10.1007/s00431-025-06086-9. PMID- 40096906 OWN - NLM STAT- MEDLINE DCOM- 20260115 LR - 20260413 IS - 1532-8414 (Electronic) IS - 1071-9164 (Linking) VI - 32 IP - 1 DP - 2026 Jan TI - Impact of Embedded Interdisciplinary Heart Failure Teams on Achieving Guideline-Directed Medical Therapy Within Community-Based Cardiology Practices. PG - 17-26 LID - S1071-9164(25)00109-5 [pii] LID - 10.1016/j.cardfail.2025.01.029 [doi] AB - BACKGROUND: Guideline-directed medical therapy (GDMT) for patients with heart failure with reduced ejection fraction (HFrEF) is under-prescribed. Real-world data regarding contemporary GDMT prescribing and the impact of scalable interdisciplinary heart failure (HF) teams are needed. METHODS AND RESULTS: We retrospectively identified 2121 patients with HFrEF seen in 2022 in 4 community-based cardiology-practice sites that contained an embedded interdisciplinary HF team. After excluding 203 patients with missing data or encounters, GDMT prescribing was compared among those with (n = 1029) and without (n = 889) the support of the interdisciplinary HF teams. Patients were 33% female, 34% Black/African American, with an average age of 69 years. Patients seen by interdisciplinary HF teams achieved more comprehensive GDMT regimens compared to patients receiving routine care alone, as shown by higher 4-Pillar Intensification Scores (6.5 vs 4.7; P < 0.001). Using multivariable logistic regression models, patients whose care included an interdisciplinary HF team had higher odds (OR; 95% CI) of receiving sodium-glucose cotransporter-2 inhibitors (SGLT2is) (3.08; 2.37-3.99), angiotensin receptor/neprilysin inhibitors [ARNis] (1.84; 1.45-2.35) and mineralocorticoid receptor antagonists (MRAs) (1.41; 1.11-1.8) than patients receiving routine care alone. CONCLUSIONS: Access to embedded interdisciplinary HF teams within community cardiology practices was associated with improved GDMT prescribing, supporting broader adoption of interdisciplinary care models for optimizing GDMT. CI - Copyright (c) 2025 Elsevier Inc. All rights reserved. FAU - Bregier, Jessica AU - Bregier J AD - Novant Health Heart & Vascular Institute, Charlotte, NC. Electronic address: jbregier@novanthealth.org. FAU - Krupski, Rebekah AU - Krupski R AD - Novant Health Heart & Vascular Institute, Charlotte, NC. FAU - Gale, Stormi AU - Gale S AD - Novant Health Heart & Vascular Institute (at the time of the research), Charlotte, NC. FAU - Sparling, Alica AU - Sparling A AD - Novant Health (at the time of the research), Charlotte, NC. FAU - Pisano, Mary Ellen AU - Pisano ME AD - Novant Health Heart & Vascular Institute, Charlotte, NC. FAU - Choy-Ames, Maryann AU - Choy-Ames M AD - Novant Health Heart & Vascular Institute, Charlotte, NC. FAU - Cheuvront, Jessica AU - Cheuvront J AD - Novant Health Heart & Vascular Institute (at the time of the research), Charlotte, NC. FAU - Spence, Rowan AU - Spence R AD - Novant Health Ambulatory Pharmacy, Charlotte, NC. FAU - Reeves, Gordon R AU - Reeves GR AD - Novant Health Heart & Vascular Institute (at the time of the research), Charlotte, NC; Wake Forest University School of Medicine, Winston-Salem, NC. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20250315 PL - United States TA - J Card Fail JT - Journal of cardiac failure JID - 9442138 SB - IM MH - Humans MH - Female MH - *Heart Failure/drug therapy/physiopathology/therapy MH - Male MH - Aged MH - Retrospective Studies MH - *Patient Care Team/standards MH - Middle Aged MH - *Practice Guidelines as Topic/standards MH - *Cardiology/methods/standards MH - *Guideline Adherence MH - Stroke Volume/physiology OTO - NOTNLM OT - Heart failure with reduced ejection fraction OT - guideline-directed medical therapy OT - interdisciplinary care COIS- Disclosures None. EDAT- 2025/03/18 00:26 MHDA- 2026/01/16 19:24 CRDT- 2025/03/17 20:33 PHST- 2024/05/27 00:00 [received] PHST- 2025/01/21 00:00 [revised] PHST- 2025/01/23 00:00 [accepted] PHST- 2026/01/16 19:24 [medline] PHST- 2025/03/18 00:26 [pubmed] PHST- 2025/03/17 20:33 [entrez] AID - S1071-9164(25)00109-5 [pii] AID - 10.1016/j.cardfail.2025.01.029 [doi] PST - ppublish SO - J Card Fail. 2026 Jan;32(1):17-26. doi: 10.1016/j.cardfail.2025.01.029. Epub 2025 Mar 15. PMID- 40095104 OWN - NLM STAT- MEDLINE DCOM- 20250513 LR - 20250515 IS - 1559-131X (Electronic) IS - 1357-0560 (Print) IS - 1357-0560 (Linking) VI - 42 IP - 4 DP - 2025 Mar 17 TI - Diagnosis and treatment of cardiac tumors. PG - 110 LID - 10.1007/s12032-025-02661-0 [doi] LID - 110 AB - Cardiac tumors, though rare, present significant diagnostic and therapeutic challenges due to their diverse nature and potential severity. These tumors, which can be primary or metastatic, are often detected incidentally through imaging modalities such as echocardiography or CT scans. Differentiating between benign and malignant forms is crucial for guiding appropriate management strategies. This review synthesizes current diagnostic approaches and treatment modalities for cardiac tumors, with a focus on the role of imaging techniques like UCG, CT, MRI, and PET in tumor characterization. Multidisciplinary treatment plans are necessary, including surgical resection for benign tumors, chemotherapy, and radiotherapy for malignant tumors, and novel targeted therapies such as MDM2 inhibitors for selected cases. While primary malignant tumors like sarcomas and mesotheliomas exhibit rapid progression and poor prognosis, recent advances in multimodal therapy offer potential improvements in survival. The incidence of primary cardiac tumors is low, with an autopsy-reported occurrence rate of 0.02%. Benign cardiac tumors, such as myxomas and fibromas, generally have favorable outcomes with surgical resection. In contrast, primary malignant tumors like sarcomas and mesotheliomas exhibit rapid progression and poor prognosis, necessitating aggressive treatment including surgery, chemotherapy, and radiotherapy. Metastatic cardiac tumors occur in approximately 10% of cancer patients at autopsy and are managed according to the treatment plan for the primary malignancy. The management of cardiac tumors requires a multidisciplinary approach tailored to tumor type, location, and systemic effects. While benign tumors often respond well to surgical management, malignant and metastatic tumors demand more complex strategies to optimize patient outcomes. CI - (c) 2025. The Author(s). FAU - Imai, Toru AU - Imai T AD - Department of Medical Oncology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo, 104-0045, Japan. FAU - Shimoi, Tatsunori AU - Shimoi T AD - Department of Medical Oncology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo, 104-0045, Japan. tshimoi@ncc.go.jp. FAU - Kawai, Akira AU - Kawai A AD - Department of Musculoskeletal Oncology and Rehabilitation, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo, 104-0045, Japan. FAU - Yonemori, Kan AU - Yonemori K AD - Department of Medical Oncology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo, 104-0045, Japan. LA - eng PT - Journal Article PT - Review DEP - 20250317 PL - United States TA - Med Oncol JT - Medical oncology (Northwood, London, England) JID - 9435512 SB - IM MH - Humans MH - *Heart Neoplasms/therapy/diagnosis PMC - PMC11914324 OTO - NOTNLM OT - Benign tumors OT - Malignant soft tissue sarcoma OT - Metastatic cardiac tumors OT - Primary cardiac tumors COIS- Declarations. Conflicts of interest: No potential conflict of interest relevant to this review was reported. Ethical approval: Not applicable. Consent for publication: Not applicable. EDAT- 2025/03/17 18:31 MHDA- 2025/03/17 18:32 PMCR- 2025/03/17 CRDT- 2025/03/17 12:19 PHST- 2024/11/14 00:00 [received] PHST- 2025/03/04 00:00 [accepted] PHST- 2025/03/17 18:32 [medline] PHST- 2025/03/17 18:31 [pubmed] PHST- 2025/03/17 12:19 [entrez] PHST- 2025/03/17 00:00 [pmc-release] AID - 10.1007/s12032-025-02661-0 [pii] AID - 2661 [pii] AID - 10.1007/s12032-025-02661-0 [doi] PST - epublish SO - Med Oncol. 2025 Mar 17;42(4):110. doi: 10.1007/s12032-025-02661-0. PMID- 40094211 OWN - NLM STAT- MEDLINE DCOM- 20250416 LR - 20260918 IS - 2047-9980 (Electronic) IS - 2047-9980 (Linking) VI - 14 IP - 8 DP - 2025 Apr 15 TI - Blood Culture-Negative Endocarditis: A Scientific Statement From the American Heart Association: Endorsed by the International Society for Cardiovascular Infectious Diseases. PG - e040218 LID - 10.1161/JAHA.124.040218 [doi] LID - e040218 AB - Blood culture-negative endocarditis has been associated with worse outcomes when compared with blood culture-positive endocarditis, because pathogen-directed antimicrobial therapy and other management aspects have been difficult to achieve. Novel diagnostic tools, however, have changed the landscape of this syndrome and will likely improve patient outcomes. This American Heart Association scientific statement highlights these advances. The writing group, which represents a multidisciplinary team, provides an update on blood culture-negative endocarditis. Clinical scenarios representative of real-world experiences are included to assist frontline clinicians in the diagnosis and management of this syndrome. FAU - DeSimone, Daniel C AU - DeSimone DC FAU - Garrigos, Zerelda Esquer AU - Garrigos ZE FAU - Marx, Grace E AU - Marx GE FAU - Tattevin, Pierre AU - Tattevin P FAU - Hasse, Barbara AU - Hasse B FAU - McCormick, David W AU - McCormick DW FAU - Hannan, Margaret M AU - Hannan MM FAU - Zuhlke, Liesl J AU - Zuhlke LJ FAU - Radke, Connie S AU - Radke CS FAU - Baddour, Larry M AU - Baddour LM CN - American Heart Association Council on Lifelong Congenital Heart Disease and Heart Health in the Young; Council on Clinical Cardiology; and Council on Quality of Care and Outcomes Research LA - eng PT - Journal Article PT - Practice Guideline PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20250317 PL - England TA - J Am Heart Assoc JT - Journal of the American Heart Association JID - 101580524 RN - 0 (Anti-Bacterial Agents) SB - IM EIN - J Am Heart Assoc. 2025 May 6;14(9):e10928. doi: 10.1161/JAHA.124.035178. PMID: 40265600 MH - Humans MH - *Blood Culture/standards MH - American Heart Association MH - United States MH - *Endocarditis, Bacterial/diagnosis/microbiology/blood/drug therapy MH - *Endocarditis/diagnosis/microbiology MH - Anti-Bacterial Agents/therapeutic use PMC - PMC12132861 OTO - NOTNLM OT - AHA Scientific Statements OT - blood culture-negative infective endocarditis OT - diagnosis OT - management OT - prevention EDAT- 2025/03/17 15:20 MHDA- 2025/04/16 06:19 PMCR- 2025/03/17 CRDT- 2025/03/17 07:03 PHST- 2025/04/16 06:19 [medline] PHST- 2025/03/17 15:20 [pubmed] PHST- 2025/03/17 07:03 [entrez] PHST- 2025/03/17 00:00 [pmc-release] AID - JAH310450 [pii] AID - 10.1161/JAHA.124.040218 [doi] PST - ppublish SO - J Am Heart Assoc. 2025 Apr 15;14(8):e040218. doi: 10.1161/JAHA.124.040218. Epub 2025 Mar 17. PMID- 40091554 OWN - NLM STAT- MEDLINE DCOM- 20250525 LR - 20260304 IS - 1879-0844 (Electronic) IS - 1388-9842 (Print) IS - 1388-9842 (Linking) VI - 27 IP - 5 DP - 2025 May TI - How to handle polypharmacy in heart failure. A clinical consensus statement of the Heart Failure Association of the ESC. PG - 747-759 LID - 10.1002/ejhf.3642 [doi] AB - The multiplicity of coexisting comorbidities affecting patients with heart failure (HF), together with the availability of multiple treatments improving prognosis in HF with reduced ejection fraction, has led to an increase in the number of prescribed medications to each patient. Polypharmacy is defined as the regular use of multiple medications, and over the last years has become an emerging aspect of HF care, particularly in older and frailer patients who are more frequently on multiple treatments, and are therefore more likely exposed to tolerability issues, drug-drug interactions and practical difficulties in management. Polypharmacy negatively affects adherence to treatment, and is associated with a higher risk of adverse drug reactions, impaired quality of life, more hospitalizations and worse prognosis. It is important to adopt and implement strategies for the management of polypharmacy from other medical disciplines, including medication reconciliation, therapeutic revision and treatment prioritization. It is also essential to develop new HF-specific strategies, with the primary goal of avoiding the use of redundant treatments, minimizing adverse drug reactions and interactions, and finally improving adherence. This clinical consensus statement document from the Heart Failure Association of the European Society of Cardiology proposes a rationale, pragmatic and multidisciplinary approach to drug prescription in the current era of multimorbidity and 'multi-medication' in HF. CI - (c) 2025 The Author(s). European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. FAU - Stolfo, Davide AU - Stolfo D AD - Department of Clinical Science and Education, Sodersjukhuset; Karolinska Institutet, Stockholm, Sweden. AD - Division of Cardiology, Cardiothoracic Department, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy. FAU - Iacoviello, Massimo AU - Iacoviello M AD - Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy. FAU - Chioncel, Ovidiu AU - Chioncel O AD - University of Medicine Carol Davila, Bucharest, Romania. AD - Emergency Institute for Cardiovascular Diseases 'Prof. C.C. Iliescu', Bucharest, Romania. FAU - Anker, Markus S AU - Anker MS AD - German Heart Center Charite CBF and German Centre for Cardiovascular Research DZHK, Berlin, Germany. AD - Berlin Institute of Health Center for Regenerative Therapies BCRT, Charite Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin and Humboldt Universitat zu Berlin, Berlin, Germany. FAU - Bayes-Genis, Antoni AU - Bayes-Genis A AD - Heart Institute, Hospital Universitari Germans Trias i Poujol, Badalona, Spain. FAU - Braunschweig, Frieder AU - Braunschweig F AD - Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden. FAU - Cannata, Antonio AU - Cannata A AD - British Heart Foundation Centre of Research Excellence, School of Cardiovascular Medicine, Faculty of Life Science, King's College London, London, UK. AD - Cardiovascular Department, King's College Hospital NHS Foundation Trust, London, UK. FAU - El Hadidi, Seif AU - El Hadidi S AD - University of Hertfordshire in Egypt, Cairo, Egypt. FAU - Filippatos, Gerasimos AU - Filippatos G AD - National & Kapodistrian University of Athens School of Medicine, Athens University Hospital Attikon, Athens, Greece. FAU - Jhund, Pardeep AU - Jhund P AD - School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK. FAU - Mebazaa, Alexandre AU - Mebazaa A AD - Universite de Paris, INSERM, U942 MASCOT, Paris, France. AD - Department of Anesthesia and Critical Care Medicine, AP-HP, Hopital Lariboisiere, Paris, France. FAU - Moura, Brenda AU - Moura B AD - Armed Forces Hospital, Faculty of Medicine of University of Porto, Porto, Portugal. FAU - Piepoli, Massimo AU - Piepoli M AD - Clinical Cardiology, IRCCS Policlinico San Donato, Milan, Italy. AD - Department of Biomedical Sciences for Health, University of Milan, Milan, Italy. FAU - Ray, Robin AU - Ray R AD - Cardiovascular Clinical Academic Group and Cardiology Research Centre, St. George's, University of London, St. George's University Hospitals NHS Foundation Trust, London, UK. FAU - Ristic, Arsen D AU - Ristic AD AD - Medical Faculty, University of Belgrade, Belgrade, Serbia. AD - Clinic for Cardiology, University Clinical Centre of Serbia, Belgrade, Serbia. FAU - Seferovic, Petar AU - Seferovic P AD - Serbian Academy of Sciences and Arts, Heart Failure Center, Faculty of Medicine, Belgrade University Medical Center, Belgrade, Serbia. FAU - Simpson, Maggie AU - Simpson M AD - Department of Cardiology, Queen Elizabeth University Hospital, NHS Greater Glasgow & Clyde, Glasgow, UK. FAU - Skouri, Hadi AU - Skouri H AD - Department of Cardiology, Balamand university school of Medicine, Beirut, Lebanon. FAU - Tocchetti, Carlo Gabriele AU - Tocchetti CG AD - Department of Translational Medical Sciences (DISMET), Center for Basic and Clinical Immunology Research (CISI), Interdepartmental Center of Clinical and Translational Sciences (CIRCET), Interdepartmental Hypertension Research Center (CIRIAPA), Federico II University, Naples, Italy. FAU - Van Linthout, Sophie AU - Van Linthout S AD - Berlin Institute of Health (BIH) at Charite-Universitatsmedizin Berlin, BIH Center for Regenerative Therapies (BCRT), Berlin, Germany. AD - German Center for Cardiovascular Research (DZHK), partner site Berlin, Berlin, Germany. FAU - Vitale, Cristiana AU - Vitale C AD - Cardiovascular Clinical Academic Group and Cardiology Research Centre, St. George's, University of London, St. George's University Hospitals NHS Foundation Trust, London, UK. FAU - Volterrani, Maurizio AU - Volterrani M AD - Department of Human Science and Promotion of Quality of Life, San Raffaele Open University, Rome, Italy. AD - Cardio-Pulmonary Department, IRCCS San Raffaele, Rome, Italy. FAU - Keramida, Kalliopi AU - Keramida K AD - General Anti-Cancer Oncological Hospital 'Agios Savvas', Athens, Greece. FAU - Wassmann, Sven AU - Wassmann S AD - Cardiology Pasing, Munich, and Faculty of Medicine, University of the Saarland, Homburg, Germany. FAU - Lewis, Basil S AU - Lewis BS AD - Lady Davis Carmel Medical Center, Technion-Israel Institute of Technology, Haifa, Israel. FAU - Metra, Marco AU - Metra M AD - ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy. FAU - Rosano, Giuseppe M C AU - Rosano GMC AD - Department of Human Sciences and Promotion of Quality of Life, Chair of Pharmacology, San Raffaele University of Rome, Rome, Italy. AD - Cardiology, San Raffaele Cassino Hospital, Cassino, Italy. FAU - Savarese, Gianluigi AU - Savarese G AUID- ORCID: 0000-0001-7732-0887 AD - Department of Clinical Science and Education, Sodersjukhuset; Karolinska Institutet, Stockholm, Sweden. LA - eng PT - Consensus Statement PT - Journal Article PT - Review DEP - 20250317 PL - England TA - Eur J Heart Fail JT - European journal of heart failure JID - 100887595 SB - IM MH - Humans MH - *Heart Failure/drug therapy/epidemiology MH - *Polypharmacy MH - *Societies, Medical MH - Medication Adherence MH - Quality of Life MH - Drug Interactions PMC - PMC12103960 OTO - NOTNLM OT - Adherence OT - Comorbidities OT - Heart failure OT - Polypharmacy EDAT- 2025/03/17 15:19 MHDA- 2025/05/26 00:29 PMCR- 2025/05/26 CRDT- 2025/03/17 03:43 PHST- 2024/12/23 00:00 [revised] PHST- 2024/07/03 00:00 [received] PHST- 2025/02/18 00:00 [accepted] PHST- 2025/05/26 00:29 [medline] PHST- 2025/03/17 15:19 [pubmed] PHST- 2025/03/17 03:43 [entrez] PHST- 2025/05/26 00:00 [pmc-release] AID - EJHF3642 [pii] AID - 10.1002/ejhf.3642 [doi] PST - ppublish SO - Eur J Heart Fail. 2025 May;27(5):747-759. doi: 10.1002/ejhf.3642. Epub 2025 Mar 17. PMID- 40090512 OWN - NLM STAT- In-Process LR - 20260115 IS - 1532-8414 (Electronic) IS - 1071-9164 (Linking) VI - 32 IP - 1 DP - 2026 Jan TI - Patient Focus: Teamwork to Make the Heart Work: An Explanation of the Impact of Embedded Interdisciplinary Heart Failure Teams on Achieving Guideline-Directed Medical Therapy in Community-Based Cardiology Practices. PG - 27-28 LID - S1071-9164(25)00111-3 [pii] LID - 10.1016/j.cardfail.2025.03.002 [doi] FAU - Jawaid, Anas AU - Jawaid A AD - Division of Cardiology, University of Rochester Medical Center, Rochester, NY. FAU - Thibodeau, Jennifer T AU - Thibodeau JT AD - Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX. Electronic address: Jennifer.thibodeau@utsouthwestern.edu. LA - eng PT - Journal Article DEP - 20250314 PL - United States TA - J Card Fail JT - Journal of cardiac failure JID - 9442138 SB - IM EDAT- 2025/03/17 00:42 MHDA- 2025/03/17 00:42 CRDT- 2025/03/16 20:36 PHST- 2025/03/10 00:00 [received] PHST- 2025/03/10 00:00 [accepted] PHST- 2025/03/17 00:42 [pubmed] PHST- 2025/03/17 00:42 [medline] PHST- 2025/03/16 20:36 [entrez] AID - S1071-9164(25)00111-3 [pii] AID - 10.1016/j.cardfail.2025.03.002 [doi] PST - ppublish SO - J Card Fail. 2026 Jan;32(1):27-28. doi: 10.1016/j.cardfail.2025.03.002. Epub 2025 Mar 14. PMID- 40088931 OWN - NLM STAT- MEDLINE DCOM- 20250513 LR - 20250513 IS - 2753-670X (Electronic) IS - 2753-670X (Linking) VI - 40 IP - 3 DP - 2025 Mar 5 TI - Contribution of cardiac surgeons in transcatheter aortic valve replacement activity in France. LID - 10.1093/icvts/ivaf068 [doi] LID - ivaf068 AB - OBJECTIVES: This study provides a thorough analysis of cardiac surgeons' involvement in transcatheter aortic valve replacement (TAVR) activities in France, covering decision-making, procedural roles, training and outcome analysis. METHODS: A nationwide survey was sent to all cardiac surgeons and all cardiac surgery trainees in France. Subgroup analysis was performed for age, status (established versus in-training) and type of practice facility. RESULTS: A total of 172 surgeons from both private and public sectors responded to the survey. Most respondents (71%) had TAVR activity, and there were no significant differences between subgroups. Most respondents with TAVR activities (30%) had average access (once per week). Almost one-third of centres had >3 established surgeons with TAVR activity, whereas 19% had no in-training surgeons with TAVR activity. TAVR was the only structural practice for 67% of surgeons, while 33% practiced other structural procedures. When asked, 82% of surgeons were against establishing TAVR programmes in centres without a cardiac surgery programme. Most TAVR patients (72%) were discussed by the Heart Team, and only 9% of surgeons said their relationship with the interventional cardiologist was disrupted. Two-thirds of vascular complications were managed by cardiac surgery, and only 6% of cardiac surgeons admitted were unfit to handle any vascular complications. CONCLUSIONS: In France, cardiac surgeons are becoming increasingly involved in TAVR procedures as an integral part of the Heart Team. CI - (c) The Author(s) 2025. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. FAU - Saiydoun, Gabriel AU - Saiydoun G AUID- ORCID: 0000-0003-0630-8332 AD - Department of Cardiac Surgery, Pitie Salpetriere University Hospital, Sorbonne University, Paris, France. AD - Department of Cardiac Surgery, Henri Mondor University Hospital, UPEC, Creteil, France. FAU - Saade, Saade AU - Saade S AD - Department of Cardiac Surgery, Strasbourg University Hospital, Nouvel Hopital Civil, Strasbourg, France. FAU - Aludaat, Chadi AU - Aludaat C AUID- ORCID: 0000-0002-9825-3852 AD - Department of Thoracic and Cardiac Surgery, Rouen University Hospital, Rouen, France. FAU - Bernard, Chloe AU - Bernard C AD - Department of Cardiac Surgery, Dijon University Hospital, Dijon, France. FAU - Lebreton, Guillaume AU - Lebreton G AUID- ORCID: 0000-0003-4308-506X AD - Department of Cardiac Surgery, Pitie Salpetriere University Hospital, Sorbonne University, Paris, France. FAU - Modine, Thomas AU - Modine T AD - Department of Cardiac Surgery, Bordeaux University Hospital, Bordeaux, France. FAU - Folliguet, Thierry AU - Folliguet T AUID- ORCID: 0000-0003-0009-6543 AD - Department of Cardiac Surgery, Henri Mondor University Hospital, UPEC, Creteil, France. FAU - Juvin, Charles AU - Juvin C AD - Department of Cardiac Surgery, Pitie Salpetriere University Hospital, Sorbonne University, Paris, France. FAU - Eid, Maroua AU - Eid M AUID- ORCID: 0000-0001-5433-2607 AD - Department of Cardiac Surgery, Angers University Hospital, Angers, France. FAU - D'Journo, Xavier-Benoit AU - D'Journo XB AD - Department of Thoracic Surgery, Marseille University Hospital, Marseille, France. FAU - Labrousse, Louis AU - Labrousse L AUID- ORCID: 0000-0001-8542-9049 AD - Department of Cardiac Surgery, Bordeaux University Hospital, Bordeaux, France. FAU - Kindo, Michel AU - Kindo M AUID- ORCID: 0000-0001-8884-4395 AD - Department of Cardiac Surgery, Strasbourg University Hospital, Nouvel Hopital Civil, Strasbourg, France. FAU - Guihaire, Julien AU - Guihaire J AUID- ORCID: 0000-0001-7414-3176 AD - Department of Cardiac Surgery, Marie-Lannelongue Hospital, Le Plessis-Robinson, France. FAU - Baste, Jean-Marc AU - Baste JM AUID- ORCID: 0000-0002-1739-4523 AD - Department of Thoracic and Cardiac Surgery, Rouen University Hospital, Rouen, France. FAU - Fouquet, Olivier AU - Fouquet O AUID- ORCID: 0000-0002-5094-3336 AD - Department of Cardiac Surgery, Angers University Hospital, Angers, France. FAU - Para, Marylou AU - Para M AUID- ORCID: 0000-0002-4857-5474 AD - Department of Cardiac Surgery, Bichat University Hospital, Paris, France. FAU - Cattan, Johann AU - Cattan J AD - Department of Cardiac Surgery, Bordeaux University Hospital, Bordeaux, France. FAU - Alghamdi, Mohammed AU - Alghamdi M AD - Department of Cardiac Surgery, Pitie Salpetriere University Hospital, Sorbonne University, Paris, France. FAU - Guimbretiere, Guillaume AU - Guimbretiere G AD - Department of Cardiothoracic Surgery, Nantes University Hospital, Nantes, France. FAU - Bouchot, Olivier AU - Bouchot O AUID- ORCID: 0000-0002-4127-7327 AD - Department of Cardiac Surgery, Dijon University Hospital, Dijon, France. FAU - Vincentelli, Andre AU - Vincentelli A AD - Department of Cardiac Surgery, Lille University Hospital, Lille, France. FAU - Leprince, Pascal AU - Leprince P AD - Department of Cardiac Surgery, Pitie Salpetriere University Hospital, Sorbonne University, Paris, France. FAU - Verhoye, Jean-Philippe AU - Verhoye JP AD - Department of Cardiac Surgery, Rennes University Hospital, Rennes, France. LA - eng GR - French Society of Thoracic and Cardiovascular Surgery/ PT - Journal Article PL - England TA - Interdiscip Cardiovasc Thorac Surg JT - Interdisciplinary cardiovascular and thoracic surgery JID - 9918540787006676 SB - IM MH - Humans MH - *Transcatheter Aortic Valve Replacement/adverse effects/trends/education MH - France MH - *Surgeons/trends/education MH - Male MH - Female MH - *Practice Patterns, Physicians'/trends MH - Health Care Surveys MH - Surveys and Questionnaires MH - *Physician's Role PMC - PMC11938354 OTO - NOTNLM OT - Heart Team OT - TAVR OT - aortic stenosis OT - cardiac surgery COIS- C.A. reports receiving training and educational support from Edwards Lifesciences, Medtronic and Abbott. T.M. is a consultant for Medtronic, Edwards Lifesciences and Abbott Structural. There are no other potential conflicts of interest to declare. EDAT- 2025/03/16 12:44 MHDA- 2025/03/27 06:03 PMCR- 2025/03/14 CRDT- 2025/03/15 20:03 PHST- 2024/11/04 00:00 [received] PHST- 2025/02/06 00:00 [revised] PHST- 2025/03/11 00:00 [accepted] PHST- 2025/03/27 06:03 [medline] PHST- 2025/03/16 12:44 [pubmed] PHST- 2025/03/15 20:03 [entrez] PHST- 2025/03/14 00:00 [pmc-release] AID - 8079075 [pii] AID - ivaf068 [pii] AID - 10.1093/icvts/ivaf068 [doi] PST - ppublish SO - Interdiscip Cardiovasc Thorac Surg. 2025 Mar 5;40(3):ivaf068. doi: 10.1093/icvts/ivaf068. PMID- 40084845 OWN - NLM STAT- MEDLINE DCOM- 20250630 LR - 20260120 IS - 0301-1526 (Print) IS - 0301-1526 (Linking) VI - 54 IP - 4 DP - 2025 Jul TI - Cutting-edge European guidelines for managing lower extremity peripheral arterial disease - Featuring selected insights on PAD management. PG - 225-234 LID - 10.1024/0301-1526/a001186 [doi] AB - The new guidelines for the management of peripheral arterial and aortic diseases (PAAD) from the European Society of Cardiology and endorsed by the European Society of Vascular Medicine (ESVM), emphasize on a comprehensive and multidisciplinary approach focusing on prevention, diagnosis, treatment, and follow-up of patients with a wide range of PAAD, including lower extremity peripheral arterial disease (PAD). The aim of this summary, focusing on PAD and coordinated by the Young Academy of ESVM, is to provide young angiologists with the fundamental principles of these guidelines and to assist them in navigating their everyday clinical practice. PAD diagnosis relies on objective evaluation of flow/oxygen reduction at rest, with arterial ultrasound as the first imaging modality to confirm the presence of arterial lesions. The main goals of PAD management are not only to improve functioning and prevent the occurrence of adverse events at the lower limb level, but also to reduce the overall atherosclerotic burden and achieve the general well-being of patients. To this end, traditional and nontraditional cardiovascular risk factors need to be properly addressed through lifestyle changes and tailored drug therapies. For patients with exertional limb symptoms, supervised exercise training is recommended. Interventional treatment is indicated for limb salvage in patients with chronic limb threatening ischemia and may also be discussed in a multidisciplinary setting in less severe patients with persisting symptoms and reduced quality of life after a minimum period of optimal medical treatment including exercise therapy. For trainees or young specialists in Angiology/Vascular Medicine, these guidelines provide essential elements to improve patient management, encourage interdisciplinary collaboration, and ensure an integrated approach to vascular diseases. FAU - Buso, Giacomo AU - Buso G AUID- ORCID: 0000-0002-5645-9553 AD - Department of Clinical and Experimental Sciences, Division of Internal Medicine, ASST Spedali Civili Brescia, University of Brescia, Italy. AD - University of Lausanne, Switzerland. FAU - Hersant, Jeanne AU - Hersant J AUID- ORCID: 0000-0002-7126-0534 AD - Department of Vascular Medicine, University Hospital of Angers, France. FAU - Keller, Sanjiv AU - Keller S AUID- ORCID: 0009-0000-5567-9290 AD - Angiology Division, Heart and Vessel Department, Lausanne University Hospital, University of Lausanne, Switzerland. FAU - Kalaja, Igli AU - Kalaja I AUID- ORCID: 0000-0003-1082-5578 AD - Department for Cardiology III - Angiology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany. FAU - Bigolin, Paola AU - Bigolin P AUID- ORCID: 0000-0002-2582-5119 AD - Angiology Unit, Azienda ULSS 2 Marca Trevigiana, Castelfranco Veneto, Italy. FAU - Porceddu, Enrica AU - Porceddu E AD - Angiology Division, Heart and Vessel Department, Lausanne University Hospital, University of Lausanne, Switzerland. FAU - Ghirardini, Francesca AU - Ghirardini F AD - Angiology Unit, AULSS 1 Dolomiti, San Martino Hospital, Belluno, Italy. FAU - Novakovic, Marko AU - Novakovic M AUID- ORCID: 0000-0002-7576-5505 AD - Department of Vascular Diseases, University Medical Centre Ljubljana, Slovenia. FAU - Meilak, Darren Galea AU - Meilak DG AD - Vascular Unit, Mater Dei Hospital, Malta. FAU - Dzupina, Andrej AU - Dzupina A AD - Department of Cardiology and Angiology, National Institute of Cardiovascular Diseases, Bratislava, Slovakia. FAU - Gary, Thomas AU - Gary T AD - Division of Angiology, Department of Internal Medicine, Medical University of Graz, Austria. FAU - Bura-Riviere, Alessandra AU - Bura-Riviere A AD - Department of Vascular Medicine, Toulouse University Hospital, France. AD - Department of Medicine, Faculte de Sante Universite Toulouse III, France. FAU - Heiss, Christian AU - Heiss C AUID- ORCID: 0000-0002-3212-8995 AD - Vascular Department, Surrey and Sussex Healthcare NHS Trust, East Surrey Hospital, Redhill, UK. AD - Department of Clinical and Experimental Medicine, Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK. FAU - Lanzi, Stefano AU - Lanzi S AUID- ORCID: 0000-0003-1089-6309 AD - Angiology Division, Heart and Vessel Department, Lausanne University Hospital, University of Lausanne, Switzerland. FAU - Madaric, Juraj AU - Madaric J AUID- ORCID: 0000-0003-1326-2336 AD - Department of Angiology, Comenius University and National Institute of Cardiovascular Diseases, Bratislava, Slovakia. FAU - Boc, Vinko AU - Boc V AUID- ORCID: 0000-0002-2171-7794 AD - Department of Vascular Diseases, University Medical Centre Ljubljana, Slovenia. AD - Department of Internal Medicine, Faculty of Medicine, University of Ljubljana, Slovenia. FAU - Sprynger, Muriel AU - Sprynger M AUID- ORCID: 0000-0003-4358-0183 AD - Department of Cardiology, University Hospital of Liege, Belgium. FAU - Mirault, Tristan AU - Mirault T AD - Universite Paris Cite, PARCC Inserm U970, CRMR MARS, VASCERN, Vascular Medicine, Hopital Europeen Georges-Pompidou APHP, Paris, France. FAU - Brodmann, Marianne AU - Brodmann M AD - Division of Angiology, Department of Internal Medicine, Medical University of Graz, Austria. FAU - Schlager, Oliver AU - Schlager O AUID- ORCID: 0000-0001-6934-5355 AD - Division of Angiology, Department of Medicine II, Medical University of Vienna, Austria. FAU - Mazzolai, Lucia AU - Mazzolai L AD - Angiology Division, Heart and Vessel Department, Lausanne University Hospital, University of Lausanne, Switzerland. LA - eng PT - Journal Article PT - Review DEP - 20250314 PL - Switzerland TA - Vasa JT - VASA. Zeitschrift fur Gefasskrankheiten JID - 0317051 SB - IM MH - Humans MH - Consensus MH - *Endovascular Procedures/standards/adverse effects MH - Europe MH - Evidence-Based Medicine/standards MH - Limb Salvage MH - *Lower Extremity/blood supply MH - *Peripheral Arterial Disease/therapy/diagnosis/physiopathology/epidemiology MH - *Practice Guidelines as Topic MH - Risk Factors MH - Treatment Outcome OTO - NOTNLM OT - Peripheral arterial disease OT - guidelines OT - management OT - training EDAT- 2025/03/14 11:17 MHDA- 2025/07/01 04:52 CRDT- 2025/03/14 08:52 PHST- 2025/07/01 04:52 [medline] PHST- 2025/03/14 11:17 [pubmed] PHST- 2025/03/14 08:52 [entrez] AID - 10.1024/0301-1526/a001186 [doi] PST - ppublish SO - Vasa. 2025 Jul;54(4):225-234. doi: 10.1024/0301-1526/a001186. Epub 2025 Mar 14. PMID- 40082373 OWN - NLM STAT- MEDLINE DCOM- 20250522 LR - 20261008 IS - 1179-1985 (Electronic) IS - 1120-9879 (Linking) VI - 32 IP - 3 DP - 2025 May TI - Pre-participation Cardiovascular Evaluation for Paris 2024 Olympic Games in Elite Athletes: The Italian Experience. PG - 299-309 LID - 10.1007/s40292-025-00709-w [doi] AB - INTRODUCTION: Olympic athletes represent a special subset of the athletic population and deserve a specialized medical approach. In view of the 2024 Paris Olympic Games, we developed and implemented a comprehensive medical protocol including (other than the standard screening with ECG, physical and history) cardiopulmonary exercise test, echocardiography and full blood and urine tests. AIM: Our aim was to assess the prevalence and type of cardiovascular abnormalities in athletes candidate to Paris 2024 Olympic Games, after implementation of this Olympic medical program. METHODS: We enrolled 772 elite athletes, who underwent a comprehensive, multidisciplinary evaluation, including full panel of blood and urine tests, electrocardiography, trans-thoracic echocardiography (TTE) and a cardiopulmonary exercise test (CPET). RESULTS: Of the 772 elite athletes, 363 (47%) were female. A substantial subset of 145 athletes (18.8%) showed one or more abnormalities. Specifically, either abnormal basal ECG findings (n = 26, 17.9%), abnormal TTE results (n = 45, 31%), high blood pressure (n = 2, 1.4%) or exercise induced arrhythmias (n = 49, 33.8%) were detected. 10 athletes (6.9%) showed both abnormal ECGs and exercise induced arrhythmias, and 13 athletes (9%) showed both ECG and echocardiographic abnormal findings. After further and more detailed investigations, of the 145 athletes showing cardiovascular abnormalities at the initial screening, in 4 of them were cardiac conditions implying potential risk of sudden cardiac death were identified and therefore they were withdrawn from competitive sport. Full blood test analysis identified metabolic abnormalities in 200 subjects. Of these, 165 (21%) showed hypercholesterolemia. CONCLUSIONS: Olympic athletes, despite the highest level of physical performance, are not exempt from cardiovascular and metabolic diseases, including a small proportion of cardiac conditions at risk of SCD. More advanced diagnostic tools, including CPET, echocardiography and full blood tests, implemented in our protocol, were required to identify hidden cardiovascular abnormalities that could have jeopardized athlete's health and performance. CI - (c) 2025. The Author(s). FAU - Squeo, Maria Rosaria AU - Squeo MR AD - Institute of Sports Medicine and Science, National Italian Olympic Committee, Largo Piero Gabrielli, 1, 00197, Rome, Italy. mariarosaria.squeo@coni.it. FAU - Ferrera, Armando AU - Ferrera A AD - Institute of Sports Medicine and Science, National Italian Olympic Committee, Largo Piero Gabrielli, 1, 00197, Rome, Italy. AD - Clinical and Molecular Medicine Department, Sapienza University of Rome, 00198, Rome, Italy. FAU - Di Gioia, Giuseppe AU - Di Gioia G AD - Institute of Sports Medicine and Science, National Italian Olympic Committee, Largo Piero Gabrielli, 1, 00197, Rome, Italy. AD - Department of Movement, Human and Health Sciences, University of Rome "Foro Italico", Piazza Lauro De Bosis, 15- 00135, Rome, Italy. FAU - Mango, Federica AU - Mango F AD - Institute of Sports Medicine and Science, National Italian Olympic Committee, Largo Piero Gabrielli, 1, 00197, Rome, Italy. FAU - Maestrini, Viviana AU - Maestrini V AD - Institute of Sports Medicine and Science, National Italian Olympic Committee, Largo Piero Gabrielli, 1, 00197, Rome, Italy. AD - Department of Clinical, Internal, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, Piazzale Aldo Moro, 5, 00185, Rome, Italy. FAU - Monosilio, Sara AU - Monosilio S AD - Institute of Sports Medicine and Science, National Italian Olympic Committee, Largo Piero Gabrielli, 1, 00197, Rome, Italy. AD - Department of Clinical, Internal, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, Piazzale Aldo Moro, 5, 00185, Rome, Italy. FAU - Lemme, Erika AU - Lemme E AD - Institute of Sports Medicine and Science, National Italian Olympic Committee, Largo Piero Gabrielli, 1, 00197, Rome, Italy. FAU - Crotta, Simone AU - Crotta S AD - Institute of Sports Medicine and Science, National Italian Olympic Committee, Largo Piero Gabrielli, 1, 00197, Rome, Italy. FAU - Spinelli, Alessandro AU - Spinelli A AD - Institute of Sports Medicine and Science, National Italian Olympic Committee, Largo Piero Gabrielli, 1, 00197, Rome, Italy. FAU - Serdoz, Andrea AU - Serdoz A AD - Institute of Sports Medicine and Science, National Italian Olympic Committee, Largo Piero Gabrielli, 1, 00197, Rome, Italy. FAU - Fiore, Roberto AU - Fiore R AD - Institute of Sports Medicine and Science, National Italian Olympic Committee, Largo Piero Gabrielli, 1, 00197, Rome, Italy. FAU - Zampaglione, Domenico AU - Zampaglione D AD - Institute of Sports Medicine and Science, National Italian Olympic Committee, Largo Piero Gabrielli, 1, 00197, Rome, Italy. FAU - Daniello, Cosimo Damiano AU - Daniello CD AD - Careggi University Hospital, University of Florence, Florence, Italy. FAU - Volpe, Massimo AU - Volpe M AD - Department of Clinical and Molecular Medicine, University of Rome Sapienza and IRCCS San Raffaele, Rome, Italy. FAU - Bernardi, Marco AU - Bernardi M AD - Department of Physiology and Pharmacology "V. Erspamer", Sapienza University of Rome, Rome, Italy. FAU - Pelliccia, Antonio AU - Pelliccia A AD - Institute of Sports Medicine and Science, National Italian Olympic Committee, Largo Piero Gabrielli, 1, 00197, Rome, Italy. LA - eng PT - Journal Article DEP - 20250314 PL - New Zealand TA - High Blood Press Cardiovasc Prev JT - High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension JID - 9421087 SB - IM EIN - High Blood Press Cardiovasc Prev. 2025 May;32(3):367. doi: 10.1007/s40292-025-00715-y. PMID: 40268831 MH - Humans MH - Female MH - Male MH - *Athletes MH - Adult MH - *Cardiovascular Diseases/epidemiology/diagnosis/physiopathology MH - Young Adult MH - Prevalence MH - Predictive Value of Tests MH - Electrocardiography MH - Exercise Test MH - Echocardiography MH - Risk Assessment MH - Italy/epidemiology MH - Adolescent MH - Heart Disease Risk Factors MH - Anniversaries and Special Events OTO - NOTNLM OT - Cardiovascular pre-participation screening OT - Cardiovascular prevention OT - Elite athletes OT - Olympic games COIS- Declarations. Ethical Approval: information: the study design of the present investigation was evaluated and approved by the Ethical Committee (CET - Comitato Etico Territoriale Lazio Area 1, date of approval 06\03\2024 IRB number 0208/2024). All athletes included in this study were fully informed of the types and nature of the evaluation and signed the consent form, according to Italian Law and Institute policy. All clinical data assembled from the study population are maintained in an institutional database. Data Availability: De-identified participant data are available upon reasonable request from the corresponding author. Conflict of interest: None. EDAT- 2025/03/14 11:24 MHDA- 2025/05/22 12:32 CRDT- 2025/03/14 00:16 PHST- 2025/01/08 00:00 [received] PHST- 2025/02/12 00:00 [accepted] PHST- 2025/05/22 12:32 [medline] PHST- 2025/03/14 11:24 [pubmed] PHST- 2025/03/14 00:16 [entrez] AID - 10.1007/s40292-025-00709-w [pii] AID - 10.1007/s40292-025-00709-w [doi] PST - ppublish SO - High Blood Press Cardiovasc Prev. 2025 May;32(3):299-309. doi: 10.1007/s40292-025-00709-w. Epub 2025 Mar 14. PMID- 40079503 OWN - NLM STAT- MEDLINE DCOM- 20250613 LR - 20260331 IS - 1531-7072 (Electronic) IS - 1070-5295 (Linking) VI - 31 IP - 3 DP - 2025 Jun 1 TI - ICU imperatives in open abdomen management after trauma or emergency surgery. PG - 262-269 LID - 10.1097/MCC.0000000000001264 [doi] AB - PURPOSE OF REVIEW: This review is both timely and relevant as the open abdomen approach to manage injury, emergency general surgery (EGS) conditions, as well as secondary intra-abdominal hypertension (IAH) and the abdominal compartment syndrome (ACS) remain prevalent throughout ICUs. RECENT FINDINGS: IAH is not limited to those with injury or EGS conditions, as it is increasingly recognized following cardiac surgery as well as cardiac transplantation. IAH monitoring techniques benefit from technological advances including noninvasive devices. Time to primary fascial closure (PFC) is a key determinant of patient-centered outcomes, with worse outcomes in those with delayed or failed closure attempts. Visceral edema avoidance or mitigation techniques remain controversial. Nutrition support and its impact on the gastrointestinal microbiome appear to influence infection risk and anastomotic integrity. Team-based approaches to successful as well as failed open abdomen management help optimize outcomes. SUMMARY: These findings bear broad implications for intensive care medicine clinicians who care for open abdomen patients, as they address resuscitation, intra-abdominal pressure monitoring, and nutrition support all of which influence the likelihood of achieving PFC - a key goal regardless of whether the abdomen was initially left open after injury, EGS, or intestinal ischemia management. CI - Copyright (c) 2025 Wolters Kluwer Health, Inc. All rights reserved. FAU - Leonard, Jennifer Marie AU - Leonard JM AD - Division of Trauma and Acute Care Surgery, Department of Surgery, Baylor College of Medicine, Houston, Texas, USA. FAU - Cecconi, Maurizio AU - Cecconi M AD - Department of Biomedical Sciences, Humanitas University. AD - Department of Anesthesia and Intensive Care Medicine, IRCCS Humanitas Research Hospital, Milan, Italy. FAU - Kaplan, Lewis J AU - Kaplan LJ AD - Surgical Critical Care, Corporal Michael J. Crescenz VA Medical Center. AD - Division of Trauma, Surgical Critical Care and Emergency Surgery, Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. LA - eng GR - L70 HL165646/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Review DEP - 20250306 PL - United States TA - Curr Opin Crit Care JT - Current opinion in critical care JID - 9504454 SB - IM MH - Humans MH - *Intra-Abdominal Hypertension/etiology/therapy/prevention & control MH - *Intensive Care Units/organization & administration MH - *Critical Care/methods MH - *Open Abdomen Techniques MH - *Abdominal Injuries/surgery OTO - NOTNLM OT - emergency surgery OT - injury OT - microbiome OT - open abdomen OT - resuscitation EDAT- 2025/03/13 14:06 MHDA- 2025/06/13 12:31 CRDT- 2025/03/13 08:23 PHST- 2025/06/13 12:31 [medline] PHST- 2025/03/13 14:06 [pubmed] PHST- 2025/03/13 08:23 [entrez] AID - 00075198-990000000-00255 [pii] AID - 10.1097/MCC.0000000000001264 [doi] PST - ppublish SO - Curr Opin Crit Care. 2025 Jun 1;31(3):262-269. doi: 10.1097/MCC.0000000000001264. Epub 2025 Mar 6. PMID- 40079478 OWN - NLM STAT- MEDLINE DCOM- 20250616 LR - 20250620 IS - 1528-1167 (Electronic) IS - 0013-9580 (Print) IS - 0013-9580 (Linking) VI - 66 IP - 6 DP - 2025 Jun TI - Epilepsy-heart syndrome: Concept, clinical context, and opportunity for integrated care. PG - 1830-1837 LID - 10.1111/epi.18356 [doi] AB - In this concept paper, we introduce epilepsy-heart syndrome as a shared burden of illness between epilepsy and cardiac disorders. This pragmatic definition is agnostic of which condition came first (the epilepsy or the cardiac disorder), recognising that these conditions can each serve as a risk factor for the other owing to a bidirectional relationship that exists between the brain and the heart. To provide clinical context, we include ictal asystole as an example phenotype of epilepsy-heart syndrome. We highlight evidence of patients with ictal asystole coming to harm owing to the failure of integrated care between neurology and cardiology. This underscores epilepsy-heart syndrome as an unmet need for collaborative care between neurology and cardiology. To address this, we propose a framework for integrated care, drawing upon our own centre's recently established and successful multidisciplinary team meeting (MDT) between neurologists and cardiologists, our joint cardiology-neurology PhD programme, and our work developing a joint national guideline on ictal asystole management between the Association of British Neurologists (ABN) and the British Heart Rhythm Society (BHRS). CI - (c) 2025 The Author(s). Epilepsia published by Wiley Periodicals LLC on behalf of International League Against Epilepsy. FAU - Mbizvo, Gashirai K AU - Mbizvo GK AUID- ORCID: 0000-0002-9588-2944 AD - Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart and Chest Hospital, Liverpool, UK. AD - Pharmacology and Therapeutics, Institute of Systems, Molecular, and Integrative Biology, University of Liverpool, Liverpool, UK. AD - Walton Centre National Health Service (NHS) Foundation Trust, Liverpool, UK. FAU - Buchan, Iain E AU - Buchan IE AD - Department of Public Health, Policy, and Systems, Institute of Population Health, University of Liverpool, Liverpool, UK. FAU - Marson, Anthony G AU - Marson AG AD - Pharmacology and Therapeutics, Institute of Systems, Molecular, and Integrative Biology, University of Liverpool, Liverpool, UK. AD - Walton Centre National Health Service (NHS) Foundation Trust, Liverpool, UK. FAU - Lip, Gregory Y H AU - Lip GYH AD - Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart and Chest Hospital, Liverpool, UK. AD - Danish Center for Health Services Research, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. LA - eng GR - CL-2022-07-002/National Institute for Health and Care Research/ GR - F2401/Epilepsy Research Institute UK/ GR - SGL030\1029/AMS_/Academy of Medical Sciences/United Kingdom PT - Journal Article DEP - 20250313 PL - United States TA - Epilepsia JT - Epilepsia JID - 2983306R SB - IM MH - Humans MH - *Delivery of Health Care, Integrated MH - *Epilepsy/therapy/complications MH - *Heart Arrest/therapy/etiology MH - *Heart Diseases/therapy/complications MH - Syndrome PMC - PMC12169406 OTO - NOTNLM OT - Cardiovascular disease OT - Epileptic heart OT - Ictal asystole OT - SUDEP OT - Seizures COIS- The authors report no competing interests. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines. EDAT- 2025/03/13 14:06 MHDA- 2025/06/16 18:25 PMCR- 2025/06/16 CRDT- 2025/03/13 08:04 PHST- 2025/02/18 00:00 [revised] PHST- 2025/01/13 00:00 [received] PHST- 2025/02/19 00:00 [accepted] PHST- 2025/06/16 18:25 [medline] PHST- 2025/03/13 14:06 [pubmed] PHST- 2025/03/13 08:04 [entrez] PHST- 2025/06/16 00:00 [pmc-release] AID - EPI18356 [pii] AID - 10.1111/epi.18356 [doi] PST - ppublish SO - Epilepsia. 2025 Jun;66(6):1830-1837. doi: 10.1111/epi.18356. Epub 2025 Mar 13. PMID- 40071866 OWN - NLM STAT- MEDLINE DCOM- 20250402 LR - 20250526 IS - 1467-1107 (Electronic) IS - 1047-9511 (Linking) VI - 35 IP - 4 DP - 2025 Apr TI - Building a sustainable neurocardiac critical care program in a paediatric cardiac ICU: insights and lessons learned. PG - 738-744 LID - 10.1017/S104795112500037X [doi] AB - INTRODUCTION: Children with CHD are at increased risk for neurodevelopmental disabilities and neuropsychological impairments throughout their life span. The purpose of this report is to share our experience building a sustainable, novel, inpatient, interdisciplinary Neurocardiac Critical Care Program to mitigate risks and optimize outcomes during the ICU stay. MATERIAL AND METHODS: A descriptive review was chosen to identify meaningful characteristics, challenges and lessons learned related to the establishment, expansion of and sustainability of Neurocardiac Critical Care Program in a 26-bed pediatric cardiac ICU. RESULTS: We successfully launched, expanded, and sustained an interdisciplinary Neurocardiac Critical Care Program. Here, we share the foundation, framework, challenges, and lessons learned as we established and sustained the Neurocardiac Critical Care Program. The key elements of our program are (1) consistent engagement by pediatric neurologists in the cardiac ICU, (2) comprehensive education initiatives, (3) evidence-based clinical practice changes, and (4) quality improvement and research projects. DISCUSSION: The development of a pediatric Neurocardiac Critical Care Program is feasible and sustainable. This program was informed by recent research related to perioperative and psychosocial risk factors that impact brain development and neurodevelopmental outcomes in this vulnerable population. By aligning our efforts, our multidisciplinary team is helping shift the paradigm in pediatric cardiac critical care to actively manage complex heart disease, while simultaneously and proactively mitigating risks to the developing brain and family unit. FAU - Jones, Melissa B AU - Jones MB AUID- ORCID: 0000-0001-9526-6992 AD - Division of Cardiac Critical Care, Children's National Hospital, Washington, DC, USA. FAU - Caprarola, Sherrill D AU - Caprarola SD AUID- ORCID: 0000-0001-9523-6291 AD - Division of Cardiology, Children's Hospital Colorado, Denver, CO, USA. FAU - Schlatterer, Sarah AU - Schlatterer S AD - Zickler Family Prenatal Pediatrics Institute at Children's National Hospital, Children's National Medical Center, Washington, DC, USA. FAU - O'Donnell, Mandana AU - O'Donnell M AD - Division of Physical Medicine and Rehabilitation, Children's National Hospital, Washington, DC, USA. FAU - Pleau, Cara AU - Pleau C AD - Division of Nursing, Children's National Hospital, Washington, DC, USA. FAU - Staso, Katelyn AU - Staso K AD - Division of Neurology, Children's National Hospital, Washington, DC, USA. FAU - Jonas, Richard A AU - Jonas RA AD - Division of Cardiac Surgery, Children's National Hospital, Washington, DC, USA. FAU - D'Udekem D'Acoz, Yves AU - D'Udekem D'Acoz Y AUID- ORCID: 0000-0003-1851-7836 AD - Division of Cardiac Surgery, Children's National Hospital, Washington, DC, USA. FAU - Munoz, Ricardo AU - Munoz R AD - Division of Cardiac Critical Care, Children's National Hospital, Washington, DC, USA. FAU - Carpenter, Jessica L AU - Carpenter JL AD - Division of Pediatric Neurology, University of Maryland Medical System, Baltimore, MD, USA. FAU - Limperopolous, Catherine AU - Limperopolous C AUID- ORCID: 0000-0003-1735-0069 AD - Developing Brain Institute, Children's National Hospital, Washington, DC, USA. FAU - Wernovsky, Gil AU - Wernovsky G AD - Division of Cardiac Critical Care, Children's National Hospital, Washington, DC, USA. AD - Division of Pediatric Cardiology, Children's National Hospital, Washington, DC, USA. LA - eng PT - Journal Article PT - Review DEP - 20250312 PL - England TA - Cardiol Young JT - Cardiology in the young JID - 9200019 SB - IM MH - Humans MH - *Critical Care/organization & administration/methods MH - *Intensive Care Units, Pediatric/organization & administration MH - Child MH - *Heart Defects, Congenital/complications/therapy MH - Patient Care Team/organization & administration MH - *Neurodevelopmental Disorders OTO - NOTNLM OT - CHD OT - brain development OT - brain injury OT - cardiac critical care OT - neurodevelopment EDAT- 2025/03/12 12:31 MHDA- 2025/04/02 06:26 CRDT- 2025/03/12 08:43 PHST- 2025/04/02 06:26 [medline] PHST- 2025/03/12 12:31 [pubmed] PHST- 2025/03/12 08:43 [entrez] AID - S104795112500037X [pii] AID - 10.1017/S104795112500037X [doi] PST - ppublish SO - Cardiol Young. 2025 Apr;35(4):738-744. doi: 10.1017/S104795112500037X. Epub 2025 Mar 12. PMID- 40071400 OWN - NLM STAT- MEDLINE DCOM- 20250513 LR - 20260903 IS - 1462-0332 (Electronic) IS - 1462-0324 (Linking) VI - 64 IP - 12 Suppl 2 DP - 2025 Mar 1 TI - Highlights from the breakout session: vasculitis in paediatric rheumatology. PG - i131-i133 LID - 10.1093/rheumatology/keae406 [doi] AB - The 21st International Vasculitis Workshop, held in Barcelona, Spain, from April 7 to 10, 2024, highlighted advances in pediatric vasculitis, focusing on a holistic, multidisciplinary approach. Common childhood vasculitides, including IgA Vasculitis (IgAV) and Kawasaki Disease (KD), were discussed. The Ankara 2008 criteria for IgAV, endorsed by EULAR and PReS, were evaluated for their performance in adults, showing high sensitivity but necessitating further refinement for improved specificity. Studies on genetic associations, such as Human Leukocyte Antigen (HLA) polymorphisms in IgAV, and biomarkers like S100A8/A9, HMGB1, and RAGE, were presented. Kawasaki disease research included novel anti-apolipoprotein A-2 antibodies, showing promise in reducing coronary arteritis. Monogenic vasculitides, such as deficiency of ADA2, were addressed with new consensus-driven recommendations. The workshop underscored the importance of continued research and tailored therapeutic strategies to improve outcomes in pediatric vasculitis, paving the way for advancements in diagnosis, management, and understanding of these complex diseases. CI - (c) The Author(s) 2025. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com. FAU - Bayindir, Yagmur AU - Bayindir Y AUID- ORCID: 0000-0001-5274-3285 AD - Department of Paediatric Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey. FAU - Jelusic, Marija AU - Jelusic M AUID- ORCID: 0000-0002-1728-4260 AD - Department of Paediatrics, University Hospital Centre Zagreb, School of Medicine, University of Zagreb, Zagreb, Croatia. FAU - Ozen, Seza AU - Ozen S AUID- ORCID: 0000-0003-2883-7868 AD - Department of Paediatric Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey. LA - eng GR - Novartis/ PT - Journal Article PL - England TA - Rheumatology (Oxford) JT - Rheumatology (Oxford, England) JID - 100883501 RN - 0 (Biomarkers) SB - IM MH - Humans MH - Child MH - *Vasculitis/diagnosis/therapy MH - *Mucocutaneous Lymph Node Syndrome/diagnosis/therapy MH - *Rheumatology MH - *IgA Vasculitis/diagnosis/therapy/genetics MH - Pediatrics MH - Biomarkers OTO - NOTNLM OT - childhood vasculitis OT - monogenic vasculitis OT - paediatric vasculitis EDAT- 2025/03/12 11:33 MHDA- 2025/03/12 11:34 CRDT- 2025/03/12 05:23 PHST- 2024/07/08 00:00 [received] PHST- 2024/07/09 00:00 [accepted] PHST- 2025/03/12 11:34 [medline] PHST- 2025/03/12 11:33 [pubmed] PHST- 2025/03/12 05:23 [entrez] AID - 8069378 [pii] AID - 10.1093/rheumatology/keae406 [doi] PST - ppublish SO - Rheumatology (Oxford). 2025 Mar 1;64(12 Suppl 2):i131-i133. doi: 10.1093/rheumatology/keae406. PMID- 40069533 OWN - NLM STAT- MEDLINE DCOM- 20250513 LR - 20260104 IS - 1863-2491 (Electronic) IS - 1863-2483 (Print) IS - 1863-2483 (Linking) VI - 19 IP - 1 DP - 2025 Mar 11 TI - The environmental impact of multi-specialty robotic-assisted surgery: a waste audit analysis. PG - 113 LID - 10.1007/s11701-025-02278-5 [doi] LID - 113 AB - Modern advances in medicine and technology have led to an increase in robotic-assisted surgery (RAS) cases. However, concerns have been raised about the potential environmental impact of RAS. Despite this, only limited quantitative evidence is currently available. Therefore, this study aims to objectively quantify the environmental impact of a multi-specialty RAS caseload at an Australian public tertiary hospital. An analysis was performed to quantify the amount of waste produced on a consecutive multi-specialty RAS caseload performed between August 2016 and March 2023 at a major public hospital. The weight of each instrument and consumable was measured and the total weight of discarded waste was calculated for each RAS case. A total of 671 patients underwent RAS using the da Vinci Xi System, including Urology (n = 341, 50.8%), Cardiothoracic (n = 158, 23.5%), Gynaecology (n = 107, 16.0%), and Colorectal (n = 65, 9.7%). Overall, the amount of waste was 2,948.9 kg, with single-use items contributing the largest volume (93.9%). Cardiothoracic generated the lowest average weight of waste per case (3.04 kg) while Colorectal generated the highest (5.27 kg). Overall, the da Vinci Xi instrument arm drape was the single item with the largest contribution to the total weight of waste (32.9%). RAS generates substantial waste, primarily from single-use items. These findings underscore the need for strategies to mitigate the environmental footprint of RAS as its adoption continues to grow. CI - (c) 2025. The Author(s). FAU - Tjahyadi, Gerald AU - Tjahyadi G AD - Surgical Outcomes Research Centre (SOuRCe), Royal Prince Alfred Hospital, PO Box M157, Camperdown, Sydney, NSW, 2050, Australia. geraldtjahyadi11@gmail.com. AD - Faculty of Medicine and Health, Concord Clinical School, The University of Sydney, Sydney, NSW, Australia. geraldtjahyadi11@gmail.com. FAU - Treacy, Patrick-Julien AU - Treacy PJ AD - Surgical Outcomes Research Centre (SOuRCe), Royal Prince Alfred Hospital, PO Box M157, Camperdown, Sydney, NSW, 2050, Australia. AD - Institute of Academic Surgery (IAS), Royal Prince Alfred Hospital, Sydney, NSW, Australia. FAU - Alexander, Kate AU - Alexander K AD - Surgical Outcomes Research Centre (SOuRCe), Royal Prince Alfred Hospital, PO Box M157, Camperdown, Sydney, NSW, 2050, Australia. AD - Institute of Academic Surgery (IAS), Royal Prince Alfred Hospital, Sydney, NSW, Australia. AD - Faculty of Medicine and Health, Central Clinical School, The University of Sydney, Sydney, NSW, Australia. FAU - Bird, Jacob AU - Bird J AD - Surgical Outcomes Research Centre (SOuRCe), Royal Prince Alfred Hospital, PO Box M157, Camperdown, Sydney, NSW, 2050, Australia. AD - Institute of Academic Surgery (IAS), Royal Prince Alfred Hospital, Sydney, NSW, Australia. AD - Faculty of Medicine and Health, Central Clinical School, The University of Sydney, Sydney, NSW, Australia. FAU - Karunaratne, Sascha AU - Karunaratne S AD - Surgical Outcomes Research Centre (SOuRCe), Royal Prince Alfred Hospital, PO Box M157, Camperdown, Sydney, NSW, 2050, Australia. AD - Institute of Academic Surgery (IAS), Royal Prince Alfred Hospital, Sydney, NSW, Australia. AD - Faculty of Medicine and Health, Central Clinical School, The University of Sydney, Sydney, NSW, Australia. FAU - Leslie, Scott AU - Leslie S AD - Institute of Academic Surgery (IAS), Royal Prince Alfred Hospital, Sydney, NSW, Australia. AD - Faculty of Medicine and Health, Central Clinical School, The University of Sydney, Sydney, NSW, Australia. AD - Department of Urology, Royal Prince Alfred Hospital, Sydney, NSW, Australia. FAU - McBride, Kate AU - McBride K AD - Surgical Outcomes Research Centre (SOuRCe), Royal Prince Alfred Hospital, PO Box M157, Camperdown, Sydney, NSW, 2050, Australia. AD - Institute of Academic Surgery (IAS), Royal Prince Alfred Hospital, Sydney, NSW, Australia. FAU - Steffens, Daniel AU - Steffens D AD - Surgical Outcomes Research Centre (SOuRCe), Royal Prince Alfred Hospital, PO Box M157, Camperdown, Sydney, NSW, 2050, Australia. AD - Institute of Academic Surgery (IAS), Royal Prince Alfred Hospital, Sydney, NSW, Australia. AD - Faculty of Medicine and Health, Central Clinical School, The University of Sydney, Sydney, NSW, Australia. FAU - Thanigasalam, Ruban AU - Thanigasalam R AD - Institute of Academic Surgery (IAS), Royal Prince Alfred Hospital, Sydney, NSW, Australia. AD - Faculty of Medicine and Health, Central Clinical School, The University of Sydney, Sydney, NSW, Australia. AD - Department of Urology, Concord Repatriation General Hospital, Sydney, NSW, Australia. LA - eng PT - Journal Article DEP - 20250311 PL - England TA - J Robot Surg JT - Journal of robotic surgery JID - 101300401 RN - 0 (Medical Waste) SB - IM MH - *Robotic Surgical Procedures/statistics & numerical data/instrumentation MH - Humans MH - Australia MH - *Environment MH - *Medical Waste/statistics & numerical data PMC - PMC11897078 OTO - NOTNLM OT - Environment OT - Environmental waste OT - Robot-assisted surgery OT - Robotic surgery OT - Waste audit COIS- Declarations. Conflict of interest: The authors have no relevant financial or non-financial interests to disclose. Ethics approval: This study was conducted under a waiver of consent approved by RPAH HREC for the BEST Database (2019/ETH08903). EDAT- 2025/03/12 11:34 MHDA- 2025/03/12 11:35 PMCR- 2025/03/11 CRDT- 2025/03/12 00:33 PHST- 2024/12/16 00:00 [received] PHST- 2025/03/03 00:00 [accepted] PHST- 2025/03/12 11:35 [medline] PHST- 2025/03/12 11:34 [pubmed] PHST- 2025/03/12 00:33 [entrez] PHST- 2025/03/11 00:00 [pmc-release] AID - 10.1007/s11701-025-02278-5 [pii] AID - 2278 [pii] AID - 10.1007/s11701-025-02278-5 [doi] PST - epublish SO - J Robot Surg. 2025 Mar 11;19(1):113. doi: 10.1007/s11701-025-02278-5. PMID- 40066957 OWN - NLM STAT- MEDLINE DCOM- 20250507 LR - 20260504 IS - 1897-4279 (Electronic) IS - 0022-9032 (Linking) VI - 83 IP - 4 DP - 2025 TI - Interdisciplinary expert team statement on the treatment of multi-bed atherosclerotic disease - endorsed by Polish Cardiac Society, Polish Lipid Association, Polish Society of Diabetology, Polish Neurological Society, Polish Society of Nephrology. PG - 531-539 LID - 10.33963/v.phj.105235 [doi] AB - Atherosclerosis is a systemic disease which involves not only the coronary vessels but also occurs in other vascular beds (e.g., cervical, cerebral, and peripheral vessels), increasing cardiovascular risk. One of the causes of atherosclerosis is lipid disorders. In addition, other diseases, such as diabetes, chronic kidney disease, or familial hypercholesterolemia, accelerate the development of multi-bed (multilevel) atherosclerosis. Such patients are often treated by physicians of various specialties, and in our country there is no integrated system for managing these patients and their further treatment. This frequently results in the inability to achieve the therapeutic goals for low-density lipoprotein cholesterol set by the guidelines despite the availability of modern therapy for the treatment of lipid disorders in our country. The presented expert position paper postulates modification of the treatment of patients with multi-bed atherosclerosis by strengthening cooperation between physicians of many specialties (cardiologists, diabetologists, nephrologists, vascular surgeons, pediatricians, etc.) to improve the effectiveness of treatment and better educate the medical community and the treated patients. FAU - Dyrbus, Krzysztof AU - Dyrbus K AD - 3rd Department of Cardiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Silesian Center for Heart Disease, Zabrze, Poland. dyrbusk@gmail.com. FAU - Banach, Maciej AU - Banach M AD - Department of Cardiology and Congenital Diseases of Adults, Polish Mother's Memorial Hospital Research Institute, Department of Preventive Cardiology and Lipidology, Medical University of Lodz, Lodz, Poland. AD - Ciccarone Center for the Prevention of Cardiovascular Disease, Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States. AD - Faculty of Medicine, The John Paul II Catholic University of Lublin, Lublin, Poland. FAU - Gil, Robert AU - Gil R AD - Department of Invasive Cardiology, National Medical Institute of the Ministry of the Interior and Administration, Warszawa, Poland. FAU - Gasior, Mariusz AU - Gasior M AD - 3rd Department of Cardiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Silesian Center for Heart Disease, Zabrze, Poland. FAU - Broncel, Marlena AU - Broncel M AD - Department of Internal Diseases and Clinical Pharmacology, Medical University of Lodz, Lodz, Poland. FAU - Gellert, Ryszard AU - Gellert R AD - Department of Nephrology and Internal Medicine, Medical Center for Postgraduate Education, Warszawa, Poland. FAU - Stompor, Tomasz AU - Stompor T AD - Department of Nephrology, Hypertension and Internal Medicine, University of Warmia and Mazury, Olsztyn, Poland. FAU - Jankowski, Piotr AU - Jankowski P AD - Department of Internal Medicine and Geriatric Cardiology, Center of Postgraduate Medical Education, Warszawa, Poland. FAU - Gierlotka, Marek AU - Gierlotka M AD - Department of Cardiology, Institute of Medical Sciences, University of Opole, Poland. FAU - Gruchala, Marcin AU - Gruchala M AD - 1st Department of Cardiology, Medical University of Gdansk, Gdansk, Poland. FAU - Dzida, Grzegorz AU - Dzida G AD - Division Diabetes, Chair and Department of Internal Diseases, Medical University of Lublin, Lublin, Poland. FAU - Mitkowski, Przemyslaw AU - Mitkowski P AD - 1st Department of Cardiology, University of Medical Sciences, Poznan, Poland. FAU - Kowalska, Irina AU - Kowalska I AD - Department of Internal Medicine and Metabolic Diseases, Medical University of Bialystok, Bialystok, Poland. FAU - Szymanski, Filip M AU - Szymanski FM AD - Department of Civilization Diseases, Collegium Medicum, Cardinal Stefan Wyszynski University in Warsaw, Warszawa, Poland. FAU - Slowik, Agnieszka AU - Slowik A AD - Clinical Department of Neurology, University Hospital in Krakow, Krakow, Poland. FAU - Slawek, Jaroslaw AU - Slawek J AD - Department of Neurological-Psychiatric Nursing, Department of Neurology and Stroke, Faculty of Health Sciences, St. Adalbert Hospital, Medical University of Gdansk, Gdansk, Poland. FAU - Lasek-Bal, Anetta AU - Lasek-Bal A AD - Department of Neurology, Faculty of Health Sciences in Katowice, Medical University of Silesia, Katowice, Poland. FAU - Kulakowska, Alina AU - Kulakowska A AD - Department of Neurology, Medical University of Bialystok, Bialystok, Poland. FAU - Kobayashi, Adam AU - Kobayashi A AD - Department of Neurology, Pharmacology and Clinical Pharmacology, Institute of Medical Sciences, Faculty of Medicine - Collegium Medicum, Cardinal Stefan Wyszynski University in Warsaw, Warszawa, Poland. FAU - Rejdak, Konrad AU - Rejdak K AD - Department of Neurology, Medical University of Lublin, Lublin, Poland. FAU - Strojek, Krzysztof AU - Strojek K AD - Department of Internal Diseases, Diabetology, and Cardiometabolic Diseases, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland. FAU - Malecki, Maciej AU - Malecki M AD - Department of Metabolic Diseases, Jagiellonian University Medical College, Krakow, Poland. FAU - Naumnik, Beata AU - Naumnik B AD - Department of Nephrology and Transplantation with Dialysis Unit, Medical University of Bialystok, Bialystok, Poland. FAU - Krajewska, Magdalena AU - Krajewska M AD - Department of Nephrology and Transplantation Medicine, 4th Military Hospital, Faculty of Medicine, Wroclaw University of Science and Technology, Wroclaw, Poland. FAU - Kuczmik, Waclaw AU - Kuczmik W AD - Department of General, Vascular Surgery, Angiology, and Phlebology, Medical University of Silesia, Katowice, Poland. FAU - Wiewiora, Maciej AU - Wiewiora M AD - Department of General, Vascular Surgery, Angiology, and Phlebology, Medical University of Silesia, Katowice, Poland. FAU - Witkowski, Adam AU - Witkowski A AD - Department of Interventional Cardiology and Angiology, National Institute of Cardiology, Warszawa, Poland. LA - eng PT - Journal Article PT - Practice Guideline DEP - 20250311 PL - Poland TA - Kardiol Pol JT - Kardiologia polska JID - 0376352 SB - IM MH - Humans MH - *Atherosclerosis/therapy MH - Poland MH - Societies, Medical MH - Cardiology/standards MH - *Patient Care Team OTO - NOTNLM OT - LDL cholesterol OT - interdisciplinary management OT - multi-bed atherosclerosis EDAT- 2025/03/12 11:35 MHDA- 2025/05/07 06:27 CRDT- 2025/03/11 08:53 PHST- 2025/03/06 00:00 [received] PHST- 2025/03/06 00:00 [accepted] PHST- 2025/05/07 06:27 [medline] PHST- 2025/03/12 11:35 [pubmed] PHST- 2025/03/11 08:53 [entrez] AID - VM/OJS/J/105235 [pii] AID - 10.33963/v.phj.105235 [doi] PST - ppublish SO - Kardiol Pol. 2025;83(4):531-539. doi: 10.33963/v.phj.105235. Epub 2025 Mar 11. PMID- 40066797 OWN - NLM STAT- MEDLINE DCOM- 20260625 LR - 20260625 IS - 2532-5264 (Electronic) IS - 1122-0643 (Linking) VI - 96 IP - 2 DP - 2026 May 7 TI - Promoting effective teamwork in the cardiothoracic surgery department: strategies for success. LID - 10.4081/monaldi.2025.2977 [doi] AB - In daily practice, teamwork is of paramount importance within the healthcare settings, particularly in specialized fields such as cardiothoracic surgery. This is due to the fact that collaboration, communication, and synchronization play a vital role in ensuring successful patient outcomes. The aim of this paper is to propose strategies to promote effective teamwork within a cardiothoracic surgical setting, elaborating general teamwork principles and applicable concepts from healthcare. FAU - Aljanadi, Firas AU - Aljanadi F AUID- ORCID: 0000-0001-8654-5877 AD - Cardiothoracic Surgery Department, Royal Victoria Hospital, Belfast. LA - eng PT - Journal Article DEP - 20250310 PL - Italy TA - Monaldi Arch Chest Dis JT - Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace JID - 9307314 SB - IM MH - Humans MH - *Patient Care Team/organization & administration/standards MH - Cooperative Behavior MH - Leadership MH - *Thoracic Surgery/organization & administration MH - *Thoracic Surgical Procedures MH - Communication MH - Quality of Health Care OTO - NOTNLM OT - Teamwork OT - cardiothoracic OT - leadership OT - management OT - quality of care EDAT- 2025/03/12 11:34 MHDA- 2026/06/25 12:38 CRDT- 2025/03/11 06:54 PHST- 2024/03/06 00:00 [received] PHST- 2026/06/25 12:38 [medline] PHST- 2025/03/12 11:34 [pubmed] PHST- 2025/03/11 06:54 [entrez] AID - 10.4081/monaldi.2025.2977 [doi] PST - ppublish SO - Monaldi Arch Chest Dis. 2026 May 7;96(2). doi: 10.4081/monaldi.2025.2977. Epub 2025 Mar 10. PMID- 40064123 OWN - NLM STAT- MEDLINE DCOM- 20250512 LR - 20260829 IS - 1527-3288 (Electronic) IS - 0147-9563 (Linking) VI - 71 DP - 2025 May-Jun TI - A multidisciplinary transition of care approach to reduce 30-day readmissions in heart failure patients. PG - 76-80 LID - S0147-9563(25)00041-X [pii] LID - 10.1016/j.hrtlng.2025.03.001 [doi] AB - BACKGROUND: While advancements in pharmacologic and device therapies have improved survival, one in five adults with heart failure (HF) patients is readmitted within 30 days of discharge. Thus, the epidemic of HF is largely one of increasing hospitalizations. OBJECTIVE: To determine if a comprehensive HF program reduces 30-day readmission rate. METHODS: A convenience sample of adults with Medicare and HF (N = 1617) admitted to a large academic medical center were identified. Patients received HF education by a specialized registered nurse while inpatient and were seen by a pharmacist prior to discharge. Post-discharge, patients were called by a pharmacist within 72 h, followed by an ambulatory care manager for 90 days, and scheduled for a multidisciplinary clinic visit with a nurse practitioner within 7 days of hospitalization. High risk patients were referred to a community health worker (CHW). Clinic services included phlebotomy, education, point-of-care ultrasound, intravenous diuretic administration, and referrals to appropriate services. Data were analyzed descriptively. RESULTS: The 30-day readmission rate was 18.39 % (N = 930) during the intervention period compared to 22.71 % (N = 617) at baseline, resulting in a 4.32 % reduction, p value 0.0325. Approximately 40 percent of the patient cohort was over age 85. Pharmacy was able to contact greater than 86 % of patients post discharge. Only half of patients were agreeable to ambulatory care management. Less than half (42 %) of eligible patients were seen in the post-discharge clinic. The CHW supported approximately 146 patients in a 9-month period. CONCLUSIONS: A real-world comprehensive multidisciplinary team approach to the management of HF patients can reduce 30-day hospital readmissions. CI - Copyright (c) 2025 Elsevier Inc. All rights reserved. FAU - Craigo, Christina L AU - Craigo CL AD - Cedars Sinai Medical Center, 8700 Beverly Blvd, 5ST, Los Angeles, CA 90048, USA. Electronic address: Christina.Craigo@cshs.org. FAU - Dow, Claire M AU - Dow CM AD - Cedars Sinai Medical Center, 8700 Beverly Blvd, 5ST, Los Angeles, CA 90048, USA. Electronic address: Claire.Dow@cshs.org. FAU - Malkhasian, Yervant M AU - Malkhasian YM AD - Cedars Sinai Medical Center, 8700 Beverly Blvd, 5ST, Los Angeles, CA 90048, USA. Electronic address: Yervant.Malkhasian@cshs.org. FAU - Minissian, Margo B AU - Minissian MB AD - Cedars Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA 90048, USA. Electronic address: Margo.Minissian@cshs.org. FAU - Zadikany, Ronit AU - Zadikany R AD - 8501 Wilshire Blvd., Suite 200, Beverly Hills, CA 90211, USA. Electronic address: Ronit.Zadikany@cshs.org. FAU - Zimmer, Raymond AU - Zimmer R AD - 8501 Wilshire Blvd., Suite 200, Beverly Hills, CA 90211, USA. Electronic address: Raymond.Zimmer@cshs.org. LA - eng PT - Journal Article DEP - 20250309 PL - United States TA - Heart Lung JT - Heart & lung : the journal of critical care JID - 0330057 SB - IM MH - Humans MH - *Patient Readmission/statistics & numerical data/trends MH - *Heart Failure/therapy MH - Male MH - Female MH - Aged MH - *Patient Care Team/organization & administration MH - United States MH - Aged, 80 and over MH - *Transitional Care/organization & administration MH - Middle Aged MH - Time Factors MH - Retrospective Studies OTO - NOTNLM OT - Cardiac OT - Medicare OT - Nurse practitioner OT - Pharmacy OT - Transition of care COIS- Declaration of competing interest The authors report no conflicts of interest. No relationship with industry. EDAT- 2025/03/11 00:25 MHDA- 2025/03/28 00:24 CRDT- 2025/03/10 19:04 PHST- 2024/10/09 00:00 [received] PHST- 2025/01/31 00:00 [revised] PHST- 2025/03/04 00:00 [accepted] PHST- 2025/03/28 00:24 [medline] PHST- 2025/03/11 00:25 [pubmed] PHST- 2025/03/10 19:04 [entrez] AID - S0147-9563(25)00041-X [pii] AID - 10.1016/j.hrtlng.2025.03.001 [doi] PST - ppublish SO - Heart Lung. 2025 May-Jun;71:76-80. doi: 10.1016/j.hrtlng.2025.03.001. Epub 2025 Mar 9. PMID- 40062457 OWN - NLM STAT- MEDLINE DCOM- 20250310 LR - 20250702 IS - 1476-4954 (Electronic) IS - 1476-4954 (Linking) VI - 38 IP - 1 DP - 2025 Dec TI - Pregnancy in ACHD women: crucial role of multidisciplinary clinical roadmap. PG - 2470411 LID - 10.1080/14767058.2025.2470411 [doi] AB - PURPOSE: Pregnancy in women with adult congenital heart disease (ACHD), whether in its natural history or after surgical correction, represents a unique pathophysiological model that requires careful, multidisciplinary management to ensure favorable maternal, fetal and neonatal outcomes. Investigating the impact of congenital cardiac conditions on maternal and feto-neonatal health, the effect of pregnancy-related cardiovascular changes on maternal cardiac health, and the outcomes for offspring born from ACHD mothers is highly relevant, due to the increasing number of ACHD women reaching adulthood and the significant burden these pregnancies can pose. The aim of this article is to provide food for thought to those who have always been involved in ACHD and pregnancy, but also to provide a training tool for young doctors who are approaching at this wonderful world for the first time. MATERIALS AND METHODS: This article was conceived and structured as an "educational and debate". In this article we describe our experience in the ACHD outpatient clinic and the High-Risk Pregnancies Division of Fondazione Policlinico A. Gemelli Hospital IRCCS from 2013 and now includes over 100 patients evaluated over a 10-year period. RESULTS: In this article we describe our clinical pathway and the clinical history of our first patient, a 30-year-old woman with univentricular heart (criss-cross heart, double outlet right ventricle and pulmonary stenosis) who underwent a Glenn operation as a child. Our plan included scheduled cardiological and obstetrical follow-ups, as well as planned hospitalizations. An elective C-section was carried out at 38 gestational weeks under spinal anesthesia, with Extracorporeal Membrane Oxygenation and the heart surgery team stand by. It was an uncomplicated delivery. As a result, we developed a specific clinical pathway named "ACHD Pregnancy Pink Pathway." CONCLUSIONS: The strength of this idea dwells in the synergy between different experts in deciding for the best decision regarding the required monitoring strictness and the more appropriate obstetric surveillance and delivery plan for the patient. The lesson we learned over the years is that to ensure the best diagnosis and treatment for our young unique patients, we must create a detailed "ROADMAP" for them. We propose a pioneering pathway divided into the three essential phases: maternal, obstetrics and fetal-neonatal. FAU - Grandinetti, M AU - Grandinetti M AD - Dipartimento di Scienze Cardiovascolari, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma. AD - Dipartimento di Scienza cardiovascolari e Polmonari, Universita Cattolica del Sacro Cuore, Roma. FAU - Salvi, S AU - Salvi S AD - UOC di Ostetricia e Patologia Ostetrica, del bambino e di sanita Pubblica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma. AD - Dipartimento Universitario di Scienze della Vita e Sanita pubblica, sezione di Ginecologia ed ostetricia, Universita Cattolica del Sacro Cuore, Roma. FAU - Olimpieri, A AU - Olimpieri A AD - Dipartimento di Scienze Cardiovascolari, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma. AD - Dipartimento di Scienza cardiovascolari e Polmonari, Universita Cattolica del Sacro Cuore, Roma. FAU - Fruci, S AU - Fruci S AD - UOC di Ostetricia e Patologia Ostetrica, del bambino e di sanita Pubblica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma. AD - Dipartimento Universitario di Scienze della Vita e Sanita pubblica, sezione di Ginecologia ed ostetricia, Universita Cattolica del Sacro Cuore, Roma. FAU - Portinaro, E AU - Portinaro E AD - Dipartimento di Scienze Cardiovascolari, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma. AD - Dipartimento di Scienza cardiovascolari e Polmonari, Universita Cattolica del Sacro Cuore, Roma. FAU - Corigliano, K AU - Corigliano K AD - Dipartimento di Scienze Cardiovascolari, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma. FAU - Lillo, R AU - Lillo R AD - Dipartimento di Scienze Cardiovascolari, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma. AD - Dipartimento di Scienza cardiovascolari e Polmonari, Universita Cattolica del Sacro Cuore, Roma. FAU - Meucci, M C AU - Meucci MC AD - Dipartimento di Scienze Cardiovascolari, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma. AD - Dipartimento di Scienza cardiovascolari e Polmonari, Universita Cattolica del Sacro Cuore, Roma. FAU - Graziani, F AU - Graziani F AD - Dipartimento di Scienze Cardiovascolari, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma. AD - Dipartimento di Scienza cardiovascolari e Polmonari, Universita Cattolica del Sacro Cuore, Roma. FAU - Delogu, A B AU - Delogu AB AD - UOC di Pediatria, del bambino e di sanita Pubblica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma. AD - Dipartimento di Pediatria, Universita Cattolica del Sacro Cuore, Roma. FAU - Narducci, M L AU - Narducci ML AD - Dipartimento di Scienze Cardiovascolari, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma. AD - Dipartimento di Scienza cardiovascolari e Polmonari, Universita Cattolica del Sacro Cuore, Roma. FAU - De Carolis, S AU - De Carolis S AD - UOC di Ostetricia e Patologia Ostetrica, del bambino e di sanita Pubblica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma. AD - Dipartimento Universitario di Scienze della Vita e Sanita pubblica, sezione di Ginecologia ed ostetricia, Universita Cattolica del Sacro Cuore, Roma. FAU - Vento, G AU - Vento G AD - UOC di Pediatria, del bambino e di sanita Pubblica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma. AD - Dipartimento di Pediatria, Universita Cattolica del Sacro Cuore, Roma. AD - Universita Cattolica del Sacro Cuore, Roma. FAU - Arduini, D AU - Arduini D AD - Universita Cattolica del Sacro Cuore, Roma. FAU - Amodeo, A AU - Amodeo A AD - Dipartimento di Scienze Cardiovascolari, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma. AD - Dipartimento di Scienza cardiovascolari e Polmonari, Universita Cattolica del Sacro Cuore, Roma. AD - Universita Cattolica del Sacro Cuore, Roma. FAU - Lanzone, A AU - Lanzone A AD - UOC di Ostetricia e Patologia Ostetrica, del bambino e di sanita Pubblica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma. AD - Universita Cattolica del Sacro Cuore, Roma. FAU - Massetti, M AU - Massetti M AD - Dipartimento di Scienze Cardiovascolari, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma. AD - Dipartimento di Scienza cardiovascolari e Polmonari, Universita Cattolica del Sacro Cuore, Roma. AD - Universita Cattolica del Sacro Cuore, Roma. LA - eng PT - Journal Article DEP - 20250310 PL - England TA - J Matern Fetal Neonatal Med JT - The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians JID - 101136916 SB - IM MH - Adult MH - Female MH - Humans MH - Pregnancy MH - *Critical Pathways MH - *Heart Defects, Congenital/surgery/therapy MH - Patient Care Team MH - *Pregnancy Complications, Cardiovascular/therapy OTO - NOTNLM OT - ACHD OT - Pregnancy OT - cardiovascular OT - multidisciplinary OT - obstetrics EDAT- 2025/03/10 12:32 MHDA- 2025/03/10 12:33 CRDT- 2025/03/10 07:13 PHST- 2025/03/10 12:33 [medline] PHST- 2025/03/10 12:32 [pubmed] PHST- 2025/03/10 07:13 [entrez] AID - 10.1080/14767058.2025.2470411 [doi] PST - ppublish SO - J Matern Fetal Neonatal Med. 2025 Dec;38(1):2470411. doi: 10.1080/14767058.2025.2470411. Epub 2025 Mar 10. PMID- 40061172 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250311 IS - 2432-7026 (Electronic) IS - 2432-7026 (Linking) VI - 8 IP - 1 DP - 2025 Feb 25 TI - Integrated Pediatric Intensive Care and Hematopoietic Stem Cell Transplantation Service Improves The Peri-Transplant Survival In Children. PG - 173-180 LID - 10.31547/bct-2024-014 [doi] AB - BACKGROUND: Peri-transplant is a critical period which is associated with a myriad of complications that require pediatric intensive care unit (PICU) referral. PICU outcomes have been historically poor post-hematopoietic stem cell transplantation (HSCT), especially when associated with inotrope support, invasive ventilation, and renal replacement therapy. The study aimed to assess the outcomes of PICU referral in children undergoing HSCT. PATIENTS & METHODS: A retrospective analysis was performed of children between 1 to 18 years of age who underwent HSCT between 2016 to 2023. A clinical deteriorating event (CDE) was defined as an unplanned transfer to the intensive care unit (ICU) or requiring ICU-level intervention on the floor. The reason for PICU referral, place of intervention, cause for the CDE, and requirement of respiratory, renal, and cardiac support were noted. The study period was divided into two 4-year intervals to assess change over time, 2016-2019 and 2020-2023. RESULTS: In an eight-year period, a total of 934 HSCTs were performed, with 272 patients requiring PICU referral. A total of 415 CDEs were recorded. CDEs for PICU referrals were hypotension (43%), disproportionate tachycardia (42%), respiratory distress (26%), hypertension (22%), altered sensorium (8%), seizures (7.4%), and major bleeds (7.3%). Overall peri-transplant survival was 73.8% (n=201/272). Comparing the two study intervals, 2016-2019 and 2020-2023, the survival of patients on mechanical ventilation had improved from 4.5% to 27.5% (p=0.005) and from 39.4% to 55.9% (p=0.11) among those who received inotropes. Patients with three organ dysfunctions had worse outcomes. Disproportionate tachycardia [OR 0.19 CI 95% (0.06-0.64); p=0.008], hypotension [OR 0.177 CI 95% (0.04-0.84); p=0.029] and acute GVHD [OR 28.46 CI 95% (3.66-221); p=0.001] were significant risk factors for peri-transplant mortality as per multivariate analysis. CONCLUSION: Integrated care with the PICU team is the first step towards improving survival in these critically ill children. With timely intervention on the floors for CDEs and protocol-driven care in the PICU, we have demonstrated an increase in overall survival over the past four years and would recommend similar team-based care for units catering to children. CI - Copyright Ⓒ2025 Asia-Pacific Blood and Marrow Transplantation Group (APBMT). FAU - Reddy, Nalla Anuraag AU - Reddy NA AD - Department of Paediatric Haematology, Oncology; Blood & Marrow Transplants, Apollo Cancer Centres, Teynampet, Chennai, India. FAU - Mehta, Rachit AU - Mehta R AD - Department of Paediatric Intensive Care, Apollo Cancer Centres, Teynampet, Chennai, India. FAU - Jayakumar, Indira AU - Jayakumar I AD - Department of Paediatric Intensive Care, Apollo Cancer Centres, Teynampet, Chennai, India. FAU - Nair, Anupama AU - Nair A AD - Department of Paediatric Haematology, Oncology; Blood & Marrow Transplants, Apollo Cancer Centres, Teynampet, Chennai, India. FAU - Muthukumar, Vijayshree AU - Muthukumar V AD - Department of Paediatric Haematology, Oncology; Blood & Marrow Transplants, Apollo Cancer Centres, Teynampet, Chennai, India. FAU - Duraisamy, Suresh AU - Duraisamy S AD - Department of Paediatric Haematology, Oncology; Blood & Marrow Transplants, Apollo Cancer Centres, Teynampet, Chennai, India. FAU - Swaminathan, Venkateswaran Vellaichamy AU - Swaminathan VV AD - Department of Paediatric Haematology, Oncology; Blood & Marrow Transplants, Apollo Cancer Centres, Teynampet, Chennai, India. FAU - Uppuluri, Ramya AU - Uppuluri R AD - Department of Paediatric Haematology, Oncology; Blood & Marrow Transplants, Apollo Cancer Centres, Teynampet, Chennai, India. FAU - Raj, Revathi AU - Raj R AD - Department of Paediatric Haematology, Oncology; Blood & Marrow Transplants, Apollo Cancer Centres, Teynampet, Chennai, India. LA - eng PT - Journal Article DEP - 20250225 PL - Japan TA - Blood Cell Ther JT - Blood cell therapy JID - 9918333884906676 PMC - PMC11883477 OTO - NOTNLM OT - HSCT OT - PICU OT - children OT - outcome OT - survival COIS- The authors declare no conflict of interest. Disclosure forms provided by the authors are available on the website. EDAT- 2025/03/10 17:19 MHDA- 2025/03/10 17:20 PMCR- 2025/02/25 CRDT- 2025/03/10 06:30 PHST- 2024/07/04 00:00 [received] PHST- 2024/12/09 00:00 [accepted] PHST- 2025/03/10 17:20 [medline] PHST- 2025/03/10 17:19 [pubmed] PHST- 2025/03/10 06:30 [entrez] PHST- 2025/02/25 00:00 [pmc-release] AID - 10.31547/bct-2024-014 [doi] PST - epublish SO - Blood Cell Ther. 2025 Feb 25;8(1):173-180. doi: 10.31547/bct-2024-014. eCollection 2025 Feb 25. PMID- 40060208 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250311 IS - 2589-790X (Electronic) IS - 2589-790X (Linking) VI - 7 IP - 2 DP - 2025 Feb TI - Implementation of a Multidisciplinary Cardiogenic Shock Team in a Nonacademic Canadian Heart Centre: An Implementation Study. PG - 231-238 LID - 10.1016/j.cjco.2024.11.007 [doi] AB - BACKGROUND: In this study we evaluated our ability to implement team-based cardiogenic shock (CS-Team), focussing on: 1) early screening; 2) CS-Team activation; and 3) use of invasive monitoring to guide therapy. METHODS: All patients admitted to the coronary care unit (CCU) over 12 months were screened for CS. A diagnosis of CS was made when both hypotension and hypoperfusion were present. The CS-Team was composed of the CCU attending, an interventional cardiologist, and a cardiac surgeon. Multivariate analysis was carried out with mortality as the outcome of interest. RESULTS: Screening was documented in 74% (1160 of 1562) of patients admitted to a critical care unit; of these, 1080 were not in CS. We identified 80 patients in CS (Society for Cardiovascular Angiography & Interventions [SCAI] stages C-E), which represented 6.9% of all screened patients. Patients in CS had significantly higher in-hospital mortality (35% vs 2%, P < 0.0001). CS-Team was activated in 35 of 80 patients (44%). CS-Team activation resulted in significantly greater use of invasive monitoring (pulmonary artery catheter [49% vs 7%, P < 0.0001], cardiac catheterization [94% vs 76%, P < 0.032], and mechanical circulatory support [51% vs 2%, P < 0.001]). Independent predictors of mortality were severity of CS (SCAI grades D or E) (odds ratio [OR] 18.78, 95% confidence interval [CI] 4.89-96.65) and age, in years (OR 1.07, 95% CI 1.01-1.14), whereas CS-Team was not predictive of mortality (OR 0.66, 95% CI 0.16-2.41). CONCLUSIONS: We found that: 1) early screening by frontline staff was feasible but had limitations (26% screening failure); 2) CS-Team activation appeared discretionary (limited activation to 45% of patients); and 3) CS-Team activation resulted in a significant increase in the use of invasive monitoring that helped guide therapy. CI - (c) 2024 The Authors. FAU - El-Mughayyar, Dana AU - El-Mughayyar D AD - New Brunswick Heart Centre, Saint John, New Brunswick, Canada. AD - Dalhousie Medicine New Brunswick, Saint John, New Brunswick, Canada. AD - IMPART Investigator Team Canada, Saint John, New Brunswick, Canada. FAU - Marshall, Terrel AU - Marshall T AD - Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada. FAU - D'Souza, Kenneth AU - D'Souza K AD - New Brunswick Heart Centre, Saint John, New Brunswick, Canada. AD - Dalhousie Medicine New Brunswick, Saint John, New Brunswick, Canada. AD - IMPART Investigator Team Canada, Saint John, New Brunswick, Canada. FAU - MacLeod, Jeffrey B AU - MacLeod JB AD - New Brunswick Heart Centre, Saint John, New Brunswick, Canada. AD - IMPART Investigator Team Canada, Saint John, New Brunswick, Canada. FAU - McCoy, Amanda AU - McCoy A AD - New Brunswick Heart Centre, Saint John, New Brunswick, Canada. FAU - Morris, Susan AU - Morris S AD - New Brunswick Heart Centre, Saint John, New Brunswick, Canada. FAU - Smith, Meaghan AU - Smith M AD - New Brunswick Heart Centre, Saint John, New Brunswick, Canada. FAU - White, Christopher W AU - White CW AD - New Brunswick Heart Centre, Saint John, New Brunswick, Canada. AD - Dalhousie Medicine New Brunswick, Saint John, New Brunswick, Canada. FAU - Sarkar, Shreya AU - Sarkar S AD - New Brunswick Heart Centre, Saint John, New Brunswick, Canada. AD - Dalhousie Medicine New Brunswick, Saint John, New Brunswick, Canada. FAU - Brunt, Keith R AU - Brunt KR AD - Dalhousie Medicine New Brunswick, Saint John, New Brunswick, Canada. AD - IMPART Investigator Team Canada, Saint John, New Brunswick, Canada. FAU - Legare, Jean-Francois AU - Legare JF AD - New Brunswick Heart Centre, Saint John, New Brunswick, Canada. AD - Dalhousie Medicine New Brunswick, Saint John, New Brunswick, Canada. AD - IMPART Investigator Team Canada, Saint John, New Brunswick, Canada. LA - eng PT - Journal Article DEP - 20241117 PL - United States TA - CJC Open JT - CJC open JID - 101763635 PMC - PMC11886362 EDAT- 2025/03/10 17:18 MHDA- 2025/03/10 17:19 PMCR- 2024/11/17 CRDT- 2025/03/10 06:18 PHST- 2024/09/20 00:00 [received] PHST- 2024/11/08 00:00 [revised] PHST- 2024/11/11 00:00 [accepted] PHST- 2025/03/10 17:19 [medline] PHST- 2025/03/10 17:18 [pubmed] PHST- 2025/03/10 06:18 [entrez] PHST- 2024/11/17 00:00 [pmc-release] AID - S2589-790X(24)00527-4 [pii] AID - 10.1016/j.cjco.2024.11.007 [doi] PST - epublish SO - CJC Open. 2024 Nov 17;7(2):231-238. doi: 10.1016/j.cjco.2024.11.007. eCollection 2025 Feb. PMID- 40057297 OWN - NLM STAT- MEDLINE DCOM- 20260130 LR - 20260808 IS - 1556-3871 (Electronic) IS - 1547-5271 (Linking) VI - 23 IP - 2 DP - 2026 Feb TI - Adherence to CPAP for patients with atrial fibrillation undergoing catheter ablation: A "real-world" analysis. PG - 349-355 LID - S1547-5271(25)00382-0 [pii] LID - 10.1016/j.hrthm.2025.03.163 [doi] AB - BACKGROUND: The relationship between obstructive sleep apnea (OSA) and atrial fibrillation (AF) is well established, as the existing literature has concluded that sleep apnea creates a unique, complex, and dynamic substrate for AF with various pathophysiological mechanisms. Little is known about the role of continuous positive airway pressure (CPAP) therapy in reversing the risk of AF recurrence in patients with OSA. Awareness of the therapeutic effects of CPAP in preventing AF recurrence postablation will help create a multidisciplinary team of doctors to treat this complex population of patients. OBJECTIVES: The goals of this study were to examine the effect of CPAP adherence on AF-free survival post-catheter ablation and to identify the indicated average CPAP use to maximize AF-free survival postablation. METHODS: We selected 190 consecutive patients who underwent catheter ablation for AF at Lenox Hill Hospital in New York and who had a concurrent diagnosis of OSA. In this retrospective case-control study, 97 (51%) patients with OSA adherent to CPAP use were carefully matched with 93 (49%) patients who were not adherent to CPAP guidelines for patients with OSA. RESULTS: The mean age of the population was 66.3 +/- 9.4 years, and 78% were male. Patients in the adherent group had a recurrence rate of 24% until their last follow-up visit compared with 42% in the nonadherent group (P=.02). In a stepwise multivariate regression model, adherence to CPAP was independently associated with lower chances of composite AF recurrence with an odds ratio of 0.24 (CI 95% = 0.08-0.68; P = .007). Using the receiver operating characteristic curve, we identified the optimal average nightly CPAP duration required to observe a clinical benefit and reperformed the above analysis. With a new cutoff set at 287 minutes of CPAP per night, the adjusted odds ratio for AF recurrence was 0.17 (CI 95% = 0.12-0.71; P=.004). In a secondary analysis, patients who were not adherent to optimal CPAP use did not show any benefit compared with patients who did not use CPAP at all (56% vs 59%; P = .75). CONCLUSION: Consistent nightly CPAP use offers a 3-year AF-free survival postablation in 1 of 5 patients with OSA who undergo ablation for AF. Inconsistent CPAP use, defined as <287 minutes per night, offers no benefit compared with no CPAP. CI - Copyright (c) 2025 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved. FAU - Varrias, Dimitrios AU - Varrias D AD - Northwell Cardiovascular Institute, New Hyde Park, New York; Lenox Hill Hospital, New York, New York. FAU - Kossack, Andrew AU - Kossack A AD - Northwell Cardiovascular Institute, New Hyde Park, New York. FAU - Leavitt, Jonas AU - Leavitt J AD - Northwell Cardiovascular Institute, New Hyde Park, New York; Lenox Hill Hospital, New York, New York. FAU - Chhetri, Chandra AU - Chhetri C AD - Northwell Cardiovascular Institute, New Hyde Park, New York. FAU - Roselli, Victoria AU - Roselli V AD - Lenox Hill Hospital, New York, New York; Northwell Lung Institute, New York City, New York. FAU - Velichkovikj, Sara AU - Velichkovikj S AD - Lenox Hill Hospital, New York, New York; Northwell Lung Institute, New York City, New York. FAU - Altschul, Erica AU - Altschul E AD - Lenox Hill Hospital, New York, New York; Northwell Lung Institute, New York City, New York. FAU - Bhasin, Kabir AU - Bhasin K AD - Northwell Cardiovascular Institute, New Hyde Park, New York; Lenox Hill Hospital, New York, New York. FAU - Mina, Bushra AU - Mina B AD - Lenox Hill Hospital, New York, New York; Northwell Lung Institute, New York City, New York. FAU - Oks, Margarita AU - Oks M AD - Lenox Hill Hospital, New York, New York; Northwell Lung Institute, New York City, New York. FAU - Coleman, Kristie M AU - Coleman KM AD - Northwell Cardiovascular Institute, New Hyde Park, New York; Lenox Hill Hospital, New York, New York. FAU - Mountantonakis, Stavros E AU - Mountantonakis SE AD - Northwell Cardiovascular Institute, New Hyde Park, New York; Lenox Hill Hospital, New York, New York. Electronic address: smountanto@northwell.edu. LA - eng PT - Journal Article DEP - 20250306 PL - United States TA - Heart Rhythm JT - Heart rhythm JID - 101200317 SB - IM MH - Humans MH - *Atrial Fibrillation/surgery/complications/physiopathology MH - Male MH - *Continuous Positive Airway Pressure/methods MH - Female MH - *Catheter Ablation/methods MH - *Sleep Apnea, Obstructive/therapy/complications MH - Retrospective Studies MH - Aged MH - *Patient Compliance/statistics & numerical data MH - Recurrence MH - Middle Aged MH - Follow-Up Studies MH - Treatment Outcome OTO - NOTNLM OT - Ablation OT - Adherence OT - Atrial fibrillation OT - CPAP OT - OSA OT - Recurrence COIS- Disclosures The authors have no conflicts of interest to disclose. EDAT- 2025/03/09 15:10 MHDA- 2026/01/31 00:29 CRDT- 2025/03/08 19:20 PHST- 2024/12/06 00:00 [received] PHST- 2025/02/14 00:00 [revised] PHST- 2025/03/01 00:00 [accepted] PHST- 2026/01/31 00:29 [medline] PHST- 2025/03/09 15:10 [pubmed] PHST- 2025/03/08 19:20 [entrez] AID - S1547-5271(25)00382-0 [pii] AID - 10.1016/j.hrthm.2025.03.163 [doi] PST - ppublish SO - Heart Rhythm. 2026 Feb;23(2):349-355. doi: 10.1016/j.hrthm.2025.03.163. Epub 2025 Mar 6. PMID- 40051776 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250308 IS - 2641-2225 (Electronic) IS - 2641-2225 (Linking) VI - 6 IP - 2 DP - 2024 Summer TI - Predictive Analytics in Cardiothoracic Care: Enhancing Outcomes with the Healthcare Enabled by Artificial Intelligence in Real Time (HEART) Project. LID - 11 [pii] LID - 10.46804/2641-2225.1195 [doi] AB - PROBLEM: Postoperative complications after cardiac surgery significantly impact both the short-term and long-term survival of patients. Cardiovascular diseases are a major health concern, accounting for 12% of health expenditures in the United States. A substantial number of patients with cardiovascular disease undergo invasive procedures, including cardiac surgery, and the incidence of postoperative complications is notable. This information underscores the need to effectively prevent postoperative adverse events to improve outcomes, reduce morbidity, shorten hospital stays, and lower health care costs. APPROACH: The Healthcare Enabled by Artificial Intelligence in Real Time (HEART) project is a collaborative effort involving clinicians from MaineHealth, industry experts from Nihon Kohden, and data scientists from the Roux Institute. The project aims to develop a real-time predictive analytics model as a decision support tool for clinicians in the cardiothoracic intensive care unit who care for patients after cardiac surgery. The team is using a supervised, closed-loop, machine learning design to train the model. The initiative involves collecting static and dynamic preoperative, intraoperative, and postoperative variables from a cohort of patients undergoing cardiac surgery at Maine Medical Center. These variables, including data on blood product transfusions and inotropic and vasoactive medications administered, are being transmitted from the electronic health record to a data warehouse. The model will predict the following adverse outcomes: acute kidney injury, renal failure, new onset postoperative atrial fibrillation, prolonged ventilation, reoperation, operative mortality, delirium, stroke, deep sternal wound infection, and extended hospital length of stay. OUTCOMES: The HEART team successfully established a data-collecting infrastructure. Data collection and validation are ongoing, with an emphasis on accuracy and completeness. NEXT STEPS: The project will advance by developing a user-friendly, real-time interface, incorporating feedback from clinicians in the operating room and cardiothoracic intensive care unit to ensure practicality and acceptance of the technology. This interface will provide adverse outcome predictions in real time, support clinical decision-making, and become a regular part of patient care. FAU - Mazhude, Felistas AU - Mazhude F AD - Department of Cardiovascular Services, MaineHealth Maine Medical Center, Portland, Maine. FAU - Kramer, Robert S AU - Kramer RS AD - Department of Cardiovascular Services, MaineHealth Maine Medical Center, Portland, Maine. FAU - Hicks, Anne AU - Hicks A AD - Department of Anesthesiology and Perioperative Medicine, MaineHealth Maine Medical Center, Portland, Maine. FAU - Jin, Qingchu AU - Jin Q AD - Life Sciences and Medical Research Team, The Roux Institute at Northeastern University, Portland, Maine. FAU - Tory, Melanie AU - Tory M AD - College Arts, Media and Design, The Roux Institute at Northeastern University, Portland, Maine. AD - Khoury College of Computer Sciences, The Roux Institute at Northeastern University, Portland, Maine. FAU - Rabb, Jaime B AU - Rabb JB AD - Department of Cardiovascular Services, MaineHealth Maine Medical Center, Portland, Maine. FAU - Nourani, Mahsan AU - Nourani M AD - Khoury College of Computer Sciences, The Roux Institute at Northeastern University, Portland, Maine. FAU - Sawyer, Douglas B AU - Sawyer DB AD - Department of Cardiovascular Services, MaineHealth Maine Medical Center, Portland, Maine. AD - MaineHealth Institute for Research, Portland, Maine. FAU - Winslow, Raimond L AU - Winslow RL AD - College of Engineering, The Roux Institute at Northeastern University, Portland, Maine. AD - Khoury College of Computer Sciences, The Roux Institute at Northeastern University, Portland, Maine. AD - Bouve College of Health Sciences, The Roux Institute at Northeastern University, Portland, Maine. LA - eng GR - P20 GM139745/GM/NIGMS NIH HHS/United States GR - UM1 HL147371/HL/NHLBI NIH HHS/United States PT - Journal Article DEP - 20240930 PL - United States TA - J Maine Med Cent JT - Journal of Maine Medical Center JID - 9918315986306676 PMC - PMC11883866 MID - NIHMS2059197 OTO - NOTNLM OT - Cardiac surgical procedures OT - Clinical decision support systems OT - Forecasting machine learning OT - Postoperative complications EDAT- 2025/03/07 06:22 MHDA- 2025/03/07 06:23 PMCR- 2025/03/06 CRDT- 2025/03/07 04:20 PHST- 2025/03/07 06:23 [medline] PHST- 2025/03/07 06:22 [pubmed] PHST- 2025/03/07 04:20 [entrez] PHST- 2025/03/06 00:00 [pmc-release] AID - 11 [pii] AID - 10.46804/2641-2225.1195 [doi] PST - ppublish SO - J Maine Med Cent. 2024 Summer;6(2):11. doi: 10.46804/2641-2225.1195. Epub 2024 Sep 30. PMID- 40050877 OWN - NLM STAT- MEDLINE DCOM- 20250511 LR - 20250527 IS - 2047-783X (Electronic) IS - 0949-2321 (Print) IS - 0949-2321 (Linking) VI - 30 IP - 1 DP - 2025 Mar 6 TI - Application of family-centered care in cardiac surgery: a scoping review. PG - 156 LID - 10.1186/s40001-025-02415-8 [doi] LID - 156 AB - BACKGROUND: Family-centered care (FCC) has been widely implemented in various medical settings, its application in cardiac surgery remains underexplored. Given the complexity of cardiac surgery and the significant impact on both patients and families, understanding FCC's role in this context is essential to improving patient outcomes and family well-being. OBJECTIVES: To identify the current state of the application of FCC in the families of cardiac surgery. METHODS: This study followed Arksey and O'Malley's methodology and the PRISMA extension for Scoping Reviews. A systematic search was conducted across ten databases between July and August 2024. Two researchers independently retrieved literature, extracted data, and cross-checked findings following predefined inclusion and exclusion criteria. The results were organized and synthesized using a structured spreadsheet. RESULTS: A total of 23 studies were included, 95.65% of which were quantitative, spanning nine countries. FCC interventions focused on collaboration, communication, negotiation, and support, primarily delivered by healthcare professionals. The main intervention formats were training sessions (100.00%), written materials (71.43%), and visual media (42.86%). FCC was linked to improved psychological well-being and greater satisfaction, with anxiety (52.38%) being the most commonly assessed outcome using validated scales. Qualitative findings highlighted the importance of FCC in patient recovery, emphasizing the need for systematic support to alleviate caregiving burden. CONCLUSIONS: This scoping review highlights the core characteristics and interventions of FCC for cardiac surgery patients, emphasizing the need for a multidisciplinary approach. While FCC has shown benefits in improving emotional well-being and satisfaction, there is a lack of robust longitudinal studies and objective outcome measures. Future research should focus on interactive, personalized interventions, integrate technology, and include a broader range of outcome indicators to better assess FCC's clinical effectiveness. CI - (c) 2025. The Author(s). FAU - Zhang, Duo AU - Zhang D AD - Department of Nursing, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. FAU - Zheng, Haoyang AU - Zheng H AD - Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. FAU - Gan, Yong AU - Gan Y AD - Department of Social Medicine and Health Management, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. FAU - Chai, Xichen AU - Chai X AD - Department of Traditional Chinese Medicine, Peking University Third Hospital, Beijing, China. FAU - Zeng, Ying AU - Zeng Y AD - Department of Nursing, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. FAU - Yu, Xiaoyan AU - Yu X AD - Department of Nursing, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. FAU - Cheng, Wencan AU - Cheng W AD - School of Nursing, Sun Yat-Sen University, Guangzhou, Guangdong, China. FAU - Zhao, Ya AU - Zhao Y AD - Department of Nursing, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. FAU - Chen, Zelin AU - Chen Z AD - Department of Virology, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan. FAU - Zhou, Yanrong AU - Zhou Y AD - Department of Nursing, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. 1002406585@qq.com. LA - eng GR - 2024D30/Huazhong University of science and technology/ GR - 2023C09/Huazhong University of science and technology/ GR - HL202309/Huazhong University of science and technology/ GR - WJ2023M007/Hubei Provincial Health Commission/ GR - CMAPH-NRI2022063/Chinese Medical Association Publishing House/ PT - Journal Article PT - Scoping Review DEP - 20250306 PL - England TA - Eur J Med Res JT - European journal of medical research JID - 9517857 SB - IM MH - Humans MH - *Cardiac Surgical Procedures/psychology MH - *Family/psychology MH - *Patient-Centered Care PMC - PMC11887250 OTO - NOTNLM OT - Cardiac surgery OT - Family-centered care OT - Scoping review COIS- Declarations. Ethics approval and consent to participate: This scoping review used data from published studies, and thus, ethical approval and consent to participate were not required. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2025/03/07 00:21 MHDA- 2025/03/07 06:22 PMCR- 2025/03/06 CRDT- 2025/03/06 23:42 PHST- 2024/11/26 00:00 [received] PHST- 2025/02/27 00:00 [accepted] PHST- 2025/03/07 06:22 [medline] PHST- 2025/03/07 00:21 [pubmed] PHST- 2025/03/06 23:42 [entrez] PHST- 2025/03/06 00:00 [pmc-release] AID - 10.1186/s40001-025-02415-8 [pii] AID - 2415 [pii] AID - 10.1186/s40001-025-02415-8 [doi] PST - epublish SO - Eur J Med Res. 2025 Mar 6;30(1):156. doi: 10.1186/s40001-025-02415-8. PMID- 40050766 OWN - NLM STAT- MEDLINE DCOM- 20250307 LR - 20250527 IS - 1471-2415 (Electronic) IS - 1471-2415 (Linking) VI - 25 IP - 1 DP - 2025 Mar 6 TI - Is there an association between retinal vein occlusion and cerebrovascular accident? A systematic review and meta-analysis. PG - 112 LID - 10.1186/s12886-025-03944-w [doi] LID - 112 AB - BACKGROUND: Retinal vein occlusion (RVO) is a significant retinal vascular disorder that has been hypothesized to increase the risk of cerebrovascular accidents (CVA). Given the shared vascular pathology between the retina and cerebral circulation, understanding the association between RVO and stroke incidence is critical for early intervention and risk management. This systematic review and meta-analysis aim to evaluate the risk of CVA, including ischemic and hemorrhagic subtypes, in patients with RVO. METHODS: This study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and was registered in PROSPERO (CRD42024557820). A systematic search of PubMed, Cochrane Library, Scopus, Web of Science, and Embase was conducted from inception to February 2025. Studies assessing the incidence of CVA post-RVO in adult patients (>/= 18 years) were included. Two independent reviewers performed study selection, data extraction, and quality assessment using the Cochrane Risk of Bias tool for Non-Randomized studies (ROBINS-I) was used for observational cohort studies. Meta-analysis was conducted using Comprehensive Meta-Analysis (CMA) software version 3.7, applying a fixed-effects model for low heterogeneity. Subgroup and sensitivity analyses were performed based on RVO type (BRVO vs. CRVO) and stroke subtype (ischemic vs. hemorrhagic CVA). Publication bias was evaluated using Egger's test and funnel plots. RESULTS: A total of 14 studies (n = 97,812 patients) were included. The pooled event rate for CVA post-RVO was 37.5% (95% CI: 37.3%-37.8%), with no significant heterogeneity (I(2) = 0%, p = 0.97). Subgroup analysis showed that both ischemic CVA (37.8%; 95% CI: 37.3%-38.3%) and hemorrhagic CVA (32.7%; 95% CI: 32.3%-33.1%) occurred at similar rates across branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO). The mortality rate post-CVA in RVO patients was 69.0% (95% CI: 68.4%-69.5%), highlighting the severity of stroke outcomes in this population. The incidence of ischemic cardiovascular events, including myocardial infarction, was 15.7% (95% CI: 15.4%-16.0%), reinforcing the need for cardiovascular monitoring in RVO patients. The incidence of deep vein thrombosis (DVT) was relatively low (0.05%) but still warrants clinical attention in high-risk populations. Publication bias was minimal, as confirmed by Egger's test (p > 0.24) and funnel plot symmetry. Sensitivity analyses confirmed the robustness of the pooled estimates. CONCLUSION: This meta-analysis provides strong evidence linking RVO to an increased risk of CVA and mortality. Given the high incidence of stroke (37.5%) and mortality post-CVA (69%), early cardiovascular risk assessment and intervention are crucial. Patients with RVO should undergo comprehensive vascular risk evaluation, including blood pressure control, lipid regulation, and anticoagulation therapy when indicated. The findings support a multidisciplinary approach involving ophthalmologists, neurologists, and cardiologists for proactive stroke prevention strategies in RVO patients. Future research should explore genetic predispositions, inflammatory markers, and AI-based predictive models to improve early risk stratification and intervention. CI - (c) 2025. The Author(s). FAU - Chen, Kai-Yang AU - Chen KY AD - School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan. FAU - Chan, Hoi-Chun AU - Chan HC AD - School of Pharmacy, China Medical University, Taichung, Taiwan. FAU - Chan, Chi-Ming AU - Chan CM AD - Department of Ophthalmology, Cardinal Tien Hospital, New Taipei City, Taiwan. m212092001@tmu.edu.tw. AD - School of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan. m212092001@tmu.edu.tw. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20250306 PL - England TA - BMC Ophthalmol JT - BMC ophthalmology JID - 100967802 SB - IM MH - Humans MH - *Retinal Vein Occlusion/complications MH - *Stroke/epidemiology/etiology MH - Incidence MH - Risk Factors PMC - PMC11887117 OTO - NOTNLM OT - Cardiovascular risk OT - Cerebrovascular accident OT - Hemorrhagic stroke OT - Ischemic stroke OT - Meta-analysis OT - Mortality OT - Retinal vein occlusion COIS- Declarations. Ethics approval and consent to participate: Not applicable. This study does not involve human participants, human data or human tissue. Consent for publication: Not applicable. This study does not involve individual data. Competing interests: The authors declare no competing interests. EDAT- 2025/03/07 00:21 MHDA- 2025/03/07 06:21 PMCR- 2025/03/06 CRDT- 2025/03/06 23:36 PHST- 2025/01/07 00:00 [received] PHST- 2025/02/24 00:00 [accepted] PHST- 2025/03/07 06:21 [medline] PHST- 2025/03/07 00:21 [pubmed] PHST- 2025/03/06 23:36 [entrez] PHST- 2025/03/06 00:00 [pmc-release] AID - 10.1186/s12886-025-03944-w [pii] AID - 3944 [pii] AID - 10.1186/s12886-025-03944-w [doi] PST - epublish SO - BMC Ophthalmol. 2025 Mar 6;25(1):112. doi: 10.1186/s12886-025-03944-w. PMID- 40046036 OWN - NLM STAT- MEDLINE DCOM- 20250511 LR - 20250511 IS - 1532-2807 (Electronic) IS - 1219-4956 (Print) IS - 1219-4956 (Linking) VI - 31 DP - 2025 TI - Management and surveillance of metastatic giant cell tumour of bone. PG - 1611916 LID - 10.3389/pore.2025.1611916 [doi] LID - 1611916 AB - Giant cell tumour of bone (GCTB) is viewed as a benign, locally aggressive primary bone tumour with metastatic potential. Current management is surgery with bone curettage or resection and systemic therapy with denosumab. Diagnosis is confirmed histologically prior to surgery, with staging for pulmonary disease, as pulmonary metastases (PM) reportedly occur in <8%. This study aimed to assess incidence, surveillance and management of PM in patients with GCTB, with histopathological review. A retrospective audit of the Oxford bone tumour registry was performed from January 2014 - October 2023. Inclusion criterion was histological confirmation of GCTB. Exclusion criteria were incomplete medical, imaging or histology records, or referral for secondary MDT opinion for diagnosis. From an initial group of 126 GCTB patients, 83 patients met the full selection criteria. Pulmonary metastases were identified in 11 patients. Three with PM were excluded on histopathological review as being giant cell rich osteosarcoma rather than metastatic GCTB. This left 8 (9.6%) patients, one had PM at presentation and seven at follow-up between 2 and 42 months. Two were histologically confirmed after cardiothoracic surgery and biopsy, six radiologically diagnosed. Three (37.5%) patients with PM have died (between 1 and 12 months after confirmed PM), five are alive with stable disease. Seven (87.5%) of patients with pulmonary disease were treated with denosumab/chemotherapy (three before, four after pulmonary diagnosis). Five (62.5%) with pulmonary disease had recurrence of local disease requiring further surgery. Local recurrence was an independent risk factor for PM on statistical analysis. GCTB may present with PM, but more commonly, metastasis occurs after surgery, presenting on surveillance and can progress. There were no distinct differences in histopathological appearance between patients with GCTB that developed PM and those that did not, therefore morphological features of the tumour cannot be currently used to predict tumour behaviour. PM can behave aggressively, necessitating identifying histological markers to recognise patients at risk of metastatic GCTB, for example, through mRNA single cell analysis. We propose GCTB patients with PM receive regular chest surveillance with PET scan and/or CT to monitor disease progression, and a multi-centre audit of GCTB outcome undertaken to further define optimal clinical management. CI - Copyright (c) 2025 Fellows, Kotowska, Stevenson, Brown, Orosz, Siddiqi, Whitwell, Cosker and GIbbons. FAU - Fellows, David AU - Fellows D AD - Oxford Sarcoma Service, Nuffield Orthopaedic Centre, Oxford, England, United Kingdom. FAU - Kotowska, Julia AU - Kotowska J AD - Trauma and Orthopaedics, Hampshire Hospitals NHS Foundation Trust, Basingstoke, United Kingdom. FAU - Stevenson, Thomas AU - Stevenson T AD - Trauma and Orthopaedics, Institute of Naval Medicine, Alverstoke, United Kingdom. FAU - Brown, Jennifer AU - Brown J AD - Oxford Sarcoma Service, Nuffield Orthopaedic Centre, Oxford, England, United Kingdom. FAU - Orosz, Zsolt AU - Orosz Z AD - Oxford Sarcoma Service, Nuffield Orthopaedic Centre, Oxford, England, United Kingdom. FAU - Siddiqi, Ather AU - Siddiqi A AD - Oxford Sarcoma Service, Nuffield Orthopaedic Centre, Oxford, England, United Kingdom. FAU - Whitwell, Duncan AU - Whitwell D AD - Oxford Sarcoma Service, Nuffield Orthopaedic Centre, Oxford, England, United Kingdom. FAU - Cosker, Thomas AU - Cosker T AD - Oxford Sarcoma Service, Nuffield Orthopaedic Centre, Oxford, England, United Kingdom. FAU - GIbbons, Christopher L M H AU - GIbbons CLMH AD - Oxford Sarcoma Service, Nuffield Orthopaedic Centre, Oxford, England, United Kingdom. LA - eng PT - Journal Article DEP - 20250219 PL - Switzerland TA - Pathol Oncol Res JT - Pathology oncology research : POR JID - 9706087 SB - IM MH - Humans MH - *Bone Neoplasms/pathology/therapy MH - *Giant Cell Tumor of Bone/pathology/therapy/secondary MH - Male MH - Female MH - Retrospective Studies MH - Adult MH - Middle Aged MH - *Lung Neoplasms/secondary/epidemiology/therapy MH - Young Adult MH - Adolescent MH - Aged MH - Follow-Up Studies MH - Prognosis MH - Disease Management PMC - PMC11879744 OTO - NOTNLM OT - giant cell tumor of bone OT - orthopaedic oncology OT - pulmonary metastasis OT - sarcoma OT - surveillance COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2025/03/06 06:22 MHDA- 2025/03/06 06:23 PMCR- 2025/02/19 CRDT- 2025/03/06 04:35 PHST- 2024/07/19 00:00 [received] PHST- 2025/02/05 00:00 [accepted] PHST- 2025/03/06 06:23 [medline] PHST- 2025/03/06 06:22 [pubmed] PHST- 2025/03/06 04:35 [entrez] PHST- 2025/02/19 00:00 [pmc-release] AID - 1611916 [pii] AID - 10.3389/pore.2025.1611916 [doi] PST - epublish SO - Pathol Oncol Res. 2025 Feb 19;31:1611916. doi: 10.3389/pore.2025.1611916. eCollection 2025. PMID- 40044479 OWN - NLM STAT- MEDLINE DCOM- 20250412 LR - 20260618 IS - 1532-8422 (Electronic) IS - 1053-0770 (Linking) VI - 39 IP - 5 DP - 2025 May TI - Implementation of a Multidisciplinary Team for Initiation of Extracorporeal Cardiopulmonary Resuscitation in Patients Presenting After Out-of-hospital Cardiac Arrest. PG - 1236-1241 LID - S1053-0770(25)00138-7 [pii] LID - 10.1053/j.jvca.2025.02.018 [doi] AB - OBJECTIVES: Patents with out-of-hospital cardiac arrest (OHCA) are at high risk of death or poor neurologic recovery if spontaneous circulation is not rapidly restored. Emergent mechanical circulatory support with venoarterial extracorporeal membrane oxygenation (VA-ECMO) in the setting of extracorporeal cardiopulmonary resuscitation (ECPR) offers a bridge to diagnostic and therapeutic interventions but can be challenging to provide in a timely fashion. Coordination of multidisciplinary institutional resources into an ECMO Shock Team (ECMO-ST) may improve the survival of ECPR patients while concurrently increasing the number of OHCA patients placed on ECMO. DESIGN: Retrospective cohort study. SETTING: Single-center urban university hospital in the United States with an active mechanical circulatory support and cardiac transplantation program. PARTICIPANTS: 55 OHCA patients who received ECPR after presenting to the emergency department from May 2013 to December 2022. INTERVENTIONS: Ad hoc emergent ECPR support versus activation of the ECMO-ST. MEASUREMENTS AND MAIN RESULTS: The primary outcome was survival to hospital discharge. Secondary outcomes included time to ECMO cannulation, duration of ECMO support, renal failure requiring dialysis, diagnosis of hypoxic brain injury, intensive care unit length of stay, 6-month survival, and functional neurologic recovery quantified by cerebral performance category score at discharge and 6 months. Implementation of the ECMO-ST was associated with an increase in the rate of survival to hospital discharge from 22% (2/9 patients) to 52% (24/46 patients), although the result was not statistically significant due to the small sample size of the preintervention cohort. A total of 69% of those discharged from the hospital had favorable neurologic function as defined by cerebral performance category scores of 1-2. CONCLUSIONS: The organization and implementation of a multidisciplinary institutional ECPR response team trended toward an association with higher rates of survival to hospital discharge, with favorable neurologic function in patients presenting to the emergency department after OHCA. CI - Published by Elsevier Inc. FAU - Hickey, Sean AU - Hickey S AD - Division of Critical Care Medicine, Department of Anesthesiology and Perioperative Medicine, University of California, Los Angeles, Los Angeles, CA. Electronic address: sean.hickey@med.usc.edu. FAU - Ortiz, Christopher AU - Ortiz C AD - Division of Critical Care Medicine, Department of Anesthesiology and Perioperative Medicine, University of California, Los Angeles, Los Angeles, CA. FAU - Chen, Wei-Ting AU - Chen WT AD - Division of Critical Care Medicine, Department of Anesthesiology and Perioperative Medicine, University of California, Los Angeles, Los Angeles, CA. FAU - Black, Phoebe Johnson AU - Black PJ AD - Departments of Neurology and Neurosurgery, David Geffen School of Medicine, UCLA, Los Angeles, CA. FAU - Grogan, Tristan AU - Grogan T AD - Division of General Internal Medicine and Health Services Research, University of California, Los Angeles, Los Angeles, CA. FAU - Benharash, Peyman AU - Benharash P AD - Division of Cardiac Surgery, Department of Surgery, University of California, Los Angeles, Los Angeles, CA. FAU - Gudzenko, Vadim AU - Gudzenko V AD - Division of Critical Care Medicine, Department of Anesthesiology and Perioperative Medicine, University of California, Los Angeles, Los Angeles, CA. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20250215 PL - United States TA - J Cardiothorac Vasc Anesth JT - Journal of cardiothoracic and vascular anesthesia JID - 9110208 SB - IM MH - Humans MH - *Extracorporeal Membrane Oxygenation/methods/trends MH - *Out-of-Hospital Cardiac Arrest/therapy/mortality/diagnosis MH - Retrospective Studies MH - Male MH - Female MH - *Cardiopulmonary Resuscitation/methods/trends MH - Middle Aged MH - *Patient Care Team/trends MH - Aged MH - Cohort Studies MH - Survival Rate/trends OTO - NOTNLM OT - ECMO OT - ECPR OT - cardiac arrest OT - critical care OT - emergency medicine OT - extracorporeal cardiopulmonary resuscitation OT - extracorporeal membrane oxygenation OT - intensive care OT - resuscitation OT - shock COIS- Declaration of competing interest None. EDAT- 2025/03/06 05:05 MHDA- 2025/04/13 00:44 CRDT- 2025/03/05 21:53 PHST- 2024/11/02 00:00 [received] PHST- 2025/01/28 00:00 [revised] PHST- 2025/02/12 00:00 [accepted] PHST- 2025/04/13 00:44 [medline] PHST- 2025/03/06 05:05 [pubmed] PHST- 2025/03/05 21:53 [entrez] AID - S1053-0770(25)00138-7 [pii] AID - 10.1053/j.jvca.2025.02.018 [doi] PST - ppublish SO - J Cardiothorac Vasc Anesth. 2025 May;39(5):1236-1241. doi: 10.1053/j.jvca.2025.02.018. Epub 2025 Feb 15. PMID- 40043861 OWN - NLM STAT- MEDLINE DCOM- 20260130 LR - 20260808 IS - 1556-3871 (Electronic) IS - 1547-5271 (Linking) VI - 23 IP - 2 DP - 2026 Feb TI - Risk scores inconsistently predict sudden death and ventricular arrhythmias in repaired tetralogy of Fallot. PG - 296-305 LID - S1547-5271(25)00212-7 [pii] LID - 10.1016/j.hrthm.2025.02.041 [doi] AB - BACKGROUND: Risk scores designed to predict adverse events (AEs) including sudden death and ventricular arrhythmias can guide heightened surveillance and defibrillator (ICD) implantation. Variability in risk stratification derived from differing scores and guidelines has not been examined in repaired tetralogy of Fallot (rTOF). OBJECTIVES: We aimed to determine the consistency in risk prediction of AEs across published scoring systems in patients with rTOF without a secondary prevention ICD indication. METHODS: We undertook a retrospective review of patients with rTOF without a secondary prevention ICD indication or severe left ventricular impairment from an institutional database. Predicted AEs were calculated across 5 published scores and 3 clinical management guidelines. The prediction of a "high-risk" cohort, using a 4% predicted AE threshold, was compared across the scoring criteria. Observed AE, ICD implantation, and device complications were recorded. RESULTS: A total of 156 patients (median 32, interquartile range [IQR] 25-46 years; 53% female) had 4 AEs (3 sustained ventricular tachycardias [VTs], 1 sudden death) over a median of 24 months (IQR 15-36 months). In total, 41% of patients (n = 64) had risk score variability affecting assignment of high-risk status. Heterogeneity in the predicted AE risk was associated with moderate or worse right ventricular impairment or significant late gadolinium enhancement (P < .001). No criteria predicted all AEs with 2 events only predicted by 1 score. Seven ICD implants treated 3 sustained VT episodes with 3 device-related complications. CONCLUSION: Risk scores are heterogeneous and imperfect for determination of those at high risk of AEs in rTOF. Use of multiple criteria alongside adjuvant stratification strategies and multidisciplinary discussion remains necessary. CI - Copyright (c) 2025 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved. FAU - Kakarla, Jayant AU - Kakarla J AD - University Health Network Toronto, Peter Munk Cardiac Centre, Adult Congenital Heart Disease Program, and University of Toronto, Toronto, Ontario, Canada. FAU - Ishikita, Ayako AU - Ishikita A AD - University Health Network Toronto, Peter Munk Cardiac Centre, Adult Congenital Heart Disease Program, and University of Toronto, Toronto, Ontario, Canada. FAU - Suszko, Adrian AU - Suszko A AD - University Health Network Toronto, Peter Munk Cardiac Centre, Adult Congenital Heart Disease Program, and University of Toronto, Toronto, Ontario, Canada. FAU - Wald, Rachel AU - Wald R AD - University Health Network Toronto, Peter Munk Cardiac Centre, Adult Congenital Heart Disease Program, and University of Toronto, Toronto, Ontario, Canada. FAU - Nair, Krishnakumar AU - Nair K AD - University Health Network Toronto, Peter Munk Cardiac Centre, Adult Congenital Heart Disease Program, and University of Toronto, Toronto, Ontario, Canada. Electronic address: Krishnakumar.Nair@uhn.ca. LA - eng PT - Journal Article DEP - 20250306 PL - United States TA - Heart Rhythm JT - Heart rhythm JID - 101200317 SB - IM MH - Humans MH - *Tetralogy of Fallot/surgery/complications/mortality MH - Female MH - Male MH - Retrospective Studies MH - Risk Assessment/methods MH - Adult MH - *Death, Sudden, Cardiac/etiology/epidemiology/prevention & control MH - *Tachycardia, Ventricular/etiology/mortality MH - Middle Aged MH - Defibrillators, Implantable MH - *Cardiac Surgical Procedures/adverse effects/methods MH - Risk Factors MH - Follow-Up Studies OTO - NOTNLM OT - Congenital heart disease OT - Repaired tetralogy of Fallot OT - Risk prediction OT - Sudden death OT - Ventricular tachycardia COIS- Disclosures The authors have no conflicts of interest to disclose. EDAT- 2025/03/06 05:01 MHDA- 2026/01/31 00:29 CRDT- 2025/03/05 19:15 PHST- 2024/11/03 00:00 [received] PHST- 2025/02/17 00:00 [revised] PHST- 2025/02/26 00:00 [accepted] PHST- 2026/01/31 00:29 [medline] PHST- 2025/03/06 05:01 [pubmed] PHST- 2025/03/05 19:15 [entrez] AID - S1547-5271(25)00212-7 [pii] AID - 10.1016/j.hrthm.2025.02.041 [doi] PST - ppublish SO - Heart Rhythm. 2026 Feb;23(2):296-305. doi: 10.1016/j.hrthm.2025.02.041. Epub 2025 Mar 6. PMID- 40041763 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250306 IS - 2052-3211 (Print) IS - 2052-3211 (Electronic) IS - 2052-3211 (Linking) VI - 18 IP - 1 DP - 2025 TI - Impact of a clinical pharmacy intervention on medication adherence and the quality use of medicines in patients with acute coronary syndrome: a single centre nonrandomised controlled clinical trial. PG - 2468782 LID - 10.1080/20523211.2025.2468782 [doi] LID - 2468782 AB - BACKGROUND: Acute coronary syndrome is a major global disease burden with high morbidity and mortality. This study aims to assess the impact of clinical pharmacy interventions on improving the quality use of medicines and drug-related problems in acute coronary syndrome patients. METHODS: An open, prospective, controlled, nonrandomised clinical trial was conducted at the Teaching Hospital, Peradeniya, Sri Lanka. Consenting patients were recruited and divided into control and intervention groups. Medication history, medication adherence and drug-related problems were assessed. The intervention group received clinical pharmacy interventions for six months. Improvements in medication adherence, discharge medication appropriateness, reduction of hospital readmissions for six months, and responses from the healthcare team's awareness and perception on clinical pharmacy services were recorded. RESULTS: Both groups (control - 180 patients, intervention - 185 patients) showed poor medication adherence at baseline. Medication adherence improved significantly after 6-months post-discharge in the intervention group compared to the control group (49.3% vs 18.8%). The clinical pharmacists successfully identified drug-related problems and provided suggestions for resolving them. The treating team accepted the majority (60%) of these suggestions. Discharge medication appropriateness in the intervention group was significantly higher compared to the control group. There was no significant difference in hospital readmissions related to cardiovascular disorders between the groups. Most doctors and nurses were aware of clinical pharmacists but none of them had previously worked with one. CONCLUSION: Clinical pharmacist-led interventions significantly improved medication adherence and appropriateness, underscoring the added value of clinical pharmacists in a multidisciplinary healthcare team. While most doctors and nurses were aware of clinical pharmacists, none of them had prior experience working with them, emphasising an opportunity to foster greater multidisciplinary integration for improved health outcomes. Overall findings highlight the potential role of clinical pharmacists in enhancing good patient outcomes and improving real-world patient care. CI - (c) 2025 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. FAU - Bagyawantha, N M Y AU - Bagyawantha NMY AUID- ORCID: 0000-0002-8692-3927 AD - Department of Pharmacy, Faculty of Allied Health Sciences, University of Peradeniya, Peradeniya, Sri Lanka. AD - South Asian Clinical Toxicology Research Collaboration, Faculty of Medicine, University of Peradeniya, Peradeniya, Sri Lanka. AD - Collaboration of Australian and Sri Lankans for Pharmacy Practice Education and Research (CASPPER), Brisbane, Australia. FAU - Coombes, I D AU - Coombes ID AUID- ORCID: 0000-0002-1009-6136 AD - Collaboration of Australian and Sri Lankans for Pharmacy Practice Education and Research (CASPPER), Brisbane, Australia. AD - School of Pharmacy, Pharmacy Australia Centre of Excellence, University of Queensland, Woolloongabba, Australia. AD - Department of Pharmacy, Royal Brisbane and Women's Hospital, Queensland, Australia. FAU - Gawarammana, I AU - Gawarammana I AUID- ORCID: 0000-0001-6795-0113 AD - South Asian Clinical Toxicology Research Collaboration, Faculty of Medicine, University of Peradeniya, Peradeniya, Sri Lanka. AD - Department of Medicine, Faculty of Medicine, University of Peradeniya, Peradeniya, Sri Lanka. FAU - Mohamed, F AU - Mohamed F AUID- ORCID: 0000-0003-2849-7269 AD - South Asian Clinical Toxicology Research Collaboration, Faculty of Medicine, University of Peradeniya, Peradeniya, Sri Lanka. AD - Collaboration of Australian and Sri Lankans for Pharmacy Practice Education and Research (CASPPER), Brisbane, Australia. AD - Clinical School Randwick Campus, Faculty of Medicine and Health, The University of New South Wales, and the Edith Collins Centre (Translational Research in Alcohol Drugs and Toxicology), Sydney, Australia. LA - eng PT - Journal Article DEP - 20250303 PL - England TA - J Pharm Policy Pract JT - Journal of pharmaceutical policy and practice JID - 101627192 PMC - PMC11878162 OTO - NOTNLM OT - Acute coronary syndrome OT - clinical pharmacy interventions medication adherence OT - drug-related problems OT - medication appropriateness OT - quality use of medicines COIS- No potential conflict of interest was reported by the author(s). EDAT- 2025/03/05 06:22 MHDA- 2025/03/05 06:23 PMCR- 2025/03/03 CRDT- 2025/03/05 05:19 PHST- 2025/03/05 06:23 [medline] PHST- 2025/03/05 06:22 [pubmed] PHST- 2025/03/05 05:19 [entrez] PHST- 2025/03/03 00:00 [pmc-release] AID - 2468782 [pii] AID - 10.1080/20523211.2025.2468782 [doi] PST - epublish SO - J Pharm Policy Pract. 2025 Mar 3;18(1):2468782. doi: 10.1080/20523211.2025.2468782. eCollection 2025. PMID- 40037591 OWN - NLM STAT- MEDLINE DCOM- 20250430 LR - 20260816 IS - 2047-2412 (Electronic) IS - 2047-2404 (Linking) VI - 26 IP - 5 DP - 2025 Apr 30 TI - The role of FDG-PET/CT in assessing cardiac sarcoidosis with no high-risk cardiac features and normal CMR. PG - 830-837 LID - 10.1093/ehjci/jeaf074 [doi] AB - AIMS: Diagnosing cardiac sarcoidosis (CS) is challenging due to the variable presentation and the lack of consensus on optimal screening strategies. Early identification is critical to prevent adverse outcomes. This study evaluates the role of 18F-fluorodeoxyglucose positron emission tomography with computed tomography (FDG-PET/CT) in assessing CS in patients with no high-risk cardiac features and normal cardiac magnetic resonance (CMR). METHODS AND RESULTS: This retrospective, single-centre cohort included biopsy-confirmed extracardiac sarcoidosis patients who underwent CMR and FDG-PET/CT. Patients with no high-risk cardiac features and normal CMR were included. The primary outcome was the diagnostic value of FDG-PET/CT in the assessment for CS by a multi-disciplinary team (MDT). Secondary outcome included the occurrence of adverse cardiac events. In total, 305 (94.1%) patients were classified as 'unlikely CS', 17 (5.3%) as 'possible CS' and 2 (0.6%) as 'probable CS'. Cardiac FDG uptake was observed in 69 of 324 patients (21.3%). Within the MDT, FDG-PET/CT findings demonstrated limited diagnostic value, as 55.2% with uptake patterns suggestive of CS were ultimately classified as 'unlikely CS' based on other clinical and imaging findings. During a median follow-up of 38.1 months, the overall event rate was low: 15 events (3.4%; annualized 1.1%), with all five cardiac deaths occurring in the 'unlikely CS' group. Only five of 69 patients (7.2%) with cardiac FDG uptake experienced an adverse cardiac event. CONCLUSION: FDG-PET/CT offers limited diagnostic and prognostic value in sarcoidosis patients with no high-risk cardiac features and normal CMR. Our findings confirm that this population has a low risk of adverse cardiac events. CI - (c) The Author(s) 2025. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com. FAU - Shuduyeva, F AU - Shuduyeva F AD - Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands. FAU - Bakker, A L M AU - Bakker ALM AUID- ORCID: 0000-0001-7673-9459 AD - Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands. AD - Department of Cardiology, Amphia Hospital, Breda, The Netherlands. FAU - Akdim, F AU - Akdim F AD - Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands. FAU - Keijsers, R G M AU - Keijsers RGM AD - Department of Nuclear Medicine, St. Antonius Hospital, Nieuwegein, The Netherlands. FAU - Veltkamp, M AU - Veltkamp M AD - Department of Pulmonology, St. Antonius Hospital, Nieuwegein, The Netherlands. AD - Division of Heart and Lungs, Utrecht University Medical Center, Utrecht, The Netherlands. FAU - Grutters, J C AU - Grutters JC AD - Department of Pulmonology, St. Antonius Hospital, Nieuwegein, The Netherlands. AD - Division of Heart and Lungs, Utrecht University Medical Center, Utrecht, The Netherlands. FAU - Post, M C AU - Post MC AD - Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands. AD - Division of Heart and Lungs, Utrecht University Medical Center, Utrecht, The Netherlands. FAU - Mathijssen, H AU - Mathijssen H AD - Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands. LA - eng PT - Journal Article PL - England TA - Eur Heart J Cardiovasc Imaging JT - European heart journal. Cardiovascular Imaging JID - 101573788 RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18) RN - 0 (Radiopharmaceuticals) SB - IM CIN - Eur Heart J Cardiovasc Imaging. 2025 Apr 30;26(5):838-840. doi: 10.1093/ehjci/jeaf073. PMID: 39999382 MH - Humans MH - *Positron Emission Tomography Computed Tomography/methods MH - Female MH - *Sarcoidosis/diagnostic imaging/pathology/mortality MH - Male MH - Retrospective Studies MH - *Fluorodeoxyglucose F18 MH - *Cardiomyopathies/diagnostic imaging/mortality/pathology MH - Middle Aged MH - Radiopharmaceuticals MH - *Magnetic Resonance Imaging, Cine/methods MH - Risk Assessment MH - Adult MH - Prognosis MH - Aged MH - Cohort Studies OTO - NOTNLM OT - FDG-PET/CT OT - cardiac sarcoidosis OT - no high-risk OT - normal CMR OT - screening COIS- Conflict of interest: none declared. EDAT- 2025/03/05 00:21 MHDA- 2025/04/30 18:31 CRDT- 2025/03/04 19:24 PHST- 2024/12/15 00:00 [received] PHST- 2025/01/29 00:00 [revised] PHST- 2025/02/09 00:00 [accepted] PHST- 2025/04/30 18:31 [medline] PHST- 2025/03/05 00:21 [pubmed] PHST- 2025/03/04 19:24 [entrez] AID - 8051140 [pii] AID - 10.1093/ehjci/jeaf074 [doi] PST - ppublish SO - Eur Heart J Cardiovasc Imaging. 2025 Apr 30;26(5):830-837. doi: 10.1093/ehjci/jeaf074. PMID- 40037333 OWN - NLM STAT- MEDLINE DCOM- 20251027 LR - 20260127 IS - 2047-4881 (Electronic) IS - 2047-4873 (Linking) VI - 32 IP - 15 DP - 2025 Oct 28 TI - Identification and management of cardiopulmonary risk in patients with chronic obstructive pulmonary disease: a multidisciplinary consensus and modified Delphi study. PG - 1445-1460 LID - 10.1093/eurjpc/zwaf119 [doi] AB - AIMS: Cardiovascular disease is a common comorbidity in chronic obstructive pulmonary disease. Yet, cardiovascular disease and risk are underdiagnosed in chronic obstructive pulmonary disease and are often undertreated, increasing the risk of cardiopulmonary events. METHODS AND RESULTS: We formed a Global Working Group of experts in chronic obstructive pulmonary disease and cardiovascular disease to produce a consensus statement detailing the identification and management of cardiopulmonary risk in patients with chronic obstructive pulmonary disease. We conducted virtual meetings supplemented by remote working and communication. The Chairs (C.P.G., M.B.) proposed a draft consensus statement, which was further developed by the Global Working Group. The selection of the final consensus statement and key points were obtained using the modified Delphi method. The consensus statement is, 'Given the high burden of fatal and non-fatal major cardiovascular and respiratory events in patients with COPD it is important that cardiopulmonary risk is assessed and managed'. Patients with cardiovascular risk factors or disease who have regular cough or expectoration, recurrent 'chest infections', a significant smoking history, or dyspnoea should complete spirometry to confirm the presence of chronic obstructive pulmonary disease. Prevalent and incident cardiovascular disease and risk in patients with chronic obstructive pulmonary disease, including heart failure, dyslipidaemia, hypertension, ischaemic heart disease, and atrial fibrillation, should be managed according to clinical guidelines. In addition, chronic obstructive pulmonary disease exacerbation risk in patients with chronic obstructive pulmonary disease should be addressed to reduce cardiopulmonary risk. Enhanced integration with specialists in cardiology, pulmonology, and primary care is recommended. CONCLUSION: The identification and management of cardiopulmonary risk in patients with chronic obstructive pulmonary disease are an unmet public health need that can be addressed through shared understanding and multidisciplinary working to improve cardiopulmonary outcomes. CI - (c) The Author(s) 2025. Published by Oxford University Press on behalf of the European Society of Cardiology. FAU - Gale, Chris P AU - Gale CP AUID- ORCID: 0000-0003-4732-382X AD - Department of Cardiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK. AD - Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK. AD - Leeds Institute for Data Analytics, University of Leeds, Leeds, UK. FAU - Hurst, John R AU - Hurst JR AUID- ORCID: 0000-0002-7246-6040 AD - UCL Respiratory, University College London, London, UK. FAU - Hawkins, Nathaniel M AU - Hawkins NM AD - Division of Cardiology, University of British Columbia, Vancouver, Canada. FAU - Bourbeau, Jean AU - Bourbeau J AUID- ORCID: 0000-0002-7649-038X AD - Department of Medicine, Respiratory Division McGill University Health Centre, Quebec, Canada. FAU - Han, MeiLan K AU - Han MK AD - Department of Medicine, Division of Pulmonary & Critical Care, University of Michigan, Ann Arbor, MI, USA. FAU - Lam, Carolyn S P AU - Lam CSP AD - Department of Cardiology, National Heart Centre Singapore and Duke-National University of Singapore, Singapore. FAU - Marciniuk, Darcy D AU - Marciniuk DD AD - Division of Respirology, Critical Care and Sleep Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada. FAU - Price, David AU - Price D AD - Observational and Pragmatic Research Institute, Singapore, Singapore. AD - Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Aberdeen, UK. FAU - Stolz, Daiana AU - Stolz D AD - Clinic of Respiratory Medicine and Pulmonary Cell Research, University Hospital Basel, Basel, Switzerland. AD - Department of Clinical Research, University Hospital Basel, Basel, Switzerland. AD - Clinic of Respiratory Medicine and Faculty of Medicine, University of Freiburg, Freiburg, Germany. FAU - Gluckman, Ty AU - Gluckman T AD - Center for Cardiovascular Analytics, Research, and Data Science (CARDS), Providence Heart Institute, Portland, OR, USA. FAU - Zieroth, Shelley AU - Zieroth S AD - Section of Cardiology, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada. FAU - Nadarajah, Ramesh AU - Nadarajah R AUID- ORCID: 0000-0001-9895-9356 AD - Department of Cardiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK. AD - Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK. AD - Leeds Institute for Data Analytics, University of Leeds, Leeds, UK. FAU - Young, Robert P AU - Young RP AD - Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand. FAU - Singh, Dave AU - Singh D AD - Medicines Evaluation Unit, Manchester University NHS Foundation Trust, University of Manchester, Manchester, UK. FAU - Martinez, Fernando J AU - Martinez FJ AD - Division of Pulmonary and Critical Care Medicine, Weill Cornell Medical College, New York City, USA. FAU - Berg, David D AU - Berg DD AD - Cardiovascular Division, TIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, USA. FAU - Bhutani, Mohit AU - Bhutani M AD - Department of Medicine, Division of Pulmonary Medicine, University of Alberta, Edmonton, Alberta, Canada. CN - Global Working Group on Cardiopulmonary Risk LA - eng PT - Consensus Statement PT - Journal Article PL - England TA - Eur J Prev Cardiol JT - European journal of preventive cardiology JID - 101564430 SB - IM MH - Humans MH - *Cardiovascular Diseases/epidemiology/diagnosis/therapy MH - Comorbidity MH - Delphi Technique MH - Heart Disease Risk Factors MH - Prognosis MH - *Pulmonary Disease, Chronic Obstructive/therapy/diagnosis/epidemiology/physiopathology MH - Risk Assessment MH - Risk Factors OAB - This paper, produced by the Global Working Group of experts in chronic obstructive pulmonary disease and cardiovascular disease, is about the identification and management of cardiopulmonary risk in patients with chronic obstructive pulmonary disease.Individuals with cardiovascular risk factors or disease who have a regular cough or expectoration, recurrent 'chest infections', a significant smoking history, or breathlessness should complete spirometry to confirm the presence of chronic obstructive pulmonary disease.Cardiovascular disease and risk in individuals with chronic obstructive pulmonary disease, including heart failure, dyslipidaemia, hypertension, ischaemic heart disease, and atrial fibrillation, should be managed according to clinical guidelines.Identifying cardiopulmonary risk to prevent exacerbations of chronic obstructive pulmonary disease, treat established cardiovascular disease, and reduce cardiovascular risk in patients with chronic obstructive pulmonary disease offers the prospect to improve cardiopulmonary outcomes. OABL- eng OTO - NOTNLM OT - Cardiopulmonary risk OT - Cardiovascular disease OT - Chronic obstructive pulmonary disease COIS- Conflict of interest: There are no declarations with respect to this manuscript. Outside this work: A. Abdin reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Boston Scientific and Bayer GmbH. A.B.A. reports honoraria for lectures from AstraZeneca, GlaxoSmithKline, and Pfizer; leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid as a member of the Board of Trustees for the Philippine College of Chest Physicians. B.A.N. reports grants or contracts from AstraZeneca and GlaxoSmithKline; consulting fees from AstraZeneca, GlaxoSmithKline, and Sanofi; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Zambon, and MSD; support for attending meetings and/or travel from Menarini, Sanofi, and AstraZeneca. L.A. reports consulting fees from AstraZeneca, Merck Sharp & Dohme, and GlaxoSmithKline; support for attending meetings and/or travel from Boehringer Ingelheim, Mylan LDA, and BIAL. S.A. reports research grants from the Australian Government Department of Health Medical Research Future Fund and Royal Australian College of General Practitioners; consulting fees from WHO Western Pacific Regional Office (WPRO), Division of Pacific Technical Support (DPS); honoraria from Asthma Australia, National Health and Medical Research Council, and Macquarie University Faculty of Medicine; sponsorship for travel and accommodation from Asthma Australia; secretariat role for the Pacific Health Information Health Network; other financial or non-financial interests as their academic appointment at UNSW Sydney are salaried through two Australian Government Medical Research Future Fund grants. A. Anzueto reports consulting fees from GlaxoSmithKline, AstraZeneca, and Sanofi/Regeneron; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from GlaxoSmithKline, AstraZeneca, and Viatrix Pharmaceutical. D.D.B. reports grants or contracts from Pfizer and AstraZeneca; consulting fees from AstraZeneca, Pfizer, Mobility Bio, Inc., and Youngene Therapeutics; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Medical Education Speakers Network (MESN) and USV Private Limited; participation on a data safety monitoring board or advisory board for AstraZeneca, Beckman Coulter (CEC), Kowa Pharmaceuticals (CEC), and Tosoh Biosciences (CEC). M.B. reports grants or contracts from AstraZeneca, GlaxoSmithKline, Sanofi, Mereo Pharma, Takeda, Covis Pharma, and Valeo; consulting fees from AstraZeneca, GlaxoSmithKline, Sanofi, Mereo Pharma, Takeda, Covis Pharma, and Valeo; support for attending meetings and/or travel from AstraZeneca; leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid via a position with Canadian Thoracic Society Executive and Board of Directors. G.B.Z. reports consulting fees from Aleph, Amarin, Balmed, Cardionovum, Crannmedical, Endocore Lab, Eukon, Guidotti, Innovheart, Meditrial, Menarini, Microport, Opsens Medical, Terumo, and Translumina. J.B. reports grants or contracts from Canadian Institute of Health Research (CIHR), Reseau en sante respiratoire du FRQS, McGill University, McGill University Health Centre Foundation, AstraZeneca Canada Ltd, Boehringer Ingelheim Canada Ltd, GlaxoSmithKline Canada Ltd, Grifols, Novartis, Sanofi, and Trudell Canada Ltd; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca Canada Ltd, Boehringer Ingelheim Canada Ltd, GlaxoSmithKline Canada Ltd, Trudell Canada Ltd, Pfizer Canada Ltd, and COVIS Pharma Canada Ltd. R.B. reports participation on the data safety monitoring board of Aptabio Therapeutics, Inc. D.C. reports consulting fees from Bayer and AstraZeneca; payment or honoraria for educational events from Bayer, AstraZeneca, and Lilly; support for attending meetings and/or travel from Bayer, Novartis, and AstraZeneca; participation on a data safety monitoring board or advisory board. A.C.T. reports honoraria for lectures and presentations from AstraZeneca, GlaxoSmithKline, Chiesi, and Johnson & Johnson; participation on advisory boards for AstraZeneca and GlaxoSmithKline. M.G.C. reports contracts or grants from National Institute for Health and Care Research, Asthma + Lung UK, AstraZeneca, Chiesi, and Phillips; royalties or licenses from AstraZeneca; consulting fees from AstraZeneca, Synairgen, and Sanofi; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca, Chiesi, and Sanofi; support for attending meetings and/or travel from AstraZeneca and Chiesi; participation on a data safety monitoring board or advisory board for Synairgen, Astra Zeneca, and Chisi; leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid as Clinical Lead for Humber and North Yorkshire Respiratory Network; receipt of equipment, materials, drugs, medical writing, gifts, or other services from AstraZeneca. D.F.E. reports grants or contracts from Boehringer Ingelheim; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Boehringer Ingelheim; payment for expert testimony from Merk Sharp Dome; support for attending meetings and/or travel Boehringer Ingelheim. F.L.A.F. reports consulting fees from GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, Sanofi, and ACHE; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, Sanofi, and ACHE; leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid with the Brazilian Respiratory Society. F.M.E.F. reports grants or contracts from AstraZeneca, Boehringer Ingelheim, TEVA, and Chiesi; consulting fees from AstraZeneca, Chiesi, Sanofi, and Verona Pharma; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca, Chiesi, and GlaxoSmithKline; support for attending meetings and/or travel from AstraZeneca and Chiesi; receipt of equipment, materials, drugs, medical writing, gifts, or other services from Novartis and Chiesi. C.P.G. reports grants or contracts from Alan Turing Institute, British Heart Foundation, National Institute for Health Research, Horizon 2020, Abbott Diabetes, Bristol Myers Squibb, and European Society of Cardiology; consulting fees from AI Nexus, AstraZeneca, Amgen, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, CardioMatics, Chiesi, Daiichi Sankyo, GPRI Research B.V., Menarini, Novartis, iRhythm, Organon, and The Phoenix Group; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca, Boston Scientific, Menarini, Novartis, Raisio Group, Wondr Medical, and Zydus; support for attending meetings and/or travel from AstraZeneca; participation on a data safety monitoring board or advisory board with DANBLOCK trial and TARGET CTCA trial; leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid as Deputy Editor of EHJ Quality of Care and Clinical Outcomes, member of NICE Indicator Advisory Committee and Chair of ESC Quality Indicator Committee; stock or stock options with CardioMatics; receipt of equipment, materials, drugs, medical writing, gifts, or other services from Kosmos. O.M.G.M. reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca and GlaxoSmithKline; payment for expert testimony from AstraZeneca; support for attending meetings and/or travel from AstraZeneca and Pint Pharma. T.G. reports leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid as Board Member of the American Society for Preventive Cardiology. M.G. reports consulting fees from Novartis and Esperion; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Medtronic; participation on a data safety monitoring board or advisory board from Merck; leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid as President of the American Society for Preventive Cardiology. M.H. reports grants or contacts from NIH, Sanofi, Novartis, Nuvaira, Sunovion, Gala Therapeutics, COPD Foundation, AstraZeneca, American Lung Association, Boehringer Ingelheim, and Biodesix; royalties or licenses from Uptodate, Norton Publishing, and Penguin Random House; consulting fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pulmonx, Teva, Verona, Merck, Mylan, Sanofi, DevPro, Aerogen, Polarian, Regeneron, Altesa BioPharma, Amgen, Roche, RS Biotherapeutics, Apreo Health, and Genentech; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Cipla, Chiesi, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Medscape, Integrity, NACE, and Medwiz; participation on a data safety monitoring board or advisory board with Novartis and Medtronic; leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid COPD Foundation Board, COPD Foundation Scientific Advisory Committee, ALA advisory committee, American Thoracic Society journal editor, ALA volunteer spokesperson, GOLD scientific committee, Emerson School Board, Ann Arbor, MI; stock or stock options with Meissa Vaccines and Altesa BioPharma; receipt of equipment, materials, drugs, medical writing, gifts, or other services from GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, and Novartis. N.M.H. reports consulting fees from AstraZeneca; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca, Boehringer Ingelheim, and Novo-Nordisk. J.R.H. reports grants or contacts from AstraZeneca; consulting fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Sanofi, and Takeda; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Sanofi, and Takeda; support for attending meetings and/or travel from AstraZeneca. M.I. reports speaking/presentation honoraria from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Sanofi, Bayer, Hikma, Sudair, Ferrer, Novartis, Merk, and Janssen; support for attending meetings and/or travel from Ferrer, Janssen, Hickma, AstraZeneca, and GlaxoSmithKline; participation on a data safety monitoring board or advisory board with AstraZeneca, GlaxoSmithKline, Sanofi, Bayer, Janssen, Merk, and Ferrer; leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid with the Saudi Thoracic Society and the Saudi Association of Pulmonary Hypertension. T.J. reports speakers honoraria from Janssen and authors payment from Medicine Journal. E.M.K. reports grants or contracts from National Institute for Health Research Global Health Research Unit on Respiratory Health; consulting fees from AstraZeneca; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca; support for attending meetings and/or travel from AstraZeneca; leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid as Board Director of International Primary Care Respiratory Group, Ex-President of International Primary Care Respiratory Group 2022-24, President of Primary Care Respiratory Group Malaysia, Council Member of Malaysian Society of Hypertension, Council Member of Academy of Family Physicians of Malaysia, Associate Editor of nPJPCRM, Editorial Board Member of Malaysia Family Physician; receipt of equipment, materials, drugs, medical writing, gifts, or other services from AstraZeneca. L.K. reports leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid as President-elect of Association of Cardiovascular Nurses and allied Professionals (ACAP) within the European Society of Cardiology and Chair patient of Heart and Lung patient organization Linkoping in Sweden. C.S.P.L. reports grants or contracts from National Medical Research Council of Singapore, Novo Nordisk, and Roche Diagnostics; consulting fees from Alleviant Medical, Allysta Pharma, AnaCardio AB, Applied Therapeutics, AstraZeneca, Bayer, Biopeutics, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, CardioRenal, CPC Clinical Research, Eli Lilly, Impulse Dynamics, Intellia Therapeutics, Ionis Pharmaceutical, Janssen Research & Development LLC, Medscape/WebMD Global LLC, Merck, Novartis, Novo Nordisk, Prosciento Inc, Quidel Corporation, Radcliffe Group Ltd., Recardio Inc, ReCor Medical, Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics, and Us2.ai; patents planned, issued or pending PCT/SG2016/050217 and US Patent No. 10,702, 247; leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid with Us2.ai; stock or stock options from Us2.ai. B.L. reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca, MSD, and GlaxoSmithKline; support for attending meetings and/or travel from AstraZeneca and Chiesi; participation on a data safety monitoring board or advisory board with AstraZeneca and Chiesi; leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid as a member of the French respiratory society board. L.T.T.L. reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca, GlaxoSmithKline, and Boehringer Ingelheim. D.L. reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Biosense, Zoll, CardioFocus, Biotronik, Ablacon, and Bayer. A.H.E.M.M. reports consulting fees from Organon and Abbott; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Organon, Omron, and Philips. D.D.M. reports grants or contracts from AstraZeneca, Boehringer Ingelheim, Canadian Institute of Health Research, GlaxoSmithKline, Grifols, Lung Association of Saskatchewan, Lung Health Institute of Canada, McGill University, Novartis, Sanofi, Saskatchewan Health Research Foundation, and Schering-Plough; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Canadian Thoracic Society, American College of Chest Physicians, American Thoracic Society; leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid from Saskatchewan Health Research Foundation and CHEST Journal; other financial or non-financial interests as an employee at University of Saskatchewan. F.J.M. reports grants or contracts from AstraZeneca, Chiesi, GlaxoSmithKline, Sanofi/Regeneron, NHLBI-AstraZeneca, Chiesi, Boehringer-Ingelheim, GlaxoSmithKline, Novartis, Polarean, Sanofi/Regeneron, Sunovion, and TEVA Pharmaceuticals; consulting fees from AstraZeneca, Boehringer Ingelheim, Chiesi, CSL Behring, GlaxoSmithKline, Novartis, Polarean, Pulmonx, Sanofi/Regeneron, Sunovion, Teva, Theravance/Viatris, and UpToDate; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca and GlaxoSmithKline; participation on a Data Safety Monitoring Board or Advisory Board with MedTronic and GlaxoSmithKline. W.M. reports leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid as President of Asociacion Argentina de Medicina Respiratoria. R.G.M. reports support for attending meetings and/or travel from Fundacao de Amparo a Pesquisa do Estado de Sao Paulo. T.M. reports grants or contracts from Novo Nordisk Foundation, European Commission, and The Regional Health Authority in Central Norway; honoraria for lecture from Norwegian School of Sport Science; support to attend meeting from European Association for Preventive Cardiology, Swedish Sports Medicine Society, Puijo symposium, and Kupio Research Institute of Exercise Medicine; leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid with European Association for Preventive Cardiology. F.M.A. reports grants or contracts from AstraZeneca, Novartis, Moderna, and PPD; payment or honoraria for lectures and presentations from AstraZeneca, GlaxoSmithKline, Roche, Novartis, and Ferrer; support for attending meetings and/or travel from AstraZeneca, GlaxoSmithKline, Novartis, and Ferrer; participation on a Data Safety Monitoring Board or Advisory Board with AstraZeneca, GlaxoSmithKline, Novartis, and Roche; leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid as President of the Costa Rican Thoracic Society; receipt of equipment, materials, drugs, medical writing, gifts, or other services from AstraZeneca. C.M.L. reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca, Boehringer Ingelheim, and Berlin Chemie; support for attending meetings and/or travel from AstraZeneca, Boehringer Ingelheim, Berlin Chemie, and Insmed; participation on a Data Safety Monitoring Board or Advisory Board with AstraZeneca, Boehringer Ingelheim, and Berlin Chemie; stock or stock options with GlaxoSmithKline; receipt of equipment, materials, drugs, medical writing, gifts, or other services from AstraZeneca. S.M. reports grants or contracts from ROHTO Pharmaceutical Co. Ltd and CHUGAI Pharmaceutical Co. Ltd; consulting fees from AstraZeneca K.K. and GlaxoSmithKline in Japan; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Nippon Boehringer Ingelheim Co. Ltd, AstraZeneca K.K., and GlaxoSmithKline in Japan; leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid as Senior Director of the Japanese Respiratory Society. K.N. reports grants or contracts from Meiji Yasuda Life Insurance Company. Y.M.N. reports grants or contracts from Bayer. J.O.C. reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca, Novartis, and Boehringer Ingelheim; support for attending meetings and/or travel from Novartis, Boehringer Ingelheim, and A. Menarini; participation on a Data Safety Monitoring Board or Advisory Board with Chiesi; leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid as a member of Clinical Advisory Group with the Asthma Society of Ireland. A.P. reports grants or contracts from Chiesi, AstraZeneca, GlaxoSmithKline, and Sanofi; consulting fees from Chiesi, AstraZeneca, GlaxoSmithKline, Sanofi, Avillion, Moderna, and Roche; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Chiesi, AstraZeneca, GlaxoSmithKline, Menarini, Zambon, Mundipharma, Sanofi, Iqvia, Avillion, Sanofi, Regeneron, and Zambon; participation on a Data Safety Monitoring Board or Advisory Board with Chiesi, AstraZeneca, GlaxoSmithKline, Sanofi, Iqvia, Avillion, and Moderna. G.P. reports consulting fees from VIATRIS Mexico and Menarini; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from VIATRIS, Novartis, Bayer, Pfizer, and Menarini; support for attending meetings and/or travel from Pfizer; participation on a Data Safety Monitoring Board or Advisory Board with Bayer. M. Piepoli reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Menarini, and Servier; support for attending meetings and/or travel from Novo Nordisk; leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid as European Society of Cardiology Vice President. M. Polovina reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Boehringer Ingelheim, AstraZeneca, Novartis, Pfizer, Pharmaswiss, and Hemofarm/STADA; support for attending meetings and/or travel from Hemofarm/STADA. D. Price reports grants or contracts from AstraZeneca, Chiesi, Viatris, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, and United Kingdom National Health Service; consulting fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis, Teva Pharamaceuticals, and Viatris; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Inside Practice, GlaxoSmithKline, Novartis, Medscape, Regeneron Pharmaceuticals, Sanofi Genzyme, Teva Pharmaceuticals, and Viatris; payment for expert testimony from GlaxoSmithKline; support for attending meetings and/or travel from AstraZeneca, Boehringer Ingelheim, Novartis, Medscape, and Teva Pharmaceuticals; leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid from AstraZeneca, Amgen, Boehringer Ingelheim, Chiesi, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyma, Teva Pharmaceuticals, and Viatris; stock or stock options with AKL Research and Development Ltd, Optimum Patient Care Ltd (Australia and UK), Observational and Pragmatic Research Institute Pte Ltd (Singapore), 5% shareholding in Timestamp which develops adherence monitoring technology; other financial or non-financial interests with UK Efficacy and Mechanism Evaluation programme and Health Technology Assessment. R.E.K.R. reports grants or contracts from AstraZeneca, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca, Sanofi, and Chiesi; participation on a Data Safety Monitoring Board or Advisory Board with AstraZeneca; leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid as Chairman of the British Thoracic Society. J.S. reports grants or contracts from National Institute of Health Research and Barts Charity; support for attending meetings and/or travel from European Society of Cardiology; participation on a Data Safety Monitoring Board or Advisory Board as part of VAL-CARD study data monitoring committee; leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid as ESC ACNAP science committee chair (2020-24), The Aortic Dissection Charitable Trust Research Advisory Group (2021-23), Society of Cardiothoracic Surgery Ambassador, and NIHR Doctoral and Clinical Practitioner Academic Fellowship (2022-). T.S. reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca, GlaxoSmithKline, and Boehringer; support for attending meetings and/or travel from AstraZeneca, GlaxoSmithKline, and Boehringer; participation on a Data Safety Monitoring Board or Advisory Board with GlaxoSmithKline; leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid as President of Thoracic Society of Trinidad and Tobago and Vice President of Palliative Care Society of T&T. D. Shrikrishna reports honoraria for lectures, presentations, and educational events from GlaxoSmithKline, AstraZeneca, Chiesi, Boehringer Ingelheim, Bayer, BMS, TEVA, and Pfizer; support for attending meetings and/or travel from AstraZeneca; participation on a Data Safety Monitoring Board or Advisory Board with Chiesi; leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid as Co-chair of UK Cardiopulmonary Taskforce which is funded by Astra Zeneca; receipt of equipment, materials, drugs, medical writing, gifts, or other services from AstraZeneca. S.O.S. reports grants or contracts from Roche, Dutch Research Council (NWO) and Lung Foundation Netherlands (Longfonds); consulting fees from AstraZeneca, Chiesi, and GlaxoSmithKline; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca and Chiesi; support for attending meetings and/or travel from AstraZeneca and Chiesi. D. Singh reports consulting fees from Aerogen, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, CSL Behring, EpiEndo, Genentech, GlaxoSmithKline, Glenmark, Gossamer Bio, Kinaset Therapeutics, Menarini, Novartis, Orion, Pulmatrix, Sanofi, Synairgen, Teva, Theravance Biopharma, and Verona Pharma. D. Stolz reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca, Berline-Chemie/Menarini, Boehringer Ingelheim, Chiesi, CSL Behring, Curetis AG, GlaxoSmithKline, Merck, MSD, Novartis, Sanofi, Vifor, and Roche; participation on a Data Safety Monitoring Board or Advisory Board with AstraZeneca, Berline-Chemie/Menarini, Boehringer Ingelheim, Chiesi, CSL Behring, Curetis AG, GlaxoSmithKline, Merck, MSD, Novartis, Sanofi, Vifor, and Roche; leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid as current GOLD representative for Switzerland. R.T. reports consulting fees from AstraZeneca, Bayer, Novartis, and Omron; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Daiichi Sankyo, Bayer, Novartis, and Edwards; support for attending meetings and/or travel from AstraZeneca and Bayer; participation on a Data Safety Monitoring Board or Advisory Board with Abbott, Boehringer Ingelheim, and AstraZeneca; leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid as President of Primary Care Cardio Society, Board Observer of British Society of Heart Failure, UK Clinical Director of Healthy.io and cardiac expert advisory groups with NHSE; stock or stock options with Healthy.io; receipt of equipment, materials, drugs, medical writing, gifts, or other services from Reister; other financial or non-financial interests with Avegen. F.T. reports consulting fees from AstraZeneca, Berlin Chemie, Boehringer Ingelheim, GlaxoSmithKline, Merck Healthcare, Novartis, Omron, OM-Pharma, Roche, Sanofi-Aventis, and Thorasys; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events AstraZeneca, Berlin Chemie, Boehringer Ingelheim, Bristol-Myers Squibb, Fisher & Paykel, GlaxoSmithKline, Janssen-Cilag, Merck Healthcare, Novartis, Omron, OM-Pharma, Roche, Sanofi-Aventis, Thorasys, Pfizer, TEVA, Actelion, and Mundipharma. L.E.G.W.V. reports grants or contracts from The Family Kamprad Foundation, the Swedish government and country council ALF grant, The Swedish Heart and Lung Foundation, and Svensk Lungmedicinsk Forening; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events GlaxoSmithKline, AstraZeneca, Boehringer, Novartis, Chiesi, Resmed, Pulmonx, and Grifols. T.W. reports consulting fees from AZ, Chiesi, GlaxoSmithKline, Novartis, MSD, Roche, and Sanofi Regeneron; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AZ, Chiesi, GlaxoSmithKline, Novartis, MSD, Roche, and Sanofi Regeneron. R.P.Y. reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca and GlaxoSmithKline; support for attending meetings and/or travel from GlaxoSmithKline; patents planned, issued or pending with Synergenz BioScience Ltd; leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid with Asthma and Respiratory Foundation of New Zealand (NZ); stock or stock options with Synergenz BioScience Ltd. J.Z. reports consulting fees from AstraZeneca; honoraria for presentations from AstraZeneca; participation on a Data Safety Monitoring Board or Advisory Board with AstraZeneca. S.Z. served on advisory boards for, or speaker engagements with Abbott, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Cytokinetics, Eli Lilly, GSK, Medtronic, Merck, Novartis, Novo-Nordisk, Pfizer, and Vifor Pharma; and serves on a clinical trial committee or as a national lead for studies sponsored by AstraZeneca, Boehringer Ingelheim, Merck, Novartis, Pfizer, and Salubris Bio; and participation on a Data Safety Monitoring Board or Advisory Board with Pfizer. D.A.; F.B.; A.B.; N.F.; S.F.; M.C.G.; B.G.; G.E.G.M.; K.H.G.; J.M.H.; A.T.H.D.; N.K.; B.K.; M.K.; A. Massouh; A. Mohan; M.M.; R.N.; T.N.N.P.; D. Panagiotakos; B.A.P.; H.I.R.; K.R.; C.M.R.; C.R.; A.L.P.R.; L.S.; J.S.S.; R.J.S.; Y. Song; A.S.; Y. Sun; I.U.; V.V.; R.V.; J.W.; M.Z. have nothing to declare. FIR - Abdin, Amr IR - Abdin A FIR - Ahadzi, Dzifa IR - Ahadzi D FIR - Albay, Albert B IR - Albay AB FIR - Alcazar Navarrete, Bernardino IR - Alcazar Navarrete B FIR - Alves, Luis IR - Alves L FIR - Ansari, Sameera IR - Ansari S FIR - Anzueto, Antonio IR - Anzueto A FIR - Barasa, Felix IR - Barasa F FIR - Berg, David D IR - Berg DD FIR - Bevan, Andy IR - Bevan A FIR - Bhutani, Mohit IR - Bhutani M FIR - Biondi-Zoccai, Giuseppe IR - Biondi-Zoccai G FIR - Bourbeau, Jean IR - Bourbeau J FIR - Bugiardini, Raffaele IR - Bugiardini R FIR - Calderaro, Daniela IR - Calderaro D FIR - Cortes-Telles, Arturo IR - Cortes-Telles A FIR - Crooks, Michael G IR - Crooks MG FIR - Echazarreta, Diego F IR - Echazarreta DF FIR - Farag, Nabil IR - Farag N FIR - Fernandes, Fredrico L A IR - Fernandes FLA FIR - Franssen, Frits M E IR - Franssen FME FIR - Fredericks, Suzanne IR - Fredericks S FIR - Gale, Chris P IR - Gale CP FIR - Garcia Morales, Olga M IR - Garcia Morales OM FIR - Gaviria, Maria C IR - Gaviria MC FIR - Gencer, Baris IR - Gencer B FIR - Gianella Malca, Gonzalo Ernesto IR - Gianella Malca GE FIR - Gjeilo, Kari Hanne IR - Gjeilo KH FIR - Gluckman, Ty IR - Gluckman T FIR - Gulati, Martha IR - Gulati M FIR - Han, MeiLan K IR - Han MK FIR - Hawkins, Nathaniel M IR - Hawkins NM FIR - Hendriks, Jeroen M IR - Hendriks JM FIR - Hurst, John R IR - Hurst JR FIR - Huynh Dang, Anh-Thu IR - Huynh Dang AT FIR - Idrees, Majdy M IR - Idrees MM FIR - Joseph, Tobin IR - Joseph T FIR - Kanj, Nadim IR - Kanj N FIR - Khoo, Ee Ming IR - Khoo EM FIR - Kirenga, Bruce IR - Kirenga B FIR - Klompstra, Leonie IR - Klompstra L FIR - Kyriakou, Martha IR - Kyriakou M FIR - Lam, Carolyn S P IR - Lam CSP FIR - Lamia, Bouchra IR - Lamia B FIR - Lan, Le Thi Tuyet IR - Lan LTT FIR - Linz, Dominik IR - Linz D FIR - Maas, Angela H E M IR - Maas AHEM FIR - Marciniuk, Darcy D IR - Marciniuk DD FIR - Martinez, Fernando J IR - Martinez FJ FIR - Massouh, Angela IR - Massouh A FIR - Mattarucco, Walter IR - Mattarucco W FIR - Mendes, Renata G IR - Mendes RG FIR - Mohan, Anant IR - Mohan A FIR - Moholdt, Trine IR - Moholdt T FIR - Mokhtari, Majid IR - Mokhtari M FIR - Montero-Arias, Felicia IR - Montero-Arias F FIR - Munks-Lederer, Claudia IR - Munks-Lederer C FIR - Muro, Shigeo IR - Muro S FIR - Nadarajah, Ramesh IR - Nadarajah R FIR - Nakao, Kazuhiro IR - Nakao K FIR - Nakao, Yoko M IR - Nakao YM FIR - Phuong, Thu Nguyen Ngoc IR - Phuong TNN FIR - O'Callaghan, Johanna IR - O'Callaghan J FIR - Panagiotakos, Demosthenes IR - Panagiotakos D FIR - Papi, Alberto IR - Papi A FIR - Payro, Gerardo IR - Payro G FIR - Piepoli, Massimo IR - Piepoli M FIR - Polovina, Marija IR - Polovina M FIR - Popescu, Bogdan A IR - Popescu BA FIR - Price, David IR - Price D FIR - Ragy, Hany I IR - Ragy HI FIR - Raveendra, Keerthenan IR - Raveendra K FIR - Reid, Christopher M IR - Reid CM FIR - Reynolds, Catherine IR - Reynolds C FIR - Ribeiro, Antonio Luiz P IR - Ribeiro ALP FIR - Russell, Richard E K IR - Russell REK FIR - Saiva, Lavanya IR - Saiva L FIR - Segura, Juliana Salas IR - Segura JS FIR - Sanders, Julie IR - Sanders J FIR - Scott, Raewyn J IR - Scott RJ FIR - Seemungal, Terence IR - Seemungal T FIR - Shrikrishna, Dinesh IR - Shrikrishna D FIR - Simons, Sami O IR - Simons SO FIR - Singh, Dave IR - Singh D FIR - Song, Yuanlin IR - Song Y FIR - Stolz, Daiana IR - Stolz D FIR - Subramaniam, Abirami IR - Subramaniam A FIR - Sun, Yongchang IR - Sun Y FIR - Thakkar, Raj IR - Thakkar R FIR - Trinkmann, Frederik IR - Trinkmann F FIR - Uchmanowicz, Izabella IR - Uchmanowicz I FIR - Vaccarino, Viola IR - Vaccarino V FIR - Vanfleteren, Lowie E G W IR - Vanfleteren LEGW FIR - Vedanthan, Rajesh IR - Vedanthan R FIR - Winders, Tonya IR - Winders T FIR - Wu, Jianhua IR - Wu J FIR - Young, Robert P IR - Young RP FIR - Zheng, Jinping IR - Zheng J FIR - Zhou, Min IR - Zhou M FIR - Zieroth, Shelley IR - Zieroth S EDAT- 2025/03/05 00:22 MHDA- 2025/10/28 00:26 CRDT- 2025/03/04 18:33 PHST- 2024/09/13 00:00 [received] PHST- 2024/11/08 00:00 [revised] PHST- 2025/01/03 00:00 [accepted] PHST- 2025/10/28 00:26 [medline] PHST- 2025/03/05 00:22 [pubmed] PHST- 2025/03/04 18:33 [entrez] AID - 8050097 [pii] AID - 10.1093/eurjpc/zwaf119 [doi] PST - ppublish SO - Eur J Prev Cardiol. 2025 Oct 28;32(15):1445-1460. doi: 10.1093/eurjpc/zwaf119. PMID- 40036781 OWN - NLM STAT- MEDLINE DCOM- 20250801 LR - 20260307 IS - 1522-9645 (Electronic) IS - 0195-668X (Print) IS - 0195-668X (Linking) VI - 46 IP - 29 DP - 2025 Aug 1 TI - Cardio-oncology rehabilitation and exercise: evidence, priorities, and research standards from the ICOS-CORE working group. PG - 2847-2865 LID - 10.1093/eurheartj/ehaf100 [doi] AB - The aim of this whitepaper is to review the current state of the literature on the effects of cardio-oncology rehabilitation and exercise (CORE) programmes and provide a roadmap for improving the evidence-based to support the implementation of CORE. There is an urgent need to reinforce and extend the evidence informing the cardiovascular care of cancer survivors. CORE is an attractive model that is potentially scalable to improve the cardiovascular health of cancer survivors as it leverages many of the existing frameworks developed through decades of delivery of cardiac rehabilitation. However, there are several challenges within this burgeoning field, including limited evidence of the efficacy of this approach in patients with cancer. In this paper, a multidisciplinary team of international experts highlights priorities for future research in this field and recommends standards for the conduct of research. CI - (c) The Author(s) 2025. Published by Oxford University Press on behalf of the European Society of Cardiology. FAU - Adams, Scott C AU - Adams SC AD - Cancer Fatigue Services Inc., Toronto, ON, Canada. FAU - Rivera-Theurel, Fernando AU - Rivera-Theurel F AD - Ted Rogers Cardiotoxicity Prevention Program, University Health Network, Toronto, ON, Canada. AD - Faculty of Medicine, University of Toronto, Toronto, ON, Canada. AD - Cardiovascular Prevention and Rehabilitation Program, Toronto Rehabilitation Institute, University Health Network, Toronto, ON, Canada. FAU - Scott, Jessica M AU - Scott JM AD - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Nadler, Michelle B AU - Nadler MB AD - Division of Medical Oncology and Hematology, Department of Medicine, University of Toronto, Toronto, ON, Canada. AD - Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada. FAU - Foulkes, Stephen AU - Foulkes S AUID- ORCID: 0000-0001-7651-3740 AD - Faculty of Nursing, College of Health Sciences, University of Alberta, Edmonton, AB, Canada. FAU - Leong, Darryl AU - Leong D AD - The Population Health Research Institute and Department of Medicine, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada. FAU - Nilsen, Tormod AU - Nilsen T AD - Department of Physical Performance, Norwegian School of Sports Sciences, Oslo, Norway. FAU - Porter, Charles AU - Porter C AD - Department of Cardiovascular Medicine, University of Kansas Medical Center, Kansas City, KS, USA. FAU - Haykowsky, Mark AU - Haykowsky M AD - Faculty of Nursing, College of Health Sciences, University of Alberta, Edmonton, AB, Canada. FAU - Abdel-Qadir, Husam AU - Abdel-Qadir H AD - Ted Rogers Cardiotoxicity Prevention Program, University Health Network, Toronto, ON, Canada. AD - Faculty of Medicine, University of Toronto, Toronto, ON, Canada. AD - Women's College Hospital and Peter Munk Cardiac Centre, Toronto, ON, Canada. FAU - Hull, Sarah C AU - Hull SC AD - Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, CT, USA. AD - Program for Biomedical Ethics, Yale School of Medicine, New Haven, CT, USA. FAU - Iyengar, Neil M AU - Iyengar NM AD - Breast Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. AD - Department of Medicine, Weill Cornell Medicine, New York, NY, USA. FAU - Dieli-Conwright, Christina M AU - Dieli-Conwright CM AD - Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. AD - Harvard Medical School, Harvard University, Boston, MA, USA. AD - Department of Nutrition, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA, USA. FAU - Dent, Susan F AU - Dent SF AD - Wilmot Cancer Institute, Department of Medicine, University of Rochester, Rochester, NY, USA. FAU - Howden, Erin J AU - Howden EJ AUID- ORCID: 0000-0002-6657-4395 AD - Cardiometabolic Health and Exercise Physiology Laboratory, Baker Heart and Diabetes Institute, 75 Commercial Road, Melbourne, VIC 3004, Australia. LA - eng GR - P30 CA008748/CA/NCI NIH HHS/United States PT - Journal Article PT - Review PL - England TA - Eur Heart J JT - European heart journal JID - 8006263 SB - IM MH - Humans MH - *Cardiac Rehabilitation/methods/standards MH - *Exercise Therapy/methods MH - *Neoplasms/rehabilitation/complications MH - Cancer Survivors MH - Medical Oncology MH - *Cardiovascular Diseases MH - Biomedical Research/standards MH - Cardio-Oncology PMC - PMC12314747 EDAT- 2025/03/04 23:05 MHDA- 2025/08/01 12:35 PMCR- 2025/02/28 CRDT- 2025/03/04 17:02 PHST- 2025/08/01 12:35 [medline] PHST- 2025/03/04 23:05 [pubmed] PHST- 2025/03/04 17:02 [entrez] PHST- 2025/02/28 00:00 [pmc-release] AID - 8046087 [pii] AID - ehaf100 [pii] AID - 10.1093/eurheartj/ehaf100 [doi] PST - ppublish SO - Eur Heart J. 2025 Aug 1;46(29):2847-2865. doi: 10.1093/eurheartj/ehaf100. PMID- 40035249 OWN - NLM STAT- MEDLINE DCOM- 20250511 LR - 20251113 IS - 1308-4488 (Electronic) IS - 1016-5169 (Linking) VI - 53 IP - 2 DP - 2025 Mar TI - Adaptation of the Enhanced Recovery After Surgery (ERAS(R)) Protocol in Transcatheter Aortic Valve Replacement Patients. PG - 127-133 LID - 10.5543/tkda.2024.98566 [doi] AB - Enhanced Recovery After Surgery (ERAS(R)) is a multimodal, multidisciplinary care and recovery protocol designed to facilitate faster recovery for patients undergoing surgery during the perioperative period. These programs aim to encourage an earlier return to normal activities by reducing complications. While ERAS(R) protocols have become standard practice in many surgical specialties, their application in the transcatheter aortic valve replacement (TAVI) procedure is relatively recent. TAVI patients are often high-risk and medically fragile. We believe that managing these patients with a multidisciplinary approach, such as the ERAS(R) protocol, during the preoperative and postoperative periods will reduce morbidity and mortality, enhance patient satisfaction, and lower hospital costs. FAU - Yilmaz Ak, Hulya AU - Yilmaz Ak H AD - Department of Anesthesiology and Reanimation, Kartal Dr. Lutfi Kirdar City Hospital, Istanbul, Turkiye. FAU - Yildiz, Mustafa AU - Yildiz M AD - Department of Cardiology, Istanbul University-Cerrahpasa, Cardiology Institute, Istanbul, Turkiye. FAU - Yildiz, Ahmet AU - Yildiz A AD - Department of Cardiology, Memorial Bahcelievler Hospital, Istanbul, Turkiye. FAU - Dogan, Sait Mesut AU - Dogan SM AD - Department of Cardiology, Istanbul University-Cerrahpasa, Cardiology Institute, Istanbul, Turkiye. FAU - Salihoglu, Ziya AU - Salihoglu Z AD - Department of Anesthesiology and Reanimation, Istanbul University-Cerrahpasa, Cardiology Institute, Istanbul, Turkiye. FAU - Erkalp, Kerem AU - Erkalp K AD - Department of Anesthesiology and Reanimation, Istanbul University-Cerrahpasa, Cardiology Institute, Istanbul, Turkiye. FAU - Okcun, Emir Ozgur Baris AU - Okcun EOB AD - Department of Cardiology, Istanbul University-Cerrahpasa, Cardiology Institute, Istanbul, Turkiye. FAU - Ozsahin, Yasemin AU - Ozsahin Y AD - Department of Anesthesiology and Reanimation, Istanbul University-Cerrahpasa, Cardiology Institute, Istanbul, Turkiye. LA - eng PT - Journal Article TT - Transkateter Aort Kapak Replasmani Hastalarinda Cerrahi Sonrasi Hizlandirilmis Iyilesme (ERAS(R)) Protokolunun Uyarlanmasi. PL - Turkey TA - Turk Kardiyol Dern Ars JT - Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir JID - 9426239 SB - IM MH - Humans MH - *Transcatheter Aortic Valve Replacement/rehabilitation MH - *Enhanced Recovery After Surgery MH - Clinical Protocols MH - Postoperative Complications/prevention & control EDAT- 2025/03/04 12:25 MHDA- 2025/03/04 12:26 CRDT- 2025/03/04 06:13 PHST- 2025/03/04 12:26 [medline] PHST- 2025/03/04 12:25 [pubmed] PHST- 2025/03/04 06:13 [entrez] AID - 10.5543/tkda.2024.98566 [doi] PST - ppublish SO - Turk Kardiyol Dern Ars. 2025 Mar;53(2):127-133. doi: 10.5543/tkda.2024.98566. PMID- 40028867 OWN - NLM STAT- MEDLINE DCOM- 20250510 LR - 20260910 IS - 1365-2060 (Electronic) IS - 0785-3890 (Print) IS - 0785-3890 (Linking) VI - 57 IP - 1 DP - 2025 Dec TI - Elucidating cognitive processes in cardiac arrest team leaders: a virtual reality-based cued-recall study of experts and novices. PG - 2470976 LID - 10.1080/07853890.2025.2470976 [doi] LID - 2470976 AB - BACKGROUND: Team leadership during medical emergencies like cardiac arrest resuscitation is cognitively demanding, especially for trainees. These cognitive processes remain poorly characterized due to measurement challenges. Using virtual reality simulation, this study aimed to elucidate and compare communication and cognitive processes-such as decision-making, cognitive load, perceived pitfalls, and strategies-between expert and novice code team leaders to inform strategies for accelerating proficiency development. METHODS: A simulation-based mixed methods approach was utilized within a single large academic medical center, involving twelve standardized virtual reality cardiac arrest simulations. These 10- to 15-minutes simulation sessions were performed by seven experts and five novices. Following the simulations, a cognitive task analysis was conducted using a cued-recall protocol to identify the challenges, decision-making processes, and cognitive load experienced across the seven stages of each simulation. RESULTS: The analysis revealed 250 unique cognitive processes. In terms of reasoning patterns, experts used inductive reasoning, while novices tended to use deductive reasoning, considering treatments before assessments. Experts also demonstrated earlier consideration of potential reversible causes of cardiac arrest. Regarding team communication, experts reported more critical communications, with no shared subthemes between groups. Experts identified more teamwork pitfalls, and suggested more strategies compared to novices. For cognitive load, experts reported lower median cognitive load (53) compared to novices (80) across all stages, with the exception of the initial presentation phase. CONCLUSIONS: The identified patterns of expert performance - superior teamwork skills, inductive clinical reasoning, and distributed cognitive strategiesn - can inform training programs aimed at accelerating expertise development. FAU - Popov, Vitaliy AU - Popov V AUID- ORCID: 0000-0003-2348-5285 AD - Department of Learning Health Sciences, University of Michigan Medical School, Ann Arbor, MI, USA. AD - School of Information, University of Michigan, Ann Arbor, MI, USA. FAU - Harmer, Bryan AU - Harmer B AD - Department of Learning Health Sciences, University of Michigan Medical School, Ann Arbor, MI, USA. FAU - Raphael, Sophie AU - Raphael S AD - Department of Learning Health Sciences, University of Michigan Medical School, Ann Arbor, MI, USA. FAU - Scott, Isabella AU - Scott I AD - Department of Learning Health Sciences, University of Michigan Medical School, Ann Arbor, MI, USA. FAU - Sample, Alanson P AU - Sample AP AD - Electrical Engineering and Computer Science Department, University of Michigan, Ann Arbor, MI, USA. FAU - Cooke, James M AU - Cooke JM AD - Department of Learning Health Sciences, University of Michigan Medical School, Ann Arbor, MI, USA. AD - Department of Family Medicine, University of Michigan, Ann Arbor, MI, USA. FAU - Cole, Michael AU - Cole M AD - Department of Emergency Medicine, University of Michigan, Ann Arbor, MI, USA. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20250303 PL - England TA - Ann Med JT - Annals of medicine JID - 8906388 SB - IM MH - Humans MH - Virtual Reality MH - *Heart Arrest/therapy MH - *Cognition MH - Male MH - *Leadership MH - Female MH - *Patient Care Team/organization & administration MH - *Cardiopulmonary Resuscitation/education MH - Cues MH - Decision Making MH - Adult MH - Clinical Competence MH - Communication MH - Simulation Training/methods MH - Mental Recall PMC - PMC11878170 OAB - Novel combination of virtual reality simulation and cognitive task analysis provides a promising educational tool for identifying and addressing gaps in resuscitation team leadership skills, offering a valuable approach to competency-based medical education in critical care scenarios.The consistently high cognitive load reported by team leaders, regardless of experience level, suggests a need for guidance on strategies to better distribute cognitive demands among team members during cardiac arrest resuscitations.Experts demonstrate more advanced teamwork skills, inductive reasoning, and distributed cognition during cardiac arrest management, highlighting areas for focused skill development in novice leaders. OABL- eng OTO - NOTNLM OT - Cognitive load OT - clinical simulation OT - emergency medicine OT - medical education OT - virtual reality COIS- No potential conflict of interest was reported by the author(s). EDAT- 2025/03/03 17:12 MHDA- 2025/03/03 17:13 PMCR- 2025/03/03 CRDT- 2025/03/03 07:33 PHST- 2025/03/03 17:13 [medline] PHST- 2025/03/03 17:12 [pubmed] PHST- 2025/03/03 07:33 [entrez] PHST- 2025/03/03 00:00 [pmc-release] AID - 2470976 [pii] AID - 10.1080/07853890.2025.2470976 [doi] PST - ppublish SO - Ann Med. 2025 Dec;57(1):2470976. doi: 10.1080/07853890.2025.2470976. Epub 2025 Mar 3. PMID- 40028730 OWN - NLM STAT- MEDLINE DCOM- 20250303 LR - 20260813 IS - 1969-6213 (Electronic) IS - 1774-024X (Print) IS - 1774-024X (Linking) VI - 21 IP - 5 DP - 2025 Mar 3 TI - Transcatheter annuloplasty with the K-Clip system for tricuspid regurgitation: one-year results from the TriStar study. PG - e262-e271 LID - EIJ-D-24-00591 [pii] LID - 10.4244/EIJ-D-24-00591 [doi] AB - BACKGROUND: Despite the fact that morbidity and mortality rates significantly increase with tricuspid regurgitation (TR) severity, limited treatment options are available for treating severe TR. AIMS: The single-arm, multicentre, prospective Confirmatory Clinical Study of Treating Tricuspid Regurgitation With K-Clip TM Transcatheter Annuloplasty System (TriStar) evaluated the 1-year outcomes of the novel transcatheter K-Clip annuloplasty system in treating secondary TR. METHODS: Between May 2022 and October 2022, patients with >/=severe secondary TR despite optimal medical therapy at 11 centres in China were deemed candidates for transcatheter tricuspid repair by the local Heart Team and a multidisciplinary screening committee. Echocardiographic parameters, clinical and quality-of-life measures, and major adverse events were collected at 1 year. RESULTS: Ninety-six patients were enrolled (mean age 72.6+/-7.0 years, 60.4% female, mean TRI-SCORE 5.4+/-2.1). The technical success rate was 97.9%. At 1 year, echocardiographic follow-up showed an average reduction in the annular septolateral diameter of 11.3% (41.9 mm vs 37.1 mm; p<0.01), compared with baseline, with marked right ventricular remodelling. A total of 82.5% of patients had /=1 grade reduction. Patients experienced significant clinical improvements in New York Heart Association Functional Class I/II (32.6% to 96.5%; p<0.001), the 6-minute walk distance increased by 31.9+/-71.8 m (p<0.001), and the overall Kansas City Cardiomyopathy Questionnaire score increased by 7.6+/-17.7 points (p<0.001). Neither cardiovascular death nor reintervention were recorded at the 30-day or 1-year follow-up, while severe bleeding requiring further treatment was noted in 5 patients at 1 year. The Kaplan-Meier estimates of survival and freedom from heart failure rehospitalisation were 97.8% and 95.1%, respectively, at 1 year. CONCLUSIONS: The 1-year experience using the K-Clip tricuspid annuloplasty system demonstrated high survival and low rehospitalisation rates with durable TR reduction and clinical benefits in functional status and quality-of-life outcomes. FAU - Zhang, Xiaochun AU - Zhang X AD - Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai, China. AD - National Clinical Research Center for Interventional Medicine, Shanghai, China. FAU - Jin, Qinchun AU - Jin Q AD - Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai, China. AD - National Clinical Research Center for Interventional Medicine, Shanghai, China. FAU - Li, Wei AU - Li W AD - Department of Echocardiography, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Disease, Shanghai Institute of Medical Imaging, Shanghai, China. FAU - Pan, Cuizhen AU - Pan C AD - Department of Echocardiography, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Disease, Shanghai Institute of Medical Imaging, Shanghai, China. FAU - Guo, Kefang AU - Guo K AD - Department of Anaesthesiology, Zhongshan Hospital, Fudan University, Shanghai, China. FAU - Yang, Xue AU - Yang X AD - Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai, China. FAU - Li, Weidong AU - Li W AD - Department of Cardiovascular Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China. FAU - Song, Guangyuan AU - Song G AD - Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing, China. FAU - Luo, Jiangfang AU - Luo J AD - Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China. FAU - Li, Jie AU - Li J AD - Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China. FAU - Liu, Xianbao AU - Liu X AD - Department of Cardiology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. FAU - Chen, Shasha AU - Chen S AD - Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai, China. AD - National Clinical Research Center for Interventional Medicine, Shanghai, China. FAU - Zhang, Lei AU - Zhang L AD - Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai, China. AD - National Clinical Research Center for Interventional Medicine, Shanghai, China. FAU - Chen, Dandan AU - Chen D AD - Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai, China. AD - National Clinical Research Center for Interventional Medicine, Shanghai, China. FAU - Hou, Shiqiang AU - Hou S AD - Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai, China. AD - National Clinical Research Center for Interventional Medicine, Shanghai, China. FAU - Qian, Juying AU - Qian J AD - Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai, China. AD - National Clinical Research Center for Interventional Medicine, Shanghai, China. FAU - Wang, Jianan AU - Wang J AD - Department of Cardiology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. FAU - Zhou, Daxin AU - Zhou D AD - Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai, China. AD - National Clinical Research Center for Interventional Medicine, Shanghai, China. FAU - Ge, Junbo AU - Ge J AD - Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai, China. AD - National Clinical Research Center for Interventional Medicine, Shanghai, China. LA - eng PT - Clinical Study PT - Journal Article PT - Multicenter Study DEP - 20250303 PL - France TA - EuroIntervention JT - EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology JID - 101251040 SB - IM MH - Aged MH - Aged, 80 and over MH - Female MH - Humans MH - Male MH - Middle Aged MH - *Cardiac Catheterization/methods/instrumentation MH - *Cardiac Valve Annuloplasty/methods/instrumentation MH - Echocardiography MH - *Heart Valve Prosthesis Implantation/methods/instrumentation MH - Prospective Studies MH - Quality of Life MH - Treatment Outcome MH - *Tricuspid Valve/surgery/diagnostic imaging MH - *Tricuspid Valve Insufficiency/surgery/physiopathology/diagnostic imaging PMC - PMC11849535 COIS- The authors have no conflicts of interest relevant to the contents of this paper to declare. EDAT- 2025/03/03 17:12 MHDA- 2025/03/03 17:13 PMCR- 2026/03/03 CRDT- 2025/03/03 06:42 PHST- 2025/03/03 17:13 [medline] PHST- 2025/03/03 17:12 [pubmed] PHST- 2025/03/03 06:42 [entrez] PHST- 2026/03/03 00:00 [pmc-release] AID - EIJ-D-24-00591 [pii] AID - 10.4244/EIJ-D-24-00591 [doi] PST - epublish SO - EuroIntervention. 2025 Mar 3;21(5):e262-e271. doi: 10.4244/EIJ-D-24-00591. PMID- 40027994 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250304 IS - 1758-3764 (Electronic) IS - 1758-3756 (Print) IS - 1758-3756 (Linking) VI - 20 DP - 2025 TI - Interdisciplinary Management of Cardiotoxicity in Outpatient Settings: A Survey on Practices, Perceptions and Potential for Improvement. PG - e02 LID - 10.15420/ecr.2023.49 [doi] LID - e02 AB - BACKGROUND: Cardiotoxicity is a major concern in patients undergoing chemotherapy, requiring interdisciplinary management. However, the extent to which cardiotoxicity is managed in the outpatient setting among these specialists may vary, potentially leading to gaps in patient care. METHODS: This questionnaire study assessed the current practices and perceptions of cardiologists, oncologists and gynaecologists regarding the management of cardiotoxicity in patients undergoing outpatient chemotherapy in Germany. RESULTS: A total of 1,329 medical professionals were contacted via an online questionnaire; 132 (9.9%) were included in the survey. The participants in our survey reported treating a total of 1,905 chemotherapy patients per month (range 1-200). Of these patients, only 37% of those treated by oncologists (n=13) and 48% of those treated by gynaecologists (n=53) received cardiological care. The results showed that 37% (49/132) of the healthcare professionals surveyed said they performed cardiovascular toxicity risk assessment of chemotherapy in their clinical practice. More than half of the participants (56%, 39/70) expressed a need for simplified cardio-oncology guidelines. The majority of participants (84% [59/70] and 83% [58/70], respectively) requested tools to assist in cardiovascular toxicity risk assessment and the implementation of appropriate therapeutic measures for patients undergoing chemotherapy. CONCLUSION: Our study underscores potential interdisciplinary care gaps, possibly increasing the risk of undetected cardiotoxicity. Variations in cardiotoxicity management among specialities highlight the need for increased awareness and improved collaboration. Interdisciplinary clinical pathways could address these issues, as could a dedicated cardio-oncology network for primary care physicians' support. CI - Copyright (c) The Author(s), 2025. Published by Radcliffe Group Ltd. FAU - Quick, Silvio AU - Quick S AD - Department of Internal Medicine I, Cardiology, Angiology and Intensive Care, Klinikum Chemnitz gGmbH, Medical Campus Chemnitz of the TUD Dresden University of Technology Dresden, Germany. FAU - Payo-Anez, Lorena AU - Payo-Anez L AD - Department of Internal Medicine I, Cardiology, Angiology and Intensive Care, Klinikum Chemnitz gGmbH, Medical Campus Chemnitz of the TUD Dresden University of Technology Dresden, Germany. FAU - Casimiro de Almeida, Clara Marx AU - Casimiro de Almeida CM AD - Department of Internal Medicine I, Cardiology, Angiology and Intensive Care, Klinikum Chemnitz gGmbH, Medical Campus Chemnitz of the TUD Dresden University of Technology Dresden, Germany. FAU - Schmitt, Jochen AU - Schmitt J AD - Center of Evidence-Based Health Care, University Hospital and Faculty of Medicine Carl Gustav Carus, TUD Dresden University of Technology Dresden, Germany. FAU - Ibrahim, Karim AU - Ibrahim K AD - Department of Internal Medicine I, Cardiology, Angiology and Intensive Care, Klinikum Chemnitz gGmbH, Medical Campus Chemnitz of the TUD Dresden University of Technology Dresden, Germany. FAU - Kosters, Markus AU - Kosters M AD - Center of Evidence-Based Health Care, University Hospital and Faculty of Medicine Carl Gustav Carus, TUD Dresden University of Technology Dresden, Germany. FAU - Christoph, Marian AU - Christoph M AD - Department of Internal Medicine I, Cardiology, Angiology and Intensive Care, Klinikum Chemnitz gGmbH, Medical Campus Chemnitz of the TUD Dresden University of Technology Dresden, Germany. FAU - Haase, Tina AU - Haase T AD - Center of Evidence-Based Health Care, University Hospital and Faculty of Medicine Carl Gustav Carus, TUD Dresden University of Technology Dresden, Germany. FAU - Harst, Lorenz AU - Harst L AD - Center of Evidence-Based Health Care, University Hospital and Faculty of Medicine Carl Gustav Carus, TUD Dresden University of Technology Dresden, Germany. LA - eng PT - Journal Article DEP - 20250213 PL - England TA - Eur Cardiol JT - European cardiology JID - 101574780 PMC - PMC11865667 OTO - NOTNLM OT - Cardiotoxicity OT - cardio-oncology guidelines OT - cardiovascular risk assessment OT - healthcare practices OT - interdisciplinary management OT - survey COIS- Disclosure: JS has received institutional grants for investigator-initiated research from the German GBA, the BMG, BMBF, EU, Federal State of Saxony, Novartis, Sanofi, ALK, and Pfizer; has participated in advisory board meetings as a paid consultant for Sanofi, Lilly, and ALK; and serves the German Ministry of Health as a member of the Sachverstandigenrat Gesundheit und Pflege. TH has received travel support from the German Ministry of Health; and is updating the QISA volume C6 Depression for the aQua-Institut fur angewandte Qualitatsforderung und Forschung im Gesundheitswesen GmbH. MK has received institutional grants for investigator-initiated research from the German GBA, BMBF and the EU. LH has received financial support from the Volkswagen Foundation, Thieme-Verlag and the Fliedner Hochschule. All other authors have no conflicts of interest to declare. Data availability: The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions. Authors' contributions: Conceptualisation: SQ, JS, TH, LH; data curation: SQ, LPA, LH, TH; formal analysis: SQ, LPA, CMC, LH, TH; funding acquisition: JS, LH; investigation: LH, TH, SQ; methodology: SQ, LH; project administration: SQ; resources: JS, KI, MK, CMC; software: LH, TH, LPA; supervision: SQ, JS, KI, MK, MC; validation: SQ, JS, MK; visualisation: SQ, LPA; writing - original draft preparation: SQ, LPA; writing - review & editing: SQ, LPA, CMC, JS, KI, MK, MC, TH, LH. Ethics: This is an anonymous observational study. The ethics commission of TUD Dresden University of Technology has confirmed that no ethical approval is required. Consent: Written informed consent was obtained from all individuals included in the study. EDAT- 2025/03/03 17:12 MHDA- 2025/03/03 17:13 PMCR- 2025/02/13 CRDT- 2025/03/03 06:29 PHST- 2023/12/04 00:00 [received] PHST- 2024/08/16 00:00 [accepted] PHST- 2025/03/03 17:13 [medline] PHST- 2025/03/03 17:12 [pubmed] PHST- 2025/03/03 06:29 [entrez] PHST- 2025/02/13 00:00 [pmc-release] AID - 10.15420/ecr.2023.49 [doi] PST - epublish SO - Eur Cardiol. 2025 Feb 13;20:e02. doi: 10.15420/ecr.2023.49. eCollection 2025. PMID- 40027264 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250304 IS - 2468-4287 (Print) IS - 2468-4287 (Electronic) IS - 2468-4287 (Linking) VI - 10 IP - 6 DP - 2024 Dec TI - Early experience with baroreflex activation therapy from a vascular surgery perspective. PG - 101464 LID - 10.1016/j.jvscit.2024.101464 [doi] LID - 101464 AB - Baroreflex activation therapy (BAT) is an emerging device-based treatment for patients with heart failure with a reduced ejection fraction refractory to maximally tolerated goal-directed medical therapy. Currently, there is sparse literature on the critical role that vascular surgeons serve in the delivery of this novel therapy. This single-institution series describes the creation of a BAT program and elaborates on the function of vascular surgeons in the multidisciplinary heart failure team. The preoperative evaluation, perioperative care, and postoperative course of patients receiving BAT from March 2022 to August 2023 were retrospectively analyzed. Eleven patients were evaluated by a dedicated heart failure cardiologist for medical eligibility and assessed by a vascular surgeon for technical feasibility. Of the 11 patients, 7 were men (63.6%). The median age was 60.5 years (range, 44-73 years). No patient (0.00%) had existing carotid artery disease, and one patient (9.1%) had undergone previous neck radiation therapy. All 11 patients (100%) had an existing cardiac implantable electronic device, and BAT implantation was performed on the same side as the cardiac implantable electronic device in two patients (18.1%). Four patients (36.4%) required preoperative hospital admission for medical optimization before surgery. The median length of surgery was 82 minutes (range, 58-113 minutes), and the median length of stay in the hospital after surgery was 1 day (range, 0-6 days). No major adverse neurologic or cardiovascular events, cranial nerve injuries, device complications requiring reintervention, or heart failure-related mortality at 6 months occurred. Three patients (27.3%) experienced extraneous stimulations, which affected BAT tolerability. Within 6 months after BAT implantation, no significant improvements were observed for several heart failure disease burden markers compared with 6 months before BAT implantation. Our early results demonstrate that BAT implantation is a safe procedure with rare complications. Vascular surgeons play an important role in the multidisciplinary delivery of this novel device-based therapy. More data are needed to understand whether BAT is beneficial in the treatment of heart failure with a reduced ejection fraction refractory to maximally tolerated goal-directed medical therapy. CI - (c) 2024 Published by Elsevier Inc. on behalf of Society for Vascular Surgery. FAU - Chow, Christopher Yu AU - Chow CY AD - Division of Vascular and Endovascular Surgery, Department of Surgery, University of Miami, Miami, FL. FAU - Montoya, Christopher AU - Montoya C AD - Division of Vascular and Endovascular Surgery, Department of Surgery, University of Miami, Miami, FL. FAU - Sussman, Matthew AU - Sussman M AD - Division of Vascular and Endovascular Surgery, Department of Surgery, University of Miami, Miami, FL. FAU - Kenel-Pierre, Stefan AU - Kenel-Pierre S AD - Division of Vascular and Endovascular Surgery, Department of Surgery, University of Miami, Miami, FL. FAU - Velazquez, Omaida Caridad AU - Velazquez OC AD - Division of Vascular and Endovascular Surgery, Department of Surgery, University of Miami, Miami, FL. FAU - Grazette, Luanda AU - Grazette L AD - Division of Cardiovascular Medicine, University of Miami Health System, Miami, FL. FAU - Shao, Tony AU - Shao T AD - Division of Vascular and Endovascular Surgery, Department of Surgery, University of Miami, Miami, FL. LA - eng PT - Journal Article DEP - 20240224 PL - United States TA - J Vasc Surg Cases Innov Tech JT - Journal of vascular surgery cases and innovative techniques JID - 101701125 PMC - PMC11868725 OTO - NOTNLM OT - Baroreflex activation therapy OT - Barostim OT - Carotid OT - Extraneous stimulation OT - Heart failure COIS- L.G. is a consultant for CVRx and receives financial compensation from the company. EDAT- 2025/03/03 17:13 MHDA- 2025/03/03 17:14 PMCR- 2024/02/24 CRDT- 2025/03/03 06:19 PHST- 2023/12/29 00:00 [received] PHST- 2024/02/16 00:00 [accepted] PHST- 2025/03/03 17:14 [medline] PHST- 2025/03/03 17:13 [pubmed] PHST- 2025/03/03 06:19 [entrez] PHST- 2024/02/24 00:00 [pmc-release] AID - S2468-4287(24)00048-0 [pii] AID - 101464 [pii] AID - 10.1016/j.jvscit.2024.101464 [doi] PST - epublish SO - J Vasc Surg Cases Innov Tech. 2024 Feb 24;10(6):101464. doi: 10.1016/j.jvscit.2024.101464. eCollection 2024 Dec. PMID- 40026547 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250304 IS - 2994-5593 (Electronic) IS - 2994-5593 (Linking) VI - 3 IP - 4 DP - 2024 TI - Enhancing Team Dynamics and Leadership Skills for Residents Leading Multidisciplinary In-Patient Cardiac Arrest Teams. PG - 36-40 LID - 10.56305/001c.123597 [doi] AB - BACKGROUND: Cardiac arrest is a prevalent event with low survival rates, both in out-of-hospital and in-hospital settings. There is a lack of specific training programs addressing team dynamics and leadership skills during resuscitation events, creating a clinical gap. This project aimed to enhance team dynamics and improve leadership skills during IHCA resuscitation events. METHODS: We implemented the Mock Code Project for resident physicians from our Internal Medicine Residency Programs in the simulation center (i.e., in a controlled environment) to address this gap. Multidisciplinary team mock code scenarios were created for residents, allowing them to lead resuscitation simulations. The scenarios were based upon common conditions encountered during codes (Cardiac arrest). Trained evaluators provided real-time feedback, and pre-and post-surveys were conducted to assess team perception and gather feedback. RESULTS: Baseline data revealed that 98.6% (143 of 145 residents total) felt uncertain or lacked confidence in leading effective codes in our hospital prior to the intervention. Post-test survey outcome data revealed that 95.1% of participants (136 residents of 143) reported that the sessions challenged their skills at leading codes and improved their skills at managing resuscitation teams. CONCLUSION: Organized codes with clear roles, responsibilities, bed positioning, and clear leadership significantly improve closed-loop communication, effective team interaction, and patient outcomes. The Mock Code Project fills the gap in training programs by focusing on team dynamics and leadership skills during IHCA resuscitation. Ongoing evaluations and feedback ensure continual improvement in resident confidence and skills. Implementing organized codes benefits residents and healthcare teams, ultimately improving patient care during IHCA. Well-designed mock code scenarios with real-time feedback from senior physicians are an effective way for trainees to develop these skills and this awareness without compromising patient safety. FAU - Akwe, Joyce AU - Akwe J AUID- ORCID: 0000-0001-9561-6358 AD - Department of Medicine Emory University School of Medicine. AD - Department of Medicine Atlanta VA Health Care System/VISN 7 CRH. LA - eng PT - Journal Article DEP - 20241001 PL - United States TA - J Brown Hosp Med JT - Journal of Brown hospital medicine JID - 9918917745006676 PMC - PMC11864444 OTO - NOTNLM OT - Cardiac Arrest OT - Leadership OT - Mock Code OT - Residents OT - Resuscitation OT - Simulation COIS- The authors declare they have no conflicts of interest EDAT- 2025/03/03 17:13 MHDA- 2025/03/03 17:14 PMCR- 2024/10/01 CRDT- 2025/03/03 06:09 PHST- 2024/08/06 00:00 [received] PHST- 2024/09/11 00:00 [accepted] PHST- 2025/03/03 17:14 [medline] PHST- 2025/03/03 17:13 [pubmed] PHST- 2025/03/03 06:09 [entrez] PHST- 2024/10/01 00:00 [pmc-release] AID - 123597 [pii] AID - 10.56305/001c.123597 [doi] PST - epublish SO - J Brown Hosp Med. 2024 Oct 1;3(4):36-40. doi: 10.56305/001c.123597. eCollection 2024. PMID- 40021441 OWN - NLM STAT- MEDLINE DCOM- 20250614 LR - 20260620 IS - 1532-8422 (Electronic) IS - 1053-0770 (Linking) VI - 39 IP - 7 DP - 2025 Jul TI - Thirty Years of Perfusion Licensure in the United States: Exploring Current Concepts and Developing New Strategies for the Future. PG - 1832-1841 LID - S1053-0770(25)00083-7 [pii] LID - 10.1053/j.jvca.2025.01.025 [doi] AB - Over the past 30 years, licensure and certification requirements for cardiovascular perfusionists have varied considerably in the United States. In addition to intraoperative perfusion for cardiac surgery, the role of cardiovascular perfusion has recently expanded to include extracorporeal membrane oxygenation and the management of organ recovery systems used for transplantation. Efforts by organizations such as the American Society of ExtraCorporeal Technology and the American Board of Cardiovascular Perfusion have led to the recognition of perfusion as a distinct allied health profession in many states. However, in other states, perfusionists remain less regulated, potentially compromising patient safety . This work will review the current perfusion licensure landscape in the United States and suggest strategies to regulate an increasingly complex and technological profession . We describe successful experiences from licensed and unlicensed states and highlight national variations in adoption. These examples emphasize the importance of ongoing legislative and regulatory focus on perfusion and the potential positive impact of active perfusion licensure. As the role of the certified clinical perfusionist evolves, innovative technologies and techniques such as extracorporeal membrane oxygenation, ex situ organ perfusion, in vivo lung perfusion, and normothermic regional perfusion continue to expand the scope of perfusion practice. One strategy to improve the quality of perfusion services nationwide is the broad adoption and implementation of compact perfusion licensure, an agreement between states allowing licensed professionals to practice in multiple states while maintaining a single license. Such a compact would pave the way for a more consistent and safer practice across states, underscoring the necessity of a multidisciplinary approach between perfusionists, anesthesiologists, and surgeons in improving patient safety. CI - Copyright (c) 2025 Elsevier Inc. All rights reserved. FAU - Johnson, Blaine AU - Johnson B AD - Perfusion Services, UChicago Medicine, Chicago, IL, United States; Perfusion Education Program, University of Iowa Carver College of Medicine, Iowa City, IA, United States. Electronic address: blaine.johnson@uchicagomedicine.org. FAU - Martin, Mark AU - Martin M AD - Redline Perfusion & Consulting, LLC, Gainesville, FL, United States. FAU - Reagor, James AU - Reagor J AD - Department of Cardiovascular Perfusion, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, United States. FAU - Tung, Avery AU - Tung A AD - Department of Anesthesia and Critical Care, University of Chicago, Chicago, IL, United States. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20250122 PL - United States TA - J Cardiothorac Vasc Anesth JT - Journal of cardiothoracic and vascular anesthesia JID - 9110208 SB - IM MH - Humans MH - United States MH - *Perfusion/trends/standards/methods MH - *Extracorporeal Membrane Oxygenation/trends/methods/standards MH - *Licensure/trends/standards MH - *Cardiac Surgical Procedures/trends/methods MH - Forecasting MH - *Licensure, Medical/trends OTO - NOTNLM OT - certification OT - history OT - licensure OT - patient safety OT - perfusion COIS- Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Avery Tung reports a relationship with Critical Care & Resuscitation, Anesthesia & Analgesia that includes consulting or advisory. The other authors declare they are volunteer members of the American Society of ExtraCorporeal Technology Government Relations Committee. EDAT- 2025/03/01 14:39 MHDA- 2025/06/15 04:45 CRDT- 2025/02/28 21:59 PHST- 2024/11/17 00:00 [received] PHST- 2025/01/05 00:00 [revised] PHST- 2025/01/20 00:00 [accepted] PHST- 2025/06/15 04:45 [medline] PHST- 2025/03/01 14:39 [pubmed] PHST- 2025/02/28 21:59 [entrez] AID - S1053-0770(25)00083-7 [pii] AID - 10.1053/j.jvca.2025.01.025 [doi] PST - ppublish SO - J Cardiothorac Vasc Anesth. 2025 Jul;39(7):1832-1841. doi: 10.1053/j.jvca.2025.01.025. Epub 2025 Jan 22. PMID- 40021355 OWN - NLM STAT- MEDLINE DCOM- 20250510 LR - 20260715 IS - 1937-710X (Electronic) IS - 1062-3264 (Linking) VI - 34 IP - 2 DP - 2025 Mar 1 TI - Virtual Reality Simulation to Improve Postoperative Cardiothoracic Surgical Patient Outcomes. PG - 111-118 LID - 10.4037/ajcc2025704 [doi] AB - BACKGROUND: Patients undergoing medical procedures benefit from preprocedural education. OBJECTIVE: To evaluate a multisensory virtual reality preoperative educational program for patients undergoing elective cardiovascular surgical procedures with postoperative recovery in the intensive care unit (ICU) and assess its impact on patients' outcomes and experience. METHODS: Patients scheduled for elective cardiovascular surgical procedures with expected recovery in the ICU were enrolled. A multidisciplinary team designed the virtual reality simulation. Educational objectives focused on patient safety, family presence, ICU machinery and activities, reorientation, and communication with the care team. Historical control patients (n = 94) underwent medical record review and were contacted to complete surveys. Virtual reality simulation patients (n = 44) underwent medical record review, viewed the simulation at a preoperative appointment, and completed surveys. The study included patients admitted from June 4, 2019, to May 12, 2022. RESULTS: Durations of postoperative sedation and mechanical ventilation were lower in patients receiving virtual reality simulation. Most patients in the virtual reality simulation group (92%) said the simulation alleviated their anxiety and helped them understand what to expect in the ICU. The simulation improved their feeling of safety and decreased their fear of the unknown. Delirium incidence was not different in the 2 groups. CONCLUSIONS: Preprocedural education via virtual reality simulation can improve the experience and outcomes of patients undergoing elective cardiothoracic surgery with recovery in the ICU. CI - (c)2025 American Association of Critical-Care Nurses. FAU - Anderson, Robert J AU - Anderson RJ AD - Robert J. Anderson is a nurse practitioner, Department of Pulmonary and Critical Care, Mayo Clinic, Rochester, Minnesota. FAU - Bauer, Philippe R AU - Bauer PR AD - Philippe R. Bauer is a pulmonary/critical care physician, Department of Pulmonary and Critical Care, Mayo Clinic, Rochester. FAU - Arghami, Arman AU - Arghami A AD - Arman Arghami is a cardiovascular surgeon, Department of Cardiovascular Surgery, Mayo Clinic, Rochester. FAU - Haney, Rory M AU - Haney RM AD - Rory M. Haney is a nurse practitioner, Department of Cardiovascular Surgery, Mayo Clinic, Rochester. FAU - Reisdorf, Emily M AU - Reisdorf EM AD - Emily M. Reisdorf is a registered nurse, Department of Nursing, Mayo Clinic, Rochester. FAU - Baalson, Kiersten AU - Baalson K AD - Kiersten Baalson is a registered nurse, Department of Nursing, Mayo Clinic, Rochester. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Am J Crit Care JT - American journal of critical care : an official publication, American Association of Critical-Care Nurses JID - 9211547 SB - IM MH - Humans MH - Male MH - Female MH - *Virtual Reality MH - Middle Aged MH - Aged MH - Intensive Care Units MH - *Cardiac Surgical Procedures MH - Elective Surgical Procedures EDAT- 2025/03/01 14:39 MHDA- 2025/03/01 14:40 CRDT- 2025/02/28 21:22 PHST- 2025/03/01 14:40 [medline] PHST- 2025/03/01 14:39 [pubmed] PHST- 2025/02/28 21:22 [entrez] AID - 32664 [pii] AID - 10.4037/ajcc2025704 [doi] PST - ppublish SO - Am J Crit Care. 2025 Mar 1;34(2):111-118. doi: 10.4037/ajcc2025704. PMID- 40019616 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250321 IS - 2198-6576 (Print) IS - 2198-6584 (Electronic) IS - 2198-6576 (Linking) VI - 12 IP - 2 DP - 2025 Apr TI - The Cardiovascular Safety of Tumour Necrosis Factor Inhibitors in Arthritic Conditions: A Structured Review with Recommendations. PG - 211-236 LID - 10.1007/s40744-025-00753-x [doi] AB - There is accumulating evidence that inflammation is a key driver of atherosclerosis development and thrombotic complications. This pathophysiological mechanism explains, at least in part, the increased cardiovascular risk of patients with immune-mediated arthritis. Experimental and clinical studies have shown that tumour necrosis factor (TNF) plays a pathological role in both vascular and joint diseases, suggesting that TNF inhibitors (TNFis) may limit cardiovascular events in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) or spondyloarthritis (SpA). This review summarizes studies exploring the effects of TNFis on cardiovascular outcomes in patients with RA, PsA or SpA. Clinical studies suggest that TNFis reduce vascular inflammation and may improve (or prevent worsening of) endothelial dysfunction and arterial stiffness. There is evidence that TNFis reduce the incidence of cardiovascular events in patients with inflammatory arthritis compared with non-biological treatments, particularly in patients with rheumatoid arthritis. Fewer studies have compared the effects of different classes of biological therapy on outcomes, but found no significant difference in the risk of cardiovascular events between patients taking TNFis and other biological therapy. In contrast, patients at high cardiovascular risk may derive greater benefit from a TNFi than from a Janus kinase inhibitor (JAKi). The cardiovascular impact of JAKis is still under debate, with a recent safety warning. Targeted control of inflammation is a key strategy to reduce the risk of major adverse cardiovascular events in patients with inflammatory arthritis. Cardiovascular evaluation and risk stratification, using a multidisciplinary approach involving rheumatology and cardiology teams, are recommended to guide optimal immunomodulatory treatment. CI - (c) 2025. The Author(s). FAU - Avouac, Jerome AU - Avouac J AUID- ORCID: 0000-0002-2463-218X AD - Service de Rhumatologie, Hopital Cochin, AP-HP, Centre-Universite Paris Cite, Universite de Paris, 27 Rue du Faubourg Saint-Jacques, 75014, Paris, France. jerome.avouac@aphp.fr. FAU - Ait-Oufella, Hafid AU - Ait-Oufella H AUID- ORCID: 0000-0002-2955-0183 AD - INSERM U970, Paris Cardiovascular Research Center, Universite Paris Cite, Paris, France. AD - Service de Medecine Intensive-Reanimation, Hopital Saint-Antoine, AP-HP, Sorbonne Universite, Paris, France. FAU - Habauzit, Caroline AU - Habauzit C AD - Celltrion Healthcare France S.A.S., Issy-Les-Moulineaux, France. FAU - Benkhalifa, Salim AU - Benkhalifa S AD - Celltrion Healthcare France S.A.S., Issy-Les-Moulineaux, France. FAU - Combe, Bernard AU - Combe B AUID- ORCID: 0000-0003-4002-1861 AD - Montpellier University, Montpellier, France. LA - eng PT - Journal Article PT - Review DEP - 20250228 PL - England TA - Rheumatol Ther JT - Rheumatology and therapy JID - 101674543 PMC - PMC11920476 OAB - Inflammation in blood vessel walls can lead to serious cardiovascular conditions, such as heart attacks, strokes or sudden death. Excess inflammation in autoimmune arthritic conditions like rheumatoid arthritis (RA), psoriatic arthritis (PsA) and spondyloarthritis (SpA) places people with these conditions at high risk of developing cardiovascular disease (CVD). Treatments for inflammatory arthritis suppress inflammation, so they may also reduce the risk of CVD. Potent anti-inflammatory drugs called biologicals (injected into the blood vessels [intravenous] or beneath the skin [subcutaneous]) are used when conventional drugs cannot control symptoms. This review evaluates research into the effects of biologicals called tumour necrosis factor inhibitors (TNFis) on CVD in people with RA, PsA or SpA. TNFis suppress some of the changes to the structure and function of blood vessels that can lead to CVD. TNFis also reduce the incidence of cardiovascular events in people with inflammatory arthritis compared with non-biological treatments, particularly in people with RA. Less is known about whether TNFis reduce the risk of CVD compared with other types of biological treatment or Janus kinase inhibitors (JAKis), but people at high cardiovascular risk may derive greater benefit from a TNFi than a JAKi. Assessing and managing cardiovascular risk is important when caring for people with inflammatory arthritis. Effective control of inflammation relieves arthritic symptoms and reduces the CVD risk. People with inflammatory arthritis and CVD may also need treatment for other cardiovascular risk factors (e.g. high blood pressure or cholesterol), requiring effective communication between different healthcare providers (e.g. rheumatologists and cardiologists). OABL- eng OTO - NOTNLM OT - Cardiovascular outcomes OT - Psoriatic arthritis OT - Rheumatoid arthritis OT - Spondyloarthropathy OT - Tumour necrosis factor inhibitors COIS- Declarations. Conflict of interest: Jerome Avouac has received honoraria from Galapagos, Lilly, Pfizer, Abbvie, Bristol-Myers Squibb, Sanofi, Roche-Chugai, Nordic Pharma, Medac, Novartis, Biogen, Fresenius Kabi, Janssen, Celltrion and MSD; and research grants from Bristol-Myers Squibb, Pfizer (Passerelle), Novartis (Dreamer), Fresenius Kabi, Galapagos and Nordic Pharma. Hafid Ait-Oufella is the co-founder of POLYGON Therapeutics, a biotech company that is developing therapeutic monoclonal antibodies to limit CV disease burden. Caroline Habauzit and Salim Benkhalifa are employees of Celltrion Healthcare. Bernard Combe has received honoraria from Abbvie, Celltrion, Chugai, Lilly, Nordic and Pfizer. Ethical Approval: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. EDAT- 2025/02/28 12:24 MHDA- 2025/02/28 12:25 PMCR- 2025/02/28 CRDT- 2025/02/28 11:17 PHST- 2024/12/20 00:00 [received] PHST- 2025/02/13 00:00 [accepted] PHST- 2025/02/28 12:25 [medline] PHST- 2025/02/28 12:24 [pubmed] PHST- 2025/02/28 11:17 [entrez] PHST- 2025/02/28 00:00 [pmc-release] AID - 10.1007/s40744-025-00753-x [pii] AID - 753 [pii] AID - 10.1007/s40744-025-00753-x [doi] PST - ppublish SO - Rheumatol Ther. 2025 Apr;12(2):211-236. doi: 10.1007/s40744-025-00753-x. Epub 2025 Feb 28. PMID- 40018912 OWN - NLM STAT- MEDLINE DCOM- 20250510 LR - 20250511 IS - 1532-950X (Electronic) IS - 0161-3499 (Print) IS - 0161-3499 (Linking) VI - 54 IP - 4 DP - 2025 May TI - Improvement in short-term outcome over time, in a single center embarking on a canine mitral valve repair program using a structured multidisciplinary approach. PG - 675-685 LID - 10.1111/vsu.14229 [doi] AB - OBJECTIVE: To describe a structured approach to the development of a mitral valve repair (MVR) program for dogs with myxomatous mitral valve disease (MMVD) and to document the change in short term outcome over time. STUDY DESIGN: Clinical prospective study. ANIMALS: Dogs (n = 132) with MMVD undergoing MVR at a single hospital. METHODS: Using a carefully structured multidisciplinary approach to patient selection, surgical treatment, and postoperative care that incorporated both "reflective" and "deliberate" practice, we embarked on an MVR program alongside our pre-existing open heart surgery program. Data were gathered for the first 132 dogs undergoing MVR in this program (between July 2015 and November 2022). Short-term survival was defined as dogs that were discharged from the hospital. The dogs were divided into four groups of equal size based on chronological order and the data within each group compared using descriptive statistics. RESULTS: The breeds most represented were Cavalier King Charles Spaniels (CKCS) and Chihuahuas. The MMVD was categorized clinically as stage D in 36/132 (27%), stage C in 88/132 (67%) and stage B2 in 8/132 (6%) of affected dogs. Overall, 107/132 (81%) of the dogs survived to discharge. A consistent trend of improved short-term outcome was observed, with survival rate of 22/33 in the first quartile, 27/33 in the second quartile, 28/33 in the third quartile, and 30/33 dogs in the fourth quartile. CONCLUSION: A structured organized approach by a team of consistent personnel resulted in an improvement in outcome over time. This improvement most likely reflected improvement in both technical and non-technical skills within this complex sociotechnical environment. CLINICAL SIGNIFICANCE: What constitutes an acceptable performance for MVR in the dog has not been defined so the number of cases that constitute the "learning curve" during program development and the number of cases required in the "skills maintenance" phase remain unknown. The data reported here, however, describe the level of organizational commitment and the case throughput required to begin the process of establishing a successful MVR program and as such, should be useful to any team considering this therapy. CI - (c) 2025 The Author(s). Veterinary Surgery published by Wiley Periodicals LLC on behalf of American College of Veterinary Surgeons. FAU - Brockman, Daniel J AU - Brockman DJ AUID- ORCID: 0000-0002-2133-9500 AD - Royal Veterinary College, University of London, London, UK. FAU - Greensmith, Thomas D AU - Greensmith TD AD - Royal Veterinary College, University of London, London, UK. FAU - Rossanese, Matteo AU - Rossanese M AUID- ORCID: 0000-0001-8884-4088 AD - Royal Veterinary College, University of London, London, UK. FAU - Young, Alison AU - Young A AD - Royal Veterinary College, University of London, London, UK. FAU - Carey, Sarah L AU - Carey SL AD - Royal Veterinary College, University of London, London, UK. FAU - Boswood, Adrian AU - Boswood A AD - Royal Veterinary College, University of London, London, UK. FAU - Stathopoulou, Thaleia-Rengina AU - Stathopoulou TR AD - Royal Veterinary College, University of London, London, UK. FAU - Jimenez, Carolina Palacios AU - Jimenez CP AD - Royal Veterinary College, University of London, London, UK. FAU - Cross, Nigel AU - Cross N AD - Royal Veterinary College, University of London, London, UK. LA - eng GR - Tailwaggers Club to the Royal Veterinary College/ PT - Journal Article DEP - 20250228 PL - United States TA - Vet Surg JT - Veterinary surgery : VS JID - 8113214 SB - IM MH - Animals MH - Dogs MH - *Dog Diseases/surgery MH - Prospective Studies MH - Male MH - Female MH - Treatment Outcome MH - *Mitral Valve Insufficiency/veterinary/surgery MH - *Mitral Valve/surgery PMC - PMC12063714 COIS- The authors declare no conflict of interest related to this report. EDAT- 2025/02/28 12:24 MHDA- 2025/05/11 00:46 PMCR- 2025/05/09 CRDT- 2025/02/28 06:23 PHST- 2024/12/05 00:00 [revised] PHST- 2024/08/06 00:00 [received] PHST- 2025/02/03 00:00 [accepted] PHST- 2025/05/11 00:46 [medline] PHST- 2025/02/28 12:24 [pubmed] PHST- 2025/02/28 06:23 [entrez] PHST- 2025/05/09 00:00 [pmc-release] AID - VSU14229 [pii] AID - 10.1111/vsu.14229 [doi] PST - ppublish SO - Vet Surg. 2025 May;54(4):675-685. doi: 10.1111/vsu.14229. Epub 2025 Feb 28. PMID- 40017837 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250301 IS - 2474-8714 (Electronic) IS - 2474-8706 (Print) IS - 2474-8706 (Linking) VI - 9 IP - 1 DP - 2025 Jan TI - Tricuspid Regurgitation in the Setting of Cardiac Implantable Electronic Devices. PG - 100319 LID - 10.1016/j.shj.2024.100319 [doi] LID - 100319 AB - Cardiac implantable electronic devices (CIEDs) have been increasingly used in the management of various rhythm disorders amidst an aging population with more prevalent cardiovascular comorbidities. Although generally well-tolerated and safe, implantation of CIEDs may result in or worsen tricuspid regurgitation (TR), which is associated with a higher risk of morbidity and mortality. Several mechanisms of TR following device implantation have been proposed, and multiple diagnostic tests, percutaneous and surgical interventions, and alternative pacing methods have been developed to address this. CIED-related TR thus requires a multidisciplinary team of experts in cardiac imaging, interventional cardiology, electrophysiology, and cardiothoracic surgery with a comprehensive understanding of this multifaceted disease. The objective of this review is to summarize the epidemiology, clinical presentation, and management of CIED-related TR. CI - (c) 2024 The Author(s). FAU - Aldaas, Omar M AU - Aldaas OM AD - Division of Cardiology, University of California San Diego, La Jolla, California. FAU - Ma, Gary AU - Ma G AD - Division of Cardiology, University of California San Diego, La Jolla, California. FAU - Bui, Quan AU - Bui Q AD - Division of Cardiology, University of California San Diego, La Jolla, California. FAU - Reeves, Ryan R AU - Reeves RR AD - Division of Cardiology, University of California San Diego, La Jolla, California. FAU - Birgersdotter-Green, Ulrika AU - Birgersdotter-Green U AD - Division of Cardiology, University of California San Diego, La Jolla, California. LA - eng PT - Journal Article PT - Review DEP - 20240522 PL - United States TA - Struct Heart JT - Structural heart : the journal of the Heart Team JID - 101743256 PMC - PMC11864137 OTO - NOTNLM OT - Cardiac implantable electronic devices OT - Cardiac resynchronization therapy OT - Defibrillator OT - Pacemaker OT - Tricuspid regurgitation COIS- The authors report no conflict of interest. EDAT- 2025/02/28 06:22 MHDA- 2025/02/28 06:23 PMCR- 2024/05/22 CRDT- 2025/02/28 05:00 PHST- 2024/03/14 00:00 [received] PHST- 2024/04/18 00:00 [revised] PHST- 2024/04/25 00:00 [accepted] PHST- 2025/02/28 06:23 [medline] PHST- 2025/02/28 06:22 [pubmed] PHST- 2025/02/28 05:00 [entrez] PHST- 2024/05/22 00:00 [pmc-release] AID - S2474-8706(24)00067-8 [pii] AID - 100319 [pii] AID - 10.1016/j.shj.2024.100319 [doi] PST - epublish SO - Struct Heart. 2024 May 22;9(1):100319. doi: 10.1016/j.shj.2024.100319. eCollection 2025 Jan. PMID- 40017833 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250301 IS - 2474-8714 (Electronic) IS - 2474-8706 (Print) IS - 2474-8706 (Linking) VI - 9 IP - 1 DP - 2025 Jan TI - A Review of "Access to Care" Issues in Aortic Stenosis Patients: A Negative Report Card. PG - 100351 LID - 10.1016/j.shj.2024.100351 [doi] LID - 100351 AB - The identification and management of patients with aortic stenosis exist along a continuum that includes healthy living, latent progression, diagnosis, treatment, and posttreatment recovery. Barriers to the provision of appropriate care for these patients can occur at any stage along this continuum. Despite the presence of diagnostic echocardiograms, many patients with aortic stenosis are never clinically recognized, and the rate of mismanagement worsens among underrepresented minority groups and women. Regarding the treatment of clinically recognized aortic stenosis, only about half of patients with symptomatic severe aortic stenosis actually undergo aortic valve replacement within 2 ​years of diagnosis. Treatment rates are even lower among patients with symptomatic low-gradient severe aortic stenosis. Although several strategies have been raised by experts within the field to help and improve the diagnosis and treatment of patients with aortic valve disease, timely referral to a heart valve team specialist whenever aortic valve replacement is being considered likely remains the most pertinent intervention. Connecting these patients with fully informed aortic valve disease experts helps facilitate shared decision-making discussions, thus ensuring that patients have the opportunity to learn about and potentially receive the lifesaving interventions available to them. CI - (c) 2024 The Author(s). FAU - Reisman, Adam M AU - Reisman AM AD - Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, New York. FAU - Elmariah, Sammy AU - Elmariah S AD - Division of Cardiology, Department of Medicine, University of California San Francisco, San Francisco, California. LA - eng PT - Journal Article PT - Review DEP - 20240817 PL - United States TA - Struct Heart JT - Structural heart : the journal of the Heart Team JID - 101743256 PMC - PMC11864121 OTO - NOTNLM OT - Access to care OT - Aortic stenosis OT - Aortic valve disease OT - Aortic valve replacement OT - Health disparities OT - TAVR COIS- The authors report no conflict of interest. EDAT- 2025/02/28 06:21 MHDA- 2025/02/28 06:22 PMCR- 2024/08/17 CRDT- 2025/02/28 05:00 PHST- 2023/12/21 00:00 [received] PHST- 2024/06/22 00:00 [revised] PHST- 2024/07/03 00:00 [accepted] PHST- 2025/02/28 06:22 [medline] PHST- 2025/02/28 06:21 [pubmed] PHST- 2025/02/28 05:00 [entrez] PHST- 2024/08/17 00:00 [pmc-release] AID - S2474-8706(24)00106-4 [pii] AID - 100351 [pii] AID - 10.1016/j.shj.2024.100351 [doi] PST - epublish SO - Struct Heart. 2024 Aug 17;9(1):100351. doi: 10.1016/j.shj.2024.100351. eCollection 2025 Jan. PMID- 40016983 OWN - NLM STAT- MEDLINE DCOM- 20250510 LR - 20250510 IS - 1878-4429 (Electronic) IS - 1878-4429 (Linking) VI - 17 IP - 6 DP - 2024 Nov TI - An evidence-based treatment algorithm for congenital diaphragmatic hernia. PG - 750-762 LID - 10.1177/19345798241308462 [doi] AB - BACKGROUND: Congenital diaphragmatic hernia (CDH) affects more than 1100 newborns in the United States each year. Severity of clinical presentation is highly variable. Standardized care improves outcomes by promoting consistency in decision-making and clarifying goals of treatment, but CDH management has not yet been standardized. METHODS: We performed a comprehensive literature review with special consideration for-cardiac dysfunction, indications for extracorporeal membrane oxygenation (ECMO), and timing of repair. In collaboration with experts across specialties, we sought to develop and implement a treatment algorithm based on current CDH literature and our own institutional experience. RESULTS: Left ventricular (LV) hypoplasia and dysfunction is increasingly recognized as an important contributor to the severity of clinical presentation and cardiac dysfunction seen with CDH. Cardiac dysfunction is associated with poor outcomes and increased mortality. CDH-associated severe hypoxic respiratory failure refractory to medical therapy is one of the most common indications for ECMO in the neonatal period. The decision to initiate ECMO and selection of configuration should be shared by members of a multidisciplinary care team. The optimal timing of repair with respect to ECMO has been evolving in the last 3 decades. CONCLUSION: Following our review, we recommend (1) timely and detailed cardiac evaluation with echocardiogram after birth, and (2) early repair on ECMO for high-risk patients and delayed repair post-ECMO for low-risk patients with anticipated short ECMO run. This treatment algorithm is a step toward standardization of CDH management practices, which we expect will improve CDH outcomes at our institution and others. FAU - Stewart, Latoya A AU - Stewart LA AD - Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA. FAU - Wu, Yeu Sanz AU - Wu YS AUID- ORCID: 0009-0005-3224-3204 AD - Division of Pediatric Surgery, Columbia University Irving Medical Center / New York Presbyterian-Morgan Stanley Children's Hospital, New York, NY, USA. FAU - Channing, Alexandra AU - Channing A AD - Department of Pediatrics, Columbia University Irving Medical Center / New York Presbyterian-Morgan Stanley Children's Hospital, New York, NY, USA. FAU - Krishnan, Usha S AU - Krishnan US AD - Department of Pediatrics, Columbia University Irving Medical Center / New York Presbyterian-Morgan Stanley Children's Hospital, New York, NY, USA. FAU - Leone, Tina A AU - Leone TA AD - Department of Pediatrics, Columbia University Irving Medical Center / New York Presbyterian-Morgan Stanley Children's Hospital, New York, NY, USA. FAU - Goldshtrom, Nimrod AU - Goldshtrom N AD - Department of Pediatrics, Columbia University Irving Medical Center / New York Presbyterian-Morgan Stanley Children's Hospital, New York, NY, USA. FAU - Vargas Chaves, Diana P AU - Vargas Chaves DP AD - Department of Pediatrics, Columbia University Irving Medical Center / New York Presbyterian-Morgan Stanley Children's Hospital, New York, NY, USA. FAU - Penn, Anna AU - Penn A AD - Department of Pediatrics, Columbia University Irving Medical Center / New York Presbyterian-Morgan Stanley Children's Hospital, New York, NY, USA. FAU - DeFazio, Jennifer AU - DeFazio J AD - Division of Pediatric Surgery, Columbia University Irving Medical Center / New York Presbyterian-Morgan Stanley Children's Hospital, New York, NY, USA. FAU - Fallon, Erica M AU - Fallon EM AD - Division of Pediatric Surgery, Columbia University Irving Medical Center / New York Presbyterian-Morgan Stanley Children's Hospital, New York, NY, USA. FAU - Middlesworth, William AU - Middlesworth W AD - Division of Pediatric Surgery, Columbia University Irving Medical Center / New York Presbyterian-Morgan Stanley Children's Hospital, New York, NY, USA. FAU - Stylianos, Steven AU - Stylianos S AD - Division of Pediatric Surgery, Columbia University Irving Medical Center / New York Presbyterian-Morgan Stanley Children's Hospital, New York, NY, USA. FAU - Duron, Vincent P AU - Duron VP AD - Division of Pediatric Surgery, Columbia University Irving Medical Center / New York Presbyterian-Morgan Stanley Children's Hospital, New York, NY, USA. LA - eng PT - Journal Article PT - Review DEP - 20241219 PL - United States TA - J Neonatal Perinatal Med JT - Journal of neonatal-perinatal medicine JID - 101468335 SB - IM MH - Humans MH - *Hernias, Diaphragmatic, Congenital/therapy/complications/surgery MH - *Extracorporeal Membrane Oxygenation/methods MH - *Algorithms MH - Infant, Newborn MH - Echocardiography MH - Respiratory Insufficiency/therapy/etiology MH - Evidence-Based Medicine OTO - NOTNLM OT - CDH congenital Diaphragmatic hernia OT - ECMO extracorporeal membrane oxygenation OT - Level III evidence OT - left ventricular dysfunction OT - timing of repair OT - treatment protocols COIS- Conflicting interestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2025/02/28 06:21 MHDA- 2025/02/28 06:22 CRDT- 2025/02/28 01:03 PHST- 2025/02/28 06:22 [medline] PHST- 2025/02/28 06:21 [pubmed] PHST- 2025/02/28 01:03 [entrez] AID - 10.1177/19345798241308462 [doi] PST - ppublish SO - J Neonatal Perinatal Med. 2024 Nov;17(6):750-762. doi: 10.1177/19345798241308462. Epub 2024 Dec 19. PMID- 40015547 OWN - NLM STAT- MEDLINE DCOM- 20251220 LR - 20260813 IS - 1552-6259 (Electronic) IS - 0003-4975 (Print) IS - 0003-4975 (Linking) VI - 121 IP - 1 DP - 2026 Jan TI - Surgical vs Transcatheter Aortic Valve Replacement in Patients 65 Years of Age and Older. PG - 110-119 LID - S0003-4975(25)00165-1 [pii] LID - 10.1016/j.athoracsur.2025.02.003 [doi] AB - BACKGROUND: Approval of transcatheter aortic valve replacement (TAVR) for all risk profiles has extended TAVR use in patients not otherwise examined in clinical trials. We sought to evaluate contemporary real-world outcomes of surgical aortic valve replacement (SAVR) vs TAVR in Medicare beneficiaries by risk strata. METHODS: Using the US Centers for Medicare Services database, all patients aged 65-85 years undergoing isolated first-time SAVR (n = 34,215) or TAVR (n = 124,897) were evaluated (2018-2022). Predicted patient risk accounting for comorbidities simulating The Society of Thoracic Surgeons predicted risk of surgical mortality, but including frailty, were stratified by low (<4%, n = 36,297 TAVR; n = 14,693 SAVR), intermediate (4%-8%, n = 44,026 TAVR; n = 9693 SAVR), or high (>8%, n = 44,574 TAVR; n = 9841 SAVR) risk. Doubly robust risk adjustment with inverse probability weighting and multilevel regression with competing-risk time-to-event analyses compared outcomes. RESULTS: SAVR was associated with higher risk-adjusted in-hospital mortality, acute kidney injury, and bleeding but lower pacemaker rate compared with TAVR across all risk strata (all P < .05). Longitudinal 5-year analysis highlighted that, compared with TAVR, SAVR was associated with superior freedom from composite death, stroke, or valve reintervention in low- and intermediate-risk patients (hazard ratio [HR] 0.85, P = .044, and HR 0.86, P = .039, respectively) as well as lower overall readmission for stroke in low- (HR 0.72, P = .038) and intermediate- (HR 0.78, P = .042) risk patients. CONCLUSIONS: In low- and intermediate-risk Medicare beneficiaries, SAVR was associated with higher in-hospital mortality but superior 5-year longitudinal freedom from death, stroke, or valve reintervention compared to TAVR. These data may further enhance heart team decision-making and patient counseling. CI - Copyright (c) 2025 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved. FAU - Wolfe, Stanley AU - Wolfe S AD - Department of Cardiovascular and Thoracic Surgery, West Virginia University, Morgantown, West Virginia. FAU - Jagadeesan, Vikrant AU - Jagadeesan V AD - Department of Cardiology, West Virginia University, Morgantown, West Virginia. FAU - Wei, Lawrence AU - Wei L AD - Department of Cardiovascular and Thoracic Surgery, West Virginia University, Morgantown, West Virginia. FAU - Hayanga, J W AU - Hayanga JW AD - Department of Cardiovascular and Thoracic Surgery, West Virginia University, Morgantown, West Virginia. FAU - Chauhan, Dhaval AU - Chauhan D AD - Department of Cardiovascular and Thoracic Surgery, West Virginia University, Morgantown, West Virginia. FAU - Evans, R Tyler AU - Evans RT AD - Department of Surgery, UPMC Central Pennsylvania, Harrisburg, Pennsylvania. FAU - Mascio, Christopher AU - Mascio C AD - Department of Cardiovascular and Thoracic Surgery, West Virginia University, Morgantown, West Virginia. FAU - Rankin, J Scott AU - Rankin JS AD - Department of Cardiovascular and Thoracic Surgery, West Virginia University, Morgantown, West Virginia. FAU - Daggubati, Ramesh AU - Daggubati R AD - Department of Cardiology, West Virginia University, Morgantown, West Virginia. FAU - Badhwar, Vinay AU - Badhwar V AD - Department of Cardiovascular and Thoracic Surgery, West Virginia University, Morgantown, West Virginia. FAU - Mehaffey, J Hunter AU - Mehaffey JH AD - Department of Cardiovascular and Thoracic Surgery, West Virginia University, Morgantown, West Virginia. Electronic address: james.mehaffey@wvumedicine.org. LA - eng GR - UM1 HL088925/HL/NHLBI NIH HHS/United States PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20250225 PL - Netherlands TA - Ann Thorac Surg JT - The Annals of thoracic surgery JID - 15030100R SB - IM MH - Humans MH - Aged, 80 and over MH - *Transcatheter Aortic Valve Replacement/methods MH - Male MH - Female MH - Aged MH - *Aortic Valve Stenosis/surgery/mortality MH - United States/epidemiology MH - Postoperative Complications/epidemiology MH - Hospital Mortality/trends MH - Retrospective Studies MH - Risk Assessment MH - *Heart Valve Prosthesis Implantation/methods MH - Treatment Outcome MH - Medicare PMC - PMC13454763 MID - NIHMS2201077 COIS- Disclosures The authors have no conflicts of interest to disclose. EDAT- 2025/02/28 00:20 MHDA- 2025/12/21 01:48 PMCR- 2026/08/10 CRDT- 2025/02/27 19:34 PHST- 2024/11/13 00:00 [received] PHST- 2025/01/15 00:00 [revised] PHST- 2025/02/18 00:00 [accepted] PHST- 2025/12/21 01:48 [medline] PHST- 2025/02/28 00:20 [pubmed] PHST- 2025/02/27 19:34 [entrez] PHST- 2026/08/10 00:00 [pmc-release] AID - S0003-4975(25)00165-1 [pii] AID - 10.1016/j.athoracsur.2025.02.003 [doi] PST - ppublish SO - Ann Thorac Surg. 2026 Jan;121(1):110-119. doi: 10.1016/j.athoracsur.2025.02.003. Epub 2025 Feb 25. PMID- 40014801 OWN - NLM STAT- MEDLINE DCOM- 20251021 LR - 20260623 IS - 1526-7598 (Electronic) IS - 0003-2999 (Print) IS - 0003-2999 (Linking) VI - 141 IP - 5 DP - 2025 Nov 1 TI - Design and Staged Implementation of a Multidisciplinary Preoperative Anemia Clinic at a Tertiary Care Medical Center. PG - 964-974 LID - 10.1213/ANE.0000000000007435 [doi] AB - BACKGROUND: Preoperative anemia is common and associated with adverse outcomes in surgical patients. There is limited information to guide the design and implementation of preoperative anemia clinics (PAC), which represents a critical barrier to entry for many practices. METHODS: This is a descriptive observational study highlighting the design and implementation of a multidisciplinary PAC, including key steps in planning, stakeholder engagement, organizational structure, identification of target populations, establishing anemia treatments, information technology and electronic health record integration, provider training, and data infrastructure. Demographic and clinical characteristics, laboratory results, and anemia treatments for individuals evaluated in the PAC from November 4, 2019 through September 15, 2023 are enumerated. Patient-reported outcomes (PROs) assessing changes in anemia symptoms and well-being after surgery are evaluated for 2 subsets of patients (one before PAC implementation [pre-PAC], another after PAC implementation [post-PAC]), without formal statistical comparison given limited sample sizes. RESULTS: The PAC was initiated as a multidisciplinary effort under support from a Mayo Clinic Practice Transformation Award in 2019, including broad representation from anesthesiology, surgery, and medical practices, along with institutional project management support (eg, project manager, information technologists, systems engineers). While initially limited to cardiac surgery patients, the PAC underwent planned incremental expansion to include other surgical services. Over the study period, 1188 PAC consultations across 1159 unique patients met eligibility criteria, with a median age of 66 (57-73) years and 58.1% women. The most common etiology of anemia was iron deficiency (69.1%) followed by anemia related to cancer (17.3%). Anemia-directed therapies were recommended in 1038 (87.4%) encounters, with 730 (70.3%) of those receiving recommended treatment preoperatively. Seven hundred nine (97.1%) treatments included intravenous iron and 146 (20.0%) included erythropoiesis-stimulating agents. Fifteen pre-PAC and 38 post-PAC implementation patients completed PROs. PAC implementation was accompanied by earlier resolution of anemia symptoms and less pronounced declines in postoperative well-being scores. CONCLUSIONS: This report highlights the key steps for successful PAC implementation. Treatment is possible for most patients and may be accompanied by improvements in patient-important outcomes. CI - Copyright (c) 2025 International Anesthesia Research Society. FAU - Crispell, Ethan H AU - Crispell EH AD - From the Mayo Clinic Alix School of Medicine, Rochester, Minnesota. FAU - Cassianni, Claire E AU - Cassianni CE AD - From the Mayo Clinic Alix School of Medicine, Rochester, Minnesota. FAU - Burt, Jennifer M AU - Burt JM AD - Patient Blood Management Program, Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota. AD - Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota. FAU - Gonzalez, Jessica A AU - Gonzalez JA AD - Patient Blood Management Program, Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota. AD - Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota. FAU - Petsch, Jamie L AU - Petsch JL AD - Patient Blood Management Program, Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota. AD - Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota. FAU - Hanson, Andrew C AU - Hanson AC AD - Department of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota. FAU - Robbins, Kellie A AU - Robbins KA AD - Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota. FAU - Go, Ronald S AU - Go RS AD - Division of Hematology, Department of General Internal Medicine, Mayo Clinic, Rochester, Minnesota. FAU - Crestanello, Juan A AU - Crestanello JA AD - Department of Cardiovascular Surgery, Mayo Clinic, Rochester, Minnesota. FAU - Jacob, Adam K AU - Jacob AK AD - Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota. FAU - Kor, Daryl J AU - Kor DJ AD - Patient Blood Management Program, Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota. AD - Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota. FAU - Warner, Matthew A AU - Warner MA AD - Patient Blood Management Program, Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota. AD - Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota. LA - eng GR - K23 HL153310/HL/NHLBI NIH HHS/United States GR - K23HL153310/Mayo Clinic Kern Center for the Science of Health Care Delivery Practice Transformation Award/ PT - Journal Article PT - Observational Study DEP - 20250227 PL - United States TA - Anesth Analg JT - Anesthesia and analgesia JID - 1310650 SB - IM MH - Humans MH - *Anemia/therapy/diagnosis/epidemiology MH - *Tertiary Care Centers/organization & administration MH - Female MH - Male MH - *Preoperative Care/methods MH - Middle Aged MH - *Patient Care Team/organization & administration MH - Aged MH - Patient Reported Outcome Measures PMC - PMC12353018 MID - NIHMS2045932 COIS- Conflicts of Interest, Funding : Please see DISCLOSURES at the end of this article. EDAT- 2025/02/27 18:20 MHDA- 2025/10/21 12:35 PMCR- 2026/02/27 CRDT- 2025/02/27 15:17 PHST- 2025/10/21 12:35 [medline] PHST- 2025/02/27 18:20 [pubmed] PHST- 2025/02/27 15:17 [entrez] PHST- 2026/02/27 00:00 [pmc-release] AID - 00000539-202511000-00008 [pii] AID - 10.1213/ANE.0000000000007435 [doi] PST - ppublish SO - Anesth Analg. 2025 Nov 1;141(5):964-974. doi: 10.1213/ANE.0000000000007435. Epub 2025 Feb 27. PMID- 40013804 OWN - NLM STAT- Publisher LR - 20250227 IS - 1538-4683 (Electronic) IS - 1061-5377 (Linking) DP - 2025 Feb 27 TI - Updated Review of Transcatheter Strategies and Intervention for Mitral Regurgitation. LID - 10.1097/CRD.0000000000000876 [doi] AB - Mitral regurgitation (MR) is a prevalent valvular heart disease with significant morbidity, particularly in aging populations. Management strategies for MR have evolved from traditional open-heart surgery to innovative transcatheter approaches, addressing the limitations of surgical repair in high-risk patients. Transcatheter edge-to-edge repair, exemplified by devices such as MitraClip and PASCAL, has shown efficacy in reducing MR severity, improving functional capacity, and decreasing heart failure hospitalizations in selected patients. Advances in annuloplasty and chordal repair offer minimally invasive options with promising early outcomes. Transcatheter mitral valve replacement represents the frontier of MR treatment, addressing anatomical complexities unsuitable for repair, though complications such as left ventricular outflow tract obstruction persist. Emerging data from clinical trials underscore the importance of patient selection and a multidisciplinary heart team approach. In this review, each modality is discussed concerning its indications, procedural techniques, outcomes, and associated challenges. It highlights the transformative potential of transcatheter mitral valve interventions while emphasizing the need for ongoing innovation and research to optimize outcomes and expand therapeutic options for patients with severe MR. CI - Copyright (c) 2025 Wolters Kluwer Health, Inc. All rights reserved. FAU - Passey, Siddhant AU - Passey S AD - From the Department of Internal Medicine, University of Connecticut, Farmington, CT. FAU - Patail, Haris AU - Patail H AD - Departments of Cardiology and Medicine, Westchester Medical Center, Valhalla, NY. FAU - Spevack, Daniel AU - Spevack D AD - Departments of Cardiology and Medicine, Westchester Medical Center, Valhalla, NY. FAU - Ahmad, Hasan AU - Ahmad H AD - Departments of Cardiology and Medicine, Westchester Medical Center, Valhalla, NY. FAU - Ohira, Suguru AU - Ohira S AD - Department of Cardiac Surgery, Westchester Medical Center, Valhalla, NY. FAU - Shimamura, Junichi AU - Shimamura J AD - Department of Cardiac Surgery, Westchester Medical Center, Valhalla, NY. FAU - Frishman, William H AU - Frishman WH AD - Department of Medicine, New York Medical College, Valhalla, NY. FAU - Aronow, Wilbert S AU - Aronow WS AD - Departments of Cardiology and Medicine, Westchester Medical Center, Valhalla, NY. AD - Department of Medicine, New York Medical College, Valhalla, NY. FAU - Haidry, Syed Abbas AU - Haidry SA AD - Departments of Cardiology and Medicine, Westchester Medical Center, Valhalla, NY. LA - eng PT - Journal Article DEP - 20250227 PL - United States TA - Cardiol Rev JT - Cardiology in review JID - 9304686 SB - IM COIS- Disclosure: The authors declare no conflict of interest. EDAT- 2025/02/27 12:27 MHDA- 2025/02/27 12:27 CRDT- 2025/02/27 09:03 PHST- 2025/02/27 12:27 [medline] PHST- 2025/02/27 12:27 [pubmed] PHST- 2025/02/27 09:03 [entrez] AID - 00045415-990000000-00421 [pii] AID - 10.1097/CRD.0000000000000876 [doi] PST - aheadofprint SO - Cardiol Rev. 2025 Feb 27. doi: 10.1097/CRD.0000000000000876. PMID- 40012319 OWN - NLM STAT- MEDLINE DCOM- 20250402 LR - 20260115 IS - 1467-1107 (Electronic) IS - 1047-9511 (Linking) VI - 35 IP - 4 DP - 2025 Apr TI - Cardiac treatment for Duchenne muscular dystrophy: consensus recommendations from the ACTION muscular dystrophy committee. PG - 770-775 LID - 10.1017/S1047951125000587 [doi] AB - INTRODUCTION: Duchenne muscular dystrophy is a devastating neuromuscular disorder characterized by the loss of dystrophin, inevitably leading to cardiomyopathy. Despite publications on prophylaxis and treatment with cardiac medications to mitigate cardiomyopathy progression, gaps remain in the specifics of medication initiation and optimization. METHOD: This document is an expert opinion statement, addressing a critical gap in cardiac care for Duchenne muscular dystrophy. It provides thorough recommendations for the initiation and titration of cardiac medications based on disease progression and patient response. Recommendations are derived from the expertise of the Advance Cardiac Therapies Improving Outcomes Network and are informed by established guidelines from the American Heart Association, American College of Cardiology, and Duchenne Muscular Dystrophy Care Considerations. These expert-derived recommendations aim to navigate the complexities of Duchenne muscular dystrophy-related cardiac care. RESULTS: Comprehensive recommendations for initiation, titration, and optimization of critical cardiac medications are provided to address Duchenne muscular dystrophy-associated cardiomyopathy. DISCUSSION: The management of Duchenne muscular dystrophy requires a multidisciplinary approach. However, the diversity of healthcare providers involved in Duchenne muscular dystrophy can result in variations in cardiac care, complicating treatment standardization and patient outcomes. The aim of this report is to provide a roadmap for managing Duchenne muscular dystrophy-associated cardiomyopathy, by elucidating timing and dosage nuances crucial for optimal therapeutic efficacy, ultimately improving cardiac outcomes, and improving the quality of life for individuals with Duchenne muscular dystrophy. CONCLUSION: This document seeks to establish a standardized framework for cardiac care in Duchenne muscular dystrophy, aiming to improve cardiac prognosis. FAU - Esteso, Paul AU - Esteso P AUID- ORCID: 0000-0003-3697-6972 AD - Cardiology, Boston Children's Hospital, Boston, MA, USA. FAU - Auerbach, Scott R AU - Auerbach SR AD - Cardiology, Denver Children's Hospital, Aurora, CO, USA. FAU - Bansal, Neha AU - Bansal N AD - Pediatric Cardiology, Mount Sinai Kravis Children's Hospital, New York, NY, USA. FAU - Harris, Rachel AU - Harris R AD - Pediatrics, Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN, USA. FAU - Soslow, Jonathan H AU - Soslow JH AUID- ORCID: 0000-0001-9194-5330 AD - Pediatrics, Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN, USA. FAU - Birnbaum, Brian F AU - Birnbaum BF AD - Cardiology, Children's Mercy, Kansas City, MO, USA. FAU - Conway, Jennifer AU - Conway J AD - Cardiology, Stollery Children's Hospital, Edmonton, AB, Canada. FAU - Cripe, Linda H AU - Cripe LH AD - Cardiology, Nationwide Children's Hospital, Columbus, OH, USA. FAU - Nandi, Deipanjan AU - Nandi D AD - Cardiology, Nationwide Children's Hospital, Columbus, OH, USA. FAU - Hayes, Emily AU - Hayes E AUID- ORCID: 0000-0002-4569-6860 AD - Cardiology, Nationwide Children's Hospital, Columbus, OH, USA. FAU - Gambetta, Katheryn E AU - Gambetta KE AD - Cardiology, Ann & Robert Lurie Children's Hospital of Chicago, Chicago, IL, USA. FAU - Hall, E Kevin AU - Hall EK AD - Pediatric Cardiology, Yale Children's Hospital, New Heaven, CT, USA. FAU - Hsu, Daphne T AU - Hsu DT AD - Cardiology, The Children's Hospital at Montefiore, Bronx, NY, USA. FAU - Kaufman, Beth D AU - Kaufman BD AD - Pediatric Cardiology, Lucille Packard Children's Hospital, Palo Alto, CA, USA. FAU - Rosenthal, David AU - Rosenthal D AD - Pediatric Cardiology, Lucille Packard Children's Hospital, Palo Alto, CA, USA. FAU - Kirmani, Sonya AU - Kirmani S AD - Cardiology, American Family Children's Hospital at the University of Wisconsin-Madison, Madison, WI, USA. FAU - Ploutz, Michelle S AU - Ploutz MS AD - Pediatric Cardiology, Primary Children's Hospital, Salt Lake City, UT, USA. FAU - Lal, Ashwin K AU - Lal AK AD - Pediatric Cardiology, Primary Children's Hospital, Salt Lake City, UT, USA. FAU - Peng, David M AU - Peng DM AD - Cardiology, C.S Mott Children's Hospital, Ann Arbor, MI, USA. FAU - Villa, Chet R AU - Villa CR AD - Cardiology, Cincinnati Children's Hospital, Cincinnati, OH, USA. FAU - Shugh, Svetlana AU - Shugh S AD - Pediatric Cardiology, Joe DiMaggio Children's Hospital, Hollywood, FL, USA. FAU - Wittlieb-Weber, Carol A AU - Wittlieb-Weber CA AD - Pediatric Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA, USA. FAU - Shih, Renata AU - Shih R AD - Child Health Research Institute at University of Florida Shands Children's Hospital, Gainesville, FL, USA. LA - eng PT - Consensus Statement PT - Journal Article DEP - 20250227 PL - England TA - Cardiol Young JT - Cardiology in the young JID - 9200019 SB - IM MH - Humans MH - *Cardiomyopathies/etiology/drug therapy/therapy MH - *Muscular Dystrophy, Duchenne/complications OTO - NOTNLM OT - Duchenne muscular dystrophy OT - cardiac medications OT - cardiomyopathy OT - heart failure EDAT- 2025/02/27 06:22 MHDA- 2025/04/02 06:25 CRDT- 2025/02/27 02:24 PHST- 2025/04/02 06:25 [medline] PHST- 2025/02/27 06:22 [pubmed] PHST- 2025/02/27 02:24 [entrez] AID - S1047951125000587 [pii] AID - 10.1017/S1047951125000587 [doi] PST - ppublish SO - Cardiol Young. 2025 Apr;35(4):770-775. doi: 10.1017/S1047951125000587. Epub 2025 Feb 27. PMID- 40007983 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250227 IS - 2451-0629 (Print) IS - 2451-0629 (Electronic) IS - 2451-0629 (Linking) VI - 9 DP - 2024 TI - Cardiac complications of arteriovenous access: a narrative review from a multidisciplinary team perspective. PG - e217-e225 LID - 10.5114/amsad/196826 [doi] AB - Although cardiovascular disease is common among hemodialysis patients, arteriovenous access creation has been invariably implicated in the evolution of adverse cardiac outcomes or deterioration of pre-existing cardiovascular disease. In most cases, these effects are subclinical but with potential underlying echocardiographic findings. Compared with grafts, arteriovenous fistulas are implicated more often, due to the progressively increased flow from the continuous dilatation of the venous outflow tract in the long term. The increasing flow is in the majority of patients well tolerated by cardiac adaptive alterations. However, the clinical impact is based on the balance between the amount of flow volume and the patient's cardiac reserves. Having extensively reviewed the existing English literature, we present the pathophysiology and the different types of cardiovascular complications, the indications, types, and efficacy of flow-restrictive procedures in the context of a high-flow AVF, as well as some precautions and considerations for AVF creation in high-risk patients. CI - Copyright: (c) 2024 Termedia & Banach. FAU - Stathopoulou, Melina AU - Stathopoulou M AD - Department of Vascular Surgery, General University Hospital of Patras, Patras, Greece. AD - Department of Surgery, General University Hospital of Patras, Patras, Greece. FAU - Tsimpoukis, Andreas AU - Tsimpoukis A AD - Department of Vascular Surgery, General University Hospital of Patras, Patras, Greece. FAU - Tasios, Konstantinos AU - Tasios K AD - Department of Surgery, General University Hospital of Patras, Patras, Greece. FAU - Papageorgopoulou, Chrysanthi AU - Papageorgopoulou C AD - Department of Vascular Surgery, General University Hospital of Patras, Patras, Greece. FAU - Mulita, Francesk AU - Mulita F AD - Department of Surgery, General University Hospital of Patras, Patras, Greece. AD - Department of Surgery, General Hospital of Eastern Achaia, Unit of Aigio, Aigio, Greece. FAU - Leivaditis, Vasileios AU - Leivaditis V AD - Department of Cardiothoracic and Vascular Surgery, Westpfalz Klinikum, Kaiserslautern, Germany. FAU - Papasotiriou, Marios AU - Papasotiriou M AD - Department of Nephrology and Kidney Transplantation, General University Hospital of Patras, Patras, Greece. FAU - Tchabashvili, Levan AU - Tchabashvili L AD - Department of Surgery, General Hospital of Eastern Achaia, Unit of Aigio, Aigio, Greece. FAU - Koutsogiannis, Nikolaos AU - Koutsogiannis N AD - Department of Cardiology, General University Hospital of Patras, Patras, Greece. FAU - Antzoulas, Andreas AU - Antzoulas A AD - Department of Surgery, General University Hospital of Patras, Patras, Greece. FAU - Kitrou, Panagiotis AU - Kitrou P AD - Department of Interventional Radiology, General University Hospital of Patras, Patras, Greece. FAU - Dimopoulos, Platon AU - Dimopoulos P AD - Department of Interventional Radiology, General University Hospital of Patras, Patras, Greece. FAU - Panagiotopoulos, Ioannis AU - Panagiotopoulos I AD - Department of Cardiac Surgery, Hippokratio General Hospital of Athens, Athens, Greece. FAU - Karydis, Nikolaos AU - Karydis N AD - Department of Transplantation Surgery, Department of Surgery General University Hospital of Patras, Patras, Greece. FAU - Papadoulas, Spyros AU - Papadoulas S AD - Department of Vascular Surgery, General University Hospital of Patras, Patras, Greece. LA - eng PT - Journal Article DEP - 20241231 PL - Poland TA - Arch Med Sci Atheroscler Dis JT - Archives of medical sciences. Atherosclerotic diseases JID - 101701205 PMC - PMC11851310 OTO - NOTNLM OT - arteriovenous fistula OT - end stage renal disease OT - flow-restrictive procedures OT - heart failure OT - high flow vascular access COIS- The authors declare no conflict of interest. EDAT- 2025/02/26 10:53 MHDA- 2025/02/26 10:54 PMCR- 2024/12/31 CRDT- 2025/02/26 04:41 PHST- 2024/11/01 00:00 [received] PHST- 2024/12/04 00:00 [accepted] PHST- 2025/02/26 10:54 [medline] PHST- 2025/02/26 10:53 [pubmed] PHST- 2025/02/26 04:41 [entrez] PHST- 2024/12/31 00:00 [pmc-release] AID - 196826 [pii] AID - 10.5114/amsad/196826 [doi] PST - epublish SO - Arch Med Sci Atheroscler Dis. 2024 Dec 31;9:e217-e225. doi: 10.5114/amsad/196826. eCollection 2024. PMID- 40007407 OWN - NLM STAT- MEDLINE DCOM- 20250510 LR - 20250510 IS - 1512-0112 (Print) IS - 1512-0112 (Linking) IP - 357 DP - 2024 Dec TI - PREVENTION OF COMPLICATIONS OF SURGICAL TREATMENT OF PATIENTS WITH OCCLUSION OF THE AORTOILIAC SEGMENT. PG - 159-167 AB - INTRODUCTION: The relevance of studying this topic is confirmed not only by the high incidence of aortoiliac segment occlusions, but also by the difficulty of preventing complications after surgical treatment. These complications can range from local infectious processes to serious systemic disorders such as renal failure, cardiovascular complications, and even death. AIM: to study the influence of concomitant pathologies on the outcome of surgical treatment with occlusion of the aortoiliac segment. Materias and methods. The study was conducted at the Semey Medical University. It was aimed at analyzing methods for minimizing complications in surgical treatment of patients suffering from aortoiliac segment occlusion. The study covered a wide range of aspects, from diagnostics to postoperative rehabilitation, and was implemented through a retrospective analysis of medical records of 300 patients who underwent open surgical treatment of this disease between September 2018 and September 2023. RESULTS: As part of a large clinical study, two groups of patients, each comprising 150 people, were compared. One group underwent preoperative drug correction of diabetes mellitus and chronic obstructive pulmonary disease (COPD), while the other group continued to receive standard treatment without additional corrections. During the analysis of postoperative complications, it was found that in the group of patients who underwent preoperative correction of comorbidities, complications were observed in 27 patients, which accounted for 18% of the total number. In contrast, in the group without such correction, postoperative complications were recorded in 51 patients, which is equal to 34%. Statistical analysis revealed a significant difference in the incidence of complications between the two groups (p=0.005, t=2.82), confirming the importance of preoperative optimization in reducing the risk of postoperative complications. Complications that arose after surgery included infectious manifestations such as wound infections and pneumonia, cardiovascular problems including myocardial infarction and cardiac arrhythmias, and thrombotic complications including deep vein thrombosis and pulmonary embolism (PE). For example, wound infections were observed in 13 cases among patients without correction and only in 6 cases among those who underwent correction. Pneumonia occurred in 19 cases in the non-corrected group and in 10 cases in the corrected group. These data indicate that preoperative optimization significantly reduces the risk of infectious complications after surgery. CONCLUSIONS: The study provided valuable data on the impact of preoperative preparation, including medical management of diabetes mellitus and COPD, on surgical outcomes in patients with aortoiliac occlusion. Based on the results, it can be concluded that careful preoperative assessment and preparation play a key role in reducing the risk of complications and improving clinical outcomes. In particular, preoperative correction of concomitant diseases significantly improves the condition of patients, as evidenced by higher functional test results, improved glycemic control, and decreased blood pressure. This, in turn, reduces the frequency and severity of intra- and postoperative complications, and reduces overall mortality. Analysis of predictors of complications showed that the duration of surgery and concomitant diabetes mellitus significantly increase the risk of postoperative complications. This emphasizes the need to develop and implement new surgical and anesthetic approaches aimed at optimizing the duration of operations and more careful monitoring of the condition of patients with diabetes. The results of the study also indicate the importance of a multidisciplinary approach to the treatment of this category of patients, including vascular surgeons, anesthesiologists, therapists, endocrinologists, pulmonologists and other specialists. This allows for comprehensive preoperative preparation, adequate intraoperative management and high-quality postoperative monitoring. Overall, the results of this study provide a basis for the development of new treatment strategies for patients with aortoiliac segment occlusion aimed at improving clinical outcomes and quality of life of patients. Further prospective studies are needed to confirm the effectiveness of the proposed approaches and their implementation in clinical practice. FAU - Imanbayev, M AU - Imanbayev M AD - 1Department of Cardiovascular and Thoracic Surgery named after B.S. Bulanov, Non-Commercial Joint-Stock Company "Semey Medical University" (NCJSC <>), Republic of Kazakhstan. FAU - Dyussupov, A AU - Dyussupov A AD - 2Non-Commercial Joint-Stock Company "Semey Medical University" (NCJSC <>), Republic of Kazakhstan. FAU - Sabitov, Y AU - Sabitov Y AD - 3Emergency Medical Care Hospital, Semey, Republic of Kazakhstan. FAU - Omarov, N AU - Omarov N AD - 4Department of Hospital Surgery, Anesthesiology and Reanimatology, Non-Commercial Joint-Stock Company "Semey Medical University" (NCJSC <>), Republic of Kazakhstan. FAU - Kazymov, Y AU - Kazymov Y AD - 1Department of Cardiovascular and Thoracic Surgery named after B.S. Bulanov, Non-Commercial Joint-Stock Company "Semey Medical University" (NCJSC <>), Republic of Kazakhstan. FAU - Kozhakhmetov, Zh AU - Kozhakhmetov Z AD - 1Department of Cardiovascular and Thoracic Surgery named after B.S. Bulanov, Non-Commercial Joint-Stock Company "Semey Medical University" (NCJSC <>), Republic of Kazakhstan. FAU - Toleutayeva, D AU - Toleutayeva D AD - 5Department of Epidemiology and Biostatistics, Non-Commercial Joint-Stock Company "Semey Medical University" (NCJSC <>), Republic of Kazakhstan. FAU - Abdrakhmanov, S AU - Abdrakhmanov S AD - 4Department of Hospital Surgery, Anesthesiology and Reanimatology, Non-Commercial Joint-Stock Company "Semey Medical University" (NCJSC <>), Republic of Kazakhstan. FAU - Akkaliyev, M AU - Akkaliyev M AD - 6Department of Surgical Disciplines, Non-Commercial Joint-Stock Company "Semey Medical University" (NCJSC <>), Republic of Kazakhstan. FAU - Masalov, A AU - Masalov A AD - 4Department of Hospital Surgery, Anesthesiology and Reanimatology, Non-Commercial Joint-Stock Company "Semey Medical University" (NCJSC <>), Republic of Kazakhstan. LA - eng PT - Journal Article PL - Georgia (Republic) TA - Georgian Med News JT - Georgian medical news JID - 101218222 SB - IM MH - Humans MH - *Postoperative Complications/prevention & control/etiology MH - Male MH - Female MH - Retrospective Studies MH - *Iliac Artery/surgery/pathology MH - Middle Aged MH - *Arterial Occlusive Diseases/surgery MH - Aged MH - Pulmonary Disease, Chronic Obstructive/drug therapy/complications/surgery EDAT- 2025/02/26 06:28 MHDA- 2025/02/26 06:29 CRDT- 2025/02/26 03:33 PHST- 2025/02/26 06:29 [medline] PHST- 2025/02/26 06:28 [pubmed] PHST- 2025/02/26 03:33 [entrez] PST - ppublish SO - Georgian Med News. 2024 Dec;(357):159-167. PMID- 40004919 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250228 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 14 IP - 4 DP - 2025 Feb 19 TI - Diabetes in Peripheral Artery Disease: Prevalence, Complications, and Polypharmacy. LID - 10.3390/jcm14041383 [doi] LID - 1383 AB - Background: Patients with peripheral artery disease (PAD) and diabetes face high risks of comorbidities, tissue loss, and cardiovascular events. As global type 2 diabetes (T2DM) prevalence rises, so does its incidence in symptomatic patients with PAD, though this population is under-studied in Australia. This cross-sectional analysis sought to characterize PAD patients with diabetes regarding prevalence, major complications, medication use, and prescribing patterns, comparing them to non-diabetic PAD patients. We also examined PAD complications in relation to diabetic control. Methods: This cross-sectional study looked at the baseline data from 105 PAD participants in the TEAM-PAD randomized controlled trial that were analyzed using descriptive statistics, prevalence odds ratios and regression analysis. Participants were recruited between June 2023 and August 2024 from public clinics, private surgeons, and Concord Repatriation General Hospital, Sydney. Results: Diabetes prevalence was 52.83% (n = 56) with 29.5% (n = 31) of participants with T2DM having uncontrolled hyperglycemia (HbA1c >/= 7%), which was weakly negatively correlated with age (r = -0.372, p = 0.039). Participants with T2DM were twice as likely to have a history of coronary artery disease (POR 2.43; 95% with a 95% confidence interval (CI) between 1.09-5.43, and over three times as likely to have tissue loss (POR 3.39; 95% CI 1.22-9.43). The odds of polypharmacy (>/=5 medications) were 10 times greater in participants with T2DM (POR 10.8; 95% CI 2.31-50.4), affecting 96.4% of this group. Conclusions: Diabetes prevalence and associated complications were higher than previous estimates, underscoring the challenges in managing diabetes and polypharmacy in participants with PAD. A multidisciplinary approach may improve outcomes. FAU - Baty, Mason AU - Baty M AD - Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW 2050, Australia. FAU - Chimoriya, Ritesh AU - Chimoriya R AUID- ORCID: 0000-0003-1121-2829 AD - Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW 2050, Australia. AD - Concord Institute of Academic Surgery, Concord Repatriation General Hospital, Concord, NSW 2139, Australia. FAU - James, Sophie AU - James S AD - Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW 2050, Australia. AD - Concord Institute of Academic Surgery, Concord Repatriation General Hospital, Concord, NSW 2139, Australia. FAU - Kritharides, Leonard AU - Kritharides L AUID- ORCID: 0000-0001-5818-8024 AD - Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW 2050, Australia. AD - Department of Cardiology, Concord Hospital, The University of Sydney, 1 Hospital Road, Concord, NSW 2139, Australia. FAU - Behdasht, Samim AU - Behdasht S AD - Department of Pharmacy, Concord Repatriation General Hospital, Concord, NSW 2139, Australia. FAU - Suryawanshi, Avinash AU - Suryawanshi A AD - Department of Endocrinology and Metabolism, Concord Repatriation General Hospital, Concord, NSW 2139, Australia. FAU - Aitken, Sarah J AU - Aitken SJ AUID- ORCID: 0000-0002-6701-6213 AD - Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW 2050, Australia. AD - Concord Institute of Academic Surgery, Concord Repatriation General Hospital, Concord, NSW 2139, Australia. CN - TEAM-PAD Collaborators LA - eng GR - ID: 107591/National Heart Foundation of Australia Vanguard Grant/ GR - 2022/Vascular Foundation of the ANZSVS/ PT - Journal Article DEP - 20250219 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC11856835 OTO - NOTNLM OT - PAD OT - cardiovascular complications OT - diabetes mellitus OT - diabetic control OT - multidisciplinary care OT - peripheral artery disease OT - polypharmacy COIS- The authors declare no conflicts of interest. Author R.C. is a Topical Advisory Panel for 'Endocrinology & Metabolism' of the Journal of Clinical Medicine but did not play any role in the peer-review and decision-making processes for this manuscript. EDAT- 2025/02/26 06:28 MHDA- 2025/02/26 06:29 PMCR- 2025/02/19 CRDT- 2025/02/26 01:20 PHST- 2024/12/22 00:00 [received] PHST- 2025/02/07 00:00 [revised] PHST- 2025/02/14 00:00 [accepted] PHST- 2025/02/26 06:29 [medline] PHST- 2025/02/26 06:28 [pubmed] PHST- 2025/02/26 01:20 [entrez] PHST- 2025/02/19 00:00 [pmc-release] AID - jcm14041383 [pii] AID - jcm-14-01383 [pii] AID - 10.3390/jcm14041383 [doi] PST - epublish SO - J Clin Med. 2025 Feb 19;14(4):1383. doi: 10.3390/jcm14041383. PMID- 40002818 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250228 IS - 2227-9059 (Print) IS - 2227-9059 (Electronic) IS - 2227-9059 (Linking) VI - 13 IP - 2 DP - 2025 Feb 7 TI - The Role of Early Risk Factor Modification and Ablation in Atrial Fibrillation Substrate Remodeling Prevention. LID - 10.3390/biomedicines13020405 [doi] LID - 405 AB - Atrial fibrillation (AF) is the most common sustained arrhythmia, contributing to significant morbidity and healthcare burden worldwide. This review evaluates the role of early risk factor modification and timely catheter ablation in preventing AF progression and improving patient outcomes. A comprehensive literature search was conducted using PubMed, MEDLINE, and Google Scholar, focusing on studies published after the ESC 2020 guidelines for the diagnosis and management of AF up to the release of the updated ESC 2024 guidelines for the management of AF. Keywords included "atrial fibrillation", "catheter ablation", "risk factor management", and "psychological stress". Relevant clinical trials, randomized controlled trials, systematic reviews, and meta-analyses were included, with particular emphasis on novel studies contributing to the ESC 2024 updated recommendations. Traditional risk factors such as obesity, hypertension, diabetes, sleep apnea, alcohol consumption, and physical exertion are well established in AF progression. Early evidence also suggests a role for psychological stress and mood disorders, including depression and post-traumatic stress disorder (PTSD), in increasing AF susceptibility. Psychological stress and mood disorders are linked to AF primarily through behavioral changes such as poor medication adherence, unhealthy lifestyle choices, and increased substance use. Recent guidelines recommend early catheter ablation in selected patients to reduce AF burden, prevent atrial remodeling, and improve quality of life, particularly in those resistant to antiarrhythmic drugs or individuals with AF-induced cardiomyopathy. Furthermore, we highlight the importance of a patient-centered, multidisciplinary approach, integrating electrophysiologists, cardiologists, and primary care providers with structured risk factor interventions and shared decision-making. Despite these advances, gaps remain in defining optimal timing, patient selection, and long-term benefits of catheter ablation in persistent AF, necessitating the need for further research. By integrating early intervention, personalized treatment strategies, and collaborative care models, we may usher in a paradigm shift in AF management, improving long-term cardiovascular outcomes and patient quality of life. FAU - Koniari, Ioanna AU - Koniari I AUID- ORCID: 0000-0002-1033-5299 AD - Department of Medicine, Division of Cardiology, University Hospital of Patras, 265 04 Patras, Greece. AD - Liverpool Centre for Cardiovascular Science, Liverpool L14 3PE, UK. FAU - Bozika, Maria AU - Bozika M AUID- ORCID: 0009-0004-8215-427X AD - Department of Medicine, Division of Cardiology, University Hospital of Patras, 265 04 Patras, Greece. FAU - Nastouli, Kassiani-Maria AU - Nastouli KM AD - Department of Medicine, Division of Cardiology, University Hospital of Patras, 265 04 Patras, Greece. FAU - Tzegka, Dimitra AU - Tzegka D AD - Department of Medicine, Division of Cardiology, University Hospital of Patras, 265 04 Patras, Greece. FAU - Apostolos, Anastasios AU - Apostolos A AUID- ORCID: 0000-0003-2616-7952 AD - First Department of Cardiology, Hippocration General Hospital, National and Kapodistrian University of Athens, 157 72 Athens, Greece. FAU - Velissaris, Dimitrios AU - Velissaris D AUID- ORCID: 0000-0002-9319-323X AD - Department of Internal Medicine, University Hospital of Patras, 265 04 Patras, Greece. FAU - Leventopoulos, Georgios AU - Leventopoulos G AD - Department of Medicine, Division of Cardiology, University Hospital of Patras, 265 04 Patras, Greece. FAU - Perperis, Angelos AU - Perperis A AUID- ORCID: 0000-0003-2290-3940 AD - Department of Medicine, Division of Cardiology, University Hospital of Patras, 265 04 Patras, Greece. FAU - Kounis, Nicholas G AU - Kounis NG AUID- ORCID: 0000-0002-9751-6710 AD - Department of Medicine, Division of Cardiology, University Hospital of Patras, 265 04 Patras, Greece. FAU - Tsigkas, Grigorios AU - Tsigkas G AUID- ORCID: 0000-0002-2779-0765 AD - Department of Medicine, Division of Cardiology, University Hospital of Patras, 265 04 Patras, Greece. FAU - Davlouros, Periklis AU - Davlouros P AD - Department of Medicine, Division of Cardiology, University Hospital of Patras, 265 04 Patras, Greece. LA - eng PT - Journal Article PT - Review DEP - 20250207 PL - Switzerland TA - Biomedicines JT - Biomedicines JID - 101691304 PMC - PMC11852994 OTO - NOTNLM OT - atrial fibrillation OT - catheter ablation OT - paroxysmal atrial fibrillation OT - risk factor modification COIS- The authors declare no conflict of interest. EDAT- 2025/02/26 06:28 MHDA- 2025/02/26 06:29 PMCR- 2025/02/07 CRDT- 2025/02/26 01:09 PHST- 2025/01/05 00:00 [received] PHST- 2025/02/02 00:00 [revised] PHST- 2025/02/05 00:00 [accepted] PHST- 2025/02/26 06:29 [medline] PHST- 2025/02/26 06:28 [pubmed] PHST- 2025/02/26 01:09 [entrez] PHST- 2025/02/07 00:00 [pmc-release] AID - biomedicines13020405 [pii] AID - biomedicines-13-00405 [pii] AID - 10.3390/biomedicines13020405 [doi] PST - epublish SO - Biomedicines. 2025 Feb 7;13(2):405. doi: 10.3390/biomedicines13020405. PMID- 39997497 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250227 IS - 2308-3425 (Electronic) IS - 2308-3425 (Linking) VI - 12 IP - 2 DP - 2025 Feb 10 TI - Transfemoral Transcatheter Aortic Valve Implantation at Hospitals Without On-Site Cardiac Surgery (TAVI at Home): A Multicenter Prospective Interventional Study. LID - 10.3390/jcdd12020063 [doi] LID - 63 AB - Transcatheter aortic valve implantation (TAVI) has become the standard of care for elderly patients with aortic stenosis. International guidelines recommend that TAVI should be performed only in centers with on-site cardiac surgery (CS). However, rapidly evolving TAVI technology and increasing operator expertise have significantly reduced peri-procedural complications, including those requiring rescue surgery, which occur in less than 0.5% of cases. Furthermore, only a minority of major complications are treated with CS, and the outcomes remain unfavorable. TAVI in centers without CS could represent a solution to reduce waiting times and ensure continuity of care for fragile patients. "TAVI at Home" is a single-arm prospective interventional study. According to sample size calculations based on literature data, the study aims to enroll a total of 200 patients, beginning with a run-in phase of 20 patients to establish safety. The primary endpoint is 30-day all-cause mortality. Secondary endpoints include technical success and the evaluation of single complications 30 days after the procedure. Hospitals without CS that are eligible to perform TAVI must have a high volume of coronary percutaneous interventions, operators with established TAVI experience, collaboration with vascular surgeons, and regular Heart Team meetings to ensure rigorous patient selection. FAU - Compagnone, Miriam AU - Compagnone M AUID- ORCID: 0000-0002-3458-8717 AD - Interventional and Structural Cardiology Unit Forli-Cesena, 47121 Forli, Italy. FAU - Dall'Ara, Gianni AU - Dall'Ara G AD - Interventional and Structural Cardiology Unit Forli-Cesena, 47121 Forli, Italy. AD - Department of Medical and Surgical Sciences-DIMEC-Alma Mater Studiorum, University of Bologna, 40138 Bologna, Italy. FAU - Grotti, Simone AU - Grotti S AD - Interventional and Structural Cardiology Unit Forli-Cesena, 47121 Forli, Italy. FAU - Mambelli, Greta AU - Mambelli G AUID- ORCID: 0009-0009-0359-0871 AD - IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy. FAU - Fabbri, Elisabetta AU - Fabbri E AD - U.O. Ricerca Valutativa e Policy dei Servizi Sanitari, AUSL Romagna, 48121 Ravenna, Italy. FAU - Savini, Carlo AU - Savini C AD - Department of Medical and Surgical Sciences-DIMEC-Alma Mater Studiorum, University of Bologna, 40138 Bologna, Italy. AD - GVM Care & Research Maria Cecilia Hospital, 48033 Cotignola, Italy. FAU - Balducelli, Marco AU - Balducelli M AD - Division of Cardiology, S. Maria delle Croci Hospital, Ravenna, AUSL Romagna, 48121 Ravenna, Italy. FAU - Santarelli, Andrea AU - Santarelli A AUID- ORCID: 0000-0001-7575-6118 AD - Cardiology Unit, Bufalini Hospital, 47521 Cesena, Italy. FAU - Iorio, Elia AU - Iorio E AD - UOC Cardiologia e UTIC, Ente Ecclesiastico Ospedale Generale Regionale F Miulli, Acquaviva delle Fonti, 70021 Bari, Italy. FAU - Vaquerizo, Beatriz AU - Vaquerizo B AUID- ORCID: 0000-0002-1428-3596 AD - Hospital del Mar, 08003 Barcelona, Spain. FAU - Marchese, Alfredo AU - Marchese A AD - Ospedale S. Maria GVM Care & Research, 70124 Bari, Italy. FAU - Tarantini, Giuseppe AU - Tarantini G AD - Department of Cardiac-Thoracic-Vascular Sciences and Public Health, University of Padova, 35128 Padua, Italy. FAU - Saia, Francesco AU - Saia F AD - Interventional Cardiology Unit, IRCCS University Hospital of Bologna, Policlinico S. Orsola, 40138 Bologna, Italy. FAU - Zingaretti, Chiara AU - Zingaretti C AD - IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy. FAU - Moretti, Carolina AU - Moretti C AD - Division of Cardiology, S. Maria delle Croci Hospital, Ravenna, AUSL Romagna, 48121 Ravenna, Italy. FAU - Cavazza, Caterina AU - Cavazza C AD - Cardiovascular Department, Infermi Hospital, AUSL Romagna, 47921 Rimini, Italy. FAU - Vertogen, Bernadette AU - Vertogen B AUID- ORCID: 0000-0002-5683-6363 AD - IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy. FAU - Ottani, Filippo AU - Ottani F AD - Cardiovascular Department, Infermi Hospital, AUSL Romagna, 47921 Rimini, Italy. FAU - Rubboli, Andrea AU - Rubboli A AD - Division of Cardiology, S. Maria delle Croci Hospital, Ravenna, AUSL Romagna, 48121 Ravenna, Italy. FAU - Nanni, Oriana AU - Nanni O AD - IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy. FAU - Pizzi, Carmine AU - Pizzi C AUID- ORCID: 0000-0002-4048-675X AD - Department of Medical and Surgical Sciences-DIMEC-Alma Mater Studiorum, University of Bologna, 40138 Bologna, Italy. AD - Cardiology Division, Morgagni Pierantoni University Hospital, AUSL Romagna, 47121 Forli, Italy. FAU - Galvani, Marcello AU - Galvani M AUID- ORCID: 0000-0001-5897-667X AD - Cardiovascular Research Unit, Fondazione Cardiologica Sacco, 47100 Forli, Italy. FAU - Tarantino, Fabio Felice AU - Tarantino FF AD - Interventional and Structural Cardiology Unit Forli-Cesena, 47121 Forli, Italy. LA - eng PT - Journal Article DEP - 20250210 PL - Switzerland TA - J Cardiovasc Dev Dis JT - Journal of cardiovascular development and disease JID - 101651414 PMC - PMC11856494 OTO - NOTNLM OT - aortic valve stenosis OT - heart team OT - transcatheter aortic valve implantation COIS- Abbott S.r.l., Eukon S.r.l., Lopez S.p.a., Medstep S.r.l., Sintec S.r.l. are study sponsors, but there aren't conflicts of interest with the authors. This is also evaluated by Etich Comitee. EDAT- 2025/02/25 12:26 MHDA- 2025/02/25 12:27 PMCR- 2025/02/10 CRDT- 2025/02/25 08:25 PHST- 2024/12/27 00:00 [received] PHST- 2025/02/06 00:00 [revised] PHST- 2025/02/07 00:00 [accepted] PHST- 2025/02/25 12:27 [medline] PHST- 2025/02/25 12:26 [pubmed] PHST- 2025/02/25 08:25 [entrez] PHST- 2025/02/10 00:00 [pmc-release] AID - jcdd12020063 [pii] AID - jcdd-12-00063 [pii] AID - 10.3390/jcdd12020063 [doi] PST - epublish SO - J Cardiovasc Dev Dis. 2025 Feb 10;12(2):63. doi: 10.3390/jcdd12020063. PMID- 39997472 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250227 IS - 2308-3425 (Electronic) IS - 2308-3425 (Linking) VI - 12 IP - 2 DP - 2025 Jan 22 TI - Feeding Approach to Optimizing Nutrition in Infants with Congenital Heart Disease. LID - 10.3390/jcdd12020038 [doi] LID - 38 AB - Congenital heart disease (CHD) affects 1% of live births globally. Infants with CHD often experience growth faltering and malnutrition due to increased metabolic demands, malabsorption, and feeding intolerance, further worsened by surgical interventions and frequent hospitalizations. Malnutrition in this population is linked to higher morbidity, extended hospital stays, and poor neurodevelopmental outcomes. The physiological diversity among CHD types presents significant challenges in developing a universal feeding strategy to optimize nutrition. This narrative review explores the interplay between CHD physiology and nutritional management. CHD types could be categorized into three hemodynamic groups-systemic hypoperfusion, global hypoxia, and pulmonary overcirculation-which help to consider a feeding approach based on such physiology. Nutritional management in these infants could be further tailored based on the disease severity, co-morbidities, and evolving hemodynamic changes. Based on clinical opinions, this review proposes a hemodynamic-focused risk-stratified feeding approach, considering ways that may enhance growth while possibly minimizing complications such as necrotizing enterocolitis (NEC), pulmonary overload, and worsening heart failure. This approach may help individualize nutritional management to address the complex needs of infants with CHD. Further quality improvement studies are needed to assess this approach. Beyond meeting macronutrient needs, micronutrients, including zinc, thiamine, magnesium, vitamin A, and calcium, potentially play a role in cardiovascular health. Given the complexity of nutritional management in these infants, a multidisciplinary team may be needed to optimize care, including cardiologists, neonatologists, pediatricians, dietitians, speech therapists, and pharmacists. With the current knowledge gap and lack of strong evidence, research should focus on nutritional interventions and study their potential impact on infant outcomes with CHDs. FAU - Chan, Belinda AU - Chan B AUID- ORCID: 0000-0002-2421-2572 AD - Department of Pediatrics, University of Utah, Salt Lake City, UT 84108, USA. AD - Department of Pediatrics, Division of Neonatology, University of California Davis Health, Sacramento, CA 95817, USA. FAU - Woodbury, Anne AU - Woodbury A AD - Nutrition Service, University of Utah Hospital, Salt Lake City, UT 84112, USA. FAU - Hazelwood, Libbi AU - Hazelwood L AD - Nutrition Service, University of Utah Hospital, Salt Lake City, UT 84112, USA. FAU - Singh, Yogen AU - Singh Y AUID- ORCID: 0000-0002-5207-9019 AD - Nutrition Service, University of Utah Hospital, Salt Lake City, UT 84112, USA. LA - eng PT - Journal Article PT - Review DEP - 20250122 PL - Switzerland TA - J Cardiovasc Dev Dis JT - Journal of cardiovascular development and disease JID - 101651414 PMC - PMC11856444 OTO - NOTNLM OT - congenital heart disease (CHD) OT - enteral feed (EN) OT - feeding protocol OT - feeding strategies OT - hypoperfusion OT - hypoxia OT - malnutrition OT - necrotizing enterocolitis (NEC) OT - parenteral nutrition (PN) OT - pulmonary overcirculation COIS- The authors declare no conflicts of interest. EDAT- 2025/02/25 12:26 MHDA- 2025/02/25 12:27 PMCR- 2025/01/22 CRDT- 2025/02/25 08:25 PHST- 2024/11/27 00:00 [received] PHST- 2025/01/20 00:00 [revised] PHST- 2025/01/21 00:00 [accepted] PHST- 2025/02/25 12:27 [medline] PHST- 2025/02/25 12:26 [pubmed] PHST- 2025/02/25 08:25 [entrez] PHST- 2025/01/22 00:00 [pmc-release] AID - jcdd12020038 [pii] AID - jcdd-12-00038 [pii] AID - 10.3390/jcdd12020038 [doi] PST - epublish SO - J Cardiovasc Dev Dis. 2025 Jan 22;12(2):38. doi: 10.3390/jcdd12020038. PMID- 39996092 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250226 IS - 2283-5733 (Electronic) IS - 2284-2403 (Print) IS - 2284-2403 (Linking) VI - 12 DP - 2025 Jan-Dec TI - Cost of illness of Heart Valve Diseases (HVDs): A real-world analysis in Italy. PG - 34-42 LID - 10.33393/grhta.2025.3243 [doi] AB - INTRODUCTION: Heart valve diseases constitute a significant public health challenge with substantial clinical and economic implications. The ageing population, coupled with advancements in surgical techniques, has led to increased hospitalizations for cardiac valve interventions over the past decade. Despite progress, the economic burden of heart valve diseases remains underexplored, particularly in the context of the Italian healthcare system. This study aims to comprehensively assess the economic burden of heart valve diseases in Italy through a real-world analysis. METHODS: Using data from the national Italian Hospital Discharge Records (SDO), we identified the number of adult patients undergoing interventions on the aortic, mitral, and tricuspid valves, along with the associated costs borne by the National Health System. Additionally, we estimated indirect costs by analyzing social security benefit applications related to valve diseases from 2016 to 2019. RESULTS: A notable rise in hospitalizations for cardiac valve interventions, particularly for the aortic (+53.3%) and mitral valves (+29.5%) was revealed through the study period. In-hospital mortality rates declined, reflecting advancements in perioperative care. The economic burden of heart valve diseases in Italy was substantial, with hospitalization costs reaching euro808 million in 2018. Social security benefit applications also increased, adding an annual cost of euro29 million. CONCLUSIONS: Heart valve diseases represent a growing clinical and socio-economic challenge in Italy. This study underscores the imperative for a multidisciplinary approach to effectively manage these conditions. Emphasizing prevention, early diagnosis, and timely interventions is crucial to mitigate the economic impact and enhance the quality of life for patients. CI - (c) 2025 The Authors. FAU - Sciattella, Paolo AU - Sciattella P AD - Centre for Economics and International Studies - Economic Evaluation and Health Technology Assessment, Faculty of Economics, University of Rome "Tor Vergata", Rome - Italy. FAU - Scortichini, Matteo AU - Scortichini M AD - Centre for Economics and International Studies - Economic Evaluation and Health Technology Assessment, Faculty of Economics, University of Rome "Tor Vergata", Rome - Italy. LA - eng PT - Journal Article DEP - 20250219 PL - Italy TA - Glob Reg Health Technol Assess JT - Global & regional health technology assessment JID - 9918417986506676 PMC - PMC11848861 OTO - NOTNLM OT - Direct costs OT - Economic burden OT - Heart Valve Diseases (HVD) OT - Indirect costs OT - Italy OT - Real-world evidence COIS- Conflicts of interest: The authors have no relevant financial or non-financial interests to disclose. EDAT- 2025/02/25 06:21 MHDA- 2025/02/25 06:22 PMCR- 2025/02/19 CRDT- 2025/02/25 04:44 PHST- 2024/08/02 00:00 [received] PHST- 2025/01/14 00:00 [accepted] PHST- 2025/02/25 06:22 [medline] PHST- 2025/02/25 06:21 [pubmed] PHST- 2025/02/25 04:44 [entrez] PHST- 2025/02/19 00:00 [pmc-release] AID - 10.33393/grhta.2025.3243 [doi] PST - epublish SO - Glob Reg Health Technol Assess. 2025 Feb 19;12:34-42. doi: 10.33393/grhta.2025.3243. eCollection 2025 Jan-Dec. PMID- 39988645 OWN - NLM STAT- MEDLINE DCOM- 20250920 LR - 20261008 IS - 1863-6713 (Electronic) IS - 1863-6705 (Linking) VI - 73 IP - 10 DP - 2025 Oct TI - Postoperative outcomes of cardiovascular surgery managed by nurse practitioners. PG - 723-727 LID - 10.1007/s11748-025-02132-3 [doi] AB - OBJECTIVE: The significant workload of cardiovascular surgeons in Japan has led to a growing interest in implementing nurse practitioners as a means to address this issue. This study seeks to evaluate the postoperative outcomes of cardiovascular surgeries in which nurse practitioners were involved at our institution. METHODS: This study utilized a retrospective observational study design. This study included patients who underwent scheduled cardiovascular surgeries at our hospital between April 1, 2019, and March 31, 2024. Patients were divided into two groups for postoperative care management: the DR group (physician only) and the NP group (co-management by physician and nurse practitioner). The primary end point was the 30-day mortality. We compared the two groups. RESULTS: A total of 394 patients were classified into two groups: DR group (n = 101) and NP group (n = 293). There was no significant difference in the 30-day mortality between the two groups. The NP group had significantly shorter hospital stay (NP 20.6 +/- 11.1 vs. DR 24.0 +/- 11.8; p = 0.01; effect size = 0.299), postoperative length of stay (NP 14.5 +/- 8.9 vs. DR 18.0 +/- 10.4; p = 0.001; effect size = 0.376), ICU stay (NP 5.2 +/- 3.5 vs. DR 6.3 +/- 4.5; p = 0.014; effect size = 0.284), and time until 50-m walking (NP 3.8 +/- 3.5 vs. DR 5.1 +/- 5.1; p = 0.004; effect size = 0.342). There were no significant differences in the incidence of postoperative complications between the two groups. CONCLUSIONS: Nurse practitioners have the potential to provide safe care equivalent to that of physicians, and it may contribute to reduced hospital stays and improved postoperative recovery in patients. CI - (c) 2025. The Author(s), under exclusive licence to The Japanese Association for Thoracic Surgery. FAU - Saitoh, Masato AU - Saitoh M AUID- ORCID: 0009-0006-9328-3581 AD - Department of Cardiovascular Surgery, Ayase Heart Hospital, 2-16-7 Yanaka, Adachi-Ku, Tokyo, 120-0006, Japan. m.saito@ayaseheart.or.jp. FAU - Yamasaki, Takuma AU - Yamasaki T AD - Department of Cardiovascular Surgery, Ayase Heart Hospital, 2-16-7 Yanaka, Adachi-Ku, Tokyo, 120-0006, Japan. FAU - Tanabe, Tomoaki AU - Tanabe T AD - Department of Cardiovascular Surgery, Ayase Heart Hospital, 2-16-7 Yanaka, Adachi-Ku, Tokyo, 120-0006, Japan. FAU - Tochigi, Shuichi AU - Tochigi S AD - Department of Cardiovascular Surgery, Ayase Heart Hospital, 2-16-7 Yanaka, Adachi-Ku, Tokyo, 120-0006, Japan. FAU - Hirayama, Daiki AU - Hirayama D AD - Department of Cardiovascular Surgery, Ayase Heart Hospital, 2-16-7 Yanaka, Adachi-Ku, Tokyo, 120-0006, Japan. FAU - Aoyama, Kiyotaka AU - Aoyama K AD - Department of Cardiovascular Surgery, Ayase Heart Hospital, 2-16-7 Yanaka, Adachi-Ku, Tokyo, 120-0006, Japan. FAU - Tei, Imun AU - Tei I AD - Department of Cardiovascular Surgery, Ayase Heart Hospital, 2-16-7 Yanaka, Adachi-Ku, Tokyo, 120-0006, Japan. LA - eng PT - Comparative Study PT - Journal Article PT - Observational Study DEP - 20250223 PL - Japan TA - Gen Thorac Cardiovasc Surg JT - General thoracic and cardiovascular surgery JID - 101303952 SB - IM CIN - Gen Thorac Cardiovasc Surg. 2026 May;74(5):559-560. doi: 10.1007/s11748-026-02271-1. PMID: 41739413 MH - Humans MH - *Nurse Practitioners/organization & administration MH - Retrospective Studies MH - Male MH - Female MH - Middle Aged MH - Aged MH - Treatment Outcome MH - Time Factors MH - Length of Stay MH - *Postoperative Complications/mortality MH - Risk Factors MH - Japan MH - *Cardiovascular Surgical Procedures/adverse effects/mortality MH - *Postoperative Care MH - Patient Care Team/organization & administration MH - *Nurse's Role OTO - NOTNLM OT - Cardiovascular surgery OT - Nurse practitioner OT - Postoperative outcome COIS- Declarations. Conflict of interest: All authors have no conflicts of interest to disclose. Ethical approval: This study was approved by the Research Ethics Review Committee of Ayase heart hospital in Japan (Approval No. 2024-0004-1). This study was conducted in accordance with the Declaration of Helsinki and the Ethical Guidelines for Medical and Health Research Involving Human Subjects. EDAT- 2025/02/24 02:10 MHDA- 2025/09/20 12:32 CRDT- 2025/02/23 23:06 PHST- 2024/12/17 00:00 [received] PHST- 2025/02/12 00:00 [accepted] PHST- 2025/09/20 12:32 [medline] PHST- 2025/02/24 02:10 [pubmed] PHST- 2025/02/23 23:06 [entrez] AID - 10.1007/s11748-025-02132-3 [pii] AID - 10.1007/s11748-025-02132-3 [doi] PST - ppublish SO - Gen Thorac Cardiovasc Surg. 2025 Oct;73(10):723-727. doi: 10.1007/s11748-025-02132-3. Epub 2025 Feb 23. PMID- 39988458 OWN - NLM STAT- MEDLINE DCOM- 20251125 LR - 20260510 IS - 1477-111X (Electronic) IS - 0267-6591 (Print) IS - 0267-6591 (Linking) VI - 40 IP - 8 DP - 2025 Nov TI - ECMO for the pregnant and peripartum patient: A practical review of indications, unique management considerations, and an approach framework. PG - 1727-1742 LID - 10.1177/02676591251321070 [doi] AB - The use of extracorporeal membrane oxygenation (ECMO) to support the pregnant patient and fetus requires a complex decision-making process. Peripartum ECMO requires coordinated and informed decision-making between an interdisciplinary team of experts, incorporating the unique considerations and, at times, competing physiologic priorities of the pregnant patient. It is often confounded by a scarcity of local relevant experience engendered by its rare occurrence. No event has made the need for an organized approach to the utilization of ECMO in pregnant patients more pressing than the COVID pandemic. The conditions affecting pregnant patients that warrant ECMO consideration are high stakes and, at times, ethically challenging, although outcomes are favourable compared to the general population. This review provides background information and context, followed by a practical approach to the care and specific medical management of patients who are facing life-threatening conditions warranting ECMO while pregnant. FAU - Hrymak, Carmen S AU - Hrymak CS AUID- ORCID: 0000-0002-2515-380X AD - Department of Emergency Medicine and Section of Critical Care, University of Manitoba, Winnipeg, MB, Canada. FAU - Labib, Ahmed AU - Labib A AUID- ORCID: 0000-0003-1863-0484 AD - Medical Intensive Care Unit, Hamad General Hospital, Doha, Qatar. AD - Weill Cornell Medicine, Doha, Qatar. FAU - Akkanti, Bindu AU - Akkanti B AD - Division of Critical Care Medicine and Advanced Cardiopulmonary Therapeutics and Transplantation, UT Health- Houston, Houston, TX, USA. FAU - Antonini, Marta V AU - Antonini MV AUID- ORCID: 0000-0003-4276-3404 AD - Bufalini Hospital, AUSL Romagna, Cesena, Italy. FAU - Bruggeman, Bradley AU - Bruggeman B AD - Department of Obstetrics and Gynecology, University of Florida College of Medicine, Gainesville, FL, USA. FAU - Griffee, Matthew J AU - Griffee MJ AUID- ORCID: 0000-0002-4217-4565 AD - Department of Anesthesiology, University of Utah School of Medicine, Salt Lake City, Utah, USA. FAU - Heinsar, Silver AU - Heinsar S AUID- ORCID: 0000-0002-5004-4816 AD - Critical Care Research Group, The University of Queensland, Brisbane, QLD, Australia. AD - Department of Intensive Care, North Estonia Medical, Tallinn, Estonia. FAU - Jacobs, Jeffrey P AU - Jacobs JP AD - University of Florida Congenital Heart Center, Gainesville, FL, USA. FAU - Larzelere, Michelle AU - Larzelere M AD - Department of Obstetrics and Gynecology, University of Florida College of Medicine, Gainesville, FL, USA. FAU - Naoum, Emily AU - Naoum E AD - Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Boston, MA, USA. FAU - O'Neil, Erika AU - O'Neil E AUID- ORCID: 0000-0002-2747-7760 AD - Department of Pediatrics, United States Air Force, Brooke Army Medical Center, San Antonio, TX, USA. FAU - Roussos-Ross, Dikea AU - Roussos-Ross D AD - Department of Obstetrics and Gynecology, University of Florida College of Medicine, Gainesville, FL, USA. FAU - Zaaqoq, Akram M AU - Zaaqoq AM AUID- ORCID: 0000-0003-3147-5044 AD - Department of Anesthesiology, Division of Critical Care, University of Virginia, Charlottesville, VA, USA. FAU - Peek, Giles J AU - Peek GJ AUID- ORCID: 0000-0002-1313-6498 AD - University of Florida Congenital Heart Center, Gainesville, FL, USA. FAU - Arora, Rakesh C AU - Arora RC AD - Department of Surgery, Division of Cardiac Surgery, University Hospitals - Harrington Heart Vascular Institute, Cleveland, OH, USA. LA - eng PT - Journal Article PT - Review DEP - 20250223 PL - England TA - Perfusion JT - Perfusion JID - 8700166 SB - IM MH - Humans MH - Pregnancy MH - *Extracorporeal Membrane Oxygenation/methods MH - Female MH - *Peripartum Period MH - *COVID-19/therapy MH - SARS-CoV-2 PMC - PMC12602728 OTO - NOTNLM OT - ARDS OT - COVID-19 OT - ECMO OT - amniotic fluid embolism OT - cardiogenic shock OT - fetal OT - fetal heart rate OT - maternal OT - pre-eclampsia OT - pregnancy/pregnant OT - pulmonary embolism OT - right ventricular failure COIS- Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2025/02/24 02:10 MHDA- 2025/11/25 06:26 PMCR- 2025/11/11 CRDT- 2025/02/23 22:02 PHST- 2025/11/25 06:26 [medline] PHST- 2025/02/24 02:10 [pubmed] PHST- 2025/02/23 22:02 [entrez] PHST- 2025/11/11 00:00 [pmc-release] AID - 10.1177_02676591251321070 [pii] AID - 10.1177/02676591251321070 [doi] PST - ppublish SO - Perfusion. 2025 Nov;40(8):1727-1742. doi: 10.1177/02676591251321070. Epub 2025 Feb 23. PMID- 39985723 OWN - NLM STAT- MEDLINE DCOM- 20250509 LR - 20250509 IS - 2509-9280 (Electronic) IS - 2509-9280 (Linking) VI - 9 IP - 1 DP - 2025 Feb 22 TI - 3D cinematic reconstructions of cardiovascular CT presented in augmented reality: subjective assessment of clinical feasibility and potential use cases. PG - 27 LID - 10.1186/s41747-025-00566-1 [doi] LID - 27 AB - Augmented reality (AR) is a new technique enabling interaction with three-dimensional (3D) holograms of cinematic rendering (CR) reconstructions. Research in this field is in its very early steps, and data is scarce. We evaluated image quality, usability, and potential applications of AR in cardiovascular image datasets. Ten CR reconstructions of cardiovascular computed tomography (CT) datasets with complex anatomical abnormalities were presented to six radiologists and three cardiologists first on diagnostic screens and subsequently in AR. Subjective image quality and user experience were rated on 5-point Likert scales to assess usability and potential applications of AR. CR of CT datasets covering multiple images series of the same exam with differing kernels was performed in 143 +/- 31 s (mean +/- standard deviation); reconstruction of single CT image series took 84 +/- 30 s. Mean subjective image quality was excellent, and observers showed high endorsement of the intuitive usability of the AR device and improvement of anatomical comprehensibility. AR devices were expected to have the greatest impact on patient and student education as well as multidisciplinary discussions, with less potential in clinical care. Clinical testing and preclinical implementation of AR seem feasible due to reasonable computation times and intuitive usability even for first-time users. RELEVANCE STATEMENT: The presentation of 3D cinematic rendering in augmented reality provides excellent image quality, facilitating the comprehension of anatomical structures in CT datasets. Concurrently, reasonable computation times and the intuitive usability of augmented reality devices make preclinical implementation and clinical testing feasible. KEY POINTS: 3D cinematic reconstructions presented in augmented reality improve the anatomical comprehensibility of chest CT scans. Augmented reality devices are expected to be highly beneficial in educational settings and multidisciplinary discussions. Usability and computation times are feasible for initial preclinical use cases. CI - (c) 2025. The Author(s). FAU - Bottcher, Benjamin AU - Bottcher B AD - Translational Laboratory for Cardiothoracic Imaging and Artificial Intelligence, Department of Radiology and Imaging Sciences, Emory University, Atlanta, USA. AD - Institute of Diagnostic and Interventional Radiology, Pediatric Radiology and Neuroradiology, University Medical Centre Rostock, Rostock, Germany. FAU - van Assen, Marly AU - van Assen M AD - Translational Laboratory for Cardiothoracic Imaging and Artificial Intelligence, Department of Radiology and Imaging Sciences, Emory University, Atlanta, USA. FAU - Fari, Roberto AU - Fari R AD - Translational Laboratory for Cardiothoracic Imaging and Artificial Intelligence, Department of Radiology and Imaging Sciences, Emory University, Atlanta, USA. AD - Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy. FAU - von Knebel Doeberitz, Philipp L AU - von Knebel Doeberitz PL AD - Translational Laboratory for Cardiothoracic Imaging and Artificial Intelligence, Department of Radiology and Imaging Sciences, Emory University, Atlanta, USA. AD - Institute of Clinical Radiology and Nuclear Medicine, University Medical Center Mannheim, Medical Faculty Mannheim of Heidelberg University, Mannheim, Germany. FAU - Gershon, Gabrielle AU - Gershon G AD - Translational Laboratory for Cardiothoracic Imaging and Artificial Intelligence, Department of Radiology and Imaging Sciences, Emory University, Atlanta, USA. FAU - Meinel, Felix G AU - Meinel FG AD - Institute of Diagnostic and Interventional Radiology, Pediatric Radiology and Neuroradiology, University Medical Centre Rostock, Rostock, Germany. FAU - De Cecco, Carlo N AU - De Cecco CN AUID- ORCID: 0000-0002-2956-3101 AD - Translational Laboratory for Cardiothoracic Imaging and Artificial Intelligence, Department of Radiology and Imaging Sciences, Emory University, Atlanta, USA. carlo.dececco@emory.edu. AD - Division of Cardiothoracic Imaging, Department of Radiology and Imaging Sciences, Emory University, Atlanta, USA. carlo.dececco@emory.edu. LA - eng PT - Journal Article DEP - 20250222 PL - England TA - Eur Radiol Exp JT - European radiology experimental JID - 101721752 SB - IM MH - Humans MH - *Augmented Reality MH - Feasibility Studies MH - *Tomography, X-Ray Computed/methods MH - *Imaging, Three-Dimensional/methods PMC - PMC11846813 OTO - NOTNLM OT - Augmented reality OT - Cardiovascular system OT - Education (medical) OT - Imaging (three-dimensional) OT - Tomography (x-ray computed) COIS- Declarations. Ethics approval and consent to participate: Ethical approval was authorized by the responsible Institutional Review Board of Emory University (IRB number STUDY00002503, November 8, 2021) and need for written informed consent was waived. Consent for publication: Not applicable. Competing interests: CNDC receives research funding from Siemens Healthineers and Cleerly. MvA receives research funding from Siemens Healthineers and is a member of the Scientific Editorial Board of European Radiology Experimental (section: Artificial intelligence, augmented reality, computer science, and radiomics) and, as such, did not participate in the selection nor review processes for this article. FGM has received research funding from GE Healthcare and speaker honoraria from GE Healthcare, Circle Cardiovascular Imaging and Bayer Vital. Others have no disclosures to report. EDAT- 2025/02/22 20:11 MHDA- 2025/02/22 20:12 PMCR- 2025/02/22 CRDT- 2025/02/22 11:15 PHST- 2024/10/10 00:00 [received] PHST- 2025/01/28 00:00 [accepted] PHST- 2025/02/22 20:12 [medline] PHST- 2025/02/22 20:11 [pubmed] PHST- 2025/02/22 11:15 [entrez] PHST- 2025/02/22 00:00 [pmc-release] AID - 10.1186/s41747-025-00566-1 [pii] AID - 566 [pii] AID - 10.1186/s41747-025-00566-1 [doi] PST - epublish SO - Eur Radiol Exp. 2025 Feb 22;9(1):27. doi: 10.1186/s41747-025-00566-1. PMID- 39985232 OWN - NLM STAT- MEDLINE DCOM- 20250608 LR - 20250610 IS - 1440-0960 (Electronic) IS - 0004-8380 (Print) IS - 0004-8380 (Linking) VI - 66 IP - 4 DP - 2025 Jun TI - Improving Cardiovascular Outcomes in the Psoriasis Cohort. Psoriasis and Cardiovascular Disease-Clinician Knowledge, Practice and Perceptions. PG - e187-e196 LID - 10.1111/ajd.14436 [doi] AB - BACKGROUND: Psoriasis is a risk factor for cardiovascular disease (CVD). This risk is independent and incremental to traditional cardiovascular (CV) risk factors, but clinician and patient perspectives on this risk are unclear. This study aims to assess the knowledge, perceptions, and practice of clinicians and patients with respect to psoriasis and CVD. METHODS: This cross-sectional study consisted of a self-administered questionnaire capturing demographic characteristics, knowledge of the association between psoriasis and CVD, and perspectives on CV screening and management. This was distributed to members of relevant Australasian Speciality Medical Colleges, speciality societies, and psoriasis patients in public and private clinic settings. Survey data were assessed using descriptive statistics. Logistic regression was used to investigate the relationship between categorical variables and the outcome variable, for example, to determine factors predictive of clinician knowledge and perceptions. For all analyses, a p-value of less than 0.05 was considered statistically significant. RESULTS: A total of 298 clinicians (dermatologists (86), rheumatologists (56), cardiologists (53), general practitioners (103)) and 102 patients with psoriasis were surveyed. Regarding clinician knowledge of the association between psoriasis and CVD, dermatologists and rheumatologists indicated knowledge of this association (98.8%) (85/86) and 91.1% (51/56) respectively, while only 54.7% (29/53) of cardiologists and 29.1% (30/103) of GPs indicated knowledge of this association. Only 23.5% (24/102) of patients surveyed indicated knowledge of this association. Clinicians with a higher proportion of their caseload including psoriasis patients were significantly more likely to be aware of the association between psoriasis and CVD (OR 3.05 [1.64, 5.68]; p < 0.001). Most clinicians nominated GPs as best placed to facilitate CV risk factor screening and management (dermatologists 80.2% (69/86); rheumatologists 83.9% (47/56); cardiologists 75.5% (40/53); GPs 88.3% (91/103)). Patients preferred specialist input and multidisciplinary care for CVD risk management; 34.3% (35/102) nominated a cardiologist as the preferred clinician, and 23.5% (24/102) indicated preference for a multidisciplinary team. LIMITATIONS: The possibility of sampling and response bias, inherent in the study design, is acknowledged; however, responses are likely representative of clinician and patient sentiments on this issue and in keeping with similar study findings. CONCLUSION: Clinician and patient knowledge of the relationship between psoriasis and CVD needs to be improved. The establishment of a national consensus approach to address this gap in clinical care is needed. CI - (c) 2025 The Author(s). Australasian Journal of Dermatology published by John Wiley & Sons Australia, Ltd on behalf of Australasian College of Dermatologists. FAU - Smith, Annika AU - Smith A AUID- ORCID: 0000-0001-9520-920X AD - Westmead Applied Research Centre, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia. AD - Department of Dermatology, Westmead Hospital, Westmead, New South Wales, Australia. FAU - Lai, Belinda AU - Lai B AD - Westmead Applied Research Centre, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia. AD - Department of Dermatology, Westmead Hospital, Westmead, New South Wales, Australia. FAU - Zaman, Sarah AU - Zaman S AD - Westmead Applied Research Centre, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia. AD - Department of Cardiology, Westmead Hospital, Westmead, New South Wales, Australia. FAU - Wong, Peter AU - Wong P AD - Department of Rheumatology, Westmead Hospital, Westmead, Australia. AD - Westmead Clinical School, Faculty of Medicine and Health, Sydney University, Camperdown, Australia. FAU - Foo, Fiona AU - Foo F AD - Department of Cardiology, Macquarie University Hospital, Macquarie Park, New South Wales, Australia. FAU - Bell, Katy J L AU - Bell KJL AD - Sydney School of Public Health, Faculty of Medicine and Health, Sydney University, Camperdown, Australia. FAU - Fernandez-Penas, Pablo AU - Fernandez-Penas P AD - Westmead Applied Research Centre, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia. AD - Department of Dermatology, Westmead Hospital, Westmead, New South Wales, Australia. FAU - Chow, Clara K AU - Chow CK AD - Westmead Applied Research Centre, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia. AD - Department of Cardiology, Westmead Hospital, Westmead, New South Wales, Australia. LA - eng PT - Journal Article PT - Review DEP - 20250222 PL - Australia TA - Australas J Dermatol JT - The Australasian journal of dermatology JID - 0135232 SB - IM MH - Humans MH - *Psoriasis/complications/therapy MH - *Cardiovascular Diseases/therapy/epidemiology/etiology/diagnosis MH - Cross-Sectional Studies MH - Male MH - Female MH - *Health Knowledge, Attitudes, Practice MH - Middle Aged MH - Adult MH - Surveys and Questionnaires MH - Heart Disease Risk Factors MH - Aged MH - *Clinical Competence MH - Dermatologists PMC - PMC12145733 OTO - NOTNLM OT - cardiovascular disease OT - clinicians OT - patients OT - psoriasis OT - survey COIS- Dr. Pablo Fernandez-Penas is an Editorial Board member of Australasian Journal of Dermatology and a co-author of this article. To minimise bias, they were excluded from all editorial decision-making related to the acceptance of this article for publication. EDAT- 2025/02/22 20:09 MHDA- 2025/06/08 13:02 PMCR- 2025/06/08 CRDT- 2025/02/22 03:33 PHST- 2025/02/02 00:00 [revised] PHST- 2024/11/13 00:00 [received] PHST- 2025/02/11 00:00 [accepted] PHST- 2025/06/08 13:02 [medline] PHST- 2025/02/22 20:09 [pubmed] PHST- 2025/02/22 03:33 [entrez] PHST- 2025/06/08 00:00 [pmc-release] AID - AJD14436 [pii] AID - 10.1111/ajd.14436 [doi] PST - ppublish SO - Australas J Dermatol. 2025 Jun;66(4):e187-e196. doi: 10.1111/ajd.14436. Epub 2025 Feb 22. PMID- 39981516 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260828 IS - 2589-0042 (Electronic) IS - 2589-0042 (Linking) VI - 28 IP - 2 DP - 2025 Feb 21 TI - The hypertrophic cardiomyopathy-associated A331P actin variant enhances basal contractile activity and elicits resting muscle dysfunction. PG - 111816 LID - 10.1016/j.isci.2025.111816 [doi] LID - 111816 AB - Previous studies aimed at defining the mechanistic basis of hypertrophic cardiomyopathy caused by A331P cardiac actin have reported conflicting results. The mutation is located along an actin surface strand, proximal to residues that interact with tropomyosin. These F-actin-tropomyosin associations are vital for proper contractile inhibition. To help resolve disease pathogenesis, we implemented a multidisciplinary approach. Transgenic Drosophila, expressing A331P actin, displayed skeletal muscle hypercontraction and elevated basal myocardial activity. A331P thin filaments, reconstituted using recombinant human cardiac actin, exhibited higher in vitro myosin-based sliding speeds, exclusively at low Ca(2+) concentrations. Cryo-EM-based reconstructions revealed no detectable A331P-related structural perturbations in F-actin. In silico, however, the P331-containing actin surface strand was less mobile and established diminished van der Waal's attractive forces with tropomyosin, which correlated with greater variability in inhibitory tropomyosin positioning. Such mutation-induced effects potentially elevate resting contractile activity among our models and may stimulate pathology in patients. CI - (c) 2025 The Authors. FAU - Doran, Matthew H AU - Doran MH AD - Department of Pharmacology, Physiology & Biophysics, Boston University Chobanian & Avedisian School of Medicine, 72 E. Concord St, Boston, MA 02118, USA. FAU - Rynkiewicz, Michael J AU - Rynkiewicz MJ AD - Department of Pharmacology, Physiology & Biophysics, Boston University Chobanian & Avedisian School of Medicine, 72 E. Concord St, Boston, MA 02118, USA. FAU - Despond, Evan AU - Despond E AD - Department Molecular and Cellular Biology, University of Guelph, 50 Stone Road E, Guelph, ON N1G 2W1, Canada. FAU - Viswanathan, Meera C AU - Viswanathan MC AD - Department of Medicine, Division of Cardiology, Johns Hopkins University, 720 Rutland Avenue, Baltimore, MD 21205, USA. FAU - Madan, Aditi AU - Madan A AD - Department of Medicine, Division of Cardiology, Johns Hopkins University, 720 Rutland Avenue, Baltimore, MD 21205, USA. FAU - Chitre, Kripa AU - Chitre K AD - Department of Medicine, Division of Cardiology, Johns Hopkins University, 720 Rutland Avenue, Baltimore, MD 21205, USA. FAU - Fenwick, Axel J AU - Fenwick AJ AD - Department of Medicine, Division of Cardiology, Johns Hopkins University, 720 Rutland Avenue, Baltimore, MD 21205, USA. FAU - Sousa, Duncan AU - Sousa D AD - Department of Biophysics, Johns Hopkins University, 725 N. Wolfe Street, Baltimore, MD 21205, USA. FAU - Lehman, William AU - Lehman W AD - Department of Pharmacology, Physiology & Biophysics, Boston University Chobanian & Avedisian School of Medicine, 72 E. Concord St, Boston, MA 02118, USA. FAU - Dawson, John F AU - Dawson JF AD - Department Molecular and Cellular Biology, University of Guelph, 50 Stone Road E, Guelph, ON N1G 2W1, Canada. FAU - Cammarato, Anthony AU - Cammarato A AD - Department of Medicine, Division of Cardiology, Johns Hopkins University, 720 Rutland Avenue, Baltimore, MD 21205, USA. AD - Department of Physiology, Johns Hopkins University School of Medicine, 720 Rutland Avenue, Baltimore, MD 21205, USA. LA - eng GR - R01 HL036153/HL/NHLBI NIH HHS/United States GR - R01 HL124091/HL/NHLBI NIH HHS/United States GR - R37 HL036153/HL/NHLBI NIH HHS/United States GR - R56 HL124091/HL/NHLBI NIH HHS/United States PT - Journal Article DEP - 20250116 PL - United States TA - iScience JT - iScience JID - 101724038 PMC - PMC11841076 OTO - NOTNLM OT - Biological sciences OT - Cell biology OT - Molecular Structure OT - Molecular interaction OT - Structural biology COIS- The authors declare no competing interests. EDAT- 2025/02/21 06:22 MHDA- 2025/02/21 06:23 PMCR- 2025/01/16 CRDT- 2025/02/21 04:59 PHST- 2024/07/15 00:00 [received] PHST- 2024/10/29 00:00 [revised] PHST- 2025/01/13 00:00 [accepted] PHST- 2025/02/21 06:23 [medline] PHST- 2025/02/21 06:22 [pubmed] PHST- 2025/02/21 04:59 [entrez] PHST- 2025/01/16 00:00 [pmc-release] AID - S2589-0042(25)00076-8 [pii] AID - 111816 [pii] AID - 10.1016/j.isci.2025.111816 [doi] PST - epublish SO - iScience. 2025 Jan 16;28(2):111816. doi: 10.1016/j.isci.2025.111816. eCollection 2025 Feb 21. PMID- 39979142 OWN - NLM STAT- MEDLINE DCOM- 20250403 LR - 20260824 IS - 1879-0828 (Electronic) IS - 0953-6205 (Linking) VI - 134 DP - 2025 Apr TI - Assessment of cardiovascular, thromboembolic and cancer risk in patients eligible for treatment with Janus Kinase inhibitors: The JAK-ERA multidisciplinary consensus. PG - 114-118 LID - S0953-6205(25)00062-7 [pii] LID - 10.1016/j.ejim.2025.02.021 [doi] AB - INTRODUCTION: JAK inhibitors (JAKi) have emerged as effective treatments for chronic inflammatory diseases, including gastrointestinal, dermatological, and rheumatological conditions. Despite their efficacy, concerns about their safety profile necessitate a comprehensive framework for their optimal use. This study aimed to establish an expert consensus (the JAK-ERA [Janus Kinase-inhibitors Evidence-based Risk Analysis] Multidisciplinary Expert Consensus) on the principles guiding JAKi therapy to maximize therapeutic benefits while mitigating risks. METHODS: A Delphi method was employed, gathering opinions from experts across multiple disciplines. This iterative process involved rounds of surveys and feedbacks to synthesize diverse expert knowledge into a cohesive set of principles and consensus statements. The multidisciplinary panel included specialists in cardiology, oncology, hematology, gastroenterology, dermatology, and rheumatology. RESULTS: A total of 6 overarching principles and 13 expert consensus statements were developed. The percentage of agreement ranged between 78 and 100 %. The principles highlight the importance of rapid intervention to prevent complications and alleviate psychological burdens. Detailed risk assessments for cardiovascular (CV), thromboembolic, and cancer risks were deemed essential. Recommendations included using validated tools for CV risk evaluation, comprehensive thromboembolic risk assessment, and routine cancer screenings based on standard protocols. Multidisciplinary collaboration was stressed to ensure precise risk management and optimal therapeutic outcomes. CONCLUSION: The consensus provides a structured approach to JAKi therapy, balancing efficacy with safety considerations. The overarching principles and expert consensus statements offer a robust framework for clinical practice, ensuring that JAKi use is tailored to individual patient profiles, thereby enhancing outcomes and minimizing risks. Ongoing validation through prospective studies and real-world data is essential to further refine these recommendations. CI - Copyright (c) 2025 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved. FAU - Dagna, Lorenzo AU - Dagna L AD - Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. Electronic address: dagna.lorenzo@unisr.it. FAU - Alunno, Alessia AU - Alunno A AD - UOC Medicina Interna e Nefrologia, Dipartimento di Medicina Clinica, Scienze della Vita e Dell'Ambiente, Universita degli Studi di L'Aquila, L'Aquila, Italy. FAU - Farina, Nicola AU - Farina N AD - Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. FAU - Agnelli, Giancarlo AU - Agnelli G AD - ICS Maugeri IRCCS, Pavia, Italy; and University of Perugia, Perugia, Italy. FAU - Borghi, Claudio AU - Borghi C AD - Hypertension and Cardiovascular Risk Research Group, Department of Medical and Surgical Science, Alma Mater Studiorum University of Bologna, Bologna, Italy. FAU - Caporali, Roberto AU - Caporali R AD - Department of Rheumatology, ASST PINI-CTO, University of Milan, Milan, Italy. FAU - Costanzo, Antonio AU - Costanzo A AD - Dermatology Unit, Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy. FAU - Danese, Silvio AU - Danese S AD - Vita-Salute San Raffaele University, Milan, Italy; Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele, Milan, Italy. FAU - De Braud, Filippo AU - De Braud F AD - Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milan, Milan, Italy. FAU - Sebastiani, Gian Domenico AU - Sebastiani GD AD - UOC di Reumatologia, Azienda Ospedaliera San Camillo Forlanini, Roma, Italy. FAU - Montecucco, Carlo Maurizio AU - Montecucco CM AD - Division of Rheumatology, University and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy. LA - eng PT - Consensus Statement PT - Journal Article DEP - 20250220 PL - Netherlands TA - Eur J Intern Med JT - European journal of internal medicine JID - 9003220 RN - 0 (Janus Kinase Inhibitors) SB - IM MH - Humans MH - *Janus Kinase Inhibitors/adverse effects/therapeutic use MH - *Neoplasms/chemically induced MH - Delphi Technique MH - *Thromboembolism/chemically induced MH - *Cardiovascular Diseases/chemically induced MH - Risk Assessment OTO - NOTNLM OT - Cancer OT - Cardiovascular OT - Delphi OT - JAK inhibitors OT - Risk OT - Venous thromboembolism EDAT- 2025/02/21 00:21 MHDA- 2025/04/04 00:25 CRDT- 2025/02/20 22:24 PHST- 2025/01/23 00:00 [received] PHST- 2025/02/12 00:00 [revised] PHST- 2025/02/14 00:00 [accepted] PHST- 2025/04/04 00:25 [medline] PHST- 2025/02/21 00:21 [pubmed] PHST- 2025/02/20 22:24 [entrez] AID - S0953-6205(25)00062-7 [pii] AID - 10.1016/j.ejim.2025.02.021 [doi] PST - ppublish SO - Eur J Intern Med. 2025 Apr;134:114-118. doi: 10.1016/j.ejim.2025.02.021. Epub 2025 Feb 20. PMID- 39973449 OWN - NLM STAT- MEDLINE DCOM- 20250509 LR - 20260813 IS - 2214-3602 (Electronic) IS - 2214-3599 (Print) IS - 2214-3599 (Linking) VI - 12 IP - 1 DP - 2025 Jan-Feb TI - Comprehensive multidisciplinary care for adult Duchenne muscular dystrophy in South Korea. PG - 22143602241304996 LID - 10.1177/22143602241304996 [doi] AB - BACKGROUND: With advancements in cardiorespiratory care, the lifespan of patients with Duchenne Muscular Dystrophy (DMD) has significantly increased, shifting the focus from merely extending life to enhancing quality of life and managing complications effectively. However, there is a lack of interest in the management of adult DMD, highlighting a gap in holistic care approaches for this aging population. OBJECTIVE: This study aims to assess the current state of care for adult DMD patients in South Korea, focusing on multidisciplinary management and identifying key areas for improvement. METHODS: We retrospectively reviewed the medical records of 168 adult DMD patients who visited the Pulmonary Rehabilitation Center at [blinded for review] from 2022 to 2023. Demographic data, ventilatory support status, cardiac function, gastrointestinal, renal, and skeletal health were analyzed. RESULTS: Of the patients, 93.8% required non-invasive ventilatory support, while 6.2% used invasive ventilation. Cardiac medications were prescribed to 82.1% of patients, with beta-blockers being the most common. Renal dysfunction was found in 10.1% of patients, with one patient requiring dialysis. A significant portion (54.8%) were on anti-constipation medications due to gastrointestinal issues, and 41.7% of patients had undergone scoliosis correction surgery. Bone mineral density was significantly reduced in most patients, with an average Z-score of -3.3. CONCLUSIONS: This study emphasizes the need for improved care protocols that enhance lifespan and quality of life and manage complications for patients with DMD. This study advocates a shift in healthcare strategies toward a more integrated and holistic care model for adult patients with DMD. FAU - Choi, Won Ah AU - Choi WA AD - Rehabilitation Institute of Neuromuscular Disease, Yonsei University College of Medicine, Seoul, Republic of Korea. AD - Department of Rehabilitation Medicine, Gangnam Severance Hospital, Seoul, Republic of Korea. FAU - Park, Hee Jae AU - Park HJ AD - Rehabilitation Institute of Neuromuscular Disease, Yonsei University College of Medicine, Seoul, Republic of Korea. AD - Department of Rehabilitation Medicine, Gangnam Severance Hospital, Seoul, Republic of Korea. FAU - Kang, Seong-Woong AU - Kang SW AD - Rehabilitation Institute of Neuromuscular Disease, Yonsei University College of Medicine, Seoul, Republic of Korea. AD - Department of Rehabilitation Medicine, Gangnam Severance Hospital, Seoul, Republic of Korea. FAU - Cho, Sung-Rae AU - Cho SR AD - Rehabilitation Institute of Neuromuscular Disease, Yonsei University College of Medicine, Seoul, Republic of Korea. AD - Graduate Program of Biomedical Engineering, Yonsei University College of Medicine, Seoul, Republic of Korea. AD - Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, Republic of Korea. AD - Department and Research Institute of Rehabilitation Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea. AD - Brain Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea. FAU - Cho, Han Eol AU - Cho HE AD - Rehabilitation Institute of Neuromuscular Disease, Yonsei University College of Medicine, Seoul, Republic of Korea. AD - Department of Rehabilitation Medicine, Gangnam Severance Hospital, Seoul, Republic of Korea. LA - eng PT - Journal Article PL - United States TA - J Neuromuscul Dis JT - Journal of neuromuscular diseases JID - 101649948 SB - IM EIN - J Neuromuscul Dis. 2026 May;13(3):548. doi: 10.1177/22143602251324632. PMID: 40088053 MH - Humans MH - *Muscular Dystrophy, Duchenne/therapy/complications MH - Adult MH - Republic of Korea MH - Retrospective Studies MH - Male MH - Middle Aged MH - Young Adult MH - Female MH - Quality of Life MH - *Patient Care Team MH - *Comprehensive Health Care PMC - PMC13142842 OTO - NOTNLM OT - Duchenne muscular dystrophy OT - cardiomyopathies OT - mechanical OT - patient care team OT - ventilators COIS- Declaration of conflicting interestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2025/02/20 06:22 MHDA- 2025/02/20 06:23 PMCR- 2025/01/01 CRDT- 2025/02/20 04:24 PHST- 2025/02/20 06:23 [medline] PHST- 2025/02/20 06:22 [pubmed] PHST- 2025/02/20 04:24 [entrez] PHST- 2025/01/01 00:00 [pmc-release] AID - 10.1177_22143602241304996 [pii] AID - 10.1177/22143602241304996 [doi] PST - ppublish SO - J Neuromuscul Dis. 2025 Jan-Feb;12(1):22143602241304996. doi: 10.1177/22143602241304996. PMID- 39970681 OWN - NLM STAT- MEDLINE DCOM- 20250508 LR - 20250508 IS - 1873-4111 (Electronic) IS - 0378-5122 (Linking) VI - 195 DP - 2025 Apr TI - Exploring the experiences of adult patients with turner syndrome at a multidisciplinary clinic. PG - 108214 LID - S0378-5122(25)00022-2 [pii] LID - 10.1016/j.maturitas.2025.108214 [doi] AB - OBJECTIVE: To explore the experiences of adults with Turner syndrome 1) attending a multidisciplinary Turner syndrome clinic regarding reproductive and general health; and 2) interacting with a multidisciplinary team for the management of their Turner syndrome. STUDY DESIGN: In this descriptive, qualitative study, 21 adults with Turner syndrome who attend a multidisciplinary Turner syndrome clinic participated in semi-structured interviews. An inductive approach was used to code data and determine themes. RESULTS: Five themes were identified. 1) Differing feelings toward fertility status. Experiences with fertility differed widely, based on timing and communication of diagnosis, and feelings toward having children. 2) Adaptability and overcoming challenges. Participants sought ways to adapt to living with Turner syndrome. 3) Engagement in one's own care. Participants were engaged in their care and sought support in learning about their condition, especially around reproductive health. 4) Desire for comprehensive healthcare. Participants felt the multidisciplinary Turner syndrome clinic provided knowledgeable, convenient, and comprehensive care. 5) Barriers to accessing healthcare. Participants identified challenges both in accessing healthcare providers with expertise in Turner syndrome and in navigating the financial impact of Turner syndrome. CONCLUSION: Infertility had differing impacts on adults with Turner syndrome. Participants were satisfied with the multidisciplinary care model. Our findings highlight the importance of multidisciplinary care for optimizing the experience of adults with Turner syndrome. CI - Crown Copyright (c) 2025. Published by Elsevier B.V. All rights reserved. FAU - Shin, Sooyoun AU - Shin S AD - Department of Medicine, University of Toronto, 6 Queen's Park Crescent West, Third Floor, Toronto, ON M5S 3H2, Canada. FAU - Liang, Laurel AU - Liang L AD - Clinical Pharmacy Department, Women's College Hospital, 76 Grenville St, Toronto, ON M5S 1B2, Canada. FAU - Korenvain, Clara AU - Korenvain C AD - Specialized Medicine, Women's College Hospital, 76 Grenville St, Toronto, ON M5S 1B2, Canada. FAU - McCarthy, Lisa M AU - McCarthy LM AD - Women's College Research Institute, Women's College Hospital, 76 Grenville St, Toronto, ON M5S 1B2, Canada; Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College St, Toronto, ON M5S 3M2, Canada; Department of Family and Community Medicine, University of Toronto, 500 University Ave, Toronto, ON M5G 1V7, Canada; Institute for Better Health, Trillium Health Partners, 100 Queensway W, Mississauga, ON L5B 1B8, Canada. FAU - Lega, Iliana C AU - Lega IC AD - Department of Medicine, University of Toronto, 6 Queen's Park Crescent West, Third Floor, Toronto, ON M5S 3H2, Canada; Women's College Research Institute, Women's College Hospital, 76 Grenville St, Toronto, ON M5S 1B2, Canada. Electronic address: iliana.lega@wchospital.ca. LA - eng PT - Journal Article DEP - 20250207 PL - Ireland TA - Maturitas JT - Maturitas JID - 7807333 SB - IM MH - Humans MH - *Turner Syndrome/psychology/therapy/complications MH - Female MH - Adult MH - Qualitative Research MH - Young Adult MH - Patient Care Team MH - Middle Aged MH - Health Services Accessibility MH - *Infertility, Female/etiology/psychology MH - Fertility MH - *Patient Satisfaction MH - Reproductive Health MH - Adaptation, Psychological OTO - NOTNLM OT - Infertility OT - Multidisciplinary OT - Qualitative study OT - Turner syndrome COIS- Declaration of competing interest IL is an Endocrinologist and clinic lead of the Turner Syndrome clinic at Women's College Hospital; however, she was not involved in recruitment process, nor did she participate in data collection. SS, LL, CK, and LM were not involved in the care of the participants in the TS clinic. The authors do not have other competing interests to report. EDAT- 2025/02/20 00:21 MHDA- 2025/03/14 11:18 CRDT- 2025/02/19 18:06 PHST- 2024/07/30 00:00 [received] PHST- 2025/01/10 00:00 [revised] PHST- 2025/02/03 00:00 [accepted] PHST- 2025/03/14 11:18 [medline] PHST- 2025/02/20 00:21 [pubmed] PHST- 2025/02/19 18:06 [entrez] AID - S0378-5122(25)00022-2 [pii] AID - 10.1016/j.maturitas.2025.108214 [doi] PST - ppublish SO - Maturitas. 2025 Apr;195:108214. doi: 10.1016/j.maturitas.2025.108214. Epub 2025 Feb 7. PMID- 29489231 STAT- Publisher CTDT- 20250220 PB - StatPearls Publishing DP - 2025 Jan TI - Peripartum Cardiomyopathy. BTI - StatPearls AB - Peripartum cardiomyopathy (PPCM) is a rare cause of cardiomyopathy that occurs during late pregnancy or the early postpartum period. This condition can be life-threatening and is characterized by significant left ventricular dysfunction and heart failure. However, PPCM has had various definitions. In 2000, The National Heart Lung and Blood Institute and The Office of Rare Diseases workshop established the following 4 criteria for PPCM, becoming the condition's first case definition: Cardiac failure in the last month of pregnancy or within 5 months of delivery. Absence of a determinable etiology for the cardiac failure. Absence of demonstrable structural cardiac disease before the last month of pregnancy. Echocardiographic evidence of diminished left ventricular systolic function noted by one of the following: Left ventricular ejection fraction (LVEF) <45%. Motion-mode fractional shortening <30%. Left ventricular end-diastolic dimension exceeding 2.7 cm/m2. Then, the 2019 European Society of Cardiology Working Group used the following 3 key criteria: Development of heart failure toward the end of pregnancy or in the postpartum period. Absence of another identifiable cause of heart failure. Left ventricular systolic dysfunction with a left ventricle (LV) ejection fraction <45%; LV may or may not be dilated . An expanded definition of PPCM has been proposed to include 2 additional categories: early PPCM, which is diagnosed from the first to the ninth month of pregnancy, and late PPCM, which is identified between 6 and 12 months after delivery. This broader framework acknowledges variations in the timing of disease onset and extends beyond the traditional postpartum focus. Patients with PPCM typically present with dyspnea, fatigue, cough, orthopnea, paroxysmal nocturnal dyspnea, pedal edema, and hemoptysis, though clinicians may not promptly recognize the condition as these symptoms are nonspecific. The primary diagnostic studies used to assess whether peripartum patients meet the definition of PPCM are the electrocardiogram (ECG) and echocardiogram. Though peripartum cardiomyopathy is acutely treated similarly to other forms of systolic heart failure with pregnancy-safe therapies (eg, dietary sodium restriction, loop diuretics, beta-blockers, hydralazine or nitrates, and digoxin), the overall management of cardiomyopathy associated with pregnancy requires the collaboration of a multidisciplinary team to address the various aspects of patient care the condition affects including labor and delivery, lactation, contraception, and family planning. Though many patients may recover depending on their left ventricular ejection fraction at the time of diagnosis, the condition is associated with many adverse outcomes, including brain injury, cardiopulmonary arrest, pulmonary edema, and death. Therefore, prompt evaluation and treatment are essential to improving patient outcomes. CI - Copyright (c) 2025, StatPearls Publishing LLC. FAU - Rodriguez Ziccardi, Mary AU - Rodriguez Ziccardi M FAU - Siddique, Momin S AU - Siddique MS AD - SIU LA - eng PT - Study Guide PT - Book Chapter PL - Treasure Island (FL) COIS- Disclosure: Mary Rodriguez Ziccardi declares no relevant financial relationships with ineligible companies. Disclosure: Momin S Siddique declares no relevant financial relationships with ineligible companies. EDAT- 2025/02/20 00:00 CRDT- 2025/02/20 00:00 AID - NBK482185 [bookaccession] PMID- 39967840 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250220 IS - 2050-0904 (Print) IS - 2050-0904 (Electronic) IS - 2050-0904 (Linking) VI - 13 IP - 2 DP - 2025 Feb TI - Multidisciplinary Treatment With Adjunctive Orthodontics, Surgical Crown Lengthening, and Esthetic Rehabilitation. PG - e70217 LID - 10.1002/ccr3.70217 [doi] LID - e70217 AB - Anterior spacing caused by missing upper lateral incisors and edge-to-edge position in the front teeth can negatively affect the appearance of a person's smile, leading to mental and social distress. A 29-year-old woman approached with the issue of edge-to-edge anterior occlusion, upper and lower spacing, missing lateral teeth, and improper occlusion. The treatment plan involved an interdisciplinary approach with orthodontics, implants, periodontics, and prosthodontics. After orthodontic treatment, third molar extraction and two buccal shelf mini screws were recommended to distalize the lower posterior teeth and retract the lower incisors using a power chain. Gingivoplasty and veneer restorations were performed on teeth 14-24 to improve the patient's smile aesthetics. The interdisciplinary approach used in this case involved fixed orthodontics, periodontal surgery, and prosthodontics to manage and improve the patient's smile and facial appearance. CI - (c) 2025 The Author(s). Clinical Case Reports published by John Wiley & Sons Ltd. FAU - Viet, Hoang AU - Viet H AUID- ORCID: 0009-0000-5139-452X AD - Department of Orthodontics & Pedodontics, Faculty of Dentistry Van Lang University Ho Chi Minh Vietnam. AD - Singdent Dental Group Ho Chi Minh city Vietnam. FAU - Thao, Dang Thi Nhu AU - Thao DTN AD - Department of Orthodontics & Pedodontics, Faculty of Dentistry Van Lang University Ho Chi Minh Vietnam. FAU - Phuoc, Tran Hong AU - Phuoc TH AD - Department of Oral Surgery Sai Gon Dental Private Hospital Ho Chi Minh Vietnam. FAU - Hung, Do The AU - Hung DT AD - Department of Implantology Sai Gon Dental Private Hospital Ho Chi Minh Vietnam. FAU - Marya, Anand AU - Marya A AUID- ORCID: 0000-0003-2009-4393 AD - Department of Orthodontics University of Puthisastra Phnom Penh Cambodia. AD - Center for Transdisciplinary Research, Saveetha Dental College Saveetha Institute of Medical and Technical Science, Saveetha University Chennai Tamilnadu India. LA - eng PT - Journal Article DEP - 20250217 PL - England TA - Clin Case Rep JT - Clinical case reports JID - 101620385 PMC - PMC11832903 OTO - NOTNLM OT - class III OT - gingivoplasty OT - implant OT - mini-screws OT - prosthodontics EDAT- 2025/02/19 06:22 MHDA- 2025/02/19 06:23 PMCR- 2025/02/17 CRDT- 2025/02/19 04:27 PHST- 2024/07/30 00:00 [received] PHST- 2025/01/29 00:00 [revised] PHST- 2025/02/04 00:00 [accepted] PHST- 2025/02/19 06:23 [medline] PHST- 2025/02/19 06:22 [pubmed] PHST- 2025/02/19 04:27 [entrez] PHST- 2025/02/17 00:00 [pmc-release] AID - CCR370217 [pii] AID - 10.1002/ccr3.70217 [doi] PST - epublish SO - Clin Case Rep. 2025 Feb 17;13(2):e70217. doi: 10.1002/ccr3.70217. eCollection 2025 Feb. PMID- 39966036 OWN - NLM STAT- MEDLINE DCOM- 20250510 LR - 20250510 IS - 1444-2892 (Electronic) IS - 1443-9506 (Linking) VI - 34 IP - 5 DP - 2025 May TI - Practice Change in Surgical Treatment Strategies for Ischaemic Mitral Regurgitation and Late Outcomes. PG - 485-496 LID - S1443-9506(24)01926-7 [pii] LID - 10.1016/j.hlc.2024.11.024 [doi] AB - BACKGROUND: Ischaemic mitral regurgitation (IMR) results from dysfunctional myocardial remodelling, which portends a poor clinical prognosis. This study assessed the surgical treatment of IMR and its associations with clinical and echocardiographic outcomes in the context of 2014 reports suggesting non-surgical management of non-severe IMR. METHOD: Patients who underwent mitral valve (MV) procedures for IMR at Liverpool Hospital (Sydney, Australia) between 2008 and 2020 were included based on coronary disease and echocardiographic criteria. Data were obtained from patient records and linkage with the Australian Institute of Health and Welfare National Death Index. The primary outcome was the type of MV surgery performed in 2008-2014 and 2015-2020. Secondary outcomes were survival and freedom from combination of mortality and congestive heart failure (CHF) readmission, comparing MV repair and MV replacement and the outcomes for two periods by MV procedure. RESULTS: Of 106 patients treated surgically for IMR, 78 had MV repair (59 in 2008-2014, 19 in 2015-2020) and 28 had MV replacement (14 in 2008-2014, 14 in 2015-2020). Patients were followed up for 7.2 years (interquartile range 5.2-9.1). Compared to 2008-2014, there was a reduced proportion of MV procedures for IMR (4.2% and 2.0%; p<0.001) and MV repair for IMR (80.8% and 57.6%; p=0.012) post-2014. Freedom from a combination of mortality and CHF readmission over 10 years was significantly better in the MV repair than in the MV replacement group (log rank p<0.001). Over 5 years, freedom from mortality and the combination of mortality and CHF readmission were similar in both periods (log rank p=0.675 and p=0.433). In the earlier period, freedom from combined outcome was better in the MV repair group than the MV replacement group (log rank p<0.001) but not different in the second period (log rank p=0.149). Mitral regurgitation recurrence was less in the later period (25.8% and 3.6%; p=0.013). CONCLUSIONS: The proportion of MV procedures and MV repairs performed for IMR declined significantly after 2014, indicating a significant change in practice towards conservative surgical correction of IMR. The combined long-term outcomes were unchanged after the change in practice, but the incidence of mitral regurgitation recurrence was significantly improved. CI - Copyright (c) 2024. Published by Elsevier B.V. FAU - Shin, Yaerhim AU - Shin Y AD - Cardiothoracic Surgery and Cardiology Departments, Liverpool Hospital, South West Sydney, NSW, Australia; South West Sydney Clinical School, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia. FAU - French, John K AU - French JK AD - Cardiothoracic Surgery and Cardiology Departments, Liverpool Hospital, South West Sydney, NSW, Australia; South West Sydney Clinical School, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia. FAU - Mian, Mahnoor AU - Mian M AD - Cardiothoracic Surgery and Cardiology Departments, Liverpool Hospital, South West Sydney, NSW, Australia. FAU - Leung, Dominic Y AU - Leung DY AD - Cardiothoracic Surgery and Cardiology Departments, Liverpool Hospital, South West Sydney, NSW, Australia; South West Sydney Clinical School, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia. FAU - Tran, Nguyen Giang Tien AU - Tran NGT AD - South West Sydney Clinical School, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia. FAU - Wolfenden, Hugh D AU - Wolfenden HD AD - Cardiothoracic Surgery and Cardiology Departments, Liverpool Hospital, South West Sydney, NSW, Australia. FAU - Dignan, Rebecca AU - Dignan R AD - South West Sydney Clinical School, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia. Electronic address: r.dignan@unsw.edu.au. LA - eng PT - Journal Article DEP - 20250217 PL - Australia TA - Heart Lung Circ JT - Heart, lung & circulation JID - 100963739 SB - IM MH - Humans MH - *Mitral Valve Insufficiency/surgery/etiology/mortality MH - Male MH - Female MH - Aged MH - *Myocardial Ischemia/complications/surgery MH - Retrospective Studies MH - Follow-Up Studies MH - *Mitral Valve/surgery/diagnostic imaging MH - Middle Aged MH - *Heart Valve Prosthesis Implantation/methods MH - Echocardiography MH - Treatment Outcome MH - Time Factors MH - Australia/epidemiology MH - Survival Rate/trends OTO - NOTNLM OT - Ischaemic mitral regurgitation OT - Mitral regurgitation recurrence OT - Mitral valve repair OT - Mitral valve replacement OT - Multidisciplinary heart team COIS- Declaration of Competing Interests The authors declare no competing interests. EDAT- 2025/02/19 00:15 MHDA- 2025/05/11 00:45 CRDT- 2025/02/18 21:59 PHST- 2024/04/04 00:00 [received] PHST- 2024/11/08 00:00 [revised] PHST- 2024/11/21 00:00 [accepted] PHST- 2025/05/11 00:45 [medline] PHST- 2025/02/19 00:15 [pubmed] PHST- 2025/02/18 21:59 [entrez] AID - S1443-9506(24)01926-7 [pii] AID - 10.1016/j.hlc.2024.11.024 [doi] PST - ppublish SO - Heart Lung Circ. 2025 May;34(5):485-496. doi: 10.1016/j.hlc.2024.11.024. Epub 2025 Feb 17. PMID- 39965867 OWN - NLM STAT- MEDLINE DCOM- 20250508 LR - 20250508 IS - 2399-9772 (Electronic) IS - 2399-9772 (Linking) VI - 9 IP - 1 DP - 2025 Feb 18 TI - Cardiac-related neonatal collapse presenting to the emergency department: a retrospective cohort study. LID - 10.1136/bmjpo-2024-003149 [doi] LID - e003149 AB - BACKGROUND: To describe the characteristics of cardiac-related neonatal collapses referred to a critical care transport service and evaluate the diagnostic accuracy and management at referral and retrieval. METHODS: Retrospective cohort analysis of cardiac-related neonatal collapses who were referred to and transferred by a paediatric intensive care retrieval team based in London, UK between 2013 and 2021. Patients with antenatal diagnoses were excluded. RESULTS: There were 71 neonates identified of whom 49 (69%) had structural heart defect, 12 (17%) arrhythmia and 10 (14%) with cardiomyopathy/myocarditis. Among structural defects, left ventricular outflow tract (LVOT) obstruction (71%) and mixing of circulation (22%) were the predominant pathologies. Cardiac murmur was absent in 66% of the patients. The referring teams' diagnostic performance was suboptimal for LVOT obstruction and cardiomyopathy/myocarditis, with 63% and 30% recognised as cardiac cause of collapse at referral. Less than half of neonates with duct-dependent lesions received prostaglandin at referral, which later improved to 97% during retrieval. The number of patients requiring intubation and inotropic support also increased at various time points throughout the patient journey. 98% of patients with structural defects required cardiac interventions at a median of 1 day after admission. CONCLUSIONS: Structural heart defect, particularly LVOT obstruction, was the leading cause of cardiac-related neonatal collapses. However, a significant portion were initially misdiagnosed leading to delay in prostaglandin administration. Our findings highlight the importance of a high index of suspicion for cardiac pathologies as a cause of neonatal collapse, which is essential for appropriate treatment and timely referral. CI - (c) Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. FAU - Kuok, Manson Chon In AU - Kuok MCI AUID- ORCID: 0000-0002-8608-350X AD - Paediatric Intensive Care Unit and South Thames Retrieval Service, Evelina London Children's Hospital, London, UK. FAU - Lambert, Jennie AU - Lambert J AD - Paediatric Intensive Care Unit and South Thames Retrieval Service, Evelina London Children's Hospital, London, UK. FAU - Janjanam, Anitha AU - Janjanam A AD - Paediatric Intensive Care Unit and South Thames Retrieval Service, Evelina London Children's Hospital, London, UK. FAU - Lillie, Jon AU - Lillie J AUID- ORCID: 0000-0003-1776-5184 AD - Paediatric Intensive Care Unit and South Thames Retrieval Service, Evelina London Children's Hospital, London, UK Jonathan.Lillie@gstt.nhs.uk. AD - King's College University London, London, UK. LA - eng PT - Journal Article DEP - 20250218 PL - England TA - BMJ Paediatr Open JT - BMJ paediatrics open JID - 101715309 SB - IM MH - Humans MH - Retrospective Studies MH - Infant, Newborn MH - Female MH - Male MH - *Emergency Service, Hospital/statistics & numerical data MH - London/epidemiology MH - *Heart Defects, Congenital/complications/diagnosis/therapy MH - Referral and Consultation PMC - PMC11836824 OTO - NOTNLM OT - Cardiology OT - Neonatology COIS- Competing interests: No, there are no competing interests. EDAT- 2025/02/19 00:15 MHDA- 2025/02/19 00:16 PMCR- 2025/02/18 CRDT- 2025/02/18 20:52 PHST- 2024/10/23 00:00 [received] PHST- 2025/01/30 00:00 [accepted] PHST- 2025/02/19 00:16 [medline] PHST- 2025/02/19 00:15 [pubmed] PHST- 2025/02/18 20:52 [entrez] PHST- 2025/02/18 00:00 [pmc-release] AID - 10.1136/bmjpo-2024-003149 [pii] AID - bmjpo-2024-003149 [pii] AID - 10.1136/bmjpo-2024-003149 [doi] PST - epublish SO - BMJ Paediatr Open. 2025 Feb 18;9(1):e003149. doi: 10.1136/bmjpo-2024-003149. PMID- 39960925 OWN - NLM STAT- MEDLINE DCOM- 20250217 LR - 20250629 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 104 IP - 7 DP - 2025 Feb 14 TI - Effect of early readmission on subsequent hospital admissions within 1 year in patients with heart failure: A retrospective cohort study. PG - e41567 LID - 10.1097/MD.0000000000041567 [doi] LID - e41567 AB - This study aimed to identify the factors influencing multiple admissions within 1 year for patients with heart failure (HF) and to examine the impact of early readmission on subsequent admissions. A retrospective questionnaire survey was conducted on 498 patients with HF admitted to our hospital's Cardiology department between January 1, 2020, and December 31, 2022. Multivariate regression analysis identified factors influencing multiple admissions, and propensity score matching (PSM) assessed the impact of readmissions within 30 days and 31 to 90 days post-discharge on unplanned admissions within a year. The incidence of multiple admissions was 22.09% (110/498), with first readmissions within 30 days post-discharge at 13.25% (66/498) and within 31 to 90 days at 15.86% (79/498). Influential factors for multiple unplanned hospital admissions included age, history of atrial fibrillation, chronic kidney disease, chronic obstructive pulmonary disease, New York Heart Association grade >/= III, hemoglobin (Hb) < 110g/L, taking 7 or more medications, and readmission within 31 to 90 days (P < .05). Post-PSM analysis showed that the first admission within 30 days (odds ratio [OR] = 6.400, 95% confidence interval [Cl] = 2.638-15.527, P = .001), and the first admission within 31 to 90 days significantly increased the risk of multiple admissions (OR = 5.694, 95% Cl = 2.615-12.402, P = .001). Patients with HF exhibit a high rate of numerous readmissions within 1 year. Clinical medical staff should focus more on patients with early readmissions, enhance self-management, and improve management of comorbidities and medications through a multidisciplinary team approach. Enhancing continuous nursing and improving access to medical services may reduce patient readmission rates. CI - Copyright (c) 2025 the Author(s). Published by Wolters Kluwer Health, Inc. FAU - Liang, Mengyao AU - Liang M AD - Department of Nursing, The Sixth People's Hospital of Nantong, Jiangsu, China. FAU - Yang, Qingqing AU - Yang Q AD - Department of Cardiology, The Sixth People's Hospital of Nantong, Jiangsu, China. FAU - Lu, Yi AU - Lu Y AD - Department of Cardiology, The Sixth People's Hospital of Nantong, Jiangsu, China. FAU - Wang, Yanmei AU - Wang Y AUID- ORCID: 0009-0004-8323-1791 AD - Department of Outpatient, The Sixth People's Hospital of Nantong, Jiangsu, China. LA - eng PT - Journal Article PT - Observational Study PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R SB - IM MH - Humans MH - *Patient Readmission/statistics & numerical data MH - *Heart Failure/therapy/epidemiology MH - Retrospective Studies MH - Male MH - Female MH - Aged MH - Middle Aged MH - Risk Factors MH - Propensity Score MH - Aged, 80 and over MH - Time Factors MH - Surveys and Questionnaires PMC - PMC11835086 COIS- The authors have no conflicts of interest to disclose. EDAT- 2025/02/17 18:21 MHDA- 2025/02/17 18:22 PMCR- 2025/02/14 CRDT- 2025/02/17 13:53 PHST- 2025/02/17 18:22 [medline] PHST- 2025/02/17 18:21 [pubmed] PHST- 2025/02/17 13:53 [entrez] PHST- 2025/02/14 00:00 [pmc-release] AID - 00005792-202502140-00031 [pii] AID - MD-D-24-00902 [pii] AID - 10.1097/MD.0000000000041567 [doi] PST - ppublish SO - Medicine (Baltimore). 2025 Feb 14;104(7):e41567. doi: 10.1097/MD.0000000000041567. PMID- 39959760 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260924 IS - 2666-5352 (Electronic) IS - 2666-5352 (Linking) VI - 9 DP - 2025 Jun TI - Qualitative analysis of cardiovascular disease prevention in dental practice. PG - 100586 LID - 10.1016/j.puhip.2025.100586 [doi] LID - 100586 AB - BACKGROUND: The primary prevention of periodontal disease is a global health concern due to its increasing incidence and evolving evidence of its role in cardiovascular disease (CVD). This study aimed to describe dentists' perceptions and practices regarding CVD prevention in practice. STUDY DESIGN AND METHODS: A qualitative study design, using semi-structured interviews, was used to determine the perceptions, practices, barriers, and enablers of dentists towards the implementation of CVD prevention in practice. Interviews were analysed using a thematic analysis framework. NVivo 12 Pro software was utilised to support the data analysis. RESULTS: Eleven participants (eight female) with a mean employment history of 17.45 years, were interviewed, at which point data saturation was reached. The semi-structured interviews ranged in duration from 45 to 86 min, with a mean duration of 62.5 min. All dentists interviewed were in private practice. Inductive thematic analysis revealed four major themes - dentists' current practices in relation to preventive cardiology in practice; professional identity and role expectations; barriers to preventive cardiology in practice; and facilitators of preventive cardiology in dental practice. CONCLUSIONS: This study highlights the current practices, perceptions and identified barriers and enablers to preventive cardiology in Irish dental practice. Future research should focus on educational interventions to improve the implementation of CVD prevention guidelines in dental practice. CI - (c) 2025 The Authors. FAU - O'Farrell, Aine AU - O'Farrell A AD - School of Medicine, College of Medicine, Nursing and Health Sciences, University of Galway, Galway, Ireland. AD - National Institute for Prevention and Cardiovascular Health, Galway, Ireland. FAU - Liew, Chee H AU - Liew CH AD - School of Medicine, College of Medicine, Nursing and Health Sciences, University of Galway, Galway, Ireland. AD - National Institute for Prevention and Cardiovascular Health, Galway, Ireland. FAU - Geoghegan, Rosemary AU - Geoghegan R AD - School of Medicine, College of Medicine, Nursing and Health Sciences, University of Galway, Galway, Ireland. FAU - Flaherty, Gerard T AU - Flaherty GT AD - School of Medicine, College of Medicine, Nursing and Health Sciences, University of Galway, Galway, Ireland. AD - National Institute for Prevention and Cardiovascular Health, Galway, Ireland. LA - eng PT - Journal Article DEP - 20250125 PL - England TA - Public Health Pract (Oxf) JT - Public health in practice (Oxford, England) JID - 101774776 PMC - PMC11830329 OTO - NOTNLM OT - Cardiovascular disease OT - Multidisciplinary healthcare team OT - Periodontal disease OT - Primary prevention OT - Risk factor modification OT - Secondary prevention COIS- The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/02/17 11:03 MHDA- 2025/02/17 11:04 PMCR- 2025/01/25 CRDT- 2025/02/17 05:59 PHST- 2024/04/25 00:00 [received] PHST- 2024/11/29 00:00 [revised] PHST- 2024/12/06 00:00 [accepted] PHST- 2025/02/17 11:04 [medline] PHST- 2025/02/17 11:03 [pubmed] PHST- 2025/02/17 05:59 [entrez] PHST- 2025/01/25 00:00 [pmc-release] AID - S2666-5352(25)00005-9 [pii] AID - 100586 [pii] AID - 10.1016/j.puhip.2025.100586 [doi] PST - epublish SO - Public Health Pract (Oxf). 2025 Jan 25;9:100586. doi: 10.1016/j.puhip.2025.100586. eCollection 2025 Jun. PMID- 39957539 OWN - NLM STAT- MEDLINE DCOM- 20260601 LR - 20260622 IS - 1939-9278 (Electronic) IS - 0018-5868 (Linking) VI - 104 IP - 2 DP - 2026 Apr-Jun TI - Effectiveness of Interdisciplinary Simulation Training on the Self-Efficacy and Anxiety of Healthcare Professionals in Managing a Medical Emergency. PG - 142-149 LID - 10.1080/00185868.2025.2464125 [doi] AB - Basic life support and advanced cardiovascular life support training are required every two years; however, these skills often deteriorate due to lack of routine practice which can increase anxiety in healthcare workers. The purpose of this project is to determine the effect of interdisciplinary simulation training on self-efficacy and anxiety levels of healthcare professionals in managing a medical emergency. Sessions simulating emergent situations were held every two weeks for eight weeks. Surveys (GAD-7) were completed two weeks pre- and postintervention, and an effectiveness questionnaire (SET) was completed immediately post-intervention. Participants agreed that the simulation sessions were an effective means of increasing confidence in responding to a medical emergency. Overall anxiety was decreased post-intervention. FAU - Simpler, Brandy AU - Simpler B AD - School of Nursing, Troy University, Troy, AL, USA. FAU - Jones, Stacey AU - Jones S AD - School of Nursing, Troy University, Troy, AL, USA. FAU - Chance, Kasey AU - Chance K AD - School of Nursing, Troy University-Dothan Campus, Dothan, AL, USA. LA - eng PT - Journal Article DEP - 20250217 PL - United States TA - Hosp Top JT - Hospital topics JID - 0411772 SB - IM MH - Humans MH - *Self Efficacy MH - *Anxiety/psychology/etiology MH - *Simulation Training/methods/standards MH - Surveys and Questionnaires MH - *Health Personnel/psychology/education/statistics & numerical data MH - Female MH - Male MH - Adult MH - Clinical Competence/standards OTO - NOTNLM OT - Interdisciplinary simulation training OT - anxiety OT - cardiac arrest OT - healthcare professionals OT - medical emergencies OT - nurses EDAT- 2025/02/17 11:03 MHDA- 2026/06/01 08:04 CRDT- 2025/02/17 04:33 PHST- 2026/06/01 08:04 [medline] PHST- 2025/02/17 11:03 [pubmed] PHST- 2025/02/17 04:33 [entrez] AID - 10.1080/00185868.2025.2464125 [doi] PST - ppublish SO - Hosp Top. 2026 Apr-Jun;104(2):142-149. doi: 10.1080/00185868.2025.2464125. Epub 2025 Feb 17. PMID- 39956764 OWN - NLM STAT- MEDLINE DCOM- 20250508 LR - 20260428 IS - 2174-2030 (Electronic) IS - 0870-2551 (Linking) VI - 44 Suppl 1 DP - 2025 Feb TI - Suspicion and referral of patients with transthyretin amyloid cardiomyopathy: Recommendations by a Portuguese multidisciplinary expert panel. PG - 59-68 LID - S0870-2551(25)00021-6 [pii] LID - 10.1016/j.repc.2024.12.002 [doi] AB - Early diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) is crucial for better disease management and outcome. To ensure timely diagnosis, a multidisciplinary panel of Portuguese experts, including cardiologists, internal medicine specialists, and general practitioners, have developed a national consensus to aid physicians in enhancing the referral of patients with suspicion of ATTR-CM in Portugal. A structured approach was used to develop the consensus: (1) an online survey aimed at identifying clinical red flags, patient journeys, and diagnostic tools related to ATTR-CM; (2) a face-to-face roundtable meeting where the survey findings were discussed and a consensus was reached on referral and diagnostic algorithms for ATTR-CM in Portugal; and (3) critical review of the proposed algorithms. The referral and diagnostic algorithms for ATTR-CM in Portugal were developed considering current recommendations, but also the existence of a nationwide network of specialized cardiomyopathy clinics and national reference centers for familial amyloid polyneuropathy due to the endemic p.V50M variant. This collaborative effort aims to enhance awareness, facilitate timely referrals and improve early diagnosis, ultimately ensuring better management of ATTR-CM patients in Portugal. CI - Copyright (c) 2025 Sociedade Portuguesa de Cardiologia. Publicado por Elsevier Espana, S.L.U. All rights reserved. FAU - Brito, Dulce AU - Brito D AD - Unidade Local de Saude Santa Maria, Lisboa, Portugal. Electronic address: dulcebrito59@gmail.com. FAU - Agostinho, Joao AU - Agostinho J AD - Unidade Local de Saude Santa Maria, Lisboa, Portugal. FAU - Aguiar, Carlos AU - Aguiar C AD - Unidade Local de Saude Lisboa Ocidental, Hospital de Santa Cruz, Carnaxide, Portugal. FAU - Aguiar Rosa, Silvia AU - Aguiar Rosa S AD - Unidade Local de Saude S. Jose, Lisboa, Portugal. FAU - Cardim, Nuno AU - Cardim N AD - Hospital CUF Descobertas, Lisboa, Portugal. FAU - Fonseca, Candida AU - Fonseca C AD - Unidade Local de Saude de Lisboa Ocidental, Hospital S. Francisco Xavier, Lisboa, Portugal. FAU - Marques, Nuno AU - Marques N AD - Unidade Local de Saude do Alentejo Central, Evora, Portugal. FAU - Moraes Sarmento, Pedro AU - Moraes Sarmento P AD - Hospital da Luz, Lisboa, Portugal. FAU - Rodrigues, Patricia AU - Rodrigues P AD - Unidade Local de Saude de Santo Antonio, Porto, Portugal. FAU - Santos, Jonathan AU - Santos J AD - Faculdade de Medicina da Universidade do Porto, Porto, Portugal. FAU - Vidigal Ferreira, Maria Joao AU - Vidigal Ferreira MJ AD - Centro Academico e Clinico de Coimbra, Coimbra, Portugal. FAU - Azevedo, Olga AU - Azevedo O AD - Unidade Local de Saude do Alto Ave, Guimaraes, Portugal. LA - eng LA - por PT - Consensus Statement PT - Journal Article PT - Practice Guideline PL - Portugal TA - Rev Port Cardiol JT - Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology JID - 8710716 RN - Amyloidosis, Hereditary, Transthyretin-Related SB - IM MH - Humans MH - *Amyloid Neuropathies, Familial/diagnosis MH - Portugal MH - *Referral and Consultation MH - *Cardiomyopathies/diagnosis/etiology MH - Algorithms OTO - NOTNLM OT - Algorithm OT - Algoritmo OT - Amiloidose cardiaca OT - Cardiac amyloidosis OT - Consenso OT - Consensus OT - Diagnosis OT - Diagnostico OT - Miocardiopatia por amiloidose de transtirretina OT - Referenciacao OT - Referral OT - Transthyretin amyloid cardiomyopathy EDAT- 2025/02/17 00:21 MHDA- 2025/02/17 00:22 CRDT- 2025/02/16 22:30 PHST- 2024/11/22 00:00 [received] PHST- 2024/12/06 00:00 [accepted] PHST- 2025/02/17 00:22 [medline] PHST- 2025/02/17 00:21 [pubmed] PHST- 2025/02/16 22:30 [entrez] AID - S0870-2551(25)00021-6 [pii] AID - 10.1016/j.repc.2024.12.002 [doi] PST - ppublish SO - Rev Port Cardiol. 2025 Feb;44 Suppl 1:59-68. doi: 10.1016/j.repc.2024.12.002. PMID- 39955235 OWN - NLM STAT- MEDLINE DCOM- 20250403 LR - 20260918 IS - 1879-0828 (Electronic) IS - 0953-6205 (Linking) VI - 134 DP - 2025 Apr TI - Hypertensive heart disease in older patients: considerations for clinical practice. PG - 75-88 LID - S0953-6205(24)00540-5 [pii] LID - 10.1016/j.ejim.2024.12.034 [doi] AB - Appropriate management of older people with hypertension is essential to reduce the burden of hypertensive heart disease and further cardiovascular sequelae but there may be challenges given the presence of concurrent senescent changes, comorbidities and impairment in functionality. It is recommended that frailty level and functional status are assessed periodically to understand patient needs and to guide treatment decisions. Office blood pressure should be measured with an appropriate cuff as per standard guidelines. There should be a high index of suspicion for orthostatic hypotension and white coat/masked hypertension, both common in older individuals. Cardiac imaging often identifies age-related changes that may not result from hypertension alone, including smaller ventricular volumes, a sigmoid septum and non-ischaemic fibrosis. Diastolic dysfunction is common and other pathologies, including cardiac amyloidosis, may need to be considered in the presence of red flags. Screening for atrial fibrillation during blood pressure evaluation is advised. Decisions for blood pressure management should follow current recommendations and take into consideration the patient's age and tolerance. There is limited evidence regarding heart failure management in older patients, however, disease-modifying therapy as per guidelines should be pursued. Sufficient outcome data are lacking for this patient group and a multidisciplinary approach is often needed to design optimal therapy. CI - Copyright (c) 2024. Published by Elsevier B.V. FAU - Camafort, Miguel AU - Camafort M AD - Hypertension Unit, Department of Internal Medicine, Hospital Clinic, University of Barcelona, Spain; Biomedical Research Network Center for the Pathophysiology of Obesity and Nutrition (CIBER-OBN), Carlos III Health Institute, Spain. FAU - Kasiakogias, Alexandros AU - Kasiakogias A AD - First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Hippokration General Hospital, Athens, Greece. Electronic address: akasiakogias@gmail.com. FAU - Agabiti-Rosei, Enrico AU - Agabiti-Rosei E AD - Department of Clinical and Experimental Sciences, University of Brescia, Italy and IRCCS Multimedica, Milan, Italy. FAU - Masi, Stefano AU - Masi S AD - Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy. FAU - Iliakis, Panagiotis AU - Iliakis P AD - First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Hippokration General Hospital, Athens, Greece. FAU - Benetos, Athanase AU - Benetos A AD - Department of Geriatric Medicine and INSERM DCAC, CHRU-Nancy, Universite de Lorraine, Nancy, France. FAU - Jeong, Jin-Ok AU - Jeong JO AD - Division of Cardiology, Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Republic of Korea. FAU - Lee, Hae-Young AU - Lee HY AD - Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea. FAU - Muiesan, Maria Lorenza AU - Muiesan ML AD - Department of Clinical and Experimental Sciences, Centro per la Prevenzione e Cura dell'ipertensione Arteriosa, University of Brescia and ASST Spedali Civili, Brescia, Italy. FAU - Sudano, Isabella AU - Sudano I AD - University Hospital Zurich University Heart Center, Cardiology and University of Zurich, Zurich, Switzerland. FAU - Tsioufis, Costas AU - Tsioufis C AD - First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Hippokration General Hospital, Athens, Greece. CN - European Society of Hypertension Working Group on Hypertension and the Heart LA - eng PT - Journal Article PT - Review DEP - 20250215 PL - Netherlands TA - Eur J Intern Med JT - European journal of internal medicine JID - 9003220 RN - 0 (Antihypertensive Agents) SB - IM MH - Humans MH - *Hypertension/complications/diagnosis MH - Aged MH - *Heart Diseases/etiology MH - Atrial Fibrillation/diagnosis MH - Antihypertensive Agents/therapeutic use MH - Hypotension, Orthostatic MH - Blood Pressure OTO - NOTNLM OT - Frailty OT - Heart failure OT - Hypertensive heart disease OT - Older patients COIS- Conflict of Interest None. EDAT- 2025/02/16 01:32 MHDA- 2025/04/04 00:25 CRDT- 2025/02/15 21:59 PHST- 2024/09/27 00:00 [received] PHST- 2024/12/21 00:00 [revised] PHST- 2024/12/30 00:00 [accepted] PHST- 2025/04/04 00:25 [medline] PHST- 2025/02/16 01:32 [pubmed] PHST- 2025/02/15 21:59 [entrez] AID - S0953-6205(24)00540-5 [pii] AID - 10.1016/j.ejim.2024.12.034 [doi] PST - ppublish SO - Eur J Intern Med. 2025 Apr;134:75-88. doi: 10.1016/j.ejim.2024.12.034. Epub 2025 Feb 15. PMID- 39952552 OWN - NLM STAT- MEDLINE DCOM- 20250315 LR - 20260611 IS - 1559-2030 (Electronic) IS - 1551-7144 (Linking) VI - 151 DP - 2025 Apr TI - A randomised controlled trial of a multidisciplinary TEAM-based approach to guide secondary cardiovascular risk reduction for patients with Peripheral Artery Disease (TEAM-PAD) study protocol. PG - 107844 LID - S1551-7144(25)00038-2 [pii] LID - 10.1016/j.cct.2025.107844 [doi] AB - BACKGROUND: Peripheral arterial disease (1) is a vascular condition associated with significant cardiovascular morbidity and mortality. Effective secondary prevention strategies are essential to improve cardiovascular outcomes in patients with PAD. The TEAM-PAD study aims to determine if a centralised virtual multidisciplinary team (MDT) model of care is effective in improving guideline-recommended secondary cardiovascular risk reduction for outpatients with PAD. METHODS: TEAM-PAD is a multicentre, randomised controlled trial involving patients with PAD. Participants will be randomised into two groups: the intervention group, who will receive care supported by cardiovascular risk reduction recommendations from a centralised MDT; and the control group, who will receive usual care by their vascular surgeon. The MDT will consist of the following clinicians: vascular surgeon, cardiologist, endocrinologist, nephrologist, geriatrician, drug health physician and clinical pharmacist. The primary outcome is the change in a composite measure of an individual's 10-year cardiovascular risk between baseline to 9-months follow-up. Secondary outcomes include control of modifiable cardiovascular risk factors and medication optimisation, cardiovascular and limb outcomes, PAD symptom control, quality of life outcomes, and health-service use outcomes. CONCLUSION: This article details the TEAM-PAD trial protocol, which will provide robust evidence on the benefits of an MDT-based approach to cardiovascular risk reduction in PAD patients. TEAM-PAD has the potential to inform clinical practice by demonstrating whether coordinated, personalised care recommendations can improve cardiovascular risk and potentially reduce cardiovascular events in this high-risk population. TRIAL REGISTRATION: This study has been registered at the Australia New Zealand Clinical Trial Registry (Registration number: ACTRN12623000995673). CI - Copyright (c) 2025 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Chimoriya, Ritesh AU - Chimoriya R AD - Institute of Academic Surgery, Vascular Department, Concord Repatriation General Hospital, Concord, Sydney, New South Wales, Australia; Faculty of Medicine and Health, The University of Sydney, Camperdown, New South Wales, Australia; Department of Vascular Surgery, Concord Hospital, The University of Sydney, 1 Hospital Road, Concord, NSW 2139, Australia. FAU - James, Sophie AU - James S AD - Faculty of Medicine and Health, The University of Sydney, Camperdown, New South Wales, Australia; Department of Vascular Surgery, Concord Hospital, The University of Sydney, 1 Hospital Road, Concord, NSW 2139, Australia; Department of Cardiology, Concord Hospital, The University of Sydney, 1 Hospital Road, Concord, NSW 2139, Australia. FAU - Kritharides, Leonard AU - Kritharides L AD - Faculty of Medicine and Health, The University of Sydney, Camperdown, New South Wales, Australia; Department of Cardiology, Concord Hospital, The University of Sydney, 1 Hospital Road, Concord, NSW 2139, Australia. FAU - Thillainadesan, Janani AU - Thillainadesan J AD - Faculty of Medicine and Health, The University of Sydney, Camperdown, New South Wales, Australia; Centre for Education and Research on Ageing, Concord Hospital, Concord, Sydney, NSW, Australia; Department of Geriatric Medicine, Concord Hospital, Hospital Road, Building 12, Concord, Sydney, NSW 2139, Australia. FAU - Behdasht, Samim AU - Behdasht S AD - Department of Pharmacy, Concord Repatriation General Hospital, Concord, Australia. FAU - Sen, Shaundeep AU - Sen S AD - Faculty of Medicine and Health, The University of Sydney, Camperdown, New South Wales, Australia; Department of Renal Medicine, Concord Repatriation General Hospital, Concord, Australia. FAU - Suryawanshi, Avinash AU - Suryawanshi A AD - Department of Endocrinology and Metabolism, Concord Repatriation General Hospital, Concord, New South Wales, 2139, Australia. FAU - Davie, Huw AU - Davie H AD - Department of Addiction Medicine, Concord Repatriation General Hospital, Concord, New South Wales, 2139, Australia. FAU - Kitajima, Amy AU - Kitajima A AD - Department of Addiction Medicine, Concord Repatriation General Hospital, Concord, New South Wales, 2139, Australia. FAU - Aitken, Sarah Joy AU - Aitken SJ AD - Institute of Academic Surgery, Vascular Department, Concord Repatriation General Hospital, Concord, Sydney, New South Wales, Australia; Faculty of Medicine and Health, The University of Sydney, Camperdown, New South Wales, Australia; Department of Vascular Surgery, Concord Hospital, The University of Sydney, 1 Hospital Road, Concord, NSW 2139, Australia. Electronic address: sarah.aitken@sydney.edu.au. LA - eng SI - ANZCTR/ACTRN12623000995673 PT - Clinical Trial Protocol PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20250212 PL - United States TA - Contemp Clin Trials JT - Contemporary clinical trials JID - 101242342 SB - IM MH - Humans MH - *Peripheral Arterial Disease/therapy/complications MH - *Patient Care Team/organization & administration MH - *Secondary Prevention/methods/organization & administration MH - Randomized Controlled Trials as Topic MH - *Cardiovascular Diseases/prevention & control MH - Multicenter Studies as Topic MH - Quality of Life MH - Risk Reduction Behavior MH - Heart Disease Risk Factors OTO - NOTNLM OT - Cardiovascular OT - Clinical trial OT - MDT OT - Multidisciplinary team OT - Peripheral arterial disease OT - Secondary prevention OT - Vascular surgery COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/02/15 15:10 MHDA- 2025/03/16 12:44 CRDT- 2025/02/14 19:32 PHST- 2024/08/01 00:00 [received] PHST- 2025/01/24 00:00 [revised] PHST- 2025/02/11 00:00 [accepted] PHST- 2025/03/16 12:44 [medline] PHST- 2025/02/15 15:10 [pubmed] PHST- 2025/02/14 19:32 [entrez] AID - S1551-7144(25)00038-2 [pii] AID - 10.1016/j.cct.2025.107844 [doi] PST - ppublish SO - Contemp Clin Trials. 2025 Apr;151:107844. doi: 10.1016/j.cct.2025.107844. Epub 2025 Feb 12. PMID- 39950496 OWN - NLM STAT- MEDLINE DCOM- 20250507 LR - 20260722 IS - 2047-9980 (Electronic) IS - 2047-9980 (Linking) VI - 14 IP - 4 DP - 2025 Feb 18 TI - Relationship Between Health Care Team Segregation and Receipt of Care by a Cardiologist According to Patient Race in a Midwestern State. PG - e037197 LID - 10.1161/JAHA.124.037197 [doi] LID - e037197 AB - BACKGROUND: Segregation index (SI) has been associated with worsened health. However, the relationship between SI within health care teams (degree of heterogeneity between teams caring for Black compared with White patients) and cardiovascular care is unclear among adequately insured populations. We sought to assess the relationship between health care team SI, patient race, receipt of care by a cardiologist, 1-year survival, and 30-day readmission rates for Black compared with White patients admitted with heart failure, ischemic heart disease, or valvular heart disease. METHODS: Using Optum's de-identified Clinformatics Data Mart Database (CDM) from 2009 to 2020, generalized linear mixed-effects were used to analyze effects of patient race and SI on receipt of care by a cardiologist, and care by a cardiologist on 1-year survival and 30-day readmission. RESULTS: Among 6572 patients (17.1% Black), the odds of receiving care by a cardiologist were 31.3% less for Black than White patients (adjusted odds ratio 0.687 [95% CI, 0.545-0.872]; P=0.001). However, there was no statistically significant association of SI on receipt of care by a cardiologist (P=0.14). For those seen by a cardiologist, the adjusted odds ratio (Black-to-White) of 1-year survival increased with increasing SI (P=0.02). SI had no statistically significant effect on 30-day readmission (P=0.86). CONCLUSIONS: Among patients hospitalized for heart failure, ischemic heart disease, or valvular heart disease, segregation of health care teams was not associated with receipt of care by cardiologists in Indiana hospitals. When cardiologists were included, the odds of 1-year survival increased for Black versus White patients with increasing segregation of clinicians, and segregation was not associated with 30-day readmission. FAU - Quintero Bisono, Janina AU - Quintero Bisono J AUID- ORCID: 0000-0002-0208-8048 AD - Department of Internal Medicine Indiana University Indianapolis Indiana USA. AD - Indiana University Health Indianapolis Indiana USA. FAU - Knapp, Shannon M AU - Knapp SM AUID- ORCID: 0000-0002-9017-7007 AD - Division of Cardiovascular Medicine Indiana University Indianapolis Indiana USA. AD - Department of Biostatistics and Health Data Science Richard M. Fairbanks School of Public Health Indianapolis Indiana USA. FAU - Trabue, Dalancee AU - Trabue D AD - Division of Cardiovascular Medicine Indiana University Indianapolis Indiana USA. FAU - Yee, Ryan AU - Yee R AUID- ORCID: 0000-0003-4515-3476 AD - Division of Cardiovascular Medicine Indiana University Indianapolis Indiana USA. FAU - Williamson, Francesca AU - Williamson F AUID- ORCID: 0000-0002-7065-7089 AD - Department of Learning Health Sciences University of Michigan Ann Arbor Michigan USA. FAU - Johnson, Adedoyin AU - Johnson A AD - Department of Internal Medicine Indiana University Indianapolis Indiana USA. AD - Indiana University Health Indianapolis Indiana USA. FAU - Watty, Stephen AU - Watty S AD - Department of Internal Medicine Indiana University Indianapolis Indiana USA. AD - Indiana University Health Indianapolis Indiana USA. FAU - Pool, Natalie AU - Pool N AUID- ORCID: 0000-0002-1038-7574 AD - School of Nursing University of Northern Colorado Greeley Colorado USA. FAU - Hebdon, Megan AU - Hebdon M AUID- ORCID: 0000-0003-1916-5043 AD - School of Nursing University of Texas at Austin Austin Texas USA. FAU - Moore, Wanda AU - Moore W AD - Sarver Heart Center Minority Outreach Program University of Arizona Tucson Arizona USA. FAU - Yankah, Ekow AU - Yankah E AD - Department of Law and Philosophy University of Michigan Ann Arbor Michigan USA. FAU - Ezema, Nneamaka AU - Ezema N AD - Clinical Trials Operations Manager Indianapolis Indiana USA. FAU - Kimbrough, Nia AU - Kimbrough N AD - Centers of Wellness for Urban Women Indianapolis Indiana USA. FAU - Lightbourne, Karen AU - Lightbourne K AD - Division of Community Networks Collaborations for the East Region Indianapolis Indiana USA. FAU - Tucker Edmonds, Brownsyne AU - Tucker Edmonds B AUID- ORCID: 0000-0003-0023-4440 AD - Indiana University Health Indianapolis Indiana USA. AD - Department of Obstetrics and Gynecology Indiana University Indianapolis Indiana USA. FAU - Capers, Quinn AU - Capers Q AUID- ORCID: 0000-0003-1345-7758 AD - Department of Medicine Howard University Medical Center Washington DC USA. FAU - Brown, David AU - Brown D AD - Department of Otolaryngology-Head and Neck Surgery and Pediatric Otolaryngology University of Michigan Ann Arbor Michigan USA. FAU - Johnson, Denee AU - Johnson D AUID- ORCID: 0009-0001-0433-3772 AD - Indiana University Health Indianapolis Indiana USA. FAU - Evans, Jalynn AU - Evans J AD - Indiana University Health Indianapolis Indiana USA. FAU - Foree, Brandi AU - Foree B AD - Indiana University Health Indianapolis Indiana USA. FAU - Holman, Anastasia AU - Holman A AD - Division of Chaplaincy Education Indiana University Health System Indianapolis Indiana USA. FAU - Blount, Courtland AU - Blount C AD - Indiana University Health Indianapolis Indiana USA. AD - Division of Cardiovascular Medicine Indiana University Indianapolis Indiana USA. FAU - Nallamothu, Brahmajee AU - Nallamothu B AUID- ORCID: 0000-0003-4331-6649 AD - Division of Cardiovascular Diseases University of Michigan Ann Arbor Michigan USA. FAU - Hollingsworth, John M AU - Hollingsworth JM AD - Quality Department Endeavor Health NorthShore Hospitals Evanston Illinois USA. FAU - Breathett, Khadijah AU - Breathett K AUID- ORCID: 0000-0001-5397-6419 AD - Indiana University Health Indianapolis Indiana USA. AD - Division of Cardiovascular Medicine Indiana University Indianapolis Indiana USA. LA - eng GR - K01 HL142848/HL/NHLBI NIH HHS/United States GR - R56 HL159216/HL/NHLBI NIH HHS/United States GR - R01 HL159216/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20250214 PL - England TA - J Am Heart Assoc JT - Journal of the American Heart Association JID - 101580524 SB - IM MH - Aged MH - Female MH - Humans MH - Male MH - Middle Aged MH - *Black or African American/statistics & numerical data MH - *Cardiologists MH - *Healthcare Disparities/ethnology MH - *Patient Care Team MH - Patient Readmission/statistics & numerical data MH - *White/statistics & numerical data PMC - PMC12074763 OTO - NOTNLM OT - cardiovascular diseases OT - health equity OT - quality of care OT - racial disparities OT - readmission OT - segregation index OT - survival COIS- None. EDAT- 2025/02/14 12:29 MHDA- 2025/02/19 06:21 PMCR- 2025/02/18 CRDT- 2025/02/14 06:52 PHST- 2025/02/19 06:21 [medline] PHST- 2025/02/14 12:29 [pubmed] PHST- 2025/02/14 06:52 [entrez] PHST- 2025/02/18 00:00 [pmc-release] AID - JAH310618 [pii] AID - 10.1161/JAHA.124.037197 [doi] PST - ppublish SO - J Am Heart Assoc. 2025 Feb 18;14(4):e037197. doi: 10.1161/JAHA.124.037197. Epub 2025 Feb 14. PMID- 39948014 OWN - NLM STAT- MEDLINE DCOM- 20250611 LR - 20260406 IS - 1532-429X (Electronic) IS - 1097-6647 (Print) IS - 1097-6647 (Linking) VI - 27 IP - 1 DP - 2025 Summer TI - Highlights of the Cardiovascular Magnetic Resonance 2024 Conference: the first joint European Association of Cardiovascular Imaging, European Society of Cardiovascular Radiology, and Society for Cardiovascular Magnetic Resonance conference. PG - 101848 LID - S1097-6647(25)00010-9 [pii] LID - 10.1016/j.jocmr.2025.101848 [doi] LID - 101848 AB - Cardiovascular Magnetic Resonance 2024 Conference (CMR2024) convened in London, UK, from 24 to 26 January 2024 and brought together 2705 learners and renowned cardiac imaging professionals to discuss and learn about the latest advancements. Organized by the Society for Cardiovascular Magnetic Resonance (SCMR) and the European Association of Cardiovascular Imaging (EACVI), in collaboration with the European Society of Cardiovascular Radiology (ESCR), CMR2024 was the largest international cardiac magnetic resonance conference to date. This conference underscored the collaboration between cardiologists, radiologists, scientists, and technologists by bringing together three major societies-SCMR, EACVI, and ESCR. Innovative session formats like 'Shark Tank' and 'Workflow, Innovations & Patients' facilitated expert opinion and practical experiences sharing in a 'TED-talk style'. With over 1168 abstract submissions and 75% acceptance rate, the programme featured multiple Early Career Award sessions, oral scientific sessions, oral case sessions, and rapid-fire sessions, all categorized by topic. Highlights included patient- and physician-centred imaging sessions, sharing referring physicians' and patients' insights of incremental value of cardiovascular magnetic resonance (CMR) in patient's management. The programme offered invited lectures in eight parallel tracks with three plenary and two keynote speakers. In addition, the interactive workshops and panel discussions provided a platform for knowledge exchange, support, and collaboration. A great emphasis was placed on collaboration between radiologists, cardiologists, scientists, and technologists, showcasing an ideal cardiac imaging marriage as a model for enhanced patient care around the globe. The event also featured exhibitions of the latest CMR technology and software, offering attendees a glimpse into the future cardiac imaging. CMR2024 emerged as a remarkable scientific, educational, and networking event, in-spiring attendees to learn and collaborate within the global CMR community. CI - Copyright (c) 2025 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Stojanovska, Jadranka AU - Stojanovska J AD - Department of Radiology, Langone Health, New York University, Grossman School of Medicine, New York, New York, USA. Electronic address: jadranka.stojanovska@nyulangone.org. FAU - Nijveldt, Robin AU - Nijveldt R AD - Department of Cardiology, Radboud University Medical Center, Nijmegen, the Netherlands. FAU - Ordovas, Karen AU - Ordovas K AD - Division of Cardiothoracic Imaging, Department of Radiology, Washington University, Seattle, Washington, USA. FAU - Vliegenthart, Rozemarijn AU - Vliegenthart R AD - Department of Radiology, University Medical Center Groningen/University of Groningen, Groningen, the Netherlands. FAU - Seiberlich, Nicole AU - Seiberlich N AD - Department of Radiology, University of Michigan, Ann Arbor, Michigan, USA. FAU - Prieto, Claudia AU - Prieto C AD - School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK. FAU - Ojha, Vineeta AU - Ojha V AD - Department of Cardiovascular Radiology, All India Institute of Medical Sciences (AIIMS), New Delhi, India. FAU - Hanneman, Kate AU - Hanneman K AD - Department of Radiology, University of Toronto, Toronto, Ontario, Canada. FAU - Lawton, Benny AU - Lawton B AD - Department of Cardiac Imaging, St Joseph's Hospital, Newport, UK. FAU - Hughes, Marina AU - Hughes M AD - Department of Cardiology, Norfolk and Norwich University Hospital, Norwich, UK. FAU - Ferreira, Vanessa AU - Ferreira V AD - Oxford Centre for Clinical Magnetic Resonance Research (OCMR), Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK. FAU - Grizzard, John AU - Grizzard J AD - Department of Radiology, VCU Health Systems, Richmond, Virginia, USA. FAU - Natale, Luigi AU - Natale L AD - Department of Radiological and Radiotherapic Sciences, Catholic University, Fondazione Policlinico Gemelli IRCCS, Rome, Italy. FAU - Kim, Daniel AU - Kim D AD - Department of Radiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. FAU - Bucciarelli-Ducci, Chiara AU - Bucciarelli-Ducci C AD - Royal Brompton and Harefield Hospitals, King's College London, London, UK. FAU - Petersen, Steffen AU - Petersen S AD - Cardiovascular Medicine, Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK. FAU - Treibel, Thomas A AU - Treibel TA AD - Cardiovascular Medicine, Institute of Cardiovascular Sciences, University College London, Barts Heart Centre, London, UK. LA - eng PT - Conference Proceedings DEP - 20250212 PL - England TA - J Cardiovasc Magn Reson JT - Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance JID - 9815616 SB - IM MH - Humans MH - *Cardiovascular Diseases/diagnostic imaging/therapy/physiopathology MH - Cooperative Behavior MH - Diffusion of Innovation MH - Interdisciplinary Communication MH - *Magnetic Resonance Imaging MH - Predictive Value of Tests MH - Prognosis PMC - PMC12182811 OTO - NOTNLM OT - CMR OT - CMR2024 meeting OT - Cardiomyopathy OT - Patient-centred imaging COIS- Declaration of competing interests None declared. EDAT- 2025/02/14 00:24 MHDA- 2025/06/12 00:38 PMCR- 2025/02/12 CRDT- 2025/02/13 22:01 PHST- 2025/06/12 00:38 [medline] PHST- 2025/02/14 00:24 [pubmed] PHST- 2025/02/13 22:01 [entrez] PHST- 2025/02/12 00:00 [pmc-release] AID - S1097-6647(25)00010-9 [pii] AID - 101848 [pii] AID - 10.1016/j.jocmr.2025.101848 [doi] PST - ppublish SO - J Cardiovasc Magn Reson. 2025 Summer;27(1):101848. doi: 10.1016/j.jocmr.2025.101848. Epub 2025 Feb 12. PMID- 39945384 OWN - NLM STAT- MEDLINE DCOM- 20250522 LR - 20260605 IS - 1552-4876 (Electronic) IS - 1552-4868 (Print) IS - 1552-4868 (Linking) VI - 199 IP - 1 DP - 2025 Mar TI - Turner Syndrome and Psychosocial Interventions: Recommendations for Collaborative Communication Between Medical and School Teams. PG - e32134 LID - 10.1002/ajmg.c.32134 [doi] AB - Individuals with Turner Syndrome (TS) can experience not only physical and medical differences but are also at risk for neurocognitive and associated psychosocial challenges. Specifically, research shows increased likelihood of difficulties with visual-spatial reasoning, executive functioning, attention, and mathematics skills. One emerging area of research focuses on deficits in social skills and increased prevalence of anxiety within this population. This review introduces relevant genetic influences of TS and examines existing research on social skills and anxiety in individuals with TS. The importance of collaboration between the medical team and school personnel for patients with TS is emphasized, and specific clinical recommendations, such as the use of the TS School Support Plan, are provided to facilitate this collaboration. This paper services as a brief introduction to orient the reader to considerations of strengthening collaboration between medical and school systems; however, future research is needed to investigate the effectiveness and acceptability of the School Support Plan to enhance liaison between the patient's medical and school teams. CI - (c) 2025 Wiley Periodicals LLC. FAU - Norman, Mackenzie Z AU - Norman MZ AUID- ORCID: 0000-0003-2098-1582 AD - Pediatric Psychology, Oregon Health & Science University, Portland, Oregon, USA. FAU - Hutaff-Lee, Christa AU - Hutaff-Lee C AUID- ORCID: 0009-0000-4591-1025 AD - Department of Pediatrics, University of Colorado School of Medicine and eXtraOrdinarY Kids Clinic, Children's Hospital Colorado, Aurora, Colorado, USA. FAU - Knickmeyer, Rebecca C AU - Knickmeyer RC AUID- ORCID: 0000-0001-7708-1388 AD - Department of Pediatrics and Human Development, Michigan State University, East Lansing, Michigan, USA. AD - Institute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, Michigan, USA. FAU - Fadoju, Doris AU - Fadoju D AUID- ORCID: 0000-0002-8117-8438 AD - Department of Pediatrics, Division of Endocrinology, Emory University School of Medicine/Children's Healthcare of Atlanta, Atlanta, Georgia, USA. FAU - Wolstencroft, Jeanne AU - Wolstencroft J AUID- ORCID: 0000-0001-6160-9731 AD - Great Ormond Street Institute of Child Health, University College London, London, UK. FAU - Hong, David S AU - Hong DS AUID- ORCID: 0000-0001-9515-881X AD - Division of Interdisciplinary Brain Sciences and Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California, USA. FAU - Sandberg, David E AU - Sandberg DE AUID- ORCID: 0000-0002-7389-8283 AD - Department of Pediatrics, Susan B. Meister Child Health Evaluation and Research (CHEAR) Center, University of Michigan Medical School, Ann Arbor, Michigan, USA. LA - eng GR - K23 MH097120/MH/NIMH NIH HHS/United States GR - R01 HD093450/HD/NICHD NIH HHS/United States GR - National Institute of Health/ GR - Eunice Kennedy Shriver National Institute of Child Health and Human Development/ PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20250213 PL - United States TA - Am J Med Genet C Semin Med Genet JT - American journal of medical genetics. Part C, Seminars in medical genetics JID - 101235745 SB - IM MH - Humans MH - *Turner Syndrome/psychology/therapy MH - Schools MH - Female MH - *Psychosocial Intervention MH - Patient Care Team MH - Cooperative Behavior MH - Anxiety PMC - PMC12097950 MID - NIHMS2057552 OTO - NOTNLM OT - Turner Syndrome OT - anxiety OT - medical-school collaboration OT - psychology OT - psychosocial interventions OT - social skills EDAT- 2025/02/13 12:27 MHDA- 2025/05/22 06:28 PMCR- 2026/03/01 CRDT- 2025/02/13 07:13 PHST- 2025/01/24 00:00 [revised] PHST- 2024/09/30 00:00 [received] PHST- 2025/01/31 00:00 [accepted] PHST- 2025/05/22 06:28 [medline] PHST- 2025/02/13 12:27 [pubmed] PHST- 2025/02/13 07:13 [entrez] PHST- 2026/03/01 00:00 [pmc-release] AID - 10.1002/ajmg.c.32134 [doi] PST - ppublish SO - Am J Med Genet C Semin Med Genet. 2025 Mar;199(1):e32134. doi: 10.1002/ajmg.c.32134. Epub 2025 Feb 13. PMID- 39941551 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250215 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 14 IP - 3 DP - 2025 Jan 29 TI - Hybrid Coronary Revascularisation: Indications, Techniques, and Outcomes. LID - 10.3390/jcm14030880 [doi] LID - 880 AB - Hybrid coronary revascularisation (HCR) integrates coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) to combine the benefits of minimally invasive surgery and advanced stent technology. Typically, HCR involves off-pump left internal mammary artery (LIMA) to left anterior descending artery (LAD) bypass via minimally invasive direct coronary artery bypass (MIDCAB), complemented by PCI to non-LAD vessels. This approach avoids a full sternotomy and cardiopulmonary bypass while preserving the advantages of surgical revascularisation. Patient selection for HCR should be guided by a multidisciplinary heart team, targeting those with severe LAD disease and suitable non-LAD lesions for PCI. This review outlines the surgical techniques, anticoagulation strategies, and procedural sequencing employed in HCR, along with real-world outcomes from observational studies and randomised trials. While current evidence supports the safety and feasibility of HCR in appropriately selected patients, further large-scale randomised trials are needed to clarify its role in comparison to standalone CABG or PCI. FAU - Fazmin, Ibrahim T AU - Fazmin IT AUID- ORCID: 0000-0002-3300-6279 AD - Royal Papworth Hospital, Cambridge CB2 0AY, UK. FAU - Ali, Jason M AU - Ali JM AD - Royal Papworth Hospital, Cambridge CB2 0AY, UK. LA - eng PT - Journal Article PT - Review DEP - 20250129 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC11818765 OTO - NOTNLM OT - coronary artery bypass grafting OT - coronary artery disease OT - percutaneous coronary intervention COIS- The authors declare no conflicts of interest. EDAT- 2025/02/13 11:01 MHDA- 2025/02/13 11:02 PMCR- 2025/01/29 CRDT- 2025/02/13 01:08 PHST- 2025/01/10 00:00 [received] PHST- 2025/01/26 00:00 [revised] PHST- 2025/01/28 00:00 [accepted] PHST- 2025/02/13 11:02 [medline] PHST- 2025/02/13 11:01 [pubmed] PHST- 2025/02/13 01:08 [entrez] PHST- 2025/01/29 00:00 [pmc-release] AID - jcm14030880 [pii] AID - jcm-14-00880 [pii] AID - 10.3390/jcm14030880 [doi] PST - epublish SO - J Clin Med. 2025 Jan 29;14(3):880. doi: 10.3390/jcm14030880. PMID- 39941421 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250215 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 14 IP - 3 DP - 2025 Jan 24 TI - Telemedicine/Telerehabilitation to Expand Enhanced Recovery After Surgery Interventions in Minimally Invasive Mitral Valve Surgery. LID - 10.3390/jcm14030750 [doi] LID - 750 AB - Objectives: Having achieved a consolidated in-hospital experience with enhanced recovery after cardiac surgery, we explored the feasibility of expanding our protocol to pre-admission and post-discharge periods. Methods: A multidisciplinary team including cardiac surgeons, anaesthetists/intensivists, physiatrists, physiotherapists, perfusionists, nurses, psychiatrists, and engineers, elaborated a new therapeutic offer, based on current ERAS evidence and using telerehabilitation, to enhance preoperative communication and education and improve pre- and postoperative health and psychological state. Results: An institutional web-based platform for remote rehabilitation will host digital content that covers three main areas, including information and communication, prehabilitation and rehabilitation with the offer of respiratory and muscular exercises and aerobic activities, and psychological and patient experience evaluations. These interventions will be achieved through purposely developed video tutorials that present the hospital environments, the relevant healthcare personnel, and their role during the in-hospital patient's journey, and illustrate tailored prehabilitation activities. A series of questionnaires will be administered to evaluate and follow the patient's psychological state and collect patient-reported experience measures. The platform was activated in September 2024 and this service will initially involve 100 patients undergoing minimally invasive mitral valve surgery. A first review of compliance and engagement will be carried out after four months and a complete review of the results after the first year. Conclusions: ERAS is associated with improved surgical outcomes. A person-centred treatment should also address the health and psychological difficulties that patients face before hospitalisation and after discharge. Telemedicine is a valid tool to expand treatment and monitoring outside the hospital. This experience may give new insights into the feasibility and effectiveness of providing home-based remote interventions aimed at a global improvement in results throughout the overall cardiac surgery journey. FAU - Malvindi, Pietro Giorgio AU - Malvindi PG AUID- ORCID: 0000-0002-3508-2670 AD - Cardiac Surgery Unit, Azienda Ospedaliero Universitaria delle Marche, Polytechnic University of Marche, 60126 Ancona, Italy. FAU - Ceravolo, Maria Gabriella AU - Ceravolo MG AUID- ORCID: 0000-0002-2694-4638 AD - Neurorehabilitation Clinic, Department of Experimental and Clinical Medicine, Azienda Ospedaliero Universitaria delle Marche, Polytechnic University of Marche, 60126 Ancona, Italy. FAU - Capecci, Marianna AU - Capecci M AD - Neurorehabilitation Clinic, Department of Experimental and Clinical Medicine, Azienda Ospedaliero Universitaria delle Marche, Polytechnic University of Marche, 60126 Ancona, Italy. FAU - Balestra, Stefania AU - Balestra S AD - Rehabilitation Unit, Azienda Ospedaliero Universitaria delle Marche, 60126 Ancona, Italy. FAU - Cini, Emanuela AU - Cini E AUID- ORCID: 0009-0008-7468-9038 AD - Rehabilitation Unit, Azienda Ospedaliero Universitaria delle Marche, 60126 Ancona, Italy. FAU - Antoniello, Antonia AU - Antoniello A AUID- ORCID: 0009-0003-4788-8254 AD - Department of Experimental and Clinical Medicine, Polytechnic University of Marche, 60126 Ancona, Italy. FAU - Pepa, Lucia AU - Pepa L AD - Department of Information Engineering, Polytechnic University of Marche, 60121 Ancona, Italy. FAU - Carbonetti, Antonella AU - Carbonetti A AD - Rehabilitation Unit, Azienda Ospedaliero Universitaria delle Marche, 60126 Ancona, Italy. FAU - Ricci, Maurizio AU - Ricci M AD - Rehabilitation Unit, Azienda Ospedaliero Universitaria delle Marche, 60126 Ancona, Italy. FAU - Berretta, Paolo AU - Berretta P AD - Cardiac Surgery Unit, Azienda Ospedaliero Universitaria delle Marche, Polytechnic University of Marche, 60126 Ancona, Italy. FAU - Mazzocca, Francesca AU - Mazzocca F AD - Cardiac Surgery Unit, Azienda Ospedaliero Universitaria delle Marche, Polytechnic University of Marche, 60126 Ancona, Italy. FAU - Fioretti, Marco AU - Fioretti M AD - Cardiac Surgery Unit, Azienda Ospedaliero Universitaria delle Marche, Polytechnic University of Marche, 60126 Ancona, Italy. FAU - Volpe, Umberto AU - Volpe U AUID- ORCID: 0000-0001-9166-7609 AD - Unit of Clinical Psychiatry, Department of Clinical Neurosciences, Azienda Ospedaliero Universitaria delle Marche, Polytechnic University of Marche, 60126 Ancona, Italy. FAU - Munch, Christopher AU - Munch C AUID- ORCID: 0000-0001-7766-5957 AD - Cardiac Anaesthesia and Intensive Care Unit, Azienda Ospedaliero Universitaria delle Marche, 60126 Ancona, Italy. FAU - Di Eusanio, Marco AU - Di Eusanio M AD - Cardiac Surgery Unit, Azienda Ospedaliero Universitaria delle Marche, Polytechnic University of Marche, 60126 Ancona, Italy. LA - eng PT - Journal Article DEP - 20250124 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC11818710 OTO - NOTNLM OT - ERAS OT - cardiac surgery OT - minimally invasive surgery OT - mitral valve OT - telemedicine COIS- The authors declare no conflicts of interest. EDAT- 2025/02/13 11:00 MHDA- 2025/02/13 11:01 PMCR- 2025/01/24 CRDT- 2025/02/13 01:07 PHST- 2024/11/29 00:00 [received] PHST- 2024/12/25 00:00 [revised] PHST- 2025/01/20 00:00 [accepted] PHST- 2025/02/13 11:01 [medline] PHST- 2025/02/13 11:00 [pubmed] PHST- 2025/02/13 01:07 [entrez] PHST- 2025/01/24 00:00 [pmc-release] AID - jcm14030750 [pii] AID - jcm-14-00750 [pii] AID - 10.3390/jcm14030750 [doi] PST - epublish SO - J Clin Med. 2025 Jan 24;14(3):750. doi: 10.3390/jcm14030750. PMID- 39941169 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250215 IS - 2075-4418 (Print) IS - 2075-4418 (Electronic) IS - 2075-4418 (Linking) VI - 15 IP - 3 DP - 2025 Jan 21 TI - Echocardiography with Strain Assessment in Psychiatric Diseases: A Narrative Review. LID - 10.3390/diagnostics15030239 [doi] LID - 239 AB - Mental disorders (MDs) are among the major causes of morbidity and mortality worldwide. Individuals with severe MDs have a shorter life expectancy, primarily due to cardiovascular diseases. Echocardiography facilitates the evaluation of alterations in cardiac morphology and function, resulting from various cardiac pathologies. The aim of this review was to explore the current evidence base behind the myocardial deformation observed in echocardiography in patients with MDs. We primarily focused on the data regarding speckle tracking echocardiography. PubMed, using medical subject headings, was searched to identify studies on this topic. The collected data demonstrated changes in myocardial function in schizophrenia, bipolar disorder, depression, anxiety disorder, stressor-related disorder, post-traumatic stress disorder, eating disorders, sleep-wake disorders, substance-related and addictive disorders, neurocognitive disorders, and borderline personality disorder. The recurrent findings included impaired Left Ventricular Ejection Fraction and Left Ventricular Hypertrophy. Global Longitudinal Strain was significantly altered in patients with anorexia nervosa, bipolar disorder, and substance-related disorders. All reported studies support the consideration of cardiology consultations and a multidisciplinary approach in the care of patients with MDs with suspected cardiac dysfunction. Further investigation is warranted to determine the significance and prognostic value of myocardial deformation and strain measurements among individuals with MDs, focusing on the value of early detection, especially in asymptomatic cases. FAU - Spyra, Aleksandra AU - Spyra A AUID- ORCID: 0009-0007-2288-6411 AD - Student Research Group, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, 40-055 Katowice, Poland. FAU - Sierpinska, Aleksandra AU - Sierpinska A AD - Student Research Group, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, 40-055 Katowice, Poland. FAU - Suchodolski, Alexander AU - Suchodolski A AUID- ORCID: 0000-0002-5006-7700 AD - Doctoral School, Medical University of Silesia in Katowice, 40-055 Katowice, Poland. AD - Department of Cardiology and Electrotherapy, Silesian Center for Heart Diseases, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, 40-055 Katowice, Poland. FAU - Florek, Szymon AU - Florek S AUID- ORCID: 0000-0001-7526-1430 AD - Doctoral School, Medical University of Silesia in Katowice, 40-055 Katowice, Poland. AD - Department of Psychoprophylaxis in Tarnowskie Gory, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, 40-055 Katowice, Poland. FAU - Szulik, Mariola AU - Szulik M AUID- ORCID: 0000-0002-8229-7279 AD - Department of Cardiology and Electrotherapy, Silesian Center for Heart Diseases, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, 40-055 Katowice, Poland. AD - Collegium Medicum-Faculty of Medicine and Faculty of Applied Sciences, Department of Medical and Health Sciences, WSB University, 41-300 Dabrowa Gornicza, Poland. LA - eng PT - Journal Article PT - Review DEP - 20250121 PL - Switzerland TA - Diagnostics (Basel) JT - Diagnostics (Basel, Switzerland) JID - 101658402 PMC - PMC11817037 OTO - NOTNLM OT - echocardiography OT - global longitudinal strain OT - mental disorders OT - speckle tracking echocardiography COIS- The authors declare no conflicts of interest. EDAT- 2025/02/13 11:01 MHDA- 2025/02/13 11:02 PMCR- 2025/01/21 CRDT- 2025/02/13 01:06 PHST- 2024/11/19 00:00 [received] PHST- 2025/01/12 00:00 [revised] PHST- 2025/01/13 00:00 [accepted] PHST- 2025/02/13 11:02 [medline] PHST- 2025/02/13 11:01 [pubmed] PHST- 2025/02/13 01:06 [entrez] PHST- 2025/01/21 00:00 [pmc-release] AID - diagnostics15030239 [pii] AID - diagnostics-15-00239 [pii] AID - 10.3390/diagnostics15030239 [doi] PST - epublish SO - Diagnostics (Basel). 2025 Jan 21;15(3):239. doi: 10.3390/diagnostics15030239. PMID- 39938716 OWN - NLM STAT- MEDLINE DCOM- 20250606 LR - 20250606 IS - 1916-7075 (Electronic) IS - 0828-282X (Linking) VI - 41 IP - 6 DP - 2025 Jun TI - The Etiology and Management of Critical Acute Right Heart Failure. PG - 1096-1110 LID - S0828-282X(25)00113-8 [pii] LID - 10.1016/j.cjca.2025.02.006 [doi] AB - Right ventricular failure contributes to the morbidity and mortality of acute myocardial function, massive pulmonary embolism, and chronic pulmonary hypertension. Understanding how the normal physiology of the right ventricle (RV) is disrupted is integral to managing patients who present with RV decompensation. Therapeutic advances in mechanical circulatory support, pharmacotherapies to reduce afterload, mechanical and chemical lytic therapies for acute pulmonary embolism have improved outcomes of patients by offloading the RV. In this report we provide an overview of the physiology of the RV, medical management (volume optimization, hemodynamic targets, rhythm management), along with critical care-specific topics (induction with mechanical ventilation, sedation strategies, and mechanical circulatory support) and provide a framework for managing patients who present with leveraging principles of preload, contractility, and afterload. Last, because of the complexity of right ventricular failure management, and the complexity of presentation, we also discuss the role of team-based approach (cardiogenic shock and pulmonary embolism response teams), and highlight its benefits at improving outcomes. CI - Copyright (c) 2025 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Luk, Adriana AU - Luk A AD - Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada. Electronic address: adriana.luk@uhn.ca. FAU - Teijeiro-Paradis, Ricardo AU - Teijeiro-Paradis R AD - Interdepartmental Division of Critical Care, University of Toronto, Toronto, Ontario, Canada. FAU - Kochan, Andrew AU - Kochan A AD - Interdepartmental Division of Critical Care, University of Toronto, Toronto, Ontario, Canada. FAU - Billia, Filio AU - Billia F AD - Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada. FAU - Doufle, Ghislaine AU - Doufle G AD - Interdepartmental Division of Critical Care, University of Toronto, Toronto, Ontario, Canada. FAU - Magder, Sheldon AU - Magder S AD - Department of Critical Care, McGill University Health Centre, Montreal, Quebec, Canada. FAU - Mendelson, Asher A AU - Mendelson AA AD - Section of Critical Care, Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada. FAU - McGuinty, Caroline AU - McGuinty C AD - University of Ottawa Heart Institute, Ottawa, Ontario, Canada. FAU - Granton, John AU - Granton J AD - Interdepartmental Division of Critical Care, University of Toronto, Toronto, Ontario, Canada. LA - eng PT - Journal Article PT - Review DEP - 20250210 PL - England TA - Can J Cardiol JT - The Canadian journal of cardiology JID - 8510280 SB - IM MH - Humans MH - *Heart Failure/therapy/etiology/physiopathology MH - Acute Disease MH - *Ventricular Dysfunction, Right/therapy/etiology/physiopathology MH - *Disease Management MH - *Ventricular Function, Right/physiology MH - Pulmonary Embolism/complications EDAT- 2025/02/13 00:22 MHDA- 2025/06/07 16:44 CRDT- 2025/02/12 19:30 PHST- 2024/11/13 00:00 [received] PHST- 2025/02/03 00:00 [revised] PHST- 2025/02/05 00:00 [accepted] PHST- 2025/06/07 16:44 [medline] PHST- 2025/02/13 00:22 [pubmed] PHST- 2025/02/12 19:30 [entrez] AID - S0828-282X(25)00113-8 [pii] AID - 10.1016/j.cjca.2025.02.006 [doi] PST - ppublish SO - Can J Cardiol. 2025 Jun;41(6):1096-1110. doi: 10.1016/j.cjca.2025.02.006. Epub 2025 Feb 10. PMID- 39937368 OWN - NLM STAT- MEDLINE DCOM- 20250506 LR - 20261010 IS - 1826-6983 (Electronic) IS - 0033-8362 (Linking) VI - 130 IP - 3 DP - 2025 Mar TI - Comprehensive CT study to assess local and systemic involvement in patients with infective endocarditis: experience from a multidisciplinary team of a tertiary referral center. PG - 302-314 LID - 10.1007/s11547-025-01960-w [doi] AB - PURPOSE: To evaluate the value of a computed tomography (CT) protocol, including ECG-gated cardiac angiographic and venous phase, in patients with infective endocarditis (IE). MATERIAL AND METHODS: From January 2019 to October 2022, consecutive patients with IE submitted to total-body CT, including ECG-gated cardiac acquisition in angiographic and venous phase, were enrolled. Transesophageal echocardiography was performed in all cases. Rate of local complications including vegetation, pseudoaneurysm, abscess, fistula and valve dehiscence was compared in CT and echocardiography. Systemic embolization was identified through CT scans. RESULTS: Seventy-six adults (median age 69 [IQR 55-77] years old; males 54/76, 71%] were enrolled. Most patients underwent surgery (51/76, 67%), and the in-hospital mortality rate was 8% (6/76). CT showed higher detection rate of valve vegetation compared to echocardiography (67/76, 88% vs 58/76, 76%; p = 0.008), including vegetation smaller than 10 mm (24/76, 36% vs 16/76, 28%; p = 0.013) and higher detection rate of pseudoaneurysm and abscess (p = 0.004 and p = 0.009, respectively). Abscess showed higher contrast-to-noise ratio (CNR) in the venous scan compared to angiographic scan (2.75 [IQR 2.27; 5.17] vs 1.97 [IQR 1.21; 3.32], p = 0.039) and higher density of perivalvular and epicardial fat compared to pseudoaneurysm (35 [IQR 31; 52]HU and - 50 [IQR - 62; - 35]HU versus 52 [IQR - 60; - 18]HU; p = 0.001, and - 91 [IQR - 95; - 81]HU; p = 0.007, respectively), for greater inflammation. CT overestimated valve dehiscence when compared to echocardiography and surgery. CONCLUSION: A comprehensive CT study enhances the diagnostic assessment of patients with IE, not only by detecting distant sites of embolization, but also increasing sensitivity for valve vegetation and local complications. CI - (c) 2025. Italian Society of Medical Radiology. FAU - Palmisano, Anna AU - Palmisano A AD - Clinical and Experimental Radiology Unit, Experimental Imaging Center, IRCCS San Raffaele Scientific Institute, Milan, Italy. AD - School of Medicine, Vita-Salute San Raffaele University, Milan, Italy. FAU - Bruno, Elisa AU - Bruno E AD - Clinical and Experimental Radiology Unit, Experimental Imaging Center, IRCCS San Raffaele Scientific Institute, Milan, Italy. AD - School of Medicine, Vita-Salute San Raffaele University, Milan, Italy. FAU - Vignale, Davide AU - Vignale D AD - Clinical and Experimental Radiology Unit, Experimental Imaging Center, IRCCS San Raffaele Scientific Institute, Milan, Italy. AD - School of Medicine, Vita-Salute San Raffaele University, Milan, Italy. FAU - Bognoni, Ludovica AU - Bognoni L AD - Cardio-Thoracic-Vascular Department, IRCCS San Raffaele Scientific Institute, Milan, Italy. FAU - Ascione, Raffaele AU - Ascione R AD - Clinical and Experimental Radiology Unit, Experimental Imaging Center, IRCCS San Raffaele Scientific Institute, Milan, Italy. FAU - Ingallina, Giacomo AU - Ingallina G AD - Cardio-Thoracic-Vascular Department, IRCCS San Raffaele Scientific Institute, Milan, Italy. FAU - Scarpellini, Paolo AU - Scarpellini P AD - Unit of Infectious Diseases, IRCCS Ospedale San Raffaele, 20132, Milan, Italy. FAU - Ripa, Marco AU - Ripa M AD - School of Medicine, Vita-Salute San Raffaele University, Milan, Italy. AD - Unit of Infectious Diseases, IRCCS Ospedale San Raffaele, 20132, Milan, Italy. FAU - Carletti, Silvia AU - Carletti S AD - Laboratory of Microbiology and Virology, San Raffaele Scientific Institute, Milan, Italy. FAU - Bettinelli, Andrea AU - Bettinelli A AD - Clinical and Experimental Radiology Unit, Experimental Imaging Center, IRCCS San Raffaele Scientific Institute, Milan, Italy. AD - School of Medicine, Vita-Salute San Raffaele University, Milan, Italy. FAU - Mapelli, Roberto AU - Mapelli R AD - Clinical and Experimental Radiology Unit, Experimental Imaging Center, IRCCS San Raffaele Scientific Institute, Milan, Italy. AD - School of Medicine, Vita-Salute San Raffaele University, Milan, Italy. FAU - Busnardo, Elena AU - Busnardo E AD - Department of Nuclear Medicine, IRCCS San Raffaele Scientific Institute, Milan, Italy. FAU - Pajoro, Ursula AU - Pajoro U AD - Department of Nuclear Medicine, IRCCS San Raffaele Scientific Institute, Milan, Italy. FAU - Del Forno, Benedetto AU - Del Forno B AD - Department of Cardiac Surgery, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy. FAU - Trumello, Cinzia AU - Trumello C AD - Department of Cardiac Surgery, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy. FAU - La Penna, Elisabetta AU - La Penna E AD - Department of Cardiac Surgery, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy. FAU - Maisano, Francesco AU - Maisano F AD - Department of Cardiac Surgery, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy. FAU - De Bonis, Michele AU - De Bonis M AD - Department of Cardiac Surgery, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy. FAU - Agricola, Eustachio AU - Agricola E AD - School of Medicine, Vita-Salute San Raffaele University, Milan, Italy. AD - Cardio-Thoracic-Vascular Department, IRCCS San Raffaele Scientific Institute, Milan, Italy. FAU - Esposito, Antonio AU - Esposito A AUID- ORCID: 0000-0002-1170-6266 AD - Clinical and Experimental Radiology Unit, Experimental Imaging Center, IRCCS San Raffaele Scientific Institute, Milan, Italy. esposito.antonio@hsr.it. AD - School of Medicine, Vita-Salute San Raffaele University, Milan, Italy. esposito.antonio@hsr.it. LA - eng PT - Journal Article DEP - 20250212 PL - Italy TA - Radiol Med JT - La Radiologia medica JID - 0177625 SB - IM MH - Humans MH - Male MH - Middle Aged MH - Female MH - Aged MH - *Endocarditis/diagnostic imaging/complications MH - *Tomography, X-Ray Computed/methods MH - Tertiary Care Centers MH - Echocardiography, Transesophageal MH - Retrospective Studies MH - Cardiac-Gated Imaging Techniques OTO - NOTNLM OT - Cardiac computed tomography OT - Computed tomography OT - Echocardiography OT - Endocarditis OT - Multidisciplinary team OT - Multimodality imaging COIS- Declarations. Conflict of interest: The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article. Ethical approval: Institutional Review Board approval was obtained. Informed consent: Written informed consent was obtained from all subjects (patients) in this study. EDAT- 2025/02/12 12:24 MHDA- 2025/03/12 18:17 CRDT- 2025/02/12 11:22 PHST- 2024/04/01 00:00 [received] PHST- 2025/01/23 00:00 [accepted] PHST- 2025/03/12 18:17 [medline] PHST- 2025/02/12 12:24 [pubmed] PHST- 2025/02/12 11:22 [entrez] AID - 10.1007/s11547-025-01960-w [pii] AID - 10.1007/s11547-025-01960-w [doi] PST - ppublish SO - Radiol Med. 2025 Mar;130(3):302-314. doi: 10.1007/s11547-025-01960-w. Epub 2025 Feb 12. PMID- 39935113 OWN - NLM STAT- MEDLINE DCOM- 20250703 LR - 20250703 IS - 0310-057X (Print) IS - 0310-057X (Linking) VI - 53 IP - 4 DP - 2025 Jul TI - The impact of the introduction of monitored anaesthesia care in the cardiac catheterisation laboratory on Clinical Review, Rapid Response, and Blue Code rates, and mortality. PG - 265-271 LID - 10.1177/0310057X241304423 [doi] AB - Most procedures in cardiac catheterisation laboratories (CCLs) have traditionally been performed under conscious sedation under the supervision of the treating proceduralist. With growing demand for more complex procedures to be performed, in emergencies and in patients with limited cardiorespiratory reserve, a reconsideration of the level of supervision provided is required. We conducted a retrospective cohort study of all patients who had CCL procedures and required an overnight stay at Royal North Shore Hospital during a 12-month period prior to introducing monitored anaesthesia care (MAC), compared with a 12-month period following introduction of MAC on selected weekdays. Primary outcomes were the difference in rates of Code Blue calls (triggering the cardiac arrest team), Clinical Reviews and Rapid Responses (defined as per the NSW Health 'Between the Flags' Deteriorating Patient Safety Net System) in the 24 h post-procedure between patients who did and did not have MAC. The secondary outcome was a difference in mortality (within 24 h of a procedure and in-hospital) between patients who did and did not have MAC. One thousand nine hundred and eight patients were analysed (926 pre-intervention, 982 post-intervention). We found no statistically significant difference in any of the primary or secondary outcomes between the pre-intervention and post-intervention patients overall. However, we found a statistically significant lower rate of Code Blue calls in patients who had MAC (n = 3, 0.6%) compared with no MAC (n = 31, 2.3%). We also found a significantly lower 24-h mortality in patients who had MAC (n = 1, 0.2%) compared with no MAC (n = 22, 1.6%), but no difference in overall in-hospital mortality. FAU - Meyerson, Sophie A AU - Meyerson SA AUID- ORCID: 0009-0005-3099-8849 AD - Department of Anaesthesia and Pain Medicine, Royal North Shore Hospital, St Leonards, Australia. FAU - Olesnicky, Ben AU - Olesnicky B AD - Department of Anaesthesia and Pain Medicine, Royal North Shore Hospital, St Leonards, Australia. FAU - Lee, Gene AU - Lee G AD - Department of Anaesthesia and Pain Medicine, Royal North Shore Hospital, St Leonards, Australia. FAU - Santoro, Andrea S AU - Santoro AS AD - Department of Anaesthesia and Pain Medicine, Royal North Shore Hospital, St Leonards, Australia. FAU - Bhindi, Ravinay AU - Bhindi R AD - Department of Cardiology, Royal North Shore Hospital, St Leonards, Australia. RINGGOLD: 60086 LA - eng PT - Journal Article DEP - 20250211 PL - United States TA - Anaesth Intensive Care JT - Anaesthesia and intensive care JID - 0342017 SB - IM MH - Humans MH - Retrospective Studies MH - Female MH - Male MH - *Anesthesia/methods MH - Aged MH - *Cardiac Catheterization/methods/mortality MH - Middle Aged MH - Hospital Mortality MH - Cohort Studies MH - Hospital Rapid Response Team/statistics & numerical data OTO - NOTNLM OT - Anaesthesia/adverse effects OT - anaesthesia/monitoring OT - cardiac arrest OT - cardiac catheterization OT - conscious sedation/adverse effects OT - conscious sedation/methods OT - hospital mortality OT - patient safety EDAT- 2025/02/12 06:21 MHDA- 2025/07/03 06:27 CRDT- 2025/02/12 01:23 PHST- 2025/07/03 06:27 [medline] PHST- 2025/02/12 06:21 [pubmed] PHST- 2025/02/12 01:23 [entrez] AID - 10.1177/0310057X241304423 [doi] PST - ppublish SO - Anaesth Intensive Care. 2025 Jul;53(4):265-271. doi: 10.1177/0310057X241304423. Epub 2025 Feb 11. PMID- 39933049 OWN - NLM STAT- MEDLINE DCOM- 20250506 LR - 20250506 IS - 1539-0705 (Electronic) IS - 1522-2179 (Linking) VI - 27 IP - 2 DP - 2025 Apr 1 TI - Charting New Paths: The Nurse Practitioner's Role in Leading Specialty-Aligned Palliative Care Consult Teams. PG - 59-66 LID - 10.1097/NJH.0000000000001109 [doi] AB - Palliative care has expanded beyond its traditional focus on the oncology population to meet the growing needs of patients with diverse diagnoses. A model of specialty-aligned palliative care has emerged as a means of integrating palliative care into various clinical specialties. Equipped with expert clinical skills, a holistic approach to patient care, and an emphasis on interprofessional collaboration, nurse practitioners are uniquely positioned to lead these teams. This article examines the role nurse practitioners play as leaders of 4 specialty-aligned palliative care teams at a major metropolitan academic medical center. It highlights key contributions to the successful integration of palliative care into oncology, cardiac, renal, and medical-surgical specialties. Although there are clear benefits of nurse practitioner-led specialty-aligned teams, further research and advocacy is needed to strengthen this model and increase access to quality palliative care. CI - Copyright (c) 2025 by The Hospice and Palliative Nurses Association. All rights reserved. FAU - O'Brien, Callie A AU - O'Brien CA FAU - Brain, Jessie M AU - Brain JM FAU - Jehle, Jonathan AU - Jehle J FAU - McGuire, Hilary Carroll AU - McGuire HC FAU - O'Shea, Lauren K AU - O'Shea LK FAU - Sciacca, Kate AU - Sciacca K LA - eng PT - Journal Article DEP - 20250211 PL - United States TA - J Hosp Palliat Nurs JT - Journal of hospice and palliative nursing : JHPN : the official journal of the Hospice and Palliative Nurses Association JID - 100887419 SB - IM MH - *Nurse Practitioners/trends MH - Humans MH - *Palliative Care/methods/trends MH - *Nurse's Role/psychology MH - *Patient Care Team/trends MH - *Referral and Consultation/trends/standards COIS- The authors have no conflicts of interest to disclose. EDAT- 2025/02/11 18:22 MHDA- 2025/03/05 12:26 CRDT- 2025/02/11 14:23 PHST- 2025/03/05 12:26 [medline] PHST- 2025/02/11 18:22 [pubmed] PHST- 2025/02/11 14:23 [entrez] AID - 00129191-202504000-00004 [pii] AID - 10.1097/NJH.0000000000001109 [doi] PST - ppublish SO - J Hosp Palliat Nurs. 2025 Apr 1;27(2):59-66. doi: 10.1097/NJH.0000000000001109. Epub 2025 Feb 11. PMID- 39932002 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260518 IS - 2753-670X (Electronic) IS - 2753-670X (Linking) VI - 40 IP - 2 DP - 2025 Feb 5 TI - The modified heart team protocol facilitated the revascularization decision-making quality in complex coronary artery disease. LID - 10.1093/icvts/ivaf023 [doi] LID - ivaf023 AB - OBJECTIVES: A lack of standardization in heart team implementation potentially leads to suboptimal decision-making quality, and we previously established a modified heart team protocol to improve the decision-making quality. The present trial was to validate the effect of the modified heart team implementation protocol on improving the decision-making quality versus the conventional protocol in complex coronary artery disease (CAD). METHODS: Eligible interventional cardiologists, cardiac surgeons and non-interventional cardiologists were randomly allocated to the intervention or control arm and established 12 heart teams in each arm. The 12 heart teams in each arm were randomly divided into 6 pairs, and 480 historic cases with complex CAD into 6 sets of 80 cases. In each arm, each set of 80 cases was discussed independently by one pair of heart teams, with each case finally receiving two heart team decisions ('pairwise decisions'). The intervention arm conducted heart team decision-making according to the previously established protocol and the control arm based on guideline recommendations. The primary outcome was the overall percent agreement of the inter-team pairwise decisions. Decision-making appropriateness was further analysed. RESULTS: A total of 36 cardiac surgeons, 36 interventional cardiologists and 12 non-interventional cardiologists from 26 centres were enrolled. The overall percent agreement was significantly higher in the intervention arm than the control arm (72.1% vs 65.8%, P = 0.04; kappa 0.51 vs 0.37). Both team-level (19.4% vs 33.0%; P < 0.001) and specialist-level (interventional cardiologists, 19.8% vs 37.7%, P < 0.001; cardiac surgeons, 19.8% vs 28.7%, P < 0.001) inappropriateness rate of decision-making was significantly lower in the intervention arm than the control arm. CONCLUSIONS: The modified heart team implementation protocol improved the decision-making quality and appropriateness compared with the guideline-based protocol. CI - (c) The Author(s) 2025. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. FAU - Ma, Hanping AU - Ma H AD - National Clinical Research Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Lin, Shen AU - Lin S AD - National Clinical Research Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. AD - Department of Cardiovascular Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Li, Xi AU - Li X AD - National Clinical Research Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. AD - Central China Subcenter of the National Center for Cardiovascular Diseases, Zhengzhou, China. FAU - Wang, Yang AU - Wang Y AD - Medical Research and Biometrics Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Yang, Weixian AU - Yang W AD - National Clinical Research Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. AD - Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Dou, Kefei AU - Dou K AUID- ORCID: 0000-0002-8372-6338 AD - National Clinical Research Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. AD - Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Liu, Sheng AU - Liu S AUID- ORCID: 0000-0001-8929-7178 AD - National Clinical Research Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. AD - Department of Cardiovascular Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Zheng, Zhe AU - Zheng Z AUID- ORCID: 0000-0003-3604-8383 AD - National Clinical Research Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. AD - National Health Commission Key Laboratory of Cardiovascular Regenerative Medicine, Fuwai Central China Cardiovascular Hospital, Central China Subcenter of National Center for Cardiovascular Diseases, Zhengzhou, China. CN - Modified Heart Team Protocol Study Group LA - eng GR - 2022-1-4031/Capital's Funds for Health Improvement and Research/ PT - Journal Article PL - England TA - Interdiscip Cardiovasc Thorac Surg JT - Interdisciplinary cardiovascular and thoracic surgery JID - 9918540787006676 SB - IM PMC - PMC11845249 OTO - NOTNLM OT - complex coronary artery disease OT - heart team OT - revascularization decision-making FIR - Ling, Yunpeng IR - Ling Y FIR - Zhang, Lufeng IR - Zhang L FIR - Liu, Jian IR - Liu J FIR - Chen, Yu IR - Chen Y FIR - Liu, Chuanfen IR - Liu C FIR - Ma, Yuliang IR - Ma Y FIR - Liu, Gang IR - Liu G FIR - Gao, Chuanyu IR - Gao C FIR - Cheng, Zhaoyun IR - Cheng Z FIR - Shao, Fang IR - Shao F FIR - Sun, Yuxiao IR - Sun Y FIR - Wang, Xianpei IR - Wang X FIR - Qi, Datun IR - Qi D FIR - An, Songtao IR - An S FIR - Hu, Junlong IR - Hu J FIR - Zhao, Ziniu IR - Zhao Z FIR - Dou, Kefei IR - Dou K FIR - Wu, Yuan IR - Wu Y FIR - Liu, Rong IR - Liu R FIR - Song, Weihua IR - Song W FIR - Zhang, Jun IR - Zhang J FIR - Zhao, Jie IR - Zhao J FIR - Yang, Weixian IR - Yang W FIR - Yin, Dong IR - Yin D FIR - Song, Lei IR - Song L FIR - Zhao, Hanjun IR - Zhao H FIR - Hu, Fenghuan IR - Hu F FIR - Gao, Lijian IR - Gao L FIR - Qian, Jie IR - Qian J FIR - Cui, Bin IR - Cui B FIR - Yang, Yan IR - Yang Y FIR - Luo, Xinjin IR - Luo X FIR - Gao, Ge IR - Gao G FIR - Wang, Liqing IR - Wang L FIR - Cui, Jingang IR - Cui J FIR - Wang, Xianqiang IR - Wang X FIR - Hu, Xiaopeng IR - Hu X FIR - Liu, Sheng IR - Liu S FIR - Zheng, Zhe IR - Zheng Z FIR - Wei, Lai IR - Wei L FIR - Lin, Yi IR - Lin Y FIR - Sun, Xiaoning IR - Sun X FIR - Xia, Limin IR - Xia L FIR - Yang, Junqing IR - Yang J FIR - Xie, Nianjin IR - Xie N FIR - Dong, Haojian IR - Dong H FIR - Li, Yue IR - Li Y FIR - Gong, Yongtai IR - Gong Y FIR - Sheng, Li IR - Sheng L FIR - Yu, Bo IR - Yu B FIR - Yang, Shuang IR - Yang S FIR - Xing, Lei IR - Xing L FIR - Yang, Guang IR - Yang G FIR - Chen, Tao IR - Chen T FIR - Ma, Qianli IR - Ma Q FIR - Chen, Lihua IR - Chen L FIR - Pan, Hongwei IR - Pan H FIR - Cheng, Xiang IR - Cheng X FIR - Dong, Nianguo IR - Dong N FIR - Li, Ming IR - Li M FIR - Li, Fei IR - Li F FIR - Liu, Juanwei IR - Liu J FIR - He, Yuquan IR - He Y FIR - Bai, Ming IR - Bai M FIR - Zhu, Youqi IR - Zhu Y FIR - Chen, Xin IR - Chen X FIR - Huang, Fuhua IR - Huang F FIR - Qiu, Zhibing IR - Qiu Z FIR - Pu, Jun IR - Pu J FIR - Zhang, Qing IR - Zhang Q FIR - Jin, Shuxuan IR - Jin S FIR - Du, Yongping IR - Du Y FIR - Han, Lin IR - Han L FIR - Tang, Yangfeng IR - Tang Y FIR - Zhang, Guanxin IR - Zhang G FIR - Song, Xiantao IR - Song X FIR - Dong, Ran IR - Dong R FIR - Tu, Chenchen IR - Tu C FIR - Zhang, Dongfeng IR - Zhang D FIR - Zhang, Mingduo IR - Zhang M FIR - Zhang, Min IR - Zhang M FIR - Zhao, Yang IR - Zhao Y FIR - Zheng, Jubing IR - Zheng J FIR - Song, Yue IR - Song Y FIR - Li, Yang IR - Li Y FIR - He, Yong IR - He Y FIR - Liu, Zhigang IR - Liu Z FIR - Lu, Wanli IR - Lu W FIR - Zhang, Jianliang IR - Zhang J FIR - Wang, Zhengqing IR - Wang Z FIR - Wang, Lianqun IR - Wang L FIR - Yang, Dongyan IR - Yang D FIR - Li, Junshan IR - Li J FIR - Jin, Zening IR - Jin Z FIR - Meng, Shuai IR - Meng S FIR - Jia, Ruofei IR - Jia R FIR - Zhang, Qi IR - Zhang Q FIR - You, Jieyun IR - You J FIR - Luo, Yu IR - Luo Y FIR - Tao, Liang IR - Tao L FIR - Feng, Xueguo IR - Feng X FIR - Yu, Huadong IR - Yu H FIR - Li, Yan IR - Li Y FIR - Guo, Wangang IR - Guo W FIR - Zhang, Dongwei IR - Zhang D FIR - Xue, Yusheng IR - Xue Y FIR - Jiang, Jun IR - Jiang J FIR - Wang, Huishan IR - Wang H FIR - Liu, Tao IR - Liu T FIR - Xu, Shu IR - Xu S FIR - Yang, Zhonglu IR - Yang Z EDAT- 2025/02/11 12:24 MHDA- 2025/02/11 12:25 PMCR- 2025/02/11 CRDT- 2025/02/11 06:32 PHST- 2024/12/12 00:00 [received] PHST- 2025/02/07 00:00 [accepted] PHST- 2025/02/11 12:25 [medline] PHST- 2025/02/11 12:24 [pubmed] PHST- 2025/02/11 06:32 [entrez] PHST- 2025/02/11 00:00 [pmc-release] AID - 8008584 [pii] AID - ivaf023 [pii] AID - 10.1093/icvts/ivaf023 [doi] PST - ppublish SO - Interdiscip Cardiovasc Thorac Surg. 2025 Feb 5;40(2):ivaf023. doi: 10.1093/icvts/ivaf023. PMID- 39929202 OWN - NLM STAT- MEDLINE DCOM- 20250211 LR - 20250210 IS - 1440-1797 (Electronic) IS - 1320-5358 (Linking) VI - 30 IP - 2 DP - 2025 Feb TI - Atrial Fibrillation in Advanced Chronic Kidney Disease: A Survey of Current Management in Australia and New Zealand. PG - e14422 LID - 10.1111/nep.14422 [doi] AB - AIM: There is limited evidence to support the use of oral anticoagulation (OAC) in people with advanced chronic kidney disease (CKD) and atrial fibrillation (AF). The aim of this study is to characterise the practice patterns and priorities of clinicians in the management of non-valvular AF and primary prevention of AF-related stroke in people with stage 4-5D CKD. METHODS: This was an annonymous, multiple-choice, electronic survey distributed to and undertaken by nephrology and cardiology clinicians in Australia and New Zealand. RESULTS: Responses eligible for analysis were received from 181 clinicians (121 nephrology and 60 cardiology respondents). Management with close specialty collaboration was reported by 47% of all respondents. OAC use was predominantly based on estimated individual stroke risk (i.e., CHA(2)DS(2)-VASc score) in people with stage 4 CKD and kidney transplant recipients. In stage 5/5D CKD, nephrology respondents were more likely to withhold all antithrombotic therapy or individualise OAC use (p < 0.05), whilst cardiology respondents were more likely to defer OAC decision-making to another specialist (p < 0.01). Varied use and dosing of OAC agents were noted between specialties. Left atrial appendage occlusion experience was limited amongst nephrology respondents but cardiology respondents would consider in individualised cases. Impact of CKD severity was noted in some rate and/or rhythm control management decisions. CONCLUSIONS: This survey provides important contemporary insights into the management of AF in people with advanced CKD in Australia and New Zealand. There was inter- and intra-specialty heterogeneity in practice, highlighting the need for multidisciplinary care and research to improve cardiovascular outcomes in this population. CI - (c) 2025 Asian Pacific Society of Nephrology. FAU - Law, Mandy M AU - Law MM AUID- ORCID: 0000-0001-7927-7616 AD - Department of Nephrology, the Royal Melbourne Hospital, Parkville, Victoria, Australia. AD - Department of Medicine, University of Melbourne, Parkville, Victoria, Australia. FAU - Tan, Sven-Jean AU - Tan SJ AD - Department of Nephrology, the Royal Melbourne Hospital, Parkville, Victoria, Australia. AD - Department of Medicine, University of Melbourne, Parkville, Victoria, Australia. FAU - Wong, Michael C G AU - Wong MCG AD - Department of Medicine, University of Melbourne, Parkville, Victoria, Australia. AD - Department of Cardiology, the Royal Melbourne Hospital, Parkville, Victoria, Australia. FAU - Toussaint, Nigel D AU - Toussaint ND AUID- ORCID: 0000-0002-2853-5096 AD - Department of Nephrology, the Royal Melbourne Hospital, Parkville, Victoria, Australia. AD - Department of Medicine, University of Melbourne, Parkville, Victoria, Australia. LA - eng PT - Journal Article PL - Australia TA - Nephrology (Carlton) JT - Nephrology (Carlton, Vic.) JID - 9615568 RN - 0 (Anticoagulants) SB - IM MH - *Atrial Fibrillation/complications/therapy MH - *Renal Insufficiency, Chronic/complications MH - Stroke/etiology/prevention & control MH - *Nephrologists/statistics & numerical data MH - *Cardiologists/statistics & numerical data MH - Australia MH - New Zealand MH - Anticoagulants/administration & dosage MH - Surveys and Questionnaires MH - Patient Care Team/statistics & numerical data MH - Kidney Function Tests/statistics & numerical data MH - Risk Assessment MH - *Practice Patterns, Physicians'/statistics & numerical data MH - Humans OTO - NOTNLM OT - cardiovascular disease OT - chronic kidney disease (CKD) OT - haemodialysis OT - peritoneal dialysis EDAT- 2025/02/11 00:19 MHDA- 2025/02/11 00:20 CRDT- 2025/02/10 18:53 PHST- 2024/10/31 00:00 [received] PHST- 2024/12/11 00:00 [accepted] PHST- 2025/02/11 00:20 [medline] PHST- 2025/02/11 00:19 [pubmed] PHST- 2025/02/10 18:53 [entrez] AID - 10.1111/nep.14422 [doi] PST - ppublish SO - Nephrology (Carlton). 2025 Feb;30(2):e14422. doi: 10.1111/nep.14422. PMID- 39928915 OWN - NLM STAT- MEDLINE DCOM- 20250506 LR - 20260611 IS - 1449-8944 (Electronic) IS - 0156-5788 (Linking) VI - 49 DP - 2025 Feb TI - Optimal lung cancer care pathways: a Tasmanian perspective. LID - AH24249 [pii] LID - 10.1071/AH24249 [doi] AB - Objective In Australia, Tasmania has the second highest rate of incident lung cancer cases at 44.0 per 100,000 population, with an overall 5year relative survival rate of 20%. The aim of this retrospective study was to map and compare patient transit timelines from referral, diagnosis and treatment, to national care quality indicators (NCQI) and optimal care pathway (OCP) benchmarks. Methods Data were extracted from the weekly lung cancer multidisciplinary team meeting minutes, digital medical records and the ARIA Oncology-Information System for newly diagnosed small cell and non-small cell lung cancer cases between 2019 and 2022, at a regional, university-affiliated tertiary hospital in Tasmania. Sociodemographic data and key dates were extracted, including first general practitioner (GP) referral, specialist appointments (respiratory, medical oncology, radiation oncology and cardiothoracic), investigations, diagnosis, staging and treatment of any intent. Timelines were benchmarked against NCQI and the OCP. Results A total of 165 cases were included; mean patient age was 72years, and 57% were male. A total of 153 patients (93%) were diagnosed with non-small cell cancer and 12 (7%) with small cell lung cancer. Results for all years showed that 93% of patients were seen by the respiratory service within 14days of their GP referral and 71% diagnosed within 28days of their referral, in accordance with current standards. The time taken between GP referrals and diagnosis to any treatment was greater than the required standards, with on average 7% of patients meeting the quality standards (range, 0-16%) for all treatment intents. Conclusion Current national benchmarks have proven challenging to achieve, with prolonged time to treatment of any intent. Challenges both at a patient and systemic level will need to be assessed to improve clinical indicator outcomes. FAU - Leong, Chui Lyn AU - Leong CL AD - Department of Respiratory and Sleep Medicine, Royal Hobart Hospital, Tas 7000, Australia. FAU - Cox, Ingrid AU - Cox I AD - Menzies Institute for Medical Research, University of Tasmania, Tas, Australia. FAU - Grundy, Renae AU - Grundy R AD - Department of Respiratory and Sleep Medicine, Royal Hobart Hospital, Tas 7000, Australia. FAU - Harkness, Nick AU - Harkness N AD - Department of Respiratory and Sleep Medicine, Royal Hobart Hospital, Tas 7000, Australia. FAU - Palmer, Andrew J AU - Palmer AJ AD - Menzies Institute for Medical Research, University of Tasmania, Tas, Australia. FAU - de Graaff, Barbara AU - de Graaff B AD - Menzies Institute for Medical Research, University of Tasmania, Tas, Australia. FAU - Ball, Emma AU - Ball E AD - Department of Respiratory and Sleep Medicine, Royal Hobart Hospital, Tas 7000, Australia. LA - eng PT - Journal Article PL - Australia TA - Aust Health Rev JT - Australian health review : a publication of the Australian Hospital Association JID - 8214381 SB - IM MH - Humans MH - Tasmania/epidemiology MH - *Lung Neoplasms/therapy/diagnosis MH - Male MH - Retrospective Studies MH - Female MH - Aged MH - *Carcinoma, Non-Small-Cell Lung/therapy/diagnosis MH - Middle Aged MH - *Critical Pathways MH - Aged, 80 and over MH - Benchmarking MH - Quality Indicators, Health Care MH - Referral and Consultation/statistics & numerical data MH - *Small Cell Lung Carcinoma/therapy/diagnosis EDAT- 2025/02/10 18:16 MHDA- 2025/04/03 18:25 CRDT- 2025/02/10 16:42 PHST- 2024/09/10 00:00 [received] PHST- 2025/01/19 00:00 [accepted] PHST- 2025/04/03 18:25 [medline] PHST- 2025/02/10 18:16 [pubmed] PHST- 2025/02/10 16:42 [entrez] AID - AH24249 [pii] AID - 10.1071/AH24249 [doi] PST - ppublish SO - Aust Health Rev. 2025 Feb;49:AH24249. doi: 10.1071/AH24249. PMID- 39924368 OWN - NLM STAT- MEDLINE DCOM- 20250510 LR - 20250522 IS - 1444-2892 (Electronic) IS - 1443-9506 (Linking) VI - 34 IP - 5 DP - 2025 May TI - Transcatheter Aortic Valve Implantation in Patients at Intermediate and Low Risk Is Not (Yet) the Existential Threat That Surgeons Feared: A Retrospective Analysis of Medicare Claims Data. PG - 467-471 LID - S1443-9506(24)01924-3 [pii] LID - 10.1016/j.hlc.2024.11.022 [doi] AB - BACKGROUND: In Australia, the role of surgical aortic valve replacement (SAVR) and transcatheter aortic valve implantation (TAVI) in patients who are suitable for both procedures remains controversial. In 2022, new Items were added to the Medicare Benefits Schedule (MBS) to allow patients at intermediate and low risk with appropriate private health insurance to undergo TAVI. The Cardiac Society of Australia and New Zealand supported these changes whereas the Australian and New Zealand Society of Cardiac and Thoracic Surgeons opposed them. The aim of this study was to document subsequent private TAVI activity in patients at intermediate and low risk, relative to both private TAVI activity in patients at high risk and private SAVR activity. METHOD: A retrospective population-level descriptive study was undertaken, using Medicare claims data obtained from Services Australia. RESULTS: Among private patients who underwent TAVI, the groups at high, intermediate, and low risk all had a median age between 75 and 84 years. Only 1% were aged /= 70 years, median follow-up 486 days) consecutively included, subjects with DM (N = 174, 27.8 %) had a higher prevalence of comorbidities like obesity (27.3 % vs. 9.2 %, p < 0.001), arterial hypertension (91.4 % vs. 83.7 %, p = 0.013), renal insufficiency (63.8 % vs. 43.9 %, p < 0.001), coronary artery disease (77.0 % vs. 59.8 %, p < 0.001) and peripheral artery disease (14.4 % vs. 8.4 %, p = 0.026). Patients with DM presented with higher median logistic Euroscore I (29.4 % [20.0/43.0] vs. 25.0 % [16.7/36.6], p = 0.001) and more severely reduced systolic function (LVEF 35 % [30/50] vs. 45 % [30/55], p < 0.001). No difference in short- and long-term survival was detected between patients with and without DM (in-hospital mortality 1.7 vs. 2.6 %, p = 0.771; at 30-days 5.0 vs. 6.0 %, p = 0.842, 1-year 28.7 vs. 25.0 %, p = 0.419, 3-years 49.2 vs. 44.1 %, p = 0.554, 5-years 69.0 vs. 68.3 %, p = 0.497). The presence of DM was not attributed as an individual risk factor for elevated mortality (HR 1-year 1.17 [95 % CI 0.80-1.71], p = 0.419; HR long-term 1.13 [95 %CI 0.86-1.49], p = 0.373). CONCLUSION: Although linked to a more vulnerable clinical profile and despite being factored in common risk factor models, DM was not associated with an elevated short- and long-term mortality after TEER of MR. CI - (c) 2025 Published by Elsevier B.V. FAU - Schmitt, Volker H AU - Schmitt VH AD - Department of Cardiology, Cardiology I, University Medical Center, Johannes Gutenberg-University Mainz, Mainz, Germany. AD - German Center for Cardiovascular Research (DZHK), Partner Site Rhine Main, Mainz, Germany. FAU - Geyer, Martin AU - Geyer M AD - Department of Cardiology, Cardiology I, University Medical Center, Johannes Gutenberg-University Mainz, Mainz, Germany. FAU - Born, Sonja AU - Born S AD - Department of Cardiology, Cardiology I, University Medical Center, Johannes Gutenberg-University Mainz, Mainz, Germany. FAU - Bachmann, Kevin AU - Bachmann K AD - Department of Cardiology, Cardiology I, University Medical Center, Johannes Gutenberg-University Mainz, Mainz, Germany. FAU - Schnitzler, Katharina AU - Schnitzler K AD - Department of Cardiology, Cardiology I, University Medical Center, Johannes Gutenberg-University Mainz, Mainz, Germany. FAU - Hell, Michaela AU - Hell M AD - Department of Cardiology, Cardiology I, University Medical Center, Johannes Gutenberg-University Mainz, Mainz, Germany. FAU - Tamm, Alexander R AU - Tamm AR AD - Department of Cardiology, Cardiology I, University Medical Center, Johannes Gutenberg-University Mainz, Mainz, Germany. FAU - Ruf, Tobias Friedrich AU - Ruf TF AD - Department of Cardiology, Cardiology I, University Medical Center, Johannes Gutenberg-University Mainz, Mainz, Germany. FAU - Gossler, Theresa Ann Maria AU - Gossler TAM AD - Department of Cardiology, Cardiology I, University Medical Center, Johannes Gutenberg-University Mainz, Mainz, Germany. FAU - Rogmann, Marc A AU - Rogmann MA AD - Department of Cardiology, Cardiology I, University Medical Center, Johannes Gutenberg-University Mainz, Mainz, Germany. FAU - Hahad, Omar AU - Hahad O AD - Department of Cardiology, Cardiology I, University Medical Center, Johannes Gutenberg-University Mainz, Mainz, Germany. AD - German Center for Cardiovascular Research (DZHK), Partner Site Rhine Main, Mainz, Germany. FAU - Hobohm, Lukas AU - Hobohm L AD - Department of Cardiology, Cardiology I, University Medical Center, Johannes Gutenberg-University Mainz, Mainz, Germany. FAU - Herzog, Johannes AU - Herzog J AD - Department of Cardiology, Cardiology I, University Medical Center, Johannes Gutenberg-University Mainz, Mainz, Germany. FAU - Windschmitt, Johannes AU - Windschmitt J AD - Department of Cardiology, Cardiology I, University Medical Center, Johannes Gutenberg-University Mainz, Mainz, Germany. FAU - Schwuchow-Thonke, Soren AU - Schwuchow-Thonke S AD - Department of Cardiology, Cardiology I, University Medical Center, Johannes Gutenberg-University Mainz, Mainz, Germany. FAU - Blessing, Recha AU - Blessing R AD - Department of Cardiology, Cardiology I, University Medical Center, Johannes Gutenberg-University Mainz, Mainz, Germany. FAU - Schulz, Eberhard AU - Schulz E AD - Department of Cardiology, Cardiology I, University Medical Center, Johannes Gutenberg-University Mainz, Mainz, Germany. FAU - Lurz, Philipp AU - Lurz P AD - Department of Cardiology, Cardiology I, University Medical Center, Johannes Gutenberg-University Mainz, Mainz, Germany. FAU - Munzel, Thomas AU - Munzel T AD - Department of Cardiology, Cardiology I, University Medical Center, Johannes Gutenberg-University Mainz, Mainz, Germany. AD - German Center for Cardiovascular Research (DZHK), Partner Site Rhine Main, Mainz, Germany. AD - Center for Thrombosis and Hemostasis (CTH), University Medical Center, Johannes Gutenberg-University Mainz, Mainz, Germany. FAU - Keller, Karsten AU - Keller K AD - Department of Cardiology, Cardiology I, University Medical Center, Johannes Gutenberg-University Mainz, Mainz, Germany. AD - Center for Thrombosis and Hemostasis (CTH), University Medical Center, Johannes Gutenberg-University Mainz, Mainz, Germany. FAU - von Bardeleben, Ralph Stephan AU - von Bardeleben RS AD - Department of Cardiology, Cardiology I, University Medical Center, Johannes Gutenberg-University Mainz, Mainz, Germany. LA - eng PT - Journal Article DEP - 20250125 PL - Ireland TA - Int J Cardiol Heart Vasc JT - International journal of cardiology. Heart & vasculature JID - 101649525 PMC - PMC11800078 OTO - NOTNLM OT - Diabetes mellitus OT - MitraClip(R) OT - Mitral valve regurgitation OT - Mitral valve repair OT - Multidisciplinary heart team OT - Transcatheter edge-to-edge repair COIS- The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: VHS, MG, SB, KB, KS, MH, ART, TAMG, MAR, OH, JH, JW, SS-T, RB, ES and KK report no conflicts of interests. TFR is an advisor to and proctor/preceptor for Abbott Laboratories, Edwards Lifesciences and NeoChord Inc. LH received lecture/consultant fees from MSD, Johnson&Johnson, Inari Medical and Boston Scientific, outside the submitted work. PL has received institutional fees and research grants from Abbott Vascular, Edwards Lifesciences, and ReCor, honoraria from Edwards Lifesciences, Abbott Medical, Innoventric, ReCor and Boehringer Ingelheim and has stock options with Innoventric. TM is PI of the DZHK (German Center for Cardiovascular Research), Partner Site Rhine-Main, Mainz, Germany. RSvB reports unpaid trial activity as well as speaker, consultant and advisory board activity for Abbott Structural and unpaid trial activity as well as speaker and consultant activity for Edwards Lifesciences.. EDAT- 2025/02/07 11:12 MHDA- 2025/02/07 11:13 PMCR- 2025/01/25 CRDT- 2025/02/07 04:59 PHST- 2024/11/01 00:00 [received] PHST- 2024/12/26 00:00 [revised] PHST- 2025/01/03 00:00 [accepted] PHST- 2025/02/07 11:13 [medline] PHST- 2025/02/07 11:12 [pubmed] PHST- 2025/02/07 04:59 [entrez] PHST- 2025/01/25 00:00 [pmc-release] AID - S2352-9067(25)00004-1 [pii] AID - 101601 [pii] AID - 10.1016/j.ijcha.2025.101601 [doi] PST - epublish SO - Int J Cardiol Heart Vasc. 2025 Jan 25;56:101601. doi: 10.1016/j.ijcha.2025.101601. eCollection 2025 Feb. PMID- 39915960 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20261019 LR - 20261019 IS - 1467-1107 (Electronic) IS - 1047-9511 (Linking) VI - 35 IP - 3 DP - 2025 Mar TI - An intervention in the paediatric cardiac ICU to standardise pre-family meeting huddles is feasible, acceptable, and improves clinician teamwork. PG - 520-528 LID - 10.1017/S1047951125000010 [doi] AB - INTRODUCTION: Interprofessional teams in the pediatric cardiac ICU consolidate their management plans in pre-family meeting huddles, a process that affects the course of family meetings but often lacks optimal communication and teamwork. METHODS: Cardiac ICU clinicians participated in an interprofessional intervention to improve how they prepared for and conducted family meetings. We conducted a pretest-posttest study with clinicians participating in huddles before family meetings. We assessed feasibility of clinician enrollment, assessed clinician perception of acceptability of the intervention via questionnaire and semi-structured interviews, and impact on team performance using a validated tool. Wilcoxon rank sum test assessed intervention impact on team performance at meeting level comparing pre- and post-intervention data. RESULTS: Totally, 24 clinicians enrolled in the intervention (92% retention) with 100% completion of training. All participants recommend cardiac ICU Teams and Loved ones Communicating to others and 96% believe it improved their participation in family meetings. We exceeded an acceptable level of protocol fidelity (>75%). Team performance was significantly (p < 0.001) higher in post-intervention huddles (n = 30) than in pre-intervention (n = 28) in all domains. Median comparisons: Team structure [2 vs. 5], Leadership [3 vs. 5], Situation Monitoring [3 vs. 5], Mutual Support [ 3 vs. 5], and Communication [3 vs. 5]. CONCLUSION: Implementing an interprofessional team intervention to improve team performance in pre-family meeting huddles is feasible, acceptable, and improves team function. Future research should further assess impact on clinicians, patients, and families. FAU - Walter, Jennifer K AU - Walter JK AUID- ORCID: 0000-0003-0723-2464 AD - Justin Ingerman Center for Palliative Care, Children's Hospital of Philadelphia, Philadelphia, USA. AD - Clinical Futures, Children's Hospital of Philadelphia, Philadelphia, USA. FAU - Cetin, Arzu AU - Cetin A AUID- ORCID: 0009-0004-7354-0523 AD - Clinical Futures, Children's Hospital of Philadelphia, Philadelphia, USA. FAU - Gramszlo, Colette AU - Gramszlo C AUID- ORCID: 0000-0003-2644-936X AD - Department of Child and Adolescent Psychiatry and Behavioral Sciences, Children's Hospital of Philadelphia, Philadelphia, USA. FAU - DeWitt, Aaron G AU - DeWitt AG AD - Cardiac Center, Children's Hospital of Philadelphia, Philadelphia, PA, USA. FAU - Quarshie, William AU - Quarshie W AD - Data Science and Biostatistics Unit, Department of Biomedical and Health Informatics, Children's Hospital of Philadelphia, Philadelphia, USA. FAU - Griffis, Heather AU - Griffis H AD - Data Science and Biostatistics Unit, Department of Biomedical and Health Informatics, Children's Hospital of Philadelphia, Philadelphia, USA. FAU - Johnson, Victoria AU - Johnson V AD - Justin Ingerman Center for Palliative Care, Children's Hospital of Philadelphia, Philadelphia, USA. FAU - Nelson, Selena AU - Nelson S AD - Justin Ingerman Center for Palliative Care, Children's Hospital of Philadelphia, Philadelphia, USA. FAU - Shults, Justine AU - Shults J AD - Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA. FAU - Arnold, Robert M AU - Arnold RM AD - University of Pittsburgh Medical Center, Pittsburgh, USA. FAU - Trowbridge, Amy AU - Trowbridge A AD - Division of Bioethics and Palliative Care, Department of Pediatrics, University of Washington and Seattle Children's Hospital, Seattle, USA. FAU - Hurd, Caroline AU - Hurd C AUID- ORCID: 0000-0002-1789-6283 AD - Harborview Medical Center, University of Washington, Seattle, USA. FAU - Curley, Martha A Q AU - Curley MAQ AD - Department of Family and Community Health, University of Pennsylvania School of Nursing, Philadelphia, USA. FAU - Feudtner, Chris AU - Feudtner C AD - Justin Ingerman Center for Palliative Care, Children's Hospital of Philadelphia, Philadelphia, USA. AD - Clinical Futures, Children's Hospital of Philadelphia, Philadelphia, USA. LA - eng PT - Journal Article DEP - 20250207 PL - England TA - Cardiol Young JT - Cardiology in the young JID - 9200019 SB - IM OTO - NOTNLM OT - Cardiac intensive care unit OT - Interprofessional teamwork OT - Intervention OT - Pediatric EDAT- 2025/02/07 11:12 MHDA- 2025/02/07 11:13 CRDT- 2025/02/07 00:42 PHST- 2025/02/07 11:13 [medline] PHST- 2025/02/07 11:12 [pubmed] PHST- 2025/02/07 00:42 [entrez] AID - S1047951125000010 [pii] AID - 10.1017/S1047951125000010 [doi] PST - ppublish SO - Cardiol Young. 2025 Mar;35(3):520-528. doi: 10.1017/S1047951125000010. Epub 2025 Feb 7. PMID- 39915147 OWN - NLM STAT- MEDLINE DCOM- 20251003 LR - 20260428 IS - 2173-5727 (Electronic) IS - 2173-5727 (Linking) VI - 49 IP - 10 DP - 2025 Oct TI - Impact of COVID-19 in the in-hospital cardiac arrest activations: Retrospective study. PG - 502137 LID - S2173-5727(25)00013-X [pii] LID - 10.1016/j.medine.2025.502137 [doi] AB - OBJECTIVE: To analyze whether the characteristics of the patients treated by the in-hospital cardiorespiratory arrest team, IHCA and cardiopulmonary resuscitation (CPR) were different in the period before the COVID-19 compared to the pandemic period; also analyzing the differences between COVID+ and COVID- patients. DESIGN: Observational and retrospective study from January 1st, 2018, to December 31st, 2021. SETTING: Tertiary hospital. PATIENTS: All adult patients over 18 years old requiring attention from the IHCA response team. INTERVENTIONS: CPR maneuvers according to the advanced life support guidelines of the European Resuscitation Council published in 2015, as well as the modifications made in the COVID era (2020). MAIN VARIABLES: Demographic and epidemiological data, activations of the IHCA response team, CA data, hospital and intensive care unit (ICU) length of stay, survival and neurological outcome at hospital discharge. RESULTS: A total of 368 patients were analyzed: 173 in the pre-pandemic group and 195 in the pandemic group. The neurological outcome was better in the pre-pandemic group, and COVID+ patients had a longer ICU length of stay. However, no differences in the response time of the CPR team or in CPR duration were found, nor in immediate survival or at hospital discharge, between both groups or between COVID+ and COVID- patients. CONCLUSIONS: Changes in CPR care protocols due to the COVID-19 pandemia did not seem to affect response times from IHCA team neither immediate nor discharge survival. CI - Copyright (c) 2025 Elsevier Espana, S.L.U. and SEMICYUC. All rights reserved. FAU - Ballout, Ghali AU - Ballout G AD - Servicio de Anestesiologia y Reanimacion, Hospital Clinic, Barcelona, Spain. FAU - Magaldi Mendana, Marta AU - Magaldi Mendana M AD - Servicio de Anestesiologia y Reanimacion, Hospital Clinic, Barcelona, Spain. Electronic address: mmagaldi@clinic.cat. FAU - Ramis Bou, Bartomeu AU - Ramis Bou B AD - Servicio de Anestesiologia y Reanimacion, Hospital Universitario Son Espases, Palma de Mallorca, Spain. FAU - Torres Quevedo, Cristian AU - Torres Quevedo C AD - Servicio de Anestesiologia y Reanimacion, Hospital Univesitario Joan XXIII, Tarragona, Spain. FAU - Capdevila Freixas, Adriana AU - Capdevila Freixas A AD - Servicio de Anestesiologia y Reanimacion, Hospital Clinic, Barcelona, Spain. FAU - Moreno-Jurico, Silvia AU - Moreno-Jurico S AD - Servicio de Anestesiologia y Reanimacion, Hospital Clinic, Barcelona, Spain. FAU - Carrero Cardenal, Enrique Jesus AU - Carrero Cardenal EJ AD - Servicio de Anestesiologia y Reanimacion, Hospital Clinic, Barcelona, Spain. FAU - Fontanals Dotras, Jaime AU - Fontanals Dotras J AD - Servicio de Anestesiologia y Reanimacion, Hospital Clinic, Barcelona, Spain. CN - Comision a la Atencion a la Parada Cardiorrespiratoria del Hospital Clinic de Barcelona LA - eng PT - Journal Article PT - Observational Study DEP - 20250205 PL - Spain TA - Med Intensiva (Engl Ed) JT - Medicina intensiva JID - 101717568 SB - IM MH - Humans MH - Retrospective Studies MH - *COVID-19/epidemiology/complications MH - Male MH - Female MH - *Heart Arrest/therapy/epidemiology/mortality MH - *Cardiopulmonary Resuscitation/statistics & numerical data MH - Middle Aged MH - Aged MH - Length of Stay/statistics & numerical data MH - Intensive Care Units/statistics & numerical data MH - Aged, 80 and over MH - Hospital Rapid Response Team/statistics & numerical data MH - Pandemics OTO - NOTNLM OT - Advanced life support OT - COVID-19 OT - Cardiac arrest team OT - Equipo de atencion a la parada cardiorrespiratoria OT - Estancia hospitalaria OT - Hospital stay OT - In-hospital cardiac arrest OT - Neurological prognosis OT - Pandemia OT - Pandemic OT - Parada cardiorrespiratoria intrahospitalaria OT - Pronostico neurologico OT - Soporte vital avanzado OT - Supervivencia OT - Survival COIS- Declaration of competing interest The authors declare that they have no conflicts of interest. EDAT- 2025/02/07 00:20 MHDA- 2025/10/04 00:30 CRDT- 2025/02/06 21:58 PHST- 2024/07/16 00:00 [received] PHST- 2024/09/12 00:00 [revised] PHST- 2024/10/11 00:00 [accepted] PHST- 2025/10/04 00:30 [medline] PHST- 2025/02/07 00:20 [pubmed] PHST- 2025/02/06 21:58 [entrez] AID - S2173-5727(25)00013-X [pii] AID - 10.1016/j.medine.2025.502137 [doi] PST - ppublish SO - Med Intensiva (Engl Ed). 2025 Oct;49(10):502137. doi: 10.1016/j.medine.2025.502137. Epub 2025 Feb 5. PMID- 39915068 OWN - NLM STAT- MEDLINE DCOM- 20250722 LR - 20250722 IS - 1472-0213 (Electronic) IS - 1472-0205 (Linking) VI - 42 IP - 4 DP - 2025 Mar 25 TI - Understanding cardiac arrest dispatch of physician-paramedic critical care prehospital teams: a survey-based evaluation. PG - 249-255 LID - 10.1136/emermed-2024-214178 [doi] AB - BACKGROUND: Appropriate dispatch of critical care teams to out-of-hospital cardiac arrest (OHCA) has been identified as a research priority emergency care in the UK. The study aimed to understand the criteria informing the decision to dispatch a critical care physician-paramedic prehospital team to OHCA in one UK region. METHODS: An invitation to participate in an anonymised online survey was sent by email to clinicians and non-clinicians working on the critical care (physician-paramedic) dispatch desk for the East of England Ambulance Service NHS Trust between June and July 2023. Demographic data relating to the experience of the dispatchers were collected alongside evaluating the effect of 15 predetermined criteria on OHCA dispatch (based on a pilot survey) on their decision to dispatch a physician-paramedic team. Responses to closed-end questions were calculated as percentages. A compulsory free text question on dispatching the physician-paramedic team was included. Free text data were interpreted by one author and the interpretation reviewed by all authors. RESULTS: 20 respondents (19 critical care paramedics and one non-clinical dispatcher) participated, yielding a 79% response rate for clinical and 17% for non-clinical dispatchers. 'Witnessed cardiac arrest' and return of spontaneous circulation achieved on scene were criteria used by 100% of respondents in informing dispatch of a physician-paramedic team to OHCA. 10 of the 15 preidentified criteria were considered important in their decision-making by at least 75% of respondents. 'Age' was considered as more than just a number, instead incorporating both the nuances of a paediatric cardiac arrest and the importance of physiological reserve and frailty. CONCLUSION: The only 100% agreement in dispatch criteria was 'witnessed arrest'. Otherwise, variation existed and additional information, like identification of frailty, was gathered to support nuanced decision-making. Wider research across the UK would help identify factors and commonalities in OHCA physician-paramedic dispatch to target improved survival rates. CI - (c) Author(s) (or their employer(s)) 2025. No commercial re-use. See rights and permissions. Published by BMJ Group. FAU - Morton, Sarah AU - Morton S AUID- ORCID: 0000-0002-9112-8821 AD - Essex and Herts Air Ambulance, Colchester, UK sarah.morton@doctors.org.uk. AD - Imperial College London, London, UK. FAU - Eagle, Chris AU - Eagle C AD - Essex and Herts Air Ambulance, Colchester, UK. FAU - Wallman, Scott AU - Wallman S AD - Essex and Herts Air Ambulance, Colchester, UK. FAU - Wareham, Gaynor AU - Wareham G AD - Essex and Herts Air Ambulance, Colchester, UK. FAU - Major, Rob AU - Major R AD - East Anglian Air Ambulance, Norwich, UK. AD - University of East Anglia, Norwich, UK. FAU - Edmunds, Christopher AU - Edmunds C AD - East Anglian Air Ambulance, Norwich, UK. AD - University of East Anglia, Norwich, UK. FAU - McLachlan, Sarah AU - McLachlan S AD - Essex and Herts Air Ambulance, Colchester, UK. AD - Anglia Ruskin University, Chelmsford, UK. LA - eng PT - Journal Article DEP - 20250325 PL - England TA - Emerg Med J JT - Emergency medicine journal : EMJ JID - 100963089 SB - IM MH - *Critical Care MH - *Patient Care Team MH - Paramedics MH - Physicians MH - *Out-of-Hospital Cardiac Arrest/epidemiology/therapy MH - *Emergency Medical Dispatch/statistics & numerical data MH - Surveys and Questionnaires MH - Humans MH - *Emergency Medical Services MH - United Kingdom/epidemiology OTO - NOTNLM OT - Out-of-Hospital Cardiac Arrest OT - critical care OT - critical care transport COIS- Competing interests: None declared. EDAT- 2025/02/07 00:20 MHDA- 2025/03/27 05:36 CRDT- 2025/02/06 21:32 PHST- 2024/04/30 00:00 [received] PHST- 2025/01/26 00:00 [accepted] PHST- 2025/03/27 05:36 [medline] PHST- 2025/02/07 00:20 [pubmed] PHST- 2025/02/06 21:32 [entrez] AID - emermed-2024-214178 [pii] AID - 10.1136/emermed-2024-214178 [doi] PST - epublish SO - Emerg Med J. 2025 Mar 25;42(4):249-255. doi: 10.1136/emermed-2024-214178. PMID- 39912466 OWN - NLM STAT- MEDLINE DCOM- 20250206 LR - 20250526 IS - 1952-4013 (Electronic) IS - 1167-1122 (Linking) VI - 34 IP - 6 DP - 2024 Dec 1 TI - Acne in transgender patients: disease management and treatment recommendations from a group of experts on acne. PG - 609-615 LID - 10.1684/ejd.2024.4788 [doi] AB - In transmen (women to men), the testosterone (T) therapy used to support the masculinizing process may cause acne. Conversely, in transwomen (men to women), feminising hormones may reduce acne but cause skin dryness and irritation which may be further exacerbated if mild acne persists, requiring topical treatments. Gonadotropin-releasing hormone analogues suppress endogenous sex hormones, thus avoiding the onset of acne in prepubertal individuals. To identify the specific issues of acne in transgender patients and propose suitable medical care for dermatologists. A group of five experts on acne reviewed and discussed 68 publications regarding the issue of acne in transgender patients. Key words included "acne+transgender", "acne+transgender+treatment", "transgender+skin diseases+treatment", "transmen+acne+treatment," and "transwomen+acne+treatment". The gender affirming process in transgender patients requires a multidisciplinary approach involving endocrinologists, psychiatrists, cardiologists and dermatologists, especially if the hormonal treatment causes or worsens acne. Treatment of "transgender" acne differs from "classic" acne treatment. The administration of masculinizing hormones frequently causes moderate to severe acne which requires the administration of oral treatments involving specific conditions of use and, conversely, the use of feminising hormones reduces the risk of more severe forms of acne. However, mild to moderate acne may persist, requiring topical treatments that may further increase skin dryness and irritation. The risk of relapse after stopping treatment may be very high and justifies a maintenance topical treatment. The use of ceramide-enriched emollients is mandatory in all patients. The treatment of "transgender" acne may be challenging, however, efficacious treatment options exist. FAU - Auffret, Nicole AU - Auffret N AD - Private practice Paris, France. FAU - Ballanger, Fabienne AU - Ballanger F AD - Private practice, Talence, France. FAU - Leccia, Marie-Therese AU - Leccia MT AD - Department of Dermatology, Allergology and Photobiology, CHU A Michaelson, Grenoble, France. FAU - Claudel, Jean-Paul AU - Claudel JP AD - Private practice, Tours, France. FAU - Dreno, Brigitte AU - Dreno B AD - Nantes Universite, INSERM, CNRS, Immunology and New Concepts in Immuno Therapy, INCIT, UMR 1302/EMR6001. F-44000 Nantes, France. LA - eng PT - Journal Article PT - Review PL - France TA - Eur J Dermatol JT - European journal of dermatology : EJD JID - 9206420 RN - 3XMK78S47O (Testosterone) RN - 0 (Dermatologic Agents) SB - IM MH - Humans MH - *Acne Vulgaris/drug therapy/therapy/etiology MH - *Transgender Persons MH - Female MH - Male MH - Testosterone/adverse effects/therapeutic use MH - Dermatologic Agents/therapeutic use OTO - NOTNLM OT - acne OT - isotretinoin OT - oestrogens OT - retinoids OT - spironolactone OT - transfeminine OT - transgender OT - transmasculine EDAT- 2025/02/06 12:22 MHDA- 2025/02/06 12:23 CRDT- 2025/02/06 07:12 PHST- 2025/02/06 12:23 [medline] PHST- 2025/02/06 12:22 [pubmed] PHST- 2025/02/06 07:12 [entrez] AID - ejd.2024.4788 [pii] AID - 10.1684/ejd.2024.4788 [doi] PST - ppublish SO - Eur J Dermatol. 2024 Dec 1;34(6):609-615. doi: 10.1684/ejd.2024.4788. PMID- 39910538 OWN - NLM STAT- MEDLINE DCOM- 20250505 LR - 20250703 IS - 1471-2482 (Electronic) IS - 1471-2482 (Linking) VI - 25 IP - 1 DP - 2025 Feb 5 TI - The surgical time-out: the relationship between perceptions of a safety-task anchor and surgical team workflow. PG - 55 LID - 10.1186/s12893-025-02789-w [doi] LID - 55 AB - BACKGROUND: The surgical time-out is a critical safety measure used in the operating room (OR). We examined the mediating relationship of the length of the time-out between team perceived usefulness of the time-out, and the rate at which the circulating nurse left the OR to retrieve instruments. METHODS: 60 cardiac surgical teams were observed performing their work. The length of the time-out and the rate at which the circulating nurse left the OR was obtained by observation of the surgical team. We administered a survey with a 7-point Likert scale to assess the surgical staff's perceived usefulness of the time-out at the end of the surgery. An analysis was conducted to test if length of the time-out mediated the relationship between perceived usefulness of the time-out and rate at which the nurse leaves the OR to retrieve an instrument useful for the surgery. RESULTS: The relationship of the length of the time-out with the rate at which the nurse leaves the OR was non-significant (beta = 0.089, p = .496). However, the relationship between perceived usefulness of the time-out with the length of the time-out was significant (beta = 0.346, p < .05) and the effect between perceived usefulness of the time-out and the rate at which the nurse left the OR was statistically significant (beta= - 0.424, p = < 0.001). CONCLUSION: In this study we explore how surgical teams' attitudes towards the usefulness of the time-out affect its utilization, and how attitudes about time-outs are related to the important process measure of rate at which the circulating nurse leaves the OR. The full mediation model was not supported by the data; however, there appears to be a relationship between the perceived usefulness of the time-out and the rate at which the circulating nurse leaves the OR. CI - (c) 2025. The Author(s). FAU - Zagarese, Vivian J AU - Zagarese VJ AD - Department of Psychology, Virginia Tech, Blacksburg, VA, USA. vivianz@vt.edu. AD - , 1325 N Pierce St. Apt 102, Arlington, VA, 22209, USA. vivianz@vt.edu. FAU - Hernandez, Ivan AU - Hernandez I AD - Department of Psychology, Virginia Tech, Blacksburg, VA, USA. FAU - Hauenstein, Neil M A AU - Hauenstein NMA AD - Department of Psychology, Virginia Tech, Blacksburg, VA, USA. FAU - Foti, Roseanne J AU - Foti RJ AD - Department of Psychology, Virginia Tech, Blacksburg, VA, USA. FAU - Parker, Sarah H AU - Parker SH AD - Department of Psychology, Virginia Tech, Blacksburg, VA, USA. AD - Department of Health Systems and Implementation Science, Virginia Tech Carilion School of Medicine, Roanoke, VA, USA. LA - eng PT - Journal Article DEP - 20250205 PL - England TA - BMC Surg JT - BMC surgery JID - 100968567 SB - IM MH - Humans MH - *Operating Rooms/organization & administration MH - *Workflow MH - *Patient Care Team/organization & administration MH - *Patient Safety MH - *Attitude of Health Personnel MH - *Cardiac Surgical Procedures MH - Female MH - Male MH - Surveys and Questionnaires PMC - PMC11796080 OTO - NOTNLM OT - Surgery OT - Teams OT - Teamwork OT - Time-out OT - Workflow COIS- Declarations. Ethics approval and consent to participate: This study was approved through the Virginia Tech Institutional Review Board and the Carilion Clinic Institutional Review Board (Carilion Clinic IRB-19-620). The need for consent to participate in this study was waived by the IRB. The research carried out in this study adhered to the Declaration of Helsinki. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2025/02/06 00:21 MHDA- 2025/02/06 06:20 PMCR- 2025/02/05 CRDT- 2025/02/05 23:48 PHST- 2024/05/23 00:00 [received] PHST- 2025/01/24 00:00 [accepted] PHST- 2025/02/06 06:20 [medline] PHST- 2025/02/06 00:21 [pubmed] PHST- 2025/02/05 23:48 [entrez] PHST- 2025/02/05 00:00 [pmc-release] AID - 10.1186/s12893-025-02789-w [pii] AID - 2789 [pii] AID - 10.1186/s12893-025-02789-w [doi] PST - epublish SO - BMC Surg. 2025 Feb 5;25(1):55. doi: 10.1186/s12893-025-02789-w. PMID- 39909577 OWN - NLM STAT- MEDLINE DCOM- 20250604 LR - 20250604 IS - 1535-5675 (Electronic) IS - 0091-4916 (Linking) VI - 53 IP - 2 DP - 2025 Jun 4 TI - Assessment of Cardiac Sarcoidosis with PET/CT. PG - 123-129 LID - 10.2967/jnmt.124.268142 [doi] AB - (18)F-FDG PET with CT is an important advanced imaging modality used to assess patients with suspected or known cardiac sarcoidosis (CS). (18)F-FDG PET is indicated for CS work-up in patients with extra-CS and abnormal screening results for cardiac involvement, patients under 60 y old presenting with unexplained high-grade atrioventricular heart block, and patients with suspected CS and idiopathic ventricular arrhythmias. In patients with established CS, serial (18)F-FDG PET can be used to assess response to immunosuppressive therapy and long-term surveillance for reactivation of myocardial inflammation in patients with low-grade or quiescent disease. Patient preparation before (18)F-FDG PET scanning is key in ensuring adequate suppression of physiologic myocardial (18)F-FDG uptake, to maximize the power of the test to detect pathology. Inadequate dietary preparation can cause diffuse or focal-on-diffuse (18)F-FDG uptake in the absence of active inflammation. It is important to assess resting myocardial perfusion, typically with (82)Rb cardiac PET. Several different patterns of abnormalities have been reported in patients with CS, including normal myocardial perfusion with focal or patchy (18)F-FDG uptake suggesting myocardial inflammation without scarring; the presence of a myocardial perfusion defect with abnormal (18)F-FDG uptake suggesting myocardial scarring with inflammation; and the presence of a myocardial perfusion defect without (18)F-FDG uptake indicating myocardial scarring without inflammation. Prognostically, the presence of myocardial perfusion defects and abnormal (18)F-FDG uptake has been shown to be an independent predictor of death or ventricular arrythmias. A high myocardial SUV(max) in the left and right ventricles has been shown to be an independent predictor of adverse clinical outcomes. Although the diagnostic performance of (18)F-FDG PET has been studied, the reference standard for CS tended to rely on clinical criteria, which may be less sensitive than (18)F-FDG PET at detecting CS. Therefore, the diagnosis of CS should rely on a multidisciplinary team approach involving multimodality advanced imaging, including echocardiography, cardiovascular MR, and (18)F-FDG PET. CI - (c) 2025 by the Society of Nuclear Medicine and Molecular Imaging. FAU - Liu, Alexander AU - Liu A AD - Royal Brompton Hospital, London, United Kingdom. FAU - Munemo, Lionel T AU - Munemo LT AD - Royal Brompton Hospital, London, United Kingdom. FAU - Martins, Nuno AU - Martins N AD - Royal Brompton Hospital, London, United Kingdom. FAU - Kouranos, Vasileios AU - Kouranos V AD - Royal Brompton Hospital, London, United Kingdom. FAU - Wells, Athol U AU - Wells AU AD - Royal Brompton Hospital, London, United Kingdom. FAU - Sharma, Rakesh K AU - Sharma RK AD - Royal Brompton Hospital, London, United Kingdom. FAU - Wechalekar, Kshama AU - Wechalekar K AD - Royal Brompton Hospital, London, United Kingdom k.wechalekar@rbht.nhs.uk. LA - eng PT - Journal Article PT - Review DEP - 20250604 PL - United States TA - J Nucl Med Technol JT - Journal of nuclear medicine technology JID - 0430303 RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18) SB - IM MH - Humans MH - *Sarcoidosis/diagnostic imaging MH - *Positron Emission Tomography Computed Tomography/methods MH - *Cardiomyopathies/diagnostic imaging MH - Fluorodeoxyglucose F18 OTO - NOTNLM OT - FDG OT - PET OT - PET/CT OT - cardiac OT - cardiology OT - sarcoidosis EDAT- 2025/02/06 00:21 MHDA- 2025/06/05 00:28 CRDT- 2025/02/05 20:53 PHST- 2024/09/16 00:00 [received] PHST- 2024/10/31 00:00 [accepted] PHST- 2025/06/05 00:28 [medline] PHST- 2025/02/06 00:21 [pubmed] PHST- 2025/02/05 20:53 [entrez] AID - jnmt.124.268142 [pii] AID - 10.2967/jnmt.124.268142 [doi] PST - epublish SO - J Nucl Med Technol. 2025 Jun 4;53(2):123-129. doi: 10.2967/jnmt.124.268142. PMID- 42575669 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260810 LR - 20260810 IS - 1558-2264 (Electronic) IS - 0733-8651 (Linking) VI - 43 IP - 1S DP - 2025 Feb TI - Radiation Therapy-Induced Valvular Heart Disease: A Comprehensive Review with a Multi-Modality Imaging and Multidisciplinary Approach. PG - e1-e13 LID - S0733-8651(26)00037-8 [pii] LID - 10.1016/j.ccl.2026.04.005 [doi] AB - The increasing number of cancer survivors has highlighted the long-term cardiovascular implications of cancer treatment. Despite improvements in thoracic radiation therapy (RT) and cardiac sparing techniques, associated cardiovascular disease, most notably valvular heart disease (VHD), poses a significant challenge for cancer survivors. This systematic review examines the pathophysiology, prevalence, diagnosis, and treatment of VHD in cancer patients, with a focus on RT-related VHD, emphasizing the need for active surveillance and multidisciplinary care. The incidence of VHD increases over time post-radiation exposure. Valve regurgitation is more common than stenosis, with the aortic valve being most frequently affected. CI - Copyright (c) 2026 Elsevier Inc. All rights reserved. FAU - Alkhatib, Deya A AU - Alkhatib DA AD - Division of Cardiovascular Medicine, Medical College of Georgia, Augusta University, Augusta, GA, USA. Electronic address: dalkhatib@augusta.edu. FAU - Akintoye, Emmanuel AU - Akintoye E AD - Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, CT, USA. FAU - Khattab, Mohamad AU - Khattab M AD - Saint Francis Heart and Vascular Institute, Tulsa, OK, USA. FAU - Reinhardt, Samuel W AU - Reinhardt SW AD - Division of Cardiovascular Medicine, University of Chicago, Chicago, IL, USA. FAU - Baldassarre, Lauren A AU - Baldassarre LA AD - Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, CT, USA. LA - eng PT - Journal Article PT - Review DEP - 20260612 PL - Netherlands TA - Cardiol Clin JT - Cardiology clinics JID - 8300331 SB - IM OTO - NOTNLM OT - Aortic stenosis OT - Cancer OT - Cancer-related valvular disease OT - Mitral regurgitation OT - Radiation cardiotoxicity OT - Radiation therapy OT - Radiation-related valvular disease OT - Valvular heart disease EDAT- 2025/02/01 00:00 MHDA- 2025/02/01 00:01 CRDT- 2026/08/10 20:55 PHST- 2025/02/01 00:01 [medline] PHST- 2025/02/01 00:00 [pubmed] PHST- 2026/08/10 20:55 [entrez] AID - S0733-8651(26)00037-8 [pii] AID - 10.1016/j.ccl.2026.04.005 [doi] PST - ppublish SO - Cardiol Clin. 2025 Feb;43(1S):e1-e13. doi: 10.1016/j.ccl.2026.04.005. Epub 2026 Jun 12. PMID- 39890043 OWN - NLM STAT- MEDLINE DCOM- 20250504 LR - 20250525 IS - 1535-6280 (Electronic) IS - 0146-2806 (Linking) VI - 50 IP - 4 DP - 2025 Apr TI - Practical guidance for management of atrial fibrillation in sports cardiology. PG - 102995 LID - S0146-2806(25)00018-0 [pii] LID - 10.1016/j.cpcardiol.2025.102995 [doi] AB - IMPORTANCE: Atrial fibrillation (AF), the most prevalent sustained arrhythmia, portends higher risk of cardiovascular morbidity and mortality, and is associated with quantifiable impairment in quality of life. While physical activity is widely recognized for its cardiovascular benefits, recent evidence challenges its role in the development of AF. OBSERVATIONS: Emerging data suggest a U-shaped relationship between physical activity and AF risk. Mild to moderate exercise appears protective, whereas prolonged, high-intensity activity is associated with an increased risk, possibly driven by cardiac remodeling, autonomic alterations, and atrial substrate changes typical of the so-called athlete's heart. This relationship is further modulated by other factors, including genetic predisposition, acquired cardiac conditions, and stimulant use. With the growing participation of aging populations in sports, the clinical management of AF in athletes presents unique challenges. Pharmacological strategies for rhythm and rate control may conflict with performance goals, and the use of anticoagulants must be carefully balanced against the risk of traumatic bleeding in contact sports. Recent evidence supports strategies such as short-term anticoagulant withdrawal to mitigate hemorrhagic risk while maintaining thromboembolic protection. A personalized approach, incorporating shared decision-making, is essential, particularly for elite athletes. CONCLUSIONS AND RELEVANCE: While regular physical activity generally confers cardiovascular benefits, prolonged intense exercise bouts may paradoxically increase the risk of AF. The evaluation and management of AF in athletes require a tailored, multidisciplinary approach that accounts for the distinct needs of this population. CI - Copyright (c) 2025 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Palermi, Andrea AU - Palermi A AD - Department of Neuroscience, Imaging and Clinical Sciences, "G. d'Annunzio" University of Chieti-Pescara, Chieti 66100, Italy. FAU - Molinari, Lorenzo Vilhelm AU - Molinari LV AD - Department of Neuroscience, Imaging and Clinical Sciences, "G. d'Annunzio" University of Chieti-Pescara, Chieti 66100, Italy. FAU - Ricci, Fabrizio AU - Ricci F AD - Department of Neuroscience, Imaging and Clinical Sciences, "G. d'Annunzio" University of Chieti-Pescara, Chieti 66100, Italy; Heart Department, SS. Annunziata Hospital, University Cardiology Division, Chieti, Italy; Institute for Advanced Biomedical Technologies, G. D'Annunzio University of Chieti-Pescara, Chieti 66100, Italy; Department of Clinical Sciences, Lund University, Jan Waldenstroms gata 35, Malmo 214 28, Sweden. FAU - Gallina, Sabina AU - Gallina S AD - Department of Neuroscience, Imaging and Clinical Sciences, "G. d'Annunzio" University of Chieti-Pescara, Chieti 66100, Italy; Heart Department, SS. Annunziata Hospital, University Cardiology Division, Chieti, Italy. FAU - Renda, Giulia AU - Renda G AD - Department of Neuroscience, Imaging and Clinical Sciences, "G. d'Annunzio" University of Chieti-Pescara, Chieti 66100, Italy; Heart Department, SS. Annunziata Hospital, University Cardiology Division, Chieti, Italy. Electronic address: giulia.renda@unich.it. LA - eng PT - Journal Article PT - Review DEP - 20250129 PL - Netherlands TA - Curr Probl Cardiol JT - Current problems in cardiology JID - 7701802 RN - 0 (Anticoagulants) SB - IM MH - Humans MH - *Atrial Fibrillation/therapy/physiopathology/diagnosis MH - *Sports Medicine/methods MH - Athletes MH - *Practice Guidelines as Topic MH - Anticoagulants/therapeutic use MH - Exercise/physiology MH - Disease Management MH - *Sports MH - Risk Factors OTO - NOTNLM OT - Athletes OT - Atrial fibrillation OT - Oral anticoagulants OT - Physical activity OT - Sport OT - Thromboembolic risk COIS- Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Giulia Renda reports a relationship with Bayer, BMS- Janssen, Boehringer Ingelheim, Daiichi Sankyo that includes: funding grants and speaking and lecture fees. The other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/02/01 20:44 MHDA- 2025/03/06 05:05 CRDT- 2025/01/31 19:18 PHST- 2025/01/17 00:00 [received] PHST- 2025/01/28 00:00 [accepted] PHST- 2025/03/06 05:05 [medline] PHST- 2025/02/01 20:44 [pubmed] PHST- 2025/01/31 19:18 [entrez] AID - S0146-2806(25)00018-0 [pii] AID - 10.1016/j.cpcardiol.2025.102995 [doi] PST - ppublish SO - Curr Probl Cardiol. 2025 Apr;50(4):102995. doi: 10.1016/j.cpcardiol.2025.102995. Epub 2025 Jan 29. PMID- 39885109 OWN - NLM STAT- MEDLINE DCOM- 20250504 LR - 20261010 IS - 1534-6277 (Electronic) IS - 1534-6277 (Linking) VI - 26 IP - 2 DP - 2025 Feb TI - Advancements in Diagnosis and Treatment of Cardiac Sarcomas: A Comprehensive Review. PG - 103-127 LID - 10.1007/s11864-024-01287-0 [doi] AB - Cardiac sarcomas are rare, aggressive malignancies originating from various cardiac cell types, presenting significant challenges in both diagnosis and treatment. This comprehensive review explores recent advancements in diagnosis and treatment of cardiac angiosarcoma, fibrosarcoma, leiomyosarcoma, and rhabdomyosarcoma. And we briefly discuss the exceedingly rare occurrence of cardiac osteosarcoma and present our perspectives on its treatment. Development of these tumors is influenced by genetic mutations, environmental factors, and chromosomal abnormalities, necessitating a multidisciplinary approach for accurate diagnosis and management. Advanced imaging techniques, biomarkers, and immunohistochemical analysis assist in confirming the diagnosis and guiding treatment decisions. Surgical resection, adjuvant therapies, and personalized treatment strategies based on genetic profiling offer promising avenues for improving patient outcomes. Emerging therapeutic approaches, such as targeted therapies and immunotherapies, have shown promising progress in recent years. Despite these advancements, the prognosis for patient with cardiac sarcomas remains poor, highlighting the urgent need for continued research to refine treatment methods and enhance long-term survival outcomes. Ongoing efforts and clinical trials are essential for advancing the management of these rare and aggressive tumors, ultimately improving quality of life for affected patients. CI - (c) 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Wang, Xuezhe AU - Wang X AD - Department of Cardiology, The Affiliated Hospital of Qingdao University, Qingdao, China. AD - School of Basic Medicine, Qingdao University, Qingdao, Shandong, China. FAU - Luan, Xinchi AU - Luan X AD - Department of Oncology, Key Laboratory of Cancer Molecular and Translational Research, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China. FAU - Yin, Wenwen AU - Yin W AD - Department of Pulmonology, The Sixth Affiliated Hospital of Qingdao University, Weihai, Shandong, China. FAU - Wang, Yilin AU - Wang Y AD - School of Basic Medicine, Qingdao University, Qingdao, Shandong, China. FAU - Li, Xiaoxuan AU - Li X AD - Department of Oncology, Key Laboratory of Cancer Molecular and Translational Research, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China. FAU - Chen, Ruolan AU - Chen R AD - Department of Cardiology, The Affiliated Hospital of Qingdao University, Qingdao, China. FAU - Zhang, Guoliang AU - Zhang G AD - Department of Cardiology, The Affiliated Hospital of Qingdao University, Qingdao, China. FAU - Zhao, Ruizhe AU - Zhao R AD - School of Basic Medicine, Qingdao University, Qingdao, Shandong, China. FAU - Dong, Xue AU - Dong X AD - School of Basic Medicine, Qingdao University, Qingdao, Shandong, China. FAU - Zhang, Zhishang AU - Zhang Z AD - Department of Joint Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China. FAU - Fan, Yuchen AU - Fan Y AD - School of Basic Medicine, Qingdao University, Qingdao, Shandong, China. FAU - Li, Zhaodong AU - Li Z AD - School of Basic Medicine, Qingdao University, Qingdao, Shandong, China. FAU - Chu, Xianming AU - Chu X AD - Department of Cardiology, The Affiliated Hospital of Qingdao University, Qingdao, China. chuxianming@qdu.edu.cn. FAU - Wang, Shuang AU - Wang S AD - School of Basic Medicine, Qingdao University, Qingdao, Shandong, China. wangshuang85@qdu.edu.cn. LA - eng PT - Journal Article PT - Review DEP - 20250131 PL - United States TA - Curr Treat Options Oncol JT - Current treatment options in oncology JID - 100900946 RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Heart Neoplasms/diagnosis/therapy/etiology MH - *Sarcoma/diagnosis/therapy/etiology MH - Disease Management MH - Combined Modality Therapy MH - Prognosis MH - Biomarkers, Tumor MH - Treatment Outcome OTO - NOTNLM OT - Cardiac sarcomas OT - Diagnosis OT - Etiology OT - Prognostic Effect OT - Treatment COIS- Declarations. Ethics Approval and Consent to Participate: Not applicable. Human and Animal Rights and Informed Consent: This article does not contain any studies with human or animal subjects performed by any of the authors. Consent for Publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2025/01/31 00:21 MHDA- 2025/02/19 00:15 CRDT- 2025/01/30 23:18 PHST- 2024/12/08 00:00 [accepted] PHST- 2025/02/19 00:15 [medline] PHST- 2025/01/31 00:21 [pubmed] PHST- 2025/01/30 23:18 [entrez] AID - 10.1007/s11864-024-01287-0 [pii] AID - 10.1007/s11864-024-01287-0 [doi] PST - ppublish SO - Curr Treat Options Oncol. 2025 Feb;26(2):103-127. doi: 10.1007/s11864-024-01287-0. Epub 2025 Jan 31. PMID- 39880469 OWN - NLM STAT- MEDLINE DCOM- 20250523 LR - 20260910 IS - 1468-201X (Electronic) IS - 1355-6037 (Linking) VI - 111 IP - 12 DP - 2025 May 23 TI - Risk stratification and exercise recommendations in cardiomyopathies and channelopathies: a practical guide for the multidisciplinary team. PG - 583-592 LID - 10.1136/heartjnl-2024-324318 [doi] AB - Exercise offers a plethora of health benefits. However, certain genetic and acquired diseases such as cardiomyopathies and channelopathies are associated with sudden cardiac death during exercise. Several factors complicate exercise prescription in individuals living with these conditions. The lack of high-quality evidence supporting exercise recommendations, variation in the clinical phenotypes within the same condition and sparse physician education around exercise prescription all leads to a reluctance to provide specific guidance on how to engage in physical activity.This article aims to summarise the latest evidence underpinning risk stratification and current guideline recommendations for physical activity in individuals with cardiomyopathies and channelopathies wishing to engage in exercise. It also aims to provide a basic practical approach to exercise prescription for health professionals involved in the care of these patients. This approach may then serve as a foundation that can be easily personalised. Since risk can never be completely eliminated, all decisions regarding exercise participation should be taken following shared dialogue between the physician, patient and wider stake holders where appropriate. CI - (c) Author(s) (or their employer(s)) 2025. No commercial re-use. See rights and permissions. Published by BMJ Group. FAU - Basu, Joyee AU - Basu J AUID- ORCID: 0000-0003-1339-665X AD - Department of Cardiology, Buckinghamshire Healthcare NHS Trust, High Wycombe, UK joyee.basu2@nhs.net. AD - Cardiovascular Clinical Academic Group and Cardiology Research Centre, St George's University of London, London, UK. FAU - MacLachlan, Hamish AU - MacLachlan H AD - Department of Cardiology, St Bartholomew's Hospital, London, UK. FAU - Bhatia, Raghav AU - Bhatia R AUID- ORCID: 0000-0002-3604-7957 AD - Cardiovascular Clinical Academic Group and Cardiology Research Centre, St George's University of London, London, UK. AD - Department of Cardiology, Hull University Teaching Hospitals NHS Trust, Hull, UK. FAU - Alexander, Helen AU - Alexander H AD - Nuffield Health, London, UK. FAU - Cooper, Robert AU - Cooper R AD - Department of Cardiology, Liverpool Heart and Chest Hospital, Liverpool, UK. AD - Research Institute for Sports and Exercise Science, Liverpool John Moores University, Liverpool, UK. FAU - Sheikh, Nabeel AU - Sheikh N AD - Department of Cardiology, Guy's and St Thomas' Hospitals NHS Trust, London, UK. AD - King's College London, London, UK. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20250523 PL - England TA - Heart JT - Heart (British Cardiac Society) JID - 9602087 SB - IM MH - Humans MH - *Channelopathies/physiopathology/therapy/diagnosis/complications MH - *Cardiomyopathies/physiopathology/therapy/diagnosis/complications MH - Risk Assessment MH - *Death, Sudden, Cardiac/prevention & control/etiology MH - *Exercise Therapy/methods MH - *Patient Care Team MH - *Exercise/physiology MH - Practice Guidelines as Topic MH - Risk Factors OTO - NOTNLM OT - arrhythmias, cardiac OT - cardiac rehabilitation OT - cardiomyopathies OT - risk assessment COIS- Competing interests: None declared. EDAT- 2025/01/30 00:19 MHDA- 2025/05/24 00:45 CRDT- 2025/01/29 20:53 PHST- 2025/05/24 00:45 [medline] PHST- 2025/01/30 00:19 [pubmed] PHST- 2025/01/29 20:53 [entrez] AID - heartjnl-2024-324318 [pii] AID - 10.1136/heartjnl-2024-324318 [doi] PST - epublish SO - Heart. 2025 May 23;111(12):583-592. doi: 10.1136/heartjnl-2024-324318. PMID- 39878665 OWN - NLM STAT- In-Process LR - 20250129 IS - 2327-2228 (Electronic) VI - 108 IP - 2 DP - 2025 Feb 3 TI - Structural Heart Interventional Cardiology Planning and Procedures - The Heart Team Approach. PG - 56-62 FAU - Kadiyala, Vishnu AU - Kadiyala V AD - Alpert Medical School of Brown University, Department of Medicine, Division of Cardiology, Rhode Island Hospital. FAU - Ding, Eric AU - Ding E AD - Department of Medicine, Rhode Island Hospital, Alpert Medical School of Brown University. FAU - Jedlinski, Rafael AU - Jedlinski R AD - Department of Medicine, Rhode Island Hospital, Alpert Medical School of Brown University. FAU - Netto, Tiffany AU - Netto T AD - Alpert Medical School of Brown University. FAU - Agarwal, Saurabh AU - Agarwal S AD - Department of Radiology, Rhode Island Hospital, Alpert Medical School of Brown University. FAU - Atalay, Michael AU - Atalay M AD - Department of Radiology, Rhode Island Hospital, Alpert Medical School of Brown University. FAU - Patel, Yash AU - Patel Y AD - Alpert Medical School of Brown University, Department of Medicine, Division of Cardiology, Rhode Island Hospital. FAU - Saad, Marwan AU - Saad M AD - Alpert Medical School of Brown University, Department of Medicine, Division of Cardiology, Rhode Island Hospital. FAU - Abbott, Brian G AU - Abbott BG AD - Alpert Medical School of Brown University, Department of Medicine, Division of Cardiology, Rhode Island Hospital. FAU - Hulten, Edward AU - Hulten E AD - Alpert Medical School of Brown University, Department of Medicine, Division of Cardiology, Rhode Island Hospital. LA - eng PT - Journal Article DEP - 20250203 PL - United States TA - R I Med J (2013) JT - Rhode Island medical journal (2013) JID - 101605827 SB - IM OTO - NOTNLM OT - Atrial Septal Defect OT - Cardiology OT - Mitral Regurgitation OT - TAVR OT - Watchman EDAT- 2025/01/29 12:30 MHDA- 2025/01/29 12:30 CRDT- 2025/01/29 10:23 PHST- 2025/01/29 12:30 [medline] PHST- 2025/01/29 12:30 [pubmed] PHST- 2025/01/29 10:23 [entrez] PST - epublish SO - R I Med J (2013). 2025 Feb 3;108(2):56-62. PMID- 39876584 OWN - NLM STAT- MEDLINE DCOM- 20250504 LR - 20250524 IS - 1099-0496 (Electronic) IS - 8755-6863 (Print) IS - 1099-0496 (Linking) VI - 60 IP - 1 DP - 2025 Jan TI - Pulmonary Morbidity in Congenital Diaphragmatic Hernia Survivors Treated at a Non-ECMO Center From 1998 to 2015: A Cross-Sectional Study. PG - e27468 LID - 10.1002/ppul.27468 [doi] LID - e27468 AB - INTRODUCTION: A main feature of CDH is lung hypoplasia and the related presentation of pulmonary hypertension and cardiac dysfunction. Multiple factors influence pulmonary status after CDH: degree of hypoplasia, ventilator-induced injury, altered growth and development of pulmonary structures, reduced diaphragm function and chest wall abnormalities. The evolution of pulmonary sequela in this population is still unclear. We aimed to describe the pulmonary status of our population of CDH-survivors and evaluated on risk factors. METHODS: CDH-survivors (1998-2015) were included and performed lung function tests and chest X-rays. RESULTS: Fifty-one (51/71, 71.8%) participated. Median age was 12.2 (5.5-21.4) years, 28 (54.9%) male, 42 (82.4%) had left-sided hernias, 10 (19.6%) needed patch-repair and median length of stay in hospital was 28.0 (IQR 18.5-61.6) days in Table 1. Spirometry including bronchodilator response (BDR)-test, body plethysmography, and diffusion capacity, were available for 48, 42, and 40 participants. The mean (SD) z-score for FEV1 and FVC was -0.26 (1.70) and -0.28 (1.70). Twenty-one (43.8%) had obstructive patterns and six had positive BDR. TLC mean (SD) z-score was -0.18 (1.10). Four showed restricted/mixed patterns and 13 showed signs of hyperinflation. Increased RV/TLC-ratio and reduced FEV1 was associated with longer time on mechanical ventilation. Diffusion capacity was decreased in three cases. Chest X-ray revealed hernia recurrence (13.9%) and scoliosis (38.9%). CONCLUSION: Mild obstructive impairment and hyperinflation was frequent in our CDH cohort and only a small subset of restrictive disorders were identified. We advocate follow-up by a specialized multidisciplinary team through childhood and into adulthood. CI - (c) 2025 The Author(s). Pediatric Pulmonology published by Wiley Periodicals LLC. FAU - Larsen, Ulla Lei AU - Larsen UL AUID- ORCID: 0000-0002-6986-2907 AD - Research Unit for Department of Anaesthesiology & Intensive Care, Odense University Hospital, Odense, Denmark. AD - Department of Clinical Research, Faculty of Health sciences, University of Southern Denmark, Odense, Denmark. AD - OPEN, Odense Patient Data Explorative Network, Odense University Hospital and Institute of Clinical Research, University of Southern Denmark, Odense, Denmark. FAU - Agertoft, Lone AU - Agertoft L AD - Department of Paediatrics, University Hospital of Southern Denmark, Aabenraa, Denmark. FAU - Herskind, Anne Maria AU - Herskind AM AD - H.C. Andersen Children's Hospital, Odense University Hospital, Odense, Denmark. FAU - Strom, Thomas AU - Strom T AD - Research Unit for Department of Anaesthesiology & Intensive Care, Odense University Hospital, Odense, Denmark. AD - Department of Anaesthesia and Critical Care Medicine, Hospital Sonderjylland, University of Southern Denmark, Odense, Denmark. FAU - Toft, Palle AU - Toft P AD - Research Unit for Department of Anaesthesiology & Intensive Care, Odense University Hospital, Odense, Denmark. AD - Department of Clinical Research, Faculty of Health sciences, University of Southern Denmark, Odense, Denmark. FAU - Halken, Susanne AU - Halken S AD - Department of Clinical Research, Faculty of Health sciences, University of Southern Denmark, Odense, Denmark. AD - H.C. Andersen Children's Hospital, Odense University Hospital, Odense, Denmark. LA - eng GR - This study was supported by The Child Lung Foundation in Denmark (Bornelungefonden); Laege Else Poulsens Mindelegat (grant number 53-A2591); and DASAIMs Research initiative fond (Danske Selskab for Anaestesiologi og Intensiv Medicin). Also, through scholarships from The University of Southern Denmark (Syddansk Universitet) and The Research Council of the region of Southern Denmark (grant number 18/17564)./ PT - Journal Article PL - United States TA - Pediatr Pulmonol JT - Pediatric pulmonology JID - 8510590 SB - IM MH - Humans MH - Male MH - Cross-Sectional Studies MH - *Hernias, Diaphragmatic, Congenital/complications/physiopathology/surgery/therapy MH - Female MH - Child MH - Adolescent MH - Young Adult MH - Child, Preschool MH - Respiratory Function Tests MH - *Lung/physiopathology MH - Survivors MH - Risk Factors MH - *Lung Diseases/etiology/epidemiology/physiopathology MH - Length of Stay PMC - PMC11775427 COIS- The authors declare no conflicts of interest. EDAT- 2025/01/29 06:20 MHDA- 2025/01/29 06:21 PMCR- 2025/01/29 CRDT- 2025/01/29 02:12 PHST- 2024/12/10 00:00 [revised] PHST- 2024/05/30 00:00 [received] PHST- 2024/12/19 00:00 [accepted] PHST- 2025/01/29 06:21 [medline] PHST- 2025/01/29 06:20 [pubmed] PHST- 2025/01/29 02:12 [entrez] PHST- 2025/01/29 00:00 [pmc-release] AID - PPUL27468 [pii] AID - 10.1002/ppul.27468 [doi] PST - ppublish SO - Pediatr Pulmonol. 2025 Jan;60(1):e27468. doi: 10.1002/ppul.27468. PMID- 39875816 OWN - NLM STAT- MEDLINE DCOM- 20250128 LR - 20250611 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 25 IP - 1 DP - 2025 Jan 28 TI - Rationale and design of APOLLO: a personalized rehAbilitation PrOgram in aLLOgeneic bone marrow transplantation. PG - 163 LID - 10.1186/s12885-025-13502-8 [doi] LID - 163 AB - BACKGROUND: Hematopoietic stem cell transplantation (HSCT) is a common therapy for many hematologic malignancies. While advances in transplant practice have improved cancer-specific outcomes, multiple and debilitating long term physical and psychologic effects remain. Patients undergoing allogeneic bone marrow transplantation (allo-BMT) are often critically ill at initial diagnosis and with necessary sequential treatments become increasingly frail and deconditioned. Despite modern treatment regimens and support, cardiovascular disease remains a leading cause of non-relapse mortality among allo-BMT survivors. Well-established multi-disciplinary care models such as cardiac rehabilitation offer holistic care including exercise training, nursing support, physical/occupational therapy, psychosocial support and nutritional education. HSCT patients may be excluded from conventional outpatient physical rehabilitation programs due to prolonged pancytopenia and frequent hospital admissions. In Canada, dedicated cancer-specific rehabilitation programs are available only at major tertiary academic centers. METHODS: The primary aim of this study will evaluate the feasibility and acceptability of a multimodal care navigation (nursing, exercise, nutrition) intervention with content delivery facilitated by a supportive care web-based 'app' extending from diagnosis to 1 year in the allogeneic bone marrow transplant population. Adult patients scheduled for allo-BMT will receive support from exercise specialist, nursing support and dietician expertise alongside a supportive care 'app' with additional in-person or virtual cardiac rehabilitation support. DISCUSSION: To our knowledge, no research team is taking such a holistic, multidisciplinary approach to address the debilitating physiologic and psychological consequences of allo-BMT. We expect the findings to inform the optimal timing and patient preferences to develop studies examining risk-specific, individualized interventions (including exercise, pharmacotherapy, combination treatments) to reduce or prevent symptoms and dysfunction. We expect this innovative program to identify ways to benefit innumerable patients with hematologic and other malignancies. Ultimately, we hope to transform supportive care in hematopoietic stem cell transplantation. TRIAL REGISTRATION: Clinicaltrials.gov ID: NCT05579678. CI - (c) 2025. The Author(s). FAU - Pituskin, Edith AU - Pituskin E AD - Faculty of Nursing, University of Alberta, Edmonton, AB, Canada. pituskin@ualberta.ca. AD - Edmonton Clinic Health Academy (ECHA), University of Alberta, Edmonton, AB, 141, T6G 1C9, Canada. pituskin@ualberta.ca. FAU - Foulkes, Stephen AU - Foulkes S AD - Faculty of Nursing, University of Alberta, Edmonton, AB, Canada. AD - Cardiometabolic Health and Exercise Physiology Lab, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia. FAU - Skow, Rachel J AU - Skow RJ AD - Faculty of Nursing, University of Alberta, Edmonton, AB, Canada. FAU - McMurtry, Thomas AU - McMurtry T AD - Faculty of Nursing, University of Alberta, Edmonton, AB, Canada. FAU - Kruger, Calvin AU - Kruger C AD - Faculty of Nursing, University of Alberta, Edmonton, AB, Canada. AD - Alberta Health Services, Edmonton, AB, Canada. FAU - Bates, Janet E AU - Bates JE AD - Faculty of Nursing, University of Alberta, Edmonton, AB, Canada. FAU - Lamoureux, Daena AU - Lamoureux D AD - Faculty of Nursing, University of Alberta, Edmonton, AB, Canada. FAU - Brandwein, Joseph AU - Brandwein J AD - Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB, Canada. FAU - Lieuw, Elena AU - Lieuw E AD - Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB, Canada. FAU - Wu, Cynthia AU - Wu C AD - Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB, Canada. FAU - Zhu, Nancy AU - Zhu N AD - Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB, Canada. FAU - Wang, Peng AU - Wang P AD - Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB, Canada. FAU - Sawler, Daniel AU - Sawler D AD - Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB, Canada. FAU - Taparia, Minakshi AU - Taparia M AD - Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB, Canada. FAU - Hamilton, Marlene AU - Hamilton M AD - Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB, Canada. FAU - Comfort-Riddle, Tiffany AU - Comfort-Riddle T AD - Alberta Health Services, Edmonton, AB, Canada. FAU - Meyer, Tara AU - Meyer T AD - Alberta Health Services, Edmonton, AB, Canada. FAU - Gyenes, Gabor T AU - Gyenes GT AD - Alberta Health Services, Edmonton, AB, Canada. AD - Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB, Canada. FAU - Paterson, Ian AU - Paterson I AD - University of Ottawa Heart Institute, Ottawa, ON, Canada. FAU - Prado, Carla M AU - Prado CM AD - Department of Agricultural, Food and Nutritional Science, University of Alberta, Edmonton, AB, Canada. FAU - Haykowsky, Mark J AU - Haykowsky MJ AD - Faculty of Nursing, University of Alberta, Edmonton, AB, Canada. FAU - Greiner, Justin G AU - Greiner JG AD - Department of Radiology and Diagnostic Imaging, University of Alberta, Edmonton, AB, Canada. AD - Department of Biomedical Engineering, University of Alberta, Edmonton, AB, Canada. FAU - McNeely, Margaret L AU - McNeely ML AD - Department of Physical Therapy, University of Alberta, Edmonton, AB, Canada. AD - Cancer Care Alberta, Alberta Health Services, Edmonton, AB, Canada. FAU - Tandon, Puneeta AU - Tandon P AD - Department of Medicine, Division of Gastroenterology (Liver Unit), University of Alberta, Edmonton, AB, Canada. FAU - Thompson, Richard B AU - Thompson RB AD - Department of Radiology and Diagnostic Imaging, University of Alberta, Edmonton, AB, Canada. AD - Department of Biomedical Engineering, University of Alberta, Edmonton, AB, Canada. LA - eng SI - ClinicalTrials.gov/NCT05579678 GR - 933631/Leukemia and Lymphoma Society of Canada/ GR - 933631/Canadian Cancer Society/ PT - Journal Article PT - Observational Study DEP - 20250128 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 SB - IM MH - Adult MH - Humans MH - *Bone Marrow Transplantation/rehabilitation/adverse effects/methods MH - *Hematologic Neoplasms/therapy/rehabilitation MH - Hematopoietic Stem Cell Transplantation MH - *Precision Medicine/methods MH - Transplantation, Homologous PMC - PMC11773870 OTO - NOTNLM OT - Allogeneic bone marrow transplant OT - Cardiac rehabilitation OT - Cardiovascular diseases OT - Cardiovascular risk factors OT - Deconditioning OT - MRI OT - Malnutrition OT - Sarcopenia COIS- Declarations. Ethics approval and consent to participate: This study was reviewed and approved by the Health Research Ethics Board of Alberta (HREBA) - Cancer Committee, Ethics ID#: HREBA.CC-22-0164. Written informed consent is provided by all study participants. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2025/01/29 00:20 MHDA- 2025/01/29 00:21 PMCR- 2025/01/28 CRDT- 2025/01/28 23:33 PHST- 2024/03/20 00:00 [received] PHST- 2025/01/13 00:00 [accepted] PHST- 2025/01/29 00:21 [medline] PHST- 2025/01/29 00:20 [pubmed] PHST- 2025/01/28 23:33 [entrez] PHST- 2025/01/28 00:00 [pmc-release] AID - 10.1186/s12885-025-13502-8 [pii] AID - 13502 [pii] AID - 10.1186/s12885-025-13502-8 [doi] PST - epublish SO - BMC Cancer. 2025 Jan 28;25(1):163. doi: 10.1186/s12885-025-13502-8. PMID- 39874243 OWN - NLM STAT- MEDLINE DCOM- 20250329 LR - 20260816 IS - 2047-2412 (Electronic) IS - 2047-2404 (Linking) VI - 26 IP - 4 DP - 2025 Mar 27 TI - The role of multi-modality imaging in multiple valvular heart diseases: a clinical consensus statement of the European Association of Cardiovascular Imaging of the European Society of Cardiology. PG - 593-608 LID - 10.1093/ehjci/jeaf026 [doi] AB - With this document, the European Association of Cardiovascular Imaging provides an Expert Consensus on the role of multi-modality imaging (MMI) in the management of patients with multiple valvular heart disease (MVD). Emphasis is given to the use of MMI to unravel the diagnostic challenges that characterize these patients and to improve risk stratification. Complementing the last European Society of Cardiology and European Association of Cardio-Thoracic Surgery guidelines on valvular heart disease, this Expert Consensus document also outlines how MMI assessment should form an integral part of the multi-disciplinary heart team discussion for patients with MVD to help with complex decision-making regarding the choice and timing of treatment. CI - (c) The Author(s) 2025. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com. FAU - Donal, Erwan AU - Donal E AUID- ORCID: 0000-0003-2677-3389 AD - Department of Cardiology, University of Rennes, CHU Rennes, Inserm, LTSI-UMR 1099, Pontchaillou Hospital-CHU Rennes, F-35033 Rennes, France. FAU - Unger, Philippe AU - Unger P AUID- ORCID: 0000-0001-6154-1546 AD - Department of Cardiology, University Hospital Brussels, Laarbeeklaan 101, Jette, Brussels 1090, Belgium. AD - Department of Cardiology, Centre Hospitalier Universitaire Saint-Pierre, Universite libre de Bruxelles, 322 rue Haute, Brussels 1000, Belgium. FAU - Coisne, Augustin AU - Coisne A AUID- ORCID: 0000-0002-1662-7874 AD - University of Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, F-59000 Lille, France. FAU - Pibarot, Philippe AU - Pibarot P AUID- ORCID: 0000-0002-3607-279X AD - Institut Universitaire de Cardiologie et de Pneumologie, Universite Laval, Quebec, Canada. FAU - Magne, Julien AU - Magne J AUID- ORCID: 0000-0001-5290-531X AD - INSERM, Universite de Limoges, CHU de Limoges, EpiMaCT-Epidemiology of Chronic Diseases in Tropical Zone, OmegaHealth, Limoges, France. AD - Center of Clinical and Research Data, CHU de Limoges, 87000 Limoges, France. FAU - Sitges, Marta AU - Sitges M AUID- ORCID: 0000-0003-1300-4732 AD - Cardiovascular Institute, Hospital Clinic, Universitat de Barcelona, Barcelona, Spain. AD - Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. AD - CIBER, Centro de Investigacion Biomedica en Red, Barcelona, Spain. FAU - Habib, Gilbert AU - Habib G AUID- ORCID: 0000-0003-3899-9983 AD - Cardiology Department, Hopital La Timone, Marseille, France. FAU - Clavel, Marie-Annick AU - Clavel MA AUID- ORCID: 0000-0002-8924-740X AD - Zentrum fur Kardiologie, Johannes Gutenberg-Universitat, Mainz, Germany. FAU - von Bardeleben, Ralph Stephan AU - von Bardeleben RS AUID- ORCID: 0000-0002-1356-0037 AD - Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, UK. FAU - Plein, Sven AU - Plein S AUID- ORCID: 0000-0002-0997-4384 AD - Department of Cardiology, Universite Paris Cite, Hopital Lariboisiere, Assistance Publique-Hopitaux de Paris, Inserm U-942, MIRACL.ai, Paris, France. FAU - Pezel, Theo AU - Pezel T AUID- ORCID: 0000-0002-6716-8444 AD - BHF Centre for Cardiovascular Science, University of Edinburgh, Edinburgh. FAU - Dweck, Marc R AU - Dweck MR AUID- ORCID: 0000-0001-9847-5917 AD - Cardiology Department, University Hospital Ramon y Cajal, Madrid, Spain. FAU - Zamorano, Pepe L AU - Zamorano PL AUID- ORCID: 0000-0002-0487-1749 AD - Cardiology Department, University Hospital Ramon y Cajal, Madrid, Spain. AD - Instituto Ramon y Cajal de Investigacion Sanitaria (IRYCIS), Madrid, Spain. AD - CIBERCV, Instituto de Salud Carlos III (ISCIII), Spain. FAU - Bertrand, Philippe B AU - Bertrand PB AUID- ORCID: 0000-0003-2412-8503 AD - Department of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium. FAU - Dahl, Jordi S AU - Dahl JS AUID- ORCID: 0000-0002-8345-204X AD - Department of Cardiology, Odense University Hospital, Odense, Denmark. FAU - Popescu, Bogdan A AU - Popescu BA AUID- ORCID: 0000-0003-3654-4096 AD - University of Medicine and Pharmacy 'Carol Davila'-Euroecolab, Emergency Institute for Cardiovascular Diseases 'Prof. Dr. C.C. Iliescu', Bucharest, Romania. FAU - Cosyns, Bernard AU - Cosyns B AUID- ORCID: 0000-0001-9419-8019 AD - Department of Cardiology, University Hospital Brussels, Laarbeeklaan 101, Jette, Brussels 1090, Belgium. FAU - Ajmone-Marsan, Nina AU - Ajmone-Marsan N AUID- ORCID: 0000-0001-7208-5769 AD - Department of Cardiology, Leiden University Medical Center, Albinusdreef 2, 2300RC Leiden, The Netherlands. FAU - Bohbot, Yohann AU - Bohbot Y FAU - Di Salvo, Giovanni AU - Di Salvo G FAU - Keenan, Niall AU - Keenan N FAU - Petrescu, Aniela Monica AU - Petrescu AM FAU - Stankovic, Ivan AU - Stankovic I LA - eng PT - Consensus Statement PT - Journal Article PL - England TA - Eur Heart J Cardiovasc Imaging JT - European heart journal. Cardiovascular Imaging JID - 101573788 SB - IM EIN - Eur Heart J Cardiovasc Imaging. 2025 Mar 27;26(4):609. doi: 10.1093/ehjci/jeaf075. PMID: 40037718 MH - Female MH - Humans MH - Male MH - Cardiology MH - Europe MH - *Heart Valve Diseases/diagnostic imaging MH - Magnetic Resonance Imaging, Cine MH - *Multimodal Imaging/methods MH - Risk Assessment MH - Societies, Medical MH - Review Literature as Topic OTO - NOTNLM OT - heart team OT - multi-modality imaging OT - multivalvular disease OT - myocardial damage COIS- Conflict of interest: E.D. declares some activities leading to fees from GE Healthcare, Pfizer, Abbott Vascular, Astra Zeneca, and Alnylam General Electric Healthcare is providing research facilities to Rennes University Hospital. E.D. is a member of the European Heart Journal Cardiovascular Imaging Editorial Board. N.A. Marsan declares speaker fees from GE Healthcare, Philips Ultrasound, Pfizer, Abbott Vascular, and Omron; research grants from Alnylam, Pfizer, and Pie Medical imaging. M.-A.C. declares core laboratory contract with Edwards Lifesciences and Research grants with Edwards Lifesciences, Medtronic, and Pi-Cardia without direct compensation and is a member of the European Heart Journal Cardiovascular Imaging Editorial Board. S.P. declares speaker fees with Circle Cardiovascular Imaging and Philips. P.U. declares consultancy fees from Abbott. J.D. declares speaker fees with Edwards Lifesciences. B.A.P. declares speaker fees and research equipment from GE Healthcare and FUJI. EDAT- 2025/01/28 18:21 MHDA- 2025/03/29 16:14 CRDT- 2025/01/28 13:32 PHST- 2024/11/09 00:00 [received] PHST- 2024/12/28 00:00 [revised] PHST- 2024/12/31 00:00 [accepted] PHST- 2025/03/29 16:14 [medline] PHST- 2025/01/28 18:21 [pubmed] PHST- 2025/01/28 13:32 [entrez] AID - 7985671 [pii] AID - 10.1093/ehjci/jeaf026 [doi] PST - ppublish SO - Eur Heart J Cardiovasc Imaging. 2025 Mar 27;26(4):593-608. doi: 10.1093/ehjci/jeaf026. PMID- 39872596 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260923 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 16 IP - 12 DP - 2024 Dec TI - The Pathophysiology and Vascular Complications of Diabetes in Chronic Kidney Disease: A Comprehensive Review. PG - e76498 LID - 10.7759/cureus.76498 [doi] LID - e76498 AB - The coexistence of type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) represents a significant global health challenge, contributing to substantial morbidity, mortality, and economic burden. T2DM is the leading cause of CKD, and CKD exacerbates diabetes-related complications, creating a bidirectional relationship driven by oxidative stress, inflammation, and endothelial dysfunction. Diabetic kidney disease (DKD), affecting some individuals with T2DM, accelerates progression to end-stage renal disease (ESRD) and increases cardiovascular mortality. Microvascular complications, including nephropathy, retinopathy, and neuropathy, and macrovascular complications, such as coronary artery disease and stroke, are prevalent in this population, further diminishing the quality of life. The pathophysiology underlying these complications is multifaceted. Hyperglycemia-induced oxidative stress and inflammation drive kidney damage and systemic vascular complications, while CKD alters glucose metabolism and antidiabetic drug pharmacokinetics. Endothelial dysfunction exacerbates vascular complications through impaired nitric oxide production and heightened thrombogenicity. Emerging insights into genetic and epigenetic mechanisms, including DNA methylation and mitochondrial dysfunction, have highlighted new therapeutic targets. Management strategies emphasize early screening, glycemic control, and a multidisciplinary approach integrating lifestyle modifications, pharmacotherapy, and patient education. Interventions targeting oxidative stress, inflammation, and endothelial dysfunction have shown promise in mitigating disease progression. Current evidence on the interconnected mechanisms driving DKD and associated vascular complications highlights the critical need for proactive, patient-centered management and further research into innovative diagnostic and therapeutic approaches to address this global health challenge. CI - Copyright (c) 2024, Hauwanga et al. FAU - Hauwanga, Wilhelmina N AU - Hauwanga WN AD - Cardiology, Gaffree and Guinle University Hospital, Federal University of the State of Rio de Janeiro, Rio de Janeiro, BRA. FAU - Abdalhamed, Tibyan Y AU - Abdalhamed TY AD - Neurosurgery, Federal Fluminense University, Niteroi, BRA. FAU - Ezike, Lynda A AU - Ezike LA AD - General Medicine, Garki Hospital, Garki, NGA. FAU - Chukwulebe, Ifeoma S AU - Chukwulebe IS AD - Internal Medicine, University of Nigeria, Enugu, NGA. FAU - Ko Oo, Aung AU - Ko Oo A AD - Medicine, Monash University, Melbourne, AUS. FAU - Wilfred, Amal AU - Wilfred A AD - Neurosurgery, Federal Fluminense University, Niteroi, BRA. FAU - Khan, Abdul Rahman Anuz Khan A AU - Khan ARAKA AD - Neurosurgery, Federal Fluminense University, Niteroi, BRA. FAU - Chukwuwike, Johnny AU - Chukwuwike J AD - Neurosurgery, Federal Fluminense University, Niteroi, BRA. FAU - Florial, Edisond AU - Florial E AD - General Medicine, Hopital Sainte Therese de Hinche, Port-au-Prince, HTI. FAU - Lawan, Habeebah AU - Lawan H AD - Neurosurgery, Federal Fluminense University, Niteroi, BRA. FAU - Felix, Asaju AU - Felix A AD - General Practice, Dorset County Hospital, Dorchester, GBR. FAU - McBenedict, Billy AU - McBenedict B AD - Neurosurgery, Federal Fluminense University, Niteroi, BRA. LA - eng PT - Journal Article PT - Review DEP - 20241228 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC11770394 OTO - NOTNLM OT - chronic kidney disease OT - diabetic nephropathy OT - inflammation OT - oxidative stress OT - type 2 diabetes OT - vascular complications COIS- Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. EDAT- 2025/01/28 11:26 MHDA- 2025/01/28 11:27 PMCR- 2024/12/28 CRDT- 2025/01/28 05:04 PHST- 2024/12/10 00:00 [received] PHST- 2024/12/27 00:00 [accepted] PHST- 2025/01/28 11:27 [medline] PHST- 2025/01/28 11:26 [pubmed] PHST- 2025/01/28 05:04 [entrez] PHST- 2024/12/28 00:00 [pmc-release] AID - 10.7759/cureus.76498 [doi] PST - epublish SO - Cureus. 2024 Dec 28;16(12):e76498. doi: 10.7759/cureus.76498. eCollection 2024 Dec. PMID- 39872419 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250130 IS - 1758-3764 (Electronic) IS - 1758-3756 (Print) IS - 1758-3756 (Linking) VI - 19 DP - 2024 TI - Shifting Paradigms in the Management of Pulmonary Hypertension. PG - e25 LID - 10.15420/ecr.2024.11 [doi] LID - e25 AB - Pulmonary arterial hypertension (PAH) is a long-term condition characterised by increased resistance to blood flow in the pulmonary circulation. The disease has a progressive course and is associated with a poor prognosis. Without treatment, PAH is associated with mortality in <3 years. Over the past decade, many advances have been made in revising the haemodynamic definition, clinical classification, risk calculation score, treatment options etc. Suggestions from the Sixth World Symposium on Pulmonary Hypertension were incorporated into a literature review that was included in the European Society of Cardiology/European Respiratory Society (ESC/ERS)'s most recent iteration of their guidelines in 2022. The traditional cut-off for pulmonary hypertension (PH), i.e., mean pulmonary artery pressure (mPAP) >25 mm Hg, has been challenged by observational cohort studies, which have shown poor outcomes for values of 21-24 mmHg; the new consensus is that PH is defined at mPAP >20 mm Hg. Although the gold standard for diagnosis and the major source of therapy guidance continues to be right cardiac catheterisation, echocardiography remains the initial test of choice. A multidisciplinary approach is highly recommended when treating PH patients and careful evaluation of patients will aid in proper diagnosis and prognosis. Pharmacotherapy for PAH has seen a paradigm shift with the successful use of newer agents in more extensive, longer and more inclusive trials driven by hard endpoints. Macitentan, selexipag and riociguat are three oral agents that have shown astounding success in PAH randomised studies in the past decade. Upfront combination therapy with two agents is now becoming the norm (following the AMBITION, OPTIMA and ITALY trials) and the momentum is shifting towards triple therapy as for essential hypertension. More recently, inhaled treprostinil was shown to improve exercise capacity in PH associated with interstitial lung disease in the phase III INCREASE study and has been granted regulatory approval for World Health Organization group 3 PH. A new class of drug, sotatercept (a tumour growth factor-beta signalling inhibitor), has also been recently approved by the Food and Drug Administration for management of PAH based on positive results from the phase III STELLAR study. Pulmonary artery denervation and balloon pulmonary angioplasty have emerged as viable alternatives in PH that are resistant to drug therapy. This article aims to summarise the key changes and recent advances in diagnosis and managing PH in general, with an emphasis on certain subgroups. CI - Copyright (c) The Author(s), 2024. Published by Radcliffe Group Ltd. FAU - Pradhan, Akshyaya AU - Pradhan A AD - Department of Cardiology, King George's Medical University Lucknow, Uttar Pradesh, India. FAU - Tyagi, Richa AU - Tyagi R AD - Department of Pulmonary Medicine, Sanjay Gandhi PG Institute of Medical Sciences Lucknow, Uttar Pradesh, India. FAU - Sharma, Prachi AU - Sharma P AD - Department of Cardiology, King George's Medical University Lucknow, Uttar Pradesh, India. FAU - Bajpai, Jyoti AU - Bajpai J AD - Department of Respiratory Medicine, King George's Medical University Lucknow, Uttar Pradesh, India. FAU - Kant, Surya AU - Kant S AD - Department of Respiratory Medicine, King George's Medical University Lucknow, Uttar Pradesh, India. LA - eng PT - Journal Article PT - Review DEP - 20241223 PL - England TA - Eur Cardiol JT - European cardiology JID - 101574780 PMC - PMC11770536 OTO - NOTNLM OT - Definition OT - REVEAL 2.0 OT - balloon pulmonary angioplasty OT - riociguat OT - selexipag OT - upfront combination therapy COIS- Disclosure: The authors have no conflicts of interest to declare. EDAT- 2025/01/28 11:26 MHDA- 2025/01/28 11:27 PMCR- 2024/12/23 CRDT- 2025/01/28 05:01 PHST- 2024/03/03 00:00 [received] PHST- 2024/08/07 00:00 [accepted] PHST- 2025/01/28 11:27 [medline] PHST- 2025/01/28 11:26 [pubmed] PHST- 2025/01/28 05:01 [entrez] PHST- 2024/12/23 00:00 [pmc-release] AID - 10.15420/ecr.2024.11 [doi] PST - epublish SO - Eur Cardiol. 2024 Dec 23;19:e25. doi: 10.15420/ecr.2024.11. eCollection 2024. PMID- 39866976 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250130 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 16 IP - 12 DP - 2024 Dec TI - Cutaneous Manifestations of Systemic Lupus Erythematosus and Their Correlation With Cardiac Involvement. PG - e76478 LID - 10.7759/cureus.76478 [doi] LID - e76478 AB - Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder characterized by widespread immune dysregulation that affects multiple organ systems, including the skin and cardiovascular system. The crosstalk between different cell death pathways-such as apoptosis, necroptosis, and neutrophil extracellular trap (NETosis), plays a pivotal role in the pathogenesis of SLE, influencing both cutaneous and cardiac manifestations. Cutaneous lupus erythematosus (CLE) is one of the most common early signs of SLE, affecting up to 80% of patients. CLE presents in several forms, including acute, subacute, and chronic lesions, each with varying degrees of association with systemic disease. Cardiac involvement, although often underrecognized, significantly contributes to morbidity and mortality in SLE patients, manifesting as pericarditis, myocarditis, valvular disease, and accelerated atherosclerosis. Emerging research suggests that these cutaneous and cardiac manifestations may be connected through shared immune mechanisms, including immune complex deposition, endothelial dysfunction, and chronic inflammation driven by cytokines such as Interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha). The severity of skin involvement may correlate with an increased risk of cardiovascular events, underscoring the importance of early diagnosis and a multidisciplinary approach to treatment. This review explores the crosstalk among cell death pathways in SLE and examines how these pathways contribute to both cutaneous and cardiac manifestations. Furthermore, it highlights the clinical implications of this crosstalk and discusses potential therapeutic strategies aimed at modulating these cell death pathways to improve patient outcomes. Challenges and gaps in current research are also addressed, emphasizing the need for further investigation into these complex interactions. CI - Copyright (c) 2024, Zeb et al. FAU - Zeb, Romasa AU - Zeb R AD - Internal Medicine, Army Medical College, Rawalpindi, PAK. FAU - Chinome, Daniela Valentina Combariza AU - Chinome DVC AD - Internal Medicine, New Granada Military University, Bogota, COL. FAU - Chacon, Maria AU - Chacon M AD - Internal Medicine, Universidad de Especialidades Espiritu Santo, Guayaquil, ECU. FAU - Singh, Taranpreet AU - Singh T AD - Internal Medicine, Mahatma Gandhi Mission (MGM) Medical College and Hospital, Navi Mumbai, IND. FAU - Chowdary, Machineni Meghana AU - Chowdary MM AD - Internal Medicine, Siddhartha Medical College, Vijayawada, IND. FAU - Manzanares Vidals, Claudia Jeanette AU - Manzanares Vidals CJ AD - Internal Medicine, General Hospital of Toluca Dr. Nicolas San Juan, Toluca, MEX. FAU - Mehnaz, Sunjida AU - Mehnaz S AD - Internal Medicine, Medway Maritime Hospital, Kent, GBR. FAU - Medina, Andres Felipe Torres AU - Medina AFT AD - Internal Medicine, Universidad de Ciencias Aplicadas y Ambientales U.D.C.A, Bogota, COL. FAU - Gadde, Prashanthi Sarayu AU - Gadde PS AD - Internal Medicine, MNR Medical College, Hyderabad, IND. FAU - Lingamgunta, Raaj Pawan Kumar AU - Lingamgunta RPK AD - Internal Medicine, NRI Medical College & General Hospital, Guntur, IND. FAU - Barakat, Aly AU - Barakat A AD - Internal Medicine, Medway NHS Foundation Trust, Kent, GBR. FAU - Rai, Manju AU - Rai M AD - Biotechnology, Shri Venkateshwara University, Gajraula, IND. LA - eng PT - Journal Article PT - Review DEP - 20241227 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC11769098 OTO - NOTNLM OT - autoimmune disease and heart complications OT - biologics in lupus management OT - cardiac involvement in sle OT - cutaneous manifestations OT - immunosuppressive therapy in sle OT - lupus skin lesions OT - multidisciplinary care in sle OT - skin-cardiac correlation in lupus OT - systemic lupus erythematosus (sle) COIS- Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. EDAT- 2025/01/27 06:20 MHDA- 2025/01/27 06:21 PMCR- 2024/12/27 CRDT- 2025/01/27 05:45 PHST- 2024/12/27 00:00 [accepted] PHST- 2025/01/27 06:21 [medline] PHST- 2025/01/27 06:20 [pubmed] PHST- 2025/01/27 05:45 [entrez] PHST- 2024/12/27 00:00 [pmc-release] AID - 10.7759/cureus.76478 [doi] PST - epublish SO - Cureus. 2024 Dec 27;16(12):e76478. doi: 10.7759/cureus.76478. eCollection 2024 Dec. PMID- 39865567 OWN - NLM STAT- MEDLINE DCOM- 20250503 LR - 20260916 IS - 2369-3762 (Electronic) IS - 2369-3762 (Linking) VI - 11 DP - 2025 Jan 24 TI - Barriers to and Facilitators of Implementing Team-Based Extracorporeal Membrane Oxygenation Simulation Study: Exploratory Analysis. PG - e57424 LID - 10.2196/57424 [doi] LID - e57424 AB - INTRO: Extracorporeal membrane oxygenation (ECMO) is a critical tool in the care of severe cardiorespiratory dysfunction. Simulation training for ECMO has become standard practice. Therefore, Keck Medicine of the University of California (USC) holds simulation-training sessions to reinforce and improve providers knowledge. OBJECTIVE: This study aimed to understand the impact of simulation training approaches on interprofessional collaboration. We believed simulation-based ECMO training would improve interprofessional collaboration through increased communication and enhance teamwork. METHODS: This was a single-center, mixed methods study of the Cardiac and Vascular Institute Intensive Care Unit at Keck Medicine of USC conducted from September 2021 to April 2023. Simulation training was offered for 1 hour monthly to the clinical team focused on the collaboration and decision-making needed to evaluate the initiation of ECMO therapy. Electronic surveys were distributed before, after, and 3 months post training. The survey evaluated teamwork and the effectiveness of training, and focus groups were held to understand social environment factors. Additionally, trainee and peer evaluation focus groups were held to understand socioenvironmental factors. RESULTS: In total, 37 trainees attended the training simulation from August 2021 to August 2022. Using 27 records for exploratory factor analysis, the standardized Cronbach alpha was 0.717. The survey results descriptively demonstrated a positive shift in teamwork ability. Qualitative themes identified improved confidence and decision-making. CONCLUSIONS: The study design was flawed, indicating improvement opportunities for future research on simulation training in the clinical setting. The paper outlines what to avoid when designing and implementing studies that assess an educational intervention in a complex clinical setting. The hypothesis deserves further exploration and is supported by the results of this study. CI - (c) Joan Brown, Sophia De-Oliveira, Christopher Mitchell, Rachel Carmen Cesar, Li Ding, Melissa Fix, Daniel Stemen, Krisda Yacharn, Se Fum Wong, Anahat Dhillon. Originally published in JMIR Medical Education (https://mededu.jmir.org). FAU - Brown, Joan AU - Brown J AUID- ORCID: 0000-0003-3492-2858 AD - Department of Surgery, Keck School of Medicine, University of South California, Los Angeles, CA, United States. FAU - De-Oliveira, Sophia AU - De-Oliveira S AUID- ORCID: 0009-0001-8521-8986 AD - Office of Performance & Transformation, Keck Hospital of USC, Los Angeles, CA, United States, United States. FAU - Mitchell, Christopher AU - Mitchell C AUID- ORCID: 0009-0009-8774-5083 AD - Department of Surgery, Keck School of Medicine, University of South California, Los Angeles, CA, United States. AD - Department of Nursing, Keck Hospital of USC, Los Angeles, CA, United States, United States. FAU - Cesar, Rachel Carmen AU - Cesar RC AUID- ORCID: 0000-0002-9205-9514 AD - Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States, United States. FAU - Ding, Li AU - Ding L AUID- ORCID: 0000-0001-8565-430X AD - Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States, United States. FAU - Fix, Melissa AU - Fix M AUID- ORCID: 0009-0006-2635-8643 AD - Department of Surgery, Keck School of Medicine, University of South California, Los Angeles, CA, United States. AD - Department of Nursing, Keck Hospital of USC, Los Angeles, CA, United States, United States. FAU - Stemen, Daniel AU - Stemen D AUID- ORCID: 0009-0006-9430-4938 AD - Deparment of Respiratory Therapy, Keck Hospital of USC, Los Angeles, CA, United States, United States. FAU - Yacharn, Krisda AU - Yacharn K AUID- ORCID: 0009-0005-0054-0087 AD - Department of Surgery, Keck School of Medicine, University of South California, Los Angeles, CA, United States. AD - Department of Nursing, Keck Hospital of USC, Los Angeles, CA, United States, United States. FAU - Wong, Se Fum AU - Wong SF AUID- ORCID: 0009-0003-7594-1438 AD - Department of Anesthesia, Kaiser Permanante, Los Angeles, CA, United States. FAU - Dhillon, Anahat AU - Dhillon A AUID- ORCID: 0009-0009-2753-441X AD - Department of Anesthesia Critical Care Medicine, Keck School of Medicine, University of South California, Los Angeles, CA, United States, United States. LA - eng GR - UL1 TR001855/TR/NCATS NIH HHS/United States PT - Journal Article DEP - 20250124 PL - Canada TA - JMIR Med Educ JT - JMIR medical education JID - 101684518 SB - IM MH - *Extracorporeal Membrane Oxygenation/education/methods MH - Humans MH - *Patient Care Team/organization & administration MH - *Simulation Training/methods MH - Focus Groups MH - Cooperative Behavior MH - Clinical Competence MH - Surveys and Questionnaires MH - Female MH - Male MH - Interprofessional Relations PMC - PMC11788224 OTO - NOTNLM OT - ECMO OT - ICU OT - cardiology OT - cardiorespiratory OT - cardiorespiratory dysfunction OT - collaboration OT - extracorporeal membrane oxygenation OT - heart OT - intensive care unit OT - interprofessional collaboration OT - life support OT - lungs OT - respiratory OT - simulation OT - simulation training OT - team dynamics OT - teamwork in the ICU COIS- Conflicts of Interest: None declared. EDAT- 2025/01/27 06:20 MHDA- 2025/01/27 06:21 PMCR- 2025/01/24 CRDT- 2025/01/27 00:33 PHST- 2024/02/23 00:00 [received] PHST- 2024/05/16 00:00 [revised] PHST- 2024/12/03 00:00 [accepted] PHST- 2025/01/27 06:21 [medline] PHST- 2025/01/27 06:20 [pubmed] PHST- 2025/01/27 00:33 [entrez] PHST- 2025/01/24 00:00 [pmc-release] AID - v11i1e57424 [pii] AID - 57424 [pii] AID - 10.2196/57424 [doi] PST - epublish SO - JMIR Med Educ. 2025 Jan 24;11:e57424. doi: 10.2196/57424. PMID- 39865287 OWN - NLM STAT- MEDLINE DCOM- 20250127 LR - 20250130 IS - 1749-8090 (Electronic) IS - 1749-8090 (Linking) VI - 20 IP - 1 DP - 2025 Jan 27 TI - Management and outcomes of thoracic sarcomas - a collaboration between Orthopaedic Oncology and cardiothoracic surgery: seven-year clinical data from a tertiary referral centre. PG - 98 LID - 10.1186/s13019-025-03341-w [doi] LID - 98 AB - INTRODUCTION: Sarcomas are rare cancers originating from mesenchymal tissues, manifesting in diverse anatomical locations, but notably in connective tissue, muscles and the skeleton. Thoracic sarcomas present a unique diagnostic and surgical challenge attributable to their rarity and pathoanatomy. Standard practice currently comprises wide surgical excision, often accompanied by adjuvant chemotherapy and/or radiotherapy. This approach necessitates a multidisciplinary team, ideally in specialised cancer centres. The Oxford Bone and Soft Tissue Tumour Service is one such centre, and routinely treats such cancers through collaboration between orthopaedic oncology and cardiothoracic surgeons, as well as members of the wider MDT. This study reports the current management and outcomes of primary thoracic sarcoma patients at the Oxford Sarcoma Service over a seven-year period. OBJECTIVES: Given the rarity of thoracic sarcomas, and their associated diagnostic and management complexities, our aim is to report on the treatment strategies and outcomes of primary thoracic sarcoma patients treated at the Oxford Sarcoma Service from 2017 to 2023. METHODS: Data pertaining to all thoracic sarcoma cases discussed in multidisciplinary meetings at the Oxford tertiary centre from 2017 to 2023 were retrieved from the local electronic database. These were analysed using appropriate statistical tests to determine significance of the various observations made. RESULTS: Of 113 identified cases, chondrosarcoma emerged as the most prevalent histological subtype among 22 distinct varieties. 58% of cases exhibited high-grade features. 32 sarcoma-related deaths occurred, with a mean time from diagnosis to death of 23.16 months. A notable association was observed between high-grade sarcomas and mortality (p = 0.0280). Surgical resection was performed in 77 cases, with 49% of these undergoing surgical resection alone i.e. the patient received no radio- or chemotherapy. Both surgical intervention (p < 0.0001) and clear margins (p = 0.0051) were significantly linked to improved survival. Local recurrence was noted in 28.6% of the 77 surgical cases, and predominantly in the high-grade sarcomas (81.8%). However, no statistical association was found between recurrence and margin status in our data. CONCLUSION: Our results indicate that primary resection remains the cornerstone of thoracic sarcoma treatment, representing the single strongest independent factor for survival in treatable cases. Variability in outcomes and overall survival likely stems from factors such as histological diversity, predominance of high-grade sarcomas, and wide age range at diagnosis. Ongoing prospective database update and collaborative efforts across centres would further clarify prognoses and recommendations for specific tumours, based on observational data. CI - (c) 2025. Crown. FAU - Shamsi, Zaid Ahmed AU - Shamsi ZA AD - Nuffield Orthopaedic Centre, OUH, Oxford, UK. zaid.shamsi@ouh.nhs.uk. FAU - Paraoan, Vlad AU - Paraoan V AD - UHCW NHS Trust, Coventry, UK. FAU - Kim, Chang AU - Kim C AD - Nuffield Orthopaedic Centre, OUH, Oxford, UK. FAU - Saifuddin, Sarah Raihanah AU - Saifuddin SR AD - University Hospitals of North Midlands NHS Trust, Stoke-On-Trent, UK. FAU - Cosker, Thomas D A AU - Cosker TDA AD - Nuffield Orthopaedic Centre, OUH, Oxford, UK. AD - Director of Surgical Anatomy, University of Oxford, Oxford, United Kingdom. FAU - Whitwell, Duncan AU - Whitwell D AD - Nuffield Orthopaedic Centre, OUH, Oxford, UK. FAU - Gibbons, Christopher L M H AU - Gibbons CLMH AD - Nuffield Orthopaedic Centre, OUH, Oxford, UK. FAU - Stavroulias, Dionisios AU - Stavroulias D AD - John Radcliffe Hospital, Oxford, UK. FAU - DiChiara, Francesco AU - DiChiara F AD - John Radcliffe Hospital, Oxford, UK. LA - eng PT - Journal Article DEP - 20250127 PL - England TA - J Cardiothorac Surg JT - Journal of cardiothoracic surgery JID - 101265113 SB - IM MH - Humans MH - Male MH - Female MH - Child, Preschool MH - Child MH - Adolescent MH - Young Adult MH - Adult MH - Middle Aged MH - Aged MH - Aged, 80 and over MH - *Sarcoma/mortality/pathology/therapy MH - Treatment Outcome MH - *Thoracic Neoplasms/mortality/pathology/therapy MH - Recurrence MH - Survival Analysis MH - Neoplasm Grading MH - Tertiary Care Centers MH - *Patient Care Team MH - Retrospective Studies MH - Medical Oncology/organization & administration PMC - PMC11770954 OTO - NOTNLM OT - Cardiothoracic surgery OT - Orthopaedic oncology OT - Sarcoma OT - Thoracic sarcoma OT - Thorax COIS- Declarations. Ethics approval: Approved and registered under Ulysses at Oxford University Hospitals (Number 9455). Human Ethics and Consent to participate declarations: All participants provided informed consent for their data to be utilized in research studies. Competing interests: The authors declare no competing interests. EDAT- 2025/01/27 00:20 MHDA- 2025/01/27 00:21 PMCR- 2025/01/27 CRDT- 2025/01/26 23:25 PHST- 2024/09/08 00:00 [received] PHST- 2025/01/19 00:00 [accepted] PHST- 2025/01/27 00:21 [medline] PHST- 2025/01/27 00:20 [pubmed] PHST- 2025/01/26 23:25 [entrez] PHST- 2025/01/27 00:00 [pmc-release] AID - 10.1186/s13019-025-03341-w [pii] AID - 3341 [pii] AID - 10.1186/s13019-025-03341-w [doi] PST - epublish SO - J Cardiothorac Surg. 2025 Jan 27;20(1):98. doi: 10.1186/s13019-025-03341-w. PMID- 39865147 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250129 IS - 2363-9024 (Electronic) IS - 2363-9024 (Linking) VI - 11 IP - 1 DP - 2025 Jan 27 TI - Simultaneous transcatheter aortic valve implantation and femoral osteosynthesis: a case report. PG - 4 LID - 10.1186/s40981-025-00769-w [doi] LID - 4 AB - BACKGROUND: Simultaneous cardiac and non-cardiac surgeries can be beneficial for patients, but there are still few reports on this approach. CASE PRESENTATION: A 90-year-old woman was diagnosed with a femoral trochanteric fracture and severe aortic stenosis. A heart team conference decided to perform transcatheter aortic valve implantation (TAVI) and femoral osteosynthesis under general anesthesia on the same day. A preoperative simulation was conducted to review the surgical procedure and confirm the arrangement of the operating table and instruments. Preoperative management was carried out with attention to the risk of myocardial ischemia caused by bleeding or pain from the fracture. Transfemoral TAVI was completed without trouble, and after the patient was moved to the traction table, osteosynthesis was started. Back-up pacing with a temporary pacemaker was activated for atrioventricular block and bradycardia. After completing the surgery, the patient recovered from anesthesia, and extubation was performed after confirming the absence of paralysis. The patient had no noticeable postoperative complications and successfully underwent rehabilitation. CONCLUSIONS: Through meticulous preparation and perioperative management, we were able to perform TAVI and femoral osteosynthesis simultaneously, achieving a favorable outcome. CI - (c) 2025. The Author(s). FAU - Mitsuta, Yuki AU - Mitsuta Y AUID- ORCID: 0009-0000-6933-8454 AD - Department of Anesthesiology, Japanese Red Cross Kumamoto Hospital, 2-1-1, Nagamine-Minami, Higashi-Ku, Kumamoto, 861-8520, Japan. yuu0042001@yahoo.co.jp. FAU - Okamura, Yukiko AU - Okamura Y AD - Department of Anesthesiology, Japanese Red Cross Kumamoto Hospital, 2-1-1, Nagamine-Minami, Higashi-Ku, Kumamoto, 861-8520, Japan. FAU - Miyamoto, Yosuke AU - Miyamoto Y AD - Department of Anesthesiology, Japanese Red Cross Kumamoto Hospital, 2-1-1, Nagamine-Minami, Higashi-Ku, Kumamoto, 861-8520, Japan. FAU - Tanahira, Dai AU - Tanahira D AD - Department of Anesthesiology, Japanese Red Cross Kumamoto Hospital, 2-1-1, Nagamine-Minami, Higashi-Ku, Kumamoto, 861-8520, Japan. LA - eng PT - Journal Article DEP - 20250127 PL - Germany TA - JA Clin Rep JT - JA clinical reports JID - 101682121 PMC - PMC11769877 OTO - NOTNLM OT - Aortic stenosis OT - Hip fracture OT - Osteosynthesis OT - Transcatheter aortic valve implantation COIS- Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Written informed consent was obtained from the patient for publication of this case report. Competing interests: The authors declare that they have no competing interests. EDAT- 2025/01/27 00:20 MHDA- 2025/01/27 00:21 PMCR- 2025/01/27 CRDT- 2025/01/26 23:17 PHST- 2024/11/22 00:00 [received] PHST- 2025/01/18 00:00 [accepted] PHST- 2025/01/10 00:00 [revised] PHST- 2025/01/27 00:21 [medline] PHST- 2025/01/27 00:20 [pubmed] PHST- 2025/01/26 23:17 [entrez] PHST- 2025/01/27 00:00 [pmc-release] AID - 10.1186/s40981-025-00769-w [pii] AID - 769 [pii] AID - 10.1186/s40981-025-00769-w [doi] PST - epublish SO - JA Clin Rep. 2025 Jan 27;11(1):4. doi: 10.1186/s40981-025-00769-w. PMID- 39864981 OWN - NLM STAT- MEDLINE DCOM- 20250326 LR - 20260617 IS - 1532-8422 (Electronic) IS - 1053-0770 (Linking) VI - 39 IP - 4 DP - 2025 Apr TI - Preoperative Cardiac Assessment for Coronary Artery Disease: From Symptoms to Angiography. PG - 889-896 LID - S1053-0770(24)01009-7 [pii] LID - 10.1053/j.jvca.2024.12.036 [doi] AB - Although cardiovascular anesthesiologists play a role in the multidisciplinary heart team, they are generally not involved prior to the diagnosis of coronary artery disease. This work was designed to broadly cover the factors influencing decision-making when proceeding with coronary angiography in a patient with suspected coronary artery disease. The authors cover the principles, rationale, benefits, and downsides of common tests involved. CI - Copyright (c) 2024 Elsevier Inc. All rights reserved. FAU - Li, Michael H-G AU - Li MH AD - Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Boston, MA. Electronic address: Michael.Huagen.Li@gmail.com. FAU - McGrail, Daniel AU - McGrail D AD - Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Boston, MA. FAU - Mahmood, Feroze AU - Mahmood F AD - Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Boston, MA. FAU - Bose, Ruma AU - Bose R AD - Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Boston, MA. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20250107 PL - United States TA - J Cardiothorac Vasc Anesth JT - Journal of cardiothoracic and vascular anesthesia JID - 9110208 SB - IM MH - Humans MH - *Coronary Angiography/methods MH - *Coronary Artery Disease/diagnostic imaging/diagnosis/surgery MH - *Preoperative Care/methods OTO - NOTNLM OT - cardiac imaging techniques OT - coronary artery disease OT - education OT - exercise test COIS- Declaration of competing interest The authors declare the following financial interests and/or personal relationships that may be considered potential competing interests: Michael Li reports a relationship with the Society of Cardiovascular Anesthesiologists that includes honoraria for an oral presentation; a relationship with Wolters Kluwer that includes honoraria for writing a book chapter; and a relationship with the Australian and New Zealand College of Anaesthetists that includes funding grants. The other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/01/27 00:20 MHDA- 2025/03/28 19:39 CRDT- 2025/01/26 21:53 PHST- 2024/07/29 00:00 [received] PHST- 2024/11/24 00:00 [revised] PHST- 2024/12/20 00:00 [accepted] PHST- 2025/03/28 19:39 [medline] PHST- 2025/01/27 00:20 [pubmed] PHST- 2025/01/26 21:53 [entrez] AID - S1053-0770(24)01009-7 [pii] AID - 10.1053/j.jvca.2024.12.036 [doi] PST - ppublish SO - J Cardiothorac Vasc Anesth. 2025 Apr;39(4):889-896. doi: 10.1053/j.jvca.2024.12.036. Epub 2025 Jan 7. PMID- 39863280 OWN - NLM STAT- MEDLINE DCOM- 20250428 LR - 20250428 IS - 1615-5947 (Electronic) IS - 0890-5096 (Linking) VI - 114 DP - 2025 May TI - Nonocclusive Mesenteric Ischemia in Aortic Surgery: What You Need to Know. PG - 373-379 LID - S0890-5096(25)00005-6 [pii] LID - 10.1016/j.avsg.2025.01.001 [doi] AB - BACKGROUND: Nonocclusive mesenteric ischemia (NOMI), a subtype of acute mesenteric ischemia (AMI), is primarily caused by mesenteric arterial vasoconstriction and decreased vascular resistance, leading to impaired intestinal perfusion.Commonly observed after cardiac surgery, NOMI affects older patients with cardiovascular or systemic diseases, accounting for 20-30% of AMI cases with a mortality rate of approximately 50%. This review explores NOMI's pathophysiology, clinical implications in aortic dissection, and the unmet needs in diagnosis and management, emphasizing its prognostic significance. METHODS: A comprehensive literature review was conducted using multiple electronic databases to extract relevant data and information. RESULTS: NOMI is a life-threatening condition characterized by mesenteric vasoconstriction and reduced splanchnic blood flow, often triggered by cardiac surgery, hemodialysis, or hypotensive episodes. Epidemiological studies highlight its prevalence in intensive care unit settings, with a high mortality rate linked to delayed diagnosis and systemic hypoperfusion. Risk factors include advanced age, vasopressor use, and inflammatory markers. Biomarkers such as intestinal fatty acid binding protein, citrulline, and D-lactate show potential for early detection but lack robust clinical validation. Management includes fluid resuscitation, vasodilators, and surgical intervention for bowel necrosis. Emerging endovascular approaches show promise but are limited to select cases without bowel infarction. This review underscores the critical need for timely diagnosis, risk factor identification, and tailored interventions to improve outcomes. CONCLUSION: NOMI remains poorly understood despite advances in surgical and perioperative care. Its pathophysiology, linked to cardiopulmonary bypass and intraoperative factors, requires heightened clinical vigilance. Limited evidence underscores the need for a multidisciplinary approach involving surgeons, radiologists, and anesthetists to improve diagnosis, management, and outcomes in aortic surgery patients. CI - Copyright (c) 2025 Elsevier Inc. All rights reserved. FAU - Murtada, Ali AU - Murtada A AD - Department of General Surgery, Glan Clwyd Hospital, Rhyl, UK. Electronic address: ali.murtada@wales.nhs.uk. FAU - Jubouri, Matti AU - Jubouri M AD - Hull York Medical School, University of York, York, UK. FAU - Refaie, Mohamed AU - Refaie M AD - Department of General Surgery, Glan Clwyd Hospital, Rhyl, UK. FAU - Mohammed, Idhrees AU - Mohammed I AD - Institute of Cardiac and Aortic Disorders, SRM Institutes for Medical Science (SIMS Hospitals), Chennai, India. LA - eng PT - Journal Article PT - Review DEP - 20250123 PL - Netherlands TA - Ann Vasc Surg JT - Annals of vascular surgery JID - 8703941 SB - IM MH - Humans MH - *Mesenteric Ischemia/physiopathology/therapy/mortality/diagnosis/epidemiology/diagnostic imaging/etiology MH - Risk Factors MH - *Splanchnic Circulation MH - Treatment Outcome MH - *Vascular Surgical Procedures/adverse effects/mortality MH - *Aortic Dissection/surgery/physiopathology/mortality/diagnostic imaging MH - Predictive Value of Tests MH - Risk Assessment MH - Vasoconstriction MH - *Aortic Aneurysm/surgery/mortality/physiopathology MH - *Mesenteric Arteries/physiopathology EDAT- 2025/01/26 02:11 MHDA- 2025/04/28 06:27 CRDT- 2025/01/25 19:19 PHST- 2025/01/01 00:00 [received] PHST- 2025/01/15 00:00 [accepted] PHST- 2025/04/28 06:27 [medline] PHST- 2025/01/26 02:11 [pubmed] PHST- 2025/01/25 19:19 [entrez] AID - S0890-5096(25)00005-6 [pii] AID - 10.1016/j.avsg.2025.01.001 [doi] PST - ppublish SO - Ann Vasc Surg. 2025 May;114:373-379. doi: 10.1016/j.avsg.2025.01.001. Epub 2025 Jan 23. PMID- 39863067 OWN - NLM STAT- MEDLINE DCOM- 20250227 LR - 20250612 IS - 2254-8874 (Electronic) IS - 2254-8874 (Linking) VI - 225 IP - 3 DP - 2025 Mar TI - Analysis of clinical features and prognosis in cardiac amyloidosis patients from Spanish hospitals (2016-2021). PG - 131-139 LID - S2254-8874(25)00005-0 [pii] LID - 10.1016/j.rceng.2025.01.001 [doi] AB - INTRODUCTION AND OBJECTIVES: Cardiac amyloidosis (CA) is a prevalent yet underdiagnosed heart condition characterized by the abnormal accumulation of amyloid fibres, frequently resulting in heart failure (HF), particularly in older people. Despite advancements in non-invasive diagnostic techniques and treatments, the epidemiology of CA patients remains inadequately understood. This nationwide retrospective observational study sought to comprehensively investigate CA patients' characteristics, mortality, and readmission patterns. METHODS: A retrospective observational study encompassed all patients hospitalized with CA between 2016 and 2021 across Spanish hospitals. Standardized incidence rates were calculated using age and sex-adjusted methods, utilizing the Spanish population as the reference. The investigation delved into demographic variables, comorbidities, mortality during the index episode, and 30 and 365-day readmissions for circulatory system diseases. Predictors of readmission were also examined. RESULTS: A total of 5739 index episodes were identified, with CA being the primary cause of admission in 14.1% of cases. The mean age was 81.4 +/- 9.9 years, predominantly males (70.3%). The age and sex-standardized hospital attendance rate was 3.90 admissions per 100,000 population (95% CI: 3.82-3.98), higher in males. Common comorbidities included HF (96.4%), atrial fibrillation (46.3%), and renal failure (44.4%). The mortality rate during the index episode was 11.7%, with cardiogenic shock (OR: 9.03; 95% CI: 4.22-19.32) and major psychiatric disorders (OR: 3.36; 95% CI: 1.42-7.94) identified as predictors. Over the follow-up period, 13.1% were readmitted at 30 days and 36.6% at 365. Nephritis (IRR: 2.05; 95% CI: 1.42-2.96) and asthma (IRR: 1.52; 95% CI 1.11-2.07) were associated with increased 30-day readmissions, while renal failure (IRR: 1.43; 95% CI: 1.28-1.59) and chronic pulmonary disease (IRR: 1.40; 95% CI: 1.18-1.67) were linked to higher 365-day readmissions. Predictors of mortality risk in 365-day readmissions included advanced cancer (HR: 1.31; 95% CI: 1.00-1.71), cardiogenic shock in the index episode (HR: 2.72; 95% CI: 1.33-5.57), and a higher number of readmissions during that period (HR: 1.64; 95% CI: 1.56-1.73). CONCLUSIONS: This study contributes valuable insights into the significant prevalence of CA, which is often overlooked and underestimated. Afflicting predominantly elderly males with concomitant HF and multiple comorbidities, CA poses a significant clinical challenge. The findings underscore the need for enhanced awareness, early detection, and a multidisciplinary approach to manage this complex cardiac condition. CI - Copyright (c) 2025 Elsevier Espana, S.L.U. and Sociedad Espanola de Medicina Interna (SEMI). All rights reserved. FAU - Esteban-Fernandez, A AU - Esteban-Fernandez A AD - Cardiology Department, Hospital Universitario Severo Ochoa, Leganes, Madrid, Spain; Faculty of Health Sciences, Universidad Alfonso X el Sabio (UAX), Villanueva de la Canada, Madrid, Spain. Electronic address: athalbertus@gmail.com. FAU - Anguita-Sanchez, M AU - Anguita-Sanchez M AD - Cardiology Department, Hospital Universitario Reina Sofia, Cordoba, Spain; The Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba University, Cordoba, Spain, Centro de Investigacion Biomedica en Red Enfermedades Cardiovasculares (CIBERCV), Spain. FAU - Rosillo, N AU - Rosillo N AD - Institute for the Improvement of Health Care (IMAS Foundation), Madrid, Spain; Preventive Medicine Department, Hospital Universitario 12 de Octubre, Madrid, Spain. FAU - Bonilla-Palomas, J L AU - Bonilla-Palomas JL AD - Cardiology Department, Hospital San Juan de la Cruz, Ubeda, Jaen, Spain. FAU - Bernal Sobrino, J L AU - Bernal Sobrino JL AD - Institute for the Improvement of Health Care (IMAS Foundation), Madrid, Spain. FAU - Del Prado, N AU - Del Prado N AD - Institute for the Improvement of Health Care (IMAS Foundation), Madrid, Spain. FAU - Fernandez Perez, C AU - Fernandez Perez C AD - Institute for the Improvement of Health Care (IMAS Foundation), Madrid, Spain; Preventive Medicine Department, Area Sanitaria de Santiago y Barbanza, Instituto de Investigaciones Sanitarias de Santiago, Santiago de Compostela, A Coruna, Spain. FAU - Rodriguez Padial, L AU - Rodriguez Padial L AD - Cardiology Department, Hospital General Universitario de Toledo, Toledo, Spain. FAU - Elola Somoza, F J AU - Elola Somoza FJ AD - Institute for the Improvement of Health Care (IMAS Foundation), Madrid, Spain. LA - eng PT - Journal Article PT - Multicenter Study PT - Observational Study PT - Research Support, Non-U.S. Gov't DEP - 20250123 PL - Spain TA - Rev Clin Esp (Barc) JT - Revista clinica espanola JID - 101632437 SB - IM MH - Humans MH - Male MH - Female MH - Spain/epidemiology MH - Retrospective Studies MH - *Amyloidosis/diagnosis/mortality/epidemiology/complications MH - Aged, 80 and over MH - Aged MH - Prognosis MH - Patient Readmission/statistics & numerical data MH - *Cardiomyopathies/diagnosis/mortality/epidemiology MH - Middle Aged OTO - NOTNLM OT - Amiloidosis cardiaca OT - Ancianos OT - Cardiac amyloidosis OT - Elderly OT - Heart failure OT - Hospitalizacion OT - Hospitalization OT - Insuficiencia cardiaca OT - Prognosis OT - Pronostico COIS- Declaration of competing interest The authors declare not to have a conflict of interest in this study. EDAT- 2025/01/26 02:11 MHDA- 2025/02/28 00:20 CRDT- 2025/01/25 19:16 PHST- 2024/09/05 00:00 [received] PHST- 2024/10/09 00:00 [accepted] PHST- 2025/02/28 00:20 [medline] PHST- 2025/01/26 02:11 [pubmed] PHST- 2025/01/25 19:16 [entrez] AID - S2254-8874(25)00005-0 [pii] AID - 10.1016/j.rceng.2025.01.001 [doi] PST - ppublish SO - Rev Clin Esp (Barc). 2025 Mar;225(3):131-139. doi: 10.1016/j.rceng.2025.01.001. Epub 2025 Jan 23. PMID- 39859077 OWN - NLM STAT- MEDLINE DCOM- 20250503 LR - 20250524 IS - 1648-9144 (Electronic) IS - 1010-660X (Print) IS - 1010-660X (Linking) VI - 61 IP - 1 DP - 2025 Jan 9 TI - Etiological Aspects of Infectious Endocarditis in a Tertiary Hospital in Northeastern Romania. LID - 10.3390/medicina61010095 [doi] LID - 95 AB - Background and Objectives: Infective endocarditis (IE) is a severe, life-threatening infection of the endocardial surface. Its incidence has shifted towards older, immunocompromised patients and those with cardiac devices. Materials and Methods: This study was conducted at the "Sf. Parascheva" Clinical Hospital of Infectious Diseases in Iasi, Romania, and retrospectively analyzed cases of IE from January 1, 2019, to September 30, 2024. It received ethical approval (Approval No. 7/17 June 2024). Results: The study included 130 patients with infectious endocarditis, predominantly men (75.38%), with a median age of 55 years. The most affected age groups were 50-59 and over 60 years, each representing 30.76% of cases. The most frequently implicated etiological agent was Staphylococcus aureus in 33% of cases. The most common antibiotic regimen combined glycopeptides and fluoroquinolones/polymyxins (27% cases). Conclusions: A multidisciplinary approach involving infectious disease specialists, cardiologists, and cardiovascular surgeons is essential for effective treatment. Immediate combined antibiotic therapy is vital for presumed IE cases. Despite advances in diagnosis and treatment, the high mortality rates highlight the importance of timely intervention. Future research should focus on improving preventive and therapeutic strategies for IE. FAU - Loghin, Isabela Ioana AU - Loghin II AD - Department of Infectious Diseases, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 lasi, Romania. AD - Department of Infectious Diseases, "St. Parascheva" Clinical Hospital of Infectious Diseases, 700116 Iasi, Romania. FAU - Surdu, Amelia Elena AU - Surdu AE AUID- ORCID: 0000-0002-8995-3873 AD - Department of Implantology, Removable Prostheses and Technology, Faculty of Dental Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania. FAU - Rusu, Serban Alin AU - Rusu SA AD - Department of Infectious Diseases, "St. Parascheva" Clinical Hospital of Infectious Diseases, 700116 Iasi, Romania. FAU - Cecan, Ion AU - Cecan I AD - Department of Infectious Diseases, "St. Parascheva" Clinical Hospital of Infectious Diseases, 700116 Iasi, Romania. FAU - Dorobat, Victor Daniel AU - Dorobat VD AD - Department of Intensive Care, University Hospital of Emergency, 050098 Bucharest, Romania. FAU - Mihaescu, Amelia Andreea AU - Mihaescu AA AD - Department of Infectious Diseases, "St. Parascheva" Clinical Hospital of Infectious Diseases, 700116 Iasi, Romania. FAU - Dorobat, Carmen Mihaela AU - Dorobat CM AD - Department of Infectious Diseases, "St. Parascheva" Clinical Hospital of Infectious Diseases, 700116 Iasi, Romania. LA - eng PT - Journal Article DEP - 20250109 PL - Switzerland TA - Medicina (Kaunas) JT - Medicina (Kaunas, Lithuania) JID - 9425208 RN - 0 (Anti-Bacterial Agents) SB - IM MH - Humans MH - Romania/epidemiology MH - Male MH - Middle Aged MH - Female MH - Tertiary Care Centers/organization & administration/statistics & numerical data MH - Retrospective Studies MH - Aged MH - Adult MH - *Endocarditis/etiology/epidemiology MH - Anti-Bacterial Agents/therapeutic use MH - Aged, 80 and over MH - Staphylococcus aureus/pathogenicity MH - *Endocarditis, Bacterial/epidemiology MH - Staphylococcal Infections/epidemiology MH - Incidence PMC - PMC11766891 OTO - NOTNLM OT - antibiotics OT - duke criteria OT - echocardiography OT - etiological agents OT - infective endocarditis COIS- The authors declare no conflicts of interest. EDAT- 2025/01/25 13:53 MHDA- 2025/01/25 13:54 PMCR- 2025/01/09 CRDT- 2025/01/25 01:14 PHST- 2024/12/09 00:00 [received] PHST- 2024/12/30 00:00 [revised] PHST- 2025/01/06 00:00 [accepted] PHST- 2025/01/25 13:54 [medline] PHST- 2025/01/25 13:53 [pubmed] PHST- 2025/01/25 01:14 [entrez] PHST- 2025/01/09 00:00 [pmc-release] AID - medicina61010095 [pii] AID - medicina-61-00095 [pii] AID - 10.3390/medicina61010095 [doi] PST - epublish SO - Medicina (Kaunas). 2025 Jan 9;61(1):95. doi: 10.3390/medicina61010095. PMID- 39859023 OWN - NLM STAT- MEDLINE DCOM- 20250503 LR - 20250524 IS - 1648-9144 (Electronic) IS - 1010-660X (Print) IS - 1010-660X (Linking) VI - 61 IP - 1 DP - 2024 Dec 30 TI - Long-Term Outcome Following Concomitant Surgical Ablation for Atrial Fibrillation at University Hospital Basel: A Retrospective Study. LID - 10.3390/medicina61010041 [doi] LID - 41 AB - Background and Objectives: This study aims to examine the success of concomitant surgical ablation in patients with atrial fibrillation after one, three, and five years. Additionally, important predictors for rhythm outcome and rates of permanent pacemaker implantations were analyzed. Materials and Methods: In this retrospective study, we included patients who were referred to the University Hospital of Basel, Switzerland, between 2011 and 2017. Primary outcome was one-year success of surgical ablation. Secondary outcomes include heart rhythm during entire follow-up, three- and five-years success, and need for additional arrhythmia interventions (incl. pacemaker implantation). Results: A total of 120 patients were analyzed and divided into two groups: pulmonary vein isolation (n = 55) and left atrial (n = 65). The median follow-up time was 4.4 years. Sinus rhythm was present in 66%, 64%, and 67% after one, three, and five years, respectively. When adjusted for preoperative type of atrial fibrillation, left atrial lesion set increased the chance of achieving sinus rhythm within 5 years by factor 6.5. The pacemaker-implantation rate was 22%, with significantly more pacemaker implantations in the left atrial group (9% vs. 32%, p = 0.0043). Conclusions: These real-world data demonstrate the high success rate of concomitant surgical ablation for atrial fibrillation. Our study highlights the importance of preoperative discussion in an interdisciplinary heart team to weigh the effectiveness of surgical ablation against the risk of a pacemaker implantation. FAU - Hersperger, Elodie AU - Hersperger E AUID- ORCID: 0000-0002-0053-7217 AD - University Heart Center, University Hospital Basel, 4031 Basel, Switzerland. FAU - Schaerli, Nicolas AU - Schaerli N AD - University Heart Center, University Hospital Basel, 4031 Basel, Switzerland. FAU - Gahl, Brigitta AU - Gahl B AUID- ORCID: 0000-0001-8123-0438 AD - University Heart Center, University Hospital Basel, 4031 Basel, Switzerland. FAU - Reuthebuch, Oliver AU - Reuthebuch O AUID- ORCID: 0000-0003-1386-0686 AD - University Heart Center, University Hospital Basel, 4031 Basel, Switzerland. FAU - Eckstein, Friedrich S AU - Eckstein FS AD - Herzchirurgie Aarau, Hirslanden Medical Center, 5000 Aarau, Switzerland. FAU - Winkler, Bernhard AU - Winkler B AD - Department of Cardiovascular Surgery KFL, Vienna Health Network, 1210 Vienna, Austria. FAU - Grapow, Martin T R AU - Grapow MTR AD - Heart Center Hirslanden Zurich, 8008 Zurich, Switzerland. LA - eng PT - Journal Article DEP - 20241230 PL - Switzerland TA - Medicina (Kaunas) JT - Medicina (Kaunas, Lithuania) JID - 9425208 SB - IM MH - Humans MH - *Atrial Fibrillation/surgery MH - Retrospective Studies MH - Female MH - Male MH - Middle Aged MH - Aged MH - Hospitals, University/organization & administration/statistics & numerical data MH - Treatment Outcome MH - *Catheter Ablation/methods/statistics & numerical data MH - Switzerland MH - Time Factors MH - Follow-Up Studies MH - Pacemaker, Artificial/statistics & numerical data PMC - PMC11767106 OTO - NOTNLM OT - atrial fibrillation OT - cardiac surgery OT - surgical ablation COIS- The authors declare no conflicts of interest. EDAT- 2025/01/25 13:53 MHDA- 2025/01/25 13:54 PMCR- 2024/12/30 CRDT- 2025/01/25 01:14 PHST- 2024/11/22 00:00 [received] PHST- 2024/12/18 00:00 [revised] PHST- 2024/12/24 00:00 [accepted] PHST- 2025/01/25 13:54 [medline] PHST- 2025/01/25 13:53 [pubmed] PHST- 2025/01/25 01:14 [entrez] PHST- 2024/12/30 00:00 [pmc-release] AID - medicina61010041 [pii] AID - medicina-61-00041 [pii] AID - 10.3390/medicina61010041 [doi] PST - epublish SO - Medicina (Kaunas). 2024 Dec 30;61(1):41. doi: 10.3390/medicina61010041. PMID- 39857820 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250128 IS - 2227-9059 (Print) IS - 2227-9059 (Electronic) IS - 2227-9059 (Linking) VI - 13 IP - 1 DP - 2025 Jan 20 TI - Venoarterial Membrane Oxygenation in Cardiogenic Shock Complicated from an Acute Myocardial Infarction: An Overview and Comprehensive Meta-Analysis. LID - 10.3390/biomedicines13010237 [doi] LID - 237 AB - Background: Cardiogenic shock remains a significant cause of mortality in patients with acute coronary syndrome, despite early interventions, such as coronary revascularization. Mechanical circulatory support devices, particularly venoarterial extracorporeal membrane oxygenation (VA-ECMO), are increasingly being utilized to address this issue. Limited randomized controlled trials (RCTs) exist to evaluate the efficacy of VA-ECMO in cardiogenic shock related to acute coronary syndrome. Methods: A meta-analysis was conducted to assess the effectiveness of VA-ECMO in adult patients with infarct-related cardiogenic shock. Trials were identified through database searches and selected based on specific inclusion criteria. The primary outcome was 30-day all-cause mortality, with secondary outcomes including bleeding and vascular complications. Results: A total of 24 studies met the inclusion criteria and were included in the meta-analysis, involving 4706 patients. The median age of the patients was 61.8 +/- 4.1 years, with 76% of them being males. The analysis revealed that 30-day mortality rates for patients with cardiogenic shock receiving ECMO were still high, with a mortality of 63%. Vascular complications were identified as factors associated with a worse prognosis. Conclusions: The meta-analysis highlights the ongoing challenge of high mortality rates in cardiogenic shock patients despite the use of VA-ECMO. While VA-ECMO shows promise in providing circulatory support, further research is needed to explore ways to improve outcomes and reduce complications associated with the use of these devices. The complexity of patient management in cardiogenic shock cases underscores the need for a multidisciplinary approach to optimize treatment strategies and enhance patient outcomes. FAU - Sassani, Kiarash AU - Sassani K AD - Department of Cardiology, Angiology and Intensive Care, Philipps University Marburg, 35043 Marburg, Germany. FAU - Syntila, Styliani AU - Syntila S AD - Department of Cardiology, Angiology and Intensive Care, Philipps University Marburg, 35043 Marburg, Germany. FAU - Waechter, Christian AU - Waechter C AUID- ORCID: 0000-0003-1558-0696 AD - Department of Cardiology, Angiology and Intensive Care, Philipps University Marburg, 35043 Marburg, Germany. FAU - Kreutz, Julian AU - Kreutz J AD - Department of Cardiology, Angiology and Intensive Care, Philipps University Marburg, 35043 Marburg, Germany. FAU - Markus, Birgit AU - Markus B AD - Department of Cardiology, Angiology and Intensive Care, Philipps University Marburg, 35043 Marburg, Germany. FAU - Patsalis, Nikolaos AU - Patsalis N AD - Department of Cardiology, Angiology and Intensive Care, Philipps University Marburg, 35043 Marburg, Germany. FAU - Schieffer, Bernhard AU - Schieffer B AD - Department of Cardiology, Angiology and Intensive Care, Philipps University Marburg, 35043 Marburg, Germany. FAU - Chatzis, Georgios AU - Chatzis G AUID- ORCID: 0000-0003-2258-0846 AD - Department of Cardiology, Angiology and Intensive Care, Philipps University Marburg, 35043 Marburg, Germany. LA - eng PT - Journal Article DEP - 20250120 PL - Switzerland TA - Biomedicines JT - Biomedicines JID - 101691304 PMC - PMC11760826 OTO - NOTNLM OT - ECLS OT - VA-ECMO OT - cardiogenic shock OT - meta-analysis OT - myocardial infarction COIS- J.K. received research funding from CytoSorbents; B.M. received research funding from Abiomed; J.K., G.C., B.S., and B.M. received speakers' honoraria from Abiomed; J.K. and B.M. received speakers' honoraria from Astra Zeneca; B.S. received speakers' honoraria from Bayer and GSK. K.S., S.S., C.W., and N.P. have no disclosures to refer to. EDAT- 2025/01/25 13:53 MHDA- 2025/01/25 13:54 PMCR- 2025/01/20 CRDT- 2025/01/25 01:07 PHST- 2024/12/15 00:00 [received] PHST- 2025/01/09 00:00 [revised] PHST- 2025/01/16 00:00 [accepted] PHST- 2025/01/25 13:54 [medline] PHST- 2025/01/25 13:53 [pubmed] PHST- 2025/01/25 01:07 [entrez] PHST- 2025/01/20 00:00 [pmc-release] AID - biomedicines13010237 [pii] AID - biomedicines-13-00237 [pii] AID - 10.3390/biomedicines13010237 [doi] PST - epublish SO - Biomedicines. 2025 Jan 20;13(1):237. doi: 10.3390/biomedicines13010237. PMID- 39857023 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260923 IS - 2075-4418 (Print) IS - 2075-4418 (Electronic) IS - 2075-4418 (Linking) VI - 15 IP - 2 DP - 2025 Jan 9 TI - Anderson-Fabry Disease: An Overview of Current Diagnosis, Arrhythmic Risk Stratification, and Therapeutic Strategies. LID - 10.3390/diagnostics15020139 [doi] LID - 139 AB - Anderson-Fabry disease (AFD) is a rare X-linked lysosomal storage disorder characterized by the accumulation of globotriaosylceramide, leading to multi-organ involvement and significant morbidity. Cardiovascular manifestations, particularly arrhythmias, are common and pose a considerable risk to affected individuals. This overview examines current approaches to arrhythmic risk stratification in AFD, focusing on the identification, assessment, and management of cardiac arrhythmias associated with the disease. We explore advancements in diagnostic techniques, including echocardiography, cardiac MRI, and ambulatory ECG monitoring, to enhance the detection of arrhythmogenic substrate. Furthermore, we discuss the role of genetic and biochemical markers in predicting arrhythmic risk and the implications for personalized treatment strategies. Current therapeutic interventions, including enzyme replacement therapy and antiarrhythmic medications, are reviewed in the context of their efficacy and limitations. Finally, we highlight ongoing research and future directions with the aim of improving arrhythmic risk assessment and management in AFD. This overview underscores the need for a multidisciplinary approach to optimize care and outcomes for patients with AFD. FAU - Tognola, Chiara AU - Tognola C AUID- ORCID: 0009-0003-7782-8949 AD - Clinical Cardiology Unit, De Gasperis Cardio Center, Niguarda Hospital, 20162 Milan, Italy. FAU - Ruzzenenti, Giacomo AU - Ruzzenenti G AUID- ORCID: 0009-0001-6538-6907 AD - Clinical Cardiology Unit, De Gasperis Cardio Center, Niguarda Hospital, 20162 Milan, Italy. FAU - Maloberti, Alessandro AU - Maloberti A AUID- ORCID: 0000-0002-2612-6264 AD - Clinical Cardiology Unit, De Gasperis Cardio Center, Niguarda Hospital, 20162 Milan, Italy. AD - School of Medicine and Surgery, University of Milano-Bicocca, 20126 Milan, Italy. FAU - Varrenti, Marisa AU - Varrenti M AUID- ORCID: 0000-0003-4375-5991 AD - Electrophysiology Unit, De Gasperis Cardio Center, Niguarda Hospital, 20162 Milan, Italy. FAU - Mazzone, Patrizio AU - Mazzone P AUID- ORCID: 0000-0001-5775-1874 AD - Electrophysiology Unit, De Gasperis Cardio Center, Niguarda Hospital, 20162 Milan, Italy. FAU - Giannattasio, Cristina AU - Giannattasio C AD - Clinical Cardiology Unit, De Gasperis Cardio Center, Niguarda Hospital, 20162 Milan, Italy. AD - School of Medicine and Surgery, University of Milano-Bicocca, 20126 Milan, Italy. FAU - Guarracini, Fabrizio AU - Guarracini F AUID- ORCID: 0000-0003-3473-1058 AD - Electrophysiology Unit, De Gasperis Cardio Center, Niguarda Hospital, 20162 Milan, Italy. LA - eng PT - Journal Article PT - Review DEP - 20250109 PL - Switzerland TA - Diagnostics (Basel) JT - Diagnostics (Basel, Switzerland) JID - 101658402 PMC - PMC11763368 OTO - NOTNLM OT - Anderson-Fabry disease OT - arrhythmic risk stratification OT - atrial fibrillation OT - conduction system disorders OT - sudden cardiac death OT - tachyarrhythmias COIS- The authors declare no conflicts of interest. EDAT- 2025/01/25 13:54 MHDA- 2025/01/25 13:55 PMCR- 2025/01/09 CRDT- 2025/01/25 01:03 PHST- 2024/11/28 00:00 [received] PHST- 2024/12/22 00:00 [revised] PHST- 2025/01/06 00:00 [accepted] PHST- 2025/01/25 13:55 [medline] PHST- 2025/01/25 13:54 [pubmed] PHST- 2025/01/25 01:03 [entrez] PHST- 2025/01/09 00:00 [pmc-release] AID - diagnostics15020139 [pii] AID - diagnostics-15-00139 [pii] AID - 10.3390/diagnostics15020139 [doi] PST - epublish SO - Diagnostics (Basel). 2025 Jan 9;15(2):139. doi: 10.3390/diagnostics15020139. PMID- 39854101 OWN - NLM STAT- MEDLINE DCOM- 20250502 LR - 20260309 IS - 1540-8175 (Electronic) IS - 0742-2822 (Linking) VI - 42 IP - 1 DP - 2025 Jan TI - Imaging Lessons From Multidisciplinary Team Meetings at a Quaternary Referral Center: A Case-Based Review of Radiology Findings in Complex Adult Congenital Heart Disease. PG - e70082 LID - 10.1111/echo.70082 [doi] AB - Optimal management of adult congenital heart disease (ACHD) requires a multidisciplinary team (MDT) approach, fostering a collaborative culture over an individualistic approach. Within this framework, subspecialty-trained radiologists provide crucial imaging expertise, supporting cardiologists, surgeons, and interventional cardiologists in diagnoses, treatment planning, and follow-up evaluations. Advanced imaging tools and a nuanced understanding of surgical and interventional procedures enable radiologists to provide valuable insights to clinicians. In this review, we discuss the structure of ACHD MDT meeting at a quaternary center, briefly review the general principles of interventions in ACHD and the subsequent complications encountered in adulthood, formulate an approach to imaging and reporting such complex repaired cases, and review the key information to be mentioned in the report for further surgery/intervention. In this review, we use the format of eight key take-home lessons from an MDT management practice in ACHD. CI - (c) 2025 Wiley Periodicals LLC. FAU - Reghunath, Anjuna AU - Reghunath A AD - Radiology Department, Liverpool Heart and Chest Hospital NHS Foundation Trust, Liverpool, UK. FAU - Kharabish, Ahmed AU - Kharabish A AD - Radiology Department, Liverpool Heart and Chest Hospital NHS Foundation Trust, Liverpool, UK. AD - Radiology Department, Cairo University Hospitals, Cairo, Egypt. FAU - Radike, Monika AU - Radike M AUID- ORCID: 0000-0002-4004-4150 AD - Radiology Department, Liverpool Heart and Chest Hospital NHS Foundation Trust, Liverpool, UK. AD - Liverpool Centre for Cardiovascular Science at the University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, UK. LA - eng PT - Journal Article PT - Review PL - United States TA - Echocardiography JT - Echocardiography (Mount Kisco, N.Y.) JID - 8511187 SB - IM MH - Adult MH - Female MH - Humans MH - Male MH - *Echocardiography/methods MH - *Heart Defects, Congenital/diagnostic imaging/surgery MH - *Patient Care Team MH - Referral and Consultation OTO - NOTNLM OT - cardiovascular computed tomography OT - cardiovascular magnetic resonance OT - complex adult congenital heart disease OT - multidisciplinary team EDAT- 2025/01/24 17:37 MHDA- 2025/01/24 18:25 CRDT- 2025/01/24 11:54 PHST- 2025/01/03 00:00 [revised] PHST- 2024/11/29 00:00 [received] PHST- 2025/01/08 00:00 [accepted] PHST- 2025/01/24 18:25 [medline] PHST- 2025/01/24 17:37 [pubmed] PHST- 2025/01/24 11:54 [entrez] AID - 10.1111/echo.70082 [doi] PST - ppublish SO - Echocardiography. 2025 Jan;42(1):e70082. doi: 10.1111/echo.70082. PMID- 39840669 OWN - NLM STAT- MEDLINE DCOM- 20250512 LR - 20260427 IS - 1651-2227 (Electronic) IS - 0803-5253 (Print) IS - 0803-5253 (Linking) VI - 114 IP - 6 DP - 2025 Jun TI - Children With Sydenham Chorea and Psychiatric Disorders Had Variable Long-Term Outcomes and Required Multidisciplinary Management. PG - 1437-1444 LID - 10.1111/apa.17590 [doi] AB - AIM: Sydenham chorea (SC) is a globally significant, post-streptococcal, childhood neuropsychiatric condition that is rare in western Europe. This retrospective single-centre study focused on children with neuropsychiatric features of SC. METHODS: Participants were recruited from neuropsychiatry referrals to a regional paediatric neurology department in Glasgow, Scotland, from 2009 to 2012. Interviews established the course of SC and the children's medical and family histories. Semi-structured psychiatric interviews explored current and past episodes of psychopathology. RESULTS: We studied 12 children (seven girls) with a mean age of 13 (range 10-15) years, and an average of six (range 4-10) years after their SC symptoms began. Before they displayed symptoms, seven children had been suspected or diagnosed neurodevelopmental problems and four had separation anxiety. Their physical symptoms were often debilitating. Psychopathology was most severe during their first episode and SC diagnoses were sometimes delayed. Educational problems were frequent. Multiple psychiatric conditions were diagnosed in 11 children and anxiety and attention deficit hyperactivity disorder were the most common. Relapses occurred in nine cases. Additional services that were accessed included cardiology, rheumatology, physiotherapy, occupational therapy and speech therapy. Medication included prophylactic penicillin and symptomatic treatment. CONCLUSION: Children with SC and psychiatric disorders had variable long-term outcomes and required multidisciplinary management. CI - (c) 2025 The Author(s). Acta Paediatrica published by John Wiley & Sons Ltd on behalf of Foundation Acta Paediatrica. FAU - Mushet, Nadine AU - Mushet N AUID- ORCID: 0009-0005-8654-765X AD - Children and Young People's Services, Cumbria, Northumberland, Tyne & Wear NHS Trust, Newcastle, UK. AD - Department of Health and Wellbeing, University of Glasgow, Glasgow, UK. FAU - Morton, Michael AU - Morton M AD - Department of Health and Wellbeing, University of Glasgow, Glasgow, UK. FAU - Minnis, Helen AU - Minnis H AD - Department of Health and Wellbeing, University of Glasgow, Glasgow, UK. FAU - Gillberg, Christopher AU - Gillberg C AUID- ORCID: 0000-0001-8848-1934 AD - Department of Health and Wellbeing, University of Glasgow, Glasgow, UK. AD - Gillberg Neuropsychiatry Centre, Institute of Neuroscience and Physiology, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden. LA - eng GR - Royal College of Psychiatrists in Scotland/ GR - Yorkhill Children's Charity/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20250122 PL - Norway TA - Acta Paediatr JT - Acta paediatrica (Oslo, Norway : 1992) JID - 9205968 SB - IM MH - Humans MH - Child MH - *Chorea/therapy/complications/diagnosis/psychology MH - Female MH - Male MH - Adolescent MH - Retrospective Studies MH - *Mental Disorders/therapy/complications/diagnosis PMC - PMC12066885 OTO - NOTNLM OT - Sydenham chorea OT - auto-immune neuropsychiatric disorders OT - movement disorder in childhood OT - post-streptococcal disorder OT - rheumatic fever COIS- The authors declare no conflicts of interest. EDAT- 2025/01/22 12:28 MHDA- 2025/05/12 06:33 PMCR- 2025/05/12 CRDT- 2025/01/22 06:42 PHST- 2025/01/07 00:00 [revised] PHST- 2023/11/20 00:00 [received] PHST- 2025/01/09 00:00 [accepted] PHST- 2025/05/12 06:33 [medline] PHST- 2025/01/22 12:28 [pubmed] PHST- 2025/01/22 06:42 [entrez] PHST- 2025/05/12 00:00 [pmc-release] AID - APA17590 [pii] AID - 10.1111/apa.17590 [doi] PST - ppublish SO - Acta Paediatr. 2025 Jun;114(6):1437-1444. doi: 10.1111/apa.17590. Epub 2025 Jan 22. PMID- 39836291 OWN - NLM STAT- MEDLINE DCOM- 20250326 LR - 20250623 IS - 1435-4373 (Electronic) IS - 0934-9723 (Print) IS - 0934-9723 (Linking) VI - 44 IP - 4 DP - 2025 Apr TI - Vertebral osteomyelitis in patients with infective endocarditis: prevalence, risk factors and mortality. PG - 819-825 LID - 10.1007/s10096-025-05041-8 [doi] AB - PURPOSE: Infective endocarditis (IE) can be complicated by vertebral osteomyelitis (VO). This study investigates risk factors associated with VO in patients with infective endocarditis, and 6-month mortality and relapse rates in patients with IE and concomitant VO. METHODS: We performed a observational study in two hospitals between September 2016 and October 2022. Patients with possible or definite IE according European Society of Cardiology (2015) modified criteria were retrieved from the local endocarditis team registries. The VO diagnosis was based on radiological signs, irrespective of clinical symptoms. Multivariable logistic regression analysis was performed to identify risk factors for vertebral osteomyelitis. RESULTS: We included 633 consecutive patients with IE. A total of 229 (36.2%) patients had prosthetic valves and 127 (20.1%) had cardiac implantable electronic devices. The most frequent causative micro-organism was Streptococcus species (217, 34.3%), followed by Staphylococcus aureus (167, 26.4%). VO was diagnosed in 73 patients (11.5%, 95% CI 9.0%-14.0%). Enterococcus spp.(OR 2.48, 95% CI 1.31-4.52) and age (OR 1.04 per year, 95% CI 1.02-1.06) were independently associated with concomitant VO. The 6-month mortality risk did not differ between patients with (16/73, 21.9%) or without (110/560, 19.6%) VO (HR 1.13, 95% CI 0.67-1.91). Relapse rate was higher in patients with VO but the difference was not statistically significant (16.1 vs. 7.5%, OR 3.62, 95% CI 0.94-13.34). CONCLUSIONS: Twelve percent of patients with IE also had VO. Among older patients and patients with IE caused by enterococci, there should be a higher index of suspicion for vertebral infection. CI - (c) 2025. The Author(s). FAU - Douiyeb, S AU - Douiyeb S AUID- ORCID: 0000-0002-2533-4627 AD - Department of Internal Medicine, Amsterdam UMC location AMC, Amsterdam, The Netherlands. s.douiyeb@amsterdamumc.nl. AD - Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands. s.douiyeb@amsterdamumc.nl. FAU - Sigaloff, K C E AU - Sigaloff KCE AD - Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands. AD - Department of Internal Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. FAU - Ulas, E G AU - Ulas EG AD - Department of Cardiology, Noordwest Hospital, Alkmaar, The Netherlands. FAU - Duffels, M G J AU - Duffels MGJ AD - Department of Cardiology, Noordwest Hospital, Alkmaar, The Netherlands. FAU - Drexhage, O AU - Drexhage O AD - Department of Cardiology, Noordwest Hospital, Alkmaar, The Netherlands. FAU - Germans, T AU - Germans T AD - Department of Cardiology, Noordwest Hospital, Alkmaar, The Netherlands. FAU - Wagenaar, J F P AU - Wagenaar JFP AD - Department of Internal Medicine, Noordwest Hospital, Alkmaar, The Netherlands. FAU - Buis, D T P AU - Buis DTP AD - Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands. AD - Department of Internal Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. FAU - van der Vaart, T W AU - van der Vaart TW AD - Department of Internal Medicine, Amsterdam UMC location AMC, Amsterdam, The Netherlands. AD - Julius Center for Health Sciences and Primary Care, UMC Utrecht, Utrecht University, Utrecht, The Netherlands. FAU - van Werkhoven, C H AU - van Werkhoven CH AD - Julius Center for Health Sciences and Primary Care, UMC Utrecht, Utrecht University, Utrecht, The Netherlands. FAU - Prins, J M AU - Prins JM AD - Department of Internal Medicine, Amsterdam UMC location AMC, Amsterdam, The Netherlands. FAU - Umans, V A W M AU - Umans VAWM AD - Department of Cardiology, Noordwest Hospital, Alkmaar, The Netherlands. LA - eng PT - Journal Article PT - Observational Study DEP - 20250121 PL - Germany TA - Eur J Clin Microbiol Infect Dis JT - European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology JID - 8804297 SB - IM MH - Humans MH - Male MH - Female MH - *Osteomyelitis/epidemiology/mortality/microbiology/etiology MH - Risk Factors MH - Aged MH - Middle Aged MH - Prevalence MH - Aged, 80 and over MH - *Endocarditis/complications/mortality/microbiology/epidemiology MH - *Endocarditis, Bacterial/complications/mortality MH - Adult MH - Recurrence PMC - PMC11947019 OTO - NOTNLM OT - Age OT - Enterococci OT - Infectious endocarditis OT - Spondylodiscitis OT - Vertebral osteomyelitis COIS- Declarations. Ethical approval: This study is an observational study. The study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of University of Amsterdam UMC (Date 12-10-2023./No METC2023.0424). In the Noordwest Hospital the Research Ethics Committee has confirmed that no ethical approval is required. Competing interests: Dr. van Werkhoven has received grants from DaVolterra, bioMerieux and LimmaTech which were paid to the institution. Dr. van Werkhoven has received consulting fees from Merck/MSD and Sanofi-Pasteur in regards to pneumococcal vaccines. These payments were made to the institution. EDAT- 2025/01/21 12:26 MHDA- 2025/03/27 05:34 PMCR- 2025/01/21 CRDT- 2025/01/21 11:17 PHST- 2024/11/01 00:00 [received] PHST- 2025/01/12 00:00 [accepted] PHST- 2025/03/27 05:34 [medline] PHST- 2025/01/21 12:26 [pubmed] PHST- 2025/01/21 11:17 [entrez] PHST- 2025/01/21 00:00 [pmc-release] AID - 10.1007/s10096-025-05041-8 [pii] AID - 5041 [pii] AID - 10.1007/s10096-025-05041-8 [doi] PST - ppublish SO - Eur J Clin Microbiol Infect Dis. 2025 Apr;44(4):819-825. doi: 10.1007/s10096-025-05041-8. Epub 2025 Jan 21. PMID- 39833881 OWN - NLM STAT- MEDLINE DCOM- 20250121 LR - 20250522 IS - 1472-6920 (Electronic) IS - 1472-6920 (Linking) VI - 25 IP - 1 DP - 2025 Jan 17 TI - Exploring effects of a booster workshop on progression and retention of resuscitation skills of residents when added to regular low-dose simulation. PG - 85 LID - 10.1186/s12909-025-06705-x [doi] LID - 85 AB - BACKGROUND: Improving the resuscitation and teamwork skills of residents is key to better outcomes of in-hospital cardiac arrest events. This study aims to explore the effects of regular low-dose simulation combined with a booster workshop on the progression and retention of resuscitation skills and teamwork among residents. METHODS: This comparative study took place at a teaching hospital in Northern Taiwan from August 2019 to June 2021. Residents were divided into two groups: the control group received regular low-dose simulation with faculty-led debriefing at the 1st, 6th, and 11th months, while the intervention group participated in an additional 3-hour simulation workshop one week before the 6th-month scenario. The workshop focused on resuscitation and teamwork skills. The study evaluated medical task performance, teamwork, patient safety attitudes, and timing of key resuscitation actions through standardized simulation scenarios, with the assessments occurring at the 1st, 6th, and 11th months (pre-test, mid-test, post-test, respectively). RESULTS: Outcome measures in medical task performance and team leader behavior showed statistically significant improvement in both groups (p < 0.05) from pre-test to mid-test. After the intervention, the exposure group demonstrated significantly better results in medical task performance, team leader behavior, patient safety attitudes, and the timing of chest compression initiation compared to the control group (p < 0.05). Five months after the intervention, a significant decline in most measured outcomes was observed in the exposure group (p < 0.05). Despite this decline, the exposure group still performed significantly higher than the control group across most measured outcomes. CONCLUSIONS: This study demonstrates the potential and advantages of integrating simulation-based training into the clinical training curriculum for residents to improve medical task performance and teamwork behaviors for handling in-hospital cardiac arrest scenarios. The observed decline in skills over time supports the inclusion of regular refresher courses to maintain and advance these vital competencies. CI - (c) 2025. The Author(s). FAU - Chen, Hui-Wen AU - Chen HW AD - Center for Education in Medical Simulation, Taipei Medical University, 250 Wuxing Street, Taipei, 110301, Taiwan. FAU - Tsai, Hung-Wei AU - Tsai HW AD - Department of Education and Humanities in Medicine, School of Medicine, College of Medicine, Taipei Medical University, 250 Wuxing Street, Taipei, 110301, Taiwan. AD - Department of Emergency Medicine, Taipei Medical University Hospital, 252 Wuxing Street, Taipei, 110301, Taiwan. FAU - Chen, Yi-Chun AU - Chen YC AD - Department of Education and Humanities in Medicine, School of Medicine, College of Medicine, Taipei Medical University, 250 Wuxing Street, Taipei, 110301, Taiwan. AD - Department of Emergency Medicine, Taipei Medical University Hospital, 252 Wuxing Street, Taipei, 110301, Taiwan. FAU - Chiu, Yu-Jui AU - Chiu YJ AD - Department of Emergency Medicine, Taipei Medical University Hospital, 252 Wuxing Street, Taipei, 110301, Taiwan. FAU - Kang, Enoch Yi-No AU - Kang EY AD - Institute of Health Policy & Management, College of Public Health, National Taiwan University, No. 1, Section 4, Roosevelt Rd, Taipei, 106319, Taiwan. AD - Department of Health Care Management, College of Health Technology, National Taipei University of Nursing and Health Sciences, No. 365, Mingde Rd, Taipei, 112303, Taiwan. AD - Evidence-Based Medicine Center, Wan Fang Hospital, Taipei Medical University, No. 111, Sec. 3, Xinglong Rd, Taipei, 116079, Taiwan. FAU - Hsu, Yi-Ting AU - Hsu YT AD - Department of Emergency Medicine, Taipei Medical University Hospital, 252 Wuxing Street, Taipei, 110301, Taiwan. FAU - Issenberg, S Barry AU - Issenberg SB AD - University of Miami Gordon Center for Simulation and Innovation in Medical Education, 1120 NW 14th St, Miami, FL, 33136, USA. bissenbe@med.miami.edu. FAU - Wu, Jen-Chieh AU - Wu JC AD - Department of Emergency Medicine, Taipei Medical University Hospital, 252 Wuxing Street, Taipei, 110301, Taiwan. lendiswu@tmu.edu.tw. AD - Department of Education and Humanities in Medicine, School of Medicine, College of Medicine, Taipei Medical University, 250 Wuxing Street, Taipei, 110301, Taiwan. lendiswu@tmu.edu.tw. LA - eng PT - Comparative Study PT - Journal Article DEP - 20250117 PL - England TA - BMC Med Educ JT - BMC medical education JID - 101088679 SB - IM MH - Humans MH - *Internship and Residency MH - Taiwan MH - *Clinical Competence MH - *Simulation Training/methods MH - Male MH - Female MH - *Cardiopulmonary Resuscitation/education MH - Patient Care Team MH - Heart Arrest/therapy MH - Adult MH - *Resuscitation/education MH - Educational Measurement PMC - PMC11744814 COIS- Declarations. Ethics approval and consent to participate: The study was approved by the institutional review board approved this study of the Taipei Medical University (IRB # N202308050). After explaining the purposes and procedures of the study, informed consent was obtained from all students. All methods were conducted following the relevant guidelines and regulations. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2025/01/21 09:03 MHDA- 2025/01/21 09:04 PMCR- 2025/01/17 CRDT- 2025/01/20 23:44 PHST- 2024/06/06 00:00 [received] PHST- 2025/01/13 00:00 [accepted] PHST- 2025/01/21 09:04 [medline] PHST- 2025/01/21 09:03 [pubmed] PHST- 2025/01/20 23:44 [entrez] PHST- 2025/01/17 00:00 [pmc-release] AID - 10.1186/s12909-025-06705-x [pii] AID - 6705 [pii] AID - 10.1186/s12909-025-06705-x [doi] PST - epublish SO - BMC Med Educ. 2025 Jan 17;25(1):85. doi: 10.1186/s12909-025-06705-x. PMID- 39833651 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250307 IS - 1568-5888 (Print) IS - 1876-6250 (Electronic) IS - 1568-5888 (Linking) VI - 33 IP - 2 DP - 2025 Feb TI - Yield of family screening for dilated cardiomyopathy: 10-year experience at a multidisciplinary cardiogenetic outpatient clinic. PG - 46-54 LID - 10.1007/s12471-024-01924-1 [doi] AB - INTRODUCTION: Current family screening approaches in dilated cardiomyopathy (DCM) depend on the presence or absence of a familial genetic variant, in which variant pathogenicity (i.e. benign or pathogenic) classification drives screening recommendations. However, this approach has never been systematically evaluated. METHODS: To describe the yield of DCM family screening stratified by variant classification in the Netherlands, we included 358 relatives (mean age +/- standard deviation: 44.4 +/- 15.9 years at baseline; 52% female; 41% (likely) pathogenic (LP/P) variant carriers from 210 families). Demographics, symptoms and genetic/cardiac test results were obtained. Endpoints were the development of DCM (left ventricular ejection fraction < 50% of non-ischaemic aetiology) or occurrence of major adverse cardiovascular events (MACE) (i.e. heart failure hospitalisation, ventricular arrhythmia or death). Probability of DCM or MACE was assessed with the Kaplan-Meier method. RESULTS: DCM was present in 32 relatives (9%) (25/32 (78%) with LP/P variant) at baseline and in an additional 10/97 relatives (10%) (9/10 (90%) with LP/P variant) who were re-evaluated during a median follow-up time of 5.0 years (interquartile range: 3.2-7.4). Of the 128 relatives without the familial LP/P variant, none developed DCM. MACE was experienced by 5 relatives (1%) (4/5 (80%) with LP/P variant), all of whom had DCM at the time of the event. CONCLUSION: The yield of DCM family screening was ~10% at baseline and another ~10% during 5‑year follow-up. Relatives without the familial LP/P variant could be safely discharged. These results reinforce the use of a genetics-first screening approach in relatives from families with an LP/P variant. This will lower the burden on resources in Dutch hospitals and help allocate resources to those who are most likely to benefit. CI - (c) 2025. The Author(s). FAU - Thierry, Isabelle P AU - Thierry IP AD - Department of Cardiology, University Medical Centre Utrecht, Utrecht, The Netherlands. FAU - Muller, Steven A AU - Muller SA AD - Department of Cardiology, University Medical Centre Utrecht, Utrecht, The Netherlands. AD - Netherlands Heart Institute, Utrecht, The Netherlands. AD - Member of the European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart: ERN GUARD-Heart' (ERN GUARDHEART; http://guardheart.ern-net.eu), Utrecht, The Netherlands. FAU - Baas, Annette F AU - Baas AF AD - Member of the European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart: ERN GUARD-Heart' (ERN GUARDHEART; http://guardheart.ern-net.eu), Utrecht, The Netherlands. AD - Department of Genetics, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands. FAU - Dooijes, Dennis AU - Dooijes D AD - Netherlands Heart Institute, Utrecht, The Netherlands. AD - Department of Genetics, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands. FAU - van Loon, R Laura E AU - van Loon RLE AD - Member of the European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart: ERN GUARD-Heart' (ERN GUARDHEART; http://guardheart.ern-net.eu), Utrecht, The Netherlands. AD - Department of Genetics, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands. FAU - Schoemaker, Angela E AU - Schoemaker AE AD - Member of the European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart: ERN GUARD-Heart' (ERN GUARDHEART; http://guardheart.ern-net.eu), Utrecht, The Netherlands. AD - Department of Genetics, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands. FAU - van der Harst, Pim AU - van der Harst P AD - Department of Cardiology, University Medical Centre Utrecht, Utrecht, The Netherlands. AD - Member of the European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart: ERN GUARD-Heart' (ERN GUARDHEART; http://guardheart.ern-net.eu), Utrecht, The Netherlands. FAU - Oerlemans, Marish I F J AU - Oerlemans MIFJ AD - Department of Cardiology, University Medical Centre Utrecht, Utrecht, The Netherlands. AD - Member of the European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart: ERN GUARD-Heart' (ERN GUARDHEART; http://guardheart.ern-net.eu), Utrecht, The Netherlands. FAU - Baars, Hubert F AU - Baars HF AD - HartKliniek, Almere-Stad, The Netherlands. FAU - Hassink, Rutger J AU - Hassink RJ AD - Department of Cardiology, University Medical Centre Utrecht, Utrecht, The Netherlands. AD - Member of the European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart: ERN GUARD-Heart' (ERN GUARDHEART; http://guardheart.ern-net.eu), Utrecht, The Netherlands. FAU - Asselbergs, Folkert W AU - Asselbergs FW AD - Member of the European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart: ERN GUARD-Heart' (ERN GUARDHEART; http://guardheart.ern-net.eu), Utrecht, The Netherlands. AD - Institute of Cardiovascular Science, Faculty Netherlands Health Sciences, University College London, London, UK. AD - Department of Cardiology, Amsterdam University Medical Centres, University of Amsterdam, Amsterdam, The Netherlands. AD - Health Data Research UK and Institute of Health Informatics, University College London, London, UK. FAU - van Tintelen, J Peter AU - van Tintelen JP AD - Netherlands Heart Institute, Utrecht, The Netherlands. AD - Member of the European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart: ERN GUARD-Heart' (ERN GUARDHEART; http://guardheart.ern-net.eu), Utrecht, The Netherlands. AD - Department of Genetics, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands. FAU - Te Riele, Anneline S J M AU - Te Riele ASJM AD - Department of Cardiology, University Medical Centre Utrecht, Utrecht, The Netherlands. ariele@umcutrecht.nl. AD - Netherlands Heart Institute, Utrecht, The Netherlands. ariele@umcutrecht.nl. AD - Member of the European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart: ERN GUARD-Heart' (ERN GUARDHEART; http://guardheart.ern-net.eu), Utrecht, The Netherlands. ariele@umcutrecht.nl. LA - eng GR - #101115536/HORIZON EUROPE Framework Programme/ GR - Young Talent Program Predict2/Netherlands Heart Institute/ GR - Off Road Grant 2021/ZONMW_/ZonMw/Netherlands PT - Journal Article DEP - 20250120 PL - Netherlands TA - Neth Heart J JT - Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation JID - 101095458 PMC - PMC11757811 OTO - NOTNLM OT - Cardiac screening OT - Cardiac testing OT - Cascade screening OT - Cascade testing OT - DCM OT - Dilated cardiomyopathy OT - Family screening COIS- Declarations. Conflict of interest: I.P. Thierry, S.A. Muller, A.F. Baas, D. Dooijes, R.L.E. van Loon, A.E. Schoemaker, M.I.F.J. Oerlemans, H.F. Baars, R.J. Hassink, F.W. Asselbergs and J.P. van Tintelen declare that they have no competing interests. A.S.J.M. te Riele is a consultant for Tenaya Therapeutics, BioMarin and Rocket Pharmaceuticals for unrelated work. P. van der Harst is the Editor-in-Chief of the Netherlands Heart Journal. Ethical standards: For this article no studies with human participants or animals were performed by any of the authors. All studies mentioned were in accordance with the ethical standards indicated in each case. EDAT- 2025/01/21 09:02 MHDA- 2025/01/21 09:03 PMCR- 2025/01/20 CRDT- 2025/01/20 23:34 PHST- 2024/12/02 00:00 [accepted] PHST- 2025/01/21 09:03 [medline] PHST- 2025/01/21 09:02 [pubmed] PHST- 2025/01/20 23:34 [entrez] PHST- 2025/01/20 00:00 [pmc-release] AID - 10.1007/s12471-024-01924-1 [pii] AID - 1924 [pii] AID - 10.1007/s12471-024-01924-1 [doi] PST - ppublish SO - Neth Heart J. 2025 Feb;33(2):46-54. doi: 10.1007/s12471-024-01924-1. Epub 2025 Jan 20. PMID- 39832540 OWN - NLM STAT- MEDLINE DCOM- 20250502 LR - 20250502 IS - 1535-6280 (Electronic) IS - 0146-2806 (Linking) VI - 50 IP - 6 DP - 2025 Jun TI - The diagnosis and treatment of asymptomatic and symptomatic patients with carotid artery stenosis. PG - 102992 LID - S0146-2806(25)00015-5 [pii] LID - 10.1016/j.cpcardiol.2025.102992 [doi] AB - Carotid artery atherosclerotic stenosis is an important annual cause of stroke in the United States. Moreover, the incidence of carotid artery stenosis is significantly increasing due to the widespread popularity of high fat and high salt diets, sedentary lifestyles, and the increasing age of the population. Of major importance to cardiovascular specialists is the fact that individuals with atherosclerotic carotid artery stenosis can have a prevalence of atherosclerotic coronary artery disease as high as 50 to 75%. Vascular screening for carotid artery stenosis with Doppler ultrasound should be considered for all symptomatic patients with possible carotid stenosis and also considered for asymptomatic patients with (1) symptomatic peripheral arterial disease, coronary artery disease, or atherosclerotic aortic aneurysm or, (2) multiple atherosclerotic risk factors. Carotid artery atherosclerotic plaques that are at high risk for rupture and thrombosis or cerebral embolization are characterized by large lipid cores, intraplaque hemorrhage, thin fibrous caps less than 165 mums that are infiltrated by macrophages and T cells or have surface ulcer(s) or fissures. Carotid artery plaque rupture with cerebral embolism can cause a stroke, transient ischemic attacks (TIA), or ipsilateral blindness (amaurosis fugax). Medical treatment based on the recommendations of the American and European Societies for Vascular Surgery and the American Heart Association for symptomatic patients with carotid stenosis and also asymptomatic patients with high risk carotid stenosis plaques include antiplatelet drugs, antihypertensive drugs for hypertension control and lipid lowering drugs. Management strategies and decisions about carotid revascularization in asymptomatic patients with high risk carotid stenosis should involve a multidisciplinary team and shared decision-making is recommended. The 30 day and five to 10 year outcomes in asymptomatic carotid stenosis patients who have undergone carotid endarterectomy, carotid stenting and/or optimal medical therapy are summarized from the Veterans Administration Cooperative Study, the Asymptomatic Carotid Atherosclerosis Study and the Asymptomatic Carotid Surgery Trials. The current Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial (CREST-2) should help to resolve the debate regarding carotid artery revascularization versus primary medical treatment in asymptomatic patients with >70% carotid artery stenosis. Symptomatic patients who present within 4.5 hours of stroke onset require evaluation for acute intravenous pharmacologic thrombolysis and patients who present with large vessel occlusion within 24 hours of symptom onset should be considered for mechanical thrombectomy to reduce the neurologic deficit. Patients with carotid artery stenosis who present with a history of cerebral infarct in the preceding six months due to cerebral embolism require medical treatment and evaluation by a multidisciplinary team for carotid revascularization in order to prevent future strokes or TIAs. The outcomes of the North American Symptomatic Carotid Endarterectomy Trial, Carotid Revascularization Endarterectomy Versus Stent Trial, Stent-Supported Percutaneous Angioplasty of the Carotid Artery vs. Endarterectomy Trial, and the Safety and Efficacy Study for Reverse Flow Used during Carotid Artery Stenting Procedure trials for symptomatic patients with carotid stenosis are reviewed. A synopsis of treatment guidelines for symptomatic and asymptomatic carotid stenosis patients from the American and European Societies of Vascular Surgery and the American Heart Association/American Stroke Association are presented. Each patient with carotid artery stenosis must be carefully evaluated to determine the best treatment based on the clinical presentation, the imaging and laboratory diagnostic information, the treatment guidelines, and the patient needs and preferences as well as the patient's social and cultural factors. CI - Copyright (c) 2025 Elsevier Inc. All rights reserved. FAU - Henning, Robert J AU - Henning RJ AD - University of South Florida and The University Of Florida College Of Medicine, Florida, United States. Electronic address: roberthenningmd@gmail.com. FAU - Hoh, Brian L AU - Hoh BL AD - University of South Florida and The University Of Florida College Of Medicine, Florida, United States. LA - eng PT - Journal Article PT - Review DEP - 20250118 PL - Netherlands TA - Curr Probl Cardiol JT - Current problems in cardiology JID - 7701802 SB - IM MH - Humans MH - *Carotid Stenosis/diagnosis/therapy/complications/epidemiology MH - *Endarterectomy, Carotid/methods MH - Asymptomatic Diseases MH - Risk Factors MH - Stroke/etiology/prevention & control MH - Stents OTO - NOTNLM OT - Carotid artery plaque OT - Carotid plaque embolization OT - Carotid revascularization OT - Carotid stenting OT - Stroke COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/01/21 09:00 MHDA- 2025/05/03 00:37 CRDT- 2025/01/20 19:11 PHST- 2025/01/15 00:00 [received] PHST- 2025/01/16 00:00 [accepted] PHST- 2025/05/03 00:37 [medline] PHST- 2025/01/21 09:00 [pubmed] PHST- 2025/01/20 19:11 [entrez] AID - S0146-2806(25)00015-5 [pii] AID - 10.1016/j.cpcardiol.2025.102992 [doi] PST - ppublish SO - Curr Probl Cardiol. 2025 Jun;50(6):102992. doi: 10.1016/j.cpcardiol.2025.102992. Epub 2025 Jan 18. PMID- 39830183 OWN - NLM STAT- MEDLINE DCOM- 20250120 LR - 20250606 IS - 2296-2565 (Electronic) IS - 2296-2565 (Linking) VI - 12 DP - 2024 TI - Implementation of a value-based approach for older people who have suffered an acute myocardial infarction: study protocol. PG - 1518469 LID - 10.3389/fpubh.2024.1518469 [doi] LID - 1518469 AB - INTRODUCTION: Due to the rapid aging of the global population, new approaches are required to improve the quality of life of older people and to reduce healthcare system expenditures. One of the approaches that can be used is value-based healthcare. This article describes a value-based solution for older people who have suffered a myocardial infarction. METHODS: This solution combines the work of healthcare professionals and informal caregivers and the use of modern and user-friendly technologies to support the achievement of patients' values. Patients older than 65 years who have suffered a myocardial infarction will be divided into control and intervention groups within a pre-post-controlled design research study. Members of the intervention group will be provided with a personalized plan developed by healthcare professionals and based on the results from the baseline questionnaire. DISCUSSION: Two ValueCare digital solution components will be developed: a mobile application for the participants and a web platform for the professionals, researchers, and informal caregivers. Together with smartwatches, which will track important health aspects, and applications, this approach would enable older people to improve their health through correct lifestyle choices and their professional and informal caregivers to track their progress. With the use of the described technology and the multidisciplinary approach, the unmet needs and values of participants could be achieved. Using this approach, it could be possible to reduce overall healthcare expenses through the active involvement of both older people and their informal caregivers through a shared decision-making process with healthcare professionals. CLINICAL TRIAL REGISTRATION: The ISRCTN registry number is 25089186. The date of trial registration is 16/11/2021. CI - Copyright (c) 2025 Juraga, Rukavina, Marinovic Glavic, Bilajac, Racz, Bally, Zanutto, Alhambra-Borras, Ferrando, Subotic, Raat and Vasiljev. FAU - Juraga, Denis AU - Juraga D AD - Department of Social Medicine and Epidemiology, Faculty of Medicine, University of Rijeka, Rijeka, Croatia. FAU - Rukavina, Tomislav AU - Rukavina T AD - Department of Social Medicine and Epidemiology, Faculty of Medicine, University of Rijeka, Rijeka, Croatia. AD - Teaching Institute of Public Health of Primorje-Gorski Kotar County, Rijeka, Croatia. FAU - Marinovic Glavic, Mihaela AU - Marinovic Glavic M AD - Department of Social Medicine and Epidemiology, Faculty of Medicine, University of Rijeka, Rijeka, Croatia. FAU - Bilajac, Lovorka AU - Bilajac L AD - Department of Social Medicine and Epidemiology, Faculty of Medicine, University of Rijeka, Rijeka, Croatia. AD - Teaching Institute of Public Health of Primorje-Gorski Kotar County, Rijeka, Croatia. AD - Department of Public Health, Faculty of Health Studies, University of Rijeka, Rijeka, Croatia. FAU - Racz, Aleksandar AU - Racz A AD - University of Applied Health Sciences, Zagreb, Croatia. FAU - Bally, Esmee L S AU - Bally ELS AD - Department of Public Health, Erasmus University Medical Centre, Rotterdam, Netherlands. FAU - Zanutto, Oscar AU - Zanutto O AD - European Project Office Department, Istituto Per Servizi Di Ricovero E Assistenza Agli Anziani (Institute for Hospitalization and Care for the Elderly), Treviso, Italy. FAU - Alhambra-Borras, Tamara AU - Alhambra-Borras T AD - Polibienestar Research Institute, University of Valencia, Valencia, Spain. FAU - Ferrando, Maite AU - Ferrando M AD - R&D+I Consultancy, Kveloce I+D+i (Senior Europa SL), Valencia, Spain. FAU - Subotic, Alen AU - Subotic A AD - Department of Emergency Medicine, Velika Gorica, Croatia. FAU - Raat, Hein AU - Raat H AD - Department of Public Health, Erasmus University Medical Centre, Rotterdam, Netherlands. FAU - Vasiljev, Vanja AU - Vasiljev V AD - Department of Social Medicine and Epidemiology, Faculty of Medicine, University of Rijeka, Rijeka, Croatia. LA - eng PT - Journal Article DEP - 20250103 PL - Switzerland TA - Front Public Health JT - Frontiers in public health JID - 101616579 SB - IM MH - Aged MH - Aged, 80 and over MH - Female MH - Humans MH - Male MH - Caregivers MH - Mobile Applications MH - *Myocardial Infarction/therapy MH - *Quality of Life MH - Surveys and Questionnaires MH - Research Design MH - Evaluation Studies as Topic PMC - PMC11738907 OTO - NOTNLM OT - decision making OT - elderly OT - health care professionals OT - myocardial infarction OT - shared OT - value-based health care COIS- MF was employed by R&D+I Consultancy, Kveloce I+D+i (Senior Europa SL). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2025/01/20 22:54 MHDA- 2025/01/20 22:55 PMCR- 2025/01/03 CRDT- 2025/01/20 05:13 PHST- 2024/10/28 00:00 [received] PHST- 2024/12/06 00:00 [accepted] PHST- 2025/01/20 22:55 [medline] PHST- 2025/01/20 22:54 [pubmed] PHST- 2025/01/20 05:13 [entrez] PHST- 2025/01/03 00:00 [pmc-release] AID - 10.3389/fpubh.2024.1518469 [doi] PST - epublish SO - Front Public Health. 2025 Jan 3;12:1518469. doi: 10.3389/fpubh.2024.1518469. eCollection 2024. PMID- 39827716 OWN - NLM STAT- MEDLINE DCOM- 20250501 LR - 20260901 IS - 1527-3288 (Electronic) IS - 0147-9563 (Linking) VI - 70 DP - 2025 Mar-Apr TI - Reducing heart failure events via individualized patient education program in patients with reduced ejection fraction. PG - 313-320 LID - S0147-9563(25)00003-2 [pii] LID - 10.1016/j.hrtlng.2025.01.001 [doi] AB - BACKGROUND: Disease management programs for heart failure (HF) often include various strategies such as medication management and lifestyle modifications, and are known to improve clinical outcomes. OBJECTIVES: To evaluate the effectiveness of an individualized patient education program (IPEP) specifically designed for patients with reduced ejection fraction (HFrEF) on clinical outcomes. METHODS: In our prospective interventional study involving 164 patients, participants were divided into control (CG) and intervention (IG) groups. The IG received the IPEP facilitated by the academic pharmacist, while both the IG and the CG continued to receive standard care from the healthcare team without any differences in the care provided. Self-care practices, medication adherence, quality of life, and clinical outcomes were assessed at both the 6th and 12th months. Statistical analysis included Chi-square tests, Kaplan-Meier survival plots, and Multivariable Cox proportional regression analysis. Data analysis was conducted using JAMOVI and R software. RESULTS: The demographic and clinical characteristics of sample population were largely homogeneous in both the groups. The unadjusted 1-year rehospitalization (RH) rate was significantly lower in the IG at 33 % compared to 48 % in the CG, with a hazard ratio of 0.55 (95 % CI: 0.34-0.90, p = 0.018). Kaplan-Meier survival analysis depicts a higher RH rate for HFrEF participants over time, with a significant difference observed between CG and IG (log-rank P = 0.017). Notable disparities in self-care practices emerged & at the 6th and 12th-month assessments medication adherence & QoL were significantly improved in the IG (p 50%. In the experimental group, there was 1 case of cardiac death and 6 cases of heart failure-related readmission, while the control group had 2 cases of cardiac death and 8 cases of heart failure-related readmission. There were no significant differences between the two groups in terms of hypoglycemia, urinary tract infections, and gastrointestinal adverse reactions (all P > 0.05). CONCLUSION: The multidisciplinary discharge preparation service model significantly improves the clinical condition of patients with chronic heart failure, reducing the risk of heart failure-related deaths and rehospitalizations. CI - AJTR Copyright (c) 2024. FAU - Song, Wei AU - Song W AD - Department of Cardiology, Wuhan Asia Heart Hospital Wuhan 430022, Hubei, China. FAU - Hu, Liu AU - Hu L AD - Department of Nursing, Wuhan Asia Heart Hospital Wuhan 430022, Hubei, China. FAU - Geng, Li AU - Geng L AD - Department of Nursing, Wuhan Asia Heart Hospital Wuhan 430022, Hubei, China. FAU - Hu, Ping AU - Hu P AD - Department of Cardiology, Wuhan Asia Heart Hospital Wuhan 430022, Hubei, China. LA - eng PT - Journal Article DEP - 20241215 PL - United States TA - Am J Transl Res JT - American journal of translational research JID - 101493030 PMC - PMC11733367 OTO - NOTNLM OT - Multidisciplinary involvement OT - cardiac function OT - chronic heart failure OT - discharge preparation COIS- None. EDAT- 2025/01/17 18:23 MHDA- 2025/01/17 18:24 PMCR- 2024/12/15 CRDT- 2025/01/17 14:56 PHST- 2024/06/04 00:00 [received] PHST- 2024/12/01 00:00 [accepted] PHST- 2025/01/17 18:24 [medline] PHST- 2025/01/17 18:23 [pubmed] PHST- 2025/01/17 14:56 [entrez] PHST- 2024/12/15 00:00 [pmc-release] AID - 10.62347/BQYW5913 [doi] PST - epublish SO - Am J Transl Res. 2024 Dec 15;16(12):7803-7816. doi: 10.62347/BQYW5913. eCollection 2024. PMID- 39817189 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250928 IS - 1179-1608 (Print) IS - 1179-1608 (Electronic) IS - 1179-1608 (Linking) VI - 17 DP - 2025 TI - Exploring the Relationship Between Sleep Apnea, Myocardial Infarct Size, and Coronary Collaterals in Acute Myocardial Infarction: A Multidisciplinary Study. PG - 27-42 LID - 10.2147/NSS.S489788 [doi] AB - PURPOSE: We designed a study investigating the cardioprotective role of sleep apnea (SA) in patients with acute myocardial infarction (AMI), focusing on its association with infarct size and coronary collateral circulation. METHODS: We recruited adults with AMI, who underwent Level-III SA testing during hospitalization. Delayed-enhancement cardiac magnetic resonance (CMR) imaging was performed to quantify AMI size (percent-infarcted myocardium). Rentrop Score quantified coronary collateralization (scores 0-3, higher scores indicating augmented collaterals). Group differences in Rentrop grade and infarct size were compared using the Wilcoxon Rank-Sum test and Fisher's Exact test as appropriate, with a significance threshold set at p <0.05. RESULTS: Among 33 adults, mean age was 54.4+/-11.5 and mean BMI was 28.4+/-5.9. 8 patients (24%) had no SA, and 25 (76%) had SA (mild n=10, moderate n=8, severe n=7). 66% (n=22) underwent CMR, and all patients had Rentrop scores. Median infarct size in the no-SA group was 22% versus 28% in the SA group (p=0.79). While we did not find statistically significant differences, moderate SA had a trend toward a smaller infarct size (median 15.5%; IQR 9.23) compared to the other groups (no SA [22.0%; 16.8,31.8], mild SA [27%; 23.8,32.5], and severe SA [34%; 31.53], p=0.12). A higher proportion of moderate SA patients had a Rentrop grade >0, with a trend toward significance (moderate SA versus other groups: 62.5% versus 28%, p=0.08). CONCLUSION: Our study did not find statistically significant differences in cardiac infarct size and the presence of coronary collaterals by sleep apnea severity among patients with AMI. However, our results are hypothesis-generating, and suggest that moderate SA may potentially offer cardioprotective benefits through enhanced coronary collaterals. These insights call for future research to explore the heterogeneity in ischemic preconditioning by SA severity and hypoxic burden to guide tailored clinical strategies for SA management in patients with AMI. CI - (c) 2025 Kundel et al. FAU - Kundel, Vaishnavi AU - Kundel V AUID- ORCID: 0000-0002-2923-9539 AD - Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Devarakonda, Kavya AU - Devarakonda K AD - Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Khan, Samira AU - Khan S AUID- ORCID: 0000-0003-4480-9162 AD - Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Suarez-Farinas, Mayte AU - Suarez-Farinas M AD - Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Cohen, Oren AU - Cohen O AD - Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Santos-Gallego, Carlos AU - Santos-Gallego C AUID- ORCID: 0000-0003-1408-8958 AD - Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Menegus, Mark A AU - Menegus MA AD - Albert Einstein College of Medicine, Bronx, NY, USA. FAU - Kini, Annapoorna AU - Kini A AD - Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Vengrenyuk, Yuliya AU - Vengrenyuk Y AD - Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Okamoto, Naotaka AU - Okamoto N AD - Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Ueda, Hiroshi AU - Ueda H AD - Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Gidwani, Umesh AU - Gidwani U AD - Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Kizer, Jorge R AU - Kizer JR AD - Cardiology Section, San Francisco Veterans Affairs Health Care System and Departments of Medicine, Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USA. FAU - Redline, Susan AU - Redline S AD - Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. FAU - Kaplan, Robert AU - Kaplan R AD - Albert Einstein College of Medicine, Bronx, NY, USA. AD - Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. FAU - Shah, Neomi AU - Shah N AD - Icahn School of Medicine at Mount Sinai, New York, NY, USA. LA - eng GR - R01 HL168897/HL/NHLBI NIH HHS/United States GR - K23 HL125923/HL/NHLBI NIH HHS/United States GR - T32 HL160511/HL/NHLBI NIH HHS/United States GR - K23 HL161324/HL/NHLBI NIH HHS/United States GR - R01 HL143221/HL/NHLBI NIH HHS/United States PT - Journal Article DEP - 20250109 PL - New Zealand TA - Nat Sci Sleep JT - Nature and science of sleep JID - 101537767 PMC - PMC11733186 OTO - NOTNLM OT - MI OT - Rentrop OT - cardiac MRI OT - ischemic preconditioning OT - myocardial infarction OT - sleep apnea COIS- Dr. Kundel reports fees from Zoll Respicardia. Dr. Cohen reports fees from Zoll Respicardia. Dr. Okamoto reports fees from Boston Scientific Japan and Abiomed Japan, unrelated to this topic. Dr. Kizer reports stock ownership in AbbVie, Abbott, Bristol Myers Squibb, Johnson & Johnson, Eli Lilly, Medtronic, Merck, and Pfizer. Dr Santos-Gallego reports grants from Robert A Winn Career Development Award, grants from Merck as a Principal Investigator of an Investigator-Initiated Study, advisory board for NovoNordisk, outside the submitted work. Dr. Redline has received consulting fees from Eli Lilly unrelated to this topic and is an unpaid member of the Scientific Advisory Board for ApniMed Inc; the National Sleep Foundation; and the Alliance of Sleep Apnea Partners. Dr. Shah reports fees from Zoll Respicardia. The authors report no other conflicts of interest in this work. EDAT- 2025/01/16 06:21 MHDA- 2025/01/16 06:22 PMCR- 2025/01/09 CRDT- 2025/01/16 04:49 PHST- 2024/08/09 00:00 [received] PHST- 2024/11/28 00:00 [accepted] PHST- 2025/01/16 06:22 [medline] PHST- 2025/01/16 06:21 [pubmed] PHST- 2025/01/16 04:49 [entrez] PHST- 2025/01/09 00:00 [pmc-release] AID - 489788 [pii] AID - 10.2147/NSS.S489788 [doi] PST - epublish SO - Nat Sci Sleep. 2025 Jan 9;17:27-42. doi: 10.2147/NSS.S489788. eCollection 2025. PMID- 39817096 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250129 IS - 2772-963X (Electronic) IS - 2772-963X (Linking) VI - 3 IP - 12 DP - 2024 Dec TI - Valvular Heart Disease Care in Pakistan: Impact of the Multidisciplinary Valve Heart Team. PG - 101378 LID - 10.1016/j.jacadv.2024.101378 [doi] LID - 101378 AB - BACKGROUND: Patients with complex valvular heart disease (VHD) should be evaluated by a multidisciplinary heart team (HT). In low- and middle-income countries, referral practices are more variable, permitting any physician to refer patients directly to a cardiac surgeon without prior formal evaluation by a cardiologist with expertise in VHD. OBJECTIVES: The goal of the study was to examine the demographics of VHD patients seen in a large heart valve center in a low- and middle-income country and to assess the impact of the multidisciplinary HT in patients referred for valve surgery. METHODS: Over a 20-month period, all patients with VHD seen in the National Institute of Cardiovascular Diseases (Karachi, Pakistan) outpatient cardiovascular surgery clinic were referred to the heart valve center and assessed by a multidisciplinary HT. The multidisciplinary HT developed individualized plans for each patient. RESULTS: A total of 2,003 patients (52.8% female, mean age: 43.9 +/- 14.4 years) were enrolled. Rheumatic heart disease was identified as the predominant cause of mitral valve disease, whereas bicuspid valve was the most common cause of significant aortic stenosis. All patients had been referred for valve surgery. Based on the HT's evaluation, 1,521 patients (76%) were deemed suitable for surgery, 335 patients (17%) were recommended for medical therapy, and 147 patients (7%) were considered candidates for transcatheter treatments. Notably, the HT reclassified the management strategies for 24% of the patients, all of whom had initially been referred for surgical intervention. CONCLUSIONS: The integration of collaborative decision-making through a multidisciplinary HT led to individualized and tailored treatment strategies, with a significant proportion of patients receiving alternative interventions or medical management instead of surgery. CI - (c) 2024 The Authors. FAU - Bhatti, Sabha AU - Bhatti S AD - Department of Cardiovascular imaging & Adult Cardiology, National Institute of Cardiovascular Diseases (NICVD), Karachi, Pakistan. FAU - Rehman, Samir AU - Rehman S AD - Department of Cardiovascular imaging & Adult Cardiology, National Institute of Cardiovascular Diseases (NICVD), Karachi, Pakistan. FAU - Usman, Muhammad AU - Usman M AD - Department of Cardiovascular imaging & Adult Cardiology, National Institute of Cardiovascular Diseases (NICVD), Karachi, Pakistan. FAU - Iqbal, Zafar AU - Iqbal Z AD - Department of Cardiovascular imaging & Adult Cardiology, National Institute of Cardiovascular Diseases (NICVD), Karachi, Pakistan. FAU - Atif, Uzma AU - Atif U AD - Department of Cardiovascular imaging & Adult Cardiology, National Institute of Cardiovascular Diseases (NICVD), Karachi, Pakistan. FAU - Gurmani, Sumyia AU - Gurmani S AD - Department of Cardiovascular imaging & Adult Cardiology, National Institute of Cardiovascular Diseases (NICVD), Karachi, Pakistan. FAU - Hussain, Wajid AU - Hussain W AD - Department of Cardiovascular imaging & Adult Cardiology, National Institute of Cardiovascular Diseases (NICVD), Karachi, Pakistan. FAU - Memon, Rizwan AU - Memon R AD - Department of Cardiovascular Surgery, NICVD, Karachi, Pakistan. FAU - Awan, Asad Bilal AU - Awan AB AD - Department of Cardiovascular Surgery, NICVD, Karachi, Pakistan. FAU - Mangi, Abdul Jabbar AU - Mangi AJ AD - Department of Cardiovascular imaging & Adult Cardiology, National Institute of Cardiovascular Diseases (NICVD), Karachi, Pakistan. FAU - Karim, Musa AU - Karim M AD - Department of Research and Clinical Outcomes, NICVD, Karachi, Pakistan. FAU - Qamar, Nadeem AU - Qamar N AD - Department of Interventional Cardiology& structural heart interventions, NICVD, Karachi, Pakistan. FAU - Saghir, Tahir AU - Saghir T AD - Department of Interventional Cardiology& structural heart interventions, NICVD, Karachi, Pakistan. FAU - Hakeem, Abdul AU - Hakeem A AD - Department of Interventional Cardiology& structural heart interventions, NICVD, Karachi, Pakistan. LA - eng PT - Journal Article DEP - 20241120 PL - United States TA - JACC Adv JT - JACC. Advances JID - 9918419284106676 PMC - PMC11734041 OTO - NOTNLM OT - cardiac surgery OT - heart valve registry OT - multidisciplinary valve team OT - shared decision-making OT - valve clinic OT - valvular heart disease COIS- The authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2025/01/16 06:21 MHDA- 2025/01/16 06:22 PMCR- 2024/11/20 CRDT- 2025/01/16 04:48 PHST- 2024/08/12 00:00 [received] PHST- 2024/09/20 00:00 [revised] PHST- 2024/09/25 00:00 [accepted] PHST- 2025/01/16 06:22 [medline] PHST- 2025/01/16 06:21 [pubmed] PHST- 2025/01/16 04:48 [entrez] PHST- 2024/11/20 00:00 [pmc-release] AID - S2772-963X(24)00658-6 [pii] AID - 101378 [pii] AID - 10.1016/j.jacadv.2024.101378 [doi] PST - epublish SO - JACC Adv. 2024 Nov 20;3(12):101378. doi: 10.1016/j.jacadv.2024.101378. eCollection 2024 Dec. PMID- 39817047 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250129 IS - 2772-4875 (Electronic) IS - 2772-4875 (Linking) VI - 24 DP - 2025 Mar TI - Effect of chronic total occlusion of coronary arteries on cardiovascular outcomes in patients undergoing transcatheter aortic valve replacement: A systematic review and meta-analysis. PG - 200356 LID - 10.1016/j.ijcrp.2024.200356 [doi] LID - 200356 AB - BACKGROUND: Transcatheter aortic valve replacement (TAVR) has significantly advanced the treatment of severe aortic stenosis (AS), particularly in elderly patients who often have coexisting coronary artery disease (CAD). Chronic total occlusion (CTO), a severe form of CAD, may negatively impact outcomes in TAVR patients, though data are limited. This meta-analysis aims to evaluate the impact of CTO on TAVR outcomes. METHODS: A comprehensive literature search was conducted across multiple electronic databases to identify studies comparing TAVR outcomes in patients with and without CTO. Pooled risk ratios (RR) with 95 % confidence intervals (CIs) were calculated using a random-effects model. The primary outcome was all-cause mortality, with several secondary endpoints also assessed. RESULTS: Six studies involving a total of 331,159 TAVR patients were included in this meta-analysis. CTO was associated with a significantly increased risk of in-hospital mortality (RR: 1.24; 95 % CI: 1.01, 1.52; p = 0.04), acute myocardial infarction (RR: 1.67; 95 % CI: 1.48, 1.89; p < 0.00001), acute kidney injury (RR: 1.46; 95 % CI: 1.37, 1.56; p < 0.00001), and vascular complications (RR: 1.47; 95 % CI: 1.28, 1.69; p < 0.00001). No significant differences were observed in all-cause mortality (RR: 1.21; 95 % CI: 0.76, 1.93; p = 0.42), stroke (RR: 1.09; 95 % CI: 0.91, 1.30; p = 0.37), or bleeding events (RR: 1.19; 95 % CI: 1.00, 1.41; p = 0.06). CONCLUSION: CTO poses a significant risk in TAVR patients, particularly for in-hospital mortality and acute myocardial infarction. A multidisciplinary approach is recommended for these patients, with consideration given to revascularization before TAVR. Further studies are needed to evaluate the potential benefits of prior CTO-PCI. CI - (c) 2024 The Authors. FAU - Goyal, Aman AU - Goyal A AD - Department of Internal Medicine, Seth GS Medical College and KEM Hospital, Mumbai, India. FAU - Tariq, Muhammad Daoud AU - Tariq MD AD - Department of Internal Medicine, Foundation University Medical College, Islamabad, Pakistan. FAU - Ahsan, Areeba AU - Ahsan A AD - Department of Internal Medicine, Foundation University Medical College, Islamabad, Pakistan. FAU - Hurjkaliani, Sonia AU - Hurjkaliani S AD - Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan. FAU - Singh, Ajeet AU - Singh A AD - Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan. FAU - Hamza, Hafiz Muhammad AU - Hamza HM AD - Department of Internal Medicine, Foundation University Medical College, Islamabad, Pakistan. FAU - Jain, Hritvik AU - Jain H AD - Department of Internal Medicine, All India Institute of Medical Sciences (AIIMS), Jodhpur, India. FAU - Bharadwaj, Hareesha Rishab AU - Bharadwaj HR AD - Faculty of Biology Medicine and Health, The University of Manchester, Manchester, UK. FAU - Daoud, Mohamed AU - Daoud M AD - Department of Internal Medicine, Bogomolets National Medical University, Kyiv, Ukraine. FAU - Sheikh, Abu Baker AU - Sheikh AB AD - Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM, USA. LA - eng PT - Journal Article PT - Review DEP - 20241218 PL - Netherlands TA - Int J Cardiol Cardiovasc Risk Prev JT - International journal of cardiology. Cardiovascular risk and prevention JID - 9918282077306676 PMC - PMC11733188 OTO - NOTNLM OT - Aortic stenosis OT - Chronic total occlusion OT - Coronary artery disease OT - TAVR OT - Transcatheter aortic valve replacement COIS- The authors declare no conflicts of interest. EDAT- 2025/01/16 06:21 MHDA- 2025/01/16 06:22 PMCR- 2024/12/18 CRDT- 2025/01/16 04:48 PHST- 2024/08/14 00:00 [received] PHST- 2024/12/07 00:00 [revised] PHST- 2024/12/08 00:00 [accepted] PHST- 2025/01/16 06:22 [medline] PHST- 2025/01/16 06:21 [pubmed] PHST- 2025/01/16 04:48 [entrez] PHST- 2024/12/18 00:00 [pmc-release] AID - S2772-4875(24)00121-1 [pii] AID - 200356 [pii] AID - 10.1016/j.ijcrp.2024.200356 [doi] PST - epublish SO - Int J Cardiol Cardiovasc Risk Prev. 2024 Dec 18;24:200356. doi: 10.1016/j.ijcrp.2024.200356. eCollection 2025 Mar. PMID- 39816426 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250129 IS - 1302-7123 (Print) IS - 1308-5123 (Electronic) IS - 1302-7123 (Linking) VI - 58 IP - 4 DP - 2024 TI - Endovascular Treatment in Symptomatic Intracranial Artery Stenosis: Experience from Two Centers. PG - 430-436 LID - 10.14744/SEMB.2024.75317 [doi] AB - OBJECTIVES: To assess the efficacy of endovascular treatment and clinical outcomes in individuals with symptomatic intracranial stenosis who had not responded adequately to medical intervention. METHODS: The study included 32 patients who received endovascular treatment due to high-grade (70%-99% severity) intracranial atherosclerotic stenosis from December 2021 to December 2023. The patients had not experienced any acute ischemic or hemorrhagic infarction within the last three weeks, had a Modified Rankin Scale score of /=2) in three boroughs by working with general practitioners (GPs) and practice-based pharmacists. Using digital 'proactive care frameworks' created by UCLPartners and the Clinical Effectiveness Group, Queen Mary University of London, baseline searches of GP records enabled clinical teams to risk stratify and prioritise patients with AF for review. Patients not on anticoagulation were categorised as high risk and were reviewed for initiation of anticoagulation. The second priority was patients on dual antithrombotic therapy to determine if antiplatelet therapy could be stopped to minimise bleeding risk.At baseline (March 2020), nationally available data (extracted from CVDPREVENT) showed that 81% of patients with AF at high ischaemic risk across the three selected boroughs were anticoagulated. Repeated data extraction in March 2023, showed 94% of patients with AF at high ischaemic risk were anticoagulated, an absolute improvement of 13%, with 415 patients initiated on anticoagulant therapy over 3 years, translating to 17 strokes prevented. There was a 52% reduction in dual antithrombotic therapy, preventing an estimated three major bleeds.Improvements were achieved through a combination of specialist pharmacist reviews, GP and practice-based pharmacist training and virtual multidisciplinary reviews supporting the integration of specialists into a primary care setting to enable joined-up pathways for effective stroke prevention. CI - (c) Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. FAU - Patel, Mital AU - Patel M AUID- ORCID: 0009-0002-4780-0462 AD - Department of Pharmacy, Barts Health NHS Trust, London, UK mital.patel12@nhs.net. FAU - Chahal, Jagjot Kaur AU - Chahal JK AD - Department of Pharmacy, Barts Health NHS Trust, London, UK. FAU - Robson, John AU - Robson J AD - Clinical Effectiveness Group, Queen Mary University of London, London, UK. FAU - Ali, Shabana AU - Ali S AD - NHS Redbridge Place, London, UK. FAU - Clements, Richard AU - Clements R AD - North East London Integrated Care Board, London, UK. FAU - Theodoulou, Angela AU - Theodoulou A AD - Department of Haematology, Barts Health NHS Trust, London, UK. FAU - Kearney, Matt AU - Kearney M AD - UCLPartners, London, UK. FAU - Sohaib, Afzal AU - Sohaib A AD - Department of Cardiology, Barts Health NHS Trust, London, UK. AD - Department of Cardiology, Barking, Havering and Redbridge University Hospitals NHS Trust, Romford, UK. FAU - Patel, Riyaz AU - Patel R AD - Department of Cardiology, Barts Health NHS Trust, London, UK. FAU - Antoniou, Sotiris AU - Antoniou S AD - Department of Pharmacy, Barts Health NHS Trust, London, UK. FAU - Wright, Paul AU - Wright P AD - Department of Pharmacy, Barts Health NHS Trust, London, UK. LA - eng PT - Journal Article DEP - 20250111 PL - England TA - BMJ Open Qual JT - BMJ open quality JID - 101710381 RN - 0 (Anticoagulants) SB - IM MH - Humans MH - *Atrial Fibrillation/complications/drug therapy MH - London/epidemiology MH - *Stroke/prevention & control MH - *Pharmacists/statistics & numerical data MH - Primary Health Care/organization & administration/statistics & numerical data MH - *Patient Care Team/standards/statistics & numerical data/trends MH - Aged MH - Male MH - Female MH - Anticoagulants/therapeutic use MH - Aged, 80 and over PMC - PMC11751773 OTO - NOTNLM OT - Evidence-based medicine OT - General practice OT - Healthcare quality improvement OT - Hospital medicine OT - Pharmacists COIS- Competing interests: MK has received honoraria for workshops and educational talks from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Lilly, Novartis, and Sanofi. AS has had travel support from Daiichi Sankyo, otherwise there is nothing else relevant to this manuscript. EDAT- 2025/01/13 00:20 MHDA- 2025/01/13 00:21 PMCR- 2025/01/11 CRDT- 2025/01/12 20:43 PHST- 2024/02/20 00:00 [received] PHST- 2024/12/15 00:00 [accepted] PHST- 2025/01/13 00:21 [medline] PHST- 2025/01/13 00:20 [pubmed] PHST- 2025/01/12 20:43 [entrez] PHST- 2025/01/11 00:00 [pmc-release] AID - bmjoq-2024-002804 [pii] AID - 10.1136/bmjoq-2024-002804 [doi] PST - epublish SO - BMJ Open Qual. 2025 Jan 11;14(1):e002804. doi: 10.1136/bmjoq-2024-002804. PMID- 39792580 OWN - NLM STAT- MEDLINE DCOM- 20250110 LR - 20261018 IS - 1399-0012 (Electronic) IS - 0902-0063 (Linking) VI - 39 IP - 1 DP - 2025 Jan TI - Does Weekend Discharge Affect Readmission and Survival in Liver Transplant Patients? Insights From a Cohort Study. PG - e70081 LID - 10.1111/ctr.70081 [doi] AB - BACKGROUND: Weekend hospital discharges are often associated with reduced staffing, potentially impacting the quality of patient care. We studied the effects of weekend discharge after liver transplantation (LT) on early readmission rates, overall survival (OS), and graft survival (GS). METHOD: We analyzed data from the Ohio State University Wexner Medical Center database (January 2016 to December 2023). The study included initial LT recipients (LTRs) including donation after brain death (DBD) and donation after cardiac death (DCD). Primary outcomes encompassed early readmission rates, and secondary outcomes included OS and GS. RESULTS: The cohort comprised 915 LTRs (645 DBD, 270 DCD), with 156 (17.0%) weekend and 759 (83.0%) weekday discharges. Regarding discharge disposition, 681 (74.4%) patients were discharged home, 210 (22.9%) were discharged to healthcare facilities. No significant differences were identified in the length of hospital stay (8 days vs. 9 days, weekend vs. weekday, respectively, p = 0.22) or 30-day readmission (29.5% vs. 32.5%, weekend vs. weekday, respectively, p = 0.75). There were no significant differences in OS (90.9% vs. 92.7% at 1-year, 84.4% vs. 88.0% at 3-year, weekend vs. weekday, p = 0.27) and GS (90.9% vs. 91.5% at 1-year, 84.0% vs. 86.6% at 3-year, weekend vs. weekday, p = 0.50). Multivariate logistic analysis showed no significant impact of weekend discharge (OR: 0.84 [0.57-1.22], p = 0.35) or discharge disposition (OR: 1.00 [0.75-1.33], p = 1.00) on 30-day readmission. Multivariate Cox regression analysis found no significant impact of weekend discharge or discharge disposition on OS and GS (all p > 0.05). CONCLUSION: Weekend discharge does not impact early readmission, OS, or GS in LTRs. These findings are a testament to our multidisciplinary team efforts and suggest that with appropriate discharge planning and follow-up care, the timing of discharge may be less critical than previously assumed. CI - (c) 2025 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. FAU - Obana, Ayato AU - Obana A AUID- ORCID: 0000-0003-0322-4299 AD - Department of Surgery, Comprehensive Transplant Center, Ohio State University Wexner Medical Center, Columbus, Ohio, USA. FAU - Akabane, Miho AU - Akabane M AD - Department of Surgery, Comprehensive Transplant Center, Ohio State University Wexner Medical Center, Columbus, Ohio, USA. FAU - Chi, Hannah AU - Chi H AD - Department of Internal Medicine, Ohio State University Wexner Medical Center, Columbus, Ohio, USA. FAU - Ladd, Nolan AU - Ladd N AD - Department of Internal Medicine, Ohio State University Wexner Medical Center, Columbus, Ohio, USA. FAU - Yoder, Matthew AU - Yoder M AD - Department of Internal Medicine, Ohio State University Wexner Medical Center, Columbus, Ohio, USA. FAU - Kaufman, Lily AU - Kaufman L AD - Department of Internal Medicine, Ohio State University Wexner Medical Center, Columbus, Ohio, USA. FAU - Punjala, Rithin AU - Punjala R AD - Department of Surgery, Comprehensive Transplant Center, Ohio State University Wexner Medical Center, Columbus, Ohio, USA. FAU - Shah, Kejal AU - Shah K AD - Department of Surgery, Comprehensive Transplant Center, Ohio State University Wexner Medical Center, Columbus, Ohio, USA. FAU - Hamilton, Matthew AU - Hamilton M AD - Department of Surgery, Comprehensive Transplant Center, Ohio State University Wexner Medical Center, Columbus, Ohio, USA. FAU - Limkemann, Ashley AU - Limkemann A AUID- ORCID: 0000-0002-4613-7083 AD - Department of Surgery, Comprehensive Transplant Center, Ohio State University Wexner Medical Center, Columbus, Ohio, USA. FAU - Schenk, Austin AU - Schenk A AD - Department of Surgery, Comprehensive Transplant Center, Ohio State University Wexner Medical Center, Columbus, Ohio, USA. FAU - Singh, Navdeep AU - Singh N AUID- ORCID: 0000-0003-2879-5768 AD - Department of Surgery, Comprehensive Transplant Center, Ohio State University Wexner Medical Center, Columbus, Ohio, USA. FAU - Slyvester, Black AU - Slyvester B AD - Department of Surgery, Comprehensive Transplant Center, Ohio State University Wexner Medical Center, Columbus, Ohio, USA. FAU - Mumtaz, Khalid AU - Mumtaz K AD - Department of Hepatology, Comprehensive Transplant Center, Ohio State University Wexner Medical Center, Columbus, Ohio, USA. FAU - Washburn, Kenneth AU - Washburn K AD - Department of Surgery, Comprehensive Transplant Center, Ohio State University Wexner Medical Center, Columbus, Ohio, USA. FAU - Alebrahim, Musab AU - Alebrahim M AD - Department of Surgery, Comprehensive Transplant Center, Ohio State University Wexner Medical Center, Columbus, Ohio, USA. LA - eng GR - Grant of the Clinical Research Promotion Foundation/ PT - Journal Article PL - Denmark TA - Clin Transplant JT - Clinical transplantation JID - 8710240 SB - IM MH - Humans MH - *Patient Readmission/statistics & numerical data MH - Female MH - Male MH - *Liver Transplantation/mortality MH - *Patient Discharge/statistics & numerical data MH - Middle Aged MH - Prognosis MH - Follow-Up Studies MH - Survival Rate MH - *Graft Survival MH - Risk Factors MH - Length of Stay/statistics & numerical data MH - Retrospective Studies MH - Time Factors MH - Adult MH - Cohort Studies MH - Postoperative Complications/mortality OTO - NOTNLM OT - graft survival OT - liver transplantation OT - overall survival OT - readmission rates OT - weekend discharge EDAT- 2025/01/10 18:19 MHDA- 2025/01/10 18:20 CRDT- 2025/01/10 12:53 PHST- 2024/11/21 00:00 [revised] PHST- 2024/10/13 00:00 [received] PHST- 2025/01/01 00:00 [accepted] PHST- 2025/01/10 18:20 [medline] PHST- 2025/01/10 18:19 [pubmed] PHST- 2025/01/10 12:53 [entrez] AID - 10.1111/ctr.70081 [doi] PST - ppublish SO - Clin Transplant. 2025 Jan;39(1):e70081. doi: 10.1111/ctr.70081. PMID- 39791071 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250111 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 16 IP - 12 DP - 2024 Dec TI - Bridging the Gap: The Importance of Non-technical Skills in Cardiology for Enhanced Patient Care and Team Performance. PG - e75460 LID - 10.7759/cureus.75460 [doi] LID - e75460 AB - Cardiology, a high-acuity medical specialty, has traditionally emphasised technical expertise, often overshadowing the critical role of non-technical skills (NTS). This imbalance stems from the historical focus on procedural competence and clinical knowledge in cardiology training and practice, leaving a significant gap in the development of crucial interpersonal and cognitive abilities. However, emerging evidence highlights the significant impact of NTS on patient outcomes, team dynamics, and overall healthcare efficiency. This review explores the importance of NTS in cardiology whilst drawing parallels with other high-stakes fields, such as aviation, surgery, and emergency medicine, which have successfully integrated NTS frameworks. These fields are particularly relevant due to their similar requirements for rapid decision-making under pressure, team-based approaches, and the potential for severe consequences in case of errors. Key NTS domains relevant to cardiology include leadership, such as in guiding cardiac teams effectively during procedures and emergencies; cooperation and resource management, such as focusing on optimising team performance and resource allocation in cardiac care units; communication and interaction, such as clear and concise information exchange during complex cardiac interventions; assessment and decision-making such as making critical choices in time-sensitive situations; situational awareness (SA) that maintains a comprehensive understanding of the patient's condition and surrounding environment; and coping with stress, which involves managing personal and team stress during and after high-pressure situations. The integration of NTS into cardiology practice is essential for improving patient care, reducing healthcare costs, and preventing clinician burnout. Despite the recognition of NTS' importance, there is a notable lack of structured training and validated assessment tools in cardiology. This absence poses a significant challenge to the implementation of NTS, as it hinders the systematic development and evaluation of these crucial skills amongst cardiologists. For instance, whilst technical skills in procedures like angiography are rigorously assessed, there is limited formal evaluation of NTS, for instance, a cardiologist's ability to lead a team effectively during a cardiac emergency. This review advocates for the development and implementation of NTS training and evaluation methods suitable for cardiology, emphasising the need for a balanced skill set that complements technical proficiency with social and cognitive abilities. Future research should focus on adapting existing tools or developing new ones to address the unique challenges of cardiology teams and foster safer, more effective patient care. Specific areas for investigation include developing cardiology-specific NTS assessment tools, creating structured NTS training programmes for cardiology fellows, evaluating the impact of NTS training on patient outcomes in cardiac care, and exploring the relationship between NTS proficiency and technical skill performance in cardiology procedures. By addressing these research gaps and developing targeted NTS interventions, cardiology can foster a more comprehensive approach to professional development, ultimately leading to improved patient care and healthcare efficiency in this critical field. CI - Copyright (c) 2024, Farooq et al. FAU - Farooq, Faiq AU - Farooq F AD - Internal Medicine, Portsmouth Hospitals University NHS Trust, Portsmouth, GBR. FAU - Hassan, Shabee U AU - Hassan SU AD - Cardiology, Portsmouth Hospitals University NHS Trust, Portsmouth, GBR. FAU - Farooq, Fahad AU - Farooq F AD - Neurology, Cork University Hospital, Cork, IRL. FAU - Farooq, Faizan AU - Farooq F AD - Intensive Care Unit, Pakistan Kidney and Liver Institute, Lahore, PAK. FAU - Tareen, Muhammad Samee Khan AU - Tareen MSK AD - Acute Medicine, Portsmouth Hospitals University NHS Trust, Portsmouth, GBR. LA - eng PT - Journal Article PT - Review DEP - 20241210 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC11717399 OTO - NOTNLM OT - cardiology OT - communication OT - decision-making OT - healthcare costs OT - leadership OT - non-technical skills OT - situational awareness OT - stress management OT - t-notechs OT - teamwork COIS- Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. EDAT- 2025/01/10 06:19 MHDA- 2025/01/10 06:20 PMCR- 2024/12/10 CRDT- 2025/01/10 04:25 PHST- 2024/12/09 00:00 [accepted] PHST- 2025/01/10 06:20 [medline] PHST- 2025/01/10 06:19 [pubmed] PHST- 2025/01/10 04:25 [entrez] PHST- 2024/12/10 00:00 [pmc-release] AID - 10.7759/cureus.75460 [doi] PST - epublish SO - Cureus. 2024 Dec 10;16(12):e75460. doi: 10.7759/cureus.75460. eCollection 2024 Dec. PMID- 39790199 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250111 IS - 2223-3652 (Print) IS - 2223-3660 (Electronic) IS - 2223-3652 (Linking) VI - 14 IP - 6 DP - 2024 Dec 31 TI - Pregnancy & cardiovascular disease: the PREG-CVD-HH registry. PG - 1058-1069 LID - 10.21037/cdt-24-248 [doi] AB - BACKGROUND: Cardiovascular disease (CVD) remains the leading cause of death in pregnant and peripartal women in western countries. Physiological changes during pregnancy can lead to cardiovascular complications in the mother; women with pre-existing heart disease may not tolerate these changes well, increasing their susceptibility to adverse cardiovascular outcomes during pregnancy. The aim of this study is to characterize pregnancy-induced changes in cardiac function, biomarker concentrations and cardiovascular outcomes in women with CVD during pregnancy at a tertiary care hospital in Germany. METHODS: The PREG-CVD-HH study is a prospective single-center observational study of pregnant women with prevalent CVD treated at the University Medical Center Hamburg, Germany and currently includes 63 women with congenital or acquired heart disease and ten women from the general population included as controls. Participants underwent baseline assessment and dedicated comprehensive echocardiography. Biomarkers N-terminal pro B-type natriuretic peptide (NT-proBNP), MR-proadrenomedullin (MRproADM) and high-sensitivity cardiac troponin I (hs-cTnI) were measured serially throughout pregnancy and until 6 and 12 months postpartum. A maternal cardiac event was defined as death due to cardiovascular cause, arrhythmia, heart failure or hospitalization for other cardiac intervention. RESULTS: Mean maternal age was 34 years. A majority had a congenital heart disease (N=41), 10 patients developed pregnancy-associated CVD (e.g., preeclampsia, peripartum cardiomyopathy) and 12 women had known acquired heart disease (e.g., valvular disease, arrhythmia, cardiomyopathy). New-onset heart failure was observed in 14.1% of patients (N=9). Five patients developed arrhythmia and three patients developed preeclampsia. About 21.2% of patients were hospitalized due to cardiovascular events. Death from any or cardiovascular cause did not occur over the study period. Left and right ventricular global longitudinal strain (LV GLS, RV GLS) showed a transient worsening in the third trimester and peripartum period. NT-proBNP ranges broadened during the pregnancy and tended to progressively decrease postpartum in women with CVD. Hs-cTnI levels tended to trend upwards during pregnancy in patients with CVD, however, the hs-cTnI levels remained consistently low throughout pregnancy. CONCLUSIONS: In our cohort, pregnancy was associated with a transient increase in cardiac biomarkers and worsening of cardiac function during the third trimester and peripartum. These temporal changes reversed at 6-12 months postpartum, potentially due to decreased cardiac load, fluid shifts and hormonal changes. Overall, data on reference ranges in echocardiographic and biomarker measurements in the pregnant cardiac population are limited and require further investigation. Albeit one third of our cohort was deemed at high and highest maternal risk during pregnancy, there was no maternal death. We recommend that women with CVD receive preconceptional counselling and ongoing management by a specialized "Pregnancy Heart Team" to optimize care and, potentially, maternal outcomes. CI - 2024 AME Publishing Company. All rights reserved. FAU - Csengeri, Dora AU - Csengeri D AUID- ORCID: 0000-0002-6210-349X AD - Department of Cardiology, University Heart & Vascular Center, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany. AD - German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Luebeck/Kiel, Germany. FAU - Unger, Elisabeth AU - Unger E AD - Department of Cardiology, University Heart & Vascular Center, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany. AD - German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Luebeck/Kiel, Germany. FAU - Weimann, Jessica AU - Weimann J AD - Department of Cardiology, University Heart & Vascular Center, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany. FAU - Huntgeburth, Michael AU - Huntgeburth M AD - Center for Adults with Congenital Heart Disease, Clinic III for Internal Medicine, Department of Cardiology, Heart Center, Medical Faculty, University Hospital of Cologne, Cologne, Germany. AD - Department of Congenital Heart Disease and Pediatric Cardiology, German Heart Center Munich, Technical University of Munich, Munich, Germany. FAU - von Kodolitsch, Yskert AU - von Kodolitsch Y AD - Department of Vascular Medicine, University Heart Centre Hamburg-Eppendorf, Hamburg, Germany. FAU - Zeller, Tanja AU - Zeller T AD - Department of Cardiology, University Heart & Vascular Center, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany. AD - German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Luebeck/Kiel, Germany. FAU - Blankenberg, Stefan AU - Blankenberg S AD - Department of Cardiology, University Heart & Vascular Center, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany. AD - German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Luebeck/Kiel, Germany. AD - Center for Population Health Innovation (POINT), University Heart and Vascular Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Kirchhof, Paulus AU - Kirchhof P AD - Department of Cardiology, University Heart & Vascular Center, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany. AD - German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Luebeck/Kiel, Germany. FAU - Diemert, Anke AU - Diemert A AD - Department of Obstetrics and Fetal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Schnabel, Renate B AU - Schnabel RB AD - Department of Cardiology, University Heart & Vascular Center, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany. AD - German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Luebeck/Kiel, Germany. FAU - Sinning, Christoph R AU - Sinning CR AD - Department of Cardiology, University Heart & Vascular Center, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany. AD - German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Luebeck/Kiel, Germany. FAU - Zengin-Sahm, Elvin AU - Zengin-Sahm E AD - Department of Cardiology, University Heart & Vascular Center, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany. AD - German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Luebeck/Kiel, Germany. LA - eng PT - Journal Article DEP - 20241219 PL - China TA - Cardiovasc Diagn Ther JT - Cardiovascular diagnosis and therapy JID - 101601613 PMC - PMC11707486 OTO - NOTNLM OT - Pregnancy OT - biomarker OT - echocardiography COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://cdt.amegroups.com/article/view/10.21037/cdt-24-248/coif). The series "Current Management Aspects in Adult Congenital Heart Disease (ACHD): Part VI" was commissioned by the editorial office without any funding or sponsorship. D.C. received a research grant from Wolfgang Seefried Project funding of the German Heart Foundation e.V. Y.V.K. reports that he is a member of the VASCERN HTAD and Marfan Hilfe Deutschland e.V. T.Z. has received funding from the German Research Foundation, the EU Horizon 2020 programme, the EU ERANet and ERAPreMed Programmes, the German Centre for Cardiovascular Research (DZHK, 81Z0710102) and the German Ministry of Education and Research (BMBF 01ZX1408A) and the German Research Foundation. T.Z. is listed as co-inventor of an international patent on the use of a computing device to estimate the probability of myocardial infarction (International Publication Number WO2022043229A1). T.Z. is a shareholder of the ART.EMIS GmbH Hamburg. S.B. is supported by the Innovative medicine initiative (IMI) under grant No. 116074, the Foundation Leducq under grant No. 16 CVD 03, Siemens, Bayer, Astra Zeneca, Deutsche Gesetzliche Unfallversicherung (DGUV) and Novartis. P.K. has received research support for basic, translational, and clinical research projects from European Union, British Heart Foundation, Leducq Foundation, Medical Research Council (UK), German Centre for Cardiovascular Research, and from several drug and device companies active in atrial fibrillation; is listed on 2 patents held by the University of Birmingham (Atrial Fibrillation Therapy WO 2015140571 and Markers for Atrial Fibrillation WO 2016012783); and has been partially supported by European Union BigData@Heart (grant agreement EU IMI 116074), AFFECT-AF (grant agreement 847770), and MAESTRIA (grant agreement 965286), British Heart Foundation (PG/17/30/32961 and PG/20/22/35093; AA/18/2/34218), German Centre for Cardiovascular Research supported by the German Ministry of Education and Research (DZHK), and Leducq Foundation. A.D. has received funding by the German Research Foundation (Clinical Research Unit 296: DI2103/2-2) and the Authority for Science, Research and Equality, Hanseatic City of Hamburg, Germany (LFF-FV73). R.B.S. has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme under the grant agreement No. 648131, from the European Union's Horizon 2020 research and innovation programme under the grant agreement No. 847770 (AFFECT-EU) and German Center for Cardiovascular Research (DZHK e.V.) (81Z1710103 and 81Z0710114); German Ministry of Research and Education (BMBF 01ZX1408A) and ERACoSysMed3 (031L0239). RBS has received lecture fees and advisory board fees from BMS/Pfizer and Bayer outside this work. C.R.S. has received lecture fees from Bohringer Ingelheim and Johnson & Johnson outside this work. The authors have no other conflicts of interest to declare. EDAT- 2025/01/10 06:19 MHDA- 2025/01/10 06:20 PMCR- 2024/12/31 CRDT- 2025/01/10 04:15 PHST- 2024/06/03 00:00 [received] PHST- 2024/11/13 00:00 [accepted] PHST- 2025/01/10 06:20 [medline] PHST- 2025/01/10 06:19 [pubmed] PHST- 2025/01/10 04:15 [entrez] PHST- 2024/12/31 00:00 [pmc-release] AID - cdt-14-06-1058 [pii] AID - 10.21037/cdt-24-248 [doi] PST - ppublish SO - Cardiovasc Diagn Ther. 2024 Dec 31;14(6):1058-1069. doi: 10.21037/cdt-24-248. Epub 2024 Dec 19. PMID- 39789430 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250112 IS - 1865-1372 (Print) IS - 1865-1380 (Electronic) IS - 1865-1372 (Linking) VI - 18 IP - 1 DP - 2025 Jan 9 TI - Percutaneous closure of a traumatic ventricular septal defect: a case report and literature review. PG - 10 LID - 10.1186/s12245-024-00805-z [doi] LID - 10 AB - BACKGROUND: Penetrating cardiac trauma is an entity with high pre and intrahospital mortality due to complications such as cardiac tamponade and massive hemothorax. A ventricular septal defect (VSD) occurs in 1-5% of cases and can present early or late. The management strategy for VSD resulting from penetrating cardiac trauma is uncertain. CASE PRESENTATION: A 19-year-old man was admitted in cardiorespiratory arrest after a precordial stab wound. Cardiopulmonary resuscitation was initiated achieving return of spontaneous circulation. eFAST evaluation revealed cardiac tamponade, he was taken to emergency left thoracotomy finding a perforation of the free wall of the left ventricle and a tear of the upper lobe of the left lung that were sutured. The patient was discharged and six days later was readmitted with fever and dyspnea. During treatment for a surgical site infection a new-onset pansystolic murmur was found: A transthoracic echocardiogram revealed a 13-mm VSD with left-to-right shunt. A multidisciplinary team recommended percutaneous closure of the defect which was successfully performed without complications. CONCLUSIONS: Traumatic VSD is a rare complication of penetrating cardiac trauma. A thorough clinical and echocardiographic evaluation is essential for its diagnosis and characterization. Symptomatic septal defects, those 10 mm or larger, with Qp: Qs greater than 1.5, or causing complications such as pulmonary hypertension or valvular involvement, are usually closed to prevent progression of heart failure. Management of traumatic VSD has traditionally been surgical. However, a percutaneous intervention is a viable alternative in selected stable patients. Unlike ischemic VSD, early intervention after patient stabilization generally yields favorable outcomes. CI - (c) 2024. The Author(s). FAU - Calderon-Miranda, Camilo Andres AU - Calderon-Miranda CA AD - Departamento de Cardiologia, Fundacion Valle del Lili, Carrera 98 No. 18 - 49, Cali, 760032, Colombia. camilo.calderon@fvl.org.co. AD - Facultad de Ciencias de la Salud, Universidad Icesi, Calle 18 No. 122-135, Cali, 760031, Colombia. camilo.calderon@fvl.org.co. FAU - Reyes-Cardona, Maria Juliana AU - Reyes-Cardona MJ AD - Centro de Investigaciones Clinicas, Fundacion Valle del Lili, Carrera 98 No. 18 - 49, Cali, 760032, Colombia. FAU - Lopez-Mora, Gabriel Roberto AU - Lopez-Mora GR AD - Facultad de Ciencias de la Salud, Universidad Icesi, Calle 18 No. 122-135, Cali, 760031, Colombia. AD - Departamento de Medicina Interna, Fundacion Valle del Lili, Carrera 98 No. 18 - 49, Cali, 760032, Colombia. FAU - Guerrero-Pinedo, Fernando Andres AU - Guerrero-Pinedo FA AD - Facultad de Ciencias de la Salud, Universidad Icesi, Calle 18 No. 122-135, Cali, 760031, Colombia. AD - Unidad de Intervencionismo Vascular, Fundacion Valle del Lili, Carrera 98 No. 18 - 49, Cali, 760032, Colombia. FAU - Sanchez-Blanco, Jairo AU - Sanchez-Blanco J AD - Departamento de Cardiologia, Fundacion Valle del Lili, Carrera 98 No. 18 - 49, Cali, 760032, Colombia. AD - Facultad de Ciencias de la Salud, Universidad Icesi, Calle 18 No. 122-135, Cali, 760031, Colombia. FAU - Vesga-Reyes, Carlos Enrique AU - Vesga-Reyes CE AD - Departamento de Cardiologia, Fundacion Valle del Lili, Carrera 98 No. 18 - 49, Cali, 760032, Colombia. AD - Facultad de Ciencias de la Salud, Universidad Icesi, Calle 18 No. 122-135, Cali, 760031, Colombia. FAU - Zambrano-Franco, Jorge Alexander AU - Zambrano-Franco JA AD - Departamento de Cardiologia, Fundacion Valle del Lili, Carrera 98 No. 18 - 49, Cali, 760032, Colombia. AD - Facultad de Ciencias de la Salud, Universidad Icesi, Calle 18 No. 122-135, Cali, 760031, Colombia. FAU - Olaya, Pastor AU - Olaya P AD - Departamento de Cardiologia, Fundacion Valle del Lili, Carrera 98 No. 18 - 49, Cali, 760032, Colombia. AD - Facultad de Ciencias de la Salud, Universidad Icesi, Calle 18 No. 122-135, Cali, 760031, Colombia. LA - eng PT - Journal Article DEP - 20250109 PL - England TA - Int J Emerg Med JT - International journal of emergency medicine JID - 101469435 PMC - PMC11715082 OTO - NOTNLM OT - Echocardiography OT - Emergency thoracotomy OT - Penetrating cardiac trauma OT - Percutaneous closure OT - Ventricular septal defect COIS- Declarations. Ethics approval and consent to participate: This case report was reviewed and approved by the Institutional Review Board (IRB) of Fundacion Valle del Lili, Cali, Colombia. The patient provided informed consent for the use and publication of their medical information, and all identifying details have been anonymized to ensure confidentiality. Consent for publication: Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal. Competing interests: The authors declare no competing interests. EDAT- 2025/01/10 00:21 MHDA- 2025/01/10 00:22 PMCR- 2025/01/09 CRDT- 2025/01/09 23:34 PHST- 2024/11/20 00:00 [received] PHST- 2024/12/25 00:00 [accepted] PHST- 2025/01/10 00:22 [medline] PHST- 2025/01/10 00:21 [pubmed] PHST- 2025/01/09 23:34 [entrez] PHST- 2025/01/09 00:00 [pmc-release] AID - 10.1186/s12245-024-00805-z [pii] AID - 805 [pii] AID - 10.1186/s12245-024-00805-z [doi] PST - epublish SO - Int J Emerg Med. 2025 Jan 9;18(1):10. doi: 10.1186/s12245-024-00805-z. PMID- 39787142 OWN - NLM STAT- MEDLINE DCOM- 20250109 LR - 20260922 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 20 IP - 1 DP - 2025 TI - Like milk on the stove: Healthcare professionals navigating uncertainty when caring for families with 22q11DS. PG - e0313845 LID - 10.1371/journal.pone.0313845 [doi] LID - e0313845 AB - INTRODUCTION: 22q11 deletion syndrome (22q11DS) results from a microdeletion on chromosome 22 and is the most common microdeletion disorder in humans, affecting 1 in 2148 live births. Clinical manifestations vary widely among individuals and across different life stages. Effective management requires the involvement of a specialized multidisciplinary team. This study aims to explore the experiences of healthcare professionals in caring for the families of children with 22q11DS, focusing on their challenges, rewards, and coping strategies. METHODS: Data for this interview study were collected as part of a broader mixed methods research project aimed at enhancing the psychosocial well-being of children aged 3-15 years with 22q11DS and their families. The qualitative aspect of this study focused on capturing the experiences of healthcare professionals involved in their care, recruited purposively through collaborators and snowball sampling methods. Reflexive thematic analysis of semi-structured interviews was performed after verbatim transcription. RESULTS: Twenty healthcare providers from different specialties were interviewed. The majority had a working experience of more than 10 years and were part of a 22q11DS clinic. After data analysis, four themes (and many sub-themes) were identified that were all related to the topic of uncertainty: acknowledging uncertainty, sharing uncertainty, acting on uncertainty and coping with uncertainty. Many experts showed a sense of humbleness when caring for the families and most of the participants emphasized the role of peer support and multidisciplinary teams. CONCLUSION: Our study reveals how healthcare professionals manage the uncertainty associated with 22q11DS, highlighting the importance of peer support and multidisciplinary team collaboration. Providers recognize the limits of their medical expertise and value the perspectives of families living with the condition. Their coping strategies play a critical role in handling uncertainty and suggest a need for further emphasis in the literature on the experiences of healthcare professionals dealing with rare diseases. CI - Copyright: (c) 2025 Ayoub et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. FAU - Ayoub, Sophie AU - Ayoub S AUID- ORCID: 0009-0004-0822-4364 AD - Institute for Biomedical Ethics, University of Basel, Basel, Switzerland. FAU - De Clercq, Eva AU - De Clercq E AD - Institute for Biomedical Ethics, University of Basel, Basel, Switzerland. FAU - Cytrynbaum, Cheryl AU - Cytrynbaum C AUID- ORCID: 0000-0002-3742-1250 AD - Division of Clinical & Metabolic Genetics and the Department of Genetic Counselling, The Hospital for Sick Children, Toronto, Canada. AD - Department of Molecular Genetics, University of Toronto, Toronto, Canada. FAU - Steiner, Luzius A AU - Steiner LA AUID- ORCID: 0000-0002-1437-3532 AD - Department of Anesthesiology, University Hospital Basel, Basel, Switzerland. AD - Department of Clinical Research, University of Basel, Basel, Switzerland. FAU - Elger, Bernice S AU - Elger BS AD - Institute for Biomedical Ethics, University of Basel, Basel, Switzerland. AD - Center for Legal Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20250109 PL - United States TA - PLoS One JT - PloS one JID - 101285081 SB - IM MH - Humans MH - Uncertainty MH - *Health Personnel/psychology MH - Female MH - Male MH - *Adaptation, Psychological MH - Child MH - Adolescent MH - Child, Preschool MH - Adult MH - Family/psychology MH - Middle Aged MH - 22q11 Deletion Syndrome/psychology/genetics MH - DiGeorge Syndrome/psychology PMC - PMC11717309 COIS- The authors have declared that no competing interests exist. EDAT- 2025/01/09 18:21 MHDA- 2025/01/09 18:22 PMCR- 2025/01/09 CRDT- 2025/01/09 13:44 PHST- 2024/07/16 00:00 [received] PHST- 2024/10/31 00:00 [accepted] PHST- 2025/01/09 18:22 [medline] PHST- 2025/01/09 18:21 [pubmed] PHST- 2025/01/09 13:44 [entrez] PHST- 2025/01/09 00:00 [pmc-release] AID - PONE-D-24-28835 [pii] AID - 10.1371/journal.pone.0313845 [doi] PST - epublish SO - PLoS One. 2025 Jan 9;20(1):e0313845. doi: 10.1371/journal.pone.0313845. eCollection 2025. PMID- 39786180 OWN - NLM STAT- MEDLINE DCOM- 20250206 LR - 20260817 IS - 1531-7080 (Electronic) IS - 0268-4705 (Linking) VI - 40 IP - 2 DP - 2025 Mar 1 TI - Surgical and multimodal approaches to right-sided cardiac tumours. PG - 63-71 LID - 10.1097/HCO.0000000000001197 [doi] AB - PURPOSE OF REVIEW: Cardiac tumours present significant clinical challenges due to their wide differential, complex anatomical and physiological implications, as well as the potential for widespread invasion in the case of malignancies. This review synthesizes recent findings surrounding the diagnosis and management of specifically right-sided cardiac tumours, with a particular focus on surgical resection and reconstructive techniques. RECENT FINDINGS: Management of cardiac tumours can be categorized into three key phases. First: early and accurate diagnosis is critical for improving outcomes, especially in malignancies. Advances in imaging modalities like MRI, CT, PET-CT, and biopsy techniques enhance diagnostic accuracy. Second: surgical resection is a cornerstone treatment for both benign and malignant right-sided cardiac tumours. Surgery is often curative for benign tumours, while for malignant tumours, R0 resection (complete microscopic removal) in appropriate candidates correlates with better survival. Third: managing cardiac malignancies necessitates a multidisciplinary approach, integrating additional therapies such as chemotherapy, radiation, and emerging immunotherapies tailored to patient and tumour characteristics. SUMMARY: Managing right-sided cardiac tumours demands interdisciplinary expertise. Standardized protocols are limited by the rarity of cases and insufficient high-quality data. International collaboration and sharing of experiences through prospective registries and clinical studies are essential to advancing knowledge and improving patient outcomes. CI - Copyright (c) 2025 Wolters Kluwer Health, Inc. All rights reserved. FAU - Patel, Shubh K AU - Patel SK AD - Temerty Faculty of Medicine. FAU - Dhingra, Nitish K AU - Dhingra NK AD - Division of Cardiac Surgery, Peter Munk Cardiac Centre, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada. FAU - Cusimano, Robert J AU - Cusimano RJ AD - Division of Cardiac Surgery, Peter Munk Cardiac Centre, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada. LA - eng PT - Journal Article PT - Review DEP - 20250109 PL - United States TA - Curr Opin Cardiol JT - Current opinion in cardiology JID - 8608087 SB - IM MH - Humans MH - *Heart Neoplasms/diagnosis/surgery/therapy MH - *Cardiac Surgical Procedures/methods MH - Multimodal Imaging MH - Combined Modality Therapy EDAT- 2025/01/09 16:59 MHDA- 2025/02/06 06:20 CRDT- 2025/01/09 10:24 PHST- 2025/02/06 06:20 [medline] PHST- 2025/01/09 16:59 [pubmed] PHST- 2025/01/09 10:24 [entrez] AID - 00001573-202503000-00002 [pii] AID - 10.1097/HCO.0000000000001197 [doi] PST - ppublish SO - Curr Opin Cardiol. 2025 Mar 1;40(2):63-71. doi: 10.1097/HCO.0000000000001197. Epub 2025 Jan 9. PMID- 39780802 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250925 LR - 20250925 IS - 2666-2736 (Electronic) IS - 2666-2736 (Linking) VI - 22 DP - 2024 Dec TI - Rapid-recovery protocol for minimally invasive mitral valve repair. PG - 49-60 LID - 10.1016/j.xjon.2024.08.006 [doi] AB - BACKGROUND: Minimally invasive mitral valve repair (MIMVR), often performed within specialized care pathways, has been shown to reduce hospital length of stay and improve patient recovery. The relative value of rapid-recovery protocols as a component of care pathways, including enhanced recovery programs (ERPs), has not been well described. This study compared clinical outcomes following implementation of a new, comprehensive rapid-recovery protocol within a previously established, mature ERP for patients undergoing MIMVR. METHODS: The rapid-recovery protocol was developed and implemented by a multidisciplinary team to further optimize patient recovery within an existing ERP. The protocol was applied to 75 consecutive patients undergoing MIMVR between September 2022 and December 2023. Outcomes were compared retrospectively to 75 ERP control patients who did not receive the rapid-recovery protocol but experienced the ERP. The primary outcome was a composite of discharge from the intensive care unit (ICU) by postoperative day (POD) 1, discharge to home by POD 4, and no all-cause hospital readmission by 30 days. RESULTS: Baseline characteristics were similar in the 2 groups. Patients in the rapid-recovery group achieved the primary composite outcome significantly more often compared to the control group (60% vs 40%, respectively). There was no between-group difference in postoperative complications. Multivariable logistic regression showed that age /=70 years, 49 (62%) were male, and 28 (35%) died. The preoperative mean ejection fraction was 35%. Cardiogenic shock (CS) was observed in 53% (alive vs dead: 39% vs 79%, p = 0.001), while 6% required cardiopulmonary resuscitation (alive vs dead: 2% vs 14%, p = 0.05). MCS devices including extracorporeal membrane oxygenation were used in 22% (alive vs dead: 4% vs 54%, p <0.001). Emergent surgery was performed in 37% (alive vs dead: 18% vs 71%, p <0.001), concomitant aortic valve replacement in 10% (alive vs dead: 11% vs 9%, p = 0.029), and delayed intervention (beyond 7 days) in 44% (alive vs dead: 57% vs 21%, p = 0.002). Intraoperatively, blood products were used in 49% (alive vs dead: 45% vs 57%, p = 0.005). Following repair, 22% suffered from renal failure (alive vs dead: 19% vs 48%, p = 0.021). Patients who experienced delayed intervention had higher survival rates probably related to survival bias. Patients who suffered in-hospital mortality were more likely to have CS and to require MCS. Improvement in patient selection by a "Heart Team" approach and new therapeutic options are needed as part of advanced care for mechanical complications of AMI. CI - Copyright (c) 2025 Elsevier Inc. All rights reserved. FAU - Moumneh, Mohamad B AU - Moumneh MB AD - Inova Center of Outcomes Research, Inova Heart and Vascular, Fairfax, Virginia. FAU - Quader, Mohammed A AU - Quader MA AD - Division of Cardiothoracic Surgery, Department of Surgery, Virginia Commonwealth University, Richmond, Virginia. FAU - Teman, Nicholas R AU - Teman NR AD - Department of Surgery, University of Virginia, Charlottesville, Virginia. FAU - Tang, Daniel AU - Tang D AD - Inova Center of Outcomes Research, Inova Heart and Vascular, Fairfax, Virginia. FAU - Ryan, Liam AU - Ryan L AD - Inova Center of Outcomes Research, Inova Heart and Vascular, Fairfax, Virginia. FAU - Strobel, Raymond J AU - Strobel RJ AD - Division of Cardiothoracic Surgery, Department of Surgery, University of Virginia, Charlottesville, Virginia. FAU - Joseph, Mark AU - Joseph M AD - Division of Cardiothoracic Surgery, Department of Surgery, Virginia Tech Carilion School of Medicine, Roanoke, Virginia. FAU - Mazzeffi, Michael AU - Mazzeffi M AD - Department of Anesthesiology, University of Virginia School of Medicine, Charlottesville, Virginia. FAU - Gertz, Zachary M AU - Gertz ZM AD - Pauley Heart Center, Virginia Commonwealth University, Richmond, Virginia. FAU - Kontos, Michael C AU - Kontos MC AD - Pauley Heart Center, Virginia Commonwealth University, Richmond, Virginia. FAU - Singh, Ramesh AU - Singh R AD - Inova Center of Outcomes Research, Inova Heart and Vascular, Fairfax, Virginia. FAU - Spier, Alan AU - Spier A AD - Inova Center of Outcomes Research, Inova Heart and Vascular, Fairfax, Virginia. FAU - Sarin, Eric AU - Sarin E AD - Inova Center of Outcomes Research, Inova Heart and Vascular, Fairfax, Virginia. FAU - Damluji, Abdulla A AU - Damluji AA AD - Inova Center of Outcomes Research, Inova Heart and Vascular, Fairfax, Virginia. Electronic address: Abdulla.Damluji@inova.org. LA - eng GR - K23 HL153771/HL/NHLBI NIH HHS/United States GR - P30 AG021334/AG/NIA NIH HHS/United States PT - Journal Article DEP - 20241230 PL - United States TA - Am J Cardiol JT - The American journal of cardiology JID - 0207277 SB - IM MH - Humans MH - Male MH - Female MH - *Registries MH - Hospital Mortality/trends MH - Aged MH - *Myocardial Infarction/complications MH - Middle Aged MH - *Heart Septal Defects, Ventricular/surgery/etiology/mortality MH - *Cardiac Surgical Procedures/methods MH - Extracorporeal Membrane Oxygenation MH - Retrospective Studies MH - Shock, Cardiogenic/epidemiology/therapy MH - Survival Rate/trends MH - Heart-Assist Devices/statistics & numerical data MH - Treatment Outcome PMC - PMC12063186 MID - NIHMS2050025 OTO - NOTNLM OT - acute OT - aging OT - heart rupture OT - heart septal defects OT - myocardial infarction OT - reperfusion OT - ventricular COIS- Declaration of competing interest The authors have no competing interests to declare. EDAT- 2025/01/02 00:21 MHDA- 2025/03/10 07:59 PMCR- 2026/04/01 CRDT- 2025/01/01 19:16 PHST- 2024/10/10 00:00 [received] PHST- 2024/12/08 00:00 [revised] PHST- 2024/12/22 00:00 [accepted] PHST- 2025/03/10 07:59 [medline] PHST- 2025/01/02 00:21 [pubmed] PHST- 2025/01/01 19:16 [entrez] PHST- 2026/04/01 00:00 [pmc-release] AID - S0002-9149(24)00884-1 [pii] AID - 10.1016/j.amjcard.2024.12.028 [doi] PST - ppublish SO - Am J Cardiol. 2025 Apr 1;240:64-67. doi: 10.1016/j.amjcard.2024.12.028. Epub 2024 Dec 30. PMID- 39742228 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250104 IS - 2153-8174 (Electronic) IS - 1530-6550 (Print) IS - 1530-6550 (Linking) VI - 25 IP - 12 DP - 2024 Dec TI - Atrial Functional Tricuspid Regurgitation: A Comprehensive Review of Pathophysiology, Diagnosis, and Management Strategies. PG - 435 LID - 10.31083/j.rcm2512435 [doi] LID - 435 AB - Atrial fibrillation (AF), the most prevalent sustained cardiac arrhythmia, is intricately linked with atrial functional tricuspid regurgitation (AFTR), a condition distinguished from ventricular functional tricuspid regurgitation by its unique pathophysiological mechanisms and clinical implications. This review article delves into the multifaceted aspects of AFTR, exploring its epidemiology, pathophysiology, diagnostic evaluation, and management strategies. Further, we elucidate the mechanisms underlying AFTR, including tricuspid annular dilatation, right atrial enlargement, and dysfunction, which collectively contribute to the development of tricuspid regurgitation in the absence of significant pulmonary hypertension or left-sided heart disease. The section on diagnostic evaluation highlights the pivotal role of echocardiography, supplemented by cardiac magnetic resonance (CMR) imaging and computed tomography (CT), in assessing disease severity and guiding treatment decisions. Management strategies for AFTR are explored, ranging from medical therapy and rhythm control to surgical and percutaneous interventions, underscoring the importance of a tailored, multidisciplinary approach. Furthermore, the article identifies gaps in current knowledge and proposes future research directions to enhance our understanding and management of AFTR. By providing a comprehensive overview of AFTR, this review aims to raise awareness among healthcare professionals and stimulate further research to improve patient care and outcomes in this increasingly recognized condition. CI - Copyright: (c) 2024 The Author(s). Published by IMR Press. FAU - Mohyeldin, Moiud AU - Mohyeldin M AUID- ORCID: 0000-0002-5373-2163 AD - Department of Medicine, BronxCare Health System, Bronx, NY 10457, USA. FAU - Abdelghafar, Ahmed AU - Abdelghafar A AD - Department of Medicine, University of Medical Sciences and Technology (UMST), 12810 Khartoum, Sudan. FAU - Allu, Sai AU - Allu S AD - Department of Medicine, BronxCare Health System, Bronx, NY 10457, USA. FAU - Shrivastava, Shitij AU - Shrivastava S AD - Department of Medicine, BronxCare Health System, Bronx, NY 10457, USA. FAU - Mustafa, Ahmed AU - Mustafa A AD - Department of Medicine, Salaam Clinic, Cleveland, OH 44106, USA. FAU - Mohamed, Feras O AU - Mohamed FO AD - Department of Radiology, Texas Medical Center Memorial Hermann Hospital, Houston, TX 77030, USA. FAU - Norman, Sarah J AU - Norman SJ AD - American University of the Caribbean School of Medicine, Cupecoy, Sint Maarten. LA - eng PT - Journal Article PT - Review DEP - 20241211 PL - Singapore TA - Rev Cardiovasc Med JT - Reviews in cardiovascular medicine JID - 100960007 PMC - PMC11683701 OTO - NOTNLM OT - atrial fibrillation OT - atrial functional tricuspid regurgitation OT - leaflet tethering OT - right atrial remodeling OT - right ventricular function OT - surgical tricuspid valve repair OT - transcatheter tricuspid valve interventions OT - tricuspid annular dilatation OT - tricuspid valve replacement COIS- The authors declare no conflict of interest. EDAT- 2025/01/01 21:24 MHDA- 2025/01/01 21:25 PMCR- 2024/12/11 CRDT- 2025/01/01 04:36 PHST- 2024/05/22 00:00 [received] PHST- 2024/08/25 00:00 [revised] PHST- 2024/08/30 00:00 [accepted] PHST- 2025/01/01 21:25 [medline] PHST- 2025/01/01 21:24 [pubmed] PHST- 2025/01/01 04:36 [entrez] PHST- 2024/12/11 00:00 [pmc-release] AID - S1530-6550(24)01580-1 [pii] AID - 10.31083/j.rcm2512435 [doi] PST - epublish SO - Rev Cardiovasc Med. 2024 Dec 11;25(12):435. doi: 10.31083/j.rcm2512435. eCollection 2024 Dec. PMID- 39740973 OWN - NLM STAT- MEDLINE DCOM- 20241231 LR - 20260715 IS - 1937-710X (Electronic) IS - 1062-3264 (Linking) VI - 34 IP - 1 DP - 2025 Jan 1 TI - Impact of a Quality Cardiopulmonary Resuscitation Coach on Pediatric Intensive Care Unit Resuscitation Teams. PG - 21-29 LID - 10.4037/ajcc2025828 [doi] AB - BACKGROUND: The quality cardiopulmonary resuscitation (CPR) coach role was developed for hospital-based resuscitation teams. This supplementary team member (CPR coach) provides real-time, verbal feedback on chest compression quality to compressors during a cardiac arrest. OBJECTIVES: To evaluate the impact of a quality CPR coach training intervention on resuscitation teams, including presence of coaches on teams and physiologic metrics of quality CPR delivery in real compression events. METHODS: The quality CPR coach curriculum and role implementation were designed and evaluated using a logic model framework. Medical records of patients who had in-unit cardiopulmonary arrests were reviewed retrospectively. Data included physiologic metrics of quality CPR delivery. Analysis included descriptive statistics and comparison of arrest data before and after the intervention. RESULTS: A total of 79 cardiopulmonary arrests were analyzed: 40 before and 39 after the intervention. Presence of a quality CPR coach on resuscitation teams was more frequent after training, increasing from 35% before the intervention to 72% after (P = .002). No significant difference was found in the frequency of application of Zoll defibrillator pads. Metrics of quality CPR delivery and adherence with American Heart Association recommendations were either unchanged or improved after the intervention. CONCLUSIONS: The quality CPR coach training intervention significantly increased coach presence on code teams, which was associated with clinically significant improvements in some metrics of quality CPR delivery in real cardiopulmonary arrests. CI - (c)2025 American Association of Critical-Care Nurses. FAU - McDermott, Katie L AU - McDermott KL AD - Katie L. McDermott is a critical care pediatric nurse practitioner, Children's Wisconsin, Milwaukee/Medical College of Wisconsin, Milwaukee, and part-time nursing faculty, Marquette University, Milwaukee, Wisconsin. FAU - Rajzer-Wakeham, Kari L AU - Rajzer-Wakeham KL AD - Kari L. Rajzer-Wakeham is a critical care pediatric nurse practitioner, Children's Wisconsin, Milwaukee/Medical College of Wisconsin, Milwaukee. FAU - Andres, Jennifer M AU - Andres JM AD - Jennifer M. Andres is quality and outcomes manager, Children's Wisconsin, Milwaukee. FAU - Yan, Ke AU - Yan K AD - Ke Yan is a biostatistican and associate professor in the Division of Quantitative Health Sciences, Medical College of Wisconsin, Milwaukee. FAU - Liegl, Melodee A AU - Liegl MA AD - Melodee A. Liegl is a biostatistician and program manager, Quantitative Health Sciences, , Medical College of Wisconsin, Milwaukee. FAU - Schindler, Christine A AU - Schindler CA AD - Christine A. Schindler is a critical care pediatric nurse practitioner, critical care advanced practice provider program director, Children's Wisconsin/Medical College of Wisconsin, and a clinical professor, Marquette University, Milwaukee, Wisconsin. LA - eng PT - Journal Article PL - United States TA - Am J Crit Care JT - American journal of critical care : an official publication, American Association of Critical-Care Nurses JID - 9211547 SB - IM MH - Humans MH - *Cardiopulmonary Resuscitation/education/standards/methods MH - Retrospective Studies MH - Female MH - Male MH - *Heart Arrest/therapy MH - *Intensive Care Units, Pediatric/organization & administration MH - Child MH - Child, Preschool MH - Infant MH - Patient Care Team/organization & administration MH - Mentoring/methods MH - Adolescent EDAT- 2025/01/01 12:42 MHDA- 2025/01/01 12:43 CRDT- 2024/12/31 21:12 PHST- 2025/01/01 12:43 [medline] PHST- 2025/01/01 12:42 [pubmed] PHST- 2024/12/31 21:12 [entrez] AID - 32630 [pii] AID - 10.4037/ajcc2025828 [doi] PST - ppublish SO - Am J Crit Care. 2025 Jan 1;34(1):21-29. doi: 10.4037/ajcc2025828. PMID- 39740200 OWN - NLM STAT- MEDLINE DCOM- 20250507 LR - 20250508 IS - 2055-5822 (Electronic) IS - 2055-5822 (Linking) VI - 12 IP - 3 DP - 2025 Jun TI - Early genetic screening and cardiac intervention in patients with cardiomyopathies in a multidisciplinary clinic. PG - 1942-1955 LID - 10.1002/ehf2.15202 [doi] AB - AIMS: Patients with cardiomyopathies are a heterogeneous group of patients who experience high morbidity and mortality. Early cardiac assessment and intervention with access to genetic counselling in a multidisciplinary Cardiomyopathy Clinic may improve outcomes and prevent progression to advanced heart failure. METHODS AND RESULTS: Our prospective cohort study was conducted at a multidisciplinary Cardiomyopathy Clinic with 421 patients enrolled (42.5% female, median age 58 years), including 224 patients with dilated cardiomyopathy (DCM, 42.9% female, median age 57 years), 72 with hypertrophic cardiomyopathy (HCM, 43.1% female, median age 60 years), 79 with infiltrative cardiomyopathy (65.8% female, median age 70 years) and 46 who were stage A/at risk for genetic cardiomyopathy (54.3% female, median age 36 years). Patients were seen in follow-up at a median of 18 months. A pathogenic/likely pathogenic variant was identified in 28.5% of the total cohort, including 33.3% of the DCM cohort (28% TTN mutations) and 34.1% of the HCM cohort (60% MYBPC3 and 20% MYH7) who underwent genetic testing. The use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/angiotensin receptor neprilysin inhibitor (48.3-69.5% of total cohort, P < 0.001), beta-blockers (58.4-72.4%, P < 0.001), mineralocorticoid receptor antagonists (33.9-41.4%, P = 0.0014) and sodium/glucose cotransporter-2 inhibitors (5.3-27.9%, P < 0.001) all increased at follow-up. Precision-based therapies were also implemented, including tafamidis for transthyretin amyloidosis (n = 21), enzyme replacement therapy for Fabry disease (n = 14) and mavacamten (n = 4) for HCM. Optimization of medications and devices resulted in improvements in left ventricular ejection fraction (LVEF) from 27% to 43% at follow-up for DCM patients with reduced LVEF at baseline (P < 0.001) and reduction in left ventricular mass index (LVMI) from 156 g/m(2) to 128 g/m(2) at follow-up for HCM patients with abnormal LVMI at baseline (P = 0.009). Optimization of therapies was associated with stable plasma biomarkers in stage B patients while lowering levels of BNP (619-517.5 pg/mL, P = 0.048), NT-proBNP (777.5-356 ng/L, P < 0.001) and hsTropT (31-22 ng/L, P = 0.005) at follow-up relative to baseline values for stage C patients. Despite stage B patients having overt cardiomyopathy at baseline, stage A and B patients had a similarly high probability of survival (chi2 = 0.204, P = 0.652). The overall cardiovascular mortality rate was low at 1.7% for the cohort (0.5% for stage B and 3.3% for stage C) over a median of 34-month follow-up. CONCLUSION: Our study demonstrates that a multidisciplinary cardiomyopathy clinic can improve the clinical profiles of patients with diverse genetic cardiomyopathies. CI - (c) 2024 The Author(s). ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. FAU - Sadasivan, Chandu AU - Sadasivan C AD - Division of Cardiology, Department of Medicine, Mazankowski Alberta Heart Institute, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada. FAU - Gagnon, Luke R AU - Gagnon LR AD - Division of Cardiology, Department of Medicine, Mazankowski Alberta Heart Institute, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada. FAU - Hazra, Deepan AU - Hazra D AD - Division of Cardiology, Department of Medicine, Mazankowski Alberta Heart Institute, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada. FAU - Wang, Kaiming AU - Wang K AD - Division of Cardiology, Department of Medicine, Mazankowski Alberta Heart Institute, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada. FAU - Youngson, Erik AU - Youngson E AD - The Alberta Strategy for Patient Oriented Research Support Unit (AbSPORU), Edmonton, AB, Canada. AD - Provincial Research Data Services, Alberta Health Services, Edmonton, AB, Canada. FAU - Thomas, Jissy AU - Thomas J AD - Division of Cardiology, Department of Medicine, Mazankowski Alberta Heart Institute, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada. FAU - Chan, Anita Y M AU - Chan AYM AD - Division of Cardiology, Department of Medicine, Mazankowski Alberta Heart Institute, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada. FAU - Paterson, D Ian AU - Paterson DI AD - University of Ottawa Heart Institute, Ottawa, ON, Canada. FAU - McAlister, Finlay A AU - McAlister FA AD - The Alberta Strategy for Patient Oriented Research Support Unit (AbSPORU), Edmonton, AB, Canada. AD - Division of General Internal Medicine, Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada. FAU - Dzwiniel, Tara AU - Dzwiniel T AD - Department of Medical Genetics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada. FAU - Tymchak, Wayne AU - Tymchak W AD - Division of Cardiology, Department of Medicine, Mazankowski Alberta Heart Institute, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada. FAU - Christian, Susan AU - Christian S AD - Department of Medical Genetics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada. FAU - Oudit, Gavin Y AU - Oudit GY AD - Division of Cardiology, Department of Medicine, Mazankowski Alberta Heart Institute, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada. LA - eng GR - Heart and Stroke Foundation of Canada/ PT - Journal Article DEP - 20241230 PL - England TA - ESC Heart Fail JT - ESC heart failure JID - 101669191 SB - IM MH - Humans MH - Female MH - Male MH - Middle Aged MH - Prospective Studies MH - *Genetic Testing/methods MH - Aged MH - Follow-Up Studies MH - *Cardiomyopathies/genetics/diagnosis/therapy MH - Adult MH - *Mutation PMC - PMC12055407 OTO - NOTNLM OT - Cardiac imaging OT - Cardiomyopathy OT - Genetic testing OT - Genetics OT - Medical therapy OT - Multidisciplinary care COIS- None. EDAT- 2025/01/01 12:42 MHDA- 2025/05/07 06:27 PMCR- 2024/12/30 CRDT- 2024/12/31 16:23 PHST- 2024/10/19 00:00 [revised] PHST- 2024/07/13 00:00 [received] PHST- 2024/12/13 00:00 [accepted] PHST- 2025/05/07 06:27 [medline] PHST- 2025/01/01 12:42 [pubmed] PHST- 2024/12/31 16:23 [entrez] PHST- 2024/12/30 00:00 [pmc-release] AID - EHF215202 [pii] AID - 10.1002/ehf2.15202 [doi] PST - ppublish SO - ESC Heart Fail. 2025 Jun;12(3):1942-1955. doi: 10.1002/ehf2.15202. Epub 2024 Dec 30. PMID- 39738825 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250104 IS - 2090-911X (Electronic) IS - 1110-2608 (Print) IS - 1110-2608 (Linking) VI - 76 IP - 1 DP - 2024 Dec 30 TI - Clinical outcomes following shock team implementation for cardiogenic shock: a systematic review. PG - 163 LID - 10.1186/s43044-024-00594-z [doi] LID - 163 AB - BACKGROUND: Cardiogenic shock is a critical cardiac condition characterized by low cardiac output leading to end-organ hypoperfusion and associated with high in-hospital mortality rates. It can manifest following acute myocardial infarction or acute exacerbation of chronic heart failure. Despite advancements, mortality rates remain elevated, prompting interest in multidisciplinary approaches to improve outcomes. This manuscript presents a review focused on the concept of a cardiogenic shock team and its potential impact on patient management and outcomes. METHODS: A comprehensive search was performed on March 19, 2023, covering PubMed, Web of Science, Scopus, Embase, and Cochrane Library. We included primary studies (prospective and retrospective) only and evaluated their quality using the Newcastle-Ottawa Quality Scale. This review was registered in PROSPERO (CRD42023440354). RESULTS: Six relevant studies with 2066 cardiogenic shock patients were included, of which 1071 were managed by shock teams and 995 received standard care. Findings from the reviewed studies indicated the favorable outcomes associated with implementing cardiogenic shock teams. Patients managed by these teams exhibited higher 30-day and in-hospital survival rates compared to those without team intervention. The implementation of cardiogenic shock teams was linked to reduced in-hospital and intensive care unit mortality rates. Additionally, shock team involvement was associated with shorter door-to-balloon times. CONCLUSION: The findings suggest that cardiogenic shock teams play a crucial role in improving patient outcomes through earlier detection and timely interventions. Despite challenges in team implementation, their potential to reduce mortality and improve efficiency in patient care warrants further research and greater integration of multidisciplinary strategies into clinical practice. CI - (c) 2024. The Author(s). FAU - Abdelnabi, Mohamed AU - Abdelnabi M AD - Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, Stanford University, Stanford, California, 94305, USA. FAU - Elsaeidy, Ahmed Saad AU - Elsaeidy AS AUID- ORCID: 0000-0002-1643-9750 AD - Faculty of Medicine, Benha University, Benha, Egypt. Ahmed.Saad.Elsaeidy@gmail.com. FAU - Aboutaleb, Aya Moustafa AU - Aboutaleb AM AD - Neurology and Psychiatry resident, Nasr City health insurance hospital, Cairo, Egypt. FAU - Johanis, Amit AU - Johanis A AD - School of Medicine, Creighton University, Phoenix, USA. FAU - Ghanem, Ahmed K AU - Ghanem AK AD - Internal Medicine department, Loma Linda University Medical Center, Murrieta, CA, USA. FAU - Rezq, Hazem AU - Rezq H AD - Faculty of Medicine, Al-Azhar University, Cairo, Egypt. FAU - Abdelazeem, Basel AU - Abdelazeem B AD - Department of Cardiology, West Virginia University, Morgantown, WV, USA. LA - eng PT - Journal Article PT - Review DEP - 20241230 PL - Germany TA - Egypt Heart J JT - The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology JID - 9106952 PMC - PMC11685370 OTO - NOTNLM OT - Cardiogenic shock OT - Mechanical circulatory support OT - Multidisciplinary care OT - Resuscitation OT - Shock team COIS- Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: The authors declare that they have no competing interests. EDAT- 2025/01/01 12:42 MHDA- 2025/01/01 12:43 PMCR- 2024/12/30 CRDT- 2024/12/31 12:59 PHST- 2024/04/02 00:00 [received] PHST- 2024/12/09 00:00 [accepted] PHST- 2025/01/01 12:43 [medline] PHST- 2025/01/01 12:42 [pubmed] PHST- 2024/12/31 12:59 [entrez] PHST- 2024/12/30 00:00 [pmc-release] AID - 10.1186/s43044-024-00594-z [pii] AID - 594 [pii] AID - 10.1186/s43044-024-00594-z [doi] PST - epublish SO - Egypt Heart J. 2024 Dec 30;76(1):163. doi: 10.1186/s43044-024-00594-z. PMID- 39737532 OWN - NLM STAT- MEDLINE DCOM- 20250704 LR - 20250708 IS - 1096-9098 (Electronic) IS - 0022-4790 (Linking) VI - 131 IP - 8 DP - 2025 Jun TI - Recommendations of the Brazilian Society of Surgical Oncology for the Treatment of Neoplastic Pericardial Effusion. PG - 1499-1507 LID - 10.1002/jso.28059 [doi] AB - This document presents guidelines to assist surgeons in the diagnosis and management of this condition, emphasizing a multidisciplinary approach. Recommendations described by a group of physicians members of the Brazilian Society of Oncological Surgery regarding the treatment of neoplastic pericardial effusion, developed to guide oncological surgeons, cardiothoracic surgeons and general surgeons in their clinical practice. Members of the Thoracic Neoplasms Committee carried out a literature review and discussion among expert peers to create a guideline that would help in managing this very serious clinical condition in our oncology practice: Neoplastic pericardial effusion. CI - (c) 2024 Wiley Periodicals LLC. FAU - Carvalho, Erlon de Avila AU - Carvalho EA AUID- ORCID: 0000-0002-5587-937X AD - Brazilian Society of Surgical Oncology, Sao Paulo, Brazil. AD - Thoracic Surgery and Pneumology Service, Hospital das Clinicas of UFMG, Mario Penna Institute, Belo Horizonte, Minas Gerais, Brazil. FAU - Oliveira, Rachid Eduardo Noleto da Nobrega AU - Oliveira RENDN AUID- ORCID: 0000-0002-6020-238X AD - Brazilian Society of Surgical Oncology, Sao Paulo, Brazil. AD - Thoracic Surgery Service, Barretos Cancer Hospital, Sao Paulo, Sao Paulo, Brazil. FAU - Ribeiro, Jose Henrique Agner AU - Ribeiro JHA AUID- ORCID: 0000-0001-8922-9933 AD - Brazilian Society of Surgical Oncology, Sao Paulo, Brazil. FAU - Gross, Jefferson Luis AU - Gross JL AUID- ORCID: 0000-0001-5124-2235 AD - Brazilian Society of Surgical Oncology, Sao Paulo, Brazil. AD - Thoracic Surgery Service, AC Camargo Cancer Center, Sao Paulo, Sao Paulo, Brazil. FAU - Galhardo, Cezar Augusto Vendas AU - Galhardo CAV AUID- ORCID: 0000-0002-6364-2196 AD - Thoracic Surgery Service, Alfredo Abrao Cancer Hospital, Campo Grande, Mato Grosso do Sul, Brazil. FAU - Neto, Heladio Feitosa E Castro AU - Neto HFEC AUID- ORCID: 0000-0001-6455-916X AD - Brazilian Society of Surgical Oncology, Sao Paulo, Brazil. AD - Surgical Oncology Service, Cancer Institute of Ceara, Firtaleza, Ceara, Brazil. FAU - Santos, Giovana Dos AU - Santos GD AUID- ORCID: 0000-0002-4668-1548 AD - Brazilian Society of Surgical Oncology, Sao Paulo, Brazil. FAU - Ribeiro, Reitan AU - Ribeiro R AUID- ORCID: 0000-0002-4323-3854 AD - Brazilian Society of Surgical Oncology, Sao Paulo, Brazil. AD - Surgical Oncology Service, Erasto Gaertner Hospital, Curitiba, Parana, Brazil. FAU - Oliveira, Alexandre Ferreira AU - Oliveira AF AUID- ORCID: 0000-0002-7500-6752 AD - Brazilian Society of Surgical Oncology, Sao Paulo, Brazil. AD - Surgical Oncology Service, Federal University of Juiz de Fora, Juiz de Fora, Minas Gerais, Brazil. FAU - Pinheiro, Rodrigo Nascimento AU - Pinheiro RN AUID- ORCID: 0000-0002-2715-7628 AD - Brazilian Society of Surgical Oncology, Sao Paulo, Brazil. AD - Surgical Oncology Department, Hospital de Base of the District Federal, Brasilia, District Federal, Brazil. LA - eng PT - Journal Article PT - Practice Guideline DEP - 20241229 PL - United States TA - J Surg Oncol JT - Journal of surgical oncology JID - 0222643 SB - IM MH - Humans MH - Brazil MH - *Neoplasms/complications MH - *Pericardial Effusion/therapy/etiology/diagnosis MH - Societies, Medical MH - Surgical Oncology OTO - NOTNLM OT - consensus OT - neoplastic pericardial effusion OT - surgery EDAT- 2024/12/31 12:21 MHDA- 2025/07/04 06:27 CRDT- 2024/12/31 09:24 PHST- 2024/11/21 00:00 [received] PHST- 2024/11/28 00:00 [accepted] PHST- 2025/07/04 06:27 [medline] PHST- 2024/12/31 12:21 [pubmed] PHST- 2024/12/31 09:24 [entrez] AID - 10.1002/jso.28059 [doi] PST - ppublish SO - J Surg Oncol. 2025 Jun;131(8):1499-1507. doi: 10.1002/jso.28059. Epub 2024 Dec 29. PMID- 39732311 OWN - NLM STAT- MEDLINE DCOM- 20250429 LR - 20250520 IS - 1879-1913 (Electronic) IS - 0002-9149 (Linking) VI - 240 DP - 2025 Apr 1 TI - The Integrated Multidisciplinary Pathway for Large-Scale Management of Dyslipidemia in High-Risk Patients (ENNA) Project: Rationale and Project Design. PG - 71-75 LID - S0002-9149(24)00885-3 [pii] LID - 10.1016/j.amjcard.2024.12.027 [doi] AB - Atherosclerotic cardiovascular disease is a leading cause of morbidity and mortality globally, significantly influenced by modifiable risk factors, particularly hypercholesterolemia. Despite the availability of effective lipid-reducing drugs, achieving the low-density lipoprotein cholesterol (LDL-C) target levels remains a significant challenge in clinical practice, contributing to persistently high rates of cardiovascular events. The intEgrated multidiscipliNary pathway for large-scale maNagement of dyslipidemiA in high-risk patients (ENNA) Project was designed to address the alarming rates of suboptimal lipid management in patients at high and very-high risk in the province of Enna, Sicily. This program aims to optimize LDL-C control through an integrated care model that fosters collaboration among pharmacists, general practitioners, and cardiologists, ultimately promoting a patient-centered approach to therapy. The patients who are eligible are identified using data-driven methods through prescription claims, laboratory results, and hospital discharge data, facilitated by local pharmacies. General practitioners play a crucial role as the primary care providers for initiating or optimizing lipid-reducing therapy, whereas cardiologists are involved in managing more complex cases requiring specialized intervention. The primary objective of the ENNA Project is to increase the percentage of patients at great risk in whom LDL-C targets are achieved, improving overall lipid management and therapeutic adherence. CI - Copyright (c) 2024 Elsevier Inc. All rights reserved. FAU - Agnello, Federica AU - Agnello F AD - Universita degli Studi di Enna "Kore," Enna, Italy; Division of Cardiology, Ospedale Umberto I, ASP 4 di Enna, Enna, Italy. FAU - Russo, Calogero AU - Russo C AD - Division of Territorial Pharmacy, ASP 4 di Enna, Enna, Italy. FAU - Laterra, Giulia AU - Laterra G AD - Universita degli Studi di Enna "Kore," Enna, Italy; Division of Cardiology, Ospedale Umberto I, ASP 4 di Enna, Enna, Italy. FAU - Ingala, Salvatore AU - Ingala S AD - Division of Cardiology, Ospedale Umberto I, ASP 4 di Enna, Enna, Italy. FAU - Saragoni, Stefania AU - Saragoni S AD - CliCon S.r.l., Societa Benefit, Health, Economics and Outcomes Research, Bologna, Italy. FAU - Giuffrida, Mario AU - Giuffrida M AD - Division of Territorial Pharmacy, ASP 4 di Enna, Enna, Italy. FAU - Greca, Paola Maria AU - Greca PM AD - Division of Territorial Pharmacy, ASP 4 di Enna, Enna, Italy. FAU - La Tona, Francesco AU - La Tona F AD - Department of Primary Health Care, ASP 4 di Enna, Enna, Italy. FAU - Rinaldi, Noemi AU - Rinaldi N AD - Territorial Medicine, ASP 4 di Enna, Enna, Italy. FAU - Gagliano, Ilaria AU - Gagliano I AD - Territorial Medicine, ASP 4 di Enna, Enna, Italy. FAU - Nappi, Carmela AU - Nappi C AD - CliCon S.r.l., Societa Benefit, Health, Economics and Outcomes Research, Bologna, Italy. FAU - Ghigi, Alessandro AU - Ghigi A AD - CliCon S.r.l., Societa Benefit, Health, Economics and Outcomes Research, Bologna, Italy. FAU - Cappuccilli, Maria AU - Cappuccilli M AD - CliCon S.r.l., Societa Benefit, Health, Economics and Outcomes Research, Bologna, Italy. FAU - Esposti, Luca Degli AU - Esposti LD AD - CliCon S.r.l., Societa Benefit, Health, Economics and Outcomes Research, Bologna, Italy. FAU - Scalia, Lorenzo AU - Scalia L AD - Division of Cardiology, Ospedale Umberto I, ASP 4 di Enna, Enna, Italy. FAU - Cassara, Emanuele AU - Cassara E AD - Territorial Medicine, ASP 4 di Enna, Enna, Italy. FAU - Barbanti, Marco AU - Barbanti M AD - Universita degli Studi di Enna "Kore," Enna, Italy; Division of Cardiology, Ospedale Umberto I, ASP 4 di Enna, Enna, Italy. Electronic address: mbarbanti83@gmail.com. LA - eng PT - Journal Article DEP - 20241226 PL - United States TA - Am J Cardiol JT - The American journal of cardiology JID - 0207277 RN - 0 (Cholesterol, LDL) RN - 0 (Hypolipidemic Agents) RN - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors) SB - IM MH - Humans MH - *Dyslipidemias/therapy/blood/drug therapy MH - Cholesterol, LDL/blood MH - Sicily/epidemiology MH - Risk Factors MH - *Patient Care Team MH - Hypolipidemic Agents/therapeutic use MH - *Disease Management MH - Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use MH - Male MH - Female OTO - NOTNLM OT - PCSK9i OT - atherosclerotic cardiovascular disease OT - bempedoic acid OT - coronary artery disease OT - high cardiovascular risk OT - hypercholesterolemia OT - lipid-lowering therapy OT - siRNA COIS- Declaration of competing interest The authors have no competing interests to declare. EDAT- 2024/12/29 00:20 MHDA- 2025/03/10 07:59 CRDT- 2024/12/28 19:14 PHST- 2024/12/03 00:00 [received] PHST- 2024/12/20 00:00 [accepted] PHST- 2025/03/10 07:59 [medline] PHST- 2024/12/29 00:20 [pubmed] PHST- 2024/12/28 19:14 [entrez] AID - S0002-9149(24)00885-3 [pii] AID - 10.1016/j.amjcard.2024.12.027 [doi] PST - ppublish SO - Am J Cardiol. 2025 Apr 1;240:71-75. doi: 10.1016/j.amjcard.2024.12.027. Epub 2024 Dec 26. PMID- 39723980 OWN - NLM STAT- MEDLINE DCOM- 20241226 LR - 20241229 IS - 1524-4539 (Electronic) IS - 0009-7322 (Linking) VI - 151 IP - 1 DP - 2025 Jan 7 TI - Cardiovascular-Liver-Metabolic Health: Recommendations in Screening, Diagnosis, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease in Cardiovascular Disease via Modified Delphi Approach. PG - 98-119 LID - 10.1161/CIRCULATIONAHA.124.070535 [doi] AB - There is a new awareness of the widespread nature of metabolic dysfunction-associated steatotic liver disease (MASLD) and its connection to cardiovascular disease (CVD). This has catalyzed collaboration between cardiologists, hepatologists, endocrinologists, and the wider multidisciplinary team to address the need for earlier identification of those with MASLD who are at increased risk for CVD. The overlap in the pathophysiologic processes and parallel prevalence of CVD, metabolic syndrome, and MASLD highlight the multisystem consequences of poor cardiovascular-liver-metabolic health. Metabolic dysfunction and associated insulin resistance, together with the predilection for ectopic fat deposition in the liver and surrounding tissues, are associated with elevated risk of endothelial dysfunction, systemic inflammatory response, and ectopic fat deposition in the epicardium. This complex pathophysiology can accelerate atherogenic dyslipidemia, atherogenesis, diastolic dysfunction, valvular calcification, and cardiac arrhythmias. Despite the mounting evidence of mechanistic pathways underpinning MASLD and CVD, current recommendations have not clearly focused upon MASLD as a risk factor or target for intervention in CVD. We have brought together a diverse range of international experts committed to promoting cardiovascular-liver-metabolic health and related outcomes across the globe. The overarching goal of this document is to offer a construct for clinicians in the cardiovascular field with regards to (1) diagnosis and screening of MASLD through the use of noninvasive serum and imaging tests; (2) screening for CVD in all individuals with MASLD regardless of established atherosclerotic risk factors; and (3) the approach to management of MASLD with respect to prevention of CVD through lifestyle, as well as pharmacologic and surgical strategies. To achieve this, the modified Delphi method was applied and a series of evidence-based quality standard recommendations have been identified. FAU - Chew, Nicholas W S AU - Chew NWS AUID- ORCID: 0000-0002-0640-0430 AD - Department of Cardiology, National University Heart Centre (N.W.S.C., A.Z., R.F., M.Y.C.), National University Health System, Singapore. AD - Yong Loo Lin School of Medicine (N.S.W.C., R.G., Y.C., B.C., D.Q.H., R.F., M.Y.C., M.M., D.J.H.), National University of Singapore, Singapore. FAU - Mehta, Anurag AU - Mehta A AUID- ORCID: 0000-0002-6910-5551 AD - Virginia Commonwealth University Health Pauley Heart Center, Division of Cardiology (A.M.), Department of Internal Medicine, Virginia Commonwealth University School of Medicine, Richmond. FAU - Goh, Rachel Sze Jen AU - Goh RSJ AD - Yong Loo Lin School of Medicine (N.S.W.C., R.G., Y.C., B.C., D.Q.H., R.F., M.Y.C., M.M., D.J.H.), National University of Singapore, Singapore. FAU - Zhang, Audrey AU - Zhang A AUID- ORCID: 0000-0002-5201-0038 AD - Department of Cardiology, National University Heart Centre (N.W.S.C., A.Z., R.F., M.Y.C.), National University Health System, Singapore. FAU - Chen, Yiming AU - Chen Y AD - Yong Loo Lin School of Medicine (N.S.W.C., R.G., Y.C., B.C., D.Q.H., R.F., M.Y.C., M.M., D.J.H.), National University of Singapore, Singapore. FAU - Chong, Bryan AU - Chong B AUID- ORCID: 0000-0002-3565-7657 AD - Yong Loo Lin School of Medicine (N.S.W.C., R.G., Y.C., B.C., D.Q.H., R.F., M.Y.C., M.M., D.J.H.), National University of Singapore, Singapore. FAU - Chew, Han Shi Jocelyn AU - Chew HSJ AD - Alice Lee Centre for Nursing Studies (J.C.), National University of Singapore, Singapore. FAU - Shabbir, Asim AU - Shabbir A AD - National University of Singapore, Department of Surgery (A.Shabbir), National University Hospital, Singapore. FAU - Brown, Adrian AU - Brown A AUID- ORCID: 0000-0003-1818-6192 AD - University College London Centre for Obesity Research; Bariatric Centre for Weight Management and Metabolic Surgery, University College London Hospital NHS Trust; and National Institute of Health Research, UCLH Biomedical Research Centre, London, UK (A.B.). FAU - Dimitriadis, Georgios K AU - Dimitriadis GK AUID- ORCID: 0000-0002-6662-804X AD - Department of Endocrinology ASO/EASO COM, King's College Hospital NHS Foundation Trust; and Faculty of Cardiovascular Medicine and Sciences, Department of Diabetes, Obesity, Type 2 Diabetes and Immunometabolism Research Group, School of Life Course Sciences, King's College, London, UK (G.K.D.). FAU - Huang, Daniel Q AU - Huang DQ AD - National University Centre for Organ Transplantation (D.Q.H., M.M.), National University Health System, Singapore. AD - Yong Loo Lin School of Medicine (N.S.W.C., R.G., Y.C., B.C., D.Q.H., R.F., M.Y.C., M.M., D.J.H.), National University of Singapore, Singapore. AD - Division of Gastroenterology and Hepatology, Department of Medicine (D.Q.H., M.M.), National University Hospital, Singapore. FAU - Foo, Roger AU - Foo R AUID- ORCID: 0000-0002-8079-4618 AD - Department of Cardiology, National University Heart Centre (N.W.S.C., A.Z., R.F., M.Y.C.), National University Health System, Singapore. AD - Yong Loo Lin School of Medicine (N.S.W.C., R.G., Y.C., B.C., D.Q.H., R.F., M.Y.C., M.M., D.J.H.), National University of Singapore, Singapore. FAU - le Roux, Carel W AU - le Roux CW AUID- ORCID: 0000-0001-5521-5445 AD - Diabetes Complications Research Centre, University College Dublin, Ireland (C.R.l.R.). FAU - Figtree, Gemma A AU - Figtree GA AUID- ORCID: 0000-0002-5080-6083 AD - Department of Cardiology, Royal North Shore Hospital, Australia (G.A.F.). FAU - Fudim, Marat AU - Fudim M AUID- ORCID: 0000-0002-8671-7007 AD - Duke University Medical Center; and Duke Clinical Research Institute, Durham, NC (M.F.). FAU - Pandey, Ambarish AU - Pandey A AUID- ORCID: 0000-0001-9651-3836 AD - Department of Internal Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas (A.P.). FAU - Mamas, Mamas A AU - Mamas MA AUID- ORCID: 0000-0001-9241-8890 AD - Keele Cardiovascular Research Group, School of Medicine, Keele University, UK (M.A.M.). FAU - Hausenloy, Derek J AU - Hausenloy DJ AD - Yong Loo Lin School of Medicine (N.S.W.C., R.G., Y.C., B.C., D.Q.H., R.F., M.Y.C., M.M., D.J.H.), National University of Singapore, Singapore. AD - Duke-NUS Medical School, Cardiovascular and Metabolic Disorders Programme; and National Heart Centre Singapore, National Heart Research Institute, Singapore (D.J.H.). AD - University College London, The Hatter Cardiovascular Institute, UK (D.J.H.). FAU - Richards, A Mark AU - Richards AM AUID- ORCID: 0000-0002-2023-8177 AD - Christchurch Heart Institute, University of Otago, New Zealand (A.M.R.). AD - Cardiovascular Research Institute, National University Heart Centre Singapore, Singapore (A.M.R.). FAU - Nicholls, Stephen J AU - Nicholls SJ AD - Victorian Heart Institute, Monash University, Australia (S.J.N.). FAU - Chan, Mark Y AU - Chan MY AUID- ORCID: 0000-0003-0389-7450 AD - Department of Cardiology, National University Heart Centre (N.W.S.C., A.Z., R.F., M.Y.C.), National University Health System, Singapore. AD - Yong Loo Lin School of Medicine (N.S.W.C., R.G., Y.C., B.C., D.Q.H., R.F., M.Y.C., M.M., D.J.H.), National University of Singapore, Singapore. FAU - Muthiah, Mark D AU - Muthiah MD AUID- ORCID: 0000-0002-9724-4743 AD - National University Centre for Organ Transplantation (D.Q.H., M.M.), National University Health System, Singapore. AD - Yong Loo Lin School of Medicine (N.S.W.C., R.G., Y.C., B.C., D.Q.H., R.F., M.Y.C., M.M., D.J.H.), National University of Singapore, Singapore. AD - Division of Gastroenterology and Hepatology, Department of Medicine (D.Q.H., M.M.), National University Hospital, Singapore. FAU - Sanyal, Arun AU - Sanyal A AD - Division of Gastroenterology, Hepatology and Nutrition (A.Sanyal), Department of Internal Medicine, Virginia Commonwealth University School of Medicine, Richmond. FAU - Sperling, Laurence S AU - Sperling LS AUID- ORCID: 0000-0001-9417-6370 AD - Division of Cardiology, Department of Medicine, Emory Clinical Cardiovascular Research Institute; and Emory University School of Medicine, Atlanta, GA (L.S.S.). LA - eng PT - Journal Article PT - Review DEP - 20241226 PL - United States TA - Circulation JT - Circulation JID - 0147763 SB - IM MH - Humans MH - *Cardiovascular Diseases/complications/diagnosis/metabolism/therapy MH - *Delphi Technique MH - *Fatty Liver/diagnosis/therapy/complications/metabolism MH - Mass Screening/standards/methods MH - *Metabolic Syndrome/diagnosis/therapy/complications/metabolism MH - Risk Factors OTO - NOTNLM OT - atherosclerosis OT - cardiovascular diseases OT - fatty liver OT - isk factors OT - liver diseases OT - metabolic syndrome COIS- N.W.S.C reports research support from the National University Health System's Seed Fund (grant No. NUHSRO/2022/RO5+6/Seed-Mar/03) and Clinician Scientist Program (grant No. NCSP2.0/2024/NUHS/NCWS), National Medical Research Council Research Training Fellowship (grant No. MH 095:003/008-303), and National University of Singapore Yong Loo Lin School of Medicine's Academic Fellowship Scheme. A.M. reports research grants from Novartis and Amgen. G.K.D reports research grants from National Institute for Health and Care Research, Novo Nordisk UK Research Foundation, and DDM, as well as payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Novo Nordisk, Rhythm Pharmaceuticals, Johnson & Johnson/Ethicon, and Medtronic. C.W.l.R reports grants from the Irish Research Council, Science Foundation Ireland, Anabio, and the Health Research Board; serves on advisory boards of Novo Nordisk, Herbalife, GI Dynamics, Eli Lilly, Johnson & Johnson, Glia, and Boehringer Ingelheim; is a member of the Irish Society for Nutrition and Metabolism, outside the area of work commented on here; was Chief Medical Officer and Director of the Medical Device Division of Keyron in 2011 (both unremunerated positions); and was a previous investor in Keyron, which develops endoscopically implantable medical devices intended to mimic the surgical procedures of sleeve gastrectomy and gastric bypass. The product has only been tested in rodents and none of Keyron's products are currently licensed. They do not have any contracts with other companies to put their products into clinical practice. No patients have been included in any of Keyron's studies and they are not listed on the stock market. C.W.l.R was also gifted stock holdings in September 2021 and divested all stock holdings in Keyron in September 2021, and continues to provide scientific advice to Keyron for no remuneration. G.A.F. reports grants from National Health and Medical Research Council (Australia), Abbott Diagnostic, Sanofi, Janssen Pharmaceuticals, and NSW Health; reports honorarium from CSL, CPC Clinical Research, Sanofi, Boehringer-Ingelheim, Heart Foundation, and Abbott; serves as Board Director for the Australian Cardiovascular Alliance, Executive Committee Member for CPC Clinical Research, Founding Director and CMO for Prokardia and Kardiomics, and Executive Committee member for the CAD Frontiers A2D2 Consortium. In addition, G.A.F serves as Chief Medical Office of the nonprofit, CAD Frontiers, with industry partners including Novartis, Amgen, Siemens Healthineers, ELUCID, Foresite Labs LLC, HeartFlow, Cleerly, Caristo, Genetech, Artyra, Bitterroot Bio, and Allelica. G.A.F. reports the following patents: "Patent Biomarkers and Oxidative Stress" awarded May 2017 (US9638699B2), issued to Northern Sydney Local Health District; "Use of P2X7R antagonists in cardiovascular disease" (PCT/AU2018/050905), licensed to Prokardia; "Methods for treatment and prevention of vascular disease" (PCT/AU2015/000548), issued to The University of Sydney/Northern Sydney Local Health District; "Wound healing methods" (PCT/AU2022/050129), issued to The University of Sydney; "Wound healing compositions" (PCT/AU2022/050130), issued to The University of Sydney; "Methods for predicting coronary artery disease" (AU202290266), issued to The University of Sydney; and "Novel P2X7 Receptor Antagonists" (PCT/AU2022/051400 [November 23, 2022], International Application No. WO/2023/092175 [June 1, 2023]), issued to The University of Sydney. M.F reports support from the National Institutes of Health, Alleviant, Gradient, Reprieve, Sardocor, and Doris Duke; and is a consultant/has ownership interest in Abbott, Alleviant, xonTherapies, Merck, and NovoNordisk. A.P. has received research support from the National Institute of Health, American Heart Association, Applied Therapeutics, Roche, Ultromics, and ScPharmaceuticals; has received honoraria outside of the present study as an advisor/consultant for Tricog Health Inc, Lilly USA, Rivus, Cytokinetics, Roche Diagnostics, Axon therapies, Medtronic, Edward Lifesciences, Science37, Novo Nordisk, Bayer, Merck, Sarfez Pharmaceuticals, Emmi Solutions, Anumana, Semler Scientific, Ultromics, Merck, Encarda, Kieele Health, Acorai; and has received nonfinancial support from Pfizer and Merck. A.P. is also a consultant for Palomarin with stock options. D.J.H. is supported by the Duke-NUS Signature Research Programme funded by the Ministry of Health's National Medical Research Council under its Singapore Translational Research Investigator Award (MOH-STaR21jun-0003). M.D.M. is supported by the Singapore Ministry of Health through the National Medical Research Council (NMRC) Office, MOH Holdings Pte Ltd under the NMRC Clinician Scientist-Individual Research Grant (MOH-001228) and NMRC Clinician Scientist Award (MOH-001631), as well as the National Research Foundation, Singapore (NRF) under the NMRC Open Fund - Large Collaborative Grant (MOH-001325) and administered by the Singapore Ministry of Health through the NMRC Office, MOH Holdings Pte Ltd. M.D.M is a consultant/on the advisory panel or has paid speaking engagements in Roche, Astellas, Gilead, LernaBio, Boston Scientific, Olympus Medical, and Perspectum. M.M serves as an associate editor of Circulation: Cardiovascular Interventions. A.M.R is the New Zealand Heart Foundation Chair of Cardiovascular Studies; is on the advisory board for Roche Diagnostics; receives speakers fees from Roche Diagnostics; and receives research grant support, in cash or in mind, from Roche Diagnostics, Abbott Laboratories, Sphingotec, Thermo Fisher, Astra Zeneca, and Novo Nordisk. S.J.N reports research grant support from AstraZeneca, Amgen, Anthera, Cerenis, Eli Lilly, Esperion, InfraReDx, LipoScience, The Medicines Company, New Amsterdam Pharma, Novartis, Resverlogix, Roche, and Sanofi-Regeneron; and consulting fees from Akcea, Amarin, Anthera, AstraZeneca, Boehringer Ingelheim, CSL Behring, Eli Lilly, Esperion, Omthera, Merck, Resverlogix, Sanofi-Regeneron, Takeda, and Vaxxinity. M.Y.C receives salary support from an National Medical Council Research Clinician Scientist Award (Senior Investigator Category; No. MOH-000280-00). The other authors report no conflicts. EDAT- 2024/12/26 18:15 MHDA- 2024/12/26 18:16 CRDT- 2024/12/26 15:46 PHST- 2024/12/26 18:16 [medline] PHST- 2024/12/26 18:15 [pubmed] PHST- 2024/12/26 15:46 [entrez] AID - 10.1161/CIRCULATIONAHA.124.070535 [doi] PST - ppublish SO - Circulation. 2025 Jan 7;151(1):98-119. doi: 10.1161/CIRCULATIONAHA.124.070535. Epub 2024 Dec 26. PMID- 39722275 OWN - NLM STAT- MEDLINE DCOM- 20241226 LR - 20260709 IS - 1876-7605 (Electronic) IS - 1936-8798 (Linking) VI - 17 IP - 24 DP - 2024 Dec 23 TI - End of Life After Transcatheter Aortic Valve Replacement: A Danish Nationwide Cohort Study. PG - 2936-2946 LID - S1936-8798(24)01206-8 [pii] LID - 10.1016/j.jcin.2024.09.021 [doi] AB - BACKGROUND: Survival after transcatheter aortic valve replacement (TAVR) has markedly increased. Thus, other comorbidities will intersect patient trajectories and challenge follow-up. OBJECTIVES: The aim of this study was to describe patient characteristics and hospitalizations at end of life to further improve the quality of life for patients undergoing TAVR. METHODS: Using Danish nationwide registers, all patients who underwent TAVR were matched 1:10 at the time of death on age, sex, and calendar year of death to controls from the general population. RESULTS: From 2008 to 2022, 2,544 TAVR patients who died were matched with 25,440 controls (median age 86 years, 55.1% males). Frailty and comorbidities were more prevalent in the TAVR group (eg, intermediate/high frailty: 2,200/2,544 [86.4%] vs 18,966/25,440 [74.6%]; heart failure: 1,407/2,544 [55.3%] vs 4,641/25,440 [18.2%]; chronic kidney disease: 633/2,544 [24.9%] vs 3,353/25,440 [13.2%]). In the last year of life, 650 of 2,544 patients (25.6%) in the TAVR group were hospitalized >28 days vs 4,160 of 25,440 (16.4%) for the controls. Of hospitalizations in the last year of life, 4,900 of 6,943 (70.6%) vs 38,833 of 49,438 (78.5%) were for a noncardiovascular cause, 1,253 of 6,943 (18.0%) vs 4,924 of 49,438 (10.0%) were cardiovascular, and 790 of 6,943 (11.4%) vs 5,681 of 49,438 (11.5%) were because of symptoms (eg, dyspnea, vomiting, or urine retention) in the TAVR group and the control group, respectively. Of cardiovascular hospitalizations, 529 of 1,253 (42.2%) vs 1,322 of 4,924 (26.8%) were because of heart failure in the TAVR group vs the controls. CONCLUSIONS: End of life for TAVR patients is characterized by high frailty and comorbidity burden. Importantly, most hospitalizations are of noncardiovascular cause, underscoring the need for a multidisciplinary approach toward end of life for TAVR patients. Future research is needed to improve follow-up and care in this patient population. CI - Copyright (c) 2024 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Strange, Jarl Emanuel AU - Strange JE AD - Department of Cardiology, The Heart Center, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark; Department of Cardiology, Copenhagen University Hospital Herlev and Gentofte, Hellerup, Denmark. Electronic address: Jarl.emanuel.strange.02@regionh.dk. FAU - Holt, Anders AU - Holt A AD - Department of Cardiology, Copenhagen University Hospital Herlev and Gentofte, Hellerup, Denmark. FAU - Christensen, Daniel Molager AU - Christensen DM AD - Department of Cardiology, Copenhagen University Hospital Herlev and Gentofte, Hellerup, Denmark; Department of Cardiology, Zealand University Hospital Roskilde, Roskilde, Denmark. FAU - Nouhravesh, Nina AU - Nouhravesh N AD - Department of Cardiology, Copenhagen University Hospital Herlev and Gentofte, Hellerup, Denmark. FAU - Petersen, Jeppe Kofoed AU - Petersen JK AD - Department of Cardiology, The Heart Center, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark. FAU - Baekke, Pernille Steen AU - Baekke PS AD - Department of Cardiology, The Heart Center, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark. FAU - De Backer, Ole AU - De Backer O AD - Department of Cardiology, The Heart Center, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark. FAU - Schou, Morten AU - Schou M AD - Department of Cardiology, Copenhagen University Hospital Herlev and Gentofte, Hellerup, Denmark. FAU - Kober, Lars AU - Kober L AD - Department of Cardiology, The Heart Center, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark. FAU - Fosbol, Emil Loldrup AU - Fosbol EL AD - Department of Cardiology, The Heart Center, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark. LA - eng PT - Journal Article PL - United States TA - JACC Cardiovasc Interv JT - JACC. Cardiovascular interventions JID - 101467004 SB - IM CIN - JACC Cardiovasc Interv. 2024 Dec 23;17(24):2947-2949. doi: 10.1016/j.jcin.2024.10.008. PMID: 39722276 MH - Humans MH - *Transcatheter Aortic Valve Replacement/adverse effects/mortality MH - Denmark/epidemiology MH - Male MH - Female MH - Aged, 80 and over MH - *Registries MH - Time Factors MH - Aged MH - Risk Factors MH - Treatment Outcome MH - *Aortic Valve Stenosis/surgery/mortality/diagnostic imaging/physiopathology MH - *Comorbidity MH - *Quality of Life MH - Frailty/diagnosis/epidemiology MH - Risk Assessment MH - Aortic Valve/surgery/physiopathology/diagnostic imaging MH - Frail Elderly MH - Hospitalization MH - Prevalence OTO - NOTNLM OT - end of life OT - epidemiology OT - hospitalizations OT - mortality OT - transcatheter aortic valve replacement COIS- Funding Support and Author Disclosures Dr Christensen has received an independent research grant from the Lundbeck Foundation. Dr Nouhravesh has received unrelated speaker honoraria from Bayer and AstraZeneca. Dr Baekke has received funding from Boston Scientific, Abbott, and Medtronic not related to this manuscript. Dr De Backer has received institutional grants and consulting fees from Abbott and Boston Scientific. Dr Schou has received lecture fees from Boehringer, AstraZeneca, Novartis, and Novo Nordisk. Dr Kober has received speaker fees from AstraZeneca, Bayer, Boehringer, and Novatis. Dr Fosbol has received an independent research grant from Novo Nordisk Foundation. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2024/12/26 06:20 MHDA- 2024/12/26 06:21 CRDT- 2024/12/26 01:09 PHST- 2024/05/19 00:00 [received] PHST- 2024/08/13 00:00 [revised] PHST- 2024/09/10 00:00 [accepted] PHST- 2024/12/26 06:21 [medline] PHST- 2024/12/26 06:20 [pubmed] PHST- 2024/12/26 01:09 [entrez] AID - S1936-8798(24)01206-8 [pii] AID - 10.1016/j.jcin.2024.09.021 [doi] PST - ppublish SO - JACC Cardiovasc Interv. 2024 Dec 23;17(24):2936-2946. doi: 10.1016/j.jcin.2024.09.021. PMID- 39716223 OWN - NLM STAT- MEDLINE DCOM- 20241224 LR - 20250104 IS - 1472-6920 (Electronic) IS - 1472-6920 (Linking) VI - 24 IP - 1 DP - 2024 Dec 24 TI - The effect of a team-based blended simulation training program on cardiopulmonary resuscitation on healthcare professionals' perception, performance, and costs: a mixed-method study. PG - 1524 LID - 10.1186/s12909-024-06543-3 [doi] LID - 1524 AB - BACKGROUND: The quality of Cardio Pulmonary Resuscitation (CPR) and Automated External Defibrillations (AED) treatment provided by individual practitioners is the most important factor in surviving an in-hospital cardiac arrest (IHCA); therefore, healthcare professionals (HCPs) require sufficient resuscitation competency. This study aimed to analyze the effects of a blended team-based CPR and AED simulation training (riAniMO program) on HCPs performance, satisfaction and perception on transferability, and costs. METHODS: The riAniMO is based on a multimedia training program with video lessons and a virtual CPR resuscitation simulation, and a team-based CPR and AED simulation. The study utilized a mixed-method design. The quantitative phase involved a retrospective cohort study with a comparison group to assess the impact of the riAniMO. Meanwhile, the qualitative phase involved four focus groups (FGs) to investigate the viewpoints of professionals on the strengths and limitations of the riAniMO. We compared the 845 HCPs who participated in the BLSD (Basic Life Support- early Defibrillation) re-training program with ERC (European Resuscitation Council) approach and the 1,167 who participated in the riAniMO re-training program. BLSD re-training took place between January and December 2019 and riAniMO re-training took place between January and December 2022. RESULTS: From quantitative analysis, a slight increase in the number of HCPs satisfied with retraining in the riAniMO group compared to the BLSD group was found. However, the percentage of HCPs certified decreased by 9% in the riAniMo group (90.2%) compared to the BLSD group (99.2%). The RiAniMO approach resulted in cost savings by training 322 more healthcare providers and saving euro 61.7 per participant. From the FG analysis, five themes emerged: 1) Realism in Learning: Experimenting in your own operating context and using your own devices; 2) Strength of the working group and multidisciplinarity; 3) Improved perception of training burden; 4) Facilitator as consultant and guide, which provides real-time situational feedback; 5) Transparency on evaluations and certifications for the simulations. CONCLUSIONS: The riAniMO approach maintained high standards in terms of HCPs' satisfaction and performance and seemed to be cost-saving. Further studies are necessary to verify the long-term effectiveness of training methods for team-based CPR and AED simulation. CI - (c) 2024. The Author(s). FAU - Palmisano, Francesco AU - Palmisano F AD - Continuing Education Service, Azienda Provinciale Per I Servizi Sanitari, Trento, Italy. francesco.palmisano@apss.tn.it. FAU - Santuari, Nadia AU - Santuari N AD - Continuing Education Service, Azienda Provinciale Per I Servizi Sanitari, Trento, Italy. FAU - Moletta, Cristina AU - Moletta C AD - Continuing Education Service, Azienda Provinciale Per I Servizi Sanitari, Trento, Italy. FAU - Ambrosi, Elisa AU - Ambrosi E AD - Department of Diagnostics and Public Health, University of Verona, Verona, Italy. FAU - Rizzoli, Andrea AU - Rizzoli A AD - Urgent Care and Medical Emergency Unit, Azienda Provinciale Per i Servizi Sanitari, Trento, Italy. LA - eng PT - Journal Article DEP - 20241224 PL - England TA - BMC Med Educ JT - BMC medical education JID - 101088679 SB - IM MH - Humans MH - *Cardiopulmonary Resuscitation/education MH - Retrospective Studies MH - *Simulation Training MH - Female MH - Male MH - Patient Care Team MH - Health Personnel/education MH - Clinical Competence MH - Adult MH - Defibrillators MH - Attitude of Health Personnel MH - Heart Arrest/therapy PMC - PMC11667884 OTO - NOTNLM OT - Cardiopulmonary Resuscitation OT - Education OT - Mixed-methods design OT - Team-based simulation COIS- Declarations. Ethics approval and consent to participate: As the present study was part of a Quality Improvement Project promoted by APSS, the guidelines of the Local Ethical Committee "Comitato Etico Territoriale della Provincia Autonoma di Trento per le sperimentazioni cliniche (CET-PAT)" did not require ethical approval. However, the study has been reviewed and approved by the Directors of all involved hospitals, which requested that informed consent should be obtained from healthcare professionals participating in the study. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2024/12/24 06:20 MHDA- 2024/12/24 06:21 PMCR- 2024/12/24 CRDT- 2024/12/24 00:01 PHST- 2024/02/20 00:00 [received] PHST- 2024/12/16 00:00 [accepted] PHST- 2024/12/24 06:21 [medline] PHST- 2024/12/24 06:20 [pubmed] PHST- 2024/12/24 00:01 [entrez] PHST- 2024/12/24 00:00 [pmc-release] AID - 10.1186/s12909-024-06543-3 [pii] AID - 6543 [pii] AID - 10.1186/s12909-024-06543-3 [doi] PST - epublish SO - BMC Med Educ. 2024 Dec 24;24(1):1524. doi: 10.1186/s12909-024-06543-3. PMID- 39714874 OWN - NLM STAT- MEDLINE DCOM- 20250429 LR - 20260910 IS - 2380-6591 (Electronic) IS - 2380-6583 (Print) VI - 10 IP - 3 DP - 2025 Mar 1 TI - Representation of Women Among Cardiology Grand Rounds Speakers in the United States. PG - 290-294 LID - 10.1001/jamacardio.2024.4255 [doi] AB - IMPORTANCE: Women are underrepresented in leadership positions in cardiology. Institutional grand rounds (GR) are platforms through which faculty can gain professional exposure and access to career development opportunities. The gender diversity of invited cardiology GR speakers has not been investigated. OBJECTIVE: To examine the representation of women among cardiology GR speakers in the United States. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study reviewed all 626 internal medicine residency training program websites in the American Medical Association's FRIEDA directory to identify publicly available records of cardiology GR. Grand rounds from September 1997 through December 2022 were included; GR with more than 1 speaker and trainee-led case conferences were excluded. EXPOSURES: Grand rounds speaker gender. MAIN OUTCOMES AND MEASURES: Data on GR topic focus, speaker gender, and academic rank were collected. RESULTS: A total of 3806 GR lectures at 42 institutions were included; 799 (21%) were delivered by women and 3007 (79%) by men. The proportion of women GR speakers increased by 1% per year and increased for each topic over time with the exception of electrophysiology and basic/translational science. Women were most likely to speak on women's cardiovascular health (80 lectures [10.0%] vs 17 [0.6%] for men; P < .001). CONCLUSIONS AND RELEVANCE: Women compose about 1 in 5 cardiology GR speakers with modest growth in representation over time but remain underrepresented as GR speakers for procedural cardiology and basic/translational science topics. FAU - DeFilippis, Ersilia M AU - DeFilippis EM AD - Center for Advanced Cardiac Care, Division of Cardiology, Columbia University Irving Medical Center, New York, New York. FAU - Muppala, Supriya AU - Muppala S AD - Division of Cardiovascular Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania. FAU - Kaur, Gurleen AU - Kaur G AD - Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts. FAU - Huston, Jessica H AU - Huston JH AD - Ascension Saint Thomas Heart, Nashville, Tennessee. FAU - Harrington, Robert A AU - Harrington RA AD - Weill Cornell Medicine and Cornell University, New York, New York. FAU - Capers, Quinn 4th AU - Capers Q 4th AD - Department of Medicine, Howard University, Washington, DC. FAU - Douglas, Pamela S AU - Douglas PS AD - Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina. FAU - Mahmud, Nadim AU - Mahmud N AD - Department of Gastroenterology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania. FAU - Reza, Nosheen AU - Reza N AD - Division of Cardiovascular Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania. LA - eng GR - K08 DK124577/DK/NIDDK NIH HHS/United States GR - K23 HL166961/HL/NHLBI NIH HHS/United States GR - R03 DK134794/DK/NIDDK NIH HHS/United States PT - Journal Article PL - United States TA - JAMA Cardiol JT - JAMA cardiology JID - 101676033 SB - IM MH - Humans MH - Female MH - United States MH - *Cardiology/education MH - Cross-Sectional Studies MH - *Physicians, Women/statistics & numerical data MH - Male MH - *Teaching Rounds/statistics & numerical data MH - *Internship and Residency MH - Leadership PMC - PMC11904703 MID - NIHMS2057765 COIS- Conflict of Interest Disclosures: Dr DeFilippis reported personal fees from AstraZeneca and serving on a clinical trial committee for Abiomed outside the submitted work. Dr Harrington reported research grants/contracts from the National Heart, Lung, and Blood Institute (NHLBI) (ISCHEMIA), Duke/PCORI (ADAPTABLE), Janssen, and CSL Behring; serving on a data and safety monitoring board for the Baim Institute, Colorado Prevention Center, and Merck; consulting and/or advising for the NHLBI (COVID/CONNECTS), Atropos Health, Bitterroot Bio, Bristol Myers Squibb, Bridge Bio, Chiesi, Colorado Prevention Center, CSL Behring, Edwards Lifesciences Corp, Element Science, Foresight, Merck, and WebMD; and serving on the board of directors for the American Heart Association and Cytokinetics. Dr Mahmud reported support from the National Institute of Diabetes and Digestive and Kidney Diseases (K08DK124577) and research support from Grifols. Dr Reza reported support from the NHLBI (K23HL166961), speaking honoraria from Zoll, advisor fees from American Regent and Bristol Myers Squibb, and research grants to their institution from Bristol Myers Squibb outside the submitted work. No other disclosures were reported. EDAT- 2024/12/23 12:22 MHDA- 2025/03/12 12:31 PMCR- 2025/12/23 CRDT- 2024/12/23 11:43 PHST- 2025/03/12 12:31 [medline] PHST- 2024/12/23 12:22 [pubmed] PHST- 2024/12/23 11:43 [entrez] PHST- 2025/12/23 00:00 [pmc-release] AID - 2828585 [pii] AID - hbr240017 [pii] AID - 10.1001/jamacardio.2024.4255 [doi] PST - ppublish SO - JAMA Cardiol. 2025 Mar 1;10(3):290-294. doi: 10.1001/jamacardio.2024.4255. PMID- 39712420 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250104 IS - 0899-8280 (Print) IS - 1525-3252 (Electronic) IS - 0899-8280 (Linking) VI - 38 IP - 1 DP - 2025 TI - Institution of a formal multidisciplinary heart team for high-risk coronary revascularization. PG - 28-33 LID - 10.1080/08998280.2024.2426925 [doi] AB - INTRODUCTION: The heart team approach is now the standard of care for patients with complex coronary artery disease; however, the definition of a heart team is variable. We embarked on a project to create an extended, multidisciplinary heart team to evaluate patients we deemed high risk for coronary revascularization. In doing so, we created a new service, workflow, and paradigm. METHODS: Herein, we describe the process through which we created our high-risk percutaneous coronary intervention team, our criteria for determining risk, our process for evaluating these patients, and quality assurance. Additionally, we describe the design of our prospective study assessing 200 patients with complex coronary artery disease. The primary outcomes include the final heart team revascularization decision, all-cause mortality, major adverse cardiac events, acute kidney injury, postintervention bleeding, and length of stay. CONCLUSION: Establishing a multidisciplinary heart team may help with complex and high-risk patient and family scenarios and potentially improve patient outcomes. A study has been initiated to test this hypothesis formally. CI - Copyright (c) 2024 Baylor University Medical Center. FAU - Potluri, Srinivasa AU - Potluri S AUID- ORCID: 0009-0002-3645-3506 AD - Department of Cardiology, Baylor Scott & White The Heart Hospital - Plano, Plano, Texas, USA. FAU - Sawhney, Rahul AU - Sawhney R AUID- ORCID: 0000-0001-5580-0396 AD - Department of Cardiology, Baylor Scott & White The Heart Hospital - Plano, Plano, Texas, USA. FAU - Dorton, Cody AU - Dorton C AUID- ORCID: 0009-0003-5789-2986 AD - Baylor Scott & White Research Institute, Plano, Texas, USA. FAU - McCullough, Kyle AU - McCullough K AUID- ORCID: 0000-0001-8984-4354 AD - Baylor Scott & White Research Institute, Plano, Texas, USA. FAU - Moubarak, Ghadi AU - Moubarak G AUID- ORCID: 0009-0002-9280-5238 AD - Baylor Scott & White Research Institute, Plano, Texas, USA. FAU - Shih, Emily AU - Shih E AUID- ORCID: 0000-0002-2426-513X AD - Department of Cardiothoracic Surgery, Baylor Scott & White The Heart Hospital - Plano, Plano, Texas, USA. FAU - Christensen, Jared AU - Christensen J AD - Department of Cardiology, Baylor Scott & White The Heart Hospital - Plano, Plano, Texas, USA. FAU - DiMaio, J Michael AU - DiMaio JM AUID- ORCID: 0000-0002-6064-5869 AD - Baylor Scott & White Research Institute, Plano, Texas, USA. AD - Department of Cardiothoracic Surgery, Baylor Scott & White The Heart Hospital - Plano, Plano, Texas, USA. FAU - Al-Azizi, Karim AU - Al-Azizi K AUID- ORCID: 0000-0003-0195-4984 AD - Department of Cardiology, Baylor Scott & White The Heart Hospital - Plano, Plano, Texas, USA. FAU - Dib, Chadi AU - Dib C AD - Department of Cardiology, Baylor Scott & White The Heart Hospital - Plano, Plano, Texas, USA. FAU - Sayfo, Sameh AU - Sayfo S AUID- ORCID: 0009-0004-4979-6107 AD - Department of Cardiology, Baylor Scott & White The Heart Hospital - Plano, Plano, Texas, USA. FAU - Szerlip, Molly AU - Szerlip M AUID- ORCID: 0000-0002-4907-1825 AD - Department of Cardiology, Baylor Scott & White The Heart Hospital - Plano, Plano, Texas, USA. AD - Baylor Scott & White Research Institute, Plano, Texas, USA. FAU - Thomas, Sibi AU - Thomas S AD - Department of Cardiology, Baylor Scott & White The Heart Hospital - Plano, Plano, Texas, USA. FAU - Levy, Alfred AU - Levy A AD - Department of Palliative Care, Baylor Scott & White The Heart Hospital - Plano, Plano, Texas, USA. FAU - Hutcheson, Kelly AU - Hutcheson K AUID- ORCID: 0009-0008-1008-9244 AD - Department of Cardiothoracic Surgery, Baylor Scott & White The Heart Hospital - Plano, Plano, Texas, USA. FAU - Carranza, Melissa AU - Carranza M AD - Baylor Scott & White Research Institute, Plano, Texas, USA. FAU - Douthit, Samantha AU - Douthit S AD - Baylor Scott & White Research Institute, Plano, Texas, USA. FAU - Pettijohn, Trent AU - Pettijohn T AD - Department of Cardiology, Baylor Scott & White The Heart Hospital - Plano, Plano, Texas, USA. FAU - Ryan, William AU - Ryan W AUID- ORCID: 0009-0004-9946-1807 AD - Department of Cardiothoracic Surgery, Baylor Scott & White The Heart Hospital - Plano, Plano, Texas, USA. FAU - Mack, Michael AU - Mack M AUID- ORCID: 0000-0002-3148-9158 AD - Baylor Scott & White Research Institute, Plano, Texas, USA. AD - Department of Cardiothoracic Surgery, Baylor Scott & White The Heart Hospital - Plano, Plano, Texas, USA. LA - eng PT - Journal Article DEP - 20241122 PL - United States TA - Proc (Bayl Univ Med Cent) JT - Proceedings (Baylor University. Medical Center) JID - 9302033 PMC - PMC11657062 OTO - NOTNLM OT - Coronary artery bypass graft OT - National Cardiovascular Data Registry OT - coronary artery disease OT - heart team OT - high risk COIS- Funding was provided by the Cardiovascular Research Review Committee of the Baylor Scott & White Research Institute. Financial support of CD, KM, and GM is a generous philanthropic gift of the Baylor Scott & White Dallas Foundation, the Roberts Foundation, and the family of Satish and Yasmin Gupta. The authors report no conflicts of interest. EDAT- 2024/12/23 17:24 MHDA- 2024/12/23 17:25 PMCR- 2024/11/22 CRDT- 2024/12/23 06:06 PHST- 2024/12/23 17:25 [medline] PHST- 2024/12/23 17:24 [pubmed] PHST- 2024/12/23 06:06 [entrez] PHST- 2024/11/22 00:00 [pmc-release] AID - 2426925 [pii] AID - 10.1080/08998280.2024.2426925 [doi] PST - epublish SO - Proc (Bayl Univ Med Cent). 2024 Nov 22;38(1):28-33. doi: 10.1080/08998280.2024.2426925. eCollection 2025. PMID- 39710597 OWN - NLM STAT- MEDLINE DCOM- 20250701 LR - 20250701 IS - 1531-1937 (Electronic) IS - 0897-1900 (Linking) VI - 38 IP - 4 DP - 2025 Aug TI - Evaluation of Pharmacist Involvement in Emergency Response. PG - 403-409 LID - 10.1177/08971900241310308 [doi] AB - Purpose: Emergency response teams are designed to promptly deliver care to hospitalized patients experiencing acute decompensation events. Pharmacists are an integrated part of emergency response teams and their presence at emergency response events has been shown to improve adherence to institutional and advanced cardiac life support (ACLS) guidelines. This study assesses the impact of pharmacist involvement at emergency responses and time clinical pharmacists dedicate to emergency response. Methods: A single-center, retrospective chart review assessed inpatient and ambulatory emergency responses for patients 18 and older from August 2021 through January 2022. Emergency response event-specific information was assessed using intervention documentations in the hospital electronic health record (EHR). The amount of time dedicated to emergency response by pharmacists was then converted to full-time equivalents (FTE). Results: Of the 296 emergency response documentations assessed, 242 responses were included in analysis. The primary outcome of time pharmacists dedicate to emergency responses over a six-month period was found to be 9480 minutes (158 hours). The average amount of time spent at each response was 40.7 minutes (SD 27.4 minutes), ranging from 5-210 minutes. Conclusion: The total time spent by clinical pharmacists at emergency responses within a six-month period was equivalent to approximately 26% of an FTE. Due to inability of pharmacists to document all emergency responses, this may be under-represented. More than 70% of emergency responses required 6-10 medications be prepared by pharmacists. Pharmacists made interventions 47% of the time, indicating that pharmacists play an integral role as members of emergency response teams. FAU - Jeghers, Melissa A AU - Jeghers MA AUID- ORCID: 0009-0004-4093-1210 AD - Department of Pharmacy, Massachusetts General Hospital, Boston, MA, USA. RINGGOLD: 2348 FAU - Ji, Christine AU - Ji C AD - Department of Pharmacy, Massachusetts General Hospital, Boston, MA, USA. RINGGOLD: 2348 FAU - Newman, Kelly AU - Newman K AD - Department of Pharmacy, Massachusetts General Hospital, Boston, MA, USA. RINGGOLD: 2348 FAU - Leung, Natalie AU - Leung N AUID- ORCID: 0009-0007-0677-0195 AD - Department of Pharmacy, Massachusetts General Hospital, Boston, MA, USA. RINGGOLD: 2348 FAU - Roberts, Russel J AU - Roberts RJ AD - Department of Pharmacy, Massachusetts General Hospital, Boston, MA, USA. RINGGOLD: 2348 LA - eng PT - Journal Article DEP - 20241222 PL - United States TA - J Pharm Pract JT - Journal of pharmacy practice JID - 8900945 SB - IM MH - Humans MH - *Pharmacists/standards MH - Retrospective Studies MH - *Professional Role MH - Male MH - Female MH - *Pharmacy Service, Hospital MH - Middle Aged MH - Aged MH - *Emergency Service, Hospital MH - *Hospital Rapid Response Team MH - *Emergency Medical Services MH - Patient Care Team MH - Adult OTO - NOTNLM OT - critical care OT - drug information OT - emergency medicine OT - medication safety OT - pharmacy education COIS- Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2024/12/23 00:19 MHDA- 2025/07/01 09:30 CRDT- 2024/12/22 22:23 PHST- 2025/07/01 09:30 [medline] PHST- 2024/12/23 00:19 [pubmed] PHST- 2024/12/22 22:23 [entrez] AID - 10.1177/08971900241310308 [doi] PST - ppublish SO - J Pharm Pract. 2025 Aug;38(4):403-409. doi: 10.1177/08971900241310308. Epub 2024 Dec 22. PMID- 39705195 OWN - NLM STAT- MEDLINE DCOM- 20241220 LR - 20260520 IS - 1936-2692 (Electronic) IS - 1088-0224 (Linking) VI - 30 IP - 10 Suppl DP - 2024 Dec TI - Diabetes, cardiorenal, and metabolic multispecialty practice recommendations and early intensive management of cardio-renal-metabolic disease. PG - S189-S196 LID - 10.37765/ajmc.2024.89671 [doi] AB - In recent years, evidence has continued to mount showing a strong relationship between diabetes, cardiovascular disease, and chronic kidney disease. This, in turn, has driven a shift to a more integrated and holistic approach in the treatment of patients with cardio-renal-metabolic (CRM) disease. The 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations were the first multispecialty consensus on the comprehensive management of patients with diabetes, cardiorenal, and/or metabolic diseases, providing evidence-based recommendations that are simple to implement. The recommendations provide guidance on assessments and treatments, including both lifestyle therapy and pharmacotherapy, for patients across the DCRM spectrum, and are an invaluable tool for clinicians who need to develop treatment plans for complex patients with cardio-renal-metabolic disease. This article reviews the key elements of the DCRM recommendations and summarizes the updates included in the DCRM 2.0. FAU - Handelsman, Yehuda AU - Handelsman Y AD - Metabolic Institute of America, 18372 Clark St #212, Tarzana, CA 91356. Email: yhandelsman@gmail.com. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review PT - Video-Audio Media PL - United States TA - Am J Manag Care JT - The American journal of managed care JID - 9613960 SB - IM MH - Humans MH - *Cardio-Renal Syndrome/metabolism/therapy MH - Diabetes Mellitus/metabolism/therapy MH - Metabolic Diseases/metabolism/therapy MH - Practice Guidelines as Topic MH - Renal Insufficiency, Chronic/therapy EDAT- 2024/12/20 18:20 MHDA- 2024/12/20 18:21 CRDT- 2024/12/20 13:13 PHST- 2024/12/20 18:21 [medline] PHST- 2024/12/20 18:20 [pubmed] PHST- 2024/12/20 13:13 [entrez] AID - 89671 [pii] AID - 10.37765/ajmc.2024.89671 [doi] PST - ppublish SO - Am J Manag Care. 2024 Dec;30(10 Suppl):S189-S196. doi: 10.37765/ajmc.2024.89671. PMID- 39704826 OWN - NLM STAT- MEDLINE DCOM- 20251107 LR - 20261010 IS - 1432-1998 (Electronic) IS - 0301-0449 (Linking) VI - 55 IP - 11 DP - 2025 Oct TI - Imaging of common coronary artery anomalies and imaging features important for clinical decision-making. PG - 2303-2313 LID - 10.1007/s00247-024-06135-9 [doi] AB - Anomalous coronary arteries are associated with sudden cardiac death, although only in a relatively small percentage. Although this has been a field of study for years and there are many ongoing studies of larger patient cohorts and longer term follow-up, important questions remain at present in clinical decision-making, particularly whether or not to have surgery. Advanced imaging techniques including coronary computed tomography (CT) and cardiac magnetic resonance (MR) play an important role in the workup of patients with known or suspected anomalies including delineating origin and course as well as defining presence of high-risk imaging features. Multidisciplinary decision-making is important when considering whether patients might need to undergo surgery. This review will describe types of anomalies, imaging techniques, and features as well as types of surgeries and postoperative imaging with highlights of imaging and surgical literature and several case examples. CI - (c) 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Malone, LaDonna J AU - Malone LJ AUID- ORCID: 0000-0001-8995-8490 AD - Department of Radiology, Children's Hospital of Colorado, University of Colorado, 13123 E 16th Ave B125, Aurora, CO, 80045, USA. Ladonna.malone@childrenscolorado.org. FAU - Jadhav, Siddharth P AU - Jadhav SP AUID- ORCID: 0000-0002-3683-1514 AD - Edward Singleton Department of Radiology, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA. FAU - Han, B Kelly AU - Han BK AD - Intermountain Primary Children's Hospital, University of Utah, Salt Lake City, UT, USA. FAU - Sachdeva, Shagun AU - Sachdeva S AUID- ORCID: 0000-0003-1919-870X AD - Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA. LA - eng PT - Journal Article PT - Review DEP - 20241220 PL - Germany TA - Pediatr Radiol JT - Pediatric radiology JID - 0365332 SB - IM MH - Humans MH - *Coronary Vessel Anomalies/diagnostic imaging/surgery MH - *Clinical Decision-Making MH - *Tomography, X-Ray Computed/methods MH - *Magnetic Resonance Imaging/methods OTO - NOTNLM OT - Anomalous left coronary artery OT - Cardiovascular surgery OT - Computed tomography angiography OT - Coronary vessels OT - Magnetic resonance OT - Sudden cardiac death COIS- Declarations. Conflicts of interest: None EDAT- 2024/12/20 12:21 MHDA- 2025/11/07 12:45 CRDT- 2024/12/20 11:14 PHST- 2024/06/07 00:00 [received] PHST- 2024/12/01 00:00 [accepted] PHST- 2024/11/01 00:00 [revised] PHST- 2025/11/07 12:45 [medline] PHST- 2024/12/20 12:21 [pubmed] PHST- 2024/12/20 11:14 [entrez] AID - 10.1007/s00247-024-06135-9 [pii] AID - 10.1007/s00247-024-06135-9 [doi] PST - ppublish SO - Pediatr Radiol. 2025 Oct;55(11):2303-2313. doi: 10.1007/s00247-024-06135-9. Epub 2024 Dec 20. PMID- 39701371 OWN - NLM STAT- MEDLINE DCOM- 20250825 LR - 20260413 IS - 1532-8414 (Electronic) IS - 1071-9164 (Linking) VI - 31 IP - 8 DP - 2025 Aug TI - Effectiveness of Virtual Care Team Guided Management of Hospitalized Patients with HFrEF by Ethnicity. PG - 1127-1135 LID - S1071-9164(24)00976-X [pii] LID - 10.1016/j.cardfail.2024.11.018 [doi] AB - BACKGROUND: The Implementation of Medical Therapy in Hospitalized Patients with Heart Failure with Reduced Ejection Fraction (IMPLEMENT-HF) study demonstrated that a virtual team-based care strategy was safe and improved prescription of guideline-directed medical therapy (GDMT) in hospitalized patients with heart failure and reduced ejection fraction (HFrEF). We evaluated differences in efficacy and safety outcomes by ethnicity in IMPLEMENT-HF. METHODS: IMPLEMENT-HF evaluated a provider-facing virtual team-based care strategy versus usual care in hospitalized patients with HFrEF from October 2021 to June 2022. The primary outcome was change in a GDMT optimization score from hospital admission to discharge, with positive changes reflecting net optimization. In this post-hoc analysis, we assessed heterogeneity in treatment effects by ethnicity (Hispanic vs. non-Hispanic). Outcomes included prespecified primary and secondary effectiveness outcomes and adjudicated safety events. RESULTS: Of 808 screened patient admissions, 252 (31%) from 198 unique patients met inclusion criteria. Hispanic patients (n = 43) were more likely to have diabetes and end-stage kidney disease than non-Hispanics; 70% spoke Spanish as a primary language. GDMT optimization score was lower among Hispanic versus non-Hispanic patients (-0.44; 95% CI -1.88 to 0.99 vs. +1.62, 95% CI +1.02 to +2.21; P value of interaction by ethnicity = .002). Allocation to the virtual care team intervention versus usual care increased the proportion of patients experiencing >1 new initiation or dose up-titration among non-Hispanic patients but did not among Hispanic patients (absolute difference non-Hispanic vs. Hispanic: +31% vs. -19%; P value of interaction = .003). Similar trends were seen among individual HF therapy and for the proportion of patients with optimization score >0 (absolute difference non-Hispanic vs. Hispanic: +29% vs. -20%; P value of interaction = .005). Safety outcomes were similar among Hispanic and non-Hispanic patients. CONCLUSION: A provider-facing, virtual care team-guided strategy for HFrEF GDMT optimization was less effective in Hispanic patients. Efforts to identify and reduce bias and equity assessments in implementation studies are needed. CI - Copyright (c) 2024. Published by Elsevier Inc. FAU - Bertot, John H AU - Bertot JH AD - Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts. FAU - Varshney, Anubodh S AU - Varshney AS AD - Division of Cardiovascular Medicine, Stanford University School of Medicine, Palo Alto, California. FAU - Moscone, Alea AU - Moscone A AD - Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts. FAU - Claggett, Brian L AU - Claggett BL AD - Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. FAU - Miao, Zi Michael AU - Miao ZM AD - Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. FAU - Akash, Muhammad AU - Akash M AD - Salem Hospital, Mass General Brigham, Salem, Massachusetts. FAU - Pabon, Maria AU - Pabon M AD - Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. FAU - Cunningham, Jonathan W AU - Cunningham JW AD - Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. FAU - Makuvire, Tracy AU - Makuvire T AD - Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. FAU - Solomon, Scott D AU - Solomon SD AD - Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. FAU - Adler, Dale S AU - Adler DS AD - Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts; Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. FAU - Vaduganathan, Muthiah AU - Vaduganathan M AD - Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. FAU - Bhatt, Ankeet S AU - Bhatt AS AD - Division of Cardiovascular Medicine, Stanford University School of Medicine, Palo Alto, California; Kaiser Permanente San Francisco Medical Center and Division of Research, San Francisco, California. Electronic address: ankeet.s.bhatt@kp.org. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20241217 PL - United States TA - J Card Fail JT - Journal of cardiac failure JID - 9442138 SB - IM MH - Humans MH - Female MH - Male MH - *Heart Failure/therapy/ethnology/physiopathology MH - Aged MH - *Patient Care Team/standards MH - *Hospitalization MH - Middle Aged MH - *Stroke Volume/physiology MH - *Ethnicity MH - Hispanic or Latino MH - Treatment Outcome MH - White OTO - NOTNLM OT - Implementation science OT - disparities of care OT - equity OT - heart failure with reduced ejection fraction EDAT- 2024/12/20 00:23 MHDA- 2025/09/08 07:43 CRDT- 2024/12/19 19:16 PHST- 2024/05/20 00:00 [received] PHST- 2024/11/11 00:00 [revised] PHST- 2024/11/12 00:00 [accepted] PHST- 2025/09/08 07:43 [medline] PHST- 2024/12/20 00:23 [pubmed] PHST- 2024/12/19 19:16 [entrez] AID - S1071-9164(24)00976-X [pii] AID - 10.1016/j.cardfail.2024.11.018 [doi] PST - ppublish SO - J Card Fail. 2025 Aug;31(8):1127-1135. doi: 10.1016/j.cardfail.2024.11.018. Epub 2024 Dec 17. PMID- 39699331 OWN - NLM STAT- MEDLINE DCOM- 20241219 LR - 20260427 IS - 1983-1447 (Electronic) IS - 0102-6933 (Linking) VI - 45 IP - spe1 DP - 2024 TI - Knowledge of the nursing team about cardiac arrest and cardiopulmonary resuscitation: mixed methods studies. PG - e20230280 LID - S1983-14472024000200407 [pii] LID - 10.1590/1983-1447.2024.20230280.en [doi] AB - OBJECTIVE: To analyze the knowledge and perceptions of the nursing team about arrest and cardiopulmonary resuscitation in adults before and after in situ simulation in emergency care. METHOD: A sequential explanatory mixed methods study conducted in an Emergency Care Unit. Quantitative data were obtained through pre- and post-simulation questionnaire answered by 21 professionals and analyzed using descriptive and inferential statistics. The qualitative data was obtained through individual structured interviews with 19 professionals, analyzed according to thematic content analysis. The data was combined through connection. RESULTS: In situ simulation did not significantly change pre- and post-simulation knowledge. Hand positioning for cardiac compressions and handling the automatic external defibrillator had the lowest number of correct answers. The qualitative data indicated difficulties related to knowledge, such as lack of training and insufficient experience with cardiopulmonary resuscitation. CONCLUSION: No statistically significant differences were identified in the proportions of answers obtained through the pre- and post-simulation in situ questionnaire regarding correct answers and wrong answers. Furthermore, the qualitative data reinforced the professionals' lack of experience in critical situations, the lack of training and ongoing studies on the subject. FAU - Turra, Luana AU - Turra L AUID- ORCID: 0000-0002-0951-6711 AD - Universidade Federal de Santa Catarina (UFSC). Florianopolis, Santa Catarina, Brasil. FAU - Lazzari, Daniele Delacanal AU - Lazzari DD AUID- ORCID: 0000-0003-1788-866X AD - Universidade Federal de Santa Catarina (UFSC). Florianopolis, Santa Catarina, Brasil. FAU - Martini, Jussara Gue AU - Martini JG AUID- ORCID: 0000-0003-2629-293X AD - Universidade Federal de Santa Catarina (UFSC). Florianopolis, Santa Catarina, Brasil. FAU - Nascimento, Eliane Regina Pereira do AU - Nascimento ERPD AUID- ORCID: 0000-0003-2215-4222 AD - Universidade Federal de Santa Catarina (UFSC). Florianopolis, Santa Catarina, Brasil. FAU - Ramos, Francine Carpes AU - Ramos FC AUID- ORCID: 0000-0003-2946-2770 AD - Universidade Federal de Santa Catarina (UFSC). Florianopolis, Santa Catarina, Brasil. FAU - Malfussi, Luciana Bihain Hagemann de AU - Malfussi LBH AUID- ORCID: 0000-0002-3199-9529 AD - Universidade Federal de Santa Catarina (UFSC). Florianopolis, Santa Catarina, Brasil. FAU - Becker, Alex AU - Becker A AUID- ORCID: 0000-0002-6421-3836 AD - Universidade Federal de Santa Catarina (UFSC). Florianopolis, Santa Catarina, Brasil. FAU - Mendes, Nicasio Urinque AU - Mendes NU AUID- ORCID: 0000-0002-7636-5941 AD - Universidade Federal de Santa Catarina (UFSC). Florianopolis, Santa Catarina, Brasil. LA - eng LA - por PT - Journal Article DEP - 20241216 PL - Brazil TA - Rev Gaucha Enferm JT - Revista gaucha de enfermagem JID - 8504882 SB - IM MH - Humans MH - *Cardiopulmonary Resuscitation MH - *Heart Arrest/therapy/nursing MH - Adult MH - Female MH - Male MH - Nursing, Team MH - Clinical Competence MH - Middle Aged MH - Qualitative Research MH - Surveys and Questionnaires MH - Health Knowledge, Attitudes, Practice MH - Simulation Training EDAT- 2024/12/19 12:21 MHDA- 2024/12/19 12:22 CRDT- 2024/12/19 10:03 PHST- 2023/11/30 00:00 [received] PHST- 2024/06/27 00:00 [accepted] PHST- 2024/12/19 12:22 [medline] PHST- 2024/12/19 12:21 [pubmed] PHST- 2024/12/19 10:03 [entrez] AID - S1983-14472024000200407 [pii] AID - 10.1590/1983-1447.2024.20230280.en [doi] PST - epublish SO - Rev Gaucha Enferm. 2024 Dec 16;45(spe1):e20230280. doi: 10.1590/1983-1447.2024.20230280.en. eCollection 2024. PMID- 39698292 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20251030 IS - 2575-9108 (Electronic) IS - 2575-9108 (Linking) VI - 7 IP - 12 DP - 2024 Dec 13 TI - Combination of Autodisplay and Dynamic Pharmacophore Modeling Reveals New Insights into Cyclic Nucleotide Binding in Hyperpolarization-Activated and Cyclic Nucleotide-Gated Ion Channel 4 (HCN4). PG - 4010-4020 LID - 10.1021/acsptsci.4c00497 [doi] AB - Hyperpolarization-activated cyclic nucleotide-gated (HCN) ion channels play a critical role in regulating neuronal and cardiac rhythmicity, with their function being modulated by cyclic nucleotide binding. Dysfunction of HCN ion channels leads to the genesis of several diseases such as arrhythmia, bradycardia, or epilepsy. This study employs a multidisciplinary approach integrating mutagenesis, ligand binding assays, and molecular dynamics (MD) simulations combined with dynamic pharmacophore studies to investigate the impact of single residue mutations within the cyclic nucleotide-binding domain (CNBD) of HCN4 channels. Utilizing an autodisplay-based ligand binding assay, surface-displayed HCN4 CNBD mutants were evaluated for their interaction with 8-Fluo-cAMP, providing insights into the ligand binding properties. While some known mutational effects could be confirmed (R669, T670), we identified L652 to be crucial for successful ligand binding. Surprisingly, C662, located in the center of the binding pocket, was discovered to play a negligible role in cAMP-binding. Both E660 and R710 were shown to substantially affect 8-Fluo-cAMP-binding, uncovering the direct ligand binding capability of the R710A mutant for the first time. Furthermore, MD simulations coupled with dynamic pharmacophore analysis offered detailed insights into dynamic ligand-protein interactions, elucidating the structural basis of ligand binding and modulation induced by single residue mutations. Here, a novel bypass mechanism of R713 that interacts with cAMP in the absence of R710 was demonstrated. These findings unveil new perspectives on cyclic nucleotide binding in HCN4 channels, providing a foundation for future studies of pathogenic HCN4 ion channel mutations. CI - (c) 2024 The Authors. Published by American Chemical Society. FAU - Wojciechowski, Magdalena N AU - Wojciechowski MN AD - University of Munster, Institute of Pharmaceutical and Medicinal Chemistry, Pharma Campus, Corrensstr. 48, 48149 Munster, Germany. FAU - Jokiel, Johannes AU - Jokiel J AD - University of Munster, Institute of Pharmaceutical and Medicinal Chemistry, Pharma Campus, Corrensstr. 48, 48149 Munster, Germany. FAU - Kuss, Hanna AU - Kuss H AD - University of Munster, Institute of Pharmaceutical and Medicinal Chemistry, Pharma Campus, Corrensstr. 48, 48149 Munster, Germany. FAU - Bermudez, Marcel AU - Bermudez M AUID- ORCID: 0000-0002-7421-3282 AD - University of Munster, Institute of Pharmaceutical and Medicinal Chemistry, Pharma Campus, Corrensstr. 48, 48149 Munster, Germany. FAU - Jose, Joachim AU - Jose J AUID- ORCID: 0000-0002-0666-2676 AD - University of Munster, Institute of Pharmaceutical and Medicinal Chemistry, Pharma Campus, Corrensstr. 48, 48149 Munster, Germany. LA - eng PT - Journal Article DEP - 20241029 PL - United States TA - ACS Pharmacol Transl Sci JT - ACS pharmacology & translational science JID - 101721411 PMC - PMC11651207 COIS- The authors declare no competing financial interest. EDAT- 2024/12/19 06:23 MHDA- 2024/12/19 06:24 PMCR- 2025/10/29 CRDT- 2024/12/19 05:22 PHST- 2024/08/16 00:00 [received] PHST- 2024/10/10 00:00 [revised] PHST- 2024/10/22 00:00 [accepted] PHST- 2024/12/19 06:24 [medline] PHST- 2024/12/19 06:23 [pubmed] PHST- 2024/12/19 05:22 [entrez] PHST- 2025/10/29 00:00 [pmc-release] AID - 10.1021/acsptsci.4c00497 [doi] PST - epublish SO - ACS Pharmacol Transl Sci. 2024 Oct 29;7(12):4010-4020. doi: 10.1021/acsptsci.4c00497. eCollection 2024 Dec 13. PMID- 39696639 OWN - NLM STAT- MEDLINE DCOM- 20241219 LR - 20250122 IS - 1745-6215 (Electronic) IS - 1745-6215 (Linking) VI - 25 IP - 1 DP - 2024 Dec 18 TI - The IMproving treatment decisions for Patients with AortiC stenosis Through Shared Decision Making (IMPACT SDM) Study: study protocol for a cluster randomized stepped wedge trial. PG - 820 LID - 10.1186/s13063-024-08640-6 [doi] LID - 820 AB - BACKGROUND: The American College of Cardiology, American Heart Association, and Centers for Medicare and Medicaid Services recommend shared decision-making (SDM) for patients with severe aortic stenosis choosing between transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR). Although tools such as patient decision aids (DAs) and training in SDM have been shown to improve SDM, implementation of SDM and DAs is limited. The IMproving treatment decisions for Patients with AortiC stenosis Through Shared Decision Making (IMPACT SDM) study aims to (1) determine the effectiveness of the interventions (a DA and clinician SDM training) in achieving SDM (primary outcome) and improving the quality of decisions about aortic valve replacement, (2) determine the reach of the DAs and adoption of training, and (3) explore potential mechanisms of effectiveness and implementation at the patient-, clinician-, and clinic-level. METHODS: The study is a hybrid type II effectiveness-implementation study using a cluster randomized batched stepped wedge trial with 8 sites across the USA. Eligible patients will be surveyed before and after visits with the heart valve team; clinicians will be surveyed after visits. Reach of DAs and adoption of training will be tracked. Clinicians will be interviewed regarding barriers and facilitators to implementation. DISCUSSION: The IMPACT SDM Study seeks to provide evidence of the ability of the interventions to improve SDM and decision quality, and also to shed light on barriers and facilitators to SDM implementation to promote future implementation efforts. TRIAL REGISTRATION: ClinicalTrials.gov NCT06171737. Registered on December 15, 2023. CI - (c) 2024. The Author(s). FAU - Sepucha, Karen AU - Sepucha K AD - Division of General Internal Medicine, Massachusetts General Hospital, Boston, MA, USA. AD - Harvard Medical School, Boston, MA, USA. FAU - Elmariah, Sammy AU - Elmariah S AD - Division of Cardiology, University of California San Francisco, San Francisco, CA, USA. FAU - Valentine, K D AU - Valentine KD AUID- ORCID: 0000-0001-6349-5395 AD - Division of General Internal Medicine, Massachusetts General Hospital, Boston, MA, USA. kvalentine2@mgh.harvard.edu. AD - Harvard Medical School, Boston, MA, USA. kvalentine2@mgh.harvard.edu. FAU - Cavender, Matthew A AU - Cavender MA AD - Division of Cardiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. FAU - Chang, Yuchiao AU - Chang Y AD - Division of General Internal Medicine, Massachusetts General Hospital, Boston, MA, USA. FAU - Devireddy, Chandan M AU - Devireddy CM AD - Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, USA. FAU - Dickert, Neal W AU - Dickert NW AD - Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, USA. FAU - Gama, Kristy D AU - Gama KD AD - Division of Cardiology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA. FAU - Knoepke, Christopher E AU - Knoepke CE AD - Division of Cardiology, Adult and Child Center for Outcomes Research and Delivery Science (ACCORDS), Colorado Program for Patient-Centered Decisions, University of Colorado School of Medicine, Aurora, USA. FAU - Korngold, Ethan AU - Korngold E AD - Division of Cardiology, Providence Heart Institute, Portland, OR, USA. FAU - Kumbhani, Dharam J AU - Kumbhani DJ AD - Division of Cardiology, UT Southwestern Medical Center, Dallas, TX, USA. FAU - Matlock, Daniel D AU - Matlock DD AD - Division of Geriatric Medicine, Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA. AD - VA Eastern Colorado Geriatric Research Education and Clinical Center, Denver, CO, USA. FAU - Messenger, John C AU - Messenger JC AD - Division of Cardiology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA. FAU - Strong, Susan AU - Strong S AD - Heart Valve Voice-US, Washington, D.C., USA. FAU - Thourani, Vinod H AU - Thourani VH AD - Department of Cardiovascular Surgery, Marcus Valve Center, Piedmont Heart Institute, Atlanta, GA, USA. FAU - Nathan, Ashwin AU - Nathan A AD - Division of Cardiovascular Medicine, University of Pennsylvania, Philadelphia, PA, USA. FAU - Quader, Nishath AU - Quader N AD - Cardiovascular Division, Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA. FAU - Brescia, Alexander A AU - Brescia AA AD - Division of Cardiothoracic Surgery, Washington University in St. Louis, St. Louis, MO, USA. LA - eng SI - ClinicalTrials.gov/NCT06171737 PT - Clinical Trial Protocol PT - Journal Article DEP - 20241218 PL - England TA - Trials JT - Trials JID - 101263253 SB - IM MH - Humans MH - Aortic Valve/surgery MH - *Aortic Valve Stenosis/surgery MH - Clinical Decision-Making MH - *Decision Making, Shared MH - Decision Support Techniques MH - Heart Valve Prosthesis Implantation/methods MH - *Multicenter Studies as Topic MH - Patient Participation MH - *Randomized Controlled Trials as Topic MH - *Transcatheter Aortic Valve Replacement/methods MH - Treatment Outcome MH - United States MH - Clinical Trials, Phase II as Topic PMC - PMC11654330 OTO - NOTNLM OT - Aortic valve stenosis OT - Cardiology OT - Continuing medical education OT - Decision aid OT - Decision-making OT - Shared OT - Transcatheter aortic valve replacement COIS- Declarations. Ethics approval and consent to participate 24: Ethical approval for the study will be provided by each site individually. The majority of sites approved waiver of written consent to participate in this minimal risk trial, and consent is implied by completion of the survey. Consent for publication 32: At 6 sites, participants will receive an information sheet reviewing options, benefits, and risks of the trial and consent will be implied by return of the pre-visit survey. At one site, research staff will obtain written consent and at one site research staff will obtain and document verbal consent. Competing interests 28: NL reports being a consultant for Edwards Lifesciences. CK reports a K23 from NHLBI (K23HL153892). CD reports paid consulting fees from Medtronic and Record Medical. EK reports receiving honoraria from Abbott, Boston Scientific, Edwards, and Medtronic. ND receives research support from the American Heart Association, NIH, AHRQ, and Merck and research funding and consulting for Abiomed. KS reports receiving funding for shared decision-making research from PCORI, AHRQ, and NIH, outside submitted work. KS developed the Shared Decision-Making Process scale (copyright Massachusetts General Hospital) that is being used as an outcome measure in the study. KV reports receiving support for shared decision-making research from PCORI and AHRQ outside submitted work and receiving research funding from Google LLC outside the submitted work. SE reports receiving research funding and consulting fees from Edwards Lifesciences and Medtronic. VT reports advising and research with Artivion, AtriCure, Boston Scientific, Abbott Vascular, CroiValve, Edwards Lifesciences, Medtronic, JenaValve, HighLife, Innovalve, and DASI Simulations. JM reports institutional grant support from the University of Colorado School of Medicine: Philips Medical Systems, Medtronic Corporation. SS reports travel sponsored by the ACC, Global Heart Hub, TCT, and Heart Valve Collaboratory and significant financial interests in Heart Valve Voice US. AN has received institutional research funding and speaker fees from Edwards Lifesciences, which is involved in products for the treatment of aortic stenosis. AB reports receiving honoraria for teaching a course at Edwards Lifesciences. DM, MC, YC, KG, NQ, and DK report no conflicts of interest. EDAT- 2024/12/19 06:23 MHDA- 2024/12/19 06:24 PMCR- 2024/12/18 CRDT- 2024/12/19 00:55 PHST- 2024/04/25 00:00 [received] PHST- 2024/11/17 00:00 [accepted] PHST- 2024/12/19 06:24 [medline] PHST- 2024/12/19 06:23 [pubmed] PHST- 2024/12/19 00:55 [entrez] PHST- 2024/12/18 00:00 [pmc-release] AID - 10.1186/s13063-024-08640-6 [pii] AID - 8640 [pii] AID - 10.1186/s13063-024-08640-6 [doi] PST - epublish SO - Trials. 2024 Dec 18;25(1):820. doi: 10.1186/s13063-024-08640-6. PMID- 39694094 OWN - NLM STAT- MEDLINE DCOM- 20250428 LR - 20250519 IS - 1473-4893 (Electronic) IS - 1470-2118 (Print) IS - 1470-2118 (Linking) VI - 25 IP - 1 DP - 2025 Jan TI - Clinical approach to palpitations in pregnancy. PG - 100276 LID - S1470-2118(24)05461-7 [pii] LID - 10.1016/j.clinme.2024.100276 [doi] LID - 100276 AB - Palpitations are common in pregnancy and warrant investigation. Palpitations may be caused by non-cardiac and cardiac causes. Patients with structural or functional abnormalities or inherited cardiovascular disease are more likely to develop arrhythmia, especially during pregnancy when the mother's body undergoes extensive physiological adaptations, which further contribute to an increased arrhythmia risk. While isolated ectopic beats do not require treatment, some heart rhythm disturbances can be life-threatening for mother and baby and mandate prompt intervention. Haemodynamically unstable patients should be electrically cardioverted. If the patient is stable, medical management is indicated, and early involvement of the pregnancy heart team can help facilitate appropriate treatment. In complex arrhythmia, consultation of an arrhythmia expert should be sought . Many anti-arrhythmics are safe in pregnancy, and it is important to reassure the pregnant patient of this. CI - Crown Copyright (c) 2024. Published by Elsevier Ltd. All rights reserved. FAU - Saeed, Ferha AU - Saeed F AD - Department of Obstetrics and Gynaecology, Newham University Hospital, Barts Health NHS Trust, Honorary Clinical Senior Lecturer, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, UK. FAU - Gunganah, Kirun AU - Gunganah K AD - Department of Diabetes and Endocrinology, Newham University Hospital, Barts Health NHS Trust, London, UK. FAU - Herrey, Anna S AU - Herrey AS AD - Department of Cardiology, Barts Heart Centre and Newham University Hospital, Barts Health NHS Trust, Honorary Senior Lecturer, William Harvey Research Institute, Queen Mary University of London, London, UK. Electronic address: a.herrey@nhs.net. LA - eng PT - Journal Article PT - Review DEP - 20241216 PL - England TA - Clin Med (Lond) JT - Clinical medicine (London, England) JID - 101092853 RN - 0 (Anti-Arrhythmia Agents) SB - IM MH - Humans MH - Pregnancy MH - Female MH - *Arrhythmias, Cardiac/therapy/diagnosis/physiopathology/etiology MH - *Pregnancy Complications, Cardiovascular/therapy/diagnosis MH - Anti-Arrhythmia Agents/therapeutic use PMC - PMC11773050 OTO - NOTNLM OT - Arrhythmia OT - Investigation OT - Pregnancy OT - Treatment COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/12/19 00:20 MHDA- 2025/02/07 00:20 PMCR- 2024/12/16 CRDT- 2024/12/18 19:13 PHST- 2024/09/15 00:00 [received] PHST- 2024/12/04 00:00 [revised] PHST- 2024/12/06 00:00 [accepted] PHST- 2025/02/07 00:20 [medline] PHST- 2024/12/19 00:20 [pubmed] PHST- 2024/12/18 19:13 [entrez] PHST- 2024/12/16 00:00 [pmc-release] AID - S1470-2118(24)05461-7 [pii] AID - 100276 [pii] AID - 10.1016/j.clinme.2024.100276 [doi] PST - ppublish SO - Clin Med (Lond). 2025 Jan;25(1):100276. doi: 10.1016/j.clinme.2024.100276. Epub 2024 Dec 16. PMID- 39693114 OWN - NLM STAT- MEDLINE DCOM- 20250123 LR - 20260823 IS - 1873-734X (Electronic) IS - 1010-7940 (Print) IS - 1010-7940 (Linking) VI - 67 IP - 1 DP - 2024 Dec 26 TI - The current state of the multidisciplinary heart team approach: a systematic review. LID - 10.1093/ejcts/ezae461 [doi] LID - ezae461 AB - The heart team (HT) approach, recommended for managing cardiovascular diseases, emphasizes multidisciplinary collaboration. Despite its potential benefits, evidence on its effectiveness and implementation is varied and sparse. This review assesses the HT approach's impact on patient outcomes and care delivery in cardiovascular care. A systematic review was conducted across MEDLINE, EMBASE, PubMed, Cochrane and Google Scholar up to July 2023, focusing on studies that implemented an HT approach in coronary and heart valve disease management. Exclusion criteria included non-human studies, case reports and studies not focusing on HT outcomes. From 6270 identified articles, 20 met the inclusion criteria. These studies demonstrated significant variability in HT composition and organization, coupled with a lack of standardized metrics for evaluating clinical outcomes and the impact of the HT. Significant variability was observed in HT composition, with 13 of the 20 studies did not utilize structured templates, those that did demonstrated more consistent decision-making. In mitral valve interventions, HTs were linked to reduced in-hospital mortality and improved long-term survival (5-year survival probability of 0.74 vs 0.70, P = 0.04). In aortic valve interventions, 80% of patients underwent tailored valve procedures following HT evaluation. The HT approach in cardiovascular care demonstrates improved patient outcomes, particularly in specialized interventions for mitral and aortic valve diseases and coronary artery disease management. Despite these positive findings, the variability in HT implementation and the need for standardized outcome metrics call for further advances to optimize this collaborative care model. CI - (c) The Author(s) 2024. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. FAU - Arjomandi Rad, Arian AU - Arjomandi Rad A AUID- ORCID: 0000-0002-4931-4049 AD - Department of Cardiothoracic Surgery, Maastricht University Medical Center, Maastricht, The Netherlands. AD - Department of Cardiothoracic Surgery, Bristol Heart Institute, University of Bristol, Bristol, UK. FAU - Streukens, Sebastian AU - Streukens S AD - Department of Cardiology, Maastricht University Medical Center, Maastricht, The Netherlands. FAU - Vainer, Jindra AU - Vainer J AD - Department of Cardiology, Maastricht University Medical Center, Maastricht, The Netherlands. FAU - Athanasiou, Thanos AU - Athanasiou T AUID- ORCID: 0000-0002-2525-5515 AD - Department of Surgery and Cancer, Imperial College London, London, UK. FAU - Maessen, Jos AU - Maessen J AD - Department of Cardiothoracic Surgery, Maastricht University Medical Center, Maastricht, The Netherlands. FAU - Sardari Nia, Peyman AU - Sardari Nia P AUID- ORCID: 0000-0003-2296-1497 AD - Department of Cardiothoracic Surgery, Maastricht University Medical Center, Maastricht, The Netherlands. LA - eng PT - Journal Article PT - Systematic Review PL - Germany TA - Eur J Cardiothorac Surg JT - European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery JID - 8804069 SB - IM MH - Humans MH - *Patient Care Team/organization & administration MH - *Cardiovascular Diseases/therapy PMC - PMC11754862 OTO - NOTNLM OT - Aortic Valve Interventions OT - Cardiovascular Diseases (CVDs) OT - Coronary Artery Disease (CAD) OT - Mitral Valve Interventions OT - Multidisciplinary Heart Team (HT) OT - Standardized Outcome Metrics EDAT- 2024/12/18 12:24 MHDA- 2025/01/23 12:36 PMCR- 2024/12/18 CRDT- 2024/12/18 11:43 PHST- 2024/08/24 00:00 [received] PHST- 2024/11/30 00:00 [revised] PHST- 2024/12/16 00:00 [accepted] PHST- 2025/01/23 12:36 [medline] PHST- 2024/12/18 12:24 [pubmed] PHST- 2024/12/18 11:43 [entrez] PHST- 2024/12/18 00:00 [pmc-release] AID - 7927829 [pii] AID - ezae461 [pii] AID - 10.1093/ejcts/ezae461 [doi] PST - ppublish SO - Eur J Cardiothorac Surg. 2024 Dec 26;67(1):ezae461. doi: 10.1093/ejcts/ezae461. PMID- 39691882 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250104 IS - 2666-0849 (Electronic) IS - 2666-0849 (Linking) VI - 29 IP - 22 DP - 2024 Nov 20 TI - Inferolateral Fibrosis in a Nonhypertrophic Left Ventricle. PG - 102735 LID - 10.1016/j.jaccas.2024.102735 [doi] LID - 102735 AB - A 62-year-old recreational cyclist presented with transient loss of consciousness and common electrocardiographic findings. Despite absence of left ventricular hypertrophy, multidisciplinary evaluation and a positive family history led to the diagnosis of non-classical Fabry disease. This case emphasizes the added value of multidisciplinary analysis of nonspecific findings to diagnose a rare disease. CI - (c) 2024 The Authors. FAU - Van Diepen, Maarten A AU - Van Diepen MA AD - Amsterdam UMC location of the University of Amsterdam, Department of Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands. FAU - Speleman, Manou AU - Speleman M AD - Amsterdam UMC location of the University of Amsterdam, Department of Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands. AD - Cardiology Centre the Netherlands, Amsterdam, the Netherlands. FAU - Robbers, Lourens F H J AU - Robbers LFHJ AD - Amsterdam UMC location of the University of Amsterdam, Department of Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands. FAU - Groenink, Maarten AU - Groenink M AD - Amsterdam UMC location of the University of Amsterdam, Department of Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands. FAU - van Randen, Adrienne AU - van Randen A AD - Amsterdam UMC location University of Amsterdam, Department of Radiology and Nuclear Medicine, Amsterdam, the Netherlands; Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands. FAU - Langeveld, Mirjam AU - Langeveld M AD - Department of Endocrinology and Metabolism, Amsterdam UMC, Amsterdam Gastroenterology Endocrinology Metabolism (AGEM) Research Institute, University of Amsterdam, Amsterdam, the Netherlands. FAU - Van der Crabben, Saskia N AU - Van der Crabben SN AD - Amsterdam UMC location of the University of Amsterdam, Department of Human Genetics, Amsterdam, the Netherlands; Amsterdam Cardiovascular Sciences. AD - European Reference Network for rare, low prevalence, and/or complex diseases of the heart: ERN GUARD-Heart. FAU - Bijsterveld, Nick R AU - Bijsterveld NR AD - Amsterdam UMC location of the University of Amsterdam, Department of Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands. FAU - Jorstad, Harald T AU - Jorstad HT AD - Amsterdam UMC location of the University of Amsterdam, Department of Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands. AD - Amsterdam Movement Sciences, Amsterdam, the Netherlands. LA - eng PT - Journal Article DEP - 20241120 PL - Netherlands TA - JACC Case Rep JT - JACC. Case reports JID - 101757292 PMC - PMC11646883 OTO - NOTNLM OT - Anderson-Fabry disease OT - athlete OT - cardiac magnetic resonance imaging OT - cardiomyopathy OT - electrocardiography OT - genetic cardiac disorders COIS- The authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2024/12/18 11:32 MHDA- 2024/12/18 11:33 PMCR- 2024/11/20 CRDT- 2024/12/18 04:29 PHST- 2024/06/20 00:00 [received] PHST- 2024/09/09 00:00 [revised] PHST- 2024/09/23 00:00 [accepted] PHST- 2024/12/18 11:33 [medline] PHST- 2024/12/18 11:32 [pubmed] PHST- 2024/12/18 04:29 [entrez] PHST- 2024/11/20 00:00 [pmc-release] AID - S2666-0849(24)00735-6 [pii] AID - 102735 [pii] AID - 10.1016/j.jaccas.2024.102735 [doi] PST - epublish SO - JACC Case Rep. 2024 Nov 20;29(22):102735. doi: 10.1016/j.jaccas.2024.102735. eCollection 2024 Nov 20. PMID- 39691347 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250104 IS - 2666-0849 (Electronic) IS - 2666-0849 (Linking) VI - 29 IP - 23 DP - 2024 Dec 4 TI - Cardiac Tumor Within the Left Ventricle: Thrombus or Something Else? PG - 102719 LID - 10.1016/j.jaccas.2024.102719 [doi] LID - 102719 AB - Papillary fibroelastoma is a benign cardiac tumor that most commonly arises from the valvular endocardium and is typically resected because of its predisposition to cause embolic complications. In this clinical vignette, we describe the case of a patient who presented with a round, mobile 1.3 x 1.1-cm sessile mass attached to the left ventricular apex discovered on transthoracic echocardiography at an outside institution. A multidisciplinary team and multimodality imaging approach were taken to treat a diagnostically challenging presentation of a papillary fibroelastoma due to lack of visualization on higher-resolution imaging studies. CI - (c) 2024 The Authors. FAU - Barron, Kyle T AU - Barron KT AD - University of Alabama Birmingham, Birmingham, Alabama, USA. FAU - Landrum, Archie AU - Landrum A AD - University of Alabama Birmingham, Birmingham, Alabama, USA. FAU - Abu Daya, Hussein AU - Abu Daya H AD - University of Alabama Birmingham, Birmingham, Alabama, USA. FAU - Clarkson, Stephen AU - Clarkson S AD - University of Alabama Birmingham, Birmingham, Alabama, USA. LA - eng PT - Journal Article DEP - 20241204 PL - Netherlands TA - JACC Case Rep JT - JACC. Case reports JID - 101757292 PMC - PMC11646900 OTO - NOTNLM OT - echocardiography OT - imaging OT - multidisciplinary OT - multimodality OT - tumor COIS- The authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2024/12/18 11:33 MHDA- 2024/12/18 11:34 PMCR- 2024/12/04 CRDT- 2024/12/18 04:17 PHST- 2024/08/08 00:00 [received] PHST- 2024/09/02 00:00 [revised] PHST- 2024/09/10 00:00 [accepted] PHST- 2024/12/18 11:34 [medline] PHST- 2024/12/18 11:33 [pubmed] PHST- 2024/12/18 04:17 [entrez] PHST- 2024/12/04 00:00 [pmc-release] AID - S2666-0849(24)00719-8 [pii] AID - 102719 [pii] AID - 10.1016/j.jaccas.2024.102719 [doi] PST - epublish SO - JACC Case Rep. 2024 Dec 4;29(23):102719. doi: 10.1016/j.jaccas.2024.102719. eCollection 2024 Dec 4. PMID- 39689169 OWN - NLM STAT- MEDLINE DCOM- 20241217 LR - 20260518 IS - 1941-7705 (Electronic) IS - 1941-7713 (Print) IS - 1941-7713 (Linking) VI - 17 IP - 12 DP - 2024 Dec TI - Multicenter Analysis of the Relationship Between Operative Team Familiarity and Safety and Efficiency Outcomes in Cardiac Surgery. PG - e011065 LID - 10.1161/CIRCOUTCOMES.124.011065 [doi] AB - BACKGROUND: Safety in cardiac surgical procedures is predicated on effective team dynamics. This study associated operative team familiarity (ie, the extent of clinical collaboration among surgical team members) with procedural efficiency and Society of Thoracic Surgeons (STS) adjudicated patient outcomes. METHODS: Institutional STS adult cardiac surgery registry and electronic health record data from 2014 to 2021 were evaluated across 3 quaternary hospitals. Team familiarity was defined as the mean number of cardiac operations performed by surgeon-anesthesiologist, surgeon-perfusionist, and anesthesiologist-perfusionist dyads within 1 year of the operation. The primary outcomes were (1) safety, measured by the STS' composite major morbidity and operative mortality measure, and (2) procedural efficiency, assessed by cardiopulmonary bypass duration. Team familiarity was stratified by terciles (low, moderate, and high) for crude analyses and analyzed continuously for adjusted analyses. Multivariable logistic and linear regression models were used to assess the association between team familiarity and outcomes. RESULTS: Team familiarity was calculated for 13 581 operations. The median (interquartile range) patient age was 64 (55-72) years, and 31.9% (4328/13 581) were women. Terciles of team familiarity were defined as low (<6.00 average shared operations), moderate (6.00-9.67), and high (>9.67). Teams in lower terciles had higher observed STS morbidity and mortality rates (low, 17.9%; moderate, 18.0%; high, 16.0%; P=0.02) and longer median cardiopulmonary bypass duration (low, 137 minutes; moderate, 131 minutes; high, 118 minutes; P<0.001). After risk adjustment, team familiarity was not significantly associated with STS morbidity and mortality (estimate, -0.001 [95% CI, -0.998 to 0.997]) but was inversely associated with cardiopulmonary bypass duration (estimate, -2.02 minutes per 1 unit increase in team familiarity [95% CI, -2.30 to -1.75]). CONCLUSIONS: Increased team familiarity was not associated with STS morbidity and mortality but was inversely correlated with cardiopulmonary bypass duration, demonstrating potential benefit. Interventions aimed at improving team familiarity among operative teams may increase procedural efficiency. FAU - Bauer, Tyler M AU - Bauer TM AUID- ORCID: 0000-0002-5430-5104 AD - Department of Cardiac Surgery (T.M.B., X.W., C.L., F.D.P., D.S.L.), University of Michigan, Ann Arbor. FAU - Janda, Allison M AU - Janda AM AUID- ORCID: 0000-0001-5080-5630 AD - Department of Anesthesiology, Michigan Medicine (A.M.J., M.R.M.), University of Michigan, Ann Arbor. FAU - Wu, Xiaoting AU - Wu X AD - Department of Cardiac Surgery (T.M.B., X.W., C.L., F.D.P., D.S.L.), University of Michigan, Ann Arbor. FAU - Ling, Carol AU - Ling C AUID- ORCID: 0009-0008-7206-1095 AD - Department of Cardiac Surgery (T.M.B., X.W., C.L., F.D.P., D.S.L.), University of Michigan, Ann Arbor. FAU - Shook, Douglas C AU - Shook DC AUID- ORCID: 0000-0002-4799-3295 AD - Department of Anesthesiology (D.C.S., G.Q.-R.), Brigham and Women's Hospital/Harvard Medical School, Boston, MA. FAU - Querejeta-Roca, Gabriela AU - Querejeta-Roca G AD - Department of Anesthesiology (D.C.S., G.Q.-R.), Brigham and Women's Hospital/Harvard Medical School, Boston, MA. FAU - Shann, Kenneth G AU - Shann KG AUID- ORCID: 0000-0002-1488-5124 AD - Division of Cardiac Surgery, Massachusetts General Hospital/Harvard Medical School, Boston (K.G.S., T.M.S.). FAU - Smith, Trevor AU - Smith T AD - Division of Cardiac Surgery (T.S.), Brigham and Women's Hospital/Harvard Medical School, Boston, MA. FAU - Mathis, Michael R AU - Mathis MR AUID- ORCID: 0000-0002-9697-2212 AD - Department of Anesthesiology, Michigan Medicine (A.M.J., M.R.M.), University of Michigan, Ann Arbor. FAU - Kaneko, Tsuyoshi AU - Kaneko T AUID- ORCID: 0000-0001-6500-7471 AD - Department of Surgery, Washington University School of Medicine, St. Louis, MO (T.K.). FAU - Sundt, Thoralf M 3rd AU - Sundt TM 3rd AUID- ORCID: 0000-0002-0409-7028 AD - Division of Cardiac Surgery, Massachusetts General Hospital/Harvard Medical School, Boston (K.G.S., T.M.S.). FAU - Schonberger, Robert B AU - Schonberger RB AUID- ORCID: 0000-0002-5180-5189 AD - Department of Anesthesiology, Yale School of Medicine, New Haven, CT (R.B.S.). FAU - Harrington, Steven D AU - Harrington SD AD - Department of Cardiac Surgery, Henry Ford Macomb Hospital, Clinton Township, MI (S.D.H.). FAU - Dias, Roger D AU - Dias RD AD - Department of Emergency Medicine (R.D.D.), Brigham and Women's Hospital/Harvard Medical School, Boston, MA. FAU - Pagani, Francis D AU - Pagani FD AUID- ORCID: 0000-0003-4430-9969 AD - Department of Cardiac Surgery (T.M.B., X.W., C.L., F.D.P., D.S.L.), University of Michigan, Ann Arbor. FAU - Likosky, Donald S AU - Likosky DS AUID- ORCID: 0000-0003-0416-9359 AD - Department of Cardiac Surgery (T.M.B., X.W., C.L., F.D.P., D.S.L.), University of Michigan, Ann Arbor. FAU - Yule, Steven AU - Yule S AUID- ORCID: 0000-0001-9889-9090 AD - Surgical Sabermetrics Laboratory, Centre for Medical Informatics, Usher Institute, The University of Edinburgh, Scotland (S.Y.). AD - Department of Clinical Surgery, Royal Infirmary of Edinburgh, The University of Edinburgh, Scotland (S.Y.). CN - VARSITY Surgery Investigators LA - eng GR - K23 HL166685/HL/NHLBI NIH HHS/United States GR - R01 HL146619/HL/NHLBI NIH HHS/United States GR - UL1 TR001863/TR/NCATS NIH HHS/United States PT - Journal Article PT - Multicenter Study DEP - 20241209 PL - United States TA - Circ Cardiovasc Qual Outcomes JT - Circulation. Cardiovascular quality and outcomes JID - 101489148 SB - IM MH - Humans MH - Female MH - Middle Aged MH - Male MH - Aged MH - *Patient Care Team/organization & administration MH - *Cardiac Surgical Procedures/adverse effects/mortality MH - *Registries MH - Risk Factors MH - Treatment Outcome MH - Time Factors MH - Patient Safety MH - Quality Indicators, Health Care MH - Surgeons MH - Risk Assessment MH - Cooperative Behavior MH - Interdisciplinary Communication MH - Postoperative Complications/mortality/epidemiology MH - Operative Time MH - Outcome and Process Assessment, Health Care MH - United States MH - Retrospective Studies MH - Clinical Competence MH - Anesthesiologists MH - Health Knowledge, Attitudes, Practice MH - Cardiopulmonary Bypass/adverse effects/mortality PMC - PMC11654451 OTO - NOTNLM OT - adult OT - cardiopulmonary bypass OT - hospitals OT - linear models OT - morbidity COIS- Dr Janda received a research grant from the US National Institutes of Health (NHLBI) and research support paid to the University of Michigan from Becton, Dickinson and Company, Bio Intellisense, Inc, and Hiasco-USA Pharmaceuticals, Inc, unrelated to this present work. Dr Shook is a speaker and consultant for Baylis and Edwards. Dr Kaneko is a consultant for Edwards Lifesciences and Medtronic. Dr Mathis has received research grants from the US National Institutes of Health (NHLBI, National Institute of Diabetes and Digestive and Kidney Diseases ) and research support paid to the University of Michigan from Chiesi, USA, unrelated to this present work. Dr Likosky receives partial salary support through Blue Cross Blue Shield, is a consultant to the American Society of ExtraCorporeal Technology, and receives funding from the Agency for Healthcare Research and Quality and the National Institutes of Health. Dr Yule is a past member of the advisory board for General Education Council, Johnson and Johnson Institute. Dr Pagani is a noncompensated ad hoc scientific advisor for Abbott, CH Biomedical, FineHeart, and Medtronic; receives grant funding from the National Heart, Lung, and Blood Institute and the Agency for Healthcare Research and Quality; and receives partial salary support from Blue Cross Blue Shield of Michigan as associate director of the Michigan Society of Thoracic and Cardiovascular Surgeons Quality Collaborative. Dr Schonberger reports that he owns stock in Johnson and Johnson, unrelated to the present article, and that his institution has received research funds from Merck, Inc, for a study in which he was involved, unrelated to the present article. The other authors report no conflicts. FIR - Caldwell, Matthew D IR - Caldwell MD FIR - Corso, Jason J IR - Corso JJ FIR - Louis, Nathan IR - Louis N FIR - Krein, Sarah L IR - Krein SL FIR - Manojlovich, Milisa IR - Manojlovich M FIR - Stakich-Alpirez, Korana IR - Stakich-Alpirez K FIR - Sturmer, David IR - Sturmer D FIR - Yalamuri, Suraj IR - Yalamuri S FIR - Lawton, Jennifer IR - Lawton J FIR - Abernathy, Jake IR - Abernathy J FIR - Cleveland, Joseph IR - Cleveland J FIR - Clendenen, Nathan IR - Clendenen N FIR - Justison, George IR - Justison G FIR - Fried, Michael IR - Fried M FIR - Nemeh, Hassan IR - Nemeh H FIR - Fitzsimons, Michael G IR - Fitzsimons MG FIR - Dickinson, Timothy IR - Dickinson T FIR - Stulak, John IR - Stulak J FIR - de la Cruz, Kim I IR - de la Cruz KI EDAT- 2024/12/17 18:24 MHDA- 2024/12/17 18:25 PMCR- 2024/12/18 CRDT- 2024/12/17 14:02 PHST- 2024/12/17 18:25 [medline] PHST- 2024/12/17 18:24 [pubmed] PHST- 2024/12/17 14:02 [entrez] PHST- 2024/12/18 00:00 [pmc-release] AID - CIRCCQO-2024-011065 [pii] AID - 10.1161/CIRCOUTCOMES.124.011065 [doi] PST - ppublish SO - Circ Cardiovasc Qual Outcomes. 2024 Dec;17(12):e011065. doi: 10.1161/CIRCOUTCOMES.124.011065. Epub 2024 Dec 9. PMID- 39688488 OWN - NLM STAT- MEDLINE DCOM- 20241217 LR - 20260408 IS - 1527-1315 (Electronic) IS - 0033-8419 (Linking) VI - 313 IP - 3 DP - 2024 Dec TI - Cardiac CT, MRI, and PET in 2023: Exploration of Key Articles across Imaging and Multidisciplinary Journals. PG - e240975 LID - 10.1148/radiol.240975 [doi] AB - In this review, the authors examine recent advancements in noninvasive cardiac imaging, focusing on cardiac CT, MRI, and PET, reviewing key publications from imaging and multidisciplinary journals from 2023. The authors discuss the increasing adoption of photon-counting CT and its applications in coronary and structural imaging, and explore various aspects of plaque and functional assessment, emphasizing their clinical implications. Radiation exposure analysis from the SCOT-HEART (Scottish Computed Tomography of the Heart) trial is also discussed. The authors highlight the integration of artificial intelligence applications in cardiac imaging. Three-year follow-up data from the ADVANCE Registry are described, showcasing the potential of using artificial intelligence to improve diagnostic accuracy and patient outcomes in cardiovascular care. The authors explore the latest studies evaluating different cardiomyopathies using cardiac MRI. Radiologists' growing understanding of the brain-heart axis is presented through discussion of several studies. The authors also discuss the prognostic advantages of MRI over PET in patients with cardiac sarcoidosis. Finally, the authors outline society statements and guidelines from 2023 that are pertinent to cardiac imaging, offering a comprehensive review of current trends and applications in noninvasive imaging modalities. CI - (c) RSNA, 2024. FAU - Flynn, Sebastian AU - Flynn S AUID- ORCID: 0000-0002-6597-5648 AD - From the Department of Radiology, St Vincent's University Hospital, Elm Park, Dublin 4, D04 T6F4, Ireland (S.F., S.C., J.D.D.); Department of Radiology, University of British Columbia, St Paul's Hospital, Vancouver, British Columbia, Canada (A.H., F.C., J.A.L.); and School of Medicine, University College Dublin, Dublin, Ireland (S.F., J.D.D.). FAU - Haenel, Alexander AU - Haenel A AUID- ORCID: 0000-0002-5672-0547 AD - From the Department of Radiology, St Vincent's University Hospital, Elm Park, Dublin 4, D04 T6F4, Ireland (S.F., S.C., J.D.D.); Department of Radiology, University of British Columbia, St Paul's Hospital, Vancouver, British Columbia, Canada (A.H., F.C., J.A.L.); and School of Medicine, University College Dublin, Dublin, Ireland (S.F., J.D.D.). FAU - Coughlan, Fionn AU - Coughlan F AUID- ORCID: 0000-0001-5070-5330 AD - From the Department of Radiology, St Vincent's University Hospital, Elm Park, Dublin 4, D04 T6F4, Ireland (S.F., S.C., J.D.D.); Department of Radiology, University of British Columbia, St Paul's Hospital, Vancouver, British Columbia, Canada (A.H., F.C., J.A.L.); and School of Medicine, University College Dublin, Dublin, Ireland (S.F., J.D.D.). FAU - Crilly, Shane AU - Crilly S AD - From the Department of Radiology, St Vincent's University Hospital, Elm Park, Dublin 4, D04 T6F4, Ireland (S.F., S.C., J.D.D.); Department of Radiology, University of British Columbia, St Paul's Hospital, Vancouver, British Columbia, Canada (A.H., F.C., J.A.L.); and School of Medicine, University College Dublin, Dublin, Ireland (S.F., J.D.D.). FAU - Leipsic, Jonathon A AU - Leipsic JA AUID- ORCID: 0000-0002-6133-8334 AD - From the Department of Radiology, St Vincent's University Hospital, Elm Park, Dublin 4, D04 T6F4, Ireland (S.F., S.C., J.D.D.); Department of Radiology, University of British Columbia, St Paul's Hospital, Vancouver, British Columbia, Canada (A.H., F.C., J.A.L.); and School of Medicine, University College Dublin, Dublin, Ireland (S.F., J.D.D.). FAU - Dodd, Jonathan D AU - Dodd JD AUID- ORCID: 0000-0002-3476-8793 AD - From the Department of Radiology, St Vincent's University Hospital, Elm Park, Dublin 4, D04 T6F4, Ireland (S.F., S.C., J.D.D.); Department of Radiology, University of British Columbia, St Paul's Hospital, Vancouver, British Columbia, Canada (A.H., F.C., J.A.L.); and School of Medicine, University College Dublin, Dublin, Ireland (S.F., J.D.D.). LA - eng PT - Journal Article PT - Review PL - United States TA - Radiology JT - Radiology JID - 0401260 SB - IM MH - Humans MH - *Magnetic Resonance Imaging/methods MH - *Positron-Emission Tomography/methods MH - *Tomography, X-Ray Computed/methods MH - Cardiac Imaging Techniques/methods MH - Heart/diagnostic imaging MH - Periodicals as Topic MH - Heart Diseases/diagnostic imaging EDAT- 2024/12/17 12:32 MHDA- 2024/12/17 12:33 CRDT- 2024/12/17 09:53 PHST- 2024/12/17 12:33 [medline] PHST- 2024/12/17 12:32 [pubmed] PHST- 2024/12/17 09:53 [entrez] AID - 10.1148/radiol.240975 [doi] PST - ppublish SO - Radiology. 2024 Dec;313(3):e240975. doi: 10.1148/radiol.240975. PMID- 39687662 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250104 IS - 2050-0904 (Print) IS - 2050-0904 (Electronic) IS - 2050-0904 (Linking) VI - 12 IP - 12 DP - 2024 Dec TI - McIndoe Vaginoplasty in MRKHS: Case Report and Literature Review. PG - e70009 LID - 10.1002/ccr3.70009 [doi] LID - e70009 AB - Mayer-Rokitansky-Kuster-Hauser syndrome (MRKHS) is a rare congenital disorder characterized by agenesis of the uterus and upper two-thirds of the vagina. It affects around 1 in 4000-5000 females and is of two types: type 1, also known as isolated Mullerian aplasia or Rokitansky, which involves only uterovaginal agenesis, and type 2, presents as uterovaginal agenesis along with renal, cardiac, and other organ anomalies. Despite the absence of vaginal and uterine structures, individuals with MRKHS typically present with normal secondary sexual characteristics and ovarian functions. A 26-year-old female presented with primary amenorrhea. Despite this, she had typical secondary sexual characteristics. Physical examination revealed normal pubic hair distribution and external genitalia, consistent with Tanner's stage 5 development. Further evaluation via magnetic resonance imaging (MRI) confirmed diagnosis of MRKHS type II, revealing the absence of the uterus and upper two-thirds of the vagina, with normal ovaries and absent left kidney. A multidisciplinary team performed McIndoe vaginoplasty creating a successful neovagina, measuring 7 cm in length, using split-thickness skin graft. MRKHS, a rare congenital anomaly involving Mullerian duct abnormalities, poses diagnostic and therapeutic challenges. The etiology remains unknown, but it likely stems from defective Mullerian fusion during embryologic development. Differential diagnosis from conditions like androgen insensitivity syndrome (AIS) is crucial. MRI is important in diagnosis, revealing associated anomalies. Treatment aims to restore sexual function. This case presents that MRKHS can occur with normal hormonal function and typical secondary sexual characteristics. Neovagina creation is an effective surgical intervention for young females seeking to restore sexual function. CI - (c) 2024 The Author(s). Clinical Case Reports published by John Wiley & Sons Ltd. FAU - Shah, Newton Ashish AU - Shah NA AUID- ORCID: 0000-0002-6147-4942 AD - Tribhuvan University Institute of Medicine Kathmandu Nepal. FAU - Yadav, Manish AU - Yadav M AUID- ORCID: 0000-0003-0415-0199 AD - Tribhuvan University Institute of Medicine Kathmandu Nepal. FAU - Verma, Suman AU - Verma S AD - Department of Obstetrics and Gynecology Tribhuvan University, Institute of Medicine Kathmandu Nepal. FAU - Yadav, Digraj AU - Yadav D AD - Tribhuvan University Institute of Medicine Kathmandu Nepal. FAU - Yadav, Aalok Kumar AU - Yadav AK AD - Department of Radiology Tribhuvan University, Institute of Medicine Kathmandu Nepal. FAU - Ghimire, Asmita AU - Ghimire A AD - Department of Obstetrics and Gynecology Tribhuvan University, Institute of Medicine Kathmandu Nepal. FAU - Rijal, Hima AU - Rijal H AD - Department of Obstetrics and Gynecology Tribhuvan University, Institute of Medicine Kathmandu Nepal. FAU - Koirala, Poonam AU - Koirala P AD - Department of Obstetrics and Gynecology Tribhuvan University, Institute of Medicine Kathmandu Nepal. LA - eng PT - Journal Article DEP - 20241215 PL - England TA - Clin Case Rep JT - Clinical case reports JID - 101620385 PMC - PMC11646812 OTO - NOTNLM OT - MRKHS OT - Mayer-Rokitansky-Kuster-Hauser syndrome OT - Mullerian aplasia OT - Vaginoplasty COIS- The authors declare no conflicts of interest. EDAT- 2024/12/17 11:50 MHDA- 2024/12/17 11:51 PMCR- 2024/12/15 CRDT- 2024/12/17 04:48 PHST- 2024/05/07 00:00 [received] PHST- 2024/10/16 00:00 [revised] PHST- 2024/10/21 00:00 [accepted] PHST- 2024/12/17 11:51 [medline] PHST- 2024/12/17 11:50 [pubmed] PHST- 2024/12/17 04:48 [entrez] PHST- 2024/12/15 00:00 [pmc-release] AID - CCR370009 [pii] AID - 10.1002/ccr3.70009 [doi] PST - epublish SO - Clin Case Rep. 2024 Dec 15;12(12):e70009. doi: 10.1002/ccr3.70009. eCollection 2024 Dec. PMID- 39687661 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260923 IS - 2050-0904 (Print) IS - 2050-0904 (Electronic) IS - 2050-0904 (Linking) VI - 12 IP - 12 DP - 2024 Dec TI - Paradoxical Infarction? Inferior STEMI With Unexpected Discovery of ASD in an Oncology Patient: A Case of Combined Percutaneous Intervention. PG - e9569 LID - 10.1002/ccr3.9569 [doi] LID - e9569 AB - This case report explores the management of a 56-year-old female oncology patient presenting with acute ST-elevation myocardial infarction (STEMI) and an incidental atrial septal defect (ASD). The patient, with a history of rectal cancer and hypothyroidism, experienced acute chest pain and dyspnea. She was diagnosed with an inferior STEMI and underwent percutaneous coronary intervention (PCI) with the placement of three medicated stents in the right coronary artery. During hospitalization, an echocardiogram revealed a significant ostium secundum ASD. Angiography indicated thrombi, suggesting a potential paradoxical embolism. Percutaneous ASD closure was performed during the same hospital stay, leading to a favorable clinical course without immediate complications. This case highlights the importance of a multidisciplinary approach and comprehensive evaluation in managing complex cardiovascular conditions, particularly in patients with increased thrombotic risk due to malignancy. CI - (c) 2024 The Author(s). Clinical Case Reports published by John Wiley & Sons Ltd. FAU - Balbuena Madera, Miguel Angel AU - Balbuena Madera MA AUID- ORCID: 0000-0002-1361-244X AD - Department of Cardiology National Medical Center November 20 Mexico City Mexico. AD - Universidad Nacional Autonoma de Mexico Mexico. FAU - Garcia Garcia, Juan Francisco AU - Garcia Garcia JF AD - Department of Cardiology National Medical Center November 20 Mexico City Mexico. FAU - Vargas Cruz, Antonio AU - Vargas Cruz A AD - Department of Cardiology National Medical Center November 20 Mexico City Mexico. FAU - Aquino Bruno, Heberto AU - Aquino Bruno H AD - Department of Cardiology National Medical Center November 20 Mexico City Mexico. AD - Universidad Nacional Autonoma de Mexico Mexico. FAU - Gonzalez Jasso, Jesus Guadalupe AU - Gonzalez Jasso JG AD - Department of Cardiology National Medical Center November 20 Mexico City Mexico. AD - Universidad Nacional Autonoma de Mexico Mexico. LA - eng PT - Journal Article DEP - 20241216 PL - England TA - Clin Case Rep JT - Clinical case reports JID - 101620385 PMC - PMC11647179 OTO - NOTNLM OT - acute myocardial infarction OT - atrial septal defect OT - oncology patient OT - paradoxical coronary artery embolism OT - percutaneous coronary intervention COIS- The authors declare no conflicts of interest. EDAT- 2024/12/17 11:49 MHDA- 2024/12/17 11:50 PMCR- 2024/12/16 CRDT- 2024/12/17 04:48 PHST- 2024/07/14 00:00 [received] PHST- 2024/09/26 00:00 [revised] PHST- 2024/10/13 00:00 [accepted] PHST- 2024/12/17 11:50 [medline] PHST- 2024/12/17 11:49 [pubmed] PHST- 2024/12/17 04:48 [entrez] PHST- 2024/12/16 00:00 [pmc-release] AID - CCR39569 [pii] AID - 10.1002/ccr3.9569 [doi] PST - epublish SO - Clin Case Rep. 2024 Dec 16;12(12):e9569. doi: 10.1002/ccr3.9569. eCollection 2024 Dec. PMID- 39685895 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250104 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 13 IP - 23 DP - 2024 Dec 6 TI - Management of Acute Ischemic Stroke Following Transcatheter Aortic Valve Implantation: A Systematic Review and Multidisciplinary Treatment Recommendations. LID - 10.3390/jcm13237437 [doi] LID - 7437 AB - Background/Objectives: Acute ischemic stroke is an uncommon but potentially devastating complication of Transcatheter Aortic Valve Implantation (TAVI). Despite improvements in device technology and procedural techniques, stroke rates have remained stable, with cerebral embolic protection devices demonstrating only limited efficacy to date. Therefore, the management of acute ischemic stroke complicating TAVI (AISCT) remains a key priority. We conducted a systematic review of the management of AISCT and provided multidisciplinary consensus recommendations for optimal management. Methods: PubMed, Google Scholar, and Cochrane databases were searched from inception to October 2023. All the original studies focusing on the treatment of AISCT were included. Non-English language studies, review articles, and studies in pediatric populations were excluded. Consensus recommendations were made by a working group comprising experts in stroke medicine and structural interventional cardiology. Results: A total of 18 studies met the inclusion criteria, including 14 case reports/series and 4 observational studies. No clinical trials were identified. The included case reports and series suggest that tissue-type plasminogen activator (tPA) and mechanical thrombectomy (MT) might be effective strategies for managing AISCT. However, significant bleeding complications were reported in two out of the four patients receiving tPA. Four observational studies also suggest an association between tPA and/or MT and improved functional outcomes and survival compared to conservative management. Higher bleeding rates were reported following tPA. Observational data suggest that there is currently little real-world utilization of either reperfusion strategy. Conclusions: There is an absence of high-quality randomized data to guide clinical decision making in this important area. Observational data suggest reperfusion strategies are associated with improved clinical outcomes once important confounders such as stroke severity have been accounted for. While MT can be recommended as the standard of care in appropriately selected patients, significantly increased rates of bleeding with tPA following large-bore arterial access raise important safety concerns. We present simple clinical guidance for AISCT based on the limited available data. Close multidisciplinary work and patient-specific consideration of ischemic and bleeding risk is essential. FAU - Hammond-Haley, Matthew AU - Hammond-Haley M AD - National Heart and Lung Institute, Hammersmith Hospital, Imperial College London, London SW7 2BX, UK. FAU - Almohtadi, Ahmad AU - Almohtadi A AD - National Heart and Lung Institute, Hammersmith Hospital, Imperial College London, London SW7 2BX, UK. FAU - Gonnah, Ahmed R AU - Gonnah AR AD - National Heart and Lung Institute, Hammersmith Hospital, Imperial College London, London SW7 2BX, UK. FAU - Raha, Oishik AU - Raha O AD - Oxford University Hospitals NHS Trust, Oxford OX3 9DU, UK. FAU - Khokhar, Arif AU - Khokhar A AD - National Heart and Lung Institute, Hammersmith Hospital, Imperial College London, London SW7 2BX, UK. FAU - Hartley, Adam AU - Hartley A AD - National Heart and Lung Institute, Hammersmith Hospital, Imperial College London, London SW7 2BX, UK. FAU - Khawaja, Saud AU - Khawaja S AUID- ORCID: 0000-0001-5349-6087 AD - National Heart and Lung Institute, Hammersmith Hospital, Imperial College London, London SW7 2BX, UK. FAU - Hadjiloizou, Nearchos AU - Hadjiloizou N AD - National Heart and Lung Institute, Hammersmith Hospital, Imperial College London, London SW7 2BX, UK. FAU - Ruparelia, Neil AU - Ruparelia N AUID- ORCID: 0000-0003-3968-2750 AD - National Heart and Lung Institute, Hammersmith Hospital, Imperial College London, London SW7 2BX, UK. FAU - Mikhail, Ghada AU - Mikhail G AD - National Heart and Lung Institute, Hammersmith Hospital, Imperial College London, London SW7 2BX, UK. FAU - Malik, Iqbal AU - Malik I AUID- ORCID: 0000-0002-0883-5614 AD - National Heart and Lung Institute, Hammersmith Hospital, Imperial College London, London SW7 2BX, UK. FAU - Banerjee, Soma AU - Banerjee S AD - Department of Brain Sciences, Imperial College London, London SW7 2BX, UK. FAU - Kwan, Joseph AU - Kwan J AUID- ORCID: 0000-0003-4635-3322 AD - Department of Brain Sciences, Imperial College London, London SW7 2BX, UK. LA - eng PT - Journal Article PT - Review DEP - 20241206 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC11642222 OTO - NOTNLM OT - TAVI OT - TAVR OT - acute ischemic stroke OT - mechanical thrombectomy OT - stroke OT - thrombolysis COIS- The authors declare no conflict of interest. EDAT- 2024/12/17 11:48 MHDA- 2024/12/17 11:49 PMCR- 2024/12/06 CRDT- 2024/12/17 01:21 PHST- 2024/11/01 00:00 [received] PHST- 2024/11/27 00:00 [revised] PHST- 2024/12/04 00:00 [accepted] PHST- 2024/12/17 11:49 [medline] PHST- 2024/12/17 11:48 [pubmed] PHST- 2024/12/17 01:21 [entrez] PHST- 2024/12/06 00:00 [pmc-release] AID - jcm13237437 [pii] AID - jcm-13-07437 [pii] AID - 10.3390/jcm13237437 [doi] PST - epublish SO - J Clin Med. 2024 Dec 6;13(23):7437. doi: 10.3390/jcm13237437. PMID- 39677218 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250104 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 16 IP - 11 DP - 2024 Nov TI - The Relationship Between Periodontitis, Gingivitis, Smoking, Missing Teeth, Endodontic Infections, Aortic Aneurysm, and Coronary Artery Disease: The 10-Year Results of 25 Patients. PG - e73584 LID - 10.7759/cureus.73584 [doi] LID - e73584 AB - Background Emerging research suggests a correlation between poor oral health and cardiovascular diseases (CVDs), with inflammation being a central mechanism. Periodontitis and gingivitis are chronic inflammatory diseases that can lead to systemic health issues if untreated. It has been indicated previously that endodontic infections and missing teeth may contribute to elevated cardiovascular risk, and smoking exacerbates both periodontal and cardiovascular conditions. This study expands upon existing research by examining both periodontal and endodontic health factors together and investigating smoking as a potentially amplifying factor. Poor periodontal health may contribute to systemic inflammation, which is a recognized risk factor for atherosclerosis and cardiovascular events. This study aims to evaluate these relationships over a decade, providing insights into the potential preventive impact of periodontal care on cardiovascular health. Materials and methods This 10-year retrospective study examines the complex relationships among periodontal health factors (including periodontitis, gingivitis, and missing teeth), endodontic infections, smoking, and cardiovascular conditions, specifically coronary artery disease (CAD) and aortic aneurysm. By analyzing data from 25 patients aged 45-75, the study aims to assess whether these oral health indicators correlate with increased cardiovascular risks. The study's methodology included comprehensive dental and cardiovascular evaluations for each patient, with baseline data collected at the study's inception and follow-ups over the next decade. Oral health assessments documented the severity of periodontal diseases and recorded the presence of endodontic infections. Cardiovascular evaluations were conducted to establish the incidence and progression of CAD and aortic aneurysm, while lifestyle factors, particularly smoking, were noted as significant contributors. This approach allowed for an in-depth exploration of the possible causal pathways linking oral health to cardiovascular outcomes. Results Results demonstrated that severe periodontitis, high numbers of missing teeth, and the presence of endodontic infections were significantly associated with higher incidences of CAD and aortic aneurysm. Smoking, as expected, acted as a compounding factor, intensifying the risk of cardiovascular outcomes in patients with poor oral health. Interaction terms further highlighted how smoking combined with advanced periodontitis notably increased CAD risk. The findings align with the hypothesis that severe periodontal disease and endodontic infections contribute to cardiovascular risk, especially among smokers. These results indicate that periodontal disease may serve as a marker for systemic inflammation, which has far-reaching effects beyond oral health alone. Conclusion The 10-year study showed a strong association between periodontal disease, smoking, hypertension, periodontitis and CVDs. This study underscores the importance of maintaining good oral health and cessation of smoking to mitigate cardiovascular risk. The results advocate for a multidisciplinary approach to patient care, integrating dental health with broader cardiovascular risk management. Future research is recommended to confirm these findings in larger, more diverse cohorts and to explore further the underlying mechanisms connecting oral infections and systemic inflammation with cardiovascular health. CI - Copyright (c) 2024, Litvinov et al. FAU - Litvinov, Elizabeth AU - Litvinov E AD - Microbiology and Immunology, University of Miami, Coral Gables, USA. FAU - Litvinov, Alan AU - Litvinov A AD - Dentistry, Private Practice, Penfield, USA. LA - eng PT - Journal Article DEP - 20241113 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC11639035 OTO - NOTNLM OT - aortic aneurysm OT - cad OT - coronary artery disease OT - endodontic infections OT - periodontitis OT - smoking COIS- Human subjects: Consent for treatment and open access publication was obtained or waived by all participants in this study. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. EDAT- 2024/12/16 17:25 MHDA- 2024/12/16 17:26 PMCR- 2024/11/13 CRDT- 2024/12/16 06:25 PHST- 2024/11/12 00:00 [accepted] PHST- 2024/12/16 17:26 [medline] PHST- 2024/12/16 17:25 [pubmed] PHST- 2024/12/16 06:25 [entrez] PHST- 2024/11/13 00:00 [pmc-release] AID - 10.7759/cureus.73584 [doi] PST - epublish SO - Cureus. 2024 Nov 13;16(11):e73584. doi: 10.7759/cureus.73584. eCollection 2024 Nov. PMID- 39676528 OWN - NLM STAT- MEDLINE DCOM- 20241224 LR - 20241224 IS - 1479-683X (Electronic) IS - 0804-4643 (Linking) VI - 191 IP - 6 DP - 2024 Nov 27 TI - Synchronous bilateral adrenalectomy for ACTH-independent Cushing's syndrome in children: multidisciplinary management. PG - 646-657 LID - 10.1093/ejendo/lvae158 [doi] AB - OBJECTIVE: Adreno CorticoTropic Hormone (ACTH)-independent Cushing's syndrome (CS) in children is very rare but potentially fatal. In bilateral nodular hyperplasia, synchronous bilateral adrenalectomy (SBA) represents the definitive treatment to correct hypercortisolism. We aim to report the multidisciplinary management of this rare condition. METHODS: Presentation, management, and outcomes of all children with ACTH-independent CS who underwent SBA in a tertiary reference center between 1992 and 2022 were retrospectively analyzed. RESULTS: Ten children were included: 6 with McCune-Albright syndrome, 4 with primary pigmented nodular adrenocortical disease (3 with Carney complex). Presentation varied according to age at diagnosis. In infants (n = 7), failure to thrive with anorexia (n = 7), cushingoid facies (n = 7), arterial hypertension (n = 6), hypotonia (n = 5), hyperglycemia (n = 4), liver dysfunction (n = 4), and hypercalcemia with nephrocalcinosis (n = 4) were the main reasons for urgent hospitalization. Prepubertal children (n = 3) presented with linear growth arrest associated with obesity, cushingoid facies, and hirsutism. SBA was indicated in severe neonatal hypercortisolism, or in those that were non-responsive to medical treatment. SBA was performed by robot-assisted laparoscopy (n = 6), laparoscopy (n = 2) or laparotomy (n = 2). One post-operative complication occurred (seroma in the adrenal bed). During follow-up, (median: 4.8 years) no deaths or acute adrenal crisis occurred. CONCLUSION: Pediatric CS must be referred to a pediatric center with medical and surgical expertise. Shared decision-making regarding SBA must be prompt to allow rapid cure of CS, even if it implies lifelong steroid replacement. This avoids long-term complications of hypercortisolism, particularly cognitive decline. Robot-assisted SBA is feasible and safe, even in infants when performed by an experienced robotic team. CI - (c) The Author(s) 2024. Published by Oxford University Press on behalf of European Society of Endocrinology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com. FAU - Tulelli, Berenice AU - Tulelli B AUID- ORCID: 0000-0001-5796-0414 AD - Department of Pediatric Surgery and Urology, Hopital Universitaire Necker-Enfants Malades, Assistance Publique-Hopitaux de Paris, 149 Rue de Sevres, 75015 Paris, France. FAU - Besancon, Alix AU - Besancon A AD - Department of Paediatric Endocrinology, Diabetology and Gynecology, Hopital Universitaire Necker-Enfants Malades, Assistance Publique-Hopitaux de Paris, 149 Rue de Sevres, 75015 Paris, France. FAU - Stoupa, Athanasia AU - Stoupa A AUID- ORCID: 0000-0002-1164-5862 AD - Department of Paediatric Endocrinology, Diabetology and Gynecology, Hopital Universitaire Necker-Enfants Malades, Assistance Publique-Hopitaux de Paris, 149 Rue de Sevres, 75015 Paris, France. FAU - Pinto, Graziella AU - Pinto G AUID- ORCID: 0000-0002-5237-0631 AD - Department of Paediatric Endocrinology, Diabetology and Gynecology, Hopital Universitaire Necker-Enfants Malades, Assistance Publique-Hopitaux de Paris, 149 Rue de Sevres, 75015 Paris, France. FAU - Samara-Boustani, Dinane AU - Samara-Boustani D AUID- ORCID: 0000-0002-1135-933X AD - Department of Paediatric Endocrinology, Diabetology and Gynecology, Hopital Universitaire Necker-Enfants Malades, Assistance Publique-Hopitaux de Paris, 149 Rue de Sevres, 75015 Paris, France. FAU - Capito, Carmen AU - Capito C AD - Department of Pediatric Surgery and Urology, Hopital Universitaire Necker-Enfants Malades, Assistance Publique-Hopitaux de Paris, 149 Rue de Sevres, 75015 Paris, France. FAU - Kariyawasam, Dulanjalee AU - Kariyawasam D AUID- ORCID: 0000-0002-3870-202X AD - Department of Paediatric Endocrinology, Diabetology and Gynecology, Hopital Universitaire Necker-Enfants Malades, Assistance Publique-Hopitaux de Paris, 149 Rue de Sevres, 75015 Paris, France. AD - Universite de Paris Cite, 15 Rue de l'Ecole de Medecine, 75006 Paris, France. FAU - Barbet, Patrick AU - Barbet P AD - Universite de Paris Cite, 15 Rue de l'Ecole de Medecine, 75006 Paris, France. AD - Department of Pathology, Hopital Universitaire Necker-Enfants Malades, Assistance Publique-Hopitaux de Paris, 149 Rue de Sevres, 75015 Paris, France. FAU - Taghavi, Kiarash AU - Taghavi K AD - Department of Pediatric Surgery and Urology, Hopital Universitaire Necker-Enfants Malades, Assistance Publique-Hopitaux de Paris, 149 Rue de Sevres, 75015 Paris, France. AD - Department of Paediatric Urology, Monash Children's Hospital, Melbourne, 246 Clayton Rd, Clayton 3168, VIC, Australia. AD - Department of Paediatrics, Monash University, Melbourne, 246 Clayton Rd, Clayton 3168, VIC, Australia. FAU - Sarnacki, Sabine AU - Sarnacki S AD - Department of Pediatric Surgery and Urology, Hopital Universitaire Necker-Enfants Malades, Assistance Publique-Hopitaux de Paris, 149 Rue de Sevres, 75015 Paris, France. AD - Universite de Paris Cite, 15 Rue de l'Ecole de Medecine, 75006 Paris, France. FAU - Bertherat, Jerome AU - Bertherat J AD - Universite de Paris Cite, 15 Rue de l'Ecole de Medecine, 75006 Paris, France. AD - Department of Endocrinology, Hopital Universitaire Cochin, Assistance Publique-Hopitaux de Paris, 27 Rue du Faubourg Saint-Jacques, 75014 Paris, France. FAU - Polak, Michel AU - Polak M AD - Department of Paediatric Endocrinology, Diabetology and Gynecology, Hopital Universitaire Necker-Enfants Malades, Assistance Publique-Hopitaux de Paris, 149 Rue de Sevres, 75015 Paris, France. AD - Universite de Paris Cite, 15 Rue de l'Ecole de Medecine, 75006 Paris, France. FAU - Blanc, Thomas AU - Blanc T AD - Department of Pediatric Surgery and Urology, Hopital Universitaire Necker-Enfants Malades, Assistance Publique-Hopitaux de Paris, 149 Rue de Sevres, 75015 Paris, France. AD - Universite de Paris Cite, 15 Rue de l'Ecole de Medecine, 75006 Paris, France. LA - eng PT - Journal Article PL - England TA - Eur J Endocrinol JT - European journal of endocrinology JID - 9423848 RN - 9002-60-2 (Adrenocorticotropic Hormone) SB - IM MH - Humans MH - *Adrenalectomy/methods MH - *Cushing Syndrome/surgery MH - Female MH - Male MH - Child MH - Retrospective Studies MH - Child, Preschool MH - Infant MH - Fibrous Dysplasia, Polyostotic/surgery/complications MH - Treatment Outcome MH - Adolescent MH - Carney Complex/surgery MH - Adrenocorticotropic Hormone/blood OTO - NOTNLM OT - Carney complex OT - Cushing's syndrome OT - McCune-Albright syndrome OT - bilateral adrenalectomy OT - children OT - robotic surgery COIS- Conflict of interest: J.B. has received grants to his institution from Novartis, HRA Pharma, and Recordati, and personal honoraria for consulting, lectures, and/or meeting attendance from Novartis, HRA Pharma, Ipsen, Corcept and Recordati. T.B. is an official proctor for Intuitive Surgical. No financial conflicts are declared by the other authors. EDAT- 2024/12/16 11:36 MHDA- 2024/12/24 18:20 CRDT- 2024/12/16 03:23 PHST- 2024/02/05 00:00 [received] PHST- 2024/06/26 00:00 [revised] PHST- 2024/12/13 00:00 [accepted] PHST- 2024/12/24 18:20 [medline] PHST- 2024/12/16 11:36 [pubmed] PHST- 2024/12/16 03:23 [entrez] AID - 7925157 [pii] AID - 10.1093/ejendo/lvae158 [doi] PST - ppublish SO - Eur J Endocrinol. 2024 Nov 27;191(6):646-657. doi: 10.1093/ejendo/lvae158. PMID- 39676425 OWN - NLM STAT- MEDLINE DCOM- 20250703 LR - 20261017 IS - 2046-2344 (Electronic) IS - 2046-2336 (Linking) VI - 37 IP - 4 DP - 2025 Jul 3 TI - Caring for children and young people with inherited cardiac conditions: the evolving role of specialist nurses. PG - 27-33 LID - 10.7748/ncyp.2024.e1532 [doi] AB - Inherited cardiac conditions (ICCs) encompass a range of rare genetic heart diseases and require the expert care of a skilled multidisciplinary team. Increased awareness of these conditions and advances in genetic testing have led to a rise in demand for specialist ICC services. The Centre for Inherited Cardiovascular Diseases at Great Ormond Street Hospital in London, England, is a tertiary centre for the diagnosis and management of ICCs in children and young people. Specialist nursing roles have developed at the centre in recent years in parallel with the growth of ICC nursing. There are also increasing opportunities for advanced and autonomous nursing practice to support the provision of high-quality care for children and young people affected by ICCs and their families. CI - (c) 2024 RCN Publishing Company Ltd. All rights reserved. Not to be copied, transmitted or recorded in any way, in whole or part, without prior permission of the publishers. FAU - Tollit, Jennifer AU - Tollit J AD - Institute of Cardiovascular Science, Rayne Institute, University College London, London, England. FAU - Oates, Stephanie AU - Oates S AD - Great Ormond Street Hospital for Children NHS Foundation Trust, London, England. FAU - Odori, Alessia AU - Odori A AD - Great Ormond Street Hospital for Children NHS Foundation Trust, London, England. FAU - Smyth, Sorcha AU - Smyth S AD - Great Ormond Street Hospital for Children NHS Foundation Trust, London, England. FAU - Kaski, Juan Pablo AU - Kaski JP AD - Institute of Cardiovascular Science, University College London, London, England. FAU - Field, Ella AU - Field E AD - Great Ormond Street Hospital for Children NHS Foundation Trust, London, England. LA - eng GR - FS/RTF/23/30061/BHF_/British Heart Foundation/United Kingdom GR - MR/T024062/1/MRC_/Medical Research Council/United Kingdom PT - Journal Article DEP - 20241216 PL - England TA - Nurs Child Young People JT - Nursing children and young people JID - 101554473 SB - IM MH - Humans MH - Child MH - *Nurse's Role MH - Adolescent MH - *Heart Diseases/nursing/genetics MH - *Nurse Specialists OTO - NOTNLM OT - cardiology OT - cardiorespiratory OT - child health OT - clinical OT - genetic counselling OT - genetic disorders OT - genetic testing OT - genetics OT - heart diseases OT - management OT - service development COIS- None declared EDAT- 2024/12/16 11:35 MHDA- 2025/07/03 06:28 CRDT- 2024/12/16 02:33 PHST- 2024/07/25 00:00 [accepted] PHST- 2025/07/03 06:28 [medline] PHST- 2024/12/16 11:35 [pubmed] PHST- 2024/12/16 02:33 [entrez] AID - e1532 [pii] AID - 10.7748/ncyp.2024.e1532 [doi] PST - ppublish SO - Nurs Child Young People. 2025 Jul 3;37(4):27-33. doi: 10.7748/ncyp.2024.e1532. Epub 2024 Dec 16. PMID- 39675157 OWN - NLM STAT- MEDLINE DCOM- 20250427 LR - 20250518 IS - 1531-5037 (Electronic) IS - 0022-3468 (Linking) VI - 60 IP - 3 DP - 2025 Mar TI - Congenital Tracheal Stenosis With Complete Cartilage Rings: Proposal of A Multidisciplinary and Tailored Surgical Approach. PG - 162085 LID - S0022-3468(24)01047-9 [pii] LID - 10.1016/j.jpedsurg.2024.162085 [doi] AB - INTRODUCTION: Congenital Tracheal Stenosis (CTS) with complete cartilaginous rings is a rare but potentially life-threatening condition in paediatric patients. Currently, the most common approach is slide tracheoplasty (ST) with sternotomy under cardiopulmonary bypass (CPB). Intending to make the procedure less invasive and consider the variety of associated conditions, we have tailored the approach to our patients, who were treated by a multidisciplinary airway team. METHODS: Patients with CTS treated surgically between 2012 and 2022 at Gaslini Institute were enrolled. Preoperative, surgical and postoperative details were collected and analysed retrospectively. All patients had angio-computerized tomography (CT) scan, echocardiography and bronchoscopy with bronchography before surgery. Each patient and each procedure have been discussed at Airway Team meetings. RESULTS: Among 20 patients with CTS, 15 underwent ST and 5 tracheal resection and anastomosis (TRA). 60 % were younger than 12 months. 30 % patients had previous tracheal/cardiac surgery. Combined cardiac surgery was performed in 8 patients. 4 patients were approached with cervicotomy and extracorporeal membrane oxygenation (ECMO). Mortality within 30 days was 5 %. 8 patients (40 %) needed endoscopic dilatation after the surgery and 1 underwent revision surgery. No patient had tracheostomy after the surgery. We did not find a higher rate of mortality and morbidity in patients who had cervicotomy and ECMO. CONCLUSION: We propose a multidisciplinary and tailored approach for patients with CTS. After evaluating each patient through detailed preoperative studies, including bronchography, the team can choose alternatives to the traditional ST under CPB, such as TRA, cervical approach, and ECMO. LEVEL OF EVIDENCE: Level IV. TYPE OF STUDY: Original Article. CI - Copyright (c) 2024 Elsevier Inc. All rights reserved. FAU - Genova Gaia, Luca AU - Genova Gaia L AD - Division of Pediatric Surgery, Department of Surgery, IRCCS Istituto Giannina Gaslini, Via Gerolamo Gaslini 5, 16147, Genova, Italy; Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, DINOGMI, Universita di Genova, Largo Paolo Daneo 3, 16132, Genova, Italy. FAU - Moscatelli, Andrea AU - Moscatelli A AD - Neonatal and Pediatric Intensive Care Unit, Emergency Department IRCCS Istituto Giannina Gaslini, Via Gerolamo Gaslini 5, 16147, Genova, Italy. Electronic address: andreamoscatelli@gaslini.org. FAU - Sacco, Oliviero AU - Sacco O AD - Pneumology Unit, Department of Pediatrics, IRCCS Istituto Giannina Gaslini, Via Gerolamo Gaslini 5, 16147, Genova, Italy; Pediatric Thoracic and Airway Surgery Unit, Department of Surgery, IRCCS Istituto Giannina Gaslini, Via Gerolamo Gaslini 5, 16147, Genova, Italy. FAU - Guerriero, Vittorio AU - Guerriero V AD - Division of Pediatric Surgery, Department of Surgery, IRCCS Istituto Giannina Gaslini, Via Gerolamo Gaslini 5, 16147, Genova, Italy; Pediatric Thoracic and Airway Surgery Unit, Department of Surgery, IRCCS Istituto Giannina Gaslini, Via Gerolamo Gaslini 5, 16147, Genova, Italy. FAU - Rizzo, Francesca AU - Rizzo F AD - Division of Radiology, Department of Imaging, IRCCS Istituto Giannina Gaslini, Via Gerolamo Gaslini 5, 16147, Genova, Italy; Pediatric Thoracic and Airway Surgery Unit, Department of Surgery, IRCCS Istituto Giannina Gaslini, Via Gerolamo Gaslini 5, 16147, Genova, Italy. FAU - Santoro, Francesco AU - Santoro F AD - Cardiac and Vascular Surgery Unit, Department of Surgery, IRCCS Istituto Giannina Gaslini, Via Gerolamo Gaslini 5, 16147, Genova, Italy; Pediatric Thoracic and Airway Surgery Unit, Department of Surgery, IRCCS Istituto Giannina Gaslini, Via Gerolamo Gaslini 5, 16147, Genova, Italy. FAU - Torre, Michele AU - Torre M AD - Division of Pediatric Surgery, Department of Surgery, IRCCS Istituto Giannina Gaslini, Via Gerolamo Gaslini 5, 16147, Genova, Italy; Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, DINOGMI, Universita di Genova, Largo Paolo Daneo 3, 16132, Genova, Italy; Pediatric Thoracic and Airway Surgery Unit, Department of Surgery, IRCCS Istituto Giannina Gaslini, Via Gerolamo Gaslini 5, 16147, Genova, Italy. LA - eng PT - Journal Article DEP - 20241205 PL - United States TA - J Pediatr Surg JT - Journal of pediatric surgery JID - 0052631 RN - Congenital tracheal stenosis SB - IM MH - Humans MH - *Tracheal Stenosis/surgery/congenital/mortality MH - Retrospective Studies MH - Infant MH - Female MH - Male MH - *Trachea/surgery/abnormalities MH - *Patient Care Team MH - Infant, Newborn MH - *Plastic Surgery Procedures/methods MH - Extracorporeal Membrane Oxygenation MH - Bronchoscopy MH - Treatment Outcome MH - Child, Preschool MH - *Cartilage/surgery/abnormalities OTO - NOTNLM OT - Cervical tracheoplasty OT - Congenital tracheal stenosis OT - Extracorporeal membrane oxygenation ECMO OT - Pediatric airways surgery OT - Slide tracheoplasty EDAT- 2024/12/16 11:30 MHDA- 2025/02/25 00:22 CRDT- 2024/12/15 18:04 PHST- 2024/09/22 00:00 [received] PHST- 2024/11/19 00:00 [revised] PHST- 2024/12/01 00:00 [accepted] PHST- 2025/02/25 00:22 [medline] PHST- 2024/12/16 11:30 [pubmed] PHST- 2024/12/15 18:04 [entrez] AID - S0022-3468(24)01047-9 [pii] AID - 10.1016/j.jpedsurg.2024.162085 [doi] PST - ppublish SO - J Pediatr Surg. 2025 Mar;60(3):162085. doi: 10.1016/j.jpedsurg.2024.162085. Epub 2024 Dec 5. PMID- 39674523 OWN - NLM STAT- MEDLINE DCOM- 20250210 LR - 20250603 IS - 1097-6744 (Electronic) IS - 0002-8703 (Linking) VI - 281 DP - 2025 Mar TI - The contemporary cardio-obstetrics team: The path to improving maternal outcomes in high-risk patients. PG - 140-148 LID - S0002-8703(24)00330-2 [pii] LID - 10.1016/j.ahj.2024.12.001 [doi] AB - The field of Cardio-Obstetrics is focused on mitigating cardiovascular risk among pregnant and post-partum individuals. Due to the complexity of caring for pregnant people with acquired or congenital cardiac disease, patients with these conditions are increasingly managed in multidisciplinary Cardio-Obstetrics teams, which are now considered essential to optimize maternal care in high-risk patients. Cardio-Obstetrics teams are composed of multiple subspecialists and have at least 3 roles: (1) provide preconception counseling and risk stratification to patients with known cardiac disease, (2) organize prenatal and postpartum care for patients who develop or present with cardiac disease during pregnancy, and (3) plan for emergent care for patients whose pregnancy "unmasks" cardiac disease, whether acquired disease or an unknown ACHD. Here we describe our experience at Einstein/Montefiore to aid other institutions in developing their own programs. CI - Copyright (c) 2024 Elsevier Inc. All rights reserved. FAU - Wolfe, Diana S AU - Wolfe DS AD - Maternal Fetal Medicine Cardiology Joint Program, Division of Maternal Fetal Medicine, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY. Electronic address: dwolfe@montefiore.org. FAU - Guerrero, Kerly AU - Guerrero K AD - Maternal Fetal Medicine Cardiology Joint Program, Division of Maternal Fetal Medicine, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY. LA - eng PT - Journal Article DEP - 20241212 PL - United States TA - Am Heart J JT - American heart journal JID - 0370465 SB - IM MH - Female MH - Humans MH - Pregnancy MH - *Obstetrics/organization & administration MH - *Patient Care Team/organization & administration MH - *Pregnancy Complications, Cardiovascular/therapy MH - Pregnancy Outcome MH - Pregnancy, High-Risk MH - Prenatal Care MH - Risk Assessment COIS- Conflict of interest None reported. EDAT- 2024/12/15 00:42 MHDA- 2025/02/11 00:19 CRDT- 2024/12/14 19:17 PHST- 2023/11/27 00:00 [received] PHST- 2024/12/04 00:00 [revised] PHST- 2024/12/05 00:00 [accepted] PHST- 2025/02/11 00:19 [medline] PHST- 2024/12/15 00:42 [pubmed] PHST- 2024/12/14 19:17 [entrez] AID - S0002-8703(24)00330-2 [pii] AID - 10.1016/j.ahj.2024.12.001 [doi] PST - ppublish SO - Am Heart J. 2025 Mar;281:140-148. doi: 10.1016/j.ahj.2024.12.001. Epub 2024 Dec 12. PMID- 39674228 OWN - NLM STAT- MEDLINE DCOM- 20241214 LR - 20250609 IS - 2468-1253 (Electronic) VI - 10 IP - 1 DP - 2025 Jan TI - Interdisciplinary perspectives on the co-management of metabolic dysfunction-associated steatotic liver disease and coronary artery disease. PG - 82-94 LID - S2468-1253(24)00310-8 [pii] LID - 10.1016/S2468-1253(24)00310-8 [doi] AB - Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as a public health threat as it affects approximately 38% of the adult population worldwide, with its prevalence rising in step with that of obesity and type 2 diabetes. Beyond the implications of MASLD for liver health, it is also associated with cardiovascular and vascular dysfunction. Although the many shared risk factors and common metabolic milieu might indicate that cardiovascular disease and MASLD are discrete outcomes from common systemic pathogeneses, a growing body of evidence has identified a potential causal relationship between MASLD and coronary artery disease, which is the leading cause of morbidity and mortality in people with MASLD and all-cause mortality worldwide. This Review takes an interdisciplinary approach, drawing on hepatology, cardiology, endocrinology, and metabolic and internal medicine specialists to help to delineate the intricate interplay between MASLD and coronary artery disease. It sheds light on novel opportunities for targeted interventions and personalised management strategies. CI - Copyright (c) 2024 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies. FAU - Gries, Jacob J AU - Gries JJ AD - Department of Internal Medicine, Geisinger Medical Center, Danville, PA, USA. FAU - Lazarus, Jeffrey V AU - Lazarus JV AD - CUNY Graduate School of Public Health and Health Policy, New York, NY, USA; Barcelona Institute for Global Health, Hospital Clinic, University of Barcelona, Barcelona, Spain. FAU - Brennan, Paul N AU - Brennan PN AD - Division of Molecular and Clinical Medicine, School of Medicine, Ninewells Hospital & Medical School, University of Dundee, Dundee, UK. FAU - Siddiqui, Mohammad S AU - Siddiqui MS AD - Division of Gastroenterology, Hepatology, and Nutrition, Virginia Commonwealth University, Richmond, VA, USA. FAU - Targher, Giovanni AU - Targher G AD - Metabolic Diseases Research Unit, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella (VR), Italy. FAU - Lang, Chim C AU - Lang CC AD - Division of Molecular and Clinical Medicine, School of Medicine, Ninewells Hospital & Medical School, University of Dundee, Dundee, UK; Faculty of Medicine, National University of Malaysia, Kuala Lumpur, Malaysia. FAU - Virani, Salim S AU - Virani SS AD - The Aga Khan University, Karachi, Pakistan; Section of Cardiology and Cardiovascular Research, Department of Medicine, Baylor College of Medicine, Houston, TX, USA. FAU - Lavie, Carl J AU - Lavie CJ AD - John Ochsner Heart and Vascular Institute, Ochsner Clinical School, New Orleans, LA, USA. FAU - Isaacs, Scott AU - Isaacs S AD - Division of Endocrinology, Metabolism, and Lipids, Emory University School of Medicine, Atlanta, GA, USA. FAU - Arab, Juan Pablo AU - Arab JP AD - Division of Gastroenterology, Hepatology, and Nutrition, Virginia Commonwealth University, Richmond, VA, USA; Department of Gastroenterology, Escuela de Medicina, Pontificia Universidad Catolica de Chile, Santiago, Chile. FAU - Cusi, Kenneth AU - Cusi K AD - Division of Endocrinology, Diabetes and Metabolism, The University of Florida, Gainesville, FL, USA. FAU - Krittanawong, Chayakrit AU - Krittanawong C AD - Cardiology Division, NYU Langone Health and NYU School of Medicine, New York, NY, USA. Electronic address: Chayakrit.Krittanawong@va.gov. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review PL - Netherlands TA - Lancet Gastroenterol Hepatol JT - The lancet. Gastroenterology & hepatology JID - 101690683 SB - IM MH - Humans MH - *Coronary Artery Disease/therapy/etiology MH - Risk Factors MH - Non-alcoholic Fatty Liver Disease/therapy/metabolism/complications MH - Fatty Liver/therapy/complications/metabolism COIS- Declaration of interests JVL has received grant funding from AbbVie, Boehringer Ingelheim, Echosens, Gilead Sciences, Madrigal, Merck, Sharp, & Dohme (MSD), Novo Nordisk, Pfizer, and Roche Diagnostics; consulting fees from Echosens, Novovax, GlaxoSmithKline, Novo Nordisk, and Pfizer; payment or honoraria for presentations from AbbVie, Echosens, Gilead Sciences, Janssen, Moderna, MSD, Novo Nordisk, and Pfizer; participated on a data safety monitoring board or advisory board; had a leadership or fiduciary role on Healthy Livers, Health Livers (formed by AASLD, ALEH, APASL, EASL, and Global NASH Council); and was HIV Outcomes co-chair, all unrelated to the current study. PNB has received grant funding for the National Institute for Health and Care Research (NIHR); consulting fees for Resolution Therapeutics; payment or honoraria for presentations from Takeda; support for attending meetings for EASL Bursary for EASL International Liver Conference 2024 and EASL Bursary for School of Hepatology, Steatotic Liver Disease, Aarhus; and leadership or fiduciary role in the Global NASH Council; all unrelated to the current study. CCL has received grant funding from the British Heart Foundation, UK Research and Innovation, NIHR, Chief Scientist Office, European Commission, Juvenile Diabetes Research Foundation, Applied Therapeutics, Anacardia, AstraZeneca, Boehringher Ingelheim, Eli Lilly, Moderna, Roche Diagnostics, Novo Nordisk, and Novartis; and has participated on a data safety monitoring board or advisory board with The International Coronary Microvascular Angina study, TIME Study, and the Dapagliflozin, Exercise Training and physicAl function: the DETA trial; all unrelated to the current study. SSV received grant funding from the Department of Veterans Affairs, National Institutes of Health, UK NIHR, Tahir and Jooma Family, and Asharia Family, all unrelated to the current study. CJL has received payment or honoraria for presentations from Amgen, Global Organization for EPA and DHA Omega-3s, and Diagnostic and Statistical Manual of Mental Disorders; and participated on a data safety monitoring board or advisory board with Novo Nordisk; all unrelated to the current study. SI has received payment for expert testimonies and had a leadership or fiduciary role on the American Association of Clinical Endocrinology, all unrelated to the current study. KC received grant funding from Boehringer Ingelheim, Echosens, Inventiva, LabCorp, Perspectum, and Target-NASH; and consulting fees from Aligos Therapeutics, Arrowhead, AstraZeneca, 89Bio, Bristol Myers Squibb, Boehringer Ingelheim, Covance, Eli Lilly & Co, Molecular Genetics & Genomic Medicine, Novo Nordisk, Prosciento, Sagimet Biosciences, Siemens USA, and Terns Pharma, all unrelated to the current study. All other authors declare no competing interests. EDAT- 2024/12/15 00:41 MHDA- 2024/12/15 00:42 CRDT- 2024/12/14 18:52 PHST- 2024/07/25 00:00 [received] PHST- 2024/09/11 00:00 [revised] PHST- 2024/09/12 00:00 [accepted] PHST- 2024/12/15 00:42 [medline] PHST- 2024/12/15 00:41 [pubmed] PHST- 2024/12/14 18:52 [entrez] AID - S2468-1253(24)00310-8 [pii] AID - 10.1016/S2468-1253(24)00310-8 [doi] PST - ppublish SO - Lancet Gastroenterol Hepatol. 2025 Jan;10(1):82-94. doi: 10.1016/S2468-1253(24)00310-8. PMID- 39670630 OWN - NLM STAT- MEDLINE DCOM- 20250103 LR - 20250103 IS - 1473-6500 (Electronic) IS - 0952-7907 (Linking) VI - 38 IP - 1 DP - 2025 Feb 1 TI - Preventing, identifying and managing myocardial injury after non cardiac surgery - a narrative review. PG - 17-24 LID - 10.1097/ACO.0000000000001454 [doi] AB - PURPOSE OF REVIEW: There is mounting and convincing evidence that patients with postoperative troponin elevation, with or without any clinical symptoms, are at higher risk for both, short- and long-term morbidity and mortality. Myocardial injury after noncardiac surgery (MINS) is a relatively newly described syndrome, and the pathogenesis is not fully understood yet. MINS is now an established syndrome and multiple guidelines address potential etiologies, triggers, as well as preventive and management strategies. RECENT FINDINGS: Surveillance in high-risk patients is required, as most MINS would otherwise be missed. There is no reliable and established preventive strategy, but several potentially avoidable triggers like hypotension, pain and anemia have been identified. Managing patients with MINS postoperatively includes minimizing triggers (such as hemodynamic abnormalities and anemia) that can continue the damage. Long-term pharmacologic strategies include beta-blockers, statins, antiplatelet agents, and anticoagulation. SUMMARY: MINS affects up to 20% of surgical patients, remains clinically mostly silent, but is associated with elevated morbidity and mortality. A multidisciplinary approach, that includes involvement of anesthesiologists, for the prevention, diagnosis, and treatment of MINS is recommended. CI - Copyright (c) 2024 Wolters Kluwer Health, Inc. All rights reserved. FAU - Wittmann, Maria AU - Wittmann M AD - Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn, Bonn, Germany. FAU - Dinc, Tugce AU - Dinc T AD - Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn, Bonn, Germany. FAU - Kunsorg, Andrea AU - Kunsorg A AD - Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn, Bonn, Germany. FAU - Marcucci, Maura AU - Marcucci M AD - Population Health Research Institute, Hamilton, Canada. AD - Clinical Epidemiology and Research Centre, Humanitas University & IRCCS Humanitas Research Hospital, Milan, Italy. AD - Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada. FAU - Ruetzler, Kurt AU - Ruetzler K AD - Center for OUTCOMES RESEARCH and Department of Anesthesiology, UTHealth, Houston, Texas. AD - Division of Multispecialty Anesthesiology, Department of General Anesthesiology, Cleveland Clinic, Cleveland, Ohio, USA. LA - eng PT - Journal Article PT - Review DEP - 20241209 PL - United States TA - Curr Opin Anaesthesiol JT - Current opinion in anaesthesiology JID - 8813436 RN - 0 (Troponin) RN - 0 (Adrenergic beta-Antagonists) SB - IM MH - Humans MH - *Postoperative Complications/prevention & control/diagnosis/etiology/therapy MH - Troponin/blood MH - Surgical Procedures, Operative/adverse effects MH - Risk Factors MH - Adrenergic beta-Antagonists/therapeutic use EDAT- 2024/12/13 12:26 MHDA- 2025/01/03 06:21 CRDT- 2024/12/13 07:52 PHST- 2025/01/03 06:21 [medline] PHST- 2024/12/13 12:26 [pubmed] PHST- 2024/12/13 07:52 [entrez] AID - 00001503-990000000-00249 [pii] AID - 10.1097/ACO.0000000000001454 [doi] PST - ppublish SO - Curr Opin Anaesthesiol. 2025 Feb 1;38(1):17-24. doi: 10.1097/ACO.0000000000001454. Epub 2024 Dec 9. PMID- 39667515 OWN - NLM STAT- MEDLINE DCOM- 20250427 LR - 20250518 IS - 1879-1913 (Electronic) IS - 0002-9149 (Linking) VI - 238 DP - 2025 Mar 1 TI - Noninvasive Multimodality Imaging and Special Treatment Considerations for Pericarditis in Pregnancy. PG - 70-77 LID - S0002-9149(24)00851-8 [pii] LID - 10.1016/j.amjcard.2024.12.007 [doi] AB - Pericarditis in women who are pregnant or of childbearing age poses a challenge to clinicians. At present, there are no guidelines regarding the optimal approach for managing pericarditis in pregnancy regarding selecting the appropriate method of diagnostic imaging or tailoring the treatment regimen to gestational age. Pericarditis in pregnancy may manifest as an autoimmune or autoinflammatory phenotype but the predominant etiology is idiopathic. Transthoracic echocardiography and cardiac magnetic resonance are considered safe, but data are lacking on the use of gadolinium-based contrast agents. Shared decision-making is paramount to balance the risks and benefits of radiation and contrast exposure to the mother and fetus. The safety profile of treatment options differs at each time interval from preconception to the 3 trimesters and postpartum phase. A multidisciplinary approach using imaging guidance can improve outcomes in pregnant patients with pericarditis. Further studies are needed to ascertain the safety of interleukin-1 blocking agents in pregnancy. CI - Copyright (c) 2024 Elsevier Inc. All rights reserved. FAU - Karmali, Rehan AU - Karmali R AD - Center for Diagnosis and Treatment of Pericardial Diseases, Section of Cardiovascular Imaging, Robert and Suzanne Tomsich Department of Cardiovascular Medicine, Sydell and Arnold Miller Family Heart, Vascular and Thoracic Institute. FAU - Motairek, Issam AU - Motairek I AD - Center for Diagnosis and Treatment of Pericardial Diseases, Section of Cardiovascular Imaging, Robert and Suzanne Tomsich Department of Cardiovascular Medicine, Sydell and Arnold Miller Family Heart, Vascular and Thoracic Institute. FAU - Mazumder, Samia AU - Mazumder S AD - Center for Diagnosis and Treatment of Pericardial Diseases, Section of Cardiovascular Imaging, Robert and Suzanne Tomsich Department of Cardiovascular Medicine, Sydell and Arnold Miller Family Heart, Vascular and Thoracic Institute. FAU - Berglund, Felix AU - Berglund F AD - Center for Diagnosis and Treatment of Pericardial Diseases, Section of Cardiovascular Imaging, Robert and Suzanne Tomsich Department of Cardiovascular Medicine, Sydell and Arnold Miller Family Heart, Vascular and Thoracic Institute. FAU - Braghieri, Lorenzo AU - Braghieri L AD - Center for Diagnosis and Treatment of Pericardial Diseases, Section of Cardiovascular Imaging, Robert and Suzanne Tomsich Department of Cardiovascular Medicine, Sydell and Arnold Miller Family Heart, Vascular and Thoracic Institute. FAU - Al-Dalakta, Astefanos AU - Al-Dalakta A AD - Center for Diagnosis and Treatment of Pericardial Diseases, Section of Cardiovascular Imaging, Robert and Suzanne Tomsich Department of Cardiovascular Medicine, Sydell and Arnold Miller Family Heart, Vascular and Thoracic Institute. FAU - Singh, Katherine AU - Singh K AD - Department of Obstetrics and Gynecology, Cleveland Clinic, Cleveland, Ohio. FAU - Weber, Brittany AU - Weber B AD - Heart and Vascular Center, Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. FAU - Klein, Allan AU - Klein A AD - Center for Diagnosis and Treatment of Pericardial Diseases, Section of Cardiovascular Imaging, Robert and Suzanne Tomsich Department of Cardiovascular Medicine, Sydell and Arnold Miller Family Heart, Vascular and Thoracic Institute. Electronic address: kleina@ccf.org. LA - eng PT - Journal Article PT - Review DEP - 20241210 PL - United States TA - Am J Cardiol JT - The American journal of cardiology JID - 0207277 SB - IM MH - Humans MH - Pregnancy MH - Female MH - *Pericarditis/therapy/diagnosis/diagnostic imaging MH - *Pregnancy Complications, Cardiovascular/therapy/diagnostic imaging/diagnosis MH - *Multimodal Imaging/methods MH - Echocardiography MH - Magnetic Resonance Imaging, Cine MH - Magnetic Resonance Imaging OTO - NOTNLM OT - autoimmune pericarditis OT - cardio-obstetrics OT - diagnostic challenges OT - gestational cardiology OT - inflammatory pericarditis OT - maternal health OT - multimodality imaging OT - pericarditis OT - pregnancy OT - treatment considerations COIS- Declaration of competing interest Dr. Klein has received research funding from Kiniksa Pharmaceuticals, Ltd and has served on scientific advisory boards for Kiniksa Pharmaceuticals, Ltd. and Pfizer, Inc. The remaining authors have no competing interests to declare. EDAT- 2024/12/13 00:23 MHDA- 2025/02/09 06:20 CRDT- 2024/12/12 19:24 PHST- 2024/10/16 00:00 [received] PHST- 2024/11/12 00:00 [revised] PHST- 2024/12/05 00:00 [accepted] PHST- 2025/02/09 06:20 [medline] PHST- 2024/12/13 00:23 [pubmed] PHST- 2024/12/12 19:24 [entrez] AID - S0002-9149(24)00851-8 [pii] AID - 10.1016/j.amjcard.2024.12.007 [doi] PST - ppublish SO - Am J Cardiol. 2025 Mar 1;238:70-77. doi: 10.1016/j.amjcard.2024.12.007. Epub 2024 Dec 10. PMID- 39667009 OWN - NLM STAT- MEDLINE DCOM- 20241212 LR - 20250723 IS - 1857-8985 (Electronic) IS - 1857-9345 (Linking) VI - 45 IP - 3 DP - 2024 Nov 1 TI - Implementing an Antimicrobial Stewardship Program and Complete Screening in an Intensive Care Unit in Relation to the Overall Clinical Outcome of Patients. PG - 13-24 LID - 10.2478/prilozi-2024-0019 [doi] AB - BACKGROUND: The high prevalence of resistant microorganisms indicates a multidisciplinary approach, which will ensure efficiency and balance between resistance therapy of choice and the implementation of an antimicrobial stewardship (AMS) program in intensive unit care (ICU). OBJECTIVES: The objectives are based on the assessment of AMS in a cardiac surgical intensive care unit (CICU), by determination with the reduction of: inotropic support, length of antibiotic treatment, and need for renal replacement therapy (RRT). MATERIAL AND METHODS: The research is a retrospective, group comparative, analytical cross-sectional study, in the period from 2020-2023, within the Cardiosurgery department, at Acibadem Sistina. 1277 patients participated in the research, divided into two groups: group 1 (2020-2021) and group 2 (2022-2023). Primary endpoints investigated: inotropic support, need for RRT and length of antibiotic treatment. Secondary endpoints investigated: optimization of antibiotic therapeutic regimen and clinical outcome assessment of patients (survival). RESULTS: The inotropic support during 24, 48 and 72 h was statistically significantly lower in group 2. A statistically significant shorter length of time for antibiotic treatment was determined in patients in group 2 (p=0.000), as well as a lower value of the need for RRT. A statistically significant difference in time to event (fatal outcome) was determined between the two groups (p=0.000). A significant difference (p=0.000) was determined in the prescription and optimization of the therapeutic regimen. CONCLUSION: Integrating AMS, initial comprehensive microbiological screening and application of biomarkers in the CICU, established appropriately, will result in improved overall clinical outcome for patients. CI - (c) 2024 Jelena Micik et al., published by Sciendo. FAU - Micik, Jelena AU - Micik J AD - 1Acibadem Sistina, Skopje, RN Macedonia. FAU - Dimovski, Aleksandar AU - Dimovski A AD - 2Faculty of Pharmacy, University "Ss. Cyril and Methodius", Skopje, RN Macedonia. FAU - Sterjev, Zoran AU - Sterjev Z AD - 2Faculty of Pharmacy, University "Ss. Cyril and Methodius", Skopje, RN Macedonia. FAU - Shuturkova, Ljubica AU - Shuturkova L AD - 2Faculty of Pharmacy, University "Ss. Cyril and Methodius", Skopje, RN Macedonia. FAU - Grozdanova, Aleksandra AU - Grozdanova A AD - 2Faculty of Pharmacy, University "Ss. Cyril and Methodius", Skopje, RN Macedonia. LA - eng PT - Comparative Study PT - Journal Article DEP - 20241212 PL - North Macedonia TA - Pril (Makedon Akad Nauk Umet Odd Med Nauki) JT - Prilozi (Makedonska akademija na naukite i umetnostite. Oddelenie za medicinski nauki) JID - 101677081 RN - 0 (Anti-Bacterial Agents) RN - 0 (Cardiotonic Agents) SB - IM MH - Humans MH - *Antimicrobial Stewardship/methods MH - Retrospective Studies MH - Cross-Sectional Studies MH - *Anti-Bacterial Agents/therapeutic use MH - *Intensive Care Units MH - Male MH - Female MH - Middle Aged MH - Aged MH - *Renal Replacement Therapy/methods MH - Treatment Outcome MH - Time Factors MH - Cardiac Surgical Procedures MH - Cardiotonic Agents/therapeutic use OTO - NOTNLM OT - AMS in CICU OT - Acibadem Sistina OT - antimicrobial resistance OT - biomarkers OT - microbiological screening EDAT- 2024/12/12 18:23 MHDA- 2024/12/12 18:24 CRDT- 2024/12/12 17:22 PHST- 2024/12/12 18:24 [medline] PHST- 2024/12/12 18:23 [pubmed] PHST- 2024/12/12 17:22 [entrez] AID - prilozi-2024-0019 [pii] AID - 10.2478/prilozi-2024-0019 [doi] PST - epublish SO - Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2024 Dec 12;45(3):13-24. doi: 10.2478/prilozi-2024-0019. Print 2024 Nov 1. PMID- 39667008 OWN - NLM STAT- MEDLINE DCOM- 20241212 LR - 20250723 IS - 1857-8985 (Electronic) IS - 1857-9345 (Linking) VI - 45 IP - 3 DP - 2024 Nov 1 TI - Diabetic Kidney Disease Position Paper of the Macedonian Society of Nephrology, Dialysis, Transplantation and Artificial Organs (MSNDTAO), Macedonian Society of Cardiology (MSC), and Scientific Association of Endocrinologists and Diabetologists of Macedonia (SAEDM). PG - 107-116 LID - 10.2478/prilozi-2024-0027 [doi] AB - Diabetic kidney disease (DKD) is a significant and growing global health concern, affecting a substantial proportion of individuals with diabetes mellitus. This position paper of Scientific societies of endocrinologists, nephrologists and cardiologists has been consensually brought at a couple of mutual meetings, aiming to synthesize current knowledge on screening, diagnosis and staging of DKD, emphasizing the need for an early detection and intervention in order to prevent progression to end-stage renal disease (ESRD). The role of glycemic control, blood pressure management, lipid management and the use of reno and cardioprotective agents, including angiotensin-converting enzyme inhibitors, sodium-glucose co-transporter 2 inhibitors and non-steroidal mineralocorticisteroid receptor antagonist has been entirely considered. Furthermore, we highlight the importance of a multidisciplinary approach in the care of patients with DKD, integrating lifestyle modifications and patient education into the clinical practice. This paper advocates for the implementation of standardized screening protocols and the development of personalized treatment strategies to optimize patient outcomes. By addressing the complexities of DKD, we aim to provide a comprehensive framework for healthcare professionals to enhance the quality of care for individuals at risk of or living with this condition. CI - (c) 2024 Goce Spasovski et al., published by Sciendo. FAU - Spasovski, Goce AU - Spasovski G AD - 1University Department of Nephrology, Medical Faculty, Sts Cyril and Methodius University in Skopje, RN Macedonia. FAU - Markovska, Zaklina Sterjova AU - Markovska ZS AD - 1University Department of Nephrology, Medical Faculty, Sts Cyril and Methodius University in Skopje, RN Macedonia. FAU - Gjorgjievski, Nikola AU - Gjorgjievski N AD - 1University Department of Nephrology, Medical Faculty, Sts Cyril and Methodius University in Skopje, RN Macedonia. FAU - Poposka, Lidija AU - Poposka L AD - 2University Department of Cardiology, Medical Faculty, Sts Cyril and Methodius University in Skopje, RN Macedonia. FAU - Kostov, Jorgo AU - Kostov J AD - 2University Department of Cardiology, Medical Faculty, Sts Cyril and Methodius University in Skopje, RN Macedonia. FAU - Bosevski, Marijan AU - Bosevski M AD - 2University Department of Cardiology, Medical Faculty, Sts Cyril and Methodius University in Skopje, RN Macedonia. FAU - Ahmeti, Irfan AU - Ahmeti I AD - 3University Department of Endocrinology and metabolic disease, Medical Faculty, Sts Cyril and Methodius University in Skopje, RN Macedonia. FAU - Jovanovska-Mishevska, Sasha AU - Jovanovska-Mishevska S AD - 3University Department of Endocrinology and metabolic disease, Medical Faculty, Sts Cyril and Methodius University in Skopje, RN Macedonia. FAU - Milenkovic, Tatjana AU - Milenkovic T AD - 3University Department of Endocrinology and metabolic disease, Medical Faculty, Sts Cyril and Methodius University in Skopje, RN Macedonia. LA - eng PT - Journal Article PT - Practice Guideline DEP - 20241212 PL - North Macedonia TA - Pril (Makedon Akad Nauk Umet Odd Med Nauki) JT - Prilozi (Makedonska akademija na naukite i umetnostite. Oddelenie za medicinski nauki) JID - 101677081 RN - 0 (Hypoglycemic Agents) SB - IM MH - Humans MH - Cardiology/standards MH - Consensus MH - *Diabetic Nephropathies/therapy MH - Endocrinologists/standards MH - Endocrinology/standards/methods MH - Hypoglycemic Agents/therapeutic use MH - Kidney Failure, Chronic/therapy MH - Nephrologists/standards MH - Nephrology/standards MH - Republic of North Macedonia MH - Risk Factors MH - Societies, Medical/standards OTO - NOTNLM OT - Diabetic kidney disease OT - angiotensin-converting enzyme inhibitors OT - lifestyle modifications OT - non-steroidal mineralocorticosteroid receptor antagonist OT - sodium-glucose co-transporter 2 inhibitors EDAT- 2024/12/12 18:23 MHDA- 2024/12/12 18:24 CRDT- 2024/12/12 17:22 PHST- 2024/12/12 18:24 [medline] PHST- 2024/12/12 18:23 [pubmed] PHST- 2024/12/12 17:22 [entrez] AID - prilozi-2024-0027 [pii] AID - 10.2478/prilozi-2024-0027 [doi] PST - epublish SO - Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2024 Dec 12;45(3):107-116. doi: 10.2478/prilozi-2024-0027. Print 2024 Nov 1. PMID- 39664733 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260518 IS - 2050-0904 (Print) IS - 2050-0904 (Electronic) IS - 2050-0904 (Linking) VI - 12 IP - 12 DP - 2024 Dec TI - A Case of BRASH Syndrome Presenting With Refractory Hyperkalemia Requiring Intermittent Hemodialysis. PG - e9693 LID - 10.1002/ccr3.9693 [doi] LID - e9693 AB - BRASH syndrome characterized by bradycardia, renal dysfunction, atrioventricular nodal blockade (AVNB), shock, and hyperkalemia presents diagnostic and management challenges due to its complex pathophysiology and varied clinical presentations. We describe a 90-year-old woman with a history of multiple comorbidities who was on beta blockers bisoprolol for heart failure, presented with shock, refractory hyperkalemia along with bradycardia that required intermittent hemodialysis. Initial management involved aggressive hyperkalemia medical therapy and fluid resuscitation, with subsequent consideration of renal replacement therapy hemodialysis following collaboration with a multidisciplinary team, including cardiology and nephrology specialists. Despite aggressive medical management for hyperkalemia, some cases of BRASH syndrome may remain challenging to treat, requiring intermittent hemodialysis highlighting the need for further research and understanding of this complex clinical entity to improve treatment outcomes. CI - (c) 2024 The Author(s). Clinical Case Reports published by John Wiley & Sons Ltd. FAU - Khadka, Bikash AU - Khadka B AUID- ORCID: 0000-0002-4114-8285 AD - Department of Anaesthesiology and Critical Care Nepal Mediciti Lalitpur Nepal. FAU - Poudel, Saroj AU - Poudel S AUID- ORCID: 0000-0003-0879-176X AD - Department of Anaesthesiology and Critical Care Nepal Mediciti Lalitpur Nepal. FAU - Khanal, Kishor AU - Khanal K AD - Department of Anaesthesiology and Critical Care Nepal Mediciti Lalitpur Nepal. FAU - Regmi, Ashim AU - Regmi A AD - Department of Anaesthesiology and Critical Care Nepal Mediciti Lalitpur Nepal. FAU - Ghimire, Anup AU - Ghimire A AD - Department of Anaesthesiology and Critical Care Nepal Mediciti Lalitpur Nepal. FAU - Shrestha, Sharad AU - Shrestha S AD - Department of Anaesthesiology and Critical Care Nepal Mediciti Lalitpur Nepal. FAU - Kc, Shirish AU - Kc S AD - Department of Clinical Research Doctors on Wheels Kathmandu Nepal. FAU - Nepal, Rohini AU - Nepal R AD - Department of Clinical Research Doctors on Wheels Kathmandu Nepal. CN - Doctors on Wheels (DOW) LA - eng PT - Journal Article DEP - 20241210 PL - England TA - Clin Case Rep JT - Clinical case reports JID - 101620385 PMC - PMC11631838 OTO - NOTNLM OT - atrioventricular blockade OT - bradycardia OT - hyperkalemia OT - renal failure OT - shock FIR - Kc, Shirish IR - Kc S FIR - Nepal, Rohini IR - Nepal R FIR - Duwal, Dinesh IR - Duwal D FIR - Tiwari, Vikram IR - Tiwari V FIR - Khadka, Bikash IR - Khadka B FIR - Kc, Priyesh IR - Kc P FIR - Adhikari, Sinju IR - Adhikari S FIR - Maharjan, Smriti IR - Maharjan S FIR - Gurung, Ritika IR - Gurung R FIR - Bisunke, Rashika IR - Bisunke R FIR - Khadka, Roshan IR - Khadka R FIR - Singh, Bijay Bikram IR - Singh BB FIR - Rijal, Rika IR - Rijal R FIR - Kc, Pushpa Bahadur IR - Kc PB EDAT- 2024/12/12 11:29 MHDA- 2024/12/12 11:30 PMCR- 2024/12/10 CRDT- 2024/12/12 04:55 PHST- 2024/04/24 00:00 [received] PHST- 2024/11/04 00:00 [revised] PHST- 2024/11/14 00:00 [accepted] PHST- 2024/12/12 11:30 [medline] PHST- 2024/12/12 11:29 [pubmed] PHST- 2024/12/12 04:55 [entrez] PHST- 2024/12/10 00:00 [pmc-release] AID - CCR39693 [pii] AID - 10.1002/ccr3.9693 [doi] PST - epublish SO - Clin Case Rep. 2024 Dec 10;12(12):e9693. doi: 10.1002/ccr3.9693. eCollection 2024 Dec. PMID- 39664312 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241213 IS - 2296-858X (Print) IS - 2296-858X (Electronic) IS - 2296-858X (Linking) VI - 11 DP - 2024 TI - Fontan-associated liver disease: the importance of multidisciplinary teamwork in its management. PG - 1354857 LID - 10.3389/fmed.2024.1354857 [doi] LID - 1354857 AB - The Fontan operation, which directly connects the superior and inferior vena cava to the pulmonary artery, is a palliative surgery for children with a functional or anatomic single ventricle. This procedure leads to hemodynamic changes (Fontan circulation) in patients, who tend to develop congestive hepatic fibrosis characterized by sinusoidal fibrosis and dilatation beginning approximately 10 years after the procedure. In addition, in the context of severe fibrosis and cirrhosis, hepato-gastrointestinal complications including hepatocellular carcinoma, focal nodular hyperplasia, and portal hypertension can arise. Fontan-associated liver disease (FALD) encompasses the broad spectrum of liver alterations secondary to postoperative hemodynamic changes, and the effective management of FALD requires contributions from specialists in hepatology, gastroenterology, surgery, radiology, histopathology, and pediatric and adult cardiology. In this article, we outline the pathogenesis of FALD and discuss the importance of a multidisciplinary collaborative approach to its management. CI - Copyright (c) 2024 Tsuchihashi, Cho and Tokuhara. FAU - Tsuchihashi, Tomoya AU - Tsuchihashi T AD - Department of Pediatrics, Wakayama Medical University, Wakayama, Japan. FAU - Cho, Yuki AU - Cho Y AD - Department of Pediatrics, Wakayama Medical University, Wakayama, Japan. FAU - Tokuhara, Daisuke AU - Tokuhara D AD - Department of Pediatrics, Wakayama Medical University, Wakayama, Japan. AD - Department of Pediatrics, Osaka Metropolitan University, Osaka, Japan. LA - eng PT - Journal Article PT - Review DEP - 20241127 PL - Switzerland TA - Front Med (Lausanne) JT - Frontiers in medicine JID - 101648047 PMC - PMC11631589 OTO - NOTNLM OT - Fontan procedure OT - Fontan-associated liver disease OT - gastroesophageal varix OT - hepatocellular carcinoma OT - liver fibrosis OT - liver stiffness OT - protein-losing enteropathy COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2024/12/12 11:29 MHDA- 2024/12/12 11:30 PMCR- 2024/11/27 CRDT- 2024/12/12 04:48 PHST- 2023/12/13 00:00 [received] PHST- 2024/11/12 00:00 [accepted] PHST- 2024/12/12 11:30 [medline] PHST- 2024/12/12 11:29 [pubmed] PHST- 2024/12/12 04:48 [entrez] PHST- 2024/11/27 00:00 [pmc-release] AID - 10.3389/fmed.2024.1354857 [doi] PST - epublish SO - Front Med (Lausanne). 2024 Nov 27;11:1354857. doi: 10.3389/fmed.2024.1354857. eCollection 2024. PMID- 39663054 OWN - NLM STAT- MEDLINE DCOM- 20241211 LR - 20260708 IS - 1876-7605 (Electronic) IS - 1936-8798 (Linking) VI - 17 IP - 23 DP - 2024 Dec 9 TI - Eligibility for Transcatheter Tricuspid Valve Interventions in Patients With Tricuspid Regurgitation. PG - 2732-2744 LID - S1936-8798(24)01203-2 [pii] LID - 10.1016/j.jcin.2024.09.019 [doi] AB - BACKGROUND: It remains unclear what proportion of patients with tricuspid regurgitation (TR) are suitable candidates for transcatheter tricuspid valve intervention (TTVI) in clinical practice. OBJECTIVES: The aim of this study was to ascertain the prevalence of eligibility for tricuspid transcatheter edge-to-edge repair (T-TEER) and transcatheter tricuspid valve replacement (TTVR) devices among patients with TR. METHODS: The tricuspid valve anatomy of all consecutive patients with TR who were considered for TTVI in local heart team conferences was retrospectively reviewed. According to current expert consensus, the anatomical feasibility for T-TEER was classified into 3 groups: favorable, feasible, and unfavorable anatomy. Clinical and anatomical eligibility for TTVR was evaluated in patients with cardiac computed tomographic (CCT) images. RESULTS: Among 491 patients, 99 (20.2%) and 235 (47.9%) were considered to have favorable and feasible anatomy for T-TEER, respectively. In contrast, 157 patients (32.0%) had unfavorable anatomy for T-TEER. The most common reason for unfavorable anatomy for T-TEER was large coaptation gap width (66.2%), followed by anteroposterior TR jet location (62.4%). Among 327 patients with CCT images, 205 (62.7%) were judged to be clinically or anatomically ineligible for TTVR, mainly because of tricuspid annuli larger than commercially available prosthesis sizes (65.4%). Combined echocardiographic and CCT assessment showed that 23.2% of the patients with TR were ineligible for both T-TEER and TTVR. CONCLUSIONS: Of 491 patients requiring TTVI, 32.0% had unfavorable anatomy for T-TEER, and 37.3% of patients with CCT images were eligible for TTVR. Despite the emergence of TTVR devices, 23.2% of patients with TR remained ineligible for both T-TEER and TTVR. CI - Copyright (c) 2024 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Tanaka, Tetsu AU - Tanaka T AD - Department of Internal Medicine II, University Hospital Bonn, Bonn, Germany. Electronic address: ta.chi.tsu.tetsu@gmail.com. FAU - Vogelhuber, Johanna AU - Vogelhuber J AD - Department of Internal Medicine II, University Hospital Bonn, Bonn, Germany. FAU - Ozturk, Can AU - Ozturk C AD - Department of Internal Medicine II, University Hospital Bonn, Bonn, Germany. FAU - Silaschi, Miriam AU - Silaschi M AD - Department of Cardiac Surgery, University Hospital Bonn, Bonn, Germany. FAU - Bakhtiary, Farhad AU - Bakhtiary F AD - Department of Cardiac Surgery, University Hospital Bonn, Bonn, Germany. FAU - Zimmer, Sebastian AU - Zimmer S AD - Department of Internal Medicine II, University Hospital Bonn, Bonn, Germany. FAU - Nickenig, Georg AU - Nickenig G AD - Department of Internal Medicine II, University Hospital Bonn, Bonn, Germany. FAU - Weber, Marcel AU - Weber M AD - Department of Internal Medicine II, University Hospital Bonn, Bonn, Germany. FAU - Sugiura, Atsushi AU - Sugiura A AD - Department of Internal Medicine II, University Hospital Bonn, Bonn, Germany. LA - eng PT - Journal Article PL - United States TA - JACC Cardiovasc Interv JT - JACC. Cardiovascular interventions JID - 101467004 SB - IM CIN - JACC Cardiovasc Interv. 2024 Dec 9;17(23):2745-2748. doi: 10.1016/j.jcin.2024.10.029. PMID: 39663055 MH - Humans MH - *Tricuspid Valve Insufficiency/diagnostic imaging/surgery/physiopathology MH - *Cardiac Catheterization/instrumentation/adverse effects MH - *Tricuspid Valve/diagnostic imaging/surgery/physiopathology MH - Female MH - Retrospective Studies MH - Male MH - *Heart Valve Prosthesis Implantation/instrumentation/adverse effects MH - Aged MH - *Patient Selection MH - Treatment Outcome MH - Aged, 80 and over MH - *Heart Valve Prosthesis MH - *Eligibility Determination MH - Middle Aged MH - Clinical Decision-Making MH - Risk Factors MH - Predictive Value of Tests MH - Tomography, X-Ray Computed OTO - NOTNLM OT - cardiac computed tomography OT - echocardiography OT - transcatheter tricuspid valve intervention OT - transcatheter tricuspid valve replacement OT - tricuspid regurgitation OT - tricuspid transcatheter edge-to-edge repair COIS- Funding Support and Author Disclosures Dr Tanaka has received grants from the Japanese College of Cardiology and the Uehara Memorial Foundation; and has received honoraria from Canon Medical Systems. Dr Sugiura has received honoraria for lectures and proctoring from Edwards Lifesciences. Dr Nickenig has received research funding from Deutsche Forschungsgemeinschaft, the German Federal Ministry of Education and Research, the European Union, Abbott, Edwards Lifesciences, Medtronic, and St. Jude Medical; and has received honoraria for lectures or advisory board membership from Abbott, Edwards Lifesciences, Medtronic, and St. Jude Medical. Dr Weber has received lecture or proctoring fees from Abbott and Edwards Lifesciences. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2024/12/12 00:24 MHDA- 2024/12/12 00:25 CRDT- 2024/12/11 20:57 PHST- 2024/03/05 00:00 [received] PHST- 2024/09/07 00:00 [revised] PHST- 2024/09/10 00:00 [accepted] PHST- 2024/12/12 00:25 [medline] PHST- 2024/12/12 00:24 [pubmed] PHST- 2024/12/11 20:57 [entrez] AID - S1936-8798(24)01203-2 [pii] AID - 10.1016/j.jcin.2024.09.019 [doi] PST - ppublish SO - JACC Cardiovasc Interv. 2024 Dec 9;17(23):2732-2744. doi: 10.1016/j.jcin.2024.09.019. PMID- 39658643 OWN - NLM STAT- MEDLINE DCOM- 20250802 LR - 20251211 IS - 1476-5543 (Electronic) IS - 0743-8346 (Print) IS - 0743-8346 (Linking) VI - 45 IP - 7 DP - 2025 Jul TI - Structured pre-delivery huddles enhance confidence in managing newborns with critical congenital heart disease in the delivery room. PG - 1009-1016 LID - 10.1038/s41372-024-02196-8 [doi] AB - BACKGROUND: Newborns with critical congenital heart disease (CCHD) require specialized delivery room management, but varying experience and knowledge can reduce confidence and impact care. METHODS: A pre-delivery, structured huddle checklist was introduced, addressing team roles, expected physiology, and management plans. PDSA cycles incorporated guidelines and simulation-based education to improve confidence in specialized resuscitation strategies. Surveys were conducted at baseline and 6 months. RESULTS: Baseline, all-respondent confidence in managing "all types of CCHD" was somewhat confident (median 3/5; IQR 2-4) increasing to moderately confident (4/5; IQR 2-4) at 6 months (p = 0.59). Respondents with 0-3 years' experience showed increased confidence over 6 months in identifying unstable infants (from baseline 24% to 67% moderately/very confident, p = 0.005), prostaglandin E1 needs (from 24% to 62%, p = 0.013) and sedation requirements (from 5% to 33%, p = 0.045). CONCLUSION: Structured huddles improved confidence among less experienced team members, emphasizing the importance of shared mental models before CCHD deliveries. CI - (c) 2024. The Author(s), under exclusive licence to Springer Nature America, Inc. FAU - Thomas, Alyssa R AU - Thomas AR AUID- ORCID: 0000-0002-8097-7385 AD - Division of Newborn Medicine, Department of Pediatrics, Brigham & Women's Hospital, Boston, MA, USA. AThomas20@mgb.org. FAU - Bowen, Caitlin AU - Bowen C AD - Department of Cardiology, Boston Children's Hospital, Boston, MA, USA. FAU - Abdulhayoglu, Elisa AU - Abdulhayoglu E AD - Division of Newborn Medicine, Department of Pediatrics, Brigham & Women's Hospital, Boston, MA, USA. FAU - Brennick, Elizabeth AU - Brennick E AD - Division of Newborn Medicine, Department of Pediatrics, Brigham & Women's Hospital, Boston, MA, USA. FAU - Woo, Kendra AU - Woo K AD - Division of Newborn Medicine, Department of Pediatrics, Brigham & Women's Hospital, Boston, MA, USA. FAU - Everett, Margaret F AU - Everett MF AD - Division of Newborn Medicine, Department of Pediatrics, Brigham & Women's Hospital, Boston, MA, USA. FAU - Valencia, Eleonore AU - Valencia E AD - Department of Cardiology, Boston Children's Hospital, Boston, MA, USA. FAU - Leeman, Kristen T AU - Leeman KT AUID- ORCID: 0000-0002-3410-9675 AD - Division of Newborn Medicine, Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA. FAU - Manning, Simon M AU - Manning SM AD - Division of Newborn Medicine, Department of Pediatrics, Brigham & Women's Hospital, Boston, MA, USA. FAU - Kaza, Elisabeth AU - Kaza E AD - Division of Newborn Medicine, Department of Pediatrics, Brigham & Women's Hospital, Boston, MA, USA. LA - eng GR - T32 HD098061/HD/NICHD NIH HHS/United States GR - T32 HL007572/HL/NHLBI NIH HHS/United States GR - T32 HD 098061/U.S. Department of Health & Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)/ PT - Journal Article DEP - 20241210 PL - United States TA - J Perinatol JT - Journal of perinatology : official journal of the California Perinatal Association JID - 8501884 SB - IM MH - Humans MH - Infant, Newborn MH - *Heart Defects, Congenital/therapy MH - *Delivery Rooms/organization & administration MH - *Patient Care Team/organization & administration MH - Female MH - Checklist MH - *Clinical Competence MH - Resuscitation/methods MH - Pregnancy MH - Surveys and Questionnaires PMC - PMC12149332 MID - NIHMS2048355 COIS- Competing interests: The authors declare no competing interests. EDAT- 2024/12/11 00:23 MHDA- 2025/08/02 10:42 PMCR- 2025/12/10 CRDT- 2024/12/10 23:21 PHST- 2024/10/02 00:00 [received] PHST- 2024/12/04 00:00 [accepted] PHST- 2024/11/26 00:00 [revised] PHST- 2025/08/02 10:42 [medline] PHST- 2024/12/11 00:23 [pubmed] PHST- 2024/12/10 23:21 [entrez] PHST- 2025/12/10 00:00 [pmc-release] AID - 10.1038/s41372-024-02196-8 [pii] AID - 10.1038/s41372-024-02196-8 [doi] PST - ppublish SO - J Perinatol. 2025 Jul;45(7):1009-1016. doi: 10.1038/s41372-024-02196-8. Epub 2024 Dec 10. PMID- 39650581 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241211 IS - 0973-1075 (Print) IS - 1998-3735 (Electronic) IS - 0973-1075 (Linking) VI - 30 IP - 4 DP - 2024 Oct-Dec TI - Unmet Palliative Care Needs of Patients with Stage B Chronic Heart Failure Classified by the American Heart Association/American College of Cardiology. PG - 384-387 LID - 10.25259/IJPC_37_2023 [doi] AB - This study sought to explore the unmet palliative care needs of patients diagnosed with Stage B chronic heart failure (CHF) according to the American Heart Association (AHA) and American College of Cardiology (ACC) classifications. We conducted this cross-sectional study between June 1 and August 31, 2020, at Kobe University Hospital. Patients were asked to complete the Integrated Palliative care Outcome Scale (IPOS) along with a customized questionnaire developed by a multidisciplinary team. These tools were filled out by the patients themselves or with help from family members. A total of 101 patients participated in the study, with 55 of them (55%) falling into the Stage B CHF group as classified by AHA/ACC. Among the physical symptoms, 22% reported dyspnea and 20% reported drowsiness as common concerns. Regarding specific problems, 47% identified issues related to exercise, 62% with eating, 26% with finances, and 18% with employment. Notably, financial difficulties were found to be significantly more common among Stage B patients when compared to those in Stages C and D (odds ratio [OR]: 5.22; 95% confidence interval [95% CI]: 1.03-26.5; p = 0.032). Almost 79% of Stage B patients expressed a desire to understand the progression of their disease. In conclusion, stage B CHF patients may face financial difficulties and have unmet informational needs. Therefore, further research is necessary to explore these aspects in greater detail. CI - (c) 2024 Published by Scientific Scholar on behalf of Indian Journal of Palliative Care. FAU - Matsunuma, Ryo AU - Matsunuma R AD - Department of Palliative Medicine, Kobe University Graduate School of Medicine, Kobe, Japan. FAU - Yamaguchi, Takashi AU - Yamaguchi T AUID- ORCID: 0000-0003-3060-0245 AD - Department of Palliative Medicine, Kobe University Graduate School of Medicine, Kobe, Japan. FAU - Matsumoto, Kensuke AU - Matsumoto K AD - Department of Cardiology, Kobe University Hospital, Kobe, Japan. FAU - Sakashita, Akihiro AU - Sakashita A AD - Division of Palliative Medicine, Hyogo Prefectural Harima-Himeji General Medical Center, Himeji, Japan. FAU - Hashiguchi, Chikako AU - Hashiguchi C AD - Palliative Care Center, Kobe University Hospital, Kobe, Japan. FAU - Iida, Masashi AU - Iida M AD - Department of Pharmacy, Kobe University Hospital, Kobe, Japan. FAU - Kizawa, Yoshiyuki AU - Kizawa Y AD - Department of Palliative and Supporive Care, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan. LA - eng PT - Journal Article DEP - 20241115 PL - United States TA - Indian J Palliat Care JT - Indian journal of palliative care JID - 101261221 PMC - PMC11618809 OTO - NOTNLM OT - Chronic heart failure OT - Financial problems OT - Informational needs OT - Palliative care needs COIS- There are no conflicts of interest. EDAT- 2024/12/09 17:34 MHDA- 2024/12/09 17:35 PMCR- 2024/10/01 CRDT- 2024/12/09 06:16 PHST- 2023/02/10 00:00 [received] PHST- 2024/10/02 00:00 [accepted] PHST- 2024/12/09 17:35 [medline] PHST- 2024/12/09 17:34 [pubmed] PHST- 2024/12/09 06:16 [entrez] PHST- 2024/10/01 00:00 [pmc-release] AID - 10.25259/IJPC_37_2023 [pii] AID - 10.25259/IJPC_37_2023 [doi] PST - ppublish SO - Indian J Palliat Care. 2024 Oct-Dec;30(4):384-387. doi: 10.25259/IJPC_37_2023. Epub 2024 Nov 15. PMID- 39645270 OWN - NLM STAT- MEDLINE DCOM- 20241207 LR - 20260109 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 14 IP - 8 DP - 2024 Aug 31 TI - Discontinuation of beta-blocker therapy in stabilised patients after acute myocardial infarction (SMART-DECISION): rationale and design of the randomised controlled trial. PG - e086971 LID - 10.1136/bmjopen-2024-086971 [doi] LID - e086971 AB - INTRODUCTION: There is a lack of evidence to support the effectiveness of prolonged beta-blocker therapy after stabilisation of patients with acute myocardial infarction (AMI) without heart failure (HF) or left ventricular systolic dysfunction. METHODS AND ANALYSIS: The SMart Angioplasty Research Team: DEcision on Medical Therapy in Patients with Coronary Artery DIsease or Structural Heart Disease Undergoing InterventiON (SMART-DECISION) trial is a multicentre, prospective, open-label, randomised, non-inferiority trial designed to determine whether discontinuing beta-blocker therapy after >/=1 year of maintenance in stabilised patients after AMI is non-inferior to continuing it. Patients eligible for participation are those without HF or left ventricular systolic dysfunction (ejection fraction >40%) who have been continuing beta-blocker therapy for >/=1 year after AMI. A total of 2540 patients will be randomised 1:1 to continuation of beta-blocker therapy or not. Randomisation will be stratified according to the type of AMI (ie, ST-segment-elevation MI or non-ST-segment-elevation MI), type of beta-blocker (carvedilol, bisoprolol, nebivolol or other) and participating centre. The primary study endpoint is a composite of all-cause death, MI and hospitalisation for HF over a median follow-up period of 3.5 years (minimum, 2.5 years; maximum, 4.5 years). Adverse effects related to beta-blocker therapy, the occurrence of atrial fibrillation, medical costs and Patient-reported Outcomes Measurement Information system-29 questionnaire responses will also be collected as secondary endpoints. ETHICS AND DISSEMINATION: Ethics approval for this study was granted by the Institutional Review Board of Samsung Medical Center (no. 2020-10-176). Informed consent is obtained from every participant before randomisation. The results of this study will be submitted for publication in international peer-reviewed journals and the key findings will be presented at international scientific conferences. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov, NCT04769362. CI - (c) Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Choi, Ki Hong AU - Choi KH AD - Department of Cardiology, Samsung Medical Center, Seoul, Republic of Korea. FAU - Kim, Juwon AU - Kim J AD - Department of Cardiology, Samsung Medical Center, Seoul, Republic of Korea. FAU - Kang, Danbee AU - Kang D AD - Clinical Research Design and Evaluation, SAIHST, Sungkyunkwan University, Seoul, Republic of Korea. FAU - Doh, Joon-Hyung AU - Doh JH AD - Department of Medicine, University Ilsan-Paik Hospital, Goyang, Republic of Korea. FAU - Kim, Juhan AU - Kim J AD - Chonnam National University, Gwangju, Republic of Korea. FAU - Park, Yong Hwan AU - Park YH AD - Samsung Changwon Hospital, Changwon, Gyeonsangnam-do, Republic of Korea. FAU - Ahn, Sung Gyun AU - Ahn SG AD - Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea. FAU - Kim, Weon AU - Kim W AD - Department of Internal Medicine Division of Cardiology, Kyung Hee University Medical Center, Dongdaemun-gu, Seoul, Republic of Korea. FAU - Park, Jong Pil AU - Park JP AD - Presbyterian Medical Center, Jeonju, Jeollabuk-do, Republic of Korea. FAU - Kim, Sang Min AU - Kim SM AD - Chungbuk National University Hospital, Cheongju, Chungcheongbuk-do, Republic of Korea. FAU - Cho, Byung-Ryul AU - Cho BR AD - Kangwon National University Hospital, Chuncheon, Kangwon, Republic of Korea. FAU - Nam, Chang-Wook AU - Nam CW AD - Department of Medicine, Keimyung University Dongsan Medical Center, Daegu, Republic of Korea. FAU - Cho, Jang Hyun AU - Cho JH AD - Saint Carollo Hospital, Suncheon, Jeollanam-do, Republic of Korea. FAU - Joo, Seung-Jae AU - Joo SJ AD - Jeju National University, Jeju, Republic of Korea. FAU - Suh, Jon AU - Suh J AD - Soonchunhyang University Hospital Bucheon, Bucheon, Gyeonggi-do, Republic of Korea. FAU - Jeong, Jin-Ok AU - Jeong JO AD - Division of Cardiology, Chungnam National University Hospital, Daejeon, Daejeon, Republic of Korea. FAU - Jang, Woo AU - Jang W AD - Ewha Woman's University Seoul Hospital, Seoul, Republic of Korea. FAU - Yoon, Chang-Hwan AU - Yoon CH AD - Seoul National University Bundang Hospital, Seongnam, Republic of Korea. FAU - Hwang, Jin-Yong AU - Hwang JY AD - Gyeongsang National University Hospital, Jinju, Republic of Korea. FAU - Lim, Seong-Hoon AU - Lim SH AD - Dankook University Hospital, Cheonan, Chungcheongnam-do, Republic of Korea. FAU - Lee, Sang-Rok AU - Lee SR AD - Chonbuk National University Hospital, Jeonju, Jeollabuk-do, Republic of Korea. FAU - Shin, Eun-Seok AU - Shin ES AUID- ORCID: 0000-0002-9169-6968 AD - Ulsan University Hospital, Ulsan, Republic of Korea. FAU - Kim, Byung Jin AU - Kim BJ AD - Kangbuk Samsung Hospital, Jongno-gu, Seoul, Republic of Korea. FAU - Yu, Cheol Woong AU - Yu CW AD - Korea University Anam Hospital, Seoul, Republic of Korea. FAU - Her, Sung-Ho AU - Her SH AD - Department of Cardiology, The Catholic University of Korea. Daejeon St. Mary's Hospital, Daejeon, Republic of Korea. FAU - Kim, Hyun Kuk AU - Kim HK AD - Chosun University Hospital, Gwangju, Republic of Korea. FAU - Park, Kyu Tae AU - Park KT AD - Chuncheon Sacred Heart Hospital, Chuncheon, Gangwon-do, Republic of Korea. FAU - Kim, Jihoon AU - Kim J AD - Department of Cardiology, Samsung Medical Center, Seoul, Republic of Korea. FAU - Park, Taek Kyu AU - Park TK AD - Department of Cardiology, Samsung Medical Center, Seoul, Republic of Korea. FAU - Lee, Joo-Myung AU - Lee JM AD - Department of Cardiology, Samsung Medical Center, Seoul, Republic of Korea. FAU - Cho, Juhee AU - Cho J AUID- ORCID: 0000-0001-9081-0266 AD - Clinical Research Design and Evaluation, SAIHST, Sungkyunkwan University, Seoul, Republic of Korea. FAU - Yang, Jeong Hoon AU - Yang JH AD - Department of Cardiology, Samsung Medical Center, Seoul, Republic of Korea. FAU - Song, Young Bin AU - Song YB AUID- ORCID: 0000-0003-3986-9152 AD - Department of Cardiology, Samsung Medical Center, Seoul, Republic of Korea. FAU - Choi, Seung Hyuk AU - Choi SH AD - Department of Cardiology, Samsung Medical Center, Seoul, Republic of Korea. FAU - Gwon, Hyeon-Cheol AU - Gwon HC AD - Department of Cardiology, Samsung Medical Center, Seoul, Republic of Korea. FAU - Guallar, Eliseo AU - Guallar E AD - Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA. FAU - Hahn, Joo-Yong AU - Hahn JY AUID- ORCID: 0000-0002-4412-377X AD - Department of Cardiology, Samsung Medical Center, Seoul, Republic of Korea jyhahn@skku.edu. CN - SMART-DECISION investigators LA - eng SI - ClinicalTrials.gov/NCT04769362 PT - Clinical Trial Protocol PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240831 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 RN - 0 (Adrenergic beta-Antagonists) RN - Y41JS2NL6U (Bisoprolol) SB - IM MH - Humans MH - *Adrenergic beta-Antagonists/therapeutic use/administration & dosage MH - *Myocardial Infarction/drug therapy MH - Prospective Studies MH - Withholding Treatment MH - Bisoprolol/therapeutic use/administration & dosage MH - Multicenter Studies as Topic MH - Equivalence Trials as Topic PMC - PMC11367310 OTO - NOTNLM OT - clinical trial OT - heart failure OT - myocardial infarction OT - patient reported outcome measures COIS- Competing interests: J-YH received an Institutional Research Grant from the National Evidence-based Healthcare Collaborating Agency, Ministry of Health & Welfare, Korea as well as Abbott Vascular, Biosensors, Boston Scientific, Daiichi Sankyo, Donga-ST, Hanmi Pharmaceutical and Medtronic. None of the other authors have conflicts of interest to declare. EDAT- 2024/12/08 01:11 MHDA- 2024/12/08 01:12 PMCR- 2024/08/31 CRDT- 2024/12/07 20:53 PHST- 2024/12/08 01:12 [medline] PHST- 2024/12/08 01:11 [pubmed] PHST- 2024/12/07 20:53 [entrez] PHST- 2024/08/31 00:00 [pmc-release] AID - bmjopen-2024-086971 [pii] AID - 10.1136/bmjopen-2024-086971 [doi] PST - epublish SO - BMJ Open. 2024 Aug 31;14(8):e086971. doi: 10.1136/bmjopen-2024-086971. PMID- 39644913 OWN - NLM STAT- MEDLINE DCOM- 20241221 LR - 20250516 IS - 1474-547X (Electronic) IS - 0140-6736 (Linking) VI - 404 IP - 10471 DP - 2025 Dec 21 TI - TransCatheter aortic valve implantation and fractional flow reserve-guided percutaneous coronary intervention versus conventional surgical aortic valve replacement and coronary bypass grafting for treatment of patients with aortic valve stenosis and complex or multivessel coronary disease (TCW): an international, multicentre, prospective, open-label, non-inferiority, randomised controlled trial. PG - 2593-2602 LID - S0140-6736(24)02100-7 [pii] LID - 10.1016/S0140-6736(24)02100-7 [doi] AB - BACKGROUND: Patients with severe aortic stenosis present frequently ( approximately 50%) with concomitant obstructive coronary artery disease. Current guidelines recommend combined surgical aortic valve replacement (SAVR) and coronary artery bypass grafting (CABG) as the preferred treatment. Transcatheter aortic valve implantation (TAVI) and fractional flow reserve (FFR)-guided percutaneous coronary intervention (PCI) represent a valid treatment alternative. We aimed to test the non-inferiority of FFR-guided PCI plus TAVI versus SAVR plus CABG in patients with severe aortic stenosis and complex coronary artery disease. METHODS: This international, multicentre, prospective, open-label, non-inferiority, randomised controlled trial was conducted at 18 tertiary medical centres across Europe. Patients (aged >/=70 years) with severe aortic stenosis and complex coronary artery disease, deemed feasible for percutaneous or surgical treatment according to the on-site Heart Team, were randomly assigned (1:1) to FFR-guided PCI plus TAVI or SAVR plus CABG according to a computer-generated sequence with random permuted blocks sizes stratified by site. The primary endpoint was a composite of all-cause mortality, myocardial infarction, disabling stroke, clinically driven target-vessel revascularisation, valve reintervention, and life-threatening or disabling bleeding at 1 year post-treatment. The trial was powered for non-inferiority (with a margin of 15%) and if met, for superiority. The primary and safety analyses were done per an intention-to-treat principle. This trial is registered with ClinicalTrials.gov (NCT03424941) and is closed. FINDINGS: Between May 31, 2018, and June 30, 2023, 172 patients were enrolled, of whom 91 were assigned to the FFR-guided PCI plus TAVI group and 81 to the SAVR plus CABG group. The mean age of patients was 76.5 years (SD 3.9). 118 (69%) of 172 patients were male and 54 (31%) patients were female. FFR-guided PCI plus TAVI resulted in favourable outcomes for the primary endpoint (four [4%] of 91 patients) versus SAVR plus CABG (17 [23%] of 77 patients; risk difference -18.5 [90% CI -27.8 to -9.7]), which was below the 15% prespecified non-inferiority margin (p(non-inferiority)<0.001). FFR-guided PCI plus TAVI was superior to SAVR plus CABG (hazard ratio 0.17 [95% CI 0.06-0.51]; p(superiority)<0.001), which was driven mainly by all-cause mortality (none [0%] of 91 patients vs seven (10%) of 77 patients; p=0.0025) and life-threatening bleeding (two [2%] vs nine [12%]; p=0.010). INTERPRETATION: The TCW trial is the first trial to compare percutaneous treatment versus surgical treatment in patients with severe aortic stenosis and complex coronary artery disease, showing favourable primary endpoint and mortality outcomes with percutaneous treatment. FUNDING: Isala Heart Centre and Medtronic. CI - Copyright (c) 2024 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies. FAU - Kedhi, Elvin AU - Kedhi E AD - Royal Victoria Hospital, McGill University Health Center, Montreal, QC, Canada; Department of Cardiology and Structural Heart Disease, Medical University of Silesia, Katowice, Poland. Electronic address: elvin.kedhi@mcgill.ca. FAU - Hermanides, Renicus S AU - Hermanides RS AD - Department of Cardiology, Isala Heart Center, Zwolle, Netherlands. FAU - Dambrink, Jan-Henk E AU - Dambrink JE AD - Department of Cardiology, Isala Heart Center, Zwolle, Netherlands. FAU - Singh, Sandeep K AU - Singh SK AD - Department of Thoracic Surgery, Isala Heart Center, Zwolle, Netherlands. FAU - Ten Berg, Jurrien M AU - Ten Berg JM AD - Department of Cardiology, St Antonius Hospital, Nieuwegein, Netherlands; Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, Maastricht, Netherlands. FAU - van Ginkel, DirkJan AU - van Ginkel D AD - Department of Cardiology, St Antonius Hospital, Nieuwegein, Netherlands; Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, Maastricht, Netherlands. FAU - Hudec, Martin AU - Hudec M AD - Stredoslovensky Ustav Srdcovych a Cievnych Chorob, Banska, Bystrica, Slovakia. FAU - Amoroso, Giovanni AU - Amoroso G AD - Department of Cardiology, Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands. FAU - Amat-Santos, Ignacio J AU - Amat-Santos IJ AD - Centro de Investigacion Biomedica en Red, Enfermedades Cardiovasculares, Madrid, Spain; Hospital Clinico Universitario de Valladolid, Valladolid, Spain. FAU - Andreas, Martin AU - Andreas M AD - Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria. FAU - Campante Teles, Rui AU - Campante Teles R AD - Hospital de Santa Cruz, Carnaxide, Portugal; Comprehensive Health Research Center, Nova Medical School, Lisbon, Portugal. FAU - Bonnet, Guillaume AU - Bonnet G AD - Hopital haut Leveque, Unite Medico Chirurgicale, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France. FAU - Van Belle, Eric AU - Van Belle E AD - Department of Cardiology, Department of Interventional Cardiology for Coronary, Valves and Structural Heart Diseases and Institut Coeur Poumon, Centre Hospitalier Universitaire Lille, Lille, France; INSERM U1011, Lille, France; Universite de Lille, Lille, France. FAU - Conradi, Lenard AU - Conradi L AD - Klinik und Poliklinik fur Herz- und Gefasschirurgie, Universitares Herz- und Gefasszentrum Hamburg, Hamburg, Germany. FAU - van Garsse, Leen AU - van Garsse L AD - Department of Cardiothoracic Surgery, Radboud University Medical Centre, Nijmegen, Netherlands. FAU - Wojakowski, Wojtek AU - Wojakowski W AD - Department of Cardiology and Structural Heart Disease, Medical University of Silesia, Katowice, Poland. FAU - Voudris, Vassilis AU - Voudris V AD - Interventional Department of Cardiology, Onassis Cardiac Surgery Center, Athens, Greece. FAU - Sacha, Jerzy AU - Sacha J AD - Department of Cardiology, University Hospital, Institute of Medical Sciences, University of Opole, Opole, Poland; Faculty of Physical Education and Physiotherapy, Opole University of Technology, Opole, Poland. FAU - Cervinka, Pavel AU - Cervinka P AD - 1st Department Medicine-Cardioangiology, Charles University Prague, Medical Faculty and University Hospital Hradec Kralove, Prague, Czech Republic; University of Jan Evangelista Purkyne, Usti nad Labem, Czech Republic. FAU - Lipsic, Erik AU - Lipsic E AD - Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands. FAU - Somi, Samer AU - Somi S AD - Department of Cardiology, Haga Hospital, The Hague, Netherlands. FAU - Nombela-Franco, Luis AU - Nombela-Franco L AD - Cardiovascular Institute, Hospital Clinico San Carlos IdISSC, Madrid, Spain. FAU - Postma, Sonja AU - Postma S AD - Diagram Research, Zwolle, Netherlands. FAU - Piayda, Kerstin AU - Piayda K AD - Department of Cardiology and Vascular Medicine, Medical Faculty, Justus-Liebig-University Giessen, Giessen, Germany. FAU - De Luca, Giuseppe AU - De Luca G AD - Division of Cardiology, Azienda Ospedaliera Universitaria Policlinico Gaetano Martino, University of Messina, Messina, Italy; Division of Cardiology, IRCCS Hospital Galeazzi-Sant'Ambrogio, Milan, Italy. FAU - Kolkman, Evelien AU - Kolkman E AD - Diagram Research, Zwolle, Netherlands. FAU - Malinowski, Krzysztof P AU - Malinowski KP AD - Center for Digital Medicine and Robotics, Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland; Department of Bioinformatics and Telemedicine, Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland. FAU - Modine, Thomas AU - Modine T AD - Hopital haut Leveque, Unite Medico Chirurgicale, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France. CN - TCW study group LA - eng SI - ClinicalTrials.gov/NCT03424941 PT - Comparative Study PT - Equivalence Trial PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't DEP - 20241204 PL - England TA - Lancet JT - Lancet (London, England) JID - 2985213R SB - IM CIN - Lancet. 2025 Dec 21;404(10471):2492-2493. doi: 10.1016/S0140-6736(24)02318-3. PMID: 39644912 MH - Aged MH - Aged, 80 and over MH - Female MH - Humans MH - Male MH - *Aortic Valve Stenosis/surgery/complications MH - *Coronary Artery Bypass/methods MH - *Coronary Artery Disease/surgery/complications/therapy MH - *Fractional Flow Reserve, Myocardial MH - Heart Valve Prosthesis Implantation/methods MH - *Percutaneous Coronary Intervention/methods MH - Prospective Studies MH - *Transcatheter Aortic Valve Replacement/methods MH - Treatment Outcome COIS- Declaration of interests EKe reports institutional research grants from Abbott Vascular Laboratories and Medtronic and proctor or lecture fees from Abbott Vascular. RSH reports lecture fees from Abbott Vascular, Amgen, Novartis, Edwards Lifesciences, and Meril. DvG reports lecture fees from Cardiovasculair Onderwijs Instituut. GA reports lecture fees from Medtronic, Abbott, and Meril Life, patents planned for Tdaflo, and being a data and safety monitoring board member for Vivasure. IJA-S reports proctor, lecture, and consultant fees from Medtronic, Boston Scientific, Meril Life, and Products&Features. MA reports institutional research grants from Edwards, Abbott, Medtronic, and LSI, and proctor, lecture, and consultant fees from Edwards Lifesciences, Abbott, Medtronic, Boston, Zoll, and BBraun. GB reports a consulting grant from Medtronic. LC reports consulting fees from Medtronic, Abbott, JenaValve, Edwards Lifesciences, BostonScientific, PiCardia, MicroPort, VenusMedtech, 4C Medical, Smartcanula, MicroInterventions, and Neovasc, support for attending meetings or travel (or both) from Medtronic, Abbott, JenaValve, Edwards Lifesciences, and BostonScientific, and being a data and safety monitoring board member for Medtronic, Abbott, and JenaValve. LvG reports proctor fees from Edwards Lifesciences and support for attending meetings or travel (or both) from Edwards Lifesciences, Corcym, and Atricure. WW reports lecture fees from Medtronic and is a data safety monitoring board member for Medtronic. VV reports consulting fees from Medtronic. JS reports lecture fees from Abiomed. EL reports institutional research grants from Abbott. LN-F reports consulting fees from Abbot, Edwards Lifesciences, and Boston, and proctor, lecture, and consultant fees from Abbott, Edwards Lifesciences, Medtronic, and Boston. All other authors declare no competing interests. EDAT- 2024/12/08 01:11 MHDA- 2024/12/22 00:28 CRDT- 2024/12/07 18:53 PHST- 2024/06/24 00:00 [received] PHST- 2024/08/21 00:00 [revised] PHST- 2024/09/19 00:00 [accepted] PHST- 2024/12/22 00:28 [medline] PHST- 2024/12/08 01:11 [pubmed] PHST- 2024/12/07 18:53 [entrez] AID - S0140-6736(24)02100-7 [pii] AID - 10.1016/S0140-6736(24)02100-7 [doi] PST - ppublish SO - Lancet. 2025 Dec 21;404(10471):2593-2602. doi: 10.1016/S0140-6736(24)02100-7. Epub 2024 Dec 4. PMID- 39634697 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241207 IS - 2369-8543 (Electronic) IS - 2369-8543 (Print) IS - 2369-8543 (Linking) VI - 9 IP - 2 DP - 2024 TI - Team-Based Learning & Point of Care Ultrasound (POCUS) to Augment a Preclinical Cardiovascular Physiology Course. PG - 80-87 LID - 10.24908/pocus.v9i2.17241 [doi] AB - Introduction: There has been increasing interest in point of care ultrasound (POCUS) as a learning tool in preclinical medical anatomy and physiology courses. Few interventions have used team-based learning (TBL) to teach cardiac POCUS. This study investigates a novel TBL exercise designed to integrate cardiac anatomy, physiology, and cardiac POCUS education within a first-year cardiovascular (CV) course called Team-Based Learning - Ultrasound (TBL-US). Methods: The TBL-US exercise consisted of four phases: preparation, individual and team readiness assurance, image acquisition and application, and knowledge assessment. Six second-year students were trained to facilitate the session under physician supervision. Pre- and post-session knowledge assessments were administered to determine knowledge acquisition. Pre- and post-session surveys were administered to assess attitudes, beliefs, and confidence surrounding cardiac POCUS. Final exam scores were compared between participants and non-participants of TBL-US and stratified into high- and low-performing subgroups to account for pre-TBL baseline differences in ability between the groups. Results: A total of 54 first-year medical students completed TBL-US. Students showed significant improvement on the post-knowledge assessment compared to the pre-knowledge assessment (70.5% vs. 54.9% [p< 0.001]) and scored significantly higher on the final CV exam compared to non-participants (low-performing group: 85.92% vs. 81.02% [p=0.039], high-performing group: 89.22% vs. 85.95% [p=0.038]). Between 43.3-72.7% of students reported that TBL-US increased their understanding of CV anatomy, physiology, and cardiac POCUS. Discussion: Students found TBL-US to be a valuable teaching modality and improved student knowledge of CV anatomy, physiology, and cardiac POCUS. TBL-US effectively augments the learning of cardiac anatomy and physiology during the preclinical undergraduate medical curriculum. CI - Copyright (c) 2024 Mark Danila MD, Cynthia Zheng MD, Ryan Salvatore MS, Rachel Cary , Sara Youssef MPH MBS, Grace Pinhal-Enfield PhD, Catherine Chen MD. FAU - Danila, Mark AU - Danila M AD - Department of Anesthesiology and Critical Care, Hospital of the University of Pennsylvania Philadelphia, PA USA. FAU - Zheng, Cynthia AU - Zheng C AD - Department of Medicine, The Warren Alpert Medical School of Brown University Providence, RI USA. FAU - Salvatore, Ryan J AU - Salvatore RJ AD - Rutgers Robert Wood Johnson Medical School Piscataway, NJ USA. FAU - Cary, Rachel AU - Cary R AD - Rutgers Robert Wood Johnson Medical School Piscataway, NJ USA. FAU - Youssef, Sara AU - Youssef S AD - Rutgers Robert Wood Johnson Medical School Piscataway, NJ USA. FAU - Pinhal-Eenfield, Grace AU - Pinhal-Eenfield G AD - Department of Neuroscience and Cell Biology, Rutgers Robert Wood Johnson Medical School Piscataway, NJ USA. FAU - Chen, Catherine AU - Chen C AD - Department of Medicine, Rutgers Robert Wood Johnson Medical School New Brunswick, NJ USA. LA - eng PT - Journal Article DEP - 20241115 PL - Canada TA - POCUS J JT - POCUS journal JID - 9918434088906676 PMC - PMC11616896 OTO - NOTNLM OT - Education OT - Flipped Classroom OT - Point of Care Echocardiography OT - Preclinical OT - Undergraduate Clerkship COIS- Ultrasound machines were provided by General Electric (GE) through the GE Healthcare Grants and Sponsorships - Ultrasound Initiatives Program. The authors declare that they have no competing interests. EDAT- 2024/12/05 11:21 MHDA- 2024/12/05 11:22 PMCR- 2024/11/15 CRDT- 2024/12/05 05:41 PHST- 2024/12/05 11:22 [medline] PHST- 2024/12/05 11:21 [pubmed] PHST- 2024/12/05 05:41 [entrez] PHST- 2024/11/15 00:00 [pmc-release] AID - 10.24908/pocus.v9i2.17241 [doi] PST - epublish SO - POCUS J. 2024 Nov 15;9(2):80-87. doi: 10.24908/pocus.v9i2.17241. eCollection 2024. PMID- 39628551 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241205 IS - 2297-055X (Print) IS - 2297-055X (Electronic) IS - 2297-055X (Linking) VI - 11 DP - 2024 TI - The role of pre-existing left-sided valvular heart disease in the prognosis of patients with acute myocardial infarction. PG - 1465723 LID - 10.3389/fcvm.2024.1465723 [doi] LID - 1465723 AB - Acute myocardial infarction (AMI) and valvular heart disease (VHD) are the leading causes of cardiovascular morbidity and mortality. The epidemiology of VHD has changed in recent decades with an aging population, increasing risk factors for cardiovascular disease and migration, all of which have a significant implifications for healthcare systems. Due to common pathophysiological mechanisms and risk factors, AMI and VHD often coexist. These patients have more complicated clinical characteristics, in-hospital course and outcomes, and are less likely to receive guideline-directed therapy. Because of the reciprocal negative pathophysiological influence, these patients need to be referred to VHD specialists and further discussed within the Heart team to assess the need for earlier intervention. Since the results of the number of studies show that one third of the patients are referred to the heart teams either too early or too late, there is a need to better define the communication networks between the treating physicians, including internists, general practitioners, outpatient cardiologists and heart teams, after the discharge of patients with pre-existing VHD and AMI. CI - (c) 2024 Muzafarova and Motovska. FAU - Muzafarova, Tamilla AU - Muzafarova T AD - Cardiocenter, Third Faculty of Medicine, Charles University and University Hospital Vinohrady, Prague, Czechia. FAU - Motovska, Zuzana AU - Motovska Z AD - Cardiocenter, Third Faculty of Medicine, Charles University and University Hospital Vinohrady, Prague, Czechia. LA - eng PT - Journal Article PT - Review DEP - 20241119 PL - Switzerland TA - Front Cardiovasc Med JT - Frontiers in cardiovascular medicine JID - 101653388 PMC - PMC11612903 OTO - NOTNLM OT - aortic stenosis OT - mitral regurgitation OT - myocardial infarction OT - outcome OT - prognosis COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2024/12/04 06:22 MHDA- 2024/12/04 06:23 PMCR- 2024/01/01 CRDT- 2024/12/04 04:35 PHST- 2024/07/16 00:00 [received] PHST- 2024/10/16 00:00 [accepted] PHST- 2024/12/04 06:23 [medline] PHST- 2024/12/04 06:22 [pubmed] PHST- 2024/12/04 04:35 [entrez] PHST- 2024/01/01 00:00 [pmc-release] AID - 10.3389/fcvm.2024.1465723 [doi] PST - epublish SO - Front Cardiovasc Med. 2024 Nov 19;11:1465723. doi: 10.3389/fcvm.2024.1465723. eCollection 2024. PMID- 39625188 OWN - NLM STAT- MEDLINE DCOM- 20241203 LR - 20241203 IS - 1827-1839 (Electronic) IS - 0392-9590 (Linking) VI - 43 IP - 5 DP - 2024 Oct TI - Organization of angiology in countries with associate societies of International Union of Angiology. PG - 548-552 LID - 10.23736/S0392-9590.24.05336-7 [doi] AB - Angiology is a multidisciplinary medical discipline, consequently in some countries multidisciplinary vascular centres were organized, which provide comprehensive management of patients with different vascular diseases. However, the organization of the care for vascular patients differs between the countries. Therefore, we aimed to check the organization of angiology (vascular surgery and vascular medicine) in countries-associate members of IUA and to stimulate the development of multidisciplinary vascular centres. The questionnaire was sent to 60 countries- associate members of IUA, and 35 societies from 30 countries responded. The responses showed that in most countries vascular patients are treated by vascular surgeons. Vascular surgeons and radiologists are also main providers of peripheral arterial diagnostics and invasive treatment. In most countries vascular medicine is marginalized. With the exception of some west European countries multidisciplinary vascular centres are rare and facilities for management of vascular patients insufficient. National societies expect from IUA more educational activities and creating consensus documents. Therefore, IUA should promote the foundation of vascular centres and provide systemic education in angiology. FAU - Poredos, Pavel AU - Poredos P AD - Department of Vascular Diseases, University Medical Center of Ljubljana, Ljubljana, Slovenia - peter.poredos@kclj.si. AD - Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia - peter.poredos@kclj.si. FAU - Antignani, Pier L AU - Antignani PL AD - Vascular Center, Nuova Villa Claudia, Rome, Italy. FAU - Poredos, Peter AU - Poredos P AD - Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia. AD - Department of Anesthesiology and Surgical Intensive Care, University Medical Center of Ljubljana, Ljubljana, Slovenia. FAU - Mansilha, Armando AU - Mansilha A AD - Faculty of Medicine, University of Porto, Porto, Portugal. AD - Department of Angiology and Vascular Surgery, Hospital de S. Joao, Porto, Portugal. LA - eng PT - Journal Article PL - Italy TA - Int Angiol JT - International angiology : a journal of the International Union of Angiology JID - 8402693 SB - IM MH - Humans MH - *Societies, Medical MH - Surveys and Questionnaires MH - *Vascular Surgical Procedures MH - Vascular Diseases/therapy/diagnosis MH - Cardiology MH - International Cooperation MH - Patient Care Team/organization & administration EDAT- 2024/12/03 12:27 MHDA- 2024/12/03 12:28 CRDT- 2024/12/03 08:05 PHST- 2024/12/03 12:28 [medline] PHST- 2024/12/03 12:27 [pubmed] PHST- 2024/12/03 08:05 [entrez] AID - S0392-9590.24.05336-7 [pii] AID - 10.23736/S0392-9590.24.05336-7 [doi] PST - ppublish SO - Int Angiol. 2024 Oct;43(5):548-552. doi: 10.23736/S0392-9590.24.05336-7. PMID- 39621640 OWN - NLM STAT- MEDLINE DCOM- 20241202 LR - 20261006 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 19 IP - 12 DP - 2024 TI - Development and internal validation of time-to-event risk prediction models for major medical complications within 30 days after elective colectomy. PG - e0314526 LID - 10.1371/journal.pone.0314526 [doi] LID - e0314526 AB - BACKGROUND: Patients undergoing colectomy are at risk of numerous major complications. However, existing binary risk stratification models do not predict when a patient may be at highest risks of each complication. Accurate prediction of the timing of complications facilitates targeted, resource-efficient monitoring. We sought to develop and internally validate Cox proportional hazards models to predict time-to-complication of major complications within 30 days after elective colectomy. METHODS: We studied a retrospective cohort from the multicentered American College of Surgeons National Surgical Quality Improvement Program procedure-targeted colectomy dataset. Patients aged 18 years or above, who underwent elective colectomy between January 1, 2014 and December 31, 2019 were included. A priori candidate predictors were selected based on variable availability, literature review, and multidisciplinary team consensus. Outcomes were mortality, hospital readmission, myocardial infarction, cerebral vascular events, pneumonia, venous thromboembolism, acute renal failure, and sepsis or septic shock within 30 days after surgery. RESULTS: The cohort consisted of 132145 patients (mean +/- SD age, 61 +/- 15 years; 52% females). Complication rates ranged between 0.3% (n = 383) for cardiac arrest and acute renal failure to 5.3% (n = 6986) for bleeding requiring transfusion, with readmission rate of 8.6% (n = 11415). We observed distinct temporal patterns for each complication: the median [quartiles] postoperative day of complication diagnosis ranged from 1 [0, 2] days for bleeding requiring transfusion to 12 [6, 18] days for venous thromboembolism. Models for mortality, myocardial infarction, pneumonia, and renal failure showed good discrimination with a concordance > 0.8, while models for readmission, venous thromboembolism, and sepsis performed poorly with a concordance of 0.6 to 0.7. Models exhibited good calibration but ranges were limited to low probability areas. CONCLUSIONS: We developed and internally validated time-to-event prediction models for complications after elective colectomy. Once further validated, the models can facilitate tailored monitoring of high risk patients during high risk periods. TRIAL REGISTRATION: Clinicaltrials.gov (NCT05150548; Principal Investigator: Janny Xue Chen Ke, M.D., M.Sc., F.R.C.P.C.; initial posting: November 25, 2021). CI - Copyright: (c) 2024 Ke et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. FAU - Ke, Janny X C AU - Ke JXC AUID- ORCID: 0000-0002-3121-9780 AD - Department of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, The University of British Columbia, Vancouver, British Columbia, Canada. AD - Department of Anesthesia, St. Paul's Hospital/Providence Health Care, Vancouver, British Columbia, Canada. FAU - Jen, Tim T H AU - Jen TTH AUID- ORCID: 0000-0002-6999-0458 AD - Department of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, The University of British Columbia, Vancouver, British Columbia, Canada. AD - Department of Anesthesia, St. Paul's Hospital/Providence Health Care, Vancouver, British Columbia, Canada. FAU - Gao, Sihaoyu AU - Gao S AUID- ORCID: 0000-0002-1319-4188 AD - Department of Statistics, Faculty of Science, The University of British Columbia, Vancouver, British Columbia, Canada. FAU - Ngo, Long AU - Ngo L AD - Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts, United States of America. AD - Division of General Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America. FAU - Wu, Lang AU - Wu L AD - Department of Statistics, Faculty of Science, The University of British Columbia, Vancouver, British Columbia, Canada. FAU - Flexman, Alana M AU - Flexman AM AD - Department of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, The University of British Columbia, Vancouver, British Columbia, Canada. AD - Department of Anesthesia, St. Paul's Hospital/Providence Health Care, Vancouver, British Columbia, Canada. FAU - Schwarz, Stephan K W AU - Schwarz SKW AUID- ORCID: 0000-0002-3584-1032 AD - Department of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, The University of British Columbia, Vancouver, British Columbia, Canada. AD - Department of Anesthesia, St. Paul's Hospital/Providence Health Care, Vancouver, British Columbia, Canada. FAU - Brown, Carl J AU - Brown CJ AD - Department of Surgery, Faculty of Medicine, The University of British Columbia, Vancouver, British Columbia, Canada. AD - Department of Surgery, St. Paul's Hospital/Providence Health Care, Vancouver, British Columbia, Canada. FAU - Gorges, Matthias AU - Gorges M AUID- ORCID: 0000-0003-2193-178X AD - Department of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, The University of British Columbia, Vancouver, British Columbia, Canada. AD - BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada. LA - eng SI - ClinicalTrials.gov/NCT05150548 PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Validation Study DEP - 20241202 PL - United States TA - PLoS One JT - PloS one JID - 101285081 SB - IM MH - Aged MH - Female MH - Humans MH - Male MH - Middle Aged MH - *Colectomy/adverse effects MH - *Elective Surgical Procedures/adverse effects MH - Patient Readmission/statistics & numerical data MH - *Postoperative Complications/etiology/epidemiology MH - Proportional Hazards Models MH - Retrospective Studies MH - Risk Assessment/methods MH - Risk Factors MH - Time Factors MH - Observational Studies as Topic PMC - PMC11611139 COIS- We have read the journal's policy and the authors of this manuscript have the following declarations. This does not alter our adherence to PLOS ONE policies on sharing data and materials. The funders below did not contribute to this project, and this project has no relation with the projects below. Dr. Janny Ke received salary support as the Clinical Data Lead, St. Paul's Hospital, Vancouver, BC, Canada, for the project "Reducing Opioid Use for Pain Management" DIGITAL, Canada's Global Innovation Cluster for digital technologies, and a project consortium from commercial funders (Careteam Technologies Inc, Thrive Health Inc, Excelar Technologies (Connected Displays Inc), Providence Health Care Ventures Inc, and Xerus Inc [now part of Excelar]). Dr. Ke provided paid consulting for commercial funder Careflow Technologies (Connected Displays Inc), funded via Providence Health Care Ventures (Vancouver, BC, Canada). Dr. Ke receives research and salary support for Project "Continuous Connected Patient Care", funded by DIGITAL and a project consortium of commercial funders (Medtronic Canada ULC, Cloud Diagnostics Canada ULC, Excelar Technologies [Connected Displays Inc.], Providence Health Care Ventures Inc, 3D Bridge Solutions Inc, and FluidAI [NERv Technology Inc.]). Dr. Stephan K. W. Schwarz is the Editor-in-Chief of the Canadian Journal of Anesthesia and holds the Dr. Jean Templeton Hugill Chair in Anesthesia, supported by the Dr. Jean Templeton Hugill Endowment for Anesthesia Memorial Fund at The University of British Columbia (Vancouver, BC, Canada). He gratefully receives academic support from the Department of Anesthesia, St. Paul's Hospital/Providence Health Care (Vancouver, BC, Canada). Dr. Matthias Gorges holds a Michael Smith Health Research BC scholar award, is supported by a 2020 BC Children's Hospital Research Institute External Salary Recognition Award, and was the research lead for the "Reducing Opioid Use for Pain Management" DIGITAL project consortium (see above for commercial funders). Dr. Alana Flexman declares consultant fees from Wolter Kluwer (Up To Date), research salary support from Michael Smith Health Research BC and operational research support from commercial funder Eisai, Inc. There is no other employment, consultancy, patents, products in development, or marketed products from commercial entities. EDAT- 2024/12/02 18:28 MHDA- 2024/12/02 18:29 PMCR- 2024/12/02 CRDT- 2024/12/02 13:42 PHST- 2024/06/12 00:00 [received] PHST- 2024/11/12 00:00 [accepted] PHST- 2024/12/02 18:29 [medline] PHST- 2024/12/02 18:28 [pubmed] PHST- 2024/12/02 13:42 [entrez] PHST- 2024/12/02 00:00 [pmc-release] AID - PONE-D-24-22778 [pii] AID - 10.1371/journal.pone.0314526 [doi] PST - epublish SO - PLoS One. 2024 Dec 2;19(12):e0314526. doi: 10.1371/journal.pone.0314526. eCollection 2024. PMID- 39621157 OWN - NLM STAT- MEDLINE DCOM- 20241202 LR - 20261010 IS - 1432-1750 (Electronic) IS - 0341-2040 (Linking) VI - 203 IP - 1 DP - 2024 Dec 2 TI - Holter Monitoring and Cardiac Biomarkers in Screening for Cardiac Sarcoidosis. PG - 10 LID - 10.1007/s00408-024-00772-5 [doi] AB - INTRODUCTION: Early detection of cardiac sarcoidosis (CS) is crucial due to its association with severe complications such as ventricular arrhythmias, heart failure, and sudden cardiac death. Advanced imaging techniques like cardiac magnetic resonance imaging (CMR) and 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG-PET/CT) are effective in detecting CS but not easily accessible. The optimal method for selecting patients for advanced screening remains uncertain. METHODS: In this retrospective cohort study, all extracardiac sarcoidosis patients screened for CS were reviewed. CS was defined as a multidisciplinary team (MDT) consensus diagnosis. Univariate and multivariate binary logistic regressions were used to identify factors associated with CS, assessing their diagnostic performance, and integrating them into a diagnostic model. RESULTS: Out of 354 patients (average age 51.5 years, 52.5% male), 18.4% were diagnosed with CS. In our cohort, male gender, a QRS duration > 120 ms, and nsVT on Holter monitoring were identified as significant markers associated with CS. Combining age, gender, AV-block or QRS > 120ms on ECG, and nsVT on Holter monitoring provided the highest diagnostic accuracy (AUC of 0.82). Cardiac biomarkers NT-proBNP and troponin T did not improve the diagnostic performance. CONCLUSION: In our cohort, male gender, a QRS duration > 120 ms, and nsVT on Holter monitoring were identified as significant markers associated with the presence of cardiac sarcoidosis. These clinical markers may aid in selecting sarcoidosis patients for screening with advanced cardiac imaging, potentially leading to earlier detection and management of the disease. CI - (c) 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Bakker, A L M AU - Bakker ALM AUID- ORCID: 0009-0006-3625-8064 AD - Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands. abakker3@amphia.nl. AD - Department of Cardiology Amphia Hospital, Breda, The Netherlands. abakker3@amphia.nl. FAU - Mathijssen, H AU - Mathijssen H AD - Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands. FAU - Huitema, M P AU - Huitema MP AD - Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands. FAU - Kapteijns, L AU - Kapteijns L AD - Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands. FAU - Grutters, J C AU - Grutters JC AD - ILD Center of Excellence, Member of European Reference Network-Lung, St Antonius Hospital, Nieuwegein, The Netherlands. AD - Division of Heart and Lungs, University Medical Center Utrecht, Utrecht, The Netherlands. FAU - Veltkamp, M AU - Veltkamp M AD - ILD Center of Excellence, Member of European Reference Network-Lung, St Antonius Hospital, Nieuwegein, The Netherlands. AD - Division of Heart and Lungs, University Medical Center Utrecht, Utrecht, The Netherlands. FAU - Keijsers, R G AU - Keijsers RG AD - Department of Nuclear Medicine, St Antonius Hospital, Nieuwegein, The Netherlands. FAU - Akdim, F AU - Akdim F AD - Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands. FAU - van Es, H W AU - van Es HW AD - Department of Radiology, St Antonius Hospital, Nieuwegein, The Netherlands. FAU - Peper, J AU - Peper J AD - Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands. FAU - Post, M C AU - Post MC AD - Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands. AD - Division of Heart and Lungs, University Medical Center Utrecht, Utrecht, The Netherlands. LA - eng PT - Journal Article DEP - 20241202 PL - United States TA - Lung JT - Lung JID - 7701875 RN - 0 (Biomarkers) RN - 114471-18-0 (Natriuretic Peptide, Brain) RN - 0 (Troponin T) RN - 0 (pro-brain natriuretic peptide (1-76)) RN - 0 (Peptide Fragments) SB - IM MH - Humans MH - Male MH - Female MH - Middle Aged MH - *Sarcoidosis/diagnosis/blood/complications MH - *Cardiomyopathies/diagnosis/blood MH - *Electrocardiography, Ambulatory MH - Retrospective Studies MH - *Biomarkers/blood MH - *Natriuretic Peptide, Brain/blood MH - *Troponin T/blood MH - Adult MH - Peptide Fragments/blood MH - Sex Factors MH - Aged MH - Early Diagnosis MH - Predictive Value of Tests MH - Tachycardia, Ventricular/diagnosis OTO - NOTNLM OT - Cardiac biomarkers OT - Cardiac sarcoidosis OT - Holter monitoring OT - Screening COIS- Declarations. Conflict of interest: The authors declare no competing interests. EDAT- 2024/12/02 12:32 MHDA- 2024/12/02 12:33 CRDT- 2024/12/02 11:17 PHST- 2024/08/11 00:00 [received] PHST- 2024/11/14 00:00 [accepted] PHST- 2024/12/02 12:33 [medline] PHST- 2024/12/02 12:32 [pubmed] PHST- 2024/12/02 11:17 [entrez] AID - 10.1007/s00408-024-00772-5 [pii] AID - 10.1007/s00408-024-00772-5 [doi] PST - epublish SO - Lung. 2024 Dec 2;203(1):10. doi: 10.1007/s00408-024-00772-5. PMID- 39615540 OWN - NLM STAT- MEDLINE DCOM- 20241130 LR - 20260813 IS - 1940-8250 (Electronic) IS - 0279-5442 (Linking) VI - 44 IP - 6 DP - 2024 Dec 1 TI - Improving Cardiogenic Shock Team Activation Through Nurse Education and Alert Implementation. PG - 24-30 LID - 10.4037/ccn2024259 [doi] AB - BACKGROUND: Patients with cardiogenic shock have a 25% to 50% mortality rate despite the introduction of mechanical circulatory devices and coordinated medical treatment. The use of shock teams has improved outcomes for these patients. LOCAL PROBLEM: A cardiovascular hospital with a multidisciplinary shock team had inconsistency and delays in recognition and diagnosis of patients with cardiogenic shock. METHODS: A nurse-led, preintervention-postintervention quality improvement project was performed in April and May 2021 and in April and May 2022 within a cardiovascular hospital in north Texas. The 2 nursing staff interventions regarding shock team activation were education and shock alert implementation. Time from first signs to diagnosis (for inpatients) and time from initial transfer request to acceptance (for transferring patients) were measured. Descriptive and statistical analyses were conducted using R, version 4.0.0 (R Foundation for Statistical Computing). RESULTS: The mean (SD) time to diagnosis of cardiogenic shock decreased significantly from 17.98 (28.39) hours in the preintervention group (n = 25) to 8.15 (12.26) hours in the postintervention group (n = 45; P = .045). For patients with cardiogenic shock transferring from referring hospitals, the median (IQR) time to acceptance was 1.55 (0.08-3.18) hours in the preintervention group and 0.35 (0.00-0.72) hours in the postintervention group (P < .001). CONCLUSIONS: Nursing staff interventions regarding shock team activation significantly improved the time of diagnosis and acceptance of patients with cardiogenic shock in a cardiovascular hospital, enhancing the overall quality of care provided to these patients. CI - (c)2024 American Association of Critical-Care Nurses. FAU - Krais, Suzanne AU - Krais S AD - Suzanne Krais is the chief nursing officer and vice president of patient care services at Baylor Scott & White Heart Hospital-Plano, Texas. FAU - Sheasby, Jenelle AU - Sheasby J AD - Jenelle Sheasby is an extracorporeal membrane oxygenation coordinator and cardiogenic shock coordinator at Baylor Scott & White Heart Hospital-Plano. FAU - Banwait, Jasjit AU - Banwait J AD - Jasjit Banwait is a biostatistician at Baylor Scott & White Research Institute, Dallas, Texas. FAU - Lewis, Natalie AU - Lewis N AD - Natalie Lewis is the assistant to the chief nursing officer at Baylor Scott & White Heart Hospital-Plano. FAU - Liu, Zhaoli AU - Liu Z AD - Zhaoli Liu is an advanced practice nurse and an assistant professor, College of Nursing and Health Innovation, the University of Texas at Arlington. LA - eng PT - Journal Article PL - United States TA - Crit Care Nurse JT - Critical care nurse JID - 8207799 SB - IM MH - Humans MH - *Shock, Cardiogenic/nursing/therapy MH - Female MH - Texas MH - Male MH - *Quality Improvement MH - Middle Aged MH - *Patient Care Team/standards MH - Aged MH - Adult MH - Critical Care Nursing/education/standards MH - Nursing Staff, Hospital/education MH - Aged, 80 and over EDAT- 2024/12/01 15:22 MHDA- 2024/12/01 15:23 CRDT- 2024/11/30 19:12 PHST- 2024/12/01 15:23 [medline] PHST- 2024/12/01 15:22 [pubmed] PHST- 2024/11/30 19:12 [entrez] AID - 32586 [pii] AID - 10.4037/ccn2024259 [doi] PST - ppublish SO - Crit Care Nurse. 2024 Dec 1;44(6):24-30. doi: 10.4037/ccn2024259. PMID- 39611751 OWN - NLM STAT- MEDLINE DCOM- 20250416 LR - 20260127 IS - 1535-2900 (Electronic) IS - 1079-2082 (Linking) VI - 82 IP - 7 DP - 2025 Apr 16 TI - Outcomes of a multidisciplinary approach to management of mavacamten in obstructive hypertrophic cardiomyopathy. PG - e384-e390 LID - 10.1093/ajhp/zxae372 [doi] AB - PURPOSE: Traditional treatments for obstructive hypertrophic cardiomyopathy (oHCM) include beta-blockers, calcium channel blockers, and disopyramide. Mavacamten, a novel cardiac myosin inhibitor, is a promising oHCM therapy but has practical challenges limiting its use. This descriptive study aimed to describe a clinic workflow for mavacamten management in a real-world setting, addressing challenges such as cost, drug interactions, and monitoring requirements. The focus was on reducing patient-level costs while ensuring feasibility and efficiency. SUMMARY: A retrospective analysis was conducted on 34 patients with oHCM for whom mavacamten was considered between May 2022 and May 2023. The clinic workflow involved cardiologist assessment, pharmacist evaluation of drug interactions, enrollment in the mavacamten risk evaluation and mitigation strategy program, cost reduction measures, and initiation of monitoring through scheduled echocardiograms. Of the 34 patients, 21 (62%) were initiated on mavacamten and followed for up to 1 year on therapy. The median time from referral to prior authorization approval and first fill was 5 and 22 days, respectively. Patients demonstrated high adherence (99.1%) as measured by the proportion of days covered. Echocardiogram follow-up showed improvements in left ventricular outflow tract parameters with no patients having a decrease in left ventricular ejection fraction to less than 50%. CONCLUSION: The described workflow effectively addressed challenges associated with mavacamten management, emphasizing roles for clinic personnel, cost reduction strategies, and structured patient monitoring. While the workflow's specifics may need adaptation in different settings, this report provides valuable insights for clinics implementing structured mavacamten management approaches. CI - (c) American Society of Health-System Pharmacists 2024. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com. FAU - Jensen, Hanna AU - Jensen H AD - Department of Pharmacy, UC San Diego Health, San Diego, CA, USA. FAU - Yousif, Zaid AU - Yousif Z AD - UC San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, CA, USA. FAU - Huynh, Trina AU - Huynh T AD - Department of Pharmacy, UC San Diego Health, San Diego, CA, USA. FAU - Kraushaar, Megan AU - Kraushaar M AD - Division of Cardiovascular Medicine, Department of Medicine, UC San Diego Health, San Diego, CA, USA. FAU - Reed, Marcy AU - Reed M AD - Division of Cardiovascular Medicine, Department of Medicine, UC San Diego Health, San Diego, CA, USA. FAU - Boarman, Trista AU - Boarman T AD - Division of Cardiovascular Medicine, Department of Medicine, UC San Diego Health, San Diego, CA, USA. FAU - Enciso, Jorge Silva AU - Enciso JS AD - Division of Cardiovascular Medicine, Department of Medicine, UC San Diego Health, San Diego, CA, USA. FAU - Willeford, Andrew AU - Willeford A AD - UC San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, CA, USA. LA - eng PT - Journal Article PL - England TA - Am J Health Syst Pharm JT - American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists JID - 9503023 RN - 0 (MYK-461) RN - OF5P57N2ZX (Alanine) RN - 0 (Sulfonamides) RN - 0 (Benzylamines) RN - 56HH86ZVCT (Uracil) SB - IM MH - Humans MH - *Cardiomyopathy, Hypertrophic/drug therapy/economics MH - Retrospective Studies MH - Male MH - Female MH - Middle Aged MH - Aged MH - *Alanine/analogs & derivatives/therapeutic use/economics MH - Workflow MH - Treatment Outcome MH - Pharmacists/organization & administration MH - *Patient Care Team/organization & administration MH - Drug Interactions MH - *Sulfonamides/therapeutic use/economics MH - Benzylamines MH - Uracil/analogs & derivatives OTO - NOTNLM OT - MYK-461 OT - hypertrophic cardiomyopathy OT - patient care team OT - workflow EDAT- 2024/11/29 12:22 MHDA- 2025/04/17 00:24 CRDT- 2024/11/29 10:03 PHST- 2025/04/17 00:24 [medline] PHST- 2024/11/29 12:22 [pubmed] PHST- 2024/11/29 10:03 [entrez] AID - 7913356 [pii] AID - 10.1093/ajhp/zxae372 [doi] PST - ppublish SO - Am J Health Syst Pharm. 2025 Apr 16;82(7):e384-e390. doi: 10.1093/ajhp/zxae372. PMID- 39610582 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241130 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 16 IP - 10 DP - 2024 Oct TI - Cardiovascular Findings in Klippel-Feil Syndrome: A Systematic Review. PG - e72540 LID - 10.7759/cureus.72540 [doi] LID - e72540 AB - Klippel-Feil syndrome (KFS) is a congenital disease defined by an abnormal fusion between cervical vertebrae. Due to the rarity of the disorder, its prevalence, along with its pathogenesis and associated conditions, remains to be clearly defined. The aim of this review is to summarize the findings of all case reports of KFS in PubMed over the last 10 years that describe cardiovascular disease, defects, or abnormalities. A total of 43 articles containing 46 reports were included from the 157 case reports considered. Cases were reviewed for commonality in biological sex and vertebral fusion and level using the Samartzis classification system to determine what association, if any, exists with the cardiovascular findings analyzed. A total of 72% of cases reported one or more findings consistent with congenital heart disease. Using the Samartzis classification system, type III KFS was the most common fusion profile overall in this subset of patients. The heterogeneity of disease manifestations makes the treatment and management of KFS case-dependent, though current guidelines highlight the importance of a multidisciplinary care team for pediatric patients. Our findings support this notion and provide evidence for the inclusion of a care provider who specializes in cardiovascular medicine in patients of all ages, as well as the consideration of additional diagnostic screening exams for cardiovascular abnormalities. Future studies into the embryological origin of KFS and a more robust search for a genetic marker are needed to better understand the development of the disease and its various associated conditions. CI - Copyright (c) 2024, Niewchas et al. FAU - Niewchas, Abbigail AU - Niewchas A AD - Medical School, Kansas City University of Medicine and Biosciences, Joplin, USA. FAU - Alkhatib, Salma AU - Alkhatib S AD - Medical School, Kansas City University of Medicine and Biosciences, Joplin, USA. FAU - Stewart, Christopher AU - Stewart C AD - Medical School, Kansas City University of Medicine and Biosciences, Joplin, USA. FAU - Fisher, Mitchell AU - Fisher M AD - Medical School, Kansas City University of Medicine and Biosciences, Joplin, USA. FAU - Hansen, Randall AU - Hansen R AD - Otolaryngology, Head and Neck Surgery, Freeman Health System, Joplin, USA. FAU - Otto, Alex L AU - Otto AL AD - Otolaryngology, Head and Neck Surgery, Freeman Health System, Joplin, USA. FAU - McIntire, Kent AU - McIntire K AD - Otolaryngology, Head and Neck Surgery, Freeman Health System, Joplin, USA. FAU - Sukpraprut-Braaten, Suporn AU - Sukpraprut-Braaten S AD - Graduate Medical Education, Unity Health, Searcy, USA. AD - Graduate Medical Education, Kansas City University, Kansas City, USA. LA - eng PT - Journal Article PT - Review DEP - 20241028 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC11602407 OTO - NOTNLM OT - cardiac OT - cardiovascular OT - congenital heart defect OT - kfs OT - klippel-feil syndrome COIS- Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Intellectual property info: The American Board of Internal Medicine (ABIM) granted permission to adapt the cardiovascular disease examination blueprint into a table for this article. Relevant information can be found in the "Copyright and Examination Nondisclosure Information" listed under the table. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. EDAT- 2024/11/29 06:22 MHDA- 2024/11/29 06:23 PMCR- 2024/10/28 CRDT- 2024/11/29 04:17 PHST- 2024/09/24 00:00 [received] PHST- 2024/10/25 00:00 [accepted] PHST- 2024/11/29 06:23 [medline] PHST- 2024/11/29 06:22 [pubmed] PHST- 2024/11/29 04:17 [entrez] PHST- 2024/10/28 00:00 [pmc-release] AID - 10.7759/cureus.72540 [doi] PST - epublish SO - Cureus. 2024 Oct 28;16(10):e72540. doi: 10.7759/cureus.72540. eCollection 2024 Oct. PMID- 39604607 OWN - NLM STAT- MEDLINE DCOM- 20250426 LR - 20260714 IS - 1573-7322 (Electronic) IS - 1382-4147 (Print) IS - 1382-4147 (Linking) VI - 30 IP - 2 DP - 2025 Mar TI - Hyperkalemia management: a multidisciplinary expert panel's perspective on the role of new potassium binders. PG - 271-286 LID - 10.1007/s10741-024-10461-3 [doi] AB - Hyperkalemia is a potentially life-threatening condition frequently encountered in clinical practice, particularly among patients with chronic kidney disease, heart failure, diabetes, and hypertension and those undergoing treatment with renin-angiotensin-aldosterone system inhibitors (RAASi). The management of chronic and acute hyperkalemia is complex and requires timely intervention to prevent severe complications such as cardiac arrhythmias and sudden death. Traditional therapeutic approaches to chronic hyperkalemia, including dietary potassium restriction, use of diuretics, and administration of cation-exchange resins like sodium polystyrene sulfonate, often suffer from limitations like gastrointestinal side effects, variable efficacy, delayed onset of action, and RAASi treatment discontinuation. In recent years, the development of new potassium binders, specifically patiromer and sodium zirconium cyclosilicate (SZC), has revolutionized the management of hyperkalemia. Patiromer, a non-absorbed polymer, binds potassium in the gastrointestinal tract in exchange for calcium, thus facilitating its excretion. SZC operates by exchanging sodium and hydrogen ions for potassium, leading to efficient potassium removal. Both agents have demonstrated rapid and sustained reductions in serum potassium levels, coupled with favorable safety and tolerability profiles, in multiple clinical trials. This review article, authored by a multidisciplinary group of Portuguese experts in hyperkalemia management, provides an in-depth analysis of the efficacy and safety of current therapeutic strategies and highlights the clinical potential of new potassium binders. The introduction of patiromer and SZC offers significant advantages over traditional therapies, providing effective and better-tolerated options for patients. The review highlights the role of these novel agents in contemporary hyperkalemia management and calls for ongoing research to further refine treatment protocols and improve patient outcomes. CI - (c) 2024. The Author(s). FAU - Fonseca, Candida AU - Fonseca C AUID- ORCID: 0000-0003-3019-5956 AD - Heart Failure Clinic, Department of Internal Medicine, Unidade Local de Saude Lisboa Ocidental (ULSLO), Lisbon, Portugal. mcandidafonseca@gmail.com. AD - NOVA Medical School, Faculdade de Ciencias Medicas, Universidade Nova de Lisboa, Lisbon, Portugal. mcandidafonseca@gmail.com. FAU - Garagarza, Cristina AU - Garagarza C AD - Department of Nutrition, Nephrocare, 1750-233, Lisbon, Portugal. AD - Faculty of Medicine, University of Lisbon, 1649-028, Lisbon, Portugal. FAU - Silva, Gil AU - Silva G AD - SESARAM, Department of Nephrology, 9004-514, Funchal, Madeira, Portugal. FAU - Caires, Graca AU - Caires G AD - SESARAM, Department of Cardiology, 9004-514, Funchal, Madeira, Portugal. FAU - Marques, Irene AU - Marques I AD - Department of Internal Medicine, Hospital de Santo Antonio, Unidade Local de Saude Santo Antonio, 4099-001, Porto, Portugal. AD - Unidade Multidisciplinar de Investigacao Biomedica (UMIB) - Instituto de Ciencias Biomedicas de Abel Salazar (ICBAS), University of Porto, 4050-313, Porto, Portugal. FAU - Lopes, Jose Antonio AU - Lopes JA AD - Faculty of Medicine, University of Lisbon, 1649-028, Lisbon, Portugal. AD - Department of Nephrology and Kidney Transplantation, Unidade Local de Saude Santa Maria, 1649-035, Lisbon, Portugal. FAU - Branco, Patricia AU - Branco P AD - Department of Nephrology, Hospital Beatriz Angelo, Unidade Local de Saude de Loures-Odivelas, 2674-514, Loures, Portugal. FAU - Alves, Rui AU - Alves R AD - Department of Nephrology, Unidade Local de Saude Coimbra, 3004-561, Coimbra, Portugal. AD - Faculty of Medicine, University of Coimbra, 3000-548, Coimbra, Portugal. FAU - Ferreira, Anibal AU - Ferreira A AD - NOVA Medical School, Faculdade de Ciencias Medicas, Universidade Nova de Lisboa, Lisbon, Portugal. AD - Department of Nephrology, Hospital Curry Cabral, Unidade Local de Saude Sao Jose, Lisbon, Portugal. LA - eng PT - Journal Article PT - Review DEP - 20241127 PL - United States TA - Heart Fail Rev JT - Heart failure reviews JID - 9612481 RN - 1FQ2RY5YHH (patiromer) RN - D652ZWF066 (sodium zirconium cyclosilicate) RN - 0 (Silicates) RN - 0 (Polymers) RN - RWP5GA015D (Potassium) RN - 0 (Polyamines) RN - 0 (Chelating Agents) SB - IM MH - Humans MH - *Hyperkalemia/drug therapy/blood/etiology MH - *Silicates/therapeutic use/pharmacology MH - *Polymers/therapeutic use/pharmacology MH - *Potassium/blood MH - *Polyamines/therapeutic use/pharmacology MH - *Chelating Agents/therapeutic use MH - Disease Management PMC - PMC11802687 OTO - NOTNLM OT - Chronic kidney disease OT - Heart failure OT - Hyperkalemia OT - Patiromer OT - RAASi therapy OT - Sodium zirconium cyclosilicate COIS- Declarations. Ethics approval: Not applicable. Consent for publication: All the authors have read and approved the final version of the manuscript and gave their consent for publication. Competing interests: C.F received consultancy fees, lectures, or sponsorship of scientific meetings from AstraZeneca, Bayer, Bial, Boehringer Ingelheim, Novartis, Novo Nordisk, Pfizer, Roche Diagnosis, Servier, CSL Vifor, companies that research and commercialize drugs for the treatment of heart failure patients. G.C. received speaking fees from Servier, Novartis, CSL Vifor, and Boehringer. C.G. is employed by Fresenius Medical Care as Head of the Nutrition Department. G.S. received speaking fees from CSL Vifor, AstraZeneca, Alnylam and Baxter. I.M. received speaking fees from AstraZeneca, Bayer, Bial, CSL Vifor, Daiichi-Sankyo, Novartis, Pfizer, Roche Diagnostics, and Servier. I.M. served on advisory boards for AstraZeneca, Bayer, Bial, CSL Vifor, Novartis, Novo Nordisk, and Servier. A.F. received Advisory Board and consultancy fees, lectures, or sponsorship of scientific meetings from AstraZeneca, Astellas, CSL Vifor, Fresenius Medical Care, MSD-Merck Sharp & Dohme companies. EDAT- 2024/11/28 06:34 MHDA- 2025/02/06 12:21 PMCR- 2024/11/27 CRDT- 2024/11/28 03:05 PHST- 2024/10/21 00:00 [accepted] PHST- 2025/02/06 12:21 [medline] PHST- 2024/11/28 06:34 [pubmed] PHST- 2024/11/28 03:05 [entrez] PHST- 2024/11/27 00:00 [pmc-release] AID - 10.1007/s10741-024-10461-3 [pii] AID - 10461 [pii] AID - 10.1007/s10741-024-10461-3 [doi] PST - ppublish SO - Heart Fail Rev. 2025 Mar;30(2):271-286. doi: 10.1007/s10741-024-10461-3. Epub 2024 Nov 27. PMID- 39599631 OWN - NLM STAT- MEDLINE DCOM- 20241127 LR - 20241130 IS - 2072-6643 (Electronic) IS - 2072-6643 (Linking) VI - 16 IP - 22 DP - 2024 Nov 10 TI - Nutritional, Metabolic, and Inflammatory Alterations in Children with Chylous Effusion in the Postoperative Period of Cardiac Surgery: A Descriptive Cohort. LID - 10.3390/nu16223845 [doi] LID - 3845 AB - OBJECTIVE: The occurrence of chylous effusion in children undergoing cardiac surgery is progressively increasing due to technical advances that have led to a rise in the number of surgeries. In this context, the objective was to describe the clinical profile of a cohort of patients at the time of chylous effusion diagnosis. METHODS: A retrospective cohort analysis was conducted between January 2011 and July 2023, involving 23 patients, aged 0 to 18 years, treated at a quaternary university hospital in southeastern Brazil. Data were obtained from the follow-up records of the Multidisciplinary Nutritional Therapy Team (MNTT) for patients who received nutritional support after developing chylous effusion in the postoperative period of cardiac surgery. RESULTS: The younger population predominated (median age of 6 months), with a high prevalence of malnutrition (60.9%). At the time of chylous effusion diagnosis, 83% had lymphopenia, and 74% had hypoalbuminemia. The longer the time elapsed after surgery for the onset of chylous effusion, the lower the HDL cholesterol, the lower the albumin levels, the greater the surgical complexity, the younger the patient, and the lower their weight. Hypocalcemia occurred in nearly half of the sample and hypophosphatemia in 26% of the analyzed cases. CONCLUSIONS: There was a notable presence of lymphopenia, hypoalbuminemia, and low HDL cholesterol, as well as a high incidence of mineral imbalances, particularly hypocalcemia and hypophosphatemia, which, if untreated, may lead to unfavorable outcomes. Therefore, clinical and laboratory monitoring of children in the postoperative period of cardiac surgery is important and can aid in the early diagnosis of chylous effusion and, consequently, in the timely initiation of treatment. FAU - Silva, Sidney V AU - Silva SV AD - Department of Pediatrics, State University of Campinas (UNICAMP), Campinas 13083-970, Brazil. FAU - Hortencio, Tais D R AU - Hortencio TDR AD - Medicine Department, Sao Leopoldo Mandic Faculty, Campinas 13045-755, Brazil. FAU - Teles, Lidiane O S AU - Teles LOS AD - Multidisciplinary Nutritional Therapy Team, State University of Campinas (UNICAMP), Campinas 13083-970, Brazil. FAU - Esteves, Alexandre L AU - Esteves AL AD - Multidisciplinary Nutritional Therapy Team, State University of Campinas (UNICAMP), Campinas 13083-970, Brazil. FAU - Nogueira, Roberto J N AU - Nogueira RJN AUID- ORCID: 0000-0002-4833-3571 AD - Medical Clinical Department, State University of Campinas (UNICAMP), Campinas 13083-970, Brazil. LA - eng PT - Journal Article DEP - 20241110 PL - Switzerland TA - Nutrients JT - Nutrients JID - 101521595 SB - IM MH - Humans MH - Infant MH - Child, Preschool MH - Male MH - Female MH - *Cardiac Surgical Procedures/adverse effects MH - Retrospective Studies MH - Child MH - *Postoperative Complications/epidemiology/etiology MH - Adolescent MH - Brazil/epidemiology MH - Infant, Newborn MH - Postoperative Period MH - Hypoalbuminemia/epidemiology/etiology MH - Chylothorax/etiology/epidemiology MH - Nutritional Status MH - Malnutrition/epidemiology/diagnosis/etiology MH - Lymphopenia/etiology/epidemiology MH - Hypocalcemia/epidemiology/etiology MH - Nutritional Support MH - Inflammation MH - Cohort Studies PMC - PMC11597181 OTO - NOTNLM OT - cardiac surgery OT - children OT - chylothorax OT - chylous effusion COIS- The authors declare no conflicts of interest. EDAT- 2024/11/27 06:19 MHDA- 2024/11/27 06:20 PMCR- 2024/11/10 CRDT- 2024/11/27 01:42 PHST- 2024/10/15 00:00 [received] PHST- 2024/11/01 00:00 [revised] PHST- 2024/11/06 00:00 [accepted] PHST- 2024/11/27 06:20 [medline] PHST- 2024/11/27 06:19 [pubmed] PHST- 2024/11/27 01:42 [entrez] PHST- 2024/11/10 00:00 [pmc-release] AID - nu16223845 [pii] AID - nutrients-16-03845 [pii] AID - 10.3390/nu16223845 [doi] PST - epublish SO - Nutrients. 2024 Nov 10;16(22):3845. doi: 10.3390/nu16223845. PMID- 39598138 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241130 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 13 IP - 22 DP - 2024 Nov 20 TI - Evaluating a New Short Self-Management Tool in Heart Failure Against the Traditional Flinders Program. LID - 10.3390/jcm13226994 [doi] LID - 6994 AB - Background/Objective: Heart failure (HF) is a complex syndrome, with multiple causes. Numerous pathophysiological pathways are activated. Comprehensive and guideline-derived care is complex. A multidisciplinary approach is required. The current guidelines report little evidence for chronic disease self-management (CDSM) programs for reducing readmission and major adverse cardiovascular events (MACE). CDSM programs can be complex and are not user-friendly in clinical settings, particularly for vulnerable patients. The aim of this study was to investigate whether a simplified one-page CDSM tool, the SCReening in Heart Failure (SCRinHF), is comparable to a comprehensive Flinders Program of Chronic Disease Management, specifically in triaging self-management capabilities and in predicting readmission and MACE. Methods:SELFMAN-HF is a prospective, observational study based on community cardiology. Eligible patients, consecutively recruited, had HF with left ventricular ejection fraction <40% and were placed on sodium-glucose co-transporter-2 inhibitors (SGLT2-i) within 3 months of recruitment. SGLT2-i is the newest of the four HF treatment pillars; self-management skills are assessed at this juncture. CDSM was assessed and scored independently via the long-form (LF) and short-form (SF) tools, and concordance between forms was estimated. The primary endpoint is the 80% concordance across the two CDSM scales for predicting hospital readmission and MACE. Results: Of the 117 patients, aged 66.8 years (+/-SD 13.5), 88 (75%) were male. The direct comparisons for SF versus LF patient scores are as follows: "good self-managers", 13 vs. 30 patients (11.1% vs. 25.6%); "average", 46 vs. 21 patients (39.3% vs. 17.9%), "borderline", 20 vs. 31 patients (17.1% vs. 26.5%), and "poor self-managers" (vulnerable), 38 vs. 35 patients (32.5% vs. 29.9%). These findings underscore the possibility of SF tools in picking up patients whose scores infer poor self-management capabilities. This concordance of the SF with the LF scores for patients who have poor self-management capabilities (38 vs. 35 patients p = 0.01), alongside readmission (31/38 vs. 31/35 p = 0.01) or readmission risk for poor self-managers versus good self-managers (31/38 vs. 5/13 p = 0.01), validates the simplification of the CDSM tools for the vulnerable population with HF. Similarly, when concurrent and predictive validity was tested on 52 patients, the results were 39 (75%) for poor self-managers and 14 (27%) for good self-managers in both groups, who demonstrated significant correlations between SF and LF scores. Conclusions: Simplifying self-management scoring with an SF tool to improve clinical translation is justifiable, particularly for vulnerable populations. Poor self-management capabilities and readmission risk for poor self-managers can be significantly predicted, and trends for good self-managers are observed. However, correlations of SF to LF scores across an HF cohort for self-management abilities and MACE are more complex. Translation to patients of all skill levels requires further research. FAU - Iyngkaran, Pupalan AU - Iyngkaran P AD - Melbourne Clinical School, University of Notre Dame, Melbourne, VIC 3000, Australia. AD - Centre for Healthy Futures, Torrens University Australia, Surry Hills, NSW 2000, Australia. FAU - Smith, David AU - Smith D AD - College of Medicine & Public Health, Flinders University, Adelaide, SA 5042, Australia. FAU - McLachlan, Craig AU - McLachlan C AUID- ORCID: 0000-0001-9843-8980 AD - Centre for Healthy Futures, Torrens University Australia, Surry Hills, NSW 2000, Australia. FAU - Battersby, Malcolm AU - Battersby M AUID- ORCID: 0000-0001-7306-5591 AD - College of Medicine and Public Health, Flinders University, Norwood, SA 5067, Australia. FAU - de Courten, Maximilian AU - de Courten M AUID- ORCID: 0000-0001-9997-9359 AD - Australian Health Policy Collaboration, Institute for Health and Sport (IHES), Victoria University, Melbourne, VIC 8001, Australia. FAU - Hanna, Fahad AU - Hanna F AUID- ORCID: 0000-0002-0494-9585 AD - Centre for Healthy Futures, Torrens University Australia, Surry Hills, NSW 2000, Australia. LA - eng GR - 2023RES00137/Royal Australasian College of Physicians/ PT - Journal Article DEP - 20241120 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC11594953 OTO - NOTNLM OT - Flinders Program OT - clinical treatment OT - heart failure OT - readmission OT - risk assessment OT - self-management COIS- Professor Malcolm Battersby is co-inventor of the "Flinders Model of Chronic Condition Self-Management" and has received competitive and Federal Government funding for research in chronic condition self-management. All other authors have received government and non-governmental funding. None pose a conflict of interest for this publication. EDAT- 2024/11/27 06:20 MHDA- 2024/11/27 06:21 PMCR- 2024/11/20 CRDT- 2024/11/27 01:33 PHST- 2024/10/23 00:00 [received] PHST- 2024/11/09 00:00 [revised] PHST- 2024/11/12 00:00 [accepted] PHST- 2024/11/27 06:21 [medline] PHST- 2024/11/27 06:20 [pubmed] PHST- 2024/11/27 01:33 [entrez] PHST- 2024/11/20 00:00 [pmc-release] AID - jcm13226994 [pii] AID - jcm-13-06994 [pii] AID - 10.3390/jcm13226994 [doi] PST - epublish SO - J Clin Med. 2024 Nov 20;13(22):6994. doi: 10.3390/jcm13226994. PMID- 39597982 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260923 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 13 IP - 22 DP - 2024 Nov 14 TI - The Unique Challenge of Coronary Artery Disease in Adult Patients with Congenital Heart Disease. LID - 10.3390/jcm13226839 [doi] LID - 6839 AB - Advances in medical and surgical interventions have resulted in a steady increase in the number of patients with congenital heart disease (CHD) reaching adult age. Unfortunately, this ever-growing population faces an added challenge: an increased risk of acquiring coronary artery disease. This review provides insight into the complex interactions between coronary artery disease and CHD in adults. We describe the peculiar features of cardiac anatomy in these patients, the possible role cardiac sequelae may play in an increased risk of myocardial ischemia, and the diagnostic challenges in this patient group. Furthermore, this review outlines the risk factors and potential mechanisms of accelerated atherosclerosis in adults with CHD by pointing out areas where current knowledge is incomplete and highlighting areas for further research. The review concludes by examining potential management strategies for this particular population, emphasizing the necessity for a multidisciplinary approach. Understanding the unique coronary risks that adults with CHD experience can enhance patient care and improve long-term results. FAU - Borrelli, Nunzia AU - Borrelli N AD - Adult Congenital Heart Disease and Familiar Arrhythmias Unit, Monaldi Hospital, 80131 Naples, Italy. FAU - Merola, Assunta AU - Merola A AD - Adult Congenital Heart Disease and Familiar Arrhythmias Unit, Monaldi Hospital, 80131 Naples, Italy. FAU - Barracano, Rosaria AU - Barracano R AD - Adult Congenital Heart Disease and Familiar Arrhythmias Unit, Monaldi Hospital, 80131 Naples, Italy. FAU - Palma, Michela AU - Palma M AD - Adult Congenital Heart Disease and Familiar Arrhythmias Unit, Monaldi Hospital, 80131 Naples, Italy. FAU - Altobelli, Ippolita AU - Altobelli I AD - Adult Congenital Heart Disease and Familiar Arrhythmias Unit, Monaldi Hospital, 80131 Naples, Italy. FAU - Abbate, Massimiliana AU - Abbate M AD - Adult Congenital Heart Disease and Familiar Arrhythmias Unit, Monaldi Hospital, 80131 Naples, Italy. FAU - Papaccioli, Giovanni AU - Papaccioli G AUID- ORCID: 0000-0002-7416-9728 AD - Adult Congenital Heart Disease and Familiar Arrhythmias Unit, Monaldi Hospital, 80131 Naples, Italy. FAU - Ciriello, Giovanni Domenico AU - Ciriello GD AUID- ORCID: 0000-0001-6115-9435 AD - Adult Congenital Heart Disease and Familiar Arrhythmias Unit, Monaldi Hospital, 80131 Naples, Italy. FAU - Liguori, Carmen AU - Liguori C AD - Adult Congenital Heart Disease and Familiar Arrhythmias Unit, Monaldi Hospital, 80131 Naples, Italy. FAU - Sorice, Davide AU - Sorice D AD - Adult Congenital Heart Disease and Familiar Arrhythmias Unit, Monaldi Hospital, 80131 Naples, Italy. FAU - De Luca, Lorenzo AU - De Luca L AD - Adult Congenital Heart Disease and Familiar Arrhythmias Unit, Monaldi Hospital, 80131 Naples, Italy. FAU - Scognamiglio, Giancarlo AU - Scognamiglio G AD - Adult Congenital Heart Disease and Familiar Arrhythmias Unit, Monaldi Hospital, 80131 Naples, Italy. FAU - Sarubbi, Berardo AU - Sarubbi B AD - Adult Congenital Heart Disease and Familiar Arrhythmias Unit, Monaldi Hospital, 80131 Naples, Italy. LA - eng PT - Journal Article PT - Review DEP - 20241114 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC11594384 OTO - NOTNLM OT - atherosclerosis OT - cardiovascular risk factors OT - congenital heart disease OT - coronary artery disease COIS- The authors declare no conflicts of interest. EDAT- 2024/11/27 06:20 MHDA- 2024/11/27 06:21 PMCR- 2024/11/14 CRDT- 2024/11/27 01:32 PHST- 2024/09/10 00:00 [received] PHST- 2024/11/08 00:00 [revised] PHST- 2024/11/12 00:00 [accepted] PHST- 2024/11/27 06:21 [medline] PHST- 2024/11/27 06:20 [pubmed] PHST- 2024/11/27 01:32 [entrez] PHST- 2024/11/14 00:00 [pmc-release] AID - jcm13226839 [pii] AID - jcm-13-06839 [pii] AID - 10.3390/jcm13226839 [doi] PST - epublish SO - J Clin Med. 2024 Nov 14;13(22):6839. doi: 10.3390/jcm13226839. PMID- 39594211 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241130 IS - 2075-4418 (Print) IS - 2075-4418 (Electronic) IS - 2075-4418 (Linking) VI - 14 IP - 22 DP - 2024 Nov 13 TI - Fetal Tele-Echocardiography-An Approach to Improving Diagnosis and Management. LID - 10.3390/diagnostics14222545 [doi] LID - 2545 AB - Introduction: Antenatal diagnosis of cardiac abnormalities and counselling parents about postnatal care require a multidisciplinary team, which includes a paediatric cardiologist, a neonatologist, and a fetal medicine physician. Some of these kinds of expertise are not available in all centres with fetal medicine expertise. However, with modern technology, this could be provided remotely. Our objective was to assess the feasibility and outcomes of prenatal multidisciplinary tele-echocardiography diagnostic and counselling services. Materials and Methods: Two centres based in separate countries provided a joint diagnostic and counselling service over a period of 14 months. The primary centre performed the fetal echocardiography with a Voluson E10 machine, and images were transmitted live using Zoom OPS system with video-consultation and counselling. The fetal echo was performed using the ISUOG Guidelines check list. Results: There was an initial feasibility period of 2 months during which 10 women whose fetuses had normal hearts were scanned to test the workability of the system. Over a period of 12 months, 513 high-risk fetuses were then scanned, and out of these, 27 had congenital malformations. The most common were hypoplastic left heart syndrome (HHLS) and atrio-ventricular septal defect. Tele-echocardiography and counselling were successful in all the cases. Satisfaction with the service was 3.8/4, with the main limitation being the need for further referral to a tertiary centre for delivery. Conclusions: Tele-echocardiography is reliable, and when combined with live counselling and support from a paediatric cardiologist, it is an option acceptable to patients. The greatest benefit was from being counselled by a team of experts at a single consultation rather than having to travel to another centre for consultation. With rapidly evolving technology, making video transmission easier and less expensive, we feel that consideration should be given not only to the development of tele-echocardiography but also to extending it to other aspects of fetal medicine. FAU - Ahmed, Badreldeen AU - Ahmed B AD - Feto Maternal Centre, Al Markhiya Doha, Doha P.O. Box 34181, Qatar. AD - Obstetrics and Gynaecology, Qatar University, Doha P.O. Box 2713, Qatar. AD - Obstetrics and Gynecology, Weill Cornell Medicine, Doha P.O. Box 24144, Qatar. FAU - Elsisi, Amal AU - Elsisi A AD - Paediatric Cardiology, Cairo University, Cairo 12613, Egypt. FAU - Konje, Justin C AU - Konje JC AUID- ORCID: 0000-0001-9736-6938 AD - Feto Maternal Centre, Al Markhiya Doha, Doha P.O. Box 34181, Qatar. AD - Obstetrics and Gynecology, Weill Cornell Medicine, Doha P.O. Box 24144, Qatar. AD - Obstetrics and Gynaecology, Department of Health Studies, University of Leicester, Leicester LE1 7RH, UK. LA - eng PT - Journal Article DEP - 20241113 PL - Switzerland TA - Diagnostics (Basel) JT - Diagnostics (Basel, Switzerland) JID - 101658402 PMC - PMC11592742 OTO - NOTNLM OT - congenital heart diseases OT - fetal echo OT - prenatal diagnosis OT - tele-medicine OT - zoom platform COIS- The authors declare no conflict of interest. EDAT- 2024/11/27 06:20 MHDA- 2024/11/27 06:21 PMCR- 2024/11/13 CRDT- 2024/11/27 01:10 PHST- 2024/10/06 00:00 [received] PHST- 2024/11/03 00:00 [revised] PHST- 2024/11/10 00:00 [accepted] PHST- 2024/11/27 06:21 [medline] PHST- 2024/11/27 06:20 [pubmed] PHST- 2024/11/27 01:10 [entrez] PHST- 2024/11/13 00:00 [pmc-release] AID - diagnostics14222545 [pii] AID - diagnostics-14-02545 [pii] AID - 10.3390/diagnostics14222545 [doi] PST - epublish SO - Diagnostics (Basel). 2024 Nov 13;14(22):2545. doi: 10.3390/diagnostics14222545. PMID- 39593241 OWN - NLM STAT- MEDLINE DCOM- 20250501 LR - 20260629 IS - 1537-6591 (Electronic) IS - 1058-4838 (Print) IS - 1058-4838 (Linking) VI - 80 IP - 4 DP - 2025 Apr 30 TI - Predictors of Persistent Fever Among Patients With Suspected Infective Endocarditis: Think Outside the box. PG - 795-803 LID - 10.1093/cid/ciae588 [doi] AB - BACKGROUND: Fever is common in infective endocarditis (IE), yet little is known about fever duration in such patients. We aim to identify predictors of persistent fever in patients with suspected IE. METHODS: This study was conducted at the Lausanne University Hospital, Switzerland, from January 2014 to June 2023. All patients with suspected IE being febrile upon presentation were included. Fever (>38 degrees C) was considered persistent if it continued for at least 96 hours from antimicrobial treatment initiation. A case was classified as IE by the Endocarditis Team. RESULTS: Among 1399 episodes with suspected IE, persistent fever was observed in 260 (19%) episodes. IE was diagnosed in 536 (41%) episodes, of which 82 (15%) had persistent fever. Among episodes with suspected IE, persistent bacteremia/candidemia for 96 hours (P < .001), spondylodiscitis (P = .039), intrabdominal infection (P = .001) were associated with persistent fever. Conversely, bacteremia by streptococci (P = .049), or enterococci (P = .001), source control performed withing 96 hours (P = .015) and appropriate antimicrobial treatment within 48 hours (P = .018) were associated with early defervescence. No association between persistent fever and infective endocarditis was found (P = .207). Among 536 IE episodes, persistent bacteremia/candidemia for 96 hours (P < .001), and native bone and joint infection (P = .020) were associated with persistent fever. Conversely, bacteremia by streptococci or enterococci (P = .001; adjusted odds ratio [aOR] 0.25, 95% confidence interval [CI] .11-.58) were associated with early defervescence. CONCLUSIONS: In episodes with suspected IE, persistent fever was associated with spondylodiscitis, inappropriate antimicrobial treatment and absence of source control interventions. Among IE patients, persistent fever was associated with native bone and joint infections. CI - (c) The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. FAU - Stavropoulou, Elisavet AU - Stavropoulou E AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Monney, Pierre AU - Monney P AUID- ORCID: 0000-0002-3083-7333 AD - Department of Cardiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Tzimas, Georgios AU - Tzimas G AUID- ORCID: 0000-0002-2810-8887 AD - Department of Cardiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Ianculescu, Nicoleta AU - Ianculescu N AD - Department of Cardiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Tozzi, Piergiorgio AU - Tozzi P AUID- ORCID: 0000-0002-2608-7568 AD - Department of Cardiac Surgery, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Kirsch, Matthias AU - Kirsch M AUID- ORCID: 0000-0002-9213-7578 AD - Department of Cardiac Surgery, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Guery, Benoit AU - Guery B AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Papadimitriou-Olivgeris, Matthaios AU - Papadimitriou-Olivgeris M AUID- ORCID: 0000-0003-0565-5105 AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. AD - Infectious Diseases Service, Cantonal Hospital of Sion and Institut Central des Hopitaux, Sion, Switzerland. LA - eng PT - Journal Article PL - United States TA - Clin Infect Dis JT - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America JID - 9203213 RN - 0 (Anti-Bacterial Agents) SB - IM MH - Humans MH - Male MH - Female MH - *Fever/etiology/microbiology/diagnosis MH - Aged MH - Middle Aged MH - Bacteremia/complications MH - *Endocarditis/diagnosis/complications/drug therapy MH - Switzerland/epidemiology MH - Aged, 80 and over MH - Anti-Bacterial Agents/therapeutic use MH - *Endocarditis, Bacterial/diagnosis MH - Adult MH - Risk Factors MH - Discitis/complications PMC - PMC12043059 OTO - NOTNLM OT - infective endocarditis OT - persistent bacteremia OT - persistent fever OT - source control OT - spondylodiscitis COIS- Potential conflicts of interest . The authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. EDAT- 2024/11/27 06:20 MHDA- 2025/05/01 06:27 PMCR- 2024/11/27 CRDT- 2024/11/27 00:33 PHST- 2024/09/13 00:00 [received] PHST- 2025/05/01 06:27 [medline] PHST- 2024/11/27 06:20 [pubmed] PHST- 2024/11/27 00:33 [entrez] PHST- 2024/11/27 00:00 [pmc-release] AID - 7909225 [pii] AID - ciae588 [pii] AID - 10.1093/cid/ciae588 [doi] PST - ppublish SO - Clin Infect Dis. 2025 Apr 30;80(4):795-803. doi: 10.1093/cid/ciae588. PMID- 39590204 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241128 IS - 2308-3425 (Electronic) IS - 2308-3425 (Linking) VI - 11 IP - 11 DP - 2024 Nov 7 TI - Sternal Wound Reconstruction Following Deep Sternal Wound Infection: Past, Present and Future: A Literature Review. LID - 10.3390/jcdd11110361 [doi] LID - 361 AB - This literature review critically examines the historical, current, and prospective dimensions of sternal wound reconstruction in the specific context of deep sternal wound infection (DSWI), aiming to enhance patient outcomes and optimise surgical techniques. Preventive measures, including prophylactic antibiotic administration and surgical site preparation, are crucial in reducing the incidence of DSWI. Effective management necessitates a multidisciplinary approach encompassing surgical debridement, drainage, and sternum repair utilising diverse procedures in conjunction with antibiotic therapy. Traditional approaches to managing DSWI involved closed irrigation and drainage techniques. While these methods exhibited certain advantages, they also exhibited limitations and varying degrees of success. The current care paradigms emphasise prophylactic antibiotic administration and surgical interventions like closed suction and irrigation, vacuum-assisted closure, and flap reconstruction. Future advancements in surgical techniques and technology hold promise for further enhancing sternal wound reconstruction. This review separates and emphasises the distinct roles of prophylaxis, antibiotic treatment, and reconstructive techniques, each relevant specifically to DSWI management. Collaborative efforts between cardiac and plastic surgeons, supported by ongoing research and innovation, are indispensable to advance sternal wound restoration and achieve superior outcomes in terms of patient welfare, morbidity and mortality reduction, and surgical efficacy. FAU - Khashkhusha, Arwa AU - Khashkhusha A AUID- ORCID: 0000-0002-7407-8404 AD - School of Medicine, Faculty of Health and Life Science, University of Liverpool, Liverpool L3 5TR, UK. FAU - Butt, Sundas AU - Butt S AUID- ORCID: 0000-0003-0519-0715 AD - Department of Plastic Surgery, Nottingham City Hospital, Nottingham NG5 1PB, UK. FAU - Abdelghaffar, Mariam AU - Abdelghaffar M AD - School of Medicine, Royal College of Surgeons in Ireland, Building No. 2441, Road 2835, Busaiteen 228, Muharraq P.O. Box 15503, Bahrain. FAU - Wang, William AU - Wang W AD - Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AD, UK. FAU - Rajananthanan, Asveny AU - Rajananthanan A AD - Northampton General Hospital, Northampton NN1 5BD, UK. FAU - Roy, Sakshi AU - Roy S AUID- ORCID: 0000-0002-3519-9318 AD - School of Medicine, Queen's University Belfast, Belfast BT9 7BL, UK. FAU - Khurshid, Bakht Noor AU - Khurshid BN AD - Department of Medicine, University Medical & Dental College (UMDC), Sargodha Rd, University Town, Faisalabad 38000, Punjab, Pakistan. FAU - Zeinah, Mohamed AU - Zeinah M AD - Faculty of Medicine, Ain Sham University, Cairo 11566, Egypt. FAU - Harky, Amer AU - Harky A AD - Department of Cardiothoracic Surgery, Liverpool Heart and Chest Hospital, Liverpool L14 3PE, UK. LA - eng PT - Journal Article PT - Review DEP - 20241107 PL - Switzerland TA - J Cardiovasc Dev Dis JT - Journal of cardiovascular development and disease JID - 101651414 PMC - PMC11595137 OTO - NOTNLM OT - deep sternal wound reconstruction OT - flaps OT - infection OT - multidisciplinary team OT - plastic surgery OT - reconstruction OT - surgical intervention OT - wound infection COIS- The authors declare no conflicts of interest. EDAT- 2024/11/26 18:23 MHDA- 2024/11/26 18:24 PMCR- 2024/11/07 CRDT- 2024/11/26 12:54 PHST- 2024/09/07 00:00 [received] PHST- 2024/10/24 00:00 [revised] PHST- 2024/10/28 00:00 [accepted] PHST- 2024/11/26 18:24 [medline] PHST- 2024/11/26 18:23 [pubmed] PHST- 2024/11/26 12:54 [entrez] PHST- 2024/11/07 00:00 [pmc-release] AID - jcdd11110361 [pii] AID - jcdd-11-00361 [pii] AID - 10.3390/jcdd11110361 [doi] PST - epublish SO - J Cardiovasc Dev Dis. 2024 Nov 7;11(11):361. doi: 10.3390/jcdd11110361. PMID- 39588999 OWN - NLM STAT- MEDLINE DCOM- 20241126 LR - 20260608 IS - 1878-0369 (Electronic) IS - 0001-2092 (Linking) VI - 120 IP - 6 DP - 2024 Dec TI - Caring for Patients With Pheochromocytomas in the Perioperative Setting: Earn 1.4 Contact Hours. PG - 363-369 LID - 10.1002/aorn.14248 [doi] AB - Pheochromocytomas are rare, complex catecholamine-secreting tumors of the adrenal medulla. Patients with pheochromocytomas may experience episodes of life-threatening hypertension, and untreated tumors can be fatal. The nonspecific signs and symptoms (eg, headaches, palpitations, sweating) make diagnosing these tumors difficult. A comprehensive patient history, clinical evaluation during episodic hypertension, and biochemical test results can facilitate a definitive diagnosis. The only curative treatment is minimally invasive tumor removal. Because the tumor may recur, patients require follow-up visits for approximately 10 years after surgery. Preoperative evaluations can include cardiac and imaging studies and genetic testing. Preoperative preparation involves controlling hypertension and planning for hypotension after tumor removal. Perioperative nurses should be prepared to assist anesthesia professionals with placing invasive hemodynamic monitors and responding to blood pressure changes. An interdisciplinary team can create a guideline or protocol for nurses to follow to enhance outcomes when caring for patients with pheochromocytomas. CI - (c) AORN, Inc, 2024. FAU - Criscitelli, Theresa M AU - Criscitelli TM LA - eng PT - Journal Article PL - United States TA - AORN J JT - AORN journal JID - 0372403 SB - IM MH - *Pheochromocytoma/surgery MH - Humans MH - *Adrenal Gland Neoplasms/surgery MH - Perioperative Nursing/methods MH - Perioperative Care/methods/standards/nursing OTO - NOTNLM OT - alpha (alpha)-adrenergic receptor blockers OT - catecholamines OT - hypertension OT - neuroendocrine tumors OT - pheochromocytomas EDAT- 2024/11/26 12:30 MHDA- 2024/11/26 12:31 CRDT- 2024/11/26 08:03 PHST- 2024/03/14 00:00 [revised] PHST- 2024/01/05 00:00 [received] PHST- 2024/03/18 00:00 [accepted] PHST- 2024/11/26 12:31 [medline] PHST- 2024/11/26 12:30 [pubmed] PHST- 2024/11/26 08:03 [entrez] AID - 10.1002/aorn.14248 [doi] PST - ppublish SO - AORN J. 2024 Dec;120(6):363-369. doi: 10.1002/aorn.14248. PMID- 39586428 OWN - NLM STAT- MEDLINE DCOM- 20250426 LR - 20260919 IS - 1873-6513 (Electronic) IS - 0885-3924 (Linking) VI - 69 IP - 3 DP - 2025 Mar TI - Navigating Uncertainty during Family Meetings in the Pediatric Cardiac Intensive Care Unit: A Qualitative Investigation of Team Communication and Family Engagement. PG - 261-268 LID - S0885-3924(24)01129-1 [pii] LID - 10.1016/j.jpainsymman.2024.11.014 [doi] AB - CONTEXT: Uncertainty is a known barrier to effective communication during family meetings in the pediatric cardiac intensive care unit (CICU), however, limited data has characterized patterns of communication during these meetings, limiting our ability to make best practice recommendations to clinicians. OBJECTIVES: To characterize how uncertainty is communicated by cardiac critical care teams during family meetings, to characterize family responses to uncertainty, and to explore how expressions of uncertainty impact specific responses. METHODS: We conducted a retrospective study of 58 family meetings recorded in a pediatric CICU. Participants were families of patients admitted to the CICU and members of the interprofessional CICU team. We coded uncertainty statements expressed by clinicians and family responses to uncertainty statements. Codes were extracted and analyzed for thematic content. RESULTS: We identified three themes around which clinicians expressed uncertainty: prognosis, treatment trajectories, and discharge planning. Expressions were most frequently unburied (62.3%) and implicit (66.5%). Five themes were identified within family responses to uncertainty: Brief acknowledgment (36.7%); clarification (30.0%); summary (12.3%); child information (12.3%); and emotions, preferences, and reflections (8.6%). Brief acknowledgements often followed lengthy, complex medical information provided by clinicians. Families often responded to implicitly communicated uncertainty by summarizing, clarifying, and providing additional details about their experiences, observations, and preferences. CONCLUSIONS: Our results encourage clinicians to communicate uncertainty in an unburied and explicit manner, which may reduce the burden on families to engage in effective communication strategies, such as clarifying and summarizing opaquely stated information. CI - Copyright (c) 2024 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved. FAU - Gramszlo, Colette AU - Gramszlo C AD - Department of Child and Adolescent Psychiatry and Behavioral Sciences (C.G.), Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA; Department of Clinical Psychiatry (C.G.), Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA. Electronic address: gramszloc@chop.edu. FAU - Cetin, Arzu AU - Cetin A AD - Clinical Futures (A.C.), Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. FAU - Walter, Jennifer K AU - Walter JK AD - Department of Medical Ethics and Department of Pediatrics (J.W.), The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA; Department of Medical Ethics and Health Policy (J.W.), Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA. LA - eng GR - K23 HL141700/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20241124 PL - United States TA - J Pain Symptom Manage JT - Journal of pain and symptom management JID - 8605836 SB - IM MH - Humans MH - Uncertainty MH - *Intensive Care Units, Pediatric MH - *Professional-Family Relations MH - Retrospective Studies MH - Female MH - *Communication MH - Male MH - *Patient Care Team MH - Child MH - Qualitative Research MH - *Family/psychology MH - Child, Preschool MH - Infant MH - *Coronary Care Units MH - Adult OTO - NOTNLM OT - Family meetings OT - cardiac intensive care unit OT - communication OT - pediatrics OT - uncertainty EDAT- 2024/11/26 00:16 MHDA- 2025/02/07 00:20 CRDT- 2024/11/25 19:13 PHST- 2024/05/23 00:00 [received] PHST- 2024/11/10 00:00 [revised] PHST- 2024/11/15 00:00 [accepted] PHST- 2025/02/07 00:20 [medline] PHST- 2024/11/26 00:16 [pubmed] PHST- 2024/11/25 19:13 [entrez] AID - S0885-3924(24)01129-1 [pii] AID - 10.1016/j.jpainsymman.2024.11.014 [doi] PST - ppublish SO - J Pain Symptom Manage. 2025 Mar;69(3):261-268. doi: 10.1016/j.jpainsymman.2024.11.014. Epub 2024 Nov 24. PMID- 39585169 OWN - NLM STAT- MEDLINE DCOM- 20250109 LR - 20260102 IS - 1529-7535 (Print) IS - 1529-7535 (Linking) VI - 26 IP - 1 DP - 2025 Jan 1 TI - Targeted Temperature Management After Pediatric Cardiac Arrest: A Quality Improvement Program With Multidisciplinary Implementation in the PICU. PG - e42-e50 LID - 10.1097/PCC.0000000000003640 [doi] AB - OBJECTIVES: We aimed to implement a post-cardiac arrest targeted temperature management (TTM) bundle to reduce the percent of time with a fever from 7% to 3.5%. DESIGN: A prospective, quality improvement (QI) initiative utilizing the Method for Improvement. The pre-intervention historical control period was February 2019 to March 2021, and the intervention test period was April 2021 to June 2022. SETTING: The PICU of a freestanding, tertiary children's hospital, in the United States. PATIENTS: Pediatric patients 2 days old or older to 18 young or younger than years old who experienced cardiac arrest, received greater than or equal to 2 minutes of chest compressions, required invasive mechanical ventilation post-resuscitation, and had no documented limitations of care. INTERVENTIONS: We developed and implemented a TTM bundle that included standard temperature goals, instructions and training on cooling blanket use, scheduled prescription of antipyretics, an algorithm for managing shivering, and standardized orders in our electronic health record. MEASUREMENTS AND RESULTS: We reviewed data from 29 patients in the pre-intervention period and studied 46 in the intervention period. In comparison with historical controls, the reduction in median (interquartile range [IQR]) percentage of febrile (> 38 degrees C) time per patient associated with the TTM bundle was 0% (IQR, 0-3%) vs. 7% (IQR, 0-13%; p < 0.001). The intervention period, vs. pre-intervention, was associated with fewer patients with fever at any time (16/46 vs. 21/29; mean reduction, 37%; 95% CI, 13.8-54.8%; p = 0.002). We failed to identify an association between the intervention period, vs. pre-intervention, and the development of hypothermia (< 35 degrees C; 8/46 vs. 3/29; mean change, 7%; 95% CI, -10.9% to 21.8%; p = 0.40). CONCLUSIONS: In this QI project, we have demonstrated that implementation of a TTM bundle is associated with reduced duration and frequency of fever in patients who survive cardiac arrest. CI - Copyright (c) 2024 by the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies. FAU - McMullin, Mason P AU - McMullin MP AD - Department of Pediatrics, Uniformed Services University, Bethesda, MD. AD - Department of Pediatrics, Tripler Army Medical Center, Honolulu, HI. FAU - Cadotte, Noelle B AU - Cadotte NB AD - Department of Pediatrics, Navy Medicine Readiness and Training Command, San Diego, CA. FAU - Fuchs, Erin M AU - Fuchs EM AD - Division of Critical Care, Department of Pediatrics, University of Utah, Salt Lake City, UT. FAU - Kartchner, Cory A AU - Kartchner CA AD - Department of Pediatric Critical Care Services, Primary Children's Hospital, Intermountain Health, Salt Lake City, UT. FAU - Vincent, Brian AU - Vincent B AD - Department of Pediatric Critical Care Services, Primary Children's Hospital, Intermountain Health, Salt Lake City, UT. FAU - Parker, Gretchen AU - Parker G AD - Department of Pediatric Critical Care Services, Primary Children's Hospital, Intermountain Health, Salt Lake City, UT. FAU - Sweney, Jill S AU - Sweney JS AD - Division of Critical Care, Department of Pediatrics, University of Utah, Salt Lake City, UT. FAU - Flaherty, Brian F AU - Flaherty BF AD - Division of Critical Care, Department of Pediatrics, University of Utah, Salt Lake City, UT. LA - eng GR - UM1 TR004409/TR/NCATS NIH HHS/United States PT - Journal Article DEP - 20241125 PL - United States TA - Pediatr Crit Care Med JT - Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies JID - 100954653 SB - IM MH - Humans MH - *Quality Improvement MH - *Intensive Care Units, Pediatric/organization & administration MH - *Heart Arrest/therapy MH - Infant MH - Child, Preschool MH - *Hypothermia, Induced/methods MH - Child MH - Prospective Studies MH - Female MH - Male MH - Adolescent MH - Infant, Newborn MH - Fever/therapy PMC - PMC11717638 MID - NIHMS2028340 COIS- Dr. Flaherty's institution received funding from the Utah Clinical and Translational Science Institute (UM1TR004409) Partner Scholars Program Award and the National Institutes of Health (NIH); he received support for article research from the NIH. The remaining authors have disclosed that they do not have any potential conflicts of interest. EDAT- 2024/11/25 12:32 MHDA- 2025/01/09 18:22 PMCR- 2026/01/01 CRDT- 2024/11/25 09:33 PHST- 2025/01/09 18:22 [medline] PHST- 2024/11/25 12:32 [pubmed] PHST- 2024/11/25 09:33 [entrez] PHST- 2026/01/01 00:00 [pmc-release] AID - 00130478-202501000-00006 [pii] AID - 10.1097/PCC.0000000000003640 [doi] PST - ppublish SO - Pediatr Crit Care Med. 2025 Jan 1;26(1):e42-e50. doi: 10.1097/PCC.0000000000003640. Epub 2024 Nov 25. PMID- 39579916 OWN - NLM STAT- MEDLINE DCOM- 20250426 LR - 20250610 IS - 1879-1913 (Electronic) IS - 0002-9149 (Linking) VI - 237 DP - 2025 Feb 15 TI - Diagnosis and Prognosis of Isolated Cardiac Sarcoidosis: Multidisciplinary Diagnosis Versus Japanese Circulation Society Criteria. PG - 45-53 LID - S0002-9149(24)00815-4 [pii] LID - 10.1016/j.amjcard.2024.11.018 [doi] AB - The prognosis of isolated cardiac sarcoidosis (ICS) has not been fully elucidated. The only diagnostic criteria available for ICS, the Japanese Circulation Society (JCS) criteria, have not been validated. We aimed to study the prognosis of ICS according to 2 different diagnostic strategies. We prospectively included patients with a high suspicion for cardiac sarcoidosis by a multidisciplinary sarcoidosis team from November 2016 to June 2021. We included only incident cases. We applied the JCS ICS criteria and our multidisciplinary diagnosis (MDD) ICS criteria. We included 198 incident patients who had a final diagnosis of cardiac sarcoidosis. The median follow-up time was 2.4 years (twenty-fifth to seventy-fifth percentile: 1.2 to 3.7). The prevalence of ICS was 7% (14 of 198) per the JCS criteria and 29% (57 of 198) per our MDD criteria. Compared with patients with non-ICS, patients with ICS per either criterion had similar rates of major cardiovascular outcomes (progression of atrioventricular block, worsening ejection fraction >/=10%, appropriate implantable cardioverter-defibrillator therapies, heart transplant, and death). The Kaplan-Meier analyses showed similar prognosis for ICS and non-ICS in all outcomes, except for an association between ICS by MDD criteria and a shorter time to cardiac hospitalization. The multivariable Cox regression analyses showed that ICS was not an independent predictor of death, heart transplant, or clinical worsening. In conclusion, our MDD ICS criteria were more inclusive than the JCS ICS criteria. The prognosis was similar between patients with ICS and patients with non-ICS, regardless of which criteria were used. CI - Copyright (c) 2024 Elsevier Inc. All rights reserved. FAU - Ribeiro Neto, Manuel L AU - Ribeiro Neto ML AD - Department of Pulmonary and Critical Care Medicine, Integrated Hospital Care Institute. Electronic address: ribeirm@ccf.org. FAU - Jellis, Christine L AU - Jellis CL AD - Department of Cardiovascular Medicine, Heart, Vascular & Thoracic Institute, Cleveland Clinic, Cleveland, Ohio. FAU - Taimeh, Ziad AU - Taimeh Z AD - Department of Cardiovascular Medicine, Heart, Vascular & Thoracic Institute, Cleveland Clinic, Cleveland, Ohio. FAU - Cremer, Paul AU - Cremer P AD - Department of Cardiovascular Medicine, Heart, Vascular & Thoracic Institute, Cleveland Clinic, Cleveland, Ohio. FAU - Pulapaka, Anuhya V AU - Pulapaka AV AD - Tulane School of Medicine, New Orleans, Louisiana. FAU - Wimer, Allison AU - Wimer A AD - Department of Cardiovascular Medicine, Heart, Vascular & Thoracic Institute, Cleveland Clinic, Cleveland, Ohio. FAU - Rozenbaum, Daniel AU - Rozenbaum D AD - Pulmonary and Critical Care Department, Indiana University. FAU - Ganeriwal, Simran AU - Ganeriwal S AD - Critical Care Medicine Fellowship, Cleveland Clinic, Cleveland, Ohio. FAU - Culver, Daniel A AU - Culver DA AD - Department of Pulmonary and Critical Care Medicine, Integrated Hospital Care Institute. LA - eng PT - Journal Article DEP - 20241122 PL - United States TA - Am J Cardiol JT - The American journal of cardiology JID - 0207277 SB - IM MH - Aged MH - Female MH - Humans MH - Male MH - Middle Aged MH - *Cardiomyopathies/diagnosis/epidemiology/physiopathology/therapy MH - Follow-Up Studies MH - Heart Transplantation/statistics & numerical data MH - Japan/epidemiology MH - Prognosis MH - Prospective Studies MH - *Sarcoidosis/diagnosis/epidemiology/physiopathology MH - Societies, Medical OTO - NOTNLM OT - cardiac sarcoidosis OT - sarcoidosis COIS- Declaration of competing interest The authors have no competing interests to declare. EDAT- 2024/11/24 00:44 MHDA- 2025/01/25 13:53 CRDT- 2024/11/23 19:13 PHST- 2024/09/14 00:00 [received] PHST- 2024/11/09 00:00 [revised] PHST- 2024/11/17 00:00 [accepted] PHST- 2025/01/25 13:53 [medline] PHST- 2024/11/24 00:44 [pubmed] PHST- 2024/11/23 19:13 [entrez] AID - S0002-9149(24)00815-4 [pii] AID - 10.1016/j.amjcard.2024.11.018 [doi] PST - ppublish SO - Am J Cardiol. 2025 Feb 15;237:45-53. doi: 10.1016/j.amjcard.2024.11.018. Epub 2024 Nov 22. PMID- 39575019 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241123 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 16 IP - 10 DP - 2024 Oct TI - Cardiac Failure and Cardiogenic Shock: Insights Into Pathophysiology, Classification, and Hemodynamic Assessment. PG - e72106 LID - 10.7759/cureus.72106 [doi] LID - e72106 AB - Heart failure is defined as increased intracardiac pressures, either alone or combined with reduced cardiac output. Clinically, it is presented with signs and symptoms of congestion and compensated perfusion. Cardiogenic shock, on the other hand, is the spectrum of hemodynamic disturbances that lead to hypoperfusion or need for circulatory support, due to cardiac disease. Both entities affect millions of people worldwide, have a dismal prognosis, and constitute a severe socioeconomic burden. Heart failure can be the aftermath of ischemic heart disease, hypertension, arrhythmias, or cardiomyopathies. It undergoes multiple classifications, facilitating its investigation and treatment. The pathogenetic mechanisms differ in various types of heart failure, regarding the affected ventricles, the duration of symptoms, and their primary/secondary onset. These mechanisms reflect the complex interactions between cardiopulmonary, vascular, and hepatorenal systems. Acute deterioration of cardiac function can lead to cardiogenic shock. Myocardial infarction accounts for 81% of such cases. Healthy lifestyle and timely management of coronary artery disease are paramount, as they can prevent this life-threatening situation and reduce mortality and the economic burden for healthcare systems. Irrespective of the etiology, cardiogenic shock is interpreted using the pressure-volume loop. This can be modified for each ventricle, the underlying pathophysiology, and the time since symptoms' onset. It therefore provides valuable information about the native circulation and the expected alterations under mechanical or pharmacological support, facilitating the decision-making progress. In 2019, given the phenotypical heterogeneity of cardiogenic shock, the Society for Cardiovascular Angiography and Interventions introduced a classification system. According to this, patients are stratified in five stages proportionally to the severity of their condition. Aside from this classification, various biochemical, imaging, and hemodynamic monitoring indices are used to assess coagulation pathway and cardiac, hepatorenal, and pulmonary function, enabling the heart team to tailor therapy. Additionally, the prognostication progress is facilitated by scores, such as the Observatoire Regional Breton sur l'Infarctus (ORBI) score, the intra-aortic balloon pump (IABP) SHOCK-II score, and the CardShock score, indicating suitable escalation or de-escalation strategies. Despite the current progress, there are several areas of advancement regarding the role of vasoactive drugs in cardiogenic shock, revascularization options, mechanical ventilation patterns, hypothermia treatment, and mechanical circulatory support protocols. CI - Copyright (c) 2024, Siopi et al. FAU - Siopi, Stavroula A AU - Siopi SA AD - Cardiovascular Medicine, Aristotle University of Thessaloniki, Thessaloniki, GRC. FAU - Antonitsis, Polychronis AU - Antonitsis P AD - Cardiothoracic Surgery, Aristotle University of Thessaloniki, Thessaloniki, GRC. FAU - Karapanagiotidis, Georgios T AU - Karapanagiotidis GT AD - Cardiothoracic Surgery, Aristotle University of Thessaloniki, Thessaloniki, GRC. FAU - Tagarakis, Georgios AU - Tagarakis G AD - Cardiothoracic Surgery, Aristotle University of Thessaloniki, Thessaloniki, GRC. FAU - Voucharas, Christos AU - Voucharas C AD - Cardiothoracic Surgery, Aristotle University of Thessaloniki, Thessaloniki, GRC. FAU - Anastasiadis, Kyriakos AU - Anastasiadis K AD - Cardiothoracic Surgery, Aristotle University of Thessaloniki, Thessaloniki, GRC. LA - eng PT - Journal Article PT - Review DEP - 20241022 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC11581444 OTO - NOTNLM OT - acute heart failure OT - cardiogenic shock OT - hemodynamics OT - left heart failure OT - pressure-volume loop OT - right heart failure COIS- Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. EDAT- 2024/11/22 06:23 MHDA- 2024/11/22 06:24 PMCR- 2024/10/22 CRDT- 2024/11/22 04:26 PHST- 2024/10/22 00:00 [accepted] PHST- 2024/11/22 06:24 [medline] PHST- 2024/11/22 06:23 [pubmed] PHST- 2024/11/22 04:26 [entrez] PHST- 2024/10/22 00:00 [pmc-release] AID - 10.7759/cureus.72106 [doi] PST - epublish SO - Cureus. 2024 Oct 22;16(10):e72106. doi: 10.7759/cureus.72106. eCollection 2024 Oct. PMID- 39571836 OWN - NLM STAT- MEDLINE DCOM- 20241213 LR - 20250711 IS - 1535-6280 (Electronic) IS - 0146-2806 (Linking) VI - 50 IP - 2 DP - 2025 Feb TI - Linking psoriasis to atrial fibrillation: Insights from "Association between psoriasis and atrial fibrillation: A systematic review and meta-analysis". PG - 102933 LID - S0146-2806(24)00568-1 [pii] LID - 10.1016/j.cpcardiol.2024.102933 [doi] AB - Patients with psoriasis indeed face an elevated risk of developing atrial fibrillation (AF), underscoring the need for vigilant monitoring to facilitate early detection and intervention. Given the current body of evidence linking psoriasis and AF is derived from observational studies, there is a clear need for more robust, multicenter, large-scale randomized studies. Such research would help to validate and reinforce the findings from observational data. Large-scale, randomized studies are necessary to confirm the association between psoriasis and AF, addressing potential biases and confounding factors present in observational research. Future studies should consider a broader range of factors that may influence the incidence of AF in psoriasis patients. This includes assessing the impact of AF "burden," which could refer to the frequency, duration, or overall impact of AF episodes on patients' health. Research should delve into the role of genetic predispositions that may contribute to the development of AF in patients with psoriasis. The influence of smoking and lipid levels, among other lifestyle and environmental factors, should be examined for their potential effects on the incidence of AF in psoriasis patients. An interdisciplinary team, including dermatologists, cardiologists, and other healthcare professionals, should collaborate to provide comprehensive care for patients with psoriasis. CI - Copyright (c) 2024. Published by Elsevier Inc. FAU - Zeng, Hong AU - Zeng H AD - Department of Dermatology, Chengdu Qingbaijiang District People's Hospital, Chengdu, Sichuan, 610300, China. Electronic address: misszeng0722@qq.com. FAU - Shu, Qi AU - Shu Q AD - Department of Dermatology, Chengdu Qingbaijiang District People's Hospital, Chengdu, Sichuan, 610300, China. Electronic address: 274760367@qq.com. FAU - Fang, Jing AU - Fang J AD - Department of Dermatology, Chengdu Qingbaijiang District People's Hospital, Chengdu, Sichuan, 610300, China. Electronic address: 1016401781@qq.com. FAU - Du, Hailin AU - Du H AD - Cardiovascular Internal Medicine Department, Chengdu Qingbaijiang District People's Hospital, Chengdu, Sichuan, 610300. Electronic address: 21569531@qq.com. FAU - Xue, Ying AU - Xue Y AD - Department of Dermatology, Chengdu Qingbaijiang District People's Hospital, Chengdu, Sichuan, 610300, China. Electronic address: 731255094@qq.com. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20241119 PL - Netherlands TA - Curr Probl Cardiol JT - Current problems in cardiology JID - 7701802 SB - IM MH - Humans MH - *Atrial Fibrillation/epidemiology/etiology MH - *Psoriasis/complications/epidemiology MH - Risk Factors MH - Incidence OTO - NOTNLM OT - Arrhythmia OT - Atrial fibrillation OT - Cardiovascular complications OT - Inflammation OT - Psoriasis COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/11/22 00:22 MHDA- 2024/12/14 00:24 CRDT- 2024/11/21 19:27 PHST- 2024/11/18 00:00 [received] PHST- 2024/11/18 00:00 [accepted] PHST- 2024/12/14 00:24 [medline] PHST- 2024/11/22 00:22 [pubmed] PHST- 2024/11/21 19:27 [entrez] AID - S0146-2806(24)00568-1 [pii] AID - 10.1016/j.cpcardiol.2024.102933 [doi] PST - ppublish SO - Curr Probl Cardiol. 2025 Feb;50(2):102933. doi: 10.1016/j.cpcardiol.2024.102933. Epub 2024 Nov 19. PMID- 39571050 OWN - NLM STAT- MEDLINE DCOM- 20241121 LR - 20250707 IS - 1424-3997 (Electronic) IS - 0036-7672 (Linking) VI - 154 DP - 2024 Nov 14 TI - Cardiac amyloidosis. PG - 4186 LID - 10.57187/s.4186 [doi] AB - Cardiac amyloidosis is a disease characterised by the accumulation of amyloid protein in the heart tissue. There are several types of amyloidosis, but the most common types affecting the heart are ATTR amyloidosis (caused by transthyretin protein) and AL amyloidosis (caused by abnormal immunoglobulin light chains). Cardiac amyloidosis causes typical signs and symptoms of heart failure. Diagnosis involves a combination of imaging tests such as echocardiography and cardiac magnetic resonance imaging, as well as nuclear imaging scans and tissue biopsies to confirm the presence of amyloid deposits in the heart. Treatment of cardiac amyloidosis depends on the type and severity of the disease and includes medications to manage symptoms as well as treatments targeting the underlying cause of amyloidosis. Importantly, cardiac amyloidosis is a serious condition requiring specialised care from a multidisciplinary team including cardiologists and haematologists as well as other specialists familiar with the management of this rare disease. This is crucial, as early diagnosis and treatment are important for improving outcomes. FAU - Laptseva, Natallia AU - Laptseva N AD - Amyloidosis Network Zurich, University Hospital Zurich, Zurich, Switzerland. AD - University Heart Center, University Hospital Zurich, Zurich, Switzerland. FAU - Benz, Dominik C AU - Benz DC AD - Amyloidosis Network Zurich, University Hospital Zurich, Zurich, Switzerland. AD - University Heart Center, University Hospital Zurich, Zurich, Switzerland. AD - Cardiac Imaging, Department of Nuclear Medicine, University Hospital of Zurich, Zurich, Switzerland. FAU - Schwotzer, Rahel AU - Schwotzer R AD - Amyloidosis Network Zurich, University Hospital Zurich, Zurich, Switzerland. AD - Hematology and Oncology, University Hospital Zurich, Zurich, Switzerland. FAU - Flammer, Andreas J AU - Flammer AJ AD - Amyloidosis Network Zurich, University Hospital Zurich, Zurich, Switzerland. AD - University Heart Center, University Hospital Zurich, Zurich, Switzerland. LA - eng PT - Journal Article PT - Review DEP - 20241114 PL - Switzerland TA - Swiss Med Wkly JT - Swiss medical weekly JID - 100970884 RN - 0 (Prealbumin) RN - Amyloidosis, Hereditary, Transthyretin-Related SB - IM MH - Humans MH - *Amyloidosis/diagnosis/therapy MH - *Echocardiography MH - Magnetic Resonance Imaging MH - Cardiomyopathies/diagnosis/therapy MH - Heart Failure/etiology MH - Amyloid Neuropathies, Familial/diagnosis/therapy/complications MH - Biopsy MH - Immunoglobulin Light-chain Amyloidosis/diagnosis/therapy MH - Prealbumin/metabolism EDAT- 2024/11/21 18:21 MHDA- 2024/11/21 18:22 CRDT- 2024/11/21 14:13 PHST- 2024/11/21 18:22 [medline] PHST- 2024/11/21 18:21 [pubmed] PHST- 2024/11/21 14:13 [entrez] AID - 4186 [pii] AID - 10.57187/s.4186 [doi] PST - epublish SO - Swiss Med Wkly. 2024 Nov 14;154:4186. doi: 10.57187/s.4186. PMID- 39570717 OWN - NLM STAT- MEDLINE DCOM- 20241121 LR - 20241125 IS - 1538-8646 (Electronic) IS - 0730-4625 (Linking) VI - 44 IP - 1 DP - 2025 Jan-Feb 01 TI - Team-Based Care of the Patient Receiving Venovenous Extracorporeal Membrane Oxygenation. PG - 2-11 LID - 10.1097/DCC.0000000000000674 [doi] AB - BACKGROUND: Guideline-based care of patients requiring extracorporeal membranous oxygenation, a form of life support for patients with refractory respiratory and/or cardiac failure, requires a multidisciplinary approach, yet a detailed description of the ideal integration of teams of physicians, acute care nurse practitioners, critical care nurses, and other disciplines is lacking in the literature. OBJECTIVES: We sought to define team-based care of the patient receiving venovenous extracorporeal membrane oxygenation with an emphasis on the roles of the critical care nurse and the acute care nurse practitioner. METHODS: A narrative literature review was conducted using the keywords or MeSH terms "team-based care" AND "ECMO" and "nurse practitioner" AND "ECMO." Electronic databases searched included PubMed, Cumulative Index for Nursing and Allied Health Literature, and PsycINFO. RESULTS: Sixty-five articles met the search criteria, with 21% (n = 10) focusing on characteristics of team-based care for patients receiving ECMO. Articles describe the ideal composition of teams and their education and training, frameworks for the formation of ECMO teams, and aspects of communication. One article details the role of the acute care nurse practitioner in managing ECMO, but several omit or barely describe the nurse's role as a team member. DISCUSSION: No articles were found that specifically define the key elements, structure, and dynamics of effective team-based care of the patient receiving ECMO. A holistic definition of team-based care of the patient receiving ECMO is proposed. Further research is warranted to correlate aspects of team-based care that optimize patient, team, and organization outcomes. CI - Copyright (c) 2025 Wolters Kluwer Health, Inc. All rights reserved. FAU - Presti, Carmen Rosa AU - Presti CR AUID- ORCID: 0000-0002-2042-9483 FAU - Casey, Jessica AU - Casey J LA - eng PT - Journal Article PT - Review PL - United States TA - Dimens Crit Care Nurs JT - Dimensions of critical care nursing : DCCN JID - 8211489 SB - IM MH - *Extracorporeal Membrane Oxygenation MH - Humans MH - *Patient Care Team/organization & administration MH - *Nurse Practitioners MH - Nurse's Role MH - Critical Care Nursing EDAT- 2024/11/21 18:21 MHDA- 2024/11/21 18:22 CRDT- 2024/11/21 12:30 PHST- 2024/11/21 18:22 [medline] PHST- 2024/11/21 18:21 [pubmed] PHST- 2024/11/21 12:30 [entrez] AID - 00003465-202501000-00002 [pii] AID - 10.1097/DCC.0000000000000674 [doi] PST - ppublish SO - Dimens Crit Care Nurs. 2025 Jan-Feb 01;44(1):2-11. doi: 10.1097/DCC.0000000000000674. PMID- 39570387 OWN - NLM STAT- MEDLINE DCOM- 20241217 LR - 20260716 IS - 1432-0711 (Electronic) IS - 0932-0067 (Linking) VI - 310 IP - 6 DP - 2024 Dec TI - When pulmonary arterial hypertension and pregnancy meet: a multidisciplinary clinical experts review. PG - 2839-2852 LID - 10.1007/s00404-024-07827-1 [doi] AB - Pulmonary hypertension (PH) is a rare condition characterized by elevated pulmonary arterial pressure and pulmonary vascular resistance, potentially leading to right ventricular failure. Pulmonary arterial hypertension (PAH) is the most common type of PH in women of childbearing age and, as per the modified World Health Organization (mWHO) classification of maternal cardiovascular risk, it falls into mWHO class IV and pregnancy is contraindicated. These patients face an exceptionally high risk of maternal mortality and morbidity, with estimated maternal cardiac event rates ranging from 40 to 100% during pregnancy, because physiological changes happening in pregnancy exacerbate the disorder. Despite these recommendations, there is a growing incidence of pregnancy among women with PAH. Early referral to specialized centers, personalized therapies and expert multidisciplinary care involving pulmonary hypertension specialists, obstetricians, critical care specialists, anesthesiologists, and neonatologists are crucial steps to ensure positive outcomes for both mother and fetus. This review aims to examine the current understanding of pregnancy in patients with PAH, drawing on the experience of our center in the multidisciplinary management of pregnant women with this condition. In particular, we want to focus the attention of clinicians on the following aspects: early referral of pregnant patients to specialized centers, detailed counseling on the implications of pregnancy, initiation of therapy in treatment-naive patients and potential adjustment of therapy in non-naive patients, periodic risk assessment, evaluation of the appropriate timing of delivery, multidisciplinary management of the most critical periods, which are delivery and the post-partum phase. CI - (c) 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Dominoni, Mattia AU - Dominoni M AUID- ORCID: 0000-0002-6322-607X AD - Department of Clinical, Surgical, Diagnostic and Paediatric Sciences, University of Pavia, Corso Strada Nuova, 65, 27100, Pavia, Italy. matti.domino@gmail.com. AD - Department of Obstetrics and Gynecology, IRCCS Foundation Policlinico San Matteo, Viale Camillo Golgi, 19, 27100, Pavia, Italy. matti.domino@gmail.com. FAU - Melito, Chiara AU - Melito C AD - Department of Clinical, Surgical, Diagnostic and Paediatric Sciences, University of Pavia, Corso Strada Nuova, 65, 27100, Pavia, Italy. AD - Department of Obstetrics and Gynecology, IRCCS Foundation Policlinico San Matteo, Viale Camillo Golgi, 19, 27100, Pavia, Italy. FAU - Schirinzi, Sandra AU - Schirinzi S AD - Division of Cardiology, Fondazione IRCCS Policlinico San Matteo, 27100, Pavia, Italy. FAU - Ghio, Stefano AU - Ghio S AD - Division of Cardiology, Fondazione IRCCS Policlinico San Matteo, 27100, Pavia, Italy. FAU - Scelsi, Laura AU - Scelsi L AD - Division of Cardiology, Fondazione IRCCS Policlinico San Matteo, 27100, Pavia, Italy. FAU - Greco, Alessandra AU - Greco A AD - Division of Cardiology, Fondazione IRCCS Policlinico San Matteo, 27100, Pavia, Italy. FAU - Turco, Annalisa AU - Turco A AD - Division of Cardiology, Fondazione IRCCS Policlinico San Matteo, 27100, Pavia, Italy. FAU - Broglia, Federica AU - Broglia F AD - Department of Anesthesia and Intensive Care 1, Unit of Obstetric Anesthesia, I Fondazione IRCCS Policlinico San Matteo, 27100, Pavia, Italy. FAU - Fuardo, Marinella AU - Fuardo M AD - Department of Anesthesia and Intensive Care 1, Unit of Obstetric Anesthesia, I Fondazione IRCCS Policlinico San Matteo, 27100, Pavia, Italy. FAU - Delmonte, Maria Paola AU - Delmonte MP AD - Department of Anesthesia and Intensive Care 1, Unit of Obstetric Anesthesia, I Fondazione IRCCS Policlinico San Matteo, 27100, Pavia, Italy. FAU - Perotti, Francesca AU - Perotti F AD - Department of Clinical, Surgical, Diagnostic and Paediatric Sciences, University of Pavia, Corso Strada Nuova, 65, 27100, Pavia, Italy. AD - Department of Obstetrics and Gynecology, IRCCS Foundation Policlinico San Matteo, Viale Camillo Golgi, 19, 27100, Pavia, Italy. FAU - Gardella, Barbara AU - Gardella B AD - Department of Clinical, Surgical, Diagnostic and Paediatric Sciences, University of Pavia, Corso Strada Nuova, 65, 27100, Pavia, Italy. AD - Department of Obstetrics and Gynecology, IRCCS Foundation Policlinico San Matteo, Viale Camillo Golgi, 19, 27100, Pavia, Italy. FAU - Spinillo, Arsenio AU - Spinillo A AD - Department of Clinical, Surgical, Diagnostic and Paediatric Sciences, University of Pavia, Corso Strada Nuova, 65, 27100, Pavia, Italy. AD - Department of Obstetrics and Gynecology, IRCCS Foundation Policlinico San Matteo, Viale Camillo Golgi, 19, 27100, Pavia, Italy. LA - eng PT - Journal Article PT - Review DEP - 20241121 PL - Germany TA - Arch Gynecol Obstet JT - Archives of gynecology and obstetrics JID - 8710213 SB - IM MH - Female MH - Humans MH - Pregnancy MH - Patient Care Team MH - *Pregnancy Complications, Cardiovascular/diagnosis/epidemiology/physiopathology/therapy MH - *Pulmonary Arterial Hypertension/diagnosis/epidemiology/physiopathology/therapy MH - Risk Assessment OTO - NOTNLM OT - Delivery OT - Obstetrics OT - Pregnancy OT - Pulmonary arterial hypertension COIS- Declarations. Conflict of interest: The authors declare no competing interests. Ethics approval: Not applicable. Consent to participate: Not applicable. Consent for publication: Not applicable. EDAT- 2024/11/21 12:26 MHDA- 2024/12/17 12:31 CRDT- 2024/11/21 11:14 PHST- 2024/07/08 00:00 [received] PHST- 2024/11/03 00:00 [accepted] PHST- 2024/12/17 12:31 [medline] PHST- 2024/11/21 12:26 [pubmed] PHST- 2024/11/21 11:14 [entrez] AID - 10.1007/s00404-024-07827-1 [pii] AID - 10.1007/s00404-024-07827-1 [doi] PST - ppublish SO - Arch Gynecol Obstet. 2024 Dec;310(6):2839-2852. doi: 10.1007/s00404-024-07827-1. Epub 2024 Nov 21. PMID- 39569385 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241122 IS - 1756-1485 (Electronic) IS - 1756-1477 (Print) IS - 1756-1485 (Linking) VI - 19 DP - 2024 TI - Outcomes and Complications of Mitral and Tricuspid Transcatheter Edge-to-edge Repair. PG - e20 LID - 10.15420/icr.2024.08 [doi] LID - e20 AB - In the realm of innovative medical procedures, TEER (transcatheter edge-to-edge repair) has emerged as a promising field, showcasing significant growth and advancements. Mitral TEER has been performed for the last two decades; in contrast, tricuspid TEER is newer, with long-term outcomes pending. This article aims to provide a comprehensive review of the current literature, with a primary focus on outcomes and potential complications associated with both procedures. Both procedures carry a low risk of complications when done by experienced providers. A team approach involving specialists in cardiology, cardiothoracic surgery, cardiac imaging and heart failure ensures comprehensive care. A unified approach encompassing preprocedural workup, risk assessment, and standardised care throughout the procedure and recovery contributes to successful outcomes. CI - Copyright (c) The Author(s), 2024. Published by Radcliffe Group Ltd. FAU - Arnautovic, Jelena Z AU - Arnautovic JZ AD - Department of Cardiovascular Medicine and Internal Medicine Henry Ford Macomb Clinton Township, MI, US. FAU - Ya'Qoub, Lina AU - Ya'Qoub L AD - Department of Cardiovascular Medicine, Saint Mary's Regional Medical Center Reno, NV, US. FAU - Wajid, Zarghoona AU - Wajid Z AD - Department of Internal Medicine, Henry Ford Rochester Rochester, MI, US. FAU - Jacob, Chris AU - Jacob C AD - Department of Cardiovascular Medicine, Henry Ford Warren Warren, MI, US. FAU - Murlidhar, Manish AU - Murlidhar M AD - Department of Internal Medicine, Mayo Clinic Rochester, MN, US. FAU - Damlakhy, Ahmad AU - Damlakhy A AD - Department of Internal Medicine, Detroit Medical Center/Sinai Grace Hospital/Wayne State University Detroit, MI, US. FAU - Walji, Mohammed AU - Walji M AD - Department of Cardiovascular Medicine and Internal Medicine Henry Ford Macomb Clinton Township, MI, US. LA - eng PT - Journal Article PT - Review DEP - 20241028 PL - England TA - Interv Cardiol JT - Interventional cardiology (London, England) JID - 101559687 PMC - PMC11577872 OTO - NOTNLM OT - MitraClip OT - PASCAL OT - TEER OT - TriClip OT - mitral and tricuspid regurgitation OT - mitral and tricuspid valve repair OT - transcatheter edge-to-edge repair COIS- Disclosure: LY is the guest co-editor of the special collection containing this paper. All other authors have no conflicts of interest to declare. EDAT- 2024/11/21 06:21 MHDA- 2024/11/21 06:22 PMCR- 2024/10/28 CRDT- 2024/11/21 04:50 PHST- 2024/03/21 00:00 [received] PHST- 2024/08/07 00:00 [accepted] PHST- 2024/11/21 06:22 [medline] PHST- 2024/11/21 06:21 [pubmed] PHST- 2024/11/21 04:50 [entrez] PHST- 2024/10/28 00:00 [pmc-release] AID - 10.15420/icr.2024.08 [doi] PST - epublish SO - Interv Cardiol. 2024 Oct 28;19:e20. doi: 10.15420/icr.2024.08. eCollection 2024. PMID- 39569384 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241122 IS - 1756-1485 (Electronic) IS - 1756-1477 (Print) IS - 1756-1485 (Linking) VI - 19 DP - 2024 TI - British Cardiovascular Intervention Society Training Culture Focus Group Position Statement: Bringing Trainees and Trainers Together. PG - e22 LID - 10.15420/icr.2024.07 [doi] LID - e22 AB - Unprofessional behaviour within cardiology has been well documented and commonly occurs within the cardiac catheterisation laboratory, with higher rates in interventional subspecialities. While most trainees have positive experiences and encounters within the catheterisation laboratory, around one in five report experiencing bullying. This not only has a significant negative impact on the individuals directly involved, but also on the wider multidisciplinary team; importantly, it will have a deleterious effect on patient safety. The British Cardiovascular Intervention Society established the Training Culture Focus Group in 2022 to analyse and offer potential solutions to this pressing issue. We recommend that a cohesive approach between trainers and trainees is the most effective way to reduce unprofessional behaviour incidents, thus improving departmental workplace culture and a subsequent reduction in adverse patient safety events. CI - Copyright (c) The Author(s), 2024. Published by Radcliffe Group Ltd. FAU - Gilpin, Thomas R AU - Gilpin TR AD - Coronary Research Group, University Hospital Southampton UK. AD - Faculty of Medicine, University of Southampton UK. FAU - Morgan, Holly AU - Morgan H AD - Faculty of Cardiovascular Medicine, Kings College London UK. FAU - Camm, Christian Fielder AU - Camm CF AD - Keeble College, University of Oxford UK. FAU - Moss, Alexandra AU - Moss A AD - Heart and Lung Centre, New Cross Hospital Wolverhampton, UK. FAU - Cotton, James AU - Cotton J AD - Heart and Lung Centre, New Cross Hospital Wolverhampton, UK. FAU - Bhatia, Raghav T AU - Bhatia RT AD - Hull University Teaching Hospitals NHS Trust Hull, UK. AD - Cardiovascular Clinical Academic Group, St George's, University of London UK. FAU - McKenzie, Dan AU - McKenzie D AD - Cardiology Department, Royal United Hospital Bath, UK. FAU - Al-Lamee, Rasha AU - Al-Lamee R AD - National Heart and Lung Institute, Imperial College London London, UK. FAU - Ray, Simon AU - Ray S AD - Cardiology, Manchester University Hospitals Manchester, UK. FAU - Curzen, Nick AU - Curzen N AD - Coronary Research Group, University Hospital Southampton UK. AD - Faculty of Medicine, University of Southampton UK. LA - eng PT - Journal Article PT - Review DEP - 20241104 PL - England TA - Interv Cardiol JT - Interventional cardiology (London, England) JID - 101559687 PMC - PMC11577867 OTO - NOTNLM OT - Cardiology training culture OT - bullying in the workplace OT - cardiac catheterisation laboratory OT - interventional cardiology OT - patient safety COIS- Disclosure: TRG has received a research grant from Caviar Biotech and Wessex Heartbeat, speaker honoraria from Novartis, Astra Zeneca and Cordis, and travel support for attending meetings from Cordis, Abbott, British Cardiovascular Society and British Cardiovascular Intervention Society. HM was on a Boehringer medical advisory board. RTB has received a research grant from the charitable organization Cardiac Risk in the Young and is a British Junior Cardiology Association council representee for the North and East Yorkshire. RAL has participated in a trial steering committee for Janssen Pharmaceuticals and has received speakers' honoraria from Abbott Vascular, Fondazione Internazionale Menarini, Medtronic, Philips and Servier Pharmaceuticals. NC has received grants from Boston Scientific, Beckmann Coulter, Haemonetics and Heartflow and speaker honoraria from Heartflow and CAD International; and is on the editorial board of Interventional Cardiology; this did not influence peer review. All other authors have no conflicts of interest to declare. EDAT- 2024/11/21 06:21 MHDA- 2024/11/21 06:22 PMCR- 2024/11/04 CRDT- 2024/11/21 04:50 PHST- 2024/03/03 00:00 [received] PHST- 2024/06/05 00:00 [accepted] PHST- 2024/11/21 06:22 [medline] PHST- 2024/11/21 06:21 [pubmed] PHST- 2024/11/21 04:50 [entrez] PHST- 2024/11/04 00:00 [pmc-release] AID - 10.15420/icr.2024.07 [doi] PST - epublish SO - Interv Cardiol. 2024 Nov 4;19:e22. doi: 10.15420/icr.2024.07. eCollection 2024. PMID- 39566820 OWN - NLM STAT- MEDLINE DCOM- 20250301 LR - 20250529 IS - 1885-5857 (Electronic) IS - 1885-5857 (Linking) VI - 78 IP - 3 DP - 2025 Mar TI - Catheter-directed interventions in acute pulmonary embolism. Position statement of SEC-Interventional Cardiology Association/SEC-Ischemic Heart Disease and Acute Cardiovascular Care Association/SEC-Working Group on Pulmonary Hypertension. PG - 239-251 LID - S1885-5857(24)00333-5 [pii] LID - 10.1016/j.rec.2024.09.011 [doi] AB - Pulmonary embolism (PE) is the leading cause of hospital death and the third most frequent cause of cardiovascular mortality. Traditionally, treatment options have included anticoagulation, thrombolysis, or surgery; however, catheter-directed interventions (CDI), including catheter-directed thrombolysis and aspiration thrombectomy, have been developed for patients with intermediate- or high-risk PE. These techniques can rapidly improve right ventricular function, hemodynamic status, and mortality in some patients, although there is a lack of evidence from randomized controlled trials. This document, prepared by the Interventional Cardiology Association, the Association of Ischemic Heart Disease and Acute Cardiovascular Care, and the Working Group on Pulmonary Hypertension of the Spanish Society of Cardiology (SEC), reviews the current recommendations and available evidence on the management of PE. It emphasizes the importance of rapid response teams, risk stratification, and early patient monitoring in identifying candidates for reperfusion. Based on existing clinical evidence on CDI, the document discusses various clinical scenarios and provides guidance on patient selection, particularly in situations of uncertainty due to insufficient evidence. Lastly, it describes periprocedural support, highlighting the necessary multidisciplinary approach to improve outcomes and reduce morbidity and mortality in patients with PE. CI - Copyright (c) 2024 Sociedad Espanola de Cardiologia. Published by Elsevier Espana, S.L.U. All rights reserved. FAU - Salinas, Pablo AU - Salinas P AD - Servicio de Cardiologia, Hospital Universitario Clinico San Carlos, Instituto de Investigacion Sanitaria del Hospital Clinico San Carlos (IdISSC), Madrid, Spain. Electronic address: salinas.pablo@gmail.com. FAU - Cid Alvarez, Ana Belen AU - Cid Alvarez AB AD - Servicio de Cardiologia, Complexo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, A Coruna, Spain; Centro de Investigacion Biomedica en Red de Enfermedades Cardiovasculares (CIBERCV), Spain. FAU - Jorge Perez, Pablo AU - Jorge Perez P AD - Unidad de Cuidados Cardiacos Agudos, Complejo Hospitalario Universitario de Canarias, Santa Cruz de Tenerife, Spain. FAU - Vazquez-Alvarez, Maria Eugenia AU - Vazquez-Alvarez ME AD - Servicio de Cardiologia, Hospital General Universitario Gregorio Maranon, Instituto de Investigacion Sanitaria Gregorio Maranon, Madrid, Spain; Centro de Investigacion Biomedica en Red de Enfermedades Cardiovasculares (CIBERCV), Spain. FAU - Jurado-Roman, Alfonso AU - Jurado-Roman A AD - Servicio de Cardiologia, Hospital Universitario La Paz, Madrid, Spain. FAU - Juarez, Miriam AU - Juarez M AD - Unidad de Cuidados Cardiologicos Agudos, Hospital Gregorio Maranon, Instituto de Investigacion Sanitaria Gregorio Maranon, Madrid, Spain; Centro de Investigacion Biomedica en Red de Enfermedades Cardiovasculares (CIBERCV), Spain. FAU - Corbi-Pascual, Miguel AU - Corbi-Pascual M AD - Unidad de Cuidados Intensivos Cardiologicos, Servicio de Cardiologia, Complejo Hospitalario Universitario de Albacete, Albacete, Spain. FAU - Velazquez Martin, Maite AU - Velazquez Martin M AD - Servicio de Cardiologia, Hospital Universitario 12 de Octubre, Instituto de Investigacion Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain; Centro de Investigacion Biomedica en Red de Enfermedades Cardiovasculares (CIBERCV), Spain. FAU - Jimenez-Mazuecos, Jesus AU - Jimenez-Mazuecos J AD - Servicio de Cardiologia, Complejo Hospitalario Universitario de Albacete, Albacete, Spain. FAU - Rosillo Rodriguez, Sandra Ofelia AU - Rosillo Rodriguez SO AD - Unidad de Cuidados Agudos Cardiologicos, Hospital Universitario La Paz, Instituto de Investigacion Hospital Universitario La Paz (IdiPAZ), Madrid, Spain. FAU - Ruiz Quevedo, Valeriano AU - Ruiz Quevedo V AD - Seccion de Hemodinamica y Cardiologia Intervencionista, Area Clinica del Corazon, Hospital Universitario de Navarra, Pamplona, Navarra, Spain. FAU - Lazaro, Maria AU - Lazaro M AD - Servicio de Cardiologia, Hospital General Universitario de Toledo, Toledo, Spain. FAU - Viana-Tejedor, Ana AU - Viana-Tejedor A AD - Servicio de Cardiologia, Hospital Universitario Clinico San Carlos, Instituto de Investigacion Sanitaria del Hospital Clinico San Carlos (IdISSC), Universidad Complutense de Madrid, Madrid, Spain. FAU - Martin Moreiras, Javier AU - Martin Moreiras J AD - Servicio de Cardiologia, Complejo Asistencial Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), Salamanca, Spain; Centro de Investigacion Biomedica en Red de Enfermedades Cardiovasculares (CIBERCV), Spain. FAU - Martin-Asenjo, Roberto AU - Martin-Asenjo R AD - Servicio de Cardiologia, Hospital Universitario 12 de Octubre, Instituto de Investigacion Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain. LA - eng LA - spa PT - Journal Article PT - Practice Guideline PT - Review DEP - 20241119 PL - Spain TA - Rev Esp Cardiol (Engl Ed) JT - Revista espanola de cardiologia (English ed.) JID - 101587954 SB - IM MH - Humans MH - *Pulmonary Embolism/therapy MH - *Thrombolytic Therapy/methods MH - *Societies, Medical MH - Acute Disease MH - *Cardiology MH - *Thrombectomy/methods MH - *Hypertension, Pulmonary/therapy MH - *Cardiac Catheterization/methods OTO - NOTNLM OT - Embolia pulmonar OT - Pulmonary embolism OT - Thrombectomy OT - Thrombolytic therapy OT - Tratamiento trombolitico OT - Trombectomia EDAT- 2024/11/21 00:22 MHDA- 2025/03/03 00:54 CRDT- 2024/11/20 19:24 PHST- 2024/07/23 00:00 [received] PHST- 2024/09/18 00:00 [accepted] PHST- 2025/03/03 00:54 [medline] PHST- 2024/11/21 00:22 [pubmed] PHST- 2024/11/20 19:24 [entrez] AID - S1885-5857(24)00333-5 [pii] AID - 10.1016/j.rec.2024.09.011 [doi] PST - ppublish SO - Rev Esp Cardiol (Engl Ed). 2025 Mar;78(3):239-251. doi: 10.1016/j.rec.2024.09.011. Epub 2024 Nov 19. PMID- 39565818 OWN - NLM STAT- MEDLINE DCOM- 20241120 LR - 20260904 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 19 IP - 11 DP - 2024 TI - Training providers to implement heart failure shared medical appointments: A qualitative evaluation. PG - e0310639 LID - 10.1371/journal.pone.0310639 [doi] LID - e0310639 AB - Shared medical appointments (SMA) help patients learn skills to self-manage chronic medical conditions. While this model of care delivery is thought to improve access to care with an efficient use of healthcare providers' time, many healthcare teams struggle to implement this healthcare model. Guidance and training resources on the implementation of SMAs is expected to improve adoption, implementation and sustainability of SMAs. Our evaluation team collaborated with the HF SMA trainer to complete a developmental formative evaluation of a two-day training program with a goal of adapting the training program and to better suit the needs and resources of healthcare teams interested in implementing HF-SMAs. Our evaluation team interviewed members of healthcare teams participating during each stage of training: pre-training, post-training, and post-implementation. The evaluation team also observed training sessions and reviewed minutes from debrief and training team meetings. Qualitative data collected from interviews, observations and document reviews were analyzed using matrix analysis with a focus on identifying potential adaptations to improve the HF-SMA training program. Data summaries were presented by the evaluation team to the training team for consideration. Training program participants found the training comprehensive, useful, and helpful; they highlighted how the trainers were experienced SMA providers who shared lessons learned. While participants found the training to be useful, opportunities for improvement, success of the virtual format and identified six adaptations: 1) the two-day training was reduced to short online modules, 2) curriculum was adapted to fit local site's needs, 3) added periodic one-on-one coaching, 4) shifted training to focus on skills and knowledge needed for each team member requirements, 5) adapted curriculum provides for more team building during premeeting assignments, and 6) training had more information included. We offer/present an improved model for a HF-SMA training program. Future studies, potentially using comparative designs to measure success and sustainability are needed. CI - Copyright: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication. FAU - Hearns, Rene AU - Hearns R AUID- ORCID: 0009-0003-6394-4068 AD - VA Northeast Ohio Healthcare System, Medicine Service, Cleveland, OH, United States of America. FAU - Ball, Sherry L AU - Ball SL AD - VA Northeast Ohio Healthcare System, Medicine Service, Cleveland, OH, United States of America. FAU - Wilkerson, Tai-Lyn AU - Wilkerson TL AD - VA Northeast Ohio Healthcare System, Medicine Service, Cleveland, OH, United States of America. FAU - Gee, Julie AU - Gee J AD - VA Northeast Ohio Healthcare System, Medicine Service, Cleveland, OH, United States of America. FAU - LaForest, Sharon AU - LaForest S AUID- ORCID: 0000-0003-4076-186X AD - VA Northeast Ohio Healthcare System, Medicine Service, Cleveland, OH, United States of America. FAU - Schaub, Kimberley AU - Schaub K AD - VA Northeast Ohio Healthcare System, Medicine Service, Cleveland, OH, United States of America. FAU - Taveira, Tracey AU - Taveira T AD - VA Providence Health Care System, Medicine Service, Providence, RI, United States of America. AD - The University of Rhode Island, College of Pharmacy, Kingston, RI, United States of America. FAU - Wu, Wen-Chih AU - Wu WC AUID- ORCID: 0000-0002-2834-2024 AD - VA Providence Health Care System, Medicine Service, Providence, RI, United States of America. AD - Department of Medicine, Alpert Medical School & Department of Epidemiology School of Public Health, Brown University, Providence, RI, United States of America. LA - eng GR - IRP 20-003/VA Health Services/ PT - Journal Article PT - Research Support, U.S. Gov't, Non-P.H.S. DEP - 20241120 PL - United States TA - PLoS One JT - PloS one JID - 101285081 SB - IM MH - Humans MH - *Heart Failure/therapy MH - *Shared Medical Appointments MH - *Health Personnel/education MH - Qualitative Research MH - Patient Care Team PMC - PMC11578495 COIS- The authors have declared that no competing interests exist. EDAT- 2024/11/20 18:22 MHDA- 2024/11/20 18:23 PMCR- 2024/11/20 CRDT- 2024/11/20 13:43 PHST- 2024/03/04 00:00 [received] PHST- 2024/08/30 00:00 [accepted] PHST- 2024/11/20 18:23 [medline] PHST- 2024/11/20 18:22 [pubmed] PHST- 2024/11/20 13:43 [entrez] PHST- 2024/11/20 00:00 [pmc-release] AID - PONE-D-24-07219 [pii] AID - 10.1371/journal.pone.0310639 [doi] PST - epublish SO - PLoS One. 2024 Nov 20;19(11):e0310639. doi: 10.1371/journal.pone.0310639. eCollection 2024. PMID- 39565324 OWN - NLM STAT- MEDLINE DCOM- 20250115 LR - 20250517 IS - 1522-9645 (Electronic) IS - 0195-668X (Linking) VI - 46 IP - 3 DP - 2025 Jan 16 TI - Non-bacterial thrombotic endocarditis: a clinical and pathophysiological reappraisal. PG - 236-249 LID - 10.1093/eurheartj/ehae788 [doi] AB - Non-bacterial thrombotic endocarditis (NBTE), formerly recognized as marantic endocarditis, represents a rare cardiovascular pathology intricately linked with hypercoagulable states, notably malignancy and autoimmune disorders. Characterized by the development of sterile vegetations comprised of fibrin and platelets on cardiac valves, NBTE poses a diagnostic challenge due to its resemblance to infective endocarditis. Therapeutic endeavours primarily revolve around addressing the underlying aetiology and instituting anticoagulant regimens to forestall embolic events, with surgical intervention seldom warranted. Non-bacterial thrombotic endocarditis frequently coexists with malignancies and autoimmune conditions, such as lupus and antiphospholipid antibody syndrome, and, more recently, has been associated with COVID-19. Its pathogenesis is underpinned by a complex interplay of endothelial dysfunction, hypercoagulability, hypoxia, and immune complex deposition. Clinical manifestations typically manifest as embolic phenomena, particularly cerebrovascular accidents, bearing substantial mortality rates. Diagnosis necessitates a high index of suspicion and meticulous exclusion of infective endocarditis, often facilitated by advanced cardiac imaging modalities. Anticoagulation, typically employing low molecular weight heparin or warfarin, constitutes the cornerstone of pharmacological intervention. Surgical recourse may be warranted in instances of refractory heart failure or recurrent embolic events. Given its multifaceted nature, the management of NBTE mandates a multidisciplinary approach, with prognosis contingent upon individual clinical intricacies. Future endeavours should prioritize further research to refine therapeutic strategies and enhance patient outcomes. CI - (c) The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com. FAU - Ahmed, Omair AU - Ahmed O AUID- ORCID: 0000-0002-8674-0506 AD - Department of Internal Medicine, Henry Ford Jackson Hospital, Jackson, MI 49201, USA. FAU - King, Nicholas E AU - King NE AD - Division of Cardiovascular Medicine, McGovern Medical School, University of Texas Health Sciences Center at Houston, Houston, TX 77030, USA. FAU - Qureshi, Muhammad Ahmad AU - Qureshi MA AD - Department of Internal Medicine, Henry Ford Jackson Hospital, Jackson, MI 49201, USA. FAU - Choudhry, Abira Afzal AU - Choudhry AA AD - Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI 48109, USA. FAU - Osama, Muhammad AU - Osama M AD - Department of Internal Medicine, Rochester Regional Health, Rochester, NY 14617, USA. FAU - Zehner, Carl AU - Zehner C AUID- ORCID: 0000-0002-4368-767X AD - Department of Cardiology, University of Texas Health Sciences Center, MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA. FAU - Ali, Abdelrahman AU - Ali A AD - Department of Cardiology, University of Texas Health Sciences Center, MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA. FAU - Hamzeh, Ihab R AU - Hamzeh IR AD - Department of Cardiology, University of Texas Health Sciences Center, MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA. FAU - Palaskas, Nicolas L AU - Palaskas NL AUID- ORCID: 0000-0001-7565-1797 AD - Department of Cardiology, University of Texas Health Sciences Center, MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA. FAU - Thompson, Kara A AU - Thompson KA AD - Department of Cardiology, University of Texas Health Sciences Center, MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA. FAU - Koutroumpakis, Efstratios AU - Koutroumpakis E AUID- ORCID: 0000-0002-6757-6480 AD - Department of Cardiology, University of Texas Health Sciences Center, MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA. FAU - Deswal, Anita AU - Deswal A AUID- ORCID: 0000-0002-6147-9591 AD - Department of Cardiology, University of Texas Health Sciences Center, MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA. FAU - Yusuf, Syed Wamique AU - Yusuf SW AUID- ORCID: 0000-0002-6966-6068 AD - Department of Cardiology, University of Texas Health Sciences Center, MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA. LA - eng PT - Journal Article PT - Review PL - England TA - Eur Heart J JT - European heart journal JID - 8006263 RN - 0 (Anticoagulants) SB - IM MH - Humans MH - *Endocarditis, Non-Infective/diagnosis/physiopathology/therapy/etiology MH - COVID-19/complications MH - Anticoagulants/therapeutic use MH - *Thrombosis/diagnosis/physiopathology MH - SARS-CoV-2 OTO - NOTNLM OT - Cardio-embolism OT - Endocarditis OT - Marantic endocarditis OT - Non-bacterial thrombotic endocarditis EDAT- 2024/11/20 12:25 MHDA- 2025/01/16 00:20 CRDT- 2024/11/20 10:34 PHST- 2024/05/06 00:00 [received] PHST- 2024/08/11 00:00 [revised] PHST- 2024/10/30 00:00 [accepted] PHST- 2025/01/16 00:20 [medline] PHST- 2024/11/20 12:25 [pubmed] PHST- 2024/11/20 10:34 [entrez] AID - 7905393 [pii] AID - 10.1093/eurheartj/ehae788 [doi] PST - ppublish SO - Eur Heart J. 2025 Jan 16;46(3):236-249. doi: 10.1093/eurheartj/ehae788. PMID- 39564155 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250130 IS - 0974-2069 (Print) IS - 0974-5149 (Electronic) IS - 0974-5149 (Linking) VI - 17 IP - 3 DP - 2024 May-Jun TI - Challenges in congenital heart disease in the Amazon region countries: A scoping review. PG - 188-195 LID - 10.4103/apc.apc_73_24 [doi] AB - INTRODUCTION: This study aimed to systematically analyze and describe the main challenges of congenital heart diseases (CHDs) in the countries in the Amazon region. METHODS: The methodology followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews checklist utilizing the Medline, Embase, Lilacs, and Google Scholar databases. The inclusion criteria were articles addressing any topic involving CHD in the Amazon region. Incomplete articles, book chapters, lectures, conference abstracts, and editorials were excluded. RESULTS: Nine studies were identified, 7 of which were published in the last decade and were of Colombian and Brazilian origin. The methodology of the studies was cross-sectional and ecological, evaluating the regional and epidemiological factors, challenges to diagnosis and treatment, multidisciplinary team challenges, and the impact of the COVID-19 pandemic. Studies carried out by surgeons demonstrate more existing data regarding the challenges of the health-care system. CONCLUSIONS: There is growing interest in analyzing the situation of CHD in the region. However, only a few studies are available, mostly on ecological and cross-sectional analysis. These records show the lack of hospital infrastructure and multidisciplinary teams for the diagnosis and treatment of CHD in the Amazon region; we see an initiative by specialists from two countries (Colombia and Brazil) to demonstrate the difficulties by seeking international training programs and government aid to improve the health system situation. CI - Copyright: (c) 2024 Annals of Pediatric Cardiology. FAU - Almeida, Sophia Livas de Morais AU - Almeida SLM AD - Postgraduate Program in Health Sciences, Medical School, Federal University of Amazonas, Manaus, AM, Brazil. FAU - da Cunha, Andreza Dos Santos Laranjeira AU - da Cunha ADSL AD - Postgraduate Program in Health Sciences, Medical School, Federal University of Amazonas, Manaus, AM, Brazil. FAU - Silva, Renata de Castro AU - Silva RC AD - Postgraduate Program in Health Sciences, Medical School, Federal University of Amazonas, Manaus, AM, Brazil. FAU - Dos Santos, Raillon Keven AU - Dos Santos RK AD - Postgraduate Program in Health Sciences, Medical School, Federal University of Amazonas, Manaus, AM, Brazil. FAU - Novelleto, Ana Luiza Menezes Teles AU - Novelleto ALMT AD - Postgraduate Program in Health Sciences, Medical School, Federal University of Amazonas, Manaus, AM, Brazil. FAU - Estevam, Thayla Lais Lima AU - Estevam TLL AD - Postgraduate Program in Health Sciences, Medical School, Federal University of Amazonas, Manaus, AM, Brazil. FAU - de Carvalho, Luana Izabela Azevedo AU - de Carvalho LIA AD - Medical School, Amazonas State University (UEA), Manaus, AM, Brazil. FAU - Tuda, Luisa Tiemi Souza AU - Tuda LTS AD - Medical School, Federal University of Amazonas, Manaus, AM, Brazil. FAU - Souza, Celsa da Silva Moura AU - Souza CDSM AD - Postgraduate Program in Health Sciences, Medical School, Federal University of Amazonas, Manaus, AM, Brazil. FAU - Araujo Junior, Edward AU - Araujo Junior E AD - Department of Obstetrics, Paulista School of Medicine, Federal University of Sao Paulo (EPM-UNIFESP), Sao Paulo, SP, Brazil. AD - Discipline of Woman Health, Municipal University of Sao Caetano do Sul, Sao Caetano do Sul, SP, Brazil. FAU - Amorim, Luciane Alves da Rocha AU - Amorim LADR AD - Postgraduate Program in Health Sciences, Medical School, Federal University of Amazonas, Manaus, AM, Brazil. LA - eng PT - Journal Article PT - Scoping Review DEP - 20241001 PL - India TA - Ann Pediatr Cardiol JT - Annals of pediatric cardiology JID - 101495459 PMC - PMC11573190 OTO - NOTNLM OT - Developing countries OT - heart abnormality OT - heart surgery OT - low- and middle-income countries COIS- There are no conflicts of interest. EDAT- 2024/11/20 11:04 MHDA- 2024/11/20 11:05 PMCR- 2024/05/01 CRDT- 2024/11/20 04:31 PHST- 2024/04/19 00:00 [received] PHST- 2024/05/24 00:00 [revised] PHST- 2024/08/28 00:00 [accepted] PHST- 2024/11/20 11:04 [pubmed] PHST- 2024/11/20 11:05 [medline] PHST- 2024/11/20 04:31 [entrez] PHST- 2024/05/01 00:00 [pmc-release] AID - APC-17-188 [pii] AID - 10.4103/apc.apc_73_24 [doi] PST - ppublish SO - Ann Pediatr Cardiol. 2024 May-Jun;17(3):188-195. doi: 10.4103/apc.apc_73_24. Epub 2024 Oct 1. PMID- 39563912 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241121 IS - 2634-3916 (Electronic) IS - 2634-3916 (Linking) VI - 5 IP - 6 DP - 2024 Nov TI - Cardiac anatomic digital twins: findings from a single national centre. PG - 725-734 LID - 10.1093/ehjdh/ztae070 [doi] AB - AIMS: New three-dimensional cardiac visualization technologies are increasingly employed for anatomic digital twins in pre-operative planning. However, the role and influence of extended reality (virtual, augmented, or mixed) within heart team settings remain unclear. We aimed to assess the impact of mixed reality visualization of the intracardiac anatomy on surgical decision-making in patients with complex heart defects. METHODS AND RESULTS: Between September 2020 and December 2022, we recruited 50 patients and generated anatomic digital twins and visualized them in mixed reality. These anatomic digital twins were presented to the heart team after initial decisions were made using standard visualization methods. Changes in the surgical strategy were recorded. Additionally, heart team members rated their mixed reality experience through a questionnaire, and post-operative outcomes were registered. Anatomic digital twins changed the initially decided upon surgical strategies for 68% of cases. While artificial intelligence facilitated the rapid creation of digital anatomic twins, manual corrections were always necessary. CONCLUSION: In conclusion, mixed reality anatomic digital twins added information to standard visualization methods and significantly influenced surgical planning, with evidence that these strategies can be implemented safely without additional risk. CI - (c) The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. FAU - Lippert, Matthias AU - Lippert M AUID- ORCID: 0000-0003-0259-292X AD - The Intervention Centre, Division for Technology and Innovation, Oslo University Hospital, Rikshospitalet, PO Box 4950 Nydalen, Oslo 0424, Norway. AD - Institute of Clinical Medicine, University of Oslo, Kirkeveien 166, Oslo 0450, Norway. FAU - Dumont, Karl-Andreas AU - Dumont KA AD - Department of Cardiothoracic Surgery, Oslo University Hospital, Oslo, Norway. FAU - Birkeland, Sigurd AU - Birkeland S AD - Department of Cardiothoracic Surgery, Oslo University Hospital, Oslo, Norway. FAU - Nainamalai, Varatharajan AU - Nainamalai V AD - The Intervention Centre, Division for Technology and Innovation, Oslo University Hospital, Rikshospitalet, PO Box 4950 Nydalen, Oslo 0424, Norway. FAU - Solvin, Havard AU - Solvin H AD - The Intervention Centre, Division for Technology and Innovation, Oslo University Hospital, Rikshospitalet, PO Box 4950 Nydalen, Oslo 0424, Norway. AD - Institute of Clinical Medicine, University of Oslo, Kirkeveien 166, Oslo 0450, Norway. FAU - Suther, Kathrine Ryden AU - Suther KR AD - Department of Radiology, Division of Radiology and Nuclear Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway. FAU - Bendz, Bjorn AU - Bendz B AUID- ORCID: 0000-0002-1392-6481 AD - Institute of Clinical Medicine, University of Oslo, Kirkeveien 166, Oslo 0450, Norway. AD - Department of Cardiology, Oslo University Hospital, Oslo, Norway. FAU - Elle, Ole Jakob AU - Elle OJ AD - The Intervention Centre, Division for Technology and Innovation, Oslo University Hospital, Rikshospitalet, PO Box 4950 Nydalen, Oslo 0424, Norway. AD - Department of Informatics, University of Oslo, Oslo, Norway. FAU - Brun, Henrik AU - Brun H AD - The Intervention Centre, Division for Technology and Innovation, Oslo University Hospital, Rikshospitalet, PO Box 4950 Nydalen, Oslo 0424, Norway. AD - Department for Pediatric Cardiology, Oslo University Hospital, Oslo, Norway. LA - eng PT - Journal Article DEP - 20240918 PL - England TA - Eur Heart J Digit Health JT - European heart journal. Digital health JID - 101778323 PMC - PMC11570384 OTO - NOTNLM OT - Artificial intelligence OT - Cardiothoracic surgery OT - Congenital heart disease OT - Extended reality OT - HoloLens COIS- Conflict of interest: H.B. and O.J.E. are co-inventors of technology licensed by the company HoloCare AS and hold shares in the company indirectly through Inven2 AS. All other authors declare no financial or non-financial competing interests. EDAT- 2024/11/20 11:04 MHDA- 2024/11/20 11:05 PMCR- 2024/09/18 CRDT- 2024/11/20 04:26 PHST- 2024/03/26 00:00 [received] PHST- 2024/07/11 00:00 [revised] PHST- 2024/07/30 00:00 [accepted] PHST- 2024/11/20 11:05 [medline] PHST- 2024/11/20 11:04 [pubmed] PHST- 2024/11/20 04:26 [entrez] PHST- 2024/09/18 00:00 [pmc-release] AID - ztae070 [pii] AID - 10.1093/ehjdh/ztae070 [doi] PST - epublish SO - Eur Heart J Digit Health. 2024 Sep 18;5(6):725-734. doi: 10.1093/ehjdh/ztae070. eCollection 2024 Nov. PMID- 39563855 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241121 IS - 2050-0904 (Print) IS - 2050-0904 (Electronic) IS - 2050-0904 (Linking) VI - 12 IP - 11 DP - 2024 Nov TI - A Comprehensive Insight Into Primary Intimal Sarcoma of the Pulmonary Artery; From Diagnosis to Management: A Case Report and Review of the Literature. PG - e9580 LID - 10.1002/ccr3.9580 [doi] LID - e9580 AB - Primary intimal sarcoma of the pulmonary artery is a rare and aggressive malignancy that presents significant diagnostic and therapeutic challenges due to its nonspecific symptoms and propensity for late detection. This case report aimed to elucidate the diagnostic journey, surgical intervention, and multidisciplinary management of this rare entity. In September 2023, a 42-year-old male presented with dyspnea on exertion and retrosternal chest pain, classified as NYHA FC II. Initial investigations, including ECG and lab tests, indicated tachycardia and elevated troponin and NT-pro-BNP levels. Transthoracic and transesophageal echocardiography identified a multilobulated mass in the right ventricular outflow tract and main pulmonary artery. Cardiac MRI and CT angiography confirmed a high-grade pleomorphic spindle cell tumor, leading to surgical resection in October 2023. Histopathology confirmed intimal sarcoma. Postsurgery, the patient underwent chemotherapy and radiotherapy, showing significant clinical improvement and no recurrence on follow-up PET-CT. This case highlights the importance of a multidisciplinary approach in diagnosing and managing primary intimal sarcoma of the pulmonary artery, emphasizing the role of advanced imaging, timely surgical intervention, and combined chemotherapy with radiotherapy in improving patient outcomes. CI - (c) 2024 The Author(s). Clinical Case Reports published by John Wiley & Sons Ltd. FAU - Alizadehasl, Azin AU - Alizadehasl A AD - Cardio-Oncology Research Center Rajaie Cardiovascular Medical and Research Institute Tehran Iran. FAU - Najdaghi, Soroush AU - Najdaghi S AD - Heart Failure Research Center, Cardiovascular Research Institute Isfahan University of Medical Science Isfahan Iran. FAU - Mohseni Salehi, Maryam AU - Mohseni Salehi M AD - Cardio-Oncology Research Center Rajaie Cardiovascular Medical and Research Institute Tehran Iran. FAU - Meshgi, Shahla AU - Meshgi S AD - Department of Cardiac Imaging, Rajaie Cardiovascular Medical and Research Center, School of Medicine Iran University of Medical Sciences Tehran Iran. FAU - Hosseini Jebelli, Seyedeh Fatemeh AU - Hosseini Jebelli SF AD - Cardio-Oncology Research Center Rajaie Cardiovascular Medical and Research Institute Tehran Iran. FAU - Yalameh Aliabadi, Azam AU - Yalameh Aliabadi A AD - Cardio-Oncology Research Center Rajaie Cardiovascular Medical and Research Institute Tehran Iran. FAU - Hakimian, Hoda AU - Hakimian H AD - Cardio-Oncology Research Center Rajaie Cardiovascular Medical and Research Institute Tehran Iran. FAU - Forati, Sara AU - Forati S AD - Cardio-Oncology Research Center Rajaie Cardiovascular Medical and Research Institute Tehran Iran. FAU - Safavirad, Amineh AU - Safavirad A AD - Cardio-Oncology Research Center Rajaie Cardiovascular Medical and Research Institute Tehran Iran. FAU - Narimani Davani, Delaram AU - Narimani Davani D AD - Heart Failure Research Center, Cardiovascular Research Institute Isfahan University of Medical Science Isfahan Iran. LA - eng PT - Journal Article DEP - 20241118 PL - England TA - Clin Case Rep JT - Clinical case reports JID - 101620385 PMC - PMC11573721 OTO - NOTNLM OT - cardiac MRI OT - case report OT - chemotherapy OT - intimal sarcoma OT - pulmonary artery mass OT - radiotherapy COIS- The authors declare no conflicts of interest. EDAT- 2024/11/20 11:04 MHDA- 2024/11/20 11:05 PMCR- 2024/11/18 CRDT- 2024/11/20 04:26 PHST- 2024/08/10 00:00 [received] PHST- 2024/09/16 00:00 [revised] PHST- 2024/10/25 00:00 [accepted] PHST- 2024/11/20 11:05 [medline] PHST- 2024/11/20 11:04 [pubmed] PHST- 2024/11/20 04:26 [entrez] PHST- 2024/11/18 00:00 [pmc-release] AID - CCR39580 [pii] AID - 10.1002/ccr3.9580 [doi] PST - epublish SO - Clin Case Rep. 2024 Nov 18;12(11):e9580. doi: 10.1002/ccr3.9580. eCollection 2024 Nov. PMID- 39561238 OWN - NLM STAT- MEDLINE DCOM- 20241119 LR - 20250730 IS - 1941-7632 (Electronic) IS - 1941-7640 (Linking) VI - 17 IP - 11 DP - 2024 Nov TI - Contemporary State-of-the-Art PCI of Left Main Coronary Artery Disease. PG - e014026 LID - 10.1161/CIRCINTERVENTIONS.124.014026 [doi] AB - The left main coronary artery (LMCA) supplies over 70% of the myocardium, and significant LMCA disease is associated with high morbidity and mortality. With remarkable advances in percutaneous coronary intervention (PCI), including stent technology, antithrombotic agents, and evolving procedural techniques, PCI has become an important treatment option in clinical practice guidelines for the revascularization of LMCA disease. In contemporary clinical practice, a heart-team approach to shared decision-making, considering clinical/anatomic factors along with patient preferences, is emphasized for patients with significant LMCA disease requiring myocardial revascularization. Furthermore, recent progress in PCI procedures combined with intravascular imaging or functional guidance has resulted in significant improvements in PCI outcomes, especially for complex lesions, including LMCA disease. Nevertheless, owing to inherent anatomic complexities and frequent multivessel involvement, several unmet issues remain regarding the determination of the appropriate treatment approach for significant LMCA disease, for which further clinical research is required. This contemporary review article provides a comprehensive overview of left main PCI based on current guidelines and underlying trial data, addresses important unresolved diagnostic and therapeutic issues, and identifies future perspectives likely to advance progress in this field. FAU - Wee, Seong-Bong AU - Wee SB AD - Division of Interventional Cardiology, Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea (S.-B.W., J.-M.A., D.-Y.K., S.-J.P., D.-W.P.). FAU - Ahn, Jung-Min AU - Ahn JM AUID- ORCID: 0000-0003-4031-391X AD - Division of Interventional Cardiology, Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea (S.-B.W., J.-M.A., D.-Y.K., S.-J.P., D.-W.P.). FAU - Kang, Do-Yoon AU - Kang DY AUID- ORCID: 0000-0002-6307-0562 AD - Division of Interventional Cardiology, Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea (S.-B.W., J.-M.A., D.-Y.K., S.-J.P., D.-W.P.). FAU - Park, Seung-Jung AU - Park SJ AUID- ORCID: 0000-0002-9187-5405 AD - Division of Interventional Cardiology, Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea (S.-B.W., J.-M.A., D.-Y.K., S.-J.P., D.-W.P.). FAU - Park, Duk-Woo AU - Park DW AUID- ORCID: 0000-0001-6643-0239 AD - Division of Interventional Cardiology, Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea (S.-B.W., J.-M.A., D.-Y.K., S.-J.P., D.-W.P.). LA - eng PT - Journal Article PT - Review DEP - 20241119 PL - United States TA - Circ Cardiovasc Interv JT - Circulation. Cardiovascular interventions JID - 101499602 SB - IM MH - Humans MH - *Coronary Artery Disease/therapy/diagnostic imaging/mortality MH - *Percutaneous Coronary Intervention/adverse effects/mortality/instrumentation MH - Treatment Outcome MH - Risk Factors MH - Clinical Decision-Making MH - Stents MH - Practice Guidelines as Topic MH - Patient Selection MH - Decision Making, Shared OTO - NOTNLM OT - fractional flow reserve OT - intravascular ultrasonography OT - left main coronary artery diesase OT - percutaneous coronary intervention OT - tomography, optical coherence COIS- Dr Kang reports receiving speaker fees from Abbott Vascular, Daiichi-Sankyo, Viatris, Boryoung, and Daewoong Pharm. S.-J. Park reports receiving research grants or speaker fees from Abbott Vascular, Medtronic, Daiichi-Sankyo, ChongKunDang Pharm, Daewoong Pharm, and Edwards. D.-W. Park reports receiving research grants or speaker fees from Abbott Vascular, Medtronic, Daiichi-Sankyo, Edwards Lifesciences, ChongKunDang Pharm, and Daewoong Pharm. The other authors report no conflicts. EDAT- 2024/11/19 22:19 MHDA- 2024/11/20 04:19 CRDT- 2024/11/19 14:03 PHST- 2024/11/20 04:19 [medline] PHST- 2024/11/19 22:19 [pubmed] PHST- 2024/11/19 14:03 [entrez] AID - 10.1161/CIRCINTERVENTIONS.124.014026 [doi] PST - ppublish SO - Circ Cardiovasc Interv. 2024 Nov;17(11):e014026. doi: 10.1161/CIRCINTERVENTIONS.124.014026. Epub 2024 Nov 19. PMID- 39556701 OWN - NLM STAT- MEDLINE DCOM- 20241217 LR - 20260813 IS - 2047-9980 (Electronic) IS - 2047-9980 (Linking) VI - 13 IP - 24 DP - 2024 Dec 17 TI - Pharmacist Medication Titration Program for Patients With Cardiac Sarcoidosis and Systolic Heart Failure: A Retrospective Cohort Study. PG - e038965 LID - 10.1161/JAHA.124.038965 [doi] LID - e038965 AB - BACKGROUND: A multidisciplinary approach improves guideline-directed medical therapy in systolic heart failure (HF), but its efficacy in patients with HF due to cardiac sarcoidosis is unreported. METHODS AND RESULTS: In a retrospective cohort study, we reviewed 848 patients from our institutional cardiac sarcoidosis clinics, identifying those with a cardiac sarcoidosis diagnosis, HF (left ventricular ejection fraction <50%) at index evaluation, and echocardiograms within 90 days and 11 to 36 months. Patients were stratified by participation in a pharmacist-led medication therapy management (MTM) program for guideline-directed medical therapy optimization (MTM versus non-MTM [NMTM]) without randomization. Demographics, left ventricular ejection fraction, guideline-directed medical therapy (quantified by Kansas City Medical Optimization score), and immunosuppressive therapy were assessed. Primary outcomes included changes in Kansas City Medical Optimization score, left ventricular ejection fraction, and cardiovascular event-free survival (unplanned HF hospitalization, left ventricular assist device /heart transplant, or death). The final cohort included 111 patients (median age, 57 years; 34% women; 64% New York Heart Association class I-II); 43 (39%) were MTM and 68 (61%) were NMTM. Mean Kansas City Medical Optimization score was similar at index evaluation (MTM, 23.2; NMTM, 29.6; P=0.83). At follow-up (median, 16 months), the Kansas City Medical Optimization score increased significantly in both groups (MTM, 23.2 to 74.8; P<0.001; NMTM, 29.6 to 58.7; P<0.001) but was higher in MTM (P=0.001). Mean left ventricular ejection fraction trended toward higher values in MTM (44.4% versus 40.0%, P=0.05). The primary clinical outcome occurred in 1 MTM (2.3%) and 16 NMTM (23.5%) patients, with higher risk in NMTM (hazard ratio, 11.97 [95% CI, 1.58-90.54]; P=0.002). CONCLUSIONS: In this retrospective cohort study, a pharmacist-led MTM program was associated with favorable guideline-directed medical therapy optimization and lower risk of adverse cardiovascular outcomes in patients with cardiac sarcoidosis with HF. FAU - Sykora, Daniel AU - Sykora D AUID- ORCID: 0000-0002-6195-8541 AD - Mayo Clinic School of Graduate Medical Education Rochester MN. FAU - Olson, Nicole AU - Olson N AD - Department of Pharmacy Mayo Clinic Rochester Rochester MN. FAU - Churchill, Robert AU - Churchill R AD - Mayo Clinic Alix School of Medicine Rochester MN. FAU - Kim, B Michelle AU - Kim BM AD - Mayo Clinic Alix School of Medicine Rochester MN. FAU - Bratcher, Melanie AU - Bratcher M AD - Department of Cardiovascular Medicine Mayo Clinic Rochester Rochester MN. FAU - Elwazir, Mohamed AU - Elwazir M AUID- ORCID: 0000-0002-9168-5855 AD - Department of Cardiovascular Medicine Mayo Clinic Rochester Rochester MN. AD - Department of Cardiovascular Medicine Suez Canal University Ismailia Egypt. FAU - Young, Kathleen AU - Young K AUID- ORCID: 0000-0002-7071-192X AD - Department of Cardiovascular Medicine Mayo Clinic Rochester Rochester MN. FAU - Ryan, Sami AU - Ryan S AD - Department of Cardiovascular Medicine Mayo Clinic Rochester Rochester MN. FAU - Brodin, Michelle AU - Brodin M AD - Department of Pharmacy Mayo Clinic Rochester Rochester MN. FAU - Anderson, Jan AU - Anderson J AD - Department of Pharmacy Mayo Clinic Rochester Rochester MN. FAU - Saunders, Jeremiah AU - Saunders J AD - Department of Pharmacy Mayo Clinic Rochester Rochester MN. FAU - Abou Ezzeddine, Omar AU - Abou Ezzeddine O AD - Department of Cardiovascular Medicine Mayo Clinic Rochester Rochester MN. FAU - Bois, John AU - Bois J AD - Department of Cardiovascular Medicine Mayo Clinic Rochester Rochester MN. AD - Department of Diagnostic Radiology Mayo Clinic Rochester Rochester MN. FAU - Giudicessi, John AU - Giudicessi J AUID- ORCID: 0000-0001-5871-0265 AD - Department of Cardiovascular Medicine Mayo Clinic Rochester Rochester MN. FAU - Cooper, Leslie AU - Cooper L AUID- ORCID: 0000-0003-1002-3313 AD - Department of Cardiovascular Medicine Mayo Clinic Florida Jacksonville FL. FAU - Rosenbaum, Andrew AU - Rosenbaum A AUID- ORCID: 0000-0001-9202-0233 AD - Department of Cardiovascular Medicine Mayo Clinic Rochester Rochester MN. LA - eng GR - UL1 TR002377/TR/NCATS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20241214 PL - England TA - J Am Heart Assoc JT - Journal of the American Heart Association JID - 101580524 RN - 0 (Immunosuppressive Agents) SB - IM MH - Humans MH - Female MH - Male MH - Retrospective Studies MH - Middle Aged MH - *Sarcoidosis/drug therapy/complications/physiopathology MH - *Cardiomyopathies/drug therapy/physiopathology/complications MH - *Heart Failure, Systolic/drug therapy/physiopathology/mortality/diagnosis MH - *Pharmacists/organization & administration MH - *Stroke Volume/physiology MH - Aged MH - Ventricular Function, Left MH - Medication Therapy Management/statistics & numerical data/standards MH - Immunosuppressive Agents/therapeutic use MH - Treatment Outcome PMC - PMC11935548 OTO - NOTNLM OT - cardiac sarcoidosis OT - guideline-directed medical therapy OT - heart failure OT - pharmacist OT - team-based care EDAT- 2024/11/18 22:18 MHDA- 2024/12/17 12:31 PMCR- 2024/12/17 CRDT- 2024/11/18 14:33 PHST- 2024/12/17 12:31 [medline] PHST- 2024/11/18 22:18 [pubmed] PHST- 2024/11/18 14:33 [entrez] PHST- 2024/12/17 00:00 [pmc-release] AID - JAH310403 [pii] AID - 10.1161/JAHA.124.038965 [doi] PST - ppublish SO - J Am Heart Assoc. 2024 Dec 17;13(24):e038965. doi: 10.1161/JAHA.124.038965. Epub 2024 Dec 14. PMID- 39553168 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250729 IS - 1753-495X (Print) IS - 1753-4968 (Electronic) IS - 1753-495X (Linking) VI - 18 IP - 3 DP - 2025 Sep TI - Bullous lung disease in pregnancy: a case report. PG - 190-192 LID - 10.1177/1753495X241265528 [doi] AB - Bullous lung disease presenting as a pneumothorax in pregnancy has not been reported in the literature to date. We present the case of a woman in her third pregnancy presenting to routine antenatal clinic with a secondary spontaneous pneumothorax in the third trimester. We describe the multidisciplinary approach to her management with obstetrics, obstetric anaesthesiology, cardiothoracic surgery and midwifery. This included decision making around conservative management in the initial disease course, preparation for delivery and a plan for definitive surgery postnatally. Caesarean section was performed at 36 weeks' gestation owing to worsening chest pain. The underlying pathological process was deemed to be bullous lung disease which was confirmed on histology obtained from a video-assisted thoracoscopic surgery procedure done postnatally. We demonstrate the importance of the multidisciplinary team approach in the care of complex and rare medical conditions in pregnancy. CI - (c) The Author(s) 2024. FAU - McMahon, Gabriela AU - McMahon G AUID- ORCID: 0000-0003-1511-6172 AD - Department of Obstetrics and Gynaecology, Rotunda Hospital, Dublin, Ireland. RINGGOLD: 58009 FAU - McCarthy, Claire M AU - McCarthy CM AUID- ORCID: 0000-0001-8342-8050 AD - Department of Obstetrics and Gynaecology, Rotunda Hospital, Dublin, Ireland. RINGGOLD: 58009 FAU - Weedle, Rebecca AU - Weedle R AD - Department of Cardiothoracic Surgery, Mater Misericordiae University Hospital, Dublin, Ireland. RINGGOLD: 8881 FAU - Magee, Colm AU - Magee C AD - Department of Nephrology, Beaumont Hospital, Dublin, Ireland. RINGGOLD: 57978 FAU - Eaton, Donna AU - Eaton D AD - Department of Cardiothoracic Surgery, Mater Misericordiae University Hospital, Dublin, Ireland. RINGGOLD: 8881 FAU - Donnelly, Jennifer C AU - Donnelly JC AD - Department of Obstetrics and Gynaecology, Rotunda Hospital, Dublin, Ireland. RINGGOLD: 58009 LA - eng PT - Journal Article DEP - 20240726 PL - England TA - Obstet Med JT - Obstetric medicine JID - 101464191 PMC - PMC11563499 OTO - NOTNLM OT - Bullous lung disease OT - pneumothorax in pregnancy COIS- The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2024/11/18 11:07 MHDA- 2024/11/18 11:08 PMCR- 2025/07/26 CRDT- 2024/11/18 06:00 PHST- 2024/03/14 00:00 [received] PHST- 2024/06/14 00:00 [accepted] PHST- 2024/11/18 11:08 [medline] PHST- 2024/11/18 11:07 [pubmed] PHST- 2024/11/18 06:00 [entrez] PHST- 2025/07/26 00:00 [pmc-release] AID - 10.1177_1753495X241265528 [pii] AID - 10.1177/1753495X241265528 [doi] PST - epublish SO - Obstet Med. 2024 Jul 26;18(3):190-192. doi: 10.1177/1753495X241265528. eCollection 2025 Sep. PMID- 39551696 OWN - NLM STAT- MEDLINE DCOM- 20250208 LR - 20260616 IS - 1532-8422 (Electronic) IS - 1053-0770 (Linking) VI - 39 IP - 2 DP - 2025 Feb TI - The Year in Cardiothoracic Transplant Anesthesia: Selected Highlights From 2022 Part II: Cardiac Transplantation. PG - 364-397 LID - S1053-0770(24)00812-7 [pii] LID - 10.1053/j.jvca.2024.10.026 [doi] AB - These highlights focus on research published in the year 2022 and is divided into preoperative, intraoperative, and postoperative sections. The preoperative section includes research on the assessment and optimization of candidates for heart transplantation; donor optimization and the use of extended donors; organ protection systems; donation after circulatory death allografts; recipient factors including cannabis use, sex, race, and comorbidities such as obesity, diabetes mellitus, and peripartum cardiomyopathy; the effects of the 2018 heart allocation policy change on waitlist and postoperative mortality; updates on heart transplantation in patients with coronavirus disease 2019; in pediatric patients; and those who require a bridge to transplant. The intraoperative section includes the use of a multidisciplinary team, a proposed transfusion algorithm, bench surgery on the allograft, and size matching. The postoperative section focuses on the research on the development and management of tricuspid regurgitation, echocardiography, arrhythmia management, and, finally, xenotransplantation. CI - Copyright (c) 2024 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Ungerman, Elizabeth AU - Ungerman E AD - Department of Anesthesiology and Perioperative Medicine, University of Pittsburgh, Pittsburgh, PA. FAU - Hunter, Oriana C AU - Hunter OC AD - University of Pittsburgh, Pittsburgh, PA. FAU - Jayaraman, Arun L AU - Jayaraman AL AD - Department of Anesthesiology and Perioperative Medicine, Department of Critical Care Medicine, Mayo Clinic, Pheonix, AZ. FAU - Khoche, Swapnil AU - Khoche S AD - University of California, San Diego, CA. FAU - Bartels, Steven AU - Bartels S AD - Loyola University Medical Center, Chicago, IL. FAU - Owen, Robert M AU - Owen RM AD - Case Western Reserve School of Medicine, Cleveland, OH. FAU - Smart, Klint AU - Smart K AD - West Virginia University, University Avenue, Morgantown, WV. FAU - Hayanga, Heather K AU - Hayanga HK AD - West Virginia University, University Avenue, Morgantown, WV. FAU - Patel, Bhoumesh AU - Patel B AD - Department of Anesthesiology, Yale School of Medicine, New Haven, CT. FAU - Whyte, Alice M AU - Whyte AM AD - Department of Anesthesiology and Perioperative Medicine, University of Pittsburgh, Pittsburgh, PA. FAU - Knight, Joshua AU - Knight J AD - Department of Anesthesiology and Perioperative Medicine, University of Pittsburgh, Pittsburgh, PA. FAU - Jones, T Everett AU - Jones TE AD - Department of Anesthesiology, University of Florida, Gainesville, FL. FAU - Roberts, S Michael AU - Roberts SM AD - Department of Anesthesiology and Perioperative Medicine, Penn State University, Philadelphia, PA. FAU - Ball, Ryan AU - Ball R AD - Department of Anesthesiology and Perioperative Medicine, University of Pittsburgh, Pittsburgh, PA. FAU - Hoyler, Marguerite AU - Hoyler M AD - Department of Anesthesiology, Weill Cornell Medicine, New York, NY. FAU - Gelzinis, Theresa A AU - Gelzinis TA AD - University of Pittsburgh, Pittsburgh, PA. Electronic address: gelzinista@anes.upmc.edu. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20241022 PL - United States TA - J Cardiothorac Vasc Anesth JT - Journal of cardiothoracic and vascular anesthesia JID - 9110208 SB - IM MH - Humans MH - *Heart Transplantation/trends/methods MH - *Anesthesia/methods/trends OTO - NOTNLM OT - donation after cardiac death OT - mechanical circulatory support OT - pediatric heart transplantation OT - prehabilitation OT - tricuspid regurgitation OT - xenotransplantation COIS- Declaration of competing interest The authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (eg, honoraria; educational grants; participation in speakers' bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or nonfinancial interest (eg, personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript. EDAT- 2024/11/18 04:18 MHDA- 2025/02/09 06:20 CRDT- 2024/11/17 22:35 PHST- 2024/10/11 00:00 [received] PHST- 2024/10/13 00:00 [accepted] PHST- 2025/02/09 06:20 [medline] PHST- 2024/11/18 04:18 [pubmed] PHST- 2024/11/17 22:35 [entrez] AID - S1053-0770(24)00812-7 [pii] AID - 10.1053/j.jvca.2024.10.026 [doi] PST - ppublish SO - J Cardiothorac Vasc Anesth. 2025 Feb;39(2):364-397. doi: 10.1053/j.jvca.2024.10.026. Epub 2024 Oct 22. PMID- 39551558 OWN - NLM STAT- MEDLINE DCOM- 20241117 LR - 20241117 IS - 1558-2264 (Electronic) IS - 0733-8651 (Linking) VI - 43 IP - 1 DP - 2025 Feb TI - Cardio-Oncology Program Building: A Practical Guide. PG - 195-207 LID - S0733-8651(24)00091-2 [pii] LID - 10.1016/j.ccl.2024.09.005 [doi] AB - The organization of a cardio-oncology clinic and overall program is designed to provide comprehensive cardiovascular care to patients who are at risk of or have developed cardiovascular sequelae during or following cancer treatments. In this article, we summarize the core components of a contemporary cardio-oncology program, including its core members (cardiologists, oncologists, clinical pharmacists, advanced practice providers, nurses, and coordinators), key services (risk assessment, treatment planning, cardiac imaging, intervention, and management), and practical integration within the health care system. CI - Copyright (c) 2024 Elsevier Inc. All rights reserved. FAU - Bloom, Michelle Weisfelner AU - Bloom MW AD - Division of Cardiology, NYU Langone Health, NYU Grossman School of Medicine, New York, NY, USA. FAU - Ferrari, Alana M AU - Ferrari AM AD - Division of Hematology/Oncology, University of Virginia Health, Charlottesville, VA, USA. FAU - Stojanovska, Jadranka AU - Stojanovska J AD - Department of Radiology, NYU Langone Hospital, NYU Grossman School of Medicine, New York, NY, USA. FAU - Harnden, Kathleen Kiernan AU - Harnden KK AD - Breast Medical Oncology Program, Inova Schar Cancer, Fairfax, VA, USA. FAU - Beckford, Yaisa AU - Beckford Y AD - Department of Cardiology, Inova Schar Heart and Vascular, Fairfax, VA, USA. FAU - Skurka, Kerry AU - Skurka K AD - Cardio-Oncology Nurse/Program Consultant, International Cardio-Oncology (IC-OS) Society. FAU - Barac, Ana AU - Barac A AD - Department of Cardiology, Inova Schar Heart and Vascular, Fairfax, VA, USA. Electronic address: Ana.Barac@inova.org. LA - eng PT - Journal Article PT - Review DEP - 20241018 PL - Netherlands TA - Cardiol Clin JT - Cardiology clinics JID - 8300331 SB - IM MH - Humans MH - *Medical Oncology MH - *Neoplasms/therapy MH - *Cardiovascular Diseases/therapy MH - *Cardiology/education MH - Cardiotoxicity MH - Patient Care Team/organization & administration MH - Cardio-Oncology OTO - NOTNLM OT - Cardiac imaging OT - Cardio-oncology clinic OT - Cardio-oncology program OT - Cardiovascular toxicity OT - Chemotherapy OT - Health care system OT - Integrated care OT - Prevention COIS- Disclosure All authors report no conflict of interest relevant to this article. EDAT- 2024/11/18 04:18 MHDA- 2024/11/18 04:19 CRDT- 2024/11/17 21:07 PHST- 2024/11/18 04:19 [medline] PHST- 2024/11/18 04:18 [pubmed] PHST- 2024/11/17 21:07 [entrez] AID - S0733-8651(24)00091-2 [pii] AID - 10.1016/j.ccl.2024.09.005 [doi] PST - ppublish SO - Cardiol Clin. 2025 Feb;43(1):195-207. doi: 10.1016/j.ccl.2024.09.005. Epub 2024 Oct 18. PMID- 39544262 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251029 LR - 20251029 IS - 1941-8744 (Print) IS - 1941-8752 (Electronic) IS - 1941-8744 (Linking) VI - 15 IP - 2 DP - 2025 Apr TI - The In-Hospital Code Stroke: A Look Back and the Road Ahead. PG - 124-132 LID - 10.1177/19418744241298035 [doi] AB - With increased patient volumes and complexity, stroke occurrence in hospitalized patients has become relatively more common. The process of activating a code stroke in-hospital differs in many institutions. An emergency team-based response to inpatient acute code stroke is warranted, with many protocols modeled similarly to the cardiac arrest response. However, several studies have demonstrated delays in recognition and management of acute stroke in-hospital as compared to those arriving directly to the emergency department (ED). Furthermore, there are several shared challenges with code stroke resuscitation in the ED and the ward, which include the assembly of ad hoc teams and requirement of access to urgent imaging. Delays in activating in-hospital code stroke contributes to increased morbidity, mortality, prolonged hospitalization, and associated health care costs. In the following commentary, we discuss the current landscape of acute in-hospital code stroke protocols, review the differences in neurologic outcomes between inpatient vs ED/out-of-hospital code stroke patients, and propose future directions for in-hospital code stroke paradigms for improved patient outcomes and quality of care. CI - (c) The Author(s) 2024. FAU - Kuczynski, Andrea M AU - Kuczynski AM AUID- ORCID: 0000-0001-7268-3275 AD - Division of Neurology, Department of Medicine, University of Toronto, Toronto, ON, Canada. RINGGOLD: 7938 AD - Hurvitz Brain Sciences Program, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada. RINGGOLD: 7938 FAU - Freeman, W David AU - Freeman WD AUID- ORCID: 0000-0003-2326-0633 AD - Department of Neurologic Surgery, Neurology, and Critical Care, Mayo Clinic, Jacksonville, FL, USA. FAU - Mooney, Lesia H AU - Mooney LH AD - Department of Neurologic Surgery, Neurology, and Critical Care, Mayo Clinic, Jacksonville, FL, USA. FAU - Huang, Josephine F AU - Huang JF AD - Department of Neurologic Surgery, Neurology, and Critical Care, Mayo Clinic, Jacksonville, FL, USA. FAU - Demchuk, Andrew M AU - Demchuk AM AD - Division of Neurology, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. RINGGOLD: 2129 FAU - Khosravani, Houman AU - Khosravani H AUID- ORCID: 0000-0002-4059-9420 AD - Division of Neurology, Department of Medicine, University of Toronto, Toronto, ON, Canada. RINGGOLD: 7938 AD - Hurvitz Brain Sciences Program, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada. RINGGOLD: 7938 LA - eng PT - Journal Article PT - Review DEP - 20241029 PL - United States TA - Neurohospitalist JT - The Neurohospitalist JID - 101558199 PMC - PMC11559452 OTO - NOTNLM OT - acute stroke OT - hemorrhagic stroke OT - inpatients OT - ischemic stroke OT - quality improvement COIS- The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2024/11/15 06:26 MHDA- 2024/11/15 06:27 PMCR- 2025/10/29 CRDT- 2024/11/15 04:25 PHST- 2024/09/24 00:00 [received] PHST- 2024/10/18 00:00 [revised] PHST- 2024/10/21 00:00 [accepted] PHST- 2024/11/15 06:27 [medline] PHST- 2024/11/15 06:26 [pubmed] PHST- 2024/11/15 04:25 [entrez] PHST- 2025/10/29 00:00 [pmc-release] AID - 10.1177_19418744241298035 [pii] AID - 10.1177/19418744241298035 [doi] PST - ppublish SO - Neurohospitalist. 2025 Apr;15(2):124-132. doi: 10.1177/19418744241298035. Epub 2024 Oct 29. PMID- 39539138 OWN - NLM STAT- MEDLINE DCOM- 20241114 LR - 20260407 IS - 1540-8175 (Electronic) IS - 0742-2822 (Linking) VI - 41 IP - 11 DP - 2024 Nov TI - Multi-Modality Imaging to Detect Ischemic and Valvular Heart Disease in Adult Cancer Patients. PG - e70030 LID - 10.1111/echo.70030 [doi] AB - Thanks to impressive advances in the field of oncology over the last 30 years, there has been a significant rise in cancer survivors. Nowadays, cardiovascular disease is one of the leading causes of death in this patient population. Coronary artery disease (CAD) is a major problem due to shared risk factors, an aging population and in many cases induced and/or accelerated atherosclerosis by antitumoral treatment during and even decades after the end of cancer therapy. Furthermore, the presence of CAD or valvular heart disease (VHD) at the time point of cancer diagnosis largely increases the risk of any cancer therapy-related cardiovascular toxicity (CTR-CVT). It is therefore of utmost importance to detect CAD and VHD before, during, and after certain types of chemotherapy, target therapies, and radiotherapy. Multimodality cardiovascular imaging plays a central role in this vulnerable population where individual risk stratification and multidisciplinary decision-making are critical. CI - (c) 2024 The Author(s). Echocardiography published by Wiley Periodicals LLC. FAU - Hugelshofer, Sarah AU - Hugelshofer S AUID- ORCID: 0000-0002-3037-0497 AD - Cardiology Unit, Cardio-Vascular Department, University Hospital of Canton Vaud (CHUV), Lausanne, Switzerland. FAU - Giacomuzzi-Moore, Bianca AU - Giacomuzzi-Moore B AD - Department of Oncology, University Hospital of Canton Vaud (CHUV), Lausanne, Switzerland. FAU - Auberson, Denise AU - Auberson D AD - Cardiology Unit, Cardio-Vascular Department, University Hospital of Canton Vaud (CHUV), Lausanne, Switzerland. FAU - Tzimas, Georgios AU - Tzimas G AD - Cardiology Unit, Cardio-Vascular Department, University Hospital of Canton Vaud (CHUV), Lausanne, Switzerland. FAU - Kamani, Christel H AU - Kamani CH AD - Cardiology Unit, Cardio-Vascular Department, University Hospital of Canton Vaud (CHUV), Lausanne, Switzerland. AD - Department of Nuclear Medicine, University Hospital of Canton Vaud (CHUV), Lausanne, Switzerland. FAU - Masi, Ambra AU - Masi A AD - Cardiology Unit, Cardio-Vascular Department, University Hospital of Canton Vaud (CHUV), Lausanne, Switzerland. FAU - Monney, Pierre AU - Monney P AD - Cardiology Unit, Cardio-Vascular Department, University Hospital of Canton Vaud (CHUV), Lausanne, Switzerland. FAU - Arangalage, Dimitri AU - Arangalage D AD - Cardiology Unit, Cardio-Vascular Department, University Hospital of Canton Vaud (CHUV), Lausanne, Switzerland. FAU - Poku, Nana K AU - Poku NK AD - Cardiology Unit, Medical Department, University Hospital of Canton Geneva (HUG), Geneva, Switzerland. LA - eng PT - Journal Article PT - Review PL - United States TA - Echocardiography JT - Echocardiography (Mount Kisco, N.Y.) JID - 8511187 SB - IM MH - Adult MH - Humans MH - Echocardiography/methods MH - *Heart Valve Diseases/diagnostic imaging/etiology MH - *Multimodal Imaging/methods MH - Myocardial Ischemia/diagnostic imaging/etiology MH - *Neoplasms/complications/diagnostic imaging/therapy OTO - NOTNLM OT - cancer survivors OT - cancer therapy-related cardiovascular toxicity OT - computed tomography coronary angiography OT - coronary functional imaging OT - ischemic heart disease OT - multidisciplinary decision-making OT - valvular heart disease EDAT- 2024/11/14 17:34 MHDA- 2024/11/14 17:35 CRDT- 2024/11/14 03:13 PHST- 2024/10/21 00:00 [revised] PHST- 2024/10/02 00:00 [received] PHST- 2024/10/27 00:00 [accepted] PHST- 2024/11/14 17:35 [medline] PHST- 2024/11/14 17:34 [pubmed] PHST- 2024/11/14 03:13 [entrez] AID - 10.1111/echo.70030 [doi] PST - ppublish SO - Echocardiography. 2024 Nov;41(11):e70030. doi: 10.1111/echo.70030. PMID- 39537434 OWN - NLM STAT- MEDLINE DCOM- 20250220 LR - 20250220 IS - 1532-8449 (Electronic) IS - 0882-5963 (Linking) VI - 80 DP - 2025 Jan-Feb TI - A novel simulation to prepare maternal caregivers of children diagnosed with a critical congenital heart defect. PG - e16-e23 LID - S0882-5963(24)00395-6 [pii] LID - 10.1016/j.pedn.2024.10.034 [doi] AB - PURPOSE: The purpose of this feasibility study was to determine the effectiveness of an interprofessional led low-fidelity simulation program over three timepoints on maternal caregivers' perceived stress, sense of competence and discharge readiness for care of critical congenital heart disease (CCHD) infants requiring neonatal cardiac surgery. DESIGN AND METHODS: The Perceived Stress Scale (PSS) was administered to simulation and non-intervention groups at three timepoints: prenatal period, Cardiac Acute Care Unit (CACU) transfer, and rooming-in. Parental Sense of Competence (PSOC) was measured at timepoint two and three, and Readiness for Hospital Discharge (RDHS) was measured at timepoint three for the simulation group. A linear mixed model was used to examine PSS and PSOC scores over time. RESULTS: Of the thirty-three maternal caregivers, twelve were in the simulation group and twenty-one were in the non-intervention group. In the simulation group, the odds of having moderate-high stress were significantly lower at rooming-in compared to the prenatal period. From timepoint two to rooming-in, there was a positive change in PSOC scores. RDHS scores represented good readiness for discharge. CONCLUSION: Findings suggest that simulation may improve maternal caregiver stress from prenatal CCHD diagnosis to discharge home after cardiac surgery. Future work should include random treatment assignment to assess causal relationships. PRACTICE IMPLICATIONS: Infants with CCHD require extensive postoperative recovery and specialized home care. Maternal caregivers of critically ill CCHD neonates are at increased risk for stress. Results from this study suggest engagement with nurses and interdisciplinary team during the prenatal period may reduce caregiver stress. CI - Copyright (c) 2024 Elsevier Inc. All rights reserved. FAU - Murphy, Kathy AU - Murphy K AD - Clinical Nurse Specialist, Children's Healthcare of Atlanta, Atlanta, Georgia. Electronic address: kathy.murphy@choa.org. FAU - Shackleford, Jenna AU - Shackleford J AD - Wellstar School of Nursing, Kennesaw State University, Kennesaw, Georgia. FAU - Alexander, Nneka AU - Alexander N AD - Senior Pediatric Psychologist, Cardiac Services and Department of Neuropsychology, Children's Healthcare of Atlanta, Atlanta, Georgia. FAU - Brunson, Leslie AU - Brunson L AD - Children's Healthcare of Atlanta, Atlanta, Georgia. FAU - Morgan, Kathryn AU - Morgan K AD - Children's Healthcare of Atlanta, Atlanta, Georgia. FAU - McKemie, Brittany AU - McKemie B AD - Children's Healthcare of Atlanta, Atlanta, Georgia. FAU - Weido, Ginger AU - Weido G AD - Children's Healthcare of Atlanta, Atlanta, Georgia. FAU - Haney, Kendall AU - Haney K AD - Children's Healthcare of Atlanta, Atlanta, Georgia. FAU - Castillo, Laura Lei AU - Castillo LL AD - Children's Healthcare of Atlanta, Atlanta, Georgia. FAU - Pierson, Ashley AU - Pierson A AD - Children's Healthcare of Atlanta, Atlanta, Georgia. FAU - Calamaro, Christina AU - Calamaro C AD - Director of Nursing & Allied Health Research and EBP, Children's Healthcare of Atlanta, Nell Hodgson Woodruff School of Nursing, Emory University, Atlanta, Georgia. FAU - Prempeh, Leandra AU - Prempeh L AD - Mercer University, Atlanta, Georgia. FAU - Osborne, Melissa AU - Osborne M AD - Wellstar School of Nursing, Kennesaw State University, Kennesaw, Georgia. LA - eng PT - Journal Article DEP - 20241112 PL - United States TA - J Pediatr Nurs JT - Journal of pediatric nursing JID - 8607529 SB - IM MH - *Caregivers MH - Mothers MH - *Heart Defects, Congenital/nursing/therapy MH - *Patient Education as Topic/methods MH - Feasibility Studies MH - Interprofessional Relations MH - Perception MH - Stress, Psychological MH - Manikins MH - Humans MH - Female MH - Pregnancy MH - Infant, Newborn MH - Young Adult MH - Adult OTO - NOTNLM OT - Critical congenital heart disease OT - Maternal caregiver competence OT - Maternal caregiver stress OT - Readiness for discharge COIS- Declaration of competing interest The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this review. EDAT- 2024/11/14 03:55 MHDA- 2025/02/01 20:42 CRDT- 2024/11/13 21:56 PHST- 2024/07/26 00:00 [received] PHST- 2024/10/22 00:00 [revised] PHST- 2024/10/23 00:00 [accepted] PHST- 2025/02/01 20:42 [medline] PHST- 2024/11/14 03:55 [pubmed] PHST- 2024/11/13 21:56 [entrez] AID - S0882-5963(24)00395-6 [pii] AID - 10.1016/j.pedn.2024.10.034 [doi] PST - ppublish SO - J Pediatr Nurs. 2025 Jan-Feb;80:e16-e23. doi: 10.1016/j.pedn.2024.10.034. Epub 2024 Nov 12. PMID- 39537269 OWN - NLM STAT- MEDLINE DCOM- 20241113 LR - 20260918 IS - 1876-7605 (Electronic) IS - 1936-8798 (Linking) VI - 17 IP - 21 DP - 2024 Nov 11 TI - Decision-Making Approach to the Treatment of Young and Low-Risk Patients With Aortic Stenosis. PG - 2455-2471 LID - S1936-8798(24)01152-X [pii] LID - 10.1016/j.jcin.2024.08.032 [doi] AB - Over a decade of randomized controlled trial data demonstrate excellent outcomes with transcatheter aortic valve replacement or surgical aortic valve replacement for patients with symptomatic severe aortic stenosis regardless of surgical risk. The 2020 American College of Cardiology/American Heart Association guidelines recommend both options for low-risk AS patients aged 65 to 80 years. However, the fastest growing population of patients receiving transcatheter aortic valve replacement in the United States is <65 years old, with little data to support the practice. The American College of Cardiology's Cardiac Surgery Team Section Leadership and Interventional Cardiology Councils, a multidisciplinary collaboration of cardiologists and cardiac surgeons, sought to summarize the relevant data into a decision-making tool for heart valve teams. A literature review was completed, and guidelines, randomized controlled trials, and large observational studies were summarized into a pragmatic decision-making approach to treating young and low-risk patients with AS. CI - Copyright (c) 2024 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. FAU - Gupta, Tanush AU - Gupta T AD - Division of Cardiology, University of Vermont Medical Center, Burlington, Vermont, USA. FAU - Malaisrie, S Chris AU - Malaisrie SC AD - Department of Cardiac Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. FAU - Batchelor, Wayne AU - Batchelor W AD - Inova Schar Heart and Vascular Institute, Falls Church, Virginia, USA. FAU - Boudoulas, Konstantinos Dean AU - Boudoulas KD AD - Division of Cardiovascular Medicine, The Ohio State University, Columbus, Ohio, USA. FAU - Davidson, Laura AU - Davidson L AD - Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. FAU - Ibebuogu, Uzoma N AU - Ibebuogu UN AD - Division of Cardiovascular Diseases, Department of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA. FAU - Kpodonu, Jacques AU - Kpodonu J AD - Division of Cardiac Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA. FAU - Singh, Ramesh AU - Singh R AD - Inova Schar Heart and Vascular Institute, Falls Church, Virginia, USA. FAU - Sultan, Ibrahim AU - Sultan I AD - Division of Cardiac Surgery, Department of Cardiothoracic Surgery, Center for Heart Valve Disease, University of Pittsburgh Medical Center Heart and Vascular Institute, Pittsburgh, Pennsylvania, USA. FAU - Theriot, Misty AU - Theriot M AD - Lake Charles Memorial Hospital Heart & Vascular Center, Lake Charles, Louisiana, USA. FAU - Reardon, Michael J AU - Reardon MJ AD - Department of Cardiovascular Surgery, Houston Methodist DeBakey Heart and Vascular Center, Houston, Texas, USA. FAU - Leon, Martin B AU - Leon MB AD - Division of Cardiology, Columbia University Medical Center, New York, New York, USA; Cardiovascular Research Foundation, New York, New York, USA. FAU - Grubb, Kendra J AU - Grubb KJ AD - Division of Cardiothoracic Surgery, Emory University School of Medicine, Atlanta, Georgia, USA. Electronic address: kjgrubb@emory.edu. CN - A Perspective From the American College of Cardiology Cardiac Surgery Team and Interventional Cardiology Councils LA - eng PT - Journal Article PT - Review PL - United States TA - JACC Cardiovasc Interv JT - JACC. Cardiovascular interventions JID - 101467004 SB - IM MH - Humans MH - *Aortic Valve Stenosis/surgery/diagnostic imaging/physiopathology MH - Risk Assessment MH - *Clinical Decision-Making MH - Risk Factors MH - Treatment Outcome MH - Age Factors MH - *Decision Support Techniques MH - *Patient Selection MH - *Aortic Valve/surgery/diagnostic imaging/physiopathology MH - *Transcatheter Aortic Valve Replacement/adverse effects/instrumentation MH - Aged MH - *Heart Valve Prosthesis Implantation/adverse effects/instrumentation MH - Aged, 80 and over MH - Middle Aged MH - Male OTO - NOTNLM OT - aortic stenosis OT - clinical practice guidelines OT - heart valve team OT - shared decision-making OT - surgical aortic valve replacement OT - transcatheter aortic valve replacement COIS- Funding Support and Author Disclosures Dr Gupta has received consulting fees from Medtronic; Dr Malaisrie has received honoraria from Edwards Lifesciences, Artivion, and Atricure; and has received research grants from Edwards Lifesciences, Medtronic, Artivion, and Terumo. Dr Batchelor has received consultant and Speakers Bureau fees and research grant support from Abbott; has received consultant fees and research grant support from Boston Scientific; and is a consultant for V-Wave and Medtronic. Dr Davidson has received research support from Edwards Lifesciences. Dr Kpodonu has received National Institutes of Health (National Institute of Biomedical Imaging and Bioengineering) funding (R33 grant). Dr Sultan has received institutional research funding from Abbott, Artivion, Atricure, Boston Scientific, Edwards Lifesciences, Medtronic, and Terumo Aortic. Dr Theroit serves on the Speakers Bureau for Edwards Lifesciences. Dr Reardon has received research support from Abbott, Boston Scientific, Jena Valve, Medtronic, and St. Jude Medical; and has received honoraria from Abbott, Boston Scientific, and Medtronic. Dr Leon has received personal and institutional grant support from Abbott Vascular, Boston Scientific, Edwards Lifesciences, and Medtronic. Dr Grubb has received consulting fees from Medtronic, Abbott, Boston Scientific, Ancora Heart, 4C Medical, Edwards Lifesciences, and OpSens. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2024/11/14 03:57 MHDA- 2024/11/14 03:58 CRDT- 2024/11/13 21:02 PHST- 2024/06/06 00:00 [received] PHST- 2024/08/16 00:00 [revised] PHST- 2024/08/27 00:00 [accepted] PHST- 2024/11/14 03:58 [medline] PHST- 2024/11/14 03:57 [pubmed] PHST- 2024/11/13 21:02 [entrez] AID - S1936-8798(24)01152-X [pii] AID - 10.1016/j.jcin.2024.08.032 [doi] PST - ppublish SO - JACC Cardiovasc Interv. 2024 Nov 11;17(21):2455-2471. doi: 10.1016/j.jcin.2024.08.032. PMID- 39537128 OWN - NLM STAT- MEDLINE DCOM- 20260212 LR - 20260505 IS - 1439-1902 (Electronic) IS - 0171-6425 (Linking) VI - 74 IP - 2 DP - 2026 Mar TI - Predictors for Length of Stay after Surgical Aortic Valve Replacement. PG - 106-113 LID - 10.1055/a-2466-7245 [doi] AB - Aortic valve replacement improves and prolongs lives of patients with aortic valve disease, but requires significant healthcare resources, which are mainly determined by the length of associated hospital stays. Therefore, this study aims to identify risk factors for extended length of stay after surgical aortic valve replacement.Between 2018 and 2023, 458 consecutive patients underwent isolated surgical aortic valve replacement at our center and were included in our analysis. To identify independent predictors for hospital and intensive care unit stay, multivariable linear regression analysis using backward elimination process was performed.Upon multivariable linear regression, endocarditis (regression coefficient [beta] 2.98; 95% confidence interval [CI] 1.51, 4.45; p < 0.001]) and prior aortic valve surgery (beta 1.72; 95% CI 0.18, 3.26; p = 0.029) were associated with prolonged hospital stay. Prior aortic valve surgery was associated with prolonged intensive care unit stay (beta 0.99; 95% CI 0.39, 1.59; p = 0.001) as well as chronic obstructive pulmonary disease (COPD) (beta 1.61; 95% CI 0.66, 2.55; p = 0.001), smaller prosthetic valve sizes (beta -0.18; 95% CI -0.30, -0.06; p = 0.003), preoperative atrial fibrillation (beta 1.06; 95% CI 0.32, 1.79; p = 0.005), and reduced left ventricular ejection fraction (beta -0.03; 95% CI -0.05, -0.01; p = 0.006).Pending further validation, structured programs aiming to accelerate intensive care unit and hospital discharge after surgical aortic valve replacement should focus on patients with prior cardiac surgery, atrial fibrillation, and COPD. Surgeons should aim to implant large-diameter valves. Furthermore, the identified predictors should be used to discuss surgical versus transcatheter procedures in the interdisciplinary heart team. CI - Thieme. All rights reserved. FAU - Demal, Till Joscha AU - Demal TJ AD - Department of Cardiac and Vascular Surgery, University Medical Center Hamburg-Eppendorf University Heart & Vascular Center, Hamburg, Germany. FAU - Arndt, Nico AU - Arndt N AUID- ORCID: 0009-0008-5852-2879 AD - Department of Cardiac and Vascular Surgery, University Medical Center Hamburg-Eppendorf University Heart & Vascular Center, Hamburg, Germany. FAU - Bhadra, Oliver D AU - Bhadra OD AD - Department of Cardiac and Vascular Surgery, University Medical Center Hamburg-Eppendorf University Heart & Vascular Center, Hamburg, Germany. FAU - Ludwig, Sebastian AU - Ludwig S AD - Department of Cardiology, University Medical Center Hamburg-Eppendorf University Heart & Vascular Center, Hamburg, Hamburg, Germany. FAU - Grundmann, David AU - Grundmann D AD - Department of Cardiology, University Medical Center Hamburg-Eppendorf University Heart & Vascular Center, Hamburg, Hamburg, Germany. FAU - Voigtlaender-Buschmann, Lisa AU - Voigtlaender-Buschmann L AD - Department of Cardiology, University Medical Center Hamburg-Eppendorf University Heart & Vascular Center, Hamburg, Hamburg, Germany. FAU - Waldschmidt, Lara AU - Waldschmidt L AD - Department of Cardiology, University Medical Center Hamburg-Eppendorf University Heart & Vascular Center, Hamburg, Hamburg, Germany. FAU - Hannen, Laura AU - Hannen L AD - Department of Cardiology, University Medical Center Hamburg-Eppendorf University Heart & Vascular Center, Hamburg, Hamburg, Germany. FAU - Blankenberg, Stefan AU - Blankenberg S AD - Department of Cardiology, University Medical Center Hamburg-Eppendorf University Heart & Vascular Center, Hamburg, Hamburg, Germany. FAU - Kirchhof, Paulus AU - Kirchhof P AD - Department of Cardiology, University Medical Center Hamburg-Eppendorf University Heart & Vascular Center, Hamburg, Hamburg, Germany. FAU - Conradi, Lenard AU - Conradi L AD - Department of Cardiac and Vascular Surgery, University Medical Center Hamburg-Eppendorf University Heart & Vascular Center, Hamburg, Germany. FAU - Reichenspurner, Hermann AU - Reichenspurner H AD - Department of Cardiac and Vascular Surgery, University Medical Center Hamburg-Eppendorf University Heart & Vascular Center, Hamburg, Germany. FAU - Schofer, Niklas AU - Schofer N AD - Department of Cardiology, University Medical Center Hamburg-Eppendorf University Heart & Vascular Center, Hamburg, Hamburg, Germany. FAU - Schaefer, Andreas AU - Schaefer A AD - Department of Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Hamburg, Germany. LA - eng SI - ClinicalTrials.gov/NCT04227002 PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20241113 PL - Germany TA - Thorac Cardiovasc Surg JT - The Thoracic and cardiovascular surgeon JID - 7903387 SB - IM MH - Humans MH - *Heart Valve Prosthesis Implantation/adverse effects/instrumentation MH - Risk Factors MH - Male MH - *Length of Stay MH - Female MH - *Aortic Valve/surgery/physiopathology/diagnostic imaging MH - Aged MH - Treatment Outcome MH - Retrospective Studies MH - Time Factors MH - Risk Assessment MH - Middle Aged MH - Heart Valve Prosthesis MH - Aged, 80 and over MH - Postoperative Complications/therapy/etiology MH - *Aortic Valve Disease/surgery/physiopathology/diagnostic imaging COIS- A.S. received lecture fees/travel support from Abbott, Boston Scientific, and Edwards Lifesciences. A.S. is a proctor for Abbott. EDAT- 2024/11/14 03:54 MHDA- 2026/02/13 01:26 CRDT- 2024/11/13 19:33 PHST- 2026/02/13 01:26 [medline] PHST- 2024/11/14 03:54 [pubmed] PHST- 2024/11/13 19:33 [entrez] AID - 10.1055/a-2466-7245 [doi] PST - ppublish SO - Thorac Cardiovasc Surg. 2026 Mar;74(2):106-113. doi: 10.1055/a-2466-7245. Epub 2024 Nov 13. PMID- 39536843 OWN - NLM STAT- MEDLINE DCOM- 20250426 LR - 20260422 IS - 1097-6809 (Electronic) IS - 0741-5214 (Print) IS - 0741-5214 (Linking) VI - 81 IP - 3 DP - 2025 Mar TI - Impact of preoperative risk factors on 5-year survival after fenestrated/branched endovascular aortic repair. PG - 539-547 LID - S0741-5214(24)02061-5 [pii] LID - 10.1016/j.jvs.2024.11.002 [doi] AB - OBJECTIVE: To investigate which preoperative factors most impact the 5-year survival of patients undergoing fenestrated/branched endovascular aortic repair (F/BEVAR) and to identify modifiable elements that, if time allows, should be actively managed and adequately controlled preoperatively. METHODS: Patients treated for aortic aneurysms with complex anatomy using either patient-specific company-manufactured or off-the-shelf F/BEVAR devices were included. The exposure of interest was aneurysm type (group I: type I-III thoracoabdominal aneurysms vs group II: type IV thoracoabdominal aneurysms vs group III: juxtarenal or suprarenal aneurysms), and the primary outcome was 5-year risk of all-cause mortality. Generalized linear models were used to estimate each group's crude 5-year risk of death and the 5-year risk of death across groups. Each preoperative factor was added to the model individually, and a change in estimate was calculated between the new risks and the crude risk. Preoperative factors with a change of estimate of >/=10% were used to create an inverse probability of treatment weights for multivariable analysis. RESULTS: A total of 408 F/BEVAR patients were included, of whom 71.6% were male (mean age: 72.0 +/- 7.9 years). Eleven of the 22 preoperative factors analyzed had a change in estimate >/=10%. The greatest changes in estimates were observed for history of congestive heart failure (CHF), arrhythmia, overweight, obesity, and chronic obstructive pulmonary disease. Almost 60% of patients with CHF in group I died within 5 years. Current smoking or overweight at the time of F/BEVAR increases the 5-year risk of death more significantly than having a history of myocardial infarction. After adjustment, patients in group I had a significantly higher risk of 5-year all-cause mortality than those in group III (log-rank, P value = .0082). CONCLUSIONS: The present findings suggest that cardiac arrhythmias, CHF, overweight, obesity, chronic obstructive pulmonary disease, and aneurysm diameter above 7 cm are the most relevant preoperative factors that impact the 5-year survival after F/BEVAR. More specifically, CHF and arrhythmias should be used to alter patient selection and identify those individuals more likely to benefit from repair. Moreover, modifiable risk factors such as weight loss and smoking cessation during the surveillance period before the F/BEVAR procedure might improve survival in this population. Considering that, preoperatively, many patients are periodically evaluated by a vascular surgery team until the aneurysm diameter meets criteria for repair, a multidisciplinary approach that could address these modifiable risk factors might be an impactful strategy. CI - Copyright (c) 2024 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved. FAU - Gomes, Vivian Carla AU - Gomes VC AD - Division of Vascular Surgery, University of North Carolina, Chapel Hill, NC. FAU - Parodi, F Ezequiel AU - Parodi FE AD - Division of Vascular Surgery, University of North Carolina, Chapel Hill, NC. FAU - Browder, Sydney E AU - Browder SE AD - Department of Biostatistics, University of North Carolina, Chapel Hill, NC. FAU - Motta, Fernando AU - Motta F AD - Department of Vascular Surgery, University of Oklahoma, Tulsa, OK. FAU - Vasan, Priya AU - Vasan P AD - Division of Vascular Surgery, University of North Carolina, Chapel Hill, NC. FAU - Sun, Dichen AU - Sun D AD - Division of Vascular Surgery, University of North Carolina, Chapel Hill, NC. FAU - Marston, William A AU - Marston WA AD - Division of Vascular Surgery, University of North Carolina, Chapel Hill, NC. FAU - Pascarella, Luigi AU - Pascarella L AD - Division of Vascular Surgery, University of North Carolina, Chapel Hill, NC. FAU - McGinigle, Katharine L AU - McGinigle KL AD - Division of Vascular Surgery, University of North Carolina, Chapel Hill, NC. FAU - Wood, Jacob C AU - Wood JC AD - Division of Vascular Surgery, University of North Carolina, Chapel Hill, NC. FAU - Farber, Mark A AU - Farber MA AD - Division of Vascular Surgery, University of North Carolina, Chapel Hill, NC. Electronic address: mark_farber@med.unc.edu. LA - eng GR - T32 HL007055/HL/NHLBI NIH HHS/United States PT - Journal Article DEP - 20241112 PL - United States TA - J Vasc Surg JT - Journal of vascular surgery JID - 8407742 SB - IM MH - Humans MH - Male MH - Aged MH - Female MH - *Endovascular Procedures/mortality/adverse effects/instrumentation MH - Risk Factors MH - Time Factors MH - Risk Assessment MH - Treatment Outcome MH - *Aortic Aneurysm, Thoracic/surgery/mortality/diagnostic imaging MH - *Blood Vessel Prosthesis Implantation/mortality/adverse effects/instrumentation MH - *Aortic Aneurysm, Abdominal/mortality/surgery/diagnostic imaging MH - Retrospective Studies MH - Aged, 80 and over MH - Blood Vessel Prosthesis MH - Middle Aged MH - Prosthesis Design MH - Endovascular Aneurysm Repair PMC - PMC11866699 MID - NIHMS2047998 OTO - NOTNLM OT - 5-year survival OT - Complex anatomy aortic aneurysms OT - F/BEVAR OT - Preoperative risk factors OT - Thoracoabdominal aneurysms COIS- Disclosures F.E.P. has stock options in Centerline Biomedical. W.A.M. is a consultant for InterVene Inc and Molnlycke Inc, and reports research and clinical trial support from InterVene and Reapplix Medical. K.L.M. reports speaker fees from Penumbra Inc and Shockwave Medical, is a consultant for Vascular Technology Inc, and has received research support from NovoNordisk Foundation. M.A.F. is a consultant for WL Gore, Getinge, and ViTTA; received clinical trial support from WL Gore, Cook, ViTTA, and Centerline Biomedical; received research support from Cook; and has stock options in Centerline Biomedical. The remaining authors report no conflicts. EDAT- 2024/11/14 03:56 MHDA- 2025/02/22 00:22 PMCR- 2025/03/01 CRDT- 2024/11/13 19:23 PHST- 2024/07/10 00:00 [received] PHST- 2024/09/29 00:00 [revised] PHST- 2024/11/02 00:00 [accepted] PHST- 2025/02/22 00:22 [medline] PHST- 2024/11/14 03:56 [pubmed] PHST- 2024/11/13 19:23 [entrez] PHST- 2025/03/01 00:00 [pmc-release] AID - S0741-5214(24)02061-5 [pii] AID - 10.1016/j.jvs.2024.11.002 [doi] PST - ppublish SO - J Vasc Surg. 2025 Mar;81(3):539-547. doi: 10.1016/j.jvs.2024.11.002. Epub 2024 Nov 12. PMID- 39536194 OWN - NLM STAT- MEDLINE DCOM- 20241113 LR - 20260505 IS - 1678-4170 (Electronic) IS - 0066-782X (Print) IS - 0066-782X (Linking) VI - 121 IP - 10 DP - 2024 TI - Potentially Inappropriate Cardioverter Defibrillator Implants in Secondary Prevention of Death. PG - e20220899 LID - S0066-782X2024001000309 [pii] LID - 10.36660/abc.20220899 [doi] LID - e20220899 AB - BACKGROUND: Implantable cardioverter defibrillators (ICDs) are recommended for patients experiencing malignant tachyarrhythmias due to irreversible causes, who are clinically stable, and have a life expectancy exceeding one year. However, adverse socioeconomic and psychosocial conditions can adversely affect short-term survival and may render implantation inappropriate. OBJECTIVE: To assess whether economic and psychosocial markers (EPSM) are associated with higher mortality in the first year (indicating potentially inappropriate implants) following ICD implantation. METHODS: A prospective cohort study conducted between 2017 and 2021 included patients with heart failure and left ventricular ejection fraction (LVEF) < 50% who underwent ICD implantation for secondary prophylaxis. Prior to the procedure, patients were evaluated by an MDT, which examined four EPSM variables, namely socioeconomic vulnerability, self-care capacity, pharmacological adherence, and mood disorders. The participants were monitored for at least 12 months. Statistical significance was considered to be p-values < 0.05. RESULTS: A total of 208 individuals were included, with 144 (68.9%) being male. The mean LVEF was 32% +/-9 and 107 (51%) had Chagas disease etiology. The mortality rate in the first year was 54/208 (25.8%). All patients who died had at least one of the EPSM and there no deaths were reported among the 73 (35.4%) who did not have EPSM. In multivariate analysis, having EPSM and LVEF were the only independent predictors of mortality under 1 year: RR 20.48 (2.75 - 52.29); p=0.003 and RR 0.97 (0.93 - 0.99); p=0.047, respectively. CONCLUSION: Socioeconomic and psychosocial conditions should be identified and, where possible, resolved before implantation, as they may make device implantation a potentially inappropriate procedure. FAU - Carvalho, William Neves de AU - Carvalho WN AUID- ORCID: 0000-0001-7782-4567 AD - Universidade Federal da Bahia - UFBA, Salvador, BA - Brasil. FAU - Viana, Taina Teixeira AU - Viana TT AUID- ORCID: 0000-0003-1194-8246 AD - Universidade Federal da Bahia - UFBA, Salvador, BA - Brasil. FAU - Figueiredo, Clara Salles AU - Figueiredo CS AUID- ORCID: 0000-0002-7722-9087 AD - Universidade Federal da Bahia - UFBA, Salvador, BA - Brasil. FAU - Martins, Fernanda AU - Martins F AD - Universidade Federal da Bahia - UFBA, Salvador, BA - Brasil. FAU - Passos, Luiz Carlos Santana AU - Passos LCS AD - Universidade Federal da Bahia - UFBA, Salvador, BA - Brasil. LA - eng LA - por PT - Journal Article TT - Implantes Potencialmente Inapropriados de Cardioversor-Desfibrilador na Prevencao Secundaria de Morte. DEP - 20241111 PL - Brazil TA - Arq Bras Cardiol JT - Arquivos brasileiros de cardiologia JID - 0421031 SB - IM MH - Humans MH - Male MH - *Defibrillators, Implantable/adverse effects MH - Female MH - Prospective Studies MH - Middle Aged MH - *Secondary Prevention MH - *Socioeconomic Factors MH - Aged MH - *Death, Sudden, Cardiac/prevention & control MH - Heart Failure/mortality MH - Risk Factors MH - Time Factors MH - Stroke Volume/physiology MH - Adult PMC - PMC11634201 OAB - BACKGROUND: Implantable cardioverter defibrillators (ICDs) are recommended for patients experiencing malignant tachyarrhythmias due to irreversible causes, who are clinically stable, and have a life expectancy exceeding one year. However, adverse socioeconomic and psychosocial conditions can adversely affect short-term survival and may render implantation inappropriate. OBJECTIVE: To assess whether economic and psychosocial markers (EPSM) are associated with higher mortality in the first year (indicating potentially inappropriate implants) following ICD implantation. METHODS: A prospective cohort study conducted between 2017 and 2021 included patients with heart failure and left ventricular ejection fraction (LVEF) < 50% who underwent ICD implantation for secondary prophylaxis. Prior to the procedure, patients were evaluated by an MDT, which examined four EPSM variables, namely socioeconomic vulnerability, self-care capacity, pharmacological adherence, and mood disorders. The participants were monitored for at least 12 months. Statistical significance was considered to be p-values < 0.05. RESULTS: A total of 208 individuals were included, with 144 (68.9%) being male. The mean LVEF was 32% +/-9 and 107 (51%) had Chagas disease etiology. The mortality rate in the first year was 54/208 (25.8%). All patients who died had at least one of the EPSM and there no deaths were reported among the 73 (35.4%) who did not have EPSM. In multivariate analysis, having EPSM and LVEF were the only independent predictors of mortality under 1 year: RR 20.48 (2.75 - 52.29); p=0.003 and RR 0.97 (0.93 - 0.99); p=0.047, respectively. CONCLUSION: Socioeconomic and psychosocial conditions should be identified and, where possible, resolved before implantation, as they may make device implantation a potentially inappropriate procedure. OABL- eng COIS- Potencial conflito de interesse: Nao ha conflito com o presente artigo EDAT- 2024/11/14 03:55 MHDA- 2024/11/14 03:56 PMCR- 2024/10/22 CRDT- 2024/11/13 15:33 PHST- 2022/12/12 00:00 [received] PHST- 2024/07/31 00:00 [accepted] PHST- 2024/11/14 03:56 [medline] PHST- 2024/11/14 03:55 [pubmed] PHST- 2024/11/13 15:33 [entrez] PHST- 2024/10/22 00:00 [pmc-release] AID - S0066-782X2024001000309 [pii] AID - 10.36660/abc.20220899 [doi] PST - epublish SO - Arq Bras Cardiol. 2024 Nov 11;121(10):e20220899. doi: 10.36660/abc.20220899. eCollection 2024. PMID- 39524820 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241114 IS - 2405-8440 (Print) IS - 2405-8440 (Electronic) IS - 2405-8440 (Linking) VI - 10 IP - 21 DP - 2024 Nov 15 TI - Exploring synergistic effects of Achyranthes bidentata Blume and Paeonia lactiflora Pall. on hypertension with liver yang hyperactivity using the multidisciplinary integrative strategy. PG - e38649 LID - 10.1016/j.heliyon.2024.e38649 [doi] LID - e38649 AB - Traditional Chinese Medicine (TCM) formulations serve as a multi-component pharmacological combination therapy with various potential targets and have collected extensive knowledge regarding the in vivo efficacy of treating cardiovascular disorders in clinical practice for thousands of years. However, the obscurity of the chemicals and the molecular mechanisms are impediments to their continued growth and globalization. Therefore, new modern medications based on the combination of beneficial TCM components with precise clinical efficacy are required. The goal of this study was to find the best combination of Achyranthes bidentata Blume (AB) and Paeonia lactiflora Pall. (PL) for hypertension with liver yang hyperactivity (HLYH). The integrated research consisting of principal component analysis (PCA), metabolomics, microbiology, and weighted correlation network analysis (WGCNA) were used to find the optimal combination of AB-PL combinations and reveal the mechanism of action. The result showed AB-PL (2:3) had a substantial protective impact on HLYH, as shown by lower blood pressure, improved liver yang hyperactivity, reduced cardiac remodeling and malondialdehyde (MDA), and increased NO content. Furthermore, the essential elements for AB-PL reducing hypertension may be related to 135 metabolites and 23 microorganisms. In conclusion, our findings support the efficacy of herbal remedies in the treatment of hypertension and provide some pharmacological evidence for the ongoing development of novel modern Chinese drugs for cardiovascular disorders. CI - (c) 2024 Published by Elsevier Ltd. FAU - Zhang, Yanyan AU - Zhang Y AD - Center of Scientific Research, School of Basic Medicine, Qiqihar Medical University, Qiqihar, 161006, China. FAU - Yan, Peimei AU - Yan P AD - Center of Scientific Research, School of Basic Medicine, Qiqihar Medical University, Qiqihar, 161006, China. FAU - He, Yuhui AU - He Y AD - Center of Scientific Research, School of Basic Medicine, Qiqihar Medical University, Qiqihar, 161006, China. FAU - Ren, Shan AU - Ren S AD - Department of Pathophysiology, School of Basic Medicine, Qiqihar Medical University, Qiqihar, 161006, China. FAU - Wu, Dingxiao AU - Wu D AD - Department of Pathophysiology, School of Basic Medicine, Qiqihar Medical University, Qiqihar, 161006, China. FAU - Wang, Yingwanqi AU - Wang Y AD - Center of Scientific Research, School of Basic Medicine, Qiqihar Medical University, Qiqihar, 161006, China. FAU - Song, Siyao AU - Song S AD - Department of Pathophysiology, School of Basic Medicine, Qiqihar Medical University, Qiqihar, 161006, China. FAU - Lu, Peng AU - Lu P AD - Department of Pathophysiology, School of Basic Medicine, Qiqihar Medical University, Qiqihar, 161006, China. FAU - Li, Xue AU - Li X AD - Department of Physiology, School of Basic Medicine, Qiqihar Medical University, Qiqihar, 161006, China. FAU - Li, Guangwei AU - Li G AD - Department of Pathophysiology, School of Basic Medicine, Qiqihar Medical University, Qiqihar, 161006, China. FAU - Jia, Weiwei AU - Jia W AD - Center of Scientific Research, School of Basic Medicine, Qiqihar Medical University, Qiqihar, 161006, China. FAU - Lyu, Ying AU - Lyu Y AD - Center of Scientific Research, School of Basic Medicine, Qiqihar Medical University, Qiqihar, 161006, China. FAU - Dong, Haiying AU - Dong H AD - Department of Clinical Pathology Diagnosis, Qiqihar Medical University, Qiqihar, 161006, China. FAU - Xiao, Dan AU - Xiao D AD - School of Medicine and Health, Harbin Institute of Technology, Harbin, 150000, China. FAU - Ding, Lin AU - Ding L AD - Department of Scientific Research, Science and Technology Achievement Transformation Center, Qiqihar Medical University, Qiqihar, 161006, China. FAU - Lin, Song AU - Lin S AD - Center of Scientific Research, School of Basic Medicine, Qiqihar Medical University, Qiqihar, 161006, China. AD - Key Laboratory of Homology of Medicine and Food Resources and Metabolic Disease Prevention and Treatment of Heilongjiang Province, Qiqihar, Heilongjiang Province, 161006, China. FAU - Lin, Yan AU - Lin Y AD - Center of Scientific Research, School of Basic Medicine, Qiqihar Medical University, Qiqihar, 161006, China. AD - Key Laboratory of Homology of Medicine and Food Resources and Metabolic Disease Prevention and Treatment of Heilongjiang Province, Qiqihar, Heilongjiang Province, 161006, China. LA - eng PT - Journal Article DEP - 20241005 PL - England TA - Heliyon JT - Heliyon JID - 101672560 PMC - PMC11550124 OTO - NOTNLM OT - 16s rRNA OT - Achyranthes bidentata Blume OT - Hypertension OT - Metabolomics OT - Paeonia lactiflora Pall. OT - Principal component analysis OT - Weighted correlation network analysis COIS- The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/11/14 03:57 MHDA- 2024/11/14 03:58 PMCR- 2024/10/05 CRDT- 2024/11/11 05:34 PHST- 2024/01/27 00:00 [received] PHST- 2024/09/05 00:00 [revised] PHST- 2024/09/26 00:00 [accepted] PHST- 2024/11/14 03:58 [medline] PHST- 2024/11/14 03:57 [pubmed] PHST- 2024/11/11 05:34 [entrez] PHST- 2024/10/05 00:00 [pmc-release] AID - S2405-8440(24)14680-4 [pii] AID - e38649 [pii] AID - 10.1016/j.heliyon.2024.e38649 [doi] PST - epublish SO - Heliyon. 2024 Oct 5;10(21):e38649. doi: 10.1016/j.heliyon.2024.e38649. eCollection 2024 Nov 15. PMID- 39530490 OWN - NLM STAT- MEDLINE DCOM- 20241119 LR - 20260420 IS - 1469-7793 (Electronic) IS - 0022-3751 (Print) IS - 0022-3751 (Linking) VI - 602 IP - 22 DP - 2024 Nov TI - Impaired oxytocin signalling in the central amygdala in rats with chronic heart failure. PG - 6259-6280 LID - 10.1113/JP286297 [doi] AB - Heart failure (HF) patients suffer from cognitive decline and mood impairments, but the molecular signals and brain circuits underlying these effects remain elusive. The hypothalamic neuropeptide oxytocin (OT) is critically involved in regulating mood, and OTergic signalling in the central amygdala (CeA) is a key mechanism that controls emotional responses including anxiety-like behaviours. Still, whether an altered OTergic signalling contributes to mood disorders in HF remains unknown. To address this, we used an ischaemic rat HF model, along with a highly multidisciplinary approach, to mechanistically study multiple levels of the hypothalamus-to-CeA OTergic circuit in male rats with HF. We aimed to test the hypothesis that sustained activation of the OT system following an infarct leads to depletion of OT content in this pathway, with subsequent changes in OT receptor expression and blunted modulation of local GABAergic circuits. We found that most of OTergic innervation of the CeA originated from the supraoptic nucleus (SON). While no differences in the numbers of SON-->CeA OTergic neurons was observed between sham and HF rats, we observed a blunted content and release of OT from axonal terminals within the CeA. Moreover, we report downregulation of neuronal and astrocytic OT receptors, and impaired OTR-driven GABAergic synaptic activity within the CeA microcircuit of HF rats. We provide the first evidence that male HF rats display perturbations in the hypothalamus-to-amygdala OTergic circuit, laying the foundation for future translational studies targeting either the OT system or GABAergic amygdalar microcircuit to ameliorate mood impairments in rats or patients with chronic HF. KEY POINTS: Heart failure patients suffer from cognitive decline, depression and mood impairments, but the underlying mechanisms remain elusive. Acting within the central amygdala, the neuropeptide oxytocin regulates emotional responses, including anxiety-like behaviours. However, whether changes in oxytocin signalling occurs during heart failure is unknown. In this study, we used an ischaemic rat heart failure model to mechanistically study multiple levels of the hypothalamus-to-amygdala oxytocinergic circuit in this disease. We report an overall blunted oxytocinergic signalling pathway in rats with heart failure, including blunted content and release of oxytocin from axonal terminals, downregulation of neuronal and astrocytic oxytocin receptors, and impaired oxytocin-driven GABAergic synaptic activity within the central amygdala microcircuit of HF rats. These studies shed light on mechanisms that contribute to mood disorders in cardiovascular disease states and help to identify potential molecular targets for their improved treatment. CI - (c) 2024 The Authors. The Journal of Physiology (c) 2024 The Physiological Society. FAU - Althammer, Ferdinand AU - Althammer F AD - Center for Neuroinflammation and Cardiometabolic Diseases, Georgia State University, Atlanta, GA, USA. AD - Institute of Human Genetics, Heidelberg University, Heidelberg, Germany. FAU - Roy, Ranjan K AU - Roy RK AUID- ORCID: 0000-0001-6234-8043 AD - Center for Neuroinflammation and Cardiometabolic Diseases, Georgia State University, Atlanta, GA, USA. AD - Neuroscience Institute, Georgia State University, Atlanta, GA, USA. FAU - Kirchner, Matthew K AU - Kirchner MK AUID- ORCID: 0000-0001-6960-7685 AD - Center for Neuroinflammation and Cardiometabolic Diseases, Georgia State University, Atlanta, GA, USA. AD - Neuroscience Institute, Georgia State University, Atlanta, GA, USA. FAU - Lira, Elba Campos AU - Lira EC AUID- ORCID: 0009-0001-9476-5287 AD - Center for Neuroinflammation and Cardiometabolic Diseases, Georgia State University, Atlanta, GA, USA. AD - Neuroscience Institute, Georgia State University, Atlanta, GA, USA. FAU - Schimmer, Stephanie AU - Schimmer S AUID- ORCID: 0000-0002-9004-7405 AD - Department of Neuropeptide Research in Psychiatry, Central Institute of Mental Health, Heidelberg University, Mannheim, Germany. FAU - Charlet, Alexandre AU - Charlet A AUID- ORCID: 0000-0003-4837-3706 AD - Centre National de la Recherche Scientifique and University of Strasbourg, Institute of Cellular and Integrative Neuroscience, Strasbourg, France. FAU - Grinevich, Valery AU - Grinevich V AD - Department of Neuropeptide Research in Psychiatry, Central Institute of Mental Health, Heidelberg University, Mannheim, Germany. FAU - Stern, Javier E AU - Stern JE AUID- ORCID: 0000-0002-9310-0486 AD - Center for Neuroinflammation and Cardiometabolic Diseases, Georgia State University, Atlanta, GA, USA. AD - Neuroscience Institute, Georgia State University, Atlanta, GA, USA. LA - eng GR - R01 NS094640/NS/NINDS NIH HHS/United States GR - K99 HL168434/HL/NHLBI NIH HHS/United States GR - R01 HL162575/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20241112 PL - England TA - J Physiol JT - The Journal of physiology JID - 0266262 RN - 50-56-6 (Oxytocin) RN - 0 (Receptors, Oxytocin) SB - IM UOF - bioRxiv. 2023 Nov 22:2023.11.22.568271. doi: 10.1101/2023.11.22.568271. PMID: 38045233 MH - Animals MH - *Oxytocin/metabolism MH - *Heart Failure/metabolism/physiopathology MH - Male MH - Rats MH - *Central Amygdaloid Nucleus/metabolism MH - *Receptors, Oxytocin/metabolism MH - Rats, Sprague-Dawley MH - Signal Transduction MH - Chronic Disease MH - Hypothalamus/metabolism MH - Neurons/metabolism PMC - PMC11576253 MID - NIHMS2025526 OTO - NOTNLM OT - GABA OT - amygdala OT - astrocyte OT - depression OT - electrophysiology OT - heart failure OT - mood OT - oxytocin COIS- Additional information section Competing interests The authors declare no competing interests. EDAT- 2024/11/13 13:54 MHDA- 2024/11/19 13:19 PMCR- 2025/11/12 CRDT- 2024/11/12 07:53 PHST- 2024/01/19 00:00 [received] PHST- 2024/09/13 00:00 [accepted] PHST- 2024/11/19 13:19 [medline] PHST- 2024/11/13 13:54 [pubmed] PHST- 2024/11/12 07:53 [entrez] PHST- 2025/11/12 00:00 [pmc-release] AID - 10.1113/JP286297 [doi] PST - ppublish SO - J Physiol. 2024 Nov;602(22):6259-6280. doi: 10.1113/JP286297. Epub 2024 Nov 12. PMID- 39527048 OWN - NLM STAT- MEDLINE DCOM- 20241217 LR - 20250530 IS - 1538-3598 (Electronic) IS - 0098-7484 (Linking) VI - 332 IP - 23 DP - 2024 Dec 17 TI - Calcific Aortic Stenosis: A Review. PG - 2014-2026 LID - 10.1001/jama.2024.16477 [doi] AB - IMPORTANCE: Calcific aortic stenosis (AS) restricts the aortic valve opening during systole due to calcification and fibrosis of either a congenital bicuspid or a normal trileaflet aortic valve. In the US, AS affects 1% to 2% of adults older than 65 years and approximately 12% of adults older than 75 years. Worldwide, AS leads to more than 100 000 deaths annually. OBSERVATIONS: Calcific AS is characterized by aortic valve leaflet lipid infiltration and inflammation with subsequent fibrosis and calcification. Symptoms due to severe AS, such as exercise intolerance, exertional dyspnea, and syncope, are associated with a 1-year mortality rate of up to 50% without aortic valve replacement. Echocardiography can detect AS and measure the severity of aortic valve dysfunction. Although progression rates vary, once aortic velocity is higher than 2 m/s, progression to severe AS occurs typically within 10 years. Severe AS is defined by an aortic velocity 4 m/s or higher, a mean gradient 40 mm Hg or higher, or a valve area less than or equal to 1.0 cm2. Management of mild to moderate AS and asymptomatic severe AS consists of patient education about the typical progression of disease; clinical and echocardiographic surveillance at intervals of 3 to 5 years for mild AS, 1 to 2 years for moderate AS, and 6 to 12 months for severe AS; and treatment of hypertension, hyperlipidemia, and cigarette smoking as indicated. When a patient with severe AS develops symptoms, surgical aortic valve replacement (SAVR) or transcatheter aortic valve implantation (TAVI) is recommended, which restores an average life expectancy; in patients aged older than 70 years with a low surgical risk, 10-year all-cause mortality was 62.7% with TAVI and 64.0% with SAVR. TAVI is associated with decreased length of hospitalization, more rapid return to normal activities, and less pain compared with SAVR. However, evidence supporting TAVI for patients aged younger than 65 years and long-term outcomes of TAVI are less well defined than for SAVR. For patients with symptomatic severe AS, the 2020 American College of Cardiology/American Heart Association guideline recommends SAVR for individuals aged 65 years and younger, SAVR or TAVI for those aged 66 to 79 years, and TAVI for individuals aged 80 years and older or those with an estimated surgical mortality of 8% or higher. CONCLUSIONS: Calcific AS is a common chronic progressive condition among older adults and is diagnosed via echocardiography. Symptomatic patients with severe AS have a mortality rate of up to 50% after 1 year, but treatment with SAVR or TAVI reduces mortality to that of age-matched control patients. The type and timing of valve replacement should be built on evidence-based guidelines, shared decision-making, and involvement of a multidisciplinary heart valve team. FAU - Otto, Catherine M AU - Otto CM AD - Division of Cardiology, University of Washington School of Medicine, Seattle. FAU - Newby, David E AU - Newby DE AD - University of Edinburgh, British Heart Foundation Centre of Research Excellence, Royal Infirmary, Edinburgh, United Kingdom. FAU - Hillis, Graham S AU - Hillis GS AD - Department of Cardiology, Royal Perth Hospital and Medical School, University of Western Australia, Perth. LA - eng GR - RG/F/22/110093/BHF_/British Heart Foundation/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review PL - United States TA - JAMA JT - JAMA JID - 7501160 RN - Aortic Valve, Calcification of SB - IM MH - Aged MH - Humans MH - *Aortic Valve Stenosis/diagnosis/mortality/pathology/surgery MH - *Calcinosis/diagnosis/mortality/pathology/surgery MH - Disease Progression MH - Echocardiography MH - Heart Valve Prosthesis Implantation MH - Transcatheter Aortic Valve Replacement MH - Aortic Valve/diagnostic imaging/pathology/surgery MH - Aged, 80 and over EDAT- 2024/11/13 13:55 MHDA- 2024/12/17 12:31 CRDT- 2024/11/11 11:33 PHST- 2024/12/17 12:31 [medline] PHST- 2024/11/13 13:55 [pubmed] PHST- 2024/11/11 11:33 [entrez] AID - 2826117 [pii] AID - 10.1001/jama.2024.16477 [doi] PST - ppublish SO - JAMA. 2024 Dec 17;332(23):2014-2026. doi: 10.1001/jama.2024.16477. PMID- 39524987 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241114 IS - 2049-9361 (Print) IS - 2049-937X (Electronic) IS - 2049-9361 (Linking) VI - 11 DP - 2024 Jan-Dec TI - Emerging trends in fungal endocarditis: clinical complexity, diagnostic challenges, and therapeutic implications - a case series and literature review. PG - 20499361241293655 LID - 10.1177/20499361241293655 [doi] LID - 20499361241293655 AB - BACKGROUND: Fungal infective endocarditis (IE) is a rare, yet increasingly recognised condition associated with substantial mortality rates. Candida and Histoplasma are among the notable causative agents, presenting diverse clinical manifestations and complexities in diagnosis and management. OBJECTIVES: This study was undertaken to examine the clinical profiles, diagnostic challenges, treatment modalities, and outcomes of four compelling cases involving Candida and Histoplasma endocarditis. METHODS & DESIGN: This was a descriptive case series study conducted from July 2021 to July 2023. All patients with definite/possible endocarditis diagnosed based on modified Duke's criteria were reviewed in this study. Data on demographics, risk factors, clinical signs and symptoms, echocardiography findings, microbiological aetiology, complications, treatment, and outcomes were collected. RESULTS: Among 212 suspected IE cases reviewed, 54 met the modified Duke's criteria for possible or definite IE, with four instances identified as fungal endocarditis. Candida species accounted for three cases, while an uncommon instance of Histoplasma Endocarditis (HE) was also observed. Clinical presentations varied, with fever and dyspnoea being prominent symptoms. Risk factors included chronic kidney disease, prior surgeries, prosthetic valves, and immunocompromised states. Diagnosis posed challenges due to the resemblance to bacterial IE, low blood culture yields, and delayed suspicion. Various diagnostic approaches, including blood cultures, serological markers, and imaging, were employed. Therapeutic strategies involved antifungal agents and surgical intervention, where feasible. However, despite prompt treatment initiation, many patients faced rapid clinical deterioration, emphasising the severity and aggressive nature of fungal endocarditis. Mortality rates remained notably high across the cohort. CONCLUSION: This study highlights the criticality of early suspicion, prompt diagnosis, and a multidisciplinary approach to managing fungal endocarditis. While recognising the limitations in current diagnostic tools and therapeutic options, the study underscores the urgent need for enhanced diagnostic modalities and novel treatment strategies to improve outcomes in these challenging cases. CI - (c) The Author(s), 2024. FAU - Naguthevar, Santhanam AU - Naguthevar S AD - Infectious Diseases Division, Department of Medicine, All India Institute of Medical Sciences, Jodhpur, India. FAU - Ravindra, Akshatha AU - Ravindra A AD - Infectious Diseases Division, Department of Medicine, All India Institute of Medical Sciences, Jodhpur, India. FAU - Kumar, Deepak AU - Kumar D AUID- ORCID: 0000-0001-6298-3565 AD - Department of Medicine & Infectious Diseases, All India Institute of Medical Sciences, Jodhpur 342005, India. FAU - Meena, Durga Shankar AU - Meena DS AUID- ORCID: 0000-0001-9524-5278 AD - Infectious Diseases Division, Department of Medicine, All India Institute of Medical Sciences, Jodhpur, India. FAU - Bohra, Gopal Krishana AU - Bohra GK AD - Infectious Diseases Division, Department of Medicine, All India Institute of Medical Sciences, Jodhpur, India. FAU - Jain, Vidhi AU - Jain V AD - Department of Microbiology, All India Institute of Medical Sciences, Jodhpur, India. FAU - Garg, M K AU - Garg MK AD - Infectious Diseases Division, Department of Medicine, All India Institute of Medical Sciences, Jodhpur, India. FAU - Deora, Surender AU - Deora S AD - Department of Cardiology, AIIMS Jodhpur, Jodhpur, India. FAU - Choudhary, Rahul AU - Choudhary R AD - Department of Cardiology, AIIMS Jodhpur, Jodhpur, India. LA - eng PT - Journal Article DEP - 20241109 PL - England TA - Ther Adv Infect Dis JT - Therapeutic advances in infectious disease JID - 101606715 PMC - PMC11550493 OTO - NOTNLM OT - candida OT - echocardiography OT - endocarditis OT - fungal biomarker OT - histoplasma EDAT- 2024/11/13 13:53 MHDA- 2024/11/13 13:54 PMCR- 2024/11/09 CRDT- 2024/11/11 05:36 PHST- 2023/12/13 00:00 [received] PHST- 2024/10/03 00:00 [accepted] PHST- 2024/11/13 13:54 [medline] PHST- 2024/11/13 13:53 [pubmed] PHST- 2024/11/11 05:36 [entrez] PHST- 2024/11/09 00:00 [pmc-release] AID - 10.1177_20499361241293655 [pii] AID - 10.1177/20499361241293655 [doi] PST - epublish SO - Ther Adv Infect Dis. 2024 Nov 9;11:20499361241293655. doi: 10.1177/20499361241293655. eCollection 2024 Jan-Dec. PMID- 39524214 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241115 IS - 2574-1209 (Electronic) IS - 2574-1209 (Linking) VI - 8 DP - 2024 TI - The heart team: the multidisciplinary approach to coronary artery disease. LID - 6 [pii] LID - 10.20517/2574-1209.2023.122 [doi] AB - The recommendation to employ a heart team to guide revascularization has persisted for over a decade. Despite evidence for improved adherence to guidelines, widespread adoption of the heart team approach has been limited. This review delves into the history of the guidelines endorsing the use of a heart team and the supporting data. Additionally, it outlines some attributes of a successful heart team, and how the heart team has been run at several large academic centers. Finally, it reviews some of the barriers to a heart team and future considerations. FAU - Riojas, Ramon A AU - Riojas RA AD - Division of Cardiac Surgery, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. AD - Malcolm Grow Medical Clinics and Surgery Center, Joint Base-Andrews, MD 20762, USA. FAU - Lawton, Jennifer S AU - Lawton JS AD - Division of Cardiac Surgery, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. FAU - Metkus, Thomas S Jr AU - Metkus TS Jr AD - Division of Cardiac Surgery, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. AD - Divison of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. LA - eng GR - L30 HL134072/HL/NHLBI NIH HHS/United States PT - Journal Article DEP - 20240124 PL - United States TA - Vessel Plus JT - Vessel plus JID - 101726367 PMC - PMC11545650 MID - NIHMS1990037 OTO - NOTNLM OT - CABG OT - Multidisciplinary team OT - PCI OT - complex coronary artery disease OT - heart team COIS- Conflicts of interest All authors declared that there are no conflicts of interest. The views expressed in this manuscript are solely of the authors and do not reflect the views of the United States Air Force or the Department of Defense. EDAT- 2024/11/13 13:48 MHDA- 2024/11/13 13:49 PMCR- 2024/11/08 CRDT- 2024/11/11 05:27 PHST- 2024/11/13 13:49 [medline] PHST- 2024/11/13 13:48 [pubmed] PHST- 2024/11/11 05:27 [entrez] PHST- 2024/11/08 00:00 [pmc-release] AID - 6 [pii] AID - 10.20517/2574-1209.2023.122 [doi] PST - ppublish SO - Vessel Plus. 2024;8:6. doi: 10.20517/2574-1209.2023.122. Epub 2024 Jan 24. PMID- 39521370 OWN - NLM STAT- MEDLINE DCOM- 20250731 LR - 20260325 IS - 1097-685X (Electronic) IS - 0022-5223 (Linking) VI - 170 IP - 2 DP - 2025 Aug TI - Impact of transcatheter aortic valve replacement use ratio on outcomes in patients with aortic valve disease. PG - 468-475.e2 LID - S0022-5223(24)01002-X [pii] LID - 10.1016/j.jtcvs.2024.10.046 [doi] AB - OBJECTIVE: Use of the Heart Team has been the standard of care for the treatment of aortic valve disease; however, its efficacy has not been evaluated. We sought to analyze its impact using the transcatheter aortic valve replacement (TAVR) use ratio (number of TAVR/total aortic valve replacement [AVR] volume) on TAVR, surgical aortic valve replacement (SAVR), and overall AVR outcomes. METHODS: We analyzed all TAVRs and SAVRs sampled by the National Readmissions Database between 2016 and 2020. Hospitals were stratified into quartiles on the basis of their TAVR/AVR ratio. Centers with a ratio below the first quartile were considered "low ratio," centers in the second and the third quartile "balanced ratio," and centers above the third quartile "high ratio." Primary outcomes were 30-day mortality and complication rate, which included stroke, renal failure, heart block, pacemaker placement, and valve regurgitation. RESULTS: For overall AVR outcomes, centers with a balanced ratio had lower mortality compared with centers with low ratio (1.9% vs 2.1%, P = .01) and lower complication rate compared with centers with high ratio (34.8% vs 36.8%, P < .001). Centers with a balanced ratio had lower TAVR complication rate compared with centers with low ratio (37.3% vs 39%, P < .001). For SAVR outcome, centers with an balanced ratio had lower post-SAVR mortality (2.1% vs 2.6%, P < .001) and complication rate (28.6% vs 30.3%, P < .001) than centers with high ratio. CONCLUSIONS: Centers with balanced TAVR ratios had superior outcomes compared with centers with low or high ratios. These data support the use of a balanced Heart Team to optimize AVR outcomes. CI - Copyright (c) 2024 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Marghitu, Theodore AU - Marghitu T AD - Division of Cardiothoracic Surgery, Department of Surgery, Washington University in St Louis School of Medicine, St Louis, Mo. FAU - Roberts, Sophia H AU - Roberts SH AD - Division of Cardiothoracic Surgery, Department of Surgery, Washington University in St Louis School of Medicine, St Louis, Mo. FAU - He, June AU - He J AD - Division of Cardiothoracic Surgery, Department of Surgery, Washington University in St Louis School of Medicine, St Louis, Mo. FAU - Kouchoukos, Nicholas AU - Kouchoukos N AD - Division of Cardiothoracic Surgery, Department of Surgery, Washington University in St Louis School of Medicine, St Louis, Mo. FAU - Kachroo, Puja AU - Kachroo P AD - Division of Cardiothoracic Surgery, Department of Surgery, Washington University in St Louis School of Medicine, St Louis, Mo. FAU - Roberts, Harold AU - Roberts H AD - Division of Cardiothoracic Surgery, Department of Surgery, Washington University in St Louis School of Medicine, St Louis, Mo. FAU - Damiano, Ralph AU - Damiano R AD - Division of Cardiothoracic Surgery, Department of Surgery, Washington University in St Louis School of Medicine, St Louis, Mo. FAU - Zajarias, Alan AU - Zajarias A AD - Division of Cardiology, Department of Medicine, Washington University in St Louis School of Medicine, St Louis, Mo. FAU - Sintek, Marc AU - Sintek M AD - Division of Cardiology, Department of Medicine, Washington University in St Louis School of Medicine, St Louis, Mo. FAU - Lasala, John AU - Lasala J AD - Division of Cardiology, Department of Medicine, Washington University in St Louis School of Medicine, St Louis, Mo. FAU - Brescia, Alexander A AU - Brescia AA AD - Division of Cardiothoracic Surgery, Department of Surgery, Washington University in St Louis School of Medicine, St Louis, Mo. FAU - Kaneko, Tsuyoshi AU - Kaneko T AD - Division of Cardiothoracic Surgery, Department of Surgery, Washington University in St Louis School of Medicine, St Louis, Mo. Electronic address: kaneko@wustl.edu. LA - eng PT - Journal Article DEP - 20241107 PL - United States TA - J Thorac Cardiovasc Surg JT - The Journal of thoracic and cardiovascular surgery JID - 0376343 SB - IM MH - Humans MH - *Transcatheter Aortic Valve Replacement/adverse effects/mortality/statistics & numerical data MH - Male MH - Female MH - Aged MH - Aged, 80 and over MH - Treatment Outcome MH - *Aortic Valve/surgery MH - Postoperative Complications/epidemiology/mortality/etiology MH - United States/epidemiology MH - Databases, Factual MH - *Aortic Valve Disease/surgery/mortality MH - Time Factors MH - *Heart Valve Prosthesis Implantation/adverse effects/mortality MH - Risk Factors MH - Retrospective Studies MH - *Aortic Valve Stenosis/surgery/mortality OTO - NOTNLM OT - Heart Team OT - SAVR OT - TAVR COIS- Conflict of Interest Statement T.K. is a speaker for Edwards Life Sciences and Medtronic and a consultant for Baylis Medical and 4C. All other authors reported no conflicts of interest. The Journal policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest. EDAT- 2024/11/13 13:54 MHDA- 2025/08/01 00:29 CRDT- 2024/11/09 19:29 PHST- 2024/06/28 00:00 [received] PHST- 2024/10/05 00:00 [revised] PHST- 2024/10/20 00:00 [accepted] PHST- 2025/08/01 00:29 [medline] PHST- 2024/11/13 13:54 [pubmed] PHST- 2024/11/09 19:29 [entrez] AID - S0022-5223(24)01002-X [pii] AID - 10.1016/j.jtcvs.2024.10.046 [doi] PST - ppublish SO - J Thorac Cardiovasc Surg. 2025 Aug;170(2):468-475.e2. doi: 10.1016/j.jtcvs.2024.10.046. Epub 2024 Nov 7. PMID- 39520453 OWN - NLM STAT- MEDLINE DCOM- 20250425 LR - 20260627 IS - 1097-6760 (Electronic) IS - 0196-0644 (Linking) VI - 85 IP - 2 DP - 2025 Feb TI - Development and Evaluation of a Novel Resuscitation Teamwork Model for Out-of-Hospital Cardiac Arrest in the Emergency Department. PG - 163-178 LID - S0196-0644(24)01074-6 [pii] LID - 10.1016/j.annemergmed.2024.09.008 [doi] AB - STUDY OBJECTIVE: Cardiopulmonary resuscitation (CPR) is critical for out-of-hospital cardiac arrest patients but is prone to rapid changes and errors. Effective teamwork and leadership are essential for high-quality CPR. We aimed to introduce the Airway-Circulation-Leadership-Support (A-C-L-S) teamwork model in the emergency department (ED) to address these challenges. METHODS: The study comprised 2 phases. The development phase involved reviewing CPR videos, categorizing problems, and formulating strategies using the Systems Engineering Initiative for Patient Safety model. Resuscitation tasks were organized into A-C-L-S domains using hierarchical task analysis. Equipment and environmental deficits were optimized ergonomically with a pit-crew style arrangement. Mnemonics enhanced teamwork and leadership. The evaluation phase assessed postimplementation ED resuscitation team performance, focusing on adherence, timeliness, and quality of A-C-L-S tasks. RESULTS: The development phase produced a structured teamwork model, assigning tasks, tools, mnemonics, and positions based on A-C-L-S domains. The A-team manages the airway and optimizes end-tidal CO(2) levels; the C-team focuses on high-quality chest compressions and defibrillation. Leadership coordinates resuscitation efforts using goal-directed mnemonics (DABCD(2)E(3)), whereas the S-team handles medications, timekeeping, and recording. The evaluation phase showed improvements in adherence and timeliness of A-C-L-S tasks, with sustained increases in chest compression fraction before mechanical CPR, from 67.2% preimplementation to 83.0% postimplementation, 89.1% after 1 year, and 86.1% after 2 years. Overall, chest compression fraction also improved from 81.7% to 88.6%, peaking at 92.2% after 1 year and maintaining 90.8% after 2 years. CONCLUSION: The A-C-L-S teamwork model is feasible, applicable, and effective. Further research is needed to assess its influence on patient outcomes. CI - Copyright (c) 2024 American College of Emergency Physicians. Published by Elsevier Inc. All rights reserved. FAU - Chong, Kah Meng AU - Chong KM AD - Department of Emergency Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan. FAU - Chou, Eric Hao-Chang AU - Chou EH AD - Department of Emergency Medicine, Baylor Scott & White All Saints Medical Center, Fort Worth, TX. FAU - Chiang, Wen-Chu AU - Chiang WC AD - Department of Emergency Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan; Department of Emergency Medicine, National Taiwan University Hospital Yun-Lin Branch, Yunlin County, Taiwan. FAU - Wang, Hui-Chih AU - Wang HC AD - Department of Emergency Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan. FAU - Liu, Yeh-Ping AU - Liu YP AD - Department of Emergency Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan. FAU - Ko, Patrick Chow-In AU - Ko PC AD - Department of Emergency Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan. FAU - Huang, Edward Pei-Chuan AU - Huang EP AD - Department of Emergency Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan; Department of Emergency Medicine, National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Taiwan. FAU - Hsieh, Ming-Ju AU - Hsieh MJ AD - Department of Emergency Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan. FAU - Lin, Hao-Yang AU - Lin HY AD - Department of Emergency Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan. FAU - Lien, Wan-Ching AU - Lien WC AD - Department of Emergency Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan. FAU - Huang, Chien-Hua AU - Huang CH AD - Department of Emergency Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan. FAU - Fang, Cheng-Chung AU - Fang CC AD - Department of Emergency Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan. FAU - Chen, Shyr-Chyr AU - Chen SC AD - Department of Emergency Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan. FAU - Bhanji, Farhan AU - Bhanji F AD - Department of Pediatrics, McGill University, Montreal, Canada. FAU - Yang, Chih-Wei AU - Yang CW AD - Department of Medical Education, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan. Electronic address: cwyang0413@gmail.com. FAU - Ma, Matthew Huei-Ming AU - Ma MH AD - Department of Emergency Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan; Department of Emergency Medicine, National Taiwan University Hospital Yun-Lin Branch, Yunlin County, Taiwan. LA - eng PT - Journal Article DEP - 20241108 PL - United States TA - Ann Emerg Med JT - Annals of emergency medicine JID - 8002646 SB - IM MH - Humans MH - *Out-of-Hospital Cardiac Arrest/therapy MH - *Emergency Service, Hospital/organization & administration MH - *Cardiopulmonary Resuscitation/methods/standards/education MH - *Patient Care Team/organization & administration MH - Leadership EDAT- 2024/11/13 13:50 MHDA- 2025/01/23 05:17 CRDT- 2024/11/09 10:34 PHST- 2024/04/20 00:00 [received] PHST- 2024/09/03 00:00 [revised] PHST- 2024/09/16 00:00 [accepted] PHST- 2025/01/23 05:17 [medline] PHST- 2024/11/13 13:50 [pubmed] PHST- 2024/11/09 10:34 [entrez] AID - S0196-0644(24)01074-6 [pii] AID - 10.1016/j.annemergmed.2024.09.008 [doi] PST - ppublish SO - Ann Emerg Med. 2025 Feb;85(2):163-178. doi: 10.1016/j.annemergmed.2024.09.008. Epub 2024 Nov 8. PMID- 39518647 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241116 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 13 IP - 21 DP - 2024 Oct 30 TI - Clinical Recommendations for Managing Genitourinary Adverse Effects in Patients Treated with SGLT-2 Inhibitors: A Multidisciplinary Expert Consensus. LID - 10.3390/jcm13216509 [doi] LID - 6509 AB - Background: SGLT-2 inhibitors (SGLT-2is) are considered to be a first-line treatment for common conditions like type 2 diabetes, chronic kidney disease, and heart failure due to their proven ability to reduce cardiovascular and renal morbidity and mortality. Despite these benefits, SGLT-2is are associated with certain adverse effects (AEs), particularly genitourinary (GU) events, which can lead to treatment discontinuation in some patients. Preventing these AEs is essential for maintaining the cardiorenal benefits of SGLT-2is. Methods: A multidisciplinary panel of experts from various medical specialties reviewed the best available evidence on GU AEs associated with SGLT-2i therapy. The panel focused on the prevention and management of genital mycotic infections, urinary tract infections, and lower urinary tract symptoms in both the general population and high-risk groups, such as renal and cardiac transplant recipients. Results: The panel found that permanent discontinuation of SGLT-2is results in a rapid loss of cardiorenal benefits. Preventive strategies, including identifying high-risk patients before initiating therapy, are critical for minimizing GU AEs. Clinical trials show that most GU infections linked to SGLT-2i therapy are mild to moderate in severity and typically respond to standard antimicrobial treatment, without the need for discontinuation. Conclusions: Routine discontinuation of SGLT-2is due to GU AEs is not recommended. Therapy should be resumed as soon as possible, unless severe or persistent conditions contraindicate their use, in order to preserve the significant benefits of SGLT-2is in reducing cardiovascular and renal events. FAU - Gorgojo-Martinez, Juan J AU - Gorgojo-Martinez JJ AUID- ORCID: 0000-0002-8679-0968 AD - Department of Endocrinology and Nutrition, Hospital Universitario Fundacion Alcorcon, Alcorcon, 28922 Madrid, Spain. FAU - Gorriz, Jose L AU - Gorriz JL AUID- ORCID: 0000-0002-1134-9051 AD - Department of Nephrology, Valencia Clinic University Hospital, Instituto de Investigacion Sanitaria (INCLIVA), Universitat de Valencia, 46010 Valencia, Spain. FAU - Cebrian-Cuenca, Ana AU - Cebrian-Cuenca A AUID- ORCID: 0000-0003-3710-6370 AD - Health Centre Casco Antiguo Cartagena, Primary Care Research Group, Biomedical Research Institute of Murcia (IMIB), 30201 Cartagena, Murcia, Spain. FAU - Castro Conde, Almudena AU - Castro Conde A AD - Department of Cardiology, University Hospital La Paz, IdiPAZ, Biomedical Research Center-Cardiovascular Diseases (CIBERCV-ISCIII), 28046 Madrid, Spain. FAU - Velasco Arribas, Maria AU - Velasco Arribas M AUID- ORCID: 0000-0001-6554-2095 AD - Department of Infectious Diseases, Research Department, Hospital Universitario Fundacion Alcorcon, 28922 Madrid, Spain. LA - eng PT - Journal Article PT - Review DEP - 20241030 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC11546491 OTO - NOTNLM OT - SGLT-2 inhibitors OT - genital mycotic infection OT - genitourinary infection OT - urinary tract infection COIS- Juan J Gorgojo-Martinez has the following financial relationships: advisor on scientific boards for Amgen, Astra-Zeneca, Bayer, Boehringer Ingelheim Pharmaceuticals Inc and Novo-Nordisk; lectures for Amarin, Astra-Zeneca, Boehringer Ingelheim Pharmaceuticals Inc, Menarini and Novo-Nordisk, and research activities for Astra-Zeneca, Mundipharma Pharmaceuticals and NovoNordisk. Jose L Gorriz Teruel declares funding to conduct clinical trials from AstraZeneca, Bayer, Boehringer Ingelheim, and Novo Nordisk (all to the INCLIVA Research Institute); consulting fees from AstraZeneca, Bayer, Boehringer-Ingelheim and Novo Nordisk; payment of honoraria for lectures from AstraZeneca, Novo Nordisk, Bayer, Menarini, Boehringer-Ingelheim and Eli Lilly. Ana Cebrian Cuenca declares funding to conduct clinical trials MSD and Sanofi (all to the IMIB institute); consulting fees from AstraZeneca, Bayer, Eli Lilly, MSD, Novo Nordisk and Sanofi; payment of honoraria for lectures from AstraZeneca, Bayer, Boehringer-Ingelheim, Eli Lilly, Menarini, MSD, Sanofi and Novo Nordisk. Almudena Castro Conde has the following financial relationships: consulting fees and payment of honoraria for lectures from Novo Nordisk, Bayer, Lilly, Novartis, MSD and Servier. Maria Velasco Arribas has received research funding from the Carlos III Health Institute, Gilead Sciences, and Angellini; funding for teaching activities from Gilead Sciences, Merck Sharp & Dohme, ViiV Healthcare, Janssen Cilag, Cinfa, and Takeda; financial compensation for educational presentations from Gilead Sciences; compensation for scientific advisory services from Gilead Sciences, ViiV, and Angellini, and funding for conference attendance from ViiV Healthcare, Gilead Sciences, Janssen Cilag, and Angellini. EDAT- 2024/11/13 13:48 MHDA- 2024/11/13 13:49 PMCR- 2024/10/30 CRDT- 2024/11/09 01:09 PHST- 2024/09/29 00:00 [received] PHST- 2024/10/23 00:00 [revised] PHST- 2024/10/29 00:00 [accepted] PHST- 2024/11/13 13:49 [medline] PHST- 2024/11/13 13:48 [pubmed] PHST- 2024/11/09 01:09 [entrez] PHST- 2024/10/30 00:00 [pmc-release] AID - jcm13216509 [pii] AID - jcm-13-06509 [pii] AID - 10.3390/jcm13216509 [doi] PST - epublish SO - J Clin Med. 2024 Oct 30;13(21):6509. doi: 10.3390/jcm13216509. PMID- 39516918 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241116 IS - 2731-6203 (Electronic) IS - 2731-6203 (Linking) VI - 3 IP - 1 DP - 2024 Oct 28 TI - Successful surgical repair of aortic root rupture during transcatheter aortic valve implantation: a case report. PG - 47 LID - 10.1186/s44215-024-00172-4 [doi] LID - 47 AB - BACKGROUND: Aortic root rupture is a rare but potentially fatal complication of transcatheter aortic valve implantation (TAVI). Herein, we report a case of aortic root rupture during TAVI that was successfully managed with partial aortic root repair and aortic valve replacement. CASE PRESENTATION: An 83-year-old woman with severe bicuspid aortic stenosis underwent transfemoral TAVI using a 26 mm SAPIEN 3 Ultra RESILIA valve. Soon after valve implantation, transesophageal echocardiography detected pericardial effusion, which was accompanied by immediate hemodynamic instability. Subxiphoid pericardial drainage was performed, and extracorporeal membrane oxygenation was promptly initiated. Owing to the eruptive hemorrhage, we converted to open-heart surgery. Direct visualization enabled the detection of the aortic root rupture and the performance of partial aortic root repair using bovine pericardium and aortic valve replacement using a 19 mm INSPIRIS RESILIA valve. The patient was transferred to a different hospital 60 days after surgery without complications and is currently doing well as an outpatient. CONCLUSIONS: In the present case, prompt treatment decisions and smooth cooperation among the institutional heart team led to the successful repair of aortic root rupture during TAVI and good clinical outcomes. CI - (c) 2024. The Author(s). FAU - Numaguchi, Ryosuke AU - Numaguchi R AUID- ORCID: 0000-0002-1277-3831 AD - Department of Cardiovascular Surgery, Hakodate Municipal Hospital, 1-10-1 Minato-cho, Hakodate City, Hokkaido, 041-8680, Japan. sapmed.numaguchi@gmail.com. FAU - Yokoyama, Noriyuki AU - Yokoyama N AD - Department of Cardiovascular Surgery, Hakodate Municipal Hospital, 1-10-1 Minato-cho, Hakodate City, Hokkaido, 041-8680, Japan. FAU - Ishikawa, Kazunori AU - Ishikawa K AD - Department of Cardiovascular Surgery, Hakodate Municipal Hospital, 1-10-1 Minato-cho, Hakodate City, Hokkaido, 041-8680, Japan. FAU - Koya, Atsuhiro AU - Koya A AD - Department of Cardiovascular Surgery, Hakodate Municipal Hospital, 1-10-1 Minato-cho, Hakodate City, Hokkaido, 041-8680, Japan. FAU - Tokuda, Yusuke AU - Tokuda Y AD - Department of Cardiology, Hakodate Municipal Hospital, 1-10-1 Minato-cho, Hakodate City, Hokkaido, 041-8680, Japan. FAU - Shingaki, Masami AU - Shingaki M AD - Department of Cardiovascular Surgery, Hakodate Municipal Hospital, 1-10-1 Minato-cho, Hakodate City, Hokkaido, 041-8680, Japan. LA - eng PT - Journal Article DEP - 20241028 PL - England TA - Gen Thorac Cardiovasc Surg Cases JT - General thoracic and cardiovascular surgery cases JID - 9918900337406676 PMC - PMC11533707 OTO - NOTNLM OT - Aortic root repair OT - Aortic root rupture OT - Aortic valve replacement OT - Transcatheter aortic valve implantation COIS- The authors declare that they have no competing interests. EDAT- 2024/11/13 14:00 MHDA- 2024/11/13 14:01 PMCR- 2024/10/28 CRDT- 2024/11/09 00:00 PHST- 2024/08/14 00:00 [received] PHST- 2024/10/16 00:00 [accepted] PHST- 2024/11/13 14:01 [medline] PHST- 2024/11/13 14:00 [pubmed] PHST- 2024/11/09 00:00 [entrez] PHST- 2024/10/28 00:00 [pmc-release] AID - 10.1186/s44215-024-00172-4 [pii] AID - 172 [pii] AID - 10.1186/s44215-024-00172-4 [doi] PST - epublish SO - Gen Thorac Cardiovasc Surg Cases. 2024 Oct 28;3(1):47. doi: 10.1186/s44215-024-00172-4. PMID- 39515477 OWN - NLM STAT- MEDLINE DCOM- 20250425 LR - 20250516 IS - 1532-2939 (Electronic) IS - 0195-6701 (Linking) VI - 155 DP - 2025 Jan TI - Mycobacteroides abscessus outbreak and mitigation in a cardiothoracic transplant population: the problem with tap water. PG - 150-157 LID - S0195-6701(24)00364-5 [pii] LID - 10.1016/j.jhin.2024.10.016 [doi] AB - BACKGROUND: Hospital outbreaks caused by Mycobacteroides abscessus complex are a major cause for concern in vulnerable patients such as the cardiothoracic transplant population. AIM: To describe the outbreak investigation and mitigation steps undertaken to address an increase in healthcare-associated M. abscessus complex cases in an inpatient cardiothoracic transplant population. METHODS: We extracted clinical characteristics from patients with M. abscessus pre-outbreak (March 2018 to December 2020) and during the outbreak (January 2021 to June 2022) from the electronic medical record. A multi-disciplinary team conducted the outbreak investigation and devised a mitigation strategy to implement at our institution. FINDINGS: The baseline incidence of healthcare-associated M. abscessus was 0.11 cases per 10,000 patient-days; this increased to 0.24 cases per 10,000 patient-days during the outbreak. There were 1/9 (11%) cardiothoracic transplant patients in the pre-outbreak group compared with 7/12 (58%) during the outbreak, and respiratory specimen types compromised 6/9 (67%) of M. abscessus results in the pre-outbreak group compared with 10/12 (83%) during the outbreak. Among the clinical care activities involving water, a variety of water sources were utilized, including filtered and tap water. The incidence of healthcare-associated M. abscessus subsequently decreased to 0.06 cases per 10,000 patient-days after implementing an outbreak-mitigation strategy of sterile water precautions. CONCLUSIONS: Robust educational efforts from a multi-disciplinary team on eliminating exposure to tap water were effective measures to reduce healthcare-associated M. abscessus incidence at our institution. Non-tuberculous mycobacteria infection surveillance, targeted education, and water mitigation strategies may be beneficial preventative strategies for other lung transplant centres facing similar issues. CI - Copyright (c) 2024 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved. FAU - Rathod, S N AU - Rathod SN AD - Department of Healthcare Epidemiology and Infection Prevention, Northwestern Memorial Hospital, Chicago, IL, USA. Electronic address: shardul.rathod@nm.org. FAU - Weber, R T AU - Weber RT AD - Department of Healthcare Epidemiology and Infection Prevention, Northwestern Memorial Hospital, Chicago, IL, USA. FAU - Salim, A A AU - Salim AA AD - Department of Healthcare Epidemiology and Infection Prevention, Northwestern Memorial HealthCare, Chicago, IL, USA. FAU - Tanna, S D AU - Tanna SD AD - Division of Infectious Disease, Department of Medicine, Inova Fairfax Medical Center, Falls Church, VA, USA. FAU - Stosor, V AU - Stosor V AD - Divisions of Infectious Diseases and Organ Transplantation, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. FAU - Malczynski, M AU - Malczynski M AD - Department of Pathology, Northwestern University Feinberg School of Medicine, Clinical Microbiology Laboratory, Northwestern Memorial Hospital and Northwestern University Feinberg School of Medicine, Chicago, IL, USA. FAU - O'Boye, A AU - O'Boye A AD - Department of Thoracic Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. FAU - Hoke, K AU - Hoke K AD - Cardiac Intensive Care Unit, Northwestern Medicine Central DuPage Hospital, Chicago, IL, USA. FAU - Landon, J AU - Landon J AD - Pulmonary Medicine, Northwestern Memorial Hospital, Chicago, IL, USA. FAU - McCarthy, S AU - McCarthy S AD - Cardiac, Vascular, and Thoracic Stepdown, Northwestern Memorial Hospital, Chicago, IL, USA. FAU - Qi, C AU - Qi C AD - Department of Pathology, Northwestern University Feinberg School of Medicine, Clinical Microbiology Laboratory, Northwestern Memorial Hospital and Northwestern University Feinberg School of Medicine, Chicago, IL, USA. FAU - Angarone, M P AU - Angarone MP AD - Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. FAU - Ison, M G AU - Ison MG AD - Respiratory Diseases Branch, Division of Microbiology and Infectious Diseases, NIAID/NIH, Rockville, MD, USA. FAU - Williams, J L AU - Williams JL AD - Division of Infectious Diseases, Corewell Health Medical Group, Michigan State University College of Human Medicine, Grand Rapids, MI, USA. FAU - Zembower, T R AU - Zembower TR AD - Department of Healthcare Epidemiology and Infection Prevention, Northwestern Memorial Hospital, Chicago, IL, USA; Department of Pathology, Northwestern University Feinberg School of Medicine, Clinical Microbiology Laboratory, Northwestern Memorial Hospital and Northwestern University Feinberg School of Medicine, Chicago, IL, USA; Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. FAU - Bolon, M K AU - Bolon MK AD - Department of Healthcare Epidemiology and Infection Prevention, Northwestern Memorial Hospital, Chicago, IL, USA; Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. LA - eng PT - Journal Article DEP - 20241107 PL - England TA - J Hosp Infect JT - The Journal of hospital infection JID - 8007166 RN - 0 (Drinking Water) SB - IM MH - Humans MH - *Disease Outbreaks/prevention & control MH - *Mycobacterium Infections, Nontuberculous/epidemiology/prevention & control/microbiology MH - Male MH - Female MH - Middle Aged MH - *Mycobacterium abscessus/isolation & purification MH - *Cross Infection/epidemiology/prevention & control/microbiology MH - Aged MH - Incidence MH - *Infection Control/methods MH - Adult MH - *Drinking Water/microbiology MH - Heart Transplantation MH - Transplant Recipients OTO - NOTNLM OT - Cardiothoracic transplant OT - Heart transplant OT - Lung transplant OT - Mycobacteroides abscessus OT - Non-tuberculous mycobacteria OT - Tap water COIS- Conflict of interest statement M.P.A. is a consultant for Abbvie. M.G.I. declares that research support from GSK was paid to Northwestern; received consulting fees from Adagio Therapeutics, ADMA Biologics, Adamis Pharmaceuticals, AlloVir, Atea, Cidara Therapeutics, Genentech/Roche, Janssen, Shionogi, Takeda, Telaris, and Eurofins Viracor; and payment for participating in data safety monitoring boards or advisory boards from Adamis Pharmaceuticals, AlloVir, National Institutes of Health, CSL Behring, Janssen, Merck, Seqirus, Takeda, and Talaris; all of these ended December 2022; he also receives author royalties from UpToDate, which is ongoing; M.G.I. also serves as Chair of the International Society for Influenza and other Respiratory Virus Diseases Antiviral Group and was Editor-in-Chief of Transplant Infectious Disease. All other authors report no conflicts of interest relevant to this article. EDAT- 2024/11/13 13:49 MHDA- 2025/01/11 13:59 CRDT- 2024/11/08 19:25 PHST- 2024/08/11 00:00 [received] PHST- 2024/10/12 00:00 [revised] PHST- 2024/10/27 00:00 [accepted] PHST- 2025/01/11 13:59 [medline] PHST- 2024/11/13 13:49 [pubmed] PHST- 2024/11/08 19:25 [entrez] AID - S0195-6701(24)00364-5 [pii] AID - 10.1016/j.jhin.2024.10.016 [doi] PST - ppublish SO - J Hosp Infect. 2025 Jan;155:150-157. doi: 10.1016/j.jhin.2024.10.016. Epub 2024 Nov 7. PMID- 39513933 OWN - NLM STAT- MEDLINE DCOM- 20250331 LR - 20260428 IS - 1469-7793 (Electronic) IS - 0022-3751 (Print) IS - 0022-3751 (Linking) VI - 603 IP - 7 DP - 2025 Mar TI - Comparative specialization of intrinsic cardiac neurons in humans, mice and pigs. PG - 2043-2070 LID - 10.1113/JP286714 [doi] AB - Intrinsic cardiac neurons (ICNs) play a crucial role in the proper functioning of the heart; yet a paucity of data pertaining to human ICNs exist. We took a multidisciplinary approach to complete a detailed cellular comparison of the structure and function of ICNs from mice, pigs and humans. Immunohistochemistry of whole and sectioned ganglia, transmission electron microscopy, intracellular microelectrode recording and dye filling for quantitative morphometry were used to define the neurophysiology, histochemistry and ultrastructure of these neurons across species. The densely packed, smaller ICNs of mouse lacked dendrites, formed axosomatic connections and had high synaptic efficacy constituting an obligatory synapse. At pig ICNs, a convergence of subthreshold cholinergic inputs onto extensive dendritic arbors supported greater summation and integration of synaptic input. Human ICNs were tonically firing, with synaptic stimulation evoking large suprathreshold EPSPs like mouse, and subthreshold potentials like pig. Ultrastructural examination of synaptic terminals revealed conserved architecture, yet small clear vesicles were larger in pigs and humans. The presence and localization of ganglionic neuropeptides was distinct, with abundant vasoactive intestinal polypeptide observed in human but not pig or mouse ganglia, and little substance P or calcitonin gene-related peptide in pig ganglia. Action potential waveforms were similar, but human ICNs had larger after-hyperpolarizations. Intrinsic excitability differed; 95% of human neurons were tonic, all pig neurons were phasic, and both phasic and tonic phenotypes were observed in mouse. In combination, this publicly accessible, multimodal atlas of ICNs from mice, pigs and humans identifies similarities and differences in the evolution of ICNs. KEY POINTS: Intrinsic cardiac neurons (ICNs) are essential to the regulation of cardiac function. We investigated the neurochemistry, morphology, ultrastructure, membrane physiology and synaptic transmission of ICNs from donated human hearts in parallel with identical studies of ICNs from mice and pigs to create a publicly accessible cellular atlas detailing the structure and function of these neurons across species. In addition to presenting foundational data on human ICNs, this comparative study identifies both conserved and derived attributes of these neurons within mammals. The findings have significant implications for understanding the regulation of cardiac autonomic function in humans and may greatly influence strategies for neuromodulation in conditions such as atrial fibrillation and heart failure. CI - (c) 2024 The Author(s). The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society. FAU - Tompkins, John D AU - Tompkins JD AUID- ORCID: 0000-0001-9496-7930 AD - UCLA Cardiac Arrhythmia Center and Neurocardiology Research Program of Excellence, David Geffen School of Medicine at UCLA, Los Angeles, California, USA. FAU - Hoover, Donald B AU - Hoover DB AUID- ORCID: 0000-0002-0845-2488 AD - Department of Biomedical Sciences, Quillen College of Medicine, East Tennessee State University, Johnson City, Tennessee, USA. FAU - Havton, Leif A AU - Havton LA AUID- ORCID: 0000-0003-1561-4331 AD - Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, New York, USA. AD - Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York, USA. FAU - Patel, Janaki C AU - Patel JC AD - UCLA Cardiac Arrhythmia Center and Neurocardiology Research Program of Excellence, David Geffen School of Medicine at UCLA, Los Angeles, California, USA. FAU - Cho, Youngjin AU - Cho Y AUID- ORCID: 0000-0001-8106-3713 AD - UCLA Cardiac Arrhythmia Center and Neurocardiology Research Program of Excellence, David Geffen School of Medicine at UCLA, Los Angeles, California, USA. FAU - Smith, Elizabeth H AU - Smith EH AD - Department of Biomedical Sciences, Quillen College of Medicine, East Tennessee State University, Johnson City, Tennessee, USA. FAU - Biscola, Natalia P AU - Biscola NP AUID- ORCID: 0000-0001-9345-085X AD - Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York, USA. FAU - Ajijola, Olujimi A AU - Ajijola OA AUID- ORCID: 0000-0001-6197-7593 AD - UCLA Cardiac Arrhythmia Center and Neurocardiology Research Program of Excellence, David Geffen School of Medicine at UCLA, Los Angeles, California, USA. FAU - Shivkumar, Kalyanam AU - Shivkumar K AUID- ORCID: 0000-0002-4121-1766 AD - UCLA Cardiac Arrhythmia Center and Neurocardiology Research Program of Excellence, David Geffen School of Medicine at UCLA, Los Angeles, California, USA. FAU - Ardell, Jeffrey L AU - Ardell JL AUID- ORCID: 0000-0001-9241-0864 AD - UCLA Cardiac Arrhythmia Center and Neurocardiology Research Program of Excellence, David Geffen School of Medicine at UCLA, Los Angeles, California, USA. LA - eng GR - OT2 OD026585/OD/NIH HHS/United States GR - OT2 OD023848/OD/NIH HHS/United States GR - P01 HL164311/HL/NHLBI NIH HHS/United States PT - Comparative Study PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20241108 PL - England TA - J Physiol JT - The Journal of physiology JID - 0266262 SB - IM UOF - bioRxiv. 2024 Apr 08:2024.04.04.588174. doi: 10.1101/2024.04.04.588174. PMID: 38645175 MH - Animals MH - Humans MH - Mice MH - Swine MH - *Neurons/physiology/ultrastructure MH - Male MH - *Heart/innervation/physiology MH - Female MH - Mice, Inbred C57BL MH - Action Potentials MH - Middle Aged MH - Adult PMC - PMC11957936 MID - NIHMS2030818 OTO - NOTNLM OT - Homo sapiens OT - autonomic ganglia OT - cardiac physiology OT - ganglionic neurotransmission OT - intracardiac neuron OT - neurocardiology OT - neuromodulation OT - neurophysiology COIS- Conflict of Interest: The authors declare no competing financial interests. EDAT- 2024/11/13 13:48 MHDA- 2025/03/31 20:04 PMCR- 2026/03/01 CRDT- 2024/11/08 09:52 PHST- 2024/04/19 00:00 [received] PHST- 2024/10/16 00:00 [accepted] PHST- 2025/03/31 20:04 [medline] PHST- 2024/11/13 13:48 [pubmed] PHST- 2024/11/08 09:52 [entrez] PHST- 2026/03/01 00:00 [pmc-release] AID - 10.1113/JP286714 [doi] PST - ppublish SO - J Physiol. 2025 Mar;603(7):2043-2070. doi: 10.1113/JP286714. Epub 2024 Nov 8. PMID- 39513568 OWN - NLM STAT- MEDLINE DCOM- 20250206 LR - 20260817 IS - 1531-7080 (Electronic) IS - 0268-4705 (Linking) VI - 40 IP - 2 DP - 2025 Mar 1 TI - Current trends and challenges in infective endocarditis. PG - 75-84 LID - 10.1097/HCO.0000000000001192 [doi] AB - PURPOSE OF REVIEW: Infective endocarditis (IE) is a complex disease with increasing global incidence. This review explores recent trends in IE infection patterns, including healthcare-associated IE (HAIE), drug-use-associated IE (DUA-IE), multidrug-resistant organisms (MDROs), and challenges in managing prosthetic valve and device-related infections. RECENT FINDINGS: Staphylococcus aureus has emerged as the leading cause of IE, especially in HAIE and DUA-IE cases. Increasingly prevalent MDROs, such as methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci, pose further clinical challenges. Advances in molecular diagnostics have improved the detection of culture-negative endocarditis. The introduction of the AngioVAC percutaneous aspiration device promises to change the management of right and possibly some left sided IE. Multidisciplinary team management and early surgery have demonstrated improved outcomes including partnerships with psychiatry and addictions services for those with intravenous DUA-IE. SUMMARY: IE presents significant diagnostic and therapeutic challenges due to evolving infection patterns, MDROs, and HAIE. Early diagnosis using advanced imaging, appropriate early antimicrobial therapy, and multidisciplinary care, including timely surgery, are critical for optimizing patient outcomes. CI - Copyright (c) 2024 Wolters Kluwer Health, Inc. All rights reserved. FAU - Patel, Shubh K AU - Patel SK AD - Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. FAU - Hassan, Syed M Ali AU - Hassan SMA AD - Division of Cardiac Surgery, St. Michael's Hospital of Unity Health Toronto, Toronto, Ontario. FAU - Cote, Mahee AU - Cote M AD - Universite de Sherbrooke, Centre de formation medicale du Nouveau Brunswick, Moncton. FAU - Leis, Benjamin AU - Leis B AD - Department of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada. FAU - Yanagawa, Bobby AU - Yanagawa B AD - Division of Cardiac Surgery, St. Michael's Hospital of Unity Health Toronto, Toronto, Ontario. LA - eng PT - Journal Article PT - Review DEP - 20241107 PL - United States TA - Curr Opin Cardiol JT - Current opinion in cardiology JID - 8608087 RN - 0 (Anti-Bacterial Agents) SB - IM MH - Humans MH - *Endocarditis, Bacterial/diagnosis/therapy/epidemiology/microbiology MH - *Endocarditis/diagnosis/therapy/epidemiology MH - *Prosthesis-Related Infections/therapy/diagnosis/epidemiology/microbiology MH - Anti-Bacterial Agents/therapeutic use MH - *Cross Infection/diagnosis/therapy/epidemiology/microbiology MH - Staphylococcal Infections/diagnosis/therapy/epidemiology EDAT- 2024/11/13 13:53 MHDA- 2025/02/06 06:20 CRDT- 2024/11/08 07:53 PHST- 2025/02/06 06:20 [medline] PHST- 2024/11/13 13:53 [pubmed] PHST- 2024/11/08 07:53 [entrez] AID - 00001573-202503000-00004 [pii] AID - 10.1097/HCO.0000000000001192 [doi] PST - ppublish SO - Curr Opin Cardiol. 2025 Mar 1;40(2):75-84. doi: 10.1097/HCO.0000000000001192. Epub 2024 Nov 7. PMID- 39513386 OWN - NLM STAT- MEDLINE DCOM- 20241205 LR - 20260703 IS - 1531-6971 (Electronic) IS - 1070-5287 (Linking) VI - 31 IP - 1 DP - 2025 Jan 1 TI - Whole lung lavage: considerations from the anesthesiology perspective. PG - 53-58 LID - 10.1097/MCP.0000000000001132 [doi] AB - PURPOSE OF REVIEW: Whole lung lavage (WLL) remains the standard treatment for pulmonary alveolar proteinosis (PAP). The procedure involves meticulous preparation, including a multidisciplinary team and appropriate facilities, to ensure patient safety and procedural success. Effective anesthesia management is essential to allow for successful completion of the procedure and prevent complications. RECENT FINDINGS: Effective anesthesia management, including total intravenous anesthesia (TIVA) and careful intraoperative monitoring, is essential to prevent complications such as hypoxemia and fluid overload. Proper airway control with a double-lumen tube, careful positioning, and continuous monitoring during the lavage phase are key to minimizing risks. Challenges such as fluid spillage and ventilation-perfusion mismatch must be managed proactively with techniques such as fiberoptic bronchoscopy and recruitment maneuvers. In cases of severe hypoxemia, advanced options like extra-corporeal membrane oxygenation (ECMO) or sequential lavage may be required. SUMMARY: WLL is a pivotal treatment for PAP, offering significant relief and improvement for many patients despite the challenges in standardizing the procedure due to the rare nature of the condition. Involvement of a multidisciplinary team involving pulmonologist, anesthesiologist, critical care personnel, operating room personnel and in some cases and centers, cardiothoracic surgeon and perfusionist is critical to the success of the procedure. CI - Copyright (c) 2024 Wolters Kluwer Health, Inc. All rights reserved. FAU - Sikachi, Rutuja AU - Sikachi R AD - Department of Anesthesiology, Northwell, New Hyde Park, New York. FAU - Anders, Megan AU - Anders M AD - Department of Anesthesiology, University of Maryland School of Medicine, Baltimore, Maryland, USA. LA - eng PT - Journal Article PT - Review DEP - 20241107 PL - United States TA - Curr Opin Pulm Med JT - Current opinion in pulmonary medicine JID - 9503765 SB - IM MH - Humans MH - *Bronchoalveolar Lavage/methods MH - *Pulmonary Alveolar Proteinosis/therapy/diagnosis MH - Bronchoscopy/methods MH - Anesthesia/methods MH - Anesthesiology/methods MH - Patient Care Team/organization & administration EDAT- 2024/11/13 13:56 MHDA- 2024/12/05 17:32 CRDT- 2024/11/08 06:13 PHST- 2024/12/05 17:32 [medline] PHST- 2024/11/13 13:56 [pubmed] PHST- 2024/11/08 06:13 [entrez] AID - 00063198-990000000-00208 [pii] AID - 10.1097/MCP.0000000000001132 [doi] PST - ppublish SO - Curr Opin Pulm Med. 2025 Jan 1;31(1):53-58. doi: 10.1097/MCP.0000000000001132. Epub 2024 Nov 7. PMID- 39513376 OWN - NLM STAT- MEDLINE DCOM- 20250425 LR - 20250516 IS - 1879-0844 (Electronic) IS - 1388-9842 (Print) IS - 1388-9842 (Linking) VI - 27 IP - 2 DP - 2025 Feb TI - Examining the clinical role and educational preparation of heart failure nurses across Europe. A survey of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) and the Association of Cardiovascular Nursing and Allied Professions (ACNAP) of the ESC. PG - 388-397 LID - 10.1002/ejhf.3519 [doi] AB - AIMS: To describe the clinical practice and educational preparation of heart failure (HF) nurses across Europe and determine the key differences between countries. METHODS AND RESULTS: A survey tool was developed, in English, by the Heart Failure Association Patient Care committee of the European Society of Cardiology (ESC). It was translated into eight languages, before electronically disseminated by nurse ambassadors, presidents of HF national societies and through social media. A total of 837 nurses involved in the daily care of patients with HF from 15 countries completed the survey. Most nurses, 78% (n = 395) worked within a hospital outpatient setting, and 51% (n = 431) had access to a specialized HF multidisciplinary team. Nurses performed a range of activities including patient education to promote self-care, virtual and in-person symptom monitoring. A third had more than 5-year experience in cardiac care and 22% (n = 182) prescribed HF medications. There was a significant correlation between HF nurses that prescribed HF medications and access to a specialist multidisciplinary team (p = 0.04). A small number of nurses, mainly from Belgium, supported invasive monitoring (n = 68, 8%) with 14% (n = 120) of mostly Danish nurses supporting exercise programmes. The majority of nurses surveyed were committed to further academic professional development, with 41% (n = 343) having completed a HF course. CONCLUSION: The role of the HF nurse varies across Europe, however involvement in patient education, symptom monitoring and follow-up remain core to their practice. In specific activities including the prescribing of HF medications and involvement in invasive monitoring, practice has advanced with collaboration in the multidisciplinary team. Consequently, harmonization of education, training and career pathways are required to standardize HF care aligned with expert guidelines across Europe. CI - (c) 2024 The Author(s). European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. FAU - Hill, Loreena AU - Hill L AUID- ORCID: 0000-0001-5232-0936 AD - School of Nursing & Midwifery, Queen's University, Belfast, UK. AD - College of Nursing, Mohammed Bin Rashid University Of Medicine and Health Sciences, Dubai, United Arab Emirates. FAU - Girerd, Nicolas AU - Girerd N AUID- ORCID: 0000-0002-3278-2057 AD - Universite de Lorraine, INSERM, Centre d'Investigations Cliniques 1433, CHRU de Nancy, Inserm 1116 and INI-CRCT (Cardiovascular and Renal Clinical Trialists) F-CRIN Network, Nancy, France. FAU - Castiello, Teresa AU - Castiello T AUID- ORCID: 0000-0002-7925-9714 AD - Croydon Health Service, Cardiovascular Imaging, Cardiology Department and Kings College London, London, UK. FAU - Jaarsma, Tiny AU - Jaarsma T AUID- ORCID: 0000-0002-4197-4026 AD - Department of Health, Medicine, and Care, Linkoping University, Linkoping, Sweden. FAU - Metra, Marco AU - Metra M AUID- ORCID: 0000-0001-6691-8568 AD - Institute of Cardiology, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy. FAU - Rosano, Giuseppe AU - Rosano G AUID- ORCID: 0000-0002-6868-4248 AD - Department of Cardiology, St George's University Hospital, London, UK. FAU - Savage, Patrick AU - Savage P AUID- ORCID: 0000-0003-3518-5984 AD - Cardiology Research Fellow, Queens University Belfast, Belfast, UK. FAU - Schuuring, Mark J AU - Schuuring MJ AUID- ORCID: 0000-0002-2843-1852 AD - Department of Cardiology, Medical Spectrum Twente, Enschede, The Netherlands. AD - Department of Biomedical Signals and Systems, University of Twente, Enschede, The Netherlands. FAU - Simpson, Maggie AU - Simpson M AUID- ORCID: 0000-0003-1781-4978 AD - Queen Elizabeth University Hospital, NHS Greater Glasgow & Clyde, Glasgow, UK. FAU - Uchmanowicz, Izabella AU - Uchmanowicz I AUID- ORCID: 0000-0001-5452-0210 AD - Department of Nursing and Obstetrics, Faculty of Health Sciences, Wroclaw Medical University, Wroclaw, Poland. FAU - Volterrani, Maurizio AU - Volterrani M AUID- ORCID: 0000-0002-2624-9213 AD - Cardiopulmonary Department, IRCCS San Raffaele Roma, Rome, Italy. AD - Exercise Science and Medicine -San Raffaele Open University in Rome, Rome, Italy. FAU - Williams, Rhys AU - Williams R AUID- ORCID: 0000-0003-0840-9292 AD - Princess of Wales Hospital, Cwm Taf Morgannwg University Health Board, Wales, UK. FAU - Lambrinou, Ekaterini AU - Lambrinou E AUID- ORCID: 0000-0002-2601-8861 AD - Department of Nursing, Cyprus University of Technology, Limassol, Cyprus. FAU - Hage, Camilla AU - Hage C AUID- ORCID: 0000-0002-4142-2416 AD - Department of Cardiology, Heart Failure GUCH Arrhythmia and Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. AD - Department of Medicine, Unit of Cardiology, Stockholm, Sweden. LA - eng GR - European Society of Cardiology/ PT - Journal Article DEP - 20241108 PL - England TA - Eur J Heart Fail JT - European journal of heart failure JID - 100887595 SB - IM MH - Humans MH - *Heart Failure/nursing MH - Europe MH - *Cardiovascular Nursing/education MH - Surveys and Questionnaires MH - *Nurse's Role MH - Societies, Medical MH - Male MH - Female MH - Cardiology MH - *Clinical Competence MH - Patient Education as Topic MH - Patient Care Team PMC - PMC11860739 OTO - NOTNLM OT - Disease management OT - Heart failure OT - Nurses OT - Role EDAT- 2024/11/13 13:58 MHDA- 2025/02/26 00:20 PMCR- 2025/02/26 CRDT- 2024/11/08 06:04 PHST- 2024/10/10 00:00 [revised] PHST- 2024/07/05 00:00 [received] PHST- 2024/10/24 00:00 [accepted] PHST- 2025/02/26 00:20 [medline] PHST- 2024/11/13 13:58 [pubmed] PHST- 2024/11/08 06:04 [entrez] PHST- 2025/02/26 00:00 [pmc-release] AID - EJHF3519 [pii] AID - 10.1002/ejhf.3519 [doi] PST - ppublish SO - Eur J Heart Fail. 2025 Feb;27(2):388-397. doi: 10.1002/ejhf.3519. Epub 2024 Nov 8. PMID- 39513219 OWN - NLM STAT- MEDLINE DCOM- 20241203 LR - 20260528 IS - 1744-8298 (Electronic) IS - 1479-6678 (Print) IS - 1479-6678 (Linking) VI - 20 IP - 14 DP - 2024 TI - miRNAs in the diagnosis and therapy of cardiac and mediastinal tumors: a new dawn for cardio-oncology? PG - 795-806 LID - 10.1080/14796678.2024.2419225 [doi] AB - Dysfunctions in miRNA production have been recently investigated as predictors of neoplasms and their therapeutic strategies. In this review, we summarize the available knowledge on miRNAs and cardiac tumors (such as myxoma) and mediastinal tumors (such as thymoma) and propose new avenues for future research. MiRNAs are crucial for cardiac development through the expression of cardiac transcription factors (miR-335-5p), hinder the cell cycle by modulating the activity of transcription factors (miR-126-3p, miR-320a), modulate the production of inflammatory factors such as interleukins (miR-217), and interfere with cell proliferation or apoptosis (miR-218, miR-634 and miR-122). Current and future research on miRNAs is essential, as a deep understanding could lead to a revolution in the field of diagnostics and prevention of neoplastic diseases. FAU - Loreni, Francesco AU - Loreni F AD - Cardiac Surgery, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, 00128, Italy. FAU - Nenna, Antonio AU - Nenna A AUID- ORCID: 0000-0002-4069-6781 AD - Cardiac Surgery, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, 00128, Italy. FAU - Nappi, Francesco AU - Nappi F AD - Cardiac Surgery, Centre Cardiologique du Nord, Saint Denis, 93200, France. FAU - Ferrisi, Chiara AU - Ferrisi C AD - Cardiac Surgery, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, 00128, Italy. FAU - Chello, Camilla AU - Chello C AD - PhD Course of Integrated Biomedical Sciences, Universita Campus Bio-Medico di Roma, Rome, 00128, Italy. FAU - Lusini, Mario AU - Lusini M AD - Cardiac Surgery, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, 00128, Italy. FAU - Vincenzi, Bruno AU - Vincenzi B AD - Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, 00128, Italy. FAU - Tonini, Giuseppe AU - Tonini G AD - Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, 00128, Italy. FAU - Chello, Massimo AU - Chello M AD - Cardiac Surgery, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, 00128, Italy. LA - eng PT - Journal Article PT - Review DEP - 20241108 PL - England TA - Future Cardiol JT - Future cardiology JID - 101239345 RN - 0 (MicroRNAs) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *MicroRNAs MH - *Heart Neoplasms/diagnosis/genetics MH - *Mediastinal Neoplasms/diagnosis/genetics MH - Biomarkers, Tumor MH - Cardio-Oncology PMC - PMC11622773 OAB - [Box: see text]. OABL- eng OTO - NOTNLM OT - cardiac surgery OT - cardiac tumors OT - diagnosis OT - heart team OT - mesothelioma OT - miRNA OT - myxoma OT - prevention OT - thoracic surgery COIS- The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. EDAT- 2024/11/13 13:51 MHDA- 2024/12/03 06:24 PMCR- 2025/11/08 CRDT- 2024/11/08 04:52 PHST- 2024/12/03 06:24 [medline] PHST- 2024/11/13 13:51 [pubmed] PHST- 2024/11/08 04:52 [entrez] PHST- 2025/11/08 00:00 [pmc-release] AID - 2419225 [pii] AID - 10.1080/14796678.2024.2419225 [doi] PST - ppublish SO - Future Cardiol. 2024;20(14):795-806. doi: 10.1080/14796678.2024.2419225. Epub 2024 Nov 8. PMID- 39510937 OWN - NLM STAT- MEDLINE DCOM- 20241129 LR - 20241205 IS - 0035-3787 (Print) IS - 0035-3787 (Linking) VI - 180 IP - 10 DP - 2024 Dec TI - Reprint of: Scientific statement from the French neurovascular and cardiac societies for improved detection of atrial fibrillation after ischaemic stroke and transient ischaemic attack. PG - 1000-1020 LID - S0035-3787(24)00619-2 [pii] LID - 10.1016/j.neurol.2024.10.001 [doi] AB - Atrial fibrillation (AF) is the primary cause of ischaemic stroke and transient ischaemic attack (TIA). AF is associated with a high risk of recurrence, which can be reduced using optimal prevention strategies, mainly anticoagulant therapy. The availability of effective prophylaxis justifies the need for a significant, coordinated and thorough transdisciplinary effort to screen for AF associated with stroke. A recent French national survey, initiated and supported by the Societe francaise neurovasculaire (SFNV) and the Societe francaise de cardiologie (SFC), revealed many shortcomings, such as the absence or inadequacy of telemetry equipment in more than half of stroke units, insufficient and highly variable access to monitoring tools, delays in performing screening tests, heterogeneous access to advanced or connected ambulatory monitoring techniques, and a lack of dedicated human resources. The present scientific document has been prepared on the initiative of the SFNV and the SFC with the aim of helping to address the current shortcomings and gaps, to promote efficient and cost-effective AF detection, and to improve and, where possible, homogenize the quality of practice in AF screening among stroke units and outpatient post-stroke care networks. The working group, composed of cardiologists and vascular neurologists who are experts in the field and are nominated by their peers, reviewed the literature to propose statements, which were discussed in successive cycles, and maintained, either by consensus or by vote, as appropriate. The text was then submitted to the SFNV and SFC board members for review. This scientific statement document argues for the widespread development of patient pathways to enable the most efficient AF screening after stroke. This assessment should be carried out by a multidisciplinary team, including expert cardiologists and vascular neurologists. CI - Copyright (c) 2024 The Author(s). Published by Elsevier Masson SAS.. All rights reserved. FAU - Gaillard, Nicolas AU - Gaillard N AD - Service de Neurologie, Clinique Beau Soleil, Institut Mutualiste Montpellierain, 19, avenue de Lodeve, 34070 Montpellier, France; Departement de Neurologie, Hopital Universitaire Gui-de-Chauliac, 80, avenue Augustin-Fliche, 34080 Montpellier, France. FAU - Deharo, Jean-Claude AU - Deharo JC AD - Assistance publique-Hopitaux de Marseille, Centre Hospitalier Universitaire La Timone, Service de Cardiologie, Marseille, France; Aix-Marseille Universite, C2VN, 13005 Marseille, France. Electronic address: jean-claude.deharo@ap-hm.fr. FAU - Suissa, Laurent AU - Suissa L AD - Stroke Unit, University Hospital La Timone, AP-HM, Marseille, France; Centre de recherche en CardioVasculaire et Nutrition (C2VN), 13005 Marseille, France. FAU - Defaye, Pascal AU - Defaye P AD - Cardiology Department, University Hospital, Grenoble Alpes University, CS 10217, 38043 Grenoble, France. FAU - Sibon, Igor AU - Sibon I AD - Universite Bordeaux, CHU de Bordeaux, Unite Neurovasculaire, Hopital Pellegrin, 33000 Bordeaux, France; INCIA-UMR 5287-CNRS Equipe ECOPSY, Universite de Bordeaux, Bordeaux, France. FAU - Leclercq, Christophe AU - Leclercq C AD - Department of Cardiology, University of Rennes, CHU de Rennes, lTSI-UMR1099, 35000 Rennes, France. FAU - Alamowitch, Sonia AU - Alamowitch S AD - Urgences Cerebro-Vasculaires, Hopital Pitie-Salpetriere, AP-HP, Hopital Saint-Antoine, Sorbonne Universite, Paris, France; STARE Team, iCRIN, Institut du Cerveau et de la Moelle epiniere, ICM, 75013 Paris, France. FAU - Guidoux, Celine AU - Guidoux C AD - Department of Neurology and Stroke Unit, Bichat Hospital, Assistance publique-Hopitaux de Paris, 75018 Paris, France. FAU - Cohen, Ariel AU - Cohen A AD - Hopitaux de l'est parisien (Saint-Antoine-Tenon), AP-HP, Sorbonne Universite, Inserm ICAN 1166, 184, Faubourg-Saint-Antoine, 75571 Paris cedex 12, France. CN - French Neurovascular Society CN - French Society of Cardiology LA - eng PT - Journal Article PT - Practice Guideline DEP - 20241106 PL - France TA - Rev Neurol (Paris) JT - Revue neurologique JID - 2984779R SB - IM MH - Humans MH - *Atrial Fibrillation/diagnosis/complications MH - Cardiology/standards/methods MH - France/epidemiology MH - *Ischemic Attack, Transient/diagnosis/complications MH - *Ischemic Stroke/diagnosis/etiology/prevention & control MH - Neurology/standards/methods/organization & administration MH - *Societies, Medical/standards OTO - NOTNLM OT - Atrial cardiomyopathy OT - Atrial fibrillation OT - Atrial fibrillation screening OT - Cryptogenic stroke OT - Stroke EDAT- 2024/11/13 13:47 MHDA- 2024/11/30 11:16 CRDT- 2024/11/07 22:43 PHST- 2024/06/04 00:00 [received] PHST- 2024/06/10 00:00 [accepted] PHST- 2024/11/30 11:16 [medline] PHST- 2024/11/13 13:47 [pubmed] PHST- 2024/11/07 22:43 [entrez] AID - S0035-3787(24)00619-2 [pii] AID - 10.1016/j.neurol.2024.10.001 [doi] PST - ppublish SO - Rev Neurol (Paris). 2024 Dec;180(10):1000-1020. doi: 10.1016/j.neurol.2024.10.001. Epub 2024 Nov 6. PMID- 39507804 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250205 IS - 2752-4191 (Electronic) IS - 2752-4191 (Linking) VI - 4 IP - 6 DP - 2024 Nov TI - Call to action for acute myocardial infarction in women: international multi-disciplinary practical roadmap. PG - oeae087 LID - 10.1093/ehjopen/oeae087 [doi] LID - oeae087 AB - Cardiovascular diseases are the leading cause of death among women, and the incidence among younger women has shown the greatest increase over the last decades, in particular for acute myocardial infarction (AMI). Moreover, the prognosis of women post-AMI is poor when compared with men of similar ages. Since the 1990s, an abundant literature has highlighted the existing differences between sexes with regard to presentation, burden, and impact of traditional risk factors and of risk factors pertaining predominantly to women, the perception of risk by women and men, and the pathophysiological causations, their treatment, and prognosis. These data that have been accumulated over recent years highlight several targets for improvement. The objective of this collaborative work is to define the actions required to reverse the growing incidence of AMI in women and improve the patient pathway and care, as well as the prognosis. We aim to provide practical toolkits for different health professionals involved in the care of women, so that each step, from cardiovascular risk assessment to symptom recognition, to the AMI pathway and rehabilitation, thus facilitating that from prevention to intervention of AMI, can be optimized. CI - (c) The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. FAU - Manzo-Silberman, Stephane AU - Manzo-Silberman S AUID- ORCID: 0000-0002-0703-1331 AD - Sorbonne University, Paris, France. AD - Institute of Cardiology Hopital Pitie-Salpetriere (AP-HP), ACTION Study Group, Women as One, 75651 Paris CEDEX 13, France. FAU - Hawranek, Michal AU - Hawranek M AD - Department of Cardiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland. FAU - Banerjee, Shrilla AU - Banerjee S AUID- ORCID: 0000-0002-3702-7616 AD - Department of Cardiology, Surrey and Sussex Healthcare NHS Trust, Redhill, Surrey. FAU - Kaluzna-Oleksy, Marta AU - Kaluzna-Oleksy M AUID- ORCID: 0000-0003-4048-6247 AD - 1st Department of Cardiology, Poznan University of Medical Sciences, Poznan, Poland. FAU - Alasnag, Mirvat AU - Alasnag M AD - Cardiac Center, King Fahd Armed Forces Hospital, Jeddah, Saudi Arabia. FAU - Paradies, Valeria AU - Paradies V AUID- ORCID: 0000-0003-3513-7819 AD - Department of Cardiology, Maasstad Hospital, Rotterdam, the Netherlands. FAU - Parapid, Biljana AU - Parapid B AUID- ORCID: 0000-0002-1071-2496 AD - Division of Cardiology, University Clinical Center of Serbia. AD - Faculty of Medicine, University of Belgrade, Belgrade, Serbia. FAU - Sabouret, Pierre AU - Sabouret P AUID- ORCID: 0000-0002-0243-3673 AD - Institute of Cardiology Hopital Pitie-Salpetriere (AP-HP), ACTION Study Group, National College of French Cardiologists, Paris, France. FAU - Wolczenko, Agnieszka AU - Wolczenko A AD - Nationwide Association of Patients with Heart and Vascular Diseases EcoSerce, Milosc, Poland. AD - Global Heart Hub, FH Europe Foundation. FAU - Kunadian, Vijay AU - Kunadian V AD - Faculty of Medical Sciences, Cardiothoracic Centre, Freeman Hospital, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK. FAU - Uchmanowicz, Izabella AU - Uchmanowicz I AUID- ORCID: 0000-0001-5452-0210 AD - Faculty of Nursing and Midwives, Department of Nursing, Wroclaw Medical University, Wroclaw, Poland. FAU - Nizard, Jacky AU - Nizard J AD - Sorbonne University, Paris, France. AD - Department of Gynecology and Obstetrics, APHP, Pitie-Salpetriere Hospital, Paris, France. FAU - Gilard, Martine AU - Gilard M AD - INSERM UMR 1304 GETBO, Medical University of Brest, Brest, France. FAU - Mehran, Roxana AU - Mehran R AD - Icahn School of Medicine at Mount Sinai, New York, NY USA. FAU - Chieffo, Alaide AU - Chieffo A AD - Interventional Cardiology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy. AD - University Vita-Salute San Raffaele, Milan, Italy. LA - eng PT - Journal Article PT - Review DEP - 20241012 PL - England TA - Eur Heart J Open JT - European heart journal open JID - 9918282081406676 PMC - PMC11539024 OTO - NOTNLM OT - Acute coronary syndromes OT - Cardiovascular risk factor OT - Prevention OT - Sex differences OT - Women COIS- Conflict of interest S.M.S. has received consulting fees from Bayer, Organon, and Exeltis; has received lecture fees from Astra Zeneca, Bayer, BMS, Exeltis, and Organon; has served in the adjudication board for a study for Biotronik. M.H. has received consulting fees from Abbott, Shockwave, Boston Scientific, Acist, and Medtronic. S.B. has received fees for Advisory Board participation with Shockwave and SMT and lecture fees from Medtronic and Boston Scientific. M.K.-O. has received consulting fees from Sanofi, Astra Zeneca, Beohringer Ingelheim, Shockwave, and Boston Scientific. V.P. declares a research grant from Abbott via the institution; speaker fees from Abbott, Boston Scientific, and Lithix; and an educational grant from Terumo via the institution. P.S. declares consulting or lecture fees from Axis TV, BMS, Les Laboratoires Servier, Novartis, Novonordisk, and Sanofi, outside the submitted work. R.M. reports institutional research payments from Abbott, Affluent Medical, Alleviant Medical, Amgen, Boston Scientific, Bristol Myers Squibb, CardiaWave, Chiesi, Concept Medical, Daiichi Sankyo, Duke, Faraday, Idorsia, Janssen, MedAlliance, Medscape, Mediasphere, Medtelligence, Medtronic, Novartis, OrbusNeich, Pi-Cardia, Protembis, RM Global Bioaccess Fund Management, and Sanofi; personal fees from Affluent Medical, Boehringer Ingelheim, Chiesi USA, Cordis, IQVIA, Medscape/WebMD Global, NovoNordisk, PeerView Institute for Medical Education, and Radcliffe. A.C. has received Speaker Consultant fees from Abiomed, Abbott Vasc, Boehringer, Boston Scientifioc, Medtronic, Menarini, and Penumbra. The remaining authors report no conflict of interest. EDAT- 2024/11/12 04:45 MHDA- 2024/11/12 04:46 PMCR- 2024/10/12 CRDT- 2024/11/07 04:40 PHST- 2024/09/27 00:00 [received] PHST- 2024/10/04 00:00 [revised] PHST- 2024/10/08 00:00 [accepted] PHST- 2024/11/12 04:46 [medline] PHST- 2024/11/12 04:45 [pubmed] PHST- 2024/11/07 04:40 [entrez] PHST- 2024/10/12 00:00 [pmc-release] AID - oeae087 [pii] AID - 10.1093/ehjopen/oeae087 [doi] PST - epublish SO - Eur Heart J Open. 2024 Oct 12;4(6):oeae087. doi: 10.1093/ehjopen/oeae087. eCollection 2024 Nov. PMID- 39507449 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241121 IS - 2305-5839 (Print) IS - 2305-5847 (Electronic) IS - 2305-5839 (Linking) VI - 12 IP - 5 DP - 2024 Oct 20 TI - Comparing surgical techniques and results of secondary ischemic mitral regurgitation: a state-of-the-art literature review. PG - 91 LID - 10.21037/atm-24-39 [doi] LID - 91 AB - BACKGROUND AND OBJECTIVE: Surgery for mitral valve disease is a developing area with a wide range of surgical options. There is growing evidence on the best approach for secondary ischemic mitral regurgitation (SIMR) when the pathology is within the ventricle. The goal of this literature review is to provide a comprehensive comparison of surgical treatments for SIMR. METHODS: The initial screening process included PubMed, Medline and Embase to identify randomized controlled trials, propensity-matched observational series, meta-analyses and unmatched observational series. The terms used were 'mitral valve disease', 'secondary mitral regurgitation', 'secondary ischemic mitral regurgitation', 'functional mitral regurgitation', 'restrictive mitral annuloplasty', 'subvalvular repair', 'Trans Catheter Edge to Edge Repair and echocardiography coupled with secondary mitral regurgitation', 'secondary ischemic mitral regurgitation', and 'functional mitral regurgitation'. Six strategies have been identified for treating SIMR. These include mitral valve replacement (MVR), restrictive mitral annuloplasty, surgical revascularisation (with and without mitral annuloplasty), subvalvular procedures [papillary muscle (PM) approximation, PM relocation, ring and string procedure], procedures directly targeting the mitral valve (edge-to-edge repair and anterior leaflet enlargement), and transcatheter heart valve therapy. KEY CONTENT AND FINDINGS: There is a deficiency of robust empirical data to enable meaningful comparisons between MVR, mitral valve repair (including subvalvular repair), and transcatheter mitral valve procedure. This review will definitively analyze the current outcomes of transcatheter mitral valve procedure using the edge-to-edge mitral valve repair technique and standard surgical mitral valve procedures in patients with secondary mitral regurgitation (MR). In addition, the seminar highlights the role of left ventricular assist devices in managing SIMR. It discusses the advantages and limitations of each intervention. CONCLUSIONS: Currently, there is no consensus on the optimal management strategy for patients with SIMR. Therefore, a multidisciplinary cardiac team should manage patients with secondary MR to ensure the best outcome by matching the ideal intervention with the patient. CI - 2024 AME Publishing Company. All rights reserved. FAU - Nappi, Francesco AU - Nappi F AUID- ORCID: 0000-0002-9705-5360 AD - Department of Cardiac Surgery, Centre Cardiologique du Nord, Saint-Denis, France. LA - eng PT - Journal Article PT - Review DEP - 20240913 PL - China TA - Ann Transl Med JT - Annals of translational medicine JID - 101617978 PMC - PMC11534758 OTO - NOTNLM OT - Secondary ischemic mitral regurgitation (SIMR) OT - functional mitral regurgitation OT - restrictive mitral annuloplasty (RMA) OT - subvalvular repair (SVR) OT - trans catheter edge to edge repair COIS- Conflicts of Interest: The author has completed the ICMJE uniform disclosure form (available at https://atm.amegroups.com/article/view/10.21037/atm-24-39/coif). F.N. serves as an unpaid editorial board member of Annals of Translational Medicine from March 2023 to February 2025. The author has no other conflicts of interest to declare. EDAT- 2024/11/12 04:45 MHDA- 2024/11/12 04:46 PMCR- 2024/10/20 CRDT- 2024/11/07 04:33 PHST- 2024/02/23 00:00 [received] PHST- 2024/06/19 00:00 [accepted] PHST- 2024/11/12 04:46 [medline] PHST- 2024/11/12 04:45 [pubmed] PHST- 2024/11/07 04:33 [entrez] PHST- 2024/10/20 00:00 [pmc-release] AID - atm-12-05-91 [pii] AID - 10.21037/atm-24-39 [doi] PST - ppublish SO - Ann Transl Med. 2024 Oct 20;12(5):91. doi: 10.21037/atm-24-39. Epub 2024 Sep 13. PMID- 39506505 OWN - NLM STAT- MEDLINE DCOM- 20241224 LR - 20250827 IS - 1522-726X (Electronic) IS - 1522-1946 (Print) IS - 1522-1946 (Linking) VI - 104 IP - 7 DP - 2024 Dec TI - Developing a Women's Heart Center With a Specialization in Coronary Microvascular and Vasomotor Dysfunction: If You Build It, They Will Come. PG - 1337-1343 LID - 10.1002/ccd.31281 [doi] AB - BACKGROUND: Women's Heart Centers (WHC) are comprehensive, multidisciplinary care centers designed to close the existing gap in women's cardiovascular care. The WHC at The Christ Hospital Heart and Vascular Institute (TCH-WHC) in Cincinnati, Ohio was established in October of 2020, and is a specialized coronary microvascular and vasomotor dysfunction (CMVD) program. METHODS: The TCH-WHC focuses its efforts across five pillars: patient care, research, education, community outreach and advocacy, and grants and philanthropy. These areas, centered around providing specalized CMVD care and treatment have allowed for substantial growth. RESULTS: From October 2020-December 2023, TCH-WHC saw a total of 3219 patients, 42% of which were apart of the CMVD program. Since establishment, patient volume has consistently increased year over year. CONCLUSION: The CMVD program at TCH-WHC is one of the fastest growing in the U. S. and is nationally recognized for specialized clinical care, diagnostics, and research. The goal of this review is to provide an overview of the TCH-WHC structure that allows for the establishment and growth of a CMVD program and to outline core activities supporting the TCH-WHC approach. CI - (c) 2024 Wiley Periodicals LLC. FAU - Tapp, Danielle N AU - Tapp DN AD - Women's Heart Center, Heart & Vascular Institute, The Christ Hospital Health Network, Cincinnati, Ohio, USA. FAU - Ashokprabhu, Namrita D AU - Ashokprabhu ND AD - Women's Heart Center, Heart & Vascular Institute, The Christ Hospital Health Network, Cincinnati, Ohio, USA. FAU - Hamstra, Michelle S AU - Hamstra MS AD - Women's Heart Center, Heart & Vascular Institute, The Christ Hospital Health Network, Cincinnati, Ohio, USA. FAU - Losekamp, Melissa AU - Losekamp M AD - Women's Heart Center, Heart & Vascular Institute, The Christ Hospital Health Network, Cincinnati, Ohio, USA. FAU - Schmidt, Christian AU - Schmidt C AUID- ORCID: 0000-0002-9333-1620 AD - Carl and Edyth Lindner Center for Research and Education, The Christ Hospital Health Network, Cincinnati, Ohio, USA. FAU - Palmer, Cassady AU - Palmer C AD - Women's Heart Center, Heart & Vascular Institute, The Christ Hospital Health Network, Cincinnati, Ohio, USA. FAU - Julie Gallatin, N P AU - Julie Gallatin NP AD - Women's Heart Center, Heart & Vascular Institute, The Christ Hospital Health Network, Cincinnati, Ohio, USA. FAU - Tierney, Darlene AU - Tierney D AD - Women's Heart Center, Heart & Vascular Institute, The Christ Hospital Health Network, Cincinnati, Ohio, USA. FAU - Trenaman, Tammy AU - Trenaman T AD - Women's Heart Center, Heart & Vascular Institute, The Christ Hospital Health Network, Cincinnati, Ohio, USA. FAU - Canoniero, Mariana AU - Canoniero M AD - Carl and Edyth Lindner Center for Research and Education, The Christ Hospital Health Network, Cincinnati, Ohio, USA. FAU - Frizzell, Jarrod AU - Frizzell J AUID- ORCID: 0000-0002-2722-1239 AD - Carl and Edyth Lindner Center for Research and Education, The Christ Hospital Health Network, Cincinnati, Ohio, USA. FAU - Henry, Timothy D AU - Henry TD AUID- ORCID: 0000-0003-1123-0533 AD - Carl and Edyth Lindner Center for Research and Education, The Christ Hospital Health Network, Cincinnati, Ohio, USA. FAU - Quesada, Odayme AU - Quesada O AUID- ORCID: 0000-0002-7285-5994 AD - Women's Heart Center, Heart & Vascular Institute, The Christ Hospital Health Network, Cincinnati, Ohio, USA. AD - Carl and Edyth Lindner Center for Research and Education, The Christ Hospital Health Network, Cincinnati, Ohio, USA. LA - eng GR - K23 HL151867/HL/NHLBI NIH HHS/United States GR - This work was supported by the Accreditation Foundation Committee ("AFC") of the American College of Cardiology Foundation ("ACCF"), The Women's Heart Center, Heart & Vascular Institute, The Christ Hospital Health Network. K23HL151867./ PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20241106 PL - United States TA - Catheter Cardiovasc Interv JT - Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions JID - 100884139 SB - IM MH - Humans MH - Female MH - *Microcirculation MH - *Vasomotor System/physiopathology MH - Program Development MH - Coronary Circulation MH - Women's Health MH - Patient Care Team/organization & administration MH - Sex Factors MH - Women's Health Services MH - Healthcare Disparities MH - Ohio PMC - PMC12376972 MID - NIHMS2034798 OTO - NOTNLM OT - ANOCA OT - INOCA OT - MINOCA OT - Women's Heart Center OT - coronary microvascular and vasomotor dysfunction OT - sex differences COIS- Conflicts of Interest The authors declare no conflicts of interest. EDAT- 2024/11/12 04:44 MHDA- 2024/12/24 06:20 PMCR- 2025/08/25 CRDT- 2024/11/07 02:44 PHST- 2024/10/15 00:00 [received] PHST- 2024/10/21 00:00 [accepted] PHST- 2024/12/24 06:20 [medline] PHST- 2024/11/12 04:44 [pubmed] PHST- 2024/11/07 02:44 [entrez] PHST- 2025/08/25 00:00 [pmc-release] AID - 10.1002/ccd.31281 [doi] PST - ppublish SO - Catheter Cardiovasc Interv. 2024 Dec;104(7):1337-1343. doi: 10.1002/ccd.31281. Epub 2024 Nov 6. PMID- 39505122 OWN - NLM STAT- MEDLINE DCOM- 20241209 LR - 20260722 IS - 1097-6744 (Electronic) IS - 0002-8703 (Linking) VI - 280 DP - 2025 Feb TI - Transcatheter aortic-valve implantation with or without on-site cardiac surgery: The TRACS trial. PG - 7-17 LID - S0002-8703(24)00281-3 [pii] LID - 10.1016/j.ahj.2024.10.019 [doi] AB - BACKGROUND: Transcatheter aortic valve implantation (TAVI) has emerged as an effective and safe treatment for patients with symptomatic aortic stenosis. The indication to TAVI should be agreed upon by a Heart Team, and the procedure should be performed in centers with on-site cardiac surgery. However, TAVI complications requiring emergent cardiac surgery (ECS) have become very rare. Concurrently, access disparities and prolonged waiting times are pressing issues due to increasing clinical demand of TAVI. Many solutions have been proposed and one of them is the possibility of performing TAVI in centers without on-site cardiac surgery. METHODS AND DESIGN: The Transcatheter Aortic-Valve Implantation with or without on-site Cardiac Surgery (TRACS) trial is a prospective, randomized, multicenter, open-label study with blinded adjudicated evaluation of outcomes. Patients with symptomatic severe aortic stenosis and deemed inoperable, at high surgical risk, or presenting with at least 1 clinical factor compromising the benefit/risk ratio for ECS, will be randomized to undergo TAVI either in centers with or without on-site cardiac surgery. The primary endpoint will be the composite occurrence of all-cause death, stroke, and hospital readmission for cardiovascular causes at one year. The safety endpoint will include death attributable to periprocedural complications actionable by ECS. The study aims to enroll 566 patients. IMPLICATIONS: The TRACS trial aims to address critical gaps in knowledge regarding the safety and efficacy of TAVI procedures performed in centers without on-site cardiac surgery, potentially improving access and outcomes for high-risk patients. TRIAL REGISTRATION: ClinicalTrials.gov NCT05751577. CI - Copyright (c) 2024 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Iannopollo, Gianmarco AU - Iannopollo G AD - Cardiology Unit, Ospedale Maggiore, Bologna, Italy. FAU - Cocco, Marta AU - Cocco M AD - Cardiovascular Institute, Azienda Ospedaliero Universitaria di Ferrara, Ferrara, Italy. FAU - Leone, Alessandro AU - Leone A AD - Cardiac Surgery Department, S. Orsola Hospital, University of Bologna, Bologna, Italy. FAU - Sacca, Salvatore AU - Sacca S AD - Department of Cardiology, Ospedale Civile di Mirano, Mirano, Venice, Italy. FAU - Mangino, Domenico AU - Mangino D AD - Cardiac Surgery Unit, Ospedale dell'Angelo, Venice-Mestre, Italy. FAU - Picchi, Andrea AU - Picchi A AD - Cardiovascular Department, Azienda USL Toscana Sud-Est, Misericordia Hospital, Grosseto, Italy. FAU - Reccia, Matteo Rocco AU - Reccia MR AD - Cardiovascular Department, San Donato Hospital, Arezzo, Italy. FAU - Fineschi, Massimo AU - Fineschi M AD - Interventional Cardiology UOSA, Azienda Ospedaliera Universitaria Senese, Siena, Italy. FAU - Meliga, Emanuele AU - Meliga E AD - Department of Cardiology, Cardinal Massaia Hospital, Asti, Italy. FAU - Audo, Andrea AU - Audo A AD - Department of Cardiac Surgery, AO SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy. FAU - Nobile, Giampiero AU - Nobile G AD - Cardiology Unit, Ospedale Maggiore, Bologna, Italy. FAU - Tumscitz, Carlo AU - Tumscitz C AD - Cardiovascular Institute, Azienda Ospedaliero Universitaria di Ferrara, Ferrara, Italy. FAU - Penzo, Carlo AU - Penzo C AD - Cardiovascular Institute, Azienda Ospedaliero Universitaria di Ferrara, Ferrara, Italy. FAU - Saia, Francesco AU - Saia F AD - Division of Interventional Cardiology, IRCCS University Hospital of Bologna, Policlinico Sant'Orsola, Bologna, Italy. FAU - Rubboli, Andrea AU - Rubboli A AD - Division of Cardiology, S.Maria delle Croci Hospital, Ravenna, Italy. FAU - Moretti, Carolina AU - Moretti C AD - Division of Cardiology, S.Maria delle Croci Hospital, Ravenna, Italy. FAU - Vignali, Luigi AU - Vignali L AD - Division of Cardiology, Parma University Hospital, Parma, Italy. FAU - Niccoli, Giampaolo AU - Niccoli G AD - Division of Cardiology, Parma University Hospital, Parma, Italy. FAU - Cimaglia, Paolo AU - Cimaglia P AD - Cardiovascular Institute, Azienda Ospedaliero Universitaria di Ferrara, Ferrara, Italy. FAU - Rognoni, Andrea AU - Rognoni A AD - Division of Cardiology, Ospedale degli Infermi, Azienda Sanitaria Locale di Biella, Biella, Italy. FAU - Aschieri, Daniela AU - Aschieri D AD - Cardiology Unit of Emergency Department, Guglielmo da Saliceto Hospital, Piacenza, Italy. FAU - Iaccarino, Daniele AU - Iaccarino D AD - Cardiology Department, Nuovo Ospedale S. Agostino Estense, Modena, Italy. FAU - Ottani, Filippo AU - Ottani F AD - Cardiovascular Department, Infermi Hospital, Rimini, Italy. FAU - Cavazza, Caterina AU - Cavazza C AD - Cardiovascular Department, Infermi Hospital, Rimini, Italy. FAU - Varbella, Ferdinando AU - Varbella F AD - Rivoli Infermi Hospital, Rivoli, Turin, Italy. FAU - Secco, Gioel Gabrio AU - Secco GG AD - Department of Cardiology, AO SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy. FAU - Bolognese, Leonardo AU - Bolognese L AD - Cardiovascular Department, San Donato Hospital, Arezzo, Italy. FAU - Limbruno, Ugo AU - Limbruno U AD - Cardiovascular Department, Azienda USL Toscana Sud-Est, Misericordia Hospital, Grosseto, Italy. FAU - Guiducci, Vincenzo AU - Guiducci V AD - Cardiology Unit, Azienda USL-IRCCS Reggio Emilia, S. Maria Nuova Hospital, Reggio Emilia, Italy. FAU - Campo, Gianluca AU - Campo G AD - Cardiovascular Institute, Azienda Ospedaliero Universitaria di Ferrara, Ferrara, Italy. Electronic address: cmpglc@unife.it. FAU - Casella, Gianni AU - Casella G AD - Cardiology Unit, Ospedale Maggiore, Bologna, Italy. LA - eng SI - ClinicalTrials.gov/NCT05751577 PT - Clinical Trial Protocol PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20241104 PL - United States TA - Am Heart J JT - American heart journal JID - 0370465 SB - IM MH - Aged MH - Female MH - Humans MH - Male MH - *Aortic Valve Stenosis/surgery MH - Cardiac Surgical Procedures/methods MH - Patient Readmission/statistics & numerical data MH - Postoperative Complications/epidemiology MH - Prospective Studies MH - Stroke/etiology MH - *Transcatheter Aortic Valve Replacement/methods MH - Treatment Outcome EDAT- 2024/11/07 04:20 MHDA- 2024/12/10 00:22 CRDT- 2024/11/06 19:30 PHST- 2024/07/27 00:00 [received] PHST- 2024/10/27 00:00 [revised] PHST- 2024/10/28 00:00 [accepted] PHST- 2024/12/10 00:22 [medline] PHST- 2024/11/07 04:20 [pubmed] PHST- 2024/11/06 19:30 [entrez] AID - S0002-8703(24)00281-3 [pii] AID - 10.1016/j.ahj.2024.10.019 [doi] PST - ppublish SO - Am Heart J. 2025 Feb;280:7-17. doi: 10.1016/j.ahj.2024.10.019. Epub 2024 Nov 4. PMID- 39502128 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260923 IS - 2050-0904 (Print) IS - 2050-0904 (Electronic) IS - 2050-0904 (Linking) VI - 12 IP - 11 DP - 2024 Nov TI - HUSM endocarditis team's approach to acute ruptured chordae tendineae in chronic rheumatic heart disease. PG - e9482 LID - 10.1002/ccr3.9482 [doi] LID - e9482 AB - Neglected rheumatic heart disease (RHD) can lead to severe complications and change patients' quality of life, particularly that of young patients. This report highlights the importance of public health education for patients and families in preventing RHD complications. In RHD management, prevention is better than cure. CI - (c) 2024 The Author(s). Clinical Case Reports published by John Wiley & Sons Ltd. FAU - Othman, Mohd Khairi AU - Othman MK AUID- ORCID: 0009-0005-4588-3681 AD - Cardiology Unit Hospital Universiti Sains Malaysia Kota Bharu Malaysia. AD - Internal Medicine Department, School of Medicine Universiti Sains Malaysia Kota Bharu Malaysia. FAU - Abdullahilhai, Anis Alyani AU - Abdullahilhai AA AD - Cardiology Unit Hospital Universiti Sains Malaysia Kota Bharu Malaysia. AD - Internal Medicine Department, School of Medicine Universiti Sains Malaysia Kota Bharu Malaysia. FAU - Yusof, Zurkurnai AU - Yusof Z AUID- ORCID: 0000-0002-2483-8145 AD - Cardiology Unit Hospital Universiti Sains Malaysia Kota Bharu Malaysia. AD - Internal Medicine Department, School of Medicine Universiti Sains Malaysia Kota Bharu Malaysia. FAU - W Isa, W Yus Haniff AU - W Isa WYH AUID- ORCID: 0000-0001-9887-8441 AD - Cardiology Unit Hospital Universiti Sains Malaysia Kota Bharu Malaysia. AD - Internal Medicine Department, School of Medicine Universiti Sains Malaysia Kota Bharu Malaysia. FAU - Muhd Besari Hashim, Alwi AU - Muhd Besari Hashim A AD - Internal Medicine Department, School of Medicine Universiti Sains Malaysia Kota Bharu Malaysia. AD - Infectious Disease Unit Hospital Universiti Sains Malaysia Kota Bharu Malaysia. FAU - Mokhtar, Ariffin Marzuki AU - Mokhtar AM AD - Anesthesiology and Critical Care Department, School of Medicine Universiti Sains Malaysia Kota Bharu Malaysia. FAU - Hussain, Aimatnuddin Husairi AU - Hussain AH AD - Cardiothoracic Unit Hospital Universiti Sains Malaysia Kota Bharu Malaysia. AD - Surgery Department, School of Medicine Universiti Sains Malaysia Kota Bharu Malaysia. FAU - Hassan, Mohamad Hasyizan AU - Hassan MH AD - Cardiology Unit Hospital Universiti Sains Malaysia Kota Bharu Malaysia. AD - Anesthesiology and Critical Care Department, School of Medicine Universiti Sains Malaysia Kota Bharu Malaysia. FAU - Mamat, Ahmad Zuhdi AU - Mamat AZ AD - Cardiothoracic Unit Hospital Universiti Sains Malaysia Kota Bharu Malaysia. AD - Surgery Department, School of Medicine Universiti Sains Malaysia Kota Bharu Malaysia. LA - eng PT - Journal Article DEP - 20241104 PL - England TA - Clin Case Rep JT - Clinical case reports JID - 101620385 PMC - PMC11534624 OTO - NOTNLM OT - dental procedure OT - infective endocarditis OT - rheumatic heart disease OT - ruptured chordae tendineae COIS- The authors declare no conflicts of interest regarding the publication of this manuscript. EDAT- 2024/11/06 10:53 MHDA- 2024/11/06 10:54 PMCR- 2024/11/04 CRDT- 2024/11/06 05:05 PHST- 2024/05/17 00:00 [received] PHST- 2024/09/01 00:00 [revised] PHST- 2024/09/25 00:00 [accepted] PHST- 2024/11/06 10:54 [medline] PHST- 2024/11/06 10:53 [pubmed] PHST- 2024/11/06 05:05 [entrez] PHST- 2024/11/04 00:00 [pmc-release] AID - CCR39482 [pii] AID - 10.1002/ccr3.9482 [doi] PST - epublish SO - Clin Case Rep. 2024 Nov 4;12(11):e9482. doi: 10.1002/ccr3.9482. eCollection 2024 Nov. PMID- 39502077 OWN - NLM STAT- MEDLINE DCOM- 20241119 LR - 20241119 IS - 1941-7632 (Electronic) IS - 1941-7640 (Linking) VI - 17 IP - 11 DP - 2024 Nov TI - Enhancing Coronary Revascularization Decisions: The Promising Role of Large Language Models as a Decision-Support Tool for Multidisciplinary Heart Team. PG - e014201 LID - 10.1161/CIRCINTERVENTIONS.124.014201 [doi] AB - BACKGROUND: While clinical practice guidelines advocate for multidisciplinary heart team (MDHT) discussions in coronary revascularization, variability in implementation across health care settings remains a challenge. This variability could potentially be addressed by language learning models like ChatGPT, offering decision-making support in diverse health care environments. Our study aims to critically evaluate the concordance between recommendations made by MDHT and those generated by language learning models in coronary revascularization decision-making. METHODS: From March 2023 to July 2023, consecutive coronary angiography cases (n=86) that were referred for revascularization (either percutaneous or surgical) were analyzed using both ChatGPT-3.5 and ChatGPT-4. Case presentation formats included demographics, medical background, detailed description of angiographic findings, and SYNTAX score (Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery; I and II), which were presented in 3 different formats. The recommendations of the models were compared with those of an MDHT. RESULTS: ChatGPT-4 showed high concordance with decisions made by the MDHT (accuracy 0.82, sensitivity 0.8, specificity 0.83, and kappa 0.59), while ChatGPT-3.5 (0.67, 0.27, 0.84, and 0.12, respectively) showed lower concordance. Entropy and Fleiss kappa of ChatGPT-4 were 0.09 and 0.9, respectively, indicating high reliability and repeatability. The best correlation between ChatGPT-4 and MDHT was achieved when clinical cases were presented in a detailed context. Specific subgroups of patients yielded high accuracy (>0.9) of ChatGPT-4, including those with left main disease, 3 vessel disease, and diabetic patients. CONCLUSIONS: The present study demonstrates that advanced language learning models like ChatGPT-4 may be able to predict clinical recommendations for coronary artery disease revascularization with reasonable accuracy, especially in specific patient groups, underscoring their potential role as a supportive tool in clinical decision-making. FAU - Sudri, Karin AU - Sudri K AUID- ORCID: 0000-0002-5118-8619 AD - ARC Innovation Center, Sagol Big Data and AI Hub (K.S., M.C.-S.), Sheba Medical Center, Tel Hashomer, Israel. FAU - Motro-Feingold, Iris AU - Motro-Feingold I AD - Sheba Education Authority (I.M.-F.), Sheba Medical Center, Tel Hashomer, Israel. FAU - Ramon-Gonen, Roni AU - Ramon-Gonen R AD - The Graduate School of Business Administration (R.R.-G.), Bar-Ilan University, Ramat-Gan, Israel. AD - Data Science Institute (R.R.-G.), Bar-Ilan University, Ramat-Gan, Israel. FAU - Barda, Noam AU - Barda N AUID- ORCID: 0000-0002-3400-235X AD - ARC Innovation Center (N.B.), Sheba Medical Center, Tel Hashomer, Israel. AD - Software and Information Systems Engineering (N.B.), Ben-Gurion University of the Negev, Be'er Sheva, Israel. AD - Epidemiology, Biostatistics and Community Health Sciences (N.B.), Ben-Gurion University of the Negev, Be'er Sheva, Israel. FAU - Klang, Eyal AU - Klang E AD - The Division of Data Driven and Digital Medicine, Icahn School of Medicine at Mount Sinai, New York, NY (E.K.). FAU - Fefer, Paul AU - Fefer P AD - Interventional Cardiology Unit, Leviev Heart Institute (P.F., A.S., I.M.B.), Sheba Medical Center, Tel Hashomer, Israel. AD - Faculty of Medicine, Tel Aviv University, Israel (P.F., S.A., A.S., I.M.B.). FAU - Amunts, Sergei AU - Amunts S AUID- ORCID: 0000-0001-8108-8099 AD - Department of Cardiac Surgery, Leviev Cardiothoracic and Vascular Center (S.A.), Sheba Medical Center, Tel Hashomer, Israel. AD - Faculty of Medicine, Tel Aviv University, Israel (P.F., S.A., A.S., I.M.B.). FAU - Attia, Zachi Itzhak AU - Attia ZI AUID- ORCID: 0000-0002-9706-7900 AD - Department of Cardiovascular Medicine (Z.I.A., M.A.), Mayo Clinic, Rochester, MN. AD - Department of Artificial Intelligence and Informatics (Z.I.A.), Mayo Clinic, Rochester, MN. FAU - Alkhouli, Mohamad AU - Alkhouli M AUID- ORCID: 0000-0003-3847-0959 AD - Department of Cardiovascular Medicine (Z.I.A., M.A.), Mayo Clinic, Rochester, MN. FAU - Segev, Amitai AU - Segev A AUID- ORCID: 0000-0002-6653-7543 AD - Interventional Cardiology Unit, Leviev Heart Institute (P.F., A.S., I.M.B.), Sheba Medical Center, Tel Hashomer, Israel. AD - Faculty of Medicine, Tel Aviv University, Israel (P.F., S.A., A.S., I.M.B.). FAU - Cohen-Shelly, Michal AU - Cohen-Shelly M AUID- ORCID: 0009-0007-6532-9252 AD - ARC Innovation Center, Sagol Big Data and AI Hub (K.S., M.C.-S.), Sheba Medical Center, Tel Hashomer, Israel. AD - The Olga and Lev Leviev Heart Center (M.C.-S.), Sheba Medical Center, Tel Hashomer, Israel. FAU - Barbash, Israel Moshe AU - Barbash IM AUID- ORCID: 0000-0002-7416-5989 AD - Interventional Cardiology Unit, Leviev Heart Institute (P.F., A.S., I.M.B.), Sheba Medical Center, Tel Hashomer, Israel. AD - Faculty of Medicine, Tel Aviv University, Israel (P.F., S.A., A.S., I.M.B.). LA - eng PT - Comparative Study PT - Journal Article DEP - 20241106 PL - United States TA - Circ Cardiovasc Interv JT - Circulation. Cardiovascular interventions JID - 101499602 SB - IM CIN - Circ Cardiovasc Interv. 2024 Nov;17(11):e014775. doi: 10.1161/CIRCINTERVENTIONS.124.014775. PMID: 39503053 MH - Humans MH - *Clinical Decision-Making MH - *Patient Care Team MH - Male MH - Aged MH - Female MH - *Decision Support Techniques MH - Middle Aged MH - *Coronary Angiography MH - *Percutaneous Coronary Intervention MH - *Coronary Artery Disease/diagnostic imaging/therapy/physiopathology MH - *Predictive Value of Tests MH - Interdisciplinary Communication MH - Patient Selection MH - Coronary Artery Bypass/adverse effects MH - Treatment Outcome OTO - NOTNLM OT - artificial intelligence OT - coronary angiography OT - coronary artery diseases OT - delivery of health care OT - natural language processing COIS- None. EDAT- 2024/11/06 06:22 MHDA- 2024/11/19 22:19 CRDT- 2024/11/06 05:04 PHST- 2024/11/19 22:19 [medline] PHST- 2024/11/06 06:22 [pubmed] PHST- 2024/11/06 05:04 [entrez] AID - 10.1161/CIRCINTERVENTIONS.124.014201 [doi] PST - ppublish SO - Circ Cardiovasc Interv. 2024 Nov;17(11):e014201. doi: 10.1161/CIRCINTERVENTIONS.124.014201. Epub 2024 Nov 6. PMID- 39500250 OWN - NLM STAT- MEDLINE DCOM- 20241209 LR - 20241209 IS - 1873-491X (Electronic) IS - 0020-7489 (Linking) VI - 161 DP - 2025 Jan TI - Long-term patient outcomes from a multidisciplinary cardiac rehabilitation programme with integrated nurse specialist support: A retrospective cohort study. PG - 104945 LID - S0020-7489(24)00258-X [pii] LID - 10.1016/j.ijnurstu.2024.104945 [doi] AB - BACKGROUND: Cardiac rehabilitation programmes, while demonstrating benefits, face challenges in universal adoption, particularly in New Zealand. This study evaluates the long-term impact of cardiac rehabilitation participation and attendance on survival and readmission rates in the Auckland Health District. OBJECTIVE: To examine the impact of patient participation in nurse-led lifestyle rehabilitation and physiotherapy exercise rehabilitation on key outcomes, including all-cause mortality, and all-cause, cardiac-specific, and kidney disease readmission rates. DESIGN: Retrospective cohort study. SETTING: Auckland Health District, New Zealand. PARTICIPANTS: 3331 patients registered in the Auckland cardiac rehabilitation programme between 2016 and 2020. METHODS: Data analysis included examining associations between attendance at nurse-led lifestyle and physiotherapy-led exercise sessions and outcomes at 12, 24 months, and 2022 year-end, including all-cause mortality, all-cause readmission, and cardiac-specific readmission rates. Analysis methods included survival analysis, Cox proportional regression, and logistic binary regression, controlling for confounders using propensity score weights and baseline factors. RESULTS: 1363 (40.9 %) patients attended at least one lifestyle rehabilitation session (average 5.0 +/- 2.9 sessions), 1121 (33.7 %) patients attended at least one exercise rehabilitation session (average 6.8 +/- 7.4 sessions), and 649 (19.5 %) patients attended at least one lifestyle and one exercise rehabilitation session. Increased likelihood of participation in rehabilitation was explained by ethnicity, while current and historical tobacco use, history of heart failure, receiving an angiogram, PCI, or other treatment such as medical management or implantable devices were associated with lower odds of participation. Participation in rehabilitation (average 7.9 +/- 6.1 sessions) was associated with a higher mean survival estimate (7.6 years vs. 6.4 years, p < 0.001) while Cox proportional hazard regression, controlling for baseline factors and propensity score weights showed that a single session of rehabilitation attended had a 2.1 % decreased risk of mortality (hazard ratio = 0.98, 95 % CI: 0.96 to 0.99, p = 0.29). The cumulative hazard ratio for average attendance (7.9 +/- 6.1 sessions) was 0.85 (95 % CI: 0.83 to 0.86, p < 0.001) indicating a 15 % decreased risk of mortality during follow-up. 20 % lower kidney disease readmission rates were observed among participants over the next 24 months (p < 0.05). However, no differences in all-cause or cardiac-specific readmission rates were observed. CONCLUSIONS: The study supports the effectiveness of cardiac rehabilitation in improving long-term survival for Auckland Health District patients. The positive impact of nurse-led interventions and integrated support throughout the cardiac rehabilitation process highlights the need for translating this model to other health districts in New Zealand to optimise patient care and outcomes. CI - Copyright (c) 2024 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Marshall, Paul W AU - Marshall PW AD - Department of Exercise Sciences, Faculty of Sciences, University of Auckland, New Zealand. Electronic address: p.marshall@auckland.ac.nz. FAU - Benatar, Jocelyne R AU - Benatar JR AD - Department of Exercise Sciences, Faculty of Sciences, University of Auckland, New Zealand; Green Lane Cardiovascular Service, Auckland City Hospital, New Zealand. FAU - Hennessy, Angie AU - Hennessy A AD - Health Information and Technology, Te Whatu Ora Te Toka Tumai, Auckland, New Zealand. FAU - Lindbom, Tia AU - Lindbom T AD - Department of Exercise Sciences, Faculty of Sciences, University of Auckland, New Zealand. FAU - Gallagher, Cara AU - Gallagher C AD - Department of Exercise Sciences, Faculty of Sciences, University of Auckland, New Zealand. FAU - Khan-Niazi, Imran AU - Khan-Niazi I AD - Centre for Chiropractic Research, New Zealand College of Chiropractic, New Zealand; Health and Rehabilitation Research Institute, Auckland University of Technology, Auckland, New Zealand. FAU - Rashid, Usman AU - Rashid U AD - Centre for Chiropractic Research, New Zealand College of Chiropractic, New Zealand. FAU - Kingsley, Michael AU - Kingsley M AD - Department of Exercise Sciences, Faculty of Sciences, University of Auckland, New Zealand; Holsworth Research Initiative, La Trobe Rural Health School, La Trobe University, Melbourne, Australia. LA - eng PT - Journal Article DEP - 20241026 PL - England TA - Int J Nurs Stud JT - International journal of nursing studies JID - 0400675 SB - IM MH - Humans MH - Retrospective Studies MH - *Cardiac Rehabilitation/methods MH - Female MH - Male MH - New Zealand MH - Middle Aged MH - Aged MH - Nurse Specialists/statistics & numerical data MH - Cohort Studies MH - Patient Readmission/statistics & numerical data OTO - NOTNLM OT - Acute coronary syndrome OT - Ethnicity OT - Exercise rehabilitation OT - Kidney disease OT - Lifestyle rehabilitation OT - Survival COIS- Declaration of competing interest There are no conflicts of interest to declare. EDAT- 2024/11/06 00:22 MHDA- 2024/12/10 00:22 CRDT- 2024/11/05 18:10 PHST- 2024/03/20 00:00 [received] PHST- 2024/10/20 00:00 [revised] PHST- 2024/10/23 00:00 [accepted] PHST- 2024/12/10 00:22 [medline] PHST- 2024/11/06 00:22 [pubmed] PHST- 2024/11/05 18:10 [entrez] AID - S0020-7489(24)00258-X [pii] AID - 10.1016/j.ijnurstu.2024.104945 [doi] PST - ppublish SO - Int J Nurs Stud. 2025 Jan;161:104945. doi: 10.1016/j.ijnurstu.2024.104945. Epub 2024 Oct 26. PMID- 39499433 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241125 IS - 1568-5888 (Print) IS - 1876-6250 (Electronic) IS - 1568-5888 (Linking) VI - 32 IP - 12 DP - 2024 Dec TI - The effects of spondylodiscitis on the inflammation burden in infective endocarditis. PG - 455-461 LID - 10.1007/s12471-024-01908-1 [doi] AB - BACKGROUND: This study investigates the effects of spondylodiscitis on the inflammation burden in infective endocarditis patients. METHODS: A prospective, observational study was conducted between September 2018 and October 2022 in a non-surgical teaching hospital. Patients with a definite or possible and treated as infective endocarditis were recruited from the Alkmaar Endocarditis Team meetings. Spondylodiscitis was diagnosed based on symptoms and radiological findings. The inflammation burden was defined as the area under the C‑reactive protein (CRP) curve. RESULTS: 174 consecutive patients with infective endocarditis were included (mean age 73 years, 34.5% female). Concomitant spondylodiscitis was present in 32 patients (18%), frequently associated with Streptococcus species (38%). At admission, the mean level of CRP was significantly higher in patients with concomitant spondylodiscitis (p = 0.004). The median CRP area under the curve was significantly higher in spondylodiscitis patients (4.2 x 10(6) min.mg/l [1.2 x 10(5) - 1.6 x 10(7) min.mg/l] vs 2.0 x 10(6) min.mg/l [8.7 x 10(4) - 1.6 x 10(7) min.mg/l], p < 0.001). This difference remained during the whole treatment period. At 6 months of follow-up, rates of mortality and relapse of infective endocarditis were not significantly different. CONCLUSION: The prevalence of spondylodiscitis in non-referred patients with infective endocarditis was 18%. Endocarditis patients with spondylodiscitis had an increased inflammation burden at and during admission. This difference in normalisation of CRP levels was particularly apparent in the final phase of antibiotic treatment but not related to infectious complications. Despite an augmented inflammation burden, spondylodiscitis was not associated with mortality, cardiac surgery or infectious relapse. CI - (c) 2024. The Author(s). FAU - Ulas, Esen AU - Ulas E AD - Department of Cardiology, Northwest Clinics, Alkmaar, The Netherlands. FAU - Duffels, Marielle AU - Duffels M AD - Department of Cardiology, Northwest Clinics, Alkmaar, The Netherlands. FAU - Drexhage, Olivier AU - Drexhage O AD - Department of Cardiology, Northwest Clinics, Alkmaar, The Netherlands. FAU - Germans, Tjeerd AU - Germans T AD - Department of Cardiology, Northwest Clinics, Alkmaar, The Netherlands. FAU - Wagenaar, Jiri AU - Wagenaar J AD - Department of Infectious Diseases, Northwest Clinics, Alkmaar, The Netherlands. FAU - Umans, Victor AU - Umans V AUID- ORCID: 0000-0002-5587-9097 AD - Department of Cardiology, Northwest Clinics, Alkmaar, The Netherlands. v.a.w.m.umans@nwz.nl. LA - eng PT - Journal Article DEP - 20241105 PL - Netherlands TA - Neth Heart J JT - Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation JID - 101095458 PMC - PMC11584835 OTO - NOTNLM OT - Infective endocarditis OT - Inflammation OT - Spondylodiscitis COIS- Conflict of interest: E. Ulas, M. Duffels, O. Drexhage, T. Germans, J. Wagenaar and V. Umans declare that they have no competing interests. EDAT- 2024/11/05 19:20 MHDA- 2024/11/05 19:21 PMCR- 2024/11/05 CRDT- 2024/11/05 11:22 PHST- 2024/09/26 00:00 [accepted] PHST- 2024/11/05 19:21 [medline] PHST- 2024/11/05 19:20 [pubmed] PHST- 2024/11/05 11:22 [entrez] PHST- 2024/11/05 00:00 [pmc-release] AID - 10.1007/s12471-024-01908-1 [pii] AID - 1908 [pii] AID - 10.1007/s12471-024-01908-1 [doi] PST - ppublish SO - Neth Heart J. 2024 Dec;32(12):455-461. doi: 10.1007/s12471-024-01908-1. Epub 2024 Nov 5. PMID- 39499284 OWN - NLM STAT- MEDLINE DCOM- 20251103 LR - 20251106 IS - 1432-1971 (Electronic) IS - 0172-0643 (Print) IS - 0172-0643 (Linking) VI - 46 IP - 8 DP - 2025 Dec TI - Associations Between Exercise Capacity and Psychological Functioning in Children and Adolescents with Fontan Circulation. PG - 2482-2488 LID - 10.1007/s00246-024-03701-8 [doi] AB - Individuals with Fontan circulation (FC) often have diminished exercise capacity and are at risk for psychological problems. The current study examines associations between exercise capacity and psychological functioning in children and adolescents with FC. A multidisciplinary team evaluated participants in a clinic for pediatric patients with FC. Participants completed cardiopulmonary exercise testing (CPET). Parent and child were administered a psychological questionnaire (BASC-3) to measure child depression, anxiety, and inattention symptoms. Individuals who completed CPET with adequate effort and a psychological measure were eligible for inclusion. Clinical sample (n = 51) was 55% male with a mean age of 13.6 years (SD = 2.5). A majority had hypoplastic left heart syndrome (51%). Parent-report of inattention was negatively correlated with peak VO2 (R = - .307, 95% CI - .549/ - .018, P = 0.038). Self-report of anxiety was positively correlated with HR recovery at 3 (R = .438, 95% CI .155/.655, P = 0.004) and 8 (R = .432, 95% CI .147/.651, P = 0.004) minutes post exercise. Depression was positively correlated with HR recovery at 3 min for parent-report (R = .294, 95% CI .004/.538, P = 0.047) and 8 min for self-report (R = .410, 95% CI .122/.635, P = 0.007). Greater inattention may have negatively impacted CPET engagement, reflected in lower peak VO2. The more rapid decline from max HR to recovery for those with greater depression and anxiety symptoms was unexpected, perhaps explained by a reduction in anxiety state after exercise or possibly an age effect, as a blunted HR decline has been found in adult cardiac patients with depression/anxiety. CI - (c) 2024. The Author(s). FAU - Seivert, Nicholas P AU - Seivert NP AD - Department of Child & Adolescent Psychiatry & Behavioral Sciences, Children's Hospital of Philadelphia, Philadelphia, USA. seivertn@chop.edu. AD - Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA. seivertn@chop.edu. FAU - Dodds, Kathryn M AU - Dodds KM AD - Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA. AD - Cardiac Center, Children's Hospital of Philadelphia, Philadelphia, USA. FAU - O'Malley, Shannon AU - O'Malley S AD - Cardiac Center, Children's Hospital of Philadelphia, Philadelphia, USA. FAU - Goldberg, David J AU - Goldberg DJ AD - Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA. AD - Cardiac Center, Children's Hospital of Philadelphia, Philadelphia, USA. FAU - Paridon, Stephen AU - Paridon S AD - Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA. AD - Cardiac Center, Children's Hospital of Philadelphia, Philadelphia, USA. FAU - McBride, Michael AU - McBride M AD - Cardiac Center, Children's Hospital of Philadelphia, Philadelphia, USA. FAU - Rychik, Jack AU - Rychik J AD - Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA. AD - Cardiac Center, Children's Hospital of Philadelphia, Philadelphia, USA. LA - eng PT - Journal Article DEP - 20241105 PL - United States TA - Pediatr Cardiol JT - Pediatric cardiology JID - 8003849 SB - IM MH - Humans MH - Male MH - Female MH - *Fontan Procedure/psychology MH - Adolescent MH - Child MH - Exercise Test MH - *Exercise Tolerance/physiology MH - *Anxiety/psychology MH - *Depression/psychology MH - *Heart Defects, Congenital/psychology/surgery/physiopathology MH - Surveys and Questionnaires MH - *Hypoplastic Left Heart Syndrome/surgery/psychology/physiopathology PMC - PMC12583415 OTO - NOTNLM OT - CPET OT - Congenital heart disease OT - Mental health OT - Multidisciplinary OT - Physical activity OT - Single ventricle COIS- Declarations. Competing interest: The authors declare no competing interests. Ethical Approval: This retrospective chart review study was approved by the Children's Hospital of Philadelphia Institutional Review Board as "exempt." EDAT- 2024/11/05 19:20 MHDA- 2025/11/03 18:31 PMCR- 2024/11/05 CRDT- 2024/11/05 11:14 PHST- 2024/08/19 00:00 [received] PHST- 2024/10/25 00:00 [accepted] PHST- 2025/11/03 18:31 [medline] PHST- 2024/11/05 19:20 [pubmed] PHST- 2024/11/05 11:14 [entrez] PHST- 2024/11/05 00:00 [pmc-release] AID - 10.1007/s00246-024-03701-8 [pii] AID - 3701 [pii] AID - 10.1007/s00246-024-03701-8 [doi] PST - ppublish SO - Pediatr Cardiol. 2025 Dec;46(8):2482-2488. doi: 10.1007/s00246-024-03701-8. Epub 2024 Nov 5. PMID- 39499123 OWN - NLM STAT- MEDLINE DCOM- 20250113 LR - 20250516 IS - 1827-1898 (Electronic) IS - 0031-0808 (Linking) VI - 66 IP - 4 DP - 2024 Dec TI - Tricuspid regurgitation: a contemporary review. PG - 392-407 LID - 10.23736/S0031-0808.24.05216-9 [doi] AB - Tricuspid regurgitation (TR), an underrecognized disease, overlooked by clinicians for many years due to its assumed benign nature. Recent epidemiological studies suggest significant TR may be seen in up to 6% of elderly patients. An increase in prevalence is expected due to the higher incidence of various clinical predictors of TR progression. Increasing severity of TR is associated with worse outcomes with a novel morphologic classification providing a more refined prediction of outcomes. Advances in cardiac imaging, particularly echocardiography, are integral to the diagnosis of disease severity which not only includes quantitation of TR, but also an assessment of the right atrium, right ventricle and pulmonary arterial circulation. Once identified and quantified, TR management requires a multi-disciplinary heart team management including structural imagers, heart failure specialists, electrophysiologist, cardiac surgeons and interventionalists. Data to support medical therapies are lacking although guidelines support the management of congestive signs and symptoms, as well as comorbidities such as left heart failure and rhythm management. The risks of surgical interventions are slowly improving, however, transcatheter therapies are now available to treat patients with high surgical risk. This manuscript will provide a state-of-art review of this fast-moving field, including current scientific evidences, but also upcoming perspectives with multiple ongoing clinical studies. FAU - LE Ruz, Robin AU - LE Ruz R AD - Department of Interventional Cardiology, Institut du Thorax, University Hospital Center of Nantes, University of Nantes, Nantes, France. AD - Institut du Thorax, University Hospital Center of Nantes, University of Nantes, Nantes, France. AD - Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA. FAU - Hahn, Rebecca T AU - Hahn RT AD - Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA - rth2@columbia.edu. LA - eng PT - Journal Article PT - Review DEP - 20241105 PL - Italy TA - Panminerva Med JT - Panminerva medica JID - 0421110 SB - IM MH - Humans MH - *Tricuspid Valve Insufficiency/therapy/epidemiology/physiopathology/diagnosis/diagnostic imaging MH - *Tricuspid Valve/physiopathology/diagnostic imaging/surgery MH - Echocardiography MH - Risk Factors MH - Severity of Illness Index MH - Treatment Outcome EDAT- 2024/11/05 19:20 MHDA- 2025/01/13 12:36 CRDT- 2024/11/05 09:25 PHST- 2025/01/13 12:36 [medline] PHST- 2024/11/05 19:20 [pubmed] PHST- 2024/11/05 09:25 [entrez] AID - S0031-0808.24.05216-9 [pii] AID - 10.23736/S0031-0808.24.05216-9 [doi] PST - ppublish SO - Panminerva Med. 2024 Dec;66(4):392-407. doi: 10.23736/S0031-0808.24.05216-9. Epub 2024 Nov 5. PMID- 39498851 OWN - NLM STAT- MEDLINE DCOM- 20241105 LR - 20250429 IS - 1531-7013 (Electronic) IS - 1087-2418 (Linking) VI - 29 IP - 6 DP - 2024 Dec 1 TI - Collaborative care models in adult congenital heart disease transplant. PG - 420-427 LID - 10.1097/MOT.0000000000001173 [doi] AB - PURPOSE OF REVIEW: While multidisciplinary collaboration is a tenant of quality heart failure care and critical to the success of transplant programs, this essay challenges the temptation to shoehorn adult congenital heart disease (ACHD) patients into preexisting processes and paradigms. We explore the development of more relevant models, purposefully designed to improve ACHD transplant volumes and outcomes. RECENT FINDINGS: Globally, the rapid acceleration of ACHD patients living with and dying from HF stands in stark contrast to their access to transplant. Inferior early outcomes after ACHD transplant remain an undeniable barrier. And yet while all large registry datasets attest to this statistic, a few centers have achieved results comparable to those in acquired heart disease. This despite increases in both ACHD candidate complexity and referrals for Fontan Circulatory Failure. Perhaps something in their approach to care delivery is key?. SUMMARY: Alone, neither ACHD nor transplant programs can provide optimal management of HF in ACHD. A siloed approach is similarly inadequate. Building new ACHD-HF-Transplant teams, centered on the patient and supplemented by ad hoc expert partnerships, is an exciting approach that can improve outcomes, create a high-quality training environment, and in our experience, is a truly rewarding way of working together. CI - Copyright (c) 2024 Wolters Kluwer Health, Inc. All rights reserved. FAU - Kearney, Katherine AU - Kearney K AD - University Health Network, Peter Munk Cardiac Centre, Toronto ACHD Program. AD - Temertry Faculty of Medicine, University of Toronto. FAU - McDonald, Michael AU - McDonald M AD - Temertry Faculty of Medicine, University of Toronto. AD - University Health Network, Peter Munk Cardiac Centre, Ajmera Transplant Centre, Heart Transplant Program, Toronto, Ontario, Canada. FAU - Roche, Lucy AU - Roche L AD - University Health Network, Peter Munk Cardiac Centre, Toronto ACHD Program. AD - Temertry Faculty of Medicine, University of Toronto. LA - eng PT - Journal Article PT - Review DEP - 20240916 PL - United States TA - Curr Opin Organ Transplant JT - Current opinion in organ transplantation JID - 9717388 SB - IM MH - Humans MH - *Heart Defects, Congenital/surgery MH - *Patient Care Team/organization & administration MH - *Heart Transplantation MH - Adult MH - Heart Failure/surgery/therapy MH - Treatment Outcome MH - Delivery of Health Care, Integrated/organization & administration MH - Models, Organizational EDAT- 2024/11/05 17:02 MHDA- 2024/11/05 19:20 CRDT- 2024/11/05 07:04 PHST- 2024/11/05 19:20 [medline] PHST- 2024/11/05 17:02 [pubmed] PHST- 2024/11/05 07:04 [entrez] AID - 00075200-202412000-00012 [pii] AID - 10.1097/MOT.0000000000001173 [doi] PST - ppublish SO - Curr Opin Organ Transplant. 2024 Dec 1;29(6):420-427. doi: 10.1097/MOT.0000000000001173. Epub 2024 Sep 16. PMID- 39491599 OWN - NLM STAT- MEDLINE DCOM- 20241213 LR - 20260518 IS - 1872-7913 (Electronic) IS - 0924-8579 (Linking) VI - 64 IP - 6 DP - 2024 Dec TI - Access to phage therapy at Hospices Civils de Lyon in 2022: Implementation of the PHAGEinLYON Clinic programme. PG - 107372 LID - S0924-8579(24)00288-7 [pii] LID - 10.1016/j.ijantimicag.2024.107372 [doi] AB - OBJECTIVES: To describe the PHAGEinLYON Clinic programme, set up in 2022 to improve access to phage therapy in France using pharmaceutical-grade phages. METHODS: All phage therapy requests received during 2022 were collected prospectively, and reviewed retrospectively to analyse the decision and the patient care pathway (NCT05883995). RESULTS: Of 143 requests for phage therapy, the indication was confirmed at a multidisciplinary team meeting for 57 (40%) patients. Forty-four patients were infected with bacteria that could be targeted easily by phages in France. Finally, 33 patients were treated, including 26 at the study institution, through a compassionate access programme or in a clinical trial. The main indication were complex bone and joint infections, endovascular infection and lung infection. In order to manage these patients, 172 pharmaceutical phage cocktails targeting Staphylococcus aureus and/or Pseudomonas aeruginosa were prepared: 57 for local injection and 99 for intravenous injection. During follow-up, 18 (69%) patients showed a favourable clinical evolution, and six (23%) patients required subsequent phage therapy, either with the same phage with greater exposure, or with a different phage from elsewhere. CONCLUSIONS: Implementation of the PHAGEinLYON Clinic programme in 2022 was associated with groundbreaking access to phage therapy in France. CI - Copyright (c) 2024 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Ferry, Tristan AU - Ferry T AD - Service de Maladies Infectieuses et Tropicales, Hopital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France; Universite Claude Bernard Lyon 1, Villeurbanne, France; Centre de References des IOA Complexes de Lyon, Lyon, France; Laboratoire de Biometrie et Biologie Evolutive, CNRS, UMR 5558, Universite Lyon 1, Villeurbanne, France. Electronic address: tristan.ferry@univ-lyon1.fr. FAU - Bouar, Myrtille Le AU - Bouar ML AD - Service de Maladies Infectieuses et Tropicales, Hopital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France. FAU - Briot, Thomas AU - Briot T AD - Pharmacie Hospitaliere, Hopital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France. FAU - Roussel-Gaillard, Tiphaine AU - Roussel-Gaillard T AD - Laboratoire de Bacteriologie, Institut des Agents Infectieux, Hopital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France. FAU - Perpoint, Thomas AU - Perpoint T AD - Service de Maladies Infectieuses et Tropicales, Hopital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France; Centre de References des IOA Complexes de Lyon, Lyon, France. FAU - Roux, Sandrine AU - Roux S AD - Service de Maladies Infectieuses et Tropicales, Hopital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France; Centre de References des IOA Complexes de Lyon, Lyon, France. FAU - Ader, Florence AU - Ader F AD - Service de Maladies Infectieuses et Tropicales, Hopital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France; Universite Claude Bernard Lyon 1, Villeurbanne, France; Centre de References des IOA Complexes de Lyon, Lyon, France; Laboratoire de Biometrie et Biologie Evolutive, CNRS, UMR 5558, Universite Lyon 1, Villeurbanne, France. FAU - Valour, Florent AU - Valour F AD - Service de Maladies Infectieuses et Tropicales, Hopital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France; Universite Claude Bernard Lyon 1, Villeurbanne, France; Centre de References des IOA Complexes de Lyon, Lyon, France; Laboratoire de Biometrie et Biologie Evolutive, CNRS, UMR 5558, Universite Lyon 1, Villeurbanne, France. FAU - Kassai, Behrouz AU - Kassai B AD - Clinical Investigation Centre, Inserm-Hospices Civils de Lyon, Bron, France. FAU - Boussaha, Inesse AU - Boussaha I AD - Clinical Investigation Centre, Inserm-Hospices Civils de Lyon, Bron, France. FAU - Ndiaye, Marietou AU - Ndiaye M AD - Clinical Investigation Centre, Inserm-Hospices Civils de Lyon, Bron, France. FAU - Craighero, Fabien AU - Craighero F AD - Service de Radiologie, Hopital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France. FAU - Javaux, Clement AU - Javaux C AD - Service de Maladies Infectieuses et Tropicales, Hopital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France. FAU - Lustig, Sebastien AU - Lustig S AD - Service de Chirurgie Orthopedique et de Medecine du Sport, Hopital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France. FAU - Batailler, Cecile AU - Batailler C AD - Service de Chirurgie Orthopedique et de Medecine du Sport, Hopital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France. CN - PHAGEinLYON Clinic Study Group LA - eng SI - ClinicalTrials.gov/NCT05883995 PT - Journal Article PT - Observational Study DEP - 20241102 PL - Netherlands TA - Int J Antimicrob Agents JT - International journal of antimicrobial agents JID - 9111860 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Female MH - Humans MH - Male MH - Middle Aged MH - Compassionate Use Trials MH - France MH - Hospices MH - *Phage Therapy/methods MH - Prospective Studies MH - *Pseudomonas aeruginosa/virology MH - Pseudomonas Infections/therapy MH - Retrospective Studies MH - Staphylococcal Infections/therapy MH - Staphylococcus aureus/virology OTO - NOTNLM OT - Bacteriophage OT - Endocarditis OT - Lung infection OT - Phage therapy OT - Prosthetic joint infection FIR - Ferry, Tristan IR - Ferry T FIR - Le Bouar, Myrtille IR - Le Bouar M FIR - Briot, Thomas IR - Briot T FIR - Roussel-Gaillard, Tiphaine IR - Roussel-Gaillard T FIR - Perpoint, Thomas IR - Perpoint T FIR - Roux, Sandrine IR - Roux S FIR - Valour, Florent IR - Valour F FIR - Javaux, Clement IR - Javaux C FIR - Wan, Marie IR - Wan M FIR - Conrad, Anne IR - Conrad A FIR - Becker, Agathe IR - Becker A FIR - Triffault-Fillit, Claire IR - Triffault-Fillit C FIR - Simon, Marie IR - Simon M FIR - Braun, Evelyne IR - Braun E FIR - Van der Bogaart, Lorena IR - Van der Bogaart L FIR - Chauvelot, Pierre IR - Chauvelot P FIR - Bahuaud, Olivier IR - Bahuaud O FIR - Landre, Sophie IR - Landre S FIR - Soueges, Sarah IR - Soueges S FIR - Eberl, Isabelle IR - Eberl I FIR - Dallosto, Karine IR - Dallosto K FIR - Boulant, Johanna IR - Boulant J FIR - Marrocco, Nathalie IR - Marrocco N FIR - Ader, Florence IR - Ader F FIR - Lustig, Sebastien IR - Lustig S FIR - Batailler, Cecile IR - Batailler C FIR - Schmidt, Axel IR - Schmidt A FIR - Craighero, Fabien IR - Craighero F FIR - Fleury, Andrea IR - Fleury A FIR - El-Ameen, Ali IR - El-Ameen A FIR - Schleef, Arnaud IR - Schleef A FIR - Miailhes, Jade IR - Miailhes J FIR - Fustier, Anne IR - Fustier A FIR - Himpens, Paul-Henri IR - Himpens PH FIR - Boussel, Loic IR - Boussel L FIR - Buisson, Marielle IR - Buisson M FIR - Boussaha, Inesse IR - Boussaha I FIR - Kassai, Berhouz IR - Kassai B EDAT- 2024/11/04 06:22 MHDA- 2024/12/14 00:24 CRDT- 2024/11/04 01:20 PHST- 2024/07/08 00:00 [received] PHST- 2024/10/12 00:00 [revised] PHST- 2024/10/24 00:00 [accepted] PHST- 2024/12/14 00:24 [medline] PHST- 2024/11/04 06:22 [pubmed] PHST- 2024/11/04 01:20 [entrez] AID - S0924-8579(24)00288-7 [pii] AID - 10.1016/j.ijantimicag.2024.107372 [doi] PST - ppublish SO - Int J Antimicrob Agents. 2024 Dec;64(6):107372. doi: 10.1016/j.ijantimicag.2024.107372. Epub 2024 Nov 2. PMID- 39490254 OWN - NLM STAT- MEDLINE DCOM- 20250425 LR - 20250516 IS - 1532-7361 (Electronic) IS - 0039-6060 (Linking) VI - 179 DP - 2025 Mar TI - Gastrointestinal complications requiring operative intervention after cardiovascular surgery: Predictors of in-hospital mortality. PG - 108899 LID - S0039-6060(24)00836-5 [pii] LID - 10.1016/j.surg.2024.07.091 [doi] AB - BACKGROUND: Risk factors for in-hospital mortality related to gastrointestinal complications requiring operative intervention after cardiovascular surgery have not been previously described. METHODS: Adult patients who underwent cardiovascular surgery followed by gastrointestinal surgery during the same admission between January 2010 and June 2023 were included. Multivariable logistic regression was used to identify predictors of in-hospital mortality. Kaplan-Meier survival analysis was performed to assess overall survival based on identified risk factors. RESULTS: Gastrointestinal complications requiring operative intervention after cardiac surgery occurred in 151 patients, with an overall in-hospital mortality of 35.76% (n = 54). The most common diagnosis was bowel ischemia (50.33%). On multivariable logistic regression, the history of cirrhosis (odds ratio: 37.96, 95% confidence interval: 3.57-543.90) and the clinical condition at the time of emergency general surgery consultation, described by elevated lactate (odds ratio: 5.76, 95% confidence interval: 1.71-22.82), platelets <50 x 10(9)/L (odds ratio: 11.34, 95% confidence interval: 1.60-162.37), >/=3 vasoactive medications (odds ratio: 4.93, 95% CI: 1.29-20.14), and the need for renal replacement therapy (odds ratio: 5.18, 95% confidence interval: 1.46-20.79) were predictive of in-hospital mortality. In-hospital mortality was low when none of the risk factors identified on multivariable analysis were present (2.38%, n = 1 of 42), but in-hospital mortality was universal among patients with 4-5 risk factors (100%, n = 8 of 8). CONCLUSIONS: Gastrointestinal complications after cardiac surgery are disastrous when patient illness becomes severe. Clinicians should maintain a high index of suspicion for gastrointestinal complications to promote early involvement of general surgery. Knowledge of these risk factors could help guide discussions among the multidisciplinary care team, patients, and their families. CI - Copyright (c) 2024 Elsevier Inc. All rights reserved. FAU - Gross, Abby AU - Gross A AD - Department of General Surgery, Digestive Disease Institute, Cleveland Clinic, OH. Electronic address: grossa8@ccf.org. FAU - Larson, Sarah L AU - Larson SL AD - Department of General Surgery, Digestive Disease Institute, Cleveland Clinic, OH. FAU - Wehrle, Chase J AU - Wehrle CJ AD - Department of General Surgery, Digestive Disease Institute, Cleveland Clinic, OH. FAU - Izda, Aleksandar AU - Izda A AD - Department of General Surgery, Digestive Disease Institute, Cleveland Clinic, OH. FAU - Quick, Joseph D AU - Quick JD AD - Department of General Surgery, Digestive Disease Institute, Cleveland Clinic, OH. FAU - Ellis, Ryan AU - Ellis R AD - Department of General Surgery, Digestive Disease Institute, Cleveland Clinic, OH. FAU - Simon, Robert AU - Simon R AD - Department of General Surgery, Digestive Disease Institute, Cleveland Clinic, OH. Electronic address: https://twitter.com/pancreas_eraser. LA - eng PT - Journal Article DEP - 20241026 PL - United States TA - Surgery JT - Surgery JID - 0417347 SB - IM MH - Humans MH - Male MH - Female MH - *Hospital Mortality MH - Aged MH - Middle Aged MH - *Gastrointestinal Diseases/mortality/surgery/etiology MH - Risk Factors MH - *Postoperative Complications/mortality/surgery/etiology MH - Retrospective Studies MH - *Digestive System Surgical Procedures MH - *Cardiac Surgical Procedures/adverse effects MH - *Cardiovascular Surgical Procedures/adverse effects MH - Aged, 80 and over COIS- Conflict of Interest/Disclosure The authors have no related conflicts of interest to declare. EDAT- 2024/11/04 00:31 MHDA- 2025/02/01 20:43 CRDT- 2024/11/03 23:40 PHST- 2024/05/05 00:00 [received] PHST- 2024/06/30 00:00 [revised] PHST- 2024/07/09 00:00 [accepted] PHST- 2025/02/01 20:43 [medline] PHST- 2024/11/04 00:31 [pubmed] PHST- 2024/11/03 23:40 [entrez] AID - S0039-6060(24)00836-5 [pii] AID - 10.1016/j.surg.2024.07.091 [doi] PST - ppublish SO - Surgery. 2025 Mar;179:108899. doi: 10.1016/j.surg.2024.07.091. Epub 2024 Oct 26. PMID- 39481823 OWN - NLM STAT- MEDLINE DCOM- 20250625 LR - 20260505 IS - 1552-6259 (Electronic) IS - 0003-4975 (Linking) VI - 120 IP - 1 DP - 2025 Jul TI - Robotic Aortic Valve Replacement vs Transcatheter Aortic Valve Replacement: A Propensity-Matched Analysis. PG - 62-70 LID - S0003-4975(24)00921-4 [pii] LID - 10.1016/j.athoracsur.2024.10.013 [doi] AB - BACKGROUND: Current evidence supports equipoise between surgical aortic valve replacement (AVR) and transcatheter AVR (TAVR) for the management of symptomatic severe aortic stenosis (AS). The optimal interventional management for lower-risk patients is controversial. Minimally invasive robotic AVR (RAVR) was developed as a potential option. METHODS: A total of 605 consecutive patients (2017-2023) managed by the identical structural heart team, 174 RAVR and 431 TAVR, were propensity matched and evaluated for in-hospital and 1-year outcomes. RESULTS: There were 288 low- to intermediate-risk (The Society of Thoracic Surgeons predicted risk of mortality <8%) patients matched in 2 well-balanced groups (144 RAVR vs 144 TAVR). In-hospital and 30-day mortality were similar. There were 2 conversions to sternotomy in the TAVR group (cardiac arrest and coronary occlusion) and none in the RAVR group. Eight RAVR patients (5.6%) required reoperation for hemothorax evacuation. TAVR was associated with higher new pacemaker (11 vs 3, P = .028) and major vascular complications (13 vs 0, P < .0001), and a higher postprocedural stroke trend (6 vs 1, P = .056). There was no difference in 30-day transfusions, atrial fibrillation, or 1-year mean valve gradients. However, 1-year mortality (12.5% vs 1.4%, P < .0001) and paravalvular leak greater than mild (32.6% vs 2.3%, P < 0.0001) were significantly higher in TAVR. CONCLUSIONS: These data highlight lower pacemaker and vascular complications, as well as less 1-year paravalvular leak and mortality with RAVR compared with TAVR. RAVR may provide a safe and effective minimally invasive alternative to TAVR for low- and intermediate-risk patients presenting with severe symptomatic AS. CI - Copyright (c) 2025 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved. FAU - Jagadeesan, Vikrant AU - Jagadeesan V AD - Department of Cardiology, West Virginia University, Morgantown, West Virginia. FAU - Mehaffey, J Hunter AU - Mehaffey JH AD - Department of Cardiovascular and Thoracic Surgery, West Virginia University, Morgantown, West Virginia. FAU - Darehzereshki, Ali AU - Darehzereshki A AD - Department of Cardiovascular and Thoracic Surgery, West Virginia University, Morgantown, West Virginia. FAU - Alharbi, Anas AU - Alharbi A AD - Department of Cardiology, West Virginia University, Morgantown, West Virginia. FAU - Kawsara, Mohammad AU - Kawsara M AD - Department of Cardiology, West Virginia University, Morgantown, West Virginia. FAU - Daggubati, Ramesh AU - Daggubati R AD - Department of Cardiology, West Virginia University, Morgantown, West Virginia. FAU - Wei, Lawrence AU - Wei L AD - Department of Cardiovascular and Thoracic Surgery, West Virginia University, Morgantown, West Virginia. FAU - Badhwar, Vinay AU - Badhwar V AD - Department of Cardiovascular and Thoracic Surgery, West Virginia University, Morgantown, West Virginia. Electronic address: vinay.badhwar@wvumedicine.org. LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20241030 PL - Netherlands TA - Ann Thorac Surg JT - The Annals of thoracic surgery JID - 15030100R SB - IM MH - Humans MH - *Transcatheter Aortic Valve Replacement/methods MH - Female MH - Male MH - *Propensity Score MH - *Aortic Valve Stenosis/surgery/mortality MH - *Robotic Surgical Procedures/methods MH - Aged, 80 and over MH - Retrospective Studies MH - Aged MH - Treatment Outcome MH - *Aortic Valve/surgery MH - Postoperative Complications/epidemiology MH - Hospital Mortality/trends MH - *Heart Valve Prosthesis Implantation/methods COIS- Disclosures The authors have no conflicts of interest to disclose. EDAT- 2024/11/01 00:22 MHDA- 2025/06/26 00:27 CRDT- 2024/10/31 20:31 PHST- 2024/04/07 00:00 [received] PHST- 2024/10/09 00:00 [revised] PHST- 2024/10/21 00:00 [accepted] PHST- 2025/06/26 00:27 [medline] PHST- 2024/11/01 00:22 [pubmed] PHST- 2024/10/31 20:31 [entrez] AID - S0003-4975(24)00921-4 [pii] AID - 10.1016/j.athoracsur.2024.10.013 [doi] PST - ppublish SO - Ann Thorac Surg. 2025 Jul;120(1):62-70. doi: 10.1016/j.athoracsur.2024.10.013. Epub 2024 Oct 30. PMID- 39479521 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241121 IS - 2472-1972 (Electronic) IS - 2472-1972 (Linking) VI - 8 IP - 12 DP - 2024 Oct 29 TI - Acquired Partial Lipodystrophy: Clinical Management in a Pregnant Patient. PG - bvae181 LID - 10.1210/jendso/bvae181 [doi] LID - bvae181 AB - BACKGROUND: Pregnancy represents an additional challenge to the complex clinical picture of lipodystrophy disorders, and the management of such conditions with related comorbidities has been underreported. This work aims to outline the risk associated with a pregnancy event for women dealing with acquired partial lipodystrophy and the need for diverse but specialized care. CASE: We report on the successful pregnancy outcome of a 28-year-old woman with an acquired partial form of lipodystrophy related to an allogenic bone marrow transplant that occurred at pediatric age. Although metabolic control was challenging, glucose levels progressively improved during the pregnancy, and triglycerides increased less than expected. The periodic monitoring of leptin levels showed a progressive increase with a peak in the third trimester (41.53 ng/mL), followed by a fast decline the day after giving birth, with a lower basal level than the prepregnancy period. However, preterm delivery occurred associated with cardiac complications in the mother. RESULTS: A total of 12 studies were retrieved concerning women aged 14 to 38 years with various lipodystrophy phenotypes. Diabetes and hypertriglyceridemia were the most common comorbidities. Most women had successful pregnancies despite gestational complications (including miscarriages), preterm and emergency deliveries, and newborns undergoing partum or postpartum transient or chronic complications. CONCLUSION: Lipodystrophy disorders expose both mothers and children to very high risk. Intensive monitoring and care of all potential clinical complications should be planned and carried out by a multidisciplinary team before, during, and after the pregnancy. Leptin secretion during pregnancy should be investigated more deeply in these patients. CI - (c) The Author(s) 2024. Published by Oxford University Press on behalf of the Endocrine Society. FAU - Romanisio, Martina AU - Romanisio M AD - Endocrinology, Department of Translational Medicine, Universita del Piemonte Orientale, Novara 28100, Italy. FAU - Bighetti, Leonardo AU - Bighetti L AD - Endocrinology, Department of Translational Medicine, Universita del Piemonte Orientale, Novara 28100, Italy. FAU - Daffara, Tommaso AU - Daffara T AD - Endocrinology, Department of Translational Medicine, Universita del Piemonte Orientale, Novara 28100, Italy. FAU - Mollero, Edoardo Luigi Maria AU - Mollero ELM AD - Endocrinology, Department of Translational Medicine, Universita del Piemonte Orientale, Novara 28100, Italy. FAU - Pelosini, Caterina AU - Pelosini C AD - Chemistry and Endocrinology Laboratory, Department of Laboratory Medicine, University Hospital of Pisa, Pisa 56126, Italy. FAU - Antoniotti, Valentina AU - Antoniotti V AD - Endocrinology, Department of Translational Medicine, Universita del Piemonte Orientale, Novara 28100, Italy. AD - Department of Health Sciences, Universita del Piemonte Orientale, Novara 28100, Italy. FAU - Ciamparini, Carola AU - Ciamparini C AD - Endocrinology, Department of Translational Medicine, Universita del Piemonte Orientale, Novara 28100, Italy. FAU - Aimaretti, Gianluca AU - Aimaretti G AD - Endocrinology, Department of Translational Medicine, Universita del Piemonte Orientale, Novara 28100, Italy. FAU - Caputo, Marina AU - Caputo M AD - Endocrinology, Department of Translational Medicine, Universita del Piemonte Orientale, Novara 28100, Italy. AD - Department of Health Sciences, Universita del Piemonte Orientale, Novara 28100, Italy. FAU - Prodam, Flavia AU - Prodam F AUID- ORCID: 0000-0001-9660-5335 AD - Endocrinology, Department of Translational Medicine, Universita del Piemonte Orientale, Novara 28100, Italy. AD - Department of Health Sciences, Universita del Piemonte Orientale, Novara 28100, Italy. LA - eng PT - Journal Article PT - Review DEP - 20241021 PL - United States TA - J Endocr Soc JT - Journal of the Endocrine Society JID - 101697997 PMC - PMC11521335 OTO - NOTNLM OT - acquired partial lipodystrophy OT - glucose levels OT - leptin levels OT - pregnancy OT - triglycerides EDAT- 2024/10/31 10:18 MHDA- 2024/10/31 10:19 PMCR- 2024/10/21 CRDT- 2024/10/31 04:57 PHST- 2024/08/06 00:00 [received] PHST- 2024/10/31 10:19 [medline] PHST- 2024/10/31 10:18 [pubmed] PHST- 2024/10/31 04:57 [entrez] PHST- 2024/10/21 00:00 [pmc-release] AID - bvae181 [pii] AID - 10.1210/jendso/bvae181 [doi] PST - epublish SO - J Endocr Soc. 2024 Oct 21;8(12):bvae181. doi: 10.1210/jendso/bvae181. eCollection 2024 Oct 29. PMID- 39475333 OWN - NLM STAT- MEDLINE DCOM- 20250212 LR - 20260910 IS - 2380-6591 (Electronic) IS - 2380-6583 (Print) VI - 10 IP - 2 DP - 2025 Feb 1 TI - Outcomes of Balloon-Expandable Transcatheter Aortic Valve Replacement in Younger Patients in the Low-Risk Era. PG - 127-135 LID - 10.1001/jamacardio.2024.4237 [doi] AB - IMPORTANCE: Guidelines advise heart team assessment for all patients with aortic stenosis, with surgical aortic valve replacement recommended for patients younger than 65 years or with a life expectancy greater than 20 years. If bioprosthetic valves are selected, repeat procedures may be needed given limited durability of tissue valves; however, younger patients with aortic stenosis may have major comorbidities that can limit life expectancy, impacting decision-making. OBJECTIVE: To characterize patients younger than 65 years who received transcatheter aortic valve replacement (TAVR) and compare their outcomes with patients aged 65 to 80 years. DESIGN, SETTING, AND PARTICIPANTS: This retrospective registry-based analysis used data on 139 695 patients from the Society for Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy (TVT) Registry, inclusive of patients 80 years and younger undergoing TAVR from August 2019 to September 2023. INTERVENTION: Balloon-expandable valve (BEV) TAVR with the SAPIEN family of devices. MAIN OUTCOMES AND MEASURES: Comorbidities (heart failure, coronary artery disease, dialysis, and others) and outcomes (death, stroke, and hospital readmission) of patients younger than 65 years compared to patients aged 65 to 80 years. RESULTS: In the years surveyed, 13 849 registry patients (5.7%) were younger than 65 years, 125 846 (52.1%) were aged 65 to 80 years, and 101 725 (42.1%) were 80 years and older. Among those younger than 65, the mean (SD) age was 59.7 (4.8) years, and 9068 of 13 849 patients (65.5%) were male. Among those aged 65 to 80 years, the mean (SD) age was 74.1 (4.2) years, and 77 817 of 125 843 patients (61.8%) were male. Those younger than 65 years were more likely to have a bicuspid aortic valve than those aged 65 to 80 years (3472/13 755 [25.2%] vs 9552/125 001 [7.6%], respectively; P < .001). They were more likely to have congestive heart failure, chronic lung disease, diabetes, immunocompromise, and end stage kidney disease receiving dialysis. Patients younger than 65 years had worse baseline quality of life (mean [SD] Kansas City Cardiomyopathy Questionnaire score, 47.7 [26.3] vs 52.9 [25.8], respectively; P < .001) and mean (SD) gait speed (5-meter walk test, 6.6 [5.8] seconds vs 7.0 [4.9] seconds, respectively; P < .001) than those aged 65 to 80 years. At 1 year, patients younger than 65 years had significantly higher readmission rates (2740 [28.2%] vs 23 178 [26.1%]; P < .001) and all-cause mortality (908 [9.9%] vs 6877 [8.2%]; P < .001) than older patients. When propensity matched, younger patients still had higher 1-year readmission rates (2732 [28.2%] vs 2589 [26.8%]; P < .03) with similar mortality to their older counterparts (905 [9.9%] vs 827 [10.1%]; P = .55). CONCLUSIONS AND RELEVANCE: Among US patients receiving BEV TAVR for severe aortic stenosis in the low-surgical risk era, those younger than 65 years represent a small subset. Patients younger than 65 years had a high burden of comorbidities and incurred higher rates of death and readmission at 1 year compared to their older counterparts. These observations suggest that heart team decision-making regarding TAVR for most patients in this age group is clinically valid. FAU - Coylewright, Megan AU - Coylewright M AD - University of Tennessee Health Science Center, Chattanooga. FAU - Grubb, Kendra J AU - Grubb KJ AD - Emory University, Atlanta, Georgia. FAU - Arnold, Suzanne V AU - Arnold SV AD - Saint Luke's Mid America Heart Institute, Kansas City, Missouri. FAU - Batchelor, Wayne AU - Batchelor W AD - Inova Schar Heart and Vascular, Falls Church, Virginia. FAU - Dhoble, Abhijeet AU - Dhoble A AD - University of Texas Health Science Center, Houston. FAU - Horne, Aaron Jr AU - Horne A Jr AD - Summit Health, Berkeley Heights, New Jersey. FAU - Leon, Martin B AU - Leon MB AD - New York-Presbyterian Hospital/Columbia University Irving Medical Center, New York. AD - Cardiovascular Research Foundation, New York, New York. FAU - Thourani, Vinod AU - Thourani V AD - Department of Cardiovascular Surgery, Marcus Valve Center, Piedmont Heart Institute, Atlanta, Georgia. FAU - Nazif, Tamim M AU - Nazif TM AD - New York-Presbyterian Hospital/Columbia University Irving Medical Center, New York. FAU - Lindman, Brian R AU - Lindman BR AD - Vanderbilt University Medical Center, Nashville, Tennessee. FAU - Szerlip, Molly AU - Szerlip M AD - Baylor Scott and White The Heart Hospital, Plano, Texas. LA - eng PT - Journal Article PL - United States TA - JAMA Cardiol JT - JAMA cardiology JID - 101676033 SB - IM CIN - JAMA Cardiol. 2025 Feb 1;10(2):136. doi: 10.1001/jamacardio.2024.4300. PMID: 39475343 EIN - JAMA Cardiol. 2025 Feb 1;10(2):201. doi: 10.1001/jamacardio.2024.4925. PMID: 39630461 EIN - JAMA Cardiol. 2025 Feb 1;10(2):202. doi: 10.1001/jamacardio.2025.0009. PMID: 39937198 MH - Humans MH - *Transcatheter Aortic Valve Replacement/methods MH - Male MH - Female MH - Aged MH - Aged, 80 and over MH - *Aortic Valve Stenosis/surgery MH - Retrospective Studies MH - Registries MH - Treatment Outcome MH - Age Factors MH - *Heart Valve Prosthesis MH - Aortic Valve/surgery MH - Risk Factors PMC - PMC11525662 COIS- Conflict of Interest Disclosures: Dr Coylewright reported personal fees from Boston Scientific, Edwards Lifesciences, Medtronic, and Alleviant outside the submitted work. Dr Grubb reported personal fees from Medtronic, Abbott, 4C Medical, and Ancora and other from Edwards Lifesciences (institutional educational grant) outside the submitted work. Dr Batchelor reported consulting fees from Edwards, Medtronic, Abbott, and Boston Scientific outside the submitted work. Dr Nazif reported personal fees from Edwards Lifesciences, Medtronic, and Boston Scientific outside the submitted work. Dr Lindman reported personal fees and grants from Edwards Lifesciences and consulting fees from Medtronic (paid to institution) during the conduct of the study and personal fees from Astra Zeneca outside the submitted work. Dr Szerlip reported other from Edwards Lifesciences (consulting), Boston Scientific (advisory board), Abbott (advisory board), and Medtronic (steering committee) during the conduct of the study. No other disclosures were reported. EDAT- 2024/10/30 16:18 MHDA- 2025/02/12 12:27 PMCR- 2024/10/30 CRDT- 2024/10/30 09:32 PHST- 2025/02/12 12:27 [medline] PHST- 2024/10/30 16:18 [pubmed] PHST- 2024/10/30 09:32 [entrez] PHST- 2024/10/30 00:00 [pmc-release] AID - 2825505 [pii] AID - hoi240070 [pii] AID - 10.1001/jamacardio.2024.4237 [doi] PST - ppublish SO - JAMA Cardiol. 2025 Feb 1;10(2):127-135. doi: 10.1001/jamacardio.2024.4237. PMID- 39474849 OWN - NLM STAT- MEDLINE DCOM- 20241227 LR - 20250730 IS - 1477-030X (Electronic) IS - 0269-2163 (Print) IS - 0269-2163 (Linking) VI - 39 IP - 1 DP - 2025 Jan TI - Components of home-based palliative and supportive care for adults with heart failure: A scoping review. PG - 86-98 LID - 10.1177/02692163241290350 [doi] AB - BACKGROUND: Palliative care and supportive care provided in the home for people with heart failure can improve quality of life, caregiver wellbeing and reduce healthcare costs. Identifying components of home-based palliative and supportive care in heart failure is useful to inform tailored care to people with heart failure. AIM: To identify and describe components of home-based palliative and supportive care in adults with heart failure. DESIGN: A scoping review was undertaken in accordance with Joanna Briggs Institute guidelines. The protocol was registered prospectively with the Open Science Framework (https://doi.org/10.17605/OSF.IO/GHCME). DATA SOURCES: Embase, PubMed, CINAHL and Cochrane databases were searched from inception in May 2023 and re-run in January 2024. Original research focussed on palliative and supportive care in the home setting that included adults diagnosed with heart failure who have not undergone nor awaiting a heart transplant was included. RESULTS: Results were extracted from 13 papers based on eight studies. The findings highlight that nurses supported by a multidisciplinary team, providing symptom management, patient and carer education and discussion of goals of care and advance care planning, facilitates home-based palliative and supportive care for people with heart failure. CONCLUSION: Ensuring patient and caregiver-centred care supported by a multidisciplinary team is essential to delivering home-based palliative and supportive care for people with heart failure. Further research focussed on the role of digital interventions in home-based palliative and supportive care, the composition of the multidisciplinary team and research which includes individuals across all stages of heart failure is needed. FAU - Perera, Madhurangi AU - Perera M AUID- ORCID: 0000-0002-6916-9010 AD - Cancer and Palliative Care Outcomes Centre, School of Nursing, Queensland University of Technology, Brisbane, QLD, Australia. AD - Centre for Healthcare Transformation, Faculty of Health, Queensland University of Technology, Brisbane, QLD, Australia. FAU - Halahakone, Ureni AU - Halahakone U AD - Centre for Healthcare Transformation, Faculty of Health, Queensland University of Technology, Brisbane, QLD, Australia. AD - Australian Centre for Health Service Innovation, Queensland University of Technology, Brisbane, QLD, Australia. FAU - Senanayake, Sameera AU - Senanayake S AD - Centre for Healthcare Transformation, Faculty of Health, Queensland University of Technology, Brisbane, QLD, Australia. AD - Australian Centre for Health Service Innovation, Queensland University of Technology, Brisbane, QLD, Australia. AD - Health Services and Systems Research, Duke-NUS Medical School, Singapore, Singapore. AD - National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore, Singapore. FAU - Kularatna, Sanjeewa AU - Kularatna S AD - Centre for Healthcare Transformation, Faculty of Health, Queensland University of Technology, Brisbane, QLD, Australia. AD - Australian Centre for Health Service Innovation, Queensland University of Technology, Brisbane, QLD, Australia. AD - Health Services and Systems Research, Duke-NUS Medical School, Singapore, Singapore. AD - National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore, Singapore. FAU - Parsonage, William AU - Parsonage W AD - Centre for Healthcare Transformation, Faculty of Health, Queensland University of Technology, Brisbane, QLD, Australia. AD - Australian Centre for Health Service Innovation, Queensland University of Technology, Brisbane, QLD, Australia. AD - Department of Cardiology, Royal Brisbane & Women's Hospital, Brisbane, QLD, Australia. FAU - Yates, Patsy AU - Yates P AD - Cancer and Palliative Care Outcomes Centre, School of Nursing, Queensland University of Technology, Brisbane, QLD, Australia. AD - Centre for Healthcare Transformation, Faculty of Health, Queensland University of Technology, Brisbane, QLD, Australia. FAU - Singh, Gursharan K AU - Singh GK AUID- ORCID: 0000-0003-1945-7556 AD - Cancer and Palliative Care Outcomes Centre, School of Nursing, Queensland University of Technology, Brisbane, QLD, Australia. AD - Centre for Healthcare Transformation, Faculty of Health, Queensland University of Technology, Brisbane, QLD, Australia. LA - eng PT - Journal Article PT - Scoping Review DEP - 20241030 PL - England TA - Palliat Med JT - Palliative medicine JID - 8704926 SB - IM MH - Humans MH - *Heart Failure/therapy MH - *Palliative Care MH - *Home Care Services MH - Adult MH - Quality of Life MH - Aged MH - Female MH - Male MH - Middle Aged MH - Aged, 80 and over MH - Caregivers PMC - PMC11673332 OTO - NOTNLM OT - Supportive care OT - heart failure OT - home-based care OT - palliative care OT - scoping review COIS- Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2024/10/30 16:18 MHDA- 2024/12/27 12:20 PMCR- 2024/12/27 CRDT- 2024/10/30 06:23 PHST- 2024/12/27 12:20 [medline] PHST- 2024/10/30 16:18 [pubmed] PHST- 2024/10/30 06:23 [entrez] PHST- 2024/12/27 00:00 [pmc-release] AID - 10.1177_02692163241290350 [pii] AID - 10.1177/02692163241290350 [doi] PST - ppublish SO - Palliat Med. 2025 Jan;39(1):86-98. doi: 10.1177/02692163241290350. Epub 2024 Oct 30. PMID- 39469652 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241030 IS - 2667-2766 (Electronic) IS - 2667-2766 (Linking) VI - 16 DP - 2024 Dec TI - Improving patient safety and access to healthcare: The role of pharmacist-managed clinics in optimizing therapeutic outcomes. PG - 100527 LID - 10.1016/j.rcsop.2024.100527 [doi] LID - 100527 AB - Contemporary patient care requires a multidisciplinary approach to monitoring, assessing, and managing diseases. Promoting multidisciplinary approaches encourages the purposeful participation of many healthcare professionals and harnessing their combined knowledge to provide tailored treatment plans. Pharmacists, skilled and knowledgeable professionals in medication management, drug-related problems, and disease prevention, can offer vital interventions that contribute to improved patient outcomes. Advances in healthcare and information technology have expanded pharmacists' professional roles and made them essential in healthcare. Pharmacist-managed clinics (PMCs), an innovative healthcare approach, could potentially improve patient safety, satisfaction, accessibility, and affordability to quality healthcare. Spread across the healthcare continuum, pharmacists have a well-defined role in providing comprehensive pharmaceutical care and interprofessional collaboration, further reinforcing the necessity of establishing PMCs. This narrative review aims to compile and summarize information on PMCs from PubMed, Scopus, Web of Science, and Google Scholar till December 2023. The PMC shortlist covers specialties such as cardiovascular, hematologic, endocrine, pain medicine, respiratory medicine, infectious diseases, gastrointestinal, nephrology, neurology, and oncology. Pharmacists in disease-specific PMCs have demonstrated improved treatment outcomes and access to specialty care. Additionally, based on peer-reviewed literature, the review also highlights how PMCs enhance the pharmacist's role in improving disease-specific outcomes, overall quality of care, and medication management. The inclusion criteria are randomized controlled trials, case-control studies, cohort studies, and pre-post studies involving patients from cardiology, hematology, endocrinology, pain medicine, respiratory medicine, infectious diseases, neurology, nephrology, gastroenterology, and oncology specialties, focusing on pharmacist-driven clinics, published in English, and covering any geographical location. The exclusion criteria include review articles, proposed models, commentaries, editorials, and those published in languages other than English. Our findings reveal that PMCs are underutilized globally. PMCs work better in developed countries, possibly on account of robust healthcare infrastructure, adequate healthcare budgets, availability of trained pharmacists, and supportive regulatory environments. The review found that pharmacist-led interventions, such as medication monitoring and patient education, significantly enhance therapeutic outcomes. Pharmacist Managed Clinics improve affordability and acceptability, expanding healthcare access in outpatient and inpatient settings. This review also highlights the critical need for implementing PMCs to improve healthcare delivery, particularly in providing comprehensive and accessible services in developing countries. CI - (c) 2024 The Authors. FAU - Thorakkattil, Shabeer Ali AU - Thorakkattil SA AD - Pharmacy Services Department, Johns Hopkins Aramco Healthcare (JHAH), Dhahran 34465, Saudi Arabia. AD - Department of Pharmacy Practice and Clinical Pharmacy, Faculty of Pharmacy, Universiti Teknologi MARA (UiTM), Selangor Branch, Puncak Alam Campus, Selangor, Malaysia. FAU - Parakkal, Sainul Abideen AU - Parakkal SA AD - Pharmacy Services Department, Johns Hopkins Aramco Healthcare (JHAH), Dhahran 34465, Saudi Arabia. FAU - Mohammed Salim, K T AU - Mohammed Salim KT AD - Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal 576104, India. FAU - Arain, Savera AU - Arain S AD - Pharmacy Services Department, Johns Hopkins Aramco Healthcare (JHAH), Dhahran 34465, Saudi Arabia. FAU - Krishnan, Gopika AU - Krishnan G AD - Department of Pharmacy Practice, The Erode College of Pharmacy, Tamil Nadu 638112, India. FAU - Madathil, Hafees AU - Madathil H AD - Pharmacy Services Department, Johns Hopkins Aramco Healthcare (JHAH), Dhahran 34465, Saudi Arabia. FAU - Kuzhiyil, Ajmal Karumbaru AU - Kuzhiyil AK AD - Department of Pharmacy, Sidra Medicine, Qatar. FAU - Aslam, Ammad AU - Aslam A AD - Pharmacy Services Department, Johns Hopkins Aramco Healthcare (JHAH), Dhahran 34465, Saudi Arabia. FAU - Abdulsalim, Suhaj AU - Abdulsalim S AD - Department of Pharmacy Practice, College of Pharmacy, Qassim University, Saudi Arabia. FAU - Karuppannan, Mahmathi AU - Karuppannan M AD - Department of Pharmacy Practice and Clinical Pharmacy, Faculty of Pharmacy, Universiti Teknologi MARA (UiTM), Selangor Branch, Puncak Alam Campus, Selangor, Malaysia. FAU - Sridhar, Sathvik Belagodu AU - Sridhar SB AD - Department of Clinical Pharmacy & Pharmacology, RAK College of Pharmacy, RAK Medical and Health Sciences University, Ras Al Khaimah 11172, United Arab Emirates. FAU - Shareef, Javedh AU - Shareef J AD - Department of Clinical Pharmacy & Pharmacology, RAK College of Pharmacy, RAK Medical and Health Sciences University, Ras Al Khaimah 11172, United Arab Emirates. FAU - Unnikrishnan, Mazhuvanchery Kesavan AU - Unnikrishnan MK AD - Department of Pharmacy Practice, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, Kochi, India. LA - eng PT - Journal Article PT - Review DEP - 20241011 PL - United States TA - Explor Res Clin Soc Pharm JT - Exploratory research in clinical and social pharmacy JID - 9918266300706676 PMC - PMC11513600 OTO - NOTNLM OT - Access to care OT - Chronic disease management OT - Cost-effective healthcare OT - Patient outcomes OT - Pharmacist OT - Pharmacist interventions OT - Pharmacist-managed clinics OT - Specialty clinics COIS- The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/10/29 06:23 MHDA- 2024/10/29 06:24 PMCR- 2024/10/11 CRDT- 2024/10/29 04:46 PHST- 2024/07/10 00:00 [received] PHST- 2024/10/07 00:00 [revised] PHST- 2024/10/10 00:00 [accepted] PHST- 2024/10/29 06:24 [medline] PHST- 2024/10/29 06:23 [pubmed] PHST- 2024/10/29 04:46 [entrez] PHST- 2024/10/11 00:00 [pmc-release] AID - S2667-2766(24)00124-0 [pii] AID - 100527 [pii] AID - 10.1016/j.rcsop.2024.100527 [doi] PST - epublish SO - Explor Res Clin Soc Pharm. 2024 Oct 11;16:100527. doi: 10.1016/j.rcsop.2024.100527. eCollection 2024 Dec. PMID- 39468966 OWN - NLM STAT- MEDLINE DCOM- 20241029 LR - 20241107 IS - 2532-1900 (Electronic) IS - 1128-2460 (Print) IS - 1128-2460 (Linking) VI - 43 IP - 3 DP - 2024 Sep TI - Transition and management of patients with Duchenne Muscular Dystrophy: a narrative review based on Italian experts' opinion and real-world experience. PG - 102-107 LID - 10.36185/2532-1900-447 [doi] AB - OBJECTIVES: Duchenne Muscular Dystrophy (DMD) is a severe, progressive, X-linked disorder resulting in muscle wasting, progressive functional loss and cardiomyopathy. Therapeutic strategies feature glucocorticoid corticosteroids plus gene therapy/stop codon read-through, plus standards of care. Prolonged survival, delayed loss of ambulation (LoA), and innovative treatment prescriptions pose new clinical challenges, including identification of new outcome measures/targets and implementation of continuity of care. METHODS: We report on the results of an Italian experts' meeting held in Rome, Italy on 20(th) April 2022. We aimed to: discuss challenges linked to transitioning from the ambulatory to the non-ambulatory phase, and from pediatric to adult care; collect experience on the importance of ongoing care and treatment in advanced disease stages and on the need to measure clinically relevant outcomes during disease progression after LoA. RESULTS: Following LoA the main management focus shifts to cardiac, respiratory, orthopaedics, nutrition and upper limbs function. More data on clinical needs, available treatments, standards of care, frequency of follow-up, and transition should be collected in order to facilitate management optimisation. Shared protocols should be developed, especially to improve patients' management in the acute setting. CONCLUSIONS: Transition from paediatric to adult services and from the ambulatory to the non-ambulatory phase require a multidisciplinary approach and the Identification of clinically meaningful outcome measures, which should be described in long-term longitudinal studies. CI - Copyright (c) 2024 Gaetano Conte Academy - Mediterranean Society of Myology. FAU - Spagnoli, Carlotta AU - Spagnoli C AD - Child Neurology Unit, Presidio Ospedaliero Provinciale Santa Maria Nuova, AUSL-IRCCS di Reggio Emilia, Reggio Emilia, Italy. FAU - Adorisio, Rachele AU - Adorisio R AD - Heart Failure, Transplant and Mechanical Cardiocirculatory Support Unit, Department of Pediatric Cardiology and Cardiac Surgery, Heart Lung Transplantation, ERN GUARD HEART: Bambino Gesu Hospital and Research Institute, Rome, Italy. FAU - Bello, Luca AU - Bello L AD - Department of Neurosciences, University of Padua, Padua, Veneto, Italy. FAU - D'Amico, Adele AU - D'Amico A AD - Department of Neuroscience, Catholic University, Rome, Italy. FAU - D'Angelo, Maria Grazia AU - D'Angelo MG AD - Istituto di Ricerca e Cura a Carattere Scientifico E. Medea, La Nostra Famiglia, Bosisio Parini, Italy. FAU - Pane, Marika AU - Pane M AD - Pediatric Neurology and Nemo Clinical Centre, Fondazione Policlinico Universitario A. Gemelli IRCSS, Universita Cattolica del Sacro Cuore, Roma, Italy. FAU - Penzo, Martina AU - Penzo M AD - Department of Neurosciences, University of Padua, Padua, Veneto, Italy. FAU - Riguzzi, Pietro AU - Riguzzi P AD - Department of Neurosciences, University of Padua, Padua, Veneto, Italy. FAU - Sansone, Valeria AU - Sansone V AD - Centro Clinico Nemo Milan, Neurorehabilitation Unit, Dipartimento di Scienze Biomediche della Salute, University of Milan, Milan, Italy. FAU - Vianello, Andrea AU - Vianello A AD - Respiratory Pathophysiology Division, University of Padua, Padua, Italy. FAU - Fusco, Carlo AU - Fusco C AD - Child Neurology Unit, Presidio Ospedaliero Provinciale Santa Maria Nuova, AUSL-IRCCS di Reggio Emilia, Reggio Emilia, Italy. LA - eng PT - Journal Article PT - Review PL - Italy TA - Acta Myol JT - Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology JID - 9811169 SB - IM MH - Humans MH - *Muscular Dystrophy, Duchenne/therapy MH - Italy MH - Transition to Adult Care MH - Disease Management MH - Disease Progression PMC - PMC11537712 OTO - NOTNLM OT - Duchenne muscular dystrophy OT - ataluren OT - loss of ambulation OT - transition COIS- Luca Bello reports honoraria (speaker, consultancy) for PTC Therapeutics, Sarepta Therapeutics, Epirium Bio, Edgewise Therapeutics; research funding from PTC Therapeutics, Santhera Pharmaceuticals. Carlotta Spagnoli, Rachele Adorisio, Adele D'Amico, Maria Grazia D'Angelo, Marika Pane, Valeria Sansone, Andrea Vianello, and Carlo Fusco report no conflicts of interest to disclose. EDAT- 2024/10/29 06:23 MHDA- 2024/10/29 06:24 PMCR- 2024/09/30 CRDT- 2024/10/29 04:23 PHST- 2024/02/13 00:00 [received] PHST- 2024/05/09 00:00 [accepted] PHST- 2024/10/29 06:24 [medline] PHST- 2024/10/29 06:23 [pubmed] PHST- 2024/10/29 04:23 [entrez] PHST- 2024/09/30 00:00 [pmc-release] AID - 10.36185/2532-1900-447 [doi] PST - ppublish SO - Acta Myol. 2024 Sep;43(3):102-107. doi: 10.36185/2532-1900-447. PMID- 32644611 STAT- Publisher CTDT- 20241028 PB - StatPearls Publishing DP - 2024 Jan TI - Heart-Lung Transplantation. BTI - StatPearls AB - Pioneered in the 1960s and successfully implemented in the 1980s, with a declining number of candidates since the 1990s, simultaneous heart and lung transplantation is only indicated for patients in the end stages of both cardiac and pulmonary failure. Suppose only 1 of the 2 thoracic organ systems has irreversibly failed, and the other is salvageable. In that case, most treatment centers forego dual transplants as the risk-benefit analyses suggest salvage should be attempted, and only the irreversibly failed organ should be replaced. This strategy spares the patient the cumulative risk of 2 simultaneous transplants, shortens their time on the waiting list, and allocates more organs to more patients. Therefore, in the current era, most patients are preferentially placed as candidates for either lung transplant or advanced heart failure therapies, including mechanical circulatory support and heart transplant. In 2014, the United Network for Organ Sharing initiated a critical review of its heart transplantation donor allocation policy. This review was driven by several factors, including a growing imbalance between organ availability and demand, high mortality rates among the sickest patients on the waitlist, and an increase in candidates being bridged to transplant with left ventricular assist devices. The thoracic subcommittee expanded the number of priority tiers to 6 in the revised allocation policy to address these concerns, allowing for more precise risk stratification and reducing the need for status exceptions. While the subcommittee considered posttransplant survival, the main goal of the new system was to reduce mortality among waitlisted patients. Allocation Tiers and Descriptions Tier 1: Veno-arterial extracorporeal membrane oxygenation. Nondischargeable biventricular assist device (BiVAD). Mechanical circulatory support (MCS) with arrhythmia. Tier 2: Dischargeable right ventricular assist device/BiVAD. Nondischargeable left ventricular assist devices (LVAD). Intraaortic balloon pump or other percutaneous MCS. MCS with malfunction. Tier 3: Continuous intravenous (IV) inotropes with hemodynamic monitoring. 30-day exception period for LVAD. MCS with complications. Tier 4: Continuous IV inotropes without hemodynamic monitoring. Stable LVAD. Congenital heart disease. Restrictive cardiomyopathy. Retransplantation. Tier 5: Multiorgan transplant. Tier 6: All other candidates. Despite the advancements in organ transplantation and donor allocation strategies, heart-lung transplantation remains a rare and complex procedure, with only about 100 new cases reported annually. The challenges associated with patient selection, donor availability, and postoperative management necessitate a highly coordinated and multidisciplinary approach. Given the limited number of cases and stringent indications, healthcare professionals must stay informed about evolving guidelines, allocation policies, and therapeutic alternatives. This introduction aims to provide a comprehensive understanding of the unique considerations and current state of heart-lung transplantation, serving as a foundation for in-depth discussions on patient management, surgical techniques, and long-term outcomes in this niche area of transplant medicine. CI - Copyright (c) 2024, StatPearls Publishing LLC. FAU - Tully, Andy AU - Tully A AD - Wake Forest University FAU - Sharma, Sanjeev AU - Sharma S FAU - Nagalli, Shivaraj AU - Nagalli S AD - Yuma Regional Medical Center LA - eng PT - Study Guide PT - Book Chapter PL - Treasure Island (FL) COIS- Disclosure: Andy Tully declares no relevant financial relationships with ineligible companies. Disclosure: Sanjeev Sharma declares no relevant financial relationships with ineligible companies. Disclosure: Shivaraj Nagalli declares no relevant financial relationships with ineligible companies. EDAT- 2024/10/28 00:00 CRDT- 2024/10/28 00:00 AID - NBK559185 [bookaccession] PMID- 39458194 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241028 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 13 IP - 20 DP - 2024 Oct 19 TI - Fetal Teratomas: Advances in Diagnosis and Management. LID - 10.3390/jcm13206245 [doi] LID - 6245 AB - Fetal teratomas, though rare, represent a significant proportion of tumors arising during fetal development. These tumors arise from pluripotent cells and can present in varying degrees of severity, ranging from incidental findings to life-threatening conditions. Prenatal imaging, via ultrasound and MRI, is necessary for diagnosis and risk assessment. The management of fetal teratomas, particularly those associated with complications like hydrops or airway obstruction, often requires a multidisciplinary approach. Interventions such as ex-utero intrapartum treatment (EXIT) procedures and minimally invasive alternatives have emerged as critical tools to improve neonatal outcomes in severe cases. Despite advances in fetal therapies, careful prenatal monitoring and individualized management remain essential, especially for tumors with high vascularity or those that risk compromising cardiac output. This review explores the diagnostic methods, management strategies, and outcomes associated with fetal teratomas, highlighting recent advancements that contribute to improving survival and reducing morbidity in affected neonates. FAU - Abiad, May AU - Abiad M AD - Fetal Care and Surgery Center (FCSC), Division of Fetal Medicine and Surgery, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA. FAU - Zargarzadeh, Nikan AU - Zargarzadeh N AD - Fetal Care and Surgery Center (FCSC), Division of Fetal Medicine and Surgery, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA. FAU - Javinani, Ali AU - Javinani A AD - Fetal Care and Surgery Center (FCSC), Division of Fetal Medicine and Surgery, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA. FAU - Krispin, Eyal AU - Krispin E AUID- ORCID: 0000-0001-5859-9528 AD - Fetal Care and Surgery Center (FCSC), Division of Fetal Medicine and Surgery, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA. FAU - Shamshirsaz, Alireza A AU - Shamshirsaz AA AD - Fetal Care and Surgery Center (FCSC), Division of Fetal Medicine and Surgery, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA. LA - eng PT - Journal Article PT - Review DEP - 20241019 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC11508798 OTO - NOTNLM OT - ex utero intrapartum treatment (EXIT) OT - fetal surgery OT - fetal teratomas OT - sacrococcygeal teratoma COIS- The authors declare no conflicts of interest. EDAT- 2024/10/26 19:26 MHDA- 2024/10/26 19:27 PMCR- 2024/10/19 CRDT- 2024/10/26 01:13 PHST- 2024/09/19 00:00 [received] PHST- 2024/10/14 00:00 [revised] PHST- 2024/10/17 00:00 [accepted] PHST- 2024/10/26 19:27 [medline] PHST- 2024/10/26 19:26 [pubmed] PHST- 2024/10/26 01:13 [entrez] PHST- 2024/10/19 00:00 [pmc-release] AID - jcm13206245 [pii] AID - jcm-13-06245 [pii] AID - 10.3390/jcm13206245 [doi] PST - epublish SO - J Clin Med. 2024 Oct 19;13(20):6245. doi: 10.3390/jcm13206245. PMID- 39458093 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241029 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 13 IP - 20 DP - 2024 Oct 15 TI - Diagnosis, Management and Outcome of Truncus Arteriosus Communis Diagnosed during Fetal Life-Cohort Study and Systematic Literature Review. LID - 10.3390/jcm13206143 [doi] LID - 6143 AB - Background/Objectives: Truncus arteriosus communis (TAC) is a rare congenital heart defect characterized by a single arterial trunk that supplies systemic, pulmonary, and coronary circulations. This defect, constituting approximately 1-4% of congenital heart diseases, poses significant challenges in prenatal diagnosis, management, and postnatal outcomes. Methods: A retrospective analysis was conducted at the local tertiary referral center on cases of TAC diagnosed prenatally between 2019 and 2024. Additionally, a systematic literature review was performed to evaluate the accuracy of prenatal diagnostics and the presence of associated anomalies in fetuses with TAC and compare already published data with the local results. The review included studies that especially described the use of fetal echocardiography, the course and outcome of affected pregnancies, and subsequent management strategies. Results: The analysis of local prenatal diagnoses revealed 14 cases. Of the 11 neonates who survived to birth, the TAC diagnosis was confirmed in 7 instances. With all seven neonates undergoing surgery, the intention-to-treat survival rate was 86%, and the overall survival rate was 55%. By reviewing published case series, a total of 823 TAC cases were included in the analysis, of which 576 were diagnosed prenatally and 247 postnatally. The presence of associated cardiac and extracardiac manifestations as well as genetic anomalies was common, with a 22q11 microdeletion identified in 27% of tested cases. Conclusions: Advances in prenatal imaging and early diagnosis have enhanced the management of TAC, allowing for the detailed planning of delivery and immediate postnatal care in specialized centers. The frequent association with genetic syndromes underscores the importance of genetic counseling in managing TAC. An early surgical intervention remains crucial for improving long-term outcomes, although the condition is still associated with significant risks. Long-term follow-up studies are essential to monitor potential complications and guide future management strategies. Overall, a coordinated multidisciplinary approach from prenatal diagnosis to postnatal care is essential for improving outcomes for individuals with TAC. FAU - Wittek, Agnes AU - Wittek A AD - Department of Obstetrics and Prenatal Medicine, University Hospital Bonn, Venusberg Campus 1, 53127 Bonn, Germany. FAU - Ploger, Ruben AU - Ploger R AD - Department of Obstetrics and Prenatal Medicine, University Hospital Bonn, Venusberg Campus 1, 53127 Bonn, Germany. FAU - Walter, Adeline AU - Walter A AUID- ORCID: 0000-0001-8302-3854 AD - Department of Obstetrics and Prenatal Medicine, University Hospital Bonn, Venusberg Campus 1, 53127 Bonn, Germany. FAU - Strizek, Brigitte AU - Strizek B AUID- ORCID: 0000-0003-3625-7097 AD - Department of Obstetrics and Prenatal Medicine, University Hospital Bonn, Venusberg Campus 1, 53127 Bonn, Germany. FAU - Geipel, Annegret AU - Geipel A AD - Department of Obstetrics and Prenatal Medicine, University Hospital Bonn, Venusberg Campus 1, 53127 Bonn, Germany. FAU - Gembruch, Ulrich AU - Gembruch U AUID- ORCID: 0000-0001-8284-4669 AD - Department of Obstetrics and Prenatal Medicine, University Hospital Bonn, Venusberg Campus 1, 53127 Bonn, Germany. FAU - Neubauer, Ricarda AU - Neubauer R AUID- ORCID: 0000-0001-9856-8988 AD - Department of Obstetrics and Prenatal Medicine, University Hospital Bonn, Venusberg Campus 1, 53127 Bonn, Germany. FAU - Recker, Florian AU - Recker F AUID- ORCID: 0000-0001-9135-4338 AD - Department of Obstetrics and Prenatal Medicine, University Hospital Bonn, Venusberg Campus 1, 53127 Bonn, Germany. LA - eng PT - Journal Article DEP - 20241015 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC11508351 OTO - NOTNLM OT - Truncus arteriosus communis OT - common arterial trunk OT - congenital heart defects OT - fetal echocardiography COIS- The authors have no relevant financial or non-financial interests to disclose. EDAT- 2024/10/26 19:24 MHDA- 2024/10/26 19:25 PMCR- 2024/10/15 CRDT- 2024/10/26 01:12 PHST- 2024/09/18 00:00 [received] PHST- 2024/10/02 00:00 [revised] PHST- 2024/10/08 00:00 [accepted] PHST- 2024/10/26 19:25 [medline] PHST- 2024/10/26 19:24 [pubmed] PHST- 2024/10/26 01:12 [entrez] PHST- 2024/10/15 00:00 [pmc-release] AID - jcm13206143 [pii] AID - jcm-13-06143 [pii] AID - 10.3390/jcm13206143 [doi] PST - epublish SO - J Clin Med. 2024 Oct 15;13(20):6143. doi: 10.3390/jcm13206143. PMID- 39456560 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241028 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 16 IP - 20 DP - 2024 Oct 12 TI - Pericardial Disease in Patients with Cancer: Clinical Insights on Diagnosis and Treatment. LID - 10.3390/cancers16203466 [doi] LID - 3466 AB - Pericardial disease is increasingly recognized in cancer patients, including acute pericarditis, pericardial effusion, and constrictive pericarditis, often indicating a poor prognosis. Acute pericarditis arises from direct tumor involvement, cancer therapies, and radiotherapy. Immune checkpoint inhibitor (ICI)-related pericarditis, though rare, entails significant mortality risk. Treatment includes NSAIDs, colchicine, and corticosteroids or anti-IL1 drugs in refractory cases. Pericardial effusion is the most frequent manifestation, primarily caused by lung cancer, followed by breast cancer, lymphoma, leukemia, gastrointestinal tumors, and melanoma. Chemotherapy, immunotherapy, and radiotherapy may also cause fluid accumulation in the pericardial space. Symptomatic relief for pericardial effusion may require pericardiocentesis, prolonged catheter drainage, or a pericardial window. Instillation of intrapericardial cytostatic agents may reduce recurrence. Constrictive pericarditis, though less common, often develops from radiotherapy and requires multimodality imaging for diagnosis, with pericardiectomy as the definitive treatment. Primary pericardial tumors are rare, with metastases being more frequent. Patients with cancer and pericardial disease generally have poor survival, emphasizing the need for early detection. A multidisciplinary approach involving hematologists, oncologists, and cardiologists is crucial to tailoring pericardial disease treatment to a patient's clinical status, thereby improving the quality of life and prognosis. FAU - Lorenzo-Esteller, Laia AU - Lorenzo-Esteller L AUID- ORCID: 0000-0002-0066-0573 AD - Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, 08907 Barcelona, Spain. FAU - Ramos-Polo, Raul AU - Ramos-Polo R AUID- ORCID: 0000-0001-7475-4145 AD - Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, 08907 Barcelona, Spain. AD - Cardio-Oncology Unit, Bellvitge University Hospital-Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain. AD - Bio-Heart Cardiovascular, Respiratory and Systemic Diseases and Cellular Aging Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain. FAU - Pons Riverola, Alexandra AU - Pons Riverola A AD - Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, 08907 Barcelona, Spain. AD - Cardio-Oncology Unit, Bellvitge University Hospital-Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain. AD - Bio-Heart Cardiovascular, Respiratory and Systemic Diseases and Cellular Aging Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain. FAU - Morillas, Herminio AU - Morillas H AD - Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, 08907 Barcelona, Spain. AD - Cardio-Oncology Unit, Bellvitge University Hospital-Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain. AD - Bio-Heart Cardiovascular, Respiratory and Systemic Diseases and Cellular Aging Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain. FAU - Berdejo, Javier AU - Berdejo J AD - Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, 08907 Barcelona, Spain. AD - Cardio-Oncology Unit, Bellvitge University Hospital-Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain. FAU - Pernas, Sonia AU - Pernas S AUID- ORCID: 0000-0002-1485-5080 AD - Medical Oncology Department, Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain. FAU - Pomares, Helena AU - Pomares H AD - Clinical Haematology Department, Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain. FAU - Asiain, Leyre AU - Asiain L AUID- ORCID: 0000-0001-6941-0575 AD - Radiation Oncology Department, Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain. FAU - Garay, Alberto AU - Garay A AD - Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, 08907 Barcelona, Spain. AD - Cardio-Oncology Unit, Bellvitge University Hospital-Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain. AD - Bio-Heart Cardiovascular, Respiratory and Systemic Diseases and Cellular Aging Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain. AD - Preclinical and Experimental Research in Thoracic Tumors (PRETT), Oncobell, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain. FAU - Martinez Perez, Evelyn AU - Martinez Perez E AD - Radiation Oncology Department, Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain. FAU - Jimenez-Marrero, Santiago AU - Jimenez-Marrero S AD - Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, 08907 Barcelona, Spain. AD - Cardio-Oncology Unit, Bellvitge University Hospital-Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain. AD - Bio-Heart Cardiovascular, Respiratory and Systemic Diseases and Cellular Aging Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain. AD - Centro de Investigacion Biomedica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto Salud Carlos III, 28029 Madrid, Spain. FAU - Alcoberro, Lidia AU - Alcoberro L AUID- ORCID: 0000-0003-1904-7880 AD - Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, 08907 Barcelona, Spain. AD - Bio-Heart Cardiovascular, Respiratory and Systemic Diseases and Cellular Aging Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain. FAU - Nadal, Ernest AU - Nadal E AUID- ORCID: 0000-0002-9674-5554 AD - Medical Oncology Department, Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain. AD - Preclinical and Experimental Research in Thoracic Tumors (PRETT), Oncobell, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain. FAU - Gubern-Prieto, Paula AU - Gubern-Prieto P AD - Medical Oncology Department, Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain. FAU - Gual-Capllonch, Francisco AU - Gual-Capllonch F AD - Cardiology Department, Hospital Universitari Son Espases, 07120 Palma, Spain. FAU - Hidalgo, Encarna AU - Hidalgo E AD - Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, 08907 Barcelona, Spain. AD - Cardio-Oncology Unit, Bellvitge University Hospital-Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain. FAU - Enjuanes, Cristina AU - Enjuanes C AD - Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, 08907 Barcelona, Spain. AD - Bio-Heart Cardiovascular, Respiratory and Systemic Diseases and Cellular Aging Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain. AD - Centro de Investigacion Biomedica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto Salud Carlos III, 28029 Madrid, Spain. FAU - Comin-Colet, Josep AU - Comin-Colet J AUID- ORCID: 0000-0001-8780-720X AD - Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, 08907 Barcelona, Spain. AD - Bio-Heart Cardiovascular, Respiratory and Systemic Diseases and Cellular Aging Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain. AD - Centro de Investigacion Biomedica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto Salud Carlos III, 28029 Madrid, Spain. AD - Department of Clinical Sciences, School of Medicine, Universitat de Barcelona (UB), L'Hospitalet de Llobregat, 08036 Barcelona, Spain. FAU - Moliner, Pedro AU - Moliner P AUID- ORCID: 0000-0002-5511-8597 AD - Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, 08907 Barcelona, Spain. AD - Cardio-Oncology Unit, Bellvitge University Hospital-Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain. AD - Bio-Heart Cardiovascular, Respiratory and Systemic Diseases and Cellular Aging Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain. AD - Centro de Investigacion Biomedica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto Salud Carlos III, 28029 Madrid, Spain. LA - eng PT - Journal Article PT - Review DEP - 20241012 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC11505731 OTO - NOTNLM OT - cancer OT - chemotherapy OT - pericardial disease OT - pericardiocentesis OT - radiotherapy COIS- The authors declare that they have no conflicts of interest relevant to the contents of this manuscript. EDAT- 2024/10/26 19:22 MHDA- 2024/10/26 19:23 PMCR- 2024/10/12 CRDT- 2024/10/26 01:03 PHST- 2024/08/06 00:00 [received] PHST- 2024/10/02 00:00 [revised] PHST- 2024/10/04 00:00 [accepted] PHST- 2024/10/26 19:23 [medline] PHST- 2024/10/26 19:22 [pubmed] PHST- 2024/10/26 01:03 [entrez] PHST- 2024/10/12 00:00 [pmc-release] AID - cancers16203466 [pii] AID - cancers-16-03466 [pii] AID - 10.3390/cancers16203466 [doi] PST - epublish SO - Cancers (Basel). 2024 Oct 12;16(20):3466. doi: 10.3390/cancers16203466. PMID- 39453286 OWN - NLM STAT- MEDLINE DCOM- 20251214 LR - 20260304 IS - 1557-3117 (Electronic) IS - 1053-2498 (Linking) VI - 45 IP - 1 DP - 2026 Jan TI - ISHLT Consensus Statement on the Perioperative use of ECLS in Lung Transplantation: Part II: Intraoperative Considerations. PG - e35-e62 LID - S1053-2498(24)01830-8 [pii] LID - 10.1016/j.healun.2024.08.027 [doi] AB - The use of extracorporeal life support (ECLS) throughout the perioperative phase of lung transplantation requires nuanced planning and execution by an integrated team of multidisciplinary experts. To date, no multidisciplinary consensus document has examined the perioperative considerations of how to best manage these patients. To address this challenge, this perioperative utilization of ECLS in lung transplantation consensus statement was approved for development by the International Society for Heart and Lung Transplantation Standards and Guidelines Committee. International experts across multiple disciplines, including cardiothoracic surgery, anesthesiology, critical care, pediatric pulmonology, adult pulmonology, pharmacy, psychology, physical therapy, nursing, and perfusion, were selected based on expertise and divided into subgroups examining the preoperative, intraoperative, and postoperative periods. Following a comprehensive literature review, each subgroup developed recommendations to examine via a structured Delphi methodology. Following 2 rounds of Delphi consensus, a total of 39 recommendations regarding intraoperative considerations for ECLS in lung transplantation met consensus criteria. These recommendations focus on the planning, implementation, management, and monitoring of ECLS throughout the entire intraoperative period. CI - Copyright (c) 2025 International Society for the Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved. FAU - Martin, Archer Kilbourne AU - Martin AK AD - Division of Cardiovascular and Thoracic Anesthesiology, Mayo Clinic Florida, Jacksonville, Florida. Electronic address: martin.archer@mayo.edu. FAU - Mercier, Olaf AU - Mercier O AD - Department of Thoracic Surgery and Heart-Lung Transplantation, Marie Lannelongue Hospital, Universite' Paris-Saclay, Le Plessis-Robinson, France. FAU - Fritz, Ashley Virginia AU - Fritz AV AD - Division of Cardiovascular and Thoracic Anesthesiology, Mayo Clinic Florida, Jacksonville, Florida. FAU - Gelzinis, Theresa A AU - Gelzinis TA AD - Division of Cardiovascular and Thoracic Anesthesiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. FAU - Hoetzenecker, Konrad AU - Hoetzenecker K AD - Division of Thoracic Surgery, Department of Surgery, Medical University of Vienna, Vienna, Austria. FAU - Lindstedt, Sandra AU - Lindstedt S AD - Department of Cardiothoracic Surgery and Transplantation, Lund University, Lund, Sweden. FAU - Marczin, Nandor AU - Marczin N AD - Department of Anaesthesia and Critical Care, Royal Brompton & Harefield Hospitals, Part of Guy's and St Thomas' NHS Foundation Trust and Imperial College London, London, United Kingdom. FAU - Wilkey, Barbara J AU - Wilkey BJ AD - Department of Anesthesiology, University of Colorado, Aurora, Colorado. FAU - Schecter, Marc AU - Schecter M AD - Division of Pulmonary Medicine, University of Florida, Gainesville, Florida. FAU - Lyster, Haifa AU - Lyster H AD - Department of Cardiothoracic Transplantation & Mechanical Circulatory Support, Royal Brompton & Harefield Hospitals, Part of Guy's and St Thomas' NHS Foundation Trust and King's College London, London, United Kingdom. FAU - Sanchez, Melissa AU - Sanchez M AD - Department of Clinical Health Psychology, Kensington & Chelsea, West Middlesex Hospitals, London, United Kingdom. FAU - Walsh, James AU - Walsh J AD - Department of Physiotherapy, The Prince Charles Hospital, Brisbane, Australia. FAU - Morrissey, Orla AU - Morrissey O AD - Division of Infectious Disease, Alfred Health and Monash University, Melbourne, Australia. FAU - Levvey, Bronwyn AU - Levvey B AD - Faculty of Nursing & Health Sciences, The Alfred Hospital, Monah University, Melbourne, Australia. FAU - Landry, Caroline AU - Landry C AD - Division of Perfusion Services, Universite' de Montreal, Montreal, Quebec, Canada. FAU - Saatee, Siavosh AU - Saatee S AD - Division of Cardiovascular and Thoracic Anesthesiology and Critical Care, University of Texas-Southwestern, Dallas, Texas. FAU - Kotecha, Sakhee AU - Kotecha S AD - Lung Transplant Service, Alfred Hospital and Monash University, Melbourne, Australia. FAU - Behr, Juergen AU - Behr J AD - Department of Medicine V, German Center for Lung Research, LMU University Hospital, Ludwig Maximilian University of Munich, Munich, Germany. FAU - Kukreja, Jasleen AU - Kukreja J AD - Division of Cardiothoracic Surgery, Department of Surgery, University of California, San Francisco, California. FAU - Dellgren, Goran AU - Dellgren G AD - Department of Cardiothoracic Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden. FAU - Fessler, Julien AU - Fessler J AD - Department of Anesthesiology and Pain Medicine, Hopital Foch, Universite' Versailles-Saint-Quentin-en-Yvelines, Suresnes, France. FAU - Bottiger, Brandi AU - Bottiger B AD - Division of Cardiothoracic Anesthesiology, Duke University School of Medicine, Durham, North Carolina. FAU - Wille, Keith AU - Wille K AD - Division of Pulmonary and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, Alabama. FAU - Dave, Kavita AU - Dave K AD - Department of Cardiothoracic Transplantation & Mechanical Circulatory Support, Royal Brompton & Harefield Hospitals, Part of Guy's and St Thomas' NHS Foundation Trust and King's College London, London, United Kingdom. FAU - Nasir, Basil S AU - Nasir BS AD - Division of Thoracic Surgery, Centre Hospitalier de l'Universite de Montreal (CHUM), Montreal, Quebec, Canada. FAU - Gomez-De-Antonio, David AU - Gomez-De-Antonio D AD - Department of Thoracic Surgery and Lung Transplantation, Hospital Universitario Puerta de Hierro-Majadahonda, Universidad Autonoma de Madria, Madrid, Spain. FAU - Cypel, Marcelo AU - Cypel M AD - Toronto Lung Transplant Program, Ajmera Transplant Center, University Health Network, Toronto, Ontario, Canada. FAU - Reed, Anna K AU - Reed AK AD - Respiratory & Transplant Medicine, Royal Brompton and Harefield Hospitals, Part of Guy's and St Thomas' NHS Foundation Trust and Imperial College London, London, United Kingdom. LA - eng PT - Consensus Statement PT - Journal Article PT - Practice Guideline PT - Review DEP - 20241023 PL - United States TA - J Heart Lung Transplant JT - The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation JID - 9102703 SB - IM MH - *Lung Transplantation/methods MH - Humans MH - *Extracorporeal Membrane Oxygenation/methods/standards MH - *Perioperative Care/methods/standards MH - Delphi Technique MH - *Societies, Medical OTO - NOTNLM OT - ECLS OT - ECMO OT - end-stage lung disease OT - lung transplant OT - multidisciplinary EDAT- 2024/10/25 12:25 MHDA- 2025/12/15 00:28 CRDT- 2024/10/25 10:32 PHST- 2024/08/07 00:00 [received] PHST- 2024/08/26 00:00 [revised] PHST- 2024/08/31 00:00 [accepted] PHST- 2025/12/15 00:28 [medline] PHST- 2024/10/25 12:25 [pubmed] PHST- 2024/10/25 10:32 [entrez] AID - S1053-2498(24)01830-8 [pii] AID - 10.1016/j.healun.2024.08.027 [doi] PST - ppublish SO - J Heart Lung Transplant. 2026 Jan;45(1):e35-e62. doi: 10.1016/j.healun.2024.08.027. Epub 2024 Oct 23. PMID- 39452299 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241027 IS - 2308-3425 (Electronic) IS - 2308-3425 (Linking) VI - 11 IP - 10 DP - 2024 Oct 16 TI - Gender-Tailored Heart Team Decision Making Equalizes Outcomes for Female Patients after Aortic Valve Replacement through Right Anterior Small Thoracotomy (RAST). LID - 10.3390/jcdd11100329 [doi] LID - 329 AB - BACKGROUND: Little is known about gender-dependent outcomes after aortic valve replacement (AVR) through right anterior thoracotomy (RAST). The aim of our study was to analyze the mid-term outcomes of our cohort. METHODS: This study is a retrospective analysis of 338 patients (2013-2022). Subgroup analysis included a gender-dependent comparison of age groups 60 years. RESULTS: Women were older (69.27 +/- 7.98 vs. 64.15 +/- 11.47, p < 0.001) with higher Euroscore II (1.25 +/- 0.73 vs. 0.94 +/- 0.45, p < 0.001). Bypass and cross-clamp time were shorter (109.36 +/- 30.8 vs. 117.65 +/- 33.1 minutes, p = 0.01; 68.26 +/- 21.5 vs. 74.36 +/- 23.3 minutes, p = 0.01), while ICU, hospital stay and atrial fibrillation were higher (2.48 +/- 8.2 vs. 1.35 +/- 1.4 days, p = 0.005; 11 +/- 7.8 vs. 9.48 +/- 2.3 days, p = 0.002; 6.7% vs. 4.4%, p = 0.024). Mortality was 0.9%, while stroke was 0.6%. Age subgroup analysis showed that women were older (p = 0.025) with longer ICU and hospital stays (p < 0.001, p = 0.007). On mid-term follow-up (4.52 +/- 2.67 years) of 315 patients (94.3%), there was no significant difference in survival, MACCE and re-intervention comparing gender and age groups. CONCLUSIONS: Despite older age, higher Euroscore II, longer ICU and hospital stay in women, mortality, MACCE and reoperation were low and comparable in gender and age groups. We believe that our patient-tailored heart team decision making combined with RAST translates into gender-tailored medicine, which equalizes the widely reported negative outcomes of female patients after cardiac surgery. FAU - Lavanchy, Isabel AU - Lavanchy I AD - Department of Cardiac Surgery and Cardiology, Heart Clinic, Hirslanden Hospital, Witellikerstrasse 40, 8032 Zurich, Switzerland. FAU - Passos, Laina AU - Passos L AD - Department of Cardiac and Vascular Surgery, University Hospital Bern, Freiburgstrasse 20, 3010 Bern, Switzerland. FAU - Aymard, Thierry AU - Aymard T AD - Department of Cardiac Surgery and Cardiology, Heart Clinic, Hirslanden Hospital, Witellikerstrasse 40, 8032 Zurich, Switzerland. FAU - Grunenfelder, Jurg AU - Grunenfelder J AUID- ORCID: 0009-0001-7796-8517 AD - Department of Cardiac Surgery and Cardiology, Heart Clinic, Hirslanden Hospital, Witellikerstrasse 40, 8032 Zurich, Switzerland. FAU - Emmert, Maximilian Y AU - Emmert MY AD - Deutsches Herzzentrum der Charite (DHZC), Department of Cardiothoracic and Vascular Surgery, 13353 Berlin, Germany. AD - Charite-Universitatsmedizin Berlin, 13353 Berlin, Germany. FAU - Corti, Roberto AU - Corti R AUID- ORCID: 0000-0003-4598-7470 AD - Department of Cardiac Surgery and Cardiology, Heart Clinic, Hirslanden Hospital, Witellikerstrasse 40, 8032 Zurich, Switzerland. FAU - Gaemperli, Oliver AU - Gaemperli O AD - Department of Cardiac Surgery and Cardiology, Heart Clinic, Hirslanden Hospital, Witellikerstrasse 40, 8032 Zurich, Switzerland. FAU - Biaggi, Patric AU - Biaggi P AD - Department of Cardiac Surgery and Cardiology, Heart Clinic, Hirslanden Hospital, Witellikerstrasse 40, 8032 Zurich, Switzerland. FAU - Reser, Diana AU - Reser D AD - Department of Cardiac Surgery and Cardiology, Heart Clinic, Hirslanden Hospital, Witellikerstrasse 40, 8032 Zurich, Switzerland. LA - eng PT - Journal Article DEP - 20241016 PL - Switzerland TA - J Cardiovasc Dev Dis JT - Journal of cardiovascular development and disease JID - 101651414 PMC - PMC11508425 OTO - NOTNLM OT - aortic stenosis OT - aortic valve replacement OT - gender-related outcomes OT - minimally invasive aortic valve replacement (MIAVR) OT - minimally invasive aortic valve surgery OT - right anterior small thoracotomy (RAST) COIS- Our clinic is "Center of Excellence" facility of Edwards Lifesciences Heart-Team courses (up to 5 times annually) where we provide visiting surgeons and interventional cardiologists from around the world with insight into our patient-tailored Heart Team practice. For the current study, the authors have not conflict of interest. EDAT- 2024/10/25 12:25 MHDA- 2024/10/25 12:26 PMCR- 2024/10/16 CRDT- 2024/10/25 09:59 PHST- 2024/08/26 00:00 [received] PHST- 2024/09/25 00:00 [revised] PHST- 2024/10/09 00:00 [accepted] PHST- 2024/10/25 12:26 [medline] PHST- 2024/10/25 12:25 [pubmed] PHST- 2024/10/25 09:59 [entrez] PHST- 2024/10/16 00:00 [pmc-release] AID - jcdd11100329 [pii] AID - jcdd-11-00329 [pii] AID - 10.3390/jcdd11100329 [doi] PST - epublish SO - J Cardiovasc Dev Dis. 2024 Oct 16;11(10):329. doi: 10.3390/jcdd11100329. PMID- 39451626 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241027 IS - 2075-4418 (Print) IS - 2075-4418 (Electronic) IS - 2075-4418 (Linking) VI - 14 IP - 20 DP - 2024 Oct 16 TI - Secondary Angle Closure Glaucoma in Weill-Marchesani Syndrome. LID - 10.3390/diagnostics14202303 [doi] LID - 2303 AB - We report a case of a 16-year-old girl presenting to our clinic with decreased visual acuity and increased intraocular pressure in both eyes. The ophthalmological examination revealed best-corrected visual acuity (BCVA) of 0.3 in the right eye (R.E.) and 0.4 in the left eye (L.E.) and intraocular pressure (IOP) of 46 mmHg in the R.E. and 42 mmHg in the L.E., with a 360 degrees closed angle on gonioscopy, pupillary block due to bulging, a hyper-spherical lens and high corneal thickness, without ectopia lentis or cataract. The eyes responded poorly to pharmacological mydriasis; therefore, the lens equator could not be visualised. The patient had a history of pulmonary stenosis, short stature and no significant cognitive deficits. These elements point to the diagnosis of Weill-Marchesani syndrome, and the ophthalmological management was surgical, including lens extraction and the installation of a capsular tension ring, an intraocular lens and a Shunt ExPress implantation. Evolution was favourable, with improved BCVA of 0.7 in the R.E. and 0.63 in the L.E. and IOP of 14 mmHg in the R.E. and 13 mmHg in the L.E., without topical or systemic treatment at the 6-month follow-up. Weill-Marchesani syndrome has a complex presentation, with ophthalmological, musculoskeletal, cardiac and psychiatric manifestations. Usually, this leads to a need for a multidisciplinary approach. The ophthalmologic symptoms are often the cause of presentation to a specialist, and glaucoma is the most threatening of the ocular pathologies, with possible evolution into irreversible blindness; therefore, prompt surgery and careful follow-up become key components of the treatment plan. As a take-home message, we encourage a high degree of suspicion of Weill-Marchesani syndrome in such cases. FAU - Coviltir, Valeria AU - Coviltir V AD - Ophthalmology Discipline, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania. AD - Clinical Hospital for Ophthalmological Emergencies, 010464 Bucharest, Romania. FAU - Burcel, Miruna Gabriela AU - Burcel MG AUID- ORCID: 0000-0002-9701-4104 AD - Brasov County Emergency Clinical Hospital, 500326 Brasov, Romania. AD - Faculty of Medicine, Transilvania University of Brasov, 500036 Brasov, Romania. FAU - Marinescu, Maria Cristina AU - Marinescu MC AUID- ORCID: 0000-0001-8242-8809 AD - Physiology III Discipline, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania. FAU - Urse, Bianca Maria AU - Urse BM AUID- ORCID: 0009-0007-9806-4588 AD - Clinical Hospital for Ophthalmological Emergencies, 010464 Bucharest, Romania. FAU - Danielescu, Ciprian AU - Danielescu C AUID- ORCID: 0000-0002-1639-2921 AD - Ophthalmology Discipline, Surgery II Department, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania. LA - eng PT - Journal Article DEP - 20241016 PL - Switzerland TA - Diagnostics (Basel) JT - Diagnostics (Basel, Switzerland) JID - 101658402 PMC - PMC11506838 OTO - NOTNLM OT - Weill-Marchesani syndrome OT - glaucoma OT - microspherophakia COIS- The authors declare no conflicts of interest. EDAT- 2024/10/25 12:23 MHDA- 2024/10/25 12:24 PMCR- 2024/10/16 CRDT- 2024/10/25 09:55 PHST- 2024/08/18 00:00 [received] PHST- 2024/10/03 00:00 [revised] PHST- 2024/10/15 00:00 [accepted] PHST- 2024/10/25 12:24 [medline] PHST- 2024/10/25 12:23 [pubmed] PHST- 2024/10/25 09:55 [entrez] PHST- 2024/10/16 00:00 [pmc-release] AID - diagnostics14202303 [pii] AID - diagnostics-14-02303 [pii] AID - 10.3390/diagnostics14202303 [doi] PST - epublish SO - Diagnostics (Basel). 2024 Oct 16;14(20):2303. doi: 10.3390/diagnostics14202303. PMID- 39451564 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241027 IS - 1467-3045 (Electronic) IS - 1467-3037 (Print) IS - 1467-3037 (Linking) VI - 46 IP - 10 DP - 2024 Oct 16 TI - Cardiac Amyloidosis: State-of-the-Art Review in Molecular Pathology. PG - 11519-11536 LID - 10.3390/cimb46100684 [doi] AB - Amyloidosis refers to a group of diseases caused by extracellular deposits of misfolded proteins, which alter tissue function and structure, potentially affecting any organ. The term "amyloid" was introduced in the 19th century and later associated with pathological protein deposits. Amyloid fibrils, which are insoluble and resistant to degradation, originate from soluble proteins that undergo misfolding. This process can be triggered by several factors, such as aging, elevated protein concentrations, or pathogenic variants. Amyloid deposits damage organs both by disrupting tissue architecture and through direct cytotoxic effects, leading to conditions such as heart failure. Amyloidosis can be classified into acquired or inherited forms and can be systemic or localized. Diagnosing cardiac amyloidosis is complex and often requires tissue biopsies, which are supported by Congo Red dye staining. In some cases, bisphosphonate bone scans may provide a less invasive diagnostic option. In this state-of-the-art review, we focus on the most common forms of cardiac amyloidosis, from epidemiology to therapy, emphasizing the differences in molecular mechanisms and the importance of pathological diagnosis for appropriate treatment using a multidisciplinary approach. FAU - Salzillo, Cecilia AU - Salzillo C AUID- ORCID: 0009-0002-7531-3178 AD - Department of Experimental Medicine, PhD Course in Public Health, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy. AD - Department of Precision and Regenerative Medicine and Ionian Area, Pathology Unit, University of Bari "Aldo Moro", 70121 Bari, Italy. FAU - Franco, Renato AU - Franco R AD - Department of Mental and Physical Health and Preventive Medicine, Pathology Unit, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy. FAU - Ronchi, Andrea AU - Ronchi A AD - Department of Mental and Physical Health and Preventive Medicine, Pathology Unit, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy. FAU - Quaranta, Andrea AU - Quaranta A AUID- ORCID: 0009-0005-5329-6575 AD - Department of Precision and Regenerative Medicine and Ionian Area, Pathology Unit, University of Bari "Aldo Moro", 70121 Bari, Italy. FAU - Marzullo, Andrea AU - Marzullo A AUID- ORCID: 0000-0003-1265-3685 AD - Department of Precision and Regenerative Medicine and Ionian Area, Pathology Unit, University of Bari "Aldo Moro", 70121 Bari, Italy. LA - eng PT - Journal Article PT - Review DEP - 20241016 PL - Switzerland TA - Curr Issues Mol Biol JT - Current issues in molecular biology JID - 100931761 PMC - PMC11506355 OTO - NOTNLM OT - cardiac amyloidosis OT - cardiomyopathies OT - cardiovascular diseases OT - heart diseases OT - molecular mechanisms OT - molecular pathology COIS- The authors declare no conflicts of interest. EDAT- 2024/10/25 12:24 MHDA- 2024/10/25 12:25 PMCR- 2024/10/16 CRDT- 2024/10/25 09:55 PHST- 2024/08/30 00:00 [received] PHST- 2024/10/05 00:00 [revised] PHST- 2024/10/14 00:00 [accepted] PHST- 2024/10/25 12:25 [medline] PHST- 2024/10/25 12:24 [pubmed] PHST- 2024/10/25 09:55 [entrez] PHST- 2024/10/16 00:00 [pmc-release] AID - cimb46100684 [pii] AID - cimb-46-00684 [pii] AID - 10.3390/cimb46100684 [doi] PST - epublish SO - Curr Issues Mol Biol. 2024 Oct 16;46(10):11519-11536. doi: 10.3390/cimb46100684. PMID- 39446511 OWN - NLM STAT- MEDLINE DCOM- 20241024 LR - 20260508 IS - 1538-7488 (Electronic) IS - 0002-936X (Linking) VI - 124 IP - 11 DP - 2024 Nov 1 TI - Nursing Roles in Extracorporeal Membrane Oxygenation. PG - 30-37 LID - 10.1097/01.NAJ.0001081100.87718.df [doi] AB - Extracorporeal membrane oxygenation (ECMO) is a type of mechanical circulatory support that is increasingly utilized in the United States for severe respiratory and/or cardiac failure refractory to conventional therapies. It is an expensive and complex life support modality. Moreover, patients on ECMO are critically ill and require a strong multidisciplinary care team. A successful ECMO program involves a trained team consisting of physicians, perfusionists, nurses, and respiratory therapists. This article discusses the multiple roles of ECMO nurses, the various ECMO delivery care models, and the potential cost savings of an RN ECMO specialist staffing model-and introduces the novel role of the ECMO lead. CI - Copyright (c) 2024 Wolters Kluwer Health, Inc. All rights reserved. FAU - Parrett, Michelle AU - Parrett M AD - Michelle Parrett is an assistant ECMO coordinator and ECMO lead at UC San Diego Health, La Jolla, CA, where Cassia Yi is a clinical coordinator in the Mechanical Circulatory Support Program, Brooke Weaver is an ECMO lead, Meghan Jones is an NP in the Division of Cardiothoracic Surgery, Judy Davidson is a nurse scientist, Mazen Odish is an assistant professor of medicine in the Division of Pulmonary and Critical Care Medicine, and Travis Pollema is an associate clinical professor of surgery in the Division of Cardiovascular and Thoracic Surgery and medical director of the UC San Diego ECMO Program. Marites B. Almachar is a cardiac acute care float advanced practice provider and teaching associate in the Division of Cardiology at the University of Washington Medical Center, Seattle. Contact author: Michelle Parrett, mparrett@health.ucsd.edu . Cassia Yi, Mazen Odish, and Travis Pollema are Extracorporeal Life Support Organization instructors. The authors and planners have disclosed no potential conflicts of interest, financial or otherwise. FAU - Yi, Cassia AU - Yi C FAU - Weaver, Brooke AU - Weaver B FAU - Jones, Meghan AU - Jones M FAU - Almachar, Marites B AU - Almachar MB FAU - Davidson, Judy AU - Davidson J FAU - Odish, Mazen AU - Odish M FAU - Pollema, Travis AU - Pollema T LA - eng PT - Journal Article DEP - 20241024 PL - United States TA - Am J Nurs JT - The American journal of nursing JID - 0372646 SB - IM MH - *Extracorporeal Membrane Oxygenation/nursing/methods MH - Humans MH - *Nurse's Role MH - United States MH - Patient Care Team MH - Heart Failure/nursing/therapy MH - Respiratory Insufficiency/therapy/nursing EDAT- 2024/10/25 07:20 MHDA- 2024/10/25 07:21 CRDT- 2024/10/24 12:04 PHST- 2024/10/25 07:21 [medline] PHST- 2024/10/25 07:20 [pubmed] PHST- 2024/10/24 12:04 [entrez] AID - 00000446-202411000-00018 [pii] AID - 10.1097/01.NAJ.0001081100.87718.df [doi] PST - ppublish SO - Am J Nurs. 2024 Nov 1;124(11):30-37. doi: 10.1097/01.NAJ.0001081100.87718.df. Epub 2024 Oct 24. PMID- 39444856 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241025 IS - 2072-1439 (Print) IS - 2077-6624 (Electronic) IS - 2072-1439 (Linking) VI - 16 IP - 9 DP - 2024 Sep 30 TI - Respiratory issues and current management in neuromuscular diseases: a narrative review. PG - 6292-6307 LID - 10.21037/jtd-23-1931 [doi] AB - BACKGROUND AND OBJECTIVE: Respiratory care is often embedded as a component of the overlapping management strategies in many patients with neuromuscular disease (NMD). Implementation of respiratory care strategies requires a sensitivity to the nature of the disease, the vulnerability during rapid eye movement (REM) sleep and complicating comorbidities specific to each patient. Care must adjust to progression of the disease as well as the comfort and preferences of the patient. Clinical presentations are usually heterogenous based on the specific NMD and overall course of the disease making diagnosis and respiratory care challenging. The aim of this review was to review the state-of-the-art evidence-based clinical practices and updates in the management of respiratory complications in patients with NMDs. METHODS: We conducted a search on the PubMed and Medline databases using these keywords: secretions, neuromuscular disease, neuromuscular disorders, non-invasive ventilator, neuromuscular respiratory weakness, respiratory failure. The specified timeframe began from 1980 to 2024. KEY CONTENT AND FINDINGS: Timely use of non-invasive ventilation and overall respiratory care is most important as emerging evidence shows some benefits with improved mortality in this group of patients. In some settings, comorbid complications that dictate need for airway management and oral diversion may have a more profound impact on mortality than the effectiveness of ventilatory support that are chosen. A multidisciplinary team approach to care has been shown to improve the quality of life and survival in these patients in centers of excellence. Patients should have the ability to access services provided by neurology, pulmonology, speech pathology, sleep medicine, cardiology and respiratory therapy services. CONCLUSIONS: The cornerstone for management of respiratory failure and sleep disordered breathing in NMD is non-invasive ventilation (NIV). Initiation of this support and other respiratory cares need to be timely, and patients may have very subtle symptoms during the early stages of the disease which makes it challenging in recognizing the onset of respiratory muscle stress and fatigue. Close attention to these symptoms as well as respiratory and radiologic parameters is essential for appropriate incorporation of these cares. CI - 2024 AME Publishing Company. All rights reserved. FAU - Akpa, Bimaje AU - Akpa B AUID- ORCID: 0009-0009-4176-8271 AD - Division of Pulmonary, Critical Care & Sleep Medicine, University of Minnesota Medical School, Minneapolis, MN, USA. FAU - Pusalavidyasagar, Snigdha AU - Pusalavidyasagar S AD - Division of Pulmonary, Critical Care & Sleep Medicine, University of Minnesota Medical School, Minneapolis, MN, USA. FAU - Iber, Conrad AU - Iber C AD - Division of Pulmonary, Critical Care & Sleep Medicine, University of Minnesota Medical School, Minneapolis, MN, USA. LA - eng PT - Journal Article PT - Review DEP - 20240926 PL - China TA - J Thorac Dis JT - Journal of thoracic disease JID - 101533916 PMC - PMC11494593 OTO - NOTNLM OT - Neuromuscular disease (NMD) OT - neuromuscular respiratory weakness OT - non-invasive ventilation (NIV) OT - respiratory failure COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-23-1931/coif). The authors have no conflicts of interest to declare. EDAT- 2024/10/24 16:50 MHDA- 2024/10/24 16:51 PMCR- 2024/09/30 CRDT- 2024/10/24 04:23 PHST- 2023/12/27 00:00 [received] PHST- 2024/07/12 00:00 [accepted] PHST- 2024/10/24 16:51 [medline] PHST- 2024/10/24 16:50 [pubmed] PHST- 2024/10/24 04:23 [entrez] PHST- 2024/09/30 00:00 [pmc-release] AID - jtd-16-09-6292 [pii] AID - 10.21037/jtd-23-1931 [doi] PST - ppublish SO - J Thorac Dis. 2024 Sep 30;16(9):6292-6307. doi: 10.21037/jtd-23-1931. Epub 2024 Sep 26. PMID- 39441327 OWN - NLM STAT- MEDLINE DCOM- 20241224 LR - 20260629 IS - 1534-3170 (Electronic) IS - 1523-3782 (Print) IS - 1523-3782 (Linking) VI - 26 IP - 12 DP - 2024 Dec TI - The Good (Tumor Killing) and the Bad (Cardiovascular Complications) of Immunologic Checkpoint Inhibitors. PG - 1487-1498 LID - 10.1007/s11886-024-02147-x [doi] AB - PURPOSE OF REVIEW: This review details the significant advancement in knowledge of Immune-checkpoint inhibitor (ICI) and its potential deleterious cardiac immune-related adverse effects (irAE). We explore their mechanisms on the cardiac tissue, providing guidance on risk factors, clinical presentations, diagnostic strategies along with treatment. RECENT FINDINGS: Recent findings have provided insights of cardiac irAEs that exist beyond the previously well-known ICI-induced myocarditis. We have a better understanding of the wide variety of cardiac irAEs pathologies both early and late onset. Moreover, there is more data on mechanisms of cardiotoxicity and patient and therapy-related risk factors, supporting closer routine cardiac monitoring with biomarkers and imaging for prevention and early detection. Diagnosing cardiac irAEs is a challenge given its broad clinical presentation. A high-level of suspicion in addition to early work-up is crucial to prevent serious cardiac events. A multi-disciplinary team including Cardiologists and Oncologists is essential for closely monitor patients' cardiac status on ICI therapy. There is a need of updated guidelines to establish clear recommendations in patients on ICIs. CI - (c) 2024. The Author(s). FAU - Gamero, Maria T AU - Gamero MT AD - Department of Medicine, Division of Cardiovascular Disease, Jefferson Heart Institute, Thomas Jefferson University Hospital, Philadelphia, PA, USA. maria.gamerohuaman@jefferson.edu. FAU - Patel, Avish AU - Patel A AD - Department of Medicine, Division of Cardiovascular Disease, Jefferson Heart Institute, Thomas Jefferson University Hospital, Philadelphia, PA, USA. FAU - Storozynsky, Eugene AU - Storozynsky E AD - Department of Medicine, Division of Cardiovascular Disease, Jefferson Heart Institute, Thomas Jefferson University Hospital, Philadelphia, PA, USA. LA - eng PT - Journal Article PT - Review DEP - 20241023 PL - United States TA - Curr Cardiol Rep JT - Current cardiology reports JID - 100888969 RN - 0 (Immune Checkpoint Inhibitors) SB - IM MH - Humans MH - *Immune Checkpoint Inhibitors/adverse effects MH - *Cardiotoxicity/etiology/prevention & control MH - *Neoplasms/drug therapy MH - Cardiovascular Diseases/chemically induced/prevention & control MH - Risk Factors PMC - PMC11668830 OTO - NOTNLM OT - CTLA 4 cytotoxic T lymphocyte associated protein 4 OT - ICI Immune checkpoint inhibitor OT - IrAE immune related adverse events OT - PD 1 programmed cell death protein 1 OT - PD L1 programmed death ligand 1 COIS- Compliance with Ethical Standards. Conflict of interest: The authors declare no competing interests. Human and Animal Rights and Informed Consent: This article does not contain any studies with human or animal subjects performed by any of the authors. EDAT- 2024/10/23 12:40 MHDA- 2024/12/24 12:21 PMCR- 2024/10/23 CRDT- 2024/10/23 11:07 PHST- 2024/09/23 00:00 [accepted] PHST- 2024/12/24 12:21 [medline] PHST- 2024/10/23 12:40 [pubmed] PHST- 2024/10/23 11:07 [entrez] PHST- 2024/10/23 00:00 [pmc-release] AID - 10.1007/s11886-024-02147-x [pii] AID - 2147 [pii] AID - 10.1007/s11886-024-02147-x [doi] PST - ppublish SO - Curr Cardiol Rep. 2024 Dec;26(12):1487-1498. doi: 10.1007/s11886-024-02147-x. Epub 2024 Oct 23. PMID- 39441182 OWN - NLM STAT- MEDLINE DCOM- 20241109 LR - 20241109 IS - 1744-8344 (Electronic) IS - 1477-9072 (Linking) VI - 22 IP - 10 DP - 2024 Oct TI - Managing elderly patients with atrial fibrillation and multimorbidity: call for a systematic approach. PG - 523-536 LID - 10.1080/14779072.2024.2416666 [doi] AB - INTRODUCTION: Atrial fibrillation (AF) is often accompanied by comorbidities. Not only cardiovascular but also non-cardiovascular comorbidities have been associated with AF. Multimorbidity is therefore a common finding in patients with AF, especially in elderly patients. Multimorbidity is associated with adverse outcomes, adds complexity to AF management, and poses a significant burden on healthcare costs. It is expected that the prevalence of elderly patients with multimorbidity will increase significantly. It is therefore crucial to outline implications for clinical practice and guide comprehensive multimorbidity management. AREAS COVERED: This perspective article outlines multimorbidity in AF and the importance of comprehensive comorbidity management. It addresses current clinical practice guided by international guidelines and the need for integrated care including a patient-centered focus, comprehensive AF management, coordinated multidisciplinary care, and supporting technology. Moreover, it proposes a novel model of care delivery following a systematic approach to multimorbidity management. EXPERT OPINION: Providing comprehensive care by means of a multidisciplinary team and patient engagement is crucial to provide optimal personalized care for elderly patients with AF and multimorbidity. A systematic integrated care approach seems promising, but further studies are needed to investigate the feasibility of a systematic approach and prioritization of comorbidity management in patients with multimorbidity. FAU - van Deutekom, Colinda AU - van Deutekom C AUID- ORCID: 0000-0001-5116-7378 AD - Department of Cardiology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands. FAU - Hendriks, Jeroen M L AU - Hendriks JML AUID- ORCID: 0000-0003-4326-9256 AD - Caring Futures Institute, College of Nursing and Health Sciences, Flinders University, Adelaide, Australia. AD - Centre for Heart Rhythm Disorders, University of Adelaide and Royal Adelaide Hospital, Adelaide, Australia. FAU - Myrstad, Marius AU - Myrstad M AUID- ORCID: 0000-0002-9682-5255 AD - Department of Internal Medicine, Baerum Hospital Vestre Viken Hospital Trust, Gjettum, Norway. FAU - Van Gelder, Isabelle C AU - Van Gelder IC AUID- ORCID: 0000-0002-7579-1201 AD - Department of Cardiology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands. FAU - Rienstra, Michiel AU - Rienstra M AUID- ORCID: 0000-0002-2581-070X AD - Department of Cardiology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands. LA - eng PT - Journal Article PT - Review DEP - 20241024 PL - England TA - Expert Rev Cardiovasc Ther JT - Expert review of cardiovascular therapy JID - 101182328 SB - IM MH - Humans MH - *Atrial Fibrillation/therapy/epidemiology/complications MH - *Multimorbidity MH - Aged MH - *Patient-Centered Care MH - *Patient Care Team/organization & administration MH - Practice Guidelines as Topic MH - Delivery of Health Care, Integrated/organization & administration MH - Age Factors MH - Health Care Costs MH - Comprehensive Health Care/organization & administration MH - Patient Participation MH - Prevalence MH - Delivery of Health Care/organization & administration OTO - NOTNLM OT - Atrial fibrillation OT - comorbidities OT - integrated care OT - management OT - multimorbidity OT - systematic approach EDAT- 2024/10/23 16:18 MHDA- 2024/11/13 13:52 CRDT- 2024/10/23 10:44 PHST- 2024/11/13 13:52 [medline] PHST- 2024/10/23 16:18 [pubmed] PHST- 2024/10/23 10:44 [entrez] AID - 10.1080/14779072.2024.2416666 [doi] PST - ppublish SO - Expert Rev Cardiovasc Ther. 2024 Oct;22(10):523-536. doi: 10.1080/14779072.2024.2416666. Epub 2024 Oct 24. PMID- 39437511 OWN - NLM STAT- MEDLINE DCOM- 20241117 LR - 20261002 IS - 1532-1967 (Electronic) IS - 0305-7372 (Linking) VI - 131 DP - 2024 Dec TI - Follow-up of early breast cancer in a public health system: A 2024 AIGOM consensus project. PG - 102832 LID - S0305-7372(24)00160-9 [pii] LID - 10.1016/j.ctrv.2024.102832 [doi] AB - Breast cancer stands as the most frequently diagnosed cancer and the primary cause of cancer-related mortality among women worldwide, including Italy. With the increasing number of survivors, many are enrolled in regular follow-up programs. However, adherence to recommendations from scientific societies (such as ASCO, ESMO, AIOM) for breast cancer follow-up management varies in daily clinical practice across different cancer centers, potentially resulting in unequal management and escalating costs. To address these concerns, the Italian Association of Multidisciplinary Oncology Groups (AIGOM) orchestrated a Consensus on early Breast Cancer follow-up utilizing the Estimate-Talk-Estimate methodology. Following the identification of 18 Items and 38 statements by a select Board, 46 out of 54 (85.1%) experts comprising a multidisciplinary and multiprofessional panel expressed their degree of consensus (Expert Panel). The Expert Panel underscores the potential for the multidisciplinary team to tailor follow-up intensity based on the individual risk of recurrence. In selected cases, the general practitioner may be recommended as the clinical lead for breast cancer follow-up, both after completion of adjuvant treatment and at early initiation of endocrine therapy in low-risk patients. Throughout follow-up, and alongside oncologic surveillance, the expert panel advises osteometabolic, cardiologic, and gynecologic surveillance for the early detection and management of early and late treatment toxicities. Moreover, preserving quality of life is emphasized, with provisions for psycho-oncologic support and encouragement to adopt protective lifestyle behaviors. CI - Copyright (c) 2024 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Gori, Stefania AU - Gori S AD - Medical Oncology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy. Electronic address: stefania.gori@sacroccuore.it. FAU - De Rose, Fiorenza AU - De Rose F AD - Radiation Oncology, APSS, Trento, Italy. FAU - Ferro, Antonella AU - Ferro A AD - Oncologia Medica, Breast Unit APSS, Trento, Italy. FAU - Fabi, Alessandra AU - Fabi A AD - Head of Precision Medicine Unit in Senology, Responsabile UOSD Medicina di Precisione in Senologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Universita Cattolica del Sacro Cuore, Largo Agostino Gemelli, 8, 00168 Roma, Italy. FAU - Angiolini, Catia AU - Angiolini C AD - Breast Medical Oncology, Oncology Department, Careggi Hospital, Firenze, Italy. FAU - Azzarello, Giuseppe AU - Azzarello G AD - Unita Operativa Complessa Oncologia, AULSS 3 Serenissima, Mirano-Dolo (Venezia), Italy. FAU - Cancian, Maurizio AU - Cancian M AD - General Practitioner, Coordinatore MGI De Gironcoli, Conegliano, Treviso, Italy; National Executive Council of the Italian Society of General Medicine (S.I.M.G.), Florence, Italy. FAU - Cinquini, Michela AU - Cinquini M AD - Laboratorio di metodologia delle revisioni sistematiche e produzione di linee guida, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy. FAU - Arecco, Luca AU - Arecco L AD - Department of Internal Medicine and Medical Specialties (DIMI), School of Medicine, University of Genova, Genova, Italy; Medical Oncology Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy. FAU - Aristei, Cynthia AU - Aristei C AD - Radiation Oncology Section, Department of Medicine and Surgery, University of Perugia and Perugia General Hospital, Italy. FAU - Bernardi, Daniela AU - Bernardi D AD - Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090 Pieve Emanuele - Milan, Italy; IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano - Milan, Italy. FAU - Biganzoli, Laura AU - Biganzoli L AD - Department of Oncology, Hospital of Prato, Azienda USL Toscana Centro, Prato, Italy. FAU - Cariello, Anna AU - Cariello A AD - Oncologia di Ravenna-AUSL Romagna, Ravenna, Italy. FAU - Cortesi, Laura AU - Cortesi L AD - Oncologia, Ematologia e Malattie dell'apparato respiratorio, Azienda Ospedaliera-Universitaria, Policlinico di Modena, Italy. FAU - Cretella, Elisabetta AU - Cretella E AD - Oncologia Medica, Ospedale di Bolzano, Italy. FAU - Criscitiello, Carmen AU - Criscitiello C AD - Sviluppo Nuovi farmaci per le terapie innovative, Istituto Europeo di Oncologia (IEO) IRCCS, Universita degli studi di Milano, Milano, Italy. FAU - De Giorgi, Ugo AU - De Giorgi U AD - IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola FC, Italy. FAU - Carmen De Santis, Maria AU - Carmen De Santis M AD - Radiation Oncology Fondazione I.R.C.C.S. Istituto Nazionale Tumori di Milano, Italy. FAU - Deledda, Giuseppe AU - Deledda G AD - Clinical Psychology Unit, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy. FAU - Dessena, Massimo AU - Dessena M AD - S.S. Senologia Chirurgica, Chirurgia Polispecialistica, Policlinico Universitario di Monserrato, Azienda Ospedaliera Universitaria, Cagliari, Italy. FAU - Donati, Sara AU - Donati S AD - Oncologia Ospedale Versilia, Camaiore, Lucca, Italy. FAU - Dri, Arianna AU - Dri A AD - Dipartimento di Oncologia Medica - Centro di Riferimento Oncologico (CRO) - IRCCS Aviano, Pordenone, Universita degli Studi di Udine, Italy. FAU - Ferretti, Gianluigi AU - Ferretti G AD - Divisione Oncologia Medica 1, IRCCS Regina Elena National Cancer Institute, Roma, Italy. FAU - Foglietta, Jennifer AU - Foglietta J AD - Oncologia Medica e Traslazionale, Ospedale Santa Maria di Terni, Italy. FAU - Franceschini, Davide AU - Franceschini D AD - Department of Radiotherapy and Radiosurgery, IRCCS - Humanitas Research Hospital, Rozzano, Milano, Italy. FAU - Franco, Pierfrancesco AU - Franco P AD - Department of Translational Medicine (DIMET), University of Eastern Piedmont, Novara, Italy; Department of Radiation Oncology, "Maggiore della Carita" University Hospital, Novara, Italy. FAU - Schirone, Alessio AU - Schirone A AD - Unita Operativa Interaziendale di Oncologia Clinica, Azienda Ospedaliero Universitaria di Ferrara, Italy. FAU - Generali, Daniele AU - Generali D AD - Dipartimento Universitario Clinico di Scienze Mediche, Chirurgiche e della Salute, Universita degli Studi di Trieste, Italy. FAU - Gianni, Lorenzo AU - Gianni L AD - UO Operativa di Oncologia-Ospedale Infermi, Rimini, Italy. FAU - Giordani, Stefano AU - Giordani S AD - Oncologia Territoriale - AUSL, Bologna, Italy. FAU - Grandi, Giovanni AU - Grandi G AD - Associate Professor in Obstetrics and Gynecology, Department of Medical and Surgical Sciences for Mother, Child and Adult, University of Modena and Reggio Emilia, Azienda Ospedaliero Universitaria Policlinico, Via del Pozzo 71, 41124 Modena, Italy. FAU - Cristina Leonardi, Maria AU - Cristina Leonardi M AD - Division of Radiation Oncology, IEO European Institute of Oncology, IRCCS, Milan, Italy. FAU - Magno, Stefano AU - Magno S AD - UOS Terapie integrate in Senologia, Fondazione Policlinico Universitario A.Gemelli IRCCS, Roma, Italy. FAU - Malorni, Luca AU - Malorni L AD - S.O.S. Ricerca Traslazionale, S.O.C. Oncologia Medica, Nuovo Ospedale di Prato Santo Stefano, Azienda USL Toscana Centro, Prato, Italy. FAU - Mantoan, Carlotta AU - Mantoan C AD - Dirigente delle Professioni Sanitarie - Ospedale Fracastoro - San Bonifacio, Azienda Ulss9 Scaligera, Verona, Italy. FAU - Martorana, Federica AU - Martorana F AD - Dipartimento di Medicina Clinica e Sperimentale, Universita di Catania, Italy. FAU - Meattini, Icro AU - Meattini I AD - Department of Experimental and Clinical Biomedical Sciences "M. Serio" - University of Florence, Italy; Breast Unit & Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy. FAU - Meduri, Bruno AU - Meduri B AD - Department of Radiation Oncology, University Hospital of Modena, Modena, Italy. FAU - Merlini, Laura AU - Merlini L AD - UOC Oncologia, Ospedali Riuniti Padova Sud, Azienda ULSS 6 Euganea, Italy. FAU - Miglietta, Federica AU - Miglietta F AD - Oncologia Medica 2, IRCCS Istituto Oncologico Veneto, DiSCOG Universita degli Studi di Padova, Padova, Italy. FAU - Modena, Alessandra AU - Modena A AD - Medical Oncology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy. FAU - Nicolis, Fabrizio AU - Nicolis F AD - Medical Direction, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy. FAU - Palumbo, Isabella AU - Palumbo I AD - IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano - Milan, Italy. FAU - Panizza, Pietro AU - Panizza P AD - Breast Imaging Unit, IRCCS Ospedale San Raffaele, Milano, Italy. FAU - Angela Rovera, Francesca AU - Angela Rovera F AD - S.S.D. Breast Unit, ASST Sette Laghi - Universita degli Studi dell'Insubria, Varese, Italy. FAU - Salvini, Piermario AU - Salvini P AD - Responsabile Medicina Oncologica, Policlinico Ponte S Pietro di Istituti Ospedalieri Bergamaschi, Ponte San Pietro, Bergamo, Italy. FAU - Santoro, Armando AU - Santoro A AD - Humanitas Cancer Center - Istituto Clinico Humanitas IRCCS - Humanitas University - Rozzano, Milano, Italy. FAU - Taffurelli, Mario AU - Taffurelli M AD - IRCCS Policlinico sant'Orsola, Universita di Bologna, Italy. FAU - Toss, Angela AU - Toss A AD - Department of Oncology and Hematology, Azienda Ospedaliero-Universitaria di Modena, 41124 Modena, Italy; Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, 41124 Modena, Italy. FAU - Tralongo, Paolo AU - Tralongo P AD - Struttura Complessa di Oncologia, Dipartimento di Oncologia, Ospedale Umberto I Siracusa, Italy. FAU - Turazza, Monica AU - Turazza M AD - Medical Oncology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy. FAU - Valerio, Matteo AU - Valerio M AD - Medical Oncology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy. FAU - Verze, Matteo AU - Verze M AD - Medical Direction, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy. FAU - Vici, Patrizia AU - Vici P AD - UOSD Sperimentazioni Fase IV, IRCCS Istituto Nazionale Tumori Regina Elena, 00144 Rome, Italy. FAU - Zamagni, Claudio AU - Zamagni C AD - Head Breast & Gynecological Medical Oncology Unit, IRCCS Azienda Ospedaliero Universitaria di Bologna, Italy. FAU - Curigliano, Giuseppe AU - Curigliano G AD - Istituto Europeo di Oncologia, IRCCS, Milano, Italy; Dipartimento di Oncologia ed Emato-Oncologia, Universita di Milano, Milano, Italy. FAU - Pappagallo, Giovanni AU - Pappagallo G AD - Methodology School of Clinical Research, IRCCS Sacro Cuore Don Calabria, Negrar di Valpolicella, Verona, Italy. FAU - Zambelli, Alberto AU - Zambelli A AD - Medical Oncology Unity, IRCCS Istituto Clinico Humanitas and Department of Biomedical Sciences Humanitas University, Milano, Rozzano. CN - Italian Association of Multidisciplinary Oncology Groups (AIGOM) LA - eng PT - Consensus Statement PT - Journal Article PT - Review DEP - 20241005 PL - Netherlands TA - Cancer Treat Rev JT - Cancer treatment reviews JID - 7502030 SB - IM MH - Female MH - Humans MH - *Breast Neoplasms/therapy MH - Follow-Up Studies MH - Italy MH - Public Health OTO - NOTNLM OT - Consensus OT - Early Breast Cancer OT - Estimate-Talk-Estimate methodology OT - Follow-up COIS- Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: None of the authors has any interests to report directly related to this manuscript. Outside the scope of this manuscript: Stefania Gori, Fiorenza De Rose, no conflict of interests to declare. Antonella Ferro, honoraria from Novartis, MDS, Daiichi Sankyo, Astra Zeneca, Ely Lilly, Gentili. Alessandra Fabi grants from Astra Zeneca (steering committee); consulting fees from Roche, Lilly, Novartis, AstraZeneca, Pfizer, Seagen, Gilead, MSD, Menarini; honoraria from Astra Zeneca, Roche, Lilly, Novartis, Gilead, Pfizer, Daiichi Sankyo Exact Sciences; travel grants from Roche, Lilly, Novartis, AstraZeneca, Pfizer, Seagen, Gilead, MSD, Menarini; advisory board from Roche, Lilly, Novartis, AstraZeneca, Pfizer, Seagen, Gilead, MSD, Menarini. Catia Angiolini, Giuseppe Azzarello, Maurizio Cancian, Michela Cinquini, Luca Arecco no conflict of interests to declare. Cynthia Aristei, grants from PRIN 2023, from the Ministry of University and Research. Project title "The microbiome in breast cancer therapy and its potential for pRobIOtics to improve treatment outcome. Acronym: BARRIO". Daniela Bernardi, Laura Biganzoli, Anna Cariello no conflict of interests to declare. Laura Cortesi, report grants from Astra Zeneca, MSD, Pfizer; consulting fees and honoraria from Astra Zeneca, Gilead, MSD, Roche, Pfizer, Daijchii Sanchio, Novartis; travel grants from Gilead, Pfizer, Daijchi Sanchio; Advisory Board from Astra Zeneca, MSD, Novartis. Elisabetta Cretella no conflict of interests to declare. Carmen Criscitiello, grants from Seagen, Gilead; consulting fees and honoraria from Pfizer, Novartis, Lilly, MSD; Seagen, Daiichi Sankyo, Gilead, AstraZeneca, Roche. Ugo De Giorgi consulting fees from Amgen, Astellas Pharma, Astrazeneca, Bayer, Bristol-Myers Squibb, Eisai, Ipsen, Janssen, Merck KGaA, MSD, Novartis, Pfizer; travel grants from Pfizer, Ipsen, Astrazeneca. Maria Carmen De Santis, Giuseppe Deledda, Massimo Dessena, Sara Donati, Arianna Dri, Gianluigi Ferretti no conflict of interests to declare. Jennifer Foglietta, honoraria from Novartis; travel grants from Roche, Sophos, Pfizer; Advisory Board from Menarini Stem Line. Davide Franceschini, Pierfrancesco Franco, Alessio Schirone no conflict of interests to declare. Daniele Generali, grants from LILT, University of Trieste, Novartis, Roche; consulting fees from Lilly, Novartis, Pfizer, Roche, Accord, Daiichi Dankyo; honoraria from Lilly, Novartis, Pfizer, Roche, Accord, Daiichi Dankyo, Astrazeneca, Istituto Gentili; travel grants from Roche, Menarini; Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid from Mednote. Lorenzo Gianni, travel grants from Novartis, Lilly, Pfizer; Advisory Board from Astra Zeneca, Novartis, Seagen. Stefano Giordani, Giovanni Grandi, Maria Cristina Leonardi, Stefano Magno, no conflict of interests to declare. Luca Malorni, consulting fees from Menarini, Pfizer, Lilly, Novartis, Roche; travel grants from Roche, Menarini, Celgene, IT Health Fusion; Advisory Board from Novartis. Carlotta Mantoan no conflict of interests to declare. Federica Martorana honoraria from Lilly, Daychii-Sankyo, Pfizer, Astra-Zeneca, Novartis; travel grants from Gilead, Roche, Pfizer, Lilly; advisory board from Amgen. Icro Meattini consulting fees from Pfizer, Astra Zeneca, Daiichi Sankyo, Novartis, Eli Lilly, Seagen, Gilead, Menarini StemLine. Bruno Meduri, Laura Merlini, Federica Miglietta, Alessandra Modena, Fabrizio Nicolis, Isabella Palumbo, no conflict of interests to declare. Pietro Panizza honoraria and travel grants from Bayer AG. Francesca Angela Rovera, Piermario Salvini, Armando Santoro, Mario Taffurelli, no conflict of interests to declare. Angela Toss consulting fees and grants from Lilly, Pfizer, Novartis, MSD, Astrazeneca, Gilead, Seagen, Daiichi Sankyo; travel grants from Gilead, Daiichi Sankyo, Menarini, Astrazeneca. Paolo Tralongo, Monica Turazza, Matteo Valerio, Matteo Verze no conflict of interests to declare. Patrizia Vici consulting fees from Lilly, Daiichi-Sankyo, Pfizer, MSD, Novartis; honoraria from EISAI, Daiichi-Sankyo, Lilly, Novartis, Pfizer; travel grants from Roche, Pfizer, Daiichi-Sankyo, Novartis, IPSEN; advisory board from Pfizer, Novartis. Claudio Zamagni no conflict of interests to declare. Giuseppe Curigliano advisory board from Roche, Novartis, Lilly, Pfizer, Astra Zeneca, Daichii Sankyo, Ellipsis, Veracyte, Exact Science, Celcuity, Merck, BMS, Gilead, Sanofi, Menarini. Giovanni Pappagallo no conflict of interests to declare. Alberto Zambelli consulting fees Pfizer, Lilly, Novartis, Roche, AstraZeneca, DaiichiSankyo, Seagen, ExactSciences, MSD, Gentili, Gilead; travel grants from Roche, DaiichiSankyo, AstraZeneca, Novartis; advisory board from Roche. EDAT- 2024/10/23 04:22 MHDA- 2024/11/18 00:31 CRDT- 2024/10/22 18:02 PHST- 2024/06/21 00:00 [received] PHST- 2024/08/08 00:00 [revised] PHST- 2024/09/30 00:00 [accepted] PHST- 2024/11/18 00:31 [medline] PHST- 2024/10/23 04:22 [pubmed] PHST- 2024/10/22 18:02 [entrez] AID - S0305-7372(24)00160-9 [pii] AID - 10.1016/j.ctrv.2024.102832 [doi] PST - ppublish SO - Cancer Treat Rev. 2024 Dec;131:102832. doi: 10.1016/j.ctrv.2024.102832. Epub 2024 Oct 5. PMID- 39436891 OWN - NLM STAT- MEDLINE DCOM- 20241203 LR - 20241203 IS - 1557-8674 (Electronic) IS - 1096-2964 (Linking) VI - 25 IP - 10 DP - 2024 Dec TI - Severe Deep Fascial Spaces Infections with Pregnancy: A Retrospective Study. PG - 762-767 LID - 10.1089/sur.2024.143 [doi] AB - Background: Odontogenic infections are common and self-limiting in most cases, but, they can lead to severe consequences and considerable morbidity and can even be fetal in spite of modern medical therapy. Patients and Methods: Retrospective study included data of pregnant patients with deep fascial space infections, done in Oral & Maxillofacial Surgery Department, Faculty of Dentistry. Alexandria University, and Oral & Maxillofacial Surgery Department, King Fahd Specialist Hospital, Burayda, Qassim, Saudi Arabia, from June2017 to Dec2022. Data were analyzed to study incidence, etiology, pattern, treatment modalities, outcomes, complications, and effects on pregnancy. Results: Thirty-eight pregnant patients, with a mean age of 30.8 +/- 6.21 years, were included. The mean age of pregnancy was 24.5 +/- 4.3 weeks. Diabetes mellitus was identified in seven cases (18.42%) and combined with hypertension in one case (2.63%) and with valvular heart disease in another one. The commonest affected single space was the submandibular space that occurred in six cases (15.8%). Canine space was the second single commonly involved one which occurred in five patients (13.2%). Complications occurred in 11 patients. Unesthetic scar occurred in three patients (7.9%). Trismus was observed in two patients (5.3%). Recurrent abscess was found in one case. Complications affecting the developing fetus and considered the most serious occurred in four patients: two cases of preterm labor and two cases of abortion. Conclusion: These infections may lead to serious outcomes and may have irreversible effects on the pregnancy and the developing fetus. Urgent intervention with multidisciplinary team to provide adequate care. FAU - Mahran, Hamada AU - Mahran H AD - Maxillofacial Surgery Unit, General Surgery Department, Faculty of Medicine, Assiut University, Assiut, Egypt. AD - Consultant Oral & Maxillofacial Surgery, King Fahd Specialist hospital, Burayda, Saudi Arabia. FAU - Al Ashwah, Adham AU - Al Ashwah A AD - Faculty of Dentistry, Department of Oral & Maxillofacial Surgery, Alexandria University, Alexandria, Egypt. FAU - Rizq, Moataz AU - Rizq M AD - Consultant Oral & Maxillofacial Surgeon, Private practice, Alexandria, Egypt. LA - eng PT - Journal Article DEP - 20241022 PL - United States TA - Surg Infect (Larchmt) JT - Surgical infections JID - 9815642 SB - IM MH - Humans MH - Female MH - Pregnancy MH - Retrospective Studies MH - Adult MH - *Pregnancy Complications, Infectious/epidemiology MH - Young Adult MH - Saudi Arabia/epidemiology MH - Incidence OTO - NOTNLM OT - dental caries OT - fascial spaces OT - odontogenic infections OT - periodontal diseases OT - pregnancy EDAT- 2024/10/22 18:22 MHDA- 2024/12/03 12:26 CRDT- 2024/10/22 13:33 PHST- 2024/12/03 12:26 [medline] PHST- 2024/10/22 18:22 [pubmed] PHST- 2024/10/22 13:33 [entrez] AID - 10.1089/sur.2024.143 [doi] PST - ppublish SO - Surg Infect (Larchmt). 2024 Dec;25(10):762-767. doi: 10.1089/sur.2024.143. Epub 2024 Oct 22. PMID- 39434709 OWN - NLM STAT- MEDLINE DCOM- 20241118 LR - 20241118 IS - 1744-7666 (Electronic) IS - 1465-6566 (Linking) VI - 25 IP - 16 DP - 2024 Nov TI - Pharmacological management of heart failure: a patient-centred approach. PG - 2151-2165 LID - 10.1080/14656566.2024.2418414 [doi] AB - INTRODUCTION: Heart failure (HF) is a global health challenge that requires a multidisciplinary approach. Despite recent advances in pharmacological and interventional therapy, morbidity and mortality in these patients remain high. For this reason, and because of its interplay with other cardiovascular and non-cardiovascular diseases, HF represents a major area of research, with new trials being published every year and international guidelines constantly updated. AREAS COVERED: The authors review the current status and possible future developments in HF pharmacotherapy. EXPERT OPINION: The treatment of HF has made significant advances in recent years, and the current recommendations are based on large outcome trials. This has led to significant reductions in both mortality and morbidity, but the death rate remains unacceptably high. In this context, a patient-centered approach that considers comorbidities and specific clinical scenarios when dosing HF medication is essential. Prevention of hospital admissions for cardiac decompensation is of utmost importance in patients with HF as is the enablement of activities of daily living, an endpoint which has only recently been incorporated into major HF trials. FAU - Fibbi, Guglielmo AU - Fibbi G AUID- ORCID: 0009-0001-1937-1157 AD - Department of Cardiology and Pneumology, University Medical Center Gottingen, Gottingen, Germany. AD - German Center for Cardiovascular Research (DZHK), Partner Site Gottingen, Gottingen, Germany. AD - Department of Geriatrics, University Medical Center Gottingen, Gottingen, Germany. FAU - Sato, Ryosuke AU - Sato R AD - Department of Cardiology and Pneumology, University Medical Center Gottingen, Gottingen, Germany. AD - German Center for Cardiovascular Research (DZHK), Partner Site Gottingen, Gottingen, Germany. FAU - Vatic, Mirela AU - Vatic M AD - Department of Cardiology and Pneumology, University Medical Center Gottingen, Gottingen, Germany. AD - German Center for Cardiovascular Research (DZHK), Partner Site Gottingen, Gottingen, Germany. FAU - Genreith, Frederik Pascal AU - Genreith FP AUID- ORCID: 0000-0003-3169-6584 AD - Department of Cardiology and Pneumology, University Medical Center Gottingen, Gottingen, Germany. FAU - von Haehling, Stephan AU - von Haehling S AD - Department of Cardiology and Pneumology, University Medical Center Gottingen, Gottingen, Germany. AD - German Center for Cardiovascular Research (DZHK), Partner Site Gottingen, Gottingen, Germany. LA - eng PT - Journal Article PT - Review DEP - 20241111 PL - England TA - Expert Opin Pharmacother JT - Expert opinion on pharmacotherapy JID - 100897346 RN - 0 (Cardiovascular Agents) SB - IM MH - Humans MH - *Heart Failure/drug therapy MH - *Patient-Centered Care MH - Cardiovascular Agents/therapeutic use MH - Hospitalization MH - Practice Guidelines as Topic MH - Activities of Daily Living MH - Drug Development OTO - NOTNLM OT - angiotensin receptor-neprilysin inhibitors (ARNI) OT - drugs OT - heart failure OT - iron deficiency OT - mineralocorticoid receptor antagonists (MRAs) OT - pharmacotherapy OT - sodium-glucose co-transporter 2 (SGTL2) inhibitors OT - vericiguat EDAT- 2024/10/22 06:27 MHDA- 2024/11/18 06:22 CRDT- 2024/10/22 04:13 PHST- 2024/11/18 06:22 [medline] PHST- 2024/10/22 06:27 [pubmed] PHST- 2024/10/22 04:13 [entrez] AID - 10.1080/14656566.2024.2418414 [doi] PST - ppublish SO - Expert Opin Pharmacother. 2024 Nov;25(16):2151-2165. doi: 10.1080/14656566.2024.2418414. Epub 2024 Nov 11. PMID- 39432316 OWN - NLM STAT- MEDLINE DCOM- 20241021 LR - 20260407 IS - 1540-8175 (Electronic) IS - 0742-2822 (Linking) VI - 41 IP - 10 DP - 2024 Oct TI - Echocardiography in Endocarditis. PG - e15945 LID - 10.1111/echo.15945 [doi] AB - Infective endocarditis (IE) continues to have high rates of adverse outcomes, despite recent advances in diagnosis and management. Although the use of computer tomography and nuclear imaging appears to be increasing, echocardiography, widely available in most centers, is the recommended initial modality of choice to diagnose and consequently guide the management of IE in a timely-dependent fashion. Echocardiographic imaging should be performed as soon as the IE diagnosis is suspected. Several factors may delay diagnosis, for example, echocardiography findings may be negative early in the disease course. Thus, repeated echocardiography is recommended in patients with negative initial echocardiography if high suspicion for IE persists in patients at high risk. However, systematic echocardiographic screening should not be utilized as a common tool for fever, but only in the presence of a reasonable clinical suspicion of IE. It may increase the risk of false-positive rates of patients requiring IE therapy or may exacerbate diagnostic uncertainty about subtle findings. Considering the complexity of the disease, the echocardiographic use should be increasingly time-efficient and should focus on the correct identification of IE lesions and associated complications. The path to identify patients who need surgery passes through an echocardiographic skill ensuring the identification of the cardiac anatomical structures and their involvement in the destructive infective extension. We pointed out the role of echocardiography focused on the correct identification of IE distinctive lesions and the associated complications, as part of a diagnostic strategy, within an integrated multimodality imaging, managed by an "endocarditis team". CI - (c) 2024 Wiley Periodicals LLC. FAU - Greco, Cosimo Angelo AU - Greco CA AUID- ORCID: 0000-0001-8654-9755 AD - Cardiac Surgery Unit, "Vito Fazzi" Hospital, ASL Le, Lecce, Italy. AD - Cardiology and Intensive Cardiac Care Unit, "Veris Delli Ponti" Hospital, Scorrano, ASL Le, Lecce, Italy. FAU - Zaccaria, Salvatore AU - Zaccaria S AD - Cardiac Surgery Unit, "Vito Fazzi" Hospital, ASL Le, Lecce, Italy. FAU - Casali, Giovanni AU - Casali G AD - Cardiac Surgery Unit, "Vito Fazzi" Hospital, ASL Le, Lecce, Italy. AD - Cardiac Surgery Unit, "AOU Maggiore della Carita" Hospital, Novara, Italy. FAU - Nicolardi, Salvatore AU - Nicolardi S AD - Cardiac Surgery Unit, "Vito Fazzi" Hospital, ASL Le, Lecce, Italy. FAU - Albanese, Miriam AU - Albanese M AD - Cardiac Surgery Unit, "Vito Fazzi" Hospital, ASL Le, Lecce, Italy. LA - eng PT - Journal Article PT - Review PL - United States TA - Echocardiography JT - Echocardiography (Mount Kisco, N.Y.) JID - 8511187 SB - IM MH - Humans MH - *Endocarditis/diagnostic imaging MH - *Echocardiography/methods OTO - NOTNLM OT - echocardiography OT - infective endocarditis OT - multimodality imaging OT - three-dimensional transesophageal echocardiography EDAT- 2024/10/21 12:49 MHDA- 2024/10/22 00:21 CRDT- 2024/10/21 11:42 PHST- 2024/09/16 00:00 [revised] PHST- 2024/08/20 00:00 [received] PHST- 2024/09/21 00:00 [accepted] PHST- 2024/10/22 00:21 [medline] PHST- 2024/10/21 12:49 [pubmed] PHST- 2024/10/21 11:42 [entrez] AID - 10.1111/echo.15945 [doi] PST - ppublish SO - Echocardiography. 2024 Oct;41(10):e15945. doi: 10.1111/echo.15945. PMID- 39425571 OWN - NLM STAT- MEDLINE DCOM- 20241202 LR - 20250721 IS - 1445-5994 (Electronic) IS - 1444-0903 (Linking) VI - 54 IP - 12 DP - 2024 Dec TI - Epidemiology and outcome of medical emergency team calls within 48 hours of intensive care unit discharge. PG - 1981-1989 LID - 10.1111/imj.16538 [doi] AB - BACKGROUND: Some patients experience early (within 48 h) clinical deterioration and medical emergency team (MET) review following intensive care unit (ICU) discharge. Few studies have explored early MET review, despite it being a recognised quality and safety indicator. AIMS: To evaluate the (i) proportion of patients discharged from ICU receiving MET review and timing of reviews; (ii) characteristics of patients who received early MET review and (iii) predictors of early MET review and associations with clinical outcomes. METHODS: This is a retrospective observational study of ICU discharges over 2 years in a tertiary hospital and involves descriptive and inferential statistics, including logistic regression analysis. RESULTS: Of 3712 patients, 312 (8.4%) had an early MET review. Patients with cardiothoracic, cardiovascular, gastrointestinal and general surgical diagnoses, higher illness severity or who received invasive ventilation had a higher risk of early MET review. On multivariable analysis, early MET review was associated with an increased risk of ICU re-admission (odds ratio (OR) 6.76, 95% confidence interval (CI) 5.01-9.13, P < 0.001), in-hospital mortality (OR 3.62, 95% CI 2.19-5.99, P < 0.001) and discharge to a nursing home (OR 2.49, 95% CI 1.25-4.97, P = 0.01). Length of stay was longer in patients requiring early post-ICU MET review compared to those who did not (median 16 days vs. 10 days, P < 0.001). CONCLUSIONS: One in 12 patients received post-ICU early MET review. This was more likely in patients who were invasively ventilated, had higher illness severity and had certain admission diagnoses. Such patients were at risk for worse outcomes. There is a need to identify reversible factors contributing to such increased risk. CI - (c) 2024 Royal Australasian College of Physicians. FAU - Ransom, Jessica AU - Ransom J AD - Intensive Care Unit, Austin Health, Melbourne, Victoria, Australia. FAU - See, Emily AU - See E AUID- ORCID: 0000-0003-4436-4319 AD - ANZIC Research Centre, School of Public Health and Preventative Medicine, Monash University, Melbourne, Victoria, Australia. AD - Intensive Care Unit, Royal Melbourne Hospital, Melbourne, Victoria, Australia. AD - Nephrology, Royal Melbourne Hospital, Melbourne, Victoria, Australia. FAU - Eastwood, Glenn AU - Eastwood G AD - Intensive Care Unit, Austin Health, Melbourne, Victoria, Australia. AD - ANZIC Research Centre, School of Public Health and Preventative Medicine, Monash University, Melbourne, Victoria, Australia. FAU - Opdam, Helen AU - Opdam H AD - Intensive Care Unit, Austin Health, Melbourne, Victoria, Australia. AD - Australian Organ and Tissue Authority, Canberra, Australian Capital Territory, Australia. FAU - Bellomo, Rinaldo AU - Bellomo R AD - Intensive Care Unit, Austin Health, Melbourne, Victoria, Australia. AD - ANZIC Research Centre, School of Public Health and Preventative Medicine, Monash University, Melbourne, Victoria, Australia. AD - Department of Critical Care, Melbourne University, Melbourne, Victoria, Australia. AD - Australia Data Analytics Research Evaluation Centre, Austin Hospital, Melbourne, Victoria, Australia. FAU - Jones, Daryl AU - Jones D AUID- ORCID: 0000-0002-6446-3595 AD - Intensive Care Unit, Austin Health, Melbourne, Victoria, Australia. AD - ANZIC Research Centre, School of Public Health and Preventative Medicine, Monash University, Melbourne, Victoria, Australia. AD - Department of Critical Care, Melbourne University, Melbourne, Victoria, Australia. LA - eng PT - Journal Article PT - Observational Study DEP - 20241019 PL - Australia TA - Intern Med J JT - Internal medicine journal JID - 101092952 SB - IM MH - Humans MH - Male MH - Female MH - Retrospective Studies MH - *Patient Discharge MH - *Intensive Care Units MH - Middle Aged MH - Aged MH - *Hospital Mortality MH - Hospital Rapid Response Team MH - Time Factors MH - Length of Stay/statistics & numerical data MH - Patient Readmission/statistics & numerical data MH - Aged, 80 and over OTO - NOTNLM OT - clinical deterioration OT - medical emergency team OT - rapid response system OT - rapid response team EDAT- 2024/10/19 16:23 MHDA- 2024/12/02 12:32 CRDT- 2024/10/19 05:33 PHST- 2024/06/15 00:00 [received] PHST- 2024/09/09 00:00 [accepted] PHST- 2024/12/02 12:32 [medline] PHST- 2024/10/19 16:23 [pubmed] PHST- 2024/10/19 05:33 [entrez] AID - 10.1111/imj.16538 [doi] PST - ppublish SO - Intern Med J. 2024 Dec;54(12):1981-1989. doi: 10.1111/imj.16538. Epub 2024 Oct 19. PMID- 39424119 OWN - NLM STAT- MEDLINE DCOM- 20241219 LR - 20260304 IS - 1552-6259 (Electronic) IS - 0003-4975 (Linking) VI - 119 IP - 1 DP - 2025 Jan TI - The Society of Thoracic Surgeons Expert Consensus on the Multidisciplinary Management and Resectability of Locally Advanced Non-small Cell Lung Cancer. PG - 16-33 LID - S0003-4975(24)00861-0 [pii] LID - 10.1016/j.athoracsur.2024.09.041 [doi] AB - BACKGROUND: The contemporary management and resectability of locally advanced lung cancer are undergoing significant changes as new data emerge regarding immunotherapy and targeted treatments. The objective of this document is to review the literature and present consensus among a group of multidisciplinary experts to guide the determination of resectability and management of locally advanced non-small cell lung cancer (NSCLC) in the context of contemporary evidence. METHODS: The Society of Thoracic Surgeon Workforce on Thoracic Surgery assembled a multidisciplinary expert panel composed of thoracic surgeons and medical and radiation oncologists with established expertise in the management of lung cancer. A focused literature review was performed, and expert consensus statements were developed using a modified Delphi process to address 3 major themes: (1) assessing resectability and multidisciplinary management of locally advanced lung cancer, (2) neoadjuvant (including perioperative) therapy, and (3) adjuvant therapy. RESULTS: A consensus was reached on 19 recommendations. These consensus statements reflect updated insights on resectability and multidisciplinary management of locally advanced lung cancer based on the latest literature and current clinical experience, mainly focusing on the appropriateness of surgical therapy and emerging data regarding neoadjuvant and adjuvant therapies. CONCLUSIONS: Despite the complex decision-making process in managing locally advanced lung cancer, this expert panel agreed on several key recommendations. This document provides guidance for thoracic surgeons and other medical professionals in the optimal management of locally advanced lung cancer based on the most updated evidence and literature. CI - Copyright (c) 2024 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Kim, Samuel S AU - Kim SS AD - Canning Thoracic Institute, Northwestern Memorial Hospital, Northwestern University Feinberg School of Medicine, Chicago, Illinois. Electronic address: samuel.kim2@nm.org. FAU - Cooke, David T AU - Cooke DT AD - Division of General Thoracic Surgery, University of California Davis Health, Sacramento, California. FAU - Kidane, Biniam AU - Kidane B AD - Section of Thoracic Surgery, CancerCare Manitoba and University of Manitoba, Winnipeg, Manitoba, Canada. FAU - Tapias, Luis F AU - Tapias LF AD - Division of Thoracic Surgery, Mayo Clinic, Rochester, Minnesota. FAU - Lazar, John F AU - Lazar JF AD - Division of Thoracic Surgery, Ascension Saint Thomas Hospital, University of Tennessee Health Science Center, Nashville, Tennessee. FAU - Awori Hayanga, Jeremiah W AU - Awori Hayanga JW AD - Department of Cardiothoracic and Vascular Surgery, West Virginia University Medicine, Morgantown, West Virginia. FAU - Patel, Jyoti D AU - Patel JD AD - Division of Hematology/Oncology, Department of Medicine, Northwestern University, Chicago, Illinois. FAU - Neal, Joel W AU - Neal JW AD - Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford, California. FAU - Abazeed, Mohamed E AU - Abazeed ME AD - Department of Radiation Oncology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois. FAU - Willers, Henning AU - Willers H AD - Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. FAU - Shrager, Joseph B AU - Shrager JB AD - Division of Thoracic Surgery, Department of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, California; Department of Surgery, Veterans Affairs Palo Altos Health Care System, Stanford, California. LA - eng PT - Consensus Statement PT - Journal Article PT - Review DEP - 20241017 PL - Netherlands TA - Ann Thorac Surg JT - The Annals of thoracic surgery JID - 15030100R SB - IM MH - Humans MH - *Carcinoma, Non-Small-Cell Lung/pathology/therapy MH - Combined Modality Therapy/methods/standards MH - *Lung Neoplasms/pathology/therapy MH - Neoadjuvant Therapy/methods/standards MH - Neoplasm Staging MH - Pneumonectomy/methods/standards MH - *Societies, Medical/standards MH - *Thoracic Surgery/standards COIS- Disclosures Samuel S. Kim reports a relationship with Intuitive Surgical Inc that includes: funding grants and speaking and lecture fees. David T. Cooke reports a relationship with Bristol-Myers Squibb Co that includes: speaking and lecture fees. Biniam Kidane reports a relationship with AstraZeneca Pharmaceuticals LP that includes: consulting or advisory and speaking and lecture fees; with Merck & Co Inc that includes: consulting or advisory and speaking and lecture fees; with Roche that includes: consulting or advisory and speaking and lecture fees; with Medtronic that includes: consulting or advisory and speaking and lecture fees; and with Olympus Corporation that includes: consulting or advisory and speaking and lecture fees. Samuel S. Kim reports a relationship with AstraZeneca Pharmaceuticals LP that includes: consulting or advisory. Luis Tapia Vargas reports a relationship with AstraZeneca Pharmaceuticals LP that includes: consulting or advisory. Jyoti Patel reports a relationship with AbbVie Inc that includes: consulting or advisory; with AstraZeneca Pharmaceuticals LP that includes: consulting or advisory; with Bristol-Myers Squibb Co that includes: consulting or advisory; with Gilead Sciences Inc that includes: consulting or advisory; with Guardant Health Inc that includes: consulting or advisory; with Sanofi that includes: consulting or advisory; with Tempus that includes: consulting or advisory; with AnHeart Therapeutics that includes: consulting or advisory; with Blueprint Genetics that includes: consulting or advisory; and with Black Diamond Therapeutics that includes: consulting or advisory. Joel Neal reports a relationship with AstraZeneca Pharmaceuticals LP that includes: consulting or advisory; with Genetec Inc that includes: consulting or advisory; with Exelixis Inc that includes: consulting or advisory; with Takeda Pharmaceutical Company Ltd that includes: consulting or advisory; with Eli Lilly and Company that includes: consulting or advisory; with Amgen Inc that includes: consulting or advisory; with Sanofi that includes: consulting or advisory; and with Bristol-Myers Squibb Co that includes: consulting or advisory. Joseph Shrager reports a relationship with AstraZeneca Pharmaceuticals LP that includes: consulting or advisory and with Becton Dickinson and Company that includes: consulting or advisory. The other authors have no conflicts of interest to disclose. EDAT- 2024/10/19 16:23 MHDA- 2024/12/20 00:23 CRDT- 2024/10/18 19:21 PHST- 2024/06/21 00:00 [received] PHST- 2024/09/09 00:00 [revised] PHST- 2024/09/26 00:00 [accepted] PHST- 2024/12/20 00:23 [medline] PHST- 2024/10/19 16:23 [pubmed] PHST- 2024/10/18 19:21 [entrez] AID - S0003-4975(24)00861-0 [pii] AID - 10.1016/j.athoracsur.2024.09.041 [doi] PST - ppublish SO - Ann Thorac Surg. 2025 Jan;119(1):16-33. doi: 10.1016/j.athoracsur.2024.09.041. Epub 2024 Oct 17. PMID- 39424017 OWN - NLM STAT- MEDLINE DCOM- 20241123 LR - 20241123 IS - 1879-1336 (Electronic) IS - 1054-8807 (Linking) VI - 74 DP - 2025 Jan-Feb TI - Cause of death for heart transplant patients, an autopsy study. PG - 107701 LID - S1054-8807(24)00097-8 [pii] LID - 10.1016/j.carpath.2024.107701 [doi] AB - INTRODUCTION: Heart transplantations are lifesaving for patients with end-stage heart failure. It is pertinent for the multidisciplinary care team to understand how heart transplant patients succumbed to death and the complications that occurred. In this study, we performed a comprehensive retrospective review of all the autopsies performed in our institute for heart transplant patients and report the trend of demographic data, cause of death, and autopsy findings. MATERIALS AND METHODS: Reports, photos, and slides of autopsies performed at our institute from 1990 to 2023 for heart transplant patients were reviewed. Pertinent demographic data (age, gender, pretransplant diagnosis), clinical data (clinical history of rejection, complication, time interval from transplant to death, clinical cause of death) and pathological findings (allograft pathology, infectious etiology, other findings related to cause of death) were reviewed, documented, and analyzed. RESULTS: We identified 88 cases, consisting of 53 male and 35 female patients. The median age at transplant was 26 years, while 28.5 years was the median age at death. The median interval from transplant to death was 10 months. The cases were classified in three categories based on length of survival post-transplant: Superacute (<1 month, 21%), Early (1 month-12 months, 30%), and Late (> 12 months, 49%). Slides were unavailable for review in 15 cases, which were excluded from cause of death (COD) evaluation. We categorized 41.1% of cases as allograft-related COD and 58.9% as non-allograft-related COD. Six of the CODs were not perceived premortem. These unexpected CODs included moderate/severe acute cellular rejection in a patient with a recently negative biopsy, dehiscent suture caused by a fungal abscess, an aorto-bronchial fistula, CMV myocarditis, acute abdominal bleeding, and ruptured atherosclerotic plaques with acute myocardial infarction. CONCLUSION: We systematically reviewed 33 years of heart transplant autopsies. We found that 41.1% of deaths were allograft related, with infection being the most frequent COD. While the rate of unexpected findings was low, the findings demonstrate the continued utility of autopsy in patient evaluation. CI - Copyright (c) 2024 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Burk, Justin AU - Burk J AD - Department of Pathology and Immunology, Washington University in St. Louis School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, USA. FAU - Bernadt, Cory T AU - Bernadt CT AD - Department of Pathology and Immunology, Washington University in St. Louis School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, USA. FAU - Ritter, Jon AU - Ritter J AD - Department of Pathology and Immunology, Washington University in St. Louis School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, USA. FAU - Lin, Chieh-Yu AU - Lin CY AD - Department of Pathology and Immunology, Washington University in St. Louis School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, USA. Electronic address: chieh-yu@wustl.edu. LA - eng PT - Journal Article DEP - 20241016 PL - United States TA - Cardiovasc Pathol JT - Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology JID - 9212060 SB - IM MH - Humans MH - Male MH - Female MH - *Heart Transplantation/mortality/adverse effects MH - *Autopsy MH - Retrospective Studies MH - Adult MH - *Cause of Death MH - Middle Aged MH - Young Adult MH - Adolescent MH - Time Factors MH - Child MH - Risk Factors MH - Child, Preschool MH - Treatment Outcome MH - Heart Failure/mortality/surgery/pathology MH - Aged MH - Postoperative Complications/mortality OTO - NOTNLM OT - Autopsy OT - Cause of death OT - Heart transplant OT - Transplant OT - Transplantation COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/10/19 16:23 MHDA- 2024/11/24 00:44 CRDT- 2024/10/18 19:19 PHST- 2024/08/14 00:00 [received] PHST- 2024/10/02 00:00 [revised] PHST- 2024/10/03 00:00 [accepted] PHST- 2024/11/24 00:44 [medline] PHST- 2024/10/19 16:23 [pubmed] PHST- 2024/10/18 19:19 [entrez] AID - S1054-8807(24)00097-8 [pii] AID - 10.1016/j.carpath.2024.107701 [doi] PST - ppublish SO - Cardiovasc Pathol. 2025 Jan-Feb;74:107701. doi: 10.1016/j.carpath.2024.107701. Epub 2024 Oct 16. PMID- 39421961 OWN - NLM STAT- MEDLINE DCOM- 20241119 LR - 20241119 IS - 1941-3297 (Electronic) IS - 1941-3289 (Linking) VI - 17 IP - 11 DP - 2024 Nov TI - Cost-Effectiveness of a Shock Team Approach in Refractory Cardiogenic Shock. PG - e011709 LID - 10.1161/CIRCHEARTFAILURE.124.011709 [doi] AB - BACKGROUND: Multidisciplinary Shock Teams have improved clinical outcomes for cardiogenic shock, but their implementation costs have not been studied. This study's objective was to compare costs between patients treated with and without a Shock Team and determine if the team's implementation is cost-effective compared with standard of care. METHODS: We examined patients with refractory cardiogenic shock treated with or without a Shock Team at a tertiary academic hospital from 2009 to 2018. Real-world hospital data were used to compare costs and outcomes, including survival at discharge, 1-year survival, and quality-adjusted life years gained at 1 year. Incremental cost-effectiveness ratios were calculated over a 1-year time horizon, with parameter uncertainty evaluated through probabilistic sensitivity analysis using 1000 second-order Monte Carlo simulations. RESULTS: The study involved 244 patients, with 123 treated by the Shock Team and 121 receiving standard of care. Patients were predominantly male (77.5%), with a mean age of 58 (18-92) years. The Shock Team approach improved survival rates at hospital discharge and 1-year follow-up (61.0% versus 47.9%; P=0.04 and 55.0% versus 40.5%; P=0.03, respectively). The incremental cost-effectiveness ratio for increases in survival probability at discharge for the multidisciplinary Shock Team compared with standard of care was $102 088. The incremental cost-effectiveness ratio for increases in survival probability at 1-year was estimated at $96 152 and at $127 862 per 1 quality-adjusted life year gained. Probabilistic sensitivity analysis estimates showed that the Shock Team was cost-effective in the majority of simulations using a willingness-to-pay threshold of $150 000, while it was also dominant in almost one-third of the simulations. CONCLUSIONS: The Shock Team approach for treating refractory cardiogenic shock may be a cost-effective alternative to traditional standard of care. These findings can help prioritize the implementation of Shock Team initiatives to further improve cardiogenic shock outcomes. FAU - Taleb, Iosif AU - Taleb I AUID- ORCID: 0000-0002-0029-5019 AD - Division of Cardiovascular Medicine (I.T., C.P.K., K.S., E.T., K.S.S., E.D., T.L.J., S.J.C., J.C.F., J.S., T.C.H., S.G.D.), University of Utah School of Medicine, Salt Lake City. FAU - Giannouchos, Theodoros V AU - Giannouchos TV AD - Department of Health Policy and Organization, School of Public Health, University of Alabama at Birmingham (T.V.G.). FAU - Kyriakopoulos, Christos P AU - Kyriakopoulos CP AUID- ORCID: 0000-0001-9415-1245 AD - Division of Cardiovascular Medicine (I.T., C.P.K., K.S., E.T., K.S.S., E.D., T.L.J., S.J.C., J.C.F., J.S., T.C.H., S.G.D.), University of Utah School of Medicine, Salt Lake City. FAU - Clawson, Antoine AU - Clawson A AUID- ORCID: 0009-0009-9559-9506 AD - Division of Cardiovascular Medicine, University of Utah Health, Salt Lake City (A.C.). FAU - Davis, Erin S AU - Davis ES AUID- ORCID: 0000-0002-6112-0685 AD - Division of Cardiovascular Medicine, University of Utah Health Transplant Service Line, Salt Lake City (E.S.D.). FAU - Sideris, Konstantinos AU - Sideris K AUID- ORCID: 0009-0007-9369-0782 AD - Division of Cardiovascular Medicine (I.T., C.P.K., K.S., E.T., K.S.S., E.D., T.L.J., S.J.C., J.C.F., J.S., T.C.H., S.G.D.), University of Utah School of Medicine, Salt Lake City. FAU - Tseliou, Eleni AU - Tseliou E AUID- ORCID: 0000-0002-9350-2282 AD - Division of Cardiovascular Medicine (I.T., C.P.K., K.S., E.T., K.S.S., E.D., T.L.J., S.J.C., J.C.F., J.S., T.C.H., S.G.D.), University of Utah School of Medicine, Salt Lake City. FAU - Shah, Kevin S AU - Shah KS AD - Division of Cardiovascular Medicine (I.T., C.P.K., K.S., E.T., K.S.S., E.D., T.L.J., S.J.C., J.C.F., J.S., T.C.H., S.G.D.), University of Utah School of Medicine, Salt Lake City. FAU - Tonna, Joseph E AU - Tonna JE AUID- ORCID: 0000-0001-8879-2628 AD - Division of Cardiothoracic Surgery, Department of Surgery (J.E.T., C.H.S.), University of Utah School of Medicine, Salt Lake City. AD - Department of Emergency Medicine, University of Utah Health, Salt Lake City (J.E.T.). FAU - Dranow, Elizabeth AU - Dranow E AUID- ORCID: 0000-0002-5324-192X AD - Division of Cardiovascular Medicine (I.T., C.P.K., K.S., E.T., K.S.S., E.D., T.L.J., S.J.C., J.C.F., J.S., T.C.H., S.G.D.), University of Utah School of Medicine, Salt Lake City. FAU - Jones, Tara L AU - Jones TL AUID- ORCID: 0000-0002-4516-9796 AD - Division of Cardiovascular Medicine (I.T., C.P.K., K.S., E.T., K.S.S., E.D., T.L.J., S.J.C., J.C.F., J.S., T.C.H., S.G.D.), University of Utah School of Medicine, Salt Lake City. FAU - Carter, Spencer J AU - Carter SJ AUID- ORCID: 0000-0001-7268-3689 AD - Division of Cardiovascular Medicine (I.T., C.P.K., K.S., E.T., K.S.S., E.D., T.L.J., S.J.C., J.C.F., J.S., T.C.H., S.G.D.), University of Utah School of Medicine, Salt Lake City. FAU - Fang, James C AU - Fang JC AUID- ORCID: 0000-0003-2427-9504 AD - Division of Cardiovascular Medicine (I.T., C.P.K., K.S., E.T., K.S.S., E.D., T.L.J., S.J.C., J.C.F., J.S., T.C.H., S.G.D.), University of Utah School of Medicine, Salt Lake City. FAU - Stehlik, Josef AU - Stehlik J AUID- ORCID: 0000-0002-7362-0513 AD - Division of Cardiovascular Medicine (I.T., C.P.K., K.S., E.T., K.S.S., E.D., T.L.J., S.J.C., J.C.F., J.S., T.C.H., S.G.D.), University of Utah School of Medicine, Salt Lake City. FAU - Ohsfeldt, Robert L AU - Ohsfeldt RL AUID- ORCID: 0000-0002-6117-056X AD - Population Informatics Lab, Department of Health Policy and Management, School of Public Health, Texas A&M University, College Station (R.L.O.). FAU - Selzman, Craig H AU - Selzman CH AUID- ORCID: 0000-0001-9218-4764 AD - Division of Cardiothoracic Surgery, Department of Surgery (J.E.T., C.H.S.), University of Utah School of Medicine, Salt Lake City. FAU - Hanff, Thomas C AU - Hanff TC AUID- ORCID: 0000-0003-3096-1227 AD - Division of Cardiovascular Medicine (I.T., C.P.K., K.S., E.T., K.S.S., E.D., T.L.J., S.J.C., J.C.F., J.S., T.C.H., S.G.D.), University of Utah School of Medicine, Salt Lake City. FAU - Drakos, Stavros G AU - Drakos SG AUID- ORCID: 0000-0002-1223-327X AD - Division of Cardiovascular Medicine (I.T., C.P.K., K.S., E.T., K.S.S., E.D., T.L.J., S.J.C., J.C.F., J.S., T.C.H., S.G.D.), University of Utah School of Medicine, Salt Lake City. LA - eng PT - Journal Article DEP - 20241018 PL - United States TA - Circ Heart Fail JT - Circulation. Heart failure JID - 101479941 SB - IM MH - Humans MH - *Shock, Cardiogenic/therapy/economics/mortality MH - Male MH - *Cost-Benefit Analysis MH - Female MH - Aged MH - Middle Aged MH - *Quality-Adjusted Life Years MH - Adult MH - Aged, 80 and over MH - *Patient Care Team/economics MH - Young Adult MH - Adolescent MH - Treatment Outcome MH - Hospital Costs OTO - NOTNLM OT - cost-effectiveness analysis OT - patient discharge OT - quality-adjusted life years OT - shock, cardiogenic OT - standard of care COIS- Dr Drakos serves as a consultant for Abbott Laboratories and Pfizer and has received research support from Novartis and Merck. Dr Ohsfeldt reports grant support from Bayer. Dr. Tonna is the Chair of the Extracorporeal Life Support Organization Registry. E.S. Davis serves as a consultant for Abbott Laboratories and Medtronic Inc. The other authors report no conflicts. EDAT- 2024/10/18 06:23 MHDA- 2024/11/19 18:22 CRDT- 2024/10/18 05:13 PHST- 2024/11/19 18:22 [medline] PHST- 2024/10/18 06:23 [pubmed] PHST- 2024/10/18 05:13 [entrez] AID - 10.1161/CIRCHEARTFAILURE.124.011709 [doi] PST - ppublish SO - Circ Heart Fail. 2024 Nov;17(11):e011709. doi: 10.1161/CIRCHEARTFAILURE.124.011709. Epub 2024 Oct 18. PMID- 39420596 OWN - NLM STAT- MEDLINE DCOM- 20250126 LR - 20260726 IS - 2055-5822 (Electronic) IS - 2055-5822 (Linking) VI - 12 IP - 1 DP - 2025 Feb TI - Association between clinician team segregation, receipt of cardiovascular care and outcomes in valvular heart diseases. PG - 564-572 LID - 10.1002/ehf2.15078 [doi] AB - AIMS: Racial disparities exist in clinical outcomes for valvular heart disease (VHD). It is unknown whether clinician segregation contributes to these disparities. Among an adequately insured population, we evaluated the relationship between clinician segregation in a hospital and receipt of care by a cardiologist according to patient race. We also evaluated the association between clinician segregation, race and care by a cardiologist on 30-day readmission and 1-year survival. METHODS AND RESULTS: Using Optum's Clinformatics(R) Data Mart Database (CDM, US commercial and Medicare beneficiaries) from 2010 to 2018, we identified patients with a primary diagnosis of VHD. Hospitals were categorized into low, medium and high segregation groups (SG), according to clinician segregation index (SI). SI can range from 0-1 (0: the ratio of Black to White patients is the same for all clinicians; 1: each clinician treats only Black or only White patients). Outcomes were analysed using generalized linear mixed effect models. Among 8649 patients [median age 75 (67-82), 45.4% female, 16.1% Black, 83.9% White], odds of care from a cardiologist did not vary across race for all SGs [Low SG adjusted odds ratio (aOR): 0.79 (95% CI: 0.58-1.08), P = 0.14; Medium SG aOR: 0.86 (95% CI: 0.60-1.25), P = 0.43; High SG aOR: 1.07 (95% CI: 0.68-1.69), P = 0.76]. Among those that received care from a cardiologist, there was no difference in the 30-day readmission between Black and White patients across SGs [Low SG aOR: 1.05 (95% CI: 0.83-1.31), P = 0.70; Medium SG aOR: 1.22 (95% CI: 0.92-1.61), P = 0.17; High SG aOR: 0.81 (95% CI: 0.57-1.17), P = 0.27]. Among patients that did not receive care from a cardiologist, Black patients in low SG had higher odds of 30-day readmission compared to White patients [aOR: 2.74 (95%CI:1.38-5.43), P < 0.01]. Odds of 1-year survival were similar across race for all SG irrespective of receipt of care from a cardiologist [seen by a cardiologist: Low SG aOR: 1.13 (95% CI: 0.86-1.48), P = 0.38; Medium SG aOR: 0.83 (95% CI: 0.59-1.17), P = 0.29; High SG aOR: 1.01 (95% CI: 0.66-1.52), P = 0.98; not seen by a cardiologist: Low SG aOR: 0.56 (95% CI: 0.23-1.34), P = 0.19; Medium SG aOR: 0.81 (95% CI: 0.28-2.37), P = 0.70; High SG aOR: 0.63 (95% CI: 0.23-1.74), P = 0.37]. CONCLUSIONS: Among an insured population, race was not associated with care by a cardiologist for VHD or survival. Black patients not seen by cardiologists had higher odds of 30-day readmission in low clinician SG. CI - (c) 2024 The Author(s). ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. FAU - Bolakale-Rufai, Ikeoluwapo Kendra AU - Bolakale-Rufai IK AUID- ORCID: 0000-0002-5994-8010 AD - Division of Cardiovascular Medicine, Indiana University, Indianapolis, Indiana, USA. FAU - Knapp, Shannon M AU - Knapp SM AD - Division of Cardiovascular Medicine, Indiana University, Indianapolis, Indiana, USA. AD - Department of Biostatistics and Health Data Science, Richard M. Fairbanks School of Public Health, Indianapolis, Indiana, USA. FAU - Bisono, Janina Quintero AU - Bisono JQ AD - Department of Internal Medicine, Indiana University, Indianapolis, Indiana, USA. AD - Indiana University Health, Indianapolis, Indiana, USA. FAU - Johnson, Adedoyin AU - Johnson A AD - Department of Internal Medicine, Indiana University, Indianapolis, Indiana, USA. AD - Indiana University Health, Indianapolis, Indiana, USA. FAU - Moore, Wanda AU - Moore W AD - Sarver Heart Center Minority Outreach Program, University of Arizona, Tucson, Arizona, USA. FAU - Yankah, Ekow AU - Yankah E AD - Department of Law and Philosophy, University of Michigan, Ann Arbor, Michigan, USA. FAU - Yee, Ryan AU - Yee R AD - Division of Cardiovascular Medicine, Indiana University, Indianapolis, Indiana, USA. FAU - Trabue, Dalancee AU - Trabue D AD - Division of Cardiovascular Medicine, Indiana University, Indianapolis, Indiana, USA. FAU - Nallamothu, Brahmajee AU - Nallamothu B AD - Division of Cardiovascular Diseases, University of Michigan, Ann Arbor, Michigan, USA. FAU - Hollingsworth, John M AU - Hollingsworth JM AD - Quality Department, Endeavor Health NorthShore Hospitals, Evanston, Illinois, USA. FAU - Watty, Stephen AU - Watty S AD - Department of Internal Medicine, Indiana University, Indianapolis, Indiana, USA. FAU - Williamson, Francesca AU - Williamson F AD - Department of Learning Health Sciences, University of Michigan Medical School, Ann Arbor, Michigan, USA. FAU - Pool, Natalie AU - Pool N AD - School of Nursing, University of Northern Colorado, Greeley, Colorado, USA. FAU - Hebdon, Megan AU - Hebdon M AD - School of Nursing, University of Texas at Austin, Austin, Texas, USA. FAU - Ezema, Nneamaka AU - Ezema N AD - Division of Clinical Trials Operations Management, Nex Gen Research, Dayton, Ohio, USA. FAU - Capers, Quinn AU - Capers Q AD - Department of Medicine, Howard University College of Medicine, Washington, D.C., USA. FAU - Blount, Courtland AU - Blount C AD - Division of Cardiovascular Medicine, Indiana University, Indianapolis, Indiana, USA. FAU - Kimbrough, Nia AU - Kimbrough N AD - Sisters Together Centers of Wellness for Urban Women, Indianapolis, Indiana, USA. FAU - Johnson, Denee AU - Johnson D AD - Indiana University Health, Indianapolis, Indiana, USA. FAU - Evans, Jalynn AU - Evans J AD - Indiana University Health, Indianapolis, Indiana, USA. FAU - Foree, Brandi AU - Foree B AD - Indiana University Health, Indianapolis, Indiana, USA. FAU - Holman, Anastacia AU - Holman A AD - Division of Chaplaincy Education, IU Health System, Indianapolis, Indiana, USA. FAU - Lightbourne, Karen AU - Lightbourne K AD - Division of Community Networks collaborations for the East Region, Indianapolis, Indiana, USA. FAU - Brown, David AU - Brown D AD - Department of Otolaryngology-Head and Neck Surgery and Pediatric Otolaryngology, Michigan Medicine, Ann Arbor, Michigan, USA. FAU - Edmonds, Brownsyne Tucker AU - Edmonds BT AD - Indiana University Health, Indianapolis, Indiana, USA. AD - Department of Obstetrics and Gynecology, Indiana University, Indianapolis, Indiana, USA. FAU - Breathett, Khadijah AU - Breathett K AUID- ORCID: 0000-0001-5397-6419 AD - Division of Cardiovascular Medicine, Indiana University, Indianapolis, Indiana, USA. AD - Indiana University Health, Indianapolis, Indiana, USA. LA - eng GR - K01 HL142848/HL/NHLBI NIH HHS/United States GR - US Department of Health and Human Services/ GR - R01HL159216/HL/NHLBI NIH HHS/United States GR - R01HL160734/HL/NHLBI NIH HHS/United States GR - R01 HL159216/HL/NHLBI NIH HHS/United States GR - R01 HL160734/HL/NHLBI NIH HHS/United States GR - K01HL142848/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Multicenter Study DEP - 20241017 PL - England TA - ESC Heart Fail JT - ESC heart failure JID - 101669191 SB - IM MH - Humans MH - Female MH - Male MH - Aged MH - Aged, 80 and over MH - *Heart Valve Diseases/therapy/ethnology MH - United States/epidemiology MH - *Healthcare Disparities MH - Retrospective Studies MH - *Cardiologists MH - Patient Readmission MH - Follow-Up Studies MH - Survival Rate/trends MH - *Patient Care Team PMC - PMC11769615 OTO - NOTNLM OT - cardiovascular diseases OT - health equity OT - quality of care OT - racial disparities OT - segregation index OT - structural racism COIS- The authors of this article disclose no financial or personal relationships with a third party whose interests could be positively or negatively influenced by the article's content. Ikeoluwapo Kendra Bolakale-Rufai, MD, MS; Shannon M. Knapp, PhD; Janina Quintero Bisono, MD; Adedoyin Johnson, MD, PhD; Wanda Moore CCHE; Ekow Yankah Esq; Ryan Yee, MS; Dalancee Trabue MS; Brahmajee Nallamothu, MD, MPH; John M. Hollingsworth, MD, MS; Stephen Watty, MD; Francesca Williamson, PhD; Natalie Pool, PhD; Megan Hebdon, PhD; Nneamaka Ezema, PM, CCRA, MBA; Quinn Capers, MD, FACC; Courtland Blount, MD; Nia Kimbrough; Johnnie Washington, MSW; Denee Johnson; Jalynn Evans; Brandi Foree, NP; Chaplain Rev Anastacia Holman; Karen Lightbourne; David Brown, MD; Brownsyne Tucker Edmonds, MD, MPH, MS; Khadijah Breathett, MD, MS all declare that they have no conflict of interest. EDAT- 2024/10/18 06:23 MHDA- 2025/01/27 05:22 PMCR- 2024/10/17 CRDT- 2024/10/18 02:23 PHST- 2024/08/27 00:00 [revised] PHST- 2024/05/17 00:00 [received] PHST- 2024/09/02 00:00 [accepted] PHST- 2025/01/27 05:22 [medline] PHST- 2024/10/18 06:23 [pubmed] PHST- 2024/10/18 02:23 [entrez] PHST- 2024/10/17 00:00 [pmc-release] AID - EHF215078 [pii] AID - 10.1002/ehf2.15078 [doi] PST - ppublish SO - ESC Heart Fail. 2025 Feb;12(1):564-572. doi: 10.1002/ehf2.15078. Epub 2024 Oct 17. PMID- 39420265 OWN - NLM STAT- MEDLINE DCOM- 20241018 LR - 20260428 IS - 1471-2261 (Electronic) IS - 1471-2261 (Linking) VI - 24 IP - 1 DP - 2024 Oct 17 TI - Preoperative visit-care for transcatheter aortic valve replacement: a review. PG - 573 LID - 10.1186/s12872-024-04241-y [doi] LID - 573 AB - AIM: The aim of this review is to evaluate and summarize the evidence for preoperative visit-care of transcatheter aortic valve replacement (TAVR) and to provide evidence-based support for clinical intervention. DESIGN: The review presents an evidence summary report, following the standard of the Fudan University Center for Evidence-based Nursing. METHODS: Literature related to preoperative visit-care for transcatheter aortic valve replacement have been retrieved based on the "6S" pyramid model of evidence. The types of literature included systematic reviews, expert consensus, evidence summary, and guidelines. DATA SOURCES: Up To Date, Cochrane Library, Joanna Briggs Institute, National Institute for Health and Care Excellence, Medlive, American Heart Association, Registered Nurses Association of Ontario, Scottish Intercollegiate Guidelines Network, European Society of Cardiology, American College of Cardiology, PubMed, CINAHL, Wanfang database, VIP database, Chinese biomedical literature database, CNKI. The search period is limited to the time when each database was established until February 2024. RESULTS: A total of 18 articles were included in this review, consisting of 1 systematic review, 1 evidence summary, 3 guidelines and 13 expert consensuses. This review summarized 30 pieces of the best evidence for preoperative visit-care for transcatheter aortic valve replacement, encompassing three evidence themes: multidisciplinary team collaboration, preoperative assessment, and preoperative education. CONCLUSION: The study has established an ideal foundation of evidence for preoperative visit-care in TAVR. However, throughout the particular application process, it was crucial to assess the feasibility and relevance of the evidence in clinical practice by taking into account elements such as the application setting, recommendations from experts with diverse expertise, and the preferences of the patients. CI - (c) 2024. The Author(s). FAU - Tan, JunYang AU - Tan J AD - Cardiology Department, People's Hospital of Yuxi City, Yuxi, China. FAU - Wei, GuanXing AU - Wei G AD - Cardiology Department, The First Affiliated Hospital of Kunming Medical University, No. 295, Xichang Road, Kunming, 650032, China. FAU - Ma, Fang AU - Ma F AD - Department of Nursing, The First Affiliated Hospital of Kunming Medical University, Kunming, China. FAU - Yan, Han AU - Yan H AD - Cardiology Department, The First Affiliated Hospital of Kunming Medical University, No. 295, Xichang Road, Kunming, 650032, China. FAU - Wang, XiTing AU - Wang X AD - Cardiology Department, The First Affiliated Hospital of Kunming Medical University, No. 295, Xichang Road, Kunming, 650032, China. FAU - Hu, QiuLan AU - Hu Q AD - Geriatric Intensive Care Unit Department, The First Affiliated Hospital of Kunming Medical University, Kunming, China. FAU - Wei, Wei AU - Wei W AD - Digestive Surgery Department, The First Affiliated Hospital of Kunming Medical University, Kunming, China. FAU - Yang, MingFang AU - Yang M AD - Department of Nursing, The First Affiliated Hospital of Kunming Medical University, Kunming, China. FAU - Bai, YangJuan AU - Bai Y AD - Cardiology Department, The First Affiliated Hospital of Kunming Medical University, No. 295, Xichang Road, Kunming, 650032, China. Baiyangjuan300325@126.com. LA - eng PT - Journal Article PT - Systematic Review DEP - 20241017 PL - England TA - BMC Cardiovasc Disord JT - BMC cardiovascular disorders JID - 100968539 SB - IM MH - Humans MH - *Aortic Valve/surgery/physiopathology MH - *Aortic Valve Stenosis/surgery/diagnostic imaging/physiopathology MH - *Preoperative Care/standards MH - Risk Factors MH - *Transcatheter Aortic Valve Replacement/adverse effects/standards MH - Treatment Outcome PMC - PMC11487718 OTO - NOTNLM OT - Evidence-based nursing OT - Preoperative visit-care OT - Transcatheter aortic valve replacement COIS- The authors declare no competing interests. EDAT- 2024/10/18 00:30 MHDA- 2024/10/18 06:23 PMCR- 2024/10/17 CRDT- 2024/10/17 23:53 PHST- 2024/05/10 00:00 [received] PHST- 2024/10/07 00:00 [accepted] PHST- 2024/10/18 06:23 [medline] PHST- 2024/10/18 00:30 [pubmed] PHST- 2024/10/17 23:53 [entrez] PHST- 2024/10/17 00:00 [pmc-release] AID - 10.1186/s12872-024-04241-y [pii] AID - 4241 [pii] AID - 10.1186/s12872-024-04241-y [doi] PST - epublish SO - BMC Cardiovasc Disord. 2024 Oct 17;24(1):573. doi: 10.1186/s12872-024-04241-y. PMID- 39419165 OWN - NLM STAT- MEDLINE DCOM- 20250424 LR - 20260413 IS - 1532-8414 (Electronic) IS - 1071-9164 (Print) IS - 1071-9164 (Linking) VI - 31 IP - 2 DP - 2025 Feb TI - Cardio-Oncology and Heart Failure: a Scientific Statement From the Heart Failure Society of America. PG - 415-455 LID - S1071-9164(24)00363-4 [pii] LID - 10.1016/j.cardfail.2024.08.045 [doi] AB - Heart failure and cancer remain 2 of the leading causes of morbidity and mortality, and the 2 disease entities are linked in a complex manner. Patients with cancer are at increased risk of cardiovascular complications related to the cancer therapies. The presence of cardiomyopathy or heart failure in a patient with new cancer diagnosis portends a high risk for adverse oncology and cardiovascular outcomes. With the rapid growth of cancer therapies, many of which interfere with cardiovascular homeostasis, heart failure practitioners need to be familiar with prevention, risk stratification, diagnosis, and management strategies in cardio-oncology. This Heart Failure Society of America statement addresses the complexities of heart failure care among patients with active cancer diagnoses and cancer survivors. Risk stratification, monitoring and management of cardiotoxicity are presented across stages A through D heart failure, with focused discussion on heart failure with preserved ejection fraction and special populations, such as survivors of childhood and young-adulthood cancers. We provide an overview of the shared risk factors between cancer and heart failure, highlighting heart failure as a form of cardiotoxicity associated with many different cancer therapeutics. Finally, we discuss disparities in the care of patients with cancer and cardiac disease and present a framework for a multidisciplinary-team approach and critical collaboration among heart failure, oncology, palliative care, pharmacy, and nursing teams in the management of these complex patients. CI - Copyright (c) 2024. Published by Elsevier Inc. FAU - Bloom, Michelle Weisfelner AU - Bloom MW AD - Division of Cardiology, NYU Langone Health, NYU Grossman School of Medicine, New York, NY. Electronic address: michelle.bloom@nyulangone.org. FAU - Vo, Jacqueline B AU - Vo JB AD - Radiation Epidemiology Branch, Division of Cancer Epidemiology & Genetics, National Cancer Institute, Bethesda, MD. FAU - Rodgers, Jo E AU - Rodgers JE AD - Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, Chapel Hill, NC. FAU - Ferrari, Alana M AU - Ferrari AM AD - Division of Hematology/ Oncology, University of Virginia Health, Charlottesville, VA. FAU - Nohria, Anju AU - Nohria A AD - Cardio-Oncology Program, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA. FAU - Deswal, Anita AU - Deswal A AD - Department of Cardiology, University of Texas MD Anderson Cancer Center, Houston, TX. FAU - Cheng, Richard K AU - Cheng RK AD - Division of Cardiology, University of Washington, Seattle, WA. FAU - Kittleson, Michelle M AU - Kittleson MM AD - Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA. FAU - Upshaw, Jenica N AU - Upshaw JN AD - Division of Cardiology, Tufts Medical Center, Boston, MA. FAU - Palaskas, Nicolas AU - Palaskas N AD - Department of Cardiology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX. FAU - Blaes, Anne AU - Blaes A AD - Division of Hematology/Oncology/Transplantation, University of Minnesota, Minneapolis, MN. FAU - Brown, Sherry-Ann AU - Brown SA AD - Department of Medicine, Medical College of Wisconsin, Milwaukee, WI; Research Collaborator, Mayo Clinic, Rochester, MN. FAU - Ky, Bonnie AU - Ky B AD - Division of Cardiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; Thalheimer Center for Cardio-Oncology, Abramson Cancer Center and Division of Cardiovascular Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. FAU - Lenihan, Daniel AU - Lenihan D AD - Saint Francis Healthcare, Cape Girardeau, MO and the International Cardio-Oncology Society, Tampa, FL. FAU - Maurer, Mathew S AU - Maurer MS AD - Division of Cardiology, Columbia University Irving Medical Center, New York, NY. FAU - Fadol, Anecita AU - Fadol A AD - MD Anderson Cancer Center, Houston, TX. FAU - Skurka, Kerry AU - Skurka K AD - Cardio-Oncology Nurse/Program Consultant. FAU - Cambareri, Christine AU - Cambareri C AD - Clinical Oncology Pharmacist, Hospital of the University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA. FAU - Chauhan, Cynthia AU - Chauhan C AD - Patient Advocate. FAU - Barac, Ana AU - Barac A AD - Department of Cardiology, Inova Schar Heart and Vascular, Inova Schar Cancer, Falls Church, VA. LA - eng GR - K24 HL167127/HL/NHLBI NIH HHS/United States GR - P01 CA261669/CA/NCI NIH HHS/United States GR - R01 AG081582/AG/NIA NIH HHS/United States GR - R01 HL139671/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20241015 PL - United States TA - J Card Fail JT - Journal of cardiac failure JID - 9442138 RN - 0 (Antineoplastic Agents) SB - IM MH - Humans MH - *Heart Failure/therapy/epidemiology/diagnosis MH - *Neoplasms/therapy/epidemiology/complications/drug therapy MH - *Medical Oncology/methods/standards MH - *Societies, Medical MH - Cardiotoxicity MH - *Cardiology MH - United States/epidemiology MH - *Antineoplastic Agents/adverse effects MH - Cardio-Oncology PMC - PMC12317758 MID - NIHMS2099928 OTO - NOTNLM OT - Heart failure OT - and social determinants OT - bone marrow/stem cell transplant OT - cancer OT - cancer survivorship OT - cancer treatment-related cardiac dysfunction OT - cardio-oncology OT - cardiomyopathy OT - cardiotoxicity OT - health disparities OT - heart failure with preserved ejection fraction OT - heart failure with reduced ejection fraction OT - mechanical circulatory support OT - multidisciplinary care OT - myocarditis OT - palliative care OT - pregnancy OT - pulmonary hypertension OT - stress cardiomyopathy COIS- Disclosures MWB reports compensation for serving as faculty or as a speaker for a medical education program and consulting fees for Astra Zeneca. AN receives research support from Bristol Myers Squibb and consulting fees from AstraZeneca and Takeda Oncology. AD reports being a consultant for Bayer. NP reports support from the Cancer Prevention & Research Institute of 23 Texas (CPRIT) RP200670, NIH/NCI 1P01CA261669-01, Andrew Sabin Family Foundation, Replimmune, and Kiniksa. Pharmaceuticals. BK reports consulting for Astra Zeneca, Roche, BMS, IIS, and Pfizer. DL reports consultant fees from Myocardial Solutions, Clementia, OncXerna, AstraZeneca, Roche, SecuraBio, Intellia and Novo-Nordisk. MSM reports grant support from NIH R01HL139671, 1R01AG081582-01 and grants and personal fees from Attralus, Alnylam, Pfizer, Eidos, and Ionis, and personal fees from Astra Zeneca and Intellia. AB reports consulting fees for Astra Zeneca. All other authors report no disclosures. EDAT- 2024/10/18 07:19 MHDA- 2025/02/14 00:24 PMCR- 2025/11/01 CRDT- 2024/10/17 19:13 PHST- 2024/04/16 00:00 [received] PHST- 2024/08/27 00:00 [revised] PHST- 2024/08/28 00:00 [accepted] PHST- 2025/02/14 00:24 [medline] PHST- 2024/10/18 07:19 [pubmed] PHST- 2024/10/17 19:13 [entrez] PHST- 2025/11/01 00:00 [pmc-release] AID - S1071-9164(24)00363-4 [pii] AID - 10.1016/j.cardfail.2024.08.045 [doi] PST - ppublish SO - J Card Fail. 2025 Feb;31(2):415-455. doi: 10.1016/j.cardfail.2024.08.045. Epub 2024 Oct 15. PMID- 39417276 OWN - NLM STAT- MEDLINE DCOM- 20250409 LR - 20250409 IS - 1439-7609 (Electronic) IS - 1439-7595 (Linking) VI - 35 IP - 3 DP - 2025 Apr 8 TI - Mortality and associated factors in patients with systemic sclerosis-associated pulmonary hypertension with and without interstitial lung disease: A long-term follow-up study. PG - 478-483 LID - 10.1093/mr/roae095 [doi] AB - OBJECTIVES: We aimed to investigate mortality and prognostic factors in systemic sclerosis (SSc) patients with pulmonary hypertension (PH) with or without interstitial lung disease (ILD). METHODS: The associations between mortality and demographics, transthoracic echocardiography, right heart catheterization (RHC), pulmonary functional parameters at baseline, and treatment modalities were evaluated. RESULTS: Survival rates for PH-SSc patients (42 female, mean age 56.6 +/- 13.5, median follow-up 45 months) were 91% at the first year, 75% at 2 years, and 43.1% at 5 years. The majority of the deceased patients had PH + ILD (P = .007). The PH + ILD group had more diffuse skin involvement, anti-Scl-70, high C-reactive protein, low FVC, and lower DLCO. The deceased patients had higher estimated pulmonary arterial systolic pressure (PASP), low cardiac output, and FVC values. Median survival time was significantly better in patients on combined therapy. Mortality-related factors in the PH + ILD group were decreased initial FVC, high estimated PASP, low cardiac output, deteriorated functional class, and monotherapy. CONCLUSION: This is the first reported SSc-PH cohort from Turkey by a multidisciplinary team. PH is a severe complication of SSc with high mortality especially in patients with accompanying severe ILD. CI - (c) Japan College of Rheumatology 2024. Published by Oxford University Press. FAU - Amikishiyev, Shirkhan AU - Amikishiyev S AUID- ORCID: 0000-0002-8355-0176 AD - Division of Rheumatology, Istanbul Faculty of Medicine, Istanbul University, Fatih, Istanbul, Turkey. FAU - Yalcinkaya, Yasemin AU - Yalcinkaya Y AD - Division of Rheumatology, Istanbul Faculty of Medicine, Istanbul University, Fatih, Istanbul, Turkey. FAU - Mammadova, Konul AU - Mammadova K AD - Department of Chest Diseases, Istanbul Faculty of Medicine, Istanbul University, Fatih, Istanbul, Turkey. FAU - Aliyeva, Numune AU - Aliyeva N AD - Division of Rheumatology, Istanbul Faculty of Medicine, Istanbul University, Fatih, Istanbul, Turkey. FAU - Durak, Gorkem AU - Durak G AD - Department of Radiology, Istanbul Faculty of Medicine, Istanbul University, Fatih, Istanbul, Turkey. FAU - Artim-Esen, Bahar AU - Artim-Esen B AD - Division of Rheumatology, Istanbul Faculty of Medicine, Istanbul University, Fatih, Istanbul, Turkey. FAU - Gul, Ahmet AU - Gul A AD - Division of Rheumatology, Istanbul Faculty of Medicine, Istanbul University, Fatih, Istanbul, Turkey. FAU - Bilge, Ahmet Kaya AU - Bilge AK AD - Department of Cardiology, Istanbul Faculty of Medicine, Istanbul University, Fatih, Istanbul, Turkey. FAU - Okumus, Gulfer AU - Okumus G AD - Department of Chest Diseases, Istanbul Faculty of Medicine, Istanbul University, Fatih, Istanbul, Turkey. FAU - Inanc, Murat AU - Inanc M AD - Division of Rheumatology, Istanbul Faculty of Medicine, Istanbul University, Fatih, Istanbul, Turkey. LA - eng PT - Journal Article PL - England TA - Mod Rheumatol JT - Modern rheumatology JID - 100959226 SB - IM MH - Humans MH - *Scleroderma, Systemic/complications/mortality MH - Female MH - *Lung Diseases, Interstitial/mortality/complications/physiopathology/etiology MH - *Hypertension, Pulmonary/mortality/etiology/physiopathology MH - Middle Aged MH - Male MH - Follow-Up Studies MH - Aged MH - Adult MH - Prognosis MH - Survival Rate MH - Echocardiography MH - Turkey/epidemiology OTO - NOTNLM OT - PAH-specific therapy OT - Systemic sclerosis OT - interstitial lung disease OT - pulmonary function tests OT - pulmonary hypertension EDAT- 2024/10/17 10:05 MHDA- 2025/04/08 13:54 CRDT- 2024/10/17 05:23 PHST- 2024/08/17 00:00 [received] PHST- 2024/10/14 00:00 [accepted] PHST- 2025/04/08 13:54 [medline] PHST- 2024/10/17 10:05 [pubmed] PHST- 2024/10/17 05:23 [entrez] AID - 7824571 [pii] AID - 10.1093/mr/roae095 [doi] PST - ppublish SO - Mod Rheumatol. 2025 Apr 8;35(3):478-483. doi: 10.1093/mr/roae095. PMID- 39411633 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241018 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 16 IP - 9 DP - 2024 Sep TI - Mechanical Circulatory Support in Cardiogenic Shock: A Narrative Review. PG - e69379 LID - 10.7759/cureus.69379 [doi] LID - e69379 AB - Cardiogenic shock (CS) remains a critical condition with high mortality rates, often arising from acute myocardial infarction and advanced heart failure. Despite advancements in medical therapy, traditional interventions frequently fall short of reversing the profound hemodynamic instability seen in CS. Mechanical circulatory support (MCS) devices have emerged as crucial therapeutic options, offering temporary stabilization and bridging to recovery, heart transplantation, or long-term ventricular assist device implantation. This narrative review explores the current landscape of MCS in CS, highlighting the various types of support devices, including intra-aortic balloon pumps (IABP), veno-arterial extracorporeal membrane oxygenation (VA-ECMO), and percutaneous ventricular assist devices (pVADs) such as Impella and TandemHeart. We examine their mechanisms of action, clinical indications, and outcomes alongside the challenges and complications associated with their use. Additionally, we discuss the evolving guidelines and the role of MCS in contemporary CS management, emphasizing the need for timely intervention and a multidisciplinary approach. The review underscores the importance of individualized patient selection and device choice to optimize outcomes in this critically ill population. CI - Copyright (c) 2024, Shah et al. FAU - Shah, Dhruv AU - Shah D AD - Anaesthesiology, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Wardha, IND. FAU - Sen, Jayshree AU - Sen J AD - Anaesthesiology, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Wardha, IND. LA - eng PT - Journal Article PT - Review DEP - 20240913 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC11473205 OTO - NOTNLM OT - cardiogenic shock OT - extracorporeal membrane oxygenation (ecmo) OT - hemodynamic stabilization OT - intra-aortic balloon pump OT - mechanical circulatory support OT - ventricular assist devices (vads) COIS- Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. EDAT- 2024/10/16 06:22 MHDA- 2024/10/16 06:23 PMCR- 2024/09/13 CRDT- 2024/10/16 04:27 PHST- 2024/08/29 00:00 [received] PHST- 2024/09/13 00:00 [accepted] PHST- 2024/10/16 06:23 [medline] PHST- 2024/10/16 06:22 [pubmed] PHST- 2024/10/16 04:27 [entrez] PHST- 2024/09/13 00:00 [pmc-release] AID - 10.7759/cureus.69379 [doi] PST - epublish SO - Cureus. 2024 Sep 13;16(9):e69379. doi: 10.7759/cureus.69379. eCollection 2024 Sep. PMID- 39407933 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241019 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 13 IP - 19 DP - 2024 Oct 1 TI - Diagnosing AL and ATTR Amyloid Cardiomyopathy: A Multidisciplinary Approach. LID - 10.3390/jcm13195873 [doi] LID - 5873 AB - Amyloidosis with cardiac involvement is a fatal disease leading to progressive heart failure. The most common forms of amyloidosis with cardiac involvement are light chain (AL) and transthyretin (ATTR) amyloidosis. To allow effective specific treatment for both forms, precise and early diagnosis is important. This review focuses on diagnostic approaches for AL and ATTR amyloidosis with cardiac involvement, including different strategies, the role of imaging and biomarkers and possible pitfalls. FAU - Aus dem Siepen, Fabian AU - Aus dem Siepen F AD - Department of Cardiology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany. FAU - Hansen, Timon AU - Hansen T AD - Onkologicum HOPA, 22767 Hamburg, Germany. LA - eng PT - Journal Article PT - Review DEP - 20241001 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC11477302 OTO - NOTNLM OT - AL OT - ATTR OT - ATTR-CM OT - amyloidosis OT - cardiomyopathy COIS- The authors declare no conflict of interest. EDAT- 2024/10/16 10:18 MHDA- 2024/10/16 10:19 PMCR- 2024/10/01 CRDT- 2024/10/16 01:03 PHST- 2024/07/24 00:00 [received] PHST- 2024/09/22 00:00 [revised] PHST- 2024/09/30 00:00 [accepted] PHST- 2024/10/16 10:19 [medline] PHST- 2024/10/16 10:18 [pubmed] PHST- 2024/10/16 01:03 [entrez] PHST- 2024/10/01 00:00 [pmc-release] AID - jcm13195873 [pii] AID - jcm-13-05873 [pii] AID - 10.3390/jcm13195873 [doi] PST - epublish SO - J Clin Med. 2024 Oct 1;13(19):5873. doi: 10.3390/jcm13195873. PMID- 39397577 OWN - NLM STAT- In-Process LR - 20250424 IS - 2150-136X (Electronic) IS - 2150-1351 (Print) IS - 2150-1351 (Linking) VI - 16 IP - 3 DP - 2025 May TI - Clinical Assessment of the Utility of Pulsatile Over Nonpulsatile Flow for Neonatal and Pediatric Cardiopulmonary Bypass Procedures Using Multidisciplinary Translational Research at a Tertiary Care Center. PG - 354-356 LID - 10.1177/21501351241269912 [doi] FAU - Hayes, Christopher Collin AU - Hayes CC AD - Penn State Hershey Pediatric Cardiovascular Research Center, Department of Pediatrics, Penn State College of Medicine, Penn State Health Children's Hospital, Hershey, PA, USA. RINGGOLD: 12310 FAU - Undar, Akif AU - Undar A AUID- ORCID: 0000-0003-3334-2886 AD - Penn State Hershey Pediatric Cardiovascular Research Center, Department of Pediatrics, Penn State College of Medicine, Penn State Health Children's Hospital, Hershey, PA, USA. RINGGOLD: 12310 AD - Penn State Hershey Pediatric Cardiovascular Research Center, Department of Surgery, Penn State College of Medicine, Penn State Health Children's Hospital, Hershey, PA, USA. RINGGOLD: 12310 AD - Penn State Hershey Pediatric Cardiovascular Research Center, Department of Biomedical Engineering, Penn State College of Medicine, Penn State Health Children's Hospital, Hershey, PA, USA. RINGGOLD: 12310 LA - eng PT - Journal Article DEP - 20241014 PL - United States TA - World J Pediatr Congenit Heart Surg JT - World journal for pediatric & congenital heart surgery JID - 101518415 SB - IM PMC - PMC12012267 OTO - NOTNLM OT - cardiopulmonary bypass OT - congenital heart surgery OT - neonates OT - nonpulsatile flow OT - pediatrics OT - pulsatile flow COIS- Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2024/10/14 06:22 MHDA- 2024/10/14 06:22 PMCR- 2025/04/22 CRDT- 2024/10/14 04:33 PHST- 2024/10/14 06:22 [pubmed] PHST- 2024/10/14 06:22 [medline] PHST- 2024/10/14 04:33 [entrez] PHST- 2025/04/22 00:00 [pmc-release] AID - 10.1177_21501351241269912 [pii] AID - 10.1177/21501351241269912 [doi] PST - ppublish SO - World J Pediatr Congenit Heart Surg. 2025 May;16(3):354-356. doi: 10.1177/21501351241269912. Epub 2024 Oct 14. PMID- 39396714 OWN - NLM STAT- MEDLINE DCOM- 20250226 LR - 20250623 IS - 1558-3597 (Electronic) IS - 0735-1097 (Linking) VI - 85 IP - 8 DP - 2025 Mar 4 TI - The Effect of Teleprehabilitation on Adverse Events After Elective Cardiac Surgery: A Randomized Controlled Trial. PG - 788-800 LID - S0735-1097(24)09919-4 [pii] LID - 10.1016/j.jacc.2024.10.064 [doi] AB - BACKGROUND: Patients scheduled for cardiac surgery and procedures often present with modifiable risk factors for adverse perioperative outcomes. Prehabilitation has shown potential to enhance mental and physical fitness; however, its effect on clinical cardiovascular endpoints in this population has not been studied. OBJECTIVES: The current trial was designed to evaluate the effect of a personalized multimodal teleprehabilitation on the incidence of composite endpoint on major adverse cardiovascular events in patients scheduled for elective cardiac surgery. METHODS: In a multicenter randomized controlled trial, 394 patients awaiting elective cardiac surgery and procedures were enrolled. Of these, 197 patients were randomized to an online multimodal personalized teleprehabilitation program through shared decision-making by a multidisciplinary team, and 197 were assigned to a control group. The primary outcome was major adverse cardiovascular events (ie, cardiovascular death, myocardial infarction, stroke, hospitalization for heart failure or other life-threatening cardiac events, and earlier or repeated intervention), as measured from the randomization until 1-year postoperatively. All events were adjudicated by a blinded event committee. Secondary outcomes included length of hospital stay, postoperative complications, quality of life, adherence to the program, and effect on the incidence of modifiable risk factors. Sensitivity analyses of the primary outcome were conducted adjusting for baseline characteristics to evaluate the consistency of treatment effects. RESULTS: From randomization until 1 year postoperatively, the primary endpoint occurred in 33 patients (16.8%) in the teleprehabilitation group and 50 patients (25.5%) in the control group (difference 8.8%; 95% CI: 0.7%-16.8%; P = 0.032). This difference was primarily driven by a reduction in hospitalizations, and the sensitivity analyses showed that treatment effect was mainly in the patients undergoing a cardiac surgery rather than transcatheter procedures with adjusted OR of 0.54 (95% CI: 0.30-0.96; P = 0.035). Teleprehabilitation also reduced the incidence of active smokers, elevated pulmonary risk scores, and elevated depression scores. There was no significant difference in postoperative length of hospital stay, occurrence of postoperative complications, physical fitness, incidence of obesity, or malnutrition. CONCLUSIONS: Multimodal personalized teleprehabilitation resulted in a clinically relevant and statistically significant reduction of the primary endpoint in patients undergoing cardiac surgery. (Digital Cardiac Counseling Trial: DCC Trial [DCC]; NCT04393636). CI - Copyright (c) 2025 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Scheenstra, Bart AU - Scheenstra B AD - Department of Cardiothoracic Surgery, Heart and Vascular Center, Maastricht University Medical Center, Maastricht, the Netherlands; Department of Cardiothoracic Surgery, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, the Netherlands. FAU - van Susante, Lieke AU - van Susante L AD - Department of Cardiothoracic Surgery, Heart and Vascular Center, Maastricht University Medical Center, Maastricht, the Netherlands. FAU - Bongers, Bart C AU - Bongers BC AD - Department of Nutrition and Movement Sciences, Institute of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, the Netherlands; Department of Surgery, Institute of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, the Netherlands. FAU - Lenssen, Ton AU - Lenssen T AD - Department of Physical therapy, Maastricht University Medical Center, Maastricht, the Netherlands. FAU - Knols, Henriette AU - Knols H AD - Department of Psychiatry and Psychology, Maastricht University Medical Center, Maastricht, the Netherlands. FAU - van Kuijk, Sander AU - van Kuijk S AD - Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Center, Maastricht, the Netherlands. FAU - Nieman, Maxime AU - Nieman M AD - Department of Pulmonology, Maastricht University Medical Center, Maastricht, the Netherlands. FAU - Maessen, Jos AU - Maessen J AD - Department of Cardiothoracic Surgery, Heart and Vascular Center, Maastricht University Medical Center, Maastricht, the Netherlands; Department of Cardiothoracic Surgery, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, the Netherlands. FAU - Van't Hof, Arnoud AU - Van't Hof A AD - Department of Cardiology, Heart and Vascular Center, Maastricht University Medical Center, Maastricht, the Netherlands; Department of Cardiology, Zuyderland Medical Center, Heerlen, the Netherlands. FAU - Sardari Nia, Peyman AU - Sardari Nia P AD - Department of Cardiothoracic Surgery, Heart and Vascular Center, Maastricht University Medical Center, Maastricht, the Netherlands; Department of Cardiothoracic Surgery, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, the Netherlands. Electronic address: peyman.sardari.nia@mumc.nl. CN - DCC Trial Investigators LA - eng SI - ClinicalTrials.gov/NCT04393636 PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial DEP - 20241011 PL - United States TA - J Am Coll Cardiol JT - Journal of the American College of Cardiology JID - 8301365 SB - IM MH - Aged MH - Female MH - Humans MH - Male MH - Middle Aged MH - *Cardiac Surgical Procedures/adverse effects MH - *Elective Surgical Procedures/adverse effects MH - *Postoperative Complications/prevention & control/epidemiology MH - Quality of Life MH - Risk Factors MH - *Telemedicine MH - *Preoperative Exercise OTO - NOTNLM OT - cardiac surgery OT - cardiothoracic surgery OT - care pathway OT - prehabilitation OT - preoperative care OT - telemonitoring COIS- Funding Support and Author Disclosures This trial was supported by the Department of Cardiothoracic Surgery at Maastricht University Medical Center. Dr van't Hof has received unrestricted grants from Abbott Vascular, Boehringer Ingelheim, and Sanofi; and has received consultancy fees from Celecor Therapeutics in the past 36 months. Dr Sardari Nia is the inventor of various cardiac surgery simulators that are commercialized by Simurghy; and has consultancy agreements with NeoChord, Edwards Lifesciences, Medtronic, Abbott, and Fujifilm in the past 36 months. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2024/10/14 04:18 MHDA- 2025/02/27 05:00 CRDT- 2024/10/13 19:14 PHST- 2024/09/21 00:00 [received] PHST- 2024/10/06 00:00 [revised] PHST- 2024/10/07 00:00 [accepted] PHST- 2025/02/27 05:00 [medline] PHST- 2024/10/14 04:18 [pubmed] PHST- 2024/10/13 19:14 [entrez] AID - S0735-1097(24)09919-4 [pii] AID - 10.1016/j.jacc.2024.10.064 [doi] PST - ppublish SO - J Am Coll Cardiol. 2025 Mar 4;85(8):788-800. doi: 10.1016/j.jacc.2024.10.064. Epub 2024 Oct 11. PMID- 39387620 OWN - NLM STAT- MEDLINE DCOM- 20250425 LR - 20250715 IS - 1445-5994 (Electronic) IS - 1444-0903 (Print) IS - 1444-0903 (Linking) VI - 55 IP - 3 DP - 2025 Mar TI - A national study of infective endocarditis models of care in Australia. PG - 376-383 LID - 10.1111/imj.16537 [doi] AB - BACKGROUND: Multidisciplinary endocarditis team (MDET) management is supported by current evidence and recommended in international society guidelines. The extent to which this recommendation has been implemented in Australian centres and the attitudes, barriers and facilitators of this model are unclear. AIM: To describe current infective endocarditis (IE) models of care in Australian specialist referral centres and evaluate facilitators, barriers and attitudes towards MDET implementation. METHODS: Aims were addressed using two online surveys. Survey 1 audited IE models of care and was distributed to infectious disease physicians at specialist referral centres. Survey 2 assessed barriers, facilitators and attitudes towards MDETs and was distributed via societal email listings. RESULTS: From 56 identified cardiac surgery centres, survey 1 received 47 responses (84%). A total of 28% (13/47) of participating institutions had an existing MDET. A total of 85% (11/13) of MDETs were in public hospitals and 85% (11/13) were in high IE volume centres. Survey 2 had 109 respondents from seven specialties. Attitudes towards MDET implementation were generally favourable. Identified barriers to MDET implementation included a lack of funding, resources, expertise, time and collaboration. Facilitators included strong leadership, engagement from key stakeholders and tangible benefits. CONCLUSIONS: Even though it is recommended in international guidelines, the MDET model is used by less than one-third of Australian specialist referral centres. Stakeholders in IE care have generally favourable attitudes towards MDET implementation but cite a lack of resources, funding, collaboration and time as barriers to this. Dedication of financial and administrative support and leadership from key stakeholders are required to increase MDET utilisation. CI - (c) 2024 The Author(s). Internal Medicine Journal published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Physicians. FAU - Robson, Christopher AU - Robson C AUID- ORCID: 0000-0002-4393-3308 AD - Monash Infectious Diseases, Monash Health, Melbourne, Victoria, Australia. AD - Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia. AD - Australasian Collaboration in Endocarditis, Brisbane, Queensland, Australia. FAU - Horvath, Robert AU - Horvath R AD - Australasian Collaboration in Endocarditis, Brisbane, Queensland, Australia. AD - Infection Management Services, The Prince Charles Hospital, Brisbane, Queensland, Australia. AD - Pathology Queensland, Brisbane, Queensland, Australia. FAU - Stuart, Rhonda L AU - Stuart RL AUID- ORCID: 0000-0002-3487-7244 AD - Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia. AD - South Eastern Public Health Unit, Monash Health, Melbourne, Victoria, Australia. FAU - Nicholls, Stephen J AU - Nicholls SJ AD - Monash Heart, Monash Health, Melbourne, Victoria, Australia. AD - Victorian Heart Institute, Monash University, Melbourne, Victoria, Australia. FAU - Smith, Julian A AU - Smith JA AD - Department of Surgery, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia. AD - Department of Cardiothoracic Surgery, Monash Health, Melbourne, Victoria, Australia. FAU - Rogers, Benjamin A AU - Rogers BA AUID- ORCID: 0000-0001-6515-2118 AD - Monash Infectious Diseases, Monash Health, Melbourne, Victoria, Australia. AD - Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia. LA - eng GR - Australian Government Research Training Program Stipend/ GR - APP2017661/NHMRC Investigator Grant/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20241010 PL - Australia TA - Intern Med J JT - Internal medicine journal JID - 101092952 SB - IM MH - Humans MH - Australia/epidemiology MH - *Endocarditis/therapy/epidemiology/diagnosis MH - *Patient Care Team/organization & administration MH - Surveys and Questionnaires MH - Attitude of Health Personnel PMC - PMC11900844 OTO - NOTNLM OT - infective endocarditis OT - model of care OT - multidisciplinary team EDAT- 2024/10/13 21:10 MHDA- 2025/03/12 12:31 PMCR- 2025/03/12 CRDT- 2024/10/10 09:23 PHST- 2024/06/14 00:00 [received] PHST- 2024/09/18 00:00 [accepted] PHST- 2025/03/12 12:31 [medline] PHST- 2024/10/13 21:10 [pubmed] PHST- 2024/10/10 09:23 [entrez] PHST- 2025/03/12 00:00 [pmc-release] AID - IMJ16537 [pii] AID - 10.1111/imj.16537 [doi] PST - ppublish SO - Intern Med J. 2025 Mar;55(3):376-383. doi: 10.1111/imj.16537. Epub 2024 Oct 10. PMID- 39391821 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241012 IS - 2515-4826 (Electronic) IS - 2515-4826 (Linking) VI - 7 DP - 2024 TI - Factors influencing implementation of digital cardiac rehabilitation: A qualitative analysis of health workers perspectives. PG - 50 LID - 10.12688/hrbopenres.13929.1 [doi] LID - 50 AB - BACKGROUND: Despite growing evidence for the effectiveness of digital cardiac rehabilitation (CR) uptake of this technology remains low. Understanding the factors that influence implementation of digital CR in clinical practice is a growing area of research. The aim of this nested qualitative study was to explore health worker perspectives on factors influencing implementation of a digital CR programme. METHODS: Using convenience sampling, semi-structured interviews were conducted with health workers, including health care professionals (nurses, dietitians, physiotherapists) and those in administrative and managerial roles who were involved in delivering and referring patients to Croi MySlainte, a 12-week digital CR intervention delivered during the Coronavirus 2019 pandemic. The updated Consolidated Framework for Implementation Research (CFIR) guided data collection and framework analysis. RESULTS: Interviews were conducted with 14 health workers. Factors influencing implementation of Croi MySlainte were multiple, with some operating independently and others in combination. They related to: (i) characteristics of individuals (e.g., senior leadership support, commitment and motivation of Health workers to meet patient needs, technical capability, workload and perceived fit with role); (ii) features of the programme (e.g., accessibility and convenience for patients, the digital platform, patient self- monitoring tools, the multidisciplinary team and core components); (iii) the external environment (e.g., partnership and connections between organisations, broadband and COVID-19); (iv) the internal environment (e.g., organisational culture, teamwork, resources including funding, digital infrastructure and staffing); and (v) the implementation process (e.g., engaging patients through provision of technical support). CONCLUSION: The study findings suggest that factors influencing implementation of digital CR operate at multiple levels. Therefore, multi-level implementation strategies are required if the true potential of digital health in improving equitable cardiac rehabilitation access, participation and patient outcomes is to be realised. CI - Copyright: (c) 2024 Gibson I et al. FAU - Gibson, Irene AU - Gibson I AUID- ORCID: 0000-0002-5700-2280 AD - School of Medicine, University of Galway, Galway, County Galway, Ireland. AD - National Institute for Prevention and Cardiovascular Health, Galway, Ireland. FAU - Kerins, Claire AU - Kerins C AUID- ORCID: 0000-0002-5690-6202 AD - Health Promotion Research Centre, University of Galway, Galway, County Galway, Ireland. FAU - Foley, Louise AU - Foley L AUID- ORCID: 0000-0002-0773-3712 AD - School of Allied Health, University of Limerick, Limerick, County Limerick, Ireland. FAU - Hynes, Lisa AU - Hynes L AD - Croi, West of Ireland Cardiac and Stroke Foundation, Galway, Ireland. FAU - Byrne, Molly AU - Byrne M AD - Health Behaviour Change Research Group, University of Galway, Galway, County Galway, Ireland. FAU - Murphy, Andrew William AU - Murphy AW AD - Health Research Board Primary Care Clinical Trials Network Ireland, University of Galway, Galway, County Galway, Ireland. FAU - Reardon, Caitlin Marie AU - Reardon CM AUID- ORCID: 0000-0002-9547-7981 AD - Veteran Affairs (VA) Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, Michigan, USA. FAU - McEvoy, John William AU - McEvoy JW AD - School of Medicine, University of Galway, Galway, County Galway, Ireland. AD - National Institute for Prevention and Cardiovascular Health, Galway, Ireland. FAU - Meade, Oonagh AU - Meade O AD - School of Psychology, University of Galway, Galway, County Galway, Ireland. LA - eng PT - Journal Article DEP - 20240726 PL - Ireland TA - HRB Open Res JT - HRB open research JID - 101754913 PMC - PMC11464961 OTO - NOTNLM OT - Cardiovascular disease; secondary prevention; cardiac rehabilitation; digital health; implementation science; Consolidated Framework for Implementation Research COIS- No competing interests were disclosed. EDAT- 2024/10/11 06:22 MHDA- 2024/10/11 06:23 PMCR- 2024/07/26 CRDT- 2024/10/11 04:27 PHST- 2024/07/18 00:00 [accepted] PHST- 2024/10/11 06:23 [medline] PHST- 2024/10/11 06:22 [pubmed] PHST- 2024/10/11 04:27 [entrez] PHST- 2024/07/26 00:00 [pmc-release] AID - 10.12688/hrbopenres.13929.1 [doi] PST - epublish SO - HRB Open Res. 2024 Jul 26;7:50. doi: 10.12688/hrbopenres.13929.1. eCollection 2024. PMID- 39389747 OWN - NLM STAT- MEDLINE DCOM- 20241010 LR - 20260409 IS - 1532-8414 (Electronic) IS - 1071-9164 (Linking) VI - 30 IP - 10 DP - 2024 Oct TI - Multidisciplinary Care Teams in Acute Cardiovascular Care: A Review of Composition, Logistics, Outcomes, Training, and Future Directions. PG - 1367-1383 LID - S1071-9164(24)00279-3 [pii] LID - 10.1016/j.cardfail.2024.06.020 [doi] AB - As cardiovascular care continues to advance and with an aging population with higher comorbidities, the epidemiology of the cardiac intensive care unit has undergone a paradigm shift. There has been increasing emphasis on the development of multidisciplinary teams (MDTs) for providing holistic care to complex critically ill patients, analogous to heart teams for chronic cardiovascular care. Outside of cardiovascular medicine, MDTs in critical care medicine focus on implementation of guideline-directed care, prevention of iatrogenic harm, communication with patients and families, point-of-care decision-making, and the development of care plans. MDTs in acute cardiovascular care include physicians from cardiovascular medicine, critical care medicine, interventional cardiology, cardiac surgery, and advanced heart failure, in addition to nonphysician team members. In this document, we seek to describe the changes in patients in the cardiac intensive care unit, health care delivery, composition, logistics, outcomes, training, and future directions for MDTs involved in acute cardiovascular care. As a part of the comprehensive review, we performed a scoping of concepts of MDTs, acute hospital care, and cardiovascular conditions and procedures. CI - Copyright (c) 2024 Elsevier Inc. All rights reserved. FAU - Vallabhajosyula, Saraschandra AU - Vallabhajosyula S AD - Division of Cardiology, Department of Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island; Lifespan Cardiovascular Institute, Providence, Rhode Island. Electronic address: svallabhajosyula@lifespan.org. FAU - Ogunsakin, Adebola AU - Ogunsakin A AD - Division of Cardiology, Department of Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island; Lifespan Cardiovascular Institute, Providence, Rhode Island. FAU - Jentzer, Jacob C AU - Jentzer JC AD - Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota. FAU - Sinha, Shashank S AU - Sinha SS AD - Inova Schar Heart and Vascular Institute, Inova Fairfax Medical Campus, Fairfax, Virginia. FAU - Kochar, Ajar AU - Kochar A AD - Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. FAU - Gerberi, Dana J AU - Gerberi DJ AD - Mayo Clinic Libraries, Mayo Clinic, Rochester, Minnesota. FAU - Mullin, Christopher J AU - Mullin CJ AD - Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island; Lifespan Physicians Group, Providence, Rhode Island. FAU - Ahn, Sun Ho AU - Ahn SH AD - Lifespan Physicians Group, Providence, Rhode Island; Division of Interventional Radiology, Department of Radiology, Warren Alpert Medical School of Brown University, Providence, Rhode Island. FAU - Sodha, Neel R AU - Sodha NR AD - Lifespan Cardiovascular Institute, Providence, Rhode Island; Division of Cardiothoracic Surgery, Department of Surgery, Warren Alpert Medical School of Brown University, Providence, Rhode Island. FAU - Ventetuolo, Corey E AU - Ventetuolo CE AD - Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island; Department of Health Services, Policy and Practice, Brown University, Rhode Island. FAU - Levine, Daniel J AU - Levine DJ AD - Division of Cardiology, Department of Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island; Lifespan Cardiovascular Institute, Providence, Rhode Island. FAU - Abbott, Brian G AU - Abbott BG AD - Division of Cardiology, Department of Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island; Lifespan Cardiovascular Institute, Providence, Rhode Island. FAU - Aliotta, Jason M AU - Aliotta JM AD - Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island; Lifespan Physicians Group, Providence, Rhode Island. FAU - Poppas, Athena AU - Poppas A AD - Division of Cardiology, Department of Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island; Lifespan Cardiovascular Institute, Providence, Rhode Island. FAU - Abbott, J Dawn AU - Abbott JD AD - Division of Cardiology, Department of Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island; Lifespan Cardiovascular Institute, Providence, Rhode Island. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review PL - United States TA - J Card Fail JT - Journal of cardiac failure JID - 9442138 SB - IM MH - Humans MH - *Patient Care Team/organization & administration MH - *Cardiovascular Diseases/therapy/epidemiology MH - Critical Care/trends/methods MH - Forecasting OTO - NOTNLM OT - Cardiac intensive care unit OT - acute heart failure OT - cardiothoracic surgery OT - critical care cardiology OT - interventional cardiology COIS- Declaration of competing interest JDA reports research funding from Boston Scientific, Shockwave, Med Alliance, and Microport, and consults for Medtronic, Abbott, Penumbra, and Recor. All other authors have no relevant financial or intellectual conflicts of interest. EDAT- 2024/10/11 07:19 MHDA- 2024/10/11 07:20 CRDT- 2024/10/10 20:59 PHST- 2024/03/28 00:00 [received] PHST- 2024/05/27 00:00 [revised] PHST- 2024/06/21 00:00 [accepted] PHST- 2024/10/11 07:20 [medline] PHST- 2024/10/11 07:19 [pubmed] PHST- 2024/10/10 20:59 [entrez] AID - S1071-9164(24)00279-3 [pii] AID - 10.1016/j.cardfail.2024.06.020 [doi] PST - ppublish SO - J Card Fail. 2024 Oct;30(10):1367-1383. doi: 10.1016/j.cardfail.2024.06.020. PMID- 39389742 OWN - NLM STAT- MEDLINE DCOM- 20241010 LR - 20260409 IS - 1532-8414 (Electronic) IS - 1071-9164 (Linking) VI - 30 IP - 10 DP - 2024 Oct TI - Secondary Mitral Regurgitation: Updated Review with Focus on Percutaneous Interventional Management. PG - 1302-1318 LID - S1071-9164(24)00274-4 [pii] LID - 10.1016/j.cardfail.2024.06.018 [doi] AB - Secondary mitral regurgitation (SMR) is associated with increased mortality and heart failure hospitalizations. The management of heart failure patients with SMR is complex and requires a multidisciplinary Heart Team approach. Guideline-directed medical therapies remain fundamental, yet in a proportion of patients SMR persists. In the past decade, transcatheter edge-to-edge repair (TEER) has been shown to improve survival in patients with SMR who remain symptomatic despite medical therapy. Technical advancements across newer generations of devices, improved imaging, and greater operator expertise have collectively contributed to the increased safety and efficacy of this procedure over time. Various emerging transcatheter mitral valve repair and replacement devices are currently under investigation and may offer superior, complementary or synergistic treatment options in patients ineligible for TEER. This review provides a state-of-the-art overview regarding the diagnosis of SMR, and currently available transcatheter mitral valve interventions and describes a contemporary approach to the management of SMR. CI - Copyright (c) 2024 Elsevier Inc. All rights reserved. FAU - Vinayak, Manish AU - Vinayak M AD - Division of Cardiology, Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: https://twitter.com/manishvinayak. FAU - Prandi, Francesca R AU - Prandi FR AD - Division of Cardiology, Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: https://twitter.com/prandi_fr. FAU - Safi, Lucy AU - Safi L AD - Division of Cardiology, Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: https://twitter.com/LucySafi. FAU - Sharma, Anupam AU - Sharma A AD - Division of Cardiology, Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, New York, NY. FAU - Tang, Gilbert H L AU - Tang GHL AD - Department of Cardiovascular Surgery, Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: https://twitter.com/GilbertTangMD. FAU - Lerakis, Stamatios AU - Lerakis S AD - Division of Cardiology, Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, New York, NY. FAU - Kini, Annapoorna S AU - Kini AS AD - Division of Cardiology, Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: https://twitter.com/DoctorKini. FAU - Sharma, Samin K AU - Sharma SK AD - Division of Cardiology, Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, New York, NY. FAU - Pinney, Sean AU - Pinney S AD - Division of Cardiology, Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: https://twitter.com/spinneymd. FAU - Lala, Anuradha AU - Lala A AD - Division of Cardiology, Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: https://twitter.com/dranulala. FAU - Khera, Sahil AU - Khera S AD - Division of Cardiology, Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: sahil.khera@mountsinai.org. LA - eng PT - Journal Article PT - Review PL - United States TA - J Card Fail JT - Journal of cardiac failure JID - 9442138 SB - IM MH - Humans MH - *Mitral Valve Insufficiency/surgery/therapy MH - *Cardiac Catheterization/methods MH - *Heart Valve Prosthesis Implantation/methods MH - Mitral Valve/surgery/diagnostic imaging MH - Disease Management OTO - NOTNLM OT - mitral valve interventions OT - secondary mitral regurgitation OT - valvular heart disease COIS- Conflicts of interest statement Dr. Safi is a speaker for Medtronic and Abbott. Dr. Tang has received speaker's honoraria and served as a physician proctor, consultant, advisory board member, TAVR publications committee member, APOLLO trial screening committee member and IMPACT MR steering committee member for Medtronic, has received speaker's honoraria and served as a physician proctor, consultant, advisory board member and TRILUMINATE trial anatomic eligibility and publications committee member for Abbott Structural Heart, has served as an advisory board member for Boston Scientific and JenaValve, a consultant for NeoChord, Shockwave Medical, Peija Medical and Shenqi Medical Technology, and has received speaker's honoraria from Siemens Healthineers. Dr. Sharma has received speaker's bureau fees from Abbott Vascular, Boston Scientific, and Cardiovascular Systems. Dr. Khera is a consultant and proctor for Medtronic, consultant and proctor for Abbott Structural Heart, consultant for Terumo and W. L. Gore & Associates, consultant and advisory board member of EastEnd Medical, and serves on the speaker's bureau for Zoll Medical and Edwards Lifesciences. Dr. Pinney reports receiving consulting fees from: Abbott, ADI, Ancora, BMS, CareDx, Cordio, Impulse Dynamics, Medtronic, Nuwellis, Procyrion, Restore Medical, Transmedics, Valgen Medtech. The remaining authors have nothing to disclose. EDAT- 2024/10/11 07:19 MHDA- 2024/10/11 07:20 CRDT- 2024/10/10 20:59 PHST- 2024/04/06 00:00 [received] PHST- 2024/05/26 00:00 [revised] PHST- 2024/06/10 00:00 [accepted] PHST- 2024/10/11 07:20 [medline] PHST- 2024/10/11 07:19 [pubmed] PHST- 2024/10/10 20:59 [entrez] AID - S1071-9164(24)00274-4 [pii] AID - 10.1016/j.cardfail.2024.06.018 [doi] PST - ppublish SO - J Card Fail. 2024 Oct;30(10):1302-1318. doi: 10.1016/j.cardfail.2024.06.018. PMID- 39386378 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20251009 IS - 2329-4302 (Print) IS - 2329-4310 (Electronic) IS - 2329-4302 (Linking) VI - 11 IP - 6 DP - 2024 Nov TI - Augmented and virtual reality imaging for collaborative planning of structural cardiovascular interventions: a proof-of-concept and validation study. PG - 062606 LID - 10.1117/1.JMI.11.6.062606 [doi] LID - 062606 AB - PURPOSE: Virtual reality (VR) and augmented reality (AR) have led to significant advancements in cardiac preoperative planning, shaping the world in profound ways. A noticeable gap exists in the availability of a comprehensive multi-user, multi-device mixed reality application that can be used in a multidisciplinary team meeting. APPROACH: A multi-user, multi-device mixed reality application was developed, supporting AR and VR implementations. Technical validation involved a standardized testing protocol and comparison of AR and VR measurements regarding absolute error and time. Preclinical validation engaged experts in interventional cardiology, evaluating the clinical applicability prior to clinical validation. Clinical validation included patient-specific measurements for five patients in VR compared with standard computed tomography (CT) for preoperative planning. Questionnaires were used at all stages for subjective evaluation. RESULTS: Technical validation, including 106 size measurements, demonstrated an absolute median error of 0.69 mm (0.25 to 1.18 mm) compared with ground truth. The time to complete the entire task was 892 +/- 407 s on average, with VR measurements being faster than AR ( 804 +/- 483 versus 957 +/- 257 s , P = 0.045 ). On clinical validation of five preoperative patients, there was no statistically significant difference between paired CT and VR measurements (0.58 [95% CI, - 1.58 to 2.74], P = 0.586 ). Questionnaires showcased unanimous agreement on the user-friendly nature, effectiveness, and clinical value. CONCLUSIONS: The mixed reality application, validated through technical, preclinical, and clinical assessments, demonstrates precision and user-friendliness. Further research of our application is needed to validate the generalizability and impact on patient outcomes. CI - (c) 2024 Society of Photo-Optical Instrumentation Engineers (SPIE). FAU - Jacquemyn, Xander AU - Jacquemyn X AUID- ORCID: 0000-0001-8421-0686 AD - KU Leuven, Department of Cardiovascular Sciences, Leuven, Belgium. FAU - Bamps, Kobe AU - Bamps K AUID- ORCID: 0000-0002-3248-2142 AD - KU Leuven, Department of Cardiovascular Sciences, Leuven, Belgium. AD - University Hospitals Leuven, Division of Cardiology, Leuven, Belgium. FAU - Moermans, Ruben AU - Moermans R AD - KU Leuven, Medical Imaging Research Center, Leuven, Belgium. FAU - Dubois, Christophe AU - Dubois C AD - KU Leuven, Department of Cardiovascular Sciences, Leuven, Belgium. AD - University Hospitals Leuven, Division of Cardiology, Leuven, Belgium. FAU - Rega, Filip AU - Rega F AD - KU Leuven, Department of Cardiovascular Sciences, Leuven, Belgium. AD - University Hospitals Leuven, Division of Cardiac Surgery, Leuven, Belgium. FAU - Verbrugghe, Peter AU - Verbrugghe P AD - KU Leuven, Department of Cardiovascular Sciences, Leuven, Belgium. AD - University Hospitals Leuven, Division of Cardiac Surgery, Leuven, Belgium. FAU - Weyn, Barbara AU - Weyn B AD - KU Leuven, Medical Imaging Research Center, Leuven, Belgium. FAU - Dymarkowski, Steven AU - Dymarkowski S AD - University Hospitals Leuven, Division of Radiology, Leuven, Belgium. FAU - Budts, Werner AU - Budts W AD - KU Leuven, Department of Cardiovascular Sciences, Leuven, Belgium. AD - University Hospitals Leuven, Division of Congenital and Structural Cardiology, Leuven, Belgium. FAU - Van De Bruaene, Alexander AU - Van De Bruaene A AUID- ORCID: 0000-0002-0469-8640 AD - KU Leuven, Department of Cardiovascular Sciences, Leuven, Belgium. AD - University Hospitals Leuven, Division of Congenital and Structural Cardiology, Leuven, Belgium. LA - eng PT - Journal Article DEP - 20241008 PL - United States TA - J Med Imaging (Bellingham) JT - Journal of medical imaging (Bellingham, Wash.) JID - 101643461 EIN - J Med Imaging (Bellingham). 2024 Nov;11(6):069801. doi: 10.1117/1.JMI.11.6.069801. PMID: 39678141 PMC - PMC11460359 OTO - NOTNLM OT - augmented reality OT - cardiac imaging techniques OT - cardiac surgery OT - cardiology OT - interventional cardiology OT - virtual reality EDAT- 2024/10/10 06:23 MHDA- 2024/10/10 06:24 PMCR- 2025/10/08 CRDT- 2024/10/10 05:04 PHST- 2024/02/08 00:00 [received] PHST- 2024/09/03 00:00 [revised] PHST- 2024/09/11 00:00 [accepted] PHST- 2024/10/10 06:23 [pubmed] PHST- 2024/10/10 06:24 [medline] PHST- 2024/10/10 05:04 [entrez] PHST- 2025/10/08 00:00 [pmc-release] AID - 24042SSR [pii] AID - 10.1117/1.JMI.11.6.062606 [doi] PST - ppublish SO - J Med Imaging (Bellingham). 2024 Nov;11(6):062606. doi: 10.1117/1.JMI.11.6.062606. Epub 2024 Oct 8. PMID- 39386082 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241011 IS - 2057-7540 (Print) IS - 2057-7559 (Electronic) IS - 2057-7540 (Linking) VI - 10 DP - 2024 TI - Transcatheter Aortic Valve Replacement is Ready for Most Low-risk Patients: A Systematic Review of the Literature. PG - e11 LID - 10.15420/cfr.2023.23 [doi] LID - e11 AB - Transcatheter aortic valve replacement (TAVR) has undergone rapid expansion, emerging as a viable therapeutic option for low-risk patients in lieu of surgical aortic valve replacement. This paper aims to provide a review of the scientific evidence concerning TAVR in low-risk patients, encompassing both observational and clinical trial data. Furthermore, a substantial proportion of low-risk patients possesses a bicuspid aortic valve, necessitating careful examination of the pertinent anatomic and clinical considerations to TAVR that is highlighted in this review. Additionally, the review expands upon some of the unique challenges associated with alternate access in low-risk patients evaluated for TAVR. Last, this review outlines the pivotal role of a multidisciplinary heart team approach in the execution of all TAVR procedures and the authors' vision of 'minimalist TAVR' as a new era in low-risk TAVR. CI - Copyright (c) The Author(s), 2024. Published by Radcliffe Group Ltd. FAU - Jabri, Ahmad AU - Jabri A AD - Division of Cardiology, Structural Heart Disease Center, Henry Ford Hospital Detroit, MI, US. FAU - Alameh, Anas AU - Alameh A AD - Division of Cardiology, Structural Heart Disease Center, Henry Ford Hospital Detroit, MI, US. FAU - Giustino, Gennaro AU - Giustino G AD - Division of Cardiology, Structural Heart Disease Center, Henry Ford Hospital Detroit, MI, US. FAU - Gonzalez, Pedro Engel AU - Gonzalez PE AD - Division of Cardiology, Structural Heart Disease Center, Henry Ford Hospital Detroit, MI, US. FAU - O'Neill, Brian AU - O'Neill B AD - Division of Cardiology, Department of Medicine, London Health Sciences Centre, Western University London, Ontario, Canada. AD - Department of Epidemiology and Biostatistics, Western University London, Ontario, Canada. FAU - Bagur, Rodrigo AU - Bagur R AD - Division of Cardiology, Department of Medicine, London Health Sciences Centre, Western University London, Ontario, Canada. AD - Department of Epidemiology and Biostatistics, Western University London, Ontario, Canada. FAU - Cox, Pedro AU - Cox P AD - Division of Cardiology, Department of Medicine, Louisiana State University New Orleans, LA, US. FAU - Frisoli, Tiberio AU - Frisoli T AD - Division of Cardiology, Structural Heart Disease Center, Henry Ford Hospital Detroit, MI, US. FAU - Lee, James AU - Lee J AD - Division of Cardiology, Structural Heart Disease Center, Henry Ford Hospital Detroit, MI, US. FAU - Wang, Dee Dee AU - Wang DD AD - Division of Cardiology, Structural Heart Disease Center, Henry Ford Hospital Detroit, MI, US. FAU - O'Neill, William W AU - O'Neill WW AD - Division of Cardiology, Structural Heart Disease Center, Henry Ford Hospital Detroit, MI, US. FAU - Villablanca, Pedro AU - Villablanca P AD - Division of Cardiology, Structural Heart Disease Center, Henry Ford Hospital Detroit, MI, US. LA - eng PT - Journal Article PT - Review DEP - 20240913 PL - England TA - Card Fail Rev JT - Cardiac failure review JID - 101696210 PMC - PMC11462515 OTO - NOTNLM OT - Transcatheter aortic valve replacement OT - low risk OT - systematic review OT - transcatheter aortic valve intervention COIS- Disclosure: The authors have no conflicts of interest to declare. EDAT- 2024/10/10 10:19 MHDA- 2024/10/10 10:20 PMCR- 2024/09/13 CRDT- 2024/10/10 04:59 PHST- 2023/11/07 00:00 [received] PHST- 2024/01/26 00:00 [accepted] PHST- 2024/10/10 10:20 [medline] PHST- 2024/10/10 10:19 [pubmed] PHST- 2024/10/10 04:59 [entrez] PHST- 2024/09/13 00:00 [pmc-release] AID - 10.15420/cfr.2023.23 [doi] PST - epublish SO - Card Fail Rev. 2024 Sep 13;10:e11. doi: 10.15420/cfr.2023.23. eCollection 2024. PMID- 39385503 OWN - NLM STAT- MEDLINE DCOM- 20241025 LR - 20241029 IS - 1467-1107 (Electronic) IS - 1047-9511 (Linking) VI - 34 IP - 7 DP - 2024 Jul TI - The potential use of game theory in decision-making in CHD. PG - 1424-1431 LID - 10.1017/S104795112402643X [doi] AB - Background: Congenital cardiac care involves multiple stakeholders including patients and their families, surgeons, cardiologists, anaesthetists, the wider multidisciplinary team, healthcare providers, and manufacturers, all of whom are involved in the decision-making process to some degree. Game theory utilises human behaviour to address the dynamics involved in a decision and what the best payoff is depending on the decision of other players. Aim: By presenting these interactions as a strategic game, this paper aims to provide a descriptive analysis on the utility and effectiveness of game theory in optimising decision-making in congenital cardiac care. Methodology: The comprehensive literature was searched to identify papers on game theory, and its application within surgery. Results: The analysis demonstrated that by utilising game theories, decision-making can be more aligned with patient-centric approaches, potentially improving clinical outcomes. Conclusion: Game theory is a useful tool for improving decision-making and may pave the way for more efficient and improved patient-centric approaches. FAU - Francis, Jeevan AU - Francis J AUID- ORCID: 0000-0002-8017-8727 AD - Department of Cardiothoracic Surgery, Aberdeen Royal Infirmary, Aberdeen, UK. FAU - Prothasis, Sneha AU - Prothasis S AD - Department of Cardiothoracic Surgery, Aberdeen Royal Infirmary, Aberdeen, UK. FAU - Ganesh, Ayalvadi AU - Ganesh A AD - School of Mathematics, University of Bristol, Bristol, UK. FAU - Ekkunagul, Thanapon AU - Ekkunagul T AD - Department of Cardiothoracic Surgery, Aberdeen Royal Infirmary, Aberdeen, UK. FAU - Stoica, Serban AU - Stoica S AD - Bristol Children's Hospital. University of Bristol, Bristol, UK. LA - eng PT - Journal Article PT - Review DEP - 20241010 PL - England TA - Cardiol Young JT - Cardiology in the young JID - 9200019 SB - IM MH - Humans MH - *Game Theory MH - *Heart Defects, Congenital/psychology MH - Decision Making MH - Clinical Decision-Making OTO - NOTNLM OT - CHD OT - congenital heart surgery OT - game theory EDAT- 2024/10/10 06:22 MHDA- 2024/10/25 16:19 CRDT- 2024/10/10 02:03 PHST- 2024/10/25 16:19 [medline] PHST- 2024/10/10 06:22 [pubmed] PHST- 2024/10/10 02:03 [entrez] AID - S104795112402643X [pii] AID - 10.1017/S104795112402643X [doi] PST - ppublish SO - Cardiol Young. 2024 Jul;34(7):1424-1431. doi: 10.1017/S104795112402643X. Epub 2024 Oct 10. PMID- 39385321 OWN - NLM STAT- MEDLINE DCOM- 20250326 LR - 20250729 IS - 1834-7819 (Electronic) IS - 0045-0421 (Linking) VI - 69 Suppl 1 DP - 2024 Jun TI - The interdisciplinary field of Sleep Medicine-time for dentists to sink their teeth into it! PG - S108-S111 LID - 10.1111/adj.13044 [doi] AB - Sleep Medicine has evolved into a highly multidisciplinary field over the last few decades, involving respiratory physicians, neurologists, cardiologists, ENT surgeons, psychiatrists and psychologists to name a few. It is within this highly multidisciplinary context that we have seen an increasing role for dentists in the recognition, diagnosis and management of select sleep disturbances and disorders. Over the last couple of decades, this growing role for dentists has seen the informal emergence of a new interdisciplinary field of Dental Sleep Medicine-a field that bridges medicine and dentistry as it pertains to the diagnosis and management of sleep disorders. This article describes this new field in terms of its history, the evolving scope of practice for dentists, the implications for education and training, and the importance of multidisciplinary care that optimises outcomes for patients. CI - (c) 2024 Australian Dental Association. FAU - Cistulli, P A AU - Cistulli PA AUID- ORCID: 0000-0002-7920-4924 AD - Department of Respiratory and Sleep Medicine, Centre for Sleep Health and Research, Royal North Shore Hospital, St Leonards, New South Wales, Australia. AD - Faculty of Medicine and Health, Charles Perkins Centre and Northern Clinical School, The University of Sydney, Sydney, New South Wales, Australia. FAU - Balasubramaniam, R AU - Balasubramaniam R AD - UWA Dental School, The University of Western Australia, Perth, Western Australia, Australia. AD - Department of Dental and Maxillofacial Surgery, Perth Children's Hospital, Perth, Western Australia, Australia. LA - eng PT - Journal Article DEP - 20241009 PL - Australia TA - Aust Dent J JT - Australian dental journal JID - 0370612 SB - IM MH - Humans MH - *Sleep Medicine Specialty/trends MH - *Sleep Wake Disorders/therapy/diagnosis MH - *Patient Care Team MH - Dentists OTO - NOTNLM OT - dental sleep medicine OT - sleep disorders EDAT- 2024/10/10 06:23 MHDA- 2025/03/27 05:25 CRDT- 2024/10/10 00:05 PHST- 2024/09/22 00:00 [accepted] PHST- 2025/03/27 05:25 [medline] PHST- 2024/10/10 06:23 [pubmed] PHST- 2024/10/10 00:05 [entrez] AID - 10.1111/adj.13044 [doi] PST - ppublish SO - Aust Dent J. 2024 Jun;69 Suppl 1:S108-S111. doi: 10.1111/adj.13044. Epub 2024 Oct 9. PMID- 39385045 OWN - NLM STAT- In-Process LR - 20261010 IS - 1546-170X (Electronic) IS - 1078-8956 (Linking) VI - 30 IP - 11 DP - 2024 Nov TI - People with cardiac pacemakers require multidisciplinary care. PG - 3061-3062 LID - 10.1038/s41591-024-03296-w [doi] FAU - Vernooy, Kevin AU - Vernooy K AUID- ORCID: 0000-0002-8818-5964 AD - Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Center, Maastricht, The Netherlands. kevin.vernooy@mumc.nl. FAU - van Stipdonk, Antonius M W AU - van Stipdonk AMW AD - Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Center, Maastricht, The Netherlands. FAU - Joza, Jacqueline AU - Joza J AD - Department of Medicine, McGill University Health Center, Montreal, Canada. LA - eng PT - Journal Article PL - United States TA - Nat Med JT - Nature medicine JID - 9502015 SB - IM COIS- Competing interests The authors declare no competing interests. EDAT- 2024/10/10 00:38 MHDA- 2024/10/10 00:38 CRDT- 2024/10/09 23:53 PHST- 2024/10/10 00:38 [pubmed] PHST- 2024/10/10 00:38 [medline] PHST- 2024/10/09 23:53 [entrez] AID - 10.1038/s41591-024-03296-w [pii] AID - 10.1038/s41591-024-03296-w [doi] PST - ppublish SO - Nat Med. 2024 Nov;30(11):3061-3062. doi: 10.1038/s41591-024-03296-w. PMID- 39384638 OWN - NLM STAT- MEDLINE DCOM- 20241009 LR - 20261010 IS - 1437-9813 (Electronic) IS - 0179-0358 (Linking) VI - 40 IP - 1 DP - 2024 Oct 9 TI - Surgical management protocol for disk battery ingestion. PG - 268 LID - 10.1007/s00383-024-05849-z [doi] AB - PURPOSE: Disk battery (DB) ingestion in children can lead to severe complications and mortality. This study details our experience in managing DB ingestion and its complications. METHODS: We analyzed data from all patients treated for DB ingestion at our hospital from June 2010 to January 2024. A protocol established in 2010 requires angio-CT scans for esophageal DB cases and a multidisciplinary approach involving gastroenterologists, otolaryngologists, pediatric and airway surgeons, and cardiac surgeons. RESULTS: We treated 22 patients. In June 2010, following the tragic death of a patient from an undiagnosed DB ingestion that led to an aortoesophageal fistula, our protocol was established. All DBs were removed endoscopically. Four patients needed additional surgery: two had tracheal resection/anastomosis and esophageal repair for large tracheoesophageal fistulas; one required aortic wall reinforcement with a patch; one underwent endoscopic removal with a sternal split to explore the aortic arch. All 22 patients survived and recovered clinically. One developed bilateral vocal cord palsy as a complication. CONCLUSION: Effective management of DB ingestion complications necessitates a collaborative, multidisciplinary approach. Our protocol has improved management strategies and patient outcomes. CI - (c) 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Roggero, Arianna AU - Roggero A AD - Pediatric Surgery Department, IRCCS Istituto Giannina Gaslini, Via Gerolamo Gaslini 5, 16147, Genoa, Italy. arianna.roggero@gmail.com. AD - Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics and Maternal and Child Science, University of Genoa, Genoa, Italy. arianna.roggero@gmail.com. FAU - Guerriero, Vittorio AU - Guerriero V AD - Pediatric Surgery Department, IRCCS Istituto Giannina Gaslini, Via Gerolamo Gaslini 5, 16147, Genoa, Italy. AD - Pediatric Thoracic and Airway Surgery Unit, IRCCS Istituto Giannina Gaslini, Largo Gaslini 5, 16147, Genoa, Italy. FAU - Lena, Federica AU - Lena F AD - Pediatric Surgery Department, IRCCS Istituto Giannina Gaslini, Via Gerolamo Gaslini 5, 16147, Genoa, Italy. AD - Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics and Maternal and Child Science, University of Genoa, Genoa, Italy. FAU - Arrigo, Serena AU - Arrigo S AD - Pediatric Gastroenterology and Endoscopy Unit, Institute Giannina Gaslini, Genoa, Italy. FAU - Santoro, Francesco AU - Santoro F AD - Department of Pediatric Cardiovascular Surgery, Institute Giannina Gaslini, Genoa, Italy. FAU - D'Agostino, Roberto AU - D'Agostino R AD - Otolaryngology Unit, Institute Giannina Gaslini, Genoa, Italy. FAU - Damasio, Maria Beatrice AU - Damasio MB AD - Department of Radiology, IRCCS Istituto Giannina Gaslini, Largo Gaslini 5, 16147, Genoa, Italy. FAU - Rizzo, Francesca AU - Rizzo F AD - Department of Radiology, IRCCS Istituto Giannina Gaslini, Largo Gaslini 5, 16147, Genoa, Italy. FAU - Gandullia, Paolo AU - Gandullia P AD - Pediatric Gastroenterology and Endoscopy Unit, Institute Giannina Gaslini, Genoa, Italy. FAU - Moscatelli, Andrea AU - Moscatelli A AD - Neonatal and Pediatric Intensive Care Unit, IRCCS Istituto Giannina Gaslini 5, 16147, Genoa, Italy. FAU - Mattioli, Girolamo AU - Mattioli G AD - Pediatric Surgery Department, IRCCS Istituto Giannina Gaslini, Via Gerolamo Gaslini 5, 16147, Genoa, Italy. FAU - Torre, Michele AU - Torre M AD - Pediatric Surgery Department, IRCCS Istituto Giannina Gaslini, Via Gerolamo Gaslini 5, 16147, Genoa, Italy. AD - Pediatric Thoracic and Airway Surgery Unit, IRCCS Istituto Giannina Gaslini, Largo Gaslini 5, 16147, Genoa, Italy. LA - eng PT - Journal Article PT - Review DEP - 20241009 PL - Germany TA - Pediatr Surg Int JT - Pediatric surgery international JID - 8609169 SB - IM MH - Humans MH - Male MH - *Foreign Bodies/surgery/complications MH - Female MH - Child, Preschool MH - Infant MH - Child MH - *Electric Power Supplies MH - Retrospective Studies MH - Esophagus/surgery MH - Clinical Protocols MH - Esophageal Fistula/surgery/etiology MH - Tomography, X-Ray Computed MH - Tracheoesophageal Fistula/surgery OTO - NOTNLM OT - Complication disk battery ingestion OT - Disk battery ingestion OT - Protocol EDAT- 2024/10/10 00:38 MHDA- 2024/10/10 00:39 CRDT- 2024/10/09 23:18 PHST- 2024/09/30 00:00 [accepted] PHST- 2024/10/10 00:39 [medline] PHST- 2024/10/10 00:38 [pubmed] PHST- 2024/10/09 23:18 [entrez] AID - 10.1007/s00383-024-05849-z [pii] AID - 10.1007/s00383-024-05849-z [doi] PST - epublish SO - Pediatr Surg Int. 2024 Oct 9;40(1):268. doi: 10.1007/s00383-024-05849-z. PMID- 39384082 OWN - NLM STAT- MEDLINE DCOM- 20250731 LR - 20260325 IS - 1097-685X (Electronic) IS - 0022-5223 (Linking) VI - 170 IP - 2 DP - 2025 Aug TI - Strategic implementation of a new robotic mitral repair program: Early experience and outcomes. PG - 495-501 LID - S0022-5223(24)00906-1 [pii] LID - 10.1016/j.jtcvs.2024.09.052 [doi] AB - BACKGROUND: Despite numerous reported benefits of robotic mitral repair, the absolute number of procedures performed remain low in part to uncertainties about the necessary steps to launch a program. In this report, we describe our early outcomes and strategy with launching a successful new robotic mitral repair program. METHODS: Our multimodal strategic plan emphasized team education, hands-on technical preparation, stepwise advancement, and careful patient selection. Consultant service analytics and team debriefings allowed for iterative improvements. RESULTS: Between March 2022 and February 2024, 50 patients underwent robotic mitral repair at our institution. Average age at time of operation was 62 years with a Society of Thoracic Surgeons risk score of 0.58. Successful repairs were performed in 98% of patients. There was 1 conversion to sternotomy. There were no deaths, and there was minimal perioperative morbidity. On both predischarge and follow-up echocardiography, no patients had greater than mild mitral regurgitation. CONCLUSIONS: Our work provides a model for establishing a successful robotic mitral program. An up-front emphasis on team education, careful preparation, proper patient selection, and feedback-driven improvements can accelerate the attainment of standards set by high-volume centers. CI - Copyright (c) 2024 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved. FAU - Shin, Max AU - Shin M AD - Division of Cardiovascular Surgery, Department of Surgery, Hospital of the University of Pennsylvania, University of Pennsylvania, Philadelphia, Pa. FAU - Szeto, Jonathan J AU - Szeto JJ AD - Division of Cardiovascular Surgery, Department of Surgery, Hospital of the University of Pennsylvania, University of Pennsylvania, Philadelphia, Pa. FAU - Brown, Chase AU - Brown C AD - Division of Cardiovascular Surgery, Department of Surgery, Hospital of the University of Pennsylvania, University of Pennsylvania, Philadelphia, Pa. FAU - Toubat, Omar AU - Toubat O AD - Division of Cardiovascular Surgery, Department of Surgery, Hospital of the University of Pennsylvania, University of Pennsylvania, Philadelphia, Pa. FAU - Helmers, Mark R AU - Helmers MR AD - Division of Cardiovascular Surgery, Department of Surgery, Hospital of the University of Pennsylvania, University of Pennsylvania, Philadelphia, Pa. FAU - Iyengar, Amit AU - Iyengar A AD - Division of Cardiovascular Surgery, Department of Surgery, Hospital of the University of Pennsylvania, University of Pennsylvania, Philadelphia, Pa. FAU - Acker, Michael A AU - Acker MA AD - Division of Cardiovascular Surgery, Department of Surgery, Hospital of the University of Pennsylvania, University of Pennsylvania, Philadelphia, Pa. FAU - Geirsson, Arnar AU - Geirsson A AD - Section of Cardiac Surgery, Department of Surgery, Columbia University, New York, NY. FAU - Smith, Robert L AU - Smith RL AD - Department of Cardiovascular Surgery, Baylor Scott & White - The Heart Hospital, Plano, Tex. FAU - Ibrahim, Michael E AU - Ibrahim ME AD - Division of Cardiovascular Surgery, Department of Surgery, Hospital of the University of Pennsylvania, University of Pennsylvania, Philadelphia, Pa. Electronic address: Michael.ibrahim@pennmedicine.upenn.edu. LA - eng PT - Journal Article DEP - 20241008 PL - United States TA - J Thorac Cardiovasc Surg JT - The Journal of thoracic and cardiovascular surgery JID - 0376343 SB - IM MH - Humans MH - Middle Aged MH - *Robotic Surgical Procedures/adverse effects/education MH - Male MH - Female MH - *Mitral Valve/surgery/diagnostic imaging/physiopathology MH - *Mitral Valve Insufficiency/surgery/diagnostic imaging/physiopathology MH - Treatment Outcome MH - Aged MH - Time Factors MH - Patient Care Team/organization & administration MH - Patient Selection OTO - NOTNLM OT - minimally invasive OT - mitral repair OT - robotic mitral repair COIS- Conflict of Interest Statement The authors reported no conflicts of interest. The Journal policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest. EDAT- 2024/10/10 00:37 MHDA- 2025/08/01 00:29 CRDT- 2024/10/09 19:14 PHST- 2024/07/22 00:00 [received] PHST- 2024/09/17 00:00 [revised] PHST- 2024/09/28 00:00 [accepted] PHST- 2025/08/01 00:29 [medline] PHST- 2024/10/10 00:37 [pubmed] PHST- 2024/10/09 19:14 [entrez] AID - S0022-5223(24)00906-1 [pii] AID - 10.1016/j.jtcvs.2024.09.052 [doi] PST - ppublish SO - J Thorac Cardiovasc Surg. 2025 Aug;170(2):495-501. doi: 10.1016/j.jtcvs.2024.09.052. Epub 2024 Oct 8. PMID- 39379799 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241011 IS - 1865-1372 (Print) IS - 1865-1380 (Electronic) IS - 1865-1372 (Linking) VI - 17 IP - 1 DP - 2024 Oct 8 TI - Acute mesenteric ischemia secondary to complete AV block and acute systolic heart failure: a case report. PG - 147 LID - 10.1186/s12245-024-00737-8 [doi] LID - 147 AB - BACKGROUND: Acute mesenteric ischemia (AMI) usually presents with abrupt and severe abdominal pain associated with nausea and vomiting. This case is notable due to the occurrence of AMI secondary to acute systolic heart failure caused by new onset complete heart block. CASE PRESENTATION: A 65-year-old male presented with sudden onset epigastric pain. ECG showed complete AV block and acute ischemia, and a subsequent CTA revealed complete occlusion of the mid superior mesenteric artery. His emergent left heart catheterization showed non-occlusive coronary artery disease. The patient underwent emergent laparotomy and SMA thrombectomy. Postoperative complications included worsening congestive heart failure and persistent bradycardia, requiring a permanent pacemaker. The patient was discharged to a skilled nursing facility in stable condition. CONCLUSIONS: This case highlights the diagnostic challenges of AMI in the setting of acute heart failure and new onset AV block mimicking acute cardiac events and emphasizes the importance of a multidisciplinary approach in managing such complex cases. CI - (c) 2024. The Author(s). FAU - Cui, Jian AU - Cui J AD - Department of Emergency Medicine, Mercy Health St. Rita's Medical Center, 730 W. Market Street, Lima, OH, 45801, USA. jcui@mercy.com. LA - eng PT - Journal Article DEP - 20241008 PL - England TA - Int J Emerg Med JT - International journal of emergency medicine JID - 101469435 PMC - PMC11463034 OTO - NOTNLM OT - Acute mesenteric ischemia OT - Acute systolic heart failure OT - Case report OT - Complete AV block COIS- The authors declare no competing interests. EDAT- 2024/10/09 00:23 MHDA- 2024/10/09 00:24 PMCR- 2024/10/08 CRDT- 2024/10/08 23:44 PHST- 2024/07/29 00:00 [received] PHST- 2024/09/28 00:00 [accepted] PHST- 2024/10/09 00:24 [medline] PHST- 2024/10/09 00:23 [pubmed] PHST- 2024/10/08 23:44 [entrez] PHST- 2024/10/08 00:00 [pmc-release] AID - 10.1186/s12245-024-00737-8 [pii] AID - 737 [pii] AID - 10.1186/s12245-024-00737-8 [doi] PST - epublish SO - Int J Emerg Med. 2024 Oct 8;17(1):147. doi: 10.1186/s12245-024-00737-8. PMID- 39373691 OWN - NLM STAT- MEDLINE DCOM- 20250424 LR - 20260603 IS - 1932-8095 (Electronic) IS - 1932-8087 (Linking) VI - 30 IP - 3 DP - 2025 May-Jun 01 TI - Reducing Readmissions Using Collaborative Care. PG - 93-99 LID - 10.1097/NCM.0000000000000767 [doi] AB - PURPOSE OF INITIATIVE: After noting an elevated chronic obstructive pulmonary disease readmission rate for 2022, the inpatient Nurse Navigator at a rural nonprofit, 116-bed acute care facility in the State of Virginia met with interdisciplinary team (IDT) members to identify improvement efforts to decrease 30-day readmission rates. PRIMARY PRACTICE SETTING: A 116-bed health care facility in Southside Virginia. METHODOLOGY AND SAMPLE: Quality improvement initiative aimed to decrease 30-day penalty readmission rates using a collaborative IDT approach, focusing on patients 65 years or older who are discharged home or to an assisted living facility with a diagnosis of acute myocardial infarction, heart failure, chronic obstructive pulmonary disease, and pneumonia. RESULTS: Compared to the readmission rates obtained in 2022, the 2023 readmission rates among the four diagnoses groups met or were under the disease-specific targets for 2023, supporting the efforts of the collaborative interdisciplinary approach to decrease 30-day readmission rates. IMPLICATIONS FOR CASE MANAGEMENT PRACTICE: Addressing community barriers and social determinants of health at the index admission. Collaborating with IDT members for a safe transition of care. Using the community paramedic program to provide additional resources to a rural community. CI - Copyright (c) 2025 Wolters Kluwer Health, Inc. All rights reserved. FAU - Cawley-Chambers, Melissa AU - Cawley-Chambers M AD - Melissa Cawley-Chambers, MHA, BSN, RN, CV-BC, is a Clinical Nurse Navigator, born and raised in rural Southside Virginia having served as a nurse for 15 years in a hospital setting and worked in acute and critical care for most of her career until transitioning to nurse navigation 3 years ago. Nurse Navigation gives her the fulfillment of giving back to the community and helping patients succeed in their chronic disease management. LA - eng PT - Journal Article DEP - 20250328 PL - United States TA - Prof Case Manag JT - Professional case management JID - 101291585 SB - IM MH - Humans MH - *Patient Readmission/statistics & numerical data MH - Aged MH - Male MH - Female MH - Virginia MH - *Cooperative Behavior MH - *Quality Improvement MH - Aged, 80 and over MH - *Patient Care Team MH - *Case Management MH - Pulmonary Disease, Chronic Obstructive/therapy MH - Heart Failure/therapy COIS- The author declares no conflict of interest. EDAT- 2024/10/07 12:57 MHDA- 2025/03/31 21:16 CRDT- 2024/10/07 10:33 PHST- 2025/03/31 21:16 [medline] PHST- 2024/10/07 12:57 [pubmed] PHST- 2024/10/07 10:33 [entrez] AID - 01269241-990000000-00025 [pii] AID - 10.1097/NCM.0000000000000767 [doi] PST - ppublish SO - Prof Case Manag. 2025 May-Jun 01;30(3):93-99. doi: 10.1097/NCM.0000000000000767. Epub 2025 Mar 28. PMID- 39372129 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241008 IS - 2049-9361 (Print) IS - 2049-937X (Electronic) IS - 2049-9361 (Linking) VI - 11 DP - 2024 Jan-Dec TI - Management of isolated native tricuspid valve infective endocarditis by a multidisciplinary program: a single-center retrospective cohort study. PG - 20499361241280690 LID - 10.1177/20499361241280690 [doi] LID - 20499361241280690 AB - BACKGROUND: Isolated native tricuspid valve infective endocarditis remains a challenging disease to treat given the large number of patients with substance use disorder. There is limited data on the optimal treatment strategy and the impact of a multidisciplinary endocarditis program on outcomes for this population. OBJECTIVES: To assess the clinical outcomes associated with management of native tricuspid valve infective endocarditis by a multidisciplinary team. DESIGN: Single-center, retrospective cohort study. METHODS: Patient cases were identified from the registry of the institutional multidisciplinary endocarditis team. Patients with left-sided endocarditis, multivalvular endocarditis, prosthetic tricuspid valves and cardiac implantable electronic devices were excluded. RESULTS: Between September 7th, 2021 and February 1st, 2024 72 consecutive patients with isolated native tricuspid valve infective endocarditis were identified. Sixty-six (91.7%) patients were managed medically. Five patients underwent percutaneous mechanical aspiration of tricuspid valve vegetations and one patient underwent tricuspid valve replacement during the index hospitalization. In-hospital mortality was 1.4% and 90-day mortality was 2.8%. Nineteen (26.4%) patients discharged before medically advised and 25% were re-admitted within 30 days. Ten (13.9%) patients underwent elective tricuspid valve replacements after outpatient follow-up. CONCLUSION: Among 72 patients with isolated native tricuspid valve infective endocarditis managed by a multidisciplinary endocarditis program over a 2.5-year period, in-hospital, 90-day mortality and 1-year mortality were very low despite low rates of percutaneous mechanical aspiration and tricuspid valve surgery. Multidisciplinary follow-up can lead to elective tricuspid valve surgery in a delayed fashion. CI - (c) The Author(s), 2024. FAU - Collis, Bennett AU - Collis B AD - University of Kentucky College of Medicine, Lexington, KY, USA. FAU - Alnabelsi, Talal AU - Alnabelsi T AD - Division of Cardiology, Department of Internal Medicine, University of Kentucky Medical Center, Lexington, KY, USA. FAU - Hall, Evan AU - Hall E AD - University of Kentucky College of Medicine, Lexington, KY, USA. FAU - Cao, Chloe AU - Cao C AD - Department of Internal Medicine, HCA Healthcare/USF Morsani College of Medicine GME/HCA Florida Trinity, Trinity, FL, USA. FAU - Johnson, Meredith AU - Johnson M AD - Department of Surgery, University of Kentucky Medical Center, Lexington, KY, USA. FAU - Gurley, John AU - Gurley J AD - Division of Cardiology, Department of Internal Medicine, University of Kentucky Medical Center, Lexington, KY, USA. FAU - Strnad, Luke AU - Strnad L AD - Division of Infectious Diseases, Department of Internal Medicine, Oregon Health and Science University, Portland, OR, USA. FAU - Reda, Hassan AU - Reda H AD - Division of Cardiac Surgery, University of Kentucky Medical Center, Lexington, KY, USA. FAU - London, Tessa AU - London T AD - Division of Cardiac Surgery, University of Kentucky Medical Center, Lexington, KY, USA. FAU - Ogburn, Erinn AU - Ogburn E AD - Division of Cardiac Surgery, University of Kentucky Medical Center, Lexington, KY, USA. FAU - Sekela, Michael AU - Sekela M AD - Division of Cardiac Surgery, University of Kentucky Medical Center, Lexington, KY, USA. FAU - Stoner, Bobbi Jo AU - Stoner BJ AD - University of Kentucky College of Pharmacy, Lexington, KY, USA. FAU - El-Dalati, Sami AU - El-Dalati S AUID- ORCID: 0000-0003-2603-2951 AD - Division of Infectious Diseases, Department of Internal Medicine, University of Kentucky Medical Center, 3101 Beaumont Centre Circle, Lexington, KY 40506, USA. LA - eng PT - Journal Article DEP - 20240927 PL - England TA - Ther Adv Infect Dis JT - Therapeutic advances in infectious disease JID - 101606715 PMC - PMC11452872 OTO - NOTNLM OT - endocarditis OT - multidisciplinary teams OT - patients who use drugs OT - tricuspid valve disease EDAT- 2024/10/07 11:22 MHDA- 2024/10/07 11:23 PMCR- 2024/09/27 CRDT- 2024/10/07 05:45 PHST- 2024/04/08 00:00 [received] PHST- 2024/08/15 00:00 [accepted] PHST- 2024/10/07 11:23 [medline] PHST- 2024/10/07 11:22 [pubmed] PHST- 2024/10/07 05:45 [entrez] PHST- 2024/09/27 00:00 [pmc-release] AID - 10.1177_20499361241280690 [pii] AID - 10.1177/20499361241280690 [doi] PST - epublish SO - Ther Adv Infect Dis. 2024 Sep 27;11:20499361241280690. doi: 10.1177/20499361241280690. eCollection 2024 Jan-Dec. PMID- 39371719 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241008 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 16 IP - 9 DP - 2024 Sep TI - Associated Factors and Mortality of Arrhythmia in Emergency Department: A Narrative Review. PG - e68645 LID - 10.7759/cureus.68645 [doi] LID - e68645 AB - Cardiac arrhythmias represent a major concern in the emergency department (ED), particularly given their association with significant morbidity and mortality. This narrative review examines the various factors influencing arrhythmias and their impact on patient outcomes in emergency settings. Managing complex supraventricular and ventricular arrhythmias (VAs) during acute myocardial infarction (AMI) and severe cardiovascular conditions remains challenging, despite advancements in diagnostic and therapeutic techniques. Ventricular arrhythmias frequently forecast worse outcomes during hospital stays and heighten the chances of sudden cardiac death and cardiac arrest, especially within the initial 30 days after a heart attack. The incidence of arrhythmias in ED is increasing due to demographic changes and higher rates of chronic illnesses such as diabetes, hypertension, and chronic kidney disease. These comorbidities, coupled with lifestyle factors such as smoking and alcohol consumption, complicate arrhythmia management, especially among older adults and males. Rapid and precise ECG interpretation in the ED is crucial for identifying specific arrhythmia types and initiating appropriate treatments. Atrial fibrillation (AF), the most prevalent form of rapid heart rhythm originating above the ventricles, notably impacts patient outcomes, particularly in cases of AMI and heart failure. In the ED, managing AF focuses on preventing strokes with thromboprophylaxis and employing risk assessment tools such as CHA2DS2-VASc and HAS-BLED scores. The analysis highlights how risk factors like hypertension, obesity, obstructive sleep apnea (OSA), and diabetes intricately influence the development and worsening of AF. Optimizing AF treatment outcomes requires a multidisciplinary approach involving cardiologists, emergency physicians, and critical care specialists. Future research should prioritize evaluating the effectiveness of preventive and therapeutic interventions for AF, integrating new risk factors and genetic insights to enhance prediction and management strategies. Understanding the factors contributing to arrhythmias and mortality in the ED underscores the importance of timely and accurate diagnostic and therapeutic measures to improve patient care and outcomes. CI - Copyright (c) 2024, Gaur et al. FAU - Gaur, Utkarsh AU - Gaur U AD - Emergency Medicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Wardha, IND. FAU - Gadkari, Charuta AU - Gadkari C AD - Emergency Medicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Wardha, IND. FAU - Pundkar, Aditya AU - Pundkar A AD - Orthopedics, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Wardha, IND. LA - eng PT - Journal Article PT - Review DEP - 20240904 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC11451514 OTO - NOTNLM OT - arrhythmia OT - cardiovascular diseases OT - emergency department OT - hypertension OT - management OT - mortality OT - risk factors COIS- Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. EDAT- 2024/10/07 11:22 MHDA- 2024/10/07 11:23 PMCR- 2024/09/04 CRDT- 2024/10/07 05:34 PHST- 2024/06/15 00:00 [received] PHST- 2024/09/04 00:00 [accepted] PHST- 2024/10/07 11:23 [medline] PHST- 2024/10/07 11:22 [pubmed] PHST- 2024/10/07 05:34 [entrez] PHST- 2024/09/04 00:00 [pmc-release] AID - 10.7759/cureus.68645 [doi] PST - epublish SO - Cureus. 2024 Sep 4;16(9):e68645. doi: 10.7759/cureus.68645. eCollection 2024 Sep. PMID- 39370330 OWN - NLM STAT- MEDLINE DCOM- 20241213 LR - 20250404 IS - 1095-9157 (Electronic) IS - 0896-8411 (Linking) VI - 149 DP - 2024 Dec TI - Extrapulmonary sarcoidosis. PG - 103323 LID - S0896-8411(24)00157-4 [pii] LID - 10.1016/j.jaut.2024.103323 [doi] AB - Sarcoidosis is a chronic disease of unknown origin that develops when a genetically susceptible host is exposed to an antigen, leading to an exuberant immune response characterized by granulomatous inflammation. Although lung involvement is almost universal as well as the leading cause of morbidity and mortality, virtually any organ can be affected. In particular, sarcoidosis of the heart, nervous system, and eyes can be devastating, leading to death, debilitation and blindness, and a multidisciplinary approach involving expert specialists is required for prompt diagnosis and appropriate treatment. Sarcoidosis of the skin can be disfiguring, thus posing a substantial psychologic and social impact on the patients. The diagnosis is often straightforward in the presence of compatible clinical manifestations in patients with biopsy-proven sarcoidosis, but is challenging when extrapulmonary signs/symptoms occur in isolation. Corticosteroids remain the first line therapy, with immunosuppressive or biologic agents being reserved to patients failing or experiencing side effects from steroids or developing refractory disease. CI - Copyright (c) 2024 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Spagnolo, Paolo AU - Spagnolo P AD - Respiratory Disease Unit, Department of Cardiac Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy. Electronic address: paolo.spagnolo@unipd.it. FAU - Kouranos, Vasileios AU - Kouranos V AD - Interstitial Lung Disease/Sarcoidosis Unit, Royal Brompton Hospital, London, United Kingdom; National Heart and Lung Institute, Imperial College London, London, United Kingdom. FAU - Singh-Curry, Victoria AU - Singh-Curry V AD - Interstitial Lung Disease/Sarcoidosis Unit, Royal Brompton Hospital, London, United Kingdom; Department of Neurology, Chelsea and Westminster Hospital NHS Foundation Trust, London, United Kingdom; Department of Neurology, Imperial College NHS Trust, London, United Kingdom. FAU - El Jammal, Thomas AU - El Jammal T AD - Department of Internal Medicine, Hopital de la Croix-Rousse, Universite Claude Bernard Lyon 1, Lyon, France. FAU - Rosenbach, Misha AU - Rosenbach M AD - Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States. LA - eng PT - Journal Article PT - Review DEP - 20241005 PL - England TA - J Autoimmun JT - Journal of autoimmunity JID - 8812164 RN - 0 (Adrenal Cortex Hormones) RN - 0 (Immunosuppressive Agents) SB - IM MH - Humans MH - *Sarcoidosis/diagnosis MH - Adrenal Cortex Hormones/therapeutic use MH - Immunosuppressive Agents/therapeutic use OTO - NOTNLM OT - Cardiac sarcoidosis OT - Cutaneous sarcoidosis OT - Extrapulmonary manifestations OT - Neurosarcoidosis OT - Ocular sarcoidosis OT - Sarcoidosis OT - Uveitis EDAT- 2024/10/07 04:17 MHDA- 2024/12/14 00:25 CRDT- 2024/10/06 21:53 PHST- 2024/04/10 00:00 [received] PHST- 2024/09/24 00:00 [revised] PHST- 2024/09/25 00:00 [accepted] PHST- 2024/12/14 00:25 [medline] PHST- 2024/10/07 04:17 [pubmed] PHST- 2024/10/06 21:53 [entrez] AID - S0896-8411(24)00157-4 [pii] AID - 10.1016/j.jaut.2024.103323 [doi] PST - ppublish SO - J Autoimmun. 2024 Dec;149:103323. doi: 10.1016/j.jaut.2024.103323. Epub 2024 Oct 5. PMID- 39368735 OWN - NLM STAT- MEDLINE DCOM- 20250424 LR - 20260915 IS - 1931-3543 (Electronic) IS - 0012-3692 (Linking) VI - 167 IP - 3 DP - 2025 Mar TI - Bringing PERT to Pediatrics: Initial Experience and Outcomes of a Pediatric Multidisciplinary Pulmonary Embolism Response Team (PERT). PG - 851-862 LID - S0012-3692(24)05286-3 [pii] LID - 10.1016/j.chest.2024.09.028 [doi] AB - BACKGROUND: Multidisciplinary pulmonary embolism response teams (PERTs) streamline care of adults with life-threatening pulmonary embolism (PE). Given rarity of pediatric PE, developing a clinical, educational, and research PERT paradigm is a novel and underused concept in pediatrics. RESEARCH QUESTION: Is a PERT feasible in pediatrics, and does it improve PE care? STUDY DESIGN AND METHODS: A strategy-to-execution proposal to launch a pediatric PERT was developed for institutional buy-in. Key stakeholders collectively implemented the PERT. Data were collected for the 2-year pre-PERT and post-PERT eras, and outcomes were compared. RESULTS: PERT implementation took 12 months. Our PERT, led by hematology, is composed of pediatric experts in emergency medicine, critical care, interventional cardiology, anesthesiology, and interventional radiology. Data on 30 patients pre-PERT and 31 patients post-PERT were analyzed. Pre-PERT, 10% (3 of 30), 13% (4 of 30), 20% (6 of 30), and 57% (17 of 30), and post-PERT, 3% (1 of 31), 10% (3 of 31), 16% (5 of 31), and 71% (22 of 31) were categorized as high-risk, intermediate-low-risk, intermediate-high-risk, and low-risk PE, respectively. Post-PERT, there were 13 unique PERT activations. PERT was activated on all eligible patients with PE and, additionally, on four low-risk PEs. Time to echocardiogram was shorter post-PERT (4.7 vs 2 hours; P = .0147). Anticoagulation was ordered (90 vs 54 min; P = .003) and given sooner (154 vs 113 min; P = .049) post-PERT. There were no differences in time to reperfusion therapies (12 hours pre-PERT vs 8.7 hours post-PERT, P = .10). Five of six (83.3%) eligible (intermediate-high and high-risk) patients received reperfusion therapies in the post-PERT era compared to three of eight (37.5%) eligible patients in the pre-PERT era (P = .0001). There were no differences in major bleeding, mortality, or length of stay in either era. INTERPRETATION: The pediatric PERT paradigm was successfully created and adopted locally. Our PERT enhanced access to experts, facilitated timely advanced therapies, and held value for low-risk PE. The University of Texas Southwestern Medical Center and Children's Medical Center pediatric PERT may serve as a best practice model for streamlining care for pediatric PE. CI - Copyright (c) 2024 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved. FAU - Dang, Mary P AU - Dang MP AD - Division of Pediatric Hematology and Oncology, Department of Pediatrics, University of Texas Southwestern Medical Center and Children's Medical Center, Dallas, TX. FAU - Cheng, Anna AU - Cheng A AD - Department of Pediatrics, University of Texas Southwestern Medical Center and Children's Medical Center, Dallas, TX. FAU - Garcia, Jessica AU - Garcia J AD - Division of Pediatric Hematology and Oncology, Department of Pediatrics, University of Texas Southwestern Medical Center and Children's Medical Center, Dallas, TX. FAU - Lee, Ying AU - Lee Y AD - Division of Pediatric Hematology and Oncology, Department of Pediatrics, University of Texas Southwestern Medical Center and Children's Medical Center, Dallas, TX. FAU - Parikh, Mihir AU - Parikh M AD - Department of Anesthesia, University of Texas Southwestern Medical Center and Children's Medical Center, Dallas, TX. FAU - McMichael, Ali B V AU - McMichael ABV AD - Phoenix Children's, Department of Child Health, University of Arizona College of Medicine, Phoenix, AZ. FAU - Han, Brian L AU - Han BL AD - Division of Pediatric Radiology, Department of Radiology, University of Texas Southwestern Medical Center and Children's Medical Center, Dallas, TX. FAU - Pimpalwar, Sheena AU - Pimpalwar S AD - Division of Pediatric Radiology, Department of Radiology, University of Texas Southwestern Medical Center and Children's Medical Center, Dallas, TX. FAU - Rinzler, Elliot S AU - Rinzler ES AD - Division of Pediatric Radiology, Department of Radiology, University of Texas Southwestern Medical Center and Children's Medical Center, Dallas, TX. FAU - Hoffman, Olivia L AU - Hoffman OL AD - Division of Pediatric Critical Care, Department of Pediatrics, University of Texas Southwestern Medical Center and Children's Medical Center, Dallas, TX. FAU - Baltagi, Sirine A AU - Baltagi SA AD - Division of Pediatric Critical Care, Department of Pediatrics, University of Texas Southwestern Medical Center and Children's Medical Center, Dallas, TX; Division of Pediatric Cardiology, University of Texas Southwestern Medical Center and Children's Medical Center, Dallas, TX. FAU - Bowens, Cindy AU - Bowens C AD - Division of Pediatric Critical Care, Department of Pediatrics, University of Texas Southwestern Medical Center and Children's Medical Center, Dallas, TX. FAU - Divekar, Abhay A AU - Divekar AA AD - Division of Pediatric Cardiology, University of Texas Southwestern Medical Center and Children's Medical Center, Dallas, TX. FAU - Davis Volk, A Paige AU - Davis Volk AP AD - Division of Pediatric Critical Care, Department of Pediatrics, University of Texas Southwestern Medical Center and Children's Medical Center, Dallas, TX. FAU - Huang, Craig J AU - Huang CJ AD - Division of Pediatric Emergency Medicine, Department of Pediatrics, University of Texas Southwestern Medical Center and Children's Medical Center, Dallas, TX. FAU - Veeram Reddy, Surendranath R AU - Veeram Reddy SR AD - Division of Pediatric Cardiology, University of Texas Southwestern Medical Center and Children's Medical Center, Dallas, TX. FAU - Arar, Yousef AU - Arar Y AD - Division of Pediatric Cardiology, University of Texas Southwestern Medical Center and Children's Medical Center, Dallas, TX. FAU - Zia, Ayesha AU - Zia A AD - Division of Pediatric Hematology and Oncology, Department of Pediatrics, University of Texas Southwestern Medical Center and Children's Medical Center, Dallas, TX. Electronic address: ayesha.zia@utsouthwestern.edu. LA - eng PT - Journal Article DEP - 20241003 PL - United States TA - Chest JT - Chest JID - 0231335 SB - IM MH - Humans MH - *Pulmonary Embolism/therapy/diagnosis MH - Child MH - Female MH - Male MH - *Patient Care Team/organization & administration MH - Adolescent MH - *Pediatrics MH - Child, Preschool OTO - NOTNLM OT - PERT OT - catheter-directed thrombolysis OT - pediatric pulmonary embolism OT - pediatrics OT - pulmonary embolism OT - pulmonary embolism response team OT - reperfusion therapies OT - venous thromboembolism COIS- Financial/Nonfinancial Disclosures None declared. EDAT- 2024/10/06 13:43 MHDA- 2025/03/13 00:33 CRDT- 2024/10/05 19:20 PHST- 2024/04/24 00:00 [received] PHST- 2024/08/29 00:00 [revised] PHST- 2024/09/09 00:00 [accepted] PHST- 2025/03/13 00:33 [medline] PHST- 2024/10/06 13:43 [pubmed] PHST- 2024/10/05 19:20 [entrez] AID - S0012-3692(24)05286-3 [pii] AID - 10.1016/j.chest.2024.09.028 [doi] PST - ppublish SO - Chest. 2025 Mar;167(3):851-862. doi: 10.1016/j.chest.2024.09.028. Epub 2024 Oct 3. PMID- 39368042 OWN - NLM STAT- MEDLINE DCOM- 20250424 LR - 20260127 IS - 2210-7711 (Electronic) IS - 2210-7703 (Print) VI - 47 IP - 1 DP - 2025 Feb TI - Implementation and evaluation of specialist heart failure pharmacist prescribing clinics. PG - 8-14 LID - 10.1007/s11096-024-01808-9 [doi] AB - BACKGROUND: Medications form the basis of treatment for heart failure (HF) and adherence is crucial as untreated HF has a mortality of greater than 30%. As such, specialist HF pharmacists with expertise in prescribing and promoting adherence have become an integral part of the wider HF multidisciplinary team (MDT). AIM: To implement specialist HF pharmacist prescribing clinics and evaluate their impact. SETTING: An integrated HF team at a tertiary London hospital. DEVELOPMENT: The clinic was initially developed to facilitate the introduction of sacubitril-valsartan evolving to 6 dedicated clinics/week. IMPLEMENTATION: A dedicated electronic referral pathway was created to channel referrals to the specialist clinic, and referral criteria expanded to all patients requiring optimisation of medical therapy. EVALUATION: Data were retrospectively collected for patients with heart failure with reduced ejection fraction seen in the HF pharmacist clinic between September 2021 and July 2022. Overall, 114 patients were seen (mean age 66 years, 78 male). The mean time to medication optimisation was 3 months (averaging 1 appointment/month). The number on optimised doses of guideline-directed medical therapy, increased significantly from 8% at first appointment to 76% on discharge (p < 0.001). The HF pharmacists reviewed all medications and optimised non-HF medications for 17.5% (n = 20) of patients. CONCLUSION: HF pharmacists can optimise patients' HF and non-HF medical therapy typically within 3 months. By reviewing all prescribed medications, HF pharmacists provide a holistic review of all medications. They can play a vital role in addressing the underutilisation of HF medical therapy and thereby improving patient outcomes. CI - (c) 2024. The Author(s). FAU - Campbell, Gayle AU - Campbell G AUID- ORCID: 0000-0001-6249-8797 AD - Cardiology Department, Guy's and St Thomas' NHS Foundation Trust, London, SE1 7EH, UK. gayle.campbell2@nhs.net. FAU - Doherty, Ciara AU - Doherty C AD - Cardiology Department, Guy's and St Thomas' NHS Foundation Trust, London, SE1 7EH, UK. FAU - D'Silva, Andrew AU - D'Silva A AUID- ORCID: 0000-0002-8700-1545 AD - Cardiology Department, Guy's and St Thomas' NHS Foundation Trust, London, SE1 7EH, UK. FAU - Carr-White, Gerald AU - Carr-White G AD - Cardiology Department, Guy's and St Thomas' NHS Foundation Trust, London, SE1 7EH, UK. FAU - Webb, Jessica AU - Webb J AD - Cardiology Department, Guy's and St Thomas' NHS Foundation Trust, London, SE1 7EH, UK. FAU - Ismail, Tevfik F AU - Ismail TF AUID- ORCID: 0000-0002-1691-7599 AD - School of BMEIS, King's College London, London, UK. LA - eng PT - Journal Article DEP - 20241005 PL - Netherlands TA - Int J Clin Pharm JT - International journal of clinical pharmacy JID - 101554912 RN - 0 (Drug Combinations) RN - 0 (Biphenyl Compounds) RN - WB8FT61183 (sacubitril and valsartan sodium hydrate drug combination) RN - 0 (Aminobutyrates) RN - 80M03YXJ7I (Valsartan) SB - IM MH - Humans MH - *Heart Failure/drug therapy MH - Male MH - Aged MH - Female MH - *Pharmacists/standards MH - Retrospective Studies MH - Middle Aged MH - Professional Role MH - Drug Combinations MH - Aged, 80 and over MH - Biphenyl Compounds MH - *Pharmacy Service, Hospital/organization & administration MH - Drug Prescriptions/standards MH - Aminobutyrates/therapeutic use MH - Patient Care Team MH - Valsartan PMC - PMC11742339 OTO - NOTNLM OT - Adherence OT - Heart failure OT - Pharmacist OT - Prescribing COIS- Conflicts of interest: The authors have no relevant financial or non-financial interests to disclose. EDAT- 2024/10/06 13:41 MHDA- 2025/01/17 18:22 PMCR- 2024/10/05 CRDT- 2024/10/05 11:16 PHST- 2024/05/30 00:00 [received] PHST- 2024/09/17 00:00 [accepted] PHST- 2025/01/17 18:22 [medline] PHST- 2024/10/06 13:41 [pubmed] PHST- 2024/10/05 11:16 [entrez] PHST- 2024/10/05 00:00 [pmc-release] AID - 10.1007/s11096-024-01808-9 [pii] AID - 1808 [pii] AID - 10.1007/s11096-024-01808-9 [doi] PST - ppublish SO - Int J Clin Pharm. 2025 Feb;47(1):8-14. doi: 10.1007/s11096-024-01808-9. Epub 2024 Oct 5. PMID- 39365883 OWN - NLM STAT- MEDLINE DCOM- 20250629 LR - 20260509 IS - 1477-111X (Electronic) IS - 0267-6591 (Linking) VI - 40 IP - 5 DP - 2025 Jul TI - Ambulation in patients with peripheral veno-arterial extracorporeal membrane oxygenation and concomitant femoral intra-aortic balloon pump support. PG - 1124-1128 LID - 10.1177/02676591241290402 [doi] AB - IntroductionThe mobilization and ambulation of patients with severe cardiogenic shock supported with peripheral veno-arterial extracorporeal membrane oxygenation (pVA-ECMO) and concomitant femoral intra-aortic balloon pump (IABP) support is not well-described. This technical paper describes an ambulation protocol to prevent deconditioning in this critically ill patient population.MethodsA protocol for the ambulation of patients with pVA-ECMO and concomitant IABP support was created in December 2022 and implemented at a single center. To initiate ambulation, patients were initially placed in a vertical position utilizing the VitalGo Total Lift Bed (VitalGo Systems, Miramar, FL) with mechanical circulatory support device monitoring performed by a critical care multidisciplinary team. Retrospective analysis of successfully ambulated patients was performed from December 2022 to January 2024.ResultsA total of 35 patients out of 112 patients with ECMO support were ambulated in the study period. Four of these patients had pVA-ECMO with concomitant IABP support with this cohort completing a total of 11 sessions during the study period. Patients ambulated an average of 200 feet per session without any adverse events, including cannula and balloon pump migration or displacement. Three of the four patients studied were either bridged to an advanced therapy including orthotopic heart transplant or durable left ventricular assist device or were discharged.ConclusionA protocol for ambulation of CS patients with pVA-ECMO support and concomitant femoral IABP support is feasible and can safely be implemented in this critically ill patient population. Further multicenter studies are necessary to determine the overall impact of ambulation on patient outcomes. FAU - Modi, Shan P AU - Modi SP AUID- ORCID: 0009-0004-5466-7932 AD - Cardiovascular Institute, Allegheny Health Network, Pittsburgh, PA, USA. FAU - Klipa, Ilija AU - Klipa I AD - Cardiovascular Institute, Allegheny Health Network, Pittsburgh, PA, USA. FAU - Cronin, Melissa A AU - Cronin MA AD - Cardiovascular Institute, Allegheny Health Network, Pittsburgh, PA, USA. FAU - Lukens, Jennifer E AU - Lukens JE AD - Cardiovascular Institute, Allegheny Health Network, Pittsburgh, PA, USA. FAU - Hollowell, Leelyn R AU - Hollowell LR AD - Cardiovascular Institute, Allegheny Health Network, Pittsburgh, PA, USA. FAU - Stawski, Tracie A AU - Stawski TA AD - Cardiovascular Institute, Allegheny Health Network, Pittsburgh, PA, USA. FAU - Criste, Taylor J AU - Criste TJ AD - Cardiovascular Institute, Allegheny Health Network, Pittsburgh, PA, USA. FAU - Nissley, Trevor J AU - Nissley TJ AD - Cardiovascular Institute, Allegheny Health Network, Pittsburgh, PA, USA. FAU - Ramirez, Philip AU - Ramirez P AD - Cardiovascular Institute, Allegheny Health Network, Pittsburgh, PA, USA. FAU - VanDyck, Tyler J AU - VanDyck TJ AD - Cardiovascular Institute, Allegheny Health Network, Pittsburgh, PA, USA. LA - eng PT - Journal Article DEP - 20241004 PL - England TA - Perfusion JT - Perfusion JID - 8700166 SB - IM MH - Humans MH - *Extracorporeal Membrane Oxygenation/methods MH - *Intra-Aortic Balloon Pumping/methods MH - Male MH - Female MH - Middle Aged MH - Retrospective Studies MH - *Shock, Cardiogenic/therapy MH - *Walking MH - Aged OTO - NOTNLM OT - ECMO OT - IABP OT - ambulation OT - physical therapy COIS- Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2024/10/04 18:59 MHDA- 2025/07/01 07:06 CRDT- 2024/10/04 14:13 PHST- 2025/07/01 07:06 [medline] PHST- 2024/10/04 18:59 [pubmed] PHST- 2024/10/04 14:13 [entrez] AID - 10.1177/02676591241290402 [doi] PST - ppublish SO - Perfusion. 2025 Jul;40(5):1124-1128. doi: 10.1177/02676591241290402. Epub 2024 Oct 4. PMID- 39364534 OWN - NLM STAT- MEDLINE DCOM- 20250109 LR - 20250109 IS - 1467-1107 (Electronic) IS - 1047-9511 (Linking) VI - 34 IP - 10 DP - 2024 Oct TI - Team dynamics after implementation of guidelines for anaesthesia for children with CHD. PG - 2249-2252 LID - 10.1017/S1047951124026337 [doi] AB - Guidelines were created at our single centrer institution for which anesthesiology team should care for pediatric cardiac patients for noncardiac surgery. The goal of the survey was to assess inter-team dynamics after the implementation of guidelines and revealed that practice behaviour can quickly change but a sustained change in team dynamics and workplace culture takes time. FAU - Vogt, Peggy AU - Vogt P AUID- ORCID: 0000-0003-1673-5311 AD - Division of Pediatric Cardiac Anesthesiology, Children's Healthcare of Atlanta, Atlanta, GA, USA. AD - Emory University Anesthesiology, Atlanta, GA, USA. FAU - Libby, Julie AU - Libby J AD - Department of Surgical Services, Children's Healthcare of Atlanta, Atlanta, GA, USA. FAU - Long, Justin B AU - Long JB AUID- ORCID: 0000-0002-7660-6063 AD - Division of Pediatric Cardiac Anesthesiology, Children's Healthcare of Atlanta, Atlanta, GA, USA. AD - Emory University Anesthesiology, Atlanta, GA, USA. LA - eng PT - Journal Article DEP - 20241004 PL - England TA - Cardiol Young JT - Cardiology in the young JID - 9200019 SB - IM MH - Humans MH - *Heart Defects, Congenital/surgery MH - *Patient Care Team MH - Child MH - *Practice Guidelines as Topic MH - Anesthesia/standards/methods MH - Anesthesiology MH - Surveys and Questionnaires OTO - NOTNLM OT - anesthesia for non-cardiac surgery OT - congenital heart disease OT - pediatric cardiac anesthesia guidelines OT - team dynamics EDAT- 2024/10/04 08:43 MHDA- 2025/01/09 17:00 CRDT- 2024/10/04 04:32 PHST- 2025/01/09 17:00 [medline] PHST- 2024/10/04 08:43 [pubmed] PHST- 2024/10/04 04:32 [entrez] AID - S1047951124026337 [pii] AID - 10.1017/S1047951124026337 [doi] PST - ppublish SO - Cardiol Young. 2024 Oct;34(10):2249-2252. doi: 10.1017/S1047951124026337. Epub 2024 Oct 4. PMID- 39364022 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241005 IS - 2296-858X (Print) IS - 2296-858X (Electronic) IS - 2296-858X (Linking) VI - 11 DP - 2024 TI - Neurological and cardiopulmonary manifestations of pulmonary arteriovenous malformations. PG - 1449496 LID - 10.3389/fmed.2024.1449496 [doi] LID - 1449496 AB - Pulmonary arteriovenous malformations (PAVMs) are direct pulmonary artery-to-vein connections without pulmonary capillaries that result in intrapulmonary right-to-left blood shunts. Although most patients with PAVMs may be entirely asymptomatic, PAVMs can induce a series of complications involving the neurological, cardiovascular, and respiratory systems that can lead to catastrophic and often fatal clinical sequelae. In this study we review the available literature and summarize the reported PAVM-related complications among patients with PAVMs. The reviewed studies included observational studies, case studies, prospective studies, and cohort studies, and we provide an overview of PAVM-related neurological and cardiopulmonary manifestations, including stroke, cerebral abscess, transient ischemic attack, cerebral hemorrhage, migraine, seizure, dizziness, cardiac failure, arrhythmia, myocardial infarction, cough, hypoxemia, dyspnea, respiratory failure, hemoptysis, and hemothorax. Identifying and treating PAVMs before the presentation of major complication is important because this can prevent the occurrence of complications and can result in better outcomes. PAVM patients should thus be better evaluated and managed by a multidisciplinary team because they may be in a treatable phase prior to their condition becoming life-threatening. CI - Copyright (c) 2024 Lu, Dai, Li and Meng. FAU - Lu, Weida AU - Lu W AD - Key Laboratory of Cardiovascular Proteomics of Shandong Province, Department of Geriatric Medicine, Qilu Hospital of Shandong University, Jinan, China. FAU - Dai, Honggang AU - Dai H AD - State Key Laboratory for Innovation and Transformation of Luobing Theory, Key Laboratory of Cardiovascular Remodeling and Function Research, Department of Cardiology, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences, Qilu Hospital of Shandong University, Jinan, China. FAU - Li, Yunyi AU - Li Y AD - State Key Laboratory for Innovation and Transformation of Luobing Theory, Key Laboratory of Cardiovascular Remodeling and Function Research, Department of Cardiology, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences, Qilu Hospital of Shandong University, Jinan, China. FAU - Meng, Xiao AU - Meng X AD - State Key Laboratory for Innovation and Transformation of Luobing Theory, Key Laboratory of Cardiovascular Remodeling and Function Research, Department of Cardiology, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences, Qilu Hospital of Shandong University, Jinan, China. LA - eng PT - Journal Article PT - Review DEP - 20240919 PL - Switzerland TA - Front Med (Lausanne) JT - Frontiers in medicine JID - 101648047 PMC - PMC11446853 OTO - NOTNLM OT - cerebral abscess OT - hypoxemia OT - pulmonary arteriovenous malformations OT - stroke OT - treatment COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2024/10/04 08:44 MHDA- 2024/10/04 08:45 PMCR- 2024/09/19 CRDT- 2024/10/04 04:18 PHST- 2024/06/15 00:00 [received] PHST- 2024/09/06 00:00 [accepted] PHST- 2024/10/04 08:45 [medline] PHST- 2024/10/04 08:44 [pubmed] PHST- 2024/10/04 04:18 [entrez] PHST- 2024/09/19 00:00 [pmc-release] AID - 10.3389/fmed.2024.1449496 [doi] PST - epublish SO - Front Med (Lausanne). 2024 Sep 19;11:1449496. doi: 10.3389/fmed.2024.1449496. eCollection 2024. PMID- 39358116 OWN - NLM STAT- MEDLINE DCOM- 20250828 LR - 20260304 IS - 0929-6646 (Print) IS - 0929-6646 (Linking) VI - 124 IP - 9 DP - 2025 Sep TI - Insights of Fabry disease: Expert consensus approach for screening, diagnosis, and multidisciplinary management in chronic kidney disease. PG - 794-799 LID - S0929-6646(24)00453-4 [pii] LID - 10.1016/j.jfma.2024.09.033 [doi] AB - The prevalence of Fabry disease (FD) among males with chronic kidney disease (CKD) of unknown etiology in Taiwan is 0.6%. Despite this, FD is frequently overlooked in clinical settings. To address this issue, two consensus meetings were conducted in Taiwan-one in August 2022 and another in April 2023. The first meeting established screening criteria based on age, gender, family history, cardiac involvement, and symptoms. The second meeting, with a multidisciplinary team, developed treatment recommendations. The consensus emphasizes the importance of proactive data collection in dialysis units and outpatient follow-ups to enhance FD detection and management. The screening algorithm recommends incorporating FD screening into the diagnostic process for CKD patients, regardless of age. Priority is given to patients with a family history of FD, early stroke history, or classical FD symptoms. Comprehensive screening is also advised for CKD patients without obvious classical symptoms. Screening protocols for males include measuring alpha-galactosidase A enzyme activity, with reduced activity leading to further tests such as lyso-Gb3 level quantification and genetic analysis. For females, the protocol involves evaluating lyso-Gb3 plasma levels and genetic testing. FD, though often underestimated, is more prevalent than recognized and necessitates a multidisciplinary approach for timely diagnosis. Enhancing awareness and adopting a comprehensive approach are essential for improving patient outcomes. CI - Copyright (c) 2025 Formosan Medical Association. Published by Elsevier B.V. All rights reserved. FAU - Lin, Cheng-Jui AU - Lin CJ AD - Division of Nephrology, Department of Internal Medicine, MacKay Memorial Hospital, Taipei, Taiwan. FAU - Yang, Feng-Jung AU - Yang FJ AD - Department of Medical Genetics, National Taiwan University Hospital, Taipei, Taiwan; Division of Nephrology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; College of Medicine, National Taiwan University, Taipei, Taiwan; Division of Nephrology, Department of Internal Medicine, National Taiwan University Hospital, Yunlin Branch, Douliu, Taiwan. FAU - Wu, Chih-Jen AU - Wu CJ AD - Division of Nephrology, Department of Internal Medicine, MacKay Memorial Hospital, Taipei, Taiwan. Electronic address: yaliwcj@gmail.com. FAU - Wu, Ming-Ju AU - Wu MJ AD - Division of Nephrology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan; Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan. Electronic address: wmj530@gmail.com. FAU - Wu, Mai-Szu AU - Wu MS AD - Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan. LA - eng PT - Consensus Statement PT - Journal Article PT - Review DEP - 20241002 PL - Singapore TA - J Formos Med Assoc JT - Journal of the Formosan Medical Association = Taiwan yi zhi JID - 9214933 RN - EC 3.2.1.22 (alpha-Galactosidase) RN - 0 (Sphingolipids) RN - 0 (Glycolipids) RN - 126550-86-5 (globotriaosyl lysosphingolipid) SB - IM MH - Humans MH - *Fabry Disease/diagnosis/therapy/complications/epidemiology MH - *Renal Insufficiency, Chronic/therapy/etiology/complications/diagnosis MH - Male MH - Taiwan/epidemiology MH - Female MH - *Mass Screening/methods MH - alpha-Galactosidase/blood MH - Algorithms MH - Prevalence MH - Patient Care Team MH - Sphingolipids/blood MH - Genetic Testing MH - Glycolipids/blood OTO - NOTNLM OT - Chronic kidney disease (CKD) OT - Enzyme replacement therapy (ERT) OT - Fabry disease OT - Fabry nephropathy OT - Taiwan COIS- Declaration of competing interest Aconflict of interest occurs when an \ndlvldual's objectivity 1s potentially compromised by a desire for flnanclal gain, prominence, professional advancement or a successful outcome. JFK Editors strlve to ensure that what is pubt\shed In the Journal is as balanced, objective and evidence-based as possible. Since It can be difficult to dist1ngulsh between an actual conflict of Interest and a perceived conflict of interest, the Journal requires authors to disclose al\ and any potentlal conf\Acts of interest. EDAT- 2024/10/03 04:22 MHDA- 2025/08/31 19:35 CRDT- 2024/10/02 21:54 PHST- 2024/03/23 00:00 [received] PHST- 2024/08/15 00:00 [revised] PHST- 2024/09/22 00:00 [accepted] PHST- 2025/08/31 19:35 [medline] PHST- 2024/10/03 04:22 [pubmed] PHST- 2024/10/02 21:54 [entrez] AID - S0929-6646(24)00453-4 [pii] AID - 10.1016/j.jfma.2024.09.033 [doi] PST - ppublish SO - J Formos Med Assoc. 2025 Sep;124(9):794-799. doi: 10.1016/j.jfma.2024.09.033. Epub 2024 Oct 2. PMID- 39355597 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241003 IS - 2153-8174 (Electronic) IS - 1530-6550 (Print) IS - 1530-6550 (Linking) VI - 25 IP - 9 DP - 2024 Sep TI - Advances in the Management of Spontaneous Coronary Artery Dissection (SCAD): A Comprehensive Review. PG - 345 LID - 10.31083/j.rcm2509345 [doi] LID - 345 AB - Spontaneous coronary artery dissection (SCAD) is a rare but significant cause of acute coronary syndrome (ACS), primarily affecting young women, often during pregnancy. Despite its rarity, SCAD poses challenges due to limited evidence on management strategies. This review examines the current state of art of SCAD management, integrating interventional and clinical insights from recent studies. The epidemiology of SCAD is related to its elusive nature, representing only a small fraction of ACS cases, while certainly underestimated. Proposed risk factors include genetic, hormonal, and environmental influences. Angiographic classification may help in SCAD diagnosis, but confirmation often relies on intracoronary imaging. Conservative management constitutes the primary approach, showing efficacy in most cases, although optimal antiplatelet therapy (APT) remains debated due to bleeding risks associated with intramural hematoma. Revascularization is reserved for high-risk cases, guided by angiographic and clinical criteria, with a focus on restoring flow rather than resolving dissection. Interventional strategies emphasize a minimalist approach to reduce complications, utilizing techniques such as balloon dilation and stent placement tailored to individual cases. Long-term outcomes highlight the risk of recurrence, necessitating vigilant follow-up and arrhythmic risk assessment, particularly in patients presenting with ventricular arrhythmias. In conclusion, SCAD management always represents a challenge for the physician, both from a clinical and interventional point of view. Recent clinical evidence and a multidisciplinary approach are vital for optimizing patient outcomes and preventing recurrence. This review offers a concise framework for navigating the complexities of SCAD management in clinical practice and proposes an algorithm for its management. CI - Copyright: (c) 2024 The Author(s). Published by IMR Press. FAU - Morena, Arianna AU - Morena A AD - Division of Cardiology, Cardiovascular and Thoracic Department, Citta della Salute e della Scienza, 10126 Torino, Italy. AD - Division of Cardiology, Department of Medical Sciences, University of Turin, 10124 Torino, Italy. FAU - Giacobbe, Federico AU - Giacobbe F AD - Division of Cardiology, Cardiovascular and Thoracic Department, Citta della Salute e della Scienza, 10126 Torino, Italy. AD - Division of Cardiology, Department of Medical Sciences, University of Turin, 10124 Torino, Italy. FAU - De Filippo, Ovidio AU - De Filippo O AD - Division of Cardiology, Cardiovascular and Thoracic Department, Citta della Salute e della Scienza, 10126 Torino, Italy. FAU - Angelini, Filippo AU - Angelini F AD - Division of Cardiology, Cardiovascular and Thoracic Department, Citta della Salute e della Scienza, 10126 Torino, Italy. FAU - Bruno, Francesco AU - Bruno F AD - Division of Cardiology, Cardiovascular and Thoracic Department, Citta della Salute e della Scienza, 10126 Torino, Italy. FAU - Siliano, Stefano AU - Siliano S AD - Division of Cardiology, Cardiovascular and Thoracic Department, Citta della Salute e della Scienza, 10126 Torino, Italy. AD - Division of Cardiology, Department of Medical Sciences, University of Turin, 10124 Torino, Italy. FAU - Giannino, Giuseppe AU - Giannino G AD - Division of Cardiology, Cardiovascular and Thoracic Department, Citta della Salute e della Scienza, 10126 Torino, Italy. AD - Division of Cardiology, Department of Medical Sciences, University of Turin, 10124 Torino, Italy. FAU - Dusi, Veronica AU - Dusi V AD - Division of Cardiology, Cardiovascular and Thoracic Department, Citta della Salute e della Scienza, 10126 Torino, Italy. AD - Division of Cardiology, Department of Medical Sciences, University of Turin, 10124 Torino, Italy. FAU - Bianco, Matteo AU - Bianco M AD - Division of Cardiology, A.O.U San Luigi Gonzaga, 10043 Orbassano, Italy. FAU - Biole, Carloalberto AU - Biole C AD - Division of Cardiology, A.O.U San Luigi Gonzaga, 10043 Orbassano, Italy. FAU - Varbella, Ferdinando AU - Varbella F AD - Interventional Cardiology Unit, Rivoli Infermi Hospital, 10098 Torino, Italy. FAU - Cerrato, Enrico AU - Cerrato E AD - Interventional Cardiology Unit, San Luigi Gonzaga University Hospital, 10043 Orbassano, Italy. FAU - D'Ascenzo, Fabrizio AU - D'Ascenzo F AD - Division of Cardiology, Cardiovascular and Thoracic Department, Citta della Salute e della Scienza, 10126 Torino, Italy. AD - Division of Cardiology, Department of Medical Sciences, University of Turin, 10124 Torino, Italy. FAU - De Ferrari, Gaetano Maria AU - De Ferrari GM AD - Division of Cardiology, Cardiovascular and Thoracic Department, Citta della Salute e della Scienza, 10126 Torino, Italy. AD - Division of Cardiology, Department of Medical Sciences, University of Turin, 10124 Torino, Italy. LA - eng PT - Journal Article PT - Review DEP - 20240924 PL - Singapore TA - Rev Cardiovasc Med JT - Reviews in cardiovascular medicine JID - 100960007 PMC - PMC11440404 OTO - NOTNLM OT - acute coronary syndrome (ACS) OT - antiplatelet therapy OT - fibromuscular dysplasia OT - myocardial infarction OT - percutaneous coronary intervention (PCI) OT - pregnancy-associated OT - spontaneous coronary artery dissection (SCAD) OT - women COIS- The authors declare no conflict of interest. Fabrizio D'Ascenzo is serving as one of the Editorial Board members of this journal. We declare that Fabrizio D'Ascenzo had no involvement in the peer review of this article and has no access to information regarding its peer review. Full responsibility for the editorial process for this article was delegated to Dimitris Tousoulis. EDAT- 2024/10/02 07:01 MHDA- 2024/10/02 07:02 PMCR- 2024/09/24 CRDT- 2024/10/02 04:33 PHST- 2024/05/18 00:00 [received] PHST- 2024/06/17 00:00 [revised] PHST- 2024/06/27 00:00 [accepted] PHST- 2024/10/02 07:02 [medline] PHST- 2024/10/02 07:01 [pubmed] PHST- 2024/10/02 04:33 [entrez] PHST- 2024/09/24 00:00 [pmc-release] AID - S1530-6550(24)01509-6 [pii] AID - 10.31083/j.rcm2509345 [doi] PST - epublish SO - Rev Cardiovasc Med. 2024 Sep 24;25(9):345. doi: 10.31083/j.rcm2509345. eCollection 2024 Sep. PMID- 39355001 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241003 IS - 2632-1297 (Electronic) IS - 2632-1297 (Linking) VI - 6 IP - 5 DP - 2024 TI - Sudden death in epilepsy: the overlap between cardiac and neurological factors. PG - fcae309 LID - 10.1093/braincomms/fcae309 [doi] LID - fcae309 AB - People with epilepsy are at risk of premature death, of which sudden unexpected death in epilepsy (SUDEP), sudden cardiac death (SCD) and sudden arrhythmic death syndrome (SADS) are the primary, partly overlapping, clinical scenarios. We discuss the epidemiologies, risk factors and pathophysiological mechanisms for these sudden death events. We reviewed the existing evidence on sudden death in epilepsy. Classification of sudden death depends on the presence of autopsy and expertise of the clinician determining aetiology. The definitions of SUDEP, SCD and SADS lead to substantial openings for overlap. Seizure-induced arrhythmias constitute a minority of SUDEP cases. Comorbid cardiovascular conditions are the primary determinants of increased SCD risk in chronic epilepsy. Genetic mutations overlap between the states, yet whether these are causative, associated or incidentally present is often unclear. Risk stratification for sudden death in people with epilepsy requires a multidisciplinary approach, including a review of clinical history, toxicological analysis and complete autopsy with histologic and, preferably, genetic examination. We recommend pursuing genetic testing of relatives of people with epilepsy who died suddenly, mainly if a post-mortem genetic test contained a Class IV/V (pathogenic/likely pathogenic) gene variant. Further research may allow more precise differentiation of SUDEP, SCD and SADS and the development of algorithms for risk stratification and preventative strategies. CI - (c) The Author(s) 2024. Published by Oxford University Press on behalf of the Guarantors of Brain. FAU - Shlobin, Nathan A AU - Shlobin NA AUID- ORCID: 0000-0003-2079-6125 AD - Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA. AD - Stichting Epilepsie Instellingen Nederland (SEIN), 2103 SW Heemstede, The Netherlands. AD - Department of Neurology and Clinical Neurophysiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands. FAU - Thijs, Roland D AU - Thijs RD AD - Stichting Epilepsie Instellingen Nederland (SEIN), 2103 SW Heemstede, The Netherlands. AD - Department of Neurology and Clinical Neurophysiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands. AD - UCL Queen Square Institute of Neurology, NIHR University College London Hospitals Biomedical Research Centre, London WC1N 3BG, UK. FAU - Benditt, David G AU - Benditt DG AD - Cardiac Arrhythmia and Syncope Center, University of Minnesota, Minneapolis, MN 55455, USA. FAU - Zeppenfeld, Katja AU - Zeppenfeld K AUID- ORCID: 0000-0002-7034-1017 AD - Department of Cardiology, Leiden University Medical Centre, Albinusdreef 2, 2333 ZA Leiden, The Netherlands. FAU - Sander, Josemir W AU - Sander JW AUID- ORCID: 0000-0001-6041-9661 AD - Stichting Epilepsie Instellingen Nederland (SEIN), 2103 SW Heemstede, The Netherlands. AD - UCL Queen Square Institute of Neurology, NIHR University College London Hospitals Biomedical Research Centre, London WC1N 3BG, UK. AD - Chalfont Centre for Epilepsy, Chalfont St Peter SL9 0RJ, UK. AD - Department of Neurology, West China Hospital, Sichuan University, Chengdu 610041, China. LA - eng PT - Journal Article PT - Review DEP - 20241001 PL - England TA - Brain Commun JT - Brain communications JID - 101755125 PMC - PMC11443455 OTO - NOTNLM OT - epidemiology OT - seizure OT - sudden arrhythmic death syndrome OT - sudden cardiac death OT - sudden unexpected death in epilepsy COIS- N.A.S., D.G.B. and K.Z. report no conflicts of interest. R.D.T. has received personal compensation for serving on the Advisory Boards or Speaker's Bureau for Xenon, Theravance, Novartis, Esai, Angelini Pharma and UCB. J.W.S. or his department has received grants from Esai, Angelini Pharma and UCB. He has received personal compensation for serving on the Advisory Boards or Speaker's Bureau for UCB and Angelini Pharma. EDAT- 2024/10/02 07:01 MHDA- 2024/10/02 07:02 PMCR- 2024/10/01 CRDT- 2024/10/02 04:24 PHST- 2024/04/15 00:00 [received] PHST- 2024/06/21 00:00 [revised] PHST- 2024/09/25 00:00 [accepted] PHST- 2024/10/02 07:02 [medline] PHST- 2024/10/02 07:01 [pubmed] PHST- 2024/10/02 04:24 [entrez] PHST- 2024/10/01 00:00 [pmc-release] AID - fcae309 [pii] AID - 10.1093/braincomms/fcae309 [doi] PST - epublish SO - Brain Commun. 2024 Oct 1;6(5):fcae309. doi: 10.1093/braincomms/fcae309. eCollection 2024. PMID- 39351849 OWN - NLM STAT- MEDLINE DCOM- 20241029 LR - 20260624 IS - 1473-5598 (Electronic) IS - 0263-6352 (Linking) VI - 42 IP - 12 DP - 2024 Dec 1 TI - Baseline characteristics of the first 302 patients included for acute malignant hypertension crisis in the prospective multidisciplinary HAMA cohort. PG - 2131-2138 LID - 10.1097/HJH.0000000000003851 [doi] AB - BACKGROUND: Malignant hypertension has not disappeared and remains the most severe form of hypertension. More than 100 years after its description, many points remain unanswered. Mechanisms, definitions, and optimal treatment are still controversial. In 2019, we decided to launch a prospective multicentre multidisciplinary cohort in France to try to fill these gaps. METHOD: This study aimed to describe the baseline characteristics of the first 302 included patients and compared these data to already published cohorts. We included patients with severe hypertension associated with severe hypertensive retinopathy and patients filling the HYP MOD (HYPertension MultiOrgan Damage) definition from a broad range of departments (cardiology, nephrology, neurology intensive care unit, emergency department, internal medicine). We collected clinical, biological, imaging, and target organ damage data at admission, along with social and demographic data. We also recorded diagnostic and therapeutic management, adverse events during hospitalization, and characteristics at discharge. RESULTS: We enrolled 302 patients in 32 months (105/year) among 40 centres and different specialties. They mainly included young men (68%, mean age 48.7 +/- 14.5 years). Target organ damage involved the eye in 86.7% of patients, kidney in 58.6%, heart in 50%, brain in 32.8%, and Thrombotic Microangiopathy stigmata in 15.6%. Patients with severe retinopathy shared characteristics similar to those included in the most important cohorts already published. We also reported several additional subgroups of interest: one-third of our patients were less than 40 years old, one-third were of non-European origin, 14.3% were included through the multiorgan damage definition, without fundus severe injuries, 22.8% were treated without the use of IV therapy, 40.9% had normal or low renin level, and almost all patients were not on antihypertensive therapy at the time of the enrolment. CONCLUSION: These preliminary findings already challenge long-standing dogma, raise numerous questions, and provide a solid basis to address them in ancillary studies of the cohort. CI - Copyright (c) 2024 Wolters Kluwer Health, Inc. All rights reserved. FAU - Boulestreau, Romain AU - Boulestreau R AD - Vascular and Coronary Disease Department, Bordeaux University Hospital, Haut Leveque Hospital. AD - INI CRCT Network. AD - University Bordeaux, INSERM, Biologie des maladies cardiovasculaires, U1034, Pessac. FAU - Lorthioir, Aurelien AU - Lorthioir A AD - Department of Hypertension, Hopital Europeen Georges-Pompidou, Assistance Publique-Hopitaux de Paris, Paris. FAU - Dreau, Herve AU - Dreau H AD - Biostatistics and Methodology Unit, Pau Hospital, France. FAU - Persu, Alexandre AU - Persu A AD - Division of Cardiology, Cliniques Universitaires Saint-Luc and Pole of Cardiovascular Research, Institut de Recherche Experimentale et Clinique, Universite Catholique de Louvain, Brussels, Belgium. FAU - Cremer, Antoine AU - Cremer A AD - European Hypertension Excellence Center, Bordeaux University Hospital, Bordeaux. FAU - Tharaux, Pierre-Louis AU - Tharaux PL AD - Paris Cardiovascular Center (PARCC), Institut de la Sante et de la Recherche Medicale (Inserm), Universite Paris Cite, Paris. FAU - Rubin, Sebastien AU - Rubin S AD - University Bordeaux, INSERM, Biologie des maladies cardiovasculaires, U1034, Pessac. AD - Service de Nephrologie, Transplantation, Dialyse et Aphereses (S.R., C.C.), Hopital Pellegrin, CHU de Bordeaux. FAU - Maier, Benjamin AU - Maier B AD - Department of Neurology, Hopital Saint Joseph, Universite Paris Cite et FHU Neurovasc. FAU - Mazighi, Mikael AU - Mazighi M AD - Departments of Neurology, Hopital Lariboisere, APHP Nord, Interventional Neuroradiology, Rothschild Foundation Hospital, INSERM U1144, Universite Paris cite et FHU Neurovasc. FAU - Seris, Alice AU - Seris A AD - European Hypertension Excellence Center, Bordeaux University Hospital, Bordeaux. FAU - Paques, Michel AU - Paques M AD - Centre hospitalier national d'ophtalmologie des Quinze-Vingts, centre d'investigation clinique 1423, Institut de la Vision, IHU FOReSIGHT, Sorbonne universite. FAU - Bonnin, Sophie AU - Bonnin S AD - Ophthalmoloy Department, Rothschild Foundation Hospital, Paris. FAU - Halimi, Jean Michel AU - Halimi JM AD - Service de nephrologie, centre d'excellence europeen en Hypertension Arterielle, CHRU de Tours, F-CRIN INI-CRCT, 10, Tours, France. FAU - Debeugny, Stephane AU - Debeugny S AD - Biostatistics and Methodology Unit, Pau Hospital, France. FAU - Gosse, Philippe AU - Gosse P AD - European Hypertension Excellence Center, Bordeaux University Hospital, Bordeaux. LA - eng SI - ClinicalTrials.gov/NCT03755726 PT - Journal Article PT - Multicenter Study PT - Observational Study DEP - 20241007 PL - Netherlands TA - J Hypertens JT - Journal of hypertension JID - 8306882 RN - 0 (Antihypertensive Agents) SB - IM MH - Adult MH - Aged MH - Female MH - Humans MH - Male MH - Middle Aged MH - Acute Disease MH - Antihypertensive Agents/therapeutic use MH - Cohort Studies MH - France/epidemiology MH - *Hypertension, Malignant/complications MH - Hypertensive Retinopathy MH - Prospective Studies EDAT- 2024/10/01 16:18 MHDA- 2024/10/29 16:14 CRDT- 2024/10/01 06:33 PHST- 2024/03/22 00:00 [received] PHST- 2024/08/01 00:00 [accepted] PHST- 2024/10/29 16:14 [medline] PHST- 2024/10/01 16:18 [pubmed] PHST- 2024/10/01 06:33 [entrez] AID - 00004872-202412000-00011 [pii] AID - 10.1097/HJH.0000000000003851 [doi] PST - ppublish SO - J Hypertens. 2024 Dec 1;42(12):2131-2138. doi: 10.1097/HJH.0000000000003851. Epub 2024 Oct 7. PMID- 39348330 OWN - NLM STAT- MEDLINE DCOM- 20240930 LR - 20241018 IS - 1119-3077 (Print) VI - 27 IP - 9 DP - 2024 Sep 1 TI - Assessment of Hospital Medical Emergency Team Operations in a Tertiary Care Center in Turkey. PG - 1095-1101 LID - 10.4103/njcp.njcp_150_24 [doi] AB - BACKGROUND: Rapid Response Teams, strategically devised to mitigate mortality and morbidity stemming from unforeseen deteriorations and cardiac arrests within healthcare facilities, are ubiquitously implemented on a global scale. AIM: The aim of the study is to compare emergency physicians (EPs) and non-EPs on management protocols of Hospital Medical Emergency Teams (HoMET). METHODS: This was a retrospective cross-sectional study. The hospital archive underwent a retrospective scanning process, and patient records were meticulously examined. The assessment encompassed various facets, including demographic characteristics, activation locations, and response and intervention times of HoMET teams, composed of both EPs and other healthcare professionals. Data analysis was conducted using SPSS software version 20.0. RESULTS: A total of 1056 calls were included, with 52% (n = 549) involving male patients. The average age was 67.15 +/- 19.45 years. EPs served as the team leader in 53% of the calls. Cardiac arrest was considered in 93.6% of the cases. The EPs group exhibited a higher average patient age, longer intervention times, and shorter arrival times (P < 0.001, P = 0.027, P < 0.001, respectively). A significant difference was observed in the locations of the calls and the groups of calls considering cardiac arrest (P < 0.001, P < 0.001, respectively). CONCLUSION: The optimization of intervention teams is imperative given the persistently high incidence and mortality rates associated with in-hospital cardiac arrests. Leveraging the expertise of EPs in the management of arrests and critical patients can potentially enhance the effectiveness of these teams. Nonetheless, further research is warranted to comprehensively explore and validate this aspect. CI - Copyright (c) 2024 Copyright: (c) 2024 Nigerian Journal of Clinical Practice. FAU - Yilmaz, A AU - Yilmaz A AD - Department of Emergency Medicine, Usak Research and Training Hospital, Usak, Turkey. FAU - Sevil, H AU - Sevil H AD - Department of Emergency Medicine, Usak Research and Training Hospital, Usak, Turkey. FAU - Can, S AU - Can S AD - Department of Emergency Medicine, Usak Research and Training Hospital, Usak, Turkey. FAU - Ararat, E AU - Ararat E AD - Department of Emergency Medicine, Antalya Kepez State Hospital, Antalya, Turkey. FAU - Guvenc, E AU - Guvenc E AD - Department of Emergency Medicine, Buca Seyfi Demirsoy Research and Training Hospital, Izmir, Turkey. FAU - Diker, S AU - Diker S AD - Department of Internal Medicine, Usak Research and Training Hospital, Usak, Turkey. LA - eng PT - Journal Article DEP - 20240930 PL - India TA - Niger J Clin Pract JT - Nigerian journal of clinical practice JID - 101150032 SB - IM MH - Humans MH - Male MH - Cross-Sectional Studies MH - Retrospective Studies MH - Female MH - *Hospital Rapid Response Team/statistics & numerical data/organization & administration MH - Turkey MH - *Tertiary Care Centers MH - Middle Aged MH - Aged MH - *Heart Arrest/epidemiology/therapy MH - Adult MH - Emergency Service, Hospital/statistics & numerical data MH - Aged, 80 and over EDAT- 2024/09/30 18:52 MHDA- 2024/09/30 18:53 CRDT- 2024/09/30 13:23 PHST- 2024/02/18 00:00 [received] PHST- 2024/08/12 00:00 [accepted] PHST- 2024/09/30 18:53 [medline] PHST- 2024/09/30 18:52 [pubmed] PHST- 2024/09/30 13:23 [entrez] AID - 01253091-202427090-00009 [pii] AID - 10.4103/njcp.njcp_150_24 [doi] PST - ppublish SO - Niger J Clin Pract. 2024 Sep 1;27(9):1095-1101. doi: 10.4103/njcp.njcp_150_24. Epub 2024 Sep 30. PMID- 39348001 OWN - NLM STAT- MEDLINE DCOM- 20250424 LR - 20260225 IS - 1435-1803 (Electronic) IS - 0300-8428 (Linking) VI - 120 IP - 1 DP - 2025 Feb TI - Cardio-oncology: chances and challenges. PG - 3-9 LID - 10.1007/s00395-024-01080-y [doi] AB - Cardio-oncology is an emerging field that aims to ensure optimal cancer treatment while minimising cardiovascular toxicity. The management of cardiovascular toxicity is critical because it can lead to premature discontinuation of treatment, increasing the risk of cancer recurrence and mortality. The 2022 European Society of Cardiology guidelines were a milestone in advocating a patient-centred, multidisciplinary approach. Key components include risk stratification and a standardised criterion for adverse events, incorporating definitions from the International Cardio-Oncology Society. Effective risk stratification, supported by imaging and biomarkers, helps to anticipate cardiovascular problems and implement preventive measures. Future research should focus on understanding mechanisms, developing preventive strategies and implementing personalised medicine. Education and reducing disparities in care are essential to advance cardio-oncology and improve patient outcomes. CI - (c) 2024. Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Vinas-Mendieta, Adriana E AU - Vinas-Mendieta AE AUID- ORCID: 0000-0003-1018-8695 AD - Cardio-Oncology Unit, Cardiology Department, La Paz University Hospital, IdiPAZ Research Institute, C/ Paseo de la Castellana n masculine 261, 28046, Madrid, Spain. AD - Cardiology Department, Guillermo Almenara Irigoyen Hospital, Lima, Peru. FAU - Gallardo-Grajeda, Andrea AU - Gallardo-Grajeda A AUID- ORCID: 0009-0004-1547-7415 AD - Cardio-Oncology Unit, Cardiology Department, La Paz University Hospital, IdiPAZ Research Institute, C/ Paseo de la Castellana n masculine 261, 28046, Madrid, Spain. AD - Cardiology Department, National Institute of Cardiology Ignacio Chavez, Mexico City, Mexico. FAU - Lopez-Fernandez, Teresa AU - Lopez-Fernandez T AUID- ORCID: 0000-0002-3414-7022 AD - Cardio-Oncology Unit, Cardiology Department, La Paz University Hospital, IdiPAZ Research Institute, C/ Paseo de la Castellana n masculine 261, 28046, Madrid, Spain. tlfernandez8@gmail.com. AD - Cardiology Department, Quironsalud Madrid University Hospital, Madrid, Spain. tlfernandez8@gmail.com. LA - eng PT - Journal Article PT - Review DEP - 20240930 PL - Germany TA - Basic Res Cardiol JT - Basic research in cardiology JID - 0360342 RN - 0 (Antineoplastic Agents) SB - IM MH - Humans MH - *Neoplasms/therapy/drug therapy MH - *Medical Oncology MH - *Cardiovascular Diseases/chemically induced/therapy/diagnosis/prevention & control MH - *Cardiology MH - Cardiotoxicity MH - *Antineoplastic Agents/adverse effects MH - Risk Assessment MH - Risk Factors MH - Cardio-Oncology OTO - NOTNLM OT - Cardio-oncology OT - Cardiotoxicity OT - Prevention OT - Risk score EDAT- 2024/09/30 12:45 MHDA- 2025/02/03 12:23 CRDT- 2024/09/30 11:14 PHST- 2024/06/02 00:00 [received] PHST- 2024/09/21 00:00 [accepted] PHST- 2024/09/19 00:00 [revised] PHST- 2025/02/03 12:23 [medline] PHST- 2024/09/30 12:45 [pubmed] PHST- 2024/09/30 11:14 [entrez] AID - 10.1007/s00395-024-01080-y [pii] AID - 10.1007/s00395-024-01080-y [doi] PST - ppublish SO - Basic Res Cardiol. 2025 Feb;120(1):3-9. doi: 10.1007/s00395-024-01080-y. Epub 2024 Sep 30. PMID- 39346098 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250401 IS - 2297-055X (Print) IS - 2297-055X (Electronic) IS - 2297-055X (Linking) VI - 11 DP - 2024 TI - Early detection of chemotherapy-induced cardiotoxicity in breast cancer patients: a comprehensive analysis using speckle tracking echocardiography. PG - 1413827 LID - 10.3389/fcvm.2024.1413827 [doi] LID - 1413827 AB - INTRODUCTION: Chemotherapy-induced cardiotoxicity poses a significant challenge in the treatment of breast cancer, potentially compromising both the efficacy of cancer therapy and cardiac health of patients. This study aimed to enhance the early detection of cardiotoxic effects by integrating advanced imaging modalities and biomarker analysis, thereby facilitating timely interventions to mitigate cardiac risk. METHODS: A prospective cohort design was employed, enrolling breast cancer patients scheduled for potentially cardiotoxic chemotherapy regimens. The study utilized a comprehensive diagnostic toolkit, including echocardiography with strain imaging, cardiac MRI, and serial measurements of cardiac biomarkers such as high-sensitivity troponins and natriuretic peptides. RESULTS: The analysis revealed that subtle changes in myocardial strain parameters and early biomarker elevations were predictive of subsequent declines in left ventricular function, preceding conventional echocardiographic evidence of cardiotoxicity. Logistic regression analysis highlighted the additive predictive value of integrating biomarker data with advanced imaging findings to identify patients with the highest risk of significant cardiotoxicity. DISCUSSION: The study concluded that an integrated diagnostic approach, combining detailed imaging assessments with sensitive biomarker analysis, offers a superior strategy for the early detection of chemotherapy-induced cardiotoxicity in breast cancer patients. This proactive diagnostic strategy empowers clinicians to tailor cancer therapy more precisely, balancing oncologic efficacy with cardiovascular safety and underscores the importance of a multidisciplinary approach in the management of patients undergoing potentially cardiotoxic chemotherapy. CI - (c) 2024 Zhang, Wang, Zhang, Liu, Pei, Liu, Jia and Guo. FAU - Zhang, Ning AU - Zhang N AD - Department of Ultrasound, The First Hospital of Hebei Medical University, Shijiazhuang, China. FAU - Wang, Na AU - Wang N AD - Department of Ultrasound, The First Hospital of Hebei Medical University, Shijiazhuang, China. FAU - Zhang, Yanyan AU - Zhang Y AD - Department of Ultrasound, The First Hospital of Hebei Medical University, Shijiazhuang, China. FAU - Liu, Ya AU - Liu Y AD - Department of Ultrasound, The First Hospital of Hebei Medical University, Shijiazhuang, China. FAU - Pei, Miaomiao AU - Pei M AD - Department of Ultrasound, The First Hospital of Hebei Medical University, Shijiazhuang, China. FAU - Liu, Gaiqin AU - Liu G AD - Department of Ultrasound, The First Hospital of Hebei Medical University, Shijiazhuang, China. FAU - Jia, Xinle AU - Jia X AD - Department of Ultrasound, The First Hospital of Hebei Medical University, Shijiazhuang, China. FAU - Guo, Xuejia AU - Guo X AD - Department of Ultrasound, The First Hospital of Hebei Medical University, Shijiazhuang, China. LA - eng PT - Journal Article DEP - 20240913 PL - Switzerland TA - Front Cardiovasc Med JT - Frontiers in cardiovascular medicine JID - 101653388 EIN - Front Cardiovasc Med. 2025 Mar 03;12:1548119. doi: 10.3389/fcvm.2025.1548119. PMID: 40099272 PMC - PMC11427351 OTO - NOTNLM OT - biomarkers OT - breast cancer OT - cardiac MRI OT - chemotherapy-induced cardiotoxicity OT - early detection OT - echocardiography COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2024/09/30 17:42 MHDA- 2024/09/30 17:43 PMCR- 2024/01/01 CRDT- 2024/09/30 09:50 PHST- 2024/04/14 00:00 [received] PHST- 2024/08/23 00:00 [accepted] PHST- 2024/09/30 17:42 [pubmed] PHST- 2024/09/30 17:43 [medline] PHST- 2024/09/30 09:50 [entrez] PHST- 2024/01/01 00:00 [pmc-release] AID - 10.3389/fcvm.2024.1413827 [doi] PST - epublish SO - Front Cardiovasc Med. 2024 Sep 13;11:1413827. doi: 10.3389/fcvm.2024.1413827. eCollection 2024. PMID- 39345047 OWN - NLM STAT- MEDLINE DCOM- 20241231 LR - 20250103 IS - 1525-1594 (Electronic) IS - 0160-564X (Linking) VI - 49 IP - 1 DP - 2025 Jan TI - Preemptive temporary right ventricular assist device implantation for severe biventricular heart failure: A case series. PG - 156-163 LID - 10.1111/aor.14853 [doi] AB - PURPOSE: We sought to investigate the clinical results of preemptive temporary right ventricular assist device (RVAD) placement with left ventricular assist device (LVAD) implantation for anticipated right ventricular failure. METHODS: Patients at risk for right ventricular failure were identified by the heart team. After median sternotomy, Protekduo (LivaNova, London, UK) dual-stage cannula was inserted from the right internal jugular vein under fluoroscopy guidance, and advanced into the pulmonary artery to the bifurcation of the main pulmonary artery. This was then connected to the venous drainage from the right atrium for cardiopulmonary bypass (CPB). After LVAD implantation, we connected the Protekduo cannula to the RVAD with oxygenator, and weaned CPB. RESULTS: A total of 17 patients have received BiVAD implantation with this technique. The median age of patients was 55 years [Interquartile range (IQR): 51-63.5] and 94% (16/17) patients were male. 63.6% (7/11) of the patients were INTERMACS profile 1 or 2. Preoperatively, the median pulmonary artery pulsatility index was 4.0 [1.5-4.9] and median right ventricular stroke work index was 454.1 g/m/beat/m(2) [436.5-530.2]. Postoperatively, the oxygenators were removed on median postoperative day (POD) 3.5 [3 - 5]. Patients received mechanical ventilation for a median of 4 days [1.5-12] and RVADs were explanted on median POD 8 [7-19] at bedside with local anesthesia. Median ICU stay was 15 days [11.4-24]. Perioperative complications included delayed sternal closure [54.5% (6/11)], re-exploration for bleeding [18% (2/11)], acute kidney injury [36% (4/11)], and heparin induced thrombocytopenia [18% (2/11)]. 30-day mortality was 0% (0/11) and 1 year survival was 85.9%. CONCLUSION: Preemptive temporary RVAD implantation strategy for right heart failure post-LVAD showed acceptable clinical outcomes without any 30-day mortality. CI - (c) 2024 International Center for Artificial Organ and Transplantation (ICAOT) and Wiley Periodicals LLC. FAU - Miyamoto, Takuma AU - Miyamoto T AD - Division of Cardiac Surgery, Department of Surgery, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA. FAU - Rahimov, Daler AU - Rahimov D AD - Division of Cardiac Surgery, Department of Surgery, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA. FAU - Ahmad, Danial AU - Ahmad D AD - Division of Cardiac Surgery, Department of Surgery, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA. FAU - Wood, Chelsey T AU - Wood CT AD - Department of Surgery, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA. FAU - Leong, Ron AU - Leong R AUID- ORCID: 0000-0002-4962-1524 AD - Division of Cardiac Surgery, Department of Surgery, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA. FAU - Marek-Iannucci, Stefanie AU - Marek-Iannucci S AUID- ORCID: 0000-0001-9621-3198 AD - Division of Cardiology, Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA. FAU - Brailovsky, Yevgeniy AU - Brailovsky Y AD - Division of Cardiology, Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA. FAU - Rajapreyar, Indranee AU - Rajapreyar I AD - Division of Cardiology, Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA. FAU - Rame, J Eduardo AU - Rame JE AD - Division of Cardiology, Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA. FAU - Alvarez, Rene J AU - Alvarez RJ AD - Division of Cardiology, Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA. FAU - Entwistle, John W AU - Entwistle JW AUID- ORCID: 0000-0002-1492-6483 AD - Division of Cardiac Surgery, Department of Surgery, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA. FAU - Tchantchaleishvili, Vakhtang AU - Tchantchaleishvili V AUID- ORCID: 0000-0002-4357-3533 AD - Division of Cardiac Surgery, Department of Surgery, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA. FAU - Massey, Howard T AU - Massey HT AD - Division of Cardiac Surgery, Department of Surgery, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA. LA - eng PT - Journal Article DEP - 20240930 PL - United States TA - Artif Organs JT - Artificial organs JID - 7802778 SB - IM MH - Female MH - Humans MH - Male MH - Middle Aged MH - Cardiopulmonary Bypass/methods MH - *Heart Failure/surgery/therapy MH - *Heart-Assist Devices MH - Prosthesis Implantation/methods/adverse effects/instrumentation MH - Treatment Outcome MH - Ventricular Dysfunction, Right/etiology/therapy/surgery MH - Ventricular Function, Right OTO - NOTNLM OT - mechanical circulatory support OT - right heart failure OT - right ventricular support EDAT- 2024/09/30 12:47 MHDA- 2024/12/31 12:21 CRDT- 2024/09/30 08:43 PHST- 2024/07/23 00:00 [revised] PHST- 2024/02/13 00:00 [received] PHST- 2024/08/22 00:00 [accepted] PHST- 2024/12/31 12:21 [medline] PHST- 2024/09/30 12:47 [pubmed] PHST- 2024/09/30 08:43 [entrez] AID - 10.1111/aor.14853 [doi] PST - ppublish SO - Artif Organs. 2025 Jan;49(1):156-163. doi: 10.1111/aor.14853. Epub 2024 Sep 30. PMID- 39337045 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240930 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 13 IP - 18 DP - 2024 Sep 19 TI - Silent Threats of the Heart: A Case Series and Narrative Review on Suicide Left Ventricle Post-Aortic Valve Replacement in Patients with Dynamic LVOT Obstruction and Aortic Stenosis. LID - 10.3390/jcm13185555 [doi] LID - 5555 AB - Aortic stenosis (AS) is the most prevalent valvular heart disease in Europe and North America, with transcatheter aortic valve implantation (TAVI) revolutionizing its management. Hypertrophic left ventricle (HLV) frequently coexists with AS, complicating treatment due to the associated risk of left ventricular outflow tract (LVOT) obstruction, heart failure, and sudden death. A rare but severe post-aortic valve replacement (AVR) complication, termed "suicide left ventricle" (SLV), has emerged, necessitating further study. This report synthesizes current literature on SLV, its pathophysiology, and management strategies, alongside four patient case studies. The patients aged 79-87 years, underwent AVR for symptomatic AS with HLV. Post-AVR, all experienced severe complications, including dynamicLVOT gradients, systolic anterior motion (SAM) of the mitral valve, and severe hypotension, leading to death in two cases. One patient survived following surgical aortic valve replacement (SAVR) with surgical myectomy. One patient survived after TAVI. These cases highlight the critical importance of multidisciplinary Heart Team evaluations and personalized treatment plans in managing SLV. Despite advancements in AVR, SLV remains a complex, life-threatening condition, requiring an exhaustive and multifaceted approach for optimal patient outcomes. This report offers valuable insights into SLV occurrence and management from a clinical perspective. FAU - Romano, Silvia AU - Romano S AD - Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padova, 35128 Padova, Italy. FAU - D'Andrea, Emilio AU - D'Andrea E AD - Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padova, 35128 Padova, Italy. FAU - Cozac, Dan Alexandru AU - Cozac DA AUID- ORCID: 0000-0002-9390-7263 AD - Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padova, 35128 Padova, Italy. AD - Doctoral School of the University of Medicine, Pharmacy, Science and Technology of Targu Mures, 540136 Targu Mures, Romania. AD - Cardiology Unit, Cardio-Thoracic-Vascular, and Public Health Department, Padova University Hospital, 35128 Padova, Italy. FAU - Savo, Maria Teresa AU - Savo MT AUID- ORCID: 0000-0003-1877-8550 AD - Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padova, 35128 Padova, Italy. FAU - Cecchetto, Antonella AU - Cecchetto A AUID- ORCID: 0000-0003-4069-4177 AD - Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padova, 35128 Padova, Italy. FAU - Baritussio, Anna AU - Baritussio A AD - Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padova, 35128 Padova, Italy. FAU - Martini, Marika AU - Martini M AUID- ORCID: 0009-0000-0522-8408 AD - Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padova, 35128 Padova, Italy. FAU - Napodano, Massimo AU - Napodano M AD - Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padova, 35128 Padova, Italy. FAU - Bauce, Barbara AU - Bauce B AUID- ORCID: 0000-0001-7357-293X AD - Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padova, 35128 Padova, Italy. FAU - Pergola, Valeria AU - Pergola V AUID- ORCID: 0000-0002-3317-7342 AD - Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padova, 35128 Padova, Italy. LA - eng PT - Journal Article PT - Review DEP - 20240919 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC11432347 OTO - NOTNLM OT - aortic stenosis OT - hypertrophic left ventricle OT - multidisciplinary management OT - suicide left ventricle COIS- The authors declare no conflicts of interest. EDAT- 2024/09/28 22:44 MHDA- 2024/09/28 22:45 PMCR- 2024/09/19 CRDT- 2024/09/28 01:14 PHST- 2024/08/27 00:00 [received] PHST- 2024/09/16 00:00 [revised] PHST- 2024/09/17 00:00 [accepted] PHST- 2024/09/28 22:45 [medline] PHST- 2024/09/28 22:44 [pubmed] PHST- 2024/09/28 01:14 [entrez] PHST- 2024/09/19 00:00 [pmc-release] AID - jcm13185555 [pii] AID - jcm-13-05555 [pii] AID - 10.3390/jcm13185555 [doi] PST - epublish SO - J Clin Med. 2024 Sep 19;13(18):5555. doi: 10.3390/jcm13185555. PMID- 39337032 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240930 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 13 IP - 18 DP - 2024 Sep 19 TI - Simultaneous Percutaneous Coronary Intervention (PCI) and Endovascular Aneurysm Repair (EVAR): A Preliminary Report. LID - 10.3390/jcm13185545 [doi] LID - 5545 AB - Background: Performing percutaneous coronary intervention (PCI) and endovascular aneurysm repair (EVAR) at the same time represents a groundbreaking development in the multidisciplinary treatment of cardiovascular disease. This combined PCI-EVAR approach bridges a critical gap by offering treatment for patients who have both coronary artery disease and aortic aneurysms. This innovative strategy exemplifies the evolving landscape of cardiovascular care, providing a new solution for complex clinical situations that previously required separate procedures. Methods: Six patients with critical coronary artery lesions and asymptomatic infrarenal aortic aneurysms (AAAs) >/= 6 cm diameter, as well as one patient with critical coronary artery lesions and endoleak type 1A with aneurysms >/= 6 cm, underwent simultaneous coronary artery revascularization through percutaneous intervention (PCI) and endovascular aneurysm repair (EVAR). The occurrence of any intraoperative or postoperative complication was considered to be the primary endpoint of the study, including the abortion or failure of either PCI or EVAR, bleeding requiring a conversion to open surgical procedures, the failure of local anesthesia, postoperative myocardial or lower limb ischemia, and a postoperative serum creatinine level of >125 mmol/L or of >180 mmol/L in patients affected by chronic renal failure. The overall length of the procedure, X-ray exposure, the quantity of iodine contrast medium administered, and the length of recovery were considered to be secondary endpoints. Results: Postoperative complications included two episodes of acute renal failure in the two patients already affected by chronic renal failure, which were easily resolved with adequate daily hydration and the elimination of nephrotoxic drugs. In no cases did cardiac ischemia or lower limb ischemia occur. The average procedure duration was 198 min (range: 180-240 min), the average fluoroscopy duration was 41.7 min (range: 35-50 min), the average amount of iodinated contrast medium was 34.8 mL (range: 30-40 mL), and the mean length of hospitalization was 2.7 days (range: 2-5 days). Conclusions: In selected patients, this surgical approach has demonstrated safety, reduced hospitalization times, minimized risks associated with complications from the untreated condition if procedures were performed at different times, and facilitated the effective management of intraoperative complications due to the presence of a multidisciplinary team. However, the limited number of patients necessitates further research. FAU - Nardi, Priscilla AU - Nardi P AD - Department of Surgery, Sapienza University of Rome, Viale Regina Elena, 324, 00161 Rome, Italy. FAU - Rinaldi, Valerio AU - Rinaldi V AUID- ORCID: 0009-0005-1778-9399 AD - Department of Surgery, Sapienza University of Rome, Viale Regina Elena, 324, 00161 Rome, Italy. FAU - Costanzo, Maria Ludovica AU - Costanzo ML AD - Department of Surgery, Sapienza University of Rome, Viale Regina Elena, 324, 00161 Rome, Italy. FAU - Pasqua, Rocco AU - Pasqua R AD - Department of Surgery, Sapienza University of Rome, Viale Regina Elena, 324, 00161 Rome, Italy. FAU - Loiacono, Francesco AU - Loiacono F AD - Department of Surgery, Sapienza University of Rome, Viale Regina Elena, 324, 00161 Rome, Italy. FAU - Palumbo, Piergaspare AU - Palumbo P AD - Department of Surgery, Sapienza University of Rome, Viale Regina Elena, 324, 00161 Rome, Italy. FAU - Miraldi, Fabio AU - Miraldi F AUID- ORCID: 0000-0002-2404-3369 AD - Department of Cardiac Surgery, Sapienza University of Rome, Viale Regina Elena, 324, 00161 Rome, Italy. FAU - Tanzilli, Gaetano AU - Tanzilli G AUID- ORCID: 0000-0003-4685-0898 AD - Department of Interventional Cardiology, Sapienza University of Rome, Viale Regina Elena, 324, 00161 Rome, Italy. FAU - D'Andrea, Vito AU - D'Andrea V AUID- ORCID: 0000-0001-5709-2530 AD - Department of Surgery, Sapienza University of Rome, Viale Regina Elena, 324, 00161 Rome, Italy. FAU - Illuminati, Giulio AU - Illuminati G AD - Department of Surgery, Sapienza University of Rome, Viale Regina Elena, 324, 00161 Rome, Italy. LA - eng PT - Journal Article DEP - 20240919 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC11432325 OTO - NOTNLM OT - AAA OT - CAD OT - combined approach OT - simultaneous PCI and EVAR COIS- The authors declare no conflicts of interest. EDAT- 2024/09/28 22:42 MHDA- 2024/09/28 22:43 PMCR- 2024/09/19 CRDT- 2024/09/28 01:14 PHST- 2024/07/25 00:00 [received] PHST- 2024/08/19 00:00 [revised] PHST- 2024/09/16 00:00 [accepted] PHST- 2024/09/28 22:43 [medline] PHST- 2024/09/28 22:42 [pubmed] PHST- 2024/09/28 01:14 [entrez] PHST- 2024/09/19 00:00 [pmc-release] AID - jcm13185545 [pii] AID - jcm-13-05545 [pii] AID - 10.3390/jcm13185545 [doi] PST - epublish SO - J Clin Med. 2024 Sep 19;13(18):5545. doi: 10.3390/jcm13185545. PMID- 39336981 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240930 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 13 IP - 18 DP - 2024 Sep 17 TI - A Routine Coronary Angiography before Carotid Endarterectomy as an Example of Interdisciplinary Work: The Immediate Results of the Surgery. LID - 10.3390/jcm13185495 [doi] LID - 5495 AB - The aim: to evaluate the incidence of obstructive lesions of the coronary arteries during routine coronary angiography (CAG) before carotid endarterectomy (CEA) and the incidence of perioperative complications. Materials and Methods: We examined a continuous sample of 498 patients before CEA who underwent an invasive evaluation of the coronary bed during CAG. Depending on the hemodynamic significance of coronary artery lesions, the patients were divided into three groups: group I-obstructive coronary artery disease (>/=70%) (n = 309, 62.0%); group II-non-obstructive lesions of the coronary arteries (<70%) (n = 118, 23.7%); group III-intact coronary arteries (n = 71, 14.3%). The groups were compared with each other according to the data of the preoperative examination (clinical and anamnestic parameters, laboratory data and results of echocardiography), as well as according to the immediate results of the operation. In the hospital period, adverse cardiovascular events were assessed: death, myocardial infarction (MI), stroke, arrhythmias, atrial fibrillation or flutter (AF/AFL) and combined endpoint. Results: The groups differed significantly in the presence of symptoms of angina pectoris, myocardial infarction and myocardial revascularization procedures in their medical history and in the presence of chronic ischemia of the lower extremities. However, in the group of intact coronary arteries, the symptoms of angina were in 14.1% of patients, and a history of myocardial infarction was in 12.7%. Myocardial revascularization before CEA or simultaneously with it was performed in 43.0% of patients. As a result, it was possible to reduce the number of perioperative cardiac complications (mortality 0.7%, perioperative myocardial infarction 1.96%). Conclusions: The high incidence of obstructive lesions in the coronary arteries in our patients and the minimum number of perioperative complications favor routine CAG before CEA. FAU - Sumin, Alexey N AU - Sumin AN AUID- ORCID: 0000-0002-0963-4793 AD - Federal State Budgetary Scientific Institution "Research Institute of Complex Problems of Cardiovascular Diseases", Kemerovo 650002, Russia. FAU - Shcheglova, Anna V AU - Shcheglova AV AD - Federal State Budgetary Scientific Institution "Research Institute of Complex Problems of Cardiovascular Diseases", Kemerovo 650002, Russia. FAU - Adyakova, Olesya V AU - Adyakova OV AD - Federal State Budgetary Scientific Institution "Research Institute of Complex Problems of Cardiovascular Diseases", Kemerovo 650002, Russia. FAU - Fedorova, Darina N AU - Fedorova DN AUID- ORCID: 0000-0002-0308-8760 AD - Federal State Budgetary Scientific Institution "Research Institute of Complex Problems of Cardiovascular Diseases", Kemerovo 650002, Russia. FAU - Yakovlev, Denis D AU - Yakovlev DD AD - Federal State Budgetary Educational Institution of Higher Education "Kemerovo State Medical University" of the Ministry of Health of the Russian Federation, Kemerovo 650056, Russia. FAU - Svinolupova, Natalia A AU - Svinolupova NA AD - Federal State Budgetary Educational Institution of Higher Education "Kemerovo State Medical University" of the Ministry of Health of the Russian Federation, Kemerovo 650056, Russia. FAU - Kabanova, Svetlana V AU - Kabanova SV AD - Federal State Budgetary Educational Institution of Higher Education "Kemerovo State Medical University" of the Ministry of Health of the Russian Federation, Kemerovo 650056, Russia. FAU - Malysheva, Anastasia V AU - Malysheva AV AD - Federal State Budgetary Educational Institution of Higher Education "Kemerovo State Medical University" of the Ministry of Health of the Russian Federation, Kemerovo 650056, Russia. FAU - Karachenko, Marina Yu AU - Karachenko MY AUID- ORCID: 0009-0003-5947-2803 AD - Federal State Budgetary Educational Institution of Higher Education "Kemerovo State Medical University" of the Ministry of Health of the Russian Federation, Kemerovo 650056, Russia. FAU - Kashtalap, Vasily V AU - Kashtalap VV AD - Federal State Budgetary Scientific Institution "Research Institute of Complex Problems of Cardiovascular Diseases", Kemerovo 650002, Russia. FAU - Barbarash, Olga L AU - Barbarash OL AUID- ORCID: 0000-0002-4642-3610 AD - Federal State Budgetary Scientific Institution "Research Institute of Complex Problems of Cardiovascular Diseases", Kemerovo 650002, Russia. LA - eng PT - Journal Article DEP - 20240917 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC11432148 OTO - NOTNLM OT - carotid endarterectomy OT - coronary angiography OT - myocardial revascularization OT - obstructive lesion of the coronary arteries OT - perioperative complications OT - risk assessment COIS- The authors declare no conflicts of interest. EDAT- 2024/09/28 22:42 MHDA- 2024/09/28 22:43 PMCR- 2024/09/17 CRDT- 2024/09/28 01:14 PHST- 2024/09/05 00:00 [received] PHST- 2024/09/12 00:00 [revised] PHST- 2024/09/16 00:00 [accepted] PHST- 2024/09/28 22:43 [medline] PHST- 2024/09/28 22:42 [pubmed] PHST- 2024/09/28 01:14 [entrez] PHST- 2024/09/17 00:00 [pmc-release] AID - jcm13185495 [pii] AID - jcm-13-05495 [pii] AID - 10.3390/jcm13185495 [doi] PST - epublish SO - J Clin Med. 2024 Sep 17;13(18):5495. doi: 10.3390/jcm13185495. PMID- 39336971 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240930 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 13 IP - 18 DP - 2024 Sep 15 TI - Management of Myocardial Infarction and the Role of Cardiothoracic Surgery. LID - 10.3390/jcm13185484 [doi] LID - 5484 AB - Myocardial infarction (MI) is a leading cause of mortality globally and is predominantly attributed to coronary artery disease (CAD). MI is categorized as ST-elevation MI (STEMI) or non-ST-elevation MI (NSTEMI), each with distinct etiologies and treatment pathways. The goal in treatment for both is restoring blood flow back to the myocardium. STEMI, characterized by complete occlusion of a coronary artery, is managed urgently with reperfusion therapy, typically percutaneous coronary intervention (PCI). In contrast, NSTEMI involves a partial occlusion of a coronary artery and is treated with medical management, PCI, or coronary artery bypass grafting (CABG) depending on risk scores and clinical judgment. The Heart Team approach can assist in deciding which reperfusion technique would provide the greatest benefit to the patient and is especially useful in complicated cases. Despite advances in treatment, complications such as cardiogenic shock (CS) and ischemic heart failure (HF) remain significant. While percutaneous coronary intervention (PCI) is considered the primary treatment for MI, it is important to recognize the significance of cardiac surgery in treatment, especially when there is complex disease or MI-related complications. This comprehensive review analyzes the role of cardiac surgery in MI management, recognizing when it is useful, or not. FAU - Parness, Shannon AU - Parness S AUID- ORCID: 0009-0003-7425-6738 AD - Division of Cardiothoracic Surgery, Department of Surgery, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. FAU - Tasoudis, Panagiotis AU - Tasoudis P AD - Division of Cardiothoracic Surgery, Department of Surgery, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. FAU - Agala, Chris B AU - Agala CB AUID- ORCID: 0000-0001-7157-814X AD - Department of Surgery, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. FAU - Merlo, Aurelie E AU - Merlo AE AUID- ORCID: 0000-0002-1010-7341 AD - Division of Cardiothoracic Surgery, Department of Surgery, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. LA - eng PT - Journal Article PT - Review DEP - 20240915 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC11432415 OTO - NOTNLM OT - CABG OT - PCI OT - cardiac surgery OT - myocardial infarction OT - post-MI complications COIS- The authors declare no conflicts of interest. EDAT- 2024/09/28 22:43 MHDA- 2024/09/28 22:44 PMCR- 2024/09/15 CRDT- 2024/09/28 01:14 PHST- 2024/08/20 00:00 [received] PHST- 2024/09/09 00:00 [revised] PHST- 2024/09/12 00:00 [accepted] PHST- 2024/09/28 22:44 [medline] PHST- 2024/09/28 22:43 [pubmed] PHST- 2024/09/28 01:14 [entrez] PHST- 2024/09/15 00:00 [pmc-release] AID - jcm13185484 [pii] AID - jcm-13-05484 [pii] AID - 10.3390/jcm13185484 [doi] PST - epublish SO - J Clin Med. 2024 Sep 15;13(18):5484. doi: 10.3390/jcm13185484. PMID- 39335749 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240930 IS - 2075-4418 (Print) IS - 2075-4418 (Electronic) IS - 2075-4418 (Linking) VI - 14 IP - 18 DP - 2024 Sep 19 TI - The Aortic Prosthesis and Aortic Valve Bioprosthesis Trombosis as a Late Complication in Patients after the Bentall Procedure Followed by a Valve-in-Valve Transcatheter Aortic Valve Implantation. LID - 10.3390/diagnostics14182070 [doi] LID - 2070 AB - Background: Valve-in-Valve (ViV) transcatheter aortic valve implantation (TAVI) has emerged as a viable therapeutic option for structural valve degeneration following surgical aortic valve replacement (SAVR) or prior TAVI. However, the understanding of long-term complications and their management remains limited. Case presentation: We present the case of a 69-year-old male with a history of ViV-TAVI, who presented with symptoms of non-ST elevation myocardial infarction (NSTEMI) and transient ischemic attack (TIA). Computed tomography (CT) revealed thrombosis of the ascending aortic graft and aortic valve prosthesis. Transthoracic echocardiography (TTE) further confirmed new valve dysfunction, indicated by an increase in the aortic valve mean gradient. Treatment with low-molecular-weight heparin (LMWH) resulted in partial thrombus resolution. The multidisciplinary Heart Team opted against coronary angiography and recommended the long-term administration of vitamin K antagonists (VKAs). Follow-up CT showed the complete resolution of the thrombus. Conclusions: Thrombosis of the aortic graft and aortic valve following ViV-TAVI may be attributed to alterations in blood flow or mechanical manipulations during the TAVI procedure, yet it can be effectively managed with VKA therapy. CT is a valuable tool in coronary assessment in patients with NSTEMI and aortic valve and/or aortic graft thrombosis. FAU - Muszynski, Pawel AU - Muszynski P AUID- ORCID: 0000-0003-0974-7138 AD - Department of Invasive Cardiology, Medical University of Bialystok, M. Sklodowskiej-Curie 24A, 15-276 Bialystok, Poland. AD - Department of General and Experimental Pathology, Medical University of Bialystok, Mickiewicza 2C, 15-230 Bialystok, Poland. AD - Department of Cardiology, Lipidology and Internal Diseases, Medical University of Bialystok, Zurawia 14, 15-569 Bialystok, Poland. FAU - Grunwald, Oliwia AU - Grunwald O AD - Department of Invasive Cardiology, Medical University of Bialystok, M. Sklodowskiej-Curie 24A, 15-276 Bialystok, Poland. FAU - Poludniewski, Maciej AU - Poludniewski M AD - Department of Invasive Cardiology, Medical University of Bialystok, M. Sklodowskiej-Curie 24A, 15-276 Bialystok, Poland. FAU - Kralisz, Pawel AU - Kralisz P AD - Department of Invasive Cardiology, Medical University of Bialystok, M. Sklodowskiej-Curie 24A, 15-276 Bialystok, Poland. FAU - Kocanda, Szymon AU - Kocanda S AD - Department of Cardiac Surgery, Medical University of Bialystok, M. Sklodowskiej-Curie 24A, 15-276 Bialystok, Poland. FAU - Hirnle, Tomasz AU - Hirnle T AD - Department of Cardiac Surgery, Medical University of Bialystok, M. Sklodowskiej-Curie 24A, 15-276 Bialystok, Poland. FAU - Dobrzycki, Slawomir AU - Dobrzycki S AD - Department of Invasive Cardiology, Medical University of Bialystok, M. Sklodowskiej-Curie 24A, 15-276 Bialystok, Poland. FAU - Kozuch, Marcin AU - Kozuch M AUID- ORCID: 0000-0002-1430-7455 AD - Department of Invasive Cardiology, Medical University of Bialystok, M. Sklodowskiej-Curie 24A, 15-276 Bialystok, Poland. LA - eng GR - B.SUB.24.290, SUB/1/DN/20/003/1124 and SUB/1/DN/22/001/1124/Medical University of Bialystok/ PT - Journal Article DEP - 20240919 PL - Switzerland TA - Diagnostics (Basel) JT - Diagnostics (Basel, Switzerland) JID - 101658402 PMC - PMC11431767 OTO - NOTNLM OT - ViV TAVI OT - aortic dissection OT - cardiovascular imaging OT - valve thrombosis OT - vascular complication COIS- The authors declare no conflicts of interest. EDAT- 2024/09/28 22:43 MHDA- 2024/09/28 22:44 PMCR- 2024/09/19 CRDT- 2024/09/28 01:07 PHST- 2024/08/29 00:00 [received] PHST- 2024/09/14 00:00 [revised] PHST- 2024/09/18 00:00 [accepted] PHST- 2024/09/28 22:44 [medline] PHST- 2024/09/28 22:43 [pubmed] PHST- 2024/09/28 01:07 [entrez] PHST- 2024/09/19 00:00 [pmc-release] AID - diagnostics14182070 [pii] AID - diagnostics-14-02070 [pii] AID - 10.3390/diagnostics14182070 [doi] PST - epublish SO - Diagnostics (Basel). 2024 Sep 19;14(18):2070. doi: 10.3390/diagnostics14182070. PMID- 39326915 OWN - NLM STAT- MEDLINE DCOM- 20241107 LR - 20260304 IS - 1399-3003 (Electronic) IS - 0903-1936 (Linking) VI - 64 IP - 5 DP - 2024 Nov TI - Multidisciplinary management of adult patients with chylothorax: a consensus statement. LID - 2400470 [pii] LID - 10.1183/13993003.00470-2024 [doi] AB - The management of chylothorax remains challenging given the limited evidence and significant heterogeneity in practice. In addition, there are no practical guidelines on the optimal approach to manage this complex condition. We convened an international group of 27 experts from 20 institutions across five countries and four specialties (pulmonary, interventional radiology, thoracic surgery and nutrition) with experience and expertise in managing adult patients with chylothorax. We performed a literature and internet search for reports addressing seven clinically relevant PICO (Patient, Intervention, Comparison and Outcome) questions pertaining to the management of adult patients with chylothorax. This consensus statement, consisting of best practice statements based on expert consensus addressing these seven PICO questions, was formulated by a systematic and rigorous process involving the evaluation of published evidence, augmented with provider experience. Panel members participated in the development of the final best practice statements using the modified Delphi technique. Our consensus statement aims to offer guidance in clinical decision making when managing patients with chylothorax while also identifying gaps in knowledge and informing future research. CI - Copyright (c)The authors 2024. For reproduction rights and permissions contact permissions@ersnet.org. FAU - Agrawal, Abhinav AU - Agrawal A AUID- ORCID: 0000-0003-1080-6449 AD - Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, NY, USA abhinav72@gmail.com. AD - Contributed equally as joint first authors. FAU - Chaddha, Udit AU - Chaddha U AD - Division of Pulmonary, Critical Care and Sleep Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. AD - Contributed equally as joint first authors. FAU - Shojaee, Samira AU - Shojaee S AUID- ORCID: 0000-0001-9228-209X AD - Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. FAU - Nadolski, Gregory AU - Nadolski G AD - University of Pennsylvania, Philadelphia, PA, USA. FAU - Liberman, Moishe AU - Liberman M AD - University of Montreal, Montreal, QC, Canada. FAU - Lee, Y C Gary AU - Lee YCG AD - University of Western Australia, Perth, Australia. FAU - Rahman, Najib AU - Rahman N AD - Oxford Respiratory Trials Unit, University of Oxford, Oxford, UK. FAU - Reisenauer, Janani S AU - Reisenauer JS AD - Mayo Clinic, Rochester, MN, USA. FAU - Ferguson, Mark K AU - Ferguson MK AD - University of Chicago, Chicago, IL, USA. FAU - DeCamp, Malcolm M AU - DeCamp MM AD - Division of Cardiothoracic Surgery, University of Wisconsin, Madison, WI, USA. FAU - Gillaspie, Erin A AU - Gillaspie EA AD - Creighton University Medical Center, Omaha, NE, USA. FAU - Bedawi, Eihab O AU - Bedawi EO AUID- ORCID: 0000-0001-9196-3934 AD - Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. FAU - Currie, Brian AU - Currie B AD - New York-Presbyterian Hospital, Weill Cornell Medical College, New York, NY, USA. FAU - Feller-Kopman, David J AU - Feller-Kopman DJ AD - Pulmonary and Critical Care Medicine, Darmouth-Hitchcock Medical Center, The Geisel School of Medicine at Dartmouth, Hanover, NH, USA. FAU - Desai, Ajinkya AU - Desai A AD - University of Mississippi Medical Center, Jackson, MS, USA. FAU - Yasufuku, Kazuhiro AU - Yasufuku K AD - Division of Thoracic Surgery, Toronto General Hospital, University Health Network, University of Toronto, Toronto, ON, Canada. FAU - Bishay, Vivian AU - Bishay V AD - Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Gesthalter, Yaron AU - Gesthalter Y AD - Division of Pulmonary, Critical Care, Allergy and Sleep, University of California San Francisco, San Francisco, CA, USA. FAU - Grosu, Horiana AU - Grosu H AD - University of Texas, MD Anderson Cancer Center, Houston, TX, USA. FAU - Chick, Jeffrey Forris Beecham AU - Chick JFB AD - University of Washington, Seattle, WA, USA. FAU - Lentz, Robert AU - Lentz R AD - Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. FAU - Kolli, K Pallav AU - Kolli KP AD - Division of Body Interventional Radiology, University of California San Francisco, San Francisco, CA, USA. FAU - Kaufman, Andrew AU - Kaufman A AD - Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Mehta, Ravindra M AU - Mehta RM AD - Apollo Bangalore Pulmonary Services, Apollo Hospitals Bangalore, Bangalore, India. FAU - Desai, Kush AU - Desai K AD - Northwestern University Feinberg School of Medicine, Chicago, IL, USA. FAU - Davis, Heather AU - Davis H AD - University of Texas, MD Anderson Cancer Center, Houston, TX, USA. FAU - Ghori, Uzair K AU - Ghori UK AUID- ORCID: 0000-0002-2633-977X AD - Medical College of Wisconsin, Milwaukee, WI, USA. FAU - Maldonado, Fabien AU - Maldonado F AD - Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. LA - eng PT - Consensus Statement PT - Journal Article DEP - 20241107 PL - England TA - Eur Respir J JT - The European respiratory journal JID - 8803460 SB - IM MH - *Chylothorax/therapy MH - Humans MH - *Delphi Technique MH - Adult MH - Drainage/methods MH - Radiology, Interventional MH - Thoracic Surgery MH - Clinical Decision-Making COIS- Conflict of interest: Y.C.G. Lee receives drainage kits without charge for participants of a clinical trial he leads. J.S. Reisenauer has a research grant with Intuitive Surgical and is an educational consultant for Vergent, Isola, Medview and Imvaria, outside the submitted work. M.M. DeCamp is an educational consultant for PulmonX and is on the scientific advisory board for Pleural Dynamics. D.J. Feller-Kopman is an educational consultant for AstraZeneca, Noah Medical and Boston Scientific, outside the submitted work. H. Grosu has a sponsored research agreement with Known Medicine. J.F.B. Chick is an educational consultant and speaker for Inari Medical, Guerbet, C. R. Bard, Argon Medical Devices, Boston Scientific, NXT Biomedical and AiDoc, outside the submitted work. F. Maldonado received research funding from Medtronic and personal consulting fees from J&J and Intuitive, outside of the submitted work. The remaining authors do not have any disclosures or conflicts of interest to report. EDAT- 2024/09/27 00:42 MHDA- 2024/11/13 13:55 CRDT- 2024/09/26 20:43 PHST- 2024/03/08 00:00 [received] PHST- 2024/09/04 00:00 [accepted] PHST- 2024/11/13 13:55 [medline] PHST- 2024/09/27 00:42 [pubmed] PHST- 2024/09/26 20:43 [entrez] AID - 13993003.00470-2024 [pii] AID - 10.1183/13993003.00470-2024 [doi] PST - epublish SO - Eur Respir J. 2024 Nov 7;64(5):2400470. doi: 10.1183/13993003.00470-2024. Print 2024 Nov. PMID- 39326455 OWN - NLM STAT- MEDLINE DCOM- 20250408 LR - 20260518 IS - 1098-8785 (Electronic) IS - 0735-1631 (Print) IS - 0735-1631 (Linking) VI - 42 IP - 6 DP - 2025 Apr TI - Development and Evaluation of a Rural Longitudinal Neonatal Resuscitation Program Telesimulation Program (MOOSE: Maine Ongoing Outreach Simulation Education). PG - 796-805 LID - 10.1055/a-2421-8486 [doi] AB - Neonatal resuscitation is a high-acuity, low-occurrence event and many rural pediatricians report feeling underprepared for these events. We piloted a longitudinal telesimulation (TS) program with a rural hospital's interprofessional delivery room teams aimed at improving adherence to Neonatal Resuscitation Program (NRP) guidelines and teamwork.A TS study was conducted monthly in one rural hospital over a 10-month period from November 2020 to August 2021. TS sessions were remotely viewed and debriefed by experts, a neonatologist and a simulation educator. Sessions were video recorded and assessed using a scoring tool with validity evidence for NRP adherence. Teamwork was assessed using both TeamSTEPPS 2.0 Team Performance Observation Tool and Mayo High-Performance Teamwork Scale.We conducted 10 TS sessions in one rural hospital. There were 24 total participants, who rotated through monthly sessions, ensuring interdisciplinary team composition was reflective of realistic staffing. NRP adherence rate for full code scenarios improved from a baseline of 39 to 95%. Compared with baseline data for efficiency, multiple NRP skills improved (e.g., cardiac lead placement occurred 12x faster, 0:31 seconds vs. 6:21 minutes). Teamwork scores showed improvement in all domains.Our results demonstrate that a TS program aimed at improving NRP and team performance is possible to implement in a rural setting. Our pilot study showed a trend toward improved NRP adherence, increased skill efficiency, and higher-quality teamwork and communication in one rural hospital. Additional research is needed to analyze program efficacy on a larger scale and to understand the impact of training on patient outcomes. . Optimal newborn outcomes depend on skillful implementation of NRP.. . Telesimulation can deliver medical education that circumvents challenges in rural areas.. . A longitudinal NRP TS program is possible to implement in a rural setting.. . A rural NRP telesimulation program may improve interprofessional resuscitation performance.. . A rural NRP telesimulation program may improve interprofessional resuscitation teamwork.. CI - Thieme. All rights reserved. FAU - Melendi, Misty AU - Melendi M AD - Department of Pediatrics, Tufts University School of Medicine, Boston, Massachusetts. AD - Section of Neonatal-Perinatal Medicine, Department of Pediatrics, The Barbara Bush Children's Hospital at Maine Medical Center, Portland, Maine. AD - Department of Pediatrics, The Barbara Bush Children's Hospital at Maine Medical Center, Portland, Maine. FAU - Zanno, Allison E AU - Zanno AE AD - Department of Pediatrics, Tufts University School of Medicine, Boston, Massachusetts. AD - Section of Neonatal-Perinatal Medicine, Department of Pediatrics, The Barbara Bush Children's Hospital at Maine Medical Center, Portland, Maine. AD - Department of Pediatrics, The Barbara Bush Children's Hospital at Maine Medical Center, Portland, Maine. FAU - Holmes, Jeffrey A AU - Holmes JA AD - Department of Emergency Medicine, Tufts University School of Medicine, Boston, Massachusetts. FAU - Chipman, Micheline AU - Chipman M AD - Department of Simulation Education, The Hannaford Center for Safety, Innovation and Simulation, Maine Medical Center, Portland, Maine. FAU - Cutler, Anya AU - Cutler A AD - Research Data Analyst, Maine Health Institute for Research, Center for Interdisciplinary Population and Health Research, Portland, Maine. FAU - Stoddard, Henry AU - Stoddard H AD - Research Data Analyst, Maine Health Institute for Research, Center for Interdisciplinary Population and Health Research, Portland, Maine. FAU - Seften, Leah M AU - Seften LM AD - Department of Pediatrics, The Barbara Bush Children's Hospital at Maine Medical Center, Portland, Maine. FAU - Gilbert, Anna AU - Gilbert A AD - Department of Pediatrics, The Barbara Bush Children's Hospital at Maine Medical Center, Portland, Maine. FAU - Ottolini, Mary AU - Ottolini M AD - Department of Pediatrics, The Barbara Bush Children's Hospital at Maine Medical Center, Portland, Maine. FAU - Craig, Alexa AU - Craig A AUID- ORCID: 0000-0002-6477-3390 AD - Department of Pediatrics, Tufts University School of Medicine, Boston, Massachusetts. AD - Department of Pediatrics, The Barbara Bush Children's Hospital at Maine Medical Center, Portland, Maine. AD - Division of Pediatric Neurology, Department of Pediatrics, The Barbara Bush Children's Hospital at Maine Medical Center, Portland, Maine. FAU - Mallory, Leah A AU - Mallory LA AD - Department of Pediatrics, Tufts University School of Medicine, Boston, Massachusetts. AD - Department of Simulation Education, The Hannaford Center for Safety, Innovation and Simulation, Maine Medical Center, Portland, Maine. AD - Department of Pediatrics, The Barbara Bush Children's Hospital at Maine Medical Center, Portland, Maine. LA - eng GR - P20 GM139745/GM/NIGMS NIH HHS/United States GR - 1P20GM139745-01/Center for Biomedical Research Excellence (COBRE) in Acute Care Research and Rural Disparities/ PT - Journal Article DEP - 20240926 PL - United States TA - Am J Perinatol JT - American journal of perinatology JID - 8405212 SB - IM MH - Humans MH - Infant, Newborn MH - *Resuscitation/education MH - *Simulation Training/methods MH - Hospitals, Rural MH - *Patient Care Team/organization & administration MH - Maine MH - Program Evaluation MH - Guideline Adherence MH - Pilot Projects MH - Clinical Competence MH - Rural Health Services PMC - PMC11983237 MID - NIHMS2039602 COIS- None declared. EDAT- 2024/09/27 00:42 MHDA- 2025/04/09 10:11 PMCR- 2026/04/01 CRDT- 2024/09/26 19:03 PHST- 2025/04/09 10:11 [medline] PHST- 2024/09/27 00:42 [pubmed] PHST- 2024/09/26 19:03 [entrez] PHST- 2026/04/01 00:00 [pmc-release] AID - 10.1055/a-2421-8486 [doi] PST - ppublish SO - Am J Perinatol. 2025 Apr;42(6):796-805. doi: 10.1055/a-2421-8486. Epub 2024 Sep 26. PMID- 39324696 OWN - NLM STAT- MEDLINE DCOM- 20240926 LR - 20241016 IS - 2755-0079 (Electronic) IS - 2755-0060 (Linking) VI - 12 IP - 34 DP - 2024 Sep TI - Integrating Palliative Care and Heart Failure: the PalliatHeartSynthesis realist synthesis. PG - 1-128 LID - 10.3310/FTRG5628 [doi] AB - BACKGROUND: Cardiovascular disease is the most common cause of death worldwide, highlighting the need for studies to determine options for palliative care within the management of patients with heart failure. Although there are promising examples of integrated palliative care and heart failure interventions, there is heterogeneity in terms of countries, healthcare settings, multidisciplinary team delivery, modes of delivery and intervention components. Hence, this review is vital to identify what works, for whom and in what circumstances when integrating palliative care and heart failure. OBJECTIVES: To (1) develop a programme theory of why, for whom and in what contexts desired outcomes occur; and (2) use the programme theory to co-produce with stakeholders key implications to inform best practice and future research. DESIGN: A realist review of the literature underpinned by the Realist and Meta-narrative Evidence Syntheses: Evolving Standards quality and reporting standards. DATA SOURCES: Searches of bibliographic databases were conducted in November 2021 using the following databases: EMBASE, MEDLINE, PsycInfo, AMED, HMIC and CINAHL. Further relevant documents were identified via alerts and the stakeholder group. REVIEW METHODS: Realist review is a theory-orientated and explanatory approach to the synthesis of evidence. A realist synthesis was used to synthesise the evidence as successful implementation of integrated palliative care and heart failure depends on the context and people involved. The realist synthesis followed Pawson's five iterative stages: (1) locating existing theories; (2) searching for evidence; (3) document selection; (4) extracting and organising data; and (5) synthesising the evidence and drawing conclusions. We recruited an international stakeholder group (n = 32), including National Health Service management, healthcare professionals involved in the delivery of palliative care and heart failure, policy and community groups, plus members of the public and patients, to advise and give us feedback throughout the project, along with Health Education England to disseminate findings. RESULTS: In total, 1768 documents were identified, of which 1076 met the inclusion criteria. This was narrowed down to 130 included documents based on the programme theory and discussions with stakeholders. Our realist analysis developed and refined 6 overarching context-mechanism-outcome configurations and 30 sub context-mechanism-outcome configurations. The realist synthesis of the literature and stakeholder feedback helped uncover key intervention strategies most likely to support integration of palliative care into heart failure management. These included protected time for evidence-based palliative care education and choice of educational setting (e.g. online, face to face or hybrid), and the importance of increased awareness of the benefits of palliative care as key intervention strategies, the emotive and intellectual need for integrating palliative care and heart failure via credible champions, seeing direct patient benefit, and prioritising palliative care and heart failure guidelines in practice. The implications of our findings are further outlined in the capability, opportunity, motivation, behaviour model. LIMITATIONS: The realist approach to analysis means that findings are based on our interpretation of the data. FUTURE WORK: Future work should use the implications to initiate and optimise palliative care in heart failure management. CONCLUSION: Ongoing refinement of the programme theory at each stakeholder meeting allowed us to co-produce implications. These implications outline the required steps to ensure the core components and determinants of behaviour are in place so that all key players have the capacity, opportunity and motivation to integrate palliative care into heart failure management. STUDY REGISTRATION: This study is registered as PROSPERO CRD42021240185. FUNDING: This award was funded by the National Institute for Health and Care Research (NIHR) Health and Social Care Delivery Research programme (NIHR award ref: NIHR131800) and is published in full in Health and Social Care Delivery Research; Vol. 12, No. 34. See the NIHR Funding and Awards website for further award information. FAU - McConnell, Tracey AU - McConnell T AUID- ORCID: 0000-0003-1292-8597 AD - School of Nursing and Midwifery, Queen's University Belfast, Belfast, UK. AD - Marie Curie Hospice, Belfast, UK. FAU - Blair, Carolyn AU - Blair C AUID- ORCID: 0000-0001-5454-5813 AD - School of Nursing and Midwifery, Queen's University Belfast, Belfast, UK. FAU - Wong, Geoff AU - Wong G AUID- ORCID: 0000-0002-5384-4157 AD - Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK. FAU - Duddy, Claire AU - Duddy C AUID- ORCID: 0000-0002-7083-6589 AD - Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK. FAU - Howie, Clare AU - Howie C AUID- ORCID: 0000-0002-4359-6831 AD - School of Nursing and Midwifery, Queen's University Belfast, Belfast, UK. FAU - Hill, Loreena AU - Hill L AUID- ORCID: 0000-0001-5232-0936 AD - School of Nursing and Midwifery, Queen's University Belfast, Belfast, UK. FAU - Reid, Joanne AU - Reid J AUID- ORCID: 0000-0001-5820-862X AD - School of Nursing and Midwifery, Queen's University Belfast, Belfast, UK. LA - eng PT - Journal Article PT - Review PL - England TA - Health Soc Care Deliv Res JT - Health and social care delivery research JID - 9918470788706676 SB - IM MH - Humans MH - Delivery of Health Care, Integrated/organization & administration MH - *Heart Failure/therapy MH - *Palliative Care/organization & administration OAB - People with heart failure can frequently become unwell with poor quality of life despite advanced medical therapies. Palliative care can do much to alleviate suffering for people with heart failure as it focuses on adding to patient care by treating the whole person - their physical, psychosocial and spiritual needs, which improves quality of life for both the patient and their loved ones. However, poor integration of palliative care into the management of heart failure is an ongoing problem. To understand why this is, we have undertaken a particular method of literature review called realist synthesis that looks at all types of literature to identify what works, for whom and in what circumstances. We have worked closely with our stakeholder group (including healthcare providers and patients who have heart failure and their carers) to advise and give us feedback throughout this review. We found the following: A review of education for health and social care professionals is needed to make sure that palliative care for patients with non-cancer conditions such as heart failure is adequately covered. Education is also needed for patients and those who care for them to help them understand what palliative care is (holistic care delivered alongside active heart failure management based on patient need) and what it is not (only for cancer patients and end-of-life care). All health and social care staff should work closely together when managing patients with heart failure to learn from each other. Policy, practice and service user champions must be identified and supported to share the benefits of integrated care. Visible guidelines should prioritise integrated palliative care and heart failure so they become part of everyday practice. OABL- eng OTO - NOTNLM OT - HEART FAILURE OT - INTEGRATED CARE OT - PALLIATIVE CARE OT - REALIST OT - SYNTHESIS EDAT- 2024/09/26 12:44 MHDA- 2024/09/26 12:45 CRDT- 2024/09/26 08:23 PHST- 2024/09/26 12:45 [medline] PHST- 2024/09/26 12:44 [pubmed] PHST- 2024/09/26 08:23 [entrez] AID - 10.3310/FTRG5628 [doi] PST - ppublish SO - Health Soc Care Deliv Res. 2024 Sep;12(34):1-128. doi: 10.3310/FTRG5628. PMID- 39323950 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240927 IS - 1753-4313 (Electronic) IS - 0969-6113 (Print) IS - 0969-6113 (Linking) VI - 31 IP - 1 DP - 2024 TI - Mitral valvular surgery outcomes in a centre with a dedicated mitral multi-disciplinary team. PG - 012 LID - 10.5837/bjc.2024.012 [doi] LID - 012 AB - International guidelines recommend 'heart teams' as the preferred method for decision-making. Heart team processes, mandatory attendees and investigations vary significantly between hospitals. We assessed outcomes following mitral valvular surgery in a tertiary referral centre with a dedicated mitral multi-disciplinary team (MDT). This was a single-centre retrospective review of prospectively collected data within the 'mitral database' of mitral valvular disease patients. The 'mitral MDT' meeting involved pre-operative imaging and clinical data review, including mandatory transoesophageal echocardiography; recommendation for planned procedure, as well as an appropriate surgeon; and review of echocardiography images and clinical outcomes after surgery had been performed. Between 2016 and 2020, 395 patients with mitral valvular disease were discussed at MDT. Of these, 310 patients underwent surgery. During the same time interval, 75 patients had surgery without MDT discussion: 84% of patients not discussed were urgent or emergent procedures and, in these, the most common pathology was degenerative mitral regurgitation (DMR, 46%) followed by infective endocarditis (30%). Of those discussed at MDT the pathology was: DMR 65%; mitral stenosis 14%; functional mitral regurgitation (MR) 5%; rheumatic MR 4%; endocarditis 4%; ischaemic MR 4%; and other pathologies 4%. For patients with DMR having elective surgery, the repair rate was 93% with mortality 2% and median (IQR) length of stay 5 (4-6) days. Postoperative transthoracic echocardiography demonstrated 99% of elective DMR patients had 0.05). From 2016 to 2020; mortality has not changed significantly for TTC-CS, while the use of percutaneous coronary angiogram (PCA) and MCS has down-trended (p-trend < 0.05). CONCLUSION: For TTC-CS hospitalization, males have higher in-hospital mortality and complication rates, along with higher LOS and cost of hospitalization. Despite advances in the management of CS, there was no significant difference in mortality from 2016 to 2020. CI - (c) 2024 The Authors. FAU - Ali, Shafaqat AU - Ali S AD - Department of Internal Medicine, Louisiana State University, Shreveport, LA, USA. FAU - Khlidj, Yehya AU - Khlidj Y AD - Department of Medicine, University of Algiers 1, Algiers, Algeria. FAU - Kumar, Manoj AU - Kumar M AD - Department of Medicine, John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, USA. FAU - Kumar, Sanjay AU - Kumar S AD - Department of Medicine, Icahn School of Medicine at Mount Sinai, Queens, NY, USA. FAU - Duhan, Sanchit AU - Duhan S AD - Department of Cardiology, Carle Foundation Hospital, Urbana, IL, USA. FAU - Farooq, Faryal AU - Farooq F AD - Department of Medicine, Allama Iqbal Medical College Lahore, Pakistan. FAU - Keisham, Bijeta AU - Keisham B AD - Department of Medicine, Shandong Second Medical University, Weifang, China. FAU - Ponna, Pramod Kumar AU - Ponna PK AD - Department of Internal Medicine, Louisiana State University, Shreveport, LA, USA. FAU - Modi, Kalgi AU - Modi K AD - Department of Cardiology, Louisiana State University, Shreveport, LA, USA. LA - eng PT - Journal Article DEP - 20240831 PL - United States TA - Am Heart J Plus JT - American heart journal plus : cardiology research and practice JID - 101779333 PMC - PMC11419888 OTO - NOTNLM OT - Acute heart failure OT - Acute myocardial infarction OT - Cardiogenic shock OT - Mechanical circulatory support OT - Shock team OT - Systems of care COIS- The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/09/25 10:18 MHDA- 2024/09/25 10:19 PMCR- 2024/08/31 CRDT- 2024/09/25 04:30 PHST- 2024/05/11 00:00 [received] PHST- 2024/08/27 00:00 [revised] PHST- 2024/08/28 00:00 [accepted] PHST- 2024/09/25 10:19 [medline] PHST- 2024/09/25 10:18 [pubmed] PHST- 2024/09/25 04:30 [entrez] PHST- 2024/08/31 00:00 [pmc-release] AID - S2666-6022(24)00096-X [pii] AID - 100453 [pii] AID - 10.1016/j.ahjo.2024.100453 [doi] PST - epublish SO - Am Heart J Plus. 2024 Aug 31;46:100453. doi: 10.1016/j.ahjo.2024.100453. eCollection 2024 Oct. PMID- 39318837 OWN - NLM STAT- MEDLINE DCOM- 20240925 LR - 20260923 IS - 1178-2005 (Electronic) IS - 1176-9106 (Print) IS - 1176-9106 (Linking) VI - 19 DP - 2024 TI - A Multi-Specialty Delphi Consensus on Assessing and Managing Cardiopulmonary Risk in Patients with COPD. PG - 2051-2062 LID - 10.2147/COPD.S471952 [doi] AB - BACKGROUND: In Canada, COPD represents a significant burden to the patient and health system, as it is often under or misdiagnosed and sub-optimally treated. Cardiovascular disease (CVD) is a common co-morbidity in COPD and there is significant interplay between these two chronic conditions. Across all stages of COPD disease severity, deaths can be attributed not only to respiratory causes but also to cardiovascular-related factors. The established links between COPD and CVD suggest the need for a greater degree of collaboration between respirologists and cardiologists. This modified Delphi consensus was initiated to consider how optimal COPD care can be delivered within Canada, with specific consideration of reducing cardiopulmonary risk and outcomes in COPD patients. METHODS: A steering group with interest in the management of COPD and CVD from primary care, cardiology, and respirology identified 40 statements formed from four key themes. A 4-point Likert scale questionnaire was sent to healthcare professionals working in COPD across Canada by an independent third party to assess agreement (consensus) with these statements. Consensus was defined as high if >/=75% and very high if >/=90% of respondents agreed with a statement. RESULTS: A total of 100 responses were received from respirologists (n=30), cardiologists (n=30), and primary care physicians (n=40). Consensus was very strong (>/=90%) in 28 (70%) statements, strong (>/=75 and <90%) in 7 (17.5%) statements and was not achieved (<75%) in 5 (12.5%) of statements. CONCLUSION: Based on the consensus scores, 9 key recommendations were proposed by the steering group. These focus on the need to comprehensively risk stratify and manage COPD patients to help prevent exacerbations. Consensus within this study provides a call to action for the expeditious implementation of the latest COPD guidelines from the Canadian Thoracic Society. CI - (c) 2024 Bhutani et al. FAU - Bhutani, Mohit AU - Bhutani M AD - Department of Medicine, Division of Pulmonary Medicine, University of Alberta, Edmonton, Alberta, Canada. FAU - Bourbeau, Jean AU - Bourbeau J AD - Department of Medicine, Division of Pulmonary Medicine, McGill University Health Centre, McGill University, Montreal, Quebec, Canada. FAU - Goodman, Shaun G AU - Goodman SG AD - Department of Medicine, Division of Cardiology, University of Toronto, Toronto, Ontario, Canada. FAU - Hawkins, Nathaniel Mark AU - Hawkins NM AUID- ORCID: 0000-0003-1286-2014 AD - Department of Medicine, Division of Cardiology, University of British Columbia, Vancouver, British Columbia. FAU - Kaplan, Alan G AU - Kaplan AG AUID- ORCID: 0000-0001-8795-5528 AD - Department of Family and Community Medicine, University of Toronto, Toronto, Ontario, Canada. FAU - Lin, Peter James AU - Lin PJ AD - The Canadian Heart Research Centre, Primary Care Initiatives, Toronto, Ontario, Canada. FAU - Penz, Erika Dianne AU - Penz ED AD - College of Medicine, Division of Respirology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada. FAU - Verma, Subodh AU - Verma S AD - Department of Surgery, Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada. FAU - Zieroth, Shelley AU - Zieroth S AD - College of Medicine, Section of Cardiology, University of Manitoba, Winnipeg, Manitoba, Canada. LA - eng GR - AstraZeneca Canada Ltd. (AstraZeneca)/ PT - Consensus Statement PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240919 PL - New Zealand TA - Int J Chron Obstruct Pulmon Dis JT - International journal of chronic obstructive pulmonary disease JID - 101273481 SB - IM MH - Humans MH - *Pulmonary Disease, Chronic Obstructive/diagnosis/therapy/epidemiology/physiopathology MH - *Delphi Technique MH - Risk Assessment MH - Canada/epidemiology MH - *Cardiovascular Diseases/prevention & control/epidemiology/diagnosis/therapy MH - Cardiologists/standards MH - Heart Disease Risk Factors MH - Lung/physiopathology MH - Pulmonary Medicine/standards MH - Comorbidity MH - Patient Care Team/standards MH - Pulmonologists MH - Interdisciplinary Communication MH - Risk Factors MH - Cooperative Behavior MH - Prognosis MH - Predictive Value of Tests PMC - PMC11420896 OTO - NOTNLM OT - Canada OT - chronic obstructive pulmonary disease OT - consensus development OT - consultation and referral OT - health care OT - primary care COIS- No authors received honoraria from AstraZeneca for this project. Previous honoraria received by the authors includes: M Bhutani reports grants, contracts, consulting fees, support for travel, or honoraria from CIHR, AstraZeneca, GlaxoSmithKline, Novartis, Grifols, Sanofi, Takeda, Covis, Valeo, Lung Association of Saskatchewan, Canadian Thoracic Society, Lung Association of Alberta and Northwest Territories; leadership roles with Canadian Thoracic Society and Alberta Health Services; Canadian Thoracic Society Executive Committee, Co-Chair of the CTS COPD Clinical Assembly; Chair of the Royal College of Physicians and Surgeons Adult Respiratory Examination. J Bourbeau reports grants from McGill University, the McGill University Health Centre Foundation, the Canadian Institute Health Research, Grifols, Novartis, Sanofi, and the Respiratory Health Network of the Fonds de la recherche en sante du Quebec; grants and personal fees (honoraria) from Astra Zeneca Canada Ltd, Boehringer Ingelheim Canada Ltd, GlaxoSmithKline Canada Ltd, and Trudell Canada Ltd; and personal fees (honoraria) from Pfizer Canada Ltd, and COVIS Pharma Canada Ltd, outside the submitted work. SG Goodman reports research grant support (eg, steering committee or data and safety monitoring committee) and/or speaker/consulting honoraria (eg, advisory boards) from: Amgen, Alnylam, Anthos Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CSL Behring, CYTE Ltd., Daiichi-Sankyo/American Regent, Eli Lilly, Esperion, Ferring Pharmaceuticals, HLS Therapeutics, Idorsia, JAMP Pharma, Merck, Novartis, Novo Nordisk A/C, Pendopharm/Pharmascience, Pfizer, Regeneron, Roche, Sanofi, Servier, Tolmar Pharmaceuticals, Valeo Pharma; and salary support/honoraria from the Canadian Heart Failure Society, Canadian Heart Research Centre and MD Primer, Canadian VIGOUR Centre, Cleveland Clinic Coordinating Centre for Clinical Research, Duke Clinical Research Institute, Jewish General Hospital\ CIUSSS Centre-Ouest-de-l'Ile-de-Montreal, Peter Munk Cardiac Centre Clinical Trials and Translation Unit, Ted Rogers Centre for Heart Research, New York University Clinical Coordinating Centre, PERFUSE Research Institute, TIMI Study Group (Brigham Health). NM Hawkins reports research grant support, served on advisory boards for, or speaker engagements with AstraZeneca, Bayer, Boehringer Ingelheim, Novartis, Servier. AG Kaplan reports consulting fees or honoraria from AstraZeneca, ALK, Bellus, BI, Covis, Cipla, Eisai, GSK, Merck Frosst, Metapharm, Moderna, Novo Nordisk, Pfizer Sanofi, Teva, Trudell, Valeo; Chairperson of Family Physician Airways Group of Canada; Vice president of Respiratory Effectiveness Group. AGK is an honorary professor of primary care Respiratory Research, Observational and Pragmatic Research Institute; Medical director, local pulmonary rehabilitation program; Board member, Thrombosis Canada; Senate member of the International Primary Care Respiratory Group. P Lin reports speaker honorarium for CME events from AstraZeneca, GlaxoSmithKline, Medexus, Moderna, Pfizer, Amgen, Novo Nordisk, Boehringer-Ingelheim, and Eli Lilly. ED Penz reports consulting fees, support for travel, or honoraria from AstraZeneca, GlaxoSmithKline, Sanofi, Covis, LungSask, Canadian Thoracic Society, Valeo; research funds from CIHR, Saskatchewan Health Research Foundation, Respiratory Research Center, LungSask, Saskatchewan Centre for Patient oriented research, and AstraZeneca. She reports contract with Saskatchewan Cancer Agency for her role as medical advisor for the Saskatchewan Lung Screening program, board member of Institute of Cancer Research Advisory Board (CIHR), Canadian Thoracic Society Executive Committee, and Past Co-Chair of the CTS COPD Clinical Assembly. S Verma holds a Tier 1 Canada Research Chair in Cardiovascular Surgery, and reports receiving research grants and/or speaking honoraria from Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Canadian Medical and Surgical Knowledge Translation Research Group, Eli Lilly, HLS Therapeutics, Janssen, Novartis, Novo Nordisk, Pfizer, PhaseBio, S & L Solutions Event Management Inc, and Sanofi. He is the President of the Canadian Medical and Surgical Knowledge Translation Research Group, a federally incorporated not-for-profit physician organization. S Zieroth reports research grant support, served on advisory boards for, or speaker engagements with AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Cytokinetics, Eli Lilly, GSK, Janssen, Merck, Novartis, Novo-Nordisk, Otsuka, Pfizer, Roche, Servier and Vifor Pharma; and serves on a clinical trial committee or as a national lead for studies sponsored by AstraZeneca, Bayer, Boehringer Ingelheim, Merck, Novartis, and Pfizer. The authors report no other conflicts of interest in this work. EDAT- 2024/09/25 10:18 MHDA- 2024/09/25 10:19 PMCR- 2024/09/19 CRDT- 2024/09/25 04:21 PHST- 2024/05/31 00:00 [received] PHST- 2024/09/11 00:00 [accepted] PHST- 2024/09/25 10:19 [medline] PHST- 2024/09/25 10:18 [pubmed] PHST- 2024/09/25 04:21 [entrez] PHST- 2024/09/19 00:00 [pmc-release] AID - 471952 [pii] AID - 10.2147/COPD.S471952 [doi] PST - epublish SO - Int J Chron Obstruct Pulmon Dis. 2024 Sep 19;19:2051-2062. doi: 10.2147/COPD.S471952. eCollection 2024. PMID- 39318033 OWN - NLM STAT- MEDLINE DCOM- 20240925 LR - 20241003 IS - 1526-2359 (Electronic) IS - 1073-2748 (Print) IS - 1073-2748 (Linking) VI - 31 DP - 2024 Jan-Dec TI - Unveiling the Cardiotoxicity Conundrum: Navigating the Seas of Tyrosine Kinase Inhibitor Therapies. PG - 10732748241285755 LID - 10.1177/10732748241285755 [doi] LID - 10732748241285755 AB - Background: Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of various solid and hematologic malignancies by targeting dysregulated signaling pathways critical for malignant cell growth. However, these therapeutic benefits are often accompanied by cardiotoxicities, such as hypertension, left ventricular dysfunction, QT prolongation, and tachyarrhythmias, among others. These cardiotoxicities post a significant challenge in clinical management, often limiting the use of otherwise effective therapies. The underlying mechanism of TKI-induced cardiotoxicity appears to be multifaceted, involving several pathways including: direct cardiomyocyte damage, mitochondrial dysfunction, endothelial damage, and disruption of signaling pathways critical for cardiac function. The range and severity of cardiotoxicities vary significantly across different TKIs, necessitating a comprehensive understanding of each agent's specific cardiovascular risk profile. Preventing and managing TKI-induced cardiotoxicity requires a comprehensive, multidisciplinary approach. Early identification of at-risk patients through baseline cardiovascular risk assessments and appropriate monitoring during therapy is crucial. Strategies to mitigate cardiotoxic effects include dose modification, the use of cardioprotective agents, and temporary discontinuation of therapy. Additionally, decision making via multidisciplinary teams ensures minimization of cardiovascular complications while also continuing effective cancer treatment. Historically, data have been limited regarding cardiotoxicity and most cancer therapies, which certainly includes TKIs. This review aims to synthesize the current body of knowledge on TKI-associated cardiotoxicities, while highlighting the importance of vigilance and proactive management to minimize cardiovascular complications. FAU - Ekram, Jahanzaib AU - Ekram J AD - Morsani College of Medicine, University of South Florida, Tampa, FL, USA. RINGGOLD: 33697 AD - Department of Cardio-Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. FAU - Rathore, Azeem AU - Rathore A AD - Department of Internal Medicine, University of Florida Health Science Center, Gainesville, FL, USA. RINGGOLD: 440202 FAU - Avila, Carlos AU - Avila C AD - Department of Internal Medicine, Manatee Memorial Hospital, Bradenton, FL, USA. RINGGOLD: 24499 FAU - Hussein, Rahbia AU - Hussein R AD - Department of Internal Medicine, Manatee Memorial Hospital, Bradenton, FL, USA. RINGGOLD: 24499 FAU - Alomar, Mohammed AU - Alomar M AUID- ORCID: 0000-0002-4713-7245 AD - Morsani College of Medicine, University of South Florida, Tampa, FL, USA. RINGGOLD: 33697 AD - Department of Cardio-Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. LA - eng PT - Journal Article PT - Review PL - United States TA - Cancer Control JT - Cancer control : journal of the Moffitt Cancer Center JID - 9438457 RN - 0 (Protein Kinase Inhibitors) RN - 0 (Antineoplastic Agents) RN - EC 2.7.10.1 (Protein-Tyrosine Kinases) RN - 0 (Tyrosine Kinase Inhibitors) SB - IM MH - Humans MH - *Cardiotoxicity/prevention & control/etiology MH - *Protein Kinase Inhibitors/adverse effects MH - Neoplasms/drug therapy MH - Antineoplastic Agents/adverse effects MH - Protein-Tyrosine Kinases/antagonists & inhibitors MH - Tyrosine Kinase Inhibitors PMC - PMC11440564 OAB - Many Tyrosine Kinase Inhibitors have cardiac side effects. This article provides an up-to-date review of these toxicities. OABL- eng OTO - NOTNLM OT - cardiotoxicity OT - prevention OT - tyrosine kinase inhibitors COIS- Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2024/09/25 10:18 MHDA- 2024/09/25 10:19 PMCR- 2024/09/24 CRDT- 2024/09/25 00:33 PHST- 2024/09/25 10:19 [medline] PHST- 2024/09/25 10:18 [pubmed] PHST- 2024/09/25 00:33 [entrez] PHST- 2024/09/24 00:00 [pmc-release] AID - 10.1177_10732748241285755 [pii] AID - 10.1177/10732748241285755 [doi] PST - ppublish SO - Cancer Control. 2024 Jan-Dec;31:10732748241285755. doi: 10.1177/10732748241285755. PMID- 39313026 OWN - NLM STAT- MEDLINE DCOM- 20241026 LR - 20250326 IS - 1678-4391 (Electronic) IS - 1413-8670 (Print) IS - 1413-8670 (Linking) VI - 28 IP - 5 DP - 2024 Sep-Oct TI - Impact of multidisciplinary Endocarditis Team on management of infective endocarditis. PG - 103870 LID - S1413-8670(24)00153-3 [pii] LID - 10.1016/j.bjid.2024.103870 [doi] LID - 103870 AB - Infective Endocarditis (IE) is a complex, life-threatening disease. The aim of the present study was to evaluate the impact of the Endocarditis-Team on management of IE. This observational study conducted at a university hospital (2015‒22), included adult patients with IE. The study period was divided in two periods: before (pre-Endocarditis-Team; pre-ET) and after the establishment of the Endocarditis-Team (post-Endocarditis-Team; post-ET) on January 2018. Among 505 IE episodes (187 in pre-Endocarditis-Team, 318 in post-ET period), (18)F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography was more commonly used in post-ET period (14 % vs. 28 %; p < 0.001). Overall, thirty-day and one-year mortality were 14 % and 27 %, respectively; no difference was observed between the two periods. In post-ET period, the administration of 4-weeks, rather than 6-weeks, of intravenous antimicrobial treatment was higher than in the post-ET period (15 % vs. 45 %; p < 0.001). Indication for surgery was present in 115 (61 %) patients in pre-ET and in 153 (48 %) in the post-ET period. In post-ET period, among patients with indication, valve surgery was more frequently performed (66 % vs. 78 %; p = 0.038). Such difference was due to a higher acceptance of operative indication by the cardiac surgeon (69 % vs. 94 %; p = 0.013). The observed increase in number of patients benefiting from cardiac surgery in the post-ET period led to a decrease of subsequent embolic events, since among patients with operative indication (n = 268), new embolic events after the establishment of the indication were more common in the pre-ET period compared to post-ET (23 % vs. 12 %; p = 0.033). After the implementation of the multidisciplinary Endocarditis-Team we observed several improvements in the general management of IE patients. CI - Copyright (c) 2024 Sociedade Brasileira de Infectologia. Published by Elsevier Espana, S.L.U. All rights reserved. FAU - Fourre, Nicolas AU - Fourre N AD - Lausanne University Hospital and University of Lausanne, Infectious Diseases Service, Lausanne, Switzerland. FAU - Zimmermann, Virgile AU - Zimmermann V AD - Lausanne University Hospital and University of Lausanne, Infectious Diseases Service, Lausanne, Switzerland. FAU - Guery, Benoit AU - Guery B AD - Lausanne University Hospital and University of Lausanne, Infectious Diseases Service, Lausanne, Switzerland. FAU - Ianculescu, Nicoleta AU - Ianculescu N AD - Lausanne University Hospital and University of Lausanne, Department of Cardiology, Lausanne, Switzerland. FAU - Tozzi, Piergiorgio AU - Tozzi P AD - Lausanne University Hospital and University of Lausanne, Department of Cardiac Surgery, Lausanne, Switzerland. FAU - Kirsch, Matthias AU - Kirsch M AD - Lausanne University Hospital and University of Lausanne, Department of Cardiac Surgery, Lausanne, Switzerland. FAU - Monney, Pierre AU - Monney P AD - Lausanne University Hospital and University of Lausanne, Department of Cardiology, Lausanne, Switzerland. FAU - Papadimitriou-Olivgeris, Matthaios AU - Papadimitriou-Olivgeris M AD - Lausanne University Hospital and University of Lausanne, Infectious Diseases Service, Lausanne, Switzerland; Cantonal Hospital of Sion and Institut Central des Hopitaux (ICH), Infectious Diseases Service, Sion, Switzerland. Electronic address: Matthaios.Papadimitriou-Olivgeris@hopitalvs.ch. LA - eng PT - Journal Article PT - Observational Study DEP - 20240920 PL - Brazil TA - Braz J Infect Dis JT - The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases JID - 9812937 RN - 0 (Anti-Bacterial Agents) SB - IM MH - Humans MH - Male MH - Female MH - Middle Aged MH - *Endocarditis/mortality MH - *Patient Care Team MH - Aged MH - Adult MH - Positron Emission Tomography Computed Tomography MH - Anti-Bacterial Agents/therapeutic use MH - Treatment Outcome PMC - PMC11466630 OTO - NOTNLM OT - (18)F-FDG PET/CT OT - Embolic events OT - Endocarditis-Team OT - Infective endocarditis OT - Multidisciplinary management OT - Valve surgery COIS- Conflicts of interest The authors declare no conflicts of interest. EDAT- 2024/09/24 00:42 MHDA- 2024/10/27 17:11 PMCR- 2024/09/20 CRDT- 2024/09/23 19:22 PHST- 2024/02/20 00:00 [received] PHST- 2024/07/24 00:00 [revised] PHST- 2024/09/05 00:00 [accepted] PHST- 2024/10/27 17:11 [medline] PHST- 2024/09/24 00:42 [pubmed] PHST- 2024/09/23 19:22 [entrez] PHST- 2024/09/20 00:00 [pmc-release] AID - S1413-8670(24)00153-3 [pii] AID - 103870 [pii] AID - 10.1016/j.bjid.2024.103870 [doi] PST - ppublish SO - Braz J Infect Dis. 2024 Sep-Oct;28(5):103870. doi: 10.1016/j.bjid.2024.103870. Epub 2024 Sep 20. PMID- 39305305 OWN - NLM STAT- MEDLINE DCOM- 20240921 LR - 20260320 IS - 1468-2834 (Electronic) IS - 0002-0729 (Print) IS - 0002-0729 (Linking) VI - 53 IP - 9 DP - 2024 Sep 1 TI - Preoperative clinical characteristics and 12-month outcomes following operative or non-operative management of asymptomatic aortic aneurysms. LID - 10.1093/ageing/afae193 [doi] LID - afae193 AB - DESIGN: An observational cohort study conducted at a tertiary referral center for aortic surgery to describe the medical and surgical characteristics of patients assessed for abdominal aortic aneurysm repair and examine associations with 12-month outcome. METHODS: Patients with aortic aneurysms referred for discussion at the aortic multidisciplinary meeting (MDM). Data were collected via a prospectively maintained clinical database and included aneurysm characteristics, patient demographics, co-morbidities, geriatric syndromes, including frailty, management decision and 12-month mortality, both aneurysm-related and all-cause including cause of death. The operative and non-operative groups were compared statistically. RESULTS: 621 patients referred to aortic MDM; 292 patients listed for operative management, 141 patients continued on surveillance, 138 patients for non-operative management. There was a higher 12-month mortality rate in the non-operative group compared to the operative group (41% vs 7%, P = <0.001). In the non-operative group, 16 patients (29%) died of aneurysm rupture within 12 months, with 39 patients (71%) dying from other medical causes. Non-operatively managed patients were older, more likely to have cardiac and respiratory disease and more likely to be living with frailty, cognitive impairment and functional limitation, compared to the operative group. CONCLUSION: This study shows that preoperative geriatric syndromes and increased comorbidity lead to shared decision to non-operatively manage asymptomatic aortic aneurysms. Twelve-month mortality is higher in the non-operative group with the majority of deaths occurring due to cause other than aneurysm rupture. These findings support the need for preoperative comprehensive geriatric assessment followed by multispecialty discussion and shared decision making. CI - (c) The Author(s) 2024. Published by Oxford University Press on behalf of the British Geriatrics Society. FAU - Scarfield, Phoebe AU - Scarfield P AUID- ORCID: 0000-0002-9258-2532 AD - Perioperative Medicine for Older People Undergoing Surgery (POPS), Department of Ageing and Health, Guy's and St Thomas' NHS Foundation Trust, London SE1 9RT, UK. FAU - Sharkey, Amy R AU - Sharkey AR AD - Department of Cancer Imaging, School of Biomedical Engineering and Imaging Sciences, King's College London, London SE1 9RT, UK. AD - Department of Radiology, Guy's and St Thomas' NHS Foundation Trust, London SE1 9RT, UK. FAU - Dhesi, Jugdeep K AU - Dhesi JK AD - Honorary Professor, School of Life Course and Population Sciences, Faculty of Life Sciences and Medicine, King's College London, WC2R 2LS, UK. AD - Consultant Geriatrician, Perioperative Medicine for Older People Undergoing Surgery (POPS), Department of Ageing and Health, Guy's and St Thomas' NHS Foundation Trust, London SE1 9RT, UK. AD - Honorary Associate Professor Division of Surgery and Interventional Science, University College London, WC1E 6BT, UK. FAU - Modarai, Bijan AU - Modarai B AD - Consultant Vascular Surgeon, Guy's & St. Thomas' NHS Trust, SE1 7EH. AD - Professor of Vascular Surgery at King's College London and Guy's and St Thomas' NHS Trust, SE1 7EH. AD - School of Cardiovascular and Metabolic Medicine and Sciences, BHF Centre of Excellence, London WC2R 2LS, UK. FAU - Tyrrell, Mark R AU - Tyrrell MR AD - Consultant Vascular Surgeon, Guy's & St. Thomas' NHS Trust, SE1 7EH. AD - Cleveland Clinic London, SW1X 7HY. FAU - Partridge, Judith S L AU - Partridge JSL AD - Consultant Geriatrician, Perioperative Medicine for Older People Undergoing Surgery (POPS), Department of Ageing and Health, Guy's and St Thomas' NHS Foundation Trust, London SE1 9RT, UK. AD - Honorary Senior Lecturer, School of Life Course and Population Sciences, Faculty of Life Sciences and Medicine, King's College London, WC2R 2LS. LA - eng PT - Journal Article PT - Observational Study PL - England TA - Age Ageing JT - Age and ageing JID - 0375655 SB - IM MH - Humans MH - Aged MH - Female MH - Male MH - *Aortic Aneurysm, Abdominal/surgery/mortality MH - Aged, 80 and over MH - Treatment Outcome MH - Risk Factors MH - Asymptomatic Diseases MH - Time Factors MH - Frailty/diagnosis/mortality/epidemiology MH - Comorbidity MH - Vascular Surgical Procedures/adverse effects/mortality MH - Middle Aged MH - Age Factors MH - Cause of Death MH - Watchful Waiting/statistics & numerical data PMC - PMC11416039 OTO - NOTNLM OT - aortic aneurysm repair OT - aortic multidisciplinary meeting OT - comprehensive geriatric assessment OT - older people OT - realistic medicine OT - shared decision making COIS- None. EDAT- 2024/09/21 21:50 MHDA- 2024/09/21 21:51 PMCR- 2024/09/21 CRDT- 2024/09/21 11:13 PHST- 2024/02/12 00:00 [received] PHST- 2024/09/21 21:51 [medline] PHST- 2024/09/21 21:50 [pubmed] PHST- 2024/09/21 11:13 [entrez] PHST- 2024/09/21 00:00 [pmc-release] AID - 7763115 [pii] AID - afae193 [pii] AID - 10.1093/ageing/afae193 [doi] PST - ppublish SO - Age Ageing. 2024 Sep 1;53(9):afae193. doi: 10.1093/ageing/afae193. PMID- 39301669 OWN - NLM STAT- MEDLINE DCOM- 20250802 LR - 20250802 IS - 1938-2715 (Electronic) IS - 1049-9091 (Linking) VI - 42 IP - 9 DP - 2025 Sep TI - An Authentic Learning Experience for Medical Students on Conducting a Family Meeting. PG - 882-888 LID - 10.1177/10499091241286089 [doi] AB - BackgroundMedical schools often lack training for serious illness conversations with patients and caregivers. We developed a curriculum in our elective Transitioning to Residency medical student course, focused on end-of-life discussions. This paper provides an overview of the curriculum and outcomes from an advanced preparation assignment and student evaluations.MethodsThe curriculum included a "hands-on" skills session delivered via Zoom. Small groups of students (3-4) assumed roles on an interprofessional team (Intensivist, cardiologist, nurse, social worker). They met with two adult children, played by palliative/geriatric clinical staff, of a 79-year-old patient with a complex cardiac history and on ventilator support to address: (1) the patient's status, (2) goals of care, and (3) withdrawal of ventilator support. Using a flipped classroom format, students reviewed the case, role assignments, a family meeting webinar, and other materials in advance. They completed a survey reflecting on the upcoming family meeting. Afterwards, students evaluated the session.ResultsEighty students (19.6%) participated in 2021 and 2022. The reflection survey shows students agreed the patient's prognosis was poor and decision-making should be shared. They anticipated difficulty accepting prognosis, discordance between family members and/or the team, and challenging emotions. Results show a difference between the anticipated roles of the assigned physicians compared to the other disciplines. Post-session evaluations ranged from 4.7 to 4.9/5 (1 = strongly disagree, 5 = strongly agree).ConclusionThe pre-session reflection helped students prepare for their roles. The training was well received, and we hope it prepares students to take on serious illness discussions during residency. FAU - Khawand-Azoulai, Mariana AU - Khawand-Azoulai M AUID- ORCID: 0000-0001-8298-8769 AD - Division of Geriatrics and Palliative Medicine, University of Miami Miller School of Medicine, Miami, FL, USA. RINGGOLD: 12235 FAU - Kavensky, Elisse AU - Kavensky E AD - Division of Geriatrics and Palliative Medicine, University of Miami Miller School of Medicine, Miami, FL, USA. RINGGOLD: 12235 AD - Geriatrics and Palliative Medicine Physician, Conviva Care Center, Delray Beach, FL, USA. AD - Florida Atlantic University, Boca Raton, FL, USA. FAU - Sanchez, Julia AU - Sanchez J AD - Division of Geriatrics and Palliative Medicine, University of Miami Miller School of Medicine, Miami, FL, USA. RINGGOLD: 12235 FAU - Leyva, Ileana M AU - Leyva IM AD - VITAS Healthcare, Miami, FL, USA. RINGGOLD: 138143 FAU - Ferrari, Corinne AU - Ferrari C AD - Sylvester Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA. RINGGOLD: 12235 FAU - Soares, Marcio AU - Soares M AD - Division of Geriatrics and Palliative Medicine, University of Miami Miller School of Medicine, Miami, FL, USA. RINGGOLD: 12235 FAU - Zaw, Khin M AU - Zaw KM AD - Division of Geriatrics and Palliative Care, University of Miami Miller School of Medicine, Miami, FL, USA. RINGGOLD: 12235 FAU - van Zuilen, Maria H AU - van Zuilen MH AD - Department of Medical Education, University of Miami Miller School of Medicine, Miami, FL, USA. RINGGOLD: 12235 LA - eng PT - Journal Article DEP - 20240920 PL - United States TA - Am J Hosp Palliat Care JT - The American journal of hospice & palliative care JID - 9008229 SB - IM MH - Humans MH - *Students, Medical/psychology MH - Curriculum MH - Aged MH - *Professional-Family Relations MH - *Terminal Care/organization & administration MH - Male MH - Communication MH - Female MH - *Education, Medical, Undergraduate/organization & administration MH - Palliative Care MH - Clinical Competence MH - Adult OTO - NOTNLM OT - communication skills OT - end-of-life care OT - family meeting OT - flipped classroom OT - medical education OT - medical students OT - role play OT - serious illness communication OT - withdrawal of medical interventions COIS- Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2024/09/21 13:19 MHDA- 2025/08/02 10:42 CRDT- 2024/09/20 04:32 PHST- 2025/08/02 10:42 [medline] PHST- 2024/09/21 13:19 [pubmed] PHST- 2024/09/20 04:32 [entrez] AID - 10.1177/10499091241286089 [doi] PST - ppublish SO - Am J Hosp Palliat Care. 2025 Sep;42(9):882-888. doi: 10.1177/10499091241286089. Epub 2024 Sep 20. PMID- 39302946 OWN - NLM STAT- MEDLINE DCOM- 20240920 LR - 20261001 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 19 IP - 9 DP - 2024 TI - Outcomes of in-hospital cardiac arrest managed with and without a specialized code team: A retrospective observational study. PG - e0309376 LID - 10.1371/journal.pone.0309376 [doi] LID - e0309376 AB - BACKGROUND: In-hospital cardiac arrest (IHCA) still has a poor prognosis despite medical advancements in recent decades. Early and high-quality cardiopulmonary resuscitation (CPR), as well as good teamwork, are important prognostic factors. There are no clear guidelines regarding the composition of a dedicated hospital CPR team. We compared outcomes of IHCA treated by a dedicated hospital CPR team compared to ward medical staff with advanced cardiac life support (ACLS) training. METHODS: A single-center retrospective observational study based on the cardiopulmonary resuscitation database of Soroka University Medical Center from January 2016 until December 2019. We compared the results of resuscitations conducted by regular ward medical staff, certified in ACLS, versus those conducted by the dedicated hospital's CPR team. RESULTS: Of the 360 CPR events analyzed, 141 (39.1%) ended in return of spontaneous circulation, 70 (19.4%) patients were alive after 24 hours, 23 (6.4%) survived for 30 days, and 18 (5%) survived to discharge. Of those who survived to discharge, 11 (61.1%) had a cerebral performance category (CPC) score of 1-2, and 7 (38.9%) had a score of 3-4 (mean 2.09). Survival-to-discharge was significantly higher in the CPR-team group compared to the ward-team group (7.6% vs. 1.9%, p = 0.013). However, with propensity score analysis the difference in survival became insignificant (RR = 1.97, 95% CI: 0.40-9.63, p = 0.40). CONCLUSION: We found no difference in survival between IHCA treated by a dedicated hospital CPR team compared to a standard ward team, both trained with biennial ACLS training. Nevertheless, crude survival-to-discharge was significantly higher in the CPR-team group. CI - Copyright: (c) 2024 Abu Fraiha et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. FAU - Abu Fraiha, Yasmeen AU - Abu Fraiha Y AUID- ORCID: 0000-0002-3326-397X AD - Department of Internal Medicine B, Soroka University Medical Center and Faculty of Health Sciences, Ben-Gurion University of the Negev, Be'er Sheva, Israel. FAU - Shafat, Tali AU - Shafat T AD - Infectious Diseases Unit, Soroka University Medical Center and Faculty of Health Sciences, Ben-Gurion University of the Negev, Be'er Sheva, Israel. FAU - Codish, Shlomi AU - Codish S AD - Medical Administration, Soroka University Medical Center and Faculty of Health Sciences, Ben-Gurion University of the Negev, Be'er Sheva, Israel. FAU - Frenkel, Amit AU - Frenkel A AD - Surgical Intensive Care Unit, Soroka University Medical Center and Faculty of Health Sciences, Ben-Gurion University of the Negev, Be'er Sheva, Israel. FAU - Dolfin, Dror AU - Dolfin D AUID- ORCID: 0000-0002-0755-3885 AD - Medical Administration, Soroka University Medical Center and Faculty of Health Sciences, Ben-Gurion University of the Negev, Be'er Sheva, Israel. FAU - Dreiher, Jacob AU - Dreiher J AD - Medical Administration, Soroka University Medical Center and Faculty of Health Sciences, Ben-Gurion University of the Negev, Be'er Sheva, Israel. FAU - Konstantino, Yuval AU - Konstantino Y AD - Department of Cardiology, Soroka University Medical Center and Faculty of Health Sciences, Ben-Gurion University of the Negev, Be'er Sheva, Israel. FAU - Abu Abed, Said AU - Abu Abed S AD - Pediatrics Department, Soroka University Medical Center and Faculty of Health Sciences, Ben-Gurion University of the Negev, Be'er Sheva, Israel. FAU - Schwartz, Doron AU - Schwartz D AD - Medical Administration, Soroka University Medical Center and Faculty of Health Sciences, Ben-Gurion University of the Negev, Be'er Sheva, Israel. FAU - Fichman, Alexander AU - Fichman A AD - Surgical Intensive Care Unit, Soroka University Medical Center and Faculty of Health Sciences, Ben-Gurion University of the Negev, Be'er Sheva, Israel. FAU - Kvich, Luba AU - Kvich L AD - Medical Administration, Soroka University Medical Center and Faculty of Health Sciences, Ben-Gurion University of the Negev, Be'er Sheva, Israel. FAU - Galante, Ori AU - Galante O AD - Medical Intensive Care Unit, Soroka University Medical Center and Faculty of Health Sciences, Ben-Gurion University of the Negev, Be'er Sheva, Israel. LA - eng PT - Journal Article PT - Observational Study PT - Research Support, Non-U.S. Gov't DEP - 20240920 PL - United States TA - PLoS One JT - PloS one JID - 101285081 SB - IM MH - Humans MH - Retrospective Studies MH - *Heart Arrest/therapy/mortality MH - *Cardiopulmonary Resuscitation MH - Male MH - Female MH - Aged MH - Middle Aged MH - Patient Care Team MH - Aged, 80 and over MH - Treatment Outcome MH - Advanced Cardiac Life Support PMC - PMC11414910 COIS- The authors have declared that no competing interests exist. EDAT- 2024/09/20 19:08 MHDA- 2024/09/20 19:09 PMCR- 2024/09/20 CRDT- 2024/09/20 13:34 PHST- 2024/05/16 00:00 [received] PHST- 2024/08/09 00:00 [accepted] PHST- 2024/09/20 19:09 [medline] PHST- 2024/09/20 19:08 [pubmed] PHST- 2024/09/20 13:34 [entrez] PHST- 2024/09/20 00:00 [pmc-release] AID - PONE-D-24-16710 [pii] AID - 10.1371/journal.pone.0309376 [doi] PST - epublish SO - PLoS One. 2024 Sep 20;19(9):e0309376. doi: 10.1371/journal.pone.0309376. eCollection 2024. PMID- 39300340 OWN - NLM STAT- MEDLINE DCOM- 20240919 LR - 20250714 IS - 1471-2261 (Electronic) IS - 1471-2261 (Linking) VI - 24 IP - 1 DP - 2024 Sep 19 TI - The effect of early initiation of self-management program based on multidisciplinary education in heart failure patients. PG - 503 LID - 10.1186/s12872-024-04185-3 [doi] LID - 503 AB - AIMS: To explore the effect of early initiation of self-management based on multidisciplinary education in heart failure (HF) patients. METHODS: HF patients in the Cardiology Department of Beijing Hospital were consecutively enrolled from June 2022 to February 2023. In-hospital HF patients from June 2022 to October 2022 were divided into the control group, and HF patients from November 2022 to February 2023 were divided into the cardiac rehabilitation (CR) group. A series of self-management education sessions with cardiologists, pharmacologists, nutritionists, and nurses was initiated early in the CR group. Continuous strengthening education was provided during the 3 months of discharge. Patients in the control group only received education twice during hospitalization. Minnesota Living with Heart Failure Questionnaire (MLHFQ), Pittsburgh sleep quality index (PSQI), anxiety Self-rating anxiety scale (SAS), and Self-rating depression scale (SDS) were compared between the two groups. Major cardiovascular adverse events (MACEs) were recorded during follow-up. RESULTS: A total of 91 HF patients were enrolled. There were 44 patients in the CR group and 47 in the control group. Compared with before the program, the MLHFQ and SAS scores significantly decreased at 3 months after discharge in both groups. PSQI also showed mild improvement without significant differences in both groups. Furthermore, SDS showed a significant increase in the CR group but within the normal range. MACE occurrences did not show a significant difference. CONCLUSION: Early initiation of self-management program based on multidisciplinary education may help improve quality of life, sleep quality, and reduce anxiety for hospitalized HF patients. CI - (c) 2024. The Author(s). FAU - Jia, Na AU - Jia N AD - Cardiology Department, Beijing Hospital, National Center of Gerontology, National Health Commission Institute of Geriatric medicine, Chinese Academy of medical sciences, Beijing, China. FAU - Zhao, Yajie AU - Zhao Y AD - Cardiology Department, Beijing Hospital, National Center of Gerontology, National Health Commission Institute of Geriatric medicine, Chinese Academy of medical sciences, Beijing, China. FAU - Sun, Xuelin AU - Sun X AD - Pharmacology Department, Beijing Hospital, National Center of Gerontology, National Health Commission Institute of Geriatric medicine, Chinese Academy of medical sciences, Beijing, China. FAU - Wang, Mingfang AU - Wang M AD - Nutrition Department, Beijing Hospital, National Center of Gerontology, National Health Commission Institute of Geriatric medicine, Chinese Academy of medical sciences, Beijing, China. FAU - Guo, Di AU - Guo D AD - Cardiology Department, Beijing Hospital, National Center of Gerontology, National Health Commission Institute of Geriatric medicine, Chinese Academy of medical sciences, Beijing, China. guodi3878@bjhmoh.cn. LA - eng GR - BJ-2023-137/National High Level Hospital Clinical Research Funding/ GR - BJ-2021-215/National High Level Hospital Clinical Research Funding/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240919 PL - England TA - BMC Cardiovasc Disord JT - BMC cardiovascular disorders JID - 100968539 SB - IM MH - Humans MH - Male MH - Female MH - *Heart Failure/diagnosis/physiopathology/therapy/rehabilitation/mortality MH - *Patient Education as Topic MH - Middle Aged MH - Aged MH - *Self-Management MH - *Cardiac Rehabilitation/methods MH - Time Factors MH - Treatment Outcome MH - *Quality of Life MH - Self Care MH - Patient Care Team MH - Health Knowledge, Attitudes, Practice MH - Program Evaluation MH - Beijing PMC - PMC11411793 OTO - NOTNLM OT - Cardiac rehabilitation OT - Heart failure OT - Patient education OT - Self management COIS- The authors declare no competing interests. EDAT- 2024/09/20 01:06 MHDA- 2024/09/20 01:07 PMCR- 2024/09/19 CRDT- 2024/09/19 23:41 PHST- 2024/03/16 00:00 [received] PHST- 2024/09/11 00:00 [accepted] PHST- 2024/09/20 01:07 [medline] PHST- 2024/09/20 01:06 [pubmed] PHST- 2024/09/19 23:41 [entrez] PHST- 2024/09/19 00:00 [pmc-release] AID - 10.1186/s12872-024-04185-3 [pii] AID - 4185 [pii] AID - 10.1186/s12872-024-04185-3 [doi] PST - epublish SO - BMC Cardiovasc Disord. 2024 Sep 19;24(1):503. doi: 10.1186/s12872-024-04185-3. PMID- 39300000 OWN - NLM STAT- MEDLINE DCOM- 20250708 LR - 20250708 IS - 1439-0973 (Electronic) IS - 0300-8126 (Print) IS - 0300-8126 (Linking) VI - 53 IP - 1 DP - 2025 Feb TI - Non-HACEK gram-negative bacilli infective endocarditis: data from a retrospective German cohort study. PG - 405-413 LID - 10.1007/s15010-024-02392-w [doi] AB - PURPOSE: Infective endocarditis caused by non-HACEK gram-negative bacilli (GNB-IE) is rare but associated with significant morbidity and case fatality. Evidence on optimal treatment and management is limited. We aimed to describe the characteristics and management of GNB-IE patients, investigating factors associated with disease acquisition and unfavorable outcomes. METHODS: We conducted a retrospective descriptive single-center study (tertiary care and referral hospital) between 2015 and 2021, including adult patients with definite GNB-IE. We reviewed demographic, clinical and microbiological data, focusing on predisposing factors, clinical outcomes and 1-year mortality. RESULTS: Of 1093 patients with probable or definite IE, 19 patients (median age 69 years) had definite GNB-IE, with an increasing incidence throughout the study period. Median age-adjusted Charlson Comorbidity Index score was 4 points. Prosthetic valve IE (PVIE) was present in 7/19 (37%) patients. Nosocomial acquisition occurred in 8/19 (42%) patients. Escherichia coli and Klebsiella pneumoniae were the most common pathogens. Beta-lactam (BL) based combination therapy was applied in 12/19 (63%) patients (58% BL + fluoroquinolone, 42% BL + aminoglycoside). Cardiac surgery was required in 8/19 (42%) patients (PVIE 71%, native valve IE 25%), primarily for embolism prevention and heart failure. Complications occurred in 14/19 (74%) patients. The in-hospital mortality rate was 21% (4/19); the one-year mortality rate was 44% (7/16). One-year mortality did not significantly differ between patients who underwent cardiac surgery and patients managed with anti-infective treatment alone (p = 0.633). CONCLUSIONS: GNB-IE affects elderly patients with high comorbidity levels and recent health-care exposure. GNB-IE was associated with high complication rates and high mortality. CI - (c) 2024. The Author(s). FAU - Dorfler, Juliane AU - Dorfler J AUID- ORCID: 0009-0008-8642-6067 AD - Department of Infectious Diseases, Respiratory Medicine and Critical Care, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Augustenburger Platz 1, 13353, Berlin, Germany. FAU - Grubitzsch, Herko AU - Grubitzsch H AD - Deutsches Herzzentrum der Charite - Klinik fur Herz-, Thorax- und Gefasschirurgie, (Department of Cardiothoracic and Vascular Surgery), Augustenburger Platz 1, 13353, Berlin, Germany. AD - Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Chariteplatz 1, 10117, Berlin, Germany. FAU - Schneider-Reigbert, Matthias AU - Schneider-Reigbert M AD - Deutsches Herzzentrum der Charite - Klinik fur Kardiologie, Angiologie und Intensivmedizin (Department of Cardiology, Angiology and Intensive Care Medicine), Augustenburger Platz 1, 13353, Berlin, Germany. AD - Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Chariteplatz 1, 10117, Berlin, Germany. AD - DZHK (German Center for Cardiovascular Research) Partner Site Berlin, Berlin, Germany. FAU - Pasic, Miralem AU - Pasic M AD - Deutsches Herzzentrum der Charite - Klinik fur Herz-, Thorax- und Gefasschirurgie, (Department of Cardiothoracic and Vascular Surgery), Augustenburger Platz 1, 13353, Berlin, Germany. AD - Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Chariteplatz 1, 10117, Berlin, Germany. FAU - Pfafflin, Frieder AU - Pfafflin F AD - Department of Infectious Diseases, Respiratory Medicine and Critical Care, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Augustenburger Platz 1, 13353, Berlin, Germany. FAU - Stegemann, Miriam AU - Stegemann M AD - Department of Infectious Diseases, Respiratory Medicine and Critical Care, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Augustenburger Platz 1, 13353, Berlin, Germany. FAU - Sander, Leif E AU - Sander LE AD - Department of Infectious Diseases, Respiratory Medicine and Critical Care, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Augustenburger Platz 1, 13353, Berlin, Germany. AD - German Center for Lung Research, DZL, Berlin, Germany. AD - Berlin Institute of Health, Berlin, Germany. FAU - Kurth, Florian AU - Kurth F AD - Department of Infectious Diseases, Respiratory Medicine and Critical Care, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Augustenburger Platz 1, 13353, Berlin, Germany. FAU - Lingscheid, Tilman AU - Lingscheid T AD - Department of Infectious Diseases, Respiratory Medicine and Critical Care, Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Augustenburger Platz 1, 13353, Berlin, Germany. tilman.lingscheid@charite.de. LA - eng PT - Journal Article DEP - 20240919 PL - Germany TA - Infection JT - Infection JID - 0365307 RN - 0 (beta-Lactams) SB - IM MH - *Endocarditis/diagnosis/drug therapy/microbiology/surgery MH - Humans MH - Male MH - Female MH - Aged MH - Escherichia coli/isolation & purification MH - Klebsiella pneumoniae/isolation & purification MH - *Cross Infection/complications/diagnosis/drug therapy MH - beta-Lactams/therapeutic use MH - *Escherichia coli Infections/complications/diagnosis/drug therapy MH - *Klebsiella Infections/complications/diagnosis/drug therapy MH - Germany PMC - PMC11825580 OTO - NOTNLM OT - Cardiac surgery OT - Combination antibiotic therapy OT - Echocardiography OT - Endocarditis team OT - Endoplastitis OT - Enterobacterales COIS- Declarations. Ethical approval: The study was performed in accordance with the principles of the Declaration of Helsinki. The need for informed consent was waived in line with the applicable local law ( section sign 25 LKHG Bln), as the data and samples were analyzed retrospectively, and the study was noninterventional in nature. Use of artificial intelligence tools: AI was used to correct spelling and grammar. Competing interests: The authors declare no competing interests. EDAT- 2024/09/20 01:05 MHDA- 2025/02/14 00:24 PMCR- 2024/09/19 CRDT- 2024/09/19 23:15 PHST- 2024/06/23 00:00 [received] PHST- 2024/09/09 00:00 [accepted] PHST- 2025/02/14 00:24 [medline] PHST- 2024/09/20 01:05 [pubmed] PHST- 2024/09/19 23:15 [entrez] PHST- 2024/09/19 00:00 [pmc-release] AID - 10.1007/s15010-024-02392-w [pii] AID - 2392 [pii] AID - 10.1007/s15010-024-02392-w [doi] PST - ppublish SO - Infection. 2025 Feb;53(1):405-413. doi: 10.1007/s15010-024-02392-w. Epub 2024 Sep 19. PMID- 39296347 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240920 IS - 2296-875X (Print) IS - 2296-875X (Electronic) IS - 2296-875X (Linking) VI - 11 DP - 2024 TI - Interprofessional education in cardiothoracic surgery: a narrative review. PG - 1467940 LID - 10.3389/fsurg.2024.1467940 [doi] LID - 1467940 AB - Interprofessional education, an approach where healthcare professionals from various disciplines learn with, from, and about each other, is widely recognized as an important strategy for improving collaborative practice and patient outcomes. This narrative review explores the current state and future directions of interprofessional education in cardiothoracic surgery. We conducted a literature search using the PubMed, Scopus, and Web of Science databases, focusing on English-language articles published after 2000. Our qualitative synthesis identified key themes related to interprofessional education interventions, outcomes, and challenges. The integration of interprofessional education in cardiothoracic surgery training programs varies across regions, with a common focus on teamwork and interpersonal communication. Simulation-based training has emerged as a leading modality for cultivating these skills in multidisciplinary settings, with studies showing improvements in team performance, crisis management, and patient safety. However, significant hurdles remain, including professional socialization, hierarchies, stereotypes, resistance to role expansion, and logistical constraints. Future efforts in this field should prioritize deeper curricular integration, continuous faculty development, strong leadership support, robust outcome evaluation, and sustained political and financial commitment. The integration of interprofessional education in cardiothoracic surgery offers considerable potential for enhancing patient care quality, but realizing this vision requires a multifaceted approach. This approach must address individual, organizational, and systemic factors to build an evidence-based framework for implementation. CI - (c) 2024 Lampridis, Scarci and Cerfolio. FAU - Lampridis, Savvas AU - Lampridis S AD - National Heart and Lung Institute, Faculty of Medicine, Imperial College London, London, United Kingdom. AD - Department of Thoracic Surgery, 424 General Military Hospital, Thessaloniki, Greece. FAU - Scarci, Marco AU - Scarci M AD - National Heart and Lung Institute, Faculty of Medicine, Imperial College London, London, United Kingdom. AD - Department of Cardiothoracic Surgery, Hammersmith Hospital, London, United Kingdom. FAU - Cerfolio, Robert J AU - Cerfolio RJ AD - Department of Cardiothoracic Surgery, New York University Langone Health, New York, NY, United States. LA - eng PT - Journal Article PT - Review DEP - 20240904 PL - Switzerland TA - Front Surg JT - Frontiers in surgery JID - 101645127 PMC - PMC11408362 OTO - NOTNLM OT - cardiothoracic surgery OT - curriculum OT - interprofessional collaboration OT - interprofessional education OT - multidisciplinary team OT - simulation OT - surgical education COIS- The authors declare that the review was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision. EDAT- 2024/09/19 06:43 MHDA- 2024/09/19 06:44 PMCR- 2024/09/04 CRDT- 2024/09/19 04:57 PHST- 2024/07/21 00:00 [received] PHST- 2024/08/21 00:00 [accepted] PHST- 2024/09/19 06:44 [medline] PHST- 2024/09/19 06:43 [pubmed] PHST- 2024/09/19 04:57 [entrez] PHST- 2024/09/04 00:00 [pmc-release] AID - 10.3389/fsurg.2024.1467940 [doi] PST - epublish SO - Front Surg. 2024 Sep 4;11:1467940. doi: 10.3389/fsurg.2024.1467940. eCollection 2024. PMID- 20301722 STAT- Publisher DRDT- 20240919 CTDT- 20080717 PB - University of Washington, Seattle DP - 1993 TI - Shwachman-Diamond Syndrome. BTI - GeneReviews((R)) AB - CLINICAL CHARACTERISTICS: Shwachman-Diamond syndrome (SDS) is characterized by exocrine pancreatic dysfunction with malabsorption, malnutrition, and growth failure; hematologic abnormalities with single- or multilineage cytopenias and susceptibility to myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML); and bone abnormalities. In almost all affected children, persistent or intermittent neutropenia is an early finding. Short stature and recurrent infections are common. DIAGNOSIS/TESTING: The diagnosis of SDS is established in a proband with the classic clinical findings of exocrine pancreatic dysfunction and bone marrow dysfunction and/or biallelic pathogenic variants in DNAJC21, EFL1, or SBDS or a heterozygous pathogenic variant in SRP54 identified by molecular genetic testing. MANAGEMENT: Treatment of manifestations: Care by a multidisciplinary team is highly recommended. Exocrine pancreatic insufficiency is treated with oral pancreatic enzymes and fat-soluble vitamin supplementation. Blood and/or platelet transfusions may be considered for anemia and thrombocytopenia. If recurrent infections are severe and absolute neutrophil counts are persistently /=12th grade have higher knowledge in various items and, overall, the complexity of CHD was not associated with a better performance. CONCLUSION: This study highlights the existing knowledge gaps among adults with CHD. It underscores the need for tailored information and structured educational programs to improve management. By addressing these challenges, healthcare providers can enhance patient outcomes, improve quality of life, and promote long-term well-being for individuals with CHD. CI - Copyright (c) 2024 Sociedade Portuguesa de Cardiologia. Publicado por Elsevier Espana, S.L.U. All rights reserved. FAU - Barbas de Albuquerque, Francisco AU - Barbas de Albuquerque F AD - Department of Cardiology and Reference Center for Congenital Heart Diseases CHULC, Member of the European Reference Network for Rare, Low Prevalence Complex Disease of the Heart (ERN GUARD-Heart), Hospital de Santa Marta, Unidade Local de Saude Sao Jose, Lisboa, Portugal. Electronic address: Francisco.22.albuquerque@gmail.com. FAU - Neves, Ines AU - Neves I AD - Department of Cardiology and Reference Center for Congenital Heart Diseases CHULC, Member of the European Reference Network for Rare, Low Prevalence Complex Disease of the Heart (ERN GUARD-Heart), Hospital de Santa Marta, Unidade Local de Saude Sao Jose, Lisboa, Portugal. FAU - Teixeira, Rita AU - Teixeira R AD - Department of Cardiology and Reference Center for Congenital Heart Diseases CHULC, Member of the European Reference Network for Rare, Low Prevalence Complex Disease of the Heart (ERN GUARD-Heart), Hospital de Santa Marta, Unidade Local de Saude Sao Jose, Lisboa, Portugal. FAU - Mano, Tania AU - Mano T AD - Department of Cardiology and Reference Center for Congenital Heart Diseases CHULC, Member of the European Reference Network for Rare, Low Prevalence Complex Disease of the Heart (ERN GUARD-Heart), Hospital de Santa Marta, Unidade Local de Saude Sao Jose, Lisboa, Portugal. FAU - Rito, Tiago AU - Rito T AD - Department of Pediatric Cardiology and Reference Center for Congenital Heart Diseases CHULC, Member of the European Reference Network for Rare, Low Prevalence Complex Disease of the Heart (ERN GUARD-Heart), Hospital de Santa Marta, Unidade Local de Saude Sao Jose, Lisboa, Portugal. FAU - O Costa, Pedro AU - O Costa P AD - Department of Pediatric Cardiology and Reference Center for Congenital Heart Diseases CHULC, Member of the European Reference Network for Rare, Low Prevalence Complex Disease of the Heart (ERN GUARD-Heart), Hospital de Santa Marta, Unidade Local de Saude Sao Jose, Lisboa, Portugal. FAU - Ferreira, Rui AU - Ferreira R AD - Department of Cardiology and Reference Center for Congenital Heart Diseases CHULC, Member of the European Reference Network for Rare, Low Prevalence Complex Disease of the Heart (ERN GUARD-Heart), Hospital de Santa Marta, Unidade Local de Saude Sao Jose, Lisboa, Portugal. FAU - de Sousa, Lidia AU - de Sousa L AD - Department of Cardiology and Reference Center for Congenital Heart Diseases CHULC, Member of the European Reference Network for Rare, Low Prevalence Complex Disease of the Heart (ERN GUARD-Heart), Hospital de Santa Marta, Unidade Local de Saude Sao Jose, Lisboa, Portugal. FAU - Pinto, Fatima AU - Pinto F AD - Department of Pediatric Cardiology and Reference Center for Congenital Heart Diseases CHULC, Member of the European Reference Network for Rare, Low Prevalence Complex Disease of the Heart (ERN GUARD-Heart), Hospital de Santa Marta, Unidade Local de Saude Sao Jose, Lisboa, Portugal. LA - eng LA - por PT - Journal Article PT - Observational Study DEP - 20240914 PL - Portugal TA - Rev Port Cardiol JT - Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology JID - 8710716 SB - IM MH - Humans MH - Cross-Sectional Studies MH - *Heart Defects, Congenital/therapy/psychology MH - Female MH - Male MH - Adult MH - *Health Knowledge, Attitudes, Practice MH - Middle Aged MH - Young Adult OTO - NOTNLM OT - Adult congenital heart disease OT - Anomalias congenitas OT - Cardiopatia congenita do adulto OT - Congenital anomalies OT - Health literacy OT - Leuven Knowledge Questionnaire OT - Literacia em saude OT - Medidas preventivas OT - Preventive measures EDAT- 2024/09/16 00:42 MHDA- 2025/02/03 00:19 CRDT- 2024/09/15 19:27 PHST- 2024/01/08 00:00 [received] PHST- 2024/04/08 00:00 [revised] PHST- 2024/06/27 00:00 [accepted] PHST- 2025/02/03 00:19 [medline] PHST- 2024/09/16 00:42 [pubmed] PHST- 2024/09/15 19:27 [entrez] AID - S0870-2551(24)00275-0 [pii] AID - 10.1016/j.repc.2024.06.006 [doi] PST - ppublish SO - Rev Port Cardiol. 2025 Feb;44(2):95-103. doi: 10.1016/j.repc.2024.06.006. Epub 2024 Sep 14. PMID- 39278534 OWN - NLM STAT- MEDLINE DCOM- 20241213 LR - 20260518 IS - 1097-6833 (Electronic) IS - 0022-3476 (Linking) VI - 276 DP - 2025 Jan TI - A National Simulation-Based Study of Pediatric Critical Care Transport Teams Performance. PG - 114303 LID - S0022-3476(24)00406-2 [pii] LID - 10.1016/j.jpeds.2024.114303 [doi] AB - OBJECTIVES: To assess pediatric critical care transport (CCT) teams' performance in a simulated environment and to explore the impact of team and center characteristics on performance. STUDY DESIGN: This observational, multicenter, simulation-based study enlisted a national cohort of pediatric transport centers. Teams participated in 3 scenarios: nonaccidental abusive head injury, sepsis, and cardiac arrest. The primary outcome was teams' simulation performance score. Secondary outcomes were associations between performance, center and team characteristics. RESULTS: We recruited 78 transport teams with 196 members from 12 CCT centers. Scores on performance measures that were developed were 89% (IQR 78-100) for nonaccidental abusive head injury, 63.3% (IQR 45.5-81.8) for sepsis, and 86.6% (IQR 66.6-93.3) for cardiac arrest. In multivariable analysis, overall performance was higher for teams including a respiratory therapist (0.5 points [95% CI: 0.13, 0.86]) or paramedic (0.49 points [95% CI: 0.1, 0.88]) and dedicated pediatric teams (0.37 points [95% 0.06, 0.68]). Each year increase in program age was associated with an increase of 0.04 points (95% CI: 0.02, 0.06). CONCLUSIONS: Dedicated pediatric teams, inclusion of respiratory therapists and paramedics, and center age were associated with higher simulation scores for pediatric CCT teams. These insights can guide efforts to enhance the quality of care for children during interfacility transports. CI - Copyright (c) 2024 Elsevier Inc. All rights reserved. FAU - Montgomery, Erin E AU - Montgomery EE AD - Division of Pediatric Critical Care Medicine, Department of Pediatrics, Indiana University School of Medicine and Riley Hospital for Children at Indiana University Health, Indianapolis, IN. FAU - Anderson, Ingrid M AU - Anderson IM AD - Pediatric Emergency Medicine, Case Western Reserve University Hospitals Rainbow Babies & Children's Hospital, Cleveland, OH. FAU - Scherzer, Daniel J AU - Scherzer DJ AD - Nationwide Children's Hospital, Columbus, OH. FAU - Arteaga, Grace M AU - Arteaga GM AD - Mayo Clinic College of Medicine and Science. FAU - Rozenfeld, Ranna A AU - Rozenfeld RA AD - Hasbro Children's Hospital. FAU - Wing, Robyn AU - Wing R AD - Hasbro Children's Hospital. FAU - Umoren, Rachel A AU - Umoren RA AD - University of Washington. FAU - Wall, Jessica J AU - Wall JJ AD - University of Washington. FAU - McKissic, Devin A AU - McKissic DA AD - University of Washington. FAU - Centers, Gabriela I AU - Centers GI AD - Medical City Children's Hospital, Dallas TX. FAU - Searly, Callie R AU - Searly CR AD - Children's Hospital Colorado, Aurora, CO. FAU - Mandt, Maria J AU - Mandt MJ AD - Children's Hospital Colorado, Aurora, CO. FAU - Jackson, Brian M AU - Jackson BM AD - Children's Hospital Colorado, Aurora, CO. FAU - Hulfish, Erin W AU - Hulfish EW AD - Stony Brook Children's Hospital. FAU - Maloney, Lauren M AU - Maloney LM AD - Brook University Hospital. FAU - Duman-Bender, Tina M AU - Duman-Bender TM AD - Akron Children's Hospital, Akron, OH. FAU - Kennedy, Christopher AU - Kennedy C AD - Akron Children's Hospital, Akron, OH; Children's Mercy Hospital. FAU - Adler, Mark AU - Adler M AD - Ann and Robert H Lurie Children's Hospital of Chicago. FAU - Naples, Jeffrey AU - Naples J AD - Akron Children's Hospital, Akron, OH. FAU - Luk, Jeffrey AU - Luk J AD - Pediatric Emergency Medicine, Case Western Reserve University Hospitals Rainbow Babies & Children's Hospital, Cleveland, OH. FAU - Gleich, Stephen J AU - Gleich SJ AD - Mayo Clinic College of Medicine and Science. FAU - Lutfi, Riad AU - Lutfi R AD - Division of Pediatric Critical Care Medicine, Department of Pediatrics, Indiana University School of Medicine and Riley Hospital for Children at Indiana University Health, Indianapolis, IN. FAU - Pearson, Kellie J AU - Pearson KJ AD - Division of Pediatric Critical Care Medicine, Department of Pediatrics, Indiana University School of Medicine and Riley Hospital for Children at Indiana University Health, Indianapolis, IN. FAU - Reames, Sakina Erika AU - Reames SE AD - Ann and Robert H Lurie Children's Hospital of Chicago. FAU - Auerbach, Marc A AU - Auerbach MA AD - Department of Emergency Medicine, Yale University School of Medicine, New Haven, CT. FAU - Abulebda, Kamal AU - Abulebda K AD - Division of Pediatric Critical Care Medicine, Department of Pediatrics, Indiana University School of Medicine and Riley Hospital for Children at Indiana University Health, Indianapolis, IN. Electronic address: kabulebd@iu.edu. CN - Improving Pediatric Acute Care Through Simulation (ImPACTS) LA - eng PT - Journal Article PT - Multicenter Study PT - Observational Study PT - Research Support, Non-U.S. Gov't DEP - 20240913 PL - United States TA - J Pediatr JT - The Journal of pediatrics JID - 0375410 SB - IM MH - Humans MH - *Patient Care Team/organization & administration MH - *Critical Care MH - Female MH - Child MH - Male MH - *Transportation of Patients MH - Heart Arrest/therapy MH - Simulation Training MH - Sepsis/therapy MH - Clinical Competence MH - Child, Preschool MH - Craniocerebral Trauma/therapy MH - Infant MH - Child Abuse OTO - NOTNLM OT - emergency medicine OT - pediatric critical care transport OT - simulation COIS- Declaration of Competing Interest The authors declare no conflicts of interest. FIR - Carreiro, Patricia IR - Carreiro P FIR - DeCerbo, Paul IR - DeCerbo P EDAT- 2024/09/16 00:42 MHDA- 2024/12/14 00:24 CRDT- 2024/09/15 19:27 PHST- 2023/12/20 00:00 [received] PHST- 2024/08/29 00:00 [revised] PHST- 2024/09/09 00:00 [accepted] PHST- 2024/12/14 00:24 [medline] PHST- 2024/09/16 00:42 [pubmed] PHST- 2024/09/15 19:27 [entrez] AID - S0022-3476(24)00406-2 [pii] AID - 10.1016/j.jpeds.2024.114303 [doi] PST - ppublish SO - J Pediatr. 2025 Jan;276:114303. doi: 10.1016/j.jpeds.2024.114303. Epub 2024 Sep 13. PMID- 39277051 OWN - NLM STAT- MEDLINE DCOM- 20241129 LR - 20241129 IS - 1473-4893 (Electronic) IS - 1470-2118 (Print) IS - 1470-2118 (Linking) VI - 24 IP - 6 DP - 2024 Nov TI - British Cardiovascular Society survey of the provision and structure of cardiology multidisciplinary meetings in England. PG - 100243 LID - S1470-2118(24)05428-9 [pii] LID - 10.1016/j.clinme.2024.100243 [doi] LID - 100243 AB - Multidisciplinary meetings (MDMs) are central to clinical decision-making in many areas of cardiology. This study assessed current provision and structure of cardiology MDMs in England in comparison with national guidelines. British Cardiovascular Society (BCS) members were surveyed regarding frequency, core attendees, and organisational aspects of cardiology MDMs for myocardial revascularisation, endocarditis, heart failure, aortic valve, mitral and tricuspid valve MDMs, whether local, regional or outside of the region. Access to electrophysiology (EP), inherited cardiac conditions, and adult congenital heart disease (ACHD) MDMs was also assessed. Survey responses were received from 64 hospitals across England, of which 40 (62%) were secondary care centres and 24 (38%) were tertiary care centres. All units had access to revascularisation MDMs, although 6% of them (all in secondary care centres) lacked any surgical representation. Heart failure MDMs were available in 94% of centres, but 7% reported no attendance by a cardiologist with specialist interest in heart failure, and 23% reported no attendance by a device specialist. 61% of centres had access to dedicated endocarditis MDMs; however, 11% were not attended by a microbiologist or infectious disease physician, and 22% were not attended by a surgeon. Aortic valve MDMs were available in 69% of centres, while mitral and tricuspid valve MDMs were available in 56% of centres. One quarter of centres reported no access to EP, and one third of centres reported no access to ICC or ACHD MDMs. Substantial improvements in provision and structure of cardiology MDMs in England are needed in order to meet national guidance. CI - Copyright (c) 2024 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Liu, B AU - Liu B AD - Department of Cardiology, Manchester University NHS Foundation Trust, Manchester, UK; Division of Cardiovascular Sciences, University of Manchester, Manchester, UK. FAU - Archbold, R A AU - Archbold RA AD - Department of General & Invasive Cardiology, Barts Heart Centre, St Bartholomew's Hospital Trust, London, UK. FAU - Greenwood, J P AU - Greenwood JP AD - Leeds Institute for Cardiovascular and Diabetes Research, Leeds, UK; Baker Heart and Diabetes Institute, Melbourne, Australia. FAU - Ray, S AU - Ray S AD - Department of Cardiology, Manchester University NHS Foundation Trust, Manchester, UK. FAU - Hothi, S S AU - Hothi SS AD - Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK; Department of Cardiology, Royal Wolverhampton NHS Trust, Wolverhampton, UK. Electronic address: s.hothi@nhs.net. LA - eng PT - Journal Article DEP - 20240912 PL - England TA - Clin Med (Lond) JT - Clinical medicine (London, England) JID - 101092853 SB - IM MH - Humans MH - *Cardiology MH - England MH - Surveys and Questionnaires MH - Patient Care Team/organization & administration MH - Interdisciplinary Communication MH - Societies, Medical PMC - PMC11530800 OTO - NOTNLM OT - Cardiology multidisciplinary meeting OT - GIRFT OT - Qualitative study COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper EDAT- 2024/09/15 14:09 MHDA- 2024/11/30 11:16 PMCR- 2024/09/12 CRDT- 2024/09/14 19:27 PHST- 2024/04/22 00:00 [received] PHST- 2024/08/22 00:00 [revised] PHST- 2024/09/08 00:00 [accepted] PHST- 2024/11/30 11:16 [medline] PHST- 2024/09/15 14:09 [pubmed] PHST- 2024/09/14 19:27 [entrez] PHST- 2024/09/12 00:00 [pmc-release] AID - S1470-2118(24)05428-9 [pii] AID - 100243 [pii] AID - 10.1016/j.clinme.2024.100243 [doi] PST - ppublish SO - Clin Med (Lond). 2024 Nov;24(6):100243. doi: 10.1016/j.clinme.2024.100243. Epub 2024 Sep 12. PMID- 39274298 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240916 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 13 IP - 17 DP - 2024 Aug 27 TI - Transitions and Long-Term Clinical Outcomes in Patients Admitted in Intensive Care Units Receiving Continuous Renal Replacement Therapy. LID - 10.3390/jcm13175085 [doi] LID - 5085 AB - Introduction: Acute kidney injury (AKI) significantly disrupts vital renal functions and is a common and serious condition in intensive care units (ICUs). AKI leads to extended hospital stays, increases mortality rates, and often necessitates nephrology consultations. Continuous renal replacement therapy (CRRT) plays a central role in managing AKI, requiring a multidisciplinary approach involving nephrologists, intensivists, and anesthesiologists. This study examines the clinical profile and progression of AKI in ICU patients requiring CRRT, with a focus on CRRT indications and modalities. Materials and Methods: We conducted a single-center retrospective observational study on ICU patients with AKI requiring CRRT from January to December 2019. AKI diagnosis followed the RIFLE criteria, and patients who received CRRT for less than 36 h were excluded. Data collected included demographics, hemodynamic parameters, and renal function parameters, with follow-ups at 1 week, 1 month, 6 months, and 12 months. Statistical analyses evaluated outcomes and transitions between CRRT and other renal replacement therapies. Results: Among 123 evaluated patients, 95 met inclusion criteria. Fifteen patients received CRRT for less than 36 h, with an early mortality rate of 80%. The final cohort comprised 80 patients who underwent CRRT for over 36 h, with a mean age of 65.3 years (SD = 13.6) and a Charlson index of 6.4. Patients were categorized based on primary diagnosis into heart failure, cardiac surgery, sepsis, other surgeries, and miscellanea groups. Mortality rates were highest in the heart failure and miscellanea groups. Significant variability was observed in therapy transitions and long-term outcomes. Continuous venovenous hemodiafiltration (CVVHDF) was the most frequently used CRRT modality. Conclusions: This study highlights the variability in CRRT practices and the poor prognosis for critically ill patients with AKI requiring CRRT. Timely nephrology consultation and tailored treatment plans may improve patient outcomes and optimize CRRT utilization. Future research should focus on refining CRRT protocols and exploring preventive strategies for AKI. FAU - Valdenebro, Maria AU - Valdenebro M AD - Nephrology Department, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, 28222 Majadahonda, Spain. FAU - Portoles, Jose AU - Portoles J AUID- ORCID: 0000-0002-2114-1385 AD - Nephrology Department, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, 28222 Majadahonda, Spain. AD - Medicine Department, Universidad Autonoma de Madrid, 28049 Madrid, Spain. FAU - Serrano Salazar, Maria Luisa AU - Serrano Salazar ML AD - Nephrology Department, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, 28222 Majadahonda, Spain. FAU - Munoz Sanchez, Ana AU - Munoz Sanchez A AD - Nephrology Department, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, 28222 Majadahonda, Spain. FAU - Alameda-Aguado, Ines AU - Alameda-Aguado I AD - Medicine Department, Universidad Autonoma de Madrid, 28049 Madrid, Spain. FAU - Martin Rodriguez, Leyre AU - Martin Rodriguez L AUID- ORCID: 0000-0001-5854-0577 AD - Nephrology Department, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, 28222 Majadahonda, Spain. FAU - Zalamea-Jarrin, Felipe AU - Zalamea-Jarrin F AD - Nephrology Department, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, 28222 Majadahonda, Spain. FAU - Lopez-Sanchez, Paula AU - Lopez-Sanchez P AUID- ORCID: 0000-0002-4332-5759 AD - Nephrology Department, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, 28222 Majadahonda, Spain. LA - eng GR - N/A/Fundacion Renal Inigo Alvarez de Toledo/ GR - N/A/Instituto de Investigacion Segovia Arana/ GR - N/A/Fundacion Madrilena de Nefrologia/ PT - Journal Article DEP - 20240827 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC11396298 OTO - NOTNLM OT - acute kidney injury OT - continuous venovenous hemodiafiltration OT - critical care OT - extracorporeal blood purification therapy OT - hemodynamic instability OT - mortality COIS- The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. EDAT- 2024/09/14 10:42 MHDA- 2024/09/14 10:43 PMCR- 2024/08/27 CRDT- 2024/09/14 01:13 PHST- 2024/07/22 00:00 [received] PHST- 2024/08/22 00:00 [revised] PHST- 2024/08/23 00:00 [accepted] PHST- 2024/09/14 10:43 [medline] PHST- 2024/09/14 10:42 [pubmed] PHST- 2024/09/14 01:13 [entrez] PHST- 2024/08/27 00:00 [pmc-release] AID - jcm13175085 [pii] AID - jcm-13-05085 [pii] AID - 10.3390/jcm13175085 [doi] PST - epublish SO - J Clin Med. 2024 Aug 27;13(17):5085. doi: 10.3390/jcm13175085. PMID- 39274191 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240916 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 13 IP - 17 DP - 2024 Aug 23 TI - Patient-Tailored Therapy for Complex Aortic Arch Anatomy: An Evolving Research Field with Custom-Made Solutions. LID - 10.3390/jcm13174975 [doi] LID - 4975 AB - The treatment of complex aortic pathologies requires specialized techniques and tailored approaches due to each patient's unique anatomical and clinical challenges. The European Association for Cardiothoracic Surgery (EACTS) and the Society of Thoracic Surgeons (STS) new guidelines identify the aorta as the body's 24th organ and reiterate that multidisciplinary aortic teams are recommended for shared decision-making to determine optimal treatment strategies. Patients treated for conditions such as aneurysms, dissections, intramural hematomas, or penetrating aortic ulcers may develop complex forms over time, necessitating careful follow-up and timely corrective actions. Endovascular solutions can be favorable for older patients with complex anatomies and multiple comorbidities. However, when endovascular treatment is not feasible, hybrid treatments or open surgery must be considered if the patient's condition allows it. The risk-benefit ratio of each procedure must be carefully evaluated; choosing the best intervention or deciding not to intervene becomes a critical and challenging decision. At our Cardiac Surgery Center in Verona, a multidisciplinary team with over 20 years of experience in treating complex aortic arch pathologies extensively discussed different cases of complex aortic pathologies treated with endovascular, hybrid, or surgical approaches, emphasizing the importance of considering both anatomical and patient-specific characteristics. The decisions and treatments were often challenging, and unanimity was not always achieved, reflecting the complexity of finding the best solutions. FAU - Linardi, Daniele AU - Linardi D AUID- ORCID: 0000-0003-1265-9374 AD - Cardiac Surgery Department, Azienda Ospedaliera Universitaria Integrata Verona, 37126 Verona, Italy. FAU - Gardellini, Jacopo AU - Gardellini J AD - Cardiac Surgery Department, Azienda Ospedaliera Universitaria Integrata Verona, 37126 Verona, Italy. FAU - Boschetti, Vincenzo AU - Boschetti V AD - Cardiac Surgery Department, Azienda Ospedaliera Universitaria Integrata Verona, 37126 Verona, Italy. FAU - Di Nicola, Venanzio AU - Di Nicola V AD - Cardiac Surgery Department, Azienda Ospedaliera Universitaria Integrata Verona, 37126 Verona, Italy. FAU - Denora, Mariateresa AU - Denora M AD - Cardiac Surgery Department, Azienda Ospedaliera Universitaria Integrata Verona, 37126 Verona, Italy. FAU - Puntel, Gino AU - Puntel G AD - Radiology Department, Azienda Ospedaliera Universitaria Integrata Verona, 37126 Verona, Italy. FAU - Puppini, Giovanni AU - Puppini G AD - Radiology Department, Azienda Ospedaliera Universitaria Integrata Verona, 37126 Verona, Italy. FAU - Luciani, Giovanni B AU - Luciani GB AUID- ORCID: 0000-0003-0931-018X AD - Cardiac Surgery Department, Azienda Ospedaliera Universitaria Integrata Verona, 37126 Verona, Italy. LA - eng PT - Journal Article PT - Review DEP - 20240823 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC11396027 OTO - NOTNLM OT - aortic arch treatment OT - aortic team OT - tailored therapy COIS- The authors declare no conflicts of interest. EDAT- 2024/09/14 10:46 MHDA- 2024/09/14 10:47 PMCR- 2024/08/23 CRDT- 2024/09/14 01:12 PHST- 2024/07/20 00:00 [received] PHST- 2024/08/12 00:00 [revised] PHST- 2024/08/19 00:00 [accepted] PHST- 2024/09/14 10:47 [medline] PHST- 2024/09/14 10:46 [pubmed] PHST- 2024/09/14 01:12 [entrez] PHST- 2024/08/23 00:00 [pmc-release] AID - jcm13174975 [pii] AID - jcm-13-04975 [pii] AID - 10.3390/jcm13174975 [doi] PST - epublish SO - J Clin Med. 2024 Aug 23;13(17):4975. doi: 10.3390/jcm13174975. PMID- 39272061 OWN - NLM STAT- MEDLINE DCOM- 20240914 LR - 20260623 IS - 1471-2369 (Electronic) IS - 1471-2369 (Linking) VI - 25 IP - 1 DP - 2024 Sep 13 TI - Association of chronic kidney disease with postoperative outcomes: a national surgical quality improvement program (NSQIP) multi-specialty surgical cohort analysis. PG - 305 LID - 10.1186/s12882-024-03753-1 [doi] LID - 305 AB - BACKGROUND: Chronic kidney disease (CKD) is associated with higher incidence of major surgery. No studies have evaluated the association between preoperative kidney function and postoperative outcomes across a wide spectrum of procedures. We aimed to evaluate the association between CKD and 30-day postoperative outcomes across surgical specialties. METHODS: We selected adult patients undergoing surgery across eight specialties. The primary study endpoint was major complications, defined as death, unplanned reoperation, cardiac complication, or stroke within 30 days following surgery. Secondary outcomes included Clavien-Dindo high-grade complications, as well as cardiac, pulmonary, infectious, and thromboembolic complications. Multivariable regression was performed to evaluate the association between CKD and 30-day postoperative complications, adjusted for baseline characteristics, surgical specialty, and operative time. RESULTS: In total, 1,912,682 patients were included. The odds of major complications (adjusted odds ratio [aOR] 2.14 [95% confidence interval (CI): 2.07, 2.21]), death (aOR 3.03 [95% CI: 2.88, 3.19]), unplanned reoperation (aOR 1.57 [95% CI: 1.51, 1.64]), cardiac complication (aOR 3.51 [95% CI: 3.25, 3.80]), and stroke (aOR 1.89 [95% CI: 1.64, 2.17]) were greater for patients with CKD stage 5 vs. stage 1. A similar pattern was observed for the secondary endpoints. CONCLUSION: This population-based study demonstrates the negative impact of CKD on operative outcomes across a diverse range of procedures and patients. CI - (c) 2024. The Author(s). FAU - Riveros, Carlos AU - Riveros C AD - Department of Urology, Houston Methodist Hospital, 6560 Fannin Street, Suite 2100, Houston, TX, 77030, USA. FAU - Ranganathan, Sanjana AU - Ranganathan S AD - Department of Urology, Houston Methodist Hospital, 6560 Fannin Street, Suite 2100, Houston, TX, 77030, USA. FAU - Shah, Yash B AU - Shah YB AD - Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA. FAU - Huang, Emily AU - Huang E AD - Department of Urology, Houston Methodist Hospital, 6560 Fannin Street, Suite 2100, Houston, TX, 77030, USA. FAU - Xu, Jiaqiong AU - Xu J AD - Center for Health Data Science and Analytics, Houston Methodist Research Institute, Houston, TX, USA. FAU - Hsu, Enshuo AU - Hsu E AD - Center for Health Data Science and Analytics, Houston Methodist Research Institute, Houston, TX, USA. FAU - Geng, Michael AU - Geng M AD - School of Engineering Medicine, Texas A&M University, Houston, TX, USA. FAU - Hu, Siqi AU - Hu S AD - Department of Urology, Houston Methodist Hospital, 6560 Fannin Street, Suite 2100, Houston, TX, 77030, USA. FAU - Melchiode, Zachary AU - Melchiode Z AD - Department of Urology, Houston Methodist Hospital, 6560 Fannin Street, Suite 2100, Houston, TX, 77030, USA. FAU - Miles, Brian J AU - Miles BJ AD - Department of Urology, Houston Methodist Hospital, 6560 Fannin Street, Suite 2100, Houston, TX, 77030, USA. FAU - Esnaola, Nestor AU - Esnaola N AD - Department of Surgery, Houston Methodist Hospital, Houston, TX, USA. FAU - Klaassen, Zachary AU - Klaassen Z AD - Division of Urology, Medical College of Georgia, Augusta University, Augusta, GA, USA. FAU - Jerath, Angela AU - Jerath A AD - Department of Anesthesia, Sunnybrook Health Sciences Center, Toronto, ON, Canada. FAU - Wallis, Christopher J D AU - Wallis CJD AD - Division of Urology and Surgical Oncology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada. AD - Division of Urology, University of Toronto, Toronto, ON, Canada. AD - Division of Urology, Mount Sinai Hospital, Toronto, ON, Canada. FAU - Satkunasivam, Raj AU - Satkunasivam R AD - Department of Urology, Houston Methodist Hospital, 6560 Fannin Street, Suite 2100, Houston, TX, 77030, USA. raj.satkunasivam@gmail.com. LA - eng PT - Journal Article DEP - 20240913 PL - England TA - BMC Nephrol JT - BMC nephrology JID - 100967793 SB - IM MH - Humans MH - Male MH - Female MH - *Renal Insufficiency, Chronic/epidemiology MH - *Postoperative Complications/epidemiology/etiology MH - Middle Aged MH - *Quality Improvement MH - Aged MH - Cohort Studies MH - Reoperation/statistics & numerical data MH - Adult MH - Specialties, Surgical MH - Stroke/etiology/epidemiology MH - Retrospective Studies PMC - PMC11401401 OTO - NOTNLM OT - Chronic kidney disease OT - Postoperative outcomes OT - Quality improvement COIS- The authors declare no competing interests. EDAT- 2024/09/14 10:43 MHDA- 2024/09/14 10:44 PMCR- 2024/09/13 CRDT- 2024/09/13 23:48 PHST- 2023/08/07 00:00 [received] PHST- 2024/09/10 00:00 [accepted] PHST- 2024/09/14 10:44 [medline] PHST- 2024/09/14 10:43 [pubmed] PHST- 2024/09/13 23:48 [entrez] PHST- 2024/09/13 00:00 [pmc-release] AID - 10.1186/s12882-024-03753-1 [pii] AID - 3753 [pii] AID - 10.1186/s12882-024-03753-1 [doi] PST - epublish SO - BMC Nephrol. 2024 Sep 13;25(1):305. doi: 10.1186/s12882-024-03753-1. PMID- 39271364 OWN - NLM STAT- MEDLINE DCOM- 20240926 LR - 20241016 IS - 1875-2128 (Electronic) IS - 1875-2128 (Linking) VI - 117 IP - 8-9 DP - 2024 Aug-Sep TI - Scientific statement from the French neurovascular and cardiac societies for improved detection of atrial fibrillation after ischaemic stroke and transient ischaemic attack. PG - 542-557 LID - S1875-2136(24)00287-0 [pii] LID - 10.1016/j.acvd.2024.06.002 [doi] AB - Atrial fibrillation (AF) is the primary cause of ischaemic stroke and transient ischaemic attack (TIA). AF is associated with a high risk of recurrence, which can be reduced using optimal prevention strategies, mainly anticoagulant therapy. The availability of effective prophylaxis justifies the need for a significant, coordinated and thorough transdisciplinary effort to screen for AF associated with stroke. A recent French national survey, initiated and supported by the Societe francaise neurovasculaire (SFNV) and the Societe francaise de cardiologie (SFC), revealed many shortcomings, such as the absence or inadequacy of telemetry equipment in more than half of stroke units, insufficient and highly variable access to monitoring tools, delays in performing screening tests, heterogeneous access to advanced or connected ambulatory monitoring techniques, and a lack of dedicated human resources. The present scientific document has been prepared on the initiative of the SFNV and the SFC with the aim of helping to address the current shortcomings and gaps, to promote efficient and cost-effective AF detection, and to improve and, where possible, homogenize the quality of practice in AF screening among stroke units and outpatient post-stroke care networks. The working group, composed of cardiologists and vascular neurologists who are experts in the field and are nominated by their peers, reviewed the literature to propose statements, which were discussed in successive cycles, and maintained, either by consensus or by vote, as appropriate. The text was then submitted to the SFNV and SFC board members for review. This scientific statement document argues for the widespread development of patient pathways to enable the most efficient AF screening after stroke. This assessment should be carried out by a multidisciplinary team, including expert cardiologists and vascular neurologists. CI - Copyright (c) 2024 The Author(s). Published by Elsevier Masson SAS.. All rights reserved. FAU - Gaillard, Nicolas AU - Gaillard N AD - Service de Neurologie, Clinique Beau Soleil, Institut Mutualiste Montpellierain, 19, avenue de Lodeve, 34070 Montpellier, France; Departement de Neurologie, Hopital Universitaire Gui-de-Chauliac, 80, avenue Augustin-Fliche, 34080 Montpellier, France. FAU - Deharo, Jean-Claude AU - Deharo JC AD - Assistance publique-Hopitaux de Marseille, Centre Hospitalier Universitaire La Timone, Service de Cardiologie, Marseille, France; Aix-Marseille Universite, C2VN, 13005 Marseille, France. Electronic address: jean-claude.deharo@ap-hm.fr. FAU - Suissa, Laurent AU - Suissa L AD - Stroke Unit, University Hospital La Timone, AP-HM, Marseille, France; Centre de recherche en CardioVasculaire et Nutrition (C2VN), 13005 Marseille, France. FAU - Defaye, Pascal AU - Defaye P AD - Cardiology Department, University Hospital, Grenoble Alpes University, CS 10217, 38043 Grenoble, France. FAU - Sibon, Igor AU - Sibon I AD - Universite Bordeaux, CHU de Bordeaux, Unite Neurovasculaire, Hopital Pellegrin, 33000 Bordeaux, France; INCIA-UMR 5287-CNRS Equipe ECOPSY, Universite de Bordeaux, Bordeaux, France. FAU - Leclercq, Christophe AU - Leclercq C AD - Department of Cardiology, University of Rennes, CHU de Rennes, lTSI-UMR1099, 35000 Rennes, France. FAU - Alamowitch, Sonia AU - Alamowitch S AD - Urgences Cerebro-Vasculaires, Hopital Pitie-Salpetriere, AP-HP, Hopital Saint-Antoine, Sorbonne Universite, Paris, France; STARE Team, iCRIN, Institut du Cerveau et de la Moelle epiniere, ICM, 75013 Paris, France. FAU - Guidoux, Celine AU - Guidoux C AD - Department of Neurology and Stroke Unit, Bichat Hospital, Assistance publique-Hopitaux de Paris, 75018 Paris, France. FAU - Cohen, Ariel AU - Cohen A AD - Hopitaux de l'est parisien (Saint-Antoine-Tenon), AP-HP, Sorbonne Universite, Inserm ICAN 1166, 184, Faubourg-Saint-Antoine, 75571 Paris cedex 12, France. CN - French Neurovascular Society CN - French Society of Cardiology LA - eng PT - Journal Article PT - Practice Guideline DEP - 20240902 PL - Netherlands TA - Arch Cardiovasc Dis JT - Archives of cardiovascular diseases JID - 101465655 SB - IM MH - Humans MH - *Atrial Fibrillation/diagnosis/complications/therapy/physiopathology MH - Cardiologists MH - *Cardiology/standards MH - Consensus MH - France/epidemiology MH - *Ischemic Attack, Transient/diagnosis/etiology/therapy/prevention & control MH - *Ischemic Stroke/diagnosis/etiology/prevention & control/therapy MH - *Predictive Value of Tests MH - Prognosis MH - Recurrence MH - Risk Factors OTO - NOTNLM OT - Atrial cardiomyopathy OT - Atrial fibrillation OT - Atrial fibrillation screening OT - Cryptogenic stroke OT - Stroke EDAT- 2024/09/14 10:44 MHDA- 2024/09/27 00:42 CRDT- 2024/09/13 21:56 PHST- 2024/06/04 00:00 [received] PHST- 2024/06/10 00:00 [accepted] PHST- 2024/09/27 00:42 [medline] PHST- 2024/09/14 10:44 [pubmed] PHST- 2024/09/13 21:56 [entrez] AID - S1875-2136(24)00287-0 [pii] AID - 10.1016/j.acvd.2024.06.002 [doi] PST - ppublish SO - Arch Cardiovasc Dis. 2024 Aug-Sep;117(8-9):542-557. doi: 10.1016/j.acvd.2024.06.002. Epub 2024 Sep 2. PMID- 39269886 OWN - NLM STAT- MEDLINE DCOM- 20250129 LR - 20260628 IS - 2374-4243 (Electronic) IS - 2374-4243 (Linking) VI - 57 IP - 2 DP - 2025 Feb TI - Evaluation of the 2023 Duke-ISCVID criteria for infective endocarditis in patients referred to the Lund infective endocarditis team. PG - 150-158 LID - 10.1080/23744235.2024.2402374 [doi] AB - BACKGROUND: The Duke criteria for diagnosing infective endocarditis (IE) were recently updated by the International Society for Cardiovascular Infectious Diseases (ISCVID) with the purpose of enhancing diagnostic specificity and sensitivity. This study investigated the performance of the Duke-ISCVID criteria in relation to previous criteria. METHOD: This retrospective single centre cohort study included patients referred to the Lund IE Team (LIET) between 2017 and 2022, and compared episodes classified according to the 2000 modified Duke, European Society of Cardiology (ESC) 2015, and 2023 Duke-ISCVID criteria. The LIET's decision to treat episodes as IE served as the reference standard. RESULTS: The study cohort comprised 661 episodes of potential IE. The LIET classified 498 (75%) episodes as IE. The Duke-ISCVID criteria classified a slightly higher proportion of episodes as definite IE (56.4%) compared to the ESC 2015 criteria (54.9%), and the modified Duke (51.1%). The Duke-ISCVID criteria had higher sensitivity (72.5%) for definite IE compared to ESC 2015 (70.7%, p = .57) and modified Duke (66.1%, p = .033). The specificities were similar for the Duke-ISCVID criteria (92.6%), compared to ESC 2015 (93.9%, p = .83) and the modified Duke criteria (95.0%, p = .49). When considering both definite and possible IE positive, specificity for all criteria was low: 32.5% for the Duke-ISCVID criteria, 41.7% for ESC 2015 (p = .086), and 42.3% for modified Duke criteria (p = .11), while the sensitivity was not significantly lower. DISCUSSION: The Duke-ISCVID criteria demonstrated slightly improved sensitivity for diagnosing IE whereas specificity remained unchanged. Further refinement of the Duke-ISCVID criteria is needed to balance sensitivity and specificity. FAU - Avogadri, Nils AU - Avogadri N AD - Division of Infection Medicine, Department of Clinical Sciences Lund, Lund University, Lund, Sweden. FAU - Ivarsson, Alex AU - Ivarsson A AD - Division of Infection Medicine, Department of Clinical Sciences Lund, Lund University, Lund, Sweden. FAU - Burup Kristensen, Charlotte AU - Burup Kristensen C AD - Department of Cardiology, Skane University Hospital, Lund, Sweden. AD - Cardiology, Department of Clinical Sciences, Lund University, Sweden. FAU - Ragnarsson, Sigurdur AU - Ragnarsson S AD - Department of Cardiothoracic Surgery, Skane University Hospital, Lund, Sweden. AD - Division of Cardiothoracic Surgery, Department of Clinical Sciences, Lund University, Sweden. FAU - Rasmussen, Magnus AU - Rasmussen M AD - Division of Infection Medicine, Department of Clinical Sciences Lund, Lund University, Lund, Sweden. AD - Department of Infectious Diseases, Skane University Hospital, Lund, Sweden. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240913 PL - England TA - Infect Dis (Lond) JT - Infectious diseases (London, England) JID - 101650235 SB - IM MH - Humans MH - Retrospective Studies MH - Male MH - Female MH - *Endocarditis/diagnosis MH - Middle Aged MH - Sensitivity and Specificity MH - Aged MH - Adult OTO - NOTNLM OT - Duke criteria OT - ISCVID OT - Infective endocarditis OT - single centre cohort study OT - validation study EDAT- 2024/09/13 18:44 MHDA- 2025/01/29 06:20 CRDT- 2024/09/13 12:43 PHST- 2025/01/29 06:20 [medline] PHST- 2024/09/13 18:44 [pubmed] PHST- 2024/09/13 12:43 [entrez] AID - 10.1080/23744235.2024.2402374 [doi] PST - ppublish SO - Infect Dis (Lond). 2025 Feb;57(2):150-158. doi: 10.1080/23744235.2024.2402374. Epub 2024 Sep 13. PMID- 39269034 OWN - NLM STAT- MEDLINE DCOM- 20241104 LR - 20241104 IS - 1559-0879 (Electronic) IS - 1556-9845 (Linking) VI - 19 IP - 4 DP - 2024 Jul-Aug TI - Robotic Totally Endoscopic Off-Pump Unroofing of Myocardial Bridge: Early Experience and Midterm Outcomes. PG - 409-415 LID - 10.1177/15569845241266817 [doi] AB - OBJECTIVE: Myocardial bridging (MB) occurs when a coronary artery, commonly the left anterior descending (LAD), has an intramyocardial course. In symptomatic patients who fail medical therapy, surgical unroofing can provide symptomatic relief by improving coronary blood flow. We present a series of patients undergoing robotic totally endoscopic beating-heart MB unroofing. METHODS: There were 34 patients with an LAD-MB who failed medical therapy and underwent robotic totally endoscopic, off-pump unroofing between January 2017 and October 2023. Patients were evaluated by a multidisciplinary team and underwent provocative coronary angiography to confirm hemodynamic significance. We reviewed perioperative outcomes and contacted patients for midterm follow-up, including completion of a modified Seattle Angina Questionnaire (SAQ). RESULTS: The mean age was 48 +/- 8 years, and 56% were female patients. One patient had prior septal myectomy via sternotomy. All patients had significant dobutamine Pd/Pa reduction on preoperative coronary angiography. One patient had atrial fibrillation and underwent concomitant ablation with left atrial appendage ligation. The mean procedure time was 140 +/- 69 min. All were completed totally endoscopically off-pump without intraoperative conversions. The mean MB length was 4.5 +/- 1.4 cm, and the mean depth was 1.6 +/- 0.9 cm. Of the patients, 76% were extubated in the operating room. The mean intensive care unit and hospital length of stay were 0.97 +/- 0.58 and 1.73 +/- 1.1 days, respectively. There were no mortalities or strokes. There was 1 postoperative take-back for bleeding. At midterm follow-up (19 +/- 14 months), 28 patients completed the SAQ; 86% reported "much less angina" during activity compared with before surgery, and 93% reported taking no antianginal medication since surgery. CONCLUSIONS: In appropriate patients with hemodynamically significant LAD-MB who fail medical therapy, robotic beating-heart unroofing is possible with good outcomes. Further studies are warranted. FAU - Nisivaco, Sarah AU - Nisivaco S AUID- ORCID: 0000-0003-4448-9023 AD - Department of Cardiothoracic Surgery, University of Chicago Medicine, IL, USA. FAU - Blair, John AU - Blair J AD - Department of Cardiology, University of Chicago Medicine, IL, USA. FAU - Patel, Amit AU - Patel A AD - Department of Cardiology, University of Chicago Medicine, IL, USA. FAU - Kitahara, Hiroto AU - Kitahara H AD - Department of Cardiothoracic Surgery, University of Chicago Medicine, IL, USA. FAU - Allan, Tess AU - Allan T AD - Department of Cardiology, University of Chicago Medicine, IL, USA. FAU - Patel, Brooke AU - Patel B AD - Department of Cardiothoracic Surgery, University of Chicago Medicine, IL, USA. FAU - Coleman, Charocka AU - Coleman C AD - Department of Cardiothoracic Surgery, University of Chicago Medicine, IL, USA. FAU - Balkhy, Husam H AU - Balkhy HH AUID- ORCID: 0000-0002-1154-8018 AD - Department of Cardiothoracic Surgery, University of Chicago Medicine, IL, USA. LA - eng PT - Journal Article DEP - 20240913 PL - United States TA - Innovations (Phila) JT - Innovations (Philadelphia, Pa.) JID - 101257528 SB - IM MH - Humans MH - Female MH - Middle Aged MH - Male MH - *Robotic Surgical Procedures/methods MH - *Endoscopy/methods MH - Treatment Outcome MH - *Myocardial Bridging/surgery MH - Adult MH - Coronary Angiography/methods MH - Coronary Artery Bypass, Off-Pump/methods MH - Retrospective Studies OTO - NOTNLM OT - left anterior descending artery OT - minimally invasive cardiac surgery OT - myocardial bridge OT - robotic cardiac surgery OT - unroofing COIS- Declaration of Conflicting InterestsThe authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr. Balkhy declares he is a proctor for Intuitive Surgical. The remaining authors have nothing to disclose. EDAT- 2024/09/13 14:44 MHDA- 2024/11/04 12:25 CRDT- 2024/09/13 08:43 PHST- 2024/11/04 12:25 [medline] PHST- 2024/09/13 14:44 [pubmed] PHST- 2024/09/13 08:43 [entrez] AID - 10.1177/15569845241266817 [doi] PST - ppublish SO - Innovations (Phila). 2024 Jul-Aug;19(4):409-415. doi: 10.1177/15569845241266817. Epub 2024 Sep 13. PMID- 39266665 OWN - NLM STAT- MEDLINE DCOM- 20250916 LR - 20261010 IS - 1476-5543 (Electronic) IS - 0743-8346 (Linking) VI - 45 IP - 9 DP - 2025 Sep TI - Standardizing the diagnosis of necrotizing enterocolitis in infants with congenital heart disease. PG - 1305-1310 LID - 10.1038/s41372-024-02112-0 [doi] AB - OBJECTIVE: This quality improvement initiative aimed to standardize the diagnosis of necrotizing enterocolitis (NEC) in infants with congenital heart disease (CHD). STUDY DESIGN: A multidisciplinary team developed clinical practice guidelines for the diagnosis and treatment of NEC within the Cardiac Intensive Care Unit (CICU). The diagnosis rate of NEC per 100 at-risk admissions was the primary outcome measure. NEC order set usage was employed as a process measure, and the balancing measures monitored were CICU length of stay (LOS) and mortality. RESULT: After guideline development and implementation, the diagnosis rate of NEC decreased from 3% to 1%, sustained over three years. The EMR order set enabled guideline integration into daily workflow. No change was noted in CICU LOS or mortality. CONCLUSION: Guideline implementation standardized the diagnosis of NEC in infants with CHD. Establishing a standardized definition and subsequent treatment regimen has enabled us to provide more consistent and appropriate care. CI - (c) 2024. The Author(s), under exclusive licence to Springer Nature America, Inc. FAU - Hillyer, Margot AU - Hillyer M AUID- ORCID: 0000-0003-3389-6328 AD - Emory University School of Medicine, Department of Pediatrics, Division of Critical Care Medicine, Atlanta, GA, USA. margot.hillyer@emory.edu. FAU - Fundora, Michael AU - Fundora M AUID- ORCID: 0000-0003-3204-1176 AD - Emory University School of Medicine, Department of Pediatrics, Division of Cardiology, Atlanta, GA, USA. AD - The Heart Center, Children's Healthcare of Atlanta, Atlanta, GA, USA. FAU - Williams, Feifei AU - Williams F AD - Emory University School of Medicine, Department of Pediatrics, Division of Cardiology, Atlanta, GA, USA. AD - AdventHealth Medical Group, Division of Pediatric Critical Care Medicine, AdventHealth for Children, Orlando, FL, USA. FAU - Gleason, Michelle AU - Gleason M AD - The Heart Center, Children's Healthcare of Atlanta, Atlanta, GA, USA. FAU - Lukacs, Mary AU - Lukacs M AD - The Heart Center, Children's Healthcare of Atlanta, Atlanta, GA, USA. FAU - Hamrick, Shannon AU - Hamrick S AUID- ORCID: 0000-0002-6294-3480 AD - Emory University School of Medicine, Department of Pediatrics, Division of Neonatology, Atlanta, GA, USA. FAU - Meisel, Jonathan AU - Meisel J AD - Emory University School of Medicine, Department of Pediatrics, Division of General Surgery, Atlanta, GA, USA. FAU - Clarke, Shanelle AU - Clarke S AD - Emory University School of Medicine, Department of Pediatrics, Division of Cardiology, Atlanta, GA, USA. AD - The Heart Center, Children's Healthcare of Atlanta, Atlanta, GA, USA. FAU - Korcinsky-Tillman, Natalie AU - Korcinsky-Tillman N AD - The Heart Center, Children's Healthcare of Atlanta, Atlanta, GA, USA. AD - Children's Healthcare of Atlanta Quality Department, Atlanta, GA, USA. FAU - Chanani, Nikhil AU - Chanani N AD - Emory University School of Medicine, Department of Pediatrics, Division of Cardiology, Atlanta, GA, USA. AD - The Heart Center, Children's Healthcare of Atlanta, Atlanta, GA, USA. LA - eng PT - Journal Article DEP - 20240912 PL - United States TA - J Perinatol JT - Journal of perinatology : official journal of the California Perinatal Association JID - 8501884 SB - IM MH - Humans MH - *Enterocolitis, Necrotizing/diagnosis/therapy/mortality MH - *Heart Defects, Congenital/complications MH - Infant, Newborn MH - Quality Improvement MH - *Practice Guidelines as Topic MH - Length of Stay MH - Intensive Care Units, Neonatal MH - Female MH - Male MH - Infant COIS- Competing interests: The authors declare no competing interests. EDAT- 2024/09/13 00:46 MHDA- 2025/09/16 06:38 CRDT- 2024/09/12 23:26 PHST- 2024/05/23 00:00 [received] PHST- 2024/09/04 00:00 [accepted] PHST- 2024/08/27 00:00 [revised] PHST- 2025/09/16 06:38 [medline] PHST- 2024/09/13 00:46 [pubmed] PHST- 2024/09/12 23:26 [entrez] AID - 10.1038/s41372-024-02112-0 [pii] AID - 10.1038/s41372-024-02112-0 [doi] PST - ppublish SO - J Perinatol. 2025 Sep;45(9):1305-1310. doi: 10.1038/s41372-024-02112-0. Epub 2024 Sep 12. PMID- 42038145 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260427 LR - 20260813 IS - 2322-2379 (Electronic) IS - 2588-2767 (Print) IS - 2322-2379 (Linking) VI - 13 DP - 2024 TI - Neurological Complications Following Cardiac Surgery: Management and Future Directions. PG - e3415 LID - 10.31661/gmj.v13i.3415 [doi] LID - e3415 AB - Neurological complications related to cardiac surgery present physicians with challenges. These complications severely impact patients' outcomes, the quality of their lives, and affect the resources available at healthcare centers. The treatment of neurological complications requires a multidisciplinary approach, where evidenced-based interventions work to identify the patient profiles and risk factors. In addition, ongoing investigations on alternative treatment methods like cerebral oximetry and personalized risk stratification may likely improve management and outcomes of such high-risk patients. Based on the significance that neurological problems play after cardiac surgery, this paper intends to offer the practitioners and scientists vital insights to help them provide the most suitable healthcare to the affected patients and to guide future studies. CI - Copyright(c) 2024, Galen Medical Journal. FAU - Negargar, Sohrab AU - Negargar S AD - Cardiovascular Research Center of Tabriz University of Medical Sciences, Tabriz, Iran. FAU - Sadeghi, Sahar AU - Sadeghi S AD - Cardiovascular Research Center of Tabriz University of Medical Sciences, Tabriz, Iran. LA - eng PT - Journal Article PT - Review DEP - 20240912 PL - Iran TA - Galen Med J JT - Galen medical journal JID - 101625418 PMC - PMC11826393 OTO - NOTNLM OT - Cardiac Surgery OT - Cerebral Oximetry OT - Delirium OT - ICU OT - MRI OT - Neurological Complications OT - Stroke COIS- None declared. EDAT- 2024/09/12 00:00 MHDA- 2024/09/12 00:01 PMCR- 2024/09/12 CRDT- 2026/04/27 06:48 PHST- 2024/05/12 00:00 [received] PHST- 2024/06/09 00:00 [revised] PHST- 2024/06/29 00:00 [accepted] PHST- 2024/09/12 00:01 [medline] PHST- 2024/09/12 00:00 [pubmed] PHST- 2026/04/27 06:48 [entrez] PHST- 2024/09/12 00:00 [pmc-release] AID - 10.31661/gmj.v13i.3415 [doi] PST - epublish SO - Galen Med J. 2024 Sep 12;13:e3415. doi: 10.31661/gmj.v13i.3415. eCollection 2024. PMID- 39264073 OWN - NLM STAT- MEDLINE DCOM- 20240912 LR - 20240922 IS - 1802-9973 (Electronic) IS - 0862-8408 (Print) IS - 0862-8408 (Linking) VI - 73 IP - 4 DP - 2024 Aug 31 TI - Idiopathic Pulmonary Fibrosis: Review of Current Knowledge. PG - 487-497 AB - Idiopathic pulmonary fibrosis (IPF) is a severe and currently incurable disease that is associated with irreversible fibrotic remodeling of the lung parenchyma. Pathological remodeling of the lung leads to damage of the alveolo-capillary barrier. There is a reduction in the diffusing capacity of the lungs for respiratory gases. Later, changes in the mechanical properties of lung tissue occur - their compliance decreases and respiratory work increases. Impaired respiratory gases exchange with restrictive ventilatory failure lead to tissue hypoxia and muscle weakness. Progressive respiratory insufficiency develops. The triggers of fibrotic remodeling of the lung are currently unknown, as are the pathomechanisms that keep this process active. IPF can only be slowed pharmacologically, not reversed. It is therefore very important to start its treatment as soon as possible. Early detection of IPF patients requires a multidisciplinary approach. Diagnosis, treatment initiation, and monitoring in specialized centers offer the best chance of slowing disease progression, enhancing quality of life, and extending patient survival. In addition to antifibrotic therapy, good lifestyle management, maintenance of physical fitness and treatment of associated chronic diseases such as diabetes and cardiac comorbidities are important. Lung transplantation is an option for some patients with IPF. This is a challenging treatment modality, requiring close collaboration with transplant centers and expert selection of suitable candidates, influenced, among other things, by the availability of suitable donor lungs. Our article aims to provide current information about IPF, focusing on its functional consequences and clinical manifestation. We discuss the molecular and cellular mechanisms potentially involved in IPF development, as well as the morphological changes observed in lung biopsies and high-resolution computed tomography (HRCT) images. Finally, we summarize the existing treatment options. Key words: Idiopathic pulmonary fibrosis, Lung biopsy, HRCT, Antifibrotic therapy, Lung transplantation. FAU - Muri, J AU - Muri J AD - 6Department of Anatomy of the Faculty of Medicine of Pavol Jozef Safarik University in Kosice, Slovakia. janka.vecanova@upjs.sk. FAU - Durcova, B AU - Durcova B FAU - Slivka, R AU - Slivka R FAU - Vrbenska, A AU - Vrbenska A FAU - Makovicka, M AU - Makovicka M FAU - Makovicky, P AU - Makovicky P FAU - Skarda, J AU - Skarda J FAU - Delongova, P AU - Delongova P FAU - Kamarad, V AU - Kamarad V FAU - Vecanova, J AU - Vecanova J LA - eng PT - Journal Article PT - Review PL - Czech Republic TA - Physiol Res JT - Physiological research JID - 9112413 SB - IM MH - Humans MH - *Idiopathic Pulmonary Fibrosis/therapy/diagnosis/physiopathology/pathology MH - Animals MH - Lung Transplantation MH - Lung/pathology/physiopathology PMC - PMC11414582 COIS- Conflict of Interest: There is no conflict of interest. EDAT- 2024/09/12 13:45 MHDA- 2024/09/12 13:46 PMCR- 2024/08/30 CRDT- 2024/09/12 08:04 PHST- 2024/09/12 13:46 [medline] PHST- 2024/09/12 13:45 [pubmed] PHST- 2024/09/12 08:04 [entrez] PHST- 2024/08/30 00:00 [pmc-release] AID - 935322 [pii] AID - pr73_487 [pii] AID - 10.33549/physiolres.935322 [doi] PST - ppublish SO - Physiol Res. 2024 Aug 31;73(4):487-497. doi: 10.33549/physiolres.935322. PMID- 39263820 OWN - NLM STAT- MEDLINE DCOM- 20241001 LR - 20260924 IS - 2047-9980 (Electronic) IS - 2047-9980 (Linking) VI - 13 IP - 19 DP - 2024 Oct TI - Trisomy 21 and Congenital Heart Disease: Impact on Health and Functional Outcomes From Birth Through Adolescence: A Scientific Statement From the American Heart Association. PG - e036214 LID - 10.1161/JAHA.124.036214 [doi] LID - e036214 AB - Due to improvements in recognition and management of their multisystem disease, the long-term survival of infants, children, and adolescents with trisomy 21 and congenital heart disease now matches children with congenital heart disease and no genetic condition in many scenarios. Although this improved survival is a triumph, individuals with trisomy 21 and congenital heart disease have unique and complex care needs in the domains of physical, developmental, and psychosocial health, which affect functional status and quality of life. Pulmonary hypertension and single ventricle heart disease are 2 known cardiovascular conditions that reduce life expectancy in individuals with trisomy 21. Multisystem involvement with respiratory, endocrine, gastrointestinal, hematological, neurological, and sensory systems can interact with cardiovascular health concerns to amplify adverse effects. Neurodevelopmental, psychological, and functional challenges can also affect quality of life. A highly coordinated interdisciplinary care team model, or medical home, can help address these complex and interactive conditions from infancy through the transition to adult care settings. The purpose of this Scientific Statement is to identify ongoing cardiovascular and multisystem, developmental, and psychosocial health concerns for children with trisomy 21 and congenital heart disease from birth through adolescence and to provide a framework for monitoring and management to optimize quality of life and functional status. FAU - Peterson, Jennifer K AU - Peterson JK FAU - Clarke, Shanelle AU - Clarke S FAU - Gelb, Bruce D AU - Gelb BD FAU - Kasparian, Nadine A AU - Kasparian NA FAU - Kazazian, Vanna AU - Kazazian V FAU - Pieciak, Karyn AU - Pieciak K FAU - Pike, Nancy A AU - Pike NA FAU - Setty, Shaun P AU - Setty SP FAU - Uveges, Melissa K AU - Uveges MK FAU - Rudd, Nancy A AU - Rudd NA CN - American Heart Association Pediatric Cardiovascular Nursing Committee of the Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Genomic and Precision Medicine; and Council on Cardiovascular Radiology and Intervention LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20240912 PL - England TA - J Am Heart Assoc JT - Journal of the American Heart Association JID - 101580524 SB - IM MH - Humans MH - *Down Syndrome/psychology/therapy MH - *Heart Defects, Congenital/therapy/psychology/physiopathology MH - Adolescent MH - *Quality of Life MH - Child MH - United States MH - Infant, Newborn MH - American Heart Association MH - Infant MH - Child, Preschool MH - Functional Status MH - Health Status PMC - PMC11681493 OTO - NOTNLM OT - AHA Scientific Statements OT - Down syndrome OT - autism spectrum disorder OT - cognition OT - heart defects, congenital OT - mental health OT - quality of life COIS- WRITING GROUP DISCLOSURES: [Table: see text] REVIEWER DISCLOSURES: [Table: see text] EDAT- 2024/09/12 08:42 MHDA- 2024/10/01 16:18 PMCR- 2024/10/01 CRDT- 2024/09/12 05:33 PHST- 2024/10/01 16:18 [medline] PHST- 2024/09/12 08:42 [pubmed] PHST- 2024/09/12 05:33 [entrez] PHST- 2024/10/01 00:00 [pmc-release] AID - JAH39688 [pii] AID - 10.1161/JAHA.124.036214 [doi] PST - ppublish SO - J Am Heart Assoc. 2024 Oct;13(19):e036214. doi: 10.1161/JAHA.124.036214. Epub 2024 Sep 12. PMID- 39263752 OWN - NLM STAT- MEDLINE DCOM- 20240930 LR - 20260518 IS - 1524-4539 (Electronic) IS - 0009-7322 (Print) IS - 0009-7322 (Linking) VI - 150 IP - 14 DP - 2024 Oct TI - Standardized Data Elements for Patients With Acute Pulmonary Embolism: A Consensus Report From the Pulmonary Embolism Research Collaborative. PG - 1140-1150 LID - 10.1161/CIRCULATIONAHA.124.067482 [doi] AB - Recent advances in therapy and the promulgation of multidisciplinary pulmonary embolism teams show great promise to improve management and outcomes of acute pulmonary embolism (PE). However, the absence of randomized evidence and lack of consensus leads to tremendous variations in treatment and compromises the wide implementation of new innovations. Moreover, the changing landscape of health care, where quality, cost, and accountability are increasingly relevant, dictates that a broad spectrum of outcomes of care must be routinely monitored to fully capture the impact of modern PE treatment. We set out to standardize data collection in patients with PE undergoing evaluation and treatment, and thus establish the foundation for an expanding evidence base that will address gaps in evidence and inform future care for acute PE. To do so, >100 international PE thought leaders convened in Washington, DC, in April 2022 to form the Pulmonary Embolism Research Collaborative. Participants included physician experts, key members of the US Food and Drug Administration, patient representatives, and industry leaders. Recognizing the multidisciplinary nature of PE care, the Pulmonary Embolism Research Collaborative was created with representative experts from stakeholder medical subspecialties, including cardiology, pulmonology, vascular medicine, critical care, hematology, cardiac surgery, emergency medicine, hospital medicine, and pharmacology. A list of critical evidence gaps was composed with a matching comprehensive set of standardized data elements; these data points will provide a foundation for productive research, knowledge enhancement, and advancement of clinical care within the field of acute PE, and contribute to answering urgent unmet needs in PE management. Evidence produced through the Pulmonary Embolism Research Collaborative, as it is applied to data collection, promises to provide crucial knowledge that will ultimately produce a robust evidence base that will lead to standardization and harmonization of PE management and improved outcomes. FAU - Rosenfield, Kenneth AU - Rosenfield K AUID- ORCID: 0000-0002-5633-6983 AD - Division of Cardiology, Massachusetts General Hospital, Boston (K.R., J.Y.). FAU - Bowers, Terry R AU - Bowers TR AUID- ORCID: 0009-0004-7244-4345 AD - Division of Cardiovascular Medicine, Beaumont University Hospital, Corewell Health, Royal Oak, MI (T.R.B.). FAU - Barnett, Christopher F AU - Barnett CF AUID- ORCID: 0000-0003-1095-5794 AD - Division of Cardiology, University of California, San Francisco (C.F.B.). FAU - Davis, George A AU - Davis GA AD - University of Kentucky HealthCare, University of Kentucky College of Pharmacy, Lexington (G.A.D.). FAU - Giri, Jay AU - Giri J AUID- ORCID: 0000-0002-8076-0098 AD - Cardiovascular Medicine Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia (J.G.). FAU - Horowitz, James M AU - Horowitz JM AUID- ORCID: 0000-0002-8220-5434 AD - Langone Health, Department of Medicine, Division of Cardiology, New York University, New York (J.M.H.). FAU - Huisman, Menno V AU - Huisman MV AUID- ORCID: 0000-0003-1423-5348 AD - Department of Medicine-Thrombosis and Hemostasis, Leiden University Medical Center, Netherlands (M.V.H., F.A.K.). AD - Dutch Thrombosis Network, Leiden, Netherlands (M.V.H., F.A.K.). FAU - Hunt, Beverley J AU - Hunt BJ AUID- ORCID: 0000-0002-4709-0774 AD - Department of Hematology, Kings Healthcare Partners, London, United Kingdom (B.J.H.). FAU - Keeling, Brent AU - Keeling B AD - Division of Cardiovascular Surgery, Emory University, Atlanta, GA (B.K.). FAU - Kline, Jeffrey A AU - Kline JA AUID- ORCID: 0000-0001-7190-3109 AD - Department of Emergency Medicine, School of Medicine, Wayne State University, Detroit, MI (J.A.K.). FAU - Klok, Frederikus A AU - Klok FA AUID- ORCID: 0000-0001-9961-0754 AD - Department of Medicine-Thrombosis and Hemostasis, Leiden University Medical Center, Netherlands (M.V.H., F.A.K.). AD - Dutch Thrombosis Network, Leiden, Netherlands (M.V.H., F.A.K.). FAU - Konstantinides, Stavros V AU - Konstantinides SV AUID- ORCID: 0000-0001-6359-7279 AD - Center for Thrombosis and Hemostasis, University Medical Center Mainz, Germany (S.V.K.). AD - Department of Cardiology, Democritus University of Thrace, Greece (S.V.K.). FAU - Lanno, Michelle T AU - Lanno MT AUID- ORCID: 0009-0004-7202-1027 AD - Pulmonary Embolism Response Team Consortium, Nashua, NH (M.T.L., J.L.R.). FAU - Lookstein, Robert AU - Lookstein R AD - Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY (R.L.). FAU - Moriarty, John M AU - Moriarty JM AUID- ORCID: 0000-0001-8108-520X AD - Department of Radiology, David Geffen School of Medicine, University of California, Los Angeles (J.M.M.). FAU - Ni Ainle, Fionnuala AU - Ni Ainle F AD - University College Dublin School of Medicine, Mater Misericordiae University Hospital, Ireland (F.N.A.). AD - Division of Hematology, Royal College of Surgeons in Ireland, Dublin (F.N.A.). FAU - Reed, Jamie L AU - Reed JL AUID- ORCID: 0009-0004-4859-1417 AD - Pulmonary Embolism Response Team Consortium, Nashua, NH (M.T.L., J.L.R.). FAU - Rosovsky, Rachel P AU - Rosovsky RP AUID- ORCID: 0000-0002-2392-7365 AD - Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (R.P.R.). FAU - Royce, Sara M AU - Royce SM AD - US Food and Drug Administration, Silver Spring, MD (S.M.R., E.M.W.). FAU - Secemsky, Eric A AU - Secemsky EA AUID- ORCID: 0000-0003-3861-3163 AD - Division of Cardiology, Beth Israel Deaconess Medical Center, Boston, MA (E.A.S.). FAU - Sharp, Andrew S P AU - Sharp ASP AUID- ORCID: 0000-0002-9085-8881 AD - Division of Cardiology, University Hospital of Wales and Cardiff University (A.S.P.S.). FAU - Sista, Akhilesh K AU - Sista AK AD - Department of Radiology, Weill Cornell Medicine, New York, NY (A.K.S.). FAU - Smith, Roy E AU - Smith RE AD - Department of Medicine, University of Pittsburgh Medical Center, PA (R.E.S.). FAU - Wells, Phil AU - Wells P AUID- ORCID: 0000-0002-8657-8326 AD - Department of Medicine, Ottawa Hospital, University of Ottawa, Canada (P.W.). FAU - Yang, Joanna AU - Yang J AD - Division of Cardiology, Massachusetts General Hospital, Boston (K.R., J.Y.). FAU - Whatley, Eleni M AU - Whatley EM AD - US Food and Drug Administration, Silver Spring, MD (S.M.R., E.M.W.). CN - Pulmonary Embolism Research Collaborative (PERC) Attendees LA - eng GR - K23 HL150290/HL/NHLBI NIH HHS/United States GR - U01 HL107352/HL/NHLBI NIH HHS/United States PT - Consensus Statement PT - Journal Article PT - Review DEP - 20240912 PL - United States TA - Circulation JT - Circulation JID - 0147763 SB - IM MH - *Pulmonary Embolism/therapy/diagnosis MH - Humans MH - Acute Disease PMC - PMC11698503 MID - NIHMS2017685 OTO - NOTNLM OT - data collection OT - multidisciplinary care team OT - percutaneous aspiration OT - pulmonary embolism OT - registry data OT - standardization OT - thrombectomy OT - thrombolytic therapy COIS- Dr Rosenfield reports consulting fees from Abbott Vascular, Boston Scientific, Contego, Imperative Care, Johnson & Johnson, Biosense Webster, Medtronic, Neptune Medical, and Philips; board membership for the PERT (Pulmonary Embolism Response Team) Consortium; and stock or stock options in Access Vascular, Althea Medical, Auxetics, Contego, Endospan, Imperative Care, Innova Vascular, InspireMD, JanaCare, Magneto, MedAlliance, Neptune Medical, Orchestra, Sealonix, Shockwave, Skydance, Summa Therapeutics, Thrombolex, Vantis Vascular, Vasorum, Viz.ai, and Vumedi. Dr Bowers reports consulting fees from Truvic, Inc, lecture fees from Janssen and Bristol Myers Squibb (BMS)-Pfizer, payment for expert testimony, and participation on Advisory Board of Truvic, Inc. Dr Barnett reports payment for expert testimony. Dr Davis reports travel support for attending the Pulmonary Embolism Research Collaborative meeting. Dr Giri reports research support from Boston Scientific, Inc, and Inari Medical; consulting fees from Boston Scientific, Inc, Cordis, and Abbott Vascular; support for attending meetings from Inari Medical; participation on an advisory board for Angiodynamics, Inc, and Boston Scientific, Inc; participation in leadership at Society for Cardiac Angiography and Intervention and the PERT Consortium; and stock or stock options in Endovascular Engineering. Dr Horowitz reports research support from Inari Medical; consultation and personal lecture fees from Inari Medical and Penumbra, Inc; and support for attending meetings from Inari Medical. Dr Keeling reports consulting fees from Angiodynamics, Inc, Penumbra, Inc, Viz.ai, and Dexcom. Dr Klok reports institutional research support from Bayer, Bristol Myers Squibb, Actelion, Boston Scientific, Inc, Leo Pharma, the Netherlands Organisation for Health Research and Development, the Dutch Thrombosis Association, the Dutch Heart Foundation, and the Horizon Europe program; service on the Board of the Rembrandt Institute of Cardiovascular Science; Chair of the Board of the Dutch Society of Vascular Medicine; nucleus member of the European Society of Cardiology work group on pulmonary circulation and RV function; nucleus member of ISTH SSC diagnostic and predictive variables; Chair of the Board of the Dutch Thrombosis Network; and medical lead, Anticoagulation Clinic Leiden. Dr Konstantinides reports personal and institutional consulting fees from Bayer AG, Daiichi-Sankyo, and Boston Scientific, Inc, and personal lecture fees from Bayer AG, Daiichi-Sankyo, Pfizer-Bristol Myers Squibb, and Boston Scientific, Inc. Dr Lookstein reports consulting fees from Penumbra, Inc, Boston Scientific, Inc, Medtronic, Cordis, Becton Dickinson, Abbott Vascular, Neptune Medical, Imperative Care, and Aidoc; payment for expert testimony; participation on advisory boards for Magneto, Boston Scientific, Inc, Medtronic, and Trireme; leadership roles at the PERT Consortium, Critical Limb Ischemia Global Society, and Society of Interventional Radiology; and stock or stock options in Imperative Vascular, Thrombolex, Innova Vascular, and Summa Vascular. Dr Moriarty reports research support from Angiodynamics, Inc, and Penumbra, Inc; consulting fees from Angiodynamics, Inc, Penumbra Inc, Inquis Medical, Innova Vascular, Boston Scientific Inc, Auxetics, and Retriever Medical; and participation on the data safety monitoring board for Penumbra, Inc. Dr Ni Ainle reports institutional research support from Sanofi, Daiichi-Sankyo, the Irish Health Research Board, Bayer, and Boston Scientific, Inc; patents pending for European Application No. 20166826.6; past member of World Thrombosis Day International Steering Committee; Director at Large and Member, International Network of Venous ThromboEmbolism Research Networks Council; Co-Director, InVite; Co-Founder and member of Executive Committee of Venous Thromboembolism Ireland; Advisory Committee for Human Medicines; member of "Preventing Venous Thromboembolism in Hospitals" Collaborative Advisory Group; Board Member, Thrombosis Ireland Patient Organization and Charity; and National Lead, Irish Venous Thromboembolism Patient Safety Programme. Dr Rosovsky reports research support from BMS and Janssen; consulting fees from Abbott, BMS, Dova, Inari Medical, Janssen, and Penumbra, Inc; participation on the data safety monitoring board for the Pepper Trial and Harvard Cancer Center; unpaid President-Elect of the PERT Consortium; and unpaid member of ASH Committee on Quality. Dr Secemsky reports research support from NIH/NHLBINIH/NHBLI K23HL150290, Food and Drug Administration, Becton-Dickinson, Boston Scientific, Inc, Cook Medical, Cardiovascular Systems Inc., Laminate Medical, Medtronic, and Philip; consulting fees and personal lecture fees from Abbott, Bayer, Becton-Dickinson, Boston Scientific, Inc, Cook, Cardiovascular Systems Inc., Inari Medical, Medtronic, Philips, Shockwave, and VentureMed; and participation on data safety monitoring boards for LIFE BTK, BIOMIMCS3D, HI-PEITHO, and Transcend. Dr Sharp reports consulting and lecture fees from Medtronic, Boston Scientific, Inc, Philips, Recor Medical, and Penumbra, Inc. Dr Sista reports research support from NIH/NHLBI as principal investigator of U34 and UG3 awards, unpaid participation on data safety monitoring boards for Angiodynamics, Inc, and Thrombolex, Inc; and participation on the Board of Directors for the Society of Interventional Radiology. Dr Wells reports participation on the data safety monitoring board for Anthos. The other authors report no conflicts. FIR - Abudi, Tami IR - Abudi T FIR - Adams, George IR - Adams G FIR - Ahmad, Hajira IR - Ahmad H FIR - Ajao, Adebola IR - Ajao A FIR - Archard, Erin IR - Archard E FIR - Auger, William IR - Auger W FIR - Avila-Tang, Erika IR - Avila-Tang E FIR - Barnes, Geoff IR - Barnes G FIR - Barnett, Christopher IR - Barnett C FIR - Bashir, Riyaz IR - Bashir R FIR - Benenati, James IR - Benenati J FIR - Berman, Aaron IR - Berman A FIR - Bowers, Terry IR - Bowers T FIR - Buck, Michael IR - Buck M FIR - Burnett, Allison IR - Burnett A FIR - Cameron, Scott IR - Cameron S FIR - Cavanaugh, Kenneth IR - Cavanaugh K FIR - Cerminaro, Michael IR - Cerminaro M FIR - Daniel, Daniel IR - Daniel D FIR - Daves, Seanna IR - Daves S FIR - Davis, George IR - Davis G FIR - Dicks, Andrew IR - Dicks A FIR - Elder, Mahir IR - Elder M FIR - Farrell, Ann IR - Farrell A FIR - Garman, Alissa IR - Garman A FIR - Gatzemeier, Jamee IR - Gatzemeier J FIR - Giannikopoulos, Demetri IR - Giannikopoulos D FIR - Gibson, Michael IR - Gibson M FIR - Goldberg, Joshua IR - Goldberg J FIR - Gonsalves, Carin IR - Gonsalves C FIR - Grodzin, Charles IR - Grodzin C FIR - Gundert, Emily IR - Gundert E FIR - Gurley, John IR - Gurley J FIR - Heresi, Gustavo IR - Heresi G FIR - Hlozek, Kristen IR - Hlozek K FIR - Hoerst, Stephen IR - Hoerst S FIR - Hooks, Brandon IR - Hooks B FIR - Horowitz, James IR - Horowitz J FIR - Jaber, Wissam IR - Jaber W FIR - Jaff, Michael IR - Jaff M FIR - Jimenez, David IR - Jimenez D FIR - Johnston-Cox, Hillary IR - Johnston-Cox H FIR - Kaatz, Scott IR - Kaatz S FIR - Kolluri, Raghu IR - Kolluri R FIR - Laird, John IR - Laird J FIR - Lake, Leslie IR - Lake L FIR - Langston, Matthew IR - Langston M FIR - Lossef, Steven IR - Lossef S FIR - Love, Charles IR - Love C FIR - Mackel, Julie IR - Mackel J FIR - Massaro, Lori IR - Massaro L FIR - McDaniel, Michael IR - McDaniel M FIR - McNally, Vicki IR - McNally V FIR - Merli, Geno IR - Merli G FIR - Mina, Bushra IR - Mina B FIR - Monreal, Manuel IR - Monreal M FIR - Moores, Lisa IR - Moores L FIR - Morris, Timothy IR - Morris T FIR - Nossair, Fadi IR - Nossair F FIR - O'Connell, Gregory IR - O'Connell G FIR - O'Corragain, Oisin IR - O'Corragain O FIR - Ouriel, Kenneth IR - Ouriel K FIR - Parikh, Sahil IR - Parikh S FIR - Piazza, Gregory IR - Piazza G FIR - Pohlson, Katie IR - Pohlson K FIR - Polverini, Peter IR - Polverini P FIR - Pomeroy, Jordan IR - Pomeroy J FIR - Pugliese, Steve IR - Pugliese S FIR - Pullin, Brian IR - Pullin B FIR - Quinto, Brian IR - Quinto B FIR - Rali, Parth IR - Rali P FIR - Rivera-Lebron, Belinda IR - Rivera-Lebron B FIR - Robertson, Bill IR - Robertson B FIR - Rosengard, Bruce IR - Rosengard B FIR - Shaw, Miranda IR - Shaw M FIR - Simonton, Chuck IR - Simonton C FIR - Sista, Akhilesh IR - Sista A FIR - Smith, Roy IR - Smith R FIR - Spyropoulos, Alex IR - Spyropoulos A FIR - Srivastava, Sanjay IR - Srivastava S FIR - Sterling, Keith IR - Sterling K FIR - Strauss, Jayme IR - Strauss J FIR - Taber, Margaret IR - Taber M FIR - Tapson, Victor IR - Tapson V FIR - Tawney, Adam IR - Tawney A FIR - Tu, Thomas IR - Tu T FIR - Valent, Tom IR - Valent T FIR - Venkat, Venkat IR - Venkat V FIR - Walach, Elad IR - Walach E FIR - Ward, Rebecca IR - Ward R FIR - Ward, Adam IR - Ward A FIR - Weinberg, Ido IR - Weinberg I FIR - Wells, Phil IR - Wells P FIR - West, Frances Mae IR - West FM FIR - West, Nick IR - West N FIR - Whatley, Eleni IR - Whatley E FIR - Yang, Joanna IR - Yang J FIR - Yongpravat, Charlie IR - Yongpravat C EDAT- 2024/09/12 08:42 MHDA- 2024/09/30 18:52 PMCR- 2025/10/01 CRDT- 2024/09/12 05:03 PHST- 2024/09/30 18:52 [medline] PHST- 2024/09/12 08:42 [pubmed] PHST- 2024/09/12 05:03 [entrez] PHST- 2025/10/01 00:00 [pmc-release] AID - 10.1161/CIRCULATIONAHA.124.067482 [doi] PST - ppublish SO - Circulation. 2024 Oct;150(14):1140-1150. doi: 10.1161/CIRCULATIONAHA.124.067482. Epub 2024 Sep 12. PMID- 39261867 OWN - NLM STAT- MEDLINE DCOM- 20240912 LR - 20240914 IS - 1749-799X (Electronic) IS - 1749-799X (Linking) VI - 19 IP - 1 DP - 2024 Sep 11 TI - Analysis of the impact of underlying diseases in the elderly on postoperative re-fractures after osteoporotic compression fractures. PG - 556 LID - 10.1186/s13018-024-04907-5 [doi] LID - 556 AB - BACKGROUND: Postoperative refracture of osteoporotic compression fractures in the elderly due to underlying illnesses is a complicated matter involving several variables. A multidisciplinary approach involving orthopedics, geriatrics, endocrinology, and rehabilitation medicine is necessary for an investigation of these issues. investigating the impact of older patients' underlying medical conditions on the refracture of osteoporotic compression fractures following surgery. METHODS: A retrospective analysis was conducted on 2383 patients between August 2013 and August 2023. 550 patients with comorbid geriatric underlying diseases were screened, 183 patients underwent refractories, and 367 patients were classified as non-refractories. The patients were then divided into two groups: those undergoing refractories and those not, and the underlying diseases of the patients in both groups were examined using ROC curves and unifactorial and multifactorial logistic regression analyses. RESULTS: Among the patients gathered, the frequency of re-fracture was 33.3%. A statistically significant difference was observed when re-fracture was linked to patients with long-term alcohol consumption, operated vertebrae /= 10years (P = 0.003, OR = 2.165), mental abnormality (P < 0.001, OR = 4.093), scoliosis (P < 0.001, OR = 6.243), chronic kidney disease (P = 0.002, OR = 2.208), and traumatic injuries (P = 0.029, OR = 3.512) were the risk factors examined in a binary logistic regression analysis. The results of multiple linear stepwise regression analysis indicated that re-fracture was more influenced by scoliosis. CONCLUSIONS: Hypertensive disorders were protective factors against the formation of re-fracture, while alcohol intake usage for more than ten years, psychological abnormalities, scoliosis, chronic kidney disease, and trauma were risk factors. Scoliosis had the highest influence on re-fracture. CI - (c) 2024. The Author(s). FAU - Qi, Bao AU - Qi B AD - Department of Spine Surgery, Affiliated Hospital of Jining Medical University, Gu Huai Road 89, Jining, 27200, Shandong, P.R. China. FAU - Kong, Xiangqing AU - Kong X AD - Department of Spine Surgery, Affiliated Hospital of Jining Medical University, Gu Huai Road 89, Jining, 27200, Shandong, P.R. China. FAU - Meng, Chunyang AU - Meng C AD - Department of Spine Surgery, Affiliated Hospital of Jining Medical University, Gu Huai Road 89, Jining, 27200, Shandong, P.R. China. 17661345209@163.com. FAU - Li, Qingwei AU - Li Q AD - Department of Spine Surgery, Affiliated Hospital of Jining Medical University, Gu Huai Road 89, Jining, 27200, Shandong, P.R. China. plasurg0618@163.com. AD - China Medical University, Shenyang, 11000, Liaoning, China. plasurg0618@163.com. LA - eng GR - 2023YXNS039/Jining City Bureau of Science and Technology/ PT - Journal Article DEP - 20240911 PL - England TA - J Orthop Surg Res JT - Journal of orthopaedic surgery and research JID - 101265112 SB - IM MH - Humans MH - Female MH - Aged MH - Male MH - Retrospective Studies MH - *Osteoporotic Fractures/surgery/epidemiology MH - Aged, 80 and over MH - *Fractures, Compression/surgery/etiology MH - *Postoperative Complications/etiology/epidemiology MH - Recurrence MH - Risk Factors MH - Spinal Fractures/surgery/etiology/epidemiology MH - Hypertension/complications/epidemiology MH - Alcohol Drinking/adverse effects/epidemiology PMC - PMC11389243 OTO - NOTNLM OT - Elderly OT - Osteoporotic compression fracture OT - Re-fracture OT - Underlying diseases COIS- The authors declare no competing interests. EDAT- 2024/09/12 00:42 MHDA- 2024/09/12 08:42 PMCR- 2024/09/11 CRDT- 2024/09/11 23:49 PHST- 2024/04/30 00:00 [received] PHST- 2024/07/09 00:00 [accepted] PHST- 2024/09/12 08:42 [medline] PHST- 2024/09/12 00:42 [pubmed] PHST- 2024/09/11 23:49 [entrez] PHST- 2024/09/11 00:00 [pmc-release] AID - 10.1186/s13018-024-04907-5 [pii] AID - 4907 [pii] AID - 10.1186/s13018-024-04907-5 [doi] PST - epublish SO - J Orthop Surg Res. 2024 Sep 11;19(1):556. doi: 10.1186/s13018-024-04907-5. PMID- 39259357 OWN - NLM STAT- MEDLINE DCOM- 20241112 LR - 20261010 IS - 1432-1041 (Electronic) IS - 0031-6970 (Linking) VI - 80 IP - 12 DP - 2024 Dec TI - Beta-blockers and breastfeeding: a real-life prospective study. PG - 1937-1943 LID - 10.1007/s00228-024-03753-y [doi] AB - PURPOSE: At Lille University Hospital, a pregnancy heart team including cardiologists, obstetricians, pediatricians, anesthetists, geneticists, and pharmacologists discusses about treatment compatibility taken during breastfeeding in pregnant women (or those wishing to be pregnant) with complex cardiovascular pathologies. Beta-blockers are among the drug most often used in these patients, and data are missing or suggest a risk to the breastfed child. The aim of this study was to evaluate the proportion of women treated with beta-blockers, identified during the multidisciplinary meeting, who breastfed and to monitor adverse effects (AEs) in newborns. METHODS: A prospective descriptive study was conducted from 1 December 2017 to 1 December 2021. All pregnant patients followed up by the pregnancy heart team in Lille University Hospital, treated with beta-blockers and who gave birth, were contacted as part of the pharmacovigilance follow-up. RESULTS: The proportion of women treated with beta-blockers intending to breastfeed was 69.8%. Among the 53 women interviewed, 49% did not breastfeed, including 10 because of the theoretical incompatibility of their beta-blocker with breastfeeding. Among the 27 women who breastfed, 30% breastfed while treated with a theoretically incompatible beta-blocker; 56% was changed from their initial beta-blocker to allow safe breastfeeding. No serious AE was observed. CONCLUSION: To our knowledge, our study is the largest series of patients treated with beta-blockers during breastfeeding. Taking a treatment can be an obstacle to breastfeeding, but for the particular case of beta-blockers, even if the available data are few and sometimes worrying, the data from this study are reassuring. CI - (c) 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Freppel, Romane AU - Freppel R AD - Centre de Pharmacovigilance Et de Pharmacoepidemiologie, Service de Pharmacologie Medicale, CHU de Lille, Lille, France. romane.freppel@chu-dijon.fr. FAU - Gaboriau, Louise AU - Gaboriau L AD - Centre de Pharmacovigilance Et de Pharmacoepidemiologie, Service de Pharmacologie Medicale, CHU de Lille, Lille, France. FAU - Richardson, Marjorie AU - Richardson M AD - Service d'explorations Fonctionnelles Cardiovasculaires, Institut Coeur Poumon, CHU Lille, Lille, France. FAU - Ould, Yasmine AU - Ould Y AD - Department of Obstetrics, CHU Lille, 59000, Lille, France. FAU - Domanski, Olivia AU - Domanski O AD - Service de Cardiologie Pediatrique et Congenitale, CHU Lille, Lille, France. FAU - Pincon, Claire AU - Pincon C AD - ULR2694 (METRICS : Evaluation des Technologies de Sante et des Pratiques Medicales), Univ. Lille, CHU Lille, 59000, Lille, France. FAU - Ghesquiere, Louise AU - Ghesquiere L AD - Department of Obstetrics, F-59000 Lille, France; Univ. Lille, ULR2694 - METRICS - Health Technology and Medical Practice Assessment, CHU Lille, F-59000, Lille, France. FAU - Gautier, Sophie AU - Gautier S AD - Centre de Pharmacovigilance Et de Pharmacoepidemiologie, Service de Pharmacologie Medicale, CHU de Lille, Lille, France. LA - eng PT - Journal Article DEP - 20240911 PL - Germany TA - Eur J Clin Pharmacol JT - European journal of clinical pharmacology JID - 1256165 RN - 0 (Adrenergic beta-Antagonists) SB - IM MH - Humans MH - Female MH - *Breast Feeding MH - *Adrenergic beta-Antagonists/adverse effects/therapeutic use MH - Prospective Studies MH - Pregnancy MH - Infant, Newborn MH - Adult MH - Pharmacovigilance MH - Pregnancy Complications, Cardiovascular/drug therapy OTO - NOTNLM OT - Adrenergic beta-Antagonists / pharmacology OT - Breastfeeding OT - Human milk OT - Mother-to-child transmission OT - Pharmacovigilance COIS- Declarations Ethical approval Not applicable. Competing interests The authors declare no competing interests. EDAT- 2024/09/11 12:44 MHDA- 2024/11/13 13:53 CRDT- 2024/09/11 11:17 PHST- 2023/12/18 00:00 [received] PHST- 2024/08/27 00:00 [accepted] PHST- 2024/11/13 13:53 [medline] PHST- 2024/09/11 12:44 [pubmed] PHST- 2024/09/11 11:17 [entrez] AID - 10.1007/s00228-024-03753-y [pii] AID - 10.1007/s00228-024-03753-y [doi] PST - ppublish SO - Eur J Clin Pharmacol. 2024 Dec;80(12):1937-1943. doi: 10.1007/s00228-024-03753-y. Epub 2024 Sep 11. PMID- 39256240 OWN - NLM STAT- MEDLINE DCOM- 20241014 LR - 20241120 IS - 1432-1076 (Electronic) IS - 0340-6199 (Print) IS - 0340-6199 (Linking) VI - 183 IP - 11 DP - 2024 Nov TI - Long-term health outcome and quality of life in children with multisystem inflammatory syndrome: findings from multidisciplinary follow-up at an Italian tertiary-care paediatric hospital. PG - 4885-4895 LID - 10.1007/s00431-024-05706-0 [doi] AB - Multisystem inflammatory syndrome is a severe complication of SARS-CoV-2 infection in children (MIS-C). To date, data on long-term sequelae mainly concern cardiac outcomes. All /= 18 years) with a diagnosis of any type of AF. We included RCTs comparing organised clinical service, disease-specific management interventions (including e-health models of care) for people with AF that were multicomponent and multidisciplinary in nature to usual care. DATA COLLECTION AND ANALYSIS: Three review authors independently selected studies, assessed risk of bias, and extracted data from the included studies. We calculated risk ratio (RR) for dichotomous data and mean difference (MD) or standardised mean difference (SMD) for continuous data with 95% confidence intervals (CIs) using random-effects analyses. We then calculated the number needed to treat for an additional beneficial outcome (NNTB) using the RR. We performed sensitivity analyses by only including studies with a low risk of selection and attrition bias. We assessed heterogeneity using the I(2) statistic and the certainty of the evidence according to GRADE. The primary outcomes were all-cause mortality and all-cause hospitalisation. The secondary outcomes were cardiovascular mortality, cardiovascular hospitalisation, AF-related emergency department visits, thromboembolic complications, minor cerebrovascular bleeding events, major cerebrovascular bleeding events, all bleeding events, AF-related quality of life, AF symptom burden, cost of intervention, and length of hospital stay. MAIN RESULTS: We included 8 studies (8205 participants) of collaborative, multidisciplinary care, or virtual care for people with AF. The average age of participants ranged from 60 to 73 years. The studies were conducted in China, the Netherlands, and Australia. The included studies involved either a nurse-led multidisciplinary approach (n = 4) or management using mHealth (n = 2) compared to usual care. Only six out of the eight included studies could be included in the meta-analysis (for all-cause mortality and all-cause hospitalisation, cardiovascular mortality, cardiovascular hospitalisation, thromboembolic complications, and major bleeding), as quality of life was not assessed using a validated outcome measure specific for AF. We assessed the overall risk of bias as high, as all studies had at least one domain at unclear or high risk of bias rating for performance bias (blinding) in particular. Organised AF clinical services probably result in a large reduction in all-cause mortality (RR 0.64, 95% CI 0.46 to 0.89; 5 studies, 4664 participants; moderate certainty evidence; 6-year NNTB 37) compared to usual care. However, organised AF clinical services probably make little to no difference to all-cause hospitalisation (RR 0.94, 95% CI 0.88 to 1.02; 2 studies, 1340 participants; moderate certainty evidence; 2-year NNTB 101) and may not reduce cardiovascular mortality (RR 0.64, 95% CI 0.35 to 1.19; 5 studies, 4564 participants; low certainty evidence; 6-year NNTB 86) compared to usual care. Organised AF clinical services reduce cardiovascular hospitalisation (RR 0.83, 95% CI 0.71 to 0.96; 3 studies, 3641 participants; high certainty evidence; 6-year NNTB 28) compared to usual care. Organised AF clinical services may have little to no effect on thromboembolic complications such as stroke (RR 1.14, 95% CI 0.74 to 1.77; 5 studies, 4653 participants; low certainty evidence; 6-year NNTB 588) and major cerebrovascular bleeding events (RR 1.25, 95% CI 0.79 to 1.97; 3 studies, 2964 participants; low certainty evidence; 6-year NNTB 556). None of the studies reported minor cerebrovascular events. AUTHORS' CONCLUSIONS: Moderate certainty evidence shows that organisation of clinical services for AF likely results in a large reduction in all-cause mortality, but probably makes little to no difference to all-cause hospitalisation compared to usual care. Organised AF clinical services may not reduce cardiovascular mortality, but do reduce cardiovascular hospitalisation compared to usual care. However, organised AF clinical services may make little to no difference to thromboembolic complications and major cerebrovascular events. None of the studies reported minor cerebrovascular events. Due to the limited number of studies, more research is required to compare different models of care organisation, including utilisation of mHealth. Appropriately powered trials are needed to confirm these findings and robustly examine the effect on inconclusive outcomes. The findings of this review underscore the importance of the co-ordination of care underpinned by collaborative multidisciplinary approaches and augmented by virtual care. CI - Copyright (c) 2024 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration. FAU - Ferguson, Caleb AU - Ferguson C AD - Centre for Chronic & Complex Care Research, Western Sydney Local Health District, Sydney, Australia. AD - School of Nursing, Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, Australia. FAU - Shaikh, Fahad AU - Shaikh F AD - Centre for Chronic & Complex Care Research, Western Sydney Local Health District, Sydney, Australia. AD - School of Nursing, Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, Australia. FAU - Allida, Sabine M AU - Allida SM AD - Centre for Chronic & Complex Care Research, Western Sydney Local Health District, Sydney, Australia. AD - School of Nursing, Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, Australia. FAU - Hendriks, Jeroen AU - Hendriks J AD - Caring Futures Institute, College of Nursing and Health Sciences, Flinders University, Adelaide, Australia. AD - Centre for Heart Rhythm Disorders, University of Adelaide, South Australian Health and Medical Research Institute and Royal Adelaide Hospital, Adelaide, Australia. FAU - Gallagher, Celine AU - Gallagher C AD - Centre for Heart Rhythm Disorders, University of Adelaide, South Australian Health and Medical Research Institute and Royal Adelaide Hospital, Adelaide, Australia. FAU - Bajorek, Beata V AU - Bajorek BV AD - Heart and Brain Program, Hunter Medical Research Institute, Newcastle, Australia. AD - College of Health, Medicine, and Wellbeing, University of Newcastle, Newcastle, Australia. AD - Department of Pharmacy, Hunter New England Local Health District, Newcastle, Australia. FAU - Donkor, Andrew AU - Donkor A AD - IMPACCT, Faculty of Health, University of Technology Sydney, Sydney, Australia. FAU - Inglis, Sally C AU - Inglis SC AD - IMPACCT, Faculty of Health, University of Technology Sydney, Sydney, Australia. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20240729 PL - England TA - Cochrane Database Syst Rev JT - The Cochrane database of systematic reviews JID - 100909747 SB - IM UOF - doi: 10.1002/14651858.CD013408 MH - Aged MH - Humans MH - *Atrial Fibrillation/complications/mortality/therapy MH - Bias MH - Cause of Death MH - Hospitalization/statistics & numerical data MH - Quality of Life MH - Randomized Controlled Trials as Topic MH - Stroke/epidemiology/etiology/prevention & control MH - *Telemedicine/organization & administration/statistics & numerical data MH - Middle Aged MH - *Patient Care Team/organization & administration/statistics & numerical data PMC - PMC11285297 COIS- CF declares receiving a Post-doctoral fellowship grant from the Heart Foundation of Australia and an Investigator grant from the Australian National Health and Medical Research Council (NHMRC) (APP1196262) and a grant from the National Stroke Foundation (all paid to institution, but CF benefitted from the payments). CF works as a Professor at the University of Wollongong and Western Sydney Local Health District. CF is the Chair of the Cardiovascular Nursing Council of the Cardiac Society of Australia and New Zealand (voluntary role). CF was also a member of the Guideline Working Group for the management of atrial fibrillation by the Heart Foundation, Australia and Cardiac Society of Australia and New Zealand. CF declares that he has published opinions on the topic via social media outlets. CF is affiliated with the Stroke Foundation (Australia) and the Heart Foundation (Australia), who have declared an opinion or position on the topic. SA declares having no conflicts of interest. JH works as Professor of Cardiovascular Nursing at the Flinders University. JH declares a Future Leader Fellowship from the National Heart Foundation of Australia (paid to institution) and speakers fee from Biotronik for a presentation (paid to institution; funds may have been used to support projects in which JH was involved, but JH did not have access to the funds). JH was a member of the Task Force Writing Committee to develop the 2016 European Society of Cardiology Guidelines for the management of atrial fibrillation; and the Australian clinical guidelines for the diagnosis and management of atrial fibrillation 2018, in collaboration with the National Heart Foundation and the Cardiac Society of Australia and NZ (unpaid positions). JH also declares that he is the lead author and investigator of an unfunded trial included in the analysis of this review (Hendriks 2012); he was not involved in assessing the eligibility of that study, extracting or analysing data, assessing risk of bias, or grading the certainty of the evidence. CG declares having published an opinion piece on integrated care (PMID: 33624053) and being a contributing author of a post hoc analysis of the original trial by JH and colleagues (Hendriks 2012); unfunded study. CG was not involved in assessing the eligibility of that study, extracting or analysing data, assessing risk of bias, or grading the certainty of the evidence. BB declares working as a Clinical Academic Pharmacist at the Royal North Shore and Hunter New England Local Health District as well as membership of the Guideline Working Group for the management of atrial fibrillation by the National Heart Foundation, Australia (unpaid position). AD declares having no conflicts of interest. SCI declares a Fellowship grant from the Heart Foundation Australia via their institution and being the chair of the Cardiovascular Nursing Council 2016-2022 and Professional and Ethical Standards Committee 2022-2024 (voluntary roles) with the Cardiac Society of Australia and New Zealand (CSANZ). SCI was an Editor with Cochrane Heart. She was not involved in the editorial process for this review. FS declares having no conflicts of interest. FS is supported by an Australian Government Research Training Program (RTP) Scholarship and by a PhD Scholarship from Western Sydney University. EDAT- 2024/07/29 12:42 MHDA- 2024/07/29 12:43 PMCR- 2024/07/29 CRDT- 2024/07/29 09:42 PHST- 2024/07/29 12:43 [medline] PHST- 2024/07/29 12:42 [pubmed] PHST- 2024/07/29 09:42 [entrez] PHST- 2024/07/29 00:00 [pmc-release] AID - CD013408.pub2 [pii] AID - 10.1002/14651858.CD013408.pub2 [doi] PST - epublish SO - Cochrane Database Syst Rev. 2024 Jul 29;7(7):CD013408. doi: 10.1002/14651858.CD013408.pub2. PMID- 39070515 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240730 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 16 IP - 6 DP - 2024 Jun TI - Innovations in Hybrid Laparoscopic Surgery: Integrating Advanced Technologies for Multidisciplinary Cases. PG - e63219 LID - 10.7759/cureus.63219 [doi] LID - e63219 AB - Combining conventional laparoscopic techniques with cutting-edge technologies, such as robotics, improved imaging, and flexible equipment, hybrid laparoscopic techniques represent a revolutionary advancement in minimally invasive surgery. These methods have several benefits, such as increased accuracy, quicker healing periods, and fewer complications, which makes them especially useful in complicated multidisciplinary situations. The historical evolution, uses, benefits, and drawbacks of hybrid laparoscopic procedures are examined in this narrative review, which also covers urological, gastrointestinal, cardiothoracic, and gynecological surgery. The review focuses on how these methods promote interdisciplinary cooperation and creativity by enabling more accurate and successful surgical operations. It also discusses the equipment needs, integration difficulties, and technical difficulties that need to be resolved to reach the full potential of hybrid laparoscopic surgery. For hybrid laparoscopic procedures to become more widely used and effective in the future, there is a need for specialized training programs, interdisciplinary research collaborations, and ongoing technological advancements. CI - Copyright (c) 2024, Cheema et al. FAU - Cheema, Muhammad Junaid AU - Cheema MJ AD - General Surgery, Sir Ganga Ram Hospital, Lahore, PAK. FAU - Hassan, Muhammad Mustaneer Ul AU - Hassan MMU AD - General Surgery, Sir Ganga Ram Hospital, Lahore, PAK. FAU - Asim, Aiman AU - Asim A AD - Medicine and Surgery, Jinnah Postgraduate Medical Centre, Karachi, PAK. FAU - Nathaniel, Eemaz AU - Nathaniel E AD - Research, Harvard Medical School, Boston, USA. FAU - Shafeeq, Mohamed Ishraq AU - Shafeeq MI AD - Surgery, Vitebsk State Medical University, Vitebsk, BLR. FAU - Tayyab, Muhammad Abbas AU - Tayyab MA AD - Surgery, King Edward Medical University, Lahore, PAK. FAU - Rahim Valiyakath, Cijal AU - Rahim Valiyakath C AD - Medicine, Guangxi Medical University, Nanning, CHN. FAU - Abdallah, Shenouda AU - Abdallah S AD - Surgery, Jaber Al-Ahmad Hospital, Kuwait, KWT. FAU - Usman, Ali AU - Usman A AD - General Surgery, Nishtar Medical University, Multan, PAK. LA - eng PT - Journal Article PT - Review DEP - 20240626 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC11279072 OTO - NOTNLM OT - general surgery OT - hybrid laparoscopic OT - medicine OT - prognosis OT - surgery COIS- Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. EDAT- 2024/07/29 06:42 MHDA- 2024/07/29 06:43 PMCR- 2024/06/26 CRDT- 2024/07/29 05:31 PHST- 2024/06/26 00:00 [accepted] PHST- 2024/07/29 06:43 [medline] PHST- 2024/07/29 06:42 [pubmed] PHST- 2024/07/29 05:31 [entrez] PHST- 2024/06/26 00:00 [pmc-release] AID - 10.7759/cureus.63219 [doi] PST - epublish SO - Cureus. 2024 Jun 26;16(6):e63219. doi: 10.7759/cureus.63219. eCollection 2024 Jun. PMID- 39069611 OWN - NLM STAT- MEDLINE DCOM- 20240728 LR - 20250116 IS - 1749-8090 (Electronic) IS - 1749-8090 (Linking) VI - 19 IP - 1 DP - 2024 Jul 29 TI - Surgical intervention for lung cancer in patients aged 75 and above: potential associations with increased mortality rates-a single-center observational study. PG - 471 LID - 10.1186/s13019-024-02922-5 [doi] LID - 471 AB - BACKGROUND: Lung cancer, which is diagnosed two to three times more frequently in patients over the age of 70, is a leading cause of cancer-specific mortality. Given the elevated risk of morbidity and mortality, surgical intervention may not always be the most appropriate primary treatment option. This study aims to evaluate specific risk factors associated with postoperative morbidity and mortality in elderly patients and to optimize patient selection therefore improving surgical outcomes. PATIENTS AND METHODS: The study encompassed a cohort of 73 patients aged 75 and above who underwent surgical treatment for non-small cell lung cancer (NSCLC) at the Department of Thoracic Surgery of the P. Hertsen Moscow Oncological Research Institute between 2015 and 2021. All patients underwent preoperative evaluation, including PET/CT staging and functional assessment, carried out by a multidisciplinary team comprising thoracic surgeons, anesthesiologists, and other medical specialists. RESULTS: The investigation revealed a postoperative mortality rate of 5.5% and a postoperative morbidity incidence of 16.4%, with occurrences of atrial fibrillation in 41.6%, persistent air leak in 33.3%, and pneumonia in 25% of complicated cases. At the one-year follow-up, 88% of patients remained free from relapse, whereas at three years, this rate stood at 66%. During the follow-up period, 16 patients (22%) passed away, with a median survival duration of 44 months. Survival rates at one year, three years, and five years were 71%, 66%, and 35%, respectively. Multivariate analysis disclosed several significant factors predicting a complex postoperative period, including stage IIIb (p = 0.023), pN1 (p = 0.049), pN2 (p = 0.030), and central location (p = 0.007). Additionally, overall survival was primarily influenced by a Charlson comorbidity index of 6 (p = 0.044), stage Ia2 (p = 0.033), and the necessity for thoracotomy (p = 0.045). CONCLUSION: Each case of lung cancer in patients aged 75 and older necessitates an individualized approach. Given the higher mortality rate relative to younger patients, comprehensive risk assessment and preoperative management of underlying comorbidities are imperative, with the involvement of anesthesiologists, intensive care physicians, cardiologists, and other relevant specialists as needed. CI - (c) 2024. The Author(s). FAU - Kaprin, Andrey AU - Kaprin A AD - Federal State Budget Institution National Medical Research Radiology Centre of the Ministry of Healthcare of the Russian Federation (FSBI NMRRC), Moscow, Russia. AD - Peoples' Friendship University of Russia, Moscow, Russia. FAU - Pikin, Oleg AU - Pikin O AD - P. Hertsen Moscow Oncology Research Institute, 3, 2 Botkinskiy Proezd, Moscow, 125284, Russia. FAU - Ryabov, Andrey AU - Ryabov A AD - P. Hertsen Moscow Oncology Research Institute, 3, 2 Botkinskiy Proezd, Moscow, 125284, Russia. FAU - Aleksandrov, Oleg AU - Aleksandrov O AD - P. Hertsen Moscow Oncology Research Institute, 3, 2 Botkinskiy Proezd, Moscow, 125284, Russia. alexandrov.oleg.al@gmail.com. AD - National Medical Research Center of Phthisiopulmonology, Moscow, Russia. alexandrov.oleg.al@gmail.com. FAU - Larionov, Denis AU - Larionov D AD - P. Hertsen Moscow Oncology Research Institute, 3, 2 Botkinskiy Proezd, Moscow, 125284, Russia. FAU - Garifullin, Airat AU - Garifullin A AD - P. Hertsen Moscow Oncology Research Institute, 3, 2 Botkinskiy Proezd, Moscow, 125284, Russia. LA - eng PT - Journal Article PT - Observational Study DEP - 20240729 PL - England TA - J Cardiothorac Surg JT - Journal of cardiothoracic surgery JID - 101265113 SB - IM MH - Humans MH - *Lung Neoplasms/surgery/mortality MH - Aged MH - Male MH - Female MH - Aged, 80 and over MH - *Carcinoma, Non-Small-Cell Lung/surgery/mortality MH - Postoperative Complications/epidemiology/mortality MH - Pneumonectomy MH - Risk Factors MH - Retrospective Studies MH - Survival Rate/trends MH - Neoplasm Staging PMC - PMC11285345 OTO - NOTNLM OT - Complications OT - Elderly OT - Perioperative period OT - Pulmonary surgical procedure COIS- The authors declare no competing interests. EDAT- 2024/07/29 00:42 MHDA- 2024/07/29 00:43 PMCR- 2024/07/29 CRDT- 2024/07/28 23:13 PHST- 2023/11/02 00:00 [received] PHST- 2024/06/15 00:00 [accepted] PHST- 2024/07/29 00:43 [medline] PHST- 2024/07/29 00:42 [pubmed] PHST- 2024/07/28 23:13 [entrez] PHST- 2024/07/29 00:00 [pmc-release] AID - 10.1186/s13019-024-02922-5 [pii] AID - 2922 [pii] AID - 10.1186/s13019-024-02922-5 [doi] PST - epublish SO - J Cardiothorac Surg. 2024 Jul 29;19(1):471. doi: 10.1186/s13019-024-02922-5. PMID- 39069333 OWN - NLM STAT- MEDLINE DCOM- 20240728 LR - 20240728 IS - 1557-8216 (Electronic) IS - 0272-5231 (Linking) VI - 45 IP - 3 DP - 2024 Sep TI - Respiratory Aspects of Primary Ciliary Dyskinesia. PG - 717-728 LID - S0272-5231(24)00022-4 [pii] LID - 10.1016/j.ccm.2024.02.020 [doi] AB - This review article explores the respiratory aspects of primary ciliary dyskinesia (PCD), a rare, heterogenous, genetic disorder characterized by impaired motile ciliary function. It discusses the clinical diagnosis and management strategies for PCD-related respiratory disease, including chronic sinusitis, otitis media with effusion, recurrent pneumonia, and bronchiectasis. The review emphasizes the need for a multidisciplinary approach to optimize care and clinical trials to improve outcomes in individuals with PCD, highlighting the importance of accurate diagnosis. CI - Copyright (c) 2024 Elsevier Inc. All rights reserved. FAU - De Jesus-Rojas, Wilfredo AU - De Jesus-Rojas W AD - Department of Pediatrics & Basic Science, Ponce Health Sciences University, Ponce, Puerto Rico, PR 00716, USA. FAU - Shapiro, Adam J AU - Shapiro AJ AD - The Research Institute of the McGill University Health Centre, 2155, rue Guy, 5e etage, Montreal, QC, Canada H3H 2R9. FAU - Shoemark, Amelia AU - Shoemark A AD - Division of Molecular and Clinical Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK; PCD Service, Royal Brompton Hospital, London, UK. Electronic address: a.shoemark@dundee.ac.uk. LA - eng PT - Journal Article PT - Review DEP - 20240328 PL - United States TA - Clin Chest Med JT - Clinics in chest medicine JID - 7907612 SB - IM MH - Humans MH - *Kartagener Syndrome/diagnosis/therapy/physiopathology/complications MH - *Bronchiectasis/therapy/physiopathology/diagnosis MH - Sinusitis/therapy/diagnosis/physiopathology MH - Otitis Media with Effusion/diagnosis/physiopathology/therapy MH - Pneumonia/diagnosis/therapy/physiopathology OTO - NOTNLM OT - Primary ciliary dyskinesia OT - Pulmonary management OT - Pulmonary manifestations OT - Respiratory complications COIS- Disclosure The authors declare no conflicts of interest related to this article. EDAT- 2024/07/29 00:42 MHDA- 2024/07/29 00:43 CRDT- 2024/07/28 20:55 PHST- 2024/07/29 00:43 [medline] PHST- 2024/07/29 00:42 [pubmed] PHST- 2024/07/28 20:55 [entrez] AID - S0272-5231(24)00022-4 [pii] AID - 10.1016/j.ccm.2024.02.020 [doi] PST - ppublish SO - Clin Chest Med. 2024 Sep;45(3):717-728. doi: 10.1016/j.ccm.2024.02.020. Epub 2024 Mar 28. PMID- 39067881 OWN - NLM STAT- MEDLINE DCOM- 20240728 LR - 20260813 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 14 IP - 7 DP - 2024 Jul 27 TI - Timely integration of specialist palliative home care (SPHC) for patients with congestive heart failure, chronic obstructive pulmonary disease and dementia: qualitative evaluation of the experiences of SPHC physicians in the KOPAL trial. PG - e085564 LID - 10.1136/bmjopen-2024-085564 [doi] LID - e085564 AB - OBJECTIVE: Chronic non-malignant diseases (CNMDs) are under-represented in specialist palliative home care (SPHC). The timely integration of SPHC for patients suffering from these diseases can reduce hospitalisation and alleviate symptom burdens. An intervention of an SPHC nurse-patient consultation followed by an interprofessional telephone case conference with the general practitioner (GP) was tested in the KOPAL trial ('Concept for strengthening interprofessional collaboration for patients with palliative care needs'). As part of the trial, the aim of this study was to gain in-depth insights into SPHC physicians' perspective on care with and without the KOPAL intervention for patients with congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD) and dementia (D). DESIGN: Qualitative evaluation of the KOPAL intervention from the perspective of SPHC physicians as part of the KOPAL trial. Thematic-focused narrative interviews analysed with grounded theory. SETTING: We conducted the KOPAL study and its qualitative evaluation in Lower Saxony and the greater Hamburg area, Germany. PARTICIPANTS: 11 physicians from 14 SPHC teams who participated in the trial were interviewed. RESULTS: A grounded theory of the necessity of collaboration between GPs and SPHC teams for patients with CHF, COPD and dementia was developed. From the perspective of SPHC physicians, patients with CNMD are generally difficult to manage in GP care. The timing of SPHC initiation is patient-specific, underscoring the need for collaboration between SPHC physicians and GPs. However, the primary mandate for healthcare should remain with GPs. SPHC physicians actively seek collaboration with GPs (eg, through the KOPAL intervention), viewing themselves as advisors for GPs and aspiring to collaborate as equal partners. CONCLUSION: Effective communication and the negotiation of future interprofessional collaboration are essential for SPHC teams. TRIAL REGISTRATION NUMBER: DRKS00017795. CI - (c) Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Schade, Franziska AU - Schade F AUID- ORCID: 0000-0003-3158-4259 AD - Department of Palliative Medicine, University Medical Center Gottingen, Gottingen, Germany schade.franziska3@mh-hannover.de. AD - Institute for General Practice and Palliative Care, Hannover Medical School, Hannover, Germany. FAU - Huttenrauch, Danica AU - Huttenrauch D AD - Department of Palliative Medicine, University Medical Center Gottingen, Gottingen, Germany. FAU - Schwabe, Sven AU - Schwabe S AUID- ORCID: 0000-0002-3575-3817 AD - Institute for General Practice and Palliative Care, Hannover Medical School, Hannover, Germany. FAU - Mueller, Christiane A AU - Mueller CA AUID- ORCID: 0000-0002-7871-0884 AD - Department of General Practice, University Medical Center Gottingen, Gottingen, Germany. FAU - Pohontsch, Nadine Janis AU - Pohontsch NJ AUID- ORCID: 0000-0002-0966-4087 AD - Department of General Practice and Primary Care, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Stiel, Stephanie AU - Stiel S AUID- ORCID: 0000-0002-5963-2526 AD - Institute for General Practice and Palliative Care, Hannover Medical School, Hannover, Germany. FAU - Scherer, Martin AU - Scherer M AUID- ORCID: 0000-0003-3448-9679 AD - Department of General Practice and Primary Care, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Marx, Gabriella AU - Marx G AUID- ORCID: 0000-0001-6807-9518 AD - Department of General Practice and Primary Care, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Nauck, Friedemann AU - Nauck F AD - Department of Palliative Medicine, University Medical Center Gottingen, Gottingen, Germany. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240727 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 SB - IM MH - Humans MH - *Palliative Care/methods MH - *Pulmonary Disease, Chronic Obstructive/therapy MH - *Heart Failure/therapy MH - *Dementia/therapy MH - *Qualitative Research MH - Male MH - Female MH - *Home Care Services/organization & administration MH - Germany MH - Middle Aged MH - General Practitioners MH - Attitude of Health Personnel PMC - PMC13059874 OTO - NOTNLM OT - adult palliative care OT - chronic disease OT - general medicine (see internal medicine) COIS- Competing interests: None declared. EDAT- 2024/07/28 14:51 MHDA- 2024/07/28 14:52 PMCR- 2024/07/26 CRDT- 2024/07/27 20:53 PHST- 2024/07/28 14:52 [medline] PHST- 2024/07/28 14:51 [pubmed] PHST- 2024/07/27 20:53 [entrez] PHST- 2024/07/26 00:00 [pmc-release] AID - bmjopen-2024-085564 [pii] AID - 10.1136/bmjopen-2024-085564 [doi] PST - epublish SO - BMJ Open. 2024 Jul 27;14(7):e085564. doi: 10.1136/bmjopen-2024-085564. PMID- 39065249 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240729 IS - 2076-2607 (Print) IS - 2076-2607 (Electronic) IS - 2076-2607 (Linking) VI - 12 IP - 7 DP - 2024 Jul 19 TI - Native Infective Endocarditis: A State-of-the-Art-Review. LID - 10.3390/microorganisms12071481 [doi] LID - 1481 AB - Native valve infective endocarditis (NVE) is a global phenomenon, defined by infection of a native heart valve and involving the endocardial surface. The causes and epidemiology of the disease have evolved in recent decades, with a doubling of the average patient age. A higher incidence was observed in patients with implanted cardiac devices that can result in right-sided infection of the tricuspid valve. The microbiology of the disease has also changed. Previously, staphylococci, which are most often associated with health-care contact and invasive procedures, were the most common cause of the disease. This has now been superseded by streptococci. While innovative diagnostic and therapeutic strategies have emerged, mortality rates have not improved and remain at 30%, which is higher than that for many cancer diagnoses. The lack of randomized trials and logistical constraints impede clinical management, and long-standing controversies such as the use of antibiotic prophylaxis persist. This state of the art review addresses clinical practice, controversies, and strategies to combat this potentially devastating disease. A multidisciplinary team will be established to provide care for patients with presumptive NVE. The composition of the team will include specialists in cardiology, cardiovascular surgery, and infectious disease. The prompt administration of combination antimicrobial therapy is essential for effective NVE treatment. Additionally, a meticulous evaluation of each patient is necessary in order to identify any indications for immediate valve surgery. With the intention of promoting a more comprehensive understanding of the procedural management of native infective endocarditis and to furnish clinicians with a reference, the current evidence for the utilization of distinct strategies for the diagnosis and treatment of NVE are presented. FAU - Nappi, Francesco AU - Nappi F AUID- ORCID: 0000-0002-9705-5360 AD - Department of Cardiac Surgery, Centre Cardiologique du Nord, 93200 Saint-Denis, France. LA - eng PT - Journal Article PT - Review DEP - 20240719 PL - Switzerland TA - Microorganisms JT - Microorganisms JID - 101625893 PMC - PMC11278776 OTO - NOTNLM OT - gram-positive bacteria OT - infective endocarditis OT - native valve endocarditis OT - vegetation COIS- The author declares no conflicts of interest. EDAT- 2024/07/27 10:48 MHDA- 2024/07/27 10:49 PMCR- 2024/07/19 CRDT- 2024/07/27 01:25 PHST- 2024/06/06 00:00 [received] PHST- 2024/06/18 00:00 [revised] PHST- 2024/07/12 00:00 [accepted] PHST- 2024/07/27 10:49 [medline] PHST- 2024/07/27 10:48 [pubmed] PHST- 2024/07/27 01:25 [entrez] PHST- 2024/07/19 00:00 [pmc-release] AID - microorganisms12071481 [pii] AID - microorganisms-12-01481 [pii] AID - 10.3390/microorganisms12071481 [doi] PST - epublish SO - Microorganisms. 2024 Jul 19;12(7):1481. doi: 10.3390/microorganisms12071481. PMID- 39064511 OWN - NLM STAT- MEDLINE DCOM- 20240727 LR - 20260923 IS - 1648-9144 (Electronic) IS - 1010-660X (Print) IS - 1010-660X (Linking) VI - 60 IP - 7 DP - 2024 Jul 1 TI - Transcatheter Mitral Valve Intervention: Current and Future Role of Multimodality Imaging for Device Selection and Periprocedural Guidance. LID - 10.3390/medicina60071082 [doi] LID - 1082 AB - Mitral regurgitation (MR) is a broadly diffuse valvular heart disease (VHD) with a significant impact on the healthcare system and patient prognosis. Transcatheter mitral valve interventions (TMVI) are now well-established techniques included in the therapeutic armamentarium for managing patients with mitral regurgitation, either primary or functional MR. Even if the guidelines give indications regarding the correct management of this VHD, the wide heterogeneity of patients' clinical backgrounds and valvular and heart anatomies make each patient a unique case, in which the appropriate device's selection requires a multimodal imaging evaluation and a multidisciplinary discussion. Proper pre-procedural evaluation plays a pivotal role in judging the feasibility of TMVI, while a cooperative work between imagers and interventionalist is also crucial for procedural success. This manuscript aims to provide an exhaustive overview of the main parameters that need to be evaluated for appropriate device selection, pre-procedural planning, intra-procedural guidance and post-operative assessment in the setting of TMVI. In addition, it tries to give some insights about future perspectives for structural cardiovascular imaging. FAU - Brugiatelli, Leonardo AU - Brugiatelli L AUID- ORCID: 0009-0000-8413-9701 AD - "G.M. Lancisi" Cardiovascular Center, 60126 Ancona, Italy. AD - Department of Biomedical Sciences and Public Health, Marche Polytechnic University, 60121 Ancona, Italy. FAU - Rolando, Marco AU - Rolando M AUID- ORCID: 0000-0001-8928-8626 AD - "G.M. Lancisi" Cardiovascular Center, 60126 Ancona, Italy. FAU - Lofiego, Carla AU - Lofiego C AD - "G.M. Lancisi" Cardiovascular Center, 60126 Ancona, Italy. FAU - Fogante, Marco AU - Fogante M AUID- ORCID: 0000-0003-2993-5718 AD - Maternal-Child, Senological, Cardiological Radiology and Outpatient Ultrasound, Department of Radiological Sciences, University Hospital of Marche, 60126 Ancona, Italy. FAU - Capodaglio, Irene AU - Capodaglio I AD - "G.M. Lancisi" Cardiovascular Center, 60126 Ancona, Italy. FAU - Patani, Francesca AU - Patani F AD - "G.M. Lancisi" Cardiovascular Center, 60126 Ancona, Italy. FAU - Tofoni, Paolo AU - Tofoni P AD - "G.M. Lancisi" Cardiovascular Center, 60126 Ancona, Italy. AD - Department of Biomedical Sciences and Public Health, Marche Polytechnic University, 60121 Ancona, Italy. FAU - Maurizi, Kevin AU - Maurizi K AUID- ORCID: 0009-0006-2196-5540 AD - "G.M. Lancisi" Cardiovascular Center, 60126 Ancona, Italy. AD - Department of Biomedical Sciences and Public Health, Marche Polytechnic University, 60121 Ancona, Italy. FAU - Nazziconi, Marco AU - Nazziconi M AD - "G.M. Lancisi" Cardiovascular Center, 60126 Ancona, Italy. AD - Department of Biomedical Sciences and Public Health, Marche Polytechnic University, 60121 Ancona, Italy. FAU - Massari, Arianna AU - Massari A AD - "G.M. Lancisi" Cardiovascular Center, 60126 Ancona, Italy. AD - Department of Biomedical Sciences and Public Health, Marche Polytechnic University, 60121 Ancona, Italy. FAU - Furlani, Giulia AU - Furlani G AD - "G.M. Lancisi" Cardiovascular Center, 60126 Ancona, Italy. AD - Department of Biomedical Sciences and Public Health, Marche Polytechnic University, 60121 Ancona, Italy. FAU - Signore, Giovanni AU - Signore G AD - Department of Transalational Medical Sciences, University of Campania "Luigi Vanvitelli", 80131 Naples, Italy. FAU - Esposto Pirani, Paolo AU - Esposto Pirani P AD - Maternal-Child, Senological, Cardiological Radiology and Outpatient Ultrasound, Department of Radiological Sciences, University Hospital of Marche, 60126 Ancona, Italy. FAU - Schicchi, Nicolo AU - Schicchi N AD - Cardiovascular Radiological Diagnostics, Department of Radiological Sciences, University Hospital of Marche, 60126 Ancona, Italy. FAU - Dello Russo, Antonio AU - Dello Russo A AD - "G.M. Lancisi" Cardiovascular Center, 60126 Ancona, Italy. AD - Department of Biomedical Sciences and Public Health, Marche Polytechnic University, 60121 Ancona, Italy. FAU - Di Eusanio, Marco AU - Di Eusanio M AD - Cardiac Surgery Department, Polytechnic University of Marche, AOU delle Marche, 60121 Ancona, Italy. FAU - Vagnarelli, Fabio AU - Vagnarelli F AUID- ORCID: 0009-0006-0993-061X AD - "G.M. Lancisi" Cardiovascular Center, 60126 Ancona, Italy. LA - eng PT - Journal Article PT - Review DEP - 20240701 PL - Switzerland TA - Medicina (Kaunas) JT - Medicina (Kaunas, Lithuania) JID - 9425208 SB - IM MH - Humans MH - *Mitral Valve Insufficiency/surgery/diagnostic imaging MH - *Multimodal Imaging/methods MH - *Heart Valve Prosthesis Implantation/methods/instrumentation/standards MH - *Mitral Valve/surgery/diagnostic imaging MH - *Cardiac Catheterization/methods/instrumentation PMC - PMC11278759 OTO - NOTNLM OT - MR OT - TMVI OT - intra-procedural guidance OT - multi-modality imaging OT - pre-procedural planning COIS- The authors declare no conflicts of interest. EDAT- 2024/07/27 10:44 MHDA- 2024/07/28 14:52 PMCR- 2024/07/01 CRDT- 2024/07/27 01:21 PHST- 2024/06/09 00:00 [received] PHST- 2024/06/26 00:00 [revised] PHST- 2024/06/29 00:00 [accepted] PHST- 2024/07/28 14:52 [medline] PHST- 2024/07/27 10:44 [pubmed] PHST- 2024/07/27 01:21 [entrez] PHST- 2024/07/01 00:00 [pmc-release] AID - medicina60071082 [pii] AID - medicina-60-01082 [pii] AID - 10.3390/medicina60071082 [doi] PST - epublish SO - Medicina (Kaunas). 2024 Jul 1;60(7):1082. doi: 10.3390/medicina60071082. PMID- 39064164 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240729 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 13 IP - 14 DP - 2024 Jul 15 TI - Contemporary Role of Positron Emission Tomography (PET) in Endocarditis: A Narrative Review. LID - 10.3390/jcm13144124 [doi] LID - 4124 AB - Endocarditis, a serious infectious disease, remains a diagnostic challenge in contemporary clinical practice. The advent of advanced imaging modalities has contributed significantly to the improved understanding and management of this complex disease. 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) imaging has shown remarkable potential in improving the diagnostic accuracy of endocarditis. In the update of the Modified Duke Criteria, in 2023, The International Society for Cardiovascular Infectious Diseases (ISCVID) Working Group recognized specific 18F-FDG PET/CT findings as a major diagnostic criterion, particularly in patient with prosthetic valve endocarditis. The ability of PET to visualize metabolic activity allows for the identification of infective foci and could differentiate between infective and non-infective processes. This review examines the clinical utility of PET in differentiating infective endocarditis from other cardiovascular pathologies, highlighting its sensitivity and specificity in detecting native and prosthetic valve infections, including patients with transcatheter aortic valve implantation (TAVI), cardiac implantable devices (CIEDs), and left ventricular assistance devices (LVAD). Also, practical aspects and indications are illustrated to optimize the quality of imaging and reduce potential false positive results. In conclusion, the current use of PET in endocarditis has become a valuable diagnostic tool; as technological advances continue, PET will play an increasingly important role in the multidisciplinary approach to the management of endocarditis. FAU - Sammartino, Antonio Maria AU - Sammartino AM AD - Institute of Cardiology, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, 25121 Brescia, Italy. FAU - Bonfioli, Giovanni Battista AU - Bonfioli GB AD - Institute of Cardiology, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, 25121 Brescia, Italy. FAU - Dondi, Francesco AU - Dondi F AD - Nuclear Medicine, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, 25121 Brescia, Italy. FAU - Riccardi, Mauro AU - Riccardi M AD - Institute of Cardiology, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, 25121 Brescia, Italy. FAU - Bertagna, Francesco AU - Bertagna F AD - Nuclear Medicine, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, 25121 Brescia, Italy. FAU - Metra, Marco AU - Metra M AD - Institute of Cardiology, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, 25121 Brescia, Italy. FAU - Vizzardi, Enrico AU - Vizzardi E AUID- ORCID: 0000-0002-3544-6104 AD - Institute of Cardiology, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, 25121 Brescia, Italy. LA - eng PT - Journal Article PT - Review DEP - 20240715 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC11277723 OTO - NOTNLM OT - 18F-FDG OT - CIED OT - PET OT - endocarditis OT - nuclear imaging OT - valvular cardiac infection COIS- The authors declare no conflicts of interest. EDAT- 2024/07/27 10:43 MHDA- 2024/07/27 10:44 PMCR- 2024/07/15 CRDT- 2024/07/27 01:19 PHST- 2024/05/28 00:00 [received] PHST- 2024/06/20 00:00 [revised] PHST- 2024/07/11 00:00 [accepted] PHST- 2024/07/27 10:44 [medline] PHST- 2024/07/27 10:43 [pubmed] PHST- 2024/07/27 01:19 [entrez] PHST- 2024/07/15 00:00 [pmc-release] AID - jcm13144124 [pii] AID - jcm-13-04124 [pii] AID - 10.3390/jcm13144124 [doi] PST - epublish SO - J Clin Med. 2024 Jul 15;13(14):4124. doi: 10.3390/jcm13144124. PMID- 39063949 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260923 IS - 2075-4426 (Print) IS - 2075-4426 (Electronic) IS - 2075-4426 (Linking) VI - 14 IP - 7 DP - 2024 Jun 27 TI - Ocular Manifestations and Complications of Patent Foramen Ovale: A Narrative Review. LID - 10.3390/jpm14070695 [doi] LID - 695 AB - Patent foramen ovale (PFO) is a prevalent congenital cardiac anomaly associated with a persistent opening between the atrial septum, allowing communication between the left and right atria. Despite often being asymptomatic, PFO can lead to various clinical presentations, including cryptogenic stroke and other embolic events. Transient visual disturbances, alterations in the visual field, migraine with aura, impaired eye movement and endogenous eye infections may prompt patients to seek ophthalmological consultation. Understanding these diverse clinical scenarios is crucial for early detection, appropriate management and mitigating the morbidity burden associated with PFO. This narrative review aims at examining the spectrum of clinical presentations of ocular pictures associated with PFO. The pathophysiology, diagnosis and treatment methods for PFO will be described, emphasizing the importance of a multidisciplinary approach involving ophthalmologists, cardiologists, neurologists and imaging specialists. In the future, prospective studies and clinical trials are warranted to provide further insights into the preventive role and optimal therapeutic strategies for managing PFO-related ocular complications, ultimately guiding clinical decision making and optimizing patient care. FAU - Lixi, Filippo AU - Lixi F AUID- ORCID: 0009-0008-0956-4925 AD - Eye Clinic, Department of Surgical Sciences, University of Cagliari, 09124 Cagliari, Italy. FAU - Fazzini, Luca AU - Fazzini L AUID- ORCID: 0000-0003-2407-7435 AD - Clinical Cardiology Unit, Department of Medical Sciences and Public Health, University of Cagliari, 09124 Cagliari, Italy. FAU - Cannas, Claudia AU - Cannas C AD - Eye Clinic, Department of Surgical Sciences, University of Cagliari, 09124 Cagliari, Italy. FAU - Montisci, Roberta AU - Montisci R AD - Clinical Cardiology Unit, Department of Medical Sciences and Public Health, University of Cagliari, 09124 Cagliari, Italy. FAU - Giannaccare, Giuseppe AU - Giannaccare G AUID- ORCID: 0000-0003-2617-0289 AD - Eye Clinic, Department of Surgical Sciences, University of Cagliari, 09124 Cagliari, Italy. LA - eng PT - Journal Article PT - Review DEP - 20240627 PL - Switzerland TA - J Pers Med JT - Journal of personalized medicine JID - 101602269 PMC - PMC11278285 OTO - NOTNLM OT - eye OT - eye disorders OT - impaired eye movement OT - migraine with aura OT - patent foramen ovale OT - retinal artery occlusion COIS- The authors declare no conflicts of interest. EDAT- 2024/07/27 10:48 MHDA- 2024/07/27 10:49 PMCR- 2024/06/27 CRDT- 2024/07/27 01:18 PHST- 2024/05/12 00:00 [received] PHST- 2024/06/19 00:00 [revised] PHST- 2024/06/24 00:00 [accepted] PHST- 2024/07/27 10:49 [medline] PHST- 2024/07/27 10:48 [pubmed] PHST- 2024/07/27 01:18 [entrez] PHST- 2024/06/27 00:00 [pmc-release] AID - jpm14070695 [pii] AID - jpm-14-00695 [pii] AID - 10.3390/jpm14070695 [doi] PST - epublish SO - J Pers Med. 2024 Jun 27;14(7):695. doi: 10.3390/jpm14070695. PMID- 39063087 OWN - NLM STAT- MEDLINE DCOM- 20240727 LR - 20240729 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 25 IP - 14 DP - 2024 Jul 18 TI - Debates Surrounding the Use of Antithrombotic Therapy in Hemophilic Patients with Cardiovascular Disease: Best Strategies to Minimize Severe Bleeding Risk. LID - 10.3390/ijms25147845 [doi] LID - 7845 AB - Navigating through antithrombotic therapy in patients with both hemophilia and cardiovascular pathology presents a complex scenario with inherent challenges and opportunities. The presence of hemophilia, characterized by impaired blood clotting, adds a layer of complexity to the management of cardiovascular conditions requiring antiplatelet therapy and anticoagulation. Striking a delicate balance between the necessity for antithrombotic treatment to prevent cardiovascular events and the heightened risk of severe bleeding in individuals with hemophilia demands a nuanced and carefully considered approach. The challenges revolve around identifying an optimal therapeutic strategy that effectively mitigates cardiovascular risks without exacerbating bleeding tendencies. In hemophilic patients with cardiovascular disease, the decision to use antiplatelet therapy requires careful consideration of the individual's bleeding risk profile, considering factors such as the severity of hemophilia, history of bleeding episodes, and concurrent medications. The goal is to provide effective antithrombotic treatment while minimizing the potential for excessive bleeding complications. Conventional anticoagulants like warfarin pose difficulties due to their potential to increase the risk of bleeding. On the other hand, emerging options like novel direct oral anticoagulants (DOACs) present an opportunity, offering predictable pharmacokinetics and user-friendly administration. However, a comprehensive exploration of their safety and efficacy in hemophilic patients is imperative. Achieving the right equilibrium between preventing cardiovascular events and minimizing bleeding risk is pivotal in selecting the most effective therapeutic option for individuals with hemophilia and cardiovascular pathology. A multidisciplinary approach, integrating the expertise of hematologists and cardiologists, becomes essential to customize treatments and address the intricacies of this medical challenge. FAU - Badulescu, Oana-Viola AU - Badulescu OV AUID- ORCID: 0000-0001-7050-8430 AD - Department of Pathophysiology, University of Medicine and Pharmacy Grigore T. Popa, 700115 Iasi, Romania. FAU - Scripcariu, Dragos Viorel AU - Scripcariu DV AD - Department of Surgical Sciences, University of Medicine and Pharmacy Grigore T. Popa, 700115 Iasi, Romania. FAU - Badescu, Minerva Codruta AU - Badescu MC AUID- ORCID: 0000-0001-8942-1909 AD - Department of Internal Medicine, University of Medicine and Pharmacy Grigore T. Popa, 700115 Iasi, Romania. FAU - Ciocoiu, Manuela AU - Ciocoiu M AUID- ORCID: 0000-0002-9240-2175 AD - Department of Pathophysiology, University of Medicine and Pharmacy Grigore T. Popa, 700115 Iasi, Romania. FAU - Vladeanu, Maria Cristina AU - Vladeanu MC AD - Department of Pathophysiology, University of Medicine and Pharmacy Grigore T. Popa, 700115 Iasi, Romania. FAU - Plesoianu, Carmen Elena AU - Plesoianu CE AUID- ORCID: 0000-0002-5448-7761 AD - Department of Internal Medicine, University of Medicine and Pharmacy Grigore T. Popa, 700115 Iasi, Romania. FAU - Bojan, Andrei AU - Bojan A AD - Department of Surgical Sciences, University of Medicine and Pharmacy Grigore T. Popa, 700115 Iasi, Romania. FAU - Iliescu-Halitchi, Dan AU - Iliescu-Halitchi D AD - Department of Internal Medicine, University of Medicine and Pharmacy Grigore T. Popa, 700115 Iasi, Romania. FAU - Tudor, Razvan AU - Tudor R AD - Department of Surgical Sciences, University of Medicine and Pharmacy Grigore T. Popa, 700115 Iasi, Romania. FAU - Huzum, Bogdan AU - Huzum B AD - Department of Surgical Sciences, University of Medicine and Pharmacy Grigore T. Popa, 700115 Iasi, Romania. FAU - Bararu Bojan, Iris AU - Bararu Bojan I AD - Department of Pathophysiology, University of Medicine and Pharmacy Grigore T. Popa, 700115 Iasi, Romania. LA - eng PT - Journal Article PT - Review DEP - 20240718 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (Fibrinolytic Agents) RN - 0 (Anticoagulants) RN - 0 (Platelet Aggregation Inhibitors) SB - IM MH - Humans MH - *Hemophilia A/drug therapy/complications MH - *Hemorrhage/chemically induced/etiology MH - *Cardiovascular Diseases/prevention & control/etiology/drug therapy MH - *Fibrinolytic Agents/therapeutic use/adverse effects MH - Anticoagulants/therapeutic use/adverse effects MH - Platelet Aggregation Inhibitors/therapeutic use/adverse effects MH - Risk Factors PMC - PMC11277257 OTO - NOTNLM OT - PCI in hemophilia OT - atrial fibrillation in hemophilia OT - coronary artery disease OT - hemophilia COIS- The authors declare no conflict of interest. EDAT- 2024/07/27 10:48 MHDA- 2024/07/28 14:51 PMCR- 2024/07/18 CRDT- 2024/07/27 01:13 PHST- 2024/06/24 00:00 [received] PHST- 2024/07/10 00:00 [revised] PHST- 2024/07/16 00:00 [accepted] PHST- 2024/07/28 14:51 [medline] PHST- 2024/07/27 10:48 [pubmed] PHST- 2024/07/27 01:13 [entrez] PHST- 2024/07/18 00:00 [pmc-release] AID - ijms25147845 [pii] AID - ijms-25-07845 [pii] AID - 10.3390/ijms25147845 [doi] PST - epublish SO - Int J Mol Sci. 2024 Jul 18;25(14):7845. doi: 10.3390/ijms25147845. PMID- 39061272 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240729 IS - 2079-6382 (Print) IS - 2079-6382 (Electronic) IS - 2079-6382 (Linking) VI - 13 IP - 7 DP - 2024 Jun 26 TI - Improvement in Diagnosis and Management of Nosocomial Pneumonias in a Cardiovascular Surgery Intensive Care Unit: A Multidisciplinary Approach. LID - 10.3390/antibiotics13070590 [doi] LID - 590 AB - BACKGROUND: While criteria for the diagnosis of nosocomial pneumonias exist, objective definitions are a challenge and there is no gold standard for diagnosis. We analyzed the impact of the implementation of a logical, consensus-based diagnostic and treatment protocol for managing nosocomial pneumonias in the cardiovascular surgery intensive care unit (CVS-ICU). METHODS: We conducted a quasi-experimental, interrupted time series analysis to evaluate the impact of a diagnostic and treatment protocol for nosocomial pneumonias in the CVS-ICU. Impacts were measured relative to patient outcomes, diagnostic processes, and antimicrobial stewardship improvement. Descriptive statistics were used to analyze results. RESULTS: Overall, 35 pre-protocol and 39 post-protocol patients were included. Primary clinical variables suggesting pneumonia in pre- and post-protocol patients were new lung consolidation (50% vs. 71%), new leukocytosis (59% vs. 64%), and positive culture (32% vs. 55%). Appropriate diagnostic testing improved (23% vs. 54%, p = 0.008) after protocol implementation. The proportion of patients meeting the criteria for nosocomial pneumonia (77% vs. 87%) was not statistically significant, though more patients in the post-protocol group met probable diagnostic criteria (51% vs. 77%). Duration of therapy was not significantly different (6 days [IQR = 5.0, 10.0] vs. 7 days [IQR = 6.0, 9.0]). CONCLUSIONS: The implementation of a diagnostic and treatment protocol for management of nosocomial pneumonias in the CVS-ICU resulted in improved diagnostic accuracy, advanced antimicrobial and diagnostic stewardship efforts, and laboratory cost savings without an adverse impact on patient-centered outcomes. FAU - Kooda, Kirstin J AU - Kooda KJ AD - Department of Pharmacy Services, Mayo Clinic, Rochester, MN 55902, USA. FAU - Zambrano, Alejandra A AU - Zambrano AA AUID- ORCID: 0009-0008-2375-1284 AD - Department of Infection Prevention and Control, Mayo Clinic, Rochester, MN 55902, USA. FAU - Kosaski, Dylan L AU - Kosaski DL AUID- ORCID: 0000-0002-2036-0965 AD - Department of Pharmacy Services, Mayo Clinic, Rochester, MN 55902, USA. FAU - Higbe, Leah AU - Higbe L AD - Department of Infection Prevention and Control, Mayo Clinic, Rochester, MN 55902, USA. FAU - Beam, William Brian B AU - Beam WBB AD - Department of Anesthesiology, Mayo Clinic, Rochester, MN 55902, USA. FAU - Bohman, J Kyle K AU - Bohman JKK AUID- ORCID: 0000-0001-9699-0325 AD - Department of Anesthesiology, Mayo Clinic, Rochester, MN 55902, USA. FAU - Wittwer, Erica D AU - Wittwer ED AD - Department of Anesthesiology, Mayo Clinic, Rochester, MN 55902, USA. FAU - Brady, Steven D AU - Brady SD AD - Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55902, USA. FAU - LeMahieu, Allison M AU - LeMahieu AM AUID- ORCID: 0000-0003-1554-795X AD - Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN 55902, USA. FAU - Fida, Madiha AU - Fida M AD - Division of Public Health, Infectious Diseases and Occupational Medicine, Mayo Clinic, Rochester, MN 55902, USA. FAU - Shah, Aditya AU - Shah A AD - Division of Public Health, Infectious Diseases and Occupational Medicine, Mayo Clinic, Rochester, MN 55902, USA. LA - eng PT - Journal Article DEP - 20240626 PL - Switzerland TA - Antibiotics (Basel) JT - Antibiotics (Basel, Switzerland) JID - 101637404 PMC - PMC11274194 OTO - NOTNLM OT - antimicrobial stewardship OT - diagnostic stewardship OT - infection prevention and control OT - informatics OT - nosocomial pneumonia OT - visual analytics COIS- The authors declare no conflicts of interest. EDAT- 2024/07/27 10:45 MHDA- 2024/07/27 10:46 PMCR- 2024/06/26 CRDT- 2024/07/27 01:02 PHST- 2024/04/29 00:00 [received] PHST- 2024/06/17 00:00 [revised] PHST- 2024/06/20 00:00 [accepted] PHST- 2024/07/27 10:46 [medline] PHST- 2024/07/27 10:45 [pubmed] PHST- 2024/07/27 01:02 [entrez] PHST- 2024/06/26 00:00 [pmc-release] AID - antibiotics13070590 [pii] AID - antibiotics-13-00590 [pii] AID - 10.3390/antibiotics13070590 [doi] PST - epublish SO - Antibiotics (Basel). 2024 Jun 26;13(7):590. doi: 10.3390/antibiotics13070590. PMID- 39059627 OWN - NLM STAT- MEDLINE DCOM- 20241030 LR - 20260518 IS - 1615-5947 (Electronic) IS - 0890-5096 (Linking) VI - 109 DP - 2024 Dec TI - Vascular Surgeon Involvement in Pulmonary Embolism Response Teams: Barriers, Challenges, Concerns and the Imperative for Integration. PG - 326-337 LID - S0890-5096(24)00465-5 [pii] LID - 10.1016/j.avsg.2024.06.031 [doi] AB - BACKGROUND: The effective management of pulmonary embolism (PE) necessitates coordinated care among physicians from diverse specialties within a time-sensitive framework. Pulmonary Embolism Response Teams (PERTs) have been developed as a strategic approach to optimize and expedite treatment by integrating and coordinating different specialties. The current survey audit aimed to understand the level of interest among vascular surgeons and the logistical considerations surrounding their participation within the PERT. METHODS: A deidentified Research Electronic Data Capture (REDCap) survey was disseminated to vascular surgeons, with collected data submitted to the Vascular Surgery Collaborative (VASC) database. RESULTS: A total of 139 vascular surgeons with an average of 10.6 years of practice experience responded to the VASC PERT audit. The majority (70.5%) practice in academic settings and only 24.5% currently perform PE interventions in their practice. While nearly half of respondents (52.5%) reported the existence of PERT in their institutions, only a fraction (23.3%) was actively involved in the PERT. Notably, a significant proportion in our cohort (38.1%) expressed dissatisfaction with the representation of vascular surgeons in multidisciplinary teams managing venous thromboembolism (VTE), including deep vein thrombosis (DVT) and PE. Vascular surgery (VS) representation in PERT was only 34.2%, with pulmonology (pulm) (60.3%), interventional radiology (IR) (57.5%), interventional cardiology (IC) (57.5%), and critical care (CC) (50.7%) being the most represented specialties. The primary barriers to VS participation in PERT were competing interests from other specialties and logistical scheduling challenges. CONCLUSIONS: The audit shows a global deficit in the integration of VS expertize within PERT frameworks. Primary barriers include exclusion due to competing interests from other specialties and challenges in the logistical coordination of PERT calls. CI - Copyright (c) 2024 Elsevier Inc. All rights reserved. FAU - Kabeil, Mahmood S AU - Kabeil MS AD - Division of Vascular Surgery and Endovascular Therapy, Department of Surgery, Case Western Reserve University School of Medicine, University Hospitals, Harrington Heart & Vascular Institute, Cleveland, OH. FAU - Droz, Nathan AU - Droz N AD - Division of Vascular Surgery, Washington University School of Medicine, St. Louis, MO. FAU - Mouawad, Nicolas J AU - Mouawad NJ AD - Division of Vascular & Endovascular Surgery, Department of Surgery, McLaren Health System, Bay City, MI. FAU - Khetarpaul, Vipul AU - Khetarpaul V AD - Division of Vascular Surgery, Washington University School of Medicine, St. Louis, MO. FAU - Afifi, Rana O AU - Afifi RO AD - Department of Cardiothoracic and Vascular Surgery, McGovern Medical School at UTHealth, Houston, TX. FAU - Moore, Ethan AU - Moore E AD - University of Colorado School of Medicine, Aurora, CO. FAU - Wohlauer, Max V AU - Wohlauer MV AD - Division of Vascular Surgery, University of Colorado Anschutz Medical Campus, Aurora, CO. Electronic address: max.wohlauer@cuanschutz.edu. CN - VASC Team LA - eng PT - Journal Article PT - Review DEP - 20240725 PL - Netherlands TA - Ann Vasc Surg JT - Annals of vascular surgery JID - 8703941 SB - IM MH - Humans MH - *Pulmonary Embolism/therapy MH - *Patient Care Team MH - *Surgeons MH - *Vascular Surgical Procedures MH - *Delivery of Health Care, Integrated/organization & administration MH - Health Care Surveys MH - Attitude of Health Personnel MH - Interdisciplinary Communication MH - Cooperative Behavior MH - Practice Patterns, Physicians'/trends FIR - Cuff, Robert IR - Cuff R FIR - Wohlauer, Max IR - Wohlauer M FIR - Shalhub, Sherene IR - Shalhub S FIR - Mills, Joseph L IR - Mills JL FIR - Eldrup-Jorgensen, Jens IR - Eldrup-Jorgensen J FIR - Chuen, Jason IR - Chuen J FIR - Bath, Jonathan IR - Bath J FIR - Tinelli, Giovanni IR - Tinelli G FIR - Afifi, Rana O IR - Afifi RO FIR - Coscas, Raphael IR - Coscas R FIR - Hiatt, William IR - Hiatt W FIR - Grover, Frederick IR - Grover F FIR - Wohlauer, Max IR - Wohlauer M FIR - Colborn, Kathryn IR - Colborn K FIR - MacDermott, Tracey IR - MacDermott T FIR - Al-Musawi, Mohammed IR - Al-Musawi M FIR - McNulty, Monica IR - McNulty M FIR - Burke, Jaimielyn IR - Burke J FIR - Kabeil, Mahmood IR - Kabeil M FIR - Moore, Ethan IR - Moore E FIR - Gillette, Riley IR - Gillette R FIR - Barqawi, Zuhair IR - Barqawi Z FIR - Myers, Quintin W O IR - Myers QWO FIR - Boggs, Shelbi IR - Boggs S FIR - Ivar, Allie IR - Ivar A FIR - Quinn, Jillian IR - Quinn J FIR - Jacobs, Donald IR - Jacobs D FIR - Schulick, Richard D IR - Schulick RD FIR - Hiatt, William IR - Hiatt W FIR - Bonaca, Marc IR - Bonaca M FIR - Nehler, Mark IR - Nehler M FIR - Heard, Susan IR - Heard S FIR - Jaeger, Nicole IR - Jaeger N FIR - McCartney, Vera IR - McCartney V FIR - Tinelli, Giovanni IR - Tinelli G FIR - Sica, Simona IR - Sica S FIR - Pasciuto, Tina IR - Pasciuto T FIR - D'Oria, Mario IR - D'Oria M EDAT- 2024/07/27 10:42 MHDA- 2024/10/31 00:27 CRDT- 2024/07/26 19:20 PHST- 2024/04/25 00:00 [received] PHST- 2024/06/26 00:00 [revised] PHST- 2024/06/27 00:00 [accepted] PHST- 2024/10/31 00:27 [medline] PHST- 2024/07/27 10:42 [pubmed] PHST- 2024/07/26 19:20 [entrez] AID - S0890-5096(24)00465-5 [pii] AID - 10.1016/j.avsg.2024.06.031 [doi] PST - ppublish SO - Ann Vasc Surg. 2024 Dec;109:326-337. doi: 10.1016/j.avsg.2024.06.031. Epub 2024 Jul 25. PMID- 39056585 OWN - NLM STAT- MEDLINE DCOM- 20241002 LR - 20250718 IS - 1445-5994 (Electronic) IS - 1444-0903 (Linking) VI - 54 IP - 10 DP - 2024 Oct TI - Frequency and potential causes of non-beneficial Code Blue activations at a metropolitan teaching hospital. PG - 1713-1718 LID - 10.1111/imj.16487 [doi] AB - BACKGROUND: Code Blue activations in patients who are not for resuscitation (NFR) may be regarded as non-beneficial and may cause harm to patients, relatives and hospital staff. AIMS: To estimate the prevalence of non-beneficial Code Blue calls in a metropolitan teaching hospital and identify modifiable factors that could be utilised to reduce these events. METHODS: The study consisted of two parts: (i) a retrospective analysis of all Code Blue activations over a 12-month period using prospectively collected data. Non-beneficial activations were defined as calls made in patients with a NFR order in either the current or any previous hospital admissions and (ii) an anonymous voluntary survey of staff who were present at a Code Blue activation. RESULTS: There were 186 Code Blue activations over the study period, with 48 (25.8%) defined as non-beneficial. Such patients had more comorbidities, previous hospitalisations and greater levels of frailty. Most non-beneficial calls occurred on general wards and more than three-quarters of patients had been reviewed by a consultant prior to the call. The survey determined that despite ward staff having a considerable degree of resuscitation experience, there were deficiencies in understanding of Code Blue criteria, the resuscitation status of patients under their care and the interpretation of goals of care. CONCLUSIONS: Over a quarter of Code Blue calls were deemed non-beneficial. Improving the visibility of NFR status and staff understanding of patient goals of care are needed, along with timely, proactive documentation of NFR status by experienced clinicians. CI - (c) 2024 Royal Australasian College of Physicians. FAU - Crosbie, David AU - Crosbie D AUID- ORCID: 0000-0002-1269-9790 AD - Intensive Care Unit, Northern Health Epping, Melbourne, Victoria, Australia. FAU - Barton, Josta AU - Barton J AD - Intensive Care Unit, Northern Health Epping, Melbourne, Victoria, Australia. FAU - Ghosh, Angaj AU - Ghosh A AD - Intensive Care Unit, Northern Health Epping, Melbourne, Victoria, Australia. FAU - Hayes, Barbara AU - Hayes B AUID- ORCID: 0000-0001-9930-8643 AD - Palliative Care Unit, Northern Health Epping, Melbourne, Victoria, Australia. FAU - Jones, Daryl AU - Jones D AUID- ORCID: 0000-0002-6446-3595 AD - Department of Intensive Care, Austin Health, Melbourne, Victoria, Australia. AD - Department of Epidemiology and Preventative Medicine, Monash University, Melbourne, Victoria, Australia. LA - eng PT - Journal Article DEP - 20240726 PL - Australia TA - Intern Med J JT - Internal medicine journal JID - 101092952 SB - IM MH - Humans MH - *Hospitals, Teaching MH - Retrospective Studies MH - Male MH - Female MH - *Resuscitation Orders MH - Aged MH - *Cardiopulmonary Resuscitation MH - Aged, 80 and over MH - Middle Aged MH - Hospitals, Urban MH - Hospital Rapid Response Team MH - Prospective Studies OTO - NOTNLM OT - cardiac arrest OT - clinical deterioration OT - deteriorating patient OT - do not resuscitate OT - non-beneficial care OT - not for resuscitation EDAT- 2024/07/26 12:47 MHDA- 2024/10/02 12:42 CRDT- 2024/07/26 08:23 PHST- 2024/02/07 00:00 [received] PHST- 2024/07/15 00:00 [accepted] PHST- 2024/10/02 12:42 [medline] PHST- 2024/07/26 12:47 [pubmed] PHST- 2024/07/26 08:23 [entrez] AID - 10.1111/imj.16487 [doi] PST - ppublish SO - Intern Med J. 2024 Oct;54(10):1713-1718. doi: 10.1111/imj.16487. Epub 2024 Jul 26. PMID- 39045193 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240725 IS - 2755-9637 (Electronic) IS - 2755-9637 (Linking) VI - 2 IP - 1 DP - 2024 Jan TI - Importance of experience in transoesophageal echocardiographic evaluation of vegetation size in patients with infective endocarditis: a reliability study. PG - qyae024 LID - 10.1093/ehjimp/qyae024 [doi] LID - qyae024 AB - AIMS: Vegetation size assessed by transoesophageal echocardiography (TOE) is a decisive metric in guiding surgical intervention and prognosis in patients with definite infective endocarditis (IE). The aim of this study was to assess the impact of echocardiographic experience on the reliability and reproducibility of TOE measurements of vegetations in patients with IE. METHODS AND RESULTS: Twenty-nine raters from a cardiac department at a tertiary centre were divided into three groups according to echocardiographic experience: experts, cardiologists, and novices. All raters were instructed to measure the maximum length of vegetations in 20 different TOE exams. Interrater agreement was evaluated using intraclass correlation coefficient (ICC), one-way analysis of variance, Kruskal-Wallis test, and Bland-Altmann plots. Reliability was assessed by minimal detectable change (MDC). All measurements were compared with the measured size agreed on by the multi-disciplinary IE team.There was an overall significant interrater variance between the three groups (P < 0.001). The variance was 10.1, 14.8, and 21.7 for the experts, cardiologists, and novices, respectively. ICC was excellent for experts (96.3%) and cardiologists (93.7%) and good for novices (84.6%). The three groups tended to measure smaller than the endocarditis team. MDC was 2.6 mm for experts, 3.3 mm for cardiologists, and 3.6 mm for novices. CONCLUSION: The study showed good to excellent intraclass correlation but high dispersion in all groups. Variance decreased with higher experience. Our findings support current recommendations that complicated cases should be cared for by the multi-disciplinary endocarditis team and underline the importance of echocardiographic expertise when evaluating and measuring vegetations in patients with IE. CI - (c) The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. FAU - Schmidt, Louise AU - Schmidt L AUID- ORCID: 0009-0000-9795-9645 AD - The Heart Centre, Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark. FAU - Ostergaard, Lauge AU - Ostergaard L AUID- ORCID: 0000-0003-3298-1467 AD - The Heart Centre, Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark. FAU - Grund, Frederik Fasth AU - Grund FF AD - The Heart Centre, Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark. FAU - Schmidt, Line AU - Schmidt L AD - Department of Emergency Medicine, Bispebjerg and Frederiksberg Hospital, Nielsine Nielsens Vej 41e, 2400 Copenhagen, Denmark. FAU - Linde, Jesper James AU - Linde JJ AUID- ORCID: 0000-0002-2101-5098 AD - The Heart Centre, Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark. FAU - Kober, Lars AU - Kober L AD - The Heart Centre, Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark. FAU - Fosbol, Emil L AU - Fosbol EL AD - The Heart Centre, Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark. AD - Department of Clinical Medicine, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen, Denmark. LA - eng PT - Journal Article DEP - 20240409 PL - England TA - Eur Heart J Imaging Methods Pract JT - European heart journal. Imaging methods and practice JID - 9918697088006676 PMC - PMC11195693 OTO - NOTNLM OT - agreement OT - infective endocarditis OT - interrater OT - reliability OT - transoesophageal echocardiography OT - vegetation size COIS- Conflict of interest: None declared. EDAT- 2024/07/24 06:41 MHDA- 2024/07/24 06:42 PMCR- 2024/04/09 CRDT- 2024/07/24 04:20 PHST- 2023/12/01 00:00 [received] PHST- 2024/04/02 00:00 [accepted] PHST- 2024/07/24 06:42 [medline] PHST- 2024/07/24 06:41 [pubmed] PHST- 2024/07/24 04:20 [entrez] PHST- 2024/04/09 00:00 [pmc-release] AID - qyae024 [pii] AID - 10.1093/ehjimp/qyae024 [doi] PST - epublish SO - Eur Heart J Imaging Methods Pract. 2024 Apr 9;2(1):qyae024. doi: 10.1093/ehjimp/qyae024. eCollection 2024 Jan. PMID- 39044884 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240927 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 16 IP - 6 DP - 2024 Jun TI - The Interplay Between Cardiovascular Disease and Lung Cancer. PG - e62953 LID - 10.7759/cureus.62953 [doi] LID - e62953 AB - Cardiovascular disease (CVD) and lung cancer are among the leading causes of mortality worldwide, with a significant interplay that complicates patient management and treatment outcomes. This review explores the complex relationship between various forms of CVD - such as coronary artery disease, heart failure (HF), arrhythmias, and valvular heart disease - and lung cancer. Shared risk factors, including smoking, aging, and chronic inflammation, contribute to the co-occurrence of these conditions. Additionally, treatments for lung cancer, particularly chemotherapy and radiation therapy, can exacerbate CVD, necessitating a multidisciplinary approach to patient care. We delve into specific CVD-related impacts on lung cancer prognosis and vice versa, examining mechanisms, clinical outcomes, and management strategies. Our findings highlight the need for integrated care involving oncologists, cardiologists, and other healthcare providers to optimize treatment plans and improve patient outcomes. Emphasizing comprehensive cardiovascular risk management in lung cancer patients, we advocate for further research to deepen our understanding and develop novel therapeutic approaches, ultimately enhancing the quality of life and survival rates in patients suffering from both CVD and lung cancer. CI - Copyright (c) 2024, Katic et al. FAU - Katic, Luka AU - Katic L AD - Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, USA. FAU - Choi, James AU - Choi J AD - Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, USA. FAU - Diaz Saravia, Sara AU - Diaz Saravia S AD - Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, USA. FAU - Silverman, Alexander AU - Silverman A AD - Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, USA. FAU - Nagourney, Alexander AU - Nagourney A AD - Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, USA. FAU - Torelli, Vincent AU - Torelli V AD - Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, USA. FAU - Gupta, Soumya AU - Gupta S AD - Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, USA. FAU - Glavan, Martina AU - Glavan M AD - Neuroscience, Yale University, New Haven, USA. FAU - Gulati, Amit AU - Gulati A AD - Cardiology, Icahn School of Medicine at Mount Sinai, New York, USA. FAU - Khurana, Sakshi AU - Khurana S AD - Radiology, New York Presbyterian-Columbia University Irving Medical Center, New York, USA. FAU - Tsyvkin, Elina AU - Tsyvkin E AD - Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, USA. LA - eng GR - P30 CA008748/CA/NCI NIH HHS/United States PT - Journal Article PT - Review DEP - 20240623 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC11265258 OTO - NOTNLM OT - cancer treatment complications OT - cardiovascular disease OT - lung cancer OT - multidisciplinary care OT - shared risk factors COIS- Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. EDAT- 2024/07/24 06:41 MHDA- 2024/07/24 06:42 PMCR- 2024/06/23 CRDT- 2024/07/24 04:16 PHST- 2024/06/23 00:00 [accepted] PHST- 2024/07/24 06:42 [medline] PHST- 2024/07/24 06:41 [pubmed] PHST- 2024/07/24 04:16 [entrez] PHST- 2024/06/23 00:00 [pmc-release] AID - 10.7759/cureus.62953 [doi] PST - epublish SO - Cureus. 2024 Jun 23;16(6):e62953. doi: 10.7759/cureus.62953. eCollection 2024 Jun. PMID- 39043360 OWN - NLM STAT- MEDLINE DCOM- 20250711 LR - 20250711 IS - 1545-1569 (Electronic) IS - 1055-6656 (Linking) VI - 62 IP - 9 DP - 2025 Sep TI - Multidisciplinary Velopharyngeal Dysfunction Evaluation Helps Detect Non-classic Cases of 22q11.2 Deletion. PG - 1588-1591 LID - 10.1177/10556656241266464 [doi] AB - ObjectiveTo explore the role of multidisciplinary velopharyngeal dysfunction (VPD) assessment in diagnosing 22q11.2 deletion syndrome (22q) in children.DesignRetrospective cohort study.SettingMultidisciplinary VPD clinic at a tertiary pediatric hospital.Patients, ParticipantsSeventy-five children with genetically confirmed 22q evaluated at the VPD clinic between February 2007 and February 2023, including both previously diagnosed patients and those newly diagnosed as a result of VPD evaluation.InterventionsComprehensive review of medical records, utilizing ICD-10 codes and an institutional tool for keyword searches, to identify patients and collect data on clinical variables and outcomes.Main Outcome MeasuresCharacteristics of children with 22q, pathways to diagnosis, and clinical presentations that led to genetic testing for 22q.ResultsOf the 75 children, 9 were newly diagnosed with 22q following VPD evaluation. Non-cleft VPI was a significant indicator for 22q in children not previously diagnosed, occurring in 100% of newly diagnosed cases compared to 52% of cases with existing 22q diagnosis (P = .008). Additional clinical findings leading to diagnosis included congenital heart disease, craniofacial abnormalities, and developmental delays.ConclusionsVPD evaluations, particularly the presence of non-cleft VPI, play a crucial role in identifying undiagnosed cases of 22q. This underscores the need for clinicians, including plastic surgeons, otolaryngologists, and speech-language pathologists, to maintain a high degree of suspicion for 22q in children presenting with VPI without a clear etiology. Multidisciplinary approaches are essential for early diagnosis and management of this complex condition. FAU - Stanek, Krystof AU - Stanek K AUID- ORCID: 0000-0003-2954-8849 AD - Department of Plastic and Oral Surgery, Boston Children's Hospital, Boston, MA, USA. RINGGOLD: 370835 FAU - Wang, Alice T AU - Wang AT AD - Department of Plastic and Reconstructive Surgery, Johns Hopkins University, Baltimore, MD, USA. RINGGOLD: 1466 FAU - Hseu, Anne F AU - Hseu AF AD - Department of Plastic and Oral Surgery, Boston Children's Hospital, Boston, MA, USA. RINGGOLD: 370835 AD - Department of Otolaryngology and Communication Enhancement, Boston Children's Hospital, Boston, MA, USA. RINGGOLD: 1862 FAU - Clark, Roseanne E AU - Clark RE AD - Department of Otolaryngology and Communication Enhancement, Boston Children's Hospital, Boston, MA, USA. RINGGOLD: 1862 FAU - Meara, John G AU - Meara JG AD - Department of Plastic and Oral Surgery, Boston Children's Hospital, Boston, MA, USA. RINGGOLD: 370835 AD - Harvard Medical School, Boston, MA, USA. FAU - Nuss, Roger C AU - Nuss RC AD - Department of Plastic and Oral Surgery, Boston Children's Hospital, Boston, MA, USA. RINGGOLD: 370835 AD - Department of Otolaryngology and Communication Enhancement, Boston Children's Hospital, Boston, MA, USA. RINGGOLD: 1862 FAU - Ganske, Ingrid M AU - Ganske IM AUID- ORCID: 0000-0001-6751-6990 AD - Department of Plastic and Oral Surgery, Boston Children's Hospital, Boston, MA, USA. RINGGOLD: 370835 AD - Harvard Medical School, Boston, MA, USA. FAU - Rogers-Vizena, Carolyn R AU - Rogers-Vizena CR AUID- ORCID: 0000-0002-2166-1209 AD - Department of Plastic and Oral Surgery, Boston Children's Hospital, Boston, MA, USA. RINGGOLD: 370835 AD - Harvard Medical School, Boston, MA, USA. LA - eng PT - Journal Article DEP - 20240723 PL - United States TA - Cleft Palate Craniofac J JT - The Cleft palate-craniofacial journal : official publication of the American Cleft Palate-Craniofacial Association JID - 9102566 SB - IM MH - Humans MH - *Velopharyngeal Insufficiency/diagnosis/genetics/etiology MH - Female MH - *DiGeorge Syndrome/diagnosis/complications/genetics MH - Male MH - Child MH - Child, Preschool MH - Infant MH - Genetic Testing MH - Retrospective Studies MH - Cohort Studies MH - Adolescent OTO - NOTNLM OT - 22q11.2 deletion OT - DiGeorge syndrome OT - multidisciplinary clinic OT - velocardiofacial syndrome OT - velopharyngeal dysfunction OT - velopharyngeal insufficiency COIS- Declaration of Conflicting InterestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2024/07/24 00:42 MHDA- 2025/07/11 12:30 CRDT- 2024/07/23 19:23 PHST- 2025/07/11 12:30 [medline] PHST- 2024/07/24 00:42 [pubmed] PHST- 2024/07/23 19:23 [entrez] AID - 10.1177/10556656241266464 [doi] PST - ppublish SO - Cleft Palate Craniofac J. 2025 Sep;62(9):1588-1591. doi: 10.1177/10556656241266464. Epub 2024 Jul 23. PMID- 39043359 OWN - NLM STAT- MEDLINE DCOM- 20241114 LR - 20260813 IS - 1745-9206 (Electronic) IS - 1742-3953 (Print) IS - 1742-3953 (Linking) VI - 20 IP - 3 DP - 2024 Sep TI - "I Felt Like I Mattered": Caring is a key ingredient of collaborative care for chronic illness. PG - 383-394 LID - 10.1177/17423953241264862 [doi] AB - OBJECTIVES: To identify perceptions and experiences related to caring science and collaborative care in intervention participants of the Collaborative Care to Alleviate Symptoms and Adjust to Illness (CASA) study, a randomized, multi-site clinical trial for patients with chronic heart failure and reduced health status. METHODS: Forty-five participants completed semi-structured, telephone interviews with a focus on intervention components, impact of the intervention on participants' lives, and recommendations for intervention change. Data were analyzed using an inductive content analysis approach focusing on the presence and frequency of text to identify patterns, categories, and themes across participants without an a priori code book. The validity of the identified categories was enhanced through triangulation. RESULTS: Three themes were identified: (1) intervention providers' caring/helping attitude and caring/helping communication; (2) care team availability to respond to concerns or questions; and (3) help with understanding and navigating the healthcare system. DISCUSSION: Patients highly value caring attitudes and communication, availability, and empowerment to understand and navigate healthcare systems. These attitudes and behaviors may be important mediators of the success of collaborative care programs. These are consistent with the theory of caring science, a framework that is relevant more broadly to patient-centered and team-based care models. FAU - Graney, Bridget A AU - Graney BA AUID- ORCID: 0000-0002-8239-9427 AD - Divison of Pulmonary and Critical Care, Department of Medicine, Denver Health Medical Center, Denver, Colorado, USA. AD - Department of Medicine, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, Colorado, USA. FAU - Portz, Jennifer Dickman AU - Portz JD AD - Division of General Internal Medicine, Department of Medicine, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, Colorado, USA. FAU - Bekelman, David B AU - Bekelman DB AD - Division of General Internal Medicine, Department of Medicine, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, Colorado, USA. AD - Department of Medicine, Department of Veterans Affairs, Eastern Colorado Health Care System, Aurora, Colorado, USA. LA - eng SI - ClinicalTrials.gov/NCT01739686 GR - K24 AG070322/AG/NIA NIH HHS/United States GR - R01 NR013422/NR/NINR NIH HHS/United States GR - UL1 TR001082/TR/NCATS NIH HHS/United States PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial PT - Research Support, N.I.H., Extramural DEP - 20240723 PL - United States TA - Chronic Illn JT - Chronic illness JID - 101253019 SB - IM MH - Humans MH - Chronic Disease/therapy/psychology MH - Female MH - Male MH - Middle Aged MH - Aged MH - *Empathy MH - Cooperative Behavior MH - Heart Failure/therapy/psychology MH - Communication MH - Patient Care Team MH - Qualitative Research MH - Interviews as Topic MH - Patient-Centered Care MH - Adult PMC - PMC13148793 MID - NIHMS2164866 OTO - NOTNLM OT - Collaborative care OT - caring science OT - chronic heart failure OT - chronic illness OT - qualitative research COIS- Declaration of conflicting interestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2024/07/24 00:42 MHDA- 2024/11/14 18:31 PMCR- 2026/05/06 CRDT- 2024/07/23 19:23 PHST- 2024/11/14 18:31 [medline] PHST- 2024/07/24 00:42 [pubmed] PHST- 2024/07/23 19:23 [entrez] PHST- 2026/05/06 00:00 [pmc-release] AID - 10.1177/17423953241264862 [doi] PST - ppublish SO - Chronic Illn. 2024 Sep;20(3):383-394. doi: 10.1177/17423953241264862. Epub 2024 Jul 23. PMID- 39041742 OWN - NLM STAT- MEDLINE DCOM- 20240723 LR - 20241022 IS - 1550-5022 (Electronic) IS - 1078-4659 (Linking) VI - 30 DP - 2024 Sep-Oct 01 TI - Sharing Results From the Field-Implementing Team-Based Care: Examples of Practice-Based Evidence From Recipients of CDC's Heart Disease and Stroke Prevention Funding. PG - S101-S103 LID - 10.1097/PHH.0000000000002015 [doi] FAU - Patanian, Miriam AU - Patanian M AUID- ORCID: 0000-0002-1309-8567 AD - National Association of Chronic Disease Directors, Decatur, Georgia. LA - eng PT - Journal Article DEP - 20240722 PL - United States TA - J Public Health Manag Pract JT - Journal of public health management and practice : JPHMP JID - 9505213 SB - IM CIN - J Public Health Manag Pract. 2024 Sep-Oct 01;30:S104-S106. doi: 10.1097/PHH.0000000000002016. PMID: 39041743 MH - Humans MH - *Centers for Disease Control and Prevention, U.S./organization & administration MH - United States MH - *Stroke/prevention & control MH - Heart Diseases/prevention & control/therapy MH - Evidence-Based Practice/methods MH - Patient Care Team COIS- The author declares no conflict of interest with respect to the authorship and/or publication of this article. The findings and conclusions in this report are those of the author and do not necessarily represent the official position of the Centers for Disease Control and Prevention. EDAT- 2024/07/23 12:43 MHDA- 2024/07/23 12:44 CRDT- 2024/07/23 08:53 PHST- 2024/07/23 12:44 [medline] PHST- 2024/07/23 12:43 [pubmed] PHST- 2024/07/23 08:53 [entrez] AID - 00124784-202409001-00001 [pii] AID - 10.1097/PHH.0000000000002015 [doi] PST - ppublish SO - J Public Health Manag Pract. 2024 Sep-Oct 01;30:S101-S103. doi: 10.1097/PHH.0000000000002015. Epub 2024 Jul 22. PMID- 39037950 OWN - NLM STAT- MEDLINE DCOM- 20250423 LR - 20250514 IS - 1535-2811 (Electronic) IS - 1535-2811 (Linking) VI - 24 IP - 1 DP - 2025 Mar 1 TI - Unlocking the Potential of the HEART Pathway: Predicting MACE and Facilitating Nurse-Physician Collaboration in Chest Pain Unit. PG - e0374 LID - 10.1097/HPC.0000000000000374 [doi] AB - BACKGROUND AND OBJECTIVE: The HEART pathway serves as a tool for predicting major adverse cardiac events (MACE) among patients presenting with acute chest pain, aiding in the early discharge of low-risk patients and reducing unnecessary cardiac investigations. This study aimed to evaluate physician-nurse reliability of the HEART pathway and investigate the efficacy of HEART pathway to predict 3-month MACE in patients with acute chest pain. METHODS: We conducted a prospective study on 97 patients experiencing acute chest pain. A team of 3 professionals, a nurse, a cardiology resident, and a cardiology attending physician, performed risk stratification. We assessed interrater reliability among the raters as well as explored 3-month MACE outcomes. RESULTS: Excellent pairwise agreements were found between the raters. Overall agreement among raters was excellent, with an intraclass correlation coefficient of 0.84 (95% confidence interval: 0.73-0.97). The HEART pathway score exhibited strong predictive power (area under curve: 0.85) for 3-month MACE. At a cutoff score of 4, sensitivity, specificity, and negative predictive values were 87.5%, 58.9%, and 95.8%, respectively. CONCLUSIONS: The HEART pathway score effectively predicts 3-month MACE in patients with acute nontraumatic chest pain. Moreover, the high agreement among the attending physician, the resident physician, and the nurse suggests that nurses could use this tool, potentially reducing the workload on physicians. CI - Copyright (c) 2024 Wolters Kluwer Health, Inc. All rights reserved. FAU - Behpour, Zahra AU - Behpour Z AD - From the Vascular Disease and Thrombosis Research Center, Rajaie Cardiovascular Medical and Research Institute, Tehran, Iran. AD - Rajaie Cardiovascular Medical and Research Center, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. FAU - Amirsardari, Zahra AU - Amirsardari Z AD - Cardiogenetic Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran. AD - School of medicine, Tehran University of Medical Sciences, Tehran, Iran. FAU - Aghakhani, Haniye AU - Aghakhani H AD - Cardiovascular Nursing Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran. FAU - Zanganehfar, Mohammadesmaeil AU - Zanganehfar M AD - From the Vascular Disease and Thrombosis Research Center, Rajaie Cardiovascular Medical and Research Institute, Tehran, Iran. FAU - Khaleghparast, Shiva AU - Khaleghparast S AD - Cardiovascular Nursing Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran. FAU - Shabani, Fidan AU - Shabani F AD - Cardiovascular Nursing Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran. FAU - Bakhshandeh, Hooman AU - Bakhshandeh H AD - From the Vascular Disease and Thrombosis Research Center, Rajaie Cardiovascular Medical and Research Institute, Tehran, Iran. FAU - Sadeghipour, Parham AU - Sadeghipour P AD - From the Vascular Disease and Thrombosis Research Center, Rajaie Cardiovascular Medical and Research Institute, Tehran, Iran. LA - eng PT - Journal Article DEP - 20250221 PL - United States TA - Crit Pathw Cardiol JT - Critical pathways in cardiology JID - 101165286 SB - IM MH - Humans MH - Female MH - Male MH - *Chest Pain/diagnosis/etiology MH - Prospective Studies MH - Middle Aged MH - Risk Assessment/methods MH - *Physician-Nurse Relations MH - Aged MH - Reproducibility of Results MH - Patient Care Team EDAT- 2024/07/22 18:41 MHDA- 2025/02/21 12:22 CRDT- 2024/07/22 13:21 PHST- 2025/02/21 12:22 [medline] PHST- 2024/07/22 18:41 [pubmed] PHST- 2024/07/22 13:21 [entrez] AID - 00132577-990000000-00089 [pii] AID - 10.1097/HPC.0000000000000374 [doi] PST - ppublish SO - Crit Pathw Cardiol. 2025 Mar 1;24(1):e0374. doi: 10.1097/HPC.0000000000000374. Epub 2025 Feb 21. PMID- 39037643 OWN - NLM STAT- MEDLINE DCOM- 20241210 LR - 20260921 IS - 1878-7649 (Print) IS - 1878-7657 (Electronic) IS - 1878-7649 (Linking) VI - 15 IP - 6 DP - 2024 Dec TI - Geriatricians' role in the management of aortic stenosis in frail older patients: a decade later. PG - 1635-1643 LID - 10.1007/s41999-024-01015-9 [doi] AB - INTRODUCTION: Increasing evidence supports the implementation of geriatric assessment in the workup of older patients with aortic stenosis (AS). In 2012, an online European survey revealed that geriatricians were rarely involved in the assessment of candidates for transcatheter aortic valve implantation (TAVI). After a "call to action" for early involvement of geriatricians in AS evaluation, the survey was repeated in 2022. Our aim was to investigate whether geriatricians' role changed in the last decade. METHODS: Online survey conducted between December 16th, 2021, and December 15th, 2022. All members of the European Geriatric Medicine Society were invited to participate. The survey included 26 questions regarding geriatricians' experience with AS and TAVI. RESULTS: Among 193 respondents (79.8% geriatricians), 73 (38%) reported to be involved in AS evaluation at least once a week. During 2 years prior to the survey, 43 (22.3%) had referred > 50% of their patients with severe AS for TAVI. Age influenced TAVI referral in a considerable proportion of respondents (36.8%). TAVI candidates were mainly referred to specialised cardiac centres with multidisciplinary teams (91.8%), including (47.2%) or not including (44.6%) a geriatrician. A total of 38.9% of respondents reported to be part of a multidisciplinary heart team. Geriatricians were less frequently involved (37%) than cardiologists (89.6%) and surgeons (53.4%) in pre-procedural TAVI management. Cardiologists were more frequently involved (85.5%) than geriatricians (33.7%) and surgeons (26.9%) in post-procedural management. CONCLUSIONS: Geriatricians' involvement in AS management and multidisciplinary heart teams remains scarce. More efforts should be devoted to implement geriatricians' role in AS decision-making. CI - (c) 2024. The Author(s). FAU - Ungar, Andrea AU - Ungar A AUID- ORCID: 0000-0002-8965-4523 AD - Geriatrics and Intensive Care Unit, University of Florence and Azienda Ospedaliero Universitaria Careggi, Florence, Italy. aungar@unifi.it. FAU - Rivasi, Giulia AU - Rivasi G AD - Geriatrics and Intensive Care Unit, University of Florence and Azienda Ospedaliero Universitaria Careggi, Florence, Italy. FAU - Testa, Giuseppe Dario AU - Testa GD AD - Geriatrics and Intensive Care Unit, University of Florence and Azienda Ospedaliero Universitaria Careggi, Florence, Italy. FAU - Boureau, Anne Sophie AU - Boureau AS AD - Nantes Universite, CHU Nantes, Pole de Gerontologie Clinique, 44000, Nantes, France. FAU - Mattace-Raso, Francesco AU - Mattace-Raso F AD - Division of Geriatrics, Department of Internal Medicine, Erasmus MC University Medical Center, Rotterdam, The Netherlands. FAU - Martinez-Selles, Manuel AU - Martinez-Selles M AD - Cardiology Department, Hospital General Universitario Gregorio Maranon, Instituto de Investigacion Sanitaria Gregorio Maranon, CIBERCV, Universidad Europea, Universidad Complutense, Madrid, Spain. FAU - Bo, Mario AU - Bo M AD - Section of Geriatric, Department of Medical Sciences, University of Turin, Citta della Salute e della Scienza, Molinette, Turin, Italy. FAU - Petrovic, Mirko AU - Petrovic M AD - Section of Geriatrics, Department of Internal Medicine and Paediatrics, Ghent University, Ghent, Belgium. FAU - Werner, Nikos AU - Werner N AD - Heart Center Trier, Department of Internal Medicine III, Krankenhaus der Barmherzigen Bruder Trier, Trier, Germany. FAU - Benetos, Athanase AU - Benetos A AD - Geriatric Department and Federation Hospital-University On Cardiovascular Aging (FHU-CARTAGE), University Hospital of Nancy, Universite de Lorraine, Vandoeuvre-Les-Nancy, France. CN - EuGMS Special Interest Group on Cardiovascular Medicine LA - eng PT - Journal Article DEP - 20240722 PL - Switzerland TA - Eur Geriatr Med JT - European geriatric medicine JID - 101533694 SB - IM MH - Humans MH - *Aortic Valve Stenosis/surgery MH - *Transcatheter Aortic Valve Replacement MH - *Geriatricians MH - Aged MH - Female MH - Male MH - *Frail Elderly MH - Geriatric Assessment MH - Aged, 80 and over MH - Surveys and Questionnaires MH - Physician's Role MH - Referral and Consultation MH - Europe/epidemiology MH - Geriatrics PMC - PMC11632017 OTO - NOTNLM OT - Aortic valve replacement OT - Comprehensive geriatric assessment OT - Frailty OT - Heart team OT - Transcatheter aortic valve implantation COIS- Declarations. Conflict of interest: The authors declare no conflict of interests. Ethical approval: A formal approval of an Ethical Committee was not required since personal information was not collected. The survey was developed in agreement with the guidelines for EuGMS survey ( https://www.eugms.org/about-us/eugms-and-non-eugms-surveys.html ). Informed consent: The data were fully anonymized and consent was provided by all participants. EDAT- 2024/07/22 12:43 MHDA- 2024/12/10 12:26 PMCR- 2024/07/22 CRDT- 2024/07/22 11:15 PHST- 2024/02/04 00:00 [received] PHST- 2024/06/25 00:00 [accepted] PHST- 2024/12/10 12:26 [medline] PHST- 2024/07/22 12:43 [pubmed] PHST- 2024/07/22 11:15 [entrez] PHST- 2024/07/22 00:00 [pmc-release] AID - 10.1007/s41999-024-01015-9 [pii] AID - 1015 [pii] AID - 10.1007/s41999-024-01015-9 [doi] PST - ppublish SO - Eur Geriatr Med. 2024 Dec;15(6):1635-1643. doi: 10.1007/s41999-024-01015-9. Epub 2024 Jul 22. PMID- 39036194 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240723 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 16 IP - 6 DP - 2024 Jun TI - Use of High-Fidelity Simulation as an Adjunct to Basic Life Support Training To Promote Team-Based Resuscitation Skills: A Mixed-Methods Pilot Study. PG - e62719 LID - 10.7759/cureus.62719 [doi] LID - e62719 AB - Introduction The 2020 American Heart Association's (AHA) Basic Life Support (BLS) curriculum focuses on cardiac arrest resuscitation with one or two rescuers, providing only limited opportunities to develop higher-level skills such as leadership, communication, and debriefing. This mixed-methods pilot study evaluated whether supplementing the traditional Heartcode BLS course with a high-fidelity teamwork simulation session improved mastery of these higher-level skills. Methods Twenty-four first-year medical students completed the pilot training during sessions offered in February and May of 2023. The program included the traditional AHA Heartcode BLS course, which ranges from two to four hours, and includes both online and in-person skills components. This was followed by a 90-minute high-fidelity simulation session consisting of two simulated resuscitations separated by a student-led plus/delta debriefing. Facilitators then debriefed the entire activity. Students completed an anonymous online survey that used a 0-10 slider scale to attribute their perceived proficiency for specific skills to the initial BLS course or the teamwork simulations and provided qualitative feedback. Results Twenty-one students (87.5%) completed the follow-up survey. Students credited their proficiency in technical skills (e.g., "Chest Compressions") to both sessions equally, but proficiency in higher-level skills, such as leadership, communication, and teamwork, was predominantly credited to the simulation. Additionally, students reported that the teamwork simulation promoted realism and increased self-efficacy. Conclusion Team-based resuscitation simulations using high-fidelity equipment augmented the AHA BLS course by promoting perceived competence in team dynamics domains and increasing students' self-efficacy for participating in real hospital-based resuscitations. Studies with larger sample sizes and objective data should be performed, and the use of similar resuscitation simulations or the development of a formal team-based BLS certification course should be considered. CI - Copyright (c) 2024, Berger et al. FAU - Berger, Daniel J AU - Berger DJ AD - Emergency & Internal Medicine, Virginia Commonwealth University Health System, Richmond, USA. FAU - Lum, Lauren AU - Lum L AD - Resuscitation Sciences Training Center, Penn State Health Milton S. Hershey Medical Center, Hershey, USA. FAU - Shercliffe, Ryan AU - Shercliffe R AD - Resuscitation Sciences Training Center, Penn State Health Milton S. Hershey Medical Center, Hershey, USA. FAU - Sinz, Elizabeth AU - Sinz E AD - Anesthesiology and Critical Care, West Virginia University, Morgantown, USA. LA - eng PT - Journal Article DEP - 20240619 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC11259406 OTO - NOTNLM OT - basic life support OT - bls OT - cardiac arrest OT - cpr OT - high-fidelity simulation OT - resuscitation training OT - team-dynamics COIS- Human subjects: Consent was obtained or waived by all participants in this study. Pennsylvania State University Institutional Review Board issued approval STUDY00022019. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: The project described was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant UL1 TR002014 and Grant UL1 TR00045. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The use of the Penn State College of Medicine Clinical Simulation Center & Resuscitation Science Training Center equipment, staff, and space was provided free of charge for this project. Gift cards were self-funded by the authors. Financial relationships: Elizabeth Sinz declare(s) personal fees and Travel from Sinz Healthcare Education Solutions, LLC. Sinz Healthcare Education Solutions, LLC is owned by Elizabeth Sinz to facilitate her work for the American Heart Association as an editor, updating educational materials when the guidelines are updated. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. EDAT- 2024/07/22 06:43 MHDA- 2024/07/22 06:44 PMCR- 2024/06/19 CRDT- 2024/07/22 05:29 PHST- 2024/06/18 00:00 [accepted] PHST- 2024/07/22 06:44 [medline] PHST- 2024/07/22 06:43 [pubmed] PHST- 2024/07/22 05:29 [entrez] PHST- 2024/06/19 00:00 [pmc-release] AID - 10.7759/cureus.62719 [doi] PST - epublish SO - Cureus. 2024 Jun 19;16(6):e62719. doi: 10.7759/cureus.62719. eCollection 2024 Jun. PMID- 39031491 OWN - NLM STAT- MEDLINE DCOM- 20241112 LR - 20260217 IS - 1467-9566 (Electronic) IS - 0141-9889 (Linking) VI - 46 IP - 8 DP - 2024 Nov TI - Working knowledge, uncertainty and ontological politics: An ethnography of UK long covid clinics. PG - 1881-1900 LID - 10.1111/1467-9566.13819 [doi] AB - Long covid (persistent COVID-19) is a new disease with contested aetiology and variable prognosis. We report a 2-year ethnography of UK long covid clinics. Using a preformative lens, we show that multidisciplinary teams (MDTs) built working knowledge based on shared practices, mutual trust, distributed cognition (e.g. emails, record entries), relational knowledge of what was at stake for the patient, and harnessing uncertainty to open new discursive spaces. Most long covid MDTs performed the working knowledge of 'rehabilitation', a linked set of practices oriented to ensuring that the patient understood and strove to 'correct' maladaptive physiological responses (e.g. through breathing exercises) and pursued recovery goals, supported by physiotherapists, psychologists and generalist clinicians. Some MDTs with a higher proportion of doctors (e.g. cardiologists, neurologists, immunologists) enacted the working knowledge of 'microscopic damage', seeking to elucidate and rectify long covid's underlying molecular and cellular pathology. They justified non-standard investigations and medication in selected patients by co-constructing an evidentiary narrative based on biological mechanisms. Working knowledge was ontologically concordant within MDTs but sometimes discordant between MDTs. Overt ontological conflict occurred mostly when patients attending 'rehabilitation' clinics invoked the working knowledge of microscopic damage that had been generated and circulated in online support communities. CI - (c) 2024 The Author(s). Sociology of Health & Illness published by John Wiley & Sons Ltd on behalf of Foundation for the Sociology of Health & Illness. FAU - Greenhalgh, Trisha AU - Greenhalgh T AUID- ORCID: 0000-0003-2369-8088 AD - Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK. FAU - Darbyshire, Julie AU - Darbyshire J AUID- ORCID: 0000-0002-7655-1963 AD - Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK. FAU - Ladds, Emma AU - Ladds E AUID- ORCID: 0000-0001-9864-7408 AD - Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK. FAU - Van Dael, Jackie AU - Van Dael J AUID- ORCID: 0000-0002-9949-5802 AD - Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK. FAU - Rayner, Clare AU - Rayner C AD - Independent Occupational Physician, Manchester, UK. LA - eng GR - COV-LT-0016/National Institute for Health and Care Research/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240719 PL - England TA - Sociol Health Illn JT - Sociology of health & illness JID - 8205036 SB - IM MH - Humans MH - United Kingdom MH - *COVID-19/psychology MH - *Anthropology, Cultural MH - Uncertainty MH - *SARS-CoV-2 MH - Politics MH - Post-Acute COVID-19 Syndrome MH - Patient Care Team OTO - NOTNLM OT - COVID-19 OT - distributed knowledge OT - long covid OT - multidisciplinary teams OT - ontological politics OT - working knowledge EDAT- 2024/07/20 20:46 MHDA- 2024/11/13 13:56 CRDT- 2024/07/20 12:03 PHST- 2023/10/20 00:00 [received] PHST- 2024/06/27 00:00 [accepted] PHST- 2024/11/13 13:56 [medline] PHST- 2024/07/20 20:46 [pubmed] PHST- 2024/07/20 12:03 [entrez] AID - 10.1111/1467-9566.13819 [doi] PST - ppublish SO - Sociol Health Illn. 2024 Nov;46(8):1881-1900. doi: 10.1111/1467-9566.13819. Epub 2024 Jul 19. PMID- 39025954 OWN - NLM STAT- MEDLINE DCOM- 20250513 LR - 20261010 IS - 1476-5543 (Electronic) IS - 0743-8346 (Linking) VI - 45 IP - 4 DP - 2025 Apr TI - Continuous improvement of non-emergent neonatal intubations in a level IV NICU. PG - 545-551 LID - 10.1038/s41372-024-02062-7 [doi] AB - OBJECTIVE: We sought to improve practices and outcomes related to non-emergent neonatal intubations in a level IV academic Neonatal Intensive Care Unit. STUDY DESIGN: A multidisciplinary team created guidelines for non-emergent neonatal intubations. In period 1, premedication practices were standardized. In period 2, paralytic use and video laryngoscope use were recommended. Premedication and video laryngoscopy practices were assessed along with number of intubation attempts and frequency of bradycardia and desaturation. RESULTS: 636 intubations performed by neonatology fellows and neonatal advanced practice providers were reviewed over six academic years. Two academic years were included in each of the following study periods: baseline, period 1, and period 2. In our unit, compliance with recommended premedication practices and administration of paralytic medication has increased considerably, and video laryngoscopy is now utilized in most of our procedures. The frequency of intubation success on the first attempt has increased, and the frequency of both bradycardia and desaturation during intubation has decreased. In our analysis, paralytic use (AOR 2.41, 95 CI (1.53, 3.81)) and the combination of paralytic and video laryngoscopy (AOR 4.07, 95 CI (2.09, 7.92)) are associated with increased odds of intubating successfully on the first attempt. CONCLUSIONS: This initiative increased the use of standardized premedication, paralytic medication and video laryngoscopy for non-emergent neonatal intubations with temporally associated improvement in patient outcomes including fewer intubation attempts and reduction in physiologic instability. CI - (c) 2024. The Author(s), under exclusive licence to Springer Nature America, Inc. FAU - Shay, Rebecca AU - Shay R AUID- ORCID: 0000-0002-7181-2757 AD - University of Colorado School of Medicine, Department of Pediatrics, Aurora, CO, USA. Rebecca.shay@childrenscolorado.org. AD - Children's Hospital Colorado, Section of Neonatology, Aurora, CO, USA. Rebecca.shay@childrenscolorado.org. FAU - Weikel, Blair W AU - Weikel BW AD - University of Colorado School of Medicine, Department of Pediatrics, Aurora, CO, USA. AD - Children's Hospital Colorado, Section of Neonatology, Aurora, CO, USA. FAU - Mascorro, Melanie AU - Mascorro M AUID- ORCID: 0000-0002-1007-9897 AD - University of Colorado School of Medicine, Department of Pediatrics, Aurora, CO, USA. AD - Children's Hospital Colorado, Section of Neonatology, Aurora, CO, USA. FAU - Harding, Emma AU - Harding E AD - University of Colorado School of Medicine, Department of Pediatrics, Aurora, CO, USA. AD - Children's Hospital Colorado, Section of Neonatology, Aurora, CO, USA. FAU - Beard, Lauren AU - Beard L AD - University of Colorado School of Medicine, Department of Pediatrics, Aurora, CO, USA. AD - Children's Hospital Colorado, Section of Neonatology, Aurora, CO, USA. FAU - Grover, Theresa AU - Grover T AD - University of Colorado School of Medicine, Department of Pediatrics, Aurora, CO, USA. AD - Children's Hospital Colorado, Section of Neonatology, Aurora, CO, USA. FAU - Barry, James S AU - Barry JS AD - University of Colorado School of Medicine, Department of Pediatrics, Aurora, CO, USA. AD - Children's Hospital Colorado, Section of Neonatology, Aurora, CO, USA. LA - eng PT - Journal Article DEP - 20240718 PL - United States TA - J Perinatol JT - Journal of perinatology : official journal of the California Perinatal Association JID - 8501884 SB - IM MH - Humans MH - Infant, Newborn MH - *Intensive Care Units, Neonatal/standards MH - *Intubation, Intratracheal/standards/methods/adverse effects MH - *Laryngoscopy/methods/standards MH - *Quality Improvement MH - Female MH - Bradycardia/etiology/prevention & control MH - Male MH - Premedication MH - Practice Guidelines as Topic MH - Guideline Adherence MH - Video Recording MH - Retrospective Studies COIS- Competing interests: The authors declare no competing interests. Ethics approval and consent to participate: This project was approved by the Colorado Multiple Institutional Review Board (COMIRB) under protocol reference number 19-0775. Informed consent to care was obtained from all subjects. The data collected from human patients is in accordance with the Declaration of Helsinki. EDAT- 2024/07/19 00:42 MHDA- 2025/05/13 06:33 CRDT- 2024/07/18 23:22 PHST- 2024/04/09 00:00 [received] PHST- 2024/07/11 00:00 [accepted] PHST- 2024/07/05 00:00 [revised] PHST- 2025/05/13 06:33 [medline] PHST- 2024/07/19 00:42 [pubmed] PHST- 2024/07/18 23:22 [entrez] AID - 10.1038/s41372-024-02062-7 [pii] AID - 10.1038/s41372-024-02062-7 [doi] PST - ppublish SO - J Perinatol. 2025 Apr;45(4):545-551. doi: 10.1038/s41372-024-02062-7. Epub 2024 Jul 18. PMID- 39022219 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240719 IS - 2296-2360 (Print) IS - 2296-2360 (Electronic) IS - 2296-2360 (Linking) VI - 12 DP - 2024 TI - A systematic review of prenatally diagnosed vein of Galen malformations: prenatal predictive markers and management from fetal life to childhood. PG - 1401468 LID - 10.3389/fped.2024.1401468 [doi] LID - 1401468 AB - INTRODUCTION: Vein of Galen malformations (VGMs) account for less than 1% of all intracranial vascular malformations. However, in fetal and pediatric populations, they represent the most common vascular malformation of the brain. For the effective management of this condition, an optimal knowledge of its prenatal and postnatal clinical features is mandatory. METHODS: Articles published between 1 January 2003 and 31 January 2024, reported in PubMed and EMBASE, were evaluated for a systematic review analyzing the prenatal and postnatal features and management of fetal VGMs. RESULTS: Thirty-one papers reporting information on 51 prenatally diagnosed VGMs were included. The most common prenatal features were fetal hydrocephalus (39%) and cardiomegaly (56%). Postnatal data for 43 VGM cases are described. The overall mortality was 58.14%. In total, 77.78% of the survivors had normal development. CONCLUSIONS: Close follow-up and a multidisciplinary approach are mandatory to manage this condition. Our study aimed to provide a guide for gynecologists, neonatologists, cardiologists, and neuroradiologists. CI - (c) 2024 Di Meglio, Sica, Toscano, Orlandi, Manzo, Mazzarelli, Sica and Di Meglio. FAU - Di Meglio, Lavinia AU - Di Meglio L AD - Residency School of Pediatrics, University of Rome Tor Vergata, Rome, Italy. FAU - Sica, Giordana AU - Sica G AD - University of Medicine and Surgery Luigi Vanvitelli, Naples, Italy. FAU - Toscano, Paolo AU - Toscano P AD - Department of Neuroscience, Reproductive Sciences and Dentistry, School of Medicine and Surgery Federico II of Naples, Naples, Italy. FAU - Orlandi, Giuliana AU - Orlandi G AD - Department of Neuroscience, Reproductive Sciences and Dentistry, School of Medicine and Surgery Federico II of Naples, Naples, Italy. FAU - Manzo, Luigi AU - Manzo L AD - Department of Neuroscience, Reproductive Sciences and Dentistry, School of Medicine and Surgery Federico II of Naples, Naples, Italy. FAU - Mazzarelli, Laura Letizia AU - Mazzarelli LL AD - Department of Neuroscience, Reproductive Sciences and Dentistry, School of Medicine and Surgery Federico II of Naples, Naples, Italy. AD - Diagnositica Ecografia e Prenatale di A. Di Meglio, Naples, Italy. FAU - Sica, Carmine AU - Sica C AD - Diagnositica Ecografia e Prenatale di A. Di Meglio, Naples, Italy. FAU - Di Meglio, Aniello AU - Di Meglio A AD - Diagnositica Ecografia e Prenatale di A. Di Meglio, Naples, Italy. LA - eng PT - Journal Article PT - Systematic Review DEP - 20240703 PL - Switzerland TA - Front Pediatr JT - Frontiers in pediatrics JID - 101615492 PMC - PMC11251923 OTO - NOTNLM OT - VGAM OT - VGM OT - VGMs OT - VGOM OT - fetus OT - prenatal diagnosis OT - vein of Galen aneurysmal malformations OT - vein of Galen malformations COIS- CS, LLM, and ADM are employed at Diagnositica Ecografia e Prenatale di A. Di Meglio, Naples, Italy. ADM is the Scientific Director of the center. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2024/07/18 06:43 MHDA- 2024/07/18 06:44 PMCR- 2024/07/03 CRDT- 2024/07/18 04:46 PHST- 2024/03/15 00:00 [received] PHST- 2024/06/03 00:00 [accepted] PHST- 2024/07/18 06:44 [medline] PHST- 2024/07/18 06:43 [pubmed] PHST- 2024/07/18 04:46 [entrez] PHST- 2024/07/03 00:00 [pmc-release] AID - 10.3389/fped.2024.1401468 [doi] PST - epublish SO - Front Pediatr. 2024 Jul 3;12:1401468. doi: 10.3389/fped.2024.1401468. eCollection 2024. PMID- 39022200 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240719 IS - 2231-5047 (Print) IS - 2231-5128 (Electronic) IS - 2231-5047 (Linking) VI - 14 IP - 1 DP - 2024 Jan-Jun TI - Multidisciplinary Consensus for Rationalizing the Use of Acid Suppressants in Children and Adults: CONFOR. PG - 99-119 LID - 10.5005/jp-journals-10018-1430 [doi] AB - The use of acid suppression therapy (AST) is a common approach for managing a wide spectrum of acid peptic disorders. Histamine type 2-receptor antagonists (H2RAs) and proton pump inhibitors (PPIs) are the most widely prescribed AST in routine clinical practice. However, an exponential surge in the prescriptions of PPIs, such as Omeprazole, Esomeprazole, Pantoprazole, Lansoprazole in recent years and their associated adverse effects have raised concern about their inappropriate and overuse, both in children and adults. To address these issues, a three-step modified Delphi polling process was employed to establish best practice consensus statements for rationalizing the use of acid suppressants. A multidisciplinary expert panel of 13 health professionals across medical specialties, including gastroenterologists, hepatologists, pediatric gastroenterologists, pediatricians, otolaryngologists, cardiologists, nephrologists, gynecologist and orthopedists actively contributed to this collaborative process of consensus development. The expert panel proposed 21 consensus statements providing best practice points on the general use and safety of acid suppressants based on a comprehensive review of scientific literature and clinical expertise. The panel also collaboratively developed a PPI deprescribing algorithm. Altogether, this consensus paper offers evidence-based recommendations and guidance for the rational use of acid suppressants with a blueprint for deprescribing PPIs. This consensus paper contributes to aiding primary care practitioners in improving patient outcomes and minimizing healthcare costs. Additionally, it enhances patient safety and curtail inappropriate usage. HOW TO CITE THIS ARTICLE: Prabhoo RY, Pai UA, Wadhwa A, et al. Multidisciplinary Consensus for Rationalizing the Use of Acid Suppressants in Children and Adults: CONFOR. Euroasian J Hepato-Gastroenterol 2024;14(1):99-119. CI - Copyright (c) 2024; The Author(s). FAU - Prabhoo, Ram Y AU - Prabhoo RY AD - Department of Orthopedics, Mukund Hospital, Mumbai, Maharashtra, India. FAU - Pai, Uday A AU - Pai UA AD - Department of Pediatrics, Sai Kutti Clinic, Mumbai, Maharashtra, India. FAU - Wadhwa, Arun AU - Wadhwa A AD - Department of Pediatrics, Arun Wadhwa Clinic, New Delhi, India. FAU - Pillai, Bhanu V AU - Pillai BV AD - Department of Pediatric Gastroenterology, Amrita Institute of Medical Sciences, Kochi, Kerala, India. FAU - D'souza, Chris AU - D'souza C AD - Department of ENT, Holy Family Hospital, Mumbai, Maharashtra, India. FAU - Wadhawan, Manav AU - Wadhawan M AD - Department of Hepatology and Liver Transplant, BLK-Max Super Speciality Hospital, Delhi, India. FAU - Bhatnagar, Manish AU - Bhatnagar M AD - Department of Gastroenterology, Orchid Mediservices, Ahmedabad, Gujarat, India. FAU - Prabhoo, Meena R AU - Prabhoo MR AD - Department of Gynecology, Mukund Hospital, Mumbai, Maharashtra, India. FAU - Shetty, Sadanand AU - Shetty S AD - Department of Cardiology, Somaiya Super Specialty Institute, Mumbai, Maharashtra, India. FAU - Seshadri, Venkatesh P AU - Seshadri VP AD - Department of Gastroenterology, Apollo Hospital, Chennai, Tamil Nadu, India. FAU - Bhatnagar, Shrish AU - Bhatnagar S AD - Department of Pediatric Gastroenterology, Era's Lucknow Medical College and Hospital, Lucknow, Uttar Pradesh, India. FAU - Manchanda, Subhash C AU - Manchanda SC AD - Department of Cardiology, Sir Ganga Ram Hospital, New Delhi, India. FAU - Kher, Vijay AU - Kher V AD - Department of Nephrology and Transplant Medicine, Epitome Kidney and Urology Institute, New Delhi, India. LA - eng PT - Journal Article PT - Review PL - India TA - Euroasian J Hepatogastroenterol JT - Euroasian journal of hepato-gastroenterology JID - 101577625 PMC - PMC11249898 OTO - NOTNLM OT - Deprescribing OT - Gastrointestinal OT - H2RAs OT - Proton pump inhibitors OT - Ranitidine OT - Side effects COIS- Source of support: This work was supported by JB Pharmaceuticals Ltd., Mumbai. JB Pharmaceuticals Ltd. provided an unrestricted grant for medical writing services in accordance with Good Publication Practice guidelines. Conflict of interest: None EDAT- 2024/07/18 06:43 MHDA- 2024/07/18 06:44 PMCR- 2024/01/01 CRDT- 2024/07/18 04:46 PHST- 2024/03/02 00:00 [received] PHST- 2024/04/22 00:00 [accepted] PHST- 2024/07/18 06:44 [medline] PHST- 2024/07/18 06:43 [pubmed] PHST- 2024/07/18 04:46 [entrez] PHST- 2024/01/01 00:00 [pmc-release] AID - 10.5005/jp-journals-10018-1430 [doi] PST - ppublish SO - Euroasian J Hepatogastroenterol. 2024 Jan-Jun;14(1):99-119. doi: 10.5005/jp-journals-10018-1430. PMID- 39019587 OWN - NLM STAT- MEDLINE DCOM- 20240717 LR - 20240720 IS - 2399-6641 (Electronic) IS - 2399-6641 (Linking) VI - 13 IP - 3 DP - 2024 Jul 17 TI - Effectiveness of Rapid Response Team implementation in a tertiary hospital in Egypt: an interventional study. LID - 10.1136/bmjoq-2023-002540 [doi] LID - e002540 AB - BACKGROUND: Rapid response teams (RRTs) help in the early recognition of deteriorating patients in hospital wards and provide the needed management at the bedside by a qualified team. RRT implementation is still questionable because there is insufficient evidence regarding its effects. To date, according to our knowledge, no published studies have addressed the effectiveness of RRT implementation on inpatient care outcomes in Egypt. OBJECTIVE: We aimed to assess the impact of an RRT on the rates of inpatient mortality, cardiopulmonary arrest calls and unplanned intensive care unit (ICU) admission in an Egyptian tertiary hospital. METHODS: An interventional study was conducted at a university hospital. Data was evaluated for 24 months before the intervention (January 2018 till December 2019, which included 4242 admissions). The intervention was implemented for 12 months (January 2021 till December 2021), ending with postintervention evaluation of 2338 admissions. RESULTS: RRT implementation was associated with a significant reduction in inpatient mortality rate from 88.93 to 46.44 deaths per 1000 discharges (relative risk reduction (RRR)=0.48; 95% CI, 0.36 to 0.58). Inpatient cardiopulmonary arrest rate decreased from 7.41 to 1.77 calls per 1000 discharges (RRR, 0.76; 95% CI, 0.32 to 0.92), while unplanned ICU admissions decreased from 5.98 to 4.87 per 1000 discharges (RRR, 0.19; 95% CI, -0.65 to 0.60). CONCLUSIONS: RRT implementation was associated with a significantly reduced hospital inpatient mortality rate, cardiopulmonary arrest call rate as well as reduced unplanned ICU admission rate. Our results reveal that RRT can contribute to improving the quality of care in similar settings in developing countries. CI - (c) Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Hosny, Rania AU - Hosny R AUID- ORCID: 0009-0006-8299-6340 AD - Universal Health Insurance Authority, Cairo, Egypt rhosny@med.asu.edu.eg. FAU - Hussein, Rasha Saad AU - Hussein RS AD - Department of Community, Environmental, and Occupational Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt. FAU - Hussein, Wafaa Mohamed AU - Hussein WM AD - Department of Healthcare Quality, Faculty of Medicine, Ain Shams University, Cairo, Egypt. FAU - Hakim, Sally Adel AU - Hakim SA AD - Department of Community, Environmental, and Occupational Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt. FAU - Habil, Ihab Shehad AU - Habil IS AD - Department of Healthcare Quality, Faculty of Medicine, Ain Shams University, Cairo, Egypt. LA - eng PT - Journal Article DEP - 20240717 PL - England TA - BMJ Open Qual JT - BMJ open quality JID - 101710381 SB - IM MH - Humans MH - Egypt MH - *Hospital Rapid Response Team/statistics & numerical data/standards MH - *Tertiary Care Centers/organization & administration/statistics & numerical data MH - Female MH - Male MH - Middle Aged MH - *Hospital Mortality MH - Adult MH - Intensive Care Units/organization & administration/statistics & numerical data MH - Heart Arrest/therapy/mortality PMC - PMC11256054 OTO - NOTNLM OT - Cardiopulmonary Resuscitation OT - Hospital Mortality OT - Patient safety COIS- Competing interests: None declared. EDAT- 2024/07/18 00:42 MHDA- 2024/07/18 00:43 PMCR- 2024/07/17 CRDT- 2024/07/17 21:33 PHST- 2023/08/14 00:00 [received] PHST- 2024/07/06 00:00 [accepted] PHST- 2024/07/18 00:43 [medline] PHST- 2024/07/18 00:42 [pubmed] PHST- 2024/07/17 21:33 [entrez] PHST- 2024/07/17 00:00 [pmc-release] AID - bmjoq-2023-002540 [pii] AID - 10.1136/bmjoq-2023-002540 [doi] PST - epublish SO - BMJ Open Qual. 2024 Jul 17;13(3):e002540. doi: 10.1136/bmjoq-2023-002540. PMID- 39018718 OWN - NLM STAT- MEDLINE DCOM- 20240809 LR - 20240809 IS - 1532-9453 (Electronic) IS - 1055-8586 (Linking) VI - 33 IP - 4 DP - 2024 Aug TI - Congenital diaphragmatic hernia-associated pulmonary hypertension. PG - 151437 LID - S1055-8586(24)00058-1 [pii] LID - 10.1016/j.sempedsurg.2024.151437 [doi] AB - Congenital diaphragmatic hernia (CDH) is characterized by a developmental insult which compromises cardiopulmonary embryology and results in a diaphragmatic defect, allowing abdominal organs to herniate into the hemithorax. Among the significant pathophysiologic components of this condition is pulmonary hypertension (PH), alongside pulmonary hypoplasia and cardiac dysfunction. Fetal pulmonary vascular development coincides with lung development, with the pulmonary vasculature evolving alongside lung maturation. However, in CDH, this embryologic development is impaired which, in conjunction with external compression, stifle pulmonary vascular maturation, leading to reduced lung density, increased muscularization of the pulmonary vasculature, abnormal vascular responsiveness, and altered molecular signaling, all contributing to pulmonary arterial hypertension. Understanding CDH-associated PH (CDH-PH) is crucial for development of novel approaches and effective management due to its significant impact on morbidity and mortality. Antenatal and postnatal diagnostic methods aid in CDH risk stratification and, specifically, pulmonary hypertension, including fetal imaging and gas exchange assessments. Management strategies include lung protective ventilation, fluid optimization, pharmacotherapies including pulmonary vasodilators and hemodynamic support, and extracorporeal life support (ECLS) for refractory cases. Longitudinal re-evaluation is an important consideration due to the complexity and dynamic nature of CDH cardiopulmonary physiology. Emerging therapies such as fetal endoscopic tracheal occlusion and pharmacological interventions targeting key CDH pathophysiological mechanisms show promise but require further investigation. The complexity of CDH-PH underscores the importance of a multidisciplinary approach for optimal patient care and improved outcomes. CI - Copyright (c) 2024 Elsevier Inc. All rights reserved. FAU - Holden, Kylie I AU - Holden KI AD - Department of Pediatric Surgery, McGovern Medical School at the University of Texas Health Science Center and Children's Memorial Hermann Hospital, Houston, TX, USA. FAU - Rintoul, Natalie E AU - Rintoul NE AD - Department of Neonatology, University of Pennsylvania School of Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, USA. FAU - McNamara, Patrick J AU - McNamara PJ AD - Division of Neonatology, University of Iowa Stead Family Children's Hospital, Iowa City, IA, USA. FAU - Harting, Matthew T AU - Harting MT AD - Department of Pediatric Surgery, McGovern Medical School at the University of Texas Health Science Center and Children's Memorial Hermann Hospital, Houston, TX, USA. Electronic address: matthew.t.harting@uth.tmc.edu. LA - eng PT - Journal Article PT - Review DEP - 20240702 PL - United States TA - Semin Pediatr Surg JT - Seminars in pediatric surgery JID - 9216162 SB - IM MH - *Hernias, Diaphragmatic, Congenital/complications/therapy/physiopathology MH - Humans MH - *Hypertension, Pulmonary/etiology/diagnosis/therapy/physiopathology MH - Infant, Newborn OTO - NOTNLM OT - CDH repair OT - CDH study group OT - Congenital diaphragmatic hernia OT - Diaphragm repair OT - Extracorporeal life support OT - Pulmonary hypertension OT - Registry EDAT- 2024/07/18 00:41 MHDA- 2024/08/10 15:45 CRDT- 2024/07/17 18:05 PHST- 2024/08/10 15:45 [medline] PHST- 2024/07/18 00:41 [pubmed] PHST- 2024/07/17 18:05 [entrez] AID - S1055-8586(24)00058-1 [pii] AID - 10.1016/j.sempedsurg.2024.151437 [doi] PST - ppublish SO - Semin Pediatr Surg. 2024 Aug;33(4):151437. doi: 10.1016/j.sempedsurg.2024.151437. Epub 2024 Jul 2. PMID- 39014994 OWN - NLM STAT- MEDLINE DCOM- 20250925 LR - 20260612 IS - 1365-2648 (Electronic) IS - 0309-2402 (Print) IS - 0309-2402 (Linking) VI - 81 IP - 10 DP - 2025 Oct TI - Achieving consensus on the key elements of a nurse-led multidisciplinary chronic heart failure service in Thailand: An e-Delphi study. PG - 6347-6363 LID - 10.1111/jan.16330 [doi] AB - AIMS: To describe the outcomes of an e(electronic)-Delphi survey used to achieve consensus on the essential elements that should be included in a multidisciplinary, nurse-led service for patients with chronic heart failure (CHF). DESIGN: The study design was based on a three-round e-Delphi survey. METHODS: A series of three survey rounds were used to gather expert opinions and achieve consensus on the key elements that should be included in a CHF disease management program from a sample of healthcare professionals and organizational leaders with expertise in existing CHF services. Consensus for each item was defined as at least 90% agreement. RESULTS: There were 20 participants (18 healthcare professionals and 2 organizational leaders) in round-1, 22 (20 healthcare professionals and 2 organizational leaders) in round-2, and 17 (15 healthcare professionals and 2 organizational leaders) in round-3. Fifteen participants attended a final online meeting (13 healthcare professionals and 2 organizational leaders). Consensus was obtained on five essential components: (i) consumer education, (ii) treatment optimization using a multidisciplinary approach, (iii) discharge planning, (iv) provision of supportive community care and (v) mechanisms to respond to early symptoms of decompensated CHF. CONCLUSION: Participants focused on mechanisms to improve treatment effectiveness, patient and family knowledge, communication between healthcare providers and supportive care in the community. The proposed model of care may be useful to other health service providers who are designing or adapting CHF models of care for the South-East Asian environment. IMPACT: This research provides a solid basis for using a Delphi method to resolve the challenges and issues of transferring global model-based recommendations in CHF knowledge. The Delphi method proved successful as an important step in developing a culturally acceptable model of chronic care that meets the goals of local healthcare providers. CI - (c) 2024 The Author(s). Journal of Advanced Nursing published by John Wiley & Sons Ltd. FAU - Koontalay, Apinya AU - Koontalay A AUID- ORCID: 0000-0001-8777-468X AD - Faculty of Health, School of Nursing and Midwifery, Deakin University, Geelong, Victoria, Australia. FAU - Botti, Mari AU - Botti M AD - Faculty of Health, School of Nursing and Midwifery, Deakin University, Geelong, Victoria, Australia. FAU - Hutchinson, Anastasia AU - Hutchinson A AUID- ORCID: 0000-0002-0014-689X AD - Faculty of Health, School of Nursing and Midwifery, Deakin University, Geelong, Victoria, Australia. AD - Institute of Health Transformation, Centre for Quality and Patient Safety Research-Epworth HealthCare Partnership, Deakin University, Geelong, Victoria, Australia. LA - eng PT - Consensus Statement PT - Journal Article DEP - 20240716 PL - England TA - J Adv Nurs JT - Journal of advanced nursing JID - 7609811 SB - IM MH - Humans MH - *Heart Failure/nursing MH - Delphi Technique MH - Thailand MH - Chronic Disease/nursing MH - Female MH - Male MH - Middle Aged MH - Adult MH - Aged MH - *Patient Care Team/organization & administration PMC - PMC12460982 OTO - NOTNLM OT - Delphi technique OT - cardiothoracic nursing OT - heart failure OT - research implementation COIS- The authors have no conflicts of interest to declare. EDAT- 2024/07/17 06:43 MHDA- 2025/09/25 06:28 PMCR- 2025/09/25 CRDT- 2024/07/17 03:03 PHST- 2024/06/06 00:00 [revised] PHST- 2024/02/19 00:00 [received] PHST- 2024/07/02 00:00 [accepted] PHST- 2025/09/25 06:28 [medline] PHST- 2024/07/17 06:43 [pubmed] PHST- 2024/07/17 03:03 [entrez] PHST- 2025/09/25 00:00 [pmc-release] AID - JAN16330 [pii] AID - 10.1111/jan.16330 [doi] PST - ppublish SO - J Adv Nurs. 2025 Oct;81(10):6347-6363. doi: 10.1111/jan.16330. Epub 2024 Jul 16. PMID- 39011058 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260923 IS - 2590-1613 (Electronic) IS - 2590-1613 (Linking) VI - 22 DP - 2024 Jun TI - Comparison of maternal and fetal outcomes in mothers with non-congenital mitral valve stenosis and healthy control. PG - 100290 LID - 10.1016/j.eurox.2024.100290 [doi] LID - 100290 AB - BACKGROUND: Physiological changes during pregnancy cause complications in mothers with mitral stenosis and their infants. This study was designed to assess maternal and fetal pregnancy outcomes in women with rheumatic mitral valve stenosis and compare them with the control group. MATERIALS AND METHODS: This study is a case-control study on 153 pregnant women, including 51 with mitral stenosis (MS) and 102 without MS as the control group, between 2007-2022. For each studied patient, two control participants were selected and matched in residence, age, and year of pregnancy. SPSS version 22 was used for data analysis. RESULTS: The mean age was 31.7 +/- 4.6 years in cases and 31.6 +/- 4.7 in the healthy controls. Demographic variables were not significantly different between the case and control groups. The rate of stillbirth (5.9% vs. 0.0%), %), NICU admission (13.7% vs. 2.0%), and IUGR (5.9% vs. 0.0%) were higher in the fetal case group compared with the control group. On the other hand, maternal outcomes, including pulmonary edema (13.7% vs. 0.0%), ICU admission (23.5% vs. 0.0%), limb edema (15.7% vs. 0.0%), dyspnea (37.3% vs. 0.0%), pulmonary hypertension (9.8% vs. 0.0%), palpitations (21.1% vs. 0.0%) and hospital admission during pregnancy (37.2% vs. 4.9%) were statistically more common in the case groups. CONCLUSIONS: Pregnancy is associated with significant fetomaternal morbidities in women with mitral valve heart disease. So they need a multidisciplinary approach in preconception and antenatal care. CI - (c) 2024 Published by Elsevier B.V. FAU - Shari, Sima Sobhani AU - Shari SS AD - Student Research Committee, Birjand University of Medical Sciences, Birjand, Iran. FAU - Kazemi, Tooba AU - Kazemi T AD - Cardiovascular Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran. FAU - Bidokhti, Ali AU - Bidokhti A AD - Cardiovascular Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran. FAU - Riahi, Seyed Mohammad AU - Riahi SM AD - Department of Community Medicine, School of Medicine, Cardiovascular Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran. LA - eng PT - Journal Article DEP - 20240227 PL - Netherlands TA - Eur J Obstet Gynecol Reprod Biol X JT - European journal of obstetrics & gynecology and reproductive biology: X JID - 101750520 PMC - PMC11247151 OTO - NOTNLM OT - Case-control study OT - Fetal outcomes OT - High-risk pregnancy OT - Maternal outcomes OT - Rheumatic mitral valve stenosis COIS- None of the authors has any relevant or significant industrial interests and benefit related to the research described in this article. EDAT- 2024/07/16 06:41 MHDA- 2024/07/16 06:42 PMCR- 2024/02/27 CRDT- 2024/07/16 04:06 PHST- 2023/09/06 00:00 [received] PHST- 2024/02/03 00:00 [revised] PHST- 2024/02/09 00:00 [accepted] PHST- 2024/07/16 06:42 [medline] PHST- 2024/07/16 06:41 [pubmed] PHST- 2024/07/16 04:06 [entrez] PHST- 2024/02/27 00:00 [pmc-release] AID - S2590-1613(24)00010-3 [pii] AID - 100290 [pii] AID - 10.1016/j.eurox.2024.100290 [doi] PST - epublish SO - Eur J Obstet Gynecol Reprod Biol X. 2024 Feb 27;22:100290. doi: 10.1016/j.eurox.2024.100290. eCollection 2024 Jun. PMID- 39010011 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240717 IS - 1865-1372 (Print) IS - 1865-1380 (Electronic) IS - 1865-1372 (Linking) VI - 17 IP - 1 DP - 2024 Jul 15 TI - Successful management of a delayed presentation of traumatic descending thoracic aorta pseudoaneurysm: a literature review based on a case report. PG - 87 LID - 10.1186/s12245-024-00670-w [doi] LID - 87 AB - BACKGROUND: Blunt traumatic aortic injury (BTAI) is the second leading cause of death due to traumas in young patients. The primary presentation might be chest or interscapular pain, difficulty in breathing, and, in severe cases, hypotension. Considering the rapid deterioration of these patients' clinical conditions, prompt diagnosis and treatment initiation are crucial. In these injuries, the most involved parts of the aorta are the isthmus (distal to the left subclavian artery) and the descending part in the thorax. Therefore, the main diagnostic strategies include transthoracic echocardiography, CT angiography, and endovascular diagnostic approaches. Case presentation The patient was a 19-year-old male presenting with the symptoms of chest pain, dyspnea, and extremities excruciating pain after a car turnover. The initial evaluation showed no abnormal cardiovascular finding except bilateral hemothorax, addressed with chest tubes. Twelve hours later, when the patient was under observation for orthopedic surgeries, his chest pain and dyspnea started, and TTE and CTA showed a grade three descending aneurysm of the aorta. The patient was treated immediately with an endovascular procedure of stent implantation. A delayed debranching surgery was also performed, which resulted in desirable outcomes and uneventful follow-up. CONCLUSION: Although open thoracic surgery is the main and almost the only option for treating aneurysms of the aorta in hemodynamically unstable patients, the endovascular procedure has shown superior outcomes in selected patients with appropriate anatomy. Debranching surgery, which can be done simultaneously or with delay after the initial procedure, has proven protective against thromboembolic cerebral events. CLINICAL KEY POINT: Patients with an aneurysm of the aorta should be transported to a medical center with a multidisciplinary team for an urgent evaluation and treatment. The initial resuscitation and diagnosis are challenging, considering the fatal nature of these injuries, and the selection of the treatment is based on the patient's clinical condition and evaluated anatomy in cardiovascular imaging. CI - (c) 2024. The Author(s). FAU - Sadeghian, Mohammad AU - Sadeghian M AD - Department of Cardiology, Tehran Heart Center, Tehran University of Medical Science, Tehran, Iran. FAU - Ebrahimi, Pouya AU - Ebrahimi P AD - Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran. FAU - Soltani, Parnian AU - Soltani P AD - Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran. FAU - Ghasemi, Massoud AU - Ghasemi M AD - Department of Interventional Cardiology, Imam Khomeini Hospital Complex, Tehran University of Medical Science, Tehran, Iran. FAU - Taheri, Homa AU - Taheri H AD - Cedars-Sinai Medical Center, Los Angeles, CA, USA. FAU - Mehrpooya, Maryam AU - Mehrpooya M AD - Department of Cardiology, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran. maryammehrpooya1@gmail.com. LA - eng PT - Journal Article DEP - 20240715 PL - England TA - Int J Emerg Med JT - International journal of emergency medicine JID - 101469435 PMC - PMC11247804 OTO - NOTNLM OT - Aortic pseudoaneurysm OT - Cardiac trauma OT - Endovascular repair OT - Interventional cardiology OT - Non-invasive cardiovascular imaging OT - Transthoracic echocardiography COIS- The authors declare no competing interests. EDAT- 2024/07/16 00:41 MHDA- 2024/07/16 00:42 PMCR- 2024/07/15 CRDT- 2024/07/15 23:37 PHST- 2024/05/10 00:00 [received] PHST- 2024/07/04 00:00 [accepted] PHST- 2024/07/16 00:42 [medline] PHST- 2024/07/16 00:41 [pubmed] PHST- 2024/07/15 23:37 [entrez] PHST- 2024/07/15 00:00 [pmc-release] AID - 10.1186/s12245-024-00670-w [pii] AID - 670 [pii] AID - 10.1186/s12245-024-00670-w [doi] PST - epublish SO - Int J Emerg Med. 2024 Jul 15;17(1):87. doi: 10.1186/s12245-024-00670-w. PMID- 39009113 OWN - NLM STAT- MEDLINE DCOM- 20240914 LR - 20240914 IS - 1615-5947 (Electronic) IS - 0890-5096 (Linking) VI - 108 DP - 2024 Nov TI - Optimizing Treatment of Significant Carotid Artery Stenosis in Times of Logistic Restraints as a Result of COVID-19 Pandemic. PG - 498-507 LID - S0890-5096(24)00401-1 [pii] LID - 10.1016/j.avsg.2024.05.020 [doi] AB - BACKGROUND: COVID-19 confronted medical care with many challenges. During the pandemic, several resources were limited resulting in renouncing or postponing medical care like carotid endarterectomy (CEA) for patients with significant carotid artery stenosis. Although according to international guidelines CEA is the first choice, carotid artery stenting (CAS) could potentially be a reasonable alternative especially during logistical restraints. PURPOSE: To evaluate outcomes of CAS versus CEA before, during and after the COVID-19 pandemic. Our hypothesis was that a CAS first approach yielded comparable outcomes compared to a CEA first approach. METHODS: Retrospective analysis of consecutive patients with significant carotid artery stenosis treated with CEA or CAS between September 2018 and March 2023. Each consecutive period of 1.5 year marked a new (treatment) period: pre-COVID (CEA first strategy), during COVID (CAS first strategy) and post-COVID (patient-tailored approach). Primary outcome was the composite endpoint of stroke, transient ischemic attack or death within 30 days. Secondary outcome consisted of the rate of technical success, cerebral hyperperfusion syndrome, myocardial infarction or other cardiac complications needing intervention, bleeding of the surgical site needing intervention, nerve palsy, unintended IC admission, pseudoaneurysm, restenosis, or occlusion. RESULTS: A total of 318 patients were included. Out of 137 patients treated with CEA, 55, 36 and 46 were treated pre-COVID, during COVID and post-COVID, respectively. Out of 181 CAS procedures, 38, 59 and 84, respectively, were performed in each time period. Primary outcome occurred in 5.5%, 0% and 2.2% in the CEA group and 0%, 1.7% and 3.6% in the CAS group (P = 0.27; P = 1.00; P = 1.00, respectively). Overall technical success was 100% for CEA and 99.4% for CAS (P = 1.00). Rate of restenosis was the only secondary outcome measure which was significantly better after CAS compared to CEA in the pre- and post-COVID period (CEA vs. CAS, 12.7% vs. 7.9%, and 23.9% vs. 4.8% with a P-value of 0.03 and 0.03, respectively). Hospital presentation to treatment interval did not differ significantly during the pandemic. CONCLUSIONS: Outcomes were comparable between CAS versus CEA in patients with significant carotid artery stenosis before, during and after the COVID-19 pandemic. CAS showed better results in terms of other complications (i.e., restenosis rate) in the pre- and post-COVID period compared to CEA. Our results may support a CAS first approach when no relevant contra-indications exist without exposing the patient to complications associated with an open surgical approach. Discussion in a multidisciplinary team is advised. CI - Copyright (c) 2024 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Kok, Mert AU - Kok M AD - Division of Vascular Surgery, Departments of Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. FAU - de Heide, Erik-Jan AU - de Heide EJ AD - Departments of Radiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. FAU - Hellegering, Joyce AU - Hellegering J AD - Division of Vascular Surgery, Departments of Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. FAU - van der Laan, Maarten J AU - van der Laan MJ AD - Division of Vascular Surgery, Departments of Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. FAU - Mazuri, Aryan AU - Mazuri A AD - Departments of Radiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. FAU - Uyttenboogaart, Maarten AU - Uyttenboogaart M AD - Departments of Radiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; Departments of Neurology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. FAU - Bokkers, Reinoud P H AU - Bokkers RPH AD - Departments of Radiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. FAU - Zeebregts, Clark J AU - Zeebregts CJ AD - Division of Vascular Surgery, Departments of Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. Electronic address: c.j.a.m.zeebregts@umcg.nl. LA - eng PT - Comparative Study PT - Journal Article DEP - 20240714 PL - Netherlands TA - Ann Vasc Surg JT - Annals of vascular surgery JID - 8703941 SB - IM MH - Humans MH - *COVID-19 MH - Retrospective Studies MH - *Carotid Stenosis/surgery/therapy/mortality/diagnostic imaging MH - Female MH - Male MH - *Endarterectomy, Carotid/adverse effects MH - Aged MH - *Stents MH - Treatment Outcome MH - Middle Aged MH - Time Factors MH - Aged, 80 and over MH - Risk Factors MH - Endovascular Procedures/adverse effects MH - Stroke/etiology EDAT- 2024/07/16 00:42 MHDA- 2024/09/15 14:09 CRDT- 2024/07/15 20:04 PHST- 2024/01/29 00:00 [received] PHST- 2024/05/20 00:00 [revised] PHST- 2024/05/25 00:00 [accepted] PHST- 2024/09/15 14:09 [medline] PHST- 2024/07/16 00:42 [pubmed] PHST- 2024/07/15 20:04 [entrez] AID - S0890-5096(24)00401-1 [pii] AID - 10.1016/j.avsg.2024.05.020 [doi] PST - ppublish SO - Ann Vasc Surg. 2024 Nov;108:498-507. doi: 10.1016/j.avsg.2024.05.020. Epub 2024 Jul 14. PMID- 39009076 OWN - NLM STAT- MEDLINE DCOM- 20240922 LR - 20241006 IS - 2213-3763 (Electronic) IS - 0019-4832 (Print) IS - 0019-4832 (Linking) VI - 76 IP - 4 DP - 2024 Jul-Aug TI - Results of comprehensive genetic testing in patients presenting to a multidisciplinary inherited heart disease clinic in India. PG - 260-267 LID - S0019-4832(24)00154-8 [pii] LID - 10.1016/j.ihj.2024.07.002 [doi] AB - OBJECTIVES: This study aims to analyze the results of comprehensive genetic testing in patients presenting to a dedicated multidisciplinary inherited heart disease clinic in India. METHODS: All patients presenting to our clinic from August 2017 to October 2023 with a suspected inherited heart disease and consenting for genetic testing were included. The probands were grouped into familial cardiomyopathies namely hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), arrhythmogenic cardiomyopathy (ACM) and peripartum cardiomyopathy (PPCM), channelopathies namely congenital long QT syndrome (LQTS) and Brugada syndrome (BrS), and heritable connective tissue disorder namely Marfan Syndrome (MFS). Next generation sequencing (NGS) was used, and pre-test and post-test counseling were provided to probands and cascade screening offered to relatives. RESULTS: Mean age of the subjects (n = 77; 48 probands, 29 relatives) was 43 +/- 18 years, 68 % male and 44 % symptomatic, with 36 HCM, 3 DCM, 3 ACM, 1 PPCM, 3 LQTS, 1 BrS and 1 MFS probands. The diagnostic yield of NGS-based genetic testing was 31 %; variants of uncertain significance (VUS) were identified in 54 %; and 15 % were genotype-negative. Twenty-nine relatives from 18 families with HCM (n = 12), DCM (n = 3), ACM (n = 2) and MFS (n = 1) underwent genetic testing. The genotype positive probands/relatives and VUS carriers with strong disease phenotype and/or high risk variant were advised periodic follow-up; the remaining probands/relatives were discharged from further clinical surveillance. CONCLUSIONS: Genetic testing guides treatment and follow-up of patients with inherited heart diseases and should be carried out in dedicated multidisciplinary clinics with expertise for counseling and cascade screening of family members. CI - Copyright (c) 2024 Cardiological Society of India. Published by Elsevier, a division of RELX India, Pvt. Ltd. All rights reserved. FAU - Chockalingam, Priya AU - Chockalingam P AD - Centre for Inherited Heart Disease, Department of Cardiology, Kauvery Hospital, Chennai, India. Electronic address: priyachockalingam@cardiacwellnessinstitute.com. FAU - Geetha, Thenral S AU - Geetha TS AD - Principal Scientist, Operations, Medgenome Labs, Bengaluru, India. FAU - Nair, Sandhya AU - Nair S AD - Senior Manager, Operations, Medgenome Labs, Bengaluru, India. FAU - Rajakumar, Nivedita AU - Rajakumar N AD - Senior Genetic Counselor, Neuberg Centre for Genomic Medicine, Chennai, India. FAU - Raja, Deep Chandh AU - Raja DC AD - Cardiac Electrophysiologist, Department of Cardiology, Kauvery Hospital, Chennai, India. FAU - Lokhandwala, Yash AU - Lokhandwala Y AD - Cardiac Electrophysiologist, Holy Family Hospital, Mumbai, India. FAU - Chaturvedi, Vivek AU - Chaturvedi V AD - Senior Consultant & Professor of Cardiology, Amrita Institute of Medical Science and Research, Faridabad, India. FAU - Selvaraj, Raja J AU - Selvaraj RJ AD - Professor of Cardiology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India. FAU - Ramasamy, Sakthivel AU - Ramasamy S AD - Cardiac Electrophysiologist, Dr. Kamakshi Memorial Hospitals, Chennai, India. FAU - Sharda, Sheetal AU - Sharda S AD - Director, Genomics Development and Implementation, Neuberg Centre for Genomic Medicine, Ahmedabad, India. FAU - Sundar, C AU - Sundar C AD - Interventional Cardiologist, Department of Cardiology, Kauvery Hospital, Chennai, India. FAU - Anantharaman, R AU - Anantharaman R AD - Centre for Inherited Heart Disease, Department of Cardiology, Kauvery Hospital, Chennai, India; Interventional Cardiologist, Department of Cardiology, Kauvery Hospital, Chennai, India. LA - eng PT - Journal Article DEP - 20240714 PL - India TA - Indian Heart J JT - Indian heart journal JID - 0374675 SB - IM MH - Humans MH - *Genetic Testing/methods MH - Female MH - India/epidemiology MH - Male MH - Adult MH - Pedigree MH - Retrospective Studies MH - Heart Diseases/diagnosis/genetics/congenital MH - Genetic Predisposition to Disease MH - High-Throughput Nucleotide Sequencing MH - Middle Aged MH - Genetic Counseling PMC - PMC11451389 OTO - NOTNLM OT - Cardiomyopathies OT - Channelopathies OT - Genetic testing OT - Multidisciplinary clinic OT - Sudden cardiac death prevention COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/07/16 00:41 MHDA- 2024/09/23 03:01 PMCR- 2024/07/01 CRDT- 2024/07/15 20:03 PHST- 2024/02/08 00:00 [received] PHST- 2024/07/04 00:00 [revised] PHST- 2024/07/12 00:00 [accepted] PHST- 2024/09/23 03:01 [medline] PHST- 2024/07/16 00:41 [pubmed] PHST- 2024/07/15 20:03 [entrez] PHST- 2024/07/01 00:00 [pmc-release] AID - S0019-4832(24)00154-8 [pii] AID - 10.1016/j.ihj.2024.07.002 [doi] PST - ppublish SO - Indian Heart J. 2024 Jul-Aug;76(4):260-267. doi: 10.1016/j.ihj.2024.07.002. Epub 2024 Jul 14. PMID- 39006153 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260922 IS - 2398-8835 (Electronic) IS - 2398-8835 (Linking) VI - 7 IP - 7 DP - 2024 Jul TI - The risk of premature cardiac contractions (PAC/PVC) related to caffeine consumption among healthcare workers: A comprehensive review. PG - e2222 LID - 10.1002/hsr2.2222 [doi] LID - e2222 AB - BACKGROUND AND AIMS: Premature atrial contractions (PACs) and premature ventricular contractions (PVCs) are ectopic heart rhythm disorders with implications for cardiovascular health. This study explores the relationship between caffeine consumption and the risk of PACs and PVCs, with a focus on healthcare workers, such as doctors, nurses, pharmacists, and midwives, who often rely on caffeine to combat fatigue, especially during night shifts. METHODS: A thorough review was conducted through PubMed, Scopus, Google Scholar, and Web of Science, utilizing a combination of MeSH terms and keywords. Studies examining the link between caffeine consumption and PACs and PVCs, particularly in healthcare workers, were included. RESULTS: We found that caffeine shows various effects based on dosage and can impact arrhythmia risk. Individuals working long shifts, including healthcare professionals, are prone to increased caffeine intake, leading to higher cardiovascular risk. To mitigate these risks, tailored guidelines for caffeine consumption, flexible shift scheduling, and mental health support services are recommended. Promoting caffeine alternatives within healthcare institutions can be beneficial. CONCLUSION: Although caffeine may have potential benefits, its drawbacks, particularly concerning cardiovascular health, may surpass its advantages, especially when consumed in high doses. A multidisciplinary approach is crucial for healthcare workers' well-being and quality of patient care. Further research is required to refine and support these recommendations. CI - (c) 2024 The Author(s). Health Science Reports published by Wiley Periodicals LLC. FAU - Abdolmaleki, Maryam AU - Abdolmaleki M AUID- ORCID: 0009-0001-8460-8974 AD - Department of Medicine, School of Medicine Shahid Beheshti University of Medical Sciences Tehran Iran. FAU - Ohadi, Laya AU - Ohadi L AUID- ORCID: 0000-0001-7480-8975 AD - Department of Medicine, School of Medicine Shahid Beheshti University of Medical Sciences Tehran Iran. FAU - Changizi, Faraz AU - Changizi F AUID- ORCID: 0009-0006-4944-0594 AD - Department of Medicine, School of Medicine Shahid Beheshti University of Medical Sciences Tehran Iran. FAU - Seyed, Sara AU - Seyed S AUID- ORCID: 0009-0006-2377-5214 AD - Department of Medicine, School of Medicine Semnan University of Medical Sciences Tehran Iran. FAU - Farjam, Mina AU - Farjam M AUID- ORCID: 0009-0009-0463-6915 AD - Department of Medicine, School of Medicine Shahid Beheshti University of Medical Sciences Tehran Iran. LA - eng PT - Journal Article DEP - 20240711 PL - United States TA - Health Sci Rep JT - Health science reports JID - 101728855 PMC - PMC11239532 OTO - NOTNLM OT - arrhythmias OT - caffeine OT - cardiovascular OT - doctors OT - healthcare workers COIS- The authors declare no conflicts of interest. EDAT- 2024/07/15 06:42 MHDA- 2024/07/15 06:43 PMCR- 2024/07/11 CRDT- 2024/07/15 05:26 PHST- 2023/12/20 00:00 [received] PHST- 2024/06/10 00:00 [revised] PHST- 2024/06/17 00:00 [accepted] PHST- 2024/07/15 06:43 [medline] PHST- 2024/07/15 06:42 [pubmed] PHST- 2024/07/15 05:26 [entrez] PHST- 2024/07/11 00:00 [pmc-release] AID - HSR22222 [pii] AID - 10.1002/hsr2.2222 [doi] PST - epublish SO - Health Sci Rep. 2024 Jul 11;7(7):e2222. doi: 10.1002/hsr2.2222. eCollection 2024 Jul. PMID- 39004701 OWN - NLM STAT- MEDLINE DCOM- 20240714 LR - 20240717 IS - 1471-2334 (Electronic) IS - 1471-2334 (Linking) VI - 24 IP - 1 DP - 2024 Jul 15 TI - Epidemiology, outcomes and prognosis of infective endocarditis in Northern Morocco. PG - 698 LID - 10.1186/s12879-024-09436-4 [doi] LID - 698 AB - INTRODUCTION: Infective endocarditis is a rare but potentially severe disease, associated with significant morbidity and mortality. Our study aims to describe the epidemiology and management aspects of endocarditis in northern Morocco and compare it with international management guidelines. MATERIALS AND METHODS: This is a retrospective study involving all patients hospitalized in the cardiology department of the University Hospital of Tangier for infective endocarditis over a period of 4 years and 7 months, from May 2019 to February 2024. RESULTS: Eighty patients were hospitalized for IE during the study period. The average age of the patients was 46 years, with an even sex ratio. IE concerned native valves in 77% of cases, mechanical prostheses in 19% of cases, and on bio prostheses in 4%. The average diagnostic delay was 25 days. Blood cultures were negative in 59% of cases. The predominant infective microorganism was the bacteria Staphylococcus (65.6%). Imaging results showed vegetations in 76.3% of cases, predominantly on the mitral valve (39.3%), followed by the aortic valve (21.3%). The main complications included heart failure (51.2%), peripheral arterial embolisms (22.5%) and splenic infarction (17.5%). Management wise, the most commonly used antibiotic therapy was a combination of ceftriaxone and gentamicin. Clinical and biological improvement was observed in 70% of cases, with a mortality rate of 12.5%. Twelve patients underwent surgery (15%). Urgent surgery was indicated in 66,7% of the operated patients. CONCLUSION: Our study highlights the challenges in managing infective endocarditis in northern Morocco. The prognosis of infective endocarditis can be improved through multidisciplinary management within the implementation of an Endocarditis Team. CI - (c) 2024. The Author(s). FAU - Boussaadani, Badre El AU - Boussaadani BE AD - Cardiology Department, Road of Rabat, Mohamed VI University Hospital Center Tanger-Tetouan-Al Hoceima, Abdelmalek Essaadi University, Km 17, BP 398 - Gzinaya, Tangier, Morocco. FAU - Soussan, Ilias AU - Soussan I AD - Cardiology Department, Road of Rabat, Mohamed VI University Hospital Center Tanger-Tetouan-Al Hoceima, Abdelmalek Essaadi University, Km 17, BP 398 - Gzinaya, Tangier, Morocco. FAU - Bendoudouch, Houssam AU - Bendoudouch H AD - Cardiology Department, Road of Rabat, Mohamed VI University Hospital Center Tanger-Tetouan-Al Hoceima, Abdelmalek Essaadi University, Km 17, BP 398 - Gzinaya, Tangier, Morocco. houssam.bendoudouch@gmail.com. FAU - Hara, Loubna AU - Hara L AD - Cardiology Department, Road of Rabat, Mohamed VI University Hospital Center Tanger-Tetouan-Al Hoceima, Abdelmalek Essaadi University, Km 17, BP 398 - Gzinaya, Tangier, Morocco. FAU - Ech-Chenbouli, Amine AU - Ech-Chenbouli A AD - Cardiology Department, Road of Rabat, Mohamed VI University Hospital Center Tanger-Tetouan-Al Hoceima, Abdelmalek Essaadi University, Km 17, BP 398 - Gzinaya, Tangier, Morocco. FAU - Raissuni, Zainab AU - Raissuni Z AD - Cardiology Department, Road of Rabat, Mohamed VI University Hospital Center Tanger-Tetouan-Al Hoceima, Abdelmalek Essaadi University, Km 17, BP 398 - Gzinaya, Tangier, Morocco. LA - eng PT - Journal Article DEP - 20240715 PL - England TA - BMC Infect Dis JT - BMC infectious diseases JID - 100968551 RN - 0 (Anti-Bacterial Agents) SB - IM MH - Humans MH - Morocco/epidemiology MH - Male MH - Female MH - Middle Aged MH - Retrospective Studies MH - Adult MH - Prognosis MH - *Endocarditis/epidemiology/microbiology/diagnosis/therapy/mortality MH - *Anti-Bacterial Agents/therapeutic use MH - Aged MH - Endocarditis, Bacterial/epidemiology/microbiology/mortality/diagnosis/drug therapy MH - Young Adult MH - Adolescent PMC - PMC11247857 OTO - NOTNLM OT - Antibiotic OT - Blood culture OT - Complications OT - Infective endocarditis OT - Surgery OT - Valve COIS- The authors declare no competing interests. EDAT- 2024/07/15 00:41 MHDA- 2024/07/15 00:42 PMCR- 2024/07/15 CRDT- 2024/07/14 23:13 PHST- 2024/03/10 00:00 [received] PHST- 2024/05/27 00:00 [accepted] PHST- 2024/07/15 00:42 [medline] PHST- 2024/07/15 00:41 [pubmed] PHST- 2024/07/14 23:13 [entrez] PHST- 2024/07/15 00:00 [pmc-release] AID - 10.1186/s12879-024-09436-4 [pii] AID - 9436 [pii] AID - 10.1186/s12879-024-09436-4 [doi] PST - epublish SO - BMC Infect Dis. 2024 Jul 15;24(1):698. doi: 10.1186/s12879-024-09436-4. PMID- 38999504 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240715 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 13 IP - 13 DP - 2024 Jul 5 TI - Anesthesia for Minimal Invasive Cardiac Surgery: The Bonn Heart Center Protocol. LID - 10.3390/jcm13133939 [doi] LID - 3939 AB - The development and adoption of minimally invasive techniques has revolutionized various surgical disciplines and has also been introduced into cardiac surgery, offering patients less invasive options with reduced trauma and faster recovery time compared to traditional open-heart procedures with sternotomy. This article provides a comprehensive overview of the anesthesiologic management for minimally invasive cardiac surgery (MICS), focusing on preoperative assessment, intraoperative anesthesia techniques, and postoperative care protocols. Anesthesia induction and airway management strategies are tailored to each patient's needs, with meticulous attention to maintaining hemodynamic stability and ensuring adequate ventilation. Intraoperative monitoring, including transesophageal echocardiography (TEE), processed EEG monitoring, and near-infrared spectroscopy (NIRS), facilitates real-time assessment of cardiac and cerebral perfusion, as well as function, optimizing patient safety and improving outcomes. The peripheral cannulation techniques for cardiopulmonary bypass (CPB) initiation are described, highlighting the importance of cannula placement to minimize tissue as well as vessel trauma and optimize perfusion. This article also discusses specific MICS procedures, detailing anesthetic considerations and surgical techniques. The perioperative care of patients undergoing MICS requires a multidisciplinary approach including surgeons, perfusionists, and anesthesiologists adhering to standardized treatment protocols and pathways. By leveraging advanced monitoring techniques and tailored anesthetic protocols, clinicians can optimize patient outcomes and promote early extubation and enhanced recovery. FAU - Piekarski, Florian AU - Piekarski F AUID- ORCID: 0000-0002-4095-3573 AD - Department of Anesthesiology and Intensive Care Medicine, Rheinische Friedrich-Wilhelms-University, University Hospital Bonn, 53127 Bonn, Germany. FAU - Rohner, Marc AU - Rohner M AD - Department of Anesthesiology and Intensive Care Medicine, Rheinische Friedrich-Wilhelms-University, University Hospital Bonn, 53127 Bonn, Germany. FAU - Monsefi, Nadejda AU - Monsefi N AD - Department of Cardiac Surgery, Rheinische Friedrich-Wilhelms-University, University Hospital Bonn, 53127 Bonn, Germany. FAU - Bakhtiary, Farhad AU - Bakhtiary F AD - Department of Cardiac Surgery, Rheinische Friedrich-Wilhelms-University, University Hospital Bonn, 53127 Bonn, Germany. FAU - Velten, Markus AU - Velten M AD - Department of Anesthesiology and Intensive Care Medicine, Rheinische Friedrich-Wilhelms-University, University Hospital Bonn, 53127 Bonn, Germany. AD - Department of Anesthesiology and Pain Management, Division of Cardiovascular and Thoracic Anesthesiology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. LA - eng PT - Journal Article PT - Review DEP - 20240705 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC11242163 OTO - NOTNLM OT - anesthesia OT - management OT - minimally invasive cardiac surgery COIS- FP has received support for professional training from Edwards Lifesciences and Abbott; MR has received support for professional training from Edwards Lifesciences and speakers' honoraria from Philips Healthcare; NM has no interests to be disclosed; FB discloses speakers' honoraria from Edwards Lifesciences, LSI, and Abbott; MV discloses speakers' honoraria from Edwards Lifesciences and Abbott. EDAT- 2024/07/13 07:42 MHDA- 2024/07/13 07:43 PMCR- 2024/07/05 CRDT- 2024/07/13 01:11 PHST- 2024/06/12 00:00 [received] PHST- 2024/06/29 00:00 [revised] PHST- 2024/07/03 00:00 [accepted] PHST- 2024/07/13 07:43 [medline] PHST- 2024/07/13 07:42 [pubmed] PHST- 2024/07/13 01:11 [entrez] PHST- 2024/07/05 00:00 [pmc-release] AID - jcm13133939 [pii] AID - jcm-13-03939 [pii] AID - 10.3390/jcm13133939 [doi] PST - epublish SO - J Clin Med. 2024 Jul 5;13(13):3939. doi: 10.3390/jcm13133939. PMID- 38997115 OWN - NLM STAT- MEDLINE DCOM- 20250501 LR - 20260629 IS - 1537-6591 (Electronic) IS - 1058-4838 (Print) IS - 1058-4838 (Linking) VI - 80 IP - 4 DP - 2025 Apr 30 TI - Comparison of the 2015 and 2023 Duke-European Society of Cardiology Criteria Among Patients With Suspected Infective Endocarditis. PG - 777-783 LID - 10.1093/cid/ciae370 [doi] AB - BACKGROUND: Diagnosing infective endocarditis (IE) poses a significant challenge. This study aimed to compare the diagnostic accuracy of the 2015 and 2023 Duke clinical criteria introduced by the European Society of Cardiology (ESC) in a cohort of patients suspected of having IE. METHODS: Conducted retrospectively at 2 Swiss university hospitals between 2014 and 2023, the study involved patients with suspected IE. Each hospital's endocarditis team categorized cases as either IE or not IE. The performance of each iteration of the Duke-ESC clinical criteria was assessed based on the agreement between definite IE and the diagnoses made by the endocarditis team. RESULTS: Among the 3127 episodes of suspected IE, 1177 (38%) were confirmed to have IE. Using the 2015 Duke-ESC criteria, 707 (23%) episodes were deemed definite IE, with 696 (98%) receiving a final IE diagnosis. With the 2023 Duke-ESC criteria, 855 (27%) episodes were classified as definite IE, of which 813 (95%) were confirmed as IE. The 2015 and 2023 Duke-ESC criteria categorized 1039 (33%) and 1034 (33%) episodes, respectively, as possible IE. Sensitivity for the 2015 Duke-ESC and the 2023 Duke-ESC criteria was calculated at 59% (95% confidence interval, 56%-62%), and 69% (66%-72%), respectively, with specificity at 99% (99%-100%), and 98% (97%-98%), respectively. CONCLUSIONS: The 2023 Duke-ESC criteria demonstrated significant improvements in sensitivity compared to the 2015 version, although one-third of episodes were classified as possible IE by both versions. CI - (c) The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. FAU - Papadimitriou-Olivgeris, Matthaios AU - Papadimitriou-Olivgeris M AUID- ORCID: 0000-0003-0565-5105 AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. AD - Infectious Diseases Service, Cantonal Hospital of Sion and Institut Central des Hopitaux, Sion, Switzerland. FAU - Monney, Pierre AU - Monney P AD - Department of Cardiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Frank, Michelle AU - Frank M AD - Department of Cardiology, University Hospital Zurich and University of Zurich, Zurich, Switzerland. FAU - Tzimas, Georgios AU - Tzimas G AD - Department of Cardiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Fourre, Nicolas AU - Fourre N AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Zimmermann, Virgile AU - Zimmermann V AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Tozzi, Piergiorgio AU - Tozzi P AD - Department of Cardiac Surgery, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Kirsch, Matthias AU - Kirsch M AD - Department of Cardiac Surgery, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Van Hemelrijck, Mathias AU - Van Hemelrijck M AD - Department of Cardiac Surgery, University Hospital Zurich and University of Zurich, Zurich, Switzerland. FAU - Epprecht, Jana AU - Epprecht J AD - Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich and University of Zurich, Zurich, Switzerland. FAU - Guery, Benoit AU - Guery B AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Hasse, Barbara AU - Hasse B AD - Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich and University of Zurich, Zurich, Switzerland. LA - eng GR - 32003B_219351/1/SNSF_/Swiss National Science Foundation/Switzerland GR - Clinical Research Priority/ GR - University of Zurich/ GR - CRPP Precision medicine for bacterial infections/ PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Clin Infect Dis JT - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America JID - 9203213 SB - IM MH - Humans MH - *Endocarditis/diagnosis MH - Retrospective Studies MH - Male MH - Female MH - Middle Aged MH - Aged MH - Sensitivity and Specificity MH - *Cardiology MH - Switzerland MH - Adult MH - Europe MH - Aged, 80 and over MH - Societies, Medical PMC - PMC12043060 OTO - NOTNLM OT - Duke criteria OT - European Society of Cardiology OT - infective endocarditis OT - spondylodiscitis OT - valve leaflet thickening COIS- Potential conflicts of interest . The authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. EDAT- 2024/07/13 07:42 MHDA- 2025/05/01 06:27 PMCR- 2024/07/12 CRDT- 2024/07/12 20:32 PHST- 2024/05/14 00:00 [received] PHST- 2025/05/01 06:27 [medline] PHST- 2024/07/13 07:42 [pubmed] PHST- 2024/07/12 20:32 [entrez] PHST- 2024/07/12 00:00 [pmc-release] AID - 7713035 [pii] AID - ciae370 [pii] AID - 10.1093/cid/ciae370 [doi] PST - ppublish SO - Clin Infect Dis. 2025 Apr 30;80(4):777-783. doi: 10.1093/cid/ciae370. PMID- 38996213 OWN - NLM STAT- MEDLINE DCOM- 20240712 LR - 20260127 IS - 2474-7661 (Electronic) IS - 2474-7661 (Linking) VI - 8 IP - 7 DP - 2024 Jul 1 TI - Current Concepts in the Orthopaedic Management of Duchenne Muscular Dystrophy. LID - 10.5435/JAAOSGlobal-D-24-00099 [doi] LID - e24.00099 AB - Duchenne muscular dystrophy (DMD), a genetic condition marked by progressive muscle degeneration, presents notable orthopaedic challenges, especially scoliosis, which deteriorates patients' quality of life by affecting sitting balance and complicating cardiac and respiratory functions. Current orthopaedic management strategies emphasize early intervention with corticosteroids to delay disease progression and the use of surgical spinal fusion to address severe scoliosis, aiming to enhance sitting balance, alleviate discomfort, and potentially extend patient lifespan. Despite advancements, optimal management requires ongoing research to refine therapeutic approaches, ensuring improved outcomes for patients with DMD. This review synthesizes recent findings on surgical and nonsurgical interventions, underscoring the importance of a multidisciplinary approach tailored to the dynamic needs of patients with DMD. CI - Copyright (c) 2024 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Orthopaedic Surgeons. FAU - Weintraub, Matthew AU - Weintraub M AUID- ORCID: 0000-0003-1552-5953 AD - From the Department of Orthopaedic Surgery, Rutgers New Jersey Medical School, Newark, NJ. FAU - Gupta, Arjun AU - Gupta A FAU - Khokhar, Ahmed AU - Khokhar A FAU - Vives, Michael AU - Vives M FAU - Kaushal, Neil AU - Kaushal N LA - eng PT - Journal Article PT - Review DEP - 20240710 PL - United States TA - J Am Acad Orthop Surg Glob Res Rev JT - Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews JID - 101724868 RN - 0 (Adrenal Cortex Hormones) SB - IM MH - *Muscular Dystrophy, Duchenne/surgery/therapy MH - Humans MH - *Scoliosis/surgery/therapy MH - Spinal Fusion/methods MH - Quality of Life MH - Adrenal Cortex Hormones/therapeutic use MH - Orthopedic Procedures/methods PMC - PMC11239163 EDAT- 2024/07/12 18:42 MHDA- 2024/07/12 18:43 PMCR- 2024/07/10 CRDT- 2024/07/12 16:23 PHST- 2024/03/14 00:00 [received] PHST- 2024/05/22 00:00 [accepted] PHST- 2024/07/12 18:43 [medline] PHST- 2024/07/12 18:42 [pubmed] PHST- 2024/07/12 16:23 [entrez] PHST- 2024/07/10 00:00 [pmc-release] AID - 01979360-202407000-00011 [pii] AID - JAAOSGlobal-D-24-00099 [pii] AID - 10.5435/JAAOSGlobal-D-24-00099 [doi] PST - epublish SO - J Am Acad Orthop Surg Glob Res Rev. 2024 Jul 10;8(7):e24.00099. doi: 10.5435/JAAOSGlobal-D-24-00099. eCollection 2024 Jul 1. PMID- 38990131 OWN - NLM STAT- MEDLINE DCOM- 20240711 LR - 20260330 IS - 2638-6135 (Electronic) IS - 2638-6135 (Linking) VI - 6 IP - 4 DP - 2024 Aug TI - Hypersensitivity Pneumonitis on Thin-Section Chest CT Scans: Diagnostic Performance of the ATS/JRS/ALAT versus ACCP Imaging Guidelines. PG - e230068 LID - 10.1148/ryct.230068 [doi] LID - e230068 AB - Purpose To compare the diagnostic performance of the American Thoracic Society, Japanese Respiratory Society, and Asociacion Latinoamericana del Torax (ATS/JRS/ALAT) versus the American College of Chest Physicians (ACCP) imaging classifications for hypersensitivity pneumonitis (HP). Materials and Methods Patients in the institutional review board-approved Interstitial Lung Disease (ILD) registry referred for multidisciplinary discussion (MDD) at the authors' institution (January 1, 2006-April 1, 2021) were included in this retrospective study when ILD was diagnosed at MDD. MDD diagnoses included HP, connective tissue disease-ILD, and idiopathic pulmonary fibrosis. Retrospective review of thin-section CT images was performed in consensus by two cardiothoracic radiologists blinded to the diagnosis. Diagnostic patterns were determined for thin-section CT images using both classifications. Discordance rates were determined. Sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were assessed using MDD diagnosis as the reference standard. Results A total of 297 patients were included in the study: 200 (67%) with HP, 49 (16%) with connective tissue disease-ILD, and 48 (16%) with idiopathic pulmonary fibrosis at MDD. The discordance rate between the two classifications was 21%. Assuming low HP prevalence (10%), ATS/JRS/ALAT classification outperformed ACCP classification, with greater accuracy (92.3% vs 87.6%) and greater positive predictive value (60.7% vs 42.9%). Assuming high prevalence (50%), accuracy and negative predictive value were superior using ACCP classification (81.7% vs 79.7% and 77.7% vs 72.6%, respectively), and positive predictive value was superior using ATS/JRS/ALAT classification (93.3% vs 87.1%). Conclusion Accuracy of the ATS/JRS/ALAT and ACCP HP classifications was greater in settings with low and high HP prevalence, respectively. Diagnostic performance of both classifications was discordant in a minority of cases. Keywords: CT, Thorax, Hypersensitivity Pneumonitis, Interstitial Lung Disease Supplemental material is available for this article. (c) RSNA, 2024. FAU - Chelala, Lydia AU - Chelala L AUID- ORCID: 0000-0002-6295-6150 AD - From the Department of Cardiopulmonary Imaging (L.C., J.H.C.), Department of Medicine, Section of Pulmonary & Critical Care (A.A., M.S., C.T.L., R.J., I.U.), and Department of Pathology (A.N.H.), University of Chicago Medicine, 5841 S Maryland Ave, Chicago, IL 60637. FAU - Adegunsoye, Ayodeji AU - Adegunsoye A AUID- ORCID: 0000-0002-7015-9610 AD - From the Department of Cardiopulmonary Imaging (L.C., J.H.C.), Department of Medicine, Section of Pulmonary & Critical Care (A.A., M.S., C.T.L., R.J., I.U.), and Department of Pathology (A.N.H.), University of Chicago Medicine, 5841 S Maryland Ave, Chicago, IL 60637. FAU - Strek, Mary AU - Strek M AUID- ORCID: 0000-0002-7671-1023 AD - From the Department of Cardiopulmonary Imaging (L.C., J.H.C.), Department of Medicine, Section of Pulmonary & Critical Care (A.A., M.S., C.T.L., R.J., I.U.), and Department of Pathology (A.N.H.), University of Chicago Medicine, 5841 S Maryland Ave, Chicago, IL 60637. FAU - Lee, Cathryn T AU - Lee CT AD - From the Department of Cardiopulmonary Imaging (L.C., J.H.C.), Department of Medicine, Section of Pulmonary & Critical Care (A.A., M.S., C.T.L., R.J., I.U.), and Department of Pathology (A.N.H.), University of Chicago Medicine, 5841 S Maryland Ave, Chicago, IL 60637. FAU - Jablonski, Renea AU - Jablonski R AD - From the Department of Cardiopulmonary Imaging (L.C., J.H.C.), Department of Medicine, Section of Pulmonary & Critical Care (A.A., M.S., C.T.L., R.J., I.U.), and Department of Pathology (A.N.H.), University of Chicago Medicine, 5841 S Maryland Ave, Chicago, IL 60637. FAU - Husain, Aliya N AU - Husain AN AUID- ORCID: 0000-0001-5492-7387 AD - From the Department of Cardiopulmonary Imaging (L.C., J.H.C.), Department of Medicine, Section of Pulmonary & Critical Care (A.A., M.S., C.T.L., R.J., I.U.), and Department of Pathology (A.N.H.), University of Chicago Medicine, 5841 S Maryland Ave, Chicago, IL 60637. FAU - Udofia, Inemesit AU - Udofia I AUID- ORCID: 0009-0004-7442-5324 AD - From the Department of Cardiopulmonary Imaging (L.C., J.H.C.), Department of Medicine, Section of Pulmonary & Critical Care (A.A., M.S., C.T.L., R.J., I.U.), and Department of Pathology (A.N.H.), University of Chicago Medicine, 5841 S Maryland Ave, Chicago, IL 60637. FAU - Chung, Jonathan H AU - Chung JH AUID- ORCID: 0000-0001-7011-0588 AD - From the Department of Cardiopulmonary Imaging (L.C., J.H.C.), Department of Medicine, Section of Pulmonary & Critical Care (A.A., M.S., C.T.L., R.J., I.U.), and Department of Pathology (A.N.H.), University of Chicago Medicine, 5841 S Maryland Ave, Chicago, IL 60637. LA - eng GR - K23 HL146942/HL/NHLBI NIH HHS/United States PT - Comparative Study PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PL - United States TA - Radiol Cardiothorac Imaging JT - Radiology. Cardiothoracic imaging JID - 101748663 SB - IM MH - Humans MH - *Alveolitis, Extrinsic Allergic/diagnostic imaging/diagnosis/epidemiology MH - *Tomography, X-Ray Computed/methods MH - Female MH - Male MH - Retrospective Studies MH - Middle Aged MH - Aged MH - Practice Guidelines as Topic/standards MH - Lung/diagnostic imaging MH - Sensitivity and Specificity MH - Societies, Medical MH - United States/epidemiology PMC - PMC11369651 OTO - NOTNLM OT - CT OT - Hypersensitivity Pneumonitis OT - Interstitial Lung Disease OT - Thorax COIS- Disclosures of conflicts of interest: L.C. No relevant relationships. A.A. NIH grant K23HL146942-01A1; grants/contracts from Pulmonary Fibrosis Foundation, the American College of Chest Physicians, and the National Institutes of Health; consulting fees from Roche, Boehringer Ingelheim, Inogen, PatientMpower, AbbVie, and Medscape; payment or honoraria from Boehringer Ingelheim; participation on data safety monitoring board or advisory board for Roche, Boehringer Ingelheim, Inogen, and PatientMpower; leadership role with American Thoracic Society. M.S. Grants/contracts to institution from Boehringer Ingelheim Pharmaceuticals, NIH, and Pulmonary Fibrosis Foundation; honoraria for Self-Education and Evaluation of Knowledge (SEEK) Pulmonary Board Review textbook (CHEST), medical writing support provided by Fleishman Hillard; honoraria for CME lectures (CHEST), medical writing support provided by Fleishman Hillard; payment/ honoraria from Boehringer Ingelheim Pharmaceuticals; payment to author from participation on Fibrinogen Adjudication committee and BMS Data Monitoring committee; leadership role for American Thoracic Society on Clinical Problems Committee and Research Innovation Summit Planning Committee; leadership role for Pulmonary Fibrosis Foundation on Scientific Review Committee. C.T.L. Grant from Pulmonary Fibrosis Foundation. R.J. Participation on data safety monitoring board/advisory board for AbbVie on adjudication committee for ILD events for chemotherapeutic drug (unrelated to study). A.N.H. No relevant relationships. I.U. No relevant relationships. J.H.C. Senior consulting editor for Radiology: Cardiothoracic Imaging. EDAT- 2024/07/11 12:42 MHDA- 2024/07/11 12:43 PMCR- 2024/07/11 CRDT- 2024/07/11 10:03 PHST- 2024/07/11 12:43 [medline] PHST- 2024/07/11 12:42 [pubmed] PHST- 2024/07/11 10:03 [entrez] PHST- 2024/07/11 00:00 [pmc-release] AID - 10.1148/ryct.230068 [doi] PST - ppublish SO - Radiol Cardiothorac Imaging. 2024 Aug;6(4):e230068. doi: 10.1148/ryct.230068. PMID- 38985226 OWN - NLM STAT- MEDLINE DCOM- 20240906 LR - 20261010 IS - 1534-3170 (Electronic) IS - 1523-3782 (Linking) VI - 26 IP - 9 DP - 2024 Sep TI - The Current State of Coronary Revascularization: Coronary Artery Bypass Graft Surgery Versus Percutaneous Coronary Interventions. PG - 919-933 LID - 10.1007/s11886-024-02090-x [doi] AB - PURPOSE OF REVIEW: The optimal revascularization strategy for coronary artery disease depends on various factors, such as disease complexity, patient characteristics, and preferences. Including a heart team in complex cases is crucial to ensure optimal outcomes. Decision-making between percutaneous coronary intervention and coronary artery bypass grafting must consider each patient's clinical profile and coronary anatomy. While current practice guidelines offer some insight into the optimal revascularization approach for the various phenotypes of coronary artery disease, the evidence to support either strategy continues to evolve and grow. Given the large amount of contemporary data on revascularization, this review aims to comprehensively summarize the literature on coronary artery bypass grafting and percutaneous coronary intervention in patients across the spectrum of coronary artery disease phenotypes. RECENT FINDINGS: Contemporary evidence suggests that for patients with triple vessel disease, coronary artery bypass grafting is preferred over percutaneous coronary intervention due to better long-term outcomes, including lower rates of death, myocardial infarction, and target vessel revascularization. Similarly, for patients with left main coronary artery disease, both percutaneous coronary intervention and coronary artery bypass grafting can be considered, as they have shown similar efficacy in terms of major adverse cardiac events, but there may be a slightly higher risk of death with percutaneous coronary intervention. For proximal left anterior descending artery disease, both percutaneous coronary intervention and coronary artery bypass grafting are viable options, but coronary artery bypass grafting has shown lower rates of repeat revascularization and better relief from angina. The Synergy Between PCI with Taxus and Cardiac Surgery score can help in decision-making by predicting the risk of adverse events and guiding the choice between percutaneous coronary intervention and coronary artery bypass grafting. European and American guidelines both agree with including a heart team that can develop and lay out individualized, optimal treatment options with respect for patient preferences. The debate between coronary artery bypass grafting versus percutaneous coronary intervention in multiple different scenarios will continue to develop as technology and techniques improve for both procedures. Risk factors, pre, peri, and post-procedural complications involved in both revascularization strategies will continue to be mitigated to optimize outcomes for those patients for which coronary artery bypass grafting or percutaneous coronary intervention provide ultimate benefit. Methods to avoid unnecessary revascularization continue to develop as well as percutaneous technology that may allow patients to avoid surgical intervention when possible. With such changes, revascularization guidelines for specific patient populations may change in the coming years, which can serve as a limitation of this time-dated review. CI - (c) 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Krittanawong, Chayakrit AU - Krittanawong C AD - Cardiology Division, NYU Langone Health and NYU School of Medicine, New York, NY, USA. Chayakrit.Krittanawong@nyulangone.org. FAU - Rizwan, Affan AU - Rizwan A AD - Department of Medicine, Baylor College of Medicine, Houston, TX, 77030, USA. FAU - Khawaja, Muzamil AU - Khawaja M AD - Division of Cardiology, Emory University School of Medicine, Atlanta, GA, 30322, USA. FAU - Newman, Noah AU - Newman N AD - Division of Cardiology, Emory University School of Medicine, Atlanta, GA, 30322, USA. FAU - Escobar, Johao AU - Escobar J AD - Division of Cardiology, Harlem Cardiology, NY, 10035, USA. FAU - Virk, Hafeez Ul Hassan AU - Virk HUH AD - Harrington Heart & Vascular Institute, Case Western Reserve University, University Hospitals, Cleveland Medical Center, Cleveland, USA. FAU - Alam, Mahboob AU - Alam M AD - Division of Cardiology, The Texas Heart Institute, Baylor College of Medicine, Houston, TX, 77030, USA. FAU - Al-Azzam, Fu'ad AU - Al-Azzam F AD - Division of Cardiovascular Surgery, Mayo Clinic, Rochester, MN, 55905, USA. FAU - Yong, Celina M AU - Yong CM AD - VA Palo Alto Medical Center, Department of Medicine, Stanford, University and Stanford Cardiovascular Institute, Palo AltoStanford, CACA, USA. FAU - Jneid, Hani AU - Jneid H AD - Division of Cardiology, University of Texas Medical Branch, Houston, TX, 77030, USA. LA - eng PT - Journal Article PT - Review DEP - 20240710 PL - United States TA - Curr Cardiol Rep JT - Current cardiology reports JID - 100888969 SB - IM MH - Humans MH - Clinical Decision-Making MH - *Coronary Artery Bypass/methods/standards MH - *Coronary Artery Disease/surgery MH - *Percutaneous Coronary Intervention/methods/standards MH - Practice Guidelines as Topic MH - Treatment Outcome OTO - NOTNLM OT - Coronary artery bypass grafting OT - Coronary artery disease OT - Percutaneous coronary intervention OT - Revascularization OT - SYNTAX EDAT- 2024/07/10 12:43 MHDA- 2024/09/06 12:43 CRDT- 2024/07/10 11:07 PHST- 2024/06/28 00:00 [accepted] PHST- 2024/09/06 12:43 [medline] PHST- 2024/07/10 12:43 [pubmed] PHST- 2024/07/10 11:07 [entrez] AID - 10.1007/s11886-024-02090-x [pii] AID - 10.1007/s11886-024-02090-x [doi] PST - ppublish SO - Curr Cardiol Rep. 2024 Sep;26(9):919-933. doi: 10.1007/s11886-024-02090-x. Epub 2024 Jul 10. PMID- 38984417 OWN - NLM STAT- MEDLINE DCOM- 20240819 LR - 20250530 IS - 1524-4539 (Electronic) IS - 0009-7322 (Print) IS - 0009-7322 (Linking) VI - 150 IP - 8 DP - 2024 Aug 20 TI - Periprocedural Management and Multidisciplinary Care Pathways for Patients With Cardiac Implantable Electronic Devices: A Scientific Statement From the American Heart Association. PG - e183-e196 LID - 10.1161/CIR.0000000000001264 [doi] AB - The rapid technological advancements in cardiac implantable electronic devices such as pacemakers, implantable cardioverter defibrillators, and loop recorders, coupled with a rise in the number of patients with these devices, necessitate an updated clinical framework for periprocedural management. The introduction of leadless pacemakers, subcutaneous and extravascular defibrillators, and novel device communication protocols underscores the imperative for clinical updates. This scientific statement provides an inclusive framework for the periprocedural management of patients with these devices, encompassing the planning phase, procedure, and subsequent care coordinated with the primary device managing clinic. Expert contributions from anesthesiologists, cardiac electrophysiologists, and cardiac nurses are consolidated to appraise current evidence, offer patient and health system management strategies, and highlight key areas for future research. The statement, pertinent to a wide range of health care professionals, underscores the importance of quality care pathways for patient safety, optimal device function, and minimization of hemodynamic disturbances or arrhythmias during procedures. Our primary objective is to deliver quality care to the expanding patient cohort with cardiac implanted electronic devices, offering direction in the era of evolving technologies and laying a foundation for sustained education and practice enhancement. FAU - Wan, Elaine Y AU - Wan EY FAU - Rogers, Albert J AU - Rogers AJ FAU - Lavelle, Michael AU - Lavelle M FAU - Marcus, Mason AU - Marcus M FAU - Stone, Sarah A AU - Stone SA FAU - Ottoboni, Linda AU - Ottoboni L FAU - Srivatsa, Uma AU - Srivatsa U FAU - Leal, Miguel A AU - Leal MA FAU - Russo, Andrea M AU - Russo AM FAU - Jackson, Larry R 2nd AU - Jackson LR 2nd FAU - Crossley, George H AU - Crossley GH CN - American Heart Association Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Surgery and Anesthesia; and Council on Peripheral Vascular Disease LA - eng GR - 23CDA933663/AHA/American Heart Association-American Stroke Association/United States GR - K23 HL166977/HL/NHLBI NIH HHS/United States GR - L30 HL143631/HL/NHLBI NIH HHS/United States GR - R01 HL152236/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Review DEP - 20240710 PL - United States TA - Circulation JT - Circulation JID - 0147763 SB - IM MH - Humans MH - *Defibrillators, Implantable/standards MH - *American Heart Association MH - *Pacemaker, Artificial MH - United States MH - *Perioperative Care/standards/methods MH - Patient Care Team MH - Arrhythmias, Cardiac/therapy PMC - PMC12068544 MID - NIHMS2035883 OTO - NOTNLM OT - AHA Scientific Statements OT - critical pathways OT - defibrillators, implantable OT - delivery of health care OT - pacemaker, artificial OT - patient safety OT - perioperative care EDAT- 2024/07/10 06:42 MHDA- 2024/08/19 18:42 PMCR- 2025/05/12 CRDT- 2024/07/10 05:03 PHST- 2024/08/19 18:42 [medline] PHST- 2024/07/10 06:42 [pubmed] PHST- 2024/07/10 05:03 [entrez] PHST- 2025/05/12 00:00 [pmc-release] AID - 10.1161/CIR.0000000000001264 [doi] PST - ppublish SO - Circulation. 2024 Aug 20;150(8):e183-e196. doi: 10.1161/CIR.0000000000001264. Epub 2024 Jul 10. PMID- 38981996 OWN - NLM STAT- MEDLINE DCOM- 20240825 LR - 20240828 IS - 1619-0904 (Electronic) IS - 1434-7229 (Print) IS - 1434-7229 (Linking) VI - 27 IP - 3 DP - 2024 Sep TI - Current issues of destination therapy in Japan: to achieve 5-year or even longer survival. PG - 203-211 LID - 10.1007/s10047-024-01458-8 [doi] AB - In April 2021, destination therapy (DT) was finally approved in Japan. Since DT does not aim at heart transplantation (HT), our goal is to have a patient safely remain on an implantable ventricular assist device (VAD) for the rest of his/her life. To achieve this goal, similarly to bridge-to-transplant (BTT) patients, the authors believe the following six aspects are even more crucial in DT patients: (1) to appropriately assess risks before implantation, (2) to carefully determine the ability to manage the device by multidisciplinary discussions, (3) to prevent complications by improving the quality of care, (4) to expand the number of facilities that can take care of DT patients by improving collaboration among the facilities, (5) to reduce the burden of caregivers by utilizing social resources, and (6) to establish a home palliative care system based on advance care planning. In addition, for elderly DT patients to live happy and long lives, it is essential to help them to find a purpose of life and to keep activities of daily living, such as employment, schooling, and participation in social activities, just like the general elderly population. Our goals are not only to do our best for the patients just in front of us, but also to establish a system to follow up our DT cohort, same as BTT one, by all-Japan manner. In the present review, we discuss the current state of DT in Japan and what we need to focus on to maintain or improve its long-term performance. CI - (c) 2024. The Author(s). FAU - Ando, Masahiko AU - Ando M AUID- ORCID: 0000-0002-5481-3782 AD - Department of Cardiovascular Surgery, The University of Tokyo Hospital, Hongo 7-3-1, Bunkyo, Tokyo, 113-8655, Japan. andoma-sur@h.u-tokyo.ac.jp. FAU - Ono, Minoru AU - Ono M AD - Department of Cardiovascular Surgery, The University of Tokyo Hospital, Hongo 7-3-1, Bunkyo, Tokyo, 113-8655, Japan. LA - eng PT - Journal Article PT - Review DEP - 20240709 PL - Japan TA - J Artif Organs JT - Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs JID - 9815648 SB - IM MH - Humans MH - Japan/epidemiology MH - *Heart-Assist Devices/statistics & numerical data MH - *Heart Failure/therapy/surgery/mortality MH - Palliative Care/methods MH - Heart Transplantation PMC - PMC11345326 OTO - NOTNLM OT - Destination therapy OT - Heart failure OT - Ventricular assist device COIS- The authors have no conflict of interest to disclose. EDAT- 2024/07/10 00:41 MHDA- 2024/08/26 12:39 PMCR- 2024/07/09 CRDT- 2024/07/09 23:17 PHST- 2023/12/28 00:00 [received] PHST- 2024/06/08 00:00 [accepted] PHST- 2024/08/26 12:39 [medline] PHST- 2024/07/10 00:41 [pubmed] PHST- 2024/07/09 23:17 [entrez] PHST- 2024/07/09 00:00 [pmc-release] AID - 10.1007/s10047-024-01458-8 [pii] AID - 1458 [pii] AID - 10.1007/s10047-024-01458-8 [doi] PST - ppublish SO - J Artif Organs. 2024 Sep;27(3):203-211. doi: 10.1007/s10047-024-01458-8. Epub 2024 Jul 9. PMID- 38978167 OWN - NLM STAT- MEDLINE DCOM- 20250422 LR - 20250514 IS - 1464-5491 (Electronic) IS - 0742-3071 (Print) IS - 0742-3071 (Linking) VI - 42 IP - 2 DP - 2025 Feb TI - Enhancing clinical service design for multimorbidity management: A comprehensive approach to joined-up care for diabetes, chronic kidney disease, and heart failure. PG - e15403 LID - 10.1111/dme.15403 [doi] LID - e15403 AB - BACKGROUND AND AIMS: Multimorbidity is becoming the norm rather than the exception, especially among the ageing population and people with lower socio-economic status. In addition to the rising healthcare cost, multimorbidity poses considerable difficulty in the delivery of adequate holistic care for affected patients. METHODS: This review presents a discussion of the current barriers to delivering holistic care to people with multimorbidity and proposes a model of clinical care for people living with cardiovascular-kidney-metabolic (CKM) syndrome as an exemplar of a multimorbidity cluster. RESULTS: Single organ/disease services may not be able to provide optimum care to people with multimorbidity due to the potential complex interactions between multiple disease symptoms and management. In addition, people with multimorbidity may be required to attend multiple appointments in different healthcare centres. This may negatively impact access to services due to time and financial burden. Other barriers include co-ordinating communication between healthcare professionals and reduced continuity of care. Optimising CKM health requires patient-centred care led by an interdisciplinary care team who ideally should possess CKM competencies utilising a shared care protocol to coordinate evidence-based care and use of telehealth to empower patients. Stakeholders and policymakers need to adapt new policy models to establish and enhance CKM care models by allocating funds and implementing frameworks for educational reforms. CONCLUSIONS: A CKM service has the potential to increase the uptake of cardiac and renal protective medications as well as optimising metabolic care, increase capacity in both primary and secondary care, improve quality of life and clinical outcomes, reduce patient inconvenience, and importantly allow rapid translation of advances in cardiorenal metabolic diseases into clinical practice. CI - (c) 2024 The Author(s). Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK. FAU - Al-Chalabi, Saif AU - Al-Chalabi S AUID- ORCID: 0000-0003-1669-8514 AD - Donal O'Donoghue Renal Research Centre, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Salford, UK. AD - Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK. FAU - Sinha, Smeeta AU - Sinha S AD - Donal O'Donoghue Renal Research Centre, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Salford, UK. AD - Manchester Academic Health Science Centre, University of Manchester, Manchester, UK. FAU - Kalra, Philip A AU - Kalra PA AD - Donal O'Donoghue Renal Research Centre, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Salford, UK. AD - Manchester Academic Health Science Centre, University of Manchester, Manchester, UK. LA - eng PT - Journal Article PT - Review DEP - 20240708 PL - England TA - Diabet Med JT - Diabetic medicine : a journal of the British Diabetic Association JID - 8500858 SB - IM MH - Humans MH - *Multimorbidity MH - *Heart Failure/therapy/epidemiology MH - *Renal Insufficiency, Chronic/therapy/epidemiology MH - Patient-Centered Care MH - *Diabetes Mellitus/therapy/epidemiology MH - Disease Management PMC - PMC11733658 OTO - NOTNLM OT - cardiovascular-kidney-metabolic syndrome OT - chronic kidney disease OT - diabetes mellitus OT - heart failure OT - integrated care OT - multimorbidity OT - telehealth COIS- Professor Sinha reports grants from AstraZeneca, Johnson & Johnson, and Amgen; consulting fees from CSL Vifor and Inozyme Pharma; honoraria from Bayer, Menarini, AstraZeneca, GSK, Novartis, Sanofi-Genzyme, Boehringer Ingelheim, CSL Vifor, and Medscape; and support for attending meetings from AstraZeneca, Novartis, and CSL Vifor. Professor Sinha is the NHS England National Clinical Director for Renal Medicine. Professor Kalra reports research grant support from CSL Vifor and Astellas; consulting fees from AstraZeneca, CSL Vifor, Unicyte, and UCB; honoraria from CSL Vifor, AstraZeneca, Bayer, Pharmacosmos, GSK and Pfizer; and support to attend meetings from Pharmacosmos and CSL Vifor. Dr Al-Chalabi has no conflict of interest to declare. EDAT- 2024/07/09 06:42 MHDA- 2025/01/15 06:21 PMCR- 2025/01/15 CRDT- 2024/07/09 00:22 PHST- 2024/06/10 00:00 [revised] PHST- 2024/04/04 00:00 [received] PHST- 2024/06/26 00:00 [accepted] PHST- 2025/01/15 06:21 [medline] PHST- 2024/07/09 06:42 [pubmed] PHST- 2024/07/09 00:22 [entrez] PHST- 2025/01/15 00:00 [pmc-release] AID - DME15403 [pii] AID - 10.1111/dme.15403 [doi] PST - ppublish SO - Diabet Med. 2025 Feb;42(2):e15403. doi: 10.1111/dme.15403. Epub 2024 Jul 8. PMID- 38975383 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240709 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 16 IP - 6 DP - 2024 Jun TI - Advances and Challenges in the Management of Brugada Syndrome: A Comprehensive Review. PG - e61837 LID - 10.7759/cureus.61837 [doi] LID - e61837 AB - Brugada syndrome (BrS) is an inherited arrhythmogenic disorder marked by distinctive ST-segment elevations on electrocardiograms (ECG) and an increased risk of sudden cardiac death. Characterized by mutations primarily in the SCN5A gene, BrS disrupts cardiac ion channel function, leading to abnormal electrical activity and arrhythmias. Although BrS primarily affects young, healthy males, it poses significant diagnostic challenges due to its often concealed or intermittent ECG manifestations and clinical presentation that can mimic other cardiac disorders. Current management strategies focus on symptom control and prevention of sudden death, with implantable cardioverter-defibrillators (ICD) serving as the primary intervention for high-risk patients. However, the complications associated with ICDs and the lack of effective pharmacological options necessitate a cautious and personalized approach. Recent advancements in catheter ablation have shown promise, particularly for managing ventricular fibrillation (VF) storms and reducing ICD shocks. Additionally, pharmacological treatments such as quinidine have been effective in specific cases, though their use is limited by availability and side effects. This review highlights significant gaps in the BrS literature, particularly in terms of long-term management and novel therapeutic approaches. The importance of genetic screening and tailored treatment strategies to better identify and manage at-risk individuals is emphasized. The review aims to enhance the understanding of BrS and improve patient outcomes, advocating for a multidisciplinary approach to this complex syndrome. CI - Copyright (c) 2024, McBenedict et al. FAU - McBenedict, Billy AU - McBenedict B AD - Neurosurgery, Fluminense Federal University, Niteroi, BRA. FAU - Alphonse, Berley AU - Alphonse B AD - Neurosurgery, Fluminense Federal University, Niteroi, BRA. FAU - Devan, Jeshua N AU - Devan JN AD - Cardiology, Federal University of Rio de Janeiro, Rio de Janeiro, BRA. FAU - Singh, Gurinder AU - Singh G AD - Cardiology, Federal University of Rio de Janeiro, Rio de Janeiro, BRA. FAU - Goh, Kang Suen AU - Goh KS AD - Internal Medicine, Monash University Malaysia, Johor Bahru, MYS. FAU - Yau, Ryan Chun Chien AU - Yau RCC AD - Internal Medicine, Monash University Malaysia, Johor Bahru, MYS. FAU - Elamin, Sara AU - Elamin S AD - Cardiology, Federal University of Rio de Janeiro, Rio de Janeiro, BRA. FAU - Jamched, Vaishnavi AU - Jamched V AD - Cardiology, Federal University of Rio de Janeiro, Rio de Janeiro, BRA. FAU - Abraham, Aaron A AU - Abraham AA AD - Neurosurgery, Fluminense Federal University, Niteroi, BRA. FAU - Valentim, Gabriella AU - Valentim G AD - Nursing, Fluminense Federal University, Niteroi, BRA. FAU - Lima Pessoa, Bruno AU - Lima Pessoa B AD - Neurosurgery, Fluminense Federal University, Niteroi, BRA. FAU - Hauwanga, Wilhelmina N AU - Hauwanga WN AD - Cardiology, Federal University of Rio de Janeiro, Rio de Janeiro, BRA. LA - eng PT - Journal Article PT - Review DEP - 20240606 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC11227351 OTO - NOTNLM OT - arrhythmogenic disorders OT - brugada syndrome OT - catheter ablation OT - implantable cardioverter-defibrillators OT - scn5a gene OT - sudden cardiac death COIS- Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. EDAT- 2024/07/08 12:42 MHDA- 2024/07/08 12:43 PMCR- 2024/06/06 CRDT- 2024/07/08 07:46 PHST- 2024/05/13 00:00 [received] PHST- 2024/06/06 00:00 [accepted] PHST- 2024/07/08 12:43 [medline] PHST- 2024/07/08 12:42 [pubmed] PHST- 2024/07/08 07:46 [entrez] PHST- 2024/06/06 00:00 [pmc-release] AID - 10.7759/cureus.61837 [doi] PST - epublish SO - Cureus. 2024 Jun 6;16(6):e61837. doi: 10.7759/cureus.61837. eCollection 2024 Jun. PMID- 38975366 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240709 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 16 IP - 6 DP - 2024 Jun TI - Gender Matters: A Multidimensional Approach to Optimizing Cardiovascular Health in Women. PG - e61810 LID - 10.7759/cureus.61810 [doi] LID - e61810 AB - Cardiovascular diseases remain a leading cause of mortality among women, yet they are often underestimated and insufficiently addressed. This narrative review delves into the gender disparities in cardiovascular health, underscoring the critical importance of recognizing and addressing the unique challenges women face. The article explores the pathophysiological differences between men and women, highlighting the role of hormonal factors, such as estrogen and menopause, in conferring cardioprotection or increasing risk. It examines the complexities of diagnosis and assessment, including differences in symptom presentation, diagnostic accuracy, and the challenges of interpreting non-invasive testing in women. The review also highlights the need for tailored risk assessment and prevention strategies, incorporating sex-specific conditions and pregnancy-related factors. It emphasizes the importance of lifestyle modifications and interventions, as well as the potential benefits of personalized treatment approaches, considering gender-specific variations in medication responses and cardiac interventions. Furthermore, the article sheds light on the impact of psychosocial and sociocultural factors, such as gender norms, mental health considerations, and access to healthcare, on women's cardiovascular health. It also addresses the significant gaps and challenges in research, including the historical underrepresentation of women in clinical trials and the lack of sex- and gender-sensitive studies. Finally, the review advocates for a multidisciplinary approach, involving patient-centered care, shared decision-making, and collaboration among policymakers, stakeholders, and healthcare systems. This comprehensive strategy aims to enhance awareness, prevention, diagnosis, and treatment of cardiovascular disease in women, ultimately improving health outcomes and reducing the burden of this often overlooked epidemic. CI - Copyright (c) 2024, Sinha et al. FAU - Sinha, Tanya AU - Sinha T AD - Internal Medicine, Tribhuvan University, Kathmandu, NPL. FAU - Bakht, Danyal AU - Bakht D AD - Medicine and Surgery, Mayo Hospital, Lahore, PAK. FAU - Bokhari, Syed Faqeer Hussain AU - Bokhari SFH AD - Surgery, King Edward Medical University, Lahore, PAK. FAU - Amir, Maaz AU - Amir M AD - Medicine and Surgery, King Edward Medical University, Lahore, PAK. FAU - Fatima, Rida AU - Fatima R AD - Medicine and Surgery, Fatima Jinnah Medical University, Lahore, PAK. FAU - Bakht, Kinza AU - Bakht K AD - Internal Medicine, Sheikh Zayed Medical College and Hospital, Rahim Yar Khan, PAK. FAU - Amir, Aisha AU - Amir A AD - Medicine and Surgery, Karachi Medical and Dental College, Karachi, PAK. FAU - Aslam, Asma AU - Aslam A AD - Medicine and Surgery, Karachi Medical and Dental College, Karachi, PAK. FAU - Hussain, Muzaffer AU - Hussain M AD - Surgery, Karachi Medical and Dental College, Karachi, PAK. FAU - Tariq, Tamseer AU - Tariq T AD - Medicine and Surgery, Karachi Medical and Dental College, Karachi, PAK. LA - eng PT - Journal Article PT - Review DEP - 20240606 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC11227286 OTO - NOTNLM OT - atherosclerosis OT - cardiovascular OT - coronary heart disease OT - gender comparison OT - review OT - women COIS- Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. EDAT- 2024/07/08 12:42 MHDA- 2024/07/08 12:43 PMCR- 2024/06/06 CRDT- 2024/07/08 07:46 PHST- 2024/06/06 00:00 [accepted] PHST- 2024/07/08 12:43 [medline] PHST- 2024/07/08 12:42 [pubmed] PHST- 2024/07/08 07:46 [entrez] PHST- 2024/06/06 00:00 [pmc-release] AID - 10.7759/cureus.61810 [doi] PST - epublish SO - Cureus. 2024 Jun 6;16(6):e61810. doi: 10.7759/cureus.61810. eCollection 2024 Jun. PMID- 38970655 OWN - NLM STAT- MEDLINE DCOM- 20250729 LR - 20250807 IS - 1432-1971 (Electronic) IS - 0172-0643 (Print) IS - 0172-0643 (Linking) VI - 46 IP - 6 DP - 2025 Aug TI - Early Impressions and Adoption of the AtriAmp for Managing Arrhythmias Following Congenital Heart Surgery. PG - 1592-1599 LID - 10.1007/s00246-024-03573-y [doi] AB - AtriAmp is a new medical device that displays a continuous real-time atrial electrogram on telemetry using temporary atrial pacing leads. Our objective was to evaluate early adoption of this device into patient care within our pediatric intensive care unit (PICU). This is a qualitative study using inductive analysis of semi-structured interviews to identify dominant themes. The study was conducted in a single-center, tertiary, academic 21-bed mixed PICU. The subjects were PICU multidisciplinary team members (Pediatric Cardiac Intensivists, PICU Nurse Practitioners, PICU nurses and Pediatric Cardiologists) who were early adopters of the AtriAmp (n = 14). Three prominent themes emerged: (1) Accelerated time from arrhythmia event to diagnosis and treatment; (2) Increased confidence in the accuracy of providers' arrhythmia diagnosis; and (3) Improvement in the ability to educate providers about post-operative arrhythmias. Providers also noted some learning curves, but none compromised medical care or clinical workflow. Insights from early adopters of AtriAmp signal the need for simplicity and fidelity in new PICU technologies. Our research suggests that such technologies can be pivotal to the support and growth of multi-disciplinary teams, even among those who do not participate in early implementation. Further research is needed to understand when and why novel technology adoption becomes widespread in high-stakes settings. CI - (c) 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Leopold, Scott M AU - Leopold SM AD - Division of Critical Care, Department of Pediatrics, American Family Children's Hospital, 600 Highland Ave, Mailcode 4108, Madison, WI, 53742, USA. sleopold@uwhealth.org. FAU - Brown, Diane H AU - Brown DH AD - Division of Critical Care, Department of Pediatrics, Presbyterian Hospital, Albuquerque, NM, USA. FAU - Zhang, Xiao AU - Zhang X AD - Division of Pediatric Cardiology, Department of Pediatrics, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA. FAU - Nguyen, Xuan T AU - Nguyen XT AD - Department of Sociology, University of Wisconsin-Madison, Madison, WI, USA. FAU - Al-Subu, Awni M AU - Al-Subu AM AD - Division of Critical Care, Department of Pediatrics, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA. FAU - Olson, Krisjon R AU - Olson KR AD - Division of Pediatric Cardiology, Department of Pediatrics, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA. LA - eng GR - K12 HD101368/HD/NICHD NIH HHS/United States GR - UL1 TR002373/TR/NCATS NIH HHS/United States GR - K12HD101368/NH/NIH HHS/United States PT - Journal Article DEP - 20240706 PL - United States TA - Pediatr Cardiol JT - Pediatric cardiology JID - 8003849 SB - IM UOF - Res Sq. 2024 Mar 21:rs.3.rs-4125331. doi: 10.21203/rs.3.rs-4125331/v1. PMID: 38562710 MH - Humans MH - *Arrhythmias, Cardiac/therapy/diagnosis/etiology MH - *Heart Defects, Congenital/surgery MH - Intensive Care Units, Pediatric MH - Qualitative Research MH - Female MH - *Cardiac Surgical Procedures/adverse effects MH - Male MH - *Telemetry/instrumentation MH - Child MH - *Postoperative Complications/therapy/diagnosis PMC - PMC11701211 MID - NIHMS2030066 OTO - NOTNLM OT - Arrhythmias OT - AtriAmp OT - Congenital heart surgery OT - Diffusion of innovation theory OT - Early adopters OT - PICU COIS- Declarations. Competing interests: Dr. Al-Subu has consulting agreements with Edwards Lifesciences LLC and served as a medical editor for the American Institute for Advanced Professional Studies. Dr. Olson's participation in the research reported in this publication was supported in part by the Eunice Kennedy Shriver National Institute of Child Health & Human Development, the Office of Research on Women's Health, Building Interdisciplinary Research Careers in Women's Health (BIRCWH) program, the Office of The Director, National Institutes of Health and the National Cancer Institute, under Award Number K12HD101368. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health Informed Content: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. EDAT- 2024/07/06 20:43 MHDA- 2025/07/29 23:10 PMCR- 2025/07/29 CRDT- 2024/07/06 11:13 PHST- 2024/03/18 00:00 [received] PHST- 2024/06/30 00:00 [accepted] PHST- 2025/07/29 23:10 [medline] PHST- 2024/07/06 20:43 [pubmed] PHST- 2024/07/06 11:13 [entrez] PHST- 2025/07/29 00:00 [pmc-release] AID - 10.1007/s00246-024-03573-y [pii] AID - 10.1007/s00246-024-03573-y [doi] PST - ppublish SO - Pediatr Cardiol. 2025 Aug;46(6):1592-1599. doi: 10.1007/s00246-024-03573-y. Epub 2024 Jul 6. PMID- 38969051 OWN - NLM STAT- MEDLINE DCOM- 20250422 LR - 20260808 IS - 1556-3871 (Electronic) IS - 1547-5271 (Linking) VI - 22 IP - 2 DP - 2025 Feb TI - Managing superior vena cava syndrome in patients with cardiac implantable electronic device leads: Strategies and considerations. PG - 311-317 LID - S1547-5271(24)02870-4 [pii] LID - 10.1016/j.hrthm.2024.06.060 [doi] AB - BACKGROUND: Data on transvenous (TV) lead-associated superior vena cava (SVC) syndrome are limited. The management of this problem might require a multidisciplinary approach, often involving transvenous lead extraction (TLE) followed by angioplasty and stenting. OBJECTIVE: The purpose of this study was to describe the management and outcome of TV lead-associated SVC syndrome. METHODS: We retrospectively identified patients with a diagnosis of SVC syndrome and TV leads at Emory Healthcare between 2015 and 2023. RESULTS: Fifteen patients with lead-related SVC syndrome were identified. The cohort average age was 50 years. Symptoms included swelling of the face, neck, and upper extremities (67%); shortness of breath (53%); and lightheadedness (40%). Patients had an average of 2 +/- 0.7 leads crossing the SVC, with a lead dwell time of 9.8 +/- 7.5 years. Thirteen patients were managed with TLE, followed by SVC stenting and angioplasty in 10 and angioplasty alone in 2; 1 patient had no intervention after TLE. One patient was managed with anticoagulation, and another had angioplasty and stenting with lead jailing. One patient experienced SVC perforation and cardiac tamponade during SVC stenting, which was managed successfully with a covered stent and pericardiocentesis. Among the 12 patients with TLE and angioplasty +/- stenting, 7 underwent reimplantation of a transvenous lead. Two of those patients had symptoms recurrence, and none of the 5 patients without lead reimplantation had recurrence of symptoms. CONCLUSION: Lead-related SVC syndrome management requires a multidisciplinary approach often including TLE followed by angioplasty and stenting. Avoiding TV lead reimplantation might help reduce symptoms recurrence. CI - Copyright (c) 2024 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved. FAU - Mekary, Wissam AU - Mekary W AD - Division of Cardiology, Section of Electrophysiology, Emory University School of Medicine, Atlanta, Georgia. FAU - Hebbo, Elsa AU - Hebbo E AD - Division of Cardiology, Section of Interventional Cardiology, Emory University School of Medicine, Atlanta, Georgia. FAU - Shah, Anand AU - Shah A AD - Division of Cardiology, Section of Electrophysiology, Emory University School of Medicine, Atlanta, Georgia. FAU - Westerman, Stacy AU - Westerman S AD - Division of Cardiology, Section of Electrophysiology, Emory University School of Medicine, Atlanta, Georgia. FAU - Bhatia, Neal AU - Bhatia N AD - Division of Cardiology, Section of Electrophysiology, Emory University School of Medicine, Atlanta, Georgia. FAU - Byku, Isida AU - Byku I AD - Division of Cardiology, Section of Interventional Cardiology, Emory University School of Medicine, Atlanta, Georgia. FAU - Babaliaros, Vasilis AU - Babaliaros V AD - Division of Cardiology, Section of Interventional Cardiology, Emory University School of Medicine, Atlanta, Georgia. FAU - Greenbaum, Adam AU - Greenbaum A AD - Division of Cardiology, Section of Interventional Cardiology, Emory University School of Medicine, Atlanta, Georgia. FAU - Merchant, Faisal M AU - Merchant FM AD - Division of Cardiology, Section of Electrophysiology, Emory University School of Medicine, Atlanta, Georgia. FAU - El-Chami, Mikhael F AU - El-Chami MF AD - Division of Cardiology, Section of Electrophysiology, Emory University School of Medicine, Atlanta, Georgia. Electronic address: melcham@emory.edu. LA - eng PT - Journal Article DEP - 20240703 PL - United States TA - Heart Rhythm JT - Heart rhythm JID - 101200317 SB - IM MH - Humans MH - *Superior Vena Cava Syndrome/etiology/diagnosis/therapy/surgery MH - Middle Aged MH - Male MH - Female MH - Retrospective Studies MH - *Device Removal/methods MH - *Defibrillators, Implantable/adverse effects MH - Stents MH - *Pacemaker, Artificial/adverse effects MH - *Angioplasty/methods MH - Follow-Up Studies MH - Vena Cava, Superior/surgery OTO - NOTNLM OT - Implantable cardioverter-defibrillator lead OT - Pacemaker lead OT - Superior vena cava OT - Superior vena cava balloon angioplasty OT - Superior vena cava stenting OT - Superior vena cava syndrome OT - Transvenous lead extraction COIS- Disclosures Dr El-Chami is a consultant for Medtronic and Boston Scientific. All other authors have no conflicts of interest to disclose. EDAT- 2024/07/06 10:43 MHDA- 2025/02/02 05:10 CRDT- 2024/07/05 19:27 PHST- 2024/06/01 00:00 [received] PHST- 2024/06/25 00:00 [revised] PHST- 2024/06/26 00:00 [accepted] PHST- 2025/02/02 05:10 [medline] PHST- 2024/07/06 10:43 [pubmed] PHST- 2024/07/05 19:27 [entrez] AID - S1547-5271(24)02870-4 [pii] AID - 10.1016/j.hrthm.2024.06.060 [doi] PST - ppublish SO - Heart Rhythm. 2025 Feb;22(2):311-317. doi: 10.1016/j.hrthm.2024.06.060. Epub 2024 Jul 3. PMID- 38966315 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240706 IS - 2772-6282 (Electronic) IS - 2772-6282 (Linking) VI - 4 DP - 2024 Dec TI - Patient education in multilingual groups of cardiac patients: Mission (im)possible? PG - 100304 LID - 10.1016/j.pecinn.2024.100304 [doi] LID - 100304 AB - OBJECTIVE: In Norway, cardiac rehabilitation with patient education is usually accessible only to patients who understand Norwegian. The Cardiac Care Class (CCC) in focus in this article is a unique healthcare service in that, via interpreting services, it provides patient education to patients with limited Norwegian proficiency (LNP). This article examines the adaptations carried out to make cardiac rehabilitation accessible to LNP patients. METHODS: The data stem from a qualitative study with participant observation during interpreter-mediated CCCs and from interviews with healthcare professionals, patients, and interpreters conducted by an interdisciplinary team. The collaborative data analysis focused on identifying various forms of adaptations. RESULTS: Providing interpreting in CCCs required organizational, logistical, and pedagogical adaptations, including having fewer class participants, engaging qualified interpreters, conducting pre-class meetings with the interpreters, and adjusting the course content and language. Communication was found to be satisfactory, although some critical issues (e.g., interpreters' working conditions) were raised. CONCLUSION: This study showed that interpreter-mediated CCCs can reach multilingual groups provided that the necessary adaptations are made. INNOVATION: This research is the first to show how a cardiac rehabilitation class in Norway is made accessible to multilingual patient groups by providing interpreting. CI - (c) 2024 The Authors. Published by Elsevier B.V. FAU - Felberg, Tatjana R AU - Felberg TR AD - Oslo Metropolitan University - OsloMet, Department of International Studies and Interpreting, Postboks 4, St. Olavs plass, 0130 Oslo, Norway. FAU - Sagli, Gry AU - Sagli G AD - Oslo Metropolitan University - OsloMet, Department of International Studies and Interpreting, Postboks 4, St. Olavs plass, 0130 Oslo, Norway. FAU - Hansen, Camilla AU - Hansen C AD - Oslo Metropolitan University - OsloMet, Department of Nursing and Health Promotion, Postboks 4, St. Olavs plass, 0130 Oslo, Norway. FAU - Langaas, Anne AU - Langaas A AD - Oslo Metropolitan University - OsloMet, Department of Rehabilitation Science and Health Technology, Postboks 4, St. Olavs plass, 0130 Oslo, Norway. FAU - Skaaden, Hanne AU - Skaaden H AD - Oslo Metropolitan University - OsloMet, Department of International Studies and Interpreting, Postboks 4, St. Olavs plass, 0130 Oslo, Norway. LA - eng PT - Journal Article DEP - 20240607 PL - Netherlands TA - PEC Innov JT - PEC innovation JID - 9918367980406676 PMC - PMC11222795 COIS- The authors have no competing interests to declare. EDAT- 2024/07/05 06:42 MHDA- 2024/07/05 06:43 PMCR- 2024/06/07 CRDT- 2024/07/05 04:08 PHST- 2023/11/30 00:00 [received] PHST- 2024/04/26 00:00 [revised] PHST- 2024/06/05 00:00 [accepted] PHST- 2024/07/05 06:43 [medline] PHST- 2024/07/05 06:42 [pubmed] PHST- 2024/07/05 04:08 [entrez] PHST- 2024/06/07 00:00 [pmc-release] AID - S2772-6282(24)00052-9 [pii] AID - 100304 [pii] AID - 10.1016/j.pecinn.2024.100304 [doi] PST - epublish SO - PEC Innov. 2024 Jun 7;4:100304. doi: 10.1016/j.pecinn.2024.100304. eCollection 2024 Dec. PMID- 38965102 OWN - NLM STAT- MEDLINE DCOM- 20250729 LR - 20250731 IS - 1432-1971 (Electronic) IS - 0172-0643 (Linking) VI - 46 IP - 6 DP - 2025 Aug TI - Critical Event Checklists for Simulated In-Hospital Dysrhythmias in Children with Heart Disease. PG - 1505-1513 LID - 10.1007/s00246-024-03564-z [doi] AB - Children with heart disease are at increased risk of unstable dysrhythmias and in-hospital cardiac arrest (IHCA). Clinician adherence to lifesaving processes of care is an important contributor to improving patient outcomes. This study evaluated whether critical event checklists improve adherence to lifesaving processes during simulated acute events secondary to unstable dysrhythmias. A randomized controlled trial was conducted in a cardiac ward in a tertiary care, academic children's hospital. Unannounced simulated emergencies involving dysrhythmias in pediatric patients with underlying cardiac disease were conducted weekly. Responders were pediatric and anesthesiology residents, respiratory therapists, and bedside registered nurses. Six teams were randomized into two groups-three received checklists (intervention) and three did not (control). Each team participated in four simulated scenarios over a 4-week pediatric cardiology rotation. Participants received a brief slideshow presentation, which included a checklist orientation, at the start of their rotation. Simulations were video and audio recorded and those with three or more participants were included for analysis. The primary outcome was team adherence to lifesaving processes, expressed as the percentage of completed critical management steps. Secondary outcomes included participant perceptions of the checklist usefulness in identifying and managing dysrhythmias. We used generalized estimating equations (GEE) models, which accounted for clustering within groups, to evaluate the effects of the intervention. A total of 24 simulations were conducted; one of the 24 simulations was excluded due to an insufficient number of participants. In our GEE analysis, 81.21% (78.96%, 83.47%) of critical steps were completed with checklists available versus 68.06% (59.38%, 76.74%) without checklists (p = 0.004). Ninety-three percent of study participants reported that they would use the checklists during an unstable dysrhythmia of a child with underlying cardiac disease. Checklists were associated with improved adherence to lifesaving processes during simulated resuscitations for unstable pediatric dysrhythmias. These findings support the use of scenario specific checklists for the management of unstable dysrhythmias in simulations involving pediatric patients with underlying cardiac disease. Future studies should investigate whether checklists are as effective in actual pediatric in-hospital emergencies. CI - (c) 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Spencer, Robert AU - Spencer R AD - Division of Pediatric Cardiology, Columbia University Irving Medical Center, NewYork-Presbyterian Morgan Stanley Children's Hospital, New York, NY, USA. rspencer@northwell.edu. AD - Division of Pediatric Cardiology, Staten Island University Hospital, 475 Seaview Avenue, Staten Island, NY, 10305, USA. rspencer@northwell.edu. FAU - Sen, Anita I AU - Sen AI AD - Division of Pediatric Critical Care and Hospital Medicine, Columbia University Irving Medical Center, NewYork-Presbyterian Morgan Stanley Children's Hospital, New York, NY, USA. FAU - Kessler, David O AU - Kessler DO AD - Department of Emergency Medicine, Columbia University Irving Medical Center, NewYork-Presbyterian Morgan Stanley Children's Hospital, New York, NY, USA. FAU - Salabay, Kristina AU - Salabay K AD - Division of Nursing, Department of Pediatrics, Columbia University Irving Medical Center, NewYork-Presbyterian Morgan Stanley Children's Hospital, New York, NY, USA. FAU - Compagnone, Tammy AU - Compagnone T AD - Division of Nursing, Department of Pediatrics, Columbia University Irving Medical Center, NewYork-Presbyterian Morgan Stanley Children's Hospital, New York, NY, USA. FAU - Zhang, Yun AU - Zhang Y AD - Division of Pediatric Cardiology, Columbia University Irving Medical Center, NewYork-Presbyterian Morgan Stanley Children's Hospital, New York, NY, USA. FAU - Choudhury, Tarif A AU - Choudhury TA AD - Division of Pediatric Cardiology, Columbia University Irving Medical Center, NewYork-Presbyterian Morgan Stanley Children's Hospital, New York, NY, USA. AD - Division of Pediatric Critical Care and Hospital Medicine, Columbia University Irving Medical Center, NewYork-Presbyterian Morgan Stanley Children's Hospital, New York, NY, USA. LA - eng PT - Journal Article PT - Randomized Controlled Trial DEP - 20240704 PL - United States TA - Pediatr Cardiol JT - Pediatric cardiology JID - 8003849 SB - IM MH - Humans MH - *Checklist MH - *Arrhythmias, Cardiac/therapy MH - Child MH - Female MH - Male MH - Hospitals, Pediatric MH - Patient Care Team MH - Guideline Adherence MH - *Heart Diseases/complications MH - Child, Preschool MH - *Heart Arrest/therapy/etiology OTO - NOTNLM OT - Cognitive aid OT - Congenital heart disease OT - Critical care OT - Dysrhythmias OT - In-hospital cardiac arrest OT - Resuscitation COIS- Declarations. Conflict of interest: The authors have no financial relationships relevant to this article to disclose. The authors have no conflicts of interest to disclose. EDAT- 2024/07/05 00:42 MHDA- 2025/07/29 18:33 CRDT- 2024/07/04 23:14 PHST- 2024/02/26 00:00 [received] PHST- 2024/06/22 00:00 [accepted] PHST- 2025/07/29 18:33 [medline] PHST- 2024/07/05 00:42 [pubmed] PHST- 2024/07/04 23:14 [entrez] AID - 10.1007/s00246-024-03564-z [pii] AID - 10.1007/s00246-024-03564-z [doi] PST - ppublish SO - Pediatr Cardiol. 2025 Aug;46(6):1505-1513. doi: 10.1007/s00246-024-03564-z. Epub 2024 Jul 4. PMID- 38964654 OWN - NLM STAT- MEDLINE DCOM- 20260215 LR - 20260215 IS - 2241-5955 (Electronic) IS - 1109-9666 (Linking) VI - 87 DP - 2026 Jan-Feb TI - Implementation of a cardiogenic shock team in a tertiary academic center. PG - 62-70 LID - S1109-9666(24)00135-0 [pii] LID - 10.1016/j.hjc.2024.06.011 [doi] AB - OBJECTIVE: Observational studies have shown that the management of patients with cardiogenic shock (CS) by dedicated multidisciplinary teams improves clinical outcomes. Nevertheless, these studies reflect a specific organizational setting with most patients being transferred from referring hospitals, hospitalized in cardiac intensive care units (ICU), or treated with mechanical circulatory support (MCS) devices. The purpose of this study was to document the organization and outcomes of a CS team offering acute care in an all-comer population. METHODS: A CS team was developed in a large academic tertiary institution. The team consisted of emergency care physicians, critical care cardiologists, interventional cardiologists, cardiac surgeons, ICU physicians, and heart failure specialists and was supported by a predefined operating protocol, a dedicated communication platform, and regular team meetings. RESULTS: Over 12 months, 70 CS patients (69 +/- 13 years old, 67% males) were included. Acute myocardial infarction (AMI-CS) was the most common cause (64%); 31% of the patients presented post-resuscitated cardiac arrest and 56% needed invasive mechanical ventilation (IMV). Coronary angiography was performed in 70% and 53% had percutaneous coronary intervention. MCS was used in 10% and 6% were referred for urgent cardiac surgery. The in-hospital mortality in our center was 40% with 39% of the patients dying within 24 h from presentation. Overall, 76% of the live patients were discharged home. CONCLUSION: Across an all-comer population, AMI was the most common cause of CS. A significant number of patients presented post-cardiac arrest, and the majority required IMV. Mortality was high with a significant number dying within hours of presentation. CI - Copyright (c) 2024 Hellenic Society of Cardiology. Publishing services by Elsevier Inc. All rights reserved. FAU - Karamasis, Grigoris V AU - Karamasis GV AD - Cardiology Department, National and Kapodistrian University of Athens Medical School, Attikon University Hospital, Athens, Greece. FAU - Polyzogopoulou, Effie AU - Polyzogopoulou E AD - Emergency Medicine Department, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece. FAU - Varlamos, Charalampos AU - Varlamos C AD - Cardiology Department, National and Kapodistrian University of Athens Medical School, Attikon University Hospital, Athens, Greece. FAU - Frantzeskaki, Frantzeska AU - Frantzeskaki F AD - Department of Critical Care Medicine, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece. FAU - Dragona, Vassiliki-Maria AU - Dragona VM AD - Cardiology Department, National and Kapodistrian University of Athens Medical School, Attikon University Hospital, Athens, Greece. FAU - Boultadakis, Antonios AU - Boultadakis A AD - Emergency Medicine Department, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece. FAU - Bistola, Vasiliki AU - Bistola V AD - Cardiology Department, National and Kapodistrian University of Athens Medical School, Attikon University Hospital, Athens, Greece. FAU - Fountoulaki, Katerina AU - Fountoulaki K AD - Cardiology Department, National and Kapodistrian University of Athens Medical School, Attikon University Hospital, Athens, Greece. FAU - Pappas, Christos AU - Pappas C AD - Cardiology Department, National and Kapodistrian University of Athens Medical School, Attikon University Hospital, Athens, Greece. FAU - Kolokathis, Fotios AU - Kolokathis F AD - Cardiology Department, National and Kapodistrian University of Athens Medical School, Attikon University Hospital, Athens, Greece. FAU - Pavlopoulos, Dionysios AU - Pavlopoulos D AD - Department of Cardiac Surgery, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece. FAU - Toumpoulis, Ioannis K AU - Toumpoulis IK AD - Department of Cardiac Surgery, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece. FAU - Kollias, Vasilios D AU - Kollias VD AD - Department of Cardiac Surgery, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece. FAU - Farmakis, Dimitrios AU - Farmakis D AD - Cardiology Department, National and Kapodistrian University of Athens Medical School, Attikon University Hospital, Athens, Greece. FAU - Rallidis, Loukianos S AU - Rallidis LS AD - Cardiology Department, National and Kapodistrian University of Athens Medical School, Attikon University Hospital, Athens, Greece. FAU - Angouras, Dimitrios C AU - Angouras DC AD - Department of Cardiac Surgery, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece. FAU - Tsangaris, Iraklis AU - Tsangaris I AD - Department of Critical Care Medicine, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece. FAU - Parissis, John T AU - Parissis JT AD - Emergency Medicine Department, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece. FAU - Filippatos, Gerasimos AU - Filippatos G AD - Cardiology Department, National and Kapodistrian University of Athens Medical School, Attikon University Hospital, Athens, Greece. Electronic address: gfilippatos@gmail.com. LA - eng PT - Journal Article DEP - 20240702 PL - Netherlands TA - Hellenic J Cardiol JT - Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese JID - 101257381 SB - IM MH - Humans MH - *Shock, Cardiogenic/therapy/mortality/etiology MH - Male MH - Female MH - Aged MH - Tertiary Care Centers/organization & administration MH - *Patient Care Team/organization & administration MH - Middle Aged MH - Myocardial Infarction/complications MH - Percutaneous Coronary Intervention MH - Hospital Mortality MH - Aged, 80 and over MH - Coronary Angiography MH - Critical Care/methods MH - Intensive Care Units MH - Academic Medical Centers MH - Respiration, Artificial/methods OTO - NOTNLM OT - Acute myocardial infarction OT - Cardiogenic shock OT - Cardiogenic shock team COIS- Conflicts of interest Nothing to declare. EDAT- 2024/07/05 00:41 MHDA- 2026/02/16 00:31 CRDT- 2024/07/04 19:28 PHST- 2024/04/22 00:00 [received] PHST- 2024/06/21 00:00 [revised] PHST- 2024/06/25 00:00 [accepted] PHST- 2026/02/16 00:31 [medline] PHST- 2024/07/05 00:41 [pubmed] PHST- 2024/07/04 19:28 [entrez] AID - S1109-9666(24)00135-0 [pii] AID - 10.1016/j.hjc.2024.06.011 [doi] PST - ppublish SO - Hellenic J Cardiol. 2026 Jan-Feb;87:62-70. doi: 10.1016/j.hjc.2024.06.011. Epub 2024 Jul 2. PMID- 38958578 OWN - NLM STAT- MEDLINE DCOM- 20240808 LR - 20260630 IS - 1531-6971 (Electronic) IS - 1070-5287 (Linking) VI - 30 IP - 5 DP - 2024 Sep 1 TI - Cardiac sarcoidosis and neurosarcoidosis - multidisciplinary approach for diagnosis. PG - 540-550 LID - 10.1097/MCP.0000000000001097 [doi] AB - PURPOSE OF REVIEW: The current review aims to highlight the role of multidisciplinary approach in the diagnosis of patients with cardiac and neurosarcoidosis. Multidisciplinary approach integrates the available clinical information, imaging and histopathological results aiming to reach a definite or at least provisional diagnosis and allow appropriate management. Multidisciplinary approach is the reference standard for diagnosis of interstitial lung disease and should be strongly considered in complex clinical conditions such as cardiac sarcoidosis (CS) and neurosarcoidosis. RECENT FINDINGS: Histopathological confirmation of noncaseating granulomatous inflammation provides a definite diagnosis of sarcoidosis involving any organ. However, a provisional high confidence or even definite clinical diagnosis can be reached using multidisciplinary evaluation of all available evidence. The diagnosis of cardiac sarcoidosis and neurosarcoidosis requires the integration of different expertise based on the current diagnostic criteria sets. Identifying typical or at least compatible patterns on advanced imaging modalities (CMR and Fluro-Deoxy-Glucose Positron Emission Tomography (FDG-PET)) seems key for the diagnosis of CS, while a confident diagnosis of extra-cardiac disease supports an at least provisional diagnosis. Similarly, in neurosarcoidosis integrating compatible MRI appearances and cerebrospinal fluid results in patients with systemic sarcoidosis allows an at least provisional diagnosis. Exclusion of alternative differential diagnoses is crucial and requires high clinical suspicion, imaging review expertise and appropriate tests performance. SUMMARY: There have been considerable advances in the diagnostic approach of patients with cardiac and neurosarcoidosis. Multidisciplinary approach for both diagnosis and management is required to reach a confident clinical diagnosis and should be applied when possible. CI - Copyright (c) 2024 Wolters Kluwer Health, Inc. All rights reserved. FAU - Kouranos, Vasileios AU - Kouranos V AD - Interstitial Lung Disease unit, Royal Brompton Hospital. AD - National Heart and Lung Institute, Imperial College London. FAU - Sharma, Rakesh AU - Sharma R AD - National Heart and Lung Institute, Imperial College London. AD - Cardiology Department, Royal Brompton Hospital. FAU - Wells, Athol AU - Wells A AD - Interstitial Lung Disease unit, Royal Brompton Hospital. AD - National Heart and Lung Institute, Imperial College London. FAU - Singh-Curry, Victoria AU - Singh-Curry V AD - Interstitial Lung Disease unit, Royal Brompton Hospital. AD - Department of Neurology, Chelsea and Westminster Hospital NHS Foundation Trust. AD - Department of Neurology, Imperial College NHS Trust, London UK. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20240703 PL - United States TA - Curr Opin Pulm Med JT - Current opinion in pulmonary medicine JID - 9503765 RN - Neurosarcoidosis SB - IM MH - Humans MH - *Sarcoidosis/diagnosis MH - *Central Nervous System Diseases/diagnosis MH - *Cardiomyopathies/diagnosis MH - Diagnosis, Differential MH - Magnetic Resonance Imaging MH - Positron-Emission Tomography EDAT- 2024/07/03 13:42 MHDA- 2024/08/08 06:42 CRDT- 2024/07/03 10:03 PHST- 2024/08/08 06:42 [medline] PHST- 2024/07/03 13:42 [pubmed] PHST- 2024/07/03 10:03 [entrez] AID - 00063198-202409000-00018 [pii] AID - 10.1097/MCP.0000000000001097 [doi] PST - ppublish SO - Curr Opin Pulm Med. 2024 Sep 1;30(5):540-550. doi: 10.1097/MCP.0000000000001097. Epub 2024 Jul 3. PMID- 38957100 OWN - NLM STAT- MEDLINE DCOM- 20240910 LR - 20240916 IS - 1531-698X (Electronic) IS - 1040-8703 (Linking) VI - 36 IP - 5 DP - 2024 Oct 1 TI - Optimizing management of chronic pulmonary hypertension in preterm infants: strategies for a complex population. PG - 581-590 LID - 10.1097/MOP.0000000000001383 [doi] AB - PURPOSE OF REVIEW: Pulmonary hypertension (PH) is commonly observed in premature infants with bronchopulmonary dysplasia (BPD) and is associated with poor outcomes and increased mortality. This review explores the management of this intricate condition of the pulmonary vasculature, which exhibits heterogeneous effects and may involve both arterial and postcapillary components. RECENT FINDINGS: Current management of BPD-PH should focus on optimizing ventilatory support, which involves treatment of underlying lung disease, transitioning to a chronic phase ventilation strategy and evaluation of the airway. Data on management is limited to observational studies. Diuretics are considered a part of the initial management, particularly in infants with right ventricular dilation. In many cases, pulmonary vasodilator therapy is required to induce pulmonary arterial vasodilation, reduce right ventricular strain, and prevent coronary ischemia and heart failure. Echocardiography plays a pivotal role in guiding treatment decisions and monitoring disease progression. SUMMARY: BPD-PH confers a heightened risk of mortality and long-term cardio-respiratory adverse outcomes. Echocardiography has been advocated for screening, while catheterization allows for confirmation in select more complex cases. Successful management of BPD-PH requires a multidisciplinary approach, focusing on optimizing BPD treatment and addressing underlying pathologies. CI - Copyright (c) 2024 Wolters Kluwer Health, Inc. All rights reserved. FAU - Michel-Macias, Carolina AU - Michel-Macias C AD - Universidad Autonoma de Queretaro, Facultad de Medicina, Quererato, Mexico. AD - Neonatology - McGill University Health Centre - Montreal Children's Hospital; Department of Pediatrics - McGill University, Montreal, Quebec, Canada. FAU - Hebert, Audrey AU - Hebert A AD - Division of Neonatology, CHU de Quebec, Universite Laval, Quebec City. FAU - Altit, Gabriel AU - Altit G AD - Neonatology - McGill University Health Centre - Montreal Children's Hospital; Department of Pediatrics - McGill University, Montreal, Quebec, Canada. LA - eng PT - Journal Article PT - Review DEP - 20240626 PL - United States TA - Curr Opin Pediatr JT - Current opinion in pediatrics JID - 9000850 RN - 0 (Vasodilator Agents) RN - 0 (Diuretics) SB - IM MH - Humans MH - Infant, Newborn MH - *Hypertension, Pulmonary/therapy/etiology/diagnosis MH - *Infant, Premature MH - *Bronchopulmonary Dysplasia/therapy/complications MH - Chronic Disease MH - Vasodilator Agents/therapeutic use MH - Echocardiography MH - Diuretics/therapeutic use MH - Respiration, Artificial/methods EDAT- 2024/07/03 06:42 MHDA- 2024/09/10 12:43 CRDT- 2024/07/03 03:43 PHST- 2024/09/10 12:43 [medline] PHST- 2024/07/03 06:42 [pubmed] PHST- 2024/07/03 03:43 [entrez] AID - 00008480-202410000-00014 [pii] AID - 10.1097/MOP.0000000000001383 [doi] PST - ppublish SO - Curr Opin Pediatr. 2024 Oct 1;36(5):581-590. doi: 10.1097/MOP.0000000000001383. Epub 2024 Jun 26. PMID- 38956937 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240719 IS - 1738-5520 (Print) IS - 1738-5555 (Electronic) IS - 1738-5520 (Linking) VI - 54 IP - 7 DP - 2024 Jul TI - Programmed Follow-up and Quality Control of Treatment Techniques Enhance Chronic Thromboembolic Pulmonary Hypertension Management: Lessons From a Multidisciplinary Team. PG - 409-421 LID - 10.4070/kcj.2024.0021 [doi] AB - BACKGROUND AND OBJECTIVES: The recent developments in chronic thromboembolic pulmonary hypertension (CTEPH) are emphasizing the multidisciplinary team. We report on the changes in clinical practice following the development of a multidisciplinary team, based on our 7 years of experience. METHODS: Multidisciplinary team was established in 2015 offering both balloon pulmonary angioplasty (BPA) and pulmonary endarterectomy (PEA) with technical upgrades by internal and external expertise. For operable cases, PEA was recommended as the primary treatment modality, followed by pulmonary angiography and right heart catheterization after 6 months to evaluate treatment effect and identify patients requiring further BPA. For patients with inoperable anatomy or high surgical risk, BPA was recommended as the initial treatment modality. Patient data and clinical outcomes were closely monitored. RESULTS: The number of CTEPH treatments rapidly increased and postoperative survival improved after team development. Before the team, 38 patients were treated by PEA for 18 years; however, 125 patients were treated by PEA or BPA after the team for 7 years. The number of PEA performed was 64 and that of BPA 342 sessions. World Health Organization functional class I or II was achieved in 93% of patients. The patients treated with PEA was younger, male dominant, higher pulmonary artery pressure, and smaller cardiac index, than BPA-only patients. In-hospital death after PEA was only 1 case and none after BPA. CONCLUSIONS: The balanced development of BPA and PEA through a multidisciplinary team approach proved synergistic in increasing the number of actively treated CTEPH patients and improving clinical outcomes. CI - Copyright (c) 2024. The Korean Society of Cardiology. FAU - Park, Taek Kyu AU - Park TK AUID- ORCID: 0000-0003-1440-3583 AD - Division of Cardiology, Department of Internal Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Chang, Sung-A AU - Chang SA AUID- ORCID: 0000-0001-5124-605X AD - Division of Cardiology, Department of Internal Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. elisabet.chang@gmail.com. FAU - Yang, Jeong Hoon AU - Yang JH AUID- ORCID: 0000-0001-8138-1367 AD - Division of Cardiology, Department of Internal Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. jhysmc@gmail.com. FAU - Kwon, Woochan AU - Kwon W AUID- ORCID: 0000-0002-3963-3142 AD - Division of Cardiology, Department of Internal Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Kim, Min Yeong AU - Kim MY AUID- ORCID: 0000-0002-6228-7313 AD - Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Cho, Young Seok AU - Cho YS AUID- ORCID: 0000-0003-1396-4952 AD - Division of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Park, Hye Yun AU - Park HY AUID- ORCID: 0000-0002-5937-9671 AD - Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Jeong, Dong Seop AU - Jeong DS AUID- ORCID: 0000-0002-6947-8403 AD - Division of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Kim, Hojoong AU - Kim H AUID- ORCID: 0000-0001-9207-0433 AD - Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Kim, Duk Kyung AU - Kim DK AUID- ORCID: 0000-0002-2348-8948 AD - Division of Cardiology, Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea. LA - eng PT - Journal Article DEP - 20240603 PL - Korea (South) TA - Korean Circ J JT - Korean circulation journal JID - 101247141 PMC - PMC11252637 OTO - NOTNLM OT - Pulmonary heart disease OT - Pulmonary hypertension OT - Pulmonary thromboembolism OT - Quality control OT - Treatment outcome COIS- The authors have no financial conflicts of interest. EDAT- 2024/07/03 06:42 MHDA- 2024/07/03 06:43 PMCR- 2024/07/01 CRDT- 2024/07/03 02:03 PHST- 2024/01/13 00:00 [received] PHST- 2024/03/31 00:00 [revised] PHST- 2024/05/08 00:00 [accepted] PHST- 2024/07/03 06:43 [medline] PHST- 2024/07/03 06:42 [pubmed] PHST- 2024/07/03 02:03 [entrez] PHST- 2024/07/01 00:00 [pmc-release] AID - 54.e65 [pii] AID - 10.4070/kcj.2024.0021 [doi] PST - ppublish SO - Korean Circ J. 2024 Jul;54(7):409-421. doi: 10.4070/kcj.2024.0021. Epub 2024 Jun 3. PMID- 38950668 OWN - NLM STAT- MEDLINE DCOM- 20240825 LR - 20260420 IS - 1097-6744 (Electronic) IS - 0002-8703 (Linking) VI - 276 DP - 2024 Oct TI - Electronic physician notification to facilitate the recognition and management of severe aortic stenosis: Rationale, design, and methods of the randomized controlled DETECT AS trial. PG - 39-48 LID - S0002-8703(24)00163-7 [pii] LID - 10.1016/j.ahj.2024.06.009 [doi] AB - BACKGROUND: Symptomatic severe aortic stenosis causes substantial morbidity and mortality when left untreated, yet recent data suggest its undertreatment. OBJECTIVE: To evaluate the efficacy of electronic physician notification to facilitate the guideline-directed management of patients with severe aortic stenosis. HYPOTHESIS: We hypothesize that patients with severe aortic stenosis who are in the care of physicians who receive the notification are more likely to undergo aortic valve replacement within one year. METHODS/DESIGN: The Electronic Physician Notification to Facilitate the Recognition and Management of Severe Aortic Stenosis (DETECT AS) trial is a randomized controlled trial and quality improvement initiative designed to evaluate the efficacy of electronic provider notification versus usual clinical care in the management of patients with severe aortic stenosis. Providers ordering an echocardiogram with findings potentially indicative of severe aortic stenosis are randomized to receive electronic notification with customized guideline recommendations for the management of severe aortic stenosis or usual care (no notification). Randomization continues until 940 patients are enrolled. SETTING: Multicentered, academic health system. OUTCOMES: The primary endpoint is the proportion of patients with severe aortic stenosis receiving an aortic valve replacement within one year of the index echocardiogram. Secondary endpoints include mortality, heart failure hospitalization, transthoracic echocardiogram utilization, aortic stenosis billing code, and cardiology/Valve Team referral. CONCLUSION: The DETECT AS trial will provide insight into whether electronic notification of providers on the presence of severe aortic stenosis and associated clinical guideline recommendations will facilitate recognition and guideline-directed management of severe aortic stenosis. TRIAL REGISTRATION: ClinicalTrials.gov, NCT05230225, https://clinicaltrials.gov/ct2/show/NCT05230225. CI - Copyright (c) 2024 Elsevier Inc. All rights reserved. FAU - Abou-Karam, Roukoz AU - Abou-Karam R AD - Department of Medicine, Cardiovascular Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, MA. FAU - Tanguturi, Varsha AU - Tanguturi V AD - Department of Medicine, Cardiology Division, Massachusetts General Hospital, Boston, MA. FAU - Cheng, Fangzhou AU - Cheng F AD - Department of Medicine, Cardiovascular Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, MA. FAU - Elmariah, Sammy AU - Elmariah S AD - Department of Medicine, Cardiovascular Division, University of California-San Francisco, San Francisco, CA. Electronic address: Sammy.Elmariah@ucsf.edu. LA - eng SI - ClinicalTrials.gov/NCT05230225 PT - Clinical Trial Protocol PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240629 PL - United States TA - Am Heart J JT - American heart journal JID - 0370465 SB - IM MH - Humans MH - *Aortic Valve Stenosis/diagnosis/surgery MH - Disease Management MH - *Echocardiography/methods MH - Heart Valve Prosthesis Implantation/methods MH - Practice Guidelines as Topic MH - Quality Improvement MH - Severity of Illness Index MH - Multicenter Studies as Topic MH - Randomized Controlled Trials as Topic COIS- Conflict of interest Dr Elmariah has received research grants from the American Heart Association (19TPA34910170), National Institutes of Health (R01 HL151838), Edwards Lifesciences, Svelte Medical, Abbott Vascular, and Medtronic; and has received consulting fees from Edwards Lifesciences. Dr. Tanguturi is a co-principal investigator of a grant funded by Edwards Lifesciences for the institution. Dr. Abou-Karam reports receiving consulting fees from Goodpath. EDAT- 2024/07/02 00:42 MHDA- 2024/08/26 12:38 CRDT- 2024/07/01 19:25 PHST- 2024/04/23 00:00 [received] PHST- 2024/06/21 00:00 [revised] PHST- 2024/06/22 00:00 [accepted] PHST- 2024/08/26 12:38 [medline] PHST- 2024/07/02 00:42 [pubmed] PHST- 2024/07/01 19:25 [entrez] AID - S0002-8703(24)00163-7 [pii] AID - 10.1016/j.ahj.2024.06.009 [doi] PST - ppublish SO - Am Heart J. 2024 Oct;276:39-48. doi: 10.1016/j.ahj.2024.06.009. Epub 2024 Jun 29. PMID- 33085381 STAT- Publisher CTDT- 20240702 PB - StatPearls Publishing DP - 2024 Jan TI - Tracheal Resection. BTI - StatPearls AB - While the history of mechanical ventilation dates back to at least the 1800s, positive-pressure ventilation began in the 1940s with military research into fighter pilots' respiration at high altitudes. The technique was rapidly applied to replace iron lungs in patients with polio, especially during the Scandinavian polio outbreak at that time. Engstrom patented one of the first positive-pressure ventilators designed to work by introducing air directly into the trachea via a tube inserted intraluminally in 1950, and the modern ventilator rapidly expanded from there. The initial endotracheal tubes (ETTs) were low-volume, high-pressure cuff tubes. Soon after introducing these airways, the first delayed complications from endotracheal intubation and ventilation were reported. Prolonged intubation, high cuff pressures, and excessive movement of the tracheostomy tube were found to cause ischemic injury and necrosis, leading to circumferential tracheal scarring and narrowing. The tracheobronchial cartilage was historically considered too rigid and poorly vascularized for surgical treatment. However, pioneering work by Drs Hermes Grillo and Joel Cooper showed that resection of the stenotic tracheal segment and primary reanastomosis was possible. Since then, significant advancements have been made in airway management during tracheal resection and surgical techniques to reduce tension on the anastomosis. Tracheal resection with primary anastomosis is presently a surgical procedure performed in major tertiary centers, managed by an interprofessional team of anesthesiologists, otolaryngologists, cardiothoracic surgeons, and pulmonary and critical care intensivists. Originally meant as a solution to tracheal stenosis, tracheal resection is now used to treat tracheal tumors, tracheomalacia, tracheal trauma, and tracheoesophageal and tracheoinnominate fistulas. CI - Copyright (c) 2024, StatPearls Publishing LLC. FAU - Young, Allen AU - Young A FAU - Bigcas, Jo-Lawrence M AU - Bigcas JLM LA - eng PT - Study Guide PT - Book Chapter PL - Treasure Island (FL) COIS- Disclosure: Allen Young declares no relevant financial relationships with ineligible companies. Disclosure: Jo-Lawrence M Bigcas declares no relevant financial relationships with ineligible companies. EDAT- 2024/07/02 00:00 CRDT- 2024/07/02 00:00 AID - NBK563234 [bookaccession] PMID- 38946428 OWN - NLM STAT- MEDLINE DCOM- 20240731 LR - 20240807 IS - 2047-9018 (Electronic) IS - 0029-6570 (Linking) VI - 39 IP - 8 DP - 2024 Jul 31 TI - Implementing debriefing after cardiac arrest: benefits and challenges. PG - 34-38 LID - 10.7748/ns.2024.e12273 [doi] AB - Healthcare professionals, including nurses, will be involved in the care and management of patients in cardiac arrest. This highly stressful and demanding situation can lead to breakdowns in communication, difficulty in decision-making and emotional distress for members of the healthcare team. Debriefing is a recommended tool that team members can use to acknowledge what went well, what could be improved and areas for learning or development. However, debriefing is often not prioritised due to pressures in clinical practice. This article discusses the benefits of debriefing and outlines some of the approaches and tools that may be used. The author argues that by recognising the importance of debriefing after cardiac arrests in the hospital setting and committing to best practices, nurses can be better prepared for the challenges of resuscitation and improve patient outcomes. CI - (c) 2024 RCN Publishing Company Ltd. All rights reserved. Not to be copied, transmitted or recorded in any way, in whole or part, without prior permission of the publishers. FAU - Howard, Rachel AU - Howard R AD - Liverpool John Moores University, Liverpool, England. LA - eng PT - Journal Article DEP - 20240701 PL - England TA - Nurs Stand JT - Nursing standard (Royal College of Nursing (Great Britain) : 1987) JID - 9012906 SB - IM MH - Humans MH - *Heart Arrest/therapy MH - United Kingdom MH - Patient Care Team MH - Cardiopulmonary Resuscitation/methods MH - Communication OTO - NOTNLM OT - cardiology OT - cardiopulmonary resuscitation OT - cardiorespiratory OT - clinical OT - education OT - emergency care OT - nursing care OT - professional COIS- None declared EDAT- 2024/07/01 06:42 MHDA- 2024/07/31 06:41 CRDT- 2024/07/01 04:03 PHST- 2024/03/18 00:00 [accepted] PHST- 2024/07/31 06:41 [medline] PHST- 2024/07/01 06:42 [pubmed] PHST- 2024/07/01 04:03 [entrez] AID - e12273 [pii] AID - 10.7748/ns.2024.e12273 [doi] PST - ppublish SO - Nurs Stand. 2024 Jul 31;39(8):34-38. doi: 10.7748/ns.2024.e12273. Epub 2024 Jul 1. PMID- 38944548 OWN - NLM STAT- MEDLINE DCOM- 20250525 LR - 20250525 IS - 1532-2688 (Electronic) IS - 1059-1311 (Linking) VI - 128 DP - 2025 May TI - Late-onset epilepsy clinic: From clinical diagnostics to biomarkers. PG - 68-73 LID - S1059-1311(24)00192-4 [pii] LID - 10.1016/j.seizure.2024.06.026 [doi] AB - The unique patho-clinical entity of late-onset epilepsy (LOE), distinguished by its distinct natural history, from its onset to the prognosis it portends, necessitates specialized care. We lack a universally accepted definition, but LOE is typically identified as epilepsy onset after the age of 60 or 65. Unlike epilepsy in younger individuals, LOE is almost by default focal in origin, secondary to acquired etiologies, and presents unique diagnostic and management challenges due to its atypical semiology, higher comorbidity burden, frailty, and increased risks of subsequent stroke and dementia. LOE clinics have been established to address these challenges, providing a multidisciplinary approach to optimize outcomes in patients with new-onset seizures beyond the fifth decade of life. LOE clinics are essential for comprehensive care, offering not only seizure management but also monitoring and addressing associated comorbidities. The care model involves collaboration among neurologists, primary care providers, cardiologists, mental health professionals, and social workers to manage LOE patients' complex needs effectively. The prevalence of cognitive dysfunction in LOE patients underscores the need for regular cognitive assessments and interventions. Biomarker research, particularly involving amyloid beta, offers promising avenues for early diagnosis and a better understanding of the interplay between LOE and Alzheimer's disease. Establishing LOE clinics in major referral centers can enhance provider expertise, improve patient outcomes, and facilitate research to advance diagnostic and therapeutic strategies. In conclusion, LOE clinics play a critical role in addressing the multifaceted needs of older adults with epilepsy, tailored to local resources and challenges, thus enhancing epilepsy care in an aging global population. CI - Copyright (c) 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved. FAU - Punia, Vineet AU - Punia V AD - Epilepsy Center, Cleveland Clinic, Cleveland, OH 44113, USA. Electronic address: puniav@ccf.org. FAU - Bhansali, Sakhi AU - Bhansali S AD - Epilepsy Center, Cleveland Clinic, Cleveland, OH 44113, USA. FAU - Tsai, Carolyn AU - Tsai C AD - Epilepsy Center, Cleveland Clinic, Cleveland, OH 44113, USA. LA - eng PT - Journal Article PT - Review DEP - 20240626 PL - England TA - Seizure JT - Seizure JID - 9306979 RN - 0 (Biomarkers) SB - IM MH - Humans MH - *Epilepsy/diagnosis/therapy/epidemiology/metabolism MH - Biomarkers/metabolism MH - Age of Onset MH - Aged OTO - NOTNLM OT - Dementia OT - Elderly OT - Frailty OT - Older adult OT - Seizure COIS- Declaration of competing interest None. EDAT- 2024/06/30 00:42 MHDA- 2025/05/26 00:29 CRDT- 2024/06/29 22:01 PHST- 2024/05/30 00:00 [received] PHST- 2024/06/21 00:00 [revised] PHST- 2024/06/25 00:00 [accepted] PHST- 2025/05/26 00:29 [medline] PHST- 2024/06/30 00:42 [pubmed] PHST- 2024/06/29 22:01 [entrez] AID - S1059-1311(24)00192-4 [pii] AID - 10.1016/j.seizure.2024.06.026 [doi] PST - ppublish SO - Seizure. 2025 May;128:68-73. doi: 10.1016/j.seizure.2024.06.026. Epub 2024 Jun 26. PMID- 38943716 OWN - NLM STAT- MEDLINE DCOM- 20240822 LR - 20260706 IS - 1532-4036 (Electronic) IS - 0964-3397 (Linking) VI - 84 DP - 2024 Oct TI - Registered nurses' experiences of caring for patients with hypoactive delirium after cardiac surgery - A qualitative study. PG - 103757 LID - S0964-3397(24)00142-3 [pii] LID - 10.1016/j.iccn.2024.103757 [doi] AB - OBJECTIVES: Delirium is a common post-cardiac surgery complication that presents as acute changes in mental abilities with confused thinking and a lack of awareness of the surroundings. Delirium symptoms present in hyperactive- and hypoactive forms. Hypoactive delirium is often overlooked. Although nursing interventions are important in preventing and treating hypoactive delirium, studies focusing on nurses' experiences of hypoactive delirium are scarce. This study describes registered nurses' experiences of caring for patients with hypoactive delirium after cardiac surgery. RESEARCH METHODOLOGY/DESIGN: This was a qualitative descriptive study with an inductive approach. Data was collected through focus group interviews with 12 registered nurses with experience in caring for cardiac surgery patients with hypoactive delirium. The study complied with the Consolidated Criteria for Reporting Qualitative Research. SETTING: A cardiac surgery department at a Swedish University Hospital. FINDINGS: The analysis resulted in one main category; "Navigating the complexities of care when caring for patients with hypoactive delirium" and three sub-categories: "Challenges, "Nursing interventions" and "Promoting a team approach". CONCLUSION: Delirium assessment and nursing interventions are perceived as essential yet demanding. when caring for patients with hypoactive delirium. Nursing interventions like maintaining the circadian rhythm and offering emotional support need to be prioritised by the nurses, in line with the autonomy of the registered nurse's profession. Moreover, the team around the patient is crucial for detecting and treating hypoactive delirium, and it is important to involve other professionals as well as the patient's relatives. Future research is needed to develop assessment instruments that more accurately capture hypoactive delirium in the postoperative setting. IMPLICATIONS FOR CLINICAL PRACTICE: Despite the use of screening tools, nurses still experience challenges in detecting the symptoms of hypoactive delirium, indicating a need for more clinically effective screening tools for hypoactive delirium. Nursing interventions are emphasised in the care of patients with hypoactive delirium. CI - Copyright (c) 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved. FAU - Hallberg Kristensen, Ann AU - Hallberg Kristensen A AD - Department of Cardiology, Heart and Vascular Center, Karolinska University Hospital, SE-171 76 Stockholm, Sweden. FAU - Nymark, Carolin AU - Nymark C AD - Department of Cardiology, Heart and Vascular Center, Karolinska University Hospital, SE-171 76 Stockholm, Sweden; Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Alfred Nobels Alle 23, SE-141 52 Huddinge, Sweden. FAU - Stenman, Malin AU - Stenman M AD - Perioperative Medicine and Intensive Care Function, Heart and Vascular Center, Karolinska University Hospital, SE-171 76 Stockholm, Sweden; Department of Molecular Medicine and Surgery, Karolinska Institute, L1:00, Anna Stecksens gata 53, SE-171 76 Stockholm, Sweden. FAU - Falk, Anna AU - Falk A AD - Perioperative Medicine and Intensive Care Function, Heart and Vascular Center, Karolinska University Hospital, SE-171 76 Stockholm, Sweden; Department of Molecular Medicine and Surgery, Karolinska Institute, L1:00, Anna Stecksens gata 53, SE-171 76 Stockholm, Sweden. Electronic address: anna.falk.2@ki.se. LA - eng PT - Journal Article DEP - 20240628 PL - Netherlands TA - Intensive Crit Care Nurs JT - Intensive & critical care nursing JID - 9211274 SB - IM MH - Humans MH - *Qualitative Research MH - *Delirium/nursing/etiology MH - Female MH - Male MH - *Nurses/psychology/statistics & numerical data MH - Adult MH - Sweden MH - *Focus Groups/methods MH - Middle Aged MH - *Cardiac Surgical Procedures/adverse effects/methods OTO - NOTNLM OT - Cardiac surgical procedures OT - Focus groups OT - Hypoactive delirium OT - Nurses OT - Patient care COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/06/30 00:42 MHDA- 2024/08/23 00:43 CRDT- 2024/06/29 18:01 PHST- 2024/01/14 00:00 [received] PHST- 2024/06/10 00:00 [revised] PHST- 2024/06/18 00:00 [accepted] PHST- 2024/08/23 00:43 [medline] PHST- 2024/06/30 00:42 [pubmed] PHST- 2024/06/29 18:01 [entrez] AID - S0964-3397(24)00142-3 [pii] AID - 10.1016/j.iccn.2024.103757 [doi] PST - ppublish SO - Intensive Crit Care Nurs. 2024 Oct;84:103757. doi: 10.1016/j.iccn.2024.103757. Epub 2024 Jun 28. PMID- 38943528 OWN - NLM STAT- MEDLINE DCOM- 20241023 LR - 20241114 IS - 1365-2362 (Electronic) IS - 0014-2972 (Linking) VI - 54 IP - 10 DP - 2024 Oct TI - Stroke outcomes following cardiac and aortic surgery are improved by the involvement of a stroke team. PG - e14275 LID - 10.1111/eci.14275 [doi] AB - OBJECTIVES: Post-cardiac and aortic surgery stroke is often underreported. We detail our single-centre experience the following introduction of comprehensive consultant-led daily stroke service, to demonstrate the efficacy of a stroke team in recovery from stroke following cardiac and aortic surgeries. METHODS: This retrospective, single-centre observational cohort study analysed consecutive patients undergoing cardiac and aortic surgery at our institution from August 2014 to December 2020. Main outcomes included stroke rate, predictors of stroke, and neurological deficit resolution or persistence at discharge and clinic follow-up. RESULTS: A total of 12,135 procedures were carried out in the reference period. Among these, 436 (3.6%) suffered a stroke. Overall survival to discharge and follow-up were 86.0% and 84.0% respectively. Independent risk factors for post-operative stroke included advanced age (OR 1.033, 95% CI [1.023, 1.044], p < .001), female sex (OR 1.491, 95% [1.212, 1.827], p < .001), history of previous cardiac surgeries (OR 1.670, 95% CI [1.239, 2.218], p < .001), simultaneous coronary artery bypass graft + valve procedures (OR 1.825, 95% CI [1.382, 2.382], p < .001) and CPB time longer than 240 min (OR 3.384, 95% CI [2.413, 4.705], p < .001). Stroke patients managed by the multidisciplinary team demonstrated significantly higher rates of survival at discharge (87.3% vs. 61.9%, p = .001). CONCLUSIONS: Perioperative stroke can be debilitating immediately long term. The involvement of specialist stroke teams plays a key role in reducing the long-term burden and mortality of this condition. CI - (c) 2024 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd. FAU - Harky, Amer AU - Harky A AUID- ORCID: 0000-0001-5507-5841 AD - Department of Cardiac Surgery, Liverpool Heart and Chest Hospital, Liverpool, UK. AD - Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK. AD - Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, UK. FAU - Chow, Vanessa Jane AU - Chow VJ AD - Department of Cardiac Surgery, Liverpool Heart and Chest Hospital, Liverpool, UK. FAU - Voller, Calum AU - Voller C AD - School of Medicine, University of Liverpool, Liverpool, UK. FAU - Goyal, Kartik AU - Goyal K AD - School of Medicine, University of Liverpool, Liverpool, UK. FAU - Shaw, Matthew AU - Shaw M AD - Department of Cardiac Surgery, Liverpool Heart and Chest Hospital, Liverpool, UK. AD - Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, UK. FAU - Bhawnani, Anurodh AU - Bhawnani A AD - Department of Cardiothoracic Anaesthesia and Intensive Care, Liverpool Heart and Chest Hospital, Liverpool, UK. FAU - Kenawy, Ayman AU - Kenawy A AD - Department of Cardiac Surgery, Liverpool Heart and Chest Hospital, Liverpool, UK. FAU - Wilson, Ian AU - Wilson I AD - Department of Cardiac Surgery, Liverpool Heart and Chest Hospital, Liverpool, UK. FAU - Lip, Gregory Y H AU - Lip GYH AD - Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, UK. AD - Department of Clinical Medicine, Danish Center for Health Services Research, Aalborg University, Aalborg, Denmark. FAU - Field, Mark AU - Field M AD - Department of Cardiac Surgery, Liverpool Heart and Chest Hospital, Liverpool, UK. AD - Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK. AD - Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, UK. FAU - Kuduvalli, Manoj AU - Kuduvalli M AD - Department of Cardiac Surgery, Liverpool Heart and Chest Hospital, Liverpool, UK. LA - eng PT - Journal Article PT - Observational Study DEP - 20240629 PL - England TA - Eur J Clin Invest JT - European journal of clinical investigation JID - 0245331 SB - IM MH - Humans MH - Male MH - Female MH - Aged MH - *Stroke/surgery MH - Retrospective Studies MH - Middle Aged MH - *Postoperative Complications/epidemiology MH - *Cardiac Surgical Procedures MH - *Patient Care Team MH - Risk Factors MH - Sex Factors MH - Age Factors MH - Coronary Artery Bypass MH - Aorta/surgery OTO - NOTNLM OT - cardiac surgery OT - multidisciplinary team OT - neurology OT - outcome OT - stroke EDAT- 2024/06/29 23:42 MHDA- 2024/10/23 18:21 CRDT- 2024/06/29 07:23 PHST- 2024/02/10 00:00 [received] PHST- 2024/06/10 00:00 [accepted] PHST- 2024/10/23 18:21 [medline] PHST- 2024/06/29 23:42 [pubmed] PHST- 2024/06/29 07:23 [entrez] AID - 10.1111/eci.14275 [doi] PST - ppublish SO - Eur J Clin Invest. 2024 Oct;54(10):e14275. doi: 10.1111/eci.14275. Epub 2024 Jun 29. PMID- 38942104 OWN - NLM STAT- MEDLINE DCOM- 20250106 LR - 20260807 IS - 1556-3871 (Electronic) IS - 1547-5271 (Linking) VI - 22 IP - 1 DP - 2025 Jan TI - Management of anesthesia for procedures in the cardiac electrophysiology laboratory. PG - 217-230 LID - S1547-5271(24)02822-4 [pii] LID - 10.1016/j.hrthm.2024.06.048 [doi] AB - The complexity of cardiac electrophysiology procedures has increased significantly during the past 3 decades. Anesthesia requirements of these procedures can differ on the basis of patient- and procedure-specific factors. This manuscript outlines various anesthesia strategies for cardiac implantable electronic devices and electrophysiology procedures, including preprocedural, procedural, and postprocedural management. A team-based approach with collaboration between cardiac electrophysiologists and anesthesiologists is required with careful preprocedural and intraprocedural planning. Given the recent advances in electrophysiology, there is a need for specialized cardiac electrophysiology anesthesia care to improve the efficacy and safety of the procedures. CI - Copyright (c) 2024 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved. FAU - Rajagopalan, Bharath AU - Rajagopalan B AD - Prairie Heart Institute, Springfield, Illinois. Electronic address: doctorbharath@gmail.com. FAU - Lakkireddy, Dhanunjaya AU - Lakkireddy D AD - Kansas City Heart Rhythm Institute, Overland Park, Kansas. FAU - Al-Ahmad, Amin AU - Al-Ahmad A AD - Texas Cardiac Arrhythmia Institute, Austin, Texas. FAU - Chrispin, Jonathan AU - Chrispin J AD - Department of Medicine, Johns Hopkins University, Baltimore, Maryland. FAU - Cohen, Mitchell AU - Cohen M AD - Division of Cardiology, Inova Children's Hospital, Fairfax, Virginia. FAU - Di Biase, Luigi AU - Di Biase L AD - Department of Medicine, Albert Einstein College of Medicine, New York, New York. FAU - Gopinathannair, Rakesh AU - Gopinathannair R AD - Kansas City Heart Rhythm Institute, Overland Park, Kansas. FAU - Nasr, Viviane AU - Nasr V AD - Department of Anesthesia, Boston Children's Hospital, Boston, Massachusetts. FAU - Navara, Rachita AU - Navara R AD - Department of Medicine, University of California, San Francisco, California. FAU - Patel, Parin AU - Patel P AD - Ascension St Vincent's Hospital, Indianapolis, Indiana. FAU - Santangeli, Pasquale AU - Santangeli P AD - Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio. FAU - Shah, Ronak AU - Shah R AD - Department of Anesthesiology and Critical Care, University of Pennsylvania, Philadelphia, Pennsylvania. FAU - Sotomonte, Juan AU - Sotomonte J AD - Centro Cardiovascular, San Juan, Puerto Rico. FAU - Sridhar, Arun AU - Sridhar A AD - Pulse Heart Institute, Tacoma, Washington. FAU - Tzou, Wendy AU - Tzou W AD - Department of Medicine, University of Colorado, Denver, Colorado. FAU - Cheung, Jim W AU - Cheung JW AD - Department of Medicine, Weill Cornell Medicine/NewYork-Presbyterian, New York, New York. LA - eng PT - Journal Article PT - Review DEP - 20240626 PL - United States TA - Heart Rhythm JT - Heart rhythm JID - 101200317 SB - IM MH - Humans MH - *Electrophysiologic Techniques, Cardiac/methods MH - Anesthesia/methods MH - Anesthesia, Cardiac Procedures/methods MH - Arrhythmias, Cardiac/therapy/physiopathology MH - Cardiac Electrophysiology/methods OTO - NOTNLM OT - Cardiac implantable electronic devices OT - Catheter ablation OT - General anesthesia OT - Hemodynamic monitoring OT - Postoperative period EDAT- 2024/06/29 00:42 MHDA- 2025/01/07 00:21 CRDT- 2024/06/28 19:24 PHST- 2024/01/22 00:00 [received] PHST- 2024/06/16 00:00 [revised] PHST- 2024/06/23 00:00 [accepted] PHST- 2025/01/07 00:21 [medline] PHST- 2024/06/29 00:42 [pubmed] PHST- 2024/06/28 19:24 [entrez] AID - S1547-5271(24)02822-4 [pii] AID - 10.1016/j.hrthm.2024.06.048 [doi] PST - ppublish SO - Heart Rhythm. 2025 Jan;22(1):217-230. doi: 10.1016/j.hrthm.2024.06.048. Epub 2024 Jun 26. PMID- 38939644 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240629 IS - 2772-963X (Electronic) IS - 2772-963X (Linking) VI - 3 IP - 5 DP - 2024 May TI - Aortic Stenosis Management in Patients With Acute Hip Fracture. PG - 100912 LID - 10.1016/j.jacadv.2024.100912 [doi] LID - 100912 AB - The treatment of severe aortic stenosis (SAS) has evolved rapidly with the advent of minimally invasive structural heart interventions. Transcatheter aortic valve replacement has allowed patients to undergo definitive SAS treatment achieving faster recovery rates compared to valve surgery. Not infrequently, patients are admitted/diagnosed with SAS after a fall associated with a hip fracture (HFx). While urgent orthopedic surgery is key to reduce disability and mortality, untreated SAS increases the perioperative risk and precludes physical recovery. There is no consensus on what the best strategy is either hip correction under hemodynamic monitoring followed by valve replacement or preoperative balloon aortic valvuloplasty to allow HFx surgery followed by valve replacement. However, preoperative minimalist transcatheter aortic valve replacement may represent an attractive strategy for selected patients. We provide a management pathway that emphasizes an early multidisciplinary approach to optimize time for hip surgery to improve orthopedic and cardiovascular outcomes in patients presenting with HFx-SAS. CI - (c) 2024 The Authors. FAU - Terre, Juan A AU - Terre JA AD - Section of Cardiology, Department of Medicine, Tulane University, New Orleans, Louisiana, USA. FAU - Torrado, Juan AU - Torrado J AD - Department of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA. FAU - George, Isaac AU - George I AD - Structural Heart and Valve Center, New York Presbyterian Hospital, Columbia University Medical Center, New York, New York, USA. FAU - Harari, Rafael AU - Harari R AD - Department of Cardiology, Bellevue Hospital, New York, New York, USA. FAU - Cox-Alomar, Pedro R AU - Cox-Alomar PR AD - Department of Cardiology, Louisiana State University, New Orleans, Louisiana, USA. FAU - Villablanca, Pedro A AU - Villablanca PA AD - Department of Cardiology, Henry Ford Medical Center, Detroit, Michigan, USA. FAU - Faillace, Robert T AU - Faillace RT AD - Department of Medicine, Jacobi Medical Center/North Central Bronx Hospital, Bronx, New York, USA. FAU - Granada, Juan F AU - Granada JF AD - Cardiovascular Research Foundation, New York, New York, USA. FAU - Dangas, George AU - Dangas G AD - Department of Cardiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA. FAU - Garcia, Mario J AU - Garcia MJ AD - Department of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA. FAU - Latib, Azeem AU - Latib A AD - Department of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA. FAU - Wiley, Jose AU - Wiley J AD - Section of Cardiology, Department of Medicine, Tulane University, New Orleans, Louisiana, USA. LA - eng PT - Journal Article PT - Review DEP - 20240403 PL - United States TA - JACC Adv JT - JACC. Advances JID - 9918419284106676 PMC - PMC11198465 OTO - NOTNLM OT - HOS OT - SAVR OT - TAVR OT - aortic stenosis OT - balloon aortic valvuloplasty OT - hip fracture OT - hip fracture surgery OT - management OT - minimalist transcatheter aortic valve replacement OT - non cardiac surgery OT - protocol OT - transcatheter aortic valve replacement OT - treatment algorithm COIS- Funding support was received from the Section of Cardiology, John W. Deming Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana, USA. Dr George is a consultant (honoraria) for Zimmer Biomet, Atricure, Neosurgery, Neptune Medical, Abbvie, Johnson & Johnson, Boston Scientific, Edwards Lifesciences, Medtronic, Help-TheraX, 3ive, Encompass, Summus Medical, and Abbott SJM; is on the advisory boards for Edwards Surgical, Medtronic Surgical, Medtronic Structural Mitral & Tricuspid, Trisol Medical, Abbvie, Johnson & Johnson, Foldax Medical, Zimmer Biomet, Neosurgery, Abbvie, Boston Scientific, and Summus Medical; has equity in Valcare Medical, Durvena, CardioMech, Vdyne, MitreMedical, and MITRx; and has received institutional funding to Columbia University: Edwards Lifesciences, Medtronic, Abbott Vascular, Boston Scientific, JenaValve. Dr Latib is on the advisory board for Medtronic, Abbott Vascular, Boston Scientific, Edwards Lifesciences, Shifamed, and Philips. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2024/06/28 06:42 MHDA- 2024/06/28 06:43 PMCR- 2024/04/03 CRDT- 2024/06/28 05:00 PHST- 2023/10/16 00:00 [received] PHST- 2023/12/04 00:00 [accepted] PHST- 2024/06/28 06:43 [medline] PHST- 2024/06/28 06:42 [pubmed] PHST- 2024/06/28 05:00 [entrez] PHST- 2024/04/03 00:00 [pmc-release] AID - S2772-963X(24)00094-2 [pii] AID - 100912 [pii] AID - 10.1016/j.jacadv.2024.100912 [doi] PST - epublish SO - JACC Adv. 2024 Apr 3;3(5):100912. doi: 10.1016/j.jacadv.2024.100912. eCollection 2024 May. PMID- 38939428 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240629 IS - 2772-963X (Electronic) IS - 2772-963X (Linking) VI - 2 IP - 6 DP - 2023 Aug TI - TITAN Trial: A Randomized Controlled Trial of a Cardiac Rehabilitation Care Model in Breast Cancer. PG - 100424 LID - 10.1016/j.jacadv.2023.100424 [doi] LID - 100424 AB - BACKGROUND: Cardiac rehabilitation (CR) modeled care is recommended for patients with breast cancer to mitigate risk of cardiotoxicity. However, the cardiovascular impact of CR-modeled interventions has not been studied. OBJECTIVES: The purpose of this study was to evaluate if a multidisciplinary model of CR reduces cardiotoxicity and improves cardiovascular risk in patients undergoing breast cancer treatment. METHODS: We randomly assigned patients with stage I to III breast cancer scheduled to receive anthracycline and/or trastuzumab-based chemotherapy to the CR intervention (n = 37) or usual care (n = 37). The intervention included guideline-directed management of cardiovascular risk factors, dietary counselling, and supervised exercise for 52 weeks. Cardiac magnetic resonance imaging, cardiopulmonary exercise testing, dual-energy x-ray absorptiometry, and serum biomarkers were acquired at baseline and 52 weeks. RESULTS: There was no difference in the primary outcome, left ventricular ejection fraction (LVEF), between groups at 52 weeks (61% +/- 6%). Other markers of cardiotoxicity, including high-sensitivity troponin I and brain natriuretic peptide, were similar between groups. However, total cholesterol (5.2 +/- 0.8 mmol/L to 4.7 +/- 0.8 mmol/L, P = 0.002) and low-density lipoprotein (3.0 +/- 0.7 mmol/L to 2.4 +/- 0.7 mmol/L, P < 0.001) decreased in the intervention group at 52 weeks and were unchanged in usual care. In all patients, adverse cardiac and metabolic changes occurred over 52 weeks including reductions in LVEF, left ventricular mass, high-density lipoprotein, lean body mass, insulin-like growth factor-1, as well as increased triglycerides, whole-body and truncal fat mass (all P < 0.050). CONCLUSIONS: The CR-modeled intervention had no effect on LVEF or biomarkers of cardiotoxicity. Future lifestyle intervention trials in patients with breast cancer should consider targeting other risk factors associated with incident cardiovascular disease. (Multidisciplinary Team IntervenTion in CArdio-ONcology [TITAN Study] [TITAN]; NCT01621659). CI - (c) 2023 The Authors. FAU - Kirkham, Amy A AU - Kirkham AA AD - Faculty of Medicine, University of Alberta, Edmonton, Alberta, Canada. FAU - Mackey, John R AU - Mackey JR AD - Faculty of Medicine, University of Alberta, Edmonton, Alberta, Canada. FAU - Thompson, Richard B AU - Thompson RB AD - Faculty of Medicine, University of Alberta, Edmonton, Alberta, Canada. FAU - Haykowsky, Mark J AU - Haykowsky MJ AD - Faculty of Nursing, University of Alberta, Edmonton, Alberta, Canada. FAU - Oudit, Gavin Y AU - Oudit GY AD - Faculty of Medicine, University of Alberta, Edmonton, Alberta, Canada. FAU - McNeely, Margaret AU - McNeely M AD - Faculty of Rehabilitation Medicine, University of Alberta, Edmonton, Alberta, Canada. FAU - Coulden, Richard AU - Coulden R AD - Faculty of Medicine, University of Alberta, Edmonton, Alberta, Canada. FAU - Stickland, Michael K AU - Stickland MK AD - Faculty of Medicine, University of Alberta, Edmonton, Alberta, Canada. FAU - Baracos, Vickie E AU - Baracos VE AD - Faculty of Medicine, University of Alberta, Edmonton, Alberta, Canada. FAU - Dyck, Jason R B AU - Dyck JRB AD - Faculty of Medicine, University of Alberta, Edmonton, Alberta, Canada. FAU - Haennel, Robert AU - Haennel R AD - Faculty of Rehabilitation Medicine, University of Alberta, Edmonton, Alberta, Canada. FAU - Pituskin, Edith AU - Pituskin E AD - Faculty of Nursing, University of Alberta, Edmonton, Alberta, Canada. FAU - Paterson, D Ian AU - Paterson DI AD - Faculty of Medicine, University of Alberta, Edmonton, Alberta, Canada. LA - eng SI - ClinicalTrials.gov/NCT01621659 PT - Journal Article DEP - 20230727 PL - United States TA - JACC Adv JT - JACC. Advances JID - 9918419284106676 PMC - PMC11198667 OTO - NOTNLM OT - LVEF OT - cardio-oncology OT - cardiotoxicity OT - dietary counselling OT - exercise OT - lipid profiles COIS- This trial was supported by the 10.13039/501100018911University Hospital Foundation, Edmonton, Alberta. During the study, Dr Kirkham was supported by Postdoctoral Fellowships from Susan G. Komen Foundation (PDF17483149) and the 10.13039/501100000024Canadian Institutes of Health Research. Dr Haykowsky is supported by the Faculty of Nursing Research Chair in Aging and Quality of Life at the 10.13039/501100000190University of Alberta. Dr Oudit has received study funding from 10.13039/100002429Amgen. Drs Oudit and Paterson are supported by the 10.13039/501100000024Canadian Institutes of Health Research and/or the 10.13039/100004411Heart and Stroke Foundation of Canada. Drs Dyck and Pituskin are each supported by 10.13039/501100001804Canada Research Chairs. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2024/06/28 06:42 MHDA- 2024/06/28 06:43 PMCR- 2023/07/27 CRDT- 2024/06/28 04:58 PHST- 2023/01/16 00:00 [received] PHST- 2023/05/10 00:00 [revised] PHST- 2023/05/18 00:00 [accepted] PHST- 2024/06/28 06:43 [medline] PHST- 2024/06/28 06:42 [pubmed] PHST- 2024/06/28 04:58 [entrez] PHST- 2023/07/27 00:00 [pmc-release] AID - S2772-963X(23)00283-1 [pii] AID - 100424 [pii] AID - 10.1016/j.jacadv.2023.100424 [doi] PST - epublish SO - JACC Adv. 2023 Jul 27;2(6):100424. doi: 10.1016/j.jacadv.2023.100424. eCollection 2023 Aug. PMID- 38933616 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240628 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 16 IP - 5 DP - 2024 May TI - Improved Cardiac Rehabilitation Referral Rate Utilizing a Multidisciplinary Quality Improvement Team. PG - e61157 LID - 10.7759/cureus.61157 [doi] LID - e61157 AB - Introduction Cardiac rehabilitation (CR) is an underutilized resource in patients with ischemic heart disease, despite being a Class IA recommendation. In this study, a multidisciplinary quality improvement (QI) team aimed to improve CR referrals by standardizing the ordering process at our hospital system. Method By using a collaborative approach involving the electronic medical record (EMR), medical provider education, and hospital protocols, our two-hospital healthcare system was able to successfully identify barriers to CR referral rates and implement interventions for these barriers. All physicians and medical providers, including ancillary staff, were educated on the EMR order sets to improve compliance by using automated order sets in the EMR. The CR referral order in the EMR included a statement regarding the application of evidence-based medicine, and a computerized provider order entry was included as a reminder to the ordering provider. The use of EMR was monitored monthly by the QI committee. Chi-square test and odds ratios were obtained for statistical analysis. Results Through provider-EMR education and patient education on discharge, CR referral rates significantly improved from 51.2 to 87.1% (p = 0.0001) in a 12-month period. The study included 1,499 patients in total. The improvement was statistically significant regardless of patient gender, race, or insurance coverage. Additionally, subgroup analysis in this study found that prior to standardization of the ordering process, African American patients were significantly less likely to be referred to CR compared to Caucasian patients. (51.2% vs. 41.0%, p=0.01). There was no statistically significant difference in the likelihood of CR referral between Caucasian and African American patients following the intervention (84.0% vs. 78.0%, p = 0.166). Conclusion This study shows that CR is an underutilized resource and that effective QI initiatives may not only increase CR referral rates but also close the gap between racial inequities in referral rates. Future research with multi-center randomized control trials is needed to further enhance its external generalizability to other institutions. CI - Copyright (c) 2024, Whitler et al. FAU - Whitler, Cameron AU - Whitler C AD - Department of Cardiovascular Medicine, Ascension Providence Hospital, Southfield, USA. FAU - Varkoly, Kyle S AU - Varkoly KS AD - Department of Internal Medicine, McLaren Macomb Hospital, Mount Clemens, USA. FAU - Patel, Harshil AU - Patel H AD - Department of Cardiovascular Medicine, Ascension Providence Hospital, Southfield, USA. FAU - Assaf, Andrew D AU - Assaf AD AD - Department of Cardiovascular Medicine, Ascension Providence Hospital, Southfield, USA. FAU - Hoose, Jennifer AU - Hoose J AD - Department of Cardiovascular Medicine, Ascension Providence Hospital, Southfield, USA. FAU - Brannan, Grace D AU - Brannan GD AD - Department of Research, GDB Research and Statistical Consulting, Athens, USA. FAU - Miller, Ronald AU - Miller R AD - Department of Cardiovascular Medicine, Ascension Providence Hospital, Southfield, USA. FAU - Zughaib, Marcel AU - Zughaib M AD - Department of Cardiovascular Medicine, Ascension Providence Hospital, Southfield, USA. LA - eng PT - Journal Article DEP - 20240527 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC11200930 OTO - NOTNLM OT - cardiac rehabiliation OT - ischemic heart diseases OT - management guideline OT - multidisciplinary teams OT - referral COIS- Human subjects: Consent was obtained or waived by all participants in this study. Ascension Providence, Tina Noonan issued approval N/A. Reviewed by Ascension Providence IRB, this paper does not require a full review and approval as the results are not generalizable to sites external to Ascension, Michigan. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. EDAT- 2024/06/27 06:43 MHDA- 2024/06/27 06:44 PMCR- 2024/05/27 CRDT- 2024/06/27 04:33 PHST- 2024/05/27 00:00 [accepted] PHST- 2024/06/27 06:44 [medline] PHST- 2024/06/27 06:43 [pubmed] PHST- 2024/06/27 04:33 [entrez] PHST- 2024/05/27 00:00 [pmc-release] AID - 10.7759/cureus.61157 [doi] PST - epublish SO - Cureus. 2024 May 27;16(5):e61157. doi: 10.7759/cureus.61157. eCollection 2024 May. PMID- 38928674 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240629 IS - 2075-4418 (Print) IS - 2075-4418 (Electronic) IS - 2075-4418 (Linking) VI - 14 IP - 12 DP - 2024 Jun 14 TI - Surgical Therapy of Infective Prosthesis Endocarditis following TAVI: A Single Center's Experience. LID - 10.3390/diagnostics14121259 [doi] LID - 1259 AB - BACKGROUND/OBJECTIVES: Infective prosthesis endocarditis (IE) following transcatheter aortic valve implantation (TAVI) presents significant management challenges, marked by high mortality rates. This study reviews our center's experience with surgical interventions for IE in patients post-TAVI, focusing on outcomes, challenges, and procedural complexities, and providing an overview of the limited literature surrounding this subject. METHODS: This study was executed as a comprehensive retrospective analysis, targeting the clinical outcomes of surgical treatment in patients presenting with PVE following TAVI procedures at our institution. From July 2017 to July 2022, we identified five patients who had previously undergone transfemoral transcatheter aortic valve implantation and were later diagnosed with PVE needing surgery, strictly adhering to the modified Duke criteria. RESULTS: All surgical procedures were reported successful with no intra- or postoperative mortality. Patients were predominantly male (80%), with an average age of 76 +/- 8.6 years, presenting mostly with dyspnea (NYHA Class II). The mean follow-up was between 121 and 1973 days, with outcomes showing no occurrences of stroke, myocardial infarction, or major bleeding. One patient expired from unrelated causes 3.7 years post-surgery. The operative and postoperative protocols demonstrated effective disease management with enhanced survival and minimal complications. CONCLUSIONS: The surgical treatment of IE following TAVI, though challenging, can be successfully achieved with careful patient selection and a multidisciplinary approach. The favorable outcomes suggest that surgical intervention remains a viable option for managing this high-risk patient group. Our study also highlights the scarce literature available on this topic, suggesting an urgent need for more comprehensive research to enhance understanding and improve treatment strategies. Future studies with larger cohorts are needed to further validate these findings and refine surgical strategies for this growing patient population. FAU - Weymann, Alexander AU - Weymann A AD - Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, 30625 Hannover, Germany. FAU - Merzah, Ali Saad AU - Merzah AS AD - Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, 30625 Hannover, Germany. FAU - Arjomandi Rad, Arian AU - Arjomandi Rad A AUID- ORCID: 0000-0002-4931-4049 AD - Medical Sciences Division, University of Oxford, Oxford OX1 2JD, UK. FAU - Amanov, Lukman AU - Amanov L AD - Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, 30625 Hannover, Germany. FAU - Athanasiou, Thanos AU - Athanasiou T AD - Department of Surgery and Cancer, Imperial College London, London SW7 2AZ, UK. FAU - Schmack, Bastian AU - Schmack B AD - Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, 30625 Hannover, Germany. FAU - Popov, Aron-Frederik AU - Popov AF AUID- ORCID: 0000-0003-4226-3004 AD - Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, 30625 Hannover, Germany. FAU - Ruhparwar, Arjang AU - Ruhparwar A AUID- ORCID: 0000-0003-2725-9912 AD - Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, 30625 Hannover, Germany. FAU - Zubarevich, Alina AU - Zubarevich A AD - Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, 30625 Hannover, Germany. LA - eng PT - Journal Article DEP - 20240614 PL - Switzerland TA - Diagnostics (Basel) JT - Diagnostics (Basel, Switzerland) JID - 101658402 PMC - PMC11203229 OTO - NOTNLM OT - TAVI OT - TAVI prosthesis endocarditis OT - prosthesis endocarditis OT - surgical aortic valve replacement COIS- The authors declare no conflicts of interest. EDAT- 2024/06/27 06:42 MHDA- 2024/06/27 06:43 PMCR- 2024/06/14 CRDT- 2024/06/27 01:08 PHST- 2024/04/17 00:00 [received] PHST- 2024/05/17 00:00 [revised] PHST- 2024/06/13 00:00 [accepted] PHST- 2024/06/27 06:43 [medline] PHST- 2024/06/27 06:42 [pubmed] PHST- 2024/06/27 01:08 [entrez] PHST- 2024/06/14 00:00 [pmc-release] AID - diagnostics14121259 [pii] AID - diagnostics-14-01259 [pii] AID - 10.3390/diagnostics14121259 [doi] PST - epublish SO - Diagnostics (Basel). 2024 Jun 14;14(12):1259. doi: 10.3390/diagnostics14121259. PMID- 38927180 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240629 IS - 2079-6382 (Print) IS - 2079-6382 (Electronic) IS - 2079-6382 (Linking) VI - 13 IP - 6 DP - 2024 May 31 TI - Multidisciplinary Perspectives of Challenges in Infective Endocarditis Complicated by Septic Embolic-Induced Acute Myocardial Infarction. LID - 10.3390/antibiotics13060513 [doi] LID - 513 AB - BACKGROUND: Infective endocarditis (IE) management is challenging, usually requiring multidisciplinary collaboration from cardiologists, infectious disease specialists, interventional cardiologists, and cardiovascular surgeons, as more than half of the cases will require surgical procedures. Therefore, it is essential for all healthcare providers involved in managing IE to understand the disease's characteristics, potential complications, and treatment options. While systemic embolization is one of the most frequent complications of IE, the coronary localization of emboli causing acute myocardial infarction (AMI) is less common, with an incidence ranging from 1% to 10% of cases, but it has a much higher rate of morbidity and mortality. There are no guidelines for this type of AMI management in IE. METHODS: This narrative review summarizes the current knowledge regarding septic coronary embolization in patients with IE. Additionally, this paper highlights the diagnosis and management challenges in such cases, particularly due to the lack of protocols or consensus in the field. RESULTS: Data extracted from case reports indicate that septic coronary embolization often occurs within the first two weeks of the disease. The aortic valve is most commonly involved with vegetation, and the occluded vessel is frequently the left anterior descending artery. Broad-spectrum antibiotic therapy followed by targeted antibiotic therapy for infection control is essential, and surgical treatment offers promising results through surgical embolectomy, concomitant with valve replacement or aspiration thrombectomy, with or without subsequent stent insertion. Thrombolytics are to be avoided due to the increased risk of bleeding. CONCLUSIONS: All these aspects should constitute future lines of research, allowing the integration of all current knowledge from multidisciplinary team studies on larger patient cohorts and, subsequently, creating a consensus for assessing the risk and guiding the management of this potentially fatal complication. FAU - Stamate, Elena AU - Stamate E AUID- ORCID: 0000-0001-5056-1015 AD - Department of Cardiology, University Emergency Hospital of Bucharest, 169 Splaiul Independentei St., 050098 Bucharest, Romania. AD - Faculty of Medicine and Pharmacy, Dunarea de Jos University of Galati, 35 AI Cuza St., 800010 Galati, Romania. FAU - Ciobotaru, Oana Roxana AU - Ciobotaru OR AUID- ORCID: 0000-0001-9173-6205 AD - Faculty of Medicine and Pharmacy, Dunarea de Jos University of Galati, 35 AI Cuza St., 800010 Galati, Romania. AD - Railway Hospital Galati, 6 Alexandru Moruzzi St., 800223 Galati, Romania. FAU - Arbune, Manuela AU - Arbune M AUID- ORCID: 0000-0002-4762-0755 AD - Faculty of Medicine and Pharmacy, Dunarea de Jos University of Galati, 35 AI Cuza St., 800010 Galati, Romania. AD - Infectious Diseases Clinic Hospital "Sf. Cuv. Parascheva", 393 Traian St., 800179 Galati, Romania. FAU - Piraianu, Alin Ionut AU - Piraianu AI AUID- ORCID: 0000-0001-9664-2128 AD - Faculty of Medicine and Pharmacy, Dunarea de Jos University of Galati, 35 AI Cuza St., 800010 Galati, Romania. AD - Emergency County Hospital Braila, 2 Sos. Buzaului St., 810325 Braila, Romania. FAU - Duca, Oana Monica AU - Duca OM AUID- ORCID: 0000-0002-4154-3656 AD - Faculty of Medicine and Pharmacy, Dunarea de Jos University of Galati, 35 AI Cuza St., 800010 Galati, Romania. AD - Emergency County Hospital Braila, 2 Sos. Buzaului St., 810325 Braila, Romania. FAU - Fulga, Ana AU - Fulga A AD - Faculty of Medicine and Pharmacy, Dunarea de Jos University of Galati, 35 AI Cuza St., 800010 Galati, Romania. AD - Saint Apostle Andrew Emergency County Clinical Hospital, 177 Brailei St., 800578 Galati, Romania. FAU - Fulga, Iuliu AU - Fulga I AD - Faculty of Medicine and Pharmacy, Dunarea de Jos University of Galati, 35 AI Cuza St., 800010 Galati, Romania. AD - Saint Apostle Andrew Emergency County Clinical Hospital, 177 Brailei St., 800578 Galati, Romania. FAU - Balta, Alexia Anastasia Stefania AU - Balta AAS AD - Faculty of Medicine and Pharmacy, Dunarea de Jos University of Galati, 35 AI Cuza St., 800010 Galati, Romania. AD - Saint Apostle Andrew Emergency County Clinical Hospital, 177 Brailei St., 800578 Galati, Romania. FAU - Dumitrascu, Adrian George AU - Dumitrascu AG AUID- ORCID: 0000-0003-1557-9791 AD - Division of Hospital Internal Medicine, Department of Medicine, Mayo Clinic Florida, 4500 San Pablo Rd S, Jacksonville, FL 32224, USA. FAU - Ciobotaru, Octavian Catalin AU - Ciobotaru OC AUID- ORCID: 0000-0003-4568-5237 AD - Faculty of Medicine and Pharmacy, Dunarea de Jos University of Galati, 35 AI Cuza St., 800010 Galati, Romania. AD - Railway Hospital Galati, 6 Alexandru Moruzzi St., 800223 Galati, Romania. LA - eng GR - VAT 27232142/"Dunarea de Jos" University of Galati/ PT - Journal Article PT - Review DEP - 20240531 PL - Switzerland TA - Antibiotics (Basel) JT - Antibiotics (Basel, Switzerland) JID - 101637404 PMC - PMC11201065 OTO - NOTNLM OT - antibiotic therapy OT - coronary OT - endocarditis OT - myocardial infarction OT - septic embolism COIS- The authors declare no conflicts of interest. EDAT- 2024/06/27 06:42 MHDA- 2024/06/27 06:43 PMCR- 2024/05/31 CRDT- 2024/06/27 01:01 PHST- 2024/04/29 00:00 [received] PHST- 2024/05/27 00:00 [revised] PHST- 2024/05/30 00:00 [accepted] PHST- 2024/06/27 06:43 [medline] PHST- 2024/06/27 06:42 [pubmed] PHST- 2024/06/27 01:01 [entrez] PHST- 2024/05/31 00:00 [pmc-release] AID - antibiotics13060513 [pii] AID - antibiotics-13-00513 [pii] AID - 10.3390/antibiotics13060513 [doi] PST - epublish SO - Antibiotics (Basel). 2024 May 31;13(6):513. doi: 10.3390/antibiotics13060513. PMID- 38924644 OWN - NLM STAT- MEDLINE DCOM- 20240925 LR - 20260920 IS - 2055-5822 (Electronic) IS - 2055-5822 (Linking) VI - 11 IP - 5 DP - 2024 Oct TI - Optimizing heart failure pathways to enhance patient care: the Program to Optimize Heart Failure Patient Pathways (PRO-HF). PG - 2578-2590 LID - 10.1002/ehf2.14911 [doi] AB - AIMS: Many European healthcare providers struggle to adopt multidisciplinary, integrated care pathways for people with heart failure (HF) as recommended by the European Society of Cardiology. PRO-HF (Program to Optimize Heart Failure Patient Pathways) was developed to help clinicians identify strengths, gaps, and shortcomings in their HF pathways and support tailored interventions to optimize pathways and enhance patient care. We report initial findings from baseline assessments of HF pathway characteristics and challenges from 10 hospitals in six European countries (France, Ireland, Portugal, Spain, The Netherlands, and United Kingdom). METHODS AND RESULTS: Baseline assessments were holistic appraisals of full HF services to calibrate current status and development needs and assist management teams in prioritizing improvement projects. Assessments were performed using a comprehensive checklist of measures covering the HF patient journey from diagnosis to ongoing follow-up. These included a digital survey sent to full HF care teams and one-to-one interviews. The digital survey focused on four key areas (HF outpatient clinic; remote patient management; efficient device implantation and inpatient pathways; and network maximization) and 16 dimensions of excellence. Priority areas and themes for action identified in baseline assessments were (i) provision of HF specialist care; (ii) data capture and analysis; (iii) institutional care protocols; (iv) hospital-wide strategies; and (v) multidisciplinary teams (MDTs). Suboptimal specialist care of emergency inpatients was an issue at all hospitals and prioritized at 8/10. Availability and accessibility of data on patients, activities, and outcomes was an issue at all hospitals and prioritized by 4/10. A lack of clear protocols, templates, and tools for some HF activities created variability in patient care (e.g., HF specialist consultations, diagnostic testing, follow-up appointments, medications, and device eligibility) and inefficient use of clinician time. This made it difficult to initiate new technologies (e.g., remote patient monitoring) due to the risk of overburdening staff. MDTs were frequently understaffed. Multiple interventions were identified to address gaps and shortcomings that could be tailored to specific needs of individual hospitals (e.g., inpatient pathway optimization, creation/optimization of HF outpatient clinics, development of an HF performance dashboard, enhancement of protocol adherence, streamlining cardiac resynchronisation therapy pathways, and MDT coordination). CONCLUSIONS: PRO-HF provides a valuable opportunity to identify gaps and significant shortcomings in HF pathways in European hospitals. Preliminary findings from hospitals that have initiated suggested changes to address these challenges are encouraging, though longer-term follow-up from more hospitals is needed to confirm the impact of PRO-HF on HF pathway optimization and patient care. CI - (c) 2024 The Author(s). ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. FAU - Patwala, Ashish AU - Patwala A AD - University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, UK. FAU - Barker, Diane AU - Barker D AD - University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, UK. FAU - Da Costa, Antoine AU - Da Costa A AD - Centre Hospitalier Universitaire de Saint-Etienne, Saint-Etienne, France. FAU - Bayard, Geoffrey AU - Bayard G AD - Centre Hospitalier Universitaire de Saint-Etienne, Saint-Etienne, France. FAU - Brunner-La Rocca, Hans-Peter AU - Brunner-La Rocca HP AD - Maastricht University Medical Centre, Maastricht, The Netherlands. FAU - Fontes-Carvalho, Ricardo AU - Fontes-Carvalho R AD - Centro Hospitalar Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal. AD - University of Porto, Porto, Portugal. FAU - De la Fuente, Luis AU - De la Fuente L AD - Hospital Clinico Universitario de Valladolid, Valladolid, Spain. FAU - Goralski, Marc AU - Goralski M AD - Centre Hospitalier Universitaire d'Orleans, Orleans, France. FAU - Mahon, Niall G AU - Mahon NG AD - Mater Misericordiae Hospital, Dublin, Ireland. FAU - Roque, David AU - Roque D AD - Hospital Fernando Fonseca, Amadora, Portugal. FAU - Santos, Mario AU - Santos M AD - Centro Hospitalar Universitario de Santo Antonio, Porto, Portugal. FAU - Yousef, Zaheer AU - Yousef Z AD - Cardiff and Vale University Health Board, Cardiff, UK. FAU - Ben Hamouda, Hela AU - Ben Hamouda H AD - Medtronic International Trading Sarl, Tolochenaz, Switzerland. FAU - Teal, Mark AU - Teal M AD - Medtronic International Trading Sarl, Tolochenaz, Switzerland. FAU - Christory, Francois AU - Christory F AUID- ORCID: 0000-0001-7339-6008 AD - Medical Education Global Solutions, Paris, France. FAU - Ahmed, Fozia Zahir AU - Ahmed FZ AD - Manchester University Hospitals NHS Foundation Trust, Manchester, UK. FAU - Mebazaa, Alexandre AU - Mebazaa A AUID- ORCID: 0000-0001-8715-7753 AD - Universite Paris Cite, Paris, France. LA - eng GR - Medtronic Europe/ PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't DEP - 20240624 PL - England TA - ESC Heart Fail JT - ESC heart failure JID - 101669191 SB - IM MH - Humans MH - *Heart Failure/therapy MH - Europe MH - *Critical Pathways/organization & administration MH - Patient Care/methods MH - Quality Improvement MH - Patient Care Team/organization & administration PMC - PMC11424341 OTO - NOTNLM OT - HF pathway OT - HF protocol OT - HF specialist care OT - Heart failure OT - Multidisciplinary team OT - PRO-HF OT - Pathway optimization COIS- Dr Patwala has received speaker fees from Medtronic and Abbott. Dr Barker has received speaker fees from AstraZeneca. Dr Da Costa has received consultancy fees from Medtronic, Sanofi, Boehringer Ingelheim, Novartis and Boston Scientific. Dr Bayard has received speaker fees from Boehringer Ingelheim and Lilly and consultancy fees from Novartis. Dr Brunner-La Rocca has received unrestricted research grants from Novartis, Roche Diagnostics and Vifor, consultancy fees from Novartis, Roche Diagnostics, Boehringer Ingelheim, AstraZeneca and Vifor, and has collaborated in an international project with Novo Nordisk, AstraZeneca, Lilly, Roche Diagnostics, Evotec, Decentriq, Exploris, Sananet and Nurogames. Dr Fontes-Carvalho has received speaker/consulting fees from Amgen, Amarin, AstraZeneca, Bayer, Bial, Boehringer Ingelheim, BMS, Servier, Lilly, MSD, Medinfar, Merck, Menarini, Mylan, Novartis and Pfizer. Dr Goralski has received speaker fees from AstraZeneca, MSD, BMS, Servier, Pfizer, Bayer, Novartis, Amgen, Sanofi, Novo Nordisk, consultancy fees from Sorin, congress fees from Amgen, Bayer, Pfizer, Servier, Medtronic and Organon, and has been principal investigator of clinical studies with Amgen, AstraZeneca and Medtronic. Dr Roque has received speaker fees from Novartis, AstraZeneca, Bial, Servier and Vifor Pharma. Dr Santos has received speaker fees from AOP, AstraZeneca, Bayer, Bial, Boehringer Ingelheim & Lilly Alliance, Janssen, Merck, Microport and Novartis, consultancy fees from Medtronic, Merck and Janssen, and unrestricted grants from Boston Scientific, Janssen and Novartis. Dr Youssef has received research funding from Medtronic and honoraria from AstraZeneca, Boehringer Ingelheim, Lilly, Novartis, and Bristol Meyers Squibb. Mr Christory is an employee of Medical Education Global Solutions, which has received funding from Medtronic for educational activities. Ms Ben Hamouda is an employee of Medtronic International. Mr Teal is an employee of Medtronic Integrated Health Solutions. Dr Ahmed has received a research grant funded by Medtronic and consultancy fees from AstraZeneca, Medtronic, Pfizer, Pharmacosmos, Servier and Vifor. Dr Mebazaa has received grants from Roche Diagnostics, Abbott Laboratories, 4TEEN4, and Windtree Therapeutics, speaker honoraria from Roche Diagnostics, Bayer and MSD, and consulting fees from Corteria Pharmaceuticals, S-form Pharma, FIRE-1, Implicity, 4TEEN4, and Adrenomed; he is coinventor of a patent on combination therapy for patients having acute or persistent dyspnoea. The remaining authors have nothing to disclose. EDAT- 2024/06/26 18:42 MHDA- 2024/09/26 00:42 PMCR- 2024/06/24 CRDT- 2024/06/26 15:50 PHST- 2024/03/11 00:00 [received] PHST- 2024/04/17 00:00 [accepted] PHST- 2024/09/26 00:42 [medline] PHST- 2024/06/26 18:42 [pubmed] PHST- 2024/06/26 15:50 [entrez] PHST- 2024/06/24 00:00 [pmc-release] AID - EHF214911 [pii] AID - 10.1002/ehf2.14911 [doi] PST - ppublish SO - ESC Heart Fail. 2024 Oct;11(5):2578-2590. doi: 10.1002/ehf2.14911. Epub 2024 Jun 24. PMID- 38923509 OWN - NLM STAT- MEDLINE DCOM- 20240809 LR - 20260918 IS - 1522-9645 (Electronic) IS - 0195-668X (Linking) VI - 45 IP - 30 DP - 2024 Aug 9 TI - Management of cardiac sarcoidosis. PG - 2697-2726 LID - 10.1093/eurheartj/ehae356 [doi] AB - Cardiac sarcoidosis (CS) is a form of inflammatory cardiomyopathy associated with significant clinical complications such as high-degree atrioventricular block, ventricular tachycardia, and heart failure as well as sudden cardiac death. It is therefore important to provide an expert consensus statement summarizing the role of different available diagnostic tools and emphasizing the importance of a multidisciplinary approach. By integrating clinical information and the results of diagnostic tests, an accurate, validated, and timely diagnosis can be made, while alternative diagnoses can be reasonably excluded. This clinical expert consensus statement reviews the evidence on the management of different CS manifestations and provides advice to practicing clinicians in the field on the role of immunosuppression and the treatment of cardiac complications based on limited published data and the experience of international CS experts. The monitoring and risk stratification of patients with CS is also covered, while controversies and future research needs are explored. CI - (c) The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com. FAU - Sharma, Rakesh AU - Sharma R AUID- ORCID: 0000-0002-9418-2655 AD - Department of Cardiology, Royal Brompton Hospital, part of Guy's and St Thomas's NHS Foundation Trust, London SW3 6NP, UK. AD - National Heart and Lung Institute, Imperial College London, UK. AD - King's College London, UK. FAU - Kouranos, Vasileios AU - Kouranos V AD - National Heart and Lung Institute, Imperial College London, UK. AD - Interstitial Lung Disease Unit, Royal Brompton Hospital, part of Guys and St. Thomas's Hospital, London, UK. FAU - Cooper, Leslie T AU - Cooper LT AD - Department of Cardiovascular Medicine, Mayo Clinic in Florida, 4500 San Pablo, Jacksonville, USA. FAU - Metra, Marco AU - Metra M AUID- ORCID: 0000-0001-6691-8568 AD - Cardiology Unit, ASST Spedali Civili, University of Brescia, Brescia, Italy. FAU - Ristic, Arsen AU - Ristic A AD - Department of Cardiology, University of Belgrade, Pasterova 2, Floor 9, 11000 Belgrade, Serbia. FAU - Heidecker, Bettina AU - Heidecker B AD - Department for Cardiology, Angiology and Intensive Care Medicine, Deutsches Herzzentrum der Charite, Campus Benjamin Franklin; Charite Universitatsmedizin Berlin, Berlin Institute of Health (BIH) at Charite, Berlin, Germany. FAU - Baksi, John AU - Baksi J AD - National Heart and Lung Institute, Imperial College London, UK. AD - Cardiac MRI Unit, Royal Brompton Hospital, part of Guy's and St Thomas's NHS Foundation Trust, London, UK. FAU - Wicks, Eleanor AU - Wicks E AD - Department of Cardiology, Oxford University Hospitals NHS Trust, Oxford, UK. AD - University College London, London, UK. FAU - Merino, Jose L AU - Merino JL AD - La Paz University Hospital-IdiPaz, Universidad Autonoma, Madrid, Spain. FAU - Klingel, Karin AU - Klingel K AUID- ORCID: 0000-0003-0203-2498 AD - University Hospital Tubingen, Tubingen, Germany. FAU - Imazio, Massimo AU - Imazio M AUID- ORCID: 0000-0002-5722-0245 AD - Department of Medicine, University of Udine, Udine, Italy. AD - Department of Cardiology, University Hospital Santa Maria della Misericordia, Udine, Italy. FAU - de Chillou, Christian AU - de Chillou C AD - Department of Cardiology, CHRU-Nancy, Universite de Lorraine, Nancy, France. AD - Department of Cardiology, IADI, INSERM U1254, Universite de Lorraine, Nancy, France. FAU - Tschope, Carsten AU - Tschope C AD - Department of Cardiology, Deutsches Herzzentrum der Charite (DHZC), Angiology and Intensive Medicine (Campus Virchow) and German Centre for Cardiovascular Research (DZHK)- partner site Berlin, Charite Universitatsmedizin Berlin, Berlin, Germany. AD - Berlin Institute of Health (BIH) at Charite - Center for Regenerative Therapies, Universitatsmedizin Berlin, Berlin, Germany. FAU - Kuchynka, Petr AU - Kuchynka P AD - 2nd Department of Medicine, Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic. FAU - Petersen, Steffen E AU - Petersen SE AUID- ORCID: 0000-0003-4622-5160 AD - NIHR Barts Biomedical Research Centre, William Harvey Research Institute, Queen Mary University London, Charterhouse Square, London, EC1M 6BQ, UK. AD - Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, West Smithfield, EC1A 7BE, London, UK. FAU - McDonagh, Theresa AU - McDonagh T AD - Department of Cardiology King's College Hospital, London, UK. FAU - Luscher, Thomas AU - Luscher T AD - Royal Brompton Hospital, part of Guys and St Thomas's NHS Foundation Trust, Professor of Cardiology at Imperial College and Kings College, London, UK. FAU - Filippatos, Gerasimos AU - Filippatos G AD - Department of Cardiology, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece. LA - eng PT - Consensus Statement PT - Journal Article PT - Review PL - England TA - Eur Heart J JT - European heart journal JID - 8006263 RN - 0 (Immunosuppressive Agents) SB - IM MH - Humans MH - *Sarcoidosis/diagnosis/therapy/complications MH - *Cardiomyopathies/diagnosis/therapy MH - Immunosuppressive Agents/therapeutic use MH - Death, Sudden, Cardiac/prevention & control/etiology OTO - NOTNLM OT - Cardiac sarcoidosis OT - Diagnosis OT - Epidemiology OT - Immunosuppression OT - Management OT - Multidisciplinary OT - Screening EDAT- 2024/06/26 18:42 MHDA- 2024/08/09 18:42 CRDT- 2024/06/26 12:58 PHST- 2024/03/20 00:00 [received] PHST- 2024/05/01 00:00 [revised] PHST- 2024/05/21 00:00 [accepted] PHST- 2024/08/09 18:42 [medline] PHST- 2024/06/26 18:42 [pubmed] PHST- 2024/06/26 12:58 [entrez] AID - 7699727 [pii] AID - 10.1093/eurheartj/ehae356 [doi] PST - ppublish SO - Eur Heart J. 2024 Aug 9;45(30):2697-2726. doi: 10.1093/eurheartj/ehae356. PMID- 38919180 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250702 IS - 0970-9134 (Print) IS - 0973-7723 (Electronic) IS - 0970-9134 (Linking) VI - 40 IP - 4 DP - 2024 Jul TI - Outcomes of emergency surgical intervention for complications in the cardiac catheterization laboratory. PG - 444-450 LID - 10.1007/s12055-024-01722-9 [doi] AB - BACKGROUND: In today's era, cardiac catheterization procedures are becoming increasingly safe, but they are still fraught with complications. We aimed to study the outcomes of patients who underwent emergency surgical intervention for complications in the cardiac catheterization laboratory. METHODS: A retrospective analysis of patients who required emergency surgical management following a complication in the cardiac catheterization laboratory in our institute from July 2017 to July 2022 was done. RESULT: A total of 57 patients out of a total of 52,326 patients (0.1%) were included. The average age of presentation was 10.4 years. Congenital heart disease (CHD) constituted the majority of the cases (28/57-49.1%), coronary artery disease (CAD) constituted 19.3% (11/57), and rheumatic heart disease (RHD) constituted 8.8% (5/57) of the cases. Apart from this, 22.80% patients (13/57) were grouped together in the miscellaneous group. In total, 76.9% (10/13) of these patients had pericardial effusion and they developed a right ventricular (RV) rent following an attempted pigtail drainage. Also, one patient each had a RV rent following an attempted permanent pacemaker implantation for heart block and an endocardial biopsy respectively. One patient had a left bronchial rupture following thoracic endovascular aortic repair (TEVAR) for descending thoracic aorta (DTA) aneurysm. Thirty-day mortality was 7% (4/57), and the mean time of shifting the patients from the catheterization laboratory to the operating room was 8.3 h. CONCLUSION: Cardiac catheterization procedures have become increasingly safe, but complications can still occur, for which the cardiac surgeon should be briefed in a Heart Team meeting before taking up such cases. Even though these complications form a small percentage, the cardiologist should exercise some caution in attempting cases which could have a relatively easier surgical correction. CI - (c) Indian Association of Cardiovascular-Thoracic Surgeons 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. FAU - Mishra, Anand Kumar AU - Mishra AK AD - Department of Cardiothoracic and Vascular Surgery, Post Graduate Institute of Medical Education and Research, Chandigarh, India. ROR: https://ror.org/009nfym65. GRID: grid.415131.3. ISNI: 0000 0004 1767 2903 FAU - Bansal, Vidur AU - Bansal V AUID- ORCID: 0000-0001-9635-0977 AD - Department of Cardiothoracic and Vascular Surgery, Post Graduate Institute of Medical Education and Research, Chandigarh, India. ROR: https://ror.org/009nfym65. GRID: grid.415131.3. ISNI: 0000 0004 1767 2903 FAU - Kumar, Rohit Manoj AU - Kumar RM AD - Department of Cardiology, Post Graduate Institute of Medical Education and Research, Chandigarh, India. ROR: https://ror.org/009nfym65. GRID: grid.415131.3. ISNI: 0000 0004 1767 2903 FAU - Kumar, Nitish AU - Kumar N AD - Department of Cardiothoracic and Vascular Surgery, Post Graduate Institute of Medical Education and Research, Chandigarh, India. ROR: https://ror.org/009nfym65. GRID: grid.415131.3. ISNI: 0000 0004 1767 2903 FAU - Patel, Nishit AU - Patel N AD - Department of Cardiothoracic and Vascular Surgery, Post Graduate Institute of Medical Education and Research, Chandigarh, India. ROR: https://ror.org/009nfym65. GRID: grid.415131.3. ISNI: 0000 0004 1767 2903 FAU - Mittal, Apeksha AU - Mittal A AD - Department of Cardiothoracic and Vascular Surgery, Post Graduate Institute of Medical Education and Research, Chandigarh, India. ROR: https://ror.org/009nfym65. GRID: grid.415131.3. ISNI: 0000 0004 1767 2903 LA - eng PT - Journal Article DEP - 20240319 PL - India TA - Indian J Thorac Cardiovasc Surg JT - Indian journal of thoracic and cardiovascular surgery JID - 8700105 PMC - PMC11194233 OTO - NOTNLM OT - Catheterization OT - Complications OT - Emergency OT - Rupture OT - Surgery COIS- Conflict of interestNone. EDAT- 2024/06/26 06:42 MHDA- 2024/06/26 06:43 PMCR- 2025/07/01 CRDT- 2024/06/26 04:03 PHST- 2023/12/07 00:00 [received] PHST- 2024/03/05 00:00 [revised] PHST- 2024/03/06 00:00 [accepted] PHST- 2024/06/26 06:43 [medline] PHST- 2024/06/26 06:42 [pubmed] PHST- 2024/06/26 04:03 [entrez] PHST- 2025/07/01 00:00 [pmc-release] AID - 1722 [pii] AID - 10.1007/s12055-024-01722-9 [doi] PST - ppublish SO - Indian J Thorac Cardiovasc Surg. 2024 Jul;40(4):444-450. doi: 10.1007/s12055-024-01722-9. Epub 2024 Mar 19. PMID- 38916201 OWN - NLM STAT- MEDLINE DCOM- 20240903 LR - 20260310 IS - 1558-2035 (Electronic) IS - 1558-2027 (Print) IS - 1558-2027 (Linking) VI - 25 IP - 10 DP - 2024 Oct 1 TI - The 2023 new European guidelines on infective endocarditis: main novelties and implications for clinical practice. PG - 718-726 LID - 10.2459/JCM.0000000000001651 [doi] AB - The 2023 European Society of Cardiology (ESC) guidelines for the management of infective endocarditis update the previous 2015 guidelines with main novelties in five areas: (1) antibiotic prevention for high-risk patients, and prevention measures for intermediate-risk and high-risk patients; (2) diagnosis with emphasis on multimodality imaging to assess cardiac lesions of infective endocarditis' (3) antibiotic therapy allowing an outpatient antibiotic treatment for stabilized, uncomplicated cases; (4) cardiac surgery with an emphasis on early intervention without delay for complicated cases; and (5) shared management decision by the endocarditis team. Most evidence came from observational studies and expert opinions. The guidelines strongly support a patient-centred approach with a shared decision process by a multidisciplinary team that should be implemented either in tertiary referral centres, becoming heart valve centres, and referral centres. A continuous sharing of data is warranted in the hospitals' network between heart valve centres, which are used for referrals for complicated cases of infective endocarditis, and referral centres, which should be able to manage uncomplicated cases of infective endocarditis. CI - Copyright (c) 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the Italian Federation of Cardiology. FAU - Imazio, Massimo AU - Imazio M AD - Department of Medicine (DMED), University of Udine. AD - Cardiothoracic Department, University Hospital Santa Maria della Misericordia, ASUFC, Udine, Italy. LA - eng PT - Journal Article PT - Review DEP - 20240719 PL - United States TA - J Cardiovasc Med (Hagerstown) JT - Journal of cardiovascular medicine (Hagerstown, Md.) JID - 101259752 RN - 0 (Anti-Bacterial Agents) SB - IM MH - Humans MH - *Anti-Bacterial Agents/therapeutic use MH - Antibiotic Prophylaxis/standards MH - Cardiac Surgical Procedures/standards MH - Cardiology/standards MH - Decision Making, Shared MH - *Endocarditis/diagnosis/microbiology/therapy MH - Europe MH - *Practice Guidelines as Topic MH - Risk Factors PMC - PMC11365601 COIS- There are no conflicts of interest. EDAT- 2024/06/25 12:42 MHDA- 2024/09/03 12:42 PMCR- 2024/08/31 CRDT- 2024/06/25 08:02 PHST- 2024/09/03 12:42 [medline] PHST- 2024/06/25 12:42 [pubmed] PHST- 2024/06/25 08:02 [entrez] PHST- 2024/08/31 00:00 [pmc-release] AID - 01244665-202410000-00002 [pii] AID - JCM-D-24-00208 [pii] AID - 10.2459/JCM.0000000000001651 [doi] PST - ppublish SO - J Cardiovasc Med (Hagerstown). 2024 Oct 1;25(10):718-726. doi: 10.2459/JCM.0000000000001651. Epub 2024 Jul 19. PMID- 38913163 OWN - NLM STAT- MEDLINE DCOM- 20250424 LR - 20250527 IS - 1432-1971 (Electronic) IS - 0172-0643 (Linking) VI - 46 IP - 5 DP - 2025 Jun TI - Structured Tube Weaning Using the Hunger Provocation Method in Infants with Single Ventricle Heart Defects: A Multicenter Study. PG - 1372-1380 LID - 10.1007/s00246-024-03558-x [doi] AB - Despite improvement in hemodynamics, children with single ventricle heart disease remain on feeding tubes long after stage 2 palliation (S2P). Use of a hunger provocation method in a multidisciplinary team setting has been successful at weaning these children from feeding tubes. The objective of this study is to describe patient characteristics and outcomes in the single ventricle population who underwent a formal tube weaning process using a standardized hunger provocation method. Single ventricle patients after S2P from six centers were included. Patient data collected included baseline demographics, swallow evaluation results, and feeding characteristics such as percent oral intake at the start of tube wean. Tube wean data included tube weaning process and duration, interruptions to the tube wean, adverse events, and weights before, during, and after the tube wean. 94% (60 of 64) of patients achieved oral independence. The median time to tube wean was 12.5 days. 62% of patients had transient weight loss during the tube wean. 61% of the cohort was taking less than 10% goal volumes by mouth with 90% of those patients successfully tube weaned. All patients with history of aspiration were successfully tube weaned. 75% of successfully weaned patients were above baseline weight at 1-month post-tube wean. The most common cause of tube wean interruption was contraction of a viral illness. Use of a standardized tube weaning process via hunger provocation method is both feasible and safe in the single ventricle population, resulting in successful feeding tube removal in a timely manner with minimal adverse effects. CI - (c) 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Wong, Joshua AU - Wong J AD - Division of Pediatric Cardiology, Advocate Children's Hospital, Chicago, IL, USA. Joshua.wong@aah.org. FAU - Loomba, Rohit AU - Loomba R AD - Division of Pediatric Cardiology, Advocate Children's Hospital, Chicago, IL, USA. FAU - Allen, Kiona Y AU - Allen KY AD - Division of Cardiac Critical Care, Department of Pediatrics, Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. FAU - Chan, Titus AU - Chan T AD - Division of Pediatric Cardiac Critical Care and the Heart Center, Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle, WA, USA. FAU - Coolidge, Nicole AU - Coolidge N AD - Pediatric Cardiology, Children's Healthcare of Atlanta, Atlanta, GA, USA. FAU - Del Grippo, Erica AU - Del Grippo E AD - Division of Pediatric Cardiology, Nemours Children's Hospital, Delaware, Wilmington, DE, USA. FAU - Horsley, Megan AU - Horsley M AD - Division of Nutrition Therapy, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. FAU - Slater, Nancy AU - Slater N AD - Division of Physical Medicine and Rehabilitation Services, Children's Minnesota, Minneapolis, MN, USA. FAU - Spader-Cloud, Michelle AU - Spader-Cloud M AD - , Columbus, OH, USA. FAU - Steltzer, Michelle AU - Steltzer M AD - Pediatric Cardiology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA. FAU - Marcuccio, Elisa AU - Marcuccio E AD - Heart Institute, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20240624 PL - United States TA - Pediatr Cardiol JT - Pediatric cardiology JID - 8003849 SB - IM MH - Humans MH - Male MH - Female MH - Infant MH - *Enteral Nutrition/methods MH - *Heart Ventricles/abnormalities MH - Infant, Newborn MH - *Hunger MH - Retrospective Studies MH - *Heart Defects, Congenital/surgery MH - Palliative Care/methods MH - *Univentricular Heart OTO - NOTNLM OT - Congenital heart disease OT - Single ventricle heart disease OT - Tube feeding OT - Tube weaning COIS- Declarations. Conflict of interest: The authors have no relevant financial or non-financial interests to disclose. EDAT- 2024/06/24 12:41 MHDA- 2025/04/24 12:30 CRDT- 2024/06/24 11:13 PHST- 2024/05/07 00:00 [received] PHST- 2024/06/18 00:00 [accepted] PHST- 2025/04/24 12:30 [medline] PHST- 2024/06/24 12:41 [pubmed] PHST- 2024/06/24 11:13 [entrez] AID - 10.1007/s00246-024-03558-x [pii] AID - 10.1007/s00246-024-03558-x [doi] PST - ppublish SO - Pediatr Cardiol. 2025 Jun;46(5):1372-1380. doi: 10.1007/s00246-024-03558-x. Epub 2024 Jun 24. PMID- 38912908 OWN - NLM STAT- MEDLINE DCOM- 20250610 LR - 20250916 IS - 1550-5049 (Electronic) IS - 0889-4655 (Print) IS - 0889-4655 (Linking) VI - 40 IP - 4 DP - 2025 Jul-Aug 01 TI - The Nurses' Role in the Cardiac Rehabilitation Team: Data From the Perfect-CR Study. PG - 386-394 LID - 10.1097/JCN.0000000000001113 [doi] AB - BACKGROUND: Nurses constitute a central profession in the cardiac rehabilitation (CR) team delivering comprehensive CR to individuals with cardiovascular disease. We aimed to identify specific components reflecting the nurses' role in the CR team associated with attainment of risk factor targets post myocardial infarction. METHODS: Center-level data (n = 78) was used from the Perfect-CR study, in which structure and processes applied at CR centers in Sweden (including details on the nurses' role) were surveyed. Patient-level data (n = 6755) was retrieved from the SWEDEHEART registry. Associations between structure/processes and target achievement for systolic blood pressure (BP) (<140 mm Hg) and low-density lipoprotein cholesterol (LDL-C, <1.8 mmol/L) at 1 year post myocardial infarction were assessed using logistic regression. RESULTS: Structure and processes reflecting nurses' autonomy and role in the CR team associated with patients achieving systolic BP and/or LDL-C targets included the following: nurses having treatment algorithms to adjust BP medication (odds ratio [95% confidence interval]: systolic BP, 1.22 [1.05-1.42]; LDL-C, 1.17 [1.03-1.34]) and lipid-lowering medication (systolic BP, 1.14 [1.00-1.29]; LDL-C, 1.17 [1.05-1.30]), patients having the same nurse throughout follow-up (systolic BP, 1.07 [1.03-1.11]; LDL-C, 1.10 [1.06-1.14]), number of follow-up hours with a nurse (systolic BP, 1.13 [1.07-1.19]), having regular case rounds to discuss patient cases during follow-up (LDL-C, 1.22 [1.09-1.35]), and nurses having training in counseling methods (systolic BP, 1.06 [1.03-1.10]). CONCLUSION: Components reflecting CR nurses' autonomy and role in the team are of importance for patients attaining risk factor targets post myocardial infarction. The results could provide guidance for optimizing nurses' competence and responsibilities within the CR team to improve patient care. CI - Copyright (c) 2024 The Authors. Published by Wolters Kluwer Health, Inc. FAU - Lidin, Matthias AU - Lidin M FAU - Michelsen, Halldora Ogmundsdottir AU - Michelsen HO FAU - Hag, Emma AU - Hag E FAU - Stomby, Andreas AU - Stomby A FAU - Schlyter, Mona AU - Schlyter M FAU - Back, Maria AU - Back M FAU - Hagstrom, Emil AU - Hagstrom E FAU - Leosdottir, Margret AU - Leosdottir M LA - eng PT - Journal Article PT - Observational Study DEP - 20240625 PL - United States TA - J Cardiovasc Nurs JT - The Journal of cardiovascular nursing JID - 8703516 RN - 0 (Cholesterol, LDL) SB - IM MH - Humans MH - Female MH - Male MH - *Nurse's Role MH - Middle Aged MH - *Myocardial Infarction/rehabilitation/nursing MH - Sweden MH - Aged MH - *Patient Care Team/organization & administration MH - *Cardiac Rehabilitation/nursing MH - Cholesterol, LDL/blood PMC - PMC12147747 OTO - NOTNLM OT - cardiac rehabilitation OT - data registry OT - myocardial infarction OT - nurses OT - risk factors OT - secondary prevention COIS- The authors have no funding or conflicts of interest to disclose. EDAT- 2024/06/24 12:41 MHDA- 2025/06/10 18:28 PMCR- 2025/06/09 CRDT- 2024/06/24 09:43 PHST- 2025/06/10 18:28 [medline] PHST- 2024/06/24 12:41 [pubmed] PHST- 2024/06/24 09:43 [entrez] PHST- 2025/06/09 00:00 [pmc-release] AID - 00005082-990000000-00201 [pii] AID - JCN_240329 [pii] AID - 10.1097/JCN.0000000000001113 [doi] PST - ppublish SO - J Cardiovasc Nurs. 2025 Jul-Aug 01;40(4):386-394. doi: 10.1097/JCN.0000000000001113. Epub 2024 Jun 25. PMID- 38910790 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240625 IS - 0899-8280 (Print) IS - 1525-3252 (Electronic) IS - 0899-8280 (Linking) VI - 37 IP - 4 DP - 2024 TI - Superlative performance in cardiovascular surgery. PG - 673-678 LID - 10.1080/08998280.2024.2348369 [doi] AB - Achieving excellence in surgery is an ongoing endeavor, gained through experience, observation, and practice. It is difficult to evaluate enterprise excellence, but attempts include the ratings of the Society of Thoracic Surgeons. The surgery team at Baylor University Medical Center has achieved three-star ratings for 9 of the past 10 evaluations for coronary artery bypass. This accomplishment is a result of many factors, including teamwork, multidisciplinary conferences, application of the latest evidence, continuous efforts at quality improvement, and effective governance. Some aspects of the latter include individual excellence, enjoying the work, being bold, having psychological safety, and employing meritocracy. Discernment of contemporary issues, a clear vision of the common good, and virtuous service to all must be attained while preserving the highest level of patient-centered service to patients and the institution. CI - Copyright (c) 2024 Baylor University Medical Center. FAU - Hamman, Baron AU - Hamman B AUID- ORCID: 0000-0002-4195-1246 AD - Department of Thoracic Surgery, Baylor University Medical Center, Dallas, Texas, USA. AD - Baylor Scott & White Heart and Vascular Hospital, Dallas, Texas, USA. AD - Baylor Scott & White Medical Center - Irving, Irving, Texas, USA. LA - eng PT - Journal Article DEP - 20240516 PL - United States TA - Proc (Bayl Univ Med Cent) JT - Proceedings (Baylor University. Medical Center) JID - 9302033 PMC - PMC11188807 OTO - NOTNLM OT - Cardiovascular surgery OT - leadership OT - outcomes OT - quality improvement OT - teamwork EDAT- 2024/06/24 06:41 MHDA- 2024/06/24 06:42 PMCR- 2024/05/16 CRDT- 2024/06/24 05:15 PHST- 2024/06/24 06:42 [medline] PHST- 2024/06/24 06:41 [pubmed] PHST- 2024/06/24 05:15 [entrez] PHST- 2024/05/16 00:00 [pmc-release] AID - 2348369 [pii] AID - 10.1080/08998280.2024.2348369 [doi] PST - epublish SO - Proc (Bayl Univ Med Cent). 2024 May 16;37(4):673-678. doi: 10.1080/08998280.2024.2348369. eCollection 2024. PMID- 38910113 OWN - NLM STAT- MEDLINE DCOM- 20240623 LR - 20240623 IS - 1476-4954 (Electronic) IS - 1476-4954 (Linking) VI - 37 IP - 1 DP - 2024 Dec TI - Reach and effectiveness of a non-university cardio-obstetrics program. PG - 2367090 LID - 10.1080/14767058.2024.2367090 [doi] AB - BACKGROUND: Current guidelines recommend multidisciplinary cardiovascular obstetric programs (CVOB) to manage complex pregnant patients with cardiovascular disease. Minimal evaluation of these programs exists, with most of these programs offered at university-based centers. METHODS: A cohort of 113 patients managed by a CVOB team at a non-university health system (2018-2019) were compared to 338 patients seen by cardiology prior to the program (2016-2017). CVOB patients were matched with comparison patients (controls) on modified World Health Organization (mWHO) category classification, yielding a cohort of 102 CVOB and 102 controls. RESULTS: CVOB patients were more ethnically diverse and cardiovascular risk was higher compared to controls based on mWHO >/= II-III (57% vs 17%) and. After matching, CVOB patients had more cardiology tests during pregnancy (median of 8 tests vs 5, p < .001) and were more likely to receive telemetry care (32% vs 19%, p = .025). The median number of perinatology visits was significantly higher in the CVOB group (8 vs 2, p < .001). Length of stay was a half day longer for vaginal delivery patients in the CVOB group (median 2.66 vs 2.13, p = .006). CONCLUSION: Implementation of a CVOB program resulted in a more diverse patient population than previously referred to cardiology. The CVOB program participants also experienced a higher level of care in terms of increased cardiovascular testing, monitoring, care from specialists, and appropriate use of medications during pregnancy. FAU - Saxena, Retu AU - Saxena R AD - Minneapolis Heart Institute Foundation, Minneapolis, MN, USA. AD - Minneapolis Heart Institute, Minneapolis, MN, USA. FAU - Benson, Gretchen AU - Benson G AD - Minneapolis Heart Institute Foundation, Minneapolis, MN, USA. FAU - Sidebottom, Abbey C AU - Sidebottom AC AD - Care Delivery Research, Allina Health, Minneapolis, MN, USA. FAU - Okeson, Brynn AU - Okeson B AD - Minneapolis Heart Institute Foundation, Minneapolis, MN, USA. FAU - Hayes, Joy AU - Hayes J AD - Minneapolis Heart Institute Foundation, Minneapolis, MN, USA. FAU - Shaw, Kirsten AU - Shaw K AD - Minneapolis Heart Institute Foundation, Minneapolis, MN, USA. FAU - Jordan-Baechler, Courtney AU - Jordan-Baechler C AD - Minneapolis Heart Institute Foundation, Minneapolis, MN, USA. FAU - Wagner, William AU - Wagner W AD - Minnesota Perinatal Physicians, Allina Health, Minneapolis, MN, USA. LA - eng PT - Journal Article DEP - 20240623 PL - England TA - J Matern Fetal Neonatal Med JT - The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians JID - 101136916 SB - IM MH - Humans MH - Female MH - Pregnancy MH - Adult MH - *Pregnancy Complications, Cardiovascular/therapy/epidemiology MH - Program Evaluation MH - Case-Control Studies MH - Obstetrics/statistics & numerical data/methods MH - Retrospective Studies MH - Cardiovascular Diseases/therapy/epidemiology MH - Cardiology MH - Patient Care Team/organization & administration OTO - NOTNLM OT - Cardio-obstetrics OT - cardiology OT - cardiovascular risk OT - maternal fetal medicine OT - maternal morbidity OT - multidisciplinary coordinated care EDAT- 2024/06/24 00:42 MHDA- 2024/06/24 00:43 CRDT- 2024/06/23 22:32 PHST- 2024/06/24 00:43 [medline] PHST- 2024/06/24 00:42 [pubmed] PHST- 2024/06/23 22:32 [entrez] AID - 10.1080/14767058.2024.2367090 [doi] PST - ppublish SO - J Matern Fetal Neonatal Med. 2024 Dec;37(1):2367090. doi: 10.1080/14767058.2024.2367090. Epub 2024 Jun 23. PMID- 38904778 OWN - NLM STAT- MEDLINE DCOM- 20241031 LR - 20260822 IS - 1619-7089 (Electronic) IS - 1619-7070 (Print) IS - 1619-7070 (Linking) VI - 51 IP - 13 DP - 2024 Nov TI - Using machine learning to improve the diagnostic accuracy of the modified Duke/ESC 2015 criteria in patients with suspected prosthetic valve endocarditis - a proof of concept study. PG - 3924-3933 LID - 10.1007/s00259-024-06774-y [doi] AB - INTRODUCTION: Prosthetic valve endocarditis (PVE) is a serious complication of prosthetic valve implantation, with an estimated yearly incidence of at least 0.4-1.0%. The Duke criteria and subsequent modifications have been developed as a diagnostic framework for infective endocarditis (IE) in clinical studies. However, their sensitivity and specificity are limited, especially for PVE. Furthermore, their most recent versions (ESC2015 and ESC2023) include advanced imaging modalities, e.g., cardiac CTA and [(18)F]FDG PET/CT as major criteria. However, despite these significant changes, the weighing system using major and minor criteria has remained unchanged. This may have introduced bias to the diagnostic set of criteria. Here, we aimed to evaluate and improve the predictive value of the modified Duke/ESC 2015 (MDE2015) criteria by using machine learning algorithms. METHODS: In this proof-of-concept study, we used data of a well-defined retrospective multicentre cohort of 160 patients evaluated for suspected PVE. Four machine learning algorithms were compared to the prediction of the diagnosis according to the MDE2015 criteria: Lasso logistic regression, decision tree with gradient boosting (XGBoost), decision tree without gradient boosting, and a model combining predictions of these (ensemble learning). All models used the same features that also constitute the MDE2015 criteria. The final diagnosis of PVE, based on endocarditis team consensus using all available clinical information, including surgical findings whenever performed, and with at least 1 year follow up, was used as the composite gold standard. RESULTS: The diagnostic performance of the MDE2015 criteria varied depending on how the category of 'possible' PVE cases were handled. Considering these cases as positive for PVE, sensitivity and specificity were 0.96 and 0.60, respectively. Whereas treating these cases as negative, sensitivity and specificity were 0.74 and 0.98, respectively. Combining the approaches of considering possible endocarditis as positive and as negative for ROC-analysis resulted in an excellent AUC of 0.917. For the machine learning models, the sensitivity and specificity were as follows: logistic regression, 0.92 and 0.85; XGBoost, 0.90 and 0.85; decision trees, 0.88 and 0.86; and ensemble learning, 0.91 and 0.85, respectively. The resulting AUCs were, in the same order: 0.938, 0.937, 0.930, and 0.941, respectively. DISCUSSION: In this proof-of-concept study, machine learning algorithms achieved improved diagnostic performance compared to the major/minor weighing system as used in the MDE2015 criteria. Moreover, these models provide quantifiable certainty levels of the diagnosis, potentially enhancing interpretability for clinicians. Additionally, they allow for easy incorporation of new and/or refined criteria, such as the individual weight of advanced imaging modalities such as CTA or [(18)F]FDG PET/CT. These promising preliminary findings warrant further studies for validation, ideally in a prospective cohort encompassing the full spectrum of patients with suspected IE. CI - (c) 2024. The Author(s). FAU - Ten Hove, D AU - Ten Hove D AUID- ORCID: 0000-0002-0717-6530 AD - Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Medical Microbiology & Infection Prevention, Hanzeplein 1, Groningen, 9713 GZ, The Netherlands. d.ten.hove@umcg.nl. AD - Department of Medical Microbiology and Infection Prevention, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. d.ten.hove@umcg.nl. FAU - Slart, R H J A AU - Slart RHJA AD - Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Medical Microbiology & Infection Prevention, Hanzeplein 1, Groningen, 9713 GZ, The Netherlands. AD - Biomedical Photonic Imaging group, Faculty of Science and Technology, University of Twente, Enschede, The Netherlands. FAU - Glaudemans, A W J M AU - Glaudemans AWJM AD - Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Medical Microbiology & Infection Prevention, Hanzeplein 1, Groningen, 9713 GZ, The Netherlands. FAU - Postma, D F AU - Postma DF AD - Department of Internal Medicine and Infectious Diseases, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. FAU - Gomes, A AU - Gomes A AD - Department of Medical Microbiology and Infection Prevention, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. FAU - Swart, L E AU - Swart LE AD - Department of Cardiology, Spaarne Gasthuis, Haarlem, The Netherlands. FAU - Tanis, W AU - Tanis W AD - Department of Cardiology, HagaZiekenhuis, The Hague, The Netherlands. FAU - Geel, P P van AU - Geel PPV AD - Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. FAU - Mecozzi, G AU - Mecozzi G AD - Department of Cardiothoracic Surgery, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. FAU - Budde, R P J AU - Budde RPJ AD - Department of Radiology and Nuclear Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands. FAU - Mouridsen, K AU - Mouridsen K AD - Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Medical Microbiology & Infection Prevention, Hanzeplein 1, Groningen, 9713 GZ, The Netherlands. AD - Department of Clinical Medicine, Center of Functionally Integrative Neuroscience, Aarhus University, Aarhus, Denmark. FAU - Sinha, B AU - Sinha B AUID- ORCID: 0000-0003-1634-0010 AD - Department of Medical Microbiology and Infection Prevention, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. LA - eng GR - C00227574- 15/PUSH MRA/ PT - Journal Article DEP - 20240621 PL - Germany TA - Eur J Nucl Med Mol Imaging JT - European journal of nuclear medicine and molecular imaging JID - 101140988 SB - IM MH - Humans MH - *Machine Learning MH - *Endocarditis/diagnostic imaging MH - Female MH - *Heart Valve Prosthesis/adverse effects MH - Male MH - Middle Aged MH - Proof of Concept Study MH - Prosthesis-Related Infections/diagnostic imaging MH - Positron Emission Tomography Computed Tomography MH - Retrospective Studies MH - Aged PMC - PMC11527948 OTO - NOTNLM OT - Endocarditis OT - Machine learning OT - Modified Duke/ESC 2015 criteria COIS- DtH, AG, RS, and BS report the aforementioned institutional funding through PUSH. Additionally, BS reports grants from Beatrixoord Foundation, grants from the European Union, outside the submitted work, as well as Committee work (executive boards and working parties) on a local, national, and international level dealing with guideline development of infections. RS is an editor in this journal. RB reports institutional support to Erasmus MC from Heartflow and Siemens, outside the submitted work and speakers fees from Bayer. EDAT- 2024/06/21 12:42 MHDA- 2024/11/04 07:23 PMCR- 2024/06/21 CRDT- 2024/06/21 11:14 PHST- 2023/11/14 00:00 [received] PHST- 2024/05/17 00:00 [accepted] PHST- 2024/11/04 07:23 [medline] PHST- 2024/06/21 12:42 [pubmed] PHST- 2024/06/21 11:14 [entrez] PHST- 2024/06/21 00:00 [pmc-release] AID - 10.1007/s00259-024-06774-y [pii] AID - 6774 [pii] AID - 10.1007/s00259-024-06774-y [doi] PST - ppublish SO - Eur J Nucl Med Mol Imaging. 2024 Nov;51(13):3924-3933. doi: 10.1007/s00259-024-06774-y. Epub 2024 Jun 21. PMID- 38904244 OWN - NLM STAT- MEDLINE DCOM- 20240702 LR - 20260703 IS - 2047-9980 (Electronic) IS - 2047-9980 (Linking) VI - 13 IP - 13 DP - 2024 Jul 2 TI - Gender and Sex Differences in the Management, Intervention, and Outcomes of Patients With Severe Primary Mitral Regurgitation. PG - e033635 LID - 10.1161/JAHA.123.033635 [doi] LID - e033635 AB - BACKGROUND: Gender- and sex-based disparities in mitral valve disease exist; however the factors associated with these differences are unknown. Identifying these differences is essential in devising mitigating strategies. We evaluated gender and sex differences among patients with severe primary mitral regurgitation (MR) across treatment phases. METHODS AND RESULTS: We conducted a retrospective cohort study of patients with new diagnoses of severe primary MR between 2016 and 2020. We compared multidisciplinary evaluation incidence and 2-year survival between men and women. We analyzed a subgroup meeting class 1 indications for intervention, which includes severe symptomatic MR or severe asymptomatic MR with ejection fraction <60% or left ventricular end-systolic diameter >40 mm. Logistic regression models identified predictors associated with the likelihood of multidisciplinary evaluation. Among 330 patients meeting class 1 indications, women were older (79 versus 76 years, P=0.01) and had higher Society of Thoracic Surgeons risk scores for mitral valve repair than men (2.5% versus 1.4%, P=0.003). Women were less likely to undergo multidisciplinary evaluation (57% versus 84%, P<0.001) and intervention (47% versus 69%, P<0.001) than men. Median days to intervention for women and men were 77 and 43, respectively. Women had a higher 2-year mortality rate than men (31% versus 21%, P=0.035). On a multivariable model, female sex and older age were associated with lower odds of undergoing multidisciplinary evaluation (odds ratio, 0.26; P<0.001; odds ratio, 0.95; P<0.001, respectively). CONCLUSIONS: Women with severe primary MR with class 1 indication for intervention were less likely to undergo multidisciplinary evaluation and intervention and had a longer interval to intervention than men. Survival was comparable after accounting for age and comorbidity differences. FAU - Waldron, Christina AU - Waldron C AUID- ORCID: 0000-0003-0286-6599 AD - Division of Cardiac Surgery Yale University School of Medicine New Haven CT USA. FAU - Hundito, Addiskidan AU - Hundito A AUID- ORCID: 0009-0003-1429-8274 AD - Division of Cardiac Surgery Yale University School of Medicine New Haven CT USA. FAU - Krane, Markus AU - Krane M AD - Division of Cardiac Surgery Yale University School of Medicine New Haven CT USA. AD - Department of Cardiovascular Surgery, Institute Insure, German Heart Center Munich Technical University of Munich Munich Germany. FAU - Geirsson, Arnar AU - Geirsson A AUID- ORCID: 0000-0002-8943-9962 AD - Division of Cardiac Surgery Yale University School of Medicine New Haven CT USA. FAU - Mori, Makoto AU - Mori M AUID- ORCID: 0000-0002-2367-8354 AD - Division of Cardiac Surgery Yale University School of Medicine New Haven CT USA. AD - Center for Outcomes Research and Evaluation Yale New Haven Hospital New Haven CT USA. LA - eng GR - UL1 TR001863/TR/NCATS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20240621 PL - England TA - J Am Heart Assoc JT - Journal of the American Heart Association JID - 101580524 SB - IM MH - Humans MH - *Mitral Valve Insufficiency/mortality/physiopathology/epidemiology MH - Female MH - Male MH - Aged MH - Retrospective Studies MH - Sex Factors MH - *Severity of Illness Index MH - Aged, 80 and over MH - Treatment Outcome MH - Mitral Valve/diagnostic imaging/physiopathology/surgery MH - Risk Factors MH - Middle Aged MH - Stroke Volume/physiology PMC - PMC11255693 OTO - NOTNLM OT - mitral regurgitation OT - mitral valve OT - mitral valve repair OT - sex differences EDAT- 2024/06/21 12:42 MHDA- 2024/07/02 14:44 PMCR- 2024/07/02 CRDT- 2024/06/21 06:53 PHST- 2024/07/02 14:44 [medline] PHST- 2024/06/21 12:42 [pubmed] PHST- 2024/06/21 06:53 [entrez] PHST- 2024/07/02 00:00 [pmc-release] AID - JAH39805 [pii] AID - 10.1161/JAHA.123.033635 [doi] PST - ppublish SO - J Am Heart Assoc. 2024 Jul 2;13(13):e033635. doi: 10.1161/JAHA.123.033635. Epub 2024 Jun 21. PMID- 38900060 OWN - NLM STAT- MEDLINE DCOM- 20240916 LR - 20260817 IS - 1532-0987 (Electronic) IS - 0891-3668 (Linking) VI - 43 IP - 10 DP - 2024 Oct 1 TI - One- and Two-year Multidisciplinary Follow-Up of MIS-C at a Tertiary Hospital: A Retrospective Cohort Study. PG - 980-986 LID - 10.1097/INF.0000000000004430 [doi] AB - BACKGROUND: Although 6-month follow-up of patients with multisystem inflammatory syndrome in children (MIS-C) was reassuring, there is scant data on long-term sequelae, including whether changing variants affect clinical severity and outcomes. METHODS: Children (<18 years of age) admitted to Great Ormond Street Hospital between April 4, 2020, and January 2023, meeting diagnostic criteria for MIS-C were included. Admission and follow-up data were categorized by the predominant SARS-CoV-2 circulating variant in the United Kingdom. RESULTS: One hundred and sixty children [median age, 10.1 (interquartile range, 7.9-12.6) years] were included. There was no difference in the time of symptom onset to diagnosis between waves ( P =0.23) or hospitalization days across all waves ( P =0.32). Inflammatory markers were normal for up to 2 years in all patients except one. Eleven patients (6.9%) remain in follow-up: cardiology (n=5), gastroenterology (n=5) and nephrology (n=1). The main self-reported symptoms at 2 years were abdominal pain (n=5) and myalgia (n=2). Fatigue was present in approximately a quarter of patients at admission; this reduced to 14 (9%), (2%) and 1 (2%) at 6-month, 1-year and 2-year follow-ups, respectively. Chronic fatigue or long-COVID symptomatology was rare (n=1) even with high rates of concurrent Epstein-Barr virus positivity (49/134). All patients had sustained neurological recovery with no new neurological pathology observed. CONCLUSIONS: Patients with MIS-C have a sustained recovery, which is reassuring for positive long-term outcomes. Across waves, time from symptom onset to diagnosis and treatment, symptomatology and length of stay were similar. Sustained recovery is reassuring for clinicians and parents alike. Differentiating long-COVID symptomatology from that of MIS-C is important in formulating an individualized treatment plan. CI - Copyright (c) 2024 Wolters Kluwer Health, Inc. All rights reserved. FAU - Johnson, Sarah May AU - Johnson SM AD - From theDepartment of Paediatric Infectious Diseases, Great Ormond Street Hospital for Children, London, United Kingdom. FAU - Penner, Justin AU - Penner J AUID- ORCID: 0000-0002-7911-3272 AD - From theDepartment of Paediatric Infectious Diseases, Great Ormond Street Hospital for Children, London, United Kingdom. FAU - Issitt, Richard AU - Issitt R AD - Great Ormond Street Hospital and Great Ormond Street Institute of Child Health and NIHR GOSH Biomedical Research Centre, London, United Kingdom. AD - Institute of Cardiovascular Science, University College London, London, United Kingdom. FAU - Kmentt, Laura AU - Kmentt L AD - From theDepartment of Paediatric Infectious Diseases, Great Ormond Street Hospital for Children, London, United Kingdom. FAU - Grant, Karlie AU - Grant K AD - From theDepartment of Paediatric Infectious Diseases, Great Ormond Street Hospital for Children, London, United Kingdom. FAU - Pandey, Ashwin AU - Pandey A AD - From theDepartment of Paediatric Infectious Diseases, Great Ormond Street Hospital for Children, London, United Kingdom. FAU - Champsas, Dimitrios AU - Champsas D AD - Department of Paediatric Neurology, Great Ormond Street Hospital for Children, London, United Kingdom. FAU - Abdel-Mannan, Omar AU - Abdel-Mannan O AD - Department of Paediatric Neurology, Great Ormond Street Hospital for Children, London, United Kingdom. AD - Queen Square MS Centre, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, United Kingdom. FAU - Maillard, Sue AU - Maillard S AD - Department of Physiotherapy and Rehabilitation Services, Great Ormond Street Hospital for Children, London, United Kingdom. FAU - McKenzie, Kim AU - McKenzie K AD - Department of Physiotherapy and Rehabilitation Services, Great Ormond Street Hospital for Children, London, United Kingdom. FAU - Golding, Emily AU - Golding E AD - Psychology and Mental Health Services at Great Ormond Street Hospital for Children, London, United Kingdom. FAU - Kucera, Filip AU - Kucera F AD - Department of Paediatric Cardiology, Great Ormond Street Hospital for Children, London, United Kingdom. FAU - Hacohen, Yael AU - Hacohen Y AD - Department of Paediatric Neurology, Great Ormond Street Hospital for Children, London, United Kingdom. AD - Queen Square MS Centre, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, United Kingdom. FAU - Moshal, Karyn AU - Moshal K AD - From theDepartment of Paediatric Infectious Diseases, Great Ormond Street Hospital for Children, London, United Kingdom. AD - UCL Great Ormond Street Institute of Child Health, University College London, London, United Kingdom. LA - eng GR - FS/19/52/34563/BHF_/British Heart Foundation/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240619 PL - United States TA - Pediatr Infect Dis J JT - The Pediatric infectious disease journal JID - 8701858 RN - pediatric multisystem inflammatory disease, COVID-19 related SB - IM MH - Humans MH - *COVID-19/epidemiology/diagnosis/complications MH - Child MH - Male MH - Female MH - *Tertiary Care Centers/statistics & numerical data MH - Retrospective Studies MH - *Systemic Inflammatory Response Syndrome/diagnosis/epidemiology MH - Follow-Up Studies MH - *SARS-CoV-2 MH - United Kingdom/epidemiology MH - Adolescent MH - Hospitalization/statistics & numerical data COIS- The authors have no conflicts of interest to disclose. EDAT- 2024/06/20 12:42 MHDA- 2024/09/17 10:43 CRDT- 2024/06/20 10:23 PHST- 2024/09/17 10:43 [medline] PHST- 2024/06/20 12:42 [pubmed] PHST- 2024/06/20 10:23 [entrez] AID - 00006454-202410000-00012 [pii] AID - 10.1097/INF.0000000000004430 [doi] PST - ppublish SO - Pediatr Infect Dis J. 2024 Oct 1;43(10):980-986. doi: 10.1097/INF.0000000000004430. Epub 2024 Jun 19. PMID- 38898671 OWN - NLM STAT- MEDLINE DCOM- 20240902 LR - 20240911 IS - 1099-1050 (Electronic) IS - 1057-9230 (Linking) VI - 33 IP - 10 DP - 2024 Oct TI - Primary care payment models and avoidable hospitalizations in Ontario, Canada: A multivalued treatment effects analysis. PG - 2288-2305 LID - 10.1002/hec.4872 [doi] AB - Improving access to primary care physicians' services may help reduce hospitalizations due to Ambulatory Care Sensitive Conditions (ACSCs). Ontario, Canada's most populous province, introduced blended payment models for primary care physicians in the early- to mid-2000s to increase access to primary care, preventive care, and better chronic disease management. We study the impact of payment models on avoidable hospitalizations due to two incentivized ACSCs (diabetes and congestive heart failure) and two non-incentivized ACSCs (angina and asthma). The data for our study came from health administrative data on practicing primary care physicians in Ontario between 2006 and 2015. We employ a two-stage estimation strategy on a balanced panel of 3710 primary care physicians (1158 blended-fee-for-service (FFS), 1388 blended-capitation models, and 1164 interprofessional team-based practices). First, we account for the differences in physician practices using a generalized propensity score based on a multinomial logit regression model, corresponding to three primary care payment models. Second, we use fractional regression models to estimate the average treatment effects on the treated outcome (i.e., avoidable hospitalizations). The capitation-based model sometimes increases avoidable hospitalizations due to angina (by 7 per 100,000 patients) and congestive heart failure (40 per 100,000) relative to the blended-FFS-based model. Switching capitation physicians into interprofessional teams mitigates this effect, reducing avoidable hospitalizations from congestive heart failure by 30 per 100,000 patients and suggesting better access to primary care and chronic disease management in team-based practices. CI - (c) 2024 The Author(s). Health Economics published by John Wiley & Sons Ltd. FAU - Some, Nibene Habib AU - Some NH AUID- ORCID: 0000-0003-0382-2950 AD - Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada. AD - ICES, Toronto, Ontario, Canada. AD - Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, Toronto, Ontario, Canada. AD - Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada. AD - Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada. FAU - Devlin, Rose Anne AU - Devlin RA AUID- ORCID: 0000-0002-1386-4700 AD - Department of Economics, University of Ottawa, Ottawa, Ontario, Canada. FAU - Mehta, Nirav AU - Mehta N AD - Department of Economics, Western University, London, Ontario, Canada. FAU - Sarma, Sisira AU - Sarma S AUID- ORCID: 0000-0001-9174-765X AD - Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada. AD - ICES, Toronto, Ontario, Canada. LA - eng GR - PJI-184005/CIHR/Canada GR - Ontario Ministry of Health/ GR - Ministry of Long-Term Care/ GR - Schulich School of Medicine and Dentistry/ GR - Western University, and the Lawson Health Research Institute/ GR - PJT-191804/Canadian Institute of Health Information/ GR - PJI-184005/CIHR/Canada PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240619 PL - England TA - Health Econ JT - Health economics JID - 9306780 SB - IM MH - Humans MH - Ontario MH - *Primary Health Care/economics MH - *Hospitalization/economics/statistics & numerical data MH - Male MH - Female MH - *Heart Failure/therapy/economics MH - Middle Aged MH - *Fee-for-Service Plans/economics MH - Aged MH - Diabetes Mellitus/therapy MH - Capitation Fee MH - Asthma/therapy/economics MH - Physicians, Primary Care/economics MH - Angina Pectoris/therapy/economics OTO - NOTNLM OT - Canada OT - access to medical services OT - avoidable hospitalizations OT - blended remuneration OT - capitation OT - chronic disease management OT - fee-for-service OT - financial incentives OT - interprofessional team-based primary care OT - multivalued treatment effects EDAT- 2024/06/20 06:42 MHDA- 2024/09/02 08:45 CRDT- 2024/06/20 01:53 PHST- 2024/03/28 00:00 [revised] PHST- 2023/04/24 00:00 [received] PHST- 2024/04/30 00:00 [accepted] PHST- 2024/09/02 08:45 [medline] PHST- 2024/06/20 06:42 [pubmed] PHST- 2024/06/20 01:53 [entrez] AID - 10.1002/hec.4872 [doi] PST - ppublish SO - Health Econ. 2024 Oct;33(10):2288-2305. doi: 10.1002/hec.4872. Epub 2024 Jun 19. PMID- 20301704 STAT- Publisher DRDT- 20240620 CTDT- 20040720 PB - University of Washington, Seattle DP - 1993 TI - Treacher Collins Syndrome. BTI - GeneReviews((R)) AB - CLINICAL CHARACTERISTICS: Treacher Collins syndrome (TCS) is characterized by lower eyelid abnormalities, malar hypoplasia, downslanted palpebral fissures, and micro- or retrognathia due to symmetric hypoplasia of the zygomatic bones, maxilla, and mandible. External ear anomalies include absent, small, malformed, and/or posteriorly rotated ears and atresia or stenosis of the external auditory canals. About 40%-50% of individuals have conductive hearing loss attributed most commonly to malformation of the ossicles and hypoplasia of the middle ear cavities. Inner ear structures tend to be normal. Significant respiratory and feeding difficulties can be present in infancy. Other, less common abnormalities include cleft palate and unilateral or bilateral choanal stenosis or atresia. Typically, intellect is normal. DIAGNOSIS/TESTING: The diagnosis of TCS is established in a proband with characteristic clinical features and/or a heterozygous pathogenic variant in TCOF1, POLR1D, or POLR1B, biallelic pathogenic variants in POLR1C, or, rarely, biallelic pathogenic variants in POLR1D identified by molecular genetic testing. MANAGEMENT: Treatment of manifestations: Treatment should be tailored to the specific needs of each individual, preferably by a multidisciplinary craniofacial management team. Neonates with airway issues may require airway management at delivery, special positioning, or tracheostomy to facilitate ventilation. Tube feeding may be needed for adequate caloric intake. Cleft palate repair (if needed) occurs at about age one year. Hearing loss is treated with bone conduction amplification, speech therapy, and educational intervention. Management of ocular issues is per ophthalmologist. Standard management for cardiac, gastrointestinal, renal, and limb anomalies. Craniofacial reconstruction is often necessary: zygomatic and orbital reconstruction at about age five to seven years, and bilateral microtia and/or narrow ear canal reconstruction after age six years. Botulinum toxin and subsequent surgery for coloboma of the lower eyelid. Eyelid reconstruction as needed for downslanted palpebral fissures. Orthodonture for misaligned teeth. The age of maxillomandibular reconstruction varies by severity; orthognathic therapies are typically before age 16 years. Surveillance: Annual ophthalmology and audiology evaluations; assess for manifestations of obstructive sleep apnea, growth, and caloric intake at each visit; dental exams every six months with orthodontia exams as needed; assess speech development and educational progress annually or as needed. GENETIC COUNSELING: TCS can be inherited in an autosomal dominant or autosomal recessive manner. Autosomal dominant inheritance accounts for most of TCS, most commonly heterozygous pathogenic variants in TCOF1 and less commonly heterozygous pathogenic variants in POLR1B or POLR1D. Autosomal recessive inheritance (biallelic pathogenic variants in POLR1C or POLR1D) accounts for a minority of TCS. Significant intrafamilial clinical variability is common. Autosomal dominant TCS: About 55%-61% of individuals with autosomal dominant TCS have the disorder as the result of a de novo pathogenic variant. Each child of an individual with autosomal dominant TCS has a 50% chance of inheriting the pathogenic variant. Autosomal recessive TCS: The parents of a child with autosomal recessive TCS are presumed to be heterozygous for a POLR1C or POLR1D pathogenic variant. If both parents are known to be heterozygous for a TCS-causing pathogenic variant, each sib of an individual with autosomal recessive TCS has at conception a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk relatives requires prior identification of the TCS-related pathogenic variants in the family. Once the TCS-related pathogenic variant(s) have been identified in an affected family member, prenatal and preimplantation genetic testing are possible. CI - Copyright (c) 1993-2026, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved. FED - Adam, Margaret P ED - Adam MP FED - Bick, Sarah ED - Bick S FED - Mirzaa, Ghayda M ED - Mirzaa GM FED - Wallace, Stephanie E ED - Wallace SE FED - Amemiya, Anne ED - Amemiya A FAU - Barbosa, Mafalda AU - Barbosa M AD - Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York FAU - Jabs, Ethylin Wang AU - Jabs EW AD - Department of Clinical Genomics, Mayo Clinic, Rochester, Minnesota FAU - Huston, Sara AU - Huston S AD - Department of Pediatrics, Feinberg School of Medicine, Northwestern University;, Lurie Children's Hospital, Chicago, Illinois LA - eng PT - Review PT - Book Chapter PL - Seattle (WA) OTO - NLM OT - Mandibulofacial Dysostosis OT - Treacher Collins-Franceschetti Syndrome OT - DNA-directed RNA polymerase I subunit RPA2 OT - DNA-directed RNA polymerases I and III subunit RPAC1 OT - DNA-directed RNA polymerases I and III subunit RPAC2 OT - Treacle protein OT - POLR1B OT - POLR1C OT - POLR1D OT - TCOF1 OT - Treacher Collins Syndrome OT - Mandibulofacial Dysostosis OT - Treacher Collins-Franceschetti Syndrome EDAT- 2024/06/20 00:00 CRDT- 2024/06/20 00:00 AID - NBK1532 [bookaccession] PMID- 38896579 OWN - NLM STAT- MEDLINE DCOM- 20240619 LR - 20241217 IS - 1806-9460 (Electronic) IS - 1516-3180 (Print) IS - 1516-3180 (Linking) VI - 142 IP - 5 DP - 2024 TI - Interdisciplinary training program for pediatric cardiorespiratory arrest using rapid cycle deliberate practice: A descriptive cross-sectional study. PG - e2023271 LID - S1516-31802024000500208 [pii] LID - 10.1590/1516-3180.2023.0271.16022024 [doi] LID - e2023271 AB - BACKGROUND: cardiorespiratory arrest (CRA) is a severe public health concern, and clinical simulation has proven to be a beneficial educational strategy for training on this topic. OBJECTIVE: To describe the implementation of a program for pediatric cardiac arrest care using rapid-cycle deliberate practice (RCDP), the quality of the technique employed, and participants' opinions on the methodology. DESIGN AND SETTING: This descriptive cross-sectional study of pre- and post-performance training in cardiopul monary resuscitation (CPR) techniques and reaction evaluation was conducted in a hospital in Sao Paulo. METHODS: Multidisciplinary groups performed pediatric resuscitation in a simulated scenario with RCDP mediated by a facilitator. The study sample included professionals working in patient care. During the simulation, the participants were evaluated for their compliance with the CRA care algorithm. Further, their execution of chest compressions was assessed pre- and post-intervention. RESULTS: In total, 302 professionals were trained in this study. The overall quality of CPR measured pre-intervention was inadequate, and only 26% had adequate technique proficiency, whereas it was 91% (P < 0.01) post-intervention. Of the participants, 95.7% responded to the final evaluation and provided positive comments on the method and their satisfaction with the novel simulation. Of these, 88% considered that repetition of the technique used was more effective than traditional simulation. CONCLUSIONS: The RCDP is effective for training multidisciplinary teams in pediatric CPR, with an emphasis on the quality of chest compressions. However, further studies are necessary to explore whether this trend translates to differential performances in practical settings. FAU - Pereira, Renata AU - Pereira R AUID- ORCID: 0000-0002-3863-3327 AD - Master's student; Department of Medicine; Universidade Federal de Sao Paulo (UNIFESP). Sao Paulo (SP), Brazil. FAU - Silva, Edina Mariko Koga da AU - Silva EMKD AUID- ORCID: 0000-0001-8080-8664 AD - Associate Professor; Department of Medicine; Universidade Federal de Sao Paulo (UNIFESP). Sao Paulo (SP), Brazil. LA - eng PT - Journal Article DEP - 20240617 PL - Brazil TA - Sao Paulo Med J JT - Sao Paulo medical journal = Revista paulista de medicina JID - 100897261 SB - IM MH - Humans MH - Cross-Sectional Studies MH - *Heart Arrest/therapy MH - *Cardiopulmonary Resuscitation/education MH - Male MH - Female MH - *Clinical Competence MH - Child MH - Simulation Training/methods MH - Adult MH - Patient Care Team MH - Program Evaluation PMC - PMC11185849 COIS- Conflict of interest: None EDAT- 2024/06/19 18:42 MHDA- 2024/06/19 18:43 PMCR- 2024/06/17 CRDT- 2024/06/19 14:02 PHST- 2023/08/08 00:00 [received] PHST- 2024/02/16 00:00 [accepted] PHST- 2024/06/19 18:43 [medline] PHST- 2024/06/19 18:42 [pubmed] PHST- 2024/06/19 14:02 [entrez] PHST- 2024/06/17 00:00 [pmc-release] AID - S1516-31802024000500208 [pii] AID - 10.1590/1516-3180.2023.0271.16022024 [doi] PST - epublish SO - Sao Paulo Med J. 2024 Jun 17;142(5):e2023271. doi: 10.1590/1516-3180.2023.0271.16022024. eCollection 2024. PMID- 38895810 OWN - NLM STAT- MEDLINE DCOM- 20241025 LR - 20260708 IS - 1866-0452 (Electronic) IS - 1866-0452 (Linking) VI - 121 IP - 17 DP - 2024 Aug 23 TI - The Diagnosis and Treatment of Tricuspid Regurgitation. PG - 551-558 LID - arztebl.m2024.0104 [pii] LID - 10.3238/arztebl.m2024.0104 [doi] AB - BACKGROUND: It is estimated that 6% of persons over age 75 have clinically relevant tricuspid regurgitation (TR). This condition carries a high mortality and is of particular interest because of the recent development of new interventional treatments. METHODS: This review is based on publications that were retrieved by a selective search in the PubMed database for randomized controlled trials (RCTs), observational studies, registry studies, expert recommendations, and current international guidelines. RESULTS: The evidence reveals that TR is an independent cause of mortality. Mortality is correlated with the severity of TR: approximately 35% of patients with severe TR and right heart failure die within 1 year, and about 60% within 3 years. The clinical course varies depending on the etiology (primary TR, atrial/ventricular secondary TR, association with pacemaker systems). In the outpatient setting, timely diagnosis by transthoracic echocardiography is crucial. The options for pharmacotherapy are essentially limited to diuretic treatment (grade 2a recommendation). Early referral to a specialized heart valve center is essential for the prevention of irreversible damage of the right heart and secondary end-organ damage, including cardiohepatic and cardiorenal syndromes. In the heart valve center, an extended diagnostic evaluation with multimodal imaging is followed by a case discussion by the interdisciplinary cardiac team, with individual evaluation of the treatment options. The first randomized controlled trial of treatment for TR yielded a win ratio of 1.48 (95% confidence interval, [1.06; 2.13]) for interventional treatment (edge-to-edge repair) compared to optimal medical therapy. CONCLUSION: As the understanding of tricuspid regurgitation improves, strategies for its interventional treatment are undergoing steady development, with the aim of lowering the mortality of this condition. FAU - Stocker, Thomas J AU - Stocker TJ AD - Department of Cardiology, LMU Klinikum, Ludwig Maximilian University of Munich, Munich, Germany; German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany; Department of Cardiology and Angiology, University Heart Center Freiburg/Bad Krozingen, University Hospital Freiburg, Freiburg, Germany; Department of Cardiac and Vascular Surgery, University Medical Center Mainz, Johannes Gutenberg University of Mainz, Mainz, Germany. FAU - Besler, Christian AU - Besler C FAU - Treede, Hendrik AU - Treede H FAU - Hausleiter, Jorg AU - Hausleiter J LA - eng PT - Journal Article PT - Review PL - Germany TA - Dtsch Arztebl Int JT - Deutsches Arzteblatt international JID - 101475967 SB - IM MH - *Tricuspid Valve Insufficiency/therapy/diagnosis MH - Humans MH - Survival Rate MH - Evidence-Based Medicine MH - Echocardiography/methods MH - Treatment Outcome PMC - PMC11551545 EDAT- 2024/06/19 06:42 MHDA- 2024/10/25 12:25 PMCR- 2024/08/01 CRDT- 2024/06/19 05:23 PHST- 2024/01/15 00:00 [received] PHST- 2024/05/14 00:00 [revised] PHST- 2024/05/14 00:00 [accepted] PHST- 2024/10/25 12:25 [medline] PHST- 2024/06/19 06:42 [pubmed] PHST- 2024/06/19 05:23 [entrez] PHST- 2024/08/01 00:00 [pmc-release] AID - arztebl.m2024.0104 [pii] AID - 10.3238/arztebl.m2024.0104 [doi] PST - ppublish SO - Dtsch Arztebl Int. 2024 Aug 23;121(17):551-558. doi: 10.3238/arztebl.m2024.0104. PMID- 38894578 OWN - NLM STAT- MEDLINE DCOM- 20240925 LR - 20260920 IS - 2055-5822 (Electronic) IS - 2055-5822 (Linking) VI - 11 IP - 5 DP - 2024 Oct TI - Heart failure hospitalization following surgical or transcatheter aortic valve implantation in low-risk aortic stenosis. PG - 2531-2541 LID - 10.1002/ehf2.14887 [doi] AB - AIMS: In low-risk patients with severe aortic stenosis (AS), sutureless surgical aortic valve replacement (SU-SAVR) may be an alternative to transcatheter aortic valve implantation (TAVI). The risk of heart failure hospitalization (HFH) after aortic valve replacement (AVR) in this population is incompletely characterized. This study aims to investigate the incidence, predictors, and outcomes of HFH in patients undergoing SU-SAVR versus TAVI. METHODS AND RESULTS: Patients referred for AVR between 2013 and 2020 at two centres were consecutively included. The decision for SU-SAVR or TAVI was determined by a multidisciplinary Heart Team. Cox regression and competing risk analysis were conducted to assess adverse events. Of 594 patients (mean age 77.5 +/- 6.4, 59.8% male), 424 underwent SU-SAVR, while 170 underwent TAVI. Following a mean follow-up of 34.1 +/- 23.1 months, HFH occurred in 112 (27.8%) SU-SAVR patients and in 8 (4.8%) TAVI patients (P < 0.001). The SU-SAVR cohort exhibited higher all-cause mortality (138 [32.5%] patients compared with 30 [17.6%] in the TAVI cohort [P < 0.001]). These differences remained significant after sensitivity analyses with 1:1 propensity score matching for baseline variables. SU-SAVR with HFH was associated with increased all-cause mortality (61.6% vs. 23.1%, P < 0.001). Independent associates of HFH in SU-SAVR patients included diabetes, atrial fibrillation, chronic obstructive pulmonary disease, lower glomerular filtration rate and lower left ventricular ejection fraction. SU-SAVR patients with HFH had a 12-month LVEF of 59.4 +/- 12.7. CONCLUSIONS: In low-risk AS, SU-SAVR is associated with a higher risk of HFH and all-cause mortality compared to TAVI. In patients with severe AS candidate to SU-SAVR or TAVI, TAVI may be the preferred intervention. CI - (c) 2024 The Author(s). ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. FAU - Lopez-Martinez, Helena AU - Lopez-Martinez H AUID- ORCID: 0000-0002-0963-0207 AD - Heart Institute, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. FAU - Vilalta, Victoria AU - Vilalta V AD - Heart Institute, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. FAU - Farjat-Pasos, Julio AU - Farjat-Pasos J AD - Quebec Heart & Lung Institute, Laval University, Quebec, Canada. FAU - Ferrer-Sistach, Elena AU - Ferrer-Sistach E AD - Heart Institute, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. FAU - Mohammadi, Siamak AU - Mohammadi S AD - Quebec Heart & Lung Institute, Laval University, Quebec, Canada. FAU - Escabia, Claudia AU - Escabia C AD - Heart Institute, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. FAU - Kalavrouziotis, Dimitri AU - Kalavrouziotis D AD - Quebec Heart & Lung Institute, Laval University, Quebec, Canada. FAU - Resta, Helena AU - Resta H AD - Heart Institute, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. FAU - Borrellas, Andrea AU - Borrellas A AD - Heart Institute, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. FAU - Dumont, Eric AU - Dumont E AD - Quebec Heart & Lung Institute, Laval University, Quebec, Canada. FAU - Carrillo, Xavier AU - Carrillo X AD - Heart Institute, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. FAU - Paradis, Jean-Michel AU - Paradis JM AD - Quebec Heart & Lung Institute, Laval University, Quebec, Canada. FAU - Fernandez-Nofrerias, Eduard AU - Fernandez-Nofrerias E AD - Heart Institute, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. FAU - Delgado, Victoria AU - Delgado V AD - Heart Institute, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. FAU - Rodes-Cabau, Josep AU - Rodes-Cabau J AD - Quebec Heart & Lung Institute, Laval University, Quebec, Canada. FAU - Bayes-Genis, Antoni AU - Bayes-Genis A AD - Heart Institute, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. LA - eng PT - Journal Article PT - Multicenter Study PT - Observational Study DEP - 20240618 PL - England TA - ESC Heart Fail JT - ESC heart failure JID - 101669191 SB - IM MH - Aged MH - Aged, 80 and over MH - Female MH - Humans MH - Male MH - *Aortic Valve Stenosis/surgery/complications MH - Follow-Up Studies MH - *Heart Failure/complications/epidemiology MH - Heart Valve Prosthesis Implantation/methods MH - *Hospitalization MH - Incidence MH - Postoperative Complications/epidemiology MH - Retrospective Studies MH - Risk Assessment/methods MH - Risk Factors MH - Survival Rate/trends MH - *Transcatheter Aortic Valve Replacement/methods PMC - PMC11424333 OTO - NOTNLM OT - Aortic stenosis cardiomyopathy OT - Aortic valve stenosis OT - Heart failure OT - Mortality OT - Prostheses and implants COIS- Dr. Bayes has lectured and/or participated in advisory boards for Abbott, AstraZeneca, Boehringer Ingelheim, Novartis, Bayer, Roche Diagnostics, Vifor. Dr. Rodes-Cabau is consultant for and has received institutional research grants from Edwards Lifesciences and Medtronic. Dr. Victoria Delgado received speaker fees from Edwards Lifesciences, GE Healthcare, Novartis, Philips, and MSD; consulting fees from Novo Nordisk, Edwards Lifesciences, and Abbott Vascular. The rest of authors do not report any conflict of interest with respect to the content of this article. EDAT- 2024/06/19 06:42 MHDA- 2024/09/26 00:42 PMCR- 2024/06/18 CRDT- 2024/06/19 02:03 PHST- 2024/05/08 00:00 [revised] PHST- 2024/04/13 00:00 [received] PHST- 2024/05/10 00:00 [accepted] PHST- 2024/09/26 00:42 [medline] PHST- 2024/06/19 06:42 [pubmed] PHST- 2024/06/19 02:03 [entrez] PHST- 2024/06/18 00:00 [pmc-release] AID - EHF214887 [pii] AID - 10.1002/ehf2.14887 [doi] PST - ppublish SO - ESC Heart Fail. 2024 Oct;11(5):2531-2541. doi: 10.1002/ehf2.14887. Epub 2024 Jun 18. PMID- 38885412 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240704 IS - 2753-670X (Electronic) IS - 2753-670X (Linking) VI - 39 IP - 1 DP - 2024 Jul 2 TI - Implementation of cardiac enhanced recovery after surgery at Lausanne University Hospital, our roadbook to certification. LID - 10.1093/icvts/ivae118 [doi] LID - ivae118 AB - OBJECTIVES: Enhanced recovery after surgery (ERAS) is a multidisciplinary, patient-centred approach aimed at expediting recovery, improving clinical outcomes, and reducing healthcare costs. Initially developed for colorectal surgery, ERAS principles have been successfully applied across various surgical specialties, including cardiac surgery. This study outlines the implementation and certification process of the ERAS program in a tertiary cardiac surgical centre within the Heart-Vessel Department at Lausanne University Hospital. METHODS: The implementation involved forming a multidisciplinary team, including cardiac surgeons, anaesthesiologists, intensivists, a cardiologist, clinical nurse specialists and physiotherapists. The ERAS nurse coordinator played a central role in organizing meetings, promoting the program, developing protocols, and collecting data. The certification process required adherence to ERAS guidelines, structured training and external evaluation. Key phases included pre-ERAS data collection, protocol dissemination, inclusion of the 1st patients, followed by analysis and full implementation. RESULTS: Achieving certification required maintaining a compliance rate of over 70% with established protocols. The process involved overcoming various barriers, such as inconsistent practices and the need for multidisciplinary collaboration. In this paper, we provide some solutions to these challenges, including team education, regular meetings and continuous feedback loops. Preliminary data from the initial cohort showed improvements in early mobilization, opioid use, respiratory complications and shorter hospital stays. CONCLUSIONS: The successful implementation of the ERAS program at our institution demonstrates the feasibility and benefits of a structured, multidisciplinary approach in cardiac surgery. Continuous self-assessment and adherence to guidelines are essential for sustained improvement in patient outcomes and healthcare efficiency. CI - (c) The Author(s) 2024. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. FAU - Ltaief, Zied AU - Ltaief Z AUID- ORCID: 0000-0001-9199-4415 AD - Department of Intensive Care, Lausanne University Hospital (CHUV), Lausanne, Switzerland. FAU - Verdugo-Marchese, Mario AU - Verdugo-Marchese M AUID- ORCID: 0000-0002-5354-1017 AD - Department of Cardiac Surgery, Lausanne University Hospital (CHUV), Lausanne, Switzerland. FAU - Carel, Dan AU - Carel D AUID- ORCID: 0000-0003-2985-984X AD - Department of Intensive Care, Lausanne University Hospital (CHUV), Lausanne, Switzerland. FAU - Gunga, Ziyad AU - Gunga Z AUID- ORCID: 0000-0002-4453-7630 AD - Department of Cardiac Surgery, Lausanne University Hospital (CHUV), Lausanne, Switzerland. FAU - Nowacka, Anna AU - Nowacka A AUID- ORCID: 0000-0001-6260-1635 AD - Department of Cardiac Surgery, Lausanne University Hospital (CHUV), Lausanne, Switzerland. FAU - Melly, Valentine AU - Melly V AD - Department of Cardiac Surgery, Lausanne University Hospital (CHUV), Lausanne, Switzerland. FAU - Addor, Valerie AU - Addor V AUID- ORCID: 0000-0003-2859-3971 AD - Department of Development and External Affairs, Lausanne University Hospital (CHUV), Lausanne, Switzerland. FAU - Botteau, Caroline AU - Botteau C AD - Department of Cardio-Respiratory Physiotherapy, Lausanne University Hospital (CHUV), Lausanne, Switzerland. FAU - Hennemann, Marius AU - Hennemann M AD - Department of Cardio-Respiratory Physiotherapy, Lausanne University Hospital (CHUV), Lausanne, Switzerland. FAU - Lavanchy, Luc AU - Lavanchy L AD - Department of Anesthesia, Lausanne University Hospital (CHUV), Lausanne, Switzerland. FAU - Kirsch, Matthias AU - Kirsch M AUID- ORCID: 0000-0002-9213-7578 AD - Department of Cardiac Surgery, Lausanne University Hospital (CHUV), Lausanne, Switzerland. FAU - Rancati, Valentina AU - Rancati V AUID- ORCID: 0000-0002-6313-1185 AD - Department of Anesthesia, Lausanne University Hospital (CHUV), Lausanne, Switzerland. LA - eng PT - Journal Article PL - England TA - Interdiscip Cardiovasc Thorac Surg JT - Interdisciplinary cardiovascular and thoracic surgery JID - 9918540787006676 SB - IM PMC - PMC11219240 OTO - NOTNLM OT - Cardiac surgery OT - Clinical outcomes OT - Cost-efficiency OT - Enhanced recovery after surgery OT - Multidisciplinary team OT - Patient-centred care EDAT- 2024/06/17 18:43 MHDA- 2024/06/17 18:44 PMCR- 2024/06/17 CRDT- 2024/06/17 15:14 PHST- 2024/04/26 00:00 [received] PHST- 2024/05/24 00:00 [revised] PHST- 2024/06/13 00:00 [accepted] PHST- 2024/06/17 18:44 [medline] PHST- 2024/06/17 18:43 [pubmed] PHST- 2024/06/17 15:14 [entrez] PHST- 2024/06/17 00:00 [pmc-release] AID - 7695252 [pii] AID - ivae118 [pii] AID - 10.1093/icvts/ivae118 [doi] PST - ppublish SO - Interdiscip Cardiovasc Thorac Surg. 2024 Jul 2;39(1):ivae118. doi: 10.1093/icvts/ivae118. PMID- 38883621 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240618 IS - 2072-1439 (Print) IS - 2077-6624 (Electronic) IS - 2072-1439 (Linking) VI - 16 IP - 5 DP - 2024 May 31 TI - Prevalence of concomitant aortic disease and lung cancer: an exploratory study. PG - 2800-2810 LID - 10.21037/jtd-23-1547 [doi] AB - BACKGROUND: Lung cancer and aortic disease share multiple risk factors. The co-presence of both diseases defines a peculiar type of patient who needs a specific protocol of treatment and follow-up. The aim of our study was to evaluate the prevalence of aortic disease in a population of patients with a diagnosis of primary lung cancer. METHODS: A retrospective, single center analysis of all patients admitted to the Thoracic Surgery Unit from January 2015 to January 2021. Demographic and baseline characteristics were retrieved from hospital electronic charts. All patients were screened for aortic disease, reviewing thoraco-abdominal Computed Tomography with contrast medium administration performed for oncological reasons. A cancer-free control group was obtained for comparison. Multilinear regression analysis was performed to identify the risk factors for the presence of aortic disease. RESULTS: A total of 264 patients were preliminarily identified. After reviewing for exclusion criteria, a total of 148 patients were included in the analysis. Most of the patients were male (62.2%) with a mean age of 71+/-8.7 years. Cardiovascular risk factors were extensively prevalent in the population study. The incidence of aortic pathologies in the group of patients suffering from primary lung cancer was 27% (40 patients). The majority presented thoracic aortic aneurysms (11.5%). Comparison between the lung cancer group and the control group highlighted a substantial difference in terms of aortic disease prevalence (27% vs. 2.9%; P<0.0001). The regression analysis revealed that coronary artery disease [odds ratio (OR) 4.6988, P=0.001], peripheral artery disease (OR 7.7093, P=0.002), hypertension (OR 4.0152, P=0.03) and history of previous non-aortic vascular surgery procedures (OR 6.4509, P=0.003) were risk factors for aortic disease in patients with primary lung cancer. CONCLUSIONS: Patients with lung cancer have a high prevalence of aortic disease, defining a peculiar subset of patients who deserve a specific protocol of treatment and follow-up. Further studies are needed to define a dedicated standardized multidisciplinary approach. CI - 2024 Journal of Thoracic Disease. All rights reserved. FAU - Pasqui, Edoardo AU - Pasqui E AD - Vascular Surgery Unit, Department of Medicine Surgery and Neuroscience, University of Siena, Siena, Italy. FAU - Luzzi, Luca AU - Luzzi L AD - Lung Transplantation Unit, Department of Medicine Surgery and Neuroscience, University of Siena, Siena, Italy. FAU - Lazzeri, Elisa AU - Lazzeri E AD - Vascular Surgery Unit, Department of Medicine Surgery and Neuroscience, University of Siena, Siena, Italy. FAU - Casilli, Giulia AU - Casilli G AD - Vascular Surgery Unit, Department of Medicine Surgery and Neuroscience, University of Siena, Siena, Italy. FAU - Ferrante, Giulia AU - Ferrante G AD - Vascular Surgery Unit, Department of Medicine Surgery and Neuroscience, University of Siena, Siena, Italy. FAU - Catelli, Chiara AU - Catelli C AD - Lung Transplantation Unit, Department of Medicine Surgery and Neuroscience, University of Siena, Siena, Italy. FAU - Paladini, Piero AU - Paladini P AD - Thoracic Surgery Unit, Department of Medicine Surgery and Neuroscience, University of Siena, Siena, Italy. FAU - de Donato, Gianmarco AU - de Donato G AD - Vascular Surgery Unit, Department of Medicine Surgery and Neuroscience, University of Siena, Siena, Italy. LA - eng PT - Journal Article DEP - 20240511 PL - China TA - J Thorac Dis JT - Journal of thoracic disease JID - 101533916 PMC - PMC11170407 OTO - NOTNLM OT - Aortic disease OT - aneurysm OT - lung cancer OT - risk factors COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-23-1547/coif). The authors have no conflicts of interest to declare. EDAT- 2024/06/17 12:42 MHDA- 2024/06/17 12:43 PMCR- 2024/05/31 CRDT- 2024/06/17 06:09 PHST- 2023/10/05 00:00 [received] PHST- 2024/01/12 00:00 [accepted] PHST- 2024/06/17 12:43 [medline] PHST- 2024/06/17 12:42 [pubmed] PHST- 2024/06/17 06:09 [entrez] PHST- 2024/05/31 00:00 [pmc-release] AID - jtd-16-05-2800 [pii] AID - 10.21037/jtd-23-1547 [doi] PST - ppublish SO - J Thorac Dis. 2024 May 31;16(5):2800-2810. doi: 10.21037/jtd-23-1547. Epub 2024 May 11. PMID- 38878947 OWN - NLM STAT- MEDLINE DCOM- 20240925 LR - 20250131 IS - 1552-6259 (Electronic) IS - 0003-4975 (Linking) VI - 118 IP - 4 DP - 2024 Oct TI - Early Initiation of Guideline-Directed Medical Therapy for Heart Failure After Cardiac Surgery. PG - 792-800 LID - S0003-4975(24)00463-6 [pii] LID - 10.1016/j.athoracsur.2024.05.034 [doi] AB - There is an evolving role for guideline-directed medical therapy (GDMT) in managing heart failure with reduced ejection fraction after cardiac surgery. GDMT is based on the use of pharmacologic agents from each of 4 distinct drug classes, also known as the 4 pillars of heart failure therapy: beta-blockers, renin-angiotensin system inhibitors, often paired with neprilysin inhibitors, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter-2 inhibitors. Despite the demonstrated benefits of GDMT in reducing mortality and hospitalization rates in the nonsurgical literature, there is conspicuous underuse of GDMT after cardiac surgery. The lack of published literature and practical challenges surrounding the timing for initiation of GDMT in the immediate postoperative period has limited standardized implementation strategies. A multidisciplinary approach will be necessary to assist in initiating, titrating, and monitoring the response to these therapies in patients with heart failure with reduced ejection fraction after cardiac surgery. CI - Copyright (c) 2024 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved. FAU - Schwann, Alexandra N AU - Schwann AN AD - Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut. FAU - Jaffe, Leeor M AU - Jaffe LM AD - Heart & Vascular Program, Baystate Health, University of Massachusetts Chan Medical School-Baystate, Springfield, Massachusetts. FAU - Givertz, Michael M AU - Givertz MM AD - Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. FAU - Wood, Katherine L AU - Wood KL AD - Division of Cardiac Surgery, University of Rochester Medical Center, Rochester, New York. FAU - Engelman, Daniel T AU - Engelman DT AD - Heart & Vascular Program, Baystate Health, University of Massachusetts Chan Medical School-Baystate, Springfield, Massachusetts. Electronic address: daniel.engelman@baystatehealth.org. LA - eng PT - Journal Article PT - Review DEP - 20240613 PL - Netherlands TA - Ann Thorac Surg JT - The Annals of thoracic surgery JID - 15030100R RN - 0 (Adrenergic beta-Antagonists) RN - 0 (Mineralocorticoid Receptor Antagonists) SB - IM MH - Humans MH - *Heart Failure/drug therapy/surgery MH - *Cardiac Surgical Procedures/adverse effects MH - *Practice Guidelines as Topic MH - Adrenergic beta-Antagonists/therapeutic use MH - Postoperative Complications/drug therapy MH - Stroke Volume MH - Mineralocorticoid Receptor Antagonists/therapeutic use MH - Time Factors COIS- Disclosures Daniel Engelman reports a relationship with Edwards Lifesciences Corporation, Astellas Pharma US Inc, Alexion Pharmaceuticals Inc, Medela AG, Arthrex Inc, and Renibus Therapeutics Inc that includes: consulting or advisory. Michael Givertz reports a relationship with Merck & Co Inc that includes: consulting or advisory; and with Abbott Vascular Inc, Endtronix, and Natera Inc that includes: institutional research support. Katherine Wood reports a relationship with Abbott Vascular Inc that includes: consulting or advisory. The other authors have no conflicts of interest to disclose. EDAT- 2024/06/16 11:58 MHDA- 2024/09/26 00:43 CRDT- 2024/06/15 19:27 PHST- 2023/12/19 00:00 [received] PHST- 2024/05/21 00:00 [revised] PHST- 2024/05/28 00:00 [accepted] PHST- 2024/09/26 00:43 [medline] PHST- 2024/06/16 11:58 [pubmed] PHST- 2024/06/15 19:27 [entrez] AID - S0003-4975(24)00463-6 [pii] AID - 10.1016/j.athoracsur.2024.05.034 [doi] PST - ppublish SO - Ann Thorac Surg. 2024 Oct;118(4):792-800. doi: 10.1016/j.athoracsur.2024.05.034. Epub 2024 Jun 13. PMID- 38874328 OWN - NLM STAT- MEDLINE DCOM- 20241231 LR - 20241231 IS - 1754-9485 (Electronic) IS - 1754-9477 (Linking) VI - 68 IP - 8 DP - 2024 Dec TI - Cardio-oncology and radiation oncology: How collaboration between cardiologists and oncologists can be realised in radiation oncology. PG - 962-973 LID - 10.1111/1754-9485.13724 [doi] AB - Increased survivorship, improvements in cancer treatments, and the potential for cardiac side effects from cancer treatments have resulted in increased collaboration between oncologists and cardiologists and the development of cardio-oncology clinics. This collaboration is important given its role in ensuring greater patient satisfaction, aiding teams of clinicians in making complex treatment decision, and ensuring cardiac complications are diagnosed at an early stage. The particularities of implementing this collaboration in the field of radiation oncology and how this setting is different from other areas of cardio-oncology have not been well detailed in the literature. This paper will discuss what is currently understood about the need for and role of cardio-oncology and what a cardio-oncology services involves, with a particular emphasis on patient and clinician needs in the field of radiation oncology. The literature and recent guidelines do advocate for a detailed baseline assessment of cancer patients undergoing radiotherapy, especially patients with treatment or patient risk factors that increase their risk of cancer-therapy related cardiotoxicity. Advancements in cardiac imaging techniques will be discussed as these may help to diagnose cardiac side effects of certain cancer treatments, including radiotherapy, at an early stage. A multi-disciplinary and collaborative approach is well received by patients and such an approach, guided by the aim of maintaining a patient's cancer treatment wherever possible, should be the cornerstone of cardio-oncology clinics regardless of the patient's treatment regime. CI - (c) 2024 Royal Australian and New Zealand College of Radiologists. FAU - Birch, Samuel AU - Birch S AUID- ORCID: 0000-0001-9270-9217 AD - Cardiology Department, St Vincent's Hospital, Sydney, New South Wales, Australia. FAU - Otton, James AU - Otton J AD - Victor Chang Cardiac Research Institute, Sydney, New South Wales, Australia. LA - eng PT - Journal Article PT - Review DEP - 20240614 PL - Australia TA - J Med Imaging Radiat Oncol JT - Journal of medical imaging and radiation oncology JID - 101469340 SB - IM MH - Humans MH - *Radiation Oncology MH - Neoplasms/radiotherapy/diagnostic imaging MH - Cardiologists MH - Cardiology MH - Cardiotoxicity/etiology MH - Oncologists MH - Medical Oncology MH - Patient Care Team MH - Cardio-Oncology OTO - NOTNLM OT - cardiac imaging OT - cardiology OT - oncologic imaging OT - radiation oncology OT - radiation oncology imaging EDAT- 2024/06/14 12:43 MHDA- 2024/12/31 12:21 CRDT- 2024/06/14 08:32 PHST- 2024/01/08 00:00 [received] PHST- 2024/06/02 00:00 [accepted] PHST- 2024/12/31 12:21 [medline] PHST- 2024/06/14 12:43 [pubmed] PHST- 2024/06/14 08:32 [entrez] AID - 10.1111/1754-9485.13724 [doi] PST - ppublish SO - J Med Imaging Radiat Oncol. 2024 Dec;68(8):962-973. doi: 10.1111/1754-9485.13724. Epub 2024 Jun 14. PMID- 38873894 OWN - NLM STAT- MEDLINE DCOM- 20240614 LR - 20251202 IS - 1476-4954 (Electronic) IS - 1476-7058 (Print) IS - 1476-4954 (Linking) VI - 37 IP - 1 DP - 2024 Dec TI - Strategies and outcomes of extracorporeal membrane oxygenation use in peripartum patients: a single institution experience. PG - 2355293 LID - 10.1080/14767058.2024.2355293 [doi] AB - BACKGROUND: Extracorporeal membrane oxygenation (ECMO) use in peripartum patients is rare, and there is a gap in the literature on the outcomes and guidance on using ECMO in peripartum patients. This study describes ECMO strategies our institution uses for peripartum patients and reports outcomes of ECMO use in peripartum patients with respiratory and/or cardiac failure. METHODS: A case series of all peripartum patients, defined as pregnant or up to 6 weeks after delivery of an infant >20 weeks gestation, from 2018 to 2023 from a single center requiring ECMO support. Patients were included if ECMO was initiated in the setting of cardiac, pulmonary, or combined failure. Patient demographics, operative details, ECMO data, and adverse outcomes for maternal, fetus, and neonates were all collected. RESULTS: Eighteen patients met the inclusion criteria. The cohort had a mean maternal age of 30.7 years old and was racially diverse. A majority of this cohort tested positive for COVID-19 (n = 10, 55%). ECMO was a bridge to recovery for all patients, of whom 14 (78%) were discharged out of the hospital alive. No patients received transplantation or a durable mechanical device. The most common complications were infection (25%) and postpartum hemorrhage (22%). CONCLUSIONS: ECMO use in peripartum patients in a single tertiary center was associated with a high survival rate. Furthermore, a strong multidisciplinary team, careful reevaluation of clinical trajectory, and consideration of complications and risks associated with using ECMO in peripartum patients are possible frameworks to use when challenged with critically ill peripartum patients. FAU - Wong, Ryan W AU - Wong RW AD - Tinsley Harrison Internal Medicine Residency Program, University of Alabama at Birmingham (UAB), Birmingham, AL, USA. FAU - Seasely, Angela R AU - Seasely AR AD - Division of Maternal-Fetal Medicine, UAB Department of Obstetrics and Gynecology, Birmingham, AL, USA. FAU - Gongora, Enrique AU - Gongora E AD - Division of Cardiothoracic Surgery, UAB Department of Surgery, Birmingham, AL, USA. FAU - Hoopes, Charles W AU - Hoopes CW AD - Division of Cardiothoracic Surgery, UAB Department of Surgery, Birmingham, AL, USA. FAU - Bellot, Scott AU - Bellot S AD - Division of Cardiothoracic Surgery, UAB Department of Surgery, Birmingham, AL, USA. FAU - McElwee, Samuel K AU - McElwee SK AD - Division of Cardiovascular Disease, UAB Department of Medicine, Birmingham, AL, USA. FAU - Rusanov, Victoria AU - Rusanov V AD - Division of Pulmonary, Allergy, and Critical Care Medicine, UAB Department of Medicine, Birmingham, AL, USA. FAU - Wille, Keith AU - Wille K AD - Division of Pulmonary, Allergy, and Critical Care Medicine, UAB Department of Medicine, Birmingham, AL, USA. FAU - Kaleekal, Thomas AU - Kaleekal T AD - Division of Pulmonary, Allergy, and Critical Care Medicine, UAB Department of Medicine, Birmingham, AL, USA. FAU - Marshall, Tammy AU - Marshall T AD - UAB Department of Mechanical Circulatory Support, Birmingham, AL, USA. FAU - Joly, Joanna M AU - Joly JM AD - Division of Cardiovascular Disease, UAB Department of Medicine, Birmingham, AL, USA. FAU - Lenneman, Andrew AU - Lenneman A AD - Division of Cardiovascular Disease, UAB Department of Medicine, Birmingham, AL, USA. FAU - Tallaj, Jose AU - Tallaj J AD - Division of Cardiovascular Disease, UAB Department of Medicine, Birmingham, AL, USA. FAU - Pamboukian, Salpy V AU - Pamboukian SV AD - Division of Cardiovascular Disease, University of Washington, Seattle, WA, USA. FAU - Sinkey, Rachel AU - Sinkey R AD - Division of Maternal-Fetal Medicine, UAB Department of Obstetrics and Gynecology, Birmingham, AL, USA. FAU - Orozco-Hernandez, Erik J AU - Orozco-Hernandez EJ AD - Division of Cardiothoracic Surgery, UAB Department of Surgery, Birmingham, AL, USA. LA - eng GR - K23 HL159331/HL/NHLBI NIH HHS/United States PT - Journal Article DEP - 20240614 PL - England TA - J Matern Fetal Neonatal Med JT - The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians JID - 101136916 SB - IM MH - Humans MH - *Extracorporeal Membrane Oxygenation/methods/statistics & numerical data MH - Female MH - Pregnancy MH - Adult MH - *Peripartum Period MH - *COVID-19/therapy/complications MH - Retrospective Studies MH - Infant, Newborn MH - SARS-CoV-2 MH - Respiratory Insufficiency/therapy MH - Heart Failure/therapy MH - Young Adult PMC - PMC11512991 MID - NIHMS2009145 OTO - NOTNLM OT - Acute respiratory distress syndrome OT - cardiogenic shock OT - extracorporeal membrane oxygenation OT - peripartum period OT - pregnancy COIS- Disclosure of Interest: Dr. Sinkey is supported by NHLBI K23HL159331 "The ACHIEVE Trial: Achieving longer gestation in preeclampsia via antihypertensive therapy". All other authors report there are no competing interests to declare. EDAT- 2024/06/14 06:43 MHDA- 2024/06/14 12:44 PMCR- 2025/12/01 CRDT- 2024/06/14 05:53 PHST- 2024/06/14 12:44 [medline] PHST- 2024/06/14 06:43 [pubmed] PHST- 2024/06/14 05:53 [entrez] PHST- 2025/12/01 00:00 [pmc-release] AID - 10.1080/14767058.2024.2355293 [doi] PST - ppublish SO - J Matern Fetal Neonatal Med. 2024 Dec;37(1):2355293. doi: 10.1080/14767058.2024.2355293. Epub 2024 Jun 14. PMID- 38872375 OWN - NLM STAT- MEDLINE DCOM- 20240703 LR - 20250729 IS - 1531-7072 (Electronic) IS - 1070-5295 (Linking) VI - 30 IP - 4 DP - 2024 Aug 1 TI - ICU management of cardiogenic shock before mechanical support. PG - 362-370 LID - 10.1097/MCC.0000000000001182 [doi] AB - PURPOSE OF REVIEW: Treatment of cardiogenic shock remains largely driven by expert consensus due to limited evidence from randomized controlled trials. In this review, we aim to summarize the approach to the management of patients with cardiogenic shock in the ICU prior to mechanical circulatory support (MCS). RECENT FINDINGS: Main topics covered in this article include diagnosis, monitoring, initial management and key aspects of pharmacological therapy in the ICU for patients with cardiogenic shock. SUMMARY: Despite efforts to improve therapy, short-term mortality in patients with cardiogenic shock is still reaching 40-50%. Early recognition and treatment of cardiogenic shock are crucial, including early revascularization of the culprit lesion with possible staged revascularization in acute myocardial infarction (AMI)-CS. Optimal volume management and vasoactive drugs titrated to restore arterial pressure and perfusion are the cornerstone of cardiogenic shock therapy. The choice of vasoactive drugs depends on the underlying cause and phenotype of cardiogenic shock. Their use should be limited to the shortest duration and lowest possible dose. According to recent observational evidence, assessment of the complete hemodynamic profile with a pulmonary artery catheter (PAC) was associated with improved outcomes and should be considered early in patients not responding to initial therapy or with unclear shock. A multidisciplinary shock team should be involved early in order to identify potential candidates for temporary and/or durable MCS. CI - Copyright (c) 2024 Wolters Kluwer Health, Inc. All rights reserved. FAU - Schaubroeck, Hannah AU - Schaubroeck H AD - Intensive Care Department, Ghent University Hospital, Ghent, Belgium. FAU - Rossberg, Michelle AU - Rossberg M AD - Department of Cardiology, Heart Center Leipzig at University of Leipzig, Leipzig, Germany. FAU - Thiele, Holger AU - Thiele H AD - Department of Cardiology, Heart Center Leipzig at University of Leipzig, Leipzig, Germany. FAU - Poss, Janine AU - Poss J AD - Department of Cardiology, Heart Center Leipzig at University of Leipzig, Leipzig, Germany. LA - eng PT - Journal Article PT - Review DEP - 20240613 PL - United States TA - Curr Opin Crit Care JT - Current opinion in critical care JID - 9504454 RN - 0 (Vasoconstrictor Agents) SB - IM MH - *Shock, Cardiogenic/therapy MH - Humans MH - *Intensive Care Units MH - Critical Care/methods MH - Hemodynamics MH - Heart-Assist Devices MH - Extracorporeal Membrane Oxygenation/methods MH - Vasoconstrictor Agents/therapeutic use EDAT- 2024/06/14 06:42 MHDA- 2024/07/03 13:42 CRDT- 2024/06/14 02:53 PHST- 2024/07/03 13:42 [medline] PHST- 2024/06/14 06:42 [pubmed] PHST- 2024/06/14 02:53 [entrez] AID - 00075198-202408000-00014 [pii] AID - 10.1097/MCC.0000000000001182 [doi] PST - ppublish SO - Curr Opin Crit Care. 2024 Aug 1;30(4):362-370. doi: 10.1097/MCC.0000000000001182. Epub 2024 Jun 13. PMID- 38872365 OWN - NLM STAT- MEDLINE DCOM- 20240703 LR - 20250729 IS - 1531-7072 (Electronic) IS - 1070-5295 (Linking) VI - 30 IP - 4 DP - 2024 Aug 1 TI - Building a cardiogenic shock response team: key considerations necessary to improve outcomes. PG - 354-361 LID - 10.1097/MCC.0000000000001177 [doi] AB - PURPOSE OF REVIEW: This review provides key information about cardiogenic shock (CS) teams, including published evidence and practical recommendations to create a CS team and program. RECENT FINDINGS: CS is a complex disease process with a high in-hospital mortality rate ranging from 30% to 70% according to recent registries and randomized studies. The explanation for the elevated rates is likely multifactorial, including the various etiologies of cardiogenic shock as well as delays in recognition and deployment of appropriate therapies. Accordingly, the use of cardiogenic shock team has been implemented with the aim of improving outcomes in these patients. The CS team typically consists of members with critical care or cardiac critical care expertise, heart failure, cardiothoracic surgery, and interventional cardiology. A number of retrospective studies have now supported the benefits of a CS team, particularly in selecting the appropriate candidates for tailored mechanical circulatory support therapies and providing interventions in a timely manner, which have translated into improved outcomes. SUMMARY: CS teams provides a platform for expedited recognition of CS and timely, standardized, and multidisciplinary discussions regarding appropriate management and care. CI - Copyright (c) 2024 Wolters Kluwer Health, Inc. All rights reserved. FAU - Varma, Bhavya AU - Varma B AD - The Leon H. Charney Division of Cardiovascular Medicine, New York University Grossman School of Medicine, NYU Langone Medical Center. FAU - Katz, Jason N AU - Katz JN AD - The Leon H. Charney Division of Cardiovascular Medicine, New York University Grossman School of Medicine, NYU Langone Medical Center. AD - Bellevue Hospital Center, New York, New York, USA. FAU - Alviar, Carlos L AU - Alviar CL AD - The Leon H. Charney Division of Cardiovascular Medicine, New York University Grossman School of Medicine, NYU Langone Medical Center. AD - Bellevue Hospital Center, New York, New York, USA. LA - eng PT - Journal Article PT - Review DEP - 20240610 PL - United States TA - Curr Opin Crit Care JT - Current opinion in critical care JID - 9504454 SB - IM MH - *Shock, Cardiogenic/therapy MH - Humans MH - *Patient Care Team MH - Hospital Mortality MH - Critical Care/methods MH - Quality Improvement EDAT- 2024/06/14 06:42 MHDA- 2024/07/03 13:42 CRDT- 2024/06/14 02:53 PHST- 2024/07/03 13:42 [medline] PHST- 2024/06/14 06:42 [pubmed] PHST- 2024/06/14 02:53 [entrez] AID - 00075198-202408000-00013 [pii] AID - 10.1097/MCC.0000000000001177 [doi] PST - ppublish SO - Curr Opin Crit Care. 2024 Aug 1;30(4):354-361. doi: 10.1097/MCC.0000000000001177. Epub 2024 Jun 10. PMID- 38871977 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250104 IS - 2730-664X (Electronic) IS - 2730-664X (Linking) VI - 4 IP - 1 DP - 2024 Jun 13 TI - Cardiotoxic profiles of CAR-T therapy and bispecific T-cell engagers in hematological cancers. PG - 116 LID - 10.1038/s43856-024-00540-9 [doi] LID - 116 AB - BACKGROUND: Chimeric antigen receptor (CAR) T-cell therapy and bispecific T-cell engagers, which redirect T-cells to tumor antigens, have immensely benefitted patients with relapsed/refractory B-cell cancers. How these therapies differ in cardiotoxicity is underexplored. We used the World Health Organization pharmacovigilance database, VigiBase, to compare cardiotoxicity profiles between CD19-targeted CAR-T therapy and blinatumomab (a CD19/CD3-targeted bispecific T-cell engager). METHODS: Safety reports in VigiBase were filtered for diffuse large B-cell lymphoma (DLBCL, n = 17,479) and acute lymphocytic leukemia (ALL, n = 28,803) for all adverse reactions. Data were further filtered for patients taking CAR-T therapy or blinatumomab. Reporting odds ratios (ROR) and fatality rates were compared between CAR-T cell products (e.g. tisagenlecleucel and axicabtagene ciloleucel), and between CAR-T therapy and blinatumomab. RESULTS: Tisagenlecleucel is associated with cardiac failure (IC(025) = 0.366) with fatality rates of 85.7% and 80.0% in DLBCL and pediatric ALL patients respectively. For DLBCL patients, axicabtagene ciloleucel has greater reporting for hypotension than tisagenlecleucel (ROR: 2.54; 95% CI: 1.28-5.03; p = 0.012), but tisagenlecleucel has higher fatality rates for hypotension than axicabtagene ciloleucel [50.0% (tisagenlecleucel) vs 5.6% (axicabtagene ciloleucel); p < 0.001]. Blinatumomab and tisagenlecleucel have similar fatality rates for hypotension in pediatric ALL patients [34.7% (tisagenlecleucel) vs 20.0% (blinatumomab); p = 0.66]. CONCLUSIONS: Tisagenlecleucel is associated with severe and fatal adverse cardiac events, with higher fatality rates for hypotension compared to axicabtagene ciloleucel in DLBCL patients, but similar hypotension fatality rates compared to blinatumomab in pediatric ALL patients. Effective management necessitates experienced physicians, including cardio-oncologists, skilled in interdisciplinary approaches to manage these toxicities. CI - (c) 2024. The Author(s). FAU - Karthikeyan, Badri AU - Karthikeyan B AD - Department of Medicine, Division of Cardiology, Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, 14203, USA. AD - Department of Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14203, USA. FAU - Sunder, Sunitha Shyam AU - Sunder SS AD - Department of Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14203, USA. FAU - Puzanov, Igor AU - Puzanov I AD - Department of Medicine, Division of Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14203, USA. FAU - Olejniczak, Scott H AU - Olejniczak SH AUID- ORCID: 0000-0001-6857-5554 AD - Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14203, USA. FAU - Pokharel, Saraswati AU - Pokharel S AD - Department of Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14203, USA. FAU - Sharma, Umesh C AU - Sharma UC AUID- ORCID: 0000-0003-0476-2523 AD - Department of Medicine, Division of Cardiology, Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, 14203, USA. sharmau@buffalo.edu. LA - eng GR - P30 CA016056/CA/NCI NIH HHS/United States GR - R01HL152090/U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI)/ GR - R03 CA256122/CA/NCI NIH HHS/United States GR - R01 HL152090/HL/NHLBI NIH HHS/United States GR - K08 HL131987/HL/NHLBI NIH HHS/United States GR - R01 HL150266/HL/NHLBI NIH HHS/United States PT - Journal Article DEP - 20240613 PL - England TA - Commun Med (Lond) JT - Communications medicine JID - 9918250414506676 PMC - PMC11176393 OAB - Chimeric antigen receptor (CAR) T-cell therapy and blinatumomab are two new types of cancer therapies used to treat blood cancers that fail to respond to conventional chemotherapy. Our goal is to study if there are major differences in how these treatments affect the heart. We analyzed a large, global database of patients who had these treatments. We find that in a blood cancer called diffuse large B-cell lymphoma, two CAR-T cell therapies are linked to heart failure and low blood pressure. In another type of cancer, acute lymphocytic leukemia, CAR-T cell therapy is associated with heart failure and cardiac arrest. The study suggests that given the frequency and severity of these side effects, clinical care should involve an interdisciplinary team experienced in managing these serious side effects. OABL- eng COIS- The authors declare no competing interests. EDAT- 2024/06/14 00:42 MHDA- 2024/06/14 00:43 PMCR- 2024/06/13 CRDT- 2024/06/13 23:28 PHST- 2023/10/26 00:00 [received] PHST- 2024/05/29 00:00 [accepted] PHST- 2024/06/14 00:43 [medline] PHST- 2024/06/14 00:42 [pubmed] PHST- 2024/06/13 23:28 [entrez] PHST- 2024/06/13 00:00 [pmc-release] AID - 10.1038/s43856-024-00540-9 [pii] AID - 540 [pii] AID - 10.1038/s43856-024-00540-9 [doi] PST - epublish SO - Commun Med (Lond). 2024 Jun 13;4(1):116. doi: 10.1038/s43856-024-00540-9. PMID- 38867866 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240614 IS - 1520-765X (Print) IS - 1554-2815 (Electronic) IS - 1520-765X (Linking) VI - 26 IP - Suppl 1 DP - 2024 Apr TI - The golden hour in shock management: do a lot, do it quickly. PG - i78-i83 LID - 10.1093/eurheartjsupp/suae023 [doi] AB - Cardiogenic shock can be defined as a state of inadequate organ perfusion linked primarily to cardiac pump dysfunction. The two predominant causes of this condition are acute myocardial infarction and acutely decompensated heart failure (ADHF). In recent years, a significant increase in cases of cardiogenic shock from ADHF has been described. Recent evidence has defined that the factors with the greatest impact on the prognosis in this context are the early clinical assessment, the definition of the aetiology, the timely application of pharmacological therapies, or individualized mechanical supports for the circulation. Haemodynamic monitoring can help in the phenotyping of cardiogenic shock and therefore guide therapeutic choices, especially if implemented with the aid of advanced monitoring tools such as the Swan-Ganz catheter. Finally, the presence of a dedicated shock team in the 'hub' centres is fundamental, which facilitates the choice of the best therapeutic strategy on a case-by-case basis. CI - (c) The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. FAU - Marini, Marco AU - Marini M AD - University Hospital of Marche. FAU - Belleggia, Sara AU - Belleggia S AD - University Hospital of Marche. FAU - Brugiatelli, Leonardo AU - Brugiatelli L AD - University Hospital of Marche. FAU - Francioni, Matteo AU - Francioni M AD - University Hospital of Marche. FAU - Battistoni, Ilaria AU - Battistoni I AD - University Hospital of Marche. FAU - Shkoza, Matilda AU - Shkoza M AD - University Hospital of Marche. FAU - Pongetti, Giulia AU - Pongetti G AD - University Hospital of Marche. FAU - Angelini, Luca AU - Angelini L AD - University Hospital of Marche. FAU - Belfioretti, Leonardo AU - Belfioretti L AD - University Hospital of Marche. FAU - Matassini, Maria Vittoria AU - Matassini MV AD - University Hospital of Marche. LA - eng PT - Journal Article DEP - 20240417 PL - England TA - Eur Heart J Suppl JT - European heart journal supplements : journal of the European Society of Cardiology JID - 100886647 PMC - PMC11167978 OTO - NOTNLM OT - Cardiogenic shock OT - Golden hour OT - Shock team COIS- Conflict of interest: none declared. EDAT- 2024/06/13 06:44 MHDA- 2024/06/13 06:45 PMCR- 2024/04/17 CRDT- 2024/06/13 04:25 PHST- 2024/06/13 06:45 [medline] PHST- 2024/06/13 06:44 [pubmed] PHST- 2024/06/13 04:25 [entrez] PHST- 2024/04/17 00:00 [pmc-release] AID - suae023 [pii] AID - 10.1093/eurheartjsupp/suae023 [doi] PST - epublish SO - Eur Heart J Suppl. 2024 Apr 17;26(Suppl 1):i78-i83. doi: 10.1093/eurheartjsupp/suae023. eCollection 2024 Apr. PMID- 38867859 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240614 IS - 1520-765X (Print) IS - 1554-2815 (Electronic) IS - 1520-765X (Linking) VI - 26 IP - Suppl 1 DP - 2024 Apr TI - Abnormal conduction-induced cardiomyopathy: a poorly explored entity. PG - i117-i122 LID - 10.1093/eurheartjsupp/suae028 [doi] AB - A dyssynchronous biventricular activation, which can be determined by left bundle branch block, chronic right ventricular pacing, frequent premature ventricular complexes, or pre-excitation, can cause a global abnormal contractility, thus leading to systolic dysfunction and left ventricular remodelling in a unique nosological entities: abnormal conduction-induced cardiomyopathies. In this clinical scenario, the mainstay therapy is eliminating or improving LV dyssynchrony, removing the trigger. This usually ensures the improvement and even recovery of cardiac geometry and left ventricular function, especially in the absence of genetic background. A multidisciplinary approach, integrating advanced multimodal imaging, is essential for the systematic aetiological definition and the subsequent evaluation and aetiology-guided therapies of patients and their families. This review aims to describe mechanisms, prevalence, risk factors, and diagnostic and therapeutic approach to the various abnormal conduction-induced cardiomyopathies, starting from reasonable certainties and then analysing the grey areas requiring further studies. CI - (c) The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. FAU - Lalario, Andrea AU - Lalario A AD - Centre for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste, Trieste. AD - European Reference Network for rare, low prevalence and complex diseases of the heart (ERN GUARD-Heart), Italy. FAU - Rossi, Maddalena AU - Rossi M AD - Centre for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste, Trieste. AD - European Reference Network for rare, low prevalence and complex diseases of the heart (ERN GUARD-Heart), Italy. FAU - Allegro, Valentina AU - Allegro V AD - Centre for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste, Trieste. AD - European Reference Network for rare, low prevalence and complex diseases of the heart (ERN GUARD-Heart), Italy. FAU - Gagno, Giulia AU - Gagno G AD - Centre for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste, Trieste. AD - European Reference Network for rare, low prevalence and complex diseases of the heart (ERN GUARD-Heart), Italy. FAU - Perotto, Maria AU - Perotto M AD - Centre for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste, Trieste. AD - European Reference Network for rare, low prevalence and complex diseases of the heart (ERN GUARD-Heart), Italy. FAU - De Luca, Antonio AU - De Luca A AD - Centre for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste, Trieste. AD - European Reference Network for rare, low prevalence and complex diseases of the heart (ERN GUARD-Heart), Italy. FAU - Merlo, Marco AU - Merlo M AD - Centre for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste, Trieste. AD - European Reference Network for rare, low prevalence and complex diseases of the heart (ERN GUARD-Heart), Italy. FAU - Sanna, Giuseppe Damiano AU - Sanna GD AD - Clinical and Interventional Cardiology, Sassari University Hospital, Sassari, Italy. FAU - Sinagra, Gianfranco AU - Sinagra G AD - Centre for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste, Trieste. AD - European Reference Network for rare, low prevalence and complex diseases of the heart (ERN GUARD-Heart), Italy. LA - eng PT - Journal Article DEP - 20240417 PL - England TA - Eur Heart J Suppl JT - European heart journal supplements : journal of the European Society of Cardiology JID - 100886647 PMC - PMC11167964 OTO - NOTNLM OT - Cardiac conduction disorders OT - Cardiomyopathies OT - Dyssynchronopathy OT - Genetics COIS- Conflict of interest: none declared. EDAT- 2024/06/13 06:43 MHDA- 2024/06/13 06:44 PMCR- 2024/04/17 CRDT- 2024/06/13 04:25 PHST- 2024/06/13 06:44 [medline] PHST- 2024/06/13 06:43 [pubmed] PHST- 2024/06/13 04:25 [entrez] PHST- 2024/04/17 00:00 [pmc-release] AID - suae028 [pii] AID - 10.1093/eurheartjsupp/suae028 [doi] PST - epublish SO - Eur Heart J Suppl. 2024 Apr 17;26(Suppl 1):i117-i122. doi: 10.1093/eurheartjsupp/suae028. eCollection 2024 Apr. PMID- 38862282 OWN - NLM STAT- MEDLINE DCOM- 20240714 LR - 20260611 IS - 1532-8422 (Electronic) IS - 1053-0770 (Linking) VI - 38 IP - 8 DP - 2024 Aug TI - Analysis of the 2023 European Multidisciplinary Consensus Statement on the Management of Short-term Mechanical Circulatory Support of Cardiogenic Shock in Adults in the Intensive Cardiac Care Unit. PG - 1786-1801 LID - S1053-0770(24)00290-8 [pii] LID - 10.1053/j.jvca.2024.04.035 [doi] FAU - Augustin, Katrina Joy AU - Augustin KJ AD - Division of Anesthesia and Critical Care Medicine, Department of Anesthesiology & Perioperative Medicine, Mayo Clinic, Rochester, MN; Department of Emergency Medicine, Mayo Clinic, Rochester, MN. FAU - Wieruszewski, Patrick M AU - Wieruszewski PM AD - Department of Pharmacy, Mayo Clinic, Rochester, MN; Department of Anesthesiology, Mayo Clinic, Rochester, MN. FAU - McLean, Lewis AU - McLean L AD - Intensive Care Unit, John Hunter Hospital, Newcastle, Australia. FAU - Leiendecker, Eric AU - Leiendecker E AD - Department of Anesthesiology, Emory University, Atlanta, GA. FAU - Ramakrishna, Harish AU - Ramakrishna H AD - Division of Cardiovascular and Thoracic Anesthesiology, Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN. Electronic address: Ramakrishna.Harish@mayo.edu. LA - eng PT - Journal Article PT - Review DEP - 20240425 PL - United States TA - J Cardiothorac Vasc Anesth JT - Journal of cardiothoracic and vascular anesthesia JID - 9110208 SB - IM MH - Adult MH - Humans MH - Coronary Care Units MH - Critical Care/methods/standards MH - Disease Management MH - Europe MH - Extracorporeal Membrane Oxygenation/methods MH - Heart-Assist Devices MH - *Intensive Care Units MH - *Shock, Cardiogenic/therapy MH - *Consensus Statements as Topic OTO - NOTNLM OT - cardiogenic shock OT - management OT - mechanical circulatory support COIS- Declaration of competing interest The authors declare no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/06/12 00:42 MHDA- 2024/07/15 00:41 CRDT- 2024/06/11 21:56 PHST- 2024/04/19 00:00 [received] PHST- 2024/04/21 00:00 [accepted] PHST- 2024/07/15 00:41 [medline] PHST- 2024/06/12 00:42 [pubmed] PHST- 2024/06/11 21:56 [entrez] AID - S1053-0770(24)00290-8 [pii] AID - 10.1053/j.jvca.2024.04.035 [doi] PST - ppublish SO - J Cardiothorac Vasc Anesth. 2024 Aug;38(8):1786-1801. doi: 10.1053/j.jvca.2024.04.035. Epub 2024 Apr 25. PMID- 38856806 OWN - NLM STAT- MEDLINE DCOM- 20241205 LR - 20241208 IS - 1439-0973 (Electronic) IS - 0300-8126 (Print) IS - 0300-8126 (Linking) VI - 52 IP - 6 DP - 2024 Dec TI - Clinical characteristics and outcomes of aortic prosthetic valve endocarditis: comparison between transcatheter and surgical bioprostheses. PG - 2425-2434 LID - 10.1007/s15010-024-02302-0 [doi] AB - PURPOSE: Most data regarding infective endocarditis (IE) after transcatheter aortic valve implantation (TAVI) comes from TAVI registries, rather than IE dedicated cohorts. The objective of our study was to compare the clinical and microbiological profile, imaging features and outcomes of patients with IE after SAVR with a biological prosthetic valve (IE-SAVR) and IE after TAVI (IE-TAVI) from 6 centres with an Endocarditis Team (ET) and broad experience in IE. METHODS: Retrospective analysis of prospectively collected data. From the time of first TAVI implantation in each centre to March 2021, all consecutive patients admitted for IE-SAVR or IE-TAVI were prospectively enrolled. Follow-up was monitored during admission and at 12 months after discharge. RESULTS: 169 patients with IE-SAVR and 41 with IE-TAVI were analysed. Early episodes were more frequent among IE-TAVI. Clinical course during hospitalization was similar in both groups, except for a higher incidence of atrioventricular block in IE-SAVR. The most frequently causative microorganisms were S. epidermidis, Enterococcus spp. and S. aureus in both groups. Periannular complications were more frequent in IE-SAVR. Cardiac surgery was performed in 53.6% of IE-SAVR and 7.3% of IE-TAVI (p=0.001), despite up to 54.8% of IE-TAVI patients had an indication. No differences were observed about death during hospitalization (32.7% vs 35.0%), and at 1-year follow-up (41.8% vs 37.5%), regardless of whether the patient underwent surgery or not. CONCLUSION: Patients with IE-TAVI had a higher incidence of early prosthetic valve IE. Compared to IE-SAVR, IE-TAVI patients underwent cardiac surgery much less frequently, despite having surgical indications. However, in-hospital and 1-year mortality rate was similar between both groups. CI - (c) 2024. The Author(s). FAU - Jeronimo, Adrian AU - Jeronimo A AD - Instituto Cardiovascular, Hospital Clinico San Carlos, Instituto de Investigacion Sanitaria del Hospital Clinico San Carlos (IdISSC), Profesor Martin Lagos, s/n, Madrid, 28040, Spain. FAU - Olmos, Carmen AU - Olmos C AD - Instituto Cardiovascular, Hospital Clinico San Carlos, Instituto de Investigacion Sanitaria del Hospital Clinico San Carlos (IdISSC), Profesor Martin Lagos, s/n, Madrid, 28040, Spain. carmen.olmosblanco@gmail.com. AD - Department of Medicine, Faculty of Biomedical and Health Sciences, Universidad Europea de Madrid, Madrid, Spain. carmen.olmosblanco@gmail.com. FAU - Zulet, Pablo AU - Zulet P AD - Instituto Cardiovascular, Hospital Clinico San Carlos, Instituto de Investigacion Sanitaria del Hospital Clinico San Carlos (IdISSC), Profesor Martin Lagos, s/n, Madrid, 28040, Spain. FAU - Gomez-Ramirez, Daniel AU - Gomez-Ramirez D AD - Instituto Cardiovascular, Hospital Clinico San Carlos, Instituto de Investigacion Sanitaria del Hospital Clinico San Carlos (IdISSC), Profesor Martin Lagos, s/n, Madrid, 28040, Spain. FAU - Anguita, Manuel AU - Anguita M AD - Department of Cardiology, Hospital Universitario Reina Sofia. Cordoba, Cordoba, Spain. AD - Instituto Maimonides de Investigacion Biomedica, Universidad de Cordoba, Cordoba, Spain. FAU - Carlos Castillo, Juan AU - Carlos Castillo J AD - Department of Cardiology, Hospital Universitario Reina Sofia. Cordoba, Cordoba, Spain. AD - Instituto Maimonides de Investigacion Biomedica, Universidad de Cordoba, Cordoba, Spain. FAU - Escrihuela-Vidal, Francesc AU - Escrihuela-Vidal F AD - Department of Infectious Diseases, IDIBELL (Institut d Investigacio Biomedica de Bellvitge), Hospital Universitari de Bellvitge, University of Barcelona, Barcelona, Spain. FAU - Cuervo, Guillermo AU - Cuervo G AD - Department of Infectious Diseases, IDIBELL (Institut d Investigacio Biomedica de Bellvitge), Hospital Universitari de Bellvitge, University of Barcelona, Barcelona, Spain. FAU - Calderon-Parra, Jorge AU - Calderon-Parra J AD - Department of Internal Medicine, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain. FAU - Ramos, Antonio AU - Ramos A AD - Department of Internal Medicine, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain. FAU - Cabezon, Gonzalo AU - Cabezon G AD - Department of Cardiology, Hospital Clinico Universitario de Valladolid, Valladolid, Spain. FAU - Alvarez Rodriguez, Jesus AU - Alvarez Rodriguez J AD - Department of Internal Medicine, Hospital Universitario de La Princesa, Madrid, Spain. FAU - Pulido, Paloma AU - Pulido P AD - Department of Cardiology, Hospital Clinico Universitario de Valladolid, Valladolid, Spain. FAU - de Miguel-Alava, Maria AU - de Miguel-Alava M AD - Department of Cardiology, Hospital Clinico Universitario de Valladolid, Valladolid, Spain. FAU - Saez, Carmen AU - Saez C AD - Department of Internal Medicine, Hospital Universitario de La Princesa, Madrid, Spain. FAU - Lopez, Javier AU - Lopez J AD - Department of Cardiology, Hospital Clinico Universitario de Valladolid, Valladolid, Spain. AD - Centro de Investigacion Biomedica en Red de Enfermedades Cardiovasculares (CIBER-CV), Madrid, Spain. FAU - Vilacosta, Isidre AU - Vilacosta I AD - Instituto Cardiovascular, Hospital Clinico San Carlos, Instituto de Investigacion Sanitaria del Hospital Clinico San Carlos (IdISSC), Profesor Martin Lagos, s/n, Madrid, 28040, Spain. AD - Centro de Investigacion Biomedica en Red de Enfermedades Cardiovasculares (CIBER-CV), Madrid, Spain. AD - Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain. FAU - San Roman, J Alberto AU - San Roman JA AD - Department of Cardiology, Hospital Clinico Universitario de Valladolid, Valladolid, Spain. AD - Centro de Investigacion Biomedica en Red de Enfermedades Cardiovasculares (CIBER-CV), Madrid, Spain. LA - eng PT - Comparative Study PT - Journal Article DEP - 20240610 PL - Germany TA - Infection JT - Infection JID - 0365307 SB - IM MH - Humans MH - Male MH - Female MH - Retrospective Studies MH - Aged MH - *Transcatheter Aortic Valve Replacement/adverse effects MH - Aged, 80 and over MH - *Heart Valve Prosthesis/adverse effects/microbiology MH - *Prosthesis-Related Infections/microbiology MH - *Bioprosthesis/adverse effects/microbiology MH - Endocarditis/microbiology MH - Treatment Outcome MH - Aortic Valve/surgery MH - Endocarditis, Bacterial/microbiology PMC - PMC11621159 OTO - NOTNLM OT - Bioprosthesis OT - Cardiac surgery OT - Infective endocarditis OT - TAVI OT - Transcatheter COIS- Declarations. Competing interests: The authors declare no competing interests. EDAT- 2024/06/10 13:51 MHDA- 2024/12/06 05:31 PMCR- 2024/06/10 CRDT- 2024/06/10 11:08 PHST- 2024/02/12 00:00 [received] PHST- 2024/05/17 00:00 [accepted] PHST- 2024/12/06 05:31 [medline] PHST- 2024/06/10 13:51 [pubmed] PHST- 2024/06/10 11:08 [entrez] PHST- 2024/06/10 00:00 [pmc-release] AID - 10.1007/s15010-024-02302-0 [pii] AID - 2302 [pii] AID - 10.1007/s15010-024-02302-0 [doi] PST - ppublish SO - Infection. 2024 Dec;52(6):2425-2434. doi: 10.1007/s15010-024-02302-0. Epub 2024 Jun 10. PMID- 38852020 OWN - NLM STAT- MEDLINE DCOM- 20240905 LR - 20260529 IS - 1532-8600 (Electronic) IS - 0026-0495 (Linking) VI - 159 DP - 2024 Oct TI - DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases. PG - 155931 LID - S0026-0495(24)00158-6 [pii] LID - 10.1016/j.metabol.2024.155931 [doi] AB - The spectrum of cardiorenal and metabolic diseases comprises many disorders, including obesity, type 2 diabetes (T2D), chronic kidney disease (CKD), atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), dyslipidemias, hypertension, and associated comorbidities such as pulmonary diseases and metabolism dysfunction-associated steatotic liver disease and metabolism dysfunction-associated steatohepatitis (MASLD and MASH, respectively, formerly known as nonalcoholic fatty liver disease and nonalcoholic steatohepatitis [NAFLD and NASH]). Because cardiorenal and metabolic diseases share pathophysiologic pathways, two or more are often present in the same individual. Findings from recent outcome trials have demonstrated benefits of various treatments across a range of conditions, suggesting a need for practice recommendations that will guide clinicians to better manage complex conditions involving diabetes, cardiorenal, and/or metabolic (DCRM) diseases. To meet this need, we formed an international volunteer task force comprising leading cardiologists, nephrologists, endocrinologists, and primary care physicians to develop the DCRM 2.0 Practice Recommendations, an updated and expanded revision of a previously published multispecialty consensus on the comprehensive management of persons living with DCRM. The recommendations are presented as 22 separate graphics covering the essentials of management to improve general health, control cardiorenal risk factors, and manage cardiorenal and metabolic comorbidities, leading to improved patient outcomes. CI - Copyright (c) 2024 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Handelsman, Yehuda AU - Handelsman Y AD - Metabolic Institute of America, Tarzana, CA, USA. Electronic address: yhandelsman@gmail.com. FAU - Anderson, John E AU - Anderson JE AD - The Frist Clinic, Nashville, TN, USA. FAU - Bakris, George L AU - Bakris GL AD - University of Chicago Medicine, Chicago, IL, USA. FAU - Ballantyne, Christie M AU - Ballantyne CM AD - Department of Medicine, Baylor College of Medicine, Texas Heart Institute, Houston, TX, USA. FAU - Bhatt, Deepak L AU - Bhatt DL AD - Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, NY, New York, USA. FAU - Bloomgarden, Zachary T AU - Bloomgarden ZT AD - Department of Internal Medicine, Icahn School of Medicine at Mount Sinai, NY, New York, USA. FAU - Bozkurt, Biykem AU - Bozkurt B AD - Department of Medicine, Baylor College of Medicine, Houston, TX, USA. FAU - Budoff, Matthew J AU - Budoff MJ AD - David Geffen School of Medicine, UCLA, Los Angeles, CA, USA. FAU - Butler, Javed AU - Butler J AD - University of Mississippi Medical Center, Jackson, MS, USA. FAU - Cherney, David Z I AU - Cherney DZI AD - Division of Nephrology, Department of Medicine, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Canada. FAU - DeFronzo, Ralph A AU - DeFronzo RA AD - University of Texas Health Science Center, San Antonio, TX, USA. FAU - Del Prato, Stefano AU - Del Prato S AD - Interdisciplinary Research Center "Health Science", Sant'Anna School of Advanced Studies, Pisa, Italy. FAU - Eckel, Robert H AU - Eckel RH AD - University of Colorado Anschutz Medical Campus, Aurora, CO, USA. FAU - Filippatos, Gerasimos AU - Filippatos G AD - Department of Cardiology, National and Kapodistrian University of Athens, Athens, Greece. FAU - Fonarow, Gregg C AU - Fonarow GC AD - David Geffen School of Medicine, UCLA, Los Angeles, CA, USA. FAU - Fonseca, Vivian A AU - Fonseca VA AD - Tulane University Health Sciences Center, New Orleans, LA, USA. FAU - Garvey, W Timothy AU - Garvey WT AD - University of Alabama at Birmingham, Birmingham, AL, USA. FAU - Giorgino, Francesco AU - Giorgino F AD - Department of Precision and Regenerative Medicine and Ionian Area, University of Bari Aldo Moro, Bari, Italy. FAU - Grant, Peter J AU - Grant PJ AD - University of Leeds, Leeds, United Kingdom. FAU - Green, Jennifer B AU - Green JB AD - Division of Endocrinology, Metabolism, and Nutrition, Duke University School of Medicine, Durham, NC, USA. FAU - Greene, Stephen J AU - Greene SJ AD - Division of Cardiology, Duke University School of Medicine, Durham, NC, USA. FAU - Groop, Per-Henrik AU - Groop PH AD - Department of Nephrology, University of Helsinki, Finnish Institute for Health and Helsinki University HospitalWelfare, Folkhalsan Research Center, Helsinki, Finland; Department of Diabetes, Central Clinical School, Monash University, Melbourne, Australia. FAU - Grunberger, George AU - Grunberger G AD - Grunberger Diabetes Institute, Bloomfield Hills, MI, USA; Wayne State University School of Medicine, Detroit, MI, USA; Oakland University William Beaumont School of Medicine, Rochester, MI, USA; Charles University, Prague, Czech Republic. FAU - Jastreboff, Ania M AU - Jastreboff AM AD - Yale University School of Medicine, New Haven, CT, USA. FAU - Jellinger, Paul S AU - Jellinger PS AD - The Center for Diabetes & Endocrine Care, University of Miami Miller School of Medicine, Hollywood, FL, USA. FAU - Khunti, Kamlesh AU - Khunti K AD - University of Leicester, Leicester, United Kingdom. FAU - Klein, Samuel AU - Klein S AD - Washington University School of Medicine, Saint Louis, MO, USA. FAU - Kosiborod, Mikhail N AU - Kosiborod MN AD - Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City, Kansas City, MO, USA. FAU - Kushner, Pamela AU - Kushner P AD - University of California at Irvine, Irvine, CA, USA. FAU - Leiter, Lawrence A AU - Leiter LA AD - St. Michael's Hospital, University of Toronto, Toronto, Canada. FAU - Lepor, Norman E AU - Lepor NE AD - David Geffen School of Medicine, UCLA, Los Angeles, CA, USA. FAU - Mantzoros, Christos S AU - Mantzoros CS AD - Harvard Medical School, Boston University School of Medicine, Boston, MA, USA. FAU - Mathieu, Chantal AU - Mathieu C AD - Department of Endocrinology, Katholieke Universiteit Leuven, Leuven, Belgium. FAU - Mende, Christian W AU - Mende CW AD - University of California San Diego School of Medicine, La Jolla, CA, USA. FAU - Michos, Erin D AU - Michos ED AD - Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. FAU - Morales, Javier AU - Morales J AD - Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, Advanced Internal Medicine Group, PC, East Hills, NY, USA. FAU - Plutzky, Jorge AU - Plutzky J AD - Harvard Medical School, Brigham and Women's Hospital, Boston, MA, USA. FAU - Pratley, Richard E AU - Pratley RE AD - AdventHealth Translational Research Institute, Orlando, FL, USA. FAU - Ray, Kausik K AU - Ray KK AD - Imperial College London, London, United Kingdom. FAU - Rossing, Peter AU - Rossing P AD - University of Copenhagen, Copenhagen, Denmark. FAU - Sattar, Naveed AU - Sattar N AD - University of Glasgow, Glasgow, United Kingdom. FAU - Schwarz, Peter E H AU - Schwarz PEH AD - Department for Prevention and Care of Diabetes, Faculty of Medicine Carl Gustav Carus at the Technische Universitat/TU Dresden, Dresden, Germany. FAU - Standl, Eberhard AU - Standl E AD - Munich Diabetes Research Group e.V. at Helmholtz Centre, Munich, Germany. FAU - Steg, P Gabriel AU - Steg PG AD - Universite Paris-Cite, Institut Universitaire de France, AP-HP, Hopital Bichat, Cardiology, Paris, France. FAU - Tokgozoglu, Lale AU - Tokgozoglu L AD - Hacettepe University, Ankara, Turkey. FAU - Tuomilehto, Jaakko AU - Tuomilehto J AD - University of Helsinki, Finnish Institute for Health and Welfare, Helsinki, Finland. FAU - Umpierrez, Guillermo E AU - Umpierrez GE AD - Emory University, Atlanta, GA, USA. FAU - Valensi, Paul AU - Valensi P AD - Polyclinique d'Aubervilliers, Aubervilliers and Paris-Nord University, Paris, France. FAU - Weir, Matthew R AU - Weir MR AD - Division of Nephrology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA. FAU - Wilding, John AU - Wilding J AD - University of Liverpool, Liverpool, United Kingdom. FAU - Wright, Eugene E Jr AU - Wright EE Jr AD - Department of Medicine, Duke University Medical Center, Durham, NC, USA. LA - eng PT - Journal Article PT - Practice Guideline PT - Research Support, Non-U.S. Gov't DEP - 20240607 PL - United States TA - Metabolism JT - Metabolism: clinical and experimental JID - 0375267 SB - IM MH - Humans MH - Diabetes Mellitus, Type 2/therapy MH - *Metabolic Diseases/therapy COIS- Declaration of competing interest None of the Task Force members received monetary renumeration for their contributions to the creation or writing of this consensus document. See the Supplementary Appendix for full declarations of competing interests for each author. EDAT- 2024/06/09 09:42 MHDA- 2024/09/05 06:42 CRDT- 2024/06/09 02:43 PHST- 2024/04/30 00:00 [received] PHST- 2024/04/30 00:00 [accepted] PHST- 2024/09/05 06:42 [medline] PHST- 2024/06/09 09:42 [pubmed] PHST- 2024/06/09 02:43 [entrez] AID - S0026-0495(24)00158-6 [pii] AID - 10.1016/j.metabol.2024.155931 [doi] PST - ppublish SO - Metabolism. 2024 Oct;159:155931. doi: 10.1016/j.metabol.2024.155931. Epub 2024 Jun 7. PMID- 39163435 STAT- Publisher CTDT- 20240608 PB - StatPearls Publishing DP - 2024 Jan TI - ACC/AHA Guidelines for Aortic Disease (Archived). BTI - StatPearls AB - The 2022 American College of Cardiology/American Heart Association (ACC/AHA) guidelines on aortic diseases were developed by a multidisciplinary team including representatives from the ACC, AHA, American Association for Thoracic Surgery, American College of Radiology, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, and Society for Vascular Surgery. The summary of the key recommendations from the guidelines is outlined below. CI - Copyright (c) 2024, StatPearls Publishing LLC. FAU - Hussain, Kifah AU - Hussain K AD - Northwestern University FAU - Huerter, Mary AU - Huerter M AD - University of Illinois College of Medicine LA - eng PT - Study Guide PT - Book Chapter PL - Treasure Island (FL) COIS- Disclosure: Kifah Hussain declares no relevant financial relationships with ineligible companies. Disclosure: Mary Huerter declares no relevant financial relationships with ineligible companies. EDAT- 2024/06/08 00:00 CRDT- 2024/06/08 00:00 AID - NBK606128 [bookaccession] PMID- 38849904 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240610 IS - 2052-1847 (Print) IS - 2052-1847 (Electronic) IS - 2052-1847 (Linking) VI - 16 IP - 1 DP - 2024 Jun 8 TI - A multi-method exploration of a cardiac rehabilitation service delivered by registered Clinical Exercise Physiologists in the UK: key learnings for current and new services. PG - 127 LID - 10.1186/s13102-024-00907-4 [doi] LID - 127 AB - BACKGROUND: Cardiac rehabilitation has been identified as having the most homogenous clinical exercise service structure in the United Kingdom (UK), but inconsistencies are evident in staff roles and qualifications within and across services. The recognition of Clinical Exercise Physiologists (CEPs) as a registered health professional in 2021 in the UK, provides a potential solution to standardise the cardiac rehabilitation workforce. This case study examined, in a purposefully selected cardiac exercise service that employed registered CEPs, (i) how staff knowledge, skills and competencies contribute to the provision of the service, (ii) how these components assist in creating effective service teams, and (iii) the existing challenges from staff and patient perspectives. METHODS: A multi-method qualitative approach (inc., semi-structured interviews, observations, field notes and researcher reflections) was employed with the researcher immersed for 12-weeks within the service. The Consolidated Framework for Implementation Research was used as an overarching guide for data collection. Data derived from registered CEPs (n = 5), clinical nurse specialists (n = 2), dietitians (n = 1), service managers/leads (n = 2) and patients (n = 7) were thematically analysed. RESULTS: Registered CEPs delivered innovative exercise prescription based on their training, continued professional development (CPD), academic qualifications and involvement in research studies as part of the service. Exposure to a wide multidisciplinary team (MDT) allowed skill and competency transfer in areas such as clinical assessments. Developing an effective behaviour change strategy was challenging with delivery of lifestyle information more effective during less formal conversations compared to timetabled education sessions. CONCLUSIONS: Registered CEPs have the specialist knowledge and skills to undertake and implement the latest evidence-based exercise prescription in a cardiac rehabilitation setting. An MDT service structure enables a more effective team upskilling through shared peer experiences, observations and collaborative working between healthcare professionals. CI - (c) 2024. The Author(s). FAU - Crozier, Anthony AU - Crozier A AD - Research institute for Sport and Exercise Sciences, Liverpool John Moores University, Byrom Street, Liverpool, L3 3AF, UK. FAU - Graves, Lee E AU - Graves LE AD - Research institute for Sport and Exercise Sciences, Liverpool John Moores University, Byrom Street, Liverpool, L3 3AF, UK. FAU - George, Keith P AU - George KP AD - Research institute for Sport and Exercise Sciences, Liverpool John Moores University, Byrom Street, Liverpool, L3 3AF, UK. FAU - Richardson, David AU - Richardson D AD - School of Human and Behavioural Sciences, Bangor University, North Wales, UK. FAU - Naylor, Louise AU - Naylor L AD - School of Human Science (Exercise and Sport Science), The University of Western Australia, Crawley, WA, Australia. FAU - Green, Daniel J AU - Green DJ AD - School of Human Science (Exercise and Sport Science), The University of Western Australia, Crawley, WA, Australia. FAU - Rosenberg, Michael AU - Rosenberg M AD - School of Human Science (Exercise and Sport Science), The University of Western Australia, Crawley, WA, Australia. FAU - Jones, Helen AU - Jones H AD - Research institute for Sport and Exercise Sciences, Liverpool John Moores University, Byrom Street, Liverpool, L3 3AF, UK. H.jones1@ljmu.ac.uk. LA - eng GR - i-CARDIO/Research England International Investment Initiative/ GR - i-CARDIO/Research England International Investment Initiative/ GR - i-CARDIO/Research England International Investment Initiative/ GR - i-CARDIO/Research England International Investment Initiative/ GR - i-CARDIO/Research England International Investment Initiative/ GR - i-CARDIO/Research England International Investment Initiative/ GR - i-CARDIO/Research England International Investment Initiative/ GR - i-CARDIO/Research England International Investment Initiative/ PT - Journal Article DEP - 20240608 PL - England TA - BMC Sports Sci Med Rehabil JT - BMC sports science, medicine & rehabilitation JID - 101605016 PMC - PMC11162017 OTO - NOTNLM OT - Cardiac exercise provision OT - Exercise knowledge OT - Research-based exercise prescription OT - Skills and competencies COIS- The authors declare no competing interests. EDAT- 2024/06/08 10:44 MHDA- 2024/06/08 10:45 PMCR- 2024/06/08 CRDT- 2024/06/07 23:42 PHST- 2024/03/27 00:00 [received] PHST- 2024/05/16 00:00 [accepted] PHST- 2024/06/08 10:45 [medline] PHST- 2024/06/08 10:44 [pubmed] PHST- 2024/06/07 23:42 [entrez] PHST- 2024/06/08 00:00 [pmc-release] AID - 10.1186/s13102-024-00907-4 [pii] AID - 907 [pii] AID - 10.1186/s13102-024-00907-4 [doi] PST - epublish SO - BMC Sports Sci Med Rehabil. 2024 Jun 8;16(1):127. doi: 10.1186/s13102-024-00907-4. PMID- 38846966 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240608 IS - 2666-0849 (Electronic) IS - 2666-0849 (Linking) VI - 29 IP - 13 DP - 2024 Jul 3 TI - Spontaneous Migration of Ventriculoperitoneal Shunt Into the Right Heart and Pulmonary Vasculature. PG - 102376 LID - 10.1016/j.jaccas.2024.102376 [doi] LID - 102376 AB - A 73-year-old woman with ventriculoperitoneal (VP) shunt presented for stress echocardiogram for evaluation of chest pain. Transthoracic echocardiogram revealed an incidental right heart mass representing a migrated VP shunt. This case highlights the role of multimodality cardiac imaging in diagnosing right heart masses and the multidisciplinary approach to management. FAU - Yerneni, Sharmitha AU - Yerneni S AD - Tufts University School of Medicine, Boston, Massachusetts, USA. FAU - Resnic, Frederic S AU - Resnic FS AD - Lahey Hospital and Medical Center, Department of Cardiovascular Medicine, Burlington, Massachusetts, USA. FAU - Rowin, Ethan J AU - Rowin EJ AD - Lahey Hospital and Medical Center, Department of Cardiovascular Medicine, Burlington, Massachusetts, USA. FAU - Labib, Sherif B AU - Labib SB AD - Lahey Hospital and Medical Center, Burlington, Massachusetts, USA. FAU - McCarthy, Inbar R AU - McCarthy IR AD - Lahey Hospital and Medical Center, Department of Cardiovascular Medicine, Burlington, Massachusetts, USA. LA - eng PT - Journal Article DEP - 20240527 PL - Netherlands TA - JACC Case Rep JT - JACC. Case reports JID - 101757292 PMC - PMC11153913 OTO - NOTNLM OT - cardiac imaging OT - catheter-associated thrombus OT - intracardiac mass COIS- The authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2024/06/07 06:43 MHDA- 2024/06/07 06:44 PMCR- 2024/05/27 CRDT- 2024/06/07 04:51 PHST- 2024/04/22 00:00 [received] PHST- 2024/04/24 00:00 [accepted] PHST- 2024/06/07 06:44 [medline] PHST- 2024/06/07 06:43 [pubmed] PHST- 2024/06/07 04:51 [entrez] PHST- 2024/05/27 00:00 [pmc-release] AID - S2666-0849(24)00169-4 [pii] AID - 102376 [pii] AID - 10.1016/j.jaccas.2024.102376 [doi] PST - epublish SO - JACC Case Rep. 2024 May 27;29(13):102376. doi: 10.1016/j.jaccas.2024.102376. eCollection 2024 Jul 3. PMID- 38846674 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240608 IS - 2284-2594 (Electronic) IS - 2284-2594 (Linking) VI - 11 IP - 6 DP - 2024 TI - Delayed Closure of Ventricular Septal Defect with Prolonged Mechanical Support. PG - 004549 LID - 10.12890/2024_004549 [doi] LID - 004549 AB - INTRODUCTION: Ventricular septal defect (VSD) is a severe complication following acute myocardial infarction (MI) resulting from mechanical disruption of the interventricular septum due to extensive myocardial necrosis. Despite advances in management, the mortality rate approaches 50%. We report a case of a 58-year-old male with VSD following MI who was successfully treated with a delayed surgical approach after haemodynamic support using Impella. CASE DESCRIPTION: A 58-year-old man with type 2 diabetes mellitus and hypertension presented with three days of chest pain. Testing revealed late presenting acute anterior ischaemic infarction and left-to-right shunt in the apical ventricular septum. Urgent cardiac catheterisation showed near-total occlusion of the left anterior descending artery. An Impella CP((R)) was placed before angioplasty with a drug-eluting stent to optimise haemodynamics. After a multidisciplinary discussion, the Impella CP((R)) was upgraded to Impella 5.5((R)), and surgery was delayed allowing for scar formation. The patient remained in the intensive care unit, where he underwent physical therapy, showing improvements in exercise tolerance by the time of surgery. He underwent a left ventriculotomy with a successful repair via an endocardial patch 28 days after initial presentation. Post-operative recovery was uneventful, with the patient discharged five days later, reporting no physical limitations one month post-discharge. CONCLUSION: The successful management of VSD post-MI relies on interdisciplinary collaboration, careful timing of surgical intervention and the strategic use of mechanical support devices such as the Impella. This case highlights the potential for favourable outcomes when tailored treatment approaches are employed. LEARNING POINTS: Given the rarity of ventricular septal defects (VSD) post-myocardial infarction (MI), maintaining a high index of suspicion, particularly in patients with anterior infarcts and other high-risk features, is imperative for ensuring early recognition and management of this life-threatening complication.Surgical repair is the treatment of choice for VSD post-MI, offering improved survival rates, particularly when intervention is delayed to allow for myocardial scarring.Mechanical circulatory support devices, such as the Impella, can play a crucial role in bridging patients to surgical repair by providing temporary haemodynamic stabilisation. However, timing is vital, and early initiation of mechanical support can prevent the progression of cardiogenic shock and multi-organ failure. CI - (c) EFIM 2024. FAU - Shehzad, Dawood AU - Shehzad D AD - Internal Medicine, University of South Dakota, Sioux Falls, USA. FAU - Shehzad, Mustafa AU - Shehzad M AD - Internal Medicine, Hackensack University Medical Center, Hackensack, USA. FAU - Ahmad, Muhammad AU - Ahmad M AD - Department of Medicine, Khyber Medical College, Peshawar, Pakistan. FAU - Wassey, Abdul AU - Wassey A AD - Internal Medicine, Shifa College of Medicine, Islamabad, Pakistan. FAU - Zara, Noor AU - Zara N AD - Internal Medicine, Shifa College of Medicine, Islamabad, Pakistan. FAU - Younis, Humna AU - Younis H AD - Internal Medicine, Holy Family Hospital, Rawalpindi, Pakistan. FAU - Khan, Haider Ali Babar AU - Khan HAB AD - Internal Medicine, Shifa College of Medicine, Islamabad, Pakistan. LA - eng PT - Journal Article DEP - 20240513 PL - Italy TA - Eur J Case Rep Intern Med JT - European journal of case reports in internal medicine JID - 101648453 PMC - PMC11152219 OTO - NOTNLM OT - LVAD OT - Ventricular septal defect OT - mechanical circulatory support OT - myocardial infarction COIS- Conflicts of Interests: The Authors declare that there are no competing interests. EDAT- 2024/06/07 06:43 MHDA- 2024/06/07 06:44 PMCR- 2024/05/13 CRDT- 2024/06/07 04:48 PHST- 2024/04/11 00:00 [received] PHST- 2024/04/22 00:00 [accepted] PHST- 2024/06/07 06:44 [medline] PHST- 2024/06/07 06:43 [pubmed] PHST- 2024/06/07 04:48 [entrez] PHST- 2024/05/13 00:00 [pmc-release] AID - 4549 [pii] AID - 10.12890/2024_004549 [doi] PST - epublish SO - Eur J Case Rep Intern Med. 2024 May 13;11(6):004549. doi: 10.12890/2024_004549. eCollection 2024. PMID- 38846665 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240608 IS - 2284-2594 (Electronic) IS - 2284-2594 (Linking) VI - 11 IP - 6 DP - 2024 TI - Recurrent Infective Endocarditis of the Mitral Valve after Orthotopic Heart Transplantation. PG - 004528 LID - 10.12890/2024_004528 [doi] LID - 004528 AB - INTRODUCTION: Orthotopic heart transplantation is the gold standard for the treatment of advanced heart failure in the absence of contraindications. Infective endocarditis is a rare complication in patients after heart transplantation. The treatment of endocarditis after heart transplantation is challenging since there is a need for ongoing immunosuppression. CASE DESCRIPTION: We present the case of a 51-year-old orthotopic heart transplant recipient enrolled in a chronic dialysis program, in whom we diagnosed and successfully treated recurrent infective endocarditis of the mitral valve caused by Enterococcus and Enterobacter species. Despite the complicated course of the disease, the treatment was successful. CONCLUSIONS: Recurrent infective endocarditis after heart transplantation can be treated successfully with a multidisciplinary approach and robust antimicrobial therapy. LEARNING POINTS: There is a high risk of bacteraemia and subsequent endocarditis in patients with recurrent catheter-related sepsis.The spectrum of bacteria causing endocarditis in patients after heart transplantation differs from that in the general population.Scrupulous targeted antibiotic treatment is warranted for the treatment of immunosuppressed patients with endocarditis. CI - (c) EFIM 2024. FAU - Snopek, Peter AU - Snopek P AD - Department of Cardiology, Faculty Hospital, Nitra, Slovakia. AD - Faculty of Social Sciences and Health, University of Constantin Philosopher, Nitra, Slovakia. FAU - Hasilla, Jozef AU - Hasilla J AD - Department of Cardiology, Faculty Hospital, Nitra, Slovakia. AD - Faculty of Social Sciences and Health, University of Constantin Philosopher, Nitra, Slovakia. FAU - Patrovic, Lukas AU - Patrovic L AD - Jessenius Diagnostic Centre, Nitra, Slovakia. FAU - Juskanic, Dominik AU - Juskanic D AD - Jessenius Diagnostic Centre, Nitra, Slovakia. FAU - Benko, Jakub AU - Benko J AD - Department of Cardiology, Faculty Hospital, Nitra, Slovakia. AD - Department of Internal Medicine I, Jessenius Faculty of Medicine at Comenius University, Martin, Slovakia. FAU - Pec, Martin Jozef AU - Pec MJ AD - Department of Internal Medicine I, Jessenius Faculty of Medicine at Comenius University, Martin, Slovakia. FAU - Samos, Matej AU - Samos M AD - Department of Internal Medicine I, Jessenius Faculty of Medicine at Comenius University, Martin, Slovakia. AD - Department of Acute and Interventional Cardiology, Mid-Slovakian Institute of Heart and Vessel Diseases (SUSCCH), Banska Bystrica, Slovakia. AD - Department of Cardiology, Faculty Hospital, Trencin, Slovakia. LA - eng PT - Journal Article DEP - 20240422 PL - Italy TA - Eur J Case Rep Intern Med JT - European journal of case reports in internal medicine JID - 101648453 PMC - PMC11152235 OTO - NOTNLM OT - Immunosuppression OT - antibiotics OT - bacteraemia OT - catheter sepsis OT - haemodialysis COIS- Conflicts of Interests: The Authors declare that there are no competing interests. EDAT- 2024/06/07 06:43 MHDA- 2024/06/07 06:44 PMCR- 2024/04/22 CRDT- 2024/06/07 04:48 PHST- 2024/04/01 00:00 [received] PHST- 2024/04/02 00:00 [accepted] PHST- 2024/06/07 06:44 [medline] PHST- 2024/06/07 06:43 [pubmed] PHST- 2024/06/07 04:48 [entrez] PHST- 2024/04/22 00:00 [pmc-release] AID - 4528 [pii] AID - 10.12890/2024_004528 [doi] PST - epublish SO - Eur J Case Rep Intern Med. 2024 Apr 22;11(6):004528. doi: 10.12890/2024_004528. eCollection 2024. PMID- 38846646 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240608 IS - 2284-2594 (Electronic) IS - 2284-2594 (Linking) VI - 11 IP - 6 DP - 2024 TI - Automatic Implantable Cardioverter Defibrillator (AICD) Implantation as Secondary Prevention of Cardiac Sarcoidosis-Associated Ventricular Tachycardia. PG - 004469 LID - 10.12890/2024_004469 [doi] LID - 004469 AB - BACKGROUND: Cardiac sarcoidosis can cause a wide range of symptoms, including shortness of breath, chest pain, oedema, and fatal arrhythmias such as ventricular tachycardia (VT). Because the symptoms can be nonspecific, diagnosing cardiac sarcoidosis can be challenging. Treatment options may include corticosteroids to reduce inflammation, immunosuppressive drugs to prevent further damage, medications to control symptoms, ablation procedures, and defibrillators to prevent cardiac arrest. CASE: A 60-year-old woman who has sarcoidosis affecting multiple organs including cardiac sarcoidosis, non-ischemic cardiomyopathy with reduced ejection fraction, and hypertension, was admitted with tachycardia, shortness of breath, and a recently fired automatic implantable cardioverter defibrillator (AICD). Three months prior, the patient was admitted for a syncopal episode and diagnosed with cardiac sarcoidosis through cardiac magnetic resonance imaging (MRI) and positron emission tomography (PET), which demonstrated active inflammation, and an AICD was implanted. During this admission, the patient had an episode of ventricular tachycardia and was treated with amiodarone and lidocaine. The patient received steroids, sacubitril/valsartan, and methotrexate. After 48 hours of observation, the patient was discharged without further events. CONCLUSION: Cardiac sarcoidosis is a rare but serious disease that can lead to life-threatening cardiac complications such as ventricular tachycardia. Early diagnosis and aggressive management are crucial for improving outcomes and preventing sudden cardiac death. AICD implantation as a secondary prevention in cardiac sarcoidosis might prevent cardiac arrest." LEARNING POINTS: Cardiac sarcoidosis can present with non-specific symptoms and lead to life-threatening arrhythmias such as ventricular tachycardia, emphasising the importance of early diagnosis and aggressive management to prevent sudden cardiac death.A multidisciplinary approach involving imaging modalities such as cardiac magnetic resonance imaging (MRI) and positron emission tomography (PET) scans, along with histological findings, is crucial for accurately diagnosing cardiac sarcoidosis, as endomyocardial biopsy alone has low sensitivity.Implantation of an automatic implantable cardioverter defibrillator (AICD) as a secondary prevention measure should be considered in cardiac sarcoidosis patients, even in elderly individuals with mildly to moderately reduced ejection fraction, to prevent fatal arrhythmias and sudden cardiac death. CI - (c) EFIM 2024. FAU - Saliba, Fares AU - Saliba F AD - Division of Pulmonology and Critical Care, Allegheny Health Network, Pittsburgh, USA. FAU - Mina, Jonathan AU - Mina J AD - Division of Pulmonology and Critical Care, Allegheny Health Network, Pittsburgh, USA. FAU - Aoun, Laurence AU - Aoun L AD - Division of Pulmonology and Critical Care, Allegheny Health Network, Pittsburgh, USA. FAU - Khattar, Georges AU - Khattar G AD - Division of Pulmonology and Critical Care, Allegheny Health Network, Pittsburgh, USA. FAU - Bou Sanayeh, Elie AU - Bou Sanayeh E AD - Division of Pulmonology and Critical Care, Allegheny Health Network, Pittsburgh, USA. FAU - Mourad, Omar AU - Mourad O AD - Division of Pulmonology and Critical Care, Allegheny Health Network, Pittsburgh, USA. FAU - Abu Baker, Saif AU - Abu Baker S AD - Division of Pulmonology and Critical Care, Allegheny Health Network, Pittsburgh, USA. LA - eng PT - Journal Article DEP - 20240502 PL - Italy TA - Eur J Case Rep Intern Med JT - European journal of case reports in internal medicine JID - 101648453 PMC - PMC11152217 OTO - NOTNLM OT - Sarcoidosis OT - arrhythmia OT - ventricular tachycardia COIS- Conflicts of Interests: The Authors declare that there are no competing interests. EDAT- 2024/06/07 06:42 MHDA- 2024/06/07 06:43 PMCR- 2024/05/02 CRDT- 2024/06/07 04:47 PHST- 2024/03/12 00:00 [received] PHST- 2024/04/04 00:00 [accepted] PHST- 2024/06/07 06:43 [medline] PHST- 2024/06/07 06:42 [pubmed] PHST- 2024/06/07 04:47 [entrez] PHST- 2024/05/02 00:00 [pmc-release] AID - 4469 [pii] AID - 10.12890/2024_004469 [doi] PST - epublish SO - Eur J Case Rep Intern Med. 2024 May 2;11(6):004469. doi: 10.12890/2024_004469. eCollection 2024. PMID- 38845179 OWN - NLM STAT- MEDLINE DCOM- 20240715 LR - 20260612 IS - 1001-9294 (Print) IS - 1001-9294 (Linking) VI - 39 IP - 2 DP - 2024 Jun 30 TI - A Chinese Multi-Specialty Delphi Consensus to Optimize RAASi Usage and Hyperkalaemia Management in Patients with Chronic Kidney Disease and Heart Failure. PG - 79-90 LID - 10.24920/004327 [doi] AB - Objective Variations are present in common clinical practices regarding best practice in managing hyperkalaemia (HK), there is therefore a need to establish a multi-specialty approach to optimal renin-angiotension-aldosterone system inhibitors (RAASi) usage and HK management in patients with chronic kidney disease (CKD) & heart failure (HF).This study aimed to establish a multi-speciality approach to the optimal use of RAASi and the management of HK in patients with CKD and HF. Methods A steering expert group of cardiology and nephrology experts across China were convened to discuss challenges to HK management through a nominal group technique. The group then created a list of 41 statements for a consensus questionnaire, which was distributed for a further survey in extended panel group of cardiologists and nephrologists across China. Consensus was assessed using a modified Delphi technique, with agreement defined as "strong" (>/=75% and <90%) and "very strong" (>/=90%). The steering group, data collection, and analysis were aided by an independent facilitator. Results A total of 150 responses from 21 provinces across China were recruited in the survey. Respondents were comprised of an even split (n=75, 50%) between cardiologists and nephrologists. All 41 statements achieved the 75% consensus agreement threshold, of which 27 statements attained very strong consensus (>/=90% agreement) and 14 attained strong consensus (agreement between 75% and 90%). Conclusion Based on the agreement levels from respondents, the steering group agreed a set of recommendations intended to improve patient outcomes in the use of RAASi therapy and HK management in China. FAU - Zhao, Ming-Hui AU - Zhao MH AD - Renal Division, Peking University First Hospital, Beijing 100034, China. FAU - Chen, Wei AU - Chen W AD - Department of Nephrology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510080, China. FAU - Cheng, Hong AU - Cheng H AD - Department of Nephrology, Capital Medical University, Beijing 100029, China. FAU - Liu, Bi-Cheng AU - Liu BC AD - Department of Nephrology, Southeast University Zhongda Hospital, Nanjing 210009, China. FAU - Mao, Zhi-Guo AU - Mao ZG AD - Department of Nephrology, Shanghai Changzheng Hospital, Shanghai 200003, China. FAU - Tian, Zhuang AU - Tian Z AD - Department of Cardiology, Peking Union Medical College Hospital, Beijing 100730, China. FAU - Xu, Gang AU - Xu G AD - Renal Division, Tongji Medical College of Huazhong University of Science and Technology, Wuhan 430030, China. FAU - Zhou, Jing-Min AU - Zhou JM LA - eng PT - Consensus Statement PT - Journal Article PL - Netherlands TA - Chin Med Sci J JT - Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih JID - 9112559 RN - 0 (Angiotensin-Converting Enzyme Inhibitors) SB - IM MH - Humans MH - Angiotensin-Converting Enzyme Inhibitors/therapeutic use MH - China MH - Delphi Technique MH - *Heart Failure/drug therapy MH - *Hyperkalemia/drug therapy MH - *Renal Insufficiency, Chronic/therapy/drug therapy/complications MH - Renin-Angiotensin System/drug effects MH - Surveys and Questionnaires OTO - NOTNLM OT - RAASi OT - Sardiorenal syndrome OT - chronic kidney failure OT - heart failure OT - hyperkalemia OT - multidisciplinary communication EDAT- 2024/06/07 06:42 MHDA- 2024/07/15 12:44 CRDT- 2024/06/07 01:33 PHST- 2024/07/15 12:44 [medline] PHST- 2024/06/07 06:42 [pubmed] PHST- 2024/06/07 01:33 [entrez] AID - 1717737208020-925806349 [pii] AID - 10.24920/004327 [doi] PST - ppublish SO - Chin Med Sci J. 2024 Jun 30;39(2):79-90. doi: 10.24920/004327. PMID- 38842414 OWN - NLM STAT- MEDLINE DCOM- 20240816 LR - 20250226 IS - 1537-6591 (Electronic) IS - 1058-4838 (Print) IS - 1058-4838 (Linking) VI - 79 IP - 2 DP - 2024 Aug 16 TI - Evaluation of the HANDOC Score and the 2023 International Society of Cardiovascular Infectious Diseases and European Society of Cardiology Duke Clinical Criteria for the Diagnosis of Infective Endocarditis Among Patients With Streptococcal Bacteremia. PG - 434-442 LID - 10.1093/cid/ciae315 [doi] AB - BACKGROUND: Streptococci are a common cause of infective endocarditis (IE). We aimed to evaluate the performance of the HANDOC score to identify patients at high risk for IE and the Duke clinical criteria of the European Society of Cardiology (ESC; 2015 and 2023 versions) and the 2023 version from the International Society of Cardiovascular Infectious Diseases (ISCVID) in diagnosing IE among patients with streptococcal bacteremia. METHODS: This retrospective study included adult patients with streptococcal bacteremia hospitalized at Lausanne University Hospital. Episodes were classified as IE by the Endocarditis Team. A HANDOC score >2 classified patients as high risk for IE. RESULTS: Among 851 episodes with streptococcal bacteremia, IE was diagnosed in 171 episodes (20%). Among 607 episodes with non-beta-hemolytic streptococci, 213 (35%) had HANDOC scores >2 points; 132 (22%) had IE. The sensitivity of the HANDOC score to identify episodes at high risk for IE was 95% (95% confidence interval [CI], 90%-98%), the specificity 82% (95% CI, 78%-85%), and the negative predictive value (NPV) 98% (95% CI, 96%-99%). 2015 Duke-ESC, 2023 Duke-ISCVID, and 2023 Duke-ESC clinical criteria classified 114 (13%), 145 (17%), and 126 (15%) episodes as definite IE, respectively. Sensitivity (95% CI) for the 2015 Duke-ESC, 2023 Duke-ISCVID, and 2023 Duke-ESC clinical criteria was calculated at 65% (57%-72%), 81% (74%-86%), and 73% (65%-79%), respectively, with specificity (95% CI) at 100% (98%-100%), 99% (98%-100%), and 99% (98%-100%), respectively. CONCLUSIONS: The HANDOC score showed an excellent NPV to identify episodes at high risk for IE. Among the different versions of the Duke criteria, the 2023 Duke-ISCVID version fared better for the diagnosis of IE among streptococcal bacteremia. CI - (c) The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. FAU - Fourre, Nicolas AU - Fourre N AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Zimmermann, Virgile AU - Zimmermann V AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Senn, Laurence AU - Senn L AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. AD - Infection Prevention and Control Unit, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Monney, Pierre AU - Monney P AD - Department of Cardiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Tzimas, Georgios AU - Tzimas G AD - Department of Cardiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Caruana, Giorgia AU - Caruana G AD - Institute of Microbiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Tozzi, Piergiorgio AU - Tozzi P AD - Department of Cardiac Surgery, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Kirsch, Matthias AU - Kirsch M AD - Department of Cardiac Surgery, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Guery, Benoit AU - Guery B AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Papadimitriou-Olivgeris, Matthaios AU - Papadimitriou-Olivgeris M AUID- ORCID: 0000-0003-0565-5105 AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. AD - Infection Prevention and Control Unit, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. AD - Infectious Diseases Service, Cantonal Hospital of Sion and Institut Central des Hopitaux, Sion, Switzerland. LA - eng PT - Journal Article PL - United States TA - Clin Infect Dis JT - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America JID - 9203213 SB - IM MH - Humans MH - *Streptococcal Infections/diagnosis/microbiology/complications MH - Retrospective Studies MH - Male MH - Female MH - *Bacteremia/diagnosis/microbiology MH - Middle Aged MH - Aged MH - Sensitivity and Specificity MH - Endocarditis, Bacterial/diagnosis/microbiology MH - Endocarditis/diagnosis/microbiology/complications MH - Adult PMC - PMC11327781 OTO - NOTNLM OT - Duke criteria OT - bloodstream infection OT - infective endocarditis OT - sepsis OT - streptococci COIS- Potential conflicts of interest. The authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. EDAT- 2024/06/06 12:44 MHDA- 2024/08/16 13:42 PMCR- 2024/06/06 CRDT- 2024/06/06 09:43 PHST- 2024/03/16 00:00 [received] PHST- 2024/08/16 13:42 [medline] PHST- 2024/06/06 12:44 [pubmed] PHST- 2024/06/06 09:43 [entrez] PHST- 2024/06/06 00:00 [pmc-release] AID - 7688884 [pii] AID - ciae315 [pii] AID - 10.1093/cid/ciae315 [doi] PST - ppublish SO - Clin Infect Dis. 2024 Aug 16;79(2):434-442. doi: 10.1093/cid/ciae315. PMID- 38841082 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240607 IS - 2225-319X (Print) IS - 2304-1021 (Electronic) IS - 2225-319X (Linking) VI - 13 IP - 3 DP - 2024 May 31 TI - What did the transcatheter aortic valve replacement-surgical aortic valve replacement (TAVR-SAVR) trials tell us? PG - 206-210 LID - 10.21037/acs-2023-aae-0152 [doi] AB - Two families of randomized trials comparing transcatheter aortic valve replacement (TAVR) to surgery for both the Balloon Expandable Valve and the Supra Annular Self-Expanding Valve have been completed to include all surgical risk levels. The result of these trials has led to the approval of TAVR for symptomatic severe aortic stenosis without using risk level as the sole criterion. We have seen an explosion of TAVR in the US to over 98,000 commercial cases in 2022. We have also seen a rapid increase in the use of TAVR in patients less than 65 years of age. With these increases, it is important to ask if they are being driven largely by the data or just the desire for TAVR by both patients and their physicians. Heart team input is a class I indication when deciding between TAVR and surgery. For surgical members of the heart team to appropriately counsel patients, a full understanding of what the TAVR surgery trials tell us as well as what they do not is essential. In this article we will explore those questions. CI - 2024 Annals of Cardiothoracic Surgery. All rights reserved. FAU - Atkins, Marvin D AU - Atkins MD AD - Department of Cardiovascular Surgery, Houston Methodist Hospital, Houston, TX, USA. FAU - Reardon, Michael J AU - Reardon MJ AD - Department of Cardiovascular Surgery, Houston Methodist Hospital, Houston, TX, USA. LA - eng PT - Journal Article PT - Review DEP - 20240401 PL - China TA - Ann Cardiothorac Surg JT - Annals of cardiothoracic surgery JID - 101605877 PMC - PMC11148760 OTO - NOTNLM OT - Surgical aortic valve replacement (SAVR) OT - lifetime management of aortic stenosis (lifetime management of AS) OT - transcatheter aortic valve replacement (TAVR) COIS- Conflicts of Interest: M.J.R. served as national PI for the Medtronic SURTAVI and Evolut low risk trials. The authors have no other conflicts of interest to declare. EDAT- 2024/06/06 06:44 MHDA- 2024/06/06 06:45 PMCR- 2024/05/31 CRDT- 2024/06/06 04:00 PHST- 2023/08/08 00:00 [received] PHST- 2023/12/18 00:00 [accepted] PHST- 2024/06/06 06:45 [medline] PHST- 2024/06/06 06:44 [pubmed] PHST- 2024/06/06 04:00 [entrez] PHST- 2024/05/31 00:00 [pmc-release] AID - acs-13-03-206 [pii] AID - 10.21037/acs-2023-aae-0152 [doi] PST - ppublish SO - Ann Cardiothorac Surg. 2024 May 31;13(3):206-210. doi: 10.21037/acs-2023-aae-0152. Epub 2024 Apr 1. PMID- 38839105 OWN - NLM STAT- MEDLINE DCOM- 20250626 LR - 20250626 IS - 1545-1569 (Electronic) IS - 1055-6656 (Linking) VI - 62 IP - 8 DP - 2025 Aug TI - A Nationwide Analysis of the Impact of Cardiopulmonary Anomalies on Cleft Palate Surgical Outcomes. PG - 1346-1351 LID - 10.1177/10556656241258525 [doi] AB - ObjectiveTo increase awareness and improve perioperative care of patients with cleft palate (CP) and coexisting cardiopulmonary anomalies.DesignRetrospective cohort.SettingMulti-center.Patients/ParticipantsPatients who underwent surgical repair of CP between 2012-2020 identified in the American College of Surgeons National Surgical Quality Improvement Program Pediatric Data File. Chi-squared analysis and Student's t-test were implemented to make associations between congenital heart disease (CHD) and congenital pulmonary disease (CPD) and postoperative complications. Multiple logistic regression was performed to identify associations between CP and CHD/CPD while controlling for age, gender, and ASA class. C2 values were used to assess the logistic regressions, with a significance level of 0.05 indicating statistical significance.Main Outcomes MeasuresLength of stay (LOS), perioperative complications (readmission, reoperation, reintubation, wound dehiscence, cerebrovascular accidents, and mortality).Results9 96 181 patients were identified in the database, 17 786 of whom were determined to have CP, of whom 16.0% had congenital heart defects (CHD) and 13.2% had congenital pulmonary defects (CPD). Patients with CHD and CPD were at a significantly greater risk of increased LOS and all but one operative complication rate (wound dehiscence) relative to patients with CP without a history of CHD and CPD.ConclusionThis study suggests that congenital cardiopulmonary disease is associated with increased adverse outcomes in the setting of CP repair. Thus, heightened clinical suspicion for coexisting congenital anomalies in the presence of CP should prompt referring providers to perform a comprehensive and multidisciplinary evaluation to ensure cardiopulmonary optimization prior to surgical intervention. FAU - Stanton, Eloise W AU - Stanton EW AUID- ORCID: 0000-0003-0063-8584 AD - Division of Plastic and Maxillofacial Surgery, Children's Hospital Los Angeles, Los Angeles, CA, USA. RINGGOLD: 5150 AD - Division of Plastic and Reconstructive Surgery, Keck School of Medicine, Los Angeles, CA, USA. RINGGOLD: 12223 FAU - Manasyan, Artur AU - Manasyan A AUID- ORCID: 0009-0009-0088-2991 AD - Division of Plastic and Maxillofacial Surgery, Children's Hospital Los Angeles, Los Angeles, CA, USA. RINGGOLD: 5150 AD - Division of Plastic and Reconstructive Surgery, Keck School of Medicine, Los Angeles, CA, USA. RINGGOLD: 12223 FAU - Roohani, Idean AU - Roohani I AUID- ORCID: 0009-0003-7843-583X AD - Division of Plastic and Maxillofacial Surgery, Children's Hospital Los Angeles, Los Angeles, CA, USA. RINGGOLD: 5150 AD - Division of Plastic and Reconstructive Surgery, Keck School of Medicine, Los Angeles, CA, USA. RINGGOLD: 12223 FAU - Kondra, Katelyn AU - Kondra K AUID- ORCID: 0000-0003-0739-8763 AD - Division of Plastic and Maxillofacial Surgery, Children's Hospital Los Angeles, Los Angeles, CA, USA. RINGGOLD: 5150 AD - Division of Plastic and Reconstructive Surgery, Keck School of Medicine, Los Angeles, CA, USA. RINGGOLD: 12223 FAU - Haynes, Karla AU - Haynes K AD - Division of Plastic and Maxillofacial Surgery, Children's Hospital Los Angeles, Los Angeles, CA, USA. RINGGOLD: 5150 FAU - Urata, Mark M AU - Urata MM AD - Division of Plastic and Maxillofacial Surgery, Children's Hospital Los Angeles, Los Angeles, CA, USA. RINGGOLD: 5150 AD - Division of Plastic and Reconstructive Surgery, Keck School of Medicine, Los Angeles, CA, USA. RINGGOLD: 12223 AD - Division of Oral and Maxillofacial Surgery, University of Southern California, Los Angeles, CA, USA. RINGGOLD: 12223 AD - Herman Ostrow School of Dentistry, University of Southern California, Los Angeles, CA, USA. RINGGOLD: 12223 FAU - Magee, William P 3rd AU - Magee WP 3rd AD - Division of Plastic and Maxillofacial Surgery, Children's Hospital Los Angeles, Los Angeles, CA, USA. RINGGOLD: 5150 AD - Division of Plastic and Reconstructive Surgery, Keck School of Medicine, Los Angeles, CA, USA. RINGGOLD: 12223 AD - Division of Oral and Maxillofacial Surgery, University of Southern California, Los Angeles, CA, USA. RINGGOLD: 12223 AD - Herman Ostrow School of Dentistry, University of Southern California, Los Angeles, CA, USA. RINGGOLD: 12223 FAU - Hammoudeh, Jeffrey A AU - Hammoudeh JA AUID- ORCID: 0000-0003-0030-1420 AD - Division of Plastic and Maxillofacial Surgery, Children's Hospital Los Angeles, Los Angeles, CA, USA. RINGGOLD: 5150 AD - Division of Plastic and Reconstructive Surgery, Keck School of Medicine, Los Angeles, CA, USA. RINGGOLD: 12223 AD - Division of Oral and Maxillofacial Surgery, University of Southern California, Los Angeles, CA, USA. RINGGOLD: 12223 AD - Herman Ostrow School of Dentistry, University of Southern California, Los Angeles, CA, USA. RINGGOLD: 12223 LA - eng PT - Journal Article DEP - 20240605 PL - United States TA - Cleft Palate Craniofac J JT - The Cleft palate-craniofacial journal : official publication of the American Cleft Palate-Craniofacial Association JID - 9102566 SB - IM MH - Humans MH - *Cleft Palate/surgery/complications/epidemiology MH - Male MH - Female MH - *Heart Defects, Congenital/complications/epidemiology/surgery MH - *Postoperative Complications/epidemiology MH - Infant MH - Child, Preschool MH - Length of Stay/statistics & numerical data MH - United States/epidemiology MH - Child MH - *Lung Diseases/congenital/epidemiology/complications MH - Retrospective Studies MH - Treatment Outcome OTO - NOTNLM OT - cleft palate OT - counseling OT - craniofacial surgery OT - development OT - team care COIS- Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2024/06/06 01:14 MHDA- 2025/06/26 12:29 CRDT- 2024/06/05 20:53 PHST- 2025/06/26 12:29 [medline] PHST- 2024/06/06 01:14 [pubmed] PHST- 2024/06/05 20:53 [entrez] AID - 10.1177/10556656241258525 [doi] PST - ppublish SO - Cleft Palate Craniofac J. 2025 Aug;62(8):1346-1351. doi: 10.1177/10556656241258525. Epub 2024 Jun 5. PMID- 38838987 OWN - NLM STAT- MEDLINE DCOM- 20240914 LR - 20240914 IS - 1615-5947 (Electronic) IS - 0890-5096 (Linking) VI - 108 DP - 2024 Nov TI - Thoracic Stent Grafts Induce Persistent Aortic Remodeling in Aortic Coarctation. PG - 1-9 LID - S0890-5096(24)00224-3 [pii] LID - 10.1016/j.avsg.2024.03.009 [doi] AB - BACKGROUND: This study's objective is to describe outcomes of adult patients who underwent thoracic stent graft placement treatment for primary or recurrent aortic coarctation. METHODS: This is a retrospective study of 30 adult patients who underwent thoracic stent graft placement for aortic coarctation at our institution. Average age was 46.5 years, with 53.3% of patients presented with no prior treatment or repair for coarctation. Indications for repair included gradient >/=20 mm Hg with anatomic evidence of coarctation on imaging with left ventricular hypertrophy, pseudoaneurysm, aneurysm, refractory hypertension, or claudication. Stent grafts used for repair included MDT (Medtronic, Santa Rosa, CA) and GORE TAG (W. L. Gore & Associates, Flagstaff, AZ). RESULTS: Patients were observed for a median of 979 days, with one death during the study. All patients had complete resolution of symptoms with no recurrences. Thoracic endovascular aortic repair significantly reduced the gradient across the coarctation (P < 0.0001). Aortic coarctation diameter significantly increased at 30 days postoperatively and continued to increase up to 5 years posttreatment. At 3+ years, aortic remodeling was observed at the coarctation site and surrounding regions. At 30 days, systolic, diastolic, and mean arterial pressure were all reduced. Systolic and diastolic blood pressure and mean arterial pressure continued to significantly improve 1-year posttreatment. CONCLUSIONS: Stent grafts are a safe and effective treatment for aortic coarctation. We observed a clinically significant improvement in blood pressure and longitudinal aortic remodeling of the coarctation segment and the entire aorta that persisted more than more than 3 years. CI - Copyright (c) 2024 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Yammine, Halim AU - Yammine H AD - Atrium Health, Sanger Heart and Vascular Institute, Charlotte, NC. Electronic address: hyammine@gmail.com. FAU - Frederick, John R AU - Frederick JR AD - Atrium Health, Sanger Heart and Vascular Institute, Charlotte, NC. FAU - Alegria, Jorge AU - Alegria J AD - Atrium Health, Sanger Heart and Vascular Institute, Charlotte, NC. FAU - Madjarov, Jeko M AU - Madjarov JM AD - Atrium Health, Sanger Heart and Vascular Institute, Charlotte, NC. FAU - Clemons, Garrett A AU - Clemons GA AD - Atrium Health, Sanger Heart and Vascular Institute, Charlotte, NC. FAU - Arko, Stephen J AU - Arko SJ AD - Atrium Health, Sanger Heart and Vascular Institute, Charlotte, NC. FAU - Thorne, Tre D AU - Thorne TD AD - Atrium Health, Sanger Heart and Vascular Institute, Charlotte, NC. FAU - Arko, Frank R 3rd AU - Arko FR 3rd AD - Atrium Health, Sanger Heart and Vascular Institute, Charlotte, NC. LA - eng PT - Journal Article DEP - 20240603 PL - Netherlands TA - Ann Vasc Surg JT - Annals of vascular surgery JID - 8703941 SB - IM MH - Humans MH - *Aortic Coarctation/surgery/physiopathology/diagnostic imaging/complications MH - Retrospective Studies MH - Male MH - Female MH - Middle Aged MH - *Stents MH - Treatment Outcome MH - *Vascular Remodeling MH - Adult MH - *Endovascular Procedures/instrumentation/adverse effects MH - *Blood Vessel Prosthesis Implantation/instrumentation/adverse effects MH - *Blood Vessel Prosthesis MH - Time Factors MH - *Aorta, Thoracic/surgery/physiopathology/diagnostic imaging MH - *Prosthesis Design MH - Recurrence MH - Aged MH - Young Adult EDAT- 2024/06/06 01:14 MHDA- 2024/09/15 14:09 CRDT- 2024/06/05 19:27 PHST- 2024/01/16 00:00 [received] PHST- 2024/02/29 00:00 [revised] PHST- 2024/03/04 00:00 [accepted] PHST- 2024/09/15 14:09 [medline] PHST- 2024/06/06 01:14 [pubmed] PHST- 2024/06/05 19:27 [entrez] AID - S0890-5096(24)00224-3 [pii] AID - 10.1016/j.avsg.2024.03.009 [doi] PST - ppublish SO - Ann Vasc Surg. 2024 Nov;108:1-9. doi: 10.1016/j.avsg.2024.03.009. Epub 2024 Jun 3. PMID- 38836879 OWN - NLM STAT- MEDLINE DCOM- 20250424 LR - 20250424 IS - 1432-1971 (Electronic) IS - 0172-0643 (Linking) VI - 46 IP - 5 DP - 2025 Jun TI - A Novel Mental Health Curriculum Pilot for Pediatric Cardiology Fellows: Preparing the Subspecialist to Expand the Team. PG - 1157-1162 LID - 10.1007/s00246-024-03532-7 [doi] AB - Mental health (MH) is an important, yet understudied area of care for patients with congenital heart disease (CHD). Pediatric subspecialty fellows believe MH should be within their scope of practice, but few feel confident in their ability to appropriately screen, evaluate, manage, and make treatment referrals for youth with CHD and concurrent MH concerns. A 6-session, didactic-based curriculum was designed by an interprofessional team of experts. It was administered to pediatric cardiology fellows over 9 months during two academic years. Topics included the following: Introduction to MH and CHD, MH Screening and Clinic-Based Interventions, Psychopharmacology, Delirium, Trauma-Informed Care, and Adult CHD and Transitional Care. An investigator-designed survey was developed to assess fellow comfort with MH knowledge, screening, and treatment recommendation domains. Twenty-three fellows participated with 14 completing the pre-post survey (58% participation, 11/17 in year 1, 3/6 in year 2). Most participants were in their first year of training (9/14, 57%). Overall, fellow comfort with MH topics increased significantly (mean score 2.89 +/- 0.46 vs. 3.4 +/- 0.4, p = 0.0005), with improved comfort in the MH knowledge (p = 0.003) and treatment recommendation domains (p = 0.001). A didactic-based MH curriculum improves the comfort of pediatric cardiology fellows to address the MH concerns of their patients. The topics in this curriculum will continue to be refined over time and could be generalized to training programs, both nationally and across pediatric specialties, to improve MH care for high-risk populations. CI - (c) 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - McCormick, Amanda D AU - McCormick AD AUID- ORCID: 0000-0002-4874-854X AD - Division of Pediatric Cardiology, Department of Pediatrics, C. S. Mott Children's Hospital, Michigan Medicine, 1540 E Hospital Drive, Ann Arbor, MI, 48109, USA. acdelong@med.umich.edu. FAU - Owens, Sonal T AU - Owens ST AD - Division of Pediatric Cardiology, Department of Pediatrics, C. S. Mott Children's Hospital, Michigan Medicine, 1540 E Hospital Drive, Ann Arbor, MI, 48109, USA. FAU - Lim, Heang M AU - Lim HM AD - Division of Pediatric Cardiology, Department of Pediatrics, C. S. Mott Children's Hospital, Michigan Medicine, 1540 E Hospital Drive, Ann Arbor, MI, 48109, USA. FAU - Vitale, Carolyn AU - Vitale C AD - Division of Pediatric Cardiology, Department of Pediatrics, C. S. Mott Children's Hospital, Michigan Medicine, 1540 E Hospital Drive, Ann Arbor, MI, 48109, USA. FAU - Dusing, Catherine AU - Dusing C AD - Division of Pediatric Psychology, Department of Pediatrics, Michigan Medicine, Ann Arbor, MI, USA. FAU - Rea, Kelly E AU - Rea KE AD - Division of Pediatric Psychology, Department of Pediatrics, Michigan Medicine, Ann Arbor, MI, USA. FAU - Pierce, Jessica AU - Pierce J AD - Division of Child and Adolescent Psychiatry, Department of Psychiatry, Michigan Medicine, Ann Arbor, MI, USA. FAU - Malas, Nasuh AU - Malas N AD - Division of Child and Adolescent Psychiatry, Department of Psychiatry, Michigan Medicine, Ann Arbor, MI, USA. AD - Department of Pediatrics, Michigan Medicine, Ann Arbor, MI, USA. FAU - Cousino, Melissa K AU - Cousino MK AUID- ORCID: 0000-0002-0041-0830 AD - Division of Pediatric Psychology, Department of Pediatrics, Michigan Medicine, Ann Arbor, MI, USA. LA - eng PT - Journal Article PT - Review DEP - 20240605 PL - United States TA - Pediatr Cardiol JT - Pediatric cardiology JID - 8003849 SB - IM MH - Humans MH - *Curriculum MH - *Cardiology/education MH - *Pediatrics/education MH - *Heart Defects, Congenital/psychology/therapy MH - *Mental Health/education MH - *Fellowships and Scholarships MH - Pilot Projects MH - *Education, Medical, Graduate/methods MH - Surveys and Questionnaires MH - *Patient Care Team MH - Adult MH - Female MH - Male MH - Child OTO - NOTNLM OT - Congenital heart disease OT - Medical education OT - Mental health OT - Pediatric cardiology OT - Psychology COIS- Declarations. Competing interest: The authors have no competing interests, financial or otherwise, to declare that are directly or indirectly related to the work in this manuscript. EDAT- 2024/06/05 13:13 MHDA- 2025/04/24 12:30 CRDT- 2024/06/05 11:03 PHST- 2024/03/05 00:00 [received] PHST- 2024/05/22 00:00 [accepted] PHST- 2025/04/24 12:30 [medline] PHST- 2024/06/05 13:13 [pubmed] PHST- 2024/06/05 11:03 [entrez] AID - 10.1007/s00246-024-03532-7 [pii] AID - 10.1007/s00246-024-03532-7 [doi] PST - ppublish SO - Pediatr Cardiol. 2025 Jun;46(5):1157-1162. doi: 10.1007/s00246-024-03532-7. Epub 2024 Jun 5. PMID- 38834973 OWN - NLM STAT- MEDLINE DCOM- 20240605 LR - 20241113 IS - 1471-2261 (Electronic) IS - 1471-2261 (Linking) VI - 24 IP - 1 DP - 2024 Jun 4 TI - Risk for cardiovascular disease development in rheumatoid arthritis. PG - 291 LID - 10.1186/s12872-024-03963-3 [doi] LID - 291 AB - BACKGROUND: Patients with rheumatoid arthritis have significant cardiovascular mortality and morbidity. OBJECTIVE: To investigate the effects of chronic inflammation in rheumatoid arthritis on cardiovascular morbidity association with cardiovascular risk factors risk factors. Mortality report is secondary just to show trends without sufficient statistical power as it is accidental endpoint. METHODS: A total of 201 individuals without previous cardiovascular disease, 124 with rheumatoid arthritis (investigation group) and 77 with osteoarthritis (control group), were included in the study and followed up for an average of 8 years to assess the development of fatal or non-fatal cardiovascular diseases. The incidence and prevalence of cardiovascular risk factors were also investigated. RESULTS: The total incidence of one or more fatal or nonfatal cardiovascular events was 43.9% in the investigation group and 37.5% in the control group. Of these patients, 31.7% and 30.9% survived cardiovascular events in the investigation and control groups, respectively. The most common cardiovascular disease among participants who completed the study and those who died during the study was chronic heart failure. The results of the subgroup analysis showed that strict inflammation control plays a central role in lowering cardiovascular risk. CONCLUSION: A multidisciplinary approach to these patients is of paramount importance, especially with the cooperation of immunologists and cardiologists for early detection, prevention, and management of cardiovascular risks and diseases. CI - (c) 2024. The Author(s). FAU - Bedekovic, Drazen AU - Bedekovic D AD - Department of Cardiovascular Diseases, Internal Medicine Clinic, University Hospital Osijek, J. Huttlera 4, Osijek, 31000, Croatia. AD - Faculty of Medicine Osijek, Department of Internal Medicine, University J.J. Strossmayer, J. Huttlera 4, Osijek, 31000, Croatia. FAU - Bosnjak, Ivica AU - Bosnjak I AD - Department of Cardiovascular Diseases, Internal Medicine Clinic, University Hospital Osijek, J. Huttlera 4, Osijek, 31000, Croatia. dribosnjak79@gmail.com. FAU - Bilic-Curcic, Ines AU - Bilic-Curcic I AD - Department for Pharmacology, Faculty of Medicine, J. J. Strossmayer University of Osijek, J. Huttlera 4, Osijek, 31000, Croatia. AD - Department of Endocrinology and Metabolism Disorders, Internal Medicine Clinic, University Hospital Centre Osijek, J. Huttlera 4, Osijek, 31000, Croatia. FAU - Kirner, Damir AU - Kirner D AD - Department of Cardiovascular Diseases, Internal Medicine Clinic, University Hospital Osijek, J. Huttlera 4, Osijek, 31000, Croatia. AD - Faculty of Medicine Osijek, Department of Internal Medicine, University J.J. Strossmayer, J. Huttlera 4, Osijek, 31000, Croatia. FAU - Saric, Sandra AU - Saric S AD - Department of Cardiovascular Diseases, Internal Medicine Clinic, University Hospital Osijek, J. Huttlera 4, Osijek, 31000, Croatia. AD - Faculty of Medicine Osijek, Department of Internal Medicine, University J.J. Strossmayer, J. Huttlera 4, Osijek, 31000, Croatia. FAU - Novak, Srdan AU - Novak S AD - Department of Rheumatology and Clinical Immunology, University Hospital Rijeka, Rijeka, Croatia. AD - Faculty of Medicine Rijeka, Department of Internal Medicine, University of Rijeka, Brace Branchetta 20/1, Rijeka, 51000, Croatia. LA - eng PT - Journal Article DEP - 20240604 PL - England TA - BMC Cardiovasc Disord JT - BMC cardiovascular disorders JID - 100968539 SB - IM MH - Humans MH - *Arthritis, Rheumatoid/epidemiology/mortality/complications/diagnosis MH - Male MH - Female MH - *Cardiovascular Diseases/epidemiology/mortality/diagnosis MH - Middle Aged MH - *Heart Disease Risk Factors MH - Incidence MH - Risk Assessment MH - Time Factors MH - Aged MH - Prevalence MH - Case-Control Studies MH - Prognosis MH - Adult MH - Osteoarthritis/epidemiology/mortality/diagnosis MH - Risk Factors PMC - PMC11149346 OTO - NOTNLM OT - Cardiovascular mortality OT - Cardiovascular risk OT - Chronic inflammation OT - Osteoarthritis OT - Rheumatoid arthritis COIS- The authors declare no competing interests. EDAT- 2024/06/05 01:55 MHDA- 2024/06/05 06:42 PMCR- 2024/06/04 CRDT- 2024/06/04 23:34 PHST- 2023/09/01 00:00 [received] PHST- 2024/05/28 00:00 [accepted] PHST- 2024/06/05 06:42 [medline] PHST- 2024/06/05 01:55 [pubmed] PHST- 2024/06/04 23:34 [entrez] PHST- 2024/06/04 00:00 [pmc-release] AID - 10.1186/s12872-024-03963-3 [pii] AID - 3963 [pii] AID - 10.1186/s12872-024-03963-3 [doi] PST - epublish SO - BMC Cardiovasc Disord. 2024 Jun 4;24(1):291. doi: 10.1186/s12872-024-03963-3. PMID- 38831793 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240607 IS - 2512-9465 (Electronic) IS - 2567-3459 (Print) IS - 2512-9465 (Linking) VI - 8 IP - 2 DP - 2024 Apr TI - Periprocedural Anticoagulation Management of Patients Undergoing Colonoscopy with Polypectomy. PG - e216-e223 LID - 10.1055/s-0044-1787553 [doi] AB - Introduction/Objective Colonoscopy with polypectomy is an integral component of colorectal cancer screening. There are limited data and consensus on periprocedural anticoagulation management, especially regarding bleeding risk with uninterrupted anticoagulation and thromboembolic risk with interruption. Our aim was to determine the incidence of bleeding and thromboembolic complications among colon screening participants undergoing colonoscopy following implementation of a novel patient care pathway for standardized periprocedural anticoagulation management. Methods We conducted a retrospective study including all participants (age 50-74) on an oral anticoagulant (e.g., vitamin K antagonists, direct oral anticoagulants) referred to the British Columbia Colon Screening Program for colonoscopy following abnormal fecal immunochemical test in a 6-month period (March-August 2022). Data relating to their specific periprocedural anticoagulant management and colonoscopy results including method of polypectomy were obtained. Primary outcomes were major bleeding and arterial or venous thromboembolic events from time of oral anticoagulant interruption until 14 days of postcolonoscopy. Secondary outcomes included nonmajor and minor bleeding, acute coronary syndrome, emergency room visit, hospital admission, and death due to any cause. Results Over the 6-month period, 162 participants completed standardized periprocedural anticoagulation management, colonoscopy +/- polypectomy, and 14-day follow-up. One (0.6%) had a major bleeding event and one (0.6%) had an arterial thromboembolic event. Conclusions A novel patient care pathway for standardized periprocedural anticoagulation management with a multidisciplinary team is associated with low rates of major bleeding and thrombotic complications after colonoscopy with polypectomy. CI - The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. ( https://creativecommons.org/licenses/by/4.0/ ). FAU - Chan, Melissa AU - Chan M AD - Department of Medicine, University of British Columbia, Vancouver, Canada. FAU - Yoon, Joshua AU - Yoon J AD - Department of Medicine, University of British Columbia, Vancouver, Canada. FAU - Telford, Jennifer J AU - Telford JJ AD - Department of Medicine, University of British Columbia, Vancouver, Canada. AD - Division of Gastroenterology, University of British Columbia, Vancouver, Canada. AD - British Columbia Colon Screening Program, BC Cancer, Vancouver, Canada. FAU - Drury, Chipman T AU - Drury CT AD - Department of Medicine, University of British Columbia, Vancouver, Canada. AD - Division of General Internal Medicine, University of British Columbia, Vancouver, Canada. FAU - Wan, Tony AU - Wan T AD - Department of Medicine, University of British Columbia, Vancouver, Canada. AD - Division of General Internal Medicine, University of British Columbia, Vancouver, Canada. LA - eng PT - Journal Article DEP - 20240603 PL - Germany TA - TH Open JT - TH open : companion journal to thrombosis and haemostasis JID - 101715740 PMC - PMC11147676 OTO - NOTNLM OT - anticoagulation OT - colonoscopy OT - periprocedural management OT - polypectomy COIS- Conflict of Interest T.W. received honoraria from AstraZeneca for the development of the regional direct oral anticoagulant reversal order set. M.C., J.Y., J.T., and T.D. have no conflict of interest. EDAT- 2024/06/04 06:42 MHDA- 2024/06/04 06:43 PMCR- 2024/06/01 CRDT- 2024/06/04 03:35 PHST- 2024/03/03 00:00 [received] PHST- 2024/05/06 00:00 [accepted] PHST- 2024/06/04 06:43 [medline] PHST- 2024/06/04 06:42 [pubmed] PHST- 2024/06/04 03:35 [entrez] PHST- 2024/06/01 00:00 [pmc-release] AID - THOpen-24-02-0008 [pii] AID - 10.1055/s-0044-1787553 [doi] PST - epublish SO - TH Open. 2024 Jun 3;8(2):e216-e223. doi: 10.1055/s-0044-1787553. eCollection 2024 Apr. PMID- 38831703 OWN - NLM STAT- MEDLINE DCOM- 20241030 LR - 20260709 IS - 1744-8417 (Electronic) IS - 1744-6651 (Linking) VI - 19 IP - 5 DP - 2024 Sep TI - Functional state of the kidneys in patients with acute coronary syndrome against the background of newly identified disorders of carbohydrate metabolism: a multidisciplinary problem. PG - 437-445 LID - 10.1080/17446651.2024.2363543 [doi] AB - BACKGROUND: Determining the relationship between cardiovascular risks, carbohydrate metabolism disorders, and renal dysfunction can help in creating new tools for their management and for better interaction of specialists in a multidisciplinary team. The purpose of this study was to determine the functional state of the kidneys and carbohydrate metabolism in patients with acute coronary syndrome without a history of such disorders. METHODS: 200 patients of the cardiology department of the City Clinical Hospital No. 7 in Almaty were examined using laboratory diagnostics and subsequent statistical data processing. RESULTS: Acute coronary syndrome develops in 63% of cases against the background of previous disorders of carbohydrate metabolism - prediabetes (45.5%) and type 2 diabetes mellitus (17.5%). In this group of patients, in the presence of disorders of carbohydrate metabolism, in all cases, it is accompanied by acute renal damage. It was noted that diabetes mellitus in newly diagnosed patients actually had a certain duration and occurred much earlier than cardiovascular complications - this was evidenced by an increased level of glycated hemoglobin. CONCLUSIONS: Such results indicate the need for early diagnosis of cardio-reno-metabolic syndrome in patients with cardiovascular complications, as well as timely administration of drugs that simultaneously have antidiabetic, cardio- and nephroprotective effects. FAU - Kazaryan, Svetlana AU - Kazaryan S AUID- ORCID: 0009-0000-4865-5928 AD - Department of General Practice with a Focus on Endocrinology, Kazakhstan Medical University "KSPH", Almaty, Republic of Kazakhstan. FAU - Bazarbekova, Rimma AU - Bazarbekova R AD - Department of General Practice with a Focus on Endocrinology, Kazakhstan Medical University "KSPH", Almaty, Republic of Kazakhstan. FAU - Dossanova, Ainur AU - Dossanova A AD - Department of General Practice with a Focus on Endocrinology, Kazakhstan Medical University "KSPH", Almaty, Republic of Kazakhstan. FAU - Kainarbekova, Nazgul AU - Kainarbekova N FAU - Zhakebayeva, Aigerim AU - Zhakebayeva A AD - Department of General Practice with a Focus on Endocrinology, Kazakhstan Medical University "KSPH", Almaty, Republic of Kazakhstan. LA - eng PT - Journal Article DEP - 20240603 PL - England TA - Expert Rev Endocrinol Metab JT - Expert review of endocrinology & metabolism JID - 101278293 SB - IM MH - Humans MH - *Acute Coronary Syndrome/metabolism MH - Male MH - Female MH - Middle Aged MH - Aged MH - *Kidney/metabolism/physiopathology MH - *Diabetes Mellitus, Type 2/metabolism/complications MH - Carbohydrate Metabolism MH - Prediabetic State/metabolism MH - Metabolic Syndrome/metabolism OTO - NOTNLM OT - Cardiovascular diseases OT - biochemical markers OT - diabetes mellitus OT - renal dysfunction OT - risk factors EDAT- 2024/06/04 06:42 MHDA- 2024/10/30 06:21 CRDT- 2024/06/04 03:02 PHST- 2024/10/30 06:21 [medline] PHST- 2024/06/04 06:42 [pubmed] PHST- 2024/06/04 03:02 [entrez] AID - 10.1080/17446651.2024.2363543 [doi] PST - ppublish SO - Expert Rev Endocrinol Metab. 2024 Sep;19(5):437-445. doi: 10.1080/17446651.2024.2363543. Epub 2024 Jun 3. PMID- 38829515 OWN - NLM STAT- MEDLINE DCOM- 20240710 LR - 20250408 IS - 1534-6242 (Electronic) IS - 1523-3804 (Linking) VI - 26 IP - 8 DP - 2024 Aug TI - Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American College of Cardiology Conference. PG - 367-381 LID - 10.1007/s11883-024-01218-2 [doi] AB - PURPOSE OF REVIEW: To summarize selected late-breaking science on cardiovascular (CV) disease prevention presented at the 2024 Scientific Session of the American College of Cardiology (ACC) conference. RECENT FINDINGS: The LIBerate-HR trial showed the efficacy and safety of lerodalcibep, a subcutaneous injection that prevents binding of Pro-Protein Convertase Subtilisin/Kexin (PCSK) 9 to low-density lipoprotein (LDL)-receptors resulting in LDL-cholesterol (LDL-C) lowering in patients at very high risk or high risk of atherosclerotic CV disease (ASCVD). The AEGIS-II randomized patients with type 1 myocardial infarction (MI) with multivessel coronary artery disease and additional CV risk factors and found no benefit in major adverse CV events (MACE) with CSL112, an apolipoprotein A1 infusion shown to increase cholesterol efflux capacity. The Bridge-TIMI 73a trial showed a significant reduction in triglyceride (TG) levels with olezarsen, an antisense mRNA, in patients with moderate hyperTG with elevated CV risk. The BE ACTIVE trial showed significant improvement in step counts in patients given behavioral and financial incentives. The DRIVE study showed a significant increase in the prescription of either sodium-glucose co-transporter-2 inhibitors or glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus (T2DM) at elevated CV or renal risk with a remote team-based, non-licensed navigator and clinical pharmacist approach. The TACTiC trial showed increased and sustained use of statin therapy by patient-driven use of a web-based portal that calculated the ASCVD risk score and gave prompts. The VICTORIAN-INITIATE trial showed efficacy and safety in early use of inclisiran in patients with ASCVD who did not reach target LDL-C < 70 mg/dL despite maximally tolerated statin therapy. The ARISE-HF trial showed no difference in change of peak oxygen consumption with the use of an oral aldose reductase inhibitor, AT-001, in patients with well-controlled T2DM and diabetic cardiomyopathy with high-risk features compared to placebo. The PREVENT trial showed a significant reduction in target vessel failure at 2 years in patients with non-flow limiting vulnerable plaques with percutaneous coronary intervention and optimal medical therapy (OMT) compared to OMT alone. The late-breaking clinical science presented at the 2024 Scientific Session of the ACC paves the way for an evidence-based alternative to statin therapy and provides data on several common clinical scenarios encountered in daily practice. CI - (c) 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Gupta, Kartik AU - Gupta K AD - Division of Cardiovascular Diseases, Henry Ford Hospital, Detroit, MI, USA. FAU - Rawlley, Bharat AU - Rawlley B AD - State University of New York Upstate Medical University, Syracuse, NY, USA. FAU - Meloche, Chelsea AU - Meloche C AD - The Texas Heart Institute, Houston, TX, USA. FAU - Minhas, Abdul Mannan Khan AU - Minhas AMK AD - Division of Cardiology, Baylor College of Medicine, Houston, TX, USA. FAU - Hermel, Melody AU - Hermel M AD - United Medical Doctors, La Jolla, San Diego, CA, USA. FAU - Slipczuk, Leandro AU - Slipczuk L AD - Montefiore Health System/Albert Einstein College of Medicine, Bronx, NY, USA. FAU - Sheikh, Sana AU - Sheikh S AD - Section of Cardiology, Department of Medicine, The Aga Khan University, Karachi, Pakistan. FAU - Khoja, Adeel AU - Khoja A AD - Section of Cardiology, Department of Medicine, The Aga Khan University, Karachi, Pakistan. AD - Adelaide Medical School, The University of Adelaide, Adelaide, Australia. FAU - Vaughan, Elizabeth M AU - Vaughan EM AD - Division of Cardiology, Baylor College of Medicine, Houston, TX, USA. AD - University of Texas Medical Branch, Galveston, TX, USA. FAU - Dalakoti, Mayank AU - Dalakoti M AD - Department of Cardiology, National University Heart Centre, Singapore, Singapore. AD - Cardiovascular Metabolic Translational Research Program, National University of Singapore, Singapore, Singapore. FAU - Virani, Salim S AU - Virani SS AD - The Texas Heart Institute, Houston, TX, USA. salim.virani@aku.edu. AD - Office of the Vice Provost (Research), The Aga Khan University, Karachi, Pakistan. salim.virani@aku.edu. LA - eng PT - Journal Article PT - Review DEP - 20240603 PL - United States TA - Curr Atheroscler Rep JT - Current atherosclerosis reports JID - 100897685 SB - IM MH - Humans MH - *Cardiovascular Diseases/prevention & control MH - Cardiology MH - United States/epidemiology MH - Congresses as Topic MH - Heart Disease Risk Factors OTO - NOTNLM OT - ARISE OT - BE ACTIVE OT - BRIDGE-TIMI OT - DRIVE OT - Liberate-HR OT - PREVENT OT - SHASHTA OT - TACTIC OT - VICTORIAN-INITIATE EDAT- 2024/06/03 12:45 MHDA- 2024/07/10 12:43 CRDT- 2024/06/03 11:10 PHST- 2024/05/17 00:00 [accepted] PHST- 2024/07/10 12:43 [medline] PHST- 2024/06/03 12:45 [pubmed] PHST- 2024/06/03 11:10 [entrez] AID - 10.1007/s11883-024-01218-2 [pii] AID - 10.1007/s11883-024-01218-2 [doi] PST - ppublish SO - Curr Atheroscler Rep. 2024 Aug;26(8):367-381. doi: 10.1007/s11883-024-01218-2. Epub 2024 Jun 3. PMID- 38827557 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250502 IS - 0970-9134 (Print) IS - 0973-7723 (Electronic) IS - 0970-9134 (Linking) VI - 40 IP - Suppl 1 DP - 2024 May TI - Outcomes after surgery for infective endocarditis. PG - 126-137 LID - 10.1007/s12055-023-01647-9 [doi] AB - The role of surgery in infective endocarditis is becoming established the world over. In spite of all recent advances, endocarditis remains a lethal disease following surgery. With the emergence of more difficult-to-treat microorganisms, sicker and older patients with multiple co-morbidities, and an increase in healthcare-associated infections, the need for surgery in the management of infective endocarditis is only bound to increase. Data on the use of surgery in endocarditis till date is largely from observational data due to the relative rarity of the disease and variable practice patterns around the world. Hopefully, with increasing awareness and more inter-institutional and international collaborations, more robust data will emerge to further establish the role of surgery. For the time being, individual patient management will require the active multi-disciplinary approach of an endocarditis team to provide the best possible outcomes. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12055-023-01647-9. CI - (c) Indian Association of Cardiovascular-Thoracic Surgeons 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. FAU - Gopal, Kirun AU - Gopal K AUID- ORCID: 0000-0002-9622-4230 AD - Department of Cardiovascular and Thoracic Surgery, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham (Amrita University), Kochi, India. GRID: grid.411370.0. ISNI: 0000 0000 9081 2061 FAU - Radhakrishnan, Rohik Micka AU - Radhakrishnan RM AD - Department of Cardiovascular and Thoracic Surgery, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham (Amrita University), Kochi, India. GRID: grid.411370.0. ISNI: 0000 0000 9081 2061 FAU - Jose, Rajesh AU - Jose R AUID- ORCID: 0000-0002-2116-2821 AD - Department of Cardiovascular and Thoracic Surgery, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham (Amrita University), Kochi, India. GRID: grid.411370.0. ISNI: 0000 0000 9081 2061 FAU - Krishna, Neethu AU - Krishna N AUID- ORCID: 0000-0002-1834-8086 AD - Department of Cardiovascular and Thoracic Surgery, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham (Amrita University), Kochi, India. GRID: grid.411370.0. ISNI: 0000 0000 9081 2061 FAU - Varma, Praveen Kerala AU - Varma PK AUID- ORCID: 0000-0003-3978-2874 AD - Department of Cardiovascular and Thoracic Surgery, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham (Amrita University), Kochi, India. GRID: grid.411370.0. ISNI: 0000 0000 9081 2061 LA - eng PT - Journal Article PT - Review DEP - 20231230 PL - India TA - Indian J Thorac Cardiovasc Surg JT - Indian journal of thoracic and cardiovascular surgery JID - 8700105 PMC - PMC11139833 OTO - NOTNLM OT - Endocarditis OT - Infective endocarditis OT - Outcome OT - Surgery COIS- Conflict of interestThe authors declare no conflict of interest. EDAT- 2024/06/03 06:42 MHDA- 2024/06/03 06:43 PMCR- 2025/05/01 CRDT- 2024/06/03 04:27 PHST- 2023/08/12 00:00 [received] PHST- 2023/11/03 00:00 [revised] PHST- 2023/11/06 00:00 [accepted] PHST- 2024/06/03 06:43 [medline] PHST- 2024/06/03 06:42 [pubmed] PHST- 2024/06/03 04:27 [entrez] PHST- 2025/05/01 00:00 [pmc-release] AID - 1647 [pii] AID - 10.1007/s12055-023-01647-9 [doi] PST - ppublish SO - Indian J Thorac Cardiovasc Surg. 2024 May;40(Suppl 1):126-137. doi: 10.1007/s12055-023-01647-9. Epub 2023 Dec 30. PMID- 38827543 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250502 IS - 0970-9134 (Print) IS - 0973-7723 (Electronic) IS - 0970-9134 (Linking) VI - 40 IP - Suppl 1 DP - 2024 May TI - Contemporary surgical management of infective endocarditis of the aortic root. PG - 83-92 LID - 10.1007/s12055-023-01604-6 [doi] AB - Infective endocarditis involving the aortic root is associated with a high degree of morbidity and mortality. Native aortic root infections can develop from aggressive organisms or from delays in diagnosis or definitive care, whereas prosthetic valve infections commonly result in extensive destruction of the aortic root and neighboring structures. Early detection, tailored antibiotic therapy, thoughtful pre-operative planning, and multidisciplinary heart team management are the keys to optimizing patient outcomes. Aggressive and complete surgical debridement are mandatory prior to aortic root reconstruction. Surgical experience and patient-centered decision making are critical in selecting the optimal reconstructive strategy for the aortic root and adjacent structures. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12055-023-01604-6. CI - (c) Indian Association of Cardiovascular-Thoracic Surgeons 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. FAU - Algadheeb, Muhanad S AU - Algadheeb MS AD - Division of Cardiac Surgery, Western University, B6-106 University Hospital, LHSC, 339 Windermere Road, London, ON N6A 5A5 Canada. ROR: https://ror.org/02grkyz14. GRID: grid.39381.30. ISNI: 0000 0004 1936 8884 AD - Division of Critical Care Medicine, Western University, London, Canada. ROR: https://ror.org/02grkyz14. GRID: grid.39381.30. ISNI: 0000 0004 1936 8884 FAU - Malik, Mohsyn I AU - Malik MI AD - Division of Cardiac Surgery, Western University, B6-106 University Hospital, LHSC, 339 Windermere Road, London, ON N6A 5A5 Canada. ROR: https://ror.org/02grkyz14. GRID: grid.39381.30. ISNI: 0000 0004 1936 8884 FAU - Besa-Bandeira, Santiago AU - Besa-Bandeira S AD - Division of Cardiac Surgery, Western University, B6-106 University Hospital, LHSC, 339 Windermere Road, London, ON N6A 5A5 Canada. ROR: https://ror.org/02grkyz14. GRID: grid.39381.30. ISNI: 0000 0004 1936 8884 FAU - Valdis, Matthew AU - Valdis M AD - Division of Cardiac Surgery, Western University, B6-106 University Hospital, LHSC, 339 Windermere Road, London, ON N6A 5A5 Canada. ROR: https://ror.org/02grkyz14. GRID: grid.39381.30. ISNI: 0000 0004 1936 8884 FAU - Tzemos, Niko AU - Tzemos N AD - Division of Cardiology, Western University, London, Canada. ROR: https://ror.org/02grkyz14. GRID: grid.39381.30. ISNI: 0000 0004 1936 8884 FAU - Bagur, Rodrigo AU - Bagur R AD - Division of Cardiology, Western University, London, Canada. ROR: https://ror.org/02grkyz14. GRID: grid.39381.30. ISNI: 0000 0004 1936 8884 FAU - Chu, Michael W A AU - Chu MWA AD - Division of Cardiac Surgery, Western University, B6-106 University Hospital, LHSC, 339 Windermere Road, London, ON N6A 5A5 Canada. ROR: https://ror.org/02grkyz14. GRID: grid.39381.30. ISNI: 0000 0004 1936 8884 LA - eng PT - Journal Article PT - Review DEP - 20231019 PL - India TA - Indian J Thorac Cardiovasc Surg JT - Indian journal of thoracic and cardiovascular surgery JID - 8700105 PMC - PMC11139825 OTO - NOTNLM OT - Aortic root endocarditis OT - Infective endocarditis OT - Recurrent prosthetic valve endocarditis COIS- Conflicts of interestMWC has received Speakers' honoraria from Medtronic, Edwards Lifesciences, Terumo Aortic and Artivion. The other authors have no relevant financial or non-financial interests to disclose. EDAT- 2024/06/03 06:42 MHDA- 2024/06/03 06:43 PMCR- 2025/05/01 CRDT- 2024/06/03 04:27 PHST- 2023/07/24 00:00 [received] PHST- 2023/09/01 00:00 [revised] PHST- 2023/09/04 00:00 [accepted] PHST- 2024/06/03 06:43 [medline] PHST- 2024/06/03 06:42 [pubmed] PHST- 2024/06/03 04:27 [entrez] PHST- 2025/05/01 00:00 [pmc-release] AID - 1604 [pii] AID - 10.1007/s12055-023-01604-6 [doi] PST - ppublish SO - Indian J Thorac Cardiovasc Surg. 2024 May;40(Suppl 1):83-92. doi: 10.1007/s12055-023-01604-6. Epub 2023 Oct 19. PMID- 38826995 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240604 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 16 IP - 5 DP - 2024 May TI - Multidisciplinary Management Strategies for Long COVID: A Narrative Review. PG - e59478 LID - 10.7759/cureus.59478 [doi] LID - e59478 AB - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused millions of infections to date and has led to a worldwide pandemic. Most patients had a complete recovery from the acute infection, however, a large number of the affected individuals experienced symptoms that persisted more than 3 months after diagnosis. These symptoms most commonly include fatigue, memory difficulties, brain fog, dyspnea, cough, and other less common ones such as headache, chest pain, paresthesias, mood changes, muscle pain, and weakness, skin rashes, and cardiac, endocrine, renal and hepatic manifestations. The treatment of this syndrome remains challenging. A multidisciplinary approach to address combinations of symptoms affecting multiple organ systems has been widely adopted. This narrative review aims to bridge the gap surrounding the broad treatment approaches by providing an overview of multidisciplinary management strategies for the most common long COVID conditions. CI - Copyright (c) 2024, Prusinski et al. FAU - Prusinski, Christian AU - Prusinski C AD - Department of Pain Medicine, Mayo Clinic, Jacksonville, USA. FAU - Yan, Dan AU - Yan D AD - Department of Pain Medicine, Mayo Clinic, Jacksonville, USA. FAU - Klasova, Johana AU - Klasova J AD - Department of Pain Medicine, Mayo Clinic, Jacksonville, USA. FAU - McVeigh, Kimberly H AU - McVeigh KH AD - Department of Pain Medicine, Mayo Clinic, Jacksonville, USA. FAU - Shah, Sadia Z AU - Shah SZ AD - Department of Transplantation, Mayo Clinic, Jacksonville, USA. FAU - Fermo, Olga P AU - Fermo OP AD - Department of Neurology, Mayo Clinic, Jacksonville, USA. FAU - Kubrova, Eva AU - Kubrova E AD - Department of Physical Medicine and Rehabilitation, Mayo Clinic, Rochester, USA. FAU - Farr, Ellen M AU - Farr EM AD - Department of Physical Medicine and Rehabilitation, Mayo Clinic, Rochester, USA. FAU - Williams, Linus C AU - Williams LC AD - Department of Pain Medicine, Mayo Clinic, Jacksonville, USA. AD - Department of Internal Medicine, Lahey Hospital & Medical Center, Burlington, USA. FAU - Gerardo-Manrique, Gerardo AU - Gerardo-Manrique G AD - Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, USA. FAU - Bergquist, Thomas F AU - Bergquist TF AD - Department of Physical Medicine and Rehabilitation, Mayo Clinic, Rochester, USA. AD - Department of Psychiatry and Psychology, Mayo Clinic, Rochester, USA. FAU - Pham, Si M AU - Pham SM AD - Department of Cardiothoracic Surgery, Mayo Clinic, Jacksonville, USA. FAU - Engelberg-Cook, Erica AU - Engelberg-Cook E AD - Department of Pain Medicine, Mayo Clinic, Jacksonville, USA. FAU - Hare, Joshua M AU - Hare JM AD - Department of Medicine, Cardiovascular Division and the Interdisciplinary Stem Cell Institute, Miami, USA. FAU - March, Keith L AU - March KL AD - Division of Cardiovascular Medicine, Center for Regenerative Medicine, University of Florida, Gainesville, USA. FAU - Caplan, Arnold I AU - Caplan AI AD - Department of Biology, Case Western Reserve University School of Medicine, Cleveland, USA. FAU - Qu, Wenchun AU - Qu W AD - Department of Pain Medicine, Mayo Clinic, Jacksonville, USA. AD - Center for Regenerative Biotherapeutics, Mayo Clinic, Jacksonville, USA. LA - eng PT - Journal Article PT - Review DEP - 20240501 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC11142761 OTO - NOTNLM OT - a multidisciplinary approach for long covid OT - a narrative review for long covid management OT - management strategies for long covid OT - post-acute sequelae sars-cov-2 infection OT - severe acute respiratory syndrome coronavirus 2 COIS- The authors have declared that no competing interests exist. EDAT- 2024/06/03 06:42 MHDA- 2024/06/03 06:43 PMCR- 2024/05/01 CRDT- 2024/06/03 04:17 PHST- 2024/04/02 00:00 [accepted] PHST- 2024/06/03 06:43 [medline] PHST- 2024/06/03 06:42 [pubmed] PHST- 2024/06/03 04:17 [entrez] PHST- 2024/05/01 00:00 [pmc-release] AID - 10.7759/cureus.59478 [doi] PST - epublish SO - Cureus. 2024 May 1;16(5):e59478. doi: 10.7759/cureus.59478. eCollection 2024 May. PMID- 38826798 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250802 IS - 2163-0402 (Print) IS - 2163-0933 (Electronic) IS - 2163-0402 (Linking) VI - 14 IP - 4 DP - 2024 Aug TI - Multidisciplinary Approach to Patent Foramen Ovale Closure for Cryptogenic Stroke: Brain-Heart Board Experience. PG - e200319 LID - 10.1212/CPJ.0000000000200319 [doi] LID - e200319 AB - BACKGROUND AND OBJECTIVES: Patent foramen ovale (PFO) is present in approximately 25% of adult population. The prevalence of PFO is high in patients with cryptogenic stroke suggesting paradoxical embolism. PFO closure in carefully selected patients is an effective secondary preventive strategy in these patients. We report predictors of management recommendations by the multidisciplinary Board and their impact on outcomes. METHODS: Brain-Heart Board comprises vascular and interventional neurology and cardiology subspecialties (structural, electrophysiology, and cardiac imaging). Adult patients referred to the Board for consideration of PFO closure between October 2017 to March 2021 were included in this retrospective cohort analysis. Demographics, comorbid conditions, risk of paradoxical embolism (RoPE) score, event frequencies (transient ischemic attack [TIA] or stroke, intracranial hemorrhage [ICH], post-PFO closure cardiac arrhythmias), and modified Rankin Scale (mRS) at 1 year were compared between the groups (PFO closure vs medical management). Multivariable logistic regression was used to identify factors associated with management recommendation and chi-square tests to test differences in outcomes for patients according to management. RESULTS: Two hundred seventy patients (229 stroke; 41 TIA) were discussed by the Board for PFO closure. 119 (44.0%) patients were recommended for PFO closure of which 117 (98.3%) had evidence of ischemic infarct on imaging. In univariate analysis, age was similar (50 +/- 11.9 vs 52 +/- 12.8, p = 0.17), but RoPE score was higher in closure as compared with the medical management group (6 [IQR 5-7] vs 5 [IQR 4-7], p < 0.05). In multivariable analysis, TIA as the index event was an independent predictor of Board recommendation against PFO closure (OR 0.05, 95% CI 0.01-0.19, p < 0.05). Event frequency was low in both cohorts (5.9% vs 4.8%, p > 0.05) and comprised cardiac arrhythmias (6 cases of atrial fibrillation and 1 ICH in closure group; 1 TIA and 1 recurrent stroke in medical management group). Excellent functional outcome (mRS 0-1) was similar in both cohorts (66.3% vs 70.7%, p > 0.05) at 1 year. DISCUSSION: Multidisciplinary Brain-Heart Board provides a clinical practice model of collaborative care to ensure proper patient selection for PFO closure. TIA as the index event is associated with recommendation of medical management by the multidisciplinary Brain-Heart Board. CI - (c) 2024 American Academy of Neurology. FAU - Khan, Muhib AU - Khan M AUID- ORCID: 0000-0001-6329-8703 AD - Division of Neurology (MK, MM, PM, NW, NIK, AA, EE, JM), Neuroscience Institute, Spectrum Health, Grand Rapids; Michigan State University (MK, MM, PM, JPT, WM, DB, NW, NIK, AA, MD, AG, NC, JM), Grand Rapids; Department of Neurology (MK), Mayo Clinic, Rochester, MN; Division of Neurosurgery (JPT), Neuroscience Institute, Grand Rapids; and Division of Cardiology (WM, DB, MD, AG, TM, NC), Heart and Vascular Institute, Spectrum Health, Grand Rapids, MI. FAU - Miller, Malgorzata AU - Miller M AUID- ORCID: 0000-0002-7445-6217 AD - Division of Neurology (MK, MM, PM, NW, NIK, AA, EE, JM), Neuroscience Institute, Spectrum Health, Grand Rapids; Michigan State University (MK, MM, PM, JPT, WM, DB, NW, NIK, AA, MD, AG, NC, JM), Grand Rapids; Department of Neurology (MK), Mayo Clinic, Rochester, MN; Division of Neurosurgery (JPT), Neuroscience Institute, Grand Rapids; and Division of Cardiology (WM, DB, MD, AG, TM, NC), Heart and Vascular Institute, Spectrum Health, Grand Rapids, MI. FAU - Mccarthy, Philip AU - Mccarthy P AUID- ORCID: 0009-0007-8413-1372 AD - Division of Neurology (MK, MM, PM, NW, NIK, AA, EE, JM), Neuroscience Institute, Spectrum Health, Grand Rapids; Michigan State University (MK, MM, PM, JPT, WM, DB, NW, NIK, AA, MD, AG, NC, JM), Grand Rapids; Department of Neurology (MK), Mayo Clinic, Rochester, MN; Division of Neurosurgery (JPT), Neuroscience Institute, Grand Rapids; and Division of Cardiology (WM, DB, MD, AG, TM, NC), Heart and Vascular Institute, Spectrum Health, Grand Rapids, MI. FAU - Tsai, Jenny P AU - Tsai JP AUID- ORCID: 0000-0003-4866-567X AD - Division of Neurology (MK, MM, PM, NW, NIK, AA, EE, JM), Neuroscience Institute, Spectrum Health, Grand Rapids; Michigan State University (MK, MM, PM, JPT, WM, DB, NW, NIK, AA, MD, AG, NC, JM), Grand Rapids; Department of Neurology (MK), Mayo Clinic, Rochester, MN; Division of Neurosurgery (JPT), Neuroscience Institute, Grand Rapids; and Division of Cardiology (WM, DB, MD, AG, TM, NC), Heart and Vascular Institute, Spectrum Health, Grand Rapids, MI. FAU - Merhi, William AU - Merhi W AUID- ORCID: 0009-0009-4075-9082 AD - Division of Neurology (MK, MM, PM, NW, NIK, AA, EE, JM), Neuroscience Institute, Spectrum Health, Grand Rapids; Michigan State University (MK, MM, PM, JPT, WM, DB, NW, NIK, AA, MD, AG, NC, JM), Grand Rapids; Department of Neurology (MK), Mayo Clinic, Rochester, MN; Division of Neurosurgery (JPT), Neuroscience Institute, Grand Rapids; and Division of Cardiology (WM, DB, MD, AG, TM, NC), Heart and Vascular Institute, Spectrum Health, Grand Rapids, MI. FAU - Berkompas, Duane AU - Berkompas D AUID- ORCID: 0009-0005-0235-3066 AD - Division of Neurology (MK, MM, PM, NW, NIK, AA, EE, JM), Neuroscience Institute, Spectrum Health, Grand Rapids; Michigan State University (MK, MM, PM, JPT, WM, DB, NW, NIK, AA, MD, AG, NC, JM), Grand Rapids; Department of Neurology (MK), Mayo Clinic, Rochester, MN; Division of Neurosurgery (JPT), Neuroscience Institute, Grand Rapids; and Division of Cardiology (WM, DB, MD, AG, TM, NC), Heart and Vascular Institute, Spectrum Health, Grand Rapids, MI. FAU - Wees, Nabil AU - Wees N AD - Division of Neurology (MK, MM, PM, NW, NIK, AA, EE, JM), Neuroscience Institute, Spectrum Health, Grand Rapids; Michigan State University (MK, MM, PM, JPT, WM, DB, NW, NIK, AA, MD, AG, NC, JM), Grand Rapids; Department of Neurology (MK), Mayo Clinic, Rochester, MN; Division of Neurosurgery (JPT), Neuroscience Institute, Grand Rapids; and Division of Cardiology (WM, DB, MD, AG, TM, NC), Heart and Vascular Institute, Spectrum Health, Grand Rapids, MI. FAU - Khan, Nadeem I AU - Khan NI AUID- ORCID: 0000-0001-7221-6597 AD - Division of Neurology (MK, MM, PM, NW, NIK, AA, EE, JM), Neuroscience Institute, Spectrum Health, Grand Rapids; Michigan State University (MK, MM, PM, JPT, WM, DB, NW, NIK, AA, MD, AG, NC, JM), Grand Rapids; Department of Neurology (MK), Mayo Clinic, Rochester, MN; Division of Neurosurgery (JPT), Neuroscience Institute, Grand Rapids; and Division of Cardiology (WM, DB, MD, AG, TM, NC), Heart and Vascular Institute, Spectrum Health, Grand Rapids, MI. FAU - Ahrar, Asad AU - Ahrar A AUID- ORCID: 0009-0001-6253-6236 AD - Division of Neurology (MK, MM, PM, NW, NIK, AA, EE, JM), Neuroscience Institute, Spectrum Health, Grand Rapids; Michigan State University (MK, MM, PM, JPT, WM, DB, NW, NIK, AA, MD, AG, NC, JM), Grand Rapids; Department of Neurology (MK), Mayo Clinic, Rochester, MN; Division of Neurosurgery (JPT), Neuroscience Institute, Grand Rapids; and Division of Cardiology (WM, DB, MD, AG, TM, NC), Heart and Vascular Institute, Spectrum Health, Grand Rapids, MI. FAU - Evans, Elizabeth AU - Evans E AUID- ORCID: 0009-0009-5531-2865 AD - Division of Neurology (MK, MM, PM, NW, NIK, AA, EE, JM), Neuroscience Institute, Spectrum Health, Grand Rapids; Michigan State University (MK, MM, PM, JPT, WM, DB, NW, NIK, AA, MD, AG, NC, JM), Grand Rapids; Department of Neurology (MK), Mayo Clinic, Rochester, MN; Division of Neurosurgery (JPT), Neuroscience Institute, Grand Rapids; and Division of Cardiology (WM, DB, MD, AG, TM, NC), Heart and Vascular Institute, Spectrum Health, Grand Rapids, MI. FAU - Dahu, Musa AU - Dahu M AUID- ORCID: 0000-0001-9583-1736 AD - Division of Neurology (MK, MM, PM, NW, NIK, AA, EE, JM), Neuroscience Institute, Spectrum Health, Grand Rapids; Michigan State University (MK, MM, PM, JPT, WM, DB, NW, NIK, AA, MD, AG, NC, JM), Grand Rapids; Department of Neurology (MK), Mayo Clinic, Rochester, MN; Division of Neurosurgery (JPT), Neuroscience Institute, Grand Rapids; and Division of Cardiology (WM, DB, MD, AG, TM, NC), Heart and Vascular Institute, Spectrum Health, Grand Rapids, MI. FAU - Gauri, Andre AU - Gauri A AUID- ORCID: 0009-0006-9225-4869 AD - Division of Neurology (MK, MM, PM, NW, NIK, AA, EE, JM), Neuroscience Institute, Spectrum Health, Grand Rapids; Michigan State University (MK, MM, PM, JPT, WM, DB, NW, NIK, AA, MD, AG, NC, JM), Grand Rapids; Department of Neurology (MK), Mayo Clinic, Rochester, MN; Division of Neurosurgery (JPT), Neuroscience Institute, Grand Rapids; and Division of Cardiology (WM, DB, MD, AG, TM, NC), Heart and Vascular Institute, Spectrum Health, Grand Rapids, MI. FAU - Moelker, Tarah AU - Moelker T AUID- ORCID: 0009-0004-1537-757X AD - Division of Neurology (MK, MM, PM, NW, NIK, AA, EE, JM), Neuroscience Institute, Spectrum Health, Grand Rapids; Michigan State University (MK, MM, PM, JPT, WM, DB, NW, NIK, AA, MD, AG, NC, JM), Grand Rapids; Department of Neurology (MK), Mayo Clinic, Rochester, MN; Division of Neurosurgery (JPT), Neuroscience Institute, Grand Rapids; and Division of Cardiology (WM, DB, MD, AG, TM, NC), Heart and Vascular Institute, Spectrum Health, Grand Rapids, MI. FAU - Chalfoun, Nagib AU - Chalfoun N AUID- ORCID: 0000-0001-5757-7773 AD - Division of Neurology (MK, MM, PM, NW, NIK, AA, EE, JM), Neuroscience Institute, Spectrum Health, Grand Rapids; Michigan State University (MK, MM, PM, JPT, WM, DB, NW, NIK, AA, MD, AG, NC, JM), Grand Rapids; Department of Neurology (MK), Mayo Clinic, Rochester, MN; Division of Neurosurgery (JPT), Neuroscience Institute, Grand Rapids; and Division of Cardiology (WM, DB, MD, AG, TM, NC), Heart and Vascular Institute, Spectrum Health, Grand Rapids, MI. FAU - Min, Jiangyong AU - Min J AUID- ORCID: 0000-0001-7730-3139 AD - Division of Neurology (MK, MM, PM, NW, NIK, AA, EE, JM), Neuroscience Institute, Spectrum Health, Grand Rapids; Michigan State University (MK, MM, PM, JPT, WM, DB, NW, NIK, AA, MD, AG, NC, JM), Grand Rapids; Department of Neurology (MK), Mayo Clinic, Rochester, MN; Division of Neurosurgery (JPT), Neuroscience Institute, Grand Rapids; and Division of Cardiology (WM, DB, MD, AG, TM, NC), Heart and Vascular Institute, Spectrum Health, Grand Rapids, MI. LA - eng PT - Journal Article DEP - 20240529 PL - United States TA - Neurol Clin Pract JT - Neurology. Clinical practice JID - 101577149 PMC - PMC11141343 COIS- M. Khan, P. Mccarthy, M. Miller, W. Merhi, N. Wees, N.I. Khan, A. Ahrar, E. Evans, M. Dahu, T. Moelker: No conflicts of interest relevant to the manuscript. J.P. Tsai: received compensation from Cerenovus and Microvention as a consultant. J. Min: received compensation from Abbott Laboratories and Medtronic as a consultant. Andre Gauri: received compensation from Medtronic as a consultant. N. Chalfoun: received compensation from Medtronic and Atricure as a consultant. D. Berkompas: received compensation from Medtronic and Abbott as a consultant. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/cp. EDAT- 2024/06/03 06:42 MHDA- 2024/06/03 06:43 PMCR- 2025/08/01 CRDT- 2024/06/03 04:15 PHST- 2023/08/14 00:00 [received] PHST- 2024/03/11 00:00 [accepted] PHST- 2024/06/03 06:43 [medline] PHST- 2024/06/03 06:42 [pubmed] PHST- 2024/06/03 04:15 [entrez] PHST- 2025/08/01 00:00 [pmc-release] AID - CPJ-2023-000437 [pii] AID - 10.1212/CPJ.0000000000200319 [doi] PST - ppublish SO - Neurol Clin Pract. 2024 Aug;14(4):e200319. doi: 10.1212/CPJ.0000000000200319. Epub 2024 May 29. PMID- 38821382 OWN - NLM STAT- MEDLINE DCOM- 20240718 LR - 20240719 IS - 2950-3930 (Electronic) IS - 2950-3930 (Linking) VI - 34 IP - 7-8 DP - 2024 Jul TI - Outcomes after radical nephrectomy with vena cava thrombectomy using multidisciplinary approach: A single center experience. PG - 102657 LID - S2950-3930(24)00114-1 [pii] LID - 10.1016/j.fjurol.2024.102657 [doi] AB - INTRODUCTION: To describe the perioperative outcomes in patients treated with radical nephrectomy with cava thrombectomy at all thrombi levels using a multidisciplinary approach, with or without extracorporeal circulation (ECC), and to identify factors associated with perioperative morbidity. METHODS: We retrospectively identified 42 patients who were diagnosed with renal cell carcinoma (RCC) and a vena cava thrombus and treated with radical nephrectomy and cava thrombectomy by a double surgical team at Lyon University Hospital from 2008 through 2021. The surgeons operated in the cardiothoracic operating theater to proceed with median sternotomy or ECC, if necessary. The primary endpoint of this study was perioperative morbidity and mortality assessed using the Clavien-Dindo scale. Complications were recorded until 90 days after surgery, and those classified as grade IIIa or higher were considered high-grade complications. RESULTS: Overall, 32 (76%) patients required ECC. No intraoperative mortality occurred; however, two patients (5%) died within 30 days. Complications occurred within 30 days in 30 patients (72%), with severe complications observed in 10 patients (24%). No further complications occurred between 30 and 90 days. Multivariate analysis revealed that age, thrombus level, ECC, American Society of Anesthesiologists physical status, symptoms, and metastasis at presentation were not significantly associated with high-grade complications (P>0.05). CONCLUSIONS: Multidisciplinary approach is essential and frequent use of ECC, when achieved by a trained team, may facilitate surgery, and is associated with low perioperative morbidity, especially for patients with high-level thrombi. LEVEL OF EVIDENCE: IV. CI - Copyright (c) 2024. Published by Elsevier Masson SAS. FAU - Hanquiez, Paul AU - Hanquiez P AD - Department of Urology, Lyon Sud Hospital, Lyon, France. Electronic address: paul.hanquiez@chu-lyon.fr. FAU - Neuville, Paul AU - Neuville P AD - Department of Urology, Lyon Sud Hospital, Lyon, France; Claude-Bernard University Lyon 1, Lyon, France. Electronic address: paul.neuville@chu-lyon.fr. FAU - Robin, Jacques AU - Robin J AD - Claude-Bernard University Lyon 1, Lyon, France; Department of Cardiac Surgery, "Louis-Pradel" Cardiologic Hospital, Lyon, France. Electronic address: cajrobin@gmail.com. FAU - Ruffion, Alain AU - Ruffion A AD - Department of Urology, Lyon Sud Hospital, Lyon, France; Claude-Bernard University Lyon 1, Lyon, France. Electronic address: alain.ruffion@chu-lyon.fr. FAU - Fiard, Gaelle AU - Fiard G AD - Department of Urology, Grenoble University Hospital, Grenoble, France. Electronic address: gfiard@chu-grenoble.fr. FAU - Rossello, Noemie AU - Rossello N AD - Department of Public health, Edouard Herriot Hospital, Lyon, France. Electronic address: noemie.rossello@gmail.com. FAU - Decaussin-Petrucci, Myriam AU - Decaussin-Petrucci M AD - Claude-Bernard University Lyon 1, Lyon, France; Department of Pathology, Lyon-Sud Hospital, Lyon, France. Electronic address: myriam.decaussin-petrucci@chu-lyon.fr. FAU - Paparel, Philippe AU - Paparel P AD - Department of Urology, Lyon Sud Hospital, Lyon, France; Claude-Bernard University Lyon 1, Lyon, France. Electronic address: philippe.paparel@chu-lyon.fr. LA - eng PT - Journal Article DEP - 20240529 PL - France TA - Fr J Urol JT - The French journal of urology JID - 9918752079106676 SB - IM MH - Humans MH - *Thrombectomy/adverse effects/methods MH - *Carcinoma, Renal Cell/surgery/mortality/pathology MH - *Nephrectomy/methods MH - Retrospective Studies MH - Male MH - *Kidney Neoplasms/surgery/pathology/mortality MH - Female MH - Middle Aged MH - Aged MH - Treatment Outcome MH - *Vena Cava, Inferior/surgery/pathology MH - Venous Thrombosis/surgery MH - Postoperative Complications/etiology MH - Neoplastic Cells, Circulating/pathology MH - Patient Care Team OTO - NOTNLM OT - Cancer renal OT - Caval tumor thrombi OT - Circulation extracorporelle OT - Envahissement veineux OT - Extracorporeal circulation OT - Renal cell carcinoma OT - Thrombectomie cave OT - Thrombus cave OT - Venous invasion OT - Venous thrombectomy EDAT- 2024/06/01 10:50 MHDA- 2024/07/19 00:41 CRDT- 2024/05/31 19:22 PHST- 2023/11/26 00:00 [received] PHST- 2024/05/09 00:00 [revised] PHST- 2024/05/26 00:00 [accepted] PHST- 2024/07/19 00:41 [medline] PHST- 2024/06/01 10:50 [pubmed] PHST- 2024/05/31 19:22 [entrez] AID - S2950-3930(24)00114-1 [pii] AID - 10.1016/j.fjurol.2024.102657 [doi] PST - ppublish SO - Fr J Urol. 2024 Jul;34(7-8):102657. doi: 10.1016/j.fjurol.2024.102657. Epub 2024 May 29. PMID- 38818962 OWN - NLM STAT- MEDLINE DCOM- 20240604 LR - 20260715 IS - 2047-9980 (Electronic) IS - 2047-9980 (Linking) VI - 13 IP - 11 DP - 2024 Jun 4 TI - Outcomes Following Percutaneous Coronary Intervention in Patients With Multivessel Disease Who Were Recommended for But Declined Coronary Artery Bypass Graft Surgery. PG - e033931 LID - 10.1161/JAHA.123.033931 [doi] LID - e033931 AB - BACKGROUND: Patients may prefer percutaneous coronary intervention (PCI) over coronary artery bypass graft (CABG) surgery, despite heart team recommendations. The outcomes in such patients have not been examined. We sought to examine the results of PCI in patients who were recommended for but declined CABG. METHODS AND RESULTS: Consecutive patients with stable ischemic heart disease and unprotected left main or 3-vessel disease or Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery score >22 who underwent PCI after heart team review between 2013 and 2020 were included. Patients were categorized into 3 groups according to heart team recommendations on the basis of appropriate use criteria: (1) PCI-recommended; (2) CABG-eligible but refused CABG (CABG-refusal); and (3) CABG-ineligible. The primary end point was the composite of death, myocardial infarction, or stroke at 1 year. The study included 3687 patients undergoing PCI (PCI-recommended, n=1718 [46.6%]), CABG-refusal (n=1595 [43.3%]), and CABG-ineligible (n=374 [10.1%]). Clinical and procedural risk increased across the 3 groups, with the highest comorbidity burden in CABG-ineligible patients. Composite events within 1 year after PCI occurred in 55 (4.1%), 91 (7.0%), and 41 (14.8%) of patients in the PCI-recommended, CABG-refusal, and CABG-ineligible groups, respectively. After multivariable adjustment, the risk of the primary composite outcome was significantly higher in the CABG-refusal (hazard ratio [HR], 1.67 [95% CI, 1.08-3.56]; P=0.02) and CABG-ineligible patients (HR, 3.26 [95% CI, 1.28-3.65]; P=0.004) groups compared with the reference PCI-recommended group, driven by increased death and stroke. CONCLUSIONS: Cardiovascular event rates after PCI were significantly higher in patients with multivessel disease who declined or were ineligible for CABG. Our findings provide real-world data to inform shared decision-making discussions. FAU - Koshy, Anoop N AU - Koshy AN AUID- ORCID: 0000-0002-8741-8631 AD - The Zena and Michael A. Wiener Cardiovascular Institute Icahn School of Medicine at Mount Sinai New York NY. AD - Department of Cardiology The Royal Melbourne Hospital Melbourne Victoria Australia. AD - Department of Cardiology and The University of Melbourne Austin Health Melbourne Victoria Australia. FAU - Stone, Gregg W AU - Stone GW AUID- ORCID: 0000-0002-3416-8210 AD - The Zena and Michael A. Wiener Cardiovascular Institute Icahn School of Medicine at Mount Sinai New York NY. FAU - Sartori, Samantha AU - Sartori S AUID- ORCID: 0000-0003-0618-9409 AD - The Zena and Michael A. Wiener Cardiovascular Institute Icahn School of Medicine at Mount Sinai New York NY. AD - Center for Interventional Cardiovascular Research and Clinical Trials, The Zena and Michael A. Wiener Cardiovascular Institute Icahn School of Medicine at Mount Sinai New York NY. FAU - Dhulipala, Vishal AU - Dhulipala V AUID- ORCID: 0000-0001-9764-5806 AD - The Zena and Michael A. Wiener Cardiovascular Institute Icahn School of Medicine at Mount Sinai New York NY. FAU - Giustino, Gennaro AU - Giustino G AD - The Zena and Michael A. Wiener Cardiovascular Institute Icahn School of Medicine at Mount Sinai New York NY. FAU - Spirito, Alessandro AU - Spirito A AD - The Zena and Michael A. Wiener Cardiovascular Institute Icahn School of Medicine at Mount Sinai New York NY. AD - Center for Interventional Cardiovascular Research and Clinical Trials, The Zena and Michael A. Wiener Cardiovascular Institute Icahn School of Medicine at Mount Sinai New York NY. FAU - Farhan, Serdar AU - Farhan S AD - The Zena and Michael A. Wiener Cardiovascular Institute Icahn School of Medicine at Mount Sinai New York NY. FAU - Smith, Kenneth F AU - Smith KF AUID- ORCID: 0009-0009-2646-1933 AD - Center for Interventional Cardiovascular Research and Clinical Trials, The Zena and Michael A. Wiener Cardiovascular Institute Icahn School of Medicine at Mount Sinai New York NY. FAU - Feng, Yihan AU - Feng Y AUID- ORCID: 0009-0000-0448-1321 AD - Center for Interventional Cardiovascular Research and Clinical Trials, The Zena and Michael A. Wiener Cardiovascular Institute Icahn School of Medicine at Mount Sinai New York NY. FAU - Vinayak, Manish AU - Vinayak M AUID- ORCID: 0000-0002-2189-3309 AD - The Zena and Michael A. Wiener Cardiovascular Institute Icahn School of Medicine at Mount Sinai New York NY. FAU - Salehi, Negar AU - Salehi N AUID- ORCID: 0000-0002-4430-1070 AD - The Zena and Michael A. Wiener Cardiovascular Institute Icahn School of Medicine at Mount Sinai New York NY. FAU - Tanner, Richard AU - Tanner R AD - The Zena and Michael A. Wiener Cardiovascular Institute Icahn School of Medicine at Mount Sinai New York NY. FAU - Hooda, Amit AU - Hooda A AUID- ORCID: 0000-0001-5659-5873 AD - The Zena and Michael A. Wiener Cardiovascular Institute Icahn School of Medicine at Mount Sinai New York NY. FAU - Krishnamoorthy, Parasuram AU - Krishnamoorthy P AUID- ORCID: 0000-0002-4560-7346 AD - The Zena and Michael A. Wiener Cardiovascular Institute Icahn School of Medicine at Mount Sinai New York NY. FAU - Sweeny, Joseph M AU - Sweeny JM AUID- ORCID: 0000-0001-7743-1632 AD - The Zena and Michael A. Wiener Cardiovascular Institute Icahn School of Medicine at Mount Sinai New York NY. FAU - Khera, Sahil AU - Khera S AUID- ORCID: 0000-0001-9777-5934 AD - The Zena and Michael A. Wiener Cardiovascular Institute Icahn School of Medicine at Mount Sinai New York NY. FAU - Dangas, George AU - Dangas G AUID- ORCID: 0000-0001-7502-8049 AD - The Zena and Michael A. Wiener Cardiovascular Institute Icahn School of Medicine at Mount Sinai New York NY. FAU - Filsoufi, Farzan AU - Filsoufi F AD - Department of Cardiac Surgery Icahn School of Medicine at Mount Sinai New York NY. FAU - Mehran, Roxana AU - Mehran R AUID- ORCID: 0000-0002-5546-262X AD - The Zena and Michael A. Wiener Cardiovascular Institute Icahn School of Medicine at Mount Sinai New York NY. AD - Center for Interventional Cardiovascular Research and Clinical Trials, The Zena and Michael A. Wiener Cardiovascular Institute Icahn School of Medicine at Mount Sinai New York NY. FAU - Kini, Annapoorna S AU - Kini AS AUID- ORCID: 0000-0002-7189-3307 AD - The Zena and Michael A. Wiener Cardiovascular Institute Icahn School of Medicine at Mount Sinai New York NY. FAU - Fuster, Valentin AU - Fuster V AD - The Zena and Michael A. Wiener Cardiovascular Institute Icahn School of Medicine at Mount Sinai New York NY. FAU - Sharma, Samin K AU - Sharma SK AUID- ORCID: 0000-0002-1888-0793 AD - The Zena and Michael A. Wiener Cardiovascular Institute Icahn School of Medicine at Mount Sinai New York NY. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240531 PL - England TA - J Am Heart Assoc JT - Journal of the American Heart Association JID - 101580524 SB - IM CIN - J Am Heart Assoc. 2024 Jun 4;13(11):e035891. doi: 10.1161/JAHA.124.035891. PMID: 38818930 MH - Humans MH - *Percutaneous Coronary Intervention/adverse effects MH - Male MH - *Coronary Artery Bypass/adverse effects MH - Female MH - Aged MH - *Coronary Artery Disease/surgery/mortality MH - Middle Aged MH - Treatment Outcome MH - Retrospective Studies MH - Risk Factors MH - Risk Assessment MH - Patient Selection MH - Clinical Decision-Making PMC - PMC11255644 OTO - NOTNLM OT - coronary artery disease OT - coronary revascularization OT - multivessel coronary disease OT - patient preferences OT - shared decision-making EDAT- 2024/05/31 12:43 MHDA- 2024/06/04 18:42 PMCR- 2024/06/04 CRDT- 2024/05/31 07:23 PHST- 2024/06/04 18:42 [medline] PHST- 2024/05/31 12:43 [pubmed] PHST- 2024/05/31 07:23 [entrez] PHST- 2024/06/04 00:00 [pmc-release] AID - JAH39617 [pii] AID - 10.1161/JAHA.123.033931 [doi] PST - ppublish SO - J Am Heart Assoc. 2024 Jun 4;13(11):e033931. doi: 10.1161/JAHA.123.033931. Epub 2024 May 31. PMID- 38816212 OWN - NLM STAT- MEDLINE DCOM- 20240731 LR - 20240802 IS - 1460-2385 (Electronic) IS - 0931-0509 (Print) IS - 0931-0509 (Linking) VI - 39 IP - 8 DP - 2024 Jul 31 TI - Treatment strategies of the thromboembolic risk in kidney failure patients with atrial fibrillation. PG - 1248-1257 LID - 10.1093/ndt/gfae121 [doi] AB - The incidence and prevalence of atrial fibrillation (AF) in patients affected by kidney failure, i.e. glomerular filtration rate <15 ml/min/1.73 m2, is high and probably underestimated. Numerous uncertainties remain regarding how to prevent thromboembolic events in this population because both cardiology and nephrology guidelines do not provide clear recommendations. The efficacy and safety of oral anticoagulant therapy (OAC) in preventing thromboembolism in patients with kidney failure and AF has not been demonstrated for either vitamin K antagonists (VKAs) or direct anticoagulants (DOACs). Moreover, it remains unclear which is more effective and safer, because estimated creatinine clearance <25-30 ml/min was an exclusion criterion in the randomized controlled trials (RCTs). Three RCTs comparing DOACs and VKAs in kidney failure failed to reach the primary endpoint, as they were underpowered. The left atrial appendage is the main source of thromboembolism in the presence of AF. Left atrial appendage closure (LAAC) has recently been proposed as an alternative to OAC. RCTs comparing the efficacy and safety of LAAC versus OAC in kidney failure were terminated prematurely due to recruitment failure. A recent prospective study showed a reduction in thromboembolic events in haemodialysis patients with AF and undergoing LAAC compared with patients taking or not taking OAC. We review current treatment standards and discuss recent developments in managing the thromboembolic risk in kidney failure patients with AF. The importance of shared decision-making with the multidisciplinary team and the patient to consider individual risks and benefits of each treatment option is underlined. CI - (c) The Author(s) 2024. Published by Oxford University Press on behalf of the ERA. FAU - Genovesi, Simonetta AU - Genovesi S AUID- ORCID: 0000-0002-4699-4149 AD - School of Medicine and Surgery, University of Milano-Bicocca, Nephrology Clinic, Monza, Italy. AD - Istituto Auxologico Italiano, IRCCS, Milan, Italy. FAU - Camm, A John AU - Camm AJ AUID- ORCID: 0000-0002-2536-2871 AD - St. George's University of London, London, UK. FAU - Covic, Adrian AU - Covic A AUID- ORCID: 0000-0002-9985-2486 AD - Nephrology Clinic, Dialysis and Renal Transplant Center - 'C.I. Parhon' University Hospital and 'Grigore T. Popa' University of Medicine, Iasi, Romania. FAU - Burlacu, Alexandru AU - Burlacu A AUID- ORCID: 0000-0002-3424-1588 AD - Nephrology Clinic, Dialysis and Renal Transplant Center - 'C.I. Parhon' University Hospital and 'Grigore T. Popa' University of Medicine, Iasi, Romania. FAU - Meijers, Bjorn AU - Meijers B AUID- ORCID: 0000-0002-2846-2026 AD - Nephrology Unit, University Hospitals Leuven and Department of Microbiology, Immunology and Organ Transplantation, KU Leuven, Leuven, Belgium. FAU - Franssen, Casper AU - Franssen C AUID- ORCID: 0000-0003-1004-9994 AD - Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. FAU - Luyckx, Valerie AU - Luyckx V AUID- ORCID: 0000-0001-7066-8135 AD - Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. AD - Department of Paediatrics and Child Health, University of Cape Town, South Africa. AD - Department of Public and Global Health, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland. FAU - Liakopoulos, Vassilios AU - Liakopoulos V AUID- ORCID: 0000-0002-7564-2724 AD - Second Department of Nephrology, AHEPA University Hospital, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece. FAU - Alfano, Gaetano AU - Alfano G AUID- ORCID: 0000-0003-0591-8622 AD - Nephrology Dialysis and Transplant Unit, University Hospital of Modena, Modena, Italy. FAU - Combe, Christian AU - Combe C AUID- ORCID: 0000-0002-0360-573X AD - Department of Nephrology, CHU de Bordeaux and INSERM U1026, University of Bordeaux, Bordeaux, France. FAU - Basile, Carlo AU - Basile C AUID- ORCID: 0000-0001-8152-5471 AD - Associazione Nefrologica Gabriella Sebastio, Martina Franca, Italy. LA - eng PT - Journal Article PT - Review PL - England TA - Nephrol Dial Transplant JT - Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association JID - 8706402 RN - 0 (Anticoagulants) SB - IM MH - Humans MH - *Atrial Fibrillation/complications/drug therapy MH - *Thromboembolism/etiology/prevention & control MH - *Anticoagulants/therapeutic use MH - *Renal Insufficiency/complications/etiology MH - Risk Factors PMC - PMC11288792 OTO - NOTNLM OT - atrial fibrillation OT - kidney failure OT - left atrial appendage closure OT - oral anticoagulant therapy OT - thromboembolism COIS- S.G. has received consulting and speaker fees from Boston Scientific. A.J.C. has received personal fees from Abbott, Boston Scientific, Medtronic and Sanofi. B.M. has received grant support from BMS in relation to the topics of this article. C.B. has received consulting fees from Boston Scientific. The other authors declare no conflicts of interest. EDAT- 2024/05/31 00:42 MHDA- 2024/07/31 06:42 PMCR- 2024/05/30 CRDT- 2024/05/30 21:33 PHST- 2024/02/17 00:00 [received] PHST- 2024/07/31 06:42 [medline] PHST- 2024/05/31 00:42 [pubmed] PHST- 2024/05/30 21:33 [entrez] PHST- 2024/05/30 00:00 [pmc-release] AID - 7685545 [pii] AID - gfae121 [pii] AID - 10.1093/ndt/gfae121 [doi] PST - ppublish SO - Nephrol Dial Transplant. 2024 Jul 31;39(8):1248-1257. doi: 10.1093/ndt/gfae121. PMID- 38811152 OWN - NLM STAT- MEDLINE DCOM- 20240925 LR - 20260920 IS - 2055-5822 (Electronic) IS - 2055-5822 (Linking) VI - 11 IP - 5 DP - 2024 Oct TI - Validity and reliability of the palliative care needs assessment tool in Japanese patients with heart failure. PG - 2967-2976 LID - 10.1002/ehf2.14886 [doi] AB - AIMS: Although patients with heart failure (HF) frequently experience considerable symptom burden and require significant care, most HF patients do not receive timely intervention due to the absence of a standardized method for identifying those in need of palliative care. The Needs Assessment Tool: Progressive Disease-Heart Failure (NAT: PD-HF) assesses the palliative care needs of patients with HF. However, its validity and reliability have yet to be fully examined. We aimed to assess the validity and reliability of the NAT: PD-HF in Japanese patients with HF. METHODS: We prospectively enrolled 106 consecutive patients with chronic HF admitted to our university hospital between February 2023 and July 2023. Their caregivers (n = 95) and healthcare providers (n = 17) were also included. The NAT: PD-HF was translated from English to Japanese using a forward-backward translation procedure and adapted based on Japanese cultural and medical backgrounds by our professional multidisciplinary team. We assessed the internal consistency of the Japanese NAT: PD-HF version with Cronbach's alpha coefficient and the inter-rater and test-retest reliabilities with Cohen's kappa coefficient. After using the tool, all participants were asked to complete a questionnaire about the tool to determine its validity. RESULTS: The proportion of female patients in this study was 47 (44%). The median age was 72 years [interquartile range (IQR) 59-81]. The median time spent assessing the patients' and their caregivers' needs using the Japanese NAT: PD-HF was 14 min (IQR 12-17). The Cronbach's alpha coefficient was 0.82, and the minimum kappa coefficient was 0.77 for inter-rater reliability and 0.88 for test-retest reliability. In total, 103 patients (97%) and all caregivers responded that the tool was easy to understand. One hundred (94%) patients and 89 (94%) caregivers felt that the tool would improve the quality of care, and 102 (96%) patients and 91 (96%) caregivers indicated that the discussions using this tool allowed them to confide in all their burdens and care needs. All healthcare providers expressed that this tool is helpful in understanding the burden and care needs of both patients and caregivers comprehensively. CONCLUSIONS: The NAT: PD-HF is a reliable and valid tool for Japanese patients with HF and their caregivers. This tool was very well accepted by patients, caregivers and healthcare providers to identify burdens and care needs. CI - (c) 2024 The Author(s). ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. FAU - Tatsuta, Daishiro AU - Tatsuta D AD - Department of Cardiovascular Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan. FAU - Sato, Takuma AU - Sato T AUID- ORCID: 0000-0002-7006-390X AD - Department of Cardiovascular Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan. FAU - Nagai, Toshiyuki AU - Nagai T AUID- ORCID: 0000-0002-1043-0608 AD - Department of Cardiovascular Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan. FAU - Koya, Jiro AU - Koya J AD - Department of Cardiovascular Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan. FAU - Nishino, Kotaro AU - Nishino K AD - Department of Cardiovascular Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan. FAU - Naito, Seiichiro AU - Naito S AD - Department of Cardiovascular Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan. FAU - Mizuguchi, Yoshifumi AU - Mizuguchi Y AD - Department of Cardiovascular Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan. FAU - Temma, Taro AU - Temma T AD - Department of Cardiovascular Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan. FAU - Kamiya, Kiwamu AU - Kamiya K AD - Department of Cardiovascular Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan. FAU - Narita, Hisashi AU - Narita H AD - Department of Psychiatry, Hokkaido University Graduate School of Medicine, Sapporo, Japan. FAU - Tsuruga, Kenkichi AU - Tsuruga K AD - Department of Anesthesiology and Critical Care Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan. FAU - Anzai, Toshihisa AU - Anzai T AD - Department of Cardiovascular Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan. LA - eng PT - Journal Article DEP - 20240529 PL - England TA - ESC Heart Fail JT - ESC heart failure JID - 101669191 SB - IM MH - Humans MH - *Heart Failure/therapy MH - Female MH - *Palliative Care MH - Male MH - Reproducibility of Results MH - *Needs Assessment MH - Aged MH - Japan MH - Prospective Studies MH - Middle Aged MH - Surveys and Questionnaires MH - Aged, 80 and over MH - Caregivers MH - East Asian People PMC - PMC11424344 OTO - NOTNLM OT - heart failure OT - needs assessment tool OT - palliative care COIS- The authors declare that there is no conflict of interest. EDAT- 2024/05/30 05:43 MHDA- 2024/09/26 00:42 PMCR- 2024/05/29 CRDT- 2024/05/29 21:03 PHST- 2024/04/13 00:00 [revised] PHST- 2024/02/06 00:00 [received] PHST- 2024/05/12 00:00 [accepted] PHST- 2024/09/26 00:42 [medline] PHST- 2024/05/30 05:43 [pubmed] PHST- 2024/05/29 21:03 [entrez] PHST- 2024/05/29 00:00 [pmc-release] AID - EHF214886 [pii] AID - 10.1002/ehf2.14886 [doi] PST - ppublish SO - ESC Heart Fail. 2024 Oct;11(5):2967-2976. doi: 10.1002/ehf2.14886. Epub 2024 May 29. PMID- 38806975 OWN - NLM STAT- MEDLINE DCOM- 20240710 LR - 20261010 IS - 1534-3170 (Electronic) IS - 1523-3782 (Linking) VI - 26 IP - 7 DP - 2024 Jul TI - Infection of Transcatheter Valvular Devices. PG - 767-775 LID - 10.1007/s11886-024-02076-9 [doi] AB - PURPOSE OF REVIEW: This review explores the epidemiology, clinical traits, and diagnosis of Transcatheter Aortic Valve Replacement-Associated Infective Endocarditis (TAVR-IE) and mitral transcatheter edge-to-edge repair infective endocarditis (TEER-IE), focusing on a multimodal imaging approach. It addresses the rising prevalence of TAVR and TEER, emphasizing the need to understand long-term complications and clinical consequences, which poses significant challenges despite advancements in valve technology. RECENT FINDINGS: Studies report a variable incidence of TAVR-IE and TEER-IE influenced by diverse patient risk profiles and procedural factors. Younger age, male gender, and certain comorbidities emerge as patient-related risk factors. Procedure-related factors include intervention location, valve type, and technical aspects. Microbiologically, Staphylococcus aureus, Viridans Group Streptococcus, and Enterococcus are frequently encountered pathogens. TAVR-IE and TEER-IE diagnosis involves a multimodal imaging approach due to limitations in echocardiography. Blood cultures and imaging aid identification, with Fluorescence in situ hybridization is showing promise. Treatment encompasses medical management with antibiotics and, when necessary, surgical intervention. The management approach requires a multidisciplinary "Endocarditis Team." This review underscores the need for continued research to refine risk prediction, enhance diagnostic accuracy, and optimize management strategies for TAVR-IE, considering the evolving landscape of transcatheter interventions. CI - (c) 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Hatab, Taha AU - Hatab T AD - Department of Cardiology, Houston Methodist DeBakey Heart & Vascular Center, Allison Family Distinguished Chair of Cardiovascular Research, 6550 Fannin Street, Office 1401, Houston, TX, 77030, USA. FAU - Zaid, Syed AU - Zaid S AD - Baylor School of Medicine and the Michael E DeBakey VAMC, Houston, TX, USA. FAU - Thakkar, Samarthkumar J AU - Thakkar SJ AD - Department of Cardiology, Houston Methodist DeBakey Heart & Vascular Center, Allison Family Distinguished Chair of Cardiovascular Research, 6550 Fannin Street, Office 1401, Houston, TX, 77030, USA. FAU - Bou Chaaya, Rody G AU - Bou Chaaya RG AD - Department of Cardiology, Houston Methodist DeBakey Heart & Vascular Center, Allison Family Distinguished Chair of Cardiovascular Research, 6550 Fannin Street, Office 1401, Houston, TX, 77030, USA. FAU - Goel, Sachin S AU - Goel SS AD - Department of Cardiology, Houston Methodist DeBakey Heart & Vascular Center, Allison Family Distinguished Chair of Cardiovascular Research, 6550 Fannin Street, Office 1401, Houston, TX, 77030, USA. FAU - Reardon, Michael J AU - Reardon MJ AD - Division of Cardiothoracic Surgery, Houston Methodist DeBakey Heart & Vascular Center, Allison Family Distinguished Chair of Cardiovascular Research, 6550 Fannin Street, Office 1401, Houston, TX, 77030, USA. mreardon@houstonmethodist.org. LA - eng PT - Journal Article PT - Review DEP - 20240528 PL - United States TA - Curr Cardiol Rep JT - Current cardiology reports JID - 100888969 RN - 0 (Anti-Bacterial Agents) SB - IM MH - Humans MH - *Transcatheter Aortic Valve Replacement/adverse effects MH - Risk Factors MH - *Prosthesis-Related Infections/therapy/microbiology/etiology MH - Heart Valve Prosthesis/adverse effects/microbiology MH - Anti-Bacterial Agents/therapeutic use MH - Endocarditis, Bacterial/microbiology/etiology/therapy MH - Endocarditis/microbiology/etiology OTO - NOTNLM OT - Endocarditis OT - Management OT - Multimodality imaging OT - Transcatheter aortic valve replacement EDAT- 2024/05/29 00:49 MHDA- 2024/07/10 12:43 CRDT- 2024/05/28 23:42 PHST- 2024/05/15 00:00 [accepted] PHST- 2024/07/10 12:43 [medline] PHST- 2024/05/29 00:49 [pubmed] PHST- 2024/05/28 23:42 [entrez] AID - 10.1007/s11886-024-02076-9 [pii] AID - 10.1007/s11886-024-02076-9 [doi] PST - ppublish SO - Curr Cardiol Rep. 2024 Jul;26(7):767-775. doi: 10.1007/s11886-024-02076-9. Epub 2024 May 28. PMID- 38801597 OWN - NLM STAT- MEDLINE DCOM- 20240810 LR - 20261010 IS - 1559-0100 (Electronic) IS - 1355-008X (Linking) VI - 85 IP - 3 DP - 2024 Sep TI - Muscle function, exercise capacity, physical activity level and cardiovascular disease risk factor knowledge in patients with prolactinoma. PG - 1337-1345 LID - 10.1007/s12020-024-03880-7 [doi] AB - OBJECTIVE: Prolactinoma can increase the risk of cardiovascular diseases (CVDs), such as arterial stiffness, atherosclerosis, dysrhythmia and heart failure. This study aimed to evaluate and compare muscle function, exercise capacity, physical activity (PA) level, CVD risk factor knowledge level, sleep quality, fatigue and quality of life between prolactinoma patients and healthy controls. METHODS: Nineteen female patients with prolactinomas and 19 healthy women were included in this study. Quadriceps muscle strength (QMS) was measured using a hand dynamometer, and muscular endurance was evaluated via the squat test. The 6-minute walking test (6MWT) distance was also measured. CVD risk factor knowledge levels were evaluated with the Cardiovascular Diseases Risk Factors Knowledge Level Scale (CARRF-KL), PA levels were assessed with the International Physical Activity Questionnaire-short form (IPAQ), sleep quality was assessed with the Pittsburgh Sleep Quality Index (PSQI), fatigue was assessed with the Multidimensional Fatigue Rating Scale (MAF), and quality of life was assessed with the Short Form-36 questionnaire (SF-36). RESULTS: Patients with prolactinomas had significantly lower 6MWT distances; CARRF-KL total scores; SF-36 general health and physical limitation scores; and higher IPAQ-sitting scores than did healthy controls (p < 0.05). Moreover, there were no significant differences between the groups in terms of QMS score; number of squats; severity of IPAQ score; severity, moderate, or total walking score; total PSQI score; or total MAF score (p > 0.05). CONCLUSIONS: Exercise capacity and quality of life are adversely affected, and sedentary behavior is observed in prolactinomas. Patients with prolactinomas have less knowledge about CVD risk factors than healthy individuals. CVD incidence and knowledge and functional capacity should be improved in patients with prolactinomas by the use of a multidisciplinary team for cardiac rehabilitation. CLINICAL TRIAL REGISTRATION: This study is part of a larger clinical trial registered on ClinicalTrials.gov prior to participant enrollment (NCT05236829). CI - (c) 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Erkoc, Aysegul AU - Erkoc A AUID- ORCID: 0000-0002-6374-0001 AD - Department of Cardiorespiratory Physiotherapy and Rehabilitation, Faculty of Physical Therapy and Rehabilitation, Hacettepe University, 06100, Samanpazari, Ankara, Turkey. erkcaysegl@gmail.com. FAU - Eroglu, Imdat AU - Eroglu I AUID- ORCID: 0000-0001-6619-4141 AD - Department of Internal Medicine, School of Medicine, Hacettepe University, Sihhiye, 06100, Ankara, Turkey. FAU - Erbas, Tomris AU - Erbas T AUID- ORCID: 0000-0003-1377-9394 AD - Department of Internal Medicine, School of Medicine, Hacettepe University, Sihhiye, 06100, Ankara, Turkey. AD - Department of Endocrinology and Metabolism, School of Medicine, Hacettepe University, Sihhiye, 06100, Ankara, Turkey. FAU - Kutukcu, Ebru Calik AU - Kutukcu EC AUID- ORCID: 0000-0001-5215-5125 AD - Department of Cardiorespiratory Physiotherapy and Rehabilitation, Faculty of Physical Therapy and Rehabilitation, Hacettepe University, 06100, Samanpazari, Ankara, Turkey. LA - eng SI - ClinicalTrials.gov/NCT05236829 PT - Journal Article PT - Observational Study DEP - 20240527 PL - United States TA - Endocrine JT - Endocrine JID - 9434444 SB - IM MH - Adult MH - Female MH - Humans MH - Middle Aged MH - *Cardiovascular Diseases/epidemiology/physiopathology/etiology MH - *Exercise/physiology MH - *Exercise Tolerance/physiology MH - Fatigue/physiopathology MH - Health Knowledge, Attitudes, Practice MH - Heart Disease Risk Factors MH - *Muscle Strength/physiology MH - *Pituitary Neoplasms/physiopathology/complications MH - *Prolactinoma/physiopathology/complications MH - *Quality of Life MH - Risk Factors MH - Sleep Quality OTO - NOTNLM OT - Exercise test OT - Physical activity OT - Prolactinoma OT - Quality of life EDAT- 2024/05/27 12:43 MHDA- 2024/08/10 15:46 CRDT- 2024/05/27 11:16 PHST- 2024/03/15 00:00 [received] PHST- 2024/05/16 00:00 [accepted] PHST- 2024/08/10 15:46 [medline] PHST- 2024/05/27 12:43 [pubmed] PHST- 2024/05/27 11:16 [entrez] AID - 10.1007/s12020-024-03880-7 [pii] AID - 10.1007/s12020-024-03880-7 [doi] PST - ppublish SO - Endocrine. 2024 Sep;85(3):1337-1345. doi: 10.1007/s12020-024-03880-7. Epub 2024 May 27. PMID- 38800121 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240528 IS - 2589-8450 (Electronic) IS - 2589-8450 (Linking) VI - 19 DP - 2024 Jun TI - Evaluating the safety and efficacy of a novel polysaccharide hemostatic system during surgery: A multicenter multispecialty prospective randomized controlled trial. PG - 205-211 LID - 10.1016/j.sopen.2024.04.009 [doi] AB - BACKGROUND: Operative blood loss is associated with postoperative morbidity and mortality in surgery. Hemostatic agents are used as adjuncts for hemostasis during surgery and help to prevent postoperative bleeding. We evaluated the safety and efficacy of an investigational polysaccharide hemostatic (PH) topical product compared to a U.S. Food and Drug Administration (FDA)-approved control in clinical use comprising microporous polysaccharide hemospheres (MPH) to achieve hemostasis of bleeding surfaces during surgery. STUDY DESIGN: This prospective multicenter trial enrolled patients undergoing open elective cardiac, general, or urologic surgery. Patients were stratified by bleeding severity and therapeutic area, then randomized 1:1 to receive PH or MPH. Bleeding assessments occurred intraoperatively using a novel bleeding assessment methodology. Primary endpoint was noninferiority as compared with control via effective hemostasis at 7 min. Patients were monitored and followed daily in the postoperative period until time of discharge and again at 6 weeks. Overall survival was assessed in oncology patients at 24 months. Safety of PH vs. MPH was determined by comparing relative incidence of adverse events. RESULTS: Across 19 centers, 324 (161 PH, 163 MPH) patients were randomized (48 % general surgery, 27 % cardiac surgery, and 25 % urologic surgery). PH was noninferior to MPH and met the primary endpoint of hemostatic success at 7 min at a non-inferiority margin of 10 %. No significant differences were found in adverse event rates. Six deaths were reported within the 6-week follow-up period. No difference in overall survival was observed at 2 years (76 % PH vs. 74 % MPH, P = .66) for patients undergoing cancer operations. CONCLUSION: Across three therapeutic areas, PH was noninferior to MPH at all hemostasis assessment time points with no safety concerns. PH is an effective alternative to MPH for hemostasis during surgery.ClinicalTrials.gov Identifier: NCT02359994. CI - (c) 2024 The Authors. FAU - House, Michael G AU - House MG AD - Indiana University, Indianapolis, IN, United States of America. FAU - Kim, Robin AU - Kim R AD - University of Utah Hospital, Salt Lake City, UT, United States of America. FAU - Tseng, Elaine E AU - Tseng EE AD - San Francisco Veterans Affairs Healthcare System, San Francisco, CA. FAU - Kaufman, Ronald P Jr AU - Kaufman RP Jr AD - Albany Medical College, Albany, NY, United States of America. FAU - Moon, Marc R AU - Moon MR AD - Baylor College of Medicine, Houston, TX, United States of America. FAU - Yopp, Adam AU - Yopp A AD - University of Texas Southwestern, Dallas, TX, United States of America. FAU - Master, Viraj A AU - Master VA AD - Emory University, Atlanta, GA, United States of America. LA - eng SI - ClinicalTrials.gov/NCT02359994 PT - Journal Article DEP - 20240503 PL - United States TA - Surg Open Sci JT - Surgery open science JID - 101768812 PMC - PMC11127167 OTO - NOTNLM OT - Cardiac surgery OT - General surgery OT - Hemostasis OT - Hemostatic agent OT - Intraoperative bleeding polysaccharide OT - Postoperative bleeding OT - Urologic surgery COIS- As the study sponsor, CryoLife/Artivion provided financial support to conduct the study including project management, monitoring, data management, statistical analyses, and generation of the final study report for submission to the FDA. The authors have disclosed any conflicts of interest. EDAT- 2024/05/27 06:44 MHDA- 2024/05/27 06:45 PMCR- 2024/05/03 CRDT- 2024/05/27 04:32 PHST- 2024/01/05 00:00 [received] PHST- 2024/04/10 00:00 [revised] PHST- 2024/04/28 00:00 [accepted] PHST- 2024/05/27 06:45 [medline] PHST- 2024/05/27 06:44 [pubmed] PHST- 2024/05/27 04:32 [entrez] PHST- 2024/05/03 00:00 [pmc-release] AID - S2589-8450(24)00061-7 [pii] AID - 10.1016/j.sopen.2024.04.009 [doi] PST - epublish SO - Surg Open Sci. 2024 May 3;19:205-211. doi: 10.1016/j.sopen.2024.04.009. eCollection 2024 Jun. PMID- 38796229 OWN - NLM STAT- MEDLINE DCOM- 20240525 LR - 20240525 IS - 1557-8232 (Electronic) IS - 0749-0704 (Linking) VI - 40 IP - 3 DP - 2024 Jul TI - Rapid Response Systems. PG - 583-598 LID - S0749-0704(24)00029-0 [pii] LID - 10.1016/j.ccc.2024.03.008 [doi] AB - The hospital rapid response system (RRS) is a patient safety and quality intervention that responds quickly to clinical deteriorations on general wards with the goal of preventing cardiopulmonary arrests, reducing hospital mortality, and facilitating triage and level of care escalations. The RRS is one of the first organized, and systematic, elements of the "ICU without walls" model. RRSs have been shown to be effective in preventing deterioration to cardiopulmonary arrest on general hospital wards and reducing total and unexpected hospital mortality. Recent studies have demonstrated that this benefit can be enhanced through targeted improvements and modifications of existing RRSs. CI - Copyright (c) 2024 Elsevier Inc. All rights reserved. FAU - Winters, Bradford D AU - Winters BD AD - Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, 9127 Zayed 1800 Orealns Street, Baltimore, MD 21287, USA. Electronic address: bwinters@jhmi.edu. LA - eng PT - Journal Article PT - Review DEP - 20240423 PL - United States TA - Crit Care Clin JT - Critical care clinics JID - 8507720 SB - IM MH - Humans MH - *Hospital Rapid Response Team/standards/organization & administration MH - *Heart Arrest/therapy MH - Hospital Mortality MH - Intensive Care Units/organization & administration MH - Patient Safety/standards MH - Triage OTO - NOTNLM OT - Cardiopulmonary arrest OT - Clinical deterioration OT - Mortality OT - Rapid response systems COIS- Disclosure The author has no relevant financial conflicts to disclose. EDAT- 2024/05/26 18:11 MHDA- 2024/05/26 18:12 CRDT- 2024/05/25 20:57 PHST- 2024/05/26 18:12 [medline] PHST- 2024/05/26 18:11 [pubmed] PHST- 2024/05/25 20:57 [entrez] AID - S0749-0704(24)00029-0 [pii] AID - 10.1016/j.ccc.2024.03.008 [doi] PST - ppublish SO - Crit Care Clin. 2024 Jul;40(3):583-598. doi: 10.1016/j.ccc.2024.03.008. Epub 2024 Apr 23. PMID- 38795907 OWN - NLM STAT- MEDLINE DCOM- 20250624 LR - 20260325 IS - 1097-685X (Electronic) IS - 0022-5223 (Linking) VI - 170 IP - 1 DP - 2025 Jul TI - 2022: Perioperative and critical care year in review for the cardiothoracic surgery team. PG - 279-286 LID - S0022-5223(24)00442-2 [pii] LID - 10.1016/j.jtcvs.2024.05.011 [doi] AB - This year, we have again assembled an expert opinion on several key topics that pertain to the perioperative and critical care management of patients undergoing cardiac surgery and for patients requiring extracorporeal membrane oxygenation. Approximately 1 in 3 patients undergoing cardiac surgery have diabetes mellitus; contemporary glycemic control management of these patients to minimize perioperative complications are reviewed. Goal-directed fluid therapy remains an area on interest and controversy; the use of albumin as a resuscitation fluid and recent clinical trial data are reviewed. Delirium is characterized as an acute confusion state occurring in 20% to 25% of patients after cardiac surgery. Insights on integrating the whole interdisciplinary team, including the family, with the Delirium Team Approach program are discussed. Optimal management for refractory hypoxemia with venovenous extracorporeal membrane oxygenation and the role of prone positioning remain a question. Data supporting this technique during venovenous extracorporeal membrane oxygenation is reviewed-lastly, the contemporary management and supporting evidence for refractory postoperative vasoplegic shock after cardiopulmonary bypass is provided. CI - Copyright (c) 2024 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved. FAU - Arora, Rakesh C AU - Arora RC AD - Harrington Heart and Vascular Institute, University Hospitals, Cleveland, Ohio. Electronic address: rakeshcarora@gmail.com. FAU - Chatterjee, Subhasis AU - Chatterjee S AD - Divisions of Trauma/Acute Care Surgery and Cardiothoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Tex; Department of Cardiovascular Surgery, Texas Heart Institute, Houston, Tex. FAU - Milewski, Rita AU - Milewski R AD - Division of Cardiac Surgery, Yale University, New Haven, Conn. FAU - Baciewicz, Frank A AU - Baciewicz FA AD - Division of Cardiothoracic Surgery, Wayne State, Detroit, Mich. FAU - Haft, Jonathan AU - Haft J AD - Department of Cardiac Surgery, University of Michigan, Ann Arbor, Mich. FAU - Martin, Linda AU - Martin L AD - Division of Thoracic Surgery, University of Virginia, Charlotteville, Va. LA - eng PT - Journal Article PT - Review DEP - 20240523 PL - United States TA - J Thorac Cardiovasc Surg JT - The Journal of thoracic and cardiovascular surgery JID - 0376343 SB - IM MH - Humans MH - *Cardiac Surgical Procedures/adverse effects MH - *Perioperative Care/methods/trends MH - Extracorporeal Membrane Oxygenation/adverse effects MH - *Critical Care/methods/trends MH - *Patient Care Team MH - Postoperative Complications/prevention & control OTO - NOTNLM OT - CTICU OT - ECMO OT - cardiac surgery OT - delirium OT - fluid management OT - glycemic control COIS- Conflict of Interest Statement Dr Akora has received honoraria from HLS Therapeutics Inc and Edwards Lifesciences and is on the scientific advisor board for Renibus Therapeutics Inc for work unrelated to this manuscript. Dr Chatterjee has served on advisory boards for Edwards Lifesciences, La Jolla Pharmaceutical Company, Baxter Pharmaceuticals, and Eagle Pharmaceuticals Inc. Dr Martin is on an advisory board and is the international principal investigator for stage 3 trials for AstraZeneca, part of the advisory board and speakers bureau for Genentech, on the speakers bureau for Ethicon, and on a steering committee for the ELUCIDATE trial for Ontarget laboratories. All other authors reported no conflicts of interest. The Journal policy requires editors and reviewers to disclose conflicts of interest and to decline handling manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest. EDAT- 2024/05/26 18:11 MHDA- 2025/06/24 13:14 CRDT- 2024/05/25 19:20 PHST- 2024/04/25 00:00 [received] PHST- 2024/05/10 00:00 [accepted] PHST- 2025/06/24 13:14 [medline] PHST- 2024/05/26 18:11 [pubmed] PHST- 2024/05/25 19:20 [entrez] AID - S0022-5223(24)00442-2 [pii] AID - 10.1016/j.jtcvs.2024.05.011 [doi] PST - ppublish SO - J Thorac Cardiovasc Surg. 2025 Jul;170(1):279-286. doi: 10.1016/j.jtcvs.2024.05.011. Epub 2024 May 23. PMID- 38795719 OWN - NLM STAT- MEDLINE DCOM- 20240622 LR - 20260518 IS - 1474-547X (Electronic) IS - 0140-6736 (Linking) VI - 403 IP - 10445 DP - 2024 Jun 22 TI - LANDMARK comparison of early outcomes of newer-generation Myval transcatheter heart valve series with contemporary valves (Sapien and Evolut) in real-world individuals with severe symptomatic native aortic stenosis: a randomised non-inferiority trial. PG - 2695-2708 LID - S0140-6736(24)00821-3 [pii] LID - 10.1016/S0140-6736(24)00821-3 [doi] AB - BACKGROUND: Transcatheter aortic valve implantation is an established, guideline-endorsed treatment for severe aortic stenosis. Precise sizing of the balloon-expandable Myval transcatheter heart valve (THV) series with the aortic annulus is facilitated by increasing its diameter in 1.5 mm increments, compared with the usual 3 mm increments in valve size. The LANDMARK trial aimed to show non-inferiority of the Myval THV series compared with the contemporary THVs Sapien Series (Edwards Lifesciences, Irvine, CA, USA) or Evolut Series (Medtronic, Minneapolis, MN, USA). METHODS: In this prospective, multinational, randomised, open-label, non-inferiority trial across 31 hospitals in 16 countries (Germany, France, Sweden, the Netherlands, Italy, Spain, New Zealand, Portugal, Greece, Hungary, Poland, Slovakia, Slovenia, Croatia, Estonia, and Brazil), 768 participants with severe symptomatic native aortic stenosis were randomly assigned (1:1) to the Myval THV or a contemporary THV. Eligibility was primarily decided by the heart team in accordance with 2021 European Society of Cardiology guidelines. As per the criteria of the third Valve Academic Research Consortium, the primary endpoint at 30 days was a composite of all-cause mortality, all stroke, bleeding (types 3 and 4), acute kidney injury (stages 2-4), major vascular complications, moderate or severe prosthetic valve regurgitation, and conduction system disturbances resulting in a permanent pacemaker implantation. Non-inferiority of the study device was tested in the intention-to-treat population using a non-inferiority margin of 10.44% and assuming an event rate of 26.10%. This trial is registered with ClinicalTrials.gov, NCT04275726, and EudraCT, 2020-000137-40, and is closed to new participants. FINDINGS: Between Jan 6, 2021, and Dec 5, 2023, 768 participants with severe symptomatic native aortic stenosis were randomly assigned, 384 to the Myval THV and 384 to a contemporary THV. 369 (48%) participants had their sex recorded as female, and 399 (52%) as male. The mean age of participants was 80.0 years (SD 5.7) for those treated with the Myval THV and 80.4 years (5.4) for those treated with a contemporary THV. Median Society of Thoracic Surgeons scores were the same in both groups (Myval 2.6% [IQR 1.7-4.0] vs contemporary 2.6% [1.7-4.0]). The primary endpoint showed non-inferiority of the Myval (25%) compared with contemporary THV (27%), with a risk difference of -2.3% (one-sided upper 95% CI 3.8, p(non-inferiority)<0.0001). No significant difference was seen in individual components of the primary composite endpoint. INTERPRETATION: In individuals with severe symptomatic native aortic stenosis, the Myval THV met its primary endpoint at 30 days. FUNDING: Meril Life Sciences. CI - Copyright (c) 2024 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies. FAU - Baumbach, Andreas AU - Baumbach A AD - Centre for Cardiovascular Medicine and Devices, William Harvey Research Institute, Queen Mary University of London and Barts Heart Centre, London, UK; Cleveland Clinic, London, UK. FAU - van Royen, Niels AU - van Royen N AD - Department of Cardiology, Radboud University Hospital, Nijmegen, Netherlands. FAU - Amat-Santos, Ignacio J AU - Amat-Santos IJ AD - CIVERCV, Centro de Investigacion Biomedica en red - Enfermedades Cardiovasculares, University Clinical Hospital of Valladolid, Valladolid, Spain; Department of Cardiology, University Clinical Hospital of Valladolid, Valladolid, Spain. FAU - Hudec, Martin AU - Hudec M AD - Department of Acute Cardiology, Middle-Slovak Institute Of Cardiovascular Diseases, Banska Bystrica, Slovakia. FAU - Bunc, Matjaz AU - Bunc M AD - Department of Cardiology, University Medical Centre Ljubljana, Ljubljana, Slovenia. FAU - Ijsselmuiden, Alexander AU - Ijsselmuiden A AD - Department of Cardiology, Amphia Hospital, Breda, Netherlands; Department of Interventional Cardiology, Maastricht University Medical Center, Maastricht, Netherlands; Zuyderland Hospital, Limburg, Netherlands. FAU - Laanmets, Peep AU - Laanmets P AD - Department of Invasive Cardiology, North Estonia Medical Centre, Tallinn, Estonia. FAU - Unic, Daniel AU - Unic D AD - Department of Cardiac and Transplant Surgery, University Hospital Dubrava, Zagreb, Croatia. FAU - Merkely, Bela AU - Merkely B AD - Heart and Vascular Centre, Semmelweis University Heart and Vascular Centre, Budapest, Hungary. FAU - Hermanides, Renicus S AU - Hermanides RS AD - Department of Cardiology, Isala Hospital, Zwolle, Netherlands. FAU - Ninios, Vlasis AU - Ninios V AD - Department of Cardiology, European Interbalkan Medical Center, Thessaloniki, Greece. FAU - Protasiewicz, Marcin AU - Protasiewicz M AD - Department of Cardiology, Institute of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland. FAU - Rensing, Benno J W M AU - Rensing BJWM AD - Department of Cardiology, St Antonius Hospital, Nieuwegein, Netherlands. FAU - Martin, Pedro L AU - Martin PL AD - Department of Interventional Cardiology, University Hospital of Gran Canaria Dr Negrin, Las Palmas, Spain. FAU - Feres, Fausto AU - Feres F AD - Department of Invasive Cardiology, Instituto Dante Pazzanese, Sao Paulo, Brazil. FAU - De Sousa Almeida, Manuel AU - De Sousa Almeida M AD - CHRC, NOVA Medical School, NOVA University Lisbon, Lisbon, Portugal. FAU - van Belle, Eric AU - van Belle E AD - Department of Interventional Cardiology, Lille University, Lille, France. FAU - Linke, Axel AU - Linke A AD - Department of Internal Medicine and Cardiology, University Clinic, Heart Center Dresden, University of Technology Dresden, Dresden, Germany. FAU - Ielasi, Alfonso AU - Ielasi A AD - Department of Interventional Cardiology, IRCCS Galeazzi Sant'Ambrogio Hospital, Milan, Italy. FAU - Montorfano, Matteo AU - Montorfano M AD - School of Medicine, Vita-Salute San Raffaele University, Milan, Italy; Interventional Cardiology Unit IRCCS San Raffaele Scientific Institute, Milan, Italy. FAU - Webster, Mark AU - Webster M AD - Department of Cardiology, Auckland City Hospital, Auckland, New Zealand. FAU - Toutouzas, Konstantinos AU - Toutouzas K AD - Department of Cardiology, Hippokration Hospital, Athens, Greece. FAU - Teiger, Emmanuel AU - Teiger E AD - Department of Medico-surgical Cardiovascular and Anaesthesiology, Henri-Mondor University Hospital, Creteil, France. FAU - Bedogni, Francesco AU - Bedogni F AD - Department of Clinical Cardiology, San Donato Hospital, Milan, Italy. FAU - Voskuil, Michiel AU - Voskuil M AD - Department of Interventional Cardiology, University Medical Center Utrecht, Utrecht, Netherlands. FAU - Pan, Manuel AU - Pan M AD - Department of Cardiology, University Hospital Reina Sofia, University of Cordoba, Cordoba, Spain. FAU - Angeras, Oskar AU - Angeras O AD - Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden; Department of Clinical and Molecular Medicine, Gothenburg University, Gothenburg, Sweden. FAU - Kim, Won-Keun AU - Kim WK AD - Department of Cardiology and Angiology, University of Giessen and Marburg, Giessen, Germany; Department of Cardiology, Kerckhoff Heart Center, Bad Nauheim, Germany. FAU - Rothe, Jurgen AU - Rothe J AD - Department of Cardiology and Angiology, University Heart Center Freiburg Bad Krozingen, University Medical Center Freiburg, Freiburg, Germany; Department of Cardiology and Angiology, Faculty of Medicine, University of Freiburg, Freiburg, Germany. FAU - Kristic, Ivica AU - Kristic I AD - Department of Cardiology, University Hospital of Split, Split, Croatia. FAU - Peral, Vicente AU - Peral V AD - Department of Cardiology, Son Espases University Hospital, Palma, Spain. FAU - Garg, Scot AU - Garg S AD - Department of Cardiology, Royal Blackburn Hospital, Blackburn, UK. FAU - Elzomor, Hesham AU - Elzomor H AD - Department of Cardiology, School of Medicine, University of Galway, Galway, Ireland. FAU - Tobe, Akihiro AU - Tobe A AD - Department of Cardiology, School of Medicine, University of Galway, Galway, Ireland. FAU - Morice, Marie-Claude AU - Morice MC AD - Cardiovascular European Research Center, Paris, France. FAU - Onuma, Yoshinobu AU - Onuma Y AD - Department of Cardiology, School of Medicine, University of Galway, Galway, Ireland. FAU - Soliman, Osama AU - Soliman O AD - Department of Cardiology, School of Medicine, University of Galway, Galway, Ireland. FAU - Serruys, Patrick W AU - Serruys PW AD - Department of Cardiology, School of Medicine, University of Galway, Galway, Ireland. Electronic address: patrick.w.j.c.serruys@gmail.com. CN - LANDMARK trial investigators LA - eng SI - ClinicalTrials.gov/NCT04275726 PT - Comparative Study PT - Equivalence Trial PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't DEP - 20240522 PL - England TA - Lancet JT - Lancet (London, England) JID - 2985213R SB - IM CIN - Lancet. 2024 Jun 22;403(10445):2664-2665. doi: 10.1016/S0140-6736(24)00935-8. PMID: 38795718 EIN - Lancet. 2024 Jun 22;403(10445):2694. doi: 10.1016/S0140-6736(24)01259-5. PMID: 38908879 EIN - Lancet. 2025 Mar 1;405(10480):700. doi: 10.1016/S0140-6736(25)00353-8. PMID: 40023648 MH - Aged MH - Aged, 80 and over MH - Female MH - Humans MH - Male MH - Aortic Valve/surgery MH - *Aortic Valve Stenosis/surgery MH - *Heart Valve Prosthesis MH - Postoperative Complications/epidemiology MH - Prospective Studies MH - Prosthesis Design MH - Severity of Illness Index MH - *Transcatheter Aortic Valve Replacement/methods MH - Treatment Outcome COIS- Declaration of interests NvR reports grant funding and personal fees from Abbott; grants from Philips, Biotronik, and Medtronic; and personal fees from MicroPort, Bayer, and RainMed Medical outside the submitted work. IJA-S reports being a proctor for Medtronic, Boston Scientific, and Meril Life Sciences. AIj reports consulting fees from Meril Life Sciences, Medtronic, Angiocare, Keystone Heart, PulseCath, Salveo, Abbott, Philips, Fysicon, Cardiawave, Pi Medical, and Svelte. DU reports lecture and educational event fees from Medtronic; a lecture fee from and being a proctor for Meril Life Sciences; and being a member of the Medtronic EMEA surgical advisory board. RSH reports grant funding from Bayer; and speaker fees from Amgen, Novartis, and Abbott outside the submitted work. MW reports institutional research funding from Emboline, Meril Life Sciences, Edwards Lifesciences, and TransAortic Medical. MPa reports honoraria from Boston Scientific, Philips, and Abbott. OA reports research grants and lecture fees from and being a proctor for Abbott; and advisory board participation for and support for attending meetings from Meril Life Sciences. W-KK reports honoraria or consultancy fees from Abbott, Boston Scientific, Edwards Lifesciences, Meril Life Sciences, and Hi-D Imaging; and participation on an advisory board or data and safety monitoring board for Abbott and Boston Scientific. JR reports being a consultant with Medtronic and Qatma; being a proctor for Medtronic; and travel support for attending meetings from Meril Life Sciences, Edwards Lifesciences, Abbott, Medtronic, and Boston Scientific. AT reports a grant from the Fukuda Foundation for Medical Technology. SG reports honoraria or consultancy fees from Biosensors. PWS reports consultancy fees from SMT, Novartis, Meril Life Sciences, Xeltis, and Philips. All other authors declare no competing interests. FIR - Siqueira, Dimytri IR - Siqueira D FIR - Pinto, Ibraim IR - Pinto I FIR - Cervone, Alberto IR - Cervone A FIR - Assef, Jorge IR - Assef J FIR - Vilela, Andrea IR - Vilela A FIR - Paladino, Antonio IR - Paladino A FIR - Ramos, Auristela IR - Ramos A FIR - Rezende, Mariana IR - Rezende M FIR - Ghorayeb, Samira IR - Ghorayeb S FIR - Braga Silva, Tacianne Rolemberg IR - Braga Silva TR FIR - Gjorgjievska, Savica IR - Gjorgjievska S FIR - Hadzibegovic, Irzal IR - Hadzibegovic I FIR - Jurin, Ivana IR - Jurin I FIR - Sipic, Tomislav IR - Sipic T FIR - Pavlovic, Nikola IR - Pavlovic N FIR - Rudez, Igor IR - Rudez I FIR - Manola, Sime IR - Manola S FIR - Gallet DE Saint-Aurin, Romain IR - Gallet DE Saint-Aurin R FIR - Boukantar, Madjid IR - Boukantar M FIR - Nicolas, Eroan IR - Nicolas E FIR - Ennezat, Pierre Valdimir IR - Ennezat PV FIR - Urien, Jean Marie IR - Urien JM FIR - Vincent, Flavien IR - Vincent F FIR - Delhaye, Cedric IR - Delhaye C FIR - Denimal, Tom IR - Denimal T FIR - Cosenza, Alessandro IR - Cosenza A FIR - Pamart, Thibault IR - Pamart T FIR - Porouchani, Sina IR - Porouchani S FIR - Pontana, Francois IR - Pontana F FIR - Montaigne, David IR - Montaigne D FIR - Balmette, Vincent IR - Balmette V FIR - Bechiri, Mohamed IR - Bechiri M FIR - Chen, Elisabeth IR - Chen E FIR - Janah, Dany IR - Janah D FIR - Renker, Matthias IR - Renker M FIR - Westermann, Dirk IR - Westermann D FIR - Valina, Christian IR - Valina C FIR - Ferenc, Miroslaw IR - Ferenc M FIR - Loffelhardt, Nikolaus IR - Loffelhardt N FIR - Rahimi, Faridun IR - Rahimi F FIR - Breitbart, Philipp IR - Breitbart P FIR - Franke, Kilian IR - Franke K FIR - Czerny, Martin IR - Czerny M FIR - Diab, Nawras IR - Diab N FIR - Sick, Peter IR - Sick P FIR - Adeishvili, Medea IR - Adeishvili M FIR - Mangner, Norman IR - Mangner N FIR - Haussig, Stephan IR - Haussig S FIR - Sveric, Krunuslav IR - Sveric K FIR - Crusius, Lisa IR - Crusius L FIR - Roehlig, Marie IR - Roehlig M FIR - Koliastasis, Leonidas IR - Koliastasis L FIR - Drakopoulou, Maria IR - Drakopoulou M FIR - Katsaros, Odysseas IR - Katsaros O FIR - Ktenopoulos, Nikolaos IR - Ktenopoulos N FIR - Ioanniadis, Andreas IR - Ioanniadis A FIR - Evangelou, Sotirios IR - Evangelou S FIR - Ninios, Ilias IR - Ninios I FIR - Molnar, Levente IR - Molnar L FIR - Papp, Roland IR - Papp R FIR - Arnold-Bela, Ferencz IR - Arnold-Bela F FIR - Demeterne Kiss, Orsolya IR - Demeterne Kiss O FIR - Nagy, Andrea IR - Nagy A FIR - Czimbalmos, Csilla IR - Czimbalmos C FIR - Pellegrinni, Dario IR - Pellegrinni D FIR - Montonati, Carolina IR - Montonati C FIR - Pellicano, Mariano IR - Pellicano M FIR - Guagliumi, Giulio IR - Guagliumi G FIR - Tespili, Maurizio IR - Tespili M FIR - Barbara, Bellini IR - Barbara B FIR - Filippo, Russo IR - Filippo R FIR - Marco, Ancona IR - Marco A FIR - Ciro, Vella IR - Ciro V FIR - Luca, Ferri IR - Luca F FIR - Eustachio, Agricola IR - Eustachio A FIR - Giacomo, Ingallina IR - Giacomo I FIR - Cannone, Gaspare IR - Cannone G FIR - Brambilla, Nedy IR - Brambilla N FIR - Testa, Luca IR - Testa L FIR - Avondo, Stefano IR - Avondo S FIR - Valvo, Roberto IR - Valvo R FIR - Clarke, Robin IR - Clarke R FIR - Fish, Mandy IR - Fish M FIR - Kosowski, Michal IR - Kosowski M FIR - Krawczyk, Magdalena IR - Krawczyk M FIR - Kubler, Piotr IR - Kubler P FIR - Kotwica, Tomasz IR - Kotwica T FIR - Teles, Rui IR - Teles R FIR - Goncalves, Pedro IR - Goncalves P FIR - Raposo, Luis IR - Raposo L FIR - Brito, Joa IR - Brito J FIR - Leal, Silvio IR - Leal S FIR - Freitas, Pedro IR - Freitas P FIR - Ribeiras, Regina IR - Ribeiras R FIR - Poliacikova, Petra IR - Poliacikova P FIR - Mihailovic, Peter Marko IR - Mihailovic PM FIR - Terseglav, Simon IR - Terseglav S FIR - Steblovnik, Klemen IR - Steblovnik K FIR - Cercek, Miha IR - Cercek M FIR - Vitez, Luka IR - Vitez L FIR - Sustersic, Miha IR - Sustersic M FIR - Kovac, Ana IR - Kovac A FIR - Kogoj, Polonca IR - Kogoj P FIR - Dimitrovska, Ljupka IR - Dimitrovska L FIR - Arana, J Raul Delgado IR - Arana JRD FIR - Martinez, Sandra Santos IR - Martinez SS FIR - Dieguez, Alfredo Redondo IR - Dieguez AR FIR - Barrero, Alejandro IR - Barrero A FIR - Gonzalez-Bartol, Esther IR - Gonzalez-Bartol E FIR - Aristizabal, Cristhian IR - Aristizabal C FIR - Frutos, Ana Serrador IR - Frutos AS FIR - Luna, Juan Pablo Sanchez IR - Luna JPS FIR - Gomez, Mario Garcia IR - Gomez MG FIR - Gabella, Tania Rodriguez IR - Gabella TR FIR - Nelson, Veronica Quevedo IR - Nelson VQ FIR - Medina, Jose Novoa IR - Medina JN FIR - Ojeda, Soledad IR - Ojeda S FIR - de Lezo, Javier Suarez IR - de Lezo JS FIR - Romero, Miguel IR - Romero M FIR - Gonzalez-Manzanares, Rafael IR - Gonzalez-Manzanares R FIR - Alvarado, Marco IR - Alvarado M FIR - Mesa, Dolores IR - Mesa D FIR - Perea, Jorge IR - Perea J FIR - Petursson, Petur IR - Petursson P FIR - Alchay, Moner IR - Alchay M FIR - Andreen, Sofie IR - Andreen S FIR - Gameren, Menno Van IR - Gameren MV FIR - Heijer, Peter den IR - Heijer PD FIR - Meuwissen, Martijn IR - Meuwissen M FIR - Cheng, Jin M IR - Cheng JM FIR - Vos, Jeroen IR - Vos J FIR - Scholzel, B E IR - Scholzel BE FIR - Simsek, C IR - Simsek C FIR - Hubbers, S IR - Hubbers S FIR - Van den Branden, Ben J L IR - Van den Branden BJL FIR - Stens, N A IR - Stens NA FIR - Versteeg, Gaa IR - Versteeg G FIR - Rooijakkers, Mjp IR - Rooijakkers M FIR - Gehlmann, H R IR - Gehlmann HR FIR - Verkroost, Mwa IR - Verkroost M FIR - Geuzebroek, Gsc IR - Geuzebroek G FIR - Van Wely, M H IR - Van Wely MH FIR - Van Geuns, R J IR - Van Geuns RJ FIR - van Nunen, L X IR - van Nunen LX FIR - van Garsse, Lafm IR - van Garsse L FIR - Timmers, L IR - Timmers L FIR - Ten Berg, Jurrien IR - Ten Berg J FIR - Kraaijeveld, A O IR - Kraaijeveld AO FIR - Dickinson, M G IR - Dickinson MG FIR - Dessing, T C IR - Dessing TC FIR - Mokhles, M M IR - Mokhles MM EDAT- 2024/05/26 18:11 MHDA- 2024/06/23 00:42 CRDT- 2024/05/25 18:52 PHST- 2024/03/14 00:00 [received] PHST- 2024/04/10 00:00 [revised] PHST- 2024/04/18 00:00 [accepted] PHST- 2024/06/23 00:42 [medline] PHST- 2024/05/26 18:11 [pubmed] PHST- 2024/05/25 18:52 [entrez] AID - S0140-6736(24)00821-3 [pii] AID - 10.1016/S0140-6736(24)00821-3 [doi] PST - ppublish SO - Lancet. 2024 Jun 22;403(10445):2695-2708. doi: 10.1016/S0140-6736(24)00821-3. Epub 2024 May 22. PMID- 38793110 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240527 IS - 2075-4426 (Print) IS - 2075-4426 (Electronic) IS - 2075-4426 (Linking) VI - 14 IP - 5 DP - 2024 May 15 TI - Minimally Invasive Isolated and Hybrid Surgical Revascularization for Multivessel Coronary Disease: A Single-Center Long-Term Follow-Up. LID - 10.3390/jpm14050528 [doi] LID - 528 AB - INTRODUCTION: Some evidence suggests that surgical minimally invasive (MIDCAB) and hybrid coronary revascularization (HCR) are safe and potentially effective at short-term follow-up. Data on long-term outcomes are more limited and inconclusive. METHODS: Between February 2013 and December 2023, a total of 1997 patients underwent surgical coronary artery revascularization at our institution, of whom, 92 (4.7%) received left anterior mini-thoracotomy access (MIDCAB), either isolated (N = 78) or in combination with percutaneous coronary intervention (N = 14, HCR group). RESULTS: After a median follow-up of 75 months (range 3.1: 149 months), cardiac mortality was 0% while overall mortality was 3%, with one in-hospital mortality and two additional late deaths. Conversion to sternotomy happened in two patients (2.1%), and surgical re-explorations occurred in five patients (4.6%), of whom three for bleeding and two for graft failure. All patients received left internal mammary (LIMA) to left anterior descending artery (LAD) grafting (100%). In the HCR group, 10 patients (72%) showed percutaneous revascularization (PCI) after MIDCAB, showing PCI on a mean of 1.6 +/- 0.6 vessels and implanting 2.1 +/- 0.9 drug-eluting stents. CONCLUSIONS: MIDCAB, in isolation or in association with hybrid coronary revascularization, is associated with encouraging short- and long-term results in selected patients discussed within a dedicated heart-team. FAU - Torre, Tiziano AU - Torre T AUID- ORCID: 0000-0002-8706-8563 AD - Heart Surgery Unit, Cardiocentro Ticino Institute, EOC, 6900 Lugano, Switzerland. FAU - Pozzoli, Alberto AU - Pozzoli A AUID- ORCID: 0000-0002-1184-7210 AD - Heart Surgery Unit, Cardiocentro Ticino Institute, EOC, 6900 Lugano, Switzerland. FAU - Valgimigli, Marco AU - Valgimigli M AD - Cardiology Unit, Cardiocentro Ticino Institute, EOC, 6900 Lugano, Switzerland. AD - Faculty of Biomedical Sciences, Universita della Svizzera Italiana (USI), 6900 Lugano, Switzerland. FAU - Leo, Laura Anna AU - Leo LA AD - Cardiology Unit, Cardiocentro Ticino Institute, EOC, 6900 Lugano, Switzerland. FAU - Toto, Francesca AU - Toto F AUID- ORCID: 0000-0002-8489-3234 AD - Heart Surgery Unit, Cardiocentro Ticino Institute, EOC, 6900 Lugano, Switzerland. FAU - Muretti, Mirko AU - Muretti M AD - Heart Surgery Unit, Cardiocentro Ticino Institute, EOC, 6900 Lugano, Switzerland. FAU - Birova, Sara AU - Birova S AD - Heart Surgery Unit, Cardiocentro Ticino Institute, EOC, 6900 Lugano, Switzerland. FAU - Ferrari, Enrico AU - Ferrari E AUID- ORCID: 0000-0002-2837-3242 AD - Heart Surgery Unit, Cardiocentro Ticino Institute, EOC, 6900 Lugano, Switzerland. AD - Faculty of Biomedical Sciences, Universita della Svizzera Italiana (USI), 6900 Lugano, Switzerland. AD - Faculty of Medicine, University of Zurich (UZH), 8032 Zurich, Switzerland. FAU - Pedrazzini, Giovanni AU - Pedrazzini G AD - Cardiology Unit, Cardiocentro Ticino Institute, EOC, 6900 Lugano, Switzerland. AD - Faculty of Biomedical Sciences, Universita della Svizzera Italiana (USI), 6900 Lugano, Switzerland. FAU - Demertzis, Stefanos AU - Demertzis S AD - Heart Surgery Unit, Cardiocentro Ticino Institute, EOC, 6900 Lugano, Switzerland. AD - Faculty of Biomedical Sciences, Universita della Svizzera Italiana (USI), 6900 Lugano, Switzerland. AD - Faculty of Medicine, University of Bern, 3010 Bern, Switzerland. LA - eng PT - Journal Article DEP - 20240515 PL - Switzerland TA - J Pers Med JT - Journal of personalized medicine JID - 101602269 PMC - PMC11122097 OTO - NOTNLM OT - MIDCAB OT - beating-heart coronary surgery OT - heart team OT - hybrid coronary revascularization OT - minimally invasive coronary bypass surgery OT - multivessel coronary disease OT - percutaneous coronary intervention COIS- The authors declare no conflicts of interest. EDAT- 2024/05/25 10:52 MHDA- 2024/05/25 10:53 PMCR- 2024/05/15 CRDT- 2024/05/25 01:19 PHST- 2024/04/13 00:00 [received] PHST- 2024/05/09 00:00 [revised] PHST- 2024/05/11 00:00 [accepted] PHST- 2024/05/25 10:53 [medline] PHST- 2024/05/25 10:52 [pubmed] PHST- 2024/05/25 01:19 [entrez] PHST- 2024/05/15 00:00 [pmc-release] AID - jpm14050528 [pii] AID - jpm-14-00528 [pii] AID - 10.3390/jpm14050528 [doi] PST - epublish SO - J Pers Med. 2024 May 15;14(5):528. doi: 10.3390/jpm14050528. PMID- 38792944 OWN - NLM STAT- MEDLINE DCOM- 20240525 LR - 20240528 IS - 1648-9144 (Electronic) IS - 1010-660X (Print) IS - 1010-660X (Linking) VI - 60 IP - 5 DP - 2024 May 3 TI - The Preventive Role of Glutamine Supplementation in Cardiac Surgery-Associated Kidney Injury from Experimental Research to Clinical Practice: A Narrative Review. LID - 10.3390/medicina60050761 [doi] LID - 761 AB - Acute kidney injury represents a significant threat in cardiac surgery regarding complications and costs. Novel preventive approaches are needed, as the therapeutic modalities are still limited. As experimental studies have demonstrated, glutamine, a conditionally essential amino acid, might have a protective role in this setting. Moreover, the levels of glutamine after the cardiopulmonary bypass are significantly lower. In clinical practice, various trials have investigated the effects of glutamine supplementation on cardiac surgery with encouraging results. However, these studies are heterogeneous regarding the selection criteria, timing, dose, outcomes studied, and way of glutamine administration. This narrative review aims to present the potential role of glutamine in cardiac surgery-associated acute kidney injury prevention, starting from the experimental studies and guidelines to the clinical practice and future directions. FAU - Dragan, Anca AU - Dragan A AUID- ORCID: 0000-0003-2944-6527 AD - Department of Cardiovascular Anaesthesiology and Intensive Care, Emergency Institute for Cardiovascular Diseases "Prof Dr C C Iliescu", 258 Fundeni Road, 022328 Bucharest, Romania. FAU - Dragan, Adrian Stefan AU - Dragan AS AD - Faculty of General Medicine, Carol Davila University of Medicine and Pharmacy, 8 Eroii Sanitari Blvd, 050474 Bucharest, Romania. LA - eng PT - Journal Article PT - Review DEP - 20240503 PL - Switzerland TA - Medicina (Kaunas) JT - Medicina (Kaunas, Lithuania) JID - 9425208 RN - 0RH81L854J (Glutamine) SB - IM MH - Humans MH - *Acute Kidney Injury/prevention & control/etiology MH - *Cardiac Surgical Procedures/adverse effects MH - *Dietary Supplements MH - *Glutamine/administration & dosage MH - Postoperative Complications/prevention & control MH - Animals MH - Disease Models, Animal PMC - PMC11123382 OTO - NOTNLM OT - cardiac surgery OT - cardiorenal syndrome OT - inflammation OT - kidney injury OT - multidisciplinary approach COIS- The authors declare no conflicts of interest. EDAT- 2024/05/25 10:52 MHDA- 2024/05/25 10:53 PMCR- 2024/05/03 CRDT- 2024/05/25 01:18 PHST- 2024/03/21 00:00 [received] PHST- 2024/04/23 00:00 [revised] PHST- 2024/04/30 00:00 [accepted] PHST- 2024/05/25 10:53 [medline] PHST- 2024/05/25 10:52 [pubmed] PHST- 2024/05/25 01:18 [entrez] PHST- 2024/05/03 00:00 [pmc-release] AID - medicina60050761 [pii] AID - medicina-60-00761 [pii] AID - 10.3390/medicina60050761 [doi] PST - epublish SO - Medicina (Kaunas). 2024 May 3;60(5):761. doi: 10.3390/medicina60050761. PMID- 38792742 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240527 IS - 2076-2607 (Print) IS - 2076-2607 (Electronic) IS - 2076-2607 (Linking) VI - 12 IP - 5 DP - 2024 Apr 30 TI - Analysis of Aetiological Agents in Infectious Endocarditis in the Central Military Emergency University Hospital "Dr. Carol Davila" Bucharest. LID - 10.3390/microorganisms12050910 [doi] LID - 910 AB - BACKGROUND: Infective endocarditis (IE) is a pathological condition caused by various microbial agents that can lead to severe complications affecting the heart. Accurate diagnosis is crucial for the effective management of patients with IE. Blood culture is the gold standard for identifying the primary infectious agents, which is a key factor in diagnosing IE using the modified Duke criteria. OBJECTIVE: The main objective of this study was to investigate the distribution of the etiological agents of IE and the most common secondary diagnoses associated with it. METHOD: A total of 152 patients aged 23-95 years with a diagnosis of IE and proven etiology (through blood cultures or serological tests) were included in this study. RESULTS: The most common etiological agent identified through blood tests was Enterococcus faecalis, which was detected in 39 patients (23.5%). Staphylococcus aureus was the second most common agent and was identified in 33 patients (19.9%), followed by Staphylococcus epidermidis, which was identified in 12 patients (13.1%). Nine patients (5.8%) had high levels of anti-Coxiella burnetti IgG phase I and II antibodies. CONCLUSIONS: IE is a leading cause of death in the Department of Infectious Diseases. Early and accurate diagnosis, along with interdisciplinary treatment, can significantly increase the chances of patient survival. Currently, Enterococcus faecalis and Staphylococcus aureus are the dominant etiological agents of IE, highlighting the need to revise protocols for prophylaxis, diagnosis, and initial treatment of this condition. FAU - Anton, Corina-Ioana AU - Anton CI AUID- ORCID: 0009-0007-8818-9539 AD - Department of Infectious Diseases, 'Dr. Carol Davila' Central Military Emergency University Hospital, 134 Calea Plevnei, 010242 Bucharest, Romania. AD - Department of Medico-Surgical and Prophylactic Disciplines, Titu Maiorescu University, 040441 Bucharest, Romania. AD - Faculty of General Medicine, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania. FAU - Stefan, Ion AU - Stefan I AD - Department of Infectious Diseases, 'Dr. Carol Davila' Central Military Emergency University Hospital, 134 Calea Plevnei, 010242 Bucharest, Romania. AD - Department of Medico-Surgical and Prophylactic Disciplines, Titu Maiorescu University, 040441 Bucharest, Romania. FAU - Dumitrache, Simona Mihaela AU - Dumitrache SM AD - Department of Infectious Diseases, 'Dr. Carol Davila' Central Military Emergency University Hospital, 134 Calea Plevnei, 010242 Bucharest, Romania. FAU - Stefan, Alexia-Teodora AU - Stefan AT AD - Faculty of General Medicine, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania. FAU - Radut, Diana AU - Radut D AD - Department of Infectious Diseases, 'Dr. Carol Davila' Central Military Emergency University Hospital, 134 Calea Plevnei, 010242 Bucharest, Romania. AD - Faculty of General Medicine, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania. FAU - Nistor, Claudiu-Eduard AU - Nistor CE AUID- ORCID: 0000-0002-2274-5666 AD - Faculty of General Medicine, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania. AD - Thoracic Surgery Department, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania. FAU - Ranetti, Aurelian-Emil AU - Ranetti AE AD - Faculty of General Medicine, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania. AD - Endocrinologic Department, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania. FAU - Adella-Sirbu, Carmen AU - Adella-Sirbu C AUID- ORCID: 0000-0002-1982-1066 AD - Faculty of General Medicine, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania. AD - Clinical Neurosciences Department, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania. AD - Academy of Romanian Scientists, 50041 Bucharest, Romania. FAU - Ionita-Radu, Florentina AU - Ionita-Radu F AD - Faculty of General Medicine, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania. AD - Department of Gastroenterology, 'Dr. Carol Davila' Central Military Emergency University Hospital, 134 Calea Plevnei, 010242 Bucharest, Romania. LA - eng PT - Journal Article DEP - 20240430 PL - Switzerland TA - Microorganisms JT - Microorganisms JID - 101625893 PMC - PMC11123831 OTO - NOTNLM OT - etiology OT - infective endocarditis OT - multidisciplinary approach OT - prosthetic heart valve OT - secondary diagnosis COIS- The authors declare no conflict of interest. EDAT- 2024/05/25 10:52 MHDA- 2024/05/25 10:53 PMCR- 2024/04/30 CRDT- 2024/05/25 01:17 PHST- 2023/12/28 00:00 [received] PHST- 2024/02/26 00:00 [revised] PHST- 2024/04/27 00:00 [accepted] PHST- 2024/05/25 10:53 [medline] PHST- 2024/05/25 10:52 [pubmed] PHST- 2024/05/25 01:17 [entrez] PHST- 2024/04/30 00:00 [pmc-release] AID - microorganisms12050910 [pii] AID - microorganisms-12-00910 [pii] AID - 10.3390/microorganisms12050910 [doi] PST - epublish SO - Microorganisms. 2024 Apr 30;12(5):910. doi: 10.3390/microorganisms12050910. PMID- 38792456 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240527 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 13 IP - 10 DP - 2024 May 15 TI - Anesthetic Considerations and Outcomes in Amniotic Fluid Embolism: A Retrospective Study over a 15-Year Period. LID - 10.3390/jcm13102916 [doi] LID - 2916 AB - (1) Background: A rare and unexpected consequence of childbirth, labor, or the immediate postpartum period is amniotic fluid embolism (AFE). This study aims to identify AFE cases during or immediately after birth from anesthetic management perspectives. Secondary goals include assessing patient clinical features, obstetric care techniques, birth outcomes, and case survival. (2) Methods: A retrospective observational study assessed AFE patients hospitalized in three Romanian clinical institutions from October 2007 to April 2023. Based on the Society of Maternal-Fetal Medicine (SMFM) criteria, we diagnosed 11 AFE patients. (3) Results: AFE occurred in eight cases (73%) during peripartum, two (18%) within 30 min after placental delivery, and 1 (9%) during a scheduled cesarean surgery. Only one of six cardiorespiratory arrest patients responded to external cardiac massage, while the other five (83%) needed defibrillation. The patients received, on average, five units of red blood cells, six of fresh frozen plasma, and two of activated platelets. Six patients (55%) received factor VIIa infusions. Maternal mortality was 36.3%. Six neonates (75%) needed neonatal resuscitation, and two (25%) died on the second and third days. (4) Conclusions: AFE management necessitates a multidisciplinary approach and the incorporation of advanced life support techniques to optimize outcomes for both the mother and newborn. FAU - Susanu, Carolina AU - Susanu C AD - Clinical and Surgical Department, Faculty of Medicine and Pharmacy, 'Dunarea de Jos' University, 800216 Galati, Romania. FAU - Harabor, Anamaria AU - Harabor A AUID- ORCID: 0009-0002-3405-9097 AD - Clinical and Surgical Department, Faculty of Medicine and Pharmacy, 'Dunarea de Jos' University, 800216 Galati, Romania. FAU - Vicoveanu, Petronela AU - Vicoveanu P AD - Department of Mother and Newborn Care, Faculty of Medicine and Biological Sciences, 'Stefan cel Mare' University, 720229 Suceava, Romania. FAU - Vasilache, Ingrid-Andrada AU - Vasilache IA AD - Department of Mother and Child Care, "Grigore T. Popa" University of Medicine and Pharmacy Iasi, 700115 Iasi, Romania. FAU - Calin, Alina-Mihaela AU - Calin AM AD - Clinical and Surgical Department, Faculty of Medicine and Pharmacy, 'Dunarea de Jos' University, 800216 Galati, Romania. LA - eng PT - Journal Article DEP - 20240515 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC11122586 OTO - NOTNLM OT - amniotic fluid OT - cardio-pulmonary resuscitation pregnancy OT - critical care OT - embolism COIS- The authors declare no conflict of interest. EDAT- 2024/05/25 10:52 MHDA- 2024/05/25 10:53 PMCR- 2024/05/15 CRDT- 2024/05/25 01:15 PHST- 2024/03/17 00:00 [received] PHST- 2024/04/24 00:00 [revised] PHST- 2024/05/13 00:00 [accepted] PHST- 2024/05/25 10:53 [medline] PHST- 2024/05/25 10:52 [pubmed] PHST- 2024/05/25 01:15 [entrez] PHST- 2024/05/15 00:00 [pmc-release] AID - jcm13102916 [pii] AID - jcm-13-02916 [pii] AID - 10.3390/jcm13102916 [doi] PST - epublish SO - J Clin Med. 2024 May 15;13(10):2916. doi: 10.3390/jcm13102916. PMID- 38792409 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240527 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 13 IP - 10 DP - 2024 May 13 TI - Pulmonary Embolism in Pregnancy: A Review for Clinical Practitioners. LID - 10.3390/jcm13102863 [doi] LID - 2863 AB - Diagnostic and therapeutic decision-making in pregnancy with suspected pulmonary embolism (PE) is challenging. European and other international professional societies have proposed various recommendations that are ambiguous, probably due to the unavailability of randomized controlled trials. In the following sections, we discuss the supporting diagnostic steps and treatments. We suggest a standardized diagnostic work-up in pregnant patients presenting with symptoms of PE to make evidence-based diagnostic and therapeutic decisions. We strongly recommend that clinical decisions on treatment in pregnant patients with intermediate- or high-risk pulmonary embolism should include a multidisciplinary team approach involving emergency physicians, pulmonologists, angiologist, cardiologists, thoracic and/or cardiovascular surgeons, radiologists, and obstetricians to choose a tailored management option including an interventional treatment. It is important to be aware of the differences among guidelines and to assess each case individually, considering the specific views of the different specialties. This review summarizes key concepts of the diagnostics and acute management of pregnant women with suspected PE that are supportive for the clinician on duty. FAU - Makowska, Agata AU - Makowska A AUID- ORCID: 0000-0002-4056-2943 AD - Emergency Department, Cantonal Hospital Lucerne, 6000 Lucerne, Switzerland. AD - Cardiology, Hospital Centre of Biel, 2501 Biel, Switzerland. FAU - Treumann, Thomas AU - Treumann T AD - Radiology, Cantonal Hospital Lucerne, 6000 Lucerne, Switzerland. FAU - Venturini, Stefan AU - Venturini S AD - Emergency Department, Cantonal Hospital Lucerne, 6000 Lucerne, Switzerland. FAU - Christ, Michael AU - Christ M AUID- ORCID: 0000-0001-7977-0195 AD - Emergency Department, Cantonal Hospital Lucerne, 6000 Lucerne, Switzerland. LA - eng PT - Journal Article PT - Review DEP - 20240513 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC11121909 OTO - NOTNLM OT - management OT - multidisciplinary team OT - pregnancy OT - pulmonary embolism OT - review COIS- The authors declare no conflicts of interest. EDAT- 2024/05/25 10:53 MHDA- 2024/05/25 10:54 PMCR- 2024/05/13 CRDT- 2024/05/25 01:15 PHST- 2024/03/26 00:00 [received] PHST- 2024/05/06 00:00 [revised] PHST- 2024/05/08 00:00 [accepted] PHST- 2024/05/25 10:54 [medline] PHST- 2024/05/25 10:53 [pubmed] PHST- 2024/05/25 01:15 [entrez] PHST- 2024/05/13 00:00 [pmc-release] AID - jcm13102863 [pii] AID - jcm-13-02863 [pii] AID - 10.3390/jcm13102863 [doi] PST - epublish SO - J Clin Med. 2024 May 13;13(10):2863. doi: 10.3390/jcm13102863. PMID- 38791261 OWN - NLM STAT- MEDLINE DCOM- 20240525 LR - 20240527 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 25 IP - 10 DP - 2024 May 10 TI - Molecular Mechanisms of Fetal and Neonatal Lupus: A Narrative Review of an Autoimmune Disease Transferal across the Placenta. LID - 10.3390/ijms25105224 [doi] LID - 5224 AB - This study, conducted by searching keywords such as "maternal lupus", "neonatal lupus", and "congenital heart block" in databases including PubMed and Scopus, provides a detailed narrative review on fetal and neonatal lupus. Autoantibodies like anti-Ro/SSA and anti-La/SSB may cross the placenta and cause complications in neonates, such as congenital heart block (CHB). Management options involve hydroxychloroquine, which is able to counteract some of the adverse events, although the drug needs to be used carefully because of its impact on the QTc interval. Advanced pacing strategies for neonates with CHB, especially in severe forms like hydrops, are also assessed. This review emphasizes the need for interdisciplinary care by rheumatologists, obstetricians, and pediatricians in order to achieve the best maternal and neonatal health in lupus pregnancies. This multidisciplinary approach seeks to improve the outcomes and management of the disease, decreasing the burden on mothers and their infants. FAU - Di Ludovico, Armando AU - Di Ludovico A AUID- ORCID: 0000-0002-2644-1475 AD - Paediatric Department, University of Chieti "G. D'Annunzio", 66100 Chieti, Italy. FAU - Rinaldi, Marta AU - Rinaldi M AD - Paediatric Department, Buckinghamshire Healthcare NHS Trust, Aylesbury-Thames Valley Deanery, Aylesbury HP21 8AL, UK. FAU - Mainieri, Francesca AU - Mainieri F AUID- ORCID: 0000-0002-3911-1256 AD - Paediatric Department, University of Chieti "G. D'Annunzio", 66100 Chieti, Italy. FAU - Di Michele, Stefano AU - Di Michele S AUID- ORCID: 0009-0005-9644-7919 AD - Department of Surgical Science, Division of Obstetrics and Gynecology, University of Cagliari, Cittadella Universitaria Blocco I, Asse didattico Medicina P2, Monserrato, 09042 Cagliari, Italy. FAU - Girlando, Virginia AU - Girlando V AD - Paediatric Department, University of Chieti "G. D'Annunzio", 66100 Chieti, Italy. FAU - Ciarelli, Francesca AU - Ciarelli F AD - Paediatric Department, University of Chieti "G. D'Annunzio", 66100 Chieti, Italy. FAU - La Bella, Saverio AU - La Bella S AUID- ORCID: 0000-0002-1244-0789 AD - Paediatric Department, University of Chieti "G. D'Annunzio", 66100 Chieti, Italy. FAU - Chiarelli, Francesco AU - Chiarelli F AD - Paediatric Department, University of Chieti "G. D'Annunzio", 66100 Chieti, Italy. FAU - Attanasi, Marina AU - Attanasi M AUID- ORCID: 0000-0001-6513-3160 AD - Paediatric Department, University of Chieti "G. D'Annunzio", 66100 Chieti, Italy. FAU - Mauro, Angela AU - Mauro A AUID- ORCID: 0000-0002-7008-3409 AD - Pediatric Rheumatology Unit, Department of Childhood and Developmental Medicine, Fatebenefratelli-Sacco Hospital, Piazzale Principessa Clotilde, 20121 Milan, Italy. FAU - Bizzi, Emanuele AU - Bizzi E AD - Division of Internal Medicine, ASST Fatebenefratelli Sacco, Fatebenefratelli Hospital, University of Milan, 20121 Milan, Italy. FAU - Brucato, Antonio AU - Brucato A AUID- ORCID: 0000-0002-7566-5600 AD - Division of Internal Medicine, ASST Fatebenefratelli Sacco, Fatebenefratelli Hospital, University of Milan, 20121 Milan, Italy. AD - Department of Biomedical and Clinical Sciences "Sacco", University of Milano, Ospedale Fatebenefratelli, 20121 Milan, Italy. FAU - Breda, Luciana AU - Breda L AD - Paediatric Department, University of Chieti "G. D'Annunzio", 66100 Chieti, Italy. LA - eng PT - Journal Article PT - Review DEP - 20240510 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (Autoantibodies) RN - 4QWG6N8QKH (Hydroxychloroquine) RN - Neonatal Systemic lupus erythematosus RN - Congenital heart block SB - IM MH - Humans MH - Pregnancy MH - Female MH - *Lupus Erythematosus, Systemic/immunology/therapy/congenital MH - *Placenta/metabolism/immunology MH - Infant, Newborn MH - Heart Block/congenital/therapy/immunology MH - Pregnancy Complications/immunology/therapy MH - Autoantibodies/immunology MH - Maternal-Fetal Exchange MH - Hydroxychloroquine/therapeutic use PMC - PMC11120786 OTO - NOTNLM OT - autoantibodies OT - congenital heart block OT - neonatal lupus erythematosus COIS- The authors declare no conflict of interest. No part of the review, including its graphics, are copied or published elsewhere in whole or in part. EDAT- 2024/05/25 10:54 MHDA- 2024/05/25 10:55 PMCR- 2024/05/10 CRDT- 2024/05/25 01:08 PHST- 2024/04/11 00:00 [received] PHST- 2024/05/01 00:00 [revised] PHST- 2024/05/08 00:00 [accepted] PHST- 2024/05/25 10:55 [medline] PHST- 2024/05/25 10:54 [pubmed] PHST- 2024/05/25 01:08 [entrez] PHST- 2024/05/10 00:00 [pmc-release] AID - ijms25105224 [pii] AID - ijms-25-05224 [pii] AID - 10.3390/ijms25105224 [doi] PST - epublish SO - Int J Mol Sci. 2024 May 10;25(10):5224. doi: 10.3390/ijms25105224. PMID- 38788778 OWN - NLM STAT- MEDLINE DCOM- 20260313 LR - 20260313 IS - 2047-4881 (Electronic) IS - 2047-4873 (Linking) VI - 33 IP - 4 DP - 2026 Mar 13 TI - Cost-effectiveness analysis of a cardio-oncology rehabilitation framework compared to an exercise intervention for cancer survivors with high cardiovascular risk. PG - 566-573 LID - 10.1093/eurjpc/zwae181 [doi] AB - AIMS: A cardio-oncology rehabilitation model among cancer survivors showed superior results compared with those of a community-based exercise intervention. However, questions remain about its cost-effectiveness. This study aims to assess the cost-effectiveness of a centre-based cardiac rehabilitation (CBCR) programme when compared to usual care encompassing a community-based exercise training (CBET), among cancer survivors with high cardiovascular risk. METHODS AND RESULTS: The CORE study was a single-centre, prospective, randomized controlled trial; 80 adult cancer survivors with previous exposure to cardiotoxic cancer treatment and/or with previous cardiovascular disease were assigned (1:1 ratio) to an 8-week CBCR or CBET, twice/week. Cost-effectiveness was a pre-specified secondary endpoint. Outcomes included healthcare resource use and costs, quality-adjusted life-years (QALYs), and cost-effectiveness; the incremental cost-effectiveness ratio (ICER) was computed from a societal perspective. A total of 75 patients completed the study (CBCR n = 38; CBET n = 37). The CBCR group had a significantly higher cost per patient (477.76 +/- 39.08euro) compared to the CBET group (339.32 +/- 53.88euro), with a significant between-group difference of 138.44euro [95% confidence interval (CI), 116.82-160.05euro, P < 0.01]. A between-group difference of 0.100 points in QALYs was observed, favouring CBCR (95% CI, -0.163 to -0.037, P = 0.002). When CBCR was compared with CBET, the ICER was euro1383.24 per QALY gained; at a willingness-to-pay threshold of euro5000 per QALY, the probability of CBCR being cost-effective was 99.9% (95% CI, 99.4-100.0). CONCLUSION: The CORE trial shows that CBCR is a cost-effective intervention in the management of cancer survivors with high cardiovascular risk, reinforcing the potential benefits of this multidisciplinary approach in supportive care of this specific subset of cancer patients. REGISTRATION: ClinicalTrials.gov: NCT05132998. CI - (c) The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com. FAU - Viamonte, Sofia G AU - Viamonte SG AUID- ORCID: 0000-0003-2224-9256 AD - Centro de Reabilitacao do Norte, Centro Hospitalar Vila Nova de Gaia/Espinho, Avenida Infante Sagres n degrees 22, 4250-076 Vila Nova de Gaia, Portugal. AD - ONCOMOVE(R)-Associacao de Investigacao de Cuidados de Suporte em Oncologia (AICSO), 4410-406 Vila Nova de Gaia, Portugal. FAU - Tavares, Aida AU - Tavares A AD - Lisbon School of Economics and Management, University of Lisbon, 2775-405 Lisbon, Portugal. AD - Center for Health Studies and Research, University of Coimbra, 3004-512 Coimbra, Portugal. FAU - Alves, Alberto J AU - Alves AJ AD - ONCOMOVE(R)-Associacao de Investigacao de Cuidados de Suporte em Oncologia (AICSO), 4410-406 Vila Nova de Gaia, Portugal. AD - Research Center in Sports Sciences, Health Sciences and Human Development, University of Maia, Maia, Portugal. FAU - Joaquim, Ana AU - Joaquim A AUID- ORCID: 0000-0001-7064-9639 AD - ONCOMOVE(R)-Associacao de Investigacao de Cuidados de Suporte em Oncologia (AICSO), 4410-406 Vila Nova de Gaia, Portugal. AD - Oncology Department, Centro Hospitalar Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal. FAU - Vilela, Eduardo AU - Vilela E AD - ONCOMOVE(R)-Associacao de Investigacao de Cuidados de Suporte em Oncologia (AICSO), 4410-406 Vila Nova de Gaia, Portugal. AD - Cardiology Department, Centro Hospitalar Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal. FAU - Capela, Andreia AU - Capela A AD - ONCOMOVE(R)-Associacao de Investigacao de Cuidados de Suporte em Oncologia (AICSO), 4410-406 Vila Nova de Gaia, Portugal. AD - Oncology Department, Centro Hospitalar Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal. FAU - Joao Costa, Ana AU - Joao Costa A AD - Centro de Reabilitacao do Norte, Centro Hospitalar Vila Nova de Gaia/Espinho, Avenida Infante Sagres n degrees 22, 4250-076 Vila Nova de Gaia, Portugal. AD - ONCOMOVE(R)-Associacao de Investigacao de Cuidados de Suporte em Oncologia (AICSO), 4410-406 Vila Nova de Gaia, Portugal. FAU - Duarte, Barbara AU - Duarte B AD - ONCOMOVE(R)-Associacao de Investigacao de Cuidados de Suporte em Oncologia (AICSO), 4410-406 Vila Nova de Gaia, Portugal. FAU - Dias Rato, Nuno AU - Dias Rato N AD - ONCOMOVE(R)-Associacao de Investigacao de Cuidados de Suporte em Oncologia (AICSO), 4410-406 Vila Nova de Gaia, Portugal. AD - Research Center in Sports Sciences, Health Sciences and Human Development, University of Maia, Maia, Portugal. FAU - Afreixo, Vera AU - Afreixo V AD - Center for Research and Development in Mathematics and Applications, Department of Mathematics, University of Aveiro, Aveiro, Portugal. FAU - Fontes Carvalho, Ricardo AU - Fontes Carvalho R AD - Cardiology Department, Centro Hospitalar Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal. FAU - Santos, Mario AU - Santos M AD - Cardiology Department, Centro Hospitalar Universitario do Porto, Porto, Portugal. AD - Department of Immuno-Physiology and Pharmacology, Unit for Multidisciplinary Investigation in Biomedicine, Institute for Biomedical Sciences Abel Salazar, University of Porto, Porto, Portugal. FAU - Ribeiro, Fernando AU - Ribeiro F AD - School of Health Sciences, Institute of Biomedicine, University of Aveiro, Aveiro, Portugal. LA - eng SI - ClinicalTrials.gov/NCT05132998 PT - Comparative Study PT - Journal Article PT - Randomized Controlled Trial PL - England TA - Eur J Prev Cardiol JT - European journal of preventive cardiology JID - 101564430 SB - IM CIN - Eur J Prev Cardiol. 2026 Mar 13;33(4):574-575. doi: 10.1093/eurjpc/zwae201. PMID: 38912765 MH - Humans MH - Cost-Benefit Analysis MH - Male MH - Female MH - *Cardiac Rehabilitation/economics/methods MH - *Exercise Therapy/economics/methods MH - Middle Aged MH - *Cancer Survivors MH - *Cardiovascular Diseases/economics/diagnosis MH - Prospective Studies MH - Aged MH - Quality-Adjusted Life Years MH - *Neoplasms/economics/therapy MH - Heart Disease Risk Factors MH - Treatment Outcome MH - Time Factors MH - Risk Assessment MH - *Health Care Costs MH - Cost-Effectiveness Analysis MH - Cardio-Oncology OAB - The CORE study was a randomized clinical trial including 80 cancer survivors with high cardiovascular risk; an 8-week cardio-oncology rehabilitation framework promoted superior results on cardiorespiratory fitness (peak oxygen consumption) and quality of life, but questions remained about the cost-effectiveness of this option. The findings of this study suggest the following:A centre-based cardiac rehabilitation proved to be cost-effective when compared with usual care encompassing community-based exercise training.The value-added of a comprehensive approach delivered in an oncological setting reinforces the potential benefits of including this intervention in the supportive care of a specific subset of cancer patients, within existing contemporary cardiac rehabilitation resources and infrastructures. OABL- eng OTO - NOTNLM OT - Cancer survivors OT - Cardiac rehabilitation OT - Cost-effectiveness OT - Exercise training COIS- Conflict of interest: none declared. EDAT- 2024/05/25 05:44 MHDA- 2026/03/13 19:31 CRDT- 2024/05/24 19:17 PHST- 2024/02/01 00:00 [received] PHST- 2024/04/01 00:00 [revised] PHST- 2024/05/15 00:00 [accepted] PHST- 2026/03/13 19:31 [medline] PHST- 2024/05/25 05:44 [pubmed] PHST- 2024/05/24 19:17 [entrez] AID - 7681932 [pii] AID - 10.1093/eurjpc/zwae181 [doi] PST - ppublish SO - Eur J Prev Cardiol. 2026 Mar 13;33(4):566-573. doi: 10.1093/eurjpc/zwae181. PMID- 38788765 OWN - NLM STAT- MEDLINE DCOM- 20240619 LR - 20260223 IS - 1098-9021 (Electronic) IS - 0271-8235 (Linking) VI - 44 IP - 3 DP - 2024 Jun TI - Update in Pediatric Neurocritical Care: What a Neurologist Caring for Critically Ill Children Needs to Know. PG - 362-388 LID - 10.1055/s-0044-1787047 [doi] AB - Currently nearly one-quarter of admissions to pediatric intensive care units (PICUs) worldwide are for neurocritical care diagnoses that are associated with significant morbidity and mortality. Pediatric neurocritical care is a rapidly evolving field with unique challenges due to not only age-related responses to primary neurologic insults and their treatments but also the rarity of pediatric neurocritical care conditions at any given institution. The structure of pediatric neurocritical care services therefore is most commonly a collaborative model where critical care medicine physicians coordinate care and are supported by a multidisciplinary team of pediatric subspecialists, including neurologists. While pediatric neurocritical care lies at the intersection between critical care and the neurosciences, this narrative review focuses on the most common clinical scenarios encountered by pediatric neurologists as consultants in the PICU and synthesizes the recent evidence, best practices, and ongoing research in these cases. We provide an in-depth review of (1) the evaluation and management of abnormal movements (seizures/status epilepticus and status dystonicus); (2) acute weakness and paralysis (focusing on pediatric stroke and select pediatric neuroimmune conditions); (3) neuromonitoring modalities using a pathophysiology-driven approach; (4) neuroprotective strategies for which there is evidence (e.g., pediatric severe traumatic brain injury, post-cardiac arrest care, and ischemic stroke and hemorrhagic stroke); and (5) best practices for neuroprognostication in pediatric traumatic brain injury, cardiac arrest, and disorders of consciousness, with highlights of the 2023 updates on Brain Death/Death by Neurological Criteria. Our review of the current state of pediatric neurocritical care from the viewpoint of what a pediatric neurologist in the PICU needs to know is intended to improve knowledge for providers at the bedside with the goal of better patient care and outcomes. CI - Thieme. All rights reserved. FAU - Plante, Virginie AU - Plante V AD - Division of Critical Care Medicine, Department of Anesthesiology, Perioperative and Pain Medicine, Boston Children's Hospital, Boston, Massachusetts. FAU - Basu, Meera AU - Basu M AD - Division of Critical Care Medicine, Department of Anesthesiology, Perioperative and Pain Medicine, Boston Children's Hospital, Boston, Massachusetts. AD - Department of Neurology, Boston Children's Hospital, Boston, Massachusetts. FAU - Gettings, Jennifer V AU - Gettings JV AD - Department of Neurology, Boston Children's Hospital, Boston, Massachusetts. FAU - Luchette, Matthew AU - Luchette M AD - Division of Critical Care Medicine, Department of Anesthesiology, Perioperative and Pain Medicine, Boston Children's Hospital, Boston, Massachusetts. FAU - LaRovere, Kerri L AU - LaRovere KL AD - Department of Neurology, Boston Children's Hospital, Boston, Massachusetts. CN - Pediatric Critical Nervous System Program (pCNSp) LA - eng PT - Journal Article PT - Review DEP - 20240524 PL - United States TA - Semin Neurol JT - Seminars in neurology JID - 8111343 SB - IM MH - Humans MH - *Critical Care/methods/standards MH - Child MH - *Critical Illness/therapy MH - *Neurologists MH - Intensive Care Units, Pediatric MH - Pediatrics/methods COIS- None declared. EDAT- 2024/05/25 05:44 MHDA- 2024/06/20 00:42 CRDT- 2024/05/24 19:16 PHST- 2024/06/20 00:42 [medline] PHST- 2024/05/25 05:44 [pubmed] PHST- 2024/05/24 19:16 [entrez] AID - 10.1055/s-0044-1787047 [doi] PST - ppublish SO - Semin Neurol. 2024 Jun;44(3):362-388. doi: 10.1055/s-0044-1787047. Epub 2024 May 24. PMID- 38786972 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240526 IS - 2308-3425 (Electronic) IS - 2308-3425 (Linking) VI - 11 IP - 5 DP - 2024 May 14 TI - The Impact of Acute Heart Failure on Frailty Degree and Outcomes in Elderly Patients with Severe Aortic Stenosis and Chronic Heart Failure with Preserved Ejection Fraction. LID - 10.3390/jcdd11050150 [doi] LID - 150 AB - Frailty degree plays a critical role in the decision-making and outcomes of elderly patients with severe aortic stenosis (AS). Acute heart failure (AHF) results in a severely worse clinical hemodynamic status in this population. This study aimed to evaluate the impact of AHF on frailty degree and outcomes in older patients referred for tailored interventional treatment due to AS. A total of 109 patients (68% female; mean age 83.3 +/- 5.4), evaluated by a multidisciplinary path for "frailty-based management" of valve disease, were divided into two groups, one with (AHF+) and one without AHF (AHF-) and preserved ejection fraction (mean value EF: 57.4 +/- 8.6). AHF occurred a mean value of 55 days before geriatric, clinical, and surgical assessment. A follow-up for all-cause mortality and readmission was conducted at 20 months. AHF+ patients showed a higher frequency of advanced frailty (53.3% vs. 46.7%, respectively), rehospitalization (35.5% vs. 12.8; p = 0.007), and death (41.9% vs. 12.8%; p < 0.001). In stepwise logistic regression analysis, AHF emerged as an independent risk factor for advanced frailty (OR: 3.8 CI 1.3-10.7; p = 0.01) and hospital readmission (OR: 3.6 CI 1.1-11.6; p = 0.03). In addition, preceding AHF was an independent determinant associated with a higher risk of mortality (HR 2.65; CI 95% 1.04-6.74; p-value 0.04). AHF is independently associated with advanced frailty and poor outcomes in elderly patients with severe AS. So, this population needs careful clinical and geriatric monitoring and the implementation of interventional therapy for AS in the early stages of frailty to avoid the occurrence of AHF and poor outcomes. FAU - Esposito, Augusto AU - Esposito A AUID- ORCID: 0000-0001-9698-200X AD - Fondazione Toscana Gabriele Monasterio, 54100 Massa, Italy. FAU - Foffa, Ilenia AU - Foffa I AUID- ORCID: 0000-0002-4604-0871 AD - Fondazione Toscana Gabriele Monasterio, 54100 Massa, Italy. AD - CNR Institute of Clinical Physiology, 54100 Massa, Italy. FAU - Vecoli, Cecilia AU - Vecoli C AUID- ORCID: 0000-0002-5921-3604 AD - Fondazione Toscana Gabriele Monasterio, 54100 Massa, Italy. AD - CNR Institute of Clinical Physiology, 54100 Massa, Italy. FAU - Bastiani, Luca AU - Bastiani L AD - Fondazione Toscana Gabriele Monasterio, 54100 Massa, Italy. AD - CNR Institute of Clinical Physiology, 54100 Massa, Italy. FAU - Berti, Sergio AU - Berti S AUID- ORCID: 0000-0002-5244-0556 AD - Fondazione Toscana Gabriele Monasterio, 54100 Massa, Italy. AD - CNR Institute of Clinical Physiology, 54100 Massa, Italy. FAU - Mazzone, Annamaria AU - Mazzone A AUID- ORCID: 0000-0003-4013-5922 AD - Fondazione Toscana Gabriele Monasterio, 54100 Massa, Italy. LA - eng PT - Journal Article DEP - 20240514 PL - Switzerland TA - J Cardiovasc Dev Dis JT - Journal of cardiovascular development and disease JID - 101651414 PMC - PMC11122270 OTO - NOTNLM OT - acute heart failure OT - elderly patients OT - frailty OT - hospitalization OT - mortality OT - multidisciplinary approach OT - severe aortic stenosis COIS- The authors declare that they have no conflicts of interest. EDAT- 2024/05/24 12:44 MHDA- 2024/05/24 12:45 PMCR- 2024/05/14 CRDT- 2024/05/24 09:26 PHST- 2024/03/22 00:00 [received] PHST- 2024/04/24 00:00 [revised] PHST- 2024/05/09 00:00 [accepted] PHST- 2024/05/24 12:45 [medline] PHST- 2024/05/24 12:44 [pubmed] PHST- 2024/05/24 09:26 [entrez] PHST- 2024/05/14 00:00 [pmc-release] AID - jcdd11050150 [pii] AID - jcdd-11-00150 [pii] AID - 10.3390/jcdd11050150 [doi] PST - epublish SO - J Cardiovasc Dev Dis. 2024 May 14;11(5):150. doi: 10.3390/jcdd11050150. PMID- 38784673 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240525 IS - 1520-765X (Print) IS - 1554-2815 (Electronic) IS - 1520-765X (Linking) VI - 26 IP - Suppl 2 DP - 2024 Apr TI - Cardio-oncology rehabilitation: are we ready? PG - ii252-ii263 LID - 10.1093/eurheartjsupp/suae030 [doi] AB - Cardio-oncology rehabilitation (CORE) is not only an essential component of cancer rehabilitation but also a pillar of preventive cardio-oncology. Cardio-oncology rehabilitation is a comprehensive model based on a multitargeted approach and its efficacy has been widely documented; when compared with an 'exercise only' programme, comprehensive CORE demonstrates a better outcome. It involves nutritional counselling, psychological support, and cardiovascular (CV) risk assessment, and it is directed to a very demanding population with a heavy burden of CV diseases driven by physical inactivity, cancer therapy-induced metabolic derangements, and cancer therapy-related CV toxicities. Despite its usefulness, CORE is still underused in cancer patients and we are still at the dawning of remote models of rehabilitation (tele-rehabilitation). Not all CORE is created equally: a careful screening procedure to identify patients who will benefit the most from CORE and a multidisciplinary customized approach are mandatory to achieve a better outcome for cancer survivors throughout their cancer journey. The aim of this paper is to provide an updated review of CORE not only for cardiologists dealing with this peculiar population of patients but also for oncologists, primary care providers, patients, and caregivers. This multidisciplinary team should help cancer patients to maintain a healthy and active life before, during, and after cancer treatment, in order to improve quality of life and to fight health inequities. CI - (c) The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. FAU - Bisceglia, Irma AU - Bisceglia I AD - Integrated Cardiology Services, Cardio-Thoracic-Vascular Department, Azienda Ospedaliera San Camillo Forlanini, C.ne Gianicolense, 87 00152 Rome, Italy. FAU - Venturini, Elio AU - Venturini E AD - Department of Cardiac Rehabilitation, Cecina Civil Hospital, Via Montanara, 52, 57023 Cecina (LI), Italy. FAU - Canale, Maria Laura AU - Canale ML AD - Division of Cardiology, Azienda USL Toscana Nord-Ovest, Versilia Hospital, Via Aurelia, 335, 55041 Lido di Camaiore (LU), Italy. FAU - Ambrosetti, Marco AU - Ambrosetti M AD - Unita Operativa Complessa di Riabilitazione Cardiologica, ASST Crema Ospedale Santa Marta, Rivolta D'Adda, 26027 Cremona, Italy. FAU - Riccio, Carmine AU - Riccio C AD - Dipartimento Cardio-Vascolare, AORN Sant'Anna e San Sebastiano, Caserta, Italy. FAU - Giallauria, Francesco AU - Giallauria F AD - Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy. FAU - Gallucci, Giuseppina AU - Gallucci G AD - Cardio-oncologist, Melfi, 85025 Potenza, Italy. FAU - Abrignani, Maurizio G AU - Abrignani MG AD - U.O di Cardiologia, P.O. 'P. Borsellino', Marsala, ASP Trapani, Italy. FAU - Russo, Giulia AU - Russo G AD - SC Patologie Cardiovascolari, Ospedale Maggiore, Via Slataper, 9, 34125 Trieste, Italy. FAU - Lestuzzi, Chiara AU - Lestuzzi C AD - Centro Medico Esperia, Porcia, PN, Italy. FAU - Mistrulli, Raffaella AU - Mistrulli R AD - Cardiology Unit, Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sapienza University of Rome, Sant'Andrea Hospital, Rome, Italy. FAU - De Luca, Giovanni AU - De Luca G AUID- ORCID: 0000-0002-5369-5382 AD - Health Activities and Epidemiologic Observatory Division, Health Department, Sicily Region, Piazza O. Ziino, 24, 90145 Palermo, Italy. FAU - Maria Turazza, Fabio AU - Maria Turazza F AD - Director of Cardiology, IRCCS Foundation, National Cancer Institute, via G Venezian, 1, 20133 Milano, Italy. FAU - Mureddu, Gianfrancesco AU - Mureddu G AD - Cardiology Division, S. Giovanni Hospital, Via dell'Amba Aradam, 8, 00184 Rome, Italy. FAU - Di Fusco, Stefania Angela AU - Di Fusco SA AUID- ORCID: 0000-0002-8586-9930 AD - Clinical and Rehabilitation Cardiology Unit, San Filippo Neri Hospital, Via Martinotti, 20, 00135 Roma, Italy. FAU - Luca, Fabiana AU - Luca F AD - Cardiology Department, Grande Ospedale Metropolitano, GOM, AO Bianchi Melacrino Morelli, 89129 Reggio di Calabria, Italy. FAU - De Luca, Leonardo AU - De Luca L AD - SC Cardiologia, Fondazione IRCCS San Matteo, Viale Camillo Golgi, 19, 27100 Pavia, Italy. FAU - Camerini, Andrea AU - Camerini A AD - Department of Medical Oncology, Azienda USL Toscana Nord-Ovest, Versilia Hospital,Via Aurelia, 335, 55041 Lido di Camaiore (LU), Italy. FAU - Halasz, Geza AU - Halasz G AUID- ORCID: 0000-0001-7220-123X AD - Dipartimento Cardio-Toraco-Vascolare, U.O.C. Cardiologia, Azienda Ospedaliera San Camillo-Forlanini, C.ne Gianicolense, 87, 00152 Rome, Italy. FAU - Camilli, Massimiliano AU - Camilli M AUID- ORCID: 0000-0002-2940-5349 AD - Department of Cardiovascular Medicine, Fondazione Policlinico Universitario A. Gemelli, IRCCS, L.go A. Gemelli, 1, 00168 Rome, Italy. AD - Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart, L.go Francesco Vito, 00168 Rome, Italy. FAU - Quagliariello, Vincenzo AU - Quagliariello V AD - Division of Cardiology, National Cancer Institute, Sen. Pascale Foundation, via Mariano Semmola, 80131 Napoli, Italy. FAU - Maurea, Nicola AU - Maurea N AD - Division of Cardiology, National Cancer Institute, Sen. Pascale Foundation, via Mariano Semmola, 80131 Napoli, Italy. FAU - Fattirolli, Francesco AU - Fattirolli F AD - Azienda Ospedaliero - Universitaria Careggi, Largo Brambilla, 3, 50134 Firenze, Italy. FAU - Gulizia, Michele Massimo AU - Gulizia MM AUID- ORCID: 0000-0003-1513-7125 AD - Cardiothoracic Department, Garibaldi Nesima Hospital, 95122 Catania, Italy. FAU - Gabrielli, Domenico AU - Gabrielli D AD - Dipartimento Cardio-Toraco-Vascolare, U.O.C. Cardiologia, Azienda Ospedaliera San Camillo-Forlanini, C.ne Gianicolense, 87, 00152 Rome, Italy. AD - Fondazione per il Tuo cuore-Heart Care Foundation, Firenze, Via A. La Marmora, 36, 50121 Firenze, Italy. FAU - Grimaldi, Massimo AU - Grimaldi M AUID- ORCID: 0000-0002-9347-8884 AD - Regional General Hospital F. Miulli, Strada Prov. 127 Acquaviva - Santeramo Km, 4, 100.70021 Acquaviva delle Fonti (BARI), Italy. FAU - Colivicchi, Furio AU - Colivicchi F AD - Clinical and Rehabilitation Cardiology Unit, San Filippo Neri Hospital, Via Martinotti, 20, 00135 Roma, Italy. FAU - Oliva, Fabrizio AU - Oliva F AD - Cardiologia 1-Emodinamica Dipartimento Cardiotoracovascolare 'A. De Gasperis', ASST Grande Ospedale Metropolitano Niguarda, 20162 Milan, Italy. LA - eng PT - Journal Article DEP - 20240516 PL - England TA - Eur Heart J Suppl JT - European heart journal supplements : journal of the European Society of Cardiology JID - 100886647 PMC - PMC11110456 OTO - NOTNLM OT - Cardiac rehabilitation OT - Cardio-oncology rehabilitation (CORE) OT - Core components of CORE OT - Geriatric oncologic patients OT - Reverse cardio-oncology OT - Telehealth in rehabilitation COIS- Conflict of interest: none declared. EDAT- 2024/05/24 06:42 MHDA- 2024/05/24 06:43 PMCR- 2024/05/16 CRDT- 2024/05/24 03:55 PHST- 2024/05/24 06:43 [medline] PHST- 2024/05/24 06:42 [pubmed] PHST- 2024/05/24 03:55 [entrez] PHST- 2024/05/16 00:00 [pmc-release] AID - suae030 [pii] AID - 10.1093/eurheartjsupp/suae030 [doi] PST - epublish SO - Eur Heart J Suppl. 2024 May 16;26(Suppl 2):ii252-ii263. doi: 10.1093/eurheartjsupp/suae030. eCollection 2024 Apr. PMID- 38783755 OWN - NLM STAT- MEDLINE DCOM- 20240524 LR - 20260922 IS - 1468-2834 (Electronic) IS - 0002-0729 (Print) IS - 0002-0729 (Linking) VI - 53 IP - 5 DP - 2024 May 1 TI - Evaluating palliative care case conferences in primary care for patients with advanced non-malignant chronic conditions: a cluster-randomised controlled trial (KOPAL). LID - 10.1093/ageing/afae100 [doi] LID - afae100 AB - BACKGROUND: Patients with congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD) and dementia are underrepresented in specialist palliative home care (SPHC). However, the complexity of their conditions requires collaboration between general practitioners (GPs) and SPHC teams and timely integration into SPHC to effectively meet their needs. OBJECTIVE: To facilitate joint palliative care planning and the timely transfer of patients with advanced chronic non-malignant conditions to SPHC. METHODS: A two-arm, unblinded, cluster-randomised controlled trial. 49 GP practices in northern Germany were randomised using web-based block randomisation. We included patients with advanced CHF, COPD and/or dementia. The KOPAL intervention consisted of a SPHC nurse-patient consultation followed by an interprofessional telephone case conference between SPHC team and GP. The primary outcome was the number of hospital admissions 48 weeks after baseline. Secondary analyses examined the effects on health-related quality of life and self-rated health status, as measured by the EuroQol 5D scale. RESULTS: A total of 172 patients were included in the analyses. 80.4% of GP practices had worked with SHPC before, most of them exclusively for cancer patients. At baseline, patients reported a mean EQ-VAS of 48.4, a mean quality of life index (EQ-5D-5L) of 0.63 and an average of 0.80 hospital admissions in the previous year. The intervention did not significantly reduce hospital admissions (incidence rate ratio = 0.79, 95%CI: [0.49, 1.26], P = 0.31) or the number of days spent in hospital (incidence rate ratio = 0.65, 95%CI: [0.28, 1.49], P = 0.29). There was also no significant effect on quality of life (∆ = -0.02, 95%CI: [-0.09, 0.05], P = 0.53) or self-rated health (∆ = -2.48, 95%CI: [-9.95, 4.99], P = 0.51). CONCLUSIONS: The study did not show the hypothesised effect on hospitalisations and health-related quality of life. Future research should focus on refining this approach, with particular emphasis on optimising the timing of case conferences and implementing discussed changes to treatment plans, to improve collaboration between GPs and SPHC teams. CI - (c) The Author(s) 2024. Published by Oxford University Press on behalf of the British Geriatrics Society. FAU - Mallon, Tina AU - Mallon T AD - Department of General Practice and Primary Care, University Medical Centre Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany. FAU - Schulze, Josefine AU - Schulze J AD - Department of General Practice and Primary Care, University Medical Centre Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany. FAU - Dams, Judith AU - Dams J AD - Department of Health Economics and Health Care Research, University Medical Centre Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany. FAU - Weber, Jan AU - Weber J AD - Institute for General Practice and Palliative Care, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany. FAU - Asendorf, Thomas AU - Asendorf T AD - Department of Medical Statistics, University Medical Centre Gottingen, Humboldtallee 32, 37073 Gottingen, Germany. FAU - Bottcher, Silke AU - Bottcher S AD - Division of General Practice, Carl von Ossietzky University of Oldenburg, Ammerlaender Heerstrasse 114-118, 26129 Oldenburg, Germany. FAU - Sekanina, Uta AU - Sekanina U AD - Department of General Practice, University Medical Centre Gottingen, Humboldtallee 38, 37073 Gottingen, Germany. FAU - Schade, Franziska AU - Schade F AD - Department of Palliative Medicine, University Medical Centre Gottingen, Von-Siebold-Str. 3, 37075 Gottingen and Institute for General Practice and Palliative Care, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany. FAU - Schneider, Nils AU - Schneider N AD - Institute for General Practice and Palliative Care, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany. FAU - Freitag, Michael AU - Freitag M AD - Division of General Practice, Carl von Ossietzky University of Oldenburg, Ammerlaender Heerstrasse 114-118, 26129 Oldenburg, Germany. FAU - Muller, Christiane AU - Muller C AD - Department of General Practice, University Medical Centre Gottingen, Humboldtallee 38, 37073 Gottingen, Germany. FAU - Konig, Hans-Helmut AU - Konig HH AD - Department of Health Economics and Health Care Research, University Medical Centre Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany. FAU - Nauck, Friedemann AU - Nauck F AD - Department of Palliative Medicine, University Medical Centre Gottingen, Von-Siebold-Str. 3, 37075 Gottingen, Germany. FAU - Friede, Tim AU - Friede T AUID- ORCID: 0000-0001-5347-7441 AD - Department of Medical Statistics, University Medical Centre Gottingen, Humboldtallee 32, 37073 Gottingen, Germany. FAU - Scherer, Martin AU - Scherer M AD - Department of General Practice and Primary Care, University Medical Centre Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany. FAU - Marx, Gabriella AU - Marx G AD - Department of General Practice and Primary Care, University Medical Centre Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany. LA - eng GR - 01VSF18024/Innovation Fund of the Federal Joint Committee/ PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't PL - England TA - Age Ageing JT - Age and ageing JID - 0375655 SB - IM MH - Humans MH - *Palliative Care/methods MH - Male MH - Female MH - Aged MH - *Quality of Life MH - Germany MH - *Pulmonary Disease, Chronic Obstructive/therapy/diagnosis MH - Aged, 80 and over MH - *Primary Health Care MH - *Heart Failure/therapy/diagnosis MH - Dementia/therapy MH - Chronic Disease MH - Home Care Services MH - Patient Care Team MH - Time Factors MH - Interdisciplinary Communication MH - Delivery of Health Care, Integrated/organization & administration PMC - PMC11116821 OTO - NOTNLM OT - case conference OT - chronic care OT - interprofessional communication OT - older people OT - palliative care OT - primary health care COIS- None. EDAT- 2024/05/24 06:42 MHDA- 2024/05/24 06:43 PMCR- 2024/05/23 CRDT- 2024/05/24 02:53 PHST- 2023/12/18 00:00 [received] PHST- 2024/05/24 06:43 [medline] PHST- 2024/05/24 06:42 [pubmed] PHST- 2024/05/24 02:53 [entrez] PHST- 2024/05/23 00:00 [pmc-release] AID - 7680464 [pii] AID - afae100 [pii] AID - 10.1093/ageing/afae100 [doi] PST - ppublish SO - Age Ageing. 2024 May 1;53(5):afae100. doi: 10.1093/ageing/afae100. PMID- 38783115 OWN - NLM STAT- MEDLINE DCOM- 20241129 LR - 20261010 IS - 1759-4820 (Electronic) IS - 1759-4812 (Linking) VI - 21 IP - 12 DP - 2024 Dec TI - Nocturia and obstructive sleep apnoea. PG - 735-753 LID - 10.1038/s41585-024-00887-7 [doi] AB - Nocturia, the need to urinate at night, is a common symptom in patients with obstructive sleep apnoea (OSA). Continuous positive airway pressure treatment can reduce nocturia in some patients, but the underlying mechanisms are complex and not fully understood. OSA affects the autonomic nervous system, oxidative stress and endothelial damage. Furthermore, the commonly held theory attributing polyuria to a false signal of cardiac overload and response natriuresis has limitations. A comprehensive approach to the management of nocturia in OSA, considering factors such as comorbidities, medication use, alcohol consumption and lifestyle, is needed. Effective management of nocturia in OSA requires a multidisciplinary approach, and urologists should be aware of the potential effect of OSA on physiology and refer patients for further testing at a sleep centre. In addition to continuous positive airway pressure, other interventions such as oral appliances and surgical obstruction treatment could be beneficial for some patients. Overall, understanding the complex interplay between OSA and nocturia is crucial for optimizing patient outcomes. CI - (c) 2024. Springer Nature Limited. FAU - Vrooman, Olaf P J AU - Vrooman OPJ AUID- ORCID: 0000-0002-9279-2847 AD - Department of Urology, Hospital Rijnstate Arnhem, Arnhem, Netherlands. o.vrooman@gmail.com. FAU - van Kerrebroeck, Philip E V AU - van Kerrebroeck PEV AD - Department of Urology, University Hospital Maastricht, Maastricht, Netherlands. FAU - van Balken, Michael R AU - van Balken MR AUID- ORCID: 0000-0002-2163-4972 AD - Department of Urology, Rijnstate Hospital, Arnhem, Netherlands. FAU - van Koeveringe, Gommert A AU - van Koeveringe GA AUID- ORCID: 0000-0003-2328-8265 AD - Department of Urology, University Hospital Maastricht, Maastricht, Netherlands. FAU - Rahnama'i, Mohammad S AU - Rahnama'i MS AD - Department of Urology Nij Smellinghe Hospital, Drachten, Netherlands. AD - Society of Urological research and education (SURE), Maastricht, Netherlands. LA - eng PT - Journal Article PT - Review DEP - 20240523 PL - England TA - Nat Rev Urol JT - Nature reviews. Urology JID - 101500082 SB - IM MH - Humans MH - *Nocturia/therapy/physiopathology MH - *Sleep Apnea, Obstructive/therapy/complications/physiopathology MH - Continuous Positive Airway Pressure COIS- Competing interests: The authors declare no competing interests. EDAT- 2024/05/24 00:42 MHDA- 2024/11/30 11:17 CRDT- 2024/05/23 23:42 PHST- 2024/04/12 00:00 [accepted] PHST- 2024/11/30 11:17 [medline] PHST- 2024/05/24 00:42 [pubmed] PHST- 2024/05/23 23:42 [entrez] AID - 10.1038/s41585-024-00887-7 [pii] AID - 10.1038/s41585-024-00887-7 [doi] PST - ppublish SO - Nat Rev Urol. 2024 Dec;21(12):735-753. doi: 10.1038/s41585-024-00887-7. Epub 2024 May 23. PMID- 38782600 OWN - NLM STAT- MEDLINE DCOM- 20240616 LR - 20240725 IS - 1097-0223 (Electronic) IS - 0197-3851 (Linking) VI - 44 IP - 6-7 DP - 2024 Jun TI - Maternal-fetal comorbidities and obstetrical outcomes of fetal single ventricle cardiac defects: 10 years' experience with a multidisciplinary management protocol at a single center. PG - 783-795 LID - 10.1002/pd.6591 [doi] AB - OBJECTIVES: To describe and compare maternal and fetal comorbidities and obstetrical outcomes in pregnancies with hypoplastic left and right heart (HLHS and HRH) single ventricle cardiac defects (SVCD) from a single center under a multidisciplinary protocol. METHOD: A single center retrospective review of fetal SVCD from 2013 to 2022. Maternal-fetal comorbidities, delivery, and postnatal outcomes were compared between HLHS and HRH using descriptive statistics and univariate and multivariate analyses. RESULTS: Of 181 SVCD pregnancies (131 HLHS; 50 HRH), 9% underwent termination, 4% elected comfort care, 5 died in utero and 147/152 liveborns survived to the first cardiac intervention. Cesarean delivery occurred in 57 cases (37%), planned in 36 and unplanned in 21. Comorbidities, which did not differ between HLHS and HRH, included fetal growth restriction (FGR, 17%), prematurity (14%), maternal hypertension (9%), maternal obesity (50%), fetal extracardiac anomalies and chromosome anomalies (12%, 13%). In multivariate analysis, only earlier gestational age at delivery and oligohydramnios predicted decreased odds of survival at one year. CONCLUSION: Maternal-fetal comorbidities are common in both HLHS and HRH. Earlier gestational age at delivery and oligohydramnios predict lower postnatal survival. FGR, even with severe early onset, did not significantly impact short- or long-term neonatal survival in single ventricle conditions. CI - (c) 2024 John Wiley & Sons Ltd. FAU - Wautlet, Cynthie K AU - Wautlet CK AUID- ORCID: 0000-0001-8540-1740 AD - Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, University of Colorado School of Medicine, and Colorado Fetal Care Center, Children's Hospital of Colorado, Aurora, Colorado, USA. FAU - Kops, Samantha A AU - Kops SA AD - Division of Cardiology, Department of Pediatrics, University of Colorado School of Medicine, and Colorado Fetal Care Center, Children's Hospital of Colorado, Aurora, Colorado, USA. FAU - Silveira, Lori J AU - Silveira LJ AD - Department of Pediatrics, University of Colorado School of Medicine, and Colorado Fetal Care Center, Children's Hospital of Colorado, Aurora, Colorado, USA. FAU - Young, Krista AU - Young K AD - Division of Cardiology, Department of Pediatrics, University of Colorado School of Medicine, and Colorado Fetal Care Center, Children's Hospital of Colorado, Aurora, Colorado, USA. FAU - Behrendt, Nicholas J AU - Behrendt NJ AD - Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, University of Colorado School of Medicine, and Colorado Fetal Care Center, Children's Hospital of Colorado, Aurora, Colorado, USA. FAU - Zaretsky, Michael V AU - Zaretsky MV AD - Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, University of Colorado School of Medicine, and Colorado Fetal Care Center, Children's Hospital of Colorado, Aurora, Colorado, USA. FAU - Cuneo, Bettina F AU - Cuneo BF AD - Division of Cardiology, Department of Pediatrics, University of Colorado School of Medicine, and Colorado Fetal Care Center, Children's Hospital of Colorado, Aurora, Colorado, USA. AD - Department of Obstetrics, University of Colorado School of Medicine, Aurora, Colorado, USA. FAU - Galan, Henry L AU - Galan HL AD - Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, University of Colorado School of Medicine, and Colorado Fetal Care Center, Children's Hospital of Colorado, Aurora, Colorado, USA. LA - eng PT - Journal Article DEP - 20240523 PL - England TA - Prenat Diagn JT - Prenatal diagnosis JID - 8106540 SB - IM MH - Humans MH - Female MH - Pregnancy MH - Retrospective Studies MH - Adult MH - *Comorbidity MH - *Pregnancy Outcome/epidemiology MH - Hypoplastic Left Heart Syndrome/epidemiology/surgery MH - Infant, Newborn MH - Heart Defects, Congenital/epidemiology/therapy MH - Pregnancy Complications/epidemiology MH - Univentricular Heart/surgery/epidemiology EDAT- 2024/05/24 00:42 MHDA- 2024/06/16 12:42 CRDT- 2024/05/23 21:43 PHST- 2024/05/06 00:00 [revised] PHST- 2024/02/01 00:00 [received] PHST- 2024/05/07 00:00 [accepted] PHST- 2024/06/16 12:42 [medline] PHST- 2024/05/24 00:42 [pubmed] PHST- 2024/05/23 21:43 [entrez] AID - 10.1002/pd.6591 [doi] PST - ppublish SO - Prenat Diagn. 2024 Jun;44(6-7):783-795. doi: 10.1002/pd.6591. Epub 2024 May 23. PMID- 38777587 OWN - NLM STAT- MEDLINE DCOM- 20240522 LR - 20250108 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 14 IP - 5 DP - 2024 May 22 TI - Pharmacist-led medication management services: a qualitative exploration of transition-of-care cardiovascular disease patient experiences. PG - e082228 LID - 10.1136/bmjopen-2023-082228 [doi] LID - e082228 AB - OBJECTIVE: Hospitalisation due to medication-related problems is a major health concern, particularly for those with pre-existing, or those at high risk of developing cardiovascular disease (CVD). Postdischarge medication reviews (PDMRs) may form a core component of reducing hospital readmissions due to medication-related problems. This study aimed to explore postdischarge CVD patients' perspectives of, and experiences with, pharmacist-led medication management services. A secondary aim explored attitudes towards the availability of PDMRs. DESIGN: An interpretative qualitative study involving 16 semistructured interviews. Data were analysed using an inductive thematic approach. SETTING: Patients with CVD discharged to a community setting from the John Hunter Hospital, an 820-bed tertiary referral hospital based in New South Wales, Australia. PARTICIPANTS: Patients with pre-existing or newly diagnosed CVD who were recently discharged from the hospital. RESULTS: A total of 16 interviews were conducted to reach thematic saturation. Nine participants (56%) were male. The mean age of participants was 57.5 (+/-13.2) years. Three emergent themes were identified: (1) poor medication understanding impacts transition from the hospital to home; (2) factors influencing medication concordance following discharge and (3) perceived benefits of routine PDMRs. CONCLUSIONS: There is a clear need to further improve the quality use of medicines and health literacy of transition-of-care patients with CVD. Our findings indicate that the engagement of transition-of-care patients with CVD with pharmacist-led medication management services is minimal. Pharmacists are suitable to provide essential and tailored medication review services to patients with CVD as part of a multidisciplinary healthcare team. The implementation of routine, pharmacist-led PDMRs may be a feasible means of providing patients with access to health education following their transition from hospital back to community, improving their health literacy and reducing rehospitalisations due to medication-related issues. CI - (c) Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Bennetts, Joshua AU - Bennetts J AUID- ORCID: 0000-0001-8704-752X AD - School of Biomedical Sciences and Pharmacy, The University of Newcastle, Callaghan, New South Wales, Australia. AD - Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia. FAU - White, Jennifer AU - White J AD - Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia. AD - School of Medicine and Public Health, The University of Newcastle, Callaghan, New South Wales, Australia. FAU - Croft, Hayley AU - Croft H AD - School of Biomedical Sciences and Pharmacy, The University of Newcastle, Callaghan, New South Wales, Australia. FAU - Cooper, Joyce AU - Cooper J AUID- ORCID: 0000-0003-3126-6023 AD - School of Biomedical Sciences and Pharmacy, The University of Newcastle, Callaghan, New South Wales, Australia. AD - College of Medicine and Dentistry, James Cook University, Townsville, Queensland, Australia. FAU - McIvor, Dawn AU - McIvor D AD - College of Health, Medicine, and Wellbeing, The University of Newcastle, Callaghan, New South Wales, Australia. AD - Cardiovascular Department, Hunter New England Local Health District, New Lambton Heights, New South Wales, Australia. FAU - Eadie, Nicholas AU - Eadie N AD - Department of Pharmacy, Hunter New England Local Health District, New Lambton Heights, New South Wales, Australia. FAU - Appay, Marcelle AU - Appay M AD - School of Biomedical Sciences and Pharmacy, The University of Newcastle, Callaghan, New South Wales, Australia. AD - Department of Pharmacy, Hunter New England Local Health District, New Lambton Heights, New South Wales, Australia. AD - School of Pharmacy, Faculty of Medicine and Health, University of Sydney, Camperdown, New South Wales, Australia. FAU - Sverdlov, Aaron L AU - Sverdlov AL AD - Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia. AD - School of Medicine and Public Health, The University of Newcastle, Callaghan, New South Wales, Australia. AD - Cardiovascular Department, Hunter New England Local Health District, New Lambton Heights, New South Wales, Australia. FAU - Ngo, Doan AU - Ngo D AD - School of Biomedical Sciences and Pharmacy, The University of Newcastle, Callaghan, New South Wales, Australia doan.ngo@newcastle.edu.au. AD - Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240522 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 SB - IM MH - Humans MH - Male MH - Female MH - Middle Aged MH - *Cardiovascular Diseases/drug therapy MH - *Qualitative Research MH - *Pharmacists MH - Aged MH - New South Wales MH - *Patient Discharge MH - Medication Therapy Management/organization & administration MH - Adult MH - Interviews as Topic MH - Professional Role MH - Medication Adherence PMC - PMC11116877 OTO - NOTNLM OT - CARDIOLOGY OT - Cardiovascular Disease OT - Hospital to Home Transition OT - Medication Reconciliation OT - Medication Review OT - Pharmacists COIS- Competing interests: JB is a credentialed pharmacist who can provide domiciliary medication management reviews funded by the Australian Government Department of Health and Aged Care. EDAT- 2024/05/23 00:42 MHDA- 2024/05/23 00:43 PMCR- 2024/05/22 CRDT- 2024/05/22 21:23 PHST- 2024/05/23 00:43 [medline] PHST- 2024/05/23 00:42 [pubmed] PHST- 2024/05/22 21:23 [entrez] PHST- 2024/05/22 00:00 [pmc-release] AID - bmjopen-2023-082228 [pii] AID - 10.1136/bmjopen-2023-082228 [doi] PST - epublish SO - BMJ Open. 2024 May 22;14(5):e082228. doi: 10.1136/bmjopen-2023-082228. PMID- 38775458 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240603 IS - 2753-670X (Electronic) IS - 2753-670X (Linking) VI - 38 IP - 5 DP - 2024 May 2 TI - Progression of the ascending aorta diameter after surgical or transcatheter bicuspid aortic valve replacement. LID - 10.1093/icvts/ivae100 [doi] LID - ivae100 AB - OBJECTIVES: Ascending aorta (AA) dilatation in patients with bicuspid aortic valve (AV) is related both to genetic and haemodynamic factors. The aim of this study is to compare late progression of AA dilatation in bicuspid AV patients undergoing surgical aortic valve replacement (SAVR) versus transcatheter aortic valve implantation (TAVI). METHODS: Data of 189 consecutive patients who underwent AV replacement for severe bicuspid AV stenosis were prospectively collected. Patients who underwent SAVR were compared to patients who underwent TAVI. Indication to the procedure was validated by the institutional Heart Team. Aortic diameters were evaluated by transthoracic echocardiogram. Differences between preoperative and long-term follow-up AA diameters were compared in the 2 groups. RESULTS: Between January 2015 and December 2021, 143 (76%) patients underwent SAVR and 46 (24%) patients underwent TAVI. At 4.6 (standard deviation 1.7) years follow-up, patients in the TAVI group showed significantly lower survival (P = 0.00013) and event-free survival (P < 0.0001). AA diameter progression was lower in surgical compared to transcatheter patients, 0.95 (0.60, 1.30) vs 1.65 (0.67, 2.63) mm, P = 0.02. AA diameter progression indexed for body surface area and height was lower in the surgical group: 0.72 (0.38, 1.05) vs 1.05 (0.39, 1.71) mm/m2, P = 0.02, and 0.59 (0.36, 0.81) vs 1.11 (0.44, 1.78) mm/m, P = 0.001, respectively. At multivariable linear regression analysis transcatheter procedure, baseline aortic diameter and paravalvular leak were significantly associated with increased postoperative AA dilatation. CONCLUSIONS: Bicuspid AV patients who underwent SAVR, showed significantly less long-term AA diameter progression than patients who underwent transcatheter procedure. CI - (c) The Author(s) 2024. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. FAU - Chiariello, Giovanni Alfonso AU - Chiariello GA AUID- ORCID: 0000-0003-3995-4066 AD - Department of Cardiovascular Sciences, Agostino Gemelli Foundation Polyclinic IRCCS, Rome, Italy. AD - Catholic University of the Sacred Heart, Rome, Italy. FAU - Di Mauro, Michele AU - Di Mauro M AUID- ORCID: 0000-0003-2611-5626 AD - Heart and Vascular Centre, Cardiovascular Research Institute, CARIM, Maastricht, Netherlands. FAU - Pasquini, Annalisa AU - Pasquini A AD - Department of Cardiovascular Sciences, Agostino Gemelli Foundation Polyclinic IRCCS, Rome, Italy. AD - Catholic University of the Sacred Heart, Rome, Italy. FAU - Bruno, Piergiorgio AU - Bruno P AD - Department of Cardiovascular Sciences, Agostino Gemelli Foundation Polyclinic IRCCS, Rome, Italy. AD - Catholic University of the Sacred Heart, Rome, Italy. FAU - Nesta, Marialisa AU - Nesta M AD - Department of Cardiovascular Sciences, Agostino Gemelli Foundation Polyclinic IRCCS, Rome, Italy. AD - Catholic University of the Sacred Heart, Rome, Italy. FAU - Fabiani, Ludovica AU - Fabiani L AD - Department of Cardiovascular Sciences, Agostino Gemelli Foundation Polyclinic IRCCS, Rome, Italy. AD - Catholic University of the Sacred Heart, Rome, Italy. FAU - Mazza, Andrea AU - Mazza A AD - Department of Cardiovascular Sciences, Agostino Gemelli Foundation Polyclinic IRCCS, Rome, Italy. AD - Catholic University of the Sacred Heart, Rome, Italy. FAU - Meloni, Martina AU - Meloni M AD - Department of Cardiology, Thoracic and Vascular Sciences, S. Matteo University Hospital, Pavia, Italy. FAU - Baldo, Elisabetta AU - Baldo E AD - Department of Cardiology, Cristo Re Hospital, Rome, Italy. FAU - Ponzo, Myriana AU - Ponzo M AUID- ORCID: 0000-0002-0494-5023 AD - Department of Cardiology, Cristo Re Hospital, Rome, Italy. FAU - Ferraro, Francesco AU - Ferraro F AD - Department of Cardiovascular Sciences, Agostino Gemelli Foundation Polyclinic IRCCS, Rome, Italy. AD - Catholic University of the Sacred Heart, Rome, Italy. FAU - Conserva, Antonio Davide AU - Conserva AD AD - Department of Cardiovascular Sciences, Agostino Gemelli Foundation Polyclinic IRCCS, Rome, Italy. AD - Catholic University of the Sacred Heart, Rome, Italy. FAU - D'Acierno, Edoardo AU - D'Acierno E AD - Department of Cardiovascular Sciences, Agostino Gemelli Foundation Polyclinic IRCCS, Rome, Italy. AD - Catholic University of the Sacred Heart, Rome, Italy. FAU - Villa, Emmanuel AU - Villa E AD - Department of Cardiovascular Surgery, Cardiac Surgery Unit, Poliambulanza Foundation Hospital, Brescia, Italy. FAU - Trani, Carlo AU - Trani C AD - Department of Cardiovascular Sciences, Agostino Gemelli Foundation Polyclinic IRCCS, Rome, Italy. AD - Catholic University of the Sacred Heart, Rome, Italy. FAU - Burzotta, Francesco AU - Burzotta F AD - Department of Cardiovascular Sciences, Agostino Gemelli Foundation Polyclinic IRCCS, Rome, Italy. AD - Catholic University of the Sacred Heart, Rome, Italy. FAU - Massetti, Massimo AU - Massetti M AD - Department of Cardiovascular Sciences, Agostino Gemelli Foundation Polyclinic IRCCS, Rome, Italy. AD - Catholic University of the Sacred Heart, Rome, Italy. LA - eng PT - Journal Article PL - England TA - Interdiscip Cardiovasc Thorac Surg JT - Interdisciplinary cardiovascular and thoracic surgery JID - 9918540787006676 SB - IM PMC - PMC11142625 OTO - NOTNLM OT - Aortic dilatation OT - Aortic stenosis OT - Aortic valve replacement OT - Bicuspid aortic valve OT - Transcatheter aortic valve implantation EDAT- 2024/05/22 12:42 MHDA- 2024/05/22 12:43 PMCR- 2024/05/22 CRDT- 2024/05/22 08:53 PHST- 2024/01/26 00:00 [received] PHST- 2024/03/17 00:00 [revised] PHST- 2024/05/17 00:00 [accepted] PHST- 2024/05/22 12:43 [medline] PHST- 2024/05/22 12:42 [pubmed] PHST- 2024/05/22 08:53 [entrez] PHST- 2024/05/22 00:00 [pmc-release] AID - 7679630 [pii] AID - ivae100 [pii] AID - 10.1093/icvts/ivae100 [doi] PST - ppublish SO - Interdiscip Cardiovasc Thorac Surg. 2024 May 2;38(5):ivae100. doi: 10.1093/icvts/ivae100. PMID- 38771808 OWN - NLM STAT- MEDLINE DCOM- 20240521 LR - 20260902 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 19 IP - 5 DP - 2024 TI - An interactive, online decision aid assessing patient goals and preferences for treatment of aortic stenosis to support physician-led shared decision-making: Early feasibility pilot study. PG - e0302378 LID - 10.1371/journal.pone.0302378 [doi] LID - e0302378 AB - BACKGROUND: Guidelines recommend shared decision making when choosing treatment for severe aortic stenosis but implementation has lagged. We assessed the feasibility and impact of a novel decision aid for severe aortic stenosis at point-of-care. METHODS: This prospective multi-site pilot cohort study included adults with severe aortic stenosis and their clinicians. Patients were referred by their heart team when scheduled to discuss treatment options. Outcomes included shared decision-making processes, communication quality, decision-making confidence, decisional conflict, knowledge, stage of decision making, decision quality, and perceptions of the tool. Patients were assessed at baseline (T0), after using the intervention (T1), and after the clinical encounter (T2); clinicians were assessed at T2. Before the encounter, patients reviewed the intervention, Aortic Valve Improved Treatment Approaches (AVITA), an interactive, online decision aid. AVITA presents options, frames decisions, clarifies patient goals and values, and generates a summary to use with clinicians during the encounter. RESULTS: 30 patients (9 women [30.0%]; mean [SD] age 70.4 years [11.0]) and 14 clinicians (4 women [28.6%], 7 cardiothoracic surgeons [50%]) comprised 28 clinical encounters Most patients [85.7%] and clinicians [84.6%] endorsed AVITA. Patients reported AVITA easy to use [89.3%] and helped them choose treatment [95.5%]. Clinicians reported the AVITA summary helped them understand their patients' values [80.8%] and make values-aligned recommendations [61.5%]. Patient knowledge significantly improved at T1 and T2 (p = 0.004). Decisional conflict, decision-making stage, and decision quality improved at T2 (p = 0.0001, 0.0005, and 0.083, respectively). Most patients [60%] changed treatment preference between T0 and T2. Initial treatment preferences were associated with low knowledge, high decisional conflict, and poor decision quality; final preferences were associated with high knowledge, low conflict, and high quality. CONCLUSIONS: AVITA was endorsed by patients and clinicians, easy to use, improved shared decision-making quality and helped patients and clinicians arrive at a treatment that reflected patients' values. TRIAL REGISTRATION: Trial ID: NCT04755426, Clinicaltrials.gov/ct2/show/NCT04755426. CI - Copyright: (c) 2024 Coylewright et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. FAU - Coylewright, Megan AU - Coylewright M AD - Department of Cardiovascular Medicine, University of Tennessee Health Science Center College of Medicine-Chattanooga, Chattanooga, Tennessee, United States of America. FAU - Otero, Diana AU - Otero D AD - Department of Cardiovascular Medicine, Columbia University Medical Center, New York, NY, United States of America. FAU - Lindman, Brian R AU - Lindman BR AD - Structural Heart and Valve Center, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America. FAU - Levack, Melissa M AU - Levack MM AD - Department of Cardiac Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America. FAU - Horne, Aaron Jr AU - Horne A Jr AD - Department of Medicine, Summit Health, Berkeley Heights, NJ, United States of America. FAU - Ngo, Long H AU - Ngo LH AD - Harvard Medical School, Boston, Massachusetts, United States of America. FAU - Beaudry, Melissa AU - Beaudry M AD - Central Vermont Medical Center, Berlin, Vermont, United States of America. FAU - Col, Hannah V AU - Col HV AD - Shared Decision Making Resources, Georgetown, ME and Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America. FAU - Col, Nananda F AU - Col NF AUID- ORCID: 0000-0001-7106-662X AD - Shared Decision Making Resources, Georgetown, ME and University of New England, Biddeford, Maine, United States of America. LA - eng SI - ClinicalTrials.gov/NCT04755426 PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't DEP - 20240521 PL - United States TA - PLoS One JT - PloS one JID - 101285081 SB - IM MH - Humans MH - *Aortic Valve Stenosis/therapy/surgery MH - Female MH - Male MH - Pilot Projects MH - Aged MH - *Decision Making, Shared MH - *Decision Support Techniques MH - Middle Aged MH - *Feasibility Studies MH - Prospective Studies MH - *Patient Preference MH - Aged, 80 and over MH - Patient Participation MH - Physicians/psychology MH - Physician-Patient Relations MH - Decision Making PMC - PMC11108138 COIS- I would like to disclose the following competing interests: Dr. Col has received research grants and contracts from Edwards Lifesciences. This does not alter our adherence to PLOS ONE policies on sharing data and materials. EDAT- 2024/05/21 18:43 MHDA- 2024/05/21 18:44 PMCR- 2024/05/21 CRDT- 2024/05/21 13:43 PHST- 2023/07/31 00:00 [received] PHST- 2024/04/02 00:00 [accepted] PHST- 2024/05/21 18:44 [medline] PHST- 2024/05/21 18:43 [pubmed] PHST- 2024/05/21 13:43 [entrez] PHST- 2024/05/21 00:00 [pmc-release] AID - PONE-D-23-22155 [pii] AID - 10.1371/journal.pone.0302378 [doi] PST - epublish SO - PLoS One. 2024 May 21;19(5):e0302378. doi: 10.1371/journal.pone.0302378. eCollection 2024. PMID- 38770305 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240522 IS - 2405-8440 (Print) IS - 2405-8440 (Electronic) IS - 2405-8440 (Linking) VI - 10 IP - 10 DP - 2024 May 30 TI - Summary of surgical experience of an elderly patient who underwent simultaneous dual minimally invasive TA-TAVR and McKeown procedures. PG - e30577 LID - 10.1016/j.heliyon.2024.e30577 [doi] LID - e30577 AB - BACKGROUND: Cases of simultaneous TA-TAVR and Mckeown dual minimally invasive surgery are very rare. A retrospective analysis of the clinical features, perioperative surgical cooperation and care of an elderly patient with esophageal cancer combined with moderate-to-severe aortic regurgitation. METHODS: An elderly patient with esophageal cancer combined with moderate to severe aortic valve regurgitation was admitted to the Department of Thoracic Surgery, West China Hospital, Sichuan University in September 2022. Through preoperative MDT discussion, two minimally invasive surgical options were identified and analyzed to develop personalized and standardized perioperative operating room care and surgical coordination. Informed written consent and institutional review board approval were both obtained (No. 2021-879; July 25, 2022) for the surgery and the publication of the study data. RESULTS: After a thorough preoperative MDT discussion and the development of a personalized and standardized operating room care plan, the two surgeries lasted a total of 5h 35mins with a total bleeding volume of 150 ml. The surgeries went smoothly, and the patients were sent to the ICU and transferred back to the general ward on the second day after surgery without complications. CONCLUSION: The simultaneous performance of dual minimally invasive level IV surgery is indeed a high-risk procedure, which is a new challenge for both patients and health care workers. Standardized OR care planning and surgical coordination are also important aspects of MDT, reflecting that OR care is an indispensable role in the surgical team as well. CI - (c) 2024 The Authors. FAU - He, Chunmei AU - He C AD - Operating Room, Department of Anesthesiology, West China Hospital, Sichuan University/West China School of Nursing, Sichuan University, Chengdu, Sichuan, China. FAU - Wang, Chen AU - Wang C AD - Operating Room, Department of Anesthesiology, West China Hospital, Sichuan University/West China School of Nursing, Sichuan University, Chengdu, Sichuan, China. FAU - Yang, Qian AU - Yang Q AD - Operating Room, Department of Anesthesiology, West China Hospital, Sichuan University/West China School of Nursing, Sichuan University, Chengdu, Sichuan, China. FAU - Tu, Xuehua AU - Tu X AD - Operating Room, Department of Anesthesiology, West China Hospital, Sichuan University/West China School of Nursing, Sichuan University, Chengdu, Sichuan, China. FAU - Shen, Cheng AU - Shen C AD - Department of Thoracic Surgery, West-China Hospital, Sichuan University, Chengdu, 610041, China. LA - eng PT - Journal Article DEP - 20240509 PL - England TA - Heliyon JT - Heliyon JID - 101672560 PMC - PMC11103418 OTO - NOTNLM OT - Esophageal cancer OT - MDT OT - Mckeown OT - Minimally invasive surgical OT - TAVI COIS- The authors have no conflicts of interest to declare.The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/05/21 06:43 MHDA- 2024/05/21 06:44 PMCR- 2024/05/09 CRDT- 2024/05/21 03:43 PHST- 2023/07/20 00:00 [received] PHST- 2024/04/23 00:00 [revised] PHST- 2024/04/29 00:00 [accepted] PHST- 2024/05/21 06:44 [medline] PHST- 2024/05/21 06:43 [pubmed] PHST- 2024/05/21 03:43 [entrez] PHST- 2024/05/09 00:00 [pmc-release] AID - S2405-8440(24)06608-8 [pii] AID - e30577 [pii] AID - 10.1016/j.heliyon.2024.e30577 [doi] PST - epublish SO - Heliyon. 2024 May 9;10(10):e30577. doi: 10.1016/j.heliyon.2024.e30577. eCollection 2024 May 30. PMID- 38767226 OWN - NLM STAT- MEDLINE DCOM- 20240823 LR - 20240827 IS - 1365-2362 (Electronic) IS - 0014-2972 (Linking) VI - 54 IP - 9 DP - 2024 Sep TI - Procedural and clinical outcomes of patients undergoing a TAVI in TAVI procedure: Rationale and design of the multicentre, prospective, observational ReTAVI registry. PG - e14241 LID - 10.1111/eci.14241 [doi] AB - BACKGROUND: Transcatheter aortic valve implantation (TAVI) is increasingly being used in younger patients and those with lower peri-procedural risk, meaning more patients will live long enough to experience structural valve deterioration (SVD) of the bioprosthesis, indicating repeated TAVI. Experience of repeated TAVI-transcatheter heart valve (THV) implantation into an index THV is limited. This registry aims to assess the peri-procedural and short-term safety, efficacy and durability of repeated TAVI. METHODS: The ReTAVI Prospective observational registry is an investigator-initiated, multicentre, international, prospective registry of patients undergoing repeated TAVI using balloon-expandable SAPIEN prosthesis to evaluate procedural and short-term safety, efficacy and durability as well as anatomical and procedural factors associated with optimal results. The registry will enrol at least 150 patients across 60 high-volume centres. Patients must be >/=18 years old, have had procedural success with their first TAVI, have index THV device failure, intend to undergo repeated TAVI and be considered suitable candidates by their local Heart Team. All patients will undergo a 30-day and 12-month follow-up. The estimated study completion is 2025. CONCLUSIONS: The registry will collect pre-, peri-, postoperative and 12-months data on patients undergoing repeated TAVI procedures with THVs for failure of the index THV and determine VARC-3-defined efficacy and safety at 30 days and functional outcome at 12 months. The registry will expand existing data sets and identify patient characteristics/indicators related to complications and clinical benefits for patients with symptomatic severe calcific degenerative aortic stenosis. CI - (c) 2024 The Author(s). European Journal of Clinical Investigation published by John Wiley & Sons Ltd on behalf of Stichting European Society for Clinical Investigation Journal Foundation. FAU - Parma, Radoslaw AU - Parma R AD - Department of Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland. FAU - Joner, Michael AU - Joner M AD - DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany. AD - Department of Cardiology, Deutsches Herzzentrum Munchen, Technical University of Munich, Munich, Germany. FAU - Saia, Francesco AU - Saia F AD - Cardiology Unit, Cardio-Thoraco-Vascular Department, Policlinico S. Orsola-Malpighia, University Hospital of Bologn, Bologna, Italy. FAU - Cuisset, Thomas AU - Cuisset T AD - Departement de Cardiologie, Centre Hospitalier Universitaire de Timone, Marseille, France. AD - Aix Marseille Universite, INSERM, INRA, C2VN & Faculte de Medecine, Marseille, France. FAU - Delgado, Victoria AU - Delgado V AD - Department of Cardiology, University Hospital Germans Trias i Pujol, Badalona, Spain. FAU - Rodes-Cabau, Josep AU - Rodes-Cabau J AD - Department of Cardiology, Quebec Heart and Lung Institute, Laval University, Quebec, Canada. FAU - Modine, Thomas AU - Modine T AD - Department of Cardiology, Hopital Haut Leveque-Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France. FAU - Van Belle, Eric AU - Van Belle E AD - Interventional Cardiology, Centre Hospitalier Universitaire de Lille, Lille, France. FAU - Fovino, Luca Nai AU - Fovino LN AD - Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua Medical School, Padua, Italy. FAU - Landes, Uri AU - Landes U AD - Department of Cardiology, Rabin Medical Center, Petah Tikva, Israel. FAU - Alvarez-Covarrubias, Hector Alfonso AU - Alvarez-Covarrubias HA AD - DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany. AD - Department of Cardiology, Deutsches Herzzentrum Munchen, Technical University of Munich, Munich, Germany. FAU - Abdel-Wahab, Mohamed AU - Abdel-Wahab M AD - Department of Internal Medicine/Cardiology, Heart Center Leipzig at University of Leipzig, Leipzig, Germany. FAU - Zamorano, Jose Luis AU - Zamorano JL AD - University Hospital Ramon y Cajal, Head of Cardiology, Madrid, Spain. FAU - Eden, Matthias AU - Eden M AD - Heidelberg University Clinic, Department Internal Medicine III (Cardiology, Angiology, Pneumology), Heidelberg, Germany. FAU - Cademartiri, Filippo AU - Cademartiri F AD - Department of Radiology, Fondazione Monasterio/CNR, Pisa, Italy. FAU - Skipirzepa, Joanna Nawara AU - Skipirzepa JN AD - Department of Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland. FAU - Kurucova, Jana AU - Kurucova J AD - Edwards Lifesciences, Prague, Czech Republic. FAU - Greinert, Daniel AU - Greinert D AD - IPPMed-Institute for Pharmacology and Preventive Medicine GmbH, Cloppenburg, Germany. FAU - Bramlage, Peter AU - Bramlage P AUID- ORCID: 0000-0003-4970-2110 AD - IPPMed-Institute for Pharmacology and Preventive Medicine GmbH, Cloppenburg, Germany. FAU - Tarantini, Giuseppe AU - Tarantini G AD - Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua Medical School, Padua, Italy. LA - eng GR - Edwards Lifesciences/ PT - Journal Article PT - Multicenter Study PT - Observational Study DEP - 20240520 PL - England TA - Eur J Clin Invest JT - European journal of clinical investigation JID - 0245331 SB - IM MH - Humans MH - *Transcatheter Aortic Valve Replacement/methods MH - *Registries MH - *Aortic Valve Stenosis/surgery MH - Prospective Studies MH - Treatment Outcome MH - Heart Valve Prosthesis MH - Prosthesis Failure MH - Male MH - Aged OTO - NOTNLM OT - ReTAVI registry OT - TAVI OT - aortic stenosis OT - redo- OT - transcatheter aortic valve implantation EDAT- 2024/05/20 12:42 MHDA- 2024/08/23 06:41 CRDT- 2024/05/20 07:32 PHST- 2024/04/26 00:00 [revised] PHST- 2024/03/28 00:00 [received] PHST- 2024/05/01 00:00 [accepted] PHST- 2024/08/23 06:41 [medline] PHST- 2024/05/20 12:42 [pubmed] PHST- 2024/05/20 07:32 [entrez] AID - 10.1111/eci.14241 [doi] PST - ppublish SO - Eur J Clin Invest. 2024 Sep;54(9):e14241. doi: 10.1111/eci.14241. Epub 2024 May 20. PMID- 38765213 OWN - NLM STAT- MEDLINE DCOM- 20240520 LR - 20240521 IS - 1947-6108 (Electronic) IS - 1947-6094 (Print) IS - 1947-6108 (Linking) VI - 20 IP - 3 DP - 2024 TI - From Trendelenburg to PERTs: Evolution in the Management of Massive Pulmonary Embolism. PG - 19-26 LID - 10.14797/mdcvj.1345 [doi] AB - Massive pulmonary embolism (MPE) is a serious condition affecting the pulmonary arteries and is difficult to diagnose, triage, and treat. The American College of Chest Physicians (AHA) and the European Society of Cardiology (ESC) have different classification approaches for PE, with the AHA defining three subtypes and the ESC four. Misdiagnosis is common, leading to delayed or inadequate treatment. The incidence of PE-related death rates has been increasing over the years, and mortality rates vary depending on the subtype of PE, with MPE having the highest mortality rate. The current definition of MPE originated from early surgical embolectomy cases and discussions among experts. However, this definition fails to capture patients at the point of maximal benefit because it is based on late findings of MPE. Pulmonary Embolism Response Teams (PERTs) have emerged as a fundamental shift in the management of MPE, with a focus on high-risk and MPE cases and a goal of rapidly connecting patients with appropriate therapies based on up-to-date evidence. This review highlights the challenges in diagnosing and managing MPE and emphasizes the importance of PERTs and risk stratification scores in improving outcomes for patients with PE. CI - Copyright: (c) 2024 The Author(s). FAU - Thangudu, Pavan AU - Thangudu P AUID- ORCID: 0009-0007-5323-1311 AD - Pulmonary Disease & Critical Care, Memorial Hermann Health System, The Woodlands, Texas, US. LA - eng PT - Journal Article PT - Review DEP - 20240516 PL - United States TA - Methodist Debakey Cardiovasc J JT - Methodist DeBakey cardiovascular journal JID - 101508600 SB - IM MH - *Pulmonary Embolism/therapy/mortality/diagnosis/diagnostic imaging/physiopathology MH - Humans MH - Treatment Outcome MH - Risk Factors MH - *Predictive Value of Tests MH - Risk Assessment MH - Clinical Decision-Making MH - Embolectomy/adverse effects MH - Decision Support Techniques MH - Thrombolytic Therapy MH - Patient Care Team PMC - PMC11100543 OTO - NOTNLM OT - massive pulmonary embolism OT - pulmonary embolism classification OT - pulmonary embolism misdiagnosis OT - pulmonary embolism response teams (PERTS) COIS- The author has no competing interests to declare. EDAT- 2024/05/20 06:42 MHDA- 2024/05/20 06:43 PMCR- 2024/05/16 CRDT- 2024/05/20 04:05 PHST- 2024/01/17 00:00 [received] PHST- 2024/03/27 00:00 [accepted] PHST- 2024/05/20 06:43 [medline] PHST- 2024/05/20 06:42 [pubmed] PHST- 2024/05/20 04:05 [entrez] PHST- 2024/05/16 00:00 [pmc-release] AID - 10.14797/mdcvj.1345 [doi] PST - epublish SO - Methodist Debakey Cardiovasc J. 2024 May 16;20(3):19-26. doi: 10.14797/mdcvj.1345. eCollection 2024. PMID- 38764317 OWN - NLM STAT- MEDLINE DCOM- 20240712 LR - 20250506 IS - 1522-726X (Electronic) IS - 1522-1946 (Linking) VI - 104 IP - 1 DP - 2024 Jul TI - Clinical journey for patients with aortic regurgitation: A retrospective observational study from a multicenter database. PG - 145-154 LID - 10.1002/ccd.31085 [doi] AB - BACKGROUND: Data using real-world assessments of aortic regurgitation (AR) severity to identify rates of Heart Valve Team evaluation and aortic valve replacement (AVR), as well as mortality among untreated patients, are lacking. The present study assessed these trends in care and outcomes for real-world patients with documented AR. METHODS: Using a deidentified data set (January 2018-March 2023) representing 1,002,853 patients >18 years of age from 25 US institutions participating in the egnite Database (egnite, Inc.) with appropriate permissions, patients were classified by AR severity in echocardiographic reports. Rates of evaluation by the Heart Valve Team, AVR, and all-cause mortality without AVR were examined using Kaplan-Meier estimates and compared using the log-rank test. RESULTS: Within the data set, 845,113 patients had AR severity documented. For moderate-to-severe or severe AR, respectively, 2-year rates (95% confidence interval) of evaluation by the Heart Valve Team (43.5% [41.7%-45.3%] and 65.4% [63.3%-67.4%]) and AVR (19.4% [17.6%-21.1%] and 46.5% [44.2%-48.8%]) were low. Mortality at 2 years without AVR increased with greater AR severity, up to 20.7% for severe AR (p < 0.001). In exploratory analyses, 2-year mortality for untreated patients with left ventricular end-systolic dimension index > 25 mm/m(2) was similar for moderate (34.3% [29.2%-39.1%]) and severe (37.2% [24.9%-47.5%]) AR. CONCLUSIONS: Moderate or greater AR is associated with poor clinical outcomes among untreated patients at 2 years. Rates of Heart Valve Team evaluation and AVR were low for those with moderate or greater AR, suggesting that earlier referral to the Heart Valve Team could be beneficial. CI - (c) 2024 The Author(s). Catheterization and Cardiovascular Interventions published by Wiley Periodicals LLC. FAU - Amoroso, Nicholas S AU - Amoroso NS AUID- ORCID: 0000-0001-6785-6899 AD - Division of Cardiology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA. FAU - Sharma, Rahul P AU - Sharma RP AUID- ORCID: 0000-0002-8530-5035 AD - Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, California, USA. FAU - Genereux, Philippe AU - Genereux P AUID- ORCID: 0000-0002-5507-3712 AD - Department of Cardiovascular Medicine, Morristown Medical Center, Morristown, New Jersey, USA. FAU - Pinto, Duane S AU - Pinto DS AD - Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA. AD - JenaValve Technology, Inc., Irvine, California, USA. FAU - Dobbles, Michael AU - Dobbles M AD - egnite Inc., Aliso Viejo, California, USA. FAU - Kwon, Michelle AU - Kwon M AD - egnite Inc., Aliso Viejo, California, USA. FAU - Thourani, Vinod H AU - Thourani VH AD - Department of Cardiovascular Surgery, Marcus Valve Center, Piedmont Heart Institute, Atlanta, Georgia, USA. FAU - Gillam, Linda D AU - Gillam LD AD - Department of Cardiovascular Medicine, Morristown Medical Center, Morristown, New Jersey, USA. LA - eng GR - JenaValve/ PT - Journal Article PT - Multicenter Study PT - Observational Study PT - Research Support, Non-U.S. Gov't DEP - 20240519 PL - United States TA - Catheter Cardiovasc Interv JT - Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions JID - 100884139 SB - IM MH - Humans MH - *Aortic Valve Insufficiency/diagnostic imaging/mortality/physiopathology/surgery MH - Male MH - Female MH - Retrospective Studies MH - *Databases, Factual MH - Aged MH - Time Factors MH - United States/epidemiology MH - *Aortic Valve/diagnostic imaging/surgery/physiopathology MH - Treatment Outcome MH - *Severity of Illness Index MH - Risk Factors MH - Middle Aged MH - *Heart Valve Prosthesis Implantation/adverse effects/mortality MH - Aged, 80 and over MH - Risk Assessment OTO - NOTNLM OT - Heart Valve Team OT - aortic regurgitation OT - aortic valve replacement OT - echocardiography OT - prognosis EDAT- 2024/05/20 06:42 MHDA- 2024/07/12 06:42 CRDT- 2024/05/20 02:13 PHST- 2024/02/20 00:00 [revised] PHST- 2023/10/26 00:00 [received] PHST- 2024/05/08 00:00 [accepted] PHST- 2024/07/12 06:42 [medline] PHST- 2024/05/20 06:42 [pubmed] PHST- 2024/05/20 02:13 [entrez] AID - 10.1002/ccd.31085 [doi] PST - ppublish SO - Catheter Cardiovasc Interv. 2024 Jul;104(1):145-154. doi: 10.1002/ccd.31085. Epub 2024 May 19. PMID- 38757968 OWN - NLM STAT- MEDLINE DCOM- 20261002 LR - 20261002 IS - 1538-4683 (Electronic) IS - 1061-5377 (Linking) VI - 34 IP - 6 DP - 2026 Nov-Dec 01 TI - Bloodless Cardiac Surgery in Jehovah's Witness: A Comprehensive Review. PG - 523-526 LID - 10.1097/CRD.0000000000000725 [doi] AB - This article explores the major challenges and specialized strategies involved in managing cardiovascular surgery patients who are Jehovah's Witnesses and refuse blood transfusions due to their religious beliefs. It delves into preoperative, intraoperative, and postoperative approaches aimed at minimizing blood loss and optimizing patient outcomes while respecting their autonomy. Preoperative measures focus on correcting anemia and coagulopathy through targeted interventions, such as iron supplementation and erythropoietin therapy, and meticulous screening for bleeding disorders. Intraoperative techniques include the use of vasoconstrictors, hemostatic agents, and innovative blood conservation methods like acute normovolemic hemodilution and cell salvage. Postoperative care emphasizes infection control, hemostasis, and judicious monitoring to prevent anemia and facilitate recovery. Through a multidisciplinary approach and adherence to evidence-based practices, healthcare providers can effectively meet the needs of Jehovah's Witness patients, ensuring safe and successful cardiovascular surgery outcomes without the use of blood transfusions. CI - Copyright (c) 2024 Wolters Kluwer Health, LLC. All rights reserved. FAU - Maheta, Darshil Kumar AU - Maheta DK AD - From the School of Health Science and Policy, New York Medical College, Valhalla, NY. FAU - Frishman, William H AU - Frishman WH AD - Department of Medicine, New York Medical College, Valhalla, NY. FAU - Aronow, Wilbert S AU - Aronow WS AD - Departments of Cardiology and Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY. LA - eng PT - Journal Article PT - Review DEP - 20240517 PL - United States TA - Cardiol Rev JT - Cardiology in review JID - 9304686 SB - IM MH - Humans MH - *Jehovah's Witnesses MH - *Bloodless Medical and Surgical Procedures/methods MH - *Cardiac Surgical Procedures/methods MH - *Blood Loss, Surgical/prevention & control MH - Blood Transfusion OTO - NOTNLM OT - Jehovah's Witnesses OT - blood conservation method OT - blood transfusions OT - cardiovascular surgery OT - outcomes COIS- Disclosure: The authors declare no conflict of interest. EDAT- 2024/05/17 12:44 MHDA- 2026/10/02 05:31 CRDT- 2024/05/17 09:04 PHST- 2026/10/02 05:31 [medline] PHST- 2024/05/17 12:44 [pubmed] PHST- 2024/05/17 09:04 [entrez] AID - 00045415-990000000-00268 [pii] AID - 10.1097/CRD.0000000000000725 [doi] PST - ppublish SO - Cardiol Rev. 2026 Nov-Dec 01;34(6):523-526. doi: 10.1097/CRD.0000000000000725. Epub 2024 May 17. PMID- 38755510 OWN - NLM STAT- MEDLINE DCOM- 20240927 LR - 20241023 IS - 1868-4297 (Electronic) IS - 1868-4297 (Linking) VI - 39 IP - 4 DP - 2024 Oct TI - Impact of osteoporotic risk in men undergoing transcatheter aortic valve replacement: a report from the LAPLACE-TAVI registry. PG - 460-467 LID - 10.1007/s12928-024-01011-7 [doi] AB - Low body weight and advanced age are among the best predictors of osteoporosis. Osteoporosis Self-Assessment Tool (OST) values are calculated by a simple formula [(body weight in kilograms - age in years) x 0.2] to identify patients at increased risk of osteoporosis. In our recent single-center study, we demonstrated an association between OST and poor outcomes in postmenopausal women after transcatheter aortic valve replacement (TAVR). We aimed to investigate the impact of osteoporotic risk in men with aortic stenosis who underwent TAVR in a large cohort. In this multi-center study, 1,339 men who underwent TAVR between April 2010 and July 2023 were retrospectively analyzed. Women were excluded from the present study. All patients were deemed appropriate for TAVR after a review by a multidisciplinary team. Baseline characteristics of patients were compared by dividing patients into three tertiles, based on the OST value: 3.0 (area under the curve [AUC], 0.65; sensitivity, 75.0%; specificity, 56.8%; p = 0.036) increased PMI risk by 3.661-fold, independent of external confounders. Kaplan-Meier test revealed a decrease in MACCE survival rate concomitant with an escalating TBR(max). TBR(max)>3.6 (AUC, 0.70; sensitivity, 76.9%; specificity, 73.9%; p = 0.017) increased MACCEs risk by 5.520-fold. Both TBR(max) (hazard ratio [HR], 1.298; p = 0.004) and TBR(global) (HR = 1.335; p = 0.011) were significantly correlated with recurrent angina. No significant associations were found between CAC and SYNTAX scores and between PMI occurrence and long-term MACCEs. CONCLUSION: Quantification of coronary microcalcification activity via [(18)F]NaF PET displayed a strong ability to predict early and long-term post-CABG cardiovascular outcomes, thereby outperforming conventional metrics of coronary macrocalcification burden and stenosis severity. TRIAL REGISTRATION: The trial was registered with the Chinese Clinical Trial Committee (number: ChiCTR1900022527; URL: www.chictr.org.cn/showproj.html?proj=37933 ). CI - (c) 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Gao, Mingxin AU - Gao M AD - Department of Nuclear Medicine, Molecular Imaging Lab, Beijing Anzhen Hospital, Capital Medical University, No.2, Anzhen Road, Chaoyang District, Beijing, 10029, China. AD - Department of Cardiac Surgery, Beijing Anzhen Hospital, Capital Medical University, No. 2, Anzhen Road, Chaoyang District, Beijing, 100029, China. FAU - Wen, Wanwan AU - Wen W AD - Department of Nuclear Medicine, Molecular Imaging Lab, Beijing Anzhen Hospital, Capital Medical University, No.2, Anzhen Road, Chaoyang District, Beijing, 10029, China. FAU - Li, Haiyang AU - Li H AD - Department of Cardiac Surgery, Beijing Anzhen Hospital, Capital Medical University, No. 2, Anzhen Road, Chaoyang District, Beijing, 100029, China. FAU - Zheng, Yaqi AU - Zheng Y AD - Department of Cardiac Surgery, Beijing Anzhen Hospital, Capital Medical University, No. 2, Anzhen Road, Chaoyang District, Beijing, 100029, China. FAU - Yun, Mingkai AU - Yun M AD - Department of Nuclear Medicine, Molecular Imaging Lab, Beijing Anzhen Hospital, Capital Medical University, No.2, Anzhen Road, Chaoyang District, Beijing, 10029, China. FAU - Meng, Jingjing AU - Meng J AD - Department of Nuclear Medicine, Molecular Imaging Lab, Beijing Anzhen Hospital, Capital Medical University, No.2, Anzhen Road, Chaoyang District, Beijing, 10029, China. FAU - Wang, Shipan AU - Wang S AD - Department of Cardiac Surgery, Beijing Anzhen Hospital, Capital Medical University, No. 2, Anzhen Road, Chaoyang District, Beijing, 100029, China. FAU - Wang, Bolin AU - Wang B AD - Department of Cardiac Surgery, Beijing Anzhen Hospital, Capital Medical University, No. 2, Anzhen Road, Chaoyang District, Beijing, 100029, China. FAU - Hu, Biao AU - Hu B AD - Department of Nuclear Medicine, Molecular Imaging Lab, Beijing Anzhen Hospital, Capital Medical University, No.2, Anzhen Road, Chaoyang District, Beijing, 10029, China. FAU - Mou, Tiantian AU - Mou T AD - Department of Nuclear Medicine, Molecular Imaging Lab, Beijing Anzhen Hospital, Capital Medical University, No.2, Anzhen Road, Chaoyang District, Beijing, 10029, China. FAU - Yu, Yang AU - Yu Y AD - Department of Cardiac Surgery, Beijing Anzhen Hospital, Capital Medical University, No. 2, Anzhen Road, Chaoyang District, Beijing, 100029, China. 13911524101@163.com. FAU - Zhang, Xiaoli AU - Zhang X AUID- ORCID: 0000-0002-0770-5594 AD - Department of Nuclear Medicine, Molecular Imaging Lab, Beijing Anzhen Hospital, Capital Medical University, No.2, Anzhen Road, Chaoyang District, Beijing, 10029, China. xlzhang68@126.com. FAU - Li, Xiang AU - Li X AD - Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Vienna General Hospital, Medical University of Vienna, Vienna, Austria. LA - eng PT - Comparative Study PT - Journal Article PT - Observational Study DEP - 20240511 PL - Germany TA - Eur J Nucl Med Mol Imaging JT - European journal of nuclear medicine and molecular imaging JID - 101140988 RN - 0 (Fluorine Radioisotopes) RN - GZ5I74KB8G (Fluorine-18) RN - 8ZYQ1474W7 (Sodium Fluoride) SB - IM MH - Humans MH - Male MH - Female MH - Middle Aged MH - Aged MH - *Fluorine Radioisotopes MH - *Positron Emission Tomography Computed Tomography MH - *Coronary Artery Bypass MH - Coronary Artery Disease/diagnostic imaging MH - Sodium Fluoride MH - Treatment Outcome MH - Prospective Studies MH - Coronary Vessels/diagnostic imaging MH - Prognosis OTO - NOTNLM OT - Coronary artery bypass grafting OT - Coronary artery disease OT - Positron emission tomography/computed tomography OT - Prognosis OT - Sodium [18F]fluoride EDAT- 2024/05/11 08:41 MHDA- 2024/09/02 12:43 CRDT- 2024/05/10 23:25 PHST- 2024/01/11 00:00 [received] PHST- 2024/04/26 00:00 [accepted] PHST- 2024/09/02 12:43 [medline] PHST- 2024/05/11 08:41 [pubmed] PHST- 2024/05/10 23:25 [entrez] AID - 10.1007/s00259-024-06736-4 [pii] AID - 10.1007/s00259-024-06736-4 [doi] PST - ppublish SO - Eur J Nucl Med Mol Imaging. 2024 Sep;51(11):3235-3251. doi: 10.1007/s00259-024-06736-4. Epub 2024 May 11. PMID- 38727607 OWN - NLM STAT- MEDLINE DCOM- 20241111 LR - 20260415 IS - 1527-6473 (Electronic) IS - 1527-6465 (Linking) VI - 30 IP - 12 DP - 2024 Dec 1 TI - Management of the liver transplant candidate with high cardiac risk: Multidisciplinary best practices and recommendations. PG - 1304-1315 LID - 10.1097/LVT.0000000000000396 [doi] AB - In a setting characterized by a growing prevalence of patients with alcohol-associated and metabolic dysfunction-associated steatotic liver diseases, coupled with an aging patient demographic, the incidence of cardiac comorbidities in liver transplant candidates is on the rise. These comorbidities not only pose barriers to transplant eligibility but also impact the intraoperative course and affect posttransplant outcomes. As such, there is a significant need to optimize the clinical management of these cardiac comorbidities. However, there is a scarcity of evidence regarding the best practices for managing cardiac comorbidities such as coronary and valvular heart diseases, arrhythmia, and cardiomyopathy in this population, both before and during transplant surgery. These conditions necessitate a coordinated and multidisciplinary approach to care. In this manuscript, we conduct a comprehensive review of the most recent evidence pertaining to the preoperative and intraoperative management of these cardiac comorbidities in liver transplant candidates. Our aim is to provide recommendations that improve and standardize their clinical care. CI - Copyright (c) 2024 American Association for the Study of Liver Diseases. FAU - Pagano, Giulia AU - Pagano G AUID- ORCID: 0000-0003-2395-4731 AD - Department of Hepatology, Hospital Clinic, Liver Transplant Unit, IDIBAPS, CIBERehd, University of Barcelona, Barcelona, Spain. FAU - Koshy, Anoop N AU - Koshy AN AUID- ORCID: 0000-0002-8741-8631 AD - Department of Cardiology and Victorian Liver Transplant Unit, Austin Health, University of Melbourne, Victoria, Australia. FAU - Chadha, Ryan AU - Chadha R AUID- ORCID: 0000-0002-7463-6912 AD - Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Jacksonville, Florida, USA. FAU - VanWagner, Lisa B AU - VanWagner LB AUID- ORCID: 0000-0002-6264-2573 AD - Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, Dallas, Texas, USA. FAU - Crespo, Gonzalo AU - Crespo G AUID- ORCID: 0000-0002-1178-4897 AD - Department of Hepatology, Hospital Clinic, Liver Transplant Unit, IDIBAPS, CIBERehd, University of Barcelona, Barcelona, Spain. LA - eng PT - Journal Article PT - Review DEP - 20240513 PL - United States TA - Liver Transpl JT - Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society JID - 100909185 SB - IM MH - Humans MH - *Liver Transplantation/standards/adverse effects MH - Comorbidity MH - Practice Guidelines as Topic MH - End Stage Liver Disease/surgery MH - Heart Diseases/surgery/diagnosis/therapy/epidemiology MH - Preoperative Care/standards/methods MH - Risk Factors MH - Treatment Outcome MH - Intraoperative Care/standards/methods MH - Heart Disease Risk Factors EDAT- 2024/05/10 12:43 MHDA- 2024/11/13 13:53 CRDT- 2024/05/10 10:03 PHST- 2024/02/10 00:00 [received] PHST- 2024/05/03 00:00 [accepted] PHST- 2024/11/13 13:53 [medline] PHST- 2024/05/10 12:43 [pubmed] PHST- 2024/05/10 10:03 [entrez] AID - 01445473-202412000-00012 [pii] AID - 10.1097/LVT.0000000000000396 [doi] PST - ppublish SO - Liver Transpl. 2024 Dec 1;30(12):1304-1315. doi: 10.1097/LVT.0000000000000396. Epub 2024 May 13. PMID- 38726719 OWN - NLM STAT- MEDLINE DCOM- 20240510 LR - 20250511 IS - 1969-6213 (Electronic) IS - 1774-024X (Print) IS - 1774-024X (Linking) VI - 20 IP - 9 DP - 2024 May 10 TI - Quantitative flow ratio versus fractional flow reserve for Heart Team decision-making in multivessel disease: the randomised, multicentre DECISION QFR trial. PG - 561-570 LID - EIJ-D-23-00674 [pii] LID - 10.4244/EIJ-D-23-00674 [doi] AB - BACKGROUND: Vessel-level physiological data derived from pressure wire measurements are one of the important determinant factors in the optimal revascularisation strategy for patients with multivessel disease (MVD). However, these may result in complications and a prolonged procedure time. AIMS: The feasibility of using the quantitative flow ratio (QFR), an angiography-derived fractional flow reserve (FFR), in Heart Team discussions to determine the optimal revascularisation strategy for patients with MVD was investigated. METHODS: Two Heart Teams were randomly assigned either QFR- or FFR-based data of the included patients. They then discussed the optimal revascularisation mode (percutaneous coronary intervention [PCI] or coronary artery bypass grafting [CABG]) for each patient and made treatment recommendations. The primary endpoint of the trial was the level of agreement between the treatment recommendations of both teams as assessed using Cohen's kappa. RESULTS: The trial included 248 patients with MVD from 10 study sites. Cohen's kappa in the recommended revascularisation modes between the QFR and FFR approaches was 0.73 [95% confidence interval CI : 0.62-0.83]. As for the revascularisation planning, agreements in the target vessels for PCI and CABG were substantial for both revascularisation modes (Cohen's kappa=0.72 [95% CI: 0.66-0.78] and 0.72 [95% CI: 0.66-0.78], respectively). The team assigned to the QFR approach provided consistent recommended revascularisation modes even after being made aware of the FFR data (Cohen's kappa=0.95 [95% CI:0.90-1.00]). CONCLUSIONS: QFR provided feasible physiological data in Heart Team discussions to determine the optimal revascularisation strategy for MVD. The QFR and FFR approaches agreed substantially in terms of treatment recommendations. FAU - Asano, Taku AU - Asano T AD - Department of Cardiovascular Medicine, St. Luke's International Hospital, St. Luke's International University, Tokyo, Japan. FAU - Tanigaki, Toru AU - Tanigaki T AD - Department of Cardiovascular Medicine, Gifu Heart Center, Gifu, Japan. FAU - Hoshino, Masahiro AU - Hoshino M AD - Division of Cardiovascular Medicine, Tsuchiura Kyodo General Hospital, Tsuchiura, Japan. FAU - Yasunaga, Motoki AU - Yasunaga M AD - Cardiovascular Division, Osaka Police Hospital, Osaka, Japan. FAU - Nonaka, Hideaki AU - Nonaka H AD - Division of Cardiology, Mitsui Memorial Hospital, Tokyo, Japan. FAU - Emori, Hiroki AU - Emori H AD - Department of Cardiovascular Medicine, Wakayama Medical University, Wakayama, Japan. FAU - Katagiri, Yuki AU - Katagiri Y AD - Department of Cardiovascular Medicine, Sapporo Higashi Tokushukai Hospital, Sapporo, Japan. FAU - Miyazaki, Yosuke AU - Miyazaki Y AD - Division of Cardiology, Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine, Ube, Japan. FAU - Sotomi, Yohei AU - Sotomi Y AD - Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan. FAU - Kogame, Norihiro AU - Kogame N AD - Division of Cardiovascular Medicine, Toho University Ohashi Medical Center, Tokyo, Japan. FAU - Kuramitsu, Shoichi AU - Kuramitsu S AD - Sapporo Cardiovascular Clinic, Sapporo Heart Center, Sapporo, Japan. FAU - Saito, Akira AU - Saito A AD - Department of Cardiovascular Medicine, St. Luke's International Hospital, St. Luke's International University, Tokyo, Japan. FAU - Miyata, Kotaro AU - Miyata K AD - Department of Cardiovascular Medicine, St. Luke's International Hospital, St. Luke's International University, Tokyo, Japan. FAU - Takaoka, Yoshimitsu AU - Takaoka Y AD - Department of Cardiovascular Medicine, St. Luke's International Hospital, St. Luke's International University, Tokyo, Japan. FAU - Kanie, Takayoshi AU - Kanie T AD - Department of Cardiovascular Medicine, St. Luke's International Hospital, St. Luke's International University, Tokyo, Japan. FAU - Yamasaki, Manabu AU - Yamasaki M AD - Department of Cardiovascular Surgery, St. Luke's International Hospital, St. Luke's International University, Tokyo, Japan. FAU - Yoshino, Kunihiko AU - Yoshino K AD - Department of Cardiovascular Surgery, St. Luke's International Hospital, St. Luke's International University, Tokyo, Japan. FAU - Wakabayashi, Naoki AU - Wakabayashi N AD - Department of Radiology, St. Luke's International Hospital, St. Luke's International University, Tokyo, Japan. FAU - Ouchi, Kouki AU - Ouchi K AD - Department of Radiology, St. Luke's International Hospital, St. Luke's International University, Tokyo, Japan. FAU - Kodama, Hiroyuki AU - Kodama H AD - Department of Cardiovascular Medicine, St. Luke's International Hospital, St. Luke's International University, Tokyo, Japan. FAU - Shiina, Yumi AU - Shiina Y AD - Department of Cardiovascular Medicine, St. Luke's International Hospital, St. Luke's International University, Tokyo, Japan. FAU - Tamaki, Rihito AU - Tamaki R AD - Department of Cardiovascular Surgery, St. Luke's International Hospital, St. Luke's International University, Tokyo, Japan. FAU - Nishihata, Yosuke AU - Nishihata Y AD - Department of Cardiovascular Medicine, St. Luke's International Hospital, St. Luke's International University, Tokyo, Japan. FAU - Masuda, Keita AU - Masuda K AD - Department of Cardiovascular Medicine, St. Luke's International Hospital, St. Luke's International University, Tokyo, Japan. FAU - Suzuki, Takahiro AU - Suzuki T AD - Department of Cardiovascular Medicine, St. Luke's International Hospital, St. Luke's International University, Tokyo, Japan. FAU - Reiber, Johan H C AU - Reiber JHC AD - Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands. FAU - Okamura, Takayuki AU - Okamura T AD - Division of Cardiology, Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine, Ube, Japan. FAU - Higuchi, Yoshiharu AU - Higuchi Y AD - Cardiovascular Division, Osaka Police Hospital, Osaka, Japan. FAU - Kakuta, Tsunekazu AU - Kakuta T AD - Division of Cardiovascular Medicine, Tsuchiura Kyodo General Hospital, Tsuchiura, Japan. FAU - Misumi, Hiroyasu AU - Misumi H AD - Department of Cardiovascular Surgery, St. Luke's International Hospital, St. Luke's International University, Tokyo, Japan. FAU - Abe, Kohei AU - Abe K AD - Department of Cardiovascular Surgery, St. Luke's International Hospital, St. Luke's International University, Tokyo, Japan. FAU - Komiyama, Nobuyuki AU - Komiyama N AD - Department of Cardiovascular Medicine, St. Luke's International Hospital, St. Luke's International University, Tokyo, Japan. FAU - Tanabe, Kengo AU - Tanabe K AD - Division of Cardiology, Mitsui Memorial Hospital, Tokyo, Japan. FAU - Matsuo, Hitoshi AU - Matsuo H AD - Department of Cardiovascular Medicine, Gifu Heart Center, Gifu, Japan. FAU - Qfr Investigators, On Behalf Of The Decision AU - Qfr Investigators OBOTD LA - eng PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial PL - France TA - EuroIntervention JT - EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology JID - 101251040 SB - IM MH - Humans MH - *Fractional Flow Reserve, Myocardial/physiology MH - Female MH - Male MH - *Coronary Artery Disease/physiopathology/therapy/surgery/diagnostic imaging MH - Middle Aged MH - *Percutaneous Coronary Intervention/methods MH - Aged MH - *Coronary Angiography MH - Coronary Artery Bypass/methods MH - Clinical Decision-Making MH - Cardiac Catheterization/methods MH - Patient Care Team PMC - PMC11067723 COIS- J.H.C. Reiber is the CSO of Medis Medical Imaging Systems and has a part-time appointment at Leiden University Medical Center as a Professor of Medical Imaging. The other authors have no conflicts of interest to declare. EDAT- 2024/05/10 06:42 MHDA- 2024/05/10 06:43 PMCR- 2025/05/10 CRDT- 2024/05/10 05:23 PHST- 2024/05/10 06:43 [medline] PHST- 2024/05/10 06:42 [pubmed] PHST- 2024/05/10 05:23 [entrez] PHST- 2025/05/10 00:00 [pmc-release] AID - EIJ-D-23-00674 [pii] AID - 10.4244/EIJ-D-23-00674 [doi] PST - ppublish SO - EuroIntervention. 2024 May 10;20(9):561-570. doi: 10.4244/EIJ-D-23-00674. PMID- 38719369 OWN - NLM STAT- MEDLINE DCOM- 20240508 LR - 20260616 IS - 1558-3597 (Electronic) IS - 0735-1097 (Linking) VI - 83 IP - 19 DP - 2024 May 14 TI - Ventricular Septal Rupture After Myocardial Infarction: JACC Focus Seminar 3/5. PG - 1886-1901 LID - S0735-1097(24)06612-9 [pii] LID - 10.1016/j.jacc.2024.01.041 [doi] AB - Ventricular septal rupture remains a dreadful complication of acute myocardial infarction. Although less commonly observed than during the prethrombolytic era, the condition remains complex and is often associated with refractory cardiogenic shock and death. Corrective surgery, although superior to medical treatment, has been associated with high perioperative morbidity and mortality. Transcatheter closure techniques are less invasive to surgery and offer a valuable alternative, particularly in patients with cardiogenic shock. In these patients, percutaneous mechanical circulatory support represents a novel opportunity for immediate stabilization and preserved end-organ function. Multimodality imaging can identify favorable septal anatomy for the most appropriate type of repair. The heart team approach will define optimal timing for surgery vs percutaneous repair. Emerging concepts are proposed for a deferred treatment approach, including orthotropic heart transplantation in ideal candidates. Finally, for futile situations, palliative care experts and a medical ethics team will provide the best options for end-of-life clinical decision making. CI - Copyright (c) 2024 American College of Cardiology Foundation. All rights reserved. FAU - Cubeddu, Roberto J AU - Cubeddu RJ AD - Division of Cardiology, Section for Structural Heart Disease, Naples Comprehensive Health Rooney Heart Institute, Naples Comprehensive Health Healthcare System, Naples, Florida, USA; Igor Palacios Fellows Foundation, Boston, Massachusetts, USA. FAU - Lorusso, Roberto AU - Lorusso R AD - Cardio-Thoracic Surgery Department, Maastricht University Medical Centre (MUMC), Maastricht, the Netherlands; Cardiovascular Research Institute Maastricht, Maastricht, the Netherlands. FAU - Ronco, Daniele AU - Ronco D AD - Cardio-Thoracic Surgery Department, Maastricht University Medical Centre (MUMC), Maastricht, the Netherlands; Cardiovascular Research Institute Maastricht, Maastricht, the Netherlands; Cardiac Surgery Unit, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy. FAU - Matteucci, Matteo AU - Matteucci M AD - Cardio-Thoracic Surgery Department, Maastricht University Medical Centre (MUMC), Maastricht, the Netherlands; Cardiovascular Research Institute Maastricht, Maastricht, the Netherlands; Cardiac Surgery Unit, ASSTSette Laghi, Varese, Italy. FAU - Axline, Michael S AU - Axline MS AD - Division of Cardiology, Section for Structural Heart Disease, Naples Comprehensive Health Rooney Heart Institute, Naples Comprehensive Health Healthcare System, Naples, Florida, USA. FAU - Moreno, Pedro R AU - Moreno PR AD - Igor Palacios Fellows Foundation, Boston, Massachusetts, USA; Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Electronic address: Pedro.moreno@mountsinai.org. LA - eng PT - Journal Article PT - Review PL - United States TA - J Am Coll Cardiol JT - Journal of the American College of Cardiology JID - 8301365 SB - IM MH - Humans MH - *Ventricular Septal Rupture/etiology/therapy MH - *Myocardial Infarction/complications/therapy MH - Cardiac Catheterization/methods MH - Cardiac Surgical Procedures/methods OTO - NOTNLM OT - cardiogenic shock OT - heart transplantation OT - myocardial infarction OT - percutaneous closure OT - ventricular septal rupture COIS- Funding Support and Author Disclosures Dr Lorusso has been the principal investigator of PERSIST-AVR (Perceval Sutureless Implant vs Standard Aortic Valve Replacement), sponsored by LivaNova; and has performed consulting for Medtronic, LivaNova, Abiomed, and Eurosets with all honoraria paid to the university. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2024/05/09 00:47 MHDA- 2024/05/09 00:48 CRDT- 2024/05/08 20:56 PHST- 2023/08/28 00:00 [received] PHST- 2023/12/07 00:00 [revised] PHST- 2024/01/03 00:00 [accepted] PHST- 2024/05/09 00:48 [medline] PHST- 2024/05/09 00:47 [pubmed] PHST- 2024/05/08 20:56 [entrez] AID - S0735-1097(24)06612-9 [pii] AID - 10.1016/j.jacc.2024.01.041 [doi] PST - ppublish SO - J Am Coll Cardiol. 2024 May 14;83(19):1886-1901. doi: 10.1016/j.jacc.2024.01.041. PMID- 38716527 OWN - NLM STAT- MEDLINE DCOM- 20240508 LR - 20261002 IS - 0004-5772 (Print) IS - 0004-5772 (Linking) VI - 71 IP - 10 DP - 2023 Oct TI - Consensus on Current Landscape and Treatment Trends of Obesity in India for Primary Care Physicians. PG - 69-77 LID - 10.59556/japi.71.0349 [doi] AB - Objectives: The objective of this consensus article was to form a list of expert recommendations and an easily adaptable algorithm for obesity management in India by primary care physicians (PCPs). Methods: A Delphi-based model was followed to form a list of the consensus recommendations. Consensus statements were created from the results of a literature review that were graded as per the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) criteria. After being evaluated by an expert panel comprising diabetologists, endocrinologists, cardiologists, bariatric surgeons, and gynecologists, the statements were revised and reevaluated by a larger group of practitioners, including PCPs and diabetologists, to arrive at a consensus. Results: The panel opined that obesity is increasing in prevalence in India and is projected to rise in the coming years. Body mass index and waist circumference were both recommended for better identification of people at risk of obesity-related comorbidities than either of them alone. The Edmonton Obesity Staging System (EOSS) was suggested as being most suitable for the assessment (staging) of obesity. A multidisciplinary team was considered invaluable for assessing and managing patients with obesity. The use of once-a-week semaglutide (2.4 mg) via the subcutaneous route was suggested as the first-choice anti-obesity treatment when pharmacotherapy is deemed necessary. An algorithm considering all these aspects was proposed. Conclusion: Obesity needs to be recognized as a significant contributor to other comorbidities. The diagnosis and management of obesity should be comprehensive and consider patient psychology, the presence or absence of comorbidities, available pharmacologic agents, and long-term outcomes. The proposed algorithm could help clinicians in this aspect and improve the overall outcomes. How to cite this article: Deshpande NR, Kapoor N, Dalal JJ, et al. Consensus on Current Landscape and Treatment Trends of Obesity in India for Primary Care Physicians. J Assoc Physicians India 2023;71(10):69-77. CI - (c) Journal of the Association of Physicians of India 2023. FAU - Deshpande, Neeta Rohit AU - Deshpande NR AD - Consultant Diabetologist and Obesity Physician, Belgaum Diabetes Centre; Associate Professor, USM-KLE International Medical Program; Professor and Head, Medicine, MM Dental College, Bengaluru, Karnataka, India, Corresponding Author. FAU - Kapoor, Nitin AU - Kapoor N AD - Department of Endocrinology, Diabetes and Metabolism, Christian Medical College, Vellore, Tamil Nadu, India; Non Communicable Disease & the Implementation Science Unit, Baker Heart and Diabetes Institute, Melbourne, Australia. FAU - Dalal, Jamshed J AU - Dalal JJ AD - Department of Cardiac Sciences, Kokilaben Hospital, Mumbai, Maharashtra, India. FAU - Palshetkar, Nandita AU - Palshetkar N AD - Medical Director, Bloom IVF Center, Lilavati Hospital and Research Centre, Mumbai, Maharashtra, India. FAU - Shah, Shashank AU - Shah S AD - Department of Laparoscopy and Bariatrics, Laparo Obeso Centre, Pune, Maharashtra, India. FAU - Makkar, Brij Mohan AU - Makkar BM AD - Dr Makkar's Diabetes and Obesity Centre, New Delhi, India. FAU - Wasir, Jasjeet AU - Wasir J AD - Division of Diabetes & Endocrinology, Medanta - The Medicity Multi-Speciality Hospital, Gurugram, Haryana, India. FAU - Selvan, Chitra AU - Selvan C AD - Associate Professor, Department of Endocrinology, MS Ramaiah Medical College, Bengaluru, Karnataka, India. LA - eng PT - Consensus Statement PT - Journal Article PL - India TA - J Assoc Physicians India JT - The Journal of the Association of Physicians of India JID - 7505585 SB - IM MH - Humans MH - Algorithms MH - Delphi Technique MH - India/epidemiology MH - *Obesity/epidemiology/therapy MH - *Physicians, Primary Care EDAT- 2024/05/08 06:44 MHDA- 2024/05/08 06:45 CRDT- 2024/05/08 03:56 PHST- 2024/05/08 06:45 [medline] PHST- 2024/05/08 06:44 [pubmed] PHST- 2024/05/08 03:56 [entrez] AID - 10.59556/japi.71.0349 [doi] PST - ppublish SO - J Assoc Physicians India. 2023 Oct;71(10):69-77. doi: 10.59556/japi.71.0349. PMID- 38715102 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240510 IS - 2055-0464 (Print) IS - 2055-0464 (Electronic) IS - 2055-0464 (Linking) VI - 11 IP - 1 DP - 2024 May 7 TI - Heart valve service provision in the United Kingdom and the effect of the COVID 19 pandemic; improved but must do better. A British Heart Valve Society national survey. PG - 11 LID - 10.1186/s44156-024-00047-y [doi] LID - 11 AB - BACKGROUND: Outpatient care for patients with heart valve disease (HVD) is best provided by valve clinics delivered by specialists. Modern day practice in the United Kingdom (UK) is currently poorly understood and has not been evaluated for nearly a decade. Furthermore, the COVID 19 pandemic changed the management of many chronic diseases, and how this has impacted patients with heart valve disease is unclear. METHODS: A British Heart Valve Society survey was sent to 161 hospitals throughout the UK. RESULTS: There was a general valve clinic in 46 of the 68 hospitals (68%), in 19 of 23 Heart Centres (83%) and 29 of 45 DGHs (64%). Across all settings, 3824 new patients and 17,980 follow up patients were seen in valve clinics per annum. The mean number of patients per hospital were 197 (median 150, range 48-550) for new patients and 532 (median 400, range 150-2000) for follow up. On the day echocardiography was available in 55% of valve clinics. In patients with severe HVD, serum brain natriuretic peptide (BNP) was measured routinely in 39% of clinics and exercise testing routinely performed in 49% of clinics. A patient helpline was available in 27% of clinics. 78% of centres with a valve clinic had a valve multidisciplinary team meeting (MDT). 45% centres had an MDT co-ordinator and MDT outcomes were recorded on a database in 64%. COVID-19 had a major impact on valve services in 54 (95%) hospitals. CONCLUSIONS: There has been an increase in the number of valve clinics since 2015 from 21 to 68% but the penetration is still well short of the expected 100%, meaning that valve clinics only serve a small proportion of patients requiring surveillance for HVD. COVID-19 had a major impact on the care of patients with HVD in the majority of UK centres surveyed. CI - (c) 2024. The Author(s). FAU - Mohindra, R AU - Mohindra R AD - Blackpool Victoria Hospital, Blackpool, UK. roshan.mohindra1@nhs.net. FAU - Dobson, L E AU - Dobson LE AD - Manchester University Foundation Trust, Manchester, UK. FAU - Schlosshan, D AU - Schlosshan D AD - Leeds Teaching Hospitals NHS Trust, Leeds, UK. FAU - Khan, P AU - Khan P AD - British Heart Valve Society, London, UK. FAU - Campbell, B AU - Campbell B AD - Guys and St Thomas' NHS Foundation Trust, London, UK. FAU - Garbi, M AU - Garbi M AD - Royal Papworth Hospital, Cambridge, UK. FAU - Chambers, B AU - Chambers B AD - Leeds Teaching Hospitals NHS Trust, Leeds, UK. FAU - Chambers, J B AU - Chambers JB AD - British Heart Valve Society, London, UK. LA - eng PT - Journal Article DEP - 20240507 PL - England TA - Echo Res Pract JT - Echo research and practice JID - 101664713 PMC - PMC11077841 OTO - NOTNLM OT - Cardiology OT - Cardiovascular Disease OT - Echocardiology OT - Endocarditis OT - Imaging OT - Valuvular Heart Disease COIS- The authors declare no competing interests. EDAT- 2024/05/08 02:06 MHDA- 2024/05/08 02:07 PMCR- 2024/05/07 CRDT- 2024/05/07 23:55 PHST- 2023/12/12 00:00 [received] PHST- 2024/04/12 00:00 [accepted] PHST- 2024/05/08 02:07 [medline] PHST- 2024/05/08 02:06 [pubmed] PHST- 2024/05/07 23:55 [entrez] PHST- 2024/05/07 00:00 [pmc-release] AID - 10.1186/s44156-024-00047-y [pii] AID - 47 [pii] AID - 10.1186/s44156-024-00047-y [doi] PST - epublish SO - Echo Res Pract. 2024 May 7;11(1):11. doi: 10.1186/s44156-024-00047-y. PMID- 38715086 OWN - NLM STAT- MEDLINE DCOM- 20240508 LR - 20240621 IS - 1824-7288 (Electronic) IS - 1720-8424 (Linking) VI - 50 IP - 1 DP - 2024 May 7 TI - Phenotypic variability and management of patients with mosaic monosomy X and Y chromosome material: a case series. PG - 93 LID - 10.1186/s13052-024-01618-9 [doi] LID - 93 AB - BACKGROUND: we aim to discuss the origin and the differences of the phenotypic features and the management care of rare form of disorder of sex development due to Mosaic monosomy X and Y chromosome materiel. METHODS: We report our experience with patients harboring mosaic monosomy X and Y chromosome material diagnosed by blood cells karyotypes and cared for in our department from 2005 to 2022. RESULTS: We have included five infants in our study. The current average age was 8 years. In four cases, the diagnosis was still after born and it was at the age of 15 years in one case. Physical examination revealed a variable degree of virilization, ranging from a normal male phallus with unilateral ectopic gonad to ambiguous with a genital tubercle and bilateral not palpable gonads in four cases and normal female external genitalia in patient 5. Karyotype found 45, X/46, XY mosaicism in patient 1 and 2 and 45, X/46, X, der (Y) mosaicism in patient 3, 4 and 5. Three cases were assigned to male gender and two cases were assigned to female. After radiologic and histologic exploration, four patients had been explored by laparoscopy to perform gonadectomy in two cases and Mullerian derivative resection in the other. Urethroplasty was done in two cases of posterior hypospadias. Gender identity was concordant with the sex of assignment at birth in only 3 cases. CONCLUSION: Because of the phenotypic heterogeneity of this sexual disorders and the variability of its management care, then the decision should rely on a multidisciplinary team approach. CI - (c) 2024. The Author(s). FAU - Fredj, Myriam Ben AU - Fredj MB AUID- ORCID: 0009-0009-7584-253X AD - University of Monastir Faculty of Medicine of Monastir, Universite de Monastir faculte de medicine de Monastir, Monastir, Tunisia. Myriam.benfredj@yahoo.fr. FAU - Messaoud, Marwa AU - Messaoud M AD - University of Monastir Faculty of Medicine of Monastir, Universite de Monastir faculte de medicine de Monastir, Monastir, Tunisia. FAU - Youssef, Sabrine Ben AU - Youssef SB AD - University of Monastir Faculty of Medicine of Monastir, Universite de Monastir faculte de medicine de Monastir, Monastir, Tunisia. FAU - Mani, Salma AU - Mani S AD - University of Monastir Faculty of Medicine of Monastir, Universite de Monastir faculte de medicine de Monastir, Monastir, Tunisia. FAU - Laaribi, Syrine AU - Laaribi S AD - University of Monastir Faculty of Medicine of Monastir, Universite de Monastir faculte de medicine de Monastir, Monastir, Tunisia. FAU - Sakka, Rania AU - Sakka R AD - University of Monastir Faculty of Medicine of Monastir, Universite de Monastir faculte de medicine de Monastir, Monastir, Tunisia. FAU - Hmida, Hayet Ben AU - Hmida HB AD - University of Monastir Faculty of Medicine of Monastir, Universite de Monastir faculte de medicine de Monastir, Monastir, Tunisia. FAU - Ksiaa, Amine AU - Ksiaa A AD - University of Monastir Faculty of Medicine of Monastir, Universite de Monastir faculte de medicine de Monastir, Monastir, Tunisia. FAU - Mekki, Mongi AU - Mekki M AD - University of Monastir Faculty of Medicine of Monastir, Universite de Monastir faculte de medicine de Monastir, Monastir, Tunisia. FAU - Belghith, Mohsen AU - Belghith M AD - University of Monastir Faculty of Medicine of Monastir, Universite de Monastir faculte de medicine de Monastir, Monastir, Tunisia. FAU - Sahnoun, Lassaad AU - Sahnoun L AD - University of Monastir Faculty of Medicine of Monastir, Universite de Monastir faculte de medicine de Monastir, Monastir, Tunisia. LA - eng PT - Journal Article DEP - 20240507 PL - England TA - Ital J Pediatr JT - Italian journal of pediatrics JID - 101510759 SB - IM MH - Adolescent MH - Child MH - Child, Preschool MH - Female MH - Humans MH - Infant MH - Male MH - Chromosomes, Human, X/genetics MH - *Chromosomes, Human, Y/genetics MH - Disorders of Sex Development/genetics/therapy/diagnosis MH - Karyotyping MH - Monosomy/genetics MH - *Mosaicism MH - *Phenotype MH - Turner Syndrome/genetics/therapy PMC - PMC11077738 OTO - NOTNLM OT - 45X OT - 46 OT - 46XY; 45X OT - Der(Y); mosaicism; phenotype; Monosomy OT - Disorder of sex development OT - X COIS- None of the authors have any potential sources of conflicts of interest to disclose. EDAT- 2024/05/08 02:05 MHDA- 2024/05/08 06:45 PMCR- 2024/05/07 CRDT- 2024/05/07 23:54 PHST- 2023/07/27 00:00 [received] PHST- 2024/02/24 00:00 [accepted] PHST- 2024/05/08 06:45 [medline] PHST- 2024/05/08 02:05 [pubmed] PHST- 2024/05/07 23:54 [entrez] PHST- 2024/05/07 00:00 [pmc-release] AID - 10.1186/s13052-024-01618-9 [pii] AID - 1618 [pii] AID - 10.1186/s13052-024-01618-9 [doi] PST - epublish SO - Ital J Pediatr. 2024 May 7;50(1):93. doi: 10.1186/s13052-024-01618-9. PMID- 38712554 OWN - NLM STAT- MEDLINE DCOM- 20240618 LR - 20240618 IS - 1941-7705 (Electronic) IS - 1941-7713 (Linking) VI - 17 IP - 6 DP - 2024 Jun TI - Multidomain Approach to Integration of Heart Failure and Palliative Care. PG - e010565 LID - 10.1161/CIRCOUTCOMES.123.010565 [doi] FAU - Puckett, Carrie M AU - Puckett CM AUID- ORCID: 0000-0003-3813-0612 AD - Department of Cardiology (C.M.P.). AD - Veterans Health Administration, Portland, OR (C.M.P.). AD - Division of Cardiovascular Medicine, Knight Cardiovascular (C.M.P.), Oregon Health & Science University, Portland. FAU - Thammana, Rekha V AU - Thammana RV AUID- ORCID: 0000-0001-5880-531X AD - Geriatrics and Palliative Care, Division of Rehabilitation and Long-Term Care (R.V.T.). AD - Department of Hematology and Medical Oncology (R.V.T.), Oregon Health & Science University, Portland. FAU - Goodlin, Sarah J AU - Goodlin SJ AUID- ORCID: 0000-0002-7977-8290 AD - Patient-Centered Education and Research, Department of Medicine (S.J.G.), Oregon Health & Science University, Portland. LA - eng PT - Journal Article DEP - 20240507 PL - United States TA - Circ Cardiovasc Qual Outcomes JT - Circulation. Cardiovascular quality and outcomes JID - 101489148 SB - IM MH - Humans MH - *Heart Failure/therapy/physiopathology/diagnosis MH - *Palliative Care MH - *Delivery of Health Care, Integrated/organization & administration MH - *Patient Care Team/organization & administration MH - Interdisciplinary Communication MH - Treatment Outcome OTO - NOTNLM OT - advance care planning OT - heart failure OT - palliative care OT - quality of life OT - veterans COIS- Disclosures None. EDAT- 2024/05/07 06:42 MHDA- 2024/06/18 18:42 CRDT- 2024/05/07 05:03 PHST- 2024/06/18 18:42 [medline] PHST- 2024/05/07 06:42 [pubmed] PHST- 2024/05/07 05:03 [entrez] AID - 10.1161/CIRCOUTCOMES.123.010565 [doi] PST - ppublish SO - Circ Cardiovasc Qual Outcomes. 2024 Jun;17(6):e010565. doi: 10.1161/CIRCOUTCOMES.123.010565. Epub 2024 May 7. PMID- 38708982 OWN - NLM STAT- MEDLINE DCOM- 20240506 LR - 20240521 IS - 1759-7390 (Electronic) IS - 1750-8460 (Linking) VI - 85 IP - 4 DP - 2024 Apr 30 TI - What to do with foundation therapies for heart failure for patients with end-stage kidney disease on haemodialysis. PG - 1-10 LID - 10.12968/hmed.2023.0452 [doi] AB - There is a significant burden of cardiovascular disease morbidity and mortality in the end-stage kidney disease population, driven by traditional and non-traditional risk factors. Despite its prevalence, heart failure is difficult to diagnose in the dialysis population due to overlapping clinical presentations, limitations of investigations, and the impact on the cardiorenal axis. 'Foundation therapies' are the key medications which improve patient outcomes in heart failure with reduced ejection fraction and include beta-blockers, renin-angiotensin-aldosterone system inhibitors and sodium-glucose cotransporter-2 inhibitors. They are underutilised in the dialysis population due to the exclusion of chronic kidney disease patients from major trials and legitimate clinical concerns e.g. hyperkalaemia, intradialytic hypotension and residual kidney function preservation. A coordinated cardiorenal multidisciplinary approach can guide appropriate diagnostic considerations (biomarkers interpretation, imaging, addressing unique complications of kidney disease), optimise dialysis management (prescription length, frequency and ultrafiltration targets) and when at euvolaemia facilitate the stepwise introduction of appropriate foundation therapies. FAU - Adenwalla, Sherna F AU - Adenwalla SF AD - Department of Cardiovascular Sciences, University of Leicester, Leicester, UK. AD - Department of Renal Medicine, University Hospitals of Leicester NHS Trust, Leicester, UK. FAU - Hull, Katherine L AU - Hull KL AD - Department of Cardiovascular Sciences, University of Leicester, Leicester, UK. AD - Department of Renal Medicine, University Hospitals of Leicester NHS Trust, Leicester, UK. FAU - Graham-Brown, Matthew Pm AU - Graham-Brown MP AD - Department of Cardiovascular Sciences, University of Leicester, Leicester, UK. AD - Department of Renal Medicine, University Hospitals of Leicester NHS Trust, Leicester, UK. LA - eng PT - Journal Article PT - Review PL - Singapore TA - Br J Hosp Med (Lond) JT - British journal of hospital medicine (London, England : 2005) JID - 101257109 RN - 0 (Sodium-Glucose Transporter 2 Inhibitors) RN - 0 (Adrenergic beta-Antagonists) RN - 0 (Angiotensin-Converting Enzyme Inhibitors) SB - IM MH - Humans MH - *Heart Failure/therapy MH - *Renal Dialysis MH - *Kidney Failure, Chronic/therapy/complications MH - *Sodium-Glucose Transporter 2 Inhibitors/therapeutic use MH - Adrenergic beta-Antagonists/therapeutic use MH - Angiotensin-Converting Enzyme Inhibitors/therapeutic use MH - Renin-Angiotensin System/drug effects OTO - NOTNLM OT - Dialysis OT - End-stage kidney disease OT - Foundation therapies OT - Heart failure OT - Management EDAT- 2024/05/06 12:44 MHDA- 2024/05/06 12:45 CRDT- 2024/05/06 08:33 PHST- 2024/05/06 12:45 [medline] PHST- 2024/05/06 12:44 [pubmed] PHST- 2024/05/06 08:33 [entrez] AID - 10.12968/hmed.2023.0452 [doi] PST - ppublish SO - Br J Hosp Med (Lond). 2024 Apr 30;85(4):1-10. doi: 10.12968/hmed.2023.0452. PMID- 38703970 OWN - NLM STAT- MEDLINE DCOM- 20240807 LR - 20240807 IS - 1879-1336 (Electronic) IS - 1054-8807 (Linking) VI - 72 DP - 2024 Sep-Oct TI - The cardiovascular pathologist in the aortic team. PG - 107649 LID - S1054-8807(24)00045-0 [pii] LID - 10.1016/j.carpath.2024.107649 [doi] AB - Aortic diseases require a multidisciplinary management for diagnosis, treatment and follow-up with better outcomes in referral centers using a team-based approach. The setting up of a multi-disciplinary aortic team for the discussion of complex cases has been already proposed; it is also supported by the ACC/AHA. Surgeons and radiologists, more or less other physicians such as cardiologists, geneticists, rheumatologists/internal medicine specialists and pathologists are involved into such a team. The role of the cardiovascular pathologist is to examine the aortic specimens, to diagnose and classify the aortic lesions. Herein, the role of the pathologist in the aortic team is discussed and the pathobiology of aortic diseases is reviewed for reference by pathologists. The aortic specimens are mainly obtained from emergency or elective surgical procedures on the thoracic aorta, less frequently from organ/tissue (including cardiac or heart valve) donors, post-mortem procedures or abdominal aortic surgery. In the last decade, together with the progress of medical sciences, the histological definitions and classifications of the aortic pathology are undergoing thorough revisions that are addressed to an etiopathogenetic approach because of possible clinico-pathological correlations, therapeutic and prognostic impact. Pathologists may also have an important role in research and teaching. Therefore, histological analyses of the aortic specimens require adequate sample processing and pathologist expertise because histology contributes to definite diagnosis, correct management of patients and even (in genetic diseases) families, but also to research in the challenging field of aortopathies. CI - Copyright (c) 2024 Elsevier Inc. All rights reserved. FAU - Pucci, Angela AU - Pucci A AD - Department of Histopathology, Pisa University Hospital, Pisa, Italy. Electronic address: angelapucci@libero.it. FAU - Rossetti, Martina AU - Rossetti M AD - Department of Histopathology, Pisa University Hospital, Pisa, Italy. FAU - Lenzi, Chiara AU - Lenzi C AD - Department of Histopathology, Pisa University Hospital, Pisa, Italy. FAU - Buja, Maximilian L AU - Buja ML AD - Department of Pathology and Laboratory Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX, USA. LA - eng PT - Journal Article PT - Review DEP - 20240503 PL - United States TA - Cardiovasc Pathol JT - Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology JID - 9212060 SB - IM MH - Humans MH - *Pathologists MH - *Aortic Diseases/pathology/therapy/classification/diagnosis MH - *Patient Care Team MH - Aorta/pathology/surgery MH - Predictive Value of Tests MH - Interdisciplinary Communication MH - Prognosis MH - Biopsy OTO - NOTNLM OT - Acute aortic syndrome OT - Aortic aneurysm OT - Aortic pathology OT - Aortic team OT - Cardiovascular pathology COIS- Declaration of competing interest The authors declare no conflict of interest. EDAT- 2024/05/05 07:47 MHDA- 2024/08/08 00:41 CRDT- 2024/05/04 19:26 PHST- 2023/11/11 00:00 [received] PHST- 2024/04/14 00:00 [revised] PHST- 2024/04/19 00:00 [accepted] PHST- 2024/08/08 00:41 [medline] PHST- 2024/05/05 07:47 [pubmed] PHST- 2024/05/04 19:26 [entrez] AID - S1054-8807(24)00045-0 [pii] AID - 10.1016/j.carpath.2024.107649 [doi] PST - ppublish SO - Cardiovasc Pathol. 2024 Sep-Oct;72:107649. doi: 10.1016/j.carpath.2024.107649. Epub 2024 May 3. PMID- 38700711 OWN - NLM STAT- MEDLINE DCOM- 20250422 LR - 20250513 IS - 1432-1971 (Electronic) IS - 0172-0643 (Print) IS - 0172-0643 (Linking) VI - 46 IP - 4 DP - 2025 Apr TI - A Pediatric Interprofessional Cardiac Intensive Care Unit Intervention: CICU Teams and Loved Ones Communicating (CICU TALC) is Feasible, Acceptable, and Improves Clinician Communication Behaviors in Family Meetings. PG - 785-797 LID - 10.1007/s00246-024-03497-7 [doi] AB - Parents of children in the pediatric cardiac intensive care unit (CICU) are often unprepared for family meetings (FM). Clinicians often do not follow best practices for communicating with families, adding to distress. An interprofessional team intervention for FM is feasible, acceptable, and positively impacts family preparation and conduct of FM in the CICU. We implemented a family- and team-support intervention for conducting FM and conducted a pretest-posttest study with parents of patients selected for a FM and clinicians. We measured feasibility, fidelity to intervention protocol, and parent acceptability via questionnaire and semi-structured interviews. Clinician behavior in meetings was assessed through semantic content analyses of meeting transcripts tracking elicitation of parental concerns, questions asked of parents, and responses to parental empathic opportunities. Logistic and ordinal logistic regression assessed intervention impact on clinician communication behaviors in meetings comparing pre- and post-intervention data. Sixty parents (95% of approached) were enrolled, with collection of 97% FM and 98% questionnaire data. We accomplished > 85% fidelity to intervention protocol. Most parents (80%) said the preparation worksheet had the right amount of information and felt positive about families receiving this worksheet. Clinicians were more likely to elicit parental concerns (adjusted odds ratio = 3.42; 95%CI [1.13, 11.0]) in post-intervention FM. There were no significant differences in remaining measures. Implementing an interprofessional team intervention to improve family preparation and conduct of FM is locally feasible, acceptable, and changes clinician behaviors. Future research should assess broader impact of training on clinicians, patients, and families. CI - (c) 2024. The Author(s). FAU - Walter, Jennifer AU - Walter J AD - Clinical Futures, Children's Hospital of Philadelphia, Philadelphia, PA, USA. Walterj1@chop.edu. AD - Justin Ingerman Center for Palliative Care, Children's Hospital of Philadelphia, Philadelphia, PA, USA. Walterj1@chop.edu. FAU - Hill, Douglas L AU - Hill DL AD - Justin Ingerman Center for Palliative Care, Children's Hospital of Philadelphia, Philadelphia, PA, USA. FAU - Cetin, Arzu AU - Cetin A AD - Clinical Futures, Children's Hospital of Philadelphia, Philadelphia, PA, USA. FAU - DeWitt, Aaron AU - DeWitt A AD - Cardiac Center, Children's Hospital of Philadelphia, Philadelphia, PA, USA. FAU - Kellom, Katie AU - Kellom K AD - Policy Lab, Children's Hospital of Philadelphia, Philadelphia, PA, USA. AD - Qualitative Research Core, Children's Hospital of Philadelphia, Philadelphia, PA, USA. FAU - Quarshie, William AU - Quarshie W AD - Data Science and Biostatistics Unit, Department of Biomedical and Health Informatics, Children's Hospital of Philadelphia, Philadelphia, PA, USA. FAU - Griffis, Heather AU - Griffis H AD - Data Science and Biostatistics Unit, Department of Biomedical and Health Informatics, Children's Hospital of Philadelphia, Philadelphia, PA, USA. FAU - Shults, Justine AU - Shults J AD - Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. FAU - Arnold, Robert AU - Arnold R AD - University of Pittsburgh Medical Center, Pittsburgh, PA, USA. FAU - Tjia, Jennifer AU - Tjia J AD - Department of Population and Quantitative Health Sciences, UMass Chan Medical School, Worcester, MA, USA. FAU - Puopolo, Karen AU - Puopolo K AD - Clinical Futures, Children's Hospital of Philadelphia, Philadelphia, PA, USA. FAU - Curley, Martha A Q AU - Curley MAQ AD - Department of Family and Community Health, University of Pennsylvania School of Nursing, Philadelphia, PA, USA. AD - Children's Hospital of Philadelphia Research Institute, Philadelphia, PA, USA. FAU - Feudtner, Chris AU - Feudtner C AD - Clinical Futures, Children's Hospital of Philadelphia, Philadelphia, PA, USA. AD - Justin Ingerman Center for Palliative Care, Children's Hospital of Philadelphia, Philadelphia, PA, USA. LA - eng GR - K23 HL141700/HL/NHLBI NIH HHS/United States GR - K23HL141700/HL/NHLBI NIH HHS/United States PT - Journal Article DEP - 20240503 PL - United States TA - Pediatr Cardiol JT - Pediatric cardiology JID - 8003849 SB - IM MH - Humans MH - *Intensive Care Units, Pediatric MH - Female MH - Male MH - *Patient Care Team MH - *Professional-Family Relations MH - *Communication MH - *Parents/psychology MH - Child MH - Surveys and Questionnaires MH - Feasibility Studies MH - Child, Preschool MH - Infant MH - Adult MH - *Interprofessional Relations PMC - PMC11531608 MID - NIHMS2009684 OTO - NOTNLM OT - Family meetings OT - Interprofessional teamwork OT - Pediatric cardiac intensive care unit OT - Team-family communication COIS- Declarations. Competing interests: The authors declare no competing interests. EDAT- 2024/05/03 12:52 MHDA- 2025/03/12 18:17 PMCR- 2024/05/03 CRDT- 2024/05/03 11:14 PHST- 2024/03/01 00:00 [received] PHST- 2024/04/11 00:00 [accepted] PHST- 2025/03/12 18:17 [medline] PHST- 2024/05/03 12:52 [pubmed] PHST- 2024/05/03 11:14 [entrez] PHST- 2024/05/03 00:00 [pmc-release] AID - 10.1007/s00246-024-03497-7 [pii] AID - 3497 [pii] AID - 10.1007/s00246-024-03497-7 [doi] PST - ppublish SO - Pediatr Cardiol. 2025 Apr;46(4):785-797. doi: 10.1007/s00246-024-03497-7. Epub 2024 May 3. PMID- 38699843 OWN - NLM STAT- MEDLINE DCOM- 20240810 LR - 20250507 IS - 1522-726X (Electronic) IS - 1522-1946 (Linking) VI - 104 IP - 2 DP - 2024 Aug TI - Percutaneous balloon mitral valvuloplasty with shockwave lithotripsy for the treatment of calcific mitral valve stenosis. PG - 356-364 LID - 10.1002/ccd.31063 [doi] AB - BACKGROUND: Calcific mitral stenosis (calcific MS) presents a challenge for surgical treatment and is a contraindication for most contemporary transcatheter mitral valve replacement devices (TMVR), rendering patients with very limited therapeutic options. AIMS: This study aims to assess the clinical and hemodynamic follow-up after mitral valve lithotripsy (MVL). METHODS: All consecutive patients who underwent MVL to treat symptomatic calcific MS at St Michael's Hospital, Toronto, Canada, were included. Patients were deemed unsuitable for mitral surgery or TMVR after heart team assessment. Patients with rheumatic MS or >/=moderate mitral regurgitation (MR) were excluded. The primary endpoint was a reduction in the invasive mitral gradient by >/=50% without significant (>/=moderate) MR. RESULTS: Fifteen patients underwent MVL between 2021 and 2023 with a mean age of 74 +/- 9 years; 53% were female, with a mean STS score of 10% +/- 0.1%. Following MVL, there was a reduction in the invasively measured mean trans-mitral gradient compared to baseline (14 mmHg vs. 6 mmHg; p < 0.05). The primary endpoint was achieved in 8 patients (53%) with no major procedural complications. At follow-up (median 90 days, IQR 58-115 days), 14 (93%) patients reported improved symptoms from New York Heart Association (NYHA) Class III-IV to NYHA Class I-II (p < 0.01) with stable echo-derived mean gradient (7.7 mmHg +/- 2 mmHg vs. 8.4 mmHg +/- 2.9 mmHg (p = 0.7). CONCLUSIONS: In selected patients with symptomatic inoperable calcific MS, MVL was safe and associated with significant short-term clinical and hemodynamic improvement. MVL may represent a new compassionate therapy for this challenging cohort. Further studies are needed to determine the long-term outcomes and help define the role of IVL technology in treating calcific valvular conditions. CI - (c) 2024 The Authors. Catheterization and Cardiovascular Interventions published by Wiley Periodicals LLC. FAU - Alnasser, Sami M AU - Alnasser SM AUID- ORCID: 0000-0003-2519-0739 AD - Division of Cardiology, St Michael's Hospital, University of Toronto, Ontario, Toronto, Canada. FAU - Moey, Melissa AU - Moey M AD - Division of Cardiology, St Michael's Hospital, University of Toronto, Ontario, Toronto, Canada. FAU - Ali, Noman AU - Ali N AUID- ORCID: 0000-0002-9597-4451 AD - Division of Cardiology, St Michael's Hospital, University of Toronto, Ontario, Toronto, Canada. FAU - Almazroa, Loai AU - Almazroa L AD - Division of Cardiology, St Michael's Hospital, University of Toronto, Ontario, Toronto, Canada. FAU - Al-Shaibi, Abdulaziz AU - Al-Shaibi A AD - Division of Cardiology, St Michael's Hospital, University of Toronto, Ontario, Toronto, Canada. AD - King Abdulaziz University, Jeddah, Saudi Arabia. FAU - Liauw, Samantha AU - Liauw S AD - Division of Cardiology, St Michael's Hospital, University of Toronto, Ontario, Toronto, Canada. FAU - Claeys, Mathias AU - Claeys M AD - Division of Cardiology, St Michael's Hospital, University of Toronto, Ontario, Toronto, Canada. FAU - Ong, Geraldine AU - Ong G AD - Division of Cardiology, St Michael's Hospital, University of Toronto, Ontario, Toronto, Canada. FAU - Fam, Neil P AU - Fam NP AD - Division of Cardiology, St Michael's Hospital, University of Toronto, Ontario, Toronto, Canada. LA - eng PT - Journal Article DEP - 20240503 PL - United States TA - Catheter Cardiovasc Interv JT - Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions JID - 100884139 SB - IM MH - Humans MH - Female MH - Male MH - Treatment Outcome MH - *Mitral Valve Stenosis/physiopathology/diagnostic imaging/therapy MH - Aged MH - *Lithotripsy MH - *Balloon Valvuloplasty MH - *Calcinosis/therapy/physiopathology/diagnostic imaging MH - *Mitral Valve/physiopathology/diagnostic imaging/surgery MH - *Hemodynamics MH - Time Factors MH - Aged, 80 and over MH - *Recovery of Function MH - Retrospective Studies MH - Middle Aged MH - Ontario OTO - NOTNLM OT - balloon valvuloplasty OT - calcific mitral stenosis OT - mitral annular calcification OT - shockwave lithotripsy EDAT- 2024/05/03 06:43 MHDA- 2024/08/10 15:44 CRDT- 2024/05/03 04:43 PHST- 2024/03/23 00:00 [revised] PHST- 2023/12/10 00:00 [received] PHST- 2024/04/17 00:00 [accepted] PHST- 2024/08/10 15:44 [medline] PHST- 2024/05/03 06:43 [pubmed] PHST- 2024/05/03 04:43 [entrez] AID - 10.1002/ccd.31063 [doi] PST - ppublish SO - Catheter Cardiovasc Interv. 2024 Aug;104(2):356-364. doi: 10.1002/ccd.31063. Epub 2024 May 3. PMID- 38683665 OWN - NLM STAT- MEDLINE DCOM- 20240429 LR - 20250815 IS - 1438-8871 (Electronic) IS - 1439-4456 (Print) IS - 1438-8871 (Linking) VI - 26 DP - 2024 Apr 29 TI - Effectiveness of a Smartphone App-Based Intervention With Bluetooth-Connected Monitoring Devices and a Feedback System in Heart Failure (SMART-HF Trial): Randomized Controlled Trial. PG - e52075 LID - 10.2196/52075 [doi] LID - e52075 AB - BACKGROUND: Current heart failure (HF) guidelines recommend a multidisciplinary approach, discharge education, and self-management for HF. However, the recommendations are challenging to implement in real-world clinical settings. OBJECTIVE: We developed a mobile health (mHealth) platform for HF self-care to evaluate whether a smartphone app-based intervention with Bluetooth-connected monitoring devices and a feedback system can help improve HF symptoms. METHODS: In this prospective, randomized, multicenter study, we enrolled patients 20 years of age and older, hospitalized for acute HF, and who could use a smartphone from 7 tertiary hospitals in South Korea. In the intervention group (n=39), the apps were automatically paired with Bluetooth-connected monitoring devices. The patients could enter information on vital signs, HF symptoms, diet, medications, and exercise regimen into the app daily and receive feedback or alerts on their input. In the control group (n=38), patients could only enter their blood pressure, heart rate, and weight using conventional, non-Bluetooth devices and could not receive any feedback or alerts from the app. The primary end point was the change in dyspnea symptom scores from baseline to 4 weeks, assessed using a questionnaire. RESULTS: At 4 weeks, the change in dyspnea symptom score from baseline was significantly greater in the intervention group than in the control group (mean -1.3, SD 2.1 vs mean -0.3, SD 2.3; P=.048). A significant reduction was found in body water composition from baseline to the final measurement in the intervention group (baseline level mean 7.4, SD 2.5 vs final level mean 6.6, SD 2.5; P=.003). App adherence, which was assessed based on log-in or the percentage of days when symptoms were first observed, was higher in the intervention group than in the control group. Composite end points, including death, rehospitalization, and urgent HF visits, were not significantly different between the 2 groups. CONCLUSIONS: The mobile-based health platform with Bluetooth-connected monitoring devices and a feedback system demonstrated improvement in dyspnea symptoms in patients with HF. This study provides evidence and rationale for implementing mobile app-based self-care strategies and feedback for patients with HF. TRIAL REGISTRATION: ClinicalTrials.gov NCT05668000; https://clinicaltrials.gov/study/NCT05668000. CI - (c)Minjae Yoon, Seonhwa Lee, Jah Yeon Choi, Mi-Hyang Jung, Jong-Chan Youn, Chi Young Shim, Jin-Oh Choi, Eung Ju Kim, Hyungseop Kim, Byung-Su Yoo, Yeon Joo Son, Dong-Ju Choi. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 29.04.2024. FAU - Yoon, Minjae AU - Yoon M AUID- ORCID: 0000-0003-4209-655X AD - Division of Cardiology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seognam, Republic of Korea. FAU - Lee, Seonhwa AU - Lee S AUID- ORCID: 0000-0002-1620-795X AD - Division of Cardiology, Department of Internal Medicine, Keimyung University Dongsan Hospital, Daegu, Republic of Korea. FAU - Choi, Jah Yeon AU - Choi JY AUID- ORCID: 0000-0002-6793-4137 AD - Cardiovascular Center, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea. FAU - Jung, Mi-Hyang AU - Jung MH AUID- ORCID: 0000-0003-0224-5178 AD - Division of Cardiology, Department of Internal Medicine, Seoul St. Mary's Hospital, Catholic Research Institute for Intractable Cardiovascular Disease, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. FAU - Youn, Jong-Chan AU - Youn JC AUID- ORCID: 0000-0003-0998-503X AD - Division of Cardiology, Department of Internal Medicine, Seoul St. Mary's Hospital, Catholic Research Institute for Intractable Cardiovascular Disease, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. FAU - Shim, Chi Young AU - Shim CY AUID- ORCID: 0000-0002-6136-0136 AD - Division of Cardiology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea. FAU - Choi, Jin-Oh AU - Choi JO AUID- ORCID: 0000-0002-2441-2267 AD - Cardiac and Vascular Center, Samsung Medical Center, Sungkyunkwan University, Seoul, Republic of Korea. FAU - Kim, Eung Ju AU - Kim EJ AUID- ORCID: 0000-0003-2322-6267 AD - Cardiovascular Center, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea. FAU - Kim, Hyungseop AU - Kim H AUID- ORCID: 0000-0001-7056-4221 AD - Division of Cardiology, Department of Internal Medicine, Keimyung University Dongsan Hospital, Daegu, Republic of Korea. FAU - Yoo, Byung-Su AU - Yoo BS AUID- ORCID: 0000-0002-3395-4279 AD - Department of Internal Medicine, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, Woonju, Republic of Korea. FAU - Son, Yeon Joo AU - Son YJ AUID- ORCID: 0009-0007-4823-7196 AD - Healthcare Business Department, AI/DX Convergence Business Group, KT, Seoul, Republic of Korea. FAU - Choi, Dong-Ju AU - Choi DJ AUID- ORCID: 0000-0003-0146-2189 AD - Division of Cardiology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seognam, Republic of Korea. LA - eng SI - ClinicalTrials.gov/NCT05668000 PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20240429 PL - Canada TA - J Med Internet Res JT - Journal of medical Internet research JID - 100959882 SB - IM MH - Humans MH - *Heart Failure/therapy/physiopathology MH - *Mobile Applications MH - Male MH - Female MH - Aged MH - Middle Aged MH - *Smartphone MH - Prospective Studies MH - Republic of Korea MH - Feedback MH - Telemedicine/methods MH - Self Care/methods/instrumentation MH - Monitoring, Physiologic/methods/instrumentation PMC - PMC11091801 OTO - NOTNLM OT - heart failure OT - mobile applications OT - mobile health OT - mobile phone OT - self-care OT - vital sign monitoring COIS- Conflicts of Interest: None declared. EDAT- 2024/04/29 13:58 MHDA- 2024/04/30 15:57 PMCR- 2024/04/29 CRDT- 2024/04/29 11:54 PHST- 2023/08/22 00:00 [received] PHST- 2024/03/12 00:00 [accepted] PHST- 2023/11/07 00:00 [revised] PHST- 2024/04/30 15:57 [medline] PHST- 2024/04/29 13:58 [pubmed] PHST- 2024/04/29 11:54 [entrez] PHST- 2024/04/29 00:00 [pmc-release] AID - v26i1e52075 [pii] AID - 10.2196/52075 [doi] PST - epublish SO - J Med Internet Res. 2024 Apr 29;26:e52075. doi: 10.2196/52075. PMID- 38682519 OWN - NLM STAT- MEDLINE DCOM- 20240429 LR - 20250514 IS - 1879-8365 (Electronic) IS - 0926-9630 (Linking) VI - 313 DP - 2024 Apr 26 TI - HerzMobil Tirol PreOp - A Multidisciplinary Telemonitoring Project for Heart Failure Patients Prior to Cardiac Surgery. PG - 141-142 LID - 10.3233/SHTI240026 [doi] AB - BACKGROUND: Patients with heart failure are at risk of perioperative complications with elective cardiac surgery. OBJECTIVES: Conception of a multidisciplinary telemedicine-assisted optimisation project for high-risk patients prior to elective cardiac surgery. METHODS: Multidisciplinary concept design. RESULTS: A pilot-project for 30 patients was developed. CONCLUSION: Design of the first preoperative telemonitoring-assisted optimisation project for high-risk patients undergoing cardiac surgery. FAU - Hinterbuchner, Karin AU - Hinterbuchner K AD - Department of Cardiac Surgery, Medical University of Innsbruck, Innsbruck, Austria. FAU - Kleinheinz, Elisabeth AU - Kleinheinz E AD - Tyrolean Federal Institute for Integrated Care, Tirol Kliniken GmbH, Innsbruck, Austria. FAU - Fetz, Bettina AU - Fetz B AD - Tyrolean Federal Institute for Integrated Care, Tirol Kliniken GmbH, Innsbruck, Austria. FAU - Polzl, Leo AU - Polzl L AD - Department of Cardiac Surgery, Medical University of Innsbruck, Innsbruck, Austria. FAU - Holfeld, Johannes AU - Holfeld J AD - Department of Cardiac Surgery, Medical University of Innsbruck, Innsbruck, Austria. FAU - Pfeifer, Bernhard AU - Pfeifer B AD - Department of Clinical Epidemiology, Tirol Kliniken GmbH, Innsbruck, Austria. AD - Division for Digital Health and Telemedicine, UMIT Tirol, Hall i.T., Austria. FAU - Neururer, Sabrina AU - Neururer S AD - Department of Clinical Epidemiology, Tirol Kliniken GmbH, Innsbruck, Austria. AD - Division for Digital Health and Telemedicine, UMIT Tirol, Hall i.T., Austria. FAU - Puelacher, Christian AU - Puelacher C AD - Department of Internal Medicine III, Cardiology and Angiology, Medical University of Innsbruck, Innsbruck, Austria. FAU - Gollmann-Tepekoeylue, Can AU - Gollmann-Tepekoeylue C AD - Department of Cardiac Surgery, Medical University of Innsbruck, Innsbruck, Austria. FAU - Krestan, Susanne AU - Krestan S AD - Tyrolean Federal Institute for Integrated Care, Tirol Kliniken GmbH, Innsbruck, Austria. FAU - Huber, Andreas AU - Huber A AD - Tyrolean Federal Institute for Integrated Care, Tirol Kliniken GmbH, Innsbruck, Austria. FAU - Polzl, Gerhard AU - Polzl G AD - Department of Internal Medicine III, Cardiology and Angiology, Medical University of Innsbruck, Innsbruck, Austria. LA - eng PT - Journal Article PL - Netherlands TA - Stud Health Technol Inform JT - Studies in health technology and informatics JID - 9214582 SB - IM MH - *Heart Failure MH - Humans MH - *Telemedicine MH - *Cardiac Surgical Procedures MH - Preoperative Care/methods MH - Pilot Projects OTO - NOTNLM OT - Health Education OT - Heart Failure OT - Preoperative Care OT - Telemedicine EDAT- 2024/04/29 06:44 MHDA- 2024/04/29 14:03 CRDT- 2024/04/29 05:53 PHST- 2024/04/29 14:03 [medline] PHST- 2024/04/29 06:44 [pubmed] PHST- 2024/04/29 05:53 [entrez] AID - SHTI240026 [pii] AID - 10.3233/SHTI240026 [doi] PST - ppublish SO - Stud Health Technol Inform. 2024 Apr 26;313:141-142. doi: 10.3233/SHTI240026. PMID- 38681722 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260922 IS - 0970-9134 (Print) IS - 0973-7723 (Electronic) IS - 0970-9134 (Linking) VI - 40 IP - 3 DP - 2024 May TI - Selecting the appropriate patients for coronary artery bypass grafting in ischemic cardiomyopathy-importance of myocardial viability. PG - 341-352 LID - 10.1007/s12055-023-01671-9 [doi] AB - Patients who undergo coronary artery bypass graft (CABG) surgery in ischemic cardiomyopathy have a survival advantage over medical therapy at 10 years. The survival advantage of CABG over medical therapy is due to its ability to reduce future myocardial infarction, and by conferring electrical stability. The presence of myocardial viability does not provide a differential survival advantage for CABG over medical therapy. Presence of angina and inducible ischemia are also less predictive of outcome. Moreover, CABG is associated with significant early mortality. Hence, careful patient selection is more important for reducing the early mortality and improving the long-term outcome than relying on results of myocardial viability. Younger patients with good exercise tolerance benefit the most, while patients who are frail and patients with renal dysfunction and dysfunctional right ventricle seem to have very high operative mortality. Elderly patients, because of poor life expectancy, do not benefit from CABG, but the age cutoff is not clear. Patients also need to have revascularizable targets, but this decision is often based on experience of the surgical team and heart team discussion. These recommendations are irrespective of the myocardial viability tests. Optimal medical treatment remains the cornerstone for management of ischemic cardiomyopathy. CI - (c) Indian Association of Cardiovascular-Thoracic Surgeons 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. FAU - Varma, Praveen Kerala AU - Varma PK AUID- ORCID: 0000-0003-3978-2874 AD - Department of Cardiovascular and Thoracic Surgery, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham (Amrita University), Kochi, India. GRID: grid.411370.0. ISNI: 0000 0000 9081 2061 FAU - Radhakrishnan, Rohik Micka AU - Radhakrishnan RM AD - Department of Cardiovascular and Thoracic Surgery, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham (Amrita University), Kochi, India. GRID: grid.411370.0. ISNI: 0000 0000 9081 2061 FAU - Gopal, Kirun AU - Gopal K AUID- ORCID: 0000-0002-9622-4230 AD - Department of Cardiovascular and Thoracic Surgery, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham (Amrita University), Kochi, India. GRID: grid.411370.0. ISNI: 0000 0000 9081 2061 FAU - Krishna, Neethu AU - Krishna N AUID- ORCID: 0000-0002-1834-8086 AD - Department of Cardiovascular and Thoracic Surgery, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham (Amrita University), Kochi, India. GRID: grid.411370.0. ISNI: 0000 0000 9081 2061 FAU - Jose, Rajesh AU - Jose R AUID- ORCID: 0000-0002-2116-2821 AD - Department of Cardiovascular and Thoracic Surgery, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham (Amrita University), Kochi, India. GRID: grid.411370.0. ISNI: 0000 0000 9081 2061 LA - eng PT - Journal Article PT - Review DEP - 20240104 PL - India TA - Indian J Thorac Cardiovasc Surg JT - Indian journal of thoracic and cardiovascular surgery JID - 8700105 PMC - PMC11045715 OTO - NOTNLM OT - CABG OT - Coronary artery bypass grafting OT - Ischemic cardiomyopathy OT - Left ventricular dysfunction OT - STICH trial COIS- Conflict of interestThe authors declare no conflict of interest. EDAT- 2024/04/29 06:44 MHDA- 2024/04/29 06:45 PMCR- 2025/05/01 CRDT- 2024/04/29 04:18 PHST- 2023/08/26 00:00 [received] PHST- 2023/12/19 00:00 [revised] PHST- 2023/12/19 00:00 [accepted] PHST- 2024/04/29 06:45 [medline] PHST- 2024/04/29 06:44 [pubmed] PHST- 2024/04/29 04:18 [entrez] PHST- 2025/05/01 00:00 [pmc-release] AID - 1671 [pii] AID - 10.1007/s12055-023-01671-9 [doi] PST - ppublish SO - Indian J Thorac Cardiovasc Surg. 2024 May;40(3):341-352. doi: 10.1007/s12055-023-01671-9. Epub 2024 Jan 4. PMID- 38679896 OWN - NLM STAT- MEDLINE DCOM- 20240530 LR - 20250115 IS - 1879-0844 (Electronic) IS - 1388-9842 (Linking) VI - 26 IP - 4 DP - 2024 Apr TI - Multidisciplinary care of peripartum heart failure: A scientific statement of the Heart Failure Association of the ESC. PG - 742-753 LID - 10.1002/ejhf.3246 [doi] AB - Heart failure is the most common cardiovascular complication during pregnancy and the postpartum period. It is associated with increased risk of maternal morbidity and mortality as well as potentially life-threatening foetal pathology. Management of heart failure in pregnancy requires expert knowledge of cardiovascular disease as well as obstetrics which underscores the importance of multidisciplinary cardio-obstetrics teams in order to optimize diagnosis, treatment and outcome. This includes counselling of women at risk before and during the course of pregnancy in order to strengthen the relationship between medical specialists and patients, as well as to allow patient-centred delivery of care and improve quality of life. CI - (c) 2024 European Society of Cardiology. FAU - Rakisheva, Amina AU - Rakisheva A AD - Department of Cardiology, City Cardiology Center, Almaty, Kazakhstan. AD - Qonaev City Hospital, Almaty, Kazakhstan. FAU - Sliwa, Karen AU - Sliwa K AD - Cape Heart Institute, Department of Cardiology and Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa. FAU - Bauersachs, Johann AU - Bauersachs J AD - Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany. FAU - Van Linthout, Sophie AU - Van Linthout S AD - Berlin Institute of Health (BIH) at Charite - Universitatmedizin Berlin, BIH Center for Regenerative Therapies (BCRT), Berlin, Germany. AD - German Center for Cardiovascular Research (DZHK), Partner site Berlin, Berlin, Germany. FAU - Chopra, Vijay K AU - Chopra VK AD - Max Superspeciality Hospital, Saket, New Delhi, India. FAU - Bayes-Genis, Antoni AU - Bayes-Genis A AD - CIBERCV, Carlos III Institute of Health, Madrid, Spain. AD - Institut del Cor, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain. AD - Department of Medicine, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Fruzzetti, Franca AU - Fruzzetti F AD - Department of Obstetrics and Gynecology, Pisa University Hospital, Pisa, Italy. FAU - Cannata, Antonio AU - Cannata A AD - King's College London, British Heart Foundation Centre of Research Excellence, School of Cardiovascular Medicine & Sciences, London, UK. FAU - Deniau, Benjamin AU - Deniau B AD - Department of Anesthesiology, Critical Care and Burn Unit, University Hospital Saint-Louis - Lariboisiere, AP-HP, Paris, France. AD - INSERM UMR-S 942, Cardiovascular Markers in Stress Condition (MASCOT), Universite de Paris Cite, Paris, France. AD - Universite de Paris Cite, Paris, France. AD - FHU PROMICE, DMU Parabol, Paris, France. FAU - Mebazaa, Alexandre AU - Mebazaa A AD - Department of Anesthesiology, Critical Care and Burn Unit, University Hospital Saint-Louis - Lariboisiere, AP-HP, Paris, France. AD - INSERM UMR-S 942, Cardiovascular Markers in Stress Condition (MASCOT), Universite de Paris Cite, Paris, France. AD - Universite de Paris Cite, Paris, France. AD - FHU PROMICE, DMU Parabol, Paris, France. FAU - Savarese, Gianluigi AU - Savarese G AD - Department of Medicine, Karolinska Institutet, and Heart and Vascular Theme, Karolinska University Hospital, Stockholm, Sweden. FAU - Ray, Robin AU - Ray R AD - Cardiology Clinical Academic Group, Molecular and Clinical Sciences Research Institute, St George's, University of London, St George's Hospital, London, UK. FAU - Vitale, Cristiana AU - Vitale C AD - Cardiology Clinical Academic Group, Molecular and Clinical Sciences Research Institute, St George's, University of London, St George's Hospital, London, UK. FAU - Metra, Marco AU - Metra M AD - Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy. FAU - Rosano, Giuseppe M C AU - Rosano GMC AD - IRCCS San Raffaele Pisana, Rome, Italy. LA - eng PT - Journal Article PT - Review DEP - 20240428 PL - England TA - Eur J Heart Fail JT - European journal of heart failure JID - 100887595 SB - IM MH - Humans MH - Female MH - *Heart Failure/therapy MH - Pregnancy MH - *Pregnancy Complications, Cardiovascular/therapy MH - *Peripartum Period MH - Patient Care Team MH - Societies, Medical OTO - NOTNLM OT - Counselling OT - Heart failure OT - Multidisciplinary approach OT - Peripartum OT - Pregnancy EDAT- 2024/04/29 06:44 MHDA- 2024/05/30 06:35 CRDT- 2024/04/29 01:23 PHST- 2024/01/22 00:00 [revised] PHST- 2023/08/16 00:00 [received] PHST- 2024/04/04 00:00 [accepted] PHST- 2024/05/30 06:35 [medline] PHST- 2024/04/29 06:44 [pubmed] PHST- 2024/04/29 01:23 [entrez] AID - 10.1002/ejhf.3246 [doi] PST - ppublish SO - Eur J Heart Fail. 2024 Apr;26(4):742-753. doi: 10.1002/ejhf.3246. Epub 2024 Apr 28. PMID- 38673714 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250406 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 13 IP - 8 DP - 2024 Apr 22 TI - The Impact of Shared Assistance between Dermatology and Internal Medicine on Patients with Psoriasis. LID - 10.3390/jcm13082441 [doi] LID - 2441 AB - Background: The care of psoriatic patients requires a multidisciplinary approach that addresses not only skin involvement but also cardiovascular risk factors. Coordination between dermatology and internal medicine departments, with a specific focus on treatment and long-term follow-up, can substantially improve the course of a disease and its associated complications. Objective: to evaluate the effects of the holistic management of patients with psoriasis by a multidisciplinary team consisting of dermatology and internal medicine specialists. Methods: We conducted an observational, prospective, single-center case-control study between October 2016 and December 2019 in San Jorge University Hospital (Huesca, Spain). Cases included patients undergoing follow-up in the combined dermatology and internal medicine clinic. The control group consisted of an equivalent number of randomly selected, age- and sex-matched patients with moderate-to-severe psoriasis who were seen in the general dermatology department of the same hospital during the same time period. Main outcomes and measures: The primary outcome was the control of psoriatic disease and cardiovascular risk factors such as weight, blood pressure, waist circumference, body mass index (BMI), SCORE index (Systematic Coronary Risk Evaluation), and blood test parameters, as well as diet, physical exercise, and habits such as tobacco and alcohol consumption. To compare data collected over time, data were grouped into three time periods: baseline (t1), intermediate (t2), and final (t3). Results: The case group consisted of 27 patients, and the control group consisted of 25 patients. Multivariate analysis was used to evaluate the relationship between the 10-year risk of experiencing a cardiovascular event (SCORE) and the clinical characteristics and analytical variables of patients with psoriasis and controls (n = 52). The variables that were significantly associated with a higher 10-year risk of experiencing a cardiovascular event were age (OR, 1.33; CI95% 1.21-1.50; p < 0.001); smoking (OR, 5.05, CI95% 1.07-27.37; p = 0.047); PASI (OR, 7.98, CI95% 2.32-35.86; p = 0.003); BSA (OR, 1.22, CI95% 1.01-1.49; p = 0.044); and being a control patient (OR, 3.26; CI95% 0.84-13.56; p = 0.029). Conclusions: Pharmacological and behavioral interventions carried out as part of the procedure of the multidisciplinary clinic resulted in improvements in the following variables relative to the control group: PASI, BSA, DLQI, PSOLIFE, lipid profile, insulin and HOMA-IR GGT levels, vitamin D levels, and SCORE. These findings indicate the beneficial effect of the multidisciplinary clinic, which reduced the risk of cardiovascular events in psoriatic patients with metabolic comorbidities. FAU - Garcia-Malinis, Ana Julia AU - Garcia-Malinis AJ AUID- ORCID: 0000-0003-2826-7893 AD - Dermatology Unit, San Jorge University Hospital, 22004 Huesca, Spain. FAU - Perez-Gilaberte, Juan Blas AU - Perez-Gilaberte JB AUID- ORCID: 0000-0002-0547-2600 AD - Department of Internal Medicine, Miguel Servet University Hospital, 50009 Zaragoza, Spain. FAU - Gracia-Cazana, Tamara AU - Gracia-Cazana T AUID- ORCID: 0000-0002-0523-2076 AD - Department of Dermatology, Miguel Servet University Hospital, 50009 Zaragoza, Spain. FAU - Gonzalez Garcia, Maria Pilar AU - Gonzalez Garcia MP AD - Department of Internal Medicine, San Jorge University Hospital, 22004 Huesca, Spain. FAU - Planas Linares, Dolores AU - Planas Linares D AD - Dermatology Unit, San Jorge University Hospital, 22004 Huesca, Spain. FAU - Gilaberte, Yolanda AU - Gilaberte Y AUID- ORCID: 0000-0001-8034-3617 AD - Department of Dermatology, Miguel Servet University Hospital, 50009 Zaragoza, Spain. LA - eng PT - Journal Article DEP - 20240422 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC11051363 OTO - NOTNLM OT - cardiovascular risk OT - comorbidities OT - psoriasis COIS- The authors declare no conflicts of interest. EDAT- 2024/04/27 09:53 MHDA- 2024/04/27 09:54 PMCR- 2024/04/22 CRDT- 2024/04/27 01:12 PHST- 2024/04/03 00:00 [received] PHST- 2024/04/14 00:00 [revised] PHST- 2024/04/16 00:00 [accepted] PHST- 2024/04/27 09:54 [medline] PHST- 2024/04/27 09:53 [pubmed] PHST- 2024/04/27 01:12 [entrez] PHST- 2024/04/22 00:00 [pmc-release] AID - jcm13082441 [pii] AID - jcm-13-02441 [pii] AID - 10.3390/jcm13082441 [doi] PST - epublish SO - J Clin Med. 2024 Apr 22;13(8):2441. doi: 10.3390/jcm13082441. PMID- 38673713 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240429 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 13 IP - 8 DP - 2024 Apr 22 TI - Multidisciplinary Management of Descending Necrotizing Mediastinitis: Is Thoracoscopic Treatment Feasible? LID - 10.3390/jcm13082440 [doi] LID - 2440 AB - Background: Descending necrotizing mediastinitis (DNM) is a life-threatening condition, generally caused by downward dissemination of oropharyngeal infections through cervical fascial planes. Mediastinal drainage is conventionally achieved by thoracotomy, but a Video-Assisted Thoracoscopic Surgery (VATS) approach is gaining interest due to the reduced invasiveness of procedure. We aimed to evaluate the effectiveness of VATS treatment in patients with DNM. Methods: We conducted a retrospective multicenter study including patients with descending mediastinitis that underwent mediastinal drainage through VATS (VATS group) or thoracotomy (thoracotomy group), both in association with cervical drainage. Patients with mediastinitis secondary to cardiac, pulmonary, or esophageal surgery were excluded. The intergroup differences regarding surgical outcome and postoperative morbidity and mortality were compared. Results: A total of 21 patients were treated for descending mediastinitis during the study period. Cervicotomy and thoracotomy were performed in 15 patients (71%), while cervicotomy and VATS were performed in 6 patients (29%). There were no significant differences in surgical outcome, postoperative morbidity, and mortality between groups. VATS treatment was not associated with a higher complication rate. Patients in the VATS group had a shorter operative time (p = 0.016) and shorter ICU stay (p = 0.026). Conclusions: VATS treatment of DNM is safe and effective. The comparison with thoracotomy showed no significant differences in postoperative morbidity and mortality. The VATS approach is associated with a shorter operative time and ICU stay than thoracotomy. FAU - Leonardi, Beatrice AU - Leonardi B AUID- ORCID: 0000-0002-5595-6849 AD - Thoracic Surgery Unit, University of Campania "Luigi Vanvitelli", 80131 Naples, Italy. FAU - Natale, Giovanni AU - Natale G AD - Thoracic Surgery Unit, University of Campania "Luigi Vanvitelli", 80131 Naples, Italy. FAU - Sagnelli, Caterina AU - Sagnelli C AUID- ORCID: 0000-0002-6413-7810 AD - Department of Mental Health and Public Medicine, University of Campania "Luigi Vanvitelli", 80131 Naples, Italy. FAU - Marella, Antonio AU - Marella A AD - Thoracic Surgery Unit, University of Campania "Luigi Vanvitelli", 80131 Naples, Italy. FAU - Leone, Francesco AU - Leone F AD - Thoracic Surgery Unit, University of Campania "Luigi Vanvitelli", 80131 Naples, Italy. FAU - Capasso, Francesca AU - Capasso F AD - Thoracic Surgery Unit, University of Campania "Luigi Vanvitelli", 80131 Naples, Italy. FAU - Giorgiano, Noemi Maria AU - Giorgiano NM AD - Thoracic Surgery Unit, University of Campania "Luigi Vanvitelli", 80131 Naples, Italy. FAU - Pica, Davide Gerardo AU - Pica DG AUID- ORCID: 0000-0002-8203-6562 AD - Thoracic Surgery Unit, University of Campania "Luigi Vanvitelli", 80131 Naples, Italy. FAU - Mirra, Rosa AU - Mirra R AD - Thoracic Surgery Unit, University of Campania "Luigi Vanvitelli", 80131 Naples, Italy. FAU - Di Filippo, Vincenzo AU - Di Filippo V AD - Thoracic Surgery Unit, University of Campania "Luigi Vanvitelli", 80131 Naples, Italy. FAU - Messina, Gaetana AU - Messina G AD - Thoracic Surgery Unit, University of Campania "Luigi Vanvitelli", 80131 Naples, Italy. FAU - Vicidomini, Giovanni AU - Vicidomini G AD - Thoracic Surgery Unit, University of Campania "Luigi Vanvitelli", 80131 Naples, Italy. FAU - Motta, Giovanni AU - Motta G AD - Head and Neck Surgery Unit, University of Campania "Luigi Vanvitelli", 80131 Naples, Italy. FAU - Massimilla, Eva Aurora AU - Massimilla EA AUID- ORCID: 0000-0003-2443-9133 AD - Head and Neck Surgery Unit, University of Campania "Luigi Vanvitelli", 80131 Naples, Italy. FAU - Motta, Gaetano AU - Motta G AD - Head and Neck Surgery Unit, University of Campania "Luigi Vanvitelli", 80131 Naples, Italy. FAU - Rendina, Erino Angelo AU - Rendina EA AD - Thoracic Surgery Unit, Sant'Andrea Hospital, Sapienza University, 00185 Rome, Italy. FAU - Peritone, Valentina AU - Peritone V AD - Thoracic Surgery Unit, Sant'Andrea Hospital, Sapienza University, 00185 Rome, Italy. FAU - Andreetti, Claudio AU - Andreetti C AD - Thoracic Surgery Unit, Sant'Andrea Hospital, Sapienza University, 00185 Rome, Italy. FAU - Fiorelli, Alfonso AU - Fiorelli A AUID- ORCID: 0000-0002-0628-613X AD - Thoracic Surgery Unit, University of Campania "Luigi Vanvitelli", 80131 Naples, Italy. FAU - Sica, Antonello AU - Sica A AUID- ORCID: 0000-0002-8676-4620 AD - Department of Precision Medicine, University of Campania "Luigi Vanvitelli", 80131 Naples, Italy. LA - eng PT - Journal Article DEP - 20240422 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC11051203 OTO - NOTNLM OT - descending necrotizing mediastinitis OT - mediastinitis OT - otolaryngology OT - thoracic surgery COIS- The authors declare no conflicts of interest. EDAT- 2024/04/27 09:53 MHDA- 2024/04/27 09:54 PMCR- 2024/04/22 CRDT- 2024/04/27 01:12 PHST- 2024/03/14 00:00 [received] PHST- 2024/04/06 00:00 [revised] PHST- 2024/04/19 00:00 [accepted] PHST- 2024/04/27 09:54 [medline] PHST- 2024/04/27 09:53 [pubmed] PHST- 2024/04/27 01:12 [entrez] PHST- 2024/04/22 00:00 [pmc-release] AID - jcm13082440 [pii] AID - jcm-13-02440 [pii] AID - 10.3390/jcm13082440 [doi] PST - epublish SO - J Clin Med. 2024 Apr 22;13(8):2440. doi: 10.3390/jcm13082440. PMID- 38672215 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240429 IS - 2227-9059 (Print) IS - 2227-9059 (Electronic) IS - 2227-9059 (Linking) VI - 12 IP - 4 DP - 2024 Apr 13 TI - Dual-Time-Point 18F-FDG PET/CT in Infective Endocarditis: Impact of Delayed Imaging in the Definitive Diagnosis of Endocarditis. LID - 10.3390/biomedicines12040861 [doi] LID - 861 AB - Infective endocarditis (IE) is a major public health condition due to the associated high morbidity and mortality. Our objective was to evaluate the utility of dual-time 2-deoxy-2-[18F] fluoro-D-glucose (18F-FDG) Positron Emission Tomography/Computed Tomography (PET/CT) imaging in the diagnosis of active IE in patients with suspected native valve endocarditis (NVE) and prosthetic valve endocarditis (PVE). For this purpose, a retrospective study was carried out, including patients suspicious of NVE or PVE who underwent a dual-time-point 18F-FDG PET/CT. A final diagnosis was established by the Endocarditis Team after patient follow-up using all the available findings. Sixty-nine patients were assessed. A final diagnosis of NVE was established in 3 patients of the 34 by 18F-FDG PET/CT and in the case of PVE was established in 20 patients of the 35. A statistically significant association was found when evaluating the association between PET diagnosis at early acquisition and final diagnosis of IE (chi(2) = 30.198, p < 0.001) and PET diagnosis at delayed acquisition for final diagnosis of IE (chi(2) = 9.412, p = 0.002). Delayed PET/CT imaging determined the IE diagnosis in 16/58 of the studies. In conclusion, delayed 18F-FDG PET/CT imaging seems to be useful in improving the definitive diagnosis of IE. FAU - Padilla Bermejo, Amanda AU - Padilla Bermejo A AUID- ORCID: 0009-0000-1606-1666 AD - Nuclear Medicine Department, Ciudad Real General University Hospital, 13005 Ciudad Real, Spain. FAU - Pena Pardo, Francisco Jose AU - Pena Pardo FJ AUID- ORCID: 0000-0003-1993-6813 AD - Nuclear Medicine Department, Ciudad Real General University Hospital, 13005 Ciudad Real, Spain. FAU - Noriega-Alvarez, Edel AU - Noriega-Alvarez E AUID- ORCID: 0000-0002-2725-8920 AD - Nuclear Medicine Department, Guadalajara University Hospital, 19002 Guadalajara, Spain. FAU - Amo-Salas, Mariano AU - Amo-Salas M AUID- ORCID: 0000-0002-0956-2531 AD - Mathematics Department, Castilla La Mancha University, 13071 Ciudad Real, Spain. FAU - Sicilia Pozo, Maria de Las Nieves AU - Sicilia Pozo MLN AD - Nuclear Medicine Department, Ciudad Real General University Hospital, 13005 Ciudad Real, Spain. FAU - Garcia Vicente, Ana Maria AU - Garcia Vicente AM AD - Nuclear Medicine Department, Toledo University Hospital, 45007 Toledo, Spain. FAU - Poblete-Garcia, Victor Manuel AU - Poblete-Garcia VM AD - Nuclear Medicine Department, Ciudad Real General University Hospital, 13005 Ciudad Real, Spain. LA - eng PT - Journal Article DEP - 20240413 PL - Switzerland TA - Biomedicines JT - Biomedicines JID - 101691304 PMC - PMC11048229 OTO - NOTNLM OT - PET/CT OT - dual-time-point OT - infective endocarditis OT - native valve OT - prosthetic valve COIS- The authors declare no conflicts of interest. EDAT- 2024/04/27 09:52 MHDA- 2024/04/27 09:53 PMCR- 2024/04/13 CRDT- 2024/04/27 01:04 PHST- 2024/02/07 00:00 [received] PHST- 2024/04/02 00:00 [revised] PHST- 2024/04/10 00:00 [accepted] PHST- 2024/04/27 09:53 [medline] PHST- 2024/04/27 09:52 [pubmed] PHST- 2024/04/27 01:04 [entrez] PHST- 2024/04/13 00:00 [pmc-release] AID - biomedicines12040861 [pii] AID - biomedicines-12-00861 [pii] AID - 10.3390/biomedicines12040861 [doi] PST - epublish SO - Biomedicines. 2024 Apr 13;12(4):861. doi: 10.3390/biomedicines12040861. PMID- 38671711 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241210 IS - 2227-9067 (Print) IS - 2227-9067 (Electronic) IS - 2227-9067 (Linking) VI - 11 IP - 4 DP - 2024 Apr 20 TI - Development of a Standardized Algorithm for Management of Newly Diagnosed Anorectal Malformations. LID - 10.3390/children11040494 [doi] LID - 494 AB - Neonates with a new diagnosis of anorectal malformation (ARM) present a unique challenge to the clinical team. ARM is strongly associated with additional midline malformations, such as those observed in the VACTERL sequence, including vertebral, cardiac, and renal malformations. Timely assessment is necessary to identify anomalies requiring intervention and to prevent undue stress and delayed treatment. We utilized a multidisciplinary team to develop an algorithm guiding the midline workup of patients newly diagnosed with ARM. Patients were included if born in or transferred to our neonatal intensive care unit (NICU), or if seen in clinic within one month of life. Complete imaging was defined as an echocardiogram, renal ultrasound, and spinal magnetic resonance imaging or ultrasound within the first month of life. We compared three periods: prior to implementation (2010-2014), adoption period (2015), and delayed implementation (2022); p 0.05). Multivariate logistic regression showed that FAM-TAPSE Z-score was an independent influencing factor for RDAF (OR = 0.102, p < 0.05). CONCLUSION: RV dysfunction is an independent factor leading to RDAF in EA fetus, which provides a feasible theoretical basis for further study on improvement of RV function through intrauterine treatment to delay and prevent the RDAF, to avoid death cycle and improve live-birth rate. CI - (c) 2024 Wiley Periodicals LLC. FAU - Guo, Xianfeng AU - Guo X AUID- ORCID: 0000-0001-9447-4597 AD - Maternal-Fetal Medicine Center in Fetal Heart Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing, China. FAU - Li, Yilin AU - Li Y AD - Department of Anesthesia, Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, China. FAU - Zhao, Bowen AU - Zhao B AD - Department of Diagnostic Ultrasound and Echocardiography, Sir Run Run Shaw Hospital, Zhejiang University College of Medicine, Hangzhou, Zhejiang, China. FAU - He, Yihua AU - He Y AD - Maternal-Fetal Medicine Center in Fetal Heart Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing, China. LA - eng GR - U21A20523/The National Natural Science Foundation of China/ GR - BZ0308/Beijing Key Laboratory of Maternal-Fetal Medicine in Fetal Heart Disease/ PT - Journal Article DEP - 20240424 PL - United States TA - J Clin Ultrasound JT - Journal of clinical ultrasound : JCU JID - 0401663 SB - IM MH - Humans MH - *Ebstein Anomaly/physiopathology/diagnostic imaging MH - Female MH - Retrospective Studies MH - Pregnancy MH - *Tricuspid Valve/diagnostic imaging/physiopathology/embryology MH - *Ultrasonography, Prenatal/methods MH - Adult MH - Ductus Arteriosus/diagnostic imaging/physiopathology MH - Ventricular Function, Right/physiology MH - Fetal Heart/diagnostic imaging/physiopathology MH - Cohort Studies MH - Systole MH - Echocardiography/methods OTO - NOTNLM OT - Ebstein anomaly OT - ductus arteriosus OT - fetal echocardiography OT - tricuspid annular plane systolic excursion EDAT- 2024/04/24 14:21 MHDA- 2024/07/10 06:42 CRDT- 2024/04/24 05:12 PHST- 2024/04/05 00:00 [revised] PHST- 2023/12/22 00:00 [received] PHST- 2024/04/06 00:00 [accepted] PHST- 2024/07/10 06:42 [medline] PHST- 2024/04/24 14:21 [pubmed] PHST- 2024/04/24 05:12 [entrez] AID - 10.1002/jcu.23695 [doi] PST - ppublish SO - J Clin Ultrasound. 2024 Jul-Aug;52(6):717-722. doi: 10.1002/jcu.23695. Epub 2024 Apr 24. PMID- 38655671 OWN - NLM STAT- MEDLINE DCOM- 20240816 LR - 20250226 IS - 1537-6591 (Electronic) IS - 1058-4838 (Print) IS - 1058-4838 (Linking) VI - 79 IP - 2 DP - 2024 Aug 16 TI - Make Modern Microbiology Matter More in the 2023 European Society of Cardiology Guidelines for the Management of Infective Endocarditis. PG - 336-338 LID - 10.1093/cid/ciae222 [doi] AB - The European Society of Cardiology (ESC) 2023 guidelines for the management of infective endocarditis (IE) stress that a multidisciplinary approach is needed to manage patients with IE. In our view, the guidelines do not include the relevant perspectives from modern microbiology. The diagnostic criteria for IE were changed in the ESC 2023 guidelines, and many IE-causing pathogens are either not clearly defined. Moreover, an improved understanding of the relationship between bacterial species and the risk for IE has not been implemented. The guidelines give detailed and, in our view, incorrect instructions about diagnostic testing in blood culture-negative IE without presenting proper evidence. Other important diagnostic aspects, such as the value of repeated blood cultures and incubation time for blood cultures, are not discussed. We believe that a multidisciplinary collaboration that include microbiologists would have improved these guidelines, and we hope for a future harmonization of diagnostic criteria for IE. CI - (c) The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. FAU - Oldberg, Karl AU - Oldberg K AD - Department of Clinical Sciences, Division of Infection Medicine, Lund University, Lund, Sweden. AD - Department of Clinical Microbiology, Infection Control and Prevention, Office for Medial Services, Lund, Sweden. FAU - Rasmussen, Magnus AU - Rasmussen M AUID- ORCID: 0000-0003-1588-5473 AD - Department of Clinical Sciences, Division of Infection Medicine, Lund University, Lund, Sweden. AD - Division for Infectious Diseases, Skane University Hospital, Lund, Sweden. LA - eng PT - Journal Article PL - United States TA - Clin Infect Dis JT - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America JID - 9203213 SB - IM MH - Humans MH - *Endocarditis/diagnosis/microbiology/therapy MH - Europe MH - *Practice Guidelines as Topic MH - Cardiology/standards MH - Societies, Medical PMC - PMC11327790 OTO - NOTNLM OT - blood culture OT - blood culture negative endocarditis OT - guidelines OT - infective endocarditis OT - microbiology COIS- Potential conflicts of interest. Both authors: No reported conflicts of interest. The authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. EDAT- 2024/04/24 14:20 MHDA- 2024/08/16 13:42 PMCR- 2024/04/24 CRDT- 2024/04/24 04:43 PHST- 2024/02/14 00:00 [received] PHST- 2024/08/16 13:42 [medline] PHST- 2024/04/24 14:20 [pubmed] PHST- 2024/04/24 04:43 [entrez] PHST- 2024/04/24 00:00 [pmc-release] AID - 7657105 [pii] AID - ciae222 [pii] AID - 10.1093/cid/ciae222 [doi] PST - ppublish SO - Clin Infect Dis. 2024 Aug 16;79(2):336-338. doi: 10.1093/cid/ciae222. PMID- 38652393 OWN - NLM STAT- MEDLINE DCOM- 20240604 LR - 20261010 IS - 1875-8312 (Electronic) IS - 1569-5794 (Linking) VI - 40 IP - 5 DP - 2024 May TI - Fetal transposition of the great arteries: 3D virtual and physical models from ultrasound datasets. PG - 1157-1158 LID - 10.1007/s10554-024-03106-x [doi] AB - Transposition of the great arteries (TGA) is a cyanotic congenital heart disease characterized by ventriculoarterial discordance and atrioventricular concordance with the great arteries in a parallel relationship. Prenatal diagnosis of TGA has implications for postnatal outcomes, allowing for planned delivery and perinatal management. Three-dimensional virtual or physical models of fetal TGA allow better understanding of fetal cardiac anomalies by parents and interactive discussion among the multidisciplinary team (obstetricians, pediatricians, maternal-fetal specialists, pediatric cardiologists, and cardiovascular surgeons), as well as continuing medical education. CI - (c) 2024. The Author(s), under exclusive licence to Springer Nature B.V. FAU - Nieblas, Caroline de Oliveira AU - Nieblas CO AUID- ORCID: 0000-0002-8639-5677 AD - Discipline of Woman Health, Municipal University of Sao Caetano do Sul (USCS), Sao Caetano do Sul-SP, Brazil. FAU - Bravo-Valenzuela, Nathalie Jeanne AU - Bravo-Valenzuela NJ AUID- ORCID: 0000-0003-1491-4877 AD - Department of Pediatrics, Pediatric Cardiology, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro-RJ, Brazil. FAU - Araujo Junior, Edward AU - Araujo Junior E AUID- ORCID: 0000-0002-6145-2532 AD - Discipline of Woman Health, Municipal University of Sao Caetano do Sul (USCS), Sao Caetano do Sul-SP, Brazil. araujojred@terra.com.br. AD - Department of Obstetrics, Paulista School of Medicine - Federal University of Sao Paulo (EPM- UNIFESP), Rua Belchior de Azevedo, 156 apto. 111 Torre Vitoria, Sao Paulo-SP, CEP 05089-030, Brazil. araujojred@terra.com.br. FAU - Werner, Heron AU - Werner H AUID- ORCID: 0000-0002-8620-7293 AD - Department of Fetal Medicine, Biodesign Laboratory DASA / PUC, Rio de Janeiro-RJ, Brazil. LA - eng PT - Journal Article PT - Review DEP - 20240423 PL - United States TA - Int J Cardiovasc Imaging JT - The international journal of cardiovascular imaging JID - 100969716 SB - IM MH - *Transposition of Great Vessels/diagnostic imaging/surgery/physiopathology MH - Humans MH - *Ultrasonography, Prenatal MH - *Predictive Value of Tests MH - Pregnancy MH - *Fetal Heart/diagnostic imaging/physiopathology MH - Female MH - Imaging, Three-Dimensional MH - Models, Cardiovascular MH - Gestational Age MH - Patient-Specific Modeling MH - Prognosis MH - Image Interpretation, Computer-Assisted OTO - NOTNLM OT - Prenatal diagnosis OT - Three-dimensional models OT - Three-dimensional ultrasound OT - Transposition of the great arteries EDAT- 2024/04/23 16:23 MHDA- 2024/06/04 06:42 CRDT- 2024/04/23 11:23 PHST- 2024/03/27 00:00 [received] PHST- 2024/04/02 00:00 [accepted] PHST- 2024/06/04 06:42 [medline] PHST- 2024/04/23 16:23 [pubmed] PHST- 2024/04/23 11:23 [entrez] AID - 10.1007/s10554-024-03106-x [pii] AID - 10.1007/s10554-024-03106-x [doi] PST - ppublish SO - Int J Cardiovasc Imaging. 2024 May;40(5):1157-1158. doi: 10.1007/s10554-024-03106-x. Epub 2024 Apr 23. PMID- 38649086 OWN - NLM STAT- MEDLINE DCOM- 20240531 LR - 20241021 IS - 1873-1570 (Electronic) IS - 0300-9572 (Linking) VI - 199 DP - 2024 Jun TI - The association of recent simulation training and clinical experience of team leaders with cardiopulmonary resuscitation quality during in-hospital cardiac arrest. PG - 110217 LID - S0300-9572(24)00110-2 [pii] LID - 10.1016/j.resuscitation.2024.110217 [doi] AB - OBJECTIVE: We aimed to investigate the association of recent team leader simulation training (<6 months) and years of clinical experience (>/=4 years) with chest compression quality during in-hospital cardiac arrest (IHCA). METHODS: This cohort study of IHCA in four Danish hospitals included cases with data on chest compression quality and team leader characteristics. We assessed the impact of recent simulation training and experienced team leaders on longest chest compression pause duration (primary outcome), chest compression fraction (CCF), and chest compression rates within guideline recommendations using mixed effects models. RESULTS: Of 157 included resuscitation attempts, 45% had a team leader who recently participated in simulation training and 66% had an experienced team leader. The median team leader experience was 7 years [Q1; Q3: 4; 11]. The median duration of the longest chest compression pause was 16 s [10; 30]. Having a team leader with recent simulation training was associated with significantly shorter longest pause durations (difference: -7.11 s (95%-CI: -12.0; -2.2), p = 0.004), a higher CCF (difference: 3% (95%-CI: 2.0; 4.0%), p < 0.001) and with less guideline compliant chest compression rates (odds ratio: 0.4 (95%-CI: 0.19; 0.84), p = 0.02). Having an experienced team leader was not associated with longest pause duration (difference: -1.57 s (95%-CI: -5.34; 2.21), p = 0.42), CCF (difference: 0.7% (95%-CI: -0.3; 1.7), p = 0.17) or chest compression rates within guideline recommendations (odds ratio: 1.55 (95%-CI: 0.91; 2.66), p = 0.11). CONCLUSION: Recent simulation training of team leaders, but not years of team leader experience, was associated with shorter chest compression pauses during IHCA. CI - Copyright (c) 2024 The Author(s). Published by Elsevier B.V. All rights reserved. FAU - Wittig, Johannes AU - Wittig J AD - Research Center for Emergency Medicine, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Denmark; Department of Medicine, Randers Regional Hospital, Randers, Denmark. FAU - Lofgren, Bo AU - Lofgren B AD - Research Center for Emergency Medicine, Aarhus University Hospital, Aarhus, Denmark; Department of Medicine, Randers Regional Hospital, Randers, Denmark. FAU - Nielsen, Rasmus P AU - Nielsen RP AD - Department of Anaesthesiology and Intensive Care, Godstrup Hospital, Herning, Denmark. FAU - Hojbjerg, Rikke AU - Hojbjerg R AD - Emergency Department, Aarhus University Hospital, Aarhus, Denmark. FAU - Krogh, Kristian AU - Krogh K AD - Research Center for Emergency Medicine, Aarhus University Hospital, Aarhus, Denmark; Department of Anaesthesiology and Intensive Care, Aarhus University Hospital, Aarhus, Denmark. FAU - Kirkegaard, Hans AU - Kirkegaard H AD - Research Center for Emergency Medicine, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Denmark. FAU - Berg, Robert A AU - Berg RA AD - Department of Anesthesiology and Critical Care Medicine, Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, USA. FAU - Nadkarni, Vinay M AU - Nadkarni VM AD - Department of Anesthesiology and Critical Care Medicine, Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, USA. FAU - Lauridsen, Kasper G AU - Lauridsen KG AD - Research Center for Emergency Medicine, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Denmark; Department of Medicine, Randers Regional Hospital, Randers, Denmark; Department of Anesthesiology and Critical Care Medicine, Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, USA; Department of Anaesthesiology and Intensive Care, Randers Regional Hospital, Randers, Denmark. Electronic address: kglerup@clin.au.dk. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20240420 PL - Ireland TA - Resuscitation JT - Resuscitation JID - 0332173 SB - IM MH - Humans MH - *Cardiopulmonary Resuscitation/education MH - *Heart Arrest/therapy MH - *Simulation Training/methods MH - Female MH - Male MH - *Leadership MH - Aged MH - Clinical Competence MH - Patient Care Team MH - Middle Aged MH - Denmark MH - Guideline Adherence/statistics & numerical data MH - Cohort Studies MH - Heart Massage/methods/standards OTO - NOTNLM OT - Cardiac arrest teams OT - Cardiopulmonary resuscitation OT - Chest compression pauses OT - Chest compression quality OT - Experience OT - In-hospital cardiac arrest OT - Leadership OT - Training COIS- Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: JW serves as the Chair of the Young European Resuscitation Council (ERC). VMN is an executive committee member of ILCOR. He serves on the executive committee of the Society of Critical Care Medicine (SCCM), but the views expressed in this manuscript are his, and are not intended to represent the opinion of the SCCM. VMN & RAB serves as editorial board members of Resuscitation. KGL is a member of the ILCOR Education, Implementation and Teams Task Force, serves as the Young ERC Resuscitation Plus Editor, and is an ERC Advanced Life Support Science and Education Committee member. BL, RPN, RH, KK, HK, and RAB declared no competing interest for this work. EDAT- 2024/04/23 15:04 MHDA- 2024/06/01 10:51 CRDT- 2024/04/22 19:38 PHST- 2024/02/15 00:00 [received] PHST- 2024/04/08 00:00 [revised] PHST- 2024/04/10 00:00 [accepted] PHST- 2024/06/01 10:51 [medline] PHST- 2024/04/23 15:04 [pubmed] PHST- 2024/04/22 19:38 [entrez] AID - S0300-9572(24)00110-2 [pii] AID - 10.1016/j.resuscitation.2024.110217 [doi] PST - ppublish SO - Resuscitation. 2024 Jun;199:110217. doi: 10.1016/j.resuscitation.2024.110217. Epub 2024 Apr 20. PMID- 38644069 OWN - NLM STAT- MEDLINE DCOM- 20240602 LR - 20240815 IS - 1875-2128 (Electronic) IS - 1875-2128 (Linking) VI - 117 IP - 5 DP - 2024 May TI - Management and outcomes of pregnant women with cardiovascular diseases in a cardio-obstetric team. PG - 343-350 LID - S1875-2136(24)00056-1 [pii] LID - 10.1016/j.acvd.2024.02.009 [doi] AB - BACKGROUND: Cardiovascular diseases (CVDs) are currently the leading cause of maternal death in Western countries. Although multidisciplinary cardio-obstetric teams are recommended to improve the management of pregnant women with CVD, data supporting this approach are scarce. AIMS: To describe the characteristics and outcomes of pregnant patients with CVD managed within the cardio-obstetric programme of a tertiary centre. METHODS: We included every pregnant patient with history of CVD managed by our cardio-obstetric team between June 2017 and December 2019, and collected all major cardiovascular events (death, heart failure, acute coronary syndromes, stroke, endocarditis and aortic dissection) that occurred during pregnancy, peripartum and the following year. RESULTS: We included 209 consecutive pregnancies in 202 patients. CVDs were predominantly valvular heart diseases (37.8%), rhythm disorders (26.8%), and adult congenital heart diseases (22.5%). Altogether, 47.4% were classified modified World Health Organization (mWHO)>II, 66.5% had CARdiac disease in PREGnancy score (CARPREG II)>/=2 and 80 pregnancies (38.3%) were delivered by caesarean section. Major cardiovascular events occurred in 16 pregnancies (7.7%, 95% confidence interval [CI] 4.5-12.2) during pregnancy and in three others (1.5%, 95% CI 0.3-4.1) during 1-year follow-up. Most events (63.1%) occurred in the 16.3% of patients with unknown CVD before pregnancy. CONCLUSIONS: The management of pregnant patients with CVD within a cardio-obstetric team seems encouraging as we found a relatively low rate of cardiovascular events compared to the high-risk profile of our population. However, most of the remaining events occurred in patients without cardiac monitoring before pregnancy. CI - Copyright (c) 2024 Elsevier Masson SAS. All rights reserved. FAU - Richardson, Marjorie AU - Richardson M AD - Department of Clinical Physiology and Echocardiography, Heart Valve Clinic, Heart and Lung Institute, Lille University Hospital, Lille, France. Electronic address: Marjorie.richardson@chu-lille.fr. FAU - Bonnet, Jean Philippe AU - Bonnet JP AD - Department of Clinical Physiology and Echocardiography, Heart Valve Clinic, Heart and Lung Institute, Lille University Hospital, Lille, France. FAU - Coulon, Capucine AU - Coulon C AD - Department of Obstetrics, Jeanne-de-Flandre Maternity, Lille University Hospital, Lille, France. FAU - Domanski, Olivia AU - Domanski O AD - Department of Paediatrics and Congenital Heart Diseases, Heart and Lung Institute, Lille University Hospital, Lille, France. FAU - Constans, Benjamin AU - Constans B AD - Department of Anaesthesia, Jeanne-de-Flandre Maternity, Lille University Hospital, Lille, France. FAU - Estevez, Max Gonzalez AU - Estevez MG AD - Department of Anaesthesia, Jeanne-de-Flandre Maternity, Lille University Hospital, Lille, France. FAU - Gautier, Sophie AU - Gautier S AD - Department of Pharmacology, Lille University Hospital, Lille, France. FAU - Marsili, Luisa AU - Marsili L AD - Department of Clinical Genetic, Lille University Hospital, Lille, France. FAU - Hamoud, Yasmine Ould AU - Hamoud YO AD - Department of Obstetrics, Jeanne-de-Flandre Maternity, Lille University Hospital, Lille, France. FAU - Coisne, Augustin AU - Coisne A AD - Department of Clinical Physiology and Echocardiography, Heart Valve Clinic, Heart and Lung Institute, Lille University Hospital, Lille, France; Cardiovascular Research Foundation, New York, NY, USA; Inserm, U1011-EGID, Institut Pasteur de Lille, University of Lille, CHU de Lille, 59000 Lille, France; Faculte de medecine de Lille, universite de Lille, Lille, France; European Genomic Institute for Diabetes (E.G.I.D.), FR 3508, Lille, France. FAU - Ridon, Helene AU - Ridon H AD - Department of Clinical Physiology and Echocardiography, Heart Valve Clinic, Heart and Lung Institute, Lille University Hospital, Lille, France. FAU - Polge, Anne-Sophie AU - Polge AS AD - Department of Clinical Physiology and Echocardiography, Heart Valve Clinic, Heart and Lung Institute, Lille University Hospital, Lille, France. FAU - Mouton, Stephanie AU - Mouton S AD - Department of Clinical Physiology and Echocardiography, Heart Valve Clinic, Heart and Lung Institute, Lille University Hospital, Lille, France. FAU - Haddad, Yasmine AU - Haddad Y AD - Department of Clinical Physiology and Echocardiography, Heart Valve Clinic, Heart and Lung Institute, Lille University Hospital, Lille, France. FAU - Juthier, Francis AU - Juthier F AD - Faculte de medecine de Lille, universite de Lille, Lille, France; Department of Surgery, Heart Valve Clinic, Heart and Lung Institute, Lille University Hospital, Lille, France; Inserm U1011, Institut Pasteur de Lille, Lille, France. FAU - Moussa, Mouhamed AU - Moussa M AD - Department of Anaesthesia, Heart Valve Clinic, Heart and Lung Institute, Lille University Hospital, Lille, France. FAU - Vehier, Claire Mounier AU - Vehier CM AD - Department of Vascular Medicine and Hypertension, Heart and Lung Institute, Lille University Hospital, Lille, France. FAU - Lemesle, Gilles AU - Lemesle G AD - Faculte de medecine de Lille, universite de Lille, Lille, France; Cardiac Intensive Care Unit, Heart and Lung Institute, CHU de Lille, Lille, France; FACT (French Alliance for Cardiovascular Trial), Paris, France. FAU - Schurtz, Guillaume AU - Schurtz G AD - Cardiac Intensive Care Unit, Heart and Lung Institute, CHU de Lille, Lille, France. FAU - Garabedian, Charles AU - Garabedian C AD - Department of Obstetrics, Jeanne-de-Flandre Maternity, Lille University Hospital, Lille, France; Faculte de medecine de Lille, universite de Lille, Lille, France; METRICS, ULR 2694, Assessment of Health Technologies and Medical Practices, Lille, France. FAU - Jourdain, Mercedes AU - Jourdain M AD - Faculte de medecine de Lille, universite de Lille, Lille, France; Intensive Care Unit, CHU de Lille, Lille, France; Inserm U1190, Lille, France. FAU - Ninni, Sandro AU - Ninni S AD - Faculte de medecine de Lille, universite de Lille, Lille, France; European Genomic Institute for Diabetes (E.G.I.D.), FR 3508, Lille, France; Department of Cardiology, Heart and Lung Institute, Lille University Hospital, Lille, France. FAU - Brigadeau, Francois AU - Brigadeau F AD - Department of Cardiology, Heart and Lung Institute, Lille University Hospital, Lille, France. FAU - Montaigne, David AU - Montaigne D AD - Department of Clinical Physiology and Echocardiography, Heart Valve Clinic, Heart and Lung Institute, Lille University Hospital, Lille, France; Inserm, U1011-EGID, Institut Pasteur de Lille, University of Lille, CHU de Lille, 59000 Lille, France; Faculte de medecine de Lille, universite de Lille, Lille, France; European Genomic Institute for Diabetes (E.G.I.D.), FR 3508, Lille, France. FAU - Lamblin, Nicolas AU - Lamblin N AD - Faculte de medecine de Lille, universite de Lille, Lille, France; Cardiac Intensive Care Unit, Heart and Lung Institute, CHU de Lille, Lille, France; Inserm U1167, Institut Pasteur de Lille, Lille, France. FAU - Ghesquiere, Louise AU - Ghesquiere L AD - Department of Obstetrics, Jeanne-de-Flandre Maternity, Lille University Hospital, Lille, France; Faculte de medecine de Lille, universite de Lille, Lille, France; METRICS, ULR 2694, Assessment of Health Technologies and Medical Practices, Lille, France. LA - eng PT - Journal Article PT - Observational Study DEP - 20240412 PL - Netherlands TA - Arch Cardiovasc Dis JT - Archives of cardiovascular diseases JID - 101465655 SB - IM MH - Humans MH - Female MH - Pregnancy MH - *Pregnancy Complications, Cardiovascular/epidemiology/therapy/diagnosis/mortality/physiopathology MH - Adult MH - *Patient Care Team MH - Risk Factors MH - Time Factors MH - Treatment Outcome MH - Delivery of Health Care, Integrated MH - Risk Assessment MH - Retrospective Studies MH - Cardiovascular Diseases/epidemiology/diagnosis/therapy/mortality MH - Young Adult OTO - NOTNLM OT - Adult congenital heart diseases OT - Cardiomyopathy OT - Heart valve diseases OT - Maternal mortality OT - Pregnant women EDAT- 2024/04/22 00:42 MHDA- 2024/06/03 00:42 CRDT- 2024/04/21 21:57 PHST- 2023/12/12 00:00 [received] PHST- 2024/02/24 00:00 [revised] PHST- 2024/02/26 00:00 [accepted] PHST- 2024/06/03 00:42 [medline] PHST- 2024/04/22 00:42 [pubmed] PHST- 2024/04/21 21:57 [entrez] AID - S1875-2136(24)00056-1 [pii] AID - 10.1016/j.acvd.2024.02.009 [doi] PST - ppublish SO - Arch Cardiovasc Dis. 2024 May;117(5):343-350. doi: 10.1016/j.acvd.2024.02.009. Epub 2024 Apr 12. PMID- 38643761 OWN - NLM STAT- MEDLINE DCOM- 20241210 LR - 20260715 IS - 1421-9751 (Electronic) IS - 0008-6312 (Linking) VI - 149 IP - 6 DP - 2024 TI - Current Understanding of Timing of Surgical Repair for Ventricular Septal Rupture following Acute Myocardial Infarction. PG - 618-631 LID - 10.1159/000538967 [doi] AB - BACKGROUND: Ventricular septal rupture (VSR) is a mechanical issue that can occur following an acute myocardial infarction (AMI) and has a high mortality rate. It requires a comprehensive, team-based approach for prompt diagnosis and maintaining stable blood flow. While the occurrence of VSR has lessened over the past hundred years and advancements have been made in treatment techniques, the mortality rate within 30 days can still surpass 40 percent. Surgery is the primary treatment method. For patients with stable blood flow, it is generally considered safer to perform surgery 4-6 weeks after the AMI to repair the VSR. However, the timing of surgery for patients with early instability in their blood flow is still a topic of debate. SUMMARY: There is a lack of set criteria and standards to determine the best time for surgery in patients with VSR following an infarction who have unstable blood flow, especially when considering the use of blood circulation support devices and other techniques for maintaining blood flow that are used in clinical settings. KEY MESSAGES: This review outlines the features of different mechanical circulatory support devices utilized in treating VSR, along with the current scoring system designed to direct the treatment approach for VSR patients. CI - (c) 2024 S. Karger AG, Basel. FAU - Wang, Shilin AU - Wang S AD - Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, wangshilincns@163.com. FAU - Liu, Hao AU - Liu H AD - Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Yang, Peiwen AU - Yang P AD - Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Wang, Zhiwen AU - Wang Z AD - Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Chen, Shu AU - Chen S AD - Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. LA - eng PT - Journal Article PT - Review DEP - 20240423 PL - Switzerland TA - Cardiology JT - Cardiology JID - 1266406 SB - IM MH - Humans MH - *Ventricular Septal Rupture/surgery/etiology MH - *Myocardial Infarction/surgery/complications MH - Time Factors MH - Time-to-Treatment MH - Heart-Assist Devices MH - Cardiac Surgical Procedures/methods/adverse effects OTO - NOTNLM OT - Acute myocardial infarction OT - Cardiac surgery OT - Post-infarction ventricular septal rupture OT - Ventricular septal rupture EDAT- 2024/04/22 00:43 MHDA- 2024/12/11 00:23 CRDT- 2024/04/21 18:23 PHST- 2023/11/02 00:00 [received] PHST- 2024/04/15 00:00 [accepted] PHST- 2024/12/11 00:23 [medline] PHST- 2024/04/22 00:43 [pubmed] PHST- 2024/04/21 18:23 [entrez] AID - 000538967 [pii] AID - 10.1159/000538967 [doi] PST - ppublish SO - Cardiology. 2024;149(6):618-631. doi: 10.1159/000538967. Epub 2024 Apr 23. PMID- 38642459 OWN - NLM STAT- MEDLINE DCOM- 20240422 LR - 20240422 IS - 1488-5581 (Electronic) IS - 1195-9479 (Linking) VI - 31 IP - 2 DP - 2024 Apr TI - Optimizing outcomes in men with prostate cancer: the cardiovascular event lowering (CaELo) pathways. PG - 11820-11825 AB - INTRODUCTION: Risk of cardiovascular disease is higher among men with prostate cancer than men without, and prostate cancer treatments (especially those that are hormonally based) are associated with increased cardiovascular risk. MATERIALS AND METHODS: An 11-member panel of urologic, medical, and radiation oncologists (along with a men's health specialist and an endocrinologist/preventive cardiologist) met to discuss current practices and challenges in the management of cardiovascular risk in prostate cancer patients who are taking androgen deprivation therapies (ADT) including LHRH analogues, alone and in combination with androgen-targeted therapies (ATTs). RESULTS: The panel developed an assessment algorithm to categorize patients by risk and deploy a risk-adapted management strategy, in collaboration with other healthcare providers (the patient's healthcare "village"), with the goal of preventing as well as reducing cardiovascular events. The panel also developed a patient questionnaire for cardiovascular risk as well as a checklist to ensure that all aspects of cardiovascular disease risk reduction are completed and monitored. CONCLUSIONS: Prostate cancer patients receiving ADT with or without ATT need to be more zealously assessed for prevention and aggressively managed to reduce cardiovascular events. This can and should include participation from the entire multidisciplinary healthcare team. FAU - Crawford, David E AU - Crawford DE AD - Department of Urology, University of California San Diego, La Jolla, California, USA. FAU - Albala, David AU - Albala D AD - Department of Urology, Downstate Health Sciences Center, Brooklyn, New York, USA. FAU - Garnick, Marc B AU - Garnick MB AD - Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA. FAU - Hahn, Andrew W AU - Hahn AW AD - Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. FAU - Maroni, Paul AU - Maroni P AD - Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA. FAU - McKay, Rana R AU - McKay RR AD - Department of Urology, Department of Medicine, University of California San Diego, La Jolla, California, USA. FAU - Miner, Martin AU - Miner M AD - Warren Alpert School of Medicine, Brown University, Providence, Rhode Island, USA. FAU - Orio Ⅲ, Peter AU - Orio Ⅲ P AD - Dana-Farber Brigham Cancer Center, Harvard Medical School, Boston, Massachusetts, USA. FAU - Pandit, Kshitij AU - Pandit K AD - Department of Urology, University of California San Diego, La Jolla, California, USA. FAU - Sellinger, Scott AU - Sellinger S AD - Advanced Urology Institute, Tallahassee, Florida, USA. FAU - Yu, Evan Y AU - Yu EY AD - University of Washington, Fred Hutchinson Cancer Center, Seattle, Washington, USA. FAU - Eckel, Robert H AU - Eckel RH AD - Division of Endocrinology, Metabolism, and Diabetes, Anschutz Medical Center, University of Colorado, Denver, Colorado, USA. LA - eng PT - Journal Article PL - United States TA - Can J Urol JT - The Canadian journal of urology JID - 9515842 RN - 0 (Androgen Antagonists) RN - 0 (Androgens) SB - IM MH - Male MH - Humans MH - *Prostatic Neoplasms/drug therapy MH - Androgen Antagonists/adverse effects MH - Androgens MH - *Cardiovascular Diseases/etiology/prevention & control OTO - NOTNLM OT - cardiovascular disease OT - hormonal therapy OT - lifestyle risk reduction OT - prostate cancer OT - risk assessment EDAT- 2024/04/21 00:43 MHDA- 2024/04/22 06:42 CRDT- 2024/04/20 18:03 PHST- 2024/04/22 06:42 [medline] PHST- 2024/04/21 00:43 [pubmed] PHST- 2024/04/20 18:03 [entrez] PST - ppublish SO - Can J Urol. 2024 Apr;31(2):11820-11825. PMID- 31082106 STAT- Publisher CTDT- 20240420 PB - StatPearls Publishing DP - 2024 Jan TI - Tachypnea. BTI - StatPearls AB - Tachypnea refers to rapid breathing, typically defined as a symptom and a focused problem within a medical evaluation. The normal breathing rate for an average adult is 12 to 20 breaths per minute. The number of breaths per minute in children and newborns is higher than the resting rate in adults. (Considering that the demand for oxygen and carbon dioxide (CO2) varies based on size contextualizes these different breathing rates.) Tachypnea is sometimes confused with tachycardia, which defines a high heart rate. Heart rate relates to cardiac output, whereas breathing relates to ventilation, further contextualizing tachypnea. As a symptom, tachypnea is caused by several medical conditions, including acute and chronic. This learning activity aims to consider the etiologies, pathophysiology, and general approach to medical evaluation, incorporating the results of recent studies on manual and technological monitoring. Breathing rate is termed respiratory rate when these new and tested methods obtain a measurement. After a measurement is documented, the interprofessional team may refer to a patient as having a high respiratory rate, interchangeably with tachypnea, depending on the clinical presentation. CI - Copyright (c) 2024, StatPearls Publishing LLC. FAU - Park, Sharon B AU - Park SB FAU - Khattar, Divya AU - Khattar D AD - Cincinnati Children's Hospital Medical Center, Cincinnati, OH LA - eng PT - Study Guide PT - Book Chapter PL - Treasure Island (FL) COIS- Disclosure: Sharon B Park declares no relevant financial relationships with ineligible companies. Disclosure: Divya Khattar declares no relevant financial relationships with ineligible companies. EDAT- 2024/04/20 00:00 CRDT- 2024/04/20 00:00 AID - NBK541062 [bookaccession] PMID- 38640472 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240506 IS - 2561-1011 (Electronic) IS - 2561-1011 (Linking) VI - 8 DP - 2024 Apr 19 TI - A Multidisciplinary Assessment of ChatGPT's Knowledge of Amyloidosis: Observational Study. PG - e53421 LID - 10.2196/53421 [doi] LID - e53421 AB - BACKGROUND: Amyloidosis, a rare multisystem condition, often requires complex, multidisciplinary care. Its low prevalence underscores the importance of efforts to ensure the availability of high-quality patient education materials for better outcomes. ChatGPT (OpenAI) is a large language model powered by artificial intelligence that offers a potential avenue for disseminating accurate, reliable, and accessible educational resources for both patients and providers. Its user-friendly interface, engaging conversational responses, and the capability for users to ask follow-up questions make it a promising future tool in delivering accurate and tailored information to patients. OBJECTIVE: We performed a multidisciplinary assessment of the accuracy, reproducibility, and readability of ChatGPT in answering questions related to amyloidosis. METHODS: In total, 98 amyloidosis questions related to cardiology, gastroenterology, and neurology were curated from medical societies, institutions, and amyloidosis Facebook support groups and inputted into ChatGPT-3.5 and ChatGPT-4. Cardiology- and gastroenterology-related responses were independently graded by a board-certified cardiologist and gastroenterologist, respectively, who specialize in amyloidosis. These 2 reviewers (RG and DCK) also graded general questions for which disagreements were resolved with discussion. Neurology-related responses were graded by a board-certified neurologist (AAH) who specializes in amyloidosis. Reviewers used the following grading scale: (1) comprehensive, (2) correct but inadequate, (3) some correct and some incorrect, and (4) completely incorrect. Questions were stratified by categories for further analysis. Reproducibility was assessed by inputting each question twice into each model. The readability of ChatGPT-4 responses was also evaluated using the Textstat library in Python (Python Software Foundation) and the Textstat readability package in R software (R Foundation for Statistical Computing). RESULTS: ChatGPT-4 (n=98) provided 93 (95%) responses with accurate information, and 82 (84%) were comprehensive. ChatGPT-3.5 (n=83) provided 74 (89%) responses with accurate information, and 66 (79%) were comprehensive. When examined by question category, ChatGTP-4 and ChatGPT-3.5 provided 53 (95%) and 48 (86%) comprehensive responses, respectively, to "general questions" (n=56). When examined by subject, ChatGPT-4 and ChatGPT-3.5 performed best in response to cardiology questions (n=12) with both models producing 10 (83%) comprehensive responses. For gastroenterology (n=15), ChatGPT-4 received comprehensive grades for 9 (60%) responses, and ChatGPT-3.5 provided 8 (53%) responses. Overall, 96 of 98 (98%) responses for ChatGPT-4 and 73 of 83 (88%) for ChatGPT-3.5 were reproducible. The readability of ChatGPT-4's responses ranged from 10th to beyond graduate US grade levels with an average of 15.5 (SD 1.9). CONCLUSIONS: Large language models are a promising tool for accurate and reliable health information for patients living with amyloidosis. However, ChatGPT's responses exceeded the American Medical Association's recommended fifth- to sixth-grade reading level. Future studies focusing on improving response accuracy and readability are warranted. Prior to widespread implementation, the technology's limitations and ethical implications must be further explored to ensure patient safety and equitable implementation. CI - (c)Ryan C King, Jamil S Samaan, Yee Hui Yeo, Yuxin Peng, David C Kunkel, Ali A Habib, Roxana Ghashghaei. Originally published in JMIR Cardio (https://cardio.jmir.org), 19.04.2024. FAU - King, Ryan C AU - King RC AUID- ORCID: 0000-0003-3479-0365 AD - Division of Cardiology, Department of Medicine, University of California, Irvine Medical Center, Orange, CA, United States. FAU - Samaan, Jamil S AU - Samaan JS AUID- ORCID: 0000-0002-6191-2631 AD - Karsh Division of Gastroenterology and Hepatology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, United States. FAU - Yeo, Yee Hui AU - Yeo YH AUID- ORCID: 0000-0002-2703-5954 AD - Karsh Division of Gastroenterology and Hepatology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, United States. FAU - Peng, Yuxin AU - Peng Y AUID- ORCID: 0009-0008-2737-5394 AD - School of Mathematics and Statistics, Xi'an Jiaotong University, Xi'an, China. FAU - Kunkel, David C AU - Kunkel DC AUID- ORCID: 0000-0001-7319-8677 AD - GI Motility and Physiology Program, Division of Gastroenterology, University of California, San Diego, La Jolla, CA, United States. FAU - Habib, Ali A AU - Habib AA AUID- ORCID: 0000-0003-3432-9747 AD - Division of Neurology, University of California, Irvine Medical Center, Orange, CA, United States. FAU - Ghashghaei, Roxana AU - Ghashghaei R AUID- ORCID: 0000-0002-2588-2631 AD - Division of Cardiology, Department of Medicine, University of California, Irvine Medical Center, Orange, CA, United States. LA - eng PT - Journal Article DEP - 20240419 PL - Canada TA - JMIR Cardio JT - JMIR cardio JID - 101718325 PMC - PMC11069089 OTO - NOTNLM OT - ChatGPT OT - Facebook OT - accessibility OT - accuracy OT - amyloidosis OT - amyloidosis-related OT - artificial intelligence OT - assessment OT - cardiologist OT - cardiology OT - dissemination OT - educational resources OT - gastroenterologist OT - gastroenterology OT - institution OT - institutions OT - large language model OT - large language models OT - medical society OT - multidisciplinary care OT - neurologist OT - neurology OT - patient education OT - reliability OT - reproducibility COIS- Conflicts of Interest: RG is a consultant for Pfizer, Alnylam, and AstraZeneca. None of the other authors have interests to disclose. EDAT- 2024/04/19 18:43 MHDA- 2024/04/19 18:44 PMCR- 2024/04/19 CRDT- 2024/04/19 16:53 PHST- 2023/10/10 00:00 [received] PHST- 2024/02/22 00:00 [accepted] PHST- 2024/01/31 00:00 [revised] PHST- 2024/04/19 18:44 [medline] PHST- 2024/04/19 18:43 [pubmed] PHST- 2024/04/19 16:53 [entrez] PHST- 2024/04/19 00:00 [pmc-release] AID - v8i1e53421 [pii] AID - 10.2196/53421 [doi] PST - epublish SO - JMIR Cardio. 2024 Apr 19;8:e53421. doi: 10.2196/53421. PMID- 38634941 OWN - NLM STAT- MEDLINE DCOM- 20240628 LR - 20241008 IS - 1875-8312 (Electronic) IS - 1569-5794 (Print) IS - 1569-5794 (Linking) VI - 40 IP - 6 DP - 2024 Jun TI - Clinical characteristics, imaging findings, management, and outcomes of patients with scimitar syndrome at a tertiary referral healthcare center in Colombia. PG - 1319-1328 LID - 10.1007/s10554-024-03102-1 [doi] AB - Scimitar Syndrome is part of a complex spectrum of congenital cardiovascular anomalies related to anomalous pulmonary venous return. Depending on the extent of involvement, treatment can be either expectant or surgical. Prognosis and survival have been controversial, with some results supporting early surgical management. This research aims to disclose the outcomes and describe the management, clinical and imaging characteristics of patients diagnosed with Scimitar Syndrome treated in a tertiary referral healthcare center. Longitudinal descriptive observational study. The study included all patients diagnosed with scimitar syndrome in our institution between January/2011 and December/2022. A description of the sociodemographic and clinical characteristics, diagnostic tools used, treatment features, and patient outcomes is provided. Eleven patients were included, with a mean age at diagnosis of five years (CI 0-17), six of which were female (54.55%). Nine (81.82%) patients had evidence of a scimitar vein on the chest radiograph, six (54.55%) cardiac dextroposition, six (54.55%) pulmonary hypoplasia, five (45.45%) right pulmonary artery hypoplasia, and three (27.27%) had aortopulmonary collaterals. Four (36.36%) patients had horseshoe lungs, and four (36.36%) had bronchopulmonary sequestration. In the associations, two (18.18%) patients were found to have an atrial septal defect, three (27.27%) ventricular septal defect, and one (9%) had Tetralogy of Fallot. Pulmonary hypertension was demonstrated in two (18.18%) patients. Seven (63.64%) required surgical management to correct the scimitar vein, and two patients died due to unrelated complications. Scimitar syndrome presents diagnostic and treatment challenges, necessitating a multidisciplinary approach for timely care. Chest radiography and CT scans are primary diagnostic tools, with surgical intervention often warranted alongside other heart defects or significant hemodynamic repercussions. Medical management is effective for mild to moderate cases. Long-term patient outcomes remain uncertain due to study limitations, but improved life expectancy is anticipated with ongoing care. CI - (c) 2024. The Author(s). FAU - Aristizabal, Ana M AU - Aristizabal AM AD - Facultad de Ciencias de la Salud, Facultad de Ciencias de la Salud, Universidad Icesi, Cali, Colombia. AD - Departamento materno-infantil, Fundacion Valle del Lili, Cardiologia pediatrica, Cali, Colombia. FAU - Guzman-Serrano, Carlos A AU - Guzman-Serrano CA AD - Centro de Investigaciones Clinicas, Fundacion Valle del Lili, Av. Simon Bolivar - Carrera 98 # 18-49 Cali, Cali, Colombia. carlos.guzman.s@fvl.org.co. FAU - Mondol-Villamil, Nancy Vanessa AU - Mondol-Villamil NV AD - Facultad de Ciencias de la Salud, Facultad de Ciencias de la Salud, Universidad Icesi, Cali, Colombia. FAU - Bolanos-Vallejo, Lina Maria AU - Bolanos-Vallejo LM AD - Facultad de Ciencias de la Salud, Facultad de Ciencias de la Salud, Universidad Icesi, Cali, Colombia. FAU - Mejia-Quinones, Valentina AU - Mejia-Quinones V AD - Facultad de Ciencias de la Salud, Facultad de Ciencias de la Salud, Universidad Icesi, Cali, Colombia. AD - Centro de Investigaciones Clinicas, Fundacion Valle del Lili, Av. Simon Bolivar - Carrera 98 # 18-49 Cali, Cali, Colombia. FAU - Recio-Gomez, Maria Alejandra AU - Recio-Gomez MA AD - Facultad de Ciencias de la Salud, Facultad de Ciencias de la Salud, Universidad Icesi, Cali, Colombia. FAU - Garcia-Pretelt, Enrique Carlos AU - Garcia-Pretelt EC AD - Facultad de Ciencias de la Salud, Facultad de Ciencias de la Salud, Universidad Icesi, Cali, Colombia. FAU - Mejia-Gonzalez, Mauricio AU - Mejia-Gonzalez M AD - Departamento de Radiologia e imagenes Diagnosticas, Fundacion Valle del Lili, Cali, Colombia. FAU - Alvarez, Walter Mosquera AU - Alvarez WM AD - Facultad de Ciencias de la Salud, Facultad de Ciencias de la Salud, Universidad Icesi, Cali, Colombia. AD - Departamento materno-infantil, Fundacion Valle del Lili, Cardiologia pediatrica, Cali, Colombia. FAU - Gutierrez-Gil, Jaiber Alberto AU - Gutierrez-Gil JA AD - Departamento materno-infantil, Fundacion Valle del Lili, Cardiologia pediatrica, Cali, Colombia. LA - eng PT - Journal Article PT - Observational Study DEP - 20240418 PL - United States TA - Int J Cardiovasc Imaging JT - The international journal of cardiovascular imaging JID - 100969716 SB - IM MH - Humans MH - *Scimitar Syndrome/diagnostic imaging/surgery/physiopathology/mortality/therapy MH - Female MH - Male MH - Colombia MH - *Tertiary Care Centers MH - Child, Preschool MH - Child MH - Infant MH - Adolescent MH - *Predictive Value of Tests MH - Treatment Outcome MH - Infant, Newborn MH - Longitudinal Studies MH - Time Factors MH - Retrospective Studies MH - Pulmonary Circulation MH - Cardiac Surgical Procedures PMC - PMC11213797 OTO - NOTNLM OT - Chest radiography OT - Computed tomography OT - Echocardiography OT - Heart disease OT - Magnetic resonance OT - Scimitar syndrome COIS- The authors have no relevant financial or non-financial interests to disclose. No use of any AI or large language model were used during the writing, processing or editing of the present manuscript. EDAT- 2024/04/18 12:43 MHDA- 2024/06/28 12:42 PMCR- 2024/04/18 CRDT- 2024/04/18 11:06 PHST- 2024/03/11 00:00 [received] PHST- 2024/04/02 00:00 [accepted] PHST- 2024/06/28 12:42 [medline] PHST- 2024/04/18 12:43 [pubmed] PHST- 2024/04/18 11:06 [entrez] PHST- 2024/04/18 00:00 [pmc-release] AID - 10.1007/s10554-024-03102-1 [pii] AID - 3102 [pii] AID - 10.1007/s10554-024-03102-1 [doi] PST - ppublish SO - Int J Cardiovasc Imaging. 2024 Jun;40(6):1319-1328. doi: 10.1007/s10554-024-03102-1. Epub 2024 Apr 18. PMID- 38631794 OWN - NLM STAT- MEDLINE DCOM- 20240419 LR - 20240419 IS - 1558-2264 (Electronic) IS - 0733-8651 (Linking) VI - 42 IP - 2 DP - 2024 May TI - Emergencies in Pulmonary Hypertension. PG - 273-278 LID - S0733-8651(24)00021-3 [pii] LID - 10.1016/j.ccl.2024.02.011 [doi] AB - Pulmonary hypertension is a challenging disease entity with various underlying etiologies. The management of patients with pulmonary arterial hypertension (WHO Group 1) remains challenging especially in the critical care setting. With risk of high morbidity and mortality, these patients require a multidisciplinary team approach at a speciality care facility for pulmonary hypertension for comprehensive evaluation and rapid initiation of treatment. For acute decompensated right heart failure, management should concentrate on optimizing preload and after load with use of pulmonary vasodilator therapy. A careful evaluation of specialized situations is required for appropriate treatment response. CI - Copyright (c) 2024 Elsevier Inc. All rights reserved. FAU - Bhattacharya, Sanjeeb AU - Bhattacharya S AD - Section of Heart Failure and Cardiac Transplantation, Cleveland Clinic, 9500 Euclid Avenue, Suite J3-4, Cleveland, OH 44195, USA. Electronic address: BHATTAS3@ccf.org. LA - eng PT - Journal Article PT - Review DEP - 20240323 PL - Netherlands TA - Cardiol Clin JT - Cardiology clinics JID - 8300331 RN - 0 (Vasodilator Agents) SB - IM MH - Humans MH - *Hypertension, Pulmonary MH - Emergencies MH - *Pulmonary Arterial Hypertension MH - Vasodilator Agents/therapeutic use MH - Critical Care MH - *Heart Failure OTO - NOTNLM OT - Critical care OT - Emergencies OT - PAH OT - Pulmonary hypertension EDAT- 2024/04/18 00:45 MHDA- 2024/04/19 06:43 CRDT- 2024/04/17 20:57 PHST- 2024/04/19 06:43 [medline] PHST- 2024/04/18 00:45 [pubmed] PHST- 2024/04/17 20:57 [entrez] AID - S0733-8651(24)00021-3 [pii] AID - 10.1016/j.ccl.2024.02.011 [doi] PST - ppublish SO - Cardiol Clin. 2024 May;42(2):273-278. doi: 10.1016/j.ccl.2024.02.011. Epub 2024 Mar 23. PMID- 38630058 OWN - NLM STAT- MEDLINE DCOM- 20240418 LR - 20250630 IS - 1678-9741 (Electronic) IS - 0102-7638 (Print) IS - 0102-7638 (Linking) VI - 39 IP - 3 DP - 2024 Apr 17 TI - Noncardiac Surgery in Patients with Left Ventricular Assist Devices: A 11-Year Institutional Experience. PG - e20230258 LID - 10.21470/1678-9741-2023-0258 [doi] LID - e20230258 AB - INTRODUCTION: Limited options in the end-stage treatment of heart failure have led to increased use of left ventricular assist devices. For this reason, the rate of non-cardiac surgeries in patients with left ventricular assist devices is also increasing. Our study aims to analyze surgical rate, anesthesia management, and results by reviewing our 11-year experience with patients who underwent non-cardiac surgery receiving left ventricular assist devices support. METHODS: We retrospectively evaluated 57 patients who underwent non-cardiac surgery and 67 non-cardiac surgical procedures among 274 patients who applied between January 2011 and December 2022 and underwent left ventricular assist devices implantation with end-stage heart failure. RESULTS: Fifty (74.6%) patients with left ventricular assist devices admitted to the hospital for non-cardiac surgery were emergency interventions. The most common reasons for admission were general surgery (52.2%), driveline wound revision (22.3%), and neurological surgery (14.9%). This patient group has the highest in-hospital mortality rate (12.8%) and the highest rate of neurological surgery (8.7%). While 70% of the patients who underwent neurosurgery were taken to surgery urgently, the International Normalized Ratio values of these patients were between 3.5 and 4.5 at the time of admission to the emergency department. CONCLUSION: With a perioperative multidisciplinary approach, higher morbidity and mortality risks can be reduced during emergencies and major surgical procedures. FAU - Gunduz, Emel AU - Gunduz E AUID- ORCID: 0000-0002-0306-9770 AD - Department of Anesthesiology and Reanimation, Faculty of Medicine, Akdeniz University, Antalya, Turkey. LA - eng PT - Journal Article DEP - 20240417 PL - Brazil TA - Braz J Cardiovasc Surg JT - Brazilian journal of cardiovascular surgery JID - 101677045 SB - IM MH - Humans MH - Retrospective Studies MH - Hospitals MH - Heart Ventricles MH - *Heart Failure/surgery MH - *Heart-Assist Devices PMC - PMC11021120 OTO - NOTNLM OT - Heart Failure OT - Heart-Assist Devices OT - Hospital Emergency Service OT - Hospital Mortality OT - Retrospective Studies COIS- No conflict of interest. EDAT- 2024/04/17 12:45 MHDA- 2024/04/18 06:43 PMCR- 2024/04/15 CRDT- 2024/04/17 10:45 PHST- 2024/04/18 06:43 [medline] PHST- 2024/04/17 12:45 [pubmed] PHST- 2024/04/17 10:45 [entrez] PHST- 2024/04/15 00:00 [pmc-release] AID - 10.21470/1678-9741-2023-0258 [doi] PST - epublish SO - Braz J Cardiovasc Surg. 2024 Apr 17;39(3):e20230258. doi: 10.21470/1678-9741-2023-0258. PMID- 38629741 OWN - NLM STAT- MEDLINE DCOM- 20240626 LR - 20240626 IS - 1879-0844 (Electronic) IS - 1388-9842 (Linking) VI - 26 IP - 5 DP - 2024 May TI - Long-term efficacy and safety of tailored immunosuppressive therapy in immune-mediated biopsy-proven myocarditis: A propensity-weighted study. PG - 1175-1185 LID - 10.1002/ejhf.3220 [doi] AB - AIMS: Standardized immunosuppressive therapy (IS) had been previously investigated in biopsy-proven (BP) lymphocytic myocarditis with heart failure (HF). This study evaluated efficacy and safety of tailored IS in BP immune-mediated myocarditis, irrespective of histology and clinical presentation. METHODS AND RESULTS: Consecutive BP myocarditis patients treated with long-term tailored IS on top of optimal medical therapy (OMT), were compared with OMT non-IS controls using propensity-score weighting. The primary outcome was a composite of death or heart transplant, the secondary outcome was a composite of biventricular function, New York Heart Association (NYHA) class variation, and relapse. IS was managed by a multidisciplinary Cardioimmunology Team, involved a safety checklist and active patients' education. Ninety-one IS patients were compared with 267 non-IS patients. IS patients more frequently had systemic immune-mediated diseases (35% vs. 9.7%), lower baseline echocardiographic left ventricular ejection fraction (35% vs. 43%), lower right ventricular fractional area change (34% vs. 41%) and higher frequency of active lymphocytic, eosinophilic and giant cell myocarditis (71% vs. 58%, 12% vs. 1.1%, and 6.6% vs. 1.5%, respectively). At 5-year follow up, no difference was observed in the primary outcome (survival rate 93% in IS vs. 87% in non-IS), but IS patients had a higher relapse rate. Thus, IS patients, with a lower biventricular function and a higher risk profile at baseline, presented similar biventricular function and NYHA class to non-IS patients at follow-up. Minor adverse drug reactions occurred in 13% of patients, all resolved with therapy switch. CONCLUSIONS: Prolonged tailored IS is effective and safe in BP immune-mediated myocarditis irrespective of histology and clinical presentation. CI - (c) 2024 European Society of Cardiology. FAU - Caforio, Alida Linda Patrizia AU - Caforio ALP AD - Cardiology, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy. FAU - Giordani, Andrea Silvio AU - Giordani AS AUID- ORCID: 0000-0002-1525-077X AD - Cardiology, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy. FAU - Baritussio, Anna AU - Baritussio A AD - Cardiology, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy. FAU - Marcolongo, Davide AU - Marcolongo D AD - Cardiology, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy. FAU - Vicenzetto, Cristina AU - Vicenzetto C AD - Cardiology, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy. FAU - Tarantini, Giuseppe AU - Tarantini G AD - Cardiology, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy. FAU - Napodano, Massimo AU - Napodano M AD - Cardiology, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy. FAU - Toscano, Giuseppe AU - Toscano G AD - Cardiac Surgery, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy. FAU - Gregori, Dario AU - Gregori D AD - Statistics, Department of Statistical Sciences, University of Padua, Padua, Italy. FAU - Brigiari, Gloria AU - Brigiari G AD - Statistics, Department of Statistical Sciences, University of Padua, Padua, Italy. FAU - Bartolotta, Patrizia AU - Bartolotta P AD - Statistics, Department of Statistical Sciences, University of Padua, Padua, Italy. FAU - Carturan, Elisa AU - Carturan E AD - Cardiovascular Pathology, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy. FAU - De Gaspari, Monica AU - De Gaspari M AD - Cardiovascular Pathology, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy. FAU - Rizzo, Stefania AU - Rizzo S AD - Cardiovascular Pathology, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy. FAU - Basso, Cristina AU - Basso C AD - Cardiovascular Pathology, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy. FAU - Iliceto, Sabino AU - Iliceto S AD - Cardiology, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy. FAU - Marcolongo, Renzo AU - Marcolongo R AD - Cardiology, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy. LA - eng PT - Journal Article DEP - 20240417 PL - England TA - Eur J Heart Fail JT - European journal of heart failure JID - 100887595 RN - 0 (Immunosuppressive Agents) SB - IM MH - Humans MH - *Myocarditis/drug therapy MH - Male MH - Female MH - Middle Aged MH - *Immunosuppressive Agents/therapeutic use MH - *Propensity Score MH - Biopsy/methods MH - Adult MH - Treatment Outcome MH - Retrospective Studies MH - Myocardium/pathology MH - Follow-Up Studies MH - Echocardiography/methods MH - Heart Failure/physiopathology/drug therapy MH - Stroke Volume/physiology OTO - NOTNLM OT - Endomyocardial biopsy OT - Immunosuppressive therapy OT - Myocarditis OT - Systemic immune-mediated disease EDAT- 2024/04/17 12:45 MHDA- 2024/06/26 18:41 CRDT- 2024/04/17 08:15 PHST- 2024/02/15 00:00 [revised] PHST- 2023/11/02 00:00 [received] PHST- 2024/03/12 00:00 [accepted] PHST- 2024/06/26 18:41 [medline] PHST- 2024/04/17 12:45 [pubmed] PHST- 2024/04/17 08:15 [entrez] AID - 10.1002/ejhf.3220 [doi] PST - ppublish SO - Eur J Heart Fail. 2024 May;26(5):1175-1185. doi: 10.1002/ejhf.3220. Epub 2024 Apr 17. PMID- 38629422 OWN - NLM STAT- MEDLINE DCOM- 20240418 LR - 20250416 IS - 1969-6213 (Electronic) IS - 1774-024X (Print) IS - 1774-024X (Linking) VI - 20 IP - 8 DP - 2024 Apr 15 TI - A study of ChatGPT in facilitating Heart Team decisions on severe aortic stenosis. PG - e496-e503 LID - EIJ-D-23-00643 [pii] LID - 10.4244/EIJ-D-23-00643 [doi] AB - BACKGROUND: Multidisciplinary Heart Teams (HTs) play a central role in the management of valvular heart diseases. However, the comprehensive evaluation of patients' data can be hindered by logistical challenges, which in turn may affect the care they receive. AIMS: This study aimed to explore the ability of artificial intelligence (AI), particularly large language models (LLMs), to improve clinical decision-making and enhance the efficiency of HTs. METHODS: Data from patients with severe aortic stenosis presented at HT meetings were retrospectively analysed. A standardised multiple-choice questionnaire, with 14 key variables, was processed by the OpenAI Chat Generative Pre-trained Transformer (GPT)-4. AI-generated decisions were then compared to those made by the HT. RESULTS: This study included 150 patients, with ChatGPT agreeing with the HT's decisions 77% of the time. The agreement rate varied depending on treatment modality: 90% for transcatheter valve implantation, 65% for surgical valve replacement, and 65% for medical treatment. CONCLUSIONS: The use of LLMs offers promising opportunities to improve the HT decision-making process. This study showed that ChatGPT's decisions were consistent with those of the HT in a large proportion of cases. This technology could serve as a failsafe, highlighting potential areas of discrepancy when its decisions diverge from those of the HT. Further research is necessary to solidify our understanding of how AI can be integrated to enhance the decision-making processes of HTs. FAU - Salihu, Adil AU - Salihu A AD - Department of Cardiology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland. FAU - Meier, David AU - Meier D AD - Department of Cardiology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland. FAU - Noirclerc, Nathalie AU - Noirclerc N AD - Department of Cardiology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland. FAU - Skalidis, Ioannis AU - Skalidis I AD - Department of Cardiology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland. FAU - Mauler-Wittwer, Sarah AU - Mauler-Wittwer S AD - Department of Cardiology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland. FAU - Recordon, Frederique AU - Recordon F AD - Department of Cardiology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland. FAU - Kirsch, Matthias AU - Kirsch M AD - Department of Cardiovascular Surgery, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland. FAU - Roguelov, Christan AU - Roguelov C AD - Department of Cardiology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland. FAU - Berger, Alexandre AU - Berger A AD - Department of Cardiology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland. FAU - Sun, Xiaowu AU - Sun X AD - Institute of Mathematics and School of Computer and Communication Sciences, EPFL, Lausanne, Switzerland. FAU - Abbe, Emmanuel AU - Abbe E AD - Institute of Mathematics and School of Computer and Communication Sciences, EPFL, Lausanne, Switzerland. FAU - Marcucci, Carlo AU - Marcucci C AD - Department of Anesthesiology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland. FAU - Rancati, Valentina AU - Rancati V AD - Department of Anesthesiology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland. FAU - Rosner, Lorenzo AU - Rosner L AD - Department of Anesthesiology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland. FAU - Scala, Emanuelle AU - Scala E AD - Department of Anesthesiology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland. FAU - Rotzinger, David C AU - Rotzinger DC AD - Department of Radiology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland. FAU - Humbert, Marc AU - Humbert M AD - Department of Geriatrics, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland. FAU - Muller, Olivier AU - Muller O AD - Department of Cardiology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland. FAU - Lu, Henri AU - Lu H AD - Department of Cardiology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland. AD - Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. FAU - Fournier, Stephane AU - Fournier S AD - Department of Cardiology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland. LA - eng PT - Journal Article DEP - 20240415 PL - France TA - EuroIntervention JT - EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology JID - 101251040 SB - IM MH - Humans MH - Artificial Intelligence MH - Retrospective Studies MH - Heart MH - *Heart Valve Diseases MH - *Aortic Valve Stenosis/surgery PMC - PMC11017225 COIS- The authors have no conflicts of interest to declare in relation to this manuscript. EDAT- 2024/04/17 12:44 MHDA- 2024/04/18 06:44 PMCR- 2025/04/15 CRDT- 2024/04/17 06:12 PHST- 2024/04/18 06:44 [medline] PHST- 2024/04/17 12:44 [pubmed] PHST- 2024/04/17 06:12 [entrez] PHST- 2025/04/15 00:00 [pmc-release] AID - EIJ-D-23-00643 [pii] AID - 10.4244/EIJ-D-23-00643 [doi] PST - epublish SO - EuroIntervention. 2024 Apr 15;20(8):e496-e503. doi: 10.4244/EIJ-D-23-00643. PMID- 38617787 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240416 IS - 2072-1439 (Print) IS - 2077-6624 (Electronic) IS - 2072-1439 (Linking) VI - 16 IP - 3 DP - 2024 Mar 29 TI - Choice of anesthesia technique is associated with earlier hospital discharge and reduced costs after transcatheter transfemoral aortic valve implantation. PG - 1836-1842 LID - 10.21037/jtd-23-1739 [doi] AB - BACKGROUND: Transcatheter aortic valve implantation (TAVI) has become a viable alternative to palliation in patients with severe aortic stenosis. We compared general anesthesia to conscious sedation for TAVI procedures with respect to post operative morbidity, hospital length of stay, and financial burden. METHODS: We conducted a retrospective review of prospectively collected data in patients undergoing transfemoral TAVI procedures from 2012 to 2017. Patients were matched based on age and sex and classed into either general anesthesia or conscious sedation groups respectively. Conscious sedation was provided with a dexmedetomidine infusion, and patients in general anesthesia group received a standard induction, tracheal intubation, and maintenance with sevoflurane. The hospital case costs were compared between the two groups before and after adjustment for inflation. RESULTS: We matched 124 pairs for a total of 248 patients. Both groups were similar with respect to demographic data, past medical history, medications, and intraoperative characteristics. There was no difference in postoperative morbidity and mortality between the two groups. The median hospital length of stay was 5 [interquartile range (IQR): 3, 10] and 7 (IQR: 4, 12) days, P=0.01, and after adjustment for inflation, the total hospital case costs were $48,984 (IQR: $44,802, $61,438) Canadian (CAD) vs. $55,333 (IQR: $46,832, $68,702) CAD, P=0.01, in the conscious sedation and general anesthesia groups, respectively. CONCLUSIONS: Advancements in TAVI technologies, conscious sedation and a collaborative, multidisciplinary team approach reduces overall length of hospital stay and procedure costs. CI - 2024 Journal of Thoracic Disease. All rights reserved. FAU - Luzzi, Carla AU - Luzzi C AD - Department of Anesthesia and Pain Management, Toronto General Hospital, University of Toronto, Toronto, ON, Canada. FAU - Orlov, David AU - Orlov D AD - Department of Anesthesia, Mackenzie Health, Richmond Hill, ON, Canada. FAU - Foley, Karen AU - Foley K AD - Department of Anesthesia and Pain Management, Toronto General Hospital, University of Toronto, Toronto, ON, Canada. FAU - Horlick, Eric AU - Horlick E AD - Division of Cardiology, Toronto General Hospital, University of Toronto, Toronto, ON, Canada. FAU - Osten, Mark AU - Osten M AD - Division of Cardiology, Toronto General Hospital, University of Toronto, Toronto, ON, Canada. FAU - Cusimano, Robert James AU - Cusimano RJ AD - Division of Cardiovascular Surgery, Toronto General Hospital, University of Toronto, Toronto, ON, Canada. FAU - Djaiani, George AU - Djaiani G AD - Department of Anesthesia and Pain Management, Toronto General Hospital, University of Toronto, Toronto, ON, Canada. LA - eng PT - Journal Article DEP - 20240327 PL - China TA - J Thorac Dis JT - Journal of thoracic disease JID - 101533916 PMC - PMC11009576 OTO - NOTNLM OT - Transcatheter aortic valve implantation (TAVI) OT - conscious sedation OT - costs OT - general anesthesia OT - length of stay COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-23-1739/coif). The authors have no conflicts of interest to declare. EDAT- 2024/04/15 06:43 MHDA- 2024/04/15 06:44 PMCR- 2024/03/29 CRDT- 2024/04/15 04:23 PHST- 2023/11/12 00:00 [received] PHST- 2024/01/18 00:00 [accepted] PHST- 2024/04/15 06:44 [medline] PHST- 2024/04/15 06:43 [pubmed] PHST- 2024/04/15 04:23 [entrez] PHST- 2024/03/29 00:00 [pmc-release] AID - jtd-16-03-1836 [pii] AID - 10.21037/jtd-23-1739 [doi] PST - ppublish SO - J Thorac Dis. 2024 Mar 29;16(3):1836-1842. doi: 10.21037/jtd-23-1739. Epub 2024 Mar 27. PMID- 38610866 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240415 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 13 IP - 7 DP - 2024 Apr 3 TI - Evolution of Cardiogenic Shock Management and Development of a Multidisciplinary Team-Based Approach: Ten Years Experience of a Single Center. LID - 10.3390/jcm13072101 [doi] LID - 2101 AB - Background: The management of cardiogenic shock (CS) after ACS has evolved over time, and the development of a multidisciplinary team-based approach has been shown to improve outcomes, although mortality remains high. Methods: All consecutive patients with ACS-CS admitted at our CICU from March 2012 to July 2021 were included in this single-center retrospective study. In 2019, we established a "shock team" consisting of a cardiac intensivist, an interventional cardiologist, an anesthetist, and a cardiac surgeon. The primary outcome was in-hospital mortality. Results: We included 167 patients [males 67%; age 71 (61-80) years] with ischemic CS. The proportion of SCAI shock stages from A to E were 3.6%, 6.6%, 69.4%, 9.6%, and 10.8%, respectively, with a mean baseline serum lactate of 5.2 (3.1-8.8) mmol/L. Sixty-six percent of patients had severe LV dysfunction, and 76.1% needed >/= 1 inotropic drug. Mechanical cardiac support (MCS) was pursued in 91.1% [65% IABP, 23% Impella CP, 4% VA-ECMO]. From March 2012 to July 2021, we observed a significative temporal trend in mortality reduction from 57% to 29% (OR = 0.90, p = 0.0015). Over time, CS management has changed, with a significant increase in Impella catheter use (p = 0.0005) and a greater use of dobutamine and levosimendan (p = 0.015 and p = 0.0001) as inotropic support. In-hospital mortality varied across SCAI shock stages, and the SCAI E profile was associated with a poor prognosis regardless of patient age (OR 28.50, p = 0.039). Conclusions: The temporal trend mortality reduction in CS patients is multifactorial, and it could be explained by the multidisciplinary care developed over the years. FAU - Belfioretti, Leonardo AU - Belfioretti L AD - Intensive Care Unit, Cardiology Department, Azienda Ospedaliero-Universitaria delle Marche, 60126 Ancona, Italy. FAU - Francioni, Matteo AU - Francioni M AUID- ORCID: 0000-0001-7798-1351 AD - Intensive Care Unit, Cardiology Department, Azienda Ospedaliero-Universitaria delle Marche, 60126 Ancona, Italy. FAU - Battistoni, Ilaria AU - Battistoni I AD - Intensive Care Unit, Cardiology Department, Azienda Ospedaliero-Universitaria delle Marche, 60126 Ancona, Italy. FAU - Angelini, Luca AU - Angelini L AD - Intensive Care Unit, Cardiology Department, Azienda Ospedaliero-Universitaria delle Marche, 60126 Ancona, Italy. FAU - Matassini, Maria Vittoria AU - Matassini MV AUID- ORCID: 0000-0002-2443-5370 AD - Intensive Care Unit, Cardiology Department, Azienda Ospedaliero-Universitaria delle Marche, 60126 Ancona, Italy. FAU - Pongetti, Giulia AU - Pongetti G AD - Intensive Care Unit, Cardiology Department, Azienda Ospedaliero-Universitaria delle Marche, 60126 Ancona, Italy. FAU - Shkoza, Matilda AU - Shkoza M AD - Intensive Care Unit, Cardiology Department, Azienda Ospedaliero-Universitaria delle Marche, 60126 Ancona, Italy. FAU - Piangerelli, Luca AU - Piangerelli L AD - Intensive Care Unit, Cardiology Department, Azienda Ospedaliero-Universitaria delle Marche, 60126 Ancona, Italy. FAU - Piva, Tommaso AU - Piva T AD - Intervention Cardiology, Azienda Ospedaliero-Universitaria delle Marche, 60126 Ancona, Italy. FAU - Nicolini, Elisa AU - Nicolini E AUID- ORCID: 0000-0003-2055-5516 AD - Intervention Cardiology, Azienda Ospedaliero-Universitaria delle Marche, 60126 Ancona, Italy. FAU - Maolo, Alessandro AU - Maolo A AD - Intervention Cardiology, Azienda Ospedaliero-Universitaria delle Marche, 60126 Ancona, Italy. FAU - Mucaj, Andi AU - Mucaj A AD - Intervention Cardiology, Azienda Ospedaliero-Universitaria delle Marche, 60126 Ancona, Italy. FAU - Compagnucci, Paolo AU - Compagnucci P AUID- ORCID: 0000-0003-1924-6548 AD - Cardiology and Arrhythmology Clinic, Azienda Ospedaliero-Universitaria delle Marche, 60126 Ancona, Italy. FAU - Munch, Christopher AU - Munch C AD - Cardiac Anaesthesia and Intensive Care Unit, Azienda Ospedaliero-Universitaria delle Marche, 60126 Ancona, Italy. FAU - Dello Russo, Antonio AU - Dello Russo A AD - Cardiology and Arrhythmology Clinic, Azienda Ospedaliero-Universitaria delle Marche, 60126 Ancona, Italy. FAU - Di Eusanio, Marco AU - Di Eusanio M AD - Cardiac Surgery Unit, Azienda Ospedaliero-Universitaria delle Marche, 60126 Ancona, Italy. FAU - Marini, Marco AU - Marini M AUID- ORCID: 0000-0003-2165-556X AD - Intensive Care Unit, Cardiology Department, Azienda Ospedaliero-Universitaria delle Marche, 60126 Ancona, Italy. LA - eng PT - Journal Article DEP - 20240403 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC11012883 OTO - NOTNLM OT - acute cardiovascular syndrome OT - acute heart failure OT - cardiogenic shock OT - mechanical cardiac support OT - multidisciplinary team COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2024/04/13 10:43 MHDA- 2024/04/13 10:44 PMCR- 2024/04/03 CRDT- 2024/04/13 01:04 PHST- 2024/03/11 00:00 [received] PHST- 2024/03/25 00:00 [revised] PHST- 2024/03/29 00:00 [accepted] PHST- 2024/04/13 10:44 [medline] PHST- 2024/04/13 10:43 [pubmed] PHST- 2024/04/13 01:04 [entrez] PHST- 2024/04/03 00:00 [pmc-release] AID - jcm13072101 [pii] AID - jcm-13-02101 [pii] AID - 10.3390/jcm13072101 [doi] PST - epublish SO - J Clin Med. 2024 Apr 3;13(7):2101. doi: 10.3390/jcm13072101. PMID- 38607883 OWN - NLM STAT- MEDLINE DCOM- 20240415 LR - 20260527 IS - 0974-5181 (Electronic) IS - 0971-9784 (Print) IS - 0971-9784 (Linking) VI - 27 IP - 2 DP - 2024 Apr 1 TI - Pecto-intercostal Fascial Plane Block: A Novel Technique for Analgesia in Patients with Sternal Dehiscence. PG - 169-174 LID - 10.4103/aca.aca_107_23 [doi] AB - Sternal wound complications following sternotomy need a multidisciplinary approach in high-risk postoperative cardiac surgical patients. Poorly controlled pain during surgical management of such wounds increases cardiovascular stress and respiratory complications. Multimodal analgesia including intravenous opioids, non-opioid analgesics, and regional anesthesia techniques, like central neuraxial blocks and fascial plane blocks, have been described. Pecto-intercostal fascial plane block (PIFB), a novel technique, has been effectively used in patients undergoing cardiac surgery. Under ultrasound (US) guidance PIFB is performed with the aim of depositing local anesthetic between two superficial muscles, namely the pectoralis major muscle and the external intercostal muscle. The authors report a series of five cases where US-guided bilateral PIFB was used in patients undergoing sternal wound debridement. Patients had excellent analgesia intraoperatively as well as postoperatively for 24 hours with minimal requirement of supplemental analgesia. None of the patients experienced complications due to PIFB administration. The authors concluded that bilateral PIFB can be effectively used as an adjunct to multimodal analgesia with general anesthesia and as a sole anesthesia technique in selected cases of sternal wound debridement. CI - Copyright (c) 2024 Copyright: (c) 2024 Annals of Cardiac Anaesthesia. FAU - Joshi, Pooja AU - Joshi P AD - Department of Cardiac Anaesthesia, Ozone Anaesthesia Group, Aurangabad, Maharashtra, India. FAU - Borde, Deepak AU - Borde D AD - Department of Cardiac Anaesthesia, Ozone Anaesthesia Group, Aurangabad, Maharashtra, India. FAU - Apsingekar, Pramod AU - Apsingekar P AD - Department of Cardiac Anaesthesia, Ozone Anaesthesia Group, Aurangabad, Maharashtra, India. FAU - Pande, Swati AU - Pande S AD - Department of Cardiac Anaesthesia, Ozone Anaesthesia Group, Aurangabad, Maharashtra, India. FAU - Tandale, Mangesh AU - Tandale M AD - Department of Plastic Surgery, CARE CIIGMA Hospital, Shahnoorwadi, Aurangabad, Maharashtra, India. FAU - Deodhar, Anand AU - Deodhar A AD - Department of Cardiovascular and Thoracic Surgery, CARE CIIGMA Hospital, Shahnoorwadi, Aurangabad, Maharashtra, India. FAU - Jangle, Sachin AU - Jangle S AD - Department of Plastic Surgery, CARE CIIGMA Hospital, Shahnoorwadi, Aurangabad, Maharashtra, India. LA - eng PT - Journal Article DEP - 20240412 PL - India TA - Ann Card Anaesth JT - Annals of cardiac anaesthesia JID - 9815987 SB - IM MH - Humans MH - Pain Management MH - *Analgesia MH - Sternum/surgery MH - *Anesthesia, Conduction MH - Pain PMC - PMC11095774 COIS- There are no conflicts of interest. EDAT- 2024/04/12 18:42 MHDA- 2024/04/15 06:44 PMCR- 2024/04/01 CRDT- 2024/04/12 12:37 PHST- 2023/07/06 00:00 [received] PHST- 2023/11/23 00:00 [accepted] PHST- 2024/04/15 06:44 [medline] PHST- 2024/04/12 18:42 [pubmed] PHST- 2024/04/12 12:37 [entrez] PHST- 2024/04/01 00:00 [pmc-release] AID - 00660469-202427020-00015 [pii] AID - ACA-27-169 [pii] AID - 10.4103/aca.aca_107_23 [doi] PST - ppublish SO - Ann Card Anaesth. 2024 Apr 1;27(2):169-174. doi: 10.4103/aca.aca_107_23. Epub 2024 Apr 12. PMID- 38606844 OWN - NLM STAT- MEDLINE DCOM- 20240628 LR - 20240628 IS - 1522-9645 (Electronic) IS - 0195-668X (Linking) VI - 45 IP - 24 DP - 2024 Jun 28 TI - Rising standards and applying guidelines in sub-Saharan cardiology: CardioTan 2024 Heart Team Africa. PG - 2112-2113 LID - 10.1093/eurheartj/ehae181 [doi] FAU - Kimambo, Delila AU - Kimambo D AD - Department of Cardiology, Jakaya Kikwete Cardiac Institute, Dar es Salaam, Tanzania. FAU - Guzik, Bartlomiej AU - Guzik B AUID- ORCID: 0000-0002-0630-8394 AD - Department of Interventional Cardiology, Jagiellonian University Medical College, ul.Pradnicka 80, 31-202 Krakow, Poland. AD - Jagiellonian Center for Humanitarian Medicine, ul. Sw. Anny 12, 31-008 Krakow, Poland. FAU - Kisenge, Peter AU - Kisenge P AD - Department of Cardiology, Jakaya Kikwete Cardiac Institute, Dar es Salaam, Tanzania. LA - eng PT - Journal Article PL - England TA - Eur Heart J JT - European heart journal JID - 8006263 SB - IM MH - Humans MH - Africa South of the Sahara MH - *Cardiology/standards MH - *Practice Guidelines as Topic EDAT- 2024/04/12 12:43 MHDA- 2024/06/28 18:42 CRDT- 2024/04/12 08:02 PHST- 2024/06/28 18:42 [medline] PHST- 2024/04/12 12:43 [pubmed] PHST- 2024/04/12 08:02 [entrez] AID - 7644658 [pii] AID - 10.1093/eurheartj/ehae181 [doi] PST - ppublish SO - Eur Heart J. 2024 Jun 28;45(24):2112-2113. doi: 10.1093/eurheartj/ehae181. PMID- 38599719 OWN - NLM STAT- MEDLINE DCOM- 20240412 LR - 20260616 IS - 1558-3597 (Electronic) IS - 0735-1097 (Linking) VI - 83 IP - 15 DP - 2024 Apr 16 TI - Recent Insights Into Native Valve Infective Endocarditis: JACC Focus Seminar 4/4. PG - 1431-1443 LID - S0735-1097(24)00401-7 [pii] LID - 10.1016/j.jacc.2023.12.043 [doi] AB - This focused review highlights the latest issues in native valve infective endocarditis. Native valve disease moderately increases the risk of developing infective endocarditis. In 2023, new diagnostic criteria were published by the Duke-International Society of Cardiovascular Infectious Diseases group. New pathogens were designated as typical, and findings on computed tomography imaging were included as diagnostic criteria. It is now recognized that a multidisciplinary approach to care is vital, and the role of an "endocarditis team" is highlighted. Recent studies have suggested that a transition from intravenous to oral antibiotics in selected patients may be reasonable, and the role of long-acting antibiotics is discussed. It is also now clear that an aggressive surgical approach can be life-saving in some patients. Finally, results of several recent studies have suggested there is an association between dental and other invasive procedures and an increased risk of developing infective endocarditis. Moreover, data indicate that antibiotic prophylaxis may be effective in some scenarios. CI - Copyright (c) 2024 American College of Cardiology Foundation. All rights reserved. FAU - Dayer, Mark J AU - Dayer MJ AD - Cardiovascular Research Institute, Mater Private Network, Dublin, Ireland; Faculty of Health, University of Plymouth, Plymouth, United Kingdom. Electronic address: mark.dayer@materprivate.ie. FAU - Quintero-Martinez, Juan A AU - Quintero-Martinez JA AD - Department of Internal Medicine, University of Miami Miller School of Medicine, Jackson Memorial Hospital, Miami, Florida, USA. FAU - Thornhill, Martin H AU - Thornhill MH AD - Department of Oral and Maxillofacial Medicine, Surgery and Pathology, School of Clinical Dentistry, University of Sheffield, Sheffield, United Kingdom. FAU - Chambers, John B AU - Chambers JB AD - Emeritus Professor of Clinical Cardiology at Guy's and St Thomas' NHS Trust, London, United Kingdom, and Kings College, London, United Kingdom. FAU - Pettersson, Gosta B AU - Pettersson GB AD - Cleveland Clinic, Cleveland, Ohio, USA. FAU - Baddour, Larry M AU - Baddour LM AD - Department of Medicine and Department of Cardiovascular Medicine, Division of Public Health, Infectious Diseases and Occupational Health, Mayo Clinic, Rochester, Minnesota, USA. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review PL - United States TA - J Am Coll Cardiol JT - Journal of the American College of Cardiology JID - 8301365 RN - 0 (Anti-Bacterial Agents) RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18) SB - IM MH - Humans MH - *Endocarditis/diagnosis/etiology MH - *Endocarditis, Bacterial/diagnosis MH - Tomography, X-Ray Computed MH - Anti-Bacterial Agents/therapeutic use MH - Antibiotic Prophylaxis MH - *Heart Valve Prosthesis/adverse effects MH - Fluorodeoxyglucose F18 MH - Positron Emission Tomography Computed Tomography/methods OTO - NOTNLM OT - 18F-fluorodeoxyglucose positron emission tomography-computed tomography OT - cardiac computed tomography OT - diagnostic criteria OT - endocarditis team OT - infective endocarditis COIS- Funding Support and Author Disclosures Dr Dayer has received payment for expert testimony from Bevan Brittan. Dr Thornhill has received grant support from the National Institutes for Health, Delta Dental of Michigan Research and Data Institute's Research Committee, and Renaissance Health Service Corporation. Dr Baddour has received consulting fees from Boston Scientific and Roivant Sciences; and has received royalty payments from UpToDate, Inc. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2024/04/11 00:42 MHDA- 2024/04/12 06:44 CRDT- 2024/04/10 20:57 PHST- 2023/09/22 00:00 [received] PHST- 2023/11/27 00:00 [revised] PHST- 2023/12/05 00:00 [accepted] PHST- 2024/04/12 06:44 [medline] PHST- 2024/04/11 00:42 [pubmed] PHST- 2024/04/10 20:57 [entrez] AID - S0735-1097(24)00401-7 [pii] AID - 10.1016/j.jacc.2023.12.043 [doi] PST - ppublish SO - J Am Coll Cardiol. 2024 Apr 16;83(15):1431-1443. doi: 10.1016/j.jacc.2023.12.043. PMID- 38594127 OWN - NLM STAT- MEDLINE DCOM- 20240810 LR - 20250204 IS - 1444-2892 (Electronic) IS - 1443-9506 (Linking) VI - 33 IP - 8 DP - 2024 Aug TI - Successful Implementation of Enhanced Recovery After Surgery (ERAS) in Paediatric Cardiac Surgery in Australia. PG - 1201-1208 LID - S1443-9506(24)00063-5 [pii] LID - 10.1016/j.hlc.2024.01.029 [doi] AB - BACKGROUND & AIM: Fast-track or enhanced recovery after surgery (ERAS) is a care pathway for surgical patients based on a multidisciplinary team approach aimed at optimising recovery without increasing risk with protocols based on scientific evidence, which is monitored continuously to ensure compliance and improvement. These protocols have been shown to reduce the duration of postoperative mechanical ventilation and intensive care unit (ICU) length of stay (LOS) following paediatric cardiac surgery. We present the first structured implementation of ERAS in paediatric cardiac surgery in Australia. METHODS: All patients enrolled in the ERAS pathway between October 2019 and July 2023 were identified. Demographic and perioperative data were collected retrospectively from hospital records for patients operated before June 2021 and prospectively from June 2021. A control group (non-ERAS) was identified using propensity matching from patients who underwent similar procedures and were not enrolled in the ERAS pathway (prior to October 2019). Patients were matched for age, weight, and comprehensive Aristotle score. Outcomes of interest were duration of postoperative mechanical ventilation, ICU LOS, readmission to the ICU, hospital LOS, cardiac reintervention rate, postoperative complication rate, and number of 30-day readmissions. RESULTS: Of 1,084 patients who underwent cardiac surgery during the study period (October 2019-July 2023), 121 patients (11.2%) followed the ERAS pathway. The median age at the time of surgery was 4.8 years (interquartile range [IQR] 2.8-8.8 years). The most common procedure was the closure of atrial septal defect (n=58, 47.9%). The median cardiopulmonary bypass and cross-clamp times were 40 min (IQR 28-53.5 minutes) and 24.5 min (IQR 13-34 minutes) respectively. The majority were extubated in the operating theatre (n=108, 89.3%). The median ICU and hospital LOS were 4.5 hrs (IQR 4.1-5.6 hours) and 4 days (IQR 4-5 days) respectively. None of the patients required readmission to the ICU within 24 hrs of discharge from the ICU. Three (3) patients (2.5%) required reintervention. When compared with the non-ERAS group, the duration of postoperative mechanical ventilation, ICU and hospital LOS were significantly lower in the ERAS group. There was no significant difference in the ICU readmission rate, reintervention rate, complication rate, and number of 30-day readmissions between both groups. CONCLUSIONS: ERAS after paediatric cardiac surgery is feasible and safe in select patients with low preoperative risk. This pathway reduces the duration of postoperative mechanical ventilation, ICU and hospital LOS without increasing risks, enabling the optimisation of resources. CI - Copyright (c) 2024 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights reserved. FAU - Andugala, Shalom AU - Andugala S AD - Queensland Paediatric Cardiac Service, Queensland Children's Hospital, South Brisbane, Qld, Australia; Queensland Paediatric Cardiac Research, Centre for Children's Health Research, South Brisbane, Qld, Australia; School of Clinical Medicine, Children's Health Queensland Clinical Unit, University of Queensland, Brisbane, Qld, Australia. FAU - McIntosh, Amy AU - McIntosh A AD - Queensland Paediatric Cardiac Service, Queensland Children's Hospital, South Brisbane, Qld, Australia. FAU - Orchard, Jennifer AU - Orchard J AD - Queensland Paediatric Cardiac Service, Queensland Children's Hospital, South Brisbane, Qld, Australia. FAU - Rahiman, Sarfaraz AU - Rahiman S AD - Department of Paediatric Intensive Care Medicine, Queensland Children's Hospital, South Brisbane, Qld, Australia. FAU - Miedecke, Anna AU - Miedecke A AD - Department of Anaesthesia and Pain Management, Queensland Children's Hospital, South Brisbane, Qld, Australia. FAU - Keyser, Janelle AU - Keyser J AD - Department of Anaesthesia and Pain Management, Queensland Children's Hospital, South Brisbane, Qld, Australia. FAU - Betts, Kim AU - Betts K AD - School of Population Health, Curtin University, Perth, WA, Australia. FAU - Marathe, Supreet AU - Marathe S AD - Queensland Paediatric Cardiac Service, Queensland Children's Hospital, South Brisbane, Qld, Australia; Queensland Paediatric Cardiac Research, Centre for Children's Health Research, South Brisbane, Qld, Australia; School of Clinical Medicine, Children's Health Queensland Clinical Unit, University of Queensland, Brisbane, Qld, Australia. FAU - Alphonso, Nelson AU - Alphonso N AD - Queensland Paediatric Cardiac Service, Queensland Children's Hospital, South Brisbane, Qld, Australia; Queensland Paediatric Cardiac Research, Centre for Children's Health Research, South Brisbane, Qld, Australia; School of Clinical Medicine, Children's Health Queensland Clinical Unit, University of Queensland, Brisbane, Qld, Australia. FAU - Venugopal, Prem AU - Venugopal P AD - Queensland Paediatric Cardiac Service, Queensland Children's Hospital, South Brisbane, Qld, Australia; Queensland Paediatric Cardiac Research, Centre for Children's Health Research, South Brisbane, Qld, Australia; School of Clinical Medicine, Children's Health Queensland Clinical Unit, University of Queensland, Brisbane, Qld, Australia. Electronic address: prem.venugopal@health.qld.gov.au. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20240408 PL - Australia TA - Heart Lung Circ JT - Heart, lung & circulation JID - 100963739 SB - IM MH - Humans MH - *Cardiac Surgical Procedures/methods MH - Male MH - Female MH - *Enhanced Recovery After Surgery MH - Australia MH - Retrospective Studies MH - Child, Preschool MH - Infant MH - Length of Stay/statistics & numerical data MH - Postoperative Complications/epidemiology MH - Child MH - Heart Defects, Congenital/surgery MH - Follow-Up Studies MH - Respiration, Artificial/statistics & numerical data OTO - NOTNLM OT - ERAS OT - Enhanced recovery OT - Fast-track OT - Paediatric cardiac surgery COIS- Conflict of Interest There are no conflicts of interest to disclose. EDAT- 2024/04/10 00:43 MHDA- 2024/08/11 04:43 CRDT- 2024/04/09 22:01 PHST- 2023/12/08 00:00 [received] PHST- 2024/01/20 00:00 [revised] PHST- 2024/01/22 00:00 [accepted] PHST- 2024/08/11 04:43 [medline] PHST- 2024/04/10 00:43 [pubmed] PHST- 2024/04/09 22:01 [entrez] AID - S1443-9506(24)00063-5 [pii] AID - 10.1016/j.hlc.2024.01.029 [doi] PST - ppublish SO - Heart Lung Circ. 2024 Aug;33(8):1201-1208. doi: 10.1016/j.hlc.2024.01.029. Epub 2024 Apr 8. PMID- 38592571 OWN - NLM STAT- MEDLINE DCOM- 20240529 LR - 20250112 IS - 1534-3170 (Electronic) IS - 1523-3782 (Print) IS - 1523-3782 (Linking) VI - 26 IP - 5 DP - 2024 May TI - Caring for the Critically Ill Adult Congenital Heart Disease Patient. PG - 283-291 LID - 10.1007/s11886-024-02034-5 [doi] AB - PURPOSE OF REVIEW: This review aims to discuss the unique challenges that adult congenital heart disease (ACHD) patients present in the intensive care unit. RECENT FINDINGS: Recent studies suggest that ACHD patients make up an increasing number of ICU admissions, and that their care greatly improves in centers with specialized ACHD care. Common reasons for admission include arrhythmia, hemorrhage, heart failure, and pulmonary disease. It is critical that the modern intensivist understand not only the congenital anatomy and subsequent repairs an ACHD patient has undergone, but also how that anatomy can predispose the patient to critical illness. Additionally, intensivists should rely on a multidisciplinary team, which includes an ACHD specialist, in the care of these patients. CI - (c) 2024. The Author(s). FAU - Das, Thomas AU - Das T AD - Heart, Vascular and Thoracic Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH, 44195, USA. FAU - Rampersad, Penelope AU - Rampersad P AD - Heart, Vascular and Thoracic Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH, 44195, USA. FAU - Ghobrial, Joanna AU - Ghobrial J AUID- ORCID: 0000-0003-2596-1935 AD - Heart, Vascular and Thoracic Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH, 44195, USA. ghobrij@ccf.org. LA - eng PT - Journal Article PT - Review DEP - 20240409 PL - United States TA - Curr Cardiol Rep JT - Current cardiology reports JID - 100888969 SB - IM MH - Humans MH - *Heart Defects, Congenital/therapy MH - *Critical Illness MH - Adult MH - *Critical Care MH - Intensive Care Units MH - Patient Care Team PMC - PMC11136725 OTO - NOTNLM OT - Adult congenital heart disease OT - Critical care cardiology OT - Intensive care OT - Mechanical circulatory support COIS- The authors declare that they have no conflict of interest. EDAT- 2024/04/09 12:42 MHDA- 2024/05/29 12:45 PMCR- 2024/04/09 CRDT- 2024/04/09 11:19 PHST- 2024/02/21 00:00 [accepted] PHST- 2024/05/29 12:45 [medline] PHST- 2024/04/09 12:42 [pubmed] PHST- 2024/04/09 11:19 [entrez] PHST- 2024/04/09 00:00 [pmc-release] AID - 10.1007/s11886-024-02034-5 [pii] AID - 2034 [pii] AID - 10.1007/s11886-024-02034-5 [doi] PST - ppublish SO - Curr Cardiol Rep. 2024 May;26(5):283-291. doi: 10.1007/s11886-024-02034-5. Epub 2024 Apr 9. PMID- 38592237 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240411 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 13 IP - 5 DP - 2024 Feb 28 TI - Airway and Anaesthetic Management of Adult Patients with Mucopolysaccharidoses Undergoing Cardiac Surgery. LID - 10.3390/jcm13051366 [doi] LID - 1366 AB - Background: Mucopolysaccharidoses (MPSs) are rare congenital lysosomal storage disorders due to a deficiency of enzymes metabolising glycosaminoglycans, leading to their accumulation in tissues. This multisystem disease often requires surgical intervention, including valvular cardiac surgery. Adult MPSs have complex airways making anaesthesia risky. Methods: We report novel three-dimensional (3D) modelling airway assessments and multidisciplinary peri-operative airway management. Results: Five MPS adults underwent cardiac surgery at the national MPS cardiac centre (type I = 4, type II = 1; ages 20, 24, 33, 35, 37 years; two males, three females). All had complex airway abnormalities. Assessments involved examination, nasendoscopy, imaging, functional studies, 3D reconstruction, virtual endoscopy, virtual reality and simulation using computerised, physical modelling. Awake oral fibre-optic intubation was achieved via airway conduit. Staged extubation was performed on the first post-operative day under laryngo-tracheoscopic guidance. The post-operative period involved chest physiotherapy and occupational therapy. All patients had safe intubation, ventilation and extubation. Four had good cardiac surgical outcomes, one (MPS type I; age 35 years) was inoperable due to endocarditis. None had post-operative airway complications. Conclusions: Expertise from cardiovascular-heart team, multidisciplinary airway management, use of novel techniques is vital. Traditional airway assessments are insufficient, so ENT input, radiology and computerised methods to assess and simulate the airway in 3D by collaboration with clinical engineering is essential. FAU - Mayhew, David AU - Mayhew D AD - Department of Anaesthesia, Liverpool Heart and Chest Hospital, Liverpool L14 3PE, UK. FAU - Palmer, Kenneth AU - Palmer K AD - Department of Anaesthesia, Liverpool Heart and Chest Hospital, Liverpool L14 3PE, UK. FAU - Wilson, Ian AU - Wilson I AD - Department of Cardiac Surgery, Liverpool Heart and Chest Hospital, Liverpool L14 3PE, UK. FAU - Watson, Stuart AU - Watson S AD - Medical Physics Department, Salford Care Organisation, Northern Care Alliance NHS Foundation Trust, Manchester M6 8HD, UK. FAU - Stepien, Karolina M AU - Stepien KM AUID- ORCID: 0000-0003-0148-6332 AD - Adult Inherited Metabolic Department, Salford Care Organisation, Northern Care Alliance NHS Foundation Trust, Manchester M6 8HD, UK. FAU - Jenkins, Petra AU - Jenkins P AD - Adult Congenital Heart Disease Centre, Liverpool Heart and Chest Hospital, Liverpool L14 3PE, UK. FAU - Gadepalli, Chaitanya AU - Gadepalli C AUID- ORCID: 0000-0002-9495-7764 AD - Ear Nose and Throat Department, Salford Care Organisation, Northern Care Alliance NHS Foundation Trust, Manchester M6 8HD, UK. AD - School of Medical Education, The University of Manchester, Manchester M14 4PX, UK. LA - eng PT - Journal Article DEP - 20240228 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC10932343 OTO - NOTNLM OT - airway management OT - cardiac surgery OT - mucopolysaccharidosis COIS- The authors declare no conflicts of interest. EDAT- 2024/04/09 12:42 MHDA- 2024/04/09 12:43 PMCR- 2024/02/28 CRDT- 2024/04/09 10:45 PHST- 2024/01/09 00:00 [received] PHST- 2024/02/13 00:00 [revised] PHST- 2024/02/23 00:00 [accepted] PHST- 2024/04/09 12:43 [medline] PHST- 2024/04/09 12:42 [pubmed] PHST- 2024/04/09 10:45 [entrez] PHST- 2024/02/28 00:00 [pmc-release] AID - jcm13051366 [pii] AID - jcm-13-01366 [pii] AID - 10.3390/jcm13051366 [doi] PST - epublish SO - J Clin Med. 2024 Feb 28;13(5):1366. doi: 10.3390/jcm13051366. PMID- 38592178 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240411 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 13 IP - 5 DP - 2024 Feb 27 TI - Arrhythmic Mitral Valve Prolapse and Sports Activity: Pathophysiology, Risk Stratification, and Sports Eligibility Assessment. LID - 10.3390/jcm13051350 [doi] LID - 1350 AB - Although mitral valve prolapse (MVP) is the most prevalent valvular abnormality in Western countries and generally carries a good prognosis, a small subset of patients is exposed to a significant risk of malignant ventricular arrhythmias (VAs) and sudden cardiac death (SCD), the so-called arrhythmic MVP (AMVP) syndrome. Recent work has emphasized phenotypical risk features of severe AMVP and clarified its pathophysiology. However, the appropriate assessment and risk stratification of patients with suspected AMVP remains a clinical conundrum, with the possibility of both overestimating and underestimating the risk of malignant VAs, with the inappropriate use of advanced imaging and invasive electrophysiology study on one hand, and the catastrophic occurrence of SCD on the other. Furthermore, the sports eligibility assessment of athletes with AMVP remains ill defined, especially in the grey zone of intermediate arrhythmic risk. The definition, epidemiology, pathophysiology, risk stratification, and treatment of AMVP are covered in the present review. Considering recent guidelines and expert consensus statements, we propose a comprehensive pathway to facilitate appropriate counseling concerning the practice of competitive/leisure-time sports, envisioning shared decision making and the multidisciplinary "sports heart team" evaluation of borderline cases. Our final aim is to encourage an active lifestyle without compromising patients' safety. FAU - Compagnucci, Paolo AU - Compagnucci P AUID- ORCID: 0000-0003-1924-6548 AD - Cardiology and Arrhythmology Clinic, Marche University Hospital, 60126 Ancona, Italy. FAU - Selimi, Adelina AU - Selimi A AD - Cardiology and Arrhythmology Clinic, Marche University Hospital, 60126 Ancona, Italy. AD - Department of Biomedical Sciences and Public Health, Marche Polytechnic University, 60121 Ancona, Italy. FAU - Cipolletta, Laura AU - Cipolletta L AUID- ORCID: 0000-0002-7570-4278 AD - Cardiology and Arrhythmology Clinic, Marche University Hospital, 60126 Ancona, Italy. FAU - Volpato, Giovanni AU - Volpato G AD - Cardiology and Arrhythmology Clinic, Marche University Hospital, 60126 Ancona, Italy. AD - Department of Biomedical Sciences and Public Health, Marche Polytechnic University, 60121 Ancona, Italy. FAU - Gasperetti, Alessio AU - Gasperetti A AD - Department of Biomedical Sciences and Public Health, Marche Polytechnic University, 60121 Ancona, Italy. AD - Department of Cardiology, Johns Hopkins University, Baltimore, MD 21205, USA. FAU - Valeri, Yari AU - Valeri Y AUID- ORCID: 0000-0002-0454-0739 AD - Cardiology and Arrhythmology Clinic, Marche University Hospital, 60126 Ancona, Italy. AD - Department of Biomedical Sciences and Public Health, Marche Polytechnic University, 60121 Ancona, Italy. FAU - Parisi, Quintino AU - Parisi Q AD - Cardiology and Arrhythmology Clinic, Marche University Hospital, 60126 Ancona, Italy. FAU - Curcio, Antonio AU - Curcio A AUID- ORCID: 0000-0003-3213-4436 AD - Division of Cardiology, Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy. FAU - Natale, Andrea AU - Natale A AD - Texas Cardiac Arrhythmia Institute, St David's Medical Center, Austin, TX 78705, USA. AD - Interventional Electrophysiology, Scripps Clinic, San Diego, CA 92037, USA. AD - Department of Internal Medicine, Metro Health Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH 44195, USA. FAU - Dello Russo, Antonio AU - Dello Russo A AD - Cardiology and Arrhythmology Clinic, Marche University Hospital, 60126 Ancona, Italy. AD - Department of Biomedical Sciences and Public Health, Marche Polytechnic University, 60121 Ancona, Italy. FAU - Casella, Michela AU - Casella M AUID- ORCID: 0000-0002-5322-1742 AD - Cardiology and Arrhythmology Clinic, Marche University Hospital, 60126 Ancona, Italy. AD - Department of Medical, Special and Dental Sciences, Marche Polytechnic University, 60121 Ancona, Italy. LA - eng PT - Journal Article PT - Review DEP - 20240227 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC10932446 OTO - NOTNLM OT - arrhythmic mitral valve prolapse OT - electroanatomical mapping OT - electrophysiology study OT - guidelines OT - mitral regurgitation OT - mitral valve prolapse OT - physical exercise OT - risk stratification OT - sports cardiology OT - ventricular arrhythmias COIS- Dr. Natale is a consultant for Biosense Webster, Stereotaxis, and Abbott Medical and has received speaker honoraria/travel from Medtronic, Atricure, Biotronik, and Janssen; Dr. Dello Russo is a consultant for Abbott Medical; Dr. Casella has received speaker honoraria from Biosense Webster. All other authors declared no conflicts of interest. EDAT- 2024/04/09 12:44 MHDA- 2024/04/09 12:45 PMCR- 2024/02/27 CRDT- 2024/04/09 10:35 PHST- 2024/01/09 00:00 [received] PHST- 2024/02/16 00:00 [revised] PHST- 2024/02/20 00:00 [accepted] PHST- 2024/04/09 12:45 [medline] PHST- 2024/04/09 12:44 [pubmed] PHST- 2024/04/09 10:35 [entrez] PHST- 2024/02/27 00:00 [pmc-release] AID - jcm13051350 [pii] AID - jcm-13-01350 [pii] AID - 10.3390/jcm13051350 [doi] PST - epublish SO - J Clin Med. 2024 Feb 27;13(5):1350. doi: 10.3390/jcm13051350. PMID- 38590590 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240410 IS - 1512-7680 (Print) IS - 1986-597X (Electronic) IS - 1512-7680 (Linking) VI - 36 IP - 1 DP - 2024 TI - Medical, Surgical and Experimental Approaches to Acute Mesenteric Ischemia and Reperfusion. PG - 77-81 LID - 10.5455/msm.2024.36.77-81 [doi] AB - BACKGROUND: Acute mesenteric ishemia(AMI) is a rare but very serious disease with high rate of mortality and morbidity. About 1-2% of all gastrointestinal disease is AMI. Mortality is about 60-80% and depends of time between starting of symptoms and establishing of diagnosis, type AMI, comorbidities. AMI is often in older population with coronary syndrom and atrial fibrilation. AMI may be occlusive(embolisatio arteriae mesentericae superior(AMS), or thrombosis of AMS, mesenterial vein thrombosis) and nonoclusive form(NOMI). NOMI is rising in critical ill patients in shock or sepsis. Pathophysiology of AMI is very complex and significant role in this proces has ischemia and also reperfusion. Reperfusion injury including oxidative stres, inflamation, infection. The best diagnostic approach is CT angiography but after high clinical suspicion on AMI. Patients have sudden, catastrophic abdominal pain, vomitus, bloody diarrhoea. Therapy is multidisciplinary-basic treatment(resuscitation with cristaloids, antibiotic, anticoagulans...), surgical treatment-resection necrotic segments of intestinum without anastomosis or endovascular treatment. In early phases conservative treatment is possible( vasodilatation, thrombolysis). In some countries there are Intestinal Stroke Centers (ISC) in which patients with AMI have better prognosis. Because of progressive nature of AMI( rapide worsening) rare are clinical study,but there are many experimental study on animal models. Most of experimental study investigate protective effects of some supstances on damage on intestinum and remote organs during ishemia and reperfusion. OBJECTIVE: To present literature data of clinical and experimental study, describe experiments on animal models and mention supstances whit promising results in protective strategies during AMI. METHODS: We analysed Pubmed by using mesh terms such as acute mesenteric ischemia, intestinal injury, reperfusion, experimental study, clinical and therapeutic approach. Results: Sudden abdominal pain resists on opioids analgetics, high rate of CRP, hyperlactatemia, increase of D dimer is enough for suspicion of AMI. Often is delayed in establishing of diagnosis of AMI. CT angiography has sensitivity of 94%. Pneumatosis is sign of necrosis of intestinal wall. Classical surgical approach is dominant, more than 70%,. Endovascular treatment became often last few years. Experimental studies investigate occlusion of AMS with atraumatic clamp, with schemia and reperfusion in different intervals Most animals models are on wistar male rats. CONCLUSION: AMI has still high rate of mortality. Better diagnostic and therapeutic principles (shorter interval between appearance of symptoms and starting of therapy, multidisciplinary approach, higher percent of endovascular procedures), could decrease mortality. Experimental studies on animal models may be succesfull in development of new clinical, conservative approaches in the early phases of AMI in the future. CI - (c) 2024 Zoran Matkovic, Zoran Aleksic. FAU - Matkovic, Zoran AU - Matkovic Z AD - Department of Abdominal Surgery, General Hospital Doboj. Doboj, Bosnia and Herzegovina. FAU - Aleksic, Zoran AU - Aleksic Z AD - Clinic for General and Abdominal surgery, University Clinical Centre of the Republic of Srpska, BanjaLuka. Banja Luka, Bosnia and Herzegovina. AD - Faculty of Medicine, University of Banja Luka. Banja Luka, Bosnia and Herzegovina. LA - eng PT - Journal Article PT - Review PL - Bosnia and Herzegovina TA - Mater Sociomed JT - Materia socio-medica JID - 101281595 PMC - PMC10999141 OTO - NOTNLM OT - acute mesenteric ischemia OT - experimental study OT - reperfusion COIS- There are no conflicts of interest. EDAT- 2024/04/09 06:45 MHDA- 2024/04/09 06:46 PMCR- 2024/01/01 CRDT- 2024/04/09 03:49 PHST- 2024/01/19 00:00 [received] PHST- 2024/02/25 00:00 [accepted] PHST- 2024/04/09 06:46 [medline] PHST- 2024/04/09 06:45 [pubmed] PHST- 2024/04/09 03:49 [entrez] PHST- 2024/01/01 00:00 [pmc-release] AID - MSM-36-77 [pii] AID - 10.5455/msm.2024.36.77-81 [doi] PST - ppublish SO - Mater Sociomed. 2024;36(1):77-81. doi: 10.5455/msm.2024.36.77-81. PMID- 38585184 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240409 IS - 2328-8957 (Print) IS - 2328-8957 (Electronic) IS - 2328-8957 (Linking) VI - 11 IP - 4 DP - 2024 Apr TI - Shared Decision-Making for Partial Oral Antibiotic Treatment of Infective Endocarditis: A Case Series. PG - ofae166 LID - 10.1093/ofid/ofae166 [doi] LID - ofae166 AB - Although literature has demonstrated the noninferiority of oral antibiotics in the treatment of infectious endocarditis, widespread adoption of this practice has yet to occur in the United States. We report on 32 patients with infectious endocarditis treated by a multidisciplinary endocarditis team and a standardized approach to partial oral antibiotic therapy with a high rate of clinical success. CI - (c) The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. FAU - El-Dalati, Sami AU - El-Dalati S AUID- ORCID: 0000-0003-2603-2951 AD - Division of Infectious Diseases, Department of Internal Medicine, University of Kentucky Medical Center, Lexington, Kentucky, USA. FAU - Castillo, Marice Ruiz Conejo AU - Castillo MRC AD - CrescentCare, New Orleans, Louisiana, USA. FAU - Strnad, Luke AU - Strnad L AD - Division of Infectious Diseases, Department of Internal Medicine, Oregon Health and Science University, Portland, Oregon, USA. FAU - Reda, Hassan AU - Reda H AD - Department of Cardiac Surgery, University of Kentucky College of Medicine, Lexington, Kentucky, USA. FAU - London, Tessa AU - London T AD - Department of Cardiac Surgery, University of Kentucky College of Medicine, Lexington, Kentucky, USA. FAU - Sekela, Michael AU - Sekela M AD - Department of Cardiac Surgery, University of Kentucky College of Medicine, Lexington, Kentucky, USA. FAU - Stoner, Bobbi Jo AU - Stoner BJ AD - University of Kentucky College of Pharmacy, Lexington, Kentucky, USA. LA - eng PT - Journal Article DEP - 20240319 PL - United States TA - Open Forum Infect Dis JT - Open forum infectious diseases JID - 101637045 PMC - PMC10996124 OTO - NOTNLM OT - clinical outcomes OT - endocarditis OT - multidisciplinary team OT - oral antibiotic treatment OT - patients who inject drugs COIS- Potential conflicts of interest. The authors: No reported conflicts of interest. EDAT- 2024/04/08 06:42 MHDA- 2024/04/08 06:43 PMCR- 2024/03/19 CRDT- 2024/04/08 04:25 PHST- 2023/11/13 00:00 [received] PHST- 2024/03/18 00:00 [accepted] PHST- 2024/04/08 06:43 [medline] PHST- 2024/04/08 06:42 [pubmed] PHST- 2024/04/08 04:25 [entrez] PHST- 2024/03/19 00:00 [pmc-release] AID - ofae166 [pii] AID - 10.1093/ofid/ofae166 [doi] PST - epublish SO - Open Forum Infect Dis. 2024 Mar 19;11(4):ofae166. doi: 10.1093/ofid/ofae166. eCollection 2024 Apr. PMID- 38583086 OWN - NLM STAT- MEDLINE DCOM- 20240527 LR - 20240529 IS - 1522-9645 (Electronic) IS - 0195-668X (Print) IS - 0195-668X (Linking) VI - 45 IP - 20 DP - 2024 May 27 TI - Coronary bypass surgery guided by computed tomography in a low-risk population. PG - 1804-1815 LID - 10.1093/eurheartj/ehae199 [doi] AB - BACKGROUND AND AIMS: In patients with three-vessel disease and/or left main disease, selecting revascularization strategy based on coronary computed tomography angiography (CCTA) has a high level of virtual agreement with treatment decisions based on invasive coronary angiography (ICA). METHODS: In this study, coronary artery bypass grafting (CABG) procedures were planned based on CCTA without knowledge of ICA. The CABG strategy was recommended by a central core laboratory assessing the anatomy and functionality of the coronary circulation. The primary feasibility endpoint was the percentage of operations performed without access to the ICA. The primary safety endpoint was graft patency on 30-day follow-up CCTA. Secondary endpoints included topographical adequacy of grafting, major adverse cardiac and cerebrovascular (MACCE), and major bleeding events at 30 days. The study was considered positive if the lower boundary of confidence intervals (CI) for feasibility was >/=75% (NCT04142021). RESULTS: The study enrolled 114 patients with a mean (standard deviation) anatomical SYNTAX score and Society of Thoracic Surgery score of 43.6 (15.3) and 0.81 (0.63), respectively. Unblinding ICA was required in one case yielding a feasibility of 99.1% (95% CI 95.2%-100%). The concordance and agreement in revascularization planning between the ICA- and CCTA-Heart Teams was 82.9% with a moderate kappa of 0.58 (95% CI 0.50-0.66) and between the CCTA-Heart Team and actual treatment was 83.7% with a substantial kappa of 0.61 (95% CI 0.53-0.68). The 30-day follow-up CCTA in 102 patients (91.9%) showed an anastomosis patency rate of 92.6%, whilst MACCE was 7.2% and major bleeding 2.7%. CONCLUSIONS: CABG guided by CCTA is feasible and has an acceptable safety profile in a selected population of complex coronary artery disease. CI - (c) The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. FAU - Serruys, Patrick W AU - Serruys PW AUID- ORCID: 0000-0002-9636-1104 AD - CORRIB Research Centre for Advanced Imaging and Core Lab, University of Galway, University Road, Galway H91 TK33, Ireland. FAU - Kageyama, Shigetaka AU - Kageyama S AUID- ORCID: 0000-0003-4982-3203 AD - CORRIB Research Centre for Advanced Imaging and Core Lab, University of Galway, University Road, Galway H91 TK33, Ireland. FAU - Pompilio, Giulio AU - Pompilio G AUID- ORCID: 0000-0003-2581-5735 AD - Centro Cardiologico Monzino, IRCCS, Monzino, Italy. AD - Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milano, Italy. FAU - Andreini, Daniele AU - Andreini D AUID- ORCID: 0000-0002-5996-9209 AD - Division of Cardiology and Cardiac Imaging, IRCCS Galeazzi Sant'Ambrogio, Milan, Italy. AD - Department of Biomedical and Clinical Sciences, University of Milan, Milano, Italy. FAU - Pontone, Gianluca AU - Pontone G AUID- ORCID: 0000-0002-1339-6679 AD - Centro Cardiologico Monzino, IRCCS, Monzino, Italy. FAU - Mushtaq, Saima AU - Mushtaq S AD - Centro Cardiologico Monzino, IRCCS, Monzino, Italy. FAU - La Meir, Mark AU - La Meir M AUID- ORCID: 0000-0002-6261-5110 AD - Department of Cardiac Surgery, Universitair Ziekenhuis Brussel, VUB, Brussels, Belgium. FAU - De Mey, Johan AU - De Mey J AUID- ORCID: 0000-0002-3601-3212 AD - Department of Radiology, Universitair Ziekenhuis Brussel, VUB, Brussels, Belgium. FAU - Tanaka, Kaoru AU - Tanaka K AUID- ORCID: 0000-0001-5533-3185 AD - Department of Radiology, University Hospital Brussels, Brussels, Belgium. FAU - Doenst, Torsten AU - Doenst T AUID- ORCID: 0000-0002-6411-909X AD - Department of Cardiothoracic Surgery, University Hospital Jena, Jena, Germany. FAU - Teichgraber, Ulf AU - Teichgraber U AUID- ORCID: 0000-0002-4048-3938 AD - Department of Radiology, University Hospital Jena, Jena, Germany. FAU - Schneider, Ulrich AU - Schneider U AD - Department of Cardiothoracic Surgery, University Hospital Jena, Jena, Germany. FAU - Puskas, John D AU - Puskas JD AUID- ORCID: 0000-0003-0459-4750 AD - Department of Cardiovascular Surgery, Mount Sinai Morningside, New York, NY, USA. FAU - Narula, Jagat AU - Narula J AUID- ORCID: 0000-0002-0280-3996 AD - University of Texas Health Science Center at Houston, Houston, TX, USA. FAU - Gupta, Himanshu AU - Gupta H AD - Department of Radiology, The Valley Hospital, Ridgewood, NJ, USA. FAU - Agarwal, Vikram AU - Agarwal V AD - Department of Cardiovascular Surgery, Mount Sinai Morningside, New York, NY, USA. FAU - Leipsic, Jonathon AU - Leipsic J AD - St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada. FAU - Masuda, Shinichiro AU - Masuda S AUID- ORCID: 0000-0002-2791-8538 AD - CORRIB Research Centre for Advanced Imaging and Core Lab, University of Galway, University Road, Galway H91 TK33, Ireland. FAU - Kotoku, Nozomi AU - Kotoku N AUID- ORCID: 0000-0002-7712-3733 AD - CORRIB Research Centre for Advanced Imaging and Core Lab, University of Galway, University Road, Galway H91 TK33, Ireland. FAU - Tsai, Tsung-Ying AU - Tsai TY AD - CORRIB Research Centre for Advanced Imaging and Core Lab, University of Galway, University Road, Galway H91 TK33, Ireland. FAU - Garg, Scot AU - Garg S AUID- ORCID: 0000-0002-8911-0278 AD - Department of Cardiology, Royal Blackburn Hospital, Blackburn, UK. FAU - Morel, Marie-Angele AU - Morel MA AD - CORRIB Research Centre for Advanced Imaging and Core Lab, University of Galway, University Road, Galway H91 TK33, Ireland. FAU - Onuma, Yoshinobu AU - Onuma Y AUID- ORCID: 0000-0001-7702-0649 AD - CORRIB Research Centre for Advanced Imaging and Core Lab, University of Galway, University Road, Galway H91 TK33, Ireland. LA - eng SI - ClinicalTrials.gov/NCT04142021 GR - GE HealthCare/ GR - HeartFlow/ GR - HealthCare/ PT - Journal Article PL - England TA - Eur Heart J JT - European heart journal JID - 8006263 SB - IM CIN - doi: 10.1093/eurheartj/ehae223 MH - Humans MH - *Coronary Artery Bypass/methods MH - Male MH - Female MH - *Feasibility Studies MH - Middle Aged MH - *Coronary Artery Disease/surgery/diagnostic imaging MH - Aged MH - *Computed Tomography Angiography/methods MH - *Coronary Angiography/methods MH - Prospective Studies MH - Vascular Patency/physiology PMC - PMC11129794 OTO - NOTNLM OT - Coronary artery bypass grafting OT - Coronary computed tomography OT - Feasibility OT - First-in-human OT - Proof-of-concept OT - Safety EDAT- 2024/04/07 12:42 MHDA- 2024/05/27 18:41 PMCR- 2024/04/07 CRDT- 2024/04/07 08:23 PHST- 2023/11/20 00:00 [received] PHST- 2024/02/22 00:00 [revised] PHST- 2024/03/18 00:00 [accepted] PHST- 2024/05/27 18:41 [medline] PHST- 2024/04/07 12:42 [pubmed] PHST- 2024/04/07 08:23 [entrez] PHST- 2024/04/07 00:00 [pmc-release] AID - 7641484 [pii] AID - ehae199 [pii] AID - 10.1093/eurheartj/ehae199 [doi] PST - ppublish SO - Eur Heart J. 2024 May 27;45(20):1804-1815. doi: 10.1093/eurheartj/ehae199. PMID- 38580202 OWN - NLM STAT- MEDLINE DCOM- 20240623 LR - 20250130 IS - 1552-6259 (Electronic) IS - 0003-4975 (Linking) VI - 118 IP - 1 DP - 2024 Jul TI - Cardiac Surgery After Transcatheter Aortic Valve Replacement: Trends and Outcomes. PG - 155-162 LID - S0003-4975(24)00254-6 [pii] LID - 10.1016/j.athoracsur.2024.03.024 [doi] AB - BACKGROUND: Reports of cardiac operations after transcatheter aortic valve replacement (TAVR) and early TAVR explantation are increasing. The purpose of this report is to document trends and outcomes of cardiac surgery after initial TAVR. METHODS: The Society of Thoracic Surgeons Adult Cardiac Surgery Database was queried for all adult patients undergoing cardiac surgery after a previously placed TAVR between January 2012 and March 2023. This identified an overall cohort and 2 subcohorts: nonaortic valve operations and surgical aortic valve replacement (SAVR) after previous TAVR. Cohorts were examined with descriptive statistics, trend analyses, and 30-day outcomes. RESULTS: Of 5457 patients who were identified, 2485 (45.5%) underwent non-SAVR cardiac surgery, and 2972 (54.5%) underwent SAVR. The frequency of cardiac surgery after TAVR increased 4235.3% overall and 144.6% per year throughout the study period. The incidence of operative mortality and stroke were 15.5% and 4.5%, respectively. Existing The Society of Thoracic Surgeons risk models performed poorly, because observed-to-expected mortality ratios were significantly >1.0. Among those undergoing SAVR after TAVR, increasing preoperative surgical urgency, age, dialysis, need for SAVR, and concomitant procedures were associated with increased mortality, whereas type of TAVR explant was not. CONCLUSIONS: The need for cardiac surgery, including redo SAVR after TAVR, is increasing rapidly. Risks are higher, and outcomes are worse than predicted. These data should closely inform heart team decisions if TAVR is considered at lowering age and risk profiles in the absence of longitudinal evidence. CI - Copyright (c) 2024 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved. FAU - Bowdish, Michael E AU - Bowdish ME AD - Department of Cardiac Surgery, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California. FAU - Habib, Robert H AU - Habib RH AD - STS Research and Analytic Center, The Society of Thoracic Surgeons, Chicago, Illinois. FAU - Kaneko, Tsuyoshi AU - Kaneko T AD - Division of Cardiothoracic Surgery, Washington University in St. Louis, St Louis, Missouri. FAU - Thourani, Vinod H AU - Thourani VH AD - Department of Cardiac Surgery, Piedmont Heart Institute, Atlanta, Georgia. FAU - Badhwar, Vinay AU - Badhwar V AD - Department of Cardiovascular and Thoracic Surgery, West Virginia University, Morgantown, West Virginia. Electronic address: vinay.badhwar@wvumedicine.org. LA - eng PT - Journal Article DEP - 20240403 PL - Netherlands TA - Ann Thorac Surg JT - The Annals of thoracic surgery JID - 15030100R SB - IM CIN - Ann Thorac Surg. 2024 Jul;118(1):162-163. doi: 10.1016/j.athoracsur.2024.04.009. PMID: 38663656 MH - Humans MH - *Transcatheter Aortic Valve Replacement/adverse effects MH - Female MH - Male MH - Aged MH - Aged, 80 and over MH - Treatment Outcome MH - Aortic Valve Stenosis/surgery MH - Retrospective Studies MH - Cardiac Surgical Procedures/adverse effects MH - Postoperative Complications/epidemiology MH - Reoperation/statistics & numerical data MH - United States/epidemiology MH - Incidence COIS- Disclosures Tsuyoshi Kaneko reports a relationship with Edwards, Medtronic, Baylis Medical, 4C Technologies, and Abbott that includes: consulting or advisory. Vinod H. Thourani reports a relationship with Abbott, Boston Scientific, CryoLife, Edwards, JenaValve, Medtronic, and Shockwave that includes: consulting or advisory. The other authors have no conflicts of interest to disclose. EDAT- 2024/04/06 00:42 MHDA- 2024/06/24 00:42 CRDT- 2024/04/05 19:25 PHST- 2023/09/05 00:00 [received] PHST- 2024/03/06 00:00 [revised] PHST- 2024/03/11 00:00 [accepted] PHST- 2024/06/24 00:42 [medline] PHST- 2024/04/06 00:42 [pubmed] PHST- 2024/04/05 19:25 [entrez] AID - S0003-4975(24)00254-6 [pii] AID - 10.1016/j.athoracsur.2024.03.024 [doi] PST - ppublish SO - Ann Thorac Surg. 2024 Jul;118(1):155-162. doi: 10.1016/j.athoracsur.2024.03.024. Epub 2024 Apr 3. PMID- 38577850 OWN - NLM STAT- MEDLINE DCOM- 20250422 LR - 20250513 IS - 1532-8015 (Electronic) IS - 1040-1334 (Linking) VI - 37 IP - 2 DP - 2025 Apr-May TI - Medical Care as Flea Market Bargaining? An International Interdisciplinary Study of Varieties of Shared Decision Making in Physician-Patient Interactions. PG - 192-204 LID - 10.1080/10401334.2024.2322456 [doi] AB - Phenomenon: Shared decision making (SDM) is a core ideal in the interaction between healthcare providers and patients, but the implementation of the SDM ideal in clinical routines has been a relatively slow process. Approach: In a sociological study, 71 interactions between physicians and simulated patients enacting chronic heart failure were video-recorded in China, Germany, the Netherlands, and Turkey as part of a quasi-experimental research design. Participating physicians varied in specialty and level of experience. The secondary analysis presented in this article used content analysis to study core components of SDM in all of the 71 interactions and a grounded theory approach to observe how physicians responded actively to patients even though they did not actively employ the SDM ideal. Findings: Full realization of the SDM ideal remains an exception, but various aspects of SDM in physician-patient interaction were observed in all four locations. Analyses of longer interactions show dynamic processes of interaction that sometimes surprised both patient and physician. We observed varieties of SDM that differ from the SDM ideal but arguably achieve what the SDM ideal is intended to achieve. Our analysis suggests a need to revisit the SDM ideal-to consider whether varieties of SDM may be acceptable, even valuable, in their own right. Insights: The gap between the SDM ideal and SDM as implemented in clinical practice may in part be explained by the tendency of medicine to define and teach SDM through a narrow lens of checklist evaluations. The authors support the argument that SDM defies a checklist approach. SDM is not uniform, but nuanced, dependent on circumstances and setting. As SDM is co-produced by patients and physicians in a dynamic process of interaction, medical researchers should consider and medical learners should be exposed to varieties of SDM-related practice rather than a single idealized model. Observing and discussing worked examples contributes to the physician's development of realistic expectations and personal professional growth. FAU - Sommer, Ilka AU - Sommer I AD - Institute of Sociology, University of Duisburg-Essen, Duisburg, Germany. FAU - Assa, Solmaz AU - Assa S AD - Department of Cardiology, University Medical Center Groningen, Groningen, Netherlands. FAU - Bachmann, Cadja AU - Bachmann C AD - Office of the Dean of Educational Affairs, Rostock University Medical Center, Rostock, Germany. FAU - Chen 陈未, Wei AU - Chen 陈未 W AD - Department of Cardiology, Peking Union Medical College Hospital, Beijing, PR China. FAU - Elcin, Melih AU - Elcin M AUID- ORCID: 0000-0002-1652-906X AD - Faculty of Medicine, Hacettepe University, Ankara, Turkey. FAU - Funk, Elisabeth AU - Funk E AD - Institute of Sociology, University of Duisburg-Essen, Duisburg, Germany. FAU - Kamisli, Caner AU - Kamisli C AD - Institute of German Studies, University of Hamburg, Hamburg, Germany. FAU - Liu 刘涛, Tao AU - Liu 刘涛 T AD - School of Public Affairs, Zhejiang University, Hangzhou, PR China. FAU - Maass, Alexander H AU - Maass AH AD - Department of Cardiology, University Medical Center Groningen, Groningen, Netherlands. FAU - Merse, Stefanie AU - Merse S AD - Empathische Interkulturelle Medizinische Kommunikation, University of Duisburg-Essen, Duisburg, Germany. FAU - Morbach, Caroline AU - Morbach C AUID- ORCID: 0000-0002-0920-6094 AD - Department of Clinical Research & Epidemiology, Comprehensive Heart Failure Center, and Department Medicine I, University Hospital Wurzburg, Wurzburg, Germany. FAU - Neumann, Anja AU - Neumann A AD - Institute of Healthcare Management and Research, University of Duisburg-Essen, Duisburg, Germany. FAU - Neumann, Till AU - Neumann T AD - Outpatient Department of Cardiology Cardio-Praxis, Bochum, Germany. FAU - Quasinowski, Benjamin AU - Quasinowski B AUID- ORCID: 0000-0002-3635-0200 AD - Institute of Sociology, University of Duisburg-Essen, Duisburg, Germany. FAU - Stork, Stefan AU - Stork S AUID- ORCID: 0000-0002-1771-7249 AD - Department of Clinical Research & Epidemiology, Comprehensive Heart Failure Center, and Department Medicine I, University Hospital Wurzburg, Wurzburg, Germany. FAU - Weingartz, Sarah AU - Weingartz S AD - Institute of Sociology, University of Duisburg-Essen, Duisburg, Germany. FAU - Wietasch, Gotz AU - Wietasch G AUID- ORCID: 0000-0001-8001-5648 AD - Department of Anesthesiology, University Medical Center Groningen, Groningen, Netherlands. FAU - Weiss Weiss, Anja AU - Weiss Weiss A AUID- ORCID: 0000-0002-9676-8326 AD - Institute of Sociology, University of Duisburg-Essen, Duisburg, Germany. LA - eng PT - Journal Article DEP - 20240405 PL - United States TA - Teach Learn Med JT - Teaching and learning in medicine JID - 8910884 SB - IM MH - Humans MH - *Physician-Patient Relations MH - *Decision Making, Shared MH - Netherlands MH - Male MH - Female MH - Germany MH - China MH - Turkey MH - *Patient Participation MH - Heart Failure/therapy MH - Patient Simulation MH - Video Recording OTO - NOTNLM OT - Physician-patient communication OT - international comparison OT - patient contribution OT - physician-patient interaction OT - shared decision making EDAT- 2024/04/05 12:44 MHDA- 2025/03/14 11:22 CRDT- 2024/04/05 06:03 PHST- 2025/03/14 11:22 [medline] PHST- 2024/04/05 12:44 [pubmed] PHST- 2024/04/05 06:03 [entrez] AID - 10.1080/10401334.2024.2322456 [doi] PST - ppublish SO - Teach Learn Med. 2025 Apr-May;37(2):192-204. doi: 10.1080/10401334.2024.2322456. Epub 2024 Apr 5. PMID- 38577782 OWN - NLM STAT- MEDLINE DCOM- 20241015 LR - 20250319 IS - 1467-1107 (Electronic) IS - 1047-9511 (Linking) VI - 34 IP - 5 DP - 2024 May TI - Impact of electrophysiologists at daily multidisciplinary report in a paediatric cardiac care unit. PG - 1117-1123 LID - 10.1017/S1047951124000738 [doi] AB - BACKGROUND: Paediatric cardiac electrophysiologists are essential in CHD inpatient care, but their involvement is typically limited to consultation with individual patients. In our integrated heart centre, an electrophysiologist reviews all cardiac inpatient telemetry over the preceding 24 hours and participates in daily multidisciplinary morning report. This study investigates the impact of the strategy of consistent, formalised electrophysiologist presence at multidisciplinary morning report. METHODS: This is a single-centre, prospective, observational study of electrophysiologist participation in patient encounters during heart centre multidisciplinary morning report from 10/20/2021 to 10/31/2022. Multidisciplinary morning report includes discussion of all intensive care and non-intensive care cardiac patients. An encounter was defined as reporting on one patient for one day. Electrophysiologists were initially blinded to observations. RESULTS: Two electrophysiologists were observed over 215 days encompassing 6413 patient encounters. Electrophysiologists made comments on 581(9.1%) encounters in 234 unique patients with diverse diagnoses, equating to a median of 3[interquartile range:1-4] encounters per day. These included identifications of arrhythmias and describing electrocardiographic findings. Recommendation to change management occurred in 282(48.5%) encounters, most commonly regarding medications (n = 142, 24.4%) or pacemaker management (n = 48, 8.3%). Of the 581 encounters, there were 61(10.5%) in which they corrected another physician's interpretation of rhythm or electrocardiogram. CONCLUSION: Routine electrophysiologist involvement in multidisciplinary morning report provides significant, frequent, and timely input in patient management by identifying precise rhythm-related diagnoses and allowing nuanced, patient-specific medication and pacemaker management of all cardiac patients, not just those consulted. Electrophysiologist presence at multidisciplinary morning report is a vital resource and this practice should be considered at integrated paediatric cardiac centres. FAU - Mikulski, Matthew F AU - Mikulski MF AUID- ORCID: 0000-0002-1694-7894 AD - Texas Center for Pediatric and Congenital Heart Disease, Dell Children's Medical Center & UT Health Austin, Austin, TX, USA. AD - Department of Surgery and Perioperative Care, Dell Medical School, The University of Texas at Austin, Austin, TX, USA. FAU - Well, Andrew AU - Well A AUID- ORCID: 0000-0002-0725-2791 AD - Texas Center for Pediatric and Congenital Heart Disease, Dell Children's Medical Center & UT Health Austin, Austin, TX, USA. AD - Department of Surgery and Perioperative Care, Dell Medical School, The University of Texas at Austin, Austin, TX, USA. FAU - Shmorhun, Daniel AU - Shmorhun D AD - Texas Center for Pediatric and Congenital Heart Disease, Dell Children's Medical Center & UT Health Austin, Austin, TX, USA. AD - Department of Pediatrics, Dell Medical School, The University of Texas at Austin, Austin, TX, USA. FAU - Mery, Carlos M AU - Mery CM AD - Texas Center for Pediatric and Congenital Heart Disease, Dell Children's Medical Center & UT Health Austin, Austin, TX, USA. AD - Department of Surgery and Perioperative Care, Dell Medical School, The University of Texas at Austin, Austin, TX, USA. FAU - Fenrich, Arnold L AU - Fenrich AL AD - Texas Center for Pediatric and Congenital Heart Disease, Dell Children's Medical Center & UT Health Austin, Austin, TX, USA. AD - Department of Pediatrics, Dell Medical School, The University of Texas at Austin, Austin, TX, USA. FAU - Fraser, Charles D AU - Fraser CD AD - Texas Center for Pediatric and Congenital Heart Disease, Dell Children's Medical Center & UT Health Austin, Austin, TX, USA. AD - Department of Surgery and Perioperative Care, Dell Medical School, The University of Texas at Austin, Austin, TX, USA. LA - eng PT - Journal Article PT - Observational Study DEP - 20240405 PL - England TA - Cardiol Young JT - Cardiology in the young JID - 9200019 SB - IM MH - Humans MH - Prospective Studies MH - Child MH - *Heart Defects, Congenital/therapy MH - Male MH - Female MH - Infant MH - Child, Preschool MH - Coronary Care Units MH - Patient Care Team MH - Arrhythmias, Cardiac/therapy/diagnosis MH - Adolescent MH - Cardiac Electrophysiology MH - Telemetry MH - Electrocardiography MH - Infant, Newborn OTO - NOTNLM OT - CHD OT - arrhythmias OT - inpatient management OT - pacemaker management OT - paediatric electrophysiology EDAT- 2024/04/05 06:44 MHDA- 2024/10/15 16:19 CRDT- 2024/04/05 04:53 PHST- 2024/10/15 16:19 [medline] PHST- 2024/04/05 06:44 [pubmed] PHST- 2024/04/05 04:53 [entrez] AID - S1047951124000738 [pii] AID - 10.1017/S1047951124000738 [doi] PST - ppublish SO - Cardiol Young. 2024 May;34(5):1117-1123. doi: 10.1017/S1047951124000738. Epub 2024 Apr 5. PMID- 38571386 OWN - NLM STAT- MEDLINE DCOM- 20250923 LR - 20250923 IS - 1360-046X (Electronic) IS - 0268-8697 (Linking) VI - 39 IP - 5 DP - 2025 Oct TI - Clinical characteristics of aneurysmal subarachnoid haemorrhage complicated by Takotsubo cardiomyopathy resulting in good neurological outcome. PG - 667-674 LID - 10.1080/02688697.2024.2334432 [doi] AB - BACKGROUND: Takotsubo cardiomyopathy (TC) is a well-known complication of subarachnoid haemorrhage (SAH), often accompanied by neurogenic myocardial dysfunction. Although TC has been reported to be associated with higher morbidity and mortality among patients with aneurysmal SAH (aSAH), some patients have been reported to recover, the profiles and follow-up outcomes of these survivors remain unclear. MATERIALS AND METHODS: To characterize the profiles of patients with aSAH complicated by TC who experienced favourable outcomes using long-term follow-up data, a consecutive series of patients with aSAH were enrolled and TC diagnosis was based on the revised version of the Mayo Clinic criteria. Clinical outcomes were assessed at 6 months according to modified Rankin Scale scores. RESULTS: Among 165 consecutive patients with aSAH, 15 cases were complicated by TC, corresponding to an occurrence rate of 9.0%. Five patients with aSAH complicated by TC (33.3%) experienced a favourable outcome, and the mean value of systolic blood pressure on arrival was significantly lower than in those who experienced an unfavourable outcome (p = 0.032). CONCLUSION: According to analysis, it is possible cardiac dysfunction with decreased cerebral perfusion pressure and catecholamine toxicity transiently worsens conscious disturbance in aSAH complicated by TC. Therefore, it is important to carefully screen patients with aSAH to identify those complicated by TC, and for close collaboration of the multidisciplinary team to design appropriate treatment strategies. FAU - Kawasaki, Takafumi AU - Kawasaki T AD - Department of Emergency and Critical Care, Yokohama City University Medical Center, Yokohama, Japan. FAU - Nakamura, Taishi AU - Nakamura T AD - Department of Neurosurgery, Yokohama City University Medical Center, Yokohama, Japan. FAU - Ohtake, Makoto AU - Ohtake M AD - Department of Emergency and Critical Care, Yokohama City University Medical Center, Yokohama, Japan. FAU - Akimoto, Taisuke AU - Akimoto T AD - Department of Neurosurgery, Yokohama City University Medical Center, Yokohama, Japan. FAU - Manaka, Hiroshi AU - Manaka H AD - Department of Neurosurgery, Yokohama City University Medical Center, Yokohama, Japan. FAU - Hamada, Koichi AU - Hamada K AD - Department of Neurosurgery, Yokohama City University Medical Center, Yokohama, Japan. FAU - Sakata, Katsumi AU - Sakata K AD - Department of Neurosurgery, Yokohama City University Medical Center, Yokohama, Japan. FAU - Iwashita, Masayuki AU - Iwashita M AD - Department of Emergency and Critical Care, Yokohama City University Medical Center, Yokohama, Japan. FAU - Takeuchi, Ichiro AU - Takeuchi I AD - Department of Emergency and Critical Care, Yokohama City University Medical Center, Yokohama, Japan. FAU - Yamamoto, Tetsuya AU - Yamamoto T AD - Department of Neurosurgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan. LA - eng PT - Journal Article DEP - 20240403 PL - England TA - Br J Neurosurg JT - British journal of neurosurgery JID - 8800054 SB - IM MH - Humans MH - *Takotsubo Cardiomyopathy/etiology/complications MH - *Subarachnoid Hemorrhage/complications MH - Female MH - Male MH - Middle Aged MH - Aged MH - Treatment Outcome MH - Follow-Up Studies MH - Retrospective Studies OTO - NOTNLM OT - Apical ballooning syndrome OT - SAH OT - Takotsubo cardiomyopathy OT - regional wall motion abnormality EDAT- 2024/04/04 06:44 MHDA- 2025/09/23 12:47 CRDT- 2024/04/04 02:53 PHST- 2025/09/23 12:47 [medline] PHST- 2024/04/04 06:44 [pubmed] PHST- 2024/04/04 02:53 [entrez] AID - 10.1080/02688697.2024.2334432 [doi] PST - ppublish SO - Br J Neurosurg. 2025 Oct;39(5):667-674. doi: 10.1080/02688697.2024.2334432. Epub 2024 Apr 3. PMID- 38564756 OWN - NLM STAT- MEDLINE DCOM- 20240620 LR - 20260822 IS - 1532-0987 (Electronic) IS - 0891-3668 (Linking) VI - 43 IP - 7 DP - 2024 Jul 1 TI - Mediastinal Nontuberculous Mycobacterial Infection in Children: A Multidisciplinary Approach. PG - e225-e230 LID - 10.1097/INF.0000000000004315 [doi] AB - BACKGROUND: Mediastinal infections due to nontuberculous mycobacteria remain an exceedingly rare entity. Most cases in the published literature do not include pediatric patients. Due to their clinical infrequency, poor response to antimicrobial therapy and often precarious anatomical location, the optimal management of these lesions can be challenging. METHODS: Retrospective medical record review of 4 pediatric cases of mediastinal nontuberculous mycobacteria infection was undertaken. Each child presented with nonspecific respiratory symptoms, including significant acute airway obstruction and required a range of investigations to confirm the diagnosis. Nonresponsiveness to conservative measures and antimycobacterial therapy ultimately resulted in surgical intervention to obtain clinical improvement. RESULTS: All 4 children had extensive evaluation and multidisciplinary involvement in otolaryngology, respiratory medicine, pediatric surgery, infectious diseases and cardiothoracic surgery. They all eventually had their disease debulked via thoracotomy in addition to prolonged antimycobacterial therapy, with successful clinical outcomes. CONCLUSIONS: Mediastinal nontuberculous mycobacteria infections in the pediatric population are rare and diagnostically challenging. A high clinical suspicion should be maintained, and multidisciplinary input sought. Targeted surgery with adjuvant medical therapy can reduce disease burden with minimal long-term morbidity. CI - Copyright (c) 2024 Wolters Kluwer Health, Inc. All rights reserved. FAU - Wiener, Jonathan AU - Wiener J AUID- ORCID: 0000-0003-1685-8776 AD - From the Department of Paediatric Surgery, Sydney Children's Hospital. FAU - Wanaguru, Dylan AU - Wanaguru D AD - From the Department of Paediatric Surgery, Sydney Children's Hospital. AD - Faculty of Medicine, School of Women's and Children's Health, University of New South Wales. FAU - Currie, Bruce AU - Currie B AD - From the Department of Paediatric Surgery, Sydney Children's Hospital. FAU - Grant, Peter AU - Grant P AD - Department of Cardiothoracic Surgery. FAU - Russell, Carolyn AU - Russell C AD - From the Department of Paediatric Surgery, Sydney Children's Hospital. FAU - Palasanthiran, Pamela AU - Palasanthiran P AD - Faculty of Medicine, School of Women's and Children's Health, University of New South Wales. AD - Department of Immunology and Infectious Diseases, Sydney Children's Hospital, Randwick, New South Wales, Australia. FAU - Williams, Phoebe AU - Williams P AD - Faculty of Medicine, School of Women's and Children's Health, University of New South Wales. AD - Department of Immunology and Infectious Diseases, Sydney Children's Hospital, Randwick, New South Wales, Australia. AD - School of Public Health, Faculty of Medicine, University of Sydney. FAU - Belessis, Yvonne AU - Belessis Y AD - Faculty of Medicine, School of Women's and Children's Health, University of New South Wales. AD - Department of Respiratory Medicine, Sydney Children's Hospital. FAU - Soma, Marlene AU - Soma M AUID- ORCID: 0000-0002-0043-4648 AD - Faculty of Medicine, School of Women's and Children's Health, University of New South Wales. AD - Department of Paediatric Otolaryngology, Sydney Children's Hospital, Randwick, New South Wales, Australia. LA - eng PT - Journal Article DEP - 20240614 PL - United States TA - Pediatr Infect Dis J JT - The Pediatric infectious disease journal JID - 8701858 RN - 0 (Anti-Bacterial Agents) SB - IM MH - Adolescent MH - Child MH - Child, Preschool MH - Female MH - Humans MH - Infant MH - Male MH - Anti-Bacterial Agents/therapeutic use MH - Mediastinal Diseases/microbiology/diagnosis MH - *Mycobacterium Infections, Nontuberculous/diagnosis/drug therapy/microbiology/therapy MH - *Nontuberculous Mycobacteria/isolation & purification MH - Retrospective Studies COIS- The authors have no funding or conflicts of interest to disclose. EDAT- 2024/04/02 18:44 MHDA- 2024/06/20 12:42 CRDT- 2024/04/02 16:33 PHST- 2024/06/20 12:42 [medline] PHST- 2024/04/02 18:44 [pubmed] PHST- 2024/04/02 16:33 [entrez] AID - 00006454-202407000-00008 [pii] AID - 10.1097/INF.0000000000004315 [doi] PST - ppublish SO - Pediatr Infect Dis J. 2024 Jul 1;43(7):e225-e230. doi: 10.1097/INF.0000000000004315. Epub 2024 Jun 14. PMID- 38561042 OWN - NLM STAT- MEDLINE DCOM- 20240505 LR - 20240505 IS - 1878-3511 (Electronic) IS - 1201-9712 (Linking) VI - 143 DP - 2024 Jun TI - Association of persistent positive blood cultures and infective endocarditis: A cohort study among patients with suspected infective endocarditis. PG - 107022 LID - S1201-9712(24)00093-6 [pii] LID - 10.1016/j.ijid.2024.107022 [doi] AB - OBJECTIVES: To ascertain whether infective endocarditis (IE) was associated with persistent bacteraemia/candidaemia among patients with suspected IE. METHODS: This study included bacteraemic/candidaemic adult patients with echocardiography and follow-up blood cultures. Persistent bacteraemia/candidaemia was defined as continued positive blood cultures with the same microorganism for 48 h or more after antibiotic treatment initiation. Each case was classified for IE by the Endocarditis Team. RESULTS: Among 1962 episodes of suspected IE, IE (605; 31%) was the most prevalent infection type. Persistent bacteraemia/candidaemia was observed in 426 (22%) episodes. Persistent bacteraemia was more common among episodes with Staphylococcus aureus bacteraemia compared to episodes with positive blood cultures for other pathogens (32%, 298/933 vs 12%, 128/1029; P < 0.001). Multivariable analysis demonstrated that cardiac predisposing factors (aOR 1.84, 95% CI 1.31-2.60), community or non-nosocomial healthcare-associated (2.85, 2.10-3.88), bacteraemia by high-risk bacteria, such as S. aureus, streptococci, enterococci or HACEK (1.84, 1.31-2.60), two or more positive sets of index blood cultures (6.99, 4.60-10.63), persistent bacteraemia/candidaemia for 48 h from antimicrobial treatment initiation (1.43, 1.05-1.93), embolic events within 48h from antimicrobial treatment initiation (12.81, 9.43-17.41), and immunological phenomena (3.87, 1.09-1.78) were associated with infective endocarditis. CONCLUSIONS: IE was associated with persistent bacteraemia/candidaemia, along with other commonly associated factors. CI - Copyright (c) 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved. FAU - Teixeira Antunes, Andre AU - Teixeira Antunes A AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Monney, Pierre AU - Monney P AD - Department of Cardiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Tzimas, Georgios AU - Tzimas G AD - Department of Cardiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Tozzi, Piergiorgio AU - Tozzi P AD - Department of Cardiac Surgery, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Kirsch, Matthias AU - Kirsch M AD - Department of Cardiac Surgery, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Guery, Benoit AU - Guery B AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Papadimitriou-Olivgeris, Matthaios AU - Papadimitriou-Olivgeris M AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland; Infectious Diseases Service, Cantonal Hospital of Sion and Institut Central des Hopitaux (ICH), Sion, Switzerland. Electronic address: Matthaios.Papadimitriou-Olivgeris@hopitalvs.ch. LA - eng PT - Journal Article DEP - 20240330 PL - Canada TA - Int J Infect Dis JT - International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases JID - 9610933 RN - 0 (Anti-Bacterial Agents) SB - IM MH - Humans MH - Male MH - Female MH - Middle Aged MH - *Blood Culture MH - *Bacteremia/microbiology/diagnosis/drug therapy/epidemiology MH - Aged MH - *Endocarditis/microbiology/diagnosis/drug therapy MH - Candidemia/drug therapy/diagnosis/microbiology/epidemiology MH - Cohort Studies MH - Adult MH - Risk Factors MH - Anti-Bacterial Agents/therapeutic use MH - Echocardiography MH - Staphylococcus aureus/isolation & purification MH - Endocarditis, Bacterial/microbiology/diagnosis/drug therapy/epidemiology MH - Retrospective Studies MH - Staphylococcal Infections/microbiology/drug therapy/diagnosis OTO - NOTNLM OT - Bone and joint infection OT - Follow-up blood cultures OT - Infective endocarditis OT - Persistent bacteraemia OT - Sepsis EDAT- 2024/04/02 00:42 MHDA- 2024/05/06 00:52 CRDT- 2024/04/01 20:18 PHST- 2024/03/06 00:00 [received] PHST- 2024/03/22 00:00 [revised] PHST- 2024/03/22 00:00 [accepted] PHST- 2024/05/06 00:52 [medline] PHST- 2024/04/02 00:42 [pubmed] PHST- 2024/04/01 20:18 [entrez] AID - S1201-9712(24)00093-6 [pii] AID - 10.1016/j.ijid.2024.107022 [doi] PST - ppublish SO - Int J Infect Dis. 2024 Jun;143:107022. doi: 10.1016/j.ijid.2024.107022. Epub 2024 Mar 30. PMID- 38558690 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240403 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 16 IP - 2 DP - 2024 Feb TI - Black Digits Matter: A Multispecialty Enigma. PG - e55133 LID - 10.7759/cureus.55133 [doi] LID - e55133 AB - Introduction Digital ischemia is alike any other visceral ischemic event leading to severe tissue damage ultimately causing necrosis of the involved extremity. It's like a preview of the upcoming systemic disorder and can present itself in any specialty and hence everyone, be it a physician or a surgeon must be primed toward how to proceed with a case of digital ischemia. In this case series, we present six such cases that presented with digital ischemic events either as a sole presentation or were followed by other systemic manifestations that led to their evaluation and ultimately the etiology behind it. Material and method Patients visiting Rheumatology OPD with complaints suggestive of digital ischemia were included in this study. All patients underwent thorough history taking and clinical examination to establish the cause of digital ischemia. Patients with probable infective, trauma, cardiac, and drug-induced causes and malignancies were excluded. As per probable autoimmune causes, patients underwent evaluation via antinuclear antibodies by immunofluorescence (ANA by IF), antiphospholipid antibodies like lupus anticoagulant (LAC), anticardiolipin antibodies (AcL) and anti Beta2GP1 antibodies, extractable nuclear antigens (ENA) and in cases of suspected vasculitis doppler ultrasound and angiography. Results Six patients were identified as cases primarily presenting with digital ischemia or with a prior history of digital ischemia. Two patients were of the pediatric age group, one 16-year-old male presenting with acute arthritis and a history of digital ischemia one year back, and the other was a 12-year-old female with blackening of the second toe in her left foot with a history of similar complaints in the left great toe for which she underwent amputation of that toe. Other four cases were of the adult age group, with two cases of scleroderma, one with systemic lupus erythematosus, and one with Takayasu arteritis. All of these patients primarily presented to departments other than rheumatology. Conclusion Digital ischemia is a pan-specialty problem with the etiologies spreading across a vast spectrum of rheumatological disorders, many of which may present to different specialties initially, later discovered to be part of the systemic manifestation of autoimmune diseases. Hence, it becomes imperative to have a rheumatological perspective in these cases of digital ischemia which all specialities should be aware of, and timely referral may prevent permanent loss of the digits and in some cases the entire limb. CI - Copyright (c) 2024, Agrawal et al. FAU - Agrawal, Abhijeet AU - Agrawal A AD - Department of Medicine, Jawaharlal Nehru Medical College, Wardha, IND. FAU - Bhagawati, Jahnabi AU - Bhagawati J AD - Department of Medicine, Jawaharlal Nehru Medical College, Wardha, IND. FAU - Kumar, Sunil AU - Kumar S AD - Department of Medicine, Jawaharlal Nehru Medical College, Wardha, IND. FAU - Acharya, Sourya AU - Acharya S AD - Department of Medicine, Jawaharlal Nehru Medical College, Wardha, IND. LA - eng PT - Journal Article DEP - 20240228 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC10979651 OTO - NOTNLM OT - antiphospholipid antibody OT - autoimmune OT - connective tissue disease OT - digital ischemia OT - digital ulcer OT - raynaud's phenomenon OT - scleroderma OT - systemic lupus erythematosus COIS- The authors have declared that no competing interests exist. EDAT- 2024/04/01 18:42 MHDA- 2024/04/01 18:43 PMCR- 2024/02/28 CRDT- 2024/04/01 17:02 PHST- 2024/01/28 00:00 [received] PHST- 2024/02/28 00:00 [accepted] PHST- 2024/04/01 18:43 [medline] PHST- 2024/04/01 18:42 [pubmed] PHST- 2024/04/01 17:02 [entrez] PHST- 2024/02/28 00:00 [pmc-release] AID - 10.7759/cureus.55133 [doi] PST - epublish SO - Cureus. 2024 Feb 28;16(2):e55133. doi: 10.7759/cureus.55133. eCollection 2024 Feb. PMID- 38553663 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260329 IS - 2110-5820 (Print) IS - 2110-5820 (Electronic) IS - 2110-5820 (Linking) VI - 14 IP - 1 DP - 2024 Mar 30 TI - Management of cardiogenic shock: a narrative review. PG - 45 LID - 10.1186/s13613-024-01260-y [doi] LID - 45 AB - Cardiogenic shock (CS) is characterized by low cardiac output and sustained tissue hypoperfusion that may result in end-organ dysfunction and death. CS is associated with high short-term mortality, and its management remains challenging despite recent advances in therapeutic options. Timely diagnosis and multidisciplinary team-based management have demonstrated favourable effects on outcomes. We aimed to review evidence-based practices for managing patients with ischemic and non-ischemic CS, detailing the multi-organ supports needed in this critically ill patient population. CI - (c) 2024. The Author(s). FAU - Laghlam, Driss AU - Laghlam D AUID- ORCID: 0000-0002-3204-4636 AD - Research & Innovation Department, RIGHAPH, Service de Reanimation polyvalente, CMC Ambroise Pare-Hartmann, 48 Ter boulevard Victor Hugo, 92200, Neuilly-sur-Seine, France. driss.laghlam@gmail.com. FAU - Benghanem, Sarah AU - Benghanem S AD - Service de medecine intensive-reanimation, Hopital Cochin, Assistance Publique-Hopitaux de Paris (AP-HP), Centre & Universite Paris Cite, Paris, France. AD - Universite Paris Cite, Paris, France. AD - AfterROSC, Paris, France. FAU - Ortuno, Sofia AU - Ortuno S AD - Service Medecine intensive-reanimation, Hopital Europeen Georges Pompidou, Paris, France. AD - Universite Sorbonne, Paris, France. FAU - Bouabdallaoui, Nadia AU - Bouabdallaoui N AD - Institut de cardiologie de Montreal, Universite de Montreal, Montreal, Canada. FAU - Manzo-Silberman, Stephane AU - Manzo-Silberman S AD - Universite Sorbonne, Paris, France. AD - Sorbonne University, Institute of Cardiology- Hopital Pitie-Salpetriere (AP-HP), ACTION Study Group, Paris, France. FAU - Hamzaoui, Olfa AU - Hamzaoui O AD - Service de medecine intensive-reanimation polyvalente, Hopital Robert Debre, CHU de Reims, Reims, France. AD - Unite HERVI "Hemostase et Remodelage Vasculaire Post-Ischemie" - EA 3801, Reims, France. FAU - Aissaoui, Nadia AU - Aissaoui N AD - Service de medecine intensive-reanimation, Hopital Cochin, Assistance Publique-Hopitaux de Paris (AP-HP), Centre & Universite Paris Cite, Paris, France. AD - Universite Paris Cite, Paris, France. AD - AfterROSC, Paris, France. LA - eng PT - Journal Article PT - Review DEP - 20240330 PL - France TA - Ann Intensive Care JT - Annals of intensive care JID - 101562873 PMC - PMC10980676 OTO - NOTNLM OT - Cardiogenic shock OT - ECMO OT - Hemodynamic monitoring OT - Mechanical ventilation OT - Myocardial infarction OT - Shock COIS- Manzo-Silberman S has received consulting fees from Bayer, Organon, Exeltis, lecture fees from Bayer, BMS, Exeltis and Organon, has served in the adjudication board for a study for Biotronik. Hamzaoui O has received lecture fees from BAXTER. Laghlam D, Benghanem S, Ortuno S Bouabdallaoui N and Aissaoui N have no competing interests to declare. EDAT- 2024/03/30 11:48 MHDA- 2024/03/30 11:49 PMCR- 2024/03/30 CRDT- 2024/03/30 00:28 PHST- 2023/09/15 00:00 [received] PHST- 2024/02/06 00:00 [accepted] PHST- 2024/03/30 11:49 [medline] PHST- 2024/03/30 11:48 [pubmed] PHST- 2024/03/30 00:28 [entrez] PHST- 2024/03/30 00:00 [pmc-release] AID - S2110-5820(25)00179-7 [pii] AID - 1260 [pii] AID - 10.1186/s13613-024-01260-y [doi] PST - epublish SO - Ann Intensive Care. 2024 Mar 30;14(1):45. doi: 10.1186/s13613-024-01260-y. PMID- 38553277 OWN - NLM STAT- MEDLINE DCOM- 20240830 LR - 20260513 IS - 1878-0938 (Electronic) IS - 1878-0938 (Linking) VI - 66 DP - 2024 Sep TI - Transcatheter aortic valve replacement achieves similar predicted effective orifice area to surgical aortic valve replacement in bicuspid aortic stenosis. PG - 21-26 LID - S1553-8389(24)00105-2 [pii] LID - 10.1016/j.carrev.2024.03.017 [doi] AB - BACKGROUND: Studies comparing transcatheter and surgical aortic valve replacement (TAVR and SAVR) for patients with trileaflet aortic stenosis (AS) have found similar or larger effective orifice area (EOA) for TAVR prostheses. To our knowledge, no studies have compared EOA in patients undergoing TAVR versus SAVR for bicuspid AS. METHODS: We retrospectively compared prosthetic valvular sizing and predicted EOA for patients with bicuspid AS undergoing TAVR or SAVR at our institution between January 1, 2016, and December 31, 2021. We excluded patients undergoing procedures for indications other than AS and those without a pre-procedural gated Chest CT. Comparisons included demographics, comorbidities, annular size, prosthetic valve size, predicted EOA and prosthesis-patient mismatch (PPM) for TAVR (N = 78) and SAVR (N = 74) cohorts. RESULTS: TAVR patients had smaller pre-procedural annular area (501.7 mm(2) vs. 571.8 mm(2), p < 0.05) and annular perimeter (80.6 mm vs. 86.5 mm, p < 0.05), but larger mean implanted prosthetic valve size (26.4 mm vs 24.2 mm, p < 0.001) compared to SAVR patients. No differences were observed in predicted EOA, predicted EOA indexed to patient body surface area (EOAi), or predicted PPM grade between TAVR and SAVR groups, including in cohorts sorted by pre-procedural annular size. CONCLUSIONS: For bicuspid AS patients undergoing aortic valve replacement, TAVR achieves similar predicted EOA to SAVR. These data support the use of TAVR in selected patients with bicuspid AS and can inform heart team discussions. CI - Published by Elsevier Inc. FAU - Connolly, John E AU - Connolly JE AD - Department of Internal Medicine, Johns Hopkins Hospital, Baltimore, MD 21224, USA. FAU - Herrmann, Howard C AU - Herrmann HC AD - Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA. FAU - Atluri, Pavan AU - Atluri P AD - Division of Cardiovascular Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA. FAU - Desai, Nimesh AU - Desai N AD - Division of Cardiovascular Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA. FAU - Fiorilli, Paul N AU - Fiorilli PN AD - Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA. FAU - Giri, Jay AU - Giri J AD - Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA. FAU - Li, Robert H AU - Li RH AD - Division of Cardiovascular Medicine, Penn Presbyterian Medical Center, Philadelphia, PA 19104, USA. FAU - Kobayashi, Taisei AU - Kobayashi T AD - Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA. FAU - Nathan, Ashwin S AU - Nathan AS AD - Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA. FAU - Szeto, Wilson Y AU - Szeto WY AD - Division of Cardiovascular Surgery, Penn Presbyterian Medical Center, Philadelphia, PA 19104, USA. FAU - Grimm, Joshua C AU - Grimm JC AD - Institute for Cardiovascular Health, University of Texas Health Austin, Austin, TX 78712, USA. Electronic address: joshua.grimm@austin.utexas.edu. LA - eng PT - Comparative Study PT - Journal Article DEP - 20240321 PL - United States TA - Cardiovasc Revasc Med JT - Cardiovascular revascularization medicine : including molecular interventions JID - 101238551 SB - IM MH - Humans MH - *Aortic Valve/surgery/diagnostic imaging/physiopathology/abnormalities MH - *Aortic Valve Stenosis/surgery/diagnostic imaging/physiopathology MH - *Transcatheter Aortic Valve Replacement/instrumentation/adverse effects MH - Retrospective Studies MH - Female MH - *Bicuspid Aortic Valve Disease/surgery/diagnostic imaging/physiopathology MH - Male MH - Treatment Outcome MH - Aged MH - *Heart Valve Prosthesis MH - *Prosthesis Design MH - *Heart Valve Prosthesis Implantation/instrumentation/adverse effects MH - Aged, 80 and over MH - Risk Factors MH - Heart Valve Diseases/surgery/diagnostic imaging/physiopathology MH - Hemodynamics MH - Recovery of Function MH - Middle Aged MH - Time Factors OTO - NOTNLM OT - Bicuspid aortic stenosis OT - SAVR OT - TAVR COIS- Declaration of competing interest JEC declares no relevant financial relationships or conflicts of interest. HCH reports institutional research funding from Abbott, Boston Scientific, Edwards Lifesciences, and Medtronic, as well as consultant fees from Edwards Lifesciences and Medtronic. PA reports speaking fees from Edwards Lifesciences. PNF receives consulting honoraria from Edwards Lifesciences. JG reports serving on advisory boards and receiving research funds to the institution from Abiomed, Edwards Lifesciences, Inari Medical, and Recor Medical, as well as equity in Endovascular Engineering. RHL has no relevant financial conflicts of interest. TK has no relevant financial conflicts of interest. ASN reports speaker fees and institutional research funds from Edwards Lifesciences. WYS has served on the advisory board and as an investigator and speaker for Edwards Lifesciences, Medtronic, and Abbott. EDAT- 2024/03/30 11:44 MHDA- 2024/08/31 09:45 CRDT- 2024/03/29 22:58 PHST- 2024/01/30 00:00 [received] PHST- 2024/03/07 00:00 [revised] PHST- 2024/03/19 00:00 [accepted] PHST- 2024/08/31 09:45 [medline] PHST- 2024/03/30 11:44 [pubmed] PHST- 2024/03/29 22:58 [entrez] AID - S1553-8389(24)00105-2 [pii] AID - 10.1016/j.carrev.2024.03.017 [doi] PST - ppublish SO - Cardiovasc Revasc Med. 2024 Sep;66:21-26. doi: 10.1016/j.carrev.2024.03.017. Epub 2024 Mar 21. PMID- 38552656 OWN - NLM STAT- MEDLINE DCOM- 20240415 LR - 20250224 IS - 1474-547X (Electronic) IS - 0140-6736 (Linking) VI - 403 IP - 10435 DP - 2024 Apr 13 TI - Transcatheter aortic valve implantation in patients with high-risk symptomatic native aortic regurgitation (ALIGN-AR): a prospective, multicentre, single-arm study. PG - 1451-1459 LID - S0140-6736(23)02806-4 [pii] LID - 10.1016/S0140-6736(23)02806-4 [doi] AB - BACKGROUND: Surgery remains the only recommended intervention for patients with native aortic regurgitation. A transcatheter therapy to treat patients at high risk for mortality and complications with surgical aortic valve replacement represents an unmet need. Commercial transcatheter heart valves in pure aortic regurgitation are hampered by unacceptable rates of embolisation and paravalvular regurgitation. The Trilogy transcatheter heart valve (JenaValve Technology, Irvine, CA, USA) provides a treatment option for these patients. We report outcomes with transfemoral transcatheter aortic valve implantation (TAVI) in patients with pure aortic regurgitation using this dedicated transcatheter heart valve. METHODS: The ALIGN-AR trial is a prospective, multicentre, single-arm study. We recruited symptomatic patients (aged >/=18 years) with moderate-to-severe or severe aortic regurgitation at high risk for mortality and complications after surgical aortic valve replacement at 20 US sites for treatment with the Trilogy transcatheter heart valve. The 30-day composite primary safety endpoint was compared for non-inferiority with a prespecified performance goal of 40.5%. The primary efficacy endpoint was 1-year all-cause mortality compared for non-inferiority with a performance goal of 25%. This trial is registered with ClinicalTrials.gov, NCT04415047, and is ongoing. FINDINGS: Between June 8, 2018, and Aug 29, 2022, we screened 346 patients. We excluded 166 (48%) patients and enrolled 180 (52%) patients with symptomatic aortic regurgitation deemed high risk by the heart team and independent screening committee assessments. The mean age of the study population was 75.5 years (SD 10.8), and 85 (47%) were female, 95 (53%) were male, and 131 (73%) were White. Technical success was achieved in 171 (95%) patients. At 30 days, four (2%) deaths, two (1%) disabling strokes, and two (1%) non-disabling strokes occurred. Using standard Valve Academic Research Consortium-2 definitions, the primary safety endpoint was achieved, with events occurring in 48 (27% [97.5% CI 19.2-34.0]) patients (p(non-inferiority)<0.0001), with new pacemaker implantation in 36 (24%) patients. The primary efficacy endpoint was achieved, with mortality in 14 (7.8% [3.3-12.3]) patients at 1 year (p(non-inferiority)<0.0001). INTERPRETATION: This study shows the safety and effectiveness of treating native aortic regurgitation using a dedicated transcatheter heart valve to treat patients with symptomatic moderate-to-severe or severe aortic regurgitation who are at high risk for mortality or complications after surgical aortic valve replacement. The observed short-term clinical and haemodynamic outcomes are promising as are signs of left ventricular remodelling, but long-term follow-up is necessary. FUNDING: JenaValve Technology. CI - Copyright (c) 2024 Elsevier Ltd. All rights reserved. FAU - Vahl, Torsten P AU - Vahl TP AD - Columbia University Irving Medical Center, New York, NY, USA. Electronic address: tv2193@columbia.edu. FAU - Thourani, Vinod H AU - Thourani VH AD - Piedmont Heart Institute, Atlanta, GA, USA. FAU - Makkar, Raj R AU - Makkar RR AD - Cedars Sinai Medical Center, Los Angeles, CA, USA. FAU - Hamid, Nadira AU - Hamid N AD - Minneapolis Heart Institute, Minneapolis, MN, USA. FAU - Khalique, Omar K AU - Khalique OK AD - St Francis Hospital and Heart Center, Roslyn, NY, USA. FAU - Daniels, David AU - Daniels D AD - California Pacific Medical Center, San Francisco, CA, USA. FAU - McCabe, James M AU - McCabe JM AD - University of Washington, Seattle, WA, USA. FAU - Satler, Lowell AU - Satler L AD - Medstar Washington Hospital Center, Washington, DC, USA. FAU - Russo, Mark AU - Russo M AD - Rutgers University, New Brunswick, NJ, USA. FAU - Cheng, Wen AU - Cheng W AD - Cedars Sinai Medical Center, Los Angeles, CA, USA. FAU - George, Isaac AU - George I AD - Columbia University Irving Medical Center, New York, NY, USA. FAU - Aldea, Gabriel AU - Aldea G AD - University of Washington, Seattle, WA, USA. FAU - Sheridan, Brett AU - Sheridan B AD - California Pacific Medical Center, San Francisco, CA, USA. FAU - Kereiakes, Dean AU - Kereiakes D AD - Christ Hospital, Cincinnati, OH, USA. FAU - Golwala, Harsh AU - Golwala H AD - Oregon Health Sciences, Portland, OR, USA. FAU - Zahr, Firas AU - Zahr F AD - Oregon Health Sciences, Portland, OR, USA. FAU - Chetcuti, Stanley AU - Chetcuti S AD - University of Michigan, Ann Arbor, MI, USA. FAU - Yadav, Pradeep AU - Yadav P AD - Piedmont Heart Institute, Atlanta, GA, USA. FAU - Kodali, Susheel K AU - Kodali SK AD - Columbia University Irving Medical Center, New York, NY, USA. FAU - Treede, Hendrik AU - Treede H AD - University Medical Center of the Johannes Gutenberg University, Mainz, Germany. FAU - Baldus, Stephan AU - Baldus S AD - Clinic III for Internal Medicine, University Hospital Cologne, Cologne, Germany. FAU - Amoroso, Nicholas AU - Amoroso N AD - Medical University of South Carolina, Charleston, SC, USA. FAU - Ranard, Lauren S AU - Ranard LS AD - Columbia University Irving Medical Center, New York, NY, USA. FAU - Pinto, Duane S AU - Pinto DS AD - Beth Israel Deaconess Medical Center, Interventional Cardiology Section, Division of Cardiology, Boston, MA, USA. FAU - Leon, Martin B AU - Leon MB AD - Columbia University Irving Medical Center, New York, NY, USA. LA - eng SI - ClinicalTrials.gov/NCT04415047 PT - Clinical Trial PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't DEP - 20240326 PL - England TA - Lancet JT - Lancet (London, England) JID - 2985213R SB - IM CIN - Lancet. 2024 Apr 13;403(10435):1420-1421. doi: 10.1016/S0140-6736(24)00062-X. PMID: 38552657 MH - Adolescent MH - Adult MH - Aged MH - Female MH - Humans MH - Male MH - Aortic Valve/diagnostic imaging/surgery MH - *Aortic Valve Insufficiency/etiology/surgery MH - *Aortic Valve Stenosis/surgery MH - *Heart Valve Prosthesis MH - Prospective Studies MH - Prosthesis Design MH - Risk Factors MH - *Transcatheter Aortic Valve Replacement/adverse effects MH - Treatment Outcome COIS- Declaration of interests TPV reports institutional funding to Columbia University Irving Medical Center from JenaValve Technology, Abbott Vascular, Boston Scientific, Edwards Lifesciences, and Medtronic; and he personally received consulting fees from 4C Medical and Philips. OKK reports that he is part of a core laboratory contracting with JenaValve Technology but he has not received any direct compensation; he further reports consulting fees from Edwards Lifesciences, VDyne, Siemens, Philips, Laralab, and Restore Medical. NH reports that she is part of a core laboratory contracting with JenaValve Technology but she has not received any direct compensation. JMM reports consulting fees and honoraria from Edwards Lifesciences, Medtronic, Abbott, Shockwave, and Equity in Excision Medical, and Conkay Medical. IG reports consulting fees from Edwards Lifesciences, Medtronic, Boston Scientific, Abbott SJM, and Atricure. SKK reports consultant fees (honoraria) from Admedus, Meril Lifesciences, JenaValve Technology, and Abbott Vascular; scientific advisory board participation (equity) with Dura Biotech, MicroInterventional Devices, Thubrikar Aortic Valve, Supira, and Admedus; and institutional funding to Columbia University and the Cardiovascular Research Foundation from Edwards Lifesciences, Medtronic, Abbott Vascular, Boston Scientific, and JenaValve Technology. NA reports medical advisory board fees and consultant and proctor fees from Nininger Medical, Edwards Lifesciences, V-wave, JenaValve Technology, Abbott, Vdyne, and Boston Scientific, and participation in industry-sponsored trials and research funding from Edwards Lifesciences, JenaValve Technology, Boston Scientific, V-wave, AccuCinch, Highlife, Tendyne, and preCardia. DSP is the Chief Medical officer of JenaValve Technology and a consultant for Abiomed, Abbott Vascular, Magenta, NuPulseCV, and Terumo. MBL reports institutional clinical research grants from Abbott, Boston Scientific, Edwards Lifesciences, Medtronic, and JenaValve Technology. HG reports consulting fees from Medtronic and Boston Scientific. All other authors declare no competing interests. EDAT- 2024/03/30 11:43 MHDA- 2024/04/15 06:43 CRDT- 2024/03/29 19:55 PHST- 2023/10/08 00:00 [received] PHST- 2023/11/11 00:00 [revised] PHST- 2023/12/12 00:00 [accepted] PHST- 2024/04/15 06:43 [medline] PHST- 2024/03/30 11:43 [pubmed] PHST- 2024/03/29 19:55 [entrez] AID - S0140-6736(23)02806-4 [pii] AID - 10.1016/S0140-6736(23)02806-4 [doi] PST - ppublish SO - Lancet. 2024 Apr 13;403(10435):1451-1459. doi: 10.1016/S0140-6736(23)02806-4. Epub 2024 Mar 26. PMID- 38551614 OWN - NLM STAT- MEDLINE DCOM- 20240613 LR - 20240613 IS - 1827-1596 (Electronic) IS - 0375-9393 (Linking) VI - 90 IP - 6 DP - 2024 Jun TI - Cardiogenic shock diagnosis and management in general intensive care: a nationwide survey. PG - 530-538 LID - 10.23736/S0375-9393.24.17908-4 [doi] AB - BACKGROUND: the epidemiology of cardiogenic shock has evolved over the years: in the last decades an increasing prevalence of cardiogenic shock related to acute decompensated heart failure was observed. Therefore, treatment bundles should be updated according to the underlying pathophysiology. No data exist regarding the diagnostic/therapeutic strategies in general intensive care units. METHODS: A 27-questions survey was spread through the GiViTi (Italian Group for the Evaluation of Interventions in Intensive Care Medicine). The results were then divided according to level of hospitals (1(st)-2(nd) versus 3(rd)). RESULTS: Sixty-nine general intensive care units replied to the survey. The shock team is present in 13% of institutions; Society for Cardiovascular Angiography and Interventions shock classification is applied only in 18.8%. Among the ICUs, 94.2% routinely use a cardiac output monitoring device (pulmonary artery catheter more frequently in 3(rd) level centers). The first-line adrenergic drug are vasopressors in 27.5%, inotrope in 21.7% or their combination in 50.7%; 79.7% applies fluid challenge. The first vasopressor of choice is norepinephrine (95.7%) (maximum dosage tolerated higher than 0.5 mcg/kg/min in 29%); the first line inotrope is dobutamine (52.2%), followed by epinephrine in 36.2%. The most frequently used mechanical circulatory supports are intra-aortic balloon pump (71%), Impella (34.8%) and VA-ECMO (33.3%); VA-ECMO is the first line strategy in refractory cardiogenic shock (60.8%). CONCLUSIONS: According to this survey, there is no standardized approach to cardiogenic shock amongst Italian general intensive care units. The application of shock severity stratification and the treatment bundles may play a key role in improving the outcome. FAU - Colombo, Costanza N AU - Colombo CN AD - University of Pavia, Pavia, Italy - cnj.colombo@gmail.com. AD - Department of Anesthesia and Intensive Care, IRCCS Foundation Policlinico San Matteo, Pavia, Italy - cnj.colombo@gmail.com. FAU - Tavazzi, Guido AU - Tavazzi G AD - Department of Anesthesia and Intensive Care, IRCCS Foundation Policlinico San Matteo, Pavia, Italy. AD - Department of Surgical, Pediatric, and Diagnostic Sciences, University of Pavia, Pavia, Italy. FAU - Zanetti, Michele AU - Zanetti M AD - Unit of Computer Science for Clinical Knowledge Sharing, Department of Medical Epidemiology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Ranica, Bergamo, Italy. FAU - Dore, Francesca AU - Dore F AD - Laboratory of Clinical Data Science, Department of Medical Epidemiology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Ranica, Bergamo, Italy. FAU - Finazzi, Stefano AU - Finazzi S AD - Laboratory of Clinical Data Science, Department of Medical Epidemiology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Ranica, Bergamo, Italy. CN - GiViTi LA - eng PT - Journal Article DEP - 20240329 PL - Italy TA - Minerva Anestesiol JT - Minerva anestesiologica JID - 0375272 SB - IM MH - *Shock, Cardiogenic/therapy/diagnosis MH - Humans MH - *Critical Care/methods MH - Italy MH - Intensive Care Units MH - Surveys and Questionnaires MH - Health Care Surveys EDAT- 2024/03/29 12:51 MHDA- 2024/06/13 12:42 CRDT- 2024/03/29 11:49 PHST- 2024/06/13 12:42 [medline] PHST- 2024/03/29 12:51 [pubmed] PHST- 2024/03/29 11:49 [entrez] AID - S0375-9393.24.17908-4 [pii] AID - 10.23736/S0375-9393.24.17908-4 [doi] PST - ppublish SO - Minerva Anestesiol. 2024 Jun;90(6):530-538. doi: 10.23736/S0375-9393.24.17908-4. Epub 2024 Mar 29. PMID- 38548461 OWN - NLM STAT- MEDLINE DCOM- 20240401 LR - 20240401 IS - 1557-9859 (Electronic) IS - 0025-7125 (Linking) VI - 108 IP - 3 DP - 2024 May TI - When to Consider Coronary Revascularization for Stable Coronary Artery Disease. PG - 517-538 LID - S0025-7125(23)00176-1 [pii] LID - 10.1016/j.mcna.2023.11.006 [doi] AB - Revascularization is an effective adjunct to medical therapy for some patients with chronic coronary disease. Despite numerous randomized trials, there remains significant uncertainty regarding if and how to revascularize many patients. Coronary artery bypass grafting is a class I indication for patients with significant left main stenosis or multivessel disease with ejection fraction T; p.Cys122Tyr) in an ATS1 family. To investigate its pathophysiological implications, we generated an AAV9-mediated cardiac-specific mouse model expressing the Kir2.1(C122Y) variant. We employed a multidisciplinary approach, integrating patch clamping and intracardiac stimulation, molecular biology techniques, molecular dynamics, and bioluminescence resonance energy transfer experiments. RESULTS: Kir2.1(C122Y) mice recapitulated the ECG features of ATS1 independently of sex, including corrected QT prolongation, conduction defects, and increased arrhythmia susceptibility. Isolated Kir2.1(C122Y) cardiomyocytes showed significantly reduced inwardly rectifier K+ (I(K1)) and inward Na+ (I(Na)) current densities independently of normal trafficking. Molecular dynamics predicted that the C122Y mutation provoked a conformational change over the 2000-ns simulation, characterized by a greater loss of hydrogen bonds between Kir2.1 and phosphatidylinositol 4,5-bisphosphate than wild type (WT). Therefore, the phosphatidylinositol 4,5-bisphosphate-binding pocket was destabilized, resulting in a lower conductance state compared with WT. Accordingly, on inside-out patch clamping, the C122Y mutation significantly blunted Kir2.1 sensitivity to increasing phosphatidylinositol 4,5-bisphosphate concentrations. In addition, the Kir2.1(C122Y) mutation resulted in channelosome degradation, demonstrating temporal instability of both Kir2.1 and Na(V)1.5 proteins. CONCLUSIONS: The extracellular Cys(122)-to-Cys(154) disulfide bond in the tridimensional Kir2.1 channel structure is essential for the channel function. We demonstrate that breaking disulfide bonds in the extracellular domain disrupts phosphatidylinositol 4,5-bisphosphate-dependent regulation, leading to channel dysfunction and defects in Kir2.1 energetic stability. The mutation also alters functional expression of the Na(V)1.5 channel and ultimately leads to conduction disturbances and life-threatening arrhythmia characteristic of Andersen-Tawil syndrome type 1. FAU - Cruz, Francisco M AU - Cruz FM AUID- ORCID: 0000-0001-5330-8613 AD - Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain (F.M.C., A.M., A.I.M.-M., L.K.G., M.L.V.-P., I.M.-C., P.S.P., J.M.R.R., F.J.B.-J., F.M.d.B., J.A.B., J.J.). FAU - Macias, Alvaro AU - Macias A AUID- ORCID: 0000-0002-9952-6947 AD - Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain (F.M.C., A.M., A.I.M.-M., L.K.G., M.L.V.-P., I.M.-C., P.S.P., J.M.R.R., F.J.B.-J., F.M.d.B., J.A.B., J.J.). FAU - Moreno-Manuel, Ana I AU - Moreno-Manuel AI AUID- ORCID: 0000-0002-5011-2786 AD - Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain (F.M.C., A.M., A.I.M.-M., L.K.G., M.L.V.-P., I.M.-C., P.S.P., J.M.R.R., F.J.B.-J., F.M.d.B., J.A.B., J.J.). FAU - Gutierrez, Lilian K AU - Gutierrez LK AD - Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain (F.M.C., A.M., A.I.M.-M., L.K.G., M.L.V.-P., I.M.-C., P.S.P., J.M.R.R., F.J.B.-J., F.M.d.B., J.A.B., J.J.). FAU - Vera-Pedrosa, Maria Linarejos AU - Vera-Pedrosa ML AD - Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain (F.M.C., A.M., A.I.M.-M., L.K.G., M.L.V.-P., I.M.-C., P.S.P., J.M.R.R., F.J.B.-J., F.M.d.B., J.A.B., J.J.). FAU - Martinez-Carrascoso, Isabel AU - Martinez-Carrascoso I AD - Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain (F.M.C., A.M., A.I.M.-M., L.K.G., M.L.V.-P., I.M.-C., P.S.P., J.M.R.R., F.J.B.-J., F.M.d.B., J.A.B., J.J.). FAU - Sanchez Perez, Patricia AU - Sanchez Perez P AD - Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain (F.M.C., A.M., A.I.M.-M., L.K.G., M.L.V.-P., I.M.-C., P.S.P., J.M.R.R., F.J.B.-J., F.M.d.B., J.A.B., J.J.). FAU - Ruiz Robles, Juan Manuel AU - Ruiz Robles JM AUID- ORCID: 0000-0002-0566-9315 AD - Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain (F.M.C., A.M., A.I.M.-M., L.K.G., M.L.V.-P., I.M.-C., P.S.P., J.M.R.R., F.J.B.-J., F.M.d.B., J.A.B., J.J.). FAU - Bermudez-Jimenez, Francisco J AU - Bermudez-Jimenez FJ AUID- ORCID: 0000-0003-0325-7349 AD - Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain (F.M.C., A.M., A.I.M.-M., L.K.G., M.L.V.-P., I.M.-C., P.S.P., J.M.R.R., F.J.B.-J., F.M.d.B., J.A.B., J.J.). AD - Servicio de Cardiologia (F.J.B.-J., J.J.-J.), Hospital Universitario Virgen de las Nieves, Granada, Spain. AD - Instituto de Investigacion Biosanitaria de Granada IBS (Instituto de investigaciones biosanitarias), Spain (F.J.B.-J., S.A.-S., J.J.-J.). FAU - Diaz-Agustin, Aitor AU - Diaz-Agustin A AD - Instituto de Quimica Medica, Consejo Superior de Investigaciones Cientificas, Madrid, Spain (A.D.-A., M.M.-M., M.G.-R.). FAU - Martinez de Benito, Fernando AU - Martinez de Benito F AUID- ORCID: 0000-0003-1904-5164 AD - Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain (F.M.C., A.M., A.I.M.-M., L.K.G., M.L.V.-P., I.M.-C., P.S.P., J.M.R.R., F.J.B.-J., F.M.d.B., J.A.B., J.J.). AD - CIBER (Centro de Investigacion biomedica en Red) de Enfermedades Cardiovasculares, Madrid, Spain (F.M.d.B., J.A.B., E.Z., J.J.). FAU - Arias-Santiago, Salvador AU - Arias-Santiago S AUID- ORCID: 0000-0002-4186-1435 AD - Servicio de Dermatologia (S.A.-S.), Hospital Universitario Virgen de las Nieves, Granada, Spain. AD - Instituto de Investigacion Biosanitaria de Granada IBS (Instituto de investigaciones biosanitarias), Spain (F.J.B.-J., S.A.-S., J.J.-J.). FAU - Braza-Boils, Aitana AU - Braza-Boils A AD - Unit of Inherited Cardiomyopathies and Sudden Death (CAFAMUSME [Unidad de Cardiopatias Familiares, Muerte Subita y Mecanismos de Enfermedad]), Health Research Institute La Fe, La Fe Hospital, Valencia, Spain (A.B.-B., E.Z.). FAU - Martin-Martinez, Mercedes AU - Martin-Martinez M AD - Instituto de Quimica Medica, Consejo Superior de Investigaciones Cientificas, Madrid, Spain (A.D.-A., M.M.-M., M.G.-R.). FAU - Gutierrez-Rodriguez, Marta AU - Gutierrez-Rodriguez M AUID- ORCID: 0000-0001-9855-8341 AD - Instituto de Quimica Medica, Consejo Superior de Investigaciones Cientificas, Madrid, Spain (A.D.-A., M.M.-M., M.G.-R.). FAU - Bernal, Juan A AU - Bernal JA AUID- ORCID: 0000-0002-9933-5550 AD - Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain (F.M.C., A.M., A.I.M.-M., L.K.G., M.L.V.-P., I.M.-C., P.S.P., J.M.R.R., F.J.B.-J., F.M.d.B., J.A.B., J.J.). AD - CIBER (Centro de Investigacion biomedica en Red) de Enfermedades Cardiovasculares, Madrid, Spain (F.M.d.B., J.A.B., E.Z., J.J.). FAU - Zorio, Esther AU - Zorio E AUID- ORCID: 0000-0003-3608-4210 AD - CIBER (Centro de Investigacion biomedica en Red) de Enfermedades Cardiovasculares, Madrid, Spain (F.M.d.B., J.A.B., E.Z., J.J.). AD - Unit of Inherited Cardiomyopathies and Sudden Death (CAFAMUSME [Unidad de Cardiopatias Familiares, Muerte Subita y Mecanismos de Enfermedad]), Health Research Institute La Fe, La Fe Hospital, Valencia, Spain (A.B.-B., E.Z.). FAU - Jimenez-Jaimez, Juan AU - Jimenez-Jaimez J AUID- ORCID: 0000-0001-5541-898X AD - Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain (F.M.C., A.M., A.I.M.-M., L.K.G., M.L.V.-P., I.M.-C., P.S.P., J.M.R.R., F.J.B.-J., F.M.d.B., J.A.B., J.J.). AD - Servicio de Cardiologia (F.J.B.-J., J.J.-J.), Hospital Universitario Virgen de las Nieves, Granada, Spain. AD - Instituto de Investigacion Biosanitaria de Granada IBS (Instituto de investigaciones biosanitarias), Spain (F.J.B.-J., S.A.-S., J.J.-J.). FAU - Jalife, Jose AU - Jalife J AUID- ORCID: 0000-0003-0080-3500 AD - CIBER (Centro de Investigacion biomedica en Red) de Enfermedades Cardiovasculares, Madrid, Spain (F.M.d.B., J.A.B., E.Z., J.J.). AD - Departments of Medicine and Molecular & Integrative Physiology, University of Michigan, Ann Arbor (J.J.). LA - eng GR - L60 MD007229/MD/NIMHD NIH HHS/United States GR - R01 HL163943/HL/NHLBI NIH HHS/United States PT - Journal Article DEP - 20240318 PL - United States TA - Circ Res JT - Circulation research JID - 0047103 RN - 0 (Disulfides) RN - 0 (Phosphatidylinositols) SB - IM MH - Humans MH - Mice MH - Animals MH - *Andersen Syndrome/genetics/metabolism MH - Mutation MH - Myocytes, Cardiac/metabolism MH - Cardiac Conduction System Disease MH - Disulfides MH - Phosphatidylinositols/metabolism PMC - PMC11009053 MID - NIHMS1971999 OTO - NOTNLM OT - andersen syndrome OT - arrhythmias, cardiac OT - death, sudden, cardiac OT - membrane potentials OT - organisms, genetically modified OT - tachycardia, ventricular OT - ventricular fibrillation COIS- Disclosures None. EDAT- 2024/03/18 06:42 MHDA- 2024/04/15 06:43 PMCR- 2025/04/12 CRDT- 2024/03/18 05:04 PHST- 2024/04/15 06:43 [medline] PHST- 2024/03/18 06:42 [pubmed] PHST- 2024/03/18 05:04 [entrez] PHST- 2025/04/12 00:00 [pmc-release] AID - 10.1161/CIRCRESAHA.123.323895 [doi] PST - ppublish SO - Circ Res. 2024 Apr 12;134(8):e52-e71. doi: 10.1161/CIRCRESAHA.123.323895. Epub 2024 Mar 18. PMID- 38495666 OWN - NLM STAT- MEDLINE DCOM- 20240319 LR - 20240319 IS - 1947-6108 (Electronic) IS - 1947-6094 (Print) IS - 1947-6108 (Linking) VI - 20 IP - 2 DP - 2024 TI - The Impact of Pregnancy in Patients with Thoracic Aortic Disease: Epidemiology, Risk Assessment, and Management Considerations. PG - 51-58 LID - 10.14797/mdcvj.1371 [doi] AB - Thoracic aortic disease (TAD) poses substantial risks during pregnancy, particularly for women with genetic conditions such as Marfan syndrome, Loeys-Dietz syndrome, and vascular Ehlers-Danlos syndrome. This review examines the epidemiology, risk assessment, and management of TAD in pregnancy. Preconception counseling is vital considering the hereditary nature of TAD and potential pregnancy-related complications. Genetic testing and imaging surveillance aid in risk assessment. Medical management, including beta-blockade and strict blood pressure control, is essential throughout pregnancy. Surgical interventions may be necessary in certain cases. A multidisciplinary approach involving cardiologists, obstetricians, cardiac surgeons, anesthesiologists, and other specialists with expertise in cardio-obstetrics is essential for optimal outcomes. Patient education and shared decision-making play vital roles in navigating the complexities of TAD in pregnancy and improving maternal and neonatal outcomes. CI - Copyright: (c) 2024 The Author(s). FAU - Duarte, Valeria E AU - Duarte VE AUID- ORCID: 0000-0001-6616-5412 AD - Houston Methodist DeBakey Heart & Vascular Center, Houston, Texas, US. AD - Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, US. FAU - Richardson, Jessica N AU - Richardson JN AUID- ORCID: 0009-0006-9960-1261 AD - Houston Methodist DeBakey Heart & Vascular Center, Houston, Texas, US. FAU - Singh, Michael N AU - Singh MN AUID- ORCID: 0000-0002-8667-9872 AD - Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, US. AD - Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, US. LA - eng PT - Journal Article PT - Review DEP - 20240314 PL - United States TA - Methodist Debakey Cardiovasc J JT - Methodist DeBakey cardiovascular journal JID - 101508600 SB - IM MH - Pregnancy MH - Infant, Newborn MH - Humans MH - Female MH - *Aortic Diseases MH - Aorta MH - *Loeys-Dietz Syndrome/complications MH - *Marfan Syndrome/diagnosis/epidemiology/therapy MH - Risk Assessment PMC - PMC10941705 OTO - NOTNLM OT - Marfan OT - aortopathy OT - cardiovascular genetics OT - pregnancy COIS- The authors have no competing interests to declare. EDAT- 2024/03/18 06:43 MHDA- 2024/03/19 06:44 PMCR- 2024/03/14 CRDT- 2024/03/18 04:25 PHST- 2024/02/20 00:00 [received] PHST- 2024/02/23 00:00 [accepted] PHST- 2024/03/19 06:44 [medline] PHST- 2024/03/18 06:43 [pubmed] PHST- 2024/03/18 04:25 [entrez] PHST- 2024/03/14 00:00 [pmc-release] AID - 10.14797/mdcvj.1371 [doi] PST - epublish SO - Methodist Debakey Cardiovasc J. 2024 Mar 14;20(2):51-58. doi: 10.14797/mdcvj.1371. eCollection 2024. PMID- 38495662 OWN - NLM STAT- MEDLINE DCOM- 20240319 LR - 20240319 IS - 1947-6108 (Electronic) IS - 1947-6094 (Print) IS - 1947-6108 (Linking) VI - 20 IP - 2 DP - 2024 TI - High-Risk Congenital Heart Disease in Pregnancy. PG - 24-35 LID - 10.14797/mdcvj.1306 [doi] AB - High-risk congenital heart disease (CHD) in pregnancy presents a complex clinical challenge. With improved medical care and increased survival rates, a growing population of adults with complex CHD are surviving to adulthood, including women of reproductive age. This chapter focuses on risk stratification and management of pregnant women with high-risk CHD, emphasizing the importance of considering both anatomical and physiological complexity. Maternal physiological changes, such as blood volume increase, cardiac output changes, and alterations in vascular resistance, can significantly impact high-risk CHD patients. Management of high-risk CHD in pregnancy necessitates a multidisciplinary approach and individualized care. CI - Copyright: (c) 2024 The Author(s). FAU - Rajpal, Saurabh AU - Rajpal S AUID- ORCID: 0000-0003-0772-8478 AD - The Ohio State University Wexner Medical Center, Columbus, Ohio, US. AD - Nationwide Children's Hospital, Columbus, Ohio, US. FAU - Rodriguez, Carla P AU - Rodriguez CP AUID- ORCID: 0000-0001-9297-4416 AD - Nationwide Children's Hospital, Columbus, Ohio, US. AD - Boston Children's Hospital and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, US. LA - eng PT - Journal Article PT - Review DEP - 20240314 PL - United States TA - Methodist Debakey Cardiovasc J JT - Methodist DeBakey cardiovascular journal JID - 101508600 SB - IM MH - Adult MH - Humans MH - Female MH - Pregnancy MH - *Heart Defects, Congenital/diagnostic imaging/epidemiology MH - Hemodynamics MH - Reproduction MH - *Pregnancy Complications, Cardiovascular/diagnosis/epidemiology/therapy PMC - PMC10941697 OTO - NOTNLM OT - Fontan circulation OT - cardiac risk stratification in pregnancy OT - complex congenital heart disease OT - cyanotic congenital heart disease OT - systemic right ventricle COIS- The authors have no competing interests to declare. EDAT- 2024/03/18 06:42 MHDA- 2024/03/19 06:44 PMCR- 2024/03/14 CRDT- 2024/03/18 04:24 PHST- 2023/10/25 00:00 [received] PHST- 2024/01/03 00:00 [accepted] PHST- 2024/03/19 06:44 [medline] PHST- 2024/03/18 06:42 [pubmed] PHST- 2024/03/18 04:24 [entrez] PHST- 2024/03/14 00:00 [pmc-release] AID - 10.14797/mdcvj.1306 [doi] PST - epublish SO - Methodist Debakey Cardiovasc J. 2024 Mar 14;20(2):24-35. doi: 10.14797/mdcvj.1306. eCollection 2024. PMID- 38495654 OWN - NLM STAT- MEDLINE DCOM- 20240319 LR - 20240319 IS - 1947-6108 (Electronic) IS - 1947-6094 (Print) IS - 1947-6108 (Linking) VI - 20 IP - 2 DP - 2024 TI - An Overview of Arrhythmias in Pregnancy. PG - 36-50 LID - 10.14797/mdcvj.1325 [doi] AB - Cardiovascular disease significantly jeopardizes pregnancies in the United States, impacting 1% to 4% of pregnancies annually. Among complications, cardiac arrhythmias are prevalent, posing concerns for maternal and fetal health. The incidence of arrhythmias during pregnancy is rising, partly due to advances in congenital heart surgery and a growing population of women with structural heart disease. While most arrhythmias are benign, the increasing prevalence of more serious arrhythmias warrants a proactive approach. Guidance and reassurance suffice in many cases, but persistent symptoms require cautious use of antiarrhythmic drugs or other therapies for a safe outcome. Managing more serious arrhythmias requires a comprehensive, multidisciplinary approach involving specialists, including maternal-fetal medicine physicians, cardiologists, electrophysiologists, and anesthesiologists. CI - Copyright: (c) 2024 The Author(s). FAU - Tamirisa, Kamala P AU - Tamirisa KP AUID- ORCID: 0000-0002-2808-3499 AD - Texas Cardiac Arrhythmia Institute, Dallas, Texas, US. FAU - Oliveros, Estefania AU - Oliveros E AUID- ORCID: 0000-0003-1780-1982 AD - Temple University Hospital, Philadelphia, Pennsylvania, US. FAU - Paulraj, Shweta AU - Paulraj S AUID- ORCID: 0000-0001-6891-822X AD - SUNY Upstate Medical University, Syracuse, New York, US. FAU - Mares, Adriana C AU - Mares AC AUID- ORCID: 0000-0003-3870-6263 AD - Yale University Medical School, New Haven, Connecticut, US. FAU - Volgman, Annabelle Santos AU - Volgman AS AUID- ORCID: 0000-0002-9918-0878 AD - Rush University Medical Center, Chicago, Illinois, US. LA - eng PT - Journal Article PT - Review DEP - 20240314 PL - United States TA - Methodist Debakey Cardiovasc J JT - Methodist DeBakey cardiovascular journal JID - 101508600 RN - 0 (Anti-Arrhythmia Agents) SB - IM MH - Pregnancy MH - Female MH - Humans MH - United States MH - *Arrhythmias, Cardiac/diagnosis/epidemiology/therapy MH - *Anti-Arrhythmia Agents/adverse effects PMC - PMC10941715 OTO - NOTNLM OT - antiarrhythmic OT - cardio-obstetrics OT - maternal arrhythmias OT - pregnancy COIS- Kamala Tamirisa is on the Speakers Bureau for Abbott and Sanofi; Estefania Oliveros is funded by a research grant from Johnson and Johnson; Annabelle Santos Volgman is a consultant for Sanofi, Pfizer, Janssen, Novartis, and NIH Clinical Trials and holds stock in Apple, Inc. The other authors have no competing interests to declare. EDAT- 2024/03/18 06:42 MHDA- 2024/03/19 06:44 PMCR- 2024/03/14 CRDT- 2024/03/18 04:24 PHST- 2023/12/02 00:00 [received] PHST- 2023/12/27 00:00 [accepted] PHST- 2024/03/19 06:44 [medline] PHST- 2024/03/18 06:42 [pubmed] PHST- 2024/03/18 04:24 [entrez] PHST- 2024/03/14 00:00 [pmc-release] AID - 10.14797/mdcvj.1325 [doi] PST - epublish SO - Methodist Debakey Cardiovasc J. 2024 Mar 14;20(2):36-50. doi: 10.14797/mdcvj.1325. eCollection 2024. PMID- 38495415 OWN - NLM STAT- MEDLINE DCOM- 20240319 LR - 20260519 IS - 2214-9996 (Electronic) IS - 2214-9996 (Linking) VI - 90 IP - 1 DP - 2024 TI - Adapting an Intervention to Improve Acute Myocardial Infarction Care in Tanzania: Co-Design of the MIMIC Intervention. PG - 21 LID - 10.5334/aogh.4361 [doi] LID - 21 AB - BACKGROUND: Uptake of evidence-based care for acute myocardial infarction (AMI) is suboptimal in Tanzania, but there are currently no published interventions to improve AMI care in sub-Saharan Africa. OBJECTIVES: Co-design a quality improvement intervention for AMI care tailored to local contextual factors. METHODS: An interdisciplinary design team consisting of 20 physicians, nurses, implementation scientists, and administrators met from June 2022 through August 2023. Half of the design team consisted of representatives from the target audience, emergency department physicians and nurses at a referral hospital in northern Tanzania. The design team reviewed multiple published quality improvement interventions focusing on ED-based AMI care. After selecting a multicomponent intervention to improve AMI care in Brazil (BRIDGE-ACS), the design team used the ADAPT-ITT framework to adapt the intervention to the local context. FINDINGS: The design team audited current AMI care processes at the study hospital and reviewed qualitative data regarding barriers to care. Multiple adaptations were made to the original BRIDGE-ACS intervention to suit the local context, including re-designing the physician reminder system and adding patient educational materials. Additional feedback was sought from topical experts, including patients with AMI. Draft intervention materials were iteratively refined in response to feedback from experts and the design team. The finalized intervention, Multicomponent Intervention to Improve Myocardial Infarction Care in Tanzania (MIMIC), consisted of five core components: physician reminders, pocket cards, champions, provider training, and patient education. CONCLUSION: MIMIC is the first locally tailored intervention to improve AMI care in sub-Saharan Africa. Future studies will evaluate implementation outcomes and efficacy. CI - Copyright: (c) 2024 The Author(s). FAU - Hertz, Julian T AU - Hertz JT AUID- ORCID: 0000-0002-7396-4789 AD - Duke Global Health Institute, Duke University, Durham, North Carolina, USA. AD - Department of Emergency Medicine, Duke University School of Medicine, Durham, North Carolina, USA. FAU - Stark, Kristen AU - Stark K AD - Duke Global Health Institute, Duke University, Durham, North Carolina, USA. FAU - Sakita, Francis M AU - Sakita FM AD - Kilimanjaro Christian Medical Center, Moshi, Tanzania. AD - Kilimanjaro Christian Medical University, Moshi, Tanzania. FAU - Mlangi, Jerome J AU - Mlangi JJ AD - Kilimanjaro Christian Medical Center, Moshi, Tanzania. FAU - Kweka, Godfrey L AU - Kweka GL AD - Kilimanjaro Christian Medical Center, Moshi, Tanzania. FAU - Prattipati, Sainikitha AU - Prattipati S AD - Duke Global Health Institute, Duke University, Durham, North Carolina, USA. FAU - Shayo, Frida AU - Shayo F AD - Kilimanjaro Christian Medical Center, Moshi, Tanzania. FAU - Kaboigora, Vivian AU - Kaboigora V AD - Kilimanjaro Christian Medical Center, Moshi, Tanzania. FAU - Mtui, Julius AU - Mtui J AD - Kilimanjaro Christian Medical Center, Moshi, Tanzania. FAU - Isack, Manji N AU - Isack MN AD - Kilimanjaro Christian Medical Center, Moshi, Tanzania. FAU - Kindishe, Esther M AU - Kindishe EM AD - Kilimanjaro Christian Medical Center, Moshi, Tanzania. FAU - Ngelengi, Dotto J AU - Ngelengi DJ AD - Kilimanjaro Christian Medical Center, Moshi, Tanzania. FAU - Limkakeng, Alexander T Jr AU - Limkakeng AT Jr AUID- ORCID: 0000-0002-9822-5595 AD - Department of Emergency Medicine, Duke University School of Medicine, Durham, North Carolina, USA. FAU - Thielman, Nathan M AU - Thielman NM AUID- ORCID: 0000-0001-8152-2879 AD - Duke Global Health Institute, Duke University, Durham, North Carolina, USA. AD - Department of Internal Medicine, Duke University, Durham, North Carolina, USA. FAU - Bloomfield, Gerald S AU - Bloomfield GS AUID- ORCID: 0000-0002-7176-1611 AD - Duke Global Health Institute, Duke University, Durham, North Carolina, USA. AD - Duke Clinical Research Institute, Durham, North Carolina, USA. FAU - Bettger, Janet P AU - Bettger JP AUID- ORCID: 0000-0001-9708-8413 AD - Duke Global Health Institute, Duke University, Durham, North Carolina, USA. FAU - Tarimo, Tumsifu G AU - Tarimo TG AD - Kilimanjaro Christian Medical Center, Moshi, Tanzania. LA - eng GR - K23 HL155500/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20240313 PL - United States TA - Ann Glob Health JT - Annals of global health JID - 101620864 SB - IM MH - Humans MH - Tanzania MH - *Myocardial Infarction/diagnosis/therapy MH - Quality Improvement MH - *Physicians MH - Brazil PMC - PMC10941691 OTO - NOTNLM OT - Acute Myocardial Infarction OT - Co-design OT - Implementation Science OT - quality improvement OT - sub-Saharan Africa COIS- ATL's and JTH's institution received research funding from Roche Diagnostics for a study in which they were co-investigators. ATL's institution received grant funding from Quidel Inc, Brainbox Inc, Abbott Laboratories, Forest Devices Inc, Becton Dickinson, SENSE Neuro Diagnostics, and Ophirex Inc for studies in which he was a co-investigator. ATL also served as a consultant on the advisory board of SenJam Pharma. All other authors have no competing interests to declare. EDAT- 2024/03/18 06:43 MHDA- 2024/03/19 06:43 PMCR- 2024/03/13 CRDT- 2024/03/18 04:20 PHST- 2023/11/08 00:00 [received] PHST- 2024/02/23 00:00 [accepted] PHST- 2024/03/19 06:43 [medline] PHST- 2024/03/18 06:43 [pubmed] PHST- 2024/03/18 04:20 [entrez] PHST- 2024/03/13 00:00 [pmc-release] AID - 10.5334/aogh.4361 [doi] PST - epublish SO - Ann Glob Health. 2024 Mar 13;90(1):21. doi: 10.5334/aogh.4361. eCollection 2024. PMID- 38492178 OWN - NLM STAT- MEDLINE DCOM- 20240529 LR - 20261010 IS - 1534-3170 (Electronic) IS - 1523-3782 (Linking) VI - 26 IP - 5 DP - 2024 May TI - Pacing and Defibrillation Consideration in the Era of Transcatheter Tricuspid Valve Replacement. PG - 331-338 LID - 10.1007/s11886-024-02032-7 [doi] AB - PURPOSE OF REVIEW: Tricuspid regurgitation is a commonly encountered valvular pathology in patients with trans-tricuspid pacing or implantable cardioverter-defibrillator leads. Transcatheter tricuspid valve interventions are increasingly performed in patients at high surgical risk. Implantation of these valves can lead to the "jailing" of a trans-tricuspid lead. This practice carries both short- and long-term risks of lead failure and subsequent infection without the ability to perform traditional transvenous lead extraction. Herein, this manuscript reviews available therapeutic options for lead management in patients undergoing transcatheter tricuspid valve interventions. RECENT FINDINGS: The decision to jail a lead may be appropriate in certain high-risk cases, though extraction may be a better option in most cases given the variety of options for re-implant, including leadless pacemakers, valve-sparing systems, epicardial leads, leads placed directly through prosthetic valves, and the completely subcutaneous implantable-defibrillator. A growing number of patients meet the requirement for CIED implantation in the United States. A significant proportion of these patients will have tricuspid valve dysfunction, either related to or independent of their transvenous lead. As with any percutaneous intervention that has shown efficacy, the role of TTVI is also likely to increase as this therapy advances beyond the investigational phase. As such, the role of the heart team in the management of these patients will be increasingly critical in the years to come, and in those patients that have pre-existing CIED leads, we advocate for the involvement of an electrophysiologist in the heart team. CI - (c) 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Dhindsa, Devinder S AU - Dhindsa DS AD - Department of Medicine, Division of Cardiology-Section of Electrophysiology, Emory University School of Medicine, Medical Office Tower 12th Floor, 550 Peachtree Street NE, Atlanta, GA, 30312, USA. FAU - Mekary, Wissam AU - Mekary W AD - Department of Medicine, Division of Cardiology-Section of Electrophysiology, Emory University School of Medicine, Medical Office Tower 12th Floor, 550 Peachtree Street NE, Atlanta, GA, 30312, USA. FAU - El-Chami, Mikhael F AU - El-Chami MF AD - Department of Medicine, Division of Cardiology-Section of Electrophysiology, Emory University School of Medicine, Medical Office Tower 12th Floor, 550 Peachtree Street NE, Atlanta, GA, 30312, USA. melcham@emory.edu. LA - eng PT - Journal Article PT - Review DEP - 20240316 PL - United States TA - Curr Cardiol Rep JT - Current cardiology reports JID - 100888969 SB - IM MH - Humans MH - *Tricuspid Valve Insufficiency/surgery MH - *Defibrillators, Implantable MH - *Tricuspid Valve/surgery MH - *Heart Valve Prosthesis Implantation/methods MH - *Pacemaker, Artificial MH - Cardiac Catheterization/methods MH - Cardiac Pacing, Artificial/methods MH - Heart Valve Prosthesis MH - Device Removal/methods OTO - NOTNLM OT - Extraction OT - Lead management OT - Leadless pacemaker OT - Transcatheter tricuspid valve replacement OT - Tricuspid regurgitation EDAT- 2024/03/16 21:47 MHDA- 2024/05/29 12:43 CRDT- 2024/03/16 12:20 PHST- 2024/02/26 00:00 [accepted] PHST- 2024/05/29 12:43 [medline] PHST- 2024/03/16 21:47 [pubmed] PHST- 2024/03/16 12:20 [entrez] AID - 10.1007/s11886-024-02032-7 [pii] AID - 10.1007/s11886-024-02032-7 [doi] PST - ppublish SO - Curr Cardiol Rep. 2024 May;26(5):331-338. doi: 10.1007/s11886-024-02032-7. Epub 2024 Mar 16. PMID- 38487046 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240316 IS - 2589-790X (Electronic) IS - 2589-790X (Linking) VI - 6 IP - 2Part B DP - 2024 Feb TI - Designing a Multidisciplinary Cardio-obstetrics Curriculum for General Cardiology and Obstetrics Residents: A National Survey of Educational Needs. PG - 174-181 LID - 10.1016/j.cjco.2023.12.014 [doi] AB - BACKGROUND: The increasing and potentially preventable cardiac events in pregnant patients have led to calls to enhance multidisciplinary cardio-obstetrics education. To design a multidisciplinary cardio-obstetrics curriculum for general cardiology and obstetrics and gynecology (OBGYN) residents, we need to define educational needs from the perspectives of both cardiology and OBGYN residents. Our study characterizes the educational needs of Canadian cardiology and OBGYN residents. METHODS: Canadian cardiology and OBGYN residents were surveyed on clinical exposures, perceived needs for topics, unperceived needs for topics (multiple-choice questions) and preferences for educational formats. High priorities were defined as >/= 50% of responses indicating a perceived need or >/= 50% indicating an unperceived need. RESULTS: A total of 154 residents participated (cardiology n = 44, OBGYN n = 110). Residents reported insufficient clinical exposure to nearly all cardiac disorders, with 33% of exposures occurring in multidisciplinary contexts. All topics aside from gestational hypertension were rated as high priority on perceived needs by both specialties. High-priority unperceived needs were congenital heart disease (both specialties), pre-existing acquired heart disease (both specialties), medication safety (OBGYN), peripartum management (OBGYN), and pregnancy-related heart disease (OBGYN). Cardiology and OBGYN residents shared preferences for in-person simulation, virtual simulation, and online modules. CONCLUSIONS: Residents in both specialties reported low clinical exposure to most cardiac disorders during pregnancy, identified high-priority perceived needs in multiple topics, and shared 2 high-priority unperceived needs. OBGYN residents identified 3 additional high-priority unperceived needs. These data can inform design of multidisciplinary cardio-obstetrics curricula for general cardiology and OBGYN residents. CI - (c) 2023 The Authors. FAU - Blissett, Sarah AU - Blissett S AD - Department of Medicine, Division of Cardiology, Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada. AD - Centre for Education Research & Innovation (CERI), Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada. FAU - Alphonsus, Lotus AU - Alphonsus L AD - Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada. FAU - Eastabrook, Genevieve AU - Eastabrook G AD - Department of Obstetrics and Gynecology, Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada. FAU - Banner, Harrison AU - Banner H AD - Department of Obstetrics and Gynecology, Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada. FAU - Siu, Samuel C AU - Siu SC AD - Department of Medicine, Division of Cardiology, Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada. LA - eng PT - Journal Article DEP - 20231218 PL - United States TA - CJC Open JT - CJC open JID - 101763635 PMC - PMC10935673 EDAT- 2024/03/15 06:44 MHDA- 2024/03/15 06:45 PMCR- 2023/12/18 CRDT- 2024/03/15 04:02 PHST- 2023/03/16 00:00 [received] PHST- 2023/12/10 00:00 [accepted] PHST- 2024/03/15 06:45 [medline] PHST- 2024/03/15 06:44 [pubmed] PHST- 2024/03/15 04:02 [entrez] PHST- 2023/12/18 00:00 [pmc-release] AID - S2589-790X(23)00382-7 [pii] AID - 10.1016/j.cjco.2023.12.014 [doi] PST - epublish SO - CJC Open. 2023 Dec 18;6(2Part B):174-181. doi: 10.1016/j.cjco.2023.12.014. eCollection 2024 Feb. PMID- 38486361 OWN - NLM STAT- MEDLINE DCOM- 20240422 LR - 20240422 IS - 1522-9645 (Electronic) IS - 0195-668X (Linking) VI - 45 IP - 16 DP - 2024 Apr 21 TI - Anderson-Fabry disease management: role of the cardiologist. PG - 1395-1409 LID - 10.1093/eurheartj/ehae148 [doi] AB - Anderson-Fabry disease (AFD) is a lysosomal storage disorder characterized by glycolipid accumulation in cardiac cells, associated with a peculiar form of hypertrophic cardiomyopathy (HCM). Up to 1% of patients with a diagnosis of HCM indeed have AFD. With the availability of targeted therapies for sarcomeric HCM and its genocopies, a timely differential diagnosis is essential. Specifically, the therapeutic landscape for AFD is rapidly evolving and offers increasingly effective, disease-modifying treatment options. However, diagnosing AFD may be difficult, particularly in the non-classic phenotype with prominent or isolated cardiac involvement and no systemic red flags. For many AFD patients, the clinical journey from initial clinical manifestations to diagnosis and appropriate treatment remains challenging, due to late recognition or utter neglect. Consequently, late initiation of treatment results in an exacerbation of cardiac involvement, representing the main cause of morbidity and mortality, irrespective of gender. Optimal management of AFD patients requires a dedicated multidisciplinary team, in which the cardiologist plays a decisive role, ranging from the differential diagnosis to the prevention of complications and the evaluation of timing for disease-specific therapies. The present review aims to redefine the role of cardiologists across the main decision nodes in contemporary AFD clinical care and drug discovery. CI - (c) The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com. FAU - Pieroni, Maurizio AU - Pieroni M AUID- ORCID: 0000-0002-6830-4292 AD - Cardiovascular Department, San Donato Hospital, Via Pietro Nenni 22, 52100 Arezzo, Italy. FAU - Namdar, Mehdi AU - Namdar M AD - Cardiology Division, Hopitaux Universitaires de Geneve, Geneva, Switzerland. FAU - Olivotto, Iacopo AU - Olivotto I AUID- ORCID: 0000-0003-1751-9266 AD - Cardiomyopathy Unit, Careggi Hospital and Meyer Children's Hospital IRCCS, Florence, Italy. AD - Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. FAU - Desnick, Robert J AU - Desnick RJ AD - Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA. LA - eng PT - Journal Article PT - Review PL - England TA - Eur Heart J JT - European heart journal JID - 8006263 SB - IM MH - Humans MH - *Cardiologists MH - *Fabry Disease/diagnosis/drug therapy MH - *Cardiomyopathy, Hypertrophic/diagnosis MH - Diagnosis, Differential OTO - NOTNLM OT - Anderson-Fabry disease OT - Artificial intelligence OT - Gene therapy OT - Hypertrophic cardiomyopathy EDAT- 2024/03/15 06:44 MHDA- 2024/04/22 06:43 CRDT- 2024/03/15 01:13 PHST- 2023/09/03 00:00 [received] PHST- 2024/02/04 00:00 [revised] PHST- 2024/02/27 00:00 [accepted] PHST- 2024/04/22 06:43 [medline] PHST- 2024/03/15 06:44 [pubmed] PHST- 2024/03/15 01:13 [entrez] AID - 7629175 [pii] AID - 10.1093/eurheartj/ehae148 [doi] PST - ppublish SO - Eur Heart J. 2024 Apr 21;45(16):1395-1409. doi: 10.1093/eurheartj/ehae148. PMID- 38485429 OWN - NLM STAT- MEDLINE DCOM- 20240318 LR - 20250709 IS - 2214-109X (Electronic) IS - 2214-109X (Linking) VI - 12 IP - 4 DP - 2024 Apr TI - Effects of a culturally informed model of care for Aboriginal and Torres Strait Islander patients with acute coronary syndrome in a tertiary hospital in Australia: a pre-post, quasi-experimental, interventional study. PG - e623-e630 LID - S2214-109X(23)00601-0 [pii] LID - 10.1016/S2214-109X(23)00601-0 [doi] AB - BACKGROUND: Aboriginal and Torres Strait Islander (Indigenous) peoples with cardiac disease in Australia have worse outcomes than non-Indigenous people with cardiac disease. We hypothesised that the implementation of a culturally informed model of care for Indigenous patients hospitalised with acute coronary syndrome (ACS) would improve their clinical outcomes. METHODS: For this pre-post, quasi-experimental, interventional study, cohorts of Indigenous patients before and after the implementation of a model of care were compared. The novel, culturally informed, multidisciplinary-team model of care was a local programme of care developed to reduce morbidity and mortality from cardiac conditions among Indigenous Australians. All index admissions in the 24-month pre-implementation period (Jan 1 2013, to Dec 31, 2014) were analysed, as were all index admissions in the 12-month post-implementation period (Oct 1, 2015, to Sept 30, 2016). Comparisons were also made with non-Indigenous cohorts in the same timeframes. Admissions were excluded if the patient did not survive to hospital discharge. The study was conducted at Princess Alexandra Hospital, a tertiary hospital in metropolitan Brisbane (QLD, Australia). Data on presentation, comorbidities, investigations, treatment, and for outcomes were manually collected from a consolidated clinical information application. Mortality data were obtained from the Queensland Registry of Births, Deaths, and Marriages. The primary outcome was a composite of death, acute myocardial infarction, unplanned revascularisation, and cardiac readmission at 90 days after index admission, assessed in all patients. FINDINGS: The Indigenous cohorts included 199 patients admitted with ACS before the model of care was implemented (85 [43%] were female and 114 [57%] were male) and 119 admitted post-implementation (62 [52%] were female and 57 [48%] were male). The non-Indigenous cohorts included 440 patients with ACS before the model of care was implemented (140 [32%] were female and 300 [68%] were male) and 467 admitted post-implementation (143 [31%] were female and 324 [69%] were male). Compared with the pre-implementation group, Indigenous patients admitted post-implementation had a significant reduction in the primary outcome (67 [34%] of 199 vs 24 [20%] of 119; hazard ratio 0.60, 95% CI 0.40-0.90; p=0.012), which was driven by a reduction in unplanned cardiac readmissions (64 [32%] of 199 vs 21 [18%] of 119; 0.55, 0.35-0.85; p=0.0060). There was no significant change in non-Indigenous patients between the pre-implementation and post-implementation timeframes in the composite endpoint at 90 days (81 [18%] of 440 vs 93 [20%] of 467; 1.08, 0.83-1.41; p=0.54). Pre-implementation, there was significantly more incidence of the primary outcome in Indigenous patients than non-Indigenous patients (p<0.0001), with no significant difference in the post-implementation period (p=0.92). INTERPRETATION: Clinical outcomes for Indigenous patients admitted to a tertiary hospital in Australia improved after implementation of a culturally informed model of care, with a reduction in the disparity in incidence of primary endpoints that existed between Indigenous and non-Indigenous patients before implementation. FUNDING: Queensland Department of Health Aboriginal and Torres Strait Islander Health Division (now First Nations Health Office). CI - Copyright (c) 2024 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved. FAU - Harrop, Danielle L AU - Harrop DL AD - Department of Cardiology, Princess Alexandra Hospital, Brisbane, QLD, Australia; Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia. Electronic address: danielle.harrop@health.qld.gov.au. FAU - Bryce, Vivian AU - Bryce V AD - Department of Cardiology, Princess Alexandra Hospital, Brisbane, QLD, Australia. FAU - Kitchener, Tanya AU - Kitchener T AD - Aboriginal and Torres Strait Islander Liaison Service, Mater Hospital, Brisbane, QLD, Australia. FAU - Grugan, Sean AU - Grugan S AD - Department of Cardiology, Princess Alexandra Hospital, Brisbane, QLD, Australia. FAU - Renouf, Sonia AU - Renouf S AD - Department of Cardiology, Princess Alexandra Hospital, Brisbane, QLD, Australia. FAU - Mitchell, Scott AU - Mitchell S AD - Department of Pharmacy, Princess Alexandra Hospital, Brisbane, QLD, Australia. FAU - Hasking, Gregory AU - Hasking G AD - Mersey Heart, Devonport, TAS, Australia. FAU - Pauza, Debra AU - Pauza D AD - First Nations Health Office, Queensland Health, Brisbane, QLD, Australia. FAU - Richards, Gregory AU - Richards G AD - Queensland Aboriginal and Islander Health Council, Brisbane, QLD, Australia. FAU - Ng, Arnold C T AU - Ng ACT AD - Department of Cardiology, Princess Alexandra Hospital, Brisbane, QLD, Australia. FAU - Wang, William Y S AU - Wang WYS AD - Department of Cardiology, Princess Alexandra Hospital, Brisbane, QLD, Australia; Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Lancet Glob Health JT - The Lancet. Global health JID - 101613665 SB - IM CIN - Lancet Glob Health. 2024 Apr;12(4):e541-e542. doi: 10.1016/S2214-109X(24)00080-9. PMID: 38485418 MH - Female MH - Humans MH - Male MH - *Acute Coronary Syndrome/therapy MH - Australia/epidemiology MH - *Australian Aboriginal and Torres Strait Islander Peoples MH - Tertiary Care Centers COIS- Declaration of interests We declare no competing interests. TK, SR, and DP are of Aboriginal or Torres Strait Islander heritage. EDAT- 2024/03/15 00:43 MHDA- 2024/03/18 06:42 CRDT- 2024/03/14 22:00 PHST- 2023/04/02 00:00 [received] PHST- 2023/12/07 00:00 [revised] PHST- 2023/12/13 00:00 [accepted] PHST- 2024/03/18 06:42 [medline] PHST- 2024/03/15 00:43 [pubmed] PHST- 2024/03/14 22:00 [entrez] AID - S2214-109X(23)00601-0 [pii] AID - 10.1016/S2214-109X(23)00601-0 [doi] PST - ppublish SO - Lancet Glob Health. 2024 Apr;12(4):e623-e630. doi: 10.1016/S2214-109X(23)00601-0. PMID- 38483562 OWN - NLM STAT- MEDLINE DCOM- 20240318 LR - 20250104 IS - 1433-8726 (Electronic) IS - 0724-4983 (Print) IS - 0724-4983 (Linking) VI - 42 IP - 1 DP - 2024 Mar 14 TI - Cardiovascular disease risk assessment and multidisciplinary care in prostate cancer treatment with ADT: recommendations from the APMA PCCV expert network. PG - 156 LID - 10.1007/s00345-024-04852-2 [doi] LID - 156 AB - PURPOSE: Androgen deprivation therapy (ADT) is the mainstay approach for prostate cancer (PCa) management. However, the most commonly used ADT modality, gonadotropin-releasing hormone (GnRH) agonists, has been associated with an increased risk of cardiovascular disease (CVD). METHODS: The PCa Cardiovascular (PCCV) Expert Network, consisting of multinational urologists, cardiologists and oncologists with expertise in managing PCa, convened to discuss challenges to routine cardiovascular risk assessment in PCa management, as well as how to mitigate such risks in the current treatment landscape. RESULTS: The experts identified several barriers, including lack of awareness, time constraints, challenges in implementing risk assessment tools and difficulties in establishing multidisciplinary teams that include cardiologists. The experts subsequently provided practical recommendations to improve cardio-oncology care for patients with PCa receiving ADT, such as simplifying cardiovascular risk assessment, individualising treatment based on CVD risk categories, establishing multidisciplinary teams and referral networks and fostering active patient engagement. A streamlined cardiovascular risk-stratification tool and a referral/management guide were developed for seamless integration into urologists' practices and presented herein. The PCCV Expert Network agreed that currently available evidence indicates that GnRH antagonists are associated with a lower risk of CVD than that of GnRH agonists and that GnRH antagonists are preferred for patients with PCa and a high CVD risk. CONCLUSION: In summary, this article provides insights and guidance to improve management for patients with PCa undergoing ADT. CI - (c) 2024. The Author(s). FAU - Merseburger, Axel S AU - Merseburger AS AUID- ORCID: 0000-0001-6467-3931 AD - Department of Urology, University Hospital Schleswig-Holstein, Lubeck, Germany. axel.merseburger@uksh.de. FAU - Bakshi, Ganesh AU - Bakshi G AD - Department of Surgical Oncology, P. D. Hinduja Hospital and Medical Research Center, Mumbai, India. FAU - Chen, Dong-Yi AU - Chen DY AD - Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou Branch, Chang Gung University College of Medicine, Taoyuan, Taiwan. FAU - Chiong, Edmund AU - Chiong E AD - Department of Urology, National University Hospital, and Department of Surgery, National University of Singapore, Singapore, Singapore. FAU - Jabbour, Michel AU - Jabbour M AD - Division of Urology, Saint Georges Hospital, Balamand University, Achrafieh, Beirut, Lebanon. FAU - Joung, Jae Young AU - Joung JY AD - Center for Urological Cancer, National Cancer Center, Goyang, South Korea. FAU - Lai, Allen Yu-Hung AU - Lai AY AD - Global Health Program, College of Public Health, National Taiwan University, Taipei, Taiwan. AD - Ferring Pharmaceuticals, Singapore, Singapore. FAU - Lawrentschuk, Nathan AU - Lawrentschuk N AD - Department of Urology and Department of Surgery, Royal Melbourne Hospital, University of Melbourne, Melbourne, Australia. FAU - Le, Tuan-Anh AU - Le TA AD - Cho Ray Hospital, Ho Chi Minh City, Vietnam. FAU - Ng, Chi Fai AU - Ng CF AD - SH Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Sha Tin, Hong Kong. FAU - Ng, Choon Ta AU - Ng CT AD - Department of Cardiology, National Heart Centre Singapore, Singapore, Singapore. FAU - Ong, Teng Aik AU - Ong TA AD - Department of Surgery, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. FAU - Pang, Jacob See-Tong AU - Pang JS AD - Division of Urology, Department of Surgery, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan. FAU - Rabah, Danny M AU - Rabah DM AD - The Cancer Research Chair and Department of Surgery, College of Medicine, King Saud University, Riyadh, Saudi Arabia. AD - Department of Urology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia. FAU - Ragavan, Narasimhan AU - Ragavan N AD - Department of Urology, The Tamil Nadu Dr MGR Medical University, Apollo Hospitals, Chennai, India. FAU - Sase, Kazuhiro AU - Sase K AD - Clinical Pharmacology and Regulatory Science, Graduate School of Medicine, Juntendo University, Tokyo, Japan. FAU - Suzuki, Hiroyoshi AU - Suzuki H AD - Department of Urology, Toho University Sakura Medical Center, Chiba, Japan. FAU - Teo, Michelle Mui Hian AU - Teo MMH AD - Ferring Pharmaceuticals, Singapore, Singapore. FAU - Uemura, Hiroji AU - Uemura H AD - Yokohama City University Medical Center, Yokohama, Japan. FAU - Woo, Henry H AU - Woo HH AD - Department of Urology, Blacktown Hospital, Blacktown, NSW, Australia. AD - Department of Uro-Oncology, Chris O.Brien Lifehouse, Camperdown, NSW, Australia. AD - College of Health and Medicine, Australian National University, Canberra, ACT, Australia. LA - eng PT - Journal Article PT - Review DEP - 20240314 PL - Germany TA - World J Urol JT - World journal of urology JID - 8307716 RN - 0 (Androgen Antagonists) RN - 33515-09-2 (Gonadotropin-Releasing Hormone) SB - IM MH - Male MH - Humans MH - *Prostatic Neoplasms/drug therapy/chemically induced MH - Androgen Antagonists/adverse effects MH - *Cardiovascular Diseases/chemically induced/epidemiology MH - Risk Assessment MH - Gonadotropin-Releasing Hormone PMC - PMC10940372 OTO - NOTNLM OT - Androgen deprivation therapy OT - Cardiovascular disease OT - Cardiovascular toxicity OT - Interdisciplinary OT - Prostate cancer OT - Risk management COIS- Axel S. Merseburger--lectures/speaker/honoraria: AstraZeneca, Accord Health, Astellas, Bayer, Bristol-Myers Squibb, Eisai, Ferring, Ipsen, MSD, Merck Serono, Janssen, Takeda, TEVA, Astellas, Novartis, Pfizer, Recordati and Roche; consultant: AstraZeneca, Astellas, Bayer, Bristol-Myers Squibb, Ferring, Ipsen, Janssen, EUSAPharm, MSD, Merck Serono, Novartis, Takeda, Teva, Pfizer, Recordati and Roche; research and clinical trials: AstraZeneca, Astellas, Bayer, Bristol-Myers Squibb, Ipsen, Janssen, EUSAPharm, MSD, Merck Serono, Novartis, Takeda, Teva, Pfizer und Roche. Teng Aik Ong--research grant: Ferring. Ganesh Bakshi--nothing to declare. Dong-Yi Chen--nothing to declare. Edmund Chiong--lectures/speaker/honoraria: Astellas, Janssen, Bayer, AstraZeneca, Ipsen, Amgen, Ferring and Novartis. Michel Jabbour--nothing to declare. Jae Young Joung--nothing to declare. Allen Yu-Hung Lai--an employee of Ferring Pharmaceuticals. Nathan Lawrentschuk--proctor and speaker: Device Technologies and Getz Healthcare; speaker: Astellas; advisory board: Penthrax. Tuan-Anh Le--nothing to declare. Chi Fai Ng--research grant: Astellas, Takeda, Bayer and Ipsen; investigator in studies: Bayer, Astellas and Pfizer; speaker: Janssen. Choon Ta Ng--lectures/speaker/honoraria: AstraZeneca, Ferring and Novartis. Jacob See-Tong Pang--nothing to declare. Danny M. Rabah--nothing to declare. Narasimhan Ragavan--nothing to declare. Kazuhiro Sase--nothing to declare. Hiroyoshi Suzuki--research grants: Astellas, Bayer, Janssen and Nihon Kayaku; consulting fees and honoraria: Astellas, AstraZeneca, Bayer, Chugai, Daiichi-Sankyo, Eli-Lily, Janssen, MSD, Roche and Sanofi. Michelle Mui Hian Teo--an employee of Ferring Pharmaceuticals. Hiroji Uemura--advisory board: Ferring, Bayer, AstraZeneca, Janssen, Astellas, Takeda and Ono Pharm.; speaker: Sanofi, Pfizer, MSD, Chugai, Nihon Kayaku, Nippon Shinyaku, Kissei and Kyowa-Kirin. Henry H. Woo--study sponsor: Prodeon; consulting fees: Astellas, Janssen, Mundipharma, Ferring, Medical Developments International and Boston Scientific; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Ferring and Bayer; leadership or fiduciary role in other board, society, committee or advocacy group: Royal Australasian College of Surgeons, Urological Society of Australia and New Zealand, Australasian Urological Foundation and Australian and New Zealand Urogenital and Prostate Trials Group; receipt of equipment, materials, drugs, medical writing, gifts or other services: Prospection Pty Ltd., and Prodeon. EDAT- 2024/03/14 18:42 MHDA- 2024/03/18 06:44 PMCR- 2024/03/14 CRDT- 2024/03/14 12:14 PHST- 2023/10/10 00:00 [received] PHST- 2024/02/05 00:00 [accepted] PHST- 2024/03/18 06:44 [medline] PHST- 2024/03/14 18:42 [pubmed] PHST- 2024/03/14 12:14 [entrez] PHST- 2024/03/14 00:00 [pmc-release] AID - 10.1007/s00345-024-04852-2 [pii] AID - 4852 [pii] AID - 10.1007/s00345-024-04852-2 [doi] PST - epublish SO - World J Urol. 2024 Mar 14;42(1):156. doi: 10.1007/s00345-024-04852-2. PMID- 38481044 OWN - NLM STAT- MEDLINE DCOM- 20241010 LR - 20260611 IS - 1365-2702 (Electronic) IS - 0962-1067 (Linking) VI - 33 IP - 11 DP - 2024 Nov TI - Interprofessional teams with and without nurse practitioners and the level of adherence to best practice guidelines in cardiac surgery: A retrospective study. PG - 4395-4407 LID - 10.1111/jocn.17117 [doi] AB - AIM: To examine the level of adherence to best-practice guidelines of interprofessional teams with acute care nurse practitioners (ACNPs) compared to interprofessional teams without ACNPs. DESIGN: A retrospective observational study was conducted in 2023. METHOD: A retrospective cohort was created including 280 patients who underwent a coronary artery bypass graft and/or a valve repair and hospitalised in a cardiac surgery unit of a university affiliated hospital in Quebec (Canada) between 1 January 2019 to 31 January 2020. The level of adherence to best-practice guidelines was measured from a composite score in percentage. The composite score was created from a newly developed tool including 99 items across six categories (patient information, pharmacotherapy, laboratory tests, post-operative assessment, patient and interprofessional teams' characteristics). Multivariate linear and logistic regression models were computed to examine the effect of interprofessional teams with ACNPs on the level of adherence to best-practice guidelines. RESULTS: Most of the patients of the cohort were male and underwent a coronary artery bypass graft procedure. Patients under the care of interprofessional teams with ACNP were 1.72 times more likely to reach a level of adherence higher than 80% compared to interprofessional teams without ACNPs and were 2.29 times more likely to be within the highest quartile of the scores for the level of adherence to best-practice guidelines of the cohort. IMPACT: This study provides empirical data supporting the benefits of ACNP practice for patients, interprofessional teams and healthcare organisations. RELEVANCE FOR PRACTICE: Our findings identify the important contributions of interprofessional teams that include ACNPs using a validated instrument, as well as their contribution to the delivery of high quality patient care. REPORTING METHOD: This study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting observational studies guidelines. PATIENT OR PUBLIC CONTRIBUTION: No patient or public contribution. CI - (c) 2024 The Authors. Journal of Clinical Nursing published by John Wiley & Sons Ltd. FAU - Audet, Li-Anne AU - Audet LA AUID- ORCID: 0000-0002-7805-993X AD - Ingram School of Nursing, Faculty of Medicine and Health Sciences, McGill University, Montreal, Quebec, Canada. FAU - Lavoie-Tremblay, Melanie AU - Lavoie-Tremblay M AD - Faculte des sciences infirmieres, Pavillon Marguerite-d'Youville, Universite de Montreal, Montreal, Quebec, Canada. AD - Centre de recherche de l'Institut universitaire en sante mentale de Montreal (CR-IUSMM), Montreal, Quebec, Canada. FAU - Tchouaket, Eric AU - Tchouaket E AD - Departement des sciences infirmieres, Canadian Research Chair in Economics of Infection and Prevention Control, Universite du Quebec en Outaouais, Saint-Jerome, Quebec, Canada. FAU - Kilpatrick, Kelley AU - Kilpatrick K AD - Ingram School of Nursing, Faculty of Medicine and Health Sciences, McGill University, Montreal, Quebec, Canada. AD - Centre integre universitaire de sante et de services sociaux de l'Est-de-l'Ile-de- Montreal-Hopital Maisonneuve-Rosemont (CIUSSS-EMTL-HMR), Montreal, Quebec, Canada. AD - Susan E. French Chair in Nursing Research and Innovative Practice, Faculty of Medicine and Health Sciences, Ingram School of Nursing, McGill University, Montreal, Quebec, Canada. LA - eng GR - Reseau de recherche portant sur les interventions en sciences infirmieres du Quebec/ PT - Journal Article PT - Observational Study PT - Research Support, Non-U.S. Gov't DEP - 20240313 PL - England TA - J Clin Nurs JT - Journal of clinical nursing JID - 9207302 SB - IM MH - Humans MH - Retrospective Studies MH - Male MH - *Guideline Adherence/statistics & numerical data/standards MH - Female MH - *Patient Care Team/standards MH - *Nurse Practitioners/standards MH - Middle Aged MH - Aged MH - Quebec MH - *Cardiac Surgical Procedures/standards MH - Practice Guidelines as Topic MH - Interprofessional Relations OTO - NOTNLM OT - acute care nurse practitioner OT - best practice guidelines OT - cardiac surgery OT - retrospective study EDAT- 2024/03/14 06:46 MHDA- 2024/10/10 06:22 CRDT- 2024/03/14 02:12 PHST- 2024/02/28 00:00 [revised] PHST- 2023/12/04 00:00 [received] PHST- 2024/03/01 00:00 [accepted] PHST- 2024/10/10 06:22 [medline] PHST- 2024/03/14 06:46 [pubmed] PHST- 2024/03/14 02:12 [entrez] AID - 10.1111/jocn.17117 [doi] PST - ppublish SO - J Clin Nurs. 2024 Nov;33(11):4395-4407. doi: 10.1111/jocn.17117. Epub 2024 Mar 13. PMID- 38472937 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241031 IS - 2075-4418 (Print) IS - 2075-4418 (Electronic) IS - 2075-4418 (Linking) VI - 14 IP - 5 DP - 2024 Feb 20 TI - The Surgical Treatment of Infective Endocarditis: A Comprehensive Review. LID - 10.3390/diagnostics14050464 [doi] LID - 464 AB - Infective endocarditis (IE) is a severe cardiac complication with high mortality rates, especially when surgical intervention is delayed or absent. This review addresses the expanding role of surgery in managing IE, focusing on the variation in surgical treatment rates, the impact of patient demographics, and the effectiveness of different surgical approaches. Despite varying global data, a notable increase in surgical interventions for IE is evident, with over 50% of patients undergoing surgery in tertiary centres. This review synthesizes information from focused literature searches up to July 2023, covering preoperative to postoperative considerations and surgical strategies for IE. Key preoperative concerns include accurate diagnosis, appropriate antimicrobial treatment, and the timing of surgery, which is particularly crucial for patients with heart failure or at risk of embolism. Surgical approaches vary based on valve involvement, with mitral valve repair showing promising outcomes compared to replacement. Aortic valve surgery, traditionally favouring replacement, now includes repair as a viable option. Emerging techniques such as sutureless valves and aortic homografts are explored, highlighting their potential advantages in specific IE cases. The review also delves into high-risk groups like intravenous drug users and the elderly, emphasizing the need for tailored surgical strategies. With an increasing number of patients presenting with prosthetic valve endocarditis and device-related IE, the review underscores the importance of comprehensive management strategies encompassing surgical and medical interventions. Overall, this review provides a comprehensive overview of current evidence in the surgical management of IE, highlighting the necessity of a multidisciplinary approach and ongoing research to optimize patient outcomes. FAU - Arjomandi Rad, Arian AU - Arjomandi Rad A AUID- ORCID: 0000-0002-4931-4049 AD - Medical Sciences Division, University of Oxford, Oxford OX3 9DU, UK. AD - Department of Surgery and Cancer, Imperial College London, London SW7 5NH, UK. AD - Department of Cardiothoracic Surgery, Maastricht University Medical Centre, 6229 HX Maastricht, The Netherlands. FAU - Zubarevich, Alina AU - Zubarevich A AD - Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, 30625 Hannover, Germany. FAU - Osswald, Anja AU - Osswald A AD - Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, 30625 Hannover, Germany. FAU - Vardanyan, Robert AU - Vardanyan R AD - Department of Surgery and Cancer, Imperial College London, London SW7 5NH, UK. FAU - Magouliotis, Dimitrios E AU - Magouliotis DE AUID- ORCID: 0000-0001-5417-6392 AD - Department of Cardiothoracic Surgery, University of Thessaly, 38221 Larissa, Greece. FAU - Ansaripour, Ali AU - Ansaripour A AD - Department of Cardiothoracic Surgery, John Radcliffe Hospital, Oxford OX3 9DU, UK. FAU - Kourliouros, Antonios AU - Kourliouros A AD - Department of Cardiothoracic Surgery, John Radcliffe Hospital, Oxford OX3 9DU, UK. FAU - Sa, Michel Pompeu AU - Sa MP AUID- ORCID: 0000-0001-5356-2996 AD - Department of Cardiothoracic Surgery, UPMC Heart and Vascular Institute, University of Pittsburgh, Pittsburgh, PA 15224, USA. FAU - Rassaf, Tienush AU - Rassaf T AUID- ORCID: 0000-0001-8001-0265 AD - Department of Cardiology, West German Heart and Vascular Center Essen, University Hospital of Essen, University Duisburg-Essen, 45138 Essen, Germany. FAU - Ruhparwar, Arjang AU - Ruhparwar A AD - Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, 30625 Hannover, Germany. FAU - Sardari Nia, Peyman AU - Sardari Nia P AD - Department of Cardiothoracic Surgery, Maastricht University Medical Centre, 6229 HX Maastricht, The Netherlands. FAU - Athanasiou, Thanos AU - Athanasiou T AD - Department of Surgery and Cancer, Imperial College London, London SW7 5NH, UK. FAU - Weymann, Alexander AU - Weymann A AD - Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, 30625 Hannover, Germany. LA - eng PT - Journal Article PT - Review DEP - 20240220 PL - Switzerland TA - Diagnostics (Basel) JT - Diagnostics (Basel, Switzerland) JID - 101658402 PMC - PMC10930710 OTO - NOTNLM OT - cardiac surgery OT - infective endocarditis OT - valve endocarditis COIS- Peyman Sardari Nia has a consultancy agreement with Neochord Inc., Edwards Lifesciences, Medtronic, Abbott, and Fuijfilm medical and is the inventor of MV simulators that are commercialized through his start-up (Simurghy). The other authors report no conflicts of interest. EDAT- 2024/03/13 06:46 MHDA- 2024/03/13 06:47 PMCR- 2024/02/20 CRDT- 2024/03/13 01:17 PHST- 2023/12/19 00:00 [received] PHST- 2024/02/08 00:00 [revised] PHST- 2024/02/18 00:00 [accepted] PHST- 2024/03/13 06:47 [medline] PHST- 2024/03/13 06:46 [pubmed] PHST- 2024/03/13 01:17 [entrez] PHST- 2024/02/20 00:00 [pmc-release] AID - diagnostics14050464 [pii] AID - diagnostics-14-00464 [pii] AID - 10.3390/diagnostics14050464 [doi] PST - epublish SO - Diagnostics (Basel). 2024 Feb 20;14(5):464. doi: 10.3390/diagnostics14050464. PMID- 38472080 OWN - NLM STAT- MEDLINE DCOM- 20240509 LR - 20250325 IS - 1532-7361 (Electronic) IS - 0039-6060 (Linking) VI - 175 IP - 6 DP - 2024 Jun TI - Teamwork matters: The association between nontechnical skills and cardiac arrest in trauma patients presenting with hypotension. PG - 1595-1599 LID - S0039-6060(24)00067-9 [pii] LID - 10.1016/j.surg.2024.02.004 [doi] AB - BACKGROUND: The impact of trauma team dynamics on outcomes in injured patients is not completely understood. We sought to evaluate the association between trauma team function, as measured by a modified Trauma Non-Technical Skills assessment, and cardiac arrest in hypotensive trauma patients. We hypothesized that better team function is associated with a decreased probability of developing cardiac arrest. METHODS: Trauma video review was used to collect data from resuscitations of adult hypotensive trauma patients at 19 centers. Hypotension at emergency department presentation was defined as an initial systolic blood pressure <90 mm Hg or an initial systolic blood pressure >/=90 mm Hg followed by a systolic blood pressure <90 mm Hg within the first 5 minutes. Team dynamics were scored using a modified Trauma Non-Technical Skills assessment composed of 5 domains with combined scores ranging from 5 (best) to 15 (worst). Scores were compared between cardiac arrest/noncardiac arrest cases in the trauma bay. Logistic regression was used to evaluate the independent association between the Trauma Non-Technical Skills assessment and cardiac arrest. RESULTS: A total of 430 patients were included (median age 43 years [interquartile range: 29-61]; 71.8% male; 36% penetrating mechanism; median Injury Severity Score 20 [10-33]; 11% experienced cardiac arrest in trauma bay). The median total Trauma Non-Technical Skills assessment score was 7 (6-9), higher in patients who experienced cardiac arrest in the trauma bay (9 [6-10] vs 7 [6-9]; P = .016). This association persisted after controlling for age, sex, mechanism, injury severity, initial systolic blood pressure, and initial Glasgow Coma Scale score (adjusted odds ratio: 1.28; 95% confidence interval:1.11-1.48; P < .001), indicating a approximately 3% higher predicted probability of cardiac arrest per Trauma Non-Technical Skills point. CONCLUSION: Better team function is independently associated with a decreased probability of cardiac arrest in trauma patients presenting with hypotension. This suggests that trauma team training may improve outcomes in peri-arrest patients. CI - Copyright (c) 2024 Elsevier Inc. All rights reserved. FAU - Vella, Michael A AU - Vella MA AD - University of Rochester Medical Center Division of Acute Care Surgery, Rochester, NY. Electronic address: http://www.twitter.com/MichealVella32. FAU - Zone, Alea AU - Zone A AD - UT Southwestern Medical Center, Division of Burn Trauma Acute and Critical Care Surgery, Dallas, TX. FAU - Succar, Bahaa AU - Succar B AD - UT Southwestern Medical Center, Division of Burn Trauma Acute and Critical Care Surgery, Dallas, TX. Electronic address: http://www.twitter.com/B_Succar. FAU - Cheng, Mingyuan AU - Cheng M AD - UT Southwestern Medical Center, Division of Burn Trauma Acute and Critical Care Surgery, Dallas, TX. FAU - Maiga, Amelia W AU - Maiga AW AD - Vanderbilt University Medical Center, Division of Acute Care Surgery, Nashville, TN. Electronic address: http://www.twitter.com/AmeliaMaiga. FAU - Appelbaum, Rachel D AU - Appelbaum RD AD - Vanderbilt University Medical Center, Division of Acute Care Surgery, Nashville, TN. Electronic address: http://www.twitter.com/AppelbaumMD. FAU - Notario, Lowyl AU - Notario L AD - Sunnybrook Health Sciences Centre, Toronto, Canada. FAU - Pannell, Dylan AU - Pannell D AD - Sunnybrook Health Sciences Centre, Toronto, Canada. FAU - Holena, Daniel N AU - Holena DN AD - Medical College of Wisconsin Division of Trauma and Acute Care Surgery Milwaukee, WI. Electronic address: http://www.twitter.com/Daniel_Holena. FAU - Dumas, Ryan P AU - Dumas RP AD - UT Southwestern Medical Center, Division of Burn Trauma Acute and Critical Care Surgery, Dallas, TX. Electronic address: ryan.dumas@utsouthwestern.edu. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20240312 PL - United States TA - Surgery JT - Surgery JID - 0417347 SB - IM MH - Humans MH - *Hypotension/etiology/diagnosis MH - Male MH - Female MH - Middle Aged MH - Adult MH - *Heart Arrest/therapy/complications/etiology MH - *Wounds and Injuries/complications MH - *Patient Care Team/organization & administration MH - Clinical Competence/statistics & numerical data MH - Retrospective Studies MH - Injury Severity Score MH - Trauma Centers/statistics & numerical data EDAT- 2024/03/13 00:44 MHDA- 2024/05/10 00:43 CRDT- 2024/03/12 23:01 PHST- 2023/09/01 00:00 [received] PHST- 2024/01/20 00:00 [revised] PHST- 2024/02/08 00:00 [accepted] PHST- 2024/05/10 00:43 [medline] PHST- 2024/03/13 00:44 [pubmed] PHST- 2024/03/12 23:01 [entrez] AID - S0039-6060(24)00067-9 [pii] AID - 10.1016/j.surg.2024.02.004 [doi] PST - ppublish SO - Surgery. 2024 Jun;175(6):1595-1599. doi: 10.1016/j.surg.2024.02.004. Epub 2024 Mar 12. PMID- 38467028 OWN - NLM STAT- MEDLINE DCOM- 20240313 LR - 20250803 IS - 1096-9012 (Print) IS - 1096-9012 (Linking) VI - 69 IP - 2 DP - 2024 Mar-Apr 01 TI - Sprint Team Approach Yields Rapid Improvement in Leapfrog Quality Indicators. PG - 156-163 LID - 10.1097/JHM-D-22-00223 [doi] AB - GOAL: Patient safety and quality care are two critical areas that every healthcare organization strives to grow and improve upon. At Scripps Health, specific efforts reviewed for this article were implemented to reduce hospital-acquired conditions and hospital readmissions that are components of Centers for Medicare & Medicaid Services programs and Leapfrog Hospital Survey scores. METHODS: Sprint teams, a novel approach to rapidly develop a checklist for lower-performing care improvement areas, were implemented after an internal review of existing tools and an evidence-based literature review. These areas included catheter-associated urinary tract infections (CAUTIs), central-line associated bloodstream infections (CLABSIs), Clostridioides difficile (C. diff.) and methicillin-resistant Staphylococcus aureus (MRSA) infections, chronic obstructive pulmonary disease (COPD) and heart failure readmissions, surgical site infections and handwashing, bar coding, and the computerized physician order entry components of Leapfrog scoring. The checklist for each area served as a teaching tool for staff and a guideline for case review to ensure that standard work was routinely performed. PRINCIPAL FINDINGS: The sprint teams showed dramatic results in the initial focus areas. From a baseline standardized infection ratio (SIR) of 1.141 for CLABSIs, the sprint team reduced the SIR to 0.885 in Year 1 of the program and to 0.687 in Year 2. For CAUTIs, the SIR decreased from a baseline of 1.391 in Year 1 to 0.720 in Year 2. C. diff. infections fell from 0.422 to 0.315 in Year 1 and to 0.260 in Year 2. While the MRSA SIR did not improve during the first year, the MRSA reduction sprint team showed success in Year 2 with a decrease in the SIR from 0.537 to 0.245. Readmission reduction sprint teams focused on heart failure, COPD, and total hip and knee complications. The teams also achieved positive results in reducing readmissions by following checklists and reviewing each readmission case for justification. PRACTICAL APPLICATIONS: Rapid change can be safely and effectively implemented with multidisciplinary sprint teams. Developed with an evidence-based, case review approach, sprint team checklists can help to standardize processes for the review of any infections or readmissions that occur in the inpatient arena. CI - Copyright (c) 2024 Foundation of the American College of Healthcare Executives. FAU - Sharieff, Ghazala Q AU - Sharieff GQ FAU - Uejo, Craig AU - Uejo C AD - Scripps Health, San Diego, California. LA - eng PT - Journal Article PL - United States TA - J Healthc Manag JT - Journal of healthcare management / American College of Healthcare Executives JID - 9803529 MH - Aged MH - Humans MH - United States MH - Quality Indicators, Health Care MH - *Methicillin-Resistant Staphylococcus aureus MH - Medicare MH - Patient Readmission MH - *Heart Failure MH - *Pulmonary Disease, Chronic Obstructive MH - Quality Improvement COIS- The authors declare no conflicts of interest. EDAT- 2024/03/11 18:42 MHDA- 2024/03/13 06:47 CRDT- 2024/03/11 17:24 PHST- 2024/03/13 06:47 [medline] PHST- 2024/03/11 18:42 [pubmed] PHST- 2024/03/11 17:24 [entrez] AID - 00115514-202403000-00008 [pii] AID - 10.1097/JHM-D-22-00223 [doi] PST - ppublish SO - J Healthc Manag. 2024 Mar-Apr 01;69(2):156-163. doi: 10.1097/JHM-D-22-00223. PMID- 38466060 OWN - NLM STAT- MEDLINE DCOM- 20241224 LR - 20241226 IS - 1078-6791 (Print) IS - 1078-6791 (Linking) VI - 30 IP - 12 DP - 2024 Dec TI - Effect of Interdisciplinary Collaboration in Emergency Nursing Using the SWOT Model on Acute Myocardial Infarction. PG - 126-131 LID - AT9852 [pii] AB - OBJECTIVE: To explore the effect of interdisciplinary collaboration in emergency nursing using the strengths-weaknesses-opportunities-threats (SWOT) model on patients with acute myocardial infarction (AMI). METHODS: Eighty AMI patients undergoing rescue treatment at Affiliated Hospital of Inner Mongolia Medical University from October 2020 to June 2022 were selected and randomly divided into the SWOT group and the control group. The patients in the control group received routine emergency nursing intervention, while those in the SWOT group were given interdisciplinary collaboration using the SWOT model. The emergency-related time, cardiac function indicators, incidence of adverse events, quality of life, and nursing satisfaction were compared between the two groups. RESULTS: The waiting time, triage assessment time, electrocardiogram examination time, emergency treatment time, PCI duration and ICU stay time in SWOT group were significantly shorter than those in control group. The left ventricular end-systolic diameter (LVESd), left ventricular end-diastolic diameter (LVEDd), and left ventricular ejection fraction (LVEF) in the SWOT group were all superior to those in the control group. The SWOT group had a significantly lower incidence rate of adverse events than the control group. The quality of life scores of SWOT group were higher than those of control group. The nursing satisfaction in the SWOT group was higher than that in the control group. CONCLUSION: Interdisciplinary collaboration using the SWOT model for AMI patients can effectively shorten the rescue time, ameliorate cardiac function indicators, reduce the risk of adverse events, improve patients' quality of life, and enhance nursing satisfaction. FAU - Hui, Zhang AU - Hui Z FAU - Liu, Xiaoling AU - Liu X LA - eng PT - Journal Article PT - Randomized Controlled Trial PL - United States TA - Altern Ther Health Med JT - Alternative therapies in health and medicine JID - 9502013 SB - IM MH - Humans MH - Female MH - Male MH - Middle Aged MH - *Myocardial Infarction/nursing/therapy MH - *Emergency Nursing/methods MH - Aged MH - Quality of Life MH - Patient Care Team MH - Adult MH - China EDAT- 2024/03/11 12:42 MHDA- 2024/12/24 12:21 CRDT- 2024/03/11 09:44 PHST- 2024/12/24 12:21 [medline] PHST- 2024/03/11 12:42 [pubmed] PHST- 2024/03/11 09:44 [entrez] AID - AT9852 [pii] PST - ppublish SO - Altern Ther Health Med. 2024 Dec;30(12):126-131. PMID- 38462318 OWN - NLM STAT- MEDLINE DCOM- 20240312 LR - 20240312 IS - 1551-7136 (Print) IS - 1551-7136 (Linking) VI - 20 IP - 2 DP - 2024 Apr TI - Medical Therapy and Monitoring in Adult Congenital Heart Disease Heart Failure. PG - 137-146 LID - S1551-7136(23)00097-1 [pii] LID - 10.1016/j.hfc.2023.12.002 [doi] AB - Heart failure (HF) in adult congenital heart disease (ACHD) is an increasingly common problem facing ACHD and advanced heart disease and transplant providers. Patients are highly nuanced, and therapies are poorly studied. Standard HF medications are often used in patients who are not targets of large clinical trials. HF management in this data-free zone requires focused, comprehensive team-based care and close follow-up and communication with patients. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Nicolarsen, Jeremy AU - Nicolarsen J AD - Providence Adult and Teen Congenital Heart Program (PATCH), Providence Sacred Heart Medical Center and Children's Hospital, 101 West 8th Avenue, Suite 4300, Spokane, WA 99204, USA. Electronic address: jeremy.nicolarsen@providence.org. FAU - Mudd, James AU - Mudd J AD - Center for Advanced Heart Disease and Transplantation, Providence Spokane Heart Institute, 62 West 7th Avenue, Suite 232, Spokane, WA 99204, USA. FAU - Coletti, Andrew AU - Coletti A AD - Center for Advanced Heart Disease and Transplantation, Providence Spokane Heart Institute, 62 West 7th Avenue, Suite 232, Spokane, WA 99204, USA. LA - eng PT - Journal Article PT - Review DEP - 20231229 PL - United States TA - Heart Fail Clin JT - Heart failure clinics JID - 101231934 SB - IM MH - Humans MH - Adult MH - *Heart Defects, Congenital/complications/therapy MH - *Heart Failure/therapy MH - Heart OTO - NOTNLM OT - Adult congenital heart disease OT - Eisenmenger syndrome OT - Follow-up OT - Fontan OT - Heart failure OT - Heart failure therapies OT - Systemic right ventricle COIS- Disclosure The authors have a consulting agreement with Medtronic. EDAT- 2024/03/11 00:42 MHDA- 2024/03/12 06:42 CRDT- 2024/03/10 21:58 PHST- 2024/03/12 06:42 [medline] PHST- 2024/03/11 00:42 [pubmed] PHST- 2024/03/10 21:58 [entrez] AID - S1551-7136(23)00097-1 [pii] AID - 10.1016/j.hfc.2023.12.002 [doi] PST - ppublish SO - Heart Fail Clin. 2024 Apr;20(2):137-146. doi: 10.1016/j.hfc.2023.12.002. Epub 2023 Dec 29. PMID- 38461591 OWN - NLM STAT- MEDLINE DCOM- 20240408 LR - 20240408 IS - 1873-5223 (Electronic) IS - 1471-5953 (Linking) VI - 76 DP - 2024 Mar TI - Exploring nurses' experiences of performing basic life support in hospital wards: An inductive thematic analysis. PG - 103929 LID - S1471-5953(24)00058-1 [pii] LID - 10.1016/j.nepr.2024.103929 [doi] AB - AIM: The aim of this study was to undertake an in-depth exploration of the lived experiences of in-hospital, non-intensive care, ward-based nurses' experiences of real-life CPR events. BACKGROUND: There is growing evidence suggesting that may nurses not be able to successfully perform in a cardiac arrest situation. Reasons include a lack of clear leadership at the arrest, performance anxiety, role confusion and knowledge and skill degradation over time. METHODS: In-depth semi-structured interviews were conducted with fifteen ward-based hospital nurses from three hospitals. Interviews were recorded, transcribed verbatim and inductive thematic analysis was completed using NVivo 12 software. FINDINGS: Four main themes emerged from data. The main themes are: (1) Not Being able to Perform When it Matters, (2) Working Really Well as a Team, (3) Reflecting on the Experience: The Good, the Bad & the Ugly and (4) Learning to get it Right for Next Time CONCLUSION: Performing BLS is a stressful and anxiety-provoking experience for ward-based nurses. Anxiety levels appear to decrease slightly only when nurses have had at least one previous real-life experience with resuscitation. Current BLS education does not prepare nurses for the complexities of resuscitation. Future BLS education should focus on in-depth scenarios, including interdisciplinary team training and with greater frequency than the current yearly mandatory sessions. Listening to the lived experiences of nurses who have performed BLS has given much needed insight into approaches that educators can use to improve BLS education delivery. CI - Copyright (c) 2024. Published by Elsevier Ltd. FAU - Dermer, J AU - Dermer J AD - School of Nursing, Midwifery & Paramedicine, University of the Sunshine Coast, Australia. FAU - James, S AU - James S AD - School of Nursing, Midwifery & Paramedicine, University of the Sunshine Coast, Australia. FAU - Palmer, C AU - Palmer C AD - School of Nursing, Midwifery & Paramedicine, University of the Sunshine Coast, Australia. FAU - Craft, J AU - Craft J AD - School of Nursing, Midwifery & Paramedicine, University of the Sunshine Coast, Australia. FAU - Christensen, M AU - Christensen M AD - School of Nursing, Midwifery & Paramedicine, University of the Sunshine Coast, Australia; School of Nursing, Hong Kong Polytechnic University, Hong Kong; Interdisciplinary Centre for Qualitative Research, Hong Kong Polytechnic University, Hong Kong. Electronic address: martin.christensen@polyu.edu.hk. LA - eng PT - Journal Article DEP - 20240226 PL - Scotland TA - Nurse Educ Pract JT - Nurse education in practice JID - 101090848 SB - IM MH - Humans MH - *Cardiopulmonary Resuscitation/education MH - Clinical Competence MH - Learning MH - Hospitals MH - *Nurses OTO - NOTNLM OT - Basic life support OT - CPR experiences OT - Cardiopulmonary resuscitation OT - Nurses OT - Nursing education COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/03/11 00:42 MHDA- 2024/04/08 06:42 CRDT- 2024/03/10 19:02 PHST- 2023/02/16 00:00 [received] PHST- 2024/02/05 00:00 [revised] PHST- 2024/02/22 00:00 [accepted] PHST- 2024/04/08 06:42 [medline] PHST- 2024/03/11 00:42 [pubmed] PHST- 2024/03/10 19:02 [entrez] AID - S1471-5953(24)00058-1 [pii] AID - 10.1016/j.nepr.2024.103929 [doi] PST - ppublish SO - Nurse Educ Pract. 2024 Mar;76:103929. doi: 10.1016/j.nepr.2024.103929. Epub 2024 Feb 26. PMID- 38461589 OWN - NLM STAT- MEDLINE DCOM- 20240408 LR - 20240508 IS - 1095-8606 (Electronic) IS - 0047-2484 (Linking) VI - 189 DP - 2024 Apr TI - Finite element analysis of Neanderthal and early Homo sapiens maxillary central incisor. PG - 103512 LID - S0047-2484(24)00020-4 [pii] LID - 10.1016/j.jhevol.2024.103512 [doi] AB - Neanderthal anterior teeth are very large and have a distinctive morphology characterized by robust 'shovel-shaped' crowns. These features are frequently seen as adaptive responses in dissipating heavy mechanical loads resulting from masticatory and non-masticatory activities. Although the long-standing debate surrounding this hypothesis has played a central role in paleoanthropology, is still unclear if Neanderthal anterior teeth can resist high mechanical loads or not. A novel way to answer this question is to use a multidisciplinary approach that considers together tooth architecture, dental wear and jaw movements. The aim of this study is to functionally reposition the teeth of Le Moustier 1 (a Neanderthal adolescent) and Qafzeh 9 (an early Homo sapiens adolescent) derived from wear facet mapping, occlusal fingerprint analysis and physical dental restoration methods. The restored dental arches are then used to perform finite element analysis on the left central maxillary incisor during edge-to-edge occlusion. The results show stress distribution differences between Le Moustier 1 and Qafzeh 9, with the former displaying higher tensile stress in enamel around the lingual fossa but lower concentration of stress in the lingual aspect of the root surface. These results seem to suggest that the presence of labial convexity, lingual tubercle and of a large root surface in Le Moustier 1 incisor helps in dissipating mechanical stress. The absence of these dental features in Qafzeh 9 is compensated by the presence of a thicker enamel, which helps in reducing the stress in the tooth crown. CI - Copyright (c) 2024 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Najafzadeh, Ali AU - Najafzadeh A AD - Monash Biomedicine Discovery Institute, Department of Anatomy and Developmental Biology, Monash University, Melbourne, VIC, 3800, Australia; Department of Mechanical and Aerospace Engineering, Monash University, Melbourne, VIC, 3800, Australia. FAU - Hernaiz-Garcia, Maria AU - Hernaiz-Garcia M AD - Monash Biomedicine Discovery Institute, Department of Anatomy and Developmental Biology, Monash University, Melbourne, VIC, 3800, Australia. FAU - Benazzi, Stefano AU - Benazzi S AD - Department of Cultural Heritage, University of Bologna, Ravenna, 48121, Italy. FAU - Chen, Bernard AU - Chen B AD - Department of Surgery, The University of Melbourne, Melbourne, VIC, 3010, Australia. FAU - Hublin, Jean-Jacques AU - Hublin JJ AD - Chaire de Paleoanthropologie, CIRB (UMR 7241-U1050), College de France, 11, Place Marcelin-Berthelot, 75231, Paris, Cedex 05, France; Max Planck Institute for Evolutionary Anthropology, Leipzig, 04103, Germany. FAU - Kullmer, Ottmar AU - Kullmer O AD - Division of Palaeoanthropology, Senckenberg Research Institute and Natural History Museum Frankfurt, Frankfurt a. M, 60325, Germany; Department of Palaeobiology and Environment, Institute of Ecology, Evolution, and Diversity, Goethe University, Frankfurt a. M, 60438, Germany. FAU - Pokhojaev, Ariel AU - Pokhojaev A AD - Department of Oral Biology, The Goldschleger School of Dental Medicine, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, 69978, Israel. FAU - Sarig, Rachel AU - Sarig R AD - Department of Oral Biology, The Goldschleger School of Dental Medicine, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, 69978, Israel; Dan David Center for Human Evolution and Biohistory Research, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, 69978, Israel. FAU - Sorrentino, Rita AU - Sorrentino R AD - Department of Cultural Heritage, University of Bologna, Ravenna, 48121, Italy; Department of Biological, Geological and Environmental Sciences, University of Bologna, Bologna, 40126, Italy. FAU - Vazzana, Antonino AU - Vazzana A AD - Department of Cultural Heritage, University of Bologna, Ravenna, 48121, Italy. FAU - Fiorenza, Luca AU - Fiorenza L AD - Monash Biomedicine Discovery Institute, Department of Anatomy and Developmental Biology, Monash University, Melbourne, VIC, 3800, Australia. Electronic address: luca.fiorenza@monash.edu. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240310 PL - England TA - J Hum Evol JT - Journal of human evolution JID - 0337330 SB - IM MH - Humans MH - Adolescent MH - Animals MH - *Neanderthals MH - Incisor MH - Computer Simulation MH - Finite Element Analysis MH - Crowns MH - Stress, Mechanical OTO - NOTNLM OT - Anterior dental loading hypothesis OT - Bite force OT - Dental biomechanics OT - Occlusal fingerprint analysis COIS- Declaration of competing interest There are no conflicts of interest. EDAT- 2024/03/11 00:42 MHDA- 2024/04/08 06:43 CRDT- 2024/03/10 19:01 PHST- 2023/01/09 00:00 [received] PHST- 2024/02/12 00:00 [revised] PHST- 2024/02/13 00:00 [accepted] PHST- 2024/04/08 06:43 [medline] PHST- 2024/03/11 00:42 [pubmed] PHST- 2024/03/10 19:01 [entrez] AID - S0047-2484(24)00020-4 [pii] AID - 10.1016/j.jhevol.2024.103512 [doi] PST - ppublish SO - J Hum Evol. 2024 Apr;189:103512. doi: 10.1016/j.jhevol.2024.103512. Epub 2024 Mar 10. PMID- 38460972 OWN - NLM STAT- MEDLINE DCOM- 20240801 LR - 20260427 IS - 1943-7722 (Electronic) IS - 0002-9173 (Linking) VI - 162 IP - 2 DP - 2024 Aug 1 TI - Cardiothoracic operating room blood gas workflow performance improvement initiative. PG - 167-174 LID - 10.1093/ajcp/aqae014 [doi] AB - OBJECTIVES: To evaluate the current workflow of blood gas ordering and testing in a cardiothoracic operating room to identify opportunities to streamline the process, using performance improvement methodologies. METHODS: Issues with specimen relabeling were identified that lead to delayed results and potential patient safety concerns. Blood gas specimen relabeling was evaluated for operating room cases from August 2018 to December 2022. An OpTime Epic Sidebar button for arterial blood gas and venous blood gas orders was created in January 2019 to streamline the ordering process so that laboratory barcode labels were then printed in the operating room and attached to the specimen, eliminating the need for relabeling by the technologists. RESULTS: This Epic Sidebar intervention led to a drastic improvement of appropriate labeling, which has been sustained. From March 2019 to January 2023, with our new workflow, over 95% of blood gas specimens arrived barcode labeled compared to less than 1% in the preintervention era. CONCLUSIONS: A multidisciplinary team with key stakeholders is important to address complex care issues. Performance improvement methodology is critical to develop interventions that hardwire the process. This intervention led to a sustained reduction in secondary relabeling of patient samples and improved timeliness of reporting of blood gas results. CI - (c) The Author(s) 2024. Published by Oxford University Press on behalf of American Society for Clinical Pathology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com. FAU - Forest, Stefanie K AU - Forest SK AD - Department of Pathology, Albert Einstein College of Medicine, Bronx, NY, US. FAU - Kuan, Kevin AU - Kuan K AUID- ORCID: 0000-0001-6818-2179 AD - Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto,Canada. FAU - Edema, Ukuemi AU - Edema U AD - Department of Pathology, Albert Einstein College of Medicine, Bronx, NY, US. FAU - Forest, Stephen J AU - Forest SJ AD - Department of Cardiovascular and Thoracic Surgery, and Albert Einstein College of Medicine, Bronx, NY, US. FAU - Leff, Jonathan D AU - Leff JD AD - Department of Anesthesiology, Albert Einstein College of Medicine, Bronx, NY, US. LA - eng PT - Journal Article PL - England TA - Am J Clin Pathol JT - American journal of clinical pathology JID - 0370470 SB - IM MH - Humans MH - *Workflow MH - *Operating Rooms/standards MH - *Blood Gas Analysis MH - *Quality Improvement OTO - NOTNLM OT - blood gas OT - clinical chemistry OT - performance improvement OT - quality management EDAT- 2024/03/10 00:42 MHDA- 2024/08/01 06:42 CRDT- 2024/03/09 20:53 PHST- 2023/10/17 00:00 [received] PHST- 2024/01/22 00:00 [accepted] PHST- 2024/08/01 06:42 [medline] PHST- 2024/03/10 00:42 [pubmed] PHST- 2024/03/09 20:53 [entrez] AID - 7625113 [pii] AID - 10.1093/ajcp/aqae014 [doi] PST - ppublish SO - Am J Clin Pathol. 2024 Aug 1;162(2):167-174. doi: 10.1093/ajcp/aqae014. PMID- 38456417 OWN - NLM STAT- MEDLINE DCOM- 20240320 LR - 20260627 IS - 2047-9980 (Electronic) IS - 2047-9980 (Linking) VI - 13 IP - 6 DP - 2024 Mar 19 TI - Need for a Cardiogenic Shock Team Collaborative-Promoting a Team-Based Model of Care to Improve Outcomes and Identify Best Practices. PG - e031979 LID - 10.1161/JAHA.123.031979 [doi] LID - e031979 AB - Cardiogenic shock continues to carry a high mortality rate despite contemporary care, with no breakthrough therapies shown to improve survival over the past few decades. It is a time-sensitive condition that commonly results in cardiovascular complications and multisystem organ failure, necessitating multidisciplinary expertise. Managing patients with cardiogenic shock remains challenging even in well-resourced settings, and an important subgroup of patients may require cardiac replacement therapy. As a result, the idea of leveraging the collective cognitive and procedural proficiencies of multiple providers in a collaborative, team-based approach to care (the "shock team") has been advocated by professional societies and implemented at select high-volume clinical centers. A slowly maturing evidence base has suggested that cardiogenic shock teams may improve patient outcomes. Although several registries exist that are beginning to inform care, particularly around therapeutic strategies of pharmacologic and mechanical circulatory support, none of these are currently focused on the shock team approach, multispecialty partnership, education, or process improvement. We propose the creation of a Cardiogenic Shock Team Collaborative-akin to the successful Pulmonary Embolism Response Team Consortium-with a goal to promote sharing of care protocols, education of stakeholders, and discovery of how process and performance may influence patient outcomes, quality, resource consumption, and costs of care. FAU - Senman, Balimkiz AU - Senman B AUID- ORCID: 0009-0004-7659-6135 AD - Division of Cardiology Duke University Durham NC USA. FAU - Jentzer, Jacob C AU - Jentzer JC AUID- ORCID: 0000-0002-6366-2859 AD - Department of Cardiovascular Medicine Mayo Clinic Rochester MN USA. FAU - Barnett, Christopher F AU - Barnett CF AUID- ORCID: 0000-0003-1095-5794 AD - Division of Cardiology, Department of Medicine University of California San Francisco San Francisco CA USA. FAU - Bartos, Jason A AU - Bartos JA AUID- ORCID: 0000-0003-0113-5305 AD - Department of Medicine-Cardiovascular Division University of Minnesota Minneapolis MN USA. FAU - Berg, David D AU - Berg DD AUID- ORCID: 0000-0002-0366-5492 AD - Division of Cardiovascular Medicine Brigham and Women's Hospital and Harvard Medical School Boston MA USA. FAU - Chih, Sharon AU - Chih S AUID- ORCID: 0000-0003-3634-2005 AD - Ottawa Heart Institute Ottawa Ontario Canada. FAU - Drakos, Stavros G AU - Drakos SG AUID- ORCID: 0000-0002-1223-327X AD - Department of Medicine, Division of Cardiovascular Medicine and Nora Eccles Harrison Cardiovascular Research and Training Institute University of Utah School of Medicine Salt Lake City UT USA. FAU - Dudzinski, David M AU - Dudzinski DM AUID- ORCID: 0000-0001-9363-9345 AD - Department of Cardiology Massachusetts General Hospital Boston MA USA. FAU - Elliott, Andrea AU - Elliott A AUID- ORCID: 0000-0002-3969-6848 AD - Department of Medicine-Cardiovascular Division University of Minnesota Minneapolis MN USA. FAU - Gage, Ann AU - Gage A AD - Department of Cardiovascular Medicine Centennial Medical Center Nashville TN USA. FAU - Horowitz, James M AU - Horowitz JM AUID- ORCID: 0000-0002-8220-5434 AD - Division of Cardiology New York University Grossman School of Medicine New York NY USA. FAU - Miller, P Elliott AU - Miller PE AUID- ORCID: 0000-0002-0595-1492 AD - Section of Cardiovascular Medicine, Yale School of Medicine New Haven CT USA. FAU - Sinha, Shashank S AU - Sinha SS AUID- ORCID: 0000-0001-6249-2598 AD - Inova Schar Heart and Vascular, Inova Fairfax Medical Campus Falls Church VA USA. FAU - Tehrani, Behnam N AU - Tehrani BN AD - Inova Schar Heart and Vascular, Inova Fairfax Medical Campus Falls Church VA USA. FAU - Yuriditsky, Eugene AU - Yuriditsky E AUID- ORCID: 0000-0003-2263-9297 AD - Division of Cardiology New York University Grossman School of Medicine New York NY USA. FAU - Vallabhajosyula, Saraschandra AU - Vallabhajosyula S AUID- ORCID: 0000-0002-1631-8238 AD - Division of Cardiology, Department of Medicine Warren Alpert Medical School of Brown University and Lifespan Cardiovascular Institute Providence RI USA. FAU - Katz, Jason N AU - Katz JN AUID- ORCID: 0000-0002-3460-5169 AD - Division of Cardiology NYU Grossman School of Medicine & Bellevue Hospital Center New York NY USA. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20240308 PL - England TA - J Am Heart Assoc JT - Journal of the American Heart Association JID - 101580524 SB - IM MH - Humans MH - *Shock, Cardiogenic/diagnosis/therapy/etiology PMC - PMC11009990 OTO - NOTNLM OT - cardiogenic shock OT - education OT - multidisciplinary teams OT - process improvement EDAT- 2024/03/08 12:43 MHDA- 2024/03/20 06:45 PMCR- 2024/03/19 CRDT- 2024/03/08 07:59 PHST- 2024/03/20 06:45 [medline] PHST- 2024/03/08 12:43 [pubmed] PHST- 2024/03/08 07:59 [entrez] PHST- 2024/03/19 00:00 [pmc-release] AID - JAH39336 [pii] AID - 10.1161/JAHA.123.031979 [doi] PST - ppublish SO - J Am Heart Assoc. 2024 Mar 19;13(6):e031979. doi: 10.1161/JAHA.123.031979. Epub 2024 Mar 8. PMID- 38453957 OWN - NLM STAT- MEDLINE DCOM- 20240311 LR - 20240311 IS - 2056-676X (Electronic) IS - 2056-676X (Linking) VI - 10 IP - 1 DP - 2024 Mar 7 TI - Alkaptonuria. PG - 16 LID - 10.1038/s41572-024-00498-x [doi] AB - Alkaptonuria is a rare inborn error of metabolism caused by the deficiency of homogentisate 1,2-dioxygenase activity. The consequent homogentisic acid (HGA) accumulation in body fluids and tissues leads to a multisystemic and highly debilitating disease whose main features are dark urine, ochronosis (HGA-derived pigment in collagen-rich connective tissues), and a painful and severe form of osteoarthropathy. Other clinical manifestations are extremely variable and include kidney and prostate stones, aortic stenosis, bone fractures, and tendon, ligament and/or muscle ruptures. As an autosomal recessive disorder, alkaptonuria affects men and women equally. Debilitating symptoms appear around the third decade of life, but a proper and timely diagnosis is often delayed due to their non-specific nature and a lack of knowledge among physicians. In later stages, patients' quality of life might be seriously compromised and further complicated by comorbidities. Thus, appropriate management of alkaptonuria requires a multidisciplinary approach, and periodic clinical evaluation is advised to monitor disease progression, complications and/or comorbidities, and to enable prompt intervention. Treatment options are patient-tailored and include a combination of medications, physical therapy and surgery. Current basic and clinical research focuses on improving patient management and developing innovative therapies and implementing precision medicine strategies. CI - (c) 2024. Springer Nature Limited. FAU - Bernardini, Giulia AU - Bernardini G AUID- ORCID: 0000-0003-0016-0728 AD - Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy. giulia.bernardini@unisi.it. FAU - Braconi, Daniela AU - Braconi D AUID- ORCID: 0000-0002-9657-4169 AD - Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy. FAU - Zatkova, Andrea AU - Zatkova A AUID- ORCID: 0000-0002-4105-3868 AD - Institute of Clinical and Translational Research, Biomedical Research Center of the Slovak Academy of Sciences, Bratislava, Slovakia. AD - Geneton Ltd, Bratislava, Slovakia. FAU - Sireau, Nick AU - Sireau N AD - AKU Society, Cambridge, UK. FAU - Kujawa, Mariusz J AU - Kujawa MJ AUID- ORCID: 0000-0003-4654-4321 AD - 2nd Department of Radiology, Medical University of Gdansk, Gdansk, Poland. FAU - Introne, Wendy J AU - Introne WJ AD - Human Biochemical Genetics Section, Medical Genetics Branch, Office of the Clinical Director, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA. FAU - Spiga, Ottavia AU - Spiga O AD - Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy. FAU - Geminiani, Michela AU - Geminiani M AUID- ORCID: 0000-0002-6910-0056 AD - Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy. FAU - Gallagher, James A AU - Gallagher JA AD - Department of Musculoskeletal and Ageing Science, Institute of Life Course and Medical Sciences University of Liverpool, Liverpool, UK. FAU - Ranganath, Lakshminarayan R AU - Ranganath LR AD - Department of Musculoskeletal and Ageing Science, Institute of Life Course and Medical Sciences University of Liverpool, Liverpool, UK. AD - Department of Clinical Biochemistry and Metabolic Medicine, Royal Liverpool University Hospital, Liverpool, UK. FAU - Santucci, Annalisa AU - Santucci A AD - Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy. LA - eng PT - Journal Article PT - Review DEP - 20240307 PL - England TA - Nat Rev Dis Primers JT - Nature reviews. Disease primers JID - 101672103 RN - NP8UE6VF08 (Homogentisic Acid) SB - IM MH - Male MH - Humans MH - Female MH - *Alkaptonuria/complications/diagnosis/therapy MH - Quality of Life MH - *Ochronosis/complications/diagnosis MH - Kidney/metabolism MH - Homogentisic Acid/metabolism EDAT- 2024/03/08 00:43 MHDA- 2024/03/11 06:44 CRDT- 2024/03/07 23:38 PHST- 2024/01/29 00:00 [accepted] PHST- 2024/03/11 06:44 [medline] PHST- 2024/03/08 00:43 [pubmed] PHST- 2024/03/07 23:38 [entrez] AID - 10.1038/s41572-024-00498-x [pii] AID - 10.1038/s41572-024-00498-x [doi] PST - epublish SO - Nat Rev Dis Primers. 2024 Mar 7;10(1):16. doi: 10.1038/s41572-024-00498-x. PMID- 38453208 OWN - NLM STAT- MEDLINE DCOM- 20240311 LR - 20250103 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 14 IP - 3 DP - 2024 Mar 7 TI - Home-based mobile-guided exercise-based cardiac rehabilitation among patients undergoing transcatheter aortic valve replacement (REHAB-TAVR): protocol for a randomised clinical trial. PG - e080042 LID - 10.1136/bmjopen-2023-080042 [doi] LID - e080042 AB - INTRODUCTION: Transcatheter aortic valve replacement (TAVR) is a standard treatment for aortic stenosis, particularly in older adults. Reduced exercise capacity and frailty significantly impact outcomes in TAVR patients, yet current management lacks strategies to address these issues. This study aims to assess the effectiveness of home-based mobile-guided exercise-based cardiac rehabilitation in TAVR patients, led by a multidisciplinary team with clear progression milestones. METHODS AND ANALYSIS: The study involves 90 patients aged 60-89 in a single centre who will be randomised to a 3-month novel multidomain exercise intervention or routine care. Outcome assessors will be blinded towards group allocation. The primary outcome is the 6-min walk distance at month 3. The secondary outcomes include the 6-min walk distance at month 6, physical function measured by total Short Physical Performance Battery score and exercise adherence measured by the Exercise Adherence Rating Scale at months 3 and 6. Additional outcome measures, including rehospitalisations, death, handgrip strength, frailty (Fried Criteria and Essential Toolset), cognitive function (Mini-Mental State Examination), quality of life (EuroQol 5-Dimension 5-Level), nutritional status (Mini-Nutritional Assessment), anxiety (General Anxiety Disorder-7), depression (Geriatric Depression Scale), sleep (Pittsburgh Sleep Quality Index), functional capacity (Duke Activity Status Index), clinical indices (body mass index, symptoms, signs, left ventricular ejection fraction (LVEF), N-Terminal Pro-Brain Natriuretic Peptide, etc) and social support (Lubben Social Network Scale-6), along with comprehensive cost analysis, enhance the study's significance. The study's findings hold crucial implications for crafting an effective exercise-focused cardiac rehabilitation strategy for TAVR patients. Community implementation not only deepens understanding but also fosters the potential integration of exercise-based cardiac rehabilitation into self-care, promising enhanced patient adherence and overall cardiovascular health management. ETHICS AND DISSEMINATION: Ethical approval was obtained from the Zhongshan Hospital, Fudan University Ethics Committee (B2022-062R). Results will be disseminated to local stakeholders and the research community through publications and conferences. TRIAL REGISTRATION NUMBER: NCT05989594. CI - (c) Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Shen, Zhiyun AU - Shen Z AD - Department of Nursing, Zhongshan Hospital, Fudan University, Shanghai, China. FAU - Mi, Shouling AU - Mi S AD - Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China. FAU - Huang, Chenxu AU - Huang C AD - Department of Nursing, Zhongshan Hospital, Fudan University, Shanghai, China. FAU - Zhou, Daxin AU - Zhou D AD - Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China. FAU - Pan, Wenzhi AU - Pan W AD - Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China. FAU - Xu, Xiaohua AU - Xu X AD - Department of Nursing, Zhongshan Hospital, Fudan University, Shanghai, China. FAU - Lin, Ying AU - Lin Y AD - Department of Nursing, Zhongshan Hospital, Fudan University, Shanghai, China Ying.lin@zs-hospital.sh.cn zhang.yuxia@zs-hospital.sh.cn. FAU - Zhang, Yuxia AU - Zhang Y AUID- ORCID: 0000-0003-4419-7004 AD - Department of Nursing, Zhongshan Hospital, Fudan University, Shanghai, China Ying.lin@zs-hospital.sh.cn zhang.yuxia@zs-hospital.sh.cn. LA - eng SI - ClinicalTrials.gov/NCT05989594 PT - Clinical Trial Protocol PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240307 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 SB - IM MH - Humans MH - Aged MH - *Transcatheter Aortic Valve Replacement MH - *Cardiac Rehabilitation MH - Quality of Life MH - Stroke Volume MH - *Frailty MH - Hand Strength MH - Ventricular Function, Left MH - *Aortic Valve Stenosis/surgery MH - Treatment Outcome MH - Randomized Controlled Trials as Topic MH - *Anxiety Disorders MH - Generalized Anxiety Disorder PMC - PMC10921510 OTO - NOTNLM OT - Aged OT - REHABILITATION MEDICINE OT - Valvular heart disease COIS- Competing interests: None declared. EDAT- 2024/03/08 00:42 MHDA- 2024/03/11 06:43 PMCR- 2024/03/07 CRDT- 2024/03/07 20:43 PHST- 2024/03/11 06:43 [medline] PHST- 2024/03/08 00:42 [pubmed] PHST- 2024/03/07 20:43 [entrez] PHST- 2024/03/07 00:00 [pmc-release] AID - bmjopen-2023-080042 [pii] AID - 10.1136/bmjopen-2023-080042 [doi] PST - epublish SO - BMJ Open. 2024 Mar 7;14(3):e080042. doi: 10.1136/bmjopen-2023-080042. PMID- 38453018 OWN - NLM STAT- MEDLINE DCOM- 20240509 LR - 20240815 IS - 2589-9333 (Electronic) IS - 2589-9333 (Linking) VI - 6 IP - 4 DP - 2024 Apr TI - Development and implementation of a pregnancy heart team at a Southeastern United States tertiary hospital: a qualitative study. PG - 101336 LID - S2589-9333(24)00062-4 [pii] LID - 10.1016/j.ajogmf.2024.101336 [doi] AB - BACKGROUND: The United States has seen a significant rise in maternal mortality and morbidity associated with cardiovascular disease over the past 4 decades. Contributing factors may include an increasing number of parturients with comorbid conditions, a higher rate of pregnancy among women of advanced maternal age, and more patients with congenital heart disease who survive into childbearing age and experiencing pregnancy. In response, national medical organizations have recommended the creation of multidisciplinary obstetric-cardiac teams, also known as pregnancy heart teams, to provide comprehensive preconception counseling and coordinated pregnancy management that extend through the postpartum period. OBJECTIVE: We sought to describe the development and implementation of a pregnancy heart team for parturients with cardiac disease at a southeastern United States tertiary hospital. STUDY DESIGN: This was a qualitative study that was conducted among healthcare team members involved during the pregnancy heart team formation. Semi-structured interviews were conducted between April and May 2022, professionally transcribed, and the responses were thematically coded for categories and themes using constructs from The Consolidated Framework for Implementation Research. RESULTS: Themes identified included intentional collaboration to improve outpatient and inpatient coordination through earlier awareness of patients who meet the criteria and via documented care planning. The pregnancy heart team united clinicians around best practices and coordination to promote the success and safety of pregnancies and not only to minimize maternal health risks. Developing longitudinal care plans was critical among the pathway team to build on collective expertise and to provide clarity for those on shift to reduce hesitancy and achieve timely, vetted practices without additional consults. Establishing a proactive approach of specialists offering their perspectives was viewed as positively contributing to a culture of speaking up. Barriers to the successful development and sustainability of the pregnancy heart team included unmet administrative needs and clinician turnover within a context of shortages in staffing and high workload. CONCLUSION: This study described the process of developing and implementing a pregnancy heart team at 1 institution, thereby offering insights for future multidisciplinary care for maternal cardiac patients. Establishing pregnancy heart teams can enhance quality care for high-risk patients, foster learning and collaboration among physician and nursing specialties, and improve coordination to manage complex maternal cardiac cases. CI - Copyright (c) 2024 Elsevier Inc. All rights reserved. FAU - Hart, William Michael AU - Hart WM AD - Department of Anesthesiology, University of North Carolina at Chapel Hill, Chapel Hill, NC (Drs Hart and Cobb). Electronic address: michael_hart@med.unc.edu. FAU - Cobb, Ben AU - Cobb B AD - Department of Anesthesiology, University of North Carolina at Chapel Hill, Chapel Hill, NC (Drs Hart and Cobb). FAU - Quist-Nelson, Johanna AU - Quist-Nelson J AD - Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, Chapel Hill, NC (Drs Quist-Nelson and Tully). FAU - Tully, Kristin P AU - Tully KP AD - Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, Chapel Hill, NC (Drs Quist-Nelson and Tully). LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240305 PL - United States TA - Am J Obstet Gynecol MFM JT - American journal of obstetrics & gynecology MFM JID - 101746609 SB - IM MH - Humans MH - Pregnancy MH - Female MH - *Qualitative Research MH - *Tertiary Care Centers/organization & administration MH - *Patient Care Team/organization & administration MH - Southeastern United States/epidemiology MH - *Pregnancy Complications, Cardiovascular/epidemiology/therapy MH - Adult MH - Program Development/methods OTO - NOTNLM OT - Consolidated Framework for Implementation Research OT - coordinated pregnancy management OT - cultural shift OT - maternal cardiac disease OT - multidisciplinary team formation OT - obstetric-cardiac pathway OT - perceptions of benefit OT - qualitative analysis OT - specialized care pathways OT - transformative change EDAT- 2024/03/08 00:43 MHDA- 2024/05/10 00:42 CRDT- 2024/03/07 19:18 PHST- 2023/12/21 00:00 [received] PHST- 2024/02/15 00:00 [revised] PHST- 2024/02/27 00:00 [accepted] PHST- 2024/05/10 00:42 [medline] PHST- 2024/03/08 00:43 [pubmed] PHST- 2024/03/07 19:18 [entrez] AID - S2589-9333(24)00062-4 [pii] AID - 10.1016/j.ajogmf.2024.101336 [doi] PST - ppublish SO - Am J Obstet Gynecol MFM. 2024 Apr;6(4):101336. doi: 10.1016/j.ajogmf.2024.101336. Epub 2024 Mar 5. PMID- 38452799 OWN - NLM STAT- MEDLINE DCOM- 20240311 LR - 20240311 IS - 1442-2018 (Electronic) IS - 1441-0745 (Linking) VI - 26 IP - 1 DP - 2024 Mar TI - Effects of communication team training on clinical competence in Korean Advanced Life Support: A randomized controlled trial. PG - e13106 LID - 10.1111/nhs.13106 [doi] AB - We conducted a randomized controlled trial to study the effects of interprofessional communication team training on clinical competence in the Korean Advanced Life Support provider course using a team communication framework. Our study involved 73 residents and 42 nurses from a tertiary hospital in Seoul. The participants were randomly assigned to the intervention or control group, forming 10 teams per group. The intervention group underwent interprofessional communication team training with a cardiac arrest simulation and standardized communication tools. The control group completed the Korean Advanced Life Support provider course. All participants completed a communication clarity self-reporting questionnaire. Clinical competence was assessed using a clinical competency scale comprising technical and nontechnical tools. Blinding was not possible due to the educational intervention. Data were analyzed using a Mann-Whitney U test and a multivariate Kruskal-Wallis H test. While no significant differences were observed in communication clarity between the two groups, there were significant differences in clinical competence. Therefore, the study confirmed that the intervention can enhance the clinical competence of patient care teams in cardiopulmonary resuscitation. CI - (c) 2024 John Wiley & Sons Australia, Ltd. FAU - Yun, Soyeon AU - Yun S AD - Seoul National University Hospital, Seoul, Republic of Korea. FAU - Park, Hyeoun-Ae AU - Park HA AUID- ORCID: 0000-0002-3770-4998 AD - College of Nursing, Seoul National University, Seoul, Republic of Korea. FAU - Na, Sang-Hoon AU - Na SH AD - Seoul National University Hospital, Seoul, Republic of Korea. FAU - Yun, Hee Je AU - Yun HJ AD - Seoul National University Hospital, Seoul, Republic of Korea. LA - eng PT - Journal Article PT - Randomized Controlled Trial PL - Australia TA - Nurs Health Sci JT - Nursing & health sciences JID - 100891857 SB - IM MH - Humans MH - Clinical Competence MH - *Heart Arrest/therapy MH - *Simulation Training MH - Communication MH - Patient Care Team MH - Republic of Korea OTO - NOTNLM OT - cardiopulmonary resuscitation OT - clinical competence OT - interdisciplinary communication OT - interprofessional education OT - patient care team OT - simulation training EDAT- 2024/03/08 00:42 MHDA- 2024/03/11 06:43 CRDT- 2024/03/07 19:02 PHST- 2024/02/21 00:00 [revised] PHST- 2023/08/08 00:00 [received] PHST- 2024/02/23 00:00 [accepted] PHST- 2024/03/11 06:43 [medline] PHST- 2024/03/08 00:42 [pubmed] PHST- 2024/03/07 19:02 [entrez] AID - 10.1111/nhs.13106 [doi] PST - ppublish SO - Nurs Health Sci. 2024 Mar;26(1):e13106. doi: 10.1111/nhs.13106. PMID- 38450371 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240308 IS - 2297-055X (Print) IS - 2297-055X (Electronic) IS - 2297-055X (Linking) VI - 11 DP - 2024 TI - Multidisciplinary management of cardiovascular disease in women: Delphi consensus. PG - 1315503 LID - 10.3389/fcvm.2024.1315503 [doi] LID - 1315503 AB - BACKGROUND: Current clinical guidelines on cardiovascular disease (CVD) do not specifically address the female population. The aim of this consensus is to know the opinion of a group of experts on the management of CVD in women. METHODS: Through a Delphi consensus, 31 experts in cardiology, 9 in gynecology and obstetrics, and 14 primary care physicians, showed their degree of agreement on 44 items on CVD in women divided into the following groups: (1) risk factors and prevention strategies; (2) diagnosis and clinical manifestations; and (3) treatment and follow-up. RESULTS: After two rounds, consensus in agreement was reached on 27 items (61.4%). Most of the non-consensus items (31.8%) belonged to group 3. The lack of consensus in this group was mainly among gynecologists and primary care physicians. The panelists agreed on periodic blood pressure control during pregnancy and delivery to detect hypertensive disorders, especially in women with a history of preeclampsia and/or gestational hypertension, and diabetes mellitus control in those with gestational diabetes. Also, the panelists agreed that women receive statins at a lower intensity than men, although there was no consensus as to whether the efficacy of drug treatments differs between women and men. CONCLUSIONS: The high degree of consensus shows that the panelists are aware of the differences that exist between men and women in the management of CVD and the need to propose interventions to reduce this inequality. The low level of consensus reveals the lack of knowledge, and the need for information and training on this topic. CI - (c) 2024 Gamez, Pedreira Perez, Fernandez Olmo, Fasero Laiz, Inaraja and Pallares Carratala. FAU - Gamez, Jose M AU - Gamez JM AD - Servicio de Cardiologia, Hospital Universitario Son Llatzer, Departamento de Medicina, Universidad de las Islas Baleares, Palma de Mallorca, Spain. AD - CIBER de Fisiopatologia de la Obesidad y la Nutricion (CIBEROBN CB12/03/30038), Instituto de Salud Carlos III, Madrid, Spain. FAU - Pedreira Perez, Milagros AU - Pedreira Perez M AD - Coordinadora de la Unidad de Cardio-Oncologia y de la Unidad de Enfermedad Cardiovascular en la Mujer, Hospital Clinico Universitario Santiago de Compostela, A Coruna, Spain. FAU - Fernandez Olmo, Maria Rosa AU - Fernandez Olmo MR AD - Especialista en Cardiologia en la Unidad de Rehabilitacion Cardiaca, Hospital Universitario de Jaen, Jaen, Spain. FAU - Fasero Laiz, Maria AU - Fasero Laiz M AD - Coordinadora de la Unidad de Menopausia Saludable, Hospital Universitario La Zarzuela, Madrid, Spain. AD - Unidad de Menopausia Saludable, Clinica Corofas, Madrid, Spain. AD - Facultad de Medicina, Universidad Francisco de Vitoria, Madrid, Spain. FAU - Inaraja, Veronica AU - Inaraja V AD - Departamento Medico, Organon Salud Espana, Madrid, Spain. FAU - Pallares Carratala, Vicente AU - Pallares Carratala V AD - Unidad de Vigilancia de la Salud, Union de Mutuas de Castellon, Castellon, Spain. AD - Departamento de Medicina, Universitat Jaume I, Castellon, Spain. LA - eng PT - Journal Article DEP - 20240221 PL - Switzerland TA - Front Cardiovasc Med JT - Frontiers in cardiovascular medicine JID - 101653388 PMC - PMC10914989 OTO - NOTNLM OT - Delphi OT - cardiovascular disease OT - diagnosis OT - multidisciplinary OT - statins OT - women COIS- JG has received honoraria as an expert from Organon. MP has received honoraria as an expert from Organon. M-FO has received honoraria as an expert from Organon. MF has received honoraria as an expert from Organon. VI is an employee of Organon. VP has received honoraria as an expert from Organon. EDAT- 2024/03/07 06:43 MHDA- 2024/03/07 06:44 PMCR- 2024/01/01 CRDT- 2024/03/07 04:20 PHST- 2023/10/10 00:00 [received] PHST- 2024/02/05 00:00 [accepted] PHST- 2024/03/07 06:44 [medline] PHST- 2024/03/07 06:43 [pubmed] PHST- 2024/03/07 04:20 [entrez] PHST- 2024/01/01 00:00 [pmc-release] AID - 10.3389/fcvm.2024.1315503 [doi] PST - epublish SO - Front Cardiovasc Med. 2024 Feb 21;11:1315503. doi: 10.3389/fcvm.2024.1315503. eCollection 2024. PMID- 38447954 OWN - NLM STAT- MEDLINE DCOM- 20250422 LR - 20260321 IS - 1439-359X (Electronic) IS - 0939-7248 (Print) IS - 0939-7248 (Linking) VI - 35 IP - 2 DP - 2025 Apr TI - The Diagnostics and Management of Bronchopulmonary Sequestration: An International Survey among Specialized Caregivers. PG - 147-158 LID - 10.1055/s-0044-1782237 [doi] AB - BACKGROUND: Our objective was to explore the treatment preferences for bronchopulmonary sequestration (BPS) among an international group of specialized caregivers. METHODS: Sixty-three participants from 17 countries completed an online survey concerning the diagnostics, treatment, and follow-up. Recruitment took place among members of the Collaborative Neonatal Network for the first European Congenital Pulmonary Airway Malformation Trial Consortium and through the Association for European Pediatric and Congenital Cardiology working group database. RESULTS: Most of the 63 participants were pediatric surgeons (52%), followed by pediatric pulmonologists (22%), and pediatric cardiologists (19%). The majority (65%) treated more than five cases per year and 52% standardly discussed treatment in a multidisciplinary team. Half of the participants (52%) based the management on the presence of symptoms, versus 32% on the intralobar or extralobar lesion localization. Centers with both surgical and interventional cardiac/radiological facilities (85%) preferred resection to embolization in symptomatic cases (62 vs. 15%). In asymptomatic cases too, resection was preferred over embolization (38 vs. 9%); 32% preferred noninterventional treatment, while 11% varied in preference. These treatment preferences were significantly different between surgeons and nonsurgeons (p < 0.05). Little agreement was observed in the preferred timing of intervention as also for the duration of follow-up. CONCLUSIONS: This survey demonstrates a variation in management strategies of BPS, reflecting different specialist expertise. Most centers treat only a handful of cases per year and follow-up is not standardized. Therefore, management discussion within a multidisciplinary team is recommended. Recording patient data in an international registry for the comparison of management strategies and outcomes could support the development of future guidelines. LEVEL OF EVIDENCE: Level IV. CI - The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/). FAU - Kersten, C M AU - Kersten CM AUID- ORCID: 0000-0002-6514-086X AD - Department of Paediatric Surgery, Erasmus MC Sophia Children's Hospital, Rotterdam, The Netherlands. FAU - Jansen, M D G AU - Jansen MDG AD - Medicine master's student, Leiden University Medical Centre, Leiden, The Netherlands. FAU - Zuidweg, M J P AU - Zuidweg MJP AD - Department of Paediatric Surgery, Erasmus MC Sophia Children's Hospital, Rotterdam, The Netherlands. FAU - Wijnen, R M W H AU - Wijnen RMWH AD - Department of Paediatric Surgery, Erasmus MC Sophia Children's Hospital, Rotterdam, The Netherlands. FAU - Krasemann, T B AU - Krasemann TB AD - Department of Paediatric Cardiology, Erasmus MC Sophia Children's Hospital, Rotterdam, The Netherlands. FAU - Schnater, J M AU - Schnater JM AUID- ORCID: 0000-0003-4910-8293 AD - Department of Paediatric Surgery, Erasmus MC Sophia Children's Hospital, Rotterdam, The Netherlands. LA - eng PT - Journal Article DEP - 20240306 PL - United States TA - Eur J Pediatr Surg JT - European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift fur Kinderchirurgie JID - 9105263 SB - IM MH - Humans MH - *Bronchopulmonary Sequestration/diagnosis/therapy MH - *Practice Patterns, Physicians'/statistics & numerical data MH - Surveys and Questionnaires MH - Infant, Newborn PMC - PMC11932755 COIS- None declared. EDAT- 2024/03/07 00:43 MHDA- 2025/03/25 00:38 PMCR- 2024/03/01 CRDT- 2024/03/06 19:43 PHST- 2025/03/25 00:38 [medline] PHST- 2024/03/07 00:43 [pubmed] PHST- 2024/03/06 19:43 [entrez] PHST- 2024/03/01 00:00 [pmc-release] AID - EJPS-2024-01-6869-OA [pii] AID - 10.1055/s-0044-1782237 [doi] PST - ppublish SO - Eur J Pediatr Surg. 2025 Apr;35(2):147-158. doi: 10.1055/s-0044-1782237. Epub 2024 Mar 6. PMID- 38446913 OWN - NLM STAT- MEDLINE DCOM- 20240308 LR - 20251022 IS - 2329-9185 (Electronic) IS - 2329-9185 (Linking) VI - 12 IP - 3 DP - 2024 Mar 1 TI - Team Approach: Diagnosis, Management, and Prevention of Sudden Cardiac Arrest in the Athlete. LID - 10.2106/JBJS.RVW.23.00225 [doi] AB - >> Sudden cardiac events during sports competition are rare but tragic occurrences that require a timely, comprehensive response by well-prepared athletic trainers and medical providers. This sequence should prioritize prompt emergency medical system activation, immediate initiation of cardiopulmonary resuscitation (CPR), automated early defibrillation (AED), and comprehensive advanced life support efforts.>> Exercise-induced cardiac remodeling, referred to as the "athlete's heart," refers to a host of adaptive changes that increase cardiac chamber size and wall thickness to allow for greater pressures and volumes during exercise. This remodeling phenotype may overlap with other inherited cardiomyopathies and cardiac abnormalities, which can complicate clinical care. The long-term implications of this electrical and structural remodeling on cardiac function are unknown.>> Although the best screening strategies to optimize primary prevention of sudden cardiac arrest is an evolving topic, the effectiveness of CPR and early defibrillation use in treating out-of-hospital sudden cardiac arrest has been well-established, despite their reported underuse. CI - Copyright (c) 2024 by The Journal of Bone and Joint Surgery, Incorporated. FAU - Cusano, Antonio AU - Cusano A AUID- ORCID: 0000-0002-4124-1922 AD - Sports Medicine and Shoulder Service, Hospital for Special Surgery, New York, New York. FAU - Inclan, Paul M AU - Inclan PM AD - Sports Medicine and Shoulder Service, Hospital for Special Surgery, New York, New York. FAU - Jackson, Tyler AU - Jackson T AUID- ORCID: 0009-0009-2707-3887 AD - Primary Sports Medicine, Hospital for Special Surgery, New York, New York. FAU - Weiss, Leigh J AU - Weiss LJ AUID- ORCID: 0009-0008-1431-586 AD - New York Football Giants, East Rutherford, New Jersey. FAU - Barnes, Ronnie P AU - Barnes RP AD - New York Football Giants, East Rutherford, New Jersey. FAU - Kinderknecht, James J AU - Kinderknecht JJ AUID- ORCID: 0009-0000-6927-4243 AD - Primary Sports Medicine, Hospital for Special Surgery, New York, New York. FAU - Taylor, Samuel A AU - Taylor SA AD - Sports Medicine and Shoulder Service, Hospital for Special Surgery, New York, New York. FAU - Rodeo, Scott A AU - Rodeo SA AUID- ORCID: 0000-0002-0745-9880 AD - Sports Medicine and Shoulder Service, Hospital for Special Surgery, New York, New York. LA - eng PT - Journal Article DEP - 20240306 PL - United States TA - JBJS Rev JT - JBJS reviews JID - 101674872 SB - IM MH - Humans MH - *Death, Sudden, Cardiac/etiology/prevention & control MH - Athletes MH - *Sports MH - Cognition COIS- Disclosure: The Disclosure of Potential Conflicts of Interest forms are provided with the online version of the article (http://links.lww.com/JBJSREV/B64). EDAT- 2024/03/06 18:42 MHDA- 2024/03/08 06:43 CRDT- 2024/03/06 14:13 PHST- 2024/03/08 06:43 [medline] PHST- 2024/03/06 18:42 [pubmed] PHST- 2024/03/06 14:13 [entrez] AID - 01874474-202403000-00002 [pii] AID - 10.2106/JBJS.RVW.23.00225 [doi] PST - epublish SO - JBJS Rev. 2024 Mar 6;12(3). doi: 10.2106/JBJS.RVW.23.00225. eCollection 2024 Mar 1. PMID- 38440925 OWN - NLM STAT- MEDLINE DCOM- 20240415 LR - 20250506 IS - 1522-726X (Electronic) IS - 1522-1946 (Linking) VI - 103 IP - 5 DP - 2024 Apr TI - Reasons for repeat urgent cardiac procedures within the same day. PG - 691-694 LID - 10.1002/ccd.31004 [doi] AB - BACKGROUND: With advances in technology and technique, the expectations are that patients undergoing procedures in the cardiac catheterization laboratory will not need to return for a repeat procedure within the same day. OBJECTIVES: Report why subjects undergoing cardiac procedures return urgently to the catheterization laboratory for a repeat procedure during the same day. METHODS: We retrospectively reviewed patients who were brought back to the cardiac catheterization laboratory within the same day for a repeat procedure. The reasons for index and repeat procedure were identified. Patients who were transferred from an outside center after an initial procedure at other centers were excluded. RESULTS: Between November 2013 and January 2022, 55,942 catheterization procedures were performed at our institution, of which 140 entries were included in our analysis. Common reasons for the index procedure were diagnostic angiography (35.0%), percutaneous coronary intervention (PCI, 29.2%), and transcatheter aortic valve replacement (15.0%). The most common reason for bringing these patients back to the cardiac catheterization laboratory within the same day was vascular complications (24.2%), followed by repeat PCI (20.7%), need for hemodynamic support (15.0%), heart team discussion and PCI (10%), and pacemaker implantation (10%). Acute limb ischemia was the most commonly identified vascular complication (7.1%), followed by pseudoaneurysm (5%). CONCLUSION: Our study demonstrates that a very small number of patients underwent repeat procedures within the same day. Special attention should be paid to vascular access and closure and assessment of recurrent chest pain postprocedure, as these are the main reasons for same-day repeat procedures. CI - (c) 2024 Wiley Periodicals LLC. FAU - Bhogal, Sukhdeep AU - Bhogal S AD - Section of Interventional Cardiology, Sovah Health, Martinsville, Virginia, USA. FAU - Garg, Mohil AU - Garg M AD - Department of Internal Medicine, MedStar Washington Hospital Center, Washington, District of Columbia, USA. FAU - Meda, Namratha S AU - Meda NS AUID- ORCID: 0000-0001-6136-2740 AD - Department of Internal Medicine, MedStar Washington Hospital Center, Washington, District of Columbia, USA. FAU - Merdler, Ilan AU - Merdler I AD - Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia, USA. FAU - Wermers, Jason P AU - Wermers JP AD - Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia, USA. FAU - Hashim, Hayder D AU - Hashim HD AD - Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia, USA. FAU - Ben-Dor, Itsik AU - Ben-Dor I AD - Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia, USA. FAU - Waksman, Ron AU - Waksman R AUID- ORCID: 0000-0002-4063-9226 AD - Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia, USA. LA - eng PT - Journal Article DEP - 20240305 PL - United States TA - Catheter Cardiovasc Interv JT - Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions JID - 100884139 SB - IM MH - Humans MH - *Percutaneous Coronary Intervention/adverse effects/methods MH - Retrospective Studies MH - Treatment Outcome MH - Angiography MH - *Pacemaker, Artificial MH - Cardiac Catheterization/adverse effects/methods MH - *Aortic Valve Stenosis OTO - NOTNLM OT - PCI OT - cardiac catheterization OT - chest pain OT - vascular complication EDAT- 2024/03/05 06:45 MHDA- 2024/04/15 06:43 CRDT- 2024/03/05 05:33 PHST- 2024/02/05 00:00 [received] PHST- 2024/02/25 00:00 [accepted] PHST- 2024/04/15 06:43 [medline] PHST- 2024/03/05 06:45 [pubmed] PHST- 2024/03/05 05:33 [entrez] AID - 10.1002/ccd.31004 [doi] PST - ppublish SO - Catheter Cardiovasc Interv. 2024 Apr;103(5):691-694. doi: 10.1002/ccd.31004. Epub 2024 Mar 5. PMID- 38439576 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240410 IS - 2753-670X (Electronic) IS - 2753-670X (Linking) VI - 38 IP - 4 DP - 2024 Mar 29 TI - Proposal of statistical twin as a transition to full digital twin technology for cardiovascular interventions. LID - 10.1093/icvts/ivae032 [doi] LID - ivae032 AB - OBJECTIVES: We introduced statistical twin as aggregates of multiple virtual patients' data throughout the treatment at any chosen time point. The goal of this manuscript was to provide the proof of concept of statistical twin by evaluating the feasibility of detection of distinctive aggregates of patients throughout the perioperative trajectory (prerequisite for development of statistical twin). METHODS: We used a retrospective validated cohort of all comers with mitral valve disease treated (2014-2020) at a tertiary academic hospital. The end point was overall survival based on the decision of the heart team. We applied two-step cluster analysis to detect distinct aggregated virtual patients throughout the process of care. RESULTS: The cluster procedure resulted in 5 distant clusters with relatively equal numbers of patients. Effects of the treatment (surgery, transcatheter or optimal medical therapy) on survival were as follows: For optimal medical therapy, the expected survival ranged from 95% to 96% in 30 days to 58% to 75% in 10 years independent of baseline characteristics. However, for transcatheter interventions, the 5-year survival was 60-92% and was dependant on the initial characteristics of the virtual patient. Furthermore, survival following an uncomplicated operation of normal duration was higher through all observation periods. The aggregated virtual patients of cluster 5 would have a better survival rate at all times if the intervention were done by a dedicated surgeon. CONCLUSIONS: It is possible to detect distinctive aggregates of virtual patients based on baseline characteristics and to capture the impact of perioperative events and external and other factors at multiple time points throughout the postoperative phase. CI - (c) The Author(s) 2024. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. FAU - Sardari Nia, Peyman AU - Sardari Nia P AUID- ORCID: 0000-0003-2296-1497 AD - Department of Cardiothoracic Surgery, Maastricht University Medical Centre, Maastricht, the Netherlands. AD - Foundation Heart Team Academy, Maastricht, the Netherlands. FAU - Ganushchak, Yuri AU - Ganushchak Y AD - Department of Cardiothoracic Surgery, Maastricht University Medical Centre, Maastricht, the Netherlands. AD - Foundation Heart Team Academy, Maastricht, the Netherlands. FAU - Maessen, Jos AU - Maessen J AD - Department of Cardiothoracic Surgery, Maastricht University Medical Centre, Maastricht, the Netherlands. AD - Foundation Heart Team Academy, Maastricht, the Netherlands. LA - eng PT - Journal Article PL - England TA - Interdiscip Cardiovasc Thorac Surg JT - Interdisciplinary cardiovascular and thoracic surgery JID - 9918540787006676 SB - IM PMC - PMC11001486 OTO - NOTNLM OT - Digital twin OT - Predictive models OT - Risk scoring OT - Statistical twin EDAT- 2024/03/05 06:43 MHDA- 2024/03/05 06:44 PMCR- 2024/03/04 CRDT- 2024/03/05 02:20 PHST- 2023/07/22 00:00 [received] PHST- 2024/01/17 00:00 [revised] PHST- 2024/02/29 00:00 [accepted] PHST- 2024/03/05 06:44 [medline] PHST- 2024/03/05 06:43 [pubmed] PHST- 2024/03/05 02:20 [entrez] PHST- 2024/03/04 00:00 [pmc-release] AID - 7619106 [pii] AID - ivae032 [pii] AID - 10.1093/icvts/ivae032 [doi] PST - ppublish SO - Interdiscip Cardiovasc Thorac Surg. 2024 Mar 29;38(4):ivae032. doi: 10.1093/icvts/ivae032. PMID- 38430465 OWN - NLM STAT- MEDLINE DCOM- 20240313 LR - 20260804 IS - 1873-734X (Electronic) IS - 1010-7940 (Linking) VI - 65 IP - 3 DP - 2024 Mar 1 TI - Endovascular aortic repair in patients with Marfan and Loeys-Dietz syndrome is safe and durable when employed by a multi-disciplinary aortic team. LID - ezae069 [pii] LID - 10.1093/ejcts/ezae069 [doi] AB - OBJECTIVES: The aim of this study was to report on mid-term outcomes after endovascular aortic repair (EVAR) in patients with Marfan (MFS) or Loeys-Dietz (LDS) syndrome. METHODS: We analysed data from 2 European centres of patients with MFS and LDS undergoing EVAR. Patients were analysed based on (i) timing of the procedure (planned versus emergency procedure) and (ii) the nature of the landing zone (safe versus non-safe). The primary end-point was freedom from reintervention. Secondary end-points were freedom from stroke, bleeding and death. RESULTS: A population of 419 patients with MFS (n = 352) or LDS (n = 67) was analysed for the purpose of this study. Thirty-nine patients (9%) underwent EVAR. Indications for thoracic endovascular aortic repair or EVAR were aortic dissection in 13 (33%) patients, aortic aneurysm in 22 (57%) patients and others (intercostal patch aneurysm, penetrating atherosclerotic ulcer, pseudoaneurysm, kinking of frozen elephant trunk (FET)) in 4 (10%) patients. Thoracic endovascular repair was performed in 34 patients, and abdominal endovascular aortic repair was performed in 5 patients. Mean age at 1st thoracic endovascular aortic repair/EVAR was 48.5 +/- 15.4 years. Mean follow-up after 1st thoracic endovascular aortic repair/EVAR was 5.9 +/- 4.4 years. There was no statistically significant difference in the rate of reinterventions between patients with non-safe landing zone and the patients with safe proximal landing zone (P = 0.609). Furthermore, there was no increased probability for reintervention after planned endovascular intervention compared to emergency procedures (P = 0.916). Mean time to reintervention, either open surgical or endovascular, after planned endovascular intervention was in median 3.9 years (95% confidence interval 2.0-5.9 years) and 2.0 years (95% confidence interval -1.1 to 5.1 years) (P = 0.23) after emergency procedures. CONCLUSIONS: EVAR in patients with MFS and LDS and a safe landing zone is feasible and safe. Endovascular treatment is a viable option when employed by a multi-disciplinary aortic team even if the landing zone is in native tissue. CI - (c) The Author(s) 2024. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved. FAU - Nucera, Maria AU - Nucera M AUID- ORCID: 0000-0002-5941-2232 AD - Department of Cardiac Surgery, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. AD - Department of Cardiovascular Surgery, University Heart Centre Freiburg - Bad Krozingen, Faculty of Medicine, University of Freiburg, Freiburg, Germany. FAU - Kreibich, Maximilian AU - Kreibich M AUID- ORCID: 0000-0003-3099-7254 AD - Department of Cardiovascular Surgery, University Heart Centre Freiburg - Bad Krozingen, Faculty of Medicine, University of Freiburg, Freiburg, Germany. FAU - Yildiz, Murat AU - Yildiz M AD - Department of Cardiac Surgery, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. FAU - Berger, Tim AU - Berger T AD - Department of Cardiovascular Surgery, University Heart Centre Freiburg - Bad Krozingen, Faculty of Medicine, University of Freiburg, Freiburg, Germany. FAU - Kolb, Rosa Klara AU - Kolb RK AD - Department of Cardiac Surgery, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. FAU - Kondov, Stoyan AU - Kondov S AD - Department of Cardiovascular Surgery, University Heart Centre Freiburg - Bad Krozingen, Faculty of Medicine, University of Freiburg, Freiburg, Germany. FAU - Kunzmann, Sophie AU - Kunzmann S AD - Department of Cardiovascular Surgery, University Heart Centre Freiburg - Bad Krozingen, Faculty of Medicine, University of Freiburg, Freiburg, Germany. FAU - Rylski, Bartosz AU - Rylski B AUID- ORCID: 0000-0001-6890-2172 AD - Department of Cardiovascular Surgery, University Heart Centre Freiburg - Bad Krozingen, Faculty of Medicine, University of Freiburg, Freiburg, Germany. FAU - Makaloski, Vladimir AU - Makaloski V AUID- ORCID: 0000-0001-8826-3232 AD - Department of Vascular Surgery, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. FAU - Siepe, Matthias AU - Siepe M AUID- ORCID: 0000-0003-3305-9343 AD - Department of Cardiac Surgery, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. FAU - Czerny, Martin AU - Czerny M AD - Department of Cardiovascular Surgery, University Heart Centre Freiburg - Bad Krozingen, Faculty of Medicine, University of Freiburg, Freiburg, Germany. FAU - Schoenhoff, Florian S AU - Schoenhoff FS AUID- ORCID: 0000-0002-3311-4595 AD - Department of Cardiac Surgery, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. LA - eng PT - Journal Article PL - Germany TA - Eur J Cardiothorac Surg JT - European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery JID - 8804069 SB - IM CIN - Eur J Cardiothorac Surg. 2024 Mar 29;65(4):ezae111. doi: 10.1093/ejcts/ezae111. PMID: 38519100 MH - Humans MH - Adult MH - Middle Aged MH - *Loeys-Dietz Syndrome/surgery/complications MH - Endovascular Aneurysm Repair MH - *Marfan Syndrome/complications/surgery MH - *Blood Vessel Prosthesis Implantation/adverse effects/methods MH - *Endovascular Procedures/adverse effects/methods MH - Treatment Outcome MH - Retrospective Studies MH - *Aortic Aneurysm, Thoracic/surgery MH - Postoperative Complications/epidemiology/surgery OTO - NOTNLM OT - Loeys-Dietz syndrome OT - Marfan syndrome OT - aortic aneurysm OT - aortic dissection OT - connective tissue disorders OT - endovascular aortic repair OT - thoracic endovascular aortic repair EDAT- 2024/03/02 12:46 MHDA- 2024/03/13 06:46 CRDT- 2024/03/02 11:33 PHST- 2023/09/01 00:00 [received] PHST- 2024/02/12 00:00 [revised] PHST- 2024/02/29 00:00 [accepted] PHST- 2024/03/13 06:46 [medline] PHST- 2024/03/02 12:46 [pubmed] PHST- 2024/03/02 11:33 [entrez] AID - 7617836 [pii] AID - 10.1093/ejcts/ezae069 [doi] PST - ppublish SO - Eur J Cardiothorac Surg. 2024 Mar 1;65(3):ezae069. doi: 10.1093/ejcts/ezae069. PMID- 38424490 OWN - NLM STAT- MEDLINE DCOM- 20240304 LR - 20240305 IS - 1471-2377 (Electronic) IS - 1471-2377 (Linking) VI - 24 IP - 1 DP - 2024 Mar 1 TI - Butyrylcholinesterase activity in patients with postoperative delirium after cardiothoracic surgery or percutaneous valve replacement- an observational interdisciplinary cohort study. PG - 80 LID - 10.1186/s12883-024-03580-9 [doi] LID - 80 AB - BACKGROUND AND OBJECTIVES: Postoperative delirium is a frequent and severe complication after cardiac surgery. Activity of butyrylcholinesterase (BChE) has been discussed controversially regarding a possible role in its development. This study aimed to investigate the relevance of BChE activity as a biomarker for postoperative delirium after cardiac surgery or percutaneous valve replacement. METHODS: A total of 237 patients who received elective cardiothoracic surgery or percutaneous valve replacement at a tertiary care centre were admitted preoperatively. These patients were tested with the Montreal Cognitive Assessment investigating cognitive deficits, and assessed for postoperative delirium twice daily for three days via the 3D-CAM or the CAM-ICU, depending on their level of consciousness. BChE activity was measured at three defined time points before and after surgery. RESULTS: Postoperative delirium occurred in 39.7% of patients (n = 94). Univariate analysis showed an association of pre- and postoperative BChE activity with its occurrence (p = 0.037, p = 0.001). There was no association of postoperative delirium and the decline in BChE activity (pre- to postoperative, p = 0.327). Multivariable analysis including either preoperative or postoperative BChE activity as well as age, MoCA, type 2 diabetes mellitus, coronary heart disease, type of surgery and intraoperative administration of red-cell concentrates was performed. Neither preoperative nor postoperative BChE activity was independently associated with the occurrence of postoperative delirium (p = 0.086, p = 0.484). Preoperative BChE activity was lower in older patients (B = -12.38 (95% CI: -21.94 to -2.83), p = 0.011), and in those with a history of stroke (B = -516.173 (95% CI: -893.927 to -138.420), p = 0.008) or alcohol abuse (B = -451.47 (95% CI: -868.38 to -34.55), p = 0.034). Lower postoperative BChE activity was independently associated with longer procedures (B = -461.90 (95% CI: -166.34 to -757.46), p = 0.002), use of cardiopulmonary bypass (B = -262.04 (95% CI: -485.68 to -38.39), p = 0.022), the number of administered red cell-concentrates (B = -40.99 (95% CI: -67.86 to -14.12), p = 0.003) and older age (B = -9.35 (95% CI: -16.04 to -2.66), p = 0.006). CONCLUSION: BChE activity is not independently associated with the occurrence of postoperative delirium. Preoperative BChE values are related to patients' morbidity and vulnerability, while postoperative activities reflect the severity, length and complications of surgery. CI - (c) 2024. The Author(s). FAU - Schlake, Konstantin AU - Schlake K AD - Department of Neurology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. schlake.konstantin@mh-hannover.de. FAU - Teller, Johannes AU - Teller J AD - Department of Neurology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. FAU - Hinken, Lukas AU - Hinken L AD - Department of Anaesthesiology and Intensive Care Medicine, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. FAU - Laser, Hans AU - Laser H AD - Department for Educational and Scientific IT Systems, Hannover Medical School, MHH Information Technology, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. FAU - Lichtinghagen, Ralf AU - Lichtinghagen R AD - Institute of Clinical Chemistry, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. FAU - Schafer, Andreas AU - Schafer A AD - Cardiac Arrest Center, Department of Cardiology and Angiology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. FAU - Fegbeutel, Christine AU - Fegbeutel C AD - Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. FAU - Weissenborn, Karin AU - Weissenborn K AD - Department of Neurology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. FAU - Jung, Carolin AU - Jung C AD - Department of Anaesthesiology and Intensive Care Medicine, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. FAU - Worthmann, Hans AU - Worthmann H AD - Department of Neurology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. FAU - Gabriel, Maria Magdalena AU - Gabriel MM AD - Department of Neurology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. LA - eng PT - Journal Article DEP - 20240301 PL - England TA - BMC Neurol JT - BMC neurology JID - 100968555 RN - EC 3.1.1.8 (Butyrylcholinesterase) RN - EC 3.1.1.8 (BCHE protein, human) SB - IM MH - Aged MH - Humans MH - Butyrylcholinesterase MH - Cohort Studies MH - *Delirium/epidemiology/etiology MH - *Diabetes Mellitus, Type 2/complications MH - *Emergence Delirium/complications MH - Postoperative Complications/epidemiology/etiology MH - Prospective Studies MH - Risk Factors PMC - PMC10905803 OTO - NOTNLM OT - Butyrylcholinesterase OT - Cardiac surgery OT - Percutaneous valve replacement OT - Postoperative delirium OT - Risk factors COIS- The authors declare no competing interests. EDAT- 2024/03/01 01:27 MHDA- 2024/03/04 06:47 PMCR- 2024/03/01 CRDT- 2024/02/29 23:43 PHST- 2023/10/06 00:00 [received] PHST- 2024/02/23 00:00 [accepted] PHST- 2024/03/04 06:47 [medline] PHST- 2024/03/01 01:27 [pubmed] PHST- 2024/02/29 23:43 [entrez] PHST- 2024/03/01 00:00 [pmc-release] AID - 10.1186/s12883-024-03580-9 [pii] AID - 3580 [pii] AID - 10.1186/s12883-024-03580-9 [doi] PST - epublish SO - BMC Neurol. 2024 Mar 1;24(1):80. doi: 10.1186/s12883-024-03580-9. PMID- 38421905 OWN - NLM STAT- MEDLINE DCOM- 20240304 LR - 20240620 IS - 1945-1474 (Electronic) IS - 1062-2551 (Linking) VI - 46 IP - 2 DP - 2024 Mar-Apr 01 TI - Team-Based Care Model Improves Timely Access to Care and Patient Satisfaction in General Cardiology. PG - 72-80 LID - 10.1097/JHQ.0000000000000413 [doi] AB - Appointment wait times have increased nationally since 2014, especially in cardiology. At a mid-Atlantic academic medical center, access to care in the general cardiology clinic was below national standards, which can negatively affect patient outcomes and satisfaction. Adopting a team-based care (TBC) model, advanced practice providers (APPs) were added to care teams with general cardiologists to provide timely outpatient management of cardiac conditions. This aimed to increase access to care and, consequently, patient satisfaction. A formative program evaluation using the Agency for Clinical Innovation framework assessed TBC's impact on these outcomes. Access to care and patient satisfaction measures for TBC and nonteam providers were compared with one another and national benchmarks. Nine months after implementation, the average time to new patient appointment for TBC providers was 31 days (47% decrease) and for nonteam providers was 41 days (20% decrease). TBC had a higher percentage of new patient appointments within 14 days than nonteam providers (39% and 20%, respectively). Patient satisfaction improved to the 98th percentile nationally for TBC but decreased to the 71st percentile for nonteam. These findings suggest that a TBC model using APPs can improve access to care and patient satisfaction in the outpatient general cardiology setting. CI - Copyright (c) 2023 National Association for Healthcare Quality. FAU - Sharpe, Christa M AU - Sharpe CM AUID- ORCID: 0000-0002-5717-2773 FAU - Eastham, Linda AU - Eastham L LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20231121 PL - United States TA - J Healthc Qual JT - Journal for healthcare quality : official publication of the National Association for Healthcare Quality JID - 9202994 MH - Humans MH - *Patient Satisfaction MH - Health Services Accessibility MH - Appointments and Schedules MH - *Cardiology MH - Ambulatory Care Facilities COIS- The authors declare no conflicts of interest. EDAT- 2024/02/29 18:42 MHDA- 2024/03/04 06:50 CRDT- 2024/02/29 13:03 PHST- 2024/03/04 06:50 [medline] PHST- 2024/02/29 18:42 [pubmed] PHST- 2024/02/29 13:03 [entrez] AID - 01445442-202404000-00002 [pii] AID - 10.1097/JHQ.0000000000000413 [doi] PST - ppublish SO - J Healthc Qual. 2024 Mar-Apr 01;46(2):72-80. doi: 10.1097/JHQ.0000000000000413. Epub 2023 Nov 21. PMID- 38420528 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240301 IS - 2666-2736 (Electronic) IS - 2666-2736 (Linking) VI - 17 DP - 2024 Feb TI - Advancing cardiotomy suction practices for coronary surgery via multidisciplinary collaborative learning. PG - 121-144 LID - 10.1016/j.xjon.2023.11.005 [doi] AB - OBJECTIVE: Professional standards recommend stopping cardiotomy suction at the termination of cardiopulmonary bypass before protamine administration based on perceived safety concerns. This study evaluated a multidisciplinary collaborative quality-improvement intervention promoting this agreed-upon cardiotomy suction practice during coronary artery bypass grafting (CABG). METHODS: A statewide intervention (eg, unblinded surgeon and perfusionist feedback, evidence-based lectures, evaluating barriers to change) involved 32 centers participating in the PERForm (ie, Perfusion Measures and Outcomes) Registry to standardize cardiotomy suction practices at cardiopulmonary bypass termination during CABG. Four non-Michigan registry participating centers were not exposed to collaborative learning. Cardiotomy suction practice was defined as the absence of or stopping cardiotomy suction before protamine administration. The practice changes attributed to the intervention, including Michigan and non-Michigan comparisons, were evaluated with the change of time effect modeled using splines. Multivariable regression was used to evaluate the intervention's associated impact (eg, mortality, reoperation, transfusion). RESULTS: Among 10,394 patients undergoing CABG at Michigan centers, 80.7% achieved agreed-upon cardiotomy suction practices. The Michigan centers had nonsignificant changes in agreed-upon cardiotomy suction practices during the preintervention period (P = .24), with significant increased monthly change in practice thereafter, absent adjusted morbidity and mortality increases. The Michigan centers achieved a significantly greater adjusted monthly improvement in agreed-upon practices relative to non-Michigan centers within 7 months after the intervention (adjusted odds ratio for change of trends: 2.53, P < .001). CONCLUSIONS: This initiative demonstrates the effectiveness of multidisciplinary collaborative quality improvement in advancing agreed-upon cardiotomy suction practices without negatively impacting clinical outcomes. CI - (c) 2023 The Author(s). FAU - Stewart, James W 2nd AU - Stewart JW 2nd AD - Department of Surgery, Yale School of Medicine, New Haven, Conn. AD - Department of Surgery, University of Michigan, Ann Arbor, Mich. FAU - Nieter, Donald AU - Nieter D AD - Michigan Society of Thoracic and Cardiovascular Surgeons Quality Collaborative, Ann Arbor, Mich. FAU - Wu, Xiaoting AU - Wu X AD - Department of Cardiac Surgery, Michigan Medicine, University of Michigan, Ann Arbor, Mich. FAU - DeLucia, Alphonse 3rd AU - DeLucia A 3rd AD - Department of Cardiac Surgery, Bronson Methodist Hospital, Kalamazoo, Mich. FAU - Graebner, Brittney N AU - Graebner BN AD - Perfusion Associates of Michigan, Saginaw, Mich. FAU - Paone, Gaetano AU - Paone G AD - Division of Cardiothoracic Surgery, Emory University School of Medicine, Atlanta, Ga. FAU - Fitzgerald, David C AU - Fitzgerald DC AD - Cardiovascular Perfusion Program, College of Health Professions, Medical University of South Carolina, Charleston, SC. FAU - Dickinson, Timothy A AU - Dickinson TA AD - Division of Cardiovascular Surgery, Mayo Clinic, Rochester, Minn. FAU - Zhang, Min AU - Zhang M AD - Department of Biostatistics, University of Michigan, Ann Arbor, Mich. FAU - Pagani, Francis D AU - Pagani FD AD - Michigan Society of Thoracic and Cardiovascular Surgeons Quality Collaborative, Ann Arbor, Mich. AD - Department of Cardiac Surgery, Michigan Medicine, University of Michigan, Ann Arbor, Mich. FAU - Likosky, Donald S AU - Likosky DS AD - Michigan Society of Thoracic and Cardiovascular Surgeons Quality Collaborative, Ann Arbor, Mich. AD - Department of Cardiac Surgery, Michigan Medicine, University of Michigan, Ann Arbor, Mich. LA - eng PT - Journal Article DEP - 20231121 PL - Netherlands TA - JTCVS Open JT - JTCVS open JID - 101768541 PMC - PMC10897666 OTO - NOTNLM OT - cardiac surgery OT - cardiopulmonary bypass OT - outcomes OT - quality improvement COIS- Dr Pagani receives partial salary support from Blue Cross/Blue Shield of Michigan as Associate Director of the Michigan Society of Thoracic and Cardiovascular Surgeons Quality Collaborative. Dr Likosky receives partial salary support from Blue Cross/Blue Shield of Michigan as the Perfusion Measures and Outcomes (PERForm) Registry Director of the Michigan Society of Thoracic and Cardiovascular Surgeons Quality Collaborative. Dr Pagani is an ad hoc, noncompensated scientific advisor for Medtronic, Abbott, FineHeart, and CH Biomedical; noncompensated medical monitor for Abiomed; and a member of the Data Safety Monitoring Board for Carmat and the National Heart, Lung, and Blood Institute PumpKIN Study. Dr Stewart received funds through the Veterans Affairs (VA) as a National Clinician Scholars Program research fellow. The opinions, beliefs, and viewpoints expressed by authors do not necessarily reflect those of Agency for Healthcare Research and Quality, National Institutes of Health, VA or the US Department of Health and Human Services, Blue Cross and Blue Shield of Michigan, or its employees. All other authors reported no conflicts of interest. The Journal policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest. EDAT- 2024/02/29 06:42 MHDA- 2024/02/29 06:43 PMCR- 2023/11/21 CRDT- 2024/02/29 04:14 PHST- 2023/03/06 00:00 [received] PHST- 2023/11/07 00:00 [revised] PHST- 2023/11/09 00:00 [accepted] PHST- 2024/02/29 06:43 [medline] PHST- 2024/02/29 06:42 [pubmed] PHST- 2024/02/29 04:14 [entrez] PHST- 2023/11/21 00:00 [pmc-release] AID - S2666-2736(23)00358-3 [pii] AID - 10.1016/j.xjon.2023.11.005 [doi] PST - epublish SO - JTCVS Open. 2023 Nov 21;17:121-144. doi: 10.1016/j.xjon.2023.11.005. eCollection 2024 Feb. PMID- 28613690 STAT- Publisher CTDT- 20240229 PB - StatPearls Publishing DP - 2024 Jan TI - Statin Medications. BTI - StatPearls AB - Statin medications are used in the management of hypercholesteremia. Statins are inhibitors of hydroxymethylglutaryl-CoA reductase enzyme and lower total cholesterol, low-density lipoprotein (LDL), and triglyceride concentrations. The FDA-approved statins include atorvastatin, rosuvastatin, simvastatin, pravastatin, fluvastatin, lovastatin, and pitavastatin. Individuals at high risk for atherosclerotic cardiovascular disease require more aggressive management strategies, including higher-intensity statin therapy. Participating clinicians review the mechanisms of action, dosing protocols, clinical toxicology, potential drug interactions, pharmacokinetics, and monitoring strategies pertinent to healthcare professionals in managing hypocholesteremia. The utility of coronary artery calcium scoring in situations of uncertainty is emphasized. This activity informs the interprofessional team on the best prescribing guidelines for statins. CI - Copyright (c) 2024, StatPearls Publishing LLC. FAU - Sizar, Omeed AU - Sizar O AD - St. Lucie Medical Center FAU - Khare, Swapnil AU - Khare S AD - Indiana University FAU - Patel, Preeti AU - Patel P FAU - Talati, Raja AU - Talati R AD - St.Lucie Medical Center LA - eng PT - Study Guide PT - Book Chapter PL - Treasure Island (FL) COIS- Disclosure: Omeed Sizar declares no relevant financial relationships with ineligible companies. Disclosure: Swapnil Khare declares no relevant financial relationships with ineligible companies. Disclosure: Preeti Patel declares no relevant financial relationships with ineligible companies. Disclosure: Raja Talati declares no relevant financial relationships with ineligible companies. EDAT- 2024/02/29 00:00 CRDT- 2024/02/29 00:00 AID - NBK430940 [bookaccession] PMID- 38404506 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250530 IS - 2590-1702 (Electronic) IS - 2590-1702 (Linking) VI - 21 DP - 2024 Jan TI - Enterococcus faecalis bacteraemia and infective endocarditis - what are we missing? PG - 100336 LID - 10.1016/j.clinpr.2023.100336 [doi] LID - 100336 AB - INTRODUCTION: Enterococcus faecalis is an increasingly common cause of infective endocarditis, with a recent study by Dahl et al demonstrating a prevalence of 26% of IE when transoesophageal echo was routinely undertaken. Another study undertaken by Ostergaard et al found that 16.7% of patients with E. faecalis bacteraemia developed endocarditis. Based on these findings we examined the rates of IE diagnosed in our own health board to determine if our current practice is potentially missing cases of IE and if we could improve our management of these bacteraemias. METHODS: All blood cultures in patients over 18 which were positive for E. faecalis from October 2017 to March 2022 were reviewed. We analysed the patient characteristics, clinical outcomes and included a follow up period of 6 months to assess for recrudescence and treatment failure. RESULTS: The rate of patients with E. faecalis bacteraemia diagnosed with IE was 7.1%. If polymicrobial blood cultures were excluded this rose to 13.0%. Community acquisition, patient cardiac or immune risk factors, monomicrobial culture and multiple positive blood cultures all were associated with IE. 62.1% of patients with E. faecalis bacteraemia did not have an echocardiogram during their admission, due to a variety of reasons. DISCUSSION: The lower reported rate of IE in our cohort may be explained by higher proportion of CVC related infections. However, given the low rates of echocardiography and poor correlation of echocardiography use with IE risk factors, it is likely that cases of IE are being missed, particularly in those with multiple risk factors. Despite this, there was no difference in one-year survival between those diagnosed with IE vs without IE. We have delivered education sessions and introduced a multidisciplinary team meeting to discuss infective endocarditis cases to address these issues. FAU - Nye, Clemency AU - Nye C AD - Public Health Wales, University Hospital of Wales, Heath Park, Cardiff, CF14 XW. FAU - Maxwell, Alice AU - Maxwell A AD - Public Health Wales, University Hospital of Wales, Heath Park, Cardiff, CF14 XW. FAU - Hughes, Harriet AU - Hughes H AD - Public Health Wales, University Hospital of Wales, Heath Park, Cardiff, CF14 XW. FAU - Underwood, Jonathan AU - Underwood J AD - Cardiff and Vale University Health Board, University Hospital of Wales, Heath Park, Cardiff, CF14 XW. AD - Division of Infection and Immunity, Cardiff University. LA - eng GR - MR/T023791/1/MRC_/Medical Research Council/United Kingdom PT - Journal Article PL - England TA - Clin Infect Pract JT - Clinical infection in practice JID - 101757436 PMC - PMC7615663 MID - EMS193807 OTO - NOTNLM OT - Echocardiography OT - Enterococcus faecalis OT - Infective endocarditis COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/02/26 06:45 MHDA- 2024/02/26 06:46 PMCR- 2024/02/23 CRDT- 2024/02/26 04:27 PHST- 2024/02/26 06:46 [medline] PHST- 2024/02/26 06:45 [pubmed] PHST- 2024/02/26 04:27 [entrez] PHST- 2024/02/23 00:00 [pmc-release] AID - 10.1016/j.clinpr.2023.100336 [doi] PST - ppublish SO - Clin Infect Pract. 2024 Jan;21:100336. doi: 10.1016/j.clinpr.2023.100336. PMID- 38404042 OWN - NLM STAT- MEDLINE DCOM- 20240717 LR - 20260612 IS - 1879-3479 (Electronic) IS - 0020-7292 (Linking) VI - 166 IP - 2 DP - 2024 Aug TI - Sharing the multidisciplinary clinical approach to peri- and postmenopausal women: A Delphi consensus among Italian gynecologists, endocrinologists, and cardiologists for an integrated and optimal approach to clinical practice. PG - 682-691 LID - 10.1002/ijgo.15448 [doi] AB - OBJECTIVE: The critical phase of perimenopausal period is marked by a reduction in estrogen levels, leading to various clinical issues (vasomotor and neurodegenerative symptoms, increased osteoporosis risk and cardiovascular risk). These complex clinical scenarios pose challenges to clinicians in providing the right support for diagnosis and treatment. A group of Italian cardiologists, endocrinologists, and gynecologists conducted a survey among expert colleagues to assess consensus on controversial issues and best practices for screening and treating peri- and postmenopausal women. METHODS: The Delphi methodology was used to analyze responses from a qualitative expert panel comprising 25 cardiologists, 25 endocrinologists, and 25 gynecologists, selected nationwide. Two consecutive questionnaires were proposed between February and May 2023. Agreement among experts was assessed following the Delphi method as developed by the RAND Corporation. RESULTS: The results of this Delphi Consensus have been shared by the leading scientific societies: Italian Society of Cardiology, Italian Society of Endocrinology, Italian Society of Gynecology and Obstetrics, and Italian Hospital Obstetricians Gynecologists Association. CONCLUSIONS: The experts highlighted comorbidities and hormone deprivation as crucial clinical problems to be evaluated in perimenopausal women, requiring investigation from cardiovascular and endocrinologic perspectives to assess cardiovascular risk, involving the use of BMI, standard blood samples, endocrine-metabolic tests, and lifestyle assessment, particularly in women with higher cardiovascular and metabolic risks candidates for hormone replacement therapy (HRT). The experts also agreed on the benefits of HRT in improving lipid metabolism and reducing insulin resistance, thereby mitigating the metabolic risks associated with menopause. However, this therapy should be tailored considering individual women's comorbidities and thrombotic risk. CI - (c) 2024 The Authors. International Journal of Gynecology & Obstetrics published by John Wiley & Sons Ltd on behalf of International Federation of Gynecology and Obstetrics. FAU - Colacurci, Nicola AU - Colacurci N AD - Department of Obstetrics and Gynecology, Italian Society of Gynecology and Obstetrics, University of Campania "Luigi Vanvitelli", Naples, Italy. FAU - Filardi, Pasquale Perrone AU - Filardi PP AD - Department of Advanced Biomedical Sciences, Italian Society of Cardiology, Federico II University of Naples, Naples, Italy. FAU - Chiantera, Antonio AU - Chiantera A AD - Italian Hospital Obstetricians Gynecologists Association, Naples, Italy. FAU - Colao, Annamaria AU - Colao A AD - Department of Clinical Medicine and Surgery, Endocrinology, Diabetology and Andrology Unit, Italian Society of Endocrinology, Federico II University of Naples, Naples, Italy. FAU - Pasqualetti, Patrizio AU - Pasqualetti P AUID- ORCID: 0000-0001-5560-1979 AD - Department of Public Health and Infectious Disease, Sapienza Rome University, Rome, Italy. FAU - Lenzi, Andrea AU - Lenzi A AD - Department of Experimental Medicine, Sapienza Rome University, Rome, Italy. LA - eng GR - Organon Italia/ PT - Consensus Statement PT - Journal Article DEP - 20240225 PL - United States TA - Int J Gynaecol Obstet JT - International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics JID - 0210174 SB - IM MH - Humans MH - Female MH - *Delphi Technique MH - Italy MH - *Gynecology MH - *Postmenopause MH - *Endocrinologists MH - Perimenopause MH - Cardiovascular Diseases/prevention & control MH - Cardiologists/standards MH - Middle Aged MH - Surveys and Questionnaires MH - Gynecologists OTO - NOTNLM OT - Delphi consensus OT - comorbidities OT - intersociety consensus OT - menopause OT - perimenopause OT - postmenopause EDAT- 2024/02/26 06:43 MHDA- 2024/07/17 12:43 CRDT- 2024/02/26 01:48 PHST- 2024/02/07 00:00 [revised] PHST- 2023/12/21 00:00 [received] PHST- 2024/02/12 00:00 [accepted] PHST- 2024/07/17 12:43 [medline] PHST- 2024/02/26 06:43 [pubmed] PHST- 2024/02/26 01:48 [entrez] AID - 10.1002/ijgo.15448 [doi] PST - ppublish SO - Int J Gynaecol Obstet. 2024 Aug;166(2):682-691. doi: 10.1002/ijgo.15448. Epub 2024 Feb 25. PMID- 38403184 OWN - NLM STAT- MEDLINE DCOM- 20240710 LR - 20240710 IS - 1532-2165 (Electronic) IS - 1078-5884 (Linking) VI - 68 IP - 1 DP - 2024 Jul TI - The Complementary Roles of Open and Endovascular Repair of Extent I - III Thoraco-abdominal Aortic Aneurysms in a United Kingdom Aortic Centre. PG - 62-72 LID - S1078-5884(24)00190-4 [pii] LID - 10.1016/j.ejvs.2024.02.031 [doi] AB - OBJECTIVE: A multidisciplinary approach offering both open surgical repair (OSR) and complex endovascular aortic repair (cEVAR) is essential if patients with thoraco-abdominal aortic aneurysms (TAAAs) are to receive optimal care. This study reports early and midterm outcomes of elective and non-elective OSR and cEVAR for extent I - III TAAA in a UK aortic centre. METHODS: Retrospective study of consecutive patients treated between January 2009 and December 2021. Primary endpoint was 30 day/in hospital mortality. Secondary endpoint was Kaplan-Meier estimates of midterm survival. Data are presented as median (interquartile range [IQR]). RESULTS: In total, 296 patients (176 men; median age 71 years [IQR 65, 76]; median aneurysm diameter 66 mm [IQR 61, 75]) underwent repair (222 elective, 74 non-elective). OSR patients (n = 66) were significantly younger with a higher incidence of heritable disease and chronic dissection, while cEVAR patients (n = 230) had a significantly higher prevalence of coronary, pulmonary, and renal disease. Overall, in hospital mortality after elective and non-elective repair was 3.2% (n = 7) and 23.0% (n = 17), respectively, with no significant difference between treatment modalities (elective OSR 6.5% vs. cEVAR 2.3%, p = .14; non-elective OSR 25.0% vs. cEVAR 20.3%, p = .80). Major non-fatal complications occurred in 15.3% (33/215) after elective repair (OSR 39.5%, 17/43, vs. cEVAR 9.3%, 16/172; p < .001) and 14% (8/57) after non-elective repair (OSR 26.7%, 4/15, vs. cEVAR 9.5%, 4/42; p = .19). Median follow up was 52 months (IQR 23, 78). Estimated survival +/- standard error at 1, 3, and 5 years for the entire cohort was 89.6 +/- 2.0%, 76.6 +/- 2.9%, and 69.0% +/- 3.2% after elective repair, and 67.6 +/- 5.4%, 52.1 +/- 6.0%, and 41.0 +/- 6.2% after non-elective repair. There was no difference in 5 year survival comparing modalities after elective repair for patients younger than 70 years and those with post-dissection aneurysms. CONCLUSION: A multidisciplinary approach offering OSR and cEVAR can deliver comprehensive care for extent I - III TAAA with low early mortality and good midterm survival. Further studies are required to determine the optimal complementary roles of each treatment modality. CI - Copyright (c) 2024 European Society for Vascular Surgery. Published by Elsevier B.V. All rights reserved. FAU - Adam, Donald J AU - Adam DJ AD - Department of Vascular Surgery, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. Electronic address: donald.adam@UHB.nhs.uk. FAU - Juszczak, Maciej AU - Juszczak M AD - Department of Vascular Surgery, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. FAU - Vezzosi, Massimo AU - Vezzosi M AD - Department of Vascular Surgery, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. FAU - Claridge, Martin AU - Claridge M AD - Department of Vascular Surgery, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. FAU - Quinn, David AU - Quinn D AD - Department of Cardiac Surgery, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. FAU - Senanayake, Eshan AU - Senanayake E AD - Department of Cardiac Surgery, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. FAU - Clift, Paul AU - Clift P AD - Department of Cardiac Surgery, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. FAU - Mascaro, Jorge AU - Mascaro J AD - Department of Cardiac Surgery, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. LA - eng PT - Journal Article DEP - 20240223 PL - England TA - Eur J Vasc Endovasc Surg JT - European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery JID - 9512728 SB - IM MH - Humans MH - *Aortic Aneurysm, Thoracic/surgery/mortality MH - Male MH - *Endovascular Procedures/adverse effects/mortality MH - Female MH - Aged MH - Retrospective Studies MH - United Kingdom/epidemiology MH - *Hospital Mortality MH - *Blood Vessel Prosthesis Implantation/adverse effects/mortality MH - Middle Aged MH - Treatment Outcome MH - Postoperative Complications/epidemiology/etiology MH - Risk Factors MH - Elective Surgical Procedures/adverse effects MH - Time Factors OTO - NOTNLM OT - Complex endovascular repair OT - Open repair OT - Thoraco-abdominal aneurysm EDAT- 2024/02/26 00:42 MHDA- 2024/07/11 00:42 CRDT- 2024/02/25 19:17 PHST- 2023/04/20 00:00 [received] PHST- 2024/02/07 00:00 [revised] PHST- 2024/02/22 00:00 [accepted] PHST- 2024/07/11 00:42 [medline] PHST- 2024/02/26 00:42 [pubmed] PHST- 2024/02/25 19:17 [entrez] AID - S1078-5884(24)00190-4 [pii] AID - 10.1016/j.ejvs.2024.02.031 [doi] PST - ppublish SO - Eur J Vasc Endovasc Surg. 2024 Jul;68(1):62-72. doi: 10.1016/j.ejvs.2024.02.031. Epub 2024 Feb 23. PMID- 38399746 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240227 IS - 2076-2607 (Print) IS - 2076-2607 (Electronic) IS - 2076-2607 (Linking) VI - 12 IP - 2 DP - 2024 Feb 6 TI - Prevalence of Infective Endocarditis among Patients with Staphylococcus aureus Bacteraemia and Bone and Joint Infections. LID - 10.3390/microorganisms12020342 [doi] LID - 342 AB - We aimed to evaluate the occurrence of infective endocarditis (IE) among patients with bone and joint infections (BJIs) and Staphylococcus aureus bacteraemia. This observational study was conducted at Lausanne University Hospital, Switzerland, from 2014 to 2023, and included episodes involving BJI, S. aureus bacteraemia, and cardiac imaging studies. The endocarditis team defined IE. Among the 384 included episodes, 289 (75%) involved native BJI (NBJI; 118 septic arthritis, 105 acute vertebral or non-vertebral osteomyelitis, 101 chronic osteitis), and 112 (29%) involved orthopedic implant-associated infection (OIAI; 78 prosthetic joint infection and 35 osteosynthesis/spondylodesis infection). Fifty-one episodes involved two or more types of BJI, with 17 episodes exhibiting both NBJI and OIAI. IE was diagnosed in 102 (27%) episodes. IE prevalence was 31% among patients with NBJI and 13% among patients with OIAI (p < 0.001). The study revealed a high prevalence of IE among S. aureus bacteraemic patients with NBJI, with notably lower prevalence among those with OIAI. FAU - Papadimitriou-Olivgeris, Matthaios AU - Papadimitriou-Olivgeris M AUID- ORCID: 0000-0003-0565-5105 AD - Infectious Diseases Service, Lausanne University Hospital, University of Lausanne, 1011 Lausanne, Switzerland. AD - Service of Hospital Preventive Medicine, Lausanne University Hospital, University of Lausanne, 1011 Lausanne, Switzerland. FAU - Guery, Benoit AU - Guery B AD - Infectious Diseases Service, Lausanne University Hospital, University of Lausanne, 1011 Lausanne, Switzerland. FAU - Monney, Pierre AU - Monney P AUID- ORCID: 0000-0002-3083-7333 AD - Department of Cardiology, Lausanne University Hospital, University of Lausanne, 1011 Lausanne, Switzerland. FAU - Senn, Laurence AU - Senn L AD - Infectious Diseases Service, Lausanne University Hospital, University of Lausanne, 1011 Lausanne, Switzerland. AD - Service of Hospital Preventive Medicine, Lausanne University Hospital, University of Lausanne, 1011 Lausanne, Switzerland. FAU - Steinmetz, Sylvain AU - Steinmetz S AD - Department of Orthopaedic Surgery and Traumatology, Lausanne University Hospital, University of Lausanne, 1011 Lausanne, Switzerland. FAU - Boillat-Blanco, Noemie AU - Boillat-Blanco N AUID- ORCID: 0000-0002-2490-8174 AD - Infectious Diseases Service, Lausanne University Hospital, University of Lausanne, 1011 Lausanne, Switzerland. LA - eng PT - Journal Article DEP - 20240206 PL - Switzerland TA - Microorganisms JT - Microorganisms JID - 101625893 PMC - PMC10892226 OTO - NOTNLM OT - Staphylococcus aureus OT - bloodstream infection OT - prosthetic joint infection OT - septic arthritis OT - vertebral osteomyelitis COIS- The authors declare no conflict of interest. EDAT- 2024/02/24 11:43 MHDA- 2024/02/24 11:44 PMCR- 2024/02/06 CRDT- 2024/02/24 01:21 PHST- 2023/11/29 00:00 [received] PHST- 2024/02/02 00:00 [revised] PHST- 2024/02/05 00:00 [accepted] PHST- 2024/02/24 11:44 [medline] PHST- 2024/02/24 11:43 [pubmed] PHST- 2024/02/24 01:21 [entrez] PHST- 2024/02/06 00:00 [pmc-release] AID - microorganisms12020342 [pii] AID - microorganisms-12-00342 [pii] AID - 10.3390/microorganisms12020342 [doi] PST - epublish SO - Microorganisms. 2024 Feb 6;12(2):342. doi: 10.3390/microorganisms12020342. PMID- 38398407 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241028 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 13 IP - 4 DP - 2024 Feb 15 TI - Pregnancy Arrhythmias: Management in the Emergency Department and Critical Care. LID - 10.3390/jcm13041095 [doi] LID - 1095 AB - Pregnancy is closely associated with an elevated risk of arrhythmias, constituting the predominant cardiovascular complication during this period. Pregnancy may induce the exacerbation of previously controlled arrhythmias and, in some instances, arrhythmias may present for the first time in pregnancy. The most important proarrhythmic mechanisms during pregnancy are the atrial and ventricular stretching, coupled with increased sympathetic activity. Notably, arrhythmias, particularly those originating in the ventricles, heighten the likelihood of syncope, increasing the potential for sudden cardiac death. The effective management of arrhythmias during the peripartum period requires a comprehensive, multidisciplinary approach from the prepartum to the postpartum period. The administration of antiarrhythmic drugs during pregnancy necessitates meticulous attention to potential alterations in pharmacokinetics attributable to maternal physiological changes, as well as the potential for fetal adverse effects. Electric cardioversion is a safe and effective intervention during pregnancy and should be performed immediately in patients with hemodynamic instability. This review discusses the pathophysiology of arrythmias in pregnancy and their management. FAU - Conti, Elena AU - Conti E AD - Division of Anesthesia and Critical Care Medicine, Azienda Ospedaliera Ordine Mauriziano, 10128 Turin, Italy. FAU - Cascio, Nunzio Dario AU - Cascio ND AD - Division of Anesthesia and Critical Care Medicine, Azienda Ospedaliera Ordine Mauriziano, 10128 Turin, Italy. FAU - Paluan, Patrizia AU - Paluan P AD - Division of Anesthesia and Critical Care Medicine, Azienda Ospedaliera Ordine Mauriziano, 10128 Turin, Italy. FAU - Racca, Giulia AU - Racca G AD - Division of Anesthesia and Critical Care Medicine, Azienda Ospedaliera Ordine Mauriziano, 10128 Turin, Italy. FAU - Longhitano, Yaroslava AU - Longhitano Y AUID- ORCID: 0000-0001-8831-1361 AD - Department of Anesthesiology and Perioperative Medicine, University of Pittsburgh, Pittsburgh, PA 15260, USA. AD - Department of Emergency Medicine-Emergency Medicine Residency Program, Humanitas University-Research Hospital, 20089 Rozzano, Italy. FAU - Savioli, Gabriele AU - Savioli G AUID- ORCID: 0000-0002-8679-5435 AD - Emergency Medicine and Surgery, IRCCS Fondazione Policlinico San Matteo, 27100 Pavia, Italy. FAU - Tesauro, Manfredi AU - Tesauro M AD - Geriatric Medicine Residency Program, University of Rome "Tor Vergata", 00133 Rome, Italy. AD - Department of Systems Medicine, University of Rome "Tor Vergata", 00133 Rome, Italy. FAU - Leo, Roberto AU - Leo R AD - Department of Systems Medicine, University of Rome "Tor Vergata", 00133 Rome, Italy. FAU - Racca, Fabrizio AU - Racca F AD - Division of Anesthesia and Critical Care Medicine, Azienda Ospedaliera Ordine Mauriziano, 10128 Turin, Italy. FAU - Zanza, Christian AU - Zanza C AD - Geriatric Medicine Residency Program, University of Rome "Tor Vergata", 00133 Rome, Italy. LA - eng PT - Journal Article PT - Review DEP - 20240215 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC10888682 OTO - NOTNLM OT - arrhythmias OT - pregnancy OT - structural heart disease COIS- The authors declare no conflict of interest. EDAT- 2024/02/24 11:43 MHDA- 2024/02/24 11:44 PMCR- 2024/02/15 CRDT- 2024/02/24 01:13 PHST- 2024/01/18 00:00 [received] PHST- 2024/02/09 00:00 [revised] PHST- 2024/02/13 00:00 [accepted] PHST- 2024/02/24 11:44 [medline] PHST- 2024/02/24 11:43 [pubmed] PHST- 2024/02/24 01:13 [entrez] PHST- 2024/02/15 00:00 [pmc-release] AID - jcm13041095 [pii] AID - jcm-13-01095 [pii] AID - 10.3390/jcm13041095 [doi] PST - epublish SO - J Clin Med. 2024 Feb 15;13(4):1095. doi: 10.3390/jcm13041095. PMID- 38398401 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240227 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 13 IP - 4 DP - 2024 Feb 14 TI - Learning Curve for Starting a Successful Single-Centre TAVR Programme with Multiple Devices: Early and Mid-Term Follow-Up. LID - 10.3390/jcm13041088 [doi] LID - 1088 AB - Aims: We report 30-day, 1-year, and 3-year outcomes for a new TAVR programme that used five different transcatheter heart valve (THV) systems. Methods: From 2014 to 2020, 122 consecutive patients with severe aortic stenosis (AS) received TAVR based on the Heart Team decision. Outcomes were analysed for the whole study population and in addition the first 63 patients (Cohort A, 2014 to 2019) were compared to the last 59 patients (Cohort B, 2019 to 2020). Outcomes included VARC-2 definitions and device performance assessed via transthoracic echocardiography by independent high-volume investigators. Results: The mean patient age was 77.9 +/- 6.1 years old, and 48 (39.3%) were male. The mean logistic Euroscore II was 4.2 +/- 4.5, and the mean STS score was 6.9 +/- 4.68. The systems used were as follows: Medtronic Corevalve Evolute R/PRO (82 patients-67.2%); Abbott Portico (13-10.6%); Boston Scientific Lotus (10-8.2%); Meril Myval (11-9%); and Boston Scientific Neo Accurate (6-5%). Access was transfemoral (95.9% of patients); surgical cut down (18% vs. percutaneous 77.8%); subclavian (n = 2); trans-axillary (n = 2); and direct aorta (n = 1). VARC-2 outcomes were as follows: device success rate 97.5%; stroke rate 1.6%; major vascular complication 3.3%; permanent pacemaker implantation 12.4%. At discharge, the incidences of grade I and II aortic regurgitation were 39.95 and 55.5%, respectively. At one year, all-cause mortality was 7.4% without admissions for valve-related dysfunction. The 3-year all-cause mortality and all-stroke rates were 22.9% and 4.1%, respectively. Between the 1-year and 3-year follow-ups, valve-related dysfunction was detected in three patients; one had THV system endocarditis that led to death. There was a remarkable but statistically non-significant decrease in mortality from Cohort A to Cohort B [four (6.3%) vs. one patient (1.7%), p = 0.195] and major vascular complications occurred at a significantly higher rate in the Cohort B [zero (0%) vs. four (6.8% patient, p = 0.036)]. Overall, we found that using multiple devices was safe and allowed for a learning team to achieve a high device success rate from the beginning (97.5%). Conclusions: TAVR with different THV systems showed acceptable early and mid-term outcomes for survival, technical success, and valve-related adverse events in high-risk patients with significant AS, even in the learning curve phase. FAU - Magyari, Balazs AU - Magyari B AUID- ORCID: 0000-0002-8851-9637 AD - Heart Institute, Medical School, University of Pecs, 7624 Pecs, Hungary. AD - Szentagothai Research Centre, University of Pecs, 7624 Pecs, Hungary. FAU - Kittka, Balint AU - Kittka B AD - Heart Institute, Medical School, University of Pecs, 7624 Pecs, Hungary. AD - Szentagothai Research Centre, University of Pecs, 7624 Pecs, Hungary. FAU - Gojak, Ilona AU - Gojak I AD - Heart Institute, Medical School, University of Pecs, 7624 Pecs, Hungary. FAU - Schonfeld, Kristof AU - Schonfeld K AD - Heart Institute, Medical School, University of Pecs, 7624 Pecs, Hungary. AD - Szentagothai Research Centre, University of Pecs, 7624 Pecs, Hungary. FAU - Szapary, Laszlo Botond AU - Szapary LB AD - Heart Institute, Medical School, University of Pecs, 7624 Pecs, Hungary. AD - Szentagothai Research Centre, University of Pecs, 7624 Pecs, Hungary. FAU - Simon, Mihaly AU - Simon M AD - Heart Institute, Medical School, University of Pecs, 7624 Pecs, Hungary. AD - Szentagothai Research Centre, University of Pecs, 7624 Pecs, Hungary. FAU - Kiss, Rudolf AU - Kiss R AD - Heart Institute, Medical School, University of Pecs, 7624 Pecs, Hungary. FAU - Bertalan, Andrea AU - Bertalan A AD - Heart Institute, Medical School, University of Pecs, 7624 Pecs, Hungary. FAU - Varady, Edit AU - Varady E AD - Department of Medical Imaging, Medical School, University of Pecs, 7624 Pecs, Hungary. FAU - Gyimesi, Andras AU - Gyimesi A AD - EconNet Research Group, Faculty of Business and Economics, University of Pecs, 7624 Pecs, Hungary. FAU - Szokodi, Istvan AU - Szokodi I AD - Heart Institute, Medical School, University of Pecs, 7624 Pecs, Hungary. AD - Szentagothai Research Centre, University of Pecs, 7624 Pecs, Hungary. FAU - Horvath, Ivan Gabor AU - Horvath IG AD - Heart Institute, Medical School, University of Pecs, 7624 Pecs, Hungary. AD - Szentagothai Research Centre, University of Pecs, 7624 Pecs, Hungary. LA - eng GR - NKFIH K120536/National Research, Development and Innovation Office/ PT - Journal Article DEP - 20240214 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC10889517 OTO - NOTNLM OT - TAVR OT - balloon-expandable transcatheter heart valve OT - bicuspid aortic valve and radial paradox OT - learning curve OT - paravalvular leak OT - self-expandable transcatheter heart valve COIS- The authors have no conflict of interest associated with this publication. There was no financial support for this work that would have influenced its outcome. EDAT- 2024/02/24 11:45 MHDA- 2024/02/24 11:46 PMCR- 2024/02/14 CRDT- 2024/02/24 01:13 PHST- 2024/01/19 00:00 [received] PHST- 2024/02/02 00:00 [revised] PHST- 2024/02/10 00:00 [accepted] PHST- 2024/02/24 11:46 [medline] PHST- 2024/02/24 11:45 [pubmed] PHST- 2024/02/24 01:13 [entrez] PHST- 2024/02/14 00:00 [pmc-release] AID - jcm13041088 [pii] AID - jcm-13-01088 [pii] AID - 10.3390/jcm13041088 [doi] PST - epublish SO - J Clin Med. 2024 Feb 14;13(4):1088. doi: 10.3390/jcm13041088. PMID- 38395260 OWN - NLM STAT- MEDLINE DCOM- 20240318 LR - 20260529 IS - 1874-1754 (Electronic) IS - 0167-5273 (Linking) VI - 403 DP - 2024 May 15 TI - Enhancing pre-transplant cardiac assessment: Validation and utility of the CAD-LT score with CCTA in liver transplant candidates. PG - 131895 LID - S0167-5273(24)00341-3 [pii] LID - 10.1016/j.ijcard.2024.131895 [doi] AB - BACKGROUND: Coronary computed tomography angiography (CCTA) is increasingly being used in the preoperative workup for liver transplantation (LT). We sought to assess the utility of integrating CCTA with the novel CAD-LT (Coronary Artery Disease in Liver Transplantation) score and its impact on reducing the need for invasive coronary angiography prior to LT. METHODS: We conducted a retrospective cohort study of consecutive patients (age >/= 18 years) who underwent CCTA for LT workup between 2011 and 2018 at the Victorian Liver Transplant Unit, Melbourne, Australia. CAD-LT scores, a traditional risk factor-based criteria, were calculated, and patients stratified as low-, intermediate- or high-risk. RESULTS: Overall, 229 patients underwent CCTA. The mean age was 66 +/- 5 years (82% male) with a modest-to-high risk factor burden (diabetes, 53%; hypertension, 46%; current or former smoker, 62%). The mean CAD-LT score of our cohort was 12.4 +/- 4.0. No patients were classified as low-risk, 49 patients (21.4%) were deemed intermediate-risk and 180 patients (78.6%) were deemed high-risk. A high CAD-LT score (>/= 9) showed high sensitivity (95.3% [95% CI 86-98%]) and modest specificity (27.8% [95% CI 21-35%]) for the detection of obstructive coronary artery disease on CCTA, with a negative predictive value of 94%. Following multidisciplinary discussions, only 41 patients (18%) of patients proceeded to ICA of which 27% received percutaneous coronary intervention. CONCLUSIONS: The use of CCTA in patients deemed intermediate- to high-risk by the CAD-LT score has the potential to reduce the need for invasive coronary angiography in patients undergoing LT workup. CI - Copyright (c) 2023. Published by Elsevier B.V. FAU - Sampaio Rodrigues, Thalys AU - Sampaio Rodrigues T AD - Department of Cardiology, Austin Health, Melbourne, VIC, Australia; Department of Medicine, The University of Melbourne, VIC, Australia. FAU - Narendren, Ahthavan AU - Narendren A AD - Department of Cardiology, Austin Health, Melbourne, VIC, Australia; Department of Cardiology, Northern Health, Melbourne, VIC, Australia. FAU - Cailes, Benjamin AU - Cailes B AD - Department of Cardiology, Austin Health, Melbourne, VIC, Australia; Department of Medicine, The University of Melbourne, VIC, Australia. FAU - Lim, Ruth P AU - Lim RP AD - Department of Radiology, The University of Melbourne, VIC, Australia; Department of Radiology, Austin Health, Melbourne, VIC, Australia. FAU - Weinberg, Laurence AU - Weinberg L AD - Department of Medicine, The University of Melbourne, VIC, Australia; Department of Anaesthesiology, The University of Melbourne, VIC, Australia. FAU - Testro, Adam AU - Testro A AD - Department of Medicine, The University of Melbourne, VIC, Australia; Victorian Liver Transplant Unit, Austin Health, Melbourne, VIC, Australia. FAU - Majumdar, Avik AU - Majumdar A AD - Department of Medicine, The University of Melbourne, VIC, Australia; Victorian Liver Transplant Unit, Austin Health, Melbourne, VIC, Australia. FAU - Sinclair, Marie AU - Sinclair M AD - Department of Medicine, The University of Melbourne, VIC, Australia; Victorian Liver Transplant Unit, Austin Health, Melbourne, VIC, Australia. FAU - Farouque, Omar AU - Farouque O AD - Department of Cardiology, Austin Health, Melbourne, VIC, Australia; Department of Medicine, The University of Melbourne, VIC, Australia. FAU - Koshy, Anoop N AU - Koshy AN AD - Department of Cardiology, Austin Health, Melbourne, VIC, Australia; Department of Medicine, The University of Melbourne, VIC, Australia; Department of Cardiology, Royal Melbourne Hospital, Melbourne, VIC, Australia. Electronic address: anoop.koshy@mh.org.au. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240222 PL - Netherlands TA - Int J Cardiol JT - International journal of cardiology JID - 8200291 SB - IM MH - Humans MH - Male MH - Middle Aged MH - Aged MH - Adolescent MH - Female MH - *Coronary Artery Disease/diagnostic imaging/surgery MH - Computed Tomography Angiography MH - *Liver Transplantation MH - Retrospective Studies MH - Risk Assessment/methods MH - Coronary Angiography/methods MH - Predictive Value of Tests OTO - NOTNLM OT - Atherosclerosis OT - Coronary angiography OT - Coronary artery disease OT - Coronary computed tomography angiography OT - Liver transplantation COIS- Declaration of competing interest None declared. EDAT- 2024/02/24 11:42 MHDA- 2024/03/18 06:44 CRDT- 2024/02/23 19:17 PHST- 2023/11/20 00:00 [received] PHST- 2024/01/08 00:00 [revised] PHST- 2024/02/18 00:00 [accepted] PHST- 2024/03/18 06:44 [medline] PHST- 2024/02/24 11:42 [pubmed] PHST- 2024/02/23 19:17 [entrez] AID - S0167-5273(24)00341-3 [pii] AID - 10.1016/j.ijcard.2024.131895 [doi] PST - ppublish SO - Int J Cardiol. 2024 May 15;403:131895. doi: 10.1016/j.ijcard.2024.131895. Epub 2024 Feb 22. PMID- 38390804 OWN - NLM STAT- MEDLINE DCOM- 20240507 LR - 20260701 IS - 2047-9980 (Electronic) IS - 2047-9980 (Linking) VI - 13 IP - 9 DP - 2024 May 7 TI - Implementing Formal Mitral Heart Team Improves Multidisciplinary Evaluation Rate and Survival of Patients With Severe Primary Mitral Regurgitation. PG - e033324 LID - 10.1161/JAHA.123.033324 [doi] LID - e033324 AB - BACKGROUND: Multidisciplinary heart team (HT) evaluation is recommended for patients with severe primary mitral regurgitation to optimize treatment decisions. However, its impact on patient outcomes remains unknown. We evaluated the impact of implementing mitral HT on patient survival. METHODS AND RESULTS: We conducted a retrospective cohort study of patients with new diagnoses of severe primary mitral regurgitation in a large healthcare network echocardiogram database between 2016 and 2020. We compared the incidence of multidisciplinary evaluation by structural cardiology and cardiac surgery services and 2-year survival before and after mitral HT implementation. The 1:1 propensity-score matching between pre- and post-mitral HT used Society of Thoracic Surgeons Predicted Risk of Mortality for mitral repair, age, sex, race, heart failure symptoms, inpatient setting, history of MI, and dementia as covariates. Logistic regression identified variables associated with the likelihood of undergoing multidisciplinary evaluation. Among 70 510 echocardiograms performed, 391 patients had severe primary mitral regurgitation (median age, 77 years; 46% women). Multidisciplinary evaluation increased from 29% to 89% (P<0.001), and intervention increased from 24% to 75% following mitral HT implementation (P<0.001). Among 180 propensity-score matched patients, mortality was lower post-mitral HT at 2 years (19% versus 32%, P=0.04). The multivariable model showed that mitral HT implementation and heart failure symptoms were associated with higher odds of undergoing multidisciplinary evaluation (OR [odds ratio], 18.7 and 2.72, respectively), whereas female sex and older age were associated with lower odds (OR, 0.39 and 0.93, respectively). CONCLUSIONS: Implementation of mitral HT was associated with drastic improvement in multidisciplinary evaluation for patients with severe primary mitral regurgitation. This coincided with higher proportions of patients undergoing mechanical correction of MR and improved overall patient survival. FAU - Waldron, Christina AU - Waldron C AUID- ORCID: 0000-0003-0286-6599 AD - Division of Cardiac Surgery Yale University School of Medicine New Haven CT USA. FAU - Mori, Makoto AU - Mori M AUID- ORCID: 0000-0002-2367-8354 AD - Division of Cardiac Surgery Yale University School of Medicine New Haven CT USA. AD - Center for Outcomes Research and Evaluation, Yale New Haven Hospital New Haven CT USA. FAU - Krane, Markus AU - Krane M AD - Division of Cardiac Surgery Yale University School of Medicine New Haven CT USA. AD - Department of Cardiovascular Surgery Institute Insure, German Heart Center Munich Technical University of Munich Munich Germany. FAU - Reinhardt, Samuel W AU - Reinhardt SW AUID- ORCID: 0000-0001-9168-2470 AD - Division of Cardiovascular Medicine Yale University School of Medicine New Haven CT USA. FAU - Ahmad, Yousif AU - Ahmad Y AUID- ORCID: 0000-0002-1364-8055 AD - Division of Cardiovascular Medicine Yale University School of Medicine New Haven CT USA. FAU - Kaple, Ryan AU - Kaple R AD - Division of Cardiovascular Medicine Hackensack University Medical Center Hackensack NJ USA. FAU - Forrest, John K AU - Forrest JK AUID- ORCID: 0000-0003-4079-3482 AD - Division of Cardiovascular Medicine Yale University School of Medicine New Haven CT USA. FAU - Geirsson, Arnar AU - Geirsson A AUID- ORCID: 0000-0002-8943-9962 AD - Division of Cardiac Surgery Yale University School of Medicine New Haven CT USA. LA - eng GR - UL1 TR001863/TR/NCATS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20240223 PL - England TA - J Am Heart Assoc JT - Journal of the American Heart Association JID - 101580524 SB - IM MH - Humans MH - *Mitral Valve Insufficiency/mortality/diagnostic imaging MH - Female MH - Male MH - Aged MH - Retrospective Studies MH - *Patient Care Team/organization & administration MH - Severity of Illness Index MH - Echocardiography MH - Aged, 80 and over MH - Mitral Valve/diagnostic imaging/surgery/physiopathology MH - Propensity Score MH - Survival Rate/trends PMC - PMC11179864 OTO - NOTNLM OT - heart team OT - mitral regurgitation OT - mitral valve OT - mitral valve repair EDAT- 2024/02/23 06:43 MHDA- 2024/05/07 13:45 PMCR- 2024/05/07 CRDT- 2024/02/23 05:53 PHST- 2024/05/07 13:45 [medline] PHST- 2024/02/23 06:43 [pubmed] PHST- 2024/02/23 05:53 [entrez] PHST- 2024/05/07 00:00 [pmc-release] AID - JAH39343 [pii] AID - 10.1161/JAHA.123.033324 [doi] PST - ppublish SO - J Am Heart Assoc. 2024 May 7;13(9):e033324. doi: 10.1161/JAHA.123.033324. Epub 2024 Feb 23. PMID- 38383272 OWN - NLM STAT- MEDLINE DCOM- 20240405 LR - 20240405 IS - 1579-2129 (Electronic) IS - 0300-2896 (Linking) VI - 60 IP - 4 DP - 2024 Apr TI - Multidisciplinary Management of Patients With Chronic Obstructive Pulmonary Disease and Cardiovascular Disease. PG - 226-237 LID - S0300-2896(24)00015-2 [pii] LID - 10.1016/j.arbres.2024.01.013 [doi] AB - Chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD) frequently coexist, increasing the prevalence of both entities and impacting on symptoms and prognosis. CVD should be suspected in patients with COPD who have high/very high risk scores on validated scales, frequent exacerbations, precordial pain, disproportionate dyspnea, or palpitations. They should be referred to cardiology if they have palpitations of unknown cause or angina pain. COPD should be suspected in patients with CVD if they have recurrent bronchitis, cough and expectoration, or disproportionate dyspnea. They should be referred to a pulmonologist if they have rhonchi or wheezing, air trapping, emphysema, or signs of chronic bronchitis. Treatment of COPD in cardiovascular patients should include long-acting muscarinic receptor antagonists (LAMA) or long-acting beta-agonists (LABA) in low-risk or high-risk non-exacerbators, and LAMA/LABA/inhaled corticosteroids in exacerbators who are not controlled with bronchodilators. Cardioselective beta-blockers should be favored in patients with CVD, the long-term need for amiodarone should be assessed, and antiplatelet drugs should be maintained if indicated. CI - Copyright (c) 2024 The Authors. Published by Elsevier Espana, S.L.U. All rights reserved. FAU - de Miguel-Diez, Javier AU - de Miguel-Diez J AD - Servicio de Neumologia, Hospital General Universitario Gregorio Maranon, Instituto de Investigacion Sanitaria Gregorio Maranon (IiSGM), Universidad Complutense de Madrid, Madrid, Spain. Electronic address: javiermigueldiez@gmail.com. FAU - Nunez Villota, Julio AU - Nunez Villota J AD - Servicio de Cardiologia, Hospital Clinico Universitario de Valencia, Valencia, Spain. FAU - Santos Perez, Salud AU - Santos Perez S AD - Servicio de Neumologia, Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain. FAU - Manito Lorite, Nicolas AU - Manito Lorite N AD - Unidad de Insuficiencia Cardiaca y Trasplante Cardiaco, Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain. FAU - Alcazar Navarrete, Bernardino AU - Alcazar Navarrete B AD - Servicio de Neumologia, Hospital Universitario Virgen de las Nieves, Granada, Spain. FAU - Delgado Jimenez, Juan Francisco AU - Delgado Jimenez JF AD - Servicio de Cardiologia e Instituto de Investigacion i+12, Hospital Universitario 12 de Octubre, Madrid, Spain; Departamento de Medicina, UCM, CIBERCV, Madrid, Spain. FAU - Soler-Cataluna, Juan Jose AU - Soler-Cataluna JJ AD - Servicio de Neumologia, Hospital Arnau de Vilanova-Lliria, Valencia, Spain; Departamento de Medicina, Universitat de Valencia, Valencia, Spain. FAU - Pascual Figal, Domingo AU - Pascual Figal D AD - Servicio de Cardiologia, Hospital Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain. FAU - Sobradillo Ecenarro, Patricia AU - Sobradillo Ecenarro P AD - Servicio de Neumologia, Hospital Universitario de Cruces, Barakaldo, Bizkaia, Spain. FAU - Gomez Doblas, Juan Jose AU - Gomez Doblas JJ AD - Seccion de Cardiologia, Hospital Universitario Virgen de la Victoria, Malaga, Spain. LA - eng LA - spa PT - Journal Article PT - Practice Guideline DEP - 20240201 PL - Spain TA - Arch Bronconeumol JT - Archivos de bronconeumologia JID - 0354720 RN - 0 (Muscarinic Antagonists) RN - 0 (Adrenal Cortex Hormones) RN - 0 (Adrenergic beta-2 Receptor Agonists) RN - 0 (Bronchodilator Agents) SB - IM MH - Humans MH - *Cardiovascular Diseases/complications MH - Administration, Inhalation MH - Muscarinic Antagonists/therapeutic use MH - *Pulmonary Disease, Chronic Obstructive/drug therapy MH - Drug Therapy, Combination MH - Adrenal Cortex Hormones/therapeutic use MH - Dyspnea MH - Pain/drug therapy MH - Adrenergic beta-2 Receptor Agonists/therapeutic use MH - Bronchodilator Agents/therapeutic use OTO - NOTNLM OT - Cardiopulmonary risk OT - Cardiovascular disease OT - Chronic obstructive pulmonary disease OT - Comorbidities OT - Exacerbations EDAT- 2024/02/22 00:43 MHDA- 2024/04/05 06:44 CRDT- 2024/02/21 21:57 PHST- 2023/11/28 00:00 [received] PHST- 2024/01/08 00:00 [revised] PHST- 2024/01/09 00:00 [accepted] PHST- 2024/04/05 06:44 [medline] PHST- 2024/02/22 00:43 [pubmed] PHST- 2024/02/21 21:57 [entrez] AID - S0300-2896(24)00015-2 [pii] AID - 10.1016/j.arbres.2024.01.013 [doi] PST - ppublish SO - Arch Bronconeumol. 2024 Apr;60(4):226-237. doi: 10.1016/j.arbres.2024.01.013. Epub 2024 Feb 1. PMID- 38381925 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240710 IS - 1911-6470 (Print) IS - 1920-1214 (Electronic) IS - 1911-6470 (Linking) VI - 18 IP - 6 DP - 2024 Jun TI - Analyzing the influence of expanding multispecialty adoption of robotic surgery on robotic urologic care A decade-long assessment of two Canadian academic hospitals. PG - 190-193 LID - 10.5489/cuaj.8524 [doi] AB - INTRODUCTION: Most robot-assisted surgery (RAS) systems in Canada are donor-funded, with constraints on implementation and access due to significant costs, among other factors. Herein, we evaluated the impact of the growing multispecialty use of RAS on urologic RAS access and outcomes in the past decade. METHODS: We conducted a retrospective review of all RAS performed by different surgical specialties in two high-volume academic hospitals between 2010 and 2019 (prior to the COVID pandemic). The assessed outcomes included the effect of increased robot access over the years on annual robotic-assisted radical prostatectomy (RARP) volumes, surgical waiting times (SWT), and pathologically positive surgical margins (PSM). Data were collected and analyzed from the robotic system and hospital databases. RESULTS: In total, six specialties (urology, gynecology, general, cardiac, thoracic, and otorhinolaryngologic surgery) were included over the study period. RAS access by specialty doubled since 2010 (from three to six). The number of active robotic surgeons tripled from seven surgeons in 2010 to 20 surgeons in 2019. Moreover, there was a significant drop in average case volume, from a peak of 40 cases in 2014 to 25 cases in 2019 (p=0.02). RARP annual case volume followed a similar pattern, reaching a maximum of 166 cases in 2014, then declining to 137 cases in 2019. The mean SWT was substantially increased from 52 days in 2014 to 73 days in 2019; however, PSM rates were not affected by the reduction in surgical volumes (p<0.05). CONCLUSIONS: Over the last decade, RAS access by specialty has increased at two Canadian academic centers due to growing multispecialty use. As there was a fixed, single-robotic system at each of the hospital centers, there was a substantial reduction in the number of RAS performed per surgeon over time, as well as a gradual increase in the SWT. The current low number of available robots and unsustainable funding resources may hinder universal patient access to RAS. FAU - Ibrahim, Ahmed AU - Ibrahim A AD - Division of Urology, University of Montreal Hospital Center, Montreal, QC, Canada. FAU - Matta, Imad AU - Matta I AD - Division of Urology, University of Montreal Hospital Center, Montreal, QC, Canada. FAU - Zakaria, Ahmed S AU - Zakaria AS AD - Division of Urology, Northern Ontario School of Medicine, Thunder Bay, ON, Canada. FAU - Khogeer, Abdulghani AU - Khogeer A AD - Department of Surgery, Faculty of Medicine, Rabigh, King Abdulaziz University, Jeddah, Saudi Arabia. FAU - Lee, Nick AU - Lee N AD - Division of Urology, University of Montreal Hospital Center, Montreal, QC, Canada. FAU - Elseherbini, Tawfik AU - Elseherbini T AD - Division of Urology, University of Montreal Hospital Center, Montreal, QC, Canada. FAU - Nguyen, David-Dan AU - Nguyen DD AD - Division of Urology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada. FAU - Corsi, Nicholas J AU - Corsi NJ AD - University of Texas Southwestern Medical Center Dallas, TX, United States. FAU - Bouhadana, David AU - Bouhadana D AD - Division of Urology, McGill University, Montreal, QC, Canada. FAU - Arezki, Adel AU - Arezki A AD - Division of Urology, McGill University, Montreal, QC, Canada. FAU - Chakraborty, Anindyo AU - Chakraborty A AD - Faculty of Medicine, McGill University, Montreal, QC, Canada. FAU - Meskawi, Malek AU - Meskawi M AD - Division of Urology, University of Montreal Hospital Center, Montreal, QC, Canada. FAU - Elhakim, Assaad AU - Elhakim A AD - Division of Urology, University of Montreal Hospital Center, Montreal, QC, Canada. FAU - Zorn, Kevin C AU - Zorn KC AD - Division of Urology, University of Montreal Hospital Center, Montreal, QC, Canada. AD - BPH Canada Prostate Surgery Institute, Mont-Royal Surgical Center, Montreal, QC, Canada. LA - eng PT - Journal Article PL - Canada TA - Can Urol Assoc J JT - Canadian Urological Association journal = Journal de l'Association des urologues du Canada JID - 101312644 PMC - PMC11230696 COIS- COMPETING INTERESTS: The authors do not report any competing personal or financial interests related to this work. EDAT- 2024/02/21 18:43 MHDA- 2024/02/21 18:44 PMCR- 2024/06/01 CRDT- 2024/02/21 15:03 PHST- 2024/02/21 18:44 [medline] PHST- 2024/02/21 18:43 [pubmed] PHST- 2024/02/21 15:03 [entrez] PHST- 2024/06/01 00:00 [pmc-release] AID - cuaj.8524 [pii] AID - cuaj-6-190 [pii] AID - 10.5489/cuaj.8524 [doi] PST - ppublish SO - Can Urol Assoc J. 2024 Jun;18(6):190-193. doi: 10.5489/cuaj.8524. PMID- 38376731 OWN - NLM STAT- MEDLINE DCOM- 20240624 LR - 20260304 IS - 1720-8386 (Electronic) IS - 0391-4097 (Print) IS - 0391-4097 (Linking) VI - 47 IP - 7 DP - 2024 Jul TI - Transition from pediatric to adult care in patients with Turner syndrome in Italy: a consensus statement by the TRAMITI project. PG - 1585-1598 LID - 10.1007/s40618-024-02315-4 [doi] AB - PURPOSE: Transition from pediatric to adult care is associated with significant challenges in patients with Turner syndrome (TS). The objective of the TRansition Age Management In Turner syndrome in Italy (TRAMITI) project was to improve the care provided to patients with TS by harnessing the knowledge and expertise of various Italian centers through a Delphi-like consensus process. METHODS: A panel of 15 physicians and 1 psychologist discussed 4 key domains: transition and referral, sexual and bone health and oncological risks, social and psychological aspects and systemic and metabolic disorders. RESULTS: A total of 41 consensus statements were drafted. The transition from pediatric to adult care is a critical period for patients with TS, necessitating tailored approaches and early disclosure of the diagnosis to promote self-reliance and healthcare autonomy. Fertility preservation and bone health strategies are recommended to mitigate long-term complications, and psychiatric evaluations are recommended to address the increased prevalence of anxiety and depression. The consensus also addresses the heightened risk of metabolic, cardiovascular and autoimmune disorders in patients with TS; regular screenings and interventions are advised to manage these conditions effectively. In addition, cardiac abnormalities, including aortic dissections, require regular monitoring and early surgical intervention if certain criteria are met. CONCLUSIONS: The TRAMITI consensus statement provides valuable insights and evidence-based recommendations to guide healthcare practitioners in delivering comprehensive and patient-centered care for patients with TS. By addressing the complex medical and psychosocial aspects of the condition, this consensus aims to enhance TS management and improve the overall well-being and long-term outcomes of these individuals. CI - (c) 2024. The Author(s). FAU - Aversa, T AU - Aversa T AD - Department of Human Pathology of Adulthood and Childhood, University of Messina, Messina, Italy. AD - Pediatric Unit, University Hospital "G. Martino", Via Consolare Valeria N. 1, 98124, Messina, Italy. FAU - De Sanctis, L AU - De Sanctis L AD - Pediatric Endocrinology, Regina Margherita Children Hospital, Turin, Italy. AD - Department of Public Health and Pediatric Sciences, University of Turin, Turin, Italy. FAU - Faienza, M F AU - Faienza MF AD - Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro", 70124, Bari, Italy. FAU - Gambineri, A AU - Gambineri A AD - Division of Endocrinology and Diabetes Prevention and Care, Department of Medical and Surgical Sciences (DIMEC), IRCCS Azienda Ospedaliero - Universitaria di Bologna, Bologna, Italy. FAU - Balducci, A AU - Balducci A AD - Pediatric Cardiology and Adult Congenital Heart Disease Program, Department of Cardio - Thoracic and Vascular Medicine, IRCCS Azienda Ospedaliero - Universitaria Di Bologna, Bologna, Italy. FAU - D'Aprile, R AU - D'Aprile R AD - Department of Women's and Children's Health, University of Padua, Padua, Italy. AD - A.Fa.D.O.C. Association OdV, Vicenza, Italy. FAU - Di Somma, C AU - Di Somma C AD - Unit of Endocrinology, AOU Federico II, Naples, Italy. FAU - Giavoli, C AU - Giavoli C AD - Endocrinology Unit, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Milan, Italy. FAU - Grossi, A AU - Grossi A AD - Endocrine Pathology of Chronic and Post-Tumor Diseases Unit, "Bambino Gesu" Pediatric Hospital, Rome, Italy. FAU - Meriggiola, M C AU - Meriggiola MC AD - Division of Gynecology and Physiopathology of Reproduction, Department of Medical and Surgical Sciences (DIMEC), IRCCS Azienda Ospedaliero - Universitaria di Bologna, Bologna, Italy. FAU - Profka, E AU - Profka E AD - Endocrinology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. FAU - Salerno, M AU - Salerno M AD - Pediatric Section, Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy. FAU - Stagi, S AU - Stagi S AD - Health Sciences Department, University of Florence, Florence, Italy. AD - Meyer Children's Hospital IRCCS, Florence, Italy. FAU - Scarano, E AU - Scarano E AD - Pediatric Unit, IRCCS Azienda Ospedaliero - Universitaria di Bologna, Bologna, Italy. FAU - Zatelli, M C AU - Zatelli MC AD - Section of Endocrinology, Geriatrics and Internal Medicine, Department of Medical Sciences, University of Ferrara, Ferrara, Italy. FAU - Wasniewska, M AU - Wasniewska M AUID- ORCID: 0000-0002-8299-2677 AD - Department of Human Pathology of Adulthood and Childhood, University of Messina, Messina, Italy. malgorzata.wasniewska@unime.it. AD - Pediatric Unit, University Hospital "G. Martino", Via Consolare Valeria N. 1, 98124, Messina, Italy. malgorzata.wasniewska@unime.it. LA - eng PT - Consensus Statement PT - Journal Article DEP - 20240220 PL - Italy TA - J Endocrinol Invest JT - Journal of endocrinological investigation JID - 7806594 SB - IM MH - Humans MH - *Turner Syndrome/therapy/psychology MH - Italy/epidemiology MH - *Transition to Adult Care/standards/organization & administration MH - Adult MH - Female MH - Child MH - Adolescent MH - Delphi Technique PMC - PMC11196323 OAB - The TRansition Age Management in Turner syndrome in Italy (TRAMITI) project aims to improve care for individuals with Turner Syndrome (TS) during their transition from pediatric to adult care. A team of 15 physicians and 1 psychologist collaborated to create a comprehensive set of 41 consensus statements, covering four key areas: transition and referral, sexual and bone health and oncological risks, social and psychological aspects and systemic and metabolic disorders. The consensus statements highlight the importance of patient-centered care, early intervention and long-term monitoring. They emphasize a multidisciplinary approach to address the complex medical and psychosocial aspects of TS. During the critical transition period, tailored approaches and early disclosure of the diagnosis are recommended to promote self-reliance and healthcare autonomy. To mitigate long-term complications, the consensus addresses fertility preservation and bone health strategies. It also recommends psychological or psychiatric evaluations to tackle the increased prevalence of anxiety and depression in patients with TS. In addition, strategies for addressing the heightened risk of metabolic, cardiovascular and autoimmune disorders in patients with TS are proposed. Regular screenings and interventions are advised to effectively manage these conditions. Furthermore, cardiac abnormalities, including aortic dissections, require close monitoring and early surgical intervention if specific criteria are met. Overall, the TRAMITI consensus statement provides valuable insights and evidence-based recommendations. It offers guidance for healthcare practitioners in delivering comprehensive and patient-centered care for individuals with TS. By addressing both medical and psychosocial aspects, the consensus aims to enhance TS management and improve the well-being and long-term outcomes of those affected by this genetic disorder. OABL- eng OTO - NOTNLM OT - Delphi consensus OT - Multidisciplinary care OT - Patient-centered approach OT - Transition management OT - Turner syndrome COIS- Tommaso Aversa has consulted for Pfizer and Sandoz. Anna Balducci, Roberta D'Aprile, Carolina Di Somma, Maria Felicia Faienza, Alessandra Gambineri, Claudia Giavoli, Armando Grossi, Maria Cristina Meriggiola, Eriselda Profka, Mariacarolina Salerno, and Maria Chiara Zatelli have consulted for Sandoz. Stefano Stagi has consulted for Aboca, Novonordisk, and Sandoz. Malgorzata Wasniewska is a consultant for Merck, Novonordisk, Pfizer, and Sandoz. Emanuela Scarano has consulted for Alexion, Biomarin, Novonordisk, Pfizer, and Sandoz. Luisa De Sanctis has no interests to declare. EDAT- 2024/02/20 12:50 MHDA- 2024/06/24 12:42 PMCR- 2024/02/20 CRDT- 2024/02/20 11:13 PHST- 2023/10/04 00:00 [received] PHST- 2024/01/11 00:00 [accepted] PHST- 2024/06/24 12:42 [medline] PHST- 2024/02/20 12:50 [pubmed] PHST- 2024/02/20 11:13 [entrez] PHST- 2024/02/20 00:00 [pmc-release] AID - 10.1007/s40618-024-02315-4 [pii] AID - 2315 [pii] AID - 10.1007/s40618-024-02315-4 [doi] PST - ppublish SO - J Endocrinol Invest. 2024 Jul;47(7):1585-1598. doi: 10.1007/s40618-024-02315-4. Epub 2024 Feb 20. PMID- 38369417 OWN - NLM STAT- MEDLINE DCOM- 20240322 LR - 20260429 IS - 1879-1883 (Electronic) IS - 0002-9610 (Linking) VI - 230 DP - 2024 Apr TI - Outcomes following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal malignancies: 10 ​Year experience. PG - 78-81 LID - S0002-9610(24)00033-3 [pii] LID - 10.1016/j.amjsurg.2024.01.031 [doi] AB - INTRODUCTION: The treatment of peritoneal malignancies has evolved and select patients can undergo effective surgical therapies. Access to innovative oncology procedures can be improved if programs are developed within and outside of academic cancer centers. We report the creation of a high volume, comprehensive peritoneal malignancy program developed in a community center. METHODS: A retrospective single-site study was conducted using registry data comprising all patients who underwent Cytoreductive Surgery (CRS) and Heated Intraperitoneal Chemotherapy (HIPEC) between October 2011-December 2021. RESULTS: 353 patients underwent CRS and HIPEC. 208 patients experienced in-hospital morbidity (58.9 ​%). Group comparison by disease site, PCI, and the completeness of cytoreduction demonstrated survival differences in mean overall survival and disease-free survival in 1-, 3- and 5-year ranges. CONCLUSIONS: This study demonstrates that with a standardized protocol and a surgeon-led multidisciplinary team it is possible to offer safe outcome driven, complex oncologic surgery in a community-based cancer program. CI - Copyright (c) 2024 Elsevier Inc. All rights reserved. FAU - Graham, Isabella AU - Graham I AD - Department of Surgery, Section of Surgical Oncology, Ascension St. John Hospital, Detroit, MI, USA. FAU - Boston, Anna AU - Boston A AD - Department of Surgery, Section of Surgical Oncology, Ascension St. John Hospital, Detroit, MI, USA. FAU - Hayward, Richard AU - Hayward R AD - Department of Surgery, Section of Surgical Oncology, Ascension St. John Hospital, Detroit, MI, USA. FAU - Berri, Richard AU - Berri R AD - Department of Surgery, Section of Surgical Oncology, Ascension St. John Hospital, Detroit, MI, USA. Electronic address: richard.berri@ascension.org. LA - eng PT - Journal Article DEP - 20240206 PL - United States TA - Am J Surg JT - American journal of surgery JID - 0370473 SB - IM MH - Humans MH - *Peritoneal Neoplasms/pathology MH - Hyperthermic Intraperitoneal Chemotherapy MH - Cytoreduction Surgical Procedures/methods MH - Retrospective Studies MH - *Percutaneous Coronary Intervention MH - Combined Modality Therapy MH - *Hyperthermia, Induced MH - Survival Rate MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use OTO - NOTNLM OT - Cytoreductive surgery OT - Heated intraperitoneal chemotherapy OT - Peritoneal malignancy OT - Pseudomyxoma peritonei OT - Surgical oncology COIS- Declaration of competing interest None of the authors listed in this manuscript have any financial or personal declarations of conflict or interest. EDAT- 2024/02/19 00:42 MHDA- 2024/03/22 06:44 CRDT- 2024/02/18 21:54 PHST- 2023/07/27 00:00 [received] PHST- 2024/01/11 00:00 [revised] PHST- 2024/01/26 00:00 [accepted] PHST- 2024/03/22 06:44 [medline] PHST- 2024/02/19 00:42 [pubmed] PHST- 2024/02/18 21:54 [entrez] AID - S0002-9610(24)00033-3 [pii] AID - 10.1016/j.amjsurg.2024.01.031 [doi] PST - ppublish SO - Am J Surg. 2024 Apr;230:78-81. doi: 10.1016/j.amjsurg.2024.01.031. Epub 2024 Feb 6. PMID- 38369059 OWN - NLM STAT- MEDLINE DCOM- 20240422 LR - 20240422 IS - 2666-9919 (Electronic) IS - 2666-9919 (Linking) VI - 54 IP - 3 DP - 2024 Apr TI - Suppressive antibiotic therapy for infectious endocarditis. PG - 104867 LID - S2666-9919(24)00022-8 [pii] LID - 10.1016/j.idnow.2024.104867 [doi] AB - OBJECTIVES: Suppressive antibiotic therapy (SAT) is a long-term antibiotic strategy at times applied when an indicated surgical management of infective endocarditis (IE) is not possible. Our aim was to describe the characteristics and outcomes of patients having received SAT for IE. METHODS: We conducted a retrospective, observational study at Strasbourg University Hospital, France between January 2020 and May 2023. We reviewed all medical files taken into consideration at weekly meetings of the local Multidisciplinary Endocarditis Team (MET) during the study period. We included patients having received SAT following the MET evaluation. The primary endpoint was all-cause mortality at most recent follow-up. Secondary endpoints included all-cause mortality at 3 and 6 months, infection relapse, and tolerance issues attributed to SAT. RESULTS: The MET considered 251 patients during the study time, among whom 22 (9 %) had received SAT. Mean age was 77.2 +/- 12.3 years. Patients were highly comorbid with a mean Charlson index score of 6.6 +/- 2.5. Main indication for SAT was surgery indicated but not performed or an infected device not removed (20/22). Fourteen patients had prosthetic valve IE, including 9 TAVIs. Six patients had IE affecting cardiac implantable electronic devices. Staphylococcus aureus and enterococci were the main bacteria involved (6/22 each). Median follow-up time was 249 days (IQR 95-457 days). Mortality at most recent follow-up was 23 % (5/22). Three patients (14 %) presented tolerance issues attributed to SAT, and two patients suffered late infectious relapse. CONCLUSION: Mortality at most recent follow-up was low and tolerance issues were rare for patients under SAT, which might be a palliative approach to consider when optimal surgery or device removal is not possible. CI - Copyright (c) 2024 The Author(s). Published by Elsevier Masson SAS.. All rights reserved. FAU - Lemmet, T AU - Lemmet T AD - Infectious Disease Unit, Strasbourg University Hospital, France. Electronic address: Thomas.lemmet@chru-strasbourg.fr. FAU - Bourne-Watrin, M AU - Bourne-Watrin M AD - Infectious Disease Unit, Strasbourg University Hospital, France. FAU - Gerber, V AU - Gerber V AD - Infectious Disease Unit, Strasbourg University Hospital, France. FAU - Danion, F AU - Danion F AD - Infectious Disease Unit, Strasbourg University Hospital, France. FAU - Ursenbach, A AU - Ursenbach A AD - Infectious Disease Unit, Strasbourg University Hospital, France. FAU - Hoellinger, B AU - Hoellinger B AD - Infectious Disease Unit, Strasbourg University Hospital, France. FAU - Lefebvre, N AU - Lefebvre N AD - Infectious Disease Unit, Strasbourg University Hospital, France. FAU - Mazzucotelli, J AU - Mazzucotelli J AD - Department of Cardiovascular Surgery, Strasbourg University Hospital, France. FAU - Zeyons, F AU - Zeyons F AD - Department of Cardiology, Strasbourg University Hospital, France. FAU - Hansmann, Y AU - Hansmann Y AD - Infectious Disease Unit, Strasbourg University Hospital, France. FAU - Ruch, Y AU - Ruch Y AD - Infectious Disease Unit, Strasbourg University Hospital, France. LA - eng PT - Journal Article PT - Review DEP - 20240216 PL - France TA - Infect Dis Now JT - Infectious diseases now JID - 101775152 RN - 0 (Anti-Bacterial Agents) SB - IM MH - Humans MH - Middle Aged MH - Aged MH - Aged, 80 and over MH - Retrospective Studies MH - Treatment Outcome MH - *Endocarditis, Bacterial/drug therapy/surgery/microbiology MH - Anti-Bacterial Agents/therapeutic use MH - *Endocarditis/drug therapy/surgery MH - Recurrence MH - Observational Studies as Topic OTO - NOTNLM OT - Cardiac implantable electronic device infection OT - Infectious endocarditis OT - Prosthetic valve endocarditis OT - Suppressive antibiotic therapy COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/02/19 00:42 MHDA- 2024/04/22 06:42 CRDT- 2024/02/18 19:15 PHST- 2023/11/17 00:00 [received] PHST- 2024/02/09 00:00 [revised] PHST- 2024/02/13 00:00 [accepted] PHST- 2024/04/22 06:42 [medline] PHST- 2024/02/19 00:42 [pubmed] PHST- 2024/02/18 19:15 [entrez] AID - S2666-9919(24)00022-8 [pii] AID - 10.1016/j.idnow.2024.104867 [doi] PST - ppublish SO - Infect Dis Now. 2024 Apr;54(3):104867. doi: 10.1016/j.idnow.2024.104867. Epub 2024 Feb 16. PMID- 38367739 OWN - NLM STAT- MEDLINE DCOM- 20240513 LR - 20250827 IS - 1557-3117 (Electronic) IS - 1053-2498 (Linking) VI - 43 IP - 6 DP - 2024 Jun TI - Early temporary mechanical circulatory support for cardiogenic shock: Real-life data from a regional cardiac assistance network. PG - 911-919 LID - S1053-2498(24)00052-4 [pii] LID - 10.1016/j.healun.2024.02.009 [doi] AB - BACKGROUND: Temporary mechanical circulatory support as well as multidisciplinary team approach in a regional care organization might improve survival of cardiogenic shock. No study has evaluated the relative effect of each temporary mechanical circulatory support on mortality in the context of a regional network. METHODS: Prospective observational data were retrieved from patients consecutively admitted with cardiogenic shock to the intensive care units in 3 centers organized into a regional cardiac assistance network. Temporary mechanical circulatory support indication was decided by a heart team, based on the initial shock severity or if shock was refractory to medical treatment within 24 hours of admission. A propensity score for circulatory support use was used as an adjustment co-variable to emulate a target trial. The primary endpoint was in-hospital mortality. RESULTS: Two hundred and forty-six patients were included in the study (median age: 59.5 years, 71.9% male): 121 received early mechanical assistance. The main etiologies were acute myocardial infraction (46.8%) and decompensated heart failure (27.2%). Patients who received early mechanical assistance had more severe conditions than other patients. Their crude in-hospital mortality was 38% and 22.4% in other patients but adjusted in-hospital mortality was not different (hazard ratio 0.91, 95% CI:0.65-1.26). Patients with mechanical assistance had a higher rate of complications than others with longer Intensive Care Unit and hospital stays. CONCLUSIONS: In the conditions of a cardiac assistance regional network, in-hospital mortality was not improved by early mechanical assistance implantation. A high incidence of complications of temporary mechanical circulatory support may have jeopardized its potential benefit. CI - Copyright (c) 2024 International Society for the Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved. FAU - Ughetto, Aurore AU - Ughetto A AD - Department of Anesthesiology and Critical Care Medicine, Arnaud de Villeneuve Hospital, CHU Montpellier, University of Montpellier, Montpellier, France. FAU - Eliet, Jacob AU - Eliet J AD - Department of Anesthesiology and Critical Care Medicine, Arnaud de Villeneuve Hospital, CHU Montpellier, University of Montpellier, Montpellier, France. FAU - Nagot, Nicolas AU - Nagot N AD - Clinical Research and Epidemiology Unit, CHU Montpellier, Univ Montpellier, Montpellier, France. FAU - David, Helene AU - David H AD - Department of Anesthesiology and Critical Care Medicine, Arnaud de Villeneuve Hospital, CHU Montpellier, University of Montpellier, Montpellier, France; University of Montpellier, CNRS, INSERM, PhyMedExp, Montpellier, France. FAU - Bazalgette, Florian AU - Bazalgette F AD - Department of Anesthesiology and Critical Care Medicine, Arnaud de Villeneuve Hospital, CHU Montpellier, University of Montpellier, Montpellier, France. FAU - Marin, Gregory AU - Marin G AD - Clinical Research and Epidemiology Unit, CHU Montpellier, Univ Montpellier, Montpellier, France. FAU - Kollen, Sebastien AU - Kollen S AD - Department of Critical Care Medicine, CH Perpignan, Perpignan, France. FAU - Mourad, Marc AU - Mourad M AD - Department of Anesthesiology and Critical Care Medicine, Arnaud de Villeneuve Hospital, CHU Montpellier, University of Montpellier, Montpellier, France. FAU - Zeroual, Norddine AU - Zeroual N AD - Department of Anesthesiology and Critical Care Medicine, Arnaud de Villeneuve Hospital, CHU Montpellier, University of Montpellier, Montpellier, France. FAU - Muller, Laurent AU - Muller L AD - Department of Critical Care Medicine, CHU Nimes, University of Montpellier-Nimes, Nimes, France. FAU - Gaudard, Philippe AU - Gaudard P AD - Department of Anesthesiology and Critical Care Medicine, Arnaud de Villeneuve Hospital, CHU Montpellier, University of Montpellier, Montpellier, France; University of Montpellier, CNRS, INSERM, PhyMedExp, Montpellier, France. FAU - Colson, Pascal AU - Colson P AD - Department of Anesthesiology and Critical Care Medicine, Arnaud de Villeneuve Hospital, CHU Montpellier, University of Montpellier, Montpellier, France; University of Montpellier, CNRS, INSERM, Institut de Genomique Fonctionnelle, Montpellier, France. Electronic address: p-colson@chu-montpellier.fr. LA - eng SI - ClinicalTrials.gov/NCT03528291 PT - Journal Article PT - Multicenter Study PT - Observational Study DEP - 20240215 PL - United States TA - J Heart Lung Transplant JT - The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation JID - 9102703 SB - IM MH - Humans MH - *Shock, Cardiogenic/therapy/mortality MH - Male MH - Female MH - Middle Aged MH - Prospective Studies MH - *Hospital Mortality MH - *Heart-Assist Devices MH - Extracorporeal Membrane Oxygenation/methods MH - Aged MH - Time Factors MH - Survival Rate/trends OTO - NOTNLM OT - acute myocardial infraction OT - cardiogenic shock OT - decompensated heart failure OT - extracorporeal membrane oxygenation OT - mechanical circulatory support EDAT- 2024/02/18 00:42 MHDA- 2024/05/14 00:43 CRDT- 2024/02/17 19:14 PHST- 2023/05/15 00:00 [received] PHST- 2024/02/09 00:00 [revised] PHST- 2024/02/11 00:00 [accepted] PHST- 2024/05/14 00:43 [medline] PHST- 2024/02/18 00:42 [pubmed] PHST- 2024/02/17 19:14 [entrez] AID - S1053-2498(24)00052-4 [pii] AID - 10.1016/j.healun.2024.02.009 [doi] PST - ppublish SO - J Heart Lung Transplant. 2024 Jun;43(6):911-919. doi: 10.1016/j.healun.2024.02.009. Epub 2024 Feb 15. PMID- 38361351 OWN - NLM STAT- MEDLINE DCOM- 20240219 LR - 20260127 IS - 1940-4034 (Electronic) IS - 1074-2484 (Linking) VI - 29 DP - 2024 Jan-Dec TI - Sotatercept for Pulmonary Arterial Hypertension in the Inpatient Setting. PG - 10742484231225310 LID - 10.1177/10742484231225310 [doi] AB - Patients with pulmonary arterial hypertension (PAH) who are admitted to the hospital pose a challenge to the multidisciplinary healthcare team due to the complexity of the pathophysiology of their disease state and PAH-specific medication considerations. Pulmonary arterial hypertension is a progressive disease that may lead to death as a result of right ventricular (RV) failure. During acute on chronic RV failure it is critical to decrease the pulmonary vascular resistance with the goal of improving RV function and prognosis; therefore, aggressive PAH-treatment based on disease risk stratification is essential. Pulmonary arterial hypertension treatment for acute on chronic RV failure can be impacted by end-organ damage, hemodynamic instability, drug interactions, and PAH medications dosage and delivery. Sotatercept, a first in class activin signaling inhibitor that works on the bone morphogenetic protein/activin pathway is on track for Food and Drug Administration approval for the treatment of PAH based on results of recent trials in where the medication led to clinical and hemodynamic improvements, even when added to traditional PAH-specific therapies. The purpose of this review is to highlight important considerations when starting or continuing sotatercept in patients admitted to the hospital with PAH. FAU - Torbic, Heather AU - Torbic H AUID- ORCID: 0000-0002-1961-4104 AD - Department of Pharmacy, Cleveland Clinic, Cleveland, OH, USA. FAU - Tonelli, Adriano R AU - Tonelli AR AD - Department of Pulmonary, Allergy and Critical Care Medicine, Cleveland Clinic, Cleveland, OH, USA. LA - eng PT - Journal Article PT - Review PL - United States TA - J Cardiovasc Pharmacol Ther JT - Journal of cardiovascular pharmacology and therapeutics JID - 9602617 RN - 104625-48-1 (Activins) RN - 0 (Recombinant Fusion Proteins) RN - 0QI90BTJ37 (sotatercept) SB - IM MH - United States MH - Humans MH - *Pulmonary Arterial Hypertension/diagnosis/drug therapy/metabolism MH - Inpatients MH - *Heart Failure MH - Activins MH - *Recombinant Fusion Proteins OTO - NOTNLM OT - inpatient OT - medication administration OT - pulmonary arterial hypertension OT - right ventricular failure OT - sotatercept COIS- Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2024/02/16 06:43 MHDA- 2024/02/19 06:43 CRDT- 2024/02/16 01:22 PHST- 2024/02/19 06:43 [medline] PHST- 2024/02/16 06:43 [pubmed] PHST- 2024/02/16 01:22 [entrez] AID - 10.1177/10742484231225310 [doi] PST - ppublish SO - J Cardiovasc Pharmacol Ther. 2024 Jan-Dec;29:10742484231225310. doi: 10.1177/10742484231225310. PMID- 38361241 OWN - NLM STAT- MEDLINE DCOM- 20240410 LR - 20260620 IS - 1540-8167 (Electronic) IS - 1045-3873 (Linking) VI - 35 IP - 4 DP - 2024 Apr TI - Cardiac implantable electronic devices in female patients: Esthetic, breast implant, and anatomic considerations. PG - 747-761 LID - 10.1111/jce.16196 [doi] AB - INTRODUCTION: The implantation of a cardiac implantable electronic device (CIED) can have esthetic and psychological consequences on patients. We explore a heart team model for care coordination and discuss esthetic approaches for improved cosmetic outcomes in patients undergoing (CIED)-related procedures or de novo implantation. METHODS: Patients undergoing CIED surgery for approved indications between June 2015 and June 2022 were identified. Patients were included when surgical care was provided by a collaborative relationship between the primary electrophysiologist and the plastic surgeon. Patient demographics, details of the surgical procedure, information on breast implants, complications, and outcomes related to cosmesis were recorded. RESULTS: Twenty-two female patients were included in this study. The mean age was 50.2 +/- 18.2 years. The mean follow-up duration was 2.2 +/- 5.5 months. The top two indications for the procedure included CIED generator change (n = 9, 41%) and implantable cardioverter-defibrillator (ICD) implantation (n = 7, 32%). The most common reasons for involving plastic surgery in the procedure included surgery near breast implants (n = 10, 45%) and device displacement or discomfort (n = 8, 36%). CIED pocket position was prepectoral in 10 cases (45%), subpectoral in 11 patients (50%), and intramuscular in one patient (4.5%). The majority of the patients (20, 91%) had cosmetically acceptable results postprocedure. One patient (4.5%) had breast asymmetry on the CIED side, and another continued to have skin erosion over the CIED and leads. CONCLUSION: A heart team approach incorporating the expertize of cardiac electrophysiology and plastic surgery is essential for providing optimal care for patients with breast implants and patients requesting esthetic appeal. CI - (c) 2024 Wiley Periodicals LLC. FAU - Salinas, Cristina A AU - Salinas CA AD - Department of Surgery, Division of Plastic Surgery, Mayo Clinic, Rochester, Minnesota, USA. FAU - Ezzeddine, Fatima M AU - Ezzeddine FM AUID- ORCID: 0000-0002-6204-4557 AD - Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA. FAU - Mulpuru, Siva K AU - Mulpuru SK AUID- ORCID: 0000-0002-7694-3617 AD - Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA. FAU - Asirvatham, Samuel J AU - Asirvatham SJ AUID- ORCID: 0000-0001-9835-5536 AD - Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA. FAU - Sharaf, Basel A AU - Sharaf BA AD - Department of Surgery, Division of Plastic Surgery, Mayo Clinic, Rochester, Minnesota, USA. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240215 PL - United States TA - J Cardiovasc Electrophysiol JT - Journal of cardiovascular electrophysiology JID - 9010756 SB - IM MH - Humans MH - Female MH - Adult MH - Middle Aged MH - Aged MH - *Pacemaker, Artificial/adverse effects MH - *Defibrillators, Implantable/adverse effects MH - *Breast Implants/adverse effects MH - *Cardiac Surgical Procedures/adverse effects MH - Retrospective Studies OTO - NOTNLM OT - CIED cosmetic techniques OT - cardiac device and breast implants OT - cardiac device implant techniques OT - cardiac device in young females OT - pacemaker implantation EDAT- 2024/02/16 06:43 MHDA- 2024/04/10 06:42 CRDT- 2024/02/16 00:11 PHST- 2023/11/26 00:00 [revised] PHST- 2023/09/10 00:00 [received] PHST- 2024/01/14 00:00 [accepted] PHST- 2024/04/10 06:42 [medline] PHST- 2024/02/16 06:43 [pubmed] PHST- 2024/02/16 00:11 [entrez] AID - 10.1111/jce.16196 [doi] PST - ppublish SO - J Cardiovasc Electrophysiol. 2024 Apr;35(4):747-761. doi: 10.1111/jce.16196. Epub 2024 Feb 15. PMID- 38356351 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240320 IS - 2287-8572 (Print) IS - 2287-8580 (Electronic) IS - 2287-8572 (Linking) VI - 67 IP - 2 DP - 2024 Mar TI - Fetomaternal outcomes in pregnant women with congenital heart disease: a comparative analysis from an apex institute. PG - 218-226 LID - 10.5468/ogs.23264 [doi] AB - OBJECTIVE: With advancements in cardiac surgical interventions during infancy and childhood, the incidence of maternal congenital heart disease (CHD) is increasing. This retrospective study compared fetal and cardiac outcomes in women with and without CHD, along with a sub-analysis between cyanotic versus non-cyanotic defects and operated versus non-operated cases. METHODS: A 10-year data were retrospectively collected from pregnant women with CHD and a 1:1 ratio of pregnant women without any heart disease. Adverse fetal and cardiac outcomes were noted in both groups. Statistical significance was set at P<0.05. RESULTS: A total of 86 pregnant women with CHD were studied, with atrial septal defects (29.06%) being the most common. Out of 86 participants, 27 (31.39%) had cyanotic CHD. Around 55% of cases were already operated on for their cardiac defects. Among cardiovascular complications, 5.8% suffered from heart failure, 7.0% had pulmonary arterial hypertension, 8.1% presented in New York Heart Association functional class IV, 9.3% had a need for intensive care unit admission, and one experienced maternal mortality. Adverse fetal outcomes, including operative vaginal delivery, mean duration of hospital stay, fetal growth restriction, preterm birth (<37 weeks), low birth weight (<2,500 g), 5-minute APGAR score <7, and neonatal intensive care unit admissions, were significantly higher in women with CHD than in women without heart disease. CONCLUSION: Women with CHD have a higher risk of adverse fetal and cardiac outcomes. The outcome can be improved with proper pre-conceptional optimization of the cardiac condition, good antenatal care, and multidisciplinary team management. FAU - Dhiman, Soniya AU - Dhiman S AD - Departments of Obstetrics and Gynaecology, All India Institute of Medical Science, New Delhi, India. FAU - Sharma, Aparna AU - Sharma A AD - Departments of Obstetrics and Gynaecology, All India Institute of Medical Science, New Delhi, India. FAU - Gupta, Akanksha AU - Gupta A AD - Departments of Obstetrics and Gynaecology, All India Institute of Medical Science, New Delhi, India. FAU - Vatsa, Richa AU - Vatsa R AD - Departments of Obstetrics and Gynaecology, All India Institute of Medical Science, New Delhi, India. FAU - Bharti, Juhi AU - Bharti J AD - Departments of Obstetrics and Gynaecology, All India Institute of Medical Science, New Delhi, India. FAU - Kulshrestha, Vidushi AU - Kulshrestha V AD - Departments of Obstetrics and Gynaecology, All India Institute of Medical Science, New Delhi, India. FAU - Yadav, Satyavir AU - Yadav S AD - Departments of Cardiology, All India Institute of Medical Science, New Delhi, India. FAU - Dadhwal, Vatsla AU - Dadhwal V AD - Departments of Obstetrics and Gynaecology, All India Institute of Medical Science, New Delhi, India. FAU - Malhotra, Neena AU - Malhotra N AD - Departments of Obstetrics and Gynaecology, All India Institute of Medical Science, New Delhi, India. LA - eng PT - Journal Article DEP - 20240215 PL - Korea (South) TA - Obstet Gynecol Sci JT - Obstetrics & gynecology science JID - 101602614 PMC - PMC10948205 OTO - NOTNLM OT - High-risk pregnancy OT - Intrauterine growth restriction OT - Preconception care OT - Premature birth OT - vascular disease COIS- Conflict of interest Authors declare no conflict of interest. EDAT- 2024/02/15 06:43 MHDA- 2024/02/15 06:44 PMCR- 2024/03/01 CRDT- 2024/02/15 03:05 PHST- 2023/11/06 00:00 [received] PHST- 2024/01/21 00:00 [accepted] PHST- 2024/02/15 06:44 [medline] PHST- 2024/02/15 06:43 [pubmed] PHST- 2024/02/15 03:05 [entrez] PHST- 2024/03/01 00:00 [pmc-release] AID - ogs.23264 [pii] AID - ogs-23264 [pii] AID - 10.5468/ogs.23264 [doi] PST - ppublish SO - Obstet Gynecol Sci. 2024 Mar;67(2):218-226. doi: 10.5468/ogs.23264. Epub 2024 Feb 15. PMID- 38355358 OWN - NLM STAT- MEDLINE DCOM- 20240318 LR - 20240925 IS - 1527-3288 (Electronic) IS - 0147-9563 (Linking) VI - 64 DP - 2024 Mar-Apr TI - Nursing care of the patient hospitalized with heart failure: A scientific statement from the American Association of Heart Failure Nurses. PG - e1-e16 LID - S0147-9563(24)00009-8 [pii] LID - 10.1016/j.hrtlng.2024.01.007 [doi] FAU - Fraser, Meg AU - Fraser M AD - University of Minnesota MHealth Physicians, Minneapolis, MN, USA. Electronic address: mfraser10@umphysicians.umn.edu. FAU - Barnes, Stephanie G AU - Barnes SG AD - Duke University Hospital, Durham, NC, USA. FAU - Barsness, Carol AU - Barsness C AD - MHealth Fairview, Minneapolis, MN, USA. FAU - Beavers, Craig AU - Beavers C AD - University of Kentucky College of Pharmacy, Lexington, KY, USA. FAU - Bither, Cynthia J AU - Bither CJ AD - MedStar Washington Hospital Center, Washington, DC, USA. FAU - Boettger, Samantha AU - Boettger S AD - University of Minnesota MHealth Physicians, Minneapolis, MN, USA. FAU - Hallman, Christine AU - Hallman C AD - MedStar Washington Section of Palliative Care, Washington, DC, USA. FAU - Keleman, Anne AU - Keleman A AD - MedStar Washington Section of Palliative Care, Washington, DC, USA. FAU - Leckliter, Lauren AU - Leckliter L AD - Maryville University School of Nursing, St. Louis, MO, USA. FAU - McIlvennan, Colleen K AU - McIlvennan CK AD - University of Colorado, Aurora, CO, USA. FAU - Ozemek, Cemal AU - Ozemek C AD - University of Illinois at Chicago, Cardiac Rehabilitation, College of Applied Health Sciences, Chicago, IL, USA. FAU - Patel, Amit AU - Patel A AD - Ascension St. Vincent Medical Group Cardiology, Indianapolis, IN, USA. FAU - Pierson, Natalie W AU - Pierson NW AD - University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. FAU - Shakowski, Courtney AU - Shakowski C AD - University of Colorado, Aurora, CO, USA. FAU - Thomas, S Craig AU - Thomas SC AD - UVA Health, Charlottesville, VA, USA. FAU - Whitmire, Tara AU - Whitmire T AD - Nebraska Methodist College, Omaha, NE, USA. FAU - Anderson, Kelley M AU - Anderson KM AD - Georgetown University, Washington, DC, USA. LA - eng PT - Journal Article DEP - 20240213 PL - United States TA - Heart Lung JT - Heart & lung : the journal of critical care JID - 0330057 SB - IM EIN - Heart Lung. 2024 Jun-Aug;66:46. doi: 10.1016/j.hrtlng.2024.03.009. PMID: 38579626 MH - Humans MH - United States/epidemiology MH - *Heart Failure MH - Patient Care Team MH - American Heart Association OTO - NOTNLM OT - Acute care OT - Heart failure OT - Intensive care OT - Multidisciplinary OT - Nurse OT - Transitions of care COIS- Declaration of competing interest No financial disclosures to report. EDAT- 2024/02/15 00:42 MHDA- 2024/03/18 06:43 CRDT- 2024/02/14 21:54 PHST- 2024/03/18 06:43 [medline] PHST- 2024/02/15 00:42 [pubmed] PHST- 2024/02/14 21:54 [entrez] AID - S0147-9563(24)00009-8 [pii] AID - 10.1016/j.hrtlng.2024.01.007 [doi] PST - ppublish SO - Heart Lung. 2024 Mar-Apr;64:e1-e16. doi: 10.1016/j.hrtlng.2024.01.007. Epub 2024 Feb 13. PMID- 38353507 OWN - NLM STAT- MEDLINE DCOM- 20240319 LR - 20250506 IS - 1522-726X (Electronic) IS - 1522-1946 (Linking) VI - 103 IP - 4 DP - 2024 Mar TI - Transcatheter tricuspid valve replacement for functional tricuspid regurgitation after left-sided valve surgery: A single-center experience. PG - 626-636 LID - 10.1002/ccd.30972 [doi] AB - BACKGROUND: Functional tricuspid regurgitation (FTR) following left-sided valve surgery (LSVS) is of clinical significance due to its high recurrence and mortality rates. Transcatheter therapy presents a potential solution to address this issue. AIMS: The study aimed to assess the safety and efficacy of transcatheter tricuspid valve replacement using the Lux-Valve system in a single center for patients with FTR after LSVS. METHODS: From June 2020 to April 2023, 20 patients with symptomatic severe FTR after LSVS were referred to our center. A multidisciplinary cardiac team evaluated these patients for suitability for transcatheter tricuspid valve replacement with Lux-Valve systems. Primary efficacy and safety endpoints were immediate postoperative tricuspid regurgitation severity 99%. Thirty-day mortality was 0.2% and did not differ significantly between groups (p = 0.37). Median follow-up was 48.2 months with a completeness of 95.9%. Long-term survival was similar between groups (p = 0.21). In the FS and MIC groups, 1-, 5-, and 10-year survival rates were 98.8 and 98.8%, 92.9 and 94.4%, and 87.4 and 83.1%, respectively. CONCLUSION: MV surgery, both minimally invasive and via sternotomy, is associated with high repair rates, excellent perioperative outcomes, and long-term survival. Data underscore the effectiveness of surgical repair in managing MR, even in the era of advancing interventional techniques. CI - Thieme. All rights reserved. FAU - Gotte, Julia AU - Gotte J AD - Clinic for Cardio-Thoracic Surgery, Herz- und Diabeteszentrum Nordrhein-Westfalen, Bad Oeynhausen, Nordrhein-Westfalen, Germany. FAU - Zittermann, Armin AU - Zittermann A AUID- ORCID: 0000-0001-6085-6554 AD - Clinic for Cardio-Thoracic Surgery, Herz- und Diabeteszentrum Nordrhein-Westfalen, Bad Oeynhausen, Nordrhein-Westfalen, Germany. FAU - Deutsch, Marcus-Andre AU - Deutsch MA AD - Clinic for Cardio-Thoracic Surgery, Herz- und Diabeteszentrum Nordrhein-Westfalen, Bad Oeynhausen, Nordrhein-Westfalen, Germany. FAU - Schramm, Rene AU - Schramm R AD - Clinic for Cardio-Thoracic Surgery, Herz- und Diabeteszentrum Nordrhein-Westfalen, Bad Oeynhausen, Nordrhein-Westfalen, Germany. FAU - Bleiziffer, Sabine AU - Bleiziffer S AD - Clinic for Cardio-Thoracic Surgery, Herz- und Diabeteszentrum Nordrhein-Westfalen, Bad Oeynhausen, Nordrhein-Westfalen, Germany. FAU - Renner, Andre AU - Renner A AD - Clinic for Cardio-Thoracic Surgery, Herz- und Diabeteszentrum Nordrhein-Westfalen, Bad Oeynhausen, Nordrhein-Westfalen, Germany. FAU - Gummert, Jan F AU - Gummert JF AD - Clinic for Cardio-Thoracic Surgery, Herz- und Diabeteszentrum Nordrhein-Westfalen, Bad Oeynhausen, Nordrhein-Westfalen, Germany. LA - eng PT - Journal Article DEP - 20240212 PL - Germany TA - Thorac Cardiovasc Surg JT - The Thoracic and cardiovascular surgeon JID - 7903387 SB - IM MH - Humans MH - Retrospective Studies MH - Male MH - Female MH - *Mitral Valve Insufficiency/surgery/mortality/physiopathology/diagnostic imaging MH - *Mitral Valve/surgery/physiopathology/diagnostic imaging MH - Time Factors MH - Middle Aged MH - Aged MH - Risk Factors MH - *Thoracotomy/adverse effects/mortality MH - *Sternotomy/adverse effects/mortality MH - *Postoperative Complications/etiology/mortality MH - Treatment Outcome MH - Hospitals, High-Volume MH - Mitral Valve Annuloplasty/adverse effects/mortality MH - Heart Valve Prosthesis Implantation/adverse effects/mortality MH - Recovery of Function MH - Risk Assessment MH - Reoperation MH - Severity of Illness Index COIS- None declared. EDAT- 2024/02/13 00:42 MHDA- 2024/11/27 00:21 CRDT- 2024/02/12 19:53 PHST- 2024/11/27 00:21 [medline] PHST- 2024/02/13 00:42 [pubmed] PHST- 2024/02/12 19:53 [entrez] AID - 10.1055/a-2266-7677 [doi] PST - ppublish SO - Thorac Cardiovasc Surg. 2024 Dec;72(8):624-630. doi: 10.1055/a-2266-7677. Epub 2024 Feb 12. PMID- 38344214 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240213 IS - 2297-055X (Print) IS - 2297-055X (Electronic) IS - 2297-055X (Linking) VI - 10 DP - 2023 TI - Left ventricular assist device and transcatheter edge-to-edge mitral valve repair in advanced heart failure: allies or enemies? PG - 1327927 LID - 10.3389/fcvm.2023.1327927 [doi] LID - 1327927 AB - The implantation of left ventricular assist devices (LVADs) has been increasing, with good long-term results, in parallel with a growing population with advanced heart failure (HF). However, in some European countries, LVADs are still underused, with one of the main issues being the patient's late referral. On the contrary, the use of transcatheter edge-to-edge mitral valve repair (TEER) has exponentially increased over the past decade, expanding its potential use even in patients on the heart transplantation waiting list. Even though the study populations of the main trials that investigated the prognostic impact of LVAD and TEER are different, in clinical practice a clear distinction might not be so clear. Therefore, patients with refractory HF symptoms and significant mitral regurgitation should be thoroughly evaluated through a multidisciplinary Heart Team meeting with both an advanced HF specialist and interventional cardiologist, to avoid futile procedures and to define the optimal timing for advanced HF therapies, when they are indicated. We analyzed the main available studies and registries on both TEERs and LVADs and we compared their populations and outcomes, to provide the current evidence on the use of LVAD and TEER in the HF population, especially in the light of the recently released 5-year follow-up results, giving some insights on the Italian situation, and finally to stress the importance of a solid HF network between hospitals, aiming for advanced HF patients' timely referral for LVAD or heart transplants. CI - (c) 2024 Valente, Sciaccaluga, Sorini Dini, Righini, Cameli, Bernazzali, Maccherini, Tarzia and Gerosa. FAU - Valente, S AU - Valente S AD - Division of Cardiology, Department of Medical Biotechnologies, University of Siena, Siena, Italy. FAU - Sciaccaluga, C AU - Sciaccaluga C AD - Division of Cardiology, Department of Medical Biotechnologies, University of Siena, Siena, Italy. FAU - Sorini Dini, C AU - Sorini Dini C AD - Division of Cardiology, Department of Medical Biotechnologies, University of Siena, Siena, Italy. FAU - Righini, F M AU - Righini FM AD - Division of Cardiology, Department of Medical Biotechnologies, University of Siena, Siena, Italy. FAU - Cameli, M AU - Cameli M AD - Division of Cardiology, Department of Medical Biotechnologies, University of Siena, Siena, Italy. FAU - Bernazzali, S AU - Bernazzali S AD - Department of Cardiac Surgery, University of Siena, Siena, Italy. FAU - Maccherini, M AU - Maccherini M AD - Department of Cardiac Surgery, University of Siena, Siena, Italy. FAU - Tarzia, V AU - Tarzia V AD - Cardiac Surgery Unit, Department of Cardiac, Thoracic, Vascular Sciences, and Public Health, University of Padua, Padua, Italy. FAU - Gerosa, G AU - Gerosa G AD - Cardiac Surgery Unit, Department of Cardiac, Thoracic, Vascular Sciences, and Public Health, University of Padua, Padua, Italy. LA - eng PT - Journal Article PT - Review DEP - 20240126 PL - Switzerland TA - Front Cardiovasc Med JT - Frontiers in cardiovascular medicine JID - 101653388 PMC - PMC10853372 OTO - NOTNLM OT - MitraClip OT - advanced heart failure OT - heart failure OT - left ventricular assist device (LVAD) OT - transcatheter edge-to-edge mitral valve repair COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision. EDAT- 2024/02/12 15:42 MHDA- 2024/02/12 15:43 PMCR- 2023/01/01 CRDT- 2024/02/12 04:18 PHST- 2023/10/25 00:00 [received] PHST- 2023/12/29 00:00 [accepted] PHST- 2024/02/12 15:43 [medline] PHST- 2024/02/12 15:42 [pubmed] PHST- 2024/02/12 04:18 [entrez] PHST- 2023/01/01 00:00 [pmc-release] AID - 10.3389/fcvm.2023.1327927 [doi] PST - epublish SO - Front Cardiovasc Med. 2024 Jan 26;10:1327927. doi: 10.3389/fcvm.2023.1327927. eCollection 2023. PMID- 38340179 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240213 IS - 2090-911X (Electronic) IS - 1110-2608 (Print) IS - 1110-2608 (Linking) VI - 76 IP - 1 DP - 2024 Feb 10 TI - An infective endocarditis complicated by multiple septic emboli: case report. PG - 19 LID - 10.1186/s43044-024-00451-z [doi] LID - 19 AB - BACKGROUND: Owing to challenges associated with heart failure and cardiac embolism, infectious endocarditis emerges as a critical pathology characterized by elevated mortality and morbidity rates. Our case stands out as a rare instance of endocarditis involving multisystem embolization, with a successful outcome. CASE PRESENTATION: We present the case of an 81-year-old man whose admission was further complicated by various septic emboli affecting the brain (manifesting as a brain abscess and ischemic stroke), spleen (resulting in splenic infarction), and spinal cord. The patient received a diagnosis of infective endocarditis affecting the native mitral valve. Following prompt medical and surgical intervention, the overall progression was favorable despite encountering several challenges. CONCLUSIONS: This case is notable for its detailed description and analysis of the multiple embolic events. More importantly, it underscores the significance of timely surgical intervention and the collaborative approach of a heart team in the face of complicated endocarditis marked by numerous septic emboli. Despite the typically grim prognosis associated with such cases, the outcomes emphasize the positive impact of timely surgery on prognosis. CI - (c) 2024. The Author(s). FAU - Amri, Meriam AU - Amri M AD - Cardiology Department, CHU Ibn Rochd, Casablanca, Morocco. meriam.amri@usmba.ac.ma. FAU - Tamir, El Mehdi AU - Tamir EM AD - Cardiology Department, CHU Ibn Rochd, Casablanca, Morocco. FAU - Drighil, Abdenasser AU - Drighil A AD - Cardiology Department, CHU Ibn Rochd, Casablanca, Morocco. FAU - Habbal, Rachida AU - Habbal R AD - Cardiology Department, CHU Ibn Rochd, Casablanca, Morocco. LA - eng PT - Journal Article DEP - 20240210 PL - Germany TA - Egypt Heart J JT - The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology JID - 9106952 PMC - PMC10858854 OTO - NOTNLM OT - Brain abscess OT - Infective endocarditis OT - Septic emboli OT - Spinal emboli OT - Splenic infarction COIS- There are no competing interests to disclose. EDAT- 2024/02/10 14:46 MHDA- 2024/02/10 14:47 PMCR- 2024/02/10 CRDT- 2024/02/10 11:15 PHST- 2023/08/29 00:00 [received] PHST- 2024/01/30 00:00 [accepted] PHST- 2024/02/10 14:47 [medline] PHST- 2024/02/10 14:46 [pubmed] PHST- 2024/02/10 11:15 [entrez] PHST- 2024/02/10 00:00 [pmc-release] AID - 10.1186/s43044-024-00451-z [pii] AID - 451 [pii] AID - 10.1186/s43044-024-00451-z [doi] PST - epublish SO - Egypt Heart J. 2024 Feb 10;76(1):19. doi: 10.1186/s43044-024-00451-z. PMID- 38335504 OWN - NLM STAT- MEDLINE DCOM- 20240223 LR - 20260527 IS - 1557-2501 (Electronic) IS - 1042-3931 (Linking) VI - 36 IP - 2 DP - 2024 Feb TI - Sensor-guided transcatheter aortic valve replacement. LID - 10.25270/jic/23.00242 [doi] AB - OBJECTIVES: The SavvyWire(OpSens Medical) is a support wire for transcatheter aortic valve replacement (TAVR) procedures that, in addition to its dedicated left ventricle (LV) pacing capabilities, has a distal pressure sensor that measures live transvalvular hemodynamics during the procedure. We aimed to determine the safety, efficacy, and functionality of the SavvyWire during TAVR procedures in an all-comer population. METHODS: We performed a multicentric, prospective, observational, single-arm, all-comers registry of patients with symptomatic, severe aortic stenosis undergoing TAVR in 3 Canadian centers. Data were collected in a dedicated database, and pre-specified questionnaires were fulfilled by the heart team implanters after each procedure. RESULTS: A total of 60 patients were included (mean age: 78.6 +/- 7.2 years; 51% women; mean Society of Thoracic Surgeons score: 2.2 +/- 1.6%). TAVR was performed through a transfemoral approach in 90% of cases, and balloon- and self-expandable valves were used in 73% and 27% of patients, respectively. There were no cases of LV perforation, guidewire deformation, significant loss of capture, or major software malfunction. The rate of successful delivery of the TAVR system was 100%, and effective LV pacing was achieved in 98% of patients. The pre-TAVR mean gradient was 39 +/- 14 mm Hg while the final post-TAVR gradient was 8 +/- 5 mm Hg; the mean aortic systolic pressure during rapid pacing was 54 +/- 12 mm Hg. In 97% of the TAVR procedures, SavvyWire's functionality was reported to be better or similar to other TAVR workhorse support wires. CONCLUSIONS: SavvyWire was safe, effective, and functional for live transvalvular hemodynamic evaluation and rapid pacing during TAVR procedures. More studies with larger sample sizes and comparison against different wires and gradient measurement methods are warranted. FAU - Farjat-Pasos, Julio AU - Farjat-Pasos J AD - Quebec Heart and Lung Institute, Quebec, Canada. FAU - Ibrahim, Reda AU - Ibrahim R AD - Montreal Heart Institute, Montreal, Canada. FAU - Sathananthan, Janarthanan AU - Sathananthan J AD - Vancouver General Hospital, Vancouver, Canada. FAU - Paradis, Jean-Michel AU - Paradis JM AD - Quebec Heart and Lung Institute, Quebec, Canada. FAU - Poulin, Anthony AU - Poulin A AD - Quebec Heart and Lung Institute, Quebec, Canada. FAU - Asgar, Anita W AU - Asgar AW AD - Montreal Heart Institute, Montreal, Canada. FAU - Dorval, Jean-Francois AU - Dorval JF AD - Montreal Heart Institute, Montreal, Canada. FAU - Cook, Richard AU - Cook R AD - Vancouver General Hospital, Vancouver, Canada. FAU - Rodes-Cabau, Josep AU - Rodes-Cabau J AD - Quebec Heart and Lung Institute, Quebec, Canada. Email: josep.rodes@criucpq.ulaval.ca. LA - eng PT - Journal Article PT - Multicenter Study PT - Observational Study PT - Research Support, Non-U.S. Gov't PL - United States TA - J Invasive Cardiol JT - The Journal of invasive cardiology JID - 8917477 SB - IM MH - Aged MH - Aged, 80 and over MH - Female MH - Humans MH - Male MH - Aortic Valve/diagnostic imaging/surgery MH - *Aortic Valve Stenosis/diagnosis/surgery MH - Canada MH - *Heart Valve Prosthesis MH - Hemodynamics MH - Prospective Studies MH - Prosthesis Design MH - Risk Factors MH - *Transcatheter Aortic Valve Replacement/adverse effects/methods MH - Treatment Outcome OTO - NOTNLM OT - TAVR OT - hemodynamics OT - left ventricle pacing OT - transcatheter aortic valve replacement EDAT- 2024/02/09 18:42 MHDA- 2024/02/10 14:42 CRDT- 2024/02/09 16:43 PHST- 2024/02/10 14:42 [medline] PHST- 2024/02/09 18:42 [pubmed] PHST- 2024/02/09 16:43 [entrez] AID - 10.25270/jic/23.00242 [doi] PST - ppublish SO - J Invasive Cardiol. 2024 Feb;36(2). doi: 10.25270/jic/23.00242. PMID- 38334977 OWN - NLM STAT- MEDLINE DCOM- 20251003 LR - 20260127 IS - 1538-4683 (Electronic) IS - 1061-5377 (Linking) VI - 33 IP - 6 DP - 2025 Nov-Dec 01 TI - Coronavirus Disease 2019 (COVID-19) in Heart Transplant Recipients and Anti-SARS-CoV-2 Monoclonal Antibodies: Experience, Lessons Learnt, and Future Challenges. PG - 522-530 LID - 10.1097/CRD.0000000000000640 [doi] AB - Solid organ transplant recipients (SOTRs), including heart transplant (HT) recipients, infected with Coronavirus disease 2019 (COVID-19) are at higher risk of hospitalization, mechanical ventilation, or death when compared with general population. Advances in diagnosis and treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have reduced COVID-19-related mortality rates from ~30% in the early pandemic to <3% in 2022 among HT recipients. We performed a retrospective chart review including adult HT recipients at Westchester Medical Center from January 1, 2020 to December 10, 2022, who received anti-SARS-CoV-2 monoclonal antibodies (mAbs) for treatment of mild-to-moderate COVID-19, and those who received tixagevimab/cilgavimab for preexposure prophylaxis. Additionally, a comprehensive review of the literature involving SOTRs who received mAbs for COVID-19 was conducted. In this largest single-center study in this population, 42 adult HT recipients received casirivimab/imdevimab (36%), sotrovimab (31%), or bebtelovimab (29%) for treatment of mild-to-moderate COVID-19. Among these recipients, no infusion-associated adverse effects, progression of disease, COVID-19-associated hospitalizations, or death were noted. Preexposure prophylaxis with tixagevimab/cilgavimab was given to 63 HT recipients in a dedicated infusion center (40%), inpatient setting (33%), or at time of annual heart biopsy (27%). No immediate adverse events were noted. There were 11 breakthrough infections, all mild. Overall, the data suggests that HT recipients receiving mAbs have reduced rates of hospitalization, need for intensive care unit care, or death. Use of anti-SARS-CoV-2 mAbs in SOTRs is resource intensive and requires a programmatic team approach for optimal administration and to minimize any risk of disparities in their use. CI - Copyright (c) 2024 Wolters Kluwer Health, Inc. All rights reserved. FAU - Kapur, Rohan AU - Kapur R AD - From the Departments of Medicine. FAU - Okumura, Kenji AU - Okumura K AD - Surgery, New York Medical College/Westchester Medical Center, Valhalla, NY. FAU - Ohira, Suguru AU - Ohira S AD - Division of Cardiothoracic Surgery, Department of Surgery. FAU - Isath, Ameesh AU - Isath A AD - Division of Cardiology, Department of Medicine, Westchester Medical Center, Valhalla, NY. FAU - Gandhi, Aditya AU - Gandhi A AD - New York Medical College, Valhalla, NY. FAU - Keller, Marina AU - Keller M AD - From the Departments of Medicine. FAU - Nog, Rajat AU - Nog R AD - From the Departments of Medicine. AD - Surgery, New York Medical College/Westchester Medical Center, Valhalla, NY. FAU - Gass, Alan AU - Gass A AD - Division of Cardiology, Department of Medicine, Westchester Medical Center, Valhalla, NY. FAU - Spielvogel, David AU - Spielvogel D AD - Division of Cardiothoracic Surgery, Department of Surgery. FAU - Lansman, Steven AU - Lansman S AD - Surgery, New York Medical College/Westchester Medical Center, Valhalla, NY. FAU - Dhand, Abhay AU - Dhand A AD - From the Departments of Medicine. AD - Surgery, New York Medical College/Westchester Medical Center, Valhalla, NY. LA - eng PT - Journal Article PT - Review DEP - 20240208 PL - United States TA - Cardiol Rev JT - Cardiology in review JID - 9304686 RN - 0 (Antibodies, Monoclonal, Humanized) RN - 0 (Antibodies, Monoclonal) RN - 0 (casirivimab and imdevimab drug combination) RN - 0 (Drug Combinations) RN - 0 (Antibodies, Neutralizing) SB - IM MH - Humans MH - *Heart Transplantation MH - *COVID-19/prevention & control/epidemiology MH - SARS-CoV-2 MH - Antibodies, Monoclonal, Humanized/therapeutic use MH - Male MH - Middle Aged MH - Retrospective Studies MH - Female MH - *COVID-19 Drug Treatment MH - *Antibodies, Monoclonal/therapeutic use MH - Adult MH - Aged MH - Transplant Recipients MH - Drug Combinations MH - Antibodies, Neutralizing OTO - NOTNLM OT - COVID-19 OT - coronavirus OT - heart transplant OT - monoclonal antibody OT - solid organ transplant COIS- Disclosure: The authors declare no conflict of interest. The content of this article solely represents the views of the authors. EDAT- 2024/02/09 12:44 MHDA- 2025/10/04 00:30 CRDT- 2024/02/09 11:23 PHST- 2025/10/04 00:30 [medline] PHST- 2024/02/09 12:44 [pubmed] PHST- 2024/02/09 11:23 [entrez] AID - 00045415-990000000-00208 [pii] AID - 10.1097/CRD.0000000000000640 [doi] PST - ppublish SO - Cardiol Rev. 2025 Nov-Dec 01;33(6):522-530. doi: 10.1097/CRD.0000000000000640. Epub 2024 Feb 8. PMID- 38334831 OWN - NLM STAT- MEDLINE DCOM- 20240221 LR - 20240223 IS - 1435-1544 (Electronic) IS - 0938-7412 (Print) IS - 0938-7412 (Linking) VI - 35 IP - 1 DP - 2024 Mar TI - Idiopathic ventricular fibrillation: is it a case for genetic testing? PG - 19-24 LID - 10.1007/s00399-024-00994-3 [doi] AB - Idiopathic ventricular fibrillation (IVF) is a diagnosis of exclusion in sudden cardiac arrest (SCA) survivors. Although there are clear guidelines on the clinical work-up of SCA survivors, less than one in five patients receives a complete work-up. This increases the chances of erroneously labelling these patients as having IVF, while 10-20% of them have an inherited cardiac condition (ICC). Diagnoses of ICC increase over time due to (additional) deep phenotyping or as a result of spontaneous expression of ICC over time. As SCA survivors can also harbor (likely) pathogenic variants in cardiomyopathy-associated genes in the absence of a phenotype, or can have another ICC without a clear cardiac phenotype, the question arises as to whether genetic testing in this group should be routinely performed. Family history (mainly in the case of sudden death) can increase suspicion of an ICC in an SCA victim, but does not add great value when adults underwent a complete cardiological work-up. The diagnosis of ICC has treatment consequences not only for the patient but also for their family. Genetic diagnostic yield does not appear to increase with larger gene panels, but variants of unknown significance (VUS) do. Although VUS can be confusing, careful and critical segregation analysis in the family can be performed when discussed in a multidisciplinary team at a center of expertise with at least a cardiologist as well as a clinical and laboratory geneticist, thereby degrading or promoting VUS. When to introduce genetic testing in SCA survivors remains a matter of debate, but the combination of quick, deep phenotyping with additional genetic testing for the unidentifiable phenotypes, especially in the young, seems preferable. CI - (c) 2024. The Author(s). FAU - van der Crabben, S N AU - van der Crabben SN AD - Department of Human Genetics, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. s.n.vandercrabben@amsterdamumc.nl. AD - European Reference Network for rare, low prevalence, and/or complex diseases of the heart: ERN GUARD-Heart, Amsterdam, The Netherlands. s.n.vandercrabben@amsterdamumc.nl. FAU - Wilde, A A M AU - Wilde AAM AD - European Reference Network for rare, low prevalence, and/or complex diseases of the heart: ERN GUARD-Heart, Amsterdam, The Netherlands. AD - Amsterdam UMC, Department of Cardiology, University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands. AD - Amsterdam Cardiovascular Sciences, Heart Failure and arrhythmias, Amsterdam, The Netherlands. LA - eng PT - Journal Article PT - Review TT - Idiopathisches Kammerflimmern - ist eine genetische Diagnostik indiziert? DEP - 20240209 PL - Germany TA - Herzschrittmacherther Elektrophysiol JT - Herzschrittmachertherapie & Elektrophysiologie JID - 9425873 RN - Paroxysmal ventricular fibrillation SB - IM MH - Adult MH - Humans MH - *Genetic Testing MH - *Ventricular Fibrillation/diagnosis/genetics MH - Death, Sudden, Cardiac/prevention & control MH - Phenotype PMC - PMC10879354 OTO - NOTNLM OT - DNA OT - Deep phenotyping OT - IVF OT - Inherited cardiac condition OT - Sudden cardiac death COIS- S.N. van der Crabben and A.A.M. Wilde declare that they have no competing interests. EDAT- 2024/02/09 12:43 MHDA- 2024/02/21 11:15 PMCR- 2024/02/09 CRDT- 2024/02/09 11:08 PHST- 2023/09/29 00:00 [received] PHST- 2024/01/15 00:00 [accepted] PHST- 2024/02/21 11:15 [medline] PHST- 2024/02/09 12:43 [pubmed] PHST- 2024/02/09 11:08 [entrez] PHST- 2024/02/09 00:00 [pmc-release] AID - 10.1007/s00399-024-00994-3 [pii] AID - 994 [pii] AID - 10.1007/s00399-024-00994-3 [doi] PST - ppublish SO - Herzschrittmacherther Elektrophysiol. 2024 Mar;35(1):19-24. doi: 10.1007/s00399-024-00994-3. Epub 2024 Feb 9. PMID- 38334051 OWN - NLM STAT- MEDLINE DCOM- 20240412 LR - 20251225 IS - 1477-0377 (Electronic) IS - 1358-863X (Print) IS - 1358-863X (Linking) VI - 29 IP - 2 DP - 2024 Apr TI - Advanced Raynaud's disease: A vascular medicine-initiated team-based approach and nationwide cohort analysis. PG - 120-122 LID - 10.1177/1358863X231220609 [doi] FAU - Kaushik, Milan AU - Kaushik M AUID- ORCID: 0000-0002-1860-5978 AD - Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA. AD - Harvard Medical School, Boston, MA, USA. FAU - Beyer, Sebastian E AU - Beyer SE AD - Department of Medicine, Division of Cardiology, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY, USA. FAU - Nashel, Jennifer AU - Nashel J AD - Harvard Medical School, Boston, MA, USA. AD - Division of Rheumatology, Beth Israel Deaconess Medical Center, Boston, MA, USA. FAU - Kholdani, Cyrus AU - Kholdani C AD - Harvard Medical School, Boston, MA, USA. AD - Division of Pulmonology, Beth Israel Deaconess Medical Center, Boston, MA, USA. FAU - Dowlatshahi, Arriyan S AU - Dowlatshahi AS AD - Harvard Medical School, Boston, MA, USA. AD - Division of Plastic Surgery, Beth Israel Deaconess Medical Center, Boston, MA, USA. FAU - Secemsky, Eric A AU - Secemsky EA AUID- ORCID: 0000-0003-3861-3163 AD - Harvard Medical School, Boston, MA, USA. AD - Division of Cardiology, Beth Israel Deaconess Medical Center, Boston, MA, USA. AD - Department of Medicine, Richard A and Susan F Smith Center for Outcomes Research in Cardiology, Beth Israel Deaconess Medical Center, Boston, MA, USA. FAU - Carroll, Brett J AU - Carroll BJ AUID- ORCID: 0000-0002-6704-5663 AD - Harvard Medical School, Boston, MA, USA. AD - Division of Cardiology, Beth Israel Deaconess Medical Center, Boston, MA, USA. AD - Department of Medicine, Richard A and Susan F Smith Center for Outcomes Research in Cardiology, Beth Israel Deaconess Medical Center, Boston, MA, USA. LA - eng GR - K23 HL150290/HL/NHLBI NIH HHS/United States PT - Journal Article DEP - 20240209 PL - England TA - Vasc Med JT - Vascular medicine (London, England) JID - 9610930 SB - IM MH - Humans MH - *Raynaud Disease/diagnosis/therapy MH - Cohort Studies MH - *Cardiology PMC - PMC12723403 MID - NIHMS2129935 OTO - NOTNLM OT - Raynaud's phenomenon OT - multidisciplinary team OT - sympathectomy OT - vascular medicine COIS- Declaration of conflicting interestsThe authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Brett Carroll: Bristol Myers Squibb, institutional research support; Koya Medical, scientific advisory board. Eric Secemsky: research grants to BIDMC (Beth Israel Deaconess Medical Center): NIH/NHLBI K23HL150290, Food & Drug Administration, SCAI, BD, Boston Scientific, Cook, Abbott/CSI, Laminate Medical, Medtronic and Philips; consulting/speaking: Abbott/CSI, BD, Boston Scientific, Cook, Cordis, Heartflow, InfraRedx, Medtronic, Philips, RapidAI, Shockwave, and VentureMed. The remaining authors with no disclosures. EDAT- 2024/02/09 06:42 MHDA- 2024/04/12 06:44 PMCR- 2025/12/23 CRDT- 2024/02/09 05:53 PHST- 2024/04/12 06:44 [medline] PHST- 2024/02/09 06:42 [pubmed] PHST- 2024/02/09 05:53 [entrez] PHST- 2025/12/23 00:00 [pmc-release] AID - 10.1177/1358863X231220609 [doi] PST - ppublish SO - Vasc Med. 2024 Apr;29(2):120-122. doi: 10.1177/1358863X231220609. Epub 2024 Feb 9. PMID- 38332036 OWN - NLM STAT- MEDLINE DCOM- 20240214 LR - 20240214 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 14 IP - 1 DP - 2024 Feb 8 TI - Five-year outcomes in patients with multivessel coronary artery disease undergoing surgery or percutaneous intervention. PG - 3218 LID - 10.1038/s41598-024-53905-4 [doi] LID - 3218 AB - The outcomes from real-life clinical studies regarding the optimal revascularization strategy in patients with multivessel coronary artery disease (MVD) are still poorly investigated. In this retrospective study we assessed 5-year outcomes: primary, secondary endpoints and quality of life of 1035 individuals with severe coronary artery disease (CAD) treated either with coronary artery bypass grafting (CABG)-356 patients or percutaneous coronary intervention (PCI)-679 patients according to the recommendation of a local Heart Team (HT). At 5 years no significant difference in overall mortality and rates of myocardial infarctions (MI) were observed between CABG and PCI cohorts (11.0% vs. 13.4% for PCI, P = 0.27 and 9.6% vs. 12.8% for PCI, P = 0.12, respectively). The incidence of major adverse cardiac and cerebrovascular events (MACCE), mainly driven by increased rates of repeat revascularization (RR) were higher in PCI-cohort than in CABG-group (56.1% vs. 40.4%, P < 0.01 and 26.8% vs. 12.6%, P < 0.01, respectively), while CABG-patients experienced stroke more often (7.3% vs. 3.1% for PCI, P < 0.01). In real-life practice with long-term follow-up, none of the two revascularization modalities implemented following HT decisions showed overwhelming superiority: occurrence of death and MI were similar, rates of RR favoured CABG, while incidence of strokes advocated PCI. CI - (c) 2024. The Author(s). FAU - Jonik, Szymon AU - Jonik S AUID- ORCID: 0000-0002-9230-5455 AD - 1st Department of Cardiology, Medical University of Warsaw, Banacha 1a Str, 01-267, Warsaw, Poland. szymonjonik.wum@gmail.com. FAU - Kageyama, Shigetaka AU - Kageyama S AD - Department of Cardiology, National University of Ireland, University Road Galway, Galway, H91 TK33, Ireland. FAU - Ninomiya, Kai AU - Ninomiya K AD - Department of Cardiology, National University of Ireland, University Road Galway, Galway, H91 TK33, Ireland. FAU - Onuma, Yoshinobu AU - Onuma Y AD - Department of Cardiology, National University of Ireland, University Road Galway, Galway, H91 TK33, Ireland. FAU - Kochman, Janusz AU - Kochman J AD - 1st Department of Cardiology, Medical University of Warsaw, Banacha 1a Str, 01-267, Warsaw, Poland. FAU - Grabowski, Marcin AU - Grabowski M AD - 1st Department of Cardiology, Medical University of Warsaw, Banacha 1a Str, 01-267, Warsaw, Poland. FAU - Serruys, Patrick W AU - Serruys PW AD - Department of Cardiology, National University of Ireland, University Road Galway, Galway, H91 TK33, Ireland. FAU - Mazurek, Tomasz AU - Mazurek T AD - 1st Department of Cardiology, Medical University of Warsaw, Banacha 1a Str, 01-267, Warsaw, Poland. LA - eng PT - Journal Article DEP - 20240208 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 SB - IM MH - Humans MH - *Coronary Artery Disease/surgery/epidemiology MH - *Percutaneous Coronary Intervention/adverse effects MH - Retrospective Studies MH - Quality of Life MH - Treatment Outcome MH - *Myocardial Infarction/complications MH - *Stroke/epidemiology PMC - PMC10853195 COIS- K. Ninomiya, MD reports a grant from Abbott Medical Japan, outside the submitted work. P.W. Serruys, MD, PhD, Professor reports institutional grants from Sinomedical Sciences Technology, SMT (Sahajanand Medical Technological), Philips/Volcano, Xeltis, and HeartFlow, outside the submitted work. EDAT- 2024/02/09 00:42 MHDA- 2024/02/10 14:45 PMCR- 2024/02/08 CRDT- 2024/02/08 23:51 PHST- 2023/11/18 00:00 [received] PHST- 2024/02/06 00:00 [accepted] PHST- 2024/02/10 14:45 [medline] PHST- 2024/02/09 00:42 [pubmed] PHST- 2024/02/08 23:51 [entrez] PHST- 2024/02/08 00:00 [pmc-release] AID - 10.1038/s41598-024-53905-4 [pii] AID - 53905 [pii] AID - 10.1038/s41598-024-53905-4 [doi] PST - epublish SO - Sci Rep. 2024 Feb 8;14(1):3218. doi: 10.1038/s41598-024-53905-4. PMID- 38331691 OWN - NLM STAT- MEDLINE DCOM- 20240318 LR - 20240925 IS - 1527-3288 (Electronic) IS - 0147-9563 (Linking) VI - 64 DP - 2024 Mar-Apr TI - Nursing care of the patient hospitalized with heart failure: Executive summary: A Scientific statement from the American association of heart failure nurses. PG - A1-A5 LID - S0147-9563(24)00010-4 [pii] LID - 10.1016/j.hrtlng.2024.01.008 [doi] FAU - Fraser, Meg AU - Fraser M AD - University of Minnesota MHealth Physicians, Minneapolis, MN, US. Electronic address: mfraser10@umphysicians.umn.edu. FAU - Barnes, Stephanie G AU - Barnes SG AD - Duke University Hospital, Durham, NC, US. FAU - Barsness, Carol AU - Barsness C AD - MHealth Fairview, Minneapolis, MN, US. FAU - Beavers, Craig AU - Beavers C AD - University of Kentucky College of Pharmacy, Lexington, KY, US. FAU - Bither, Cynthia J AU - Bither CJ AD - MedStar Washington Hospital Center, Washington, DC, US. FAU - Boettger, Samantha AU - Boettger S AD - University of Minnesota MHealth Physicians, Minneapolis, MN, US. FAU - Hallman, Christine AU - Hallman C AD - MedStar Washington Section of Palliative Care, Department of Medicine, Washington, DC, US. FAU - Keleman, Anne AU - Keleman A AD - MedStar Washington Section of Palliative Care, Department of Medicine, Washington, DC, US. FAU - Leckliter, Lauren AU - Leckliter L AD - Maryville University School of Nursing, St. Louis, MO, US. FAU - McIlvennan, Colleen K AU - McIlvennan CK AD - University of Colorado, Aurora, CO, US. FAU - Ozemek, Cemal AU - Ozemek C AD - University of Illinois at Chicago, Cardiac Rehabilitation, College of Applied Health Sciences, Chicago, IL, US. FAU - Patel, Amit AU - Patel A AD - Ascension St. Vincent Medical Group Cardiology, Indianapolis, IN, US. FAU - Pierson, Natalie W AU - Pierson NW AD - University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, US. FAU - Shakowski, Courtney AU - Shakowski C AD - University of Colorado, Aurora, CO, US. FAU - Thomas, S Craig AU - Thomas SC AD - UVA Health, Charlottesville, VA, US. FAU - Whitmire, Tara AU - Whitmire T AD - Nebraska Methodist College, Omaha, NE, US. FAU - Anderson, Kelley M AU - Anderson KM AD - Georgetown University, Washington, DC, US. LA - eng PT - Journal Article DEP - 20240207 PL - United States TA - Heart Lung JT - Heart & lung : the journal of critical care JID - 0330057 SB - IM MH - Humans MH - United States MH - *Heart Failure MH - Patient Care Team MH - American Heart Association OTO - NOTNLM OT - Acute care OT - Heart failure OT - Intensive care OT - Multidisciplinary OT - Nurse OT - Transitions of care COIS- Declaration of competing interest The authors declare no conflict of interests. EDAT- 2024/02/09 00:42 MHDA- 2024/03/18 06:43 CRDT- 2024/02/08 21:57 PHST- 2024/03/18 06:43 [medline] PHST- 2024/02/09 00:42 [pubmed] PHST- 2024/02/08 21:57 [entrez] AID - S0147-9563(24)00010-4 [pii] AID - 10.1016/j.hrtlng.2024.01.008 [doi] PST - ppublish SO - Heart Lung. 2024 Mar-Apr;64:A1-A5. doi: 10.1016/j.hrtlng.2024.01.008. Epub 2024 Feb 7. PMID- 38330243 OWN - NLM STAT- MEDLINE DCOM- 20240412 LR - 20250730 IS - 1537-6591 (Electronic) IS - 1058-4838 (Print) IS - 1058-4838 (Linking) VI - 78 IP - 4 DP - 2024 Apr 10 TI - Evaluation of the 2023 Duke-International Society of Cardiovascular Infectious Diseases Criteria in a Multicenter Cohort of Patients With Suspected Infective Endocarditis. PG - 949-955 LID - 10.1093/cid/ciae039 [doi] AB - BACKGROUND: Since publication of Duke criteria for infective endocarditis (IE) diagnosis, several modifications have been proposed. We aimed to evaluate the diagnostic performance of the Duke-ISCVID (International Society of Cardiovascular Infectious Diseases) 2023 criteria compared to prior versions from 2000 (Duke-Li 2000) and 2015 (Duke-ESC [European Society for Cardiology] 2015). METHODS: This study was conducted at 2 university hospitals between 2014 and 2022 among patients with suspected IE. A case was classified as IE (final IE diagnosis) by the Endocarditis Team. Sensitivity for each version of the Duke criteria was calculated among patients with confirmed IE based on pathological, surgical, and microbiological data. Specificity for each version of the Duke criteria was calculated among patients with suspected IE for whom IE diagnosis was ruled out. RESULTS: In total, 2132 episodes with suspected IE were included, of which 1101 (52%) had final IE diagnosis. Definite IE by pathologic criteria was found in 285 (13%), 285 (13%), and 345 (16%) patients using the Duke-Li 2000, Duke-ESC 2015, or the Duke-ISCVID 2023 criteria, respectively. IE was excluded by histopathology in 25 (1%) patients. The Duke-ISCVID 2023 clinical criteria showed a higher sensitivity (84%) compared to previous versions (70%). However, specificity of the new clinical criteria was lower (60%) compared to previous versions (74%). CONCLUSIONS: The Duke-ISCVID 2023 criteria led to an increase in sensitivity compared to previous versions. Further studies are needed to evaluate items that could increase sensitivity by reducing the number of IE patients misclassified as possible, but without having detrimental effect on specificity of Duke criteria. CI - (c) The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. FAU - Papadimitriou-Olivgeris, Matthaios AU - Papadimitriou-Olivgeris M AUID- ORCID: 0000-0003-0565-5105 AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Monney, Pierre AU - Monney P AD - Department of Cardiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Frank, Michelle AU - Frank M AD - Department of Cardiology, University Hospital Zurich and University of Zurich, Zurich, Switzerland. FAU - Tzimas, Georgios AU - Tzimas G AD - Department of Cardiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Tozzi, Piergiorgio AU - Tozzi P AD - Department of Cardiac Surgery, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Kirsch, Matthias AU - Kirsch M AD - Department of Cardiac Surgery, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Van Hemelrijck, Mathias AU - Van Hemelrijck M AD - Department of Cardiac Surgery, University Hospital Zurich and University of Zurich, Zurich, Switzerland. FAU - Bauernschmitt, Robert AU - Bauernschmitt R AD - Department of Cardiac Surgery, University Hospital Zurich and University of Zurich, Zurich, Switzerland. FAU - Epprecht, Jana AU - Epprecht J AD - Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich and University of Zurich, Zurich, Switzerland. FAU - Guery, Benoit AU - Guery B AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Hasse, Barbara AU - Hasse B AD - Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich and University of Zurich, Zurich, Switzerland. LA - eng GR - 320030_184918/1/SNSF_/Swiss National Science Foundation/Switzerland PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't PL - United States TA - Clin Infect Dis JT - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America JID - 9203213 RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18) SB - IM CIN - Clin Infect Dis. 2024 Apr 10;78(4):964-967. doi: 10.1093/cid/ciae037. PMID: 38330224 MH - Humans MH - *Endocarditis, Bacterial/diagnosis MH - *Endocarditis/diagnosis MH - *Heart Valve Prosthesis/microbiology MH - *Communicable Diseases MH - Fluorodeoxyglucose F18 PMC - PMC11006096 OTO - NOTNLM OT - 18F-FDG PET/CT OT - Duke criteria OT - echocardiography OT - infective endocarditis OT - prosthetic valve COIS- Potential conflicts of interest. The authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. EDAT- 2024/02/08 18:42 MHDA- 2024/04/12 06:44 PMCR- 2024/02/08 CRDT- 2024/02/08 15:43 PHST- 2023/05/09 00:00 [received] PHST- 2024/04/12 06:44 [medline] PHST- 2024/02/08 18:42 [pubmed] PHST- 2024/02/08 15:43 [entrez] PHST- 2024/02/08 00:00 [pmc-release] AID - 7603759 [pii] AID - ciae039 [pii] AID - 10.1093/cid/ciae039 [doi] PST - ppublish SO - Clin Infect Dis. 2024 Apr 10;78(4):949-955. doi: 10.1093/cid/ciae039. PMID- 38328751 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240210 IS - 2666-5204 (Electronic) IS - 2666-5204 (Linking) VI - 17 DP - 2024 Mar TI - Long-term multidisciplinary follow-up programs in pediatric cardiac arrest survivors. PG - 100563 LID - 10.1016/j.resplu.2024.100563 [doi] LID - 100563 AB - Long-term outcome studies after pediatric cardiac arrest (CA) are few. They require a CA registry and dedicated outcome teams. Learning about the long-term outcomes is very important for developing prognostication guidelines, improving post-cardiac care, counseling caregivers about the future of their child, and creating opportunities for therapeutic intervention studies to improve outcomes. Few PICUs worldwide provide a multidisciplinary follow-up program as routine practice at an outpatient clinic with standardized measurements, using validated instruments including neuropsychological assessments by psychologists. The primary goal of such a follow-up program should be to provide excellent care to children and their caregivers, thereby resulting in a high attendance. Pediatric psychologists, neurologists and pediatricians/pediatric intensivists should ideally be involved to screen for delayed development and psychosocial problems and offer appropriate care at the same time. Preferably, outcomes should consist of evaluation of morbidity (physical and neuropsychological), functional health and Health Related Quality Of Life (QoL) of the patient and their caregivers. CI - (c) 2024 The Author(s). FAU - Hunfeld, M AU - Hunfeld M AD - Department of Neonatal and Pediatric Intensive Care Unit, Division of Pediatric Intensive Care Unit, Erasmus MC Children's Hospital, Rotterdam, the Netherlands. FAU - Dulfer, K AU - Dulfer K AD - Department of Neonatal and Pediatric Intensive Care Unit, Division of Pediatric Intensive Care Unit, Erasmus MC Children's Hospital, Rotterdam, the Netherlands. FAU - Del Castillo, J AU - Del Castillo J AD - Pediatric Intensive Care Department, Hospital General Universitario Gregorio Maranon, Instituto de Investigacion Sanitaria Gregorio Maranon, Madrid, Primary Care Interventions to Prevent Maternal and Child Chronic Diseases of Perinatal and Development Origen Network (RICORS-RD21/0012/0011), Spain. FAU - Vazquez, M AU - Vazquez M AD - Pediatric Intensive Care Department, Hospital General Universitario Gregorio Maranon, Instituto de Investigacion Sanitaria Gregorio Maranon, Madrid, Primary Care Interventions to Prevent Maternal and Child Chronic Diseases of Perinatal and Development Origen Network (RICORS-RD21/0012/0011), Spain. FAU - Buysse, C M P AU - Buysse CMP AD - Department of Neonatal and Pediatric Intensive Care Unit, Division of Pediatric Intensive Care Unit, Erasmus MC Children's Hospital, Rotterdam, the Netherlands. LA - eng PT - Journal Article DEP - 20240201 PL - Netherlands TA - Resusc Plus JT - Resuscitation plus JID - 101774410 PMC - PMC10847941 OTO - NOTNLM OT - Cardiac arrest OT - Children OT - Follow-up OT - Long-term outcome OT - Neuroprognostication COIS- The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/02/08 06:42 MHDA- 2024/02/08 06:43 PMCR- 2024/02/01 CRDT- 2024/02/08 04:25 PHST- 2024/02/08 06:43 [medline] PHST- 2024/02/08 06:42 [pubmed] PHST- 2024/02/08 04:25 [entrez] PHST- 2024/02/01 00:00 [pmc-release] AID - S2666-5204(24)00014-6 [pii] AID - 100563 [pii] AID - 10.1016/j.resplu.2024.100563 [doi] PST - epublish SO - Resusc Plus. 2024 Feb 1;17:100563. doi: 10.1016/j.resplu.2024.100563. eCollection 2024 Mar. PMID- 38324706 OWN - NLM STAT- MEDLINE DCOM- 20240501 LR - 20260922 IS - 1538-943X (Electronic) IS - 1058-2916 (Print) IS - 1058-2916 (Linking) VI - 70 IP - 5 DP - 2024 May 1 TI - ECMOve: A Mobilization Device for Extracorporeal Membrane Oxygenation Patients. PG - 377-386 LID - 10.1097/MAT.0000000000002153 [doi] AB - Extracorporeal membrane oxygenation (ECMO) is a temporary lifesaving treatment for critically ill patients with severe respiratory or cardiac failure. Studies demonstrated the feasibility of in-hospital mobilizing during and after ECMO treatment preventing neuromuscular weakness and impaired physical functioning. Despite more compact mobile ECMO devices, implementation of ambulatory ECMO remains labor-intensive, complex, and challenging. It requires a large multidisciplinary team to carry equipment, monitor and physically support the patient, and to provide a back-up wheelchair in case of fatigue. Moreover, there is no adequate solution to ensure the stability of the patient's cannula and circuit management during ambulation. We developed a system contributing to improvement and innovation of current ambulatory ECMO patient programs. Our modular cart-in-cart system carries necessary ECMO equipment, features an extendable walking frame, and contains a folding seat for patient transport. An adjustable shoulder brace with lockable tubing-connectors enables safe fixation of the blood tubing. ECMOve provides safety, support, and accessibility while performing ambulatory ECMO for both patient and caregiver. Prototype evaluation in a simulated intensive care unit showed feasibility of our design, but needs to be evaluated in clinical care. CI - Copyright (c) 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the ASAIO. FAU - van Galen, Danny J M AU - van Galen DJM AUID- ORCID: 0009-0000-5216-1189 AD - From the Faculty of Engineering Technologies, Department of Biomechanical Engineering, Engineering Organ Support Technologies, University of Twente, Enschede, the Netherlands. FAU - Meinders, Quint AU - Meinders Q AUID- ORCID: 0009-0006-4402-0873 AD - From the Faculty of Engineering Technologies, Department of Biomechanical Engineering, Engineering Organ Support Technologies, University of Twente, Enschede, the Netherlands. FAU - Halfwerk, Frank R AU - Halfwerk FR AUID- ORCID: 0000-0003-2928-9728 AD - From the Faculty of Engineering Technologies, Department of Biomechanical Engineering, Engineering Organ Support Technologies, University of Twente, Enschede, the Netherlands. AD - Department of Cardiothoracic Surgery, Thorax Centrum Twente, Medisch Spectrum Twente, Enschede, the Netherlands. FAU - Arens, Jutta AU - Arens J AUID- ORCID: 0000-0002-9115-0519 AD - From the Faculty of Engineering Technologies, Department of Biomechanical Engineering, Engineering Organ Support Technologies, University of Twente, Enschede, the Netherlands. LA - eng PT - Journal Article DEP - 20240220 PL - United States TA - ASAIO J JT - ASAIO journal (American Society for Artificial Internal Organs : 1992) JID - 9204109 SB - IM MH - *Extracorporeal Membrane Oxygenation/instrumentation/methods MH - Humans MH - Equipment Design MH - Critical Illness/therapy MH - Heart Failure/therapy PMC - PMC11057491 EDAT- 2024/02/07 18:42 MHDA- 2024/05/01 13:30 PMCR- 2024/04/29 CRDT- 2024/02/07 14:52 PHST- 2024/05/01 13:30 [medline] PHST- 2024/02/07 18:42 [pubmed] PHST- 2024/02/07 14:52 [entrez] PHST- 2024/04/29 00:00 [pmc-release] AID - 00002480-202405000-00008 [pii] AID - ASAIO-23-0496 [pii] AID - 10.1097/MAT.0000000000002153 [doi] PST - ppublish SO - ASAIO J. 2024 May 1;70(5):377-386. doi: 10.1097/MAT.0000000000002153. Epub 2024 Feb 20. PMID- 38323707 OWN - NLM STAT- MEDLINE DCOM- 20240522 LR - 20250320 IS - 1471-6712 (Electronic) IS - 0283-9318 (Linking) VI - 38 IP - 2 DP - 2024 Jun TI - 'Our Voices Aren't Being Heard': A qualitative descriptive study of nurses' perceptions of interprofessional collaboration in care supporting older people's functioning during a hospital stay. PG - 398-408 LID - 10.1111/scs.13243 [doi] AB - INTRODUCTION: Older people admitted to hospital are highly susceptible to functional decline and related complications. Care supporting their functioning is complex and requires healthcare professionals working in concert, with nurses playing a central role. Yet, little is known about nurses' perceptions of interprofessional collaboration (IPC) in care supporting functioning in acutely admitted older people. To fill this knowledge gap, we elucidate the perspectives of nurses in Ontario, Canada, on IPC in care supporting older people's functioning during a hospital stay. METHODS: We employed a qualitative methodology in conjunction with a qualitative descriptive design. Thirteen focus groups were held with a purposeful, criterion-based sample of 57 acute care nurses practising in a range of acute care settings (e.g. Emergency, General Medicine, General Surgery, Intensive Care, Coronary Care). Data were thematically analysed. RESULTS: We identified two overarching themes: (1) IPC is improving, but nurses are excluded from decision-making and (2) nurse advocacy causes friction with other professionals. The first theme captures nurses' perception that IPC in older people's care is improving, but nurses are marginalised in interprofessional decision-making. As a result, nurses perceive that their knowledge is devalued, and their contributions to care supporting older people's functioning are undermined. The second theme underlines a tension between interprofessional team practices and patient- and family-centred care, while also demonstrating nurses' increasing willingness to act as patient and family advocates. CONCLUSIONS: Findings can be used to enhance IPC in care supporting the functioning of acutely hospitalised older people. To improve IPC, clinical and administrative leaders should cultivate more egalitarian team relationships that encourage nurses to contribute to decision-making and advocate on behalf of older patients and their families. CI - (c) 2024 The Authors. Scandinavian Journal of Caring Sciences published by John Wiley & Sons Ltd on behalf of Nordic College of Caring Science. FAU - Butler, Jeffrey I AU - Butler JI AUID- ORCID: 0000-0003-2765-7208 AD - Faculty of Health, School of Nursing, York University, Toronto, Ontario, Canada. AD - York University Centre for Aging Research and Education, Toronto, Ontario, Canada. FAU - Fox, Mary T AU - Fox MT AUID- ORCID: 0000-0003-0572-3892 AD - Faculty of Health, School of Nursing, York University, Toronto, Ontario, Canada. AD - York University Centre for Aging Research and Education, Toronto, Ontario, Canada. LA - eng GR - Ontario Ministry of Health & Long-Term Care/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240207 PL - Sweden TA - Scand J Caring Sci JT - Scandinavian journal of caring sciences JID - 8804206 SB - IM MH - Humans MH - *Qualitative Research MH - Aged MH - *Interprofessional Relations MH - Male MH - Female MH - Ontario MH - *Nursing Staff, Hospital/psychology MH - Focus Groups MH - Cooperative Behavior MH - Attitude of Health Personnel MH - Middle Aged MH - Adult MH - Aged, 80 and over OTO - NOTNLM OT - focus groups OT - function-focused care OT - interprofessional collaboration OT - nurse perspectives OT - older people OT - qualitative description OT - thematic analysis EDAT- 2024/02/07 12:43 MHDA- 2024/05/22 12:43 CRDT- 2024/02/07 08:22 PHST- 2024/01/10 00:00 [revised] PHST- 2023/11/24 00:00 [received] PHST- 2024/01/26 00:00 [accepted] PHST- 2024/05/22 12:43 [medline] PHST- 2024/02/07 12:43 [pubmed] PHST- 2024/02/07 08:22 [entrez] AID - 10.1111/scs.13243 [doi] PST - ppublish SO - Scand J Caring Sci. 2024 Jun;38(2):398-408. doi: 10.1111/scs.13243. Epub 2024 Feb 7. PMID- 38322766 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240210 IS - 2297-055X (Print) IS - 2297-055X (Electronic) IS - 2297-055X (Linking) VI - 11 DP - 2024 TI - Combinatorial immune checkpoint blockade increases myocardial expression of NLRP-3 and secretion of H-FABP, NT-Pro-BNP, interleukin-1beta and interleukin-6: biochemical implications in cardio-immuno-oncology. PG - 1232269 LID - 10.3389/fcvm.2024.1232269 [doi] LID - 1232269 AB - BACKGROUND: Immune checkpoint blockade in monotherapy or combinatorial regimens with chemotherapy or radiotherapy have become an integral part of oncology in recent years. Monoclonal antibodies against CTLA-4 or PD-1 or PDL-1 are the most studied ICIs in randomized clinical trials, however, more recently, an anti-LAG3 (Lymphocyte activation gene-3) antibody, Relatlimab, has been approved by FDA in combination with Nivolumab for metastatic melanoma therapy. Moreover, Atezolizumab is actually under study in association with Ipilimumab for therapy of metastatic lung cancer. Myocarditis, vasculitis and endothelitis are rarely observed in these patients on monotherapy, however new combination therapies could expose patients to more adverse cardiovascular events. METHODS: Human cardiomyocytes co-cultured with human peripheral blood lymphocytes (hPBMCs) were exposed to monotherapy and combinatorial ICIs (PD-L1 and CTLA-4 or PD-1 and LAG-3 blocking agents, at 100 nM) for 48 h. After treatments, cardiac cell lysis and secretion of biomarkers of cardiotoxicity (H-FABP, troponin-T, BNP, NT-Pro-BNP), NLRP3-inflammasome and Interleukin 1 and 6 were determined through colorimetric and enzymatic assays. Mitochondrial functions were studied in cardiomyocyte cell lysates through quantification of intracellular Ca(++), ATP content and NADH:ubiquinone oxidoreductase core subunit S1 (Ndufs1) levels. Histone deacetylases type 4 (HDAC-4) protein levels were also determined in cardiomyocyte cell lysates to study potential epigenetic changes induced by immunotherapy regimens. RESULTS: Both combinations of immune checkpoint inhibitors exert more potent cardiotoxic side effects compared to monotherapies against human cardiac cells co-cultured with human lymphocytes. LDH release from cardiac cells was 43% higher in PD-L1/CTLA-4 blocking agents, and 35.7% higher in PD-1/LAG-3 blocking agents compared to monotherapies. HDAC4 and intracellular Ca(++) levels were increased, instead ATP content and Ndufs1 were reduced in myocardial cell lysates (p < 0.001 vs. untreated cells). Troponin-T, BNP, NT-Pro-BNP and H-FABP, were also strongly increased in combination therapy compared to monotherapy regimen. NLRP3 expression, IL-6 and IL-1beta levels were also increased by PDL-1/CTLA-4 and PD-1/LAG-3 combined blocking agents compared to untreated cells and monotherapies. CONCLUSIONS: Data of the present study, although in vitro, indicate that combinatorial immune checkpoint blockade, induce a pro- inflammatory phenotype, thus indicating that these therapies should be closely monitored by the multidisciplinary team consisting of oncologists, cardiologists and immunologists. CI - (c) 2024 Quagliariello, Passariello, Bisceglia, Paccone, Inno, Maurea, Rapuano Lembo, Manna, Iovine, Canale, Scherillo, Ascierto, Gabrielli, De Lorenzo and Maurea. FAU - Quagliariello, V AU - Quagliariello V AD - Division of Cardiology, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy. FAU - Passariello, M AU - Passariello M AD - Department of Molecular Medicine and Medical Biotechnology, University of Naples "Federico II", Naples, Italy. FAU - Bisceglia, I AU - Bisceglia I AD - Servizi Cardiologici Integrati, Dipartimento Cardio-Toraco-Vascolare, Azienda Ospedaliera San Camillo Forlanini, Rome, Italy. FAU - Paccone, A AU - Paccone A AD - Division of Cardiology, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy. FAU - Inno, A AU - Inno A AD - Medical Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale Sacro Cuore Don Calabria, Negrar, Italy. FAU - Maurea, C AU - Maurea C AD - Medical Oncology, Ospedale del Mare, Naples, Italy. FAU - Rapuano Lembo, R AU - Rapuano Lembo R AD - Department of Molecular Medicine, Ceinge-Biotecnologie Avanzate s.c.a.r.l., Naples, Italy. FAU - Manna, L AU - Manna L AD - Department of Molecular Medicine and Medical Biotechnology, University of Naples "Federico II", Naples, Italy. FAU - Iovine, M AU - Iovine M AD - Division of Cardiology, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy. FAU - Canale, M L AU - Canale ML AD - U.O.C. Cardiologia, Ospedale Versilia, Lido di Camaiore (LU), Camaiore, Italy. FAU - Scherillo, M AU - Scherillo M AD - Cardiologia Interventistica e UTIC, A.O. San Pio, Presidio Ospedaliero Gaetano Rummo, Benevento, Italy. FAU - Ascierto, P A AU - Ascierto PA AD - Melanoma Cancer Immunotherapy and Innovative Therapy Unit, Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", Naples, Italy. FAU - Gabrielli, D AU - Gabrielli D AD - U.O.C. Cardiologia, Dipartimento Cardio-Toraco-Vascolare, Azienda Ospedaliera San Camillo Forlanini, Roma - Fondazione per il Tuo Cuore - Heart Care Foundation, Firenze, Italy. FAU - De Lorenzo, C AU - De Lorenzo C AD - Department of Molecular Medicine and Medical Biotechnology, University of Naples "Federico II", Naples, Italy. AD - Department of Molecular Medicine, Ceinge-Biotecnologie Avanzate s.c.a.r.l., Naples, Italy. FAU - Maurea, N AU - Maurea N AD - Division of Cardiology, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy. LA - eng PT - Journal Article DEP - 20240123 PL - Switzerland TA - Front Cardiovasc Med JT - Frontiers in cardiovascular medicine JID - 101653388 PMC - PMC10844473 OTO - NOTNLM OT - cancer OT - cardiology OT - cardiotoxicity OT - immune checkpoint inhibitors OT - inflammation OT - myocarditis OT - oncology COIS- All authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2024/02/07 06:43 MHDA- 2024/02/07 06:44 PMCR- 2024/01/01 CRDT- 2024/02/07 04:06 PHST- 2023/05/31 00:00 [received] PHST- 2024/01/10 00:00 [accepted] PHST- 2024/02/07 06:44 [medline] PHST- 2024/02/07 06:43 [pubmed] PHST- 2024/02/07 04:06 [entrez] PHST- 2024/01/01 00:00 [pmc-release] AID - 10.3389/fcvm.2024.1232269 [doi] PST - epublish SO - Front Cardiovasc Med. 2024 Jan 23;11:1232269. doi: 10.3389/fcvm.2024.1232269. eCollection 2024. PMID- 38322295 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241027 IS - 2472-0054 (Electronic) IS - 2472-0054 (Linking) VI - 9 IP - 1 DP - 2024 Jan-Feb TI - Antimicrobial Stewardship and Improved Antibiotic Utilization in the Pediatric Cardiac Intensive Care Unit. PG - e710 LID - 10.1097/pq9.0000000000000710 [doi] LID - e710 AB - BACKGROUND: We developed a multidisciplinary antimicrobial stewardship team to optimize antimicrobial use within the Pediatric Cardiac Intensive Care Unit. A quality improvement initiative was conducted to decrease unnecessary broad-spectrum antibiotic use by 20%, with sustained change over 12 months. METHODS: We conducted this quality improvement initiative within a quaternary care center. PDSA cycles focused on antibiotic overuse, provider education, and practice standardization. The primary outcome measure was days of therapy (DOT)/1000 patient days. Process measures included electronic medical record order-set use. Balancing measures focused on alternative antibiotic use, overall mortality, and sepsis-related mortality. Data were analyzed using statistical process control charts. RESULTS: A significant and sustained decrease in DOT was observed for vancomycin and meropenem. Vancomycin use decreased from a baseline of 198 DOT to 137 DOT, a 31% reduction. Meropenem use decreased from 103 DOT to 34 DOT, a 67% reduction. These changes were sustained over 24 months. The collective use of gram-negative antibiotics, including meropenem, cefepime, and piperacillin-tazobactam, decreased from a baseline of 323 DOT to 239 DOT, a reduction of 26%. There was no reciprocal increase in cefepime or piperacillin-tazobactam use. Key interventions involved electronic medical record changes, including automatic stop times and empiric antibiotic standardization. All-cause mortality remained unchanged. CONCLUSIONS: The initiation of a dedicated antimicrobial stewardship initiative resulted in a sustained reduction in meropenem and vancomycin usage. Interventions did not lead to increased utilization of alternative broad-spectrum antimicrobials or increased mortality. Future interventions will target additional broad-spectrum antimicrobials. CI - Copyright (c) 2024 the Author(s). Published by Wolters Kluwer Health, Inc. FAU - Hillyer, Margot M AU - Hillyer MM AD - Division of Critical Care Medicine, Department of Pediatrics, Emory University School of Medicine. FAU - Jaggi, Preeti AU - Jaggi P AD - Division of Infectious Disease, Department of Pediatrics, Emory University School of Medicine. FAU - Chanani, Nikhil K AU - Chanani NK AD - Division of Cardiology, Department of Pediatrics, Emory University School of Medicine. FAU - Fernandez, Alfred J AU - Fernandez AJ AD - Department of Pharmacy, Children's Healthcare of Atlanta, Atlanta, GA. FAU - Zaki, Hania AU - Zaki H AD - Department of Pharmacy, Children's Healthcare of Atlanta, Atlanta, GA. FAU - Fundora, Michael P AU - Fundora MP AD - Division of Cardiology, Department of Pediatrics, Emory University School of Medicine. LA - eng PT - Journal Article DEP - 20240205 PL - United States TA - Pediatr Qual Saf JT - Pediatric quality & safety JID - 101702480 PMC - PMC10843537 EDAT- 2024/02/07 06:43 MHDA- 2024/02/07 06:44 PMCR- 2024/02/05 CRDT- 2024/02/07 03:59 PHST- 2023/08/03 00:00 [received] PHST- 2023/11/22 00:00 [accepted] PHST- 2024/02/07 06:44 [medline] PHST- 2024/02/07 06:43 [pubmed] PHST- 2024/02/07 03:59 [entrez] PHST- 2024/02/05 00:00 [pmc-release] AID - 10.1097/pq9.0000000000000710 [doi] PST - epublish SO - Pediatr Qual Saf. 2024 Feb 5;9(1):e710. doi: 10.1097/pq9.0000000000000710. eCollection 2024 Jan-Feb. PMID- 38322273 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240210 IS - 2297-055X (Print) IS - 2297-055X (Electronic) IS - 2297-055X (Linking) VI - 10 DP - 2023 TI - Telemedical management in patients waiting for transcatheter aortic valve implantation: the ResKriVer-TAVI study design. PG - 1352592 LID - 10.3389/fcvm.2023.1352592 [doi] LID - 1352592 AB - AIMS: The majority of patients with severe aortic stenosis (AS) planned for transcatheter aortic valve implantation (TAVI) are elective outpatients. During the COVID-19 pandemic, the time between the heart team's decision and TAVI increased due to limited healthcare resources. We therefore implemented telemedical approaches to identify AS patients at risk for clinical deterioration during the waiting time. The purpose of the prospective, randomized, controlled ResKriVer-TAVI study (DRKS00027842) is to investigate whether a digital concept of telemedical interventional management (TIM) in AS patients waiting for TAVI improves the clinical outcomes. In the present article, we report the study protocol of the ResKriVer-TAVI trial. METHODS: ResKriVer-TAVI will enroll AS patients planned for elective TAVI. Randomization to the TIM group or standard care will be made on the day of the heart team's decision. TIM will include a daily assessment of weight, blood pressure, a 2-channel electrocardiogram, peripheral capillary oxygen saturation, and a self-rated health status until admission for TAVI. TIM will allow optimization of medical therapy or an earlier admission for TAVI if needed. Standard care will not include any additional support for patients with AS. All patients of the TIM group will receive a rule-based TIM including standard operating procedures when a patient is crossing prespecified values of a vital sign. RESULTS: The primary endpoint consists of days lost due to cardiovascular hospitalization and death of any cause within 180 days after the heart team's decision. Major secondary endpoints include all-cause mortality within 365 days, the number of telemedical interventions, and adherence to TIM. Follow-up visits will be conducted at admission for TAVI as well as 6 and 12 months after the heart team's decision. CONCLUSIONS: ResKriVer-TAVI will be the first randomized, controlled trial investigating a telemedical approach before TAVI in patients with AS. We hypothesize that primary and secondary endpoints of AS patients with TIM will be superior to standard care. The study will serve to establish TIM in the clinical routine and to increase the resilience of TAVI centers in situations with limited healthcare resources. CI - (c) 2024 Mattig, Koehler, Barzen, Hiddemann, Kugel, Roemmelt, Mauckisch, Vockeroth, Stangl, Hoppe, Koehler and Dreger. FAU - Mattig, Isabel AU - Mattig I AD - Deutsches Herzzentrum der Charite, Department of Cardiology, Angiology and Intensive Care Medicine, Campus Charite Mitte, Berlin, Germany. AD - Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany. AD - DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Berlin, Germany. AD - Berlin Institute of Health at Charite - Universitatsmedizin Berlin, BIH Biomedical Innovation Academy, Berlin, Germany. FAU - Koehler, Kerstin AU - Koehler K AD - Deutsches Herzzentrum der Charite, Department of Cardiology, Angiology and Intensive Care Medicine, Campus Charite Mitte, Berlin, Germany. AD - Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany. AD - Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Medical Department, Division of Cardiology and Angiology, Centre for Cardiovascular Telemedicine, Berlin, Germany. FAU - Barzen, Gina AU - Barzen G AD - Deutsches Herzzentrum der Charite, Department of Cardiology, Angiology and Intensive Care Medicine, Campus Charite Mitte, Berlin, Germany. AD - Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany. FAU - Hiddemann, Meike AU - Hiddemann M AD - Deutsches Herzzentrum der Charite, Department of Cardiology, Angiology and Intensive Care Medicine, Campus Charite Mitte, Berlin, Germany. AD - Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany. AD - Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Medical Department, Division of Cardiology and Angiology, Centre for Cardiovascular Telemedicine, Berlin, Germany. FAU - Kugel, Elias AU - Kugel E AD - Deutsches Herzzentrum der Charite, Department of Cardiology, Angiology and Intensive Care Medicine, Campus Charite Mitte, Berlin, Germany. AD - Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany. FAU - Roemmelt, Constantin AU - Roemmelt C AD - Deutsches Herzzentrum der Charite, Department of Cardiology, Angiology and Intensive Care Medicine, Campus Charite Mitte, Berlin, Germany. AD - Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany. FAU - Mauckisch, Verena AU - Mauckisch V AD - Deutsches Herzzentrum der Charite, Department of Cardiology, Angiology and Intensive Care Medicine, Campus Charite Mitte, Berlin, Germany. AD - Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany. AD - Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Medical Department, Division of Cardiology and Angiology, Centre for Cardiovascular Telemedicine, Berlin, Germany. FAU - Vockeroth, Clarissa AU - Vockeroth C AD - Deutsches Herzzentrum der Charite, Department of Cardiology, Angiology and Intensive Care Medicine, Campus Charite Mitte, Berlin, Germany. AD - Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany. AD - Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Medical Department, Division of Cardiology and Angiology, Centre for Cardiovascular Telemedicine, Berlin, Germany. FAU - Stangl, Karl AU - Stangl K AD - Deutsches Herzzentrum der Charite, Department of Cardiology, Angiology and Intensive Care Medicine, Campus Charite Mitte, Berlin, Germany. AD - Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany. AD - DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Berlin, Germany. FAU - Hoppe, Thomas AU - Hoppe T AD - Fraunhofer FOKUS, Berlin, Germany. FAU - Koehler, Friedrich AU - Koehler F AD - Deutsches Herzzentrum der Charite, Department of Cardiology, Angiology and Intensive Care Medicine, Campus Charite Mitte, Berlin, Germany. AD - Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany. AD - DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Berlin, Germany. AD - Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Medical Department, Division of Cardiology and Angiology, Centre for Cardiovascular Telemedicine, Berlin, Germany. FAU - Dreger, Henryk AU - Dreger H AD - Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany. AD - DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Berlin, Germany. AD - Deutsches Herzzentrum der Charite, Department of Cardiology, Angiology and Intensive Care Medicine, Campus Virchow Klinikum, Berlin, Germany. LA - eng PT - Journal Article DEP - 20240122 PL - Switzerland TA - Front Cardiovasc Med JT - Frontiers in cardiovascular medicine JID - 101653388 PMC - PMC10844945 OTO - NOTNLM OT - COVID-19 pandemic OT - TAVI OT - aortic stenosis OT - telemedical interventional management OT - transcatheter aortic valve implantation COIS- IM is a participant in the BIH Charite Clinician Scientist Program funded by the Charite - Universitatsmedizin Berlin and the Berlin Institute of Health at Charite (BIH). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2024/02/07 06:43 MHDA- 2024/02/07 06:44 PMCR- 2023/01/01 CRDT- 2024/02/07 03:58 PHST- 2023/12/08 00:00 [received] PHST- 2023/12/28 00:00 [accepted] PHST- 2024/02/07 06:44 [medline] PHST- 2024/02/07 06:43 [pubmed] PHST- 2024/02/07 03:58 [entrez] PHST- 2023/01/01 00:00 [pmc-release] AID - 10.3389/fcvm.2023.1352592 [doi] PST - epublish SO - Front Cardiovasc Med. 2024 Jan 22;10:1352592. doi: 10.3389/fcvm.2023.1352592. eCollection 2023. PMID- 38314600 OWN - NLM STAT- MEDLINE DCOM- 20240722 LR - 20240722 IS - 1874-4729 (Electronic) IS - 1874-4710 (Linking) VI - 17 IP - 3 DP - 2024 TI - An In-depth Analysis of the Adverse Effects of Ionizing Radiation Exposure on Cardiac Catheterization Staffs. PG - 219-228 LID - 10.2174/0118744710283181231229112417 [doi] AB - Diagnostic and interventional angiograms are instrumental in the multidisciplinary approach to CAD management, enabling accurate diagnosis and effective targeted treatments that significantly enhance patient care and cardiovascular outcomes. However, cath lab staff, including interventional cardiologists, is consistently exposed to ionizing radiation, which poses inherent health risks. Radiation exposure in the cath lab primarily results from the use of fluoroscopy and cineangiography during diagnostic and interventional procedures. Understanding these risks and implementing effective radiation protection measurements are imperative to ensure the well-being of healthcare professionals while delivering high-quality cardiac care. Prolonged and repeated exposure can lead to both deterministic and stochastic effects. Deterministic effects, such as skin erythema and tissue damage, are more likely to occur at high radiation doses. Interventional cardiologists and staff may experience these effects when safety measures are not rigorously followed. In fact, while ionizing radiation is essential in the practice of radiation cardiology ward, cath lab staff faces inherent risks from radiation exposure. Stochastic effects, on the other hand, are characterized by a probabilistic relationship between radiation exposure and the likelihood of harm. These effects include the increased risk of cancer, particularly for those with long-term exposure. Interventional cardiologists, due to their frequent presence in the cath lab, face a higher lifetime cumulative radiation dose, potentially elevating their cancer risk. Protective measures, including the use of lead aprons, thyroid shields, and radiation monitoring devices, play a crucial role in reducing radiation exposure for cath lab personnel. Adherence to strict dose optimization protocols, such as minimizing fluoroscopy time and maximizing distance from the radiation source, is also essential in mitigating these risks. Ongoing research and advancements in radiation safety technology are essential in further for minimizing the adverse effects of ionizing radiation in the cath lab. CI - Copyright(c) Bentham Science Publishers; For any queries, please email at epub@benthamscience.net. FAU - Alvandi, Maryam AU - Alvandi M AUID- ORCID: 0000-0002-1829-5068 AD - Cardiovascular Research Center, Hamadan University of Medical Sciences, Hamadan, Iran. AD - Department of Nuclear Medicine and Molecular Imaging, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran. FAU - Javid, Roozbeh Narimani AU - Javid RN AD - Student Research Committee, Hamadan University of Medical Sciences, Hamadan, Iran. FAU - Shaghaghi, Zahra AU - Shaghaghi Z AUID- ORCID: 0000-0002-7467-4820 AD - Cancer Research Center, Hamadan University of Medical Sciences, Hamadan, Iran. FAU - Farzipour, Soghra AU - Farzipour S AUID- ORCID: 0000-0003-4474-6093 AD - Department of Cardiology, Cardiovascular Diseases Research Center, Heshmat Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Guilan, Iran. FAU - Nosrati, Sahar AU - Nosrati S AD - Institute of Nuclear Chemistry and Technology, Dorodna 16 Str, 03-195, Warsaw, Poland. LA - eng PT - Journal Article PT - Review PL - Netherlands TA - Curr Radiopharm JT - Current radiopharmaceuticals JID - 101468718 SB - IM MH - Humans MH - *Occupational Exposure/adverse effects/prevention & control MH - *Cardiac Catheterization/adverse effects MH - *Radiation Exposure/adverse effects MH - *Radiation, Ionizing MH - Radiation Protection/methods MH - Fluoroscopy/adverse effects MH - Radiation Dosage MH - Radiation Injuries/prevention & control/etiology MH - Radiography, Interventional/adverse effects OTO - NOTNLM OT - CAD OT - PCI. OT - Radiation exposure OT - adverse effects OT - cardiac catheterization staffs OT - fluoroscopy EDAT- 2024/02/05 06:43 MHDA- 2024/07/22 06:43 CRDT- 2024/02/05 05:31 PHST- 2023/09/19 00:00 [received] PHST- 2023/10/30 00:00 [revised] PHST- 2023/11/08 00:00 [accepted] PHST- 2024/07/22 06:43 [medline] PHST- 2024/02/05 06:43 [pubmed] PHST- 2024/02/05 05:31 [entrez] AID - CRP-EPUB-137931 [pii] AID - 10.2174/0118744710283181231229112417 [doi] PST - ppublish SO - Curr Radiopharm. 2024;17(3):219-228. doi: 10.2174/0118744710283181231229112417. PMID- 38313339 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240206 IS - 2589-790X (Electronic) IS - 2589-790X (Linking) VI - 6 IP - 1 DP - 2024 Jan TI - Utilization of Shock Team and Veno-Arterial Extracorporeal Membrane Oxygenation (VA-ECMO) in the Management of Cardiogenic Shock in Northern Ontario. PG - 47-53 LID - 10.1016/j.cjco.2023.09.019 [doi] AB - BACKGROUND: Despite advancements in critical care and coronary revascularization, cardiogenic shock (CS) outcomes remain poor. Implementing a shock team and use of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) have been associated with improved CS outcomes, but its feasibility in remote and rural areas remains unknown. METHODS: This retrospective study included patients with CS who required mechanical circulatory support (MCS) at Health Sciences North, Sudbury, Ontario. The analysis aimed to accomplish 2 objectives: first, to review the outcomes associated with use of Impella (Abiomed, Danvers, MA) and, second, to assess the feasibility of establishing a shock team to facilitate the local implementation of VA-ECMO. The primary endpoint was in-hospital mortality. RESULTS: The outcomes of 15 patients with CS who received Impella between 2015 and 2021 were reviewed. Their average age was 65 years (standard deviation [SD]: 13), and 8 patients (53%) were female. CS was ischemic in 12 patients (80%). Transfemoral Impella CP (cardiac power) was the most frequently used (93%). Thirteen patients (87%) died during the index hospital stay post-Impella because of progressive circulatory failure. The shock team was established following consultations with several Canadian MCS centres, leading to the development of a protocol to guide use of MCS. There have been 4 cases in which percutaneous VA-ECMO using Cardiohelp (Getinge/Maquet, Wayne, NJ) has been used; 3 (75%) survived beyond the index hospitalization. CONCLUSIONS: This analysis demonstrated the feasibility of implementing a shock team in remote Northern Ontario, enabling the use of VA-ECMO with success in a centre with a sizeable rural catchment area. This initiative helps address the gap in cardiac care outcomes between rural and urban areas in Ontario. CI - (c) 2023 The Authors. FAU - Alnasser, Sami AU - Alnasser S AD - Division of Cardiology, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada. FAU - Cavanagh, Matthew AU - Cavanagh M AD - Division of Critical Care, Health Sciences North, Sudbury, Ontario, Canada. AD - Northern Ontario School of Medicine, Sudbury, Ontario, Canada. FAU - Atoui, Rony AU - Atoui R AD - Northern Ontario School of Medicine, Sudbury, Ontario, Canada. AD - Division of Cardiac Surgery, Sudbury, Ontario, Canada. FAU - Ali, Noman AU - Ali N AD - Division of Cardiology, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada. FAU - Nalla, Bhanu AU - Nalla B AD - Division of Critical Care, Health Sciences North, Sudbury, Ontario, Canada. AD - Northern Ontario School of Medicine, Sudbury, Ontario, Canada. FAU - McKechnie, Kyle AU - McKechnie K AD - Division of Critical Care, Health Sciences North, Sudbury, Ontario, Canada. AD - Northern Ontario School of Medicine, Sudbury, Ontario, Canada. FAU - Main, Anthony AU - Main A AD - Northern Ontario School of Medicine, Sudbury, Ontario, Canada. AD - Division of Cardiology, Health Sciences North, Sudbury, Ontario, Canada. FAU - Rheault-Henry, Mathieu AU - Rheault-Henry M AD - Northern Ontario School of Medicine, Sudbury, Ontario, Canada. FAU - Al-Shaibi, AbdulAziz AU - Al-Shaibi A AD - Division of Cardiology, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada. FAU - Burke, Lucas AU - Burke L AD - Division of Cardiology, Health Sciences North, Sudbury, Ontario, Canada. FAU - McIsaac, Sarah AU - McIsaac S AD - Division of Critical Care, Health Sciences North, Sudbury, Ontario, Canada. AD - Northern Ontario School of Medicine, Sudbury, Ontario, Canada. FAU - Anderson, Robert AU - Anderson R AD - Division of Critical Care, Health Sciences North, Sudbury, Ontario, Canada. AD - Northern Ontario School of Medicine, Sudbury, Ontario, Canada. FAU - Fam, Neil AU - Fam N AD - Division of Cardiology, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada. FAU - Shurrab, Mohammed AU - Shurrab M AD - Northern Ontario School of Medicine, Sudbury, Ontario, Canada. AD - Division of Cardiology, Health Sciences North, Sudbury, Ontario, Canada. FAU - Kerr, Mary Catherine AU - Kerr MC AD - Division of Critical Care, Health Sciences North, Sudbury, Ontario, Canada. AD - Northern Ontario School of Medicine, Sudbury, Ontario, Canada. FAU - Hennessey, Hooman AU - Hennessey H AD - Division of Radiology, Health Sciences North, Sudbury, Ontario, Canada. FAU - Armstrong, Craig AU - Armstrong C AD - Division of Critical Care, Health Sciences North, Sudbury, Ontario, Canada. FAU - Bittira, Bindu AU - Bittira B AD - Northern Ontario School of Medicine, Sudbury, Ontario, Canada. AD - Division of Cardiac Surgery, Sudbury, Ontario, Canada. FAU - Alqahtani, Abdulrahman AU - Alqahtani A AD - Division of Cardiology, Health Sciences North, Sudbury, Ontario, Canada. FAU - Papadopoulos, Gregory AU - Papadopoulos G AD - Northern Ontario School of Medicine, Sudbury, Ontario, Canada. AD - Division of Cardiology, Health Sciences North, Sudbury, Ontario, Canada. FAU - Kumar, Andreas AU - Kumar A AD - Northern Ontario School of Medicine, Sudbury, Ontario, Canada. AD - Division of Cardiology, Health Sciences North, Sudbury, Ontario, Canada. FAU - MacDonald, Derek AU - MacDonald D AD - Division of Cardiac Surgery, Sudbury, Ontario, Canada. FAU - O'Connor, Cormac AU - O'Connor C AD - Division of Cardiology, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada. FAU - McDonald, Michael AU - McDonald M AD - Division of Cardiology, Peter Munk Cardiac Center, Toronto General Hospital, Toronto, Ontario, Canada. FAU - Manchuk, Derek AU - Manchuk D AD - Division of Critical Care, Health Sciences North, Sudbury, Ontario, Canada. AD - Northern Ontario School of Medicine, Sudbury, Ontario, Canada. LA - eng PT - Journal Article DEP - 20231003 PL - United States TA - CJC Open JT - CJC open JID - 101763635 PMC - PMC10837701 EDAT- 2024/02/05 06:43 MHDA- 2024/02/05 06:44 PMCR- 2023/10/03 CRDT- 2024/02/05 04:39 PHST- 2023/05/07 00:00 [received] PHST- 2023/09/28 00:00 [accepted] PHST- 2024/02/05 06:44 [medline] PHST- 2024/02/05 06:43 [pubmed] PHST- 2024/02/05 04:39 [entrez] PHST- 2023/10/03 00:00 [pmc-release] AID - S2589-790X(23)00263-9 [pii] AID - 10.1016/j.cjco.2023.09.019 [doi] PST - epublish SO - CJC Open. 2023 Oct 3;6(1):47-53. doi: 10.1016/j.cjco.2023.09.019. eCollection 2024 Jan. PMID- 38311228 OWN - NLM STAT- MEDLINE DCOM- 20240305 LR - 20240305 IS - 2093-7482 (Electronic) IS - 1976-1317 (Linking) VI - 18 IP - 1 DP - 2024 Feb TI - Association Between Nurse-Led Multidisciplinary Education and Cardiac Events in Patients With Heart Failure: A Retrospective Chart Review. PG - 60-67 LID - S1976-1317(24)00009-4 [pii] LID - 10.1016/j.anr.2024.01.009 [doi] AB - PURPOSE: This study examined the modifiable factors, including nurse-led multidisciplinary education and in/out-of-hospital rehabilitation, to predict cardiac events in patients with heart failure (HF) in South Korea. METHODS: A retrospective review of the medical records was conducted using data of patients admitted for HF between June 2021 and April 2022. A total of 342 patients were included in this study. Information related to HF education, cardiac rehabilitation, and demographic and clinical characteristics were collected. Cardiac events, including emergency department visits, readmissions, and deaths, were defined as a composite of events. After adjusting for covariates, a multivariate Cox proportional hazard regression model was used to explore the association between modifiable factors and cardiac events in patients with HF. RESULTS: During the follow-up period (median, 823 days), 123 patients (36.0%) experienced at least one cardiac event. In the Cox regression model, patients who received nurse-led multidisciplinary HF education during hospitalization were less likely to experience cardiac events (hazard ratio: 0.487; 95% confidence interval [CI]:0.239-0.993). Additionally, high NT-pro BNP levels were associated with an increased risk of cardiac events. CONCLUSIONS: The education led by nurses on HF was a factor that reduced adverse prognoses in patients with HF. Our results highlight the importance of a nurse-led multidisciplinary approach during hospitalization. CI - Copyright (c) 2024. Published by Elsevier B.V. FAU - Son, Haeng-Mi AU - Son HM AD - Department of Nursing, University of Ulsan, Ulsan, Republic of Korea. Electronic address: sonhm@ulsan.ac.kr. FAU - Lee, Hyeongsuk AU - Lee H AD - College of Nursing, Gachon University, Incheon, Republic of Korea. Electronic address: leehyeongsuk@gachon.ac.kr. LA - eng PT - Journal Article DEP - 20240202 PL - Korea (South) TA - Asian Nurs Res (Korean Soc Nurs Sci) JT - Asian nursing research JID - 101321326 SB - IM MH - Humans MH - Retrospective Studies MH - *Nurse's Role MH - *Heart Failure/complications MH - Hospitalization MH - Prognosis OTO - NOTNLM OT - education OT - heart failure OT - nursing OT - patient care team OT - patient education as topic EDAT- 2024/02/05 00:42 MHDA- 2024/03/05 06:48 CRDT- 2024/02/04 19:32 PHST- 2023/08/31 00:00 [received] PHST- 2024/01/28 00:00 [revised] PHST- 2024/01/29 00:00 [accepted] PHST- 2024/03/05 06:48 [medline] PHST- 2024/02/05 00:42 [pubmed] PHST- 2024/02/04 19:32 [entrez] AID - S1976-1317(24)00009-4 [pii] AID - 10.1016/j.anr.2024.01.009 [doi] PST - ppublish SO - Asian Nurs Res (Korean Soc Nurs Sci). 2024 Feb;18(1):60-67. doi: 10.1016/j.anr.2024.01.009. Epub 2024 Feb 2. PMID- 38309610 OWN - NLM STAT- MEDLINE DCOM- 20240318 LR - 20260105 IS - 1097-6744 (Electronic) IS - 0002-8703 (Linking) VI - 270 DP - 2024 Apr TI - TransCatheter aortic valve implantation and fractional flow reserve-guided percutaneous coronary intervention versus conventional surgical aortic valve replacement and coronary bypass grafting for treatment of patients with aortic valve stenosis and multivessel or advanced coronary disease: The transcatheter valve and vessels trial (TCW trial): Design and rationale. PG - 86-94 LID - S0002-8703(24)00019-X [pii] LID - 10.1016/j.ahj.2024.01.010 [doi] AB - BACKGROUND: Patients with severe aortic stenosis (AS) frequently present with concomitant obstructive coronary artery disease (CAD). In those, current guidelines recommend combined coronary artery bypass grafting (CABG) and surgical aortic valve replacement (SAVR) as the preferred treatment option, although this surgical approach is associated with a high rate of clinical events. Combined transcatheter aortic valve implantation (TAVI) and percutaneous coronary intervention (PCI) with or without FFR have evolved as a valid alternative for cardiac surgery in patients with AS and multivessel or advanced CAD. To date, no dedicated trial has prospectively evaluated the outcomes of a percutaneous versus surgical treatment for patients with both severe AS and CAD. AIMS: To investigate whether fractional-flow reserve (FFR)-guided PCI and TAVI is noninferior to combined CABG and SAVR for the treatment of severe AS and multivessel or advanced CAD. METHODS: The Transcatheter Valve and Vessels (TCW) trial (clinicaltrial.gov: NCT03424941) is a prospective, randomized, controlled, open label, international trial. Patients >/= 70 years with severe AS and multivessel (>/= 2 vessels) or advanced CAD, deemed feasible by the heart team for both; a full percutaneous or surgical treatment, will be randomised in a 1:1 fashion to either FFR-guided PCI followed by TAVI (intervention arm) vs. CABG and SAVR (control arm). The primary endpoint is a patient-oriented composite of all-cause mortality, myocardial infarction, disabling stroke, unscheduled clinically-driven target vessel revascularization, valve reintervention, and life threatening or disabling bleeding at 1 year. The TCW trial is powered for noninferiority, and if met, superiority will be tested. Assuming a primary endpoint rate of 30% in the CABG-SAVR arm, with a significance level alpha of 5%, a noninferiority limit delta of 15% and a loss to follow-up of 2%, a total of 328 patients are needed to obtain a power of 90%. The primary endpoint analysis is performed on an intention-to-treat basis. SUMMARY: The TCW Trial is the first prospective randomized trial that will study if a less invasive percutaneous treatment for severe AS and concomitant advanced CAD (i.e., FFR-guided PCI-TAVI) is noninferior to the guidelines recommended approach (CABG-SAVR). CI - Copyright (c) 2024 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Kedhi, Elvin AU - Kedhi E AD - McGill University Health Center, Montreal, Quebec, Canada; Department of Cardiology and Structural Heart Disease, Medical University of Silesia, Katowice, Poland. Electronic address: ekedhi@me.com. FAU - Rroku, Andi AU - Rroku A AD - Department of Cardiology, Deutsches Herzzentrum der Charite, Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany; DZHK (German Centre for Cardiovascular Research), Berlin, Germany. FAU - Hermanides, Rik S AU - Hermanides RS AD - Isala Heart Center, Department of Cardiology, Zwolle, The Netherlands. FAU - Dambrink, Jan Henk AU - Dambrink JH AD - Isala Heart Center, Department of Cardiology, Zwolle, The Netherlands. FAU - Singh, Sandeep AU - Singh S AD - Isala Heart Center, Department of Thoracic Surgery, Zwolle, The Netherlands. FAU - Berg, Jurrien Ten AU - Berg JT AD - St.Antonius Ziekenhuis, Nieuwegein, The Netherlands and University Medical Center Maastricht, Maastricht, The Netherlands. FAU - van Ginkel, Dirk-Jan AU - van Ginkel DJ AD - St.Antonius Ziekenhuis, Nieuwegein, The Netherlands and University Medical Center Maastricht, Maastricht, The Netherlands. FAU - Hudec, Martin AU - Hudec M AD - SUSCCH, A.S. Banska, Bystrica, Slovak Republic. FAU - Amoroso, Giovanni AU - Amoroso G AD - Department of Cardiology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands. FAU - Amat-Santos, Ignacio J AU - Amat-Santos IJ AD - Centro de Investigacion Biomdica en Red, Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain; Hospital Clinico Universitario de Valladolid, Valladolid, Spain. FAU - Andreas, Martin AU - Andreas M AD - Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria. FAU - Teles, Rui Campante AU - Teles RC AD - Hospital de Santa Cruz, Centro Hospitalar de Lisboa Ocidental, Lisbon, Portugal. FAU - Bonnet, Guillaume AU - Bonnet G AD - Medico-Surgical Department (Valvulopathies, Cardiac Surgery, Adult Interventional Cardiology), Hopital Cardiologique de Haut-Leveque, Bordeaux University Hospital, France. FAU - Van Belle, Eric AU - Van Belle E AD - CHU Lille, Department of Cardiology, Department of Interventional Cardiology for Coronary, Valves and Structural Heart Diseases, Institut Coeur Puomon, Inserm, U1011, Institut Pasteur de Lille, EGIG, Universite de Lille, Lille, France. FAU - Conradi, Lenard AU - Conradi L AD - Department of Cardiovascular Surgery, University Heart and Vascular Center Hamburg, Germany. FAU - van Garsse, Leen AU - van Garsse L AD - Department of Cardiothoracic Surgery, Radboud University Medical Centre, The Netherlands. FAU - Wojakowski, Wojtek AU - Wojakowski W AD - Department of Cardiology and Structural Heart Disease, Medical Univ. Silesia, Katowice, Poland. FAU - Voudris, Vasileious AU - Voudris V AD - Interventional Department of Cardiology, Onassis Cardiac Surgery Center, Athens, Greece. FAU - Sacha, Jerzy AU - Sacha J AD - Department of Cardiology, University Hospital, Institute of Medical Sciences, University of Opole, Opole, Poland; Faculty of Physical Education and Physiotherapy, Opole University of Technology, Opole, Poland. FAU - Cervinka, Pavel AU - Cervinka P AD - Department of Cardiology, Krajska Zdravotni A.S., Masaryk Hospital and UJEP Usti nad Labem, Czech Republic. FAU - Lipsic, Erik AU - Lipsic E AD - Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. FAU - Somi, Samer AU - Somi S AD - Department of Cardiology, Haga Hospital, The Hague, The Netherlands. FAU - Nombela-Franco, Luis AU - Nombela-Franco L AD - Cardiovascular Institute, Hospital Clinico San Carlos IdISSC, Madrid, Spain. FAU - Postma, Sonja AU - Postma S AD - Diagram Research, Zwolle, The Netherlands. FAU - Piayda, Kerstin AU - Piayda K AD - Department of Cardiology and Vascular Medicine, Medical Faculty, Justus-Liebig-University Giessen, Giessen, Germany. FAU - De Luca, Giuseppe AU - De Luca G AD - Division of Clinical and Experimental Cardiology, AOU Sassari, University of Sassari, Sassari, Italy. FAU - Malinofski, Krzysztof AU - Malinofski K AD - Center for Digital Medicine and Robotics, Jagiellonian University Medical College, Krakow, Poland; Department of Bioinformatics and Telemedicine, Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland. FAU - Modine, Thomas AU - Modine T AD - Medico-Surgical Department (Valvulopathies, Cardiac Surgery, Adult Interventional Cardiology), Hopital Cardiologique de Haut-Leveque, Bordeaux University Hospital, France. LA - eng SI - ClinicalTrials.gov/NCT03424941 PT - Clinical Trial Protocol PT - Journal Article DEP - 20240201 PL - United States TA - Am Heart J JT - American heart journal JID - 0370465 SB - IM MH - Humans MH - *Coronary Artery Disease/complications/diagnosis/surgery MH - Aortic Valve/surgery MH - *Transcatheter Aortic Valve Replacement MH - *Fractional Flow Reserve, Myocardial MH - *Percutaneous Coronary Intervention/adverse effects MH - Prospective Studies MH - Coronary Artery Bypass MH - *Aortic Valve Stenosis/complications/diagnosis/surgery MH - Treatment Outcome MH - Randomized Controlled Trials as Topic COIS- Conflict of interest E.K. reports institutional research grants support from Abbott Vascular Laboratories and Medtronic as well as proctor/lecture fees from Abbott Vascular. R.H. reports lecture fees from Abbott Vascular, Amgen, Novartis. M.H. reports proctor for Meril Life. I.A.S. reports proctor for Boston Scientific, Medtronic and Meril Life. M.A. reports proctor/speaker/consultant fees from Edwards, Abbott, Medtronic, Boston, Zoll, Abbvie and received institutional research grants Edwards, Abbott, Medtronic, LSI. L.C: Advisory Board member for Abbott, Medtronic and JenaValve, consultant for Edwards Lifesciences, Boston Scientific, PiCardia, MicroPort, MicroInterventions. W. Wojakowski: Medtronic advisory board, lecture fees from Edwards Lifesciences, Abbott, Medtronic; E.L.Institutional Research from Abbott Medical Netherlands. All other authors don't report any conflict of interest. EDAT- 2024/02/04 00:42 MHDA- 2024/03/18 06:42 CRDT- 2024/02/03 19:33 PHST- 2023/08/08 00:00 [received] PHST- 2024/01/28 00:00 [revised] PHST- 2024/01/29 00:00 [accepted] PHST- 2024/03/18 06:42 [medline] PHST- 2024/02/04 00:42 [pubmed] PHST- 2024/02/03 19:33 [entrez] AID - S0002-8703(24)00019-X [pii] AID - 10.1016/j.ahj.2024.01.010 [doi] PST - ppublish SO - Am Heart J. 2024 Apr;270:86-94. doi: 10.1016/j.ahj.2024.01.010. Epub 2024 Feb 1. PMID- 38305384 OWN - NLM STAT- MEDLINE DCOM- 20240624 LR - 20260508 IS - 1535-2900 (Electronic) IS - 1079-2082 (Linking) VI - 81 IP - 13 DP - 2024 Jun 24 TI - Pharmacy residency training program increases residents' confidence in inpatient medical emergency response. PG - e372-e378 LID - 10.1093/ajhp/zxae021 [doi] AB - PURPOSE: The benefits of pharmacists' involvement in medical emergencies are well established, but optimal methods of training pharmacists for emergency response are unknown. The primary objective of this report is to describe the design and evaluation of a pharmacy resident medical emergency response training (PR-MERT) program for preparing trainees to respond to hospital medical emergencies, including cardiac arrest and rapid sequence intubation (RSI). SUMMARY: The PR-MERT program was a year-long longitudinal experience designed to prepare postgraduate year 1 pharmacy residents for medical emergency response. During the first month, the residents completed an orientation session that encompassed several lectures, certification by the American Heart Association in basic life support and advanced cardiovascular life support, standardized simulation scenarios, and mock medical emergencies. The trainees continued to utilize these skills and clinical knowledge through a longitudinal didactic lecture series, resident case conferences, and practice-based application by responding to real-life medical emergencies. Residents were assessed and coached throughout the program by clinical pharmacy preceptors and a "code coach" with extensive medical emergency response experience. After the year-long training, residents completed an anonymous survey assessing self-confidence and the structure of the program. The results showed improved confidence in medication selection and dosing, as well as anticipating the needs of the team and speaking up in cardiac arrest and RSI situations. Residents were satisfied with the training offered and structure of the program. CONCLUSION: The development of a PR-MERT program at an academic medical center was successful in achieving longitudinal learning objectives and improving residents' confidence in responding to medical emergencies. The implementation of a similar medical emergency training curriculum in inpatient pharmacy residency programs may be beneficial. CI - (c) American Society of Health-System Pharmacists 2024. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com. FAU - Shigle, Amanda Jo AU - Shigle AJ AD - West Virginia University Medicine, Morgantown, WV, USA. FAU - Piechowski, Kara AU - Piechowski K AD - West Virginia University Medicine, Morgantown, WV, USA. FAU - Sandoval, Nicholas AU - Sandoval N AD - West Virginia University Medicine, Morgantown, WV, USA. FAU - Chiplinski, Amber AU - Chiplinski A AD - West Virginia University Medicine, Morgantown, WV, USA. FAU - Hays, William Blake AU - Hays WB AD - Indiana University Health West Hospital, Avon, IN, USA. LA - eng PT - Journal Article PL - England TA - Am J Health Syst Pharm JT - American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists JID - 9503023 SB - IM MH - Humans MH - *Pharmacy Residencies MH - *Clinical Competence MH - Pharmacy Service, Hospital/organization & administration MH - Education, Pharmacy, Graduate/methods MH - Pharmacists/organization & administration OTO - NOTNLM OT - cardiac arrest OT - code blue OT - emergency response OT - pharmacy education OT - pharmacy residency OT - pharmacy training EDAT- 2024/02/02 12:42 MHDA- 2024/06/24 06:41 CRDT- 2024/02/02 09:29 PHST- 2024/06/24 06:41 [medline] PHST- 2024/02/02 12:42 [pubmed] PHST- 2024/02/02 09:29 [entrez] AID - 7596607 [pii] AID - 10.1093/ajhp/zxae021 [doi] PST - ppublish SO - Am J Health Syst Pharm. 2024 Jun 24;81(13):e372-e378. doi: 10.1093/ajhp/zxae021. PMID- 38303019 OWN - NLM STAT- MEDLINE DCOM- 20240213 LR - 20260109 IS - 1745-6215 (Electronic) IS - 1745-6215 (Linking) VI - 25 IP - 1 DP - 2024 Feb 1 TI - The ROCK trial-a multidisciplinary Rehabilitation intervention for sudden Out-of-hospital Cardiac arrest survivors focusing on return-to-worK: a pragmatic randomized controlled trial protocol. PG - 99 LID - 10.1186/s13063-024-07911-6 [doi] LID - 99 AB - INTRODUCTION: Most cardiac arrest survivors are classified with mild to moderate cognitive impairment; roughly, 50% experience long-term neurocognitive impairment. Postarrest challenges complicate participation in society and are associated with social issues such as failure to resume social activities and impaired return to work. The effectiveness of rehabilitation interventions for out-of-hospital cardiac arrest survivors are sparsely described, but the body of evidence describes high probabilities of survivors not returning to work, returning to jobs with modified job descriptions, returning to part-time employment, and often in combination with extensive unmet rehabilitation needs. Hence, there is a need to develop and test a pragmatic individual targeted intervention to facilitate return to work (RTW) in survivors of OHCA. The overall aim of the ROCK trial is to evaluate the effectiveness of a comprehensive individually tailored multidisciplinary rehabilitation intervention for survivors of OHCA on RTW compared to usual care. METHODS AND ANALYSIS: The ROCK trial is a two-arm parallel group multicentre investigator-initiated pragmatic randomized controlled superiority trial with primary endpoint measured 12 months after the cardiac arrest. Adult survivors who were part of the labour force prior to the OCHA and had at least 2 years until they are qualified to receive retirement state pensions are eligible for inclusion. Survivors will be randomized 1:1 to usual care group or usual care plus a comprehensive tailored rehabilitation intervention focusing on supporting RTW. After comprehensive assessment of individual rehabilitation needs, the intervention is ongoingly coordinated within a multidisciplinary rehabilitation team, and the intervention can be delivered for up until 12 months. Data for the primary outcome will be obtained from the national register on social transfer payments. The primary outcome will be analysed using logistic regression assessing RTW status at 12 months adjusting for the intervention and age at OHCA, sex, marital status, and occupation prior to OHCA. DISCUSSION: The ROCK trial is the first RCT to investigate the effectiveness of a rehabilitation intervention focusing on return to work after cardiac arrest. TRIAL REGISTRATION: ClinicalTrials.gov NCT05173740. Registered on May 2018. CI - (c) 2024. The Author(s). FAU - Christensen, Jan AU - Christensen J AUID- ORCID: 0000-0003-1114-7465 AD - Department of Occupational Therapy and Physiotherapy, Copenhagen University Hospital-Rigshospitalet, 2100, Copenhagen, Denmark. jan.christensen.02@regionh.dk. AD - Department of Public Health, University of Copenhagen, Copenhagen, Denmark. jan.christensen.02@regionh.dk. FAU - Winkel, Bo Gregers AU - Winkel BG AD - Department of Cardiology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark. FAU - Kirkeskov, Lilli AU - Kirkeskov L AD - Center of Social Medicine, Copenhagen University Hospital-Bispebjerg and Frederiksberg, Copenhagen, Denmark. FAU - Folke, Fredrik AU - Folke F AD - Department of Cardiology, Copenhagen University Hospital-Herlev and Gentofte Hospital, Hellerup, Denmark. AD - Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. FAU - Winther-Jensen, Matilde AU - Winther-Jensen M AD - Department of Data, Biostatistics and Pharmacoepidemiology, Center for Clinical Research and Prevention, Copenhagen University Hospital-Bispebjerg and Frederiksberg, Copenhagen, Denmark. FAU - Eckhardt-Bentsen, Christine AU - Eckhardt-Bentsen C AD - Center of Social Medicine, Copenhagen University Hospital-Bispebjerg and Frederiksberg, Copenhagen, Denmark. FAU - Kjaergaard, Jesper AU - Kjaergaard J AD - Department of Cardiology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark. AD - Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. FAU - Hassager, Christian AU - Hassager C AD - Department of Cardiology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark. AD - Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. FAU - Wagner, Mette Kirstine AU - Wagner MK AD - Department of Cardiology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark. LA - eng SI - ClinicalTrials.gov/NCT05173740 PT - Clinical Trial Protocol PT - Journal Article DEP - 20240201 PL - England TA - Trials JT - Trials JID - 101263253 SB - IM MH - Adult MH - Humans MH - Employment MH - Multicenter Studies as Topic MH - *Out-of-Hospital Cardiac Arrest/diagnosis/therapy MH - Randomized Controlled Trials as Topic MH - Rehabilitation, Vocational/methods MH - *Return to Work MH - Survivors/psychology MH - Pragmatic Clinical Trials as Topic MH - Equivalence Trials as Topic PMC - PMC10835971 OTO - NOTNLM OT - Cardiac arrest OT - Cardiac rehabilitation OT - Rehabilitation OT - Return-to-work OT - Sudden cardiac arrest COIS- The authors declares that they have no competing interests. EDAT- 2024/02/02 06:43 MHDA- 2024/02/05 06:42 PMCR- 2024/02/01 CRDT- 2024/02/02 00:08 PHST- 2023/06/01 00:00 [received] PHST- 2024/01/03 00:00 [accepted] PHST- 2024/02/05 06:42 [medline] PHST- 2024/02/02 06:43 [pubmed] PHST- 2024/02/02 00:08 [entrez] PHST- 2024/02/01 00:00 [pmc-release] AID - 10.1186/s13063-024-07911-6 [pii] AID - 7911 [pii] AID - 10.1186/s13063-024-07911-6 [doi] PST - epublish SO - Trials. 2024 Feb 1;25(1):99. doi: 10.1186/s13063-024-07911-6. PMID- 38301611 OWN - NLM STAT- MEDLINE DCOM- 20240424 LR - 20260527 IS - 1664-5502 (Electronic) IS - 1664-5502 (Linking) VI - 14 IP - 1 DP - 2024 TI - Practical Requirements for the Development of an Advanced Cardiorenal Unit. PG - 136-146 LID - 10.1159/000536104 [doi] AB - BACKGROUND: Heart failure is frequently associated with kidney disease, and patients with kidney disease are at increased risk of heart failure. The co-occurrence of both entities not only significantly increases morbidity and mortality but also complicates therapy. SUMMARY: Cardiorenal syndrome often requires a broad, comprehensive, and multidisciplinary approach. As a result, a need has arisen to create specialized cardiorenal units that allow for rigorous and personalized management of this condition. Moreover, in some cases, cardiorenal syndrome is more complex, owing to an acute and critical situation that requires the concept of the cardiorenal unit to be extended toward advanced diagnostic and therapeutic positions, thus confirming the need for an advanced cardiorenal unit. The creation of these units constitutes a real challenge, necessitating a specific multilevel action plan, covering governance and management, type of patient, personnel requirements, service portfolio, care process, information systems, and other resources. Specific lines of action must be proposed for each of the relevant points in order to facilitate development of these units, together with continuous evaluation of unit activity through specific indicators, and to detect areas for improvement. KEY MESSAGES: This study addresses the conditions and organizational characteristics that enable the creation, development, and continuous improvement of advanced cardiorenal units. CI - (c) 2024 The Author(s). Published by S. Karger AG, Basel. FAU - Almenar-Bonet, Luis AU - Almenar-Bonet L AD - Heart Failure and Transplantation Unit, Hospital Universitari i Politecnic La Fe, Valencia, Spain. AD - Cardiology Department, Hospital Universitari i Politecnic La Fe, Valencia, Spain. AD - Centro de Investigacion Biomedica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain. FAU - Sanchez-Lazaro, Ignacio AU - Sanchez-Lazaro I AD - Heart Failure and Transplantation Unit, Hospital Universitari i Politecnic La Fe, Valencia, Spain. AD - Cardiology Department, Hospital Universitari i Politecnic La Fe, Valencia, Spain. AD - Centro de Investigacion Biomedica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain. FAU - Soldevila, Amparo AU - Soldevila A AD - Chronic Kidney Disease and Renal Replacement Therapy Section, Hospital Universitari i Politecnic La Fe, Valencia, Spain. AD - Nephrology Department, Hospital Universitari i Politecnic La Fe, Valencia, Spain. FAU - Lopez-Vilella, Raquel AU - Lopez-Vilella R AD - Heart Failure and Transplantation Unit, Hospital Universitari i Politecnic La Fe, Valencia, Spain. AD - Cardiology Department, Hospital Universitari i Politecnic La Fe, Valencia, Spain. FAU - Donoso Trenado, Victor AU - Donoso Trenado V AD - Heart Failure and Transplantation Unit, Hospital Universitari i Politecnic La Fe, Valencia, Spain. AD - Cardiology Department, Hospital Universitari i Politecnic La Fe, Valencia, Spain. FAU - Devesa, Ramon AU - Devesa R AD - Chronic Kidney Disease and Renal Replacement Therapy Section, Hospital Universitari i Politecnic La Fe, Valencia, Spain. AD - Nephrology Department, Hospital Universitari i Politecnic La Fe, Valencia, Spain. FAU - Carmona, Paula AU - Carmona P AD - Anesthesia and Critical Care Department Hospital Universitari i Politecnic La Fe, Valencia, Spain. FAU - Tormo, Sergi AU - Tormo S AD - Intensive Care Department, Hospital Universitari i Politecnic La Fe, Valencia, Spain. FAU - Montero Hernandez, Maria Jesus AU - Montero Hernandez MJ AD - Anesthesia and Critical Care Department Hospital Universitari i Politecnic La Fe, Valencia, Spain. FAU - Hernandez, Julio AU - Hernandez J AD - Chronic Kidney Disease and Renal Replacement Therapy Section, Hospital Universitari i Politecnic La Fe, Valencia, Spain. AD - Nephrology Department, Hospital Universitari i Politecnic La Fe, Valencia, Spain. FAU - Martinez Dolz, Luis AU - Martinez Dolz L AD - Cardiology Department, Hospital Universitari i Politecnic La Fe, Valencia, Spain. AD - Centro de Investigacion Biomedica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain. FAU - Sanchez-Perez, Pilar AU - Sanchez-Perez P AD - Chronic Kidney Disease and Renal Replacement Therapy Section, Hospital Universitari i Politecnic La Fe, Valencia, Spain. AD - Nephrology Department, Hospital Universitari i Politecnic La Fe, Valencia, Spain. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20240216 PL - Switzerland TA - Cardiorenal Med JT - Cardiorenal medicine JID - 101554863 SB - IM MH - Humans MH - *Cardio-Renal Syndrome/therapy/physiopathology/diagnosis MH - Heart Failure/therapy MH - Hospital Units/organization & administration OTO - NOTNLM OT - Advanced cardiorenal clinics OT - Cardiorenal syndrome OT - Cardiorenal unit OT - Heart failure OT - Kidney disease EDAT- 2024/02/02 00:42 MHDA- 2024/04/25 00:54 CRDT- 2024/02/01 18:26 PHST- 2023/06/05 00:00 [received] PHST- 2023/12/15 00:00 [accepted] PHST- 2024/04/25 00:54 [medline] PHST- 2024/02/02 00:42 [pubmed] PHST- 2024/02/01 18:26 [entrez] AID - 000536104 [pii] AID - 10.1159/000536104 [doi] PST - ppublish SO - Cardiorenal Med. 2024;14(1):136-146. doi: 10.1159/000536104. Epub 2024 Feb 16. PMID- 38300318 OWN - NLM STAT- MEDLINE DCOM- 20250421 LR - 20261010 IS - 1432-1971 (Electronic) IS - 0172-0643 (Linking) VI - 46 IP - 2 DP - 2025 Feb TI - Improving Palivizumab Administration to High-Risk Infants with Heart Disease via a Communication-Based Quality Improvement Initiative. PG - 287-295 LID - 10.1007/s00246-023-03388-3 [doi] AB - To improve palivizumab administration in high-risk infants with congenital heart disease to 80% over 2 years at an academic children's heart center. A multidisciplinary team at our institution implemented a series of interventions over a 2-year prior. Pediatric cardiac patients were identified for palivizumab eligibility, and a baseline rate of administration was obtained. A series of communication and documentation-based interventions were implemented over the course of the next 2 years. Palivizumab eligible infants (n = 114) were determined based on guidelines after review of diagnosis code, oxygen saturation, and medications. Doses of palivizumab were tracked via the electronic health record. The primary outcome measures were the rate of monthly palivizumab doses administered per the number of eligible months and the percentage of infants who received at least 80% of eligible doses during the respiratory syncytial virus season. The rate of monthly palivizumab doses increased from 57.6% during the baseline period to 78.4% during the final year of the project (p = 0.02). The percentage of infants who received 80% of eligible doses increased from 42.1 to 60% but was not statistically significant (p = 0.20). Interventions focused on properly identifying and tracking infants eligible for palivizumab treatment significantly increased the rates of administration. CI - (c) 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Leone, David M AU - Leone DM AUID- ORCID: 0000-0002-4296-4081 AD - Section of Pediatric Cardiology, Yale University School of Medicine, PO Box 208064, New Haven, CT, 06520-8064, USA. FAU - Rodriguez, Alexis AU - Rodriguez A AD - Department of Pediatrics, Yale University School of Medicine, New Haven, CT, USA. FAU - Cowenhoven, Kirsten AU - Cowenhoven K AD - Section of Pediatric Cardiology, Yale University School of Medicine, PO Box 208064, New Haven, CT, 06520-8064, USA. FAU - O'Connell, Matthew AU - O'Connell M AD - Section of Pediatric Cardiology, Yale University School of Medicine, PO Box 208064, New Haven, CT, 06520-8064, USA. AD - Department of Pharmacy, Yale New Haven Hospital, New Haven, CT, USA. FAU - Grossman, Matthew AU - Grossman M AD - Department of Pediatrics, Yale University School of Medicine, New Haven, CT, USA. FAU - Ferdman, Dina AU - Ferdman D AD - Section of Pediatric Cardiology, Yale University School of Medicine, PO Box 208064, New Haven, CT, 06520-8064, USA. dina.ferdman@yale.edu. LA - eng PT - Journal Article DEP - 20240201 PL - United States TA - Pediatr Cardiol JT - Pediatric cardiology JID - 8003849 RN - DQ448MW7KS (Palivizumab) RN - 0 (Antiviral Agents) RN - 0 (Antibodies, Monoclonal, Humanized) SB - IM MH - Humans MH - *Palivizumab/administration & dosage MH - Infant MH - *Antiviral Agents/administration & dosage MH - *Respiratory Syncytial Virus Infections/prevention & control/drug therapy MH - *Heart Defects, Congenital/complications/drug therapy MH - *Quality Improvement MH - Female MH - Male MH - Infant, Newborn MH - Retrospective Studies MH - Antibodies, Monoclonal, Humanized/administration & dosage MH - Communication OTO - NOTNLM OT - Congenital heart disease OT - Palivizumab OT - Quality improvement OT - Respiratory syncytial virus COIS- Declarations. Conflict of interest: The authors have no conflicts of interest relevant to this article to disclose. EDAT- 2024/02/01 12:42 MHDA- 2025/02/01 20:43 CRDT- 2024/02/01 11:08 PHST- 2023/08/22 00:00 [received] PHST- 2023/12/18 00:00 [accepted] PHST- 2025/02/01 20:43 [medline] PHST- 2024/02/01 12:42 [pubmed] PHST- 2024/02/01 11:08 [entrez] AID - 10.1007/s00246-023-03388-3 [pii] AID - 10.1007/s00246-023-03388-3 [doi] PST - ppublish SO - Pediatr Cardiol. 2025 Feb;46(2):287-295. doi: 10.1007/s00246-023-03388-3. Epub 2024 Feb 1. PMID- 38296848 OWN - NLM STAT- MEDLINE DCOM- 20240306 LR - 20241115 IS - 1437-160X (Electronic) IS - 0172-8172 (Linking) VI - 44 IP - 4 DP - 2024 Apr TI - Rehabilitation of patients with inflammatory rheumatic diseases and comorbidities: unmet needs. PG - 583-591 LID - 10.1007/s00296-023-05529-6 [doi] AB - Comorbidities may contribute to inadequate response to therapy and accelerate disability in various rheumatic diseases such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and psoriatic arthritis (PsA). Cardiovascular, oncological, and infectious comorbidities are common in rheumatic patients. The rehabilitation of patients with inflammatory rheumatic diseases (IRDs) with comorbidities requires a multidisciplinary approach to improving patients' functional mobility, slowing down the disease progression and minimizing the risks of complications. The evidence suggests that cardiac rehabilitation can be implemented in daily practice in patients with IRDs to reduce mortality for those with established risk factors. Physical exercises reduce the severity, improve the clinical course, and reduce hospitalization rates in patients with rheumatic diseases. A rehabilitation program with focused physical therapy can lead to functional improvements and reduction of disease activity in patients with lowered quality of life (QoL). Health professionals should provide evidence-based recommendations for patients with rheumatic diseases and comorbidities to initiate the self-management of their diseases and prevent complications. CI - (c) 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Fedorchenko, Yuliya AU - Fedorchenko Y AUID- ORCID: 0000-0002-5042-1191 AD - Department of Pathophysiology, Ivano-Frankivsk National Medical University, Halytska Str. 2, Ivano-Frankivsk, 76018, Ukraine. juliakozubash@gmail.com. FAU - Mahmudov, Khaiyom AU - Mahmudov K AUID- ORCID: 0000-0002-3583-9442 AD - Department of Propaedeutics of Internal Diseases, Avicenna Tajik State Medical University, Dushanbe, Tajikistan. FAU - Abenov, Zhumabek AU - Abenov Z AUID- ORCID: 0009-0003-4269-5023 AD - Student Polyclinic, Shymkent, Kazakhstan. AD - South Kazakhstan Medical Academy, Shymkent, Kazakhstan. FAU - Zimba, Olena AU - Zimba O AUID- ORCID: 0000-0002-4188-8486 AD - Department of Clinical Rheumatology and Immunology, University Hospital in Krakow, Krakow, Poland. AD - National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland. AD - Department of Internal Medicine N2, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine. FAU - Yessirkepov, Marlen AU - Yessirkepov M AUID- ORCID: 0000-0003-2511-6918 AD - Department of Biology and Biochemistry, South Kazakhstan Medical Academy, Shymkent, Kazakhstan. LA - eng PT - Journal Article PT - Review DEP - 20240131 PL - Germany TA - Rheumatol Int JT - Rheumatology international JID - 8206885 SB - IM MH - Humans MH - Quality of Life MH - *Arthritis, Psoriatic/epidemiology/complications MH - *Arthritis, Rheumatoid/drug therapy MH - *Rheumatic Diseases/epidemiology/therapy/complications MH - Comorbidity MH - *Lupus Erythematosus, Systemic/complications OTO - NOTNLM OT - Cardiac rehabilitation OT - Comorbidities OT - Patient care team OT - Rehabilitation OT - Rheumatic diseases OT - Rheumatoid arthritis EDAT- 2024/02/01 00:42 MHDA- 2024/03/06 06:43 CRDT- 2024/01/31 23:13 PHST- 2023/10/05 00:00 [received] PHST- 2023/12/25 00:00 [accepted] PHST- 2024/03/06 06:43 [medline] PHST- 2024/02/01 00:42 [pubmed] PHST- 2024/01/31 23:13 [entrez] AID - 10.1007/s00296-023-05529-6 [pii] AID - 10.1007/s00296-023-05529-6 [doi] PST - ppublish SO - Rheumatol Int. 2024 Apr;44(4):583-591. doi: 10.1007/s00296-023-05529-6. Epub 2024 Jan 31. PMID- 38295115 OWN - NLM STAT- MEDLINE DCOM- 20240202 LR - 20260509 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 19 IP - 1 DP - 2024 TI - Development and initial validation of a family activation measure for acute care. PG - e0286844 LID - 10.1371/journal.pone.0286844 [doi] LID - e0286844 AB - BACKGROUND: Activation of a family member refers to their desire, knowledge, confidence, and skills that can inform engagement in healthcare. Family activation combined with opportunity can lead to engagement in care. No tool currently exists to measure family activation in acute care. Therefore, we aimed to develop and validate a tool to measure family activation in acute care. METHODS: An interdisciplinary team of content experts developed the FAMily Activation Measure (FAM-Activate) through an iterative process. The FAM-Activate tool is a 4-item questionnaire with 5 Likert-type response options (ranging from strongly agree to strongly disagree). Scale scores are converted to a 0-100 point scoring range so that higher FAM-Activate scores indicate increased family activation. An overall FAM-Activate score (range 0-100) is calculated by adding the scores for each item and dividing by 4. We conducted reliability and predictive validity assessments to validate the instrument by administering the FAM-Activate tool to family members of patients in an acute cardiac unit at a tertiary care hospital. We obtained preliminary estimates of family engagement and satisfaction with care. RESULTS: We surveyed 124 family participants (age 54.1+/-14.4; 73% women; 34% non-white). Participants were predominantly the adult child (38%) or spouse/partner (36%) of patients. The mean FAM-Activate score during hospitalization was 84.1+/-16.1. FAM-Activate had acceptable internal consistency (Cronbach's a = 0.74) and showed test-retest responsiveness. FAM-Activate was moderately correlated with engagement behavior (Pearson's correlation r = 0.47, P <0.0001). The FAM-Activate score was an independent predictor of family satisfaction, after adjusting for age, gender, relationship, and living status. CONCLUSION: The FAM-Activate tool was reliable and had predictive validity in the acute cardiac population. Further research is needed to explore whether improving family activation can lead to improved family engagement in care. CI - Copyright: (c) 2024 Hallot et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. FAU - Hallot, Sophie AU - Hallot S AD - McGill Faculty of Medicine, McGill University, Montreal, QC, Canada. FAU - Debay, Vanessa AU - Debay V AD - McGill Faculty of Medicine, McGill University, Montreal, QC, Canada. FAU - Foster, Nadine AU - Foster N AD - Patient and Family Partnership Committee, Canadian Critical Care Trials Group, Markham, ON, Canada. AD - Division of Critical Care, University of Calgary, Calgary, AB, Canada. FAU - Burns, Karen E A AU - Burns KEA AD - Interdepartmental Division of Critical Care, Department of Medicine, University of Toronto, Toronto, Canada. AD - Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Canada. AD - Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada. FAU - Goldfarb, Michael AU - Goldfarb M AUID- ORCID: 0000-0001-9790-1232 AD - Division of Cardiology, Jewish General Hospital, McGill University, Montreal, QC, Canada. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240131 PL - United States TA - PLoS One JT - PloS one JID - 101285081 SB - IM MH - Adult MH - Humans MH - Female MH - Middle Aged MH - Aged MH - Male MH - Reproducibility of Results MH - *Mental Processes MH - Surveys and Questionnaires MH - *Personal Satisfaction MH - Adult Children MH - Psychometrics PMC - PMC10830022 COIS- A member of the authorship group (MG) was involved in the developing the FAM-Activate measure. EDAT- 2024/01/31 18:42 MHDA- 2024/02/02 06:43 PMCR- 2024/01/31 CRDT- 2024/01/31 13:43 PHST- 2023/01/16 00:00 [received] PHST- 2023/05/24 00:00 [accepted] PHST- 2024/02/02 06:43 [medline] PHST- 2024/01/31 18:42 [pubmed] PHST- 2024/01/31 13:43 [entrez] PHST- 2024/01/31 00:00 [pmc-release] AID - PONE-D-23-01380 [pii] AID - 10.1371/journal.pone.0286844 [doi] PST - epublish SO - PLoS One. 2024 Jan 31;19(1):e0286844. doi: 10.1371/journal.pone.0286844. eCollection 2024. PMID- 38294776 OWN - NLM STAT- MEDLINE DCOM- 20240415 LR - 20240415 IS - 1557-8518 (Electronic) IS - 1540-4196 (Linking) VI - 22 IP - 3 DP - 2024 Apr TI - Classification, Diagnosis, and Treatment of Obesity-Related Heart Diseases. PG - 161-169 LID - 10.1089/met.2023.0134 [doi] AB - Evidence-based medicine shows that obesity is associated with a wide range of cardiovascular (CV) diseases. Obesity can lead to changes in cardiac structure and function, which can lead to obese cardiomyopathy, subclinical cardiac dysfunction, and even heart failure. It also increases the risk of atrial fibrillation and sudden cardiac death. Many invasive and noninvasive diagnostic methods can detect obesity-related heart disease at an early stage, so that appropriate measures can be selected to prevent adverse CV events. However, studies have shown a protective effect of obesity on clinical outcomes of CV disease, a phenomenon that has been termed the obesity paradox. The "obesity paradox" essentially refers to the fact that the classification of obesity defined by body mass index (BMI) does not consider the impact of obesity heterogeneity on CV disease prognosis, but simply puts subjects with different clinical and biochemical characteristics into the same category. In any case, indicators such as waist-to-hip ratio, ectopic body fat qualitative and quantitative, and CV fitness have been shown to be able to distinguish different CV risks in patients with the same BMI, which is convenient for early intervention in an appropriate way. A multidisciplinary approach, including lifestyle modification, evidence-based generic and novel pharmacotherapy, and surgical intervention, can improve CV outcomes in overweight/obese patients. FAU - Chen, Dan AU - Chen D AUID- ORCID: 0000-0001-9653-9200 AD - Department of Electrocardiogram, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China. AD - Artificial Intelligence Institute, Qilu University of Technology (Shandong Academy of Sciences), Jinan, Shandong, China. FAU - Feng, Juan AU - Feng J AD - Department of Echocardiography, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China. FAU - He, HongYan AU - He H AD - Department of Electrocardiogram, Tai'an Hospital of Traditional Chinese Medicine, Tai'an, Shandong, China. FAU - Xiao, WeiPing AU - Xiao W AD - Department of Acupuncture, Tai'an Hospital of Traditional Chinese Medicine, Tai'an, Shandong, China. FAU - Liu, XiaoJing AU - Liu X AUID- ORCID: 0009-0001-3746-4103 AD - Department of Endocrinology and Metabolism, The Second Hospital of Shandong University, Jinan, Shandong, China. LA - eng PT - Journal Article PT - Review DEP - 20240129 PL - United States TA - Metab Syndr Relat Disord JT - Metabolic syndrome and related disorders JID - 101150318 SB - IM MH - Humans MH - Obesity/complications/diagnosis/therapy MH - *Cardiovascular Diseases/complications/diagnosis MH - Prognosis MH - Overweight/complications MH - *Heart Failure MH - Body Mass Index MH - Risk Factors OTO - NOTNLM OT - cardiovascular diseases OT - diagnosis OT - obesity OT - obesity paradox OT - treatment EDAT- 2024/01/31 12:43 MHDA- 2024/04/15 06:43 CRDT- 2024/01/31 11:33 PHST- 2024/04/15 06:43 [medline] PHST- 2024/01/31 12:43 [pubmed] PHST- 2024/01/31 11:33 [entrez] AID - 10.1089/met.2023.0134 [doi] PST - ppublish SO - Metab Syndr Relat Disord. 2024 Apr;22(3):161-169. doi: 10.1089/met.2023.0134. Epub 2024 Jan 29. PMID- 38290114 OWN - NLM STAT- MEDLINE DCOM- 20240416 LR - 20240617 IS - 1536-7312 (Electronic) IS - 0196-206X (Linking) VI - 45 IP - 2 DP - 2024 Mar-Apr 01 TI - Challenging Case: A Multidisciplinary Approach to Demystifying Chronic Sleep Impairment in an Infant with a Complex Medical and Behavioral Profile. PG - e176-e179 LID - 10.1097/DBP.0000000000001251 [doi] AB - X is a 22-month-old White male infant with a complex medical history, including diagnoses of FBXO11 mutation, hypotonia, restrictive lung disease and mild intermittent asthma, laryngotracheomalacia, obstructive sleep apnea (OSA), feeding difficulties with a history of aspiration, gastroesophageal reflux disease (GERD), and developmental delays. X's medical presentation has resulted in multiple prior medical admissions for respiratory failure due to acute illnesses, procedures and treatments including gastrojejunostomy (GJ) tube dependence, supraglottoplasty to reshape tissues of the upper larynx, and the use of biphasic positive airway pressure (BiPAP) at night and room air during the day when he is at baseline. In addition, he has nocturnal events characterized by significant agitation, screaming, crying, body stiffening and limb movements with pauses in breathing, mouth breathing, restless sleep, and difficulty waking in the morning with concomitant daytime fatigue despite above treatments for OSA. There is no history of congenital heart disease or sudden unexplained death. Family history is noncontributory because parents are negative for the FBXO11 variant.X's sleep disruption has led to significant sleep deficits for both X and his caregivers, who spend much of the night strategizing on how to console him. X has undergone several sleep studies, starting when X was aged 4 months, at several children's hospitals across the nation to determine the cause of his chronic sleep disturbance, which yielded limited information and treatment success. As an infant, X received a medical workup and was subsequently treated with a proton pump inhibitor (PPI) for reflux. At 12 months, he was diagnosed with disordered sleep with myoclonic jerks and started on melatonin and gabapentin for involuntary movements. At 13 months, gabapentin was weaned back because of intolerance, and at 15 months, nortriptyline and clonidine were started because of worsening symptoms to target potential neuropathic pain. While most of his symptoms were at night, he had occasional daytime screaming episodes, particularly when experiencing illness. Gabapentin and clonidine were stopped because nortriptyline seemed most effective.At 17 months, the results from a sleep study led to a diagnosis of night terrors, and several clinicians agreed that X's sleep disruption was behavioral in nature. At this time, an infant mental health consultant met with a sleep psychologist on the family's behalf to support family in considering systematic desensitization therapy to increase tolerance to wearing his BiPAP mask, as well as other behavioral and sleep hygiene strategies, which were tried on several occasions and again, resulted in limited improvement in functioning.At 19 months, X's multidisciplinary team reconsidered a night terror diagnosis after a failed trial of clonazepam and pursued a differential diagnosis of periodic limb movement disorder (PLMD). X trialed gabapentin again, but this time only a nighttime dose, per sleep medicine and psychiatry recommendation. While this brought some temporary relief from nighttime distress, despite increasing to the highest dose for age and weight (15 mg/kg/dose), this became less effective, and he was weaned off at 22 months. He had been on iron supplementation since age 6 months and received an iron infusion at 22 months because of persistently low ferritin levels and PLMD in sleep.At 24 months, X was briefly trialed on levetiracetam. While no evidence for seizures on EEG was present, this medication was chosen for involuntary movements and genetic risk for seizures. However, this medication was not useful. At 25 months, an evaluation with a movement disorder physiatrist resulted in a diagnosis of nocturnal paroxysmal dystonia, and he was started on baclofen, which has provided some, but not complete relief to nighttime symptoms. Parents are reporting he has more "good nights" than "bad nights," but "bad nights" come in stretches of a few days in length with no known trigger or relief.Most recently, X was evaluated by general genetics. Whole exome sequencing (WES) was pursued which revealed a pathogenic de novo variant in FBXO11 and provides a likely cause for his neurodevelopmental phenotype. However, he has some features not explained by FBX011; thus, reanalysis of his WES was performed and revealed a de novo variant of uncertain significance in RAF1. Because pathogenic variants in RAF1 have been associated with dilated cardiomyopathy and Noonan spectrum disorder, it was recommended that X be followed periodically in a cardiac genetics clinic. Family is well connected into the FBXO11 community, including supportive Facebook groups. Parents have shared that they do not feel X's breathing issues and pain fit with the phenotype of other children with FBXO11 mutations.X is also enrolled in a medical child care program to facilitate development and social-emotional functioning and receives learning, speech, occupational, physical, and feeding therapy while in attendance. Despite periods of absence due to contracting numerous viral illnesses over the past several months, X continues to make progress across developmental therapies and happily engages when at the program.What additional diagnostic tests and treatment should be considered to better understand X's medical and behavioral presentation? What are the implications of chronic sleep deprivation and stress on the behavior and development of infant with X's profile? What are important psychosocial considerations because it relates to children with medical complexity (CMC), particularly for X and his family to support caregiver, family, and X's quality of life and overall well-being? CI - Copyright (c) 2024 Wolters Kluwer Health, Inc. All rights reserved. FAU - Gleason, Erica AU - Gleason E AD - Child & Adolescent Psychiatry, University of Colorado Medicine, Children's Hospital of Colorado, Aurora, CO. FAU - Malik, Kristina AU - Malik K AD - Department of Pulmonary and Sleep Medicine, KidStreet & Special Care Clinic, Children's Hospital of Colorado, Aurora, CO. FAU - Sannar, Elise AU - Sannar E AD - Child & Adolescent Psychiatry, University of Colorado Medicine, Children's Hospital of Colorado, Aurora, CO. FAU - Kamara, Dana AU - Kamara D AD - Department of Pediatrics, Pulmonary & Sleep Medicine, University of Colorado Medicine, Children's Hospital of Colorado, Aurora, CO. FAU - Serrano, Verenea AU - Serrano V AD - Psychiatry, University of Colorado Medicine, Children's Hospital of Colorado, Aurora, CO. FAU - Augustyn, Marilyn AU - Augustyn M AUID- ORCID: 0000-0001-9975-6067 AD - Boston University, Boston, MA. LA - eng PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. DEP - 20240130 PL - United States TA - J Dev Behav Pediatr JT - Journal of developmental and behavioral pediatrics : JDBP JID - 8006933 RN - 6CW7F3G59X (Gabapentin) RN - MN3L5RMN02 (Clonidine) RN - BL03SY4LXB (Nortriptyline) RN - E1UOL152H7 (Iron) RN - EC 2.1.1.319 (FBXO11 protein, human) RN - EC 2.1.1.319 (Protein-Arginine N-Methyltransferases) RN - 0 (F-Box Proteins) SB - IM MH - Infant MH - Humans MH - Male MH - Gabapentin MH - Quality of Life MH - Clonidine MH - Nortriptyline MH - *Sleep Apnea, Obstructive MH - *Sleep Wake Disorders/diagnosis/etiology/therapy MH - Sleep MH - *Dyskinesias MH - Iron MH - Seizures MH - Protein-Arginine N-Methyltransferases MH - *F-Box Proteins COIS- Disclosure: The authors declare no conflict of interest. EDAT- 2024/01/30 18:42 MHDA- 2024/04/16 12:42 CRDT- 2024/01/30 16:42 PHST- 2024/04/16 12:42 [medline] PHST- 2024/01/30 18:42 [pubmed] PHST- 2024/01/30 16:42 [entrez] AID - 00004703-202404000-00008 [pii] AID - 10.1097/DBP.0000000000001251 [doi] PST - ppublish SO - J Dev Behav Pediatr. 2024 Mar-Apr 01;45(2):e176-e179. doi: 10.1097/DBP.0000000000001251. Epub 2024 Jan 30. PMID- 38287095 OWN - NLM STAT- MEDLINE DCOM- 20240131 LR - 20241023 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 14 IP - 1 DP - 2024 Jan 29 TI - Effect of chronic lung diseases on angina pectoris among Indian adults: longitudinal ageing study in India. PG - 2372 LID - 10.1038/s41598-024-52786-x [doi] LID - 2372 AB - The study aimed to evaluate the effect of chronic lung diseases, namely chronic obstructive pulmonary diseases (COPD) and asthma, on angina pectoris in individuals aged 45 years and above. Identifying vulnerable subpopulations suffering from COPD and asthma at higher risk of future cardiovascular events using the rose angina questionnaire is imperative for tailored primary and secondary prevention approaches. The present study utilizes the data from the Longitudinal Ageing Study in India, wave 1, conducted during 2017-2018. The sample size included 58,830 individuals aged 45 years and above. Angina was measured based on seven questions from Rose's questionnaires. Descriptive statistics and bivariate analysis were employed to examine the prevalence of angina among individuals with COPD and asthma. Further, multivariable logistic regression and propensity score matching (PSM) methods were used to assess the independent effect of COPD and asthma on angina after controlling the selected background characteristics. We employed PSM in two different models and included various additional factors in model 2, such as smoking, chewing tobacco, alcohol use, ADL, IADL, body mass index, physical activity, high cholesterol, hypertension, diabetes, and chronic heart disease. The current study shows that the prevalence of angina pectoris, COPD and asthma was 6.0%, 2.3% and 4.7%, respectively, among individuals aged 45 years and above in India. The prevalence of angina pectoris was higher among individuals with COPD (9.6% vs. 5.8%) and asthma (9.9% vs. 5.7%) than those without COPD and asthma, respectively. Additionally, angina pectoris was more prevalent among females and rural respondents with COPD (10.8% and 11.0%) and asthma (10.3% and 10.3%) compared to males and urban respondents with COPD (8.0% and 5.7%) and asthma (8.9% and 7.9%). Moreover, in the adjusted model, individuals with COPD (AOR 1.43, 95% CI 1.03 1.98) and asthma (AOR 1.44, 95% CI 1.17 1.77) had nearly 1.5-fold higher odds of having angina pectoris than those without COPD and asthma. The PSM estimates showed that individuals with COPD had 8.4% and 5.0% increased risk of angina pectoris compared to those without COPD in model 1 and model 2, respectively. We observed that, after adjusting to lifestyle, health-related and morbidity factors in model 2, both average treatment effect on untreated (ATU) and average treatment effect (ATE) values decreased by nearly 3.5%. Additionally, the PSM estimates demonstrated that individuals with asthma had a 3.4% and 2.9% increased risk of angina pectoris compared to those without asthma in model 1 and model 2, respectively. The study suggests that COPD and asthma are significantly associated with angina pectoris, and individuals with COPD and asthma have a higher risk of developing angina pectoris. Additionally, angina pectoris was more prevalent among females, rural respondents and adults aged 45-54 with COPD compared to males, urban respondents and those aged 65 and above, respectively, with COPD. Moreover, the findings of our study underscore the targeted primary and secondary interventions and team-based care approach among individuals with COPD and asthma to reduce the risk of CVD events in future. CI - (c) 2024. The Author(s). FAU - Ahmed, Waquar AU - Ahmed W AD - School of Health Systems Studies, Tata Institute of Social Sciences, Mumbai, India. waquar8219@gmail.com. FAU - Dixit, Priyanka AU - Dixit P AD - School of Health Systems Studies, Tata Institute of Social Sciences, Mumbai, India. LA - eng GR - R01 AG030153/AG/NIA NIH HHS/United States GR - R01 AG042778/AG/NIA NIH HHS/United States PT - Journal Article DEP - 20240129 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 SB - IM MH - Adult MH - Male MH - Female MH - Humans MH - Risk Factors MH - *Pulmonary Disease, Chronic Obstructive/complications/epidemiology MH - Angina Pectoris/epidemiology MH - *Asthma/complications/epidemiology MH - Aging MH - India/epidemiology MH - Prevalence PMC - PMC10825144 COIS- The authors declare no competing interests. EDAT- 2024/01/30 00:42 MHDA- 2024/01/31 06:42 PMCR- 2024/01/29 CRDT- 2024/01/29 23:30 PHST- 2023/11/06 00:00 [received] PHST- 2024/01/23 00:00 [accepted] PHST- 2024/01/31 06:42 [medline] PHST- 2024/01/30 00:42 [pubmed] PHST- 2024/01/29 23:30 [entrez] PHST- 2024/01/29 00:00 [pmc-release] AID - 10.1038/s41598-024-52786-x [pii] AID - 52786 [pii] AID - 10.1038/s41598-024-52786-x [doi] PST - epublish SO - Sci Rep. 2024 Jan 29;14(1):2372. doi: 10.1038/s41598-024-52786-x. PMID- 38286206 OWN - NLM STAT- MEDLINE DCOM- 20240725 LR - 20250130 IS - 1552-6259 (Electronic) IS - 0003-4975 (Linking) VI - 118 IP - 2 DP - 2024 Aug TI - The Society of Thoracic Surgeons 2023 Clinical Practice Guidelines for the Surgical Treatment of Atrial Fibrillation. PG - 291-310 LID - S0003-4975(24)00057-2 [pii] LID - 10.1016/j.athoracsur.2024.01.007 [doi] AB - The Society of Thoracic Surgeons 2023 Clinical Practice Guidelines for the Surgical Treatment of Atrial Fibrillation incorporate the most recent evidence for surgical ablation and left atrial appendage occlusion in different clinical scenarios. Substantial new evidence regarding the risks and benefits of surgical left atrial appendage occlusion and the long-term benefits of surgical ablation has been produced in the last 5 years. Compared with the 2017 clinical practice guideline, the current update has an emphasis on surgical ablation in first-time, nonemergent cardiac surgery and its long-term benefits, an extension of the recommendation to perform surgical ablation in all patients with atrial fibrillation undergoing first-time, nonemergent cardiac surgery, and a new class I recommendation for left atrial appendage occlusion in all patients with atrial fibrillation undergoing first-time, nonemergent cardiac surgery. Further guidance is provided for patients with structural heart disease and atrial fibrillation being considered for transcatheter valve repair or replacement, as well as patients in need of isolated left atrial appendage management who are not candidates for surgical ablation. The importance of a multidisciplinary team assessment, treatment planning, and long-term follow-up are reiterated in this clinical practice guideline with a class I recommendation, along with the other recommendations from the 2017 guidelines that remained unchanged in their class of recommendation and level of evidence. CI - Copyright (c) 2024 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved. FAU - Wyler von Ballmoos, Moritz C AU - Wyler von Ballmoos MC AD - Department of Cardiovascular and Thoracic Surgery, Texas Health Fort Worth, Fort Worth, Texas. Electronic address: mcwvb@post.harvard.edu. FAU - Hui, Dawn S AU - Hui DS AD - Department of Cardiothoracic Surgery, University of Texas Health Science Center at San Antonio, San Antonio, Texas. FAU - Mehaffey, J Hunter AU - Mehaffey JH AD - Department of Cardiovascular and Thoracic Surgery, West Virginia University, Morgantown, West Virginia. FAU - Malaisrie, S Chris AU - Malaisrie SC AD - Division of Cardiac Surgery, Department of Surgery, Northwestern University, Chicago, Illinois. FAU - Vardas, Panos N AU - Vardas PN AD - Division of Cardiothoracic Surgery, Department of Surgery, University of Alabama at Birmingham, Birmingham, Alabama. FAU - Gillinov, A Marc AU - Gillinov AM AD - Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, Ohio. FAU - Sundt, Thoralf M AU - Sundt TM AD - Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts. FAU - Badhwar, Vinay AU - Badhwar V AD - Department of Cardiovascular and Thoracic Surgery, West Virginia University, Morgantown, West Virginia. LA - eng PT - Journal Article PT - Practice Guideline DEP - 20240127 PL - Netherlands TA - Ann Thorac Surg JT - The Annals of thoracic surgery JID - 15030100R SB - IM CIN - Ann Thorac Surg. 2024 Aug;118(2):310-311. doi: 10.1016/j.athoracsur.2024.03.037. PMID: 38621653 MH - *Atrial Fibrillation/surgery MH - Humans MH - *Societies, Medical MH - Thoracic Surgery MH - Atrial Appendage/surgery MH - Cardiac Surgical Procedures/methods/standards MH - Catheter Ablation/methods EDAT- 2024/01/30 00:42 MHDA- 2024/07/26 12:39 CRDT- 2024/01/29 19:12 PHST- 2023/11/10 00:00 [received] PHST- 2024/01/08 00:00 [revised] PHST- 2024/01/13 00:00 [accepted] PHST- 2024/07/26 12:39 [medline] PHST- 2024/01/30 00:42 [pubmed] PHST- 2024/01/29 19:12 [entrez] AID - S0003-4975(24)00057-2 [pii] AID - 10.1016/j.athoracsur.2024.01.007 [doi] PST - ppublish SO - Ann Thorac Surg. 2024 Aug;118(2):291-310. doi: 10.1016/j.athoracsur.2024.01.007. Epub 2024 Jan 27. PMID- 38283571 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240131 IS - 2474-8714 (Electronic) IS - 2474-8706 (Print) IS - 2474-8706 (Linking) VI - 8 IP - 1 DP - 2024 Jan TI - First Report of Evolut Pro+ Transcatheter Aortic Valve-in-Valve in a Degenerated Lotus Valve. PG - 100229 LID - 10.1016/j.shj.2023.100229 [doi] LID - 100229 AB - The increasing use of transcatheter aortic valves in patients with aortic stenosis has led to a higher number of valve-in-valve procedures due to gradual valve degeneration. We present a case of a 72-year-old woman who received transcatheter aortic valve implantation (TAVI) using a Lotus valve due to severe aortic stenosis, which showed valve degeneration several years after the initial procedure. After heart-team discussion, TAVI-in-TAVI was planned using an Evolut pro+ valve, which allowed for full coverage of the Lotus valve and maintenance of coronary flow, resulting in a well-functioning valve with no regurgitation and normal performance. Despite high-risk anatomic features, valve-in-valve using an Evolut pro+ in a degenerated Lotus valve is feasible and overcomes pitfalls such as entanglement or coronary obstruction. CI - (c) 2023 The Author(s). FAU - Stolte, Thorald AU - Stolte T AD - Department of Cardiology and Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, University of Basel, Basel, Switzerland. AD - Department of Health Sciences and Technology, Swiss Federal Institute of Technology, Zurich, Switzerland. FAU - Winkel, David AU - Winkel D AD - Department of Radiology, University Hospital Basel, University of Basel, Basel, Switzerland. FAU - Haaf, Philip AU - Haaf P AD - Department of Cardiology and Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, University of Basel, Basel, Switzerland. FAU - Nestelberger, Thomas AU - Nestelberger T AD - Department of Cardiology and Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, University of Basel, Basel, Switzerland. AD - Department of Radiology, University Hospital Basel, University of Basel, Basel, Switzerland. LA - eng PT - Journal Article DEP - 20231111 PL - United States TA - Struct Heart JT - Structural heart : the journal of the Heart Team JID - 101743256 PMC - PMC10818144 OTO - NOTNLM OT - Functional computed tomography OT - Transcatheter aortic valve implantation OT - Valve prosthesis degeneration OT - Valve-in-valve COIS- T. Nestelberger has received research support from the Swiss National Science Foundation (P400 pm_191037/1), the Prof Dr Max Cloetta Foundation, the Margarete und Walter Lichtenstein-Stiftung (3MS1038), and the University Hospital Basel as well as speaker honoraria/consulting honoraria from Edwards Lifesciences, Siemens, Beckman Coulter, Bayer, Ortho Clinical Diagnostics and Orion Pharma, outside the submitted work. All other authors have no conflict of interests. EDAT- 2024/01/29 06:44 MHDA- 2024/01/29 06:45 PMCR- 2023/11/11 CRDT- 2024/01/29 04:32 PHST- 2023/07/11 00:00 [received] PHST- 2023/09/15 00:00 [revised] PHST- 2023/09/27 00:00 [accepted] PHST- 2024/01/29 06:45 [medline] PHST- 2024/01/29 06:44 [pubmed] PHST- 2024/01/29 04:32 [entrez] PHST- 2023/11/11 00:00 [pmc-release] AID - S2474-8706(23)00123-9 [pii] AID - 100229 [pii] AID - 10.1016/j.shj.2023.100229 [doi] PST - epublish SO - Struct Heart. 2023 Nov 11;8(1):100229. doi: 10.1016/j.shj.2023.100229. eCollection 2024 Jan. PMID- 38278176 OWN - NLM STAT- MEDLINE DCOM- 20240320 LR - 20240815 IS - 2589-9333 (Electronic) IS - 2589-9333 (Linking) VI - 6 IP - 3 DP - 2024 Mar TI - Ischemic heart disease in pregnancy: a practical approach to management. PG - 101295 LID - S2589-9333(24)00021-1 [pii] LID - 10.1016/j.ajogmf.2024.101295 [doi] AB - Ischemic heart disease is a crucial issue during pregnancy. The term is composed of both preexisting conditions and acute coronary syndrome in pregnancy, including pregnancy-associated myocardial infarction, which can have a significant effect on maternal and fetal outcomes. This review provides a complete guide to managing ischemic heart disease in pregnant women, emphasizing the importance of multidisciplinary care and individualized treatment strategies. Cardiovascular disease, particularly ischemic heart disease, is now the leading cause of maternal mortality worldwide. Pregnancy introduces unique physiological changes that increase the risk of acute myocardial infarction, with pregnancy-associated myocardial infarction cases often associated with factors, such as advanced maternal age, chronic hypertension, and preexisting cardiovascular conditions. This review distinguishes between preexisting ischemic heart disease and pregnancy-associated myocardial infarction. It will emphasize the various etiologies of pregnancy-associated myocardial infarction, including coronary atherosclerosis and plaque rupture presenting as ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, and other nonatherosclerotic causes, including spontaneous coronary artery dissection, vasospasm, and embolism. Our study discusses the practical management of ischemic heart disease in pregnancy, with a focus on preconception counseling, risk assessment, and tailored antenatal planning for women with preexisting ischemic heart disease. Moreover, this document focuses on the challenges of diagnosing cardiovascular disease, especially when presented with nonclassical risk factors and presentation. It provides insight into the appropriate diagnostic testing methods, such as electrocardiogram, cardiac biomarkers, and echocardiography. In addition, the review covers various treatment strategies, from medical management to more invasive procedures, including coronary angiography, percutaneous coronary intervention, and coronary artery bypass graft. Special attention is given to medication safety during pregnancy, including anticoagulation, beta-blockers, and antiplatelet agents. The complexities of delivery planning in women with ischemic heart disease are discussed, advocating for a multidisciplinary team-based approach and careful consideration of the timing and mode of delivery. Furthermore, the roles of breastfeeding and postpartum care are explored, emphasizing the long-term benefits and the suitability of various medications during lactation. Lastly, this review provides crucial insights into the management of ischemic heart disease in pregnancy, stressing the need for heightened awareness, prompt diagnosis, and tailored management to optimize maternal and fetal health outcomes. CI - Copyright (c) 2024 Elsevier Inc. All rights reserved. FAU - Nguyen, Andrew H AU - Nguyen AH AD - Department of Internal Medicine, Inova Fairfax Hospital, Falls Church, Virginia (Drs Nguyen and Moyo). FAU - Murrin, Ellen AU - Murrin E AD - Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Inova Fairfax Hospital, Falls Church, Virginia (Drs Murrin, Sullivan, and Saad). FAU - Moyo, Axucillia AU - Moyo A AD - Department of Internal Medicine, Inova Fairfax Hospital, Falls Church, Virginia (Drs Nguyen and Moyo). FAU - Sharma, Garima AU - Sharma G AD - Department of Cardiology, Inova Schar Heart and Vascular Institute, Falls Church, Virginia (Drs Sharma and Kennedy). FAU - Sullivan, Scott A AU - Sullivan SA AD - Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Inova Fairfax Hospital, Falls Church, Virginia (Drs Murrin, Sullivan, and Saad). FAU - Maxwell, George L AU - Maxwell GL AD - Department of Obstetrics and Gynecology, Inova Fairfax Hospital, Falls Church, Virginia (Dr Maxwell). FAU - Kennedy, Jamie L W AU - Kennedy JLW AD - Department of Cardiology, Inova Schar Heart and Vascular Institute, Falls Church, Virginia (Drs Sharma and Kennedy). FAU - Saad, Antonio F AU - Saad AF AD - Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Inova Fairfax Hospital, Falls Church, Virginia (Drs Murrin, Sullivan, and Saad). Electronic address: Antonio.Saad@inova.org. LA - eng PT - Journal Article PT - Review DEP - 20240125 PL - United States TA - Am J Obstet Gynecol MFM JT - American journal of obstetrics & gynecology MFM JID - 101746609 SB - IM CIN - Am J Obstet Gynecol MFM. 2024 May;6(5):101352. doi: 10.1016/j.ajogmf.2024.101352. PMID: 38492642 MH - Female MH - Humans MH - Pregnancy MH - *Myocardial Ischemia/diagnosis/epidemiology/etiology MH - *Myocardial Infarction/diagnosis/therapy MH - Risk Factors MH - *Vascular Diseases MH - Risk Assessment OTO - NOTNLM OT - delivery planning OT - ischemic heart disease OT - medical management OT - multidisciplinary care OT - myocardial infarction OT - postpartum care OT - pregnancy EDAT- 2024/01/27 12:42 MHDA- 2024/03/20 06:46 CRDT- 2024/01/26 19:12 PHST- 2023/12/08 00:00 [received] PHST- 2024/01/03 00:00 [accepted] PHST- 2024/03/20 06:46 [medline] PHST- 2024/01/27 12:42 [pubmed] PHST- 2024/01/26 19:12 [entrez] AID - S2589-9333(24)00021-1 [pii] AID - 10.1016/j.ajogmf.2024.101295 [doi] PST - ppublish SO - Am J Obstet Gynecol MFM. 2024 Mar;6(3):101295. doi: 10.1016/j.ajogmf.2024.101295. Epub 2024 Jan 25. PMID- 38273648 OWN - NLM STAT- MEDLINE DCOM- 20240408 LR - 20240408 IS - 1742-3406 (Electronic) IS - 0144-8420 (Linking) VI - 200 IP - 5 DP - 2024 Apr 4 TI - A comparative study of boost dose delivery techniques in breast cancer radiotherapy optimising efficacy and minimising toxicity. PG - 459-466 LID - 10.1093/rpd/ncad328 [doi] AB - The present study aims to compare three techniques for delivering a boost absorbed dose: conventional reduced tangential (3D), volumetric modulated arc therapy (VMAT) and fields forward-planned technique boost (3DF). The study included 15 postoperative breast cancer patients who received a boost absorbed dose following breast-conserving surgery. The conformity index and homogeneity index were used to evaluate treatment outcomes, along with the average absorbed dose received by organs at risk (OAR). All the calculated dosimetric plans are carried out using Monaco Treatment Planning System (TPS). VMAT offers superior conformity, dose homogeneity and target coverage, it is associated with higher absorbed doses to OAR such as the heart and lung. In contrast, the 3D and 3DF techniques exhibit advantages in reducing absorbed doses to critical structures, potentially minimising the risk of cardiac and pulmonary complications. Each technique has its advantages and disadvantages. The choice of technique should be individualised, taking into account patient-specific factors and treatment goals and involves a multidisciplinary approach. CI - (c) The Author(s) 2024. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com. FAU - El Ouardy, Khalid AU - El Ouardy K AD - Laboratory of Physics of Matter and Radiation, Faculty of Sciences, Mohammed First University, Oujda, 60000, Morocco. FAU - Zerfaoui, Mustapha AU - Zerfaoui M AD - Laboratory of Physics of Matter and Radiation, Faculty of Sciences, Mohammed First University, Oujda, 60000, Morocco. FAU - Oulhouq, Yassine AU - Oulhouq Y AUID- ORCID: 0000-0002-4989-6149 AD - Laboratory of Physics of Matter and Radiation, Faculty of Sciences, Mohammed First University, Oujda, 60000, Morocco. FAU - Bahhous, Karim AU - Bahhous K AD - Faculty of Science, University Mohammed V in Rabat, Rabat B.P. 1014, Morocco. FAU - Rrhioua, Abdeslem AU - Rrhioua A AD - Laboratory of Physics of Matter and Radiation, Faculty of Sciences, Mohammed First University, Oujda, 60000, Morocco. FAU - Bakari, Dikra AU - Bakari D AD - National School of Applied Sciences, Mohammed First University, Oujda 60000, Morocco. LA - eng PT - Journal Article PL - England TA - Radiat Prot Dosimetry JT - Radiation protection dosimetry JID - 8109958 SB - IM EIN - Radiat Prot Dosimetry. 2024 Apr 4;200(5):524. doi: 10.1093/rpd/ncae061. PMID: 38427457 MH - Humans MH - Female MH - *Breast Neoplasms/radiotherapy/surgery MH - Radiotherapy Dosage MH - Radiotherapy Planning, Computer-Assisted/methods MH - Breast MH - *Radiotherapy, Intensity-Modulated/adverse effects/methods MH - Organs at Risk EDAT- 2024/01/26 06:43 MHDA- 2024/04/08 06:43 CRDT- 2024/01/26 01:22 PHST- 2023/06/17 00:00 [received] PHST- 2023/12/18 00:00 [revised] PHST- 2023/12/27 00:00 [accepted] PHST- 2024/04/08 06:43 [medline] PHST- 2024/01/26 06:43 [pubmed] PHST- 2024/01/26 01:22 [entrez] AID - 7589476 [pii] AID - 10.1093/rpd/ncad328 [doi] PST - ppublish SO - Radiat Prot Dosimetry. 2024 Apr 4;200(5):459-466. doi: 10.1093/rpd/ncad328. PMID- 38272386 OWN - NLM STAT- MEDLINE DCOM- 20240304 LR - 20241018 IS - 1873-1570 (Electronic) IS - 0300-9572 (Linking) VI - 196 DP - 2024 Mar TI - Compliance with cardiopulmonary resuscitation guidelines in witnessed in-hospital cardiac arrest events and patient outcome on monitored versus non-monitored wards. PG - 110125 LID - S0300-9572(24)00018-2 [pii] LID - 10.1016/j.resuscitation.2024.110125 [doi] AB - BACKGROUND: Adherence to cardiopulmonary resuscitation (CPR) guidelines in treatment of in-hospital cardiac arrest (IHCA) have been associated with favourable patient outcome. The aim of this study was to evaluate if compliance with initial CPR guidelines and patient outcome of witnessed IHCA events were associated with the place of arrest defined as monitored versus non-monitored ward. METHODS: A total of 956 witnessed IHCA events in adult patients at six hospitals during 2018 to 2019, were extracted from the Swedish Registry of Cardiopulmonary Resuscitation. Initial CPR guidelines were: 70%, including the identification of an extreme-risk population (2.6% of the entire cohort), which had a very high probability for not surviving beyond 1 year (hazard ratio 6.5, 95% confidence interval 3.0-14; P < .001). The top 5% of patients with the highest EuroSMR risk scores showed event rates of 72.7% for mortality and 83.2% for mortality or lack of clinical improvement at 1-year follow-up. CONCLUSIONS: The EuroSMR risk score may allow for improved prognostication in heart failure patients with severe SMR, who are considered for a M-TEER procedure. The score is expected to facilitate the shared decision-making process with heart team members and patients. CI - (c) The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. FAU - Hausleiter, Jorg AU - Hausleiter J AUID- ORCID: 0000-0003-2909-7961 AD - Medizinische Klinik und Poliklinik I, Klinikum der Universitat Munchen, Marchioninistr. 15, Munich D-81377, Germany. AD - German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany. FAU - Lachmann, Mark AU - Lachmann M AUID- ORCID: 0000-0002-1798-550X AD - German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany. AD - First Department of Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany. FAU - Stolz, Lukas AU - Stolz L AUID- ORCID: 0000-0002-1362-1493 AD - Medizinische Klinik und Poliklinik I, Klinikum der Universitat Munchen, Marchioninistr. 15, Munich D-81377, Germany. FAU - Bedogni, Francesco AU - Bedogni F AD - Department of Cardiology, IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy. FAU - Rubbio, Antonio P AU - Rubbio AP AD - Department of Cardiology, IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy. FAU - Estevez-Loureiro, Rodrigo AU - Estevez-Loureiro R AUID- ORCID: 0000-0001-5841-5514 AD - Interventional Cardiology Clinic, University Hospital Alvaro Cunqueiro, Vigo, Spain. FAU - Raposeiras-Roubin, Sergio AU - Raposeiras-Roubin S AD - Interventional Cardiology Clinic, University Hospital Alvaro Cunqueiro, Vigo, Spain. FAU - Boekstegers, Peter AU - Boekstegers P AD - Department of Cardiology, Helios Klinikum Siegburg, Siegburg, Germany. FAU - Karam, Nicole AU - Karam N AUID- ORCID: 0000-0002-3861-6914 AD - Department of Cardiology, European Hospital Georges Pompidou, Paris Cardiovascular Research Center (INSERM U970), Paris, France. FAU - Rudolph, Volker AU - Rudolph V AUID- ORCID: 0000-0001-5385-6839 AD - Department of Cardiology, Herz- und Diabeteszentrum, Bad Oeynhausen, Germany. CN - EuroSMR Investigators LA - eng PT - Journal Article PL - England TA - Eur Heart J JT - European heart journal JID - 8006263 SB - IM MH - Humans MH - *Mitral Valve Insufficiency/surgery MH - Artificial Intelligence MH - Heart MH - Echocardiography MH - Risk Factors MH - Treatment Outcome MH - *Heart Valve Prosthesis Implantation OTO - NOTNLM OT - Edge-to-edge-repair OT - Heart failure OT - Machine learning OT - Mortality prediction OT - Secondary mitral regurgitation FIR - Stocker, Thomas IR - Stocker T FIR - Orban, Mathias IR - Orban M FIR - Braun, Daniel IR - Braun D FIR - Nabauer, Michael IR - Nabauer M FIR - Massberg, Steffen IR - Massberg S FIR - Popescu, Aniela IR - Popescu A FIR - Ruf, Tobias IR - Ruf T FIR - von Bardeleben, Ralph Stephan IR - von Bardeleben RS FIR - Iliadis, Christos IR - Iliadis C FIR - Pfister, Roman IR - Pfister R FIR - Baldus, Stephan IR - Baldus S FIR - Besler, Christian IR - Besler C FIR - Kister, Tobias IR - Kister T FIR - Kresoja, Karl IR - Kresoja K FIR - Lurz, Philipp IR - Lurz P FIR - Thiele, Holger IR - Thiele H FIR - Koell, Benedikt IR - Koell B FIR - Schofer, Niklas IR - Schofer N FIR - Kalbacher, Daniel IR - Kalbacher D FIR - Neuss, Michael IR - Neuss M FIR - Butter, Christian IR - Butter C FIR - Laugwitz, Karl-Ludwig IR - Laugwitz KL FIR - Trenkwalder, Teresa IR - Trenkwalder T FIR - Xhepa, Eroion IR - Xhepa E FIR - Joner, Michael IR - Joner M FIR - Omran, Hazem IR - Omran H FIR - Fortmeier, Vera IR - Fortmeier V FIR - Gercek, Muhammed IR - Gercek M FIR - Beucher, Harald IR - Beucher H FIR - Schmitz, Thomas IR - Schmitz T FIR - Bufe, Alexander IR - Bufe A FIR - Rothe, Jurgen IR - Rothe J FIR - Seyfarth, Melchior IR - Seyfarth M FIR - Schmidt, Tobias IR - Schmidt T FIR - Frerker, Christian IR - Frerker C FIR - Rottlander, Dennis IR - Rottlander D FIR - Horn, Patrick IR - Horn P FIR - Spieker, Maximilian IR - Spieker M FIR - Zweck, Elric IR - Zweck E FIR - Kassar, Mohammad IR - Kassar M FIR - Praz, Fabien IR - Praz F FIR - Windecker, Stephan IR - Windecker S FIR - Puscas, Tania IR - Puscas T FIR - Adamo, Marianna IR - Adamo M FIR - Lupi, Laura IR - Lupi L FIR - Metra, Marco IR - Metra M FIR - Villa, Emmanuel IR - Villa E FIR - Zoccai, Giuseppe Biondi IR - Zoccai GB FIR - Tamburino, Corrado IR - Tamburino C FIR - Grasso, Carmelo IR - Grasso C FIR - Catriota, Fausto IR - Catriota F FIR - Testa, Luca IR - Testa L FIR - Tusa, Maurizio IR - Tusa M FIR - Godino, Cosmo IR - Godino C FIR - Galasso, Michele IR - Galasso M FIR - Montorfano, Matteo IR - Montorfano M FIR - Agricola, Eustachio IR - Agricola E FIR - Denti, Paolo IR - Denti P FIR - De Marco, Federico IR - De Marco F FIR - Tarantini, Giuseppe IR - Tarantini G FIR - Masiero, Giulia IR - Masiero G FIR - Crimi, Gabriele IR - Crimi G FIR - Munafo, Andrea Raffaele IR - Munafo AR FIR - Giannini, Christina IR - Giannini C FIR - Petronio, Anna IR - Petronio A FIR - Pidello, Stefano IR - Pidello S FIR - Boretto, Paolo IR - Boretto P FIR - Montefusco, Antonio IR - Montefusco A FIR - Frea, Simone IR - Frea S FIR - Angelini, Filippo IR - Angelini F FIR - Bocchino, Pier Paolo IR - Bocchino PP FIR - De Felice, Francesco IR - De Felice F FIR - Citro, Rodolfo IR - Citro R FIR - Caneiro-Queija, Berenice IR - Caneiro-Queija B FIR - Freixa, Xavier IR - Freixa X FIR - Regueiro, Ander IR - Regueiro A FIR - Sanchis, Laura IR - Sanchis L FIR - Sabate, Manel IR - Sabate M FIR - Arzamendi, Dabit IR - Arzamendi D FIR - Asmarats, Lluis IR - Asmarats L FIR - Peregrina, Estefania Fernandez IR - Peregrina EF FIR - Benito-Gonzalez, Tomas IR - Benito-Gonzalez T FIR - Fernandez-Vazquez, Felipe IR - Fernandez-Vazquez F FIR - Pascual, Isaac IR - Pascual I FIR - Avanzas, Pablo IR - Avanzas P FIR - Nombela-Franco, Luis IR - Nombela-Franco L FIR - Tirado-Conte, Gabriela IR - Tirado-Conte G FIR - Pozo, Eduardo IR - Pozo E FIR - Portoles-Hernandez, Antonio IR - Portoles-Hernandez A FIR - Palomero, Vanessa Monivas IR - Palomero VM FIR - Sampaio, Francisco IR - Sampaio F FIR - Melica, Bruno IR - Melica B FIR - Rodes-Cabau, Josep IR - Rodes-Cabau J FIR - Paradis, Jean-Michel IR - Paradis JM FIR - Alperi, Alberto IR - Alperi A FIR - Shuvy, Mony IR - Shuvy M FIR - Haberman, Dan IR - Haberman D EDAT- 2024/01/20 10:43 MHDA- 2024/03/18 06:44 CRDT- 2024/01/20 05:52 PHST- 2023/08/14 00:00 [received] PHST- 2023/11/17 00:00 [revised] PHST- 2023/12/19 00:00 [accepted] PHST- 2024/03/18 06:44 [medline] PHST- 2024/01/20 10:43 [pubmed] PHST- 2024/01/20 05:52 [entrez] AID - 7577904 [pii] AID - 10.1093/eurheartj/ehad871 [doi] PST - ppublish SO - Eur Heart J. 2024 Mar 14;45(11):922-936. doi: 10.1093/eurheartj/ehad871. PMID- 38242689 OWN - NLM STAT- MEDLINE DCOM- 20240603 LR - 20260428 IS - 1549-490X (Electronic) IS - 1083-7159 (Print) IS - 1083-7159 (Linking) VI - 29 IP - 6 DP - 2024 Jun 3 TI - Ribociclib-Induced Cutaneous Adverse Events in Metastatic HR+/HER2- Breast Cancer: Incidence, Multidisciplinary Management, and Prognostic Implication. PG - 484-492 LID - 10.1093/oncolo/oyae004 [doi] AB - BACKGROUND: Ribociclib is approved for hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC) treatment, in combination with endocrine therapy. Hematological, hepatic, and cardiac adverse events (AEs) emerged from pivotal trials, but little is known about cutaneous adverse events (CAEs). PATIENTS AND METHODS: We report data from a retrospective cohort study of all patients with HR+/HER2- ABC treated with ribociclib at Humanitas Cancer Center between June 2017 and December 2022. We recorded clinical-pathological data, the incidence, and treatment of ribociclib-related CAEs. These were evaluated according to the NCI-CTCAE v5.0 classification. Progression-free survival (PFS) was estimated by Kaplan-Meier method and the log-rank test was used to analyze differences between groups. RESULTS: Thirteen of 91 patients (14.3%) experienced treatment-related CAEs (mean time to the occurrence: 3.9 months). The most frequent CAEs were eczematous dermatitis (53.8%) and maculo-papular reaction (15.4%). Itch was reported by all 13 patients. The grade was G3 in 8 cases, G2 in 4, and G1 in 1. An integrated approach based on ribociclib dose modulation and dermatological interventions (oral antihistamine, moisturized cream, topical, and/or systemic steroids) could prevent ribociclib discontinuation in most patients. At a median follow-up of 20 months, the median PFS was 13 months (range, 1-66) with a better PFS curves for patients experiencing CAEs (P = .04). CONCLUSION: We mapped frequency and types of ribociclib-induced CAEs. An interdisciplinary management of CAEs incorporated into routine care may reduce the rate of drug discontinuation thus potentially contributing to better long-term outcomes. CI - (c) The Author(s) 2024. Published by Oxford University Press. FAU - Borroni, Riccardo Giovanni AU - Borroni RG AD - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy. AD - Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano (MI), Italy. FAU - Bartolini, Michela AU - Bartolini M AD - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy. AD - Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano (MI), Italy. FAU - Gaudio, Mariangela AU - Gaudio M AD - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy. AD - Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano (MI), Italy. FAU - Jacobs, Flavia AU - Jacobs F AD - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy. AD - Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano (MI), Italy. FAU - Benvenuti, Chiara AU - Benvenuti C AD - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy. AD - Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano (MI), Italy. FAU - Gerosa, Riccardo AU - Gerosa R AD - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy. AD - Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano (MI), Italy. FAU - Tiberio, Paola AU - Tiberio P AD - Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano (MI), Italy. FAU - Manara, Sofia Ada Assunta Maria AU - Manara SAAM AD - Pathology Unit, IRCCS Humanitas Research Hospital, Rozzano (MI), Italy. FAU - Solferino, Alessandra AU - Solferino A AD - Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano (MI), Italy. FAU - Santoro, Armando AU - Santoro A AD - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy. AD - Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano (MI), Italy. FAU - De Sanctis, Rita AU - De Sanctis R AUID- ORCID: 0000-0003-3202-1933 AD - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy. AD - Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano (MI), Italy. LA - eng PT - Journal Article PL - England TA - Oncologist JT - The oncologist JID - 9607837 RN - 0 (Purines) RN - 0 (Aminopyridines) RN - EC 2.7.10.1 (Erb-b2 Receptor Tyrosine Kinases) RN - TK8ERE8P56 (ribociclib) RN - EC 2.7.10.1 (ERBB2 protein, human) SB - IM MH - Humans MH - Female MH - *Purines/adverse effects/administration & dosage/therapeutic use MH - *Breast Neoplasms/drug therapy/pathology MH - Middle Aged MH - Retrospective Studies MH - *Aminopyridines/adverse effects/therapeutic use/administration & dosage MH - Aged MH - Adult MH - Prognosis MH - Incidence MH - Erb-b2 Receptor Tyrosine Kinases/metabolism MH - Aged, 80 and over PMC - PMC11145009 OTO - NOTNLM OT - eczematous dermatitis OT - endocrine therapy OT - metastatic breast cancer OT - progression-free survival OT - ribociclib COIS- Armando Santoro reported advisory boards for Bristol-Myers-Squibb (BMS), Servier, Gilead, Pfizer, Eisai, Bayer, Merck Sharp and Dohme (MSD); consultancy for Arqule, Sanofi, Incyte; speaker's bureau for Takeda, BMS, Roche, Abb-Vie, Amgen, Celgene, Servier, Gilead, AstraZeneca, Pfizer, Arqule, Lilly, Sandoz, Eisai, Novartis, Bayer, MSD (all outside the submitted work). Rita De Sanctis reported honoraria for advisory board consultancy from Novartis, Istituto Clinico Gentili, Amgen, EISAI, Lilly, Gilead, and Ipsen (all outside the present work). The other authors indicated no financial relationships. EDAT- 2024/01/20 05:42 MHDA- 2024/06/03 06:42 PMCR- 2024/01/18 CRDT- 2024/01/19 21:37 PHST- 2023/08/04 00:00 [received] PHST- 2023/12/04 00:00 [accepted] PHST- 2024/06/03 06:42 [medline] PHST- 2024/01/20 05:42 [pubmed] PHST- 2024/01/19 21:37 [entrez] PHST- 2024/01/18 00:00 [pmc-release] AID - 7577601 [pii] AID - oyae004 [pii] AID - 10.1093/oncolo/oyae004 [doi] PST - ppublish SO - Oncologist. 2024 Jun 3;29(6):484-492. doi: 10.1093/oncolo/oyae004. PMID- 38242561 OWN - NLM STAT- MEDLINE DCOM- 20240122 LR - 20260501 IS - 2053-3624 (Print) IS - 2053-3624 (Electronic) IS - 2053-3624 (Linking) VI - 11 IP - 1 DP - 2024 Jan 19 TI - Multiprofessional heart failure self-development framework. LID - 10.1136/openhrt-2023-002554 [doi] LID - e002554 AB - OBJECTIVE: Heart failure remains a key public health priority across the globe. The median age of people with heart failure admitted to hospital in the UK is 81 years old. Many such patients transcend the standard interventions that are well characterised and evidenced in guidelines, into holistic aspects surrounding frailty, rehabilitation and social care. Previous published competency frameworks in heart failure have focused on the value of doctors, nurses and pharmacists. We aimed to provide an expert consensus on the minimum heart failure-specific competencies necessary for multiple different healthcare professionals, including physiotherapists, occupational therapists, dietitians and cardiac physiologists. METHODS: The document has been developed focussing on four main parts, (1) establishing a project working group of expert professionals, (2) a literature review of previously existing published curricula and competency frameworks, (3) consensus building, which included developing a structure to the framework with ongoing review of the contents to adapt and be inclusive for each specialty and (4) write up and dissemination to widen the impact of the project. RESULTS: The final competency framework displays competencies across seven sections; knowledge (including subheadings on heart failure syndrome, diagnosis and clinical management); general skills; heart failure-specific skills; clinical autonomy; multidisciplinary team working; teaching and education; and research and development. CONCLUSION: People with heart failure can be complex and have needs that require input from a broad range of specialties. This publication focuses on the vital impact of wider multidisciplinary groups and should help define the generic core heart failure-specific competencies needed to support future pipelines of professionals, who regularly interact with and deliver care for patients with heart failure. CI - (c) Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Forsyth, Paul AU - Forsyth P AUID- ORCID: 0000-0003-3804-6795 AD - Pharmacy, NHS Greater Glasgow and Clyde, Glasgow, UK. FAU - Young, Susan AU - Young S AD - Physiotherapy, Aneurin Bevan University Health Board, Newport, UK. FAU - Hughes, Kirsty AU - Hughes K AD - Physiotherapy, Forth Valley Royal Hospital, Larbert, UK. FAU - James, Ruby AU - James R AD - Occupational Therapy, Cwm Taf Morgannwg University Health Board, Abercynon, UK. FAU - Oxley, Cheryl AU - Oxley C AD - Cardiac Physiology Services, University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, UK. FAU - Kelly, Ruth AU - Kelly R AD - Cardiac Physiology Services, Golden Jubilee National Hospital, Clydebank, UK. FAU - Jones, Rebecca AU - Jones R AD - Dietetics, St George's University Hospitals NHS Foundation Trust, London, UK. FAU - Briggs, Sarah AU - Briggs S AD - Rotherham NHS Foundation Trust, Rotherham, UK. FAU - Mackay-Thomas, Lynn AU - Mackay-Thomas L AD - British Society for Heart Failure, London, UK. FAU - Millerick, Yvonne AU - Millerick Y AD - Glasgow Caledonian University, Glasgow, UK. FAU - Simpson, Maggie AU - Simpson M AD - NHS Greater Glasgow and Clyde, Glasgow, UK. FAU - Taylor, Clare J AU - Taylor CJ AUID- ORCID: 0000-0001-8926-2581 AD - Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK. FAU - Beggs, Simon AU - Beggs S AD - NHS Greater Glasgow and Clyde, Glasgow, UK. FAU - Piper, Susan AU - Piper S AD - Cardiology, King's College Hospital, London, UK. FAU - Duckett, Simon AU - Duckett S AD - Department of Cardiology, Royal Stoke University Hospital, Stoke-on-Trent, UK Simon.Duckett@uhnm.nhs.uk. AD - Department of Cardiology, Keele University, Keele, UK. LA - eng PT - Consensus Statement PT - Journal Article PT - Review DEP - 20240119 PL - England TA - Open Heart JT - Open heart JID - 101631219 SB - IM MH - Humans MH - Aged, 80 and over MH - *Health Personnel/education MH - Curriculum MH - *Heart Failure/diagnosis/therapy PMC - PMC10806483 OTO - NOTNLM OT - Clinical Competence OT - Education, Medical OT - Heart Failure COIS- Competing interests: None declared. EDAT- 2024/01/20 05:42 MHDA- 2024/01/22 06:43 PMCR- 2024/01/19 CRDT- 2024/01/19 20:43 PHST- 2023/12/25 00:00 [accepted] PHST- 2024/01/22 06:43 [medline] PHST- 2024/01/20 05:42 [pubmed] PHST- 2024/01/19 20:43 [entrez] PHST- 2024/01/19 00:00 [pmc-release] AID - openhrt-2023-002554 [pii] AID - 10.1136/openhrt-2023-002554 [doi] PST - epublish SO - Open Heart. 2024 Jan 19;11(1):e002554. doi: 10.1136/openhrt-2023-002554. PMID- 38230495 OWN - NLM STAT- MEDLINE DCOM- 20240207 LR - 20260127 IS - 1897-4279 (Electronic) IS - 0022-9032 (Linking) VI - 82 IP - 1 DP - 2024 TI - The use of andexanet alpha in the Polish setting: An interdisciplinary protocol. Expert consensus statement of the Polish Cardiac Society. PG - 123-139 LID - 10.33963/v.kp.98059 [doi] AB - Andexanet alfa (AA) is a recombinant inactive analog of human activated factor X (FXa), effectively reversing the effects of its inhibitors - rivaroxaban and apixaban, which are available in Poland. The drug was approved for clinical use registration after the publication of the results of the ANNEXA-4 trial (Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of FXa Inhibitors 4), in which its efficacy in restoring hemostasis in life-threatening hemorrhages in patients receiving using the aforementioned anticoagulants was demonstrated. Hence, AA is now recommended for patients on apixaban or rivaroxaban therapy with massive and uncontrollable hemorrhages, including hemorrhagic strokes (HS) and gastrointestinal bleeding. Drug-specific chromogenic anti-Xa assays are generally best suited for estimating rivaroxaban and apixaban plasma levels, aside from direct assessment of their concentrations. The absence of anti-Xa activity, determined using these assays, allows us to rule out the presence of clinically relevant plasma concentrations of any FXa inhibitor. On the other hand, the dose of AA should not be modified based on the results of coagulation tests, as it depends solely on the time that elapsed since the last dose of FXa inhibitor and oon the dose and type of FXa inhibitor. AA is administered as an intravenous (i.v.) bolus, followed by an i.v. infusion of the drug. The maximum reversal of anti-Xa activity occurs within two minutes of the end of the bolus treatment, with the continuation of the continuous i.v. infusion allowing the effect to be maintained for up to two hours afterwards. Because anticoagulant activity can reappear after the infusion is completed, it is currently unclear at what point after AA administration FXa inhibitors or heparin should be re-administered. In Poland AA is starting to become available and its urgent need to administer it to patients with severe bleeding on apixaban or rivaroxaban. FAU - Kazimierczyk, Ewelina AU - Kazimierczyk E AD - Department of Cardiology, University Clinical Hospital in Bialystok, Bialystok, Poland. e-kazimierczyk@wp.pl. FAU - Dabrowska, Milena AU - Dabrowska M AD - Department of Hematology Diagnostic, University Clinical Hospital in Bialystok, Bialystok, Poland. FAU - Gierlotka, Marek AU - Gierlotka M AD - Department of Cardiology, University Clinical Hospital in Opole, Opole, Poland. FAU - Kapica-Topczewska, Katarzyna AU - Kapica-Topczewska K AD - Department of Neurology and Stroke Unit, University Clinical Hospital in Bialystok, Bialystok, Poland. FAU - Karaszewski, Bartosz AU - Karaszewski B AD - Department of Neurology, Medical University of Gdansk, Gdansk, Poland. FAU - Kobayashi, Adam AU - Kobayashi A AD - Department of Pharmacology and Clinical Pharmacology, Institute of Medical Sciences, Faculty of Medicine - Collegium Medicum, Cardinal Stefan Wyszynski University in Warsaw, Warszawa, Poland. FAU - Krasinski, Zbigniew AU - Krasinski Z AD - Department of Vascular, Endovascular, Angiology and Phlebology Surgery (CNWA), Poznan University of Medical Sciences, Poznan, Poland. FAU - Kubica, Jacek AU - Kubica J AD - Department of Cardiology and Internal Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland. FAU - Kulakowska, Alina AU - Kulakowska A AD - Department of Neurology and Stroke Unit, University Clinical Hospital in Bialystok, Bialystok, Poland. FAU - Kurek, Krzysztof AU - Kurek K AD - Department of Gastroenterology and Internal Medicine, University Clinical Hospital in Bialystok, Bialystok, Poland. FAU - Ladny, Robert AU - Ladny R AD - 1st Clinic of General and Endocrine Surgery, University Clinical Hospital in Bialystok, Bialystok, Poland. FAU - Pleban, Eliza AU - Pleban E AD - Vascular Surgery Clinic, Cardinal Stefan Wyszynski National Institute of Cardiology in Warsaw, Warszawa, Poland. FAU - Rejdak, Konrad AU - Rejdak K AD - Department of Neurology, Medical University of Lublin, Lublin, Poland. FAU - Rydzewska, Grazyna AU - Rydzewska G AD - Department of Internal Medicine and Gastroenterology and Subdivision of Inflammatory Bowel Diseases of the Ministry of Internal Affairs and Administration in Warsaw, Warszawa, Poland. FAU - Slowik, Agnieszka AU - Slowik A AD - Clinical Department of Neurology, University Hospital in Krakow, Krakow, Poland. FAU - Szopinski, Piotr AU - Szopinski P AD - Vascular Surgery Clinic, Cardinal Stefan Wyszynski National Institute of Cardiology in Warsaw, Warszawa, Poland. FAU - Wozniak, Arkadiusz AU - Wozniak A AD - Department of Vascular Surgery, University Clinical Hospital in Bialystok, Bialystok, Poland. FAU - Tycinska, Agnieszka AU - Tycinska A AD - Department of Cardiology, University Clinical Hospital in Bialystok, Bialystok, Poland. LA - eng PT - Consensus Statement PT - Journal Article DEP - 20240117 PL - Poland TA - Kardiol Pol JT - Kardiologia polska JID - 0376352 RN - 9NDF7JZ4M3 (Rivaroxaban) RN - 0 (PRT064445) RN - EC 3.4.21.6 (Factor Xa) RN - 0 (Factor Xa Inhibitors) RN - 0 (Recombinant Proteins) RN - 0 (Anticoagulants) SB - IM MH - Humans MH - *Rivaroxaban/therapeutic use MH - *Factor Xa/therapeutic use MH - Poland MH - Factor Xa Inhibitors/therapeutic use MH - Hemorrhage/chemically induced/drug therapy MH - Recombinant Proteins/therapeutic use MH - Anticoagulants/therapeutic use OTO - NOTNLM OT - andexanet alfa OT - antidote OT - apixaban OT - bleeding OT - non-vitamin K antagonist oral anticoagulants OT - rivaroxaban EDAT- 2024/01/17 06:42 MHDA- 2024/02/07 06:43 CRDT- 2024/01/17 04:23 PHST- 2023/10/31 00:00 [received] PHST- 2023/10/31 00:00 [accepted] PHST- 2024/02/07 06:43 [medline] PHST- 2024/01/17 06:42 [pubmed] PHST- 2024/01/17 04:23 [entrez] AID - VM/OJS/J/98059 [pii] AID - 10.33963/v.kp.98059 [doi] PST - ppublish SO - Kardiol Pol. 2024;82(1):123-139. doi: 10.33963/v.kp.98059. Epub 2024 Jan 17. PMID- 38227034 OWN - NLM STAT- MEDLINE DCOM- 20240117 LR - 20250326 IS - 1538-3598 (Electronic) IS - 0098-7484 (Print) IS - 0098-7484 (Linking) VI - 331 IP - 3 DP - 2024 Jan 16 TI - Nurse and Social Worker Palliative Telecare Team and Quality of Life in Patients With COPD, Heart Failure, or Interstitial Lung Disease: The ADAPT Randomized Clinical Trial. PG - 212-223 LID - 10.1001/jama.2023.24035 [doi] AB - IMPORTANCE: Many patients with chronic obstructive pulmonary disease (COPD), heart failure (HF), and interstitial lung disease (ILD) endure poor quality of life despite conventional therapy. Palliative care approaches may benefit this population prior to end of life. OBJECTIVE: Determine the effect of a nurse and social worker palliative telecare team on quality of life in outpatients with COPD, HF, or ILD compared with usual care. DESIGN, SETTING, AND PARTICIPANTS: Single-blind, 2-group, multisite randomized clinical trial with accrual between October 27, 2016, and April 2, 2020, in 2 Veterans Administration health care systems (Colorado and Washington), and including community-based outpatient clinics. Outpatients with COPD, HF, or ILD at high risk of hospitalization or death who reported poor quality of life participated. INTERVENTION: The intervention involved 6 phone calls with a nurse to help with symptom management and 6 phone calls with a social worker to provide psychosocial care. The nurse and social worker met weekly with a study primary care and palliative care physician and as needed, a pulmonologist, and cardiologist. Usual care included an educational handout developed for the study that outlined self-care for COPD, ILD, or HF. Patients in both groups received care at the discretion of their clinicians, which could include care from nurses and social workers, and specialists in cardiology, pulmonology, palliative care, and mental health. MAIN OUTCOMES AND MEASURES: The primary outcome was difference in change in quality of life from baseline to 6 months between the intervention and usual care groups (FACT-G score range, 0-100, with higher scores indicating better quality of life, clinically meaningful change >/=4 points). Secondary quality-of-life outcomes at 6 months included disease-specific health status (Clinical COPD Questionnaire; Kansas City Cardiomyopathy Questionnaire-12), depression (Patient Health Questionnaire-8) and anxiety (Generalized Anxiety Disorder-7) symptoms. RESULTS: Among 306 randomized patients (mean [SD] age, 68.9 [7.7] years; 276 male [90.2%], 30 female [9.8%]; 245 White [80.1%]), 177 (57.8%) had COPD, 67 (21.9%) HF, 49 (16%) both COPD and HF, and 13 (4.2%) ILD. Baseline FACT-G scores were similar (intervention, 52.9; usual care, 52.7). FACT-G completion was 76% (intervention, 117 of 154; usual care, 116 of 152) at 6 months for both groups. Mean (SD) length of intervention was 115.1 (33.4) days and included a mean of 10.4 (3.3) intervention calls per patient. In the intervention group, 112 of 154 (73%) patients received the intervention as randomized. At 6 months, mean FACT-G score improved 6.0 points in the intervention group and 1.4 points in the usual care group (difference, 4.6 points [95% CI, 1.8-7.4]; P = .001; standardized mean difference, 0.41). The intervention also improved COPD health status (standardized mean difference, 0.44; P = .04), HF health status (standardized mean difference, 0.41; P = .01), depression (standardized mean difference, -0.50; P < .001), and anxiety (standardized mean difference, -0.51; P < .001) at 6 months. CONCLUSIONS AND RELEVANCE: For adults with COPD, HF, or ILD who were at high risk of death and had poor quality of life, a nurse and social worker palliative telecare team produced clinically meaningful improvements in quality of life at 6 months compared with usual care. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02713347. FAU - Bekelman, David B AU - Bekelman DB AD - Department of Veterans Affairs, Eastern Colorado Health Care System, Aurora. AD - Seattle-Denver Center of Innovation for Veteran-Centered and Value-Driven Care, VA Eastern Colorado Health Care Systems, Aurora, Colorado. AD - Division of General Internal Medicine, Department of Medicine, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora. FAU - Feser, William AU - Feser W AD - Department of Veterans Affairs, Eastern Colorado Health Care System, Aurora. AD - Seattle-Denver Center of Innovation for Veteran-Centered and Value-Driven Care, VA Eastern Colorado Health Care Systems, Aurora, Colorado. AD - Department of Biostatistics and Informatics, Colorado School of Public Health, Anschutz Medical Campus, Aurora. FAU - Morgan, Brianne AU - Morgan B AD - Department of Veterans Affairs, Eastern Colorado Health Care System, Aurora. AD - Seattle-Denver Center of Innovation for Veteran-Centered and Value-Driven Care, VA Eastern Colorado Health Care Systems, Aurora, Colorado. FAU - Welsh, Carolyn H AU - Welsh CH AD - Department of Veterans Affairs, Eastern Colorado Health Care System, Aurora. AD - Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora. FAU - Parsons, Elizabeth C AU - Parsons EC AD - Department of Veterans Affairs, Puget Sound Health Care System, Seattle, Washington. AD - Pulmonary, Critical Care and Sleep Medicine, University of Washington, Seattle. FAU - Paden, Grady AU - Paden G AD - Department of Veterans Affairs, Puget Sound Health Care System, Seattle, Washington. AD - Division of General Internal Medicine, Department of Medicine, University of Washington School of Medicine, Seattle. FAU - Baron, Anna AU - Baron A AD - Department of Veterans Affairs, Eastern Colorado Health Care System, Aurora. AD - Seattle-Denver Center of Innovation for Veteran-Centered and Value-Driven Care, VA Eastern Colorado Health Care Systems, Aurora, Colorado. AD - Department of Biostatistics and Informatics, Colorado School of Public Health, Anschutz Medical Campus, Aurora. FAU - Hattler, Brack AU - Hattler B AD - Department of Veterans Affairs, Eastern Colorado Health Care System, Aurora. AD - Division of Cardiology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora. FAU - McBryde, Connor AU - McBryde C AD - Department of Veterans Affairs, Eastern Colorado Health Care System, Aurora. AD - Division of General Internal Medicine, Department of Medicine, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora. FAU - Cheng, Andrew AU - Cheng A AD - Department of Veterans Affairs, Puget Sound Health Care System, Seattle, Washington. AD - Division of Cardiology, Department of Medicine, University of Washington School of Medicine, Seattle. FAU - Lange, Allison V AU - Lange AV AD - Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora. FAU - Au, David H AU - Au DH AD - Seattle-Denver Center of Innovation for Veteran-Centered and Value-Driven Care, VA Eastern Colorado Health Care Systems, Aurora, Colorado. AD - Department of Veterans Affairs, Puget Sound Health Care System, Seattle, Washington. AD - Pulmonary, Critical Care and Sleep Medicine, University of Washington, Seattle. LA - eng SI - ClinicalTrials.gov/NCT02713347 GR - I01 HX001770/HX/HSRD VA/United States PT - Comparative Study PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't PL - United States TA - JAMA JT - JAMA JID - 7501160 SB - IM CIN - JAMA. 2024 Jan 16;331(3):196-198. doi: 10.1001/jama.2023.26815. PMID: 38227043 EIN - JAMA. 2025 Apr 15;333(15):1364. doi: 10.1001/jama.2025.3767. PMID: 40136260 MH - Adult MH - Aged MH - Female MH - Humans MH - Male MH - *Heart Failure/nursing/therapy MH - Lung Diseases, Interstitial/nursing/therapy MH - Quality of Life MH - Single-Blind Method MH - Social Workers MH - *Telemedicine/methods MH - Nurse's Role MH - *Palliative Care/methods MH - Pulmonary Disease, Chronic Obstructive/nursing/therapy MH - *Patient Care Team/organization & administration MH - Terminal Care/methods MH - Ambulatory Care/methods MH - Veterans Health Services MH - *Lung Diseases/nursing/therapy MH - Nurses PMC - PMC10792473 COIS- Conflict of Interest Disclosures: Dr Baron reported other (individual personnel agreement) from the Rocky Mountain Regional VA Medical Center during the conduct of the study. Dr Au reported grants from the National Heart, Lung, and Blood Institute and the American Lung Association; other grants from the VA; a contract from the Patient-Centered Outcome Research Institute; and personal fees from Boehringer Ingelheim (advisory board on COPD quality of care) and from Annals of the American Thoracic Society (Deputy Editor) outside the submitted work. No other disclosures were reported. EDAT- 2024/01/16 13:41 MHDA- 2024/01/17 06:42 PMCR- 2024/07/16 CRDT- 2024/01/16 11:07 PHST- 2024/01/17 06:42 [medline] PHST- 2024/01/16 13:41 [pubmed] PHST- 2024/01/16 11:07 [entrez] PHST- 2024/07/16 00:00 [pmc-release] AID - 2813881 [pii] AID - joi230142 [pii] AID - 10.1001/jama.2023.24035 [doi] PST - ppublish SO - JAMA. 2024 Jan 16;331(3):212-223. doi: 10.1001/jama.2023.24035. PMID- 38224253 OWN - NLM STAT- MEDLINE DCOM- 20240116 LR - 20250116 IS - 1969-6213 (Electronic) IS - 1774-024X (Print) IS - 1774-024X (Linking) VI - 20 IP - 2 DP - 2024 Jan 15 TI - Contemporary guideline-directed management of patients with severe aortic valve stenosis. PG - e158-e167 LID - EIJ-D-23-00469 [pii] LID - 10.4244/EIJ-D-23-00469 [doi] AB - BACKGROUND: Both surgical aortic valve replacement (SAVR) and transcatheter aortic valve implantation (TAVI) are Class Ia recommended therapies for specific subgroups of severe aortic stenosis (AS) patients in the latest 2021 European guidelines. AIMS: We aimed to report on the multidisciplinary Heart Team evaluation process and real-world practice of treating severe symptomatic AS in East Denmark in the context of the latest European guideline recommendations. METHODS: All consecutive patients with severe AS referred for intervention in 2021 (N=672) were discussed in a multidisciplinary Heart Team meeting. All patients (100%) had a cardiac computed tomography (CT) analysis prior to the meeting. Baseline characteristics, Heart Team decision-making, final treatment and 30-day clinical outcomes were prospectively recorded. RESULTS: The majority of severe AS patients (N=456, 68%) were referred for TAVI following discussion in the Heart Team. Ultimately, 94% of patients (N=632) received the Heart Team-recommended treatment. Patients undergoing TAVI (N=439) were significantly older (78.4+/-6.7 vs 67.2+/-8.3 years; p<0.001) and more comorbid than patients undergoing SAVR (N=189). The overall 30-day clinical outcomes were satisfactory for both treatment groups (overall 30-day mortality: 1.1%). The mean index hospitalisation length was markedly longer in the SAVR group (8.6+/-8.3 days) as compared to the TAVI group (1.8+/-3.2 days). CONCLUSIONS: TAVI was routinely performed in low surgical risk patients in 2021 with two-thirds of all severe AS patients undergoing TAVI, thereby applying the latest European guidelines. A dedicated Heart Team meeting, including CT evaluation for all AS patients, is needed to make individualised management decisions in this new era of aortic valve interventions. FAU - Wang, Xi AU - Wang X AD - The Heart Centre, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. AD - Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China. FAU - Arslani, Ketina AU - Arslani K AD - The Heart Centre, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. FAU - Nuyens, Philippe AU - Nuyens P AD - The Heart Centre, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. FAU - Montarello, Nicholas J AU - Montarello NJ AD - The Heart Centre, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. FAU - Vanhaverbeke, Maarten AU - Vanhaverbeke M AD - The Heart Centre, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. FAU - Bieliauskas, Gintautas AU - Bieliauskas G AD - The Heart Centre, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. FAU - Sondergaard, Lars AU - Sondergaard L AD - Abbott, Santa Clara, CA, USA. FAU - De Backer, Ole AU - De Backer O AD - The Heart Centre, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. LA - eng PT - Journal Article DEP - 20240115 PL - France TA - EuroIntervention JT - EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology JID - 101251040 SB - IM MH - Humans MH - Heart MH - *Transcatheter Aortic Valve Replacement MH - Hospitalization MH - Patients MH - *Aortic Valve Stenosis/surgery PMC - PMC10786179 COIS- K. Arslani has received research grants from the Swiss Academy of Medical Sciences, the Gottfried and Julia Bangerter-Rhyner-Foundation, and the Swiss National Science Foundation (P500PM_202963), Switzerland, outside the submitted work. G. Bieliauskas has received consulting fees from Abbott, Boston Scientific, and Medtronic. L. Sondergaard is Chief Medical Officer at Abbott Structural Heart; and has received institutional research grants and/or consulting fees from Abbott, Boston Scientific, Medtronic, and SMT. O. De Backer has received institutional research grants and consulting fees from Abbott and Boston Scientific. The other authors have no conflicts of interest to declare. EDAT- 2024/01/15 12:42 MHDA- 2024/01/16 06:42 PMCR- 2025/01/15 CRDT- 2024/01/15 09:33 PHST- 2024/01/16 06:42 [medline] PHST- 2024/01/15 12:42 [pubmed] PHST- 2024/01/15 09:33 [entrez] PHST- 2025/01/15 00:00 [pmc-release] AID - EIJ-D-23-00469 [pii] AID - 10.4244/EIJ-D-23-00469 [doi] PST - epublish SO - EuroIntervention. 2024 Jan 15;20(2):e158-e167. doi: 10.4244/EIJ-D-23-00469. PMID- 38223296 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240116 IS - 2666-6677 (Electronic) IS - 2666-6677 (Linking) VI - 17 DP - 2024 Mar TI - Second-year results from CINEMA: A novel, patient-centered, team-based intervention for patients with Type 2 diabetes or prediabetes at high cardiovascular risk. PG - 100630 LID - 10.1016/j.ajpc.2023.100630 [doi] LID - 100630 AB - BACKGROUND: The care for patients with type 2 diabetes mellitus (T2DM) necessitates a multidisciplinary team approach to reduce cardiovascular (CV) risk but implementation of effective integrated strategies has been limited. METHODS AND RESULTS: We report 2-year results from a patient-centered, team-based intervention called CINEMA at University Hospitals Cleveland Medical Center. Patients with T2DM or prediabetes at high-risk for CV events, including those with established atherosclerotic CVD, elevated coronary artery calcium score >/=100, chronic heart failure with reduced ejection fraction, chronic kidney disease (CKD) stages 2-4, and/or prevalent metabolic syndrome were included. From May 2020 through September 2022, 426 patients were enrolled in the CINEMA program. A total of 227 (54%) completed >/=1 follow-up visit after an initial baseline visit with median (IQR) follow-up time 4 [3], [4], [5], [6], [7] months with maximum follow-up time 19 months. Mean age was 60 years, 47 % were women, and 37 % were Black and 85% had prevalent T2DM, 48 % had established ASCVD, 29% had chronic HF, 27% had CKD and mean baseline 10-year ASCVD risk estimate was 25.1 %; baseline use of a SGLT2i or GLP-1RA was 21 % and 18 %, respectively. Patients had significant reductions from baseline in body weight (-5.5 lbs), body mass index (-0.9 kg/m(2)), systolic (-3.6 mmHg) and diastolic (-1.2 mmHg) blood pressure, Hb A1c (-0.5 %), total (-10.7 mg/dL) and low-density lipoprotein (-9.0 mg/dL) cholesterol, and triglycerides (-13.5 mg/dL) (p<0.05 for all). Absolute 10-year predicted ASCVD risk decreased by approximately 2.4 % (p<0.001) with the intervention. In addition, rates of guideline-directed cardiometabolic medication prescriptions significantly increased during follow-up with the most substantive changes seen in rates of SGLT2i and GLP-1RA use which approximately tripled from baseline (21 % to 57 % for SGLT2i and 18 % to 65 % for GLP-1RA, p<0.001 for both). CONCLUSIONS: The CINEMA program, an integrated, patient-centered, team-based intervention for patients with T2DM or prediabetes at high risk for cardiovascular disease has continued to demonstrate effectiveness with significant improvements in ASCVD risk factors and improved use of evidence-based therapies. Successful implementation and dissemination of this care delivery paradigm remains a key priority. CI - (c) 2023 The Author(s). FAU - Neeland, Ian J AU - Neeland IJ AD - Case Western Reserve University School of Medicine, Cleveland, OH 44106, United States. AD - Division of Cardiovascular Medicine, University Hospitals Harrington Heart and Vascular Institute, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, United States. FAU - Arafah, Ala' AU - Arafah A AD - Case Western Reserve University School of Medicine, Cleveland, OH 44106, United States. FAU - Bourges-Sevenier, Brendan AU - Bourges-Sevenier B AD - Division of Cardiovascular Medicine, University Hospitals Harrington Heart and Vascular Institute, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, United States. FAU - Dazard, Jean-Eudes AU - Dazard JE AD - Case Western Reserve University School of Medicine, Cleveland, OH 44106, United States. FAU - Albar, Zainab AU - Albar Z AD - Case Western Reserve University School of Medicine, Cleveland, OH 44106, United States. FAU - Landskroner, Zoe AU - Landskroner Z AD - Division of Cardiovascular Medicine, University Hospitals Harrington Heart and Vascular Institute, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, United States. FAU - Tashtish, Nour AU - Tashtish N AD - Case Western Reserve University School of Medicine, Cleveland, OH 44106, United States. AD - Division of Cardiovascular Medicine, University Hospitals Harrington Heart and Vascular Institute, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, United States. FAU - Eaton, Elke AU - Eaton E AD - Division of Cardiovascular Medicine, University Hospitals Harrington Heart and Vascular Institute, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, United States. FAU - Friswold, Janice AU - Friswold J AD - Division of Cardiovascular Medicine, University Hospitals Harrington Heart and Vascular Institute, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, United States. FAU - Porges, Jodie AU - Porges J AD - Division of Cardiovascular Medicine, University Hospitals Harrington Heart and Vascular Institute, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, United States. FAU - Nennstiel, Matthew AU - Nennstiel M AD - University Hospitals Health System, Cleveland, OH 44106, United States. FAU - Davies, Amanda AU - Davies A AD - Division of Cardiovascular Medicine, University Hospitals Harrington Heart and Vascular Institute, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, United States. FAU - Rahmani, Sara AU - Rahmani S AD - Division of Cardiovascular Medicine, University Hospitals Harrington Heart and Vascular Institute, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, United States. FAU - Howard, Quiana S AU - Howard QS AD - Division of Cardiovascular Medicine, University Hospitals Harrington Heart and Vascular Institute, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, United States. FAU - Forrest, Katherine AU - Forrest K AD - Division of Cardiovascular Medicine, University Hospitals Harrington Heart and Vascular Institute, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, United States. FAU - Sullivan, Claire AU - Sullivan C AD - Case Western Reserve University School of Medicine, Cleveland, OH 44106, United States. AD - Division of Cardiovascular Medicine, University Hospitals Harrington Heart and Vascular Institute, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, United States. FAU - Greene, Lloyd AU - Greene L AD - Case Western Reserve University School of Medicine, Cleveland, OH 44106, United States. AD - Division of Cardiovascular Medicine, University Hospitals Harrington Heart and Vascular Institute, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, United States. FAU - Al-Kindi, Sadeer G AU - Al-Kindi SG AD - Case Western Reserve University School of Medicine, Cleveland, OH 44106, United States. AD - Division of Cardiovascular Medicine, University Hospitals Harrington Heart and Vascular Institute, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, United States. FAU - Rajagopalan, Sanjay AU - Rajagopalan S AD - Case Western Reserve University School of Medicine, Cleveland, OH 44106, United States. AD - Division of Cardiovascular Medicine, University Hospitals Harrington Heart and Vascular Institute, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, United States. LA - eng PT - Journal Article DEP - 20231221 PL - Netherlands TA - Am J Prev Cardiol JT - American journal of preventive cardiology JID - 101769122 PMC - PMC10787236 OTO - NOTNLM OT - Cardiovascular disease OT - Complications OT - Diabetes, Type 2 OT - Health services OT - Quality and outcomes OT - Risk factors OT - Secondary prevention COIS- The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Ian Neeland reports a relationship with Boehringer Ingelheim GmbH that includes: consulting or advisory and speaking and lecture fees. Ian Neeland reports a relationship with Eli Lilly and Company that includes: consulting or advisory and speaking and lecture fees. Ian Neeland reports a relationship with Bayer AG that includes: consulting or advisory and speaking and lecture fees. Ian Neeland reports a relationship with AMRA that includes: consulting or advisory. Sanjay Rajagopalan reports a relationship with Novo Nordisk Inc that includes: consulting or advisory. Sanjay Rajagopalan reports a relationship with Bayer AG that includes: consulting or advisory. EDAT- 2024/01/15 06:42 MHDA- 2024/01/15 06:43 PMCR- 2023/12/21 CRDT- 2024/01/15 04:45 PHST- 2023/10/11 00:00 [received] PHST- 2023/12/11 00:00 [revised] PHST- 2023/12/18 00:00 [accepted] PHST- 2024/01/15 06:43 [medline] PHST- 2024/01/15 06:42 [pubmed] PHST- 2024/01/15 04:45 [entrez] PHST- 2023/12/21 00:00 [pmc-release] AID - S2666-6677(23)00171-X [pii] AID - 100630 [pii] AID - 10.1016/j.ajpc.2023.100630 [doi] PST - epublish SO - Am J Prev Cardiol. 2023 Dec 21;17:100630. doi: 10.1016/j.ajpc.2023.100630. eCollection 2024 Mar. PMID- 38223276 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260311 IS - 2284-2594 (Electronic) IS - 2284-2594 (Linking) VI - 11 IP - 1 DP - 2024 TI - Escherichia Coli Endocarditis and Cardiac Abscess: A Rare Presentation in a Patient with a Prosthetic Aortic Valve. PG - 004203 LID - 10.12890/2023_004203 [doi] LID - 004203 AB - INTRODUCTION: There are very few documented cases of Escherichia coli endocarditis with cardiac abscesses in the literature. Here we describe a case presentation with diagnostic challenges and a multidisciplinary approach to management. CASE DESCRIPTION: This is a rare presentation of E. coli endocarditis in a patient with a prosthetic aortic valve. Initial tests were inconclusive and further investigation with transoesophageal echocardiography was required to make the diagnosis. Despite initial improvement, the patient deteriorated and ultimately died of complications related to the presentation. DISCUSSION/CONCLUSION: E. coli is a rare causative organism for endocarditis, which can itself be difficult to diagnose. A multidisciplinary approach to investigation and treatment is required when infective endocarditis is suspected. Transoesophageal echocardiography may be required to diagnose endocarditis when there is a strong clinical suspicion and risk factors present. LEARNING POINTS: Infective endocarditis should be thoroughly investigated for in cases where there is a high clinical suspicion, but atypical organisms grown in blood cultures.A transoesophageal echocardiogram (TOE) may be a better imaging modality when endocarditis is strongly suspected, in comparison to a transthoracic echocardiogram (TTE).Escherichia coli endocarditis carries a high mortality rate, and early intervention is key in managing patients presenting with suspected endocarditis. CI - (c) EFIM 2024. FAU - Chavada, Ishan J AU - Chavada IJ AD - Acute Medicine Department, University Hospitals Coventry & Warwickshire, Coventry, UK. FAU - Anwar, Ramsha AU - Anwar R AD - Acute Medicine Department, University Hospitals Coventry & Warwickshire, Coventry, UK. FAU - Dumont, Michael W AU - Dumont MW AD - Anaesthetics Department, University Hospitals Coventry & Warwickshire, Coventry, UK. FAU - Khutubuddin, Mohammed AU - Khutubuddin M AD - Acute Medicine Department, University Hospitals Coventry & Warwickshire, Coventry, UK. LA - eng PT - Journal Article DEP - 20231213 PL - Italy TA - Eur J Case Rep Intern Med JT - European journal of case reports in internal medicine JID - 101648453 EIN - Eur J Case Rep Intern Med. 2023 Dec 14;11(1):004271. doi: 10.12890/2023_004271. PMID: 38223270 PMC - PMC10783450 OTO - NOTNLM OT - Endocarditis OT - Escherichia coli OT - echocardiogram COIS- Conflicts of Interests: The Authors declare that there are no competing interests. EDAT- 2024/01/15 06:42 MHDA- 2024/01/15 06:43 PMCR- 2023/12/13 CRDT- 2024/01/15 04:44 PHST- 2023/11/22 00:00 [received] PHST- 2023/11/27 00:00 [accepted] PHST- 2024/01/15 06:43 [medline] PHST- 2024/01/15 06:42 [pubmed] PHST- 2024/01/15 04:44 [entrez] PHST- 2023/12/13 00:00 [pmc-release] AID - 4203 [pii] AID - 10.12890/2023_004203 [doi] PST - epublish SO - Eur J Case Rep Intern Med. 2023 Dec 13;11(1):004203. doi: 10.12890/2023_004203. eCollection 2024. PMID- 38217112 OWN - NLM STAT- MEDLINE DCOM- 20240514 LR - 20240516 IS - 1365-2362 (Electronic) IS - 0014-2972 (Linking) VI - 54 IP - 6 DP - 2024 Jun TI - Early diagnosis and management of cardiac amyloidosis: A clinical perspective. PG - e14160 LID - 10.1111/eci.14160 [doi] AB - Cardiac amyloidosis multidisciplinary team (MDT). We propose the creation of a multidisciplinary team (MDT) for cardiac amyloidosis in which internal medicine physicians could take a lead role in coordinating other specialists involved in patient care. Created with BioRender.com. CI - (c) 2024 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd. FAU - Bellofatto, Ilaria Anna AU - Bellofatto IA AD - First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, Genoa, Italy. FAU - Schindler, Thomas H AU - Schindler TH AUID- ORCID: 0000-0002-2141-7716 AD - Mallinckrodt Institute of Radiology, Division of Nuclear Medicine, Cardiovascular Medicine, Washington University School of Medicine, St. Louis, Missouri, USA. FAU - Portincasa, Piero AU - Portincasa P AUID- ORCID: 0000-0001-5359-1471 AD - Clinica Medica "A. Murri", Department of Preventive and Regenerative Medicine and Ionian Area (DiMePrev-J), University of Bari Aldo Moro, Bari, Italy. FAU - Carbone, Federico AU - Carbone F AUID- ORCID: 0000-0003-2957-4078 AD - First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, Genoa, Italy. AD - IRCCS Ospedale Policlinico San Martino-Italian Cardiovascular Network, Genoa, Italy. FAU - Canepa, Marco AU - Canepa M AUID- ORCID: 0000-0001-9063-5576 AD - Cardiology Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy. AD - Department of Internal Medicine, University of Genova, Genoa, Italy. FAU - Liberale, Luca AU - Liberale L AUID- ORCID: 0000-0003-1472-7975 AD - First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, Genoa, Italy. AD - IRCCS Ospedale Policlinico San Martino-Italian Cardiovascular Network, Genoa, Italy. FAU - Montecucco, Fabrizio AU - Montecucco F AUID- ORCID: 0000-0003-0823-8729 AD - First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, Genoa, Italy. AD - IRCCS Ospedale Policlinico San Martino-Italian Cardiovascular Network, Genoa, Italy. LA - eng PT - Journal Article PT - Review DEP - 20240112 PL - England TA - Eur J Clin Invest JT - European journal of clinical investigation JID - 0245331 SB - IM MH - Humans MH - *Early Diagnosis MH - *Amyloidosis/diagnosis/therapy MH - *Cardiomyopathies/therapy/diagnosis MH - *Patient Care Team MH - Amyloid Neuropathies, Familial/diagnosis/therapy OTO - NOTNLM OT - amyloidosis management team OT - cardiac amyloidosis OT - internal medicine OT - narrative review EDAT- 2024/01/13 17:43 MHDA- 2024/05/14 06:42 CRDT- 2024/01/13 00:53 PHST- 2023/12/13 00:00 [revised] PHST- 2023/11/02 00:00 [received] PHST- 2023/12/19 00:00 [accepted] PHST- 2024/05/14 06:42 [medline] PHST- 2024/01/13 17:43 [pubmed] PHST- 2024/01/13 00:53 [entrez] AID - 10.1111/eci.14160 [doi] PST - ppublish SO - Eur J Clin Invest. 2024 Jun;54(6):e14160. doi: 10.1111/eci.14160. Epub 2024 Jan 12. PMID- 38216064 OWN - NLM STAT- MEDLINE DCOM- 20240214 LR - 20260511 IS - 1874-1754 (Electronic) IS - 0167-5273 (Linking) VI - 399 DP - 2024 Mar 15 TI - Unmet needs in end-of-life care for heart failure patients. PG - 131750 LID - S0167-5273(24)00042-1 [pii] LID - 10.1016/j.ijcard.2024.131750 [doi] AB - OBJECTIVE: To investigate end-of-life (EoL) care for heart failure (HF) in Tuscany (Italy) from healthcare professionals' perspective and identify areas for intervention. METHODS: All the directors of Cardiology units (n = 29) and palliative care (PC) units (n = 14) in Tuscany were surveyed on the practices of EoL care. RESULTS: Forty-five percent of cardiologists reported that their hospital had some EoL care services for HF patients. However, 75% did not have a multidisciplinary team providing EoL care for HF patients. Sixty-four percent stated that <25% of patients who might benefit from PC did receive it, and 18% stated that no patient received PC. For most of PC specialists, HF patients accounted for <25% of their patients. PC specialists believed that patients with cancer diseases were much more likely to receive PC than HF patients at EoL, and 36% judged that almost no HF patients were timely referred to hospice care. The majority of PC specialists reported that almost no HF patient prepared advance healthcare directives, as opposite to 57% for cancer patients, suggesting poor understanding or acceptance of their terminal condition. CONCLUSIONS: The management of HF patients in the EoL stage in Tuscany is often suboptimal. EoL care should be implemented to ensure an adequate quality of life to these patients. CI - Copyright (c) 2024 Elsevier B.V. All rights reserved. FAU - Quattrone, Filippo AU - Quattrone F AD - Interdisciplinary Center for Health Sciences, Scuola Superiore Sant'Anna, Pisa, Italy. FAU - Aimo, Alberto AU - Aimo A AD - Interdisciplinary Center for Health Sciences, Scuola Superiore Sant'Anna, Pisa, Italy; Cardiology Division, Fondazione Toscana Gabriele Monasterio, Pisa, Italy. Electronic address: a.aimo@santannapisa.it. FAU - Zuccarino, Sara AU - Zuccarino S AD - Management and Healthcare Laboratory, Institute of Management and Department EMbeDS, Scuola Superiore Sant'Anna, Pisa, Italy. FAU - Morelli, Maria Sole AU - Morelli MS AD - Bioinformatica Traslazionale e e-Health, Fondazione Toscana Gabriele Monasterio, Pisa, Italy. FAU - Morfino, Paolo AU - Morfino P AD - Interdisciplinary Center for Health Sciences, Scuola Superiore Sant'Anna, Pisa, Italy. FAU - Gioia, Angela AU - Gioia A AD - Hospice, UF Cure Palliative, Azienda USL Toscana Nord Ovest, Pisa, Italy. FAU - Passino, Claudio AU - Passino C AD - Interdisciplinary Center for Health Sciences, Scuola Superiore Sant'Anna, Pisa, Italy; Management and Healthcare Laboratory, Institute of Management and Department EMbeDS, Scuola Superiore Sant'Anna, Pisa, Italy. FAU - Ferre, Francesca AU - Ferre F AD - Interdisciplinary Center for Health Sciences, Scuola Superiore Sant'Anna, Pisa, Italy; Management and Healthcare Laboratory, Institute of Management and Department EMbeDS, Scuola Superiore Sant'Anna, Pisa, Italy. FAU - Nuti, Sabina AU - Nuti S AD - Interdisciplinary Center for Health Sciences, Scuola Superiore Sant'Anna, Pisa, Italy; Management and Healthcare Laboratory, Institute of Management and Department EMbeDS, Scuola Superiore Sant'Anna, Pisa, Italy. FAU - Emdin, Michele AU - Emdin M AD - Interdisciplinary Center for Health Sciences, Scuola Superiore Sant'Anna, Pisa, Italy; Cardiology Division, Fondazione Toscana Gabriele Monasterio, Pisa, Italy. LA - eng PT - Journal Article DEP - 20240111 PL - Netherlands TA - Int J Cardiol JT - International journal of cardiology JID - 8200291 SB - IM MH - Humans MH - *Hospice Care MH - Quality of Life MH - *Terminal Care MH - Palliative Care MH - *Heart Failure/diagnosis/therapy MH - *Neoplasms OTO - NOTNLM OT - Cardiology OT - Care OT - End-of-life OT - Heart failure OT - Palliative care OT - cancer COIS- Declaration of competing interest None. EDAT- 2024/01/13 00:42 MHDA- 2024/02/12 05:43 CRDT- 2024/01/12 19:32 PHST- 2023/08/29 00:00 [received] PHST- 2023/12/22 00:00 [revised] PHST- 2024/01/02 00:00 [accepted] PHST- 2024/02/12 05:43 [medline] PHST- 2024/01/13 00:42 [pubmed] PHST- 2024/01/12 19:32 [entrez] AID - S0167-5273(24)00042-1 [pii] AID - 10.1016/j.ijcard.2024.131750 [doi] PST - ppublish SO - Int J Cardiol. 2024 Mar 15;399:131750. doi: 10.1016/j.ijcard.2024.131750. Epub 2024 Jan 11. PMID- 38214272 OWN - NLM STAT- MEDLINE DCOM- 20240117 LR - 20260617 IS - 2047-9980 (Electronic) IS - 2047-9980 (Linking) VI - 13 IP - 2 DP - 2024 Jan 16 TI - Effectiveness of Hypertension Management Strategies in SPRINT-Eligible US Adults: A Simulation Study. PG - e032370 LID - 10.1161/JAHA.123.032370 [doi] LID - e032370 AB - BACKGROUND: Despite reducing cardiovascular disease (CVD) events and death in SPRINT (Systolic Blood Pressure Intervention Trial), intensive systolic blood pressure goals have not been adopted in the United States. This study aimed to simulate the potential long-term impact of 4 hypertension management strategies in SPRINT-eligible US adults. METHODS AND RESULTS: The validated Blood Pressure Control-Cardiovascular Disease Policy Model, a discrete event simulation of hypertension care processes (ie, visit frequency, blood pressure [BP] measurement accuracy, medication intensification, and medication adherence) and CVD outcomes, was populated with 25 000 SPRINT-eligible US adults. Four hypertension management strategies were simulated: (1) usual care targeting BP <140/90 mm Hg (Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure usual care), (2) intensive care per the SPRINT protocol targeting BP <120/90 mm Hg (SPRINT intensive), (3) usual care targeting guideline-recommended BP <130/80 mm Hg (American College of Cardiology/American Heart Association usual care), and (4) team-based care added to usual care and targeting BP <130/80 mm Hg. Relative to the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure usual care, among the 18.1 million SPRINT-eligible US adults, an estimated 138 100 total CVD events could be prevented per year with SPRINT intensive, 33 900 with American College of Cardiology/American Heart Association usual care, and 89 100 with team-based care. Compared with the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure usual care, SPRINT intensive care was projected to increase treatment-related serious adverse events by 77 600 per year, American College of Cardiology/American Heart Association usual care by 33 300, and team-based care by 27 200. CONCLUSIONS: As BP control has declined in recent years, health systems must prioritize hypertension management and invest in effective strategies. Adding team-based care to usual care may be a pragmatic way to manage risk in this high-CVD-risk population. FAU - Zhang, Fengdi AU - Zhang F AUID- ORCID: 0009-0002-2380-0708 AD - Department of Medicine Columbia University New York NY USA. FAU - Bryant, Kelsey B AU - Bryant KB AUID- ORCID: 0000-0001-7180-8064 AD - Department of Medicine Mount Sinai New York NY USA. FAU - Moran, Andrew E AU - Moran AE AUID- ORCID: 0000-0003-3554-0085 AD - Department of Medicine Columbia University New York NY USA. FAU - Zhang, Yiyi AU - Zhang Y AUID- ORCID: 0000-0002-8663-5001 AD - Department of Medicine Columbia University New York NY USA. FAU - Cohen, Jordana B AU - Cohen JB AUID- ORCID: 0000-0003-4649-079X AD - Department of Medicine and Department of Biostatistics, Epidemiology, and Informatics University of Pennsylvania Philadelphia PA USA. FAU - Bress, Adam P AU - Bress AP AUID- ORCID: 0000-0002-2259-5039 AD - Intermountain Healthcare Department of Population Health Sciences University of Utah Salt Lake City UT USA. FAU - Sheppard, James P AU - Sheppard JP AUID- ORCID: 0000-0002-4461-8756 AD - Nuffield Department of Primary Care Health Sciences University of Oxford UK. FAU - King, Jordan B AU - King JB AUID- ORCID: 0000-0002-6783-7951 AD - Intermountain Healthcare Department of Population Health Sciences University of Utah Salt Lake City UT USA. AD - Institute for Health Research Kaiser Permanente Colorado Aurora CO USA. FAU - Derington, Catherine G AU - Derington CG AUID- ORCID: 0000-0001-7382-4607 AD - Intermountain Healthcare Department of Population Health Sciences University of Utah Salt Lake City UT USA. FAU - Weintraub, William S AU - Weintraub WS AUID- ORCID: 0000-0002-5384-5571 AD - Department of Medicine Georgetown University Washington DC USA. AD - MedStar Health Research Institute Washington DC USA. FAU - Kronish, Ian M AU - Kronish IM AUID- ORCID: 0000-0003-0945-2380 AD - Department of Medicine Columbia University New York NY USA. FAU - Shea, Steven AU - Shea S AUID- ORCID: 0000-0002-7382-0603 AD - Department of Medicine Columbia University New York NY USA. FAU - Bellows, Brandon K AU - Bellows BK AUID- ORCID: 0000-0003-1395-6047 AD - Department of Medicine Columbia University New York NY USA. LA - eng GR - R01 HL152699/HL/NHLBI NIH HHS/United States GR - K24 AG080168/AG/NIA NIH HHS/United States GR - R01 HL157108/HL/NHLBI NIH HHS/United States GR - R01 HL153646/HL/NHLBI NIH HHS/United States GR - R01 HL158790/HL/NHLBI NIH HHS/United States GR - R01 HL157439/HL/NHLBI NIH HHS/United States GR - WT_/Wellcome Trust/United Kingdom GR - K01 HL140170/HL/NHLBI NIH HHS/United States GR - R01 AG074989/AG/NIA NIH HHS/United States GR - R01 HL130500/HL/NHLBI NIH HHS/United States GR - R01 AG065805/AG/NIA NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20240112 PL - England TA - J Am Heart Assoc JT - Journal of the American Heart Association JID - 101580524 RN - 0 (Antihypertensive Agents) SB - IM MH - Adult MH - Humans MH - United States/epidemiology MH - *Cardiovascular Diseases/epidemiology MH - Antihypertensive Agents/therapeutic use/pharmacology MH - Risk Factors MH - *Hypertension/diagnosis/drug therapy/epidemiology MH - Blood Pressure PMC - PMC10926802 OTO - NOTNLM OT - blood pressure OT - cardiovascular diseases OT - hypertension EDAT- 2024/01/12 12:42 MHDA- 2024/01/17 06:42 PMCR- 2024/01/16 CRDT- 2024/01/12 07:50 PHST- 2024/01/17 06:42 [medline] PHST- 2024/01/12 12:42 [pubmed] PHST- 2024/01/12 07:50 [entrez] PHST- 2024/01/16 00:00 [pmc-release] AID - JAH39152 [pii] AID - 10.1161/JAHA.123.032370 [doi] PST - ppublish SO - J Am Heart Assoc. 2024 Jan 16;13(2):e032370. doi: 10.1161/JAHA.123.032370. Epub 2024 Jan 12. PMID- 38213664 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240113 IS - 1758-3764 (Electronic) IS - 1758-3756 (Print) IS - 1758-3756 (Linking) VI - 18 DP - 2023 TI - Evidence-based Management of Left Main Coronary Artery Disease. PG - e63 LID - 10.15420/ecr.2023.36 [doi] LID - e63 AB - Left main coronary artery disease (LMCAD) is associated with high morbidity and mortality due to the large myocardial mass at risk. Although medical treatment may be an option in selected low-risk patients, revascularisation is recommended to improve survival in the majority of patients presenting with a significant left main stenosis. In the past decade, multiple randomised clinical trials and meta-analyses have compared coronary artery bypass grafting surgery (CABG) versus percutaneous coronary intervention (PCI), finding controversial results. The strategy for LMCAD revascularisation is still challenging. Coronary anatomy complexity, clinical features and patient preferences are key elements to be considered by the heart team. The current guidelines define CABG as standard therapy, but the continuous improvements in PCI techniques, the use of intracoronary imaging and functional assessment make PCI a feasible alternative in selected patients, particularly in those with comorbidities and contraindications to CABG. This review analyses the most important studies comparing CABG versus PCI in patients with LMCAD. CI - Copyright (c) The Author(s), 2023. Published by Radcliffe Group Ltd. FAU - Torres-Ruiz, Gabriel AU - Torres-Ruiz G AD - Department of Cardiology, Parc Tauli Hospital Universitari Sabadell, Spain. AD - Department of Medicine, Universitat Autonoma de Barcelona Barcelona, Spain. FAU - Mallofre-Vila, Nuria AU - Mallofre-Vila N AD - Department of Cardiology, Parc Tauli Hospital Universitari Sabadell, Spain. AD - Department of Medicine, Universitat Autonoma de Barcelona Barcelona, Spain. FAU - Rojas-Flores, Paola AU - Rojas-Flores P AD - Department of Cardiology, Parc Tauli Hospital Universitari Sabadell, Spain. AD - Department of Medicine, Universitat Autonoma de Barcelona Barcelona, Spain. FAU - Carrion-Montaner, Pablo AU - Carrion-Montaner P AD - Department of Cardiology, Parc Tauli Hospital Universitari Sabadell, Spain. AD - Department of Medicine, Universitat Autonoma de Barcelona Barcelona, Spain. FAU - Bosch-Peligero, Eduard AU - Bosch-Peligero E AD - Department of Cardiology, Parc Tauli Hospital Universitari Sabadell, Spain. AD - Department of Medicine, Universitat Autonoma de Barcelona Barcelona, Spain. FAU - Valcarcel-Paz, Daniel AU - Valcarcel-Paz D AD - Department of Cardiology, Parc Tauli Hospital Universitari Sabadell, Spain. AD - Department of Medicine, Universitat Autonoma de Barcelona Barcelona, Spain. FAU - Cardiel-Perez, Ada AU - Cardiel-Perez A AD - Department of Gynaecology and Obstetrics, Hospital Clinic i Provincial Barcelona, Spain. FAU - Guindo-Soldevila, Josep AU - Guindo-Soldevila J AD - Department of Cardiology, Parc Tauli Hospital Universitari Sabadell, Spain. AD - Department of Medicine, Universitat Autonoma de Barcelona Barcelona, Spain. FAU - Martinez-Rubio, Antoni AU - Martinez-Rubio A AD - Department of Cardiology, Parc Tauli Hospital Universitari Sabadell, Spain. AD - Department of Medicine, Universitat Autonoma de Barcelona Barcelona, Spain. LA - eng PT - Journal Article PT - Review DEP - 20231219 PL - England TA - Eur Cardiol JT - European cardiology JID - 101574780 PMC - PMC10782428 OTO - NOTNLM OT - Bypass grafting OT - coronary artery disease OT - left main stenosis OT - percutaneous coronary intervention OT - stenting COIS- Disclosure: AMR is on the European Cardiology Review eidtorial board; this did not influence peer review. All other authors have no conflicts of interest to declare. EDAT- 2024/01/12 06:42 MHDA- 2024/01/12 06:43 PMCR- 2023/12/19 CRDT- 2024/01/12 03:44 PHST- 2023/08/14 00:00 [received] PHST- 2023/10/16 00:00 [accepted] PHST- 2024/01/12 06:43 [medline] PHST- 2024/01/12 06:42 [pubmed] PHST- 2024/01/12 03:44 [entrez] PHST- 2023/12/19 00:00 [pmc-release] AID - 10.15420/ecr.2023.36 [doi] PST - epublish SO - Eur Cardiol. 2023 Dec 19;18:e63. doi: 10.15420/ecr.2023.36. eCollection 2023. PMID- 38212100 OWN - NLM STAT- MEDLINE DCOM- 20240625 LR - 20260912 IS - 1468-201X (Electronic) IS - 1355-6037 (Linking) VI - 110 IP - 14 DP - 2024 Jun 25 TI - Cardiogeriatrics: the current state of the art. PG - 933-939 LID - 10.1136/heartjnl-2022-322117 [doi] AB - It is estimated that by 2050, 17% of the world's population will be greater than 85 years old, which, combined with cardiovascular disease (CVD) being the leading cause of death and disability, sets an unprecedented burden on our health and care systems. This perfect storm will be accompanied by a rise in the prevalence of CVD due to increased survival of patients with pre-existing CVD and the incidence of CVD that is associated with the process of ageing. In this review, we will focus on the diagnosis and management of common CVD conditions in old age, namely: heart failure (HF), coronary artery disease (CAD), atrial fibrillation (AF) and valvular heart disease (VHD). Despite limited evidence, clinical guidelines are increasingly considering the complexity of management of these conditions in the older person, which often coexist, for example, AF and HF or CAD and VHD. Furthermore, they, in turn, need specific consideration in the context of comorbidities, polypharmacy, frailty and impaired cognition found in this age group. Hence, the emerging role of the geriatric cardiologist is therefore vital in performing comprehensive geriatric assessment, attending multidisciplinary team meetings and ultimately considering the patient and the sum of their diseases in their totality. There have been recent advances in CVD management but how we apply these to deliver integrated care to the elderly population is key. This review article aims to bring together emerging studies and guidelines on assessment and management of CVD in the elderly, summarising latest definitions, diagnostics, therapeutics and future challenges. CI - (c) Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Gaur, Akshay AU - Gaur A AUID- ORCID: 0009-0004-1760-7519 AD - Department of Cardiology, Doncaster and Bassetlaw Teaching Hospitals NHS Foundation Trust, Doncaster, UK gaurakshay@yahoo.com. FAU - Carr, Fiona AU - Carr F AD - Department of Cardiology, Northern General Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. AD - Department of Geriatrics, Northern General Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. AD - Department of Infection, Immunity & Cardiovascular Disease, The Univsersity of Sheffield, Sheffield, UK. FAU - Warriner, David AU - Warriner D AD - Department of Cardiology, Doncaster and Bassetlaw Teaching Hospitals NHS Foundation Trust, Doncaster, UK. AD - Department of Infection, Immunity & Cardiovascular Disease, The Univsersity of Sheffield, Sheffield, UK. AD - Department of Adult Congenital Cardiology, Leeds General Infirmary, Leeds Teaching Hospital NHS Trust, Leeds, UK. LA - eng PT - Journal Article PT - Review DEP - 20240625 PL - England TA - Heart JT - Heart (British Cardiac Society) JID - 9602087 SB - IM MH - Humans MH - Aged MH - *Cardiovascular Diseases/therapy/epidemiology/diagnosis MH - Geriatric Assessment/methods MH - Geriatrics MH - Aged, 80 and over MH - Cardiology/trends MH - Comorbidity MH - Aging OTO - NOTNLM OT - Aortic Valve Stenosis OT - Atrial Fibrillation OT - Coronary Artery Disease OT - Heart Failure OT - Mitral Valve Insufficiency COIS- Competing interests: None declared. EDAT- 2024/01/12 00:42 MHDA- 2024/06/26 00:41 CRDT- 2024/01/11 21:02 PHST- 2023/09/06 00:00 [received] PHST- 2023/12/12 00:00 [accepted] PHST- 2024/06/26 00:41 [medline] PHST- 2024/01/12 00:42 [pubmed] PHST- 2024/01/11 21:02 [entrez] AID - heartjnl-2022-322117 [pii] AID - 10.1136/heartjnl-2022-322117 [doi] PST - epublish SO - Heart. 2024 Jun 25;110(14):933-939. doi: 10.1136/heartjnl-2022-322117. PMID- 38211660 OWN - NLM STAT- MEDLINE DCOM- 20240325 LR - 20240916 IS - 2213-7173 (Electronic) IS - 2213-7165 (Linking) VI - 36 DP - 2024 Mar TI - Dalbavancin real-life utilization among diabetic patients suffering from infections in Italy and Spain: The DALBADIA retrospective cohort study. PG - 200-209 LID - S2213-7165(23)00219-9 [pii] LID - 10.1016/j.jgar.2023.11.015 [doi] AB - OBJECTIVES: To retrospectively describe the patterns of use of dalbavancin for treating infections in diabetic patients in Italian and Spanish standard clinical practice. METHODS: DALBADIA [NCT04959799] was a multicentre, observational, retrospective cohort study, conducted in Italy and Spain. The study enrolled 97 adults with type 1 or 2 diabetes mellitus, treated with dalbavancin as per standard clinical practice for a Gram-positive bacterial infection or the Gram-positive component of a mixed infection. RESULTS: Dalbavancin was used to treat cellulitis (18/92 patients, 19.6%), followed by prosthetic joint infection (14 patients, 15.2%), endocarditis (13 patients, 14.1%), and primary bacteraemia (10 patients, 10.9%); 78/92 (84.8%) patients had Gram-positive infections only, and 14 (15.2%) had mixed infections. The most frequently isolated microorganisms were Staphylococcus aureus in 43 (55.8% of the patients with microbial isolation), 25.6% of which methicillin-resistant; Staphylococcus epidermidis in 13 (16.9%), 53.8% of which methicillin-resistant; Enterococcus faecalis in 11 (14.3%). The main reason for the dalbavancin choice was the intent to simplify the antibiotic regimen (81.5% of cases). A multidisciplinary team participated in the treatment choice process for 53 (57.6%) patients. Dalbavancin was given as first-line antibiotic in 34 (37.0%) patients and administered as one infusion in 32 (34.8%), and as two infusions in 39 (42.4%). In total, 57/62 (91.9%) eligible patients with available assessment were judged clinically cured or improved at the end of observation. CONCLUSION: In clinical practice, dalbavancin was used in diabetic patients to treat ABSSSIs and other difficult-to-treat infections with a favourable safety profile and a high rate of positive clinical responses. CI - Copyright (c) 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved. FAU - Morata Ruiz, Laura AU - Morata Ruiz L AD - Hospital Clinic, Department of Infectious Diseases, University of Barcelona, Barcelona, Spain. FAU - Ruggieri, Alessandro AU - Ruggieri A AD - GMD, Angelini SpA, Rome, Italy. Electronic address: alessandro.ruggieri@angelinipharma.com. FAU - Falcone, Marco AU - Falcone M AD - AOU Pisana PO Cisanello, UO Malattie Infettive, University of Pisa, Pisa, Italy. FAU - Pasquau Liano, Juan AU - Pasquau Liano J AD - Hospital Universitario Virgen de las Nieve, Unidad de Enfermedades Infecciosas, Granada, Spain. FAU - Gentile, Ivan AU - Gentile I AD - AOU Federico II, Malattie Infettive, Patologia Clinica e Medicina Interna, Universita di Napoli Federico II, Naples, Italy. FAU - Salavert Lleti, Miguel AU - Salavert Lleti M AD - Hospital Universitario y Politecnico La Fe, Unidad de Enfermedades Infecciosas, Valencia, Spain. FAU - Moreno Nunez, Leonor AU - Moreno Nunez L AD - Hospital Universitario Fundacion Alcorcon, Enfermedades Infecciosas, Madrid, Spain. FAU - Cascio, Antonio AU - Cascio A AD - AOU Policlinico Giaccone, UOC Malattie Infettive e Tropicali, Palermo, Italy. FAU - Tascini, Carlo AU - Tascini C AD - ASUFC, SOC Clinica Malattie Infettive, Udine, Italy. FAU - Loeches Yague, Maria AU - Loeches Yague M AD - Hospital Universitario La Paz, Enfermedades Infecciosas, Madrid, Spain. FAU - De Rosa, Francesco Giuseppe AU - De Rosa FG AD - Ospedale Cardinal Massaia, SC Malattie Infettive, Asti, Italy, AOU Citta della Salute e Scienza, Presidio Molinette, Turin, Italy. FAU - Ori, Alessandra AU - Ori A AD - Medineos Observational Research - IQVIA, Modena, Italy. FAU - Comandini, Alessandro AU - Comandini A AD - GMD, Angelini SpA, Rome, Italy. FAU - Cattaneo, Agnese AU - Cattaneo A AD - GMD, Angelini SpA, Rome, Italy. FAU - Grossi, Paolo Antonio AU - Grossi PA AD - ASST Sette Laghi, SC Malattie Infettive e Tropicali, University of Insubria, Varese, Italy. CN - DALBADIA study group LA - eng SI - ClinicalTrials.gov/NCT04959799 PT - Journal Article PT - Multicenter Study PT - Observational Study PT - Research Support, Non-U.S. Gov't DEP - 20240110 PL - Netherlands TA - J Glob Antimicrob Resist JT - Journal of global antimicrobial resistance JID - 101622459 RN - 0 (Anti-Bacterial Agents) RN - 808UI9MS5K (dalbavancin) RN - 61036-62-2 (Teicoplanin) SB - IM MH - Adult MH - Humans MH - *Anti-Bacterial Agents MH - *Diabetes Mellitus MH - Italy MH - Retrospective Studies MH - Spain MH - *Teicoplanin/analogs & derivatives OTO - NOTNLM OT - ABSSSI OT - Dalbavancin OT - Diabetes OT - Gram-positive bacteria OT - Infections OT - Real-world study EDAT- 2024/01/12 00:42 MHDA- 2024/03/25 06:42 CRDT- 2024/01/11 19:12 PHST- 2023/05/26 00:00 [received] PHST- 2023/11/14 00:00 [revised] PHST- 2023/11/29 00:00 [accepted] PHST- 2024/03/25 06:42 [medline] PHST- 2024/01/12 00:42 [pubmed] PHST- 2024/01/11 19:12 [entrez] AID - S2213-7165(23)00219-9 [pii] AID - 10.1016/j.jgar.2023.11.015 [doi] PST - ppublish SO - J Glob Antimicrob Resist. 2024 Mar;36:200-209. doi: 10.1016/j.jgar.2023.11.015. Epub 2024 Jan 10. PMID- 38206255 OWN - NLM STAT- MEDLINE DCOM- 20240226 LR - 20251214 IS - 1535-7732 (Electronic) IS - 1051-0443 (Print) IS - 1051-0443 (Linking) VI - 35 IP - 3 DP - 2024 Mar TI - Intravascular Ultrasound Use in Peripheral Arterial and Deep Venous Interventions: Multidisciplinary Expert Opinion From SCAI/AVF/AVLS/SIR/SVM/SVS. PG - 335-348 LID - S1051-0443(23)00808-4 [pii] LID - 10.1016/j.jvir.2023.11.006 [doi] AB - Percutaneous revascularization is the primary strategy for treating lower extremity venous and arterial disease. Angiography is limited by its ability to accurately size vessels, precisely determine the degree of stenosis and length of lesions, characterize lesion morphology, or correctly diagnose postintervention complications. These limitations are overcome with use of intravascular ultrasound (IVUS). IVUS has demonstrated the ability to improve outcomes following percutaneous coronary intervention, and there is increasing evidence to support its benefits in the setting of peripheral vascular intervention. At this stage in its evolution, there remains a need to standardize the use and approach to peripheral vascular IVUS imaging. This manuscript represents considerations and consensus perspectives that emerged from a roundtable discussion including 15 physicians with expertise in interventional cardiology, interventional radiology, and vascular surgery, representing 6 cardiovascular specialty societies, held on February 3, 2023. The roundtable's aims were to assess the current state of lower extremity revascularization, identify knowledge gaps and need for evidence, and determine how IVUS can improve care and outcomes for patients with peripheral arterial and deep venous pathology. CI - Copyright (c) 2023. Published by Elsevier Inc. FAU - Secemsky, Eric A AU - Secemsky EA AD - Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology and Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts. Electronic address: esecemsk@bidmc.harvard.edu. FAU - Aronow, Herbert D AU - Aronow HD AD - Department of Medicine, Michigan State University, East Lansing, Michigan; Heart & Vascular Services, Henry Ford Health, Detroit, Michigan. FAU - Kwolek, Christopher J AU - Kwolek CJ AD - Harvard Medical School, Boston, Massachusetts; Newton-Wellesley Hospital, Wellesley, Massachusetts. FAU - Meissner, Mark AU - Meissner M AD - Department of Surgery, University of Washington School of Medicine, Seattle, Washington. FAU - Muck, Patrick E AU - Muck PE AD - Department of Vascular Surgery, Good Samaritan Hospital, Cincinnati, Ohio. FAU - Parikh, Sahil A AU - Parikh SA AD - Center for Interventional Cardiovascular Care, Division of Cardiology, Columbia University Irving Medical Center, New York, New York. FAU - Winokur, Ronald S AU - Winokur RS AD - Weill Cornell Vein Treatment Center and Division of Interventional Radiology, Department of Radiology, Weill Cornell Medicine, New York, New York. FAU - George, Jon C AU - George JC AD - Division of Interventional Cardiology and Endovascular Medicine, Pennsylvania Hospital, Philadelphia, Pennsylvania. FAU - Salazar, Gloria AU - Salazar G AD - Department of Radiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. FAU - Murphy, Erin H AU - Murphy EH AD - Venous and Lymphatic Center, Division of Vascular Surgery, Sanger Heart and Vascular, Atrium Health, Charlotte, North Carolina. FAU - Costantino, Mary M AU - Costantino MM AD - Advanced Vascular Centers, Portland, Oregon. FAU - Zhou, Wei AU - Zhou W AD - Division of Vascular Surgery, University of Arizona and Banner University Medical Center, Tucson, Arizona. FAU - Li, Jun AU - Li J AD - Harrington Heart and Vascular Institute, University Hospitals, Cleveland, Ohio. FAU - Lookstein, Robert AU - Lookstein R AD - Icahn School of Medicine at Mount Sinai, New York, New York. FAU - Desai, Kush R AU - Desai KR AD - Department of Radiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois. LA - eng GR - K23 HL150290/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Practice Guideline PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20240109 PL - United States TA - J Vasc Interv Radiol JT - Journal of vascular and interventional radiology : JVIR JID - 9203369 SB - IM MH - Humans MH - Support Vector Machine MH - Ultrasonography MH - *Vascular Diseases/therapy MH - Ultrasonography, Interventional/methods MH - Coronary Angiography PMC - PMC12698343 MID - NIHMS2128129 OTO - NOTNLM OT - expert opinion OT - intravascular imaging OT - peripheral vascular disease EDAT- 2024/01/11 12:43 MHDA- 2024/02/26 06:42 PMCR- 2025/12/12 CRDT- 2024/01/11 10:30 PHST- 2023/06/01 00:00 [received] PHST- 2023/09/21 00:00 [revised] PHST- 2023/10/03 00:00 [accepted] PHST- 2024/02/26 06:42 [medline] PHST- 2024/01/11 12:43 [pubmed] PHST- 2024/01/11 10:30 [entrez] PHST- 2025/12/12 00:00 [pmc-release] AID - S1051-0443(23)00808-4 [pii] AID - 10.1016/j.jvir.2023.11.006 [doi] PST - ppublish SO - J Vasc Interv Radiol. 2024 Mar;35(3):335-348. doi: 10.1016/j.jvir.2023.11.006. Epub 2024 Jan 9. PMID- 38204727 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240414 IS - 2666-2736 (Electronic) IS - 2666-2736 (Linking) VI - 16 DP - 2023 Dec TI - Surgical outcomes of patients at prohibitive risk who are reconsidered for surgery. PG - 234-241 LID - 10.1016/j.xjon.2023.08.016 [doi] AB - OBJECTIVES: Transcatheter treatment of advanced mitral and tricuspid valve disease is largely limited to patients at prohibitive surgical risk, although many are not candidates for transcatheter treatment. Here, we describe surgical outcomes of patients at prohibitive risk who were ineligible for transcatheter therapies to guide surgeons in management of this unique population. METHODS: Patients at prohibitive risk, defined per surgeon or cardiologist discretion, who were initially referred for a transcatheter mitral or tricuspid intervention in a multidisciplinary atrioventricular valve clinic, were identified from 2019 to 2022. Preoperative risk, operative outcomes, and long-term mortality were evaluated. RESULTS: A total of 337 patients at prohibitive risk were referred for evaluation in a multidisciplinary atrioventricular valve clinic. Of those, 161 underwent transcatheter therapy, 130 patients underwent continued medical management, and 45 were reevaluated and had high-risk surgery. Among surgical patients, 51% were women with a median age of 76 years (quartile 1-quartile 3, 65-81 years). Most patients presented in heart failure (83%; n = 37 out of 45), and 73% were in New York Heart Association functional class III or IV. Most patients (94%; n = 43) had a mitral valve intervention, of whom 56% (24 out of 43) had a mitral valve replacement. The 30-day mortality rate was 4% (2 out of 45) and major morbidity occurred in 33% (15 out of 45). By Kaplan-Meier analysis, 1-year survival was 86% +/- 9%. CONCLUSIONS: Select patients at prohibitive risk who were ineligible for transcatheter mitral or tricuspid valve intervention underwent surgery with overall low operative mortality and excellent 1-year survival. Patients a prohibitive risk whose anatomy is not amenable to transcatheter devices should be reconsidered for surgery. CI - (c) 2023 The Author(s). FAU - Wagner, Catherine M AU - Wagner CM AD - Department of Cardiac Surgery, University of Michigan, Ann Arbor, Mich. FAU - Schultz, Megan L AU - Schultz ML AD - Department of Cardiac Surgery, University of Michigan, Ann Arbor, Mich. FAU - Brescia, Alexander A AU - Brescia AA AD - Department of Cardiac Surgery, University of Michigan, Ann Arbor, Mich. FAU - Wang, Yoyo AU - Wang Y AD - University of Michigan Medical School, Ann Arbor, Mich. FAU - Fu, Whitney AU - Fu W AD - Department of General Surgery, University of Michigan, Ann Arbor, Mich. FAU - Hawkins, Robert B AU - Hawkins RB AD - Department of Cardiac Surgery, University of Michigan, Ann Arbor, Mich. FAU - Romano, Matthew A AU - Romano MA AD - Department of Cardiac Surgery, University of Michigan, Ann Arbor, Mich. FAU - Ailawadi, Gorav AU - Ailawadi G AD - Department of Cardiac Surgery, University of Michigan, Ann Arbor, Mich. FAU - Bolling, Steven F AU - Bolling SF AD - Department of Cardiac Surgery, University of Michigan, Ann Arbor, Mich. CN - Michigan Mitral Research Group LA - eng GR - T32 HL007749/HL/NHLBI NIH HHS/United States GR - T35 HL007690/HL/NHLBI NIH HHS/United States PT - Journal Article DEP - 20230909 PL - Netherlands TA - JTCVS Open JT - JTCVS open JID - 101768541 PMC - PMC10775058 OTO - NOTNLM OT - heart team OT - mitral disease OT - prohibitive risk OT - tricuspid disease EDAT- 2024/01/11 07:42 MHDA- 2024/01/11 07:43 PMCR- 2023/09/09 CRDT- 2024/01/11 04:05 PHST- 2023/05/22 00:00 [received] PHST- 2023/08/07 00:00 [revised] PHST- 2023/08/28 00:00 [accepted] PHST- 2024/01/11 07:43 [medline] PHST- 2024/01/11 07:42 [pubmed] PHST- 2024/01/11 04:05 [entrez] PHST- 2023/09/09 00:00 [pmc-release] AID - S2666-2736(23)00262-0 [pii] AID - 10.1016/j.xjon.2023.08.016 [doi] PST - epublish SO - JTCVS Open. 2023 Sep 9;16:234-241. doi: 10.1016/j.xjon.2023.08.016. eCollection 2023 Dec. PMID- 38204550 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240111 IS - 2666-0849 (Electronic) IS - 2666-0849 (Linking) VI - 28 DP - 2023 Dec 20 TI - First-in-Human Treatment of Severe Tricuspid Regurgitation Using a Novel Cross-Caval Heterotopic Device. PG - 102103 LID - 10.1016/j.jaccas.2023.102103 [doi] LID - 102103 AB - A 79-year-old woman, previously surgically treated for mitral and aortic valve replacement, experienced recurrent torrential tricuspid regurgitation after 2 transcatheter edge-to-edge repair procedures. Heart team assessment deemed the patient high risk for redo surgery and excluded transcatheter edge-to-edge repair and orthotopic replacement. The patient was then scheduled for a novel cross-caval device implantation. CI - (c) 2023 The Authors. FAU - Sisinni, Antonio AU - Sisinni A AD - Department of Cardiology, University Hospital Alvaro Cunqueiro, Vigo, Spain. AD - Cardiovascular Research Group, Department of Cardiology, University Hospital Alvaro Cunqueiro, Galicia Sur Health Research Institute (IIS Galicia Sur), Servizo Galego de Saude, University of Vigo, Vigo, Spain. FAU - Estevez-Loureiro, Rodrigo AU - Estevez-Loureiro R AD - Department of Cardiology, University Hospital Alvaro Cunqueiro, Vigo, Spain. AD - Cardiovascular Research Group, Department of Cardiology, University Hospital Alvaro Cunqueiro, Galicia Sur Health Research Institute (IIS Galicia Sur), Servizo Galego de Saude, University of Vigo, Vigo, Spain. FAU - Caneiro-Queija, Berenice AU - Caneiro-Queija B AD - Department of Cardiology, University Hospital Alvaro Cunqueiro, Vigo, Spain. AD - Cardiovascular Research Group, Department of Cardiology, University Hospital Alvaro Cunqueiro, Galicia Sur Health Research Institute (IIS Galicia Sur), Servizo Galego de Saude, University of Vigo, Vigo, Spain. FAU - Barreiro-Perez, Manuel AU - Barreiro-Perez M AD - Department of Cardiology, University Hospital Alvaro Cunqueiro, Vigo, Spain. AD - Cardiovascular Research Group, Department of Cardiology, University Hospital Alvaro Cunqueiro, Galicia Sur Health Research Institute (IIS Galicia Sur), Servizo Galego de Saude, University of Vigo, Vigo, Spain. FAU - Baz, Jose A AU - Baz JA AD - Department of Cardiology, University Hospital Alvaro Cunqueiro, Vigo, Spain. AD - Cardiovascular Research Group, Department of Cardiology, University Hospital Alvaro Cunqueiro, Galicia Sur Health Research Institute (IIS Galicia Sur), Servizo Galego de Saude, University of Vigo, Vigo, Spain. FAU - Pazos, Pablo AU - Pazos P AD - Department of Cardiology, University Hospital Alvaro Cunqueiro, Vigo, Spain. AD - Cardiovascular Research Group, Department of Cardiology, University Hospital Alvaro Cunqueiro, Galicia Sur Health Research Institute (IIS Galicia Sur), Servizo Galego de Saude, University of Vigo, Vigo, Spain. FAU - Gonzalez-Ferreiro, Rocio AU - Gonzalez-Ferreiro R AD - Department of Cardiology, University Hospital Alvaro Cunqueiro, Vigo, Spain. AD - Cardiovascular Research Group, Department of Cardiology, University Hospital Alvaro Cunqueiro, Galicia Sur Health Research Institute (IIS Galicia Sur), Servizo Galego de Saude, University of Vigo, Vigo, Spain. FAU - Iniguez-Romo, Andres AU - Iniguez-Romo A AD - Department of Cardiology, University Hospital Alvaro Cunqueiro, Vigo, Spain. AD - Cardiovascular Research Group, Department of Cardiology, University Hospital Alvaro Cunqueiro, Galicia Sur Health Research Institute (IIS Galicia Sur), Servizo Galego de Saude, University of Vigo, Vigo, Spain. LA - eng PT - Journal Article DEP - 20231102 PL - Netherlands TA - JACC Case Rep JT - JACC. Case reports JID - 101757292 PMC - PMC10774827 OTO - NOTNLM OT - CAVI OT - caval valve implantation OT - transcatheter therapies OT - tricuspid regurgitation COIS- Dr Estevez-Loureiro has received honoraria from Abbott Vascular, Edwards Lifesciences, Boston Scientific, and Venus Medtech. Dr Barreiro-Perez has received honoraria from Abbott Vascular and Edwards Lifesciences. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2024/01/11 07:42 MHDA- 2024/01/11 07:43 PMCR- 2023/11/02 CRDT- 2024/01/11 04:00 PHST- 2023/07/19 00:00 [received] PHST- 2023/09/18 00:00 [revised] PHST- 2023/10/12 00:00 [accepted] PHST- 2024/01/11 07:43 [medline] PHST- 2024/01/11 07:42 [pubmed] PHST- 2024/01/11 04:00 [entrez] PHST- 2023/11/02 00:00 [pmc-release] AID - S2666-0849(23)00439-4 [pii] AID - 102103 [pii] AID - 10.1016/j.jaccas.2023.102103 [doi] PST - epublish SO - JACC Case Rep. 2023 Nov 2;28:102103. doi: 10.1016/j.jaccas.2023.102103. eCollection 2023 Dec 20. PMID- 38204548 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240111 IS - 2666-0849 (Electronic) IS - 2666-0849 (Linking) VI - 28 DP - 2023 Dec 20 TI - 3-Dimensional CT Planning for TAVR With a Novel Self-Expandable Valve in a Calcified Anatomy. PG - 102116 LID - 10.1016/j.jaccas.2023.102116 [doi] LID - 102116 AB - Recently, a novel transfemoral self-expandable valve (JenaValve Trilogy) was granted a CE mark as a dedicated device for transfemoral treatment of both aortic valve stenosis and regurgitation. Here, we highlight the importance of 3-dimensional preprocedural planning for the optimal choice of a prosthesis in challenging anatomies by reporting an unusual case of a heavily calcified aortic sinus. CI - (c) 2023 Published by Elsevier on behalf of the American College of Cardiology Foundation. FAU - Geyer, Martin AU - Geyer M AD - Department of Cardiology, Cardiology I, University Medical Center Mainz of the Johannes Gutenberg-University Mainz, Mainz, Germany. FAU - Tamm, Alexander R AU - Tamm AR AD - Department of Cardiology, Cardiology I, University Medical Center Mainz of the Johannes Gutenberg-University Mainz, Mainz, Germany. FAU - Munzel, Thomas AU - Munzel T AD - Department of Cardiology, Cardiology I, University Medical Center Mainz of the Johannes Gutenberg-University Mainz, Mainz, Germany. FAU - Treede, Hendrik AU - Treede H AD - Department for Cardiac and Vascular Surgery, University Medical Center Mainz of the Johannes Gutenberg-University Mainz, Mainz, Germany. FAU - von Bardeleben, Ralph Stephan AU - von Bardeleben RS AD - Department of Cardiology, Cardiology I, University Medical Center Mainz of the Johannes Gutenberg-University Mainz, Mainz, Germany. LA - eng PT - Journal Article DEP - 20231109 PL - Netherlands TA - JACC Case Rep JT - JACC. Case reports JID - 101757292 PMC - PMC10774813 OTO - NOTNLM OT - JenaValve OT - aortic stenosis OT - multidisciplinary heart team OT - noninvasive imaging OT - transcatheter aortic valve replacement COIS- Dr Tamm has received lecture honoraria from Edwards Lifesciences and Medtronic, and has been a proctor for JenaValve Technology. Dr Teede has been a proctor and consultant for JenaValve Technology. Dr von Bardeleben has been a consultant and the recipient of lecture honoraria from Abbott Structural Heart, Boehringer Ingelheim, Cardiac Dimensions, Edwards Lifesciences, GE Health Systems, and Philips Healthcare. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2024/01/11 07:42 MHDA- 2024/01/11 07:43 PMCR- 2023/11/09 CRDT- 2024/01/11 04:00 PHST- 2023/08/20 00:00 [received] PHST- 2023/10/10 00:00 [revised] PHST- 2023/10/12 00:00 [accepted] PHST- 2024/01/11 07:43 [medline] PHST- 2024/01/11 07:42 [pubmed] PHST- 2024/01/11 04:00 [entrez] PHST- 2023/11/09 00:00 [pmc-release] AID - S2666-0849(23)00452-7 [pii] AID - 102116 [pii] AID - 10.1016/j.jaccas.2023.102116 [doi] PST - epublish SO - JACC Case Rep. 2023 Nov 9;28:102116. doi: 10.1016/j.jaccas.2023.102116. eCollection 2023 Dec 20. PMID- 38204512 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240711 IS - 1920-2903 (Electronic) IS - 0008-4123 (Print) IS - 0008-4123 (Linking) VI - 77 IP - 1 DP - 2024 TI - Impact of Multidisciplinary Heart Failure Clinic on Guideline-Directed Medical Therapy and Clinical Outcomes. PG - e3364 LID - 10.4212/cjhp.3364 [doi] LID - e3364 AB - BACKGROUND: Heart failure (HF) is associated with recurrent hospital admissions and high mortality. Guideline-directed medical therapy has been shown to improve prognosis for patients who have HF with reduced ejection fraction (HFrEF). Despite the proven benefits of guideline-directed medical therapy, its utilization is less than optimal among patients with HF in Malaysia. OBJECTIVE: To determine the impact of a multidisciplinary team HF (MDT-HF) clinic on the use of guideline-directed medical therapy and patients' clinical outcomes at 1 year. METHODS: This retrospective study was conducted in a single cardiac centre in Malaysia. Patients with HFrEF who were enrolled in the MDT-HF clinic between November 2017 and June 2020 were compared with a matched control group who received the standard of care. Data were retrieved from the hospital electronic system and were analyzed using statistical software. RESULTS: A total of 54 patients were included in each group. Patients enrolled in the MDT-HF clinic had higher usage of renin-angiotensin system blockers (54 [100%] vs 47 [87%], p < 0.001) and higher attainment of the target dose for these agents (35 [65%] vs 5 [9%], p < 0.001). At 1 year, the mean left ventricular ejection fraction (LVEF) was significantly greater in the MDT-HF group (35.7% [standard deviation 12.3%] vs 26.2% [standard deviation 8.7%], p < 0.001), and care in the MDT-HF clinic was significantly associated with better functional class, with a lower proportion of patients categorized as having New York Heart Association class III HF at 1 year (1 [2%] vs 14 [26%], p = 0.001). Patients in the MDT-HF group also had a significantly lower rate of readmission for HF (4 [7%] vs 32 [59%], p < 0.001). CONCLUSIONS: Patients who received care in the MDT-HF clinic had better use of guideline-directed medical therapy, greater improvement in LVEF, and a lower rate of readmission for HF at 1 year relative to patients who received the standard of care. CI - 2024 Canadian Society of Hospital Pharmacists. All content in the Canadian Journal of Hospital Pharmacy is copyrighted by the Canadian Society of Hospital Pharmacy. In submitting their manuscripts, the authors transfer, assign, and otherwise convey all copyright ownership to CSHP. FAU - Tan, Sie Sie AU - Tan SS AD - , BScPhm, RPh, MClinPharm, is a clinical pharmacist with Sultan Idris Shah Serdang Hospital, Selangor, Malaysia. FAU - Hisham, Shairyzah Ahmad AU - Hisham SA AD - , PhD, MedSc, is with the Faculty of Pharmacy, University of Cyberjaya, Selangor, Malaysia. FAU - Bin Abdul Malek, Abdul Muizz AU - Bin Abdul Malek AM AD - , MBBS, MMed (Internal Medicine), is a cardiologist with Sultan Idris Shah Serdang Hospital, Selangor, Malaysia. FAU - Lik, Chua Ping AU - Lik CP AD - , MBBS, MRCP, is a cardiologist with Sultan Idris Shah Serdang Hospital, Selangor, Malaysia. FAU - Lau, Glendon Seng Kiong AU - Lau GSK AD - , MBBS, MRCP, is a cardiologist with Sultan Idris Shah Serdang Hospital, Selangor, Malaysia. FAU - Bin Abdul Ghapar, Abdul Kahar AU - Bin Abdul Ghapar AK AD - , MD, MMed (Internal Medicine), is Head of the Cardiology Department, Sultan Idris Shah Serdang Hospital, Selangor, Malaysia. LA - eng PT - Journal Article DEP - 20240110 PL - Canada TA - Can J Hosp Pharm JT - The Canadian journal of hospital pharmacy JID - 0215645 PMC - PMC10754400 OTO - NOTNLM OT - guideline-directed medical therapy OT - heart failure hospitalization OT - heart failure with reduced ejection fraction OT - multidisciplinary clinic OT - target dose COIS- Competing interests: None declared. EDAT- 2024/01/11 07:43 MHDA- 2024/01/11 07:44 PMCR- 2024/07/10 CRDT- 2024/01/11 03:59 PHST- 2022/07/21 00:00 [received] PHST- 2023/07/10 00:00 [accepted] PHST- 2024/01/11 07:44 [medline] PHST- 2024/01/11 07:43 [pubmed] PHST- 2024/01/11 03:59 [entrez] PHST- 2024/07/10 00:00 [pmc-release] AID - cjhp-77-1-3364 [pii] AID - 10.4212/cjhp.3364 [doi] PST - epublish SO - Can J Hosp Pharm. 2024 Jan 10;77(1):e3364. doi: 10.4212/cjhp.3364. eCollection 2024. PMID- 38202110 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240112 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 13 IP - 1 DP - 2023 Dec 24 TI - Remote Surgical Discussion of Multivessel Coronary Artery Disease Patients without Surgery on Site-Retrospective Insights. LID - 10.3390/jcm13010103 [doi] LID - 103 AB - OBJECTIVE: The heart team approach is highly advocated for in treatment decision making in patients with multivessel disease (MVD). Nevertheless, many centers lack on-site cardiac surgical services (CSS)/formal heart team. Our local alternative is of remote surgical consultation without a structured image sharing platform. In our understanding, the incidence of anatomical complete revascularization (ACR) under this daily practice, and its clinical impact, has not been discussed before. METHODS: We analyzed 477 consecutive patients who were surgically revascularized between January 2009 and March 2018 for MVD, after remote surgical consultation. Unstable, late arrival, and ST elevation patients were excluded (n = 163). ACR was considered grafting all anatomic lesions > 50%. Syntax score (SS) calculation and ACR categorization were determined by an independent interventionalist using diagnostic angiograms and available operative reports (n = 267). Patients' outcomes were assessed in relation to multiple clinical variables including troponin result and the revascularization status. RESULTS: Three hundred and fourteen patients were included. Mean age was 64 years, and mean SS-II was 27.3 +/- 11. At the 4-year follow-up, the observed mortality (11.8% and 12.9%, with troponin-positive and -negative groups, respectively), myocardial infarction (11.8%), and repeat revascularization (9.8%) were higher than those predicted using a nomogram depicting the predicted 4-year mortality as a function of the SYNTAX II Score (5.3%, 8.8%, and 3.5%, respectively, p = 0.02). ACR was reported in 33% of 267 available patients' reports. After multivariate adjustment ACR was the only variable associated with a significant increase in 4-year mortality (12.3% vs. 6.7%, p < 0.05). CONCLUSIONS: Partial revascularization in the absence of on-site CSS and a structured heart team platform is a frequent occurrence. Not surprisingly, this occurrence was associated with a higher risk for mid-term mortality. An upfront, structured, virtual, heart team interface is mandatory to particularly prioritize the completeness of revascularization when considering the optimal revascularization mode. FAU - Roguin, Ariel AU - Roguin A AD - Department of Cardiology, Hillel Yaffe Medical Center, Faculty of Medicine, Technion Israel Institute of Technology, Haifa 3200003, Israel. FAU - Meisel, Simha-Ron AU - Meisel SR AD - Department of Cardiology, Hillel Yaffe Medical Center, Faculty of Medicine, Technion Israel Institute of Technology, Haifa 3200003, Israel. FAU - Levi, Yaniv AU - Levi Y AD - Department of Cardiology, Hillel Yaffe Medical Center, Faculty of Medicine, Technion Israel Institute of Technology, Haifa 3200003, Israel. FAU - Kobo, Ofer AU - Kobo O AD - Department of Cardiology, Hillel Yaffe Medical Center, Faculty of Medicine, Technion Israel Institute of Technology, Haifa 3200003, Israel. FAU - Yehia, Majd AU - Yehia M AD - Department of Cardiology, Hillel Yaffe Medical Center, Faculty of Medicine, Technion Israel Institute of Technology, Haifa 3200003, Israel. FAU - Amsalem, Naama AU - Amsalem N AD - Department of Cardiology, Hillel Yaffe Medical Center, Faculty of Medicine, Technion Israel Institute of Technology, Haifa 3200003, Israel. FAU - Abu Fanne, Rami AU - Abu Fanne R AD - Department of Cardiology, Hillel Yaffe Medical Center, Faculty of Medicine, Technion Israel Institute of Technology, Haifa 3200003, Israel. LA - eng PT - Journal Article DEP - 20231224 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC10779846 OTO - NOTNLM OT - SYNTAX OT - concordance OT - coronary grafts OT - heart team OT - outcomes COIS- The authors declare no conflict of interest. EDAT- 2024/01/11 07:42 MHDA- 2024/01/11 07:43 PMCR- 2023/12/24 CRDT- 2024/01/11 01:09 PHST- 2023/11/02 00:00 [received] PHST- 2023/12/03 00:00 [revised] PHST- 2023/12/19 00:00 [accepted] PHST- 2024/01/11 07:43 [medline] PHST- 2024/01/11 07:42 [pubmed] PHST- 2024/01/11 01:09 [entrez] PHST- 2023/12/24 00:00 [pmc-release] AID - jcm13010103 [pii] AID - jcm-13-00103 [pii] AID - 10.3390/jcm13010103 [doi] PST - epublish SO - J Clin Med. 2023 Dec 24;13(1):103. doi: 10.3390/jcm13010103. PMID- 38195578 OWN - NLM STAT- MEDLINE DCOM- 20240111 LR - 20240111 IS - 1745-6215 (Electronic) IS - 1745-6215 (Linking) VI - 25 IP - 1 DP - 2024 Jan 9 TI - InterVFast-effectiveness and acceptance of intermittent fasting in cardiac rehabilitation patients: study protocol of a randomized controlled trial. PG - 32 LID - 10.1186/s13063-023-07843-7 [doi] LID - 32 AB - BACKGROUND: Research on intermittent fasting has shown that it can improve a variety of health outcomes, including blood sugar control, blood lipid levels and blood pressure. Only few studies document longer periods of fasting, especially in rehabilitation participants. Cardiac inpatient rehabilitation follows a multidisciplinary approach including change of health behaviour to reduce patients' risk of future cardiovascular events. To date, evidence suggests that intermittent fasting can be an effective way to improve health and well-being, but more research is needed to fully understand its long-term effects and factors that promote the implementation. Therefore, the aim of the ongoing InterVFast trial is to investigate the effectiveness of intermittent fasting amongst cardiac rehabilitation patients after 4-week inpatient rehabilitation as well as 3 and 12 months subsequently including patients' perspective. METHODS: This single-centre randomized controlled trial evaluates the effectiveness of the InterVFast intervention in weight loss (primary outcome). We also examine patients' acceptance and the effect on relevant outcomes as blood glucose and triglyceride levels, cholesterol and high-sensitivity C-reactive protein. Weight, blood samples and clinical data are collected as part of the initial and final examination during inpatient rehabilitation. During inpatient rehabilitation, participants daily note fasting intervals and meals eaten as well as practicability in a fasting diary. In addition, interviews about perceived advantages and disadvantages and acceptance are carried out with the participants in the IG. A standardized follow-up examination (weight, blood samples) will be carried out by the family doctor after 3 and 12 months (t2 and t3). DISCUSSION: Compared to other weight-loss intervention studies, our study addresses patients with coronary heart disease and includes patients' acceptance as well as long-term maintenance. It is hypothesized that participation in the InterVfast intervention will improve relevant health outcomes in a sample of cardiac rehabilitation patients and thus constitute a behavioural prevention strategy to reduce the risk of future cardiac events and improve overall health and quality of life. TRIAL REGISTRATION: ClinicalTrials.gov DRKS00023983. Registered on February 17, 2022. CI - (c) 2024. The Author(s). FAU - Pieper, Claudia AU - Pieper C AUID- ORCID: 0000-0001-5986-9788 AD - Institute for Medical Informatics, Biometry and Epidemiology (IMIBE), University Hospital Essen, University of Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Germany. claudia.pieper@uk-essen.de. FAU - Kaistha, Florian Tim Hitesh AU - Kaistha FTH AD - Institute for Medical Informatics, Biometry and Epidemiology (IMIBE), University Hospital Essen, University of Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Germany. FAU - Schroeer, Sarah AU - Schroeer S AD - Institute for Medical Informatics, Biometry and Epidemiology (IMIBE), University Hospital Essen, University of Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Germany. FAU - Borgert, Maria AU - Borgert M AD - Institute for Medical Informatics, Biometry and Epidemiology (IMIBE), University Hospital Essen, University of Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Germany. FAU - Michalsen, Andreas AU - Michalsen A AD - Department of Internal and Integrative Medicine, Immanuel Hospital Berlin, Berlin, Germany. FAU - Mayer-Berger, Wolfgang AU - Mayer-Berger W AD - Centre for Cardiovascular Rehabilitation, 42799, Leichlingen, Germany. LA - eng GR - 200002/Rehabilitationsforschungsnetzwerk der Deutschen Rentenversicherung Rheinland refonet/ PT - Clinical Trial Protocol PT - Journal Article DEP - 20240109 PL - England TA - Trials JT - Trials JID - 101263253 SB - IM MH - Humans MH - *Cardiac Rehabilitation MH - Inpatients MH - *Intermittent Fasting MH - Quality of Life MH - Randomized Controlled Trials as Topic PMC - PMC10775558 OTO - NOTNLM OT - Acceptance OT - Effectiveness OT - Intermittent fasting OT - Prevention OT - Randomized controlled trial OT - Rehabilitation OT - Weight loss COIS- The authors declare that they have no competing interests. EDAT- 2024/01/10 00:42 MHDA- 2024/01/11 07:42 PMCR- 2024/01/09 CRDT- 2024/01/09 23:42 PHST- 2023/06/25 00:00 [received] PHST- 2023/11/30 00:00 [accepted] PHST- 2024/01/11 07:42 [medline] PHST- 2024/01/10 00:42 [pubmed] PHST- 2024/01/09 23:42 [entrez] PHST- 2024/01/09 00:00 [pmc-release] AID - 10.1186/s13063-023-07843-7 [pii] AID - 7843 [pii] AID - 10.1186/s13063-023-07843-7 [doi] PST - epublish SO - Trials. 2024 Jan 9;25(1):32. doi: 10.1186/s13063-023-07843-7. PMID- 38261713 STAT- Publisher CTDT- 20240109 PB - StatPearls Publishing DP - 2024 Jan TI - Anthracycline Toxicity. BTI - StatPearls AB - Anthracycline toxicity describes the toxic consequences of anthracycline-class medications. Anthracyclines, such as doxorubicin and epirubicin, are potent chemotherapy agents employed in managing various hematological and solid malignancies. Anthracyclines are a key component in hematological chemotherapy regimens treating lymphoma, where doxorubicin, arguably the widest-used anthracycline, features in the CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin(R) [vincristine], prednisone) and ABVD (Adriamycin(R) [doxorubicin], bleomycin, vinblastine, dacarbazine) protocols. The primary anticancer mechanism of action of anthracyclines is disruption of the topoisomerase-II enzyme (TOP2) stable intermediates, leading to a state of ever-increasing DNA damage. Other mechanisms, including the impact of reactive oxygen species, interference within intercalation, and chromatin damage, have also been proposed as anticancer mechanisms. All the proposed mechanisms lead to preferential apoptosis in rapidly replicating cells, impacting slowly replicating or quiescent cell types less significantly. The most prominent, well-studied, and clinically concerning toxicity associated with anthracycline chemotherapy is type-1 cardiotoxicity, a dose-dependent, irreversible, cumulative cardiomyocyte cell death that leads to the development of dilated cardiomyopathy and subsequent cardiac failure. Likely, anthracycline exposure may also increase the risk of secondary cancer and lead to gonadal failure, but these impacts are not as well documented. Liver, gastrointestinal tract, renal, and bone marrow toxicity may also occur but are often reversible; it is likely some degree of hepatic necrosis does occur with anthracycline administration, which may develop chronicity, but this occurs in doses well above that of cardiomyocyte death. With increasing cancer survivorship, the impact of anthracycline toxicity is growing, and the comorbidity and mortality associated with anthracycline toxicity are increasing. This activity reviews the proposed etiologic mechanisms, epidemiology, evaluation, and management of patients with anthracycline-induced cardiotoxicity and highlights the role of the interprofessional team in caring for patients exposed to anthracycline chemotherapeutics. CI - Copyright (c) 2024, StatPearls Publishing LLC. FAU - Johnson, Mark AU - Johnson M AD - Swansea University FAU - Keyes, Daniel AU - Keyes D AD - Michigan State University LA - eng PT - Study Guide PT - Book Chapter PL - Treasure Island (FL) COIS- Disclosure: Mark Johnson declares no relevant financial relationships with ineligible companies. Disclosure: Daniel Keyes declares no relevant financial relationships with ineligible companies. EDAT- 2024/01/09 00:00 CRDT- 2024/01/09 00:00 AID - NBK599501 [bookaccession] PMID- 38186795 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240109 IS - 2249-4863 (Print) IS - 2278-7135 (Electronic) IS - 2249-4863 (Linking) VI - 12 IP - 11 DP - 2023 Nov TI - Cardiovascular disease in pregnancy and its outcome: A prospective study. PG - 2714-2720 LID - 10.4103/jfmpc.jfmpc_507_23 [doi] AB - INTRODUCTION: Prevalence estimates place maternal heart illness anywhere from 0.3 to 3.5 percent. Up to 20.5% of all maternal deaths of non-obstetrical cause are attributable to cardiovascular disease. AIM: The aim of the study was the management of patients with the multidisciplinary approach to maternal cardiovascular disease and its influence on maternal and fetal outcomes in a tertiary care centre. OBJECTIVES: 1. To find out the prevalence and spectrum of heart disease in Pregnancy. 2. To find out the outcome of pregnancy with heart disease in a tertiary care centre. MATERIALS AND METHODS: This prospective study of one year was done on pregnant with heart disease coming to the Obstetrics and Gynaecology department in collaboration with the cardiology department of IGIMS, Patna. A study was done on 65 pregnant with heart disease between the age group 20 to 35 years were compared to a control group of 65 pregnant women who were hospitalised during the same time period but did not have heart disease. All the pregnant women with heart disease were included in this study. Patients with medical disorders like Kidney disease, Liver disease, Pulmonary Disease, Diabetes Mellitus were excluded from the study. We used IBM's SPSS v23 to analyse the collected data. RESULT: Prevalence of heart disease in pregnancy was 5.8% in present study and mostly of RHD (62.5%), followed by corrected CHD (12.5%) and CHD (10.9%). Patients of NYHA Class I and II (58.5%), Class III (26.2%), and Class IV (15.4%). The mitral valve was most often impacted by RHD (35.3% of all cases), followed by the tricuspid valve (15.0%). Eight (1.1%) people had cardiac surgery for therapeutic reasons. Six percent of all corrective surgeries included closing an atrial septal defect (ASD). The most common kind of congenital abnormality was a ventricular septal defect (VSD, 3%), followed by atrial septal defect (ASD, 1.5%) and pulmonary ductal atresia (PDA, 1.5%). Patients with heart disease had a higher rate of MTP, emergency LSCS and instrumental births than the controls. Deaths during pregnancy were 4 (6.2%) with cardiac disease and no maternal mortality in control group and all belonged to NYHA Class 4 were anaemic. In patients with a left ventricular ejection fraction of 45% or below, death was high. Two women died intrapartum from RHD, and two died postpartum from Peripartum cardiomyopathy. There were significantly more incidences of low-birth-weight infants (36.4%) compared to the control group (p = 0.001). Cases had a statistically significant greater frequency of obstetric problems, as well as an increased risk of developing anaemia, hypertension, hypothyroidism, cholestasis, FGR, and GDM (p-value 0.017). Multiparity, severe valvular lesion, NYHA function class III or IV, arrhythmia, and low ejection fraction were associated with poor maternal outcome in the current study. CONCLUSION: Maternal morbidity and mortality due to heart disease can be reduced appreciably by antenatal care, early diagnosis, and management with the help of cardiologists and surgery in selected cases. CI - Copyright: (c) 2023 Journal of Family Medicine and Primary Care. FAU - Prasad, Dipali AU - Prasad D AD - Department of OBG, IGIMS, Patna, Bihar, India. FAU - Prasad, Ravi Vishnu AU - Prasad RV AD - Department of Cardiology, IGIMS, Patna, Bihar, India. FAU - Choudhary, Manoj Kumar AU - Choudhary MK AD - Department of General Medicine, IGIMS, Patna, Bihar, India. FAU - Kumari, Kanchan AU - Kumari K AD - Department of OBG, IGIMS, Patna, Bihar, India. LA - eng PT - Journal Article DEP - 20231121 PL - India TA - J Family Med Prim Care JT - Journal of family medicine and primary care JID - 101610082 PMC - PMC10771193 OTO - NOTNLM OT - Fetal outcome OT - maternal outcome OT - pregnancy OT - rheumatic heart disease COIS- There are no conflicts of interest. EDAT- 2024/01/08 06:43 MHDA- 2024/01/08 06:44 PMCR- 2023/11/01 CRDT- 2024/01/08 04:31 PHST- 2023/03/20 00:00 [received] PHST- 2023/06/13 00:00 [revised] PHST- 2023/06/14 00:00 [accepted] PHST- 2024/01/08 06:44 [medline] PHST- 2024/01/08 06:43 [pubmed] PHST- 2024/01/08 04:31 [entrez] PHST- 2023/11/01 00:00 [pmc-release] AID - JFMPC-12-2714 [pii] AID - 10.4103/jfmpc.jfmpc_507_23 [doi] PST - ppublish SO - J Family Med Prim Care. 2023 Nov;12(11):2714-2720. doi: 10.4103/jfmpc.jfmpc_507_23. Epub 2023 Nov 21. PMID- 38181974 OWN - NLM STAT- MEDLINE DCOM- 20240219 LR - 20240308 IS - 1916-7075 (Electronic) IS - 0828-282X (Linking) VI - 40 IP - 2 DP - 2024 Feb TI - Do the Few Dictate Care for the Many? Revascularisation Considerations That Go Beyond the Guidelines. PG - 275-289 LID - S0828-282X(23)01884-6 [pii] LID - 10.1016/j.cjca.2023.11.007 [doi] AB - The burden of coronary artery disease (CAD) is large and growing, commonly presenting with comorbidities and older age. Patients may benefit from coronary revascularisation with percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG), yet half of patients with CAD who would benefit from revascularisation fall outside the eligibility criteria of trials to date. As such, the choice of revascularisation procedures varies depending on the CAD anatomy and complexity, surgical risk and comorbidities, the patient's preferences and values, and the treating team's expertise. The recent American guidelines on coronary revascularisation are comprehensive in describing recommendations for PCI, CABG, or conservative management in patients with CAD. However, individual challenging patient presentations cannot be fully captured in guidelines. The aim of this narrative review is to summarise common clinical scenarios that are not sufficiently described by contemporary clinical guidelines and trials in order to inform heart team members and trainees about the nuanced considerations and available evidence to manage such cases. We discuss clinical cases that fall beyond the current guidelines and summarise the relevant evidence evaluating coronary revascularisation for these patients. In addition, we highlight gaps in knowledge based on a lack of research (eg, ineligibility of certain patient populations), underrepresentation in research (eg, underenrollment of female and non-White patients), and the surge in newer minimally invasive and hybrid techniques. We argue that ultimately, evidence-based medicine, patient preference, shared decision making, and effective heart team communications are necessary to best manage complex CAD presentations potentially benefitting from revascularisation with CABG or PCI. CI - Copyright (c) 2023 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved. FAU - Vervoort, Dominique AU - Vervoort D AD - Division of Cardiac Surgery, University of Toronto, Toronto, Ontario, Canada; Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada. FAU - Sud, Maneesh AU - Sud M AD - Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada; Schulich Heart Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada. FAU - Zeis, Tessa M AU - Zeis TM AD - Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA. FAU - Haouzi, Alice A AU - Haouzi AA AD - Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA. FAU - An, Kevin R AU - An KR AD - Division of Cardiac Surgery, University of Toronto, Toronto, Ontario, Canada. FAU - Rocha, Rodolfo AU - Rocha R AD - Division of Cardiac Surgery, University of Toronto, Toronto, Ontario, Canada. FAU - Eikelboom, Rachel AU - Eikelboom R AD - Division of Cardiac Surgery, McMaster University, Hamilton, Ontario, Canada. FAU - Fremes, Stephen E AU - Fremes SE AD - Division of Cardiac Surgery, University of Toronto, Toronto, Ontario, Canada; Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada; Schulich Heart Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada. FAU - Tamis-Holland, Jacqueline E AU - Tamis-Holland JE AD - Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA. Electronic address: tamisj@ccf.org. LA - eng PT - Journal Article PT - Review DEP - 20240103 PL - England TA - Can J Cardiol JT - The Canadian journal of cardiology JID - 8510280 SB - IM MH - Humans MH - Female MH - *Percutaneous Coronary Intervention MH - *Coronary Artery Disease/surgery MH - Coronary Artery Bypass/methods MH - Treatment Outcome EDAT- 2024/01/06 10:41 MHDA- 2024/02/19 06:42 CRDT- 2024/01/05 19:20 PHST- 2023/09/01 00:00 [received] PHST- 2023/10/31 00:00 [revised] PHST- 2023/11/07 00:00 [accepted] PHST- 2024/02/19 06:42 [medline] PHST- 2024/01/06 10:41 [pubmed] PHST- 2024/01/05 19:20 [entrez] AID - S0828-282X(23)01884-6 [pii] AID - 10.1016/j.cjca.2023.11.007 [doi] PST - ppublish SO - Can J Cardiol. 2024 Feb;40(2):275-289. doi: 10.1016/j.cjca.2023.11.007. Epub 2024 Jan 3. PMID- 38180395 OWN - NLM STAT- MEDLINE DCOM- 20240205 LR - 20260616 IS - 1942-5546 (Electronic) IS - 0025-6196 (Linking) VI - 99 IP - 2 DP - 2024 Feb TI - Cancer Treatment-Related Complications in Patients With Hypertrophic Cardiomyopathy. PG - 218-228 LID - S0025-6196(23)00475-5 [pii] LID - 10.1016/j.mayocp.2023.10.003 [doi] AB - OBJECTIVE: To describe the potential clinical cardiotoxicity of oncological treatments in a cohort of consecutive patients with hypertrophic cardiomyopathy (HCM), systematically followed-up at two national referral centers for HCM. Cardiotoxicity relates to the direct effects of cancer-related treatment on heart function, commonly presenting as left ventricular contractile dysfunction. However, limited data are available regarding cardiotoxic effects on HCM as most studies have not specifically analyzed the effects of oncological treatment in HCM populations. This gap in knowledge may lead to unjustified restriction of HCM patients from receiving curative cancer treatments. METHODS: We retrospectively analyzed clinical and instrumental data of all consecutive HCM patients who underwent oncological treatment between January 2000 and December 2020 collected in a centralized database. RESULTS: Of 3256 HCM patients, 121 (3.7%) had cancer; 110 (90.9%) underwent oncological surgery, 45 (37.2%) received chemotherapy, and 22 (18.2%) received chest radiation therapy (cRT). After a median follow-up of 5.2 years (Q1-Q3: 2-13 years) from oncological diagnosis, 32 patients died. The cumulative survival at 5 years was 79.9%. The cause of death was mainly attributed to the oncological condition, whereas four patients died of sudden cardiac death without receiving previous chemotherapy or cRT. No patient interrupted or reduced the dose of oncological treatment due to cardiac dysfunction. No sustained ventricular tachyarrhythmia was induced by chemotherapy or radiation therapy. CONCLUSION: Cancer treatment was well tolerated in HCM patients. In our consecutive series, none died of cardiovascular complications induced by chemotherapy or cRT and they did not require interruption or substantial treatment tapering due to cardiovascular toxic effects. Although a multidisciplinary evaluation is necessary and regimens must be tailored individually, the diagnosis of HCM per se should not be considered a contraindication to receive optimal curative cancer treatment. CI - Copyright (c) 2023 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved. FAU - Zampieri, Mattia AU - Zampieri M AD - Cardiomyopathy Unit, Careggi University Hospital, Florence, Italy; Pediatric Cardiology, Meyer Children's University Hospital IRCCS, Florence, Italy. Electronic address: mattiazampieri29@gmail.com. FAU - Schoonvelde, Stephan A C AU - Schoonvelde SAC AD - Department of Cardiology, Thorax Center, Cardiovascular Institute, Erasmus MC, Rotterdam, Netherlands. FAU - Vinci, Michele AU - Vinci M AD - Cardiomyopathy Unit, Careggi University Hospital, Florence, Italy. FAU - Meattini, Icro AU - Meattini I AD - Radiation Oncology Unit - Oncology Department, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy; Department of Experimental and Clinical Biomedical Sciences "M. Serio", University of Florence, Florence, Italy. FAU - Visani, Luca AU - Visani L AD - Radiation Oncology Unit - Oncology Department, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy. FAU - Fornaro, Alessandra AU - Fornaro A AD - Cardiomyopathy Unit, Careggi University Hospital, Florence, Italy. FAU - Coppini, Raffaele AU - Coppini R AD - Department of Experimental and Clinical Medicine, Careggi University Hospital, Florence, Italy. FAU - Romei, Andrea AU - Romei A AD - Radiation Oncology Unit - Oncology Department, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy; Department of Experimental and Clinical Biomedical Sciences "M. Serio", University of Florence, Florence, Italy. FAU - Marchi, Alberto AU - Marchi A AD - Cardiomyopathy Unit, Careggi University Hospital, Florence, Italy. FAU - Morelli, Ilaria AU - Morelli I AD - Radiation Oncology Unit - Oncology Department, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy; Department of Experimental and Clinical Biomedical Sciences "M. Serio", University of Florence, Florence, Italy. FAU - van Slegtenhorst, Marjon A AU - van Slegtenhorst MA AD - Department of Clinical Genetics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands. FAU - Palinkas, Eszter Dalma AU - Palinkas ED AD - Cardiomyopathy Unit, Careggi University Hospital, Florence, Italy; Doctoral School of Clinical Medicine, University of Szeged, Szeged, Hungary. FAU - Livi, Lorenzo AU - Livi L AD - Radiation Oncology Unit - Oncology Department, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy; Department of Experimental and Clinical Biomedical Sciences "M. Serio", University of Florence, Florence, Italy. FAU - Michels, Michelle AU - Michels M AD - Department of Cardiology, Thorax Center, Cardiovascular Institute, Erasmus MC, Rotterdam, Netherlands. FAU - Olivotto, Iacopo AU - Olivotto I AD - Cardiomyopathy Unit, Careggi University Hospital, Florence, Italy; Pediatric Cardiology, Meyer Children's University Hospital IRCCS, Florence, Italy; Department of Experimental and Clinical Medicine, Careggi University Hospital, Florence, Italy. LA - eng PT - Journal Article DEP - 20240105 PL - England TA - Mayo Clin Proc JT - Mayo Clinic proceedings JID - 0405543 SB - IM CIN - Mayo Clin Proc. 2024 Feb;99(2):191-193. doi: 10.1016/j.mayocp.2023.12.013. PMID: 38309931 MH - Humans MH - Retrospective Studies MH - Cardiotoxicity MH - *Cardiomyopathy, Hypertrophic/complications/therapy/diagnosis MH - Death, Sudden, Cardiac MH - *Ventricular Dysfunction, Left MH - *Neoplasms/complications MH - Risk Factors EDAT- 2024/01/05 12:43 MHDA- 2024/02/05 06:43 CRDT- 2024/01/05 10:28 PHST- 2022/11/19 00:00 [received] PHST- 2023/07/25 00:00 [revised] PHST- 2023/10/05 00:00 [accepted] PHST- 2024/02/05 06:43 [medline] PHST- 2024/01/05 12:43 [pubmed] PHST- 2024/01/05 10:28 [entrez] AID - S0025-6196(23)00475-5 [pii] AID - 10.1016/j.mayocp.2023.10.003 [doi] PST - ppublish SO - Mayo Clin Proc. 2024 Feb;99(2):218-228. doi: 10.1016/j.mayocp.2023.10.003. Epub 2024 Jan 5. PMID- 38175782 OWN - NLM STAT- MEDLINE DCOM- 20240115 LR - 20260813 IS - 1873-734X (Electronic) IS - 1010-7940 (Linking) VI - 65 IP - 1 DP - 2024 Jan 2 TI - Predictive performance of surgical mortality risk scores in infective endocarditis. LID - ezad433 [pii] LID - 10.1093/ejcts/ezad433 [doi] AB - OBJECTIVES: This observational study aimed to evaluate Association pour l'Etude et la Prevention de l'Endocardite Infectieuse (AEPEI) surgery score predictive performance in comparison to general (EuroSCORE I, II) and specific (De Feo, PALSUSE) surgical risk scores for infective endocarditis (IE). METHODS: The study included patients who underwent surgery for IE during the acute phase at Bichat University Hospital (Paris, France) between 1 January 2006 and 31 December 2016 and at Nancy University Hospital (Nancy, France) between 1 January 2009 and 31 December 2019. Patients with IE complicating percutaneous aortic valve implantations or implantable intra-cardiac devices were excluded. Discrimination and calibration were assessed using receiver operating characteristic curve analysis, calibration curves and the Hosmer-Lemeshow test. RESULTS: In-hospital mortality rates were 18% at Bichat and 16% at Nancy. Discrimination was high for all risk scores at Bichat (area under the receiver operating characteristic curve = 0.77 for EuroSCORE I, 0.78 for EuroSCORE II, 0.76 for De Feo score, 0.72 for PALSUSE and 0.73 for AEPEI with 95% confidence interval ranging from 0.67 to 0.83), but lower at Nancy (0.56 for EuroSCORE I, 0.65 for EuroSCORE II, 0.63 for De Feo score, 0.67 for PALSUSE and 0.66 for AEPEI score with 95% confidence interval ranging from 0.47 to 0.75). With Brier score, all scores were adequately calibrated in both populations between 0.129 (De Feo) and 0.135 (PALSUSE) for Bichat and between 0.128 (De Feo) and 0.135 (EuroSCORE I) for Nancy. With the Hosmer-Lemeshow test, the AEPEI score exhibited the best calibration (observed/predicted ratio 1.058 in Bichat, 1.087 in Nancy). CONCLUSIONS: This surgical score external validation in 2 large independent populations demonstrated that the AEPEI surgical score had the best predictive performance compared to other prognosis scores. It could be helpful in clinical practice to assist the endocarditis team in decision-making. CI - (c) The Author(s) 2024. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved. FAU - El Hatimi, Safwane AU - El Hatimi S AUID- ORCID: 0000-0002-9127-348X AD - Cardiology Department, Universite Paris-Saclay, AP-HP, Hopital Bicetre, Le Kremlin-Bicetre, France. FAU - Erpelding, Marie-Line AU - Erpelding ML AD - Clinical Epidemiology Department, Universite de Lorraine CHRU Nancy, INSERM, CIC, Nancy, France. FAU - Selton-Suty, Christine AU - Selton-Suty C AD - Cardiology Department, Universite de Lorraine CHRU Nancy, Nancy, France. FAU - Botros, Jean-Baptiste AU - Botros JB AD - Cardiology Department, Universite Paris-Cite, AP-HP, Hopital Bichat, Paris, France. FAU - Goehringer, Francois AU - Goehringer F AD - Infectious and Tropical Diseases Department, Universite de Lorraine CHRU Nancy, Nancy, France. FAU - Berthelot, Emmanuelle AU - Berthelot E AD - Cardiology Department, Universite Paris-Saclay, AP-HP, Hopital Bicetre, Le Kremlin-Bicetre, France. FAU - Elfarra, Mazen AU - Elfarra M AD - Cardiac Surgery Department, Universite de Lorraine CHRU Nancy, Nancy, France. FAU - Deconinck, Laurene AU - Deconinck L AD - Infectious and Tropical Diseases Department, Universite Paris-Cite, AP-HP, Hopital Bichat, Paris, France. FAU - Para, Marylou AU - Para M AUID- ORCID: 0000-0002-4857-5474 AD - Cardiac Surgery Department, Universite Paris-Cite, AP-HP, Hopital Bichat, Paris, France. FAU - Provenchere, Sophie AU - Provenchere S AD - Anaesthesiology Department, Universite Paris-Cite, AP-HP, Hopital Bichat, Paris, France. FAU - Hoen, Bruno AU - Hoen B AUID- ORCID: 0000-0003-3070-3017 AD - Infectious and Tropical Diseases Department, Universite de Lorraine CHRU Nancy, Nancy, France. FAU - Agrinier, Nelly AU - Agrinier N AD - Clinical Epidemiology Department, Universite de Lorraine CHRU Nancy, INSERM, CIC, Nancy, France. FAU - Duval, Xavier AU - Duval X AD - Infectious and Tropical Diseases Department, Universite Paris-Cite, AP-HP, Hopital Bichat, Paris, France. AD - Inserm CIC 1425, IAME, Paris, France. FAU - Iung, Bernard AU - Iung B AD - Cardiology Department, Universite Paris-Cite, AP-HP, Hopital Bichat, Paris, France. AD - Inserm U1148, Laboratory for Vascular Translational Science, Paris, France. LA - eng PT - Journal Article PT - Observational Study PL - Germany TA - Eur J Cardiothorac Surg JT - European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery JID - 8804069 SB - IM MH - Humans MH - Risk Assessment MH - *Cardiac Surgical Procedures/adverse effects MH - Retrospective Studies MH - *Endocarditis/surgery MH - *Endocarditis, Bacterial/surgery MH - Risk Factors MH - Hospital Mortality OTO - NOTNLM OT - Cardiac valvular surgery outcome OT - Critical care OT - Infective endocarditis OT - Mortality OT - Predictors OT - Quality control EDAT- 2024/01/04 18:41 MHDA- 2024/01/15 12:43 CRDT- 2024/01/04 12:43 PHST- 2023/07/29 00:00 [received] PHST- 2023/12/14 00:00 [revised] PHST- 2023/12/28 00:00 [accepted] PHST- 2024/01/15 12:43 [medline] PHST- 2024/01/04 18:41 [pubmed] PHST- 2024/01/04 12:43 [entrez] AID - 7510848 [pii] AID - 10.1093/ejcts/ezad433 [doi] PST - ppublish SO - Eur J Cardiothorac Surg. 2024 Jan 2;65(1):ezad433. doi: 10.1093/ejcts/ezad433. PMID- 38175351 OWN - NLM STAT- MEDLINE DCOM- 20240105 LR - 20240105 IS - 0927-3042 (Print) IS - 0927-3042 (Linking) VI - 188 DP - 2023 TI - New Concepts in Cardio-Oncology. PG - 303-341 LID - 10.1007/978-3-031-33602-7_12 [doi] AB - Cancer and cardiovascular disease are the two major causes of morbidity and mortality in worldwide. Discovering new therapeutic agents for the management of breast cancer (BC) has increased the numbers of cancer survivors but with the risk of cardiovascular adverse events (CV-AEs). All drugs can potentially damage the cardiovascular system, with different types of clinical manifestations from ischemic myocardial disease to vasculitis, thrombosis or pericarditis. An early detection of CV-AEs guarantees an earlier treatment, which is associated with better outcomes. Cardio-oncology field enlarged its studies to improve prevention, monitoring and treatment of all cardiotoxic manifestations related to old or modern oncological agents. A multidisciplinary approach with a close partnership between oncologists and cardiologists is essential for an optimal management and therapeutic decision-making. The aim of this chapter is to review all types of cardiotoxic manifestations related to novel and old agents approved for treatment of BC patients including chemotherapy, anti-HER2 agents, cyclin-dependent kinase 4/6 inhibitors, PolyADP-ribose polymerase (PARP) inhibitors, antiangiogenic drugs and immunotherapy. We also focused our discussion on prevention, monitoring, treatment, and management of CV-AEs. CI - (c) 2023. The Author(s), under exclusive license to Springer Nature Switzerland AG. FAU - Zagami, Paola AU - Zagami P AD - Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, Milan, Italy. paola.zagami@ieo.it. AD - Department of Oncology and Hematology, University of Milano, Milan, Italy. paola.zagami@ieo.it. FAU - Nicolo, Eleonora AU - Nicolo E AD - Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, Milan, Italy. AD - Department of Oncology and Hematology, University of Milano, Milan, Italy. FAU - Corti, Chiara AU - Corti C AD - Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, Milan, Italy. AD - Department of Oncology and Hematology, University of Milano, Milan, Italy. FAU - Valenza, Carmine AU - Valenza C AD - Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, Milan, Italy. AD - Department of Oncology and Hematology, University of Milano, Milan, Italy. FAU - Curigliano, Giuseppe AU - Curigliano G AD - Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, Milan, Italy. AD - Department of Oncology and Hematology, University of Milano, Milan, Italy. LA - eng PT - Journal Article PL - United States TA - Cancer Treat Res JT - Cancer treatment and research JID - 8008541 SB - IM MH - Humans MH - Female MH - Cardio-Oncology MH - Medical Oncology MH - *Breast Neoplasms MH - Immunotherapy/adverse effects MH - *Cancer Survivors OTO - NOTNLM OT - Breast cancer OT - Cardio-vascular adverse events OT - Cardiotoxicity OT - Heart failure OT - Myocarditis EDAT- 2024/01/04 12:42 MHDA- 2024/01/05 06:42 CRDT- 2024/01/04 11:17 PHST- 2024/01/05 06:42 [medline] PHST- 2024/01/04 12:42 [pubmed] PHST- 2024/01/04 11:17 [entrez] AID - 10.1007/978-3-031-33602-7_12 [doi] PST - ppublish SO - Cancer Treat Res. 2023;188:303-341. doi: 10.1007/978-3-031-33602-7_12. PMID- 38169239 OWN - NLM STAT- MEDLINE DCOM- 20240207 LR - 20260120 IS - 2013-2514 (Electronic) IS - 2013-2514 (Linking) VI - 43 IP - 6 DP - 2023 Nov-Dec TI - Consensus document on the management of hyperkalemia. PG - 765-782 LID - S2013-2514(23)00178-5 [pii] LID - 10.1016/j.nefroe.2023.12.002 [doi] AB - Hyperkalaemia is a common electrolyte imbalance with potentially serious short-, medium- and long-term consequences on morbidity and mortality rates and the use of national health service resources. The fact that different medical specialities can manage hyperkalaemia makes it important to have a unified approach, and the recent availability of new specific drug treatments means that the approach needs to be updated. This consensus document from the scientific societies most directly involved in the management of hyperkalaemia (Sociedad Espanola de Cardiologia [Spanish Society of Cardiology], Sociedad Espanola de Endocrinologia y Nutricion [Spanish Society of Endocrinology and Nutrition], Sociedad Espanola de Medicina Interna [Spanish Society of Internal Medicine], Sociedad Espanola de Medicina de Urgencias y Emergencias [Spanish Society of Accident and Emergency Medicine] and Sociedad Espanola de Nefrologia [Spanish Society of Nephrology]) first of all reviews basic aspects of potassium balance and blood potassium. Then it goes on to focus on the concept, epidemiology, pathophysiology and diagnostic and therapeutic approaches to hyperkalaemia. The available evidence and the main published studies have been reviewed with the aim of providing a useful tool in the multidisciplinary approach to patients with hyperkalaemia. CI - Copyright (c) 2023 Sociedad Espanola de Nefrologia. Published by Elsevier Espana, S.L.U. All rights reserved. FAU - Ortiz, Alberto AU - Ortiz A AD - Sociedad Espanola de Nefrologia (S.E.N.), Spain. FAU - Galan, Carmen Del Arco AU - Galan CDA AD - Sociedad Espanola de Medicina de Urgencias y Emergencias (SEMES), Spain. FAU - Carlos Fernandez-Garcia, Jose AU - Carlos Fernandez-Garcia J AD - Sociedad Espanola de Endocrinologia y Nutricion (SEEN), Spain. FAU - Cerezo, Jorge Gomez AU - Cerezo JG AD - Sociedad Espanola de Medicina Interna (SEMI), Spain. FAU - Ochoa, Rosa Iban AU - Ochoa RI AD - Sociedad Espanola de Medicina de Urgencias y Emergencias (SEMES), Spain. FAU - Nunez, Julio AU - Nunez J AD - Sociedad Espanola de Cardiologia (SEC), Spain. FAU - Gutierrez, Francisco Pita AU - Gutierrez FP AD - Sociedad Espanola de Endocrinologia y Nutricion (SEEN), Spain. FAU - Navarro-Gonzalez, Juan F AU - Navarro-Gonzalez JF AD - Sociedad Espanola de Nefrologia (S.E.N.), Spain. Electronic address: jnavgon@gobiernodecanarias.org. LA - eng PT - Consensus Statement PT - Journal Article DEP - 20240101 PL - Spain TA - Nefrologia (Engl Ed) JT - Nefrologia JID - 101778581 RN - RWP5GA015D (Potassium) SB - IM CIN - Nefrologia (Engl Ed). 2023 Nov-Dec;43(6):799-801. doi: 10.1016/j.nefroe.2023.09.006. PMID: 38212173 CIN - Nefrologia (Engl Ed). 2023 Nov-Dec;43(6):795-796. doi: 10.1016/j.nefroe.2023.09.005. PMID: 38218664 MH - Humans MH - *Hyperkalemia/diagnosis/drug therapy MH - State Medicine MH - Potassium MH - *Cardiology OTO - NOTNLM OT - Chronic kidney disease OT - Ciclosilicato de sodio y zirconio OT - Diabetes mellitus OT - Enfermedad renal cronica OT - Heart failure OT - Hiperpotasemia OT - Hyperkalaemia OT - Insuficiencia cardiaca OT - Patiromer OT - Sodium zirconium cyclosilicate OT - Tratamiento OT - Treatment EDAT- 2024/01/04 01:18 MHDA- 2024/02/07 06:42 CRDT- 2024/01/03 11:23 PHST- 2023/05/03 00:00 [received] PHST- 2023/05/08 00:00 [accepted] PHST- 2024/02/07 06:42 [medline] PHST- 2024/01/04 01:18 [pubmed] PHST- 2024/01/03 11:23 [entrez] AID - S2013-2514(23)00178-5 [pii] AID - 10.1016/j.nefroe.2023.12.002 [doi] PST - ppublish SO - Nefrologia (Engl Ed). 2023 Nov-Dec;43(6):765-782. doi: 10.1016/j.nefroe.2023.12.002. Epub 2024 Jan 1. PMID- 38168872 OWN - NLM STAT- MEDLINE DCOM- 20240105 LR - 20240106 IS - 1590-1262 (Electronic) IS - 1124-4909 (Print) IS - 1124-4909 (Linking) VI - 29 IP - 1 DP - 2024 Jan 2 TI - ANMCO (Italian Association of Hospital Cardiologists) scientific statement: obesity in adults-an approach for cardiologists. PG - 1 LID - 10.1007/s40519-023-01630-8 [doi] LID - 1 AB - Obesity is a complex, chronic disease requiring a multidisciplinary approach to its management. In clinical practice, body mass index and waist-related measurements can be used for obesity screening. The estimated prevalence of obesity among adults worldwide is 12%. With the expected further increase in overall obesity prevalence, clinicians will increasingly be managing patients with obesity. Energy balance is regulated by a complex neurohumoral system that involves the central nervous system and circulating mediators, among which leptin is the most studied. The functioning of these systems is influenced by both genetic and environmental factors. Obesity generally occurs when a genetically predisposed individual lives in an obesogenic environment for a long period. Cardiologists are deeply involved in evaluating patients with obesity. Cardiovascular risk profile is one of the most important items to be quantified to understand the health risk due to obesity and the clinical benefit that a single patient can obtain with weight loss. At the individual level, appropriate patient involvement, the detection of potential obesity causes, and a multidisciplinary approach are tools that can improve clinical outcomes. In the near future, we will probably have new pharmacological tools at our disposal that will facilitate achieving and maintaining weight loss. However, pharmacological treatment alone cannot cure such a complex disease. The aim of this paper is to summarize some key points of this field, such as obesity definition and measurement tools, its epidemiology, the main mechanisms underlying energy homeostasis, health consequences of obesity with a focus on cardiovascular diseases and the obesity paradox.Level of evidence V: report of expert committees. CI - (c) 2024. The Author(s). FAU - Di Fusco, Stefania Angela AU - Di Fusco SA AD - Emergency Department, Clinical and Rehabilitation Cardiology Unit, San Filippo Neri Hospital, ASL Roma 1, Rome, Italy. FAU - Mocini, Edoardo AU - Mocini E AD - Department of Experimental Medicine, Sapienza University, 00161, Rome, Italy. edoardo.mocini@uniroma1.it. FAU - Gulizia, Michele Massimo AU - Gulizia MM AD - Cardiology Department, Garibaldi Nesima Hospital, 95122, Catania, Italy. FAU - Gabrielli, Domenico AU - Gabrielli D AD - Cardio-Thoracic-Vascular Department, San Camillo-Forlanini Hospital, Rome, Italy. AD - Heart Care Foundation, Florence, Italy. FAU - Grimaldi, Massimo AU - Grimaldi M AD - Department of Cardiology, General Regional Hospital "F. Miulli", Acquaviva delle Fonti, 70021, Bari, Italy. FAU - Oliva, Fabrizio AU - Oliva F AD - De Gasperis Cardio Center, Niguarda Hospital, 20162, Milan, Italy. FAU - Colivicchi, Furio AU - Colivicchi F AD - Emergency Department, Clinical and Rehabilitation Cardiology Unit, San Filippo Neri Hospital, ASL Roma 1, Rome, Italy. LA - eng PT - Journal Article PT - Review DEP - 20240102 PL - Germany TA - Eat Weight Disord JT - Eating and weight disorders : EWD JID - 9707113 SB - IM MH - Adult MH - Humans MH - *Cardiologists MH - Obesity/epidemiology MH - *Cardiovascular Diseases/complications MH - Weight Loss MH - Italy PMC - PMC10761446 OTO - NOTNLM OT - Adult OT - BMI OT - Cardiology OT - Energy homeostasis OT - Fat tissue OT - Obesity OT - Weight loss COIS- The authors have no relevant financial or non-financial interests to disclose. EDAT- 2024/01/04 01:18 MHDA- 2024/01/05 06:43 PMCR- 2024/01/02 CRDT- 2024/01/03 11:04 PHST- 2023/08/29 00:00 [received] PHST- 2023/11/27 00:00 [accepted] PHST- 2024/01/05 06:43 [medline] PHST- 2024/01/04 01:18 [pubmed] PHST- 2024/01/03 11:04 [entrez] PHST- 2024/01/02 00:00 [pmc-release] AID - 10.1007/s40519-023-01630-8 [pii] AID - 1630 [pii] AID - 10.1007/s40519-023-01630-8 [doi] PST - epublish SO - Eat Weight Disord. 2024 Jan 2;29(1):1. doi: 10.1007/s40519-023-01630-8. PMID- 38168726 OWN - NLM STAT- MEDLINE DCOM- 20240322 LR - 20241106 IS - 1537-6591 (Electronic) IS - 1058-4838 (Print) IS - 1058-4838 (Linking) VI - 78 IP - 3 DP - 2024 Mar 20 TI - Evaluation of the 2023 Duke-ISCVID and 2023 Duke-ESC Clinical Criteria for the Diagnosis of Infective Endocarditis in a Multicenter Cohort of Patients With Staphylococcus aureus Bacteremia. PG - 655-662 LID - 10.1093/cid/ciae003 [doi] AB - BACKGROUND: The Duke criteria for infective endocarditis (IE) diagnosis underwent revisions in 2023 by the European Society of Cardiology (ESC) and the International Society for Cardiovascular Infectious Diseases (ISCVID). This study aims to assess the diagnostic accuracy of these criteria, focusing on patients with Staphylococcus aureus bacteremia (SAB). METHODS: This Swiss multicenter study conducted between 2014 and 2023 pooled data from three cohorts. It evaluated the performance of each iteration of the Duke criteria by assessing the degree of concordance between definite S. aureus IE (SAIE) and the diagnoses made by the Endocarditis Team (2018-23) or IE expert clinicians (2014-17). RESULTS: Among 1344 SAB episodes analyzed, 486 (36%) were identified as cases of SAIE. The 2023 Duke-ISCVID and 2023 Duke-ESC criteria demonstrated improved sensitivity for SAIE diagnosis (81% and 82%, respectively) compared to the 2015 Duke-ESC criteria (75%). However, the new criteria exhibited reduced specificity for SAIE (96% for both) compared to the 2015 criteria (99%). Spondylodiscitis was more prevalent among patients with SAIE compared to those with SAB alone (10% vs 7%, P = .026). However, when patients meeting the minor 2015 Duke-ESC vascular criterion were excluded, the incidence of spondylodiscitis was similar between SAIE and SAB patients (6% vs 5%, P = .461). CONCLUSIONS: The 2023 Duke-ISCVID and 2023 Duke-ESC clinical criteria show improved sensitivity for SAIE diagnosis compared to 2015 Duke-ESC criteria. However, this increase in sensitivity comes at the expense of reduced specificity. Future research should aim at evaluating the impact of each component introduced within these criteria. CI - (c) The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. FAU - Papadimitriou-Olivgeris, Matthaios AU - Papadimitriou-Olivgeris M AUID- ORCID: 0000-0003-0565-5105 AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Monney, Pierre AU - Monney P AD - Department of Cardiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Frank, Michelle AU - Frank M AD - Department of Cardiology, University Hospital Zurich and University of Zurich, Zurich, Switzerland. FAU - Tzimas, Georgios AU - Tzimas G AD - Department of Cardiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Tozzi, Piergiorgio AU - Tozzi P AD - Department of Cardiac Surgery, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Kirsch, Matthias AU - Kirsch M AD - Department of Cardiac Surgery, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Van Hemelrijck, Mathias AU - Van Hemelrijck M AD - Department of Cardiac Surgery, University Hospital Zurich and University of Zurich, Zurich, Switzerland. FAU - Bauernschmitt, Robert AU - Bauernschmitt R AD - Department of Cardiac Surgery, University Hospital Zurich and University of Zurich, Zurich, Switzerland. FAU - Epprecht, Jana AU - Epprecht J AD - Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich and University of Zurich, Zurich, Switzerland. FAU - Guery, Benoit AU - Guery B AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Hasse, Barbara AU - Hasse B AD - Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich and University of Zurich, Zurich, Switzerland. LA - eng GR - SNSF_/Swiss National Science Foundation/Switzerland PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't PL - United States TA - Clin Infect Dis JT - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America JID - 9203213 SB - IM MH - Humans MH - Staphylococcus aureus MH - *Discitis MH - *Endocarditis, Bacterial/diagnosis/epidemiology MH - *Endocarditis/diagnosis MH - *Staphylococcal Infections/diagnosis/epidemiology MH - *Bacteremia/diagnosis/epidemiology MH - *Cardiology PMC - PMC10954331 OTO - NOTNLM OT - Staphylococcus aureus OT - Duke criteria OT - bacteremia OT - echocardiography OT - infective endocarditis COIS- Potential conflicts of interest. The authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. EDAT- 2024/01/04 01:18 MHDA- 2024/03/22 06:45 PMCR- 2024/01/03 CRDT- 2024/01/03 10:56 PHST- 2023/10/15 00:00 [received] PHST- 2024/03/22 06:45 [medline] PHST- 2024/01/04 01:18 [pubmed] PHST- 2024/01/03 10:56 [entrez] PHST- 2024/01/03 00:00 [pmc-release] AID - 7505219 [pii] AID - ciae003 [pii] AID - 10.1093/cid/ciae003 [doi] PST - ppublish SO - Clin Infect Dis. 2024 Mar 20;78(3):655-662. doi: 10.1093/cid/ciae003. PMID- 38167796 OWN - NLM STAT- MEDLINE DCOM- 20240105 LR - 20240121 IS - 2149-2271 (Electronic) IS - 2149-2263 (Print) IS - 2149-2263 (Linking) VI - 28 IP - 1 DP - 2024 Jan TI - Expert Recommendations to Bridge Gaps in Heart Failure Patient Support in the Middle East and Africa Region. PG - 2-18 LID - 10.14744/AnatolJCardiol.2023.3517 [doi] AB - Heart failure (HF) remains a serious health and socioeconomic problem in the Middle East and Africa (MEA). The age-standardized prevalence rate for HF in the MEA region is higher compared to countries in Eastern Europe, Latin America, and Southeast Asia. Also cardiovascular-related deaths remain high compared to their global counterparts. Moreover, in MEA, 66% of HF readmissions are elicited by potentially preventable factors, including delay in seeking medical attention, nonadherence to HF medication, suboptimal discharge planning, inadequate follow-up, and poor social support. Patient support in the form of activation, counseling, and caregiver education has been shown to improve outcomes in patients with HF. A multidisciplinary meeting with experts from different countries across the MEA region was convened to identify the current gaps and unmet needs for patient support for HF in the region. The panel provided insights into the real-world challenges in HF patient support and contributed strategic recommendations for optimizing HF care. FAU - Skouri, Hadi N AU - Skouri HN AD - Department of Cardiology, Sheikh Shakbout Medical City-Mayo Clinic, Abu Dhabi, United Arab Emirates. FAU - Cavusoglu, Yuksel AU - Cavusoglu Y AD - Department of Cardiology, Faculty of Medicine, Eskisehir Osmangazi University, Eskisehir, Turkiye. FAU - Bennis, Ahmed AU - Bennis A AD - Department of Cardiology, The Ibn Rochd University Hospital Center, Casablanca, Morocco. FAU - Klug, Eric AU - Klug E AD - Division of Cardiology, Netcare Sunninghill, Sunward Park Hospitals, School of Clinical Medicine, Faculty of Health Sciences and the University of the Witwatersrand and Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa. FAU - Ogola, Elijah N AU - Ogola EN AD - Department of Internal Medicine and Cardiology, University of Nairobi, Nairobi, Kenya. FAU - Bader, Feras AU - Bader F AD - Department of Cardiovascular Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University Section of Heart Failure and Transplant, Heart, Vascular, and Thoracic Institute, Cleveland Clinic Abu Dhabi, United Arab Emirates. FAU - Al Saffar, Hilal Bahjet AU - Al Saffar HB AD - International Advisor, RCP for Iraq, Chair, RCP Iraq Members and Fellows Network Head, Scientific Committee, Iraqi Red Crescent Society Iraq, Baghdad, Iraq. FAU - Ragy, Hany AU - Ragy H AD - Department of Cardiology, National Heart Institute, Cairo, Egypt. FAU - Alhumood, Khaldoon A AU - Alhumood KA AD - Advanced Heart Failure and Transplantation Unit, Chest Diseases Hospital, Ministry of Health, Kuwait City, Kuwait. FAU - Abdelhamid, Magdy AU - Abdelhamid M AD - Department of Cardiology, Faculty of Medicine, Cairo University, Cairo, Egypt. FAU - Yilmaz, Mehmet Birhan AU - Yilmaz MB AD - Department of Cardiology, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkiye. FAU - Tabbalat, Ramzi AU - Tabbalat R AD - Department of Cardiology, Abdali Medical Center, Amman, Jordan. LA - eng PT - Journal Article PT - Review PL - Turkey TA - Anatol J Cardiol JT - Anatolian journal of cardiology JID - 101652981 SB - IM MH - Humans MH - Africa/epidemiology MH - Middle East/epidemiology MH - *Heart Failure/epidemiology/therapy MH - Patient Discharge PMC - PMC10796245 COIS- Declaration of Interests: H.N.S. received speaker honorarium from Novartis, AstraZeneca, Boehringer Ingelheim, Abbott, Bayer and Vifor. Y.C. received a speaker honorarium or consultation fee from AstraZeneca, Novartis, Servier, Boehringer Ingelheim and Roche Diagnostics. A.B. received institutional fee from Novartis, Bayer, Amgen, AstraZeneca, Boehringer Ingelheim, Servier and Merck. E.K. received honoraria from AstraZeneca, Bayer, Boehringer-Ingelheim, Novartis, Novo-Nordisk, Pfizer, Roche, Sanofi and Servier. E.N.O. received research grants from AstraZeneca and Novartis; also received speaker fees from AstraZeneca, Servier, Novartis, Boehringer Ingelhaim, Pfizer and Merck. F.B. declares no conflict of interest. H.B.A.S. received honoraria from AstraZeneca and Merck for congress presentations and advisory boards. H.R. received honoraria from Novartis and AstraZeneca and Menarinin for congress presentations and advisory boards. K.A.A. as advisor received honorarium from Boehringer Ingelheim, AstraZeneca, Pfizer, Vifor, Novartis, Janssen, Merck, Bayer, Abbott (Heartmate3, CardioMEMS), Medtronic (Heartware) and Syncardia TAH. M.A. received speaker honoraria from Bayer, AstraZeneca, Novartis and Boehringer Ingelheim. M.B.Y. received institutional fee from Novartis, Bayer, Amgen, AstraZeneca, Boehringer Ingelheim, Servier, Roche Diagnostics and Albert Health. R.T. received honoraria as a speaker and advisory board member form AstraZeneca, BI, Pfizer, Merck, Novartis, Hikma, MSPhrma. Grant recepient from Pfizer. EDAT- 2024/01/04 01:18 MHDA- 2024/01/05 06:42 PMCR- 2024/01/01 CRDT- 2024/01/03 10:12 PHST- 2024/01/05 06:42 [medline] PHST- 2024/01/04 01:18 [pubmed] PHST- 2024/01/03 10:12 [entrez] PHST- 2024/01/01 00:00 [pmc-release] AID - ajc-28-1-2 [pii] AID - 10.14744/AnatolJCardiol.2023.3517 [doi] PST - ppublish SO - Anatol J Cardiol. 2024 Jan;28(1):2-18. doi: 10.14744/AnatolJCardiol.2023.3517. PMID- 38166642 OWN - NLM STAT- MEDLINE DCOM- 20240105 LR - 20240106 IS - 1471-2253 (Electronic) IS - 1471-2253 (Linking) VI - 24 IP - 1 DP - 2024 Jan 2 TI - Does preoperative multidisciplinary team assessment of high-risk patients improve the safety and outcomes of patients undergoing surgery? PG - 9 LID - 10.1186/s12871-023-02394-5 [doi] LID - 9 AB - BACKGROUND: International guidelines recommend preoperative multidisciplinary team (MDT) assessment for high-risk surgical patients. Preoperative MDT meetings can help to improve surgical care, but there is little evidence on whether they improve patient outcomes. METHODS: This paper aims to share our experience of MDT meetings for high-risk surgical patients to underline their added value to the current standard of care. An observational study of a retrospective cohort of preoperative high-risk MDT meetings of a tertiary referral hospital between January 2015 and December 2020. For 249 patients the outcomes preoperative data, MDT decisions, and patient outcomes were collected from electronic health records. MAIN RESULTS: A total of 249 patients were discussed at high-risk MDT meetings. Most of the patients (97%) were assessed as having an American Society of Anesthesiology score >/= 3, and 219 (88%) had a European Society of Cardiology and European Society of Anaesthesiology risk score of intermediate or high. After MDT assessment, 154 (62%) were directly approved for surgery, and 39 (16%) were considered ineligible for surgery. The remaining 56 (23%) patients underwent additional assessments before reconsideration at a high-risk MDT meeting. The main reason for patients being discussed at the high-risk MDT meeting was to assess the risk-benefit ratio of surgery. Ultimately, 184 (74%) patients underwent surgery. Of the operated patients, 122 (66%) did not have a major complication in the postoperative period, and 149 patients (81%) were alive after one year. CONCLUSIONS: This cohort study shows the vulnerability and complexity of high-risk patients but also shows that the use of an MDT assessment contributes too improved peri- and postoperative treatment strategies in high-risk patients. Most patients underwent surgery after careful risk assessment and, if deemed necessary, preoperative and perioperative treatment optimization to reduce their risk. CI - (c) 2023. The Author(s). FAU - Kuiper, B I AU - Kuiper BI AD - Department of Surgery, Amsterdam UMC location VUmc, Amsterdam, The Netherlands. AD - Cancer Center Amsterdam, Amsterdam, The Netherlands. FAU - Janssen, L M J AU - Janssen LMJ AD - Department of Anesthesiology, Amsterdam UMC location VUmc, De Boelelaan 1117, Amsterdam, 1081 HV, The Netherlands. liedewij.janssen@amsterdamumc.nl. FAU - Versteeg, K S AU - Versteeg KS AD - Department of Internal medicine, section geriatrics, Amsterdam UMC location VUmc, Amsterdam, The Netherlands. FAU - Ten Tusscher, B L AU - Ten Tusscher BL AD - Department of Intensive Care Medicine, Amsterdam UMC location VUmc, Amsterdam, The Netherlands. FAU - van der Spoel, J I AU - van der Spoel JI AD - Department of Intensive Care Medicine, Amsterdam UMC location VUmc, Amsterdam, The Netherlands. FAU - Lubbers, W D AU - Lubbers WD AD - Department of Anesthesiology, Amsterdam UMC location VUmc, De Boelelaan 1117, Amsterdam, 1081 HV, The Netherlands. FAU - Kazemier, G AU - Kazemier G AD - Department of Surgery, Amsterdam UMC location VUmc, Amsterdam, The Netherlands. AD - Cancer Center Amsterdam, Amsterdam, The Netherlands. FAU - Loer, S A AU - Loer SA AD - Department of Anesthesiology, Amsterdam UMC location VUmc, De Boelelaan 1117, Amsterdam, 1081 HV, The Netherlands. FAU - Schober, P AU - Schober P AD - Department of Anesthesiology, Amsterdam UMC location VUmc, De Boelelaan 1117, Amsterdam, 1081 HV, The Netherlands. FAU - van Halm, V P AU - van Halm VP AD - Department of Cardiology, Amsterdam UMC location VUmc, Amsterdam, The Netherlands. LA - eng PT - Journal Article PT - Observational Study DEP - 20240102 PL - England TA - BMC Anesthesiol JT - BMC anesthesiology JID - 100968535 SB - IM MH - Humans MH - Retrospective Studies MH - Cohort Studies MH - *Patient Care Team MH - *Anesthesiology PMC - PMC10759340 OTO - NOTNLM OT - Anesthesia OT - Frailty OT - High-risk surgery OT - Multidisciplinary team OT - Preoperative consultation COIS- The authors declare no competing interests. EDAT- 2024/01/04 01:18 MHDA- 2024/01/05 06:42 PMCR- 2024/01/02 CRDT- 2024/01/03 09:07 PHST- 2023/06/20 00:00 [received] PHST- 2023/12/20 00:00 [accepted] PHST- 2024/01/05 06:42 [medline] PHST- 2024/01/04 01:18 [pubmed] PHST- 2024/01/03 09:07 [entrez] PHST- 2024/01/02 00:00 [pmc-release] AID - 10.1186/s12871-023-02394-5 [pii] AID - 2394 [pii] AID - 10.1186/s12871-023-02394-5 [doi] PST - epublish SO - BMC Anesthesiol. 2024 Jan 2;24(1):9. doi: 10.1186/s12871-023-02394-5. PMID- 20301450 STAT- Publisher DRDT- 20240104 CTDT- 20000519 PB - University of Washington, Seattle DP - 1993 TI - Alagille Syndrome. BTI - GeneReviews((R)) AB - CLINICAL CHARACTERISTICS: Alagille syndrome (ALGS) is a multisystem disorder with a wide spectrum of clinical variability; this variability is seen even among individuals from the same family. The major clinical manifestations of ALGS are bile duct paucity on liver biopsy, cholestasis, congenital cardiac defects (primarily involving the pulmonary arteries), butterfly vertebrae, ophthalmologic abnormalities (most commonly posterior embryotoxon), and characteristic facial features. Renal abnormalities, growth failure, behavioral differences, splenomegaly, retinal changes, and vascular abnormalities may also occur. DIAGNOSIS/TESTING: The diagnosis of ALGS is established in a proband who meets clinical diagnostic criteria and/or has a heterozygous pathogenic variant in JAG1 or NOTCH2 identified by molecular genetic testing. MANAGEMENT: Targeted therapy: Ileal bile acid transporter inhibitors (maralixabat and odevixibat) to increase excretion of bile acids. Supportive care: Management by a multidisciplinary team according to clinical manifestations (clinical genetics, gastroenterology/hepatology, nutrition, cardiology, ophthalmology, nephrology, transplant hepatology, and child development); choleretic agents (ursodeoxycholic acid), other medications (cholestyramine, rifampin, naltrexone) for pruritus and xanthomas; liver transplantation for refractory cholestasis and/or end-stage liver disease; optimized nutrition and replacement of fat-soluble vitamins as needed; treatment of cardiovascular manifestations in a center with experience with ALGS; low vision services as needed; standard treatment for hepatocellular carcinoma and renal and neurologic involvement. Surveillance: Monitor liver function per gastroenterologist/hepatologist; serum alpha-fetoprotein and liver ultrasound every six months; at each visit, assess growth, blood pressure, and for recurrent fractures; nutrition assessment as needed; assessment for vascular manifestations per cardiologist; vision assessment per ophthalmologist; basic metabolic panel every six months; assess developmental progress and for attention and executive function impairment annually. Agents/circumstances to avoid: Contact sports; alcohol consumption if liver disease is present. GENETIC COUNSELING: ALGS is inherited in an autosomal dominant manner. Approximately 40% of individuals have an inherited pathogenic variant and about 60% have a de novo pathogenic variant. Parental somatic/germline mosaicism has been reported. Offspring of an individual with ALGS have a 50% chance of inheriting the JAG1 or NOTCH2 pathogenic variant. Prenatal testing for pregnancies at increased risk and preimplantation genetic testing are possible if the causative genetic alteration has been identified in an affected family member. Because ALGS is associated with highly variable expressivity with clinical features ranging from subclinical to severe, clinical manifestations cannot be predicted by molecular genetic prenatal testing. CI - Copyright (c) 1993-2026, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved. FED - Adam, Margaret P ED - Adam MP FED - Bick, Sarah ED - Bick S FED - Mirzaa, Ghayda M ED - Mirzaa GM FED - Wallace, Stephanie E ED - Wallace SE FED - Amemiya, Anne ED - Amemiya A FAU - Spinner, Nancy B AU - Spinner NB AD - Professor of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania AD - Chief, Division of Genomic Diagnostics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania FAU - Loomes, Kathleen M AU - Loomes KM AD - Professor of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania AD - Children's Hospital of Philadelphia, Philadelphia, Pennsylvania FAU - Krantz, Ian D AU - Krantz ID AD - Children's Hospital of Philadelphia, Philadelphia, Pennsylvania AD - Professor of Pediatrics and Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania FAU - Gilbert, Melissa A AU - Gilbert MA AD - Children's Hospital of Philadelphia, Philadelphia, Pennsylvania AD - Assistant Professor, Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania LA - eng PT - Review PT - Book Chapter PL - Seattle (WA) OTO - NLM OT - Arteriohepatic Dysplasia OT - Syndromic Bile Duct Paucity OT - Neurogenic locus notch homolog protein 2 OT - Protein jagged-1 OT - JAG1 OT - NOTCH2 OT - Alagille Syndrome OT - Arteriohepatic Dysplasia OT - Syndromic Bile Duct Paucity EDAT- 2024/01/04 00:00 CRDT- 2024/01/04 00:00 AID - NBK1273 [bookaccession] PMID- 38165269 OWN - NLM STAT- MEDLINE DCOM- 20240527 LR - 20250130 IS - 1873-1953 (Electronic) IS - 1474-5151 (Linking) VI - 23 IP - 4 DP - 2024 May 28 TI - Exploring heart failure nurse practitioner outcome measures: a scoping review. PG - 337-347 LID - 10.1093/eurjcn/zvad108 [doi] AB - AIMS: Clinical guidelines recommend people with heart failure are managed within a multidisciplinary team to receive optimal evidence-based management of the syndrome. There is increasing evidence that Nurse Practitioners (NP) in heart failure demonstrate positive patient outcomes. However, their roles as key stakeholders in a multidisciplinary heart failure team are not clearly defined. The aim of the review was to explore the literature related to NP-sensitive outcomes in heart failure. METHODS AND RESULTS: A scoping review was conducted according to accepted guidelines using the Joanna Briggs Institute framework for conducting a scoping review, to identify the literature that related to NP-sensitive outcomes in heart failure management. Sixteen texts were selected for data extraction and analysis. The most common outcome measures reported were readmission rates, self-care measurement scales, functional status scores, quality of life measurements, and medication optimization outcomes. No two studies collected or reported on the same outcome measurements. CONCLUSION: This review highlights that the reporting of heart failure (HF) NP outcome indicators was inconsistent and disparate across the literature. The outcome measures reported were not exclusive to NP interventions. Nurse Practitioner roles are not clearly defined, and resulting outcomes from care are difficult to characterize. Standardized NP-specific outcome measures would serve to highlight the effectiveness of the role in a multidisciplinary HF team. CI - (c) The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. FAU - Ryder, Mary AU - Ryder M AUID- ORCID: 0000-0003-0988-4941 AD - School of Nursing, Midwifery & Health Systems, University College Dublin, Dublin D04 C7X2, Ireland. FAU - Mannion, Tara AU - Mannion T AD - School of Nursing, Midwifery & Health Systems, University College Dublin, Dublin D04 C7X2, Ireland. AD - St Claires Integrated Care Centre, Dublin 11, Ireland. FAU - Furlong, Eileen AU - Furlong E AUID- ORCID: 0000-0002-1985-2620 AD - School of Nursing, Midwifery & Health Systems, University College Dublin, Dublin D04 C7X2, Ireland. FAU - O'Donoghue, Ethel AU - O'Donoghue E AD - School of Nursing, Midwifery & Health Systems, University College Dublin, Dublin D04 C7X2, Ireland. AD - St Vincent's University Hospital, Dublin, Ireland. FAU - Travers, Bronagh AU - Travers B AD - School of Nursing, Midwifery & Health Systems, University College Dublin, Dublin D04 C7X2, Ireland. AD - Tallaght University Hospital, Dublin, Ireland. FAU - Connolly, Michael AU - Connolly M AUID- ORCID: 0000-0002-6602-1803 AD - School of Nursing, Midwifery & Health Systems, University College Dublin, Dublin D04 C7X2, Ireland. AD - Our Lady's Hospice and Care Services, Dublin, Ireland. FAU - Lucey, Niamh AU - Lucey N AUID- ORCID: 0000-0003-3644-1580 AD - School of Nursing, Midwifery & Health Systems, University College Dublin, Dublin D04 C7X2, Ireland. AD - St Vincent's University Hospital, Dublin, Ireland. LA - eng PT - Journal Article PT - Scoping Review PL - England TA - Eur J Cardiovasc Nurs JT - European journal of cardiovascular nursing JID - 101128793 SB - IM CIN - Eur J Cardiovasc Nurs. 2024 May 28;23(4):e37-e38. doi: 10.1093/eurjcn/zvae008. PMID: 38306407 MH - Humans MH - *Heart Failure/nursing MH - *Nurse Practitioners MH - Outcome Assessment, Health Care MH - Nurse's Role MH - Quality of Life MH - Cardiovascular Nursing OTO - NOTNLM OT - Advanced Practice OT - Heart failure OT - Nurse Practitioner OT - Nursing OT - Outcomes COIS- Conflict of interest: none declared. EDAT- 2024/01/02 11:43 MHDA- 2024/05/28 00:43 CRDT- 2024/01/02 10:03 PHST- 2023/04/03 00:00 [received] PHST- 2023/10/23 00:00 [revised] PHST- 2023/10/24 00:00 [accepted] PHST- 2024/05/28 00:43 [medline] PHST- 2024/01/02 11:43 [pubmed] PHST- 2024/01/02 10:03 [entrez] AID - 7504983 [pii] AID - 10.1093/eurjcn/zvad108 [doi] PST - ppublish SO - Eur J Cardiovasc Nurs. 2024 May 28;23(4):337-347. doi: 10.1093/eurjcn/zvad108. PMID- 38163616 OWN - NLM STAT- MEDLINE DCOM- 20240219 LR - 20260105 IS - 1097-6744 (Electronic) IS - 0002-8703 (Linking) VI - 269 DP - 2024 Mar TI - Preoperative computed tomography-imaging with patient-specific computer simulation in transcatheter aortic valve implantation: Design and rationale of the GUIDE-TAVI trial. PG - 158-166 LID - S0002-8703(23)00360-5 [pii] LID - 10.1016/j.ahj.2023.12.017 [doi] AB - BACKGROUND: Transcatheter aortic valve implantation (TAVI) is an established treatment option for patients with severe aortic valve stenosis, but is still associated with relatively high rates of pacemaker implantation and paravalvular regurgitation. Routine preoperative computed tomography (CT) combined with patient-specific computer modelling can predict the interaction between the TAVI device and the patient's unique anatomy, allowing physicians to assess the risk for paravalvular regurgitation and conduction disorders in advance to the procedure. The aim of this trial is to assess potential improvement in the procedural outcome of TAVI by applying CT-based patient-specific computer simulations in patients with suitable anatomy for TAVI. METHODS: The GUIDE-TAVI trial is an international multicenter randomized controlled trial including patients accepted for TAVI by the Heart Team. Patients enrolled in the study will be randomized into 2 arms of each 227 patients. In patients randomized to the use of FEops HEARTGuide (FHG), patient-specific computer simulation with FHG is performed in addition to routine preoperative CT imaging and results of the FHG are available to the operator(s) prior to the scheduled intervention. In patients randomized to no use of FHG, only routine preoperative CT imaging is performed. The primary objective is to evaluate whether the use of FHG will reduce the incidence of mild to severe PVR, according to the Valve Academic Research Consortium 3. Secondary endpoints include the incidence of new conduction disorders requiring permanent pacemaker implantation, the difference between preoperative and final selected valve size, the difference between target and final implantation depth, change of preoperative decision, failure to implant valve, early safety composite endpoint and quality of life. CONCLUSIONS: The GUIDE-TAVI trial is the first multicenter randomized controlled trial to evaluate the value of 3-dimensional computer simulations in addition to standard preprocedural planning in TAVI procedures. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Hegeman, Romy R M J J AU - Hegeman RRMJJ AD - Department of Cardiothoracic Surgery, Sint Antonius Hospital, Nieuwegein, The Netherlands; Department of Cardiothoracic Surgery, Amsterdam University Medical Center, Amsterdam, the Netherlands. Electronic address: r.hegeman@antoniusziekenhuis.nl. FAU - van Ginkel, Dirk-Jan AU - van Ginkel DJ AD - Department of Cardiology, Sint Antonius Hospital, Nieuwegein, The Netherlands. FAU - Laengle, Severin AU - Laengle S AD - Department of Cardiothoracic Surgery, Medical University of Vienna, Vienna, Austria. FAU - Timmers, Leo AU - Timmers L AD - Department of Cardiology, Sint Antonius Hospital, Nieuwegein, The Netherlands. FAU - Rensing, Benno J W M AU - Rensing BJWM AD - Department of Cardiology, Sint Antonius Hospital, Nieuwegein, The Netherlands. FAU - de Kroon, Thomas L AU - de Kroon TL AD - Department of Cardiothoracic Surgery, Sint Antonius Hospital, Nieuwegein, The Netherlands. FAU - Sonker, Uday AU - Sonker U AD - Department of Cardiothoracic Surgery, Sint Antonius Hospital, Nieuwegein, The Netherlands. FAU - Kelder, Johannes C AU - Kelder JC AD - Department of Epidemiology, Sint Antonius Hospital, Nieuwegein, The Netherlands. FAU - Mach, Markus AU - Mach M AD - Department of Cardiothoracic Surgery, Medical University of Vienna, Vienna, Austria; Department of Cardiovascular Surgery, Heart Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. FAU - Andreas, Martin AU - Andreas M AD - Department of Cardiothoracic Surgery, Medical University of Vienna, Vienna, Austria. FAU - Swaans, Martin J AU - Swaans MJ AD - Department of Cardiology, Sint Antonius Hospital, Nieuwegein, The Netherlands. FAU - Ten Berg, Jurrien M AU - Ten Berg JM AD - Department of Cardiology, Sint Antonius Hospital, Nieuwegein, The Netherlands; Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands. FAU - Klein, Patrick AU - Klein P AD - Department of Cardiothoracic Surgery, Sint Antonius Hospital, Nieuwegein, The Netherlands; Department of Cardiothoracic Surgery, Amsterdam University Medical Center, Amsterdam, the Netherlands. LA - eng PT - Clinical Trial Protocol PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20231230 PL - United States TA - Am Heart J JT - American heart journal JID - 0370465 SB - IM MH - Humans MH - *Transcatheter Aortic Valve Replacement/methods MH - Aortic Valve/surgery MH - Computer Simulation MH - Quality of Life MH - *Aortic Valve Stenosis/diagnostic imaging/surgery MH - Tomography, X-Ray Computed/adverse effects MH - Treatment Outcome MH - *Heart Valve Prosthesis/adverse effects MH - Multicenter Studies as Topic MH - Randomized Controlled Trials as Topic COIS- Disclosures The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/01/02 11:41 MHDA- 2024/02/19 06:43 CRDT- 2024/01/01 19:14 PHST- 2023/08/30 00:00 [received] PHST- 2023/11/28 00:00 [revised] PHST- 2023/12/27 00:00 [accepted] PHST- 2024/02/19 06:43 [medline] PHST- 2024/01/02 11:41 [pubmed] PHST- 2024/01/01 19:14 [entrez] AID - S0002-8703(23)00360-5 [pii] AID - 10.1016/j.ahj.2023.12.017 [doi] PST - ppublish SO - Am Heart J. 2024 Mar;269:158-166. doi: 10.1016/j.ahj.2023.12.017. Epub 2023 Dec 30. PMID- 38161672 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240103 IS - 2772-8129 (Electronic) IS - 2772-8129 (Linking) VI - 2 IP - 6Part A DP - 2023 Dec TI - Risk Stratification for Sudden Cardiac Death in Repaired Tetralogy of Fallot. PG - 414-425 LID - 10.1016/j.cjcpc.2023.07.002 [doi] AB - There has been significant progress in the prevention of sudden cardiac death in repaired tetralogy of Fallot. Contemporary cohorts report greater survival attributable to improved surgical techniques, heart failure management, and proactive strategies for risk stratification and management of ventricular arrhythmias including defibrillator implantation and ablation technology. Over the last 25 years, our understanding of predictive risk factors has also improved from invasive and more limited measures to individualized risk prediction scores based on extensive demographic, imaging, electrophysiological, and functional data. Although each of these contemporary scoring systems improves prediction, there are important differences between the study cohorts, included risk factors, and imaging modalities that can significantly affect interpretation and implementation for the individual patient. In addition, accurate phenotyping of disease complexity and anatomic repair substantially modulates this risk and the mechanism of sudden death. Routine implementation of risk stratification within repaired tetralogy of Fallot management is important and directly informs primary prevention defibrillator implantation as well as consideration for proactive invasive strategies including ventricular tachycardia ablation and pulmonary valve replacement. Assessment and risk stratification by a multidisciplinary team of experts in adult congenital heart disease are crucial and critical. Although we have increased understanding, reconciliation of these complex factors for the individual patient remains challenging and often requires careful consideration and discussion with multidisciplinary teams, patients, and their families. CI - (c) 2023 The Authors. FAU - Kakarla, Jayant AU - Kakarla J AD - University Health Network Toronto, Peter Munk Cardiac Centre, Toronto Adult Congenital Heart Disease Program, and University of Toronto, Toronto, Ontario, Canada. FAU - Denham, Nathan C AU - Denham NC AD - University Health Network Toronto, Peter Munk Cardiac Centre, Toronto Adult Congenital Heart Disease Program, and University of Toronto, Toronto, Ontario, Canada. FAU - Ishikita, Ayako AU - Ishikita A AD - University Health Network Toronto, Peter Munk Cardiac Centre, Toronto Adult Congenital Heart Disease Program, and University of Toronto, Toronto, Ontario, Canada. FAU - Oechslin, Erwin AU - Oechslin E AD - University Health Network Toronto, Peter Munk Cardiac Centre, Toronto Adult Congenital Heart Disease Program, and University of Toronto, Toronto, Ontario, Canada. FAU - Alonso-Gonzalez, Rafael AU - Alonso-Gonzalez R AD - University Health Network Toronto, Peter Munk Cardiac Centre, Toronto Adult Congenital Heart Disease Program, and University of Toronto, Toronto, Ontario, Canada. FAU - Nair, Krishnakumar AU - Nair K AD - University Health Network Toronto, Peter Munk Cardiac Centre, Toronto Adult Congenital Heart Disease Program, and University of Toronto, Toronto, Ontario, Canada. LA - eng PT - Journal Article PT - Review DEP - 20230727 PL - United States TA - CJC Pediatr Congenit Heart Dis JT - CJC pediatric and congenital heart disease JID - 9918697364606676 PMC - PMC10755789 EDAT- 2024/01/02 11:45 MHDA- 2024/01/02 11:46 PMCR- 2023/07/27 CRDT- 2024/01/01 04:08 PHST- 2023/07/03 00:00 [received] PHST- 2023/07/18 00:00 [accepted] PHST- 2024/01/02 11:46 [medline] PHST- 2024/01/02 11:45 [pubmed] PHST- 2024/01/01 04:08 [entrez] PHST- 2023/07/27 00:00 [pmc-release] AID - S2772-8129(23)00104-5 [pii] AID - 10.1016/j.cjcpc.2023.07.002 [doi] PST - epublish SO - CJC Pediatr Congenit Heart Dis. 2023 Jul 27;2(6Part A):414-425. doi: 10.1016/j.cjcpc.2023.07.002. eCollection 2023 Dec. PMID- 38161671 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240103 IS - 2772-8129 (Electronic) IS - 2772-8129 (Linking) VI - 2 IP - 6Part A DP - 2023 Dec TI - Pregnancy Considerations in Tetralogy of Fallot. PG - 301-313 LID - 10.1016/j.cjcpc.2023.09.008 [doi] AB - The majority of women with repaired tetralogy of Fallot are able to tolerate pregnancy with a low risk of cardiovascular events. However, proactive contraceptive advice, prepregnancy counselling, and care by a pregnancy heart team with expertise in congenital heart disease are key to ensuring a good outcome for mother and baby. Maternal and fetal risks are increased in the presence of severe valvular stenosis, poorly tolerated arrhythmia, significant ventricular dysfunction, and cyanosis. It is unusual to see cyanotic adults with tetralogy of Fallot, whether unoperated or shunt palliated; pregnancy risks are greatly reduced by completing their repair before pregnancy is undertaken. The multidisciplinary pregnancy heart team should make a risk-stratified pregnancy care plan using a combination of published scoring systems and an individualized assessment of the patient's comorbidities. Low-risk patients may have the majority of their care and give birth in local units, whereas those at high risk should be managed and give birth in a tertiary centre with high-level expertise and intensive care facilities. Age-appropriate conversations about future childbearing and safe and reliable contraception should be part of routine follow-up from teenage years, so that women with tetralogy of Fallot can control their own fertility and make informed decisions about having children. CI - (c) 2023 The Author(s). FAU - Garagiola, Maria L AU - Garagiola ML AD - Division of Cardiology, University Health Network and Mount Sinai Health System, University of Toronto, Toronto, Ontario, Canada. FAU - Thorne, Sara A AU - Thorne SA AD - Division of Cardiology, University Health Network and Mount Sinai Health System, University of Toronto, Toronto, Ontario, Canada. LA - eng PT - Journal Article PT - Review DEP - 20230922 PL - United States TA - CJC Pediatr Congenit Heart Dis JT - CJC pediatric and congenital heart disease JID - 9918697364606676 PMC - PMC10755828 EDAT- 2024/01/02 11:45 MHDA- 2024/01/02 11:46 PMCR- 2023/09/22 CRDT- 2024/01/01 04:08 PHST- 2023/08/03 00:00 [received] PHST- 2023/09/12 00:00 [accepted] PHST- 2024/01/02 11:46 [medline] PHST- 2024/01/02 11:45 [pubmed] PHST- 2024/01/01 04:08 [entrez] PHST- 2023/09/22 00:00 [pmc-release] AID - S2772-8129(23)00134-3 [pii] AID - 10.1016/j.cjcpc.2023.09.008 [doi] PST - epublish SO - CJC Pediatr Congenit Heart Dis. 2023 Sep 22;2(6Part A):301-313. doi: 10.1016/j.cjcpc.2023.09.008. eCollection 2023 Dec. PMID- 38160911 OWN - NLM STAT- MEDLINE DCOM- 20240220 LR - 20260527 IS - 1874-1754 (Electronic) IS - 0167-5273 (Linking) VI - 400 DP - 2024 Apr 1 TI - Management of high and intermediate-high risk pulmonary embolism: A position paper of the Interventional Cardiology Working Group of the Italian Society of Cardiology. PG - 131694 LID - S0167-5273(23)01852-1 [pii] LID - 10.1016/j.ijcard.2023.131694 [doi] AB - Pulmonary embolism (PE) is a potentially life-threatening condition that remains a major global health concern. Noteworthy, patients with high- and intermediate-high-risk PE pose unique challenges because they often display clinical and hemodynamic instability, thus requiring rapid intervention to mitigate the risk of clinical deterioration and death. Importantly, recovery from PE is associated with long-term complications such as recurrences, bleeding with oral anticoagulant treatment, pulmonary hypertension, and psychological distress. Several novel strategies to improve risk factor characterization and management of patients with PE have recently been introduced. Accordingly, this position paper of the Working Group of Interventional Cardiology of the Italian Society of Cardiology deals with the landscape of high- and intermediate-high risk PE, with a focus on bridging the gap between the evolving standards of care and the current clinical practice. Specifically, the growing importance of catheter-directed therapies as part of the therapeutic armamentarium is highlighted. These interventions have been shown to be effective strategies in unstable patients since they offer, as compared with thrombolysis, faster and more effective restoration of hemodynamic stability with a consistent reduction in the risk of bleeding. Evolving standards of care underscore the need for continuous re-assessment of patient risk stratification. To this end, a multidisciplinary approach is paramount in refining selection criteria to deliver the most effective treatment to patients with unstable hemodynamics. In conclusion, the current management of unstable patients with PE should prioritize tailored treatment in a patient-oriented approach in which transcatheter therapies play a central role. CI - Copyright (c) 2023 The Author(s). Published by Elsevier B.V. All rights reserved. FAU - Ando, Giuseppe AU - Ando G AD - Department of Clinical and Experimental Medicine, University of Messina, AOU Policlinico "Gaetano Martino", Messina, Italy. FAU - Pelliccia, Francesco AU - Pelliccia F AD - Department of Cardiovascular Sciences, "La Sapienza" University, Rome, Italy. Electronic address: f.pelliccia@mclink.it. FAU - Saia, Francesco AU - Saia F AD - Department of Cardiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna Policlinico S Orsola-Malpighi, Bologna, Italy. FAU - Tarantini, Giuseppe AU - Tarantini G AD - Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua Medical School, Padua, Italy. FAU - Fraccaro, Chiara AU - Fraccaro C AD - Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua Medical School, Padua, Italy. FAU - D'Ascenzo, Fabrizio AU - D'Ascenzo F AD - Division of Cardiology, Cardiovascular and Thoracic Department, Citta della Salute e della Scienza Hospital and University of Turin, Turin, Italy. FAU - Zimarino, Marco AU - Zimarino M AD - Department of Neuroscience, Imaging and Clinical Sciences, "Gabriele D'Annunzio" University of Chieti-Pescara, Chieti, Italy; Department of Cardiology, "SS. Annunziata Hospital", ASL 2 Abruzzo, Chieti, Italy. FAU - Di Marino, Mario AU - Di Marino M AD - Department of Neuroscience, Imaging and Clinical Sciences, "Gabriele D'Annunzio" University of Chieti-Pescara, Chieti, Italy. FAU - Niccoli, Giampaolo AU - Niccoli G AD - Department of Medicine and Surgery, University of Parma, Parma, Italy. FAU - Porto, Italo AU - Porto I AD - Chair of Cardiovascular Disease, Department of Internal Medicine and Specialties, University of Genoa, Genoa, Italy; Cardiology Unit, Cardiothoracic and Vascular Department (DICATOV) IRCCS, Ospedale Policlinico San Martino, Genoa, Italy. FAU - Calabro, Paolo AU - Calabro P AD - Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", Italy; Division of Clinical Cardiology, AORN "Sant'Anna e San Sebastiano", Caserta, Italy. FAU - Gragnano, Felice AU - Gragnano F AD - Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", Italy; Division of Clinical Cardiology, AORN "Sant'Anna e San Sebastiano", Caserta, Italy. FAU - De Rosa, Salvatore AU - De Rosa S AD - Division of Cardiology, Department of Medical and Surgical Sciences, Magna Graecia University of Catanzaro, Catanzaro, Italy. FAU - Piccolo, Raffaele AU - Piccolo R AD - Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy. FAU - Moscarella, Elisabetta AU - Moscarella E AD - Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", Italy; Division of Clinical Cardiology, AORN "Sant'Anna e San Sebastiano", Caserta, Italy. FAU - Fabris, Enrico AU - Fabris E AD - Cardio-thoraco-vascular Department, Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), University of Trieste, Trieste, Italy. FAU - Montone, Rocco Antonio AU - Montone RA AD - Department of Cardiovascular Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. FAU - Spaccarotella, Carmen AU - Spaccarotella C AD - Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy. FAU - Indolfi, Ciro AU - Indolfi C AD - Division of Cardiology, Department of Medical and Surgical Sciences, Magna Graecia University of Catanzaro, Catanzaro, Italy. FAU - Sinagra, Gianfranco AU - Sinagra G AD - Cardio-thoraco-vascular Department, Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), University of Trieste, Trieste, Italy. FAU - Perrone Filardi, Pasquale AU - Perrone Filardi P AD - Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy. CN - Working Group of Interventional Cardiology of the Italian Society of Cardiology LA - eng PT - Consensus Statement PT - Journal Article PT - Review DEP - 20231230 PL - Netherlands TA - Int J Cardiol JT - International journal of cardiology JID - 8200291 RN - 0 (Fibrinolytic Agents) SB - IM MH - Humans MH - Thrombolytic Therapy/adverse effects MH - *Pulmonary Embolism/therapy/drug therapy MH - Thrombectomy MH - Hemorrhage/chemically induced MH - *Cardiology MH - Treatment Outcome MH - Italy/epidemiology MH - Fibrinolytic Agents/therapeutic use OTO - NOTNLM OT - Pulmonary embolism OT - Pulmonary embolism response team OT - Systemic thrombolysis OT - Thrombo-aspiration EDAT- 2024/01/02 11:42 MHDA- 2024/02/20 11:50 CRDT- 2023/12/31 19:17 PHST- 2023/12/10 00:00 [received] PHST- 2023/12/26 00:00 [revised] PHST- 2023/12/27 00:00 [accepted] PHST- 2024/02/20 11:50 [medline] PHST- 2024/01/02 11:42 [pubmed] PHST- 2023/12/31 19:17 [entrez] AID - S0167-5273(23)01852-1 [pii] AID - 10.1016/j.ijcard.2023.131694 [doi] PST - ppublish SO - Int J Cardiol. 2024 Apr 1;400:131694. doi: 10.1016/j.ijcard.2023.131694. Epub 2023 Dec 30. PMID- 38159957 OWN - NLM STAT- MEDLINE DCOM- 20240103 LR - 20240124 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 13 IP - 12 DP - 2023 Dec 30 TI - Attitude of cardiac surgery nurses on kinesiophobia management: a qualitative study. PG - e074438 LID - 10.1136/bmjopen-2023-074438 [doi] LID - e074438 AB - OBJECTIVES: This study aimed to investigate the knowledge, attitudes and practical experiences of cardiac surgery nurses regarding kinesiophobia management during early mobilisation. DESIGN: Using a descriptive qualitative research method, 21 cardiac surgery nurses participated in this study from October 2022 to January 2023, and the interview data were analysed using the Colaizzi 7-step analysis method. SETTING: Data were collected through in-depth face-to-face or online interviews in a tertiary hospital located in Nanjing, China. PARTICIPANTS: 21 cardiac surgery nurses were interviewed from October 2022 to January 2023. RESULTS: Two themes were summarised: knowledge, attitude and practice of nurses (high recognition and low participation; low knowledge reserve; low willingness); the promotion and essential elements of kinesiophobia management (efficient health education model; stable medical staff-family caregiver collaboration; simplified clinical protocol; specialist nursing team; clarify the multidisciplinary division of labour). CONCLUSION: The management of kinesiophobia in patients undergoing cardiac surgery is currently in the developmental phase. It is advisable to give due consideration to emotional support and cognitive training for medical staff. In addition, a workable management plan, consistent with clinical practice, should be formulated through multidisciplinary and medical staff-family caregiver collaboration to optimise patient outcomes. CI - (c) Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Wang, YuChen AU - Wang Y AUID- ORCID: 0009-0007-1711-5444 AD - The Third School of Clinical Medicine, Nanjing Medical University, Nanjing, Jiangsu, China. FAU - Chen, YuHong AU - Chen Y AD - Department of Nursing, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China 18951670955@163.com. FAU - Zhang, XiaoMin AU - Zhang X AD - Department of Cardiothoracic Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China. FAU - Liu, SiYu AU - Liu S AD - Department of Cardiothoracic Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China. LA - eng PT - Journal Article DEP - 20231230 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 SB - IM MH - Humans MH - *Kinesiophobia MH - Qualitative Research MH - Attitude of Health Personnel MH - *Cardiac Surgical Procedures MH - Medical Staff PMC - PMC10759056 OTO - NOTNLM OT - CARDIOLOGY OT - Nursing Care OT - QUALITATIVE RESEARCH COIS- Competing interests: None declared. EDAT- 2024/01/02 11:43 MHDA- 2024/01/03 09:43 PMCR- 2023/12/30 CRDT- 2023/12/30 20:43 PHST- 2024/01/03 09:43 [medline] PHST- 2024/01/02 11:43 [pubmed] PHST- 2023/12/30 20:43 [entrez] PHST- 2023/12/30 00:00 [pmc-release] AID - bmjopen-2023-074438 [pii] AID - 10.1136/bmjopen-2023-074438 [doi] PST - epublish SO - BMJ Open. 2023 Dec 30;13(12):e074438. doi: 10.1136/bmjopen-2023-074438. PMID- 38159830 OWN - NLM STAT- MEDLINE DCOM- 20240311 LR - 20240430 IS - 1879-3649 (Electronic) IS - 1537-1891 (Linking) VI - 154 DP - 2024 Mar TI - Therapy and guideline adherence at a multidisciplinary hypertension clinic: A prospective, observational study. PG - 107271 LID - S1537-1891(23)00131-3 [pii] LID - 10.1016/j.vph.2023.107271 [doi] AB - BACKGROUND: Hypertension is highly prevalent and remains one of the most frequent and preventable causes of cardiovascular morbidity and mortality. Yet, suboptimal blood pressure control is common. Hypertension clinics might play an important role in improving target attainment, by targeting drug therapy adherence, improving guideline compliance and by involving pharmacists. OBJECTIVES: We aimed to characterize patient drug therapy adherence, prescriber guideline compliance and pharmacist interventions at the hypertension clinic. METHODS: A prospective observational study was performed at the hypertension clinic of a large, academic hospital. Adult Dutch-speaking patients were eligible for inclusion. Following data were collected: patient demographics, medication use, patient adherence to prescribed antihypertensive drug therapies according to the BAASIS tool and prescriber compliance to the 2018 European Society of Cardiology (ESC) hypertension guidelines. RESULTS: A cohort of 108 patients was included with 51.9% male and aged 65 (IQR: 52-75) years. In total, 104 patients took at least 1 antihypertensive drug and 46 patients (44.2%) were classified as non-adherent with regard to their antihypertensive treatment; 82 patients (78.8%) had suboptimal blood pressure control. Compliance with the ESC guidelines was 66.3% prior to the consultation at the clinic and significantly increased to 77.9% thereafter (p = 0.0015). The clinical pharmacist performed a medication review for 27 patients with a total of 44 recommendations and an acceptance rate of 59.1%. CONCLUSION: A visit to the multidisciplinary hypertension clinic improved prescriber guideline compliance and the use of single pill combinations. Involvement of a clinical pharmacist could be beneficial to further improve patient drug therapy adherence and guideline compliance. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Hias, Julie AU - Hias J AD - Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium; Hospital Pharmacy Department, University Hospitals Leuven, Leuven, Belgium. FAU - Defieuw, Lise AU - Defieuw L AD - Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium. Electronic address: lise.defieuw@uzleuven.be. FAU - Vanassche, Thomas AU - Vanassche T AD - Department of Cardiovascular Sciences, KU Leuven, Leuven, Belgium; Department of Cardiology, University Hospitals Leuven, Leuven, Belgium. FAU - Verhamme, Peter AU - Verhamme P AD - Department of Cardiovascular Sciences, KU Leuven, Leuven, Belgium; Department of Cardiology, University Hospitals Leuven, Leuven, Belgium. FAU - Van der Linden, Lorenz AU - Van der Linden L AD - Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium; Hospital Pharmacy Department, University Hospitals Leuven, Leuven, Belgium. LA - eng PT - Journal Article PT - Observational Study DEP - 20231228 PL - United States TA - Vascul Pharmacol JT - Vascular pharmacology JID - 101130615 RN - 0 (Antihypertensive Agents) SB - IM MH - Adult MH - Humans MH - Male MH - Female MH - *Antihypertensive Agents/adverse effects MH - Guideline Adherence MH - Prospective Studies MH - Medication Adherence MH - *Hypertension/diagnosis/drug therapy OTO - NOTNLM OT - Drug therapy OT - Guideline compliance OT - Hypertension OT - Patient adherence OT - Pharmacist COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/01/02 11:44 MHDA- 2024/03/11 06:43 CRDT- 2023/12/30 19:17 PHST- 2023/09/26 00:00 [received] PHST- 2023/12/11 00:00 [revised] PHST- 2023/12/22 00:00 [accepted] PHST- 2024/03/11 06:43 [medline] PHST- 2024/01/02 11:44 [pubmed] PHST- 2023/12/30 19:17 [entrez] AID - S1537-1891(23)00131-3 [pii] AID - 10.1016/j.vph.2023.107271 [doi] PST - ppublish SO - Vascul Pharmacol. 2024 Mar;154:107271. doi: 10.1016/j.vph.2023.107271. Epub 2023 Dec 28. PMID- 40979849 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250922 LR - 20250924 IS - 1735-5370 (Print) IS - 2008-2371 (Electronic) IS - 1735-5370 (Linking) VI - 19 IP - Suppl 1 DP - 2024 TI - Successful Management of Post-Infarction Ventricular Septal Rupture: A Case Report. PG - 63-67 LID - 10.18502/jthc.v19is1.18480 [doi] AB - BACKGROUND: Post-infarction ventricular septal rupture (PIVSR) is a rare but severe mechanical complication of myocardial infarction (MI) associated with a high mortality rate. Hemodynamic instability is inevitable both during the progression of the condition while awaiting timely surgical intervention and in the postoperative period. Continuous hemodynamic monitoring can enhance the observation of a patient's circulatory status, facilitate prompt and targeted interventions, and ultimately improve prognosis. CASE PRESENTATION: A 65-year-old man presented with dyspnea 19 days after the onset of MI. He was referred to our hospital with symptoms of acute heart failure and a grade IV/VI pansystolic murmur audible at the apex. Echocardiography revealed a 14 mm ventricular septal defect at the apical region, accompanied by a left-to-right shunt. The patient was stabilized in the cardiovascular care unit and scheduled for ventricular septal rupture (VSR) closure and coronary artery bypass grafting. The procedure was performed on the 16th day of hospitalization. Postoperatively, the patient developed shock due to bleeding and cardiac tamponade, necessitating 2 redo surgeries. Despite these complications, the patient ultimately survived following extensive stabilization efforts. CONCLUSION: Hemodynamic monitoring and stabilization are critical factors in determining the prognosis of patients with PIVSR. Timely diagnosis of postoperative complications that compromise hemodynamics, combined with a collaborative interdisciplinary team approach, can enhance treatment strategies, significantly reduce fatal complications and morbidity, and ultimately improve the patient's likelihood of survival. CI - Copyright(c) 2024 Tehran University of Medical Sciences. Published by Tehran University of Medical Sciences. FAU - Alfredo, Paulus AU - Alfredo P AD - Department of Cardiology and Vascular Medicine, Faculty of Medicine, Diponegoro University - Dr. Kariadi General Hospital Semarang, Indonesia. FAU - Mumtazar, Muhammad Fauziar Ahnaf AU - Mumtazar MFA AD - Department of Cardiology and Vascular Medicine, Faculty of Medicine, Diponegoro University - Dr. Kariadi General Hospital Semarang, Indonesia. FAU - Ardhianto, Pipin AU - Ardhianto P AD - Department of Cardiology and Vascular Medicine, Faculty of Medicine, Diponegoro University - Dr. Kariadi General Hospital Semarang, Indonesia. FAU - Sungkar, Safir AU - Sungkar S AD - Department of Cardiology and Vascular Medicine, Faculty of Medicine, Diponegoro University - Dr. Kariadi General Hospital Semarang, Indonesia. FAU - Uddin, Ilham AU - Uddin I AD - Department of Cardiology and Vascular Medicine, Faculty of Medicine, Diponegoro University - Dr. Kariadi General Hospital Semarang, Indonesia. FAU - Fatah, Sahal AU - Fatah S AD - Department of Surgery, Faculty of Medicine, Diponegoro University - Dr. Kariadi General Hospital Semarang, Indonesia. FAU - Sofia, Sefri Noventi AU - Sofia SN AD - Department of Cardiology and Vascular Medicine, Faculty of Medicine, Diponegoro University - Dr. Kariadi General Hospital Semarang, Indonesia. LA - eng PT - Journal Article PL - Iran TA - J Tehran Heart Cent JT - The journal of Tehran Heart Center JID - 101289255 PMC - PMC12445795 OTO - NOTNLM OT - Hemodynamic OT - Myocardial infarction OT - Ventricular septal rupture EDAT- 2024/01/01 00:00 MHDA- 2024/01/01 00:01 PMCR- 2024/01/01 CRDT- 2025/09/22 08:15 PHST- 2024/05/16 00:00 [received] PHST- 2024/07/28 00:00 [accepted] PHST- 2024/01/01 00:01 [medline] PHST- 2024/01/01 00:00 [pubmed] PHST- 2025/09/22 08:15 [entrez] PHST- 2024/01/01 00:00 [pmc-release] AID - JTHC-19-63 [pii] AID - 10.18502/jthc.v19is1.18480 [doi] PST - ppublish SO - J Tehran Heart Cent. 2024;19(Suppl 1):63-67. doi: 10.18502/jthc.v19is1.18480. PMID- 38156424 OWN - NLM STAT- MEDLINE DCOM- 20250109 LR - 20260507 IS - 1477-111X (Electronic) IS - 0267-6591 (Linking) VI - 40 IP - 1 DP - 2025 Jan TI - Designing and maintaining a rescue extracorporeal life support program: A holistic simulation approach. PG - 148-156 LID - 10.1177/02676591231225717 [doi] AB - Rescue Extracorporeal Life Support Programs based at non-cardiac surgery centers have unique needs to be able to ensure successful outcomes despite low patient volumes. In this paper we describe the important role simulation had in each stage of development, implementation, and maintenance of our pediatric Rescue ECLS Program. Systems-focused simulations were used to develop robust workflows, processes, and bundles. Simulation-based education targeted the acquisition and maintenance of clinical skills for individual team members, bringing together a multidisciplinary team of local clinicians who do not routinely perform pediatric cannulation related tasks. Translational simulation ensured continued improvement by addressing adverse events or latent safety threats observed during system-focused or educational simulations. Realism of all simulations was our priority, and was achieved through in situ simulations, participation of multidisciplinary teams, use of real equipment and medical supplies, and use of a high-fidelity cannulation manikin. This holistic simulation approach allowed us to overcome the barriers to high quality care, and maintain outcomes comparable to high volume centers. A similar approach can help other centers design simulation for their own Rescue ECLS Program, and can be translated to other high-risk and high-acuity critical care programs. FAU - Spence, Tanya AU - Spence T AUID- ORCID: 0009-0000-9460-5876 AD - Pediatric Intensive Care Unit. Alberta Children's Hospital, Calgary, AB, Canada. AD - Faculty of Nursing, University of Calgary, Calgary, AB, Canada. AD - Associate Chief Nursing Office, Alberta Health Services, Calgary, AB, Canada. FAU - Nikitovic, Dejana AU - Nikitovic D AUID- ORCID: 0000-0002-1471-1263 AD - Department of Paediatrics, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. FAU - Duncan, Donovan AU - Duncan D AD - Pediatric Intensive Care Unit. Alberta Children's Hospital, Calgary, AB, Canada. AD - Department of Paediatrics, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. FAU - Menzies, Steve AU - Menzies S AD - Department of Cardiac Surgery, Foothills Medical Center, Calgary, AB, Canada. FAU - Zadunayski, Anna AU - Zadunayski A AD - Department of Paediatrics, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. FAU - Brindle, Mary AU - Brindle M AD - Pediatric Intensive Care Unit. Alberta Children's Hospital, Calgary, AB, Canada. AD - Department of Surgery, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. FAU - Blackwood, Jaime AU - Blackwood J AD - Pediatric Intensive Care Unit. Alberta Children's Hospital, Calgary, AB, Canada. AD - Department of Paediatrics, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. LA - eng GR - ELSO/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20231229 PL - England TA - Perfusion JT - Perfusion JID - 8700166 SB - IM MH - Humans MH - *Extracorporeal Membrane Oxygenation/methods/education MH - Simulation Training/methods MH - Patient Care Team OTO - NOTNLM OT - critical care OT - extracorporeal life support OT - extracorporeal membrane oxygenation OT - pediatrics OT - rescue extracorporeal life support program OT - simulation COIS- Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2023/12/29 06:43 MHDA- 2025/01/09 06:22 CRDT- 2023/12/29 04:33 PHST- 2025/01/09 06:22 [medline] PHST- 2023/12/29 06:43 [pubmed] PHST- 2023/12/29 04:33 [entrez] AID - 10.1177/02676591231225717 [doi] PST - ppublish SO - Perfusion. 2025 Jan;40(1):148-156. doi: 10.1177/02676591231225717. Epub 2023 Dec 29. PMID- 38155226 OWN - NLM STAT- MEDLINE DCOM- 20240529 LR - 20261010 IS - 1615-6692 (Electronic) IS - 0340-9937 (Linking) VI - 49 IP - 3 DP - 2024 Jun TI - Cardiac, possible cardiac, and likely non-cardiac origin of chest pain : A hitherto underestimated parameter in German chest pain units. PG - 175-180 LID - 10.1007/s00059-023-05230-1 [doi] AB - BACKGROUND: Current guidelines emphasize the diagnostic value of non-cardiac or possibly cardiac chest pain. The goal of this analysis was to determine whether German chest pain units (CPUs) adequately address conditions with "atypical" chest pain in existing diagnostic structures. METHOD: A total of 11,734 patients from the German CPU registry were included. The analyses included mode of admission, critical time intervals, diagnostic steps, and differential diagnoses. RESULTS: Patients with unspecified chest pain were younger, more often female, were less likely to have classic cardiovascular risk factors and tended to present more often as self-referrals. Patients with acute coronary syndrome (ACS) mostly had prehospital medical contact. Overall, there was no difference between these two groups regarding the time from the onset of first symptoms to arrival at the CPU. In the CPU, the usual basic diagnostic measures were performed irrespective of ACS as the primary working diagnosis. In the non-ACS group, further ischemia-specific diagnostics were rarely performed. Extra-cardiac differential diagnoses were not specified. CONCLUSION: The establishment of broader awareness programs and opening CPUs for low-threshold evaluation of self-referring patients should be discussed. Regarding the rigid focus on the clarification of cardiac causes of chest pain, a stronger interdisciplinary approach should be promoted. CI - (c) 2023. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature. FAU - Imhof, Sebastian AU - Imhof S AD - Department of Cardiology, Pneumology, Neurology and Intensive Care, Klinik Kitzinger Land, Kitzingen, Germany. FAU - Hochadel, Matthias AU - Hochadel M AD - Institute for Myocardial Infarction Research Foundation, Ludwigshafen, Germany. FAU - Konstantinides, Stavros AU - Konstantinides S AD - Center for Thrombosis and Hemostasis (CTH), University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany. FAU - Voigtlander, Thomas AU - Voigtlander T AD - CCB, Cardioangiologisches Centrum Bethanien, Frankfurt am Main, Germany. FAU - Schmitt, Claus AU - Schmitt C AD - Clinic for Cardiology and Angiology, Municipal Hospital Karlsruhe, Karlsruhe, Germany. FAU - Nowak, Bernd AU - Nowak B AD - CCB, Cardioangiologisches Centrum Bethanien, Frankfurt am Main, Germany. FAU - Rassaf, Tienush AU - Rassaf T AD - Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center Essen, University Duisburg-Essen, Essen, Germany. FAU - Senges, Jochen AU - Senges J AD - Institute for Myocardial Infarction Research Foundation, Ludwigshafen, Germany. FAU - Munzel, Thomas AU - Munzel T AD - Department of Cardiology, University Medical Center Mainz, Johannes Gutenberg-University Mainz, Mainz, Germany. FAU - Giannitsis, Evangelos AU - Giannitsis E AD - 3rd Department of Medicine, University Hospital Heidelberg, Heidelberg, Germany. FAU - Breuckmann, Frank AU - Breuckmann F AD - Department of Cardiology, Pneumology, Neurology and Intensive Care, Klinik Kitzinger Land, Kitzingen, Germany. frank.breuckmann@k-kl.de. AD - Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center Essen, University Duisburg-Essen, Essen, Germany. frank.breuckmann@k-kl.de. LA - eng PT - Journal Article TT - Kardialer, moglicherweise kardialer und wahrscheinlich nicht kardialer Thoraxschmerz : Ein bislang unterschatzter Parameter in deutschen Chest Pain Units. DEP - 20231228 PL - Germany TA - Herz JT - Herz JID - 7801231 SB - IM MH - Aged MH - Female MH - Humans MH - Male MH - Middle Aged MH - Acute Coronary Syndrome/diagnosis/epidemiology/complications MH - Age Distribution MH - *Chest Pain/etiology/diagnosis MH - Comorbidity MH - Diagnosis, Differential MH - Germany MH - Prevalence MH - Registries MH - Sex Distribution MH - Retrospective Studies OTO - NOTNLM OT - Acute coronary syndrome OT - Differential diagnosis OT - Interdisciplinary health team OT - Symptom onset OT - Underestimation EDAT- 2023/12/29 00:42 MHDA- 2024/05/29 12:43 CRDT- 2023/12/28 23:22 PHST- 2023/11/22 00:00 [accepted] PHST- 2024/05/29 12:43 [medline] PHST- 2023/12/29 00:42 [pubmed] PHST- 2023/12/28 23:22 [entrez] AID - 10.1007/s00059-023-05230-1 [pii] AID - 10.1007/s00059-023-05230-1 [doi] PST - ppublish SO - Herz. 2024 Jun;49(3):175-180. doi: 10.1007/s00059-023-05230-1. Epub 2023 Dec 28. PMID- 38154703 OWN - NLM STAT- MEDLINE DCOM- 20240214 LR - 20240214 IS - 1535-6280 (Electronic) IS - 0146-2806 (Linking) VI - 49 IP - 3 DP - 2024 Mar TI - Management of cancer patients at high and very-high risk of cardiotoxicity: Main questions and answers. PG - 102229 LID - S0146-2806(23)00646-1 [pii] LID - 10.1016/j.cpcardiol.2023.102229 [doi] AB - In recent years, important advances have been made in the field of Cardio-Oncology. The 2022 ESC Guidelines on Cardio-Oncology proposed a baseline cardiovascular risk stratification for cancer patients and preventive strategies in patients at high and very-high risk of cardiotoxicity. Cardiovascular toxic effects of anti-cancer drugs are being extensively studied; surveillance programs have been proposed, based on the baseline cardiovascular risk. On the other hand, there is little data on Cardio-Oncological management of patients at high and very-high cardiovascular risk with previous cardiovascular diseases. For example, little is known about management of cancer patients with heart failure with reduced ejection fraction (HFrEF), patients with a recent myocardial infarction or other cardiovascular diseases; when to resume anti-cancer drugs after a cardiovascular toxic event. Collaboration between Cardiologists and Oncologists and multidisciplinary team evaluations are certainly essential to decide the best therapeutic strategy for cancer patients, to treat cancer while saving the heart. Therefore, in the present review, we attempt to provide a useful guide to clinicians in treating patients with high and very-high risk of cardiotoxicity by enucleating main questions and answering them based on the evidence available as well as expert opinion and our clinical experience. CI - Copyright (c) 2023 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Di Lisi, Daniela AU - Di Lisi D AD - Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Division of Cardiology, University Hospital Paolo Giaccone, Palermo, Italy.. Electronic address: danydilis@hotmail.it. FAU - Cadeddu Dessalvi, Christian AU - Cadeddu Dessalvi C AD - Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy. FAU - Zito, Concetta AU - Zito C AD - Department of Clinical and Experimental Medicine - Cardiology Unit, University of Messina, Messina, Italy. FAU - Madaudo, Cristina AU - Madaudo C AD - Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Division of Cardiology, University Hospital Paolo Giaccone, Palermo, Italy. FAU - Manganaro, Roberta AU - Manganaro R AD - Department of Clinical and Experimental Medicine - Cardiology Unit, University of Messina, Messina, Italy. FAU - Mercurio, Valentina AU - Mercurio V AD - Department of Translational Medical Sciences, Federico II University, Naples, Italy; Interdepartmental Center of Clinical and Translational Sciences (CIRCET), Federico II University, Naples, Italy; Interdepartmental Hypertension Research Center (CIRIAPA), Federico II University, Naples, Italy. FAU - Deidda, Martino AU - Deidda M AD - Cardiovascular Disease Unit, IRCCS Ospedale Policlinico San Martino, Italy-IRCCS Italian Cardiovascular Network & Department of Internal Medicine, University of Genova, 16121 Genova, Italy. FAU - Santoro, Ciro AU - Santoro C AD - Department of Advanced Biomedical Sciences, Federico II University, 80131 Naples, Italy. FAU - Penna, Claudia AU - Penna C AD - Department of Clinical and Biological Sciences of Turin University, Orbassano, Turin, I-10043, Italy. FAU - Monte, Ines Paola AU - Monte IP AD - Department of General Surgery and Medical-Surgery Specialities- Cardiology, University of Catania, Catania, Italy. FAU - Spallarossa, Paolo AU - Spallarossa P AD - Cardiovascular Disease Unit, IRCCS Ospedale Policlinico San Martino, Italy-IRCCS Italian Cardiovascular Network & Department of Internal Medicine, University of Genova, 16121 Genova, Italy. FAU - Tocchetti, Carlo Gabriele AU - Tocchetti CG AD - Department of Translational Medical Sciences, Federico II University, Naples, Italy; Interdepartmental Center of Clinical and Translational Sciences (CIRCET), Federico II University, Naples, Italy; Interdepartmental Hypertension Research Center (CIRIAPA), Federico II University, Naples, Italy; Center for Basic and Clinical Immunology Research (CISI), Federico II University, Naples, Italy. FAU - Novo, Giuseppina AU - Novo G AD - Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Division of Cardiology, University Hospital Paolo Giaccone, Palermo, Italy. LA - eng PT - Journal Article PT - Review DEP - 20231227 PL - Netherlands TA - Curr Probl Cardiol JT - Current problems in cardiology JID - 7701802 RN - 0 (Antineoplastic Agents) SB - IM MH - Humans MH - *Heart Failure/therapy/drug therapy MH - Cardiotoxicity/etiology/prevention & control MH - Stroke Volume MH - *Neoplasms/drug therapy/chemically induced MH - *Antineoplastic Agents/adverse effects MH - *Ventricular Dysfunction, Left/chemically induced OTO - NOTNLM OT - Anticoagulant OT - CTRCD OT - Cancer OT - Cardio-oncology OT - Cardioprotection OT - Heart failure COIS- Declaration of Competing Interest CGT reports honoraria or consultation fees from VivaLyfe, Univers Formazione, Solaris, Summeet, Astra Zeneca, Myocardial Solutions, Medtronic; funding from Amgen and MSD, outside the submitted work; and is listed as an inventor of two patents related to heart failure. EDAT- 2023/12/29 00:42 MHDA- 2024/02/12 05:43 CRDT- 2023/12/28 19:28 PHST- 2023/11/19 00:00 [received] PHST- 2023/11/28 00:00 [accepted] PHST- 2024/02/12 05:43 [medline] PHST- 2023/12/29 00:42 [pubmed] PHST- 2023/12/28 19:28 [entrez] AID - S0146-2806(23)00646-1 [pii] AID - 10.1016/j.cpcardiol.2023.102229 [doi] PST - ppublish SO - Curr Probl Cardiol. 2024 Mar;49(3):102229. doi: 10.1016/j.cpcardiol.2023.102229. Epub 2023 Dec 27. PMID- 38151398 OWN - NLM STAT- MEDLINE DCOM- 20240214 LR - 20240214 IS - 1444-2892 (Electronic) IS - 1443-9506 (Linking) VI - 33 IP - 1 DP - 2024 Jan TI - Impact of a Cardiogenic Shock Program on Mortality in a Non-Transplant Hospital. PG - 38-45 LID - S1443-9506(23)04444-X [pii] LID - 10.1016/j.hlc.2023.11.010 [doi] AB - INTRODUCTION: Cardiogenic shock is associated with high in-hospital morbidity and mortality. Improvements in this care process could lead to better outcomes. METHODS: This retrospective study of patients with cardiogenic shock compared two periods: no specific program to address cardiogenic shock and implementation of a cardiogenic shock program. This program included the establishment of a multidisciplinary team (shock team), early alert to the transplant hospital, initiation of a ventricular assist extracorporeal membrane oxygenation (ECMO) program, and extension of continuous care by acute cardiovascular care specialists. The primary objective was to analyse whether there were differences between in-hospital mortality and mortality during follow-up. Predictors of in-hospital mortality were examined as a secondary objective. RESULTS: A total of 139 patients were enrolled: 69 of them in the previous period and 70 in the cardiogenic shock program period. There was a significant reduction in in-hospital mortality (55.1% vs 37.1%; p=0.03) and mortality during follow-up (62.7% vs 44.6%; p=0.03) in the second period. Diabetes mellitus, ejection fraction, out-of-hospital cardiac arrest, and implementation of the cardiogenic shock program were independent predictors of in-hospital mortality. CONCLUSIONS: The implementation of a comprehensive cardiogenic shock program in a non-transplanting hospital improved in-hospital and follow-up mortality of patients in cardiogenic shock. CI - Copyright (c) 2023 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights reserved. FAU - Aboal, Jaime AU - Aboal J AD - University Hospital Dr. Josep Trueta, Girona, Spain. Electronic address: jaimeaboal@gmail.com. FAU - Pascual, Julia AU - Pascual J AD - University Hospital Dr. Josep Trueta, Girona, Spain. FAU - Loma-Osorio, Pablo AU - Loma-Osorio P AD - University Hospital Dr. Josep Trueta, Girona, Spain. FAU - Nunez, Maria AU - Nunez M AD - University Hospital Dr. Josep Trueta, Girona, Spain. FAU - Badosa, Eulalia AU - Badosa E AD - University Hospital Dr. Josep Trueta, Girona, Spain. FAU - Martin, Carmen AU - Martin C AD - University Hospital Dr. Josep Trueta, Girona, Spain. FAU - Ferrero, Maria AU - Ferrero M AD - University Hospital Dr. Josep Trueta, Girona, Spain. FAU - Moral, Sergio AU - Moral S AD - University Hospital Dr. Josep Trueta, Girona, Spain. FAU - Ballesteros, Esther AU - Ballesteros E AD - Territorial Management of Radiology and Nuclear Medicine of Girona, Girona, Spain; Biomedical Research Institute, Girona (IdIBGi), Girona, Spain. FAU - Pedraza, Julia AU - Pedraza J AD - University Hospital Dr. Josep Trueta, Girona, Spain. FAU - Tapia, Simon AU - Tapia S AD - University Hospital Dr. Josep Trueta, Girona, Spain. FAU - Brugada, Ramon AU - Brugada R AD - University Hospital Dr. Josep Trueta, Girona, Spain; Department of Medical Sciences, School of Medicine, University of Girona, Girona, Spain; Biomedical Research Institute, Girona (IdIBGi), Girona, Spain. LA - eng PT - Journal Article DEP - 20231226 PL - Australia TA - Heart Lung Circ JT - Heart, lung & circulation JID - 100963739 SB - IM MH - Humans MH - Shock, Cardiogenic MH - Retrospective Studies MH - Hospital Mortality MH - *Out-of-Hospital Cardiac Arrest MH - *Extracorporeal Membrane Oxygenation/adverse effects OTO - NOTNLM OT - Acute heart failure OT - Cardiogenic shock OT - ECMO OT - Extracorporeal membrane oxygenation OT - Shock team OT - Ventricular assist EDAT- 2023/12/28 00:42 MHDA- 2024/02/12 05:43 CRDT- 2023/12/27 21:58 PHST- 2023/01/27 00:00 [received] PHST- 2023/10/29 00:00 [revised] PHST- 2023/11/14 00:00 [accepted] PHST- 2024/02/12 05:43 [medline] PHST- 2023/12/28 00:42 [pubmed] PHST- 2023/12/27 21:58 [entrez] AID - S1443-9506(23)04444-X [pii] AID - 10.1016/j.hlc.2023.11.010 [doi] PST - ppublish SO - Heart Lung Circ. 2024 Jan;33(1):38-45. doi: 10.1016/j.hlc.2023.11.010. Epub 2023 Dec 26. PMID- 38149081 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231228 IS - 1179-1349 (Print) IS - 1179-1349 (Electronic) IS - 1179-1349 (Linking) VI - 15 DP - 2023 TI - The Danish Atrial Fibrillation Registry: A Multidisciplinary National Pragmatic Initiative for Monitoring and Supporting Quality of Care Based on Data Retrieved from Administrative Registries. PG - 1259-1272 LID - 10.2147/CLEP.S443473 [doi] AB - AIM: The Danish Atrial Fibrillation (AF) Registry monitors and supports improvement of quality of care for all AF patients in Denmark. This report describes the registry's administrative and organizational structure, data sources, data flow, data analyses, annual reporting, and feedback between the registry, clinicians, and the administrative system. We also report the selection process of the quality indicators and the temporal trends in results from 2017-2021. METHODS AND RESULTS: The Danish AF Registry aims for complete registration and monitoring of care for all patients diagnosed with AF in Denmark. Administrative registries provide data on contacts to general practice, contacts to private cardiology practice, hospital contacts, medication prescriptions, updated vital status information, and biochemical test results. The Danish Stroke Registry provides information on stroke events. From 2017 to 2021, the proportion with a reported echocardiography among incident AF patients increased from 39.9% (95% CI: 39.3-40.6) to 82.6% (95% CI: 82.1-83.1). The initiation of oral anticoagulant therapy among patients with incident AF and a CHA(2)DS(2)-VASc score of >/=1 in men and >/=2 in women increased from 85.3% (95% CI: 84.6-85.9) to 90.4% (95% CI: 89.9-91.0). The 1-year and 2-year persistence increased from 85.2% (95% CI: 84.5-85.9) to 88.7% (95% CI: 88.0-89.3), and from 85.4% (95% CI: 84.7-86.2) to 88.2% (95% CI: 87.5-88.8), respectively. The 1-year risk of ischemic stroke among prevalent patients with AF decreased from 0.88% (95% CI: 0.83-0.93) to 0.71% (95% CI: 0.66-0.75). Variation in clinical performance between the five administrative Danish regions was reduced. CONCLUSION: Continuous nationwide monitoring of quality indicators for AF originating from administrative registries is feasible and supportive of improvements of quality of care. CI - (c) 2023 Frost et al. FAU - Frost, Lars AU - Frost L AUID- ORCID: 0000-0001-9215-9796 AD - Diagnostic Centre, Silkeborg Regional Hospital, Silkeborg, Denmark. AD - Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. FAU - Joensen, Albert Marni AU - Joensen AM AD - Department of Cardiology, North Denmark Regional Hospital, Hjorring, Denmark. FAU - Dam-Schmidt, Ulla AU - Dam-Schmidt U AD - Department of Cardiology, Bispebjerg Hospital, Copenhagen University Hospitals, Copenhagen, Denmark. FAU - Qvist, Ina AU - Qvist I AUID- ORCID: 0000-0002-9756-4587 AD - Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark. FAU - Brinck, Margit AU - Brinck M AD - Department of Cardiology, Odense University Hospital, Odense, Denmark. FAU - Brandes, Axel AU - Brandes A AUID- ORCID: 0000-0001-9145-6887 AD - Department of Cardiology, Esbjerg Hospital - University Hospital of Southern Denmark, Esbjerg, Denmark. AD - Department of Regional Health Research, University of Southern Denmark, Odense, Denmark. FAU - Davidsen, Ulla AU - Davidsen U AD - Department of Cardiology, Bispebjerg Hospital, Copenhagen University Hospitals, Copenhagen, Denmark. FAU - Pedersen, Ole Dyg AU - Pedersen OD AD - Department of Cardiology, Zealand University Hospital, Roskilde, Denmark. FAU - Damgaard, Dorte AU - Damgaard D AD - Department of Neurology, Aarhus University Hospital, Aarhus, Denmark. FAU - Molgaard, Inge AU - Molgaard I AD - Patient Representative, Aalborg and Roskilde, Denmark. FAU - Bedsted, Robert AU - Bedsted R AUID- ORCID: 0009-0004-8154-1526 AD - Patient Representative, Aalborg and Roskilde, Denmark. FAU - Damgaard Moller Schlunsen, Anders AU - Damgaard Moller Schlunsen A AD - The Danish Clinical Quality Program - National Clinical Registries (RKKP), Aarhus, Denmark. FAU - Chousa, Miriam Grijota AU - Chousa MG AD - The Danish Clinical Quality Program - National Clinical Registries (RKKP), Aarhus, Denmark. FAU - Andersen, Julie AU - Andersen J AD - The Danish Clinical Quality Program - National Clinical Registries (RKKP), Aarhus, Denmark. FAU - Pedersen, Asger Roer AU - Pedersen AR AD - Diagnostic Centre, Silkeborg Regional Hospital, Silkeborg, Denmark. FAU - Johnsen, Soren Paaske AU - Johnsen SP AD - Danish Center for Health Services Research, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. FAU - Vinter, Nicklas AU - Vinter N AUID- ORCID: 0000-0003-0558-8483 AD - Diagnostic Centre, Silkeborg Regional Hospital, Silkeborg, Denmark. AD - Danish Center for Health Services Research, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. LA - eng PT - Journal Article DEP - 20231222 PL - New Zealand TA - Clin Epidemiol JT - Clinical epidemiology JID - 101531700 PMC - PMC10750776 OTO - NOTNLM OT - atrial fibrillation OT - quality indicators OT - quality of care COIS- L.F reports being supported by a research grant from the Health Research Foundation of Central Denmark Region. Consultant for BMS/Pfizer and AstraZeneca. A.B reports lecture fees from Boehringer-Ingelheim and Bristol-Myers Squibb; research grants from Theravance, The Zealand Region, the Canadian Institutes of Health Research, and the Danish Heart Foundation, grants from Independent Research Fund Denmark outside this work. DD reports lecture fees from BMS and Pfizer. SPJ reports grants from EU, institutional research grant from BMS/Pfizer. Consultant work for BMS/Pfizer. NV reports being supported by a research grant from the Danish Cardiovascular Academy (PD2Y-2022002-DCA). Consultant for AstraZenaca. No fees were received personally. The authors report no other conflicts of interest in this work. EDAT- 2023/12/27 06:41 MHDA- 2023/12/27 06:42 PMCR- 2023/12/22 CRDT- 2023/12/27 03:47 PHST- 2023/10/06 00:00 [received] PHST- 2023/12/09 00:00 [accepted] PHST- 2023/12/27 06:42 [medline] PHST- 2023/12/27 06:41 [pubmed] PHST- 2023/12/27 03:47 [entrez] PHST- 2023/12/22 00:00 [pmc-release] AID - 443473 [pii] AID - 10.2147/CLEP.S443473 [doi] PST - epublish SO - Clin Epidemiol. 2023 Dec 22;15:1259-1272. doi: 10.2147/CLEP.S443473. eCollection 2023. PMID- 38147315 OWN - NLM STAT- MEDLINE DCOM- 20250718 LR - 20260914 IS - 1527-3350 (Electronic) IS - 0270-9139 (Print) IS - 0270-9139 (Linking) VI - 82 IP - 2 DP - 2025 Aug 1 TI - Metabolic dysfunction-associated steatotic liver disease and the heart. PG - 487-503 LID - 10.1097/HEP.0000000000000735 [doi] AB - The prevalence and severity of metabolic dysfunction-associated steatotic liver disease (MASLD) are increasing. Physicians who treat patients with MASLD may acknowledge the strong coincidence with cardiometabolic disease, including atherosclerotic cardiovascular disease (asCVD). This raises questions on co-occurrence, causality, and the need for screening and multidisciplinary care for MASLD in patients with asCVD, and vice versa. Here, we review the interrelations of MASLD and heart disease and formulate answers to these matters. Epidemiological studies scoring proxies for atherosclerosis and actual cardiovascular events indicate increased atherosclerosis in patients with MASLD, yet no increased risk of asCVD mortality. MASLD and asCVD share common drivers: obesity, insulin resistance and type 2 diabetes mellitus (T2DM), smoking, hypertension, and sleep apnea syndrome. In addition, Mendelian randomization studies support that MASLD may cause atherosclerosis through mixed hyperlipidemia, while such evidence is lacking for liver-derived procoagulant factors. In the more advanced fibrotic stages, MASLD may contribute to heart failure with preserved ejection fraction by reduced filling of the right ventricle, which may induce fatigue upon exertion, often mentioned by patients with MASLD. Some evidence points to an association between MASLD and cardiac arrhythmias. Regarding treatment and given the strong co-occurrence of MASLD and asCVD, pharmacotherapy in development for advanced stages of MASLD would ideally also reduce cardiovascular events, as has been demonstrated for T2DM treatments. Given the common drivers, potential causal factors and especially given the increased rate of cardiovascular events, comprehensive cardiometabolic risk management is warranted in patients with MASLD, preferably in a multidisciplinary approach. CI - Copyright (c) 2023 The Author(s). Published by Wolters Kluwer Health, Inc. FAU - Driessen, Stan AU - Driessen S AUID- ORCID: 0000-0003-1485-9732 AD - Department of Vascular Medicine, Amsterdam University Medical Center, Amsterdam, The Netherlands. FAU - Francque, Sven M AU - Francque SM AUID- ORCID: 0000-0002-7527-4714 AD - Department of Gastroenterology and Hepatology, University Hospital Antwerp, Antwerp, Belgium. FAU - Anker, Stefan D AU - Anker SD AUID- ORCID: 0000-0002-0805-8683 AD - Department of Cardiology (CVK) of German Heart Center Charite, Institute of Health Center for Regenerative Therapies (BCRT), German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charite Universitatsmedizin, Berlin, Germany. AD - Institute of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland. FAU - Castro Cabezas, Manuel AU - Castro Cabezas M AUID- ORCID: 0009-0009-5164-2082 AD - Julius Clinical, Zeist, The Netherlands. AD - Department of Internal Medicine, Franciscus Gasthuis and Vlietland, Rotterdam, The Netherlands. AD - Department of Internal Medicine and Endocrinology, Erasmus MC, Rotterdam, The Netherlands. FAU - Grobbee, Diederick E AU - Grobbee DE AUID- ORCID: 0000-0003-4472-4468 AD - Julius Clinical, Zeist, The Netherlands. AD - Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands. FAU - Tushuizen, Maarten E AU - Tushuizen ME AUID- ORCID: 0000-0001-6342-9056 AD - Department of Gastroenterology and Hepatology, Leiden University Medical Centre, Leiden, The Netherlands. FAU - Holleboom, Adriaan G AU - Holleboom AG AUID- ORCID: 0000-0002-2911-2917 AD - Department of Vascular Medicine, Amsterdam University Medical Center, Amsterdam, The Netherlands. LA - eng PT - Journal Article PT - Review DEP - 20231225 PL - United States TA - Hepatology JT - Hepatology (Baltimore, Md.) JID - 8302946 SB - IM MH - Humans MH - *Fatty Liver/complications/epidemiology MH - *Atherosclerosis/epidemiology/etiology PMC - PMC12266800 COIS- Stephan D. Anker consults, advises, in on the speakers' bureau, received grants, and owns stock in Abbott Vascular, Actimed, Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, Bioventrix, Brahms, Cardiac Dimensions, Cardior, Cordio, CVRx, Cytokinetics, Edwards, Farraday Pharmaceuticals, GSK, HeartKinetics, Impulse Dynamics, Novartis, Occlutech, Pfizer, Repairon, Sensible Medical, Servier, Vectorious, Vifor, and V-Wave. The remaining authors have no conflicts to report. EDAT- 2023/12/26 12:42 MHDA- 2025/07/18 18:29 PMCR- 2025/07/16 CRDT- 2023/12/26 11:23 PHST- 2023/07/26 00:00 [received] PHST- 2023/11/13 00:00 [accepted] PHST- 2025/07/18 18:29 [medline] PHST- 2023/12/26 12:42 [pubmed] PHST- 2023/12/26 11:23 [entrez] PHST- 2025/07/16 00:00 [pmc-release] AID - 01515467-990000000-00699 [pii] AID - HEP-23-1349 [pii] AID - 10.1097/HEP.0000000000000735 [doi] PST - ppublish SO - Hepatology. 2025 Aug 1;82(2):487-503. doi: 10.1097/HEP.0000000000000735. Epub 2023 Dec 25. PMID- 38141271 OWN - NLM STAT- MEDLINE DCOM- 20240129 LR - 20260120 IS - 1873-5487 (Electronic) IS - 0188-4409 (Linking) VI - 55 IP - 1 DP - 2024 Jan TI - Multidisciplinary Panel Consensus for the Management of Patients with Type 2 Diabetes: A Delphi Study. PG - 102923 LID - S0188-4409(23)00161-3 [pii] LID - 10.1016/j.arcmed.2023.102923 [doi] AB - AIM: To reach a multidisciplinary consensus on managing patients with type 2 diabetes among specialists in family medicine, cardiology, endocrinology, internal medicine, and nephrology. METHODS: A two-round Delphi study was conducted using a questionnaire with 68 positive/negative statements distributed in four thematic blocks on diabetes management: early diagnosis and prediabetes, referral criteria, treatment and comorbidities, and clinical management. The expert panel was composed of 105 physicians from different specialties (family medicine, cardiology, endocrinology, internal medicine, and nephrology) with experience in managing patients with diabetes and who were members of a diabetes-related society. RESULTS: Response rates for the first and second rounds were 86.7 and 75.2%, respectively. After both rounds, a consensus was reached on 52 (76.5%) items. The recommendations with the highest degree of consensus (median = 10, IQR = 0.00) were related to anti-smoking education, cardiovascular risk factor target control, and diabetic kidney disease. There were significant differences between family physicians and other specialties for some items. CONCLUSIONS: This study provides a set of recommendations for diabetes management agreed upon by specialists from different healthcare settings. CI - Copyright (c) 2023. Published by Elsevier Inc. FAU - Cebrian-Cuenca, Ana M AU - Cebrian-Cuenca AM AD - Family Medicine Health Center of Cartagena Casco, Primary Care Research Group, Biomedical Research Institute of Murcia, Cartagena, Spain. FAU - Moreno-Perez, Oscar AU - Moreno-Perez O AD - Endocrinology Department, Dr. Balmis General University Hospital - Alicante Institute of Health and Biomedical Research, Alicante, Spain; Medicine Department, Miguel Hernandez University, San Juan de Alicante, Spain. Electronic address: omorenoperez@hotmail.es. FAU - Campuzano-Ruiz, Raquel AU - Campuzano-Ruiz R AD - Cardiology Department, Universitary Hospital of Fundacion Alcorcon, Madrid, Spain. FAU - Soler, Maria Jose AU - Soler MJ AD - Nephrology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Research, Barcelona, Spain. FAU - Garcia de Lucas, M Dolores AU - Garcia de Lucas MD AD - Internal Medicine Department, Hospital Costa del Sol, Marbella, Malaga, Spain. FAU - Orozco-Beltran, Domingo AU - Orozco-Beltran D AD - Medicine Department, Miguel Hernandez University, San Juan de Alicante, Spain; Family Medicine Health Center of Cabo Huertas, Alicante, Spain. LA - eng PT - Consensus Statement PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20231222 PL - United States TA - Arch Med Res JT - Archives of medical research JID - 9312706 SB - IM MH - Humans MH - *Diabetes Mellitus, Type 2/therapy MH - Delphi Technique MH - Comorbidity MH - Surveys and Questionnaires OTO - NOTNLM OT - Consensus OT - Delphi technique OT - Disease management OT - Patient care team OT - Type 2 Diabetes Mellitus COIS- Conflicts of Interest The authors have no conflicts of interest to declare. EDAT- 2023/12/23 22:53 MHDA- 2024/01/29 06:42 CRDT- 2023/12/23 18:00 PHST- 2023/04/03 00:00 [received] PHST- 2023/09/29 00:00 [revised] PHST- 2023/11/16 00:00 [accepted] PHST- 2024/01/29 06:42 [medline] PHST- 2023/12/23 22:53 [pubmed] PHST- 2023/12/23 18:00 [entrez] AID - S0188-4409(23)00161-3 [pii] AID - 10.1016/j.arcmed.2023.102923 [doi] PST - ppublish SO - Arch Med Res. 2024 Jan;55(1):102923. doi: 10.1016/j.arcmed.2023.102923. Epub 2023 Dec 22. PMID- 38141128 OWN - NLM STAT- MEDLINE DCOM- 20240328 LR - 20240517 IS - 1432-1459 (Electronic) IS - 0340-5354 (Print) IS - 0340-5354 (Linking) VI - 271 IP - 4 DP - 2024 Apr TI - Immune checkpoint inhibitor-related myositis and myocarditis: diagnostic pitfalls and imaging contribution in a real-world, institutional case series. PG - 1947-1958 LID - 10.1007/s00415-023-12134-x [doi] AB - BACKGROUND: Immune checkpoint inhibitors (ICIs) are reshaping the prognosis of many cancers, but often cause immune-related adverse events (irAEs). Among neurological irAEs, myositis is the most frequently reported. Our aim is to describe clinical and non-clinical characteristics, treatment and outcome of all irMyositis (skeletal limb-girdle and/or ocular myositis) and irMyocarditis cases in our reference center. METHODS: We retrospectively enrolled all irMyositis/irMyocarditis patients seen between 2018 and 2022. We reviewed demographics, clinical characteristics, biological, neurophysiological, imaging workup, treatment and outcome. RESULTS: We included 14 consecutive patients. The most frequent treatments were pembrolizumab (35%) or ipilimumab-nivolumab combination (35%). Limb-girdle, ocular (non-fluctuating palpebral ptosis and/or diplopia with or without ophthalmoparesis) and cardiac phenotypes were equally distributed, overlapping in 40% of cases. Ocular involvement was frequently misdiagnosed; review of brain MRIs disclosed initially missed signs of skeletal myositis in one patient and ocular myositis in 3. Seven patients had other co-existing irAEs. When performed, myography showed a myogenic pattern. CK was elevated in 8/15 patients, troponin-T in 12/12 and troponin-I in 7/9 tested patients. ICI were discontinued in all cases, with further immunosuppressive treatment in nine patients. In most cases, neurological and cardiological outcome was good at last follow-up. CONCLUSION: Myositis is a potentially severe irAE. Despite its heterogeneous presentation, some highly suggestive clinical symptoms, such as ocular involvement, or radiological signs should raise physicians' attention to avoid misdiagnosis. We thus recommend a multidisciplinary assessment (including complete neuromuscular evaluation) even in case of isolated myocarditis. Our series underlines the importance of an early diagnosis, since suspension of ICI and adequate treatment are usually associated with good functional outcome. CI - (c) 2023. The Author(s). FAU - Vicino, Alex AU - Vicino A AUID- ORCID: 0000-0001-6420-8124 AD - Nerve-Muscle Unit, Neurology Service, Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. alex.vicino@chuv.ch. FAU - Hottinger, Andreas F AU - Hottinger AF AUID- ORCID: 0000-0001-7098-9414 AD - Lundin Family Brain Tumor Center, Departments of Oncology and Clinical Neurosciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Latifyan, Sofiya AU - Latifyan S AD - Department of Oncology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Boughdad, Sarah AU - Boughdad S AD - Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Becce, Fabio AU - Becce F AUID- ORCID: 0000-0001-8444-8504 AD - Department of Diagnostic and Interventional Radiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Prior, John O AU - Prior JO AUID- ORCID: 0000-0003-1429-1374 AD - Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Kuntzer, Thierry AU - Kuntzer T AUID- ORCID: 0000-0002-7788-1673 AD - Nerve-Muscle Unit, Neurology Service, Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Brouland, Jean-Philippe AU - Brouland JP AUID- ORCID: 0000-0003-3475-0101 AD - Pathology Institute, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Dunet, Vincent AU - Dunet V AUID- ORCID: 0000-0002-9897-4561 AD - Department of Diagnostic and Interventional Radiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Obeid, Michel AU - Obeid M AUID- ORCID: 0000-0003-2095-2677 AD - Immunology and Allergy Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Theaudin, Marie AU - Theaudin M AUID- ORCID: 0000-0002-3026-3595 AD - Nerve-Muscle Unit, Neurology Service, Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. LA - eng PT - Journal Article PT - Review DEP - 20231223 PL - Germany TA - J Neurol JT - Journal of neurology JID - 0423161 RN - 0 (Immune Checkpoint Inhibitors) RN - 0 (Antineoplastic Agents, Immunological) SB - IM MH - Humans MH - Immune Checkpoint Inhibitors MH - *Myocarditis/chemically induced/complications/drug therapy MH - *Antineoplastic Agents, Immunological/adverse effects MH - Retrospective Studies MH - *Myositis/diagnosis PMC - PMC10973051 OTO - NOTNLM OT - Imaging OT - Immune-checkpoint-inhibitor OT - Immune-related-adverse-event OT - Myocarditis OT - Myositis COIS- The authors declare that they have no conflict of interest. EDAT- 2023/12/23 12:46 MHDA- 2024/03/28 06:45 PMCR- 2023/12/23 CRDT- 2023/12/23 11:16 PHST- 2023/10/03 00:00 [received] PHST- 2023/11/22 00:00 [accepted] PHST- 2023/11/20 00:00 [revised] PHST- 2024/03/28 06:45 [medline] PHST- 2023/12/23 12:46 [pubmed] PHST- 2023/12/23 11:16 [entrez] PHST- 2023/12/23 00:00 [pmc-release] AID - 10.1007/s00415-023-12134-x [pii] AID - 12134 [pii] AID - 10.1007/s00415-023-12134-x [doi] PST - ppublish SO - J Neurol. 2024 Apr;271(4):1947-1958. doi: 10.1007/s00415-023-12134-x. Epub 2023 Dec 23. PMID- 38138942 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241020 IS - 2075-4426 (Print) IS - 2075-4426 (Electronic) IS - 2075-4426 (Linking) VI - 13 IP - 12 DP - 2023 Dec 15 TI - Evaluation and Management of Sudden Death Risk in Repaired Tetralogy of Fallot. LID - 10.3390/jpm13121715 [doi] LID - 1715 AB - Although substantial progress has been made to prevent sudden cardiac death in repaired tetralogy of Fallot patients, ventricular arrhythmia and sudden death continue to be major causes of morbidity and mortality in these patients. Greater survival in contemporary cohorts has been attributed to enhanced surgical techniques, more effective management of heart failure, and increased efforts in risk stratification and management of ventricular arrhythmias. More recently, our understanding of predictive risk factors has evolved into personalized risk prediction tools that rely on comprehensive demographic, imaging, functional, and electrophysiological data. However, the universal applicability of these different scoring systems is limited due to differences between study cohorts, types of anatomic repair, imaging modalities, and disease complexity. Noninvasive risk stratification is critical to identify those who may derive benefit from catheter ablation or cardioverter defibrillator implantation for primary prevention. Ultimately, assessment and risk stratification by a multidisciplinary team is crucial to analyze the various complex factors for every individual patient and discuss further options with patients and their families. FAU - Habib, Eiad AU - Habib E AD - Division of Internal Medicine, Mayo Clinic, Scottsdale, AZ 85259, USA. FAU - Srivasthan, Komandoor AU - Srivasthan K AD - Division of Cardiology, Mayo Clinic, Scottsdale, AZ 85259, USA. FAU - El Masry, Hicham AU - El Masry H AUID- ORCID: 0000-0002-2470-2862 AD - Division of Cardiology, Mayo Clinic, Scottsdale, AZ 85259, USA. LA - eng PT - Journal Article PT - Review DEP - 20231215 PL - Switzerland TA - J Pers Med JT - Journal of personalized medicine JID - 101602269 PMC - PMC10744881 OTO - NOTNLM OT - arrhythmia OT - risk stratification OT - sudden cardiac death OT - tetralogy of Fallot OT - ventricular tachycardia COIS- The authors declare no conflict of interest. EDAT- 2023/12/23 12:44 MHDA- 2023/12/23 12:45 PMCR- 2023/12/15 CRDT- 2023/12/23 01:19 PHST- 2023/11/19 00:00 [received] PHST- 2023/12/01 00:00 [revised] PHST- 2023/12/13 00:00 [accepted] PHST- 2023/12/23 12:45 [medline] PHST- 2023/12/23 12:44 [pubmed] PHST- 2023/12/23 01:19 [entrez] PHST- 2023/12/15 00:00 [pmc-release] AID - jpm13121715 [pii] AID - jpm-13-01715 [pii] AID - 10.3390/jpm13121715 [doi] PST - epublish SO - J Pers Med. 2023 Dec 15;13(12):1715. doi: 10.3390/jpm13121715. PMID- 38137806 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231225 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 12 IP - 24 DP - 2023 Dec 17 TI - Immune Checkpoint Inhibitors-Associated Myocarditis: Diagnosis, Treatment and Current Status on Rechallenge. LID - 10.3390/jcm12247737 [doi] LID - 7737 AB - Immune checkpoint molecules like cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed cell death 1 (PD-1) or its ligand, programmed cell death ligand 1 (PD-L1), play a critical role in regulating the immune response, and immune checkpoint inhibitors (ICIs) targeting these checkpoints have shown clinical efficacy in cancer treatment; however, their use is associated with immune-related adverse events (irAEs), including cardiac complications. The prevalence of cardiac irAEs, particularly myocarditis, is relatively low, but they can become a severe and potentially life-threatening condition, usually occurring shortly after initiating ICI treatment; moreover, diagnosing ICI-related myocarditis can be challenging. Diagnostic tools include serum cardiac biomarkers, electrocardiography (ECG), echocardiography, cardiac magnetic resonance (CMR) and endomyocardial biopsy (EMB). The treatment of ICI-induced myocarditis involves high-dose corticosteroids, which have been shown to reduce the risk of major adverse cardiac events (MACE). In refractory cases, second-line immunosuppressive drugs may be considered, although their effectiveness is based on limited data. The mortality rates of ICI-induced myocarditis, particularly in severe cases, are high (38-46%). Therapy rechallenge after myocarditis is associated with a risk of recurrence and severe complications. The decision to rechallenge should be made on a case-by-case basis, involving a multidisciplinary team of cardiologists and oncologists. Further research and guidance are needed to optimize the management of cancer patients who have experienced such complications, evaluating the risks and benefits of therapy rechallenge. The purpose of this review is to summarize the available evidence on cardiovascular complications from ICI therapy, with a particular focus on myocarditis and, specifically, the rechallenge of immunotherapy after a cardiac adverse event. FAU - Frascaro, Federica AU - Frascaro F AD - UO Cardiologia, Azienda Ospedaliero-Universitaria di Ferrara, 44124 Ferrara, Italy. FAU - Bianchi, Nicola AU - Bianchi N AUID- ORCID: 0000-0002-4643-1629 AD - UO Cardiologia, Azienda Ospedaliero-Universitaria di Ferrara, 44124 Ferrara, Italy. FAU - Sanguettoli, Federico AU - Sanguettoli F AD - UO Cardiologia, Azienda Ospedaliero-Universitaria di Ferrara, 44124 Ferrara, Italy. FAU - Marchini, Federico AU - Marchini F AUID- ORCID: 0000-0003-2622-4881 AD - UO Cardiologia, Azienda Ospedaliero-Universitaria di Ferrara, 44124 Ferrara, Italy. FAU - Meossi, Sofia AU - Meossi S AD - UO Cardiologia, Azienda Ospedaliero-Universitaria di Ferrara, 44124 Ferrara, Italy. FAU - Zanarelli, Luca AU - Zanarelli L AD - UO Cardiologia, Azienda Ospedaliero-Universitaria di Ferrara, 44124 Ferrara, Italy. FAU - Tonet, Elisabetta AU - Tonet E AD - UO Cardiologia, Azienda Ospedaliero-Universitaria di Ferrara, 44124 Ferrara, Italy. FAU - Serenelli, Matteo AU - Serenelli M AD - UO Cardiologia, Azienda Ospedaliero-Universitaria di Ferrara, 44124 Ferrara, Italy. FAU - Guardigli, Gabriele AU - Guardigli G AD - UO Cardiologia, Azienda Ospedaliero-Universitaria di Ferrara, 44124 Ferrara, Italy. FAU - Campo, Gianluca AU - Campo G AUID- ORCID: 0000-0002-5150-188X AD - UO Cardiologia, Azienda Ospedaliero-Universitaria di Ferrara, 44124 Ferrara, Italy. FAU - Calabro, Luana AU - Calabro L AUID- ORCID: 0000-0002-3044-0889 AD - Dipartimento di Medicina Translazionale e per la Romagna, Univerity of Ferrara, 44121 Ferrara, Italy. AD - UO Medical Oncology, Azienda Ospedaliero-Universitaria di Ferrara, 44124 Ferrara, Italy. FAU - Pavasini, Rita AU - Pavasini R AUID- ORCID: 0000-0002-1763-9711 AD - UO Cardiologia, Azienda Ospedaliero-Universitaria di Ferrara, 44124 Ferrara, Italy. LA - eng PT - Journal Article PT - Review DEP - 20231217 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC10744238 OTO - NOTNLM OT - cardio oncology OT - immune checkpoint inhibitors related myocarditis OT - rechallenge COIS- The authors declare no conflict of interest. EDAT- 2023/12/23 12:44 MHDA- 2023/12/23 12:45 PMCR- 2023/12/17 CRDT- 2023/12/23 01:12 PHST- 2023/10/30 00:00 [received] PHST- 2023/12/02 00:00 [revised] PHST- 2023/12/15 00:00 [accepted] PHST- 2023/12/23 12:45 [medline] PHST- 2023/12/23 12:44 [pubmed] PHST- 2023/12/23 01:12 [entrez] PHST- 2023/12/17 00:00 [pmc-release] AID - jcm12247737 [pii] AID - jcm-12-07737 [pii] AID - 10.3390/jcm12247737 [doi] PST - epublish SO - J Clin Med. 2023 Dec 17;12(24):7737. doi: 10.3390/jcm12247737. PMID- 38137774 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231225 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 12 IP - 24 DP - 2023 Dec 15 TI - Emergent Conversion to Open Heart Surgery during Transcatheter Aortic Valve Implantation: The Presence of a Rescue Team Improves Outcomes. LID - 10.3390/jcm12247705 [doi] LID - 7705 AB - OBJECTIVE: Transcatheter aortic valve implant (TAVI) is the gold standard for the high-surgical-risk group of patients with aortic valve disease and it is an alternative to surgery in patients at intermediate risk. Lethal complications can occur, and many of these are manageable only with emergent conversion to open heart surgery. We retrospectively evaluate the outcome of all patients undergoing TAVI in our departments and the impact of a complete cardiac rescue team to reduce 30-day mortality. METHODS: Data from all patients undergoing TAVI between January 2020 and August 2023 in our center were analyzed. An expert complete rescue was present in catheter laboratory. Primary outcomes were in-hospital and at 30-day mortality and evaluation of all cases needed for emergent conversion to open heart surgery. RESULTS: 825 patients were enrolled. The total mortality was 19/825 (2.3%). Eleven of the total patients (1.3%) required emergent conversion to open heart surgery. Among them, eight were alive (73%), with a theoretical decrease of 0.98% in overall mortality. CONCLUSIONS: surgical treatment is rare during TAVI. The presence of an expert complete rescue team as support means an increase in survival. Surgery must be used only to restore circulatory and to treat complication while percutaneous approaches should complete the procedure. FAU - Nasso, Giuseppe AU - Nasso G AUID- ORCID: 0000-0002-3519-770X AD - Department of Cardiac Surgery, Anthea Hospital, GVM Care & Research, 70124 Bari, Italy. FAU - Vignaroli, Walter AU - Vignaroli W AUID- ORCID: 0000-0002-7262-4424 AD - Department of Cardiac Surgery, Anthea Hospital, GVM Care & Research, 70124 Bari, Italy. AD - Department of Cardiac Surgery, San Carlo di Nancy, GVM Care & Research, 00165 Roma, Italy. FAU - Contegiacomo, Gaetano AU - Contegiacomo G AD - Department of Cardiac Surgery, Anthea Hospital, GVM Care & Research, 70124 Bari, Italy. FAU - Marchese, Alfredo AU - Marchese A AD - Department of Cardiac Surgery, Santa Maria Hospital, GVM Care & Research, 70124 Bari, Italy. FAU - Fattouch, Khalil AU - Fattouch K AD - Department of Cardiac Surgery, San Carlo di Nancy, GVM Care & Research, 00165 Roma, Italy. FAU - D'Alessandro, Pasquale AU - D'Alessandro P AD - Department of Cardiac Surgery, Anthea Hospital, GVM Care & Research, 70124 Bari, Italy. FAU - Brigiani, Mario Siro AU - Brigiani MS AD - Department of Cardiac Surgery, Anthea Hospital, GVM Care & Research, 70124 Bari, Italy. FAU - Vitobello, Vincenza AU - Vitobello V AD - Department of Cardiac Surgery, Anthea Hospital, GVM Care & Research, 70124 Bari, Italy. FAU - Triggiani, Vera AU - Triggiani V AD - Department of Cardiac Surgery, Anthea Hospital, GVM Care & Research, 70124 Bari, Italy. FAU - Demola, Maria Antonietta AU - Demola MA AD - Department of Cardiac Surgery, Anthea Hospital, GVM Care & Research, 70124 Bari, Italy. FAU - Tonioni, Stefano AU - Tonioni S AD - Department of Cardiac Surgery, San Carlo di Nancy, GVM Care & Research, 00165 Roma, Italy. FAU - Paparella, Domenico AU - Paparella D AD - Department of Cardiac Surgery, Santa Maria Hospital, GVM Care & Research, 70124 Bari, Italy. FAU - Sechi, Stefano AU - Sechi S AUID- ORCID: 0000-0003-4367-1632 AD - Department of Cardiac Surgery, San Carlo di Nancy, GVM Care & Research, 00165 Roma, Italy. FAU - Bonifazi, Raffaele AU - Bonifazi R AD - Department of Cardiac Surgery, Anthea Hospital, GVM Care & Research, 70124 Bari, Italy. FAU - Santarpino, Giuseppe AU - Santarpino G AD - Department of Cardiac Surgery, Anthea Hospital, GVM Care & Research, 70124 Bari, Italy. FAU - Resta, Fabrizio AU - Resta F AUID- ORCID: 0000-0001-5399-9629 AD - Department of Cardiac Surgery, Santa Maria Hospital, GVM Care & Research, 70124 Bari, Italy. FAU - Bartolomucci, Francesco AU - Bartolomucci F AD - Department of Cardiology, Hospital of Andria, 76123 Andria, Italy. FAU - Lorusso, Roberto AU - Lorusso R AD - Cardio-Thoracic Surgery Department, Heart and Vascular Centre, Maastricht University Medical Centre (MUMC), 6229 HX Maastricht, The Netherlands. FAU - Larosa, Claudio AU - Larosa C AD - Department of Cardiology, Hospital of Andria, 76123 Andria, Italy. FAU - Valenti, Giovanni AU - Valenti G AD - Department of Cardiology, Hospital of Andria, 76123 Andria, Italy. FAU - Tito, Antonio AU - Tito A AD - Department of Cardiac Surgery, Santa Maria Hospital, GVM Care & Research, 70124 Bari, Italy. FAU - Moscarelli, Marco AU - Moscarelli M AD - Department of Cardiac Surgery, Anthea Hospital, GVM Care & Research, 70124 Bari, Italy. FAU - Margari, Vito AU - Margari V AD - Department of Cardiac Surgery, Santa Maria Hospital, GVM Care & Research, 70124 Bari, Italy. FAU - Fiore, Flavio AU - Fiore F AD - Department of Cardiac Surgery, Anthea Hospital, GVM Care & Research, 70124 Bari, Italy. FAU - Condello, Ignazio AU - Condello I AUID- ORCID: 0000-0003-1192-1908 AD - Department of Cardiac Surgery, Anthea Hospital, GVM Care & Research, 70124 Bari, Italy. FAU - Speziale, Giuseppe AU - Speziale G AD - Department of Cardiac Surgery, Anthea Hospital, GVM Care & Research, 70124 Bari, Italy. AD - Department of Cardiac Surgery, San Carlo di Nancy, GVM Care & Research, 00165 Roma, Italy. LA - eng PT - Journal Article DEP - 20231215 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC10743555 OTO - NOTNLM OT - TAVI OT - cardiac surgery OT - conversion to open heart surgery OT - heart team COIS- The authors have no conflict of interest or financial relationships. EDAT- 2023/12/23 12:44 MHDA- 2023/12/23 12:45 PMCR- 2023/12/15 CRDT- 2023/12/23 01:12 PHST- 2023/10/29 00:00 [received] PHST- 2023/12/03 00:00 [revised] PHST- 2023/12/13 00:00 [accepted] PHST- 2023/12/23 12:45 [medline] PHST- 2023/12/23 12:44 [pubmed] PHST- 2023/12/23 01:12 [entrez] PHST- 2023/12/15 00:00 [pmc-release] AID - jcm12247705 [pii] AID - jcm-12-07705 [pii] AID - 10.3390/jcm12247705 [doi] PST - epublish SO - J Clin Med. 2023 Dec 15;12(24):7705. doi: 10.3390/jcm12247705. PMID- 38137699 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231225 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 12 IP - 24 DP - 2023 Dec 12 TI - Navigating the Unexpected: Iatrogenic Aortic Injuries during Transcatheter Aortic Valve Replacement (TAVR). LID - 10.3390/jcm12247630 [doi] LID - 7630 AB - The introduction of transcatheter aortic valve replacement (TAVR) has undeniably changed the landscape of valvular heart disease management over the last two decades. A reduction in complications through improvements in techniques, experience, and technology has established TAVR as a safe and effective alternative to surgical aortic valve replacement. However, it is important to consider the potential risks associated with TAVR and ways in which life-threatening complications can be identified and managed in a timely fashion. In this article, we review some catastrophic iatrogenic aortic injuries that are described in the literature and present a case of an acute iatrogenic type A aortic dissection that occurred during a transcatheter aortic valve replacement (TAVR). After valve deployment, a routine neurologic examination noted the new onset of a left-sided facial droop and upper extremity weakness. Urgent imaging revealed an extensive type A aortic dissection, and the patient was taken to the operating room for surgical repair. The coordination of our multidisciplinary team allowed for prompt recognition of her neurologic symptoms, urgent imaging, and timely transport to the operating room, all of which contributed to the successful management of this life-threatening procedural complication. FAU - Cavanaugh, Shaelyn AU - Cavanaugh S AD - Division of Cardiac Surgery, Department of Surgery, University of Rochester Medical Center, Rochester, NY 14642, USA. FAU - Amirjamshidi, Hossein AU - Amirjamshidi H AD - Division of Cardiac Surgery, Department of Surgery, University of Rochester Medical Center, Rochester, NY 14642, USA. FAU - Hisamoto, Kazuhiro AU - Hisamoto K AD - Division of Cardiac Surgery, Department of Surgery, University of Rochester Medical Center, Rochester, NY 14642, USA. LA - eng PT - Journal Article PT - Review DEP - 20231212 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC10744134 OTO - NOTNLM OT - TAVR OT - iatrogenic aortic dissection OT - type A dissection COIS- The authors declare no conflict of interest related to this manuscript. EDAT- 2023/12/23 12:43 MHDA- 2023/12/23 12:44 PMCR- 2023/12/12 CRDT- 2023/12/23 01:11 PHST- 2023/09/06 00:00 [received] PHST- 2023/09/27 00:00 [revised] PHST- 2023/12/04 00:00 [accepted] PHST- 2023/12/23 12:44 [medline] PHST- 2023/12/23 12:43 [pubmed] PHST- 2023/12/23 01:11 [entrez] PHST- 2023/12/12 00:00 [pmc-release] AID - jcm12247630 [pii] AID - jcm-12-07630 [pii] AID - 10.3390/jcm12247630 [doi] PST - epublish SO - J Clin Med. 2023 Dec 12;12(24):7630. doi: 10.3390/jcm12247630. PMID- 38136428 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231225 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 15 IP - 24 DP - 2023 Dec 18 TI - Developing Cardio-Oncology Programs in the New Era: Beyond Ventricular Dysfunction Due to Cancer Treatments. LID - 10.3390/cancers15245885 [doi] LID - 5885 AB - Cardiovascular disease is a common problem in cancer patients that is becoming more widely recognized. This may be a consequence of prior cardiovascular risk factors but could also be secondary to the anticancer treatments. With the goal of offering a multidisciplinary approach to guaranteeing optimal cancer therapy and the early detection of related cardiac diseases, and in light of the recent ESC Cardio-Oncology Guideline recommendations, we developed a Cardio-Oncology unit devoted to the prevention and management of these specific complications. This document brings together important aspects to consider for the development and organization of a Cardio-Oncology program through our own experience and the current evidence. FAU - Pons-Riverola, Alexandra AU - Pons-Riverola A AD - Cardio-Oncology Unit, Bellvitge University Hospital-Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain. AD - Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, 08907 Barcelona, Spain. AD - Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain. FAU - Morillas, Herminio AU - Morillas H AD - Cardio-Oncology Unit, Bellvitge University Hospital-Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain. AD - Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, 08907 Barcelona, Spain. AD - Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain. FAU - Berdejo, Javier AU - Berdejo J AD - Cardio-Oncology Unit, Bellvitge University Hospital-Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain. AD - Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, 08907 Barcelona, Spain. AD - Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain. FAU - Pernas, Sonia AU - Pernas S AUID- ORCID: 0000-0002-1485-5080 AD - Cardio-Oncology Unit, Bellvitge University Hospital-Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain. AD - Medical Oncology Department, Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain. FAU - Pomares, Helena AU - Pomares H AD - Cardio-Oncology Unit, Bellvitge University Hospital-Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain. AD - Clinical Haematology Department, Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain. FAU - Asiain, Leyre AU - Asiain L AD - Cardio-Oncology Unit, Bellvitge University Hospital-Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain. AD - Radiation Oncology Department, Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain. FAU - Garay, Alberto AU - Garay A AD - Cardio-Oncology Unit, Bellvitge University Hospital-Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain. AD - Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, 08907 Barcelona, Spain. AD - Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain. FAU - Fernandez-Ortega, Adela AU - Fernandez-Ortega A AD - Cardio-Oncology Unit, Bellvitge University Hospital-Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain. AD - Medical Oncology Department, Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain. FAU - Oliveira, Ana Carla AU - Oliveira AC AD - Cardio-Oncology Unit, Bellvitge University Hospital-Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain. AD - Clinical Haematology Department, Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain. AD - Haematopoietic and Lymphoid Tumours Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain. FAU - Martinez, Evelyn AU - Martinez E AD - Cardio-Oncology Unit, Bellvitge University Hospital-Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain. AD - Radiation Oncology Department, Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain. AD - Radiobiology and Cancer Group, ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain. FAU - Jimenez-Marrero, Santiago AU - Jimenez-Marrero S AD - Cardio-Oncology Unit, Bellvitge University Hospital-Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain. AD - Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, 08907 Barcelona, Spain. AD - Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain. AD - Centro de Investigacion Biomedica en Red de Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain. FAU - Pina, Elena AU - Pina E AD - Cardio-Oncology Unit, Bellvitge University Hospital-Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain. AD - Thrombosis and Haemostasis Unit, Bellvitge University Hospital, L'Hospitalet de Llobregat, 08907 Barcelona, Spain. FAU - Fort, Eduard AU - Fort E AUID- ORCID: 0009-0007-8391-202X AD - Pharmacy Department, Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain. FAU - Ramos, Raul AU - Ramos R AD - Cardio-Oncology Unit, Bellvitge University Hospital-Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain. AD - Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, 08907 Barcelona, Spain. AD - Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain. FAU - Alcoberro, Lidia AU - Alcoberro L AD - Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, 08907 Barcelona, Spain. AD - Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain. FAU - Hidalgo, Encarnacion AU - Hidalgo E AD - Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, 08907 Barcelona, Spain. FAU - Antonio-Rebollo, Maite AU - Antonio-Rebollo M AD - Oncogeriatrics Department, Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain. FAU - Alcober, Laia AU - Alcober L AD - Primary Care Service Delta del Llobregat and IDIAP, Catalan Health Service, 08007 Barcelona, Spain. FAU - Enjuanes Grau, Cristina AU - Enjuanes Grau C AD - Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, 08907 Barcelona, Spain. AD - Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain. AD - Centro de Investigacion Biomedica en Red de Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain. FAU - Comin-Colet, Josep AU - Comin-Colet J AD - Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, 08907 Barcelona, Spain. AD - Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain. AD - Centro de Investigacion Biomedica en Red de Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain. FAU - Moliner, Pedro AU - Moliner P AUID- ORCID: 0000-0002-5511-8597 AD - Cardio-Oncology Unit, Bellvitge University Hospital-Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908 Barcelona, Spain. AD - Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, 08907 Barcelona, Spain. AD - Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain. AD - Centro de Investigacion Biomedica en Red de Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain. LA - eng PT - Journal Article PT - Review DEP - 20231218 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC10742309 OTO - NOTNLM OT - Cardio-Oncology OT - cancer OT - cardiotoxicity OT - cardiovascular disease OT - optimal cancer therapy OT - program COIS- P.M. has received: Funding for research projects: Daiichi Sankyo; Speaker or consulting fees: Pfizer, Boehringer-Ingelheim, Eisai, Bayer Pharmaceuticals, Bristol Myers Squibb, Novartis, Lilly, AstraZeneca, Janssen Oncology. The rest of authors report no conflicts of interest to declare with regards to the design and preparation of the manuscript. EDAT- 2023/12/23 12:45 MHDA- 2023/12/23 12:46 PMCR- 2023/12/18 CRDT- 2023/12/23 01:04 PHST- 2023/11/24 00:00 [received] PHST- 2023/12/11 00:00 [revised] PHST- 2023/12/14 00:00 [accepted] PHST- 2023/12/23 12:46 [medline] PHST- 2023/12/23 12:45 [pubmed] PHST- 2023/12/23 01:04 [entrez] PHST- 2023/12/18 00:00 [pmc-release] AID - cancers15245885 [pii] AID - cancers-15-05885 [pii] AID - 10.3390/cancers15245885 [doi] PST - epublish SO - Cancers (Basel). 2023 Dec 18;15(24):5885. doi: 10.3390/cancers15245885. PMID- 38135570 OWN - NLM STAT- MEDLINE DCOM- 20240512 LR - 20260510 IS - 1878-0938 (Electronic) IS - 1878-0938 (Linking) VI - 62 DP - 2024 May TI - Rural versus urban outcomes following transcatheter aortic valve implantation: The importance of the heart team. PG - 3-8 LID - S1553-8389(23)00936-3 [pii] LID - 10.1016/j.carrev.2023.12.005 [doi] AB - BACKGROUND: Rural patients face known healthcare disparities and worse cardiovascular outcomes compared to urban residents due to inequitable access and delayed care. Few studies have assessed rural-urban differences in outcomes following Transcatheter Aortic Valve Implantation (TAVI). We compared short-term post-TAVI outcomes between rural and urban patients. METHODS: We performed a retrospective analysis of n = 413 patients who underwent TAVI at our large academic medical center, between 2011 and 2020 (rural/urban patients = 93/320. Rural/urban males = 53/173). Primary outcomes were all-cause mortality and cardiovascular mortality. Secondary outcomes included stroke/transient ischemic attack, myocardial infarction, atrial fibrillation, acute kidney injury, bleeding, vascular complications, and length of stay. RESULTS: The mean age in years was 77 [IQR 70-82] for rural patients and 78 [IQR 72-84] for urban patients. Baseline characteristics were similar between groups, except for a greater frequency of active smokers and diabetics as well as a greater body mass index in the rural group. There were no statistically significant differences in all-cause or cardiovascular mortality between the groups. There was also no statistically significant difference in secondary outcomes. CONCLUSION: Rural and urban patients had no statistically significant difference in all-cause mortality or cardiovascular mortality following TAVI. Given its minimally invasive nature and quality-centric, multidisciplinary care provided by the TAVI Heart Teams, TAVI may be the preferred modality for the treatment of severe aortic stenosis in rural populations. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Fogelson, Benjamin AU - Fogelson B AD - Department of Medicine, University of Tennessee Graduate School of Medicine, Knoxville, TN, USA. Electronic address: bafogelson@utmck.edu. FAU - Baljepally, Raj AU - Baljepally R AD - Department of Medicine, University of Tennessee Graduate School of Medicine, Knoxville, TN, USA. FAU - Heidel, Eric AU - Heidel E AD - Department of Medicine, University of Tennessee Graduate School of Medicine, Knoxville, TN, USA. FAU - Ferlita, Steve AU - Ferlita S AD - Department of Medicine, University of Tennessee Graduate School of Medicine, Knoxville, TN, USA. FAU - Moodie, Travis AU - Moodie T AD - Department of Medicine, University of Tennessee Graduate School of Medicine, Knoxville, TN, USA. FAU - Coombes, Tyler AU - Coombes T AD - Department of Medicine, University of Tennessee Graduate School of Medicine, Knoxville, TN, USA. FAU - Goodwin, Rachel P AU - Goodwin RP AD - Department of Medicine, University of Tennessee Graduate School of Medicine, Knoxville, TN, USA. FAU - Livesay, James AU - Livesay J AD - Department of Medicine, University of Tennessee Graduate School of Medicine, Knoxville, TN, USA. LA - eng PT - Comparative Study PT - Journal Article DEP - 20231216 PL - United States TA - Cardiovasc Revasc Med JT - Cardiovascular revascularization medicine : including molecular interventions JID - 101238551 SB - IM MH - Humans MH - Male MH - Retrospective Studies MH - Female MH - *Transcatheter Aortic Valve Replacement/adverse effects/mortality MH - Aged MH - Aged, 80 and over MH - Treatment Outcome MH - Risk Factors MH - *Aortic Valve Stenosis/surgery/mortality/diagnostic imaging/physiopathology MH - Time Factors MH - Risk Assessment MH - *Healthcare Disparities MH - Postoperative Complications/mortality MH - Patient Care Team MH - Urban Health MH - Aortic Valve/surgery/diagnostic imaging/physiopathology MH - Cause of Death MH - Rural Health OTO - NOTNLM OT - Healthcare disparities OT - Heart Team OT - Rural medicine OT - Transcatheter aortic valve implantation COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2023/12/23 12:42 MHDA- 2024/05/13 00:42 CRDT- 2023/12/22 21:59 PHST- 2023/11/03 00:00 [received] PHST- 2023/12/12 00:00 [revised] PHST- 2023/12/13 00:00 [accepted] PHST- 2024/05/13 00:42 [medline] PHST- 2023/12/23 12:42 [pubmed] PHST- 2023/12/22 21:59 [entrez] AID - S1553-8389(23)00936-3 [pii] AID - 10.1016/j.carrev.2023.12.005 [doi] PST - ppublish SO - Cardiovasc Revasc Med. 2024 May;62:3-8. doi: 10.1016/j.carrev.2023.12.005. Epub 2023 Dec 16. PMID- 38126207 OWN - NLM STAT- MEDLINE DCOM- 20240122 LR - 20250526 IS - 1531-6963 (Electronic) IS - 1040-8711 (Linking) VI - 36 IP - 2 DP - 2024 Mar 1 TI - Cardiovascular disease in spondyloarthritis: a narrative review of risk factors and the effect of treatments. PG - 95-107 LID - 10.1097/BOR.0000000000000999 [doi] AB - PURPOSE OF REVIEW: This review summarizes the recent evidence available regarding the epidemiology of cardiovascular disease in spondyloarthritis (SpA), including the effect of disease modifying drugs on cardiovascular risk. RECENT FINDINGS: People with SpA suffer from an increased risk of cardiovascular disease compared to the general population. This elevated risk is explained by the high prevalence of traditional cardiovascular risk factors and inflammation from disease activity leading to endothelial dysfunction and accelerated atherosclerosis. Consequently, the American College of Cardiology/American Heart Association and the European League Against Rheumatism recommend enhanced cardiovascular risk screening in SpA patients. There is evidence from observational studies that methotrexate and tumor necrosis factor inhibitors reduce the risk of cardiovascular events in SpA. Unlike what is observed in the general population, the use of nonsteroidal anti-inflammatory drugs does not appear to increase cardiovascular disease risk in SpA. SUMMARY: Cardiovascular diseases are increasingly recognized in patients suffering from SpA, especially axial SpA and psoriatic arthritis. Cardiovascular diseases can cause significant morbidity, mortality, and add to the overall disease burden. Disease modifying drugs may mitigate some of the cardiovascular risk; however, a multidisciplinary team is needed to monitor patients and improve cardiovascular health status. CI - Copyright (c) 2023 Wolters Kluwer Health, Inc. All rights reserved. FAU - Sen, Rouhin AU - Sen R AD - The University of Alabama Birmingham, Division of Clinical Immunology and Rheumatology. AD - Birmingham Veterans Affairs Medical Center (VAMC), Birmingham, Alabama. FAU - Caplan, Liron AU - Caplan L AD - Rocky Mountain Regional VAMC. AD - University of Colorado, Division of Rheumatology, Aurora, Colorado, USA. FAU - Danila, Maria I AU - Danila MI AD - The University of Alabama Birmingham, Division of Clinical Immunology and Rheumatology. AD - Birmingham Veterans Affairs Medical Center (VAMC), Birmingham, Alabama. LA - eng PT - Journal Article PT - Review DEP - 20231220 PL - United States TA - Curr Opin Rheumatol JT - Current opinion in rheumatology JID - 9000851 RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) SB - IM MH - Humans MH - *Cardiovascular Diseases/epidemiology/etiology MH - *Spondylarthritis/complications/drug therapy/diagnosis MH - *Arthritis, Psoriatic/drug therapy MH - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use MH - Risk Factors EDAT- 2023/12/21 06:42 MHDA- 2024/01/22 06:41 CRDT- 2023/12/21 05:34 PHST- 2024/01/22 06:41 [medline] PHST- 2023/12/21 06:42 [pubmed] PHST- 2023/12/21 05:34 [entrez] AID - 00002281-202403000-00002 [pii] AID - 10.1097/BOR.0000000000000999 [doi] PST - ppublish SO - Curr Opin Rheumatol. 2024 Mar 1;36(2):95-107. doi: 10.1097/BOR.0000000000000999. Epub 2023 Dec 20. PMID- 38124896 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231222 IS - 2297-055X (Print) IS - 2297-055X (Electronic) IS - 2297-055X (Linking) VI - 10 DP - 2023 TI - The frail patient undergoing cardiac surgery: lessons learned and future perspectives. PG - 1295108 LID - 10.3389/fcvm.2023.1295108 [doi] LID - 1295108 AB - Frailty is a geriatric condition characterized by the reduction of the individual's homeostatic reserves. It determines an increased vulnerability to endogenous and exogenous stressors and can lead to poor outcomes. It is an emerging concept in perioperative medicine, since an increasing number of patients undergoing surgical interventions are older and the traditional models of care seem to be inadequate to satisfy these patients' emerging clinical needs. Nowadays, the progressive technical and clinical improvements allow to offer cardiac operations to an older, sicker and frail population. For these reasons, a multidisciplinary team involving cardiac surgeons, clinical cardiologists, anesthesiologists, and geriatricians, is often needed to assess, select and provide tailored care to these high-risk frail patients to optimize clinical outcomes. There is unanimous agreement that frailty assessment may capture the individual's biological decline and the heterogeneity in risk profile for poor health-related outcomes among people of the same age. However, since commonly used preoperative scores for cardiac surgery fail to capture frailty, a specific preoperative assessment with dedicated tools is warranted to correctly recognize, measure and quantify frailty in these patients. On the contrary, pre-operative and post-operative interventions can reduce the risk of complications and support patient recovery promoting surgical resilience. Minimally invasive cardiac procedures aim to reduce surgical trauma and may be associated with better clinical outcome in this specific sub-group of high-risk patients. Among postoperative adverse events, the occurrence of delirium represents a risk factor for several unfavorable outcomes including mortality and subsequent cognitive decline. Its presence should be carefully recognized, triggering an adequate, evidence based, treatment. There is evidence, from several cross-section and longitudinal studies, that frailty and delirium may frequently overlap, with frailty serving both as a predisposing factor and as an outcome of delirium and delirium being a marker of a latent condition of frailty. In conclusion, frail patients are at increased risk to experience poor outcome after cardiac surgery. A multidisciplinary approach aimed to recognize more vulnerable individuals, optimize pre-operative conditions, reduce surgical invasivity and improve post-operative recovery is required to obtain optimal long-term outcome. CI - (c) 2023 Pozzi, Mariani, Scanziani, Passolunghi, Bruni, Finazzi, Lettino, Foti, Bellelli and Marchetto. FAU - Pozzi, Matteo AU - Pozzi M AD - Department of Emergency and Intensive Care, IRCCS San Gerardo dei Tintori Foundation, Monza, Italy. FAU - Mariani, Silvia AU - Mariani S AD - Cardiovascular Research Institute Maastricht (CARIM), Maastricht, Netherlands. AD - Division of Cardiac Surgery, IRCCS San Gerardo dei Tintori Foundation, Monza, Italy. FAU - Scanziani, Margherita AU - Scanziani M AD - Department of Emergency and Intensive Care, IRCCS San Gerardo dei Tintori Foundation, Monza, Italy. FAU - Passolunghi, Davide AU - Passolunghi D AD - Division of Cardiac Surgery, IRCCS San Gerardo dei Tintori Foundation, Monza, Italy. FAU - Bruni, Adriana AU - Bruni A AD - Acute Geriatrics Unit, IRCCS San Gerardo dei Tintori Foundation, Monza, Italy. FAU - Finazzi, Alberto AU - Finazzi A AD - Acute Geriatrics Unit, IRCCS San Gerardo dei Tintori Foundation, Monza, Italy. AD - School of Medicine, University of Milan Bicocca, Monza, Italy. FAU - Lettino, Maddalena AU - Lettino M AD - Department of Cardiovascular Medicine, IRCCS San Gerardo dei Tintori Foundation, Monza, Italy. FAU - Foti, Giuseppe AU - Foti G AD - Department of Emergency and Intensive Care, IRCCS San Gerardo dei Tintori Foundation, Monza, Italy. AD - School of Medicine, University of Milan Bicocca, Monza, Italy. FAU - Bellelli, Giuseppe AU - Bellelli G AD - Acute Geriatrics Unit, IRCCS San Gerardo dei Tintori Foundation, Monza, Italy. AD - School of Medicine, University of Milan Bicocca, Monza, Italy. FAU - Marchetto, Giovanni AU - Marchetto G AD - Division of Cardiac Surgery, IRCCS San Gerardo dei Tintori Foundation, Monza, Italy. LA - eng PT - Journal Article PT - Review DEP - 20231206 PL - Switzerland TA - Front Cardiovasc Med JT - Frontiers in cardiovascular medicine JID - 101653388 PMC - PMC10731467 OTO - NOTNLM OT - ERAS OT - cardiac surgery OT - comprehensive geriatric assessment OT - frailty OT - minimally invasive cardiac surgery COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision. EDAT- 2023/12/21 06:42 MHDA- 2023/12/21 06:43 PMCR- 2023/01/01 CRDT- 2023/12/21 04:06 PHST- 2023/09/15 00:00 [received] PHST- 2023/11/27 00:00 [accepted] PHST- 2023/12/21 06:43 [medline] PHST- 2023/12/21 06:42 [pubmed] PHST- 2023/12/21 04:06 [entrez] PHST- 2023/01/01 00:00 [pmc-release] AID - 10.3389/fcvm.2023.1295108 [doi] PST - epublish SO - Front Cardiovasc Med. 2023 Dec 6;10:1295108. doi: 10.3389/fcvm.2023.1295108. eCollection 2023. PMID- 38124539 OWN - NLM STAT- MEDLINE DCOM- 20240419 LR - 20260724 IS - 1559-6834 (Electronic) IS - 0899-823X (Print) IS - 0899-823X (Linking) VI - 45 IP - 5 DP - 2024 May TI - A cluster of three extrapulmonary Mycobacterium abscessus infections linked to well-maintained water-based heater-cooler devices. PG - 644-650 LID - 10.1017/ice.2023.273 [doi] AB - BACKGROUND: Various water-based heater-cooler devices (HCDs) have been implicated in nontuberculous mycobacteria outbreaks. Ongoing rigorous surveillance for healthcare-associated M. abscessus (HA-Mab) put in place following a prior institutional outbreak of M. abscessus alerted investigators to a cluster of 3 extrapulmonary M. abscessus infections among patients who had undergone cardiothoracic surgery. METHODS: Investigators convened a multidisciplinary team and launched a comprehensive investigation to identify potential sources of M. abscessus in the healthcare setting. Adherence to tap water avoidance protocols during patient care and HCD cleaning, disinfection, and maintenance practices were reviewed. Relevant environmental samples were obtained. Patient and environmental M. abscessus isolates were compared using multilocus-sequence typing and pulsed-field gel electrophoresis. Smoke testing was performed to evaluate the potential for aerosol generation and dispersion during HCD use. The entire HCD fleet was replaced to mitigate continued transmission. RESULTS: Clinical presentations of case patients and epidemiologic data supported intraoperative acquisition. M. abscessus was isolated from HCDs used on patients and molecular comparison with patient isolates demonstrated clonality. Smoke testing simulated aerosolization of M. abscessus from HCDs during device operation. Because the HCD fleet was replaced, no additional extrapulmonary HA-Mab infections due to the unique clone identified in this cluster have been detected. CONCLUSIONS: Despite adhering to HCD cleaning and disinfection strategies beyond manufacturer instructions for use, HCDs became colonized with and ultimately transmitted M. abscessus to 3 patients. Design modifications to better contain aerosols or filter exhaust during device operation are needed to prevent NTM transmission events from water-based HCDs. FAU - Seidelman, Jessica L AU - Seidelman JL AUID- ORCID: 0000-0001-7117-513X AD - Duke Center for Antimicrobial Stewardship and Infection Prevention, Durham, North Carolina. AD - Division of Infectious Diseases, Duke University Medical Center, Durham, North Carolina. FAU - Baker, Arthur W AU - Baker AW AUID- ORCID: 0000-0002-0914-0291 AD - Duke Center for Antimicrobial Stewardship and Infection Prevention, Durham, North Carolina. AD - Division of Infectious Diseases, Duke University Medical Center, Durham, North Carolina. FAU - Lewis, Sarah S AU - Lewis SS AD - Duke Center for Antimicrobial Stewardship and Infection Prevention, Durham, North Carolina. AD - Division of Infectious Diseases, Duke University Medical Center, Durham, North Carolina. FAU - Warren, Bobby G AU - Warren BG AUID- ORCID: 0000-0002-7238-0300 AD - Duke Center for Antimicrobial Stewardship and Infection Prevention, Durham, North Carolina. AD - Division of Infectious Diseases, Duke University Medical Center, Durham, North Carolina. AD - Disinfection, Resistance, Transmission and Epidemiology Laboratory, Department of Medicine, Duke University Medical Center, Durham, North Carolina. FAU - Barrett, Aaron AU - Barrett A AD - Duke Center for Antimicrobial Stewardship and Infection Prevention, Durham, North Carolina. AD - Division of Infectious Diseases, Duke University Medical Center, Durham, North Carolina. AD - Disinfection, Resistance, Transmission and Epidemiology Laboratory, Department of Medicine, Duke University Medical Center, Durham, North Carolina. FAU - Graves, Amanda AU - Graves A AD - Duke Center for Antimicrobial Stewardship and Infection Prevention, Durham, North Carolina. AD - Division of Infectious Diseases, Duke University Medical Center, Durham, North Carolina. AD - Disinfection, Resistance, Transmission and Epidemiology Laboratory, Department of Medicine, Duke University Medical Center, Durham, North Carolina. FAU - King, Carly AU - King C AD - Division of Cardiovascular and Thoracic Surgery, Duke University School of Medicine, Durham, North Carolina. FAU - Taylor, Bonnie AU - Taylor B AUID- ORCID: 0000-0001-5577-2241 AD - Division of Infectious Diseases, Duke University Medical Center, Durham, North Carolina. FAU - Engel, Jill AU - Engel J AUID- ORCID: 0000-0002-7329-2820 AD - Division of Cardiovascular and Thoracic Surgery, Duke University School of Medicine, Durham, North Carolina. FAU - Bonnadonna, Desiree AU - Bonnadonna D AD - Division of Infectious Diseases, Duke University Medical Center, Durham, North Carolina. FAU - Milano, Carmelo AU - Milano C AD - Division of Cardiovascular and Thoracic Surgery, Duke University School of Medicine, Durham, North Carolina. FAU - Wallace, Richard J AU - Wallace RJ AD - Mycobacteria/Nocardia Laboratory, University of Texas Health Science Center, Tyler, Texas. FAU - Stiegel, Matthew AU - Stiegel M AD - Occupational and Environmental Safety Office, Laboratory Safety, Duke University and Health System, Durham, North Carolina. FAU - Anderson, Deverick J AU - Anderson DJ AUID- ORCID: 0000-0001-6882-5496 AD - Duke Center for Antimicrobial Stewardship and Infection Prevention, Durham, North Carolina. AD - Division of Infectious Diseases, Duke University Medical Center, Durham, North Carolina. AD - Disinfection, Resistance, Transmission and Epidemiology Laboratory, Department of Medicine, Duke University Medical Center, Durham, North Carolina. FAU - Smith, Becky A AU - Smith BA AD - Duke Center for Antimicrobial Stewardship and Infection Prevention, Durham, North Carolina. AD - Division of Infectious Diseases, Duke University Medical Center, Durham, North Carolina. LA - eng GR - K08 AI163462/AI/NIAID NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20231221 PL - United States TA - Infect Control Hosp Epidemiol JT - Infection control and hospital epidemiology JID - 8804099 SB - IM MH - Humans MH - *Mycobacterium Infections, Nontuberculous/epidemiology MH - Nontuberculous Mycobacteria MH - Multilocus Sequence Typing MH - Disease Outbreaks MH - *Cross Infection/epidemiology MH - *Mycobacterium Infections/epidemiology PMC - PMC11027075 MID - NIHMS1985466 COIS- All authors report no conflicts of interest relevant to this article. EDAT- 2023/12/21 06:42 MHDA- 2024/04/19 06:43 PMCR- 2024/04/19 CRDT- 2023/12/21 03:16 PHST- 2024/04/19 06:43 [medline] PHST- 2023/12/21 06:42 [pubmed] PHST- 2023/12/21 03:16 [entrez] PHST- 2024/04/19 00:00 [pmc-release] AID - S0899823X23002738 [pii] AID - 10.1017/ice.2023.273 [doi] PST - ppublish SO - Infect Control Hosp Epidemiol. 2024 May;45(5):644-650. doi: 10.1017/ice.2023.273. Epub 2023 Dec 21. PMID- 38123286 OWN - NLM STAT- MEDLINE DCOM- 20231222 LR - 20240102 IS - 1557-9808 (Electronic) IS - 1557-9808 (Linking) VI - 26 IP - 4 DP - 2023 Dec TI - Interventional Radiological Treatment of Orthotopic Heart Transplant Complications. PG - 100928 LID - S1089-2516(23)00044-6 [pii] LID - 10.1016/j.tvir.2023.100928 [doi] AB - Orthotopic heart transplantation is a life-saving procedure that has substantially improved the lives of countless patients since its inception. However, there are several procedure-related complications that require prompt management. Interventional radiology, with its ever expanding toolkit, is a cornerstone of the multidisciplinary team following post-cardiac transplant patients. Percutaneous, endovascular therapy provides minimally invasive, safe, and effective treatments for immediate and delayed cardiac transplant complications and this paper serves to highlight the various management options interventional radiology can provide for orthotopic heart transplantation complications. CI - Copyright (c) 2023. Published by Elsevier Inc. FAU - Charles, Jonathan AU - Charles J AD - University of South Florida, Tampa, FL. FAU - Girgis, Monique AU - Girgis M AD - University of South Florida, Tampa, FL. FAU - Nezami, Nariman AU - Nezami N AD - Department of DIagnostic Radiology and Nuclear Medicine, University of Maryland, Baltimore, MD. FAU - Massis, Kamal AU - Massis K AD - University of South Florida Medical School, Tampa, FL. FAU - Davis, Cliff AU - Davis C AD - Department of Vascular and Interventional Radiology, University of South Florida , Tampa, FL. FAU - Hoots, Glenn AU - Hoots G AD - Department of Vascular and Interventional Radiology, University of South Florida , Tampa, FL. FAU - Shaikh, Jamil AU - Shaikh J AD - Department of Vascular and Interventional Radiology, University of South Florida , Tampa, FL. Electronic address: jshaikh1@usf.edu. LA - eng PT - Journal Article DEP - 20231102 PL - United States TA - Tech Vasc Interv Radiol JT - Techniques in vascular and interventional radiology JID - 9806675 SB - IM MH - Humans MH - *Liver Transplantation/methods MH - Radiology, Interventional MH - Treatment Outcome MH - *Heart Transplantation/adverse effects OTO - NOTNLM OT - Heart Transplant OT - Transplant Intervention OT - Venous Disease EDAT- 2023/12/21 00:41 MHDA- 2023/12/22 06:42 CRDT- 2023/12/20 21:03 PHST- 2023/12/22 06:42 [medline] PHST- 2023/12/21 00:41 [pubmed] PHST- 2023/12/20 21:03 [entrez] AID - S1089-2516(23)00044-6 [pii] AID - 10.1016/j.tvir.2023.100928 [doi] PST - ppublish SO - Tech Vasc Interv Radiol. 2023 Dec;26(4):100928. doi: 10.1016/j.tvir.2023.100928. Epub 2023 Nov 2. PMID- 38122886 OWN - NLM STAT- MEDLINE DCOM- 20240116 LR - 20250104 IS - 1873-1570 (Electronic) IS - 0300-9572 (Print) IS - 0300-9572 (Linking) VI - 194 DP - 2024 Jan TI - Prioritizing intervention preferences to potentially reduce caregiver burden in racially and ethnically diverse close family members of cardiac arrest survivors. PG - 110093 LID - S0300-9572(23)00829-8 [pii] LID - 10.1016/j.resuscitation.2023.110093 [doi] AB - AIM: Close family members of cardiac arrest patients who survive to hospital discharge have elevated levels of psychological distress and caregiver burden. We assessed their preferences toward needs during hospitalization and beyond to inform intervention development. METHODS: Through an online survey developed by a multidisciplinary team of researchers, clinicians, cardiac arrest survivors, and families, adult close family members recruited through advocacy organizations ranked top choice among 8 unique interventions addressing either information-based needs (n = 4) or well-being needs (n = 4). Logistic Regression analysis was conducted to assess the associations of family members' attributes, caregiving characteristics, and survivors' hospitalization factors with two intervention groups. RESULTS: Of 657 responses received, ranking data of 550 close family members (59% between 18-40 years of age, 65% female, 51% of minority race/ethnicity, 53% partners, provided a median of 8 hours of caregiving, for a median of 4.5 months) were analyzed. Information needs were the more commonly preferred intervention group (63%; n = 347), with education on the potential recovery of survivors ranking first (28%; n = 149). In a multivariate model, family members age >40 years, families witnessing the cardiac arrest, assuming the caregiver role either during hospitalization or within one month of hospital discharge, and discharging directly to home were significantly associated with prioritizing information needs over well-being needs, after adjusting for sex, race, intensity, and duration of caregiving. CONCLUSIONS: Interventions focusing on information needs are among the top priorities for families of cardiac arrest survivors. Prospective studies testing these hypotheses-generating findings are needed to inform further intervention development. CI - Copyright (c) 2023 Elsevier B.V. All rights reserved. FAU - Agarwal, Sachin AU - Agarwal S AD - Columbia University Irving Medical Center, USA. Electronic address: sa2512@columbia.edu. FAU - Tincher, Isabella M AU - Tincher IM AD - Columbia University Irving Medical Center, USA. FAU - Abukhadra, Sabine L AU - Abukhadra SL AD - Wake Forest University School of Medicine, USA. FAU - Rojas, Danielle A AU - Rojas DA AD - Columbia University Irving Medical Center, USA. FAU - DeForge, Christine E AU - DeForge CE AD - Columbia University School of Nursing, USA. FAU - Marchionda, Cindy AU - Marchionda C AD - The City University of New York, Family Member, USA. FAU - Wylie, Jasmine AU - Wylie J AD - Sudden Cardiac Arrest Survivors Online Group, Survivor, USA. FAU - Chap, Jennifer AU - Chap J AD - BuddyCPR, Family Member, USA. LA - eng GR - R01 HL153311/HL/NHLBI NIH HHS/United States GR - TL1 TR001875/TR/NCATS NIH HHS/United States PT - Journal Article DEP - 20231218 PL - Ireland TA - Resuscitation JT - Resuscitation JID - 0332173 SB - IM MH - Adult MH - Humans MH - Female MH - Infant MH - Male MH - *Caregiver Burden MH - Prospective Studies MH - Family/psychology MH - Caregivers/psychology MH - Survivors MH - *Heart Arrest/therapy PMC - PMC10843630 MID - NIHMS1954846 OTO - NOTNLM OT - Behavioral intervention OT - Caregiver burden OT - Education OT - Psychological distress COIS- DECLARATION All authors have disclosed that they do not have any potential conflicts of interest. EDAT- 2023/12/21 00:41 MHDA- 2024/01/16 06:41 PMCR- 2025/01/01 CRDT- 2023/12/20 19:27 PHST- 2023/10/31 00:00 [received] PHST- 2023/12/04 00:00 [revised] PHST- 2023/12/11 00:00 [accepted] PHST- 2024/01/16 06:41 [medline] PHST- 2023/12/21 00:41 [pubmed] PHST- 2023/12/20 19:27 [entrez] PHST- 2025/01/01 00:00 [pmc-release] AID - S0300-9572(23)00829-8 [pii] AID - 10.1016/j.resuscitation.2023.110093 [doi] PST - ppublish SO - Resuscitation. 2024 Jan;194:110093. doi: 10.1016/j.resuscitation.2023.110093. Epub 2023 Dec 18. PMID- 38117424 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260518 IS - 2193-8261 (Print) IS - 2193-6544 (Electronic) IS - 2193-6544 (Linking) VI - 13 IP - 1 DP - 2024 Mar TI - Clinical and Genotype Characteristics and Symptom Migration in Patients With Mixed Phenotype Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey. PG - 117-135 LID - 10.1007/s40119-023-00344-3 [doi] AB - INTRODUCTION: Transthyretin amyloidosis (ATTR amyloidosis) is primarily associated with a cardiac or neurologic phenotype, but a mixed phenotype is increasingly described. METHODS: This study describes the mixed phenotype cohort in the Transthyretin Amyloidosis Outcomes Survey (THAOS). THAOS is an ongoing, longitudinal, observational survey of patients with ATTR amyloidosis, including both hereditary (ATTRv) and wild-type disease, and asymptomatic carriers of pathogenic transthyretin variants. Baseline characteristics of patients with a mixed phenotype (at enrollment or reclassified during follow-up) are described (data cutoff: January 4, 2022). RESULTS: Approximately one-third of symptomatic patients (n = 1185/3542; 33.5%) were classified at enrollment or follow-up as mixed phenotype (median age, 66.5 years). Of those, 344 (29.0%) were reclassified to mixed phenotype within a median 1-2 years of follow-up. Most patients with mixed phenotype had ATTRv amyloidosis (75.7%). The most frequent genotypes were V30M (38.9%) and wild type (24.3%). CONCLUSIONS: These THAOS data represent the largest analysis of a real-world mixed phenotype ATTR amyloidosis population to date and suggest that a mixed phenotype may be more prevalent than previously thought. Patients may also migrate from a primarily neurologic or cardiologic presentation to a mixed phenotype over time. These data reinforce the need for multidisciplinary evaluation at initial assessment and follow-up of all patients with ATTR amyloidosis. TRIAL REGISTRATION: ClinicalTrials.gov: NCT00628745. CI - (c) 2023. The Author(s). FAU - Gonzalez-Moreno, Juan AU - Gonzalez-Moreno J AD - Servicio de Medicina Interna, Hospital Universitario Son Llatzer, Instituto de Investigacion Sanitaria Illes Balears, Palma, Spain. jgonzalez4@hsll.es. FAU - Dispenzieri, Angela AU - Dispenzieri A AD - Division of Hematology, Mayo Clinic, Rochester, MN, USA. FAU - Grogan, Martha AU - Grogan M AD - Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA. FAU - Coelho, Teresa AU - Coelho T AD - Unidade Corino Andrade, Hospital Santo Antonio, Centro Hospitalar Universitario do Porto, Porto, Portugal. FAU - Tournev, Ivailo AU - Tournev I AD - Department of Neurology, Clinic of Nervous Diseases, UMBAL Aleksandrovska, Medical University, Sofia, Bulgaria. AD - Department of Cognitive Science, New Bulgarian University, Sofia, Bulgaria. FAU - Waddington-Cruz, Marcia AU - Waddington-Cruz M AD - National Amyloidosis Referral Center, CEPARM, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil. FAU - Wixner, Jonas AU - Wixner J AUID- ORCID: 0000-0002-1536-1277 AD - Department of Public Health and Clinical Medicine, Umea University, Umea, Sweden. FAU - Diemberger, Igor AU - Diemberger I AD - Department of Medical and Surgical Sciences, DIMEC, University of Bologna, Bologna, Italy. AD - UOC di Cardiologia, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Dipartimento Cardiotoraco-vascolare, via Massarenti 9, 40138, Bologna, Italy. FAU - Garcia-Pavia, Pablo AU - Garcia-Pavia P AD - Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, CIBERCV, Madrid, Spain. AD - Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain. FAU - Chapman, Doug AU - Chapman D AD - Pfizer Inc, New York, NY, USA. FAU - Gupta, Pritam AU - Gupta P AD - Pfizer Healthcare India Pvt. Ltd, Chennai, India. FAU - Glass, Oliver AU - Glass O AD - Pfizer Inc, New York, NY, USA. FAU - Amass, Leslie AU - Amass L AD - Pfizer Inc, New York, NY, USA. CN - THAOS investigators LA - eng SI - ClinicalTrials.gov/NCT00628745 PT - Journal Article DEP - 20231220 PL - England TA - Cardiol Ther JT - Cardiology and therapy JID - 101634495 PMC - PMC10899146 OTO - NOTNLM OT - Amyloidosis OT - Cardiomyopathy OT - Mixed phenotype OT - Polyneuropathy OT - THAOS OT - Transthyretin COIS- Juan Gonzalez-Moreno reports speaker fees from Akcea, Alnylam, and Pfizer. Angela Dispenzieri reports research grants from Alnylam, Celgene, Janssen, Millennium, and Pfizer; funding for meeting expenses (travel) from Pfizer; and advisory board fees from Akcea and Intellia. Martha Grogan reports grants and advisory board/consultancy fees paid to her institution from Alnylam, Eidos, Pfizer, and Prothena. Teresa Coelho served as a medical advisor for Pfizer, without honoraria; and reports funding for meeting expenses (travel, accommodation, registration) from Pfizer. Ivailo Tournev reports research funding, honoraria for presentations, and advisory board fees from Alnylam, Pfizer, and Pharma Pro. Marcia Waddington-Cruz reports research funding, consulting fees, and travel support for advisory boards and meetings from FoldRx Pharmaceuticals and Pfizer. Jonas Wixner reports consulting fees and travel support for lectures and advisory boards from Alnylam and Pfizer; and consulting fees from Akcea. Igor Diemberger reports research funding and speaker fees from Daiichi Sankyo and Pfizer (outside scope of present research). Pablo Garcia-Pavia reports speaker fees from Akcea, Alnylam, Eidos, and Pfizer; consulting fees from Alnylam, Akcea, AstraZeneca, Eidos, Neurimmune, and Pfizer; and research/educational support to his institution from Alnylam, Eidos, and Pfizer. Doug Chapman, Pritam Gupta, Oliver Glass, and Leslie Amass are full-time employees of Pfizer and hold stock and/or stock options. FIR - Plante-Bordeneuve, Violaine IR - Plante-Bordeneuve V FIR - Conceicao, Isabel IR - Conceicao I FIR - Jeon, Eun-Seok IR - Jeon ES FIR - Maurer, Mathew IR - Maurer M FIR - Costello, Jose Gonzalez IR - Costello JG FIR - Lairez, Olivier IR - Lairez O FIR - Ueda, Mitsuharu IR - Ueda M FIR - Kristen, Arnt IR - Kristen A FIR - Sekijima, Yoshiki IR - Sekijima Y FIR - Drachman, Brian IR - Drachman B FIR - Slosky, David IR - Slosky D FIR - Husing-Kabar, Anna IR - Husing-Kabar A FIR - Briseno, Maria Alejandra Gonzalez Duarte IR - Briseno MAGD FIR - Freimer, Miriam IR - Freimer M FIR - Luigetti, Marco IR - Luigetti M FIR - Lenihan, Daniel IR - Lenihan D FIR - Polydefkis, Michael IR - Polydefkis M FIR - Hanna, Mazen IR - Hanna M FIR - Nienhuis, Hans IR - Nienhuis H FIR - Gottlieb, Stephen IR - Gottlieb S FIR - Nicolau, Jose Nativi IR - Nicolau JN FIR - Inamo, Jocelyn IR - Inamo J FIR - Emdin, Michele IR - Emdin M FIR - Azevedo, Olga IR - Azevedo O FIR - Brunkhorst, Robert IR - Brunkhorst R FIR - Miller, Edward IR - Miller E FIR - Warner, Alberta IR - Warner A FIR - Barroso, Fabio Adrian IR - Barroso FA FIR - Press, Rayomand IR - Press R FIR - Hummel, Scott IR - Hummel S FIR - Beamud, Francisco Munoz IR - Beamud FM FIR - Mazzeo, Anna IR - Mazzeo A FIR - Gentile, Luca IR - Gentile L FIR - Low, Soon Chai IR - Low SC FIR - Badelita, Sorina IR - Badelita S FIR - Quan, Dianna IR - Quan D FIR - Tauras, James IR - Tauras J FIR - Zivkovic, Sasa IR - Zivkovic S FIR - Van Cleemput, Johan IR - Van Cleemput J FIR - Moelgaard, Henning IR - Moelgaard H FIR - Plana, Josep Maria Campistol IR - Plana JMC FIR - Torron, Roberto Fernandez IR - Torron RF FIR - Sarswat, Nitasha IR - Sarswat N FIR - Murali, Srinivas IR - Murali S FIR - Mueller, Christopher IR - Mueller C FIR - Fine, Nowell IR - Fine N FIR - Darstein, Felix IR - Darstein F FIR - Adams, David IR - Adams D FIR - Dori, Amir IR - Dori A FIR - Obici, Laura IR - Obici L FIR - Cirami, Calogero Lino IR - Cirami CL FIR - Misawa, Sonoko IR - Misawa S FIR - Shah, Sanjiv IR - Shah S FIR - Tschoepe, Carsten IR - Tschoepe C FIR - Davila, Lucia Galan IR - Davila LG FIR - Oh, Jeeyoung IR - Oh J FIR - Parman, Yesim IR - Parman Y FIR - Marburger, Tessa IR - Marburger T FIR - Ralph, Jeffrey IR - Ralph J EDAT- 2023/12/20 12:41 MHDA- 2023/12/20 12:42 PMCR- 2023/12/20 CRDT- 2023/12/20 11:11 PHST- 2023/09/10 00:00 [received] PHST- 2023/11/21 00:00 [accepted] PHST- 2023/12/20 12:42 [medline] PHST- 2023/12/20 12:41 [pubmed] PHST- 2023/12/20 11:11 [entrez] PHST- 2023/12/20 00:00 [pmc-release] AID - 10.1007/s40119-023-00344-3 [pii] AID - 344 [pii] AID - 10.1007/s40119-023-00344-3 [doi] PST - ppublish SO - Cardiol Ther. 2024 Mar;13(1):117-135. doi: 10.1007/s40119-023-00344-3. Epub 2023 Dec 20. PMID- 38116841 OWN - NLM STAT- MEDLINE DCOM- 20240208 LR - 20250729 IS - 1531-7080 (Electronic) IS - 0268-4705 (Linking) VI - 39 IP - 2 DP - 2024 Mar 1 TI - Which lesions are not amenable to tricuspid clipping? PG - 79-85 LID - 10.1097/HCO.0000000000001105 [doi] AB - PURPOSE OF REVIEW: Tricuspid transcatheter edge-to-edge repair (T-TEER) has emerged as a well tolerated and effective therapeutic option for many patients with symptomatic severe tricuspid regurgitation at prohibitive surgical risk. However, there remain several important limitations to clip-based technology in the context of other rapidly emerging percutaneous treatment options for tricuspid regurgitation. RECENT FINDINGS: Tricuspid lesions pose unique challenges to treatment with the current toolbox of transcatheter clip-based technologies. This review will explore key issues related to patient factors, anatomical factors, and imaging factors that may render lesions to be unsuitable for treatment with T-TEER. SUMMARY: Selection for T-TEER must include a detailed clinical evaluation in the context of a 'heart team' approach involving multiple subspecialists, with screening for patient/lesion characteristics that make T-TEER suboptimal with current clip-based technologies. Future directions for research include patient-specific 3D modeling techniques, leaflet grasping techniques, clip deployment strategies, and personalized device sizing to increase the spectrum of lesions that may be treated with T-TEER within the context of other emerging transcatheter treatment options. CI - Copyright (c) 2023 Wolters Kluwer Health, Inc. All rights reserved. FAU - Bakar, Shahrukh N AU - Bakar SN AD - Structural Heart Program, Division of Cardiology, St. Michael's Hospital, Toronto, Ontario, Canada. FAU - Fam, Neil P AU - Fam NP LA - eng PT - Journal Article PT - Review DEP - 20231129 PL - United States TA - Curr Opin Cardiol JT - Current opinion in cardiology JID - 8608087 SB - IM MH - Humans MH - *Tricuspid Valve Insufficiency/surgery MH - *Heart Valve Prosthesis Implantation/adverse effects MH - Treatment Outcome MH - Cardiac Catheterization/methods MH - Forecasting EDAT- 2023/12/20 12:43 MHDA- 2024/02/08 06:43 CRDT- 2023/12/20 07:51 PHST- 2024/02/08 06:43 [medline] PHST- 2023/12/20 12:43 [pubmed] PHST- 2023/12/20 07:51 [entrez] AID - 00001573-202403000-00003 [pii] AID - 10.1097/HCO.0000000000001105 [doi] PST - ppublish SO - Curr Opin Cardiol. 2024 Mar 1;39(2):79-85. doi: 10.1097/HCO.0000000000001105. Epub 2023 Nov 29. PMID- 38115800 OWN - NLM STAT- MEDLINE DCOM- 20240102 LR - 20250104 IS - 2154-1671 (Electronic) IS - 2154-1663 (Print) IS - 2154-1671 (Linking) VI - 14 IP - 1 DP - 2024 Jan 1 TI - Dexmedetomidine During Therapeutic Hypothermia: A Multicenter Quality Initiative. PG - 30-36 LID - 10.1542/hpeds.2023-007403 [doi] AB - OBJECTIVES: Sedation is typically used during neonatal therapeutic hypothermia (TH). This report describes a quality improvement (QI) initiative with the aim of decreasing opioid exposure during TH by implementing dexmedetomidine as the primary sedative agent. METHODS: This dual-center QI initiative used a multidisciplinary team to create a sedation algorithm for safe implementation of dexmedetomidine as first-line therapy during TH. The primary measure in this initiative was cumulative opioid exposure during TH; balancing measures included safety parameters, primarily the rate of dexmedetomidine discontinuation because of bradycardia. Baseline demographic and clinical data were collected retrospectively for the period before implementation and prospectively during the QI period. Data were analyzed using statistical process control charts to identify change over time. RESULTS: One-hundred and fifty-four neonates in the 2-year pre-QI period were compared with 135 neonates in the 2 years after guideline implementation. Guideline compliance with dexmedetomidine initiation was 99% and compliance with initial dosing increased from 70% to 91% during the QI period. The cumulative dose of opioid during TH decreased by >90% by the end of the QI period. Dexmedetomidine was discontinued for transient bradycardia in 9.6% of the study population. No other adverse effects were observed. CONCLUSIONS: Dexmedetomidine may be used as the primary sedative during neonatal TH with a low incidence of adverse effects. Clinical trials evaluating the impact of sedation during TH on neurologic outcomes are needed. CI - Copyright (c) 2024 by the American Academy of Pediatrics. FAU - Elliott, Megan AU - Elliott M AD - Division of Neonatology, Department of Pediatrics, University of Virginia Children's Hospital, Charlottesville, Virginia. FAU - Fairchild, Karen AU - Fairchild K AD - Division of Neonatology, Department of Pediatrics, University of Virginia Children's Hospital, Charlottesville, Virginia. FAU - Zanelli, Santina AU - Zanelli S AD - Division of Neonatology, Department of Pediatrics, University of Virginia Children's Hospital, Charlottesville, Virginia. FAU - McPherson, Christopher AU - McPherson C AD - Department of Pharmacy, St Louis Children's Hospital, St Louis, Missouri. AD - Division of Newborn Medicine, Department of Pediatrics, Washington University St Louis, St Louis, Missouri. FAU - Vesoulis, Zachary AU - Vesoulis Z AD - Division of Newborn Medicine, Department of Pediatrics, Washington University St Louis, St Louis, Missouri. LA - eng GR - K23 NS111086/NS/NINDS NIH HHS/United States GR - R01 HD072071/HD/NICHD NIH HHS/United States PT - Journal Article PT - Multicenter Study PT - Research Support, N.I.H., Extramural PL - United States TA - Hosp Pediatr JT - Hospital pediatrics JID - 101585349 RN - 67VB76HONO (Dexmedetomidine) RN - 0 (Analgesics, Opioid) RN - 0 (Hypnotics and Sedatives) SB - IM MH - Infant, Newborn MH - Humans MH - *Dexmedetomidine/therapeutic use MH - Bradycardia/chemically induced/therapy MH - Analgesics, Opioid MH - Retrospective Studies MH - Hypnotics and Sedatives/therapeutic use MH - *Hypothermia, Induced PMC - PMC10750168 COIS- CONFLICT OF INTEREST DISCLOSURES: The authors have indicated they have no conflicts of interest relevant to this article to disclose. EDAT- 2023/12/20 06:42 MHDA- 2024/01/02 11:44 PMCR- 2025/01/01 CRDT- 2023/12/20 03:31 PHST- 2024/01/02 11:44 [medline] PHST- 2023/12/20 06:42 [pubmed] PHST- 2023/12/20 03:31 [entrez] PHST- 2025/01/01 00:00 [pmc-release] AID - 196237 [pii] AID - hpeds.2023-007403 [pii] AID - 10.1542/hpeds.2023-007403 [doi] PST - ppublish SO - Hosp Pediatr. 2024 Jan 1;14(1):30-36. doi: 10.1542/hpeds.2023-007403. PMID- 38115065 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231222 IS - 2052-0492 (Print) IS - 2052-0492 (Electronic) IS - 2052-0492 (Linking) VI - 11 IP - 1 DP - 2023 Dec 19 TI - Mechanical circulatory support in cardiogenic shock. PG - 64 LID - 10.1186/s40560-023-00710-2 [doi] LID - 64 AB - Cardiogenic shock is a complex and diverse pathological condition characterized by reduced myocardial contractility. The goal of treatment of cardiogenic shock is to improve abnormal hemodynamics and maintain adequate tissue perfusion in organs. If hypotension and insufficient tissue perfusion persist despite initial therapy, temporary mechanical circulatory support (t-MCS) should be initiated. This decade sees the beginning of a new era of cardiogenic shock management using t-MCS through the accumulated experience with use of intra-aortic balloon pump (IABP) and venoarterial extracorporeal membrane oxygenation (VA-ECMO), as well as new revolutionary devices or systems such as transvalvular axial flow pump (Impella) and a combination of VA-ECMO and Impella (ECPELLA) based on the knowledge of circulatory physiology. In this transitional period, we outline the approach to the management of cardiogenic shock by t-MCS. The management strategy involves carefully selecting one or a combination of the t-MCS devices, taking into account the characteristics of each device and the specific pathological condition. This selection is guided by monitoring of hemodynamics, classification of shock stage, risk stratification, and coordinated management by the multidisciplinary shock team. CI - (c) 2023. The Author(s). FAU - Nakata, Jun AU - Nakata J AUID- ORCID: 0000-0003-2476-1050 AD - Division of Cardiovascular Intensive Care, Nippon Medical School Hospital, 1-1-5 Sendagi, Bunkyo-Ku, Tokyo, 113-8603, Japan. jun-nakata@nms.ac.jp. FAU - Yamamoto, Takeshi AU - Yamamoto T AD - Division of Cardiovascular Intensive Care, Nippon Medical School Hospital, 1-1-5 Sendagi, Bunkyo-Ku, Tokyo, 113-8603, Japan. FAU - Saku, Keita AU - Saku K AD - Department of Cardiovascular Dynamics, National Cerebral and Cardiovascular Center Research, Suita, Osaka, Japan. FAU - Ikeda, Yuki AU - Ikeda Y AD - Department of Cardiovascular Medicine, Kitasato University, School of Medicine, Sagamihara, Kanagawa, Japan. FAU - Unoki, Takashi AU - Unoki T AD - Department of Cardiology and Intensive Care Unit, Saiseikai Kumamoto Hospital, Kumamoto, Japan. FAU - Asai, Kuniya AU - Asai K AD - Division of Cardiovascular Intensive Care, Nippon Medical School Hospital, 1-1-5 Sendagi, Bunkyo-Ku, Tokyo, 113-8603, Japan. LA - eng PT - Journal Article PT - Review DEP - 20231219 PL - England TA - J Intensive Care JT - Journal of intensive care JID - 101627304 PMC - PMC10731894 COIS- The authors declare that they have no competing interests. EDAT- 2023/12/20 06:42 MHDA- 2023/12/20 06:43 PMCR- 2023/12/19 CRDT- 2023/12/20 00:20 PHST- 2023/10/11 00:00 [received] PHST- 2023/11/30 00:00 [accepted] PHST- 2023/12/20 06:43 [medline] PHST- 2023/12/20 06:42 [pubmed] PHST- 2023/12/20 00:20 [entrez] PHST- 2023/12/19 00:00 [pmc-release] AID - 10.1186/s40560-023-00710-2 [pii] AID - 710 [pii] AID - 10.1186/s40560-023-00710-2 [doi] PST - epublish SO - J Intensive Care. 2023 Dec 19;11(1):64. doi: 10.1186/s40560-023-00710-2. PMID- 38112742 OWN - NLM STAT- MEDLINE DCOM- 20240321 LR - 20240522 IS - 1861-0692 (Electronic) IS - 1861-0684 (Print) IS - 1861-0684 (Linking) VI - 113 IP - 4 DP - 2024 Apr TI - A multidisciplinary pulmonary embolism response team (PERT): first experience from a single center in Germany. PG - 581-590 LID - 10.1007/s00392-023-02364-4 [doi] AB - BACKGROUND: Over the last few years, the concept of multidisciplinary pulmonary embolism response teams (PERTs) has emerged to encounter the increasing variety and complexity in managing acute pulmonary embolism (PE). PURPOSE: To investigate PERT's composition and added clinical value in a university center in Germany. METHODS: Over 4 years (01/2019-11/2022), patients with confirmed PE were enrolled in a prospective single-center cohort study (PERT Mainz). We investigated the composition of PERT and compared, after propensity score matching, patients with acute PE before and after the initiation of PERT at our Medical University Centre. The primary outcome was in-hospital PE-related mortality. RESULTS: From 2019 to 2022, 88 patients with acute PE with a PERT decision were registered. Of those, 13 (14.8%) patients died during the in-hospital stay. Patients evaluated by a PERT had a median age of 68; 48.9% were females, and 21.7% suffered from malignancy. Right ventricular dysfunction was present in 76.1% of all patients. In total, 42.0% were classified as intermediate-high-risk PE and 11.4% as high-risk PE. First PERT contact mainly originated from emergency departments (33.3%) and intensive care units (30.0%), followed by chest pain units (21.3%) and regular wards (12.0%). The participation rate of medical specialties demonstrated that cardiologists (100%) or cardiac/vascular surgeons (98.6%) were included in almost all PERT consultations, followed by radiologists (95.9%) and anesthesiologists (87.8%). Compared to the PERT era, more patients in the pre-PERT era were classified as simplified pulmonary embolism severity index (sPESI) >/= 1 (78.4% vs 71.6%) and as high-risk PE according to ESC 2019 guidelines (18.2% vs. 11.4%). In the pre-PERT era, low- and intermediate-low patients with PE received more frequently advanced reperfusion therapies such as systemic thrombolysis or surgical embolectomy compared to the PERT era (10.7% vs. 2.5%). Patients in the pre-PERT were found to have a considerably higher all-cause mortality and PE-related mortality rate (31.8% vs. 14.8%) compared to patients in the PERT era (22.7% vs. 13.6%). After propensity matching (1:1) by including parameters as age, sex, sPESI, and ESC risk classes, univariate regression analyses demonstrated that the PE management based on a PERT decision was associated with lower risk of all-cause mortality (OR, 0.37 [95%CI 0.18-0.77]; p = 0.009). For PE-related mortality, a tendency for reduction was observed (OR, 0.54 [95%CI 0.24-1.18]; p = 0.121). CONCLUSION: PERT implementation was associated with a lower risk of all-cause mortality rate in patients with acute PE. Large prospective studies are needed further to explore the impact of PERTs on clinical outcomes. CI - (c) 2023. The Author(s). FAU - Sagoschen, Ingo AU - Sagoschen I AD - Department of Cardiology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany. FAU - Scibior, Barbara AU - Scibior B AD - Center for Thrombosis and Hemostasis (CTH), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany. FAU - Farmakis, Ioannis T AU - Farmakis IT AD - Center for Thrombosis and Hemostasis (CTH), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany. FAU - Keller, Karsten AU - Keller K AD - Department of Cardiology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany. AD - Center for Thrombosis and Hemostasis (CTH), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany. AD - Medical Clinic VII, University Hospital Heidelberg, Heidelberg, Germany. FAU - Graafen, Dirk AU - Graafen D AD - Department of Diagnostic and Interventional Radiology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany. FAU - Griemert, Eva-Verena AU - Griemert EV AD - Department of Anesthesiology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany. FAU - Vosseler, Markus AU - Vosseler M AD - Department of Cardiology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany. FAU - Treede, Hendrik AU - Treede H AD - Department for Cardiac and Vascular Surgery, University Medical Center Mainz of the Johannes Gutenberg-University Mainz, Mainz, Germany. FAU - Munzel, Thomas AU - Munzel T AD - Department of Cardiology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany. FAU - Knorr, Maike AU - Knorr M AD - Department of Cardiology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany. FAU - Gori, Tommaso AU - Gori T AD - Department of Cardiology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany. FAU - Konstantinides, Stavros AU - Konstantinides S AD - Center for Thrombosis and Hemostasis (CTH), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany. AD - Department of Cardiology, Democritus University of Thrace, Komotini, Greece. FAU - Hobohm, Lukas AU - Hobohm L AUID- ORCID: 0000-0002-4312-0366 AD - Department of Cardiology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany. lukas.hobohm@unimedizin-mainz.de. AD - Center for Thrombosis and Hemostasis (CTH), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany. lukas.hobohm@unimedizin-mainz.de. LA - eng PT - Journal Article DEP - 20231219 PL - Germany TA - Clin Res Cardiol JT - Clinical research in cardiology : official journal of the German Cardiac Society JID - 101264123 SB - IM MH - Female MH - Humans MH - Male MH - *Patient Care Team MH - Prospective Studies MH - Cohort Studies MH - *Pulmonary Embolism/diagnosis/epidemiology/therapy MH - Length of Stay MH - Thrombolytic Therapy PMC - PMC10954947 OTO - NOTNLM OT - Advanced therapies OT - Catheter-directed treatment OT - Pulmonary embolism OT - Pulmonary embolism response team OT - Systemic thrombolysis COIS- I. Sagoschen reports no conflicts of interest. B. Scibior reports no conflicts of interest. K. Keller reports no conflicts of interest. I.T. Farmakis reports no conflicts of interest. D. Graafen reports lecture/consultant fees from Siemens Healthineers. E.V. Griemert reports institutional grants and lecture fees from Edwards Lifesciences Services GmbH, Medtronic GmbH and TRACOE medical GmbH; all outside the submitted work. M. Vosseler reports no conflicts of interests. H. Treede reports no conflicts of interest. T. Munzel reports no conflict of interest. Maike Knorr reports no conflict of interest. T. G. has received grant support (CARIMA study) and speaker s honoraria from Novartis, speaker s honoraria from Boehringer Ingelheim, Daiichi-Sankyo, MSD, Pfizer - Bristol-Myers Squibb and Astra Zeneca, outside the submitted work. S.V. Konstantinides reports institutional grants and personal lecture/consultant fees from Bayer AG, Daiichi-Sankyo, and Boston Scientific; and personal lecture/consultant fees from Pfizer-Bristol-Myers Squibb and MSD, all outside the submitted work. L. Hobohm reports lecture/ consultant fees from MSD, Boston Scientific, INARI and Johnson&Johnson, outside the submitted work. EDAT- 2023/12/19 19:53 MHDA- 2024/03/21 12:48 PMCR- 2023/12/19 CRDT- 2023/12/19 11:13 PHST- 2023/08/20 00:00 [received] PHST- 2023/12/07 00:00 [accepted] PHST- 2024/03/21 12:48 [medline] PHST- 2023/12/19 19:53 [pubmed] PHST- 2023/12/19 11:13 [entrez] PHST- 2023/12/19 00:00 [pmc-release] AID - 10.1007/s00392-023-02364-4 [pii] AID - 2364 [pii] AID - 10.1007/s00392-023-02364-4 [doi] PST - ppublish SO - Clin Res Cardiol. 2024 Apr;113(4):581-590. doi: 10.1007/s00392-023-02364-4. Epub 2023 Dec 19. PMID- 38112423 OWN - NLM STAT- MEDLINE DCOM- 20250606 LR - 20250606 IS - 1538-4683 (Electronic) IS - 1061-5377 (Linking) VI - 33 IP - 4 DP - 2025 Jul-Aug 01 TI - Coronary Artery Bypass Surgery: Evidence-Based Practice. PG - 344-351 LID - 10.1097/CRD.0000000000000621 [doi] AB - Coronary artery bypass graft (CABG) surgery remains a pivotal cornerstone, offering established symptomatic alleviation and prognostic advantages for patients grappling with complex multivessel and left main coronary artery diseases. Despite the lucid guidance laid out by contemporary guidelines regarding the choice between CABG and percutaneous coronary intervention (PCI), a notable hesitation persists among certain patients, characterized by psychological reservations, knowledge gaps, or individual beliefs that sway their inclination toward surgical intervention. This comprehensive review critically synthesizes the prevailing guidelines, modern practices, and outcomes pertaining to CABG surgery, delving into an array of techniques and advancements poised to enhance both short-term and enduring surgical outcomes. The exploration encompasses advances in on-pump and off-pump procedures, conduit selection strategies encompassing the bilateral utilization of internal mammary artery and radial artery conduits, meticulous graft evaluation methodologies, and the panorama of minimally invasive approaches, including those assisted by robotic technology. Furthermore, the review navigates the terrain of hybrid coronary revascularization, shedding light on the pivotal roles of shared decision-making and the heart team in shaping treatment pathways. As a comprehensive compendium, this review not only navigates the intricate landscape of CABG surgery but also aligns it with contemporary practices, envisioning its trajectory within the evolving currents of healthcare dynamics. CI - Copyright (c) 2023 The Author(s). Published by Wolters Kluwer Health, Inc. FAU - Thuan, Phan Quang AU - Thuan PQ AD - From the Department of Adult Cardiovascular Surgery, University Medical Center, Ho Chi Minh City, Vietnam. FAU - Chuong, Pham Tran Viet AU - Chuong PTV AD - From the Department of Adult Cardiovascular Surgery, University Medical Center, Ho Chi Minh City, Vietnam. FAU - Nam, Nguyen Hoai AU - Nam NH AD - Department of Cardiovascular and Thoracic Surgery, Faculty of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Vietnam. FAU - Dinh, Nguyen Hoang AU - Dinh NH AD - From the Department of Adult Cardiovascular Surgery, University Medical Center, Ho Chi Minh City, Vietnam. AD - Department of Cardiovascular and Thoracic Surgery, Faculty of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Vietnam. LA - eng SI - ClinicalTrials.gov/NCT05329285 PT - Journal Article PT - Review DEP - 20231219 PL - United States TA - Cardiol Rev JT - Cardiology in review JID - 9304686 SB - IM MH - Humans MH - *Coronary Artery Bypass/methods MH - *Coronary Artery Disease/surgery MH - *Evidence-Based Practice OTO - NOTNLM OT - arterial conduits OT - coronary artery bypass grafting OT - coronary revascularization OT - graft patency OT - heart team OT - minimally invasive OT - quality control OT - robotic COIS- Disclosure: The authors declare no conflict of interest. EDAT- 2023/12/19 19:54 MHDA- 2025/06/06 12:33 CRDT- 2023/12/19 09:03 PHST- 2025/06/06 12:33 [medline] PHST- 2023/12/19 19:54 [pubmed] PHST- 2023/12/19 09:03 [entrez] AID - 00045415-990000000-00183 [pii] AID - 10.1097/CRD.0000000000000621 [doi] PST - ppublish SO - Cardiol Rev. 2025 Jul-Aug 01;33(4):344-351. doi: 10.1097/CRD.0000000000000621. Epub 2023 Dec 19. PMID- 38110111 OWN - NLM STAT- MEDLINE DCOM- 20240201 LR - 20240223 IS - 1096-0384 (Electronic) IS - 0003-9861 (Linking) VI - 752 DP - 2024 Feb TI - A proteomic approach to investigate the role of the MECP2 gene mutation in Rett syndrome redox regulatory pathways. PG - 109860 LID - S0003-9861(23)00359-4 [pii] LID - 10.1016/j.abb.2023.109860 [doi] AB - Mutations in the X-linked methyl-CpG-binding 2 (MECP2) gene lead to Rett Syndrome (RTT; OMIM 312750), a devasting neurodevelopmental disorder. RTT clinical manifestations are complex and with different degrees of severity, going from autistic-like behavior to loss of acquired speech, motor skills and cardiac problems. Furthermore, the correlation between the type of MECP2 mutation and the clinical phenotype is still not fully understood. Contextually, different genotypes can differently affect the patient's phenotype and omics methodologies such as proteomics could be an important tool for a molecular characterization of genotype/phenotype correlation. The aim of our study was focused on evaluating RTT oxidative stress (OS) responses related to specific MECP2 gene mutations by using proteomics and bioinformatics approaches. Primary fibroblasts isolated from patients affected by R133C and R255x mutations were compared to healthy controls (HC). After clustering primary dermal fibroblasts based on their specific MECP2 mutations, fibroblast-derived protein samples were qualitative and quantitative analyzed, using a label free quantification (LFQ) analysis by mass spectrometry (MS), achieving a preliminary correlation for RTT genotype/phenotype. Among the identified proteins involved in redox regulation pathways, NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1) was found to be absent in R255x cells, while it was present in R133C and in HC fibroblasts. Moreover, NQO1 aberrant gene regulation was also confirmed when cells were challenged with 100 muM hydrogen peroxide (H(2)O(2)). In conclusion, by employing a multidisciplinary approach encompassing proteomics and bioinformatics analyses, as well as molecular biology assays, the study uncovered phenotypic responses linked to specific MECP2 gene mutations. These findings contribute to a better understanding of the complexity of RTT molecular pathways, confirming the high heterogeneity among the patients. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Pasqui, Arianna AU - Pasqui A AD - Toscana Life Science Foundation, Siena, Italy; Department of Biotechnology, Chemistry and Pharmacy, University of Siena, 53100 Siena, Italy. FAU - Cicaloni, Vittoria AU - Cicaloni V AD - Toscana Life Science Foundation, Siena, Italy. FAU - Tinti, Laura AU - Tinti L AD - Toscana Life Science Foundation, Siena, Italy. FAU - Guiotto, Anna AU - Guiotto A AD - Plants for Human Health Institute, Animal Science Department, North Carolina State University, North Carolina Research Campus, Kannapolis, NC 28081, USA; Department of Environmental and Prevention Sciences, University of Ferrara, 44121 Ferrara, Italy. FAU - Tinti, Cristina AU - Tinti C AD - Toscana Life Science Foundation, Siena, Italy. FAU - Mori, Alessia AU - Mori A AD - Diabetes Unit, Department of Medicine, Surgery and Neurosciences, University of Siena Italy; Fondazione Umberto Di Mario ONLUS c/o Toscana Life Science, Siena, Italy; Tuscany Centre for Precision Medicine (CReMeP), Siena 53100, Italy. FAU - Bruttini, Marco AU - Bruttini M AD - Diabetes Unit, Department of Medicine, Surgery and Neurosciences, University of Siena Italy; Fondazione Umberto Di Mario ONLUS c/o Toscana Life Science, Siena, Italy; Tuscany Centre for Precision Medicine (CReMeP), Siena 53100, Italy. FAU - Hayek, Joussef AU - Hayek J AD - Toscana Life Science Foundation, Siena, Italy. FAU - Pecorelli, Alessandra AU - Pecorelli A AD - Plants for Human Health Institute, Animal Science Department, North Carolina State University, North Carolina Research Campus, Kannapolis, NC 28081, USA; Department of Environmental and Prevention Sciences, University of Ferrara, 44121 Ferrara, Italy. Electronic address: alessandra.pecorelli@unife.it. FAU - Salvini, Laura AU - Salvini L AD - Toscana Life Science Foundation, Siena, Italy. FAU - Valacchi, Giuseppe AU - Valacchi G AD - Plants for Human Health Institute, Animal Science Department, North Carolina State University, North Carolina Research Campus, Kannapolis, NC 28081, USA; Department of Environmental and Prevention Sciences, University of Ferrara, 44121 Ferrara, Italy; Department of Food and Nutrition, Kyung Hee University, Seoul 02447, Republic of Korea. Electronic address: gvalacc@ncsu.edu. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20231216 PL - United States TA - Arch Biochem Biophys JT - Archives of biochemistry and biophysics JID - 0372430 RN - BBX060AN9V (Hydrogen Peroxide) RN - 0 (Methyl-CpG-Binding Protein 2) RN - 0 (Proteins) RN - 0 (MECP2 protein, human) SB - IM MH - Humans MH - Hydrogen Peroxide MH - Methyl-CpG-Binding Protein 2/genetics MH - Mutation MH - Oxidation-Reduction MH - Phenotype MH - Proteins MH - Proteomics MH - *Rett Syndrome/genetics OTO - NOTNLM OT - MECP2 mutations OT - Oxidative stress OT - Precision medicine OT - Proteomics OT - Rett syndrome EDAT- 2023/12/19 00:41 MHDA- 2024/01/29 06:43 CRDT- 2023/12/18 19:27 PHST- 2023/11/02 00:00 [received] PHST- 2023/12/11 00:00 [revised] PHST- 2023/12/11 00:00 [accepted] PHST- 2024/01/29 06:43 [medline] PHST- 2023/12/19 00:41 [pubmed] PHST- 2023/12/18 19:27 [entrez] AID - S0003-9861(23)00359-4 [pii] AID - 10.1016/j.abb.2023.109860 [doi] PST - ppublish SO - Arch Biochem Biophys. 2024 Feb;752:109860. doi: 10.1016/j.abb.2023.109860. Epub 2023 Dec 16. PMID- 38108022 OWN - NLM STAT- MEDLINE DCOM- 20231219 LR - 20260120 IS - 1178-2048 (Electronic) IS - 1176-6344 (Print) IS - 1176-6344 (Linking) VI - 19 DP - 2023 TI - Renal Denervation in the Treatment of Resistant Hypertension and Difficult-to-Control Hypertension - Consensus Document of the Croatian Hypertension League - Croatian Society of Hypertension, Croatian Cardiac Society, Croatian Endovascular Initiative, Croatian Society for Diabetes and Metabolic Diseases, Croatian Renal Association, and Croatian Society of Family Physicians of the Croatian Medical Association. PG - 805-826 LID - 10.2147/VHRM.S422773 [doi] AB - Renal denervation (RDN) as a method of treating arterial hypertension (AH) was introduced in Croatia in 2012. A multidisciplinary team and a network of hospitals that diagnose and treat patients with severe forms of AH were established, and a very strict diagnostic-treatment algorithm was prepared. At monthly meetings patients with truly resistant hypertension who were candidates for RDN were discussed. According to the 2021 ESH position statement and 2023 ESH guidelines, RDN is considered an alternative and additional, not a competitive method of treating patients with various forms of AH which must be performed by following a structured procedure and the patient's preference should be considered. In view of the changes in the global scientific community, the Croatian Hypertension League brings this consensus document on RDN conducted with radiofrequency-based catheter, the only currently available method in Croatia. In this document, exclusion and inclusion criteria are shown, as well as three groups of patients in whom RDN could be considered. The new diagnostic-treatment algorithm is prepared and follow-up procedure is explained. In Croatia, RDN is reimbursed by the national insurance company, thus pharmacoeconomic analyses is also shown. Criteria required by an individual centre to be approved of RDN are listed, and plans for prospective research on RDN in Croatia, including the Croatian registry for RDN, are discussed. CI - (c) 2023 Jelakovic et al. FAU - Jelakovic, Bojan AU - Jelakovic B AUID- ORCID: 0000-0002-2546-4632 AD - School of Medicine University of Zagreb, Zagreb, Croatia. AD - Department of Nephrology, Hypertension, Dialysis and Transplantation, University Hospital Centre Zagreb, Zagreb, Croatia. FAU - Perkov, Drazen AU - Perkov D AUID- ORCID: 0000-0001-5398-059X AD - Department of Diagnostic and Interventional Radiology, University Hospital Centre Zagreb, Zagreb, Croatia. FAU - Barisic, Klara AU - Barisic K AUID- ORCID: 0009-0007-6002-0707 AD - Department of Nephrology, Hypertension, Dialysis and Transplantation, University Hospital Centre Zagreb, Zagreb, Croatia. FAU - Bukal, Nikolina AU - Bukal N AUID- ORCID: 0000-0002-7655-6078 AD - Department of Internal Medicine, Nephrology and Pulmonology, General Hospital "Dr. J. Bencevic", Slavonski Brod, Croatia. FAU - Gellineo, Lana AU - Gellineo L AD - Department of Nephrology, Hypertension, Dialysis and Transplantation, University Hospital Centre Zagreb, Zagreb, Croatia. FAU - Jelakovic, Ana AU - Jelakovic A AUID- ORCID: 0000-0002-9262-4667 AD - Department of Nephrology, Hypertension, Dialysis and Transplantation, University Hospital Centre Zagreb, Zagreb, Croatia. FAU - Josipovic, Josipa AU - Josipovic J AUID- ORCID: 0000-0001-5545-6484 AD - Croatian Catholic University, Zagreb, Croatia. AD - Department of Nephrology and Dialysis, University Hospital Centre Sestre Milosrdnice, Zagreb, Croatia. FAU - Prkacin, Ingrid AU - Prkacin I AUID- ORCID: 0000-0002-5830-7131 AD - Department for Emergency Medicine, Clinical Hospital Merkur, Zagreb, Croatia. FAU - Zeljkovic Vrkic, Tajana AU - Zeljkovic Vrkic T AD - Institute for Cardiovascular Prevention and Rehabilitation, Zagreb, Croatia. FAU - Zivko, Marijana AU - Zivko M AUID- ORCID: 0000-0002-3523-6262 AD - Department of Nephrology, Hypertension, Dialysis and Transplantation, University Hospital Centre Zagreb, Zagreb, Croatia. CN - On the behalf of Task force for the Resistant Hypertension and Renal Denervation of the Croatian Hypertension League LA - eng PT - Consensus Statement PT - Journal Article DEP - 20231211 PL - New Zealand TA - Vasc Health Risk Manag JT - Vascular health and risk management JID - 101273479 SB - IM MH - Humans MH - Croatia/epidemiology MH - Physicians, Family MH - Prospective Studies MH - Renal Artery/surgery MH - *Hypertension/diagnosis/surgery MH - Kidney MH - *Diabetes Mellitus MH - *Metabolic Diseases MH - Denervation/methods MH - Sympathectomy/adverse effects/methods MH - Blood Pressure MH - Treatment Outcome MH - *Catheter Ablation/adverse effects PMC - PMC10724019 OTO - NOTNLM OT - Croatia OT - catheter- radiofrequency ablation OT - consensus OT - hypertension OT - renal denervation COIS- The authors report no conflicts of interest in this work. EDAT- 2023/12/18 06:42 MHDA- 2023/12/19 06:41 PMCR- 2023/12/11 CRDT- 2023/12/18 05:10 PHST- 2023/07/13 00:00 [received] PHST- 2023/11/21 00:00 [accepted] PHST- 2023/12/19 06:41 [medline] PHST- 2023/12/18 06:42 [pubmed] PHST- 2023/12/18 05:10 [entrez] PHST- 2023/12/11 00:00 [pmc-release] AID - 422773 [pii] AID - 10.2147/VHRM.S422773 [doi] PST - epublish SO - Vasc Health Risk Manag. 2023 Dec 11;19:805-826. doi: 10.2147/VHRM.S422773. eCollection 2023. PMID- 38094997 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231214 IS - 2772-3747 (Electronic) IS - 2772-3747 (Linking) VI - 3 IP - 5 DP - 2023 Oct TI - Short-Term Outcomes Following Transcatheter Edge-to-Edge Repair: Insights From the OCEAN-Mitral Registry. PG - 766-773 LID - 10.1016/j.jacasi.2023.06.008 [doi] AB - BACKGROUND: Transcatheter edge-to-edge repair (TEER) is a less invasive treatment for patients with mitral regurgitation (MR). Limited safety and efficacy data of TEER with MitraClip, including the fourth-generation (G4) system, in a large cohort, are available. OBJECTIVES: This study aimed to summarize the initial experience of the TEER system in patients with MR from a large registry in Japan. METHODS: The OCEAN (Optimized CathEter vAlvular iNtervention)-Mitral Registry is an ongoing, prospective, investigator-initiated, multicenter, observational registry for patients with primary and secondary MR undergoing transcatheter mitral valve therapies. A total of 21 centers participated in the registry. Patients undergoing TEER were enrolled, and their characteristics, procedural details, and clinical outcomes were recorded. RESULTS: In total, 2,150 patients including 1,605 patients (75.0%) with secondary MR, were enrolled between April 2018 and June 2021. The median age was 80 years, and 43.7% were women. The median device and fluoroscopy times were 60 and 26 minutes, respectively. Those with the G4 system (618/2,150 [28.7%]) were significantly shorter than those with the second generation (G2) system (1,532/2,150 [71.3%]). Overall, 94.6% met acute procedural success without significant differences between the 2 systems (G2 94.7% vs G4 94.6%; P = 0.961). CONCLUSIONS: The OCEAN-Mitral registry has demonstrated the short-term outcomes of TEER systems, including the G4 system, in symptomatic patients with primary and secondary MR. The acute procedural success rate in the G2 system was excellent, and that in the G4 system was expected to improve with the multidisciplinary heart valve team approach. (Japanese Registry study of valvular heart diseases treatment and prognosis; UMIN000023653). CI - (c) 2023 The Authors. FAU - Saji, Mike AU - Saji M AD - Department of Cardiology, Sakakibara Heart Institute, Fuchu, Japan. AD - Division of Cardiovascular Medicine, Department of Internal Medicine, Toho University Faculty of Medicine, Tokyo, Japan. FAU - Yamamoto, Masanori AU - Yamamoto M AD - Department of Cardiology, Toyohashi Heart Center, Toyohashi, Japan. AD - Department of Cardiology, Nagoya Heart Center, Nagoya, Japan. AD - Department of Cardiology, Gifu Heart Center, Gifu, Japan. FAU - Kubo, Shunsuke AU - Kubo S AD - Department of Cardiology, Kurashiki Central Hospital, Kurashiki, Japan. FAU - Asami, Masahiko AU - Asami M AD - Division of Cardiology, Mitsui Memorial Hospital, Tokyo, Japan. FAU - Enta, Yusuke AU - Enta Y AD - Department of Cardiology, Sendai Kosei Hospital, Sendai, Japan. FAU - Shirai, Shinichi AU - Shirai S AD - Division of Cardiology, Kokura Memorial Hospital, Kitakyushu, Japan. FAU - Izumo, Masaki AU - Izumo M AD - Division of Cardiology, St. Marianna University School of Medicine Hospital, Kawasaki, Japan. FAU - Mizuno, Shingo AU - Mizuno S AD - Department of Cardiology, Shonan Kamakura General Hospital, Kanagawa, Japan. FAU - Watanabe, Yusuke AU - Watanabe Y AD - Department of Cardiology, Teikyo University School of Medicine, Tokyo, Japan. FAU - Amaki, Makoto AU - Amaki M AD - Department of Cardiology, National Cerebral and Cardiovascular Center, Suita, Japan. FAU - Kodama, Kazuhisa AU - Kodama K AD - Division of Cardiology, Saiseikai Kumamoto Hospital Cardiovascular Center, Kumamoto, Japan. FAU - Yamaguchi, Junichi AU - Yamaguchi J AD - Department of Cardiology Tokyo Woman's Medical University, Tokyo, Japan. FAU - Nakajima, Yoshifumi AU - Nakajima Y AD - Division of Cardiology, Department of Internal Medicine, Iwate Medical University, Iwate, Japan. FAU - Naganuma, Toru AU - Naganuma T AD - Department of Cardiology, New Tokyo Hospital, Chiba, Japan. FAU - Bota, Hiroki AU - Bota H AD - Department of Cardiology, Sapporo Higashi Tokushukai Hospital, Sapporo, Japan. FAU - Ohno, Yohei AU - Ohno Y AD - Department of Cardiology, Tokai University School of Medicine, Isehara, Japan. FAU - Yamawaki, Masahiro AU - Yamawaki M AD - Department of Cardiology, Saiseikai Yokohama City Eastern Hospital, Kanagawa, Japan. FAU - Ueno, Hiroshi AU - Ueno H AD - Second Department of Internal Medicine, Toyama University Hospital, Toyama, Japan. FAU - Mizutani, Kazuki AU - Mizutani K AD - Division of Cardiology, Department of Medicine, Kinki University Faculty of Medicine, Osaka, Japan. FAU - Adachi, Yuya AU - Adachi Y AD - Department of Cardiology, Toyohashi Heart Center, Toyohashi, Japan. AD - Department of Cardiology, Nagoya Heart Center, Nagoya, Japan. FAU - Otsuka, Toshiaki AU - Otsuka T AD - Department of Hygiene and Public Health, Nippon Medical School, Tokyo, Japan. FAU - Hayashida, Kentaro AU - Hayashida K AD - Department of Cardiology, Keio University School of Medicine, Tokyo, Japan. CN - OCEAN-Mitral Investigators LA - eng PT - Journal Article DEP - 20230829 PL - United States TA - JACC Asia JT - JACC. Asia JID - 9918452380106676 PMC - PMC10715870 OTO - NOTNLM OT - G4 OT - OCEAN OT - mitral regurgitation OT - transcatheter mitral valve repair COIS- The OCEAN-Mitral registry, which is part of the OCEAN-SHD registry, is supported by Edwards Lifesciences, Medtronic Japan, Boston Scientific, Abbott Medical Japan, and Daiichi Sankyo. Drs Saji, Kubo, Izumo, Watanabe, and Amaki are clinical proctors of transcatheter edge-to-edge repair for Abbott Medical, and have received consultant fees from Abbott Medical. Drs Asami and Kodama have received speaker fees from Abbott Medical. Drs Yamamoto and Nakajima are clinical proctors of transcatheter edge-to-edge repair for Abbott Medical, and have received lecture fees from Abbott Medical. Dr Yamaguchi is clinical proctor of transcatheter edge-to-edge repair for Abbott Medical, and has received a lecture fee and a scholarship donation from Abbott Medical. Dr Ohno has received consultant, advisor, and speaker fees from Abbott Medical. Drs Enta, Shirai, Mizuno, Naganuma, and Bota are clinical proctors of transcatheter edge-to-edge repair for Abbott Medical. All other authors have reported that they have no relationships relevant to the content of this paper to disclose. EDAT- 2023/12/14 06:42 MHDA- 2023/12/14 06:43 PMCR- 2023/08/29 CRDT- 2023/12/14 04:26 PHST- 2023/02/17 00:00 [received] PHST- 2023/06/01 00:00 [revised] PHST- 2023/06/19 00:00 [accepted] PHST- 2023/12/14 06:43 [medline] PHST- 2023/12/14 06:42 [pubmed] PHST- 2023/12/14 04:26 [entrez] PHST- 2023/08/29 00:00 [pmc-release] AID - S2772-3747(23)00185-0 [pii] AID - 10.1016/j.jacasi.2023.06.008 [doi] PST - epublish SO - JACC Asia. 2023 Aug 29;3(5):766-773. doi: 10.1016/j.jacasi.2023.06.008. eCollection 2023 Oct. PMID- 38094126 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231214 IS - 2297-055X (Print) IS - 2297-055X (Electronic) IS - 2297-055X (Linking) VI - 10 DP - 2023 TI - Early outcome of endoscopic mitral valve surgery in elderly patients: a high-volume single center experience. PG - 1182752 LID - 10.3389/fcvm.2023.1182752 [doi] LID - 1182752 AB - INTRODUCTION: Despite increasing use of transcatheter approaches, endoscopic mitral valve surgery (MVS) remains an established option for treatment of mitral regurgitation (MR). Nevertheless, as perioperative risk increases with age, outcome of endoscopic MVS in elderly patients is uncertain. METHODS: We retrospectively analyzed 756 consecutive patients with MR >/=2, who underwent minimally-invasive MVS at our institution between 2016 and 2022. Patients were stratified by age >/=75 (elderly-group; n = 91) or <75 years (control-group; n = 665). All patients received endoscopic MVS via right anterolateral minithoracotomy with non-rib spreading soft tissue retraction and 3D-camera visualization. RESULTS: Overall surgical risk was increased in the elderly-group (median age of 77 (76-80) years vs. 58 (51-67) years, p < 0.001) with STS-PROM Scores of 1.9% vs. 0.4% (p < 0.001) and increased prevalence of hypertension, diabetes, coronary artery disease and atrial fibrillation (AFib). Elderly patients were also more symptomatic (NYHA class III 45.7% vs. 29.8%; p = 0.002). Axillo-femoral perfusion was more frequently used in the elderly-group (27.5% vs. 4.2%; p < 0.001). Cross-clamp and cardiopulmonary bypass times were similar. Rate of MV repair was 85.7% vs. 93.8% (p = 0.005). Closure of the left atrial appendage was more frequently performed in the elderly-group (45.1% vs. 23.9%; p < 0.001), whereas rate of concomitant tricuspid valve repair was similar (11.0% vs. 8.9%; p = 0.511). Postoperative complications including perioperative hemodialysis (3.3% vs. 2.9%; p = 0.739), low cardiac output (5.3% vs. 3.8%; p = 0.393), perioperative stroke (1.1% vs. 0.15%; p = 0.224) and myocardial infarction (0% vs. 0.15%) were favorably low in both groups. Acute mortality at 30 days was 2.2% vs. 0.4% (p = 0.112). CONCLUSION: Despite increased prevalence of outcome-relevant comorbidities and surgical risk, perioperative outcome of patients aged >/=75 years undergoing endoscopic MVS is favorable. Therefore, endoscopic MVS is a valuable therapeutic option for selected elderly patients and should be taken in consideration during routine heart-team discussion. CI - (c) 2023 Pausch, Bhadra, Hua, Stolfa, Kuhlmann, Voss, Girdauskas, Reichenspurner and Conradi. FAU - Pausch, Jonas AU - Pausch J AD - Department of Cardiovascular Surgery, University Heart and Vascular Center Hamburg, Hamburg, Germany. FAU - Bhadra, Oliver D AU - Bhadra OD AD - Department of Cardiovascular Surgery, University Heart and Vascular Center Hamburg, Hamburg, Germany. FAU - Hua, Xiaoqin AU - Hua X AD - Department of Cardiovascular Surgery, University Heart and Vascular Center Hamburg, Hamburg, Germany. FAU - Stolfa, Philipp AU - Stolfa P AD - Department of Cardiovascular Surgery, University Heart and Vascular Center Hamburg, Hamburg, Germany. FAU - Kuhlmann, Carolin AU - Kuhlmann C AD - Department of Cardiovascular Surgery, University Heart and Vascular Center Hamburg, Hamburg, Germany. FAU - Voss, Mirko AU - Voss M AD - Department of Cardiovascular Surgery, University Heart and Vascular Center Hamburg, Hamburg, Germany. FAU - Girdauskas, Evaldas AU - Girdauskas E AD - Department of Cardiovascular Surgery, University Heart and Vascular Center Hamburg, Hamburg, Germany. AD - Department of Cardiovascular and Thoracic Surgery, University Hospital Augsburg, Augsburg, Germany. FAU - Reichenspurner, Hermann AU - Reichenspurner H AD - Department of Cardiovascular Surgery, University Heart and Vascular Center Hamburg, Hamburg, Germany. FAU - Conradi, Lenard AU - Conradi L AD - Department of Cardiovascular Surgery, University Heart and Vascular Center Hamburg, Hamburg, Germany. LA - eng PT - Journal Article DEP - 20231128 PL - Switzerland TA - Front Cardiovasc Med JT - Frontiers in cardiovascular medicine JID - 101653388 PMC - PMC10718653 OTO - NOTNLM OT - endoscopic mitral valve surgery OT - minimally-invasive mitral valve surgery OT - mitral regurgitation OT - mitral valve repair OT - transcatheter mitral valve repair COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor [PD] declared a past co-authorship with the author(s) [ODB, HR, LC]. EDAT- 2023/12/14 06:42 MHDA- 2023/12/14 06:43 PMCR- 2023/01/01 CRDT- 2023/12/14 04:10 PHST- 2023/03/09 00:00 [received] PHST- 2023/11/07 00:00 [accepted] PHST- 2023/12/14 06:43 [medline] PHST- 2023/12/14 06:42 [pubmed] PHST- 2023/12/14 04:10 [entrez] PHST- 2023/01/01 00:00 [pmc-release] AID - 10.3389/fcvm.2023.1182752 [doi] PST - epublish SO - Front Cardiovasc Med. 2023 Nov 28;10:1182752. doi: 10.3389/fcvm.2023.1182752. eCollection 2023. PMID- 38093934 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241202 IS - 0970-9134 (Print) IS - 0973-7723 (Electronic) IS - 0970-9134 (Linking) VI - 39 IP - Suppl 2 DP - 2023 Dec TI - The modified branch-first open repair of thoracoabdominal aortic aneurysms-video article. PG - 363-364 LID - 10.1007/s12055-023-01563-y [doi] AB - Open thoracoabdominal aortic aneurysm (TAAA) surgeries are complex and challenging that warrant an experienced multidisciplinary team effort to achieve good results. We present a technical description of the modified branch-first technique (MBFT) of open TAAA repair which helps minimize overall morbidity and mortality associated with the procedure. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12055-023-01563-y. CI - (c) Indian Association of Cardiovascular-Thoracic Surgeons 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. FAU - Hiremath, Niranjan AU - Hiremath N AUID- ORCID: 0000-0001-9639-1242 AD - St. Michael's Hospital, University of Toronto, Toronto, M5B 1W8 Canada. GRID: grid.17063.33. ISNI: 0000 0001 2157 2938 FAU - Park, Woosup Michael AU - Park WM AD - Cleveland Clinic Foundation, Cleveland, OH USA. GRID: grid.239578.2. ISNI: 0000 0001 0675 4725 LA - eng PT - Journal Article DEP - 20230729 PL - India TA - Indian J Thorac Cardiovasc Surg JT - Indian journal of thoracic and cardiovascular surgery JID - 8700105 PMC - PMC10713882 OTO - NOTNLM OT - Aortic aneurysm OT - Aortic surgery OT - Cardiovascular surgery OT - Modified branch-first technique OT - Thoracoabdominal aortic aneurysm COIS- Conflict of interestThe authors have no conflicts of interest pertaining to this article. EDAT- 2023/12/14 06:42 MHDA- 2023/12/14 06:43 PMCR- 2024/12/01 CRDT- 2023/12/14 04:03 PHST- 2023/05/04 00:00 [received] PHST- 2023/06/19 00:00 [revised] PHST- 2023/06/26 00:00 [accepted] PHST- 2023/12/14 06:43 [medline] PHST- 2023/12/14 06:42 [pubmed] PHST- 2023/12/14 04:03 [entrez] PHST- 2024/12/01 00:00 [pmc-release] AID - 1563 [pii] AID - 10.1007/s12055-023-01563-y [doi] PST - ppublish SO - Indian J Thorac Cardiovasc Surg. 2023 Dec;39(Suppl 2):363-364. doi: 10.1007/s12055-023-01563-y. Epub 2023 Jul 29. PMID- 38093471 OWN - NLM STAT- MEDLINE DCOM- 20240511 LR - 20250730 IS - 1365-2648 (Electronic) IS - 0309-2402 (Linking) VI - 80 IP - 6 DP - 2024 Jun TI - Effects of a collaborative health management model on people with congestive heart failure: A systematic review and meta-analysis. PG - 2290-2307 LID - 10.1111/jan.16011 [doi] AB - AIM: To determine the effects of collaborative health management of congestive heart failure through the rigorous evaluation and extraction of evidence. BACKGROUND: Over the past two decades, cardiovascular disease has been the leading cause of death worldwide. Multidisciplinary team intervention for congestive heart failure has increased with population ageing and congestive heart failure incidence rate as well as cost of care. However, the effectiveness and feasibility of collaborative health management need to be explored. DESIGN: Systematic review and meta-analysis. METHODS: We conducted systematic literature searches in the Cochrane Library, PubMed, CINAHL and Medline for articles published between 2002 and 2022. After screening based on the inclusion and exclusion criteria, 13 articles were included in a rigorous review and evidence extraction process, evaluated methodological quality using the Jadad Quality Scale. Statistical heterogeneity was evaluated using Review Manager (RevMan Version 5.4) for the meta-analysis. RESULTS: In this study, a systematic review and meta-analysis were performed on 13 studies regarding the collaborative health management of people with congestive heart failure. The common result is that the collaborative health management model enables the enhancement of self-care and monitoring abilities, the strengthening of cardiac function, the alleviation of physiological and psychological symptoms and the improvement of readmission rates, mortality rate and quality of life. CONCLUSION: The congestive heart failure collaborative health management model could decrease the hospitalization rate related to congestive heart failure, all-cause mortality rate, and all-cause hospitalization rate, and improve the quality of life. IMPLICATIONS FOR PRACTICE: The collaborative health management model could effectively coordinate interdisciplinary team cooperation and provide information, which decreases hospitalization and mortality risks and improves their quality of life. NO PATIENT OR PUBLIC CONTRIBUTION: Our paper is a systematic review and meta-analysis, and such details do not apply to our work. WHAT DOES THIS PAPER CONTRIBUTE TO THE WIDER GLOBAL CLINICAL COMMUNITY?: The Collaborative Health Management Model provides in-depth insights, aiding in the design tailored to the specific circumstances of each country. Highlighting its critical role in the context of a global shortage of nursing staff, the model emphasizes the integration of multidisciplinary professional roles and the strengthening of collaboration as essential elements in addressing challenges posed by workforce shortages. Implementation of the Collaborative Health Management Model not only enhances patient care outcomes but also relieves pressure on healthcare systems, lowers medical costs, and addresses challenges arising from the shortage of nursing staff. Consequently, this model not only contributes to individual patient care improvement but also holds broader implications for enhancing the efficiency and sustainability of global healthcare systems. TRIAL AND PROTOCOL REGISTRATION: The detailed study protocol can be found on the PROSPERO website. CI - (c) 2023 John Wiley & Sons Ltd. FAU - Chen, Chih Wen AU - Chen CW AUID- ORCID: 0009-0001-8277-3829 AD - School of Nursing, National Taipei University of Nursing and Health Sciences, Taipei, Taiwan. AD - Antai Medical Care Cooperation Antai Tian-Sheng Memorial Hospital/Department of Nursing/Nurse Practitioner Leader, Tungkang, Taiwan. FAU - Lee, Mei-Chen AU - Lee MC AUID- ORCID: 0000-0002-8710-8676 AD - School of Nursing, National Taipei University of Nursing and Health Sciences, Taipei, Taiwan. FAU - Wu, Shu-Fang Vivienne AU - Wu SV AUID- ORCID: 0000-0003-1563-5618 AD - School of Nursing, National Taipei University of Nursing and Health Sciences, Taipei, Taiwan. AD - Queensland University of Technology, Brisbane City, Australia. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20231213 PL - England TA - J Adv Nurs JT - Journal of advanced nursing JID - 7609811 SB - IM MH - Humans MH - *Heart Failure/therapy MH - Aged MH - Patient Care Team/organization & administration MH - Quality of Life/psychology MH - Female MH - Male MH - Aged, 80 and over MH - Middle Aged OTO - NOTNLM OT - heart failure OT - meta-analysis OT - mortality OT - patient care team OT - systematic review EDAT- 2023/12/14 06:42 MHDA- 2024/05/11 19:44 CRDT- 2023/12/14 00:53 PHST- 2023/10/16 00:00 [revised] PHST- 2023/06/29 00:00 [received] PHST- 2023/11/26 00:00 [accepted] PHST- 2024/05/11 19:44 [medline] PHST- 2023/12/14 06:42 [pubmed] PHST- 2023/12/14 00:53 [entrez] AID - 10.1111/jan.16011 [doi] PST - ppublish SO - J Adv Nurs. 2024 Jun;80(6):2290-2307. doi: 10.1111/jan.16011. Epub 2023 Dec 13. PMID- 38090346 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231213 IS - 2225-319X (Print) IS - 2304-1021 (Electronic) IS - 2225-319X (Linking) VI - 12 IP - 6 DP - 2023 Nov 27 TI - Obstetric considerations for aortopathy in pregnancy. PG - 526-535 LID - 10.21037/acs-2023-adw-0164 [doi] AB - Aortic dissection (AD) associated with pregnancy can have catastrophic consequences for the mother and/or fetus. AD occurs in 4-5 per 1,000,000 pregnancies and, despite its rarity, is the third most frequent maternal cardiovascular cause of death. AD associated with pregnancy is most likely to occur in the third trimester or postpartum period. In individuals with genetic aortopathy, pregnancy is considered a high-risk time for AD. There are management strategies in the preconception, antepartum, delivery and postpartum periods to optimize patient care. A multi-disciplinary team that includes capability to perform cardiovascular surgery is critical. Imaging modalities including maternal echocardiogram and magnetic resonance imaging can be safely performed in pregnancy for surveillance of the aortic size. Computed tomography (CT) scan is reserved for scenarios where there is a high index of suspicion for AD in a pregnant person to limit fetal exposure to radiation. After counseling about the potential risks of a pregnancy, the decision to pursue pregnancy is ultimately at the discretion of the individual. The duty of the cardio-obstetric team is to ensure that the patient and their family understand the risks of a pregnancy and the plan of care. CI - 2023 Annals of Cardiothoracic Surgery. All rights reserved. FAU - Whelan, Anna R AU - Whelan AR AD - Department of Maternal-Fetal Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA. FAU - Ringel, Myles E AU - Ringel ME AD - Brown University, Providence, RI, USA. FAU - Shalhub, Sherene AU - Shalhub S AD - Division of Vascular and Endovascular Surgery, Department of Surgery, Oregon Health & Science University, Portland, OR, USA. FAU - Russo, Melissa L AU - Russo ML AD - Department of Maternal-Fetal Medicine, Warren Alpert School of Medicine, Brown University, Providence, RI, USA. LA - eng PT - Journal Article PT - Review DEP - 20231120 PL - China TA - Ann Cardiothorac Surg JT - Annals of cardiothoracic surgery JID - 101605877 PMC - PMC10711402 OTO - NOTNLM OT - Aortic dissection (AD) OT - aortopathy OT - cardio-obstetrics OT - pregnancy COIS- Conflicts of Interest: The authors have no conflicts of interest to declare. EDAT- 2023/12/13 18:42 MHDA- 2023/12/13 18:43 PMCR- 2023/11/27 CRDT- 2023/12/13 13:07 PHST- 2023/09/05 00:00 [received] PHST- 2023/10/22 00:00 [accepted] PHST- 2023/12/13 18:43 [medline] PHST- 2023/12/13 18:42 [pubmed] PHST- 2023/12/13 13:07 [entrez] PHST- 2023/11/27 00:00 [pmc-release] AID - acs-12-06-526 [pii] AID - 10.21037/acs-2023-adw-0164 [doi] PST - ppublish SO - Ann Cardiothorac Surg. 2023 Nov 27;12(6):526-535. doi: 10.21037/acs-2023-adw-0164. Epub 2023 Nov 20. PMID- 38088175 OWN - NLM STAT- MEDLINE DCOM- 20240118 LR - 20240401 IS - 1941-3297 (Electronic) IS - 1941-3289 (Linking) VI - 17 IP - 1 DP - 2024 Jan TI - Case Implementing 2022 AHA/ACC/HFSA Guidelines: Heart Failure Management in Pregnancy: Early Planning, Close Surveillance, and Multidisciplinary Care. PG - e010580 LID - 10.1161/CIRCHEARTFAILURE.123.010580 [doi] FAU - Chandra, Neha V AU - Chandra NV AD - Division of Cardiology, Department of Medicine, University of California, Los Angeles (N.V.C., M.Y.K.). FAU - Stroud, Steven AU - Stroud S AUID- ORCID: 0009-0002-5183-6185 AD - Advanced Heart Failure Center, Department of Cardiology, Oklahoma Heart Institute, Tulsa (S.S.). FAU - Kamath, Megan Y AU - Kamath MY AD - Division of Cardiology, Department of Medicine, University of California, Los Angeles (N.V.C., M.Y.K.). LA - eng PT - Journal Article DEP - 20231213 PL - United States TA - Circ Heart Fail JT - Circulation. Heart failure JID - 101479941 SB - IM MH - Humans MH - Pregnancy MH - United States MH - Female MH - *Heart Failure/diagnosis/therapy MH - American Heart Association MH - *Cardiology OTO - NOTNLM OT - adult OT - clinical guidelines OT - congestive heart failure OT - female OT - pregnancy COIS- Disclosures None. EDAT- 2023/12/13 06:42 MHDA- 2024/01/18 06:43 CRDT- 2023/12/13 05:27 PHST- 2024/01/18 06:43 [medline] PHST- 2023/12/13 06:42 [pubmed] PHST- 2023/12/13 05:27 [entrez] AID - 10.1161/CIRCHEARTFAILURE.123.010580 [doi] PST - ppublish SO - Circ Heart Fail. 2024 Jan;17(1):e010580. doi: 10.1161/CIRCHEARTFAILURE.123.010580. Epub 2023 Dec 13. PMID- 38085860 OWN - NLM STAT- MEDLINE DCOM- 20231220 LR - 20250601 IS - 1473-6500 (Electronic) IS - 0952-7907 (Linking) VI - 37 IP - 1 DP - 2024 Feb 1 TI - Team-based care of the thoracic surgical patient. PG - 79-85 LID - 10.1097/ACO.0000000000001324 [doi] AB - PURPOSE OF REVIEW: Although team-based care has been shown in many sectors to improve outcomes, very little work has been done with the thoracic surgical patient. This review article focuses on this and, extrapolating from other closely related surgical fields, teamwork in thoracic surgery will be reviewed for outcome efficacy and substance. RECENT FINDINGS: The optimal team has been shown to display behaviors that allow them to model future needs, predict disaster, be adaptable to change, and promote team cohesiveness all with a positive effect on perioperative outcome. The suboptimal team will have transactional leadership, poor communication, ineffective conflict resolution, and hold rigid beliefs about other team members. SUMMARY: To improve outcome, the thoracic surgical team, centered on the anesthesiologist and surgeon, will display the 'Big 5' attributes of highly effective teams. There are attributes of poor teams, which the dyad should avoid in order to increase the team's function and thus outcome. CI - Copyright (c) 2023 Wolters Kluwer Health, Inc. All rights reserved. FAU - Slowey, Charlie AU - Slowey C AD - Department of Anesthesiology and Critical Care, Orleans Street, Baltimore, Maryland, USA. FAU - Abernathy, Jake AU - Abernathy J LA - eng PT - Journal Article PT - Review DEP - 20231129 PL - United States TA - Curr Opin Anaesthesiol JT - Current opinion in anaesthesiology JID - 8813436 SB - IM MH - Humans MH - *Patient Care Team MH - Leadership MH - *Thoracic Surgery MH - Patients EDAT- 2023/12/12 18:42 MHDA- 2023/12/20 06:42 CRDT- 2023/12/12 14:33 PHST- 2023/12/20 06:42 [medline] PHST- 2023/12/12 18:42 [pubmed] PHST- 2023/12/12 14:33 [entrez] AID - 00001503-202402000-00014 [pii] AID - 10.1097/ACO.0000000000001324 [doi] PST - ppublish SO - Curr Opin Anaesthesiol. 2024 Feb 1;37(1):79-85. doi: 10.1097/ACO.0000000000001324. Epub 2023 Nov 29. PMID- 38085353 OWN - NLM STAT- MEDLINE DCOM- 20240126 LR - 20241023 IS - 1432-0711 (Electronic) IS - 0932-0067 (Print) IS - 0932-0067 (Linking) VI - 309 IP - 2 DP - 2024 Feb TI - Unraveling the challenges of intravenous leiomyomatosis: a retrospective analysis of 11 cases. PG - 621-629 LID - 10.1007/s00404-023-07308-x [doi] AB - OBJECTIVE: This study provides a concise overview of diagnostic and treatment strategies for intravenous leiomyomatosis (IVL), a rare disease with nonspecific clinical manifestations, based on cases from a tertiary referral hospital in China. METHODS: We retrospectively analyzed 11 premenopausal patients with confirmed IVL between 2018 and 2022. Clinical data from Ultrasound, Enhanced CT, and MRI were studied, along with surgical details, postoperative pathology, and follow-up information. RESULTS: Premenopausal patients showed no disease-specific symptoms, with 90.9% having a history of gynecological or obstetric surgery, and 72.7% having prior uterine fibroids. Cardiac involvement was evident in two cases, with echocardiography detecting abnormal floating masses from the inferior vena cava. Pelvic ultrasound indicated leiomyoma in 90.9% of cases, with >/= 50 mm size. Surgery was the primary treatment, and lesions above the internal iliac vein resulted in significantly higher intraoperative blood loss (median 1300 ml vs. 50 ml, p = 0.005) and longer hospital stays (median 10 days vs. 4 days, p = 0.026). Three patients with lesions above the inferior vena cava required combined surgery with cardiac specialists. Recurrence occurred in 2 out of 11 patients with incomplete lesion resection. CONCLUSIONS: IVL mainly affects premenopausal women with uterine masses, primarily in the pelvic cavity (Stage I). Pelvic ultrasound aids early screening, while Enhanced CT or MR assists in diagnosing and assessing venous lesions. Complete resection is crucial to prevent recurrence. Lesions invading the internal iliac vein and above pose higher risks during surgery. A multidisciplinary team approach is essential for patients with lesions above the inferior vena cava, with simultaneous surgery as a potential treatment option. CI - (c) 2023. The Author(s). FAU - Wang, Qun AU - Wang Q AUID- ORCID: 0000-0003-4969-718X AD - Department of Gynecology and Obstetrics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin Er Road, Shanghai, 200025, China. FAU - Liu, Hua AU - Liu H AD - Department of Gynecology and Obstetrics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin Er Road, Shanghai, 200025, China. FAU - Feng, Weiwei AU - Feng W AD - Department of Gynecology and Obstetrics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin Er Road, Shanghai, 200025, China. wfeng7347@aliyun.com. LA - eng PT - Journal Article DEP - 20231212 PL - Germany TA - Arch Gynecol Obstet JT - Archives of gynecology and obstetrics JID - 8710213 SB - IM MH - Humans MH - Female MH - Retrospective Studies MH - *Leiomyomatosis/diagnostic imaging/surgery/pathology MH - *Heart Neoplasms/diagnostic imaging/surgery/pathology MH - Vena Cava, Inferior/diagnostic imaging/surgery/pathology MH - Ultrasonography MH - *Uterine Neoplasms/diagnostic imaging/surgery/pathology MH - *Vascular Neoplasms/diagnostic imaging/surgery/pathology PMC - PMC10808418 OTO - NOTNLM OT - IVL OT - Intravenous leiomyomatosis OT - Leiomyoma OT - Uterine fibroids COIS- The authors declare that they have no competing interests. EDAT- 2023/12/12 12:43 MHDA- 2024/01/26 06:43 PMCR- 2023/12/12 CRDT- 2023/12/12 11:07 PHST- 2023/07/28 00:00 [received] PHST- 2023/11/14 00:00 [accepted] PHST- 2024/01/26 06:43 [medline] PHST- 2023/12/12 12:43 [pubmed] PHST- 2023/12/12 11:07 [entrez] PHST- 2023/12/12 00:00 [pmc-release] AID - 10.1007/s00404-023-07308-x [pii] AID - 7308 [pii] AID - 10.1007/s00404-023-07308-x [doi] PST - ppublish SO - Arch Gynecol Obstet. 2024 Feb;309(2):621-629. doi: 10.1007/s00404-023-07308-x. Epub 2023 Dec 12. PMID- 38078413 OWN - NLM STAT- MEDLINE DCOM- 20231216 LR - 20240519 IS - 1744-8298 (Electronic) IS - 1479-6678 (Linking) VI - 19 IP - 14 DP - 2023 Nov TI - Long-term prognosis in patients undergoing redo-isolated aortic valve replacement. PG - 685-694 LID - 10.2217/fca-2023-0050 [doi] AB - Aim: To evaluate clinical outcomes after redo aortic valve replacement (AVR) with sutured valves, versus valve-in-valve transcatheter aortic valve replacement (ViV-TAVR), versus sutureless valves. Methods: We identified 113 consecutive patients undergoing redo AVR with either ViV-TAVR, redo-sutured and redo-sutureless valves between August 2010 to March 2020. Heart-team made the decision whether patient should undergo redo-sutureless versus ViV-TAVR, versus redo-sutured AVR. Results: Preoperatively, redo-sutured (n = 57), ViV-TAVR (n = 31) and redo-sutureless (n = 25) patients were compared. Postoperatively, after propensity-adjustment analysis, the redo surgical aortic valve replacement group had a higher incidence of new postoperative atrial fibrillation (POAF; p = 0.04) compared with redo-sutureless group. Follow-up outcomes analysis did not show differences among groups. Conclusion: Patients undergoing redo-sutureless AVR experienced a higher incidence of POAF compared with patients undergoing redo-sutured. FAU - Dokollari, Aleksander AU - Dokollari A AUID- ORCID: 0000-0002-9928-3316 AD - Cardiovascular Research Institute Maastricht - CARIM, Maastricht University Medical Centre, Maastricht, Netherlands. AD - Cardiac Surgery Department, St. Boniface Hospital, University of Manitoba, Winnipeg M3B1W7, Canada. FAU - Torregrossa, Gianluca AU - Torregrossa G AD - Lankenau Institute for Medical Research, Wynnewood, PA 19096, USA. FAU - Sicouri, Serge AU - Sicouri S AD - Lankenau Institute for Medical Research, Wynnewood, PA 19096, USA. FAU - Cameli, Matteo AU - Cameli M AD - Department of Medical Biotechnologies, Division of Cardiology, University Hospital of Siena, Siena, Italy. FAU - Mandoli, Giulia Elena AU - Mandoli GE AD - Department of Medical Biotechnologies, Division of Cardiology, University Hospital of Siena, Siena, Italy. FAU - Kjelstrom, Stephanie AU - Kjelstrom S AD - Lankenau Institute for Medical Research, Wynnewood, PA 19096, USA. FAU - Prifti, Edvin AU - Prifti E AD - Division of Cardiac Surgery University Hospital Center "Mother Teresa" Tirana Albania. FAU - Veshti, Altin AU - Veshti A AD - Division of Cardiac Surgery University Hospital Center "Mother Teresa" Tirana Albania. FAU - Bonacchi, Massimo AU - Bonacchi M AD - Department of Experimental & Clinical Medicine, University of Florence, Firenze, Italy. FAU - Gelsomino, Sandro AU - Gelsomino S AD - Cardiovascular Research Institute Maastricht - CARIM, Maastricht University Medical Centre, Maastricht, Netherlands. LA - eng PT - Journal Article DEP - 20231211 PL - England TA - Future Cardiol JT - Future cardiology JID - 101239345 SB - IM MH - Humans MH - Aortic Valve/surgery MH - *Heart Valve Prosthesis Implantation MH - Treatment Outcome MH - Risk Factors MH - *Bioprosthesis MH - Prosthesis Design MH - *Heart Valve Prosthesis MH - *Transcatheter Aortic Valve Replacement MH - Prognosis MH - *Aortic Valve Stenosis/surgery OTO - NOTNLM OT - ViV-TAVR OT - aorta OT - bioprosthesis OT - redo-sutured OT - redo-sutureless OT - surgery EDAT- 2023/12/11 12:43 MHDA- 2023/12/17 09:44 CRDT- 2023/12/11 07:56 PHST- 2023/12/17 09:44 [medline] PHST- 2023/12/11 12:43 [pubmed] PHST- 2023/12/11 07:56 [entrez] AID - 10.2217/fca-2023-0050 [doi] PST - ppublish SO - Future Cardiol. 2023 Nov;19(14):685-694. doi: 10.2217/fca-2023-0050. Epub 2023 Dec 11. PMID- 38077651 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231211 IS - 2666-6677 (Electronic) IS - 2666-6677 (Linking) VI - 17 DP - 2024 Mar TI - Association of health information technology-driven multidisciplinary approaches with low-density lipoprotein cholesterol target achievement in patients with an acute coronary syndrome. PG - 100613 LID - 10.1016/j.ajpc.2023.100613 [doi] LID - 100613 AB - OBJECTIVE: Controlling of low-density lipoprotein cholesterol (LDL-C) in patients with acute coronary syndrome (ACS) remains a challenge. Health information technology (HIT) is increasingly being applied to close quality gaps in chronic illness care. The aim of this study was to perform a qualitative review of the association of implementing HIT on lipid management processes of care and LDL-C goal attainment in patients with ACS. METHOD: Eligible patients with a discharge diagnosis of ACS from January 2018 to December 2021 at a tertiary medical center were retrospectively reviewed. An HIT system with a multidisciplinary approach including initiating high-intensity statin therapy, periodic laboratory follow-up, titration of lipid-lowering agents, patient education, patient-level and system-level interventions involving database monitoring and outreach by centralized care teams was introduced in October 2018. Electronical medical records including data on medications and laboratory findings at discharge and within 1 year were compared before and after implementing the HIT system. RESULTS: A total of 2001 ACS patients (average age 63 +/- 12.7 years, 79.66 % men) were analyzed. The LDL-C < 70 mg/dL goal attainment rates (36.52 %, 53.57 %, 59.22 %, 62.18 % in 2018-2021) and medium serum LDL-C levels (80.5 mg/dL, 68 mg/dL, 65 mg/dL, 64 mg/dL in 2018-2021) significantly improved within 6 months (2018 as the reference, all p<0.001). The LDL-C attainment rate at 12 months also steadily increased (53.80 %, 61.82 %, 64.21 % in 2019-2021, p = 0.019). Most of the patients switched to a high-intensity statins regimen at discharge (0.57 %, 63.67 %, 72.41 %, 84.44 %, in 2018-2021, p<0.001 with 2018 as the reference), with low adverse event rates. The maintenance rates of high-intensity statin regimens at 12 months continued to improve (41.36 %, 49.04 %, 61.39 % in 2019-2021, p<0.001). CONCLUSIONS: Efforts to control LDL-C should be increased in ACS patients by initiating and intensifying statin treatment earlier. Our results confirmed that a team-based strategy with HIT improved LDL-C target achievement for most patients with ACS. CI - (c) 2023 The Authors. Published by Elsevier B.V. FAU - Chen, Yi-Sheng AU - Chen YS AD - Division of Cardiology, Cardiovascular Medical Center, Far Eastern Memorial Hospital, New Taipei City, Taiwan. FAU - Lin, Heng Hsu AU - Lin HH AD - Division of Cardiology, Cardiovascular Medical Center, Far Eastern Memorial Hospital, New Taipei City, Taiwan. FAU - Tsai, Hao-Yuan AU - Tsai HY AD - Division of Cardiology, Cardiovascular Medical Center, Far Eastern Memorial Hospital, New Taipei City, Taiwan. FAU - Lee, Chien-Lin AU - Lee CL AD - Division of Cardiology, Cardiovascular Medical Center, Far Eastern Memorial Hospital, New Taipei City, Taiwan. FAU - Yeh, Yen-Ting AU - Yeh YT AD - Division of Cardiology, Cardiovascular Medical Center, Far Eastern Memorial Hospital, New Taipei City, Taiwan. FAU - Wu, Yen-Wen AU - Wu YW AD - Division of Cardiology, Cardiovascular Medical Center, Far Eastern Memorial Hospital, New Taipei City, Taiwan. AD - Department of Nuclear Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan. AD - School of Medicine, National Yang Ming Chiao Tung University, New Taipei City, Taiwan. AD - Graduate Institute of Medicine, Yuan Ze University, Taoyuan, Taiwan. LA - eng PT - Journal Article DEP - 20231121 PL - Netherlands TA - Am J Prev Cardiol JT - American journal of preventive cardiology JID - 101769122 PMC - PMC10698243 OTO - NOTNLM OT - Acute coronary syndrome OT - Health information technology OT - High intensity statin OT - Lowdensity lipoprotein cholesterol COIS- All authors declare no conflicts of interest. EDAT- 2023/12/11 12:43 MHDA- 2023/12/11 12:44 PMCR- 2023/11/21 CRDT- 2023/12/11 06:33 PHST- 2023/07/27 00:00 [received] PHST- 2023/09/25 00:00 [revised] PHST- 2023/11/20 00:00 [accepted] PHST- 2023/12/11 12:44 [medline] PHST- 2023/12/11 12:43 [pubmed] PHST- 2023/12/11 06:33 [entrez] PHST- 2023/11/21 00:00 [pmc-release] AID - S2666-6677(23)00154-X [pii] AID - 100613 [pii] AID - 10.1016/j.ajpc.2023.100613 [doi] PST - epublish SO - Am J Prev Cardiol. 2023 Nov 21;17:100613. doi: 10.1016/j.ajpc.2023.100613. eCollection 2024 Mar. PMID- 38075989 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231211 IS - 1301-5680 (Print) IS - 2149-8156 (Electronic) IS - 1301-5680 (Linking) VI - 31 IP - 4 DP - 2023 Oct TI - Effect of cardiac surgery on survival in patients with trisomy 18: A single-center experience. PG - 440-445 LID - 10.5606/tgkdc.dergisi.2023.24741 [doi] AB - BACKGROUND: In this study, we aimed to compare the results of operated patients diagnosed with trisomy 18 with those who were followed with medical treatment alone. METHODS: Between May 2014 and January 2022, a total of 18 patients (6 males, 12 females; median age: 39 days; range, 32 to 79 days) diagnosed with trisomy 18 were retrospectively analyzed. Patient data were obtained from the pediatric cardiovascular surgery digital database. The patients were divided into two groups: those who underwent surgery (n=10) and those who were followed with medical treatment (n=8). RESULTS: Cardiac pathology was detected in all 18 patients included in the study. Three (30%) patients in the surgical group and two (25%) patients in the medical treatment group were discharged and followed with medical treatment. One of the three patients discharged after surgery died during follow-up. The median survival in surgical and medical treatment groups was 150 (range, 75 to 308) days and eight (range, 3 to 51) days, respectively (p=0.009). While patients in the medical treatment group died due to multi-organ failure, those in surgical group died due to sepsis, heart failure, and respiratory failure. CONCLUSION: Although cardiac surgery contributed positively to survival in patients with trisomy 18, the mortality rate was still high due to non-cardiac causes. We believe that a multidisciplinary approach would contribute positively to the treatment of this patient group with multi-organ failure and would aid in prolonging their life span. CI - Copyright (c) 2023, Turkish Society of Cardiovascular Surgery. FAU - Celik, Mehmet AU - Celik M AUID- ORCID: 0000-0002-5018-0068 AD - Department of Cardiovascular Surgery, Baskent University Hospital, Konya, Turkiye. FAU - Gokdemir, Mahmut AU - Gokdemir M AUID- ORCID: 0000-0002-5676-2747 AD - Department of Pediatric Cardiology, Baskent University Hospital, Konya, Turkiye. FAU - Cindik, Nimet AU - Cindik N AUID- ORCID: 0000-0001-8544-0125 AD - Department of Pediatric Cardiology, Baskent University Hospital, Konya, Turkiye. FAU - Cagri Gunaydin, Asim AU - Cagri Gunaydin A AUID- ORCID: 0000-0001-5011-8187 AD - Department of Cardiovascular Surgery, Baskent University Hospital, Konya, Turkiye. LA - eng PT - Journal Article DEP - 20231019 PL - Turkey TA - Turk Gogus Kalp Damar Cerrahisi Derg JT - Turk gogus kalp damar cerrahisi dergisi JID - 100887967 PMC - PMC10704526 OTO - NOTNLM OT - Cardiac surgery OT - congenital heart disease OT - trisomy 18. COIS- Conflict of Interest: The authors declared no conflicts of interest with respect to the authorship and/or publication of this article. EDAT- 2023/12/11 12:42 MHDA- 2023/12/11 12:43 PMCR- 2023/10/19 CRDT- 2023/12/11 06:05 PHST- 2023/02/07 00:00 [received] PHST- 2023/07/07 00:00 [accepted] PHST- 2023/12/11 12:43 [medline] PHST- 2023/12/11 12:42 [pubmed] PHST- 2023/12/11 06:05 [entrez] PHST- 2023/10/19 00:00 [pmc-release] AID - 10.5606/tgkdc.dergisi.2023.24741 [doi] PST - epublish SO - Turk Gogus Kalp Damar Cerrahisi Derg. 2023 Oct 19;31(4):440-445. doi: 10.5606/tgkdc.dergisi.2023.24741. eCollection 2023 Oct. PMID- 38074201 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241202 IS - 1753-495X (Print) IS - 1753-4968 (Electronic) IS - 1753-495X (Linking) VI - 16 IP - 4 DP - 2023 Dec TI - Outcomes of pregnant women hospitalized with unrepaired congenital heart disease: Insights from a multidisciplinary center in Vietnam. PG - 228-235 LID - 10.1177/1753495X221148819 [doi] AB - BACKGROUND: In developing countries, fewer women have access to multidisciplinary congenital heart disease and reproductive programs staffed by experts. We report pregnancy outcomes of a multidisciplinary healthcare strategy utilizing an in-hospital teamwork approach in Vietnam. METHODS: This retrospective cohort study included pregnant women with unrepaired congenital heart disease managed at a referral cardiovascular center. RESULTS: Undiagnosed congenital heart disease before pregnancy, a lack of pre-pregnancy cardiology counseling, and modified World Health Organization class III/IV were common. Under the multispecialty healthcare strategy, although the rate of maternal death was 8.2% in the modified World Health Organization class IV group, no deaths occurred in any other group. Fetal/neonatal complications occurred in 54% of pregnancies, and 49.4% of neonates survived. Poor pregnancy outcomes were associated with admission during the first/seconde trimester for fetus/neonates, third trimester for mother, modified World Health Organization class III/IV, cyanosis, and heart failure. CONCLUSION: The outcomes of pregnant women with unrepaired congenital heart disease were poor but seemed to improve with a multidisciplinary in-hospital healthcare teamwork strategy. CI - (c) The Author(s) 2023. FAU - Truong, Thanh-Huong AU - Truong TH AUID- ORCID: 0000-0003-0316-9330 AD - Vietnam National Heart Institute, Bach Mai Hospital, Hanoi, Vietnam. RINGGOLD: 434407 AD - Department of Cardiology, Hanoi Medical University, Hanoi, Vietnam. RINGGOLD: 106156 FAU - Kim, Ngoc-Thanh AU - Kim NT AD - Vietnam National Heart Institute, Bach Mai Hospital, Hanoi, Vietnam. RINGGOLD: 434407 AD - Department of Cardiology, Hanoi Medical University, Hanoi, Vietnam. RINGGOLD: 106156 FAU - Nguyen, Dinh-Phuc AU - Nguyen DP AD - Department of Cardiology, Hanoi Medical University, Hanoi, Vietnam. RINGGOLD: 106156 FAU - Thi Nguyen, Mai-Ngoc AU - Thi Nguyen MN AD - Vietnam National Heart Institute, Bach Mai Hospital, Hanoi, Vietnam. RINGGOLD: 434407 AD - Department of Cardiology, Hanoi Medical University, Hanoi, Vietnam. RINGGOLD: 106156 FAU - Do, Doan-Loi AU - Do DL AD - Vietnam National Heart Institute, Bach Mai Hospital, Hanoi, Vietnam. RINGGOLD: 434407 AD - Department of Cardiology, Hanoi Medical University, Hanoi, Vietnam. RINGGOLD: 106156 FAU - Le, Thanh-Tung AU - Le TT AD - Vietnam National Heart Institute, Bach Mai Hospital, Hanoi, Vietnam. RINGGOLD: 434407 FAU - Le, Hong-An AU - Le HA AD - Vietnam National Heart Institute, Bach Mai Hospital, Hanoi, Vietnam. RINGGOLD: 434407 LA - eng PT - Journal Article DEP - 20230110 PL - England TA - Obstet Med JT - Obstetric medicine JID - 101464191 PMC - PMC10710195 OTO - NOTNLM OT - cardiovascular OT - congenital heart disease OT - multidisciplinary OT - pregnancy complications COIS- The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2023/12/11 06:45 MHDA- 2023/12/11 06:46 PMCR- 2024/12/01 CRDT- 2023/12/11 05:40 PHST- 2022/03/26 00:00 [received] PHST- 2022/12/12 00:00 [revised] PHST- 2022/12/13 00:00 [accepted] PHST- 2023/12/11 06:46 [medline] PHST- 2023/12/11 06:45 [pubmed] PHST- 2023/12/11 05:40 [entrez] PHST- 2024/12/01 00:00 [pmc-release] AID - 10.1177_1753495X221148819 [pii] AID - 10.1177/1753495X221148819 [doi] PST - ppublish SO - Obstet Med. 2023 Dec;16(4):228-235. doi: 10.1177/1753495X221148819. Epub 2023 Jan 10. PMID- 38073869 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240311 IS - 2434-0790 (Electronic) IS - 2434-0790 (Linking) VI - 5 IP - 12 DP - 2023 Dec 8 TI - Preprocedural Controlling Nutritional Status Score as a Predictor of Mortality in Patients Undergoing Transcatheter Mitral Valve Repair　- A Single Center Experience in Japan. PG - 442-449 LID - 10.1253/circrep.CR-23-0055 [doi] AB - Background: A high score for controlling nutritional status (CONUT) due to poor nutritional status has been associated with adverse outcomes in patients with chronic heart failure. However, because little is known about the effect of CONUT score on mortality rates after transcatheter mitral valve repair, we evaluated nutrition screening tools for prognosis prediction in patients undergoing transcatheter mitral valve repair using the MitraClip(TM) system. Methods and Results: We retrospectively analyzed 148 patients with severe mitral regurgitation (MR) who underwent MitraClip(TM) implantation between April 2018 and April 2021. The preprocedural CONUT scores were assessed at the time of hospitalization, the primary outcome was all-cause death, and the analysis was of the mortality and incidence rates of cardiac events 1 year post-operation. Functional MR was of ischemic origin in the majority of patients (69.6%), with a mean left ventricular ejection fraction of 48.9+/-15.8%. Kaplan-Meier curves indicated that all-cause death was significantly worse in the high-CONUT score group than in the low-CONUT score group. Cox hazard analysis showed a significant association between all-cause death and CONUT score, as well as MitraScore. Conclusions: Preprocedural CONUT score, as well as MitraScore, in patients undergoing transcatheter edge-to-edge mitral valve repair may predict an increased risk of all-cause death. This knowledge should allow the heart team to accurately assess the clinical implications and prognostic benefits of the procedure in individual patients. CI - Copyright (c) 2023, THE JAPANESE CIRCULATION SOCIETY. FAU - Noda, Airi AU - Noda A AD - Department of Cardiology, St. Marianna University School of Medicine Kawasaki Japan. FAU - Doi, Shunichi AU - Doi S AD - Department of Cardiology, St. Marianna University School of Medicine Kawasaki Japan. FAU - Kuwata, Shingo AU - Kuwata S AD - Department of Cardiology, St. Marianna University School of Medicine Kawasaki Japan. FAU - Shiokawa, Noriko AU - Shiokawa N AD - Ultrasound Center, St. Marianna University School of Medicine Kawasaki Japan. FAU - Suzuki, Norio AU - Suzuki N AD - St. Marianna University Toyoko Hospital Kawasaki Japan. FAU - Kanamitsu, Yoko AU - Kanamitsu Y AD - Department of Emergency and Critical Care Medicine, St. Marianna University School of Medicine Kawasaki Japan. FAU - Sato, Yukio AU - Sato Y AD - Department of Cardiology, St. Marianna University School of Medicine Kawasaki Japan. FAU - Tatsuro, Shoji AU - Tatsuro S AD - Department of Cardiology, St. Marianna University School of Medicine Kawasaki Japan. FAU - Okuno, Taishi AU - Okuno T AD - Department of Cardiology, St. Marianna University School of Medicine Kawasaki Japan. FAU - Kai, Takahiko AU - Kai T AD - Department of Cardiology, St. Marianna University School of Medicine Kawasaki Japan. FAU - Koga, Masashi AU - Koga M AD - Department of Cardiology, St. Marianna University School of Medicine Kawasaki Japan. FAU - Tanabe, Yasuhiro AU - Tanabe Y AD - Department of Cardiology, St. Marianna University School of Medicine Kawasaki Japan. FAU - Izumo, Masaki AU - Izumo M AD - Department of Cardiology, St. Marianna University School of Medicine Kawasaki Japan. FAU - Ishibashi, Yuki AU - Ishibashi Y AD - Department of Cardiology, St. Marianna University School of Medicine Kawasaki Japan. FAU - Akashi, Yoshihiro J AU - Akashi YJ AD - Department of Cardiology, St. Marianna University School of Medicine Kawasaki Japan. LA - eng PT - Journal Article DEP - 20231202 PL - Japan TA - Circ Rep JT - Circulation reports JID - 101746642 EIN - Circ Rep. 2024 Mar 8;6(3):97. doi: 10.1253/circrep.CR-66-0015. PMID: 38464993 PMC - PMC10700033 OTO - NOTNLM OT - Controlling nutritional status (CONUT) OT - Death OT - Transcatheter mitral valve repair COIS- S.K. and M.I. are consultants at Abbott Medical in Japan. Y.J.A. is a member of Circulation Reports' Editorial Team. The other authors have no conflicts of interest to declare. EDAT- 2023/12/11 06:45 MHDA- 2023/12/11 06:46 PMCR- 2023/12/02 CRDT- 2023/12/11 05:36 PHST- 2023/05/28 00:00 [received] PHST- 2023/10/07 00:00 [revised] PHST- 2023/10/12 00:00 [accepted] PHST- 2023/12/11 06:46 [medline] PHST- 2023/12/11 06:45 [pubmed] PHST- 2023/12/11 05:36 [entrez] PHST- 2023/12/02 00:00 [pmc-release] AID - 10.1253/circrep.CR-23-0055 [doi] PST - epublish SO - Circ Rep. 2023 Dec 2;5(12):442-449. doi: 10.1253/circrep.CR-23-0055. eCollection 2023 Dec 8. PMID- 38073289 OWN - NLM STAT- Publisher LR - 20231211 IS - 2047-9018 (Electronic) IS - 0029-6570 (Linking) DP - 2023 Dec 11 TI - Managing post-operative stroke following cardiac surgery. LID - 10.7748/ns.2023.e12093 [doi] AB - Stroke is a complication that can occur in patients who have undergone cardiac surgery and can lead to life-threatening consequences. The causes of post-operative stroke following cardiac surgery are varied, and it is essential to identify patients who are at risk to support early recognition and effective management. Nurses caring for patients following cardiac surgery should understand the causes of stroke, risk factors, preventive measures, early recognition and treatment. A multidisciplinary approach is crucial in ensuring effective therapeutic interventions and optimising outcomes for patients who have experienced stroke following cardiac surgery. CI - (c) 2023 RCN Publishing Company Ltd. All rights reserved. Not to be copied, transmitted or recorded in any way, in whole or part, without prior permission of the publishers. FAU - Navales, Vanna AU - Navales V AD - St Bartholomew's Hospital, London, England. FAU - Bowden, Tracey AU - Bowden T AD - City University of London, London, England. FAU - Magboo, Rosalie AU - Magboo R AD - Clinical doctoral research fellow, Queen Mary University of London, London and senior sister, St Bartholomew's Hospital, London, England. LA - eng PT - Journal Article DEP - 20231211 PL - England TA - Nurs Stand JT - Nursing standard (Royal College of Nursing (Great Britain) : 1987) JID - 9012906 OTO - NOTNLM OT - cardiorespiratory OT - cardiovascular OT - clinical OT - post-operative care OT - stroke OT - surgical OT - theatre nurses COIS- None declared EDAT- 2023/12/11 06:45 MHDA- 2023/12/11 06:45 CRDT- 2023/12/11 02:53 PHST- 2023/02/27 00:00 [accepted] PHST- 2023/12/11 06:45 [medline] PHST- 2023/12/11 06:45 [pubmed] PHST- 2023/12/11 02:53 [entrez] AID - e12093 [pii] AID - 10.7748/ns.2023.e12093 [doi] PST - aheadofprint SO - Nurs Stand. 2023 Dec 11. doi: 10.7748/ns.2023.e12093. PMID- 38072363 OWN - NLM STAT- MEDLINE DCOM- 20240219 LR - 20240308 IS - 1916-7075 (Electronic) IS - 0828-282X (Linking) VI - 40 IP - 2 DP - 2024 Feb TI - Degenerated Transcatheter Aortic Valve Replacement: Investigation and Management Options. PG - 300-312 LID - S0828-282X(23)01972-4 [pii] LID - 10.1016/j.cjca.2023.12.002 [doi] AB - With the expansion of transcatheter aortic valve replacement (TAVR) to younger and lower-surgical-risk patients, many younger and less comorbid patients will be treated with TAVR and are expected to have a life expectancy that will exceed the durability of their transcatheter heart valve. Consequently, the number of patients requiring reintervention will undoubtedly increase in the near future. Redo-TAVR and TAVR explantation followed by surgical aortic valve replacement are the different therapeutic options in the event of bioprosthetic valve failure and the need for reintervention. Patients often anticipate being able to benefit from a redo-TAVR in the event of bioprosthetic valve failure after TAVR, despite the lack of long-term data and the risk of unfavourable anatomy. Our understanding of the feasibility of redo-TAVR is constantly improving thanks to bench test studies and growing worldwide experience. However, much remains unknown. In clinical practice, one of the heart team's objectives is to anticipate the need to reaccess the coronary arteries and implant a second or even a third valve when life expectancy may exceed the durability of the transcatheter heart valve. In this review, we address key definitions in the diagnosis of structural valve deterioration and bioprosthetic valve failure, as well as patient selection and procedural planning for redo-TAVR to reduce periprocedural risk, optimise hemodynamic performance, and maintain coronary access. We describe the bench testing and literature in the redo-TAVR and TAVR explantation fields. CI - Copyright (c) 2023 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Mauler-Wittwer, Sarah AU - Mauler-Wittwer S AD - Cardiology Division, University Hospital of Lausanne, Lausanne, Switzerland. FAU - Giannakopoulos, Georgios AU - Giannakopoulos G AD - Structural Heart Unit, University Hospital of Geneva, Geneva, Switzerland. FAU - Arcens, Marc AU - Arcens M AD - Structural Heart Unit, University Hospital of Geneva, Geneva, Switzerland. FAU - Noble, Stephane AU - Noble S AD - Structural Heart Unit, University Hospital of Geneva, Geneva, Switzerland. Electronic address: stephane.noble@hcuge.ch. LA - eng PT - Journal Article PT - Review DEP - 20231210 PL - England TA - Can J Cardiol JT - The Canadian journal of cardiology JID - 8510280 SB - IM MH - Humans MH - *Transcatheter Aortic Valve Replacement/adverse effects MH - Treatment Outcome MH - Aortic Valve/surgery MH - *Heart Valve Prosthesis Implantation/adverse effects MH - *Heart Valve Prosthesis/adverse effects MH - *Aortic Valve Stenosis/diagnosis/surgery/etiology MH - Risk Factors MH - *Bioprosthesis/adverse effects MH - Prosthesis Design EDAT- 2023/12/11 00:42 MHDA- 2024/02/19 06:42 CRDT- 2023/12/10 19:33 PHST- 2023/10/18 00:00 [received] PHST- 2023/12/04 00:00 [revised] PHST- 2023/12/04 00:00 [accepted] PHST- 2024/02/19 06:42 [medline] PHST- 2023/12/11 00:42 [pubmed] PHST- 2023/12/10 19:33 [entrez] AID - S0828-282X(23)01972-4 [pii] AID - 10.1016/j.cjca.2023.12.002 [doi] PST - ppublish SO - Can J Cardiol. 2024 Feb;40(2):300-312. doi: 10.1016/j.cjca.2023.12.002. Epub 2023 Dec 10. PMID- 38069919 OWN - NLM STAT- MEDLINE DCOM- 20240115 LR - 20260518 IS - 1557-3117 (Electronic) IS - 1053-2498 (Linking) VI - 43 IP - 2 DP - 2024 Feb TI - Consensus statements from the International Society for Heart and Lung Transplantation consensus conference: Heart failure-related cardiogenic shock. PG - 204-216 LID - S1053-2498(23)02065-X [pii] LID - 10.1016/j.healun.2023.10.007 [doi] AB - The last decade has brought tremendous interest in the problem of cardiogenic shock. However, the mortality rate of this syndrome approaches 50%, and other than prompt myocardial revascularization, there have been no treatments proven to improve the survival of these patients. The bulk of studies have been in patients with acute myocardial infarction, and there is little evidence to guide the clinician in those patients with heart failure cardiogenic shock (HF-CS). An International Society for Heart and Lung Transplant consensus conference was organized to better define, diagnose, and manage HF-CS. There were 54 participants (advanced heart failure and interventional cardiologists, cardiothoracic surgeons, critical care cardiologists, intensivists, pharmacists, and allied health professionals) with vast clinical and published experience in CS, representing 42 centers worldwide. This consensus report summarizes the results of a premeeting survey answered by participants and the breakout sessions where predefined clinical issues were discussed to achieve consensus in the absence of robust data. Key issues discussed include systems for CS management, including the "hub-and-spoke" model vs a tier-based network, minimum levels of data to communicate when considering transfer, disciplines that should be involved in a "shock team," goals for mechanical circulatory support device selection, and optimal flow on such devices. Overall, the document provides expert consensus on some important issues facing practitioners managing HF-CS. It is hoped that this will clarify areas where consensus has been reached and stimulate future research and registries to provide insight regarding other crucial knowledge gaps. CI - Copyright (c) 2023 International Society for the Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved. FAU - Baran, David A AU - Baran DA AD - Cleveland Clinic, Florida. Electronic address: Barand@ccf.org. FAU - Billia, Filio AU - Billia F AD - University of Toronto, Toronto, Ontario, Canada. FAU - Randhawa, Varinder AU - Randhawa V AD - University of Toronto, Toronto, Ontario, Canada. FAU - Cowger, Jennifer A AU - Cowger JA AD - Henry Ford Health, Detroit, Michigan. FAU - Barnett, Christopher M AU - Barnett CM AD - University of California, San Francisco, California. FAU - Chih, Sharon AU - Chih S AD - University of Ottawa Heart Institute, Ottawa, Ontario, Canada. FAU - Ensminger, Stephan AU - Ensminger S AD - University of Lubeck, Germany. FAU - Hernandez-Montfort, Jaime AU - Hernandez-Montfort J AD - Baylor Scott and White, Texas. FAU - Sinha, Shashank S AU - Sinha SS AD - Inova Fairfax Medical Campus, Virginia. FAU - Vorovich, Esther AU - Vorovich E AD - Northwestern University, Illinois. FAU - Proudfoot, Alastair AU - Proudfoot A AD - St. Bartholomew's Hospital, United Kingdom. FAU - Lim, Hoong Sern AU - Lim HS AD - University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. FAU - Blumer, Vanessa AU - Blumer V AD - Inova Fairfax Medical Campus, Virginia. FAU - Jennings, Douglas L AU - Jennings DL AD - Columbia University, New York. FAU - Reshad Garan, A AU - Reshad Garan A AD - Beth Israel Deaconess Medical Center, Massachusetts. FAU - Renedo, Maria Florencia AU - Renedo MF AD - Fundacion Favaloro, Argentina. FAU - Hanff, Thomas C AU - Hanff TC AD - University of Utah, Utah. FAU - Kanwar, Manreet K AU - Kanwar MK AD - Allegheny Health Network, Pennsylvania. Electronic address: Manreet.Kanwar@ahn.org. CN - Consensus Conference participants/collaborators LA - eng PT - Consensus Statement PT - Journal Article DEP - 20231208 PL - United States TA - J Heart Lung Transplant JT - The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation JID - 9102703 SB - IM MH - Humans MH - Shock, Cardiogenic/etiology/therapy/diagnosis MH - *Heart Failure/surgery MH - *Myocardial Infarction/therapy OTO - NOTNLM OT - cardiogenic shock OT - conference OT - consensus OT - management OT - shock severity OT - temporary mechanical circulatory support FIR - Overgaard, Chris IR - Overgaard C IRAD- South Lake Regional (Canada). FIR - Teuteberg, Jeffrey IR - Teuteberg J IRAD- Stanford University (USA). FIR - Rosner, Carolyn IR - Rosner C IRAD- INOVA Fairfax (USA). FIR - Nagpal, Dave IR - Nagpal D IRAD- University Hospital (Canada). FIR - Taimeh, Ziad IR - Taimeh Z IRAD- Cleveland Clinic (USA). FIR - Abraham, Jacob IR - Abraham J IRAD- Providence (USA). FIR - Ton, Van-Khue IR - Ton VK IRAD- Massachusetts General Hospital (USA). FIR - Drakos, Stavros IR - Drakos S IRAD- University of Utah (USA). FIR - Tehrani, Behnam IR - Tehrani B IRAD- INOVA Fairfax (USA). FIR - Bernhardt, Alexander IR - Bernhardt A IRAD- (Germany). FIR - Meeran, Talha IR - Meeran T IRAD- HN Reliance Foundation Hospital (India). FIR - Douglas Greig, P IR - Douglas Greig P IRAD- Universidad Catolica de Chile (Chile). FIR - Farrero, Marta IR - Farrero M IRAD- Hospital Clinic de Barcelona (Spain). FIR - Katz, Jason IR - Katz J IRAD- New York University (USA). FIR - Luk, Adriana IR - Luk A IRAD- University of Toronto (Canada). FIR - Bennett, Courtney IR - Bennett C IRAD- Mayo Clinic (USA). FIR - Bertolotti, Alejandro IR - Bertolotti A IRAD- Universidad Nacional de Rosario (Argentina). FIR - Tedford, Ryan J IR - Tedford RJ IRAD- Medical University of South Carolina (USA). FIR - Cogswell, Rebecca IR - Cogswell R IRAD- University of Minnesota (USA). FIR - Klein, Liviu IR - Klein L IRAD- University of California San Francisco (USA). FIR - Guerrero-Miranda, Cesar Y IR - Guerrero-Miranda CY IRAD- Baylor Scott and White (USA). FIR - Rampersad, Penelope IR - Rampersad P IRAD- Cleveland Clinic (USA). FIR - Potena, Luciano IR - Potena L IRAD- IRCCS Azienda Ospedaliero Universitaria di Bologna (Italy). FIR - Boeken, Udo IR - Boeken U IRAD- University Hospital (Germany). FIR - Copeland, Hannah IR - Copeland H IRAD- Lutheran Medical Group (USA). FIR - Hall, Shelley IR - Hall S IRAD- Baylor University Medical Center (USA). FIR - Gonzalez-Costello, Jose IR - Gonzalez-Costello J IRAD- University Hospital of Bellvitge, IDIBELL, Ciber-CV (Spain). FIR - Kapur, Navin K IR - Kapur NK IRAD- Tufts Medical Center (USA). FIR - Loforte, Antonio IR - Loforte A IRAD- University of Turin (Italy). FIR - Burkhoff, Daniel IR - Burkhoff D IRAD- Cardiovascular Research Foundation (USA). FIR - LePrince, Pascal IR - LePrince P IRAD- Sorbonne University (France). FIR - Gustafsson, Finn IR - Gustafsson F IRAD- Rigshospitalet (Denmark). FIR - Uriel, Nir IR - Uriel N IRAD- New York Presbyterian (USA). FIR - Kataria, Rachna IR - Kataria R IRAD- Brown University (USA). FIR - Arora, Sonali IR - Arora S IRAD- KIMS Hospital Heart and Lung Transplant Unit (India). FIR - Masetti, Marco IR - Masetti M IRAD- IRCCS Azienda Ospedaliero Universitaria di Bologna (Italy). FIR - Saeed, Diyar IR - Saeed D IRAD- Leipzig Heart Center (Germany). EDAT- 2023/12/10 06:42 MHDA- 2024/01/15 12:43 CRDT- 2023/12/09 10:33 PHST- 2024/01/15 12:43 [medline] PHST- 2023/12/10 06:42 [pubmed] PHST- 2023/12/09 10:33 [entrez] AID - S1053-2498(23)02065-X [pii] AID - 10.1016/j.healun.2023.10.007 [doi] PST - ppublish SO - J Heart Lung Transplant. 2024 Feb;43(2):204-216. doi: 10.1016/j.healun.2023.10.007. Epub 2023 Dec 8. PMID- 38065583 OWN - NLM STAT- MEDLINE DCOM- 20231216 LR - 20251216 IS - 2053-3624 (Print) IS - 2053-3624 (Electronic) IS - 2053-3624 (Linking) VI - 10 IP - 2 DP - 2023 Dec 7 TI - Facility-based approach for the management of acute ST segment elevation myocardial infarction with cardiogenic shock in a rural medical centre: the Durango model. LID - 10.1136/openhrt-2023-002299 [doi] LID - e002299 AB - INTRODUCTION: Cardiogenic shock (CS) complicates 5%-15% of cases of acute myocardial infarction (AMI) with inpatient mortality greater than 40%. The implementation of standardised protocols may improve clinical outcomes in patients with AMI-CS. METHODS AND ANALYSIS: The Durango model is a prospective single-centre registry designed to enable early identification of patients with STEMI-CS to facilitate primary reperfusion therapy with a shock team management algorithm in a rural level II heart attack centre. This prospective registry includes all patients >18 years of age presenting with STEMI with or without CS beginning on 1 February 2023. The primary outcome measures are adherence to model-based documentation of SCAI shock Classification prehospital and in the ED with appropriate STEMI shock alert for AMI and stages C, D, E shock; use of mechanical circulatory support Pre-PCI and door to support time <90 min. ETHICS AND DISSEMINATION: This study was approved by the Institutional Review Board with a waiver of informed consent. The findings will be submitted for publication in a peer-review open access journal on completion of the study. CONCLUSIONS: The Durango model will demonstrate that the implementation of a STEMI shock team can be feasible in a rural medical centre through comprehensive education of a diverse group providers with different levels of experience, continuous model/device proficiency training and performance feedback. CI - (c) Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Carter, Andrew Joseph AU - Carter AJ AUID- ORCID: 0000-0003-4727-4642 AD - Cardiology, Mercy Regional Medical Center, Durango, Colorado, USA ajcarter@communitymed.org. FAU - Raffoul, Jad AU - Raffoul J AD - Cardiology, Mercy Regional Medical Center, Durango, Colorado, USA. FAU - Lane, Linden AU - Lane L AD - Cardiology, Mercy Regional Medical Center, Durango, Colorado, USA. FAU - LeSage, Leah AU - LeSage L AD - Cardiology, Mercy Regional Medical Center, Durango, Colorado, USA. FAU - Langenhorst, Shelley AU - Langenhorst S AD - Cardiology, Mercy Regional Medical Center, Durango, Colorado, USA. FAU - Smolin, Matthew AU - Smolin M AD - Cardiology, Mercy Regional Medical Center, Durango, Colorado, USA. FAU - Dempsey, Michael AU - Dempsey M AD - Critical Care, Mercy Regional Medical Center, Durango, Colorado, USA. FAU - Hughes, David AU - Hughes D AD - Emergency Department, Mercy Regional Medical Center, Durango, Colorado, USA. FAU - Gleason, Michael AU - Gleason M AD - Emergency Department, Mercy Regional Medical Center, Durango, Colorado, USA. FAU - Weiss, Steven AU - Weiss S AD - Critical Care, Mercy Regional Medical Center, Durango, Colorado, USA. FAU - Anderson, William D AU - Anderson WD AD - Centura Health, Englewood, Colorado, USA. LA - eng PT - Journal Article DEP - 20231207 PL - England TA - Open Heart JT - Open heart JID - 101631219 SB - IM MH - Humans MH - Shock, Cardiogenic/diagnosis/etiology/therapy MH - *ST Elevation Myocardial Infarction/complications/diagnosis/therapy MH - *Percutaneous Coronary Intervention/adverse effects MH - *Myocardial Infarction/complications/diagnosis/therapy MH - *Anterior Wall Myocardial Infarction MH - Arrhythmias, Cardiac/etiology PMC - PMC10711864 OTO - NOTNLM OT - Heart-Assist Devices OT - Myocardial Infarction OT - Percutaneous Coronary Intervention COIS- Competing interests: None declared. EDAT- 2023/12/09 05:43 MHDA- 2023/12/17 13:19 PMCR- 2023/12/08 CRDT- 2023/12/08 20:33 PHST- 2023/06/14 00:00 [received] PHST- 2023/11/14 00:00 [accepted] PHST- 2023/12/17 13:19 [medline] PHST- 2023/12/09 05:43 [pubmed] PHST- 2023/12/08 20:33 [entrez] PHST- 2023/12/08 00:00 [pmc-release] AID - openhrt-2023-002299 [pii] AID - 10.1136/openhrt-2023-002299 [doi] PST - epublish SO - Open Heart. 2023 Dec 7;10(2):e002299. doi: 10.1136/openhrt-2023-002299. PMID- 38064896 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240105 IS - 2052-0573 (Print) IS - 2052-0573 (Electronic) IS - 2052-0573 (Linking) VI - 2023 IP - 4 DP - 2023 Oct 1 TI - Calciphylaxis in a patient with hypoparathyroidism and MEN-1 syndrome. LID - 23-0009 [pii] LID - 10.1530/EDM-23-0009 [doi] AB - SUMMARY: Calciphylaxis is a rare disorder characterised by the development of painful necrotic skin lesions. Occlusion of cutaneous arterioles due to ectopic calcification leads to potentially life-threatening widespread skin loss. Most cases occur in patients with chronic renal disease, which leads to dysregulation of calcium and phosphate homeostasis. Only a handful of case reports exist describing calciphylaxis occurring in patients without chronic renal disease but with hypoparathyroidism. We report on a unique case of a 53-year-old man with multiple endocrine neoplasia type 1 syndrome and acquired hypoparathyroidism due to total parathyroidectomy who went on to develop calciphylaxis following cardiac surgery. LEARNING POINTS: Calciphylaxis most commonly occurs in the context of chronic renal disease but can rarely occur in its absence as a consequence of calcium and phosphate dysregulation. Patients who develop necrotic skin lesions in the presence of hypoparathyroidism require an urgent dermatological opinion. Mortality from calciphylaxis is high, with the majority of deaths occurring secondary to sepsis. Management of calciphylaxis requires a multidisciplinary team approach to manage wound healing, infections and pain. Recovery with full rehabilitation from calciphylaxis can take months to years. FAU - van Heeswijk, Isabelle AU - van Heeswijk I AUID- ORCID: 0000-0002-9152-9828 AD - Department of Endocrinology, University Hospitals Derby & Burton NHS Trust, Derby, UK. FAU - Ugur, Antonia AU - Ugur A AD - Department of Endocrinology, University Hospitals Derby & Burton NHS Trust, Derby, UK. FAU - Havill, Lynsey AU - Havill L AD - Department of Endocrinology, University Hospitals Derby & Burton NHS Trust, Derby, UK. FAU - Kinton, Rebecca AU - Kinton R AD - Department of Endocrinology, University Hospitals Derby & Burton NHS Trust, Derby, UK. FAU - Hughes, David AU - Hughes D AUID- ORCID: 0000-0003-0994-1977 AD - Department of Endocrinology, University Hospitals Derby & Burton NHS Trust, Derby, UK. LA - eng PT - Journal Article DEP - 20231208 PL - England TA - Endocrinol Diabetes Metab Case Rep JT - Endocrinology, diabetes & metabolism case reports JID - 101618943 PMC - PMC10762544 COIS- There is no conflict of interest that could be perceived as prejudicing the impartiality of the study reported. EDAT- 2023/12/09 05:43 MHDA- 2023/12/09 05:44 PMCR- 2023/12/08 CRDT- 2023/12/08 18:06 PHST- 2023/01/17 00:00 [received] PHST- 2023/11/08 00:00 [accepted] PHST- 2023/12/09 05:44 [medline] PHST- 2023/12/09 05:43 [pubmed] PHST- 2023/12/08 18:06 [entrez] PHST- 2023/12/08 00:00 [pmc-release] AID - 23-0009 [pii] AID - EDM230009 [pii] AID - 10.1530/EDM-23-0009 [doi] PST - epublish SO - Endocrinol Diabetes Metab Case Rep. 2023 Dec 8;2023(4):23-0009. doi: 10.1530/EDM-23-0009. Print 2023 Oct 1. PMID- 38061608 OWN - NLM STAT- MEDLINE DCOM- 20240115 LR - 20260508 IS - 1874-1754 (Electronic) IS - 0167-5273 (Linking) VI - 397 DP - 2024 Feb 15 TI - Beyond a team: The comprehensive interdisciplinary endocarditis program in the United States. PG - 131638 LID - S0167-5273(23)01773-4 [pii] LID - 10.1016/j.ijcard.2023.131638 [doi] AB - Although multidisciplinary teams have been shown to decrease in-hospital mortality for patient with infectious endocarditis, most studies have focused on the inpatient role of these teams, and are primarily based at European tertiary care centers. There is limited literature available on the optimal longitudinal care of this patient population. Here we outline our experience developing an interdisciplinary endocarditis program at the University of Kentucky, which cares for patients from their index hospitalization into the outpatient setting, while also coordinating transfers from regional hospitals and offering education to regional providers. CI - Copyright (c) 2023 Elsevier B.V. All rights reserved. FAU - El-Dalati, Sami AU - El-Dalati S AD - University of Kentucky Medical Center, Division of Infectious Diseases, Department of Internal Medicine, 740 S. Limestone Street, Lexington, KY 40536, United States of America. Electronic address: s.eldalati10@gmail.com. FAU - Thornton, Alice AU - Thornton A AD - University of Kentucky Medical Center, Division of Infectious Diseases, Department of Internal Medicine, 740 S. Limestone Street, Lexington, KY 40536, United States of America. FAU - Reda, Hassan AU - Reda H AD - University of Kentucky Medical Center, Division of Cardiovascular & Thoracic Surgery, 800 Rose Street, Lexington, KY 40536, United States of America. FAU - Alnabelsi, Talal AU - Alnabelsi T AD - University of Kentucky Medical Center, Gill Heart and Vascular Institute, 800 Rose Street, Lexington, KY 40536, United States of America. FAU - Gurley, John AU - Gurley J AD - University of Kentucky Medical Center, Gill Heart and Vascular Institute, 800 Rose Street, Lexington, KY 40536, United States of America. FAU - Stoner, Bobbi Jo AU - Stoner BJ AD - University of Kentucky College of Pharmacy, United States of America. FAU - Gill, Deborah AU - Gill D AD - University of Kentucky Medical Center, Division of Infectious Diseases, Department of Internal Medicine, 740 S. Limestone Street, Lexington, KY 40536, United States of America. FAU - Kennedy, Kara AU - Kennedy K AD - University of Kentucky Medical Center, Department of Neurology, 740 S. Limestone, Lexington, KY 40536, United States of America. FAU - Dornbos, David L 3rd AU - Dornbos DL 3rd AD - University of Kentucky Medical Center, Department of Neurosurgery, 780 Rose Street, Lexington, KY 40536, United States of America. FAU - Fraser, Justin AU - Fraser J AD - University of Kentucky Medical Center, Department of Neurosurgery, 780 Rose Street, Lexington, KY 40536, United States of America. FAU - Cremeans, Kelli AU - Cremeans K AD - University of Kentucky Medical Center, Division of Infectious Diseases, Department of Internal Medicine, 740 S. Limestone Street, Lexington, KY 40536, United States of America. FAU - Mansoor, Armaghan-E-Rehman AU - Mansoor AE AD - University of Kentucky Medical Center, Division of Infectious Diseases, Department of Internal Medicine, 740 S. Limestone Street, Lexington, KY 40536, United States of America. FAU - Laugherty, Grant AU - Laugherty G AD - University of Kentucky Medical Center, Division of Infectious Diseases, Department of Internal Medicine, 740 S. Limestone Street, Lexington, KY 40536, United States of America. FAU - Norris, Kathyrn AU - Norris K AD - University of Kentucky Medical Center, Division of Infectious Diseases, Department of Internal Medicine, 740 S. Limestone Street, Lexington, KY 40536, United States of America. FAU - Tremblay, Alyssa AU - Tremblay A AD - University of Kentucky Medical Center, Division of Infectious Diseases, Department of Internal Medicine, 740 S. Limestone Street, Lexington, KY 40536, United States of America. FAU - Annichiarico, Nicholas AU - Annichiarico N AD - University of Kentucky Medical Center, Department of Physical Medicine and Rehabilitation, Cardinal Hill Hospital, 2050 Versailles Road, Lexington, KY 40504, United States of America. FAU - Van Sickels, Nicholas AU - Van Sickels N AD - University of Kentucky Medical Center, Division of Infectious Diseases, Department of Internal Medicine, 740 S. Limestone Street, Lexington, KY 40536, United States of America. FAU - Ogburn, Erinn AU - Ogburn E AD - University of Kentucky Medical Center, Division of Cardiovascular & Thoracic Surgery, 800 Rose Street, Lexington, KY 40536, United States of America. FAU - London-Bounds, Tessa AU - London-Bounds T AD - University of Kentucky Medical Center, Division of Cardiovascular & Thoracic Surgery, 800 Rose Street, Lexington, KY 40536, United States of America. FAU - Sekela, Michael AU - Sekela M AD - University of Kentucky Medical Center, Division of Cardiovascular & Thoracic Surgery, 800 Rose Street, Lexington, KY 40536, United States of America. LA - eng PT - Journal Article PT - Review DEP - 20231206 PL - Netherlands TA - Int J Cardiol JT - International journal of cardiology JID - 8200291 SB - IM MH - Humans MH - United States/epidemiology MH - *Hospitals MH - Hospitalization MH - *Endocarditis/diagnosis/epidemiology/therapy MH - Hospital Mortality MH - Patient Care Team OTO - NOTNLM OT - Endocarditis OT - Multidisciplinary teams OT - Substance use disorder OT - Valvular heart disease COIS- Declaration of Competing Interest The authors have no conflicts of interest to disclose. EDAT- 2023/12/08 00:42 MHDA- 2024/01/15 12:43 CRDT- 2023/12/07 19:27 PHST- 2023/10/29 00:00 [received] PHST- 2023/11/26 00:00 [revised] PHST- 2023/12/03 00:00 [accepted] PHST- 2024/01/15 12:43 [medline] PHST- 2023/12/08 00:42 [pubmed] PHST- 2023/12/07 19:27 [entrez] AID - S0167-5273(23)01773-4 [pii] AID - 10.1016/j.ijcard.2023.131638 [doi] PST - ppublish SO - Int J Cardiol. 2024 Feb 15;397:131638. doi: 10.1016/j.ijcard.2023.131638. Epub 2023 Dec 6. PMID- 38059343 OWN - NLM STAT- MEDLINE DCOM- 20240530 LR - 20240530 IS - 1879-0844 (Electronic) IS - 1388-9842 (Linking) VI - 26 IP - 4 DP - 2024 Apr TI - European Society of Cardiology Core Curriculum for cardio-oncology. PG - 754-771 LID - 10.1002/ejhf.3102 [doi] AB - Cardio-oncology is a rapidly growing field of cardiovascular (CV) medicine that has resulted from the continuously increasing clinical demand for specialized CV evaluation, prevention and management of patients suffering or surviving from malignant diseases. Dealing with CV disease in patients with cancer requires special knowledge beyond that included in the general core curriculum for cardiology. Therefore, the European Society of Cardiology (ESC) has developed a special core curriculum for cardio-oncology, a consensus document that defines the level of experience and knowledge required for cardiologists in this particular field. It is structured into 8 chapters, including (i) principles of cancer biology and therapy; (ii) forms and definitions of cancer therapy-related cardiovascular toxicity (CTR-CVT); (iii) risk stratification, prevention and monitoring protocols for CTR-CVT; (iv) diagnosis and management of CV disease in patients with cancer; (v) long-term survivorship programmes and cardio-oncology rehabilitation; (vi) multidisciplinary team management of special populations; (vii) organization of cardio-oncology services; (viii) research in cardio-oncology. The core curriculum aims at promoting standardization and harmonization of training and evaluation in cardio-oncology, while it further provides the ground for an ESC certification programme designed to recognize the competencies of certified specialists. CI - (c) 2023 European Society of Cardiology. FAU - Lopez-Fernandez, Teresa AU - Lopez-Fernandez T AD - Cardiology Department, La Paz University Hospital, IdiPAZ Research Institute, Madrid, Spain. AD - Cardiology Department, Hospital Universitario Quironsalud Madrid, Madrid, Spain. FAU - Farmakis, Dimitrios AU - Farmakis D AD - Department of Cardiology, Athens University Hospital Attikon, National and Kapodistrian University of Athens Medical School, Athens, Greece. FAU - Ameri, Pietro AU - Ameri P AD - IRCCS Ospedale Policlinico San Martino, Genova, Italy. AD - Department of Internal Medicine, University of Genova, Genova, Italy. FAU - Asteggiano, Riccardo AU - Asteggiano R AD - Faculty of Medicine, Insubria University, Varese, Italy. AD - LARC (Laboratorio Analisi e Ricerca Clinica), Turin, Italy. FAU - de Azambuja, Evandro AU - de Azambuja E AD - Institut Jules Bordet and l'Universite Libre de Bruxelles (ULB), Brussels, Belgium. FAU - Aznar, Marianne AU - Aznar M AD - Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester; The Christie NHS Foundation Trust, Manchester, UK. FAU - Barac, Ana AU - Barac A AD - Inova Schar Heart and Vascular and Inova Schar Cancer Institute, Falls Church, VA, USA. FAU - Bayes-Genis, Antoni AU - Bayes-Genis A AD - Heart Institute, Hospital Universitari Germans Trias i Pujol, Badalona, CIBERCV, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Bax, Jeroen J AU - Bax JJ AD - Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands. FAU - Bergler-Klein, Jutta AU - Bergler-Klein J AD - Department of Cardiology, University Clinic of Internal Medicine II, Medical University of Vienna, Vienna, Austria. FAU - Boriani, Giuseppe AU - Boriani G AD - Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy. FAU - Celutkiene, Jelena AU - Celutkiene J AD - Clinic of Cardiac and Vascular Diseases, Faculty of Medicine, Institute of Clinical Medicine, Vilnius University, Vilnius, Lithuania. FAU - Coats, Andrew AU - Coats A AD - Heart Research Institute, Sydney, Australia. FAU - Cohen-Solal, Alain AU - Cohen-Solal A AD - Department of Cardiology, Lariboisiere Hospital, Paris Cite University, INSERM U-942, Paris, France. FAU - Cordoba, Raul AU - Cordoba R AD - Fundacion Jimenez Diaz University Hospital, Health Research Institute, Instituto de Investigacion Sanitaria-Fundacion Jimenez-Diaz (IIS-FJD), Madrid, Spain. FAU - Cosyns, Bernard AU - Cosyns B AD - Cardiology, CHVZ (Centrum voor Hart en Vaatziekten), ICMI (In Vivo Cellular and Molecular Imaging) Laboratory, Universitair ziekenhuis Brussel, Brussels, Belgium. FAU - Filippatos, Gerasimos AU - Filippatos G AD - Department of Cardiology, Athens University Hospital Attikon, National and Kapodistrian University of Athens Medical School, Athens, Greece. FAU - Fox, Kevin AU - Fox K AD - Imperial College Healthcare NHS Trust; NHS Orkney, Orkney, UK. FAU - Gulati, Geeta AU - Gulati G AD - Department of Cardiology, Division of Medicine, Oslo University Hospital, Ulleval, Norway. AD - K.G. Jebsen Center for Cardiac Biomarkers, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway. FAU - Inciardi, Riccardo M AU - Inciardi RM AD - ASST Spedali Civili di Brescia and Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy. FAU - Lee, Geraldine AU - Lee G AD - Florence Nightingale Faculty of Nursing Midwifery & Palliative Care, King's College London, London, UK. FAU - Mamas, Mamas A AU - Mamas MA AD - Keele Cardiovascular Research Group, Keele University, UK. FAU - Novo, Giuseppina AU - Novo G AD - Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE), University of Palermo, Palermo, Italy. AD - Cardiology Unit, University Hospital Paolo Giaccone, Palermo, Italy. FAU - Plummer, Chris AU - Plummer C AD - Department of Cardiology, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK. FAU - Psyrri, Amanda AU - Psyrri A AD - Department of Internal Medicine, Section of Medical Oncology, Attikon University Hospital, Athens, Greece. FAU - Rakisheva, Amina AU - Rakisheva A AD - City Cardiolocal Center, Almaty, Kazakhstan. AD - Qonaev city hospital, Almaty, Kazakhstan. FAU - Suter, Thomas AU - Suter T AD - Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. FAU - Tini, Giacomo AU - Tini G AD - Cardiology, Department of Clinical and Molecular Medicine, Sapienza University of Rome, Azienda Ospedaliera Universitaria Sant'Andrea, Rome, Italy. FAU - Tocchetti, Carlo Gabriele AU - Tocchetti CG AD - Department of Translational Medical Sciences (DISMET), Center for Basic and Clinical Immunology Research (CISI), Interdepartmental Center for Clinical and Translational Research (CIRCET), Interdepartmental Hypertension Research Center (CIRIAPA), Federico II University, Naples, Italy. FAU - Toutouzas, Konstantinos AU - Toutouzas K AD - The First Department of Cardiology, Athens Medical School, Athens, Greece. FAU - Wilhelm, Matthias AU - Wilhelm M AD - Rehabilitation & Sports Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. FAU - Metra, Marco AU - Metra M AD - ASST Spedali Civili di Brescia and Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy. FAU - Lyon, Alexander R AU - Lyon AR AD - Cardio-Oncology Service, Royal Brompton Hospital, Guys and St. Thomas NHS Foundation Trust, London, UK. FAU - Rosano, Giuseppe M C AU - Rosano GMC AD - IRCCS San Raffaele Pisana, Rome, Italy. LA - eng GR - Italian Ministry of Health/ GR - Horizon 2020/ PT - Journal Article PT - Review DEP - 20231220 PL - England TA - Eur J Heart Fail JT - European journal of heart failure JID - 100887595 SB - IM MH - Humans MH - *Cardiology/education MH - *Curriculum MH - *Medical Oncology/education MH - *Societies, Medical MH - *Neoplasms/complications MH - Europe MH - *Cardiovascular Diseases/prevention & control MH - Cardiotoxicity/prevention & control/etiology MH - Cardio-Oncology OTO - NOTNLM OT - Anticancer therapy OT - Cancer OT - Cardiotoxicity OT - Cardio-oncology OT - Chemotherapy OT - Hormonal therapy OT - Immunotherapy OT - Radiotherapy OT - Targeted therapies EDAT- 2023/12/07 06:42 MHDA- 2024/05/30 06:35 CRDT- 2023/12/07 04:44 PHST- 2023/11/06 00:00 [revised] PHST- 2023/09/21 00:00 [received] PHST- 2023/12/01 00:00 [accepted] PHST- 2024/05/30 06:35 [medline] PHST- 2023/12/07 06:42 [pubmed] PHST- 2023/12/07 04:44 [entrez] AID - 10.1002/ejhf.3102 [doi] PST - ppublish SO - Eur J Heart Fail. 2024 Apr;26(4):754-771. doi: 10.1002/ejhf.3102. Epub 2023 Dec 20. PMID- 38058180 OWN - NLM STAT- MEDLINE DCOM- 20240311 LR - 20260814 IS - 1873-734X (Electronic) IS - 1010-7940 (Print) IS - 1010-7940 (Linking) VI - 65 IP - 3 DP - 2024 Mar 1 TI - The additive effects of anaemia and transfusion on long-term survival after coronary artery bypass surgery. LID - 10.1093/ejcts/ezad403 [doi] LID - ezad403 AB - OBJECTIVES: To compare the independent and combined effects of anaemia and red blood cell transfusion on late survival after isolated coronary artery bypass grafting. METHODS: Retrospective analysis of 5243 consecutive patients undergoing primary isolated coronary artery bypass grafting, performed from 2000 to 2015, in a Portuguese Academic Hospital. We identified 1649 patients with preoperative anaemia (A+) and 1422 patients who received a perioperative transfusion (T+)-the 4 possible combinations allowed for the creation of 4 subgroups (A-/T-, A-/T+, A+/T- and A+/T+). The primary endpoint was all-cause mortality at 10 years. We employed inverse probability weighting to control for confounding variables. RESULTS: Thirty-one percent of the patients had preoperative anaemia, and 27.0% had at least one packed red blood cell transfusion. Inverse probability weighting was effective in eliminating differences in all significant baseline characteristics. The primary endpoint of all-cause mortality at 10 years occurred in 568 patients (20.5%) in the A-/T- group, as compared with 204 (24.4%) in the A-/T+ group (hazard ratio, 1.14; 95% confidence interval, 1.00 to 1.31; P = 0.053), 358 (33.8%) in the A+/T- group (hazard ratio, 1.53; 95% confidence interval, 1.38 to 1.71; P < 0.001), 254 (43.6%) in the A+/T+ group (hazard ratio, 2.25; 95% confidence interval, 1.97 to 2.56; P < 0.001). CONCLUSIONS: This longitudinal, population-level study emphasizes the adverse long-term outcomes of preoperative anaemia and perioperative red blood cell transfusion. It stresses the importance of an evidence-based, multimodal and multidisciplinary approach to conserving blood resources and optimizing outcomes in patients at high risk for transfusion. CI - (c) The Author(s) 2023. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. FAU - Abreu, Armando AU - Abreu A AUID- ORCID: 0000-0003-4876-5179 AD - Department of Surgery and Physiology, Cardiovascular R&D Center-UnIC@RISE, Faculty of Medicine of the University of Porto, Porto, Portugal. AD - Department of Cardiothoracic Surgery, Sao Joao University Hospital Center, Porto, Portugal. FAU - Maximo, Jose AU - Maximo J AUID- ORCID: 0000-0001-8275-5500 AD - Department of Surgery and Physiology, Cardiovascular R&D Center-UnIC@RISE, Faculty of Medicine of the University of Porto, Porto, Portugal. AD - Department of Cardiothoracic Surgery, Sao Joao University Hospital Center, Porto, Portugal. FAU - Almeida, Claudia AU - Almeida C AD - Department of Anesthesiology, Sao Joao University Hospital Center, Porto, Portugal. FAU - Lourenco, Andre AU - Lourenco A AD - Department of Surgery and Physiology, Cardiovascular R&D Center-UnIC@RISE, Faculty of Medicine of the University of Porto, Porto, Portugal. AD - Department of Anesthesiology, Sao Joao University Hospital Center, Porto, Portugal. FAU - Leite-Moreira, Adelino AU - Leite-Moreira A AD - Department of Surgery and Physiology, Cardiovascular R&D Center-UnIC@RISE, Faculty of Medicine of the University of Porto, Porto, Portugal. AD - Department of Cardiothoracic Surgery, Sao Joao University Hospital Center, Porto, Portugal. LA - eng GR - FCT-Portuguese Foundation for Science and Technology/ GR - UIDB/00051/2020/Cardiovascular R&D Center-UnIC/ PT - Journal Article PL - Germany TA - Eur J Cardiothorac Surg JT - European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery JID - 8804069 SB - IM MH - Humans MH - Retrospective Studies MH - *Coronary Artery Bypass/adverse effects MH - Blood Transfusion MH - Erythrocyte Transfusion MH - *Anemia/complications/therapy PMC - PMC10924300 OTO - NOTNLM OT - Anaemia OT - Blood transfusion OT - Coronary artery bypass OT - Survival analysis EDAT- 2023/12/07 06:42 MHDA- 2024/03/11 06:43 PMCR- 2023/12/07 CRDT- 2023/12/07 03:41 PHST- 2023/10/10 00:00 [received] PHST- 2023/11/20 00:00 [revised] PHST- 2023/12/05 00:00 [accepted] PHST- 2024/03/11 06:43 [medline] PHST- 2023/12/07 06:42 [pubmed] PHST- 2023/12/07 03:41 [entrez] PHST- 2023/12/07 00:00 [pmc-release] AID - 7460229 [pii] AID - ezad403 [pii] AID - 10.1093/ejcts/ezad403 [doi] PST - ppublish SO - Eur J Cardiothorac Surg. 2024 Mar 1;65(3):ezad403. doi: 10.1093/ejcts/ezad403. PMID- 38057124 OWN - NLM STAT- MEDLINE DCOM- 20231211 LR - 20231211 IS - 1476-4954 (Electronic) IS - 1476-4954 (Linking) VI - 36 IP - 2 DP - 2023 Dec TI - Evaluation of maternal-fetal outcomes in pregnancy complicated with severe pulmonary hypertension and its influencing factors: a single-center retrospective study in China. PG - 2290923 LID - 10.1080/14767058.2023.2290923 [doi] AB - OBJECTIVE: Pregnancy is not recommended for patients with severe pulmonary hypertension (PH) due to the significant risks it poses to both the mother and fetus. The objective of this study is to describe the maternal-fetal outcomes in pregnant women with PH and identify the factors that influence these outcomes. METHOD: This retrospective study analyzed clinical data from 25 patients with severe PH who were admitted to our hospital between January 2018 and December 2022. The data we used came from a public general hospital in Fujian Province. RESULTS: The mean systolic pulmonary artery pressure (sPAP) of 25 patients was 105.12 +/- 22.70 mmHg. All patients had received one or more multidisciplinary team (MDT) treatments before terminating their pregnancies. Among the pregnant women, four experienced a pulmonary hypertensive crisis (PHC), seven had heart failure, and one had postpartum hemorrhage (PPH). Among them, seven (28%) pregnant women died primarily due to heart failure and PHC. Among the fetal outcomes, twelve resulted in therapeutic abortion, and eleven resulted in preterm birth. Among the perinatal complications, eleven infants (84.6%) were born prematurely, six infants (46.2%) experienced neonatal asphyxia, eight infants (61.5%) had low birth weight, and two infants (15.4%) died during the perinatal period. According to the etiology, seven individuals had idiopathic pulmonary arterial hypertension (iPAH), ten had pulmonary arterial hypertension associated with congenital heart disease (CHD-PAH), six had pulmonary hypertension associated with left heart disease (LDH-PH), and two had pulmonary arterial hypertension caused by other diseases (oPAH). The sPAP levels of iPAH and CHD-PAH were significantly higher than those of LDH-PH and oPAH (p < 0.05). Additionally, the gestational weeks of LDH-PH were higher than those of iPAH (p < 0.05). The number of patients with New York Heart Association (NYHA) heart function grade III-V was higher in the death group compared to the non-death group (p < 0.05). CONCLUSION: Pregnancy in women with severe PH carries a high risk of mortality. Therefore, contraception is strongly recommended for these women. NYHA cardiac function grade III-IV was useful in predicting the risk of mortality. FAU - Dai, Qiulan AU - Dai Q AD - Department of Obstetrics and Gynecology, Fujian Medical University Union Hospital, Fuzhou, China. FAU - Shang, Manman AU - Shang M AD - School of Public Health, Fujian Medical University, Fuzhou, China. FAU - Zhou, Yu AU - Zhou Y AD - Department of Obstetrics and Gynecology, Fujian Medical University Union Hospital, Fuzhou, China. FAU - Wei, Qin AU - Wei Q AD - Department of Medical Administration, Fujian Medical University Union Hospital, Fuzhou, China. LA - eng PT - Journal Article DEP - 20231206 PL - England TA - J Matern Fetal Neonatal Med JT - The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians JID - 101136916 SB - IM MH - Infant MH - Female MH - Pregnancy MH - Infant, Newborn MH - Humans MH - *Hypertension, Pulmonary/etiology/complications MH - *Pulmonary Arterial Hypertension/complications MH - Retrospective Studies MH - Cesarean Section/adverse effects MH - *Premature Birth/epidemiology MH - Familial Primary Pulmonary Hypertension/complications MH - *Heart Defects, Congenital/complications MH - *Heart Failure MH - Parturition MH - Pregnancy Outcome/epidemiology OTO - NOTNLM OT - Pregnancy OT - maternal-fetal outcome OT - multidisciplinary team OT - pulmonary hypertension EDAT- 2023/12/07 00:42 MHDA- 2023/12/11 12:42 CRDT- 2023/12/06 21:13 PHST- 2023/12/11 12:42 [medline] PHST- 2023/12/07 00:42 [pubmed] PHST- 2023/12/06 21:13 [entrez] AID - 10.1080/14767058.2023.2290923 [doi] PST - ppublish SO - J Matern Fetal Neonatal Med. 2023 Dec;36(2):2290923. doi: 10.1080/14767058.2023.2290923. Epub 2023 Dec 6. PMID- 38057076 OWN - NLM STAT- MEDLINE DCOM- 20231211 LR - 20240208 IS - 1558-3597 (Electronic) IS - 0735-1097 (Linking) VI - 82 IP - 24 DP - 2023 Dec 12 TI - Role of Advanced Practice Providers in the Cardiac Intensive Care Unit Team. PG - 2338-2342 LID - S0735-1097(23)07751-3 [pii] LID - 10.1016/j.jacc.2023.08.061 [doi] FAU - Tennyson, Carolina D AU - Tennyson CD AD - Duke University School of Nursing, Division of Cardiology, Duke Department of Medicine, Durham, North Carolina, USA. Electronic address: carolina.tennyson@duke.edu. FAU - Bowers, Margaret T AU - Bowers MT AD - Duke University School of Nursing, Division of Cardiology, Duke Department of Medicine, Durham, North Carolina, USA. FAU - Dimsdale, Allison W AU - Dimsdale AW AD - Duke University Health System, Advanced Practice Center, Division of Cardiology, Duke Department of Medicine, Durham, North Carolina, USA. FAU - Dickinson, Sharon M AU - Dickinson SM AD - Heart One Associates, Phoenix, Arizona, USA. FAU - Sanford, R Monica AU - Sanford RM AD - University of West Florida, Pensacola, Florida, USA. FAU - McKenzie-Solis, Jordan D AU - McKenzie-Solis JD AD - Division of Cardiology, Duke Department of Medicine, Durham, North Carolina, USA. FAU - Schimmer, Hannah D AU - Schimmer HD AD - The Leon H. Charney Division of Cardiology, New York University Langone Medical Center & Bellevue Hospital Center, New York, New York, USA. FAU - Alviar, Carlos L AU - Alviar CL AD - The Leon H. Charney Division of Cardiology, New York University Langone Medical Center & Bellevue Hospital Center, New York, New York, USA. FAU - Sinha, Shashank S AU - Sinha SS AD - Inova Heart and Vascular Institute, Inova Fairfax Medical Campus, Falls Church, Virginia, USA. FAU - Katz, Jason N AU - Katz JN AD - Division of Cardiology, Duke Department of Medicine, Durham, North Carolina, USA. LA - eng PT - Journal Article PL - United States TA - J Am Coll Cardiol JT - Journal of the American College of Cardiology JID - 8301365 SB - IM MH - Humans MH - Intensive Care Units MH - Critical Care MH - *Nurse Practitioners MH - *Physician Assistants MH - Patient Care Team OTO - NOTNLM OT - advanced practice provider OT - cardiac intensive care unit OT - critical care cardiology OT - nurse practitioner OT - physician assistant COIS- Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2023/12/07 00:42 MHDA- 2023/12/11 12:42 CRDT- 2023/12/06 21:00 PHST- 2023/05/31 00:00 [received] PHST- 2023/07/31 00:00 [revised] PHST- 2023/08/02 00:00 [accepted] PHST- 2023/12/11 12:42 [medline] PHST- 2023/12/07 00:42 [pubmed] PHST- 2023/12/06 21:00 [entrez] AID - S0735-1097(23)07751-3 [pii] AID - 10.1016/j.jacc.2023.08.061 [doi] PST - ppublish SO - J Am Coll Cardiol. 2023 Dec 12;82(24):2338-2342. doi: 10.1016/j.jacc.2023.08.061. PMID- 20301446 STAT- Publisher DRDT- 20231207 CTDT- 20000727 PB - University of Washington, Seattle DP - 1993 TI - Gaucher Disease. BTI - GeneReviews((R)) AB - CLINICAL CHARACTERISTICS: Gaucher disease (GD) encompasses a continuum of clinical findings from a perinatal-lethal disorder to an asymptomatic type. The characterization of three major clinical types (1, 2, and 3) and two clinical forms (perinatal-lethal and cardiovascular) is useful in determining prognosis and management. Cardiopulmonary complications have been described with all the clinical phenotypes, although varying in frequency and severity. Type 1 GD is characterized by the presence of clinical or radiographic evidence of bone disease (osteopenia, focal lytic or sclerotic lesions, and osteonecrosis), hepatosplenomegaly, anemia, thrombocytopenia, lung disease, and the absence of primary central nervous system disease. Type 2 GD is characterized by primary central nervous system disease with onset before age two years, limited psychomotor development, and a rapidly progressive course with death by age two to four years. Type 3 GD is characterized by primary central nervous system disease with childhood onset, a more slowly progressive course, and survival into the third or fourth decade. The perinatal-lethal form is associated with ichthyosiform or collodion skin abnormalities or with nonimmune hydrops fetalis. The cardiovascular form is characterized by calcification of the aortic and mitral valves, mild splenomegaly, corneal opacities, and supranuclear ophthalmoplegia. DIAGNOSIS/TESTING: The diagnosis of GD relies on demonstration of deficient glucocerebrosidase (glucosylceramidase) enzyme activity in peripheral blood leukocytes or other nucleated cells, or by the identification of biallelic pathogenic variants in GBA1 on molecular genetic testing. MANAGEMENT: Targeted therapy: Options include enzyme replacement therapy (ERT) or substrate reduction therapy (SRT; e.g., miglustat, eliglustat). Hematopoietic stem cell transplantation may be an option in individuals with severe GD, primarily those with chronic neurologic involvement (type 3 GD). Supportive care: When possible, management by a multidisciplinary team at a GD Comprehensive Treatment Center. Symptomatic treatment includes partial or total splenectomy for those with massive splenomegaly, significant areas of splenic fibrosis, and persistent significant thrombocytopenia (platelets <30,000/mm(3)) with a risk of bleeding; splenectomy may be needed even in those on targeted therapy. Supportive care for all affected individuals may include: orthopedic management of bone disease; analgesics for bone pain; joint replacement surgery for relief from chronic pain and restoration of function; anti-bone resorptive agents, calcium, and vitamin D for osteoporosis; transfusion of blood products for severe anemia and bleeding; the use of anticoagulants in individuals with severe thrombocytopenia and/or coagulopathy should be discussed with a hematologist to avoid the possibility of excessive bleeding; treatment of cholelithiasis, pulmonary disease, pulmonary hypertension, multiple myeloma, psychological manifestations, parkinsonism, and seizures according to the relevant specialist; social work support and care coordination as needed. Surveillance: Clinical assessment of disease progression at least every six months to include hematologic, orthopedic, pulmonary, cardiac, psychiatric, and neurologic assessment; clinical assessment for abdominal pain, early satiety, evidence of bleeding diathesis, growth and weight gain, clinical disease markers, and liver enzymes; imaging for spleen and liver volumes at least every one to two years. Additional evaluations to be done as needed include radiographs, MRI, and dual-energy x-ray absorptiometry (DXA) scan; bone age in children with growth and pubertal delay; ultrasound for gallstones; serum iron, ferritin, and vitamin B(12) in those with anemia; and EKG and echocardiography with Doppler in individuals after splenectomy and those with elevated pulmonary artery pressure. Agents/circumstances to avoid: Nonsteroidal anti-inflammatory drugs in individuals with moderate-to-severe thrombocytopenia. Evaluation of relatives at risk: It is appropriate to offer testing to asymptomatic at-risk relatives so that those with glucocerebrosidase enzyme deficiency or biallelic pathogenic variants can benefit from early diagnosis and treatment if indicated. Pregnancy management: Pregnancy can exacerbate preexisting symptoms and trigger new features in affected women. Those with severe thrombocytopenia and/or clotting abnormalities are at increased risk for bleeding around the time of delivery. Evaluation by a hematologist prior to delivery is recommended. The lack of studies on the safety of eliglustat use during pregnancy and lactation has led to the recommendation that this medication be avoided during pregnancy, if possible. GENETIC COUNSELING: GD is inherited in an autosomal recessive manner. The parents of an affected individual are typically heterozygous for a GBA1 pathogenic variant; in some families, an asymptomatic parent may be found to be homozygous rather than heterozygous. If both parents are known to be heterozygous for a GBA1 pathogenic variant, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being a heterozygote, and a 25% chance of inheriting neither of the familial GBA1 pathogenic variants. Once the GBA1 pathogenic variants have been identified in an affected family member, molecular genetic carrier testing for at-risk family members, preimplantation genetic testing, and prenatal testing for GD are possible. The identification of 0%-15% of normal glucocerebrosidase enzyme activity in fetal samples obtained by chorionic villus sampling (CVS) or amniocentesis - ideally complemented by molecular genetic testing - can also be used to establish affected status in a fetus. CI - Copyright (c) 1993-2026, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved. FED - Adam, Margaret P ED - Adam MP FED - Bick, Sarah ED - Bick S FED - Mirzaa, Ghayda M ED - Mirzaa GM FED - Wallace, Stephanie E ED - Wallace SE FED - Amemiya, Anne ED - Amemiya A FAU - Hughes, Derralynn A AU - Hughes DA AD - Professor of Experimental Haematology, Department of Academic Haematology, University College Medical School, London, United Kingdom FAU - Pastores, Gregory M AU - Pastores GM AD - Clinical Professor, Medicine (Genetics), University College, Dublin, Ireland LA - eng PT - Review PT - Book Chapter PL - Seattle (WA) OTO - NLM OT - Glucocerebrosidase Deficiency OT - Glucosylceramidase Deficiency OT - Glucocerebrosidase Deficiency OT - Glucosylceramidase Deficiency OT - Type 1 Gaucher Disease OT - Type 2 Gaucher disease (Acute; Infantile) OT - Type 3 Gaucher disease (Subacute; Juvenile) OT - Gaucher Disease, Perinatal-Lethal Form OT - Gaucher Disease, Cardiovascular Form OT - Lysosomal acid glucosylceramidase OT - GBA1 OT - Gaucher Disease EDAT- 2023/12/07 00:00 CRDT- 2023/12/07 00:00 AID - NBK1269 [bookaccession] PMID- 38052300 OWN - NLM STAT- MEDLINE DCOM- 20240516 LR - 20250826 IS - 1916-7075 (Electronic) IS - 0828-282X (Linking) VI - 40 IP - 5 DP - 2024 May TI - Invasive Management of Hypertrophic Cardiomyopathy With Clinically Important Obstruction: Surgical Myectomy Is Superior, but Only When Accessible. PG - 843-850 LID - S0828-282X(23)01967-0 [pii] LID - 10.1016/j.cjca.2023.11.040 [doi] AB - For patients with hypertrophic cardiomyopathy (HCM), a thickened intraventricular septum and systolic anterior motion of the mitral valve (SAM) can contribute to significant left ventricular outflow tract obstruction (LVOTO), mitral regurgitation, and debilitating symptoms. Current guidelines recommend septal reduction therapy through alcohol septal ablation or surgical septal myectomy for patients whose symptoms persist despite medical therapy. Although alcohol septal ablation is a less invasive treatment option, it is not suitable for patients with septal perforator branch anatomy that is not compatible with the procedure, those with midcavitary obstruction, and patients in whom the mechanism of LVOTO is primarily related to SAM. Septal ablation also has a notably higher rate of atrioventricular block requiring permanent pacemaker insertion, and the need for reintervention has been reported to be 15% or more. In contrast, septal myectomy offers direct visualisation and can address thickened septum and mitral valve (MV) anomalies. It can be used to treat a wider variety of anatomies, with lower rates of reoperation. Aside from the more invasive nature of the procedure, a major limitation of septal myectomy, however, is access, because relatively few surgeons specialise in the procedure. This is important because there is a significant correlation between procedural volumes and outcomes. Patients should be evaluated by a multidisciplinary heart team to ensure that they are aware of all treatment options. In this review, we explore the 2 methods of septal reduction therapy and highlight the need for further training of septal myectomy surgeons to ensure access to optimal septal reduction therapies for Canadian patients with HCM. CI - Copyright (c) 2024 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved. FAU - Fortier, Jacqueline H AU - Fortier JH AD - Division of Cardiothoracic Surgery, The Valley Hospital, Ridgewood, New Jersey, USA. FAU - Thapa, Yashaswi AU - Thapa Y AD - Department of Neuroscience, Carleton University, Ottawa, Ontario, Canada. FAU - Crean, Andrew M AU - Crean AM AD - Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Division of Cardiology, University of Manchester, Manchester, United Kingdom. FAU - Gupta, Himanshu AU - Gupta H AD - Division of Cardiac Imaging, Valley Heart and Vascular Institute, Ridgewood, New Jersey, USA. FAU - Grau, Juan B AU - Grau JB AD - Division of Cardiothoracic Surgery, The Valley Hospital, Ridgewood, New Jersey, USA; Division of Cardiac Surgery, University of Ottawa Heart Institute, Ottawa, Ontario, Canada. Electronic address: GRAUJU@valleyhealth.com. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20231203 PL - England TA - Can J Cardiol JT - The Canadian journal of cardiology JID - 8510280 SB - IM MH - Humans MH - *Cardiomyopathy, Hypertrophic/surgery/complications/diagnosis MH - *Ventricular Outflow Obstruction/surgery/etiology MH - Heart Septum/surgery MH - Cardiac Surgical Procedures/methods MH - Myotomy/methods MH - Mitral Valve/surgery/diagnostic imaging EDAT- 2023/12/06 03:43 MHDA- 2024/05/17 00:43 CRDT- 2023/12/05 19:20 PHST- 2023/09/28 00:00 [received] PHST- 2023/11/16 00:00 [revised] PHST- 2023/11/28 00:00 [accepted] PHST- 2024/05/17 00:43 [medline] PHST- 2023/12/06 03:43 [pubmed] PHST- 2023/12/05 19:20 [entrez] AID - S0828-282X(23)01967-0 [pii] AID - 10.1016/j.cjca.2023.11.040 [doi] PST - ppublish SO - Can J Cardiol. 2024 May;40(5):843-850. doi: 10.1016/j.cjca.2023.11.040. Epub 2023 Dec 3. PMID- 38044216 OWN - NLM STAT- MEDLINE DCOM- 20240516 LR - 20260304 IS - 1875-595X (Electronic) IS - 0020-6539 (Print) IS - 0020-6539 (Linking) VI - 74 IP - 3 DP - 2024 Jun TI - Update on Focal Infection Management: A Czech Interdisciplinary Consensus. PG - 510-518 LID - S0020-6539(23)00966-8 [pii] LID - 10.1016/j.identj.2023.11.001 [doi] AB - BACKGROUND: The focal infection theory has been used to explain several chronic systemic diseases in the past. Systemic diseases were thought to be caused by focal infections, such as caries and periodontal diseases, and dentists were held responsible for these diseases due to the spread of oral infections. As knowledge of the interrelationship between oral microorganisms and the host immune response has evolved over the last few decades, the focal infection theory has been modified in various ways. The relationship between oral and systemic health appears to be more complex than that suggested by the classical theory of focal infections. Indeed, the contribution of the oral microbiota to some systemic diseases is gaining acceptance, as there are strong associations between periodontal disease and atherosclerotic vascular disease, diabetes, and hospital-associated pneumonia, amongst others. As many jurisdictions have various protocols for managing this oral-systemic axis of disease, we sought to provide a consensus on this notion with the help of a multidisciplinary team from the Czech Republic. METHODS: A multidisciplinary team comprising physicians/surgeons in the specialities of dentistry, ear-nose and throat (ENT), cardiology, orthopaedics, oncology, and diabetology were quetioned with regard to their conceptual understanding of the focal infection theory particularly in relation to the oral-systemic axis. The team also established a protocol to determine the strength of these associations and to plan the therapeutic steps needed to treat focal odontogenic infections whenever possible. RESULTS: Scoring algorithms were devised for odontogenic inflammatory diseases and systemic risks, and standardised procedures were developed for general use. CONCLUSIONS: The designed algorithm of the oral-systemic axis will be helpful for all health care workers in guiding their patient management protocol. CI - Copyright (c) 2023 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Perina, Vojtech AU - Perina V AD - Department of Oral and Maxillofacial Surgery, Masaryk University, Faculty of Medicine and University Hospital Brno, Brno, Czech Republic; Czech Dental Chamber, Prague, Czech Republic. Electronic address: perina.vojtech@fnbrno.cz. FAU - Smucler, Roman AU - Smucler R AD - Czech Dental Chamber, Prague, Czech Republic; Department of Stomatology, 1st Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic; Department of Stomatology, Faculty of Medicine, Slovak Medical University, Bratislava, Slovak Republic. FAU - Nemec, Petr AU - Nemec P AD - Department of Cardiovascular Surgery and Transplantations, Masaryk University, Faculty of Medicine and St. Anne s University Hospital, Brno, Czech Republic. FAU - Bartak, Vladislav AU - Bartak V AD - 1. Orthopedic Clinic of the 1st Medical Faculty of Charles University and University Hospital Motol, Prague, Czech Republic. LA - eng PT - Consensus Statement PT - Journal Article DEP - 20231203 PL - England TA - Int Dent J JT - International dental journal JID - 0374714 SB - IM MH - Humans MH - Czech Republic MH - *Focal Infection, Dental/complications/therapy MH - Patient Care Team MH - Periodontal Diseases/therapy MH - Dental Caries/therapy PMC - PMC11123548 OTO - NOTNLM OT - Focal infection OT - Microbiota OT - Oral health OT - Systemic diseases EDAT- 2023/12/04 00:42 MHDA- 2024/05/17 00:43 PMCR- 2023/12/03 CRDT- 2023/12/03 22:00 PHST- 2023/07/03 00:00 [received] PHST- 2023/10/17 00:00 [revised] PHST- 2023/11/01 00:00 [accepted] PHST- 2024/05/17 00:43 [medline] PHST- 2023/12/04 00:42 [pubmed] PHST- 2023/12/03 22:00 [entrez] PHST- 2023/12/03 00:00 [pmc-release] AID - S0020-6539(23)00966-8 [pii] AID - 10.1016/j.identj.2023.11.001 [doi] PST - ppublish SO - Int Dent J. 2024 Jun;74(3):510-518. doi: 10.1016/j.identj.2023.11.001. Epub 2023 Dec 3. PMID- 38042339 OWN - NLM STAT- MEDLINE DCOM- 20240219 LR - 20240308 IS - 1916-7075 (Electronic) IS - 0828-282X (Linking) VI - 40 IP - 2 DP - 2024 Feb TI - Mitral Valve Intervention in Elderly or High-Risk Patients: A Review of Current Surgical and Interventional Management. PG - 250-262 LID - S0828-282X(23)01958-X [pii] LID - 10.1016/j.cjca.2023.11.031 [doi] AB - Mitral regurgitation is a prevalent valvular disease, and its management has gained increasing importance because of the aging population. Although traditional surgery remains the gold standard, the field of transcatheter therapies, including transcatheter edge-to-edge repair and, more recently transcatheter mitral valve replacement are advancing and are being explored as viable alternatives, particularly for patients at high surgical risk. It is essential to emphasize the necessity of a multidisciplinary team approach, involving specialized valve teams, imaging experts, cardiac anaesthesiologists, and other relevant specialists, is crucial in achieving optimal outcomes. Furthermore, proper execution of procedures, postprocedural care, and diligent follow-up for these patients are essential components for successful results. It is essential to underscore that traditional mitral valve surgery continues to play a significant role. Simultaneously, it is important to acknowledge the expanding array of transcatheter interventions available for this specific patient population. CI - Copyright (c) 2023 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved. FAU - Gedela, Maheedhar AU - Gedela M AD - Heartland Cardiology, Wesley Medical Center, Wichita, Kansas, USA. FAU - Cangut, Busra AU - Cangut B AD - Department of Cardiovascular Surgery, Icahn School of Medicine at Mount Sinai, New York, New York, USA. FAU - Safi, Lucy AU - Safi L AD - Division of Cardiology, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, New York, USA. FAU - Krishnamoorthy, Parasuram AU - Krishnamoorthy P AD - Division of Cardiology, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, New York, USA. FAU - Pandis, Dimosthenis AU - Pandis D AD - Department of Cardiovascular Surgery, Icahn School of Medicine at Mount Sinai, New York, New York, USA. FAU - El-Eshmawi, Ahmed AU - El-Eshmawi A AD - Department of Cardiovascular Surgery, Icahn School of Medicine at Mount Sinai, New York, New York, USA. FAU - Tang, Gilbert H L AU - Tang GHL AD - Department of Cardiovascular Surgery, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Electronic address: gilbert.tang@mountsinai.org. LA - eng PT - Journal Article PT - Review DEP - 20231130 PL - England TA - Can J Cardiol JT - The Canadian journal of cardiology JID - 8510280 SB - IM MH - Humans MH - Aged MH - Mitral Valve/diagnostic imaging/surgery MH - *Heart Valve Prosthesis Implantation/methods MH - Cardiac Catheterization/methods MH - *Mitral Valve Insufficiency/diagnosis/surgery/etiology MH - *Cardiac Surgical Procedures/adverse effects MH - Treatment Outcome EDAT- 2023/12/03 00:42 MHDA- 2024/02/19 06:42 CRDT- 2023/12/02 19:28 PHST- 2023/11/05 00:00 [received] PHST- 2023/11/25 00:00 [revised] PHST- 2023/11/26 00:00 [accepted] PHST- 2024/02/19 06:42 [medline] PHST- 2023/12/03 00:42 [pubmed] PHST- 2023/12/02 19:28 [entrez] AID - S0828-282X(23)01958-X [pii] AID - 10.1016/j.cjca.2023.11.031 [doi] PST - ppublish SO - Can J Cardiol. 2024 Feb;40(2):250-262. doi: 10.1016/j.cjca.2023.11.031. Epub 2023 Nov 30. PMID- 38041702 OWN - NLM STAT- MEDLINE DCOM- 20240318 LR - 20261010 IS - 1573-7322 (Electronic) IS - 1382-4147 (Linking) VI - 29 IP - 2 DP - 2024 Mar TI - Multidisciplinary approach in cardiomyopathies: From genetics to advanced imaging. PG - 445-462 LID - 10.1007/s10741-023-10373-8 [doi] AB - Cardiomyopathies are myocardial diseases characterized by mechanical and electrical dysfunction of the heart muscle which could lead to heart failure and life-threatening arrhythmias. Certainly, an accurate anamnesis, a meticulous physical examination, and an ECG are cornerstones in raising the diagnostic suspicion. However, cardiovascular imaging techniques are indispensable to diagnose a specific cardiomyopathy, to stratify the risk related to the disease and even to track the response to the therapy. Echocardiography is often the first exam that the patient undergoes, because of its non-invasiveness, wide availability, and cost-effectiveness. Cardiac magnetic resonance imaging allows to integrate and implement the information obtained with the echography. Furthermore, cardiomyopathies' genetic basis has been investigated over the years and the list of genetic mutations deemed potentially pathogenic is expected to grow further. The aim of this review is to show echocardiographic, cardiac magnetic resonance imaging, and genetic features of several cardiomyopathies: dilated cardiomyopathy (DMC), hypertrophic cardiomyopathy (HCM), arrhythmogenic cardiomyopathy (ACM), left ventricular noncompaction cardiomyopathy (LVNC), myocarditis, and takotsubo cardiomyopathy. CI - (c) 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Santoro, Francesco AU - Santoro F AUID- ORCID: 0000-0001-9909-6513 AD - Department of Medical and Surgical Sciences, Cardiology Unit, Policlinico "Riuniti", University of Foggia, Viale Pinto n.1, 71122, Foggia, Italy. dr.francesco.santoro.it@gmail.com. FAU - Vitale, Enrica AU - Vitale E AD - Department of Medical and Surgical Sciences, Cardiology Unit, Policlinico "Riuniti", University of Foggia, Viale Pinto n.1, 71122, Foggia, Italy. FAU - Ragnatela, Ilaria AU - Ragnatela I AD - Department of Medical and Surgical Sciences, Cardiology Unit, Policlinico "Riuniti", University of Foggia, Viale Pinto n.1, 71122, Foggia, Italy. FAU - Cetera, Rosa AU - Cetera R AD - Department of Medical and Surgical Sciences, Cardiology Unit, Policlinico "Riuniti", University of Foggia, Viale Pinto n.1, 71122, Foggia, Italy. FAU - Leopzzi, Alessandra AU - Leopzzi A AD - Department of Cardiology, Perrino Hospital, Brindisi, Italy. FAU - Mallardi, Adriana AU - Mallardi A AD - Department of Cardiology, Di Venere Hospital, Bari, Italy. FAU - Matera, Annalisa AU - Matera A AD - Department of Medical and Surgical Sciences, Cardiology Unit, Policlinico "Riuniti", University of Foggia, Viale Pinto n.1, 71122, Foggia, Italy. FAU - Mele, Marco AU - Mele M AD - Department of Medical and Surgical Sciences, Cardiology Unit, Policlinico "Riuniti", University of Foggia, Viale Pinto n.1, 71122, Foggia, Italy. FAU - Correale, Michele AU - Correale M AD - Department of Medical and Surgical Sciences, Cardiology Unit, Policlinico "Riuniti", University of Foggia, Viale Pinto n.1, 71122, Foggia, Italy. FAU - Brunetti, Natale Daniele AU - Brunetti ND AD - Department of Medical and Surgical Sciences, Cardiology Unit, Policlinico "Riuniti", University of Foggia, Viale Pinto n.1, 71122, Foggia, Italy. LA - eng PT - Journal Article PT - Review DEP - 20231202 PL - United States TA - Heart Fail Rev JT - Heart failure reviews JID - 9612481 SB - IM MH - Humans MH - *Cardiomyopathies/diagnostic imaging/genetics MH - *Cardiomyopathy, Hypertrophic/diagnosis MH - Heart MH - *Cardiomyopathy, Dilated/diagnosis MH - Myocardium OTO - NOTNLM OT - CMR OT - Cardiac magnetic resonance OT - Cardiomyopathy OT - Echocardiography OT - Genetics OT - Sudden cardiac death EDAT- 2023/12/02 12:42 MHDA- 2024/03/18 06:42 CRDT- 2023/12/02 11:03 PHST- 2023/11/23 00:00 [accepted] PHST- 2024/03/18 06:42 [medline] PHST- 2023/12/02 12:42 [pubmed] PHST- 2023/12/02 11:03 [entrez] AID - 10.1007/s10741-023-10373-8 [pii] AID - 10.1007/s10741-023-10373-8 [doi] PST - ppublish SO - Heart Fail Rev. 2024 Mar;29(2):445-462. doi: 10.1007/s10741-023-10373-8. Epub 2023 Dec 2. PMID- 38040450 OWN - NLM STAT- MEDLINE DCOM- 20240325 LR - 20260910 IS - 1468-201X (Electronic) IS - 1355-6037 (Linking) VI - 110 IP - 8 DP - 2024 Mar 22 TI - Incremental value of machine learning for risk prediction in tetralogy of Fallot. PG - 560-568 LID - 10.1136/heartjnl-2023-323296 [doi] AB - OBJECTIVE: Machine learning (ML) can facilitate prediction of major adverse cardiovascular events (MACEs) in repaired tetralogy of Fallot (rTOF). We sought to determine the incremental value of ML above expert clinical judgement for risk prediction in rTOF. METHODS: Adult congenital heart disease (ACHD) clinicians (>/=10 years of experience) participated (one cardiac surgeon and four cardiologists (two paediatric and two adult cardiology trained) with expertise in heart failure (HF), electrophysiology, imaging and intervention). Clinicians identified 10 high-yield variables for 5-year MACE prediction (defined as a composite of mortality, resuscitated sudden death, sustained ventricular tachycardia and HF). Risk for MACE (low, moderate or high) was assigned by clinicians blinded to outcome for adults with rTOF identified from an institutional database (n=25 patient reviews conducted by five independent observers). A validated ML model identified 10 variables for risk prediction in the same population. RESULTS: Prediction by ML was similar to the aggregate score of all experts (area under the curve (AUC) 0.85 (95% CI 0.58 to 0.96) vs 0.92 (0.72 to 0.98), p=0.315). Experts with >/=20 years of experience had superior discriminative capacity compared with <20 years (AUC 0.98 (95% CI 0.86 to 0.99) vs 0.80 (0.56 to 0.93), p=0.027). In those with <20 years of experience, ML provided incremental value such that the combined (clinical+ML) AUC approached >/=20 years (AUC 0.85 (95% CI 0.61 to 0.95), p=0.055). CONCLUSIONS: Robust prediction of 5-year MACE in rTOF was achieved using either ML or a multidisciplinary team of ACHD experts. Risk prediction of some clinicians was enhanced by incorporation of ML suggesting that there may be incremental value for ML in select circumstances. CI - (c) Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Ishikita, Ayako AU - Ishikita A AUID- ORCID: 0000-0003-0387-6078 AD - Division of Cardiology, Peter Munk Cardiac Centre, University Health Network, University of Toronto, Toronto, ON, Canada. FAU - McIntosh, Chris AU - McIntosh C AD - Division of Cardiology, Peter Munk Cardiac Centre, University Health Network, University of Toronto, Toronto, ON, Canada. AD - Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada. AD - Joint Department of Medical Imaging, University of Toronto, Toronto, Ontario, Canada. FAU - Roche, S Lucy AU - Roche SL AD - Division of Cardiology, Peter Munk Cardiac Centre, University Health Network, University of Toronto, Toronto, ON, Canada. FAU - Barron, David J AU - Barron DJ AD - Department of Cardiovascular Surgery, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada. FAU - Oechslin, Erwin AU - Oechslin E AUID- ORCID: 0000-0001-7084-8494 AD - Division of Cardiology, Peter Munk Cardiac Centre, University Health Network, University of Toronto, Toronto, ON, Canada. FAU - Benson, Lee AU - Benson L AD - Division of Cardiology, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada. FAU - Nair, Krishnakumar AU - Nair K AD - Division of Cardiology, Peter Munk Cardiac Centre, University Health Network, University of Toronto, Toronto, ON, Canada. FAU - Lee, Myunghyun M AU - Lee MM AD - Department of Cardiovascular Surgery, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada. FAU - Gritti, Michael N AU - Gritti MN AD - Division of Cardiology, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada. FAU - Hanneman, Kate AU - Hanneman K AD - Joint Department of Medical Imaging, University of Toronto, Toronto, Ontario, Canada. FAU - Karur, Gauri Rani AU - Karur GR AUID- ORCID: 0000-0002-3757-7888 AD - Joint Department of Medical Imaging, University of Toronto, Toronto, Ontario, Canada. FAU - Wald, Rachel M AU - Wald RM AUID- ORCID: 0000-0002-2373-6438 AD - Division of Cardiology, Peter Munk Cardiac Centre, University Health Network, University of Toronto, Toronto, ON, Canada Rachel.Wald@uhn.ca. AD - Joint Department of Medical Imaging, University of Toronto, Toronto, Ontario, Canada. AD - Division of Cardiology, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240322 PL - England TA - Heart JT - Heart (British Cardiac Society) JID - 9602087 SB - IM MH - Humans MH - Adult MH - Child MH - *Tetralogy of Fallot/diagnosis/surgery MH - *Heart Defects, Congenital MH - *Tachycardia, Ventricular/diagnosis/etiology MH - Heart MH - Machine Learning OTO - NOTNLM OT - Magnetic Resonance Imaging OT - Quality of Health Care OT - Risk Factors OT - Tetralogy of Fallot COIS- Competing interests: None declared. EDAT- 2023/12/02 00:42 MHDA- 2024/03/25 06:43 CRDT- 2023/12/01 20:43 PHST- 2023/08/03 00:00 [received] PHST- 2023/10/20 00:00 [accepted] PHST- 2024/03/25 06:43 [medline] PHST- 2023/12/02 00:42 [pubmed] PHST- 2023/12/01 20:43 [entrez] AID - heartjnl-2023-323296 [pii] AID - 10.1136/heartjnl-2023-323296 [doi] PST - epublish SO - Heart. 2024 Mar 22;110(8):560-568. doi: 10.1136/heartjnl-2023-323296. PMID- 38040221 OWN - NLM STAT- MEDLINE DCOM- 20240110 LR - 20240110 IS - 1535-6280 (Electronic) IS - 0146-2806 (Linking) VI - 49 IP - 2 DP - 2024 Feb TI - Methotrexate & rheumatoid arthritis associated atherosclerosis: A narrative review of multidisciplinary approach for risk modification by the international board of experts. PG - 102230 LID - S0146-2806(23)00647-3 [pii] LID - 10.1016/j.cpcardiol.2023.102230 [doi] AB - Rheumatoid arthritis (RA) is an idiopathic, autoimmune connective tissue disorder that primarily affects the synovial joints, causing symmetric, erosive-deforming polyarthritis. It is also associated with extra-articular manifestations, particularly cardiovascular (CV) diseases (CVD). CV risk modification in RA remains unsolved despite recent advances in the management of RA. RA is an independent risk factor for atherosclerosis. RA and atherosclerosis share similar pathophysiological features (such as the pro-inflammatory cascade activation including interleukin-6) and risk factors (such as microflora dysbacteriosis and smoking). Patients with RA experience an exacerbation of atherogenesis, with atheromas destabilization, endothelial dysfunction, vasculitis, and hypercytokinemia. Consequently, the inflammatory response associated with RA is the basis for CVD development. The treat-to-target strategy not only improved RA control but also had a favorable effect on the morpho-functional state of the CV system in patients living with RA. Thus, disease-modifying antirheumatic drugs (DMARDs) - in particular methotrexate - may have a beneficial effect on the prevention of CV events in RA. It must be mentioned that RA is a serious multi-system disease, not only because of a window period during which the course of RA can be reversed, but also due to early damage to the heart and blood vessels. For this reason, a thorough cardiological assessment must be performed for all patients with RA, regardless of sex, age, disease stage, and disease activity score. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Avagimyan, Ashot AU - Avagimyan A AD - MD, PhD, Assistant Professor, Department of Anatomical Pathology and Clinical Morphology, Yerevan State Medical University after M. Heratsi, Yerevan, Armenia. Electronic address: dr.ashotavagimyan@gmail.com. FAU - Fogacci, Federica AU - Fogacci F AD - MD, Research Fellow, Atherosclerosis and Metabolic Disorders Research Unit, University of Bologna, Bologna, Italy. FAU - Pogosova, Nana AU - Pogosova N AD - MD, PhD, Professor, Head of Laboratory of Preventive Cardiology, Deputy Director for Science and Preventive Cardiology, National Medical Research Center of Cardiology named after academician E. Chazov, Moscow, Russia. FAU - Kakturskiy, Lev AU - Kakturskiy L AD - MD, Ph.D, Scientific Director, A. P. Avtsyn Research Institute of Human Morphology of Petrovskiy NRCS, Moscow, Russia. FAU - Jndoyan, Zinaida AU - Jndoyan Z AD - MD, PhD, Head of Internal Diseases Propaedeutic Department, Head of Internal Medicine Unit of University Clinical Hospital, Yerevan State Medical University after M. Heratsi, Yerevan, Armenia. FAU - Faggiano, Andrea AU - Faggiano A AD - MD, PhD, Department of Cardio-Thoracic-Vascular Diseases, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Italy; Department of Clinical Sciences and Community Health, University of Milano, Italy. FAU - Bairamyan, Tamara AU - Bairamyan T AD - MD, PhD, Associate Professor, Department of Rheumatology, Yerevan State Medical University after M. Heratsi, Yerevan, Armenia. FAU - Agati, Luciano AU - Agati L AD - MD, PhD, Head of Cardiology Unit Aziendo Umberto II, Department of Cardiology, La Sapienza University of Rome, Rome, Italy. FAU - Sattar, Yasar AU - Sattar Y AD - MD, Department of Cardiology, West Virginia University, Morgantown, WV, USA. FAU - Mkrchyan, Lusine AU - Mkrchyan L AD - MD, PhD, Associate Professor, Department of Cardiology, Yerevan State Medical University after M. Heratsi, Yerevan, Armenia. FAU - Avetisyan, Gayane AU - Avetisyan G AD - MD, PhD, Associate Professor, Department of Topographical Anatomy and Operative Surgery, Yerevan State Medical University after M. Heratsi, Yerevan, Armenia. FAU - Ginosyan, Knarik AU - Ginosyan K AD - MD, PhD, Head of Rheumatology Department, Yerevan State Medical University after M. Heratsi, Yerevan, Armenia. FAU - Aznauryan, Anahit AU - Aznauryan A AD - PhD, Associate Professor, Histology Department, Yerevan State Medical University after M. Heratsi, Yerevan, Armenia. FAU - Sahakyan, Karmen AU - Sahakyan K AD - PhD, Professor, Head of Histology Department, Yerevan State Medical University after M. Heratsi, Yerevan, Armenia. FAU - Trofimenko, Artem AU - Trofimenko A AD - MD, PhD, Associate Professor, Department of Pathophysiology, Kuban State Medical University, Krasnodar, Russia. FAU - Urazova, Olga AU - Urazova O AD - MD, PhD, Professor, Head of Pathophysiology Department, Siberian State Medical University, Tomsk, Russia. FAU - Mikhaleva, Liudmila AU - Mikhaleva L AD - MD, PhD, Director, A. P. Avtsyn Research Institute of Human Morphology of Petrovskiy NRCS, Moscow, Russia. FAU - Vandysheva, Rositsa AU - Vandysheva R AD - MD, PhD, A. P. Avtsyn Research Institute of Human Morphology of Petrovskiy NRCS, Moscow, Russia. FAU - Kogan, Eugenia AU - Kogan E AD - MD, PhD, Professor, Head of Anatomical Pathology Department, I. M. Sechenov First Moscow State Medical University, Moscow, Russia. FAU - Demura, Tatiana AU - Demura T AD - MD, PhD, Professor, Director of Institute of Clinical Morphology and Digital Pathology, I. M. Sechenov First Moscow State Medical University, Moscow, Russia. FAU - Kc, Manish AU - Kc M AD - MD, North Alabama Medical Centre, Florence, Alabama, USA. FAU - Shafie, Davood AU - Shafie D AD - MD, PhD, Director of Heart Failure Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran. FAU - Nicola, Stefania AU - Nicola S AD - MD, PhD, Immunology and Allergy Unit, AO Ordine Mauriziano di Torino and Department of Medical Sciences, University of Turin, Italy. FAU - Brussino, Luisa AU - Brussino L AD - MD, PhD, Director of the Allergy and Immunology unit AO Ordine Mauriziano di Torino - Department of Medical Sciences, University of Turin, Italy. FAU - Cicero, Arrigo AU - Cicero A AD - MD, PhD, Professor, Atherosclerosis and Metabolic Disorders Research Unit, University of Bologna, Bologna, Italy. FAU - Biondi-Zoccai, Giuseppe AU - Biondi-Zoccai G AD - MD, PhD, Professor, Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy; Mediterranea Cardiocentro, Napoli, Italy. FAU - Sarrafzadegan, Nizal AU - Sarrafzadegan N AD - MD, Professor, Director of Isfahan Cardiovascular Research Center (WHO Collaboration Center), Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran; School of Population and Public Health, Faculty of Medicine, University of British Columbia, Vancouver, Canada. LA - eng PT - Journal Article PT - Review DEP - 20231129 PL - Netherlands TA - Curr Probl Cardiol JT - Current problems in cardiology JID - 7701802 RN - YL5FZ2Y5U1 (Methotrexate) RN - 0 (Antirheumatic Agents) SB - IM MH - Humans MH - Methotrexate/adverse effects MH - *Arthritis, Rheumatoid/complications/drug therapy MH - *Antirheumatic Agents/adverse effects MH - Risk Factors MH - *Atherosclerosis/etiology/prevention & control MH - *Cardiovascular Diseases/epidemiology/etiology/prevention & control COIS- Declaration of Competing Interest None. EDAT- 2023/12/02 00:42 MHDA- 2024/01/10 06:42 CRDT- 2023/12/01 19:28 PHST- 2023/11/19 00:00 [received] PHST- 2023/11/28 00:00 [accepted] PHST- 2024/01/10 06:42 [medline] PHST- 2023/12/02 00:42 [pubmed] PHST- 2023/12/01 19:28 [entrez] AID - S0146-2806(23)00647-3 [pii] AID - 10.1016/j.cpcardiol.2023.102230 [doi] PST - ppublish SO - Curr Probl Cardiol. 2024 Feb;49(2):102230. doi: 10.1016/j.cpcardiol.2023.102230. Epub 2023 Nov 29. PMID- 38039803 OWN - NLM STAT- MEDLINE DCOM- 20240108 LR - 20240108 IS - 1872-8464 (Electronic) IS - 0165-5876 (Linking) VI - 176 DP - 2024 Jan TI - Single stage pediatric airway reconstruction in solid organ transplant recipients. PG - 111804 LID - S0165-5876(23)00371-3 [pii] LID - 10.1016/j.ijporl.2023.111804 [doi] AB - OBJECTIVES: To describe results of single stage laryngotracheal reconstruction (ssLTR) in patients with solid organ transplants and to discuss modifications which need to be considered in this subset of patients pre-operatively, intra-operatively and post-operatively. STUDY DESIGN: We performed a retrospective case series review of children undergoing single stage laryngotracheal reconstruction in the context of prior solid organ transplant. SETTING: A tertiary care academic setting. METHODS: Pediatric cases undergoing Laryngotracheal reconstruction over a 3-year period. Demographic data including age, sex, presenting symptoms, operative details. RESULTS: Two cases of ssLTR in solid organ transplant patients were found, one each with renal and cardiac transplants respectively. Both patients successfully underwent ssLTR for Grade 2 subglottic stenosis. The care of these patients was multidisciplinary and required alterations in their preoperative prophylactic antibiotics. While they did not require changes to the LTR post-operative sedation protocol, their immunosuppressant doses and target ranges were lowered. Special care was taken to avoid nephrotoxic and cardiotoxic medications throughout their hospital stay. CONCLUSIONS: Although traditionally considered for double stage laryngotracheal reconstruction, single stage laryngotracheal reconstruction is a viable option in patients with solid organ transplant. These patients require a multidisciplinary approach and pharmacological protocol alterations pre-, intra-, and post-operatively. CI - Copyright (c) 2023 Elsevier B.V. All rights reserved. FAU - Belding, Emily AU - Belding E AD - University of Iowa Hospitals and Clinics, Department of Otolaryngology- Head and Neck Surgery, 200 Hawkins Drive, Iowa City, IA, 52242, USA. FAU - Kanotra, Sohit Paul AU - Kanotra SP AD - University of Iowa Hospitals and Clinics, Department of Otolaryngology- Head and Neck Surgery, 200 Hawkins Drive, Iowa City, IA, 52242, USA; University of California Los Angeles, Department of Otolaryngology- Head and Neck Surgery, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, CHS 62-132, Los Angeles, CA, 90095-1624, USA. Electronic address: skanotra@mednet.ucla.edu. LA - eng PT - Journal Article DEP - 20231125 PL - Ireland TA - Int J Pediatr Otorhinolaryngol JT - International journal of pediatric otorhinolaryngology JID - 8003603 SB - IM MH - Child MH - Humans MH - Retrospective Studies MH - *Tracheal Stenosis MH - Treatment Outcome MH - *Laryngostenosis/etiology/surgery MH - *Organ Transplantation OTO - NOTNLM OT - Airway OT - Airway reconstruction OT - Cardiac OT - Children OT - Dysphagia OT - Heart OT - Kidney OT - Laryngotracheoplasty OT - Larynx OT - Obstruction OT - Pediatric OT - Renal OT - Stridor OT - Swallowing OT - Tracheostomy OT - Transplant COIS- Declaration of competing interest None. EDAT- 2023/12/02 00:41 MHDA- 2024/01/08 06:43 CRDT- 2023/12/01 18:11 PHST- 2023/10/09 00:00 [received] PHST- 2023/11/17 00:00 [revised] PHST- 2023/11/21 00:00 [accepted] PHST- 2024/01/08 06:43 [medline] PHST- 2023/12/02 00:41 [pubmed] PHST- 2023/12/01 18:11 [entrez] AID - S0165-5876(23)00371-3 [pii] AID - 10.1016/j.ijporl.2023.111804 [doi] PST - ppublish SO - Int J Pediatr Otorhinolaryngol. 2024 Jan;176:111804. doi: 10.1016/j.ijporl.2023.111804. Epub 2023 Nov 25. PMID- 39790131 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250315 IS - 2772-9931 (Electronic) IS - 2772-9931 (Linking) VI - 2 IP - 2 DP - 2024 Jun TI - Incidence of Underreferral to Multidisciplinary Evaluation in Severe Primary Mitral Regurgitation. PG - 241-245 LID - 10.1016/j.atssr.2023.11.015 [doi] AB - BACKGROUND: Severe primary mitral regurgitation (MR) warrants multidisciplinary evaluation involving cardiac surgeons and structural interventional cardiologists. The incidence and potential impact on outcomes of missed evaluation remain unknown. METHODS: We conducted a retrospective cohort study of patients with new diagnoses of severe primary MR from an echocardiography database within a large health care network. Of 37,749 unique patients with echocardiograms, 126 had severe primary MR. We compared the 2-year survival of patients who did and did not undergo multidisciplinary evaluation. Propensity score matching was performed on the basis of The Society of Thoracic Surgeons Predicted Risk of Mortality for mitral repair. RESULTS: Of 126 patients with severe primary MR (median age, 79 years [interquartile range, 68-89 years]; 60% women), 37 (29%) underwent multidisciplinary evaluation. Evaluated patients were younger (71 [58-79] years vs 84 [73-90] years), and of those, 26 (70%) underwent operations within 37 days of evaluation. The Society of Thoracic Surgeons Predicted Risk of Mortality median was 1% (1%-5%) and 4% (1%-10%) for evaluated and unevaluated patients, respectively. Of the 74 patients matched, the mortality rate was lower in evaluated patients at 90 days (11% [n = 4] vs 27% [n = 10]; P = .08) and 2 years (16% [n = 6] vs 35% [n = 13]; P = .06). CONCLUSIONS: The multidisciplinary referral rate for newly identified severe primary MR was low at 29%, with underreferral of low-risk, potentially operative candidates. The observed improved survival with multidisciplinary evaluation calls for efforts to maximize referral of this group of patients. CI - (c) 2023 The Author(s). FAU - Waldron, Christina AU - Waldron C AD - Division of Cardiac Surgery, Yale School of Medicine, New Haven, Connecticut. FAU - Krane, Markus AU - Krane M AD - Division of Cardiac Surgery, Yale School of Medicine, New Haven, Connecticut. AD - Department of Cardiovascular Surgery, Institute Insure, German Heart Center Munich, Technical University of Munich, Munich, Germany. FAU - Hosoba, Soh AU - Hosoba S AD - Department of Cardiovascular Surgery, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Nagoya, Japan. FAU - Geirsson, Arnar AU - Geirsson A AD - Division of Cardiac Surgery, Yale School of Medicine, New Haven, Connecticut. FAU - Mori, Makoto AU - Mori M AD - Division of Cardiac Surgery, Yale School of Medicine, New Haven, Connecticut. AD - Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, Connecticut. LA - eng GR - UL1 TR001863/TR/NCATS NIH HHS/United States PT - Journal Article DEP - 20231130 PL - United States TA - Ann Thorac Surg Short Rep JT - Annals of thoracic surgery short reports JID - 9918506088006676 PMC - PMC11708365 EDAT- 2023/11/30 00:00 MHDA- 2023/11/30 00:01 PMCR- 2023/11/30 CRDT- 2025/01/10 04:14 PHST- 2023/11/06 00:00 [accepted] PHST- 2023/11/30 00:01 [medline] PHST- 2023/11/30 00:00 [pubmed] PHST- 2025/01/10 04:14 [entrez] PHST- 2023/11/30 00:00 [pmc-release] AID - S2772-9931(23)00369-8 [pii] AID - 10.1016/j.atssr.2023.11.015 [doi] PST - epublish SO - Ann Thorac Surg Short Rep. 2023 Nov 30;2(2):241-245. doi: 10.1016/j.atssr.2023.11.015. eCollection 2024 Jun. PMID- 38032188 OWN - NLM STAT- MEDLINE DCOM- 20231229 LR - 20240106 IS - 1744-7658 (Electronic) IS - 1354-3784 (Linking) VI - 32 IP - 12 DP - 2023 Jul-Dec TI - Augmentation of natriuretic peptide (NP) receptor A and B (NPR-A and NPR-B) and cyclic guanosine monophosphate (cGMP) signalling as a therapeutic strategy in heart failure. PG - 1157-1170 LID - 10.1080/13543784.2023.2290064 [doi] AB - INTRODUCTION: Heart failure is a complex, debilitating condition and despite advances in treatment, it remains a significant cause of morbidity and mortality worldwide. Therefore, the need for alternative treatment strategies is essential. In this review, we explore the therapeutic strategies of augmenting natriuretic peptide receptors (NPR-A and NPR-B) and cyclic guanosine monophosphate (cGMP) in heart failure. AREAS COVERED: We aim to provide an overview of the evidence of preclinical and clinical studies on novel heart failure treatment strategies. Papers collected in this review have been filtered and screened following PubMed searches. This includes epigenetics, modulating enzyme activity in natriuretic peptide (NP) synthesis, gene therapy, modulation of downstream signaling by augmenting soluble guanylate cyclase (sGC) and phosphodiesterase (PDE) inhibition, nitrates, c-GMP-dependent protein kinase, synthetic and designer NP and RNA therapy. EXPERT OPINION: The novel treatment strategies mentioned above have shown great potential, however, large randomized controlled trials are still lacking. The biggest challenge is translating the results seen in preclinical trials into clinical trials. We recommend a multi-disciplinary team approach with cardiologists, geneticist, pharmacologists, bioengineers, researchers, regulators, and patients to improve heart failure outcomes. Future management can involve telemedicine, remote monitoring, and artificial intelligence to optimize patient care. FAU - Ajay, Ashwin AU - Ajay A AD - Cardiology Department, Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom. FAU - Rasoul, Debar AU - Rasoul D AD - Cardiology Department, Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom. FAU - Abdullah, Alend AU - Abdullah A AD - General Medicine, The Dudley Group NHS Foundation Trust Dudley, Dudley, United Kingdom. FAU - Lee Wei En, Benjamin AU - Lee Wei En B AD - Cardiology Department, Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom. FAU - Mashida, Knievel AU - Mashida K AUID- ORCID: 0009-0001-8229-967X AD - Cedar House, University of Liverpool, Liverpool, United Kingdom. FAU - Al-Munaer, Marwan AU - Al-Munaer M AD - Cedar House, University of Liverpool, Liverpool, United Kingdom. FAU - Ajay, Hanan AU - Ajay H AD - General Medicine, Southport and Ormskirk Hospital NHS Trust, Southport, United Kingdom. FAU - Duvva, Dileep AU - Duvva D AD - Cardiology Department, Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom. FAU - Mathew, Jean AU - Mathew J AD - Cardiology Department, Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom. FAU - Adenaya, Adeoye AU - Adenaya A AD - Cardiology Department, Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom. FAU - Lip, Gregory Y H AU - Lip GYH AD - Cedar House, University of Liverpool, Liverpool, United Kingdom. AD - Cardiology Department, Liverpool Heart & Chest Hospital NHS Trust, Liverpool, United Kingdom. AD - Cardiology Department, Liverpool John Moores University, Liverpool, United Kingdom. FAU - Sankaranarayanan, Rajiv AU - Sankaranarayanan R AD - Cardiology Department, Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom. AD - Cedar House, University of Liverpool, Liverpool, United Kingdom. LA - eng PT - Journal Article PT - Review DEP - 20231228 PL - England TA - Expert Opin Investig Drugs JT - Expert opinion on investigational drugs JID - 9434197 RN - 85-32-5 (Guanosine Monophosphate) RN - 0 (Natriuretic Peptides) RN - H2D2X058MU (Cyclic GMP) SB - IM MH - Humans MH - *Guanosine Monophosphate/therapeutic use MH - Artificial Intelligence MH - *Heart Failure/drug therapy MH - Signal Transduction MH - Natriuretic Peptides/metabolism/therapeutic use MH - Cyclic GMP/metabolism OTO - NOTNLM OT - Natriuretic peptide OT - RNA based therapy OT - cyclic guanosine monophosphate OT - downstream signaling OT - epigenetic OT - gene therapy OT - heart failure OT - modulating enzyme activity EDAT- 2023/11/30 12:42 MHDA- 2023/12/29 06:43 CRDT- 2023/11/30 09:03 PHST- 2023/12/29 06:43 [medline] PHST- 2023/11/30 12:42 [pubmed] PHST- 2023/11/30 09:03 [entrez] AID - 10.1080/13543784.2023.2290064 [doi] PST - ppublish SO - Expert Opin Investig Drugs. 2023 Jul-Dec;32(12):1157-1170. doi: 10.1080/13543784.2023.2290064. Epub 2023 Dec 28. PMID- 38030300 OWN - NLM STAT- MEDLINE DCOM- 20240326 LR - 20250117 IS - 1347-4820 (Electronic) IS - 1346-9843 (Linking) VI - 88 IP - 4 DP - 2024 Mar 25 TI - Long-Term Assessment of Survival After Transcatheter Aortic Valve Implantation　- Insights From the International Transcatheter Aortic Valve Implantation Registry. PG - 462-471 LID - 10.1253/circj.CJ-23-0593 [doi] AB - BACKGROUND: Transcatheter aortic valve implantation (TAVI) is an established treatment for severe aortic stenosis (AS), but despite estimates of life expectancy after TAVI being essential in heart team discussion, these data are scarce. Therefore, the current study sought to assess long-term survival and its trends in relation to chronological age, surgical risk, and treatment period. METHODS AND RESULTS: We included 2,414 consecutive patients who underwent TAVI for severe symptomatic AS between 2008 and 2021 at 2 international centers. For the analysis, long-term survival was evaluated according to age, surgical risk, and treatment period categorized into 3 groups, respectively. The longest follow-up was 13.5 years. Overall survival was 67.6% at 5 years and 26.9% at 10 years. Younger patients, lower surgical risk, and later treatment period showed better survival (log-rank P<0.001, respectively). In the multivariate analysis, age <75years, lower surgical risk, and later time period were significantly associated with better survival. The incidence of paravalvular leakage >/=moderate, red blood cell transfusion, and acute kidney injury were independently associated with increasing risk of 5-year death. CONCLUSIONS: In a real-world registry, survival was substantial following TAVI, especially in younger and lower surgical-risk patients, with improving outcomes over time. This should be considered in heart team discussions of life-long management for AS patients after TAVI. FAU - Sugiyama, Yoichi AU - Sugiyama Y AD - Department of Cardiology and Catheterization Laboratories, Shonan Kamakura General Hospital. AD - Heart and Lung Center, Helsinki University and Helsinki University Central Hospital. FAU - Moriyama, Noriaki AU - Moriyama N AD - Department of Cardiology and Catheterization Laboratories, Shonan Kamakura General Hospital. FAU - Miyashita, Hirokazu AU - Miyashita H AD - Department of Cardiology and Catheterization Laboratories, Shonan Kamakura General Hospital. FAU - Yokoyama, Hiroaki AU - Yokoyama H AD - Department of Cardiology and Catheterization Laboratories, Shonan Kamakura General Hospital. FAU - Ochiai, Tomoki AU - Ochiai T AD - Department of Cardiology and Catheterization Laboratories, Shonan Kamakura General Hospital. FAU - Shishido, Koki AU - Shishido K AD - Department of Cardiology and Catheterization Laboratories, Shonan Kamakura General Hospital. FAU - Jalanko, Mikko AU - Jalanko M AD - Heart and Lung Center, Helsinki University and Helsinki University Central Hospital. FAU - Yamanaka, Futoshi AU - Yamanaka F AD - Department of Cardiology and Catheterization Laboratories, Shonan Kamakura General Hospital. FAU - Vahasilta, Tommi AU - Vahasilta T AD - Heart and Lung Center, Helsinki University and Helsinki University Central Hospital. FAU - Laine, Mika AU - Laine M AD - Heart and Lung Center, Helsinki University and Helsinki University Central Hospital. FAU - Saito, Shigeru AU - Saito S AD - Department of Cardiology and Catheterization Laboratories, Shonan Kamakura General Hospital. LA - eng PT - Journal Article DEP - 20231128 PL - Japan TA - Circ J JT - Circulation journal : official journal of the Japanese Circulation Society JID - 101137683 SB - IM MH - Humans MH - Aged MH - *Transcatheter Aortic Valve Replacement/methods MH - Aortic Valve/surgery MH - *Aortic Valve Stenosis MH - Treatment Outcome MH - Risk Factors MH - *Heart Valve Prosthesis Implantation/adverse effects MH - Registries OTO - NOTNLM OT - Aortic stenosis OT - Survival OT - Transcatheter aortic valve replacement/implantation EDAT- 2023/11/30 00:42 MHDA- 2024/03/26 06:44 CRDT- 2023/11/29 20:54 PHST- 2024/03/26 06:44 [medline] PHST- 2023/11/30 00:42 [pubmed] PHST- 2023/11/29 20:54 [entrez] AID - 10.1253/circj.CJ-23-0593 [doi] PST - ppublish SO - Circ J. 2024 Mar 25;88(4):462-471. doi: 10.1253/circj.CJ-23-0593. Epub 2023 Nov 28. PMID- 38025925 OWN - NLM STAT- MEDLINE DCOM- 20231204 LR - 20231218 IS - 2214-9996 (Electronic) IS - 2214-9996 (Linking) VI - 89 IP - 1 DP - 2023 TI - Leveraging School Health Programs in Africa: Integrated Screening for Rheumatic Heart Disease and Dental Caries. PG - 81 LID - 10.5334/aogh.4239 [doi] LID - 81 AB - BACKGROUND: Rheumatic heart disease (RHD) and dental caries (DC) disproportionately affect children and young adults in sub-Saharan countries, with major impact on schoolchildren's health and education. DC in children with RHD constitutes an important risk for fatal complications. Our study aimed at assessing the feasibility of simultaneous RHD and DC screening in school environment. METHODS: March 20-24, 2022, we performed an observational descriptive study of schoolchildren in a public school in Maputo City, Mozambique. RHD screening involved two stages: first, a physical examination (including cardiac auscultation and direct observation of the oral cavity), and second, an abbreviated echocardiography performed by a cardiologist. Rapid testing for group A Streptococcus (GAS) was done to every eighth child in the classroom and for those with signs suggesting recent infection, in accordance with the study protocol developed for screening. A multidisciplinary team collected the data. Data were analyzed using descriptive statistics. FINDINGS: A total of 954 students (median age 9; range 6-15) were screened. One hundred and twenty-five participants were eligible for a rapid antigen test, of which 6 (4.8%) tested positive. On clinical evaluation 52 children (5.3%) presented a heart murmur. Echocardiography on 362 children showed borderline RHD in 35 children and definite RHD in 2 (0.6%); 1 child had a ventricular septal defect. Dental cavities were present in 444 (48.4%), despite 904 out of 917 students reporting brushing of their teeth once to three times daily (98.6%). CONCLUSION: School-based integrated oral and cardiovascular screenings and use of rapid tests for GAS carriage provide crucial information to create customized preventive strategies for rheumatic fever (RF) and RHD in low- and middle-income countries (LMICs), in addition to detecting children at very high risk of bacterial endocarditis. The sustainability of such interventions and acceptability by health providers needs to be assessed. CI - Copyright: (c) 2023 The Author(s). FAU - Amade, Euridsse Sulemane AU - Amade ES AUID- ORCID: 0000-0002-7015-5003 AD - Instituto Nacional de Saude (INS), MZ. FAU - Lichucha, Edna AU - Lichucha E AUID- ORCID: 0000-0002-1702-2201 AD - Instituto Nacional de Saude (INS), MZ. FAU - Ossman, Zakir AU - Ossman Z AUID- ORCID: 0000-0002-2554-3832 AD - Instituto Nacional de Saude (INS), MZ. FAU - Jamal, Keila AU - Jamal K AUID- ORCID: 0000-0003-2143-461X AD - Public health graduate, Mozambican Institute of Health Research and Education (MIHER), MZ. FAU - Mastala, Adjine AU - Mastala A AUID- ORCID: 0000-0002-7095-4104 AD - Instituto Nacional de Saude (INS), MZ. FAU - Thorup, Lene AU - Thorup L AUID- ORCID: 0000-0002-5208-8353 AD - Department of Cardiothoracic Surgery, Copenhagen University Hospital-Rigshospitalet, DK. FAU - Soares, Carlos Jose AU - Soares CJ AUID- ORCID: 0000-0002-8830-605X AD - Department at Universidade Federal de Uberlandia, BR. FAU - N'Gueta, Roland Aka AU - N'Gueta RA AUID- ORCID: 0000-0002-6443-2588 AD - Felix Houphouet Boigny University of Abidjan, Senior Cardiologist at Abidjan Heart Institute, Ivory Coast. FAU - Mocumbi, Ana AU - Mocumbi A AUID- ORCID: 0000-0002-9564-2860 AD - Cardiologist, Universidade Eduardo Mondlane, Maputo, MZ. AD - Instituto Nacional de Saude, Marracuene, MZ. LA - eng PT - Journal Article PT - Observational Study PT - Research Support, Non-U.S. Gov't DEP - 20231122 PL - United States TA - Ann Glob Health JT - Annals of global health JID - 101620864 SB - IM MH - Child MH - Humans MH - Young Adult MH - Africa MH - *Dental Caries/diagnosis/epidemiology MH - Echocardiography/methods MH - Mass Screening/methods MH - Prevalence MH - *Rheumatic Heart Disease/diagnosis/epidemiology PMC - PMC10668885 OTO - NOTNLM OT - dental caries OT - integrated care OT - rheumatic heart disease OT - schoolchildren COIS- The authors have no competing interests to declare. EDAT- 2023/11/29 18:42 MHDA- 2023/12/01 06:44 PMCR- 2023/11/22 CRDT- 2023/11/29 16:40 PHST- 2023/07/10 00:00 [received] PHST- 2023/09/26 00:00 [accepted] PHST- 2023/12/01 06:44 [medline] PHST- 2023/11/29 18:42 [pubmed] PHST- 2023/11/29 16:40 [entrez] PHST- 2023/11/22 00:00 [pmc-release] AID - 10.5334/aogh.4239 [doi] PST - epublish SO - Ann Glob Health. 2023 Nov 22;89(1):81. doi: 10.5334/aogh.4239. eCollection 2023. PMID- 38025257 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260921 IS - 2186-2494 (Electronic) IS - 1882-4072 (Print) IS - 1882-4072 (Linking) VI - 17 IP - 11 DP - 2023 TI - Cancer-Associated Stroke and Acute Endovascular Reperfusion Therapy. PG - 272-280 LID - 10.5797/jnet.ra.2023-0056 [doi] AB - Since stroke is often associated with cancer, acute stroke patients with cancer undergoing endovascular therapy (EVT) are not uncommon. Reportedly, the proportion of such cases is approximately 6%-7% of all stroke EVT cases. Ischemic stroke in patients with active cancer (cancer-associated stroke) includes not only strokes caused by cancer-related hypercoagulability but also coincident strokes due to common etiologies, strokes associated with tumor emboli, direct tumor invasion of blood vessels, and strokes associated with cancer therapy. Stroke caused by cancer-related hypercoagulability itself encompasses various entities, including paradoxical embolism, stroke due to nonbacterial thrombotic endocarditis, and in situ arterial occlusion due to disseminated intravascular coagulation or thrombotic microangiopathy. Thus, diverse mechanisms contribute to cancer-associated stroke, emphasizing the need to consider individualized treatment strategies for acute cases involving large vessel occlusion. Observational studies have shown that EVT for cancer-associated stroke results in poorer clinical outcomes, but with comparable rates of successful reperfusion and symptomatic intracranial hemorrhage when compared with stroke patients without cancer. This suggests that denying patients EVT solely on the basis of comorbid active cancer is inappropriate, and decision-making should be shared with the patients and their families, preferably through a multidisciplinary team approach. Thrombi retrieved from patients with stroke caused by cancer-related hypercoagulability have unique characteristics, being predominantly platelet rich and difficult to retrieve. Preprocedural imaging and serum biomarkers, including the hyperdense vessel sign on non-contrast CT, susceptibility vessel sign on T2* or susceptibility-weighted MRI, three-territory sign on MRI, and D-dimer levels, are valuable in evaluating the stroke subtype and thrombus features. Thrombectomy techniques, such as contact aspiration and stent retriever monotherapy, have shown varying degrees of effectiveness for stroke caused by cancer-related hypercoagulability, warranting further study. After reperfusion therapy, appropriate treatment for the prevention of stroke recurrence should be initiated, considering the specific stroke subtypes. In conclusion, cancer-associated stroke encompasses diverse subtypes, and thrombi associated with stroke caused by cancer-related hypercoagulability present various challenges for thrombectomy. Individualized treatment approaches based on underlying mechanisms are essential for improving outcomes in acute stroke patients with active cancer. Optimization of preprocedural diagnosis, EVT techniques, and secondary prevention of stroke caused by cancer-related hypercoagulability will lead to better management of these patients and enhance their quality of life. CI - (c)2023 The Japanese Society for Neuroendovascular Therapy. FAU - Hayakawa, Mikito AU - Hayakawa M AD - Department of Stroke and Cerebrovascular Diseases, University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan. AD - Department of Neurology, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan. LA - eng PT - Journal Article PT - Review DEP - 20231006 PL - Japan TA - J Neuroendovasc Ther JT - Journal of neuroendovascular therapy JID - 101488164 PMC - PMC10657734 OTO - NOTNLM OT - cancer OT - cancer-associated stroke OT - endovascular therapy OT - nonbacterial thrombotic endocarditis OT - stroke COIS- The author declares that there are no conflicts of interest. EDAT- 2023/11/29 18:43 MHDA- 2023/11/29 18:44 PMCR- 2023/01/01 CRDT- 2023/11/29 16:25 PHST- 2023/08/10 00:00 [received] PHST- 2023/09/19 00:00 [accepted] PHST- 2023/11/29 18:44 [medline] PHST- 2023/11/29 18:43 [pubmed] PHST- 2023/11/29 16:25 [entrez] PHST- 2023/01/01 00:00 [pmc-release] AID - jnet.ra.2023-0056 [pii] AID - 10.5797/jnet.ra.2023-0056 [doi] PST - ppublish SO - J Neuroendovasc Ther. 2023;17(11):272-280. doi: 10.5797/jnet.ra.2023-0056. Epub 2023 Oct 6. PMID- 38024810 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260921 IS - 1477-7509 (Print) IS - 1758-101X (Electronic) IS - 1477-7509 (Linking) VI - 18 IP - 4 DP - 2023 Dec TI - Living bioethics, theories and children's consent to heart surgery. PG - 418-426 LID - 10.1177/14777509221091086 [doi] AB - BACKGROUND: This analysis is about practical living bioethics and how law, ethics and sociology understand and respect children's consent to, or refusal of, elective heart surgery. Analysis of underlying theories and influences will contrast legalistic bioethics with living bioethics. In-depth philosophical analysis compares social science traditions of positivism, interpretivism, critical theory and functionalism and applies them to bioethics and childhood, to examine how living bioethics may be encouraged or discouraged. Illustrative examples are drawn from research interviews and observations in two London paediatric cardiac units. This paper is one of a series on how the multidisciplinary cardiac team members all contribute to the complex mosaic of care when preparing and supporting families' informed consent to surgery. RESULTS: The living bioethics of justice, care and respect for children and their consent depends on theories and practices, contexts and relationships. These can all be undermined by unseen influences: the history of adult-centric ethics; developmental psychology theories; legal and financial pressures that require consent to be defined as an adult contract; management systems and daily routines in healthcare that can intimidate families and staff; social inequalities. Mainstream theories in the clinical ethics literature markedly differ from the living bioethics in clinical practices. CONCLUSION: We aim to contribute to raising standards of respectful paediatric bioethics and to showing the relevance of virtue and feminist ethics, childhood studies and children's rights. CI - (c) The Author(s) 2022. FAU - Alderson, Priscilla AU - Alderson P AUID- ORCID: 0000-0003-4002-4501 AD - Social Research Institute, University College London, London, UK. FAU - Bowman, Deborah AU - Bowman D AD - Medical Ethics, St George's Hospital, London, UK. RINGGOLD: 4915 FAU - Brierley, Joe AU - Brierley J AUID- ORCID: 0000-0003-0919-6882 AD - Great Ormond Street Children's Hospital, London, UK. RINGGOLD: 4956 FAU - Dedieu, Nathalie AU - Dedieu N AD - Great Ormond Street Children's Hospital, London, UK. RINGGOLD: 4956 FAU - Elliott, Martin J AU - Elliott MJ AD - Cardiothoracic Surgery, University College London, London, UK. FAU - Montgomery, Jonathan AU - Montgomery J AD - Faculty of Law, University College London, London, UK. FAU - Wellesley, Hugo AU - Wellesley H AD - Great Ormond Street Children's Hospital, London, UK. RINGGOLD: 4956 LA - eng PT - Journal Article DEP - 20220407 PL - England TA - Clin Ethics JT - Clinical ethics JID - 101294546 PMC - PMC10654030 OTO - NOTNLM OT - Philosophical aspects OT - bioethics and medical ethics OT - care for specific groups OT - clinical ethics OT - health care OT - health care quality OT - informed consent OT - minors OT - professional ethics in medicine OT - professional ethics in nursing COIS- The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2023/11/29 18:42 MHDA- 2023/11/29 18:43 PMCR- 2023/11/17 CRDT- 2023/11/29 16:17 PHST- 2023/11/29 18:43 [medline] PHST- 2023/11/29 18:42 [pubmed] PHST- 2023/11/29 16:17 [entrez] PHST- 2023/11/17 00:00 [pmc-release] AID - 10.1177_14777509221091086 [pii] AID - 10.1177/14777509221091086 [doi] PST - ppublish SO - Clin Ethics. 2023 Dec;18(4):418-426. doi: 10.1177/14777509221091086. Epub 2022 Apr 7. PMID- 38021880 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260921 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 15 IP - 10 DP - 2023 Oct TI - Revascularization Modalities in Acute Coronary Syndrome: A Review of the Current State of Evidence. PG - e47207 LID - 10.7759/cureus.47207 [doi] LID - e47207 AB - Acute coronary syndrome (ACS) stands as a leading global cause of mortality, underscoring the importance of effective prevention, early diagnosis, and timely intervention. While medications offer benefits to many patients, revascularization procedures such as coronary artery bypass grafting (CABG), percutaneous coronary intervention (PCI), and emerging hybrid approaches remain pivotal for ACS management. This review delves into the 2018 ESC/EACTS guidelines alongside an analysis of existing literature to shed light on the spectrum of revascularization methods. While both CABG and PCI demonstrate promising outcomes, the optimal choice between the two hinges on a comprehensive assessment of individual patient factors, anatomical complexity guided by advanced imaging, comorbidities, and age. The determination of whether to pursue culprit or total revascularization, as well as immediate or staged revascularization, is contingent upon various factors, including age, disease complexity, and clinical outcomes. This evidence-based decision-making process is orchestrated by a multidisciplinary heart team grounded in ongoing clinical evaluation. The primary objective of this review is to provide valuable insights into revascularization strategies and scrutinize the congruence of current guidelines with recent advancements in the field. CI - Copyright (c) 2023, Surve et al. FAU - Surve, Tahoora A AU - Surve TA AD - Internal Medicine, K. J. Somaiya Medical College, Mumbai, IND. FAU - Kazim, Maitha A AU - Kazim MA AD - Internal Medicine, Rashid Hospital, Dubai, ARE. FAU - Sughra, Mehak AU - Sughra M AD - Internal Medicine, Gujranwala Teaching Hospital, Gujranwala, PAK. FAU - Mirza, Agha Muhammad Wali AU - Mirza AMW AD - Internal Medicine, Jinnah Medical and Dental College, Karachi, PAK. FAU - Murugan, Siva Kumar AU - Murugan SK AD - Internal Medicine, Meenakshi Medical College and Research Institute, Chennai, IND. FAU - Shebani, Karima A M AU - Shebani KAM AD - Internal Medicine, University of Zawia, Zawaiya, LBY. FAU - Karishma, Fnu AU - Karishma F AD - Internal Medicine, Ghulam Muhammad Mahar Medical College, Khairpur, PAK. FAU - Trada, Ishani Jayantibhai AU - Trada IJ AD - Internal Medicine, American University of Barbados, Bridgetown, BRB. FAU - Mansour, Mohammad AU - Mansour M AD - General Medicine, University of Debrecen, Debrecen, HUN. AD - General Medicine, Jordan University Hospital, Amman, JOR. FAU - Asif, Kainat AU - Asif K AD - Medicine and Surgery, Dr. Ruth K. M. Pfau Civil Hospital Karachi, Karachi, PAK. FAU - Kaur, Loveneet AU - Kaur L AD - Medicine and Surgery, Government Medical College, Patiala, IND. FAU - Kamal, Amer AU - Kamal A AD - Medicine, School of Medicine, The University of Jordan, Amman, JOR. FAU - Unachukwu, Nkechinyere AU - Unachukwu N AD - Medicine, East Tennessee State University, Johnson City, USA. FAU - Naveed, Aiman AU - Naveed A AD - Internal Medicine, Mayo Hospital, Lahore, PAK. LA - eng PT - Journal Article PT - Review DEP - 20231017 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC10653013 OTO - NOTNLM OT - : acute coronary syndrome OT - coronary artery bypass grafting(cabg) OT - culprit only pci OT - fractional flow reserve (ffr) OT - hybrid coronary revascularization OT - immediate versus staged coronary revascularization OT - intravenous ultrasound (ivus) OT - multivessel pci OT - pci (percutaneous coronary intervention) COIS- The authors have declared that no competing interests exist. EDAT- 2023/11/29 18:41 MHDA- 2023/11/29 18:42 PMCR- 2023/10/17 CRDT- 2023/11/29 15:13 PHST- 2023/10/17 00:00 [accepted] PHST- 2023/11/29 18:42 [medline] PHST- 2023/11/29 18:41 [pubmed] PHST- 2023/11/29 15:13 [entrez] PHST- 2023/10/17 00:00 [pmc-release] AID - 10.7759/cureus.47207 [doi] PST - epublish SO - Cureus. 2023 Oct 17;15(10):e47207. doi: 10.7759/cureus.47207. eCollection 2023 Oct. PMID- 38020166 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231201 IS - 2296-858X (Print) IS - 2296-858X (Electronic) IS - 2296-858X (Linking) VI - 10 DP - 2023 TI - Acute coronary syndrome associated cardiogenic shock in the catheterization laboratory: peripheral veno-arterial extracorporeal membrane oxygenator management and recommendations. PG - 1277504 LID - 10.3389/fmed.2023.1277504 [doi] LID - 1277504 AB - Cardiogenic shock (CS) in acute coronary syndrome (ACS) is a critical disease with high mortality rates requiring complex treatment to maximize patient survival chances. Emergent coronary revascularization along with circulatory support are keys to saving lives. Mechanical circulatory support may be instigated in severe, yet still reversible instances. Of these, the peripheral veno-arterial extracorporeal membrane oxygenator (pVA-ECMO) is the most widely used system for both circulatory and respiratory support. The aim of our work is to provide a review of our current understanding of the pVA-ECMO when used in the catheterization laboratory in a CS ACS setting. We detail the workings of a Shock Team: pVA-ECMO specifics, circumstances, and timing of implantations and discuss possible complications. We place emphasis on how to select the appropriate patients for potential pVA-ECMO support and what characteristics and parameters need to be assessed. A detailed, stepwise implantation algorithm indicating crucial steps is also featured for practitioners in the catheter laboratory. To provide an overall aspect of pVA-ECMO use in CS ACS we further gave pointers including relevant human resource, infrastructure, and consumables management to build an effective Shock Team to treat CS ACS via the pVA-ECMO method. CI - Copyright (c) 2023 Ehrenberger, Nemeth, Kulyassa, Fulop, Becker, Kiss, Zima, Merkely and Edes. FAU - Ehrenberger, Reka AU - Ehrenberger R AD - Heart and Vascular Center, Semmelweis University, Budapest, Hungary. FAU - Nemeth, Balazs T AU - Nemeth BT AD - Heart and Vascular Center, Semmelweis University, Budapest, Hungary. FAU - Kulyassa, Peter AU - Kulyassa P AD - Heart and Vascular Center, Semmelweis University, Budapest, Hungary. FAU - Fulop, Gabor A AU - Fulop GA AD - Heart and Vascular Center, Semmelweis University, Budapest, Hungary. FAU - Becker, David AU - Becker D AD - Heart and Vascular Center, Semmelweis University, Budapest, Hungary. FAU - Kiss, Boldizsar AU - Kiss B AD - Heart and Vascular Center, Semmelweis University, Budapest, Hungary. FAU - Zima, Endre AU - Zima E AD - Heart and Vascular Center, Semmelweis University, Budapest, Hungary. FAU - Merkely, Bela AU - Merkely B AD - Heart and Vascular Center, Semmelweis University, Budapest, Hungary. FAU - Edes, Istvan F AU - Edes IF AD - Heart and Vascular Center, Semmelweis University, Budapest, Hungary. LA - eng PT - Journal Article PT - Review DEP - 20231107 PL - Switzerland TA - Front Med (Lausanne) JT - Frontiers in medicine JID - 101648047 PMC - PMC10661940 OTO - NOTNLM OT - acute coronary syndrome (ACS) OT - cardiogenic shock (CS) OT - extracorporeal life support (ECLS) OT - percutaneous coronary intervention (PCI) OT - veno-arterial extracorporeal membrane oxygenator (VA-ECMO) COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision. EDAT- 2023/11/29 18:43 MHDA- 2023/11/29 18:44 PMCR- 2023/11/07 CRDT- 2023/11/29 14:40 PHST- 2023/08/14 00:00 [received] PHST- 2023/09/18 00:00 [accepted] PHST- 2023/11/29 18:44 [medline] PHST- 2023/11/29 18:43 [pubmed] PHST- 2023/11/29 14:40 [entrez] PHST- 2023/11/07 00:00 [pmc-release] AID - 10.3389/fmed.2023.1277504 [doi] PST - epublish SO - Front Med (Lausanne). 2023 Nov 7;10:1277504. doi: 10.3389/fmed.2023.1277504. eCollection 2023. PMID- 38018518 OWN - NLM STAT- MEDLINE DCOM- 20240925 LR - 20260608 IS - 1464-5165 (Electronic) IS - 0963-8288 (Linking) VI - 46 IP - 20 DP - 2024 Oct TI - Reducing endocrine metabolic disease risk in adults with chronic spinal cord injury: strategic activities conducted by the Ontario-Quebec RIISC team. PG - 4835-4847 LID - 10.1080/09638288.2023.2284223 [doi] AB - PURPOSE: The Rehabilitation Interventions for Individuals with a Spinal Cord Injury in the Community (RIISC) team aimed to develop and evaluate innovative rehabilitation interventions to identify endocrine metabolic disease (EMD) risk, intending to reduce the frequency and severity of EMD related morbidity and mortality among adults living with chronic spinal cord injury or disease (SCI/D). MATERIALS AND METHODS: An interprovincial team from Ontario and Quebec reviewed available EMD literature and evidence syntheses and completed an inventory of health services, policies and practices in SCI/D care. The review outcomes were combined with expert opinion to create an EMD risk model to inform health service transformation. RESULTS: EMD risk and mortality are highly prevalent among adults with chronic SCI/D. In stark contrast, few rehabilitation interventions target EMD outcomes. The modelled solution proposes: 1) abandoning single-disease paradigms and examining a holistic perspective of the individual's EMD risk, and 2) developing and disseminating practice-based research approaches in outpatient community settings. CONCLUSIONS: RIISC model adoption could accelerate EMD care optimization, and ultimately inform the design of large-scale longitudinal pragmatic trials likely to improve health outcomes. Linking the RIISC team activities to economic evaluations and policy deliverables will strengthen the relevance and impact among policymakers, health care providers and patients. FAU - Craven, Beverley Catharine AU - Craven BC AUID- ORCID: 0000-0001-8234-6803 AD - Toronto Rehabilitation Institute, Lyndhurst Centre, University Health Network, Toronto, Canada. AD - Department of Medicine, University of Toronto, Toronto, Canada. FAU - Souza, Wagner Henrique AU - Souza WH AUID- ORCID: 0000-0003-3982-5475 AD - Kite Research Institute, University Health Network, Lyndhurst Centre, Toronto, Canada. FAU - Jaglal, Susan AU - Jaglal S AD - Department of Physical Therapy, University of Toronto, Toronto, Canada. FAU - Gibbs, Jenna AU - Gibbs J AD - Department of Kinesiology and Physical Education, McGill University, Montreal, Canada. FAU - Wiest, Matheus Joner AU - Wiest MJ AD - Policy Analyst, University Health Network, Toronto, Canada. FAU - Sweet, Shane N AU - Sweet SN AUID- ORCID: 0000-0002-6172-3769 AD - Department of Kinesiology & Physical Education, McGill University, Montreal, Canada. FAU - Athanasopoulos, Peter AU - Athanasopoulos P AD - Senior Manager Public Policy and Government Relations, Spinal Cord Injury Ontario, Toronto, Canada. FAU - Lamontagne, Marie-Eve AU - Lamontagne ME AD - Universite Laval, Quebec, Canada. FAU - Boag, Lynn AU - Boag L AD - University of Guelph, Guelph, Canada. FAU - Patsakos, Eleni AU - Patsakos E AD - Rehabilitation Sciences Institute, University of Toronto, Toronto, Canada. FAU - Wolfe, Dalton AU - Wolfe D AD - Department of Physical Medicine and Rehabilitation, Western University, Parkwood Institute Research, London, Canada. FAU - Hicks, Audrey AU - Hicks A AD - Department of Kinesiology, McMaster University, Hamilton, Canada. FAU - Maltais, Desiree B AU - Maltais DB AD - Department of Rehabilitation, Physiotherapy Program, Laval University, Quebec City, Canada. FAU - Best, Krista Lynn AU - Best KL AUID- ORCID: 0000-0001-7205-7725 AD - Department of Rehabilitation, Faculty of Medicine, Universite Laval, Quebec City, Canada. FAU - Gagnon, Dany AU - Gagnon D AUID- ORCID: 0000-0003-3464-4667 AD - School of Rehabilitation, Universite de Montreal, Montreal, Canada. AD - Centre for Interdisciplinary Research in Rehabilitation, Institut Universitaire sur la Readaptation en Deficience Physique de Montreal (IURDPM), Montreal, Canada. AD - Rehabilitation, Universite de Montreal, Ecole de Readaptation, Montreal, Canada. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20231129 PL - England TA - Disabil Rehabil JT - Disability and rehabilitation JID - 9207179 SB - IM MH - Humans MH - *Spinal Cord Injuries/rehabilitation MH - Ontario MH - Quebec MH - Chronic Disease MH - Metabolic Diseases MH - Adult MH - Endocrine System Diseases MH - Patient Care Team OAB - Living with a spinal cord injury or disease (SCI/D) increases endocrine metabolic disease (EMD) risk.EMD-related outcomes include fracture; type II diabetes; and cardiovascular disease (myocardial infarction, sudden cardiac death and stroke), directly contributing to higher morbidity and mortality.Single-disease paradigms are not the ideal strategy to address multimorbidity contexts experienced in SCI/D.Practice-based research could be an alternative/adjunct to randomized control trials at generating evidence on current and emerging rehabilitation approaches. OABL- eng OTO - NOTNLM OT - Spinal cord injury OT - cardiometabolic disease OT - endocrine metabolic disease OT - osteosarcopenia OT - prevention OT - rehabilitation EDAT- 2023/11/29 12:43 MHDA- 2024/09/25 12:43 CRDT- 2023/11/29 06:35 PHST- 2024/09/25 12:43 [medline] PHST- 2023/11/29 12:43 [pubmed] PHST- 2023/11/29 06:35 [entrez] AID - 10.1080/09638288.2023.2284223 [doi] PST - ppublish SO - Disabil Rehabil. 2024 Oct;46(20):4835-4847. doi: 10.1080/09638288.2023.2284223. Epub 2023 Nov 29. PMID- 38015147 OWN - NLM STAT- MEDLINE DCOM- 20231129 LR - 20231129 IS - 0098-9134 (Print) IS - 0098-9134 (Linking) VI - 49 IP - 12 DP - 2023 Dec TI - Outcomes of the Nurse-Led Interdisciplinary-Heart Failure Team Program (NLI-HFTP): A Pilot Study. PG - 18-23 LID - 10.3928/00989134-20231108-02 [doi] AB - Information is lacking in long-term care regarding heart failure (HF) management, including in nursing homes. The current pilot project examined the Nurse-Led Interdisciplinary-Heart Failure Team Program (NLI-HFTP) intervention for nursing home residents with HF. This study used a pre-posttest one-group design with 46 nursing home residents who were primarily female, African American, of non-Hispanic ethnicity, and with an average age of 76 years. Post-intervention Nurse-Patient Interaction Scale scores were significantly higher than pre-intervention scores (mean pretest = 124.83, mean posttest score = 103.04; t [45] = 27.78, p < 0.001). Comparison of participants' medical records found a substantial decrease in the number of HF-exacerbated hospitalizations during the 3-month post-implementation period compared with rates during the 3-month pre-implementation period (16 vs. 7). The NLI-HFTP was feasible to implement in a nursing home, reduced referral rates to acute care hospitals, and could thus provide a better resident experience through increasing nurse-patient interactions. [Journal of Gerontological Nursing, 49(12), 18-23.]. FAU - Tan, Amil Kusain Jr AU - Tan AK Jr FAU - Bagnoli, Joseph AU - Bagnoli J FAU - McKenzie-Morgan, Caroll AU - McKenzie-Morgan C FAU - Ocampo-Balabagno, Araceli AU - Ocampo-Balabagno A LA - eng PT - Journal Article DEP - 20231201 PL - United States TA - J Gerontol Nurs JT - Journal of gerontological nursing JID - 7510258 MH - Humans MH - Female MH - Aged MH - *Nurse's Role MH - Pilot Projects MH - Black or African American MH - Ethnicity MH - *Heart Failure/therapy EDAT- 2023/11/28 12:42 MHDA- 2023/11/29 06:42 CRDT- 2023/11/28 10:23 PHST- 2023/11/29 06:42 [medline] PHST- 2023/11/28 12:42 [pubmed] PHST- 2023/11/28 10:23 [entrez] AID - 10.3928/00989134-20231108-02 [doi] PST - ppublish SO - J Gerontol Nurs. 2023 Dec;49(12):18-23. doi: 10.3928/00989134-20231108-02. Epub 2023 Dec 1. PMID- 38015077 OWN - NLM STAT- MEDLINE DCOM- 20240304 LR - 20240506 IS - 1573-3599 (Electronic) IS - 1059-7700 (Linking) VI - 33 IP - 1 DP - 2024 Feb TI - Exploring the training needs of inherited cardiac conditions (ICC) nurses: Elucidating role boundaries and competencies for practice in the genomics era. PG - 197-205 LID - 10.1002/jgc4.1825 [doi] AB - Nurses represent the largest professional group within the National Health Service (NHS) and are therefore central to the successful integration of mainstreaming genomics into routine healthcare. Inherited cardiac conditions (ICC) nurse roles have been developed in recent years to streamline the care for patients and families affected by an ICC. Like many nurse specialists, ICC nurses' prior exposure to genomics and the wider implications surrounding inherited conditions is limited. The aim of the study was to explore the education needs and support required for ICC nurses to fulfill their role within the genomic medicine era. A convenience sampling approach was adopted to invite ICC nurses working within various NHS Trusts across the United Kingdom to take part. Semi-structured interviews were conducted with ICC nurses (n = 8), which were recorded, transcribed, coded, and analyzed using an inductive thematic analysis approach. Analysis of interview data highlighted four core themes, which were transferrable core competencies; managing genomic information; mixed-modality learning; defining multidisciplinary team boundaries. The study highlights areas for further training and demonstrates the importance of defining competencies and role boundaries within ICC services. The ICC nurses identified the limits of their practice and the complementary role of genetic counselors, indicating the need for both professions within the ICC service and proposing implications for practice. CI - (c) 2023 National Society of Genetic Counselors. FAU - Braddel, Amy AU - Braddel A AUID- ORCID: 0000-0001-5794-3008 AD - University Hospital Southampton NHS Foundation Trust, Southampton, UK. FAU - Watson, Melanie AU - Watson M AUID- ORCID: 0000-0002-5140-4086 AD - University Hospital Southampton NHS Foundation Trust, Southampton, UK. LA - eng GR - BHF_/British Heart Foundation/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20231127 PL - United States TA - J Genet Couns JT - Journal of genetic counseling JID - 9206865 SB - IM MH - Humans MH - *State Medicine MH - Educational Status MH - Genomics MH - Learning MH - *Counselors OTO - NOTNLM OT - education OT - genetic testing OT - genetics services OT - multidisciplinary OT - professional development OT - workforce EDAT- 2023/11/28 12:41 MHDA- 2024/03/04 06:48 CRDT- 2023/11/28 10:03 PHST- 2023/10/02 00:00 [revised] PHST- 2022/12/09 00:00 [received] PHST- 2023/10/11 00:00 [accepted] PHST- 2024/03/04 06:48 [medline] PHST- 2023/11/28 12:41 [pubmed] PHST- 2023/11/28 10:03 [entrez] AID - 10.1002/jgc4.1825 [doi] PST - ppublish SO - J Genet Couns. 2024 Feb;33(1):197-205. doi: 10.1002/jgc4.1825. Epub 2023 Nov 27. PMID- 38014676 OWN - NLM STAT- MEDLINE DCOM- 20240104 LR - 20240628 IS - 2047-9980 (Electronic) IS - 2047-9980 (Linking) VI - 12 IP - 23 DP - 2023 Dec 5 TI - Early Utilization of Mechanical Circulatory Support in Acute Myocardial Infarction Complicated by Cardiogenic Shock: The National Cardiogenic Shock Initiative. PG - e031401 LID - 10.1161/JAHA.123.031401 [doi] LID - e031401 AB - BACKGROUND: Acute myocardial infarction complicated by cardiogenic shock (AMI-CS) is associated with significant morbidity and mortality. Mechanical circulatory support (MCS) devices increase systemic blood pressure and end organ perfusion while reducing cardiac filling pressures. METHODS AND RESULTS: The National Cardiogenic Shock Initiative (NCT03677180) is a single-arm, multicenter study. The purpose of this study was to assess the feasibility and effectiveness of utilizing early MCS with Impella in patients presenting with AMI-CS. The primary end point was in-hospital mortality. A total of 406 patients were enrolled at 80 sites between 2016 and 2020. Average age was 64+/-12 years, 24% were female, 17% had a witnessed out-of-hospital cardiac arrest, 27% had in-hospital cardiac arrest, and 9% were under active cardiopulmonary resuscitation during MCS implantation. Patients presented with a mean systolic blood pressure of 77.2+/-19.2 mm Hg, 85% of patients were on vasopressors or inotropes, mean lactate was 4.8+/-3.9 mmol/L and cardiac power output was 0.67+/-0.29 watts. At 24 hours, mean systolic blood pressure improved to 103.9+/-17.8 mm Hg, lactate to 2.7+/-2.8 mmol/L, and cardiac power output to 1.0+/-1.3 watts. Procedural survival, survival to discharge, survival to 30 days, and survival to 1 year were 99%, 71%, 68%, and 53%, respectively. CONCLUSIONS: Early use of MCS in AMI-CS is feasible across varying health care settings and resulted in improvements to early hemodynamics and perfusion. Survival rates to hospital discharge were high. Given the encouraging results from our analysis, randomized clinical trials are warranted to assess the role of utilizing early MCS, using a standardized, multidisciplinary approach. FAU - Basir, Mir B AU - Basir MB AUID- ORCID: 0000-0003-3486-6753 AD - Henry Ford Hospital Detroit MI. FAU - Lemor, Alejandro AU - Lemor A AUID- ORCID: 0000-0002-4649-8479 AD - University of Mississippi Jackson MS. FAU - Gorgis, Sarah AU - Gorgis S AUID- ORCID: 0000-0001-7804-8539 AD - Henry Ford Hospital Detroit MI. FAU - Patel, Kirit C AU - Patel KC AD - St. Joseph Mercy Oakland MI. FAU - Kolski, Brian C AU - Kolski BC AD - St. Joseph Hospital Orange Orange CA. FAU - Bharadwaj, Aditya S AU - Bharadwaj AS AD - Loma Linda University Medical Center Loma Linda CA. FAU - Todd, Joshua W AU - Todd JW AD - Fort Sanders Regional Medical Center Fort Sanders TN. FAU - Tehrani, Behnam N AU - Tehrani BN AD - Inova Fairfax Hospital Fairfax VA. FAU - Truesdell, Alexander G AU - Truesdell AG AUID- ORCID: 0000-0001-5656-4401 AD - Inova Fairfax Hospital Fairfax VA. FAU - Lasorda, David M AU - Lasorda DM AD - Allegheny General Hospital Pittsburg PA. FAU - Lalonde, Thomas A AU - Lalonde TA AD - Ascension St. John Hospital Detroit MI. FAU - Kaki, Amir AU - Kaki A AD - Ascension St. John Hospital Detroit MI. FAU - Schrieber, Theodore L AU - Schrieber TL AD - Ascension St. John Hospital Detroit MI. FAU - Patel, Nainesh C AU - Patel NC AD - Lehigh Valley Hospital Allentown PA. FAU - Senter, Shaun R AU - Senter SR AD - Washington Regional Medical Center Washington AK. FAU - Gelormini, Joseph L AU - Gelormini JL AUID- ORCID: 0000-0003-0519-867X AD - Mercy Hospital Buffalo NY. FAU - Marso, Steven P AU - Marso SP AD - Overland Park Regional Medical Center Overland Park KS. FAU - Rahman, Ayaz M AU - Rahman AM AD - Parkwest Medical Center Knoxville TN. FAU - Federici, Robert E AU - Federici RE AD - Presbyterian Hospital Albuquerque NM. FAU - Wilkins, Charles E AU - Wilkins CE AUID- ORCID: 0000-0003-3934-8023 AD - San Juan Regional Medical Center San Juan NM. FAU - Thomas McRae, A 3rd AU - Thomas McRae A 3rd AD - TriStar Centennial Medical Center Nashville TN. FAU - Nsair, Ali AU - Nsair A AD - Ronald Reagan UCLA Medical Center Los Angeles CA. FAU - Caputo, Christopher P AU - Caputo CP AD - North Florida Regional Medical Center Gainesville FL. FAU - Khuddus, Matheen A AU - Khuddus MA AD - North Florida Regional Medical Center Gainesville FL. FAU - Chahin, Juan J AU - Chahin JJ AUID- ORCID: 0009-0004-4432-6683 AD - Excela Health Westmoreland Hospital Greensburg PA. FAU - Dupont, Allison G AU - Dupont AG AD - Northside Cardiovascular Institute Atlanta GA. FAU - Goldsweig, Andrew M AU - Goldsweig AM AUID- ORCID: 0000-0003-2952-7837 AD - Baystate Medical Center Springfield MA. FAU - Lim, Michael J AU - Lim MJ AUID- ORCID: 0000-0003-0392-9141 AD - Hackensack Medical Center Hackensack NJ. FAU - Kapur, Navin K AU - Kapur NK AUID- ORCID: 0000-0002-8302-6796 AD - Tufts Medical Center Boston MA. FAU - Wohns, David H W AU - Wohns DHW AUID- ORCID: 0000-0001-6606-2261 AD - Spectrum Health Butterworth Hospital Grand Rapids MI. FAU - Zhou, Yueren AU - Zhou Y AD - Henry Ford Hospital Detroit MI. FAU - Hacala, Michael J AU - Hacala MJ AD - Henry Ford Hospital Detroit MI. FAU - O'Neill, William W AU - O'Neill WW AD - Henry Ford Hospital Detroit MI. LA - eng PT - Clinical Study PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't DEP - 20231128 PL - England TA - J Am Heart Assoc JT - Journal of the American Heart Association JID - 101580524 RN - 33X04XA5AT (Lactic Acid) SB - IM MH - Aged MH - Female MH - Humans MH - Male MH - Middle Aged MH - *Heart-Assist Devices MH - Lactic Acid MH - *Myocardial Infarction/complications/therapy MH - Shock, Cardiogenic/diagnosis/etiology/therapy MH - Treatment Outcome PMC - PMC10727311 OTO - NOTNLM OT - Impella OT - acute myocardial infarction OT - cardiogenic shock OT - mechanical circulatory support OT - percutaneous coronary intervention OT - pulmonary artery catheter EDAT- 2023/11/28 12:42 MHDA- 2023/12/07 12:42 PMCR- 2023/12/05 CRDT- 2023/11/28 06:34 PHST- 2023/12/07 12:42 [medline] PHST- 2023/11/28 12:42 [pubmed] PHST- 2023/11/28 06:34 [entrez] PHST- 2023/12/05 00:00 [pmc-release] AID - JAH39002 [pii] AID - 10.1161/JAHA.123.031401 [doi] PST - ppublish SO - J Am Heart Assoc. 2023 Dec 5;12(23):e031401. doi: 10.1161/JAHA.123.031401. Epub 2023 Nov 28. PMID- 38012991 OWN - NLM STAT- MEDLINE DCOM- 20240202 LR - 20240719 IS - 1879-1913 (Electronic) IS - 0002-9149 (Linking) VI - 213 DP - 2024 Feb 15 TI - Robotic-Assisted Versus Traditional Full-Sternotomy Coronary Artery Bypass Grafting Procedures: A Propensity-Matched Analysis of Hospital Costs. PG - 12-19 LID - S0002-9149(23)01259-6 [pii] LID - 10.1016/j.amjcard.2023.10.083 [doi] AB - We aim to compare hospital costs of robotic-assisted coronary artery bypass grafting (CABG) versus conventional CABG. All consecutive 1,173 patients who underwent conventional and robotic-assisted CABG between January 2018 and June 2021 were included. After propensity-matching, 267 patients in each group (robotic-assisted vs conventional) were included in the study. Patient selection for each group was decided by a treating surgeon with a heart team based on clinical factors. Syntax score was not assessed. Total costs (direct + indirect hospital costs) of patients who underwent robotic-assisted and conventional CABG were compared. Direct cost expenses included surgical operating time, hospital stay, surgical implants and supplies, catheterization laboratory, pharmacy, radiology and ultrasound imaging, blood bank, cardiology, and so on. Indirect cost expenses included general administration medical records, and so on. Using the propensity-matched groups (n = 267), we summed the total cost by year. Results for 267 propensity-matched patients (each group) evidenced that total conventional CABG costs were $9.5 million (average of $35,580/patient), whereas robotic-assisted CABG costs were $5 million ($18,726/patient). Therefore, the differences between robotic-assisted and conventional CABG costs were $4.5 million ($16,853/patient), favoring robotic-assisted over conventional CABG. Differences in direct and indirect costs were $2.2 million and $1.8 million, respectively. When the cost of the Da Vinci robot was added ($1,200,000), the total cost was $3.3 million ($12,359 x patient) lower in the robotic-assisted CABG group. Multivariate analysis showed that, mainly, the shorter hospital length of stay (7 vs 5 days) accounts for the reduced costs observed in the robotic-assisted CABG group. In conclusion, in a mature practice, robotic-assisted CABG decreases hospital length of stay, leading to reduced hospital costs compared with conventional CABG. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Dokollari, Aleksander AU - Dokollari A AD - Department of Cardiac Surgery, St. Boniface Hospital, University of Manitoba, Winnipeg, Manitoba, Canada. Electronic address: aleksanderdokollari2@gmail.com. FAU - Sicouri, Serge AU - Sicouri S AD - Department of Cardiac Surgery, Lankenau Institute for Medical Research, Wynnewood, Pennsylvania. FAU - Prendergrast, George AU - Prendergrast G AD - Department of Cardiac Surgery, Lankenau Institute for Medical Research, Wynnewood, Pennsylvania. FAU - Ramlawi, Basel AU - Ramlawi B AD - Department of Cardiac Surgery, Lankenau Institute for Medical Research, Wynnewood, Pennsylvania; Main Line Health Center for Population Health Research, Lankenau Institute for Medical Research, Wynnewood, Pennsylvania; Cardiac Surgery Department, Lankenau Institute Heart Center, Wynnewood, Pennsylvania. FAU - Mahmud, Farah AU - Mahmud F AD - Department of Cardiac Surgery, Lankenau Institute for Medical Research, Wynnewood, Pennsylvania. FAU - Kjelstrom, Stephanie AU - Kjelstrom S AD - Department of Cardiac Surgery, Lankenau Institute for Medical Research, Wynnewood, Pennsylvania. FAU - Wertan, Maryann AU - Wertan M AD - Main Line Health Center for Population Health Research, Lankenau Institute for Medical Research, Wynnewood, Pennsylvania; Cardiac Surgery Department, Lankenau Institute Heart Center, Wynnewood, Pennsylvania. FAU - Sutter, Francis AU - Sutter F AD - Main Line Health Center for Population Health Research, Lankenau Institute for Medical Research, Wynnewood, Pennsylvania; Cardiac Surgery Department, Lankenau Institute Heart Center, Wynnewood, Pennsylvania. LA - eng PT - Journal Article DEP - 20231126 PL - United States TA - Am J Cardiol JT - The American journal of cardiology JID - 0207277 SB - IM MH - Humans MH - *Hospital Costs MH - *Robotic Surgical Procedures/methods MH - Sternotomy MH - Coronary Artery Bypass/methods MH - Length of Stay MH - Retrospective Studies MH - Treatment Outcome OTO - NOTNLM OT - clinical outcomes OT - conventional CABG OT - robotic costs OT - robotic-assisted CABG COIS- Declaration of competing interest The authors have no competing interests to declare. EDAT- 2023/11/28 06:42 MHDA- 2024/02/02 06:42 CRDT- 2023/11/28 00:25 PHST- 2023/08/24 00:00 [received] PHST- 2023/10/08 00:00 [revised] PHST- 2023/10/28 00:00 [accepted] PHST- 2024/02/02 06:42 [medline] PHST- 2023/11/28 06:42 [pubmed] PHST- 2023/11/28 00:25 [entrez] AID - S0002-9149(23)01259-6 [pii] AID - 10.1016/j.amjcard.2023.10.083 [doi] PST - ppublish SO - Am J Cardiol. 2024 Feb 15;213:12-19. doi: 10.1016/j.amjcard.2023.10.083. Epub 2023 Nov 26. PMID- 38009268 OWN - NLM STAT- MEDLINE DCOM- 20231204 LR - 20250803 IS - 1473-5598 (Electronic) IS - 0263-6352 (Linking) VI - 42 IP - 1 DP - 2024 Jan 1 TI - A cost-analysis of managing secondary and apparent treatment-resistant hypertension in a specialist multidisciplinary hypertension clinic. PG - 58-69 LID - 10.1097/HJH.0000000000003535 [doi] AB - OBJECTIVES: A knowledge gap exists around the costs and budget impact of specialist hypertension clinics. This study reports on the cost of providing care in a multidisciplinary hypertension clinic staffed by nephrologist, endocrinologist and cardiologist, which manages patients with suspected secondary hypertension and/or apparent treatment-resistant hypertension. The aim of this study is to provide the evidence required to inform policy and planning care pathways for this patient group. METHODS: A cost analysis from a healthcare provider perspective using micro-costing techniques was conducted to estimate the direct implementation costs of existing standard practice for the care pathway of patients attending the multidisciplinary hypertension clinic. Sixty-five patients originally recruited for a study of medication adherence in hypertension were included in the sample. RESULTS: The total care-pathway cost per patient, taking into account clinic visits, clinical reviews, investigations and MDT discussion, was estimated to be euro3277, on average. For the patient subgroups, the average cost was euro5644 for patients diagnosed with primary aldosteronism and euro1446 for patients diagnosed with essential hypertension. CONCLUSION: There is significant cost associated with providing specialized hypertension care for patients with apparent treatment-resistant hypertension. Given the high rates of nonadherence in this population, it is likely that some of this cost could be avoided with better detection and management of medication adherence in this challenging population. Future studies should consider the cost-effectiveness of this or similar models of care by exploring the benefit to patients and the wider healthcare context of providing care of this type. CI - Copyright (c) 2023 Wolters Kluwer Health, Inc. All rights reserved. FAU - Rabbitt, Louise AU - Rabbitt L AD - Discipline of Pharmacology and Therapeutics, School of Medicine, University of Galway. FAU - Curneen, James AU - Curneen J AD - Department of Clinical Pharmacology and Therapeutics, St James' Hospital, Dublin. FAU - Hobbins, Anna AU - Hobbins A AD - Centre for Research in Medical Devices (CURAM, SFI 13/RC/2073_P2) and Health Economics and Policy Analysis Centre, University of Galway, Ireland. FAU - Browne, Darragh AU - Browne D AD - Centre for Endocrinology, Diabetes and Metabolism. FAU - Joyce, Mary AU - Joyce M AD - Centre for Endocrinology, Diabetes and Metabolism. FAU - Lappin, David AU - Lappin D AD - Department of Nephrology, Saolta University Healthcare Group (SUHCG), Galway University Hospitals. FAU - McEvoy, John William AU - McEvoy JW AD - Department of Cardiology, School of Medicine, University of Galway. AD - National Institute for Prevention and Cardiovascular Health, Galway, Ireland. FAU - Gillespie, Paddy AU - Gillespie P AD - Centre for Research in Medical Devices (CURAM, SFI 13/RC/2073_P2) and Health Economics and Policy Analysis Centre, University of Galway, Ireland. FAU - Dennedy, Michael Conall AU - Dennedy MC AD - Discipline of Pharmacology and Therapeutics, School of Medicine, University of Galway. AD - Centre for Endocrinology, Diabetes and Metabolism. LA - eng GR - WT_/Wellcome Trust/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20231116 PL - Netherlands TA - J Hypertens JT - Journal of hypertension JID - 8306882 SB - IM MH - Humans MH - Costs and Cost Analysis MH - *Hypertension/drug therapy MH - Ambulatory Care MH - Medication Adherence EDAT- 2023/11/27 06:47 MHDA- 2023/12/04 12:43 CRDT- 2023/11/27 04:33 PHST- 2023/12/04 12:43 [medline] PHST- 2023/11/27 06:47 [pubmed] PHST- 2023/11/27 04:33 [entrez] AID - 00004872-202401000-00007 [pii] AID - 10.1097/HJH.0000000000003535 [doi] PST - ppublish SO - J Hypertens. 2024 Jan 1;42(1):58-69. doi: 10.1097/HJH.0000000000003535. Epub 2023 Nov 16. PMID- 38003927 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231127 IS - 2075-4426 (Print) IS - 2075-4426 (Electronic) IS - 2075-4426 (Linking) VI - 13 IP - 11 DP - 2023 Nov 16 TI - Periorbital Facial Necrotizing Fasciitis in Adults: A Rare Severe Disease with Complex Diagnosis and Surgical Treatment-A New Case Report and Systematic Review. LID - 10.3390/jpm13111612 [doi] LID - 1612 AB - (1) Background: Necrotizing fasciitis (NF) is a severe and aggressive pathology with a rapid progression and high mortality risk. Periocular NF is a rare condition associated with a lower mortality risk but significantly higher disabling sequelae. (2) Methods: We present the case of a 67-year-old homeless patient, a victim of assault, with multiple untreated comorbidities (diabetes mellitus, cardiac conditions, and schizophrenia) and a delayed diagnosis of periocular necrotizing fasciitis. The condition showed a cyclical evolution influenced by the existing comorbidities, and the patient underwent both surgical and medical treatment with a multidisciplinary team. Additionally, we report a systematic review of cases from the literature. (3) Results: The patient's survival outcomes were favorable; however, the sequelae were disabling, not only concerning aesthetic aspects but also due to the loss of the affected eye globe. The systematic review revealed the rarity of such cases and the peculiarities of the presented case compared to those reported in the literature up to this point. (4) Conclusions: Understanding the signs, symptoms, and predisposing factors, as well as the potential rare localizations of NF, including the periocular region, can lead to the early diagnosis and treatment with good functional and aesthetic outcomes, minimizing significant disabilities. FAU - Pertea, Mihaela AU - Pertea M AUID- ORCID: 0000-0002-5308-7192 AD - Faculty of Medicine, "Grigore T Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania. AD - Department of Plastic Surgery and Reconstructive Microsurgery, "Sf. Spiridon" Emergency County Hospital, 700111 Iasi, Romania. FAU - Fotea, Madalina-Cristina AU - Fotea MC AD - Department of Plastic Surgery and Reconstructive Microsurgery, "Sf. Spiridon" Emergency County Hospital, 700111 Iasi, Romania. FAU - Luca, Stefana AU - Luca S AUID- ORCID: 0000-0002-9192-7607 AD - Faculty of Medicine, "Grigore T Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania. AD - Department of Plastic Surgery and Reconstructive Microsurgery, "Sf. Spiridon" Emergency County Hospital, 700111 Iasi, Romania. FAU - Moraru, Dan Cristian AU - Moraru DC AD - Faculty of Medicine, "Grigore T Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania. AD - Department of Plastic Surgery and Reconstructive Microsurgery, "Sf. Spiridon" Emergency County Hospital, 700111 Iasi, Romania. FAU - Filip, Alexandru AU - Filip A AD - Faculty of Medicine, "Grigore T Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania. AD - Department of Orthopaedics and Traumatology, "Sf. Spiridon" Emergency County Hospital, 700111 Iasi, Romania. FAU - Olinici-Temelie, Doinita AU - Olinici-Temelie D AD - Faculty of Medicine, "Grigore T Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania. AD - Department of Dermatology, "Sf. Spiridon" Emergency County Hospital, 700111 Iasi, Romania. FAU - Lunca, Sorinel AU - Lunca S AD - Faculty of Medicine, "Grigore T Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania. AD - Second Surgery Clinic, Regional Institute of Oncology, 700483 Iasi, Romania. FAU - Carp, Adrian Claudiu AU - Carp AC AD - Faculty of Medicine, "Grigore T Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania. AD - Department of Orthopaedics and Traumatology, "Sf. Spiridon" Emergency County Hospital, 700111 Iasi, Romania. FAU - Grosu, Oxana-Madalina AU - Grosu OM AD - Faculty of Medicine, "Grigore T Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania. AD - Department of Plastic Surgery and Reconstructive Microsurgery, "Sf. Spiridon" Emergency County Hospital, 700111 Iasi, Romania. FAU - Amarandei, Alexandru AU - Amarandei A AD - Department of Plastic Surgery and Reconstructive Microsurgery, "Sf. Spiridon" Emergency County Hospital, 700111 Iasi, Romania. FAU - Veliceasa, Bogdan AU - Veliceasa B AUID- ORCID: 0000-0002-9941-3424 AD - Faculty of Medicine, "Grigore T Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania. AD - Department of Orthopaedics and Traumatology, "Sf. Spiridon" Emergency County Hospital, 700111 Iasi, Romania. LA - eng PT - Journal Article PT - Review DEP - 20231116 PL - Switzerland TA - J Pers Med JT - Journal of personalized medicine JID - 101602269 PMC - PMC10672041 OTO - NOTNLM OT - enucleation OT - fascial flap OT - necrosis OT - periorbital necrotizing fasciitis OT - skin graft COIS- The authors declare no conflict of interest. EDAT- 2023/11/25 12:47 MHDA- 2023/11/25 12:48 PMCR- 2023/11/16 CRDT- 2023/11/25 01:19 PHST- 2023/10/18 00:00 [received] PHST- 2023/11/07 00:00 [revised] PHST- 2023/11/14 00:00 [accepted] PHST- 2023/11/25 12:48 [medline] PHST- 2023/11/25 12:47 [pubmed] PHST- 2023/11/25 01:19 [entrez] PHST- 2023/11/16 00:00 [pmc-release] AID - jpm13111612 [pii] AID - jpm-13-01612 [pii] AID - 10.3390/jpm13111612 [doi] PST - epublish SO - J Pers Med. 2023 Nov 16;13(11):1612. doi: 10.3390/jpm13111612. PMID- 38001300 OWN - NLM STAT- MEDLINE DCOM- 20240525 LR - 20240528 IS - 1863-6713 (Electronic) IS - 1863-6705 (Print) IS - 1863-6705 (Linking) VI - 72 IP - 6 DP - 2024 Jun TI - Comprehensive multi-modality treatment of thoracic aorta pseudoaneurysms: a single-center experience. PG - 387-394 LID - 10.1007/s11748-023-01986-9 [doi] AB - INTRODUCTION: Thoracic aorta false aneurysms (TAFA) are unexplored complications after cardiac surgery associated with significant morbidity and mortality. Therefore, the purpose of this study was to examine the clinical profiles, surgical techniques, and operative outcomes, of patients treated for TAFA at a single institution. METHODS: From 1996 to 2022, 112 patients were treated for aortic pseudoaneurysm (mean age 55 +/- 14 years, 78 patients were male). In the majority of the patients (90%) TAFA developed after previous cardiovascular surgery, the most common diagnosis and surgical procedure preceding the TAFA development was an aortic dissection (52%) and Bentall procedure (47%). In the rest of the cohort, the leading cause was trauma. RESULTS: Sixty-one percent of patients were indicated for reintervention (surgical reoperation, endoluminal graft implantation, septal occluder implantation, coil embolization, or a combination of procedures). Overall, 52 patients had undergone cardiac reoperation. TAFA was resected and the aorta was repaired in 55% or replaced in 45%. Operative mortality was 5.7%. In postoperative follow-up, a hypoechogenic lesion encircling aortic prosthesis was present in 94%, therefore it was determined as a negative prognostic factor. The mean follow-up was 13.2 +/- 19.4 years. CONCLUSION: Although there is no specific approach how to prevent TAFA development, maintaining normal blood pressure and regular follow-up should be applied. More frequent follow-ups should be performed in patients with a hypoechogenic lesion encircling and aortic prosthesis. Early detection during long-term postoperative follow-up, an individually tailored approach of a multidisciplinary team is necessary for favorable treatment outcomes. CI - (c) 2023. The Author(s). FAU - Recicarova, Sandra AU - Recicarova S AUID- ORCID: 0000-0002-6873-8760 AD - Department of Cardiovascular Surgery, Institute for Clinical and Experimental Medicine (IKEM), Videnska 1958/9, Prague, 140 00, Czech Republic. sandrarecicarova@yahoo.com. AD - First Faculty of Medicine, Charles University, Prague, Czech Republic. sandrarecicarova@yahoo.com. FAU - Jonak, Michael AU - Jonak M AD - Department of Cardiovascular Surgery, Institute for Clinical and Experimental Medicine (IKEM), Videnska 1958/9, Prague, 140 00, Czech Republic. FAU - Netuka, Ivan AU - Netuka I AD - Department of Cardiovascular Surgery, Institute for Clinical and Experimental Medicine (IKEM), Videnska 1958/9, Prague, 140 00, Czech Republic. AD - Second Department of Surgery, Department of Cardiovascular Surgery, First Faculty of Medicine, Charles University, Prague, Czech Republic. LA - eng PT - Journal Article DEP - 20231125 PL - Japan TA - Gen Thorac Cardiovasc Surg JT - General thoracic and cardiovascular surgery JID - 101303952 SB - IM MH - Humans MH - Male MH - *Aneurysm, False/surgery/etiology/diagnostic imaging/therapy MH - Middle Aged MH - Female MH - *Aortic Aneurysm, Thoracic/surgery MH - Aged MH - Treatment Outcome MH - Adult MH - Retrospective Studies MH - Blood Vessel Prosthesis Implantation/adverse effects MH - Reoperation MH - Endovascular Procedures/adverse effects MH - Time Factors MH - Postoperative Complications/etiology/surgery MH - Combined Modality Therapy MH - Aorta, Thoracic/surgery/diagnostic imaging MH - Risk Factors PMC - PMC11127891 OTO - NOTNLM OT - Aortic dissection OT - Aortic pseudoaneurysm OT - Bentall surgery OT - Endoluminal graft implantation OT - Septal occluder implantation COIS- None. EDAT- 2023/11/25 07:42 MHDA- 2024/05/25 20:49 PMCR- 2023/11/25 CRDT- 2023/11/24 23:37 PHST- 2023/06/06 00:00 [received] PHST- 2023/10/25 00:00 [accepted] PHST- 2024/05/25 20:49 [medline] PHST- 2023/11/25 07:42 [pubmed] PHST- 2023/11/24 23:37 [entrez] PHST- 2023/11/25 00:00 [pmc-release] AID - 10.1007/s11748-023-01986-9 [pii] AID - 1986 [pii] AID - 10.1007/s11748-023-01986-9 [doi] PST - ppublish SO - Gen Thorac Cardiovasc Surg. 2024 Jun;72(6):387-394. doi: 10.1007/s11748-023-01986-9. Epub 2023 Nov 25. PMID- 37999706 OWN - NLM STAT- MEDLINE DCOM- 20231229 LR - 20250502 IS - 1876-7605 (Electronic) IS - 1936-8798 (Linking) VI - 16 IP - 24 DP - 2023 Dec 25 TI - Transaxillary Access for JenaValve to Treat Pure Native Aortic Regurgitation. PG - 3039-3040 LID - S1936-8798(23)01310-9 [pii] LID - 10.1016/j.jcin.2023.09.016 [doi] FAU - Geyer, Martin AU - Geyer M AD - Department of Cardiology, Cardiology I, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany. FAU - Tamm, Alexander R AU - Tamm AR AD - Department of Cardiology, Cardiology I, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany. FAU - Ahoopai, Majid AU - Ahoopai M AD - Department of Cardiology, Cardiology I, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany. FAU - Munzel, Thomas AU - Munzel T AD - Department of Cardiology, Cardiology I, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany. FAU - Treede, Hendrik AU - Treede H AD - Department of Cardiothoracic and Vascular Surgery, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany. FAU - von Bardeleben, Ralph Stephan AU - von Bardeleben RS AD - Department of Cardiology, Cardiology I, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany. Electronic address: stephan.von_bardeleben@unimedizin-mainz.de. LA - eng PT - Journal Article DEP - 20231122 PL - United States TA - JACC Cardiovasc Interv JT - JACC. Cardiovascular interventions JID - 101467004 SB - IM MH - Humans MH - *Aortic Valve Insufficiency/diagnostic imaging/etiology/surgery MH - Treatment Outcome MH - Aortic Valve/diagnostic imaging/surgery MH - *Transcatheter Aortic Valve Replacement/adverse effects MH - *Heart Valve Prosthesis MH - *Aortic Valve Stenosis/surgery MH - Risk Factors OTO - NOTNLM OT - JenaValve OT - TAVR OT - aortic valve regurgitation OT - interdisciplinary heart team OT - transaxillary access COIS- Funding Support and Author Disclosures Dr Tamm is a proctor for JenaValve Technology. Dr Treede is a proctor and consultant for JenaValve Technology. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2023/11/24 12:41 MHDA- 2023/12/29 06:42 CRDT- 2023/11/24 10:35 PHST- 2023/08/13 00:00 [received] PHST- 2023/09/04 00:00 [revised] PHST- 2023/09/12 00:00 [accepted] PHST- 2023/12/29 06:42 [medline] PHST- 2023/11/24 12:41 [pubmed] PHST- 2023/11/24 10:35 [entrez] AID - S1936-8798(23)01310-9 [pii] AID - 10.1016/j.jcin.2023.09.016 [doi] PST - ppublish SO - JACC Cardiovasc Interv. 2023 Dec 25;16(24):3039-3040. doi: 10.1016/j.jcin.2023.09.016. Epub 2023 Nov 22. PMID- 37993612 OWN - NLM STAT- MEDLINE DCOM- 20231124 LR - 20231220 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 13 IP - 1 DP - 2023 Nov 22 TI - Platform for the interdisciplinary study of cardiovascular, metabolic and neurovascular diseases (PICMAN) protocol. PG - 20521 LID - 10.1038/s41598-023-47407-y [doi] LID - 20521 AB - Through extensive multisystem phenotyping, the central aim of Project PICMAN is to correlate metabolic flexibility to measures of cardiometabolic health, including myocardial diastolic dysfunction, coronary and cerebral atherosclerosis, body fat distribution and severity of non-alcoholic fatty liver disease. This cohort will form the basis of larger interventional trials targeting metabolic inflexibility in the prevention of cardiovascular disease. Participants aged 21-72 years with no prior manifest atherosclerotic cardiovascular disease (ASCVD) are being recruited from a preventive cardiology clinic and an existing cohort of non-alcoholic fatty liver disease (NAFLD) in an academic medical centre. A total of 120 patients will be recruited in the pilot phase of this study and followed up for 5 years. Those with 10-year ASCVD risk >/= 5% as per the QRISK3 calculator are eligible. Those with established diabetes mellitus are excluded. Participants recruited undergo a detailed assessment of health behaviours and physical measurements. Participants also undergo a series of multimodality clinical phenotyping comprising cardiac tests, vascular assessments, metabolic tests, liver and neurovascular testing. Blood samples are also being collected and banked for plasma biomarkers, 'multi-omics analyses' and for generation of induced pluripotent stem cells (iPSC). Extensive evidence points to metabolic dysregulation as an early precursor of cardiovascular disease, particularly in Asia. We hypothesise that quantifiable metabolic inflexibility may be representative of an individual in his/her silent, but high-risk progression towards insulin resistance, diabetes and cardiovascular disease. The platform for interdisciplinary cardiovascular-metabolic-neurovascular diseases (PICMAN) is a pilot, prospective, multi-ethnic cohort study. CI - (c) 2023. The Author(s). FAU - Dalakoti, Mayank AU - Dalakoti M AD - Department of Cardiology, National University Heart Centre, Singapore, Singapore. mayank_dalakoti@nuhs.edu.sg. AD - Department of Medicine, Ng Teng Fong General Hospital, Singapore, Singapore. mayank_dalakoti@nuhs.edu.sg. AD - National University of Singapore Cardiovascular Disease Translational Research Program, Singapore, Singapore. mayank_dalakoti@nuhs.edu.sg. FAU - Leow, Melvin Khee Shing AU - Leow MKS AD - Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. AD - Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore. FAU - Khoo, Chin Meng AU - Khoo CM AD - Department of Medicine, National University Health System, Singapore, Singapore. AD - Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. FAU - Yang, Hayang AU - Yang H AD - National University of Singapore Cardiovascular Disease Translational Research Program, Singapore, Singapore. FAU - Ling, Lieng Hsi AU - Ling LH AD - Department of Cardiology, National University Heart Centre, Singapore, Singapore. AD - Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. FAU - Muthiah, Mark AU - Muthiah M AD - Department of Medicine, National University Health System, Singapore, Singapore. AD - Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. FAU - Tan, Eunice AU - Tan E AD - Department of Medicine, National University Health System, Singapore, Singapore. FAU - Lee, Jonathan AU - Lee J AD - Department of Medicine, National University Health System, Singapore, Singapore. AD - Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. FAU - Dan, Yock Young AU - Dan YY AD - Department of Medicine, National University Health System, Singapore, Singapore. AD - Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. FAU - Chew, Nicholas AU - Chew N AD - Department of Cardiology, National University Heart Centre, Singapore, Singapore. AD - National University of Singapore Cardiovascular Disease Translational Research Program, Singapore, Singapore. FAU - Seow, Wei Qiang AU - Seow WQ AD - Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. AD - National University of Singapore Cardiovascular Disease Translational Research Program, Singapore, Singapore. FAU - Soong, Poh Loong AU - Soong PL AD - Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. AD - National University of Singapore Cardiovascular Disease Translational Research Program, Singapore, Singapore. FAU - Gan, Louis AU - Gan L AD - Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. AD - National University of Singapore Cardiovascular Disease Translational Research Program, Singapore, Singapore. FAU - Gurung, Rijan AU - Gurung R AD - Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. AD - National University of Singapore Cardiovascular Disease Translational Research Program, Singapore, Singapore. FAU - Ackers-Johnson, Matthew AU - Ackers-Johnson M AD - Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. AD - National University of Singapore Cardiovascular Disease Translational Research Program, Singapore, Singapore. FAU - Hou, Han Wei AU - Hou HW AD - Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore. FAU - Sachaphibulkij, Karishma AU - Sachaphibulkij K AD - Center for Life Sciences, National University of Singapore-Cambridge Cell Phenotyping Centre, Singapore, Singapore. FAU - MacAry, Paul AU - MacAry P AD - Center for Life Sciences, National University of Singapore-Cambridge Cell Phenotyping Centre, Singapore, Singapore. FAU - Low, Gwen AU - Low G AD - Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. AD - National University of Singapore Cardiovascular Disease Translational Research Program, Singapore, Singapore. FAU - Ang, Christy AU - Ang C AD - Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. AD - National University of Singapore Cardiovascular Disease Translational Research Program, Singapore, Singapore. FAU - Yeo, Tee Joo AU - Yeo TJ AD - Department of Cardiology, National University Heart Centre, Singapore, Singapore. AD - Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. FAU - Djohan, Andie Hartanto AU - Djohan AH AD - Department of Cardiology, National University Heart Centre, Singapore, Singapore. AD - Department of Medicine, Ng Teng Fong General Hospital, Singapore, Singapore. FAU - Li, Tony AU - Li T AD - Department of Cardiology, National University Heart Centre, Singapore, Singapore. FAU - Yeung, Wesley AU - Yeung W AD - Department of Cardiology, National University Heart Centre, Singapore, Singapore. FAU - Soh, Rodney AU - Soh R AD - Department of Cardiology, National University Heart Centre, Singapore, Singapore. FAU - Sia, Ching Hui AU - Sia CH AD - Department of Cardiology, National University Heart Centre, Singapore, Singapore. AD - Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. AD - National University of Singapore Cardiovascular Disease Translational Research Program, Singapore, Singapore. FAU - Panday, Vinay AU - Panday V AD - Department of Cardiology, National University Heart Centre, Singapore, Singapore. FAU - Loong, Shaun S E AU - Loong SSE AD - Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. AD - National University of Singapore Cardiovascular Disease Translational Research Program, Singapore, Singapore. FAU - Tan, Benjamin Y Q AU - Tan BYQ AD - Department of Medicine, National University Health System, Singapore, Singapore. AD - Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. FAU - Yeo, Leonard L L AU - Yeo LLL AD - Department of Medicine, National University Health System, Singapore, Singapore. AD - Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. FAU - Teo, Lynette AU - Teo L AD - Department of Radiology, National University Health System, Singapore, Singapore. FAU - Chow, Pierce AU - Chow P AD - Duke-NUS Medical School, Singapore, Singapore. FAU - Foo, Roger AU - Foo R AD - Department of Cardiology, National University Heart Centre, Singapore, Singapore. AD - Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. AD - National University of Singapore Cardiovascular Disease Translational Research Program, Singapore, Singapore. LA - eng PT - Journal Article DEP - 20231122 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 SB - IM MH - Humans MH - Male MH - Female MH - *Cardiovascular Diseases MH - *Non-alcoholic Fatty Liver Disease MH - Cohort Studies MH - Prospective Studies MH - *Cardiovascular System MH - *Atherosclerosis MH - Risk Factors PMC - PMC10665389 COIS- The authors declare no competing interests. EDAT- 2023/11/23 00:42 MHDA- 2023/11/24 06:42 PMCR- 2023/11/22 CRDT- 2023/11/22 23:43 PHST- 2023/07/04 00:00 [received] PHST- 2023/11/13 00:00 [accepted] PHST- 2023/11/24 06:42 [medline] PHST- 2023/11/23 00:42 [pubmed] PHST- 2023/11/22 23:43 [entrez] PHST- 2023/11/22 00:00 [pmc-release] AID - 10.1038/s41598-023-47407-y [pii] AID - 47407 [pii] AID - 10.1038/s41598-023-47407-y [doi] PST - epublish SO - Sci Rep. 2023 Nov 22;13(1):20521. doi: 10.1038/s41598-023-47407-y. PMID- 37989788 OWN - NLM STAT- MEDLINE DCOM- 20240108 LR - 20240108 IS - 1432-086X (Electronic) IS - 0174-1551 (Print) IS - 0174-1551 (Linking) VI - 47 IP - 1 DP - 2024 Jan TI - Interdisciplinary Rendez-Vous Approach in Endovascular Stroke Treatment: A New Concept to Accelerate Mechanical Thrombectomy in Primary Stroke Centers. PG - 109-114 LID - 10.1007/s00270-023-03610-y [doi] AB - PURPOSE: Prompt endovascular treatment of patients with stroke due to intracranial Large Vessel Occlusion (LVO) is a major challenge in rural areas because neurointerventionalists are usually not available. As a result, treatment is delayed, and clinical outcomes are worse compared with patients primarily treated in comprehensive stroke centers (CSC). To address this problem, we present a concept in which interdisciplinary, on-site endovascular treatment is performed in a Primary Stroke Center (PSC) by a team of interventional neuroradiologists and cardiologists: the Rendez-Vous approach. METHODS: Thirty-five patients with LVO who underwent interdisciplinary thrombectomy on-site at the PSC as part of the Rendez-Vous concept were compared with 72 patients who were transferred from a PSCs to the CSC for thrombectomy when diagnosed with LVO in terms of temporal sequences and clinical outcomes. RESULTS: Patients treated on-site at the PSC as part of the Rendez-Vous approach were managed as successfully and without an increase in complication rates compared with patients treated secondarily at a CSC (91.7% successful interventions in Rendez-Vous vs. 87.3% in control group, p = 0.57). The time from diagnosis of LVO to groin puncture was reduced by mean 74.3 min with the Rendez-Vous concept (p < 0.01). Regarding the clinical outcome, a functionally independent status was achieved in 45.5% in the Rendez-Vous group and in 22.6% in the control group (p = 0.029). CONCLUSION: Thanks to interdisciplinary teamwork between cardiology and interventional neuroradiology in local PSCs, times to successful reperfusion can be reduced. This has a potentially positive impact on the clinical outcome of stroke patients. CI - (c) 2023. The Author(s). FAU - Krug, Nadja AU - Krug N AD - Diagnostic and Interventional Neuroradiology, University Hospital Basel, Basel, Switzerland. FAU - Braun, Holger AU - Braun H AD - Medical Department, Krankenhaus Weilheim, Weilheim, Germany. FAU - Knez, Andreas AU - Knez A AD - Medical Department, Krankenhaus Weilheim, Weilheim, Germany. FAU - Auerbach, Holger AU - Auerbach H AD - Medical Department, Krankenhaus Weilheim, Weilheim, Germany. FAU - Bodenberger, Stephen AU - Bodenberger S AD - Medical Department, Krankenhaus Weilheim, Weilheim, Germany. FAU - Eglseder, Bettina AU - Eglseder B AD - Medical Department, Krankenhaus Weilheim, Weilheim, Germany. FAU - Kirschke, Jan AU - Kirschke J AD - Department of Diagnostic and Interventional Neuroradiology, Klinikum Rechts der Isar, School of Medicine, Technical University Munich, Munich, Germany. FAU - Boeckh-Behrens, Tobias AU - Boeckh-Behrens T AD - Department of Diagnostic and Interventional Neuroradiology, Klinikum Rechts der Isar, School of Medicine, Technical University Munich, Munich, Germany. FAU - Wunderlich, Silke AU - Wunderlich S AD - Department of Neurology, Klinikum Rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany. FAU - Henninger, Julia AU - Henninger J AD - Medical Department, Klinikum Dritter Orden, Munich, Germany. FAU - Boy, Sandra AU - Boy S AD - Department of Neurology, Asklepios Stadtklinik Bad Tolz, Bad Tolz, Germany. FAU - Renz, Martin AU - Renz M AD - Department of Diagnostic and Interventional Neuroradiology, Klinikum Rechts der Isar, School of Medicine, Technical University Munich, Munich, Germany. FAU - Sepp, Dominik AU - Sepp D AD - Department of Diagnostic and Interventional Neuroradiology, Klinikum Rechts der Isar, School of Medicine, Technical University Munich, Munich, Germany. FAU - Zimmer, Claus AU - Zimmer C AD - Department of Diagnostic and Interventional Neuroradiology, Klinikum Rechts der Isar, School of Medicine, Technical University Munich, Munich, Germany. FAU - Maegerlein, Christian AU - Maegerlein C AUID- ORCID: 0000-0003-4885-7671 AD - Department of Diagnostic and Interventional Neuroradiology, Klinikum Rechts der Isar, School of Medicine, Technical University Munich, Munich, Germany. christian.maegerlein@tum.de. LA - eng PT - Journal Article DEP - 20231121 PL - United States TA - Cardiovasc Intervent Radiol JT - Cardiovascular and interventional radiology JID - 8003538 SB - IM MH - Humans MH - *Stroke/diagnostic imaging/surgery MH - Thrombectomy MH - Treatment Outcome MH - *Endovascular Procedures/adverse effects MH - *Brain Ischemia/etiology MH - Retrospective Studies PMC - PMC10769944 OTO - NOTNLM OT - Endovascular Stroke Treatment OT - Mechanical Thrombectomy OT - Primary Stroke Center OT - Rendez-Vous concept OT - Stroke EDAT- 2023/11/22 00:42 MHDA- 2024/01/08 06:43 PMCR- 2023/11/21 CRDT- 2023/11/21 23:45 PHST- 2023/10/06 00:00 [received] PHST- 2023/10/26 00:00 [accepted] PHST- 2024/01/08 06:43 [medline] PHST- 2023/11/22 00:42 [pubmed] PHST- 2023/11/21 23:45 [entrez] PHST- 2023/11/21 00:00 [pmc-release] AID - 10.1007/s00270-023-03610-y [pii] AID - 3610 [pii] AID - 10.1007/s00270-023-03610-y [doi] PST - ppublish SO - Cardiovasc Intervent Radiol. 2024 Jan;47(1):109-114. doi: 10.1007/s00270-023-03610-y. Epub 2023 Nov 21. PMID- 37989362 OWN - NLM STAT- MEDLINE DCOM- 20231127 LR - 20240122 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 13 IP - 11 DP - 2023 Nov 21 TI - Safety and feasibility of a real-time electronic heart team decision-making approach in patients with complex coronary artery disease: a protocol for a randomised controlled trial (EHEART trial). PG - e076864 LID - 10.1136/bmjopen-2023-076864 [doi] LID - e076864 AB - INTRODUCTION: The implementation of a heart team still faces many challenges which may be facilitated with advanced communication technology. There is a knowledge gap to support the use of an electronic real-time heart team decision-making approach based on communication technology in the real clinical practice and evaluate its safety and feasibility in patients with complex coronary artery disease (CAD). METHODS AND ANALYSIS: The EHEART (Electronic HEArt team with Real-Time decision-making) trial is a prospective, multicentre, two-arm, randomised controlled trial that will randomise 490 patients with complex CAD to either an electronic real-time heart team group or conventional heart team group. For patients allocated to the real-time electronic group, heart team meetings will be initiated during the coronary angiography and guided by a supporting system based on communication technology to help with information synchronisation, real-time communication between specialists, meeting process recording and assistance and joint decision-making with patients' families. The primary and safety endpoint is a composite of all-cause death, myocardial infarction, stroke, revascularisation or re-angina hospital admission at 1 year. The primary secondary outcome is the time interval from the coronary angiography to the final treatment, which is the major indicator of feasibility. We will also compare the practical feasibility from the specialist's and patient's perspectives (for example, specialist's workload and patient's decision results) between the two groups. ETHICS AND DISSEMINATION: The study was approved by the Institutional Review Board (IRB) of Fuwai Hospital (no. 2022-1749). Informed consent will be obtained from all participants. The results of this trial will be disseminated through manuscript publication and national/international conferences, and reported in the trial registry entry. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov Registry (NCT05514210). CI - (c) Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Su, Xiaoting AU - Su X AD - National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China. FAU - Ma, Hanping AU - Ma H AUID- ORCID: 0000-0002-9465-1060 AD - National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China. AD - Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China. FAU - Lin, Shen AU - Lin S AD - National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China. AD - Department of Cardiovascular Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China. FAU - Dou, Kefei AU - Dou K AUID- ORCID: 0000-0002-8372-6338 AD - National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China. AD - Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China. FAU - Zheng, Zhe AU - Zheng Z AUID- ORCID: 0000-0002-9162-6492 AD - National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China zhengzhe@fuwai.com. AD - Department of Cardiovascular Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China. AD - National Health Commission Key Laboratory of Cardiovascular Regenerative Medicine, Fuwai Central-China Hospital, Central-China Branch of National Center for Cardiovascular Diseases, Zhengzhou, People's Republic of China. LA - eng SI - ClinicalTrials.gov/NCT05514210 PT - Clinical Trial Protocol PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20231121 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 SB - IM MH - Humans MH - *Coronary Artery Disease/therapy/complications MH - Prospective Studies MH - Feasibility Studies MH - *Myocardial Infarction/etiology MH - Angina Pectoris/complications MH - Randomized Controlled Trials as Topic MH - Multicenter Studies as Topic PMC - PMC10668163 OTO - NOTNLM OT - Coronary heart disease OT - Decision Making OT - Telemedicine COIS- Competing interests: None declared. EDAT- 2023/11/22 00:42 MHDA- 2023/11/27 12:44 PMCR- 2023/11/21 CRDT- 2023/11/21 20:43 PHST- 2023/11/27 12:44 [medline] PHST- 2023/11/22 00:42 [pubmed] PHST- 2023/11/21 20:43 [entrez] PHST- 2023/11/21 00:00 [pmc-release] AID - bmjopen-2023-076864 [pii] AID - 10.1136/bmjopen-2023-076864 [doi] PST - epublish SO - BMJ Open. 2023 Nov 21;13(11):e076864. doi: 10.1136/bmjopen-2023-076864. PMID- 37983586 OWN - NLM STAT- MEDLINE DCOM- 20240115 LR - 20250104 IS - 2688-1535 (Electronic) IS - 2688-1527 (Print) IS - 2688-1527 (Linking) VI - 20 IP - 1 DP - 2024 Jan TI - Cardiotoxicity of Agents Used in Patients With Breast Cancer. PG - 38-46 LID - 10.1200/OP.23.00494 [doi] AB - Cancer and cardiovascular diseases are the two major causes of mortality, morbidity, and disability worldwide. The improvement in effective therapeutic options for the management of breast cancer (BC) has led to an increased number of BC survivors, who can experience long-term toxicities from cancer treatments. Adverse events including cardiovascular toxicities must be considered in light of effectiveness of recently approved drugs for BC treatment, including elacestrant, tucatinib, neratinib, olaparib, the immune checkpoint inhibitors, trastuzumab deruxtecan, or sacituzumab govitecan. Many cancer drugs affect the cardiovascular system with a range of clinical manifestations. Prompt diagnosis and treatment as well as a multidisciplinary approach involving a cardio-oncologist is optimal for management of these cardiovascular events. FAU - Zagami, Paola AU - Zagami P AUID- ORCID: 0000-0002-2687-6436 AD - Department of Oncology and Hematology, University of Milano, Milan, Italy. AD - Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC. AD - Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy. FAU - Trapani, Dario AU - Trapani D AUID- ORCID: 0000-0003-1672-9560 AD - Department of Oncology and Hematology, University of Milano, Milan, Italy. AD - Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy. FAU - Nicolo, Eleonora AU - Nicolo E AUID- ORCID: 0000-0001-5042-6550 AD - Department of Oncology and Hematology, University of Milano, Milan, Italy. AD - Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy. FAU - Corti, Chiara AU - Corti C AUID- ORCID: 0000-0002-0359-0267 AD - Department of Oncology and Hematology, University of Milano, Milan, Italy. AD - Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy. FAU - Valenza, Carmine AU - Valenza C AD - Department of Oncology and Hematology, University of Milano, Milan, Italy. AD - Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy. FAU - Criscitiello, Carmen AU - Criscitiello C AD - Department of Oncology and Hematology, University of Milano, Milan, Italy. AD - Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy. FAU - Curigliano, Giuseppe AU - Curigliano G AUID- ORCID: 0000-0003-1781-2518 AD - Department of Oncology and Hematology, University of Milano, Milan, Italy. AD - Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy. FAU - Carey, Lisa Anne AU - Carey LA AUID- ORCID: 0000-0003-2388-4649 AD - Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC. LA - eng GR - P50 CA058223/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20231120 PL - United States TA - JCO Oncol Pract JT - JCO oncology practice JID - 101758685 RN - 0 (Antineoplastic Agents) SB - IM CIN - JCO Oncol Pract. 2024 Jan;20(1):5-6. doi: 10.1200/OP.23.00665. PMID: 37992262 MH - Humans MH - Female MH - *Breast Neoplasms/complications/drug therapy MH - Cardiotoxicity/etiology/drug therapy MH - *Antineoplastic Agents/adverse effects MH - *Cardiovascular Diseases/complications/diagnosis/drug therapy PMC - PMC10827297 COIS- The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/op/authors/author-center. Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments). EDAT- 2023/11/20 18:44 MHDA- 2024/01/15 12:43 PMCR- 2025/01/01 CRDT- 2023/11/20 16:03 PHST- 2024/01/15 12:43 [medline] PHST- 2023/11/20 18:44 [pubmed] PHST- 2023/11/20 16:03 [entrez] PHST- 2025/01/01 00:00 [pmc-release] AID - OP.23.00494 [pii] AID - 10.1200/OP.23.00494 [doi] PST - ppublish SO - JCO Oncol Pract. 2024 Jan;20(1):38-46. doi: 10.1200/OP.23.00494. Epub 2023 Nov 20. PMID- 37980193 OWN - NLM STAT- MEDLINE DCOM- 20231225 LR - 20260518 IS - 1532-8422 (Electronic) IS - 1053-0770 (Linking) VI - 38 IP - 1 DP - 2024 Jan TI - PERSUADE Survey-PERioperative AnestheSia and Intensive Care Management of Left VentricUlar Assist DevicE Implantation in Europe and the United States. PG - 197-206 LID - S1053-0770(23)00843-1 [pii] LID - 10.1053/j.jvca.2023.10.013 [doi] AB - OBJECTIVE: To comprehensively assess relevant institutional variations in anesthesia and intensive care management during left ventricular assist device (LVAD) implantation. DESIGN: The authors used a prospective data analysis. SETTING: This was an online survey. PARTICIPANTS: Participants were from LVAD centers in Europe and the US. INTERVENTIONS: After investigating initial interest, 91 of 202 European and 93 of 195 US centers received a link to the survey targeting institutional organization and experience, perioperative hemodynamic monitoring, medical management, and postoperative intensive care aspects. MEASUREMENTS AND MAIN RESULTS: The survey was completed by 73 (36.1%) European and 60 (30.8%) US centers. Although most LVAD implantations were performed in university hospitals (>5 years of experience), significant differences were observed in the composition of the preoperative multidisciplinary team and provision of intraoperative care. No significant differences in monitoring or induction agents were observed. Propofol was used more often for maintenance in Europe (p < 0.001). The choice for inotropes changed significantly from preoperatively (more levosimendan in Europe) to intraoperatively (more use of epinephrine in both Europe and the US). The use of quantitative methods for defining right ventricular (RV) function was reported more often from European centers than from US centers (p < 0.05). Temporary mechanical circulatory support for the treatment of RV failure was more often used in Europe. Nitric oxide appeared to play a major role only intraoperatively. There were no significant differences in early postoperative complications reported from European versus US centers. CONCLUSIONS: Although the perioperative practice of care for patients undergoing LVAD implantation differs in several aspects between Europe and the US, there were no perceived differences in early postoperative complications. CI - Crown Copyright (c) 2023. Published by Elsevier Inc. All rights reserved. FAU - Kummerow, Maren AU - Kummerow M AD - Department of Anesthesiology and Intensive Care Medicine, Mathias-Spital Rheine, Rheine, Germany. FAU - von Dossow, Vera AU - von Dossow V AD - Institute of Anesthesiology and Pain Therapy, Heart and Diabetes Center North Rhine-Westphalia, University Clinic of the Ruhr University Bochum, Bad Oeynhausen, Germany. FAU - Pasero, Daniela AU - Pasero D AD - Department of Anesthesiology and Intensive Care, University Hospital, Sassari, Italy. FAU - Martinez Lopez de Arroyabe, Blanca AU - Martinez Lopez de Arroyabe B AD - Department of Cardiac Anesthesia and Intensive Care, University Hospital of Verona, Verona, Italy. FAU - Abrams, Benjamin AU - Abrams B AD - Department of Anesthesiology, University of Colorado Anschutz Medical Campus, Aurora, CO. FAU - Kowalsky, Markus AU - Kowalsky M AD - Department of Anesthesiology, University of Colorado Anschutz Medical Campus, Aurora, CO. FAU - Wilkey, Barbara J AU - Wilkey BJ AD - Department of Anesthesiology, University of Colorado Anschutz Medical Campus, Aurora, CO. FAU - Subramanian, Kathirvel AU - Subramanian K AD - Department of Anesthesiology and Perioperative Medicine, University of Pittsburgh School of Medicine, UPMC Presbyterian Hospital, Pittsburgh, PA. FAU - Martin, Archer K AU - Martin AK AD - Division of Cardiovascular and Thoracic Anesthesiology, Mayo Clinic, Jacksonville, FL. FAU - Marczin, Nandor AU - Marczin N AD - Division of Anaesthesia, Pain Medicine and Intensive Care, Imperial College London, Royal Brompton & Harefield Hospitals, Guy's & St. Thomas' NHS, London, United Kingdom; Department of Anaesthesia and Intensive Care, Semmelweis University, Budapest, Hungary. FAU - de Waal, Eric E C AU - de Waal EEC AD - Department of Anesthesiology, University Medical Center Utrecht, Utrecht, the Netherlands. Electronic address: e.e.c.dewaal@umcutrecht.nl. CN - EACTAIC Transplant and VAD Subcommittee, SATA, and writing group LA - eng PT - Journal Article DEP - 20231018 PL - United States TA - J Cardiothorac Vasc Anesth JT - Journal of cardiothoracic and vascular anesthesia JID - 9110208 SB - IM MH - Humans MH - United States/epidemiology MH - Prospective Studies MH - *Heart-Assist Devices/adverse effects MH - *Heart Failure MH - Postoperative Complications MH - *Anesthesia/adverse effects MH - Europe/epidemiology MH - *Ventricular Dysfunction, Right MH - Retrospective Studies MH - Treatment Outcome OTO - NOTNLM OT - LVAD implantation OT - anesthesia OT - center differences OT - intensive care OT - perioperative mangement OT - survey COIS- Declaration of Competing Interest This research itself did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. J.M.B. received honoraria for lectures from Edwards Lifesciences. K.B. received funding from the Agency for Healthcare Research and a grant from the National Institutes of Health. O.B. received honoraria for lectures from Medtronic, Livanova, and Werfen. M.L.B. received research funding from the US Department of Defense. B.A.B. received consulting fees from CSL Behring. J.L.B. received an SCA/IARS mid-career research grant. E.D.A. received travel expenses from GE and Carmat. E.E.C.d.W. received honoraria for lectures and research grants from Abbott and Cytosorbents. D.A.E. received payment for expert testimony from Cornelius & Collins and Husch Blackwell. P.G. received consulting fees from Abbott and honoraria for lectures from Abbott and Eurosets. F.G. received honoraria for lectures from Abbott, Amomed, Edwards, Masimi, Orion, Orphan, and Teleflex. M.H. received honoraria for lectures from AOP Health, Medtronic, and Orion Pharma. L.M.J. received an educational grant from Abbott and participated in the DSMB of Carmat. L.M.K. received honoraria for grand round presentations and for a continuing medical education lecture and payment for an expert witness review from Shumaker Law firm. Z.N.K. has stock options from Edwards and Abbott. P.K. received research grants from Netzwerk Universitatsmedizin, APEPTICO, and BMBF; consulting fees from TEVA Ratiopharm, Amicus Ltd, and Senzyme; honoraria for lectures from TEVA Ratiopharm, Vifor, Sintetica, CSL Behring, and Senzyme; and payment from Ulsenheimer Friedrich Law Firm. D.J.K. owns exchange-traded funds with diversified holdings. M.M. received honoraria for lectures from Abbott Vascular, Boston Scientific, and Edwards Lifesciences. A.K.M. received consulting fees from Attgeno AB. N.M. received consulting fees from Edwards, Air Liquide, and Attgeno; honoraria for lectures from Edwards, Cytosorbents, and SOL; and travel expenses from Cytosorbents. M.A.M. received consulting fees from Octapharma and Hemosonics, honoraria for grand rounds of Mass General, and payment for expert testimony from Goodell Devries. V.K.M. participates in the Advisory Board of Tell Health and Fize Medical. J.P.O. had a consulting agreement with Third Pole Therapeutics and received a consulting fee from La Jolla Pharmaceutical. A.O. received consulting fees from Nordic Pharma, Isep, Baxter, Orion Pharma, VIFOR Pharma, and Medtronic and participated in the DSMB of the NaPar registry organized by Nordic Pharma. S.R. received honoraria for lectures from Abiomed, Edwards Lifesciences, Orion, and Nordic. H.R. received honoraria and travel expenses from Abbott. A.R. has stock or stock options from Clinical Gene Networks AB. P.S. received financial support for attending an expert German Intensive Care Society meeting. R.E.S. received travel expenses from Phillips. S.E.S. received an Abbott investigator grant and a consulting fee for manuscript writing with Lincoln Heart and Vascular Research Institute. M.S.S. received honoraria for lectures from Medtronic. K.S. received grants for research and royalties from Springer. A.S. received consulting fees from Baxter and honoraria for lectures from Amomed. M.t.H. had a speakers agreement with CSL Behring. V.v.D. received honoraria for lectures and travel expenses from Edwards Lifesciences and Orion Pharma. B.J.W. received a research grant from Haemonetics. M.S.C., M.D., N.M.G., and B.M. did not disclose their conflict of interests. None of the other authors have any disclosures to report. FIR - Alfirevic, Andrej IR - Alfirevic A FIR - Anton, James M IR - Anton JM FIR - Antoniou, Theofani IR - Antoniou T FIR - Auci, Elisabetta IR - Auci E FIR - Badakhsh, Orode IR - Badakhsh O FIR - Banks, Dalia A IR - Banks DA FIR - Barrio, Jose M IR - Barrio JM FIR - Bartels, Karsten IR - Bartels K FIR - Belli, Erol V IR - Belli EV FIR - Bermede, Onat IR - Bermede O FIR - Bettex, Dominique IR - Bettex D FIR - Biedermann, Sebastien IR - Biedermann S FIR - Boelsen, Jonas IR - Boelsen J FIR - Boisen, Michael L IR - Boisen ML FIR - Book, Malte IR - Book M FIR - Bottiger, Brandi A IR - Bottiger BA FIR - Bouchez, Stefaan IR - Bouchez S FIR - Brauer, Anselm IR - Brauer A FIR - Brodt, Jessica L IR - Brodt JL FIR - Chaudhry, Sunit-Preet IR - Chaudhry SP FIR - Conlin, Frederick T IR - Conlin FT FIR - Cormican, Daniel S IR - Cormican DS FIR - Cristinar, Mircea IR - Cristinar M FIR - Curtis, Michael S IR - Curtis MS FIR - Dalia, Adam A IR - Dalia AA FIR - D'Avino, Emilio IR - D'Avino E FIR - Durand, Michel IR - Durand M FIR - Eberle, Balthasar IR - Eberle B FIR - Emmert, Daniel A IR - Emmert DA FIR - Erb, Joachim M IR - Erb JM FIR - Falterman, Jason IR - Falterman J FIR - Forner, Anna Flo IR - Forner AF FIR - Gatha, Nehal M IR - Gatha NM FIR - Gaudard, Philippe IR - Gaudard P FIR - Giebler, Antasia IR - Giebler A FIR - Gliga, Louise A IR - Gliga LA FIR - Guarracino, Fabio IR - Guarracino F FIR - Gurcu, Mustafa E IR - Gurcu ME FIR - Hans, Gregory A IR - Hans GA FIR - Hanson, Ross S IR - Hanson RS FIR - Heringlake, Matthias IR - Heringlake M FIR - Hilberath, Jan N IR - Hilberath JN FIR - Hommel, Matthias IR - Hommel M FIR - Huhn, Ragnar IR - Huhn R FIR - Iyer, Manoj H IR - Iyer MH FIR - Jacquet, Luc M IR - Jacquet LM FIR - Karadeniz, Umit IR - Karadeniz U FIR - Kertai, Miklos D IR - Kertai MD FIR - Martin, Archer Kilbourne IR - Martin AK FIR - Kolarczyk, Lavinia M IR - Kolarczyk LM FIR - Koller, Tobias IR - Koller T FIR - Kurian, Dinesh J IR - Kurian DJ FIR - Kornfield, Zev N IR - Kornfield ZN FIR - Koster, Andreas IR - Koster A FIR - Kranke, Peter IR - Kranke P FIR - Krauss, Bernadette IR - Krauss B FIR - Kudsioglu, Turkan IR - Kudsioglu T FIR - Kwak, Jenny IR - Kwak J FIR - Lachauer, Steffen IR - Lachauer S FIR - Lagier, David IR - Lagier D FIR - Lango, Romuald IR - Lango R FIR - Liang, Hong IR - Liang H FIR - Lilie, Craig J IR - Lilie CJ FIR - Logeman, Elisabeth Angelique IR - Logeman EA FIR - Magunia, Harry IR - Magunia H FIR - Mahmoud, Saifeldin IR - Mahmoud S FIR - Makar, Moody IR - Makar M FIR - Markovic, Dejan IR - Markovic D FIR - Mathis, Michael R IR - Mathis MR FIR - Mattei, Mathieu IR - Mattei M FIR - Mazzeffi, Michael A IR - Mazzeffi MA FIR - McCabe, Melissa D IR - McCabe MD FIR - Meers, J Brad IR - Meers JB FIR - Moitra, Vivek K IR - Moitra VK FIR - Moller-Sorensen, Hasse IR - Moller-Sorensen H FIR - Moravcova, Sarka IR - Moravcova S FIR - Muellejans, Bernd IR - Muellejans B FIR - Munch, Christopher M IR - Munch CM FIR - Murray, Andrew W IR - Murray AW FIR - Moncho, Azucena Pajares IR - Moncho AP FIR - Ngai, Jennie IR - Ngai J FIR - Nielsen, Dorthe V IR - Nielsen DV FIR - Ortoleva, Jamel P IR - Ortoleva JP FIR - Ouattara, Alexandre IR - Ouattara A FIR - Patel, Bhoumesh IR - Patel B FIR - Paul, Frank IR - Paul F FIR - Peng, Yong G IR - Peng YG FIR - Pittarello, Demetrio IR - Pittarello D FIR - Prabhu, Mahesh IR - Prabhu M FIR - Rancati, Valentina IR - Rancati V FIR - Rex, Steffen IR - Rex S FIR - Riha, Hynek IR - Riha H FIR - Robitaille, Mark J IR - Robitaille MJ FIR - Blanco, Yiliam Rodriguez IR - Blanco YR FIR - Rovira, Irene IR - Rovira I FIR - Ruusalepp, Arno IR - Ruusalepp A FIR - Samalavicius, Robertas IR - Samalavicius R FIR - Saatee, Siavosh IR - Saatee S FIR - Sauer, William J IR - Sauer WJ FIR - Scheiermann, Patrick IR - Scheiermann P FIR - Schlesinger, Rachel E IR - Schlesinger RE FIR - Schroeder, Andrew M IR - Schroeder AM FIR - Schroeder, Sarah E IR - Schroeder SE FIR - Shih, Henry IR - Shih H FIR - Slaughter, Mark S IR - Slaughter MS FIR - Sostaric, Maja IR - Sostaric M FIR - Sribar, Andrej IR - Sribar A FIR - Svalebjorg, Morten IR - Svalebjorg M FIR - Szekely, Andrea IR - Szekely A FIR - Szentgyorgyi, Lajos IR - Szentgyorgyi L FIR - Ter Horst, Maarten IR - Ter Horst M FIR - Tschernko, Edda M IR - Tschernko EM FIR - Twite, Mark IR - Twite M FIR - Ulrichs, Christoph IR - Ulrichs C FIR - van der Maaten, Joost M A A IR - van der Maaten JMAA FIR - van der Ploeg, Nathalie IR - van der Ploeg N FIR - Vilela, Hugo P IR - Vilela HP FIR - von Homeyer, Peter IR - von Homeyer P FIR - Wagner, Nana-Maria IR - Wagner NM FIR - Weiner, Menachem M IR - Weiner MM FIR - Wunder, Christian IR - Wunder C FIR - Zink, Wolfgang IR - Zink W EDAT- 2023/11/19 09:42 MHDA- 2023/12/25 06:42 CRDT- 2023/11/18 21:58 PHST- 2023/07/19 00:00 [received] PHST- 2023/09/27 00:00 [revised] PHST- 2023/10/09 00:00 [accepted] PHST- 2023/12/25 06:42 [medline] PHST- 2023/11/19 09:42 [pubmed] PHST- 2023/11/18 21:58 [entrez] AID - S1053-0770(23)00843-1 [pii] AID - 10.1053/j.jvca.2023.10.013 [doi] PST - ppublish SO - J Cardiothorac Vasc Anesth. 2024 Jan;38(1):197-206. doi: 10.1053/j.jvca.2023.10.013. Epub 2023 Oct 18. PMID- 37980065 OWN - NLM STAT- MEDLINE DCOM- 20231120 LR - 20260708 IS - 2211-7466 (Electronic) IS - 2211-7458 (Linking) VI - 13 IP - 1 DP - 2024 Jan TI - The Interventional Imager: How Do We Train the Next Interventional Imagers? PG - 29-38 LID - S2211-7458(23)00069-X [pii] LID - 10.1016/j.iccl.2023.08.007 [doi] AB - With the increase in structural heart procedural volume, interventional imagers are required. Multiple imaging modalities exist to guide these procedures. With comprehensive understanding of pathology, anatomy, and procedures, an advanced imager plays an important role in the heart team. Imaging training is part of general cardiology fellowship. Current structures do not provide adequate procedural time to fill the role. Interested graduates pursue advanced training by either focusing on echocardiography and procedural imaging or multidetector computed tomography and cardiac magnetic resonance. This yields individuals with different expertise. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Gheyath, Bashaer AU - Gheyath B AD - Department of Imaging, Cedars Sinai Medical Center, 8700 Beverly Boulevard, Taper, A238, Los Angeles, CA 90048, USA. Electronic address: https://twitter.com/bgheyath. FAU - Chau, Edward AU - Chau E AD - Division of Cardiovascular Medicine, University of California Davis Medical Center, 4680 Y Street, Suite 2820, Sacramento, CA 95817, USA. FAU - Latif, Syed AU - Latif S AD - Heart and Vascular Institute, Sutter Medical Center, Sacramento, CA, USA. FAU - Smith, Thomas W AU - Smith TW AD - Division of Cardiovascular Medicine, University of California Davis Medical Center, 4680 Y Street, Suite 2820, Sacramento, CA 95817, USA. Electronic address: twrsmith@ucdavis.edu. LA - eng PT - Journal Article PT - Review PL - Netherlands TA - Interv Cardiol Clin JT - Interventional cardiology clinics JID - 101615153 SB - IM MH - Humans MH - *Echocardiography MH - *Cardiology MH - Multidetector Computed Tomography OTO - NOTNLM OT - Cardiovascular computed tomography OT - Echocardiography OT - Interventional imaging OT - Percutaneous treatment of structural heart disease OT - Structural heart disease COIS- Disclosure The authors have nothing to disclose. EDAT- 2023/11/19 09:42 MHDA- 2023/11/20 06:55 CRDT- 2023/11/18 20:59 PHST- 2023/11/20 06:55 [medline] PHST- 2023/11/19 09:42 [pubmed] PHST- 2023/11/18 20:59 [entrez] AID - S2211-7458(23)00069-X [pii] AID - 10.1016/j.iccl.2023.08.007 [doi] PST - ppublish SO - Interv Cardiol Clin. 2024 Jan;13(1):29-38. doi: 10.1016/j.iccl.2023.08.007. PMID- 37978872 OWN - NLM STAT- MEDLINE DCOM- 20240306 LR - 20241031 IS - 2396-9881 (Electronic) IS - 2396-9873 (Print) IS - 2396-9873 (Linking) VI - 9 IP - 1 DP - 2024 Mar TI - Heart-Stroke Team: A multidisciplinary assessment of patent foramen ovale-associated stroke. PG - 219-225 LID - 10.1177/23969873231214862 [doi] AB - INTRODUCTION: Patent foramen ovale (PFO) closure prevents recurrent ischemic stroke in selected patients with a cryptogenic stroke. Trial results tend to be generalized to daily practice, often extending original trial inclusion criteria. This may result in unnecessary closure without benefit, but with risk of complications. We therefore introduced a standardized and structured evaluation by an interdisciplinary Heart-Stroke Team (HST). Our aim was to investigate the proportion of actual PFO closure of all referred patients with a cryptogenic stroke, after evaluation by the HST. PATIENTS AND METHODS: We conducted a single-center, retrospective cohort study. Patients with an assumed cryptogenic ischemic stroke or transient ischemic attack (TIA) and a PFO who were referred for PFO closure were analyzed. As part of the HST approach, all patients underwent a standardized work-up, first to demonstrate the ischemic event on neuroimaging, second to evaluate all potential causes of stroke and finally, to assess the possible relation between the PFO and stroke. Outcome was the proportion of patients treated with PFO closure after referral. RESULTS: A total of 195 patients were included. In 124 patients (64%) PFO closure was advised. Fourty-two (22%) patients had a clear alternative cause of stroke and in 13 (7%) patients the initial stroke diagnosis could not be confirmed. CONCLUSION: After careful analysis of patients referred for PFO closure a relationship between the PFO and stroke could not be demonstrated in 32% of referrals, and 3% preferred best medical treatment over percutaneous closure. This stresses the need for a complete neurovascular work-up and multidisciplinary assessment. FAU - Immens, Maikel Hm AU - Immens MH AUID- ORCID: 0000-0003-3359-4645 AD - Department of Neurology, Radboud University Medical Centre, Donders institute for Brain, Cognition and Behaviour, Nijmegen, The Netherlands. FAU - van den Hoeven, Vincent AU - van den Hoeven V AD - Department of Neurology, Radboud University Medical Centre, Donders institute for Brain, Cognition and Behaviour, Nijmegen, The Netherlands. FAU - van Lith, Theresa J AU - van Lith TJ AUID- ORCID: 0000-0003-2814-8368 AD - Department of Neurology, Radboud University Medical Centre, Donders institute for Brain, Cognition and Behaviour, Nijmegen, The Netherlands. FAU - Duijnhouwer, Toon D AU - Duijnhouwer TD AD - Department of Cardiology, Radboud University Medical Centre, Nijmegen, The Netherlands. FAU - Ten Cate, Tim Jf AU - Ten Cate TJ AD - Department of Cardiology, Radboud University Medical Centre, Nijmegen, The Netherlands. FAU - de Leeuw, Frank-Erik AU - de Leeuw FE AD - Department of Neurology, Radboud University Medical Centre, Donders institute for Brain, Cognition and Behaviour, Nijmegen, The Netherlands. LA - eng PT - Journal Article DEP - 20231118 PL - England TA - Eur Stroke J JT - European stroke journal JID - 101688446 SB - IM MH - Humans MH - *Foramen Ovale, Patent/complications MH - Retrospective Studies MH - *Stroke/diagnosis MH - *Ischemic Attack, Transient/epidemiology MH - *Ischemic Stroke/diagnosis PMC - PMC10916814 OTO - NOTNLM OT - Heart-Stroke Team OT - PFO closure OT - patent foramen ovale COIS- Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2023/11/18 12:42 MHDA- 2024/03/06 06:43 PMCR- 2023/11/18 CRDT- 2023/11/18 06:46 PHST- 2024/03/06 06:43 [medline] PHST- 2023/11/18 12:42 [pubmed] PHST- 2023/11/18 06:46 [entrez] PHST- 2023/11/18 00:00 [pmc-release] AID - 10.1177_23969873231214862 [pii] AID - 10.1177/23969873231214862 [doi] PST - ppublish SO - Eur Stroke J. 2024 Mar;9(1):219-225. doi: 10.1177/23969873231214862. Epub 2023 Nov 18. PMID- 37975543 OWN - NLM STAT- MEDLINE DCOM- 20241015 LR - 20260608 IS - 1464-5165 (Electronic) IS - 0963-8288 (Linking) VI - 46 IP - 21 DP - 2024 Oct TI - Heart failure self-management: a scoping review of interventions implemented by allied health professionals. PG - 4848-4859 LID - 10.1080/09638288.2023.2283105 [doi] AB - BACKGROUND: Heart failure (HF) is typically managed using both medical and patient self-management interventions. Individuals with HF often have frequent readmissions to hospital for medical management. Effective self-management can help to reduce the exacerbation of HF symptoms and the frequency of readmissions. METHODS: A scoping review following Preferred Reporting Items for Systematic Reviews and Meta-Analyses Scoping Review (PRISMA-ScR) guidelines was conducted to identify literature on the interventions used by allied health professionals to promote HF self-management. A search strategy was implemented, and articles were reviewed by two independent reviewers. RESULTS: Twenty articles met the inclusion criteria. Articles included interventions from physical therapy, nutrition, social work, and occupational therapy, as well as other health professions in team-based programs. The most common interventions were verbal education, textual information, monitoring resources, and skills practice. Interventions addressed diet/fluid control, exercise and activity, symptom monitoring, medication management, cardiovascular disease knowledge, and mental health. Many interventions were theory informed. CONCLUSION: There is nascent evidence that interventions promoting HF self-management positively impact health and quality of life outcomes. HF self-management is multi-faceted and requires interprofessional collaboration. Further work is warranted exploring the impact of theory-informed interventions, and the effectiveness of interventions on self-management competence and desired health outcomes. FAU - Lancey, Allyson AU - Lancey A AD - Department of Occupational Therapy, Johns Hopkins Bayview Medical Center, Baltimore, MD, USA. FAU - Slater, Craig E AU - Slater CE AD - College of Health and Rehabilitation Sciences, Sargent College, Boston University, Boston, MA, USA. LA - eng PT - Journal Article PT - Scoping Review DEP - 20231117 PL - England TA - Disabil Rehabil JT - Disability and rehabilitation JID - 9207179 SB - IM MH - Humans MH - *Self-Management MH - *Heart Failure/therapy MH - *Allied Health Personnel MH - Quality of Life MH - Self Care MH - Patient Education as Topic OAB - Verbal education, printed information, monitoring documents/systems, and skills practice were the most common intervention modalities to promote heart failure self-management.Self-management interventions address diet/fluid control, exercise and activity, symptom monitoring, medication management, cardiovascular disease knowledge, and mental health aspects of heart failure.There is indicative evidence that interventions promoting heart failure self-management lead to increased health and quality of life outcomes.An interprofessional collaborative practice approach is important given that heart failure self-management is multi-faceted. OABL- eng OTO - NOTNLM OT - Allied health OT - heart failure OT - rehabilitation OT - self-management OT - symptom management EDAT- 2023/11/17 15:24 MHDA- 2024/10/15 12:24 CRDT- 2023/11/17 07:32 PHST- 2024/10/15 12:24 [medline] PHST- 2023/11/17 15:24 [pubmed] PHST- 2023/11/17 07:32 [entrez] AID - 10.1080/09638288.2023.2283105 [doi] PST - ppublish SO - Disabil Rehabil. 2024 Oct;46(21):4848-4859. doi: 10.1080/09638288.2023.2283105. Epub 2023 Nov 17. PMID- 37972371 OWN - NLM STAT- MEDLINE DCOM- 20231127 LR - 20231129 IS - 1665-1731 (Electronic) IS - 1665-1731 (Linking) VI - 93 IP - 4 DP - 2023 TI - Heart transplantation in patients with anthracycline-induced cardiomyopathy. PG - 417-421 LID - 10.24875/ACM.22000170 [doi] AB - OBJECTIVE: The objective of this study was to describe the clinical and imaging characteristics and the evolution of heart transplantation patients due to anthracycline-induced cardiomyopathy. METHODS: Patients with a diagnosis of ACM who received a heart transplantation in our institution in the period of November 2009-April 2021 were included. Clinical characteristics, pre-transplant studies, and clinical outcomes after transplantation were collected retrospectively from the electronic medical record. RESULTS: A total of 11 patients were included in the study. The median age at the time of cancer diagnosis was 15 years (IQR 10-37 years), while the median age at the time of heart transplant was 56 years (IQR 39-62 years). Regarding post-transplant outcomes, three patients died in the post-operative period. One died 4 years after the intervention due to chronic rejection, while the other seven had a favorable evolution. No oncological relapse was observed with a median follow-up of 2.5 years (IQR 1.86-3.85 years). CONCLUSION: End-stage anthracycline-induced cardiomyopathy can occur many years after chemotherapy treatment, so close cardiovascular follow-up is extremely important. Heart transplantation is a treatment option after an exhaustive multidisciplinary evaluation, to minimize the risk of oncological relapse. CI - Copyright: (c) 2023 Permanyer. FAU - Del-Castillo, Santiago L AU - Del-Castillo SL AD - Department of Cardiology. FAU - Decotto, Santiago AU - Decotto S AD - Department of Cardiology. FAU - Fleitas, Maria M AU - Fleitas MM AD - Department of Cardiology. FAU - Marenchino, Ricardo AU - Marenchino R AD - Department of Cardiovascular Surgery. FAU - Garcia-Rivello, Hernan AU - Garcia-Rivello H AD - Department of Pathological Anatomy. Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. FAU - Kohan, Dana AU - Kohan D AD - Department of Pathological Anatomy. Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. FAU - Pizarro, Rodolfo AU - Pizarro R AD - Department of Cardiology. FAU - Belziti, Cesar A AU - Belziti CA AD - Department of Cardiology. LA - eng PT - Journal Article TT - Trasplante cardiaco en pacientes con cardiotoxicidad inducida por antraciclinas. PL - Mexico TA - Arch Cardiol Mex JT - Archivos de cardiologia de Mexico JID - 101126728 RN - 0 (Anthracyclines) SB - IM MH - Humans MH - Child MH - Adolescent MH - Young Adult MH - Adult MH - Middle Aged MH - Anthracyclines/adverse effects MH - Retrospective Studies MH - *Heart Transplantation MH - *Cardiomyopathies/chemically induced MH - Recurrence OTO - NOTNLM OT - Advanced heart failure OT - Anthracycline-induced cardiomyopathy OT - Cardiotoxicidad OT - Cardiotoxicity OT - Heart transplantation OT - Insuficiencia cardiaca avanzada OT - Miocardiopatia inducida por antraciclinas OT - Trasplante cardiaco EDAT- 2023/11/17 15:31 MHDA- 2023/11/27 12:43 CRDT- 2023/11/16 17:03 PHST- 2023/11/27 12:43 [medline] PHST- 2023/11/17 15:31 [pubmed] PHST- 2023/11/16 17:03 [entrez] AID - j93/4/417 [pii] AID - 10.24875/ACM.22000170 [doi] PST - ppublish SO - Arch Cardiol Mex. 2023;93(4):417-421. doi: 10.24875/ACM.22000170. PMID- 37971983 OWN - NLM STAT- MEDLINE DCOM- 20231120 LR - 20251231 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 18 IP - 11 DP - 2023 TI - Increased cesarean section rate and premature birth according to modified WHO maternal cardiovascular risk in pregnant women with congenital heart disease. PG - e0294323 LID - 10.1371/journal.pone.0294323 [doi] LID - e0294323 AB - BACKGROUND: During pregnancy and delivery, hemodynamics are altered and complex congenital heart disease has been associated with adverse maternal and neonatal outcomes. We sought to investigate pregnancy outcome and complications in relation to complexity of heart condition. MATERIALS AND METHODS: We studied women with ACHD discussed at multidisciplinary conferences at Lund University Hospital March 2009-May 2021. We studied 149 pregnancies in 101 women. We scored each woman retrospectively according to the modified World Health Organization (mWHO) risk classification and included patients in risk class I (n = 36, 24.1%), II (n = 43, 28.9%), II-III (n = 43, 28.9%), III (n = 24, 16.1%) and IV (n = 3, 2.0%). RESULTS: Women with mWHO class >/=III underwent cesarean section more often than women in less complex mWHO classes, (OR, 5.1; 95% CI, 2.0-12.5; p<0.001). The odds of premature delivery were significantly higher among pregnant women with mWHO class >/=III (OR, 6.7; 95% CI, 2.6-17.4; p<0.001). We found no difference in incidence of preeclampsia, gestational hypertension, gestational diabetes, hemorrhage >1000 ml or cardiac defect in the neonate depending on WHO-class. Women in mWHO classes III-IV had a higher rate of fetal growth restriction (FGR) compared to women in mWHO classes I, II, II-III (p<0.007). CONCLUSIONS: Our findings indicate that women with more complex heart disease (mWHO classes III or IV) tend to have a higher rate of cesarean section, premature birth and FGR. CI - Copyright: (c) 2023 Wedlund et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. FAU - Wedlund, Frida AU - Wedlund F AUID- ORCID: 0000-0001-6257-7655 AD - Department of Cardiology, Skane University Hospital, Lund University, Malmo, Sweden. AD - Clinical Sciences, Lund University, Lund, Sweden. FAU - von Wowern, Emma AU - von Wowern E AD - Institution of Clinical Sciences Malmo, Perinatal and Cardiovascular Epidemiology, Lund University, Lund, Sweden. AD - Dept. of Obstetrics and Gynecology, Skane University Hospital, Malmo, Sweden. FAU - Hlebowicz, Joanna AU - Hlebowicz J AD - Clinical Sciences, Lund University, Lund, Sweden. AD - Department of Cardiology, Skane University Hospital, Lund University, Lund, Sweden. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20231116 PL - United States TA - PLoS One JT - PloS one JID - 101285081 SB - IM MH - Infant, Newborn MH - Pregnancy MH - Female MH - Humans MH - *Premature Birth/epidemiology MH - Cesarean Section/adverse effects MH - Pregnant People MH - Retrospective Studies MH - *Cardiovascular Diseases/complications MH - *Pregnancy Complications, Cardiovascular/epidemiology MH - Risk Factors MH - *Heart Defects, Congenital/complications/epidemiology/surgery MH - Pregnancy Outcome/epidemiology MH - *Infant, Newborn, Diseases/epidemiology MH - Fetal Growth Retardation MH - Heart Disease Risk Factors PMC - PMC10653484 COIS- The authors have declared that no competing interests exist. EDAT- 2023/11/17 15:26 MHDA- 2023/11/20 06:55 PMCR- 2023/11/16 CRDT- 2023/11/16 13:33 PHST- 2023/02/21 00:00 [received] PHST- 2023/10/30 00:00 [accepted] PHST- 2023/11/20 06:55 [medline] PHST- 2023/11/17 15:26 [pubmed] PHST- 2023/11/16 13:33 [entrez] PHST- 2023/11/16 00:00 [pmc-release] AID - PONE-D-23-05147 [pii] AID - 10.1371/journal.pone.0294323 [doi] PST - epublish SO - PLoS One. 2023 Nov 16;18(11):e0294323. doi: 10.1371/journal.pone.0294323. eCollection 2023. PMID- 37969640 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231117 IS - 2666-0873 (Electronic) IS - 2666-0873 (Linking) VI - 5 IP - 5 DP - 2023 Oct TI - Endothelin Receptor Blocker Reverses Breast Cancer-Induced Cardiac Remodeling. PG - 686-700 LID - 10.1016/j.jaccao.2023.02.004 [doi] AB - BACKGROUND: Although some cancer therapies have overt and/or subclinical cardiotoxic effects that increase subsequent cardiovascular risk in breast cancer patients, we have recently shown that the breast tumor itself can also induce cardiac hypertrophy through the activation of the endothelin system to contribute to cardiovascular risk. However, the extent to which the suppression of the activation of the endothelin system could improve cardiac remodeling in breast cancer patients has yet to be investigated. OBJECTIVES: We aimed to retrospectively assess the cardiac morphology/function in patients with breast cancer before receiving cancer chemotherapy and to investigate if the suppression of the activation of the endothelin system improves cardiac remodeling in a mouse model of breast cancer. METHODS: Our study involved 28 previously studied women with breast cancer (including 24 after tumor resection) before receiving adjuvant therapy and 17 control healthy women. In addition, we explored how the endothelin system contributed to breast cancer-induced cardiac remodeling using a mouse model of breast cancer. RESULTS: Our results indicate that before chemotherapy, breast cancer patients already exhibit relative cardiac remodeling and subclinical cardiac dysfunction, which was associated with the activation of the endothelin system. Importantly, our mouse data also show that the endothelin receptor blocker atrasentan significantly lessened cardiac remodeling and improved cardiac function in a preclinical model of breast cancer. CONCLUSIONS: Although our findings should be further examined in other preclinical/clinical models, our data suggest that endothelin receptor blockers may play a role in cardiac health in individuals with breast cancer. (Understanding and Treating Heart Failure With Preserved Ejection Fraction: Novel Mechanisms, Diagnostics and Potential Therapeutics [Alberta HEART]; NCT02052804 and Multidisciplinary Team Intervention in Cardio-Oncology [TITAN]; NCT01621659). CI - (c) 2023 The Authors. FAU - Maayah, Zaid H AU - Maayah ZH AD - Department of Pharmaceutical Sciences, College of Pharmacy, Qatar University Health, Qatar University, Doha, Qatar. FAU - Ferdaoussi, Mourad AU - Ferdaoussi M AD - Faculty Saint-Jean, University of Alberta, Edmonton, Alberta, Canada. FAU - Boukouris, Aristeidis E AU - Boukouris AE AD - Department of Medicine, University of Alberta, Edmonton, Alberta, Canada. FAU - Takahara, Shingo AU - Takahara S AD - Division of Cardiovascular Surgery, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan. FAU - Das, Subhash K AU - Das SK AD - Department of Medicine, University of Alberta, Edmonton, Alberta, Canada. FAU - Khairy, Mostafa AU - Khairy M AD - Faculty Saint-Jean, University of Alberta, Edmonton, Alberta, Canada. AD - Cardiovascular Research Centre, Department of Pediatrics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada. FAU - Mackey, John R AU - Mackey JR AD - Cross Cancer Institute, Edmonton, Alberta, Canada. FAU - Pituskin, Edith AU - Pituskin E AD - Cross Cancer Institute, Edmonton, Alberta, Canada. FAU - Sutendra, Gopinath AU - Sutendra G AD - Department of Medicine, University of Alberta, Edmonton, Alberta, Canada. FAU - Paterson, D Ian AU - Paterson DI AD - Division of Cardiology, University of Ottawa Heart Institute, University of Ottawa, Ottawa, Ontario, Canada. FAU - Dyck, Jason R B AU - Dyck JRB AD - Cardiovascular Research Centre, Department of Pediatrics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada. LA - eng SI - ClinicalTrials.gov/NCT01621659 PT - Journal Article DEP - 20230502 PL - United States TA - JACC CardioOncol JT - JACC. CardioOncology JID - 101761697 PMC - PMC10635889 OTO - NOTNLM OT - breast tumor OT - cardiac remodeling OT - endothelin system COIS- This work was supported by a grant from the Canadian Institutes of Health Research and a grant from the generous supporters of the Lois Hole Hospital for Women through the Women and Children's Health Research Institute, University of Alberta to Dr Dyck. Dr Dyck is a Canada Research Chair in Molecular Medicine. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2023/11/16 06:44 MHDA- 2023/11/16 06:45 PMCR- 2023/05/02 CRDT- 2023/11/16 04:23 PHST- 2022/07/29 00:00 [received] PHST- 2023/02/20 00:00 [revised] PHST- 2023/02/22 00:00 [accepted] PHST- 2023/11/16 06:45 [medline] PHST- 2023/11/16 06:44 [pubmed] PHST- 2023/11/16 04:23 [entrez] PHST- 2023/05/02 00:00 [pmc-release] AID - S2666-0873(23)00104-7 [pii] AID - 10.1016/j.jaccao.2023.02.004 [doi] PST - epublish SO - JACC CardioOncol. 2023 May 2;5(5):686-700. doi: 10.1016/j.jaccao.2023.02.004. eCollection 2023 Oct. PMID- 37967981 OWN - NLM STAT- MEDLINE DCOM- 20231201 LR - 20231216 IS - 1349-3299 (Electronic) IS - 1349-2365 (Linking) VI - 64 IP - 6 DP - 2023 Nov 30 TI - Characteristics of Discharged Elderly Patients with Acute Heart Failure Followed by Board-Certified-Cardiologists in a Rural Area of Japan. PG - 1105-1112 LID - 10.1536/ihj.23-306 [doi] AB - The worldwide incidence rates of heart failure (HF) are approaching pandemic status due to aging societies. Board-certified cardiologists (BCCs) of the Japanese Circulation Society (JCS) are cardiologists who have completed the respective fellowship program and passed the examination. However, in rural areas, patients have limited access to medical care for social or geographical reasons. The clinical features of the specialist's follow-up for HF patients in rural areas are unclear.This study consists of 205 consecutive discharged elderly patients who were admitted to our hospital due to acute HF (AHF). All patients were recommended for follow-up with BCCs-JCS by the multidisciplinary HF team at the discharge-care planning meeting. The aim of this study was to investigate the clinical features and impact of BCC follow-up for discharged elderly patients with AHF in rural areas.A total of 156 patients chose follow-up with BCCs-JCS (BCC group), and 49 patients chose follow-up with non-BCCs-JCS (non-BCC group). Patients in the BCC group were younger (83 [76-86] versus 89 [75-93] years old, P < 0.001) and had more frequent use of beta-blockers (67% versus 39%, P < 0.001). The degree of frailty assessed by the clinical frailty scale was more severe in the non-BCC group than in the BCC group (4 [3-5] versus 6 [4-7], P < 0.001). The non-BCC group lived in nursing homes more frequently than the BCC group (16% versus 5%, P = 0.011).The HF patients followed by BCCS-JCS in rural areas were younger and had less frailty. FAU - Satogami, Keisuke AU - Satogami K AD - Department of Cardiovascular Medicine, Wakayama Medical University. AD - Department of Cardiology, Shingu Municipal Medical Center. FAU - Katayama, Yosuke AU - Katayama Y AD - Department of Cardiology, Shingu Municipal Medical Center. FAU - Ozaki, Yuichi AU - Ozaki Y AD - Department of Cardiovascular Medicine, Wakayama Medical University. AD - Department of Cardiology, Shingu Municipal Medical Center. FAU - Taruya, Akira AU - Taruya A AD - Department of Cardiovascular Medicine, Wakayama Medical University. FAU - Taniguchi, Motoki AU - Taniguchi M AD - Department of Cardiology, Shingu Municipal Medical Center. FAU - Ota, Shingo AU - Ota S AD - Department of Cardiovascular Medicine, Wakayama Medical University. FAU - Kuroi, Akio AU - Kuroi A AD - Department of Cardiovascular Medicine, Wakayama Medical University. FAU - Shiono, Yasutsugu AU - Shiono Y AD - Department of Cardiovascular Medicine, Wakayama Medical University. FAU - Tanimoto, Takashi AU - Tanimoto T AD - Department of Cardiovascular Medicine, Wakayama Medical University. FAU - Yamano, Takashi AU - Yamano T AD - Department of Cardiology, Shingu Municipal Medical Center. FAU - Kitabata, Hironori AU - Kitabata H AD - Department of Cardiovascular Medicine, Wakayama Medical University. FAU - Ino, Yasushi AU - Ino Y AD - Department of Cardiology, Shingu Municipal Medical Center. FAU - Tanaka, Atsushi AU - Tanaka A AD - Department of Cardiovascular Medicine, Wakayama Medical University. LA - eng PT - Journal Article DEP - 20231114 PL - Japan TA - Int Heart J JT - International heart journal JID - 101244240 SB - IM MH - Humans MH - Aged MH - Aged, 80 and over MH - Patient Discharge MH - Japan/epidemiology MH - *Cardiologists MH - *Frailty MH - *Heart Failure/epidemiology/therapy/diagnosis OTO - NOTNLM OT - Follow-up OT - Mortality OT - Post-discharge OT - Specialists EDAT- 2023/11/16 00:42 MHDA- 2023/12/01 06:44 CRDT- 2023/11/15 20:44 PHST- 2023/12/01 06:44 [medline] PHST- 2023/11/16 00:42 [pubmed] PHST- 2023/11/15 20:44 [entrez] AID - 10.1536/ihj.23-306 [doi] PST - ppublish SO - Int Heart J. 2023 Nov 30;64(6):1105-1112. doi: 10.1536/ihj.23-306. Epub 2023 Nov 14. PMID- 37967611 OWN - NLM STAT- MEDLINE DCOM- 20231211 LR - 20231217 IS - 2213-0276 (Electronic) IS - 0755-4982 (Linking) VI - 52 IP - 4 DP - 2023 Dec TI - Pulmonary hypertension in sickle cell disease. PG - 104209 LID - S0755-4982(23)00046-5 [pii] LID - 10.1016/j.lpm.2023.104209 [doi] AB - Sickle cell disease (SCD) is a complex genetic disorder that has long challenged both patients and healthcare professionals. One of its chronic and debilitating complications is pulmonary hypertension (PH). SCD-associated PH is often post-capillary, secondary to left heart disease. It can also sometimes be pre-capillary with multiple and often interrelated mechanisms including obstructive remodeling of the pulmonary vascular bed secondary to hemolysis, endothelial dysfunction, thrombosis, hypoxia, or associated risk factors like portal hypertension. Screening symptomatic patients with echocardiographic signs of PH is crucial to determine those who should undergo right heart catheterization, the cornerstone exam to diagnose and categorize patients with PH. The workup following the diagnosis relies on identifying the cause of PH to personalize treatment. Ongoing efforts are made to treat this complex condition, starting with treating the underlying disease with hydroxyurea or chronic blood exchange transfusion. Robust data on the efficacy of PAH-specific therapies are lacking in this specific population. Initiation of such therapies must be made by an expert center after a case-by-case assessment of the benefit-risk ratio according to the phenotype and the mechanisms involved in the development of PH. Efforts are also poured into studying the interventional and medical therapies used on chronic thromboembolic PH for patients presenting with a thrombotic form. The management of those patients requires a multidisciplinary approach, with conjoint efforts from PH and SCD specialists. CI - Copyright (c) 2023. Published by Elsevier Masson SAS. FAU - Al Kahf, Salma AU - Al Kahf S AD - INSERM UMR_S 999 "Pulmonary Hypertension: Pathophysiology and Novel Therapies", Hopital Marie Lannelongue, 92350 Le Plessis-Robinson, France; Universite Paris-Saclay, Faculte de Medecine, Pulmonary Hypertension: Pathophysiology and Novel Therapies 94276 Le Kremlin-Bicetre, France; Assistance Publique - Hopitaux de Paris (AP-HP), Service de Pneumologie et Soins Intensifs Respiratoires, Hopital Bicetre, 94270 Le Kremlin-Bicetre, France. FAU - Roche, Anne AU - Roche A AD - INSERM UMR_S 999 "Pulmonary Hypertension: Pathophysiology and Novel Therapies", Hopital Marie Lannelongue, 92350 Le Plessis-Robinson, France; Universite Paris-Saclay, Faculte de Medecine, Pulmonary Hypertension: Pathophysiology and Novel Therapies 94276 Le Kremlin-Bicetre, France; Assistance Publique - Hopitaux de Paris (AP-HP), Service de Pneumologie et Soins Intensifs Respiratoires, Hopital Bicetre, 94270 Le Kremlin-Bicetre, France. FAU - Baron, Audrey AU - Baron A AD - INSERM UMR_S 999 "Pulmonary Hypertension: Pathophysiology and Novel Therapies", Hopital Marie Lannelongue, 92350 Le Plessis-Robinson, France; Universite Paris-Saclay, Faculte de Medecine, Pulmonary Hypertension: Pathophysiology and Novel Therapies 94276 Le Kremlin-Bicetre, France; Assistance Publique - Hopitaux de Paris (AP-HP), Service de Pneumologie et Soins Intensifs Respiratoires, Hopital Bicetre, 94270 Le Kremlin-Bicetre, France. FAU - Chantalat-Auger, Christelle AU - Chantalat-Auger C AD - Universite Paris-Saclay, Faculte de Medecine, Pulmonary Hypertension: Pathophysiology and Novel Therapies 94276 Le Kremlin-Bicetre, France; Assistance Publique - Hopitaux de Paris (AP-HP), Service de medecine interne, Hopital Bicetre, 94270 Le Kremlin-Bicetre, France. FAU - Savale, Laurent AU - Savale L AD - INSERM UMR_S 999 "Pulmonary Hypertension: Pathophysiology and Novel Therapies", Hopital Marie Lannelongue, 92350 Le Plessis-Robinson, France; Universite Paris-Saclay, Faculte de Medecine, Pulmonary Hypertension: Pathophysiology and Novel Therapies 94276 Le Kremlin-Bicetre, France; Assistance Publique - Hopitaux de Paris (AP-HP), Service de Pneumologie et Soins Intensifs Respiratoires, Hopital Bicetre, 94270 Le Kremlin-Bicetre, France. Electronic address: laurent.savale@aphp.fr. LA - eng PT - Journal Article DEP - 20231114 PL - France TA - Presse Med JT - Presse medicale (Paris, France : 1983) JID - 8302490 RN - X6Q56QN5QC (Hydroxyurea) SB - IM MH - Humans MH - *Hypertension, Pulmonary/diagnosis/etiology/therapy MH - *Anemia, Sickle Cell/complications MH - Echocardiography MH - *Heart Diseases/complications MH - Hydroxyurea/therapeutic use OTO - NOTNLM OT - Echocardiography OT - Pulmonary hypertension OT - Right heart catheterization OT - Sickle-cell disease EDAT- 2023/11/16 00:42 MHDA- 2023/12/11 12:43 CRDT- 2023/11/15 19:20 PHST- 2023/12/11 12:43 [medline] PHST- 2023/11/16 00:42 [pubmed] PHST- 2023/11/15 19:20 [entrez] AID - S0755-4982(23)00046-5 [pii] AID - 10.1016/j.lpm.2023.104209 [doi] PST - ppublish SO - Presse Med. 2023 Dec;52(4):104209. doi: 10.1016/j.lpm.2023.104209. Epub 2023 Nov 14. PMID- 37963548 OWN - NLM STAT- MEDLINE DCOM- 20240810 LR - 20260127 IS - 1938-2715 (Electronic) IS - 1049-9091 (Print) IS - 1049-9091 (Linking) VI - 41 IP - 9 DP - 2024 Sep TI - Palliative Care for the Elderly With Heart Diseases in Tertiary Health care: A Concept Analysis. PG - 1061-1075 LID - 10.1177/10499091231213606 [doi] AB - BACKGROUND: The increasing incidence of heart failure (HF) in the elderly leads to increased mortality, hospitalization, length of hospital stay, and health care costs. Older adults often face multiple drug treatments, comorbidities, frailty, and cognitive problems, which require early palliative care. However, these patients do not receive adequate palliative care. OBJECTIVE: This concept analysis aimed to develop an in-depth understanding of palliative care for elderly patients with cardiac diseases in tertiary care. DESIGN: The analysis was guided by Walker and Avant's method, and databases were searched using keywords, such as palliative care, tertiary care, elderly, and heart. Covidence was used to review the results using the inclusion and exclusion criteria. RESULTS: The World Health Organisation's definition of palliative care is widely accepted. Palliative care for older adults with heart disease in tertiary care is preceded by chronic illness, polypharmacy, symptom burden, physical and cognitive decline, comorbidities, and psychosocial/spiritual issues. The main attributes of palliative care for this population include health care professionals and patient education, holistic patient/family-centered care, symptom management, shared decision-making, early integration, advanced care planning, and a multidisciplinary approach. Palliative care improves elderly cardiac patients' and their family satisfaction while reducing readmission, hospital stays, and unnecessary invasive procedures. CONCLUSION: Collaboration between hospitals, community organizations, transitional palliative care services, and research has the potential to improve early palliative care and the well-being of the elderly cardiac population. Advanced Practice Nurses (APNs) competencies play a crucial role in promoting palliative care in the elderly HF population. FAU - Ali, Sana AU - Ali S AUID- ORCID: 0000-0002-2366-9757 AD - School of Nursing, Faculty of Health Sciences, The University of Ottawa, Ottawa, ON, Canada. RINGGOLD: 6363 FAU - Tyerman, Jane AU - Tyerman J AD - School of Nursing, Faculty of Health Sciences, The University of Ottawa, Ottawa, ON, Canada. RINGGOLD: 6363 LA - eng PT - Journal Article DEP - 20231114 PL - United States TA - Am J Hosp Palliat Care JT - The American journal of hospice & palliative care JID - 9008229 SB - IM MH - Humans MH - *Palliative Care/organization & administration MH - Aged MH - *Heart Diseases/therapy MH - Comorbidity MH - Tertiary Health Care/organization & administration MH - Heart Failure/therapy MH - Polypharmacy MH - Patient Education as Topic/organization & administration MH - Advance Care Planning/organization & administration MH - Chronic Disease MH - Aged, 80 and over MH - Decision Making, Shared PMC - PMC11318222 OTO - NOTNLM OT - aged OT - cardiac OT - elderly OT - geriatrics OT - heart diseases OT - heart failure OT - inpatients OT - palliative care OT - tertiary healthcare COIS- Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2023/11/15 00:41 MHDA- 2024/08/10 15:46 PMCR- 2024/08/12 CRDT- 2023/11/14 19:12 PHST- 2024/08/10 15:46 [medline] PHST- 2023/11/15 00:41 [pubmed] PHST- 2023/11/14 19:12 [entrez] PHST- 2024/08/12 00:00 [pmc-release] AID - 10.1177_10499091231213606 [pii] AID - 10.1177/10499091231213606 [doi] PST - ppublish SO - Am J Hosp Palliat Care. 2024 Sep;41(9):1061-1075. doi: 10.1177/10499091231213606. Epub 2023 Nov 14. PMID- 37963173 OWN - NLM STAT- MEDLINE DCOM- 20231116 LR - 20240210 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 18 IP - 11 DP - 2023 TI - Characterization of patients receiving surgical versus non-surgical treatment for infective endocarditis in West Virginia. PG - e0289622 LID - 10.1371/journal.pone.0289622 [doi] LID - e0289622 AB - BACKGROUND: Infective endocarditis (IE) has increased in rural states such as West Virginia (WV) with high injection drug use. IE is medically managed with antimicrobial treatment alone or combined with surgical treatment. This study aimed to characterize the predictors associated with surgical treatment and rates of inpatient mortality and readmission among IE patients in WV's rural centers. METHODS: This retrospective review of electronic health records includes all adults hospitalized for IE at major rural tertiary cardiovascular centers in WV during 2014-2018. Descriptive statistics were presented on demographics, history of injection drug use, clinical characteristics, and hospital utilization by surgery status, and multivariable logistic regression examined the association of surgery with key predictor variables, generating odds ratios (OR). RESULTS: Of the 780 patients with IE, 38% had surgery, with a 26-fold increase in patients undergoing surgery between 2014-2018. Comparing surgery and non-surgery patients revealed significant differences. Surgery patients were significantly younger (median age 35.6 vs. 40.5 years; p<0.001); had higher rates of drug use history (80% vs. 65%; p<0.001), psychiatric disorders (57% vs. 31%; p<0.001), and readmissions (18% vs.12%; p = 0.015). Surgery patients had lower rates of discharge against medical advice (11% vs.17%; p = 0.028) and in-hospital mortality (5% vs.12%; p<0.001). In the multivariable logistic regression, surgery was associated with injection drug use (OR: 1.9; 95% CI:1.09-3. 3), indications for surgery (OR: 1.68; 95% CI:1.48-1.91), left-sided IE (OR: 2.14; 95%CI:1.43-3.19) and later years (OR:3.75; 95%CI:2.5-5.72). CONCLUSION: This study characterizes the predictors associated with surgical treatment and rates of inpatient mortality and readmission among IE patients across rural WV. The decision to perform cardiac surgery on IE patients is complex. Results with increased injection drug use-associated IE emphasize the importance of comprehensive care by a multidisciplinary team for optimal management of patients with IE. CI - Copyright: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication. FAU - Bhandari, Ruchi AU - Bhandari R AUID- ORCID: 0000-0002-4288-6255 AD - School of Public Health, West Virginia University, Morgantown, WV, United States of America. FAU - Abdulhay, Noor AU - Abdulhay N AD - School of Public Health, West Virginia University, Morgantown, WV, United States of America. FAU - Alexander, Talia AU - Alexander T AD - School of Public Health, West Virginia University, Morgantown, WV, United States of America. AD - National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America. FAU - Rubenstein, Jessica AU - Rubenstein J AD - School of Public Health, West Virginia University, Morgantown, WV, United States of America. FAU - Meyer, Andrew AU - Meyer A AD - School of Public Health, West Virginia University, Morgantown, WV, United States of America. FAU - Annie, Frank H AU - Annie FH AUID- ORCID: 0000-0001-8423-4119 AD - Health Education and Research Institute, Charleston Area Medical Center, Charleston, West Virginia, United States of America. FAU - Kaleem, Umar AU - Kaleem U AD - Joan C. Edwards School of Medicine, Marshall University, Huntington, WV, United States of America. FAU - Wiener, R Constance AU - Wiener RC AD - School of Dentistry, West Virginia University, Morgantown, WV, United States of America. FAU - Sedney, Cara AU - Sedney C AD - School of Medicine, West Virginia University, Morgantown, WV, United States of America. FAU - Thompson, Ellen AU - Thompson E AD - Joan C. Edwards School of Medicine, Marshall University, Huntington, WV, United States of America. FAU - Irfan, Affan AU - Irfan A AD - Mayo Clinic Health System, Rochester, MN, United States of America. LA - eng GR - U54 GM104942/GM/NIGMS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20231114 PL - United States TA - PLoS One JT - PloS one JID - 101285081 SB - IM MH - Adult MH - Humans MH - West Virginia/epidemiology MH - *Endocarditis, Bacterial MH - *Endocarditis/drug therapy/surgery MH - Retrospective Studies MH - *Cardiac Surgical Procedures/adverse effects PMC - PMC10645336 COIS- The authors have declared that no competing interests exist. EDAT- 2023/11/14 18:42 MHDA- 2023/11/16 06:44 PMCR- 2023/11/14 CRDT- 2023/11/14 13:35 PHST- 2023/03/27 00:00 [received] PHST- 2023/07/24 00:00 [accepted] PHST- 2023/11/16 06:44 [medline] PHST- 2023/11/14 18:42 [pubmed] PHST- 2023/11/14 13:35 [entrez] PHST- 2023/11/14 00:00 [pmc-release] AID - PONE-D-23-08921 [pii] AID - 10.1371/journal.pone.0289622 [doi] PST - epublish SO - PLoS One. 2023 Nov 14;18(11):e0289622. doi: 10.1371/journal.pone.0289622. eCollection 2023. PMID- 37959373 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231122 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 12 IP - 21 DP - 2023 Nov 2 TI - Practical Considerations for Cardiac Electronic Devices Reimplantation Following Transvenous Lead Extraction Due to Related Endocarditis. LID - 10.3390/jcm12216908 [doi] LID - 6908 AB - Despite progress in implantation technology and prophylactic measures, infection complications related to cardiac implantable electronic devices (CIED) are still a major concern with negative impacts on patient outcomes and the health system's resources. Infective endocarditis (IE) represents one of the most threatening CIED-related infections associated with high mortality rates and requires prompt diagnosis and management. Transvenous lead extraction (TLE), combined with prolonged antibiotic therapy, has been validated as an effective approach to treat patients with CIED-related IE. Though early complete removal is undoubtedly recommended for CIED-related IE or systemic infection, device reimplantation still represents a clinical challenge in these patients at high risk of reinfection, with many gaps in the current knowledge and international guidelines. Based on the available literature data and authors' experience, this review aims to address the practical and clinical considerations regarding CIED reimplantation following lead extraction for related IE, focusing on the reassessment of CIED indication, procedure timing, and the reimplanted CIED type and site. A tailored, multidisciplinary approach involving clinical cardiologists, electrophysiologists, cardiac imaging experts, cardiac surgeons, and infectious disease specialists is crucial to optimize these patients' management and clinical outcomes. FAU - Ali, Hussam AU - Ali H AUID- ORCID: 0000-0002-3469-1028 AD - Arrhythmia & Electrophysiology Centre, IRCCS MultiMedica, 20099 Sesto San Giovanni, Italy. FAU - Foresti, Sara AU - Foresti S AD - Arrhythmia & Electrophysiology Centre, IRCCS MultiMedica, 20099 Sesto San Giovanni, Italy. FAU - De Ambroggi, Guido AU - De Ambroggi G AD - Arrhythmia & Electrophysiology Centre, IRCCS MultiMedica, 20099 Sesto San Giovanni, Italy. FAU - Cappato, Riccardo AU - Cappato R AD - Arrhythmia & Electrophysiology Centre, IRCCS MultiMedica, 20099 Sesto San Giovanni, Italy. FAU - Lupo, Pierpaolo AU - Lupo P AD - Arrhythmia & Electrophysiology Centre, IRCCS MultiMedica, 20099 Sesto San Giovanni, Italy. LA - eng PT - Journal Article PT - Review DEP - 20231102 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC10649089 OTO - NOTNLM OT - cardiac implantable electronic devices discipline OT - infective endocarditis OT - lead extraction OT - reimplantation COIS- The authors declare no conflict of interest. EDAT- 2023/11/14 06:42 MHDA- 2023/11/14 06:43 PMCR- 2023/11/02 CRDT- 2023/11/14 02:13 PHST- 2023/08/28 00:00 [received] PHST- 2023/10/27 00:00 [revised] PHST- 2023/10/30 00:00 [accepted] PHST- 2023/11/14 06:43 [medline] PHST- 2023/11/14 06:42 [pubmed] PHST- 2023/11/14 02:13 [entrez] PHST- 2023/11/02 00:00 [pmc-release] AID - jcm12216908 [pii] AID - jcm-12-06908 [pii] AID - 10.3390/jcm12216908 [doi] PST - epublish SO - J Clin Med. 2023 Nov 2;12(21):6908. doi: 10.3390/jcm12216908. PMID- 37959355 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231122 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 12 IP - 21 DP - 2023 Nov 1 TI - Combining Minimally Invasive Direct Coronary Artery Bypass Grafting with Transapical Aortic Valve Implantation-The Next Level Heart Team Approach. LID - 10.3390/jcm12216890 [doi] LID - 6890 AB - We present the results of a combined approach for transapical aortic valve replacement and minimally invasive coronary artery bypass grafting (taTAVI-MIDCAB) in patients with combined aortic stenosis and coronary artery disease. BACKGROUND: For patients presenting with aortic stenosis and coronary artery disease, a simultaneous procedure addressing both diseases is recommended to reduce operative risk. In high-risk patients with hostile femoral or coronary axis, taTAVI-MIDCAB can be an alternative minimally invasive approach, offering the benefits of left interior mammary artery to left anterior descending coronary artery (LIMA-LAD) grafting. METHODS: From 2014 to 2022, 10 patients underwent taTAVI-MIDCAB for combined coronary and severe aortic stenosis in the hybrid operation theater at our institution. We assessed perioperative outcomes and follow-up outcomes. RESULTS: The median age was 83 years (81 to 86). The procedure was successfully performed in all patients without conversion to sternotomy. The median length of hospital and intensive care unit stay was 9 days (7 to 16) and 2.5 days (1 to 5), respectively. The median flow over the coronary artery bypass was 31 (22 to 44) mL/min, with a pulsatility index (PI) of 2.4 (2.1 to 3.2). Mild paravalvular leak occurred in 2 patients (10%). There were no neurological events nor acute kidney injury. Pacemaker implantation was required in 1 patient (10%). CONCLUSIONS: Simultaneous surgical coronary revascularization and interventional valve implantation in the setting of a hostile femoral and coronary axis appears to be safe and beneficial. FAU - Miazza, Jules AU - Miazza J AD - Department of Cardiac Surgery, University Hospital Basel, 4031 Basel, Switzerland. FAU - Vasiloi, Ion AU - Vasiloi I AD - Department of Cardiac Surgery, University Hospital Basel, 4031 Basel, Switzerland. FAU - Koechlin, Luca AU - Koechlin L AD - Department of Cardiac Surgery, University Hospital Basel, 4031 Basel, Switzerland. FAU - Gahl, Brigitta AU - Gahl B AD - Department of Cardiac Surgery, University Hospital Basel, 4031 Basel, Switzerland. FAU - Santer, David AU - Santer D AUID- ORCID: 0000-0003-4493-4326 AD - Department of Cardiac Surgery, University Hospital Basel, 4031 Basel, Switzerland. FAU - Berdajs, Denis AU - Berdajs D AD - Department of Cardiac Surgery, University Hospital Basel, 4031 Basel, Switzerland. FAU - Nestelberger, Thomas AU - Nestelberger T AUID- ORCID: 0000-0003-2173-5738 AD - Department of Cardiology, University Hospital Basel, University of Basel, 4031 Basel, Switzerland. FAU - Kaiser, Christoph AU - Kaiser C AD - Department of Cardiology, University Hospital Basel, University of Basel, 4031 Basel, Switzerland. FAU - Eckstein, Friedrich AU - Eckstein F AD - Department of Cardiac Surgery, University Hospital Basel, 4031 Basel, Switzerland. FAU - Reuthebuch, Oliver AU - Reuthebuch O AUID- ORCID: 0000-0003-1386-0686 AD - Department of Cardiac Surgery, University Hospital Basel, 4031 Basel, Switzerland. LA - eng PT - Journal Article DEP - 20231101 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC10647604 OTO - NOTNLM OT - MIDCAB OT - TAVR OT - cardiac surgery OT - intervention COIS- Nestelberger has received research support from the Swiss National Science Foundation (P400PM_191037/1), the Swiss Heart Foundation (FF20079), the Max Cloetta Foundation, the Margarete und Walter Lichtenstein-Stiftung (3MS1038), the University of Basel, and the University Hospital of Basel, as well as speaker honoraria/consulting honoraria from Siemens, Beckman Coulter, Bayer, Ortho Clinical Diagnostics, and Orion Pharma, all outside the submitted work. The remaining authors declare no conflict of interest. EDAT- 2023/11/14 06:43 MHDA- 2023/11/14 06:44 PMCR- 2023/11/01 CRDT- 2023/11/14 02:13 PHST- 2023/09/25 00:00 [received] PHST- 2023/10/23 00:00 [revised] PHST- 2023/10/27 00:00 [accepted] PHST- 2023/11/14 06:44 [medline] PHST- 2023/11/14 06:43 [pubmed] PHST- 2023/11/14 02:13 [entrez] PHST- 2023/11/01 00:00 [pmc-release] AID - jcm12216890 [pii] AID - jcm-12-06890 [pii] AID - 10.3390/jcm12216890 [doi] PST - epublish SO - J Clin Med. 2023 Nov 1;12(21):6890. doi: 10.3390/jcm12216890. PMID- 37952578 OWN - NLM STAT- MEDLINE DCOM- 20240116 LR - 20250104 IS - 1873-1570 (Electronic) IS - 0300-9572 (Print) IS - 0300-9572 (Linking) VI - 194 DP - 2024 Jan TI - Using rapid response system trigger clusters to characterize patterns of clinical deterioration among hospitalized adult patients. PG - 110041 LID - S0300-9572(23)00768-2 [pii] LID - 10.1016/j.resuscitation.2023.110041 [doi] AB - BACKGROUND: Many rapid response system (RRS) events are activated using multiple triggers. However, the patterns in which multiple RRS triggers occur together to activate RRS events are unknown. The purpose of this study was to identify these patterns (RRS trigger clusters) and determine their association with outcomes among hospitalized adult patients. METHODS: RRS events among adult patients from January 2015 to December 2019 in the Get With The Guidelines- Resuscitation registry's MET module were examined (n = 134,406). Cluster analysis methods were performed to identify RRS trigger clusters. Pearson's chi-squared and ANOVA tests were used to examine differences in patient characteristics across RRS trigger clusters. Multilevel logistic regressions were used to examine the associations between RRS trigger clusters and outcomes. RESULTS: Six RRS trigger clusters were identified. Predominant RRS triggers for each cluster were: tachypnea, new onset difficulty in breathing, decreased oxygen saturation (Cluster 1); tachypnea, decreased oxygen saturation, staff concern (Cluster 2); respiratory depression, decreased oxygen saturation, mental status changes (Cluster 3); tachycardia, staff concern (Cluster 4); mental status changes (Cluster 5); hypotension, staff concern (Cluster 6). Significant differences in patient characteristics were observed across clusters. Patients in Clusters 3 and 6 had an increased likelihood of in-hospital cardiac arrest (p < 0.01). All clusters had an increased risk of mortality (p < 0.01). CONCLUSIONS: We discovered six novel RRS trigger clusters with differing relationships to adverse patient outcomes. RRS trigger clusters may prove crucial in clarifying the associations between RRS events and adverse outcomes and aiding in clinician decision-making during RRS events. CI - Copyright (c) 2023 Elsevier B.V. All rights reserved. FAU - Piasecki, Rebecca J AU - Piasecki RJ AD - Johns Hopkins University, 3400 N. Charles St., Baltimore, MD 21218, United States. Electronic address: piasec15@msu.edu. FAU - Hunt, Elizabeth A AU - Hunt EA AD - Johns Hopkins University, 3400 N. Charles St., Baltimore, MD 21218, United States. FAU - Perrin, Nancy AU - Perrin N AD - Johns Hopkins University, 3400 N. Charles St., Baltimore, MD 21218, United States. FAU - Spaulding, Erin M AU - Spaulding EM AD - Johns Hopkins University, 3400 N. Charles St., Baltimore, MD 21218, United States. FAU - Winters, Bradford AU - Winters B AD - Johns Hopkins University, 3400 N. Charles St., Baltimore, MD 21218, United States. FAU - Samuel, Laura AU - Samuel L AD - Johns Hopkins University, 3400 N. Charles St., Baltimore, MD 21218, United States. FAU - Davidson, Patricia M AU - Davidson PM AD - University of Wollongong Australia, Northfields Ave., Wollongong, NSW 2522, Australia. FAU - Chandra Strobos, Nisha AU - Chandra Strobos N AD - Johns Hopkins University, 3400 N. Charles St., Baltimore, MD 21218, United States. FAU - Churpek, Matthew AU - Churpek M AD - University of Wisconsin-Madison, Union South, 1308 W. Dayton St., Madison, WI 53715, United States. FAU - Himmelfarb, Cheryl R AU - Himmelfarb CR AD - Johns Hopkins University, 3400 N. Charles St., Baltimore, MD 21218, United States. CN - American Heart Association's Get With The Guidelines(R)-Resuscitation Investigators LA - eng GR - F31 NR018362/NR/NINR NIH HHS/United States GR - T32 HL007024/HL/NHLBI NIH HHS/United States GR - T32 NR012704/NR/NINR NIH HHS/United States PT - Journal Article DEP - 20231110 PL - Ireland TA - Resuscitation JT - Resuscitation JID - 0332173 SB - IM UOF - medRxiv. 2023 Feb 08:2023.02.06.23285560. doi: 10.1101/2023.02.06.23285560. PMID: 36798369 MH - Adult MH - Humans MH - Intensive Care Units MH - *Clinical Deterioration MH - *Hospital Rapid Response Team MH - Hospital Mortality MH - Tachypnea PMC - PMC10842078 MID - NIHMS1947330 OTO - NOTNLM OT - Hospital mortality OT - In-hospital cardiac arrest OT - Rapid response systems COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2023/11/13 00:42 MHDA- 2024/01/16 06:41 PMCR- 2025/01/01 CRDT- 2023/11/12 19:13 PHST- 2023/06/22 00:00 [received] PHST- 2023/10/31 00:00 [revised] PHST- 2023/11/06 00:00 [accepted] PHST- 2024/01/16 06:41 [medline] PHST- 2023/11/13 00:42 [pubmed] PHST- 2023/11/12 19:13 [entrez] PHST- 2025/01/01 00:00 [pmc-release] AID - S0300-9572(23)00768-2 [pii] AID - 10.1016/j.resuscitation.2023.110041 [doi] PST - ppublish SO - Resuscitation. 2024 Jan;194:110041. doi: 10.1016/j.resuscitation.2023.110041. Epub 2023 Nov 10. PMID- 37939257 OWN - NLM STAT- MEDLINE DCOM- 20240301 LR - 20250831 IS - 1552-7557 (Electronic) IS - 1049-7323 (Print) IS - 1049-7323 (Linking) VI - 34 IP - 4 DP - 2024 Mar TI - Factors Shaping the Implementation of Strategies to Prevent Acute Kidney Injury: A Qualitative Study. PG - 287-297 LID - 10.1177/10497323231209651 [doi] AB - Reducing the prevalence of acute kidney injury (AKI) is an important patient safety objective set forth by the National Quality Forum. Despite international guidelines to prevent AKI, there continues to be an inconsistent uptake of these interventions by cardiac teams across practice settings. The IMPROVE-AKI study was designed to test the effectiveness and implementation of AKI preventive strategies delivered through team-based coaching activities. Qualitative methods were used to identify factors that shaped sites' implementation of AKI prevention strategies. Semi-structured interviews were conducted with staff in a range of roles within the cardiac catheterization laboratories, including nurses, laboratory managers, and interventional cardiologists (N = 50) at multiple time points over the course of the study. Interview transcripts were qualitatively coded, and aggregated code reports were reviewed to construct main themes through memoing. In this paper, we report insights from semi-structured interviews regarding workflow, organizational culture, and leadership factors that impacted implementation of AKI prevention strategies. FAU - Carpenter-Song, Elizabeth AU - Carpenter-Song E AUID- ORCID: 0000-0002-7545-1717 AD - Department of Anthropology, Dartmouth College, Hanover, NH, USA. FAU - Stabler, Meagan E AU - Stabler ME AD - Department of Epidemiology, Geisel School of Medicine at Dartmouth, Hanover, NH, USA. FAU - Aschbrenner, Kelly AU - Aschbrenner K AD - Department of Psychiatry, Geisel School of Medicine at Dartmouth, Hanover, NH, USA. FAU - Zubkoff, Lisa AU - Zubkoff L AD - Department of Medicine, University of Alabama at Birmingham and VA Birmingham Health Care, Birmingham, AL, USA. FAU - Cox, Kevin C AU - Cox KC AD - Department of Epidemiology, Geisel School of Medicine at Dartmouth, Hanover, NH, USA. FAU - Matheny, Michael E AU - Matheny ME AD - Vanderbilt University Medical Center, Nashville, TN, USA. AD - Tennesee Valley Health System, Nashville, TN, USA. FAU - Brown, Jeremiah R AU - Brown JR AD - Department of Epidemiology, Geisel School of Medicine at Dartmouth, Hanover, NH, USA. LA - eng GR - R01 DK113201/DK/NIDDK NIH HHS/United States PT - Journal Article DEP - 20231108 PL - United States TA - Qual Health Res JT - Qualitative health research JID - 9202144 MH - Humans MH - *Acute Kidney Injury/prevention & control/epidemiology MH - Qualitative Research MH - Leadership MH - Health Facilities MH - Patient Safety PMC - PMC12396117 MID - NIHMS2096662 OTO - NOTNLM OT - clinical trials OT - hospitals OT - illness and disease OT - patient safety OT - prevention COIS- Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2023/11/08 18:42 MHDA- 2024/03/01 06:44 PMCR- 2025/08/29 CRDT- 2023/11/08 15:13 PHST- 2024/03/01 06:44 [medline] PHST- 2023/11/08 18:42 [pubmed] PHST- 2023/11/08 15:13 [entrez] PHST- 2025/08/29 00:00 [pmc-release] AID - 10.1177/10497323231209651 [doi] PST - ppublish SO - Qual Health Res. 2024 Mar;34(4):287-297. doi: 10.1177/10497323231209651. Epub 2023 Nov 8. PMID- 37936666 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231109 IS - 2666-5018 (Electronic) IS - 2666-5018 (Linking) VI - 4 IP - 10 DP - 2023 Oct TI - Retrieval of fragmented coronary sinus catheter in the right atrium: A first novel multidisciplinary approach in sub-Saharan Africa. PG - 660-661 LID - 10.1016/j.hroo.2023.08.008 [doi] FAU - Gandye, Yona AU - Gandye Y AD - Department of Electrophysiology and Pacing, Jakaya Kikwete Cardiac Institute, Dar es Salaam, Tanzania. FAU - Mutagaywa, Reuben AU - Mutagaywa R AD - Department of Electrophysiology and Pacing, Jakaya Kikwete Cardiac Institute, Dar es Salaam, Tanzania. FAU - Sackett, Mathew AU - Sackett M AD - Electrophysiology and Pacing, Centra Heart and Vascular Institute, Lynchburg, Virginia. FAU - Minja, Dickson AU - Minja D AD - Department of Electrophysiology and Pacing, Jakaya Kikwete Cardiac Institute, Dar es Salaam, Tanzania. FAU - Kajuna, Edna AU - Kajuna E AD - Department of Electrophysiology and Pacing, Jakaya Kikwete Cardiac Institute, Dar es Salaam, Tanzania. FAU - Kisenge, Richard AU - Kisenge R AD - Department of Electrophysiology and Pacing, Jakaya Kikwete Cardiac Institute, Dar es Salaam, Tanzania. LA - eng PT - Journal Article DEP - 20230909 PL - United States TA - Heart Rhythm O2 JT - Heart rhythm O2 JID - 101768511 PMC - PMC10626180 OTO - NOTNLM OT - Coronary sinus OT - Electrophysiology OT - Fragmented catheter OT - Retrieval OT - Reuse EDAT- 2023/11/08 06:43 MHDA- 2023/11/08 06:44 PMCR- 2023/09/09 CRDT- 2023/11/08 03:51 PHST- 2023/11/08 06:44 [medline] PHST- 2023/11/08 06:43 [pubmed] PHST- 2023/11/08 03:51 [entrez] PHST- 2023/09/09 00:00 [pmc-release] AID - S2666-5018(23)00218-0 [pii] AID - 10.1016/j.hroo.2023.08.008 [doi] PST - epublish SO - Heart Rhythm O2. 2023 Sep 9;4(10):660-661. doi: 10.1016/j.hroo.2023.08.008. eCollection 2023 Oct. PMID- 37935644 OWN - NLM STAT- MEDLINE DCOM- 20231126 LR - 20261012 IS - 1545-5017 (Electronic) IS - 1545-5009 (Linking) VI - 71 IP - 1 DP - 2024 Jan TI - Balancing anticoagulation and hemostasis in an infant with severe hemophilia A during cardiac transplantation: Review of the literature and development of a surgical protocol. PG - e30759 LID - 10.1002/pbc.30759 [doi] AB - Hemophilia A is a disorder resulting in a deficiency of clotting factor VIII that can lead to life-threatening bleeding. Evidence-based guidelines for surgical interventions like cardiac surgery are limited. Anticoagulation is necessary for cardiac bypass, thus risk of bleeding in a patient with hemophilia is increased and requires careful attention to maintain hemostasis. We report the first infant with severe hemophilia A and dilated cardiomyopathy who underwent successful cardiac transplantation, and review the literature on previous cardiac transplant cases in congenital hemophilia. To ensure safe and effective management, a multidisciplinary approach was used to develop the surgical protocol for transplant. CI - (c) 2023 Wiley Periodicals LLC. FAU - Regling, Katherine AU - Regling K AUID- ORCID: 0000-0002-6212-8910 AD - Division of Hematology Oncology, Department of Pediatrics, Children's Hospital of Michigan, Central Michigan University College of Medicine, Detroit, Michigan, USA. FAU - Sehgal, Swati AU - Sehgal S AD - Division of Cardiology, Department of Pediatrics, Children's Hospital of Michigan, Central Michigan University College of Medicine, Detroit, Michigan, USA. FAU - Hollon, Wendy AU - Hollon W AD - Detroit Medical Center, Children's Hospital of Michigan, Detroit, Michigan, USA. FAU - Rayner, Patricia AU - Rayner P AUID- ORCID: 0000-0001-7423-8052 AD - Detroit Medical Center, Children's Hospital of Michigan, Detroit, Michigan, USA. FAU - Stricker, Lori AU - Stricker L AD - Department of Anesthesia, Children's Hospital of Michigan, Wayne State University School of Medicine, Detroit, Michigan, USA. FAU - Sarnaik, Ajit AU - Sarnaik A AD - Division of Pediatric Critical Care Medicine, Department of Pediatrics, Children's Hospital of Michigan, Central Michigan University College of Medicine, Detroit, Michigan, USA. FAU - Sassalos, Peter AU - Sassalos P AD - Department of Pediatric Cardiovascular Surgery, Children's Hospital of Michigan, Detroit, Michigan, USA. FAU - Al-Ahmadi, Mamdouh AU - Al-Ahmadi M AD - Department of Pediatric Cardiovascular Surgery, Children's Hospital of Michigan, Detroit, Michigan, USA. FAU - Rajpurkar, Madhvi AU - Rajpurkar M AD - Division of Hematology Oncology, Department of Pediatrics, Children's Hospital of Michigan, Central Michigan University College of Medicine, Detroit, Michigan, USA. FAU - Chitlur, Meera B AU - Chitlur MB AD - Division of Hematology Oncology, Department of Pediatrics, Children's Hospital of Michigan, Central Michigan University College of Medicine, Detroit, Michigan, USA. LA - eng GR - HTRS/Novo-Nordisk Clinical Fellowship/ GR - Hemophilia of Georgia Clinical Scientist Development/ GR - CHM Foundation/ GR - Genentech Inc/ GR - Agios Pharmaceuticals/ GR - Novartis Inc/ PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20231107 PL - United States TA - Pediatr Blood Cancer JT - Pediatric blood & cancer JID - 101186624 RN - 0 (Anticoagulants) RN - 9001-27-8 (Factor VIII) SB - IM MH - Humans MH - Infant MH - *Anticoagulants/therapeutic use MH - Factor VIII/therapeutic use MH - *Heart Transplantation MH - *Hemophilia A/complications/drug therapy MH - Hemorrhage MH - *Hemostasis OTO - NOTNLM OT - hemophilia A OT - hemostasis OT - pediatric OT - protocol OT - transplant EDAT- 2023/11/08 00:41 MHDA- 2023/11/24 06:42 CRDT- 2023/11/07 22:53 PHST- 2023/09/26 00:00 [revised] PHST- 2023/07/20 00:00 [received] PHST- 2023/10/17 00:00 [accepted] PHST- 2023/11/24 06:42 [medline] PHST- 2023/11/08 00:41 [pubmed] PHST- 2023/11/07 22:53 [entrez] AID - 10.1002/pbc.30759 [doi] PST - ppublish SO - Pediatr Blood Cancer. 2024 Jan;71(1):e30759. doi: 10.1002/pbc.30759. Epub 2023 Nov 7. PMID- 37934714 OWN - NLM STAT- MEDLINE DCOM- 20240603 LR - 20250530 IS - 1538-943X (Electronic) IS - 1058-2916 (Linking) VI - 70 IP - 6 DP - 2024 Jun 1 TI - Pumping for Two: Pregnancy in Patients Supported With a Left Ventricular Assist Device. PG - 461-468 LID - 10.1097/MAT.0000000000002082 [doi] AB - This review discusses the challenges and outcomes associated with pregnancy during left ventricular assist device (LVAD) support. Women account for a third of the heart failure population in the United States. Left ventricular assist devices have emerged as a safe and effective treatment option for patients with advanced heart failure. Pregnancy during LVAD support can occur, and it presents significant risks to both mother and fetus, including hemodynamic stress, thrombotic events, medication-associated teratogenicity, and uterine impingement. This literature review identified 10 cases of confirmed pregnancy during LVAD support, of which eight resulted in successful births. Maternal and fetal mortality occurred in one case, and there was a spontaneous abortion in one case. The review highlights the importance of a multidisciplinary approach, promotion of shared decision-making, thoughtful anticoagulation, adjustment of LVAD speed, and medication optimization to maintain hemodynamic support during pregnancy. Hemodynamic changes during pregnancy include increased cardiac output, heart rate, and plasma volume, as well as decreased systemic vascular resistance, which can impact LVAD support. Despite reduced pulsatility in LVAD-supported patients, ovulation and reproductive capacity might be preserved, and viable pregnancies may be achieved with appropriate management. The review provides insights into the risks and considerations for a viable pregnancy during LVAD support, including the need for ongoing research to inform joined decision-making. CI - Copyright (c) ASAIO 2023. FAU - Oren, Daniel AU - Oren D AD - From the Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, NY. FAU - Moeller, Cathrine M AU - Moeller CM AUID- ORCID: 0009-0000-6175-2212 AD - From the Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, NY. FAU - Haythe, Jennifer H AU - Haythe JH AD - From the Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, NY. FAU - Rubinstein, Gal AU - Rubinstein G AUID- ORCID: 0000-0003-1735-983 AD - From the Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, NY. FAU - Fernandez Valledor, Andrea AU - Fernandez Valledor A AD - From the Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, NY. FAU - Lotan, Dor AU - Lotan D AD - From the Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, NY. FAU - Rosenblum, Hannah AU - Rosenblum H AD - From the Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, NY. FAU - Colombo, Paolo C AU - Colombo PC AD - From the Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, NY. FAU - Yuzefpolskaya, Melana AU - Yuzefpolskaya M AUID- ORCID: 0000-0003-4729-8943 AD - From the Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, NY. FAU - Topkara, Veli K AU - Topkara VK AD - From the Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, NY. FAU - Clerkin, Kevin J AU - Clerkin KJ AD - From the Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, NY. FAU - Raikhelkar, Jayant K AU - Raikhelkar JK AD - From the Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, NY. FAU - Fried, Justin A AU - Fried JA AD - From the Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, NY. FAU - Naka, Yoshifumi AU - Naka Y AD - Department of Cardiothoracic Surgery, Columbia University Irving Medical Center, New York, NY. FAU - Takeda, Koji AU - Takeda K AD - Department of Cardiothoracic Surgery, Columbia University Irving Medical Center, New York, NY. FAU - Latif, Farhana AU - Latif F AD - From the Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, NY. FAU - Sayer, Gabriel AU - Sayer G AD - From the Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, NY. FAU - Uriel, Nir AU - Uriel N AD - From the Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, NY. LA - eng PT - Journal Article PT - Review DEP - 20231107 PL - United States TA - ASAIO J JT - ASAIO journal (American Society for Artificial Internal Organs : 1992) JID - 9204109 SB - IM MH - Humans MH - *Heart-Assist Devices/adverse effects MH - Pregnancy MH - Female MH - *Heart Failure/therapy/surgery MH - *Pregnancy Complications, Cardiovascular/therapy MH - Hemodynamics/physiology MH - Adult MH - Pregnancy Outcome COIS- Disclosure: N.U. is on the medical advisory board for Abbott, Abumed, and Leviticus. G.S. has been a consultant for Abbott, K.J.C. receives NIH grant support K23 HL148528, and V.K.T. receives NIH grant support (HL146964). The other authors have no conflicts of interest to report. EDAT- 2023/11/07 18:42 MHDA- 2024/06/03 12:44 CRDT- 2023/11/07 13:13 PHST- 2024/06/03 12:44 [medline] PHST- 2023/11/07 18:42 [pubmed] PHST- 2023/11/07 13:13 [entrez] AID - 00002480-202406000-00001 [pii] AID - 10.1097/MAT.0000000000002082 [doi] PST - ppublish SO - ASAIO J. 2024 Jun 1;70(6):461-468. doi: 10.1097/MAT.0000000000002082. Epub 2023 Nov 7. PMID- 29489221 STAT- Publisher CTDT- 20231107 PB - StatPearls Publishing DP - 2023 Jan TI - Citalopram. BTI - StatPearls AB - Citalopram hydrobromide is a selective serotonin reuptake inhibitor. The primary FDA-approved clinical use for citalopram hydrobromide is for treating depression in adults. Off-label uses include alcohol use disorder, coronary arteriosclerosis, obsessive-compulsive disorder, panic disorder, postmenopausal flushing, and premenstrual dysphoric disorder. Citalopram is listed in the WHO model list of essential medicines to treat depressive disorders. Citalopram hydrobromide exerts its antidepressant action by potentiating serotonergic activity in the central nervous system. Multiple studies confirmed that citalopram hydrobromide is a selective serotonin reuptake inhibitor (SSRI) that has minimal effects on norepinephrine and dopamine neuronal reuptake. This activity reviews the indications, mechanism of action, administration, contraindications, monitoring, toxicity associated with citalopram, and the interprofessional team's role in caring for patients with conditions treated with citalopram. CI - Copyright (c) 2023, StatPearls Publishing LLC. FAU - Sharbaf Shoar, Nazila AU - Sharbaf Shoar N AD - Ross University School of Medicine FAU - Fariba, Kamron A AU - Fariba KA AD - University Hospital FAU - Padhy, Ranjit K AU - Padhy RK AD - UCLA - Kern Medical LA - eng PT - Study Guide PT - Book Chapter PL - Treasure Island (FL) COIS- Disclosure: Nazila Sharbaf Shoar declares no relevant financial relationships with ineligible companies. Disclosure: Kamron A Fariba declares no relevant financial relationships with ineligible companies. Disclosure: Ranjit K Padhy declares no relevant financial relationships with ineligible companies. EDAT- 2023/11/07 00:00 CRDT- 2023/11/07 00:00 AID - NBK482222 [bookaccession] PMID- 37927222 OWN - NLM STAT- MEDLINE DCOM- 20231117 LR - 20260127 IS - 2154-8331 (Print) IS - 2154-8331 (Linking) VI - 51 IP - 4 DP - 2023 Oct TI - The effects of a multidisciplinary pathway for perioperative management of patients with hip fracture. PG - 233-239 LID - 10.1080/21548331.2023.2274307 [doi] AB - OBJECTIVES: To determine if a multidisciplinary pathway focused on non-opioid pain management, delirium assessment, and resource utilization improved outcomes in geriatric hip fracture patients. The goal was to reduce opioid usage, consultation not congruent with guidelines, and increase use of regional anesthesia to reduce delirium and improve outcomes. METHODS: An observational study was performed on hip fracture patients before and after the intervention. Hospitalists were educated on indications for preoperative cardiac consultation and specialized preoperative cardiac testing according to evidence-based guidelines with the inpatient cardiology service. Additional education on multimodal analgesia, limiting opioids, and peripheral nerve blocks was provided by the acute pain service. Pre-intervention outcomes from 1 July 20171 July 2017 to 31 May 201831 May 2018 (N = 92) were compared to post-intervention outcomes from 1 July 20181 July 2018 to 31 May 201931 May 2019 (N = 98) and included delirium, length of stay, 30-day readmission rate, time from arrival to procedure start time, time to first physical therapy session, and completion of cardiology consult time. We examined adherence, use of nerve blocks, and pre- and post-operative pain scores and opioid use. RESULTS: Delirium was reduced from 50.0% (N = 46/92) to 28.6% (N = 28/98); p = 0.002. Postoperative opioid use (IV morphine milligram equivalents) decreased from an average of 57.2 mg (+/-67.7) to 42.6 mg (+/-58.2),P < .0001. There was a significant decrease in mean pre-operative (5.4 +/- 4.14 to 5.05 +/- 2.8, P < .0001) and post-operative pain scores (4.3 +/- 5.2 to 3.2 +/- 2.2, P < .0001). There was a significant reduction in time to cardiology consultation from 18 h] to 12 h ; p < .001). CONCLUSIONS: A multidisciplinary collaboration between hospitalists, anesthesiologists, and cardiologists for hip fracture patients was associated with a reduction in pain and delirium and time to cardiologist evaluation. Prospective studies focusing on additional patient-centered outcomes are warranted. FAU - Ackermann, Lily L AU - Ackermann LL AUID- ORCID: 0000-0002-8495-2900 AD - Department of Medicine, Division of Hospital Medicine, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA. FAU - Schwenk, Eric S AU - Schwenk ES AD - Department of Anesthesiology and Perioperative Medicine, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA. FAU - Li, Chris J AU - Li CJ AD - Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA. FAU - Vaile, John R AU - Vaile JR AD - Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA. FAU - Weitz, Howard AU - Weitz H AD - Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA. LA - eng PT - Journal Article PT - Observational Study DEP - 20231116 PL - England TA - Hosp Pract (1995) JT - Hospital practice (1995) JID - 101268948 RN - 0 (Analgesics, Opioid) SB - IM MH - Humans MH - Aged MH - Analgesics, Opioid/therapeutic use MH - Prospective Studies MH - *Hip Fractures/surgery MH - Postoperative Pain/drug therapy/chemically induced/complications MH - *Delirium OTO - NOTNLM OT - Hip fracture pathway OT - delirium OT - multidisciplinary care OT - pain management OT - perioperative hip fracture EDAT- 2023/11/06 06:42 MHDA- 2023/11/17 15:23 CRDT- 2023/11/06 04:12 PHST- 2023/11/17 15:23 [medline] PHST- 2023/11/06 06:42 [pubmed] PHST- 2023/11/06 04:12 [entrez] AID - 10.1080/21548331.2023.2274307 [doi] PST - ppublish SO - Hosp Pract (1995). 2023 Oct;51(4):233-239. doi: 10.1080/21548331.2023.2274307. Epub 2023 Nov 16. PMID- 37926340 OWN - NLM STAT- MEDLINE DCOM- 20240101 LR - 20260120 IS - 1885-5857 (Electronic) IS - 1885-5857 (Linking) VI - 77 IP - 1 DP - 2024 Jan TI - Review of the allocation criteria for heart transplant in Spain in 2023. SEC-Heart Failure Association/ONT/SECCE consensus document. PG - 69-78 LID - S1885-5857(23)00284-0 [pii] LID - 10.1016/j.rec.2023.11.001 [doi] AB - Heart transplant (HT) remains the best therapeutic option for patients with advanced heart failure (HF). The allocation criteria aim to guarantee equitable access to HT and prioritize patients with a worse clinical status. To review the HT allocation criteria, the Heart Failure Association of the Spanish Society of Cardiology (HFA-SEC), the Spanish Society of Cardiovascular and Endovascular Surgery (SECCE) and the National Transplant Organization (ONT), organized a consensus conference involving adult and pediatric cardiologists, adult and pediatric cardiac surgeons, transplant coordinators from all over Spain, and physicians and nurses from the ONT. The aims of the consensus conference were as follows: a) to analyze the organization and management of patients with advanced HF and cardiogenic shock in Spain; b) to critically review heart allocation and priority criteria in other transplant organizations; c) to analyze the outcomes of patients listed and transplanted before and after the modification of the heart allocation criteria in 2017; and d) to propose new heart allocation criteria in Spain after an analysis of the available evidence and multidisciplinary discussion. In this article, by the HFA-SEC, SECCE and the ONT we present the results of the analysis performed in the consensus conference and the rationale for the new heart allocation criteria in Spain. CI - Copyright (c) 2023 Sociedad Espanola de Cardiologia. Published by Elsevier Espana, S.L.U. All rights reserved. FAU - Gonzalez-Costello, Jose AU - Gonzalez-Costello J AD - Servicio de Cardiologia, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain; Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain; Departamento de Ciencias Clinicas, Facultad de Medicina, Universitat de Barcelona, Barcelona, Spain; Centro de Investigacion Biomedica en Red Enfermedades Cardiovaculares (CIBERCV), Spain. Electronic address: jgonzalez@bellvitgehospital.cat. FAU - Perez-Blanco, Alicia AU - Perez-Blanco A AD - Organizacion Nacional de Trasplantes, Madrid, Spain. FAU - Delgado-Jimenez, Juan AU - Delgado-Jimenez J AD - Centro de Investigacion Biomedica en Red Enfermedades Cardiovaculares (CIBERCV), Spain; Servicio de Cardiologia, Hospital 12 de Octubre, Madrid, Spain; Instituto de Investigacion Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain; Departamento de Medicina, Universidad Complutense de Madrid, Madrid, Spain. FAU - Gonzalez-Vilchez, Francisco AU - Gonzalez-Vilchez F AD - Servicio de Cardiologia, Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain. FAU - Mirabet, Sonia AU - Mirabet S AD - Centro de Investigacion Biomedica en Red Enfermedades Cardiovaculares (CIBERCV), Spain; Servicio de Cardiologia, Hospital Universitari de Sant Pau, Barcelona, Spain. FAU - Sandoval, Elena AU - Sandoval E AD - Servicio de Cirugia Cardiovascular, Hospital Clinic de Barcelona, Barcelona, Spain; Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. FAU - Cuenca-Castillo, Jose AU - Cuenca-Castillo J AD - Servicio de Cirugia Cardiaca, Complejo Hospitalario Universitario de A Coruna, A Coruna, Spain. FAU - Camino, Manuela AU - Camino M AD - Unidad de Trasplante Cardiaco Pediatrico, Hospital Materno Infantil Gregorio Maranon, Madrid, Spain. FAU - Segovia-Cubero, Javier AU - Segovia-Cubero J AD - Centro de Investigacion Biomedica en Red Enfermedades Cardiovaculares (CIBERCV), Spain; Servicio de Cardiologia, Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Madrid, Spain; Instituto de Investigacion Sanitaria Puerta de Hierro-Segovia Arana (IDIPHISA), Madrid, Spain. FAU - Sanchez-Salado, Jose Carlos AU - Sanchez-Salado JC AD - Servicio de Cardiologia, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain; Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain. FAU - Perez de la Sota, Enrique AU - Perez de la Sota E AD - Servicio de Cirugia Cardiaca, Hospital Universitario 12 de Octubre, Madrid, Spain. FAU - Almenar-Bonet, Luis AU - Almenar-Bonet L AD - Centro de Investigacion Biomedica en Red Enfermedades Cardiovaculares (CIBERCV), Spain; Servicio de Cardiologia, Hospital Universitario y Politecnico La Fe, Valencia, Spain. FAU - Farrero, Marta AU - Farrero M AD - Departamento de Ciencias Clinicas, Facultad de Medicina, Universitat de Barcelona, Barcelona, Spain; Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Servicio de Cardiologia, Hospital Clinic, Barcelona, Spain. FAU - Zatarain, Eduardo AU - Zatarain E AD - Centro de Investigacion Biomedica en Red Enfermedades Cardiovaculares (CIBERCV), Spain; Servicio de Cardiologia, Hospital Universitario Gregorio Maranon, Madrid, Spain; Instituto de Investigacion Sanitaria Gregorio Maranon, Madrid, Spain. FAU - Garcia-Cosio, Maria Dolores AU - Garcia-Cosio MD AD - Centro de Investigacion Biomedica en Red Enfermedades Cardiovaculares (CIBERCV), Spain; Servicio de Cardiologia, Hospital 12 de Octubre, Madrid, Spain; Instituto de Investigacion Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain. FAU - Garrido, Iris AU - Garrido I AD - Servicio de Cardiologia, Hospital Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain. FAU - Barge-Caballero, Eduardo AU - Barge-Caballero E AD - Servicio de Cardiologia, Complejo Hospitalario Universitario de A Coruna, A Coruna, Spain; Instituto de Investigacion Biomedica de A Coruna, A Coruna, Spain; Universidade da Coruna, A Coruna, Spain. FAU - Gomez-Bueno, Manuel AU - Gomez-Bueno M AD - Centro de Investigacion Biomedica en Red Enfermedades Cardiovaculares (CIBERCV), Spain; Servicio de Cardiologia, Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Madrid, Spain; Instituto de Investigacion Sanitaria Puerta de Hierro-Segovia Arana (IDIPHISA), Madrid, Spain. FAU - de Juan Baguda, Javier AU - de Juan Baguda J AD - Centro de Investigacion Biomedica en Red Enfermedades Cardiovaculares (CIBERCV), Spain; Servicio de Cardiologia, Hospital 12 de Octubre, Madrid, Spain; Instituto de Investigacion Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain. FAU - Manito-Lorite, Nicolas AU - Manito-Lorite N AD - Servicio de Cardiologia, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain; Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain. FAU - Lopez-Granados, Amador AU - Lopez-Granados A AD - Servicio de Cardiologia, Hospital Universitario Reina Sofia, Cordoba, Spain. FAU - Garcia-Guereta, Luis AU - Garcia-Guereta L AD - Servicio de Cardiologia Pediatrica, Hospital Universitario La Paz, Madrid, Spain. FAU - Blasco-Peiro, Teresa AU - Blasco-Peiro T AD - Servicio de Cardiologia, Hospital Universitario Miguel Servet, Zaragoza, Spain. FAU - Sarralde-Aguayo, Jose Aurelio AU - Sarralde-Aguayo JA AD - Servicio de Cirugia Cardiovascular, Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain. FAU - Sobrino-Marquez, Manuel AU - Sobrino-Marquez M AD - Servicio de Cardiologia, Hospital Universitario Virgen del Rocio, Seville, Spain. FAU - de la Fuente-Galan, Luis AU - de la Fuente-Galan L AD - Centro de Investigacion Biomedica en Red Enfermedades Cardiovaculares (CIBERCV), Spain; Servicio de Cardiologia, Hospital Clinico Universitario de Valladolid, Valladolid, Spain. FAU - Crespo-Leiro, Maria Generosa AU - Crespo-Leiro MG AD - Servicio de Cardiologia, Complejo Hospitalario Universitario de A Coruna, A Coruna, Spain; Instituto de Investigacion Biomedica de A Coruna, A Coruna, Spain; Universidade da Coruna, A Coruna, Spain. FAU - Coll, Elisabeth AU - Coll E AD - Organizacion Nacional de Trasplantes, Madrid, Spain. FAU - Gran-Ipina, Ferran AU - Gran-Ipina F AD - Servicio de Cardiologia Pediatrica, Hospital Universitari Vall d'Hebron, Barcelona, Spain. FAU - Diaz-Molina, Beatriz AU - Diaz-Molina B AD - Servicio de Cardiologia, Hospital Universitario Central de Asturias, ISPA, Oviedo, Asturias, Spain. FAU - Donate, Lucia AU - Donate L AD - Servicio de Cirugia Cardiaca, Hospital Universitario de Gran Canaria Dr. Negrin, Las Palmas de Gran Canaria, Spain. FAU - Arribas-Leal, Jose Maria AU - Arribas-Leal JM AD - Servicio de Cirugia Cardiovascular, Hospital Clinico Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain. FAU - Sanchez-Vicario, Felix AU - Sanchez-Vicario F AD - Organizacion Nacional de Trasplantes, Madrid, Spain. FAU - Atienza, Felipe AU - Atienza F AD - Centro de Investigacion Biomedica en Red Enfermedades Cardiovaculares (CIBERCV), Spain; Servicio de Cardiologia, Hospital Universitario Gregorio Maranon, Madrid, Spain; Instituto de Investigacion Sanitaria Gregorio Maranon, Madrid, Spain. FAU - Rabago Juan-Aracil, Gregorio AU - Rabago Juan-Aracil G AD - Servicio de Cirugia Cardiaca, Clinica Universitaria de Navarra, Pamplona, Navarra, Spain. FAU - Garcia-Quintana, Antonio AU - Garcia-Quintana A AD - Servicio de Cardiologia, Hospital Universitario de Gran Canaria Dr. Negrin, Las Palmas de Gran Canaria, Spain. FAU - Martinez-Alpuente, Itziar AU - Martinez-Alpuente I AD - Organizacion Nacional de Trasplantes, Madrid, Spain. FAU - Riesgo-Gil, Fernando AU - Riesgo-Gil F AD - Cardiology Transplant Medicine, Royal Brompton & Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, Londres, United Kingdom. FAU - Hernandez-Montfort, Jaime AU - Hernandez-Montfort J AD - Advanced Heart Disease, Recovery and Replacement Programs, Baylor Scott and White Health, Central Texas and Greater Austin, United States. FAU - Oliver-Juan, Eva AU - Oliver-Juan E AD - Departamento de Ciencias Clinicas, Facultad de Medicina, Universitat de Barcelona, Barcelona, Spain; Servicio de Medicina Intensiva, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain. FAU - Sanchez-Rivas, Javier AU - Sanchez-Rivas J AD - Organizacion Nacional de Trasplantes, Madrid, Spain; Servicio de Medicina Intensiva, Hospital Universitario Virgen de las Nieves, Granada, Spain. FAU - Padilla-Martinez, Maria AU - Padilla-Martinez M AD - Organizacion Nacional de Trasplantes, Madrid, Spain. FAU - Perez-Villares, Jose Miguel AU - Perez-Villares JM AD - Servicio de Cardiologia, Hospital Clinico Universitario de Valladolid, Valladolid, Spain. FAU - Minambres, Eduardo AU - Minambres E AD - Servicio de Medicina Intensiva, Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain. FAU - Dominguez-Gil, Beatriz AU - Dominguez-Gil B AD - Organizacion Nacional de Trasplantes, Madrid, Spain. LA - eng LA - spa PT - Consensus Statement PT - Journal Article DEP - 20231104 PL - Spain TA - Rev Esp Cardiol (Engl Ed) JT - Revista espanola de cardiologia (English ed.) JID - 101587954 SB - IM MH - Adult MH - Humans MH - Child MH - Spain/epidemiology MH - *Heart Failure/surgery MH - *Heart Transplantation MH - Shock, Cardiogenic OTO - NOTNLM OT - Advanced heart failure OT - Asistencia circulatoria mecanica OT - Criterios de distribucion de organo solido OT - Heart transplant OT - Insuficiencia cardiaca avanzada OT - Mechanical circulatory support OT - National Transplant Organization OT - Organizacion Nacional de Trasplantes OT - Solid organ allocation OT - Trasplante cardiaco EDAT- 2023/11/06 00:41 MHDA- 2024/01/02 11:46 CRDT- 2023/11/05 19:16 PHST- 2023/05/08 00:00 [received] PHST- 2023/07/26 00:00 [accepted] PHST- 2024/01/02 11:46 [medline] PHST- 2023/11/06 00:41 [pubmed] PHST- 2023/11/05 19:16 [entrez] AID - S1885-5857(23)00284-0 [pii] AID - 10.1016/j.rec.2023.11.001 [doi] PST - ppublish SO - Rev Esp Cardiol (Engl Ed). 2024 Jan;77(1):69-78. doi: 10.1016/j.rec.2023.11.001. Epub 2023 Nov 4. PMID- 37920940 OWN - NLM STAT- MEDLINE DCOM- 20231204 LR - 20251219 IS - 1098-4275 (Electronic) IS - 0031-4005 (Linking) VI - 152 IP - 6 DP - 2023 Dec 1 TI - A Quality Improvement Initiative to Reduce Necrotizing Enterocolitis in Very Preterm Infants. LID - e2023061273 [pii] LID - 10.1542/peds.2023-061273 [doi] AB - OBJECTIVE: To reduce the incidence of necrotizing enterocolitis (NEC) among very preterm infants in the Calgary Health Region to /= stage 2). Changes in NEC rates were examined among racial and ethnic groups. Process measures included MOM feeding at discharge, the difference between actual and expected time to reach full feeds, lowest hemoglobin, and the duration of empirical antibiotics. Growth, the rate of blood transfusion, and the duration of parenteral nutrition were balancing measures. The preintervention, intervention, and sustainment periods were January 2013 to June 2016, July 2016 to December 2018, and December 2018 to December 2021, respectively. RESULTS: We included 2787 infants born at 30 mg/day or proteinuria > 150 mg/day), vascular damage (carotid intima-media thickness > 0.9 mm or presence of plaque), or cardiac damage (left ventricular mass index > 95 g/m2 in women and > 115 g/m2 in men). The severity of HMOD was considered as single-, two-, or triple-organ damage. RESULTS: TyG index values were higher in the hypertensive group than the normotensive group. An increased TyG index was independently associated with HMOD (OR: 1.33, p < 0.001). The TyG index exhibited gradually increasing threshold values for distinguishing patients with single-organ HMOD (> 8.8 with 77.8% sensitivity and 74.3% specificity), two-organ HMOD (> 9.1 with 77.6% sensitivity and 71.4% specificity), and triple-organ HMOD (> 9.4 with 71.5% sensitivity and 87.7% specificity). CONCLUSIONS: In newly diagnosed hypertensive patients, the TyG index exhibits significant diagnostic performance in predicting multiple-organ damage beyond the presence of HMOD. Since the detection of multiple-organ HMOD requires a multidisciplinary approach, the TyG index can serve as a simple and inexpensive screening tool. CI - Copyright: (c) 2023 Permanyer. FAU - Kivrak, Ahmet AU - Kivrak A AD - Department of Cardiology, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey. FAU - Yildirim, Alp AU - Yildirim A AD - Department of Cardiology, Kirsehir Training and Research Hospital, Kirsehir, Turkey. LA - eng PT - Journal Article PL - United States TA - Rev Invest Clin JT - Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion JID - 9421552 RN - IY9XDZ35W2 (Glucose) RN - 0 (Triglycerides) RN - 0 (Biomarkers) RN - 0 (Blood Glucose) SB - IM MH - Male MH - Humans MH - Female MH - Glucose MH - Carotid Intima-Media Thickness MH - Triglycerides MH - *Hypertension/complications MH - *Insulin Resistance MH - Biomarkers MH - Blood Glucose OTO - NOTNLM OT - Atherosclerosis OT - Hypertensive organ damage OT - Insulin resistance OT - Triglyceride-glucose index EDAT- 2023/11/03 00:42 MHDA- 2023/11/06 06:42 CRDT- 2023/11/02 18:43 PHST- 2023/11/06 06:42 [medline] PHST- 2023/11/03 00:42 [pubmed] PHST- 2023/11/02 18:43 [entrez] AID - j75/5/221 [pii] AID - 10.24875/RIC.23000113 [doi] PST - ppublish SO - Rev Invest Clin. 2023;75(5):221-232. doi: 10.24875/RIC.23000113. PMID- 37915742 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231103 IS - 2297-055X (Print) IS - 2297-055X (Electronic) IS - 2297-055X (Linking) VI - 10 DP - 2023 TI - Isolated annuloplasty in elderly patients with secondary mitral valve regurgitation: short- and long-term outcomes with a less invasive approach. PG - 1193156 LID - 10.3389/fcvm.2023.1193156 [doi] LID - 1193156 AB - BACKGROUND: Long-term outcomes of elderly and frail patients with secondary mitral valve regurgitation (MR) are inconclusive. Especially in patients with co-morbidities such as atherosclerosis who are suffering from heart failure, optimal medical therapy (OMT) is the preferred therapy relative to surgical or percutaneous interventions. It remains challenging to identify the most successful therapy to improve symptoms and increase life expectancy. To reduce surgical trauma for these patients, minimally invasive mitral valve surgery (MIMVS) was developed; this has shown promising medium-term results, but there is still a lack of evidence regarding long-term results. The aim of this investigation was to describe the long-term outcomes of less invasive mitral valve surgery (MVS) in elderly patients. METHODS: In this longitudinal retrospective analysis, 67 patients (aged >/=70 years) with secondary MR who underwent MV repair +/- tricuspid valve repair (TVR) were identified. MVS was performed via minithoracotomy (MT) in most cases (n = 54); in patients with contraindications for MIMVS, partial upper sternotomy (PS) was the preferred route for surgical access (n = 13). The appropriate access route was chosen according to the patient's clinical condition and comorbidities. We analyzed reoperation-free long-term survival, combined operative success (lack of residual MR, conversion to MV replacement, or larger thoracic incisions), and perioperative safety (at 30 days: mortality, re-thoracotomy, ECMO, pacemaker implantation, dialysis, longer ventilation, stroke, myocardial infarction). In a subgroup analysis, we compared long-term survival in MVS patients with and without TVR. RESULTS: The median age of patients (62.7% female) was 74 years (interquartile range: 72-76 years), with a median EuroSCORE2 of 2.8% (1.5%-4.6%) and N-terminal pro-brain natriuretic peptide plasma levels of 1,434 ng/L (1035-2149 ng/L). The median follow-up period was 5.6 years (2.7-8.5 years). The reoperation-free long-term survival rate up to 10 years was 66.2%. Combined operative success and perioperative safety were achieved in 94% and 76% of patients, respectively. Additional TVR was performed in 56.7% of patients, without any significant difference in survival rates compared to the group without TVR (p = 0.417; HR 1.473, 95% CI 0.578-3.757). CONCLUSION: Less invasive MV repair for secondary MR shows excellent operative success and safety in selected patients. Freedom from significant MR and from the need for reoperation indicates long-lasting efficacy. These results should be considered in heart team discussions regarding allocation of patients to surgical mitral procedures. CI - (c) 2023 Oezpeker, Hoefer, Barbieri, Gollmann-Tepekoeylue, Johannes, Clemens, Suat, Adel, Sasa, Mueller, Grimm and Bonaros. FAU - Oezpeker, Ulvi Cenk AU - Oezpeker UC AD - Department of Cardiac Surgery, Medical University of Innsbruck, Innsbruck, Austria. FAU - Hoefer, Daniel AU - Hoefer D AD - Department of Cardiac Surgery, Medical University of Innsbruck, Innsbruck, Austria. FAU - Barbieri, Fabian AU - Barbieri F AD - Department of Cardiology, Angiology and Intensive Care Medicine, Deutsches Herzzentrum der Charite, Berlin, Germany. AD - Department of Cardiology, Angiology and Intensive Care Medicine, Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt- Universitat zu Berlin, Berlin, Germany. FAU - Gollmann-Tepekoeylue, Can AU - Gollmann-Tepekoeylue C AD - Department of Cardiac Surgery, Medical University of Innsbruck, Innsbruck, Austria. FAU - Johannes, Holfeld AU - Johannes H AD - Department of Cardiac Surgery, Medical University of Innsbruck, Innsbruck, Austria. FAU - Clemens, Engler AU - Clemens E AD - Department of Cardiac Surgery, Medical University of Innsbruck, Innsbruck, Austria. FAU - Suat, Ersahin AU - Suat E AD - Department of Cardiovascular Surgery, Sakarya University, Adapazari, Turkiye. FAU - Adel, Sakic AU - Adel S AD - Department of Cardiac Surgery, Medical University of Innsbruck, Innsbruck, Austria. FAU - Sasa, Rajsic AU - Sasa R AD - Department of Anesthesiology and Intensive Care Medicine, Medical University of Innsbruck, Innsbruck, Austria. FAU - Mueller, Ludwig AU - Mueller L AD - Department of Cardiac Surgery, Medical University of Innsbruck, Innsbruck, Austria. FAU - Grimm, Michael AU - Grimm M AD - Department of Cardiac Surgery, Medical University of Innsbruck, Innsbruck, Austria. FAU - Bonaros, Nikolaos AU - Bonaros N AD - Department of Cardiac Surgery, Medical University of Innsbruck, Innsbruck, Austria. LA - eng PT - Journal Article DEP - 20231016 PL - Switzerland TA - Front Cardiovasc Med JT - Frontiers in cardiovascular medicine JID - 101653388 PMC - PMC10617676 OTO - NOTNLM OT - annuloplasty OT - elderly OT - heart failure OT - less and minimally invasive mitral valve surgery OT - secondary mitral valve regurgitation COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor TF declared a past co-authorship with the author NB. EDAT- 2023/11/02 06:42 MHDA- 2023/11/02 06:43 PMCR- 2023/01/01 CRDT- 2023/11/02 04:05 PHST- 2023/03/24 00:00 [received] PHST- 2023/09/06 00:00 [accepted] PHST- 2023/11/02 06:43 [medline] PHST- 2023/11/02 06:42 [pubmed] PHST- 2023/11/02 04:05 [entrez] PHST- 2023/01/01 00:00 [pmc-release] AID - 10.3389/fcvm.2023.1193156 [doi] PST - epublish SO - Front Cardiovasc Med. 2023 Oct 16;10:1193156. doi: 10.3389/fcvm.2023.1193156. eCollection 2023. PMID- 37915658 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231103 IS - 2049-0801 (Print) IS - 2049-0801 (Electronic) IS - 2049-0801 (Linking) VI - 85 IP - 11 DP - 2023 Nov TI - Recurrent paradoxical cerebral embolism caused by a thrombus entrapped in a patent foramen ovale: a case report. PG - 5765-5769 LID - 10.1097/MS9.0000000000001343 [doi] AB - INTRODUCTION: A thrombus straddling the patent foramen ovale (PFO) is a very rare clinical entity. Optimal management remains unclear due to the availability of various therapeutic options; thus, an individualized approach is recommended. CASE PRESENTATION: The authors describe a case presenting with recurrent cerebral embolism and a large and mobile thrombus straddled in the PFO. Historically, cardiac surgery, thrombolysis or anticoagulation were possible management options for this patient. However, there are no guidelines on what the optimal treatment is. Our patient was a poor surgical candidate because of advanced age and multiple comorbidities. Furthermore, she had a recent ischaemic stroke which was a relative contraindication to thrombolysis. After consulting the Heart Team, medical treatment alone with systemic anticoagulation was administered. Subsequent transthoracic echocardiography (TTE) after 1 week showed complete thrombus resolution. After 4 months, the PFO was successfully occluded with an Amplatzer device. The patient received rehabilitation therapy and had good functional recovery. CLINICAL DISCUSSION: Anticoagulant therapy alone was chosen because of high risk for surgery. Complete thrombus resolution was achieved after 1 week although the initial thrombus size was quite large. Nevertheless, this approach may not be applicable to every patient. In addition to TTE, multimodality imaging using transesophageal echocardiography and cardiac magnetic resonance is helpful to identify the mechanism of stroke, which in our case is a thrombus-straddled PFO, and to make early treatment decisions. Serial TTEs help assess the response to anticoagulation. An individualized approach should be made with a multidisciplinary Heart Team. CONCLUSION: Echocardiography plays an important role in the diagnosis and treatment evaluation for patients with a thrombus straddling a PFO. An individualized approach to manage the patient should be made with a multidisciplinary Heart Team. CI - Copyright (c) 2023 The Author(s). Published by Wolters Kluwer Health, Inc. FAU - Do, Anh Phuong AU - Do AP AD - Vietnam Heart Institute, Bach Mai Hospital. FAU - Nguyen, Hung Minh AU - Nguyen HM AD - Vietnam Heart Institute, Bach Mai Hospital. FAU - Thi Thu Nguyen, Hoai AU - Thi Thu Nguyen H AD - Vietnam Heart Institute, Bach Mai Hospital. AD - Department of Internal Medicine, VNU-University of Medicine and Pharmacy. FAU - Ta, Cuong Manh AU - Ta CM AD - Vietnam Heart Institute, Bach Mai Hospital. FAU - Bui, Son Tran Thanh AU - Bui STT AD - Vietnam Heart Institute, Bach Mai Hospital. FAU - Pham, Hung Manh AU - Pham HM AD - Vietnam Heart Institute, Bach Mai Hospital. AD - Department of Internal Medicine, Hanoi Medical University, Hanoi, Vietnam. LA - eng PT - Journal Article DEP - 20230920 PL - England TA - Ann Med Surg (Lond) JT - Annals of medicine and surgery (2012) JID - 101616869 PMC - PMC10617831 OTO - NOTNLM OT - paradoxical embolism OT - patent foramen ovale OT - recurrent cerebral embolism OT - straddling thrombus COIS- The authors declare no conflicts of interest. EDAT- 2023/11/02 06:43 MHDA- 2023/11/02 06:44 PMCR- 2023/09/20 CRDT- 2023/11/02 04:03 PHST- 2023/07/17 00:00 [received] PHST- 2023/09/12 00:00 [accepted] PHST- 2023/11/02 06:44 [medline] PHST- 2023/11/02 06:43 [pubmed] PHST- 2023/11/02 04:03 [entrez] PHST- 2023/09/20 00:00 [pmc-release] AID - AMSU-D-23-01520 [pii] AID - 10.1097/MS9.0000000000001343 [doi] PST - epublish SO - Ann Med Surg (Lond). 2023 Sep 20;85(11):5765-5769. doi: 10.1097/MS9.0000000000001343. eCollection 2023 Nov. PMID- 37915203 OWN - NLM STAT- MEDLINE DCOM- 20231216 LR - 20231216 IS - 1744-8344 (Electronic) IS - 1477-9072 (Linking) VI - 21 IP - 11 DP - 2023 Jul-Dec TI - Contemporary management of infective endocarditis in pregnancy. PG - 839-854 LID - 10.1080/14779072.2023.2276891 [doi] AB - INTRODUCTION: Infective endocarditis (IE) during pregnancy is a rare condition that is associated with a high level of morbidity and mortality. The epidemiology, diagnosis, treatment, and prognosis have changed significantly in the last two decades. The declining incidence of rheumatic heart disease, improved life expectancy with congenital heart disease, advances in cardiac surgery and cardiac devices, rise in resistant microorganisms, complications of the opioid epidemic, and increasing maternal age are some of the many factors contributing to these changes. AREAS COVERED: This article explores existing literature on the topic including case reports, case series, registry data, and clinical guidelines. The focus of this article is the evolving epidemiology, predisposing factors and preventative measures, clinical presentation, investigation, management, and potential complications of IE in pregnancy. EXPERT OPINION: Robust prospective data on the management of IE in pregnancy is lacking, and obtaining these data will be very challenging. It is imperative that international registries are used to provide data on best clinical practices and inform future clinical guidelines. Multimodal imaging should be incorporated in the investigation of complicated cases. A multidisciplinary approach to the management of this rare and life-threatening condition is essential to ensure the best outcomes for both the mother and the fetus. FAU - Pollock, Ailis AU - Pollock A AD - Department of Cardiology, University Hospital Limerick, Dooradoyle, Limerick, Ireland. FAU - Kiernan, Thomas J AU - Kiernan TJ AD - Department of Cardiology, University Hospital Limerick, Dooradoyle, Limerick, Ireland. LA - eng PT - Journal Article PT - Review DEP - 20231210 PL - England TA - Expert Rev Cardiovasc Ther JT - Expert review of cardiovascular therapy JID - 101182328 SB - IM MH - Pregnancy MH - Female MH - Humans MH - Prospective Studies MH - *Endocarditis, Bacterial/complications/diagnosis/drug therapy MH - *Endocarditis/diagnosis/epidemiology/therapy MH - Prognosis MH - *Heart Defects, Congenital/complications OTO - NOTNLM OT - Congenital heart disease OT - infective endocarditis OT - pregnancy OT - review OT - valve EDAT- 2023/11/02 06:43 MHDA- 2023/12/17 13:19 CRDT- 2023/11/02 03:38 PHST- 2023/12/17 13:19 [medline] PHST- 2023/11/02 06:43 [pubmed] PHST- 2023/11/02 03:38 [entrez] AID - 10.1080/14779072.2023.2276891 [doi] PST - ppublish SO - Expert Rev Cardiovasc Ther. 2023 Jul-Dec;21(11):839-854. doi: 10.1080/14779072.2023.2276891. Epub 2023 Dec 10. PMID- 37908951 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231102 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 15 IP - 9 DP - 2023 Sep TI - Revolutionizing Heart Transplantation: A Multidisciplinary Approach to Xenotransplantation, Immunosuppression, Regenerative Medicine, Artificial Intelligence, and Economic Sustainability. PG - e46176 LID - 10.7759/cureus.46176 [doi] LID - e46176 AB - Heart transplantation (HTx) stands as a life-saving intervention for patients with end-stage heart disease, but the field is fraught with numerous challenges that span from the scarcity of donor organs to long-term complications arising from immunosuppressive therapies. This comprehensive review article offers an in-depth exploration of the multifaceted aspects of HTx. The review covers groundbreaking advancements in xenotransplantation, enabled by cutting-edge genetic engineering techniques, and the promising role of stem cell therapies, particularly porcine mesenchymal stem cells, in cardiac regeneration. It also delves into the evolution and limitations of immunosuppressive therapies and the revolutionary potential of artificial intelligence (AI) and machine learning (ML) in enhancing donor-recipient matching and predicting patient outcomes. Economic considerations, especially in the context of rising healthcare costs, are examined to assess the sustainability of these advancements. The article further discusses the significant improvements in patient outcomes over the years, while highlighting persisting challenges, such as graft failure, rejection, and infection. It underscores the importance of experience and specialized training, evidenced by the presence of an institutional learning curve. The review concludes by advocating for a multifaceted, collaborative approach involving clinicians, researchers, and policymakers to overcome existing challenges. Through coordinated efforts that consider medical, ethical, and economic factors, the field of HTx is poised for further evolution, offering renewed hope for improved patient care and outcomes. CI - Copyright (c) 2023, Tanveer et al. FAU - Tanveer, Yousaf AU - Tanveer Y AD - Urology, Craigavon Area Hospital, Craigavon, GBR. FAU - Arif, Aleena AU - Arif A AD - Internal Medicine, Allama Iqbal Medical College, Lahore, PAK. FAU - Tsenteradze, Tamar AU - Tsenteradze T AD - General Surgery, Cardiology, and Internal Medicine, Tbilisi State Medical University, Tbilisi, GEO. FAU - Anika, Nabila N AU - Anika NN AD - Surgery, Baylor College of Medicine, Houston, USA. AD - Internal Medicine, Holy Family Red Crescent Medical College and Hospital, Dhaka, BGD. FAU - Bakht, Danyal AU - Bakht D AD - Medicine and Surgery, Mayo Hospital, Lahore, PAK. FAU - Masood, Quratulain Fatima AU - Masood QF AD - Surgery, National University of Science and Technology, Rawalpindi, PAK. FAU - Affaf, Maryam AU - Affaf M AD - Internal Medicine, Women Medical and Dental College, Abbottabad, PAK. FAU - Batool, Wajiha AU - Batool W AD - Internal Medicine, Army Medical College, Rawalpindi, PAK. FAU - Yadav, Indresh AU - Yadav I AD - Internal Medicine, Samar Hospital and Research Center Pvt. Ltd., Janakpur, NPL. AD - Internal Medicine, Community Based Medical College Bangladesh, Mymensingh, BGD. FAU - Gasim, Rayan W AU - Gasim RW AD - Internal Medicine, University of Khartoum, Khartoum, SDN. FAU - Mohamed, Youssef AU - Mohamed Y AD - Intensive Care Unit, Ibrahim Malik Teaching Hospital, Khartoum, SDN. FAU - Abdelmonim Khogali Mohamed, Mohamed AU - Abdelmonim Khogali Mohamed M AD - Cardiac Critical Care, King Abdulaziz Medical City, Riyadh, SAU. FAU - Ekhator, Chukwuyem AU - Ekhator C AD - Neuro-Oncology, New York Institute of Technology, College of Osteopathic Medicine, New York, USA. FAU - Mohsin, Syed Naveed AU - Mohsin SN AD - Orthopedics, St. James's Hospital, Dublin, IRL. AD - General Surgery, Cavan General Hospital, Cavan, IRL. FAU - Khan, Rehman AU - Khan R AD - Internal Medicine, Mayo Hospital, Lahore, PAK. LA - eng PT - Journal Article PT - Review DEP - 20230929 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC10613786 OTO - NOTNLM OT - cardiac regeneration OT - heart transplantation OT - immunosuppressive therapies OT - machine learning OT - stem cell therapy COIS- The authors have declared that no competing interests exist. EDAT- 2023/11/01 06:43 MHDA- 2023/11/01 06:44 PMCR- 2023/09/29 CRDT- 2023/11/01 04:04 PHST- 2023/09/28 00:00 [accepted] PHST- 2023/11/01 06:44 [medline] PHST- 2023/11/01 06:43 [pubmed] PHST- 2023/11/01 04:04 [entrez] PHST- 2023/09/29 00:00 [pmc-release] AID - 10.7759/cureus.46176 [doi] PST - epublish SO - Cureus. 2023 Sep 29;15(9):e46176. doi: 10.7759/cureus.46176. eCollection 2023 Sep. PMID- 37904503 OWN - NLM STAT- MEDLINE DCOM- 20231101 LR - 20231101 IS - 1476-4954 (Electronic) IS - 1476-4954 (Linking) VI - 36 IP - 2 DP - 2023 Dec TI - Novel approach to prenatal predictors of outcomes for fetuses with severe Ebstein anomaly. PG - 2271626 LID - 10.1080/14767058.2023.2271626 [doi] AB - OBJECTIVE: Ebstein anomaly (EA) is a cardiac malformation with highly variable presentation and severity with limited perinatal management options. We present incorporation of fetal lung measurements into a multidisciplinary evaluation for counseling and predicting postnatal outcomes in patients with severe EA. METHODS: Five fetuses with severe fetal EA were reviewed. Third trimester sonographic observed/expected total lung area (O/E TLA) and lung to head ratio (O/E LHR), fetal MRI total fetal lung volume ratio (O/E-TFLV), echocardiographic cardio-thoracic ratio (CT ratio), sonographic estimated fetal weight (EFW) by Hadlock formula and presence of hydrops, were used to guide perinatal management. RESULTS: Three of five had appropriate fetal growth, were delivered at term in a cardiac operative suite, and underwent immediate intervention with good neonatal outcomes. Two had severe fetal growth restriction (FGR), CT ratios > 0.8 and O/E LHR and TLA < 25%. One of which delivered prematurely with neonatal demise and one suffered in utero demise at 34 weeks. CONCLUSIONS: FGR, hydrops, increased CT ratio and reduced O/E LHR and TFLV are potential prognosticators of poor outcomes in severe EA, and should be validated in larger cohorts that would allow for a statistical analysis of the predictive utility of these measurements. FAU - Narang, Kavita AU - Narang K AUID- ORCID: 0000-0002-0270-3610 AD - Maternal-Fetal Medicine Division, Department of Obstetrics and Gynecology, Mayo Clinic College of Medicine, Rochester, MN, USA. FAU - Wyatt, Michelle AU - Wyatt M AUID- ORCID: 0000-0002-5181-4683 AD - Maternal-Fetal Medicine Division, Department of Obstetrics and Gynecology, Mayo Clinic College of Medicine, Rochester, MN, USA. FAU - O'Leary, Patrick AU - O'Leary P AUID- ORCID: 0000-0002-4922-2718 AD - Division of Pediatric Cardiology, Department of Pediatrics and Adolescent Medicine, Mayo Clinic College of Medicine, Rochester, MN, USA. FAU - Qureshi, M Yasir AU - Qureshi MY AUID- ORCID: 0000-0002-9898-2318 AD - Division of Pediatric Cardiology, Department of Pediatrics and Adolescent Medicine, Mayo Clinic College of Medicine, Rochester, MN, USA. FAU - Kolbe, Amy AU - Kolbe A AUID- ORCID: 0000-0002-3324-9043 AD - Pediatric Radiology Division, Department of Radiology, Mayo Clinic College of Medicine, Rochester, MN, USA. FAU - Stephens, Elizabeth H AU - Stephens EH AUID- ORCID: 0000-0001-8709-6794 AD - Department of Cardiovascular Surgery, Mayo Clinic College of Medicine, Rochester, MN, USA. FAU - Dearani, Joseph A AU - Dearani JA AUID- ORCID: 0000-0002-2664-1290 AD - Department of Cardiovascular Surgery, Mayo Clinic College of Medicine, Rochester, MN, USA. FAU - Ruano, Rodrigo AU - Ruano R AUID- ORCID: 0000-0002-3642-5858 AD - Division Chief of Maternal-Fetal Medicine, Director UHealth Jackson Fetal Care, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Miami Miller School of Medicine, Miami, FL, USA. LA - eng PT - Journal Article DEP - 20231030 PL - England TA - J Matern Fetal Neonatal Med JT - The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians JID - 101136916 SB - IM MH - Pregnancy MH - Infant, Newborn MH - Female MH - Humans MH - *Hernias, Diaphragmatic, Congenital MH - *Ebstein Anomaly/diagnostic imaging MH - Lung MH - Fetus MH - Edema MH - Ultrasonography, Prenatal MH - Retrospective Studies MH - Gestational Age OAB - Pulmonary hypoplasia is associated with severe morbidityThere are limited prognosticating tools to risk stratify and guide management in cases of severe prenatal Ebstein anomaliesFetal MRI may improve prognostication for fetuses with EA. OABL- eng OTO - NOTNLM OT - Ebstein anomaly OT - cardiothoracic ratio OT - fetal echocardiography OT - fetal lungs OT - fetal magnetic resonance imaging EDAT- 2023/10/31 06:42 MHDA- 2023/11/01 12:43 CRDT- 2023/10/31 03:40 PHST- 2023/11/01 12:43 [medline] PHST- 2023/10/31 06:42 [pubmed] PHST- 2023/10/31 03:40 [entrez] AID - 10.1080/14767058.2023.2271626 [doi] PST - ppublish SO - J Matern Fetal Neonatal Med. 2023 Dec;36(2):2271626. doi: 10.1080/14767058.2023.2271626. Epub 2023 Oct 30. PMID- 37902122 OWN - NLM STAT- MEDLINE DCOM- 20231222 LR - 20240603 IS - 1752-2978 (Electronic) IS - 1752-296X (Linking) VI - 31 IP - 1 DP - 2024 Feb 1 TI - Adherence to pharmacotherapy: sine qua non for reducing cumulative risk of premature coronary disease in familial hypercholesterolemia. PG - 22-30 LID - 10.1097/MED.0000000000000842 [doi] AB - PURPOSE OF REVIEW: Familial hypercholesterolemia (FH) is a dominant and highly penetrant monogenic disorder present from birth that markedly elevates plasma low-density lipoprotein (LDL)-cholesterol concentration and, if untreated, leads to atherosclerotic cardiovascular disease (ASCVD). The risk of ASCVD can be substantially reduced with lipid-lowering treatment (LLT). However, adherence to LLT remains a major challenge in FH patients and an under-recognized issue. We review several barriers to treatment adherence and implementation strategies for improving adherence in patients with FH. RECENT FINDINGS: Barriers that negatively affect patient adherence to treatment include the misunderstanding of perceived and actual risk of FH and the benefits of LLT, inadequate knowledge, lack of standardization of treatment, insufficient monitoring of LDL-cholesterol level, and inequalities in healthcare resources. Education of patients, carers and healthcare providers, guideline-directed treatment goals, regular monitoring, medication regimen simplification and greater access to established and new drugs are crucial enablers for improving adherence to treatment. However, given FH is present from birth, strategies for life-long adherence from childhood or young adulthood is critically important and requires further study. To be effective, strategies should be multifaceted, targeted and patient-centred involving a multidisciplinary-team with support from family, communities and peer groups. SUMMARY: FH confers a significant risk for ASCVD from a young age. Achieving better medication adherence is foundational for improving clinical outcomes and reducing the burden of atherosclerosis over a lifetime. Identification of key barriers and enablers are critical for implementing better adherence to treatment across the life-course of patients with FH. CI - Copyright (c) 2023 Wolters Kluwer Health, Inc. All rights reserved. FAU - Pang, Jing AU - Pang J AD - Medical School, University of Western Australia. FAU - Sanfilippo, Frank M AU - Sanfilippo FM AD - Cardiovascular Epidemiology Research Centre, School of Population and Global Health, University of Western Australia. FAU - Chan, Dick C AU - Chan DC AD - Medical School, University of Western Australia. FAU - Watts, Gerald F AU - Watts GF AD - Medical School, University of Western Australia. AD - Lipid Disorders Clinic, Departments of Cardiology and Internal Medicine, Royal Perth Hospital, Perth, Western Australia, Australia. LA - eng PT - Journal Article PT - Review DEP - 20231030 PL - England TA - Curr Opin Endocrinol Diabetes Obes JT - Current opinion in endocrinology, diabetes, and obesity JID - 101308636 RN - 0 (Cholesterol, LDL) SB - IM MH - Humans MH - Young Adult MH - Adult MH - Child MH - Cholesterol, LDL MH - *Hyperlipoproteinemia Type II/drug therapy MH - *Coronary Artery Disease MH - *Atherosclerosis EDAT- 2023/10/30 12:43 MHDA- 2023/12/22 06:42 CRDT- 2023/10/30 07:22 PHST- 2023/12/22 06:42 [medline] PHST- 2023/10/30 12:43 [pubmed] PHST- 2023/10/30 07:22 [entrez] AID - 01266029-202402000-00005 [pii] AID - 10.1097/MED.0000000000000842 [doi] PST - ppublish SO - Curr Opin Endocrinol Diabetes Obes. 2024 Feb 1;31(1):22-30. doi: 10.1097/MED.0000000000000842. Epub 2023 Oct 30. PMID- 37901600 OWN - NLM STAT- MEDLINE DCOM- 20231031 LR - 20260120 IS - 2211-8179 (Electronic) IS - 2211-8160 (Print) IS - 2211-8160 (Linking) VI - 18 IP - 1 DP - 2023 TI - World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM). PG - 59 LID - 10.5334/gh.1262 [doi] LID - 59 AB - Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive and fatal condition that requires early diagnosis, management, and specific treatment. The availability of new disease-modifying therapies has made successful treatment a reality. Transthyretin amyloid cardiomyopathy can be either age-related (wild-type form) or caused by mutations in the TTR gene (genetic, hereditary forms). It is a systemic disease, and while the genetic forms may exhibit a variety of symptoms, a predominant cardiac phenotype is often present. This document aims to provide an overview of ATTR-CM amyloidosis focusing on cardiac involvement, which is the most critical factor for prognosis. It will discuss the available tools for early diagnosis and patient management, given that specific treatments are more effective in the early stages of the disease, and will highlight the importance of a multidisciplinary approach and of specialized amyloidosis centres. To accomplish these goals, the World Heart Federation assembled a panel of 18 expert clinicians specialized in TTR amyloidosis from 13 countries, along with a representative from the Amyloidosis Alliance, a patient advocacy group. This document is based on a review of published literature, expert opinions, registries data, patients' perspectives, treatment options, and ongoing developments, as well as the progress made possible via the existence of centres of excellence. From the patients' perspective, increasing disease awareness is crucial to achieving an early and accurate diagnosis. Patients also seek to receive care at specialized amyloidosis centres and be fully informed about their treatment and prognosis. CI - Copyright: (c) 2023 The Author(s). FAU - Brito, Dulce AU - Brito D AUID- ORCID: 0000-0003-1278-1847 AD - Department of Cardiology, Centro Hospitalar Universitario Lisboa Norte, CAML, CCUL@RISE, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal. FAU - Albrecht, Fabiano Castro AU - Albrecht FC AUID- ORCID: 0000-0002-4802-4525 AD - Dante Pazzanese Institute of Cardiology - Cardiac Amyloidosis Center Dante Pazzanese Institute, Sao Paulo, Brazil. FAU - de Arenaza, Diego Perez AU - de Arenaza DP AUID- ORCID: 0000-0002-8582-5065 AD - Cardiology Department, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. FAU - Bart, Nicole AU - Bart N AD - St Vincent's Hospital, Victor Chang Cardiac Research Institute, University of New South Wales, Sydney, Australia. FAU - Better, Nathan AU - Better N AUID- ORCID: 0000-0003-1210-7983 AD - Cabrini Health, Malvern, Royal Melbourne Hospital, Parkville, Monash University and University of Melbourne, Victoria, Australia. FAU - Carvajal-Juarez, Isabel AU - Carvajal-Juarez I AUID- ORCID: 0000-0001-8764-6012 AD - Instituto Nacional de Cardiologia Ignacio Chavez, Ciudad de Mexico, Mexico. FAU - Conceicao, Isabel AU - Conceicao I AUID- ORCID: 0000-0003-0934-9631 AD - Department of Neurosciences and Mental Health, CHULN - Hospital de Santa Maria, Portugal. AD - Centro de Estudos Egas Moniz Faculdade de Medicina da Universidade de Lisboa Portugal, Portugal. FAU - Damy, Thibaud AU - Damy T AUID- ORCID: 0000-0003-4058-3848 AD - Department of Cardiology, DHU A-TVB, CHU Henri Mondor, AP-HP, INSERM U955 and UPEC, Creteil, France. AD - Referral Centre for Cardiac Amyloidosis, GRC Amyloid Research Institute, Reseau amylose, Creteil, France. Filiere CARDIOGEN. FAU - Dorbala, Sharmila AU - Dorbala S AUID- ORCID: 0000-0003-1462-1185 AD - Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. AD - Cardiac Amyloidosis Program, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. AD - CV imaging program, Cardiovascular Division and Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. FAU - Fidalgo, Jean-Christophe AU - Fidalgo JC AD - Amyloidosis Alliance The Voice of the Patients, USA. FAU - Garcia-Pavia, Pablo AU - Garcia-Pavia P AUID- ORCID: 0000-0002-5470-2257 AD - Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, CIBERCV, Madrid, Spain. AD - Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain. FAU - Ge, Junbo AU - Ge J AD - Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai, China. FAU - Gillmore, Julian D AU - Gillmore JD AUID- ORCID: 0000-0001-6174-9232 AD - National Amyloidosis Centre, University College London, Royal Free Campus, United Kingdom. FAU - Grzybowski, Jacek AU - Grzybowski J AD - Department of Cardiomyopathy, National Institute of Cardiology, Warsaw, Poland. FAU - Obici, Laura AU - Obici L AUID- ORCID: 0000-0001-7468-700X AD - Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. FAU - Pinero, Daniel AU - Pinero D AUID- ORCID: 0000-0002-0126-8194 AD - Universidad de Buenos Aires, Argentina. FAU - Rapezzi, Claudio AU - Rapezzi C AD - Cardiovascular Institute, University of Ferrara, Ferrara, Italy. FAU - Ueda, Mitsuharu AU - Ueda M AUID- ORCID: 0000-0002-6814-0582 AD - Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, Japan. FAU - Pinto, Fausto J AU - Pinto FJ AUID- ORCID: 0000-0002-8034-4529 AD - Department of Cardiology, Centro Hospitalar Universitario Lisboa Norte, CAML, CCUL@RISE, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal. LA - eng PT - Consensus Statement PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20231026 PL - England TA - Glob Heart JT - Global heart JID - 101584391 RN - 0 (Prealbumin) RN - Amyloidosis, Hereditary, Transthyretin-Related SB - IM CIN - Glob Heart. 2023 Nov 20;18(1):63. doi: 10.5334/gh.1275. PMID: 38028963 MH - Humans MH - Prealbumin/genetics MH - *Amyloid Neuropathies, Familial/complications/diagnosis/therapy MH - *Cardiomyopathies/diagnosis/therapy/genetics PMC - PMC10607607 OTO - NOTNLM OT - Amyloidosis OT - Heart Failure OT - Transthyretin amyloid cardiomyopathy (ATTR-CM) OT - diagnosis OT - patients' perspective OT - treatment COIS- D.B. declares speaking fees from Alnylam Pharmaceuticals, AstraZeneca, Bayer, Bial, Merck Serono, Novartis, Pfizer and Vifor Pharma, consulting fees from Alnylam Pharmaceuticals, AstraZeneca, Bayer, Bial, Boehringer Ingelheim, Novartis, Pfizer and Vifor Pharma, and research/educational support to her institution from Alnylam Pharmaceuticals, Novartis, and NovoNordisk. D.P.A. declares honoraria from Pfizer for lectures. N.B. declares speaking fees and research grants from Pfizer. N.B. declares medical consulting fees from Pfizer. T.D. declares honoraria or educational grants and consultancies from Alnylam, Akcea, Ionis, Pfizer, Novonordisc, GSK, Neurimmune and AstraZeneca. S.D. declares research grants from Pfizer, Attralus, GE Healthcare, Phillips and honoraria from Novo Nordisk and Astra Zeneca. P.G.P. reports speaking fees from Alnylam Pharmaceuticals, AstraZeneca, Bridgebio, Ionis Pharmaceuticals, NovoNordisk, and Pfizer; consulting fees from Alexion, Alnylam Pharmaceuticals, AstraZeneca, ATTRalus, Bridgebio, General Electric, Intellia, Neurimmune, NovoNordisk, and Pfizer. J.D.G declares consulting fee from Alnylam, Intellia, Ionis, AstraZeneca, ATTRalus, Eidos. J.G. declares honoraria consultancy from Pfizer; L.B. declares honoraria for consultancy and/or participation in speakers' bureau from Alnylam, Pfizer, SOBI, Astra Zeneca, Novo Nordisk and BridgeBio. M.U. declares grants, personal fees and non-financial support from Pfizer and Alnylam Pharmaceuticals, personal fees from Janssen Pharmaceutical K.K., outside the submitted work. The other authors declare no conflict of interests. EDAT- 2023/10/30 06:47 MHDA- 2023/10/31 06:42 PMCR- 2023/10/26 CRDT- 2023/10/30 04:54 PHST- 2023/08/10 00:00 [received] PHST- 2023/08/12 00:00 [accepted] PHST- 2023/10/31 06:42 [medline] PHST- 2023/10/30 06:47 [pubmed] PHST- 2023/10/30 04:54 [entrez] PHST- 2023/10/26 00:00 [pmc-release] AID - 10.5334/gh.1262 [doi] PST - epublish SO - Glob Heart. 2023 Oct 26;18(1):59. doi: 10.5334/gh.1262. eCollection 2023. PMID- 37901370 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241001 IS - 2477-4073 (Electronic) IS - 2528-181X (Print) IS - 2477-4073 (Linking) VI - 9 IP - 5 DP - 2023 TI - Effects of a telehealth program for wound healing promotion on the wound healing level in patients with diabetes undergoing coronary artery bypass graft surgery: A randomized controlled trial. PG - 428-436 LID - 10.33546/bnj.2775 [doi] AB - BACKGROUND: Patients with diabetes undergoing coronary artery bypass graft (CABG) are at risk of delayed wound healing. The telehealth program for wound healing promotion (TPWHP) was developed to improve wound healing in patients with diabetes undergoing CABG in a university hospital. OBJECTIVE: This study aimed to examine the effects of the TPWHP on the healing of the sternal wound and saphenous vein graft (SVG) donor site in patients with diabetes undergoing CABG. METHODS: In this randomized controlled trial, the participants were randomly assigned to the intervention (n = 30) and control (n = 30) groups. The control group received routine nursing care, whereas the intervention group received routine nursing care along with the TPWHP, which provides education and wound monitoring using multimedia and a surgical wound care booklet and monitors the wound through the LINE application on a smartphone after hospital discharge. Data were collected from June to November 2020 at two university hospitals in Bangkok, Thailand, using the demographic and health-related data form and the Thai wound assessment inventory (WAI). Data were analyzed using the Chi-squared, Fisher's exact, and Mann-Whitney U tests. RESULTS: The intervention group had significantly lower mean scores-indicating favorable wound healing-for SVG donor site wound healing level than the control group on days 14-21 after surgery (p = 0.012, mean = 0.58 +/- 0.54 and 1.08 +/- 0.82, respectively). No significant intergroup difference was observed in terms of the sternal wound healing level (p = 0.126); however, the intervention group showed lower mean scores-indicating good wound healing-than the control group. CONCLUSION: The TPWHP promotes effective wound healing of the SVG donor site; however, its efficacy on sternal wound healing was uncertain. Therefore, nurses should implement the TPWHP in collaboration with a multidisciplinary team to improve wound healing after hospital discharge. TRIAL REGISTRATION: Thai Clinical Trials Registry (TCTR20211112002). CI - (c) The Author(s) 2023. FAU - Sumrattana, Siriporn AU - Sumrattana S AUID- ORCID: 0009-0000-2431-7844 AD - Master of Nursing Science Program in Adult and Gerontological Nursing, Faculty of Nursing, Mahidol University, Bangkok, Thailand. FAU - Asdornwised, Usavadee AU - Asdornwised U AUID- ORCID: 0000-0002-5353-7114 AD - Department of Surgical Nursing, Faculty of Nursing, Mahidol University, Bangkok, Thailand. FAU - Wongkongkam, Kessiri AU - Wongkongkam K AUID- ORCID: 0000-0003-0343-9695 AD - Department of Surgical Nursing, Faculty of Nursing, Mahidol University, Bangkok, Thailand. FAU - Tantiwongkosri, Kriangkrai AU - Tantiwongkosri K AUID- ORCID: 0000-0002-8926-6715 AD - Cardiothoracic Division, Department of Surgery, Siriraj Hospital, Mahidol University, Bangkok, Thailand. LA - eng PT - Journal Article DEP - 20231026 PL - Indonesia TA - Belitung Nurs J JT - Belitung nursing journal JID - 101685037 PMC - PMC10600705 OTO - NOTNLM OT - CABG OT - Thailand OT - coronary artery bypass OT - diabetes mellitus OT - multimedia OT - patient discharge OT - saphenous vein OT - smartphone OT - telemedicine OT - wound healing COIS- The authors declared no potential conflicts of interest with respect to the research, authorship, or publication of this article. EDAT- 2023/10/30 06:47 MHDA- 2023/10/30 06:48 PMCR- 2023/10/26 CRDT- 2023/10/30 04:51 PHST- 2023/06/17 00:00 [received] PHST- 2023/07/08 00:00 [revised] PHST- 2023/08/15 00:00 [accepted] PHST- 2023/10/30 06:48 [medline] PHST- 2023/10/30 06:47 [pubmed] PHST- 2023/10/30 04:51 [entrez] PHST- 2023/10/26 00:00 [pmc-release] AID - BNJ-9-5-428 [pii] AID - 10.33546/bnj.2775 [doi] PST - epublish SO - Belitung Nurs J. 2023 Oct 26;9(5):428-436. doi: 10.33546/bnj.2775. eCollection 2023. PMID- 37900081 OWN - NLM STAT- MEDLINE DCOM- 20231031 LR - 20260127 IS - 1844-3117 (Electronic) IS - 1844-122X (Print) IS - 1844-122X (Linking) VI - 16 IP - 7 DP - 2023 Jul TI - Effect of Sulforaphane on cardiac injury induced by sepsis in a mouse model: Role of toll-like receptor 4. PG - 1120-1126 LID - 10.25122/jml-2023-0015 [doi] AB - As sepsis is associated with a 50% increase in mortality, sepsis-induced cardiomyopathy has become a critical topic. A multidisciplinary approach is required for the diagnosis and treatment of septic cardiomyopathy. This study looked at Sulforaphane, a natural product that aims to evaluate cardiac function after sepsis, and its likely mechanism of action. Twenty-four adult male Swiss albino mice were randomly divided into 4 equal groups (n=6): sham, CLP, vehicle Sulforaphane (the same amount of DMSO injected IP one hour before the CLP), and Sulforaphane group (one hour before the CLP, a 5mg/kg dose of Sulforaphane was injected). Cardiac tissue levels of toll-like receptor 4 (TLR-4), pro-inflammatory mediators, anti-inflammatory markers, oxidative stress markers, apoptosis markers, and serum cardiac damage biomarkers were assessed using ELISA. Statistical analyses, including t-tests and ANOVA tests, were performed with a significance level of 0.05 for normally distributed data. Compared to the sham group, the sepsis group had significantly elevated levels of TLR-4, IL-6, TNF-alpha, MIF, F2-isoprostane, caspase-3, cTn-I, and CK-MB (p<0.05). In contrast, the Sulforaphane pre-treated group demonstrated significantly lower levels of these markers (p<0.05). Additionally, Bcl-2 levels were significantly reduced (p<0.05) in the Sulforaphane group. Sulforaphane administration also significantly attenuated cardiac tissue injury (p<0.05). The findings suggest that Sulforaphane can decrease heart damage in male mice during CLP-induced polymicrobial sepsis by suppressing TLR-4/NF-kB downstream signal transduction pathways. CI - (c)2023 JOURNAL of MEDICINE and LIFE. FAU - Hadi, Sarah Mohammed Hussain AU - Hadi SMH AD - Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Kufa, Najaf, Iraq. FAU - Majeed, Sahar AU - Majeed S AD - Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Kufa, Najaf, Iraq. FAU - Ghafil, Fadhaa Abdulameer AU - Ghafil FA AD - Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Kufa, Najaf, Iraq. FAU - Altoraihi, Kaswer AU - Altoraihi K AD - Medical College, Department of Pharmacology and Therapeutics, University of Kufa, Najaf, Iraq. FAU - Hadi, Najah Rayish AU - Hadi NR AD - Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Kufa, Najaf, Iraq. LA - eng PT - Journal Article PL - Romania TA - J Med Life JT - Journal of medicine and life JID - 101477617 RN - 0 (Toll-Like Receptor 4) RN - GA49J4310U (sulforaphane) RN - 0 (Sulfoxides) RN - 0 (Isothiocyanates) SB - IM MH - Mice MH - Male MH - Animals MH - Toll-Like Receptor 4/metabolism/therapeutic use MH - *Cardiomyopathies/etiology/complications MH - *Heart Injuries/complications MH - *Sepsis/complications/drug therapy MH - Sulfoxides MH - Isothiocyanates PMC - PMC10600659 OTO - NOTNLM OT - ANOVA: Analysis of Variance OT - AP-1: Activator protein 1 OT - Bcl-2: B-cell lymphoma 2 OT - CK-MB: creatinine kinase MB OT - CLP OT - CLP: Cecal Ligation And Puncture OT - DMSO-Dimethyl Sulfoxide OT - ELISA: enzyme-linked immunosorbent assay OT - ERK: Extracellular signal-regulated kinase OT - IL-10: Interleukin 10 OT - IL-6: Interleukin 6 OT - IP: intraperitoneally OT - JNK: c-Jun N-terminal kinase OT - KEAP-1: Kelch-like ECH-associated protein 1 OT - LPS: lipopolysaccharide OT - MAPK: Mitogen-Activated Protein Kinase OT - MD-2: Myeloid differentiation factor-2 OT - MIF: Macrophage migration inhibitory OT - NF-kappaB: Nuclear factor kappa-light-chain-enhancer of activated B cells OT - Nrf2: nuclear factor erythroid 2-related factor 2 OT - Oxidative stress OT - ROS: reactive oxygen species OT - Sulforaphane OT - TLR- 4/NF- kB signaling pathways OT - TLR4: Toll-like receptor 4 OT - TNF- alpha: Tumor necrosis factor alpha OT - cTn-I: cardiac troponin I OT - cytokines OT - sepsis OT - degrees C: Celsius Degree COIS- The authors declare no conflict of interest. EDAT- 2023/10/30 06:46 MHDA- 2023/10/31 06:42 PMCR- 2023/07/01 CRDT- 2023/10/30 04:29 PHST- 2023/01/19 00:00 [received] PHST- 2023/04/21 00:00 [accepted] PHST- 2023/10/31 06:42 [medline] PHST- 2023/10/30 06:46 [pubmed] PHST- 2023/10/30 04:29 [entrez] PHST- 2023/07/01 00:00 [pmc-release] AID - JMedLife-16-1120 [pii] AID - 10.25122/jml-2023-0015 [doi] PST - ppublish SO - J Med Life. 2023 Jul;16(7):1120-1126. doi: 10.25122/jml-2023-0015. PMID- 37893008 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231030 IS - 2227-9059 (Print) IS - 2227-9059 (Electronic) IS - 2227-9059 (Linking) VI - 11 IP - 10 DP - 2023 Sep 26 TI - TAVI in a Heart Transplant Recipient-Rare Case Report and Review of the Literature. LID - 10.3390/biomedicines11102634 [doi] LID - 2634 AB - The global demand for cardiac transplants continues to rise, even with advancements in assistive devices. Currently, the estimated annual mortality rate stands at 3-5%, and patients often face a waiting time of approximately four years on transplant waiting lists. Consequently, many transplant centers have started to consider heart transplants from donors who may be deemed "less than ideal" or marginal. However, the decision to accept such donors must be highly individualized, taking into consideration the risks associated with remaining on the waiting list versus those posed by the transplantation procedure itself. A potential solution lies in the creation of two distinct recipient lists, matched with donor criteria, allowing marginal donors to provide the lifeline that selected patients require. This paper follows a two-step approach. Firstly, it offers an overview of the current state of affairs regarding the topic of transcatheter aortic valve implantation (TAVI) in orthotopic heart transplant (OHT) patients. Secondly, it presents firsthand experience from our clinical center with a comprehensive case presentation of a patient in this unique medical context. The clinical case refers to a 62-year-old male patient, a smoker with a history of hypertension, dyslipidemia, and a prior OHT a decade earlier, who presented with fatigue during minimal physical exertion. The Heart Team carefully reviewed the case, considering the patient's immunosuppressed status and the heightened risk associated with a repeat intervention. In this instance, transcatheter aortic valve implantation (TAVI) was deemed the appropriate treatment. The TAVI procedure yielded successful results, leading to improved clinical status and enhanced cardiac function. The inclusion of marginal donors has introduced novel challenges related to the utilization of previously diseased marginal organs. TAVI has already demonstrated its efficacy and versatility in treating high-risk patients, including heart transplant recipients. Consequently, it emerges as a vital tool in addressing the unique challenges posed by the inclusion of marginal donors. FAU - Preda, Silvia AU - Preda S AD - Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania. AD - Department of Cardiovascular Surgery, Bucharest Clinical Emergency Hospital, 014461 Bucharest, Romania. FAU - Calmac, Lucian AU - Calmac L AUID- ORCID: 0000-0002-3031-8023 AD - Department of Cardiovascular Surgery, Bucharest Clinical Emergency Hospital, 014461 Bucharest, Romania. FAU - Nica, Claudia AU - Nica C AD - Department of Cardiovascular Surgery, Bucharest Clinical Emergency Hospital, 014461 Bucharest, Romania. FAU - Cacoveanu, Mihai AU - Cacoveanu M AD - Department of Cardiovascular Surgery, Bucharest Clinical Emergency Hospital, 014461 Bucharest, Romania. FAU - Tiganasu, Robert AU - Tiganasu R AD - Department of Cardiovascular Surgery, Bucharest Clinical Emergency Hospital, 014461 Bucharest, Romania. FAU - Badea, Aida AU - Badea A AUID- ORCID: 0009-0007-7561-1702 AD - Department of Cardiovascular Surgery, Bucharest Clinical Emergency Hospital, 014461 Bucharest, Romania. FAU - Zaman, Alexandru AU - Zaman A AUID- ORCID: 0009-0006-8665-7354 AD - Department of Cardiovascular Surgery, Bucharest Clinical Emergency Hospital, 014461 Bucharest, Romania. FAU - Ciomag Ianula, Raluca AU - Ciomag Ianula R AD - Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania. AD - Department of Cardiology, "Bagdasar Arseni" Clinical Emergency Hospital, 041915 Bucharest, Romania. FAU - Nistor, Claudiu AU - Nistor C AD - Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania. AD - Department of Thoracic Surgery, Central Military Emergency University Hospital, 013058 Bucharest, Romania. FAU - Gaspar, Bogdan Severus AU - Gaspar BS AUID- ORCID: 0000-0002-0056-0740 AD - Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania. AD - Department of Cardiology, "Bagdasar Arseni" Clinical Emergency Hospital, 041915 Bucharest, Romania. FAU - Iliuta, Luminita AU - Iliuta L AUID- ORCID: 0000-0002-1439-5002 AD - Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania. AD - Cardioclass Clinic for Cardiovascular Disease, 031125 Bucharest, Romania. FAU - Dorobantu, Lucian AU - Dorobantu L AD - Faculty of Medicine, Titu Maiorescu University, 040441 Bucharest, Romania. AD - Department of Cardiovascular Surgery, Monza Metropolitan Hospital, 040204 Bucharest, Romania. FAU - Iliescu, Vlad Anton AU - Iliescu VA AUID- ORCID: 0000-0001-9069-2722 AD - Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania. AD - Department of Cardiovascular Surgery, Prof. Dr. C.C. Iliescu Emergency Institute for Cardiovascular Diseases, 022322 Bucharest, Romania. FAU - Moldovan, Horatiu AU - Moldovan H AUID- ORCID: 0000-0002-2241-279X AD - Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania. AD - Department of Cardiovascular Surgery, Bucharest Clinical Emergency Hospital, 014461 Bucharest, Romania. AD - Academy of Romanian Scientists, 54, Spl. Independentei, 050711 Bucharest, Romania. LA - eng PT - Journal Article PT - Review DEP - 20230926 PL - Switzerland TA - Biomedicines JT - Biomedicines JID - 101691304 PMC - PMC10604045 OTO - NOTNLM OT - aortic valve OT - heart valve replacement OT - orthotopic heart transplantation (OHT) OT - transcatheter aortic valve implantation (TAVI) COIS- The authors declare no conflict of interest. EDAT- 2023/10/28 11:48 MHDA- 2023/10/28 11:49 PMCR- 2023/09/26 CRDT- 2023/10/28 01:07 PHST- 2023/06/29 00:00 [received] PHST- 2023/08/18 00:00 [revised] PHST- 2023/09/18 00:00 [accepted] PHST- 2023/10/28 11:49 [medline] PHST- 2023/10/28 11:48 [pubmed] PHST- 2023/10/28 01:07 [entrez] PHST- 2023/09/26 00:00 [pmc-release] AID - biomedicines11102634 [pii] AID - biomedicines-11-02634 [pii] AID - 10.3390/biomedicines11102634 [doi] PST - epublish SO - Biomedicines. 2023 Sep 26;11(10):2634. doi: 10.3390/biomedicines11102634. PMID- 37892598 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231030 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 12 IP - 20 DP - 2023 Oct 11 TI - Rare Case Report: Left Atrial Sarcoma Obstructing the Left Ventricular Inflow. LID - 10.3390/jcm12206460 [doi] LID - 6460 AB - Malignant cardiac tumors of the heart are extremely rare and may present tremendous diagnostic and therapeutic challenges. These tumors are able to infiltrate the heart and metastasize systemically. Early detection is often elusive as the clinical presentation is highly variable, posing significant diagnostic and therapeutic difficulties. Despite a multidisciplinary approach, the prognosis for patients with malignant cardiac tumors remains guarded. Early diagnosis and a multidisciplinary approach involving cardiac surgeons, oncologists and critical care specialists are crucial in the management of this disease. Further research is needed to better understand the pathomechanisms of tumor-related complications and to develop effective treatment strategies to improve patient outcomes. The rare case of a 78-year-old woman with left atrial tumor requiring emergency surgery for acutely developing mitral valve obstruction is presented. Pathology confirmed an undifferentiated pleomorphic sarcoma. This patient tragically did not survive, highlighting the difficulties of managing such a rare and deceptive heart disease. FAU - Kaemmerer, Ann-Sophie AU - Kaemmerer AS AUID- ORCID: 0000-0001-6385-7632 AD - Department of Cardiac Surgery, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nurnberg, 91054 Erlangen, Germany. FAU - Suleiman, Mathieu N AU - Suleiman MN AUID- ORCID: 0000-0002-9541-9888 AD - Department of Cardiac Surgery, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nurnberg, 91054 Erlangen, Germany. FAU - Agaimy, Abbas AU - Agaimy A AUID- ORCID: 0000-0002-0445-8161 AD - Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nurnberg, 91054 Erlangen, Germany. FAU - Harig, Frank AU - Harig F AUID- ORCID: 0000-0002-1817-4207 AD - Department of Cardiac Surgery, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nurnberg, 91054 Erlangen, Germany. FAU - Weyand, Michael AU - Weyand M AD - Department of Cardiac Surgery, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nurnberg, 91054 Erlangen, Germany. FAU - Tandler, Rene AU - Tandler R AD - Department of Cardiac Surgery, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nurnberg, 91054 Erlangen, Germany. LA - eng GR - DE 132507686/University of Erlangen-Nuremberg/ PT - Journal Article DEP - 20231011 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC10607719 OTO - NOTNLM OT - cardiac sarcoma OT - cardiac surgery OT - left atrial tumor OT - malignant cardiac tumor OT - undifferentiated pleomorphic cardiac sarcoma COIS- The authors declare that they have no competing interests. EDAT- 2023/10/28 11:42 MHDA- 2023/10/28 11:43 PMCR- 2023/10/11 CRDT- 2023/10/28 01:05 PHST- 2023/08/15 00:00 [received] PHST- 2023/10/02 00:00 [revised] PHST- 2023/10/08 00:00 [accepted] PHST- 2023/10/28 11:43 [medline] PHST- 2023/10/28 11:42 [pubmed] PHST- 2023/10/28 01:05 [entrez] PHST- 2023/10/11 00:00 [pmc-release] AID - jcm12206460 [pii] AID - jcm-12-06460 [pii] AID - 10.3390/jcm12206460 [doi] PST - epublish SO - J Clin Med. 2023 Oct 11;12(20):6460. doi: 10.3390/jcm12206460. PMID- 37886969 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240927 IS - 1467-3045 (Electronic) IS - 1467-3037 (Print) IS - 1467-3037 (Linking) VI - 45 IP - 10 DP - 2023 Oct 15 TI - Cardiac Toxicities in Oncology: Elucidating the Dark Box in the Era of Precision Medicine. PG - 8337-8358 LID - 10.3390/cimb45100526 [doi] AB - Despite current advancements in chemotherapy, immunotherapy and targeted treatments, the potential for major adverse cardiovascular events, regardless of previous cardiac history, persists. Scoring systems, such as the Heart Failure Association-International Cardio-Oncology Society (HFA-ICOS) risk assessment tool, can be utilized to evaluate several factors including prior cardiac history, risk factors and cardiac biomarkers to categorize patients into low, moderate, high, and very high-risk groups. Common cardiotoxicity complications include new or worsening left ventricular ejection fraction (LVEF), QT interval prolongation, myocardial ischaemia, hypertension, thromboembolic disease, cardiac device malfunction and valve disease. Baseline electrocardiogram (ECG) and transthoracic echocardiogram (TTE) are routinely performed for all patients commenced on cardiotoxic treatment, while other imaging modalities and biochemical markers have proven useful for monitoring. Management mainly includes early risk stratification and prompt identification of cardiovascular complications, with patient-specific surveillance throughout treatment. A multidisciplinary approach is crucial in determining the relationship between potential treatment benefits and cardiotoxicity, and whether the continuation of treatment is appropriate on a case-by-case basis. Early risk stratification, optimizing the patient's cardiovascular status prior to treatment, and prompt identification of suspected cardiotoxicity are key in significantly reducing risk. This article provides a comprehensive review of the various types of treatment-related cardiotoxicity, offering guidance on identifying high-risk patients, recognizing early signs of cardiotoxicity, and outlining appropriate treatment approaches and follow-up care for such cases. FAU - Samuel, Younan AU - Samuel Y AUID- ORCID: 0009-0009-6748-4242 AD - Department of Cardiology, Medway NHS Foundation Trust, Windmill Road, Gillingham ME7 5NY, Kent, UK. FAU - Babu, Aswin AU - Babu A AD - Department of Cardiology, Medway NHS Foundation Trust, Windmill Road, Gillingham ME7 5NY, Kent, UK. FAU - Karagkouni, Foteini AU - Karagkouni F AD - Department of Cardiology, Medway NHS Foundation Trust, Windmill Road, Gillingham ME7 5NY, Kent, UK. FAU - Ismail, Ayden AU - Ismail A AUID- ORCID: 0000-0001-5458-4812 AD - GKT School of Medicine, King's College London, London SE1 9RT, UK. FAU - Choi, Sunyoung AU - Choi S AD - Department of Cardiology, Hampshire Hospitals NHS Foundation Trust, Aldermaston Road, Basingstoke RG24 9NA, Hampshire, UK. FAU - Boussios, Stergios AU - Boussios S AUID- ORCID: 0000-0002-2512-6131 AD - Department of Medical Oncology, Medway NHS Foundation Trust, Windmill Road, Gillingham ME7 5NY, Kent, UK. AD - Faculty of Life Sciences & Medicine, School of Cancer & Pharmaceutical Sciences, King's College London, London SE1 9RT, UK. AD - Kent Medway Medical School, University of Kent, Canterbury CT2 7LX, Kent, UK. AD - AELIA Organization, 9th Km Thessaloniki-Thermi, 57001 Thessaloniki, Greece. LA - eng PT - Journal Article PT - Review DEP - 20231015 PL - Switzerland TA - Curr Issues Mol Biol JT - Current issues in molecular biology JID - 100931761 PMC - PMC10605822 OTO - NOTNLM OT - cardiotoxicity OT - cardiovascular disease OT - chemotherapy OT - heart failure OT - immunotherapy OT - targeted therapy COIS- The authors declare no conflict of interest. EDAT- 2023/10/27 12:44 MHDA- 2023/10/27 12:45 PMCR- 2023/10/15 CRDT- 2023/10/27 06:50 PHST- 2023/10/01 00:00 [received] PHST- 2023/10/12 00:00 [revised] PHST- 2023/10/13 00:00 [accepted] PHST- 2023/10/27 12:45 [medline] PHST- 2023/10/27 12:44 [pubmed] PHST- 2023/10/27 06:50 [entrez] PHST- 2023/10/15 00:00 [pmc-release] AID - cimb45100526 [pii] AID - cimb-45-00526 [pii] AID - 10.3390/cimb45100526 [doi] PST - epublish SO - Curr Issues Mol Biol. 2023 Oct 15;45(10):8337-8358. doi: 10.3390/cimb45100526. PMID- 37883068 OWN - NLM STAT- MEDLINE DCOM- 20231227 LR - 20250130 IS - 2168-6173 (Electronic) IS - 2168-6165 (Print) IS - 2168-6165 (Linking) VI - 141 IP - 12 DP - 2023 Dec 1 TI - Risk of Stroke, Myocardial Infarction, and Death After Retinal Artery Occlusion. PG - 1110-1116 LID - 10.1001/jamaophthalmol.2023.4716 [doi] AB - IMPORTANCE: Patients with retinal artery occlusions (RAOs) are recommended to have emergent stroke workup, although the true risk of death and subsequent vascular events post-RAO is not clear. OBJECTIVE: To determine short-term and long-term rates of stroke, myocardial infarction (MI), and death in patients after RAO compared with a control cohort. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study used aggregated electronic health records from January 1, 2003, through April 14, 2023, from TriNetX, a network with data from more than 111 million patients. Patients with RAO and a cataract control group were identified and matched for age, sex, race, and comorbidities, including hypertension, diabetes, hyperlipidemia, and smoking status. Patients were excluded if they had a stroke or MI within 2 years before the diagnosis of RAO or cataract. EXPOSURE: International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, diagnosis code for RAO or age-related cataract. MAIN OUTCOMES AND MEASURES: Rate of death, stroke, and MI at 2 weeks, 30 days, 1 year, 5 years, and 10 years after RAO compared with matched controls. RESULTS: There were a total of 34 874 patients with at least 1 year of follow-up in the RAO cohort. The mean (SD) age at the RAO event was 66 (15.2) years. The rate of death after RAO diagnosis was higher than after cataract diagnosis at 2 weeks (0.14% vs 0.06%; relative risk [RR], 2.45; 95% CI, 1.46-4.12; risk difference [RD], 0.08%; 95% CI, 0.04%-0.13%; P < .001), 30 days (0.29% vs 0.14%; RR, 2.10; 95% CI, 1.49-2.97; RD, 0.15%; 95% CI, 0.08%-0.22%; P < .001), 1 year (3.51% vs 1.99%; RR, 1.78; 95% CI, 1.61-1.94; RD, 1.41%; 95% CI, 1.17%-1.66%; P < .001), 5 years (22.74% vs 17.82%; RR, 1.28; 95% CI, 1.23-1.33; RD, 4.93%; 95% CI, 4.17%-5.68%; P < .001), and 10 years (57.86% vs 55.38%; RR, 1.05; 95% CI, 1.02-1.07; RD, 2.47%; 95% CI, 1.25%-3.69%; P < .001). Risk of stroke after RAO was higher at 2 weeks (1.72% vs 0.08%; RR, 21.43; 95% CI, 14.67-31.29; RD, 1.64%; 95% CI, 1.50%-1.78%; P < .001), 30 days (2.48% vs 0.18%; RR, 14.18; 95% CI, 10.94-18.48; RD, 2.31%; 95% CI, 2.14%-2.47%; P < .001), 1 year (5.89% vs 1.13%; RR, 5.20; 95% CI, 4.67-5.79; RD, 4.64%; 95% CI, 4.37%-4.91%; P < .001), 5 years (10.85% vs 4.86%; RR, 2.24; 95% CI, 2.09-2.40; RD, 6.00%; 95% CI, 5.50%-6.50%; P < .001), and 10 years (14.59% vs 9.18%; RR, 1.59; 95% CI, 1.48-1.70; RD, 5.41%; 95% CI, 4.62%-6.21%; P < .001). Risk of MI after RAO was higher at 2 weeks (0.16% vs 0.06%; RR, 3.00; 95% CI, 1.79-5.04; RD, 0.11%; 95% CI, 0.06%-0.16%; P < .001), 30 days (0.27% vs 0.10%; RR, 2.61; 95% CI, 1.78-3.83; RD, 0.17%; 95% CI, 0.10%-0.23%; P < .001), 1 year (1.66% vs 0.97%; RR, 1.72; 95% CI, 1.51-1.97; RD, 0.59%; 95% CI, 0.42%-0.76%; P < .001), 5 years (6.06% vs 5.00%; RR, 1.21; 95% CI, 1.12-1.31; RD, 1.07%; 95% CI, 0.64%-1.50%; P < .001), and 10 years (10.55% vs 9.43%; RR, 1.12; 95% CI, 1.04-1.21; RD, 1.13%; 95% CI, 0.39%-1.87%; P = .003). CONCLUSIONS AND RELEVANCE: This study showed an increased risk of death, stroke, and MI in patients with RAO at both short-term and long-term intervals after RAO compared with a matched control population diagnosed with cataract. These findings suggest a potential need for multidisciplinary evaluation and long-term systemic follow-up of patients post-RAO. FAU - Wai, Karen M AU - Wai KM AD - Byers Eye Institute, Horngren Family Vitreoretinal Center, Department of Ophthalmology, Stanford University School of Medicine, Palo Alto, California. FAU - Knapp, Austen AU - Knapp A AD - Byers Eye Institute, Horngren Family Vitreoretinal Center, Department of Ophthalmology, Stanford University School of Medicine, Palo Alto, California. FAU - Ludwig, Cassie A AU - Ludwig CA AD - Byers Eye Institute, Horngren Family Vitreoretinal Center, Department of Ophthalmology, Stanford University School of Medicine, Palo Alto, California. FAU - Koo, Euna AU - Koo E AD - Byers Eye Institute, Horngren Family Vitreoretinal Center, Department of Ophthalmology, Stanford University School of Medicine, Palo Alto, California. FAU - Parikh, Ravi AU - Parikh R AD - Manhattan Retina and Eye Consultants, New York, New York. AD - New York University Langone Health, New York, New York. FAU - Rahimy, Ehsan AU - Rahimy E AD - Byers Eye Institute, Horngren Family Vitreoretinal Center, Department of Ophthalmology, Stanford University School of Medicine, Palo Alto, California. AD - Department of Ophthalmology, Palo Alto Medical Foundation, Palo Alto, California. FAU - Mruthyunjaya, Prithvi AU - Mruthyunjaya P AD - Byers Eye Institute, Horngren Family Vitreoretinal Center, Department of Ophthalmology, Stanford University School of Medicine, Palo Alto, California. LA - eng GR - P30 EY026877/EY/NEI NIH HHS/United States GR - K12 EY033745/EY/NEI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PL - United States TA - JAMA Ophthalmol JT - JAMA ophthalmology JID - 101589539 SB - IM MH - Aged MH - Humans MH - *Cataract MH - *Myocardial Infarction/diagnosis/epidemiology MH - *Retinal Artery Occlusion/complications/diagnosis/mortality MH - Retrospective Studies MH - Risk Factors MH - *Stroke/epidemiology/etiology/diagnosis MH - Case-Control Studies PMC - PMC10603578 COIS- Conflict of Interest Disclosures: Dr Ludwig reported funding support from the E. Matilda Ziegler Foundation for the Blind and National Institutes of Health (SUBK00015736) outside the submitted work. No other disclosures were reported. EDAT- 2023/10/26 12:42 MHDA- 2023/12/22 06:42 PMCR- 2024/10/26 CRDT- 2023/10/26 11:32 PHST- 2023/12/22 06:42 [medline] PHST- 2023/10/26 12:42 [pubmed] PHST- 2023/10/26 11:32 [entrez] PHST- 2024/10/26 00:00 [pmc-release] AID - 2810736 [pii] AID - eoi230061 [pii] AID - 10.1001/jamaophthalmol.2023.4716 [doi] PST - ppublish SO - JAMA Ophthalmol. 2023 Dec 1;141(12):1110-1116. doi: 10.1001/jamaophthalmol.2023.4716. PMID- 37877509 OWN - NLM STAT- MEDLINE DCOM- 20231206 LR - 20240408 IS - 1873-4286 (Electronic) IS - 1381-6128 (Linking) VI - 29 IP - 32 DP - 2023 TI - Is Adrenaline Always the First Choice Therapy of Anaphylaxis? An Allergist-cardiologist Interdisciplinary Point of View. PG - 2545-2551 LID - 10.2174/0113816128257514231019165809 [doi] AB - Worldwide, adrenaline is considered the first choice therapy in the international guidelines for the management of anaphylaxis. However, the heart and cardiovascular apparatus are strongly involved in anaphylaxis; for that reason, there are some cardiac conditions and certain anaphylaxis patterns that make epinephrine use problematic without adequate heart monitoring. The onset of Kounis syndrome, takotsubo cardiopathy, or the paradoxical anaphylaxis require great attention in the management of anaphylaxis and adrenaline administration by clinicians, who should be aware of the undervalued evolution of anaphylaxis and the potential cardiologic complications of epinephrine administration. Numerous case reports and studies describe the unexpected onset of cardiac diseases following epinephrine treatment, despite the latter being the recommended therapy for anaphylaxis. Our review suggests that future anaphylaxis guidelines should incorporate cardiovascular specialists since the treatment of Kounis syndrome or takotsubo cardiopathy requires cardiologist skills. CI - Copyright(c) Bentham Science Publishers; For any queries, please email at epub@benthamscience.net. FAU - Calogiuri, Gianfranco AU - Calogiuri G AD - Respiratory Diseases Department, Civil Hospital Vito Fazzi, Lecce, Italy. FAU - Savage, Michael P AU - Savage MP AD - Department of Medicine (Cardiology), Thomas Jefferson University Hospital, Philadelphia, USA. FAU - Congedo, Maurizio AU - Congedo M AD - Dermatology Unit, Civil Hospital Vito Fazzi, Lecce, Italy. FAU - Nettis, Eustachio AU - Nettis E AD - Department of Emergency and Organ Transplantation, School and Chair of Allergy and Clinical Immunology, University of Bari "Aldo Moro", Bari, Italy. FAU - Mirizzi, Alessandro Mandurino AU - Mirizzi AM AD - Cardiology Department, Vito Fazzi Hospital, Lecce, Italy. FAU - Foti, Caterina AU - Foti C AD - Section of Dermatology, Department of Biomedical Science and Human Oncology, University of Bari, Bari, Italy. FAU - Vacca, Angelo AU - Vacca A AD - Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine 'G. Baccelli', University of Bari "Aldo Moro", Bari, Italy. FAU - Kounis, Nicholas G AU - Kounis NG AD - Department of Cardiology, University of Patras Medical School, Patras 26221, Greece. LA - eng PT - Journal Article PT - Review PL - United Arab Emirates TA - Curr Pharm Des JT - Current pharmaceutical design JID - 9602487 RN - YKH834O4BH (Epinephrine) SB - IM MH - Humans MH - Epinephrine/therapeutic use MH - *Anaphylaxis/drug therapy MH - *Kounis Syndrome MH - *Cardiologists MH - Allergists MH - *Heart Diseases OTO - NOTNLM OT - Adrenaline OT - Kounis syndrome OT - anaphylaxis OT - heart attack. OT - hypertension OT - takotsubo cardiomyopathy EDAT- 2023/10/25 12:42 MHDA- 2023/12/06 06:41 CRDT- 2023/10/25 07:23 PHST- 2023/04/23 00:00 [received] PHST- 2023/09/22 00:00 [accepted] PHST- 2023/12/06 06:41 [medline] PHST- 2023/10/25 12:42 [pubmed] PHST- 2023/10/25 07:23 [entrez] AID - CPD-EPUB-135548 [pii] AID - 10.2174/0113816128257514231019165809 [doi] PST - ppublish SO - Curr Pharm Des. 2023;29(32):2545-2551. doi: 10.2174/0113816128257514231019165809. PMID- 37876991 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231026 IS - 1441-2772 (Print) IS - 2652-9335 (Electronic) IS - 1441-2772 (Linking) VI - 25 IP - 1 DP - 2023 Mar TI - Tiered escalation response systems in practice: A post hoc analysis examining the workload implications. PG - 47-52 LID - 10.1016/j.ccrj.2023.04.010 [doi] AB - OBJECTIVE: Many rapid response systems now have multiple tiers of escalation in addition to the traditional single tier of a medical emergency team. Given that the benefit to patient outcomes of this change is unclear, we sought to investigate the workload implications of a multitiered system, including the impact of trigger modification. DESIGN: The study design incorporated a post hoc analysis using a matched case-control dataset. SETTING: The study setting was an acute, adult tertiary referral hospital. PARTICIPANTS: Cases that had an adverse event (cardiac arrest or unanticipated intensive care unit admission) or a rapid response team (RRT) call participated in the study. Controls were matched by age, gender, ward and time of year, and no adverse event or RRT call. Participants were admitted between May 2014 and April 2015. MAIN OUTCOME MEASURES: The main outcome measure were the number of reviews, triggers, and modifications across three tiers of escalation; a nurse review, a multidisciplinary review (MDT-admitting medical team review), and an RRT call. RESULTS: There were 321 cases and 321 controls. Overall, there were 1948 nurse triggers, of which 1431 (73.5%) were in cases and 517 (26.5%) in controls, 798 MDT triggers (660 [82.7%] in cases and 138 [17.3%] in controls), and 379 RRT triggers (351 [92.6%] in cases and 28 [7.4%] in controls). Per patient per 24 h, there were 3.03 nurse, 1.24 MDT, and 0.59 RRT triggers. Accounting for modifications, this reduced to 2.17, 0.88, and 0.42, respectively. The proportion of triggers that were modified, so as not to trigger a review, was similar across all the tiers, being 28.6% of nurse, 29.6% of MDT, and 28.2% of RRT triggers. Per patient per 24 h, there were 0.61 nurse reviews, 0.52 MDT reviews, and 0.08 RRT reviews. CONCLUSIONS: Lower-tier triggers were more prevalent, and modifications were common. Modifications significantly mitigated the escalation workload across all tiers of a multitiered system. CI - (c) 2023 The Authors. Published by Elsevier B.V. on behalf of College of Intensive Care Medicine of Australia and New Zealand. FAU - O'Connell, Alice AU - O'Connell A AD - Consultant, Royal Adelaide Hospital, Adelaide, South Australia, Australia. AD - Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, South Australia, Australia. FAU - Flabouris, Arthas AU - Flabouris A AD - Consultant, Royal Adelaide Hospital, Adelaide, South Australia, Australia. AD - Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, South Australia, Australia. FAU - Edwards, Suzanne AU - Edwards S AD - Statistician, Adelaide Health Technology Assessment, School of Public Health, The University of Adelaide, South Australia, Australia. FAU - Thompson, Campbell H AU - Thompson CH AD - Consultant, Royal Adelaide Hospital, Adelaide, South Australia, Australia. AD - Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, South Australia, Australia. LA - eng PT - Journal Article DEP - 20230520 PL - Netherlands TA - Crit Care Resusc JT - Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine JID - 100888170 PMC - PMC10581276 OTO - NOTNLM OT - Afferent limb failure OT - Medical emergency teams OT - Observation and response charts OT - Rapid response systems OT - Vital signs EDAT- 2023/10/25 06:42 MHDA- 2023/10/25 06:43 PMCR- 2023/05/20 CRDT- 2023/10/25 04:02 PHST- 2023/10/25 06:43 [medline] PHST- 2023/10/25 06:42 [pubmed] PHST- 2023/10/25 04:02 [entrez] PHST- 2023/05/20 00:00 [pmc-release] AID - S1441-2772(23)00012-1 [pii] AID - 10.1016/j.ccrj.2023.04.010 [doi] PST - epublish SO - Crit Care Resusc. 2023 May 20;25(1):47-52. doi: 10.1016/j.ccrj.2023.04.010. eCollection 2023 Mar. PMID- 37874629 OWN - NLM STAT- MEDLINE DCOM- 20231025 LR - 20231110 IS - 2292-9495 (Electronic) IS - 2292-9495 (Linking) VI - 10 DP - 2023 Oct 24 TI - Cocreation to Facilitate Communication and Collaboration Between Multidisciplinary Stakeholders in eHealth Research and Development: Case Study of the CARRIER (Coronary Artery Disease: Risk Estimations and Interventions for Prevention and Early Detection) Consortium. PG - e45006 LID - 10.2196/45006 [doi] LID - e45006 AB - BACKGROUND: Collaboration with diverse stakeholders in eHealth research is fundamental yet complex. Stakeholders from various disciplines do not "speak the same language" and have different levels of power and interest, resulting in contrasting objectives, priorities, and expectations. An approach to constructive communication and collaboration is necessary to overcome this complex dynamic. Cocreation, known in the field of eHealth most often to involve end users, may also be suitable for facilitating stakeholder engagement and alignment. OBJECTIVE: This paper provides insights into the application of cocreation, specifically in the early phases of research that focus on involving and aligning relevant stakeholders from different academic and professional backgrounds. METHODS: The case for this study was a group discussion with members of a multidisciplinary consortium that works on developing a personalized eHealth intervention for atherosclerotic cardiovascular disease. Using stakeholder mapping, health and medicine experts, big data scientists, software developers, and an innovation manager (N=8) were invited to participate. The discussion was based on a user scenario and structured according to the Six Thinking Hats of de Bono, representing 6 different types of thinking. The discussion was recorded, transcribed verbatim, and analyzed thematically with the use of ATLAS.ti software. RESULTS: First, informative and intuitive thinking served the preparatory purpose of familiarization with the project details and other participants. Second, positive and critical thinking constituted the body of the discussion and resulted in an in-depth conversation. Third, creative and organizational thinking were action oriented and focused on solutions and planning to safeguard future progress. The participants repeatedly reflected on various intervention-related themes, ranging from intervention content to technical functionalities and from legal requirements to implementation in practice. Moreover, project-related matters were discussed, including stakeholder management and time and budget constraints. CONCLUSIONS: This paper demonstrates how cocreation can be of value for multidisciplinary stakeholder engagement and alignment. Based on stakeholder mapping (with whom to discuss), a dream user scenario (what to discuss), and the Six Thinking Hats of de Bono (how to discuss), the participants shared information, discussed differences, searched for solutions, and moved toward a collective approach regarding intervention development. The lessons learned may further improve the understanding of how cocreation can contribute to multidisciplinary collaboration. CI - (c)Elizabeth Latuapon, Laura Hochstenbach, Dominik Mahr, Bart Scheenstra, Bas Kietselaer, Marieke Spreeuwenberg. Originally published in JMIR Human Factors (https://humanfactors.jmir.org), 24.10.2023. FAU - Latuapon, Elizabeth AU - Latuapon E AUID- ORCID: 0000-0002-6327-9702 AD - Department of Health Services Research, Care and Public Health Research Institute, Maastricht University, Maastricht, Netherlands. FAU - Hochstenbach, Laura AU - Hochstenbach L AUID- ORCID: 0000-0003-2854-1055 AD - Department of Health Services Research, Care and Public Health Research Institute, Maastricht University, Maastricht, Netherlands. FAU - Mahr, Dominik AU - Mahr D AUID- ORCID: 0000-0003-1804-9622 AD - Department of Marketing & Supply Chain Management, School of Business and Economics, Maastricht University, Maastricht, Netherlands. FAU - Scheenstra, Bart AU - Scheenstra B AUID- ORCID: 0000-0001-5778-2574 AD - Department of Cardiothoracic Surgery, Cardiovascular Research Institute Maastricht, Maastricht University Medical Centre, Maastricht, Netherlands. FAU - Kietselaer, Bas AU - Kietselaer B AUID- ORCID: 0000-0002-0096-8594 AD - Department of Cardiovascular Disease, Mayo Clinic, Rochester, MN, United States. AD - Department of Cardiology, Zuyderland Medical Centre, Heerlen, Netherlands. FAU - Spreeuwenberg, Marieke AU - Spreeuwenberg M AUID- ORCID: 0000-0002-5798-0041 AD - Department of Health Services Research, Care and Public Health Research Institute, Maastricht University, Maastricht, Netherlands. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20231024 PL - Canada TA - JMIR Hum Factors JT - JMIR human factors JID - 101666561 SB - IM MH - Humans MH - *Coronary Artery Disease/diagnosis MH - Communication MH - Interdisciplinary Studies MH - *Atherosclerosis MH - *Telemedicine PMC - PMC10630860 OTO - NOTNLM OT - atherosclerosis OT - cardiology OT - cardiovascular OT - co-design OT - cocreation OT - collaborate OT - collaboration OT - eHealth OT - group dynamic OT - multidisciplinary OT - multidisciplinary collaboration OT - organizational OT - personalization OT - personalized OT - stakeholder involvement OT - team dynamic COIS- Conflicts of Interest: None declared. EDAT- 2023/10/24 12:42 MHDA- 2023/10/25 06:42 PMCR- 2023/10/24 CRDT- 2023/10/24 11:54 PHST- 2022/12/13 00:00 [received] PHST- 2023/08/20 00:00 [accepted] PHST- 2023/06/15 00:00 [revised] PHST- 2023/10/25 06:42 [medline] PHST- 2023/10/24 12:42 [pubmed] PHST- 2023/10/24 11:54 [entrez] PHST- 2023/10/24 00:00 [pmc-release] AID - v10i1e45006 [pii] AID - 10.2196/45006 [doi] PST - epublish SO - JMIR Hum Factors. 2023 Oct 24;10:e45006. doi: 10.2196/45006. PMID- 37873664 OWN - NLM STAT- MEDLINE DCOM- 20240115 LR - 20260603 IS - 2058-1742 (Electronic) IS - 2058-1742 (Linking) VI - 10 IP - 1 DP - 2024 Jan 12 TI - Surgical management of atrial fibrillation in patients undergoing cardiac surgery: a systematic review of clinical practice guidelines and recommendations. PG - 14-24 LID - 10.1093/ehjqcco/qcad060 [doi] AB - AIMS: Surgical ablation of atrial fibrillation (AF) has been demonstrated to be a safe procedure conducted concomitantly alongside cardiac surgery. However, there are conflicting guideline recommendations surrounding indications for surgical ablation. We conducted a systematic review of current recommendations on concomitant surgical AF ablation. METHODS AND RESULTS: We identified publications from MEDLINE and EMBASE between January 2011 and December 2022 and additionally searched Guideline libraries and websites of relevant organizations in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Of 895 studies screened, 4 were rigorously developed (AGREE-II > 50%) and included. All guidelines agreed on the definitions of paroxysmal, persistent, and longstanding AF based on duration and refraction to current treatment modalities. In the Australia-New Zealand (CSANZ) and European (EACTS) guidelines, opportunistic screening for patients >65 years is recommended. The EACTS recommends systematic screening for those aged >75 or at high stroke risk (Class IIa, Level B). However, this was not recommended by American Heart Association or Society of Thoracic Surgeons guidelines. All guidelines identified surgical AF ablation during concomitant cardiac surgery as safe and recommended for consideration by a Heart Team with notable variation in recommendation strength and the specific indication (three guidelines fail to specify any indication for surgery). Only the STS recommended left atrial appendage occlusion (LAAO) alongside surgical ablation (Class IIa, Level C). CONCLUSION: Disagreements exist in recommendations for specific indications for concomitant AF ablation and LAAO, with the decision subject to Heart Team assessment. Further evidence is needed to develop recommendations for specific indications for concomitant AF procedures and guidelines need to be made congruent. CI - (c) The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. FAU - Kumar, Niraj S AU - Kumar NS AD - Barts Heart Centre, St. Bartholomew's Hospital, London, UK. AD - National Medical Research Association, London, UK. FAU - Khanji, Mohammed Y AU - Khanji MY AD - Barts Heart Centre, St. Bartholomew's Hospital, London, UK. AD - Newham University Hospital, Barts Health NHS Trust, London, UK. AD - NIHR Barts Biomedical Research Centre, William Harvey Research Institute, Queen Mary University of London, London, UK. FAU - Patel, Kush P AU - Patel KP AD - Barts Heart Centre, St. Bartholomew's Hospital, London, UK. AD - Institute of Cardiovascular Sciences, University College London, UK. FAU - Ricci, Fabrizio AU - Ricci F AD - Department of Neuroscience, Imaging and Clinical Sciences, G.d'Annunzio University of Chieti-Pescara, Chieti, Italy. FAU - Providencia, Rui AU - Providencia R AD - Department of Cardiac Electrophysiology, Barts Heart Centre, St. Bartholomew's Hospital, Barts Health NHS Trust, London, UK. FAU - Chahal, Anwar AU - Chahal A AD - Division of Cardiology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA. FAU - Sohaib, Afzal AU - Sohaib A AD - NHLI, Imperial College London, London, UK. FAU - Awad, Wael I AU - Awad WI AD - Barts Heart Centre, St. Bartholomew's Hospital, London, UK. AD - Centre for Cardiovascular Medicine and Devices, William Harvey Research Institute, Queen Mary University of London, London, UK. AD - University of South Wales, Cardiff, UK. LA - eng PT - Journal Article PT - Systematic Review PL - England TA - Eur Heart J Qual Care Clin Outcomes JT - European heart journal. Quality of care & clinical outcomes JID - 101677796 SB - IM MH - United States MH - Humans MH - *Atrial Fibrillation/complications/surgery MH - *Cardiac Surgical Procedures MH - *Thoracic Surgery MH - *Stroke/etiology/prevention & control MH - Australia OTO - NOTNLM OT - Atrial fibrillation OT - Cardiac surgery OT - Guidelines OT - Surgical ablation EDAT- 2023/10/24 06:41 MHDA- 2024/01/15 12:42 CRDT- 2023/10/24 05:28 PHST- 2023/07/03 00:00 [received] PHST- 2023/09/20 00:00 [revised] PHST- 2023/10/20 00:00 [accepted] PHST- 2024/01/15 12:42 [medline] PHST- 2023/10/24 06:41 [pubmed] PHST- 2023/10/24 05:28 [entrez] AID - 7328938 [pii] AID - 10.1093/ehjqcco/qcad060 [doi] PST - ppublish SO - Eur Heart J Qual Care Clin Outcomes. 2024 Jan 12;10(1):14-24. doi: 10.1093/ehjqcco/qcad060. PMID- 37873498 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231026 IS - 2472-1972 (Electronic) IS - 2472-1972 (Linking) VI - 7 IP - 9 DP - 2023 Aug 2 TI - Diagnosis, Genetics, and Management of 24 Patients With Cardiac Paragangliomas: Experience From a Single Center. PG - bvad093 LID - 10.1210/jendso/bvad093 [doi] LID - bvad093 AB - CONTEXT: Paragangliomas located within the pericardium represent a rare yet challenging clinical situation. OBJECTIVE: The current analysis aimed to describe the clinical characteristics of cardiac paragangliomas, with emphasis on the diagnostic approach, genetic background, and multidisciplinary management. METHODS: Twenty-four patients diagnosed with cardiac paraganglioma (PGL) in Peking Union Medical College Hospital, Beijing, China, between 2003 and 2021 were identified. Clinical data was collected from medical record. Genetic screening and succinate dehydrogenase subunit B immunohistochemistry were performed in 22 patients. RESULTS: The median age at diagnosis was 38 years (range 11-51 years), 8 patients (33%) were females, and 4 (17%) had familial history. Hypertension and/or symptoms related to catecholamine secretion were present in 22 (92%) patients. Excess levels of catecholamines and/or metanephrines were detected in 22 (96%) of the 23 patients who have completed biochemical testing. Cardiac PGLs were localized with (131)I-metaiodobenzylguanidine scintigraphy in 11/22 (50%), and (99m)Tc-hydrazinonicotinyl-tyr3-octreotide scintigraphy in 24/24 (100%) patients. Genetic testing identified germline SDHx mutations in 13/22 (59%) patients, while immunohistochemistry revealed succinate dehydrogenase (SDH) deficiency in tumors from 17/22 (77%) patients. All patients were managed by a multidisciplinary team through medical preparation, surgery, and follow-up. Twenty-three patients received surgical treatment and perioperative death occurred in 2 cases. Overall, 21 patients were alive at follow-up (median 7.0 years, range 0.6-18 years). Local recurrence or metastasis developed in 3 patients, all of whom had SDH-deficient tumors. CONCLUSION: Cardiac PGLs can be diagnosed based on clinical manifestations, biochemical tests, and appropriate imaging studies. Genetic screening, multidisciplinary approach, and long-term follow-up are crucial in the management of this disease. CI - (c) The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. FAU - Shi, Chuan AU - Shi C AUID- ORCID: 0000-0002-5154-8506 AD - Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China. AD - Department of Internal Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing, China. FAU - Liu, Jian-Zhou AU - Liu JZ AD - Department of Cardiac Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing, China. FAU - Zeng, Zheng-Pei AU - Zeng ZP AUID- ORCID: 0000-0002-2708-0720 AD - Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China. FAU - Miao, Qi AU - Miao Q AUID- ORCID: 0000-0003-3370-9692 AD - Department of Cardiac Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing, China. FAU - Fang, Li-Gang AU - Fang LG AD - Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing, China. FAU - Chen, Shi AU - Chen S AUID- ORCID: 0000-0003-2205-5371 AD - Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China. FAU - Ping, Fan AU - Ping F AD - Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China. FAU - Sun, Hao AU - Sun H AD - Department of Radiology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing, China. FAU - Lu, Lin AU - Lu L AD - Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China. FAU - Chen, Li-Bo AU - Chen LB AD - Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing, China. FAU - Fu, Yong AU - Fu Y AD - Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China. FAU - Zhao, Da-Chun AU - Zhao DC AD - Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing, China. FAU - Yu, Chun-Hua AU - Yu CH AD - Department of Anesthesiology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing, China. FAU - JiaJue, Rui-Zhi AU - JiaJue RZ AD - Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China. FAU - Wang, Xi AU - Wang X AD - Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China. FAU - Liu, Xing-Rong AU - Liu XR AD - Department of Cardiac Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing, China. FAU - Ma, Guo-Tao AU - Ma GT AD - Department of Cardiac Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing, China. FAU - Zhang, Chao-Ji AU - Zhang CJ AD - Department of Cardiac Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing, China. FAU - Pan, Hui AU - Pan H AD - Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China. FAU - Yang, Hong-Bo AU - Yang HB AD - Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China. FAU - Wang, Yi-Ning AU - Wang YN AD - Department of Radiology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing, China. FAU - Li, Ming AU - Li M AD - Department of Clinical Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing, China. FAU - Li, Fang AU - Li F AD - Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing, China. FAU - Shen, Zhu-Jun AU - Shen ZJ AD - Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing, China. FAU - Liang, Zhi-Yong AU - Liang ZY AD - Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing, China. FAU - Xing, Xiao-Ping AU - Xing XP AD - Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China. FAU - Zhu, Wen-Ling AU - Zhu WL AD - Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing, China. LA - eng PT - Journal Article DEP - 20230710 PL - United States TA - J Endocr Soc JT - Journal of the Endocrine Society JID - 101697997 PMC - PMC10590637 OTO - NOTNLM OT - cardiac imaging techniques OT - cardiac paraganglioma OT - catecholamines OT - germline mutation OT - succinate dehydrogenase EDAT- 2023/10/24 06:41 MHDA- 2023/10/24 06:42 PMCR- 2023/07/10 CRDT- 2023/10/24 03:58 PHST- 2023/04/11 00:00 [received] PHST- 2023/10/24 06:42 [medline] PHST- 2023/10/24 06:41 [pubmed] PHST- 2023/10/24 03:58 [entrez] PHST- 2023/07/10 00:00 [pmc-release] AID - bvad093 [pii] AID - 10.1210/jendso/bvad093 [doi] PST - epublish SO - J Endocr Soc. 2023 Jul 10;7(9):bvad093. doi: 10.1210/jendso/bvad093. eCollection 2023 Aug 2. PMID- 37872398 OWN - NLM STAT- MEDLINE DCOM- 20240115 LR - 20261010 IS - 1439-099X (Electronic) IS - 0179-7158 (Linking) VI - 200 IP - 1 DP - 2024 Jan TI - Institutional experience report on the target contouring workflow in the radiotherapy department for stereotactic arrhythmia radioablation delivered on conventional linear accelerators. PG - 83-96 LID - 10.1007/s00066-023-02159-6 [doi] AB - PURPOSE: In stereotactic arrhythmia radioablation (STAR), the target is defined using multiple imaging studies and a multidisciplinary team consisting of electrophysiologist, cardiologist, cardiac radiologist, and radiation oncologist collaborate to identify the target and delineate it on the imaging studies of interest. This report describes the workflow employed in our radiotherapy department to transfer the target identified based on electrophysiology and cardiology imaging to the treatment planning image set. METHODS: The radiotherapy team was presented with an initial target in cardiac axes orientation, contoured on a wideband late gadolinium-enhanced (WB-LGE) cardiac magnetic resonance (CMR) study, which was subsequently transferred to the computed tomography (CT) scan used for treatment planning-i.e., the average intensity projection (AIP) image set derived from a 4D CT-via an axial CMR image set, using rigid image registration focused on the target area. The cardiac and the respiratory motion of the target were resolved using cine-CMR and 4D CT imaging studies, respectively. RESULTS: The workflow was carried out for 6 patients and resulted in an internal target defined in standard anatomical orientation that encompassed the cardiac and the respiratory motion of the initial target. CONCLUSION: An image registration-based workflow was implemented to render the STAR target on the planning image set in a consistent manner, using commercial software traditionally available for radiation therapy. CI - (c) 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany. FAU - Rosu-Bubulac, Mihaela AU - Rosu-Bubulac M AUID- ORCID: 0000-0003-0732-4115 AD - Department of Radiation Oncology, Virginia Commonwealth University, Richmond, VA, USA. Mihaela.Rosu@vcuhealth.org. FAU - Trankle, Cory R AU - Trankle CR AD - Department of Internal Medicine, Division of Cardiology, Virginia Commonwealth University, Richmond, VA, USA. AD - Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, USA. FAU - Mankad, Pranav AU - Mankad P AD - Department of Internal Medicine, Division of Cardiology, Virginia Commonwealth University, Richmond, VA, USA. AD - Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, USA. FAU - Grizzard, John D AU - Grizzard JD AD - Department of Radiology, Virginia Commonwealth University, Richmond, VA, USA. FAU - Ellenbogen, Kenneth A AU - Ellenbogen KA AD - Department of Internal Medicine, Division of Cardiology, Virginia Commonwealth University, Richmond, VA, USA. AD - Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, USA. FAU - Jordan, Jennifer H AU - Jordan JH AD - Department of Biomedical Engineering, Virginia Commonwealth University, Richmond, VA, USA. AD - Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, USA. FAU - Weiss, Elisabeth AU - Weiss E AD - Department of Radiation Oncology, Virginia Commonwealth University, Richmond, VA, USA. LA - eng PT - Journal Article DEP - 20231023 PL - Germany TA - Strahlenther Onkol JT - Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] JID - 8603469 SB - IM MH - Humans MH - Workflow MH - *Radiotherapy Planning, Computer-Assisted/methods MH - *Four-Dimensional Computed Tomography MH - Particle Accelerators MH - Arrhythmias, Cardiac OTO - NOTNLM OT - Cardiac magnetic resonance imaging OT - Mutimodality imaging OT - Stereotactic OT - Stereotactic arrhythmia radioablation OT - Target definition OT - Ventricular tachycardia EDAT- 2023/10/24 00:41 MHDA- 2024/01/15 12:43 CRDT- 2023/10/23 23:40 PHST- 2023/03/28 00:00 [received] PHST- 2023/09/17 00:00 [accepted] PHST- 2024/01/15 12:43 [medline] PHST- 2023/10/24 00:41 [pubmed] PHST- 2023/10/23 23:40 [entrez] AID - 10.1007/s00066-023-02159-6 [pii] AID - 10.1007/s00066-023-02159-6 [doi] PST - ppublish SO - Strahlenther Onkol. 2024 Jan;200(1):83-96. doi: 10.1007/s00066-023-02159-6. Epub 2023 Oct 23. PMID- 37871712 OWN - NLM STAT- MEDLINE DCOM- 20231216 LR - 20231216 IS - 1535-6280 (Electronic) IS - 0146-2806 (Linking) VI - 49 IP - 1 Pt B DP - 2024 Jan TI - Healthcare Big Data in Hong Kong: Development and Implementation of Artificial Intelligence-Enhanced Predictive Models for Risk Stratification. PG - 102168 LID - S0146-2806(23)00585-6 [pii] LID - 10.1016/j.cpcardiol.2023.102168 [doi] AB - Routinely collected electronic health records (EHRs) data contain a vast amount of valuable information for conducting epidemiological studies. With the right tools, we can gain insights into disease processes and development, identify the best treatment and develop accurate models for predicting outcomes. Our recent systematic review has found that the number of big data studies from Hong Kong has rapidly increased since 2015, with an increasingly common application of artificial intelligence (AI). The advantages of big data are that i) the models developed are highly generalisable to the population, ii) multiple outcomes can be determined simultaneously, iii) ease of cross-validation by for model training, development and calibration, iv) huge numbers of useful variables can be analyzed, v) static and dynamic variables can be analyzed, vi) non-linear and latent interactions between variables can be captured, vii) artificial intelligence approaches can enhance the performance of prediction models. In this paper, we will provide several examples (cardiovascular disease, diabetes mellitus, Brugada syndrome, long QT syndrome) to illustrate efforts from a multi-disciplinary team to identify data from different modalities to develop models using territory-wide datasets, with the possibility of real-time risk updates by using new data captured from patients. The benefit is that only routinely collected data are required for developing highly accurate and high-performance models. AI-driven models outperform traditional models in terms of sensitivity, specificity, accuracy, area under the receiver operating characteristic and precision-recall curve, and F1 score. Web and/or mobile versions of the risk models allow clinicians to risk stratify patients quickly in clinical settings, thereby enabling clinical decision-making. Efforts are required to identify the best ways of implementing AI algorithms on the web and mobile apps. CI - Copyright (c) 2023 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Tse, Gary AU - Tse G AD - School of Nursing and Health Studies, Hong Kong Metropolitan University, Hong Kong, China; Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin 300211, China. Electronic address: gary.tse@kmms.ac.uk. FAU - Lee, Quinncy AU - Lee Q AD - Family Medicine Research Unit, Cardiovascular Analytics Group, PowerHealth Research Institute, Hong Kong, China. FAU - Chou, Oscar Hou In AU - Chou OHI AD - Family Medicine Research Unit, Cardiovascular Analytics Group, PowerHealth Research Institute, Hong Kong, China; Division of Clinical Pharmacology and Therapeutics, Department of Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China. FAU - Chung, Cheuk To AU - Chung CT AD - Family Medicine Research Unit, Cardiovascular Analytics Group, PowerHealth Research Institute, Hong Kong, China. FAU - Lee, Sharen AU - Lee S AD - Family Medicine Research Unit, Cardiovascular Analytics Group, PowerHealth Research Institute, Hong Kong, China. FAU - Chan, Jeffrey Shi Kai AU - Chan JSK AD - Family Medicine Research Unit, Cardiovascular Analytics Group, PowerHealth Research Institute, Hong Kong, China. FAU - Li, Guoliang AU - Li G AD - Department of Cardiovascular Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. FAU - Kaur, Narinder AU - Kaur N AD - Family Medicine Research Unit, Cardiovascular Analytics Group, PowerHealth Research Institute, Hong Kong, China; School of Cardiovascular Science & Metabolic Health, University of Glasgow, UK. FAU - Roever, Leonardo AU - Roever L AD - Department of Clinical Research, Federal University of Uberlandia, Uberlandia, MG 38400384, Brazil. FAU - Liu, Haipeng AU - Liu H AD - Research Centre for Intelligent Healthcare, Faculty of Health and Life Sciences, Coventry University, Coventry, UK. FAU - Liu, Tong AU - Liu T AD - Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin 300211, China. FAU - Zhou, Jiandong AU - Zhou J AD - Division of Health Science, Warwick Medical School, University of Warwick, Coventry, United Kingdom. LA - eng PT - Journal Article PT - Review DEP - 20231021 PL - Netherlands TA - Curr Probl Cardiol JT - Current problems in cardiology JID - 7701802 SB - IM MH - Humans MH - *Artificial Intelligence MH - Hong Kong/epidemiology MH - Big Data MH - *Brugada Syndrome MH - Delivery of Health Care MH - Risk Assessment COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2023/10/24 00:41 MHDA- 2023/12/17 09:45 CRDT- 2023/10/23 19:28 PHST- 2023/10/19 00:00 [received] PHST- 2023/10/20 00:00 [accepted] PHST- 2023/12/17 09:45 [medline] PHST- 2023/10/24 00:41 [pubmed] PHST- 2023/10/23 19:28 [entrez] AID - S0146-2806(23)00585-6 [pii] AID - 10.1016/j.cpcardiol.2023.102168 [doi] PST - ppublish SO - Curr Probl Cardiol. 2024 Jan;49(1 Pt B):102168. doi: 10.1016/j.cpcardiol.2023.102168. Epub 2023 Oct 21. PMID- 37868882 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231030 IS - 2072-1439 (Print) IS - 2077-6624 (Electronic) IS - 2072-1439 (Linking) VI - 15 IP - 9 DP - 2023 Sep 28 TI - Integrated cardiothoracic team approach for complex lung transplantation procedures in Japan-current status and future direction. PG - 5195-5203 LID - 10.21037/jtd-22-1720 [doi] AB - The first lung transplant procedure in the world was performed in 1983, while in Japan that was first accomplished in 1998. Over the following 25 years, lung transplantation has become a viable treatment option for Japanese patients with a variety of end-stage lung diseases. Seventy cadaveric-donor lung (41 single, 29 bilateral), 11 bilateral living-donor lobar lung, and three heart-lung transplants have been performed with use of an integrated cardiothoracic team approach at medical facilities associated with Osaka University. Extremely advanced clinical and surgical skill sets are required to complete a lung transplant procedure, including surgical knowledge and techniques, as well as management of cardiovascular surgery, especially in regard to mechanical circulatory support (MCS), vascular anastomosis in difficult cases, and concomitant cardiac surgery. We have found that a collaborative effort by general thoracic and cardiac surgeons is an important key for success with lung transplantation. Complex lung transplant surgery and management in Japan are performed by use of an integrated cardiothoracic team approach, which has led to a synergistic impact on successful lung transplantation cases by capitalizing greatly on the experiences, techniques, and expertise of cardiac and thoracic experts. The present review is focused on the role of cardiac surgeons from the viewpoint of our experience with these cases. CI - 2023 Journal of Thoracic Disease. All rights reserved. FAU - Shintani, Yasushi AU - Shintani Y AD - Department of General Thoracic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan. FAU - Funaki, Soichiro AU - Funaki S AD - Department of General Thoracic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan. FAU - Kanou, Takashi AU - Kanou T AD - Department of General Thoracic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan. FAU - Ose, Naoko AU - Ose N AD - Department of General Thoracic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan. FAU - Kimura, Toru AU - Kimura T AD - Department of General Thoracic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan. FAU - Fukui, Eriko AU - Fukui E AD - Department of General Thoracic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan. FAU - Minami, Masato AU - Minami M AD - Department of General Thoracic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan. FAU - Miyagawa, Shigeru AU - Miyagawa S AD - Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Osaka, Japan. LA - eng PT - Journal Article PT - Review DEP - 20230811 PL - China TA - J Thorac Dis JT - Journal of thoracic disease JID - 101533916 PMC - PMC10586956 OTO - NOTNLM OT - Lung transplantation OT - cardiac surgery OT - cardiothoracic team OT - mechanical circulatory support (MCS) OT - vascular anastomosis COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-22-1720/coif). The special series "Why is the Outcome Good? Secrets of Lung Transplantation in Japan" was commissioned by the editorial office without any funding or sponsorship. The authors have no other conflicts of interest to declare. EDAT- 2023/10/23 06:46 MHDA- 2023/10/23 06:47 PMCR- 2023/09/28 CRDT- 2023/10/23 04:44 PHST- 2023/03/24 00:00 [received] PHST- 2023/03/26 00:00 [accepted] PHST- 2023/10/23 06:47 [medline] PHST- 2023/10/23 06:46 [pubmed] PHST- 2023/10/23 04:44 [entrez] PHST- 2023/09/28 00:00 [pmc-release] AID - jtd-15-09-5195 [pii] AID - 10.21037/jtd-22-1720 [doi] PST - ppublish SO - J Thorac Dis. 2023 Sep 28;15(9):5195-5203. doi: 10.21037/jtd-22-1720. Epub 2023 Aug 11. PMID- 37863462 OWN - NLM STAT- MEDLINE DCOM- 20231216 LR - 20240131 IS - 1535-6280 (Electronic) IS - 0146-2806 (Linking) VI - 49 IP - 1 Pt C DP - 2024 Jan TI - Multimodality Imaging for Selecting Candidates for CRT: Do We Have a Single Alley to Increase Responders? PG - 102150 LID - S0146-2806(23)00567-4 [pii] LID - 10.1016/j.cpcardiol.2023.102150 [doi] AB - Cardiac resynchronization therapy has evolved in recent years to provide a reduction of morbidity and mortality for many patients with heart failure. Its application and optimization is an evolving field and its use requires a multidisciplinary approach for patient and device selection, technical preprocedural planning, and optimization. While echocardiography has always been considered the first line for the evaluation of patients, additional imaging techniques have gained increasing evidence in recent years. Today different details about heart anatomy, function, dissynchrony can be investigated by magnetic resonance, cardiac computed tomography, nuclear imaging, and more, with the aim of obtaining clues to reach a maximal response from the electrical therapy. The purpose of this review is to provide a practical analysis of the single and combined use of different imaging techniques in the preoperative and perioperative phases of cardiac resynchronization therapy, underlining their main advantages, limitations, and information provided. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Sisti, Nicolo AU - Sisti N AD - Department of Cardiology, Hospital of Gubbio, Gubbio, Italy. Electronic address: nic.sisti@gmail.com. FAU - Cardona, Andrea AU - Cardona A AD - Division of Advanced Cardiovascular Diagnostics, Regional Healthcare Unit, Todi Hospital, Todi, Italy. FAU - Baldi, Enrico AU - Baldi E AD - Division of Cardiology, Fondazione IRCCS Policlinico San Matteo, Pavia. FAU - Sciaccaluga, Carlotta AU - Sciaccaluga C AD - Department of Medical Biotechnologies, Section of Cardiology, University of Siena, Siena, Italy. FAU - Notaristefano, Francesco AU - Notaristefano F AD - Cardiovascular Disease Department- Arrhytmology, University of Perugia, Perugia, Italy. FAU - Santoro, Amato AU - Santoro A AD - Division of Cardiology, Cardio Thoracic and Vascular Department, Azienda Ospedaliera Universitaria Senese, Siena, Italy. FAU - Mandoli, Giulia Elena AU - Mandoli GE AD - Department of Medical Biotechnologies, Section of Cardiology, University of Siena, Siena, Italy. FAU - Cameli, Matteo AU - Cameli M AD - Department of Medical Biotechnologies, Section of Cardiology, University of Siena, Siena, Italy. LA - eng PT - Journal Article PT - Review DEP - 20231018 PL - Netherlands TA - Curr Probl Cardiol JT - Current problems in cardiology JID - 7701802 SB - IM MH - Humans MH - *Cardiac Resynchronization Therapy/methods MH - Echocardiography/methods MH - *Heart Failure/diagnostic imaging/therapy MH - Multimodal Imaging/methods MH - Magnetic Resonance Imaging MH - Treatment Outcome COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2023/10/21 05:43 MHDA- 2023/12/17 09:46 CRDT- 2023/10/20 19:34 PHST- 2023/10/04 00:00 [received] PHST- 2023/10/14 00:00 [accepted] PHST- 2023/12/17 09:46 [medline] PHST- 2023/10/21 05:43 [pubmed] PHST- 2023/10/20 19:34 [entrez] AID - S0146-2806(23)00567-4 [pii] AID - 10.1016/j.cpcardiol.2023.102150 [doi] PST - ppublish SO - Curr Probl Cardiol. 2024 Jan;49(1 Pt C):102150. doi: 10.1016/j.cpcardiol.2023.102150. Epub 2023 Oct 18. PMID- 37861851 OWN - NLM STAT- MEDLINE DCOM- 20240216 LR - 20240419 IS - 1534-3170 (Electronic) IS - 1523-3782 (Linking) VI - 25 IP - 12 DP - 2023 Dec TI - Shock Teams: A Contemporary Review. PG - 1657-1663 LID - 10.1007/s11886-023-01983-7 [doi] AB - PURPOSE OF REVIEW: Cardiogenic shock (CS) is a time-sensitive and often fatal condition. To address this issue, many centers have developed multidisciplinary shock teams with a common goal of expediting the recognition and treatment of CS. In this review, we examine the mission, structure, implementation, and outcomes reported by these early shock teams. RECENT FINDINGS: To date, there have been four observational shock team analyses, each providing unique insight into the utility of the shock team. The limited available data supports that shock teams are associated with improved CS mortality. However, there is considerable operational heterogeneity among shock teams, and randomized data assessing their value and best practices in both local and regional care models are needed. CI - (c) 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Stevenson, Margaret J AU - Stevenson MJ AD - Department of Critical Care and Division of Cardiology, MedStar Washington Hospital Center, 110 Irving St NW, Suite 1A-27, Washington, DC, 20010, USA. FAU - Kenigsberg, Benjamin B AU - Kenigsberg BB AD - Department of Critical Care and Division of Cardiology, MedStar Washington Hospital Center, 110 Irving St NW, Suite 1A-27, Washington, DC, 20010, USA. FAU - Singam, Narayana Sarma V AU - Singam NSV AD - Department of Critical Care and Division of Cardiology, MedStar Washington Hospital Center, 110 Irving St NW, Suite 1A-27, Washington, DC, 20010, USA. FAU - Papolos, Alexander I AU - Papolos AI AUID- ORCID: 0000-0001-6045-5988 AD - Department of Critical Care and Division of Cardiology, MedStar Washington Hospital Center, 110 Irving St NW, Suite 1A-27, Washington, DC, 20010, USA. alexander.papolos@medstar.net. LA - eng PT - Journal Article PT - Review DEP - 20231020 PL - United States TA - Curr Cardiol Rep JT - Current cardiology reports JID - 100888969 SB - IM MH - Humans MH - *Shock, Cardiogenic/therapy MH - *Patient Care Team OTO - NOTNLM OT - Cardiogenic shock OT - Cardiogenic shock outcomes OT - Shock team EDAT- 2023/10/20 12:43 MHDA- 2024/01/26 06:44 CRDT- 2023/10/20 11:09 PHST- 2023/10/11 00:00 [accepted] PHST- 2024/01/26 06:44 [medline] PHST- 2023/10/20 12:43 [pubmed] PHST- 2023/10/20 11:09 [entrez] AID - 10.1007/s11886-023-01983-7 [pii] AID - 10.1007/s11886-023-01983-7 [doi] PST - ppublish SO - Curr Cardiol Rep. 2023 Dec;25(12):1657-1663. doi: 10.1007/s11886-023-01983-7. Epub 2023 Oct 20. PMID- 37861385 OWN - NLM STAT- MEDLINE DCOM- 20240226 LR - 20260816 IS - 2047-2412 (Electronic) IS - 2047-2404 (Print) IS - 2047-2404 (Linking) VI - 25 IP - 3 DP - 2024 Feb 22 TI - Tricuspid edge-to-edge repair for tricuspid valve prolapse and flail leaflet: feasibility in comparison to patients with secondary tricuspid regurgitation. PG - 365-372 LID - 10.1093/ehjci/jead264 [doi] AB - AIMS: Transcatheter tricuspid edge-to-edge repair (T-TEER) has gained widespread use for the treatment of tricuspid regurgitation (TR) in symptomatic patients with high operative risk. Although secondary TR is the most common pathology, some patients exhibit primary or predominantly primary TR. Characterization of patients with these pathologies in the T-TEER context has not been systematically performed. METHODS AND RESULTS: Patients assigned to T-TEER by the interdisciplinary heart team were consecutively recruited in two European centres over 4 years. Echocardiographic images were evaluated to distinguish between primary and secondary causes of TR. Both groups were compared concerning procedural results. A total of 339 patients were recruited, 13% with primary TR and 87% with secondary TR. Patients with primary TR had a smaller right ventricle (basal diameter 45 vs. 49 mm, P = 0.004), a better right ventricular function (fractional area change 45 vs. 41%, P = 0.001), a smaller right (28 vs. 34 cm2, P = 0.021) and left (52 vs. 67 mL/m2, P = 0.038) atrium, and a better left ventricular ejection fraction (60 vs. 52%, P = 0.005). The severity of TR was similar in primary and secondary TR at baseline (TR vena contracta width pre-interventional 13 +/- 4 vs. 14 +/- 5 mm, P = 0.19), and T-TEER significantly reduced TR in both groups (TR vena contracta width post-interventional 4 +/- 3 vs. 5 +/- 5 mm, P = 0.10). These findings remained stable after propensity score matching. Complications were similar between both groups. CONCLUSION: T-TEER confers equally safe and effective reduction of TR in patients with primary and secondary TR. CI - (c) The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. FAU - Dannenberg, Varius AU - Dannenberg V AUID- ORCID: 0000-0001-5722-4281 AD - Department for Internal Medicine II, Cardiology, Medical University of Vienna, Vienna, Austria. FAU - Bartko, Philipp E AU - Bartko PE AD - Department for Internal Medicine II, Cardiology, Medical University of Vienna, Vienna, Austria. FAU - Andreas, Martin AU - Andreas M AUID- ORCID: 0000-0003-4950-5432 AD - Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria. FAU - Bartunek, Anna AU - Bartunek A AD - Department of Cardiovascular, Cardiac, Thoracic and Vascular Anesthesia and Intensive Care, Medical University of Vienna, Vienna, Austria. FAU - Goncharov, Arseniy AU - Goncharov A AUID- ORCID: 0000-0003-2137-0222 AD - Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW, Ruhr-Universitat Bochum, Bad Oeynhausen, Germany. FAU - Gercek, Muhammed AU - Gercek M AUID- ORCID: 0000-0002-1822-936X AD - Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW, Ruhr-Universitat Bochum, Bad Oeynhausen, Germany. FAU - Friedrichs, Kai AU - Friedrichs K AD - Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW, Ruhr-Universitat Bochum, Bad Oeynhausen, Germany. FAU - Hengstenberg, Christian AU - Hengstenberg C AUID- ORCID: 0000-0002-8284-2994 AD - Department for Internal Medicine II, Cardiology, Medical University of Vienna, Vienna, Austria. FAU - Rudolph, Volker AU - Rudolph V AUID- ORCID: 0000-0001-5385-6839 AD - Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW, Ruhr-Universitat Bochum, Bad Oeynhausen, Germany. FAU - Ivannikova, Maria AU - Ivannikova M AD - Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW, Ruhr-Universitat Bochum, Bad Oeynhausen, Germany. LA - eng GR - KLI 818-B/Austrian Science Foundation/ PT - Journal Article PL - England TA - Eur Heart J Cardiovasc Imaging JT - European heart journal. Cardiovascular Imaging JID - 101573788 SB - IM MH - Humans MH - *Tricuspid Valve Insufficiency/diagnostic imaging/surgery/etiology MH - Tricuspid Valve/surgery MH - *Tricuspid Valve Prolapse/etiology/surgery MH - Stroke Volume MH - Feasibility Studies MH - Treatment Outcome MH - Ventricular Function, Left MH - *Heart Valve Prosthesis Implantation/methods MH - Cardiac Catheterization/methods PMC - PMC10883724 OTO - NOTNLM OT - edge-to-edge repair OT - primary leaflet defects OT - tricuspid regurgitation COIS- Conflict of interest: V.D. received speaker's and proctoring honoraria from Abbott and Edwards Lifesciences; M.A. received proctor/speaker/consulting fees from Abbott, Edwards, and Medtronic and institutional research funding (Edwards, Abbott, Medtronic, and LSI). C.H. received speaker's and proctoring honoraria from Edwards Lifesciences, Abbott, Boston Scientific, and Medtronic. K.F. has received speaker's honoraria from Abbott. V.R. has received research grants from Abbott and Edwards. M.I. has received speaker's honoraria from Edwards. The remaining authors have nothing to disclose. EDAT- 2023/10/20 12:42 MHDA- 2024/02/26 06:43 PMCR- 2023/10/20 CRDT- 2023/10/20 09:44 PHST- 2023/07/13 00:00 [received] PHST- 2023/09/06 00:00 [revised] PHST- 2023/10/13 00:00 [accepted] PHST- 2024/02/26 06:43 [medline] PHST- 2023/10/20 12:42 [pubmed] PHST- 2023/10/20 09:44 [entrez] PHST- 2023/10/20 00:00 [pmc-release] AID - 7325243 [pii] AID - jead264 [pii] AID - 10.1093/ehjci/jead264 [doi] PST - ppublish SO - Eur Heart J Cardiovasc Imaging. 2024 Feb 22;25(3):365-372. doi: 10.1093/ehjci/jead264. PMID- 37852434 OWN - NLM STAT- MEDLINE DCOM- 20231216 LR - 20250512 IS - 1097-6833 (Electronic) IS - 0022-3476 (Linking) VI - 264 DP - 2024 Jan TI - A Systematic Approach to Evaluate Sudden Unexplained Death in Children. PG - 113780 LID - S0022-3476(23)00644-3 [pii] LID - 10.1016/j.jpeds.2023.113780 [doi] AB - OBJECTIVE: To evaluate in the Netherlands the national outcomes in providing cause of and insights into sudden and unexplained child deaths among children via the Postmortem Evaluation of Sudden Unexplained Death in Youth (PESUDY) procedure. STUDY DESIGN: Children aged 0-18 years in the Netherlands who died suddenly were included in the PESUDY procedure if their death was unexplained and their parents gave consent. The PESUDY procedure consists of pediatric and forensic examination, biochemical, and microbiological tests; radiologic imaging; autopsy; and multidisciplinary discussion. Data on history, modifiable factors, previous symptoms, performed diagnostics, and cause of death were collected between October 2016 and December 2021. RESULTS: In total, 212 cases (median age 11 months, 56% boys, 33% comorbidity) were included. Microbiological, toxicological, and metabolic testing was performed in 93%, 34%, and 32% of cases. In 95% a computed tomography scan or magnetic resonance imaging was done and in 62% an autopsy was performed. The cause of death was explained in 58% of cases and a plausible cause was identified in an additional 13%. Most children died from infectious diseases. Noninfectious cardiac causes were the second leading cause of death found. Modifiable factors were identified in 24% of non-sudden infant death syndrome/unclassified sudden infant death cases and mostly involved overlooked alarming symptoms. CONCLUSIONS: The PESUDY procedure is valuable and effective for determining the cause of death in children with sudden unexplained deaths and for providing answers to grieving parents and involved health care professionals. CI - Copyright (c) 2023 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Pries, Annelotte Maretta AU - Pries AM AD - Department of General Paediatrics, Erasmus University Medical Center Sophia Children's Hospital, Rotterdam, The Netherlands. FAU - Ruskamp, Jopje Marlies AU - Ruskamp JM AD - Department of Paediatrics, University Medical Center Utrecht Wilhelmina Children's Hospital, Utrecht, The Netherlands. FAU - Edelenbos, Esther AU - Edelenbos E AD - Department of Paediatrics, Amsterdam University Medical Center Emma Children's Hospital, Amsterdam, The Netherlands. FAU - Fuijkschot, Joris AU - Fuijkschot J AD - Department of Paediatrics, Radboud University Medical Center Amalia Children's Hospital, Nijmegen, The Netherlands. FAU - Semmekrot, Ben AU - Semmekrot B AD - Department of Paediatrics, Canisius Wilhelmina Ziekenhuis, Nijmegen, The Netherlands. FAU - Verbruggen, Krijn Teunis AU - Verbruggen KT AD - Department of Paediatrics, University Medical Center Groningen Beatrix Children's Hospital, Groningen, The Netherlands. FAU - van de Putte, Elise AU - van de Putte E AD - Department of Paediatrics, University Medical Center Utrecht Wilhelmina Children's Hospital, Utrecht, The Netherlands. FAU - Puiman, Patrycja Jolanta AU - Puiman PJ AD - Department of General Paediatrics, Erasmus University Medical Center Sophia Children's Hospital, Rotterdam, The Netherlands. Electronic address: p.puiman@erasmusmc.nl. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20231016 PL - United States TA - J Pediatr JT - The Journal of pediatrics JID - 0375410 SB - IM MH - Infant MH - Male MH - Adolescent MH - Child MH - Humans MH - Female MH - *Sudden Infant Death/diagnosis/epidemiology/etiology MH - Autopsy MH - Magnetic Resonance Imaging MH - Netherlands/epidemiology MH - Cause of Death OTO - NOTNLM OT - SDY OT - SIDS OT - SUDC OT - SUDI OT - SUID OT - child death review OT - forensic COIS- Declaration of Competing Interest The authors have no conflicts of interest to disclose. EDAT- 2023/10/19 00:44 MHDA- 2023/12/17 09:44 CRDT- 2023/10/18 19:26 PHST- 2023/06/05 00:00 [received] PHST- 2023/10/10 00:00 [revised] PHST- 2023/10/11 00:00 [accepted] PHST- 2023/12/17 09:44 [medline] PHST- 2023/10/19 00:44 [pubmed] PHST- 2023/10/18 19:26 [entrez] AID - S0022-3476(23)00644-3 [pii] AID - 10.1016/j.jpeds.2023.113780 [doi] PST - ppublish SO - J Pediatr. 2024 Jan;264:113780. doi: 10.1016/j.jpeds.2023.113780. Epub 2023 Oct 16. PMID- 20301502 STAT- Publisher DRDT- 20231019 CTDT- 20041217 PB - University of Washington, Seattle DP - 1993 TI - MID1-Related Opitz G/BBB Syndrome. BTI - GeneReviews((R)) AB - CLINICAL CHARACTERISTICS: MID1-related Opitz G/BBB syndrome (MID1-OS) is characterized by facial anomalies (hypertelorism, prominent forehead, widow's peak, broad nasal bridge, anteverted nares), genitourinary abnormalities (hypospadias, cryptorchidism, and hypoplastic/bifid scrotum), and laryngotracheoesophageal defects. Developmental delay and intellectual disability are observed in about 30% of affected males. Cleft lip and/or palate are present in approximately half of affected males. Other malformations (present in <50% of affected males) include congenital heart defects, imperforate or ectopic anus, and midline brain defects (Dandy-Walker malformation and agenesis or hypoplasia of the corpus callosum and/or cerebellar vermis). Wide clinical variability occurs even among members of the same family. Female heterozygotes usually manifest hypertelorism only. DIAGNOSIS/TESTING: The diagnosis of MID1-OS is established in a male proband with suggestive findings and a hemizygous pathogenic variant in MID1 identified by molecular genetic testing. Females with a heterozygous MID1 pathogenic variant usually have isolated hypertelorism and only rarely present with other manifestations of MID1-OS. MANAGEMENT: Treatment of manifestations: Management of anomalies by a multidisciplinary team; surgical treatment of cleft lip/palate and other craniofacial anomalies; standard treatments for hearing loss including PE tubes; speech therapy; standard dental treatments as needed for hypodontia; standard surgical management of hypospadias; surgical treatment for medically significant laryngotracheoesophageal abnormalities; anti-reflux therapy as needed; neuropsychological and educational support; surgical repair of congenital heart defects and imperforate anus; surgical treatment and/or refractive lenses as needed per ophthalmologist. Surveillance: Follow up with craniofacial team for cleft lip/palate care; audiology evaluation annually or as needed; follow up with urologist as needed for those with significant hypospadias and/or other urinary tract defects; gastroenterology, pulmonology, and/or surgical team follow up for those with laryngotracheoesophageal defects; monitor developmental and educational needs at each visit; cardiology follow up per cardiologist; gastroenterology follow up as recommended for anal defects; ophthalmology evaluations as recommend by ophthalmologist; assess psychosocial and care coordination needs at each visit. GENETIC COUNSELING: MID1-OS is inherited in an X-linked manner. In a family with more than one affected individual, the mother of an affected male is an obligate heterozygote. If the mother of the proband has an MID1 pathogenic variant, the chance of transmitting it in each pregnancy is 50%: males who inherit the pathogenic variant will be affected; females who inherit the pathogenic variant will be heterozygotes and will usually manifest hypertelorism only. Once the MID1 pathogenic variant has been identified in an affected family member, heterozygote testing for at-risk female relatives and prenatal and preimplantation genetic testing are possible. CI - Copyright (c) 1993-2026, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved. FED - Adam, Margaret P ED - Adam MP FED - Bick, Sarah ED - Bick S FED - Mirzaa, Ghayda M ED - Mirzaa GM FED - Wallace, Stephanie E ED - Wallace SE FED - Amemiya, Anne ED - Amemiya A FAU - Meroni, Germana AU - Meroni G AD - Department of Life Sciences, University of Trieste, Trieste, Italy LA - eng PT - Review PT - Book Chapter PL - Seattle (WA) OTO - NLM OT - X-Linked Opitz Syndrome (XLOS) OT - X-Linked Opitz G/BBB Syndrome OT - E3 ubiquitin-protein ligase MID1 OT - MID1 OT - MID1-Related Opitz G/BBB Syndrome OT - X-Linked Opitz Syndrome (XLOS) OT - X-Linked Opitz G/BBB Syndrome EDAT- 2023/10/19 00:00 CRDT- 2023/10/19 00:00 AID - NBK1327 [bookaccession] PMID- 37851332 OWN - NLM STAT- MEDLINE DCOM- 20240313 LR - 20240313 IS - 1827-1898 (Electronic) IS - 0031-0808 (Linking) VI - 66 IP - 1 DP - 2024 Mar TI - Establishing a multi-specialty consensus in the clinical need for hypercholesterolemia management and its implication for patients access to innovative therapies. PG - 18-26 LID - 10.23736/S0031-0808.23.04999-6 [doi] AB - BACKGROUND: Increased level of blood LDL-C has a causal and cumulative effect on advancing atherosclerotic cardiovascular diseases (ASCVD). European guidelines for treating high LDL-C levels have been recently updated. However, in France, several challenges (e.g., physician and patient awareness, healthcare management) limit the application of management guidelines. The aim of this study was to understand the current opinions and perceived unmet clinical needs in recognising and managing hypercholesterolemia as an ASCVD risk factor, and to explore consensus around factors that support the effective management of elevated LDL-C. METHODS: An expert group of cardiologists, endocrinologists, biology/genetics researchers, and a health technology assessments expert, from France was convened. The current management of hypercholesterolemia and barriers to achieving LDL-C goals in France were discussed and 44 statements were developed. Wider consensus was assessed by sending the statements as a 4-point Likert Scale questionnaire to cardiologists and endocrinologists across France. The consensus threshold was defined as >/=75%. RESULTS: A total of 101 responses were received. Consensus was very high (>90%) in 25 (57%) statements, high (>/=75%) in 18 (41%) statements and was not achieved (<75%) only in 1 (2%) of statements. Overall, 43 statements achieved consensus. CONCLUSIONS: Based on consensus levels, key recommendations for improving current guidelines and approaches to care have been developed. Implementation of these recommendations will lead to better concordance with international treatment guidelines and increase levels of education for healthcare practitioners and patients. In turn, this will improve the available treatment pathways for cardiovascular diseases, potentially creating improved patient outcomes in the future. FAU - Boccara, Franck AU - Boccara F AD - Department of Cardiology, Saint-Antoine Research Center, Institut National de la Sante et de la Recherche Medicale (INSERM) UMR S938, Saint-Antoine Hospital, Hopitaux de l'Est Parisien, Assistance Publique-Hopitaux de Paris (AP-HP), Sorbonne University, Paris, France - franck.boccara@aphp.fr. FAU - Sabouret, Pierre AU - Sabouret P AD - Service of Cardiology, Institute of Cardiology, Pitie-Salpetriere University Hospital, Sorbonne University, Paris, France. FAU - Boileau, Catherine AU - Boileau C AD - Department of Genetics, LVTS - Institut National de la Sante et de la Recherche Medicale (INSERM) U1148, Bichat-Claude Bernard Hospital, Assistance Publique-Hopitaux de Paris (AP-HP), Universite Paris Cite, Paris, France. FAU - Georges, Jean-Louis AU - Georges JL AD - Service of Cardiology, Center Hospitalier de Versailles, Le Chesnay, France. AD - Annales de Cardiologie et Angeiologie, Elsevier Masson SAS, Issy les Moulineaux, France. FAU - Leclercq, Christophe AU - Leclercq C AD - Service of Cardiology, Rennes University Hospital, University of Rennes, Rennes, France. FAU - Lesnik, Philippe AU - Lesnik P AD - Institut National de la Sante et de la Recherche Medicale (INSERM) UMR_S 1166, Pitie-Salpetriere University Hospital, Sorbonne University, Paris, France. FAU - Bruckert, Eric AU - Bruckert E AD - Health Center, Paris, France. LA - eng PT - Journal Article DEP - 20231018 PL - Italy TA - Panminerva Med JT - Panminerva medica JID - 0421110 RN - 0 (Cholesterol, LDL) SB - IM MH - Humans MH - *Hypercholesterolemia/diagnosis/therapy MH - *Cardiovascular Diseases/diagnosis/therapy MH - Cholesterol, LDL MH - Consensus MH - *Atherosclerosis MH - Therapies, Investigational EDAT- 2023/10/18 12:42 MHDA- 2024/03/13 06:46 CRDT- 2023/10/18 11:15 PHST- 2024/03/13 06:46 [medline] PHST- 2023/10/18 12:42 [pubmed] PHST- 2023/10/18 11:15 [entrez] AID - S0031-0808.23.04999-6 [pii] AID - 10.23736/S0031-0808.23.04999-6 [doi] PST - ppublish SO - Panminerva Med. 2024 Mar;66(1):18-26. doi: 10.23736/S0031-0808.23.04999-6. Epub 2023 Oct 18. PMID- 37849384 OWN - NLM STAT- MEDLINE DCOM- 20240304 LR - 20240506 IS - 1573-3599 (Electronic) IS - 1059-7700 (Linking) VI - 33 IP - 1 DP - 2024 Feb TI - A team-based approach to cardiogenomic education. PG - 216-221 LID - 10.1002/jgc4.1798 [doi] AB - While many genetic professionals are involved in the education of lay and professional audiences, most do not have formal training in education theory and program design. Partnerships with adult education experts can provide additional resources and improve the level of instruction, thereby increasing the impact of an educational intervention. This report discusses the experience of a multidisciplinary team of educators, clinicians, and researchers partnering to develop evidence-based education for cardiology practitioners. It includes practical advice for how clinicians and educators can develop more effective education through collaboration, needs assessment, instructional design, and iterative content development. CI - (c) 2023 National Society of Genetic Counselors. FAU - Edelman, Emily A AU - Edelman EA AUID- ORCID: 0000-0002-5747-5715 AD - Clinical Education Program, Genomic Education, The Jackson Laboratory, Farmington, Connecticut, USA. FAU - Logan, Kalisi AU - Logan K AD - Clinical Education Program, Genomic Education, The Jackson Laboratory, Farmington, Connecticut, USA. FAU - Ingram Nissen, Therese AU - Ingram Nissen T AD - Clinical Education Program, Genomic Education, The Jackson Laboratory, Farmington, Connecticut, USA. FAU - Reed, E Kate AU - Reed EK AD - Clinical Education Program, Genomic Education, The Jackson Laboratory, Farmington, Connecticut, USA. FAU - Wicklund, Catherine AU - Wicklund C AD - Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA. FAU - Duquette, Debra AU - Duquette D AD - Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA. FAU - Dellefave-Castillo, Lisa AU - Dellefave-Castillo L AD - Center for Genetic Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA. LA - eng GR - 19SFRN34850101/American Heart Association/ GR - 19SFRN32830054/American Heart Association/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20231018 PL - United States TA - J Genet Couns JT - Journal of genetic counseling JID - 9206865 SB - IM MH - Adult MH - Humans MH - Educational Status MH - *Interdisciplinary Studies OTO - NOTNLM OT - cardiology OT - education OT - genetic literacy OT - multidisciplinary OT - professional development OT - program evaluation OT - risk assessment EDAT- 2023/10/18 06:42 MHDA- 2024/03/04 06:48 CRDT- 2023/10/18 03:45 PHST- 2023/08/07 00:00 [revised] PHST- 2022/11/30 00:00 [received] PHST- 2023/09/12 00:00 [accepted] PHST- 2024/03/04 06:48 [medline] PHST- 2023/10/18 06:42 [pubmed] PHST- 2023/10/18 03:45 [entrez] AID - 10.1002/jgc4.1798 [doi] PST - ppublish SO - J Genet Couns. 2024 Feb;33(1):216-221. doi: 10.1002/jgc4.1798. Epub 2023 Oct 18. PMID- 37844654 OWN - NLM STAT- MEDLINE DCOM- 20240129 LR - 20250324 IS - 1558-349X (Electronic) IS - 1546-1440 (Linking) VI - 21 IP - 1 DP - 2024 Jan TI - Improving On-Time Starts for Pediatric Cardiac MRI. PG - 81-87 LID - S1546-1440(23)00769-X [pii] LID - 10.1016/j.jacr.2023.10.007 [doi] AB - PURPOSE: Delayed start times for cardiac MRI examinations have resulted in longer patient fasts, extended wait times, and poor synchronization of anesthesia induction and contrast administration. The aim of this work was to improve on-time start rates from an initial baseline of 10%. METHODS: A multidisciplinary team comprising members of the cardiac and radiology services used the Realizing Improvement Through Team Empowerment methodology to target the root causes of the delays and enhance workflow. The main factors identified as contributing to examination delays were late patient arrival, variations in patient preparation time, unavailability of equipment, and inefficient scheduling processes. RESULTS: The implementation of various interventions, such as the use of standardized appointment scripts, ensuring timely patient preparation, and ensuring the availability of equipment when required, resulted in an increase in on-time start rates for cardiac MRI examinations to 34%. CONCLUSIONS: The study's systematic approach proved to be valuable in both understanding and resolving the identified problems. Through the continuous application of plan-do-study-act cycles, the authors effectively pinpointed obstacles and tested multiple potential measures to overcome them. This approach made it possible to comprehend the issue and to implement targeted interventions to address it. CI - Copyright (c) 2023 American College of Radiology. Published by Elsevier Inc. All rights reserved. FAU - Ferry, Susan M AU - Ferry SM AD - Division of Cardiology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. FAU - Jalloul, Mohammad AU - Jalloul M AD - Department of Radiology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. Electronic address: jalloulm@chop.edu. FAU - Larsen, Ethan P AU - Larsen EP AD - Department of Radiology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. Electronic address: https://twitter.com/EthanLarsen10. FAU - Montenegro, Lisa M AU - Montenegro LM AD - Division of Cardiology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; Division of Cardiovascular Anesthesiology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. FAU - Brogan, Lisa M AU - Brogan LM AD - Division of Cardiology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. FAU - Mecca, Patricia AU - Mecca P AD - Department of Radiology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. FAU - Karff, Caryn AU - Karff C AD - Department of Radiology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. FAU - Kaplan, Summer L AU - Kaplan SL AD - Department of Radiology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: https://twitter.com/slkaplanmd. FAU - Rigby, Valerie A AU - Rigby VA AD - Department of Radiology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. LA - eng PT - Journal Article DEP - 20231014 PL - United States TA - J Am Coll Radiol JT - Journal of the American College of Radiology : JACR JID - 101190326 SB - IM MH - Humans MH - Child MH - *Quality Improvement MH - *Appointments and Schedules MH - Magnetic Resonance Imaging MH - Radiography MH - Time Factors OTO - NOTNLM OT - Cardiac imaging OT - MRI OT - on-time starts OT - quality improvement OT - workflow EDAT- 2023/10/17 00:42 MHDA- 2024/01/29 06:44 CRDT- 2023/10/16 19:20 PHST- 2023/07/21 00:00 [received] PHST- 2023/10/05 00:00 [revised] PHST- 2023/10/12 00:00 [accepted] PHST- 2024/01/29 06:44 [medline] PHST- 2023/10/17 00:42 [pubmed] PHST- 2023/10/16 19:20 [entrez] AID - S1546-1440(23)00769-X [pii] AID - 10.1016/j.jacr.2023.10.007 [doi] PST - ppublish SO - J Am Coll Radiol. 2024 Jan;21(1):81-87. doi: 10.1016/j.jacr.2023.10.007. Epub 2023 Oct 14. PMID- 37840644 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240603 IS - 2161-3303 (Print) IS - 2161-3303 (Electronic) IS - 2161-3303 (Linking) VI - 12 IP - 2 DP - 2023 Jun TI - Preventing Adverse Cardiovascular Outcomes in Pregnancy Complicated by Obesity. PG - 129-137 LID - 10.1007/s13669-023-00356-9 [doi] AB - PURPOSE OF REVIEW: Obesity is a chronic disease that is becoming increasingly prevalent, and more individuals of reproductive age have obesity prior to becoming pregnant. Obesity in pregnancy is associated with short- and long-term adverse consequences for both the birthing person and their offspring which have been associated with increased long-term cardiovascular morbidity and mortality. The goal of this review is to discuss what is currently understood about the relationship between maternal obesity and adverse pregnancy outcomes (APOs), the association between APOs and future cardiovascular disease (CVD) risk, and what evidence-based interventions can be implemented to prevent adverse outcomes in this population. RECENT FINDINGS: Maternal obesity has been associated with an increased risk of APOs such as gestational diabetes, hypertensive disorders of pregnancy, and preterm birth as well as an increased risk of future CVD, such as metabolic syndrome, chronic hypertension, coronary heart disease, and stroke. The impact of maternal obesity also extends beyond the pregnant individual to the offspring, increasing the risk of fetal, neonatal, and infant mortality, as well as of congenital malformations, prematurity, and long-term health problems such as insulin resistance and childhood obesity. Prevention guidelines are incorporating the increased risk of adverse outcomes from maternal obesity into formalized risk assessments to guide both prenatal and postpartum care. It is becoming evident that a multidisciplinary cardio-obstetrics team is an important part of providing comprehensive care for pregnant individuals with obesity and other cardiovascular risk factors, including preexisting CVD and a history of prior APOs. There remains a need for further studies to better understand the mechanisms underlying the relationship between maternal obesity and APOs, as well as the racial and ethnic disparities that have been noted in the prevalence of APOs and associated CVD risk and mortality. SUMMARY: There is increasing awareness that obesity in pregnancy is associated with various short- and long-term adverse maternal and offspring outcomes. There are multiple screening and prevention strategies that may be implemented before, during, and after pregnancy to prevent these adverse outcomes. FAU - Purohit, Aarti AU - Purohit A AD - Johns Hopkins University School of Medicine, Baltimore, MD, USA. FAU - Oyeka, Chigolum Pamela AU - Oyeka CP AD - Johns Hopkins University School of Medicine, Baltimore, MD, USA. FAU - Khan, Sadiya S AU - Khan SS AD - Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. FAU - Toscano, Marika AU - Toscano M AD - Johns Hopkins University School of Medicine, Baltimore, MD, USA. FAU - Nayak, Shriddha AU - Nayak S AD - Johns Hopkins University School of Medicine, Baltimore, MD, USA. FAU - Lawson, Shari M AU - Lawson SM AD - Johns Hopkins University School of Medicine Department of Gynecology and Obstetrics, Baltimore, MD, USA. FAU - Blumenthal, Roger S AU - Blumenthal RS AD - Johns Hopkins University School of Medicine, Baltimore, MD, USA. FAU - Sharma, Garima AU - Sharma G AD - Johns Hopkins University School of Medicine, Baltimore, MD, USA. LA - eng GR - R01 HL161514/HL/NHLBI NIH HHS/United States GR - UG3 HL163121/HL/NHLBI NIH HHS/United States PT - Journal Article DEP - 20230406 PL - United States TA - Curr Obstet Gynecol Rep JT - Current obstetrics and gynecology reports JID - 101579335 PMC - PMC10575259 MID - NIHMS1888491 OTO - NOTNLM OT - adverse pregnancy outcomes OT - cardiovascular disease OT - cardiovascular risk OT - fetal outcomes OT - maternal obesity COIS- Declarations: Funding and/or Conflicts of interests/Competing interests: Dr. Sharma is supported by AHA 979462 and the Blumenthal Scholarship in Preventive Cardiology. Dr. Khan is supported by grants from NIH to her institution (R01HL161514; UG3HL163121). The other authors have no relevant financial or non-financial interests to disclose. EDAT- 2023/10/16 06:48 MHDA- 2023/10/16 06:49 PMCR- 2024/06/01 CRDT- 2023/10/16 04:18 PHST- 2023/10/16 06:49 [medline] PHST- 2023/10/16 06:48 [pubmed] PHST- 2023/10/16 04:18 [entrez] PHST- 2024/06/01 00:00 [pmc-release] AID - 10.1007/s13669-023-00356-9 [doi] PST - ppublish SO - Curr Obstet Gynecol Rep. 2023 Jun;12(2):129-137. doi: 10.1007/s13669-023-00356-9. Epub 2023 Apr 6. PMID- 37838182 OWN - NLM STAT- MEDLINE DCOM- 20240101 LR - 20240106 IS - 1885-5857 (Electronic) IS - 1885-5857 (Linking) VI - 77 IP - 1 DP - 2024 Jan TI - New technologies for the diagnosis, treatment, and monitoring of cardiovascular diseases. PG - 88-96 LID - S1885-5857(23)00267-0 [pii] LID - 10.1016/j.rec.2023.07.009 [doi] AB - Telemedicine enables the remote provision of medical care through information and communication technologies, facilitating data transmission, patient participation, promotion of heart-healthy habits, diagnosis, early detection of acute decompensation, and monitoring and follow-up of cardiovascular diseases. Wearable devices have multiple clinical applications, ranging from arrhythmia detection to remote monitoring of chronic diseases and risk factors. Integrating these technologies safely and effectively into routine clinical practice will require a multidisciplinary approach. Technological advances and data management will increase telemonitoring strategies, which will allow greater accessibility and equity, as well as more efficient and accurate patient care. However, there are still unresolved issues, such as identifying the most appropriate technological infrastructure, integrating these data into medical records, and addressing the digital divide, which can hamper patients' adoption of remote care. This article provides an updated overview of digital tools for a more comprehensive approach to atrial fibrillation, heart failure, risk factors, and treatment adherence. CI - Copyright (c) 2023 Sociedad Espanola de Cardiologia. Published by Elsevier Espana, S.L.U. All rights reserved. FAU - Facila Rubio, Lorenzo AU - Facila Rubio L AD - Servicio de Cardiologia, Consorcio Hospital General Universitario de Valencia, Universitat de Valencia, Valencia, Spain. Electronic address: lfacila@gmail.com. FAU - Lozano-Granero, Cristina AU - Lozano-Granero C AD - Servicio de Cardiologia, Hospital Universitario Ramon y Cajal y Centro de Investigacion en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain. FAU - Vidal-Perez, Rafael AU - Vidal-Perez R AD - Servicio de Cardiologia, Complejo Hospitalario Universitario de A Coruna, A Coruna, Spain. FAU - Barrios, Vivencio AU - Barrios V AD - Servicio de Cardiologia, Hospital Universitario Ramon y Cajal, Universidad de Alcala (UAH), Madrid, Spain. FAU - Freixa-Pamias, Roman AU - Freixa-Pamias R AD - Servicio de Cardiologia, Complex Hospitalari Moises Broggi, Sant Joan Despi, Barcelona, Spain. LA - eng LA - spa PT - Journal Article PT - Review DEP - 20231012 PL - Spain TA - Rev Esp Cardiol (Engl Ed) JT - Revista espanola de cardiologia (English ed.) JID - 101587954 SB - IM MH - Humans MH - *Cardiovascular Diseases/diagnosis/therapy MH - *Heart Failure/therapy MH - *Telemedicine MH - Chronic Disease MH - Early Diagnosis OTO - NOTNLM OT - Cardiovascular diseases OT - Dispositivos portatiles OT - Enfermedades cardiovasculares OT - Portable devices OT - Telemedicina OT - Telemedicine OT - Telemonitoring OT - Telemonitorizacion EDAT- 2023/10/15 05:46 MHDA- 2024/01/02 11:44 CRDT- 2023/10/14 19:27 PHST- 2023/03/16 00:00 [received] PHST- 2023/07/20 00:00 [accepted] PHST- 2024/01/02 11:44 [medline] PHST- 2023/10/15 05:46 [pubmed] PHST- 2023/10/14 19:27 [entrez] AID - S1885-5857(23)00267-0 [pii] AID - 10.1016/j.rec.2023.07.009 [doi] PST - ppublish SO - Rev Esp Cardiol (Engl Ed). 2024 Jan;77(1):88-96. doi: 10.1016/j.rec.2023.07.009. Epub 2023 Oct 12. PMID- 37829695 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231020 IS - 2297-055X (Print) IS - 2297-055X (Electronic) IS - 2297-055X (Linking) VI - 10 DP - 2023 TI - Atherosclerotic cardiovascular disease risk stratification and management in type 2 diabetes: review of recent evidence-based guidelines. PG - 1227769 LID - 10.3389/fcvm.2023.1227769 [doi] LID - 1227769 AB - Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality and morbidity in individuals with type 2 diabetes mellitus (T2DM). Accordingly, several scientific societies have released clinical practice guidelines to assist health professionals in ASCVD risk management in patients with T2DM. However, some recommendations differ from each other, contributing to uncertainty about the optimal clinical management of patients with T2DM and established ASCVD or at high risk for ASCVD. Thus, the purpose of this paper is to discuss recent evidence-based guidelines on ASCVD risk stratification and prevention in patients with T2DM, in terms of disparities and similarities. To close the gap between different guidelines, a multidisciplinary approach involving general practitioners, endocrinologists, and cardiologists may enhance the coordination of diagnosis, therapy, and long-term follow-up of ASCVD in patients with T2DM. CI - (c) 2023 Gourdy, Schiele, Halimi, Kownator, Hadjadj and Valensi. FAU - Gourdy, Pierre AU - Gourdy P AD - Diabetology Department, Toulouse University Hospital, Toulouse, France. AD - Institute of Metabolic and Cardiovascular Diseases, UMR1297 INSERM/UT3, Toulouse University, Toulouse, France. FAU - Schiele, Francois AU - Schiele F AD - Department of Cardiology, University Hospital Besancon, Besancon, France. AD - EA3920, University of Franche-Comte, Besancon, France. FAU - Halimi, Jean-Michel AU - Halimi JM AD - Nephrologie-Immunologie Clinique, Hopital Bretonneau, CHU Tours, Tours, France. AD - EA4245, University of Tours, Tours, France. AD - Investigation Network Initiative Cardiovascular and Renal Clinical Trialists (INI-CRCT), Nancy, France. FAU - Kownator, Serge AU - Kownator S AD - Cardiology and Vascular Center, Thionville, France. FAU - Hadjadj, Samy AU - Hadjadj S AD - Nantes Universite, CHU Nantes, CNRS, INSERM, l'Institut du Thorax, Nantes, France. FAU - Valensi, Paul AU - Valensi P AD - Unit of Endocrinology-Diabetology-Nutrition, AP-HP, Jean Verdier Hospital, Paris 13 University, Sorbonne Paris Cite, CRNH-IdF, CINFO, Bondy, France. AD - Polyclinique D'Aubervilliers, Aubervilliers, France. LA - eng PT - Journal Article PT - Review DEP - 20230926 PL - Switzerland TA - Front Cardiovasc Med JT - Frontiers in cardiovascular medicine JID - 101653388 PMC - PMC10566622 OTO - NOTNLM OT - atherosclerotic cardiovascular disease OT - guidelines OT - prevention OT - risk assessment OT - risk stratification OT - type 2 diabetes COIS- PG has received occasional fees, either personally or institutionally, for the activities of speaking, scientific advising, or clinical research from Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Gilead, GlaxoSmithKline, Merck Sharp & Dohme, Novo Nordisk, Organon, Pfizer, and Sanofi. FS has received research grants from and/or was a speaker (with or without lecture fees) on AO (CME accredited) meetings sponsored by Amgen, Bayer, Novartis, Novo Nordisk, Sanofi Aventis, Recordati, Servier, Mylan, and AstraZeneca. JH has received honoraria and/or travel grants from Ablynx, Alexion, AstraZeneca Rare Disease, AstraZeneca, Bayer, Bouchara-Recordati, Fresenius, GlaxoSmithKline, Mundipharma, Merck Sharp & Dohme, Roche, Servier, Sanofi, and Vifor Fresenius. SK has received personal consulting fees/honoraria from Amarin, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Lilly, Merck Sharp & Dohme, Novo Nordisk, Organon, Pfizer, Philips Healthcare, Sanofi, and Viatris. SH reports grants, personal fees, and/or non-financial support from AstraZeneca, Bayer, Boehringer Ingelheim, Dinno Sante, Eli Lilly, LVL, Merck Sharp & Dohme, Novartis, Pierre Fabre Sante, Sanofi, Servier, and Valbiotis. PV reports lectures for Abbott, AstraZeneca, Bayer, Eli Lilly, Hikma Pharmaceuticals, Merck Sharp & Dohme, Novo Nordisk, Novartis, Pfizer, Sanofi, Servier, and Stendo; research grants from Abbott, Bristol-Myers Squibb-AstraZeneca, and Novo Nordisk; and participation in expert committees for AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Daiichi Sankyo, Sanofi, and Servier. EDAT- 2023/10/13 06:45 MHDA- 2023/10/13 06:46 PMCR- 2023/01/01 CRDT- 2023/10/13 04:10 PHST- 2023/05/23 00:00 [received] PHST- 2023/09/11 00:00 [accepted] PHST- 2023/10/13 06:46 [medline] PHST- 2023/10/13 06:45 [pubmed] PHST- 2023/10/13 04:10 [entrez] PHST- 2023/01/01 00:00 [pmc-release] AID - 10.3389/fcvm.2023.1227769 [doi] PST - epublish SO - Front Cardiovasc Med. 2023 Sep 26;10:1227769. doi: 10.3389/fcvm.2023.1227769. eCollection 2023. PMID- 37827809 OWN - NLM STAT- MEDLINE DCOM- 20231023 LR - 20251216 IS - 2053-3624 (Print) IS - 2053-3624 (Electronic) IS - 2053-3624 (Linking) VI - 10 IP - 2 DP - 2023 Oct TI - Maternal mental health: a key area for future research among women with congenital heart disease. LID - 10.1136/openhrt-2023-002312 [doi] LID - e002312 AB - In this viewpoint, we respond to the recently published national priorities for research in congenital heart disease (CHD) among adults, established through the James Lind Alliance Priority Setting Partnership, with specific attention to priority 3 (mental health) and priority 5 (maternal health). Our recent policy impact project explored how maternal mental health is currently addressed in adult congenital heart disease (ACHD) services in the National Health Service, identified gaps and discussed possible ways forward. Our multidisciplinary discussion groups, which included women with lived experience of CHD and pregnancy, cardiology and obstetrics clinicians and medical anthropologists, found that while pregnancy and the postnatal period increase the mental health challenges faced by women with CHD, current services are not yet equipped to address them. Based on this work, we welcome the prioritisation of both mental health and maternal health in ACHD, and suggest that future research should focus on the overlaps between these two priority areas. CI - (c) Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Eli, Karin AU - Eli K AUID- ORCID: 0000-0001-9132-8404 AD - Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK a.c.lavis@bham.ac.uk karin.eli@warwick.ac.uk. FAU - Lavis, Anna AU - Lavis A AD - Institute of Applied Health Research, University of Birmingham, Birmingham, UK a.c.lavis@bham.ac.uk karin.eli@warwick.ac.uk. AD - Institute for Mental Health, University of Birmingham, Birmingham, UK. FAU - Castleman, James S AU - Castleman JS AD - Department of Obstetrics, Birmingham Women's Hospital, Birmingham, UK. FAU - Clift, Paul F AU - Clift PF AD - Department of Adult Congenital Cardiology, Queen Elizabeth Hospital Birmingham, Birmingham, UK. AD - Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK. FAU - Fox, Caroline E AU - Fox CE AD - Department of Obstetrics, Birmingham Women's Hospital, Birmingham, UK. FAU - Giles, Donna AU - Giles D AD - Patient and Public Involvement (PPI) Group Member, Coventry, UK. FAU - Grocott, Laura AU - Grocott L AD - Department of Adult Congenital Cardiology, Queen Elizabeth Hospital Birmingham, Birmingham, UK. FAU - Harrison, Kirsty AU - Harrison K AD - Patient and Public Involvement (PPI) Group Member, Coventry, UK. FAU - Hudsmith, Lucy E AU - Hudsmith LE AD - Department of Adult Congenital Cardiology, Queen Elizabeth Hospital Birmingham, Birmingham, UK. FAU - Kaplan, Katharina AU - Kaplan K AD - Patient and Public Involvement (PPI) Group Member, Coventry, UK. FAU - McDougall, Heather AU - McDougall H AD - Patient and Public Involvement (PPI) Group Member, Coventry, UK. FAU - Powell, Charlene AU - Powell C AD - Patient and Public Involvement (PPI) Group Member, Coventry, UK. FAU - Drury, Nigel E AU - Drury NE AUID- ORCID: 0000-0001-9012-6683 AD - Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK. AD - Paediatric Cardiac Surgery, Birmingham Children's Hospital, Birmingham, UK. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Open Heart JT - Open heart JID - 101631219 SB - IM MH - Pregnancy MH - Humans MH - Adult MH - Female MH - Mental Health MH - Maternal Health MH - State Medicine MH - *Heart Defects, Congenital/diagnosis/therapy MH - *Cardiology PMC - PMC10582993 OTO - NOTNLM OT - Health Services OT - Heart Defects, Congenital OT - Pregnancy COIS- Competing interests: None declared. EDAT- 2023/10/13 00:42 MHDA- 2023/10/23 01:18 PMCR- 2023/10/12 CRDT- 2023/10/12 21:23 PHST- 2023/06/23 00:00 [accepted] PHST- 2023/10/23 01:18 [medline] PHST- 2023/10/13 00:42 [pubmed] PHST- 2023/10/12 21:23 [entrez] PHST- 2023/10/12 00:00 [pmc-release] AID - openhrt-2023-002312 [pii] AID - 10.1136/openhrt-2023-002312 [doi] PST - ppublish SO - Open Heart. 2023 Oct;10(2):e002312. doi: 10.1136/openhrt-2023-002312. PMID- 37823758 OWN - NLM STAT- MEDLINE DCOM- 20240109 LR - 20241219 IS - 1897-4279 (Electronic) IS - 0022-9032 (Linking) VI - 81 IP - 12 DP - 2023 TI - Management of myocardial infarction complicated by cardiogenic shock: Expert opinion of the Association of Intensive Cardiac Care and Association of Cardiovascular Interventions of the Polish Society of Cardiology. PG - 1312-1324 LID - 10.33963/v.kp.97817 [doi] AB - Despite significant advances in interventional cardiology and mechanical circulatory support (MCS) techniques, outcomes for patients with myocardial infarction (MI) complicated by cardiogenic shock (CS) remain suboptimal. This expert consensus aims to provide information on the current management of patients with MI complicated by CS in Poland and to propose solutions, including systemic ones, for all stages of care. The document uses data from the Polish PL-ACS Registry of Acute Coronary Syndromes, which includes records of more than 820 000 hospital admissions. We describe the role of medical rescue teams, highlighting the necessity to expand their range of competencies at the level of prehospital care. We emphasize the importance of treating the underlying cause of CS and direct patient transfer to centers capable of performing percutaneous coronary interventions. We present current recommendations of scientific societies on MCS use. We underline the role of the Cardiac Shock Team in the management of patients with MI complicated by CS. Such teams should comprise an interventional cardiologist, a cardiothoracic surgeon, and an intensive care physician. Patients should be transferred to highly specialized CS centers, following the example of so-called Cardiac Shock Care Centers described in some other countries. We propose criteria for the operation of such centers Other important aspects discussed in the document include the role of rehabilitation, multidisciplinary care, and long-term follow-up of treatment outcomes. The document was developed in cooperation with experts from different scientific societies in Poland, which illustrates the importance of interdisciplinary care in this patient population. FAU - Trzeciak, Przemyslaw AU - Trzeciak P AD - 3rd Department of Cardiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Silesian Center for Heart Diseases, Zabrze, Poland. przemyslaw.t@wp.pl. FAU - Stepinska, Janina AU - Stepinska J AD - Department of Medical Communication, School of Public Health, Centre of Postgraduate Medical Education, Warszawa, Poland. FAU - Gil, Robert AU - Gil R AD - Department of Cardiology, Ministry of Interior and Administration National Medical Institute, Warszawa, Poland. FAU - Hawranek, Michal AU - Hawranek M AD - 3rd Department of Cardiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Silesian Center for Heart Diseases, Zabrze, Poland. FAU - Nadolny, Klaudiusz AU - Nadolny K AD - Department of Emergency Medical Service, Faculty of Medicine, Silesian Academy in Katowice, Katowice, Poland. AD - Regional Ambulance Service in Sosnowiec, Sosnowiec, Poland. FAU - Tycinska, Agnieszka AU - Tycinska A AD - Department of Cardiology, Medical University of Bialystok, Bialystok, Poland. FAU - Bartus, Stanislaw AU - Bartus S AD - 2nd Department of Cardiology, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland. FAU - Gierlotka, Marek AU - Gierlotka M AD - Department of Cardiology, University Hospital, Institute of Medical Sciences, University of Opole, Opole, Poland. FAU - Kaluzna-Oleksy, Marta AU - Kaluzna-Oleksy M AD - 1st Department of Cardiology, Poznan University of Medical Sciences, Poznan, Poland. FAU - Zymlinski, Robert AU - Zymlinski R AD - Institute of Cardiac Diseases, Wroclaw Medical University, Wroclaw, Poland. FAU - Grygier, Marek AU - Grygier M AD - 1st Department of Cardiology, Poznan University of Medical Sciences, Poznan, Poland. FAU - Wojakowski, Wojciech AU - Wojakowski W AD - Department of Cardiology and Structural Heart Diseases, Medical University of Silesia in Katowice, Poland. FAU - Gasior, Mariusz AU - Gasior M AD - 3rd Department of Cardiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Silesian Center for Heart Diseases, Zabrze, Poland. LA - eng PT - Journal Article DEP - 20231012 PL - Poland TA - Kardiol Pol JT - Kardiologia polska JID - 0376352 SB - IM MH - Humans MH - Shock, Cardiogenic/etiology/therapy MH - Poland MH - *Myocardial Infarction/complications/therapy MH - *Cardiology MH - Critical Care MH - Treatment Outcome OTO - NOTNLM OT - Cardiac Shock Care Center OT - Cardiac Shock Team OT - acute myocardial infarction OT - cardiogenic shock OT - intensive care OT - interventional treatment OT - mechanical circulatory support OT - prehospital care EDAT- 2023/10/12 12:43 MHDA- 2024/01/09 06:41 CRDT- 2023/10/12 09:34 PHST- 2023/10/12 00:00 [received] PHST- 2023/10/12 00:00 [accepted] PHST- 2024/01/09 06:41 [medline] PHST- 2023/10/12 12:43 [pubmed] PHST- 2023/10/12 09:34 [entrez] AID - VM/OJS/J/97817 [pii] AID - 10.33963/v.kp.97817 [doi] PST - ppublish SO - Kardiol Pol. 2023;81(12):1312-1324. doi: 10.33963/v.kp.97817. Epub 2023 Oct 12. PMID- 37822113 OWN - NLM STAT- MEDLINE DCOM- 20231216 LR - 20250806 IS - 2163-0763 (Electronic) IS - 2163-0755 (Linking) VI - 96 IP - 1 DP - 2024 Jan 1 TI - Extracorporeal life support in trauma: Indications and techniques. PG - 145-155 LID - 10.1097/TA.0000000000004043 [doi] AB - BACKGROUND: Clarity about indications and techniques in extracorporeal life support (ECLS) in trauma is essential for timely and effective deployment, and to ensure good stewardship of an important resource. Extracorporeal life support deployments in a tertiary trauma center were reviewed to understand the indications, strategies, and tactics of ECLS in trauma. METHODS: The provincial trauma registry was used to identify patients who received ECLS at a Level I trauma center and ECLS organization-accredited site between January 2014 and February 2021. Charts were reviewed for indications, technical factors, and outcomes following ECLS deployment. Based on this data, consensus around indications and techniques for ECLS in trauma was reached and refined by a multidisciplinary team discussion. RESULTS: A total of 25 patients underwent ECLS as part of a comprehensive trauma resuscitation strategy. Eighteen patients underwent venovenous ECLS and seven received venoarterial ECLS. Nineteen patients survived the ECLS run, of which 15 survived to discharge. Four patients developed vascular injuries secondary to cannula insertion while four patients developed circuit clots. On multidisciplinary consensus, three broad indications for ECLS and their respective techniques were described: gas exchange for lung injury, extended damage control for severe injuries associated with the lethal triad, and circulatory support for cardiogenic shock or hypothermia. CONCLUSION: The three broad indications for ECLS in trauma (gas exchange, extended damage control and circulatory support) require specific advanced planning and standardization of corresponding techniques (cannulation, circuit configuration, anticoagulation, and duration). When appropriately and effectively integrated into the trauma response, ECLS can extend the damage control paradigm to enable the management of complex multisystem injuries. LEVEL OF EVIDENCE: Therapeutic/Care Management; Level IV. CI - Copyright (c) 2023 Wolters Kluwer Health, Inc. All rights reserved. FAU - Lee, Alex AU - Lee A AD - From the Division of General Surgery, Department of Surgery (A.L., G.T., S.A.-K., N.G., E.J., S.M.H.), Division of Critical Care, Department of Medicine (A.L., S.T., N.G., G.F., H.D.K., G.I., M.H.), Department of Anesthesiology and Perioperative Care (A.L., G.F., G.I., M.C.), University of British Columbia; Perfusion Services (K.T., A.S., E.T., C.S.), Vancouver General Hospital, Vancouver, BC; and Division of General Surgery, Department of Surgery (C.G.B.), University of Calgary, Calgary, AB, Canada. FAU - Romano, Kali AU - Romano K FAU - Tansley, Gavin AU - Tansley G FAU - Al-Khaboori, Sadiq AU - Al-Khaboori S FAU - Thiara, Sonny AU - Thiara S FAU - Garraway, Naisan AU - Garraway N FAU - Finlayson, Gordon AU - Finlayson G FAU - Kanji, Hussein D AU - Kanji HD FAU - Isac, George AU - Isac G FAU - Ta, Kim Long AU - Ta KL FAU - Sidhu, Amandeep AU - Sidhu A FAU - Carolan, Mark AU - Carolan M FAU - Triana, Eleanor AU - Triana E FAU - Summers, Cara AU - Summers C FAU - Joos, Emilie AU - Joos E FAU - Ball, Chad G AU - Ball CG FAU - Hameed, Syed Morad AU - Hameed SM LA - eng PT - Journal Article DEP - 20230629 PL - United States TA - J Trauma Acute Care Surg JT - The journal of trauma and acute care surgery JID - 101570622 SB - IM MH - Humans MH - *Extracorporeal Membrane Oxygenation/methods MH - Retrospective Studies MH - Trauma Centers MH - *Vascular System Injuries MH - Resuscitation EDAT- 2023/10/12 06:43 MHDA- 2023/12/17 09:45 CRDT- 2023/10/12 02:01 PHST- 2023/12/17 09:45 [medline] PHST- 2023/10/12 06:43 [pubmed] PHST- 2023/10/12 02:01 [entrez] AID - 01586154-202401000-00019 [pii] AID - 10.1097/TA.0000000000004043 [doi] PST - ppublish SO - J Trauma Acute Care Surg. 2024 Jan 1;96(1):145-155. doi: 10.1097/TA.0000000000004043. Epub 2023 Jun 29. PMID- 37820282 OWN - NLM STAT- MEDLINE DCOM- 20240807 LR - 20250528 IS - 1932-751X (Electronic) IS - 1932-7501 (Linking) VI - 44 IP - 2 DP - 2024 Mar 1 TI - A Systematic Review of Interventions With an Educational Component Aimed at Increasing Enrollment and Participation in Cardiac Rehabilitation. PG - 83-90 LID - 10.1097/HCR.0000000000000820 [doi] AB - OBJECTIVE: The aim of this study was to systematically review the impact and characteristics of interventions with an educational component designed to improve enrollment and participation in cardiac rehabilitation (CR) among patients with cardiovascular disease. REVIEW METHODS: Five electronic databases were searched from data inception to February 2023. Randomized controlled trials and controlled, cohort, and case-control studies were considered for inclusion. Title, abstract, and full text of records were screened by two independent reviewers. The quality of included studies was rated using the Mixed Methods Assessment Tool. Results were analyzed in accordance with the Synthesis Without Meta-analysis reporting guideline. RESULTS: From 7601 initial records, 13 studies were included, six of which were randomized controlled trials ("high" quality = 53%). Two studies evaluated interventions with an educational component for health care providers (multidisciplinary team) and 11 evaluated interventions for patient participants (n = 2678). These interventions were delivered in a hybrid (n = 6; 46%), in-person (n = 4; 30%), or virtual (n = 3; 23%) environment, mainly by nurses (n = 4; 30%) via discussion and orientation. Only three studies described the inclusion of printed or electronic materials (eg, pamphlets) to support the education. Eleven of 12 studies reported that patients who participated in interventions with an educational component or were cared for by health care providers who were educated about CR benefits (inhospital and/or after discharge) were more likely to enroll and participate in CR. CONCLUSION: Interventions with an educational component for patients or health care providers play an important role in increasing CR enrollment and participation and should be pursued. Studies investigating the effects of such interventions in people from ethnic minority groups and living in low-and-middle-income countries, as well as the development of standard educational materials are recommended. CI - Copyright (c) 2023 Wolters Kluwer Health, Inc. All rights reserved. FAU - Vanzella, Lais Manata AU - Vanzella LM AD - University Health Network, Toronto Rehabilitation Institute, Toronto, Ontario, Canada (Drs Vanzella and Ghisi and Mss Konidis and Aultman); The KITE Research Institute, Toronto, Ontario, Canada (Drs Vanzella and Ghisi); Library & Information Services, University Health Network, Toronto Rehabilitation Institute, Toronto, Ontario, Canada (Ms Pakosh); and Department of Physical Therapy, University of Toronto, Toronto, Ontario, Canada (Dr Ghisi). FAU - Konidis, Renee AU - Konidis R FAU - Pakosh, Maureen AU - Pakosh M FAU - Aultman, Crystal AU - Aultman C FAU - Ghisi, Gabriela Lima de Melo AU - Ghisi GLM LA - eng PT - Journal Article PT - Systematic Review DEP - 20231004 PL - United States TA - J Cardiopulm Rehabil Prev JT - Journal of cardiopulmonary rehabilitation and prevention JID - 101291247 MH - Humans MH - *Cardiac Rehabilitation/methods MH - Patient Education as Topic/methods MH - Patient Participation/statistics & numerical data MH - Cardiovascular Diseases COIS- The authors declare no conflicts of interest. EDAT- 2023/10/11 18:43 MHDA- 2024/02/27 06:45 CRDT- 2023/10/11 15:53 PHST- 2024/02/27 06:45 [medline] PHST- 2023/10/11 18:43 [pubmed] PHST- 2023/10/11 15:53 [entrez] AID - 01273116-202403000-00003 [pii] AID - 10.1097/HCR.0000000000000820 [doi] PST - ppublish SO - J Cardiopulm Rehabil Prev. 2024 Mar 1;44(2):83-90. doi: 10.1097/HCR.0000000000000820. Epub 2023 Oct 4. PMID- 37816150 OWN - NLM STAT- MEDLINE DCOM- 20231109 LR - 20240115 IS - 1532-2092 (Electronic) IS - 1099-5129 (Print) IS - 1099-5129 (Linking) VI - 25 IP - 11 DP - 2023 Nov 2 TI - An unmet need: arrhythmia detection by implantable loop recorder in the systemic right ventricle. LID - 10.1093/europace/euad304 [doi] LID - euad304 AB - AIMS: Patients with systemic right ventricles are at high risk of sudden cardiac death. Arrhythmia is a significant risk factor. Routine Holter monitoring is opportunistic with poor adherence. The aim of this study was to determine if continuous rhythm monitoring with an implantable loop recorder (ILR) could allow early detection of clinically important arrhythmias. METHODS AND RESULTS: Implantable loop recorder implantation was offered to patients with atrial switch repair for transposition of the great arteries. Recordings were made with symptoms or, automatically for pauses, significant bradycardia or tachycardia and reviewed by the multi-disciplinary team. Twenty-four out of 36 eligible patients underwent ILR implantation with no complication. Forty-two per cent had preserved ventricular function, 75% were NYHA functional class I, 88% had low sudden cardiac death risk, 33% had previous intra-atrial re-entrant tachycardia (IART), and none had known conduction disease. Eighteen out of 24 (75%) patients made 52 recordings (52% automated) over 39.5 months (1.6-72.5). Thirty-two out of 52 (62%) recordings in 15/24 (63%) of the cohort were clinically significant and included sinus node disease (two patients), atrioventricular block (two patients), IART (seven patients), and IART with sinus node disease or atrioventricular block (four patients). Implantable loop recorder recordings prompted medication change in 11 patients [beta-blockers (n = 9), anti-coagulation (n = 5), and stopping anti-coagulation (n = 1)] and device therapy recommendation in seven patients [five pacemakers (three: atrioventricular block) and two defibrillators]. Two patients declined intervention; one suffered an arrhythmic death. Intra-atrial re-entrant tachycardia and clinically relevant conduction disease were detected in patients irrespective of sudden cardiac death risk. CONCLUSION: Continuous monitoring with an ILR in patients with systemic right ventricle following atrial switch detects clinically relevant arrhythmias that impact decision-making. In this cohort, clinically relevant arrhythmias did not correlate with sudden cardiac death risk. CI - (c) The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. FAU - Kakarla, Jayant AU - Kakarla J AUID- ORCID: 0009-0001-4760-0420 AD - Adult Congenital and Paediatric Heart Unit, Freeman Hospital, Freeman Road, High Heaton, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne NE7 7DN, UK. FAU - Crossland, David S AU - Crossland DS AD - Adult Congenital and Paediatric Heart Unit, Freeman Hospital, Freeman Road, High Heaton, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne NE7 7DN, UK. AD - Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne NE1 7RU, UK. FAU - Murray, Stephen AU - Murray S AD - Cardiology Department, Freeman Hospital, Freeman Road, High Heaton, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne NE7 7DN, UK. FAU - Adhvaryu, Kaitav AU - Adhvaryu K AUID- ORCID: 0009-0008-5729-5707 AD - Adult Congenital and Paediatric Heart Unit, Freeman Hospital, Freeman Road, High Heaton, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne NE7 7DN, UK. AD - Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne NE1 7RU, UK. FAU - Jansen, Katrijn AU - Jansen K AUID- ORCID: 0000-0002-6576-359X AD - Adult Congenital and Paediatric Heart Unit, Freeman Hospital, Freeman Road, High Heaton, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne NE7 7DN, UK. AD - Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne NE1 7RU, UK. FAU - Rybicka, Justyna AU - Rybicka J AD - Adult Congenital and Paediatric Heart Unit, Freeman Hospital, Freeman Road, High Heaton, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne NE7 7DN, UK. AD - Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne NE1 7RU, UK. FAU - Hermuzi, Antony AU - Hermuzi A AUID- ORCID: 0000-0003-4134-1867 AD - Adult Congenital and Paediatric Heart Unit, Freeman Hospital, Freeman Road, High Heaton, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne NE7 7DN, UK. AD - Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne NE1 7RU, UK. FAU - Martin, Ruairidh AU - Martin R AD - Cardiology Department, Freeman Hospital, Freeman Road, High Heaton, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne NE7 7DN, UK. FAU - Shepherd, Ewen AU - Shepherd E AD - Cardiology Department, Freeman Hospital, Freeman Road, High Heaton, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne NE7 7DN, UK. FAU - Seller, Neil AU - Seller N AUID- ORCID: 0000-0001-7877-3810 AD - Adult Congenital and Paediatric Heart Unit, Freeman Hospital, Freeman Road, High Heaton, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne NE7 7DN, UK. AD - Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne NE1 7RU, UK. FAU - Coats, Louise AU - Coats L AUID- ORCID: 0000-0003-3422-5497 AD - Adult Congenital and Paediatric Heart Unit, Freeman Hospital, Freeman Road, High Heaton, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne NE7 7DN, UK. AD - Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne NE1 7RU, UK. LA - eng PT - Journal Article PL - England TA - Europace JT - Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology JID - 100883649 SB - IM MH - Humans MH - Heart Ventricles/surgery MH - *Atrial Fibrillation/complications MH - *Atrioventricular Block/complications MH - Sick Sinus Syndrome/complications MH - *Transposition of Great Vessels/complications MH - Tachycardia MH - Electrocardiography, Ambulatory MH - *Tachycardia, Supraventricular/therapy MH - Death, Sudden, Cardiac/etiology/prevention & control PMC - PMC10634521 OTO - NOTNLM OT - Arrhythmia surveillance OT - Implantable loop recorder OT - Sudden cardiac death OT - Systemic right ventricle OT - Transposition of the great arteries COIS- Conflict of interest: Dr Stephen Murray has received honoraria from Acutus Medical and Boston Scientific. Dr Louise Coats receives funding from the British Heart Foundation and collaborates with CardiacSense. All remaining authors have declared no conflicts of interest. EDAT- 2023/10/10 18:42 MHDA- 2023/11/09 06:42 PMCR- 2023/10/10 CRDT- 2023/10/10 15:03 PHST- 2023/07/21 00:00 [received] PHST- 2023/10/05 00:00 [accepted] PHST- 2023/11/09 06:42 [medline] PHST- 2023/10/10 18:42 [pubmed] PHST- 2023/10/10 15:03 [entrez] PHST- 2023/10/10 00:00 [pmc-release] AID - 7304268 [pii] AID - euad304 [pii] AID - 10.1093/europace/euad304 [doi] PST - ppublish SO - Europace. 2023 Nov 2;25(11):euad304. doi: 10.1093/europace/euad304. PMID- 37813747 OWN - NLM STAT- MEDLINE DCOM- 20231110 LR - 20231110 IS - 1444-2892 (Electronic) IS - 1443-9506 (Linking) VI - 32 IP - 10 DP - 2023 Oct TI - Protocolised Management of Cardiogenic Shock and Shock Teams: A Narrative Review. PG - 1148-1157 LID - S1443-9506(23)04325-1 [pii] LID - 10.1016/j.hlc.2023.08.014 [doi] AB - Despite advances in therapy, the incidence of cardiogenic shock continues to increase, with significant mortality that has improved minimally over time. Treatment options for cardiogenic shock are complex and time-, resource-, and case volume-dependent, and involve multiple medical specialties. To provide early, more equitable, and standardised access to cardiogenic shock expertise with advanced therapies, cardiogenic shock teams with a protocolised treatment approach have been proposed. These processes have been applied across hospitals into integrated cardiogenic shock networks. This narrative review evaluates the role of cardiogenic shock teams, protocolised and regionalised shock networks, and the main individual components of protocolised shock management approaches. CI - Copyright (c) 2023 The Author(s). Published by Elsevier B.V. All rights reserved. FAU - Kruit, Natalie AU - Kruit N AD - Westmead Hospital, Sydney, NSW, Australia; Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia. FAU - Hambly, James AU - Hambly J AD - Westmead Hospital, Sydney, NSW, Australia; Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia. FAU - Ong, Andrew AU - Ong A AD - Westmead Hospital, Sydney, NSW, Australia. FAU - French, John AU - French J AD - Liverpool Hospital, Sydney, NSW, Australia; University of New South Wales, Sydney, NSW, Australia. FAU - Bowcock, Emma AU - Bowcock E AD - Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia; Nepean Hospital, Sydney, NSW, Australia. FAU - Kushwaha, Virag AU - Kushwaha V AD - Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia; Prince of Wales Hospital, Sydney, NSW, Australia. FAU - Jain, Pankaj AU - Jain P AD - Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia; Royal Prince Alfred Hospital, Sydney, NSW, Australia. FAU - Dennis, Mark AU - Dennis M AD - Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia; Royal Prince Alfred Hospital, Sydney, NSW, Australia. Electronic address: mark.dennis@sydney.edu.au. LA - eng PT - Journal Article PT - Review DEP - 20231008 PL - Australia TA - Heart Lung Circ JT - Heart, lung & circulation JID - 100963739 SB - IM MH - Humans MH - Shock, Cardiogenic/therapy MH - *Heart-Assist Devices MH - Intra-Aortic Balloon Pumping MH - Hospitals MH - *Extracorporeal Membrane Oxygenation OTO - NOTNLM OT - Cardiogenic shock OT - Heart team OT - Mechanical circulatory support OT - Protocolised management OT - Shock OT - Shock teams COIS- Conflicts of Interest There are no conflicts of interest to disclose. EDAT- 2023/10/10 00:42 MHDA- 2023/11/10 06:45 CRDT- 2023/10/09 22:21 PHST- 2023/04/16 00:00 [received] PHST- 2023/07/30 00:00 [revised] PHST- 2023/08/22 00:00 [accepted] PHST- 2023/11/10 06:45 [medline] PHST- 2023/10/10 00:42 [pubmed] PHST- 2023/10/09 22:21 [entrez] AID - S1443-9506(23)04325-1 [pii] AID - 10.1016/j.hlc.2023.08.014 [doi] PST - ppublish SO - Heart Lung Circ. 2023 Oct;32(10):1148-1157. doi: 10.1016/j.hlc.2023.08.014. Epub 2023 Oct 8. PMID- 37809158 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240425 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 15 IP - 9 DP - 2023 Sep TI - Implementing an Interdisciplinary Procedure Curriculum. PG - e44851 LID - 10.7759/cureus.44851 [doi] LID - e44851 AB - INTRODUCTION: This curriculum was designed to improve access to procedures for our internal medicine residents. METHODS: We created an interdisciplinary procedure course (IDPC) composed of two simulation sessions and a one-week procedural rotation supervised by multiple specialties including nephrology, cardiology, cardiothoracic anesthesiology, general anesthesiology, and interventional radiology. After the course, residents completed two surveys documenting the number of procedures and their level of confidence on a Likert scale (1 = very unconfident to 5 = very confident) prior to and after completing the curriculum. RESULTS: Sixteen residents participated in the course from September 2021 to June 2022. The collective number of procedures performed by these 16 residents increased from 176 to 343 after a one-week rotation. For arterial lines, the proportion of residents that reported an improvement in confidence scores was 0.44 (95% confidence interval 0.23 to 1, p-value of 0.60). The proportion of residents that had an increase in their confidence performing central lines was 0.63 (95% confidence interval 0.39 to 1, p-value of 0.23). For intubations, the proportion of residents that reported an improvement in confidence was 0.94 (95% confidence interval 0.72 to 1, p-value of 0.0006). CONCLUSION: By collaborating with multiple specialties, residents almost doubled the number of procedures performed during training and reported an increased level of confidence in procedural performance for airway intubation. We learned residents want to improve their access to procedures and described a curriculum that was easily implemented. CI - Copyright (c) 2023, Montane et al. FAU - Montane, Bryce AU - Montane B AD - Internal Medicine, Washington University School of Medicine, St. Louis, USA. FAU - Abraham, Abey AU - Abraham A AD - Cardiothoracic Anesthesiology, Cleveland Clinic, Cleveland, USA. FAU - Bustamante, Sergio AU - Bustamante S AD - Cardiothoracic Anesthesiology, Cleveland Clinic, Cleveland, USA. FAU - Vachharajani, Tushar AU - Vachharajani T AD - Nephrology, John D. Dingell Department of Veterans Affairs Medical Center, Detroit, USA. FAU - Ayad, Sabry AU - Ayad S AD - Outcomes Research, Cleveland Clinic, Cleveland, USA. AD - Anesthesiology, Cleveland Clinic, Cleveland, USA. FAU - Devarajan, Jagan AU - Devarajan J AD - Anesthesiology, Cleveland Clinic, Cleveland, USA. FAU - Thompson, Dustin AU - Thompson D AD - Diagnostic Radiology, Cleveland Clinic, Cleveland, USA. FAU - Lee, Ran AU - Lee R AD - Cardiovascular Medicine, Cleveland Clinic, Cleveland, USA. FAU - Rampersad, Penelope AU - Rampersad P AD - Cardiovascular Medicine, Cleveland Clinic, Cleveland, USA. FAU - Gage, Brian AU - Gage B AD - Internal Medicine, Washington University School of Medicine, St. Louis, USA. FAU - Reznicek, Emily AU - Reznicek E AD - Gastroenterology, University of Missouri, Columbia, USA. FAU - Luo, Chongliang AU - Luo C AD - Surgery, Washington University School of Medicine, St. Louis, USA. FAU - Wardrop, Richard AU - Wardrop R AD - Internal Medicine, Cleveland Clinic, Cleveland, USA. LA - eng GR - P30 CA091842/CA/NCI NIH HHS/United States GR - TL1 TR002344/TR/NCATS NIH HHS/United States PT - Journal Article DEP - 20230907 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC10559997 OTO - NOTNLM OT - academic cardiology OT - anesthesiology OT - critical OT - critical care and internal medicine education OT - interdisciplinary cooperation OT - internal medicine OT - interventional nephrology OT - interventional radiology OT - nephrology OT - procedure training COIS- The authors have declared that no competing interests exist. EDAT- 2023/10/09 06:42 MHDA- 2023/10/09 06:43 PMCR- 2023/09/07 CRDT- 2023/10/09 05:52 PHST- 2023/09/07 00:00 [accepted] PHST- 2023/10/09 06:43 [medline] PHST- 2023/10/09 06:42 [pubmed] PHST- 2023/10/09 05:52 [entrez] PHST- 2023/09/07 00:00 [pmc-release] AID - 10.7759/cureus.44851 [doi] PST - epublish SO - Cureus. 2023 Sep 7;15(9):e44851. doi: 10.7759/cureus.44851. eCollection 2023 Sep. PMID- 37802331 OWN - NLM STAT- MEDLINE DCOM- 20240914 LR - 20260326 IS - 1097-685X (Electronic) IS - 0022-5223 (Linking) VI - 168 IP - 3 DP - 2024 Sep TI - Outcomes of double-valve surgery for infective endocarditis are improving in the modern era. PG - 832-842 LID - S0022-5223(23)00898-X [pii] LID - 10.1016/j.jtcvs.2023.09.072 [doi] AB - BACKGROUND: The incidence of infective endocarditis (IE) is rapidly increasing. Contemporary outcomes following high-risk double valve surgery (DVS) for IE are not well described. METHODS: Between 2001 and 2021, 211 patients with IE underwent combined aortic and mitral valve surgery at a tertiary care referral center. Data from the Society of Thoracic Surgeons registry, including demographics, operative details, and outcomes, were collected. Risk factors for 30-day and 1-year-mortality were analyzed. Survival was analyzed using Kaplan-Meier and Cox proportional hazards modeling. RESULTS: The study cohort had a male preponderance (73%), with a median age of 56 years (interquartile range [IQR], 44 to 63 years). Forty-five patients (21%) had a history of intravenous (IV) drug abuse, 50 (24%) were on preoperative dialysis, and 50 (24%) had prosthetic valve endocarditis. Thirty-day and 1-year mortality were 14% (n = 30) and 30% (n = 61), respectively. On multivariable Cox regression adjusting for age, prosthetic valve endocarditis, postoperative intra-aortic balloon pump (IABP), history of dialysis (adjusted hazard ratio [aHR], 1.9; 95% confidence interval [CI], 1.3 to 2.9; P = .002) and IV drug abuse (aHR, 2.0; 95% CI, 1.1-3.5; P = .02) were predictive of decreased survival. Undergoing surgery after 2010 was predictive of improved survival (aHR, 0.5; 95% CI, 0.3 to 0.8; P = .006). These patients were more likely to undergo urgent/emergent surgery (83% vs 29%; P < .001) and less likely to have an aortic root abscess (40% vs 58%; P = .03) or to require the commando procedure (13% vs 33%; P = .002). CONCLUSIONS: In this large series evaluating outcomes of DVS for IE in the modern era, although the mortality risk remained elevated, improving outcomes may be associated with earlier surgical intervention before significant disease progression. Multidisciplinary evaluation for complex IE may be considered to better understand the optimal timing and repair strategy. CI - Copyright (c) 2023 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Miller, Paighton C AU - Miller PC AD - Washington University School of Medicine, St. Louis, Mo. FAU - Schulte, Linda J AU - Schulte LJ AD - Division of Cardiothoracic Surgery, Department of Surgery, Washington University School of Medicine, Barnes-Jewish Hospital, St. Louis, Mo. FAU - Marghitu, Theodore AU - Marghitu T AD - Washington University School of Medicine, St. Louis, Mo. FAU - Huang, ShengXiang AU - Huang S AD - Washington University School of Medicine, St. Louis, Mo. FAU - Kaneko, Tsuyoshi AU - Kaneko T AD - Division of Cardiothoracic Surgery, Department of Surgery, Washington University School of Medicine, Barnes-Jewish Hospital, St. Louis, Mo. FAU - Damiano, Ralph J AU - Damiano RJ AD - Division of Cardiothoracic Surgery, Department of Surgery, Washington University School of Medicine, Barnes-Jewish Hospital, St. Louis, Mo. FAU - Kachroo, Puja AU - Kachroo P AD - Division of Cardiothoracic Surgery, Department of Surgery, Washington University School of Medicine, Barnes-Jewish Hospital, St. Louis, Mo. Electronic address: puja@wustl.edu. LA - eng PT - Journal Article DEP - 20231004 PL - United States TA - J Thorac Cardiovasc Surg JT - The Journal of thoracic and cardiovascular surgery JID - 0376343 SB - IM MH - Humans MH - Male MH - Female MH - Middle Aged MH - Risk Factors MH - Treatment Outcome MH - *Mitral Valve/surgery MH - *Aortic Valve/surgery MH - *Endocarditis/surgery/mortality MH - Adult MH - Retrospective Studies MH - Heart Valve Prosthesis Implantation/adverse effects/mortality MH - Time Factors MH - Registries MH - Risk Assessment MH - Prosthesis-Related Infections/mortality/surgery/microbiology/diagnosis OTO - NOTNLM OT - aortic valve OT - double valve OT - infective endocarditis OT - mitral valve COIS- Conflict of Interest Statement Dr Kaneko reports relationships with Edwards Lifesciences, Abbott Laboratories, and Medtronic. Dr Damiano reports relationships with AtriCure, Medtronic, and Edwards Lifesciences. All other authors have no conflicts of interest to disclose. The Journal policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest. EDAT- 2023/10/07 00:42 MHDA- 2024/09/15 14:09 CRDT- 2023/10/06 19:28 PHST- 2023/05/12 00:00 [received] PHST- 2023/09/12 00:00 [revised] PHST- 2023/09/28 00:00 [accepted] PHST- 2024/09/15 14:09 [medline] PHST- 2023/10/07 00:42 [pubmed] PHST- 2023/10/06 19:28 [entrez] AID - S0022-5223(23)00898-X [pii] AID - 10.1016/j.jtcvs.2023.09.072 [doi] PST - ppublish SO - J Thorac Cardiovasc Surg. 2024 Sep;168(3):832-842. doi: 10.1016/j.jtcvs.2023.09.072. Epub 2023 Oct 4. PMID- 37801418 OWN - NLM STAT- MEDLINE DCOM- 20231009 LR - 20260127 IS - 2386-5857 (Electronic) IS - 1137-6821 (Linking) VI - 35 IP - 5 DP - 2023 Oct TI - Emergency department management of atrial fibrillation: 2023 consensus from the Spanish Society of Emergency Medicine (SEMES), the Spanish Society of Cardiology (SEC), and the Spanish Society of Thrombosis and Hemostasis (SETH). PG - 359-377 LID - 10.55633/s3me/E027.2023 [doi] AB - Atrial fibrillation (AF) is the most prevalent sustained arrhythmia managed in emergency departments, and the already high prevalence of this arrhythmia is increasing in Spain. This serious condition associated with increased mortality and morbidity has a negative impact on patient quality of life and the functioning of the health care system. The management of AF requires consideration of diverse clinical variables and a large number of possible therapeutic approaches, justifying action plans to coordinate the work of several medical specialties in the interest of providing appropriate care and optimizing resources. This consensus statement brings together recommendations for emergency department management of AF based on available evidence adapted to special circumstances. The statement was drafted by a multidisciplinary team of specialists from the Spanish Society of Emergency Medicine (SEMES), the Spanish Society of Cardiology (SEC), and the Spanish Society of Thrombosis and Hemostasis (SETH). Strategies for stroke prophylaxis, measures to bring heart rate and heart rhythm under control, and related diagnostic and logistic issues are discussed in detail. FAU - Martin, Alfonso AU - Martin A AD - Grupo de Arritmias Cardiacas y Sincope, Sociedad Espanola de Medicina de Urgencias y Emergencias. Servicio de Urgencias, Hospital Universitario de Mostoles, Madrid, Espana. FAU - Calvo, David AU - Calvo D AD - Asociacion del Ritmo Cardiaco, Sociedad Espanola de Cardiologia. Servicio de Cardiologia, Instituto Cardiovascular, Hospital Clinico San Carlos, Madrid, Espana. FAU - Llamas, Pilar AU - Llamas P AD - Sociedad Espanola de Trombosis y Hemostasia. Servicio de Hematologia, Fundacion Jimenez Diaz, Madrid, Espana. FAU - Roldan, Vanessa AU - Roldan V AD - Sociedad Espanola de Trombosis y Hemostasia. Servicio de Hematologia, Hospital Universitario Morales Messeguer, Murcia, Espana. FAU - Cozar, Rocio AU - Cozar R AD - Asociacion del Ritmo Cardiaco, Sociedad Espanola de Cardiologia. Servicio de Cardiologia, Hospital Universitario Virgen Macarena, Sevilla, Espana. FAU - Fernandez de Simon, Amparo AU - Fernandez de Simon A AD - Grupo de Arritmias Cardiacas y Sincope, Sociedad Espanola de Medicina de Urgencias y Emergencias. Servicio de Urgencias, Hospital Universitario Virgen del Rocio, Sevilla, Espana. FAU - Avila, Pablo AU - Avila P AD - Servicio de Urgencias, Hospital Universitario de Mostoles, Madrid, Espana. Servicio de Cardiologia, Hospital Universitario Gregorio Maranon, Madrid, Espana. FAU - Del Arco, Carmen AU - Del Arco C AD - Grupo de Arritmias Cardiacas y Sincope, Sociedad Espanola de Medicina de Urgencias y Emergencias. Servicio de Urgencias, Hospital Universitario de la Princesa, Madrid, Espana. FAU - Arbelo, Elena AU - Arbelo E AD - Servicio de Urgencias, Hospital Universitario de Mostoles, Madrid, Espana. Seccion de Arritmias, Servicio de Cardiologia. IDIBAPS, Hospital Clinic, Barcelona. CIBERCV. ERN GUARD-Heart, Espana. FAU - Pinera, Pascual AU - Pinera P AD - Grupo de Arritmias Cardiacas y Sincope, Sociedad Espanola de Medicina de Urgencias y Emergencias. Servicio de Urgencias, Hospital Universitario Reina Sofia, Murcia, Espana. FAU - Coll-Vinent, Blanca AU - Coll-Vinent B AD - Grupo de Arritmias Cardiacas y Sincope, Sociedad Espanola de Medicina de Urgencias y Emergencias. Area de Urgencias. Grup de Recerca "Urgencies: processos i patologies". IDIBAPS. Unitat de Fibrillacio Auricular (UFA). Hospital Clinic, Barcelona, Espana. LA - eng LA - spa PT - Consensus Statement PT - Journal Article TT - Manejo de la fibrilacion auricular en los servicios de urgencias hospitalarios: actualizacion a 2023 del consenso de la Sociedad Espanola de Medicina de Urgencias (SEMES), la Sociedad Espanola de Cardiologia (SEC) y la Sociedad Espanola de Trombosis y Hemostasia (SETH). PL - Spain TA - Emergencias JT - Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias JID - 9805751 SB - IM EIN - Emergencias. 2023 Dec;35(6):479-480. PMID: 38116980 EIN - Emergencias. 2024 Jan;36(1):80. doi: 10.55633/s3me/005.2024. PMID: 38318748 MH - Humans MH - *Workplace Violence MH - Quality of Life MH - *Atrial Fibrillation/drug therapy MH - Emergency Service, Hospital MH - Cluster Analysis MH - Health Personnel MH - Hospitals OTO - NOTNLM OT - Antiarrhythmia agents. OT - Anticoagulants. OT - Atrial fibrillation. OT - Cardioversion. OT - Control de frecuencia. OT - Control del ritmo. OT - Electric countershock. OT - Emergency health services. OT - Fibrilacion auricular. OT - Farmacos antiarritmicos. OT - Heart rate control. OT - Heart rhythm control. OT - Servicios de Urgencias. OT - Thromboembolism. OT - Tromboembolia, anticoagulacion. EDAT- 2023/10/06 18:42 MHDA- 2023/10/09 06:42 CRDT- 2023/10/06 13:03 PHST- 2023/10/09 06:42 [medline] PHST- 2023/10/06 18:42 [pubmed] PHST- 2023/10/06 13:03 [entrez] AID - 10.55633/s3me/E027.2023 [doi] PST - ppublish SO - Emergencias. 2023 Oct;35(5):359-377. doi: 10.55633/s3me/E027.2023. PMID- 37800338 OWN - NLM STAT- MEDLINE DCOM- 20231220 LR - 20250723 IS - 1528-1140 (Electronic) IS - 0003-4932 (Print) IS - 0003-4932 (Linking) VI - 279 IP - 1 DP - 2024 Jan 1 TI - Management of Pericardial Effusion in Patients With Solid Tumor: An Algorithmic, Multidisciplinary Approach Results in Reduced Mortality After Paradoxical Hemodynamic Instability. PG - 147-153 LID - 10.1097/SLA.0000000000006114 [doi] AB - OBJECTIVE: This study compared outcomes in patients with solid tumor treated for pericardial effusion with surgical drainage versus interventional radiology (IR) percutaneous drainage and compared incidence of paradoxical hemodynamic instability (PHI) between cohorts. BACKGROUND: Patients with advanced-stage solid malignancies may develop large pericardial effusions requiring intervention. PHI is a fatal and underreported complication that occurs following pericardial effusion drainage. METHODS: Clinical characteristics and outcomes were compared between patients with solid tumors who underwent s urgical drainage or IR percutaneous drainage for pericardial effusion from 2010 to 2020. RESULTS: Among 447 patients, 243 were treated with surgical drainage, of which 27 (11%) developed PHI, compared with 7 of 204 patients (3%) who were treated with IR percutaneous drainage ( P =0.002); overall incidence of PHI decreased during the study period. Rates of reintervention (30-day: 1% vs 4%; 90-day: 4% vs 6%, P =0.7) and mortality (30-day: 21% vs 17%, P =0.3; 90-day: 39% vs 37%, P =0.7) were not different between patients treated with surgical drainage and IR percutaneous drainage. For both interventions, OS was shorter among patients with PHI than among patients without PHI (surgical drainage, median [95% confidence interval] OS, 0.89 mo [0.33-2.1] vs 6.5 mo [5.0-8.9], P <0.001; IR percutaneous drainage, 3.7 mo [0.23-6.8] vs 5.0 mo [4.0-8.1], P =0.044). CONCLUSIONS: With a coordinated multidisciplinary approach focusing on prompt clinical and echocardiographic evaluation, triage with bias toward IR percutaneous drainage than surgical drainage and postintervention intensive care resulted in lower incidence of PHI and improved outcomes. CI - Copyright (c) 2023 Wolters Kluwer Health, Inc. All rights reserved. FAU - Choe, Jennie K AU - Choe JK AD - Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Byun, Alexander J AU - Byun AJ AD - Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Robinson, Eric AU - Robinson E AD - Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Drake, Lauren AU - Drake L AD - Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Tan, Kay See AU - Tan KS AD - Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - McAleer, Eileen P AU - McAleer EP AD - Cardiology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Schaffer, Wendy L AU - Schaffer WL AD - Cardiology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Liu, Jennifer E AU - Liu JE AD - Cardiology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Chen, Leon L AU - Chen LL AD - Department of Anesthesiology and Critical Care Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Buchholz, Tara AU - Buchholz T AD - Department of Anesthesiology and Critical Care Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Yohannes-Tomicich, Joanna AU - Yohannes-Tomicich J AD - Department of Anesthesiology and Critical Care Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Yarmohammadi, Hooman AU - Yarmohammadi H AD - Department of Interventional Radiology, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Ziv, Etay AU - Ziv E AD - Department of Interventional Radiology, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Solomon, Stephen B AU - Solomon SB AD - Department of Interventional Radiology, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Huang, James AU - Huang J AD - Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Park, Bernard J AU - Park BJ AD - Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Jones, David R AU - Jones DR AD - Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Adusumilli, Prasad S AU - Adusumilli PS AD - Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. AD - Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY. LA - eng GR - T32 CA009501/CA/NCI NIH HHS/United States GR - R01 CA235667/CA/NCI NIH HHS/United States GR - P30 CA008748/CA/NCI NIH HHS/United States GR - R01 CA236615/CA/NCI NIH HHS/United States GR - R01 CA240472/CA/NCI NIH HHS/United States GR - U01 CA214195/CA/NCI NIH HHS/United States GR - R01 CA217169/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20231006 PL - United States TA - Ann Surg JT - Annals of surgery JID - 0372354 SB - IM MH - Humans MH - *Pericardial Effusion/etiology/surgery MH - *Neoplasms/complications MH - *Thoracic Surgical Procedures MH - *Vascular Diseases/etiology MH - Drainage/methods MH - Retrospective Studies MH - Hemodynamics PMC - PMC11010720 MID - NIHMS1934669 COIS- J.E.L. serves as a consultant for Caption Health and on the Data and Safety Monitoring Board of Caelum Biosciences. Her research is supported by Johnson and Johnson. H.Y. serves as an advisory board member for AstraZeneca and Guerbet LLC, and he receives grant support from Guerbet LLC and the Thompson Family Foundation. E.Z. has research grants from AACR, NETRF, NANETS, Druckenmiller, MSK, SIR, RSNA, Ethicon, and Novartis. S.B.S. serves as a consultant to GE Healthcare and XACT Robotics. B.J.P. has served as a proctor for Intuitive Surgical and a consultant for COTA. D.R.J. serves as a consultant for AstraZeneca and on a Clinical Trial Steering Committee for Merck. P.S.A. declares research funding from ATARA Biotherapeutics; Scientific Advisory Board Member and Consultant for ATARA Biotherapeutics, Bayer, Bio4T2, Carisma Therapeutics, Imugene, ImmPactBio, Johnston & Johnston, Orion pharma, Outpace Bio; Patents, royalties and intellectual property on mesothelin-targeted CAR and other T-cell therapies, which have been licensed to ATARA Biotherapeutics, issued patent method for detection of cancer cells using virus, and pending patent applications on PD-1 dominant negative receptor, wireless pulse-oximetry device, and on an ex vivo malignant pleural effusion culture system. Memorial Sloan Kettering Cancer Center has licensed intellectual property related to mesothelin-targeted CARs and T-cell therapies to ATARA Biotherapeutics and has associated financial interests. The remaining authors report no conflicts of interest. EDAT- 2023/10/06 06:43 MHDA- 2023/12/20 06:42 PMCR- 2025/01/01 CRDT- 2023/10/06 05:26 PHST- 2023/12/20 06:42 [medline] PHST- 2023/10/06 06:43 [pubmed] PHST- 2023/10/06 05:26 [entrez] PHST- 2025/01/01 00:00 [pmc-release] AID - 00000658-202401000-00022 [pii] AID - 10.1097/SLA.0000000000006114 [doi] PST - ppublish SO - Ann Surg. 2024 Jan 1;279(1):147-153. doi: 10.1097/SLA.0000000000006114. Epub 2023 Oct 6. PMID- 37799221 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231026 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 15 IP - 9 DP - 2023 Sep TI - Critical Insights Into the Management of Postpartum Left Main Spontaneous Coronary Artery Dissection: Current Strategies and Future Directions. PG - e44622 LID - 10.7759/cureus.44622 [doi] LID - e44622 AB - This review article delves into the multifaceted realm of postpartum left main spontaneous coronary artery dissection (PLMSCAD), an infrequent yet critical condition affecting women during the postpartum period. Through a comprehensive exploration of its pathophysiology, clinical presentation, diagnosis, management strategies, and future directions, this review provides a holistic understanding of PLMSCAD's complexities. The article highlights challenges in diagnosis due to overlapping symptoms and underscores the significance of prompt recognition and tailored interventions. Current management strategies, encompassing medical and interventional approaches, are analysed in the context of their short-term and long-term impact on patient outcomes. Ethical considerations and the role of patient education and support networks are explored, shedding light on the broader psychosocial dimensions of PLMSCAD management. As emerging research reveals insights into genetic influences, hormonal dynamics, and the prognosis of affected individuals, this review emphasises the necessity of collaborative research endeavours and data sharing to enhance our understanding and guide future strategies. Ultimately, this review underscores the urgency of addressing the unique needs of women experiencing PLMSCAD, urging ongoing research, multidisciplinary collaboration, and a patient-centred approach to optimise maternal health outcomes and well-being. CI - Copyright (c) 2023, Rathi et al. FAU - Rathi, Arya C AU - Rathi AC AD - Community Medicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Wardha, IND. FAU - Nagtode, Nikhilesh AU - Nagtode N AD - Community Medicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Wardha, IND. FAU - Chandra, Vaibhav AU - Chandra V AD - Community Medicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Wardha, IND. FAU - Pathade, Aniket G AU - Pathade AG AD - Research and Development, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Wardha, IND. FAU - Yelne, Seema AU - Yelne S AD - Nursing, Shalinitai Meghe College of Nursing, Datta Meghe Institute of Higher Education and Research, Wardha, IND. LA - eng PT - Journal Article PT - Review DEP - 20230903 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC10548014 OTO - NOTNLM OT - collaborative research OT - diagnosis challenges OT - left main artery OT - management strategies OT - maternal health OT - multidisciplinary approach OT - postpartum OT - spontaneous coronary artery dissection COIS- The authors have declared that no competing interests exist. EDAT- 2023/10/06 06:43 MHDA- 2023/10/06 06:44 PMCR- 2023/09/03 CRDT- 2023/10/06 03:46 PHST- 2023/08/12 00:00 [received] PHST- 2023/09/03 00:00 [accepted] PHST- 2023/10/06 06:44 [medline] PHST- 2023/10/06 06:43 [pubmed] PHST- 2023/10/06 03:46 [entrez] PHST- 2023/09/03 00:00 [pmc-release] AID - 10.7759/cureus.44622 [doi] PST - epublish SO - Cureus. 2023 Sep 3;15(9):e44622. doi: 10.7759/cureus.44622. eCollection 2023 Sep. PMID- 37795380 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231031 IS - 1178-2390 (Print) IS - 1178-2390 (Electronic) IS - 1178-2390 (Linking) VI - 16 DP - 2023 TI - A Dentist-Led Oral Care System Can Prevent Stroke-Associated Pneumonia: The Effects of Early Intervention by Dental Team. PG - 2937-2945 LID - 10.2147/JMDH.S415572 [doi] AB - BACKGROUND: Our facility's dental team consists of a full-time dentists and dental hygienists who work exclusively in the wards to implement best practices in oral healthcare. We executed the dental care system (DCS) that includes lectures and practical training for nurses conducted by dentists and dental hygienists, the introduction to oral assessment, standardization of oral care procedures, a process for nurses to request the dental team, and early bedside oral screening conducted by the dental team. This study investigated the DCS's effects on the incidence of stroke-associated pneumonia (SAP). METHODS: This single-center retrospective cohort study included 2,771 acute stroke patients who were newly hospitalized between April 1, 2012, and March 31, 2020. The 8-year period was divided into four phases at two-year intervals as follows: Pre (N=632), Post-1 (N=642), Post-2 (N=716), and Post-3 (N=781). Pre was prior to DCS practice. Post-1 was an early introduction to DCS. Post-2 simplified dental team requests from nurses, and Post-3 added bedside oral screening within 72 hours of admission by the dental team. Statistical analysis was performed using the Cochran-Armitage trend test, followed by multivariate logistic regression. RESULTS: A decrease in SAP rates was observed across the four groups (P<0.0001). Logistic regression analysis revealed a significant difference for respiratory disease (odds ratio 7.74, 95% confidence interval 5.49-10.90), hypertension (2.28, 1.39-3.73), cardiac failure (1.72, 1.04-2.85), and diabetes (1.59, 1.11-2.26), 3-digit code on the Japan coma scale (3.57, 2.53-5.05 [reference /=90 years (2.34, 1.15-4.77 [reference 18-59 years]), male (1.86, 1.31-2.67), and the Post-1 (0.49, 0.31-0.76 [reference Pre]), Post-2 (0.38, 0.25-0.61 [reference Pre]), and Post-3 (0.24, 0.15-0.40 [reference Pre]) periods. CONCLUSION: The suppression of SAP is effectively achieved through early intervention and education of nurses by dental professionals. CI - (c) 2023 Ozaki et al. FAU - Ozaki, Kenichiro AU - Ozaki K AUID- ORCID: 0000-0001-9293-1248 AD - Department of Physical Medicine and Rehabilitation, Ashikaga Red Cross Hospital, Ashikaga, Tochigi, Japan. AD - Dysphagia Rehabilitation, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Bunkyo, Tokyo, Japan. FAU - Tohara, Haruka AU - Tohara H AUID- ORCID: 0000-0001-5514-6419 AD - Dysphagia Rehabilitation, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Bunkyo, Tokyo, Japan. FAU - Baba, Mikoto AU - Baba M AD - Department of Physical Medicine and Rehabilitation, Ashikaga Red Cross Hospital, Ashikaga, Tochigi, Japan. FAU - Teranaka, Satoshi AU - Teranaka S AD - Department of Physical Medicine and Rehabilitation, Ashikaga Red Cross Hospital, Ashikaga, Tochigi, Japan. AD - Gerodontology and Oral Rehabilitation, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Bunkyo, Tokyo, Japan. FAU - Kawai, Yosuke AU - Kawai Y AD - Department of Physical Medicine and Rehabilitation, Ashikaga Red Cross Hospital, Ashikaga, Tochigi, Japan. AD - Gerodontology and Oral Rehabilitation, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Bunkyo, Tokyo, Japan. FAU - Komatsumoto, Satoru AU - Komatsumoto S AD - Ashikaga Red Cross Hospital, Ashikaga, Tochigi, Japan. AD - Fujita Health University, Toyoake, Aichi, Japan. LA - eng PT - Journal Article DEP - 20230929 PL - New Zealand TA - J Multidiscip Healthc JT - Journal of multidisciplinary healthcare JID - 101512691 PMC - PMC10546933 OTO - NOTNLM OT - acute stroke OT - hospital dental services OT - hospital dentistry OT - oral care OT - oral health management OT - special care dentistry OT - stroke-associated pneumonia OT - team approach COIS- The authors report no conflicts of interest in this work. EDAT- 2023/10/05 06:43 MHDA- 2023/10/05 06:44 PMCR- 2023/09/29 CRDT- 2023/10/05 04:10 PHST- 2023/04/21 00:00 [received] PHST- 2023/08/07 00:00 [accepted] PHST- 2023/10/05 06:44 [medline] PHST- 2023/10/05 06:43 [pubmed] PHST- 2023/10/05 04:10 [entrez] PHST- 2023/09/29 00:00 [pmc-release] AID - 415572 [pii] AID - 10.2147/JMDH.S415572 [doi] PST - epublish SO - J Multidiscip Healthc. 2023 Sep 29;16:2937-2945. doi: 10.2147/JMDH.S415572. eCollection 2023. PMID- 37790845 OWN - NLM STAT- MEDLINE DCOM- 20231005 LR - 20231005 IS - 1449-1907 (Electronic) IS - 1449-1907 (Linking) VI - 20 IP - 11 DP - 2023 TI - 22q11.2 Deletion Syndrome in Taiwan: Clinical Presentation and Immune System Status of Patients. PG - 1377-1385 LID - 10.7150/ijms.86773 [doi] AB - Background: 22q11.2 deletion syndrome (22q11.2DS) is a microdeletion syndrome exhibiting significant clinical phenotype variability. This study aimed to investigate the clinical features, immune profiles, and cognitive abilities of 22q11.2DS patients receiving treatment at MacKay Memorial Hospital in Taipei, Taiwan. Methods: This is a cross-sectional analysis between January 2001 and December 2022. We recruited 27 patients with 22q11.2DS using fluorescence in situ hybridization (FISH), multiplex ligation-dependent probe amplification (MLPA) and array comparative genomic hybridization (aCGH). Our evaluation included patient history, physical examination, laboratory analysis, and cardiac and cognitive assessment. Results: We included 27 patients with 22q11.2DS, 7 (25.9%) of whom were female. The median age of the patients was 17.9 yr. Ninety-three percent of the patients exhibited the characteristic facial features associated with the syndrome. A family history of 22q11.2DS was found in 11.1% of the patients. Furthermore, 74.1% of the patients had a congenital heart defect, the most common of which was tetralogy of Fallot (40.7%). Hypocalcemia was observed in 40.7% of the patients. A low T-cell count was observed in 66.7% of the patients, whereas 18.5% had low immunoglobulin levels. Cognitive assessments revealed that four out of six evaluated patients (66.7%) had an intellectual disability, as evidenced by intellectual quotient scores less than 70. The remaining two patients (33.3%) had a borderline intellectual function. Conclusion: Tetralogy of Fallot, hypocalcemia, immunologic defects, and cognitive impairment were common among our patients. To address the potential multisystem involvement, we recommend that all affected individuals undergo a comprehensive evaluation by a multidisciplinary care team. CI - (c) The author(s). FAU - Lee, Chung-Lin AU - Lee CL AD - Department of Pediatrics, MacKay Memorial Hospital, Taipei, Taiwan. AD - Institute of Clinical Medicine, National Yang-Ming Chiao-Tung University, Taipei, Taiwan. AD - Department of Rare Disease Center, MacKay Memorial Hospital, Taipei, Taiwan. AD - Department of Medicine, Mackay Medical College, New Taipei City, Taiwan. AD - Mackay Junior College of Medicine, Nursing, and Management, Taipei, Taiwan. FAU - Lin, Shan-Miao AU - Lin SM AD - Department of Pediatrics, MacKay Memorial Hospital, Taipei, Taiwan. FAU - Chen, Ming-Ren AU - Chen MR AD - Department of Pediatrics, MacKay Memorial Hospital, Taipei, Taiwan. FAU - Chuang, Chih-Kuang AU - Chuang CK AD - Division of Genetics and Metabolism, Department of Medical Research, MacKay Memorial Hospital, Taipei, Taiwan. AD - College of Medicine, Fu-Jen Catholic University, Taipei, Taiwan. FAU - Chiu, Huei-Ching AU - Chiu HC AD - Department of Pediatrics, MacKay Memorial Hospital, Taipei, Taiwan. FAU - Tu, Yuan-Rong AU - Tu YR AD - Division of Genetics and Metabolism, Department of Medical Research, MacKay Memorial Hospital, Taipei, Taiwan. FAU - Lo, Yun-Ting AU - Lo YT AD - Department of Rare Disease Center, MacKay Memorial Hospital, Taipei, Taiwan. FAU - Chang, Ya-Hui AU - Chang YH AD - Department of Pediatrics, MacKay Memorial Hospital, Taipei, Taiwan. AD - Department of Rare Disease Center, MacKay Memorial Hospital, Taipei, Taiwan. FAU - Lin, Hsiang-Yu AU - Lin HY AD - Department of Pediatrics, MacKay Memorial Hospital, Taipei, Taiwan. AD - Department of Rare Disease Center, MacKay Memorial Hospital, Taipei, Taiwan. AD - Department of Medicine, Mackay Medical College, New Taipei City, Taiwan. AD - Mackay Junior College of Medicine, Nursing, and Management, Taipei, Taiwan. AD - Division of Genetics and Metabolism, Department of Medical Research, MacKay Memorial Hospital, Taipei, Taiwan. AD - Department of Medical Research, China Medical University Hospital, China Medical University, Taichung, Taiwan. FAU - Lin, Shuan-Pei AU - Lin SP AD - Department of Pediatrics, MacKay Memorial Hospital, Taipei, Taiwan. AD - Department of Rare Disease Center, MacKay Memorial Hospital, Taipei, Taiwan. AD - Department of Medicine, Mackay Medical College, New Taipei City, Taiwan. AD - Division of Genetics and Metabolism, Department of Medical Research, MacKay Memorial Hospital, Taipei, Taiwan. AD - Department of Infant and Child Care, National Taipei University of Nursing and Health Sciences, Taipei, Taiwan. LA - eng PT - Journal Article DEP - 20230904 PL - Australia TA - Int J Med Sci JT - International journal of medical sciences JID - 101213954 SB - IM MH - Humans MH - Female MH - Male MH - *DiGeorge Syndrome/genetics/diagnosis MH - *Tetralogy of Fallot/genetics MH - *Hypocalcemia/genetics MH - In Situ Hybridization, Fluorescence MH - Taiwan/epidemiology MH - Cross-Sectional Studies MH - Comparative Genomic Hybridization MH - *Heart Defects, Congenital/genetics MH - Immune System MH - Chromosome Deletion PMC - PMC10542185 OTO - NOTNLM OT - 22q11.2 deletion syndrome OT - T-cell defect OT - Taiwan OT - congenital heart disease OT - intellectual disability COIS- Competing Interests: The authors have declared that no competing interest exists. EDAT- 2023/10/04 06:44 MHDA- 2023/10/05 06:43 PMCR- 2023/01/01 CRDT- 2023/10/04 04:12 PHST- 2023/06/03 00:00 [received] PHST- 2023/08/23 00:00 [accepted] PHST- 2023/10/05 06:43 [medline] PHST- 2023/10/04 06:44 [pubmed] PHST- 2023/10/04 04:12 [entrez] PHST- 2023/01/01 00:00 [pmc-release] AID - ijmsv20p1377 [pii] AID - 10.7150/ijms.86773 [doi] PST - epublish SO - Int J Med Sci. 2023 Sep 4;20(11):1377-1385. doi: 10.7150/ijms.86773. eCollection 2023. PMID- 37789149 OWN - NLM STAT- MEDLINE DCOM- 20240529 LR - 20261010 IS - 1615-6692 (Electronic) IS - 0340-9937 (Linking) VI - 49 IP - 3 DP - 2024 Jun TI - Prognostic value of extended cardiac risk assessment before elective open abdominal aortic surgery. PG - 210-218 LID - 10.1007/s00059-023-05209-y [doi] AB - BACKGROUND: Major vascular surgery is associated with a high perioperative risk and significant mortality. Despite advances in risk stratification, monitoring, and management of perioperative complications, cardiac complications are still common. Stress echocardiography is well established in coronary artery disease diagnostics; however, its prognostic value before high-risk aortic surgery is unknown. This prospective, single-center study compared the outcome of patients undergoing extended cardiac risk assessment before open abdominal aortic surgery with the outcome of patients who had received standard preoperative assessment. METHODS: The study included patients undergoing elective open abdominal aortic surgery. Patients who underwent standard preoperative assessment before the start of a dedicated protocol were compared with patients who had extended cardiac risk assessment, including dobutamine stress echocardiography, as part of a stepwise interdisciplinary cardiovascular team approach. The combined primary endpoint was cardiovascular death, myocardial infarction, emergency coronary revascularization, and life-threatening arrhythmia within 30 days. The secondary endpoint was acute renal failure and severe bleeding. RESULTS: In total, 77 patients (mean age 68.1 +/- 8.1 years, 70% male) were included: 39 underwent standard and 38 underwent cardiac risk assessment. The combined primary endpoint was reached significantly more often in patients before than after implementation of the extended cardiac stratification procedure (15% vs. 0%, p = 0.025). The combined secondary endpoint did not differ between the groups. CONCLUSIONS: Patients with extended cardiac risk assessment undergoing elective open abdominal aortic surgery had better 30-day outcomes than did those who had standard preoperative assessment. CI - (c) 2023. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature. FAU - Sigl, Martin AU - Sigl M AUID- ORCID: 0000-0001-6162-6304 AD - Department of Cardiology, Angiology, Haemostaseology and Medical Intensive Care, University Medical Centre Mannheim (UMM), Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany. martin.sigl@umm.de. FAU - Baumann, Stefan AU - Baumann S AD - Department of Cardiology, Angiology, Haemostaseology and Medical Intensive Care, University Medical Centre Mannheim (UMM), Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany. FAU - Konemann, Ann-Sophie AU - Konemann AS AD - Department of Cardiology, Angiology, Haemostaseology and Medical Intensive Care, University Medical Centre Mannheim (UMM), Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany. FAU - Keese, Michael AU - Keese M AD - Division of Vascular Surgery, Department of Surgery, University Medical Center Mannheim (UMM), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. AD - European Center for AngioScience (ECAS) and German Center for Cardiovascular Research (DZHK) partner site Heidelberg/Mannheim, Mannheim, Germany. FAU - Schwenke, Kay AU - Schwenke K AD - Division of Vascular Surgery, Department of Surgery, University Medical Center Mannheim (UMM), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. FAU - Gerken, Andreas L H AU - Gerken ALH AD - Division of Vascular Surgery, Department of Surgery, University Medical Center Mannheim (UMM), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. FAU - Durschmied, Daniel AU - Durschmied D AD - Department of Cardiology, Angiology, Haemostaseology and Medical Intensive Care, University Medical Centre Mannheim (UMM), Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany. AD - European Center for AngioScience (ECAS) and German Center for Cardiovascular Research (DZHK) partner site Heidelberg/Mannheim, Mannheim, Germany. FAU - Rosenkaimer, Stephanie AU - Rosenkaimer S AD - Department of Cardiology, Angiology, Haemostaseology and Medical Intensive Care, University Medical Centre Mannheim (UMM), Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany. LA - eng PT - Journal Article TT - Prognostischer Wert der erweiterten kardialen Risikobeurteilung vor elektiver offener Bauchaortenchirurgie. DEP - 20231003 PL - Germany TA - Herz JT - Herz JID - 7801231 SB - IM MH - Humans MH - Male MH - Risk Assessment MH - Female MH - Aged MH - Prognosis MH - *Elective Surgical Procedures/mortality MH - *Aorta, Abdominal/surgery/diagnostic imaging MH - Germany/epidemiology MH - Survival Rate MH - Postoperative Complications/mortality MH - Preoperative Care/methods MH - Reproducibility of Results MH - Treatment Outcome MH - Vascular Surgical Procedures/adverse effects MH - Comorbidity MH - Sensitivity and Specificity MH - Risk Factors MH - Prevalence OTO - NOTNLM OT - Dobutamine stress echocardiography OT - Major vascular surgery OT - Perioperative cardiac complications OT - Postoperative myocardial infarction OT - Preoperative risk stratification EDAT- 2023/10/04 00:42 MHDA- 2024/05/29 12:43 CRDT- 2023/10/03 23:33 PHST- 2023/05/01 00:00 [received] PHST- 2023/09/01 00:00 [accepted] PHST- 2023/07/10 00:00 [revised] PHST- 2024/05/29 12:43 [medline] PHST- 2023/10/04 00:42 [pubmed] PHST- 2023/10/03 23:33 [entrez] AID - 10.1007/s00059-023-05209-y [pii] AID - 10.1007/s00059-023-05209-y [doi] PST - ppublish SO - Herz. 2024 Jun;49(3):210-218. doi: 10.1007/s00059-023-05209-y. Epub 2023 Oct 3. PMID- 37788169 OWN - NLM STAT- MEDLINE DCOM- 20240130 LR - 20260402 IS - 1540-8175 (Electronic) IS - 0742-2822 (Linking) VI - 41 IP - 1 DP - 2024 Jan TI - "Piggyback Pigtails": Simplifying secondary transradial access for TAVR. PG - e15700 LID - 10.1111/echo.15700 [doi] AB - Minimalist approaches have evolved for TAVR over the last years with impact on in-hospital stay and patient safety. As part of this concept, transradial secondary arterial access is capable of reducing vascular and bleeding complications. Yet, steering of the marker pigtail catheter in the descending aorta might by fluoroscopic imaging sometimes be challenging. In our manuscript, we present a very simple "piggyback" technique, simplifying management of transradial secondary access in transfemoral TAVR. CI - (c) 2023 The Authors. Echocardiography published by Wiley Periodicals LLC. FAU - Ahoopai, Majid AU - Ahoopai M AD - Department of Cardiology, Cardiology I, University Medical Center Mainz of the Johannes Gutenberg-University Mainz, Mainz, Germany. FAU - Geyer, Martin AU - Geyer M AUID- ORCID: 0000-0002-9935-8293 AD - Department of Cardiology, Cardiology I, University Medical Center Mainz of the Johannes Gutenberg-University Mainz, Mainz, Germany. FAU - Tamm, Alexander R AU - Tamm AR AUID- ORCID: 0000-0003-2017-094X AD - Department of Cardiology, Cardiology I, University Medical Center Mainz of the Johannes Gutenberg-University Mainz, Mainz, Germany. FAU - Gossler, Theresa AU - Gossler T AD - Department of Cardiology, Cardiology I, University Medical Center Mainz of the Johannes Gutenberg-University Mainz, Mainz, Germany. FAU - Oberhoffer, Martin AU - Oberhoffer M AD - Department for Cardiac and Vascular Surgery, University Medical Center Mainz of the Johannes Gutenberg-University Mainz, Mainz, Germany. FAU - Masseli, Franz AU - Masseli F AD - Department for Cardiac and Vascular Surgery, University Medical Center Mainz of the Johannes Gutenberg-University Mainz, Mainz, Germany. FAU - Munzel, Thomas AU - Munzel T AD - Department of Cardiology, Cardiology I, University Medical Center Mainz of the Johannes Gutenberg-University Mainz, Mainz, Germany. FAU - von Bardeleben, Ralph Stephan AU - von Bardeleben RS AUID- ORCID: 0000-0002-1356-0037 AD - Department of Cardiology, Cardiology I, University Medical Center Mainz of the Johannes Gutenberg-University Mainz, Mainz, Germany. LA - eng PT - Journal Article DEP - 20231003 PL - United States TA - Echocardiography JT - Echocardiography (Mount Kisco, N.Y.) JID - 8511187 SB - IM MH - Humans MH - *Transcatheter Aortic Valve Replacement/methods MH - *Aortic Valve Stenosis/diagnostic imaging/surgery MH - Retrospective Studies MH - Treatment Outcome MH - Femoral Artery/diagnostic imaging MH - Risk Factors MH - Aortic Valve/surgery OTO - NOTNLM OT - TAVI OT - access site complications OT - aortic stenosis OT - femoral access OT - multidisciplinary heart team EDAT- 2023/10/03 18:43 MHDA- 2024/01/30 12:43 CRDT- 2023/10/03 12:43 PHST- 2023/09/01 00:00 [received] PHST- 2023/09/20 00:00 [accepted] PHST- 2024/01/30 12:43 [medline] PHST- 2023/10/03 18:43 [pubmed] PHST- 2023/10/03 12:43 [entrez] AID - 10.1111/echo.15700 [doi] PST - ppublish SO - Echocardiography. 2024 Jan;41(1):e15700. doi: 10.1111/echo.15700. Epub 2023 Oct 3. PMID- 37786510 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231113 IS - 2297-055X (Print) IS - 2297-055X (Electronic) IS - 2297-055X (Linking) VI - 10 DP - 2023 TI - Cancer survivorship at heart: a multidisciplinary cardio-oncology roadmap for healthcare professionals. PG - 1223660 LID - 10.3389/fcvm.2023.1223660 [doi] LID - 1223660 AB - In cancer, a patient is considered a survivor from the time of initial diagnosis until the end of life. With improvements in early diagnosis and treatment, the number of cancer survivors (CS) has grown considerably and includes: (1) Patients cured and free from cancer who may be at risk of late-onset cancer therapy-related cardiovascular toxicity (CTR-CVT); (2) Patients with long-term control of not-curable cancers in whom CTR-CVT may need to be addressed. This paper highlights the importance of the cancer care continuum, of a patient-centered approach and of a prevention-oriented policy. The ultimate goal is a personalized care of CS, achievable only through a multidisciplinary-guided survivorship care plan, one that replaces the fragmented management of current healthcare systems. Collaboration between oncologists and cardiologists is the pillar of a framework in which primary care providers and other specialists must be engaged and in which familial, social and environmental factors are also taken into account. CI - (c) 2023 Bisceglia, Canale, Silvestris, Gallucci, Camerini, Inno, Camilli, Turazza, Russo, Paccone, Mistrulli, De Luca, Di Fusco, Tarantini, Luca, Oliva, Moreo, Maurea, Quagliariello, Ricciardi, Lestuzzi, Fiscella, Parrini, Racanelli, Russo, Incorvaia, Calabro, Curigliano, Cinieri, Gulizia, Gabrielli, Oliva and Colivicchi. FAU - Bisceglia, Irma AU - Bisceglia I AD - Integrated Cardiology Services, Cardio-Thoracic-Vascular Department, Azienda Ospedaliera San Camillo Forlanini, Rome, Italy. FAU - Canale, Maria Laura AU - Canale ML AD - Division of Cardiology, Ospedale Versilia, Azienda Usl Toscana Nord Ovest, Lido di Camaiore, Italy. FAU - Silvestris, Nicola AU - Silvestris N AD - Unit of Medical Oncology, Department of Human Pathology in Adulthood and Childhood Gaetano Barresi, University of Messina, Messina, Italy. FAU - Gallucci, Giuseppina AU - Gallucci G AD - Cardio-oncology Unit, Department of OncoHaematology, IRCCS Referral Cancer Center of Basilicata, Rionero in Vulture (PZ), Italy. FAU - Camerini, Andrea AU - Camerini A AD - Department of Medical Oncology, Ospedale Versilia, Azienda Usl Toscana Nord Ovest, Lido di Camaiore, Italy. FAU - Inno, Alessandro AU - Inno A AD - Department of Oncology, Sacro Cuore Don Calabria Hospital (IRCCS), Negrar, Italy. FAU - Camilli, Massimiliano AU - Camilli M AD - Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart and Department of Cardiovascular Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. FAU - Turazza, Fabio Maria AU - Turazza FM AD - Cardiology Department, National Cancer Institute Foundation (IRCCS), Milan, Italy. FAU - Russo, Giulia AU - Russo G AD - SC Patologie Cardiovascolari, Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), Trieste, Italy. FAU - Paccone, Andrea AU - Paccone A AD - Department of Cardiology, G. Pascale National Cancer Institute Foundation (IRCCS), Naples, Italy. FAU - Mistrulli, Raffaella AU - Mistrulli R AD - Cardiology Unit, Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sapienza University of Rome, Rome, Lazio, Italy. FAU - De Luca, Leonardo AU - De Luca L AD - Division of Cardiology, San Camillo-Forlanini Hospital, Rome, Italy. FAU - Di Fusco, Stefania Angela AU - Di Fusco SA AD - Clinical and Rehabilitation Cardiology Unit, San Filippo Neri Hospital, ASL Roma 1, Rome, Italy. FAU - Tarantini, Luigi AU - Tarantini L AD - Divisione di Cardiologia, Arcispedale S. Maria Nuova, Azienda Unita Sanitaria Locale-IRCCS di Reggio-Emilia, Reggio Emilia, Italy. FAU - Luca, Fabiana AU - Luca F AD - Cardiologia Interventistica, Utic, Grande Ospedale Metropolitano, Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy. FAU - Oliva, Stefano AU - Oliva S AD - UOSD Cardiologia di Interesse Oncologico, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy. FAU - Moreo, Antonella AU - Moreo A AD - Cardio Center De Gasperis, Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Milan, Italy. FAU - Maurea, Nicola AU - Maurea N AD - Department of Cardiology, G. Pascale National Cancer Institute Foundation (IRCCS), Naples, Italy. FAU - Quagliariello, Vincenzo AU - Quagliariello V AD - Department of Cardiology, G. Pascale National Cancer Institute Foundation (IRCCS), Naples, Italy. FAU - Ricciardi, Giuseppina Rosaria AU - Ricciardi GR AD - Unit of Medical Oncology, Papardo Hospital, Messina, Italy. FAU - Lestuzzi, Chiara AU - Lestuzzi C AD - Centro Medico Esperia, Porcia (PN), Italy. FAU - Fiscella, Damiana AU - Fiscella D AD - U.O.C. Cardiologia, Ospedale Garibaldi-Nesima, Azienda di Rilievo Nazionale e Alta Specializzazione "Garibaldi", Catania, Italy. FAU - Parrini, Iris AU - Parrini I AD - Department of Cardiology, Hospital Mauritian Turin, Turin, Italy. FAU - Racanelli, Vito AU - Racanelli V AD - Department of Interdisciplinary Medicine, School of Medicine, University of Bari Aldo Moro, Bari, Italy. FAU - Russo, Antonio AU - Russo A AD - Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, Palermo University Hospital, Palermo, Italy. FAU - Incorvaia, Lorena AU - Incorvaia L AD - Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, Palermo University Hospital, Palermo, Italy. FAU - Calabro, Fabio AU - Calabro F AD - Department of Oncology and Specialized Medicine, San Camillo-Forlanini Hospital, Rome, Italy. FAU - Curigliano, Giuseppe AU - Curigliano G AD - Department of Oncology and Hemato-Oncology, University of Milan; Division of Early Drug Development, Istituto Europeo di Oncologia, IRCCS, Milan, Italy. FAU - Cinieri, Saverio AU - Cinieri S AD - Medical Oncology Division and Breast Unit, Senatore Antonio Perrino Hospital, ASL Brindisi, Brindisi, Italy. FAU - Gulizia, Michele Massimo AU - Gulizia MM AD - U.O.C. Cardiologia, Ospedale Garibaldi-Nesima, Azienda di Rilievo Nazionale e Alta Specializzazione "Garibaldi", Catania, Italy. FAU - Gabrielli, Domenico AU - Gabrielli D AD - Division of Cardiology, San Camillo-Forlanini Hospital, Rome, Italy. AD - Division of Cardiology, San Camillo-Forlanini Hospital, Rome, Italy. FAU - Oliva, Fabrizio AU - Oliva F AD - Cardiologia 1- Emodinamica, Dipartimento Cardiotoracovascolare "A. De Gasperis", Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Milan, Italy. FAU - Colivicchi, Furio AU - Colivicchi F AD - Clinical and Rehabilitation Cardiology Unit, San Filippo Neri Hospital, ASL Roma 1, Rome, Italy. LA - eng PT - Journal Article PT - Review DEP - 20230915 PL - Switzerland TA - Front Cardiovasc Med JT - Frontiers in cardiovascular medicine JID - 101653388 EIN - Front Cardiovasc Med. 2023 Oct 25;10:1309921. doi: 10.3389/fcvm.2023.1309921. PMID: 37953759 PMC - PMC10541962 OTO - NOTNLM OT - cancer survivors (CSs) OT - cancer therapy-related cardiovascular toxicities (CTR-CVT) OT - cardiovascular disease (CVD) OT - cardiovascular risk factors (CVRF) OT - reverse cardio-oncology OT - survivorship care COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/10/03 06:47 MHDA- 2023/10/03 06:48 PMCR- 2023/01/01 CRDT- 2023/10/03 03:40 PHST- 2023/05/16 00:00 [received] PHST- 2023/08/24 00:00 [accepted] PHST- 2023/10/03 06:48 [medline] PHST- 2023/10/03 06:47 [pubmed] PHST- 2023/10/03 03:40 [entrez] PHST- 2023/01/01 00:00 [pmc-release] AID - 10.3389/fcvm.2023.1223660 [doi] PST - epublish SO - Front Cardiovasc Med. 2023 Sep 15;10:1223660. doi: 10.3389/fcvm.2023.1223660. eCollection 2023. PMID- 37777784 OWN - NLM STAT- MEDLINE DCOM- 20231002 LR - 20231120 IS - 1749-8090 (Electronic) IS - 1749-8090 (Linking) VI - 18 IP - 1 DP - 2023 Sep 30 TI - Minimally invasive valve surgery including patients of combined simultaneous surgery: a retrospective study. PG - 266 LID - 10.1186/s13019-023-02361-8 [doi] LID - 266 AB - OBJECTIVE: This study investigated the perioperative safety and advantages of performing a minimally invasive valve surgery (MIVS) and conducting a preliminary examination of the combined simultaneous surgery (CSS). METHODS: A total of 29 patients (16 men and 13 women; mean age, 58.41 +/- 13.08 years) who underwent MIVS at our center from July 2021 to March 2022 were selected. Among them, 16 patients underwent aortic valve surgery (AVS), 13 patients underwent mitral valve surgery (MVS), and four patients additionally underwent CSS. RESULTS: The MIVS time ranged from 165 to 420 min, with a mean of 230.54 +/- 54.61 min; the cardiopulmonary bypass (CPB) time ranged from 54 to 164 min, with a mean of 120.24 +/- 25.98 min; the aortic cross-clamp (ACC) time ranged from 36 to 118 min, with a mean of 78.66 +/- 21.01 min and an automatic heart resuscitating rate was 89.66%; the mean tracheal intubation time was 6.30 +/- 3.87 h, and the median total postoperative drainage was 317.5 (35, 1470) ml. No difference was observed between preoperative and postoperative left ventricular ejection fraction (LVEF) (61.90% +/- 6.28% vs. 60.21% +/- 5.52%, P = 0.281). The difference in postoperative drainage (419.20 ml +/- 377.20 ml vs. 588.75 ml +/- 673.63 ml, P = .461), tracheal intubation time (6.66 h +/- 4.27 h vs. 4.63 h +/- 1.11 h, P = .359), intensive care unit (ICU) stay (3.96 +/- 8.62 days vs. 2.00 +/- 0.816 days, P = .658), and postoperative hospital stay (9.96 +/- 8.45 days vs. 8.25 +/- 1.26 days, P = .694) between MIVS and CSS was not significant. CONCLUSION: MIVS in our center may be safe and effective. Additionally, CSS may be a feasible option that could be performed after a thorough preoperative evaluation and multidisciplinary discussion. CI - (c) 2023. BioMed Central Ltd., part of Springer Nature. FAU - Ling, Yun AU - Ling Y AD - Department of Cardiovascular Surgery, Shanghai East Hospital affiliated to Tongji University School of Medicine, 150 Jimo Rd, Shanghai, 200000, China. FAU - Chen, Huaxin AU - Chen H AD - Department of Anesthesiology, Hainan Hospital of Chinese PLA General Hospital, 80 Jianglin Rd, Sanya, 572013, China. FAU - Zhu, Pengxiong AU - Zhu P AD - Department of Cardiovascular Surgery, Shanghai East Hospital affiliated to Tongji University School of Medicine, 150 Jimo Rd, Shanghai, 200000, China. FAU - Li, Tian AU - Li T AD - School of Basic Medicine, Fourth Military Medical University, Xi'an, 710032, China. tian@fmmu.edu.cn. FAU - Xue, Bangde AU - Xue B AD - Department of Cardiovascular Surgery, Shanghai East Hospital affiliated to Tongji University School of Medicine, 150 Jimo Rd, Shanghai, 200000, China. snail_bond@hotmail.com. FAU - Liu, Jun AU - Liu J AD - Department of Cardiovascular Surgery, Shanghai East Hospital affiliated to Tongji University School of Medicine, 150 Jimo Rd, Shanghai, 200000, China. liujun52@126.com. LA - eng PT - Journal Article DEP - 20230930 PL - England TA - J Cardiothorac Surg JT - Journal of cardiothoracic surgery JID - 101265113 SB - IM MH - Male MH - Humans MH - Female MH - Middle Aged MH - Aged MH - *Heart Valve Diseases/surgery MH - Retrospective Studies MH - Mitral Valve/surgery MH - Stroke Volume MH - *Heart Valve Prosthesis Implantation MH - Ventricular Function, Left MH - Minimally Invasive Surgical Procedures MH - Treatment Outcome PMC - PMC10541706 OTO - NOTNLM OT - Cardiac surgical procedures OT - Heart valve diseases OT - Minimally invasive surgical procedures COIS- The authors declare that they have no competing interests. EDAT- 2023/10/01 04:44 MHDA- 2023/10/02 06:42 PMCR- 2023/09/30 CRDT- 2023/09/30 23:37 PHST- 2023/04/09 00:00 [received] PHST- 2023/09/02 00:00 [accepted] PHST- 2023/10/02 06:42 [medline] PHST- 2023/10/01 04:44 [pubmed] PHST- 2023/09/30 23:37 [entrez] PHST- 2023/09/30 00:00 [pmc-release] AID - 10.1186/s13019-023-02361-8 [pii] AID - 2361 [pii] AID - 10.1186/s13019-023-02361-8 [doi] PST - epublish SO - J Cardiothorac Surg. 2023 Sep 30;18(1):266. doi: 10.1186/s13019-023-02361-8. PMID- 37774510 OWN - NLM STAT- MEDLINE DCOM- 20231220 LR - 20250626 IS - 1527-3288 (Electronic) IS - 0147-9563 (Linking) VI - 63 DP - 2024 Jan-Feb TI - Effects of a Rapid Response Team on Patient Outcomes: A Systematic Review. PG - 51-64 LID - S0147-9563(23)00238-8 [pii] LID - 10.1016/j.hrtlng.2023.09.007 [doi] AB - BACKGROUND: Despite the widespread adoption of the rapid response team (RRT) by many hospitals, questions remain regarding their effectiveness in improving several aspects of patient outcomes, such as hospital mortality, cardiopulmonary arrests, unplanned intensive care unit (ICU) admissions, and length of stay (LOS). OBJECTIVES: To conduct a systematic review to understand the rapid response team's (RRT) effect on patient outcomes. METHODS: A systematic search was conducted using PubMed, Cochrane, Embase, CINAHL, Web of Science, and two trial registers. The studies published up to May 6, 2022, from the inception date of the databases were included. Two researchers filtered the title, abstract and full text. The Version 2 of the Cochrane Risk of Bias tool and Bias in Non-Randomized Studies of Interventions (ROBINS-I) tool were used separately for randomized and non-randomized controlled trials for quality appraisal. RESULTS: Sixty-one eligible studies were identified, four randomized controlled trials(RCTs), four non-randomized controlled trials, six interrupted time-series(ITS) design , and 47 pretest-posttest studies. A total of 52 studies reported hospital mortality, 51 studies reported cardiopulmonary arrests, 18 studies reported unplanned ICU admissions and ten studies reported LOS. CONCLUSION: This systematic review found the variation in context and the type of RRT interventions restricts direct comparisons. The evidence for improving several aspects of patient outcomes was inconsistent, with most studies demonstrating that RRT positively impacts patient outcomes. CI - Copyright (c) 2023. Published by Elsevier Inc. FAU - Zhang, Qiuxia AU - Zhang Q AD - Department of Nursing, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang 43400, Malaysia; Nursing Department, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310009, China. Electronic address: gs61401@student.upm.edu.my. FAU - Lee, Khuan AU - Lee K AD - Department of Nursing, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang 43400, Malaysia. Electronic address: leekhuan@upm.edu.my. FAU - Mansor, Zawiah AU - Mansor Z AD - Department of Community Health, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang 43400, Malaysia. Electronic address: zawiah.mansor@upm.edu.my. FAU - Ismail, Iskasymar AU - Ismail I AD - Department of Medicine, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang 43400, Malaysia; RESQ Stroke Emergency Unit, Hospital Sultan Abdul Aziz Shah, Universiti Putra Malaysia, Serdang 43400, Malaysia. Electronic address: iskasymar@upm.edu.my. FAU - Guo, Yi AU - Guo Y AD - Department of General Practice and International Medicine, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310009, China; Department of Neurology, Epilepsy Center, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310009, China. Electronic address: yiguo@zju.edu.cn. FAU - Xiao, Qiao AU - Xiao Q AD - Department of Community Health, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang 43400, Malaysia. Electronic address: gs61944@student.upm.edu.my. FAU - Lim, Poh Ying AU - Lim PY AD - Department of Community Health, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang 43400, Malaysia. Electronic address: pohying_my@upm.edu.my. LA - eng PT - Journal Article PT - Systematic Review DEP - 20230927 PL - United States TA - Heart Lung JT - Heart & lung : the journal of critical care JID - 0330057 SB - IM MH - Humans MH - *Hospital Rapid Response Team MH - Intensive Care Units MH - Hospitals MH - Bias MH - Length of Stay MH - *Heart Arrest/therapy OTO - NOTNLM OT - Cardiac arrest OT - Intensive care unit OT - Length of stay OT - Mortality OT - Rapid response team COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2023/09/30 09:42 MHDA- 2023/12/20 06:43 CRDT- 2023/09/29 18:04 PHST- 2023/07/24 00:00 [received] PHST- 2023/09/11 00:00 [revised] PHST- 2023/09/12 00:00 [accepted] PHST- 2023/12/20 06:43 [medline] PHST- 2023/09/30 09:42 [pubmed] PHST- 2023/09/29 18:04 [entrez] AID - S0147-9563(23)00238-8 [pii] AID - 10.1016/j.hrtlng.2023.09.007 [doi] PST - ppublish SO - Heart Lung. 2024 Jan-Feb;63:51-64. doi: 10.1016/j.hrtlng.2023.09.007. Epub 2023 Sep 27. PMID- 37772978 OWN - NLM STAT- MEDLINE DCOM- 20231109 LR - 20260921 IS - 1532-2092 (Electronic) IS - 1099-5129 (Print) IS - 1099-5129 (Linking) VI - 25 IP - 11 DP - 2023 Nov 2 TI - Lead management in patients undergoing percutaneous tricuspid valve replacement or repair: a 'heart team' approach. LID - 10.1093/europace/euad300 [doi] LID - euad300 AB - Clinically significant tricuspid regurgitation (TR) has historically been managed with either medical therapy or surgical interventions. More recently, percutaneous trans-catheter tricuspid valve (TV) replacement and tricuspid trans-catheter edge-to-edge repair have emerged as alternative treatment modalities. Patients with cardiac implantable electronic devices (CIEDs) have an increased incidence of TR. Severe TR in this population can occur for multiple reasons but most often results from the interactions between the CIED lead and the TV apparatus. Management decisions in patients with CIED leads and clinically significant TR, who are undergoing evaluation for a percutaneous TV intervention, need careful consideration as a trans-venous lead extraction (TLE) may both worsen and improve TR severity. Furthermore, given the potential risks of 'jailing' a CIED lead at the time of a percutaneous TV intervention (lead fracture and risk of subsequent infections), consideration should be given to performing a TLE prior to a percutaneous TV intervention. The purpose of this 'state-of-the-art' review is to provide an overview of the causes of TR in patients with CIEDs, discuss the available therapeutic options for patients with TR and CIED leads, and advocate for including a lead management specialist as a member of the 'heart team' when making treatment decisions in patients TR and CIED leads. CI - (c) The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. FAU - Gabriels, James K AU - Gabriels JK AD - Department of Cardiology, Zucker School of Medicine at Hofstra/Northwell, North Shore University Hospital, 300 Community Drive, Manhasset, NY, USA. FAU - Schaller, Robert D AU - Schaller RD AUID- ORCID: 0000-0001-8608-7247 AD - Electrophysiology Section, Division of Cardiovascular Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. FAU - Koss, Elana AU - Koss E AD - Department of Cardiovascular and Thoracic Surgery, Zucker School of Medicine at Hofstra/Northwell, North Shore University Hospital, Manhasset, NY, USA. FAU - Rutkin, Bruce J AU - Rutkin BJ AD - Department of Cardiovascular and Thoracic Surgery, Zucker School of Medicine at Hofstra/Northwell, North Shore University Hospital, Manhasset, NY, USA. FAU - Carrillo, Roger G AU - Carrillo RG AUID- ORCID: 0000-0002-0443-8689 AD - Cardiothoracic Surgery, Palmetto Hospital, Miami, FL, USA. FAU - Epstein, Laurence M AU - Epstein LM AUID- ORCID: 0000-0001-5410-0291 AD - Department of Cardiology, Zucker School of Medicine at Hofstra/Northwell, North Shore University Hospital, 300 Community Drive, Manhasset, NY, USA. LA - eng PT - Journal Article PL - England TA - Europace JT - Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology JID - 100883649 SB - IM MH - Humans MH - Tricuspid Valve/diagnostic imaging/surgery MH - *Tricuspid Valve Insufficiency/diagnosis/surgery/epidemiology MH - *Cardiac Surgical Procedures/adverse effects MH - Treatment Outcome MH - *Heart Valve Prosthesis Implantation/adverse effects/methods MH - Retrospective Studies PMC - PMC10629975 OTO - NOTNLM OT - Lead extraction OT - Trans-catheter tricuspid valve intervention OT - Tricuspid regurgitation COIS- Conflict of interest: R.D.S. has received speaking honoraria from Philips and Cook Medical. E.K. has received consulting fees from Abbott and Edwards Lifesciences. B.J.R. has received consulting fees from Abbott, Edwards Lifesciences, and Medtronic. R.G.C. has received consulting/speaking fees from Philips and has a research grant funded by Medtronic. L.M.E. has received consulting fees from Boston Scientific, Medtronic, and Philips. The other authors report no relevant disclosures. EDAT- 2023/09/29 12:43 MHDA- 2023/11/09 06:42 PMCR- 2023/09/29 CRDT- 2023/09/29 10:03 PHST- 2023/08/03 00:00 [received] PHST- 2023/09/24 00:00 [accepted] PHST- 2023/11/09 06:42 [medline] PHST- 2023/09/29 12:43 [pubmed] PHST- 2023/09/29 10:03 [entrez] PHST- 2023/09/29 00:00 [pmc-release] AID - 7286305 [pii] AID - euad300 [pii] AID - 10.1093/europace/euad300 [doi] PST - ppublish SO - Europace. 2023 Nov 2;25(11):euad300. doi: 10.1093/europace/euad300. PMID- 37771007 OWN - NLM STAT- MEDLINE DCOM- 20240101 LR - 20240312 IS - 1536-4801 (Electronic) IS - 0277-2116 (Linking) VI - 77 IP - 6 DP - 2023 Dec 1 TI - Recent Advances in the Genetic Pathogenesis, Diagnosis, and Management of Esophageal Atresia and Tracheoesophageal Fistula: A Review. PG - 703-712 LID - 10.1097/MPG.0000000000003952 [doi] AB - Infants born with esophageal atresia and tracheoesophageal fistula, a complex congenital malformation occurring in 1/2500-4000 live births, may suffer threats to their cardiac, respiratory, and digestive health in addition to anomalies that may exist in the genitourinary and musculoskeletal systems. Optimal care for these patients throughout their lives is best achieved through a coordinated, multidisciplinary approach that our health care system is not always well-equipped to provide. This review, though not exhaustive, highlights the components of care that pertain to initial surgical reconstruction and subsequent diagnosis and management of the complications that are most frequently encountered. Authors from among the many specialties involved in the care of these patients summarize the current best practice with attention to the most recent advances. Assessment and improvement of quality of life and transition to adult specialists as children grow to adulthood is also reviewed. CI - Copyright (c) 2023 by European Society for European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. FAU - O'Shea, Delia AU - O'Shea D AD - From the Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Columbia University Vagelos College of Physicians and Surgeons/NewYork-Presbyterian Morgan Stanley Children's Hospital, New York, NY. FAU - Schmoke, Nicholas AU - Schmoke N AD - the Division of Pediatric Surgery, Department of Surgery, Columbia University Vagelos College of Physicians and Surgeons/NewYork-Presbyterian Morgan Stanley Children's Hospital, New York, NY. FAU - Porigow, Chloe AU - Porigow C AD - the Division of Pediatric Surgery, Department of Surgery, Columbia University Vagelos College of Physicians and Surgeons/NewYork-Presbyterian Morgan Stanley Children's Hospital, New York, NY. FAU - Murray, Laurie P AU - Murray LP AD - the Division of Pediatric Pulmonology, Department of Pediatrics, Columbia University Irving Medical Center/NewYork-Presbyterian Morgan Stanley Children's Hospital, New York, NY. FAU - Chung, Wendy K AU - Chung WK AD - the Department of Pediatrics and Medicine, Columbia University Irving Medical Center, New York, NY. FAU - Kattan, Meyer AU - Kattan M AD - the Division of Pediatric Pulmonology, Department of Pediatrics, Columbia University Irving Medical Center/NewYork-Presbyterian Morgan Stanley Children's Hospital, New York, NY. FAU - Jang, Minyoung AU - Jang M AD - the Department of Otolaryngology Head and Neck Surgery, Columbia University Vagelos College of Physicians and Surgeons/NewYork-Presbyterian Morgan Stanley Children's Hospital, New York, NY. FAU - Antosy, Alexandra AU - Antosy A AD - From the Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Columbia University Vagelos College of Physicians and Surgeons/NewYork-Presbyterian Morgan Stanley Children's Hospital, New York, NY. FAU - Middlesworth, William AU - Middlesworth W AD - the Division of Pediatric Surgery, Department of Surgery, Columbia University Vagelos College of Physicians and Surgeons/NewYork-Presbyterian Morgan Stanley Children's Hospital, New York, NY. FAU - Khlevner, Julie AU - Khlevner J AD - From the Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Columbia University Vagelos College of Physicians and Surgeons/NewYork-Presbyterian Morgan Stanley Children's Hospital, New York, NY. LA - eng GR - P01 HD093363/HD/NICHD NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Review DEP - 20230929 PL - United States TA - J Pediatr Gastroenterol Nutr JT - Journal of pediatric gastroenterology and nutrition JID - 8211545 SB - IM MH - Infant MH - Infant, Newborn MH - Child MH - Humans MH - *Tracheoesophageal Fistula/diagnosis/genetics/surgery MH - *Esophageal Atresia/complications/diagnosis/genetics MH - Quality of Life MH - Retrospective Studies MH - *Infant, Newborn, Diseases COIS- The authors report no conflicts of interest. EDAT- 2023/09/29 06:44 MHDA- 2024/01/02 11:42 CRDT- 2023/09/29 00:13 PHST- 2024/01/02 11:42 [medline] PHST- 2023/09/29 06:44 [pubmed] PHST- 2023/09/29 00:13 [entrez] AID - 00005176-990000000-00498 [pii] AID - 10.1097/MPG.0000000000003952 [doi] PST - ppublish SO - J Pediatr Gastroenterol Nutr. 2023 Dec 1;77(6):703-712. doi: 10.1097/MPG.0000000000003952. Epub 2023 Sep 29. PMID- 37762834 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231003 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 12 IP - 18 DP - 2023 Sep 11 TI - Surgical Challenges in Infective Endocarditis: State of the Art. LID - 10.3390/jcm12185891 [doi] LID - 5891 AB - Infective endocarditis (IE) is still a life-threatening disease with frequent lethal outcomes despite the profound changes in its clinical, microbiological, imaging, and therapeutic profiles. Nowadays, the scenario for IE has changed since rheumatic fever has declined, but on the other hand, multiple aspects, such as elderly populations, cardiovascular device implantation procedures, and better use of multiple imaging modalities and multidisciplinary care, have increased, leading to escalations in diagnosis. Since the ESC and AHA Guidelines have been released, specific aspects of diagnostic and therapeutic management have been clarified to provide better and faster diagnosis and prognosis. Surgical treatment is required in approximately half of patients with IE in order to avoid progressive heart failure, irreversible structural damage in the case of uncontrolled infection, and the prevention of embolism. The timing of surgery has been one of the main aspects discussed, identifying cases in which surgery needs to be performed on an emergency (within 24 h) or urgent (within 7 days) basis, irrespective of the duration of antibiotic treatment, or cases where surgery can be postponed to allow a brief period of antibiotic treatment under careful clinical and echocardiographic observation. Mainly, guidelines put emphasis on the importance of an endocarditis team in the handling of systemic complications and how they affect the timing of surgery and perioperative management. Neurological complications, acute renal failure, splenic or musculoskeletal manifestations, or infections determined by multiresistant microorganisms or fungi can affect long-term prognosis and survival. Not to be outdone, anatomical and surgical factors, such as the presence of native or prosthetic valve endocarditis, a repair strategy when feasible, anatomical extension and disruption in the case of an annular abscess (mitral valve annulus, aortic mitral curtain, aortic root, and annulus), and the choice of prosthesis and conduits, can be equally crucial. It can be hard for surgeons to maneuver between correct pre-operative planning and facing unexpected obstacles during intraoperative management. The aim of this review is to provide an overview and analysis of a broad spectrum of specific surgical scenarios and how their challenging management can be essential to ensure better outcomes and prognoses. FAU - Iaccarino, Alessandra AU - Iaccarino A AD - Cardiovascular Department, UO of Cardiac Surgery of IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy. FAU - Barbone, Alessandro AU - Barbone A AUID- ORCID: 0000-0002-5120-5802 AD - Cardiovascular Department, UO of Cardiac Surgery of IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy. FAU - Basciu, Alessio AU - Basciu A AD - Cardiovascular Department, UO of Cardiac Surgery of IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy. FAU - Cuko, Enea AU - Cuko E AD - Cardiovascular Department, UO of Cardiac Surgery of IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy. FAU - Droandi, Ginevra AU - Droandi G AD - Cardiovascular Department, UO of Cardiac Surgery of IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy. FAU - Galbiati, Denise AU - Galbiati D AD - Cardiovascular Department, UO of Cardiac Surgery of IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy. FAU - Romano, Giorgio AU - Romano G AUID- ORCID: 0000-0001-8494-6159 AD - Cardiovascular Department, UO of Cardiac Surgery of IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy. FAU - Citterio, Enrico AU - Citterio E AD - Cardiovascular Department, UO of Cardiac Surgery of IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy. FAU - Fumero, Andrea AU - Fumero A AD - Cardiovascular Department, UO of Cardiac Surgery of IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy. FAU - Scarfo, Iside AU - Scarfo I AD - Cardiovascular Department, Applied Diagnostic Echocardiography of IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy. FAU - Manzo, Rossella AU - Manzo R AD - Cardiovascular Department, Applied Diagnostic Echocardiography of IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy. FAU - La Canna, Giovanni AU - La Canna G AUID- ORCID: 0000-0003-0758-3248 AD - Cardiovascular Department, Applied Diagnostic Echocardiography of IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy. FAU - Torracca, Lucia AU - Torracca L AD - Cardiovascular Department, UO of Cardiac Surgery of IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy. LA - eng PT - Journal Article PT - Review DEP - 20230911 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC10532218 OTO - NOTNLM OT - Commando procedure OT - aortic mitral curtain OT - infective endocarditis OT - mitral valve repair OT - native valve endocarditis OT - prosthetic valve endocarditis OT - tricuspid valve repair COIS- The authors declare no conflict of interest. EDAT- 2023/09/28 06:43 MHDA- 2023/09/28 06:44 PMCR- 2023/09/11 CRDT- 2023/09/28 01:22 PHST- 2023/07/20 00:00 [received] PHST- 2023/08/24 00:00 [revised] PHST- 2023/09/06 00:00 [accepted] PHST- 2023/09/28 06:44 [medline] PHST- 2023/09/28 06:43 [pubmed] PHST- 2023/09/28 01:22 [entrez] PHST- 2023/09/11 00:00 [pmc-release] AID - jcm12185891 [pii] AID - jcm-12-05891 [pii] AID - 10.3390/jcm12185891 [doi] PST - epublish SO - J Clin Med. 2023 Sep 11;12(18):5891. doi: 10.3390/jcm12185891. PMID- 37758593 OWN - NLM STAT- MEDLINE DCOM- 20240524 LR - 20241104 IS - 1875-2128 (Electronic) IS - 1875-2128 (Linking) VI - 116 IP - 11 DP - 2023 Nov TI - Outcomes of patients with active cancer undergoing transcatheter aortic valve replacement. PG - 506-513 LID - S1875-2136(23)00165-1 [pii] LID - 10.1016/j.acvd.2023.08.001 [doi] AB - BACKGROUND: Cardiovascular disease and cancer are the two leading causes of mortality worldwide, and their association presents a therapeutic challenge. Current data regarding the prognosis of active cancer in patients undergoing transcatheter aortic valve replacement are conflicting. AIM: To determine the impact and prognosis of active cancer in transcatheter aortic valve replacement. METHODS: All consecutive patients with severe aortic stenosis treated by transcatheter aortic valve replacement between February 2010 and May 2019 were enrolled in a prospective study. The cohort was divided according to the presence or absence of active cancer at baseline. The primary endpoint was all-cause mortality 1 year after the procedure. RESULTS: A total of 1,125 patients were enrolled: 1,037 (92.2%) without and 88 (7.8%) with active cancer. The most frequent cancers were haematological (36.4%), breast (14.8%) and prostate (14.8%), with 79.5% of patients receiving curative treatment and 17.0% receiving palliative treatment. The 1-year mortality rate was higher in patients with active cancer (27.3% vs. 13.9%; P<0.01), mainly driven by non-cardiovascular causes. An increased cardiovascular mortality rate at 2 years was seen in patients with active cancer (27.5% vs. 15.0%; P=0.03) compared with a similar rate at 1-year follow-up. Active cancer was a strong predictor of 1-year all-cause mortality (hazard ratio 2.46, 95% confidence interval 1.19-4.68; P=0.02). Major/life-threatening bleeding events at 1 year were more frequent in patients with active cancer (P=0.02). CONCLUSIONS: Among patients who undergo transcatheter aortic valve replacement, 1-year all-cause mortality is higher in those with active cancer. We also observed a trend towards increased long-term bleeding events in case of active cancer. CI - Copyright (c) 2023 The Author(s). Published by Elsevier Masson SAS.. All rights reserved. FAU - Trimaille, Antonin AU - Trimaille A AD - Division of Cardiovascular Medicine, Strasbourg University Hospital, Nouvel Hopital Civil, 67091 Strasbourg, France; Inserm (French National Institute of Health and Medical Research), FMTS, Regenerative Nanomedicine, UMR 1260, 67000 Strasbourg, France. FAU - Matsushita, Kensuke AU - Matsushita K AD - Division of Cardiovascular Medicine, Strasbourg University Hospital, Nouvel Hopital Civil, 67091 Strasbourg, France; Inserm (French National Institute of Health and Medical Research), FMTS, Regenerative Nanomedicine, UMR 1260, 67000 Strasbourg, France. FAU - Marchandot, Benjamin AU - Marchandot B AD - Division of Cardiovascular Medicine, Strasbourg University Hospital, Nouvel Hopital Civil, 67091 Strasbourg, France. FAU - Carmona, Adrien AU - Carmona A AD - Division of Cardiovascular Medicine, Strasbourg University Hospital, Nouvel Hopital Civil, 67091 Strasbourg, France. FAU - Hess, Sebastien AU - Hess S AD - Division of Cardiovascular Medicine, Strasbourg University Hospital, Nouvel Hopital Civil, 67091 Strasbourg, France. FAU - Reydel, Antje AU - Reydel A AD - Division of Cardiovascular Medicine, Strasbourg University Hospital, Nouvel Hopital Civil, 67091 Strasbourg, France. FAU - Faucher, Loic AU - Faucher L AD - Division of Cardiovascular Medicine, Strasbourg University Hospital, Nouvel Hopital Civil, 67091 Strasbourg, France. FAU - Granier, Amandine AU - Granier A AD - Division of Cardiovascular Medicine, Strasbourg University Hospital, Nouvel Hopital Civil, 67091 Strasbourg, France. FAU - Mai, Trung Anh AU - Mai TA AD - Division of Cardiovascular Medicine, Strasbourg University Hospital, Nouvel Hopital Civil, 67091 Strasbourg, France. FAU - Diop, Bamba AU - Diop B AD - Division of Cardiovascular Medicine, Strasbourg University Hospital, Nouvel Hopital Civil, 67091 Strasbourg, France. FAU - Ohlmann, Patrick AU - Ohlmann P AD - Division of Cardiovascular Medicine, Strasbourg University Hospital, Nouvel Hopital Civil, 67091 Strasbourg, France. FAU - Jesel, Laurence AU - Jesel L AD - Division of Cardiovascular Medicine, Strasbourg University Hospital, Nouvel Hopital Civil, 67091 Strasbourg, France; Inserm (French National Institute of Health and Medical Research), FMTS, Regenerative Nanomedicine, UMR 1260, 67000 Strasbourg, France. FAU - Morel, Olivier AU - Morel O AD - Division of Cardiovascular Medicine, Strasbourg University Hospital, Nouvel Hopital Civil, 67091 Strasbourg, France; Inserm (French National Institute of Health and Medical Research), FMTS, Regenerative Nanomedicine, UMR 1260, 67000 Strasbourg, France. Electronic address: olivier.morel@chru-strasbourg.fr. LA - eng PT - Journal Article PT - Observational Study DEP - 20230912 PL - Netherlands TA - Arch Cardiovasc Dis JT - Archives of cardiovascular diseases JID - 101465655 SB - IM MH - Humans MH - *Transcatheter Aortic Valve Replacement/adverse effects/mortality MH - Male MH - Female MH - *Aortic Valve Stenosis/surgery/mortality/physiopathology/diagnostic imaging MH - Aged, 80 and over MH - Treatment Outcome MH - Time Factors MH - Aged MH - Risk Factors MH - Prospective Studies MH - *Neoplasms/mortality MH - Risk Assessment MH - Aortic Valve/surgery/physiopathology/diagnostic imaging MH - Severity of Illness Index MH - Cause of Death OTO - NOTNLM OT - Aortic stenosis OT - Cancer OT - Heart team OT - Oncology OT - Transcatheter aortic valve replacement EDAT- 2023/09/28 00:42 MHDA- 2024/05/24 06:42 CRDT- 2023/09/27 21:55 PHST- 2023/05/16 00:00 [received] PHST- 2023/08/05 00:00 [revised] PHST- 2023/08/07 00:00 [accepted] PHST- 2024/05/24 06:42 [medline] PHST- 2023/09/28 00:42 [pubmed] PHST- 2023/09/27 21:55 [entrez] AID - S1875-2136(23)00165-1 [pii] AID - 10.1016/j.acvd.2023.08.001 [doi] PST - ppublish SO - Arch Cardiovasc Dis. 2023 Nov;116(11):506-513. doi: 10.1016/j.acvd.2023.08.001. Epub 2023 Sep 12. PMID- 37751395 OWN - NLM STAT- MEDLINE DCOM- 20231005 LR - 20250729 IS - 1531-7080 (Electronic) IS - 0268-4705 (Linking) VI - 38 IP - 6 DP - 2023 Nov 1 TI - Coronary artery bypass grafting in left ventricular dysfunction: when and how. PG - 464-470 LID - 10.1097/HCO.0000000000001090 [doi] AB - PURPOSE OF REVIEW: The surgical management of patients undergoing coronary artery bypass grafting (CABG) with low ejection fraction presents unique challenges that require meticulous attention to details and good surgical technique and judgement. This review details the latest evidence and best practices in the care of such patients. RECENT FINDINGS: CABG in patients with low ejection fraction carries a significant risk of perioperative mortality and morbidity related to the development of postcardiotomy shock. Preoperative optimization with pharmacological or mechanical support is required, especially in patients with cardiogenic shock. Rapid and complete revascularization is what CABG surgeons aim to achieve. Multiple arterial revascularization should be reserved to selected patients. Off-pump CABG, on-pump breathing heart CABG, and new cardioplegic solutions remain of uncertain benefit compared with traditional CABG. SUMMARY: Tremendous advancements in CABG allowed surgeons to offer revascularization to patients with severe left ventricular dysfunction and multivessel disease with acceptable risk. Despite that, there is a lack of comprehensive and robust studies particularly on long-term outcomes. Individualized patient assessment and a heart team approach should be used to determine the optimal surgical strategy for each patient. CI - Copyright (c) 2023 Wolters Kluwer Health, Inc. All rights reserved. FAU - Iacona, Gabriele M AU - Iacona GM AD - Coronary Center, Department of Thoracic and Cardiovascular Surgery, Heart Vascular & Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA. FAU - Bakhos, Jules J AU - Bakhos JJ FAU - Tong, Michael Z AU - Tong MZ FAU - Bakaeen, Faisal G AU - Bakaeen FG LA - eng PT - Journal Article PT - Review DEP - 20230918 PL - United States TA - Curr Opin Cardiol JT - Current opinion in cardiology JID - 8608087 SB - IM MH - Humans MH - Treatment Outcome MH - Coronary Artery Bypass/methods MH - *Ventricular Dysfunction, Left/surgery MH - *Coronary Artery Bypass, Off-Pump/methods MH - *Coronary Artery Disease/complications/surgery MH - Retrospective Studies EDAT- 2023/09/26 18:42 MHDA- 2023/10/05 06:44 CRDT- 2023/09/26 13:03 PHST- 2023/10/05 06:44 [medline] PHST- 2023/09/26 18:42 [pubmed] PHST- 2023/09/26 13:03 [entrez] AID - 00001573-202311000-00003 [pii] AID - 10.1097/HCO.0000000000001090 [doi] PST - ppublish SO - Curr Opin Cardiol. 2023 Nov 1;38(6):464-470. doi: 10.1097/HCO.0000000000001090. Epub 2023 Sep 18. PMID- 37745102 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240925 IS - 2297-055X (Print) IS - 2297-055X (Electronic) IS - 2297-055X (Linking) VI - 10 DP - 2023 TI - Comparison of procedural characteristics of percutaneous annuloplasty and edge-to-edge repair for the treatment of severe tricuspid regurgitation. PG - 1232327 LID - 10.3389/fcvm.2023.1232327 [doi] LID - 1232327 AB - BACKGROUND: In recent years, new interventional therapies for tricuspid regurgitation (TR) demonstrated their effectiveness in reducing TR severity and improving symptoms. Currently, tricuspid transcatheter edge-to-edge repair (T-TEER) and percutaneous annuloplasty are the most widely used techniques in Europe. In this retrospective study, we compared procedural characteristics and learning curves of both TR devices in a real-world cohort. MATERIAL AND METHODS: Eligible patients with severe to torrential TR underwent either percutaneous annuloplasty or T-TEER as recommended by the local heart team. Patients with combined mitral and tricuspid interventions were excluded from the analysis. The study focused on procedural characteristics, TR reduction and learning curves. RESULTS: A total of 122 patients underwent either percutaneous annuloplasty (n = 64) or T-TEER (n = 58) with a technical and device success rate of 98% and 97%, respectively. Reasons for technical failure included right coronary artery (RCA) dissection prior to percutaneous annuloplasty, and two single leaflet device attachments (SLDA) during T-TEER implantation. The mean improvement of TR severity was 2.4 +/- 0.8 degrees after T-TEER and 2.5 +/- 0.8 after percutaneous annuloplasty. T-TEER procedures were shorter in terms of both procedure time and radiation exposure, while percutaneous annuloplasty, although taking longer, showed a significant reduction in procedure time over the course of the analysed period. CONCLUSION: In summary, both interventional therapies reduce TR severity by approximately two degrees when used in the appropriate anatomy. The learning curve for annuloplasty group showed a significant decrease of procedure times. CI - (c) 2023 Mattig, Barbieri, Kasner, Romero Dorta, Heinrich-Schuler, Zhu, Stangl, Landmesser, Reinthaler and Dreger. FAU - Mattig, Isabel AU - Mattig I AD - Department of Cardiology, Angiology and Intensive Care Medicine, Deutsches Herzzentrum der Charite, Campus Charite Mitte, Berlin, Germany. AD - Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany. AD - DZHK (German Centre for Cardiovascular Research), Berlin, Germany. AD - Berlin Institute of Health at Charite - Universitatsmedizin Berlin, BIH Biomedical Innovation Academy, Berlin, Germany. FAU - Barbieri, Fabian AU - Barbieri F AD - Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany. AD - Department of Cardiology, Angiology and Intensive Care Medicine, Deutsches Herzzentrum der Charite, Campus Benjamin Franklin, Berlin, Germany. FAU - Kasner, Mario AU - Kasner M AD - Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany. AD - Department of Cardiology, Angiology and Intensive Care Medicine, Deutsches Herzzentrum der Charite, Campus Benjamin Franklin, Berlin, Germany. FAU - Romero Dorta, Elena AU - Romero Dorta E AD - Department of Cardiology, Angiology and Intensive Care Medicine, Deutsches Herzzentrum der Charite, Campus Charite Mitte, Berlin, Germany. AD - Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany. FAU - Heinrich-Schuler, Anna Lisa AU - Heinrich-Schuler AL AD - Department of Cardiology, Angiology and Intensive Care Medicine, Deutsches Herzzentrum der Charite, Campus Charite Mitte, Berlin, Germany. AD - Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany. FAU - Zhu, Miry AU - Zhu M AD - Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany. AD - Department of Cardiology, Angiology and Intensive Care Medicine, Deutsches Herzzentrum der Charite, Campus Benjamin Franklin, Berlin, Germany. FAU - Stangl, Karl AU - Stangl K AD - Department of Cardiology, Angiology and Intensive Care Medicine, Deutsches Herzzentrum der Charite, Campus Charite Mitte, Berlin, Germany. AD - Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany. AD - DZHK (German Centre for Cardiovascular Research), Berlin, Germany. FAU - Landmesser, Ulf AU - Landmesser U AD - Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany. AD - Department of Cardiology, Angiology and Intensive Care Medicine, Deutsches Herzzentrum der Charite, Campus Benjamin Franklin, Berlin, Germany. FAU - Reinthaler, Markus AU - Reinthaler M AD - Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany. AD - Department of Cardiology, Angiology and Intensive Care Medicine, Deutsches Herzzentrum der Charite, Campus Benjamin Franklin, Berlin, Germany. AD - Institute of Active Polymers and Berlin-Brandenburg Center for Regenerative Therapies, Helmholtz-Zentrum Hereon, Teltow, Germany. FAU - Dreger, Henryk AU - Dreger H AD - Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany. AD - DZHK (German Centre for Cardiovascular Research), Berlin, Germany. AD - Department of Cardiology, Angiology and Intensive Care Medicine, Deutsches Herzzentrum der Charite, Campus Virchow Klinikum, Berlin, Germany. LA - eng PT - Journal Article DEP - 20230908 PL - Switzerland TA - Front Cardiovasc Med JT - Frontiers in cardiovascular medicine JID - 101653388 PMC - PMC10515198 OTO - NOTNLM OT - percutaneous annuloplasty OT - procedural characteristics OT - transcatheter edge-to-edge repair OT - transcatheter valve intervention OT - tricuspid regurgitation COIS- IM is participant in the BIH Charite Clinician Scientist Program funded by the Charite - Universitatsmedizin Berlin and the Berlin Institute of Health at Charite (BIH). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/09/25 06:42 MHDA- 2023/09/25 06:43 PMCR- 2023/01/01 CRDT- 2023/09/25 04:54 PHST- 2023/05/31 00:00 [received] PHST- 2023/08/28 00:00 [accepted] PHST- 2023/09/25 06:43 [medline] PHST- 2023/09/25 06:42 [pubmed] PHST- 2023/09/25 04:54 [entrez] PHST- 2023/01/01 00:00 [pmc-release] AID - 10.3389/fcvm.2023.1232327 [doi] PST - epublish SO - Front Cardiovasc Med. 2023 Sep 8;10:1232327. doi: 10.3389/fcvm.2023.1232327. eCollection 2023. PMID- 37744047 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241003 IS - 2397-1991 (Electronic) IS - 2397-1983 (Print) IS - 2397-1983 (Linking) VI - 8 IP - 3 DP - 2023 Oct TI - Consensus on the assessment of systemic sclerosis-associated primary heart involvement: World Scleroderma Foundation/Heart Failure Association guidance on screening, diagnosis, and follow-up assessment. PG - 169-182 LID - 10.1177/23971983231163413 [doi] AB - INTRODUCTION: Heart involvement is a common problem in systemic sclerosis. Recently, a definition of systemic sclerosis primary heart involvement had been proposed. Our aim was to establish consensus guidance on the screening, diagnosis and follow-up of systemic sclerosis primary heart involvement patients. METHODS: A systematic literature review was performed to investigate the tests used to evaluate heart involvement in systemic sclerosis. The extracted data were categorized into relevant domains (conventional radiology, electrocardiography, echocardiography, cardiac magnetic resonance imaging, laboratory, and others) and presented to experts and one patient research partner, who discussed the data and added their opinion. This led to the formulation of overarching principles and guidance statements, then reviewed and voted on for agreement. Consensus was attained when the mean agreement was ⩾7/10 and of ⩾70% of voters. RESULTS: Among 2650 publications, 168 met eligibility criteria; the data extracted were discussed over three meetings. Seven overarching principles and 10 guidance points were created, revised and voted on. The consensus highlighted the importance of patient counseling, differential diagnosis and multidisciplinary team management, as well as defining screening and diagnostic approaches. The initial core evaluation should integrate history, physical examination, rest electrocardiography, trans-thoracic echocardiography and standard serum cardiac biomarkers. Further investigations should be individually tailored and decided through a multidisciplinary management. The overall mean agreement was 9.1/10, with mean 93% of experts voting above 7/10. CONCLUSION: This consensus-based guidance on screening, diagnosis and follow-up of systemic sclerosis primary heart involvement provides a foundation for standard of care and future feasibility studies that are ongoing to support its application in clinical practice. CI - (c) The Author(s) 2023. FAU - Bruni, Cosimo AU - Bruni C AUID- ORCID: 0000-0003-2813-2083 AD - Division of Rheumatology, Department of Experimental and Clinical Medicine, Careggi University Hospital (AOUC), University of Florence, Florence, Italy. AD - Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. FAU - Buch, Maya H AU - Buch MH AD - Centre for Musculoskeletal Research, School of Biological Sciences, Faculty of Biology, Medicine & Health, University of Manchester, Manchester, UK. AD - NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK. FAU - Djokovic, Aleksandra AU - Djokovic A AD - Department of Cardiology, University Clinical Hospital Center Bezanijska kosa, Belgrade, Serbia. AD - Faculty of Medicine, University of Belgrade, Belgrade, Serbia. FAU - De Luca, Giacomo AU - De Luca G AUID- ORCID: 0000-0002-5306-7714 AD - Unit of Immunology, Rheumatology Allergology and Rare diseases, IRCSS San Raffaele Hospital, Milan, Italy. FAU - Dumitru, Raluca B AU - Dumitru RB AD - Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK. FAU - Giollo, Alessandro AU - Giollo A AD - Rheumatology Unit, Department of Medicine, University of Padova, Padova, Italy. FAU - Galetti, Ilaria AU - Galetti I AD - Federation of European Scleroderma Associations (FESCA), Saint Maur, Belgium. FAU - Steelandt, Alexia AU - Steelandt A AD - Rheumatology Department, Paris University, Cochin Hospital, Paris, France. FAU - Bratis, Konstantinos AU - Bratis K AD - Manchester Heart Centre, Manchester University NHS Foundation Trust, Manchester, UK. AD - Division of Cardiovascular Sciences, University of Manchester, Manchester, UK. FAU - Suliman, Yossra Atef AU - Suliman YA AUID- ORCID: 0000-0003-2919-1966 AD - Department of Rheumatology and Rehabilitation, Faculty of Medicine, Assuit University Hospital, Assuit, Arab Republic of Egypt. FAU - Milinkovic, Ivan AU - Milinkovic I AD - Department of Cardiology, University Clinical Hospital Center Bezanijska kosa, Belgrade, Serbia. AD - Faculty of Medicine, University of Belgrade, Belgrade, Serbia. FAU - Baritussio, Anna AU - Baritussio A AD - Cardiology and Cardioimmunology Outpatient Clinic, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy. FAU - Hasan, Ghadeer AU - Hasan G AD - Department of Medicine, Rutgers Robert Wood Johnson Medical Centre, New Brunswick, NJ, USA. FAU - Xintarakou, Anastasia AU - Xintarakou A AD - Mitera General Hospital-Hygeia Group, Athens, Greece. FAU - Isomura, Yohei AU - Isomura Y AD - Department of Allergy and Rheumatology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan. FAU - Markousis-Mavrogenis, George AU - Markousis-Mavrogenis G AUID- ORCID: 0000-0001-8192-6670 AD - Department of Cardiology, Onassis Cardiac Surgery Centre, Athens, Greece. FAU - Mavrogeni, Sophie AU - Mavrogeni S AD - Onassis Cardiac Surgery Centre and Kapodistrian University of Athens, Athens, Greece. FAU - Gargani, Luna AU - Gargani L AD - Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine, University of Pisa, Pisa, Italy. FAU - Caforio, Alida Lp AU - Caforio AL AD - Cardiology and Cardioimmunology Outpatient Clinic, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy. FAU - Tschope, Carsten AU - Tschope C AD - Department of Internal Medicine and Cardiology, Charite-University Medicine Berlin, Berlin, Germany. FAU - Ristic, Arsen AU - Ristic A AD - Department of Cardiology, University Clinical Hospital Center Bezanijska kosa, Belgrade, Serbia. AD - Faculty of Medicine, University of Belgrade, Belgrade, Serbia. FAU - Plein, Sven AU - Plein S AD - Biomedical Imaging Science Department, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK. FAU - Behr, Elijah AU - Behr E AD - Cardiovascular Clinical Academic Group, Institute of Molecular and Clinical Sciences, St George's University of London, London, UK. FAU - Allanore, Yannick AU - Allanore Y AD - Rheumatology Department, Paris University, Cochin Hospital, Paris, France. FAU - Kuwana, Masataka AU - Kuwana M AUID- ORCID: 0000-0001-8352-6136 AD - Department of Allergy and Rheumatology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan. FAU - Denton, Christopher P AU - Denton CP AUID- ORCID: 0000-0003-3975-8938 AD - Centre for Rheumatology, Royal Free Hospital, London, UK. FAU - Furst, Daniel E AU - Furst DE AD - Division of Rheumatology, Department of Experimental and Clinical Medicine, Careggi University Hospital (AOUC), University of Florence, Florence, Italy. AD - University of California, Los Angeles, Los Angeles, CA, USA. FAU - Khanna, Dinesh AU - Khanna D AUID- ORCID: 0000-0001-6822-3401 AD - Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI, USA. FAU - Krieg, Thomas AU - Krieg T AD - Department of Dermatology, Translational Matrix Biology, University Hospital Cologne, Cologne, Germany. FAU - Marcolongo, Renzo AU - Marcolongo R AD - Cardiology and Cardioimmunology Outpatient Clinic, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy. FAU - Pepe, Alessia AU - Pepe A AD - Institute of Radiology and Department of Medicine, University of Padova, Padova, Italy. FAU - Distler, Oliver AU - Distler O AD - Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. FAU - Sfikakis, Petros AU - Sfikakis P AD - First Department of Propaedeutic and Internal Medicine and Joint Rheumatology Program, National and Kapodistrian University of Athens Medical School, Athens, Greece. FAU - Seferovic, Petar AU - Seferovic P AD - Department of Cardiology, University Clinical Hospital Center Bezanijska kosa, Belgrade, Serbia. AD - Faculty of Medicine, University of Belgrade, Belgrade, Serbia. AD - Serbian Academy of Sciences and Arts, Belgrade, Serbia. FAU - Matucci-Cerinic, Marco AU - Matucci-Cerinic M AD - Division of Rheumatology, Department of Experimental and Clinical Medicine, Careggi University Hospital (AOUC), University of Florence, Florence, Italy. AD - Unit of Immunology, Rheumatology Allergology and Rare diseases, IRCSS San Raffaele Hospital, Milan, Italy. LA - eng PT - Journal Article PT - Review DEP - 20230403 PL - England TA - J Scleroderma Relat Disord JT - Journal of scleroderma and related disorders JID - 101685427 PMC - PMC10515996 OTO - NOTNLM OT - Systemic sclerosis OT - cardiac involvement OT - consensus guidance OT - diagnosis OT - follow-up OT - screening COIS- The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Aleksandra Djokovic: no conflicts of interest to declare. Alessandro Giollo received consulting fees and/or honoraria from Novartis, Lilly, and Galapagos. Alessia Pepe: no conflicts of interest to declare. Alexia Steelandt: no conflicts of interest to declare. Alida L.P. Caforio: no conflicts of interest to declare. Anastasia Xintarakou: no conflicts of interest to declare. Anna Baritussio: no conflicts of interest to declare. Arsen Ristic: no conflicts of interest to declare. Carsten Tschope: no conflicts of interest to declare. Christopher P. Denton has received consultancy fees and/or research grant funding from Actelion, GlaxoSmithKline, Bayer, Sanofi-Aventis, Inventiva, Boehringer Ingelheim, Roche, CSL Behring, UCB Pharma, Leadiant Biosciences, Corbus, and Acceleron. Cosimo Bruni received consulting fees and/or honoraria from Actelion, Eli-Lilly, Boehringer Ingelheim; research grants from Gruppo Italiano Lotta alla Sclerodermia (GILS), European Scleroderma Trials and Research Group (EUSTAR), and Scleroderma Research Foundation (SRF), Scleroderma Clinical Trials Consortium (SCTC); and educational grants from AbbVie. Cosimo Bruni was supported by an Italian Ministry of University and Research PhD Scholarship, and this study is part of his PhD thesis. Daniel E. Furst reports grant/research support from Corbus, Galapagos GSK, Pfizer, Talaris, CSL Behring, Mitsubishi; Consultant fees from Actelion, Amgen, Corbus, Galapagos, Novartis, Pfizer, Roche/Genentech, Talaris, CSL Behring, and Boehringer Ingelheim. Dinesh Khanna reports grant support from NIH, Immune Tolerance Network, Bayer, BMS, Horizon, and Pfizer; consultant for Acceleron, Actelion, AbbVie, Amgen, Bayer, Boehringer Ingelheim, Chemomab, CSL Behring, Genentech/Roche, Horizon, Merck, Mitsubishi Tanabe Pharma, Prometheus Leadership/Equity position-Chief Medical Officer, and Eicos Sciences, Inc. Elijah R Behr: no conflicts of interest to declare. George Markousis-Mavrogenis: no conflicts of interest to declare. Ghadeer Hasan: no conflicts of interest to declare. Giacomo De Luca received honoraria from SOBI, Novartis, Pfizer, MSD, and Celgene. Ivan Milinkovic received honoraria/support from Boehringer Ingelheim and Hemofarm-Stada. Kostantinos Bratis: no conflicts of interest to declare. Luna Gargani received consultancy fees from GE Healthcare, Philips Healthcare, and Caption Health outside the submitted work. Marco Matucci-Cerinic received consultancies from Actelion, Janssen, Inventiva, Bayer, Biogen, Boehringer, CSL Behring, Corbus, Galapagos, Mitsubishi, Samsung, Regeneron, Acceleron, MSD, Chemomab, Lilly, Pfizer, and Roche. Masataka Kuwana received consultancy fees and/or research grant funding from AbbVie, Astellas, Bayer, Boehringer Ingelheim, Chugai, Corbus, Eisai, Horizon, Janssen, Mochida, Nippon Shinyaku, Ono Pharmaceuticals, Pfizer, and Mitsubishi Tanabe. Maya H. Buch: no conflicts of interest to declare. Oliver Distler has/had consultancy relationship with and/or has received research funding from and/or has served as a speaker for the following companies in the area of potential treatments for systemic sclerosis and its complications in the last three calendar years: 4P-Pharma, AbbVie, Acceleron, Alcimed, Amgen, AnaMar, Arxx, AstraZeneca, Baecon, Blade, Bayer, Boehringer Ingelheim, Corbus, CSL Behring, 4P Science, Galapagos, Glenmark, Horizon, Inventiva, Janssen, Kymera, Lupin, Medscape, Miltenyi Biotec, Mitsubishi Tanabe, MSD, Novartis, Prometheus, Redxpharma, Roivant, Sanofi, and Topadur; patent issued "mir-29 for the treatment of systemic sclerosis" (US8247389, EP2331143); research grants from Kymera, Mitsubishi Tanabe. Petar Seferovic: no conflicts of interest to declare. Petros Sfikakis reports consultancy fee from Actelion, Pfizer, Genesis, MSD, UCB, Boehringer Ingelheim, Enorasis, Farmaserv, Lilly, Gliead, AbbVie, and Novartis; grants/research support from AbbVie, Roche, Pfizer, Faran, Amgen, Jannsen, Boehringer Ingelheim, and Gilead. Raluca B. Dumitru: no conflicts of interest to declare. Renzo Marcolongo: no conflicts of interest to declare. Sophie Mavrogeni: no conflicts of interest to declare. Sven Plein: no conflicts of interest to declare. Thomas Krieg reports consultancy fee and grant funding from Actelion. Yannick Allanore reports personal fees from Actelion, Bayer, BMS, Boehringer, and Curzion and grants and personal fees from Inventiva, Roche, and Sanofi. Yohei Isomura: no conflicts of interest to declare. Yossra Atef Suliman: no conflicts of interest to declare. EDAT- 2023/09/25 06:42 MHDA- 2023/09/25 06:43 PMCR- 2024/10/01 CRDT- 2023/09/25 04:37 PHST- 2022/07/04 00:00 [received] PHST- 2023/02/24 00:00 [accepted] PHST- 2023/09/25 06:43 [medline] PHST- 2023/09/25 06:42 [pubmed] PHST- 2023/09/25 04:37 [entrez] PHST- 2024/10/01 00:00 [pmc-release] AID - 10.1177_23971983231163413 [pii] AID - 10.1177/23971983231163413 [doi] PST - ppublish SO - J Scleroderma Relat Disord. 2023 Oct;8(3):169-182. doi: 10.1177/23971983231163413. Epub 2023 Apr 3. PMID- 37743167 OWN - NLM STAT- MEDLINE DCOM- 20240722 LR - 20260531 IS - 2529-9840 (Electronic) IS - 2529-9840 (Linking) VI - 35 IP - 3 DP - 2024 Jul-Sep TI - Postoperative management and nursing care after implantation of a total artificial heart: Scoping review. PG - 213-228 LID - S2529-9840(23)00049-6 [pii] LID - 10.1016/j.enfie.2023.08.006 [doi] AB - INTRODUCTION: End-stage heart failure (HF) is a condition whose only successful long-term treatment, with a survival of more than 10 years, is heart transplantation. However, limited organ availability and the progressive increase in the number of patients with advanced HF have served as an impetus for the development of implantable mechanical assistive devices. AIM: To provide an overview of postoperative management and nursing care after the implementation of a Total Artificial Heart (TAH). METHODS: A scoping review was carried out by consulting the PUBMED, CINAHL, and COCHRANE databases. From all the documents located, information was extracted on the date of publication, country of publication, type of study, and results of interest to answer the research question. In addition, the degree of recommendation was identified. RESULTS: Twenty-three documents were included in the scoping review. Results were classified in relation to: 1) description of the CAT SynCardia(R); 2) nursing care in the immediate postoperative period (management of the device and management of hematological, infectious, nephrological, nutritional complications, related to immobilization, sleep-rest disturbances, psychological disorders, and patient and family education); and 3) follow-up at home. CONCLUSIONS: The complexity of implantation of the TAH, the multiple related complications that can arise during this process, both in the immediate post-operative and late, require a standardised and multidisciplinary management. The absence of standardised protocols raises the need for future studies to measure the effectiveness of care in patients with TAH. A multidisciplinary approach is crucial. Nurses must acquire autonomy and involvement in decision-making and develop competencies to address the patient's and family's physiological and psychosocial needs. CI - Copyright (c) 2023 The Author(s). Published by Elsevier Espana S.L.U. All rights reserved. FAU - Jimeno-San Martin, L AU - Jimeno-San Martin L AD - Servicio de Cirugia Cardiaca, Clinica Universidad de Navarra, Pamplona, Navarra, Spain. FAU - Goni-Viguria, R AU - Goni-Viguria R AD - Area de Criticos, Clinica Universidad de Navarra, Pamplona, Navarra, Spain. Electronic address: rgviguria@unav.es. FAU - Bengoechea, L AU - Bengoechea L AD - Area de Criticos, Clinica Universidad de Navarra, Pamplona, Navarra, Spain. FAU - Fernandez, E AU - Fernandez E AD - Hospitalizacion en Cardiologia, Clinica Universidad de Navarra, Pamplona, Navarra, Spain. FAU - Mendiluce, N AU - Mendiluce N AD - Hospitalizacion en Cardiologia, Clinica Universidad de Navarra, Pamplona, Navarra, Spain. FAU - Romero, C AU - Romero C AD - Area de Criticos, Clinica Universidad de Navarra, Pamplona, Navarra, Spain. FAU - Rabago, G AU - Rabago G AD - Servicio de Cirugia Cardiaca, Clinica Universidad de Navarra, Pamplona, Navarra, Spain. FAU - Regaira-Martinez, E AU - Regaira-Martinez E AD - Area de Desarrollo Profesional e Investigacion en Enfermeria, Clinica Universidad de Navarra, Pamplona, Navarra, Spain. LA - eng PT - Journal Article PT - Scoping Review DEP - 20230922 PL - Spain TA - Enferm Intensiva (Engl Ed) JT - Enfermeria intensiva JID - 101778566 SB - IM MH - Humans MH - *Heart, Artificial MH - *Postoperative Care MH - Heart Failure MH - Nursing Care OTO - NOTNLM OT - Artificial heart OT - Corazon artificial OT - Cuidados de enfermeria OT - Literature review OT - Nursing care OT - Revision de la literatura EDAT- 2023/09/25 00:42 MHDA- 2024/07/23 00:42 CRDT- 2023/09/24 21:56 PHST- 2023/01/05 00:00 [received] PHST- 2023/05/16 00:00 [revised] PHST- 2023/05/28 00:00 [accepted] PHST- 2024/07/23 00:42 [medline] PHST- 2023/09/25 00:42 [pubmed] PHST- 2023/09/24 21:56 [entrez] AID - S2529-9840(23)00049-6 [pii] AID - 10.1016/j.enfie.2023.08.006 [doi] PST - ppublish SO - Enferm Intensiva (Engl Ed). 2024 Jul-Sep;35(3):213-228. doi: 10.1016/j.enfie.2023.08.006. Epub 2023 Sep 22. PMID- 37743080 OWN - NLM STAT- MEDLINE DCOM- 20230926 LR - 20230926 IS - 1558-2264 (Electronic) IS - 0733-8651 (Linking) VI - 41 IP - 4 DP - 2023 Nov TI - Guide to Temporary Mechanical Support in Cardiogenic Shock: Choosing Wisely. PG - 583-592 LID - S0733-8651(23)00060-7 [pii] LID - 10.1016/j.ccl.2023.06.004 [doi] AB - Cardiogenic shock is a multisystem pathology that carries a high mortality rate, and initial pharmacotherapies include the use of vasopressors and inotropes. These agents can increase myocardial oxygen consumption and decrease tissue perfusion that can oftentimes result in a state of refractory cardiogenic shock for which temporary mechanical circulatory support can be considered. Numerous support devices are available, each with its own hemodynamic blueprint. Defining a patient's hemodynamic profile and understanding the phenotype of cardiogenic shock is important in device selection. Careful patient selection incorporating a multidisciplinary team approach should be utilized. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Snipelisky, David AU - Snipelisky D AD - Robert and Suzanne Tomsich Department of Cardiology, Section of Heart Failure & Cardiac Transplant Medicine, Cleveland Clinic, 2950 Cleveland Clinic Boulevard, Weston, FL 33331, USA. Electronic address: snipeld@ccf.org. FAU - Estep, Jerry D AU - Estep JD AD - Robert and Suzanne Tomsich Department of Cardiology, Section of Heart Failure & Cardiac Transplant Medicine, Cleveland Clinic, 2950 Cleveland Clinic Boulevard, Weston, FL 33331, USA. LA - eng PT - Journal Article PT - Review DEP - 20230721 PL - Netherlands TA - Cardiol Clin JT - Cardiology clinics JID - 8300331 SB - IM MH - Humans MH - *Shock, Cardiogenic/therapy MH - Patient Selection MH - Phenotype OTO - NOTNLM OT - Advanced heart failure OT - Cardiogenic shock OT - Temporary mechanical circulatory support EDAT- 2023/09/25 00:42 MHDA- 2023/09/26 13:44 CRDT- 2023/09/24 20:54 PHST- 2023/09/26 13:44 [medline] PHST- 2023/09/25 00:42 [pubmed] PHST- 2023/09/24 20:54 [entrez] AID - S0733-8651(23)00060-7 [pii] AID - 10.1016/j.ccl.2023.06.004 [doi] PST - ppublish SO - Cardiol Clin. 2023 Nov;41(4):583-592. doi: 10.1016/j.ccl.2023.06.004. Epub 2023 Jul 21. PMID- 37743079 OWN - NLM STAT- MEDLINE DCOM- 20260311 LR - 20260311 IS - 1558-2264 (Electronic) IS - 0733-8651 (Linking) VI - 41 IP - 4 DP - 2023 Nov TI - Secondary Mitral Regurgitation and Transcatheter Mitral Valve Therapies: Do They Have a Role in Advanced Heart Failure with Reduced Ejection Fraction? PG - 575-582 LID - S0733-8651(23)00064-4 [pii] LID - 10.1016/j.ccl.2023.06.008 [doi] AB - Transcatheter mitral valve repair should be considered for patients with severe secondary mitral regurgitation with symptomatic heart failure with reduced ejection fraction for symptom improvement and survival benefit. Patients with a higher severity of secondary mitral regurgitation relative to the degree of left ventricular dilation are more likely to benefit from transcatheter mitral valve repair. A multidisciplinary Heart Team should participate in patient selection for transcatheter mitral valve therapy. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Pienta, Michael J AU - Pienta MJ AD - Department of Cardiac Surgery, Michigan Medicine, University of Michigan, Ann Arbor, MI, USA. Electronic address: mpienta@med.umich.edu. FAU - Romano, Matthew A AU - Romano MA AD - Department of Cardiac Surgery, Michigan Medicine, University of Michigan, Ann Arbor, MI, USA. LA - eng PT - Journal Article PT - Review DEP - 20230728 PL - Netherlands TA - Cardiol Clin JT - Cardiology clinics JID - 8300331 SB - IM MH - Humans MH - *Mitral Valve Insufficiency/surgery/physiopathology/etiology/complications MH - *Heart Failure/physiopathology/etiology/complications/surgery MH - *Stroke Volume/physiology MH - *Cardiac Catheterization/methods MH - *Heart Valve Prosthesis Implantation/methods MH - *Mitral Valve/surgery OTO - NOTNLM OT - Heart failure OT - Secondary mitral regurgitation OT - Transcatheter edge-to-edge repair OT - Transcatheter mitral valve repair EDAT- 2023/09/25 00:42 MHDA- 2026/03/12 01:09 CRDT- 2023/09/24 20:54 PHST- 2026/03/12 01:09 [medline] PHST- 2023/09/25 00:42 [pubmed] PHST- 2023/09/24 20:54 [entrez] AID - S0733-8651(23)00064-4 [pii] AID - 10.1016/j.ccl.2023.06.008 [doi] PST - ppublish SO - Cardiol Clin. 2023 Nov;41(4):575-582. doi: 10.1016/j.ccl.2023.06.008. Epub 2023 Jul 28. PMID- 37742939 OWN - NLM STAT- MEDLINE DCOM- 20231216 LR - 20241017 IS - 1873-1570 (Electronic) IS - 0300-9572 (Linking) VI - 193 DP - 2023 Dec TI - Rapid response team activation prior to in-hospital cardiac arrest: Areas for improvements based on a national cohort study. PG - 109978 LID - S0300-9572(23)00292-7 [pii] LID - 10.1016/j.resuscitation.2023.109978 [doi] AB - INTRODUCTION: Rapid response teams (RRTs) are designed to improve the "chain of prevention" of in-hospital cardiac arrest (IHCA). We studied the 30-day survival of patients reviewed by RRTs within 24 hours prior to IHCA, as compared to patients not reviewed by RRTs. METHODS: A nationwide cohort study based on the Swedish Registry of Cardiopulmonary Resuscitation, between January 1st, 2014, and December 31st, 2021. An explorative, hypothesis-generating additional in-depth data collection from medical records was performed in a small subgroup of general ward patients reviewed by RRTs. RESULTS: In all, 12,915 IHCA patients were included. RRT-reviewed patients (n = 2,058) had a lower unadjusted 30-day survival (25% vs 33%, p < 0.001), a propensity score based Odds ratio for 30-day survival of 0.92 (95% Confidence interval 0.90-0.94, p < 0.001) and were more likely to have a respiratory cause of IHCA (22% vs 15%, p < 0.001). In the subgroup (n = 82), respiratory distress was the most common RRT trigger, and 24% of the RRT reviews were delayed. Patient transfer to a higher level of care was associated with a higher 30-day survival rate (20% vs 2%, p < 0.001). CONCLUSION: IHCA preceded by RRT review is associated with a lower 30-day survival rate and a greater likelihood of a respiratory cause of cardiac arrest. In the small explorative subgroup, respiratory distress was the most common RRT trigger and delayed RRT activation was frequent. Early detection of respiratory abnormalities and timely interventions may have a potential to improve outcomes in RRT-reviewed patients and prevent further progress into IHCA. CI - Copyright (c) 2023 The Author(s). Published by Elsevier B.V. All rights reserved. FAU - Thoren, Anna AU - Thoren A AD - Department of Medicine Solna, Center for Resuscitation Science, Karolinska Institutet, SE-171 77 Stockholm, Sweden; Department of Clinical Physiology, Danderyd University Hospital, SE-182 88 Stockholm, Sweden. Electronic address: anna.thoren@ki.se. FAU - Jonsson, Martin AU - Jonsson M AD - Department of Clinical Science and Education, Sodersjukhuset, Center for Resuscitation Science, Karolinska Institutet, SE-118 83 Stockholm, Sweden. FAU - Spangfors, Martin AU - Spangfors M AD - Department of Clinical Sciences, Anaesthesiology and Intensive Care, Lund University, SE-221 84 Lund, Sweden; Department of Anaesthesia and Intensive Care, Kristianstad Hospital, SE-291 89 Kristianstad, Sweden. FAU - Joelsson-Alm, Eva AU - Joelsson-Alm E AD - Department of Clinical Science and Education, Sodersjukhuset, Center for Resuscitation Science, Karolinska Institutet, SE-118 83 Stockholm, Sweden; Department of Anaesthesia and Intensive Care, Sodersjukhuset, SE-118 83 Stockholm, Sweden. FAU - Jakobsson, Jan AU - Jakobsson J AD - Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, SE-182 88 Stockholm, Sweden; Department of Anaesthesia and Intensive Care, Danderyd University Hospital, SE-182 88 Stockholm, Sweden. FAU - Rawshani, Araz AU - Rawshani A AD - Department of Molecular and Clinical Medicine, Institute of Medicine, Wallenberg Laboratory, University of Gothenburg, SE-413 45 Gothenburg, Sweden; Department of Cardiology, Sahlgrenska University Hospital/Molndal, SE-413 45 Gothenburg, Sweden. FAU - Kahan, Thomas AU - Kahan T AD - Division of Cardiovascular Medicine, Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, SE-182 88 Stockholm, Sweden; Department of Cardiology, Danderyd University Hospital, SE-182 88 Stockholm, Sweden. FAU - Engdahl, Johan AU - Engdahl J AD - Division of Cardiovascular Medicine, Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, SE-182 88 Stockholm, Sweden; Department of Cardiology, Danderyd University Hospital, SE-182 88 Stockholm, Sweden. FAU - Jadenius, Arvid AU - Jadenius A AD - Department of Molecular and Clinical Medicine, Institute of Medicine, Wallenberg Laboratory, University of Gothenburg, SE-413 45 Gothenburg, Sweden. FAU - Boberg von Platen, Erik AU - Boberg von Platen E AD - Department of Clinical Science and Education, Sodersjukhuset, Center for Resuscitation Science, Karolinska Institutet, SE-118 83 Stockholm, Sweden; Department of Anaesthesia and Intensive Care, Danderyd University Hospital, SE-182 88 Stockholm, Sweden. FAU - Herlitz, Johan AU - Herlitz J AD - The Center for Pre-Hospital Research in Western Sweden, University of Boras, SE-501 90 Boras, Sweden. FAU - Djarv, Therese AU - Djarv T AD - Department of Medicine Solna, Center for Resuscitation Science, Karolinska Institutet, SE-171 77 Stockholm, Sweden; Department of Acute and Reparative Medicine, Karolinska University Hospital, SE-171 64, Stockholm, Sweden. LA - eng PT - Journal Article DEP - 20230922 PL - Ireland TA - Resuscitation JT - Resuscitation JID - 0332173 SB - IM MH - Humans MH - Cohort Studies MH - *Hospital Rapid Response Team MH - *Heart Arrest/therapy MH - *Respiratory Distress Syndrome MH - Hospitals OTO - NOTNLM OT - In-hospital cardiac arrest OT - Medical Emergency Team OT - National Early Warning Score OT - Rapid response system OT - Rapid response team COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2023/09/25 00:42 MHDA- 2023/12/17 09:44 CRDT- 2023/09/24 19:18 PHST- 2023/06/14 00:00 [received] PHST- 2023/09/08 00:00 [revised] PHST- 2023/09/15 00:00 [accepted] PHST- 2023/12/17 09:44 [medline] PHST- 2023/09/25 00:42 [pubmed] PHST- 2023/09/24 19:18 [entrez] AID - S0300-9572(23)00292-7 [pii] AID - 10.1016/j.resuscitation.2023.109978 [doi] PST - ppublish SO - Resuscitation. 2023 Dec;193:109978. doi: 10.1016/j.resuscitation.2023.109978. Epub 2023 Sep 22. PMID- 37742538 OWN - NLM STAT- MEDLINE DCOM- 20231106 LR - 20231112 IS - 1879-1913 (Electronic) IS - 0002-9149 (Linking) VI - 207 DP - 2023 Nov 15 TI - Development and Feasibility of a Primary Care Provider Training Intervention to Improve Atrial Fibrillation Management. PG - 184-191 LID - S0002-9149(23)00962-1 [pii] LID - 10.1016/j.amjcard.2023.08.184 [doi] AB - The disparities in atrial fibrillation (AF) care are partially attributed to inadequate access to providers with specialized training in AF. Primary care providers (PCPs) are often the sole providers of AF care in under-resourced regions. As such, we sought to create a virtual education intervention for PCPs and to evaluate its impact on the use of stroke risk reduction strategies in patients with AF. A multidisciplinary team mentored PCPs on AF management over 6 months using a virtual case-based training format. Surveys of participant knowledge and confidence in AF care were compared before and after the intervention. Hierarchical logistic regression modeling was used to evaluate change in oral anticoagulation (OAC) therapy in the patients seen by participants before or after training. Of 41 participants trained, 49% worked in family medicine, 41% internal medicine, and 10% general cardiology. Participants attended a mean of 14 1-hour sessions. Overall, the appropriate use of OAC (for CHA(2)DS(2)-VASc score >/=1 man, >/=2 women) increased from 37% to 46% (p <0.001) comparing the patients seen before (n = 1,739) versus after (n = 610) intervention. The factors independently associated with appropriate OAC use included participant training (odds ratio [OR] 1.4, p = 0.002) and participant competence in AF management. The factors associated with decreased OAC use included patient age (OR 0.8 per 10 year, p = 0.008) and nonwhite race (OR 0.7, p = 0.028). Provider knowledge and confidence in AF care improved (p <0.001). In conclusion, we show that a virtual PCP training intervention improves the use of stroke risk reduction therapy in outpatients with AF and could be a widely scalable intervention to improve AF care in under-resourced communities. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Daw, J Michael AU - Daw JM AD - Division of Cardiology, Department of Medicine, University of North Carolina Medical Center, Chapel Hill, North Carolina. FAU - Armbruster, Tiffany AU - Armbruster T AD - Division of Cardiology, Department of Medicine, University of North Carolina Medical Center, Chapel Hill, North Carolina. FAU - Deyo, Zack AU - Deyo Z AD - Department of Pharmacy, University of North Carolina Hospitals, Chapel Hill, North Carolina; Division of Practice Advancement and Clinical Education, University of North Carolina Eshelman School of Pharmacy, Chapel Hill, North Carolina. FAU - Walker, Jennifer AU - Walker J AD - Division of Cardiology, Department of Medicine, University of North Carolina Medical Center, Chapel Hill, North Carolina. FAU - Rosman, Lindsey A AU - Rosman LA AD - Division of Cardiology, Department of Medicine, University of North Carolina Medical Center, Chapel Hill, North Carolina. FAU - Sears, Samuel F AU - Sears SF AD - Department of Psychology and Cardiovascular Sciences, East Carolina University, Greenville, North Carolina. FAU - Mazzella, Anthony J AU - Mazzella AJ AD - Division of Cardiology, Department of Medicine, University of North Carolina Medical Center, Chapel Hill, North Carolina. FAU - Jin, Wanting AU - Jin W AD - Department of Biostatistics, University of North Carolina Gillings School of Global Public Health, Chapel Hill, North Carolina. FAU - Li, Quefeng AU - Li Q AD - Department of Biostatistics, University of North Carolina Gillings School of Global Public Health, Chapel Hill, North Carolina. FAU - Gehi, Anil K AU - Gehi AK AD - Division of Cardiology, Department of Medicine, University of North Carolina Medical Center, Chapel Hill, North Carolina. Electronic address: anilgehi@med.unc.edu. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230922 PL - United States TA - Am J Cardiol JT - The American journal of cardiology JID - 0207277 RN - 0 (Anticoagulants) SB - IM UOF - medRxiv. 2023 Mar 22:2023.03.21.23287553. doi: 10.1101/2023.03.21.23287553. PMID: 36993684 MH - Male MH - Humans MH - Female MH - *Atrial Fibrillation/complications/therapy/chemically induced MH - Risk Factors MH - Feasibility Studies MH - Anticoagulants/therapeutic use MH - *Stroke/prevention & control/complications MH - Primary Health Care MH - Administration, Oral MH - Risk Assessment OTO - NOTNLM OT - atrial fibrillation OT - primary care OT - quality improvement COIS- Declaration of Competing Interest Dr. Gehi reports financial support was provided by Bristol-Myers Squibb Foundation. Anil Gehi reports a relation with Abbott that includes consulting or advisory. Dr. Gehi reports a relation with ZOLL Medical Corporation that includes consulting or advisory. Dr. Gehi reports a relation with iRhythm Technologies Inc that includes consulting or advisory. Dr. Sears reports a relation with Medtronic that includes consulting or advisory. Dr. Sears reports a relation with Abbott that includes consulting or advisory. Dr. Sears reports a relation with Milestone Pharmaceuticals that includes consulting or advisory. Dr. Sears reports a relation with BIOTRONIK Inc that includes speaking and lecture fees. Dr. Sears reports a relation with ZOLL Medical Corporation that includes speaking and lecture fees. Dr. Rosman reports a relation with National Heart Lung and Blood Institute that includes funding grants. Dr. Rosman reports a relation with Pfizer that includes consulting or advisory. Dr. Rosman reports a relation with BIOTRONIK Inc. that includes consulting or advisory. Dr. Walker reports a relation with Bristol-Myers Squibb Foundation that includes funding grants. The remaining authors have no competing interests to declare. EDAT- 2023/09/25 00:42 MHDA- 2023/11/06 06:41 CRDT- 2023/09/24 18:10 PHST- 2023/07/24 00:00 [received] PHST- 2023/08/29 00:00 [revised] PHST- 2023/08/31 00:00 [accepted] PHST- 2023/11/06 06:41 [medline] PHST- 2023/09/25 00:42 [pubmed] PHST- 2023/09/24 18:10 [entrez] AID - S0002-9149(23)00962-1 [pii] AID - 10.1016/j.amjcard.2023.08.184 [doi] PST - ppublish SO - Am J Cardiol. 2023 Nov 15;207:184-191. doi: 10.1016/j.amjcard.2023.08.184. Epub 2023 Sep 22. PMID- 37738484 OWN - NLM STAT- MEDLINE DCOM- 20230925 LR - 20230925 IS - 0038-3317 (Print) IS - 0038-3317 (Linking) VI - 76 IP - 9 DP - 2023 Sep TI - Medical Students as Simulation Educators. PG - 391 AB - INTRODUCTION: Physicians are expected to educate patients, students, colleagues, as well as members of the interdisciplinary team. However, unlike in the United Kingdom and Canada, US medical schools do not require teaching as a competency for graduation. High-quality teaching and communication skills are necessary to ensure patient safety and trust. As the field of medicine becomes increasingly expansive and complex, it can no longer rely on empiric forms of knowledge exchange. Physician training must include pedagogy to create competent educators. In this project, the educational efforts of senior medical students providing simulation-based education to junior students were compared with that provided by faculty-led education. METHODS: The "Medical Students as Simulation Educators" (MSASE) course consists of a didactic and a teaching application component. The didactic component delivers learning modules on topics such as simulation education history, learning theories, debriefing and feedback, curriculum development, teaching methods, assessment, evaluation, and essentials of running the Laerdal SimMan 3G simulation system. After completing didactic courses, student educators apply their pedagogic skills in facilitator-guided, high-fidelity clinical simulations in areas such as anaphylaxis, heart failure, and atrial fibrillation. The evaluation of MSASE compared the knowledge gain of learners led by clinical faculty to those led by student-educators. Learners completed the same multiple-choice quiz (MCQ) before and after the simulation training. In addition, student satisfaction surveys were used to assess their attitudes to being taught by their peers. RESULTS: Scores from the pre- and post-tests were nearly identical in the faculty and student-led groups. The faculty-led group's average pre- and post-activity scores were 41.67% and 72.81%, respectively. The average increase in scores was 31.14%. The student-led group's average pre- and post-activity scores were 44.43% and 75.71%, respectively. The average increase in scores was 31.28%. The results of the student satisfaction survey were supportive of peers as educators. The survey used a 5-point scale with 1 representing "strongly disagree" and 5 representing "strongly agree". Aspects surveyed include learning objective identification and achievement, educator preparedness, organization and structure, simulation realism, complexity appropriateness, engagement level, quality of debriefing, and more. The average student satisfaction score for each aspect of the survey was greater than 4.5. The average of all elements surveyed was 4.75/5. CONCLUSIONS: Data support the contention that medical students are equally effective in simulation-based teaching as clinical faculty. Participating student educators and student learners reported satisfaction with the MSASE experience. CI - Copyright(c) South Dakota State Medical Association. FAU - Durant, Ashley AU - Durant A AD - University of South Dakota Sanford School of Medicine. LA - eng PT - Journal Article PL - United States TA - S D Med JT - South Dakota medicine : the journal of the South Dakota State Medical Association JID - 101265265 SB - IM MH - Humans MH - *Students, Medical MH - *Anaphylaxis MH - *Atrial Fibrillation MH - *Heart Failure EDAT- 2023/09/22 18:42 MHDA- 2023/09/25 06:42 CRDT- 2023/09/22 15:23 PHST- 2023/09/25 06:42 [medline] PHST- 2023/09/22 18:42 [pubmed] PHST- 2023/09/22 15:23 [entrez] PST - ppublish SO - S D Med. 2023 Sep;76(9):391. PMID- 37733894 STAT- Publisher CTDT- 20230921 PB - University of Washington, Seattle DP - 1993 TI - HYAL2 Deficiency. BTI - GeneReviews((R)) AB - CLINICAL CHARACTERISTICS: HYAL2 deficiency is characterized by cardiac anomalies, cleft lip and palate (unilateral or bilateral), ophthalmic findings (including mild-to-severe myopia up to -16.75 diopters and increased risk of retinal detachment), hearing loss (typically conductive), and skeletal findings (including pectus excavatum and digital anomalies). Intellect is typically normal. To date, 17 individuals from seven families have been reported with HYAL2 deficiency. DIAGNOSIS/TESTING: The diagnosis of HYAL2 deficiency is established in a proband with suggestive findings and biallelic pathogenic variants in HYAL2 identified by molecular genetic testing. MANAGEMENT: Treatment of manifestations: There is no cure for HYAL2 deficiency. Supportive care to improve quality of life, maximize function, and reduce complications is recommended. This can include care by specialists in pediatric cardiology and cardiac surgery and a multidisciplinary craniofacial team to coordinate timing and type of surgical interventions, manage issues with feeding and nutrition, and work with speech-language pathologists (regarding speech and communication issues) and audiologists (regarding hearing loss). Surveillance: Members of the multidisciplinary care team will recommend intervals to monitor existing manifestations and the individual's response to supportive care. GENETIC COUNSELING: HYAL2 deficiency is inherited in an autosomal recessive manner. If both parents are known to be heterozygous for an HYAL2 pathogenic variant, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Once the HYAL2 pathogenic variants have been identified in an affected family member, carrier testing for relatives at risk and prenatal and preimplantation genetic testing are possible. CI - Copyright (c) 1993-2026, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved. FED - Adam, Margaret P ED - Adam MP FED - Bick, Sarah ED - Bick S FED - Mirzaa, Ghayda M ED - Mirzaa GM FED - Wallace, Stephanie E ED - Wallace SE FED - Amemiya, Anne ED - Amemiya A FAU - Fasham, James AU - Fasham J AD - University of Exeter Medical School, Exeter, United Kingdom FAU - Wenger, Olivia K AU - Wenger OK AD - New Leaf Center, Clinic for Special Children, Mount Eaton, Ohio FAU - Crosby, Andrew H AU - Crosby AH AD - University of Exeter Medical School, Exeter, United Kingdom FAU - Baple, Emma L AU - Baple EL AD - University of Exeter Medical School, Exeter, United Kingdom LA - eng PT - Review PT - Book Chapter PL - Seattle (WA) OTO - NLM OT - Orofacial Clefting and Cor Triatriatum Sinister Syndrome OT - Hyaluronidase-2 OT - HYAL2 OT - HYAL2 Deficiency OT - Orofacial Clefting and Cor Triatriatum Sinister Syndrome EDAT- 2023/09/21 00:00 CRDT- 2023/09/21 00:00 AID - NBK594824 [bookaccession] PMID- 37730292 OWN - NLM STAT- MEDLINE DCOM- 20230922 LR - 20260518 IS - 1558-3597 (Electronic) IS - 0735-1097 (Print) IS - 0735-1097 (Linking) VI - 82 IP - 13 DP - 2023 Sep 26 TI - Clinical Pathway for Coronary Atherosclerosis in Patients Without Conventional Modifiable Risk Factors: JACC State-of-the-Art Review. PG - 1343-1359 LID - S0735-1097(23)06286-1 [pii] LID - 10.1016/j.jacc.2023.06.045 [doi] AB - Reducing the incidence and prevalence of standard modifiable cardiovascular risk factors (SMuRFs) is critical to tackling the global burden of coronary artery disease (CAD). However, a substantial number of individuals develop coronary atherosclerosis despite no SMuRFs. SMuRFless patients presenting with myocardial infarction have been observed to have an unexpected higher early mortality compared to their counterparts with at least 1 SMuRF. Evidence for optimal management of these patients is lacking. We assembled an international, multidisciplinary team to develop an evidence-based clinical pathway for SMuRFless CAD patients. A modified Delphi method was applied. The resulting pathway confirms underlying atherosclerosis and true SMuRFless status, ensures evidence-based secondary prevention, and considers additional tests and interventions for less typical contributors. This dedicated pathway for a previously overlooked CAD population, with an accompanying registry, aims to improve outcomes through enhanced adherence to evidence-based secondary prevention and additional diagnosis of modifiable risk factors observed. CI - Copyright (c) 2023 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Figtree, Gemma A AU - Figtree GA AD - Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia; Cardiovascular Discovery Group, Kolling Institute of Medical Research, St Leonards, New South Wales, Australia; Department of Cardiology, Royal North Shore Hospital, St Leonards, New South Wales, Australia. Electronic address: Gemma.figtree@sydney.edu.au. FAU - Vernon, Stephen T AU - Vernon ST AD - Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia; Cardiovascular Discovery Group, Kolling Institute of Medical Research, St Leonards, New South Wales, Australia; Department of Cardiology, Royal North Shore Hospital, St Leonards, New South Wales, Australia. FAU - Harmer, Jason A AU - Harmer JA AD - Department of Cardiology, Royal North Shore Hospital, St Leonards, New South Wales, Australia; The George Institute for Global Health, Faculty of Medicine, UNSW, Sydney, New South Wales, Australia. FAU - Gray, Michael P AU - Gray MP AD - Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia; Cardiovascular Discovery Group, Kolling Institute of Medical Research, St Leonards, New South Wales, Australia. FAU - Arnott, Clare AU - Arnott C AD - The George Institute for Global Health, Faculty of Medicine, UNSW, Sydney, New South Wales, Australia; Department of Cardiology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia. FAU - Bachour, Eric AU - Bachour E AD - Consumer Representative, Agile Group Switzerland AG, Zug, Switzerland. FAU - Barsha, Giannie AU - Barsha G AD - Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia; Cardiovascular Discovery Group, Kolling Institute of Medical Research, St Leonards, New South Wales, Australia. FAU - Brieger, David AU - Brieger D AD - Department of Cardiology, Concord Repatriation General Hospital, Concord, New South Wales, Australia. FAU - Brown, Alex AU - Brown A AD - National Centre for Indigenous Genomics, Australian National University, Canberra, Australian Capitol Territory, Australia; Telethon Kids Institute, Nedlands, Western Australia, Australia. FAU - Celermajer, David S AU - Celermajer DS AD - Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia; Department of Cardiology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia. FAU - Channon, Keith M AU - Channon KM AD - British Heart Foundation Centre of Research Excellence, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom. FAU - Chew, Nicholas W S AU - Chew NWS AD - Department of Cardiology, National University Heart Centre, National University Health System, Singapore. FAU - Chong, James J H AU - Chong JJH AD - Westmead Applied Research Centre, Faculty of Medicine and Health, University of Sydney, Westmead, New South Wales, Australia; Westmead Institute for Medical Research, University of Sydney, Westmead, New South Wales, Australia; Department of Cardiology, Westmead Hospital, Westmead, New South Wales, Australia. FAU - Chow, Clara K AU - Chow CK AD - Westmead Applied Research Centre, Faculty of Medicine and Health, University of Sydney, Westmead, New South Wales, Australia; Department of Cardiology, Westmead Hospital, Westmead, New South Wales, Australia. FAU - Cistulli, Peter A AU - Cistulli PA AD - Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia; Charles Perkins Centre, The University of Sydney, Camperdown, New South Wales, Australia; Department of Respiratory & Sleep Medicine, Royal North Shore Hospital, St Leonards, New South Wales, Australia. FAU - Ellinor, Patrick T AU - Ellinor PT AD - Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; Demoulas Center for Cardiac Arrhythmias, Massachusetts General Hospital, Boston, Massachusetts, USA. FAU - Grieve, Stuart M AU - Grieve SM AD - Department of Radiology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia; Imaging and Phenotyping Laboratory, Charles Perkins Centre, University of Sydney, Sydney, New South Wales, Australia. FAU - Guzik, Tomasz J AU - Guzik TJ AD - Centre for Cardiovascular Science, Queen's Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom; Department of Internal Medicine and Omicron Medical Genomics Laboratory, Jagiellonian University Medical College, Krakow, Poland. FAU - Hagstrom, Emil AU - Hagstrom E AD - Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden. FAU - Jenkins, Alicia AU - Jenkins A AD - National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Camperdown, New South Wales, Australia; Diabetes and Vascular Medicine, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia. FAU - Jennings, Garry AU - Jennings G AD - Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia. FAU - Keech, Anthony C AU - Keech AC AD - National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Camperdown, New South Wales, Australia. FAU - Kott, Katharine A AU - Kott KA AD - Cardiovascular Discovery Group, Kolling Institute of Medical Research, St Leonards, New South Wales, Australia; Department of Cardiology, Royal North Shore Hospital, St Leonards, New South Wales, Australia. FAU - Kritharides, Leonard AU - Kritharides L AD - Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia; Department of Cardiology, Concord Repatriation General Hospital, Concord, New South Wales, Australia; The ANZAC Research Institute, Concord Repatriation General Hospital, Concord, New South Wales, Australia. FAU - Mamas, Mamas A AU - Mamas MA AD - Keele Cardiovascular Research Group, Centre for Prognostic Research, Keele University, Keele, United Kingdom; Department of Cardiology, Royal Stoke University Hospital, Stoke-on-Trent, United Kingdom. FAU - Mehran, Roxana AU - Mehran R AD - The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA. FAU - Meikle, Peter J AU - Meikle PJ AD - Baker Heart and Diabetes Institute, Melbourne, Vicotria, Australia. FAU - Natarajan, Pradeep AU - Natarajan P AD - Cardiovascular Research Center, Massachusetts General Hospital, Boston, Massachusetts, USA; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA; Program in Medical and Population Genetics and the Cardiovascular Disease Initiative, Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, Massachusetts, USA. FAU - Negishi, Kazuaki AU - Negishi K AD - Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia; Charles Perkins Centre, The University of Sydney, Camperdown, New South Wales, Australia; Department of Cardiology, Nepean Hospital, Kingswood, New South Wales, Australia. FAU - O'Sullivan, John AU - O'Sullivan J AD - Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia; Department of Cardiology, Royal North Shore Hospital, St Leonards, New South Wales, Australia; Charles Perkins Centre, The University of Sydney, Camperdown, New South Wales, Australia; Precision Cardiovascular Laboratory, University of Sydney, Camperdown, New South Wales, Australia; Heart Research Institute, University of Sydney, Camperdown, New South Wales, Australia. FAU - Patel, Sanjay AU - Patel S AD - Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia; Department of Cardiology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia; Heart Research Institute, University of Sydney, Camperdown, New South Wales, Australia. FAU - Psaltis, Peter J AU - Psaltis PJ AD - Vascular Research Centre, Heart and Vascular Program, Lifelong Health Theme, SAHMRI, Adelaide, South Australia, Australia; Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia; Department of Cardiology, Royal Adelaide Hospital, Central Adelaide Local Health Network, Adelaide, South Australia, Australia. FAU - Redfern, Julie AU - Redfern J AD - The George Institute for Global Health, Faculty of Medicine, UNSW, Sydney, New South Wales, Australia; Sydney School of Health Sciences, Faculty of Medicine and Health, University of Sydney, Camperdown, New South Wales, Australia. FAU - Steg, Philippe G AU - Steg PG AD - Universite de Paris, Assistance Publique-Hopitaux de Paris, French Alliance for Cardiovascular Trials and INSERM Unite 1148, Paris, France. FAU - Sullivan, David R AU - Sullivan DR AD - Department of Chemical Pathology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia. FAU - Sundstrom, Johan AU - Sundstrom J AD - The George Institute for Global Health, Faculty of Medicine, UNSW, Sydney, New South Wales, Australia; Department of Medical Sciences, Uppsala University, Uppsala, Sweden. FAU - Vogel, Birgit AU - Vogel B AD - The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA. FAU - Wilson, Andrew AU - Wilson A AD - Menzies Centre for Health Policy and Economics, Sydney School of Public Health, Faculty of Medicine and Health, University of Sydney, Camperdown, New South Wales, Australia. FAU - Wong, Dennis AU - Wong D AD - Monash Cardiovascular Research Centre, Monash University, Clayton, Victoria, Australia; MonashHeart, Monash Health, Clayton, Victoria, Australia. FAU - Bhatt, Deepak L AU - Bhatt DL AD - Mount Sinai Heart, Icahn School of Medicine at Mount Sinai Health System, New York, New York, USA. FAU - Kovacic, Jason C AU - Kovacic JC AD - The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA; Victor Chang Cardiac Research Institute, Darlinghurst, New South Wales, Australia; St Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia. FAU - Nicholls, Stephen J AU - Nicholls SJ AD - Victorian Heart Institute, Monash University, Clayton, Victoria, Australia. CN - CRE for CAD Collaborators LA - eng GR - CH/16/1/32013/BHF_/British Heart Foundation/United Kingdom GR - SP/17/16/33519/BHF_/British Heart Foundation/United Kingdom GR - R01 HL157635/HL/NHLBI NIH HHS/United States GR - R01 HL092577/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PT - Review PL - United States TA - J Am Coll Cardiol JT - Journal of the American College of Cardiology JID - 8301365 SB - IM MH - Humans MH - *Coronary Artery Disease/epidemiology MH - Critical Pathways MH - *Myocardial Infarction MH - *Atherosclerosis MH - Heart Disease Risk Factors PMC - PMC10522922 OTO - NOTNLM OT - atherosclerosis OT - cardiovascular risk OT - clinical pathway OT - coronary artery disease OT - primary prevention OT - secondary prevention COIS- Funding Support and Author Disclosures The Centre for Research Excellence is supported by National Health & Medical Research Council of Australia (grant number GNT1196629). Dr Figtree is funded by a National Health & Medical Research Council Practitioner Fellowship (GNT1135920). Dr Ellinor is supported by grants from the National Institutes of Health (1RO1HL092577, 1R01HL157635, 1R01HL157635), by a grant from the American Heart Association Strategically Focused Research Networks (18SFRN34110082), and by a grant from the European Union (MAESTRIA 965286). Dr Psaltis is funded by a National Heart Foundation Level 3 Future Leader Fellowship (106656). Dr Redfern is supported by grants from the National Health & Medical Research Council of Australia (GNT2007946 and GNT1182301). Dr Wilson is supported by grants from the National Health & Medical Research Council of Australia (GNT119600, GNT9100001, GNT1153479). Dr Guzik is funded by the British Heart Foundation and European Research Council (ERC-InflammaTENSION 726318). Dr Arnott has received honoraria from Amgen and AstraZeneca. Dr Brown has received consulting fees from Novartis. Dr Bhatt has received research funding from Abbott, Acesion Pharma, Afimmune, Aker Biomarine, Amarin, Amgen, AstraZeneca, Bayer, Beren, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, Cincor, Cleerly, CSL Behring, Eisai, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Pharmaceuticals, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Javelin, Lexicon, Lilly, Medtronic, Merck, Moderna, MyoKardia, NirvaMed, Novartis, Novo Nordisk, Owkin, Pfizer Inc, PhaseBio, PLx Pharma, Recardio, Regeneron, Reid Hoffman Foundation, Roche, Sanofi, Stasys, Synaptic, The Medicines Company, Youngene, and 89bio; has received royalties from Elsevier; has received consulting fees from Broadview Ventures, Hims, and McKinsey; has received payment or honoraria from the American College of Cardiology, Baim Institute for Clinical Research, Belvoir Publications, Boston Scientific, Cleveland Clinic, Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine, Novartis, Population Health Research Institute, Rutgers University, Canadian Medical and Surgical Knowledge Translation Research Group, Cowen and Company, HMP Global, Journal of the American College of Cardiology, K2P, Level Ex, Medtelligence/ReachMD, MJH Life Sciences, Oakstone CME, Piper Sandler, Slack Publications, WebMD, Wiley, and Society of Cardiovascular Patient Care; has received payment for expert testimony from Arnold and Porter law firm; has received travel or meeting support from the American College of Cardiology, Society of Cardiovascular Patient Care, and American Heart Association; has been named (no income) on a patent application for sotagliflozin, assigned to Brigham and Women's Hospital, who assigned to Lexicon; serves on a Data Safety Monitoring Board for Acesion Pharma, Assistance Publique-Hopitaux de Paris, Baim Institute, Boston Scientific, Cleveland Clinic, Contego Medical, Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine, Novartis, and Population Health Research Institute; has served on an Advisory Board for AngioWave, Bayer, Boehringer Ingelheim, Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, Janssen, Level Ex, Medscape Cardiology, Merck, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Regado Biosciences, and Stasys; has served on the Board of Directors for the American College of Cardiology, AngioWave, Boston VA Research Institute, Bristol Myers Squibb, DRS.LINQ, High Enroll, Society of Cardiovascular Patient Care, and TobeSoft; has stock or stock options with AngioWave, Bristol Myers Squibb, DRS.LINQ, and High Enroll; has financial or other nonfinancial interests in Clinical Cardiology, NCDR-ACTION Registry Steering Committee, Contego Medical, American Heart Association Quality Oversight Committee, VA CART Research and Publications Committee; and is a coinvestigator for Abbott, Biotronik, Boston Scientific, CSI, St Jude Medical, Phillips SpectraWAVE, Svelte, and Vascular Solutions. Dr Brieger has received research grant support from Novartis and has received honoraria from BMS/Pfizer. Dr Chong has received consulting fees from Implicit Bioscience Pty; and has a provisional patent for a cell surface marker signature for arrhythmogenic pluripotent stem cell-derived cardiomyocyte. Dr Cistulli has received research grant support from ResMed and SomnoMed; has received consulting fees from RedMed, SomnoMed, and Signifier Medical Technologies; and has received honoraria from ResMed and SomnoMed. Dr Ellinor has received sponsored research support from Bayer AG and IBM Research; and has served on Advisory Boards or consulted for Bayer AG, MyoKardia, and Novartis. Dr Figtree has received personal fees from Amgen, AstraZeneca, Bayer, CSL, and Janssen; has received grants from Abbott Diagnostic and Sanofi; is a founding director and chief medical officer of Prokardia; has a patent, "Biomarkers and Oxidative Stress," awarded in the United States in May 2017 (US9638699B2) licensed to Northern Sydney Local Health District; has a patent, "Use of P2X7R Antagonists in Cardiovascular Disease" (PCT/AU2018/050905), licensed to Prokardia; has a patent, "Methods for Treatment and Prevention of Vascular Disease" (PCT/AU2015/000548) licensed to the University of Sydney/Northern Sydney Local Health District; and has a filed provisional patent application, "Methods for Predicting Coronary Artery Disease" (USYD Ref: 2022-009-PRO-0; 2022902660) to the University of Sydney/Northern Sydney Local Health District. Dr Hagstrom has received research grant support to his institution from Amgen and Pfizer; and has received honoraria from Amgen, AstraZeneca, Bayer, Novo Nordisk, Amarin, and Sanofi. Dr Jenkins has received research grant support from Abbott, Medtronic, and Mylan; and has served on Advisory Boards for Abbott Diabetes Care, Amgen, Insulet, and Medtronic. Dr Keech has received grant support from Abbott, Amgen, and Mylan; has received consulting fees from AstraZeneca, Pfizer, and Sanofi; and has participated as a Data Safety Monitoring Board member for the PROMINENT trial (Kowa Research Institute). Dr Kritharides has received research grant support from Amgen; and has received consulting fees from Seqiris. Dr Meikle has a license agreement with Juvenescence Ltd; and has received consultancy payments (made to Baker Institute) from BCAL Scientific and Juvenescence Ltd. Dr Mehran has received research grant support to her institution from Abbott, Abiomed, Alleviant Medical, AM-Pharma, Amgen, Applied Therapeutics, Arena, AstraZeneca, AtriCure, BAIM, Bayer, Beth Israel Deaconess Biosensors, Biotronik, Boston Scientific, Bristol Myers Squibb, CardiaWave, CellAegis, CeloNova, CERC, Chiesi, Concept Medical, CSL Behring, Cytosorbents, Daiichi-Sankyo, Duke University, Element Science, Faraday, Humacyte, Idorsia, Insel Gruppe AG, Magenta, Medtronic, Novartis, OrbusNeich, PhaseBio, Philips, RenalPro, RM Global, Shockwave, and Vivasure Zoll; has received consulting fees from Cine-Med Research; has served on an Advisory Board with all payments made to institution for Abbott, Janssen, Medtronic, and Novartis; and she and/or her spouse has stock or stock options in Applied Therapeutics, ControlRad, Elixir Medical, and Stel. Dr Natarajan has received research grant support from Apple, Amgen, AstraZeneca, Boston Scientific, and Novartis; has received consulting fees from Apple, AstraZeneca, Blackstone Life Sciences, Foresite Labs, Genetech/Roche, Invitae, Novartis, and TenSixteen Bio; has served on Advisory Boards for Esperion Therapeutics, geneXwell, and TenSixteen Bio; and holds stock or stock options in TenSixteen Bio and geneXwell. Dr Nicholls has received research grant support from AstraZeneca, Amgen, Anthera, Cerenis, Eli Lilly, Esperion, InfraReDx, LipoScience, The Medicines Company, New Amsterdam Pharma, Novartis, Resverlogix, Roche, and Sanofi-Regeneron; and has received consulting fees from Akcea, Amarin, Anthera, AstraZeneca, Boehringer Ingelheim, CSL Behring, Eli Lilly, Esperion, Omthera, Merck, Resverlogix, Sanofi-Regeneron, Takeda, and Vaxxinity. Dr Psaltis has received consulting fees from Amgen, Esperion Therapeutics, and Novartis; has received speaker honoraria from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Novartis, Pfizer, and Sanofi; has received meeting travel support from Amgen and AstraZeneca; and has submitted a provisional patent for a method and composition for promoting neovascularization. Dr Sundstrom has stock or stock options with Anagram Kommunikation AB and Symptoms Europe AB. Dr Steg has received research grant support from Amarin, Bayer, Sanofi, and Servier Laboratories; has received consulting fees from Amgen, AstraZeneca, BMS/Myokardia, Merck, Novo Nordisk, and Regeneron; has served on Steering Committees or Critical Event Committees for Amarin, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Idorsia, Novartis, PhaseBio, Pfizer, Sanofi, and Servier; has received honoraria from AstraZeneca, Novartis, and Novo Nordisk; and has served on Data Safety Monitoring Boards for Servier, Sanofi, and PHRI. Dr Guzik has received research funding from the European Commission (ImmuneHyperCog and BrainGutCVD studies); has served as Editor-in-Chief for Cardiovascular Research; and has served as Board Committee member for the European Society of Cardiology. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. FIR - Ademi, Zanfina IR - Ademi Z FIR - Avis, Suzanne Robyn IR - Avis SR FIR - Chan, Adam IR - Chan A FIR - Contreras, Osvaldo IR - Contreras O FIR - Coorey, Craig P IR - Coorey CP FIR - Fathieh, Sina IR - Fathieh S FIR - Genetzakis, Elijah IR - Genetzakis E FIR - Gholipour, Alireza IR - Gholipour A FIR - Giles, Corey IR - Giles C FIR - Hollings, Matthew IR - Hollings M FIR - Hyun, Karice IR - Hyun K FIR - Kazi, Samia IR - Kazi S FIR - Kovacic, Jason C IR - Kovacic JC FIR - Larance, Mark IR - Larance M FIR - Marathe, Jessica A IR - Marathe JA FIR - Marquina, Clara IR - Marquina C FIR - Nelson, Adam IR - Nelson A FIR - Ng, Hooi Hooi IR - Ng HH FIR - Patrick, Ellis IR - Patrick E FIR - Peter, Karlheinz IR - Peter K FIR - Tran, Andy IR - Tran A FIR - Yang, Jean IR - Yang J FIR - Zhu, Dantong IR - Zhu D FIR - Zwack, Clara IR - Zwack C EDAT- 2023/09/21 00:42 MHDA- 2023/09/22 06:42 PMCR- 2023/09/26 CRDT- 2023/09/20 20:56 PHST- 2023/06/06 00:00 [received] PHST- 2023/06/28 00:00 [accepted] PHST- 2023/09/22 06:42 [medline] PHST- 2023/09/21 00:42 [pubmed] PHST- 2023/09/20 20:56 [entrez] PHST- 2023/09/26 00:00 [pmc-release] AID - S0735-1097(23)06286-1 [pii] AID - 10.1016/j.jacc.2023.06.045 [doi] PST - ppublish SO - J Am Coll Cardiol. 2023 Sep 26;82(13):1343-1359. doi: 10.1016/j.jacc.2023.06.045. PMID- 37729589 OWN - NLM STAT- MEDLINE DCOM- 20250203 LR - 20250513 IS - 1538-4683 (Electronic) IS - 1061-5377 (Linking) VI - 33 IP - 2 DP - 2025 Mar-Apr 01 TI - Review and Key Takeaways of the 2021 Percutaneous Coronary Intervention Guidelines. PG - 178-186 LID - 10.1097/CRD.0000000000000608 [doi] AB - The 2021 Percutaneous Coronary Intervention guidelines completed by American College of Cardiology/American Heart Association/Society for Cardiovascular Angiography and Interventions provide a set of guidelines regarding revascularization strategies. With emphasis on equity of care, multidisciplinary heart team use, revascularization for acute coronary syndrome, and stable ischemic heart disease, the guidelines create a thorough framework with recommendations regarding therapeutic strategies. In this comprehensive review, our aim is to summarize the 2021 revascularization guidelines and analyze key points regarding each recommendation. CI - Copyright (c) 2023 Wolters Kluwer Health, Inc. All rights reserved. FAU - Patail, Haris AU - Patail H AD - From the Department of Internal Medicine, University of Connecticut School of Medicine, Farmington, CT. FAU - Bali, Atul AU - Bali A AD - Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, New York. FAU - Sharma, Tanya AU - Sharma T AD - Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, New York. FAU - Frishman, William H AU - Frishman WH AD - Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, New York. FAU - Aronow, Wilbert S AU - Aronow WS AD - Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, New York. LA - eng PT - Journal Article PT - Review DEP - 20230920 PL - United States TA - Cardiol Rev JT - Cardiology in review JID - 9304686 SB - IM MH - Humans MH - *Percutaneous Coronary Intervention/standards/methods MH - *Practice Guidelines as Topic MH - *Acute Coronary Syndrome/surgery MH - American Heart Association COIS- Disclosure: The authors declare no conflict of interest. EDAT- 2023/09/20 18:42 MHDA- 2025/02/03 18:20 CRDT- 2023/09/20 15:53 PHST- 2025/02/03 18:20 [medline] PHST- 2023/09/20 18:42 [pubmed] PHST- 2023/09/20 15:53 [entrez] AID - 00045415-990000000-00151 [pii] AID - 10.1097/CRD.0000000000000608 [doi] PST - ppublish SO - Cardiol Rev. 2025 Mar-Apr 01;33(2):178-186. doi: 10.1097/CRD.0000000000000608. Epub 2023 Sep 20. PMID- 37727892 OWN - NLM STAT- MEDLINE DCOM- 20231030 LR - 20231030 IS - 1467-1107 (Electronic) IS - 1047-9511 (Linking) VI - 33 IP - 10 DP - 2023 Oct TI - Optimising motor development in the hospitalised infant with CHD: factors contributing to early motor challenges and recommendations for assessment and intervention. PG - 1800-1812 LID - 10.1017/S1047951123003165 [doi] AB - BACKGROUND: Neurodevelopmental challenges are the most prevalent comorbidity associated with a diagnosis of critical CHD, and there is a high incidence of gross and fine motor delays noted in early infancy. The frequency of motor delays in hospitalised infants with critical CHD requires close monitoring from developmental therapies (physical therapists, occupational therapists, and speech-language pathologists) to optimise motor development. Currently, minimal literature defines developmental therapists' role in caring for infants with critical CHD in intensive or acute care hospital units. PURPOSE: This article describes typical infant motor skill development, how the hospital environment and events surrounding early cardiac surgical interventions impact those skills, and how developmental therapists support motor skill acquisition in infants with critical CHD. Recommendations for healthcare professionals and those who provide medical or developmental support in promotion of optimal motor skill development in hospitalised infants with critical CHD are discussed. CONCLUSIONS: Infants with critical CHD requiring neonatal surgical intervention experience interrupted motor skill interactions and developmental trajectories. As part of the interdisciplinary team working in intensive and acute care settings, developmental therapists assess, guide motor intervention, promote optimal motor skill acquisition, and support the infant's overall development. FAU - Rogers, Stefanie C AU - Rogers SC AUID- ORCID: 0000-0003-4005-8760 AD - Children's Health Rehabilitation and Therapy Services, Children's Medical Center Dallas, Dallas, TX, USA. FAU - Malik, Lauren AU - Malik L AD - Primary Children's Hospital, Salt Lake City, UT, USA. FAU - Fogel, Jennifer AU - Fogel J AD - Advocate Children's Hospital, Oak Lawn, IL, USA. FAU - Hamilton, Bridy AU - Hamilton B AD - Nemours Children's Hospital, Wilmington, DE, USA. FAU - Huisenga, Darlene AU - Huisenga D AD - Advocate Children's Hospital, Oak Lawn, IL, USA. FAU - Lewis-Wolf, Christina AU - Lewis-Wolf C AD - Children's Hospitals and Clinics of Minnesota, Minneapolis, MN, USA. FAU - Mieczkowski, Dana AU - Mieczkowski D AD - Nemours Children's Hospital, Wilmington, DE, USA. FAU - Peterson, Jennifer K AU - Peterson JK AUID- ORCID: 0000-0001-7628-567X AD - Johns Hopkins University School of Nursing, Baltimore, MD, USA. FAU - Russell, Sarah AU - Russell S AD - Nemours Children's Hospital, Wilmington, DE, USA. FAU - Schmelzer, Anne C AU - Schmelzer AC AD - Duke University Pediatric and Congenital Heart Center, Durham, NC, USA. FAU - Smith, Jodi AU - Smith J AD - The Mended Hearts, Inc., Leesburg, GA, USA. FAU - Butler, Samantha C AU - Butler SC AUID- ORCID: 0000-0001-8576-7179 AD - Harvard Medical School, Boston Children's Hospital, Boston, MA, USA. LA - eng PT - Journal Article PT - Review DEP - 20230920 PL - England TA - Cardiol Young JT - Cardiology in the young JID - 9200019 SB - IM MH - Infant, Newborn MH - Infant MH - Humans MH - Child Development MH - Motor Skills MH - *Cardiac Surgical Procedures MH - *Motor Skills Disorders OTO - NOTNLM OT - CHD OT - cardiac neurodevelopment OT - critical care OT - occupational therapy OT - physical therapy OT - speech-language pathology EDAT- 2023/09/20 06:42 MHDA- 2023/10/30 06:46 CRDT- 2023/09/20 04:02 PHST- 2023/10/30 06:46 [medline] PHST- 2023/09/20 06:42 [pubmed] PHST- 2023/09/20 04:02 [entrez] AID - S1047951123003165 [pii] AID - 10.1017/S1047951123003165 [doi] PST - ppublish SO - Cardiol Young. 2023 Oct;33(10):1800-1812. doi: 10.1017/S1047951123003165. Epub 2023 Sep 20. PMID- 37726085 OWN - NLM STAT- MEDLINE DCOM- 20231216 LR - 20250512 IS - 1097-6833 (Electronic) IS - 0022-3476 (Linking) VI - 264 DP - 2024 Jan TI - Management Strategies for Congenital Heart Disease Comorbid with Airway Anomalies in Children. PG - 113741 LID - S0022-3476(23)00604-2 [pii] LID - 10.1016/j.jpeds.2023.113741 [doi] AB - OBJECTIVE: To assess management strategies for pediatric patients with the challenging combination of congenital heart diseases (CHDs) and airway anomalies. STUDY DESIGN: Patients diagnosed with CHD and airway anomalies in the Pediatric Cardiac Surgery Centre of Fuwai Hospital from January 2016 to December 2020 were included in this retrospective study. Patients were divided into three groups based on different management, including the conservative group, the slide group (slide tracheoplasty), and the suspension group (suspension with external stenting). Patients' data and computed tomography measurements from medical records were reviewed. RESULTS: A total of 139 patients were included in the cohort; 107 had conservative airway treatment (conservative group), 15 had slide tracheoplasty (slide group), and 17 had tracheal suspension operation (suspension group). The top three associated intracardiac anomalies were ventricular septal defect (n = 34, 24%), pulmonary artery sling (n = 22, 16%), and tetralogy of Fallot (n = 15, 11%). Compared with patients with conservative airway management (100 minutes [median], 62-152 [IQR]), the extra airway procedure prolonged cardiopulmonary bypass duration, with 202 minutes (IQR, 119-220) for the slide group and 150 minutes (IQR, 125-161) for the suspension group. Patients who underwent slide tracheoplasty required prolonged mechanical ventilation (129 minutes [median], 56-328 [IQR]). Of the total cohort, 6 in-hospital deaths, all in the conservative group, and 8 mid-to long-term deaths, with 6 in the conservative group, occurred. CONCLUSIONS: Both conservative and surgical management of CHD patients with airway anomalies have promising outcomes. Extra tracheobronchial procedures, especially the slide tracheoplasty, significantly prolonged cardiopulmonary bypass duration. Based on multidisciplinary team assessment, individualized management strategies should be developed for these patients. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Liu, Yuze AU - Liu Y AD - Pediatric Cardiac Surgery Centre, Fuwai Hospital, National Centre for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China. FAU - He, Qiyu AU - He Q AD - Pediatric Cardiac Surgery Centre, Fuwai Hospital, National Centre for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China. FAU - Dou, Zheng AU - Dou Z AD - Pediatric Cardiac Surgery Centre, Fuwai Hospital, National Centre for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China. FAU - Ma, Kai AU - Ma K AD - Pediatric Cardiac Surgery Centre, Fuwai Hospital, National Centre for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China. FAU - Chen, Weinan AU - Chen W AD - Information Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Li, Shoujun AU - Li S AD - Pediatric Cardiac Surgery Centre, Fuwai Hospital, National Centre for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China. Electronic address: drlishoujunfw@163.com. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230917 PL - United States TA - J Pediatr JT - The Journal of pediatrics JID - 0375410 SB - IM MH - Child MH - Humans MH - Infant MH - Retrospective Studies MH - *Tracheal Stenosis/congenital MH - Treatment Outcome MH - *Heart Defects, Congenital/complications/epidemiology/surgery MH - Cardiopulmonary Bypass/methods MH - Trachea/surgery OTO - NOTNLM OT - airway anomalies OT - cardiovascular surgery OT - congenital heart disease OT - management strategy COIS- Declaration of Competing Interest This study was supported by the CAMS Innovation Fund for Medical Sciences (CIFMS, 2020-I2M-C&T-A-009), Capital Health Research and Development of Special Fund (2022-1-4032), and the National High Level Hospital Clinical Research Funding (2022-GSP-GG-19). The other authors declare no conflicts of interest. This study was approved by the ethical review board of Fuwai Hospital (NO. 2021-1506). Informed consent was obtained from the legal guardians of the children who understood and participated in the study. All procedures conducted in this study were in accordance with the Declaration of Helsinki. EDAT- 2023/09/20 00:43 MHDA- 2023/12/17 09:45 CRDT- 2023/09/19 19:12 PHST- 2023/03/29 00:00 [received] PHST- 2023/09/03 00:00 [revised] PHST- 2023/09/13 00:00 [accepted] PHST- 2023/12/17 09:45 [medline] PHST- 2023/09/20 00:43 [pubmed] PHST- 2023/09/19 19:12 [entrez] AID - S0022-3476(23)00604-2 [pii] AID - 10.1016/j.jpeds.2023.113741 [doi] PST - ppublish SO - J Pediatr. 2024 Jan;264:113741. doi: 10.1016/j.jpeds.2023.113741. Epub 2023 Sep 17. PMID- 37721181 OWN - NLM STAT- MEDLINE DCOM- 20240321 LR - 20241118 IS - 1365-2753 (Electronic) IS - 1356-1294 (Linking) VI - 30 IP - 2 DP - 2024 Mar TI - Factors influencing the successful implementation of a novel digital health application to streamline multidisciplinary communication across multiple organisations for emergency care. PG - 184-198 LID - 10.1111/jep.13923 [doi] AB - RATIONALE: Delivering optimal patient health care requires interdisciplinary clinician communication. A single communication tool across multiple pre-hospital and hospital settings, and between hospital departments is a novel solution to current systems. Fit-for-purpose, secure smartphone applications allow clinical information to be shared quickly between health providers. Little is known as to what underpins their successful implementation in an emergency care context. AIMS: To identify (a) whether implementing a single, digital health communication application across multiple health care organisations and hospital departments is feasible; (b) the barriers and facilitators to implementation; and (c) which factors are associated with clinicians' intentions to use the technology. METHODS: We used a multimethod design, evaluating the implementation of a secure, digital communication application (Pulsara). The technology was trialled in two Australian regional hospitals and 25 Ambulance Victoria branches (AV). Post-training, clinicians involved in treating patients with suspected stroke or cardiac events were administered surveys measuring perceived organisational readiness (Organisational Readiness for Implementing Change), clinicians' intentions (Unified Theory of Acceptance and Use of Technology) and internal motivations (Self-Determination Theory) to use Pulsara, and the perceived benefits and barriers of use. Quantitative data were descriptively summarised with multivariable associations between factors and intentions to use Pulsara examined with linear regression. Qualitative data responses were subjected to directed content analysis (two coders). RESULTS: Participants were paramedics (n = 82, median 44 years) or hospital-based clinicians (n = 90, median 37 years), with organisations perceived to be similarly ready. Regression results (F(11, 136) = 21.28, p = <0.001, Adj R(2) = 0.60) indicated Habit, Effort Expectancy, Perceived Organisational Readiness, Performance Expectancy and Organisation membership (AV) as predictors of intending to use Pulsara. Themes relating to benefits (95% coder agreement) included improved communication, procedural efficiencies and faster patient care. Barriers (92% coder agreement) included network accessibility and remembering passwords. Pulsara(TM) was initiated 562 times. CONCLUSION: Implementing multiorganisational, digital health communication applications is feasible, and facilitated when organisations are change-ready for an easy-to-use, effective solution. Developing habitual use is key, supported through implementation strategies (e.g., hands-on training). Benefits should be emphasised (e.g., during education sessions), including streamlining communication and patient flow, and barriers addressed (e.g., identify champions and local technical support) at project commencement. CI - (c) 2023 The Authors. Journal of Evaluation in Clinical Practice published by John Wiley & Sons Ltd. FAU - Bagot, Kathleen L AU - Bagot KL AUID- ORCID: 0000-0003-2895-4327 AD - Public Health and Health Services Research, Stroke theme, The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Heidelberg, Victoria, Australia. AD - Stroke and Ageing Research, Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia. FAU - Bladin, Chris F AU - Bladin CF AUID- ORCID: 0000-0002-1729-0855 AD - Public Health and Health Services Research, Stroke theme, The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Heidelberg, Victoria, Australia. AD - Ambulance Victoria, Doncaster, Victoria, Australia. AD - Eastern Health Clinical School, Monash University, Clayton, Victoria, Australia. FAU - Vu, Michelle AU - Vu M AD - Public Health and Health Services Research, Stroke theme, The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Heidelberg, Victoria, Australia. FAU - Bernard, Stephen AU - Bernard S AD - Ambulance Victoria, Doncaster, Victoria, Australia. AD - Department of Epidemiology and Preventive Medicine, Monash University, Clayton, Victoria, Australia. FAU - Smith, Karen AU - Smith K AUID- ORCID: 0000-0002-9057-0685 AD - Ambulance Victoria, Doncaster, Victoria, Australia. AD - Department of Epidemiology and Preventive Medicine, Monash University, Clayton, Victoria, Australia. AD - Department of Paramedicine, Monash University, Clayton, Victoria, Australia. AD - Research and Innovation, Silverchain Group, Melbourne, Victoria, Australia. FAU - Hocking, Grant AU - Hocking G AD - Ambulance Victoria, Doncaster, Victoria, Australia. FAU - Coupland, Tessa AU - Coupland T AD - Bendigo Health, Bendigo, Victoria, Australia. FAU - Hutton, Debra AU - Hutton D AD - Grampians Health Ballarat, Ballarat, Victoria, Australia. FAU - Badcock, Diane AU - Badcock D AD - Bendigo Health, Bendigo, Victoria, Australia. FAU - Budge, Marc AU - Budge M AD - Bendigo Health, Bendigo, Victoria, Australia. FAU - Nadurata, Voltaire AU - Nadurata V AUID- ORCID: 0000-0002-0312-3140 AD - Bendigo Health, Bendigo, Victoria, Australia. FAU - Pearce, Wayne AU - Pearce W AD - Ambulance Victoria, Doncaster, Victoria, Australia. FAU - Hall, Howard AU - Hall H AD - Ambulance Victoria, Doncaster, Victoria, Australia. FAU - Kelly, Ben AU - Kelly B AD - Grampians Health Ballarat, Ballarat, Victoria, Australia. FAU - Spencer, Angie AU - Spencer A AD - Grampians Health Ballarat, Ballarat, Victoria, Australia. FAU - Chapman, Pauline AU - Chapman P AD - Grampians Health Ballarat, Ballarat, Victoria, Australia. FAU - Oqueli, Ernesto AU - Oqueli E AD - Grampians Health Ballarat, Ballarat, Victoria, Australia. AD - Department of Medicine, Deakin University, Burwood, Victoria, Australia. FAU - Sahathevan, Ramesh AU - Sahathevan R AUID- ORCID: 0000-0001-7643-0961 AD - Grampians Health Ballarat, Ballarat, Victoria, Australia. AD - Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville, Victoria, Australia. AD - Ballarat Clinical School, School of Medicine, Deakin University, Ballarat, Australia. FAU - Kraemer, Thomas AU - Kraemer T AD - Grampians Health Ballarat, Ballarat, Victoria, Australia. FAU - Hair, Casey AU - Hair C AD - Grampians Health Ballarat, Ballarat, Victoria, Australia. FAU - Dion, Stub AU - Dion S AUID- ORCID: 0000-0001-8686-2709 AD - Ambulance Victoria, Doncaster, Victoria, Australia. AD - Department of Epidemiology and Preventive Medicine, Monash University, Clayton, Victoria, Australia. FAU - McGuinness, Connor AU - McGuinness C AD - Public Health and Health Services Research, Stroke theme, The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Heidelberg, Victoria, Australia. FAU - Cadilhac, Dominique A AU - Cadilhac DA AUID- ORCID: 0000-0001-8162-682X AD - Public Health and Health Services Research, Stroke theme, The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Heidelberg, Victoria, Australia. AD - Stroke and Ageing Research, Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia. LA - eng GR - National Health and Medical Reserach Council Senior Research Fellowship/ GR - National Heart Foundation Future Leader Fellowship/ GR - Hospital Future Fund/ GR - Boeringher Ingelheim/ GR - Victorian Stroke Clinical Network/ GR - Victorian Cardiac Clinical Network/ GR - National Heart Foundation of Australia/ GR - Stroke Foundation/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230918 PL - England TA - J Eval Clin Pract JT - Journal of evaluation in clinical practice JID - 9609066 SB - IM MH - Humans MH - *Interdisciplinary Communication MH - Digital Health MH - Australia MH - *Emergency Medical Services MH - Delivery of Health Care OTO - NOTNLM OT - communication barriers OT - disruptive technology OT - evaluation OT - health services research OT - implementation science OT - patient-centred care EDAT- 2023/09/18 12:43 MHDA- 2024/03/21 12:42 CRDT- 2023/09/18 06:43 PHST- 2023/08/04 00:00 [revised] PHST- 2023/05/02 00:00 [received] PHST- 2023/08/15 00:00 [accepted] PHST- 2024/03/21 12:42 [medline] PHST- 2023/09/18 12:43 [pubmed] PHST- 2023/09/18 06:43 [entrez] AID - 10.1111/jep.13923 [doi] PST - ppublish SO - J Eval Clin Pract. 2024 Mar;30(2):184-198. doi: 10.1111/jep.13923. Epub 2023 Sep 18. PMID- 37716642 OWN - NLM STAT- MEDLINE DCOM- 20240219 LR - 20240308 IS - 1916-7075 (Electronic) IS - 0828-282X (Linking) VI - 40 IP - 2 DP - 2024 Feb TI - Lifetime Management of Patients With Severe Aortic Stenosis in the Era of Transcatheter Aortic Valve Replacement. PG - 210-217 LID - S0828-282X(23)01662-8 [pii] LID - 10.1016/j.cjca.2023.09.010 [doi] AB - Aortic stenosis is the most common valvular disease. Surgical aortic valve replacement (SAVR) using mechanical valves has been the preferred treatment for younger patients, but bioprosthetic valves are gaining favour to avoid anticoagulation with warfarin. Transcatheter aortic valve replacement (TAVR) was approved in recent years for the treatment of severe aortic stenosis in intermediate- and low-risk patients as an alternative to SAVR. The longer life expectancy of these groups of patients might exceed the durability of the TAVR or SAVR bioprosthetic valves. Therefore, many patients need 2 or even 3 interventions during their lifetime. Because it has important implications on the feasibility of subsequent procedures, the decision between opting for SAVR or TAVR as the primary procedure requires thorough consideration by the heart team, incorporating patient preferences, clinical indicators, and anatomic aspects. If TAVR is favoured initially, selecting the valve type and determining the implantation level should be conducted, aiming for positive outcomes in the index intervention and keeping in mind the potential for subsequent TAVR-in-TAVR procedures. When SAVR is selected as the primary procedure, the operator must make choices regarding the valve type and the potential need for aortic root enlargement, with the intention of facilitating future valve-in-valve interventions. This narrative review examines the existing evidence concerning the lifelong management of severe aortic stenosis, delving into available treatment strategies, particularly emphasising the initial procedure's selection and its impact on subsequent interventions. CI - Copyright (c) 2023 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved. FAU - Jubran, Ayman AU - Jubran A AD - Division of Cardiology, Department of Medicine, Schulich Heart Program, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Department of Medicine, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. FAU - Patel, Raumil V AU - Patel RV AD - Department of Medicine, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. FAU - Sathananthan, Janarthanan AU - Sathananthan J AD - Centre for Cardiovascular Innovation-Centre d'Innovation Cardiovasculaire, St Paul's and Vancouver General Hospitals, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Wijeysundera, Harindra C AU - Wijeysundera HC AD - Division of Cardiology, Department of Medicine, Schulich Heart Program, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Department of Medicine, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada; Institute for Health Policy, Management, and Evaluation, Toronto, Ontario, Canada; Sunnybrook Research Institute, Toronto, Ontario, Canada. Electronic address: Harindra.wijeysundera@sunnybrook.ca. LA - eng PT - Journal Article PT - Review DEP - 20230915 PL - England TA - Can J Cardiol JT - The Canadian journal of cardiology JID - 8510280 SB - IM MH - Humans MH - *Transcatheter Aortic Valve Replacement/methods MH - *Heart Valve Prosthesis Implantation/methods MH - Treatment Outcome MH - Aortic Valve/surgery MH - *Aortic Valve Stenosis/etiology MH - Risk Factors EDAT- 2023/09/17 00:42 MHDA- 2024/02/19 06:42 CRDT- 2023/09/16 19:18 PHST- 2023/07/31 00:00 [received] PHST- 2023/09/01 00:00 [revised] PHST- 2023/09/11 00:00 [accepted] PHST- 2024/02/19 06:42 [medline] PHST- 2023/09/17 00:42 [pubmed] PHST- 2023/09/16 19:18 [entrez] AID - S0828-282X(23)01662-8 [pii] AID - 10.1016/j.cjca.2023.09.010 [doi] PST - ppublish SO - Can J Cardiol. 2024 Feb;40(2):210-217. doi: 10.1016/j.cjca.2023.09.010. Epub 2023 Sep 15. PMID- 37714369 OWN - NLM STAT- MEDLINE DCOM- 20240914 LR - 20260327 IS - 1097-685X (Electronic) IS - 0022-5223 (Linking) VI - 168 IP - 3 DP - 2024 Sep TI - Optimizing care of patients undergoing cardiac surgery using a digital platform and a multidisciplinary team approach. PG - 898-904.e1 LID - S0022-5223(23)00795-X [pii] LID - 10.1016/j.jtcvs.2023.09.020 [doi] AB - OBJECTIVE: Restrictions to care access during the pandemic along with the increasing complexity of patients awaiting cardiac surgery provides unique challenges for care delivery. The University of Ottawa Heart Institute has developed a novel multidisciplinary digital platform, the Prehab Automated Follow-Up (AFU) Program, which delivers patient/caregiver teaching regarding risk factor mitigation, tracks patient symptoms, and screens for optimization using best practice guidelines. This study was conducted to quantify patient outcomes following initiation of the AFU Program. METHODS: Patients awaiting elective cardiac surgery are enrolled and screened via automated telephone conversation, according to best practice guidelines, and a Short Form-12 preoperative assessment. Following this screen, patients are referred for an in-person assessment by an appropriate multidisciplinary team member; namely, a diabetes specialist, physiotherapist, dietitian, smoking cessation counselor, social worker, vocational counselor, and/or psychologist. RESULTS: Since initiation in February 2021, the AFU Program has enrolled more than 1237 patients with 508 multidisciplinary team referrals prompted by the AFU screening platform. Before program initiation, there were no multidisciplinary team referrals for preoperative optimization. Compared with patients treated between February 2020 and February 2021, there was a 2.5% decrease in hospital readmission rate within 30 days of surgery, a 0.6-day shorter hospital stay, and a 2.5% decrease in surgical site infection. CONCLUSIONS: Our cardiac surgery AFU Program reduced adverse health outcomes for patients by identifying and optimizing risk factors that increased quality of patient care. The AFU Program provides patient/caregiver engagement through educational support and multidisciplinary team counseling. CI - Copyright (c) 2023 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved. FAU - Charlebois, Amy AU - Charlebois A AD - Division of Cardiac Surgery, University of Ottawa Heart Institute, Ottawa, Ontario, Canada. FAU - Quinlan, Bonnie AU - Quinlan B AD - Division of Cardiac Prevention & Rehabilitation, University of Ottawa Heart Institute, Ottawa, Ontario, Canada. FAU - Coulton, Ruth AU - Coulton R AD - Division of Cardiac Surgery, University of Ottawa Heart Institute, Ottawa, Ontario, Canada. FAU - Sawyer, Julie AU - Sawyer J AD - Division of Cardiac Prevention & Rehabilitation, University of Ottawa Heart Institute, Ottawa, Ontario, Canada. FAU - MacPhee, Erika AU - MacPhee E AD - University of Ottawa Heart Institute, Ottawa, Ontario, Canada. FAU - Lafreniere, Tammy AU - Lafreniere T AD - Division of Cardiac Prevention & Rehabilitation, University of Ottawa Heart Institute, Ottawa, Ontario, Canada. FAU - Serrano, Emilie AU - Serrano E AD - Division of Cardiac Prevention & Rehabilitation, University of Ottawa Heart Institute, Ottawa, Ontario, Canada. FAU - Ruel, Marc AU - Ruel M AD - Division of Cardiac Surgery, University of Ottawa Heart Institute, Ottawa, Ontario, Canada. FAU - Elmestekawy, Elsayed AU - Elmestekawy E AD - Division of Cardiac Surgery, University of Ottawa Heart Institute, Ottawa, Ontario, Canada. FAU - Chan, Vincent AU - Chan V AD - Division of Cardiac Surgery, University of Ottawa Heart Institute, Ottawa, Ontario, Canada. Electronic address: vchan@ottawaheart.ca. LA - eng PT - Journal Article DEP - 20230914 PL - United States TA - J Thorac Cardiovasc Surg JT - The Journal of thoracic and cardiovascular surgery JID - 0376343 SB - IM CIN - J Thorac Cardiovasc Surg. 2024 Sep;168(3):905-906. doi: 10.1016/j.jtcvs.2023.10.002. PMID: 37930302 MH - Humans MH - *Cardiac Surgical Procedures/adverse effects MH - *Patient Care Team/organization & administration MH - Male MH - Female MH - COVID-19/epidemiology MH - Aged MH - Middle Aged MH - Risk Factors MH - Preoperative Care/methods MH - Patient Education as Topic OTO - NOTNLM OT - cardiac surgery OT - education OT - multidisciplinary team EDAT- 2023/09/16 05:42 MHDA- 2024/09/15 14:09 CRDT- 2023/09/15 19:15 PHST- 2023/05/06 00:00 [received] PHST- 2023/08/04 00:00 [revised] PHST- 2023/09/03 00:00 [accepted] PHST- 2024/09/15 14:09 [medline] PHST- 2023/09/16 05:42 [pubmed] PHST- 2023/09/15 19:15 [entrez] AID - S0022-5223(23)00795-X [pii] AID - 10.1016/j.jtcvs.2023.09.020 [doi] PST - ppublish SO - J Thorac Cardiovasc Surg. 2024 Sep;168(3):898-904.e1. doi: 10.1016/j.jtcvs.2023.09.020. Epub 2023 Sep 14. PMID- 37713905 OWN - NLM STAT- MEDLINE DCOM- 20230918 LR - 20250503 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 102 IP - 37 DP - 2023 Sep 15 TI - The preliminary development and clinical verification of the positive index score scale of "Heart Arthralgia Syndrome". PG - e34644 LID - 10.1097/MD.0000000000034644 [doi] LID - e34644 AB - BACKGROUND: In recent years, the age of onset for coronary heart disease (CHD) has become one of the leading causes of death worldwide. The medical treatments occasionally cause side effects; therefore, there is still an urgent need to develop new therapeutic modalities for CHD in clinical practice. "Heart Arthralgia Syndrome (HAS)" is a general term for CHD with arthralgia symptoms proposed by our team based on clinical experience. At present, there is little in-depth research on the treatment of HAS by TCM. Pick Complex Therapy (PCT) is an innovative and developed theory of collateral acupuncture therapy for HAS. METHODS: We collected data from 276 patients who met the criteria for (coronary heart disease with numbness of neck, shoulder, waist, and leg). We selected 24 diagnostic criteria for HAS by means of multiple methods, including Cronbach's alpha coefficient, retest reliability, subjective evaluation, discrete trend, Pearson's rank correlation coefficient and factor analysis method. We thereafter evaluated the reliability, validity and responsiveness of the scale. In the clinical validation phase, we verified whether the preliminary developed positive index (PI) scale can guide clinical practice. Forty (40) patients with HAS were selected in the study. SPSS23.0 statistical software was used for statistical processing and analysis. RESULTS: Assessment results of the initial PI scale for HAS: the average time to complete the scale was 7.47 +/- 3.59 minutes. Cronbach's alpha coefficient for the initial table was 0.711, the retest reliability was 0.897, the Kaiser-Meyer-Olkin test result was 0.844, and the Bartlett test result was 2502.300. Following maximum variance rotation analysis, the cumulative variance contribution rate was determined to be 66.605%. In the clinical validation phase of the PI scale, we tested 40 patients before and after the PCT treatments. After 3 measurements, the correlation between the PI scale for HAS and the angina pectoris grading scoring method table decreased gradually. The last 2 measurement results of study indicated that there was a significant correlation between the PI scale and thrombin time, while physical and chemical examination showed no significant changes. CONCLUSION: The PI scale for HAS can be widely used in the clinic as a preliminary evaluation tool for guiding PCT. CI - Copyright (c) 2023 the Author(s). Published by Wolters Kluwer Health, Inc. FAU - Xu, Sai AU - Xu S AUID- ORCID: 0000-0002-9392-3001 AD - Shandong University of Traditional Chinese Medicine, Jinan, China. FAU - Chen, Shouqiang AU - Chen S AD - Second Affiliated Hospital of Shandong University of TCM, Jinan, China. FAU - Xu, Yunsheng AU - Xu Y AUID- ORCID: 0000-0001-7423-2988 AD - Second Affiliated Hospital of Shandong University of TCM, Jinan, China. LA - eng GR - No. 2018YFC1704103/Research on the Academic Viewpoints, Unique Diagnostic and Treatment Methods and Major Diseases Prevention and Treatment Experience of Illustrious Senior Traditional Chinese Medicine Practitioners in Central China/ PT - Journal Article PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R SB - IM MH - Humans MH - Reproducibility of Results MH - *Heart MH - Angina Pectoris MH - *Acupuncture Therapy MH - Arthralgia/diagnosis/therapy PMC - PMC10508379 COIS- The authors have no conflicts of interest to disclose. EDAT- 2023/09/16 05:42 MHDA- 2023/09/18 12:44 PMCR- 2023/09/15 CRDT- 2023/09/15 18:04 PHST- 2023/09/18 12:44 [medline] PHST- 2023/09/16 05:42 [pubmed] PHST- 2023/09/15 18:04 [entrez] PHST- 2023/09/15 00:00 [pmc-release] AID - 00005792-202309150-00093 [pii] AID - 10.1097/MD.0000000000034644 [doi] PST - ppublish SO - Medicine (Baltimore). 2023 Sep 15;102(37):e34644. doi: 10.1097/MD.0000000000034644. PMID- 37713615 OWN - NLM STAT- MEDLINE DCOM- 20231225 LR - 20231225 IS - 2048-8734 (Electronic) IS - 2048-8726 (Linking) VI - 12 IP - 12 DP - 2023 Dec 21 TI - Multidisciplinary cardiogenic shock team approach improves the long-term outcomes of patients suffering from refractory cardiogenic shock treated with short-term mechanical circulatory support. PG - 821-830 LID - 10.1093/ehjacc/zuad108 [doi] AB - AIMS: Short-term mechanical circulatory support (STMCS) may be used as an intentional escalation strategy to treat refractory cardiogenic shock (rCS). However, with growing technical possibilities, making the right choice at the right time can be challenging. We established a shock team in January 2013 comprising a cardiac anaesthetist-intensivist, an interventional cardiologist, and a cardiac surgeon. Since then, a diagnosis of rCS has triggered a multidisciplinary team meeting based on a common algorithm. This study aimed to compare the decision-making process for STMCS for rCS before (2007-2013) and after (2013-2019) the creation of the shock team. METHODS AND RESULTS: This before-and-after cohort study was conducted over a 156-month period. Post-cardiotomy rCS were excluded. The primary outcome was a 1-year survival rate. In total, 250 consecutive adult patients were included in the analysis (84 in the control group and 166 in the shock team group). At baseline, the CardShock score was not different between the two groups (5[3-5] vs. 5[4-6], P = 0.323). The 1-year survival rate was significantly higher in the shock team group compared with the control group (59% vs. 45%, P = 0.043). After a Cox regression analysis, the shock team intervention was independently associated with a significantly improved 1-year survival rate (HR: 0.592, 95% CI: 0.398-0.880, P = 0.010). CONCLUSION: A multidisciplinary shock team-based decision for STMCS device implantation in rCS is associated with better 1-year survival rates. CI - (c) The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. FAU - Herion, Francois-Xavier AU - Herion FX AD - Department of Cardiovascular Anaesthesia and Critical Care, University Hospital of Bordeaux, Avenue du Haut Leveque, 33604 Pessac, France. AD - University Bordeaux, INSERM, U1034 Biologie des maladies cardiovasculaires, 1 Av. Magellan, 33600 Pessac, France. FAU - Beurton, Antoine AU - Beurton A AUID- ORCID: 0000-0002-3708-4653 AD - Department of Cardiovascular Anaesthesia and Critical Care, University Hospital of Bordeaux, Avenue du Haut Leveque, 33604 Pessac, France. AD - University Bordeaux, INSERM, U1034 Biologie des maladies cardiovasculaires, 1 Av. Magellan, 33600 Pessac, France. FAU - Oddos, Claire AU - Oddos C AD - Department of Cardiovascular Anaesthesia and Critical Care, University Hospital of Bordeaux, Avenue du Haut Leveque, 33604 Pessac, France. FAU - Nubret, Karine AU - Nubret K AD - Heart Failure Unit, Cardiology Department, Hopital Cardiologique du Haut Leveque, University Hospital of Bordeaux, Avenue du Haut Leveque, 33604 Pessac, France. FAU - Aguerreche, Clement AU - Aguerreche C AD - Department of Cardiovascular Anaesthesia and Critical Care, University Hospital of Bordeaux, Avenue du Haut Leveque, 33604 Pessac, France. FAU - Quessard, Astrid AU - Quessard A AD - Department of Cardiovascular Anaesthesia and Critical Care, University Hospital of Bordeaux, Avenue du Haut Leveque, 33604 Pessac, France. FAU - Faure, Maxime AU - Faure M AD - Heart Failure Unit, Cardiology Department, Hopital Cardiologique du Haut Leveque, University Hospital of Bordeaux, Avenue du Haut Leveque, 33604 Pessac, France. FAU - Gerbaud, Edouard AU - Gerbaud E AUID- ORCID: 0000-0003-4669-3562 AD - Department of Cardiology Intensive Care Unit and Interventional Cardiology, Hopital Cardiologique du Haut Leveque, University Hospital of Bordeaux, Avenue du Haut Leveque, 33604 Pessac, France. AD - Bordeaux Cardio-Thoracic Research Centre, U1045, University Hospital of Bordeaux, Plateforme Technologique d'Innovation Biomedicale, Avenue du Haut Leveque, 33600 Pessac, France. FAU - Pernot, Mathieu AU - Pernot M AUID- ORCID: 0000-0001-5882-8925 AD - University Bordeaux, INSERM, U1034 Biologie des maladies cardiovasculaires, 1 Av. Magellan, 33600 Pessac, France. AD - Department of Cardiovascular Surgery, Hopital Cardiologique du Haut Leveque, University Hospital of Bordeaux, Avenue du Haut Leveque, 33604 Pessac, France. FAU - Imbault, Julien AU - Imbault J AD - Department of Cardiovascular Anaesthesia and Critical Care, University Hospital of Bordeaux, Avenue du Haut Leveque, 33604 Pessac, France. AD - University Bordeaux, INSERM, U1034 Biologie des maladies cardiovasculaires, 1 Av. Magellan, 33600 Pessac, France. FAU - Ouattara, Alexandre AU - Ouattara A AD - Department of Cardiovascular Anaesthesia and Critical Care, University Hospital of Bordeaux, Avenue du Haut Leveque, 33604 Pessac, France. AD - University Bordeaux, INSERM, U1034 Biologie des maladies cardiovasculaires, 1 Av. Magellan, 33600 Pessac, France. LA - eng PT - Journal Article PL - England TA - Eur Heart J Acute Cardiovasc Care JT - European heart journal. Acute cardiovascular care JID - 101591369 SB - IM MH - Adult MH - Humans MH - *Shock, Cardiogenic MH - Cohort Studies MH - Treatment Outcome MH - Retrospective Studies MH - *Heart-Assist Devices OTO - NOTNLM OT - Extracorporeal life support OT - Hospital rapid response team OT - Multidisciplinary care team OT - Myocardial infarction OT - Ventricular assist device COIS- Conflict of interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/09/15 18:42 MHDA- 2023/12/25 06:43 CRDT- 2023/09/15 15:33 PHST- 2023/04/14 00:00 [received] PHST- 2023/08/20 00:00 [revised] PHST- 2023/08/22 00:00 [accepted] PHST- 2023/12/25 06:43 [medline] PHST- 2023/09/15 18:42 [pubmed] PHST- 2023/09/15 15:33 [entrez] AID - 7274996 [pii] AID - 10.1093/ehjacc/zuad108 [doi] PST - ppublish SO - Eur Heart J Acute Cardiovasc Care. 2023 Dec 21;12(12):821-830. doi: 10.1093/ehjacc/zuad108. PMID- 37712368 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231001 IS - 2532-179X (Electronic) IS - 1124-0490 (Print) IS - 1124-0490 (Linking) VI - 40 IP - 3 DP - 2023 Sep 13 TI - Life threating onset of Cardiac Sarcoidosis with mediastinal involvement. PG - e2023042 LID - 10.36141/svdld.v40i3.14519 [doi] LID - e2023042 AB - We have described a clinical case with atypical onset of sarcoidosis. A young patient presented to the emergency room with acute heart failure and severe cardiac dysfunction simulating dilated cardiomyopathy or severe myocarditis. Hypoxic respiratory failure refractory to oxygen therapy was treated with steroids. The diagnosis was made by a multidisciplinary team who decided to perform EndoBronchial UltraSound-guided TransBronchial Needle Aspiration (EBUS TBNA) in addition to a cardiac MRI. The result was to obtain, in this case, a prompt therapeutic response in order to preserve the patient cardiac function. FAU - Ciuffreda, Marcello AU - Ciuffreda M AD - S.M.Goretti Hospital, ASL Latina. m.ciuffreda@ausl.latina.it. FAU - Valenti, Valentina AU - Valenti V AD - . valevale2012@hotmail.com. FAU - Manfre, Giuseppe AU - Manfre G AD - . g.manfre@ausl.latina.it. FAU - Barberi, Antonio AU - Barberi A AD - . a.barberi@ausl.latina.it. FAU - Porzi, Patrizia AU - Porzi P AD - . patrporz@gmail.com. FAU - Versaci, Francesco AU - Versaci F AD - . f.versaci@ausl.latina.it. FAU - Sarni, Antonella AU - Sarni A AD - . a.sarni@ausl.latina.it. LA - eng PT - Journal Article DEP - 20230913 PL - Italy TA - Sarcoidosis Vasc Diffuse Lung Dis JT - Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG JID - 9610928 PMC - PMC10540721 COIS- we declare that we have no commercial associations (e.g. consultancies, stock ownership, equity interest, patent/licensing arrangement etc.) that might pose a conflict of interest in connection with the submitted article EDAT- 2023/09/15 06:43 MHDA- 2023/09/15 06:44 PMCR- 2023/01/01 CRDT- 2023/09/15 05:43 PHST- 2023/03/25 00:00 [received] PHST- 2023/09/06 00:00 [accepted] PHST- 2023/09/15 06:44 [medline] PHST- 2023/09/15 06:43 [pubmed] PHST- 2023/09/15 05:43 [entrez] PHST- 2023/01/01 00:00 [pmc-release] AID - SVDLD-40-42 [pii] AID - 10.36141/svdld.v40i3.14519 [doi] PST - epublish SO - Sarcoidosis Vasc Diffuse Lung Dis. 2023 Sep 13;40(3):e2023042. doi: 10.36141/svdld.v40i3.14519. PMID- 37708751 OWN - NLM STAT- MEDLINE DCOM- 20231010 LR - 20231018 IS - 1879-1913 (Electronic) IS - 0002-9149 (Linking) VI - 206 DP - 2023 Nov 1 TI - Use of a Multidisciplinary Shock Team and Inhospital Mortality in Patients With Cardiogenic Shock. PG - 200-201 LID - S0002-9149(23)00853-6 [pii] LID - 10.1016/j.amjcard.2023.08.087 [doi] FAU - Khalil, Mahmoud AU - Khalil M AD - Cardiology Department, University of Connecticut, Farmington, Connecticut. FAU - Maraey, Ahmed AU - Maraey A AD - Cardiology Department, University of Toledo, Toledo, Ohio. FAU - Wahadneh, Omar Al AU - Wahadneh OA AD - Department of Internal Medicine, Carle Foundation Hospital, Urbana, Illinois. FAU - Elzanaty, Ahmed M AU - Elzanaty AM AD - Cardiology Department, University of Toledo, Toledo, Ohio. FAU - Brilakis, Emmanouil S AU - Brilakis ES AD - Division of Cardiology, Minneapolis Heart Institute, Minneapolis, Minnesota. FAU - Alaswad, Khaldoon AU - Alaswad K AD - Division of Cardiology, Henry Ford Hospital, Detroit, Michigan. FAU - Basir, Mir B AU - Basir MB AD - Division of Cardiology, Henry Ford Hospital, Detroit, Michigan. FAU - Megaly, Michael AU - Megaly M AD - Division of Cardiology, Willis Knighton Heart Institute, Shreveport, Louisiana. Electronic address: michaelmegaly3@gmail.com. LA - eng PT - Journal Article DEP - 20230913 PL - United States TA - Am J Cardiol JT - The American journal of cardiology JID - 0207277 SB - IM MH - Humans MH - Shock, Cardiogenic/therapy MH - Hospital Mortality MH - *Myocardial Infarction MH - *Shock OTO - NOTNLM OT - cardiogenic shock OT - meta-analysis OT - shock teams COIS- Declaration of Competing Interest The authors have no competing interests to declare. EDAT- 2023/09/15 00:42 MHDA- 2023/10/10 06:41 CRDT- 2023/09/14 18:07 PHST- 2023/07/28 00:00 [received] PHST- 2023/08/16 00:00 [accepted] PHST- 2023/10/10 06:41 [medline] PHST- 2023/09/15 00:42 [pubmed] PHST- 2023/09/14 18:07 [entrez] AID - S0002-9149(23)00853-6 [pii] AID - 10.1016/j.amjcard.2023.08.087 [doi] PST - ppublish SO - Am J Cardiol. 2023 Nov 1;206:200-201. doi: 10.1016/j.amjcard.2023.08.087. Epub 2023 Sep 13. PMID- 37708513 OWN - NLM STAT- MEDLINE DCOM- 20231023 LR - 20250423 IS - 1873-233X (Electronic) IS - 0029-7844 (Linking) VI - 142 IP - 5 DP - 2023 Nov 1 TI - Care and Monitoring of Pregnant Patients With Left Ventricular Assist Devices. PG - 1029-1035 LID - 10.1097/AOG.0000000000005351 [doi] AB - Cardiovascular disease is one of the leading causes of maternal mortality in the United States. Although still rare, pregnancy in patients with left ventricular assist devices (LVADs) is becoming more common. Typical indications for the use of LVADs in reproductive-aged females include ischemic cardiomyopathy, nonischemic (familial) dilated cardiomyopathy, peripartum cardiomyopathy, and some forms of myocarditis. An LVAD drains blood through a cannula placed into the apex of the left ventricle and then returns it to the proximal aorta bypassing the aortic valve allowing hemodynamic support in parallel with the native circulation. The physiologic changes associated with pregnancy, mainly increased blood volume and hypercoagulability, may adversely affect patients with LVADs, leading to many experts recommending against pregnancy. Maternal-fetal medicine specialists should have a central role within a multidisciplinary team required to provide optimal care for this high-risk group of patients. CI - Copyright (c) 2023 by the American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved. FAU - Pacheco, Luis D AU - Pacheco LD AD - Division of Maternal-Fetal Medicine, Department of Obstetrics & Gynecology, the Division of Surgical Critical Care, Department of Anesthesiology, the Division of Cardiovascular and Thoracic Surgery, and the Division of Cardiovascular Medicine, University of Texas Medical Branch, Galveston, Texas; and the Division of Maternal-Fetal Medicine, Department of Obstetrics & Gynecology, Eastern Virginia Medical School, Norfolk, Virginia. FAU - Saad, Antonio F AU - Saad AF FAU - Lick, Scott D AU - Lick SD FAU - Iturrizaga, Jose C AU - Iturrizaga JC FAU - Saade, George R AU - Saade GR LA - eng PT - Journal Article DEP - 20230913 PL - United States TA - Obstet Gynecol JT - Obstetrics and gynecology JID - 0401101 SB - IM MH - Female MH - Pregnancy MH - Humans MH - Adult MH - *Heart-Assist Devices/adverse effects MH - *Cardiomyopathies MH - Hemodynamics MH - *Cardiovascular Diseases MH - *Heart Failure/therapy COIS- Financial Disclosure The authors did not report any potential conflicts of interest. EDAT- 2023/09/14 18:43 MHDA- 2023/10/23 00:43 CRDT- 2023/09/14 17:13 PHST- 2023/05/22 00:00 [received] PHST- 2023/06/29 00:00 [accepted] PHST- 2023/10/23 00:43 [medline] PHST- 2023/09/14 18:43 [pubmed] PHST- 2023/09/14 17:13 [entrez] AID - 00006250-202311000-00007 [pii] AID - 10.1097/AOG.0000000000005351 [doi] PST - ppublish SO - Obstet Gynecol. 2023 Nov 1;142(5):1029-1035. doi: 10.1097/AOG.0000000000005351. Epub 2023 Sep 13. PMID- 37708313 OWN - NLM STAT- MEDLINE DCOM- 20260311 LR - 20260502 IS - 1540-8159 (Electronic) IS - 0147-8389 (Linking) VI - 46 IP - 10 DP - 2023 Oct TI - Coronary artery complications with left bundle branch area pacing: A review of literature. PG - 1222-1229 LID - 10.1111/pace.14822 [doi] AB - Left bundle branch area pacing (LBBAP) is an emerging technique in cardiac resynchronization therapy that shows promise in improving ventricular synchrony and clinical outcomes in patients with heart failure. However, the potential risk of coronary artery complications with LBBAP necessitates careful attention and management. This literature review explores the mechanisms, acute coronary events, and clinical implications associated with coronary artery complications in LBBAP. The mechanism of coronary injury with LBBAP involves mechanical trauma, altered coronary blood flow dynamics, and endothelial damage. Acute coronary events such as myocardial ischemia, acute coronary syndromes, and coronary artery dissection can occur during or after LBBAP, leading to significant clinical implications including the need for prompt intervention and potential impact on long-term outcomes. To avoid coronary injury and acute coronary syndrome with LBBAP, specific care strategies are recommended. These include thorough pre-procedural evaluation, expert operator technique, optimization of hemodynamics and ventricular synchrony, close monitoring for ischemic events, collaboration with cardiology specialists, and long-term follow-up. The clinical implications of coronary artery complications with LBBAP necessitate careful patient selection, informed decision-making, and a multidisciplinary approach. Future directions in this field include advancements in procedural techniques, technological innovations, risk stratification strategies, enhanced imaging modalities, research on mechanisms and prevention, and collaboration among stakeholders. By implementing these strategies and focusing on future advancements, healthcare providers can minimize the risk of coronary artery complications with LBBAP and optimize patient outcomes in cardiac resynchronization therapy. CI - (c) 2023 Wiley Periodicals LLC. FAU - Raza, Muhammad Hassan AU - Raza MH AD - Department of Medicine, Cavan General Hospital, Caven, Ireland. FAU - Maqbool, Muhammad Usama AU - Maqbool MU AD - Department of Medicine, University Hospital Kerry, Kerry, Ireland. FAU - Kumar, Sunil AU - Kumar S AD - Department of Medicine, Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan. FAU - Malik, Jahanzeb AU - Malik J AUID- ORCID: 0000-0002-9343-4187 AD - Department of Cardiovascular Research, Cardiovascular Analytics Group, Islamabad, Pakistan. FAU - Ali, Sameer AU - Ali S AD - Department of Medicine, Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan. FAU - Khan, Zahoor Aslam AU - Khan ZA AD - Department of Cardiology, Armed Forces Institute of Cardiology, Rawalpindi, Pakistan. LA - eng PT - Journal Article PT - Review DEP - 20230914 PL - United States TA - Pacing Clin Electrophysiol JT - Pacing and clinical electrophysiology : PACE JID - 7803944 SB - IM MH - Humans MH - *Cardiac Resynchronization Therapy/adverse effects MH - *Coronary Artery Disease/etiology MH - *Coronary Vessels/injuries MH - *Bundle of His/physiopathology MH - *Bundle-Branch Block/therapy MH - *Cardiac Pacing, Artificial/adverse effects EDAT- 2023/09/14 18:43 MHDA- 2026/03/11 18:59 CRDT- 2023/09/14 14:23 PHST- 2023/08/20 00:00 [revised] PHST- 2023/06/05 00:00 [received] PHST- 2023/09/04 00:00 [accepted] PHST- 2026/03/11 18:59 [medline] PHST- 2023/09/14 18:43 [pubmed] PHST- 2023/09/14 14:23 [entrez] AID - 10.1111/pace.14822 [doi] PST - ppublish SO - Pacing Clin Electrophysiol. 2023 Oct;46(10):1222-1229. doi: 10.1111/pace.14822. Epub 2023 Sep 14. PMID- 37706377 OWN - NLM STAT- MEDLINE DCOM- 20231102 LR - 20240921 IS - 0974-5181 (Electronic) IS - 0971-9784 (Print) IS - 0971-9784 (Linking) VI - 26 IP - 2 DP - 2023 Apr-Jun TI - Minimally invasive direct coronary artery bypass and percutaneous coronary intervention followed by transcatheter aortic valve implantation: A promising concept in high-risk octogenarians. PG - 143-148 LID - 10.4103/aca.aca_165_21 [doi] AB - OBJECTIVES: In this article, we present our initial clinical experience with staged minimally invasive direct coronary bypass (MIDCAB), percutaneous coronary intervention (PCI), and transcatheter aortic valve implantation (TAVI) in high-risk octogenarians (Hybrid). BACKGROUND: The use of percutaneous techniques for managing structural heart diseases, especially in elderly high-risk patients, has revolutionized the treatment of structural heart diseases. These procedures are present predominantly being offered as isolated interventions. The feasibility, clinical benefit, and outcomes of combining these techniques with MIDCAB have not been sufficiently explored and have subsequently been underreported in the contemporary literature. METHODS: Four consecutive octogenarians with severe aortic stenosis (AS) and complex coronary artery disease (CAD) that were at high risk for conventional surgery with extracorporeal circulation (ECC) were discussed in our Multidisciplinary Heart Team (MDH). Our MDH consisted of an interventional cardiologist, cardiac surgeon, and cardiac anesthesiologist. A hybrid approach with the alternative strategy comprising of MIDCAB, PCI, and TAVI in a staged fashion was agreed on. All 4 patients had both PCI/stenting and MIDCAB prior to deployment of the TAVI-prosthesis. RESULTS: From January 2019 to December 2020, 4 consecutive patients aged between 83 and 85 (3 male/1 female) years were scheduled for MIDCAB/PCI followed by percutaneous treatment of severe symptomatic AS. Intraoperatively, one patient was converted to full sternotomy, and surgery was performed by off-pump coronary artery bypass grafting. The overall procedural success rate was 100% in all 4 patients with resolution of their initial presenting cardiopulmonary symptoms. There were no severe complications associated with all hybrid procedures. There was no 30-day mortality in all patients. All patients were discharged home with a median hospital stay ranging between 9 and 25 days. All patients have since then been followed-up regularly. There was one noncardiac-related mortality at 6-months postsurgery. All other patients were well at 1-year follow-up with improved New York Heart Association Class II. CONCLUSIONS: In a selected group of elderly, high prohibitive risk patients with CAD and severe symptomatic AS, a staged approach with MIDCAB and PCI followed by TAVI can be safely performed with excellent outcomes. We advocate a MDH-based preliminary evaluation of this patient cohort in selecting suitable patients and appropriate timing of each stage of the hybrid procedure. FAU - Alozie, Anthony AU - Alozie A AD - Department of Cardiac Surgery, Heart Centre Rostock, University of Rostock, Germany. FAU - Oner, Alper AU - Oner A AD - Department of Cardiology, Heart Centre Rostock, University of Rostock, Germany. FAU - Loser, Benjamin AU - Loser B AD - Department of Anesthesiology and Intensive Care Medicine, University of Rostock, Germany. FAU - Dohmen, Pascal M AU - Dohmen PM AD - Department of Cardiac Surgery, University of Rostock, Germany; Department of Cardiothoracic Surgery, Faculty of Health Sciences, University of the Free State Bloemfontein, South Africa. LA - eng PT - Journal Article PL - India TA - Ann Card Anaesth JT - Annals of cardiac anaesthesia JID - 9815987 SB - IM MH - Aged MH - Aged, 80 and over MH - Humans MH - Male MH - Female MH - *Transcatheter Aortic Valve Replacement/methods MH - Octogenarians MH - *Percutaneous Coronary Intervention/methods MH - *Aortic Valve Stenosis/surgery/complications MH - *Coronary Artery Disease/complications MH - *Coronary Artery Bypass, Off-Pump/adverse effects MH - Treatment Outcome MH - Minimally Invasive Surgical Procedures MH - Aortic Valve/surgery PMC - PMC10284489 OTO - NOTNLM OT - Hybrid OT - MIDCAB OT - OPCAB OT - PCI OT - TAVI COIS- A. Oner received honoraria of Medtronic. All other authors have no conflict of interest to declare. EDAT- 2023/09/14 06:42 MHDA- 2023/09/14 06:43 PMCR- 2023/04/01 CRDT- 2023/09/14 05:52 PHST- 2023/09/14 06:43 [medline] PHST- 2023/09/14 06:42 [pubmed] PHST- 2023/09/14 05:52 [entrez] PHST- 2023/04/01 00:00 [pmc-release] AID - AnnCardAnaesth_2023_26_2_143_373174 [pii] AID - ACA-26-143 [pii] AID - 10.4103/aca.aca_165_21 [doi] PST - ppublish SO - Ann Card Anaesth. 2023 Apr-Jun;26(2):143-148. doi: 10.4103/aca.aca_165_21. PMID- 37703724 OWN - NLM STAT- MEDLINE DCOM- 20231114 LR - 20231121 IS - 1096-7206 (Electronic) IS - 1096-7192 (Linking) VI - 140 IP - 3 DP - 2023 Nov TI - Screening for health-related quality of life and its determinants in Fabry disease: A cross-sectional multicenter study. PG - 107692 LID - S1096-7192(23)00322-0 [pii] LID - 10.1016/j.ymgme.2023.107692 [doi] AB - BACKGROUND: Fabry disease (FD) is a rare X-linked lysosomal storage disorder caused by alpha-galactosidase A (alpha-Gal A) deficiency. The progressive accumulation of globotriaosylceramide results in life-threatening complications, including renal, cardiac, and cerebrovascular diseases. In order to improve health care of FD-patients, knowledge of its predictors is important. The aim of our study was to evaluate health-related quality of life (HrQol) in FD and to identify its independent determinants by exploring a wide range of demographic, social and clinical parameters. RESULTS: In this cross-sectional multicenter study, 135 adult patients with FD were recruited at three specialized European centers in Germany and Switzerland. Demographics, social status and clinical parameters as well as data on HrQol (EQ5D, EQ VAS) and depression were collected by means of self-reporting questionnaires and confirmed by medical records. HrQol and its predictors were evaluated by univariate and multivariate regression analyses. The study population consisted of 78 female and 57 male FD patients (median age 48 yrs) of whom 80.7% (N = 109) were on enzyme replacement therapy (ERT) and 10.4% (N = 14) were on chaperone treatment. Univariate analysis revealed various factors reducing HrQol such as age > 40 years, classic phenotype, organ involvement (kidney and heart disease, stroke/transient ischemic attack (TIA), gastrointestinal disturbances), depression, and burning limb pain. However, only the following factors were identified as independent predictors of decreased HrQol: classic phenotype, kidney and heart disease, stroke/TIA, depression, and burning limb pain. ERT and chaperone therapy were independent determinants of increased HrQol. CONCLUSIONS: Modifiable factors, such as burning limb pain and depression, identified as independent predictors of HrQol-deterioration should be addressed in programs aiming to improve HrQol in FD. A multidisciplinary approach is essential in FD-patients since diverse organ involvement prominently compromises HrQol in affected patients. Our findings showed that the classic phenotype is a strong predictor of worsening HrQol. CI - Copyright (c) 2023 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Winter, Yaroslav AU - Winter Y AD - Department of Neurology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany; Department of Neurology, Philipps-University Marburg, Germany. FAU - Hilz, Max AU - Hilz M AD - Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Neurology, University of Erlangen-Nuremberg, Erlangen, Germany. FAU - Beuschlein, Felix AU - Beuschlein F AD - Department of Endocrinology and Clinical Nutrition, University Hospital Zurich and University of Zurich, Zurich, Switzerland. FAU - Tsukimura, Takahiro AU - Tsukimura T AD - Department of Functional Bioanalysis, Meiji Pharmaceutical University, Tokyo, Japan. FAU - Seifritz, Erich AU - Seifritz E AD - Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Switzerland. FAU - Lenders, Malte AU - Lenders M AD - Internal Medicine D, Department of Nephrology, Hypertension and Rheumatology, Interdisciplinary Fabry Center Muenster (IFAZ), University Hospital Muenster, Muenster, Germany. FAU - Brand, Eva AU - Brand E AD - Internal Medicine D, Department of Nephrology, Hypertension and Rheumatology, Interdisciplinary Fabry Center Muenster (IFAZ), University Hospital Muenster, Muenster, Germany. FAU - Hennermann, Julia B AU - Hennermann JB AD - Villa Metabolica, Department of Pediatric and Adolescent Medicine, University Medical Center Mainz, Mainz, Germany. FAU - Nowak, Albina AU - Nowak A AD - Department of Endocrinology and Clinical Nutrition, University Hospital Zurich and University of Zurich, Zurich, Switzerland; Department of Internal Medicine, Psychiatry University Hospital Zurich, Zurich, Switzerland. Electronic address: albina.nowak@usz.ch. LA - eng PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't DEP - 20230829 PL - United States TA - Mol Genet Metab JT - Molecular genetics and metabolism JID - 9805456 RN - EC 3.2.1.22 (alpha-Galactosidase) SB - IM MH - Adult MH - Humans MH - Male MH - Female MH - Middle Aged MH - *Fabry Disease/diagnosis/genetics/complications MH - Quality of Life MH - *Ischemic Attack, Transient/complications/diagnosis/drug therapy MH - Cross-Sectional Studies MH - alpha-Galactosidase/genetics/therapeutic use MH - *Stroke/complications MH - Pain/drug therapy MH - *Heart Diseases OTO - NOTNLM OT - Chaperone OT - Depression OT - Enzyme replacement therapy OT - Fabry disease OT - Health-related quality of life COIS- Declaration of Competing Interest YW reports honoraria for educational presentations and consultations from Arvelle Therapeutics, Bayer AG, BIAL, Bioprojet Pharma, Eisai, Eythpharm GmbH, LivaNova, Novartis and UCB Pharma, which were not related to the topic of this study. AN received speaker honoraria and research grants from Amicus, Shire/Takeda and Sanofi Genzyme. ML received research grants and speaker honoraria from Amicus Therapeutics, Sanofi Genzyme and Shire/Takeda and consultation honoraria from Avrobio. EB received research grants and speaker honoraria from Amicus Therapeutics, Sanofi Genzyme, Shire/Takeda as well as honoraria for educational presentations and consultations from Chiesi and Greenovation/Eleva. EDAT- 2023/09/14 00:42 MHDA- 2023/11/14 06:42 CRDT- 2023/09/13 18:06 PHST- 2023/06/07 00:00 [received] PHST- 2023/08/27 00:00 [revised] PHST- 2023/08/28 00:00 [accepted] PHST- 2023/11/14 06:42 [medline] PHST- 2023/09/14 00:42 [pubmed] PHST- 2023/09/13 18:06 [entrez] AID - S1096-7192(23)00322-0 [pii] AID - 10.1016/j.ymgme.2023.107692 [doi] PST - ppublish SO - Mol Genet Metab. 2023 Nov;140(3):107692. doi: 10.1016/j.ymgme.2023.107692. Epub 2023 Aug 29. PMID- 37698649 OWN - NLM STAT- MEDLINE DCOM- 20240205 LR - 20261010 IS - 1433-0350 (Electronic) IS - 0256-7040 (Linking) VI - 40 IP - 2 DP - 2024 Feb TI - Late effects of medulloblastoma treatment: multidisciplinary approach of survivors. PG - 417-425 LID - 10.1007/s00381-023-06146-1 [doi] AB - PURPOSE: Medulloblastoma is one of the brain tumors with increased life expectancy due to improvements in treatment approaches. Besides the promising results, various undesirable effects can be encountered. This study's aim is to review long-term follow-up outcomes of our cases with medulloblastoma. METHODS: Age at diagnosis, histological type of medulloblastoma, resection extension, chemotherapy and radiotherapy schemes, follow-up duration, and endocrinological, neuropsychiatric, cardiological, auditory, and visual examination results were evaluated in 20 patients diagnosed between 2007 and 2018 and followed 5 years and more. RESULTS: Twenty of 53 patients were included to the study. Eleven (55%) were male. Mean age at diagnosis was 6.95 years; mean age at the time of the study was 14 years. Mean follow-up time was 8.95 years. In terms of surgery, 14 (70%) were gross total, 1 (5%) was near total, and 2 (10%) were subtotal resection. In histopathological examination, 14 (70%) were classical medulloblastoma, 4 (20%) were desmoplastic medulloblastoma, and 1 (5%) was anaplastic medulloblastoma. With regard to endocrinological evaluation, 15 (75%) patients had hypothyroidism, 5 (25%) had growth hormone deficiency, 7 (35%) had clinical growth hormone deficiency, and 5 (25%) had sex hormone disorders. In neuropsychiatric examination, 11 (55%) patients had neurological sequelae, 18 (90%) patients had psychiatric issues, and 14 (70%) patients had two or more neuropsychiatric problems simultaneously. One (5%) patient had mitral valve insufficiency. Twelve patients (60%) had hearing loss. According to visual examination, 6 (30%) patients had refraction problem, 4 (20%) had cataract, and 1 (5%) had dry eye. CONCLUSION: Careful monitoring of long-term side effects is important for improving the quality of life of medulloblastoma patients. Besides endocrinological and other somatic sequelae of the disease and treatment, increased neuropsychiatric problems showed us that only cure is not the issue while treating childhood medulloblastoma. CI - (c) 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Aktekin, Elif Habibe AU - Aktekin EH AUID- ORCID: 0000-0002-0394-6219 AD - Department of Pediatrics Division of Pediatric Hematology-Oncology, Baskent University, Adana, Turkey. elifaktekin@yahoo.com. FAU - Kutuk, Meryem Ozlem AU - Kutuk MO AD - Department of Child and Adolescent Psychiatry, Baskent University, Adana, Turkey. FAU - Sangun, Ozlem AU - Sangun O AD - Department of Pediatric Division of Pediatric Endocrinology, Baskent University, Adana, Turkey. FAU - Yazici, Nalan AU - Yazici N AD - Department of Pediatrics Division of Pediatric Hematology-Oncology, Baskent University, Adana, Turkey. FAU - Caylakli, Fatma AU - Caylakli F AD - Department of Ear-Nose and Throat, Baskent University, Adana, Turkey. FAU - Erol, Ilknur AU - Erol I AD - Department of Pediatrics Division of Pediatric Neurology, Baskent University, Adana, Turkey. FAU - Sarialioglu, Faik AU - Sarialioglu F AD - Department of Pediatrics Division of Pediatric Hematology-Oncology, Baskent University, Adana, Turkey. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230912 PL - Germany TA - Childs Nerv Syst JT - Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery JID - 8503227 RN - 9002-72-6 (Growth Hormone) SB - IM MH - Humans MH - Male MH - Child MH - Adolescent MH - Young Adult MH - Adult MH - Female MH - *Medulloblastoma/pathology MH - Quality of Life MH - *Cerebellar Neoplasms/radiotherapy MH - Disease Progression MH - Survivors MH - Growth Hormone OTO - NOTNLM OT - Attention deficit disorder OT - Hearing loss OT - Hypothyroidism OT - Medulloblastoma OT - Mental retardation EDAT- 2023/09/12 12:42 MHDA- 2024/02/05 06:42 CRDT- 2023/09/12 11:15 PHST- 2023/07/30 00:00 [received] PHST- 2023/09/05 00:00 [accepted] PHST- 2024/02/05 06:42 [medline] PHST- 2023/09/12 12:42 [pubmed] PHST- 2023/09/12 11:15 [entrez] AID - 10.1007/s00381-023-06146-1 [pii] AID - 10.1007/s00381-023-06146-1 [doi] PST - ppublish SO - Childs Nerv Syst. 2024 Feb;40(2):417-425. doi: 10.1007/s00381-023-06146-1. Epub 2023 Sep 12. PMID- 37698349 OWN - NLM STAT- In-Process LR - 20260310 IS - 1522-726X (Electronic) IS - 1522-1946 (Linking) VI - 102 IP - 4 DP - 2023 Oct TI - Optimal management of coronary artery disease in patients undergoing TAVI: The heart team holds the power. PG - 776-777 LID - 10.1002/ccd.30836 [doi] FAU - Atkinson, Tamara M AU - Atkinson TM AD - Portland VA Medical Center, Portland, Oregon, USA. AD - Division of Cardiology, Knight Cardiovascular Institute, OHSU, Portland, Oregon, USA. FAU - Tibayan, Yen AU - Tibayan Y AD - Portland VA Medical Center, Portland, Oregon, USA. AD - Division of Cardiology, Knight Cardiovascular Institute, OHSU, Portland, Oregon, USA. LA - eng PT - Journal Article DEP - 20230912 PL - United States TA - Catheter Cardiovasc Interv JT - Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions JID - 100884139 SB - IM OTO - NOTNLM OT - AVD: aortic valve disease OT - CAD: coronary artery disease OT - TVI: transcatheter valve implantation EDAT- 2023/09/12 12:41 MHDA- 2023/09/12 12:41 CRDT- 2023/09/12 08:33 PHST- 2023/08/26 00:00 [received] PHST- 2023/08/31 00:00 [accepted] PHST- 2023/09/12 12:41 [pubmed] PHST- 2023/09/12 12:41 [medline] PHST- 2023/09/12 08:33 [entrez] AID - 10.1002/ccd.30836 [doi] PST - ppublish SO - Catheter Cardiovasc Interv. 2023 Oct;102(4):776-777. doi: 10.1002/ccd.30836. Epub 2023 Sep 12. PMID- 37692048 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230913 IS - 2297-055X (Print) IS - 2297-055X (Electronic) IS - 2297-055X (Linking) VI - 10 DP - 2023 TI - Dismal prognosis of patients with operative indication without surgical intervention in active left-sided infective endocarditis. PG - 1223878 LID - 10.3389/fcvm.2023.1223878 [doi] LID - 1223878 AB - INTRODUCTION: Around 25% of patients with left-sided infective endocarditis and operative indication do not undergo surgery. Baseline characteristics and outcomes are underreported. This study describes characteristics and outcomes of surgical candidates with surgical intervention or medical treatment only. METHODS: Retrospective analysis of ongoing collected data from a single-center from an observational cohort of patients with infective endocarditis (ENVALVE). Kaplan-Meier estimates for survival was calculated. Factors associated with survival were assessed using a bivariable Cox model. To adjust for confounding by indication, uni- and multivariable logistic regression for the propensity to receive surgery were adjusted. RESULTS: From January 2018 and December 2021, 154 patients were analyzed: 116 underwent surgery and 38 received medical treatment only. Surgical candidates without surgery were older (70 vs. 62 years, p = 0.001). They had higher preoperative risk profile (EuroSCORE II 14% (7.2-28.6) vs. 5.8% (2.5-20.3), p = 0.002) and more comorbidities. One patient was lost-to-follow-up. Survival analysis revealed a significant higher one-year survival rate among patients following surgery (83.7% vs. 15.3% in the non-surgical group; log-rank test <0.0001). In the final multivariable adjusted model, surgery was less likely among patients with liver cirrhosis [OR = 0.03 (95% CI 0.00-0.30)] and with hemodialysis [OR = 0.014 (95% CI 0.00-0.47)]. CONCLUSION: Patients with left-sided infective endocarditis who do not undergo surgery despite an operative indication are older, have more comorbidities and therefore higher preoperative risk profile and a low 1-year survival. The role of the Endocarditis Team may be particularly important for the decision-making process in this specific group. CI - (c) 2023 Van Hemelrijck, Sromicki, Frank, Greutmann, Ledergerber, Epprecht, Padrutt, Vogt, Carrel, Dzemali, Mestres and Hasse. FAU - Van Hemelrijck, Mathias AU - Van Hemelrijck M AD - Department of Cardiac Surgery, University Hospital Zurich, Zurich, Switzerland. FAU - Sromicki, Juri AU - Sromicki J AD - Department of Cardiac Surgery, University Hospital Zurich, Zurich, Switzerland. FAU - Frank, Michelle AU - Frank M AD - Department of Cardiology, University Hospital Zurich, Zurich, Switzerland. FAU - Greutmann, Matthias AU - Greutmann M AD - Department of Cardiology, University Hospital Zurich, Zurich, Switzerland. FAU - Ledergerber, Bruno AU - Ledergerber B AD - Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland. FAU - Epprecht, Jana AU - Epprecht J AD - Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland. FAU - Padrutt, Maria AU - Padrutt M AD - Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland. FAU - Vogt, Paul R AU - Vogt PR AD - Department of Cardiac Surgery, University Hospital Zurich, Zurich, Switzerland. FAU - Carrel, Thierry P AU - Carrel TP AD - Department of Cardiac Surgery, University Hospital Zurich, Zurich, Switzerland. FAU - Dzemali, Omer AU - Dzemali O AD - Department of Cardiac Surgery, University Hospital Zurich, Zurich, Switzerland. FAU - Mestres, Carlos-A AU - Mestres CA AD - Department of Cardiac Surgery, University Hospital Zurich, Zurich, Switzerland. FAU - Hasse, Barbara AU - Hasse B AD - Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland. AD - Department of Cardiac Surgery, University Hospital Zurich, Zurich, Switzerland. LA - eng PT - Journal Article DEP - 20230824 PL - Switzerland TA - Front Cardiovasc Med JT - Frontiers in cardiovascular medicine JID - 101653388 PMC - PMC10491846 OTO - NOTNLM OT - antimicrobial treatment OT - cardiac surgery OT - endocarditis team OT - infective endocarditis OT - operative indication COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer AA declared a past co-authorship with the author TPC to the handling editor. EDAT- 2023/09/11 06:43 MHDA- 2023/09/11 06:44 PMCR- 2023/01/01 CRDT- 2023/09/11 04:31 PHST- 2023/05/16 00:00 [received] PHST- 2023/07/28 00:00 [accepted] PHST- 2023/09/11 06:44 [medline] PHST- 2023/09/11 06:43 [pubmed] PHST- 2023/09/11 04:31 [entrez] PHST- 2023/01/01 00:00 [pmc-release] AID - 10.3389/fcvm.2023.1223878 [doi] PST - epublish SO - Front Cardiovasc Med. 2023 Aug 24;10:1223878. doi: 10.3389/fcvm.2023.1223878. eCollection 2023. PMID- 37689648 OWN - NLM STAT- MEDLINE DCOM- 20230911 LR - 20231118 IS - 1472-6963 (Electronic) IS - 1472-6963 (Linking) VI - 23 IP - 1 DP - 2023 Sep 9 TI - Clusters of medical specialties around patients with multimorbidity - employing fuzzy c-means clustering to explore multidisciplinary collaboration. PG - 975 LID - 10.1186/s12913-023-09961-z [doi] LID - 975 AB - BACKGROUND: Hospital care organization, structured around medical specialties and focused on the separate treatment of individual organ systems, is challenged by the increasing prevalence of multimorbidity. To support the hospitals' realization of multidisciplinary care, we hypothesized that using machine learning on clinical data helps to identify groups of medical specialties who are simultaneously involved in hospital care for patients with multimorbidity. METHODS: We conducted a cross-sectional study of patients in a Dutch general hospital and used a fuzzy c-means clustering algorithm for the analysis. We explored the patients' membership degrees in each cluster to identify subgroups of medical specialties that provide care to the same patients with multimorbidity. We used retrospectively collected electronic health record data from 2017. We extracted data from 22,133 patients aged >/=18 years who had received outpatient clinical care for two or more chronic and/ or oncological diagnoses. RESULTS: We found six clusters of medical specialties and identified 22 subgroups. The clusters were labeled based on the specialties that most characterized them: 1. dermatology/ plastic surgery, 2. six specialties (gynecology/ rheumatology/ orthopedic surgery/ urology/ gastroenterology/ otorhinolaryngology), 3. pulmonology, 4. internal medicine/ cardiology/ geriatrics, 5. neurology/ physiatry (rehabilitation)/ anesthesiology, and 6. internal medicine. Most patients had a full or dominant membership to one of these clusters of medical specialties (11 subgroups), whereas fewer patients had a membership to two clusters. The prevalence of specific diagnosis groups, patient characteristics, and healthcare utilization differed between subgroups. CONCLUSION: Our study shows that clusters and subgroups of medical specialties simultaneously involved in hospital care for patients with multimorbidity can be identified with fuzzy c-means cluster analysis using clinical data. Clusters and subgroups differed regarding the involved medical specialties, diagnoses, patient characteristics, and healthcare utilization. With this strategy, hospitals and medical specialists can further analyze which subgroups are target populations that might benefit from improved multidisciplinary collaboration. CI - (c) 2023. BioMed Central Ltd., part of Springer Nature. FAU - Verhoeff, Marlies AU - Verhoeff M AD - Department of Geriatric Medicine, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. AD - Knowledge Institute of the Federation of Medical Specialists, Utrecht, the Netherlands. FAU - Weil, Liann I AU - Weil LI AD - Department of Geriatric Medicine, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. l.i.weil@umcg.nl. FAU - Chu, Hung AU - Chu H AD - Donald Smits Center for Information and Technology, University of Groningen, Groningen, the Netherlands. FAU - Vermeeren, Yolande AU - Vermeeren Y AD - Department of Internal Medicine, Gelre Hospitals, Apeldoorn/ Zutphen, the Netherlands. FAU - de Groot, Janke AU - de Groot J AD - Knowledge Institute of the Federation of Medical Specialists, Utrecht, the Netherlands. FAU - Burgers, Jako S AU - Burgers JS AD - Maastricht University, Care and Public Health Research Institute (CAPHRI), Maastricht, the Netherlands. FAU - Jeurissen, Patrick P T AU - Jeurissen PPT AD - Scientific Center for Quality of Healthcare (IQ healthcare), Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands. FAU - Zwerwer, Leslie R AU - Zwerwer LR AD - Donald Smits Center for Information and Technology, University of Groningen, Groningen, the Netherlands. AD - Department of Health Sciences, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. FAU - van Munster, Barbara C AU - van Munster BC AD - Department of Geriatric Medicine, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. LA - eng PT - Journal Article DEP - 20230909 PL - England TA - BMC Health Serv Res JT - BMC health services research JID - 101088677 SB - IM MH - Humans MH - Adolescent MH - Adult MH - Cross-Sectional Studies MH - *Multimorbidity MH - Retrospective Studies MH - *Anesthesiology MH - Cluster Analysis PMC - PMC10492354 OTO - NOTNLM OT - Care coordination OT - Cluster analysis OT - Electronic health records OT - Machine learning OT - Multidisciplinary collaboration OT - Multimorbidity COIS- The authors declare no competing interests. EDAT- 2023/09/10 00:42 MHDA- 2023/09/11 06:42 PMCR- 2023/09/09 CRDT- 2023/09/09 23:15 PHST- 2022/11/29 00:00 [received] PHST- 2023/08/24 00:00 [accepted] PHST- 2023/09/11 06:42 [medline] PHST- 2023/09/10 00:42 [pubmed] PHST- 2023/09/09 23:15 [entrez] PHST- 2023/09/09 00:00 [pmc-release] AID - 10.1186/s12913-023-09961-z [pii] AID - 9961 [pii] AID - 10.1186/s12913-023-09961-z [doi] PST - epublish SO - BMC Health Serv Res. 2023 Sep 9;23(1):975. doi: 10.1186/s12913-023-09961-z. PMID- 37685901 OWN - NLM STAT- MEDLINE DCOM- 20230911 LR - 20230911 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 24 IP - 17 DP - 2023 Aug 23 TI - The Role of MicroRNAs in Aortic Stenosis-Lessons from Recent Clinical Research Studies. LID - 10.3390/ijms241713095 [doi] LID - 13095 AB - Aortic stenosis (AS) is the most prevalent primary valve lesion demanding intervention. Two main treatment options are surgical aortic valve replacement or transcatheter aortic valve implantation. There is an unmet need for biomarkers that could predict treatment outcomes and become a helpful tool in guiding Heart Team in the decision-making process. Micro-ribonucleic acids (microRNAs/miRs) have emerged as potential biomarkers thoroughly studied in recent years. In this review, we aimed to summarize the current knowledge about the role of miRNAs in AS based on human subject research. Much research investigating miRNAs' role in AS has been conducted so far. We included 32 original human subject research relevant to the discussed field. Most of the presented miRNAs were studied only by a single research group. Nevertheless, several miRNAs appeared more than once, sometimes with high consistency between different studies but sometimes with apparent discrepancies. The molecular aspects of diseases are doubtlessly exciting and provide invaluable insights into the pathophysiology. Nevertheless, translating these findings, regarding biomarkers such as miRNAs, into clinical practice requires much effort, time, and further research with a focus on validating existing evidence. FAU - Krauze, Anna AU - Krauze A AD - Department of Biochemistry and Pharmacogenomics, Medical University of Warsaw, Banacha 1, 02-097 Warsaw, Poland. FAU - Procyk, Grzegorz AU - Procyk G AUID- ORCID: 0000-0001-8333-7570 AD - 1st Chair and Department of Cardiology, Medical University of Warsaw, Banacha 1A, 02-097 Warsaw, Poland. AD - Doctoral School, Medical University of Warsaw, 02-091 Warsaw, Poland. FAU - Gasecka, Aleksandra AU - Gasecka A AUID- ORCID: 0000-0001-5083-7587 AD - 1st Chair and Department of Cardiology, Medical University of Warsaw, Banacha 1A, 02-097 Warsaw, Poland. FAU - Garstka-Pacak, Izabela AU - Garstka-Pacak I AD - Department of Biochemistry and Pharmacogenomics, Medical University of Warsaw, Banacha 1, 02-097 Warsaw, Poland. FAU - Wrzosek, Malgorzata AU - Wrzosek M AUID- ORCID: 0000-0002-9820-3871 AD - Department of Biochemistry and Pharmacogenomics, Medical University of Warsaw, Banacha 1, 02-097 Warsaw, Poland. LA - eng PT - Journal Article PT - Review DEP - 20230823 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (MicroRNAs) SB - IM MH - Humans MH - *MicroRNAs/genetics MH - *Aortic Valve Stenosis/genetics MH - Heart MH - Catheters MH - *Transcatheter Aortic Valve Replacement PMC - PMC10487683 OTO - NOTNLM OT - aortic stenosis OT - aortic valve replacement OT - biomarkers OT - calcific aortic valve disease OT - microRNAs COIS- The authors declare no conflict of interest. EDAT- 2023/09/09 11:45 MHDA- 2023/09/11 06:42 PMCR- 2023/08/23 CRDT- 2023/09/09 01:10 PHST- 2023/08/07 00:00 [received] PHST- 2023/08/20 00:00 [revised] PHST- 2023/08/20 00:00 [accepted] PHST- 2023/09/11 06:42 [medline] PHST- 2023/09/09 11:45 [pubmed] PHST- 2023/09/09 01:10 [entrez] PHST- 2023/08/23 00:00 [pmc-release] AID - ijms241713095 [pii] AID - ijms-24-13095 [pii] AID - 10.3390/ijms241713095 [doi] PST - epublish SO - Int J Mol Sci. 2023 Aug 23;24(17):13095. doi: 10.3390/ijms241713095. PMID- 37678960 OWN - NLM STAT- MEDLINE DCOM- 20230911 LR - 20230919 IS - 2213-1787 (Electronic) IS - 2213-1779 (Linking) VI - 11 IP - 9 DP - 2023 Sep TI - Cardio-Obstetrics and Heart Failure: JACC: Heart Failure State-of-the-Art Review. PG - 1165-1180 LID - S2213-1779(23)00395-5 [pii] LID - 10.1016/j.jchf.2023.07.009 [doi] AB - Heart failure and cardiomyopathy are significant contributors to pregnancy-related deaths, as maternal morbidity and mortality have been increasing over time. In this setting, the role of the multidisciplinary cardio-obstetrics team is crucial to optimizing maternal, obstetrical and fetal outcomes. Although peripartum cardiomyopathy is the most common cardiomyopathy experienced by pregnant individuals, the hemodynamic changes of pregnancy may unmask a pre-existing cardiomyopathy leading to clinical decompensation. Additionally, there are unique management considerations for women with pre-existing cardiomyopathy as well as for those women with advanced heart failure who may be on left ventricular assist device support or have undergone heart transplantation. The purpose of this review is to discuss: 1) preconception counseling; 2) risk stratification and management strategies for pregnant women extending to the postpartum "fourth trimester" with pre-existing heart failure or "pre-heart failure;" 3) the safety of heart failure medications during pregnancy and lactation; and 4) management of pregnancy for women on left ventricular assist device support or after heart transplantation. CI - Copyright (c) 2023 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. FAU - DeFilippis, Ersilia M AU - DeFilippis EM AD - Division of Cardiology, NewYork-Presbyterian Columbia University Irving Medical Center, New York, New York, USA. FAU - Bhagra, Catriona AU - Bhagra C AD - Department of Cardiology, Cambridge University and Royal Papworth NHS Foundation Trusts, Cambridge, United Kingdom. FAU - Casale, Jillian AU - Casale J AD - Department of Pharmacy Services, Cooperman Barnabas Medical Center, Livingston, New Jersey, USA. FAU - Ging, Patricia AU - Ging P AD - Department of Pharmacy, Mater Misericordiae University Hospital, Dublin, Ireland. FAU - Macera, Francesca AU - Macera F AD - De Gasperis Cardio Center and Transplant Center, Niguarda Hospital, Milan, Italy; Department of Cardiology, Cliniques Universitaires de Bruxelles - Hopital Erasme, Brussels, Belgium. FAU - Punnoose, Lynn AU - Punnoose L AD - Vanderbilt Heart and Vascular Institute, Vanderbilt University Medical Center, Nashville, Tennessee, USA. FAU - Rasmusson, Kismet AU - Rasmusson K AD - Intermountain Heart Institute, Intermountain Medical Center, Salt Lake City, Utah, USA. FAU - Sharma, Garima AU - Sharma G AD - Ciccarone Center for the Prevention of Cardiovascular Disease, Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. FAU - Sliwa, Karen AU - Sliwa K AD - Cape Heart Institute, Department of Medicine, Division of Cardiology, Faculty of Health Sciences, Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa. FAU - Thorne, Sara AU - Thorne S AD - Division of Cardiology, Pregnancy & Heart Disease Program, Mount Sinai Hospital & University Health Network, University of Toronto, Toronto, Ontario, Canada. FAU - Walsh, Mary Norine AU - Walsh MN AD - Ascension St. Vincent Heart Center, Indianapolis, Indiana, USA. FAU - Kittleson, Michelle M AU - Kittleson MM AD - Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA. Electronic address: michelle.kittleson@cshs.org. LA - eng PT - Journal Article PT - Review PL - United States TA - JACC Heart Fail JT - JACC. Heart failure JID - 101598241 SB - IM MH - Pregnancy MH - Female MH - Humans MH - *Heart Failure/complications/therapy MH - *Obstetrics MH - Heart MH - *Heart Transplantation MH - *Heart-Assist Devices OTO - NOTNLM OT - cardio-obstetrics OT - heart failure OT - maternal mortality OT - pregnancy COIS- Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2023/09/08 00:42 MHDA- 2023/09/11 06:43 CRDT- 2023/09/07 20:56 PHST- 2022/11/29 00:00 [received] PHST- 2023/05/26 00:00 [revised] PHST- 2023/07/05 00:00 [accepted] PHST- 2023/09/11 06:43 [medline] PHST- 2023/09/08 00:42 [pubmed] PHST- 2023/09/07 20:56 [entrez] AID - S2213-1779(23)00395-5 [pii] AID - 10.1016/j.jchf.2023.07.009 [doi] PST - ppublish SO - JACC Heart Fail. 2023 Sep;11(9):1165-1180. doi: 10.1016/j.jchf.2023.07.009. PMID- 37678301 OWN - NLM STAT- MEDLINE DCOM- 20231102 LR - 20250806 IS - 1555-824X (Electronic) IS - 1062-8606 (Linking) VI - 38 IP - 5 DP - 2023 Sep-Oct 01 TI - Effect of Implementing a Commercial Electronic Early Warning System on Outcomes of Hospitalized Patients. PG - 229-237 LID - 10.1097/JMQ.0000000000000147 [doi] AB - Despite the widespread adoption of early warning systems (EWSs), it is uncertain if their implementation improves patient outcomes. The authors report a pre-post quasi-experimental evaluation of a commercially available EWS on patient outcomes at a 700-bed academic medical center. The EWS risk scores were visible in the electronic medical record by bedside clinicians. The EWS risk scores were also monitored remotely 24/7 by critical care trained nurses who actively contacted bedside nurses when a patient's risk levels increased. The primary outcome was inpatient mortality. Secondary outcomes were rapid response team calls and activation of cardiopulmonary arrest (code-4) response teams. The study team conducted a regression discontinuity analysis adjusting for age, gender, insurance, severity of illness, risk of mortality, and hospital occupancy at admission. The analysis included 53,229 hospitalizations. Adjusted analysis showed no significant change in inpatient mortality, rapid response team call, or code-4 activations after implementing the EWS. This study confirms the continued uncertainty in the effectiveness of EWSs and the need for further rigorous examinations of EWSs. CI - Copyright (c) 2023 the American College of Medical Quality. FAU - Singh, Siddhartha AU - Singh S AD - Collaborative for Healthcare Delivery Sciences, Medical College of Wisconsin, Milwaukee, WI. AD - Froedtert and The Medical College of Wisconsin, Milwaukee, WI. AD - Department of Medicine, Medical College of Wisconsin, Milwaukee, WI. FAU - Laud, Purushottam W AU - Laud PW AD - Collaborative for Healthcare Delivery Sciences, Medical College of Wisconsin, Milwaukee, WI. FAU - Crotty, Bradley H AU - Crotty BH AD - Collaborative for Healthcare Delivery Sciences, Medical College of Wisconsin, Milwaukee, WI. AD - Froedtert and The Medical College of Wisconsin, Milwaukee, WI. AD - Department of Medicine, Medical College of Wisconsin, Milwaukee, WI. FAU - Nanchal, Rahul S AU - Nanchal RS AD - Department of Medicine, Medical College of Wisconsin, Milwaukee, WI. FAU - Hanson, Ryan AU - Hanson R AD - Collaborative for Healthcare Delivery Sciences, Medical College of Wisconsin, Milwaukee, WI. AD - Froedtert and The Medical College of Wisconsin, Milwaukee, WI. FAU - Penlesky, Annie C AU - Penlesky AC AD - Collaborative for Healthcare Delivery Sciences, Medical College of Wisconsin, Milwaukee, WI. FAU - Fletcher, Kathlyn E AU - Fletcher KE AD - Collaborative for Healthcare Delivery Sciences, Medical College of Wisconsin, Milwaukee, WI. AD - Department of Medicine, Medical College of Wisconsin, Milwaukee, WI. FAU - Stadler, Michael E AU - Stadler ME AD - Froedtert and The Medical College of Wisconsin, Milwaukee, WI. AD - Department of Otolaryngology, Medical College of Wisconsin, Milwaukee, WI. FAU - Dong, Yilu AU - Dong Y AD - Collaborative for Healthcare Delivery Sciences, Medical College of Wisconsin, Milwaukee, WI. FAU - Nattinger, Ann B AU - Nattinger AB AD - Collaborative for Healthcare Delivery Sciences, Medical College of Wisconsin, Milwaukee, WI. AD - Department of Medicine, Medical College of Wisconsin, Milwaukee, WI. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230907 PL - Netherlands TA - Am J Med Qual JT - American journal of medical quality : the official journal of the American College of Medical Quality JID - 9300756 SB - IM MH - Humans MH - Hospitalization MH - Critical Care MH - *Heart Arrest/therapy MH - *Hospital Rapid Response Team MH - Vital Signs EDAT- 2023/09/08 00:41 MHDA- 2023/09/08 00:42 CRDT- 2023/09/07 18:55 PHST- 2023/09/08 00:42 [medline] PHST- 2023/09/08 00:41 [pubmed] PHST- 2023/09/07 18:55 [entrez] AID - 00008488-202309000-00003 [pii] AID - 10.1097/JMQ.0000000000000147 [doi] PST - ppublish SO - Am J Med Qual. 2023 Sep-Oct 01;38(5):229-237. doi: 10.1097/JMQ.0000000000000147. Epub 2023 Sep 7. PMID- 37678228 OWN - NLM STAT- MEDLINE DCOM- 20240122 LR - 20250502 IS - 1529-7535 (Print) IS - 1529-7535 (Linking) VI - 25 IP - 2 DP - 2024 Feb 1 TI - Dying and Death in a Pediatric Cardiac ICU: Mixed Methods Evaluation of Multidisciplinary Staff Responses. PG - e91-e102 LID - 10.1097/PCC.0000000000003357 [doi] AB - OBJECTIVES: Understanding factors influencing quality of pediatric end-of-life (EOL) care is necessary to identify interventions to improve family and staff experiences. We characterized pediatric cardiac ICU (PCICU) staff free-text survey responses to contextualize patterns in quality of dying and death (QODD) scoring. DESIGN: This mixed methods study reports on a cross-sectional survey of PCICU staff involved in patient deaths. SETTING: Single, quaternary PCICU from 2019-2021. PARTICIPANTS: Multidisciplinary staff (bedside nurses, allied health professionals, and medical practitioners) rated QODD and voluntarily added free-text responses. We derived descriptive categories of free-text responses using content analysis. Response sentiment was classified as positive, negative or both positive and negative. We compared category and sentiment frequency by discipline, EOL medical intensity, years of experience and QODD score quartiles. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Of 60 deaths and 713 completed staff surveys, 269 (38%) contained free-text responses, including 103 of 269 (38%) from nurses. Of six qualitative categories (i.e., relational dynamics, clinical circumstances, family experiences, emotional expressions, temporal conditions, and structural/situational factors), relational dynamics was most frequent (173 responses). When compared by discipline, family experiences were more common in nursing responses than medical practitioners or allied health. High intensity was associated with infrequent discussion of family experience and greater focus on temporal conditions and clinical circumstances. Emotional expressions and temporal conditions were more common in lowest QODD quartile surveys. Although 45% staff responses contained both sentiments, relational dynamics and family experiences were more likely positive. Negative sentiments were more common in the lowest QODD quartile surveys and responses containing temporal conditions or structural/situational factors. CONCLUSIONS: Synergistic relationships between the multidisciplinary team and family shaped clinician's positive responses. Attention to team dynamics may be a crucial ingredient in interventions to improve EOL care. Our data support that team-based education initiatives should consider differential foci between disciplines and EOL characteristics. CI - Copyright (c) 2023 by the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies. FAU - Broden, Elizabeth G AU - Broden EG AD - Department of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute, Boston, MA. FAU - Bailey, Valerie K AU - Bailey VK AD - Cardiovascular and Critical Care Nursing Patient Services, Boston Children's Hospital, Boston, MA. FAU - Beke, Dorothy M AU - Beke DM AD - Cardiovascular and Critical Care Nursing Patient Services, Boston Children's Hospital, Boston, MA. FAU - Snaman, Jennifer M AU - Snaman JM AD - Department of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute, Boston, MA. AD - Department of Pediatrics, Boston Children's Hospital, Boston, MA. FAU - Moynihan, Katie M AU - Moynihan KM AD - Department of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute, Boston, MA. AD - Cardiovascular and Critical Care Nursing Patient Services, Boston Children's Hospital, Boston, MA. AD - Department of Pediatrics, Boston Children's Hospital, Boston, MA. AD - Department of Pediatrics, Harvard Medical School, Boston, MA. AD - Department of Cardiology, Boston Children's Hospital, Boston, MA. AD - Children's Hospital at Westmead Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia. LA - eng GR - New England Congenital Cardiology Research Foundation (NECCRF)/ PT - Journal Article DEP - 20230905 PL - United States TA - Pediatr Crit Care Med JT - Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies JID - 100954653 SB - IM MH - Humans MH - Child MH - Cross-Sectional Studies MH - *Terminal Care MH - Surveys and Questionnaires MH - Intensive Care Units, Pediatric MH - Health Personnel COIS- Dr. Broden's, Ms. Bailey's, and Dr. Moynihan's institutions received funding from the New England Congenital Cardiology Research Foundation (NECCRF). Ms. Bailey and Dr. Moynihan received support for article research from the NECCRF. The remaining authors have disclosed that they do not have any potential conflicts of interest. EDAT- 2023/09/08 00:41 MHDA- 2024/01/22 06:43 CRDT- 2023/09/07 18:33 PHST- 2024/01/22 06:43 [medline] PHST- 2023/09/08 00:41 [pubmed] PHST- 2023/09/07 18:33 [entrez] AID - 00130478-202402000-00018 [pii] AID - 10.1097/PCC.0000000000003357 [doi] PST - ppublish SO - Pediatr Crit Care Med. 2024 Feb 1;25(2):e91-e102. doi: 10.1097/PCC.0000000000003357. Epub 2023 Sep 5. PMID- 37677011 OWN - NLM STAT- MEDLINE DCOM- 20230911 LR - 20230913 IS - 1940-087X (Electronic) IS - 1940-087X (Linking) IP - 199 DP - 2023 Sep 1 TI - Veno-Arterial Extracorporeal Membrane Oxygenation for Cardiogenic Shock. LID - 10.3791/62052 [doi] AB - Cardiogenic shock (CS) is a clinical condition characterized by inadequate tissue perfusion in the setting of low cardiac output. CS is the leading cause of death following acute myocardial infarction (AMI). Several temporary mechanical support devices are available for hemodynamic support in CS until clinical recovery ensues or until more definitive surgical procedures have been performed. Veno-arterial (VA) extracorporeal membrane oxygenation (ECMO) has evolved as a powerful treatment option for short-term circulatory support in refractory CS. In the absence of randomized clinical trials, the utilization of ECMO has been guided by clinical experience and based on data from registries and observational studies. Survival to hospital discharge with the use of VA-ECMO ranges from 28-67%. The initiation of ECMO requires venous and arterial cannulation, which can be performed either percutaneously or by surgical cutdown. Components of an ECMO circuit include an inflow cannula that draws blood from the venous system, a pump, an oxygenator, and an outflow cannula that returns blood to the arterial system. Management considerations post ECMO initiation include systemic anticoagulation to prevent thrombosis, left ventricle unloading strategies to augment myocardial recovery, prevention of limb ischemia with a distal perfusion catheter in cases of femoral arterial cannulation, and prevention of other complications such as hemolysis, air embolism, and Harlequin syndrome. ECMO is contraindicated in patients with uncontrolled bleeding, unrepaired aortic dissection, severe aortic insufficiency, and in futile cases such as severe neurological injury or metastatic malignancies. A multi-disciplinary shock team approach is recommended while considering patients for ECMO. Ongoing studies will evaluate whether the addition of routine ECMO improves survival in AMI patients with CS who undergo revascularization. FAU - Jhand, Aravdeep AU - Jhand A AD - Cardiovascular Medicine, Mayo Clinic; jhand.aravdeep@gmail.com. FAU - Shabbir, Muhammad Asim AU - Shabbir MA AD - Cardiovascular Medicine, University of Nebraska Medical Center. FAU - Um, John AU - Um J AD - Cardiothoracic Surgery, University of Nebraska Medical Center. FAU - Velagapudi, Poonam AU - Velagapudi P AD - Cardiovascular Medicine, University of Nebraska Medical Center. LA - eng PT - Journal Article PT - Video-Audio Media DEP - 20230901 PL - United States TA - J Vis Exp JT - Journal of visualized experiments : JoVE JID - 101313252 SB - IM MH - Humans MH - *Extracorporeal Membrane Oxygenation MH - Shock, Cardiogenic/therapy MH - Perfusion MH - *Myocardial Infarction/therapy MH - *Autonomic Nervous System Diseases EDAT- 2023/09/07 18:41 MHDA- 2023/09/11 06:43 CRDT- 2023/09/07 14:33 PHST- 2023/09/11 06:43 [medline] PHST- 2023/09/07 18:41 [pubmed] PHST- 2023/09/07 14:33 [entrez] AID - 10.3791/62052 [doi] PST - epublish SO - J Vis Exp. 2023 Sep 1;(199). doi: 10.3791/62052. PMID- 37674631 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230908 IS - 2328-8957 (Print) IS - 2328-8957 (Electronic) IS - 2328-8957 (Linking) VI - 10 IP - 9 DP - 2023 Sep TI - Multidisciplinary Teams for the Management of Infective Endocarditis: A Systematic Review and Meta-analysis. PG - ofad444 LID - 10.1093/ofid/ofad444 [doi] LID - ofad444 AB - BACKGROUND: The management of infective endocarditis (IE) is complex owing to a high burden of morbidity and mortality. Recent guidelines recommend dedicated multidisciplinary teams (MDTs) for the management of IE. The aim of this systematic review and meta-analysis was to evaluate and summarize the effect of MDT management on patient outcomes. METHODS: A systematic review was performed and, where feasible, results were meta-analyzed; otherwise, results were summarized narratively. Data extraction and quality assessment were performed in duplicate. Restricted maximum likelihood random effects models were used to calculate unadjusted risk ratios and 95% CIs. RESULTS: Screening of 2343 studies based on title and abstract yielded 60 full-text reviews; 18 studies were summarized narratively, of which 15 were included in a meta-analysis of short-term mortality. Meta-analysis resulted in a risk ratio of 0.61 (95% CI, .47-.78; I(2) = 62%) for mortality in favor of a dedicated MDT as compared with usual care. Length of stay was variable, with 55% (10/18) of studies reporting an increased length of stay. Most studies (16/18, 88.9%) reported a decreased time to surgery and an increased rate of surgery (13/18, 73%). No studies reported on patient-reported outcomes. CONCLUSIONS: This is the first systematic review and meta-analysis to assess the impact of MDT management on IE. The sum of evidence demonstrated a significant association between MDTs and improved short-term mortality. Further research is needed to evaluate benefits of virtual MDT care, cost-effectiveness, and the impact on patient-reported outcomes and long-term mortality. CI - (c) The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. FAU - Roy, Anne-Sophie AU - Roy AS AUID- ORCID: 0009-0001-1810-4065 AD - Faculty of Medicine and Health Sciences, McGill University, Montreal, Canada. FAU - Hagh-Doust, Hamila AU - Hagh-Doust H AD - Faculty of Medicine and Health Sciences, McGill University, Montreal, Canada. FAU - Abdul Azim, Ahmed AU - Abdul Azim A AD - Division of Infectious Diseases, Allergy and Immunology, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA. FAU - Caceres, Juan AU - Caceres J AD - Department of Internal Medicine, Michigan Medicine, Ann Arbor, Michigan, USA. FAU - Denholm, Justin T AU - Denholm JT AD - Victorian Infectious Diseases Service, Royal Melbourne Hospital, Parkville, Australia. AD - Department of Infectious Diseases, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia. FAU - Dong, Mei Qin Denise AU - Dong MQD AD - Antimicrobial Stewardship Pharmacy, New York Health and Hospitals, Bellevue Hospital, New York City, New York, USA. FAU - King, Madeline AU - King M AD - Outpatient Antimicrobial Stewardship Clinical Pharmacy, Cooper University Healthcare, Camden, New Jersey, USA. FAU - Yen, Christina F AU - Yen CF AD - Division of Infectious Diseases and Geographic Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA. FAU - Lee, Todd C AU - Lee TC AUID- ORCID: 0000-0002-2267-4239 AD - Clinical Practice Assessment Unit, McGill University Health Centre, Montreal, Canada. AD - Division of Infectious Diseases, McGill University Health Centre, Montreal, Canada. FAU - McDonald, Emily G AU - McDonald EG AD - Clinical Practice Assessment Unit, McGill University Health Centre, Montreal, Canada. AD - Division of General Internal Medicine, McGill University Health Centre, Montreal, Canada. LA - eng PT - Journal Article PT - Review DEP - 20230821 PL - United States TA - Open Forum Infect Dis JT - Open forum infectious diseases JID - 101637045 PMC - PMC10478154 OTO - NOTNLM OT - endocarditis OT - infectious OT - interdisciplinary OT - multidisciplinary OT - teams COIS- Potential conflicts of interest. All authors: No reported conflicts. EDAT- 2023/09/07 06:42 MHDA- 2023/09/07 06:43 PMCR- 2023/08/21 CRDT- 2023/09/07 04:02 PHST- 2023/06/12 00:00 [received] PHST- 2023/08/18 00:00 [accepted] PHST- 2023/09/07 06:43 [medline] PHST- 2023/09/07 06:42 [pubmed] PHST- 2023/09/07 04:02 [entrez] PHST- 2023/08/21 00:00 [pmc-release] AID - ofad444 [pii] AID - 10.1093/ofid/ofad444 [doi] PST - epublish SO - Open Forum Infect Dis. 2023 Aug 21;10(9):ofad444. doi: 10.1093/ofid/ofad444. eCollection 2023 Sep. PMID- 37674174 OWN - NLM STAT- MEDLINE DCOM- 20230908 LR - 20260127 IS - 1472-6963 (Electronic) IS - 1472-6963 (Linking) VI - 23 IP - 1 DP - 2023 Sep 6 TI - Facilitators and barriers to optimal home blood pressure management in patients with hypertensive disorders of pregnancy in a tertiary care facility in Abuja, Nigeria: a qualitative research study. PG - 954 LID - 10.1186/s12913-023-09976-6 [doi] LID - 954 AB - BACKGROUND: Nigeria has one of the highest burdens of maternal deaths globally, and hypertensive disorders of pregnancy (HDP) are the leading cause of maternal morbidity and mortality in the country. There is a significant implementation gap in utilizing evidence-based practices for the management of HDP in Nigeria. This study evaluated facilitators and barriers to implementing a home blood pressure monitoring program to improve management of HDP. METHODS: From August 2022 to September 2022, we conducted 15 semi-structured, key informant interviews and 4 focus group discussions among patients, health care workers, and administrators at University of Abuja Teaching Hospital (UATH), a tertiary care centre in Nigeria. The study used the Consolidated Framework for Implementation Research to assess five domains: individual characteristics, inner and outer settings, intervention characteristics, and process of implementation. Audio files were transcribed, and data were analysed using a combination of inductive and deductive approaches. We also conducted 32 brief surveys on the participants to assess acceptability, appropriateness, and feasibility of a blood pressure monitoring program. RESULTS: The study sample consisted of healthcare workers (n=22) including specialists in cardiology, obstetrics and gynaecology, maternal-foetal medicine, nurses/midwives and resident doctors as well as patients (n=10). Mean (SD) age was 39.5 (10.9), and 78% were female. Participants identified facilitators including the perceived simplicity of home blood pressure monitoring program, high burden of HDP, and availability of a multi-disciplinary team of healthcare professionals with expertise in HDP management. Barriers identified were cost, limited knowledge of HDP amongst patients, limited transportation networks, inconsistent management protocols, and inadequate manpower and facilities. Survey results indicated that between 81% and 88% of participants reported that a blood pressure monitoring program would be acceptable, 56%-72% reported that it would be appropriate, and 47%-69% reported that it would be feasible. CONCLUSION: This study identified facilitators and barriers while highlighting key implementation strategies to leverage and effectively address these respectively to enable successful implementation of a home blood pressure monitoring program. It also demonstrated that a home blood pressure monitoring program was considered acceptable, appropriate and feasible among respondents interviewed at UATH. CI - (c) 2023. BioMed Central Ltd., part of Springer Nature. FAU - Mahmoud, Zainab AU - Mahmoud Z AD - Washington University, 660 S Euclid Ave, Campus, Box 6068, St Louis, MO, 63110, USA. zmahmoud@wustl.edu. FAU - Orji, Adaego A AU - Orji AA AD - Cardiovascular Research Unit, University of Abuja and University of Abuja Teaching Hospital, Gwagwalada, Abuja, Nigeria. FAU - Okoye, Chukwuebuka F AU - Okoye CF AD - Cardiovascular Research Unit, University of Abuja and University of Abuja Teaching Hospital, Gwagwalada, Abuja, Nigeria. FAU - Ameh, Friday O AU - Ameh FO AD - Faculty of Clinical Sciences, University of Abuja, Abuja, Nigeria. FAU - Jamro-Comer, Erica AU - Jamro-Comer E AD - Washington University, 660 S Euclid Ave, Campus, Box 6068, St Louis, MO, 63110, USA. FAU - Isah, Aliyu AU - Isah A AD - Faculty of Clinical Sciences, University of Abuja, Abuja, Nigeria. FAU - Ekele, Bissallah AU - Ekele B AD - Faculty of Clinical Sciences, University of Abuja, Abuja, Nigeria. FAU - Akaba, Godwin AU - Akaba G AD - Faculty of Clinical Sciences, University of Abuja, Abuja, Nigeria. FAU - Ojji, Dike B AU - Ojji DB AD - Faculty of Clinical Sciences, University of Abuja, Abuja, Nigeria. FAU - Huffman, Mark D AU - Huffman MD AD - Washington University, 660 S Euclid Ave, Campus, Box 6068, St Louis, MO, 63110, USA. AD - The George Institute for Global Health, Sydney, Australia. LA - eng PT - Journal Article DEP - 20230906 PL - England TA - BMC Health Serv Res JT - BMC health services research JID - 101088677 SB - IM MH - Pregnancy MH - Humans MH - Female MH - Male MH - Blood Pressure MH - Nigeria MH - *Hypertension, Pregnancy-Induced/therapy MH - Tertiary Health Care MH - Qualitative Research MH - Hospitals, Teaching PMC - PMC10481544 OTO - NOTNLM OT - Barriers OT - Facilitators OT - Home blood pressure monitoring program OT - Hypertensive disorders of pregnancy OT - Pregnancy COIS- ZM receives grant funding from the American College of Cardiology, Association of Black Cardiologists and Merck Foundation. MDH has pending patents for heart failure polypills. George Health Enterprises Pty Ltd (GH) and its subsidiary, George Medicines Pty Ltd, have received investment funds to develop fixed-dose combination products, including combinations of blood pressure-lowering drugs. GH is the social enterprise arm of The George Institute for Global Health. The remaining authors have nothing to disclose. EDAT- 2023/09/07 00:41 MHDA- 2023/09/08 06:43 PMCR- 2023/09/06 CRDT- 2023/09/06 23:38 PHST- 2023/04/04 00:00 [received] PHST- 2023/08/28 00:00 [accepted] PHST- 2023/09/08 06:43 [medline] PHST- 2023/09/07 00:41 [pubmed] PHST- 2023/09/06 23:38 [entrez] PHST- 2023/09/06 00:00 [pmc-release] AID - 10.1186/s12913-023-09976-6 [pii] AID - 9976 [pii] AID - 10.1186/s12913-023-09976-6 [doi] PST - epublish SO - BMC Health Serv Res. 2023 Sep 6;23(1):954. doi: 10.1186/s12913-023-09976-6. PMID- 37670739 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241106 IS - 2639-8028 (Electronic) IS - 2639-8028 (Linking) VI - 5 IP - 9 DP - 2023 Sep TI - Perspectives on Sedation Among Interdisciplinary Team Members in ICU: A Survey Study. PG - e0972 LID - 10.1097/CCE.0000000000000972 [doi] LID - e0972 AB - OBJECTIVE: To explore the interdisciplinary team members' beliefs and attitudes about sedation when caring for mechanically ventilated patients in the ICU. DESIGN: Cross-sectional survey. SETTING: A 17-bed cardiothoracic ICU at a tertiary care academic hospital in Colorado. SUBJECTS: All nurses, physicians, advanced practice providers (APPs), respiratory therapists, physical therapists (PTs), and occupational therapists (OTs) who work in the cardiothoracic ICU. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: We modified a validated survey instrument to evaluate perspectives on sedation across members of the interdisciplinary ICU team. Survey responses were collected anonymously from 111 members (81% response rate). Respondents were predominantly female (70 [63%]). Most respondents across disciplines (94%) believed that their sedation practice made a difference in patients' outcomes. More nurses (48%), APPs (62%), and respiratory therapists (50%) believed that sedation could help alleviate the psychologic stress that patients experience on the ventilator than physicians (19%) and PTs/OTs (0%) (p = 0.008). The proportion of respondents who preferred to be sedated if they were mechanically ventilated themselves varied widely by discipline: respiratory therapists (88%), nurses (83%), APPs (54%), PTs/OTs (38%), and physicians (19%) (p < 0.001). In our exploratory analysis, listeners of an educational podcast had beliefs and attitudes more aligned with best evidence-based practices than nonlisteners. CONCLUSIONS: We discovered significant interdisciplinary differences in the beliefs and attitudes regarding sedation use in the ICU. Since all ICU team members are involved in managing mechanically ventilated patients in the ICU, aligning the mental models of sedation may be essential to enhance interprofessional collaboration and promote sedation best practices. FAU - Fuchita, Mikita AU - Fuchita M AD - Department of Anesthesiology, University of Colorado Anschutz Medical Campus, Aurora, CO. FAU - Blaine, Caitlin AU - Blaine C AD - Department of Surgery, Division of Cardiothoracic Surgery, University of Colorado Anschutz Medical Campus, Aurora, CO. FAU - Keyworth, Alexis AU - Keyworth A AD - Department of Surgery, Division of Cardiothoracic Surgery, University of Colorado Anschutz Medical Campus, Aurora, CO. FAU - Morfin, Kathryn AU - Morfin K AD - University of Colorado Hospital, University of Colorado Health, Aurora, CO. FAU - Primi, Blake AU - Primi B AD - Department of Anesthesiology, University of Colorado Anschutz Medical Campus, Aurora, CO. FAU - Ridgeway, Kyle AU - Ridgeway K AD - Inpatient Rehabilitation Therapy Department, University of Colorado Hospital, University of Colorado Health, Aurora, CO. AD - Physical Therapy Program, Department of Physical Medicine and Rehabilitation, University of Colorado Anschutz Medical Campus, Aurora, CO. FAU - Stake, Nikki AU - Stake N AD - University of Colorado Hospital, University of Colorado Health, Aurora, CO. FAU - Watson, Helen AU - Watson H AD - University of Colorado Hospital, University of Colorado Health, Aurora, CO. FAU - Matlock, Dan AU - Matlock D AD - Department of Medicine, University of Colorado School of Medicine, Aurora, CO. AD - VA Eastern Colorado Geriatric Research Education and Clinical Center, Denver, CO. FAU - Mehta, Anuj B AU - Mehta AB AD - Department of Medicine, Pulmonary Sciences and Critical Care Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO. AD - Department of Medicine, Pulmonary and Critical Care Medicine, National Jewish Health, Denver, CO. LA - eng GR - T32 GM135169/GM/NIGMS NIH HHS/United States PT - Journal Article DEP - 20230901 PL - United States TA - Crit Care Explor JT - Critical care explorations JID - 101746347 PMC - PMC10476798 OTO - NOTNLM OT - interdisciplinary care OT - mechanical ventilation OT - patient-centered care OT - sedation COIS- The authors have disclosed that they do not have any potential conflicts of interest. EDAT- 2023/09/06 06:42 MHDA- 2023/09/06 06:43 PMCR- 2023/09/01 CRDT- 2023/09/06 03:43 PHST- 2023/09/06 06:43 [medline] PHST- 2023/09/06 06:42 [pubmed] PHST- 2023/09/06 03:43 [entrez] PHST- 2023/09/01 00:00 [pmc-release] AID - 10.1097/CCE.0000000000000972 [doi] PST - epublish SO - Crit Care Explor. 2023 Sep 1;5(9):e0972. doi: 10.1097/CCE.0000000000000972. eCollection 2023 Sep. PMID- 37669844 OWN - NLM STAT- MEDLINE DCOM- 20230907 LR - 20260120 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 13 IP - 9 DP - 2023 Sep 5 TI - Consensus recommendations on holistic care in hereditary ATTR amyloidosis: an international Delphi survey of patient advocates and multidisciplinary healthcare professionals. PG - e073130 LID - 10.1136/bmjopen-2023-073130 [doi] LID - e073130 AB - BACKGROUND: Hereditary transthyretin-mediated amyloidosis is a rare, progressive and potentially life-limiting multisystem disease, affecting every aspect of a patient's life. OBJECTIVES: This online international Delphi survey aimed to evolve clinical-patient-led practical guidance, to inspire and encourage a holistic approach to care that is managed in specialist settings by multidisciplinary teams and supported by allied healthcare professionals (HCPs) and patient advocacy groups (PAGs). DESIGN: A 14-member joint patient advocate-HCP primary panel was convened including representation from PAGs and key clinical specialties (neurology, cardiology, internal medicine, physiotherapy, clinical psychology, dietetics and specialist nursing). Guidance evolved on the care provision needed to support seven core goals: early diagnosis and treatment; disease monitoring and organisation of care; maintenance of physical and mental health; family-centred care and caregiver support; patient-doctor dialogue; access to social support and social networking. PARTICIPANTS: From June to October 2022, 252 HCPs and 51 PAG representatives from 27 countries were invited to participate in a Delphi survey. Of the 122 respondents who answered at least one survey question, most were HCPs (100, 82%) from specialist centres; the remainder were PAG representatives (22, 18%). MAIN OUTCOME MEASURE: Both level of agreement and feasibility in practice of each recommendation was tested by two anonymised online Delphi voting rounds. RESULTS: Based on an a priori threshold for consensus of >/=75% agreement, the clinical-patient community endorsed all but one recommendation. However, only 17/49 (35%) recommendations were identified by most HCPs as a core part of routine care; the remainder (32/49 (65%)) were identified as part of core care by <50% of HCPs respondents, or as largely achievable by 30%-45% of HCPs. By comparison, PAGs recorded lower implementation levels. CONCLUSIONS: Further consideration is needed on how to evolve multidisciplinary services (supported by allied HCPs and PAGs) to address the complex needs of those affected by this disease. CI - (c) Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Obici, Laura AU - Obici L AUID- ORCID: 0000-0001-7468-700X AD - Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy l.obici@smatteo.pv.it. FAU - Callaghan, Rosaline AU - Callaghan R AD - Amyloidosis Ireland, Derry, Ireland. FAU - Ablett, Joanne AU - Ablett J AD - Flow Clinical Psychology, Manchester, UK. FAU - Bibiloni, Catilena AU - Bibiloni C AD - Asociacion Balear de la Enfermedad de Andrade, Palma de Mallorca, Spain. AD - Amyloidosis Alliance, Marseille, France. FAU - Bueser, Teofila AU - Bueser T AUID- ORCID: 0000-0001-9222-1705 AD - Southeast Genomic Medicine Service Alliance, Guy's & St Thomas' Hospital NHS Foundation Trust, London, UK. FAU - Conceicao, Isabel AU - Conceicao I AD - Department of Neurosciences and Mental Health, Centro Hospitalar Universitario Lisboa Norte-HSM; Lisbon University - FML, Lisbon, Portugal. FAU - Dongiglio, Francesca AU - Dongiglio F AD - Inherited and Rare Cardiovascular Disease Unit, University of Campania "Luigi Vanvitelli", Naples, Italy. FAU - Farrugia, Agnes AU - Farrugia A AD - Amyloidosis Alliance, Marseille, France. AD - Association Francaise Contre l'Amylose, Marseille, France. FAU - Knebel, Fabian AU - Knebel F AD - Clinic for Internal Medicine II: Cardiology, Sana Klinikum Lichtenberg, Berlin, Germany. AD - Amyloidosis Center Charite Berlin, Berlin, Germany. FAU - Lane, Thirusha AU - Lane T AD - Patient Advocacy and Engagement, Alnylam Pharmaceuticals, Maidenhead, UK. FAU - Larsson, Lars-Ove AU - Larsson LO AD - FAMY-Norrbotten, Pitea, Sweden. FAU - Morier, Agnes AU - Morier A AD - CHU Bicetre, Le Kremlin Bicetre, Paris, France. FAU - Nicholas, Vincent AU - Nicholas V AD - UK ATTR Amyloidosis Patients' Association, Salisbury, UK. FAU - Coelho, Teresa AU - Coelho T AD - Familial Amyloidosis Clinic Unit, Hospital Santo Antonio, Centro Hospitalar Universitario do Porto, Porto, Portugal. AD - European Reference Network - Euro-NMD, Paris, France. LA - eng PT - Consensus Statement PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230905 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 RN - Amyloidosis, Hereditary, Transthyretin-Related SB - IM MH - Humans MH - *Patient Advocacy MH - *Amyloid Neuropathies, Familial MH - Internal Medicine MH - Delivery of Health Care PMC - PMC10481833 OTO - NOTNLM OT - neuropathology OT - nutritional support OT - organisation of health services OT - patient participation OT - patient-centered care OT - rehabilitation medicine COIS- Competing interests: LO has received speaker honoraria from Pfizer, Akcea and Alnylam; and has received honoraria for participation on advisory panels from Alnylam, Sobi, AstraZeneca, Novo Nordisk, and Pfizer. RC has received honoraria for participation in webinars from Alnylam; has received honoraria for participation in symposia from Alnylam; and has received honoraria for participation on an advisory panel from Alnylam. JA has received honoraria for participation on an advisory panel from Alnylam. CB has received honoraria for participating in symposia from Alnylam; and has received honoraria for participation on an advisory panel from Alnylam. TB received honoraria for participation in webinars from Alnylam; and has received honoraria for participation on an advisory panel from Alnylam. IC has received research funding from Pfizer; has received honoraria for participation in advisory boards from Pfizer, Alnylam, and Akcea; and has received financial support as primary investigator from Alnylam, and Ionis. AF has received honoraria for participation on an advisory panel from Alnylam. FK has received honoraria for participation in educational presentations from Alnylam; and has received honoraria for participation on an advisory panel from Alnylam. TL is an employee and stockholder of Alnylam Pharmaceuticals. L-OL received honoraria for participation on an advisory panel from Alnylam. AM has received honoraria for participation in webinars from Alnylam; and has received honoraria for participation on an advisory panel from Alnylam. VN has received honoraria for participation on an advisory panel from Alnylam. TC has received speaker honoraria from Pfizer, Alnylam, GlaxoSmithKline, Prothena and Akcea; has received expenses support for scientific meetings from Pfizer, Alnylam, Ionis, and Biogen; and has received honoraria for participation on an advisory panel from Alnylam. FD has no competing interests to declare. EDAT- 2023/09/06 00:41 MHDA- 2023/09/07 06:42 PMCR- 2023/09/05 CRDT- 2023/09/05 21:04 PHST- 2023/09/07 06:42 [medline] PHST- 2023/09/06 00:41 [pubmed] PHST- 2023/09/05 21:04 [entrez] PHST- 2023/09/05 00:00 [pmc-release] AID - bmjopen-2023-073130 [pii] AID - 10.1136/bmjopen-2023-073130 [doi] PST - epublish SO - BMJ Open. 2023 Sep 5;13(9):e073130. doi: 10.1136/bmjopen-2023-073130. PMID- 37668110 OWN - NLM STAT- MEDLINE DCOM- 20231127 LR - 20231130 IS - 1522-726X (Electronic) IS - 1522-1946 (Linking) VI - 102 IP - 6 DP - 2023 Nov TI - Clinical value of CT-derived simulations of transcatheter-aortic-valve-implantation in challenging anatomies the PRECISE-TAVI trial. PG - 1140-1148 LID - 10.1002/ccd.30816 [doi] AB - BACKGROUND: Preprocedural computed tomography planning improves procedural safety and efficacy of transcatheter aortic valve implantation (TAVI). However, contemporary imaging modalities do not account for device-host interactions. AIMS: This study evaluates the value of preprocedural computer simulation with FEops HEARTguide(TM) on overall device success in patients with challenging anatomies undergoing TAVI with a contemporary self-expanding supra-annular transcatheter heart valve. METHODS: This prospective multicenter observational study included patients with a challenging anatomy defined as bicuspid aortic valve, small annulus or severely calcified aortic valve. We compared the heart team's transcatheter heart valve (THV) planning decision based on (1) conventional multislice computed tomography (MSCT) and (2) MSCT imaging with FEops HEARTguide(TM) simulations. Clinical outcomes and THV performance were followed up to 30 days. RESULTS: A total of 77 patients were included (median age 79.9 years (IQR 74.2-83.8), 42% male). In 35% of the patients, preprocedural planning changed after FEops HEARTguide(TM) simulations (change in valve size selection [12%] or target implantation height [23%]). A new permanent pacemaker implantation (PPI) was implanted in 13% and >trace paravalvular leakage (PVL) occurred in 28.5%. The contact pressure index (i.e., simulation output indicating the risk of conduction abnormalities) was significantly higher in patients with a new PPI, compared to those without (16.0% [25th-75th percentile 12.0-21.0] vs. 3.5% [25th-75th percentile 0-11.3], p < 0.01) The predicted PVL was 5.7 mL/s (25th-75th percentile 1.3-11.1) in patients with none-trace PVL, 12.7 (25th-75th percentile 5.5-19.1) in mild PVL and 17.7 (25th-75th percentile 3.6-19.4) in moderate PVL (p = 0.04). CONCLUSION: FEops HEARTguide(TM) simulations may provide enhanced insights in the risk for PVL or PPI after TAVI with a self-expanding supra-annular THV in complex anatomies. CI - (c) 2023 The Authors. Catheterization and Cardiovascular Interventions published by Wiley Periodicals LLC. FAU - Hokken, Thijmen W AU - Hokken TW AUID- ORCID: 0000-0002-9309-0011 AD - Department of Cardiology, Thoraxcenter, Erasmus University Medical Center, Rotterdam, The Netherlands. FAU - Wienemann, Hendrik AU - Wienemann H AUID- ORCID: 0000-0001-5810-2868 AD - Clinic III for Internal Medicine, Faculty of Medicine and University Hospital Cologne, Cologne, Germany. FAU - Dargan, James AU - Dargan J AD - Cardiology Clinical Academic Group, St. George's University of London, London, UK. FAU - Ginkel, Dirk-Jan van AU - Ginkel DV AD - Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands. FAU - Dowling, Cameron AU - Dowling C AD - MonashHeart, Monash Health and Vascular Surgery, Monash Cardiovascular Research Centre, Monash University, Melbourne, Victoria, Australia. AD - Stanford University School of Medicine, Division of Cardiovascular Medicine, Stanford, California, USA. FAU - Unbehaun, Axel AU - Unbehaun A AD - Department of Cardiology, German Heart Center Berlin, Berlin, Germany. FAU - Bosmans, Johan AU - Bosmans J AD - Department of Cardiology, Antwerp University Hospital, Antwerp, Belgium. FAU - Bader-Wolfe, Andreas AU - Bader-Wolfe A AD - Department of Cardiology, German Heart Center Berlin, Berlin, Germany. FAU - Gooley, Robert AU - Gooley R AD - MonashHeart, Monash Health and Vascular Surgery, Monash Cardiovascular Research Centre, Monash University, Melbourne, Victoria, Australia. FAU - Swaans, Martin AU - Swaans M AD - Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands. FAU - Brecker, Stephen J AU - Brecker SJ AD - Cardiology Clinical Academic Group, St. George's University of London, London, UK. FAU - Adam, Matti AU - Adam M AD - Clinic III for Internal Medicine, Faculty of Medicine and University Hospital Cologne, Cologne, Germany. FAU - Van Mieghem, Nicolas M AU - Van Mieghem NM AUID- ORCID: 0000-0002-2732-1205 AD - Department of Cardiology, Thoraxcenter, Erasmus University Medical Center, Rotterdam, The Netherlands. LA - eng GR - 945698/European Union's Horizon 2020 Research and Innovation Program/ PT - Journal Article PT - Multicenter Study PT - Observational Study DEP - 20230905 PL - United States TA - Catheter Cardiovasc Interv JT - Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions JID - 100884139 SB - IM CIN - Catheter Cardiovasc Interv. 2023 Nov;102(5):958-959. doi: 10.1002/ccd.30823. PMID: 37746912 MH - Humans MH - Male MH - Aged MH - Aged, 80 and over MH - Female MH - *Transcatheter Aortic Valve Replacement MH - *Aortic Valve Stenosis/diagnostic imaging/surgery MH - Computer Simulation MH - Prospective Studies MH - *Heart Valve Prosthesis MH - Treatment Outcome MH - Aortic Valve/diagnostic imaging/surgery MH - Multidetector Computed Tomography/methods MH - Prosthesis Design OTO - NOTNLM OT - computer simulations OT - conduction abnormalities OT - paravalvular leakage OT - transcatheter aortic valve implantation EDAT- 2023/09/05 12:42 MHDA- 2023/11/27 12:43 CRDT- 2023/09/05 06:43 PHST- 2023/07/28 00:00 [revised] PHST- 2023/03/30 00:00 [received] PHST- 2023/08/19 00:00 [accepted] PHST- 2023/11/27 12:43 [medline] PHST- 2023/09/05 12:42 [pubmed] PHST- 2023/09/05 06:43 [entrez] AID - 10.1002/ccd.30816 [doi] PST - ppublish SO - Catheter Cardiovasc Interv. 2023 Nov;102(6):1140-1148. doi: 10.1002/ccd.30816. Epub 2023 Sep 5. PMID- 37666643 OWN - NLM STAT- MEDLINE DCOM- 20230906 LR - 20231002 IS - 2053-3624 (Print) IS - 2053-3624 (Electronic) IS - 2053-3624 (Linking) VI - 10 IP - 2 DP - 2023 Sep TI - Time to TAVI: streamlining the pathway to treatment. LID - 10.1136/openhrt-2022-002170 [doi] LID - e002170 AB - INTRODUCTION: Severe aortic stenosis is a major cause of morbidity and mortality. The existing treatment pathway for transcatheter aortic valve implantation (TAVI) traditionally relies on tertiary Heart Valve Centre workup. However, this has been associated with delays to treatment, in breach of British Cardiovascular Intervention Society targets. A novel pathway with emphasis on comprehensive patient workup at a local centre, alongside close collaboration with a Heart Valve Centre, may help reduce the time to TAVI. METHODS: The centre performing local workup implemented a novel TAVI referral pathway. Data were collected retrospectively for all outpatients referred for consideration of TAVI to a Heart Valve Centre from November 2020 to November 2021. The main outcome of time to TAVI was calculated as the time from Heart Valve Centre referral to TAVI, or alternative intervention, expressed in days. For the centre performing local workup, referral was defined as the date of multidisciplinary team discussion. For this centre, a total pathway time from echocardiographic diagnosis to TAVI was also evaluated. A secondary outcome of the proportion of referrals proceeding to TAVI at the Heart Valve Centre was analysed. RESULTS: Mean+/-SD time from referral to TAVI was significantly lower at the centre performing local workup, when compared with centres with traditional referral pathways (32.4+/-64 to 126+/-257 days, p<0.00001). The total pathway time from echocardiographic diagnosis to TAVI for the centre performing local workup was 89.9+/-67.6 days, which was also significantly shorter than referral to TAVI time from all other centres (p<0.003). Centres without local workup had a significantly lower percentage of patients accepted for TAVI (49.5% vs 97.8%, p<0.00001). DISCUSSION: A novel TAVI pathway with emphasis on local workup within a non-surgical centre significantly reduced both the time to TAVI and rejection rates from a Heart Valve Centre. If adopted across the other centres, this approach may help improve access to TAVI. CI - (c) Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Hewitson, Lynsey Jane AU - Hewitson LJ AUID- ORCID: 0000-0003-3361-0713 AD - Great Western Hospitals NHS Foundation Trust, Swindon, UK lynsey.hewitson@nhs.net. FAU - Cadiz, Suzane AU - Cadiz S AD - Royal Brompton & Harefield NHS Foundation Trust, London, UK. FAU - Al-Sayed, Sameeha AU - Al-Sayed S AD - Royal Brompton & Harefield NHS Foundation Trust, London, UK. FAU - Fellows, Sarah AU - Fellows S AD - Great Western Hospitals NHS Foundation Trust, Swindon, UK. AD - Oxford University Hospitals NHS Foundation Trust, Oxford, UK. FAU - Amin, Alaaeldin AU - Amin A AD - Great Western Hospitals NHS Foundation Trust, Swindon, UK. FAU - Asimakopoulos, George AU - Asimakopoulos G AD - Royal Brompton & Harefield NHS Foundation Trust, London, UK. FAU - Barnes, Edward AU - Barnes E AD - Great Western Hospitals NHS Foundation Trust, Swindon, UK. FAU - Beale, Andrew AU - Beale A AD - Great Western Hospitals NHS Foundation Trust, Swindon, UK. FAU - Browne, Suzy AU - Browne S AUID- ORCID: 0000-0002-3706-648X AD - Royal Brompton & Harefield NHS Foundation Trust, London, UK. FAU - Chandrasekaran, Badrinathan AU - Chandrasekaran B AD - Great Western Hospitals NHS Foundation Trust, Swindon, UK. FAU - Dalby, Miles AU - Dalby M AD - Royal Brompton & Harefield NHS Foundation Trust, London, UK. FAU - Foley, Paul AU - Foley P AUID- ORCID: 0000-0002-4856-832X AD - Great Western Hospitals NHS Foundation Trust, Swindon, UK. FAU - Hawkins, Mark AU - Hawkins M AD - Great Western Hospitals NHS Foundation Trust, Swindon, UK. FAU - Haynes, Douglas AU - Haynes D AD - Great Western Hospitals NHS Foundation Trust, Swindon, UK. FAU - Heng, Ee Ling AU - Heng EL AD - Royal Brompton & Harefield NHS Foundation Trust, London, UK. FAU - Hyde, Tom AU - Hyde T AD - Great Western Hospitals NHS Foundation Trust, Swindon, UK. FAU - Kabir, Tito AU - Kabir T AD - Royal Brompton & Harefield NHS Foundation Trust, London, UK. FAU - Khavandi, Ali AU - Khavandi A AD - Royal United Hospitals Bath NHS Foundation Trust, Bath, UK. FAU - Mirsadraee, Saeed AU - Mirsadraee S AD - Royal Brompton & Harefield NHS Foundation Trust, London, UK. FAU - McCrea, William AU - McCrea W AD - Great Western Hospitals NHS Foundation Trust, Swindon, UK. FAU - Petrou, Mario AU - Petrou M AD - Royal Brompton & Harefield NHS Foundation Trust, London, UK. FAU - Senior, Roxy AU - Senior R AD - Royal Brompton & Harefield NHS Foundation Trust, London, UK. FAU - Smith, David AU - Smith D AD - Royal Brompton & Harefield NHS Foundation Trust, London, UK. FAU - Smith, Robert AU - Smith R AD - Royal Brompton & Harefield NHS Foundation Trust, London, UK. FAU - Spartera, Marco AU - Spartera M AD - Great Western Hospitals NHS Foundation Trust, Swindon, UK. AD - Oxford University Hospitals NHS Foundation Trust, Oxford, UK. FAU - Wamil, Malgorzata AU - Wamil M AD - Great Western Hospitals NHS Foundation Trust, Swindon, UK. FAU - Panoulas, Vasileios AU - Panoulas V AD - Royal Brompton & Harefield NHS Foundation Trust, London, UK. AD - Cardiovascular Sciences, Imperial College London National Heart and Lung Institute, London, UK. FAU - Rahbi, Hazim AU - Rahbi H AD - Great Western Hospitals NHS Foundation Trust, Swindon, UK. AD - Royal Brompton & Harefield NHS Foundation Trust, London, UK. LA - eng PT - Journal Article PL - England TA - Open Heart JT - Open heart JID - 101631219 SB - IM MH - Humans MH - Retrospective Studies MH - *Transcatheter Aortic Valve Replacement/adverse effects MH - Echocardiography MH - Outpatients MH - Referral and Consultation PMC - PMC10481834 OTO - NOTNLM OT - Aortic Valve Stenosis OT - Delivery of Health Care OT - Diagnostic Imaging OT - Epidemiology OT - Transcatheter Aortic Valve Replacement COIS- Competing interests: HR received an educational grant from Edwards Lifesciences and VP is a proctor for Medtronic Plc. EDAT- 2023/09/05 00:42 MHDA- 2023/09/06 06:42 PMCR- 2023/09/04 CRDT- 2023/09/04 21:03 PHST- 2022/11/08 00:00 [received] PHST- 2023/07/27 00:00 [accepted] PHST- 2023/09/06 06:42 [medline] PHST- 2023/09/05 00:42 [pubmed] PHST- 2023/09/04 21:03 [entrez] PHST- 2023/09/04 00:00 [pmc-release] AID - openhrt-2022-002170 [pii] AID - 10.1136/openhrt-2022-002170 [doi] PST - ppublish SO - Open Heart. 2023 Sep;10(2):e002170. doi: 10.1136/openhrt-2022-002170. PMID- 37665430 OWN - NLM STAT- MEDLINE DCOM- 20230905 LR - 20230906 IS - 1651-1999 (Electronic) IS - 0803-7051 (Linking) VI - 32 IP - 1 DP - 2023 Dec TI - Selecting patients for interventional procedures to treat hypertension. PG - 2248276 LID - 10.1080/08037051.2023.2248276 [doi] AB - Purpose: Interventional approaches to treat hypertension are an emerging option that may be suitable for patients whose BP control cannot be achieved with lifestyle and/or pharmacotherapy and possibly for those who do not wish to take drug therapy.Materials and Methods: Interventional strategies include renal denervation with radiofrequency, ultrasound and alcohol-mediated platforms as well as baroreflex activation therapy and cardiac neuromodulation therapy. Presently renal denervation is the most advanced of the therapeutic options and is currently being commercialised in the EU.Results: It is apparent that RDN is effective in both unmedicated patients and patients with more severe hypertension including those with resistant hypertension.Conclusion: However, at present there is no evidence for the use of RDN in patients with secondary forms of hypertension and thus evaluation to rule these out is necessary before proceeding with a procedure. Furthermore, there are numerous pitfalls in the diagnosis and management of secondary hypertension which need to be taken into consideration. Finally, prior to performing an intervention it is appropriate to document presence/absence of hypertension-mediated organ damage. FAU - Lobo, Melvin D AU - Lobo MD AD - William Harvey Research Institute, Barts NIHR Biomedical Research Centre, Queen Mary University of London, London, UK. FAU - Rull, Gurvinder AU - Rull G AD - William Harvey Research Institute, Barts NIHR Biomedical Research Centre, Queen Mary University of London, London, UK. FAU - Saxena, Manish AU - Saxena M AD - William Harvey Research Institute, Barts NIHR Biomedical Research Centre, Queen Mary University of London, London, UK. FAU - Kapil, Vikas AU - Kapil V AD - William Harvey Research Institute, Barts NIHR Biomedical Research Centre, Queen Mary University of London, London, UK. LA - eng PT - Journal Article PT - Review PL - England TA - Blood Press JT - Blood pressure JID - 9301454 RN - 0 (Diuretics) SB - IM MH - Humans MH - Patient Selection MH - *Hypertension/therapy MH - Kidney MH - Baroreflex MH - Diuretics OAB - RDN has emerged as a safe and effective approach to treat hypertension with BP lowering efficacy equivalent to antihypertensive monotherapy albeit with guaranteed 'adherence'Presently populations most likely to respond to RDN are not clearly defined but given the costs of the procedure it is likely to be initially made available to those with resistant hypertension and those at highest cardiovascular riskThere is no evidence to support the use of RDN in patients with secondary forms of hypertension and thus this should be thoroughly screened for prior to offering the procedure, especially in the setting of resistant hypertensionOptimisation of lifestyle and drug therapy is key to good hypertension management and should be undertaken prior to an invasive procedure such as RDN being offeredThere are numerous pitfalls in the screening process for secondary hypertension which means that hypertension specialists should be involved in this component of the pathwayRDN can be offered by interventional radiologist, interventional cardiologists or angiologists who have had appropriate trainingClinical pathways for RDN must ultimately involve a multidisciplinary team overview with hypertension specialists, interventionists and imaging specialists combining efforts to ensure appropriate patient selection. This without question must involve patients in the decision-making process. OABL- eng OTO - NOTNLM OT - Renal denervation OT - blood pressure monitoring OT - resistant hypertension OT - secondary hypertension EDAT- 2023/09/04 12:41 MHDA- 2023/09/05 06:42 CRDT- 2023/09/04 11:12 PHST- 2023/09/05 06:42 [medline] PHST- 2023/09/04 12:41 [pubmed] PHST- 2023/09/04 11:12 [entrez] AID - 10.1080/08037051.2023.2248276 [doi] PST - ppublish SO - Blood Press. 2023 Dec;32(1):2248276. doi: 10.1080/08037051.2023.2248276. PMID- 37659603 OWN - NLM STAT- MEDLINE DCOM- 20231106 LR - 20241102 IS - 2589-9333 (Electronic) IS - 2589-9333 (Linking) VI - 5 IP - 11 DP - 2023 Nov TI - Characteristics and outcomes of socioeconomically disadvantaged pregnant individuals with adult congenital heart disease presenting to a Cardio-Obstetrics Program. PG - 101146 LID - S2589-9333(23)00288-4 [pii] LID - 10.1016/j.ajogmf.2023.101146 [doi] AB - BACKGROUND: Outcomes of individuals with adult congenital heart disease who are socioeconomically disadvantaged and cared for in cardio-obstetrical programs, are lacking. OBJECTIVE: This study aimed to describe the clinical characteristics, maternal pregnancy outcomes, and contraceptive uptake in individuals with adult congenital heart disease in an urban cardio-obstetrical program. STUDY DESIGN: Retrospective data were collected for individuals with adult congenital heart disease seen in the Maternal Fetal Medicine-Cardiology Joint Program at Montefiore Health System between 2015 and 2021 and compared using modified World Health Organization class I, II vs the modified World Health Organization class >/=II/III. RESULTS: Over 90% of individuals with adult congenital heart disease were pregnant at the time of referral. Modified World Health Organization class I, II (n=77, 62.4% Black or Hispanic/Latina) had a total of 94 pregnancies and modified World Health Organization class >/=II/III (n=49, 49.0% Black or Hispanic/Latina) had a total of 56 pregnancies. Over 25% of individuals in each group had a body mass index >/=30 (P=.78), and very low summary socioeconomic scores. Modified World Health Organization class >/=II/III were more likely to be anticoagulated in the first trimester than modified World Health Organization class I, II (10.7% vs 0.0%, P=.002) and throughout pregnancy (14.3% vs 3.2% P=.02). Modified World Health Organization class >/=II/III were more likely to require arterial monitoring during delivery than modified World Health Organization class I, II (14.3% vs 0.0%, P=.001) or delivery under general anesthesia (8.9% vs 1.1%, P=.03) but had a comparable frequency of cesarean delivery (35.8% vs 41.3%, P=.68). There were no in-hospital maternal deaths. There was no difference in the type of contraception recommended by modified World Health Organization class, however, modified World Health Organization class >/=II/III were more likely to receive long-acting types or permanent sterilization (35.6% vs 54.6%, P=.045). CONCLUSION: In a socioeconomically disadvantaged cohort with adult congenital heart disease from a historically marginalized community, those with modified World Health Organization class >/=II/III had more complex antepartum and intrapartum needs but similar maternal and obstetrical outcomes as modified World Health Organization class I, II. The multidisciplinary approach offered by a cardio-obstetrics program may contribute to successful outcomes in this high-risk cohort, and these data are hypothesis-generating. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Yellin, Shira AU - Yellin S AD - Albert Einstein College of Medicine, Bronx, NY (Dr. Yellin, Dr. Wiener, Dr. Kankaria, Dr. Vorawandthanachai, Dr. Hsu, Dr. Haberer, Dr. Bortnick, and Dr. Diana). FAU - Wiener, Sara AU - Wiener S AD - Albert Einstein College of Medicine, Bronx, NY (Dr. Yellin, Dr. Wiener, Dr. Kankaria, Dr. Vorawandthanachai, Dr. Hsu, Dr. Haberer, Dr. Bortnick, and Dr. Diana). FAU - Kankaria, Rohan AU - Kankaria R AD - Albert Einstein College of Medicine, Bronx, NY (Dr. Yellin, Dr. Wiener, Dr. Kankaria, Dr. Vorawandthanachai, Dr. Hsu, Dr. Haberer, Dr. Bortnick, and Dr. Diana). FAU - Vorawandthanachai, Thammatat AU - Vorawandthanachai T AD - Albert Einstein College of Medicine, Bronx, NY (Dr. Yellin, Dr. Wiener, Dr. Kankaria, Dr. Vorawandthanachai, Dr. Hsu, Dr. Haberer, Dr. Bortnick, and Dr. Diana). FAU - Hsu, Daphne AU - Hsu D AD - Albert Einstein College of Medicine, Bronx, NY (Dr. Yellin, Dr. Wiener, Dr. Kankaria, Dr. Vorawandthanachai, Dr. Hsu, Dr. Haberer, Dr. Bortnick, and Dr. Diana); Division of Pediatric Cardiology and Adult Congenital Heart Program, Department of Pediatrics, Children's Hospital at Montefiore Medical Center, Bronx, NY (Dr. Hsu and Dr. Haberer). FAU - Haberer, Kim AU - Haberer K AD - Albert Einstein College of Medicine, Bronx, NY (Dr. Yellin, Dr. Wiener, Dr. Kankaria, Dr. Vorawandthanachai, Dr. Hsu, Dr. Haberer, Dr. Bortnick, and Dr. Diana); Division of Pediatric Cardiology and Adult Congenital Heart Program, Department of Pediatrics, Children's Hospital at Montefiore Medical Center, Bronx, NY (Dr. Hsu and Dr. Haberer). FAU - Bortnick, Anna E AU - Bortnick AE AD - Albert Einstein College of Medicine, Bronx, NY (Dr. Yellin, Dr. Wiener, Dr. Kankaria, Dr. Vorawandthanachai, Dr. Hsu, Dr. Haberer, Dr. Bortnick, and Dr. Diana); Division of Cardiology, Department of Medicine, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY (Dr. Bortnick and Dr. Diana); Maternal Fetal Medicine-Cardiology Joint Program, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY (Dr. Bortnick and Dr. Diana); Department of Women's Health, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY (Dr. Bortnick and Dr. Diana). FAU - Diana, Wolfe S AU - Diana WS AD - Albert Einstein College of Medicine, Bronx, NY (Dr. Yellin, Dr. Wiener, Dr. Kankaria, Dr. Vorawandthanachai, Dr. Hsu, Dr. Haberer, Dr. Bortnick, and Dr. Diana); Division of Cardiology, Department of Medicine, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY (Dr. Bortnick and Dr. Diana); Maternal Fetal Medicine-Cardiology Joint Program, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY (Dr. Bortnick and Dr. Diana); Department of Women's Health, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY (Dr. Bortnick and Dr. Diana). Electronic address: dwolfe@montefiore.org. LA - eng GR - K23 HL146982/HL/NHLBI NIH HHS/United States GR - R21 HD101783/HD/NICHD NIH HHS/United States GR - UL1 TR002556/TR/NCATS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20230901 PL - United States TA - Am J Obstet Gynecol MFM JT - American journal of obstetrics & gynecology MFM JID - 101746609 SB - IM MH - Pregnancy MH - Female MH - Humans MH - Adult MH - *Heart Defects, Congenital/diagnosis/epidemiology/therapy MH - Retrospective Studies MH - Pregnancy Outcome/epidemiology MH - Cesarean Section PMC - PMC11157696 MID - NIHMS1933449 OTO - NOTNLM OT - cardiac OT - cardiology OT - congenital OT - contraception OT - disparities OT - heart OT - obstetrics OT - outcomes OT - pregnancy EDAT- 2023/09/03 00:41 MHDA- 2023/11/06 06:41 PMCR- 2024/11/01 CRDT- 2023/09/02 19:26 PHST- 2023/06/13 00:00 [received] PHST- 2023/07/20 00:00 [revised] PHST- 2023/08/26 00:00 [accepted] PHST- 2023/11/06 06:41 [medline] PHST- 2023/09/03 00:41 [pubmed] PHST- 2023/09/02 19:26 [entrez] PHST- 2024/11/01 00:00 [pmc-release] AID - S2589-9333(23)00288-4 [pii] AID - 10.1016/j.ajogmf.2023.101146 [doi] PST - ppublish SO - Am J Obstet Gynecol MFM. 2023 Nov;5(11):101146. doi: 10.1016/j.ajogmf.2023.101146. Epub 2023 Sep 1. PMID- 37658551 OWN - NLM STAT- MEDLINE DCOM- 20231102 LR - 20231102 IS - 1790-5427 (Print) IS - 1790-5427 (Linking) VI - 26 Suppl DP - 2023 May-Aug TI - A comprehensive diagnostic approach to cardiac events in cancer patients receiving antineoplastic therapy: A systematic review. PG - 5-11 AB - Oncologic patients are vulnerable to a broad spectrum of cancer related cardiovascular complications during and/or after antineoplastic treatment. This article is dealing with the main drugs used in real world clinical practice, including conventional chemotherapy, targeted therapy, immunotherapy, radiotherapy and their potential cardiovascular toxicity. Diagnosis of cancer- related cardiovascular events requires thorough clinical evaluation, multimodality imaging techniques and cardiac biomarkers according to established guidelines of cardio-oncology. Multidisciplinary approach and individualized strategies are essential and crucial in confronting oncologic patients. FAU - Lafaras, C AU - Lafaras C AD - Cardiology Unit, Theagenio Cancer Hospital, Thessaloniki, Greece. lafarasc@gmail.com. FAU - Kalafatis, I AU - Kalafatis I FAU - Lafara, K AU - Lafara K FAU - Koukoulitsa, V AU - Koukoulitsa V FAU - Mandala, E AU - Mandala E LA - eng PT - Journal Article PT - Systematic Review PL - Greece TA - Hell J Nucl Med JT - Hellenic journal of nuclear medicine JID - 101257471 RN - 0 (Antineoplastic Agents) SB - IM MH - Humans MH - *Antineoplastic Agents/adverse effects MH - *Neoplasms/drug therapy/complications MH - *Heart Diseases/chemically induced/diagnostic imaging MH - Medical Oncology/methods MH - Cardiotoxicity/etiology EDAT- 2023/09/02 10:43 MHDA- 2023/09/02 10:44 CRDT- 2023/09/02 00:43 PHST- 2023/09/02 10:44 [medline] PHST- 2023/09/02 10:43 [pubmed] PHST- 2023/09/02 00:43 [entrez] PST - ppublish SO - Hell J Nucl Med. 2023 May-Aug;26 Suppl:5-11. PMID- 37655862 OWN - NLM STAT- MEDLINE DCOM- 20241024 LR - 20260109 IS - 1969-6213 (Electronic) IS - 1774-024X (Print) IS - 1774-024X (Linking) VI - 19 IP - 8 DP - 2023 Oct 23 TI - Transcatheter aortic valve implantation versus surgical aortic valve replacement in patients at low to intermediate surgical risk: rationale and design of the randomised DEDICATE Trial. PG - 652-658 LID - EIJ-D-23-00232 [pii] LID - 10.4244/EIJ-D-23-00232 [doi] AB - Transcatheter aortic valve implantation (TAVI) has become the preferred treatment option for patients with severe aortic stenosis at increased risk for surgical aortic valve replacement (SAVR) and for older patients irrespective of risk. However, in younger, low-risk patients for whom both therapeutic options, TAVI and SAVR, are applicable, the optimal treatment strategy remains controversial, as data on long-term outcomes remain limited. The DEDICATE-DZHK6 Trial is an investigator-initiated, industry-independent, prospective, multicentre, randomised controlled trial investigating the efficacy and safety of TAVI compared to SAVR in low- to intermediate-risk patients aged 65 years or older. To evaluate both treatment strategies, approximately 1,404 patients determined eligible for both TAVI and SAVR by the interdisciplinary Heart Team were randomised to TAVI or SAVR. Broad inclusion and strict exclusion criteria targeted an all-comers patient population. Procedures were performed according to local best practice with contemporary routine medical devices. The primary endpoints are a composite of mortality or stroke at 1 year and 5 years in order to incorporate midterm efficacy results and complement early safety data. Primary outcomes will be tested sequentially for non-inferiority and superiority. The DEDICATE-DZHK6 Trial has been designed to mirror clinical reality for the treatment of severe aortic stenosis and provide unique information on overall outcomes after TAVI and SAVR that can be directly applied to clinical routines. Its results will help further define optimal treatment strategies for low- to intermediate-risk patients in whom both TAVI and SAVR are currently advisable. FAU - Seiffert, Moritz AU - Seiffert M AD - Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. AD - Centre for Population Health Innovation (POINT), University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. AD - DZHK (German Centre for Cardiovascular Research) partner site Hamburg/Kiel/Lubeck, Hamburg, Germany. FAU - Vonthein, Reinhard AU - Vonthein R AD - Institute of Medical Biometry and Statistics, University of Lubeck, Lubeck, Germany. FAU - Baumgartner, Helmut AU - Baumgartner H AD - Department of Cardiology III - Adult Congenital and Valvular Heart Disease, University Hospital Muenster, Muenster, Germany. FAU - Borger, Michael A AU - Borger MA AD - Department of Cardiac Surgery, Heart Center Leipzig at University of Leipzig, Leipzig, Germany. FAU - Choi, Yeong-Hoon AU - Choi YH AD - Department of Cardiac Surgery, Kerckhoff-Klinik, Bad Nauheim, Germany. AD - DZHK (German Centre for Cardiovascular Research) partner site Rhine-Main, Rhine-Main, Germany. FAU - Falk, Volkmar AU - Falk V AD - Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charite (DHZC), Berlin, Germany. AD - DZHK (German Centre for Cardiovascular Research) partner site Berlin, Berlin, Germany. AD - Department of Health Sciences & Technology, ETH Zurich, Translational Cardiovascular Technology, Zurich, Switzerland. FAU - Frey, Norbert AU - Frey N AD - Department of Cardiology, Angiology, and Pneumology, Heidelberg University Hospital, Heidelberg, Germany. AD - DZHK (German Centre for Cardiovascular Research) partner site Heidelberg/Mannheim, Heidelberg, Germany. FAU - Hagendorff, Andreas AU - Hagendorff A AD - Department of Cardiology, University of Leipzig, Leipzig, Germany. FAU - Hagl, Christian AU - Hagl C AD - Department of Cardiac Surgery, University Hospital Munich, Ludwig-Maximilians-University Munich, Munich, Germany. AD - DZHK (German Centre for Cardiovascular Research) partner site Munich Heart Alliance, Munich, Germany. FAU - Hamm, Christian AU - Hamm C AD - DZHK (German Centre for Cardiovascular Research) partner site Rhine-Main, Rhine-Main, Germany. AD - Campus Kerckhoff and Medical Clinic I, University of Giessen, Giessen, Germany. FAU - Konig, Inke R AU - Konig IR AD - DZHK (German Centre for Cardiovascular Research) partner site Hamburg/Kiel/Lubeck, Hamburg, Germany. AD - Institute of Medical Biometry and Statistics, University of Lubeck, Lubeck, Germany. FAU - Landmesser, Ulf AU - Landmesser U AD - DZHK (German Centre for Cardiovascular Research) partner site Berlin, Berlin, Germany. AD - Department of Cardiology, Angiology and Intensive Care Medicine, Deutsches Herzzentrum der Charite (DHZC), Berlin, Germany and Charite Universitatsmedizin Berlin, Berlin, Germany. FAU - Massberg, Steffen AU - Massberg S AD - Department of Cardiac Surgery, University Hospital Munich, Ludwig-Maximilians-University Munich, Munich, Germany. AD - Department of Cardiology, University Hospital Munich, Ludwig-Maximilians-University Munich, Munich, Germany. FAU - Reichenspurner, Hermann AU - Reichenspurner H AD - DZHK (German Centre for Cardiovascular Research) partner site Hamburg/Kiel/Lubeck, Hamburg, Germany. AD - Department of Cardiovascular Surgery, University Heart and Vascular Center Hamburg, Hamburg, Germany. FAU - Thiele, Holger AU - Thiele H AD - Department of Cardiology, Heart Center Leipzig at University of Leipzig, Leipzig, Germany and Leipzig Heart Science, Leipzig, Germany. FAU - Twerenbold, Raphael AU - Twerenbold R AD - Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. AD - Centre for Population Health Innovation (POINT), University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. AD - DZHK (German Centre for Cardiovascular Research) partner site Hamburg/Kiel/Lubeck, Hamburg, Germany. FAU - Vens, Maren AU - Vens M AD - Institute of Medical Biometry and Statistics, University of Lubeck, Lubeck, Germany. FAU - Walther, Thomas AU - Walther T AD - DZHK (German Centre for Cardiovascular Research) partner site Rhine-Main, Rhine-Main, Germany. AD - Department of Thoracic and Cardiovascular Surgery, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany. FAU - Ziegler, Andreas AU - Ziegler A AD - Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. AD - Centre for Population Health Innovation (POINT), University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. AD - Cardio-CARE, Medizincampus Davos, Davos, Switzerland. AD - School of Mathematics, Statistics and Computer Science, University of KwaZulu-Natal, Pietermaritzburg, South Africa. FAU - Cremer, Jochen AU - Cremer J AD - DZHK (German Centre for Cardiovascular Research) partner site Hamburg/Kiel/Lubeck, Hamburg, Germany. AD - Department of Cardiovascular Surgery, University Hospital of Schleswig-Holstein, Kiel, Germany. FAU - Blankenberg, Stefan AU - Blankenberg S AD - Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. AD - Centre for Population Health Innovation (POINT), University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. AD - DZHK (German Centre for Cardiovascular Research) partner site Hamburg/Kiel/Lubeck, Hamburg, Germany. LA - eng PT - Clinical Trial Protocol PT - Journal Article PL - France TA - EuroIntervention JT - EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology JID - 101251040 SB - IM MH - Aged MH - Aged, 80 and over MH - Female MH - Humans MH - Male MH - Aortic Valve/surgery/diagnostic imaging MH - *Aortic Valve Stenosis/surgery/mortality MH - Heart Valve Prosthesis MH - Heart Valve Prosthesis Implantation/methods/adverse effects/instrumentation MH - Prospective Studies MH - Risk Assessment MH - Risk Factors MH - *Transcatheter Aortic Valve Replacement/methods/adverse effects MH - Treatment Outcome MH - Multicenter Studies as Topic MH - Equivalence Trials as Topic PMC - PMC10587839 COIS- M. Seiffert received speaker or advisory fees from Abbott Vascular, Abiomed, Amgen, AstraZeneca, Boston Scientific, Bristol-Myers Squibb, Daichii Sankyo, Edwards Lifesciences, Inari Medical, Medtronic, Pfizer, Shockwave Medical, and Siemens Healthineers; and aresearch grant from Boston Scientific - all unrelated to the submitted work. M. Borger declares that his hospital receives speaker honoraria and/or consulting fees on his behalf from Edwards Lifesciences, Medtronic, Abbott, and Artivion. V. Falk has relevant financial activities outside the submitted work with following commercial entities: Medtronic, Biotronik, Abbott, Boston Scientific, Edwards Lifesciences, LivaNova, Berlin Heart, Novartis, JOTEC/Artivion, and Zurich Heart. C. Hamm is amember of the International Strategic Advisory Board at Medtronic. U. Landmesser reports grants to institution from Bayer, Amgen, and Novartis; and speaker or advisory fees from Abbott and Boston Scientific. H. Reichenspurner is amember of the advisory board at Medtronic; and declares that he receives speaker honoraria from Abiomed and Abbott. R. Twerenbold holds aprofessorship in clinical cardiology at the University Medical Center Hamburg-Eppendorf, supported by the Kuhne Foundation; reports research support from the German Centre for Cardiovascular Research (DZHK) and the Swiss National Science Foundation (Grant No. P300PB_167803), speaker/consulting honoraria from Abbott, Amgen, AstraZeneca, Psyros, Roche, Siemens, Singulex, and Thermo Scientific BRAHMS, outside the submitted work. S. Blankenberg, R. Twerenbold and A. Ziegler are listed as co-inventors of an international patent on the use of acomputing device to estimate the probability of myocardial infarction (International Publication Number WO2022043229A1) as well as co-founders and shareholders of ART-EMIS Hamburg GmbH. A. Ziegler is ascientific director of Cardio-CARE, which is another shareholder of ART-EMIS Hamburg GmbH. The other authors have no conflicts of interest to declare. EDAT- 2023/09/01 12:42 MHDA- 2024/10/24 16:21 PMCR- 2024/10/23 CRDT- 2023/09/01 08:53 PHST- 2024/10/24 16:21 [medline] PHST- 2023/09/01 12:42 [pubmed] PHST- 2023/09/01 08:53 [entrez] PHST- 2024/10/23 00:00 [pmc-release] AID - EIJ-D-23-00232 [pii] AID - 10.4244/EIJ-D-23-00232 [doi] PST - ppublish SO - EuroIntervention. 2023 Oct 23;19(8):652-658. doi: 10.4244/EIJ-D-23-00232. PMID- 37654966 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240924 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 15 IP - 7 DP - 2023 Jul TI - A Multidisciplinary Algorithm for the Evaluation of Acute Neurologic Deficits Improves Management of Cryptogenic Stroke or Transient Ischemic Attack. PG - e42728 LID - 10.7759/cureus.42728 [doi] LID - e42728 AB - The appropriate diagnosis and management of cryptogenic stroke and transient ischemic attack (TIA) is challenging and requires multidisciplinary involvement. Joint societal guidelines exist to guide the comprehensive evaluation of these entities. This study aimed to implement a standardized multidisciplinary diagnostic algorithm for cryptogenic stroke/TIA. We performed a retrospective analysis of patients admitted to the largest regional military healthcare center with stroke or TIA considered to be cryptogenic at the time of discharge. We abstracted baseline demographics and rates of extra- and intracranial imaging, transthoracic and transesophageal echocardiography, and event monitor orders at the time of discharge. The incidence of event monitor results at 30 days and six months were included. A diagnostic algorithm for evaluation of cryptogenic stroke/TIA was created and disseminated hospital-wide using increased compliance with neuroimaging, echocardiography, and cardiac rhythm monitoring as primary endpoints for our intervention. Post-intervention data abstraction revealed similar rates of extra- and intracranial imaging, but significantly greater rates of transthoracic echocardiography (70% vs. 87%, p 0.0073), inclusion of agitated saline study (41% vs. 65%, p 0.0024), and event monitors ordered at discharge (18% vs. 35%, p 0.0045). At six months there was a higher rate of event monitors obtained (24% vs. 45%, p 0.001). Our study showed implementation of an evidence-based diagnostic algorithm for evaluation of cryptogenic stroke/TIA increases appropriate use of echocardiography and event monitoring. CI - Copyright (c) 2023, Hull et al. FAU - Hull, Robert AU - Hull R AD - Cardiology, Brooke Army Medical Center, Fort Sam Houston, USA. FAU - Carman, Nathaniel AU - Carman N AD - Cardiology, Brooke Army Medical Center, Fort Sam Houston, USA. FAU - Wilson, Andrew AU - Wilson A AD - Cardiology, Brooke Army Medical Center, Fort Sam Houston, USA. FAU - Moulton, Michael AU - Moulton M AD - Cardiology, Brooke Army Medical Center, Fort Sam Houston, USA. FAU - Jordan, Morgan C AU - Jordan MC AD - Neurology, Brooke Army Medical Center, Fort Sam Houston, USA. FAU - Stephens, Brian D AU - Stephens BD AD - Neurology, Brooke Army Medical Center, Fort Sam Houston, USA. FAU - Bush, Kelvin AU - Bush K AD - Cardiology, Brooke Army Medical Center, Fort Sam Houston, USA. LA - eng PT - Journal Article DEP - 20230731 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC10466960 OTO - NOTNLM OT - algorithm OT - cryptogenic stroke OT - cva OT - event monitor OT - stroke OT - tia OT - transesophageal echocardiogram COIS- The authors have declared that no competing interests exist. EDAT- 2023/09/01 06:43 MHDA- 2023/09/01 06:44 PMCR- 2023/07/31 CRDT- 2023/09/01 04:04 PHST- 2023/07/30 00:00 [accepted] PHST- 2023/09/01 06:44 [medline] PHST- 2023/09/01 06:43 [pubmed] PHST- 2023/09/01 04:04 [entrez] PHST- 2023/07/31 00:00 [pmc-release] AID - 10.7759/cureus.42728 [doi] PST - epublish SO - Cureus. 2023 Jul 31;15(7):e42728. doi: 10.7759/cureus.42728. eCollection 2023 Jul. PMID- 37653086 OWN - NLM STAT- MEDLINE DCOM- 20230904 LR - 20231002 IS - 1526-9906 (Electronic) IS - 1526-9906 (Linking) VI - 24 IP - 9 DP - 2023 Sep 1 TI - The Role of the Neonatologist in Fetuses Diagnosed with Congenital Heart Disease. PG - e553-e568 LID - 10.1542/neo.24-9-e553 [doi] AB - Prenatal diagnosis of congenital heart disease (CHD) can decrease preoperative morbidity and mortality. Delivery room planning can improve cardiac hemodynamics and time to critical catheter and surgical interventions. Care algorithms have defined lesion-specific level-of-care assignments and delivery room action plans that can facilitate team-based approaches to safe deliveries. Neonatologists play critical roles in the care of fetuses diagnosed with CHD, from the time of diagnosis through the postnatal intensive care unit (ICU) stays. Prenatally, neonatologists are members of the multidisciplinary counseling teams, with expertise to counsel expectant parents about what to expect during the ICU stay, which is especially valuable in CHD associated with extracardiac or genetic anomalies. Neonatologists' role in delivery planning includes identification of the optimal delivery location and allocation of appropriate personnel and resources. After delivery, postnatal care considerations include hemodynamic stability, optimization of end-organ function, genetics consultation, developmentally appropriate care practices to encourage caregiver bonding, and optimization of care to improve neurodevelopmental outcomes of neonates with CHD. CI - Copyright (c) 2023 by the American Academy of Pediatrics. FAU - Udine, Michelle AU - Udine M AD - Division of Cardiology, Children's National Hospital, Washington, DC. FAU - Donofrio, Mary T AU - Donofrio MT AD - Division of Cardiology, Children's National Hospital, Washington, DC. LA - eng PT - Journal Article PL - United States TA - Neoreviews JT - NeoReviews JID - 101085360 SB - IM MH - Infant, Newborn MH - Female MH - Pregnancy MH - Humans MH - *Neonatologists MH - *Heart Defects, Congenital/diagnosis/therapy MH - Prenatal Diagnosis MH - Fetus MH - Catheters EDAT- 2023/09/01 00:41 MHDA- 2023/09/04 06:42 CRDT- 2023/08/31 23:30 PHST- 2023/09/04 06:42 [medline] PHST- 2023/09/01 00:41 [pubmed] PHST- 2023/08/31 23:30 [entrez] AID - 193771 [pii] AID - 10.1542/neo.24-9-e553 [doi] PST - ppublish SO - Neoreviews. 2023 Sep 1;24(9):e553-e568. doi: 10.1542/neo.24-9-e553. PMID- 37647926 OWN - NLM STAT- MEDLINE DCOM- 20230911 LR - 20250723 IS - 1474-547X (Electronic) IS - 0140-6736 (Linking) VI - 402 IP - 10405 DP - 2023 Sep 9 TI - The Lancet Commission to reduce the global burden of sudden cardiac death: a call for multidisciplinary action. PG - 883-936 LID - S0140-6736(23)00875-9 [pii] LID - 10.1016/S0140-6736(23)00875-9 [doi] AB - Despite major advancements in cardiovascular medicine, sudden cardiac death (SCD) continues to be an enormous medical and societal challenge, claiming millions of lives every year. Efforts to prevent SCD are hampered by imperfect risk prediction and inadequate solutions to specifically address arrhythmogenesis. Although resuscitation strategies have witnessed substantial evolution, there is a need to strengthen the organisation of community interventions and emergency medical systems across varied locations and health-care structures. With all the technological and medical advances of the 21st century, the fact that survival from sudden cardiac arrest (SCA) remains lower than 10% in most parts of the world is unacceptable. Recognising this urgent need, the Lancet Commission on SCD was constituted, bringing together 30 international experts in varied disciplines. Consistent progress in tackling SCD will require a completely revamped approach to SCD prevention, with wide-sweeping policy changes that will empower the development of both governmental and community-based programmes to maximise survival from SCA, and to comprehensively attend to survivors and decedents' families after the event. International collaborative efforts that maximally leverage and connect the expertise of various research organisations will need to be prioritised to properly address identified gaps. The Commission places substantial emphasis on the need to develop a multidisciplinary strategy that encompasses all aspects of SCD prevention and treatment. The Commission provides a critical assessment of the current scientific efforts in the field, and puts forth key recommendations to challenge, activate, and intensify efforts by both the scientific and global community with new directions, research, and innovation to reduce the burden of SCD worldwide. CI - Copyright (c) 2023 Elsevier Ltd. All rights reserved. FAU - Marijon, Eloi AU - Marijon E AD - Division of Cardiology, European Georges Pompidou Hospital, AP-HP, Paris, France; Universite Paris Cite, Inserm, PARCC, Paris, France; Paris-Sudden Death Expertise Center (Paris-SDEC), Paris, France. Electronic address: eloi_marijon@yahoo.fr. FAU - Narayanan, Kumar AU - Narayanan K AD - Universite Paris Cite, Inserm, PARCC, Paris, France; Paris-Sudden Death Expertise Center (Paris-SDEC), Paris, France; Medicover Hospitals, Hyderabad, India. FAU - Smith, Karen AU - Smith K AD - School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia; Silverchain Group, Melbourne, VIC, Australia. FAU - Barra, Sergio AU - Barra S AD - Department of Cardiology, Hospital da Luz Arrabida, Vila Nova de Gaia, Portugal. FAU - Basso, Cristina AU - Basso C AD - Cardiovascular Pathology Unit-Azienda Ospedaliera and Department of Cardiac Thoracic and Vascular Sciences and Public Health, University of Padua, Padua, Italy. FAU - Blom, Marieke T AU - Blom MT AD - Department of General Practice, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands. FAU - Crotti, Lia AU - Crotti L AD - Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy; Istituto Auxologico Italiano, IRCCS, Center for Cardiac Arrhythmias of Genetic Origin, Cardiomyopathy Unit and Laboratory of Cardiovascular Genetics, Department of Cardiology, Milan, Italy. FAU - D'Avila, Andre AU - D'Avila A AD - Department of Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA; Department of Cardiology, Hospital SOS Cardio, Santa Catarina, Brazil. FAU - Deo, Rajat AU - Deo R AD - Department of Cardiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. FAU - Dumas, Florence AU - Dumas F AD - Universite Paris Cite, Inserm, PARCC, Paris, France; Paris-Sudden Death Expertise Center (Paris-SDEC), Paris, France; Emergency Department, Cochin Hospital, Paris, France. FAU - Dzudie, Anastase AU - Dzudie A AD - Cardiology and Cardiac Arrhythmia Unit, Department of Internal Medicine, DoualaGeneral Hospital, Douala, Cameroon; Yaounde Faculty of Medicine and Biomedical Sciences, University of Yaounde 1, Yaounde, Cameroon. FAU - Farrugia, Audrey AU - Farrugia A AD - Hopitaux Universitaires de Strasbourg, France, Strasbourg, France. FAU - Greeley, Kaitlyn AU - Greeley K AD - Division of Cardiology, European Georges Pompidou Hospital, AP-HP, Paris, France; Universite Paris Cite, Inserm, PARCC, Paris, France; Paris-Sudden Death Expertise Center (Paris-SDEC), Paris, France. FAU - Hindricks, Gerhard AU - Hindricks G AD - Department of Cardiology, University of Leipzig, Leipzig, Germany. FAU - Hua, Wei AU - Hua W AD - Cardiac Arrhythmia Center, FuWai Hospital, Beijing, China. FAU - Ingles, Jodie AU - Ingles J AD - Centre for Population Genomics, Garvan Institute of Medical Research and UNSW Sydney, Sydney, NSW, Australia. FAU - Iwami, Taku AU - Iwami T AD - Kyoto University Health Service, Kyoto, Japan. FAU - Junttila, Juhani AU - Junttila J AD - MRC Oulu, University of Oulu and Oulu University Hospital, Oulu, Finland. FAU - Koster, Rudolph W AU - Koster RW AD - Heart Center, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands. FAU - Le Polain De Waroux, Jean-Benoit AU - Le Polain De Waroux JB AD - AZ Sint-Jan, Bruges, Belgium. FAU - Olasveengen, Theresa M AU - Olasveengen TM AD - Department of Anesthesia and Intensive Care Medicine, Oslo University Hospital and Institute of Clinical Medicine, Oslo, Norway. FAU - Ong, Marcus E H AU - Ong MEH AD - Singapore General Hospital, Duke-NUS Medical School, Singapore. FAU - Papadakis, Michael AU - Papadakis M AD - Cardiovascular Clinical Academic Group, St George's University of London, London, UK. FAU - Sasson, Comilla AU - Sasson C AD - American Heart Association, Denver, CO, USA. FAU - Shin, Sang Do AU - Shin SD AD - Department of Emergency Medicine at the Seoul National University College of Medicine, Seoul, South Korea. FAU - Tse, Hung-Fat AU - Tse HF AD - University of Hong Kong, School of Clinical Medicine, Queen Mary Hospital, Hong Kong Special Administrative Region, China; Cardiac and Vascular Center, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China. FAU - Tseng, Zian AU - Tseng Z AD - Division of Cardiology, UCSF Health, University of California, San Francisco Medical Center, San Francisco, California. FAU - Van Der Werf, Christian AU - Van Der Werf C AD - University of Amsterdam, Heart Center, Amsterdam, Netherlands; Department of Clinical and Experimental Cardiology, Amsterdam University Medical Centers, Amsterdam, Netherlands. FAU - Folke, Fredrik AU - Folke F AD - Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. FAU - Albert, Christine M AU - Albert CM AD - Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. FAU - Winkel, Bo Gregers AU - Winkel BG AD - Department of Cardiology, University Hospital Copenhagen, Rigshospitalet, Copenhagen, Denmark. LA - eng GR - R01 HL102090/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20230827 PL - England TA - Lancet JT - Lancet (London, England) JID - 2985213R RN - 0 (Cardiovascular Agents) SB - IM MH - Humans MH - *Death, Sudden, Cardiac/prevention & control MH - *Cardiovascular Agents MH - Government MH - Health Facilities MH - Interdisciplinary Studies COIS- Declaration of interests CMA declares grants from St Jude Medical Foundation and NIH-NHLBI; consulting fees from Medtronic, Illumina, and Novartis; payment or honoraria for lectures from Medtronic; and participation on a data safety monitoring board or advisory board for Medtronic, Element Science, and Boston Scientific. J-BLPDW declares payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Medtronic, Biotronik, Boston Scientific, and Abbott. MTB declares grants from the EU ESCAPE-NET project, funded by the EU's Horizon 2020 research and innovation programme under grant agreement 733381; and grants from European Foundation for the Study of Diabetes (for project Improvement of CVD risk stratification: an innovative method for optimal timing of ECG monitoring). LC declares grants from Grant Horizon 2020 (2016-22) ESCAPE-NET; ERA-CVD Empathy (2020-23) for the electromechanical presages of sudden cardiac death in the young: integrating imaging, modelling, and genetics for patient stratification; grants from AIFA (2020-23) for novel therapy for the long QT syndrome type 2 based on the mechanism of action of the disease-causing mutations; grants from EJP RD (European Joint Program on Rare Disesase) LQTS-NEXT (2020-23) to the next level of risk prediction in patients with long QT syndrome; grants from EJP RD Silence-LQTS (2021-24) for SGK1 inhibition as a novel therapeutic approach in long QT syndrome; and participation on a data safety monitoring board or advisory board for Bristol Myers Squibb. FF declares grants and support for attending meetings or travel from Novo Nordisk Foundation NNF19OC0055142. GH declares grants from European Commission (PROFID project public grant for the development of a risk stratification tool to predict SCD and to evaluate the risk predictor in a clinical trial; NCT04540289) and German Federal Joint Committee (G-BA; RESET CRT public grant for a clinical trial comparing CRT-D versus CRT-P). JI declares research support from National Health and Medical Research Council Australia, Heart Foundation Australia, and New South Wales Health. JJ declares grants from Academy of Finland, Finnish Foundation for Cardiovascular Research, and Sigrid Juselius Foundation; support for attending meetings and travel from AstraZeneca, Bayer, Boehringer Ingelheim, Pfizer, and Orion Pharma; and participation on a data safety monitoring board or advisory board for Novo Nordisk, Bayer, and Boehringer Ingelheim. EM declares research grants from Abbott, Biotronik, Boston Scientific, Medtronic, MicroPort, and Zoll; consulting fees from Medtronic, Boston Scientific, Zoll, and Abbott; and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Medtronic, Boston Scientific, Zoll, and Abbott. MEHO declares other financial or non-financial interests from TIIM Healthcare and Global Healthcare SG. TMO declares participation on a data safety monitoring board for the COCA trial (a randomised controlled trial evaluating calcium during cardiac arrest). MP declares grants from St George's, University of London for research on cardiac risk in the young and consulting fees from Bristol Myers Squibb. CS declares being an employee at American Heart Association. H-FT declares research grants from Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Daiichi Sankyo, Medtronic, Novartis, Pfizer, and Sanofi; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Amgen, AstraZeneca, Boehringer Ingelheim, Boston Scientific, Daiichi Sankyo, Medtronic, Pfizer, and Sanofi; and support for attending meetings and travel from Boehringer Ingelheim. ZT declares grants or contracts from National Institutes of Health (NIH) and National Heart, Lung, and Blood Institute (NHLBI; NIH/NHLBI R01 HL 102090, NIH/NHLBI R01 HL 126555, NIH/NHLBI R01 HL 147035, and NIH/NHLBI R01 HL 157247), NIH and National Institute of Allergy and Infectious Diseases (NIAID; NIH/NIAID P01 AI 169606), and Centers for Disease Control and Prevention (6 NU38DP000019-01-01 and 1 NU38DP000019-01-00). All other authors declare no competing interests. EDAT- 2023/08/31 00:42 MHDA- 2023/09/11 06:43 CRDT- 2023/08/30 18:53 PHST- 2022/10/03 00:00 [received] PHST- 2023/04/13 00:00 [revised] PHST- 2023/04/25 00:00 [accepted] PHST- 2023/09/11 06:43 [medline] PHST- 2023/08/31 00:42 [pubmed] PHST- 2023/08/30 18:53 [entrez] AID - S0140-6736(23)00875-9 [pii] AID - 10.1016/S0140-6736(23)00875-9 [doi] PST - ppublish SO - Lancet. 2023 Sep 9;402(10405):883-936. doi: 10.1016/S0140-6736(23)00875-9. Epub 2023 Aug 27. PMID- 37645516 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231102 IS - 2297-055X (Print) IS - 2297-055X (Electronic) IS - 2297-055X (Linking) VI - 10 DP - 2023 TI - Contemporary European practice in transcatheter aortic valve implantation: results from the 2022 European TAVI Pathway Registry. PG - 1227217 LID - 10.3389/fcvm.2023.1227217 [doi] LID - 1227217 AB - BACKGROUND: A steep rise in the use of transcatheter aortic valve implantation (TAVI) for the management of symptomatic severe aortic stenosis occurred. Minimalist TAVI procedures and streamlined patient pathways within experienced Heart Valve Centres are designed to overcome the challenges of ever-increasing procedural volume. AIMS: The 2022 European TAVI Pathway Survey aims to describe contemporary TAVI practice across Europe. MATERIALS AND METHODS: Between October and December 2022, TAVI operators from 32 European countries were invited to complete an online questionnaire regarding their current practice. RESULTS: Responses were available from 147 TAVI centres in 26 countries. In 2021, the participating centres performed a total number of 27,223 TAVI procedures, with a mean of 185 TAVI cases per centre (median 138; IQR 77-194). Treatment strategies are usually (87%) discussed at a dedicated Heart Team meeting. Transfemoral TAVI is performed with local anaesthesia only (33%), with associated conscious sedation (60%), or under general anaesthesia (7%). Primary vascular access is percutaneous transfemoral (99%) with secondary radial access (52%). After uncomplicated TAVI, patients are transferred to a high-, medium-, or low-care unit in 28%, 52%, and 20% of cases, respectively. Time to discharge is day 1 (12%), day 2 (31%), day 3 (29%), or day 4 or more (28%). CONCLUSION: Reported adoption of minimalist TAVI techniques is common among European TAVI centres, but rates of next-day discharge remain low. This survey highlights the significant progress made in refining TAVI treatment and pathways in recent years and identifies possible areas for further improvement. CI - (c) 2023 Rosseel, Mylotte, Cosyns, Vanhaverbeke, Zweiker, Teles, Angeras, Neylon, Rudolph, Wykrzykowska, Patterson, Costa, Ojeda, Tzikas, Abras, Leroux, Van Belle, Tchetche, Bleiziffer, Swaans, Parma, Blackman, Van Mieghem, Grygier, Redwood, Prendergast, Van Camp and De Backer. FAU - Rosseel, Liesbeth AU - Rosseel L AD - Department of Cardiology, Algemeen Stedelijk Hospital, Aalst, Belgium. AD - Faculteit Geneeskunde, Vrije Universiteit Brussel (VUB), Brussels, Belgium. FAU - Mylotte, Darren AU - Mylotte D AD - Department of Cardiology, University Hospital Galway and National University of Ireland, Galway, Ireland. FAU - Cosyns, Bernard AU - Cosyns B AD - Faculteit Geneeskunde, Vrije Universiteit Brussel (VUB), Brussels, Belgium. AD - Centrum Voor Hart- en Vaatziekten (CHVZ), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium. FAU - Vanhaverbeke, Maarten AU - Vanhaverbeke M AD - Department of Cardiology, AZ Delta, Roeselare, Belgium. FAU - Zweiker, David AU - Zweiker D AD - Division of Cardiology, Department of Cardiology and Intensive Care, Clinic Ottakring, Medical University of Graz, Graz, Austria. FAU - Teles, Rui Campante AU - Teles RC AD - Centro Hospitalar de Lisboa Ocidental (CHLO), Hospital de Santa Cruz. AD - Nova Medical School, Centro de Estudo de Doencas Cronicas (CEDOC), Lisbon, Portugal. FAU - Angeras, Oskar AU - Angeras O AD - Department of Cardiology, Sahlgrenska University Hospital, Gothenberg, Sweden. AD - Department of Molecular and Clinical Medicine, Institute of Medicine, Gothenburg University, Gothenburg, Sweden. FAU - Neylon, Antoinette AU - Neylon A AD - Institut Cardiovasculaire Paris Sud, Ramsay Sante, Massy, France. FAU - Rudolph, Tanja Katharina AU - Rudolph TK AD - Clinic of General and Interventional Cardiology, Heart and Diabetes Center Nordrhine Westfalia, Ruhr-University, Bad Oeynhausen, Germany. FAU - Wykrzykowska, Joanna J AU - Wykrzykowska JJ AD - Department of Cardiology, University Medical Center Groningen, Groningen, Netherlands. FAU - Patterson, Tiffany AU - Patterson T AD - Department of Cardiology, Guys and St Thomas' NHS Foundation Trust London, London, United Kingdom. FAU - Costa, Giulia AU - Costa G AD - Cardiac Catheterization Division, Cardiothoracic and Vascular Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy. FAU - Ojeda, Soledad AU - Ojeda S AD - Division of Interventional Cardiology, Reina Sofia Hospital, Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIV), University of Cordoba, Cordoba, Spain. FAU - Tzikas, Apostolos AU - Tzikas A AD - Department of Cardiology, European Interbalkan Medical Centre, Thessaloniki, Greece. FAU - Abras, Marcel AU - Abras M AD - University Clinic of Interventional Cardiology, Nicolae Testemitanu State University of Medicine and Pharmacy from Republic of Moldova, Chisinau, Moldova. FAU - Leroux, Lionel AU - Leroux L AD - Medico-Surgical Department of Valvulopathies, CHU De Bordaux, Pessac, France. FAU - Van Belle, Eric AU - Van Belle E AD - CHU Lille, Institut Coeur Poumon, Pole Cardiovasculaire et Pulmonaire, ACTION Group, Inserm U1011, Institut Pasteur de Lille, EGID, Universite de Lille, Lille, France. FAU - Tchetche, Didier AU - Tchetche D AD - Department of Interventional Cardiology, Clinique Pasteur, Toulouse, France. FAU - Bleiziffer, Sabine AU - Bleiziffer S AD - Department of Thoracic and Cardiovascular Surgery, Heart and Diabetes Center North Rhine-Westphalia, Bad Oeynhausen, Germany. FAU - Swaans, Martin J AU - Swaans MJ AD - Department of Cardiology, St. Antonius Hospital, Nieuwegein, Netherlands. FAU - Parma, Radoslaw AU - Parma R AD - Department of Cardiology and Structural Heart Diseases, 3 Division of Cardiology, Medical University of Silesia, Katowice, Poland. FAU - Blackman, Daniel J AU - Blackman DJ AD - Department of Cardiology, Leeds Teaching Hospitals, Leeds, United Kingdom. FAU - Van Mieghem, Nicolas M AU - Van Mieghem NM AD - Department of Interventional Cardiology, Erasmus University Medical Center, Rotterdam, Netherlands. FAU - Grygier, Marek AU - Grygier M AD - Chair and 1st Department of Cardiology, Poznan University of Medical Sciences, Poznan, Poland. FAU - Redwood, Simon AU - Redwood S AD - Department of Cardiology, Guys and St Thomas' NHS Foundation Trust London, London, United Kingdom. FAU - Prendergast, Bernard AU - Prendergast B AD - Department of Cardiology, Guys and St Thomas' NHS Foundation Trust London, London, United Kingdom. FAU - Van Camp, Guy AU - Van Camp G AD - Department of Cardiology, Heart Center OLV Aalst, Aalst, Belgium. FAU - De Backer, Ole AU - De Backer O AD - Heart Center, Rigshospitalet, Copenhagen, Denmark. LA - eng PT - Journal Article DEP - 20230814 PL - Switzerland TA - Front Cardiovasc Med JT - Frontiers in cardiovascular medicine JID - 101653388 PMC - PMC10461475 OTO - NOTNLM OT - Transcatheter aortic valve implantation OT - aortic stenosis OT - early discharge OT - minimalist TAVI OT - multidisciplinary Heart Team COIS- DM: consultant for Medtronic, Boston Scientific, and Microport. TR: proctor and advisor for JenaValve, speaker's honoraria from Edwards Lifesciences, Boston Scientific, Medtronic, and JenaValve. JW: institutional grant from Medtronic and speaker's honoraria (also to the institution) from Boston Scientific and Sinomed. SO: consulting fees from Medtronic and Edwards, speaker's honoraria from Philips and World Medical, and research grant (PI21/00949) from the Spanish Ministry of Science and Innovation (Instituto de Salud Carlos III). LL: proctoring and consulting honoraria for Abbott, Edwards, and Medtronic. DB: proctoring and consulting honoraria for Abbott, Edwards, and Medtronic. NM: institutional research grant support from Abbott Vascular, Boston Scientific, Biotronik, Medtronic, Daiichi Sankyo, Astra Zeneca, and PulseCath BV; and consultancy fees from Abbott Vascular, Boston Scientific, Biotronik, Medtronic, Daiichi Sankyo, Abiomed, Amgen, JenaValve, Anteris, and PulseCath BV. MG: Boston Scientific-research and travel grants, speaker's honoraria, proctor, and advisory board member; Medtronic-research and travel grants, speaker's honoraria, proctor, advisory board member; Abbott-speaker's honoraria and travel grants; and Edwards Lifesciences-speakers honoraria and travel grants. BP: speaker's fees from Edwards Lifesciences, Abbott, and Medtronic and consulting fees from Anteris and Microport. ODB: institutional research grants and consulting fees from Abbott, Boston Scientific, and Medtronic. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer JS declared a past co-authorship with the author ODB to the handling editor. EDAT- 2023/08/30 06:48 MHDA- 2023/08/30 06:49 PMCR- 2023/01/01 CRDT- 2023/08/30 03:54 PHST- 2023/05/22 00:00 [received] PHST- 2023/07/28 00:00 [accepted] PHST- 2023/08/30 06:49 [medline] PHST- 2023/08/30 06:48 [pubmed] PHST- 2023/08/30 03:54 [entrez] PHST- 2023/01/01 00:00 [pmc-release] AID - 10.3389/fcvm.2023.1227217 [doi] PST - epublish SO - Front Cardiovasc Med. 2023 Aug 14;10:1227217. doi: 10.3389/fcvm.2023.1227217. eCollection 2023. PMID- 37641941 OWN - NLM STAT- MEDLINE DCOM- 20240304 LR - 20240304 IS - 1467-1107 (Electronic) IS - 1047-9511 (Linking) VI - 34 IP - 3 DP - 2024 Mar TI - Assessment for learning of paediatric cardiology trainees in 41 centres from 19 European countries. PG - 588-596 LID - 10.1017/S1047951123003098 [doi] AB - BACKGROUND: Limited data exist on how trainees in paediatric cardiology are assessed among countries affiliated with the Association of European Paediatric and Congenital Cardiology. METHODS: A structured and approved questionnaire was circulated to educationalists/trainers in 95 Association for European Paediatric and Congenital Cardiology training centres. RESULTS: Trainers from 46 centres responded with complete data in 41 centres. Instructional design included bedside teaching (41/41), didactic teaching (38/41), problem-based learning (28/41), cardiac catheterisation calculations (34/41), journal club (31/41), fellows presenting in the multidisciplinary meeting (41/41), fellows reporting on echocardiograms (34/41), clinical simulation (17/41), echocardiography simulation (10/41), and catheterisation simulation (3/41). Assessment included case-based discussion (n = 27), mini-clinical evaluation exercise (mini-CEX) (n = 12), directly observed procedures (n = 12), oral examination (n = 16), long cases (n = 11), written essay questions (n = 6), multiple choice questions (n = 5), and objective structured clinical examination (n = 2). Entrustable professional activities were utilised in 10 (24%) centres. Feedback was summative only in 17/41 (41%) centres, formative only in 12/41 (29%) centres and a combination of formative and summative feedback in 10/41 (24%) centres. Written feedback was provided in 10/41 (24%) centres. Verbal feedback was most common in 37/41 (90 %) centres. CONCLUSION: There is a marked variation in instructional design and assessment across European paediatric cardiac centres. A wide mix of assessment tools are used. Feedback is provided by the majority of centres, mostly verbal summative feedback. Adopting a programmatic assessment focusing on competency/capability using multiple assessment tools with regular formative multisource feedback may promote assessment for learning of paediatric cardiology trainees. FAU - McMahon, Colin J AU - McMahon CJ AUID- ORCID: 0000-0003-0337-9338 AD - Department of Paediatric Cardiology, Children's Health Ireland at Crumlin, Dublin, Ireland. AD - School of Medicine, University College Dublin, Belfield, Dublin 4, Ireland. AD - School of Health Professions Education (SHE), Maastricht University, Maastricht, Netherlands. FAU - Milanesi, Ornella AU - Milanesi O AD - Paediatric Cardiac Unit, Department of Paediatrics, University of Padova, School of Medicine, Padua, Italy. FAU - Pitkanen-Argillander, Olli AU - Pitkanen-Argillander O AD - Children's Hospital, Helsinki University Hospital and University of Helsinki, Helsinki, Finland. FAU - Albert-Brotons, Dimpna C AU - Albert-Brotons DC AUID- ORCID: 0000-0002-5101-6905 AD - Heart Center, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia. FAU - Michel-Behnke, Ina AU - Michel-Behnke I AUID- ORCID: 0000-0002-3131-573X AD - Division of Pediatric Cardiology, University Hospital for Children and Adolescent Medicine, Paediatric Heart Centre, Medical University Vienna, Vienna, Austria. FAU - Voges, Inga AU - Voges I AD - Department for Congenital Heart Disease and Paediatric Cardiology, University Hospital Schleswig Holstein, Kiel, Germany. FAU - Sendzikaite, Skaiste AU - Sendzikaite S AUID- ORCID: 0000-0002-0242-9586 AD - Faculty of Medicine, Vilnius University, Vilnius, Lithuania. FAU - Heying, Ruth AU - Heying R AUID- ORCID: 0000-0003-0743-0823 AD - Department of Paediatric Cardiology, University Hospital Leuven, Leuven, Belgium. LA - eng PT - Journal Article DEP - 20230829 PL - England TA - Cardiol Young JT - Cardiology in the young JID - 9200019 SB - IM MH - Humans MH - Child MH - *Learning MH - *Cardiology MH - Cardiac Catheterization MH - Computer Simulation MH - Echocardiography OTO - NOTNLM OT - Assessment OT - CHD OT - education OT - feedback OT - paediatric cardiology OT - training EDAT- 2023/08/29 06:42 MHDA- 2024/03/04 06:49 CRDT- 2023/08/29 05:26 PHST- 2024/03/04 06:49 [medline] PHST- 2023/08/29 06:42 [pubmed] PHST- 2023/08/29 05:26 [entrez] AID - S1047951123003098 [pii] AID - 10.1017/S1047951123003098 [doi] PST - ppublish SO - Cardiol Young. 2024 Mar;34(3):588-596. doi: 10.1017/S1047951123003098. Epub 2023 Aug 29. PMID- 37640401 OWN - NLM STAT- MEDLINE DCOM- 20230831 LR - 20250130 IS - 1488-2329 (Electronic) IS - 0820-3946 (Print) IS - 0820-3946 (Linking) VI - 195 IP - 33 DP - 2023 Aug 28 TI - Guidance on take-home naloxone distribution and use by community overdose responders in Canada. PG - E1112-E1123 LID - 10.1503/cmaj.230128 [doi] AB - BACKGROUND: The increasing toxicity of opioids in the unregulated drug market has led to escalating numbers of overdoses in Canada and worldwide; takehome naloxone (THN) is an evidence-based intervention that distributes kits containing naloxone to people in the community who may witness an overdose. The purpose of this guidance is to provide policy recommendations for territorial, provincial and federal THN programs, using evidence from scientific and grey literature and community evidence that reflects 11 years of THN distribution in Canada. METHODS: The Naloxone Guidance Development Group - a multidisciplinary team including people with lived and living experience and expertise of drug use - used the Appraisal of Guidelines for Research & Evaluation (AGREE II) instrument to inform development of this guidance. We considered published evidence identified through systematic reviews of all literature types, along with community evidence and expertise, to generate recommendations between December 2021 and September 2022. We solicited feedback on preliminary recommendations through an External Review Committee and a public input process. The project was funded by the Canadian Institutes of Health Research through the Canadian Research Initiative in Substance Misuse. We used the Guideline International Network principles for managing competing interests. RECOMMENDATIONS: Existing evidence from the literature on THN was of low quality. We incorporated evidence from scientific and grey literature, and community expertise to develop our recommendations. These were in 3 areas: routes of naloxone administration, THN kit contents and overdose response. Take-home naloxone programs should offer the choice of both intramuscular and intranasal formulations of naloxone in THN kits. Recommended kit contents include naloxone, a naloxone delivery device, personal protective equipment, instructions and a carrying case. Trained community overdose responders should prioritize rescue breathing in the case of respiratory depression, and conventional cardiopulmonary resuscitation in the case of cardiac arrest, among other interventions. INTERPRETATION: This guidance development project provides direction for THN programs in Canada in the context of limited published evidence, with recommendations developed in collaboration with diverse stakeholders. CI - (c) 2023 CMA Impact Inc. or its licensors. FAU - Ferguson, Max AU - Ferguson M AD - BC Centre for Disease Control (Ferguson, Adams, Burmeister, Choisil, Ng, Buxton), Vancouver, BC; Department of Psychiatry (Rittenbach), University of Calgary, Calgary, Alta.; Department of Psychiatry (Rittenbach), University of Alberta, Edmonton, Alta.; Public Health Ontario (PHO) (Leece); Dalla Lana School of Public Health (Leece, Elton-Marshall, Strike) and Department of Family and Community Medicine (Leece), University of Toronto; Institute for Mental Health Policy Research (Ali, Elton-Marshall), Centre for Addiction and Mental Health, Toronto, Ont.; School of Epidemiology and Public Health (Elton-Marshall), University of Ottawa, Ottawa, Ont.; Department of Medicine (Brothers), Dalhousie University, Halifax, NS; UCL Collaborative Centre for Inclusion Health (Brothers), University College London, London, UK; Center for Indigenous Health (Medley), Johns Hopkins Bloomberg School of Public Health, Baltimore, Md.; Overdose Emergency Response and Addictions Program (Medley), Vancouver Coastal Health, Vancouver, BC; Health Sciences Library (Lorenzetti), University of Calgary; Department of Community Health Sciences (Lorenzetti), Cumming School of Medicine, University of Calgary; O'Brien Institute for Public Health (Lorenzetti), University of Calgary, Calgary, Alta.; BC Centre on Substance Use (Gallant); School of Population and Public Health (Buxton), University of British Columbia, Vancouver, BC. FAU - Rittenbach, Katherine AU - Rittenbach K AD - BC Centre for Disease Control (Ferguson, Adams, Burmeister, Choisil, Ng, Buxton), Vancouver, BC; Department of Psychiatry (Rittenbach), University of Calgary, Calgary, Alta.; Department of Psychiatry (Rittenbach), University of Alberta, Edmonton, Alta.; Public Health Ontario (PHO) (Leece); Dalla Lana School of Public Health (Leece, Elton-Marshall, Strike) and Department of Family and Community Medicine (Leece), University of Toronto; Institute for Mental Health Policy Research (Ali, Elton-Marshall), Centre for Addiction and Mental Health, Toronto, Ont.; School of Epidemiology and Public Health (Elton-Marshall), University of Ottawa, Ottawa, Ont.; Department of Medicine (Brothers), Dalhousie University, Halifax, NS; UCL Collaborative Centre for Inclusion Health (Brothers), University College London, London, UK; Center for Indigenous Health (Medley), Johns Hopkins Bloomberg School of Public Health, Baltimore, Md.; Overdose Emergency Response and Addictions Program (Medley), Vancouver Coastal Health, Vancouver, BC; Health Sciences Library (Lorenzetti), University of Calgary; Department of Community Health Sciences (Lorenzetti), Cumming School of Medicine, University of Calgary; O'Brien Institute for Public Health (Lorenzetti), University of Calgary, Calgary, Alta.; BC Centre on Substance Use (Gallant); School of Population and Public Health (Buxton), University of British Columbia, Vancouver, BC. FAU - Leece, Pamela AU - Leece P AD - BC Centre for Disease Control (Ferguson, Adams, Burmeister, Choisil, Ng, Buxton), Vancouver, BC; Department of Psychiatry (Rittenbach), University of Calgary, Calgary, Alta.; Department of Psychiatry (Rittenbach), University of Alberta, Edmonton, Alta.; Public Health Ontario (PHO) (Leece); Dalla Lana School of Public Health (Leece, Elton-Marshall, Strike) and Department of Family and Community Medicine (Leece), University of Toronto; Institute for Mental Health Policy Research (Ali, Elton-Marshall), Centre for Addiction and Mental Health, Toronto, Ont.; School of Epidemiology and Public Health (Elton-Marshall), University of Ottawa, Ottawa, Ont.; Department of Medicine (Brothers), Dalhousie University, Halifax, NS; UCL Collaborative Centre for Inclusion Health (Brothers), University College London, London, UK; Center for Indigenous Health (Medley), Johns Hopkins Bloomberg School of Public Health, Baltimore, Md.; Overdose Emergency Response and Addictions Program (Medley), Vancouver Coastal Health, Vancouver, BC; Health Sciences Library (Lorenzetti), University of Calgary; Department of Community Health Sciences (Lorenzetti), Cumming School of Medicine, University of Calgary; O'Brien Institute for Public Health (Lorenzetti), University of Calgary, Calgary, Alta.; BC Centre on Substance Use (Gallant); School of Population and Public Health (Buxton), University of British Columbia, Vancouver, BC. FAU - Adams, Alison AU - Adams A AD - BC Centre for Disease Control (Ferguson, Adams, Burmeister, Choisil, Ng, Buxton), Vancouver, BC; Department of Psychiatry (Rittenbach), University of Calgary, Calgary, Alta.; Department of Psychiatry (Rittenbach), University of Alberta, Edmonton, Alta.; Public Health Ontario (PHO) (Leece); Dalla Lana School of Public Health (Leece, Elton-Marshall, Strike) and Department of Family and Community Medicine (Leece), University of Toronto; Institute for Mental Health Policy Research (Ali, Elton-Marshall), Centre for Addiction and Mental Health, Toronto, Ont.; School of Epidemiology and Public Health (Elton-Marshall), University of Ottawa, Ottawa, Ont.; Department of Medicine (Brothers), Dalhousie University, Halifax, NS; UCL Collaborative Centre for Inclusion Health (Brothers), University College London, London, UK; Center for Indigenous Health (Medley), Johns Hopkins Bloomberg School of Public Health, Baltimore, Md.; Overdose Emergency Response and Addictions Program (Medley), Vancouver Coastal Health, Vancouver, BC; Health Sciences Library (Lorenzetti), University of Calgary; Department of Community Health Sciences (Lorenzetti), Cumming School of Medicine, University of Calgary; O'Brien Institute for Public Health (Lorenzetti), University of Calgary, Calgary, Alta.; BC Centre on Substance Use (Gallant); School of Population and Public Health (Buxton), University of British Columbia, Vancouver, BC. FAU - Ali, Farihah AU - Ali F AD - BC Centre for Disease Control (Ferguson, Adams, Burmeister, Choisil, Ng, Buxton), Vancouver, BC; Department of Psychiatry (Rittenbach), University of Calgary, Calgary, Alta.; Department of Psychiatry (Rittenbach), University of Alberta, Edmonton, Alta.; Public Health Ontario (PHO) (Leece); Dalla Lana School of Public Health (Leece, Elton-Marshall, Strike) and Department of Family and Community Medicine (Leece), University of Toronto; Institute for Mental Health Policy Research (Ali, Elton-Marshall), Centre for Addiction and Mental Health, Toronto, Ont.; School of Epidemiology and Public Health (Elton-Marshall), University of Ottawa, Ottawa, Ont.; Department of Medicine (Brothers), Dalhousie University, Halifax, NS; UCL Collaborative Centre for Inclusion Health (Brothers), University College London, London, UK; Center for Indigenous Health (Medley), Johns Hopkins Bloomberg School of Public Health, Baltimore, Md.; Overdose Emergency Response and Addictions Program (Medley), Vancouver Coastal Health, Vancouver, BC; Health Sciences Library (Lorenzetti), University of Calgary; Department of Community Health Sciences (Lorenzetti), Cumming School of Medicine, University of Calgary; O'Brien Institute for Public Health (Lorenzetti), University of Calgary, Calgary, Alta.; BC Centre on Substance Use (Gallant); School of Population and Public Health (Buxton), University of British Columbia, Vancouver, BC. FAU - Elton-Marshall, Tara AU - Elton-Marshall T AD - BC Centre for Disease Control (Ferguson, Adams, Burmeister, Choisil, Ng, Buxton), Vancouver, BC; Department of Psychiatry (Rittenbach), University of Calgary, Calgary, Alta.; Department of Psychiatry (Rittenbach), University of Alberta, Edmonton, Alta.; Public Health Ontario (PHO) (Leece); Dalla Lana School of Public Health (Leece, Elton-Marshall, Strike) and Department of Family and Community Medicine (Leece), University of Toronto; Institute for Mental Health Policy Research (Ali, Elton-Marshall), Centre for Addiction and Mental Health, Toronto, Ont.; School of Epidemiology and Public Health (Elton-Marshall), University of Ottawa, Ottawa, Ont.; Department of Medicine (Brothers), Dalhousie University, Halifax, NS; UCL Collaborative Centre for Inclusion Health (Brothers), University College London, London, UK; Center for Indigenous Health (Medley), Johns Hopkins Bloomberg School of Public Health, Baltimore, Md.; Overdose Emergency Response and Addictions Program (Medley), Vancouver Coastal Health, Vancouver, BC; Health Sciences Library (Lorenzetti), University of Calgary; Department of Community Health Sciences (Lorenzetti), Cumming School of Medicine, University of Calgary; O'Brien Institute for Public Health (Lorenzetti), University of Calgary, Calgary, Alta.; BC Centre on Substance Use (Gallant); School of Population and Public Health (Buxton), University of British Columbia, Vancouver, BC. FAU - Burmeister, Charlene AU - Burmeister C AD - BC Centre for Disease Control (Ferguson, Adams, Burmeister, Choisil, Ng, Buxton), Vancouver, BC; Department of Psychiatry (Rittenbach), University of Calgary, Calgary, Alta.; Department of Psychiatry (Rittenbach), University of Alberta, Edmonton, Alta.; Public Health Ontario (PHO) (Leece); Dalla Lana School of Public Health (Leece, Elton-Marshall, Strike) and Department of Family and Community Medicine (Leece), University of Toronto; Institute for Mental Health Policy Research (Ali, Elton-Marshall), Centre for Addiction and Mental Health, Toronto, Ont.; School of Epidemiology and Public Health (Elton-Marshall), University of Ottawa, Ottawa, Ont.; Department of Medicine (Brothers), Dalhousie University, Halifax, NS; UCL Collaborative Centre for Inclusion Health (Brothers), University College London, London, UK; Center for Indigenous Health (Medley), Johns Hopkins Bloomberg School of Public Health, Baltimore, Md.; Overdose Emergency Response and Addictions Program (Medley), Vancouver Coastal Health, Vancouver, BC; Health Sciences Library (Lorenzetti), University of Calgary; Department of Community Health Sciences (Lorenzetti), Cumming School of Medicine, University of Calgary; O'Brien Institute for Public Health (Lorenzetti), University of Calgary, Calgary, Alta.; BC Centre on Substance Use (Gallant); School of Population and Public Health (Buxton), University of British Columbia, Vancouver, BC. FAU - Brothers, Thomas D AU - Brothers TD AD - BC Centre for Disease Control (Ferguson, Adams, Burmeister, Choisil, Ng, Buxton), Vancouver, BC; Department of Psychiatry (Rittenbach), University of Calgary, Calgary, Alta.; Department of Psychiatry (Rittenbach), University of Alberta, Edmonton, Alta.; Public Health Ontario (PHO) (Leece); Dalla Lana School of Public Health (Leece, Elton-Marshall, Strike) and Department of Family and Community Medicine (Leece), University of Toronto; Institute for Mental Health Policy Research (Ali, Elton-Marshall), Centre for Addiction and Mental Health, Toronto, Ont.; School of Epidemiology and Public Health (Elton-Marshall), University of Ottawa, Ottawa, Ont.; Department of Medicine (Brothers), Dalhousie University, Halifax, NS; UCL Collaborative Centre for Inclusion Health (Brothers), University College London, London, UK; Center for Indigenous Health (Medley), Johns Hopkins Bloomberg School of Public Health, Baltimore, Md.; Overdose Emergency Response and Addictions Program (Medley), Vancouver Coastal Health, Vancouver, BC; Health Sciences Library (Lorenzetti), University of Calgary; Department of Community Health Sciences (Lorenzetti), Cumming School of Medicine, University of Calgary; O'Brien Institute for Public Health (Lorenzetti), University of Calgary, Calgary, Alta.; BC Centre on Substance Use (Gallant); School of Population and Public Health (Buxton), University of British Columbia, Vancouver, BC. FAU - Medley, Andrea AU - Medley A AD - BC Centre for Disease Control (Ferguson, Adams, Burmeister, Choisil, Ng, Buxton), Vancouver, BC; Department of Psychiatry (Rittenbach), University of Calgary, Calgary, Alta.; Department of Psychiatry (Rittenbach), University of Alberta, Edmonton, Alta.; Public Health Ontario (PHO) (Leece); Dalla Lana School of Public Health (Leece, Elton-Marshall, Strike) and Department of Family and Community Medicine (Leece), University of Toronto; Institute for Mental Health Policy Research (Ali, Elton-Marshall), Centre for Addiction and Mental Health, Toronto, Ont.; School of Epidemiology and Public Health (Elton-Marshall), University of Ottawa, Ottawa, Ont.; Department of Medicine (Brothers), Dalhousie University, Halifax, NS; UCL Collaborative Centre for Inclusion Health (Brothers), University College London, London, UK; Center for Indigenous Health (Medley), Johns Hopkins Bloomberg School of Public Health, Baltimore, Md.; Overdose Emergency Response and Addictions Program (Medley), Vancouver Coastal Health, Vancouver, BC; Health Sciences Library (Lorenzetti), University of Calgary; Department of Community Health Sciences (Lorenzetti), Cumming School of Medicine, University of Calgary; O'Brien Institute for Public Health (Lorenzetti), University of Calgary, Calgary, Alta.; BC Centre on Substance Use (Gallant); School of Population and Public Health (Buxton), University of British Columbia, Vancouver, BC. FAU - Choisil, Paul AU - Choisil P AD - BC Centre for Disease Control (Ferguson, Adams, Burmeister, Choisil, Ng, Buxton), Vancouver, BC; Department of Psychiatry (Rittenbach), University of Calgary, Calgary, Alta.; Department of Psychiatry (Rittenbach), University of Alberta, Edmonton, Alta.; Public Health Ontario (PHO) (Leece); Dalla Lana School of Public Health (Leece, Elton-Marshall, Strike) and Department of Family and Community Medicine (Leece), University of Toronto; Institute for Mental Health Policy Research (Ali, Elton-Marshall), Centre for Addiction and Mental Health, Toronto, Ont.; School of Epidemiology and Public Health (Elton-Marshall), University of Ottawa, Ottawa, Ont.; Department of Medicine (Brothers), Dalhousie University, Halifax, NS; UCL Collaborative Centre for Inclusion Health (Brothers), University College London, London, UK; Center for Indigenous Health (Medley), Johns Hopkins Bloomberg School of Public Health, Baltimore, Md.; Overdose Emergency Response and Addictions Program (Medley), Vancouver Coastal Health, Vancouver, BC; Health Sciences Library (Lorenzetti), University of Calgary; Department of Community Health Sciences (Lorenzetti), Cumming School of Medicine, University of Calgary; O'Brien Institute for Public Health (Lorenzetti), University of Calgary, Calgary, Alta.; BC Centre on Substance Use (Gallant); School of Population and Public Health (Buxton), University of British Columbia, Vancouver, BC. FAU - Strike, Carol AU - Strike C AD - BC Centre for Disease Control (Ferguson, Adams, Burmeister, Choisil, Ng, Buxton), Vancouver, BC; Department of Psychiatry (Rittenbach), University of Calgary, Calgary, Alta.; Department of Psychiatry (Rittenbach), University of Alberta, Edmonton, Alta.; Public Health Ontario (PHO) (Leece); Dalla Lana School of Public Health (Leece, Elton-Marshall, Strike) and Department of Family and Community Medicine (Leece), University of Toronto; Institute for Mental Health Policy Research (Ali, Elton-Marshall), Centre for Addiction and Mental Health, Toronto, Ont.; School of Epidemiology and Public Health (Elton-Marshall), University of Ottawa, Ottawa, Ont.; Department of Medicine (Brothers), Dalhousie University, Halifax, NS; UCL Collaborative Centre for Inclusion Health (Brothers), University College London, London, UK; Center for Indigenous Health (Medley), Johns Hopkins Bloomberg School of Public Health, Baltimore, Md.; Overdose Emergency Response and Addictions Program (Medley), Vancouver Coastal Health, Vancouver, BC; Health Sciences Library (Lorenzetti), University of Calgary; Department of Community Health Sciences (Lorenzetti), Cumming School of Medicine, University of Calgary; O'Brien Institute for Public Health (Lorenzetti), University of Calgary, Calgary, Alta.; BC Centre on Substance Use (Gallant); School of Population and Public Health (Buxton), University of British Columbia, Vancouver, BC. FAU - Ng, Justin AU - Ng J AD - BC Centre for Disease Control (Ferguson, Adams, Burmeister, Choisil, Ng, Buxton), Vancouver, BC; Department of Psychiatry (Rittenbach), University of Calgary, Calgary, Alta.; Department of Psychiatry (Rittenbach), University of Alberta, Edmonton, Alta.; Public Health Ontario (PHO) (Leece); Dalla Lana School of Public Health (Leece, Elton-Marshall, Strike) and Department of Family and Community Medicine (Leece), University of Toronto; Institute for Mental Health Policy Research (Ali, Elton-Marshall), Centre for Addiction and Mental Health, Toronto, Ont.; School of Epidemiology and Public Health (Elton-Marshall), University of Ottawa, Ottawa, Ont.; Department of Medicine (Brothers), Dalhousie University, Halifax, NS; UCL Collaborative Centre for Inclusion Health (Brothers), University College London, London, UK; Center for Indigenous Health (Medley), Johns Hopkins Bloomberg School of Public Health, Baltimore, Md.; Overdose Emergency Response and Addictions Program (Medley), Vancouver Coastal Health, Vancouver, BC; Health Sciences Library (Lorenzetti), University of Calgary; Department of Community Health Sciences (Lorenzetti), Cumming School of Medicine, University of Calgary; O'Brien Institute for Public Health (Lorenzetti), University of Calgary, Calgary, Alta.; BC Centre on Substance Use (Gallant); School of Population and Public Health (Buxton), University of British Columbia, Vancouver, BC. FAU - Lorenzetti, Diane L AU - Lorenzetti DL AD - BC Centre for Disease Control (Ferguson, Adams, Burmeister, Choisil, Ng, Buxton), Vancouver, BC; Department of Psychiatry (Rittenbach), University of Calgary, Calgary, Alta.; Department of Psychiatry (Rittenbach), University of Alberta, Edmonton, Alta.; Public Health Ontario (PHO) (Leece); Dalla Lana School of Public Health (Leece, Elton-Marshall, Strike) and Department of Family and Community Medicine (Leece), University of Toronto; Institute for Mental Health Policy Research (Ali, Elton-Marshall), Centre for Addiction and Mental Health, Toronto, Ont.; School of Epidemiology and Public Health (Elton-Marshall), University of Ottawa, Ottawa, Ont.; Department of Medicine (Brothers), Dalhousie University, Halifax, NS; UCL Collaborative Centre for Inclusion Health (Brothers), University College London, London, UK; Center for Indigenous Health (Medley), Johns Hopkins Bloomberg School of Public Health, Baltimore, Md.; Overdose Emergency Response and Addictions Program (Medley), Vancouver Coastal Health, Vancouver, BC; Health Sciences Library (Lorenzetti), University of Calgary; Department of Community Health Sciences (Lorenzetti), Cumming School of Medicine, University of Calgary; O'Brien Institute for Public Health (Lorenzetti), University of Calgary, Calgary, Alta.; BC Centre on Substance Use (Gallant); School of Population and Public Health (Buxton), University of British Columbia, Vancouver, BC. FAU - Gallant, Kat AU - Gallant K AD - BC Centre for Disease Control (Ferguson, Adams, Burmeister, Choisil, Ng, Buxton), Vancouver, BC; Department of Psychiatry (Rittenbach), University of Calgary, Calgary, Alta.; Department of Psychiatry (Rittenbach), University of Alberta, Edmonton, Alta.; Public Health Ontario (PHO) (Leece); Dalla Lana School of Public Health (Leece, Elton-Marshall, Strike) and Department of Family and Community Medicine (Leece), University of Toronto; Institute for Mental Health Policy Research (Ali, Elton-Marshall), Centre for Addiction and Mental Health, Toronto, Ont.; School of Epidemiology and Public Health (Elton-Marshall), University of Ottawa, Ottawa, Ont.; Department of Medicine (Brothers), Dalhousie University, Halifax, NS; UCL Collaborative Centre for Inclusion Health (Brothers), University College London, London, UK; Center for Indigenous Health (Medley), Johns Hopkins Bloomberg School of Public Health, Baltimore, Md.; Overdose Emergency Response and Addictions Program (Medley), Vancouver Coastal Health, Vancouver, BC; Health Sciences Library (Lorenzetti), University of Calgary; Department of Community Health Sciences (Lorenzetti), Cumming School of Medicine, University of Calgary; O'Brien Institute for Public Health (Lorenzetti), University of Calgary, Calgary, Alta.; BC Centre on Substance Use (Gallant); School of Population and Public Health (Buxton), University of British Columbia, Vancouver, BC. FAU - Buxton, Jane A AU - Buxton JA AD - BC Centre for Disease Control (Ferguson, Adams, Burmeister, Choisil, Ng, Buxton), Vancouver, BC; Department of Psychiatry (Rittenbach), University of Calgary, Calgary, Alta.; Department of Psychiatry (Rittenbach), University of Alberta, Edmonton, Alta.; Public Health Ontario (PHO) (Leece); Dalla Lana School of Public Health (Leece, Elton-Marshall, Strike) and Department of Family and Community Medicine (Leece), University of Toronto; Institute for Mental Health Policy Research (Ali, Elton-Marshall), Centre for Addiction and Mental Health, Toronto, Ont.; School of Epidemiology and Public Health (Elton-Marshall), University of Ottawa, Ottawa, Ont.; Department of Medicine (Brothers), Dalhousie University, Halifax, NS; UCL Collaborative Centre for Inclusion Health (Brothers), University College London, London, UK; Center for Indigenous Health (Medley), Johns Hopkins Bloomberg School of Public Health, Baltimore, Md.; Overdose Emergency Response and Addictions Program (Medley), Vancouver Coastal Health, Vancouver, BC; Health Sciences Library (Lorenzetti), University of Calgary; Department of Community Health Sciences (Lorenzetti), Cumming School of Medicine, University of Calgary; O'Brien Institute for Public Health (Lorenzetti), University of Calgary, Calgary, Alta.; BC Centre on Substance Use (Gallant); School of Population and Public Health (Buxton), University of British Columbia, Vancouver, BC jane.buxton@bccdc.ca. CN - Naloxone Guidance Development Group LA - eng PT - Journal Article PL - Canada TA - CMAJ JT - CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne JID - 9711805 RN - 36B82AMQ7N (Naloxone) SB - IM MH - Humans MH - Canada MH - *Drug Overdose/drug therapy/prevention & control MH - Academies and Institutes MH - Advisory Committees MH - Naloxone/therapeutic use PMC - PMC10462409 COIS- Competing interests: Thomas Brothers reports receiving a research fellowship from the Canadian Institutes of Health Research (CIHR), Dalhousie University Internal Medicine Research Foundation, in support of the present manuscript. Jane Buxton reports receiving a CIHR grant to the Canadian Research Initiative in Substance Misuse (CRISM) for the work overseen and managed by the Centre for Addictions and Mental Health, in support of the present manuscript. Dr. Buxton has also received fees from the Canadian Centre on Substance Use and Addiction to write a foreword for a report, from the British Columbia Centre for Disease Control, and Glasgow Caledonian University; and received honoraria from the Canadian Association of Nurses and the Canadian Association of Hepatitis Nurses for invited presentations, all outside the present work. Katherine Rittenbach was an employee of Alberta Health Services, during the conduct of the study. During the conduct of the study, Pamela Leece reports receiving grants from the following public institutions, administered at Public Health Ontario (Ontario Agency for Health Protection and Promotion): CIHR, Health Canada, Public Health Agency of Canada. Tara Elton-Marshall reports receiving a grant from CIHR, outside the submitted work. Charlene Burmeister is executive director of the Coalition of Substance Users of the North. No other competing interests were declared. EDAT- 2023/08/29 00:41 MHDA- 2023/08/31 06:42 PMCR- 2023/08/28 CRDT- 2023/08/28 20:33 PHST- 2023/08/31 06:42 [medline] PHST- 2023/08/29 00:41 [pubmed] PHST- 2023/08/28 20:33 [entrez] PHST- 2023/08/28 00:00 [pmc-release] AID - 195/33/E1112 [pii] AID - 195e1112 [pii] AID - 10.1503/cmaj.230128 [doi] PST - ppublish SO - CMAJ. 2023 Aug 28;195(33):E1112-E1123. doi: 10.1503/cmaj.230128. PMID- 37640176 OWN - NLM STAT- MEDLINE DCOM- 20231216 LR - 20231216 IS - 1535-6280 (Electronic) IS - 0146-2806 (Linking) VI - 49 IP - 1 Pt A DP - 2024 Jan TI - Diabetic Cardiomyopathy: 2023 Update by the International Multidisciplinary Board of Experts. PG - 102052 LID - S0146-2806(23)00469-3 [pii] LID - 10.1016/j.cpcardiol.2023.102052 [doi] AB - Diabetes mellitus (DM) is considered by many the pandemic of the 21st century and is associated with multiple organ damages. Among these, cardiovascular complications are responsible for an incredible burden of mortality and morbidity in Western Countries. The study of the pathological mechanisms responsible for the cardiovascular complications in DM patients is key for the development of new therapeutic strategies. The metabolic disorders caused by hyperglycemia, insulin resistance, and dyslipidemia, results in a cascade of pathomorphological changes favoring the atherosclerotic process and leading to myocardial remodeling. Parallel to this, oxidative stress, calcium overload, mitochondrial dysfunction, activation of protein kinase C signaling pathways, myocardial lipomatosis, and low-grade inflammation of the myocardium - are the main pathways responsible for the diabetic cardiomyopathy development. This review aims to appraise and discuss the pathogenetic mechanisms behind the diabetic cardiomyopathy development. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Avagimyan, Ashot AU - Avagimyan A AD - Anatomical Pathology and Clinical Morphology Department, Yerevan State Medical University, Yerevan, Armenia. Electronic address: dr.ashotavagimyan@gmail.com. FAU - Fogacci, Federica AU - Fogacci F AD - Atherosclerosis and Metabolic Disorders Unit, Alma Mater Studiorum University of Bologna, Bologna, Italy. FAU - Pogosova, Nana AU - Pogosova N AD - Research and Preventive Cardiology, National Medical Research Centre of Cardiology, Moscow, Russia. FAU - Kakrurskiy, Lev AU - Kakrurskiy L AD - A.P. Avtsyn Research Institute of Human Morphology FSBI "Petrovskiy NRCS" Moscow, Russia. FAU - Kogan, Eugenia AU - Kogan E AD - Pathology Department, Immunohistochemistry Reference Centre of Institute of Clinical Morphology and Digital Pathology, I. M. Sechenov First Moscow State Medical University, Moscow, Russia. FAU - Urazova, Olga AU - Urazova O AD - Pathophysiology Department, Siberian State Medical University, Tomsk, Russia. FAU - Kobalava, Zhanna AU - Kobalava Z AD - Internal Disease and Cardiology Department, Peoples Friendship University of Russia, Moscow, Russia. FAU - Mikhaleva, Liudmila AU - Mikhaleva L AD - A.P. Avtsyn Research Institute of Human Morphology FSBI "Petrovskiy NRCS" Moscow, Russia. FAU - Vandysheva, Rositsa AU - Vandysheva R AD - A.P. Avtsyn Research Institute of Human Morphology FSBI "Petrovskiy NRCS" Moscow, Russia. FAU - Zarina, Gioeva AU - Zarina G AD - A.P. Avtsyn Research Institute of Human Morphology FSBI "Petrovskiy NRCS" Moscow, Russia. FAU - Trofimenko, Artem AU - Trofimenko A AD - Pathophysiology Department, Kuban State Medical University, Krasnodar, Russia. FAU - Navasardyan, Grizelda AU - Navasardyan G AD - Pathophysiology Department, Yerevan State Medical University, Yerevan, Armenia. FAU - Mkrtchyan, Lusine AU - Mkrtchyan L AD - Cardiology Department, Yerevan State Medical University, Yerevan, Armenia. FAU - Galli, Mattia AU - Galli M AD - Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy. FAU - Jndoyan, Zinaida AU - Jndoyan Z AD - Internal Diseases Propaedeutic Department, Yerevan State Medical University, Yerevan, Armenia. FAU - Aznauryan, Anait AU - Aznauryan A AD - Histology Department, Yerevan State Medical University after M. Heratsi, Yerevan, Armenia. FAU - Saahakyan, Karmen AU - Saahakyan K AD - Cardiology Department, Azienda Umberto I, Sapienza University, Rome, Italy. FAU - Agati, Luciano AU - Agati L AD - Cardiology Department, Azienda Umberto I, Sapienza University, Rome, Italy. FAU - Shafie, Davood AU - Shafie D AD - Heart Failure Research Center, Isfahan Cardiovascular Research Institute, Isfahan, Iran. FAU - Cicero, Arrigo AU - Cicero A AD - Atherosclerosis and Metabolic Disorders Unit, Alma Mater Studiorum University of Bologna, Bologna, Italy. FAU - Salvo, Giovanni Di AU - Salvo GD AD - Imperial College of London, London, Great Britain. FAU - Sarrafzadegan, Nizal AU - Sarrafzadegan N AD - Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran. LA - eng PT - Journal Article PT - Review DEP - 20230826 PL - Netherlands TA - Curr Probl Cardiol JT - Current problems in cardiology JID - 7701802 SB - IM MH - Humans MH - *Diabetic Cardiomyopathies/etiology/therapy MH - Myocardium/metabolism MH - Oxidative Stress MH - Signal Transduction MH - *Diabetes Mellitus COIS- Declaration of Competing Interest The authors declare no conflict of interest. EDAT- 2023/08/29 00:41 MHDA- 2023/12/17 09:43 CRDT- 2023/08/28 19:22 PHST- 2023/08/18 00:00 [received] PHST- 2023/08/23 00:00 [accepted] PHST- 2023/12/17 09:43 [medline] PHST- 2023/08/29 00:41 [pubmed] PHST- 2023/08/28 19:22 [entrez] AID - S0146-2806(23)00469-3 [pii] AID - 10.1016/j.cpcardiol.2023.102052 [doi] PST - ppublish SO - Curr Probl Cardiol. 2024 Jan;49(1 Pt A):102052. doi: 10.1016/j.cpcardiol.2023.102052. Epub 2023 Aug 26. PMID- 37639480 OWN - NLM STAT- MEDLINE DCOM- 20230911 LR - 20250729 IS - 1473-6551 (Electronic) IS - 1350-7540 (Linking) VI - 36 IP - 5 DP - 2023 Oct 1 TI - The current clinical perception of myotonic dystrophy type 2. PG - 474-478 LID - 10.1097/WCO.0000000000001186 [doi] AB - PURPOSE OF REVIEW: Myotonic dystrophy type 2 (DM2) is a genetic disorder belonging to the spectrum of myotonic dystrophies. DM2 is characterized by progressive muscle weakness, wasting and muscle pain (myalgia), but can also affect many other organ systems. In this review, we provide an updated overview on the research literature on DM2 with a focus on the management of multisystemic involvement and atypical clinical phenotypes. RECENT FINDINGS: Recent studies have focused on different aspects of multisystemic involvement. Early and severe cardiac involvement can occur in DM2 and needs to be managed appropriately. Diabetes has been shown to be more common in DM2 than in DM1, while a combination of symptoms (cataracts, myotonia, tremor) can be used to raise clinical suspicion and initiate genetic testing for DM2. Autoimmune disease has been shown to occur in up to one-third of DM2 patients, possibly due to altered immune pathways. New evidence also suggests a childhood-onset phenotype presenting with foot deformities. SUMMARY: The multisystemic aspects of the disease require a multidisciplinary approach for some patients, most likely even including state-of-the-art cardiac and brain imaging to detect and treat complications earlier. Of note, our concept of DM2 as an adult-onset disease is somewhat challenged by evidence suggesting a few pediatric DM2 patients and possibly anticipation, at least in some DM2 families. More studies, including larger cohorts, are needed to better understand this possible early-onset DM2 phenotype variant. CI - Copyright (c) 2023 Wolters Kluwer Health, Inc. All rights reserved. FAU - Kleefeld, Felix AU - Kleefeld F AD - Charite-Universitatsmedizin Berlin, Corporate member of Freie Universitat Berlin, Humboldt Universitat zu Berlin, and Berlin Institute of Health (BIH), Department of Neurology, Chariteplatz 1, 10117 Berlin. FAU - Schoser, Benedikt AU - Schoser B AD - Friedrich-Baur-Institute, Department of Neurology, Ludwig-Maximilians-University, Munich, Germany. LA - eng PT - Journal Article PT - Review DEP - 20230718 PL - England TA - Curr Opin Neurol JT - Current opinion in neurology JID - 9319162 SB - IM MH - Humans MH - *Myotonic Dystrophy/diagnosis/genetics/therapy MH - Affect MH - *Autoimmune Diseases MH - Perception MH - *Diabetes Mellitus, Type 2 EDAT- 2023/08/28 18:41 MHDA- 2023/09/11 06:42 CRDT- 2023/08/28 13:44 PHST- 2023/09/11 06:42 [medline] PHST- 2023/08/28 18:41 [pubmed] PHST- 2023/08/28 13:44 [entrez] AID - 00019052-202310000-00017 [pii] AID - 10.1097/WCO.0000000000001186 [doi] PST - ppublish SO - Curr Opin Neurol. 2023 Oct 1;36(5):474-478. doi: 10.1097/WCO.0000000000001186. Epub 2023 Jul 18. PMID- 37634901 OWN - NLM STAT- MEDLINE DCOM- 20230829 LR - 20231002 IS - 2053-3624 (Print) IS - 2053-3624 (Electronic) IS - 2053-3624 (Linking) VI - 10 IP - 2 DP - 2023 Aug TI - The BE-ALIVE score: assessing 30-day mortality risk in patients presenting with acute coronary syndromes. LID - 10.1136/openhrt-2023-002313 [doi] LID - e002313 AB - AIM: To create and validate a simple scoring system for predicting 30-day mortality in patients presenting with acute coronary syndromes (ACS) at their moment of admission. METHODS AND RESULTS: 2407 consecutive patients presenting to Harefield Hospital with measured arterial blood gases, from January 2011 to December 2020, were studied to build the training set. 30-day mortality in this group was 17.2%. A scoring algorithm that was built using binary logistic regression of variables available on admission was then converted to an additive risk score. The resultant scoring system is the BE-ALIVE score, which incorporates the following factors:Base Excess (1 point for <-2 mmol/L), Age (<65 years: 0 points, 65-74: 1 point, 75-84: 2 points, >/=85: 3 points), Lactate (<2 mmol/L: 0 points, 2-4.9: 1 point, 5-9.9: 3 points, >/=10: 6 points), Intubated (2 points), Left Ventricular function (mildly impaired or better: -1 point, moderately impaired: 1 point, severely impaired: 3 points) and External/out of hospital cardiac arrest 2 points).The scoring system was validated using a testing set of 515 patients presenting to Harefield Hospital in 2021. The validation metrics were excellent with a c-statistic of 0.9, Brier's score 0.06 vs a naive classifier of 0.15, Spiegelhalter's z-statistic probability of 0.267 and a calibration slope of 1.08. CONCLUSION: The BE-ALIVE score is a simple and accurate scoring system to predict 30-day mortality in patients presenting with ACS. Appreciating this mortality risk can allow prompt involvement of appropriate care such as the shock team. CI - (c) Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Tindale, Alexander AU - Tindale A AUID- ORCID: 0000-0002-8199-4275 AD - National Heart and Lung Institute, Imperial College London, London, UK alexander.tindale09@imperial.ac.uk. AD - Department of Cardiology, Harefield Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK. FAU - Panoulas, Vasileios AU - Panoulas V AD - National Heart and Lung Institute, Imperial College London, London, UK. AD - Department of Cardiology, Harefield Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Open Heart JT - Open heart JID - 101631219 RN - 33X04XA5AT (Lactic Acid) SB - IM MH - Humans MH - Aged MH - *Acute Coronary Syndrome/diagnosis/therapy MH - Algorithms MH - Hospitalization MH - Hospitals MH - Lactic Acid PMC - PMC10462941 OTO - NOTNLM OT - Acute Coronary Syndrome OT - Myocardial Infarction OT - Out-of-Hospital Cardiac Arrest COIS- Competing interests: None declared. EDAT- 2023/08/28 00:41 MHDA- 2023/08/29 12:41 PMCR- 2023/08/27 CRDT- 2023/08/27 20:42 PHST- 2023/03/21 00:00 [received] PHST- 2023/07/27 00:00 [accepted] PHST- 2023/08/29 12:41 [medline] PHST- 2023/08/28 00:41 [pubmed] PHST- 2023/08/27 20:42 [entrez] PHST- 2023/08/27 00:00 [pmc-release] AID - openhrt-2023-002313 [pii] AID - 10.1136/openhrt-2023-002313 [doi] PST - ppublish SO - Open Heart. 2023 Aug;10(2):e002313. doi: 10.1136/openhrt-2023-002313. PMID- 30969687 STAT- Publisher CTDT- 20230828 PB - StatPearls Publishing DP - 2023 Jan TI - Enoxaparin. BTI - StatPearls AB - Enoxaparin is low molecular weight heparin (LMWH) and was first approved for medical use in 1993 and is derived from heparin. It has FDA approval for the following clinical conditions - acute coronary syndromes, deep venous thrombosis (DVT) treatment and prophylaxis, treatment for pulmonary embolism (PE), venous thromboembolism (VTE) treatment, and prophylaxis in a variety of scenarios, percutaneous coronary intervention (PCI), and periprocedural anticoagulation, among others. This activity will highlight the mechanism of action, adverse event profile, pharmacology, monitoring, and relevant interactions of enoxaparin, pertinent for interprofessional team members in treating patients with conditions where this agent is indicated. CI - Copyright (c) 2023, StatPearls Publishing LLC. FAU - Jupalli, Aamani AU - Jupalli A AD - Oak Hill Hospital FAU - Iqbal, Arshad Muhammad AU - Iqbal AM AD - Oak Hill Hospital, Brooksville, FL LA - eng PT - Study Guide PT - Book Chapter PL - Treasure Island (FL) COIS- Disclosure: Aamani Jupalli declares no relevant financial relationships with ineligible companies. Disclosure: Arshad Muhammad Iqbal declares no relevant financial relationships with ineligible companies. EDAT- 2023/08/28 00:00 CRDT- 2023/08/28 00:00 AID - NBK539865 [bookaccession] PMID- 37632766 OWN - NLM STAT- MEDLINE DCOM- 20230828 LR - 20260209 IS - 1873-734X (Electronic) IS - 1010-7940 (Linking) VI - 64 IP - 2 DP - 2023 Aug 1 TI - 2022 Joint ESC/EACTS review of the 2018 guideline recommendations on the revascularization of left main coronary artery disease in patients at low surgical risk and anatomy suitable for PCI or CABG. LID - ezad286 [pii] LID - 10.1093/ejcts/ezad286 [doi] AB - Task Force structure and summary of clinical evidence of 2022 ESC/EACTS review of the 2018 guideline recommendations on the revascularization of left main coronary artery disease. CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention; LM, left main; SYNTAX, Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery. a'Event' refers to the composite of death, myocardial infarction (according to Universal Definition of Myocardial Infarction if available, otherwise protocol defined) or stroke. In October 2021, the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) jointly agreed to establish a Task Force (TF) to review recommendations of the 2018 ESC/EACTS Guidelines on myocardial revascularization as they apply to patients with left main (LM) disease with low-to-intermediate SYNTAX score (0-32). This followed the withdrawal of support by the EACTS in 2019 for the recommendations about the management of LM disease of the previous guideline. The TF was asked to review all new relevant data since the 2018 guidelines including updated aggregated data from the four randomized trials comparing percutaneous coronary intervention (PCI) with drug-eluting stents vs. coronary artery bypass grafting (CABG) in patients with LM disease. This document represents a summary of the work of the TF; suggested updated recommendations for the choice of revascularization modality in patients undergoing myocardial revascularization for LM disease are included. In stable patients with an indication for revascularization for LM disease, with coronary anatomy suitable for both procedures and a low predicted surgical mortality, the TF concludes that both treatment options are clinically reasonable based on patient preference, available expertise, and local operator volumes. The suggested recommendations for revascularization with CABG are Class I, Level of Evidence A. The recommendations for PCI are Class IIa, Level of Evidence A. The TF recognized several important gaps in knowledge related to revascularization in patients with LM disease and recognizes that aggregated data from the four randomized trials were still only large enough to exclude large differences in mortality. CI - This article has been co-published with permission in the European Heart Journal and European Journal of Cardio-Thoracic Surgery. All rights reserved. (c) 2023 the European Society of Cardiology and the European Association for Cardio-Thoracic SurgeryThe articles are identical except for minor stylistic and spelling differences in keeping with each journal's style. Either citation can be used when citing this article. FAU - Byrne, Robert A AU - Byrne RA AUID- ORCID: 0000-0001-5224-6393 AD - Department of Cardiology and Cardiovascular Research Institute (CVRI) Dublin, Mater Private Network, 73 Eccles St, Dublin D07 KWR1, Ireland. AD - School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, 123 St Stephen's Green, Dublin D02 YN77, Ireland. FAU - Fremes, Stephen AU - Fremes S AUID- ORCID: 0000-0003-1723-3049 AD - Division of Cardiac Surgery, Schulich Heart Program, Sunnybrook Health Sciences Centre, 2075 Bayview Ave, Suite H405, M4N3M5 Toronto, Canada. AD - Department of Surgery, University of Toronto, Toronto, Canada. FAU - Capodanno, Davide AU - Capodanno D AUID- ORCID: 0000-0002-5156-7723 AD - Cardio-Thoracic-Vascular and Transplant Department, Azienda Ospedaliero-Universitaria Policlinico 'Gaspare Rodolico-San Marco', University of Catania, Catania, Italy. FAU - Czerny, Martin AU - Czerny M AUID- ORCID: 0000-0003-4766-9775 AD - Clinic for Cardiovascular Surgery, University Heart Center Freiburg, Bad Krozingen, Germany. AD - Faculty of Medicine, Albert-Ludwigs-University Freiburg, Freiburg, Germany. FAU - Doenst, Torsten AU - Doenst T AD - Department of Cardiothoracic Surgery, University Hospital Jena, Friedrich-Schiller-University Jena, Jena, Germany. FAU - Emberson, Jonathan R AU - Emberson JR AUID- ORCID: 0000-0001-7792-9422 AD - Medical Research Council Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK. FAU - Falk, Volkmar AU - Falk V AD - Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany. AD - Department of Cardiovascular Surgery, Charite Universitatsmedizin Berlin, Berlin, Germany. AD - German Centre for Cardiovascular Research, DZHK, Partner Site Berlin, Berlin, Germany. AD - Department of Health Science and Technology, ETH Zurich, Zurich, Switzerland. FAU - Gaudino, Mario AU - Gaudino M AUID- ORCID: 0000-0003-4680-0815 AD - Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, NY, USA. FAU - McMurray, John J V AU - McMurray JJV AUID- ORCID: 0000-0002-6317-3975 AD - British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK. FAU - Mehran, Roxana AU - Mehran R AUID- ORCID: 0000-0002-5546-262X AD - Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Milojevic, Milan AU - Milojevic M AUID- ORCID: 0000-0003-0984-9011 AD - Department of Cardiac Surgery and Cardiovascular Research, Dedinje Cardiovascular Institute, Belgrade, Serbia. AD - Department of Cardiothoracic Surgery, Erasmus University Medical Center, Rotterdam, The Netherlands. FAU - Uva, Miguel Sousa AU - Uva MS AUID- ORCID: 0000-0001-6353-653X AD - Department of Cardiac Surgery, Hospital Santa Cruz, Carnaxide, Portugal. AD - Department of Physiology and Cardiac Surgery, Porto University Medical School, Porto, Portugal. LA - eng GR - MC_UU_00017/4/MRC_/Medical Research Council/United Kingdom GR - MC_UU_12026/6/MRC_/Medical Research Council/United Kingdom PT - Journal Article PL - Germany TA - Eur J Cardiothorac Surg JT - European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery JID - 8804069 SB - IM CIN - Eur J Cardiothorac Surg. 2023 Aug 1;64(2):ezad285. doi: 10.1093/ejcts/ezad285. PMID: 37632765 MH - Humans MH - *Cardiology MH - Coronary Artery Bypass/adverse effects MH - *Coronary Artery Disease/surgery MH - *Myocardial Infarction MH - *Percutaneous Coronary Intervention MH - *Thoracic Surgery MH - Practice Guidelines as Topic OTO - NOTNLM OT - Coronary artery disease OT - Heart Team OT - clinical practice guidelines OT - coronary artery bypass grafting OT - left main coronary artery OT - left main stenosis OT - meta-analysis OT - myocardial revascularization OT - percutaneous coronary intervention OT - randomized controlled trials EDAT- 2023/08/27 05:43 MHDA- 2023/08/28 06:42 CRDT- 2023/08/26 13:12 PHST- 2023/05/04 00:00 [received] PHST- 2023/06/06 00:00 [revised] PHST- 2023/07/15 00:00 [accepted] PHST- 2023/08/28 06:42 [medline] PHST- 2023/08/27 05:43 [pubmed] PHST- 2023/08/26 13:12 [entrez] AID - 7252193 [pii] AID - 10.1093/ejcts/ezad286 [doi] PST - ppublish SO - Eur J Cardiothorac Surg. 2023 Aug 1;64(2):ezad286. doi: 10.1093/ejcts/ezad286. PMID- 37632756 OWN - NLM STAT- MEDLINE DCOM- 20231107 LR - 20260310 IS - 1522-9645 (Electronic) IS - 0195-668X (Linking) VI - 44 IP - 41 DP - 2023 Nov 1 TI - 2022 Joint ESC/EACTS review of the 2018 guideline recommendations on the revascularization of left main coronary artery disease in patients at low surgical risk and anatomy suitable for PCI or CABG. PG - 4310-4320 LID - 10.1093/eurheartj/ehad476 [doi] AB - In October 2021, the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) jointly agreed to establish a Task Force (TF) to review recommendations of the 2018 ESC/EACTS Guidelines on myocardial revascularization as they apply to patients with left main (LM) disease with low-to-intermediate SYNTAX score (0-32). This followed the withdrawal of support by the EACTS in 2019 for the recommendations about the management of LM disease of the previous guideline. The TF was asked to review all new relevant data since the 2018 guidelines including updated aggregated data from the four randomized trials comparing percutaneous coronary intervention (PCI) with drug-eluting stents vs. coronary artery bypass grafting (CABG) in patients with LM disease. This document represents a summary of the work of the TF; suggested updated recommendations for the choice of revascularization modality in patients undergoing myocardial revascularization for LM disease are included. In stable patients with an indication for revascularization for LM disease, with coronary anatomy suitable for both procedures and a low predicted surgical mortality, the TF concludes that both treatment options are clinically reasonable based on patient preference, available expertise, and local operator volumes. The suggested recommendations for revascularization with CABG are Class I, Level of Evidence A. The recommendations for PCI are Class IIa, Level of Evidence A. The TF recognized several important gaps in knowledge related to revascularization in patients with LM disease and recognizes that aggregated data from the four randomized trials were still only large enough to exclude large differences in mortality. CI - This article has been co-published with permission in the European Heart Journal and European Journal of Cardio-Thoracic Surgery. (c) the European Society of Cardiology and the European Association for Cardio-Thoracic Surgery 2023. All rights reserved. The articles are identical except for minor stylistic and spelling differences in keeping with each journal's style. Either citation can be used when citing this article. FAU - Byrne, Robert A AU - Byrne RA AUID- ORCID: 0000-0001-5224-6393 AD - Department of Cardiology and Cardiovascular Research Institute (CVRI) Dublin, Mater Private Network, 73 Eccles St, Dublin D07 KWR1, Ireland. AD - School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, 123 St Stephen's Green, D02 YN77 Dublin, Ireland. FAU - Fremes, Stephen AU - Fremes S AUID- ORCID: 0000-0003-1723-3049 AD - Division of Cardiac Surgery, Schulich Heart Program, Sunnybrook Health Sciences Centre, 2075 Bayview Ave, Suite H405, M4N3M5 Toronto, Canada. AD - Department of Surgery, University of Toronto, Toronto, Canada. FAU - Capodanno, Davide AU - Capodanno D AUID- ORCID: 0000-0002-5156-7723 AD - Cardio-Thoracic-Vascular and Transplant Department, Azienda Ospedaliero-Universitaria Policlinico 'Gaspare Rodolico-San Marco', University of Catania, Catania, Italy. FAU - Czerny, Martin AU - Czerny M AUID- ORCID: 0000-0003-4766-9775 AD - Clinic for Cardiovascular Surgery, University Heart Center Freiburg, Bad Krozingen, Germany. AD - Faculty of Medicine, Albert-Ludwigs-University Freiburg, Freiburg, Germany. FAU - Doenst, Torsten AU - Doenst T AD - Department of Cardiothoracic Surgery, University Hospital Jena, Friedrich-Schiller-University Jena, Jena, Germany. FAU - Emberson, Jonathan R AU - Emberson JR AUID- ORCID: 0000-0001-7792-9422 AD - Medical Research Council Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK. FAU - Falk, Volkmar AU - Falk V AD - Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany. AD - Department of Cardiovascular Surgery, Charite Universitatsmedizin Berlin, Berlin, Germany. AD - German Centre for Cardiovascular Research, DZHK, Partner Site Berlin, Berlin, Germany. AD - Department of Health Science and Technology, ETH Zurich, Zurich, Switzerland. FAU - Gaudino, Mario AU - Gaudino M AUID- ORCID: 0000-0003-4680-0815 AD - Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, NY, USA. FAU - McMurray, John J V AU - McMurray JJV AUID- ORCID: 0000-0002-6317-3975 AD - British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK. FAU - Mehran, Roxana AU - Mehran R AUID- ORCID: 0000-0002-5546-262X AD - Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Milojevic, Milan AU - Milojevic M AUID- ORCID: 0000-0003-0984-9011 AD - Department of Cardiac Surgery and Cardiovascular Research, Dedinje Cardiovascular Institute, Belgrade, Serbia. AD - Department of Cardiothoracic Surgery, Erasmus University Medical Center, Rotterdam, The Netherlands. FAU - Sousa Uva, Miguel AU - Sousa Uva M AUID- ORCID: 0000-0001-6353-653X AD - Department of Cardiac Surgery, Hospital Santa Cruz, Carnaxide, Portugal. AD - Department of Physiology and Cardiac Surgery, Porto University Medical School, Porto, Portugal. LA - eng GR - MC_UU_00017/4/MRC_/Medical Research Council/United Kingdom PT - Journal Article PT - Review PL - England TA - Eur Heart J JT - European heart journal JID - 8006263 SB - IM CIN - Eur Heart J. 2025 Aug 21;46(32):3151-3153. doi: 10.1093/eurheartj/ehad506. PMID: 37632758 MH - Humans MH - *Cardiology MH - Coronary Artery Bypass/methods MH - *Coronary Artery Disease/surgery MH - *Percutaneous Coronary Intervention/methods MH - *Thoracic Surgery MH - Treatment Outcome MH - Practice Guidelines as Topic OTO - NOTNLM OT - Coronary artery disease OT - Heart Team OT - clinical practice guidelines OT - coronary artery bypass grafting OT - left main coronary artery OT - left main stenosis OT - meta-analysis OT - myocardial revascularization OT - percutaneous coronary intervention OT - randomized controlled trials EDAT- 2023/08/27 05:43 MHDA- 2023/11/07 06:45 CRDT- 2023/08/26 12:52 PHST- 2023/05/04 00:00 [received] PHST- 2023/06/06 00:00 [revised] PHST- 2023/07/15 00:00 [accepted] PHST- 2023/11/07 06:45 [medline] PHST- 2023/08/27 05:43 [pubmed] PHST- 2023/08/26 12:52 [entrez] AID - 7251120 [pii] AID - 10.1093/eurheartj/ehad476 [doi] PST - ppublish SO - Eur Heart J. 2023 Nov 1;44(41):4310-4320. doi: 10.1093/eurheartj/ehad476. PMID- 37632607 OWN - NLM STAT- MEDLINE DCOM- 20240214 LR - 20241003 IS - 1534-3170 (Electronic) IS - 1523-3782 (Print) IS - 1523-3782 (Linking) VI - 25 IP - 10 DP - 2023 Oct TI - Pericarditis Management in Individuals Contemplating Pregnancy, Currently Pregnant, or Breastfeeding. PG - 1103-1111 LID - 10.1007/s11886-023-01930-6 [doi] AB - PURPOSE OF REVIEW: Pericarditis complicates pregnancy planning, pregnancy, or the postpartum period, and the management approach requires special considerations. Here, we aim to summarize the latest research, diagnostic, and treatment strategies. RECENT FINDINGS: Physiologic cardiovascular (CV) adaptations occurring during pregnancy complicate diagnosis, but for most patients, an electrocardiogram (ECG) and transthoracic echocardiogram (TTE) are sufficient to diagnosis pericarditis in the appropriate clinical context. Aspirin and non-steroidal anti-inflammatory drugs (NSAIDs) can be used until 20 weeks gestation as needed. The use of colchicine is encouraged at any time point to reduce the risk of recurrence. Glucocorticoids may be used at the lowest possible dose for the least amount of time throughout pregnancy and breastfeeding. For incessant, recurrent, or refractory pericarditis, or when the above therapies are contraindicated, there may be a consideration of the use of IL-1 inhibition during pregnancy, recognizing the limited data in pregnant patients. Finally, we encourage the use of a multidisciplinary team approach including OB-GYN, cardiology, and rheumatology when available. The diagnosis and treatment of pericarditis in female patients of reproductive age require special considerations. Although highly effective treatment options are available, there is a need for greater data and larger international registries to improve treatment recommendations. CI - (c) 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Pryor, Katherine AU - Pryor K AD - Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA. FAU - Tarter, Laura AU - Tarter L AD - Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA. FAU - Economy, Katherine AU - Economy K AD - Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, MA, USA. FAU - Honigberg, Michael C AU - Honigberg MC AD - Cardiology Division, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. FAU - Valente, Anne Marie AU - Valente AM AD - Boston Children's Hospital, Boston, MA, USA. AD - Division of Cardiology, Department of Medicine, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, USA. FAU - Garshick, Michael AU - Garshick M AD - Leon H. Charney Division of Cardiology, Department of Medicine, New York University Langone Health, NYU Grossman School of Medicine, New York, NY, 10016, USA. AD - Ronald O. Perelman Department of Dermatology, New York University Langone Health, NYU Grossman School of Medicine, New York, NY, 10016, USA. FAU - Weber, Brittany AU - Weber B AD - Division of Cardiology, Department of Medicine, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, USA. bweber@bwh.harvard.edu. LA - eng GR - K23 HL159276/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20230826 PL - United States TA - Curr Cardiol Rep JT - Current cardiology reports JID - 100888969 RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - R16CO5Y76E (Aspirin) RN - SML2Y3J35T (Colchicine) SB - IM MH - Pregnancy MH - Humans MH - Female MH - *Breast Feeding MH - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use MH - Aspirin/therapeutic use MH - Treatment Outcome MH - Colchicine/adverse effects MH - *Pericarditis/diagnosis/drug therapy MH - Recurrence PMC - PMC10872603 MID - NIHMS1932811 OTO - NOTNLM OT - Cardio-obstetrics OT - Immunosuppressant OT - Pericarditis OT - Pregnancy OT - Women COIS- Conflict of Interest MSG reports consultant fees from Abbvie and Horizon Therapeutics. BW reports scientific advisory board fees from Kinisika, Horizon Therapeutics (no longer active), and Novonordisk. MG reports scientific advisory board fees from Kinisika. MCH reports research grants paid to the institution from Genentech, U.S. NHLBI, and American Heart Association; consulting fees from CRISPR Therapeutics (no longer active); equity from Miga Health. AMV reports royalties from UpToDate (Editor and Peer Review); consulting fees from the Journal of the American College of Cardiology (Editorial Board); honoraria for visiting professor lecture from Rutgers University, Vanderbilt Medical Center, Westchester Medical Center, Columbia University, Cedars-Sinai Medical Center; and Advisory Board for Practice Update. The other authors declare that they have no conflict of interest. EDAT- 2023/08/27 05:42 MHDA- 2024/02/12 18:42 PMCR- 2024/10/01 CRDT- 2023/08/26 11:07 PHST- 2023/07/24 00:00 [accepted] PHST- 2024/02/12 18:42 [medline] PHST- 2023/08/27 05:42 [pubmed] PHST- 2023/08/26 11:07 [entrez] PHST- 2024/10/01 00:00 [pmc-release] AID - 10.1007/s11886-023-01930-6 [pii] AID - 10.1007/s11886-023-01930-6 [doi] PST - ppublish SO - Curr Cardiol Rep. 2023 Oct;25(10):1103-1111. doi: 10.1007/s11886-023-01930-6. Epub 2023 Aug 26. PMID- 37632337 OWN - NLM STAT- MEDLINE DCOM- 20250415 LR - 20260723 IS - 1755-3245 (Electronic) IS - 0008-6363 (Linking) VI - 121 IP - 1 DP - 2025 Apr 15 TI - Stroke risk management in carotid atherosclerotic disease: a clinical consensus statement of the ESC Council on Stroke and the ESC Working Group on Aorta and Peripheral Vascular Diseases. PG - 13-43 LID - 10.1093/cvr/cvad135 [doi] AB - Carotid atherosclerotic disease continues to be an important cause of stroke, often disabling or fatal. Such strokes could be largely prevented through optimal medical therapy and carotid revascularization. Advancements in discovery research and imaging along with evidence from recent pharmacology and interventional clinical trials and registries and the progress in acute stroke management have markedly expanded the knowledge base for clinical decisions in carotid stenosis. Nevertheless, there is variability in carotid-related stroke prevention and management strategies across medical specialities. Optimal patient care can be achieved by (i) establishing a unified knowledge foundation and (ii) fostering multi-specialty collaborative guidelines. The emergent Neuro-Vascular Team concept, mirroring the multi-disciplinary Heart Team, embraces diverse specializations, tailors personalized, stratified medicine approaches to individual patient needs, and integrates innovative imaging and risk-assessment biomarkers. Proposed approach integrates collaboration of multiple specialists central to carotid artery stenosis management such as neurology, stroke medicine, cardiology, angiology, ophthalmology, vascular surgery, endovascular interventions, neuroradiology, and neurosurgery. Moreover, patient education regarding current treatment options, their risks and advantages, is pivotal, promoting patient's active role in clinical care decisions. This enables optimization of interventions ranging from lifestyle modification, carotid revascularization by stenting or endarterectomy, as well as pharmacological management including statins, novel lipid-lowering and antithrombotic strategies, and targeting inflammation and vascular dysfunction. This consensus document provides a harmonized multi-specialty approach to multi-morbidity prevention in carotid stenosis patients, based on comprehensive knowledge review, pinpointing research gaps in an evidence-based medicine approach. It aims to be a foundational tool for inter-disciplinary collaboration and prioritized patient-centric decision-making. CI - (c) The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com. FAU - Musialek, Piotr AU - Musialek P AUID- ORCID: 0000-0001-9300-4833 AD - Jagiellonian University Department of Cardiac and Vascular Diseases, St. John Paul II Hospital, ul. Pradnicka 80, 31-202 Krakow, Poland. FAU - Bonati, Leo H AU - Bonati LH AD - Reha Rheinfelden, Rheinfelden, Switzerland. FAU - Bulbulia, Richard AU - Bulbulia R AD - Medical Research Council Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Richard Doll Building, Old Road Campus, Roosevelt Drive, Oxford OX3 7LF, UK. AD - Medical Research Council Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Richard Doll Building, Old Road Campus, Roosevelt Drive, Oxford OX3 7LF, UK. FAU - Halliday, Alison AU - Halliday A AD - Medical Research Council Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Richard Doll Building, Old Road Campus, Roosevelt Drive, Oxford OX3 7LF, UK. FAU - Bock, Birgit AU - Bock B AD - Societe Madame Birgit Bock, Paris, France. FAU - Capoccia, Laura AU - Capoccia L AD - Department of Surgery 'Paride Stefanini', Policlinico Umberto I, 'Sapienza' University of Rome, Rome, Italy. FAU - Eckstein, Hans-Henning AU - Eckstein HH AD - Department for Vascular and Endovascular Surgery, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany. FAU - Grunwald, Iris Q AU - Grunwald IQ AD - Department of Radiology, Ninewells Hospital, University of Dundee, Dundee, UK. AD - Tayside Innovation MedTech Ecosystem (TIME), Division of Imaging Science and Technology, University of Dundee, Dundee, UK. FAU - Lip, Peck Lin AU - Lip PL AD - Birmingham & Midland Eye Centre, Birmingham, UK. FAU - Monteiro, Andre AU - Monteiro A AD - Department of Neurosurgery, Gates Vascular Institute at Kaleida Health, Buffalo, NY, USA. FAU - Paraskevas, Kosmas I AU - Paraskevas KI AD - Department of Vascular Surgery, Central Clinic of Athens, Athens, Greece. FAU - Podlasek, Anna AU - Podlasek A AD - Tayside Innovation MedTech Ecosystem (TIME), Division of Imaging Science and Technology, University of Dundee, Dundee, UK. AD - Division of Radiological and Imaging Sciences, University of Nottingham, Nottingham, UK. FAU - Rantner, Barbara AU - Rantner B AD - Vascular Surgery Department, Ludwig Maximilian University Hospital, Campus Grosshadern, Munich, Germany. FAU - Rosenfield, Kenneth AU - Rosenfield K AD - Division of Cardiology, Massachusetts General Hospital, Boston, MA, USA. FAU - Siddiqui, Adnan H AU - Siddiqui AH AD - Department of Radiology, Jacobs School of Medicine and Biomedical Sciences, and Canon Stroke and Vascular Research Center, University at Buffalo, Buffalo, NY, USA. AD - Jacobs Institute, Buffalo, NY, USA. FAU - Sillesen, Henrik AU - Sillesen H AD - Department of Vascular Surgery, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. AD - Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. FAU - Van Herzeele, Isabelle AU - Van Herzeele I AD - Department of Thoracic and Vascular Surgery, Ghent University Hospital, Ghent, Belgium. FAU - Guzik, Tomasz J AU - Guzik TJ AD - Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK. AD - Department of Internal Medicine, Jagiellonian University Collegium Medicum, Krakow, Poland. FAU - Mazzolai, Lucia AU - Mazzolai L AUID- ORCID: 0000-0001-9650-3822 AD - Department of Angiology, University Hospital Lausanne, Lausanne, Switzerland. FAU - Aboyans, Victor AU - Aboyans V AUID- ORCID: 0000-0002-0322-9818 AD - Department of Cardiology, CHRU Dupuytren Limoges, Limoges, France. FAU - Lip, Gregory Y H AU - Lip GYH AD - Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, UK. AD - Danish Center for Health Services Research, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. LA - eng PT - Consensus Statement PT - Journal Article PT - Review PL - England TA - Cardiovasc Res JT - Cardiovascular research JID - 0077427 SB - IM MH - Humans MH - *Carotid Artery Diseases/therapy/diagnostic imaging/complications MH - *Carotid Stenosis/therapy/diagnostic imaging/complications MH - Clinical Decision-Making MH - Cooperative Behavior MH - *Endarterectomy, Carotid/adverse effects/standards MH - Evidence-Based Medicine/standards MH - Interdisciplinary Communication MH - Patient Care Team/standards MH - Risk Assessment MH - Risk Factors MH - *Stroke/prevention & control/diagnosis/epidemiology/etiology/therapy MH - Treatment Outcome OTO - NOTNLM OT - Antithrombotic management OT - Atherosclerotic carotid disease OT - Biomarkers OT - Evidence base OT - Imaging OT - Interventional management OT - Multi-specialty team OT - Neuro-Vascular team OT - Recent trials and registries OT - State-of-the art review OT - Stroke risk reduction COIS- Conflict of interest. P.M.: Co-principal Investigator in the CGUARDIANS FDA-IDE and in the CARENET Trial. Principal investigator in the PARADIGM/PARADIGM-Extend, FLOWGUARD, OPTIMA, TOPGUARD, and SAFEGUARD-STROKE Investigator-Initiated Trials. Member of the European Society of Cardiology (ESC) Research and Grants Committee and ESC Congress Programme Committee. Voting member of the ESC WG CARE. Member of the EuroPCR VITAL. Proctor and/or consultant for the Abbott Vascular, Balton, Gore, InspireMD, and Medtronic. Grants from the Polish Committee for Scientific Research, Polish Cardiac Society, and the Jagiellonian University Medical College for research related to carotid artery disease. CArotid Revascularization systematic reviews and MEta-aNalyses (CARMEN) Collaboration. Polish Cardiac Society Board Representative for Stroke and Vascular Interventions. L.H.B.: Lead author of the 2021 European Stroke Organisation (ESO) guideline on endarterectomy and stenting for carotid artery stenosis. Principal investigator in the Precise-MRI. Co-principal investigator in the ECST-2 and ACST-2. Investigator in the ICSS, lead investigator in the ICSS-MRI sub-study. Consultant for the AstraZeneca. Grants from the Swiss National Science Foundation, the Swiss Heart Foundation, the University of Basel, and AstraZeneca for research related to carotid artery disease. R.B.: Co-author of the 2021 ESO guideline on endarterectomy and stenting for carotid artery stenosis, reviewer of the European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on the Management of Atherosclerotic Carotid and Vertebral Artery Disease and co-principal investigator in the ACST-2. A.H.: Co-author of the ESVS 2023 Clinical Practice Guidelines on the Management of Atherosclerotic Carotid and Vertebral Artery Disease, co-author of the 2021 ESO guideline on endarterectomy and stenting for carotid artery stenosis, and co-author of the ESC Guidelines on dyslipidaemias. Principal investigator in the ACST-1 and ACST-2. Steering Committee member of the ECST-2 and ICSS. Carotid Stenting Trialists' Collaboration (CSTC). Chair of the ESC Stroke Council. B.B., P.L.L., A.M., A.P., and T.J.G.: No conflicts of interest. L.C.: ACST-2 collaborator. Investigator-Initiated Studies of CEA and CAS. H.-H.E.: Co-author of the 2021 ESO guideline on endarterectomy and stenting for carotid artery stenosis, reviewer of the ESVS 2023 Clinical Practice Guidelines on the Management of Atherosclerotic Carotid and Vertebral Artery Disease, and lead author in the multidisciplinary German-Austrian guideline on the diagnosis, treatment and follow-up of extracranial carotid stenosis. Steering Committee of the SPACE-1, co-principal investigator in the SPACE-2, co-investigator in the ROADSTER 1 and ROADSTER 2, and co-investigator in the ACST-2 and CSTC. EU Horizon 2020 grant for stratification of carotid disease. I.Q.G.: Principal investigator on the first trial of mechanical thrombus aspiration in acute stroke (Penumbra). Investigator-Initiated Studies of acute stroke and CAS. Lead author of the World Federation for Interventional Stroke Treatment (WIST) multispecialty training guidelines for endovascular stroke intervention. Co-founder of the Brainomix. Research funding from the Samsung Neurologica and Johnson&Johnson and educational grant from Pulsara. Vice President of the WIST. K.I.P.: Lead author of reviews on carotid revascularization by CEA and CAS. Lead author of commentaries on the European and US carotid revascularization guidelines. Initiator of Delphi consensus document on controversial issues in the management of patients with asymptomatic and symptomatic carotid stenosis and of Delphi consensus document on transcarotid stent-assisted revascularization. B.R.: Co-chairperson of the writing committee of the ESVS 2023 Clinical Practice Guidelines on the Management of Atherosclerotic Carotid and Vertebral Artery Disease. Co-Investigator in ACST-2 and CSTC. K.R.: Writing committee for the American College of Cardiology/American Heart Association (ACC/AHA) Peripheral Arterial Disease (PAD) Guidelines, ACC/AHA Competency Statement for treatment of PAD, and Trans-Atlantic Inter-Society Consensus Document on Management of Peripheral Arterial Disease (TASC) II. Chair of Multidisciplinary writing task force developing guidelines for training, competence, and credentialing for carotid intervention, co-ordinated (through ACC/SVS/SCAI) developing novel modalities for training with the use of medical simulators and specialized training programmes (such as the FAME Programme). Consultant or on scientific advisory board for Althea Medical, Angiodynamics, Boston Scientific, Contego, InspireMD, Magneto, Mayo Clinic, Neptune Medical, Philips, Summa Therapeutics, Surmodics, Thrombolex, Terumo, and Truvic; has received institutional grant support from the National Institutes of Health, Abiomed, and Boston Scientific; owns equity interests in Accolade, Access Vascular, Aerami, Althea Medical, Contego, Cruzar Systems, Embolitech, Endospan, InspireMD, JanaCare, Magneto, Orchestra, PQ Bypass, Prosomnus, Shockwave, Summa Therapeutics, Thrombolex, Truvic, and Valcare. Member of the Society for Cardiovascular Angiography and Intervention (SCAI), Ad hoc Carotid and Cerebrovascular Disease Committee, member of Multispecialty Carotid Alliance. Chairperson of the Peripheral Arterial Disease Committee of the ACC, Chair of the SCAI Ad hoc Committee on PAD. A.H.S.: Society of Neurointerventional Surgery Standards and Guidelines Committee, and Multispecialty Carotid Alliance. Grants from National Institutes of Health/National Institute of Neurological Disorders and Stroke (co-principal investigator on Optimizing Approaches to Endovascular Therapy of Acute Ischemic Stroke; co-investigator on Virtual Intervention of Intracranial Aneurysms) and has served as the national principal investigator for or on the Steering Committee of the Cerenovus EXCELLENT and ARISE II trial; the Medtronic SWIFT PRIME, VANTAGE, EMBOLISE, and SWIFT DIRECT trials; the MicroVention FRED trial and CONFIDENCE study; the MUSC POSITIVE trial; the Penumbra 3D Separator trial, COMPASS trial, INVEST trial, MIVI neuroscience EVAQ trial; and the Rapid Medical SUCCESS trial. He owns financial interest in, is an investor in, owns stock options, or has ownership in Adona Medical, Amnis Therapeutics, Bend IT Technologies, BlinkTBI, Buffalo Technology Partners, Cardinal Consultants, Cerebrotech Medical Systems, Cerevatech Medical, Cognition Medical, CVAID, Endostream Medical, Imperative Care, Instylla, International Medical Distribution Partners, Launch NY, NeuroRadial Technologies, Neurotechnology Investors, Neurovascular Diagnostics, PerFlow Medical, Q'Apel Medical, QAS.ai, Radical Catheter Technologies, Rebound Therapeutics (purchased 2019 by Integra Lifesciences), Rist Neurovascular (purchased 2020 by Medtronic), Sense Diagnostics, Serenity Medical, Silk Road Medical, Spinnaker Medical, StimMed, Synchron, Three Rivers Medical, Truvic Medical, Vastrax, VICIS, and Viseon; has served as a consultant or on the advisory board for Amnis Therapeutics, Apellis Pharmaceuticals, Boston Scientific, Canon Medical Systems USA, Cardinal Health 200, Cerebrotech Medical Systems, Cerenovus, Cerevatech Medical, Cordis, Corindus, Endostream Medical, Imperative Care, Integra, IRRAS AB, Medtronic, MicroVention, Minnetronix Neuro, Penumbra, Q'Apel Medical, Rapid Medical, Rebound Therapeutics, Serenity Medical, Silk Road Medical, StimMed, Stryker Neurovascular, Three Rivers Medical, VasSol, Viz.ai, and W.L. Gore and Associates. Past Secretary-Society of Neurointerventional Surgery, past Chair-Joint Cerebrovascular Section of the American Association of Neurological Surgeons, and Council of State Neurosurgical Societies. H.S.: Writing committee of European Society for Vascular Surgery 2023 Clinical Practice Guidelines on the Management of Atherosclerotic Carotid and Vertebral Artery Disease. I.V.H.: Writing group of ESO guideline on endarterectomy and stenting for carotid stenosis, and a member of ESVS Guideline Committee. Co-Investigator in the ACST-2, Precise-MRI, and TOPGUARD. Research support from the SilkRoad Medical. Consultant for Medtronic; Institution support from the Simbionix. L.M.: Chair of the ESC Working Group on Aorta and Peripheral Vascular Diseases. V.A.: ESC Chairperson of the Task Force/Authors of the 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases (developed in collaboration with ESVS). Consultant and/or speaker for the Amgen, AstraZeneca, Bayer Healthcare, BMS, Boehringer Ingelheim, Lilly, NovoNordisk, Pfizer. Past Chair of the ESC Working Group on Aorta and Peripheral Vascular Diseases. G.Y.H.L.: Consultant and/or speaker for BMS/Pfizer, Boehringer Ingelheim, and Daiichi Sankyo (no personal honoraria). Chairperson-Elect of the ESC Council on Stroke. EDAT- 2023/08/27 05:42 MHDA- 2025/04/16 00:24 CRDT- 2023/08/26 06:34 PHST- 2023/08/16 00:00 [received] PHST- 2023/08/20 00:00 [revised] PHST- 2023/08/21 00:00 [accepted] PHST- 2025/04/16 00:24 [medline] PHST- 2023/08/27 05:42 [pubmed] PHST- 2023/08/26 06:34 [entrez] AID - 7250075 [pii] AID - 10.1093/cvr/cvad135 [doi] PST - ppublish SO - Cardiovasc Res. 2025 Apr 15;121(1):13-43. doi: 10.1093/cvr/cvad135. PMID- 37629681 OWN - NLM STAT- MEDLINE DCOM- 20230828 LR - 20230829 IS - 1648-9144 (Electronic) IS - 1010-660X (Print) IS - 1010-660X (Linking) VI - 59 IP - 8 DP - 2023 Jul 29 TI - Training in Aortic Arch Surgery as a Blueprint for a Structured Educational Team Approach: A Review. LID - 10.3390/medicina59081391 [doi] LID - 1391 AB - Background and objectives: The treatment of pathologies of the aortic arch is a complex field of cardiovascular surgery that has witnessed enormous progress recently. Such treatment is mainly performed in high-volume centres, and surgeons gain great experience in mastering potential difficulties even under emergency circumstances, thereby ensuring the effective therapy of more complex pathologies with lower complication rates. As the numbers of patients rise, so does the need for well-trained surgeons in aortic arch surgery. But how is it possible to learn surgical procedures in a responsible way that, in addition to surgical techniques, also places particular demands on the overall surgical management such as perfusion strategy and neuro-protection? This is why a good training programme teaching young surgeons without increasing the risk for patients is indispensable. Our intention was to highlight the most challenging aspects of aortic arch surgery teaching and how young surgeons can master them. Materials and Methods: We analysed the literature to find out which methods are most suitable for such teaching goals and what result they reveal when serving as teaching procedures. Results: Several studies were found comparing the surgical outcome of young trainees with that of specialists. It was found that the results were comparable whether the procedure was performed by a specialist or by a trainee assisted by the specialist. Conclusions: We thus came to the conclusion that even for such a complex type of intervention, the responsible training of young surgeons by experienced specialists is possible. However, it requires a clear strategy and team approach to ensure a safe outcome for the patient. FAU - Discher, Philipp AU - Discher P AD - Department of Cardiovascular Surgery, University Heart Centre, University Hospital Freiburg, 79106 Freiburg, Germany. AD - Faculty of Medicine, Albert-Ludwigs-University of Freiburg, 79110 Freiburg, Germany. FAU - Kreibich, Maximilian AU - Kreibich M AD - Department of Cardiovascular Surgery, University Heart Centre, University Hospital Freiburg, 79106 Freiburg, Germany. AD - Faculty of Medicine, Albert-Ludwigs-University of Freiburg, 79110 Freiburg, Germany. FAU - Berger, Tim AU - Berger T AD - Department of Cardiovascular Surgery, University Heart Centre, University Hospital Freiburg, 79106 Freiburg, Germany. AD - Faculty of Medicine, Albert-Ludwigs-University of Freiburg, 79110 Freiburg, Germany. FAU - Kondov, Stoyan AU - Kondov S AD - Department of Cardiovascular Surgery, University Heart Centre, University Hospital Freiburg, 79106 Freiburg, Germany. AD - Faculty of Medicine, Albert-Ludwigs-University of Freiburg, 79110 Freiburg, Germany. FAU - Eschenhagen, Matthias AU - Eschenhagen M AD - Department of Cardiovascular Surgery, University Heart Centre, University Hospital Freiburg, 79106 Freiburg, Germany. AD - Faculty of Medicine, Albert-Ludwigs-University of Freiburg, 79110 Freiburg, Germany. FAU - Schibilsky, David AU - Schibilsky D AD - Department of Cardiovascular Surgery, University Heart Centre, University Hospital Freiburg, 79106 Freiburg, Germany. AD - Faculty of Medicine, Albert-Ludwigs-University of Freiburg, 79110 Freiburg, Germany. FAU - Bork, Magdalena AU - Bork M AD - Department of Cardiovascular Surgery, University Heart Centre, University Hospital Freiburg, 79106 Freiburg, Germany. AD - Faculty of Medicine, Albert-Ludwigs-University of Freiburg, 79110 Freiburg, Germany. FAU - Walter, Tim AU - Walter T AD - Department of Cardiovascular Surgery, University Heart Centre, University Hospital Freiburg, 79106 Freiburg, Germany. AD - Faculty of Medicine, Albert-Ludwigs-University of Freiburg, 79110 Freiburg, Germany. FAU - Chikvatia, Salome AU - Chikvatia S AD - Department of Cardiovascular Surgery, University Heart Centre, University Hospital Freiburg, 79106 Freiburg, Germany. AD - Faculty of Medicine, Albert-Ludwigs-University of Freiburg, 79110 Freiburg, Germany. FAU - Gottardi, Roman AU - Gottardi R AD - Department of Cardiovascular Surgery, University Heart Centre, University Hospital Freiburg, 79106 Freiburg, Germany. AD - Faculty of Medicine, Albert-Ludwigs-University of Freiburg, 79110 Freiburg, Germany. FAU - Rylski, Bartosz AU - Rylski B AD - Department of Cardiovascular Surgery, University Heart Centre, University Hospital Freiburg, 79106 Freiburg, Germany. AD - Faculty of Medicine, Albert-Ludwigs-University of Freiburg, 79110 Freiburg, Germany. FAU - Siepe, Matthias AU - Siepe M AD - Department of Cardiac Surgery, University Heart Centre, University Hospital Bern, 3010 Bern, Switzerland. FAU - Czerny, Martin AU - Czerny M AD - Department of Cardiovascular Surgery, University Heart Centre, University Hospital Freiburg, 79106 Freiburg, Germany. AD - Faculty of Medicine, Albert-Ludwigs-University of Freiburg, 79110 Freiburg, Germany. LA - eng PT - Journal Article PT - Review DEP - 20230729 PL - Switzerland TA - Medicina (Kaunas) JT - Medicina (Kaunas, Lithuania) JID - 9425208 SB - IM MH - Humans MH - *Aorta, Thoracic/surgery MH - Educational Status MH - Learning MH - *Surgeons MH - Intention PMC - PMC10456247 OTO - NOTNLM OT - aortic arch surgery OT - endovascular OT - frozen elephant trunk (FET) OT - teaching OT - training COIS- Maximilian Kreibich has received speaking honoraria from Terumo Aortic. Stoyan Kondov has received speaking honoraria from Terumo Aortic. Roman Gottardi is a shareholder of TEVAR Ltd. and Ascense Medical GmbH. Bartosz Rylski is a consultant to and received support and speaker honoraria from Terumo Aortic, a shareholder of Ascension Medical, and holds a patent on Single Device for Transcatheter Aortic Valve Replacement and Ascending Aortic Repair, 5860/Z6551, University of Pennsylvania, USA, 2013. Martin Czerny is a consultant for Terumo aortic, Medtronic, Endospan and NEOS, received speaking honoraria from Bentley and Cryolife-Jotec and is shareholder of TEVAR Ltd. and Ascense Medical GmbH. The authors declare no conflict of interest. EDAT- 2023/08/26 10:43 MHDA- 2023/08/28 06:42 PMCR- 2023/07/29 CRDT- 2023/08/26 01:20 PHST- 2023/05/10 00:00 [received] PHST- 2023/07/26 00:00 [revised] PHST- 2023/07/26 00:00 [accepted] PHST- 2023/08/28 06:42 [medline] PHST- 2023/08/26 10:43 [pubmed] PHST- 2023/08/26 01:20 [entrez] PHST- 2023/07/29 00:00 [pmc-release] AID - medicina59081391 [pii] AID - medicina-59-01391 [pii] AID - 10.3390/medicina59081391 [doi] PST - epublish SO - Medicina (Kaunas). 2023 Jul 29;59(8):1391. doi: 10.3390/medicina59081391. PMID- 37629341 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230829 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 12 IP - 16 DP - 2023 Aug 15 TI - The Evolving Role of Surgical Aortic Valve Replacement in the Era of Transcatheter Valvular Procedures. LID - 10.3390/jcm12165299 [doi] LID - 5299 AB - Surgical aortic valve replacement (SAVR) has long been the standard treatment for severe symptomatic aortic stenosis (AS). However, transcatheter aortic valve replacement (TAVR) has emerged as a minimally invasive alternative; it was initially intended for high-risk patients and has now expanded its use to patients of all risk groups. While TAVR has demonstrated promising outcomes in diverse patient populations, uncertainties persist regarding its long-term durability and potential complications, raising the issue of the ideal lifetime management strategy for patients with AS. Therefore, SAVR continues to play an important role in clinical practice, particularly in younger patients with longer life expectancies, those with complex aortic anatomy who are unsuitable for TAVR, and those requiring concomitant surgical procedures. The choice between TAVR and SAVR warrants personalized decision-making, considering patient characteristics, comorbidities, anatomical considerations, and overall life expectancy. A multidisciplinary approach involving an experienced heart team is crucial in the preoperative evaluation process. In this review, we aimed to explore the current role of surgical management in addressing aortic valve stenosis amidst the expanding utilization of less invasive transcatheter procedures. FAU - Juarez-Casso, Fernando M AU - Juarez-Casso FM AD - Department of Cardiovascular Surgery, Mayo Clinic, Rochester, MN 55905, USA. FAU - Crestanello, Juan A AU - Crestanello JA AD - Department of Cardiovascular Surgery, Mayo Clinic, Rochester, MN 55905, USA. LA - eng PT - Journal Article PT - Review DEP - 20230815 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC10455383 OTO - NOTNLM OT - aortic valve stenosis OT - surgical aortic valve replacement OT - transcatheter aortic valve replacement COIS- The authors declare no conflict of interest. EDAT- 2023/08/26 10:46 MHDA- 2023/08/26 10:47 PMCR- 2023/08/15 CRDT- 2023/08/26 01:18 PHST- 2023/06/20 00:00 [received] PHST- 2023/07/11 00:00 [revised] PHST- 2023/07/19 00:00 [accepted] PHST- 2023/08/26 10:47 [medline] PHST- 2023/08/26 10:46 [pubmed] PHST- 2023/08/26 01:18 [entrez] PHST- 2023/08/15 00:00 [pmc-release] AID - jcm12165299 [pii] AID - jcm-12-05299 [pii] AID - 10.3390/jcm12165299 [doi] PST - epublish SO - J Clin Med. 2023 Aug 15;12(16):5299. doi: 10.3390/jcm12165299. PMID- 37629260 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231103 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 12 IP - 16 DP - 2023 Aug 10 TI - The ABC of Heart Transplantation-Part 1: Indication, Eligibility, Donor Selection, and Surgical Technique. LID - 10.3390/jcm12165217 [doi] LID - 5217 AB - Cardiac transplantation represents the gold standard of treatment for selected patients with advanced heart failure who have poor functional capacity and prognosis despite guideline-directed medical therapy and device-based therapy. Proper patient selection and appropriate referral of patients to centers for the treatment of advanced heart failure are the first but decisive steps for screening patients eligible for cardiac transplantation. The eligibility and the decision to list for cardiac transplantation, even for patients with relative contraindications, are based on a multidisciplinary evaluation of a transplant team. This review will discuss the practical indications, the process of patient eligibility for cardiac transplantation, the principle of donor selection, as well as the surgical technique. FAU - Masarone, Daniele AU - Masarone D AUID- ORCID: 0000-0002-6781-7424 AD - Heart Failure Unit, Department of Cardiology, AORN dei Colli-Monaldi Hospital, 80131 Naples, Italy. FAU - Kittleson, Michelle M AU - Kittleson MM AD - Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Hospital, Los Angeles, CA 90048, USA. FAU - Falco, Luigi AU - Falco L AUID- ORCID: 0009-0005-5669-574X AD - Heart Failure Unit, Department of Cardiology, AORN dei Colli-Monaldi Hospital, 80131 Naples, Italy. FAU - Martucci, Maria L AU - Martucci ML AD - Heart Failure Unit, Department of Cardiology, AORN dei Colli-Monaldi Hospital, 80131 Naples, Italy. FAU - Catapano, Dario AU - Catapano D AD - Heart Failure Unit, Department of Cardiology, AORN dei Colli-Monaldi Hospital, 80131 Naples, Italy. FAU - Brescia, Benedetta AU - Brescia B AD - Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", 80131 Naples, Italy. FAU - Petraio, Andrea AU - Petraio A AD - Heart Transplant Unit, Department of Cardiac Surgery and Transplants, AORN dei Colli Monaldi Hospital, 80131 Naples, Italy. FAU - De Feo, Marisa AU - De Feo M AD - Cardiac Surgery Unit, Department of Cardiac Surgery and Transplants, AORN dei Colli Monaldi Hospital, 80131 Naples, Italy. FAU - Pacileo, Giuseppe AU - Pacileo G AD - Heart Failure Unit, Department of Cardiology, AORN dei Colli-Monaldi Hospital, 80131 Naples, Italy. LA - eng PT - Journal Article PT - Review DEP - 20230810 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC10455167 OTO - NOTNLM OT - advanced heart failure OT - heart transplant OT - patient referral OT - patient selection COIS- The authors declare no conflict of interest. EDAT- 2023/08/26 10:41 MHDA- 2023/08/26 10:42 PMCR- 2023/08/10 CRDT- 2023/08/26 01:18 PHST- 2023/07/21 00:00 [received] PHST- 2023/08/04 00:00 [revised] PHST- 2023/08/09 00:00 [accepted] PHST- 2023/08/26 10:42 [medline] PHST- 2023/08/26 10:41 [pubmed] PHST- 2023/08/26 01:18 [entrez] PHST- 2023/08/10 00:00 [pmc-release] AID - jcm12165217 [pii] AID - jcm-12-05217 [pii] AID - 10.3390/jcm12165217 [doi] PST - epublish SO - J Clin Med. 2023 Aug 10;12(16):5217. doi: 10.3390/jcm12165217. PMID- 37626704 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241025 IS - 2227-9059 (Print) IS - 2227-9059 (Electronic) IS - 2227-9059 (Linking) VI - 11 IP - 8 DP - 2023 Aug 6 TI - Clinical Characteristics and Outcomes of Aortic Arch Emergencies: Takayasu Disease, Fibromuscular Dysplasia, and Aortic Arch Pathologies: A Retrospective Study and Review of the Literature. LID - 10.3390/biomedicines11082207 [doi] LID - 2207 AB - Non-atherosclerotic aortic arch pathologies (NA-AAPs) and anatomical variants are characterized as rare cardiovascular diseases with a low incidence rate, below 1 case per 2000 population, but enormous heterogeneity in terms of anatomical variants, i.e., Takayasu disease (TAK) and fibromuscular dysplasia (FMD). In specific clinical scenarios, NA-AAPs constitute life-threatening disorders. METHODS: In this study, 82 (1.07%) consecutive patients with NA-AAPs (including 38 TAKs, 26 FMDs, and 18 other AAPs) out of 7645 patients who underwent endovascular treatment (EVT) for the aortic arch and its side-branch diseases at a single institution between 2002 and 2022 were retrospectively reviewed. The recorded demographic, biochemical, diagnostic, operative, and postoperative factors were reviewed, and the functional outcomes were determined during follow-up. A systematic review of the literature was also performed. RESULTS: The study group comprised 65 (79.3%) female and 17 (21.7%) male subjects with a mean age of 46.1 +/- 14.9 years. Overall, 62 (75.6%) patients were diagnosed with either cerebral ischemia symptoms or aortic arch dissection on admission. The EVT was feasible in 59 (72%) patients, whereas 23 (28%) patients were referred for medical treatment. In EVT patients, severe periprocedural complications occurred in two (3.39%) patients, including one periprocedural death and one cerebral hyperperfusion syndrome. During a median follow-up period of 64 months, cardiovascular events occurred in 24 (29.6%) patients (5 deaths, 13 ISs, and 6 myocardial infarctions). Repeated EVT for the index lesion was performed in 21/59 (35.6%) patients, including 19/33 (57.6%) in TAK and 2/13 (15.4%) in FMD. In the AAP group, one patient required additional stent-graft implantation for progressing dissection to the iliac arteries at 12 months. A baseline white blood count (odds ratio [HR]: 1.25, 95% confidence interval [CI]: 1.11-1.39; p < 0.001) was the only independent prognostic factor for recurrent stenosis, while a baseline hemoglobin level (HR: 0.73, 95%CI: 0.59-0.89; p = 0.002) and coronary involvement (HR: 4.11, 95%CI: 1.74-9.71; p = 0.001) were independently associated with a risk of major cardiac and cerebral events according to the multivariate Cox proportional hazards regression analysis. CONCLUSIONS: This study showed that AAPs should not be neglected in clinical settings, as it can be a life-threatening condition requiring a multidisciplinary approach. The knowledge of prognostic risk factors for adverse outcomes may improve surveillance in this group of patients. FAU - Wawak, Magdalena AU - Wawak M AD - Department of Interventional Cardiology, The John Paul II Hospital, Pradnicka 80, 31-202 Krakow, Poland. FAU - Tekieli, Lukasz AU - Tekieli L AD - Department of Interventional Cardiology, The John Paul II Hospital, Pradnicka 80, 31-202 Krakow, Poland. FAU - Badacz, Rafal AU - Badacz R AUID- ORCID: 0000-0003-0122-1318 AD - Department of Interventional Cardiology, The John Paul II Hospital, Pradnicka 80, 31-202 Krakow, Poland. AD - Department of Interventional Cardiology, Institute of Cardiology, Jagiellonian University Medical College, sw. Anny 12, 31-007 Krakow, Poland. FAU - Pieniazek, Piotr AU - Pieniazek P AD - Department of Interventional Cardiology, The John Paul II Hospital, Pradnicka 80, 31-202 Krakow, Poland. AD - Department of Cardiac and Vascular Diseases, Institute of Cardiology, Jagiellonian University Medical College, sw. Anny 12, 31-007 Krakow, Poland. FAU - Maciejewski, Damian AU - Maciejewski D AD - Department of Interventional Cardiology, The John Paul II Hospital, Pradnicka 80, 31-202 Krakow, Poland. FAU - Trystula, Mariusz AU - Trystula M AD - Department of Vascular and Endovascular Surgery, The John Paul II Hospital, Pradnicka 80, 31-202 Krakow, Poland. FAU - Przewlocki, Tadeusz AU - Przewlocki T AD - Department of Interventional Cardiology, The John Paul II Hospital, Pradnicka 80, 31-202 Krakow, Poland. AD - Department of Cardiac and Vascular Diseases, Institute of Cardiology, Jagiellonian University Medical College, sw. Anny 12, 31-007 Krakow, Poland. FAU - Kablak-Ziembicka, Anna AU - Kablak-Ziembicka A AUID- ORCID: 0000-0002-8006-7840 AD - Department of Interventional Cardiology, Institute of Cardiology, Jagiellonian University Medical College, sw. Anny 12, 31-007 Krakow, Poland. AD - Noninvasive Cardiovascular Laboratory, The John Paul II Hospital, Pradnicka 80, 31-202 Krakow, Poland. LA - eng PT - Journal Article DEP - 20230806 PL - Switzerland TA - Biomedicines JT - Biomedicines JID - 101691304 PMC - PMC10452526 OTO - NOTNLM OT - Takayasu disease OT - aortic arch pathology OT - aortic dissection OT - arteritis OT - connective tissue disorders OT - fibromuscular dysplasia OT - percutaneous intervention OT - rare cardiovascular disease OT - stenosis of aortic arch COIS- The authors declare no conflict of interest. EDAT- 2023/08/26 10:47 MHDA- 2023/08/26 10:48 PMCR- 2023/08/06 CRDT- 2023/08/26 01:01 PHST- 2023/07/12 00:00 [received] PHST- 2023/08/02 00:00 [revised] PHST- 2023/08/04 00:00 [accepted] PHST- 2023/08/26 10:48 [medline] PHST- 2023/08/26 10:47 [pubmed] PHST- 2023/08/26 01:01 [entrez] PHST- 2023/08/06 00:00 [pmc-release] AID - biomedicines11082207 [pii] AID - biomedicines-11-02207 [pii] AID - 10.3390/biomedicines11082207 [doi] PST - epublish SO - Biomedicines. 2023 Aug 6;11(8):2207. doi: 10.3390/biomedicines11082207. PMID- 37624543 OWN - NLM STAT- MEDLINE DCOM- 20240118 LR - 20261010 IS - 1590-3478 (Electronic) IS - 1590-1874 (Linking) VI - 45 IP - 2 DP - 2024 Feb TI - Quality control in treating patients with patent foramen ovale: 7-year-experience of the Heart and Brain team of the Careggi University Hospital. PG - 671-678 LID - 10.1007/s10072-023-07023-0 [doi] AB - BACKGROUND: The right comprehension of ischemic stroke pathogenesis guarantees the best prevention therapy. The term "patent foramen ovale (PFO) related stroke" has been proposed for those events where PFO is supposed to be pathogenetic, but their definition is challenging. A multidisciplinary evaluation in a "Heart & Brain" team (HBteam) including stroke neurologists and interventional cardiologists was therefore highly recommended in the recent guidelines of secondary stroke prevention. OBJECTIVE: We aimed at describing the organization of the HBteam of Careggi-University-Hospital of Florence (Italy), and the results of the first seven years of activity. METHODS: In 2016 Interventional Cardiologists and Stroke Neurologists set up an outpatient clinic for the joined evaluation of patients with PFO and other cardio/neurological conditions. A specific diagnostic-therapeutic hospital plan was produced for PFO patients. Patient empowerment was guaranteed by a hospital explicative webpage, a booklet regarding risks/benefits of PFO closure and a 3D heartmodel to simulate the intervention. Data were collected in a dedicated registry. RESULTS: We evaluated 594 patients for PFO, 40 for left atrial appendage closure and 38 for other conditions. In 20% of PFO-patients, HBteam diagnosis was discordant from that of referring physicians, 14% were stroke misdiagnoses. We advised against closure in 53% of patients. At follow-up 94% of closed patients had no/minimum residual shunt; 3 patients had a cerebral ischemic event. CONCLUSIONS: A dedicated HBteam represents a unique opportunity to share decisions with patients after a thorough empowerment process. The joining of cardioneurological skills allows a better classification of PFO-patients, reducing futile interventions. CI - (c) 2023. Fondazione Societa Italiana di Neurologia. FAU - Meucci, Francesco AU - Meucci F AD - Structural Interventional Cardiology, Careggi University Hospital, Florence, Italy. FAU - Rapillo, Costanza Maria AU - Rapillo CM AUID- ORCID: 0000-0002-6380-6373 AD - NEUROFARBA Department, Neuroscience Section, University of Florence, Florence, Italy. costanzamaria.rapillo@unifi.it. FAU - Stolcova, Miroslava AU - Stolcova M AD - Structural Interventional Cardiology, Careggi University Hospital, Florence, Italy. FAU - Scrima, Giulia Domna AU - Scrima GD AD - NEUROFARBA Department, Neuroscience Section, University of Florence, Florence, Italy. FAU - Nardi, Giulia AU - Nardi G AD - Structural Interventional Cardiology, Careggi University Hospital, Florence, Italy. FAU - Nistri, Rita AU - Nistri R AD - Department of Heart and Vessel, Careggi University Hospital, Florence, Italy. FAU - Ristalli, Francesca AU - Ristalli F AD - Structural Interventional Cardiology, Careggi University Hospital, Florence, Italy. FAU - D'Ettore, Nicoletta AU - D'Ettore N AD - Structural Interventional Cardiology, Careggi University Hospital, Florence, Italy. FAU - Mattesini, Alessio AU - Mattesini A AD - Structural Interventional Cardiology, Careggi University Hospital, Florence, Italy. FAU - Buonamici, Francesco AU - Buonamici F AD - Department of Industrial Engineering, University of Florence, Florence, Italy. FAU - Piccardi, Benedetta AU - Piccardi B AD - Stroke Unit, Careggi University Hospital, Florence, Italy. FAU - Tudisco, Laura AU - Tudisco L AD - Stroke Unit, Careggi University Hospital, Florence, Italy. FAU - Cramaro, Antonella AU - Cramaro A AD - Neurosonology Unit, Careggi University Hospital, Florence, Italy. FAU - Trapani, Sara AU - Trapani S AD - Neurosonology Unit, Careggi University Hospital, Florence, Italy. FAU - Pracucci, Giovanni AU - Pracucci G AD - NEUROFARBA Department, Neuroscience Section, University of Florence, Florence, Italy. FAU - Nencini, Patrizia AU - Nencini P AD - Stroke Unit, Careggi University Hospital, Florence, Italy. FAU - Di Mario, Carlo AU - Di Mario C AD - Structural Interventional Cardiology, Careggi University Hospital, Florence, Italy. AD - Department of Experimental & Clinical Medicine, University of Florence, Florence, Italy. FAU - Sarti, Cristina AU - Sarti C AD - NEUROFARBA Department, Neuroscience Section, University of Florence, Florence, Italy. AD - Stroke Unit, Careggi University Hospital, Florence, Italy. LA - eng PT - Journal Article DEP - 20230825 PL - Italy TA - Neurol Sci JT - Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology JID - 100959175 SB - IM MH - Humans MH - *Foramen Ovale, Patent/complications/surgery MH - Neoplasm Recurrence, Local/complications MH - *Stroke/diagnosis MH - Brain MH - Secondary Prevention/methods MH - Hospitals MH - Quality Control MH - Treatment Outcome MH - Recurrence OTO - NOTNLM OT - Closure OT - Heart and brain team OT - Ischemic stroke OT - Multidisciplinary OT - PFO OT - Patent foramen ovale EDAT- 2023/08/25 12:43 MHDA- 2024/01/18 06:42 CRDT- 2023/08/25 11:10 PHST- 2023/04/23 00:00 [received] PHST- 2023/08/16 00:00 [accepted] PHST- 2024/01/18 06:42 [medline] PHST- 2023/08/25 12:43 [pubmed] PHST- 2023/08/25 11:10 [entrez] AID - 10.1007/s10072-023-07023-0 [pii] AID - 10.1007/s10072-023-07023-0 [doi] PST - ppublish SO - Neurol Sci. 2024 Feb;45(2):671-678. doi: 10.1007/s10072-023-07023-0. Epub 2023 Aug 25. PMID- 37620956 OWN - NLM STAT- MEDLINE DCOM- 20230828 LR - 20231121 IS - 1749-8090 (Electronic) IS - 1749-8090 (Linking) VI - 18 IP - 1 DP - 2023 Aug 24 TI - Wedge resection versus lobectomy in T1 lung cancer patients: a propensity matched analysis. PG - 252 LID - 10.1186/s13019-023-02303-4 [doi] LID - 252 AB - OBJECTIVES: Performing wedge resection rather than lobectomy for primary lung cancer remains controversial. Recent studies demonstrate no survival advantage for non-anatomical resection compared to lobectomy in patients with early-stage lung cancer. The objective of this study was to investigate whether in patients with T1 tumours, non-anatomical wedge resection is associated with equivalent survival to lobectomy. METHODS: This was a retrospective cohort study of patients who underwent lung resection at the Lancashire Cardiac Centre between April 2005 and April 2018. Patients were subjected to multidisciplinary team discussion. The extent of resection was decided by the team based on British Thoracic Society guidelines. The primary outcome was overall survival. Propensity matching of patients with T1 tumours was also performed to determine whether differences in survival rates exist in a subset of these patients with balanced pre-operative characteristics. RESULTS: There were 187 patients who underwent non-anatomical wedge resection and 431 patients who underwent lobectomy. Cox modelling demonstrated no survival difference between groups for the first 1.6 years then a risk of death 3-fold higher for wedge resection group after 1.6 years (HR 3.14, CI 1.98-4.79). Propensity matching yielded 152 pairs for which 5-year survival was 66.2% for the lobectomy group and 38.5% for the non-anatomical wedge group (SMD = 0.58, p = 0.003). CONCLUSIONS: Non-anatomical wedge resection was associated with significantly reduced 5-year survival compared to lobectomy in matched patients. Lobectomy should remain the standard of care for patients with early-stage lung cancer who are fit enough to undergo surgical resection. CI - (c) 2023. BioMed Central Ltd., part of Springer Nature. FAU - Moon, Robert J AU - Moon RJ AD - Department of Cardiothoracic Surgery, Lancashire Cardiac Centre, Blackpool Victoria Hospital, Blackpool, UK. robert.moon@nhs.net. FAU - Taylor, Rebecca AU - Taylor R AD - Department of Cardiothoracic Surgery, Lancashire Cardiac Centre, Blackpool Victoria Hospital, Blackpool, UK. FAU - Miklavc, Pika AU - Miklavc P AD - School of Science, Engineering and Environment, University of Salford, Manchester, UK. FAU - Mehdi, Syed B AU - Mehdi SB AD - Department of Respiratory Medicine, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK. FAU - Grant, Stuart W AU - Grant SW AD - Department of Cardiothoracic Surgery, Lancashire Cardiac Centre, Blackpool Victoria Hospital, Blackpool, UK. FAU - Bittar, Mohamad Nidal AU - Bittar MN AD - Department of Cardiothoracic Surgery, Lancashire Cardiac Centre, Blackpool Victoria Hospital, Blackpool, UK. LA - eng PT - Journal Article DEP - 20230824 PL - England TA - J Cardiothorac Surg JT - Journal of cardiothoracic surgery JID - 101265113 SB - IM MH - Humans MH - Retrospective Studies MH - *Lung Neoplasms/surgery MH - Heart MH - Thorax PMC - PMC10464042 OTO - NOTNLM OT - Cancer OT - Lobectomy OT - Lung OT - Resection OT - Survival OT - Wedge COIS- None of the authors have any competing interests. EDAT- 2023/08/25 00:42 MHDA- 2023/08/28 06:42 PMCR- 2023/08/24 CRDT- 2023/08/24 23:56 PHST- 2022/04/19 00:00 [received] PHST- 2023/06/10 00:00 [accepted] PHST- 2023/08/28 06:42 [medline] PHST- 2023/08/25 00:42 [pubmed] PHST- 2023/08/24 23:56 [entrez] PHST- 2023/08/24 00:00 [pmc-release] AID - 10.1186/s13019-023-02303-4 [pii] AID - 2303 [pii] AID - 10.1186/s13019-023-02303-4 [doi] PST - epublish SO - J Cardiothorac Surg. 2023 Aug 24;18(1):252. doi: 10.1186/s13019-023-02303-4. PMID- 37619598 OWN - NLM STAT- MEDLINE DCOM- 20240605 LR - 20240730 IS - 1098-8785 (Electronic) IS - 0735-1631 (Linking) VI - 41 IP - S 01 DP - 2024 May TI - Structured Framework for Multidisciplinary Parent Counseling and Medical Interventions for Fetuses and Infants with Trisomy 13 or Trisomy 18. PG - e2666-e2673 LID - 10.1055/s-0043-1772748 [doi] AB - OBJECTIVE: Trisomy 13 (T13) and 18 (T18) are aneuploidies associated with multiple structural congenital anomalies and high rates of fetal demise and neonatal mortality. Historically, patients with either one of these diagnoses have been treated similarly with exclusive comfort care rather than invasive interventions or intensive care, despite a wide phenotypic variation and substantial variations in survival length. However, surgical interventions have been on the rise in this population in recent years without clearly elucidated selection criterion. Our objective was to create a standardized approach to counseling expectant persons and parents of newborns with T13/T18 in order to provide collaborative and consistent counseling and thoughtful approach to interventions such as surgery. STUDY DESIGN: This article describes our process and presents our resulting clinical care guideline. RESULTS: We formed a multi- and interdisciplinary committee. We used published literature when available and otherwise expert opinion to develop an approach to care featuring individualized assessment of the patient to estimate qualitative mortality risk and potential to benefit from intensive care and/or surgeries centered within an ethical framework. CONCLUSION: Through multidisciplinary collaboration, we successfully created a patient-centered approach for counseling families facing a diagnosis of T13/T18. Other institutions may use our approach as a model for developing their own standardized approach. KEY POINTS: . Trisomy 13 and trisomy 18 are associated with high but variable morbidity and mortality.. . Research on which patients are most likely to benefit from surgery is lacking.. . We present our institution's framework to counsel families with fetal/neonatal T13/T18.. CI - Thieme. All rights reserved. FAU - Kim, Amanda J H AU - Kim AJH AD - Department of Pediatrics, Oregon Health and Science University, Portland, Oregon. FAU - Marshall, Mayme AU - Marshall M AD - Department of Pediatrics, Oregon Health and Science University, Portland, Oregon. FAU - Gievers, Ladawna AU - Gievers L AD - Department of Pediatrics, Oregon Health and Science University, Portland, Oregon. FAU - Tate, Tyler AU - Tate T AD - Department of Pediatrics, Oregon Health and Science University, Portland, Oregon. FAU - Taub, Sara AU - Taub S AD - Department of Pediatrics, Oregon Health and Science University, Portland, Oregon. FAU - Dukhovny, Stephanie AU - Dukhovny S AD - Department of Obstetrics and Gynecology, Oregon Health and Science University, Portland, Oregon. FAU - Ronai, Christina AU - Ronai C AD - Department of Pediatrics, Oregon Health and Science University, Portland, Oregon. FAU - Madriago, Erin J AU - Madriago EJ AD - Department of Pediatrics, Oregon Health and Science University, Portland, Oregon. LA - eng PT - Journal Article DEP - 20230824 PL - United States TA - Am J Perinatol JT - American journal of perinatology JID - 8405212 SB - IM MH - Humans MH - *Trisomy 18 Syndrome/therapy/diagnosis MH - *Trisomy 13 Syndrome/therapy/diagnosis MH - *Chromosomes, Human, Pair 18 MH - *Trisomy/diagnosis MH - Infant, Newborn MH - Female MH - *Parents MH - *Chromosomes, Human, Pair 13 MH - *Chromosome Disorders/diagnosis/therapy MH - Pregnancy MH - Counseling MH - Genetic Counseling COIS- None declared. EDAT- 2023/08/25 00:42 MHDA- 2024/06/05 06:42 CRDT- 2023/08/24 19:03 PHST- 2024/06/05 06:42 [medline] PHST- 2023/08/25 00:42 [pubmed] PHST- 2023/08/24 19:03 [entrez] AID - 10.1055/s-0043-1772748 [doi] PST - ppublish SO - Am J Perinatol. 2024 May;41(S 01):e2666-e2673. doi: 10.1055/s-0043-1772748. Epub 2023 Aug 24. PMID- 37611988 OWN - NLM STAT- MEDLINE DCOM- 20230825 LR - 20240929 IS - 2213-1787 (Electronic) IS - 2213-1779 (Print) IS - 2213-1779 (Linking) VI - 11 IP - 8 Pt 2 DP - 2023 Aug TI - Mitral Interventions in Heart Failure. PG - 1055-1069 LID - S2213-1779(23)00412-2 [pii] LID - 10.1016/j.jchf.2023.07.016 [doi] AB - Patients with heart failure with reduced ejection fraction who have secondary mitral regurgitation (SMR) have poorer outcomes and quality of life than those without SMR. Guideline-directed medical therapy is the cornerstone of SMR treatment. Careful evaluation of landmark trials using mitral transcatheter edge-to-edge repair in SMR has led to an improved understanding of who will benefit from percutaneous interventions with emphasis on a multidisciplinary approach. The success with mitral transcatheter edge-to-edge repair in SMR has also spurred the evaluation of its role in populations that were not initially studied, such as end-stage heart failure and cardiogenic shock. A spectrum of transcatheter devices in development and clinical trials promise to further provide a growing array of management options for heart failure with reduced ejection fraction patients with symptomatic SMR. CI - Copyright (c) 2023 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. FAU - Lander, Matthew M AU - Lander MM AD - Cardiovascular Institute at Allegheny Health Network, Pittsburgh, Pennsylvania, USA. FAU - Brener, Michael I AU - Brener MI AD - Division of Cardiology at Columbia University Irving Medical Center, New York, New York, USA. FAU - Goel, Kashish AU - Goel K AD - Vanderbilt Heart and Vascular Institute, Vanderbilt University School of Medicine, Nashville, Tennessee, USA. FAU - Tang, Paul C AU - Tang PC AD - Department of Cardiac Surgery, University of Michigan, Ann Arbor, Michigan, USA. FAU - Verlinden, Nathan J AU - Verlinden NJ AD - Cardiovascular Institute at Allegheny Health Network, Pittsburgh, Pennsylvania, USA. FAU - Zalawadiya, Sandip AU - Zalawadiya S AD - Vanderbilt Heart and Vascular Institute, Vanderbilt University School of Medicine, Nashville, Tennessee, USA. FAU - Lindenfeld, JoAnn AU - Lindenfeld J AD - Vanderbilt Heart and Vascular Institute, Vanderbilt University School of Medicine, Nashville, Tennessee, USA. FAU - Kanwar, Manreet K AU - Kanwar MK AD - Cardiovascular Institute at Allegheny Health Network, Pittsburgh, Pennsylvania, USA. Electronic address: manreet.kanwar@ahn.org. LA - eng GR - R01 HL164416/HL/NHLBI NIH HHS/United States GR - R01 HL166140/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review PL - United States TA - JACC Heart Fail JT - JACC. Heart failure JID - 101598241 SB - IM CIN - JACC Heart Fail. 2023 Dec;11(12):1771. doi: 10.1016/j.jchf.2023.09.020. PMID: 38056977 MH - Humans MH - *Heart Failure/therapy MH - Quality of Life MH - Shock, Cardiogenic MH - *Mitral Valve Insufficiency/complications/surgery PMC - PMC11433966 MID - NIHMS1997836 OTO - NOTNLM OT - MitraClip OT - guideline-directed medical therapy OT - mitral transcatheter edge-to-edge repair OT - secondary mitral regurgitation OT - transcatheter mitral valve replacement COIS- Funding Support and Author Disclosures Dr Lander has served as an advisory board member for Abiomed; and has received speaker fees from Abbott. Dr Brener has received consulting fees from Artract and Osprey Medical. Dr Goel has received consulting and proctoring fees from Edwards Lifesciences and Abbott. Dr Zalawadiya has received consulting fees from Vectorius, ADI, and Endotronix. Dr Lindenfeld has received consulting fees from Abbott, Alleviant, AstraZeneca, Boston Scientific, CVRx, Edwards Lifesciences, Merck, Medtronic, VWave, Biotronik, Vascular Dynamics, Cordio, Vectorius, and Whiteswell; and has received grant funding from AstraZeneca. Dr Kanwar has served as an advisory board member for Abiomed, CareDx, and Corwave; and has served as a speaker for Abiomed. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2023/08/24 00:42 MHDA- 2023/08/25 06:42 PMCR- 2024/09/27 CRDT- 2023/08/23 20:57 PHST- 2023/05/23 00:00 [received] PHST- 2023/07/10 00:00 [revised] PHST- 2023/07/19 00:00 [accepted] PHST- 2023/08/25 06:42 [medline] PHST- 2023/08/24 00:42 [pubmed] PHST- 2023/08/23 20:57 [entrez] PHST- 2024/09/27 00:00 [pmc-release] AID - S2213-1779(23)00412-2 [pii] AID - 10.1016/j.jchf.2023.07.016 [doi] PST - ppublish SO - JACC Heart Fail. 2023 Aug;11(8 Pt 2):1055-1069. doi: 10.1016/j.jchf.2023.07.016. PMID- 37609760 OWN - NLM STAT- MEDLINE DCOM- 20231023 LR - 20231023 IS - 1816-5370 (Electronic) IS - 0218-4923 (Linking) VI - 31 IP - 8 DP - 2023 Oct TI - Optimizing aortic valve prosthesis selection in patients with obesity: Institutional experience with multidisciplinary perspective. PG - 667-674 LID - 10.1177/02184923231197022 [doi] AB - BACKGROUND: Aortic valve diseases are life-threatening conditions with increasing prevalence worldwide. Risk factors include gender, age, hypertension, dyslipidemia, and type 2 diabetes. Obesity is closely related to these risk factors and has been linked to a higher risk of developing aortic valve diseases. However, there is no specific guideline for managing aortic valve disease in patients with obesity, and the choice of valve type remains uncertain. METHODS: A total of 130 patients with obesity who met the inclusion criteria underwent surgical aortic valve replacement. The patients were divided into two groups based on the type of prosthesis used. Among the study cohort, 50 patients received a bioprosthetic valve, while 80 patients received a mechanical valve. We compared these groups in terms of perioperative characteristics and follow-up results. Statistical significance was determined using a p-value threshold of 0.05. RESULTS: There were no significant differences in age, gender, body mass index, or cardiac comorbidities between the two groups. Preoperative blood results and echo findings also showed no significant differences. Intraoperative characteristics and postoperative outcomes, including mortality and acute kidney injury, did not differ significantly between the groups. In addition, BHVG patients had shorter ICU stays compared to MHVG patients without significance. CONCLUSION: Deliberate consideration is crucial when selecting valves for obese patients, particularly those with class II obesity. This is due to the potential influence of obesity on valve types, as well as the need to account for the possibility of bariatric surgery and its potential effects. FAU - Balkanay, Ozan Onur AU - Balkanay OO AD - Department of Cardiovascular Surgery Cerrahpasa School of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey. RINGGOLD: 532719 FAU - Bulut, Halil Ibrahim AU - Bulut HI AUID- ORCID: 0000-0002-9076-8296 AD - Cerrahpasa School of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey. RINGGOLD: 532719 FAU - Albrahimi, Ergida AU - Albrahimi E AD - Department of Cardiovascular Surgery Cerrahpasa School of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey. RINGGOLD: 532719 FAU - Mirizade, Miri AU - Mirizade M AD - Department of Cardiovascular Surgery Cerrahpasa School of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey. RINGGOLD: 532719 FAU - Yenigun, Abdulgani Orhun AU - Yenigun AO AD - Department of Cardiovascular Surgery Cerrahpasa School of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey. RINGGOLD: 532719 FAU - Tomey, Daniel AU - Tomey D AD - Department of General Surgery, Houston Methodist Hospital, Houston, TX, USA. RINGGOLD: 23534 AD - Houston Methodist, Institute for Technology, Innovation & Education, Houston, TX, USA. RINGGOLD: 23534 FAU - Bistre, Jacques AU - Bistre J AUID- ORCID: 0000-0002-5628-4562 AD - Dorrington Medical Associates, Houston, TX, USA. RINGGOLD: 538001 FAU - Oviedo, Rodolfo J AU - Oviedo RJ AD - Dorrington Medical Associates, Houston, TX, USA. RINGGOLD: 538001 AD - Weill Cornell Medical College, General Surgery, New York, NY, USA. AD - Texas A&M University College of Medicine, General Surgery, Bryan, TX, USA. FAU - Tel Ustunisik, Cigdem AU - Tel Ustunisik C AD - Department of Cardiovascular Surgery Cerrahpasa School of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey. RINGGOLD: 532719 FAU - Arapi, Berk AU - Arapi B AD - Department of Cardiovascular Surgery Cerrahpasa School of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey. RINGGOLD: 532719 FAU - Goksedef, Deniz AU - Goksedef D AD - Department of Cardiovascular Surgery Cerrahpasa School of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey. RINGGOLD: 532719 FAU - Omeroglu, Suat Nail AU - Omeroglu SN AD - Department of Cardiovascular Surgery Cerrahpasa School of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey. RINGGOLD: 532719 FAU - Ipek, Gokhan AU - Ipek G AD - Department of Cardiovascular Surgery Cerrahpasa School of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey. RINGGOLD: 532719 LA - eng PT - Journal Article DEP - 20230823 PL - England TA - Asian Cardiovasc Thorac Ann JT - Asian cardiovascular & thoracic annals JID - 9503417 SB - IM MH - Humans MH - Aortic Valve/diagnostic imaging/surgery MH - *Heart Valve Diseases/complications/diagnostic imaging/surgery MH - *Heart Valve Prosthesis Implantation MH - *Diabetes Mellitus, Type 2/etiology/surgery MH - *Heart Valve Prosthesis MH - Obesity/complications/diagnosis MH - *Aortic Valve Disease/etiology/surgery MH - Prosthesis Design MH - *Bioprosthesis MH - Retrospective Studies MH - Treatment Outcome OTO - NOTNLM OT - Aortic valve OT - bioprosthetic OT - blood OT - cardiac OT - coagulation/anticoagulation OT - eg OT - etc.) OT - heart valve prosthesis (specify type OT - mechanical OT - obesity (incl related subjects) OT - replacement EDAT- 2023/08/23 06:42 MHDA- 2023/10/23 12:44 CRDT- 2023/08/23 04:31 PHST- 2023/10/23 12:44 [medline] PHST- 2023/08/23 06:42 [pubmed] PHST- 2023/08/23 04:31 [entrez] AID - 10.1177/02184923231197022 [doi] PST - ppublish SO - Asian Cardiovasc Thorac Ann. 2023 Oct;31(8):667-674. doi: 10.1177/02184923231197022. Epub 2023 Aug 23. PMID- 37608646 OWN - NLM STAT- MEDLINE DCOM- 20240118 LR - 20260127 IS - 1839-3535 (Electronic) IS - 1037-6178 (Linking) VI - 59 IP - 6 DP - 2023 Dec TI - Pain-related fear among adult patients undergoing open-heart surgery: an interpretative phenomenological analysis. PG - 462-477 LID - 10.1080/10376178.2023.2249127 [doi] AB - BACKGROUND: One of the sources of anxiety and fear among patients undergoing open-heart surgery is the possibility of experiencing pain, such as sternotomy-related chest pain. Giving them the chance to express their feelings about the potential pain may be effective in reducing their anxiety and may support their coping strategies. OBJECTIVES: To examine pain-related fear among patients undergoing open-heart surgery and to understand the underlying reasons of their fears. METHODS: A qualitative interview based on Heidegger's interpretative phenomenological approach was conducted adhering to the COREQ guidelines. Sixteen patients who were undergoing open-heart surgery in the following day were interviewed at the cardiovascular surgery ward of a university hospital. The organization and mapping of the qualitative data was done by using ATLAS.ti 8.0. RESULTS: The patients who were afraid of experiencing pain after surgery seemed to be more concerned about open-heart surgery itself (such as pain from sternotomy and chest tubes) and the possibility of prolongation of postoperative pain. To cope with these fears, the patients employed a variety of social and self-coping strategies. Trusting the healthcare team, having a high pain tolerance, and having personal thoughts that take precedence over pain-related fear were the key factors explaining not being afraid of experiencing pain. CONCLUSIONS: This study provides a deeper understanding of the underlying reasons and the needs of patients in controlling their pain-related fears before open-heart surgery. Trusting the healthcare professionals is one of the main factors for patients to control their pain-related fears. To develop a supportive sense of trust and to help patients in controlling their pain-related fears, surgical nurses must dedicate enough time for understanding patients' concerns while planning their nursing care plans. Future studies may focus on exploring the role of nursing interventions and multidisciplinary team approaches on the management of preoperative pain-related fear. FAU - Unver, Seher AU - Unver S AUID- ORCID: 0000-0003-1320-1437 AD - Faculty of Health Sciences, Department of Surgical Nursing, Trakya University, Edirne, Turkey. FAU - Yildirim, Meltem AU - Yildirim M AUID- ORCID: 0000-0002-9699-3099 AD - Institute for Research and Innovation in Life Sciences and Health in Central Catalonia (IRIS-CC), University of Vic-Central University of Catalonia (UVic-UCC), Vic, Spain. FAU - Eyi, Semra AU - Eyi S AUID- ORCID: 0000-0003-0680-1063 AD - Faculty of Health Sciences, Department of Surgical Nursing, Osmangazi University, Eskisehir, Turkey. FAU - Huseyin, Serhat AU - Huseyin S AUID- ORCID: 0000-0003-4118-040X AD - Medicine Faculty, Department of Cardiovascular Surgery, Trakya University, Edirne, Turkey. LA - eng PT - Journal Article DEP - 20230822 PL - United States TA - Contemp Nurse JT - Contemporary nurse JID - 9211867 RN - Phobia, Specific MH - Adult MH - Humans MH - *Anxiety/etiology MH - Fear MH - Postoperative Pain/etiology MH - *Cardiac Surgical Procedures/adverse effects MH - *Phobic Disorders OTO - NOTNLM OT - open-heart surgery OT - pain-related fear OT - qualitative study OT - surgical nursing EDAT- 2023/08/23 06:42 MHDA- 2024/01/18 06:42 CRDT- 2023/08/23 02:32 PHST- 2024/01/18 06:42 [medline] PHST- 2023/08/23 06:42 [pubmed] PHST- 2023/08/23 02:32 [entrez] AID - 10.1080/10376178.2023.2249127 [doi] PST - ppublish SO - Contemp Nurse. 2023 Dec;59(6):462-477. doi: 10.1080/10376178.2023.2249127. Epub 2023 Aug 22. PMID- 37607812 OWN - NLM STAT- MEDLINE DCOM- 20240814 LR - 20260913 IS - 1468-201X (Electronic) IS - 1355-6037 (Print) IS - 1355-6037 (Linking) VI - 110 IP - 17 DP - 2024 Aug 14 TI - Management of secondary mitral regurgitation: from drugs to devices. PG - 1099-1106 LID - 10.1136/heartjnl-2022-322001 [doi] AB - Severe secondary mitral regurgitation carries a poor prognosis with one in five patients dying within 12 months of diagnosis. Fortunately, there are now a number of safe and effective therapies available to improve outcomes. Here, we summarise the most up-to-date treatments. Optimal guideline-directed medical therapy is the mainstay therapy and has been shown to reduce the severity of mitral regurgitation in 40-45% of patients. Rapid medication titration protocols reduce heart failure hospitalisation and facilitate earlier referral for device therapy. The pursuit of sinus rhythm in patients with atrial fibrillation has been shown to significantly reduce mitral regurgitation severity, as has the use of cardiac resynchronisation devices in patients who meet guideline-directed criteria. Finally, we highlight the key role of mitral valve intervention, particularly transcatheter edge-to-edge repair (TEER) for management of moderate-severe mitral regurgitation in carefully selected patients with poor left ventricular systolic function, with a number needed to treat of 3.1 to reduce heart failure hospitalisation and 5.9 to reduce all-cause death. To slow the rapid accumulation of morbidity and mortality, we advocate a proactive approach with accelerated medical optimisation, followed by management of atrial fibrillation and cardiac resynchronisation therapy if indicated, then, rapid referral to the Heart Team for consideration of mitral valve intervention in patients with ongoing symptoms and at least moderate-severe mitral regurgitation. Mitral TEER has been shown to be 'reasonably cost-effective' (but not cost-saving) in the UK in selected patients, although TEER remains underused with only 6.5 procedures per million population (pmp) compared with Germany (77 pmp), Switzerland (44 pmp) and the USA (32 pmp). CI - (c) Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Barnes, Cara AU - Barnes C AUID- ORCID: 0000-0002-8308-1592 AD - Oxford Heart Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. FAU - Sharma, Harish AU - Sharma H AUID- ORCID: 0000-0002-0525-3520 AD - Cardiology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. FAU - Gamble, James AU - Gamble J AD - Oxford Heart Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. FAU - Dawkins, Sam AU - Dawkins S AUID- ORCID: 0000-0001-9457-0570 AD - Oxford Heart Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK sam@dawkins.org. LA - eng PT - Journal Article PT - Review DEP - 20240814 PL - England TA - Heart JT - Heart (British Cardiac Society) JID - 9602087 SB - IM MH - *Mitral Valve Insufficiency/therapy/etiology MH - Humans MH - Cardiac Resynchronization Therapy/methods MH - Mitral Valve/surgery MH - Heart Valve Prosthesis Implantation/methods MH - Treatment Outcome PMC - PMC11347202 OTO - NOTNLM OT - Heart Failure OT - Heart Valve Prosthesis OT - Mitral Valve Insufficiency COIS- Competing interests: SD has received honoraria from Abbott Cardiovascular and Edwards Lifesciences. EDAT- 2023/08/23 00:42 MHDA- 2024/08/15 00:42 PMCR- 2024/08/27 CRDT- 2023/08/22 21:03 PHST- 2024/08/15 00:42 [medline] PHST- 2023/08/23 00:42 [pubmed] PHST- 2023/08/22 21:03 [entrez] PHST- 2024/08/27 00:00 [pmc-release] AID - heartjnl-2022-322001 [pii] AID - 10.1136/heartjnl-2022-322001 [doi] PST - epublish SO - Heart. 2024 Aug 14;110(17):1099-1106. doi: 10.1136/heartjnl-2022-322001. PMID- 37601732 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230823 IS - 1756-1485 (Electronic) IS - 1756-1477 (Print) IS - 1756-1485 (Linking) VI - 18 DP - 2023 TI - Transcatheter Mitral Valve Repair via MitraClip in Patients Aged <65 Years: Multicentre 2-year Outcomes. PG - e03 LID - 10.15420/icr.2021.28 [doi] LID - e03 AB - BACKGROUND: Transcatheter mitral valve repair (TMVR) using the MitraClip has become a well-established interventional therapy and is usually performed in elderly patients. The objective of this study was to assess 2-year clinical outcomes of TMVR in patients aged <65 years at three heart centres with severe mitral regurgitation (MR) and no surgical options. METHODS: A retrospective study analysed data of 36 patients aged <65 years treated with TMVR . All patients were refused surgery by Heart Team decision. Baseline MR was assessed by biplane vena contracta width in two perpendicular views (mean 8.35 +/- 1.87 mm). Degenerative MR was detected in 11 patients (30.6%); functional MR was detected in 25 patients (69.4%). RESULTS: Acute procedural success was accomplished in 88.9% of patients. No procedure-related mortality during the first 30 days was detected. Over an average of 2 years of follow-up, all-cause mortality was 19.4% and cardiovascular death was 11.1% owing to advanced heart failure. The average follow-up period was 25.8 months (median was 20 months). Statistically significant difference (p-value <0.01) was detected for N-terminal prohormone of brain natriuretic peptide (pg/ml) at baseline (mean 9,870 +/- 10,819; median 7,748) compared to follow-up visits (mean 7,645 +/- 11,292; median 3,263). New York Heart Association functional class improvement was achieved in 69% of patients. A second intervention (reclipping) was required in two patients to correct recurrent significant MR. CONCLUSION: TMVR in patients aged <65 years refused surgical repair provides satisfactory clinical outcomes at 2 years. Future studies should evaluate the outcomes of MitraClip in this population in a larger cohort. CI - Copyright (c) The Author(s), 2023. Published by Radcliffe Group Ltd. FAU - Mohammed, Hassan Mh AU - Mohammed HM AD - Cardiology Department, Faculty of Medicine, Minia University Minia, Egypt. AD - Westfalen Heart Center Dortmund, Germany. FAU - Farah, Ahmed AU - Farah A AD - Westfalen Heart Center Dortmund, Germany. FAU - Plicht, Bjoern AU - Plicht B AD - Westfalen Heart Center Dortmund, Germany. FAU - El-Garhy, Mohammad AU - El-Garhy M AD - Central Clinic Bad Berka Bad Berka, Germany. FAU - Janicke, Ilse AU - Janicke I AD - Duisburg Heart Center Duisburg, Germany. FAU - Yousef, Amr AU - Yousef A AD - Duisburg Heart Center Duisburg, Germany. FAU - AbdelWahab, Mohammad Abdelkader AU - AbdelWahab MA AD - Cardiology Department, Faculty of Medicine, Minia University Minia, Egypt. FAU - Taha, Nasser M AU - Taha NM AD - Cardiology Department, Faculty of Medicine, Minia University Minia, Egypt. FAU - Schoels, Wolfgang AU - Schoels W AD - Duisburg Heart Center Duisburg, Germany. FAU - Buck, Thomas AU - Buck T AD - Westfalen Heart Center Dortmund, Germany. LA - eng PT - Journal Article DEP - 20230217 PL - England TA - Interv Cardiol JT - Interventional cardiology (London, England) JID - 101559687 PMC - PMC10433109 OTO - NOTNLM OT - MitraClip OT - Transcatheter mitral valve repair OT - mitral regurgitation OT - mitral valve disease OT - percutaneous mitral valve intervention COIS- Disclosure: TB has received honoraria payments from Philips Medical Systems, BP has received lecture honoraria by Abbott Laboratories and Philips Medical Systems. HMHM received a scholarship grant for living and travel costs to conduct this research work in Germany from the Egyptian ministry of higher education and Minia University in Egypt. All other authors have no conflicts of interest to declare. Informed consent: All patients have given informed consent Data availability: The data that support the findings of this study are available from the corresponding author upon reasonable request. Ethics: This study was performed in lines with the principles of the Declaration of Helsinki. The study received ethics approval from the Minia University Research Ethics Committee (Reference Number: 081064M). Authors' contributions: Conceptualisation: AF, ME; Data Curation: HMHM, ME, AY; formal analysis: HMHM, AF, ME, AY; funding acquisition: HMHM; investigation: HMHM, AF, MAA, NMT, WS, TB; methodology: HMHM, AF, MAA, NMT, WS, TB;project administration: WS, TB; resources: BP, IJ, AY; software: BP, IJ, AY; supervision: MAA, NMT, WS, TB; validation: BP, IJ; visualisation: AF, BP, IJ; writing - original draft preparation: HMHM, AF, BP, WS, TB; writing - review and editing: HMHM, MAA, NMT EDAT- 2023/08/21 06:42 MHDA- 2023/08/21 06:43 PMCR- 2023/02/17 CRDT- 2023/08/21 05:05 PHST- 2021/10/04 00:00 [received] PHST- 2022/09/10 00:00 [accepted] PHST- 2023/08/21 06:43 [medline] PHST- 2023/08/21 06:42 [pubmed] PHST- 2023/08/21 05:05 [entrez] PHST- 2023/02/17 00:00 [pmc-release] AID - 10.15420/icr.2021.28 [doi] PST - epublish SO - Interv Cardiol. 2023 Feb 17;18:e03. doi: 10.15420/icr.2021.28. eCollection 2023. PMID- 37595855 OWN - NLM STAT- MEDLINE DCOM- 20231216 LR - 20250626 IS - 1535-6280 (Electronic) IS - 0146-2806 (Linking) VI - 49 IP - 1 Pt A DP - 2024 Jan TI - Clinical Outcomes With Nurse-Coordinated Multidisciplinary Care in Patients With Heart Failure: A Systematic Review and Meta-analysis. PG - 102041 LID - S0146-2806(23)00458-9 [pii] LID - 10.1016/j.cpcardiol.2023.102041 [doi] AB - The American Heart Association (AHA) and the European Society of Cardiology (ESC) recommend nurse-inclusive multidisciplinary care for patients with heart failure (HF). However, there is no meta-analysis that focuses specifically on the impact of nurse-coordinated multidisciplinary care. Considering this literature gap, we conducted this review that seeks to systematically synthesize the current evidence available regarding the impact of nurse-coordinated multidisciplinary care on clinical outcomes in patients with HF. A comprehensive search was done using PubMed/Medline, Cochrane Library, and EMBASE from inception till July 2023 for randomized controlled trials (RCTs) comparing nurse-coordinated multidisciplinary care with usual care in adult patients (>18 years) with acute or chronic HF. Data about all-cause mortality, HF-related hospitalizations, and all-cause hospitalizations was extracted, pooled, and analyzed. Forrest plots were generated using the random effects model. A total of 30 RCTs were included in the analysis with a total of 7950 HF patients. Our pooled analysis demonstrated a significant reduction in all-cause mortality in HF patients who received nurse-coordinated multidisciplinary care (RR = 0.80, 95% CI: 0.72-0.88, P = 0.0001). Similarly, there was a significantly lesser risk of HF-related hospitalizations (RR = 0.56, 95% CI: 0.45-0.71, P = 0.00001) and all-cause hospitalizations (RR = 0.78, 95% CI: 0.70-0.87, P = 0.0001) among HF patients with nurse-coordinated multidisciplinary care as compared to the usual care. Nurse-coordinated multidisciplinary care significantly reduces the risk of all-cause mortality, HF-related hospitalizations, and all-cause hospitalizations in HF patients' posthospital discharge. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Ahmed, Mushood AU - Ahmed M AD - Department of Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan. FAU - Shafiq, Aimen AU - Shafiq A AD - Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan. FAU - Zahid, Maheen AU - Zahid M AD - Department of Medicine, Liaquat University of Medical and Health Sciences, Hyderabad, Pakistan. FAU - Dhawadi, Siwar AU - Dhawadi S AD - Department of Medicine, Faculty of Medicine Monastir, Mosastir, Tunisia. FAU - Javaid, Hira AU - Javaid H AD - Department of Medicine, Allama Iqbal Medical College, Lahore, Pakistan. FAU - Rehman, Muhammad Ebaad Ur AU - Rehman MEU AD - Department of Medicine, Allama Iqbal Medical College, Lahore, Pakistan. FAU - Chachar, Muhammad Azhar AU - Chachar MA AD - Department of Medicine, Ziauddin Medical University, Karachi, Pakistan. FAU - Siddiqi, Ahmed Kamal AU - Siddiqi AK AD - Department of Medicine, Ziauddin Medical University, Karachi, Pakistan. Electronic address: Ahmedsiddiqi2020@gmail.com. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20230817 PL - Netherlands TA - Curr Probl Cardiol JT - Current problems in cardiology JID - 7701802 SB - IM MH - United States MH - Humans MH - *Heart Failure/therapy MH - Hospitalization MH - Chronic Disease COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2023/08/19 11:42 MHDA- 2023/12/17 09:44 CRDT- 2023/08/18 19:26 PHST- 2023/08/13 00:00 [received] PHST- 2023/08/15 00:00 [accepted] PHST- 2023/12/17 09:44 [medline] PHST- 2023/08/19 11:42 [pubmed] PHST- 2023/08/18 19:26 [entrez] AID - S0146-2806(23)00458-9 [pii] AID - 10.1016/j.cpcardiol.2023.102041 [doi] PST - ppublish SO - Curr Probl Cardiol. 2024 Jan;49(1 Pt A):102041. doi: 10.1016/j.cpcardiol.2023.102041. Epub 2023 Aug 17. PMID- 37595615 OWN - NLM STAT- MEDLINE DCOM- 20231101 LR - 20240109 IS - 1098-9048 (Electronic) IS - 1069-3424 (Linking) VI - 44 IP - 6 DP - 2023 Dec TI - Medical Emergencies in Pulmonary Hypertension. PG - 777-796 LID - 10.1055/s-0043-1770120 [doi] AB - The management of acute medical emergencies in patients with pulmonary hypertension (PH) can be challenging. Patients with preexisting PH can rapidly deteriorate due to right ventricular decompensation when faced with acute physiological challenges that would usually be considered low-risk scenarios. This review considers the assessment and management of acute medical emergencies in patients with PH, encompassing both pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), acknowledging these comprise the more severe groups of PH. Management protocols are described in a systems-based approach. Respiratory emergencies include pulmonary embolism, airways disease, and pneumonia; cardiac emergencies including arrhythmia and chest pain with acute myocardial infarction are discussed, alongside PH-specific emergencies such as pulmonary artery dissection and extrinsic coronary artery compression by a dilated proximal pulmonary artery. Other emergencies including sepsis, severe gastroenteritis with dehydration, syncope, and liver failure are also considered. We propose management recommendations for medical emergencies based on available evidence, international guidelines, and expert consensus. We aim to provide advice to the specialist alongside the generalist, and emergency doctors, nurses, and acute physicians in nonspecialist centers. A multidisciplinary team approach is essential in the management of patients with PH, and communication with local and specialist PH centers is paramount. Close hemodynamic monitoring during medical emergencies in patients with preexisting PH is vital, with early referral to critical care recommended given the frequent deterioration and high mortality in this setting. CI - Thieme. All rights reserved. FAU - Seitler, Samuel AU - Seitler S AD - National Pulmonary Hypertension Service, Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom. FAU - Dimopoulos, Konstantinos AU - Dimopoulos K AD - National Pulmonary Hypertension Service, Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom. AD - National Heart and Lung Institute, Imperial College London, London, United Kingdom. AD - Adult Congenital Heart Disease Service, Royal Brompton Hospital, London, United Kingdom. FAU - Ernst, Sabine AU - Ernst S AD - Adult Congenital Heart Disease Service, Royal Brompton Hospital, London, United Kingdom. FAU - Price, Laura C AU - Price LC AD - National Pulmonary Hypertension Service, Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom. AD - National Heart and Lung Institute, Imperial College London, London, United Kingdom. LA - eng PT - Journal Article PT - Review DEP - 20230818 PL - United States TA - Semin Respir Crit Care Med JT - Seminars in respiratory and critical care medicine JID - 9431858 SB - IM MH - Humans MH - *Hypertension, Pulmonary/diagnosis/etiology/therapy MH - Emergencies MH - Lung MH - *Pulmonary Embolism/complications/diagnosis/therapy MH - Pulmonary Artery MH - Chronic Disease COIS- None declared. EDAT- 2023/08/19 11:42 MHDA- 2023/11/01 12:42 CRDT- 2023/08/18 18:52 PHST- 2023/11/01 12:42 [medline] PHST- 2023/08/19 11:42 [pubmed] PHST- 2023/08/18 18:52 [entrez] AID - 10.1055/s-0043-1770120 [doi] PST - ppublish SO - Semin Respir Crit Care Med. 2023 Dec;44(6):777-796. doi: 10.1055/s-0043-1770120. Epub 2023 Aug 18. PMID- 37587977 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230818 IS - 2296-2360 (Print) IS - 2296-2360 (Electronic) IS - 2296-2360 (Linking) VI - 11 DP - 2023 TI - Vein of Galen aneurysmal malformation in newborns: a retrospective study to describe a paradigm of treatment and identify risk factors of adverse outcome in a referral center. PG - 1193738 LID - 10.3389/fped.2023.1193738 [doi] LID - 1193738 AB - BACKGROUND: Vein of Galen aneurysmal malformation (VGAM) is a rare cerebral vascular malformation associated with significant morbidity and mortality. Newborns with VGAM without adequate treatment may develop rapidly deteriorating high output heart failure (HOHF) and are at risk for severe neurological outcomes. OBJECTIVE: To describe the clinical course and management of newborns with VGAM, and identify which echocardiographic and neuroradiologic factors may be associated with severe heart failure at birth and adverse short term outcomes. METHODS: This is a single center retrospective cohort study including all consecutive newborns with VGAM admitted to Gaslini Children's Hospital between 2009 and 2022. We reviewed clinical data, intensive care support, fetal and neonatal cardiologic and neuroradiologic findings and we studied the association with severe HOHF, endovascular complications and death. RESULTS: Out of 40 newborns, 17 (42.5%) developed severe HOHF requiring early endovascular procedures. Medical treatment was focused on the main components of HOHF by providing inotropic support and peripheral vasodilation. Pulmonary vasodilators were avoided to reduce the negative effects of pulmonary overflow and prevent vascular remodeling. Reduction of the obligatory left to right shunt through the VGAM was possible only through endovascular treatment. Fetal cardiothoracic ratio was significantly associated with severe HOHF at birth and death. Cardiologic parameters of right ventricular overload, pulmonary hypertension and systemic steal were the leading findings associated with haemodynamic compromise at birth. The mediolateral diameter of the straight or falcine sinus at its shortest section (SS-MD), and arterial pseudofeeders were significantly associated with severe HOHF at birth in prenatal and postnatal assessments. None of the postnatal echocardiographic and MRI variables, nor a higher inotropic support were associated with major periprocedural complications or death. Mortality was due to palliation for congenital severe brain damage (4/40, 10%), or major periprocedural complications (3/40, 7.5%). None of the patients died due to HOHF and multiorgan failure. Overall survival at discharge was 82.5% (33/40). CONCLUSIONS: The complexity of neonatal VGAM pathophysiology requires a multidisciplinary approach, specialized intensive care management, and early endovascular treatment to reduce mortality and optimize clinical outcomes. Cardiologic and neuroradiologic parameters are key to define risk stratification and treatment strategies. CI - (c) 2023 Buratti, Mallamaci, Tuo, Severino, Tortora, Parodi, Rossi, Pasetti, Castellan, Capra, Romano, De Marco, Pavanello, Piatelli, Paladini, Calevo and Moscatelli. FAU - Buratti, Silvia AU - Buratti S AD - Neonatal and Pediatric Intensive Care Unit, Acceptance and Emergency Department, IRCCS Istituto Giannina Gaslini, Genoa, Italy. AD - Department of Neuroscience (DINOGMI), University of Genoa, Genoa, Italy. FAU - Mallamaci, Marisa AU - Mallamaci M AD - Neonatal and Pediatric Intensive Care Unit, Acceptance and Emergency Department, IRCCS Istituto Giannina Gaslini, Genoa, Italy. FAU - Tuo, Giulia AU - Tuo G AD - Pediatric Cardiology and Cardiac Surgery Unit, Surgery Department, IRCCS Istituto Giannina Gaslini, Genoa, Italy. FAU - Severino, Mariasavina AU - Severino M AD - Department of Neuroscience (DINOGMI), University of Genoa, Genoa, Italy. AD - Neuroradiology Unit, Services Department, IRCCS Istituto Giannina Gaslini, Genoa, Italy. FAU - Tortora, Domenico AU - Tortora D AD - Neuroradiology Unit, Services Department, IRCCS Istituto Giannina Gaslini, Genoa, Italy. FAU - Parodi, Costanza AU - Parodi C AD - Neuroradiology Unit, Services Department, IRCCS Istituto Giannina Gaslini, Genoa, Italy. FAU - Rossi, Andrea AU - Rossi A AD - Pediatric Cardiology and Cardiac Surgery Unit, Surgery Department, IRCCS Istituto Giannina Gaslini, Genoa, Italy. AD - Neuroradiology Unit, Services Department, IRCCS Istituto Giannina Gaslini, Genoa, Italy. FAU - Pasetti, Francesco AU - Pasetti F AD - Pediatric Radiology Unit, Services Department, IRCCS Istituto Giannina Gaslini, Genoa, Italy. FAU - Castellan, Lucio AU - Castellan L AD - Neuroradiology Unit, Diagnostic Imaging and Radiotherapy Department, San Martino Polyclinic Hospital, Genoa, Italy. FAU - Capra, Valeria AU - Capra V AD - Genomics and Clinical Genetics Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy. FAU - Romano, Ferruccio AU - Romano F AD - Genomics and Clinical Genetics Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy. FAU - De Marco, Patrizia AU - De Marco P AD - Medical Genetics Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy. FAU - Pavanello, Marco AU - Pavanello M AD - Neurosurgery Unit, Surgery Department, IRCCS Istituto Giannina Gaslini, Genoa, Italy. FAU - Piatelli, Gianluca AU - Piatelli G AD - Neurosurgery Unit, Surgery Department, IRCCS Istituto Giannina Gaslini, Genoa, Italy. FAU - Paladini, Dario AU - Paladini D AD - Fetal Medicine and Surgery Unit, Department Mother and Child, IRCCS Istituto Giannina Gaslini, Genova, Italy. FAU - Calevo, Maria Grazia AU - Calevo MG AD - Epidemiology, Biostatistics Unit, Scientific Direction, IRCCS Istituto Giannina Gaslini, Genova, Italy. FAU - Moscatelli, Andrea AU - Moscatelli A AD - Neonatal and Pediatric Intensive Care Unit, Acceptance and Emergency Department, IRCCS Istituto Giannina Gaslini, Genoa, Italy. AD - Neonatal and Pediatric Intensive Care Unit, Acceptance and Emergency Department, IRCCS Istituto Giannina Gaslini, Genoa, Italy. LA - eng PT - Journal Article DEP - 20230720 PL - Switzerland TA - Front Pediatr JT - Frontiers in pediatrics JID - 101615492 PMC - PMC10426803 OTO - NOTNLM OT - VGAM OT - brain MR OT - echocardiography OT - heart failure OT - newborn OT - outcome COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/08/17 06:42 MHDA- 2023/08/17 06:43 PMCR- 2023/07/20 CRDT- 2023/08/17 03:57 PHST- 2023/03/25 00:00 [received] PHST- 2023/07/03 00:00 [accepted] PHST- 2023/08/17 06:43 [medline] PHST- 2023/08/17 06:42 [pubmed] PHST- 2023/08/17 03:57 [entrez] PHST- 2023/07/20 00:00 [pmc-release] AID - 10.3389/fped.2023.1193738 [doi] PST - epublish SO - Front Pediatr. 2023 Jul 20;11:1193738. doi: 10.3389/fped.2023.1193738. eCollection 2023. PMID- 37586030 OWN - NLM STAT- MEDLINE DCOM- 20251021 LR - 20251021 IS - 1541-3764 (Electronic) IS - 0030-2228 (Linking) VI - 92 IP - 2 DP - 2025 Dec TI - Spiritual Well-Being and Death Anxiety: A Cross-Sectional Study Among Iranian Patients With Acute Coronary Syndrome. PG - 1066-1079 LID - 10.1177/00302228231195103 [doi] AB - Acute coronary syndrome (ACS) patients experience a tremendous psychological burden, typically in the form of death worry due to acute medical conditions and the possibility of mortality. The unfavourable conditions of ACS patients cause them to reconsider the meaning of life and their spiritual well-being. This study evaluated the association between death anxiety and spiritual well-being in a total of 241 ACS patients in Shahroud, northeast of Iran. The data were collected using the Templer Death Anxiety Scale, and the Spiritual Well-being Scale by convenience sampling method. All patients indicated a high degree of death anxiety, and roughly half reported a moderate level of spiritual well-being. There was a significant and direct correlation between death anxiety and spiritual well-being levels. Older age, single status, and non-smoking were other predictors of good spiritual well-being. A multidisciplinary health team should identify and implement approaches to promote spiritual well-being and reduce mental suffering. FAU - Mirhosseini, Seyedmohammad AU - Mirhosseini S AUID- ORCID: 0000-0002-2087-0164 AD - Department of Nursing, School of Nursing and Midwifery, Shahroud University of Medical Sciences, Shahroud, Iran. RINGGOLD: 154204 FAU - Montazeri, Ali AU - Montazeri A AD - Imam Hossein Hospital, Shahroud University of Medical Sciences, Shahroud, Iran. RINGGOLD: 154204 FAU - Khanmohammadi, Mobina AU - Khanmohammadi M AD - Student Research Committee, School of Nursing and Midwifery, Shahroud University of Medical Sciences, Shahroud, Iran. RINGGOLD: 154204 FAU - Qasemi Haddad, Aida AU - Qasemi Haddad A AD - Student Research Committee, School of Nursing and Midwifery, Shahroud University of Medical Sciences, Shahroud, Iran. RINGGOLD: 154204 FAU - Nadali, Javad AU - Nadali J AD - Department of Nursing, School of Nursing and Midwifery, Shahroud University of Medical Sciences, Shahroud, Iran. RINGGOLD: 154204 FAU - Basirinezhad, Mohammad Hasan AU - Basirinezhad MH AD - Department of Epidemiology and Biostatistics, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. RINGGOLD: 48516 FAU - Mohebbi, Sara AU - Mohebbi S AD - Student Research Committee, School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran. RINGGOLD: 154204 FAU - Ebrahimi, Hossein AU - Ebrahimi H AD - Center for Health Related Social and Behavioral Sciences Research, Shahroud University of Medical Sciences, Shahroud, Iran. RINGGOLD: 154204 LA - eng PT - Journal Article DEP - 20230810 PL - United States TA - Omega (Westport) JT - Omega JID - 1272106 SB - IM MH - Humans MH - Male MH - Female MH - Iran/epidemiology MH - Middle Aged MH - Cross-Sectional Studies MH - *Spirituality MH - *Attitude to Death MH - *Acute Coronary Syndrome/psychology MH - *Anxiety/psychology MH - Adult MH - Aged MH - Surveys and Questionnaires MH - Adaptation, Psychological OTO - NOTNLM OT - acute coronary syndrome OT - cardiovascular diseases OT - death anxiety OT - spiritual well-being COIS- Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2023/08/16 18:42 MHDA- 2025/10/22 02:35 CRDT- 2023/08/16 16:14 PHST- 2025/10/22 02:35 [medline] PHST- 2023/08/16 18:42 [pubmed] PHST- 2023/08/16 16:14 [entrez] AID - 10.1177/00302228231195103 [doi] PST - ppublish SO - Omega (Westport). 2025 Dec;92(2):1066-1079. doi: 10.1177/00302228231195103. Epub 2023 Aug 10. PMID- 37584024 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240923 IS - 1995-705X (Print) IS - 0976-5123 (Electronic) IS - 1995-705X (Linking) VI - 24 IP - 3 DP - 2023 Jul-Sep TI - Percutaneous Coronary Intervention versus Coronary Artery Bypass Grafting in Complex Coronary Artery Disease: Long-term Clinical Outcomes from a High-volume Center. PG - 141-147 LID - 10.4103/heartviews.heartviews_116_22 [doi] AB - BACKGROUND: Clinical equipoise between a percutaneous coronary intervention (PCI) and coronary artery bypass grafting surgery (CABG) in the treatment of complex coronary artery disease (CAD), including unprotected left main coronary artery (LMCA) and/or three-vessel disease (3VD), remains debatable. METHODS: A retrospective analysis of an unselected cohort undergoing contemporary PCI versus CABG at a large center in 2015. Patients who received nonemergent treatment of unprotected LMCA and/or 3VD were included. The primary study endpoint was all-cause mortality at 5 years. Secondary endpoints included a composite of all-cause mortality, spontaneous myocardial infarction (MI), or ischemia-driven repeat revascularization at 30 days and 1 year. RESULTS: Four hundred and thirty patients met the inclusion criteria, 225 had PCI, and 205 had CABG. PCI patients were older with frequent LMCA involvement and higher EuroSCORE yet they had a fourfold shorter in-hospital stay compared to CABG patients. At 5 years, there was no significant difference in the primary endpoint between CABG and PCI (adjusted Hazard ratios 0.68, 95% confidence interval: 0.38-1.22, P = 0.19). Likewise, there was no significant difference in the incidence of the secondary composite endpoint or its components at 30 days or 1 year. A propensity score-matched analysis in 220 patients revealed similar outcomes. CONCLUSIONS: In real-world long-term contemporary data, survival after PCI was comparable to CABG at 5 years in patients with unprotected LMCA and/or 3VD. At 1 year, the incidence of spontaneous MI and ischemia-driven repeat revascularization did not differ between the two cohorts. The mode of revascularization in these complex patients should be guided by the heart team. CI - Copyright: (c) 2023 Heart Views. FAU - Hesse, Kerrick AU - Hesse K AD - Department of Cardiothoracic, Freeman Hospital, Newcastle Upon Tyne, Tyne and Wear, UK. FAU - Egred, Mohaned AU - Egred M AD - Department of Cardiothoracic, Freeman Hospital, Newcastle Upon Tyne, Tyne and Wear, UK. FAU - Zaman, Azfar AU - Zaman A AD - Department of Cardiothoracic, Freeman Hospital, Newcastle Upon Tyne, Tyne and Wear, UK. FAU - Alkhalil, Mohammad AU - Alkhalil M AD - Department of Cardiothoracic, Freeman Hospital, Newcastle Upon Tyne, Tyne and Wear, UK. FAU - Farag, Mohamed AU - Farag M AD - Department of Cardiothoracic, Freeman Hospital, Newcastle Upon Tyne, Tyne and Wear, UK. LA - eng PT - Journal Article DEP - 20230705 PL - India TA - Heart Views JT - Heart views : the official journal of the Gulf Heart Association JID - 101316474 PMC - PMC10424755 OTO - NOTNLM OT - Coronary artery bypass grafting surgery OT - coronary artery disease OT - myocardial infarction OT - outcome OT - percutaneous coronary intervention OT - revascularization COIS- There are no conflicts of interest. EDAT- 2023/08/16 06:43 MHDA- 2023/08/16 06:44 PMCR- 2023/07/01 CRDT- 2023/08/16 03:57 PHST- 2022/11/30 00:00 [received] PHST- 2023/05/11 00:00 [accepted] PHST- 2023/08/16 06:44 [medline] PHST- 2023/08/16 06:43 [pubmed] PHST- 2023/08/16 03:57 [entrez] PHST- 2023/07/01 00:00 [pmc-release] AID - HV-24-141 [pii] AID - 10.4103/heartviews.heartviews_116_22 [doi] PST - ppublish SO - Heart Views. 2023 Jul-Sep;24(3):141-147. doi: 10.4103/heartviews.heartviews_116_22. Epub 2023 Jul 5. PMID- 37582169 OWN - NLM STAT- MEDLINE DCOM- 20230817 LR - 20260518 IS - 1941-7632 (Electronic) IS - 1941-7640 (Linking) VI - 16 IP - 8 DP - 2023 Aug TI - STICH3C: Rationale and Study Protocol. PG - e012527 LID - 10.1161/CIRCINTERVENTIONS.122.012527 [doi] AB - BACKGROUND: Coronary artery bypass grafting (CABG) is the recommended mode of revascularization in patients with ischemic left ventricular dysfunction (iLVSD) and multivessel disease. However, contemporary percutaneous coronary intervention (PCI) outcomes have improved with the integration of novel technologies and refinement of revascularization strategies, and PCI is often used in clinical practice in this population. There is a lack of evidence from randomized trials comparing contemporary state-of-the-art PCI versus CABG for the treatment of iLVSD and multivessel disease. This was the impetus for the STICH3C trial (Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy), described here. METHODS: The STICH3C trial is a prospective, unblinded, international, multicenter trial with an expected sample size of 754 participants from approximately 45 centers. Patients with multivessel/left main coronary artery disease and iLVSD with left ventricular ejection fraction /=1 human epidermal growth factor receptor 2 (HER2)-targeted therapies. However, interstitial lung disease (ILD) and cardiotoxicity are the most significant toxicities associated with T-DXd. Therefore, we conducted a systematic review and meta-analysis to assess the incidence and severity of these toxicities in mBC patients treated with T-DXd. MATERIALS AND METHODS: We searched PubMed, Cochrane, and Scopus databases, and conferences websites for randomized clinical trials and nonrandomized studies of intervention including HER2-low or HER2-positive mBC patients who received at least one dose of T-DXd. Statistical analysis was carried out using R software. RESULTS: We included 15 studies comprising 1970 patients with a mean follow-up of 13.3 months. Median age ranged from 53 to 59 years, 61.9% were non-Asian, and 67.4% had hormone receptor-positive mBC. In a pooled analysis, the incidence of ILD was 11.7% [222 patients; 95% confidence interval (CI) 9.1% to 15.0%]. Patients receiving T-DXd dose of 6.4 mg/kg developed a significantly higher rate of ILD (22.7%) compared to those receiving a dose of 5.4 mg/kg (9.3%) (P < 0.01). Most cases of ILD (80.2%; 174/217 patients) were mild (grade 1 or 2). Grade 3 or 4 ILD was reported in 29 patients (13.4%), and grade 5 in 14 patients (6.4%). The incidence of decreased left ventricular ejection fraction (LVEF) was 1.95% (95% CI 0.65% to 3.73%), and the QT interval (QTi) prolongation was 7.77% (95% CI 2.74% to 20.11%). Most patients were asymptomatic, but four had LV dysfunction and heart failure (0.26%). CONCLUSIONS: In this meta-analysis of 1970 patients with mBC, treatment with T-DXd was associated with a 11.7% incidence of ILD, 7.7% incidence of prolonged QTi, and 1.9% incidence of reduced LVEF. Early detection and management of T-DXd-related toxicity by a multidisciplinary team may ultimately improve patient outcomes. CI - Copyright (c) 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved. FAU - Soares, L R AU - Soares LR AD - Centro Avancado de Diagnostico da Mama (CORA), Teaching Hospital, Federal University of Goias (UFG), Goiania; Department of Medicine, Post-Graduation Program in Health Sciences, Federal University of Goias (UFG), Goiania; Dona Iris Hospital and Maternity, Municipal Health Department, Goiania, Brazil. Electronic address: ribeiroufg@hotmail.com. FAU - Vilbert, M AU - Vilbert M AD - Princess Margaret Cancer Centre, University Health Network, Toronto; Department of Medicine, Division of Medical Oncology, University of Toronto, Toronto, Canada. FAU - Rosa, V D L AU - Rosa VDL AD - Centro Avancado de Diagnostico da Mama (CORA), Teaching Hospital, Federal University of Goias (UFG), Goiania; Department of Medicine, Post-Graduation Program in Health Sciences, Federal University of Goias (UFG), Goiania. FAU - Oliveira, J L AU - Oliveira JL AD - Dona Iris Hospital and Maternity, Municipal Health Department, Goiania, Brazil. FAU - Deus, M M AU - Deus MM AD - Department of Medicine, Post-Graduation Program in Health Sciences, Federal University of Goias (UFG), Goiania. FAU - Freitas-Junior, R AU - Freitas-Junior R AD - Centro Avancado de Diagnostico da Mama (CORA), Teaching Hospital, Federal University of Goias (UFG), Goiania; Department of Medicine, Post-Graduation Program in Health Sciences, Federal University of Goias (UFG), Goiania. LA - eng PT - Journal Article PT - Meta-Analysis PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20230723 PL - England TA - ESMO Open JT - ESMO open JID - 101690685 RN - 5384HK7574 (trastuzumab deruxtecan) RN - XT3Z54Z28A (Camptothecin) RN - 0 (Immunoconjugates) RN - P188ANX8CK (Trastuzumab) SB - IM MH - Humans MH - Middle Aged MH - Female MH - *Breast Neoplasms/pathology MH - Cardiotoxicity/epidemiology/etiology MH - Incidence MH - Stroke Volume MH - Ventricular Function, Left MH - *Lung Diseases, Interstitial/chemically induced/epidemiology MH - Camptothecin/analogs & derivatives MH - Immunoconjugates MH - Trastuzumab PMC - PMC10485391 OTO - NOTNLM OT - antibody-drug conjugate OT - breast cancer OT - cardiotoxicity OT - interstitial lung disease OT - trastuzumab deruxtecan COIS- Disclosure The authors have declared no conflicts of interest. Data Sharing Data sharing is not applicable to this article as no new data were created or analyzed in this study. EDAT- 2023/07/24 00:41 MHDA- 2023/08/29 12:43 PMCR- 2023/07/23 CRDT- 2023/07/23 18:07 PHST- 2023/04/15 00:00 [received] PHST- 2023/05/30 00:00 [revised] PHST- 2023/06/24 00:00 [accepted] PHST- 2023/08/29 12:43 [medline] PHST- 2023/07/24 00:41 [pubmed] PHST- 2023/07/23 18:07 [entrez] PHST- 2023/07/23 00:00 [pmc-release] AID - S2059-7029(23)00848-7 [pii] AID - 101613 [pii] AID - 10.1016/j.esmoop.2023.101613 [doi] PST - ppublish SO - ESMO Open. 2023 Aug;8(4):101613. doi: 10.1016/j.esmoop.2023.101613. Epub 2023 Jul 23. PMID- 37480922 OWN - NLM STAT- MEDLINE DCOM- 20230825 LR - 20260303 IS - 1558-3597 (Electronic) IS - 0735-1097 (Linking) VI - 82 IP - 9 DP - 2023 Aug 29 TI - 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. PG - 833-955 LID - S0735-1097(23)05281-6 [pii] LID - 10.1016/j.jacc.2023.04.003 [doi] AB - AIM: The "2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease" provides an update to and consolidates new evidence since the "2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease" and the corresponding "2014 ACC/AHA/AATS/PCNA/SCAI/STS Focused Update of the Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease." METHODS: A comprehensive literature search was conducted from September 2021 to May 2022. Clinical studies, systematic reviews and meta-analyses, and other evidence conducted on human participants were identified that were published in English from MEDLINE (through PubMed), EMBASE, the Cochrane Library, Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. STRUCTURE: This guideline provides an evidenced-based and patient-centered approach to management of patients with chronic coronary disease, considering social determinants of health and incorporating the principles of shared decision-making and team-based care. Relevant topics include general approaches to treatment decisions, guideline-directed management and therapy to reduce symptoms and future cardiovascular events, decision-making pertaining to revascularization in patients with chronic coronary disease, recommendations for management in special populations, patient follow-up and monitoring, evidence gaps, and areas in need of future research. Where applicable, and based on availability of cost-effectiveness data, cost-value recommendations are also provided for clinicians. Many recommendations from previously published guidelines have been updated with new evidence, and new recommendations have been created when supported by published data. CI - Copyright (c) 2023 American Heart Association, Inc., and the American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. CN - Writing Committee Members FAU - Virani, Salim S AU - Virani SS FAU - Newby, L Kristin AU - Newby LK FAU - Arnold, Suzanne V AU - Arnold SV FAU - Bittner, Vera AU - Bittner V FAU - Brewer, LaPrincess C AU - Brewer LC FAU - Demeter, Susan Halli AU - Demeter SH FAU - Dixon, Dave L AU - Dixon DL FAU - Fearon, William F AU - Fearon WF FAU - Hess, Beverly AU - Hess B FAU - Johnson, Heather M AU - Johnson HM FAU - Kazi, Dhruv S AU - Kazi DS FAU - Kolte, Dhaval AU - Kolte D FAU - Kumbhani, Dharam J AU - Kumbhani DJ FAU - LoFaso, Jim AU - LoFaso J FAU - Mahtta, Dhruv AU - Mahtta D FAU - Mark, Daniel B AU - Mark DB FAU - Minissian, Margo AU - Minissian M FAU - Navar, Ann Marie AU - Navar AM FAU - Patel, Amit R AU - Patel AR FAU - Piano, Mariann R AU - Piano MR FAU - Rodriguez, Fatima AU - Rodriguez F FAU - Talbot, Amy W AU - Talbot AW FAU - Taqueti, Viviany R AU - Taqueti VR FAU - Thomas, Randal J AU - Thomas RJ FAU - van Diepen, Sean AU - van Diepen S FAU - Wiggins, Barbara AU - Wiggins B FAU - Williams, Marlene S AU - Williams MS LA - eng GR - K23 HL135438/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Practice Guideline DEP - 20230720 PL - United States TA - J Am Coll Cardiol JT - Journal of the American College of Cardiology JID - 8301365 RN - 0 (Proliferating Cell Nuclear Antigen) SB - IM EIN - J Am Coll Cardiol. 2023 Oct 31;82(18):1808. doi: 10.1016/j.jacc.2023.09.794. PMID: 37879787 EIN - J Am Coll Cardiol. 2024 Apr 30;83(17):1716. doi: 10.1016/j.jacc.2024.03.399. PMID: 38658111 MH - United States MH - Humans MH - Proliferating Cell Nuclear Antigen MH - American Heart Association MH - *Heart Diseases MH - *Cardiology MH - *Myocardial Ischemia MH - Chronic Disease MH - *Coronary Disease OTO - NOTNLM OT - ACC/AHA Clinical Practice Guidelines OT - acute coronary syndrome OT - air pollution OT - angina OT - antiplatelet therapy OT - aspirin OT - atherosclerosis OT - autoimmune diseases OT - cardiac events OT - cardiac rehabilitation OT - cardiovascular diseases OT - colchicine OT - coronary artery disease OT - coronary disease OT - cost-benefit analysis OT - depression OT - diabetes OT - diet OT - diet therapy OT - dietary supplements OT - drug therapy OT - dual antiplatelet therapy OT - environmental exposure OT - exercise tolerance OT - factor Xa inhibitors OT - fibrinolytic agents OT - glucagon-like peptide-1 receptor agonists OT - guideline-directed management and therapy OT - health care outcome assessments OT - health equity OT - heart disease risk factors OT - heart failure OT - hormone replacement therapy OT - hypercholesterolemia OT - hypertension OT - immunization OT - ischemic heart disease OT - mental health OT - multidisciplinary OT - myocardial ischemia OT - outcomes OT - outpatient OT - patient care team OT - pharmacology OT - pregnancy OT - proton pump inhibitors OT - quality of life OT - safety OT - secondary prevention OT - sexual behavior OT - sexual health OT - shared decision-making OT - smoking cessation OT - social determinants of health OT - sodium-glucose cotransporter 2 inhibitors OT - spontaneous coronary artery dissection OT - stress OT - therapeutic use OT - therapy OT - type 2 diabetes OT - vaccination EDAT- 2023/07/23 01:11 MHDA- 2023/08/25 06:42 CRDT- 2023/07/22 18:44 PHST- 2023/08/25 06:42 [medline] PHST- 2023/07/23 01:11 [pubmed] PHST- 2023/07/22 18:44 [entrez] AID - S0735-1097(23)05281-6 [pii] AID - 10.1016/j.jacc.2023.04.003 [doi] PST - ppublish SO - J Am Coll Cardiol. 2023 Aug 29;82(9):833-955. doi: 10.1016/j.jacc.2023.04.003. Epub 2023 Jul 20. PMID- 37477692 OWN - NLM STAT- MEDLINE DCOM- 20230817 LR - 20230817 IS - 1522-1539 (Electronic) IS - 0363-6135 (Linking) VI - 325 IP - 3 DP - 2023 Sep 1 TI - Scuba diving after a heart transplant: excessive daring or calculable risk? PG - H569-H577 LID - 10.1152/ajpheart.00332.2023 [doi] AB - Over the past 50 years, outcomes after heart transplantation (HTX) have continuously and significantly improved. In the meantime, many heart transplant recipients live almost normal lives with only a few limitations. In some cases, even activities that actually seemed unreasonable for these patients turn out to be feasible. This article describes the encouraging example of a patient returning to recreational scuba diving after HTX. So far, there were no scientific experiences documented in this area. We worked out the special hemodynamic features and the corresponding risks of this sport for heart transplant recipients in an interdisciplinary manner and evaluated them using the patient as an example. The results show that today, with the appropriate physical condition and compliance with safety measures, a wide range of activities, including scuba diving, are possible again after HTX. They illustrate again the significant development and the enormous potential of this therapy option, which is unfortunately only available to a limited extent.NEW & NOTEWORTHY Example for shared decision-making process for tricky questions: First scientific publication about heart transplantation (HTX)-recipient restarting scuba diving. As exercise physiology after HTX combined with specific diving medicine aspects is challenging, we formed a multidisciplinary team to identify, evaluate, and mitigate the risks involved. The results show that today, with the appropriate physical condition and compliance with safety measures, a wide range of activities are possible again after HTX. FAU - Schmidt, Thomas AU - Schmidt T AUID- ORCID: 0000-0003-4977-8414 AD - Institute for Cardiology and Sports Medicine, German Sports University Cologne, Cologne, Germany. AD - Institute for Cardiovascular Research, Schuchtermann-Klinik Bad Rothenfelde, Bad Rothenfelde, Germany. FAU - Reiss, Nils AU - Reiss N AD - Institute for Cardiovascular Research, Schuchtermann-Klinik Bad Rothenfelde, Bad Rothenfelde, Germany. FAU - Olbrich, Erk AU - Olbrich E AD - Department of Cardiac Surgery, INCCI Haerz-Zenter, Luxembourg, Luxembourg. FAU - Chalabi, Khaled AU - Chalabi K AD - Department of Cardiac Surgery, INCCI Haerz-Zenter, Luxembourg, Luxembourg. FAU - Hagedorn, Thorsten AU - Hagedorn T AD - Department of Sports Medicine, University of Wuppertal, Wuppertal, Germany. FAU - Tetzlaff, Kay AU - Tetzlaff K AD - Department of Sports Medicine, University Hospital Tuebingen, Tuebingen, Germany. LA - eng PT - Journal Article DEP - 20230721 PL - United States TA - Am J Physiol Heart Circ Physiol JT - American journal of physiology. Heart and circulatory physiology JID - 100901228 SB - IM MH - Humans MH - *Diving/adverse effects/physiology MH - *Heart Transplantation/adverse effects OTO - NOTNLM OT - heart transplantation OT - quality of life OT - scuba diving OT - shared decision making OT - sports EDAT- 2023/07/21 13:14 MHDA- 2023/08/17 06:42 CRDT- 2023/07/21 11:05 PHST- 2023/08/17 06:42 [medline] PHST- 2023/07/21 13:14 [pubmed] PHST- 2023/07/21 11:05 [entrez] AID - 10.1152/ajpheart.00332.2023 [doi] PST - ppublish SO - Am J Physiol Heart Circ Physiol. 2023 Sep 1;325(3):H569-H577. doi: 10.1152/ajpheart.00332.2023. Epub 2023 Jul 21. PMID- 37476997 OWN - NLM STAT- MEDLINE DCOM- 20230817 LR - 20230905 IS - 1941-7705 (Electronic) IS - 1941-7713 (Linking) VI - 16 IP - 8 DP - 2023 Aug TI - Illness Perception and the Impact of a Definitive Diagnosis on Women With Ischemia and No Obstructive Coronary Artery Disease: A Qualitative Study. PG - 521-529 LID - 10.1161/CIRCOUTCOMES.122.009834 [doi] AB - BACKGROUND: Ischemia and no obstructive coronary artery disease (INOCA) disproportionately impacts women, yet the underlying pathologies are often not distinguished, contributing to adverse health care experiences and poor quality of life. Coronary function testing at the time of invasive coronary angiography allows for improved diagnostic accuracy. Despite increased recognition of INOCA and expanding access to testing, data lack on first-person perspectives and the impact of receiving a diagnosis in women with INOCA. METHODS: From 2020 to 2021, we conducted structured telephone interviews with 2 groups of women with INOCA who underwent invasive coronary angiography (n=29) at Yale New Haven Hospital, New Haven, CT: 1 group underwent coronary function testing (n=20, of whom 18 received a mechanism-based diagnosis) and the other group who did not undergo coronary function testing (n=9). The interviews were analyzed using the constant comparison method by a multidisciplinary team. RESULTS: The mean age was 59.7 years, and 79% and 3% were non-Hispanic White and non-Hispanic Black, respectively. Through iterative coding, 4 themes emerged and were further separated into subthemes that highlight disease experience aspects to be addressed in patient care: (1) distress from symptoms of uncertain cause: symptom constellation, struggle for sensemaking, emotional toll, threat to personal and professional identity; (2) a long journey to reach a definitive diagnosis: self-advocacy and fortitude, healthcare interactions brought about further uncertainty and trauma, therapeutic alliance, sources of information; (3) establishing a diagnosis enabled a path forward: relief and validation, empowerment; and (4) commitment to promoting awareness and supporting other women: recognition of sex and racial/ethnic disparities, support for other women. CONCLUSIONS: Insights about how women experience the symptoms of INOCA and their interactions with clinicians and the healthcare system hold powerful lessons for more patient-centered care. A coronary function testing-informed diagnosis greatly influences the healthcare experiences, quality of life, and emotional states of women with INOCA. FAU - Tseng, Leslie Yingzhijie AU - Tseng LY AUID- ORCID: 0000-0002-5753-2046 AD - Yale School of Medicine, New Haven, CT (L.Y.T.). FAU - Goc, Nukte AU - Goc N AD - Global Health Leadership Initiative (N.G., E.J.C., L.A.C.), Yale School of Public Health, New Haven, CT. FAU - Schwann, Alexandra N AU - Schwann AN AD - Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, CT (A.N.S., S.J.K., N.O., S.M.S., E.S.S.). FAU - Cherlin, Emily J AU - Cherlin EJ AD - Global Health Leadership Initiative (N.G., E.J.C., L.A.C.), Yale School of Public Health, New Haven, CT. FAU - Kunnirickal, Steffne J AU - Kunnirickal SJ AD - Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, CT (A.N.S., S.J.K., N.O., S.M.S., E.S.S.). FAU - Odanovic, Natalija AU - Odanovic N AUID- ORCID: 0000-0003-0343-6195 AD - Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, CT (A.N.S., S.J.K., N.O., S.M.S., E.S.S.). AD - Institute for Cardiovascular Diseases "Dedinje," Belgrade, Serbia (N.O.). FAU - Curry, Leslie A AU - Curry LA AUID- ORCID: 0000-0002-3419-4654 AD - Global Health Leadership Initiative (N.G., E.J.C., L.A.C.), Yale School of Public Health, New Haven, CT. AD - Department of Health Policy and Management, Yale School of Public Health, New Haven, CT (L.A.C.). FAU - Shah, Samit M AU - Shah SM AUID- ORCID: 0000-0002-3664-4102 AD - Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, CT (A.N.S., S.J.K., N.O., S.M.S., E.S.S.). AD - Veterans Affairs Connecticut Healthcare System, West Haven (S.M.S.). FAU - Spatz, Erica S AU - Spatz ES AUID- ORCID: 0000-0002-1557-7713 AD - Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, CT (A.N.S., S.J.K., N.O., S.M.S., E.S.S.). AD - Center for Outcomes Research and Evaluation, Yale-New Haven Health System, CT (E.S.S.). LA - eng GR - U54 MD010711/MD/NIMHD NIH HHS/United States GR - R01 EB028106/EB/NIBIB NIH HHS/United States GR - R01 HL151240/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20230721 PL - United States TA - Circ Cardiovasc Qual Outcomes JT - Circulation. Cardiovascular quality and outcomes JID - 101489148 SB - IM CIN - Circ Cardiovasc Qual Outcomes. 2023 Aug;16(8):530-532. doi: 10.1161/CIRCOUTCOMES.123.010318. PMID: 37476998 MH - Humans MH - Female MH - Middle Aged MH - *Coronary Artery Disease/diagnostic imaging/therapy MH - Quality of Life/psychology MH - *Myocardial Ischemia/diagnosis MH - Ischemia MH - Perception OTO - NOTNLM OT - coronary artery disease OT - ischemia OT - narrative medicine OT - perception uncertainty OT - quality of life COIS- Disclosures Dr Spatz receives grant funding from the Centers for Disease Control and Prevention (20042801-Sub01), National Institute on Minority Health and Health Disparities (U54MD010711-01), and the US Food and Drug Administration to support projects within the Yale-Mayo Clinic Center of Excellence in Regulatory Science and Innovation (CERSI; U01FD005938), including a project to develop a novel survey tool for women with ischemia and no obstructive coronary artery disease. She also receives funding from the National Institute of Biomedical Imaging and Bioengineering (R01 EB028106-01) and the National Heart, Lung, and Blood Institute (R01HL151240). S.M. Shah receives research support from Women's Health Research at Yale, Abbott Vascular Inc and the US Food and Drug Administration to support projects within the Yale-Mayo CERSI (U01FD005938), including a project to develop a novel survey tool for women with ischemia and no obstructive coronary artery disease. The other authors report no conflicts. EDAT- 2023/07/21 06:44 MHDA- 2023/08/17 06:43 CRDT- 2023/07/21 05:27 PHST- 2023/08/17 06:43 [medline] PHST- 2023/07/21 06:44 [pubmed] PHST- 2023/07/21 05:27 [entrez] AID - 10.1161/CIRCOUTCOMES.122.009834 [doi] PST - ppublish SO - Circ Cardiovasc Qual Outcomes. 2023 Aug;16(8):521-529. doi: 10.1161/CIRCOUTCOMES.122.009834. Epub 2023 Jul 21. PMID- 37471501 OWN - NLM STAT- MEDLINE DCOM- 20230905 LR - 20260518 IS - 1524-4539 (Electronic) IS - 0009-7322 (Linking) VI - 148 IP - 9 DP - 2023 Aug 29 TI - 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. PG - e9-e119 LID - 10.1161/CIR.0000000000001168 [doi] AB - AIM: The "2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease" provides an update to and consolidates new evidence since the "2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease" and the corresponding "2014 ACC/AHA/AATS/PCNA/SCAI/STS Focused Update of the Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease." METHODS: A comprehensive literature search was conducted from September 2021 to May 2022. Clinical studies, systematic reviews and meta-analyses, and other evidence conducted on human participants were identified that were published in English from MEDLINE (through PubMed), EMBASE, the Cochrane Library, Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. STRUCTURE: This guideline provides an evidenced-based and patient-centered approach to management of patients with chronic coronary disease, considering social determinants of health and incorporating the principles of shared decision-making and team-based care. Relevant topics include general approaches to treatment decisions, guideline-directed management and therapy to reduce symptoms and future cardiovascular events, decision-making pertaining to revascularization in patients with chronic coronary disease, recommendations for management in special populations, patient follow-up and monitoring, evidence gaps, and areas in need of future research. Where applicable, and based on availability of cost-effectiveness data, cost-value recommendations are also provided for clinicians. Many recommendations from previously published guidelines have been updated with new evidence, and new recommendations have been created when supported by published data. FAU - Virani, Salim S AU - Virani SS AD - ACC/AHA representative. FAU - Newby, L Kristin AU - Newby LK AD - ACC/AHA representative. FAU - Arnold, Suzanne V AU - Arnold SV FAU - Bittner, Vera AU - Bittner V AD - National Lipid Association representative. FAU - Brewer, LaPrincess C AU - Brewer LC FAU - Demeter, Susan Halli AU - Demeter SH AD - Preventive Cardiovascular Nurses Association representative. FAU - Dixon, Dave L AU - Dixon DL AD - Former Joint Committee on Clinical Practice Guideline member; current member during the writing effort. FAU - Fearon, William F AU - Fearon WF AD - Society for Cardiovascular Angiography and Interventions representative. FAU - Hess, Beverly AU - Hess B AD - Patient representative/lay stakeholder. FAU - Johnson, Heather M AU - Johnson HM AD - American Society for Preventive Cardiology representative. FAU - Kazi, Dhruv S AU - Kazi DS FAU - Kolte, Dhaval AU - Kolte D AD - AHA/ACC Joint Committee on Clinical Data Standards. FAU - Kumbhani, Dharam J AU - Kumbhani DJ FAU - LoFaso, Jim AU - LoFaso J AD - Patient representative/lay stakeholder. FAU - Mahtta, Dhruv AU - Mahtta D FAU - Mark, Daniel B AU - Mark DB AD - Former Joint Committee on Clinical Practice Guideline member; current member during the writing effort. FAU - Minissian, Margo AU - Minissian M FAU - Navar, Ann Marie AU - Navar AM FAU - Patel, Amit R AU - Patel AR FAU - Piano, Mariann R AU - Piano MR AD - Former Joint Committee on Clinical Practice Guideline member; current member during the writing effort. FAU - Rodriguez, Fatima AU - Rodriguez F FAU - Talbot, Amy W AU - Talbot AW AD - ACC/AHA representative. FAU - Taqueti, Viviany R AU - Taqueti VR FAU - Thomas, Randal J AU - Thomas RJ FAU - van Diepen, Sean AU - van Diepen S FAU - Wiggins, Barbara AU - Wiggins B AD - American College of Clinical Pharmacy representative. FAU - Williams, Marlene S AU - Williams MS AD - AHA/ACC Joint Committee on Performance Measures. CN - Peer Review Committee Members LA - eng GR - K01 HL144607/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Practice Guideline DEP - 20230720 PL - United States TA - Circulation JT - Circulation JID - 0147763 RN - 0 (Proliferating Cell Nuclear Antigen) SB - IM EIN - Circulation. 2023 Sep 26;148(13):e148. doi: 10.1161/CIR.0000000000001183. PMID: 37747957 EIN - Circulation. 2023 Dec 5;148(23):e186. doi: 10.1161/CIR.0000000000001195. PMID: 38048397 MH - Humans MH - American Heart Association MH - *Cardiology MH - *Coronary Disease MH - *Myocardial Ischemia/diagnosis MH - Proliferating Cell Nuclear Antigen MH - United States OTO - NOTNLM OT - AHA Scientific Statements OT - acute coronary syndrome OT - air pollution OT - angina OT - antiplatelet therapy OT - aspirin OT - atherosclerosis OT - autoimmune diseases OT - cardiac events OT - cardiac rehabilitation OT - cardiovascular diseases OT - colchicine OT - coronary artery disease OT - coronary disease OT - cost-benefit analysis OT - depression OT - diabetes OT - diet OT - diet therapy OT - dietary supplements OT - drug therapy OT - dual antiplatelet therapy OT - environmental exposure OT - exercise tolerance OT - factor Xa inhibitors OT - fibrinolytic agents OT - glucagon-like peptide-1 receptor agonists OT - guideline-directed management and therapy OT - health care outcome assessments OT - health equity OT - heart disease risk factors OT - heart failure OT - hormone replacement therapy OT - hypercholesterolemia OT - hypertension OT - immunization OT - ischemic heart disease OT - mental health OT - multidisciplinary OT - myocardial ischemia OT - outcomes OT - outpatient OT - patient care team OT - pharmacology OT - pregnancy OT - proton pump inhibitors OT - quality of life OT - safety OT - secondary prevention OT - sexual behavior OT - sexual health OT - shared decision-making OT - smoking cessation OT - social determinants of health OT - sodium-glucose cotransporter 2 inhibitors OT - spontaneous coronary artery dissection OT - stress OT - therapeutic use OT - therapy OT - type 2 diabetes OT - vaccination FIR - Anderson, H Vernon IR - Anderson HV FIR - Rao, Sunil V IR - Rao SV FIR - Batiste II, Columbus IR - Batiste II C FIR - Blumenthal, Roger IR - Blumenthal R FIR - Cavender, Matthew A IR - Cavender MA FIR - Goldberg, Anne Carol IR - Goldberg AC FIR - Jackevicius, Cynthia IR - Jackevicius C FIR - Keating, Friederike K IR - Keating FK FIR - Metkus, Thomas S IR - Metkus TS FIR - Shaw, Leslee J IR - Shaw LJ FIR - Villavaso, Chloe D IR - Villavaso CD FIR - Zwischenberger, Brittany A IR - Zwischenberger BA EDAT- 2023/07/20 19:14 MHDA- 2023/08/31 06:41 CRDT- 2023/07/20 14:05 PHST- 2023/08/31 06:41 [medline] PHST- 2023/07/20 19:14 [pubmed] PHST- 2023/07/20 14:05 [entrez] AID - 10.1161/CIR.0000000000001168 [doi] PST - ppublish SO - Circulation. 2023 Aug 29;148(9):e9-e119. doi: 10.1161/CIR.0000000000001168. Epub 2023 Jul 20. PMID- 37471342 OWN - NLM STAT- MEDLINE DCOM- 20230724 LR - 20230724 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 18 IP - 7 DP - 2023 TI - The role of critical care nurses in shared decision-making for patients with severe heart failure: A qualitative study. PG - e0288978 LID - 10.1371/journal.pone.0288978 [doi] LID - e0288978 AB - AIM: Patients with severe heart failure undergo highly invasive and advanced therapies with uncertain treatment outcomes. For these patients, shared decision-making is necessary. To date, the nursing perspective of the decision-making process for patients facing difficulties and how nurses can support patients in this process have not been fully elucidated. This study aimed to clarify the perceptions of critical care nurses regarding situations with patients with severe heart failure that require difficult decision-making, and their role in supporting these patients. METHODS: Individual semi-structured interviews were conducted with 10 certified nurse specialists in critical care nursing at nine hospitals in Japan. A qualitative inductive method was used and the derived relationships among the themes were visually structured and represented. RESULTS: The nurses' perceptions on patients' difficult situations in decision-making were identified as follows: painful decisions under uncertainties; tense relationships; wavering emotions during decision-making; difficulties in coping with worsening medical conditions; patients' wishes that are difficult to realize or estimate; and difficulties in transitioning from advanced medical care. Critical care nurses' roles were summarized into six themes and performed collaboratively within the nursing team. Of these, the search for meaning and value was fundamental. Two positions underpin the role of critical care nurses. The first aims to provide direct support and includes partnerships and rights advocacy. The second aims to provide a holistic perspective to enable necessary adjustments, as indicated by situation assessments and mediation. By crossing various boundaries, co-creating, and forming a good circular relationship in the search for meaning and values, the possibility of expanding treatment and recuperation options may be considered. CONCLUSIONS: Patients with severe heart failure have difficulty participating in shared decision-making. Critical care nurses should collaborate within the nursing team to improve interprofessional shared decision-making by providing decisional support to patients that focuses on values and meaning. CI - Copyright: (c) 2023 Inagaki et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. FAU - Inagaki, Noriko AU - Inagaki N AUID- ORCID: 0000-0002-6998-5245 AD - Graduate School of Nursing, Kansai Medical University, Hirakata, Osaka, Japan. FAU - Seto, Natsuko AU - Seto N AD - Graduate School of Nursing, Kansai Medical University, Hirakata, Osaka, Japan. FAU - Lee, Kumsun AU - Lee K AD - Graduate School of Nursing, Kansai Medical University, Hirakata, Osaka, Japan. FAU - Takahashi, Yoshimitsu AU - Takahashi Y AUID- ORCID: 0000-0003-4073-9945 AD - Department of Health Informatics, School of Public Health, Kyoto University, Kyoto, Japan. FAU - Nakayama, Takeo AU - Nakayama T AD - Department of Health Informatics, School of Public Health, Kyoto University, Kyoto, Japan. FAU - Hayashi, Yuko AU - Hayashi Y AD - Graduate School of Nursing, Kansai Medical University, Hirakata, Osaka, Japan. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230720 PL - United States TA - PLoS One JT - PloS one JID - 101285081 SB - IM MH - Humans MH - Decision Making MH - Uncertainty MH - Nurse's Role/psychology MH - Critical Care MH - *Heart Failure/therapy MH - *Nurses MH - Qualitative Research PMC - PMC10358911 COIS- We have read the journal's policy and the authors of this manuscript have the following competing interests: TN received research grants from I&H Co., Ltd., Cocokarafine Co., Ltd., and Konica Minolta Inc.; consulting fees from Otsuka Pharmaceutical; honoraria from Pfizer Japan INC., MSD K.K., Chugai Pharmaceutical Co., Takeda Pharmaceutical Co., Janssen Pharmaceutical K.K., Boehringer Ingelheim International GmbH, Eli Lilly Japan K.K., Maruho Co., Ltd., Mitsubishi Tanabe Pharma Co, Novartis Pharma K.K., Allergan Japan K.K., Maruho Co., Ltd., Novo Nordisk Pharma Ltd., TOA EIYO Ltd., Dentsu co., ONO PHARMACEUTICAL CO., LTD., GSK plc, Alexion Pharmaceuticals, Inc., and Cannon Medical Systems Co.; stock options from Bon Bon Inc.; donations from CancerScan and YUYAMA co. The other authors declare that they have no conflicts of interest to disclose. This does not alter our adherence to PLOS ONE policies on sharing data and materials EDAT- 2023/07/20 19:14 MHDA- 2023/07/24 06:42 PMCR- 2023/07/20 CRDT- 2023/07/20 13:34 PHST- 2023/02/27 00:00 [received] PHST- 2023/07/09 00:00 [accepted] PHST- 2023/07/24 06:42 [medline] PHST- 2023/07/20 19:14 [pubmed] PHST- 2023/07/20 13:34 [entrez] PHST- 2023/07/20 00:00 [pmc-release] AID - PONE-D-23-05721 [pii] AID - 10.1371/journal.pone.0288978 [doi] PST - epublish SO - PLoS One. 2023 Jul 20;18(7):e0288978. doi: 10.1371/journal.pone.0288978. eCollection 2023. PMID- 37469405 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230721 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 13 DP - 2023 TI - Risk of cardiac implantable device malfunction in cancer patients receiving proton therapy: an overview. PG - 1181450 LID - 10.3389/fonc.2023.1181450 [doi] LID - 1181450 AB - Age is a risk factor for both cardiovascular disease and cancer, and as such radiation oncologists frequently see a number of patients with cardiac implantable electronic devices (CIEDs) receiving proton therapy (PT). CIED malfunctions induced by PT are nonnegligible and can occur in both passive scattering and pencil beam scanning modes. In the absence of an evidence-based protocol, the authors emphasise that this patient cohort should be managed differently to electron- and photon- external beam radiation therapy (EBRT) patients due to distinct properties of proton beams. Given the lack of a PT-specific guideline for managing this cohort and limited studies on this important topic; the process was initiated by evaluating all PT-related CIED malfunctions to provide a baseline for future reporting and research. In this review, different modes of PT and their interactions with a variety of CIEDs and pacing leads are discussed. Effects of PT on CIEDs were classified into a variety of hardware and software malfunctions. Apart from secondary neutrons, cumulative radiation dose, dose rate, CIED model/manufacturer, distance from CIED to proton field, and materials used in CIEDs/pacing leads were all evaluated to determine the probability of malfunctions. The importance of proton beam arrangements is highlighted in this study. Manufacturers should specify recommended dose limits for patients undergoing PT. The establishment of an international multidisciplinary team dedicated to CIED-bearing patients receiving PT may be beneficial. CI - Copyright (c) 2023 Mirzaei, Rowshanfarzad, Gill, Ebert and Dass. FAU - Mirzaei, Milad AU - Mirzaei M AD - Department of Radiation Oncology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia. AD - Department of Medical Imaging and Radiation Sciences, School of Biomedical Sciences, Monash University, Clayton, VIC, Australia. FAU - Rowshanfarzad, Pejman AU - Rowshanfarzad P AD - School of Physics, Mathematics and Computing, The University of Western Australia, Crawley, WA, Australia. FAU - Gill, Suki AU - Gill S AD - Department of Radiation Oncology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia. AD - School of Physics, Mathematics and Computing, The University of Western Australia, Crawley, WA, Australia. FAU - Ebert, Martin A AU - Ebert MA AD - Department of Radiation Oncology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia. AD - School of Physics, Mathematics and Computing, The University of Western Australia, Crawley, WA, Australia. FAU - Dass, Joshua AU - Dass J AD - Department of Radiation Oncology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia. LA - eng PT - Journal Article PT - Review DEP - 20230704 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC10352826 OTO - NOTNLM OT - cardiac implantable electronic device OT - implantable cardioverter defibrillators OT - implantable loop recorders OT - malfunction OT - pacemakers OT - pacing leads OT - proton therapy OT - secondary neutrons COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/07/20 06:42 MHDA- 2023/07/20 06:43 PMCR- 2023/01/01 CRDT- 2023/07/20 03:50 PHST- 2023/03/07 00:00 [received] PHST- 2023/06/12 00:00 [accepted] PHST- 2023/07/20 06:43 [medline] PHST- 2023/07/20 06:42 [pubmed] PHST- 2023/07/20 03:50 [entrez] PHST- 2023/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2023.1181450 [doi] PST - epublish SO - Front Oncol. 2023 Jul 4;13:1181450. doi: 10.3389/fonc.2023.1181450. eCollection 2023. PMID- 37468129 OWN - NLM STAT- MEDLINE DCOM- 20230905 LR - 20230905 IS - 1440-1797 (Electronic) IS - 1320-5358 (Linking) VI - 28 IP - 10 DP - 2023 Oct TI - Glomerular hyperfiltration is an independent predictor of postoperative outcomes: A NSQIP multi-specialty surgical cohort analysis. PG - 548-556 LID - 10.1111/nep.14221 [doi] AB - AIM: While high estimated glomerular filtration rate (eGFR) has been associated with increased overall mortality, its effect on postoperative outcomes is relatively understudied. We sought to investigate the association between high eGFR and 30-day postoperative outcomes using a multi-specialty surgical cohort. METHODS: Using the National Surgical Quality Improvement Program database, we selected adult for whom eGFR could be calculated using the 2021 Chronic Kidney Disease Epidemiology Collaboration equation. Based on sex-specific distributions of eGFR stratified by age quintiles, we classified patients into low (<5th percentile), normal (5-95th percentile) and high eGFR (>95th percentile). The primary outcome was a composite of any 30-day major adverse outcomes, including: death, reoperation, cardiac arrest, myocardial infarction and stroke. Secondary outcomes included 30-day infectious complications, venous thromboembolism (VTE), bleeding requiring transfusion, prolonged length of stay and unplanned readmission. After matching for demographic differences, comorbidity burden and operative characteristics, logistic regression models were used to evaluate the association between extremes of eGFR and the outcomes of interest. RESULTS: Of 1 668 447 patients, 84 115 (5.07%) had a high eGFR. High eGFR was not associated with major adverse outcomes (odds ratio [OR] 1.00 [95% confidence interval (CI): 0.97, 1.03]); however, it was associated with reoperation (OR 1.04 [95% CI: 1.00,1.08]), infectious complications (OR 1.14 [95% CI: 1.11, 1.16]), VTE (OR 1.15 [95% CI: 1.09, 1.22]) and prolonged length of stay (OR 1.19 [95% CI: 1.16, 1.21]). CONCLUSION: Our findings support an association between high eGFR and adverse 30-day postoperative outcomes. CI - (c) 2023 Asian Pacific Society of Nephrology. FAU - Riveros, Carlos AU - Riveros C AUID- ORCID: 0000-0001-8030-6605 AD - Department of Urology, Houston Methodist Hospital, Houston, Texas, USA. FAU - Ranganathan, Sanjana AU - Ranganathan S AD - Department of Urology, Houston Methodist Hospital, Houston, Texas, USA. FAU - Huang, Emily AU - Huang E AD - Department of Urology, Houston Methodist Hospital, Houston, Texas, USA. FAU - Ordonez, Adriana AU - Ordonez A AD - Center for Health Data Science and Analytics, Houston Methodist Research Institute, Houston, Texas, USA. FAU - Xu, Jiaqiong AU - Xu J AD - Center for Health Data Science and Analytics, Houston Methodist Research Institute, Houston, Texas, USA. FAU - Geng, Michael AU - Geng M AD - School of Engineering Medicine, Texas A&M University, Houston, Texas, USA. FAU - Miles, Brian J AU - Miles BJ AD - Department of Urology, Houston Methodist Hospital, Houston, Texas, USA. FAU - Esnaola, Nestor AU - Esnaola N AD - Department of Surgery, Houston Methodist Hospital, Houston, Texas, USA. FAU - Klaassen, Zachary AU - Klaassen Z AD - Division of Urology, Medical College of Georgia, Augusta University, Augusta, Georgia, USA. FAU - Jerath, Angela AU - Jerath A AD - Department of Anesthesia, Sunnybrook Health Sciences Center, Toronto, Canada. FAU - Kim, S Joseph AU - Kim SJ AD - Division of Nephrology and the Kidney Transplant Program, University Health Network, University of Toronto, Toronto, Canada. FAU - Wallis, Christopher J D AU - Wallis CJD AD - Division of Urology and Surgical Oncology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Canada. AD - Division of Urology, University of Toronto, Toronto, Canada. AD - Division of Urology, Mount Sinai Hospital, Toronto, Canada. FAU - Satkunasivam, Raj AU - Satkunasivam R AD - Department of Urology, Houston Methodist Hospital, Houston, Texas, USA. LA - eng PT - Journal Article DEP - 20230719 PL - Australia TA - Nephrology (Carlton) JT - Nephrology (Carlton, Vic.) JID - 9615568 SB - IM MH - Adult MH - Male MH - Female MH - Humans MH - *Venous Thromboembolism/diagnosis/epidemiology/etiology MH - Postoperative Complications/etiology MH - Risk Factors MH - Cohort Studies MH - *Renal Insufficiency, Chronic/diagnosis/complications MH - Retrospective Studies OTO - NOTNLM OT - chronic kidney disease OT - glomerular filtration rate OT - outcome assessment OT - postoperative complication OT - preoperative care EDAT- 2023/07/20 01:07 MHDA- 2023/09/05 06:41 CRDT- 2023/07/19 19:52 PHST- 2023/07/04 00:00 [revised] PHST- 2023/05/01 00:00 [received] PHST- 2023/07/07 00:00 [accepted] PHST- 2023/09/05 06:41 [medline] PHST- 2023/07/20 01:07 [pubmed] PHST- 2023/07/19 19:52 [entrez] AID - 10.1111/nep.14221 [doi] PST - ppublish SO - Nephrology (Carlton). 2023 Oct;28(10):548-556. doi: 10.1111/nep.14221. Epub 2023 Jul 19. PMID- 37463735 OWN - NLM STAT- MEDLINE DCOM- 20231102 LR - 20231103 IS - 1468-2044 (Electronic) IS - 0003-9888 (Linking) VI - 108 IP - 11 DP - 2023 Nov TI - Resilience in children with congenital heart disease: a comparative study with health counterparts. PG - 935-939 LID - 10.1136/archdischild-2023-325605 [doi] AB - OBJECTIVE: Resilience is a complex, yet rather unexplored topic in patients with congenital heart disease (CHD). The goal of this study was to assess and compare resilience in children with CHD with healthy controls during the COVID-19 pandemic. DESIGN AND PATIENTS: From June 2020 to June 2021, 124 children with various CHDs (14.6+/-2.1 years, 49 girls) and 124 matched healthy controls (14.8+/-2.0 years, 49 girls) completed the Resilience Scale-11 short version. RESULTS: Resilience was significantly reduced in children with CHD compared with healthy controls (CHD: 59.0+/-10.0 vs healthy controls: 64.4+/-6.5, p<0.001). That reduction was prominent in all CHD subgroups except those with left heart obstruction (aortic stenosis and coarctation of the aorta) and patients with transposition of the great arteries. Complex CHD had the lowest resilience of 57.6+/-8.4 (p<0.001) after adjusting for age and sex according to group differences. There was no difference between native CHD and CHD with open-heart surgery (native: 59.5+/-12.2 vs surgery: 58.8+/-9.3, p=0.758). CONCLUSIONS: Resilience was reduced in children and adolescents with CHD compared with healthy peers during the COVID-19 pandemic. Children with complex severity appeared to be particularly affected. These findings emphasise continued efforts to provide a holistic and multidisciplinary approach in medical aftercare of these patients and their families. CI - (c) Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Koble, Katharina AU - Koble K AUID- ORCID: 0000-0002-4113-8773 AD - Institute of Preventive Pediatrics, Technical University of Munich, Munich, Germany katharina.koeble@tum.de. FAU - Willinger, Laura AU - Willinger L AUID- ORCID: 0000-0002-8577-4480 AD - Institute of Preventive Pediatrics, Technical University of Munich, Munich, Germany. AD - Department of Pediatric Cardiology and Congenital Heart Disease, Technical University of Munich, Munich, Germany. FAU - Brudy, Leon AU - Brudy L AUID- ORCID: 0000-0001-8700-3324 AD - Department of Pediatric Cardiology and Congenital Heart Disease, Technical University of Munich, Munich, Germany. FAU - Oberhoffer-Fritz, Renate AU - Oberhoffer-Fritz R AD - Institute of Preventive Pediatrics, Technical University of Munich, Munich, Germany. AD - Department of Pediatric Cardiology and Congenital Heart Disease, Technical University of Munich, Munich, Germany. FAU - Ewert, Peter AU - Ewert P AD - Department of Pediatric Cardiology and Congenital Heart Disease, Technical University of Munich, Munich, Germany. AD - partner site Munich Heart Alliance, German Centre for Cardiovascular Research, Munich, Germany. FAU - Muller, Jan AU - Muller J AUID- ORCID: 0000-0002-7530-2025 AD - Institute of Preventive Pediatrics, Technical University of Munich, Munich, Germany. AD - Department of Pediatric Cardiology and Congenital Heart Disease, Technical University of Munich, Munich, Germany. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230718 PL - England TA - Arch Dis Child JT - Archives of disease in childhood JID - 0372434 SB - IM MH - Female MH - Adolescent MH - Humans MH - Child MH - *Transposition of Great Vessels MH - Pandemics MH - *Heart Defects, Congenital/surgery/epidemiology MH - *Aortic Coarctation MH - *COVID-19/epidemiology OTO - NOTNLM OT - Cardiology OT - Covid-19 OT - Mental health OT - Psychology COIS- Competing interests: None declared. EDAT- 2023/07/19 01:06 MHDA- 2023/11/02 12:42 CRDT- 2023/07/18 20:52 PHST- 2023/03/20 00:00 [received] PHST- 2023/07/11 00:00 [accepted] PHST- 2023/11/02 12:42 [medline] PHST- 2023/07/19 01:06 [pubmed] PHST- 2023/07/18 20:52 [entrez] AID - archdischild-2023-325605 [pii] AID - 10.1136/archdischild-2023-325605 [doi] PST - ppublish SO - Arch Dis Child. 2023 Nov;108(11):935-939. doi: 10.1136/archdischild-2023-325605. Epub 2023 Jul 18. PMID- 37461430 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230719 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 15 IP - 7 DP - 2023 Jul TI - Primary Cardiac Angiosarcoma: A Review. PG - e41947 LID - 10.7759/cureus.41947 [doi] LID - e41947 AB - Primary cardiac angiosarcoma is a rare and aggressive malignancy originating from the endothelial lining of cardiac blood vessels. This review covers various aspects of the disease, including its pathogenesis, clinical presentation, diagnosis, treatment, and prognosis. The primary characteristic of cardiac angiosarcoma is the rapid growth of abnormal blood vessels that invade the heart muscle, leading to the destruction of healthy tissue. Due to its infiltrative nature and early spread, diagnosing and treating cardiac angiosarcoma present significant challenges. Transesophageal echocardiography (TEE) plays a crucial role in diagnosing cardiac tumors such as angiosarcoma due to its high sensitivity. Additional imaging techniques such as computed tomography (CT) and cardiac magnetic resonance imaging (MRI) help assess tumor anatomy and identify metastases. Histopathological examination and immunohistochemistry are essential for confirming the diagnosis, as they reveal distinct histological features and specific endothelial markers associated with primary cardiac angiosarcoma. Targeted therapies directed at the angiogenic mechanisms and molecular abnormalities hold promise for improving treatment outcomes. Early detection of primary cardiac angiosarcoma remains challenging due to its rarity, and the prognosis is generally poor due to advanced disease at the time of diagnosis. The review emphasizes the importance of a multidisciplinary approach and collaboration among different specialties to optimize the diagnosis, treatment, and follow-up care of patients with primary cardiac angiosarcoma. The ultimate goal is to enhance diagnostic methods and therapeutic approaches by advancing knowledge and promoting further research into this aggressive malignancy. CI - Copyright (c) 2023, Kumari et al. FAU - Kumari, Naina AU - Kumari N AD - Internal Medicine, Dow Medical College, Dow University of Health Sciences, Karachi, PAK. FAU - Bhandari, Sagar AU - Bhandari S AD - Cardiology, Tucson Medical Center, Tucson, USA. FAU - Ishfaq, Anzal AU - Ishfaq A AD - Internal Medicine, Mayo Hospital, Lahore, PAK. FAU - Butt, Samia Rauf R AU - Butt SRR AD - General Practice, California Institute of Behavioral Neurosciences and Psychology, Fairfield, USA. FAU - Ekhator, Chukwuyem AU - Ekhator C AD - Neuro-Oncology, New York Institute of Technology College of Osteopathic Medicine, Old Westbury, USA. FAU - Karski, Amanda AU - Karski A AD - Emergency Medicine, American University of Antigua, Miami, USA. FAU - Kadel, Bijan AU - Kadel B AD - Internal Medicine, Nepal Medical College and Teaching Hospital, Kathmandu, NPL. FAU - Altayb Ismail, Mohamedalamin Alnoor AU - Altayb Ismail MA AD - Internal Medicine, Ibrahim Malik Teaching Hospital, Khartoum, SDN. FAU - Sherpa, Tenzin N AU - Sherpa TN AD - Internal Medicine, Kathmandu University, Nepal Medical College, Kathmandu, NPL. FAU - Al Khalifa, Ahmed AU - Al Khalifa A AD - Medicine, College of Medicine, Sulaiman Alrajhi University, Al Bukayriyah, SAU. FAU - Khalifah, Bashar AU - Khalifah B AD - Pharmacy, Al Qassim National Hospital, Buraydah, SAU. FAU - Nguyen, Nhan AU - Nguyen N AD - Internal Medicine, University of Debrecen, Debrecen, HUN. FAU - Lazarevic, Slobodan AU - Lazarevic S AD - Internal Medicine, Faculty of Medicine, University of Nis, Nis, SRB. FAU - Zaman, Mohammad Uzair AU - Zaman MU AD - Medicine, Bacha Khan Medical College, Mardan, PAK. FAU - Ullah, Ashraf AU - Ullah A AD - Internal Medicine, Mayo Hospital, Lahore, PAK. FAU - Yadav, Vikas AU - Yadav V AD - Internal Medicine, Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Rohtak, IND. LA - eng PT - Journal Article PT - Review DEP - 20230716 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC10350284 OTO - NOTNLM OT - adult cardiac surgery OT - angiosarcoma OT - cardiology OT - primary cardiac angiosarcoma OT - tumor COIS- The authors have declared that no competing interests exist. EDAT- 2023/07/18 06:42 MHDA- 2023/07/18 06:43 PMCR- 2023/07/16 CRDT- 2023/07/18 03:35 PHST- 2023/07/15 00:00 [accepted] PHST- 2023/07/18 06:43 [medline] PHST- 2023/07/18 06:42 [pubmed] PHST- 2023/07/18 03:35 [entrez] PHST- 2023/07/16 00:00 [pmc-release] AID - 10.7759/cureus.41947 [doi] PST - epublish SO - Cureus. 2023 Jul 16;15(7):e41947. doi: 10.7759/cureus.41947. eCollection 2023 Jul. PMID- 37456345 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230718 IS - 2036-2579 (Electronic) IS - 1826-1868 (Print) IS - 1826-1868 (Linking) VI - 17 IP - 1 DP - 2023 TI - Low-flow, Low-gradient Severe Aortic Stenosis: A Review. PG - 8-12 LID - 10.17925/HI.2023.17.1.8 [doi] AB - Aortic stenosis (AS) is a common valve pathology experienced by patients worldwide. There are limited population-based studies assessing its prevalence; however, epidemiological studies emphasize that the burden of disease is growing. Recognizing AS relies on accurate clinical assessment and diagnostic investigations. Patients who develop severe AS are often referred to the heart team for assessment of aortic valve intervention. Although echocardiography has traditionally been used to screen and monitor the progression of AS, there can be discordance between measurements in a low-flow state. Such patients may have truly severe AS and potentially derive long-term benefit from aortic valve intervention. Accurately identifying these patients with the use of ancillary testing has been the focus of research for several years. In this article, we discuss the contemporary approaches and challenges in identifying and managing patients with low-flow, low-gradient severe AS. CI - (c) Touch Medical Media 2023. FAU - Sharma, Nishant AU - Sharma N AD - Libin Cardiovascular Institute, Foothills Medical Centre, University of Calgary, Calgary, Canada. FAU - Sachedina, Ayaaz K AU - Sachedina AK AD - Libin Cardiovascular Institute, Foothills Medical Centre, University of Calgary, Calgary, Canada. FAU - Kumar, Sachin AU - Kumar S AD - Memorial Hermann-Texas Medical Center, University of Texas Health Science Center, Houston, TX, USA. LA - eng PT - Journal Article PT - Review DEP - 20230117 PL - England TA - Heart Int JT - Heart international JID - 101541778 PMC - PMC10339455 OTO - NOTNLM OT - Aortic stenosis OT - low-flow aortic stenosis OT - low-gradient aortic stenosis OT - severe aortic stenosis OT - surgical aortic valve replacement OT - transaortic valve replacement COIS- Disclosures: Nishant Sharma, Ayaaz K Sachedina and Sachin Kumar have no financial or non-financial relationships or activities to declare in relation to this article EDAT- 2023/07/17 06:42 MHDA- 2023/07/17 06:43 PMCR- 2023/01/17 CRDT- 2023/07/17 04:22 PHST- 2022/10/31 00:00 [received] PHST- 2022/11/25 00:00 [accepted] PHST- 2023/07/17 06:43 [medline] PHST- 2023/07/17 06:42 [pubmed] PHST- 2023/07/17 04:22 [entrez] PHST- 2023/01/17 00:00 [pmc-release] AID - 10.17925/HI.2023.17.1.8 [doi] PST - epublish SO - Heart Int. 2023 Jan 17;17(1):8-12. doi: 10.17925/HI.2023.17.1.8. eCollection 2023. PMID- 37455220 OWN - NLM STAT- MEDLINE DCOM- 20230912 LR - 20230913 IS - 1532-8422 (Electronic) IS - 1053-0770 (Linking) VI - 37 IP - 10 DP - 2023 Oct TI - Red Blood Cell Conservation and Use in the Cardiovascular Operating Rooms at Ben Taub General Hospital. PG - 1946-1950 LID - S1053-0770(23)00406-8 [pii] LID - 10.1053/j.jvca.2023.06.026 [doi] AB - OBJECTIVES: A conservative hemoglobin transfusion threshold is noninferior to a liberal threshold in cardiac surgery. However, red blood cell (RBC) transfusion remains common during cardiac surgery. The authors' single-center, retrospective study aimed to decrease RBC transfusions for hemoglobin >7.5 g/dL in nonemergent cardiovascular surgeries utilizing cardiopulmonary bypass (CPB), by educating the anesthesiology and surgical staff on the benefits of a conservative threshold for transfusions, and incorporating the discussion and routine use of blood conservation methods for all nonemergent cardiac surgeries. DESIGN: This was a single-center, retrospective study that included all nonemergent coronary artery bypass grafting and single-valve cases utilizing CPB from January 2018 to December 2021 before and after the intervention in July 2019. SETTING: The data involved a single community hospital. PARTICIPANTS: A total of 417 patients were included in the study. INTERVENTIONS: The authors adopted a conservative threshold for blood transfusion and implemented a collaborative multidisciplinary approach to blood conservation. MEASUREMENTS AND MAIN RESULTS: Baseline patient characteristics were summarized, and the incidence of RBC transfusion before and after the intervention on July 26, 2019, were compared by Wilcoxon rank sum and chi-square tests. Multivariate logistic regression was used. The intervention was significantly associated with reduced RBC transfusion rate after adjusting for confounding variables (p < 0.05). The odds of receiving an RBC transfusion among patients after the intervention was 0.615 times the odds among patients before intervention (95% CI: 0.3913-0.9663). CONCLUSIONS: The authors' goal was to improve patient outcomes and the quality of perioperative care during cardiac surgery. By implementing a protocol and educating anesthesiologists, surgeons, and perfusionists, they successfully decreased the incidence of RBC transfusion above a hemoglobin of 7.5 g/dL. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Lindgren, Taylor AU - Lindgren T AD - Department of Anesthesiology. Baylor College of Medicine, Houston, TX. Electronic address: taylor.lindgren@bcm.edu. FAU - Kodakandla, Harica AU - Kodakandla H AD - Department of Anesthesiology. Baylor College of Medicine, Houston, TX. FAU - Caraway, Shelley M AU - Caraway SM AD - Department of Anesthesiology. Baylor College of Medicine, Houston, TX. FAU - Shah, Krishna B AU - Shah KB AD - Department of Anesthesiology. Baylor College of Medicine, Houston, TX. FAU - Huang, Xiaofan AU - Huang X AD - Baylor College of Medicine, Houston, TX. FAU - Ibekwe, Stephanie Opusunju AU - Ibekwe SO AD - Department of Anesthesiology. Baylor College of Medicine, Houston, TX. CN - Baylor College of Medicine Red Blood Cell Utilization for Cardiac Surgery Working Group AD - Baylor College of Medicine, Houston, TX; Ben Taub General Hospital, Houston, TX. LA - eng PT - Journal Article DEP - 20230619 PL - United States TA - J Cardiothorac Vasc Anesth JT - Journal of cardiothoracic and vascular anesthesia JID - 9110208 RN - 0 (Hemoglobins) SB - IM MH - Humans MH - Retrospective Studies MH - *Operating Rooms MH - *Hospitals, General MH - Hemoglobins MH - Erythrocytes OTO - NOTNLM OT - blood conservation OT - cardiopulmonary bypass OT - cardiovascular surgery OT - quality improvement OT - transfusion COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2023/07/17 00:42 MHDA- 2023/09/12 06:42 CRDT- 2023/07/16 21:59 PHST- 2023/03/13 00:00 [received] PHST- 2023/06/15 00:00 [revised] PHST- 2023/06/16 00:00 [accepted] PHST- 2023/09/12 06:42 [medline] PHST- 2023/07/17 00:42 [pubmed] PHST- 2023/07/16 21:59 [entrez] AID - S1053-0770(23)00406-8 [pii] AID - 10.1053/j.jvca.2023.06.026 [doi] PST - ppublish SO - J Cardiothorac Vasc Anesth. 2023 Oct;37(10):1946-1950. doi: 10.1053/j.jvca.2023.06.026. Epub 2023 Jun 19. PMID- 39129880 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260923 IS - 2772-9303 (Electronic) IS - 2772-9303 (Linking) VI - 2 IP - 6Part A DP - 2023 Nov-Dec TI - Building and Optimizing the Interdisciplinary Heart Team. PG - 101067 LID - 10.1016/j.jscai.2023.101067 [doi] LID - 101067 AB - A multidisciplinary care team model, or Heart Team approach, has become a central tenet of cardiovascular care. Though initially applied to the management of heart transplantation and subsequently complex coronary artery disease, the Heart Team is now utilized broadly across cardiovascular medicine, including in the treatment of valvular disease, pulmonary embolism, cardiogenic shock, high-risk pregnancies in patients with pre-existing cardiovascular disease, and adult congenital heart disease. The Heart Team model improves interdisciplinary collaboration among specialties, adherence to societal guidelines, and shared decision-making with patients and families. In this review, we highlight the development and rationale supporting the Heart Team model, address the challenges of implementing a multidisciplinary care team, and discuss the optimal methods to continue to build, optimize, and implement this approach. CI - (c) 2023 The Author(s). FAU - Lee, Christopher AU - Lee C AD - Heart and Vascular Center, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire. FAU - Tully, Andrew AU - Tully A AD - Department of Cardiothoracic Surgery, Emory University, Atlanta, Georgia. FAU - Fang, James C AU - Fang JC AD - Division of Cardiology, University of Utah Health, Salt Lake City, Utah. FAU - Sugeng, Lissa AU - Sugeng L AD - Department of Cardiology, Northwell Health, Manhasset, New York. FAU - Elmariah, Sammy AU - Elmariah S AD - Division of Cardiology, University of California San Francisco, San Francisco, California. FAU - Grubb, Kendra J AU - Grubb KJ AD - Department of Cardiothoracic Surgery, Emory University, Atlanta, Georgia. FAU - Young, Michael N AU - Young MN AD - Heart and Vascular Center, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire. LA - eng PT - Journal Article PT - Review DEP - 20230714 PL - United States TA - J Soc Cardiovasc Angiogr Interv JT - Journal of the Society for Cardiovascular Angiography & Interventions JID - 9918419271306676 PMC - PMC11308725 OTO - NOTNLM OT - Heart Team OT - multidisciplinary OT - shared decision-making EDAT- 2023/07/14 00:00 MHDA- 2023/07/14 00:01 PMCR- 2023/07/14 CRDT- 2024/08/12 05:56 PHST- 2023/02/06 00:00 [received] PHST- 2023/06/16 00:00 [revised] PHST- 2023/06/22 00:00 [accepted] PHST- 2023/07/14 00:01 [medline] PHST- 2023/07/14 00:00 [pubmed] PHST- 2024/08/12 05:56 [entrez] PHST- 2023/07/14 00:00 [pmc-release] AID - S2772-9303(23)00558-6 [pii] AID - 101067 [pii] AID - 10.1016/j.jscai.2023.101067 [doi] PST - epublish SO - J Soc Cardiovasc Angiogr Interv. 2023 Jul 14;2(6Part A):101067. doi: 10.1016/j.jscai.2023.101067. eCollection 2023 Nov-Dec. PMID- 37443678 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240922 IS - 2075-4418 (Print) IS - 2075-4418 (Electronic) IS - 2075-4418 (Linking) VI - 13 IP - 13 DP - 2023 Jul 5 TI - Marfan Syndrome: Enhanced Diagnostic Tools and Follow-up Management Strategies. LID - 10.3390/diagnostics13132284 [doi] LID - 2284 AB - Marfan syndrome (MFS) is a rare inherited autosomic disorder, which encompasses a variety of systemic manifestations caused by mutations in the Fibrillin-1 encoding gene (FBN1). Cardinal clinical phenotypes of MFS are highly variable in terms of severity, and commonly involve cardiovascular, ocular, and musculoskeletal systems with a wide range of manifestations, such as ascending aorta aneurysms and dissection, mitral valve prolapse, ectopia lentis and long bone overgrowth, respectively. Of note, an accurate and prompt diagnosis is pivotal in order to provide the best treatment to the patients as early as possible. To date, the diagnosis of the syndrome has relied upon a systemic score calculation as well as DNA mutation identification. The aim of this review is to summarize the latest MFS evidence regarding the definition, differences and similarities with other connective tissue pathologies with severe systemic phenotypes (e.g., Autosomal dominant Weill-Marchesani syndrome, Loeys-Dietz syndrome, Ehlers-Danlos syndrome) and clinical assessment. In this regard, the management of MFS requires a multidisciplinary team in order to accurately control the evolution of the most severe and potentially life-threatening complications. Based on recent findings in the literature and our clinical experience, we propose a multidisciplinary approach involving specialists in different clinical fields (i.e., cardiologists, surgeons, ophthalmologists, orthopedics, pneumologists, neurologists, endocrinologists, geneticists, and psychologists) to comprehensively characterize, treat, and manage MFS patients with a personalized medicine approach. FAU - Marelli, Susan AU - Marelli S AD - Cardiovascular-Genetic Center, IRCCS Policlinico San Donato, 20097 Milan, Italy. FAU - Micaglio, Emanuele AU - Micaglio E AUID- ORCID: 0000-0002-8298-7800 AD - Arrhythmia and Electrophysiology Department, IRCCS Policlinico San Donato, 20097 Milan, Italy. FAU - Taurino, Jacopo AU - Taurino J AD - Cardiovascular-Genetic Center, IRCCS Policlinico San Donato, 20097 Milan, Italy. FAU - Salvi, Paolo AU - Salvi P AD - Istituto Auxologico Italiano, Cardiology Unit, IRCCS, 20133 Milan, Italy. FAU - Rurali, Erica AU - Rurali E AD - Unit of Vascular Biology and Regenerative Medicine, Centro Cardiologico Monzino IRCCS, 20138 Milan, Italy. FAU - Perrucci, Gianluca L AU - Perrucci GL AUID- ORCID: 0000-0002-4758-6040 AD - Unit of Vascular Biology and Regenerative Medicine, Centro Cardiologico Monzino IRCCS, 20138 Milan, Italy. FAU - Dolci, Claudia AU - Dolci C AUID- ORCID: 0000-0002-3060-4097 AD - Laboratory of Functional Anatomy of the Stomatognathic System (LAFAS), Department of Biomedical Sciences for Health, Universita degli Studi di Milano, 20133 Milan, Italy. FAU - Udugampolage, Nathasha Samali AU - Udugampolage NS AD - Cardiovascular-Genetic Center, IRCCS Policlinico San Donato, 20097 Milan, Italy. FAU - Caruso, Rosario AU - Caruso R AUID- ORCID: 0000-0002-7736-6209 AD - Clinical Research Service, IRCCS Policlinico San Donato, 20097 Milan, Italy. AD - Department of Biomedical Sciences for Health, University of Milan, 20133 Milan, Italy. FAU - Gentilini, Davide AU - Gentilini D AD - Department of Brain and Behavioral Sciences, University of Pavia, 27100 Pavia, Italy. AD - Bioinformatics and Statistical Genomics Unit, Istituto Auxologico Italiano IRCCS, Cusano Milanino, University of Milano-Bicocca, 20095 Milan, Italy. FAU - Trifiro', Giuliana AU - Trifiro' G AD - Cardiovascular-Genetic Center, IRCCS Policlinico San Donato, 20097 Milan, Italy. FAU - Callus, Edward AU - Callus E AUID- ORCID: 0000-0001-9286-1825 AD - Department of Biomedical Sciences for Health, University of Milan, 20133 Milan, Italy. AD - Clinical Psychology Service, IRCCS Policlinico San Donato, 20097 Milan, Italy. FAU - Frigiola, Alessandro AU - Frigiola A AD - Department of Congenital Cardiac Surgery, IRCCS Policlinico San Donato, San Donato Milanese, 20097 Milan, Italy. AD - Association "Bambini Cardiopatici nel Mondo" Non-Governmental Organization (NGO), 20123 Milan, Italy. FAU - De Vincentiis, Carlo AU - De Vincentiis C AUID- ORCID: 0000-0002-9945-0057 AD - Department of Cardiothoracic, Vascular Anaesthesia and Intensive Care, IRCCS Policlinico San Donato, 20097 Milan, Italy. AD - Department of Cardiac Surgery, IRCCS Policlinico San Donato, 20097 Milan, Italy. FAU - Pappone, Carlo AU - Pappone C AD - Arrhythmia and Electrophysiology Department, IRCCS Policlinico San Donato, 20097 Milan, Italy. AD - Institute of Molecular and Translational Cardiology, IRCCS Policlinico San Donato, 20097 Milan, Italy. AD - Faculty of Medicine and Surgery, Vita-Salute San Raffaele University, 20132 Milan, Italy. FAU - Parati, Gianfranco AU - Parati G AUID- ORCID: 0000-0001-9402-7439 AD - Istituto Auxologico Italiano, Cardiology Unit, IRCCS, 20133 Milan, Italy. AD - Department of Medicine and Surgery, University of Milano-Bicocca, 20126 Milan, Italy. FAU - Pini, Alessandro AU - Pini A AUID- ORCID: 0000-0002-8325-6057 AD - Cardiovascular-Genetic Center, IRCCS Policlinico San Donato, 20097 Milan, Italy. LA - eng GR - Ricerca Corrente/Ministero della Salute/ PT - Journal Article PT - Review DEP - 20230705 PL - Switzerland TA - Diagnostics (Basel) JT - Diagnostics (Basel, Switzerland) JID - 101658402 PMC - PMC10340634 OTO - NOTNLM OT - Fibrillin-1 OT - Marfan syndrome OT - connective tissue disease OT - multidisciplinary approach OT - personalized medicine COIS- The authors declare no conflict of interest. EDAT- 2023/07/14 13:07 MHDA- 2023/07/14 13:08 PMCR- 2023/07/05 CRDT- 2023/07/14 01:01 PHST- 2023/06/13 00:00 [received] PHST- 2023/07/01 00:00 [revised] PHST- 2023/07/03 00:00 [accepted] PHST- 2023/07/14 13:08 [medline] PHST- 2023/07/14 13:07 [pubmed] PHST- 2023/07/14 01:01 [entrez] PHST- 2023/07/05 00:00 [pmc-release] AID - diagnostics13132284 [pii] AID - diagnostics-13-02284 [pii] AID - 10.3390/diagnostics13132284 [doi] PST - epublish SO - Diagnostics (Basel). 2023 Jul 5;13(13):2284. doi: 10.3390/diagnostics13132284. PMID- 37438180 OWN - NLM STAT- MEDLINE DCOM- 20230912 LR - 20230913 IS - 1532-8422 (Electronic) IS - 1053-0770 (Linking) VI - 37 IP - 10 DP - 2023 Oct TI - International Survey on Perioperative Management of Patients With Infective Endocarditis. PG - 1951-1958 LID - S1053-0770(23)00389-0 [pii] LID - 10.1053/j.jvca.2023.06.019 [doi] AB - OBJECTIVES: To estimate the current practice in the perioperative management of patients undergoing cardiac surgery due to infective endocarditis. DESIGN: A prospective, open, 24-item, web-based cross-sectional survey. SETTING: Online survey endorsed by the European Association of Cardiothoracic Anesthesiology and Intensive Care (EACTAIC). PARTICIPANTS: Members of the EACTAIC. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: A total of 156 responses from 44 countries were received, with a completion rate of 99%. The response rate was 16.6%. Most respondents (76%) practiced cardiac anesthesia in European hospitals, and most respondents stated that a multidisciplinary endocarditis team was not established at their center, that cardiac anesthesiologists appeared to be involved infrequently in those teams (36%), and that they were not involved in decision-making on indication and timing of surgery (88%). In contrast, the cardiac anesthesiologist performed intraoperative antibiotic therapy (62%) and intraoperative transesophageal echocardiography (90%). Furthermore, there was a relative heterogeneity concerning perioperative monitoring, as well as for coagulation and transfusion management. CONCLUSIONS: This international survey evaluated current practice among cardiac anesthesiologists in the perioperative management of patients with infective endocarditis and the anesthesiologist's role in multidisciplinary decision-making. Heterogeneity in treatment approaches was identified, indicating relevant knowledge gaps that should encourage further clinical research to optimize treatment and postoperative outcomes in this specific population. CI - Copyright (c) 2023 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Breel, Jennifer S AU - Breel JS AD - Department of Anesthesiology, Amsterdam University Medical Center, Amsterdam, The Netherlands. FAU - Eberl, Susanne AU - Eberl S AD - Department of Anesthesiology, Amsterdam University Medical Center, Amsterdam, The Netherlands. Electronic address: s.eberl@amsterdamumc.nl. FAU - Preckel, Benedikt AU - Preckel B AD - Department of Anesthesiology, Amsterdam University Medical Center, Amsterdam, The Netherlands. FAU - Huhn, Ragnar AU - Huhn R AD - Department of Anesthesiology, Kerckhoff-Clinic, Bad Nauheim, Germany. FAU - Hollmann, Markus W AU - Hollmann MW AD - Department of Anesthesiology, Amsterdam University Medical Center, Amsterdam, The Netherlands. FAU - Rex, Steffen AU - Rex S AD - Department of Anesthesiology, University Hospitals Leuven, Leuven, Belgium. FAU - Hermanns, Henning AU - Hermanns H AD - Department of Anesthesiology, Amsterdam University Medical Center, Amsterdam, The Netherlands. LA - eng PT - Journal Article DEP - 20230614 PL - United States TA - J Cardiothorac Vasc Anesth JT - Journal of cardiothoracic and vascular anesthesia JID - 9110208 SB - IM MH - Humans MH - Cross-Sectional Studies MH - Prospective Studies MH - *Cardiac Surgical Procedures MH - Surveys and Questionnaires MH - *Endocarditis/surgery OTO - NOTNLM OT - anesthesia OT - cardiac surgery OT - infective endocarditis OT - survey COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2023/07/13 01:06 MHDA- 2023/09/12 06:41 CRDT- 2023/07/12 21:58 PHST- 2023/05/11 00:00 [received] PHST- 2023/06/02 00:00 [revised] PHST- 2023/06/11 00:00 [accepted] PHST- 2023/09/12 06:41 [medline] PHST- 2023/07/13 01:06 [pubmed] PHST- 2023/07/12 21:58 [entrez] AID - S1053-0770(23)00389-0 [pii] AID - 10.1053/j.jvca.2023.06.019 [doi] PST - ppublish SO - J Cardiothorac Vasc Anesth. 2023 Oct;37(10):1951-1958. doi: 10.1053/j.jvca.2023.06.019. Epub 2023 Jun 14. PMID- 37436647 OWN - NLM STAT- MEDLINE DCOM- 20240131 LR - 20261010 IS - 1534-3170 (Electronic) IS - 1523-3782 (Linking) VI - 25 IP - 8 DP - 2023 Aug TI - Broadening Heart Failure Care Beyond Cardiology: Challenges and Successes Within the Landscape of Multidisciplinary Heart Failure Care. PG - 851-861 LID - 10.1007/s11886-023-01907-5 [doi] AB - PURPOSE OF REVIEW: Heart failure (HF) is a growing public health concern that impairs the quality of life and is associated with significant mortality. As the prevalence of heart failure increases, multidisciplinary care is essential to provide comprehensive care to individuals. RECENT FINDINGS: The challenges of implementing an effective multidisciplinary care team can be daunting. Effective multidisciplinary care begins at the initial diagnosis of heart failure. The transition of care from the inpatient to the outpatient setting is critically important. The use of home visits, case management, and multidisciplinary clinics has been shown to decrease mortality and heart failure hospitalizations, and major society guidelines endorse multidisciplinary care for heart failure patients. Expanding heart failure care beyond cardiology entails incorporating primary care, advanced practice providers, and other disciplines. Patient education and self-management are fundamental to multidisciplinary care, as is a holistic approach to effectively address comorbid conditions. Ongoing challenges include navigating social disparities within heart failure care and limiting the economic burden of the disease. CI - (c) 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Olson, Michael AU - Olson M AD - Baylor College of Medicine, 7200 Cambridge St, Ste 6C, Houston, TX, 77030, USA. FAU - Thompson, Zachary AU - Thompson Z AD - Baylor College of Medicine, 7200 Cambridge St, Ste 6C, Houston, TX, 77030, USA. FAU - Xie, Lola AU - Xie L AD - Baylor College of Medicine, 7200 Cambridge St, Ste 6C, Houston, TX, 77030, USA. AD - The Texas Heart Institute, Cardiology, Houston, TX, 77030, USA. FAU - Nair, Ajith AU - Nair A AUID- ORCID: 0000-0002-3755-4985 AD - Baylor College of Medicine, 7200 Cambridge St, Ste 6C, Houston, TX, 77030, USA. ajith.nair@bcm.edu. AD - The Texas Heart Institute, Cardiology, Houston, TX, 77030, USA. ajith.nair@bcm.edu. LA - eng PT - Journal Article PT - Review DEP - 20230712 PL - United States TA - Curr Cardiol Rep JT - Current cardiology reports JID - 100888969 SB - IM MH - *Heart Failure/therapy MH - Humans MH - Cardiology MH - *Patient Care Team MH - Quality of Life MH - *Cardiac Rehabilitation MH - Telemedicine MH - Palliative Care MH - *Self Care OTO - NOTNLM OT - Cardiac rehabilitation OT - Device monitoring OT - Heart failure OT - Multidisciplinary care OT - Palliative care OT - Self-care OT - Telehealth EDAT- 2023/07/12 13:07 MHDA- 2023/08/07 06:42 CRDT- 2023/07/12 11:13 PHST- 2023/06/13 00:00 [accepted] PHST- 2023/08/07 06:42 [medline] PHST- 2023/07/12 13:07 [pubmed] PHST- 2023/07/12 11:13 [entrez] AID - 10.1007/s11886-023-01907-5 [pii] AID - 10.1007/s11886-023-01907-5 [doi] PST - ppublish SO - Curr Cardiol Rep. 2023 Aug;25(8):851-861. doi: 10.1007/s11886-023-01907-5. Epub 2023 Jul 12. PMID- 37435683 OWN - NLM STAT- MEDLINE DCOM- 20230803 LR - 20230807 IS - 1531-6971 (Electronic) IS - 1070-5287 (Linking) VI - 29 IP - 5 DP - 2023 Sep 1 TI - Approach to the hospitalized patient with pulmonary arterial hypertension. PG - 329-339 LID - 10.1097/MCP.0000000000000993 [doi] AB - PURPOSE OF REVIEW: Hospitalization in pulmonary arterial hypertension (PAH) patients is an important clinical worsening event significantly associated with subsequent mortality. Furthermore, irrespective of the cause of hospitalization, the overall outcome is closely related to the severity of the right ventricular (RV) dysfunction. Therefore, understanding the pathophysiology of pulmonary hypertension and RV failure is paramount in successfully managing PAH patients requiring hospitalization. This review highlights diagnostic and therapeutic approaches in various clinical scenarios that might be encountered during hospitalization of the World Health Organization group I PAH patient. RECENT FINDINGS: This article covers recent literature describing risk factors, predictors of outcome and state-of the art management approach to a hospitalized PAH patients with a special focus on management of RV failure and common complications in PAH requiring hospitalization. SUMMARY: The review highlights the importance of multidisciplinary approach to a hospitalized PAH patient and highlight important implications in clinical practice and knowledge gaps for potential future research. CI - Copyright (c) 2023 Wolters Kluwer Health, Inc. All rights reserved. FAU - Deshwal, Himanshu AU - Deshwal H AD - Pulmonary Hypertension Clinic, Section of Pulmonary, Sleep and Critical Care Medicine, Department of Medicine, West Virginia University School of Medicine, Morgantown, West Virginia 26505. FAU - Sulica, Roxana AU - Sulica R AD - Director of Pulmonary Hypertension Program, Section of Pulmonary, Sleep and Critical Care Medicine, Department of Medicine, New York University Grossman School of Medicine, New York, New York 10016, USA. LA - eng PT - Journal Article PT - Review DEP - 20230711 PL - United States TA - Curr Opin Pulm Med JT - Current opinion in pulmonary medicine JID - 9503765 SB - IM MH - Humans MH - *Pulmonary Arterial Hypertension/therapy/complications MH - Familial Primary Pulmonary Hypertension MH - *Hypertension, Pulmonary/diagnosis MH - *Heart Failure/complications MH - *Ventricular Dysfunction, Right/etiology EDAT- 2023/07/12 06:42 MHDA- 2023/08/03 06:43 CRDT- 2023/07/12 04:13 PHST- 2023/08/03 06:43 [medline] PHST- 2023/07/12 06:42 [pubmed] PHST- 2023/07/12 04:13 [entrez] AID - 00063198-202309000-00002 [pii] AID - 10.1097/MCP.0000000000000993 [doi] PST - ppublish SO - Curr Opin Pulm Med. 2023 Sep 1;29(5):329-339. doi: 10.1097/MCP.0000000000000993. Epub 2023 Jul 11. PMID- 37434598 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230718 IS - 2472-0054 (Electronic) IS - 2472-0054 (Linking) VI - 8 IP - 4 DP - 2023 Jul-Aug TI - A Quality Improvement Initiative to Improve Pediatric Discharge Medication Safety and Efficiency. PG - e671 LID - 10.1097/pq9.0000000000000671 [doi] LID - e671 AB - Medication errors are a leading safety concern, especially for families with limited English proficiency and health literacy, and patients discharged on multiple medications with complex schedules. Integration of a multilanguage electronic discharge medication platform may help decrease medication errors. This quality improvement (QI) project's primary aim (process measure) was to increase utilization in the electronic health record (EHR) of the integrated MedActionPlanPro (MAP) for cardiovascular surgery and blood and marrow transplant patients at hospital discharge and for the first clinic follow-up visit to 80% by July 2021. METHODS: This QI project occurred between August 2020 and July 2021 on 2 subspecialty pediatric acute care inpatient units and respective outpatient clinics. An interdisciplinary team developed and implemented interventions, including integration of MAP within EHR; the team tracked and analyzed outcomes for discharge medication matching, and efficacy and safety MAP integration occurred with a go-live date of February 1, 2021. Statistical process control charts tracked progress. RESULTS: Following the implementation of the QI interventions, there was an increase from 0% to 73% in the utilization of the integrated MAP in the EHR across the acute care cardiology unit-cardiovascular surgery/blood and marrow transplant units. The average user hours per patient (outcome measure) decreased 70% from the centerline of 0.89 hours during the baseline period to 0.27 hours. In addition, the medication matching between Cerner inpatient and MAP inpatient increased significantly from baseline to postintervention by 25.6% (P < 0.001). CONCLUSION: MAP integration into the EHR was associated with improved inpatient discharge medication reconciliation safety and provider efficiency. CI - Copyright (c) 2023 the Author(s). Published by Wolters Kluwer Health, Inc. FAU - Ring, Lisa M AU - Ring LM AD - Children's National Heart Institute, Children's National Hospital, Washington, D.C. AD - Department of Pediatrics, George Washington School of Medicine and Health Sciences, Washington, D.C. AD - Department of Advanced Practice Providers, Children's National Hospital, Washington, D.C. FAU - Cinotti, Jamie AU - Cinotti J AD - Global Services, Children's National Hospital, Washington, D.C. FAU - Hom, Lisa A AU - Hom LA AD - Children's National Heart Institute, Children's National Hospital, Washington, D.C. AD - Department of Pediatrics, George Washington School of Medicine and Health Sciences, Washington, D.C. FAU - Mullenholz, Mary AU - Mullenholz M AD - Children's National Heart Institute, Children's National Hospital, Washington, D.C. FAU - Mangum, Jordan AU - Mangum J AD - Children's National Heart Institute, Children's National Hospital, Washington, D.C. FAU - Ahmed-Winston, Sameeya AU - Ahmed-Winston S AD - Division of Bone Marrow Transplant, Children's National Hospital, Washington, D.C. FAU - Cheng, Jenhao Jacob AU - Cheng JJ AD - Children's National Heart Institute, Children's National Hospital, Washington, D.C. FAU - Randolph, Ellie AU - Randolph E AD - Global Services, Children's National Hospital, Washington, D.C. FAU - Harahsheh, Ashraf S AU - Harahsheh AS AD - Children's National Heart Institute, Children's National Hospital, Washington, D.C. AD - Department of Pediatrics, George Washington School of Medicine and Health Sciences, Washington, D.C. LA - eng PT - Journal Article DEP - 20230710 PL - United States TA - Pediatr Qual Saf JT - Pediatric quality & safety JID - 101702480 PMC - PMC10332828 COIS- The authors have no financial interest to declare in relation to the content of this article. EDAT- 2023/07/12 06:42 MHDA- 2023/07/12 06:43 PMCR- 2023/07/10 CRDT- 2023/07/12 03:43 PHST- 2022/12/12 00:00 [received] PHST- 2023/06/13 00:00 [accepted] PHST- 2023/07/12 06:43 [medline] PHST- 2023/07/12 06:42 [pubmed] PHST- 2023/07/12 03:43 [entrez] PHST- 2023/07/10 00:00 [pmc-release] AID - 10.1097/pq9.0000000000000671 [doi] PST - epublish SO - Pediatr Qual Saf. 2023 Jul 10;8(4):e671. doi: 10.1097/pq9.0000000000000671. eCollection 2023 Jul-Aug. PMID- 37428778 OWN - NLM STAT- MEDLINE DCOM- 20230908 LR - 20230928 IS - 1540-8159 (Electronic) IS - 0147-8389 (Linking) VI - 46 IP - 9 DP - 2023 Sep TI - Electrophysiological evaluation following development of new and persistent left bundle branch block after transcatheter aortic valve replacement: A single center pilot study. PG - 1099-1108 LID - 10.1111/pace.14784 [doi] AB - INTRODUCTION: New and persistent left bundle branch block (NP-LBBB) following Transcatheter Aortic Valve Replacement (TAVR) is an ongoing concern with incidence ranging from as low as 4% to up to 65% (varying for different types of valves). Such patients are at risk of developing high-grade atrioventricular block (HAVB) warranting permanent pacemaker (PPM) implantation. However, currently, there are no consensus guidelines or large prospective studies to risk stratify these patients for safer discharge after TAVR. OBJECTIVES: To provide insight from a single center study on using modified electrophysiology (EP) study to risk stratify post-TAVR patients to outpatient monitoring for low-risk versus pacemaker implantation for high-risk patients. METHODS AND RESULTS: Between June 2020 and March 2023, all patients who underwent a TAVR procedure (324 patients) at our institution were screened for development of NP-LBBB post-operatively. Out of 26 patients who developed NP-LBBB, after a pre-specified period of observation, 18 patients were deemed eligible for a modified EP study to assess His-Ventricular (HV) interval. 11 out of 18 patients (61.1%) had normal HV interval (HV < 55 ms). Three out of 18 patients (16.7%) had HV prolongation (55 ms < HV < 70 ms) without significant HV prolongation (defined as an increase in HV interval > 30%) with intra-procedural procainamide challenge. Four out of 18 patients (22.2%) had significant HV prolongation (HV > 70 ms) warranting PPM implantation based on a multidisciplinary approach and shared decision-making with the patients. Total of 50% of patients discharged with PPM (two out of four patients) were noted to be pacemaker dependent based on serial device interrogations. All patients who did not receive PPM were discharged with ambulatory monitoring with 30-day event monitor and did not develop HAVB on serial follow-up. CONCLUSION: Normal HV interval up to 55 ms on modified EP study after TAVR and development of NP-LBBB can be utilized as a threshold for risk stratification to facilitate safe discharge. The optimal upper limit of HV interval threshold remains unclear in determining appropriate candidacy for PPM. CI - (c) 2023 Wiley Periodicals LLC. FAU - Patel, Hiren AU - Patel H AD - Division of Cardiovascular Medicine, Saint Louis University, Saint Louis, Missouri, USA. FAU - Tsai, Christina AU - Tsai C AD - Department of Medicine, Saint Louis University, Saint Louis, Missouri, USA. FAU - Atallah, Issam AU - Atallah I AD - Division of Cardiovascular Medicine, Saint Louis University, Saint Louis, Missouri, USA. FAU - Ahmad, Ali AU - Ahmad A AD - Department of Medicine, Saint Louis University, Saint Louis, Missouri, USA. FAU - Bedi, Rohil AU - Bedi R AD - Department of Medicine, Saint Louis University, Saint Louis, Missouri, USA. FAU - Golemi, Lolita AU - Golemi L AD - Department of Medicine, Saint Louis University, Saint Louis, Missouri, USA. FAU - Mikhail, Salwa AU - Mikhail S AD - Saint Louis University School of Medicine, Saint Louis, Missouri, USA. FAU - Karickal, Jissmaria AU - Karickal J AD - Saint Louis University School of Medicine, Saint Louis, Missouri, USA. FAU - Azrak, Elie AU - Azrak E AD - SSM Health, Heart and Vascular Institute, Saint Louis, Missouri, USA. FAU - Bishara, Sam AU - Bishara S AD - SSM Health, Heart and Vascular Institute, Saint Louis, Missouri, USA. FAU - Harjai, Kishore AU - Harjai K AD - Division of Cardiovascular Medicine, Saint Louis University, Saint Louis, Missouri, USA. FAU - Bauer, Christopher AU - Bauer C AD - SSM Health, Heart and Vascular Institute, Saint Louis, Missouri, USA. FAU - Hussein, Ahmed AU - Hussein A AD - Division of Cardiovascular Medicine, Saint Louis University, Saint Louis, Missouri, USA. FAU - Gopinathannair, Rakesh AU - Gopinathannair R AD - Kansas City Heart Rhythm Institute, Kansas City, Kansas, USA. FAU - Mar, Philip L AU - Mar PL AUID- ORCID: 0000-0002-3576-0435 AD - Division of Cardiovascular Medicine, Saint Louis University, Saint Louis, Missouri, USA. LA - eng PT - Journal Article DEP - 20230710 PL - United States TA - Pacing Clin Electrophysiol JT - Pacing and clinical electrophysiology : PACE JID - 7803944 SB - IM MH - Humans MH - Bundle-Branch Block/etiology/therapy MH - *Transcatheter Aortic Valve Replacement/adverse effects MH - Pilot Projects MH - Prospective Studies MH - Treatment Outcome MH - Risk Factors MH - Arrhythmias, Cardiac/etiology MH - *Atrioventricular Block MH - *Pacemaker, Artificial/adverse effects MH - *Aortic Valve Stenosis/surgery MH - Aortic Valve/surgery OTO - NOTNLM OT - LBBB OT - TAVR OT - permanent pacemaker EDAT- 2023/07/10 19:08 MHDA- 2023/09/08 06:42 CRDT- 2023/07/10 13:35 PHST- 2023/06/13 00:00 [revised] PHST- 2023/05/09 00:00 [received] PHST- 2023/06/26 00:00 [accepted] PHST- 2023/09/08 06:42 [medline] PHST- 2023/07/10 19:08 [pubmed] PHST- 2023/07/10 13:35 [entrez] AID - 10.1111/pace.14784 [doi] PST - ppublish SO - Pacing Clin Electrophysiol. 2023 Sep;46(9):1099-1108. doi: 10.1111/pace.14784. Epub 2023 Jul 10. PMID- 37427202 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230718 IS - 2049-0801 (Print) IS - 2049-0801 (Electronic) IS - 2049-0801 (Linking) VI - 85 IP - 7 DP - 2023 Jul TI - Infective endocarditis presenting as meningitis: a case report. PG - 3638-3641 LID - 10.1097/MS9.0000000000000895 [doi] AB - Infective endocarditis (IE) primarily affects the endocardium of heart valves. Neurologic manifestations include strokes, intracerebral hemorrhages, meningitis, cerebral and spinal abscess, and mycotic aneurysms. Although rare, meningitis is a potentially life-threatening complication of IE, so physicians should be aware of this rare and fatal complication of IE. CASE PRESENTATION: Here, the authors present a case of a 53-year-old male who presented with bacterial meningitis secondary to IE. His blood culture was positive for methicillin-sensitive staphylococcal aureus. Echocardiography findings were suggestive of endocarditis. Despite aggressive intensive care management, our patient did not survive. CLINICAL DISCUSSION: The isolation of Staphylococcus aureus in culture should raise a suspicion of foci being elsewhere outside the central nervous system. Treatment of complications like meningitis may require intrathecal antibiotics. The vegetation and neurological complications are often difficult to treat and require the participation of a multidisciplinary team. CONCLUSIONS: The diagnosis of IE in patients presenting with neurologic deficits and fever should be considered. A physician should raise a suspicion of infective foci being elsewhere outside the central nervous system if the organism isolated in culture is Staphylococcus aureus. CI - Copyright (c) 2023 The Author(s). Published by Wolters Kluwer Health, Inc. FAU - Gautam, Sudarshan AU - Gautam S AD - Maimonides Medical Center, Brooklyn. FAU - Sharma, Nava R AU - Sharma NR AD - Manipal College of Medical Sciences, Pokhara, Nepal. FAU - Kansakar, Sajog AU - Kansakar S AD - Manipal College of Medical Sciences, Pokhara, Nepal. FAU - Lamichhane, Saral AU - Lamichhane S AD - Gandaki Medical College. FAU - Pokhrel, Madalasa AU - Pokhrel M AD - Montefiore New Rochelle Hospital, New York, USA. FAU - Basnet, Arjun AU - Basnet A AD - Maimonides Medical Center, Brooklyn. LA - eng PT - Journal Article DEP - 20230607 PL - England TA - Ann Med Surg (Lond) JT - Annals of medicine and surgery (2012) JID - 101616869 PMC - PMC10328663 OTO - NOTNLM OT - echocardiography OT - infective endocarditis OT - meningitis OT - staphylococcus aureus COIS- None. EDAT- 2023/07/10 06:42 MHDA- 2023/07/10 06:43 PMCR- 2023/06/07 CRDT- 2023/07/10 05:21 PHST- 2023/03/28 00:00 [received] PHST- 2023/05/14 00:00 [accepted] PHST- 2023/07/10 06:43 [medline] PHST- 2023/07/10 06:42 [pubmed] PHST- 2023/07/10 05:21 [entrez] PHST- 2023/06/07 00:00 [pmc-release] AID - AMSU-D-23-00676 [pii] AID - 10.1097/MS9.0000000000000895 [doi] PST - epublish SO - Ann Med Surg (Lond). 2023 Jun 7;85(7):3638-3641. doi: 10.1097/MS9.0000000000000895. eCollection 2023 Jul. PMID- 37427174 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230718 IS - 2049-0801 (Print) IS - 2049-0801 (Electronic) IS - 2049-0801 (Linking) VI - 85 IP - 7 DP - 2023 Jul TI - Ectopia cordis with multiple ventricular septal defect and sternal cleft in a newborn: a case report. PG - 3595-3598 LID - 10.1097/MS9.0000000000000329 [doi] AB - Ectopia cordis is a rare type of malformation where the heart is not located normally. It may be partially or completely located outside the thoracic cavity and can be associated with other congenital abnormalities. CASE PRESENTATION: This case report is of a 34-week- and 6-day-old female fetus with a birth weight of 2040 g, a height of 41 cm, and a head circumference of 32 cm. The initial physical examination revealed a responsive newborn with an externalized heart outside the chest, with pericardium protection. In addition, a thoracic wall defect was detected suggesting incomplete formation of the septum bone. Moreover, in this case, the echocardiography report showed a multiple ventricular septal defect. CONCLUSION: The management of ectopia cordis is a challenge for any obstetrician and pediatric surgeon due to its rarity. It causes mental agony and anxiety to the parents. With an early diagnosis, termination of pregnancy can be one of the options. Once it is diagnosed late, it needs a multidisciplinary approach, and the services of a very experienced pediatric surgeon to improve the prognosis. CI - Copyright (c) 2023 The Author(s). Published by Wolters Kluwer Health, Inc. FAU - Goli, Rasoul AU - Goli R AUID- ORCID: 0000-0001-7843-0084 AD - Department of Medical-Surgical Nursing. FAU - Majidi Balaneji, Sahar AU - Majidi Balaneji S AD - Department of Midwifery, School of Nursing and Midwifery, Islamic Azad University of Urmia, West Azerbaijan. FAU - Hosseinpour, Leila AU - Hosseinpour L AD - Department of Midwifery, School of Nursing and Midwifery, Islamic Azad University of Tabriz, East Azerbaijan. FAU - Abbasi, Mahdiyeh AU - Abbasi M AD - Department of Psychiatric Nursing, School of Nursing and Midwifery, Urmia University of Medical Sciences, Urmia. FAU - Feizi, Milad AU - Feizi M AD - Department of Psychiatric Nursing, School of Nursing and Midwifery, Urmia University of Medical Sciences, Urmia. FAU - Nafe, Parihan AU - Nafe P AD - Department of Nursing, School of Nursing and Midwifery, Islamic Azad University of Urmia, Urmia. FAU - Faraji, Navid AU - Faraji N AUID- ORCID: 0000-0003-0572-1694 AD - Department of Medical-Surgical Nursing. FAU - Heydari Bisafar, Mojgan AU - Heydari Bisafar M AD - Department of Nursing, School of Nursing and Midwifery, Islamic Azad University of Urmia, Urmia. FAU - Arad, Mansour AU - Arad M AD - Department of Medical-Surgical Nursing, Clinical Care Research Center, Research Institute for Health Development, Kurdistan university of Medical Science, Sanandaj, Iran. LA - eng PT - Journal Article DEP - 20230608 PL - England TA - Ann Med Surg (Lond) JT - Annals of medicine and surgery (2012) JID - 101616869 PMC - PMC10328574 OTO - NOTNLM OT - congenital cardiac anomaly OT - ectopia cordis OT - sternal cleft OT - ventricular septal defect COIS- None. EDAT- 2023/07/10 06:42 MHDA- 2023/07/10 06:43 PMCR- 2023/06/08 CRDT- 2023/07/10 05:21 PHST- 2022/11/24 00:00 [received] PHST- 2023/02/12 00:00 [accepted] PHST- 2023/07/10 06:43 [medline] PHST- 2023/07/10 06:42 [pubmed] PHST- 2023/07/10 05:21 [entrez] PHST- 2023/06/08 00:00 [pmc-release] AID - AMSU-D-22-02865 [pii] AID - 10.1097/MS9.0000000000000329 [doi] PST - epublish SO - Ann Med Surg (Lond). 2023 Jun 8;85(7):3595-3598. doi: 10.1097/MS9.0000000000000329. eCollection 2023 Jul. PMID- 37423243 OWN - NLM STAT- MEDLINE DCOM- 20230711 LR - 20230718 IS - 2208-7958 (Electronic) VI - 52 IP - 7 DP - 2023 Jul TI - Aortic stenosis and transcatheter aortic valve implantation in the elderly. PG - 458-463 LID - 10.31128/AJGP-08-22-6527 [doi] AB - BACKGROUND: Severe aortic stenosis (AS) is a condition that commonly affects elderly Australians. Once symptomatic, severe AS has a poor prognosis if untreated. Transcatheter aortic valve implantation (TAVI) is a percutaneous procedure that is now the recommended treatment for elderly patients with severe AS who are suitable for intervention. OBJECTIVE: This article provides a contemporary review of the diagnosis and management of severe AS in the elderly. DISCUSSION: Management options for severe AS include TAVI, surgical aortic valve replacement (SAVR), or medical/palliative therapy. In elderly adults, TAVI improves mortality, symptoms and quality of life compared with medical therapy, and is superior to SAVR. The decision regarding which management option is most appropriate for an individual patient is made using a collaborative multidisciplinary approach. General practitioners play key roles in providing information to risk stratify patients when considering intervention, caring for patients after the procedure and/or providing medical and palliative treatment for those deemed unsuitable for intervention. FAU - Rayner, Clare AU - Rayner C AD - BExSc, MD, MMED, Basic Physician Trainee, Royal Hobart Hospital, Hobart, Tas. FAU - Adams, Heath AU - Adams H AD - MBBS(Hons), BMedSci DipUKMP, GradDipClinLShip, FCSANZ, FRACP, Interventional Cardiologist, Royal Hobart Hospital, Hobart, Tas. LA - eng PT - Journal Article PL - Australia TA - Aust J Gen Pract JT - Australian journal of general practice JID - 101718099 SB - IM MH - Adult MH - Humans MH - Aged MH - *Transcatheter Aortic Valve Replacement/adverse effects/methods MH - Quality of Life MH - Risk Factors MH - Australia MH - *Aortic Valve Stenosis/surgery/diagnosis EDAT- 2023/07/10 00:41 MHDA- 2023/07/11 06:41 CRDT- 2023/07/09 19:02 PHST- 2023/07/11 06:41 [medline] PHST- 2023/07/10 00:41 [pubmed] PHST- 2023/07/09 19:02 [entrez] AID - 10.31128/AJGP-08-22-6527 [doi] PST - ppublish SO - Aust J Gen Pract. 2023 Jul;52(7):458-463. doi: 10.31128/AJGP-08-22-6527. PMID- 32809523 STAT- Publisher CTDT- 20230710 PB - StatPearls Publishing DP - 2023 Jan TI - Insulin. BTI - StatPearls AB - Insulin is a medication used in the treatment and management of diabetes mellitus type-1 and sometimes diabetes mellitus type-2, both of which are significant risk factors for coronary artery disease, stroke, peripheral vascular disease, and a host of other vascular conditions. This activity reviews the indications, contraindications, activity, adverse events, and other key elements of Insulin therapy in the clinical setting related to the essential points needed by members of an interprofessional team managing the care of patients with diabetes and its related conditions and sequelae. CI - Copyright (c) 2023, StatPearls Publishing LLC. FAU - Thota, Sushmita AU - Thota S AD - NTR University of Health Sciences FAU - Akbar, Aelia AU - Akbar A AD - Loyola University Medical Center LA - eng PT - Study Guide PT - Book Chapter PL - Treasure Island (FL) COIS- Disclosure: Sushmita Thota declares no relevant financial relationships with ineligible companies. Disclosure: Aelia Akbar declares no relevant financial relationships with ineligible companies. EDAT- 2023/07/10 00:00 CRDT- 2023/07/10 00:00 AID - NBK560688 [bookaccession] PMID- 30521208 STAT- Publisher CTDT- 20230710 PB - StatPearls Publishing DP - 2023 Jan TI - Labetalol. BTI - StatPearls AB - Due to their negative inotropic and chronotropic actions, beta-adrenergic receptor antagonists are typically indicated in individuals with chronic cardiovascular disease (hypertension, coronary artery disease, congestive heart failure) with a significant reduction in mortality. The FDA-approved indication for labetalol is to treat arterial hypertension, which ranges from acute hypertensive crises (urgent/emergency) to stable chronic hypertension. Labetalol in clinical practice has several common off-label uses that include acute hypertension in pregnancy and hypertension associated with acute ischemic stroke, and intracranial hemorrhage, including subarachnoid hemorrhage. Today, labetalol is usually reserved for the acute management of hypertensive crises. This activity covers labetalol, including mechanism of action, pharmacology, adverse event profiles, eligible patient populations, contraindications, monitoring, and highlights the role of the interprofessional team in the management of labetalol therapy. CI - Copyright (c) 2023, StatPearls Publishing LLC. FAU - Miller, Michael AU - Miller M AD - BAMC FAU - Maani, Christopher V AU - Maani CV AD - US Army; USUHS; BAMC; UTHSCSA; UIW LA - eng PT - Study Guide PT - Book Chapter PL - Treasure Island (FL) COIS- Disclosure: Michael Miller declares no relevant financial relationships with ineligible companies. Disclosure: Christopher V Maani declares no relevant financial relationships with ineligible companies. EDAT- 2023/07/10 00:00 CRDT- 2023/07/10 00:00 AID - NBK534787 [bookaccession] PMID- 37422897 OWN - NLM STAT- MEDLINE DCOM- 20231011 LR - 20231011 IS - 1520-7560 (Electronic) IS - 1520-7552 (Linking) VI - 39 IP - 7 DP - 2023 Oct TI - A multidisciplinary team reduces in-hospital clinical complications and mortality in patients with diabetic foot ulcers. PG - e3690 LID - 10.1002/dmrr.3690 [doi] AB - AIMS: The current study aims to evaluate the effectiveness of a multidisciplinary diabetic foot team (MDFT) in the management of in-patients affected by diabetic foot problems. MATERIALS AND METHODS: The study was a retrospective observational study. Consecutive patients with a diabetic foot problem requiring hospitalisation were included. All patients were managed by a MDFT led by diabetologists according to the guidance. The rate of in-hospital complications (IHCs), major amputation, and survival were recorded at the end of patient's hospitalisation. IHC was defined as any new infection different from wound infection, cardiovascular events, acute renal injury, severe anaemia requiring blood transfusion, and any other clinical problem not present at the assessment. RESULTS: Overall, 350 patients were included. The mean age was 67.9 +/- 12.6 years, 254 (72.6%) were males, 323 (92, 3%) showed Type 2 diabetes with a mean duration of 20.2 +/- 9.6 years; 224 (64%) had ischaemic diabetic foot ulcers (DFUs) and 299 (85.4%) had infected DFUs. IHCs were recorded in 30/350 (8.6%) patients. The main reasons for IHCs were anaemia requiring blood transfusion (2.8%), pneumonia (1.7%), acute kidney failure (1.1%). Patients with IHCs showed a higher rate of major amputation (13.3 vs. 3.1%, p = 0.02) and mortality (16.7 vs. 0.6%, p < 0.0001) in comparison to those without. Ischaemic heart disease (IHD) and wound duration at the assessment (>1 month) were independent predictors of IHC, whereas IHCs, heart failure, and dialysis were independent predictors of in-hospital mortality. CONCLUSIONS: The multidisciplinary management of diabetic foot problems leads to an IHC rate of 8%. The risk of IHCs is higher in patients with IHD and long wound duration. CI - (c) 2023 John Wiley & Sons Ltd. FAU - Meloni, Marco AU - Meloni M AUID- ORCID: 0000-0003-3789-9622 AD - Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy. AD - Division of Endocrinology and Diabetology, Department of Medical Sciences, Fondazione Policlinico "Tor Vergata", Rome, Italy. FAU - Andreadi, Aikaterini AU - Andreadi A AD - Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy. AD - Division of Endocrinology and Diabetology, Department of Medical Sciences, Fondazione Policlinico "Tor Vergata", Rome, Italy. FAU - Bellizzi, Ermanno AU - Bellizzi E AD - Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy. AD - Division of Endocrinology and Diabetology, Department of Medical Sciences, Fondazione Policlinico "Tor Vergata", Rome, Italy. FAU - Giurato, Laura AU - Giurato L AD - CTO Andrea Alesini Hospital, Division of Endocrinology and Diabetes, Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy. FAU - Ruotolo, Valeria AU - Ruotolo V AD - Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy. AD - Division of Endocrinology and Diabetology, Department of Medical Sciences, Fondazione Policlinico "Tor Vergata", Rome, Italy. FAU - Romano, Maria AU - Romano M AD - Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy. AD - Division of Endocrinology and Diabetology, Department of Medical Sciences, Fondazione Policlinico "Tor Vergata", Rome, Italy. FAU - Bellia, Alfonso AU - Bellia A AD - Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy. AD - Division of Endocrinology and Diabetology, Department of Medical Sciences, Fondazione Policlinico "Tor Vergata", Rome, Italy. FAU - Uccioli, Luigi AU - Uccioli L AD - CTO Andrea Alesini Hospital, Division of Endocrinology and Diabetes, Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy. FAU - Lauro, Davide AU - Lauro D AUID- ORCID: 0000-0002-8597-4415 AD - Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy. AD - Division of Endocrinology and Diabetology, Department of Medical Sciences, Fondazione Policlinico "Tor Vergata", Rome, Italy. LA - eng PT - Journal Article PT - Observational Study DEP - 20230709 PL - England TA - Diabetes Metab Res Rev JT - Diabetes/metabolism research and reviews JID - 100883450 SB - IM MH - Male MH - Humans MH - Middle Aged MH - Aged MH - Aged, 80 and over MH - Female MH - *Diabetic Foot/therapy MH - *Diabetes Mellitus, Type 2 MH - Retrospective Studies MH - Hospitals MH - *Coronary Artery Disease MH - Patient Care Team MH - *Anemia OTO - NOTNLM OT - diabetes OT - diabetic foot OT - hospitalisation OT - mortality OT - multidisciplinary foot team EDAT- 2023/07/09 19:13 MHDA- 2023/10/11 06:45 CRDT- 2023/07/09 14:51 PHST- 2023/04/26 00:00 [revised] PHST- 2023/03/16 00:00 [received] PHST- 2023/05/28 00:00 [accepted] PHST- 2023/10/11 06:45 [medline] PHST- 2023/07/09 19:13 [pubmed] PHST- 2023/07/09 14:51 [entrez] AID - 10.1002/dmrr.3690 [doi] PST - ppublish SO - Diabetes Metab Res Rev. 2023 Oct;39(7):e3690. doi: 10.1002/dmrr.3690. Epub 2023 Jul 9. PMID- 37422773 OWN - NLM STAT- MEDLINE DCOM- 20230921 LR - 20261010 IS - 1432-1459 (Electronic) IS - 0340-5354 (Linking) VI - 270 IP - 10 DP - 2023 Oct TI - Diagnosis and management of Becker muscular dystrophy: the French guidelines. PG - 4763-4781 LID - 10.1007/s00415-023-11837-5 [doi] AB - Becker muscular dystrophy (BMD) is one of the most frequent among neuromuscular diseases, affecting approximately 1 in 18,000 male births. It is linked to a genetic mutation on the X chromosome. In contrast to Duchenne muscular dystrophy, for which improved care and management have changed the prognosis and life expectancy of patients, few guidelines have been published for management of BMD. Many clinicians are inexperienced in managing the complications of this disease. In France, a committee of experts from a wide range of disciplines met in 2019 to establish recommendations, with the goal of improving care of patients with BMD. Here, we present the tools to provide diagnosis of BMD as quickly as possible and for differential diagnoses. Then, we describe the multidisciplinary approach essential for optimum management of BMD. We give recommendations for the initial assessment and follow-up of the neurological, respiratory, cardiac, and orthopedic consequences of males who present with BMD. Finally, we describe the optimal therapeutic management of these complications. We also provide guidance on cardiac management for female carriers. CI - (c) 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany. FAU - Magot, Armelle AU - Magot A AUID- ORCID: 0000-0002-7589-1421 AD - Centre de Reference des Maladies Neuromusculaires AOC, Laboratoire d'Explorations Fonctionnelles, FILNEMUS, Hotel-Dieu, CHU de Nantes, Nantes, France. armelle.magot@chu-nantes.fr. FAU - Wahbi, Karim AU - Wahbi K AD - Centre de Reference des Maladies Neuromusculaires Paris Est, AP-HP, Hopital Pitie salpetriere, Institut de myologie, Cardiovascular Research Center, Inserm Unit 970, Paris, France. FAU - Leturcq, France AU - Leturcq F AD - Service de Medecine Genomique des Maladies de Systeme et d'Organe, APHP, Universite de Paris, Hopital Cochin, Paris, France. FAU - Jaffre, Sandrine AU - Jaffre S AD - Service de Pneumologie, L'institut du thorax, Hopital G et R Laennec, CHU de Nantes, Nantes, France. FAU - Pereon, Yann AU - Pereon Y AD - Centre de Reference des Maladies Neuromusculaires AOC, Laboratoire d'Explorations Fonctionnelles, FILNEMUS, Euro-NMD, Hotel-Dieu, CHU de Nantes, Nantes, France. FAU - Sole, Guilhem AU - Sole G AD - Centre de Reference des Maladies Neuromusculaires AOC, FILNEMUS, Hopital Pellegrin, CHU de Bordeaux, Bordeaux, France. CN - French BMD working group LA - eng PT - Journal Article PT - Review DEP - 20230709 PL - Germany TA - J Neurol JT - Journal of neurology JID - 0423161 SB - IM MH - Humans MH - Male MH - Female MH - *Muscular Dystrophy, Duchenne/diagnosis/genetics/therapy MH - Heterozygote MH - Prognosis MH - Diagnosis, Differential MH - Mutation OTO - NOTNLM OT - Becker muscular dystrophy OT - Care management OT - Diagnosis OT - Female carriers OT - Guidelines OT - Therapeutics FIR - Ambrosi, Pierre IR - Ambrosi P FIR - Boulle, Ralph IR - Boulle R FIR - Cances, Claude IR - Cances C FIR - Cossee, Mireille IR - Cossee M FIR - Debelleix, Stephane IR - Debelleix S FIR - Delleci, Claire IR - Delleci C FIR - Duboc, Denis IR - Duboc D FIR - Feasson, Leonard IR - Feasson L FIR - Ghorab, Karima IR - Ghorab K FIR - Goizet, Cyril IR - Goizet C FIR - Gonzales, Jesus IR - Gonzales J FIR - Iriart, Xavier IR - Iriart X FIR - Juntas-Morales, Raul IR - Juntas-Morales R FIR - Llontop, Claudio IR - Llontop C FIR - Maillet, Pierre IR - Maillet P FIR - Marcorelles, Pascale IR - Marcorelles P FIR - Mercier, Sandra IR - Mercier S FIR - Peudenier, Sylviane IR - Peudenier S FIR - Rabec, Claudio IR - Rabec C FIR - Reant, Patricia IR - Reant P FIR - Rivier, Francois IR - Rivier F FIR - Segovia-Kueny, Sandrine IR - Segovia-Kueny S FIR - Urtizberea, Jon Andoni IR - Urtizberea JA FIR - Walther-Louvier, Ulrike IR - Walther-Louvier U EDAT- 2023/07/09 19:13 MHDA- 2023/09/21 06:42 CRDT- 2023/07/09 14:48 PHST- 2023/04/01 00:00 [received] PHST- 2023/06/20 00:00 [accepted] PHST- 2023/06/19 00:00 [revised] PHST- 2023/09/21 06:42 [medline] PHST- 2023/07/09 19:13 [pubmed] PHST- 2023/07/09 14:48 [entrez] AID - 10.1007/s00415-023-11837-5 [pii] AID - 10.1007/s00415-023-11837-5 [doi] PST - ppublish SO - J Neurol. 2023 Oct;270(10):4763-4781. doi: 10.1007/s00415-023-11837-5. Epub 2023 Jul 9. PMID- 37419532 OWN - NLM STAT- MEDLINE DCOM- 20230710 LR - 20260108 IS - 1558-1381 (Electronic) IS - 1047-9651 (Print) IS - 1047-9651 (Linking) VI - 34 IP - 3 DP - 2023 Aug TI - Autonomic Dysfunction Related to Postacute SARS-CoV-2 Syndrome. PG - 563-572 LID - S1047-9651(23)00026-8 [pii] LID - 10.1016/j.pmr.2023.04.003 [doi] AB - Persistence of symptoms beyond the initial acute phase of coronavirus disease-2019 (COVID-19) is termed postacute SARS-CoV-2 (PASC) and includes neurologic, autonomic, pulmonary, cardiac, psychiatric, gastrointestinal, and functional impairment. PASC autonomic dysfunction can present with dizziness, tachycardia, sweating, headache, syncope, labile blood pressure, exercise intolerance, and "brain fog." A multidisciplinary team can help manage this complex syndrome with nonpharmacologic and pharmacologic interventions. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Haloot, Justin AU - Haloot J AD - Department of Internal Medicine, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229-3900, USA. FAU - Bhavaraju-Sanka, Ratna AU - Bhavaraju-Sanka R AD - Department of Neurology, UT Health San Antonio, Joe R. & Theresa Lozano Long School of Medicine, 7703 Floyd Curl Drive, Mail Code 7883, San Antonio, TX 78229, USA. Electronic address: BhavarajuSan@uthscsa.edu. FAU - Pillarisetti, Jayasree AU - Pillarisetti J AD - Janey & Dolph Briscoe Division of Cardiology, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA. FAU - Verduzco-Gutierrez, Monica AU - Verduzco-Gutierrez M AD - Department of Rehabilitation Medicine, Joe R. & Teresa Lozano Long School of Medicine, UT Health at San Antonio Texas, 7703 Floyd Curl Drive, Room 628E, San Antonio, TX 78229, USA. LA - eng PT - Journal Article PT - Review DEP - 20230418 PL - United States TA - Phys Med Rehabil Clin N Am JT - Physical medicine and rehabilitation clinics of North America JID - 9102787 SB - IM MH - Humans MH - SARS-CoV-2 MH - *COVID-19/complications MH - *Autonomic Nervous System Diseases/diagnosis/etiology/therapy MH - Syncope MH - Syndrome PMC - PMC10110930 OTO - NOTNLM OT - Autonomic dysfunction OT - Brain fog OT - COVID-19 OT - PASC OT - Tilt table test EDAT- 2023/07/08 10:42 MHDA- 2023/07/10 06:42 PMCR- 2023/04/18 CRDT- 2023/07/07 20:55 PHST- 2023/07/10 06:42 [medline] PHST- 2023/07/08 10:42 [pubmed] PHST- 2023/07/07 20:55 [entrez] PHST- 2023/04/18 00:00 [pmc-release] AID - S1047-9651(23)00026-8 [pii] AID - 10.1016/j.pmr.2023.04.003 [doi] PST - ppublish SO - Phys Med Rehabil Clin N Am. 2023 Aug;34(3):563-572. doi: 10.1016/j.pmr.2023.04.003. Epub 2023 Apr 18. PMID- 37416979 OWN - NLM STAT- MEDLINE DCOM- 20260311 LR - 20260529 IS - 1098-4275 (Electronic) IS - 0031-4005 (Linking) VI - 152 IP - 2 DP - 2023 Aug 1 TI - Factors Associated With Improved Pediatric Resuscitative Care in General Emergency Departments. LID - e2022060790 [pii] LID - 10.1542/peds.2022-060790 [doi] AB - OBJECTIVES: To describe the quality of pediatric resuscitative care in general emergency departments (GEDs) and to determine hospital-level factors associated with higher quality. METHODS: Prospective observational study of resuscitative care provided to 3 in situ simulated patients (infant seizure, infant sepsis, and child cardiac arrest) by interprofessional GED teams. A composite quality score (CQS) was measured and the association of this score with modifiable and nonmodifiable hospital-level factors was explored. RESULTS: A median CQS of 62.8 of 100 (interquartile range 50.5-71.1) was noted for 287 resuscitation teams from 175 emergency departments. In the unadjusted analyses, a higher score was associated with the modifiable factor of an affiliation with a pediatric academic medical center (PAMC) and the nonmodifiable factors of higher pediatric volume and location in the Northeast and Midwest. In the adjusted analyses, a higher CQS was associated with modifiable factors of an affiliation with a PAMC and the designation of both a nurse and physician pediatric emergency care coordinator, and nonmodifiable factors of higher pediatric volume and location in the Northeast and Midwest. A weak correlation was noted between quality and pediatric readiness scores. CONCLUSIONS: A low quality of pediatric resuscitative care, measured using simulation, was noted across a cohort of GEDs. Hospital factors associated with higher quality included: an affiliation with a PAMC, designation of a pediatric emergency care coordinator, higher pediatric volume, and geographic location. A weak correlation was noted between quality and pediatric readiness scores. CI - Copyright (c) 2023 by the American Academy of Pediatrics. FAU - Auerbach, Marc A AU - Auerbach MA AD - Yale University School of Medicine, New Haven, Connecticut. FAU - Whitfill, Travis AU - Whitfill T AD - Yale University School of Medicine, New Haven, Connecticut. FAU - Montgomery, Erin AU - Montgomery E AD - Indiana University School of Medicine, Indianapolis, Indiana. FAU - Leung, James AU - Leung J AD - McMaster University, Hamilton, Ontario, Canada. FAU - Kessler, David AU - Kessler D AD - Columbia University Vagelos College of Physicians and Surgeons, New York, New York. FAU - Gross, Isabel T AU - Gross IT AD - Yale University School of Medicine, New Haven, Connecticut. FAU - Walsh, Barbara M AU - Walsh BM AD - Boston University School of Medicine, Boston, Massachusetts. FAU - Fiedor Hamilton, Melinda AU - Fiedor Hamilton M AD - UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania. FAU - Gawel, Marcie AU - Gawel M AD - Yale University School of Medicine, New Haven, Connecticut. FAU - Kant, Shruti AU - Kant S AD - University of California San Francisco, San Francisco, California. FAU - Janofsky, Stephen AU - Janofsky S AD - UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania. FAU - Brown, Linda L AU - Brown LL AD - The Warren Alpert Medical School of Brown University, Providence, Rhode Island. FAU - Walls, Theresa A AU - Walls TA AD - Perelman School of Medicine at the University of Pennsylvania and Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. FAU - Alletag, Michelle AU - Alletag M AD - University of Colorado Anschutz Medical Campus, Aurora, Colorado. FAU - Sessa, Anna AU - Sessa A AD - Geisel School of Medicine at Dartmouth, Hanover, New Hampshire. FAU - Arteaga, Grace M AU - Arteaga GM AD - Mayo Clinic College of Medicine and Science, Rochester, Minnesota. FAU - Keilman, Ashley AU - Keilman A AD - University of Washington and Seattle Children's Hospital, Seattle, Washington. FAU - Van Ittersum, Wendy AU - Van Ittersum W AD - Akron Children's Hospital, Akron, Ohio. FAU - Rutman, Maia S AU - Rutman MS AD - Geisel School of Medicine at Dartmouth, Hanover, New Hampshire. FAU - Zaveri, Pavan AU - Zaveri P AD - The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia. FAU - Good, Grace AU - Good G AD - Perelman School of Medicine at the University of Pennsylvania and Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. FAU - Schoen, Jessica C AU - Schoen JC AD - Mayo Clinic Health System, Albert Lea and Austin, Minnesota. FAU - Lavoie, Meghan AU - Lavoie M AD - Perelman School of Medicine at the University of Pennsylvania and Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. FAU - Mannenbach, Mark AU - Mannenbach M AD - Mayo Clinic College of Medicine and Science, Rochester, Minnesota. FAU - Bigham, Ladonna AU - Bigham L AD - Johns Hopkins School of Medicine, Baltimore, Maryland. FAU - Dudas, Robert A AU - Dudas RA AD - Johns Hopkins School of Medicine, Baltimore, Maryland. FAU - Rutledge, Chrystal AU - Rutledge C AD - The University of Alabama at Birmingham, Birmingham, Alabama. FAU - Okada, Pamela J AU - Okada PJ AD - University of Texas, Southwestern Medical Center, Dallas, Texas. FAU - Moegling, Michelle AU - Moegling M AD - Case Western Reserve University and UH Rainbow Babies and Children's Hospital, Cleveland, Ohio. FAU - Anderson, Ingrid AU - Anderson I AD - Case Western Reserve University and UH Rainbow Babies and Children's Hospital, Cleveland, Ohio. FAU - Tay, Khoon-Yen AU - Tay KY AD - Perelman School of Medicine at the University of Pennsylvania and Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. FAU - Scherzer, Daniel J AU - Scherzer DJ AD - Nationwide Children's Hospital, Columbus, Ohio. FAU - Vora, Samreen AU - Vora S AD - Children's Minnesota, Minneapolis, Minnesota. FAU - Gaither, Stacy AU - Gaither S AD - The University of Alabama at Birmingham, Birmingham, Alabama. FAU - Fenster, Daniel AU - Fenster D AD - Columbia University Irving Medical Center, New York, New York. FAU - Jones, Derick AU - Jones D AD - Mayo Clinic Health System, Albert Lea and Austin, Minnesota. FAU - Aebersold, Michelle AU - Aebersold M AD - School of Nursing. FAU - Chatfield, Jenny AU - Chatfield J AD - Alberta Children's Hospital, Calgary, Alberta, Canada. FAU - Knight, Lynda AU - Knight L AD - Stanford Medicine Children's Health, Palo Alto, California. FAU - Berg, Marc AU - Berg M AD - Stanford Medicine Children's Health, Palo Alto, California. FAU - Makharashvili, Ana AU - Makharashvili A AD - Yale University School of Medicine, New Haven, Connecticut. FAU - Katznelson, Jessica AU - Katznelson J AD - Johns Hopkins School of Medicine, Baltimore, Maryland. FAU - Mathias, Emily AU - Mathias E AD - University of Michigan, Ann Arbor, Michigan. FAU - Lutfi, Riad AU - Lutfi R AD - Indiana University School of Medicine, Indianapolis, Indiana. FAU - Abu-Sultaneh, Samer AU - Abu-Sultaneh S AD - Indiana University School of Medicine, Indianapolis, Indiana. FAU - Burns, Brian AU - Burns B AD - University of Washington and Seattle Children's Hospital, Seattle, Washington. FAU - Padlipsky, Patricia AU - Padlipsky P AD - Harbor UCLA Medical Center, Torrance, California. FAU - Lee, Jumie AU - Lee J AD - The Lundquist Institute, Torrance, California. FAU - Butler, Lucas AU - Butler L AD - Virginia Mason Medical Center, Seattle, Washington. FAU - Alander, Sarah AU - Alander S AD - Geisinger Commonwealth School of Medicine, Scranton, Pennsylvania. FAU - Thomas, Anita AU - Thomas A AD - University of Washington and Seattle Children's Hospital, Seattle, Washington. FAU - Bhatnagar, Ambika AU - Bhatnagar A AD - Yale University School of Medicine, New Haven, Connecticut. FAU - Jafri, Farrukh N AU - Jafri FN AD - White Plains Hospital Center, White Plains, New York. FAU - Crellin, Jason AU - Crellin J AD - Geisinger Commonwealth School of Medicine, Scranton, Pennsylvania. FAU - Abulebda, Kamal AU - Abulebda K AD - Indiana University School of Medicine, Indianapolis, Indiana. LA - eng PT - Journal Article PT - Observational Study PL - United States TA - Pediatrics JT - Pediatrics JID - 0376422 SB - IM MH - Humans MH - *Emergency Service, Hospital/standards MH - Prospective Studies MH - Infant MH - *Resuscitation/standards MH - Female MH - Male MH - Child MH - Child, Preschool MH - Heart Arrest/therapy MH - *Quality Improvement MH - Patient Care Team EDAT- 2023/07/07 06:42 MHDA- 2026/03/11 06:57 CRDT- 2023/07/07 04:22 PHST- 2023/05/02 00:00 [accepted] PHST- 2026/03/11 06:57 [medline] PHST- 2023/07/07 06:42 [pubmed] PHST- 2023/07/07 04:22 [entrez] AID - 192511 [pii] AID - 10.1542/peds.2022-060790 [doi] PST - ppublish SO - Pediatrics. 2023 Aug 1;152(2):e2022060790. doi: 10.1542/peds.2022-060790. PMID- 37416006 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240921 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 15 IP - 6 DP - 2023 Jun TI - Transesophageal Echocardiography vs. Transthoracic Echocardiography for Methicillin-Sensitive Staphylococcus aureus and Methicillin-Resistant Staphylococcus aureus Endocarditis. PG - e39996 LID - 10.7759/cureus.39996 [doi] LID - e39996 AB - Infective endocarditis is an infection of the inner layers of the heart, seen often in intravenous drug users and patients with valvular lesions or prosthetic heart valves. This entity has high mortality and morbidity. The most common causative microorganism is Staphylococcus aureus. In this comprehensive literature review, we focused on both Staphylococcus aureus infections, i.e., methicillin-sensitive Staphylococcus aureus (MSSA) and methicillin-resistant Staphylococcus aureus (MRSA) endocarditis, demographics, use of transthoracic echocardiogram and/or transesophageal echocardiogram for diagnostics, and treatments. Although clinical criteria are relevant, transesophageal echocardiogram plays a vital role in establishing and identifying the presence of infective endocarditis and its local complications, with higher sensitivity in patients with prosthetic valves. The antibiotic selection posed a great challenge for clinicians due to antibiotic resistance and the aggressive nature of Staphylococcus aureus. Early diagnosis of infective endocarditis, when suspected, and effective management by a multispecialty team can improve the outcome for the patients. CI - Copyright (c) 2023, Henriquez et al. FAU - Henriquez, Elvis AU - Henriquez E AD - Internal Medicine, University of Medical Sciences, Las Tunas, CUB. FAU - Fatima, Neha AU - Fatima N AD - Internal Medicine, Lisie Hospital, Kochi, IND. FAU - Sayabugari, Rithika AU - Sayabugari R AD - General Medicine, Gandhi Medical College, Hyderabad, IND. FAU - Nasim, Muhammad Hamza AU - Nasim MH AD - Internal Medicine, Lahore Medical and Dental College, Lahore, PAK. FAU - Noorayingarath, Hafseena AU - Noorayingarath H AD - Internal Medicine, Kanachur Institute of Medical Sciences, Natekal, IND. FAU - Bai, Karoona AU - Bai K AD - Internal Medicine, Dow University of Health Sciences, Civil Hospital Karachi, Karachi, PAK. FAU - Garcia, Alberto AU - Garcia A AD - Internal Medicine, Universidad Javeriana, Bogota, COL. FAU - Habib, Ayesha AU - Habib A AD - Internal Medicine, Punjab Medical College, Faisalabad, PAK. FAU - Patel, Tirth P AU - Patel TP AD - Medicine, S.S. Hospital, Petlad, IND. FAU - Shaikh, Fouziya AU - Shaikh F AD - Internal Medicine, Krishna Institute of Medical Sciences, Karad, IND. FAU - Razzaq, Waleed AU - Razzaq W AD - Internal Medicine, Services Hospital Lahore, Lahore, PAK. FAU - Abdin, Zain U AU - Abdin ZU AD - Medicine, District Head Quarters Hospital, Faisalabad, PAK. FAU - Gupta, Ishita AU - Gupta I AD - Medicine, Dr. Rajendra Prasad Government Medical College, Kangra, IND. LA - eng PT - Journal Article PT - Review DEP - 20230605 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC10321677 OTO - NOTNLM OT - duke criteria OT - infective endocarditis OT - meca gene OT - methicillin-resistant staphylococcus aureus OT - methicillin-sensitive staphylococcus aureus OT - positron emission tomography-computed tomography scan OT - radiolabeled leukocyte scintigraphy OT - transesophageal echocardiography OT - transthoracic echocardiography COIS- The authors have declared that no competing interests exist. EDAT- 2023/07/07 06:42 MHDA- 2023/07/07 06:43 PMCR- 2023/06/05 CRDT- 2023/07/07 04:02 PHST- 2023/06/05 00:00 [accepted] PHST- 2023/07/07 06:43 [medline] PHST- 2023/07/07 06:42 [pubmed] PHST- 2023/07/07 04:02 [entrez] PHST- 2023/06/05 00:00 [pmc-release] AID - 10.7759/cureus.39996 [doi] PST - epublish SO - Cureus. 2023 Jun 5;15(6):e39996. doi: 10.7759/cureus.39996. eCollection 2023 Jun. PMID- 37414917 OWN - NLM STAT- MEDLINE DCOM- 20230807 LR - 20261010 IS - 1573-7322 (Electronic) IS - 1382-4147 (Linking) VI - 28 IP - 5 DP - 2023 Sep TI - Acute mitral regurgitation with and without acute heart failure. PG - 1201-1209 LID - 10.1007/s10741-023-10322-5 [doi] AB - Acute severe mitral regurgitation (MR) is rare, but often leads to cardiogenic shock, pulmonary edema, or both. Most common causes of acute severe MR are chordae tendineae (CT) rupture, papillary muscle (PM) rupture, and infective endocarditis (IE). Mild to moderate MR is often seen in patients with acute myocardial infarction (AMI). CT rupture in patients with floppy mitral valve/mitral valve prolapse is the most common etiology of acute severe MR today. In IE, native or prosthetic valve damage can occur (leaflet perforation, ring detachment, other), as well as CT or PM rupture. Since the introduction of percutaneous revascularization in AMI, the incidence of PM rupture has substantially declined. In acute severe MR, the hemodynamic effects of the large regurgitant volume into the left atrium (LA) during left ventricular (LV) systole, and in turn back into the LV during diastole, are profound as the LV and LA have not had time to adapt to this additional volume. A rapid, but comprehensive evaluation of the patient with acute severe MR is essential in order to define the underline cause and apply appropriate management. Echocardiography with Doppler provides vital information related to the underlying pathology. Coronary arteriography should be performed in patients with an AMI to define coronary anatomy and need for revascularization. In acute severe MR, medical therapy should be used to stabilize the patient before intervention (surgery, transcatheter); mechanical support is often required. Diagnostic and therapeutic steps should be individualized, and a multi-disciplinary team approach should be utilized. CI - (c) 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Boudoulas, Konstantinos Dean AU - Boudoulas KD AD - Division of Cardiovascular Medicine, The Ohio State University, 473 W. 12th Avenue, Suite 200, Columbus, OH, 43210, USA. FAU - Triposkiadis, Filippos AU - Triposkiadis F AD - Department of Cardiology, Larissa University General Hospital, Larissa, Greece. FAU - Koenig, Sara AU - Koenig S AD - Davis Heart and Lung Research Institute, The Ohio State University, Columbus, USA. FAU - Marmagkiolis, Konstantinos AU - Marmagkiolis K AD - Tampa Heart, Tampa, FL, USA. AD - Department of Internal Medicine, University of South Florida, Tampa, FL, USA. FAU - Iliescu, Cezar AU - Iliescu C AD - Department of Cardiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Pitsis, Antonios AU - Pitsis A AD - Thessaloniki Research Heart Institute, Thessaloniki, Greece. FAU - Boudoulas, Harisios AU - Boudoulas H AD - Division of Cardiovascular Medicine, The Ohio State University, 473 W. 12th Avenue, Suite 200, Columbus, OH, 43210, USA. kdboudoulas@osumc.edu. AD - Division of Cardiovascular Medicine, The Ohio State University, Columbus, USA. kdboudoulas@osumc.edu. LA - eng PT - Journal Article PT - Review DEP - 20230706 PL - United States TA - Heart Fail Rev JT - Heart failure reviews JID - 9612481 SB - IM MH - Humans MH - *Mitral Valve Insufficiency/complications MH - Mitral Valve/pathology/surgery MH - *Mitral Valve Prolapse/complications/diagnosis/surgery MH - *Heart Valve Diseases/complications MH - *Heart Failure/complications/therapy/pathology MH - *Myocardial Infarction/complications OTO - NOTNLM OT - Acute heart failure OT - Acute mitral regurgitation OT - Chordal rupture OT - Infective endocarditis OT - Papillary muscle rupture EDAT- 2023/07/07 01:05 MHDA- 2023/08/07 06:42 CRDT- 2023/07/06 23:26 PHST- 2023/05/08 00:00 [accepted] PHST- 2023/08/07 06:42 [medline] PHST- 2023/07/07 01:05 [pubmed] PHST- 2023/07/06 23:26 [entrez] AID - 10.1007/s10741-023-10322-5 [pii] AID - 10.1007/s10741-023-10322-5 [doi] PST - ppublish SO - Heart Fail Rev. 2023 Sep;28(5):1201-1209. doi: 10.1007/s10741-023-10322-5. Epub 2023 Jul 6. PMID- 37410163 OWN - NLM STAT- MEDLINE DCOM- 20231010 LR - 20231103 IS - 1861-0692 (Electronic) IS - 1861-0684 (Print) IS - 1861-0684 (Linking) VI - 112 IP - 10 DP - 2023 Oct TI - Non-Alcoholic Fatty Liver Disease (NAFLD) and risk of new-onset heart failure: a retrospective analysis of 173,966 patients. PG - 1446-1453 LID - 10.1007/s00392-023-02250-z [doi] AB - BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) represents the leading cause of chronic liver disease. Its high mortality and morbidity are mainly caused by non-hepatic comorbidities and their clinical complications. Accumulating evidence suggests an association between NAFLD and heart failure (HF), but large-scale data analyses from Germany are scarce. METHODS: Using the Disease Analyzer database (IQVIA), this analysis retrospectively evaluated two cohorts of outpatients with and without NAFLD with respect to the cumulative incidence of HF as the primary outcome between January 2005 and December 2020. Cohorts were propensity score matched for sex, age, index year, yearly consultation frequency, and known risk factors for HF. RESULTS: A total of 173,966 patients were included in the analysis. Within 10 years of the index date, 13.2% vs. 10.0% of patients with and without NAFLD were newly diagnosed with HF (p < 0.001). This finding was supported by univariate Cox regression analysis in which NAFLD was found to be significantly associated with subsequent HF (Hazard Ratio (HR) 1.34, 95% Confidence Interval (CI) 1.28-1.39, p < 0.001). The association between NAFLD and HF was observed across all analysed age groups and as comparable between both men (HR 1.30, 95% CI 1.23-1.38; p < 0.001) and women (HR: 1.37, 95% CI 1.29-1.45; p < 0.001). CONCLUSION: NAFLD is significantly associated with an increased cumulative incidence of HF, which, given its rapidly increasing global prevalence, could be crucial to further reduce its high mortality and morbidity. We recommend risk stratification within a multidisciplinary approach for NAFLD patients, including systematic prevention or early detection strategies for HF. CI - (c) 2023. The Author(s). FAU - Roderburg, Christoph AU - Roderburg C AD - Department of Gastroenterology, Hepatology and Infectious Diseases, University Hospital Duesseldorf, Medical Faculty of Heinrich Heine University Duesseldorf, Moorenstrasse 5, 40225, Duesseldorf, Germany. FAU - Krieg, Sarah AU - Krieg S AUID- ORCID: 0000-0003-0012-0304 AD - Department of Gastroenterology, Hepatology and Infectious Diseases, University Hospital Duesseldorf, Medical Faculty of Heinrich Heine University Duesseldorf, Moorenstrasse 5, 40225, Duesseldorf, Germany. FAU - Krieg, Andreas AU - Krieg A AD - Department of Surgery (A), University Hospital Duesseldorf, Medical Faculty of Heinrich Heine University Duesseldorf, 40225, Duesseldorf, Germany. FAU - Vaghiri, Sascha AU - Vaghiri S AD - Department of Surgery (A), University Hospital Duesseldorf, Medical Faculty of Heinrich Heine University Duesseldorf, 40225, Duesseldorf, Germany. FAU - Mohr, Raphael AU - Mohr R AD - Department of Hepatology and Gastroenterology, Charite University Medicine Berlin, 13353, Berlin, Germany. FAU - Konrad, Marcel AU - Konrad M AD - FOM University of Applied, Sciences for Economics and Management, 60549, Frankfurt Am Main, Germany. FAU - Luedde, Mark AU - Luedde M AD - Christian-Albrechts-University of Kiel, 24118, Kiel, Germany. FAU - Luedde, Tom AU - Luedde T AD - Department of Gastroenterology, Hepatology and Infectious Diseases, University Hospital Duesseldorf, Medical Faculty of Heinrich Heine University Duesseldorf, Moorenstrasse 5, 40225, Duesseldorf, Germany. FAU - Kostev, Karel AU - Kostev K AD - Epidemiology, IQVIA, 60549, Frankfurt, Germany. FAU - Loosen, Sven H AU - Loosen SH AD - Department of Gastroenterology, Hepatology and Infectious Diseases, University Hospital Duesseldorf, Medical Faculty of Heinrich Heine University Duesseldorf, Moorenstrasse 5, 40225, Duesseldorf, Germany. Sven.Loosen@med.uni-duesseldorf.de. LA - eng PT - Journal Article DEP - 20230706 PL - Germany TA - Clin Res Cardiol JT - Clinical research in cardiology : official journal of the German Cardiac Society JID - 101264123 SB - IM MH - Male MH - Humans MH - Female MH - *Non-alcoholic Fatty Liver Disease/complications/diagnosis/epidemiology MH - Retrospective Studies MH - Risk Factors MH - *Heart Failure/diagnosis/epidemiology/complications MH - Comorbidity PMC - PMC10562311 OTO - NOTNLM OT - Epidemiology OT - Heart failure OT - NAFLD OT - NASH OT - Non-alcoholic fatty liver disease OT - Non-alcoholic steatohepatitis OT - Prevention COIS- The authors declare no conflict of interest. EDAT- 2023/07/06 13:14 MHDA- 2023/10/10 06:42 PMCR- 2023/07/06 CRDT- 2023/07/06 11:07 PHST- 2023/03/15 00:00 [received] PHST- 2023/06/19 00:00 [accepted] PHST- 2023/10/10 06:42 [medline] PHST- 2023/07/06 13:14 [pubmed] PHST- 2023/07/06 11:07 [entrez] PHST- 2023/07/06 00:00 [pmc-release] AID - 10.1007/s00392-023-02250-z [pii] AID - 2250 [pii] AID - 10.1007/s00392-023-02250-z [doi] PST - ppublish SO - Clin Res Cardiol. 2023 Oct;112(10):1446-1453. doi: 10.1007/s00392-023-02250-z. Epub 2023 Jul 6. PMID- 39132395 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240813 IS - 2772-9303 (Electronic) IS - 2772-9303 (Linking) VI - 2 IP - 5 DP - 2023 Sep-Oct TI - Tricuspid Valve Regurgitation: Current Understanding and Novel Treatment Options. PG - 101041 LID - 10.1016/j.jscai.2023.101041 [doi] LID - 101041 AB - Managing patients with severe symptomatic tricuspid regurgitation (TR) remains extremely challenging, with a lack of consensus on when and how to treat it. Tricuspid valve pathology has been disregarded for a very long time because of the established belief that treating left-sided heart diseases would lead to the resolution or significant improvement of TR. Initially considered benign, severe TR has been found to be a strong predictor of prognosis. Despite the increasing prevalence and the disabling nature of this disease, the great majority of patients with clinically significant TR have seldom been considered for structural interventions. Numerous surgical and transcatheter treatment options are now available; however, optimal timing and procedural selection remain crucial aspects influencing outcomes. According to recent evidence in the literature, early referral is associated with good short and long-term outcomes, and various predictors of favorable outcomes following either surgical or transcatheter treatment have been identified. Evaluation by a multidisciplinary heart team with expertise in tricuspid valve disease is of paramount importance to identify adequate treatment for every patient. CI - (c) 2023 The Author(s). FAU - Sala, Alessandra AU - Sala A AD - Department of Cardiac Surgery, Vita-Salute San Raffaele University, IRCCS San Raffaele Hospital, Milan, Italy. FAU - Hahn, Rebecca T AU - Hahn RT AD - Department of Cardiology, Columbia University Medical Center/NewYork-Presbyterian Hospital, New York, New York. FAU - Kodali, Susheel K AU - Kodali SK AD - Department of Cardiology, Columbia University Medical Center/NewYork-Presbyterian Hospital, New York, New York. FAU - Mack, Michael J AU - Mack MJ AD - Department of Cardiac Surgery, Baylor Scott & White Health, Plano, Texas. FAU - Maisano, Francesco AU - Maisano F AD - Department of Cardiac Surgery, Vita-Salute San Raffaele University, IRCCS San Raffaele Hospital, Milan, Italy. LA - eng PT - Journal Article PT - Review DEP - 20230705 PL - United States TA - J Soc Cardiovasc Angiogr Interv JT - Journal of the Society for Cardiovascular Angiography & Interventions JID - 9918419271306676 PMC - PMC11307688 OTO - NOTNLM OT - outcomes OT - surgical treatment OT - timing OT - transcatheter interventions OT - tricuspid regurgitation OT - tricuspid valve disease EDAT- 2023/07/05 00:00 MHDA- 2023/07/05 00:01 PMCR- 2023/07/05 CRDT- 2024/08/12 06:23 PHST- 2023/02/01 00:00 [received] PHST- 2023/04/08 00:00 [revised] PHST- 2023/05/03 00:00 [accepted] PHST- 2023/07/05 00:01 [medline] PHST- 2023/07/05 00:00 [pubmed] PHST- 2024/08/12 06:23 [entrez] PHST- 2023/07/05 00:00 [pmc-release] AID - S2772-9303(23)00532-X [pii] AID - 101041 [pii] AID - 10.1016/j.jscai.2023.101041 [doi] PST - epublish SO - J Soc Cardiovasc Angiogr Interv. 2023 Jul 5;2(5):101041. doi: 10.1016/j.jscai.2023.101041. eCollection 2023 Sep-Oct. PMID- 37401580 OWN - NLM STAT- MEDLINE DCOM- 20231109 LR - 20240909 IS - 1897-4279 (Electronic) IS - 0022-9032 (Linking) VI - 81 IP - 10 DP - 2023 TI - Is a Heart Team enough? The role of an interdisciplinary preoperative patient health check in the final qualification for elective cardiac surgery: Pre-Surgery Check Team study. PG - 1009-1011 LID - 10.33963/KP.a2023.0146 [doi] FAU - Sobczyk, Dorota AU - Sobczyk D AD - Department of Cardiovascular Diseases, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland. dorotasobczyk@yahoo.com. AD - Department of Cardiovascular Surgery and Transplantology, John Paul II Hospital, Krakow, Poland. dorotasobczyk@yahoo.com. FAU - Hymczak, Hubert AU - Hymczak H AD - 1st Department of Intensive Care, John Paul II Hospital, Krakow, Poland. AD - Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski Krakow University, Krakow, Poland. FAU - Batycka-Stachnik, Dominika AU - Batycka-Stachnik D AD - Department of Cardiovascular Surgery and Transplantology, John Paul II Hospital, Krakow, Poland. FAU - Siwinska, Jolanta AU - Siwinska J AD - Department of Cardiovascular Surgery and Transplantology, John Paul II Hospital, Krakow, Poland. FAU - Piatek, Jacek AU - Piatek J AD - Department of Cardiovascular Surgery and Transplantology, John Paul II Hospital, Krakow, Poland. AD - Department of Cardiovascular Surgery and Transplantology, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland. FAU - Kapelak, Boguslaw AU - Kapelak B AD - Department of Cardiovascular Surgery and Transplantology, John Paul II Hospital, Krakow, Poland. AD - Department of Cardiovascular Surgery and Transplantology, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland. FAU - Bartus, Krzysztof AU - Bartus K AD - Department of Cardiovascular Surgery and Transplantology, John Paul II Hospital, Krakow, Poland. AD - Department of Cardiovascular Surgery and Transplantology, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland. LA - eng PT - Journal Article DEP - 20230704 PL - Poland TA - Kardiol Pol JT - Kardiologia polska JID - 0376352 SB - IM MH - Humans MH - *Cardiac Surgical Procedures MH - Heart MH - Patient Care Team MH - Preoperative Care EDAT- 2023/07/04 06:42 MHDA- 2023/11/09 06:42 CRDT- 2023/07/04 05:53 PHST- 2023/06/24 00:00 [received] PHST- 2023/06/24 00:00 [accepted] PHST- 2023/11/09 06:42 [medline] PHST- 2023/07/04 06:42 [pubmed] PHST- 2023/07/04 05:53 [entrez] AID - VM/OJS/J/96166 [pii] AID - 10.33963/KP.a2023.0146 [doi] PST - ppublish SO - Kardiol Pol. 2023;81(10):1009-1011. doi: 10.33963/KP.a2023.0146. Epub 2023 Jul 4. PMID- 37398871 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230704 IS - 1756-1485 (Electronic) IS - 1756-1477 (Print) IS - 1756-1485 (Linking) VI - 18 DP - 2023 TI - Sudden Cardiac Death in Ischaemic Cardiomyopathy and the Primary Prevention ICD: Time for a More a Personalised Approach? PG - e11 LID - 10.15420/icr.2022.14 [doi] LID - e11 AB - Guidelines recommend primary prevention implantable cardioverter defibrillator (PPICD) for left ventricular ejection fraction (LVEF) <35% only after 3 months of optimal medical therapy (OMT) or 6 weeks after acute MI with persistent LVEF dysfunction. A 73-year-old woman presented with decompensated heart failure secondary to ischaemic cardiomyopathy. Severe coronary disease with sufficient dysfunctional myocardial segments on cardiac MRI suggested potential benefit from revascularisation. Following discussion with the heart team, she underwent percutaneous coronary intervention (PCI). PPICD implantation was deferred as per guideline recommendations. However, 20 days post-PCI, the patient died from malignant ventricular arrhythmia captured on a Holter monitor. This case demonstrates that some high-risk patients may not receive a potentially life-saving PPICD if guidelines are stringently adhered to. We highlight evidence that LVEF alone is of limited value in a risk assessment of arrhythmogenic death, and postulate that a more personalised ICD prescription should be considered using scar characteristics on cardiac MRI to prompt upstream ICD implantation in high-risk patients. CI - Copyright (c) 2023, Radcliffe Cardiology. FAU - Ezad, Saad M AU - Ezad SM AD - Cardiovascular Division, King's College London London, UK. AD - Dorset Heart Centre, Royal Bournemouth Hospital Bournemouth, UK. FAU - Babu, Girish AU - Babu G AD - Dorset Heart Centre, Royal Bournemouth Hospital Bournemouth, UK. FAU - O'Kane, Peter AU - O'Kane P AD - Dorset Heart Centre, Royal Bournemouth Hospital Bournemouth, UK. LA - eng PT - Journal Article PT - Review DEP - 20230405 PL - England TA - Interv Cardiol JT - Interventional cardiology (London, England) JID - 101559687 PMC - PMC10311393 OTO - NOTNLM OT - Ischaemic cardiomyopathy OT - heart failure OT - implantable cardioverter defibrillator OT - sudden cardiac death OT - ventricular arrhythmia COIS- Disclosure: POK is editor-in-chief of Interventional Cardiology; this did not influence peer review. All other authors have no conflicts of interest to declare. Consent: Informed consent for publication of this care report has been obtained from the patient's next of kin as the patient is deceased, sadly. EDAT- 2023/07/03 13:06 MHDA- 2023/07/03 13:07 PMCR- 2023/04/05 CRDT- 2023/07/03 11:51 PHST- 2022/05/06 00:00 [received] PHST- 2023/02/01 00:00 [accepted] PHST- 2023/07/03 13:07 [medline] PHST- 2023/07/03 13:06 [pubmed] PHST- 2023/07/03 11:51 [entrez] PHST- 2023/04/05 00:00 [pmc-release] AID - 10.15420/icr.2022.14 [doi] PST - epublish SO - Interv Cardiol. 2023 Apr 5;18:e11. doi: 10.15420/icr.2022.14. eCollection 2023. PMID- 37397077 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241001 IS - 2666-0873 (Electronic) IS - 2666-0873 (Linking) VI - 5 IP - 3 DP - 2023 Jun TI - How to Treat Diffuse Large B-Cell Lymphoma: Oncologic and Cardiovascular Considerations. PG - 281-291 LID - 10.1016/j.jaccao.2023.05.001 [doi] AB - Anthracycline-containing therapy is the cornerstone of frontline treatment for diffuse large B-cell lymphoma (DLBCL), and autologous stem cell transplantation, and more recently, chimeric antigen receptor T-cell therapy are the primary treatment options for relapsed refractory DLBCL. Given these therapies are all associated with cardiovascular toxicities, patients with underlying cardiac comorbidities are severely limited in treatment options. The focus of this review is to outline the cardiotoxicities associated with these standard treatments, explore strategies developed to mitigate these toxicities, and review novel treatment strategies for patients with underlying cardiovascular comorbidities. DLBCL patients with underlying cardiac complications are a high-risk patient population who require complicated management strategies that utilize a multidisciplinary approach with collaboration between cardiologists and oncologists. CI - (c) 2023 Published by Elsevier on behalf of the American College of Cardiology Foundation. FAU - Thiruvengadam, Swetha Kambhampati AU - Thiruvengadam SK AD - Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA. FAU - Herrera, Alex F AU - Herrera AF AD - Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA. FAU - Rhee, June-Wha AU - Rhee JW AD - Department of Cardiology, City of Hope National Medical Center, Duarte, California, USA. LA - eng PT - Journal Article PT - Review DEP - 20230620 PL - United States TA - JACC CardioOncol JT - JACC. CardioOncology JID - 101761697 PMC - PMC10308036 OTO - NOTNLM OT - anthracycline OT - heart failure OT - lymphoma COIS- Dr Herrera has been a consultant for AstraZeneca, ADC Therapeutics, Tubulis, Merck, Genentech, Takeda, Bristol Myers Squibb, Seagen, and Karyopharm; and has received research funding from AstraZeneca, ADC Therapeutics, Merck, Genentech, Kite (a Gilead Company), Bristol Myers Squibb, Gilead Sciences, and Seagen. Dr Rhee has received research funding from Pfizer unrelated to this work. Dr Thiruvengadam has reported that she has no relationships relevant to the contents of this paper to disclose. EDAT- 2023/07/03 13:05 MHDA- 2023/07/03 13:06 PMCR- 2023/06/20 CRDT- 2023/07/03 11:29 PHST- 2022/11/08 00:00 [received] PHST- 2023/05/05 00:00 [revised] PHST- 2023/05/10 00:00 [accepted] PHST- 2023/07/03 13:05 [pubmed] PHST- 2023/07/03 13:06 [medline] PHST- 2023/07/03 11:29 [entrez] PHST- 2023/06/20 00:00 [pmc-release] AID - S2666-0873(23)00122-9 [pii] AID - 10.1016/j.jaccao.2023.05.001 [doi] PST - epublish SO - JACC CardioOncol. 2023 Jun 20;5(3):281-291. doi: 10.1016/j.jaccao.2023.05.001. eCollection 2023 Jun. PMID- 37396431 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230704 IS - 2772-3747 (Electronic) IS - 2772-3747 (Linking) VI - 3 IP - 3 DP - 2023 Jun TI - 10 Years of SYNTAX: Closing an Era of Clinical Research After Identifying New Outcome Determinants. PG - 409-430 LID - 10.1016/j.jacasi.2023.03.014 [doi] AB - The SYNTAX trial randomized patients equally eligible for coronary artery bypass grafting or percutaneous coronary intervention using the Heart Team approach. The SYNTAXES study achieved a follow-up rate of 93.8% and reported the 10-year vital status. Factors associated with increased mortality at 10 years were pharmacologically treated diabetes mellitus, increased waist circumference, reduced left ventricular function, prior cerebrovascular and peripheral vascular disease, western Europe and North American descent, current smoking, chronic obstructive pulmonary disease, elevated C-reactive protein, anemia, and an increase in HbA1c. Procedural factors associated with higher 10 years mortality include periprocedural myocardial infarction, extensive stenting, small stents, >/=1 heavily calcified lesion, >/=1 bifurcation lesion, residual SYNTAX score >8, and staged percutaneous coronary intervention. Optimal medical therapy at 5 years, use of statins, on-pump coronary artery bypass grafting, multiple arterial grafts, and higher physical component score and mental component score were associated with lower mortality at 10 years. Numerous scores and prediction models were developed to help individualize risk assessment. Machine learning has emerged as a novel approach for developing risk models. CI - (c) 2023 The Authors. FAU - Serruys, Patrick W AU - Serruys PW AD - Department of Cardiology, National University of Ireland, Galway (NUIG), and CORRIB Research Centre for Advanced Imaging and Core Laboratory, Galway, Ireland. FAU - Revaiah, Pruthvi C AU - Revaiah PC AD - Department of Cardiology, National University of Ireland, Galway (NUIG), and CORRIB Research Centre for Advanced Imaging and Core Laboratory, Galway, Ireland. FAU - Ninomiya, Kai AU - Ninomiya K AD - Department of Cardiology, National University of Ireland, Galway (NUIG), and CORRIB Research Centre for Advanced Imaging and Core Laboratory, Galway, Ireland. FAU - Masuda, Shinichiro AU - Masuda S AD - Department of Cardiology, National University of Ireland, Galway (NUIG), and CORRIB Research Centre for Advanced Imaging and Core Laboratory, Galway, Ireland. FAU - Kotoku, Nozomi AU - Kotoku N AD - Department of Cardiology, National University of Ireland, Galway (NUIG), and CORRIB Research Centre for Advanced Imaging and Core Laboratory, Galway, Ireland. FAU - Kageyama, Shigetaka AU - Kageyama S AD - Department of Cardiology, National University of Ireland, Galway (NUIG), and CORRIB Research Centre for Advanced Imaging and Core Laboratory, Galway, Ireland. FAU - Onuma, Yoshinobu AU - Onuma Y AD - Department of Cardiology, National University of Ireland, Galway (NUIG), and CORRIB Research Centre for Advanced Imaging and Core Laboratory, Galway, Ireland. FAU - Morel, Marie Angele AU - Morel MA AD - Department of Cardiology, National University of Ireland, Galway (NUIG), and CORRIB Research Centre for Advanced Imaging and Core Laboratory, Galway, Ireland. FAU - Garg, Scot AU - Garg S AD - Department of Cardiology, Royal Blackburn Hospital, Blackburn, United Kingdom. FAU - Feldman, Ted AU - Feldman T AD - Edwards Lifesciences, Irvine, California, USA. FAU - Kappetein, Arie Pieter AU - Kappetein AP AD - Department of Cardiothoracic Surgery, Erasmus University Medical Centre, Rotterdam, the Netherlands. FAU - Holmes, David R Jr AU - Holmes DR Jr AD - Department of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA. FAU - Mack, Michael J AU - Mack MJ AD - Department of Cardiothoracic Surgery, Baylor Scott & White Health, Dallas, Texas, USA. FAU - Mohr, Friedrich-Wilhelm AU - Mohr FW AD - University Department of Cardiac Surgery, Heart Centre Leipzig, Leipzig, Germany. LA - eng PT - Journal Article PT - Review DEP - 20230530 PL - United States TA - JACC Asia JT - JACC. Asia JID - 9918452380106676 PMC - PMC10308124 OTO - NOTNLM OT - CABG OT - PCI OT - SYNTAX OT - coronary artery bypass grafting OT - machine learning OT - percutaneous coronary intervention COIS- Dr Masuda has received a grant from TERUMO corporation outside the submitted work. Dr Ninomiya has received a grant from Abbott Medical Japan outside the submitted work. Dr Kotoku has received a grant for studying overseas from Fukuda Foundation for Medical Technology. Dr Serruys has received institutional grants from Sinomedical Sciences Technology, SMT (Sahajanand Medical Technologies), Philips/Volcano, GE, Xeltis, and HeartFlow, outside the submitted work. Dr Onuma has received institutional grants from Sinomedical Sciences Technology, SMT (Sahajanand Medical technologies), Philips/Volcano, GE, Xeltis, and HeartFlow, outside the submitted work. Dr Feldman is an employee of Edwards Lifesciences. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2023/07/03 13:05 MHDA- 2023/07/03 13:06 PMCR- 2023/05/30 CRDT- 2023/07/03 11:20 PHST- 2023/01/03 00:00 [received] PHST- 2023/02/21 00:00 [revised] PHST- 2023/03/24 00:00 [accepted] PHST- 2023/07/03 13:06 [medline] PHST- 2023/07/03 13:05 [pubmed] PHST- 2023/07/03 11:20 [entrez] PHST- 2023/05/30 00:00 [pmc-release] AID - S2772-3747(23)00096-0 [pii] AID - 10.1016/j.jacasi.2023.03.014 [doi] PST - epublish SO - JACC Asia. 2023 May 30;3(3):409-430. doi: 10.1016/j.jacasi.2023.03.014. eCollection 2023 Jun. PMID- 37395507 OWN - NLM STAT- MEDLINE DCOM- 20230803 LR - 20230807 IS - 1531-6971 (Electronic) IS - 1070-5287 (Linking) VI - 29 IP - 5 DP - 2023 Sep 1 TI - Lessons learned in developing a chronic thromboembolic pulmonary hypertension program. PG - 355-362 LID - 10.1097/MCP.0000000000000983 [doi] AB - PURPOSE OF REVIEW: Chronic thromboembolic pulmonary hypertension (CTEPH) is a deadly underdiagnosed form of pulmonary hypertension, traditionally treated with surgical extraction of thrombo-fibrotic lesions via pulmonary thrombendarterectomy (PTE) surgery. More recently, treatment options have expanded to pulmonary vasodilator medical therapy and balloon pulmonary angioplasty (BPA). This has led to increased awareness and detection of CTEPH, as well as growing interest in performing PTE and BPA. This review will describe the steps required to build a successful CTEPH team in the context of the rapidly evolving treatment of CTEPH. RECENT FINDINGS: CTEPH care requires a multidisciplinary team, including a Pulmonologist or Cardiologist expert in Pulmonary Hypertension, a PTE surgeon, a BPA interventionalist, a dedicated radiologist, cardiothoracic anesthesia and Vascular Medicine or Hematology. Careful assessment of precise imaging and hemodynamic data is needed for operability assessment in the context of the experience of the CTEPH team and surgeon. Medical therapy and BPA are indicated for inoperable CTEPH and residual CTEPH after PTE. Increasingly, multimodality approaches, including surgery, BPA and medical therapy are utilized for best outcomes. SUMMARY: An expert CTEPH center requires a multidisciplinary team with dedicated specialists, and time to develop the experience and expertise to achieve high volumes and good outcomes. CI - Copyright (c) 2023 Wolters Kluwer Health, Inc. All rights reserved. FAU - Bair, Nancy D AU - Bair ND AD - Department of Pulmonary Medicine, Respiratory Institute Cleveland Clinic, Cleveland, Ohio, USA. FAU - Heresi, Gustavo A AU - Heresi GA LA - eng PT - Journal Article PT - Review DEP - 20230628 PL - United States TA - Curr Opin Pulm Med JT - Current opinion in pulmonary medicine JID - 9503765 SB - IM MH - Humans MH - *Pulmonary Embolism/complications/surgery MH - *Hypertension, Pulmonary/diagnosis/etiology/therapy MH - Chronic Disease MH - *Angioplasty, Balloon/methods MH - Endarterectomy/methods MH - Pulmonary Artery/surgery EDAT- 2023/07/03 13:05 MHDA- 2023/08/03 06:42 CRDT- 2023/07/03 08:23 PHST- 2023/08/03 06:42 [medline] PHST- 2023/07/03 13:05 [pubmed] PHST- 2023/07/03 08:23 [entrez] AID - 00063198-202309000-00005 [pii] AID - 10.1097/MCP.0000000000000983 [doi] PST - ppublish SO - Curr Opin Pulm Med. 2023 Sep 1;29(5):355-362. doi: 10.1097/MCP.0000000000000983. Epub 2023 Jun 28. PMID- 31985941 STAT- Publisher CTDT- 20230703 PB - StatPearls Publishing DP - 2023 Jan TI - Technetium 99m Sestamibi. BTI - StatPearls AB - Technetium 99m sestamibi (MIBI), also known as 99m Tc-methoxy isobutyl isonitrile, is a radiopharmaceutical used to evaluate pathology within the cardiac, breast, and parathyroid tissues. Sestamibi is part of the radioactive diagnostic agents class of medications, characterized as a lipophilic cationic radiotracer. This activity illustrates the indications, mechanism of action, and contraindications for sestamibi as a valuable diagnostic agent. Furthermore, this activity will highlight the mechanism of action, adverse event profile, and other key factors pertinent for members of the interprofessional team in the diagnosis of patients with cardiac conditions, hyperparathyroidism, and breast cancer. CI - Copyright (c) 2023, StatPearls Publishing LLC. FAU - Rizk, Tony H AU - Rizk TH AD - Edward Via College FAU - Nagalli, Shivaraj AU - Nagalli S AD - Yuma Regional Medical Center LA - eng PT - Study Guide PT - Book Chapter PL - Treasure Island (FL) COIS- Disclosure: Tony H Rizk declares no relevant financial relationships with ineligible companies. Disclosure: Shivaraj Nagalli declares no relevant financial relationships with ineligible companies. EDAT- 2023/07/03 00:00 CRDT- 2023/07/03 00:00 AID - NBK553148 [bookaccession] PMID- 31194369 STAT- Publisher CTDT- 20230703 PB - StatPearls Publishing DP - 2023 Jan TI - HMG-CoA Reductase Inhibitors. BTI - StatPearls AB - HMG-CoA reductase inhibitors (statins) are lipid-lowering medications used in the primary and secondary prevention of coronary heart disease. This activity reviews the indications, contraindications, and mechanism of action of statins for the management of coronary heart disease and familial dyslipidemias. This activity will cover the indications, contraindications, activity, adverse events, and other critical elements of statin therapy, and highlight the crucial role of the interprofessional team in the management of patients with clinically significant atherosclerotic cardiovascular disease or individuals with risk factors for heart disease who can benefit from statin therapy. CI - Copyright (c) 2023, StatPearls Publishing LLC. FAU - Bansal, Agam B AU - Bansal AB AD - Cleveland Clinic, Ohio FAU - Cassagnol, Manouchkathe AU - Cassagnol M AD - St. John's University LA - eng PT - Study Guide PT - Book Chapter PL - Treasure Island (FL) COIS- Disclosure: Agam B Bansal declares no relevant financial relationships with ineligible companies. Disclosure: Manouchkathe Cassagnol declares no relevant financial relationships with ineligible companies. EDAT- 2023/07/03 00:00 CRDT- 2023/07/03 00:00 AID - NBK542212 [bookaccession] PMID- 40416851 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250527 IS - 2641-5895 (Electronic) IS - 2096-6954 (Print) IS - 2641-5895 (Linking) VI - 5 IP - 3 DP - 2023 Jul TI - Fetal Phenotype and Prenatal Diagnosis of Kabuki Syndrome. PG - 187-191 LID - 10.1097/FM9.0000000000000070 [doi] AB - Kabuki syndrome (MIM 147920) is an autosomal dominant rare disease featured with multiple malformations and mental retardation. The main clinical manifestations of Kabuki syndrome are characteristic facial features, skeletal abnormalities, dermatoglyphic abnormalities, postpartum growth retardation, mild to moderate mental retardation, as well as other structural and functional abnormalities that may involve multiple systems. The establishment of diagnosis needs to be combined with clinical phenotype and the discovery of pathogenic mutation. Compared with the abundant descriptions and records of genotype-phenotype of postpartum patients, few prenatal diagnosis cases of Kabuki syndrome had been reported, which partially result from lacking the knowledge of its phenotype in fetuses that might suggest the diagnosis. This report performed comprehensive prenatal examinations to identify a fetus's etiology with multiple structural anomalies characterized by ascites, thickening of local skin, and cardiac abnormalities. We ruled out intrauterine infection, thalassemia, and chromosome abnormality by corresponding tests. Finally, trio whole-exome sequencing revealed a de novo heterozygous variation c.15641g > A (p.r5214h) in exon 48 of the KMT2D gene was the fetus's genetic pathogeny causing Kabuki syndrome. This result suggests that Kabuki syndrome should be in the suspected etiology list for prenatal hydrops/ascites. Our study confirmed that prenatal whole-exome sequencing is an efficient tool for diagnosing fetal abnormalities, and a multidisciplinary team is necessary for providing pregnancy guidance to patients. CI - Copyright (c) 2020 The Chinese Medical Association, published by Wolters Kluwer Health, Inc. FAU - Pan, Yan AU - Pan Y AD - Department of Gynecology & Obstetrics, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing 400030, China. FAU - Yao, Hong AU - Yao H AD - Department of Gynecology & Obstetrics, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing 400030, China. FAU - Chen, Gongli AU - Chen G AD - Department of Gynecology & Obstetrics, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing 400030, China. FAU - Tan, Qiong AU - Tan Q AD - Department of Gynecology & Obstetrics, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing 400030, China. FAU - Chang, Qing AU - Chang Q AD - Department of Gynecology & Obstetrics, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing 400030, China. FAU - Ma, Yongyi AU - Ma Y AD - Department of Gynecology & Obstetrics, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing 400030, China. FAU - Liang, Zhiqing AU - Liang Z AD - Department of Gynecology & Obstetrics, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing 400030, China. LA - eng PT - Journal Article DEP - 20200916 PL - United States TA - Matern Fetal Med JT - Maternal-fetal medicine (Wolters Kluwer Health, Inc.) JID - 101769241 PMC - PMC12096401 OTO - NOTNLM OT - KMT2D gene OT - Kabuki syndrome OT - Prenatal diagnosis OT - Ultrasonography abnormality OT - Whole exome sequencing COIS- None. EDAT- 2023/07/01 00:00 MHDA- 2023/07/01 00:01 PMCR- 2020/09/16 CRDT- 2025/05/26 06:07 PHST- 2020/05/18 00:00 [received] PHST- 2020/07/24 00:00 [accepted] PHST- 2023/07/01 00:01 [medline] PHST- 2023/07/01 00:00 [pubmed] PHST- 2025/05/26 06:07 [entrez] PHST- 2020/09/16 00:00 [pmc-release] AID - MFM_230054 [pii] AID - 10.1097/FM9.0000000000000070 [doi] PST - ppublish SO - Matern Fetal Med. 2023 Jul;5(3):187-191. doi: 10.1097/FM9.0000000000000070. Epub 2020 Sep 16. PMID- 37391518 OWN - NLM STAT- MEDLINE DCOM- 20240205 LR - 20261010 IS - 1433-0350 (Electronic) IS - 0256-7040 (Linking) VI - 40 IP - 2 DP - 2024 Feb TI - Cervical kyphosis correction in Marfan syndrome: our experience and literature review. PG - 495-502 LID - 10.1007/s00381-023-06046-4 [doi] AB - BACKGROUND: Spinal deformities are common in Marfan syndrome (MFS). They usually involve the thoraco-lumbar spine but rarely involves the cervical spine. Kyphosis is the common spine deformity of the cervical spine and mandates surgical correction as they are at risk of neurological deterioration since they are refractory to conservative management. Few studies of surgical correction of spine deformity included cervical deformity. OBJECTIVES: To analyze the challenges faced during surgery, clinical and radiological outcome, and complications following surgical correction for cervical kyphosis in Marfan syndrome. METHODS: We identified that 5 patients with a diagnosis of MFS with cervical kyphosis who underwent fusion surgery between the years 2010 and 2022 were reviewed, retrospectively. We analyzed the demographic details, radiological parameters, operative variables (blood loss and nuances), perioperative complications, length of stay, clinical and radiological outcome, and complications following fusion surgery for cervical kyphosis in MFS. RESULTS: The mean age of patients was 16.6 +/- 4.72 years (range, 12-23 years). The average kyphotic vertebra involved is 3 +/- 0.7 bodies (range 2-4) with 2 patients with thoracic deformity. All patients underwent surgical deformity correction. All patients improved clinically with Nurick grade (pre vs. post: 3.4 vs. 2.2) and mJOA (pre vs. post: 8.2 vs. 12.6). There was significant deformity correction from 37.48 degrees to 9.1 degrees . Mean blood loss encountered was 900 +/- 173.2 ml. Perioperative complications: wound complication with CSF leak (1). Late complications: ventilator dependence (1) and junctional kyphosis (1). Mean length of hospital stay was 103 +/- 178.9 days. All patients were doing symptomatically better after mean follow-up of 58 +/- 28.32 months. One patient is bedridden and hospitalized. CONCLUSION: Cervical kyphosis is a rare spine deformity in patients with MFS, and they usually present with neurological deterioration mandating surgical correction. Multidisciplinary approach (pediatrics, genetics and cardiology) is required for systematic evaluation of these patients. They should be evaluated with necessary imaging to rule out associated spinal deformity (atlanto-axial subluxation, scoliosis, and intraspinal pathology like ductal ectasia). Our results suggest better surgical outcome in terms of low operative complications with neurologic improvement in MFS patients. These patients require regular follow-up to identify late complications (instrument failure, non-union, and pseudarthrosis). CI - (c) 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Kumarasamy, Sivaraman AU - Kumarasamy S AD - Department of Neurosurgery, Neurosciences Center, All India Institute of Medical Sciences, New Delhi, 110029, India. FAU - Sawarkar, Dattaraj P AU - Sawarkar DP AD - Department of Neurosurgery, Neurosciences Center, All India Institute of Medical Sciences, New Delhi, 110029, India. FAU - Singh, Pankaj Kumar AU - Singh PK AD - Department of Neurosurgery, Neurosciences Center, All India Institute of Medical Sciences, New Delhi, 110029, India. drpankajsingh11@gmail.com. FAU - Kumar, Rajinder AU - Kumar R AD - Department of Neurosurgery, Neurosciences Center, All India Institute of Medical Sciences, New Delhi, 110029, India. FAU - Chandra, Poodipedi Sarat AU - Chandra PS AD - Department of Neurosurgery, Neurosciences Center, All India Institute of Medical Sciences, New Delhi, 110029, India. FAU - Kale, Shashank Sharad AU - Kale SS AD - Department of Neurosurgery, Neurosciences Center, All India Institute of Medical Sciences, New Delhi, 110029, India. LA - eng PT - Journal Article PT - Review DEP - 20230701 PL - Germany TA - Childs Nerv Syst JT - Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery JID - 8503227 SB - IM MH - Humans MH - Child MH - Adolescent MH - Young Adult MH - Adult MH - *Marfan Syndrome/complications/surgery MH - Retrospective Studies MH - Treatment Outcome MH - *Kyphosis/diagnostic imaging/etiology/surgery MH - Cervical Vertebrae/diagnostic imaging/surgery MH - *Spinal Fusion/methods OTO - NOTNLM OT - Cervical kyphosis OT - Fusion surgery OT - Junctional kyphosis OT - Marfan syndrome OT - Nurick grade EDAT- 2023/07/01 11:41 MHDA- 2024/02/05 06:42 CRDT- 2023/06/30 23:24 PHST- 2023/06/02 00:00 [received] PHST- 2023/06/19 00:00 [accepted] PHST- 2024/02/05 06:42 [medline] PHST- 2023/07/01 11:41 [pubmed] PHST- 2023/06/30 23:24 [entrez] AID - 10.1007/s00381-023-06046-4 [pii] AID - 10.1007/s00381-023-06046-4 [doi] PST - ppublish SO - Childs Nerv Syst. 2024 Feb;40(2):495-502. doi: 10.1007/s00381-023-06046-4. Epub 2023 Jul 1. PMID- 37390524 OWN - NLM STAT- MEDLINE DCOM- 20230904 LR - 20230926 IS - 1879-2472 (Electronic) IS - 0049-3848 (Linking) VI - 229 DP - 2023 Sep TI - Management of anticoagulation in patients with infective endocarditis. PG - 15-25 LID - S0049-3848(23)00184-6 [pii] LID - 10.1016/j.thromres.2023.06.010 [doi] AB - Infective endocarditis (IE) carries a high risk of vascular complications (e.g., cerebral embolism, intracerebral hemorrhage, and renal infarction), which are correlated with increased early and late mortality. Although anticoagulation is the cornerstone for management of thromboembolic complications, it remains controversial and challenging in patients with IE. An appropriate anticoagulation strategy is crucial to improving outcomes and requires a good understanding of the indication, timing, and regimen of anticoagulation in the setting of IE. Observational studies have shown that anticoagulant treatment failed to reduce the risk of ischemic stroke in patents with IE, supporting that IE alone is not an indication for anticoagulation. In the absence of randomized controlled trials and high-quality meta-analyses, however, current guidelines on IE were based largely on observational data and expert opinion, providing few specific recommendations on anticoagulation. A multidisciplinary approach and patient engagement are required to determine the timing and regimen of anticoagulation in patients with IE, especially in specific situations (e.g., receiving warfarin anticoagulation at the time of IE diagnosis, cerebral embolism or ischemic stroke, intracerebral hemorrhage, or urgent surgery). Collectively, individualized strategies on anticoagulation management of IE should be based on clinical evaluation, available evidence, and patient engagement, and ultimately be developed by the multidisciplinary team. CI - Copyright (c) 2023. Published by Elsevier Ltd. FAU - Zhu, Xiaogang AU - Zhu X AD - Department of Cardiology, Fu Xing Hospital, Capital Medical University, China. FAU - Wang, Zhenhua AU - Wang Z AD - Department of Cardiology, Second Affiliated Hospital of Fujian Medical University, China. FAU - Ferrari, Markus W AU - Ferrari MW AD - Clinic of Internal Medicine 1, HSK, Clinic of the City of Wiesbaden and the HELIOS Group, Germany. FAU - Ferrari-Kuehne, Katharina AU - Ferrari-Kuehne K AD - University of Jena, Jena, Germany. FAU - Hsi, David H AU - Hsi DH AD - Heart & Vascular Institute, Stamford Hospital, Stamford, CT, United States. FAU - Tse, Gary AU - Tse G AD - Faculty of Health and Medical Sciences, University of Surrey, Guildford, United Kingdom. FAU - Zhou, Quanzhong AU - Zhou Q AD - Department of Radiology, The Center for Medical Imaging of Guizhou Province, Affiliated Hospital of Zunyi Medical University, China. FAU - Liang, Haifeng AU - Liang H AD - Department of Cardiology, Fu Xing Hospital, Capital Medical University, China. FAU - Zhang, Yuhui AU - Zhang Y AD - Heart Failure Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, China. Electronic address: yuhuizhangjoy@163.com. FAU - Zhang, Jian AU - Zhang J AD - Heart Failure Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, China. Electronic address: fwzhangjian62@126.com. LA - eng PT - Journal Article PT - Review DEP - 20230610 PL - United States TA - Thromb Res JT - Thrombosis research JID - 0326377 RN - 0 (Anticoagulants) RN - 5Q7ZVV76EI (Warfarin) SB - IM MH - Humans MH - *Intracranial Embolism/chemically induced/complications/drug therapy MH - Anticoagulants/therapeutic use MH - Warfarin/therapeutic use MH - Blood Coagulation MH - Cerebral Hemorrhage/complications/drug therapy MH - *Endocarditis/complications/drug therapy/chemically induced MH - *Stroke/complications/drug therapy OTO - NOTNLM OT - Infective endocarditis OT - Intracerebral hemorrhage OT - Oral anticoagulants OT - Stroke OT - Thromboembolism OT - Vitamin K antagonist COIS- Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: This work was supported by the Key Projects in the National Science and Technology Pillar Program of the 13th Five-Year Plan Period [grant number 2017YFC1308300] for the design and conduct of the study, and the National Natural Science Foundation of China [grant number 81873472] for the preparation and review of the manuscript. EDAT- 2023/06/30 19:14 MHDA- 2023/09/04 06:42 CRDT- 2023/06/30 18:00 PHST- 2022/10/19 00:00 [received] PHST- 2023/06/05 00:00 [revised] PHST- 2023/06/09 00:00 [accepted] PHST- 2023/09/04 06:42 [medline] PHST- 2023/06/30 19:14 [pubmed] PHST- 2023/06/30 18:00 [entrez] AID - S0049-3848(23)00184-6 [pii] AID - 10.1016/j.thromres.2023.06.010 [doi] PST - ppublish SO - Thromb Res. 2023 Sep;229:15-25. doi: 10.1016/j.thromres.2023.06.010. Epub 2023 Jun 10. PMID- 37389507 OWN - NLM STAT- MEDLINE DCOM- 20240115 LR - 20241102 IS - 1097-685X (Electronic) IS - 0022-5223 (Print) IS - 0022-5223 (Linking) VI - 166 IP - 5 DP - 2023 Nov TI - 2022 ACC/AHA guideline for the diagnosis and management of aortic disease: A report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. PG - e182-e331 LID - S0022-5223(23)00347-1 [pii] LID - 10.1016/j.jtcvs.2023.04.023 [doi] AB - AIM: The "2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease" provides recommendations to guide clinicians in the diagnosis, genetic evaluation and family screening, medical therapy, endovascular and surgical treatment, and long-term surveillance of patients with aortic disease across its multiple clinical presentation subsets (ie, asymptomatic, stable symptomatic, and acute aortic syndromes). METHODS: A comprehensive literature search was conducted from January 2021 to April 2021, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from PubMed, EMBASE, the Cochrane Library, CINHL Complete, and other selected databases relevant to this guideline. Additional relevant studies, published through June 2022 during the guideline writing process, were also considered by the writing committee, where appropriate. STRUCTURE: Recommendations from previously published AHA/ACC guidelines on thoracic aortic disease, peripheral artery disease, and bicuspid aortic valve disease have been updated with new evidence to guide clinicians. In addition, new recommendations addressing comprehensive care for patients with aortic disease have been developed. There is added emphasis on the role of shared decision making, especially in the management of patients with aortic disease both before and during pregnancy. The is also an increased emphasis on the importance of institutional interventional volume and multidisciplinary aortic team expertise in the care of patients with aortic disease. CI - Copyright (c) 2022 American College of Cardiology Foundation and the American Heart Association, Inc. Published by Elsevier. Published by Elsevier Inc. All rights reserved. CN - Writing Committee Members FAU - Isselbacher, Eric M AU - Isselbacher EM FAU - Preventza, Ourania AU - Preventza O FAU - Hamilton Black, James 3rd AU - Hamilton Black J 3rd FAU - Augoustides, John G AU - Augoustides JG FAU - Beck, Adam W AU - Beck AW FAU - Bolen, Michael A AU - Bolen MA FAU - Braverman, Alan C AU - Braverman AC FAU - Bray, Bruce E AU - Bray BE FAU - Brown-Zimmerman, Maya M AU - Brown-Zimmerman MM FAU - Chen, Edward P AU - Chen EP FAU - Collins, Tyrone J AU - Collins TJ FAU - DeAnda, Abe Jr AU - DeAnda A Jr FAU - Fanola, Christina L AU - Fanola CL FAU - Girardi, Leonard N AU - Girardi LN FAU - Hicks, Caitlin W AU - Hicks CW FAU - Hui, Dawn S AU - Hui DS FAU - Schuyler Jones, William AU - Schuyler Jones W FAU - Kalahasti, Vidyasagar AU - Kalahasti V FAU - Kim, Karen M AU - Kim KM FAU - Milewicz, Dianna M AU - Milewicz DM FAU - Oderich, Gustavo S AU - Oderich GS FAU - Ogbechie, Laura AU - Ogbechie L FAU - Promes, Susan B AU - Promes SB FAU - Ross, Elsie Gyang AU - Ross EG FAU - Schermerhorn, Marc L AU - Schermerhorn ML FAU - Singleton Times, Sabrina AU - Singleton Times S FAU - Tseng, Elaine E AU - Tseng EE FAU - Wang, Grace J AU - Wang GJ FAU - Woo, Y Joseph AU - Woo YJ CN - Peer Review Committee Members FAU - Faxon, David P AU - Faxon DP FAU - Upchurch, Gilbert R Jr AU - Upchurch GR Jr FAU - Aday, Aaron W AU - Aday AW FAU - Azizzadeh, Ali AU - Azizzadeh A FAU - Boisen, Michael AU - Boisen M FAU - Hawkins, Beau AU - Hawkins B FAU - Kramer, Christopher M AU - Kramer CM FAU - Luc, Jessica G Y AU - Luc JGY FAU - MacGillivray, Thomas E AU - MacGillivray TE FAU - Malaisrie, S Christopher AU - Malaisrie SC FAU - Osteen, Kathryn AU - Osteen K FAU - Patel, Himanshu J AU - Patel HJ FAU - Patel, Parag J AU - Patel PJ FAU - Popescu, Wanda M AU - Popescu WM FAU - Rodriguez, Evelio AU - Rodriguez E FAU - Sorber, Rebecca AU - Sorber R FAU - Tsao, Philip S AU - Tsao PS FAU - Santos Volgman, Annabelle AU - Santos Volgman A CN - AHA/ACC Joint Committee Members FAU - Beckman, Joshua A AU - Beckman JA FAU - Otto, Catherine M AU - Otto CM FAU - O'Gara, Patrick T AU - O'Gara PT FAU - Armbruster, Anastasia AU - Armbruster A FAU - Birtcher, Kim K AU - Birtcher KK FAU - de las Fuentes, Lisa AU - de las Fuentes L FAU - Deswal, Anita AU - Deswal A FAU - Dixon, Dave L AU - Dixon DL FAU - Gorenek, Bulent AU - Gorenek B FAU - Haynes, Norrisa AU - Haynes N FAU - Hernandez, Adrian F AU - Hernandez AF FAU - Joglar, Jose A AU - Joglar JA FAU - Jones, W Schuyler AU - Jones WS FAU - Mark, Daniel AU - Mark D FAU - Mukherjee, Debabrata AU - Mukherjee D FAU - Palaniappan, Latha AU - Palaniappan L FAU - Piano, Mariann R AU - Piano MR FAU - Rab, Tanveer AU - Rab T FAU - Spatz, Erica S AU - Spatz ES FAU - Tamis-Holland, Jacqueline E AU - Tamis-Holland JE FAU - Woo, Y Joseph AU - Woo YJ LA - eng GR - K23 DK124515/DK/NIDDK NIH HHS/United States GR - R25 HL145817/HL/NHLBI NIH HHS/United States GR - T32 HL007444/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Practice Guideline DEP - 20230628 PL - United States TA - J Thorac Cardiovasc Surg JT - The Journal of thoracic and cardiovascular surgery JID - 0376343 SB - IM MH - Female MH - Pregnancy MH - United States MH - Humans MH - American Heart Association MH - *Aortic Diseases/diagnosis/therapy MH - *Bicuspid Aortic Valve Disease MH - Aorta MH - *Cardiology PMC - PMC10784847 MID - NIHMS1953960 OTO - NOTNLM OT - ACC/AHA Clinical Practice Guidelines OT - abdominal aortic aneurysm OT - aortic dissection OT - aortitis OT - aortopathy OT - bicuspid aortic valve OT - blunt traumatic aortic injury OT - cardiac surgery OT - endovascular aortic repair OT - guidelines OT - heritable thoracic aortic disease OT - intramural hematoma OT - loeys-dietz syndrome OT - malperfusion syndrome OT - marfan syndrome OT - penetrating atherosclerotic ulcer OT - thoracic aortic aneurysm OT - thoracic endovascular aortic repair OT - thoracoabdominal aortic aneurysm OT - vascular surgery EDAT- 2023/06/30 13:11 MHDA- 2024/01/15 12:43 PMCR- 2024/11/01 CRDT- 2023/06/30 10:29 PHST- 2024/01/15 12:43 [medline] PHST- 2023/06/30 13:11 [pubmed] PHST- 2023/06/30 10:29 [entrez] PHST- 2024/11/01 00:00 [pmc-release] AID - S0022-5223(23)00347-1 [pii] AID - 10.1016/j.jtcvs.2023.04.023 [doi] PST - ppublish SO - J Thorac Cardiovasc Surg. 2023 Nov;166(5):e182-e331. doi: 10.1016/j.jtcvs.2023.04.023. Epub 2023 Jun 28. PMID- 37383282 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230702 IS - 2220-3206 (Print) IS - 2220-3206 (Electronic) IS - 2220-3206 (Linking) VI - 13 IP - 6 DP - 2023 Jun 19 TI - Prevalence of posttraumatic stress disorder following acute coronary syndrome and clinical characteristics of patients referred to cardiac rehabilitation. PG - 376-385 LID - 10.5498/wjp.v13.i6.376 [doi] AB - BACKGROUND: Studies have demonstrated that patients who have experienced acute coronary syndrome (ACS) have an increased risk of developing posttraumatic stress disorder (PTSD) and experiencing worse survival outcomes than those who do not develop PTSD. Nevertheless, the prevalence rates of PTSD following ACS vary widely across studies, and it is noteworthy that in most cases, the diagnosis of PTSD was based on self-report symptom questionnaires, rather than being established by psychiatrists. Additionally, the individual characteristics of patients who develop PTSD after ACS can differ widely, making it difficult to identify any consistent patterns or predictors of the disorder. AIM: To investigate the prevalence of PTSD among a large sample of patients undergoing cardiac rehabilitation (CR) after ACS, as well as their characteristics in comparison to a control group. METHODS: The participants of this study are patients who have experienced ACS with or without undergoing percutaneous coronary intervention and are enrolled in a 3-wk CR program at the largest CR center in Croatia, the Special Hospital for Medical Rehabilitation Krapinske Toplice. Patient recruitment for the study took place over the course of one year, from January 1, 2022, to December 31, 2022, with a total of 504 participants. The expected average follow-up period for patients included in the study is about 18 mo, and currently ongoing. Using self-assessment questionnaire for PTSD criteria and clinical psychiatric interview, a group of patients with a PTSD diagnosis was identified. From the participants who do not have a PTSD diagnosis, patients who would match those with a PTSD diagnosis in terms of relevant clinical and medical stratification variables and during the same rehabilitation period were selected to enable comparability of the two groups. RESULTS: A total of 507 patients who were enrolled in the CR program were approached to participate in the study. Three patients declined to participate in the study. The screening PTSD Checklist-Civilian Version questionnaire was completed by 504 patients. Out of the total sample of 504 patients, 74.2% were men (n = 374) and 25.8% were women (n = 130). The mean age of all participants was 56.7 years (55.8 for men and 59.1 for women). Among the 504 participants who completed the screening questionnaire, 80 met the cutoff criteria for the PTSD and qualified for further evaluation (15.9%). All 80 patients agreed to a psychiatric interview. Among them, 51 patients (10.1%) were diagnosed with clinical PTSD by a psychiatrist according to Diagnostic and Statistical Manual of Mental Disorders criteria. Among the variables analyzed, there was a noticeable difference in the percentage of theoretical maximum achieved on exercise testing between the PTSD and non-PTSD groups. Non-PTSD group achieved a significantly higher percentage of their maximum compared to the PTSD group (P = 0.035). CONCLUSION: The preliminary results of the study indicate that a significant proportion of patients with PTSD induced by ACS are not receiving adequate treatment. Furthermore, the data suggest that these patients may exhibit reduced physical activity levels, which could be one of the possible underlying mechanisms in observed poor cardiovascular outcomes in this population. Identifying cardiac biomarkers is crucial for identifying patients at risk of developing PTSD and may derive benefits from personalized interventions based on the principles of precision medicine in multidisciplinary CR programs. CI - (c)The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. FAU - Sopek Merkas, Ivana AU - Sopek Merkas I AD - Department of Cardiology, Special Hospital for Medical Rehabilitation Krapinske Toplice, Krapinske Toplice 49217, Croatia. FAU - Lakusic, Nenad AU - Lakusic N AD - Department of Cardiology, Special Hospital for Medical Rehabilitation Krapinske Toplice, Krapinske Toplice 49217, Croatia. AD - Department of Clinical Medicine, Faculty of Dental Medicine and Health Osijek, J. J. Strossmayer University of Osijek, Osijek 31000, Croatia. AD - Department of Internal Medicine, Family Medicine and History of Medicine, Faculty of Medicine Osijek, J. J. Strossmayer University of Osijek, Osijek 31000, Croatia. nenad.lakusic@post.t-com.hr. FAU - Sonicki, Zdenko AU - Sonicki Z AD - Department of Medical Statistics, Epidemiology, and Medical Informatics, School of Public Health Andrija Stampar, School of Medicine, University of Zagreb, Zagreb 10000, Croatia. FAU - Koret, Barbara AU - Koret B AD - Department of Psychiatry, Clinic for Psychiatry "Sveti Ivan", Zagreb 10000, Croatia. FAU - Vuk Pisk, Sandra AU - Vuk Pisk S AD - Department of Psychiatry, Clinic for Psychiatry "Sveti Ivan", Zagreb 10000, Croatia. AD - Department of Psychiatry and Neurology, Faculty of Dental Medicine and Health Osijek, J. J. Strossmayer University of Osijek, Osijek 31000, Croatia. FAU - Filipcic, Igor AU - Filipcic I AD - Department of Psychiatry, Clinic for Psychiatry "Sveti Ivan", Zagreb 10000, Croatia. AD - Department of Psychiatry and Neurology, Faculty of Dental Medicine and Health Osijek, J. J. Strossmayer University of Osijek, Osijek 31000, Croatia. AD - Department of Psychiatry and Psychological Medicine, School of Medicine, University of Zagreb, Zagreb 10000, Croatia. LA - eng PT - Journal Article DEP - 20230619 PL - United States TA - World J Psychiatry JT - World journal of psychiatry JID - 101610480 PMC - PMC10294131 OTO - NOTNLM OT - Acute coronary syndrome OT - Cardiac biomarkers OT - Cardiac rehabilitation OT - Multidisciplinary team OT - Posttraumatic stress disorder OT - Psychiatric interview COIS- Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article. EDAT- 2023/06/29 13:42 MHDA- 2023/06/29 13:43 PMCR- 2023/06/19 CRDT- 2023/06/29 11:48 PHST- 2023/03/26 00:00 [received] PHST- 2023/05/04 00:00 [revised] PHST- 2023/05/25 00:00 [accepted] PHST- 2023/06/29 13:43 [medline] PHST- 2023/06/29 13:42 [pubmed] PHST- 2023/06/29 11:48 [entrez] PHST- 2023/06/19 00:00 [pmc-release] AID - 10.5498/wjp.v13.i6.376 [doi] PST - epublish SO - World J Psychiatry. 2023 Jun 19;13(6):376-385. doi: 10.5498/wjp.v13.i6.376. eCollection 2023 Jun 19. PMID- 37378065 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230701 IS - 1810-6838 (Print) IS - 2073-4735 (Electronic) IS - 1810-6838 (Linking) VI - 19 IP - 1 DP - 2023 Mar TI - Caring for patients with advanced COPD: beyond the inhalers.... PG - 220229 LID - 10.1183/20734735.0229-2022 [doi] LID - 220229 AB - COPD affects millions of people worldwide. Patients with advanced COPD have a high symptom burden. Breathlessness, cough and fatigue are frequent daily symptoms. Guidelines often focus on pharmacological treatment, especially inhaler therapy, but other approaches in combination with medications offer symptomatic benefit. In this review, we take a multidisciplinary approach with contributions from pulmonary physicians, cardiothoracic surgeons and a physiotherapist. The following areas are addressed: oxygen therapy and noninvasive ventilation (NIV), dyspnoea management, surgical and bronchoscopic options, lung transplantation and palliative care. Oxygen therapy prescribed within guidelines improves mortality in patients with COPD. NIV guidelines offer only low-certainty instruction on the use of this therapy on the basis of the limited available evidence. Dyspnoea management can take place through pulmonary rehabilitation. Specific criteria aid decisions on referral for lung volume reduction treatments through surgical or bronchoscopic approaches. Lung transplantation requires precise disease severity assessment to determine which patients have the most urgent need for lung transplantation and are likely to have the longest survival. The palliative approach runs in parallel with these other treatments, focusing on symptoms and aiming to improve the quality of life of patients and their families facing the problems associated with life-threatening illness. In combination with appropriate medication and an individual approach to symptom management, patients' experiences can be optimised. EDUCATIONAL AIMS: To understand the multidisciplinary approach to management of patients with advanced COPD.To recognise the parallel approaches to oxygen, NIV and dyspnoea management with consideration of more interventional options with lung volume reduction therapy or lung transplantation.To understand the high level of symptomatology present in advanced COPD and the relevance of palliative care alongside optimal medical management. CI - Copyright (c)ERS 2023. FAU - Murray, Michelle A AU - Murray MA AD - School of Medicine and Medical Science, University College Dublin, Dublin, Ireland. AD - Mater Misericordiae University Hospital, Dublin, Ireland. FAU - Mulryan, Kathryn AU - Mulryan K AD - Mater Misericordiae University Hospital, Dublin, Ireland. FAU - Ni Chleirigh, Maedhbh AU - Ni Chleirigh M AD - St. Vincent's University Hospital, Dublin, Ireland. FAU - Redmond, Karen C AU - Redmond KC AD - Mater Misericordiae University Hospital, Dublin, Ireland. FAU - Kelly, Emer AU - Kelly E AD - School of Medicine and Medical Science, University College Dublin, Dublin, Ireland. AD - St. Vincent's University Hospital, Dublin, Ireland. LA - eng PT - Journal Article PT - Review DEP - 20230523 PL - England TA - Breathe (Sheff) JT - Breathe (Sheffield, England) JID - 101231007 PMC - PMC10292785 COIS- Conflict of interest: The authors (M.A. Murray, K. Mulryan, M. Ni Chleirigh, K.C. Redmond, E. Kelly) have no conflict of interest to declare in relation to this manuscript. EDAT- 2023/06/28 13:08 MHDA- 2023/06/28 13:09 PMCR- 2023/03/01 CRDT- 2023/06/28 09:27 PHST- 2022/10/21 00:00 [received] PHST- 2023/04/17 00:00 [accepted] PHST- 2023/06/28 13:09 [medline] PHST- 2023/06/28 13:08 [pubmed] PHST- 2023/06/28 09:27 [entrez] PHST- 2023/03/01 00:00 [pmc-release] AID - EDU-0229-2022 [pii] AID - 10.1183/20734735.0229-2022 [doi] PST - ppublish SO - Breathe (Sheff). 2023 Mar;19(1):220229. doi: 10.1183/20734735.0229-2022. Epub 2023 May 23. PMID- 37373938 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230701 IS - 2075-4426 (Print) IS - 2075-4426 (Electronic) IS - 2075-4426 (Linking) VI - 13 IP - 6 DP - 2023 Jun 3 TI - Propensity Matched Outcomes of Minimally Invasive Mitral Surgery: Does a Heart-Team Approach Eliminate Female Gender as an Independent Risk Factor? LID - 10.3390/jpm13060949 [doi] LID - 949 AB - BACKGROUND: There is increasing evidence that female gender is an independent risk factor for cardiac surgery. Minimally invasive mitral surgery (MIV) has proven to have excellent long-term results, but little is known about gender-dependent outcomes. The aim of our study was to analyze our heart team's decision-based MIV-specialized cohort. METHODS: In-hospital and follow-up data were retrospectively collected. The cohort was divided into gender groups and propensity-matched groups. RESULTS: Between 22 July 2013 and 31 December 2022, 302 consecutive patients underwent MIV. Before matching, the total cohort showed that women were older, had a higher EuroSCORE II, were more symptomatic, and had more complex valve pathology and tricuspid regurgitation resulting in more valve replacements and tricuspid repairs. Intensive and hospital stays were longer. In-hospital deaths (n = 3, all women) were comparable, with more atrial fibrillation in women. The median follow-up time was 3.44 (0.008-8.9) years. The ejection fraction, NYHA, and recurrent regurgitation were low and comparable and atrial fibrillation more frequent in women. The calculated 5-year survival and freedom from re-intervention were comparable (p = 0.9 and p = 0.2). Propensity matching compared 101 well-balanced pairs; women still had fewer resections and more atrial fibrillation. During the follow-up, women had a better ejection fraction. The calculated 5-year survival and freedom from re-intervention were comparable (p = 0.3 and p = 0.3). CONCLUSIONS: Despite women being older and sicker, with more complex valve pathology and subsequent replacement, early and mid-term mortality and the need for reoperation were low and comparable before and after propensity matching, which might be the result of the MIV setting combined with our patient-tailored decision-making. We believe that a multidisciplinary heart team approach is crucial to optimize patient outcomes in MIV, and it might also reduce the widely reported increased surgical risk in female patients. Further studies are needed to prove our findings. FAU - Passos, Laina AU - Passos L AD - Heart Clinic Hirslanden, Witellikerstrasse 40, 8032 Zuerich, Switzerland. FAU - Lavanchy, Isabel AU - Lavanchy I AD - Heart Clinic Hirslanden, Witellikerstrasse 40, 8032 Zuerich, Switzerland. FAU - Aymard, Thierry AU - Aymard T AD - Heart Clinic Hirslanden, Witellikerstrasse 40, 8032 Zuerich, Switzerland. FAU - Morjan, Mohammed AU - Morjan M AD - Department of Cardiac Surgery, Medical Faculty, University Hospital Duesseldorf, Heinrich-Heine-University Duesseldorf, Mooren Str. 5, 40225 Duesseldorf, Germany. FAU - Kapos, Ioannis AU - Kapos I AD - Heart Clinic Hirslanden, Witellikerstrasse 40, 8032 Zuerich, Switzerland. FAU - Corti, Roberto AU - Corti R AD - Heart Clinic Hirslanden, Witellikerstrasse 40, 8032 Zuerich, Switzerland. FAU - Gruenenfelder, Juerg AU - Gruenenfelder J AD - Heart Clinic Hirslanden, Witellikerstrasse 40, 8032 Zuerich, Switzerland. FAU - Biaggi, Patric AU - Biaggi P AD - Heart Clinic Hirslanden, Witellikerstrasse 40, 8032 Zuerich, Switzerland. FAU - Reser, Diana AU - Reser D AD - Heart Clinic Hirslanden, Witellikerstrasse 40, 8032 Zuerich, Switzerland. LA - eng PT - Journal Article DEP - 20230603 PL - Switzerland TA - J Pers Med JT - Journal of personalized medicine JID - 101602269 PMC - PMC10305141 OTO - NOTNLM OT - female gender an independent risk factor OT - heart team OT - minimally invasive mitral surgery COIS- The authors declare no conflict of interest. EDAT- 2023/06/28 06:43 MHDA- 2023/06/28 06:44 PMCR- 2023/06/03 CRDT- 2023/06/28 01:23 PHST- 2023/03/29 00:00 [received] PHST- 2023/05/31 00:00 [revised] PHST- 2023/06/01 00:00 [accepted] PHST- 2023/06/28 06:44 [medline] PHST- 2023/06/28 06:43 [pubmed] PHST- 2023/06/28 01:23 [entrez] PHST- 2023/06/03 00:00 [pmc-release] AID - jpm13060949 [pii] AID - jpm-13-00949 [pii] AID - 10.3390/jpm13060949 [doi] PST - epublish SO - J Pers Med. 2023 Jun 3;13(6):949. doi: 10.3390/jpm13060949. PMID- 37372896 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230701 IS - 2227-9032 (Print) IS - 2227-9032 (Electronic) IS - 2227-9032 (Linking) VI - 11 IP - 12 DP - 2023 Jun 16 TI - Study Protocol for the Evaluation of Multidisciplinary Medication Reconciliation Service in Adult Patients Undergoing Thoracic and Cardiovascular Surgery (The MERITS Study): A Single-Center Controlled before-and-after Study. LID - 10.3390/healthcare11121778 [doi] LID - 1778 AB - Medication reconciliation (MR), which is widely implemented worldwide, aims to improve patient safety to reduce the medication errors during care transition. Despite its widespread use, MR has not yet been implemented in the Republic of Korea, and its effectiveness has not been studied. We aimed to evaluate the impact of a multidisciplinary MR service in older patients undergoing thoracic and cardiovascular surgery. This is a single-center, prospective, controlled, before-and-after study of adult patients taking at least one chronic oral medication. Depending on the period of each patient's participation, they will be allocated to an intervention group or control group. Patients in the intervention group will receive multidisciplinary MR, and those in the control group will receive usual care. The primary outcome is to assess the impact of the MR service on medication discrepancies between the best possible medication history and medication orders at care transition. Secondary outcomes include the incidence rate of medication discrepancies at each transition, the discrepancy rate between the sources of information, the impact of MR on medication appropriateness index score, drug-related problems, 30-day mortality, the emergency department visit rate, readmission rate after discharge, the rate and acceptability of pharmacists' intervention during hospitalization, and patients' satisfaction. FAU - Park, Soyoung AU - Park S AUID- ORCID: 0009-0000-6329-0656 AD - College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Republic of Korea. FAU - Kim, A Jeong AU - Kim AJ AD - Department of Pharmacy, Seoul National University Hospital, Seoul 03080, Republic of Korea. FAU - Chae, Hyun-Woo AU - Chae HW AUID- ORCID: 0009-0004-7819-3372 AD - College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Republic of Korea. FAU - Heo, Kyu-Nam AU - Heo KN AUID- ORCID: 0000-0003-3626-3999 AD - College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Republic of Korea. FAU - Kim, Yookyung AU - Kim Y AD - Department of Pharmacy, Seoul National University Hospital, Seoul 03080, Republic of Korea. FAU - Kim, Sung Hwan AU - Kim SH AD - Department of Pharmacy, Seoul National University Hospital, Seoul 03080, Republic of Korea. FAU - Cho, Yoon Sook AU - Cho YS AD - Department of Pharmacy, Seoul National University Hospital, Seoul 03080, Republic of Korea. FAU - Lee, Hyun Joo AU - Lee HJ AD - Department of Thoracic and Cardiovascular Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul 03080, Republic of Korea. FAU - Lee, Ju-Yeun AU - Lee JY AUID- ORCID: 0000-0002-2261-7330 AD - College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Republic of Korea. LA - eng GR - 800-20210481/Seoul National University, College of Medicine/ PT - Journal Article DEP - 20230616 PL - Switzerland TA - Healthcare (Basel) JT - Healthcare (Basel, Switzerland) JID - 101666525 PMC - PMC10298288 OTO - NOTNLM OT - best possible medication history OT - medication reconciliation OT - multidisciplinary OT - transition of care COIS- The authors declare no conflict of interest. EDAT- 2023/06/28 06:42 MHDA- 2023/06/28 06:43 PMCR- 2023/06/16 CRDT- 2023/06/28 01:15 PHST- 2023/05/18 00:00 [received] PHST- 2023/06/09 00:00 [revised] PHST- 2023/06/14 00:00 [accepted] PHST- 2023/06/28 06:43 [medline] PHST- 2023/06/28 06:42 [pubmed] PHST- 2023/06/28 01:15 [entrez] PHST- 2023/06/16 00:00 [pmc-release] AID - healthcare11121778 [pii] AID - healthcare-11-01778 [pii] AID - 10.3390/healthcare11121778 [doi] PST - epublish SO - Healthcare (Basel). 2023 Jun 16;11(12):1778. doi: 10.3390/healthcare11121778. PMID- 37370890 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260921 IS - 2075-4418 (Print) IS - 2075-4418 (Electronic) IS - 2075-4418 (Linking) VI - 13 IP - 12 DP - 2023 Jun 7 TI - Exploring the Intersection of Artificial Intelligence and Clinical Healthcare: A Multidisciplinary Review. LID - 10.3390/diagnostics13121995 [doi] LID - 1995 AB - Artificial intelligence (AI) plays a more and more important role in our everyday life due to the advantages that it brings when used, such as 24/7 availability, a very low percentage of errors, ability to provide real time insights, or performing a fast analysis. AI is increasingly being used in clinical medical and dental healthcare analyses, with valuable applications, which include disease diagnosis, risk assessment, treatment planning, and drug discovery. This paper presents a narrative literature review of AI use in healthcare from a multi-disciplinary perspective, specifically in the cardiology, allergology, endocrinology, and dental fields. The paper highlights data from recent research and development efforts in AI for healthcare, as well as challenges and limitations associated with AI implementation, such as data privacy and security considerations, along with ethical and legal concerns. The regulation of responsible design, development, and use of AI in healthcare is still in early stages due to the rapid evolution of the field. However, it is our duty to carefully consider the ethical implications of implementing AI and to respond appropriately. With the potential to reshape healthcare delivery and enhance patient outcomes, AI systems continue to reveal their capabilities. FAU - Stafie, Celina Silvia AU - Stafie CS AUID- ORCID: 0000-0002-9865-4349 AD - Department of Preventive Medicine and Interdisciplinarity, Grigore T. Popa University of Medicine and Pharmacy Iasi, Universitatii Street 16, 700115 Iasi, Romania. FAU - Sufaru, Irina-Georgeta AU - Sufaru IG AUID- ORCID: 0000-0001-7779-8987 AD - Department of Periodontology, Grigore T. Popa University of Medicine and Pharmacy Iasi, Universitatii Street 16, 700115 Iasi, Romania. FAU - Ghiciuc, Cristina Mihaela AU - Ghiciuc CM AUID- ORCID: 0000-0003-1791-0425 AD - Department of Morpho-Functional Sciences II-Pharmacology and Clinical Pharmacology, Grigore T. Popa University of Medicine and Pharmacy Iasi, Universitatii Street 16, 700115 Iasi, Romania. FAU - Stafie, Ingrid-Ioana AU - Stafie II AD - Endocrinology Residency Program, Sf. Spiridon Clinical Emergency Hospital, Independentei 1, 700111 Iasi, Romania. FAU - Sufaru, Eduard-Constantin AU - Sufaru EC AD - Technology Reply Romania, Ceasornicului 17, 014111 Bucharest, Romania. FAU - Solomon, Sorina Mihaela AU - Solomon SM AUID- ORCID: 0000-0002-9588-6910 AD - Department of Periodontology, Grigore T. Popa University of Medicine and Pharmacy Iasi, Universitatii Street 16, 700115 Iasi, Romania. FAU - Hancianu, Monica AU - Hancianu M AD - Pharmacognosy-Phytotherapy, Grigore T. Popa University of Medicine and Pharmacy Iasi, Universitatii Street 16, 700115 Iasi, Romania. LA - eng PT - Journal Article PT - Review DEP - 20230607 PL - Switzerland TA - Diagnostics (Basel) JT - Diagnostics (Basel, Switzerland) JID - 101658402 PMC - PMC10297646 OTO - NOTNLM OT - allergology OT - artificial intelligence OT - cardiology OT - dentistry OT - diagnosis OT - immunology OT - machine learning OT - prediction OT - treatment COIS- The authors declare no conflict of interest. EDAT- 2023/06/28 06:42 MHDA- 2023/06/28 06:43 PMCR- 2023/06/07 CRDT- 2023/06/28 01:04 PHST- 2023/04/09 00:00 [received] PHST- 2023/05/31 00:00 [revised] PHST- 2023/06/05 00:00 [accepted] PHST- 2023/06/28 06:43 [medline] PHST- 2023/06/28 06:42 [pubmed] PHST- 2023/06/28 01:04 [entrez] PHST- 2023/06/07 00:00 [pmc-release] AID - diagnostics13121995 [pii] AID - diagnostics-13-01995 [pii] AID - 10.3390/diagnostics13121995 [doi] PST - epublish SO - Diagnostics (Basel). 2023 Jun 7;13(12):1995. doi: 10.3390/diagnostics13121995. PMID- 37370884 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230701 IS - 2075-4418 (Print) IS - 2075-4418 (Electronic) IS - 2075-4418 (Linking) VI - 13 IP - 12 DP - 2023 Jun 7 TI - Long COVID in Children: A Multidisciplinary Review. LID - 10.3390/diagnostics13121990 [doi] LID - 1990 AB - Long COVID syndrome has emerged as a long-lasting consequence of acute SARS-CoV-2 infection in adults. In addition, children may be affected by Long COVID, with potential clinical issues in different fields, including problems in school performance and daily activities. Yet, the pathophysiologic bases of Long COVID in children are largely unknown, and it is difficult to predict who will develop the syndrome. In this multidisciplinary clinical review, we summarise the latest scientific data regarding Long COVID and its impact on children. Special attention is given to diagnostic tests, in order to help the physicians to find potential disease markers and quantify impairment. Specifically, we assess the respiratory, upper airways, cardiac, neurologic and motor and psychological aspects. Finally, we also propose a multidisciplinary clinical approach. FAU - Sansone, Francesco AU - Sansone F AD - Unit of Paediatrics, Rovigo Hospital, 45030 Rovigo, Italy. FAU - Pellegrino, Giulia Michela AU - Pellegrino GM AD - Department of Neurorehabilitation Sciences, Casa di Cura Igea, 20144 Milan, Italy. FAU - Caronni, Antonio AU - Caronni A AUID- ORCID: 0000-0003-3051-1031 AD - Department of Neurorehabilitation Sciences, IRCCS Istituto Auxologico Italiano, Ospedale San Luca, 20122 Milan, Italy. AD - Department of Biomedical Sciences for Health, Universita degli Studi di Milano, 20133 Milan, Italy. FAU - Bonazza, Federica AU - Bonazza F AD - Department of Health Sciences, Clinical Psychology, University of Milan, Via di Rudini 8, 20142 Milan, Italy. FAU - Vegni, Elena AU - Vegni E AD - Department of Health Sciences, Clinical Psychology, University of Milan, Via di Rudini 8, 20142 Milan, Italy. AD - Unit of Clinical Psychology, San Paolo Hospital, ASST Santi Paolo e Carlo, Via di Rudini 8, 20142 Milan, Italy. FAU - Lue, Alberto AU - Lue A AUID- ORCID: 0000-0002-9672-6038 AD - Service of Digestive Diseases, University Clinic Hospital Lozano Blesa, IIS Aragon, 50009 Zaragoza, Spain. FAU - Bocci, Tommaso AU - Bocci T AUID- ORCID: 0000-0001-8874-1070 AD - Department of Health Sciences, University of Milan, 20146 Milan, Italy. AD - Clinical Neurology Unit, Department of Health Sciences, "Azienda Socio-Sanitaria Territoriale Santi Paolo e Carlo", University of Milan, 20146 Milan, Italy. FAU - Pipolo, Carlotta AU - Pipolo C AD - Department of Health Sciences, Otorhinolaryngology Department, ASST Santi Paolo e Carlo, University of Milan, 20142 Milan, Italy. FAU - Giusti, Giuliano AU - Giusti G AD - Paediatric Cardiology Unit, Niguarda Hospital, 20162 Milan, Italy. FAU - Di Filippo, Paola AU - Di Filippo P AUID- ORCID: 0000-0001-7336-4292 AD - Paediatric Allergy and Pulmonology Unit, Department of Paediatrics, University of Chieti-Pescara, 66100 Chieti, Italy. FAU - Di Pillo, Sabrina AU - Di Pillo S AD - Paediatric Allergy and Pulmonology Unit, Department of Paediatrics, University of Chieti-Pescara, 66100 Chieti, Italy. FAU - Chiarelli, Francesco AU - Chiarelli F AD - Paediatric Allergy and Pulmonology Unit, Department of Paediatrics, University of Chieti-Pescara, 66100 Chieti, Italy. FAU - Sferrazza Papa, Giuseppe Francesco AU - Sferrazza Papa GF AUID- ORCID: 0000-0002-5245-4843 AD - School of Medicine, University of Enna "Kore", 94100 Enna, Italy. FAU - Attanasi, Marina AU - Attanasi M AUID- ORCID: 0000-0001-6513-3160 AD - Paediatric Allergy and Pulmonology Unit, Department of Paediatrics, University of Chieti-Pescara, 66100 Chieti, Italy. LA - eng GR - NA/University of Milan/ PT - Journal Article PT - Review DEP - 20230607 PL - Switzerland TA - Diagnostics (Basel) JT - Diagnostics (Basel, Switzerland) JID - 101658402 PMC - PMC10297324 OTO - NOTNLM OT - Long COVID OT - autonomic dysfunction OT - children OT - gastrointestinal OT - lung function OT - neuroCOVID OT - otorhinolaryngology OT - psychological well-being COIS- The authors declare no conflict of interest. The funders had no role in the writing of the manuscript. EDAT- 2023/06/28 06:42 MHDA- 2023/06/28 06:43 PMCR- 2023/06/07 CRDT- 2023/06/28 01:04 PHST- 2023/03/09 00:00 [received] PHST- 2023/06/01 00:00 [revised] PHST- 2023/06/01 00:00 [accepted] PHST- 2023/06/28 06:43 [medline] PHST- 2023/06/28 06:42 [pubmed] PHST- 2023/06/28 01:04 [entrez] PHST- 2023/06/07 00:00 [pmc-release] AID - diagnostics13121990 [pii] AID - diagnostics-13-01990 [pii] AID - 10.3390/diagnostics13121990 [doi] PST - epublish SO - Diagnostics (Basel). 2023 Jun 7;13(12):1990. doi: 10.3390/diagnostics13121990. PMID- 37369374 OWN - NLM STAT- MEDLINE DCOM- 20230629 LR - 20230629 IS - 1476-4954 (Electronic) IS - 1476-4954 (Linking) VI - 36 IP - 2 DP - 2023 Dec TI - Maternal cardiac disease and perinatal outcomes in a single tertiary care center. PG - 2223336 LID - 10.1080/14767058.2023.2223336 [doi] AB - OBJECTIVE: Maternal mortality in the U.S. has increased, with a substantial contribution from maternal cardiac disease. As a result of improved childhood survival, more women with congenital heart disease are reaching reproductive age leading to a growing high-risk obstetric population. We sought to determine the obstetrical and neonatal outcomes of women with maternal cardiac disease, including acquired cardiovascular disease and congenital heart disease. METHODS: We studied a retrospective cohort study of women that delivered from 2008 to 2013 (N = 9026). Singleton pregnancies without preexisting conditions were established as the unexposed group for this study. Maternal and neonatal outcomes were compared between the unexposed group (N = 7277) and women exposed to maternal (acquired or congenital) cardiac disease (N = 139) as well as only congenital heart disease (N = 85). Statistical comparisons used univariate/multivariable logistic and linear regression analysis controlling for confounders with p < .05 and 95% confidence intervals indicating statistical significance. RESULTS: Pregnancies complicated by maternal cardiac disease were associated with increased odds of preterm birth (<34 weeks, <37 weeks), intrauterine growth restriction (IUGR), need for assisted vaginal delivery, maternal ICU admission, and prolonged maternal hospitalization (>7 d). Neonatal outcomes including small for gestational age and Apgar score <7 at 5 min were increased in the pregnancies complicated by maternal cardiac disease. When pregnancies complicated by congenital heart disease were analyzed as a sub-group of the cohort, the results were similar. There were increased odds of preterm birth (<37 weeks), early-term delivery, need for assisted vaginal delivery, and prolonged hospitalization. Neonatal outcomes were only significant for small for gestational age. CONCLUSION: We observed that in a select cohort of pregnancies complicated by maternal cardiac diseases (acquired or congenital), there were significant increases of adverse perinatal outcomes. Therefore, a multidisciplinary approach including maternal-fetal medicine specialists, cardiologists, obstetric anesthesia, and dedicated ancillary support is imperative for optimal care of this high-risk obstetrics population. FAU - Gonzalez, Juan M AU - Gonzalez JM AD - Division of Maternal-Fetal Medicine and Perinatal Genetics, Department of Obstetrics and Gynecology, University of California San Francisco, San Francisco, CA, USA. FAU - Harris, Ian AU - Harris I AD - Division of Cardiology, Department of Medicine, University of California San Francisco, San Francisco, CA, USA. FAU - Jimenez Ramirez, Norma AU - Jimenez Ramirez N AUID- ORCID: 0000-0001-9391-4941 AD - Stanford School of Medicine, Stanford University, Stanford, CA, USA. FAU - Myers, Dana AU - Myers D AD - Division of Maternal-Fetal Medicine, Sutter West Bay Medical Group, San Francisco, CA, USA. FAU - Killion, Molly AU - Killion M AD - Division of Maternal-Fetal Medicine and Perinatal Genetics, Department of Obstetrics and Gynecology, University of California San Francisco, San Francisco, CA, USA. FAU - Thiet, Mari-Paule AU - Thiet MP AD - Division of Maternal-Fetal Medicine and Perinatal Genetics, Department of Obstetrics and Gynecology, University of California San Francisco, San Francisco, CA, USA. FAU - Bianco, Katherine AU - Bianco K AD - Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Stanford University, Stanford, CA, USA. LA - eng PT - Journal Article PL - England TA - J Matern Fetal Neonatal Med JT - The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians JID - 101136916 SB - IM MH - Pregnancy MH - Infant, Newborn MH - Female MH - Humans MH - Child MH - Pregnancy Outcome/epidemiology MH - *Premature Birth/epidemiology MH - Retrospective Studies MH - Tertiary Care Centers MH - *Heart Defects, Congenital/epidemiology MH - Fetal Growth Retardation/epidemiology OTO - NOTNLM OT - Congenital heart disease OT - IUGR OT - PTB OT - cardiovascular disease OT - pregnancy EDAT- 2023/06/28 01:06 MHDA- 2023/06/29 06:43 CRDT- 2023/06/27 20:32 PHST- 2023/06/29 06:43 [medline] PHST- 2023/06/28 01:06 [pubmed] PHST- 2023/06/27 20:32 [entrez] AID - 10.1080/14767058.2023.2223336 [doi] PST - ppublish SO - J Matern Fetal Neonatal Med. 2023 Dec;36(2):2223336. doi: 10.1080/14767058.2023.2223336. PMID- 37369216 OWN - NLM STAT- MEDLINE DCOM- 20231101 LR - 20240109 IS - 1098-9048 (Electronic) IS - 1069-3424 (Linking) VI - 44 IP - 6 DP - 2023 Dec TI - Management of Acutely Decompensated Pulmonary Hypertension. PG - 762-770 LID - 10.1055/s-0043-1770119 [doi] AB - Pulmonary arterial hypertension is a severe life-threatening condition associated with increased pulmonary vascular resistance and resulting right heart dysfunction. Admission to intensive care unit with acutely decompensated right heart failure is a significant negative prognostic event with a high risk of multisystem organ dysfunction and death. Presentations are heterogenous and may combine signs of both diastolic and systolic dysfunction complicating management. Renal dysfunction is often present, but other organ systems can be involved resulting in findings such as acute hepatic dysfunction or bowel wall congestion and ischemia. The goals of therapy are to rapidly reverse ventriculo-arterial decoupling and reduce right ventricular afterload to prevent progression to refractory or irreversible right heart failure. Triggering events must be investigated for and addressed urgently if identified. Volume status management is critical and both noninvasive and invasive testing can aid in prognostication and guide management, including the use of inotropes and vasopressors. In cases of refractory right heart dysfunction, consideration of urgent lung transplantation and mechanical circulatory support is necessary. These patients should be managed at expert centers in an intensive care setting with a multidisciplinary team of practitioners experienced in the management of right heart dysfunction given the high short- and long-term mortality resulting from acute decompensated right heart failure. CI - Thieme. All rights reserved. FAU - Savale, Laurent AU - Savale L AD - INSERM UMR_S 999, Pulmonary Hypertension: Pathophysiology and Novel Therapies, Hopital Marie Lannelongue, Le Plessis-Robinson, France. AD - Faculte de Medecine, Universite Paris-Saclay, Le Kremlin-Bicetre, France. AD - Service de Pneumologie et Soins Intensifs Respiratoires, Assistance Publique - Hopitaux de Paris (AP-HP), Hopital Bicetre, Le Kremlin-Bicetre, France. AD - European Reference Network on Rare Pulmonary Diseases (ERN-LUNG), Germany. FAU - Kularatne, Mithum AU - Kularatne M AD - Division of Respiratory Medicine, Department of Medicine, University of Calgary, Calgary, Canada. FAU - Roche, Anne AU - Roche A AD - INSERM UMR_S 999, Pulmonary Hypertension: Pathophysiology and Novel Therapies, Hopital Marie Lannelongue, Le Plessis-Robinson, France. AD - Faculte de Medecine, Universite Paris-Saclay, Le Kremlin-Bicetre, France. AD - Service de Pneumologie et Soins Intensifs Respiratoires, Assistance Publique - Hopitaux de Paris (AP-HP), Hopital Bicetre, Le Kremlin-Bicetre, France. AD - European Reference Network on Rare Pulmonary Diseases (ERN-LUNG), Germany. FAU - Pichon, Jeremie AU - Pichon J AD - INSERM UMR_S 999, Pulmonary Hypertension: Pathophysiology and Novel Therapies, Hopital Marie Lannelongue, Le Plessis-Robinson, France. AD - Faculte de Medecine, Universite Paris-Saclay, Le Kremlin-Bicetre, France. AD - Service de Pneumologie et Soins Intensifs Respiratoires, Assistance Publique - Hopitaux de Paris (AP-HP), Hopital Bicetre, Le Kremlin-Bicetre, France. AD - European Reference Network on Rare Pulmonary Diseases (ERN-LUNG), Germany. FAU - Baron, Audrey AU - Baron A AD - INSERM UMR_S 999, Pulmonary Hypertension: Pathophysiology and Novel Therapies, Hopital Marie Lannelongue, Le Plessis-Robinson, France. AD - Faculte de Medecine, Universite Paris-Saclay, Le Kremlin-Bicetre, France. AD - Service de Pneumologie et Soins Intensifs Respiratoires, Assistance Publique - Hopitaux de Paris (AP-HP), Hopital Bicetre, Le Kremlin-Bicetre, France. AD - European Reference Network on Rare Pulmonary Diseases (ERN-LUNG), Germany. FAU - Boucly, Athenais AU - Boucly A AD - INSERM UMR_S 999, Pulmonary Hypertension: Pathophysiology and Novel Therapies, Hopital Marie Lannelongue, Le Plessis-Robinson, France. AD - Faculte de Medecine, Universite Paris-Saclay, Le Kremlin-Bicetre, France. AD - Service de Pneumologie et Soins Intensifs Respiratoires, Assistance Publique - Hopitaux de Paris (AP-HP), Hopital Bicetre, Le Kremlin-Bicetre, France. AD - European Reference Network on Rare Pulmonary Diseases (ERN-LUNG), Germany. FAU - Sitbon, Olivier AU - Sitbon O AD - INSERM UMR_S 999, Pulmonary Hypertension: Pathophysiology and Novel Therapies, Hopital Marie Lannelongue, Le Plessis-Robinson, France. AD - Faculte de Medecine, Universite Paris-Saclay, Le Kremlin-Bicetre, France. AD - Service de Pneumologie et Soins Intensifs Respiratoires, Assistance Publique - Hopitaux de Paris (AP-HP), Hopital Bicetre, Le Kremlin-Bicetre, France. AD - European Reference Network on Rare Pulmonary Diseases (ERN-LUNG), Germany. FAU - Humbert, Marc AU - Humbert M AD - INSERM UMR_S 999, Pulmonary Hypertension: Pathophysiology and Novel Therapies, Hopital Marie Lannelongue, Le Plessis-Robinson, France. AD - Faculte de Medecine, Universite Paris-Saclay, Le Kremlin-Bicetre, France. AD - Service de Pneumologie et Soins Intensifs Respiratoires, Assistance Publique - Hopitaux de Paris (AP-HP), Hopital Bicetre, Le Kremlin-Bicetre, France. AD - European Reference Network on Rare Pulmonary Diseases (ERN-LUNG), Germany. LA - eng PT - Journal Article DEP - 20230627 PL - United States TA - Semin Respir Crit Care Med JT - Seminars in respiratory and critical care medicine JID - 9431858 SB - IM MH - Humans MH - *Hypertension, Pulmonary/diagnosis/therapy/complications MH - Intensive Care Units MH - *Lung Transplantation/adverse effects MH - Critical Care/methods MH - *Heart Failure/therapy MH - *Ventricular Dysfunction, Right/therapy/etiology COIS- L.S. reports personal fees from Janssen and Janssen and from MSD outside the submitted work. M.K. reports no conflict of interest. A.R. declares no conflict of interest. J.P. declares no conflicts of interest. A.B. declares no conflicts of interest. A.B. reports grants or contracts from Acceleron, Janssen and MSD and Payment or honoraria for lectures from Janssen, Merck, and AOP Orphan outside the submitted work. O.S. reports honoraria for speaking, steering committees, scientific advisory boards from Janssen, Bayer, Merck, Gossamer Bio, Ferrer, United Therapeutics. M.H. reports grants and personal fees from Acceleron, Aerovate, Altavant, AOP Orphan, Bayer, Chiesi, Ferrer, Janssen, Merck, MorphogenIX and United Therapeutics and payment or honoraria from janssen and Merck outside the submitted work. EDAT- 2023/06/28 01:06 MHDA- 2023/11/01 12:44 CRDT- 2023/06/27 18:43 PHST- 2023/11/01 12:44 [medline] PHST- 2023/06/28 01:06 [pubmed] PHST- 2023/06/27 18:43 [entrez] AID - 10.1055/s-0043-1770119 [doi] PST - ppublish SO - Semin Respir Crit Care Med. 2023 Dec;44(6):762-770. doi: 10.1055/s-0043-1770119. Epub 2023 Jun 27. PMID- 37369092 OWN - NLM STAT- MEDLINE DCOM- 20231120 LR - 20260518 IS - 1537-6591 (Electronic) IS - 1058-4838 (Linking) VI - 77 IP - 10 DP - 2023 Nov 17 TI - The Mortality of Infective endocarditis with and without Surgery in Elderly (MoISE) Study. PG - 1440-1448 LID - 10.1093/cid/ciad384 [doi] AB - BACKGROUND: Infective endocarditis (IE) is increasingly affecting older patients. However, data on their management are sparse, and the benefits of surgery in this population are unclear. METHODS: We included patients with left-sided IE (LSIE) aged >/= 80 years enrolled in a prospective endocarditis cohort managed in Aquitaine, France, from 2013 to 2020. Geriatric data were collected retrospectively to identify factors associated with the 1-year risk of death using Cox regression. RESULTS: We included 163 patients with LSIE (median age, 84 years; men, 59%; rate of prosthetic LSIE, 45%). Of the 105 (64%) patients with potential surgical indications, 38 (36%) underwent valve surgery: they were younger, more likely to be men with aortic involvement, and had a lower Charlson comorbidity index. Moreover, they had better functional status at admission (ie, the ability to walk unassisted and a higher median activities of daily living [ADL] score; n = 5/6 vs 3/6, P = .01). The 1-year mortality rate in LSIE patients without surgical indications was 28%; it was lower in those who were operated on compared with those who were not despite a surgical indication (16% vs 66%, P < .001). Impaired functional status at admission was strongly associated with mortality regardless of surgical status. In patients unable to walk unassisted or with an ADL score <4, there was no significant surgical benefit for 1-year mortality. CONCLUSIONS: Surgery improves the prognosis of older patients with LSIE and good functional status. Surgical futility should be discussed in patients with altered autonomy. The endocarditis team should include a geriatric specialist. CI - (c) The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. FAU - Hemar, Victor AU - Hemar V AUID- ORCID: 0000-0002-1936-5523 AD - Internal Medicine and Infectious Diseases Department, Bordeaux University Hospital-Saint-Andre Bordeaux, France. FAU - Camou, Fabrice AU - Camou F AD - Intensive Care and Infectious Diseases Department, Bordeaux University Hospital-Saint-Andre Bordeaux, France. FAU - Roubaud-Baudron, Claire AU - Roubaud-Baudron C AD - Pole de Gerontologie Clinique, Bordeaux University Hospital Bordeaux, France. AD - INSERM BRIC UMR 1312, University of Bordeaux, Bordeaux, France. FAU - Ternacle, Julien AU - Ternacle J AD - Cardiology Department, Bordeaux University Hospital-Haut-Leveque, Pessac, France. FAU - Pernot, Mathieu AU - Pernot M AD - Cardiac Surgery Department, Bordeaux University Hospital-Haut-Leveque, Pessac, France. FAU - Greib, Carine AU - Greib C AD - Internal Medicine and Infectious Diseases Department, Bordeaux University Hospital-Haut-Leveque, Pessac, France. FAU - Dijos, Marina AU - Dijos M AD - Cardiology Department, Bordeaux University Hospital-Haut-Leveque, Pessac, France. FAU - Wirth, Gaetane AU - Wirth G AD - Infectious Diseases Department, Bordeaux University Hospital-Pellegrin, Bordeaux, France. FAU - Chaussade, Helene AU - Chaussade H AD - Internal Medicine and Infectious Diseases Department, Bordeaux University Hospital-Saint-Andre Bordeaux, France. FAU - Peuchant, Olivia AU - Peuchant O AD - Bacteriology Department, Bordeaux University Hospital-Pellegrin, Bordeaux, France. FAU - Bonnet, Fabrice AU - Bonnet F AD - Internal Medicine and Infectious Diseases Department, Bordeaux University Hospital-Saint-Andre Bordeaux, France. FAU - Issa, Nahema AU - Issa N AD - Intensive Care and Infectious Diseases Department, Bordeaux University Hospital-Saint-Andre Bordeaux, France. CN - MoISE Study Group LA - eng PT - Journal Article PL - United States TA - Clin Infect Dis JT - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America JID - 9203213 SB - IM MH - Aged MH - Male MH - Humans MH - Aged, 80 and over MH - Female MH - Prospective Studies MH - Retrospective Studies MH - Activities of Daily Living MH - *Endocarditis, Bacterial MH - *Endocarditis/surgery MH - Hospital Mortality OTO - NOTNLM OT - cardiac surgery OT - functional status OT - infective endocarditis OT - older patients OT - prognosis COIS- Potential conflicts of interest . F. B. reports research grants from Gilead and ViiV Healthcare and payments for educational events from Gilead, ViiV Healthcare, and MSD. The remaining authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. FIR - Tlili, G IR - Tlili G FIR - Ngo Bell, C IR - Ngo Bell C FIR - Barret, A IR - Barret A FIR - Videcoq, M IR - Videcoq M FIR - Alexandrino, C IR - Alexandrino C FIR - Vareil, M O IR - Vareil MO FIR - Wille, H IR - Wille H FIR - Andre, K IR - Andre K FIR - Nyamankolly, E IR - Nyamankolly E FIR - Girard, D IR - Girard D FIR - Ducours, M IR - Ducours M FIR - Caubet, O IR - Caubet O FIR - Ferrand, H IR - Ferrand H FIR - Lacassin, F IR - Lacassin F FIR - Picard, W IR - Picard W FIR - Pavin, C IR - Pavin C FIR - Castan, B IR - Castan B FIR - Aguilar, C IR - Aguilar C EDAT- 2023/06/27 19:13 MHDA- 2023/11/20 06:54 CRDT- 2023/06/27 16:03 PHST- 2023/03/30 00:00 [received] PHST- 2023/11/20 06:54 [medline] PHST- 2023/06/27 19:13 [pubmed] PHST- 2023/06/27 16:03 [entrez] AID - 7208964 [pii] AID - 10.1093/cid/ciad384 [doi] PST - ppublish SO - Clin Infect Dis. 2023 Nov 17;77(10):1440-1448. doi: 10.1093/cid/ciad384. PMID- 37367409 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230701 IS - 2308-3425 (Electronic) IS - 2308-3425 (Linking) VI - 10 IP - 6 DP - 2023 May 31 TI - Surgical Mortality Risk Scores in Transcatheter Aortic Valve Implantation: Is Their Early Predictive Value Still Strong? LID - 10.3390/jcdd10060244 [doi] LID - 244 AB - BACKGROUND: Surgical mortality risk scores, even if not properly designed and rarely tested in the transcatheter aortic valve implantation (TAVI) setting, still guide the heart team in managing significant aortic stenosis. METHODS: After splitting 1763 consecutive patients retrospectively based on their mortality risk thresholds, the composite endpoint early safety (ES) was adjudicated according to Valve Academic Research Consortium (VARC)-2 and -3 consensus documents. RESULTS: ES incidence was higher if VARC-2 rather than VARC-3 defined. Despite only patients showing VARC-2 ES had significantly lower absolute values of all three main risk scores, these last still failed to foresee both VARC-2 and -3 ES in intermediate-risk patients. The receiver operating characteristic analysis also showed a significant correlation, but with poor diagnostic accuracy, among the three scores and only VARC-2 ES; moreover, the absence of VARC-2 ES and low-osmolar contrast media administration were identified as independent predictors of 1-year mortality and absence of VARC-3 ES, respectively. Finally, even a single complication included in the ES definition could significantly affect 1-year mortality. CONCLUSION: Currently, the most used mortality risk scores do not have adequate diagnostic accuracy in predicting ES after TAVI. The absence of VARC-2, instead of VARC-3, ES is an independent predictor of 1-year mortality. FAU - Iacovelli, Fortunato AU - Iacovelli F AUID- ORCID: 0000-0002-4620-678X AD - Division of University Cardiology, Cardiothoracic Department, Policlinico University Hospital, 70124 Bari, Italy. AD - Division of Cardiology, "SS. Annunziata" Hospital, 74121 Taranto, Italy. FAU - Loizzi, Francesco AU - Loizzi F AUID- ORCID: 0000-0002-6556-5227 AD - Division of Cardiology, "SS. Annunziata" Hospital, 74121 Taranto, Italy. FAU - Cafaro, Alessandro AU - Cafaro A AUID- ORCID: 0000-0002-2068-7351 AD - Division of Cardiology, "V. Fazzi" Hospital, 73100 Lecce, Italy. FAU - Burattini, Osvaldo AU - Burattini O AUID- ORCID: 0000-0002-6904-5528 AD - Division of Cardiology, "SS. Annunziata" Hospital, 74121 Taranto, Italy. FAU - Salemme, Luigi AU - Salemme L AD - Interventional Cardiology Service, "Montevergine" Clinic, GVM Care & Research, 83013 Mercogliano, Italy. FAU - Cioppa, Angelo AU - Cioppa A AD - Interventional Cardiology Service, "Montevergine" Clinic, GVM Care & Research, 83013 Mercogliano, Italy. FAU - Rizzo, Francesco AU - Rizzo F AUID- ORCID: 0000-0002-9566-0938 AD - Division of University Cardiology, Cardiothoracic Department, Policlinico University Hospital, 70124 Bari, Italy. FAU - Palmitessa, Chiara AU - Palmitessa C AUID- ORCID: 0000-0001-7575-9300 AD - Division of University Cardiology, Cardiothoracic Department, Policlinico University Hospital, 70124 Bari, Italy. FAU - D'Alessandro, Maurizio AU - D'Alessandro M AUID- ORCID: 0000-0002-4558-8157 AD - Division of University Cardiology, Cardiothoracic Department, Policlinico University Hospital, 70124 Bari, Italy. FAU - De Feo, Daniele AU - De Feo D AUID- ORCID: 0000-0003-1055-0973 AD - Division of University Cardiology, Cardiothoracic Department, Policlinico University Hospital, 70124 Bari, Italy. FAU - Pucciarelli, Armando AU - Pucciarelli A AD - Interventional Cardiology Service, "Montevergine" Clinic, GVM Care & Research, 83013 Mercogliano, Italy. FAU - De Cillis, Emanuela AU - De Cillis E AD - Division of University Heart Surgery, Cardiothoracic Department, Policlinico University Hospital, 70124 Bari, Italy. FAU - Pestrichella, Vincenzo AU - Pestrichella V AD - Interventional Cardiology Service, "Mater Dei" Hospital, 70125 Bari, Italy. FAU - Contegiacomo, Gaetano AU - Contegiacomo G AD - Interventional Cardiology Service, "Anthea" Clinic, GVM Care & Research, 70124 Bari, Italy. FAU - Tesorio, Tullio AU - Tesorio T AUID- ORCID: 0000-0002-9118-4612 AD - Interventional Cardiology Service, "Montevergine" Clinic, GVM Care & Research, 83013 Mercogliano, Italy. FAU - Bortone, Alessandro Santo AU - Bortone AS AD - Division of University Heart Surgery, Cardiothoracic Department, Policlinico University Hospital, 70124 Bari, Italy. LA - eng PT - Journal Article DEP - 20230531 PL - Switzerland TA - J Cardiovasc Dev Dis JT - Journal of cardiovascular development and disease JID - 101651414 PMC - PMC10298866 OTO - NOTNLM OT - Valve Academic Research Consortium OT - aortic stenosis OT - early safety OT - risk scores OT - transcatheter aortic valve implantation COIS- Gaetano Contegiacomo serves as a transcatheter heart valve proctor for Abbott; Fortunato Iacovelli directly received speaker fees from General Electric Healthcare; the remaining authors declare no conflicts of interest. EDAT- 2023/06/27 13:10 MHDA- 2023/06/27 13:11 PMCR- 2023/05/31 CRDT- 2023/06/27 10:05 PHST- 2023/04/27 00:00 [received] PHST- 2023/05/23 00:00 [revised] PHST- 2023/05/29 00:00 [accepted] PHST- 2023/06/27 13:11 [medline] PHST- 2023/06/27 13:10 [pubmed] PHST- 2023/06/27 10:05 [entrez] PHST- 2023/05/31 00:00 [pmc-release] AID - jcdd10060244 [pii] AID - jcdd-10-00244 [pii] AID - 10.3390/jcdd10060244 [doi] PST - epublish SO - J Cardiovasc Dev Dis. 2023 May 31;10(6):244. doi: 10.3390/jcdd10060244. PMID- 37364713 OWN - NLM STAT- MEDLINE DCOM- 20230731 LR - 20230916 IS - 1874-1754 (Electronic) IS - 0167-5273 (Linking) VI - 387 DP - 2023 Sep 15 TI - Impact of a financial incentive scheme for team-based palliative care in patients with heart failure in Japan: A nationwide database study. PG - 131145 LID - S0167-5273(23)00952-X [pii] LID - 10.1016/j.ijcard.2023.131145 [doi] AB - BACKGROUND: Palliative care provided to patients with heart failure (HF) are reported to be inadequate. Herein, we examined the impact of the recently introduced financial incentive scheme for team-based palliative care for patients with HF in acute care hospitals in Japan. METHODS: Using a nationwide inpatient database, we identified patients aged >/=65 years with HF who had died between April 2015 and March 2021. Interrupted time-series analyses were used to compare practice patterns in end-of-life care (symptom management and invasive medical procedures within one week before death) before and after the financial incentive scheme issuance in April 2018. RESULTS: Overall, 53,857 patients in 835 hospitals were eligible. The adoption of the financial incentive was 1.10 to 1.22% after the introduction. There were upward pre-trends in opioid use (+0.11% per month; 95% confidence interval [CI], 0.06 to 0.15) and antidepressant use (+0.06% per month; 95% CI, 0.04 to 0.09). Opioid use showed a downward slope change during the post-period (-0.07% change in trend; 95% CI, -0.13 to -0.01). Intensive care unit stay showed a downward pre-trend (-0.09% per month; 95% CI, -0.14 to -0.04) and upward slope changes during the post-period (+0.12% change in trend; 95% CI, 0.04 to 0.19). Invasive mechanical ventilation showed downward slope changes during the post-period (-0.11% change in trend; 95% CI, -0.18 to -0.04). CONCLUSIONS: The financial incentive scheme for team-based palliative care was rarely adopted and not associated with changes in end-of-life care. Further multifaceted strategies to promote palliative care for HF are warranted. CI - Copyright (c) 2023 Elsevier B.V. All rights reserved. FAU - Morita, Kojiro AU - Morita K AD - Global Nursing Research Center, Graduate School of Medicine, University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-0033, Japan. Electronic address: kojirom@m.u-tokyo.ac.jp. FAU - Miyamoto, Yoshihisa AU - Miyamoto Y AD - Division of Nephrology and Endocrinology, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, Japan. FAU - Mizuno, Atsushi AU - Mizuno A AD - Department of Cardiology, QI center, St. Luke's International Hospital, 9-1, Akashi-cho, Chuo-ku, Tokyo, 104-8560, Japan. FAU - Shirane, Sachie AU - Shirane S AD - Department of Palliative Therapy, Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan; Department of Palliative Care, St. Luke's International Hospital, 9-1 Akashi-cho, Chuo-ku, Tokyo 104-8560, Japan. FAU - Ohbe, Hiroyuki AU - Ohbe H AD - Department of Clinical Epidemiology and Health Economics, School of Public Health, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan. FAU - Hashimoto, Yohei AU - Hashimoto Y AD - Department of Clinical Epidemiology and Health Economics, School of Public Health, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan; Department of Ophthalmology, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan. FAU - Kaneko, Hidehiro AU - Kaneko H AD - Department of Cardiovascular Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan; Department of Advanced Cardiology, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan. FAU - Matsui, Hiroki AU - Matsui H AD - Department of Clinical Epidemiology and Health Economics, School of Public Health, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan. FAU - Fushimi, Kiyohide AU - Fushimi K AD - Department of Health Policy and Informatics, Graduate School of Medicine, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510, Japan. FAU - Yasunaga, Hideo AU - Yasunaga H AD - Department of Clinical Epidemiology and Health Economics, School of Public Health, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan. LA - eng PT - Journal Article DEP - 20230625 PL - Netherlands TA - Int J Cardiol JT - International journal of cardiology JID - 8200291 RN - 0 (Analgesics, Opioid) SB - IM MH - Humans MH - *Palliative Care/methods MH - Japan/epidemiology MH - Motivation MH - Analgesics, Opioid MH - *Heart Failure/diagnosis/epidemiology/therapy OTO - NOTNLM OT - Health policy OT - Heart failure OT - Interrupted time-series analysis OT - Palliative care OT - Terminal care COIS- Declaration of Competing Interest None declared. EDAT- 2023/06/27 01:06 MHDA- 2023/07/31 06:42 CRDT- 2023/06/26 19:22 PHST- 2023/02/09 00:00 [received] PHST- 2023/06/05 00:00 [revised] PHST- 2023/06/23 00:00 [accepted] PHST- 2023/07/31 06:42 [medline] PHST- 2023/06/27 01:06 [pubmed] PHST- 2023/06/26 19:22 [entrez] AID - S0167-5273(23)00952-X [pii] AID - 10.1016/j.ijcard.2023.131145 [doi] PST - ppublish SO - Int J Cardiol. 2023 Sep 15;387:131145. doi: 10.1016/j.ijcard.2023.131145. Epub 2023 Jun 25. PMID- 30969550 STAT- Publisher CTDT- 20230626 PB - StatPearls Publishing DP - 2023 Jan TI - Metronidazole. BTI - StatPearls AB - Metronidazole is one of the mainstay drugs for the treatment of anaerobic bacterial infections, protozoal infections, and microaerophilic bacterial infections. It is cytotoxic to facultative anaerobic microorganisms. It is used to treat intestinal amebiases, liver amebiasis, bacterial septicemia, bone and joint infections, meningitis, brain abscess, endocarditis, endometritis, bacterial vaginosis, intra-abdominal infections, lower respiratory tract infections, skin structure infections, and surgical prophylaxis colorectal surgeries. This activity will highlight the mechanism of action, adverse event profile, contraindications, monitoring, and other key factors pertinent to interprofessional team members in the care of patients being treated with this medication. CI - Copyright (c) 2023, StatPearls Publishing LLC. FAU - Weir, Connor B AU - Weir CB AD - Southeast Health Hospital FAU - Le, Jacqueline K AU - Le JK AD - Desert Regional Medical Center LA - eng PT - Study Guide PT - Book Chapter PL - Treasure Island (FL) COIS- Disclosure: Connor B Weir declares no relevant financial relationships with ineligible companies. Disclosure: Jacqueline K Le declares no relevant financial relationships with ineligible companies. EDAT- 2023/06/26 00:00 CRDT- 2023/06/26 00:00 AID - NBK539728 [bookaccession] PMID- 30085587 STAT- Publisher CTDT- 20230626 PB - StatPearls Publishing DP - 2023 Jan TI - Mexiletine. BTI - StatPearls AB - Mexiletine is largely used to suppress ventricular arrhythmias and has a role in peripheral neuropathy and chronic pain, although the use for either is limited and seldom given its extensive side effect profile. The 2017 American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society guidelines for ventricular arrhythmias published information regarding the use of mexiletine in patients with long QT syndrome type 3 presenting with Torsades de pointes. Additionally, it can be used in myotonic dystrophy to alleviate muscle pain and severe myotonia. This activity will highlight the mechanism of action, adverse event profile, pharmacology, monitoring, and relevant interactions of mexiletine, pertinent for members of the interprofessional team in treating patients with conditions where it is of clinical value. CI - Copyright (c) 2023, StatPearls Publishing LLC. FAU - Singh, Shashank AU - Singh S AD - Louisiana State Un Health Science Center FAU - Chauhan, Shaylika AU - Chauhan S AD - Geisinger Health System FAU - Zeltser, Roman AU - Zeltser R AD - Hofstra Northwell School of Medicine LA - eng PT - Study Guide PT - Book Chapter PL - Treasure Island (FL) COIS- Disclosure: Shashank Singh declares no relevant financial relationships with ineligible companies. Disclosure: Shaylika Chauhan declares no relevant financial relationships with ineligible companies. Disclosure: Roman Zeltser declares no relevant financial relationships with ineligible companies. EDAT- 2023/06/26 00:00 CRDT- 2023/06/26 00:00 AID - NBK519045 [bookaccession] PMID- 37355415 OWN - NLM STAT- MEDLINE DCOM- 20230731 LR - 20260120 IS - 1532-8422 (Electronic) IS - 1053-0770 (Linking) VI - 37 IP - 9 DP - 2023 Sep TI - Adult Cardiac Surgery-Associated Acute Kidney Injury: Joint Consensus Report. PG - 1579-1590 LID - S1053-0770(23)00340-3 [pii] LID - 10.1053/j.jvca.2023.05.032 [doi] AB - OBJECTIVES: Acute kidney injury (AKI) is increasingly recognized as a source of poor patient outcomes after cardiac surgery. The purpose of the present report is to provide perioperative teams with expert recommendations specific to cardiac surgery-associated AKI (CSA-AKI). METHODS: This report and consensus recommendations were developed during a joint, in-person, multidisciplinary conference with the Perioperative Quality Initiative and the Enhanced Recovery After Surgery Cardiac Society. Multinational practitioners with diverse expertise in all aspects of cardiac surgical perioperative care, including clinical backgrounds in anesthesiology, surgery and nursing, met from October 20 to 22, 2021, in Sacramento, California, and used a modified Delphi process and a comprehensive review of evidence to formulate recommendations. The quality of evidence and strength of each recommendation were established using the Grading of Recommendations Assessment, Development, and Evaluation methodology. A majority vote endorsed recommendations. RESULTS: Based on available evidence and group consensus, a total of 13 recommendations were formulated (4 for the preoperative phase, 4 for the intraoperative phase, and 5 for the postoperative phase), and are reported here. CONCLUSIONS: Because there are no reliable or effective treatment options for CSA-AKI, evidence-based practices that highlight prevention and early detection are paramount. Cardiac surgery-associated AKI incidence may be mitigated and postsurgical outcomes improved by focusing additional attention on presurgical kidney health status; implementing a specific cardiopulmonary bypass bundle; using strategies to maintain intravascular euvolemia; leveraging advanced tools such as the electronic medical record, point-of-care ultrasound, and biomarker testing; and using patient-specific, goal-directed therapy to prioritize oxygen delivery and end-organ perfusion over static physiologic metrics. CI - Copyright (c) 2023 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Brown, Jessica K AU - Brown JK AD - Department of Anesthesiology and Perioperative Medicine, the University of Texas, MD Anderson Cancer Center, Houston, TX. Electronic address: jkbrown@mdanderson.org. FAU - Shaw, Andrew D AU - Shaw AD AD - Department of Intensive Care and Resuscitation, Cleveland Clinic, Cleveland, Ohio. FAU - Mythen, Monty G AU - Mythen MG AD - University College London National Institute of Health Research Biomedical Research Center, London, United Kingdom. FAU - Guzzi, Lou AU - Guzzi L AD - Department of Critical Care Medicine, AdventHealth Medical Group, Orlando, Florida. FAU - Reddy, V Seenu AU - Reddy VS AD - TriStar Centennial Medical Center, Nashville, TN. FAU - Crisafi, Cheryl AU - Crisafi C AD - Heart & Vascular Program, Baystate Health, University of Massachusetts Medical School-Baystate, Springfield, MA. FAU - Engelman, Daniel T AU - Engelman DT AD - Heart & Vascular Program, Baystate Health, University of Massachusetts Medical School-Baystate, Springfield, MA. CN - PeriOperative Quality Initiative and the Enhanced Recovery After Surgery Cardiac Workgroup LA - eng PT - Consensus Statement PT - Journal Article PT - Review DEP - 20230523 PL - United States TA - J Cardiothorac Vasc Anesth JT - Journal of cardiothoracic and vascular anesthesia JID - 9110208 SB - IM MH - Humans MH - Adult MH - *Cardiac Surgical Procedures/adverse effects MH - *Acute Kidney Injury/diagnosis/epidemiology/etiology MH - Kidney MH - Treatment Outcome MH - Postoperative Complications/diagnosis/etiology/prevention & control MH - Risk Factors OTO - NOTNLM OT - acute kidney injury OT - cardiac surgery OT - expert consensus OT - goal-directed therapy OT - perioperative care COIS- Declaration of Competing Interest None. EDAT- 2023/06/25 01:08 MHDA- 2023/07/31 06:43 CRDT- 2023/06/24 21:55 PHST- 2022/11/30 00:00 [received] PHST- 2023/05/12 00:00 [revised] PHST- 2023/05/19 00:00 [accepted] PHST- 2023/07/31 06:43 [medline] PHST- 2023/06/25 01:08 [pubmed] PHST- 2023/06/24 21:55 [entrez] AID - S1053-0770(23)00340-3 [pii] AID - 10.1053/j.jvca.2023.05.032 [doi] PST - ppublish SO - J Cardiothorac Vasc Anesth. 2023 Sep;37(9):1579-1590. doi: 10.1053/j.jvca.2023.05.032. Epub 2023 May 23. PMID- 37352965 OWN - NLM STAT- MEDLINE DCOM- 20231120 LR - 20240418 IS - 1532-8414 (Electronic) IS - 1071-9164 (Linking) VI - 29 IP - 11 DP - 2023 Nov TI - Variation in Hemodynamic Assessment and Interpretation: A Call to Standardize the Right Heart Catheterization. PG - 1507-1518 LID - S1071-9164(23)00226-9 [pii] LID - 10.1016/j.cardfail.2023.06.009 [doi] AB - BACKGROUND: Invasive hemodynamic measurement via right heart catheterization has shown divergent data in its role in the treatment of patients with heart failure (HF) and cardiogenic shock. We hypothesized that variation in data acquisition technique and interpretation might contribute to these observations. We sought to assess differences in hemodynamic acquisition and interpretation by operator subspecialty as well as level of experience. METHODS AND RESULTS: Individual-level responses to how physicians both collect and interpret hemodynamic data at the time of right heart catheterization was solicited via a survey distributed to international professional societies in HF and interventional cardiology. Data were stratified both by operator subspecialty (HF specialists or interventional cardiologists [IC]) and operator experience (early career [10 years from training]) to determine variations in clinical practice. For the sensitivity analysis, we also look at differences in each subgroup. A total of 261 responses were received. There were 141 clinicians (52%) who self-identified as HF specialists, 99 (38%) identified as IC, and 20 (8%) identified as other. There were 142 early career providers (54%) and late career providers (119 [46%]). When recording hemodynamic values, there was considerable variation in practice patterns, regardless of subspecialty or level of experience for the majority of the intracardiac variables. There was no agreement or mild agreement among HF and IC as to when to record right atrial pressures or pulmonary capillary wedge pressures. HF cardiologists were more likely to routinely measure both Fick and thermodilution cardiac output compared with IC (51% vs 29%, P < .001), something mirrored in early career vs later career cardiologists. CONCLUSIONS: Significant variation exists between the acquisition and interpretation of right heart catheterization measurements between HF and IC, as well as those early and late in their careers. With the growth of the heart team approach to management of patients in cardiogenic shock, standardization of both assessment and management practices is needed. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Grinstein, Jonathan AU - Grinstein J AD - Department of Medicine, Section of Cardiology, University of Chicago, Chicago, Illinois. Electronic address: jgrinstein@medicine.bsd.uchicago.edu. FAU - Sinha, Shashank S AU - Sinha SS AD - Division of Cardiology, Inova Heart and Vascular Institute, Fairfax Virginia. FAU - Goswami, Rohan M AU - Goswami RM AD - Division of Transplant, Research and Innovation, Mayo Clinic in Florida, Jacksonville Florida. FAU - Patel, Priyesh A AU - Patel PA AD - Sanger Heart and Vascular Institute, Atrium Health, Charlotte, North Carolina. FAU - Cyrille-Superville, Nicole AU - Cyrille-Superville N AD - Sanger Heart and Vascular Institute, Atrium Health, Charlotte, North Carolina. FAU - Neyestanak, Maryam E AU - Neyestanak ME AD - Department of Medicine, Section of Cardiology, University of Chicago, Chicago, Illinois. FAU - Feliberti, Jason P AU - Feliberti JP AD - University of South Florida Heart and Vascular Institute, Transplant Cardiology, Tampa, Florida. FAU - Snipelisky, David F AU - Snipelisky DF AD - Section of Heart Failure & Cardiac Transplant Medicine, Cleveland Clinic Florida, Weston, Florida. FAU - Devore, Adam D AU - Devore AD AD - Division of Cardiology and Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina. FAU - Najjar, Samer S AU - Najjar SS AD - Medstar Heart and Vascular Institute, Baltimore Maryland. FAU - Jeng, Eric I AU - Jeng EI AD - Department of surgery, Division of cardiovascular surgery, University of Florida, Gainesville, Florida. FAU - Rao, Sriram D AU - Rao SD AD - Medstar Washington Hospital Center, Division of Cardiology, Georgetown University, Department of Medicine, Washington DC. CN - FLIGHT Working Group LA - eng PT - Journal Article DEP - 20230622 PL - United States TA - J Card Fail JT - Journal of cardiac failure JID - 9442138 SB - IM CIN - J Card Fail. 2023 Nov;29(11):1519-1521. doi: 10.1016/j.cardfail.2023.08.015. PMID: 37661053 MH - Humans MH - *Shock, Cardiogenic MH - *Heart Failure/diagnosis/therapy MH - Hemodynamics MH - Cardiac Catheterization/methods MH - Cardiac Output COIS- Declaration of Competing Interests Financial Disclosure: Statistical funding via UChicago Cardiology Data Science Gift. JG is a speaker for Abbott. ADD reports research funding through his institution from the American Heart Association, Biofourmis, Bodyport, Cytokinetics, American Regent, Inc, the NHLBI, Novartis, and Story Health. He also provides consulting services for and/or receives honoraria from Abiomed, AstraZeneca, Cardionomic, InnaMed, LivaNova, Natera, Novartis, Procyrion, Story Health, Vifor, and Zoll. He has also received nonfinancial support from Abbott for educational and research activities. All other authors have no relevant disclosures. EDAT- 2023/06/24 11:42 MHDA- 2023/11/20 06:55 CRDT- 2023/06/23 19:13 PHST- 2023/01/16 00:00 [received] PHST- 2023/05/17 00:00 [revised] PHST- 2023/06/05 00:00 [accepted] PHST- 2023/11/20 06:55 [medline] PHST- 2023/06/24 11:42 [pubmed] PHST- 2023/06/23 19:13 [entrez] AID - S1071-9164(23)00226-9 [pii] AID - 10.1016/j.cardfail.2023.06.009 [doi] PST - ppublish SO - J Card Fail. 2023 Nov;29(11):1507-1518. doi: 10.1016/j.cardfail.2023.06.009. Epub 2023 Jun 22. PMID- 37352668 OWN - NLM STAT- MEDLINE DCOM- 20230731 LR - 20230802 IS - 1879-1913 (Electronic) IS - 0002-9149 (Linking) VI - 201 DP - 2023 Aug 15 TI - Gastrointestinal Bleeding in Patients Supported with Left Ventricular Assist Devices: The Journey from Bridging to Destination. PG - 71-77 LID - S0002-9149(23)00355-7 [pii] LID - 10.1016/j.amjcard.2023.05.059 [doi] AB - End-stage heart failure is a prevalent and fatal cardiovascular disease. Almost 1 in 4 cases of mortality in the United States is attributed to heart failure. Left ventricular assist devices (LVADs) have emerged as a safe destination therapy or bridge to transplant. Despite remarkable results, LVAD is associated with significant adverse events, such as gastrointestinal bleeding (GIB). In this review, we aimed to understand the incidence and prevalence, pathophysiologic mechanisms, predictors, diagnostic mechanisms, management, and preventative measures of GIB in patients with an LVAD. GIB is a common adverse event in patients with an LVAD with an incidence of 15% to 25%. The exact pathogenesis of GIB is poorly understood. However, different mechanisms of bleeding have been described, such as arteriovenous malformations, acquired von Willebrand syndrome, coagulopathy, and treatment with antithrombotic therapy. Upper GIB is the most common site of GIB in patients with an LVAD. The management of GIB in patients with LVAD includes ensuring hemodynamic stability, holding or reversing antithrombotic therapy, and investigating and controlling the source of GIB through diagnostic and interventional endoscopic and radiologic means. Prophylactic medication use (e.g., danazol, octreotide, and bevacizumab) can decrease the risk of GIB in patients with an LVAD by decreasing arteriovenous malformations. Despite that the overall risk of GIB has decreased with new advancements in LVAD technology, further studies are needed regarding predictors, risk stratification, and optimal antithrombotic therapy to minimize the morbidity and mortality in patients with an LVAD. In conclusion, prompt diagnosis and management in a multidisciplinary team approach are crucial and lifesaving in such a life-threatening condition. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Mohamed, Mohamed Salah AU - Mohamed MS AD - Department of Internal Medicine, Rochester General Hospital, Rochester, New York. Electronic address: Mohamedsalahmohamedkassem.mohamed@rochesterregional.org. FAU - Shehadah, Ahmed AU - Shehadah A AD - Department of Internal Medicine, Rochester General Hospital, Rochester, New York. FAU - Hashem, Anas AU - Hashem A AD - Department of Internal Medicine, Rochester General Hospital, Rochester, New York. FAU - Chand, Swati AU - Chand S AD - Department of Internal Medicine, Rochester General Hospital, Rochester, New York. FAU - Bapaye, Jay AU - Bapaye J AD - Department of Internal Medicine, Rochester General Hospital, Rochester, New York. FAU - Khalouf, Amani AU - Khalouf A AD - Department of Internal Medicine, Rochester General Hospital, Rochester, New York. FAU - Rai, Devesh AU - Rai D AD - Sands Constellation Heart Institute, Rochester General Hospital, Rochester, New York. FAU - Peter, Shajan AU - Peter S AD - Department of Gastroenterology, University of Alabama, Birmingham, Alabama. LA - eng PT - Journal Article PT - Review DEP - 20230621 PL - United States TA - Am J Cardiol JT - The American journal of cardiology JID - 0207277 RN - 0 (Fibrinolytic Agents) SB - IM MH - Humans MH - United States MH - Fibrinolytic Agents/therapeutic use MH - Gastrointestinal Hemorrhage/epidemiology/etiology/therapy MH - Incidence MH - *Heart Failure MH - *Heart-Assist Devices/adverse effects MH - *Arteriovenous Malformations/complications MH - Retrospective Studies COIS- Declaration of Competing Interest The authors have no conflicts of interest to declare. EDAT- 2023/06/23 19:11 MHDA- 2023/07/31 06:42 CRDT- 2023/06/23 18:05 PHST- 2023/03/22 00:00 [received] PHST- 2023/05/15 00:00 [revised] PHST- 2023/05/31 00:00 [accepted] PHST- 2023/07/31 06:42 [medline] PHST- 2023/06/23 19:11 [pubmed] PHST- 2023/06/23 18:05 [entrez] AID - S0002-9149(23)00355-7 [pii] AID - 10.1016/j.amjcard.2023.05.059 [doi] PST - ppublish SO - Am J Cardiol. 2023 Aug 15;201:71-77. doi: 10.1016/j.amjcard.2023.05.059. Epub 2023 Jun 21. PMID- 37345215 OWN - NLM STAT- MEDLINE DCOM- 20230731 LR - 20240922 IS - 2055-5822 (Electronic) IS - 2055-5822 (Linking) VI - 10 IP - 4 DP - 2023 Aug TI - Roadmap towards an institutional Impella programme for high-risk coronary interventions. PG - 2200-2213 LID - 10.1002/ehf2.14397 [doi] AB - Coronary artery disease (CAD) and its complications remain the main cause of morbidity and mortality worldwide. Patients with extensive CAD and multiple comorbidities who require complex, high-risk percutaneous coronary intervention (HR-PCI) are at risk of haemodynamic instability and may require short-term mechanical circulatory support (MCS) during the procedure to maintain sufficient perfusion and prevent ischaemia. Impella is a microaxial continuous blood flow pump used for percutaneous support of the left ventricle in patients undergoing HR-PCI. Data from randomized controlled trials and registries suggested an advantage for Impella devices in patients undergoing HR-PCI, compared with other types of MCS. As a thorough understanding of the benefits and drawbacks of the Impella technology is crucial for patient outcomes, we provide a technological overview of Impella and share our experiences gathered during the implementation of institutional Impella programmes in Poland as a roadmap of selection and periprocedural care for patients treated with Impella in the setting of HR-PCI. We propose 10 steps for implementation of an institutional Impella programme for HR-PCI, including (i) dedicated staff training; (ii) standard operating procedure and troubleshooting algorithms prior to the first intervention; (iii) patient selection by the multidisciplinary Heart Team; (iv) patient preparation using multimodality imaging; (v) procedure planning in terms of large-bore access, equipment, and complete revascularization; (vi) starting with HR-PCI support; (vii) starting with femoral artery access in a patient without extensive peripheral artery disease; (viii) multidisciplinary care after the procedure; (ix) haemodynamic and laboratory monitoring to ensure immediate diagnosis of access-site complications, bleeding, haemolysis, acute kidney injury, and infections; and (x) careful revision of every HR-PCI case with the team. CI - (c) 2023 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. FAU - Pietrasik, Arkadiusz AU - Pietrasik A AD - 1st Chair and Department of Cardiology, Medical University of Warsaw, Warsaw, Poland. FAU - Gasecka, Aleksandra AU - Gasecka A AUID- ORCID: 0000-0001-5083-7587 AD - 1st Chair and Department of Cardiology, Medical University of Warsaw, Warsaw, Poland. FAU - Jasinska-Gniadzik, Karolina AU - Jasinska-Gniadzik K AUID- ORCID: 0000-0003-4361-6609 AD - 1st Chair and Department of Cardiology, Medical University of Warsaw, Warsaw, Poland. FAU - Szwed, Piotr AU - Szwed P AD - 1st Chair and Department of Cardiology, Medical University of Warsaw, Warsaw, Poland. FAU - Grygier, Marek AU - Grygier M AD - Department of Cardiology, Poznan University of Medical Sciences, Poznan, Poland. FAU - Pawlowski, Tomasz AU - Pawlowski T AD - Department of Invasive Cardiology, Central Clinical Hospital of the Ministry of Interior and Administration, Warsaw, Poland. FAU - Sacha, Jerzy AU - Sacha J AD - Department of Cardiology, University Hospital in Opole, Opole, Poland. AD - Faculty of Physical Education and Physiotherapy, Opole University of Technology, Opole, Poland. FAU - Kochman, Janusz AU - Kochman J AD - 1st Chair and Department of Cardiology, Medical University of Warsaw, Warsaw, Poland. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20230621 PL - England TA - ESC Heart Fail JT - ESC heart failure JID - 101669191 SB - IM MH - Humans MH - *Percutaneous Coronary Intervention/methods MH - *Heart-Assist Devices MH - *Coronary Artery Disease/complications/diagnosis/surgery MH - Heart Ventricles MH - *Peripheral Arterial Disease PMC - PMC10375112 OTO - NOTNLM OT - Cardiogenic shock OT - Coronary intervention OT - Impella OT - PCI COIS- A.P. and A.G. received a research grant from Abiomed (Grant Number 69829335). J.S. is an Impella proctor. T.P. received speaking honoraria from Abiomed and PulseCath. All other authors have nothing to disclose. EDAT- 2023/06/22 06:42 MHDA- 2023/07/31 11:43 PMCR- 2023/06/21 CRDT- 2023/06/22 01:03 PHST- 2023/04/02 00:00 [revised] PHST- 2022/10/12 00:00 [received] PHST- 2023/05/02 00:00 [accepted] PHST- 2023/07/31 11:43 [medline] PHST- 2023/06/22 06:42 [pubmed] PHST- 2023/06/22 01:03 [entrez] PHST- 2023/06/21 00:00 [pmc-release] AID - EHF214397 [pii] AID - 10.1002/ehf2.14397 [doi] PST - ppublish SO - ESC Heart Fail. 2023 Aug;10(4):2200-2213. doi: 10.1002/ehf2.14397. Epub 2023 Jun 21. PMID- 37341925 OWN - NLM STAT- MEDLINE DCOM- 20230823 LR - 20230911 IS - 1179-1942 (Electronic) IS - 0114-5916 (Print) IS - 0114-5916 (Linking) VI - 46 IP - 9 DP - 2023 Sep TI - Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians. PG - 819-833 LID - 10.1007/s40264-023-01320-5 [doi] AB - Immune checkpoint inhibitors (ICIs) have revolutionized the treatment and care of patients with cancer owing to unique features, including the occurrence of the so-called immune-related adverse events (irAEs). A multidisciplinary team, possibly including a cardio-oncology specialist, is warranted to achieve a favorable patient outcome. Cardiovascular toxicity, especially myocarditis, emerged as a life-threatening irAE in the real-word setting, and the European Society of Cardiology has recently published the first guideline on cardio-oncology to increase awareness and promote a standardized approach to tackle this complex multimodal issue, including diagnostic challenges, assessment, treatment, and surveillance of patients with cancer receiving ICIs. In this article, through a question & answer format made up of case vignettes, we offer a clinically oriented overview on the latest advancements of ICI-related cardiovascular toxicity, focusing on myocarditis and associated irAEs (myositis and myasthenia gravis within the so-called overlap syndrome), with the purpose of assisting clinicians and healthcare professionals in daily clinical practice. CI - (c) 2023. The Author(s). FAU - Raschi, Emanuel AU - Raschi E AUID- ORCID: 0000-0003-0487-7996 AD - Pharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Via Irnerio 48, 40126, Bologna, Italy. emanuel.raschi@unibo.it. FAU - Rossi, Simone AU - Rossi S AD - IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy. AD - Department of Biomedical and Neuromotor Sciences (DIBINEM), Alma Mater Studiorum, University of Bologna, Bologna, Italy. FAU - De Giglio, Andrea AU - De Giglio A AD - Pharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Via Irnerio 48, 40126, Bologna, Italy. AD - Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. FAU - Fusaroli, Michele AU - Fusaroli M AD - Pharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Via Irnerio 48, 40126, Bologna, Italy. FAU - Burgazzi, Flavio AU - Burgazzi F AD - Pharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Via Irnerio 48, 40126, Bologna, Italy. FAU - Rinaldi, Rita AU - Rinaldi R AD - IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy. FAU - Potena, Luciano AU - Potena L AD - Unit of Heart Failure and Transplantation, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20230621 PL - New Zealand TA - Drug Saf JT - Drug safety JID - 9002928 RN - 0 (Immune Checkpoint Inhibitors) RN - 0 (Antineoplastic Agents, Immunological) SB - IM MH - Humans MH - Immune Checkpoint Inhibitors/adverse effects MH - *Antineoplastic Agents, Immunological/adverse effects MH - *Myocarditis/chemically induced/diagnosis/drug therapy MH - *Neoplasms/drug therapy MH - Medical Oncology PMC - PMC10442274 COIS- The authors declare no potential conflict of interest relevant to the content of the manuscript. EDAT- 2023/06/21 13:04 MHDA- 2023/08/23 06:42 PMCR- 2023/06/21 CRDT- 2023/06/21 11:15 PHST- 2023/05/10 00:00 [accepted] PHST- 2023/08/23 06:42 [medline] PHST- 2023/06/21 13:04 [pubmed] PHST- 2023/06/21 11:15 [entrez] PHST- 2023/06/21 00:00 [pmc-release] AID - 10.1007/s40264-023-01320-5 [pii] AID - 1320 [pii] AID - 10.1007/s40264-023-01320-5 [doi] PST - ppublish SO - Drug Saf. 2023 Sep;46(9):819-833. doi: 10.1007/s40264-023-01320-5. Epub 2023 Jun 21. PMID- 37340987 OWN - NLM STAT- MEDLINE DCOM- 20231023 LR - 20231106 IS - 1365-3156 (Electronic) IS - 1360-2276 (Linking) VI - 28 IP - 8 DP - 2023 Aug TI - Pulmonary oedema in the course of severe maternal outcome in South Africa: A cohort study combined with clinical audit. PG - 677-687 LID - 10.1111/tmi.13905 [doi] AB - OBJECTIVES: To describe the incidence and outcomes of pulmonary oedema in women with severe maternal outcome during childbirth and identify possible modifiable factors through audit. METHODS: All women with severe maternal outcome (maternal deaths or near misses) who were referred to Tygerberg referral hospital from health facilities in Metro East district, South Africa, during 2014-2015 were included. Women with severe maternal outcome and pulmonary oedema during pregnancy or childbirth were evaluated using three types of critical incident audit: criterion-based case review by one consultant gynaecologist, monodisciplinary critical incident audit by a team of gynaecologists, multidisciplinary audit with expert review from anaesthesiologists and cardiologists. RESULTS: Of 32,161 pregnant women who gave birth in the study period, 399 (1.2%) women had severe maternal outcome and 72/399 (18.1%) had pulmonary oedema with a case fatality rate of 5.6% (4/72). Critical incident audit demonstrated that pre-eclampsia/HELLP-syndrome and chronic hypertension were the main conditions underlying pulmonary oedema (44/72, 61.1%). Administration of volumes of intravenous fluids in already sick women, undiagnosed underlying cardiac illness, administration of magnesium sulphate as part of pre-eclampsia management and oxytocin for augmentation of labour were identified as possible contributors to the pathophysiology of pulmonary oedema. Women-related factors (improved antenatal care attendance) and health care-related factors (earlier diagnosis and management) would potentially have improved maternal outcome. CONCLUSIONS: Although pulmonary oedema in pregnancy is rare, among women with severe maternal outcome a considerable proportion had pulmonary oedema (18.1%). Audit identified options for prevention of pulmonary oedema and improved outcome. These included early detection and management of preeclampsia with close monitoring of fluid intake and cardiac evaluation in case of suspected pulmonary oedema. Therefore, a multidisciplinary clinical approach is recommended. CI - (c) 2023 The Authors Tropical Medicine & International Health Published by John Wiley & Sons Ltd. FAU - Heitkamp, Anke AU - Heitkamp A AD - Department of Obstetrics and Gynaecology, Stellenbosch University and Tygerberg Academic Hospital, Cape Town, South Africa. AD - Department of Obstetrics and Gynaecology, Amsterdam UMC, Vrije Universiteit Amsterdam and Research Institute Amsterdam Reproduction & Development, Amsterdam, The Netherlands. FAU - Sandberg, Evelien AU - Sandberg E AD - Department of Obstetrics and Gynaecology, Leiden University Medical Centre, Leiden, The Netherlands. FAU - Moodley, Ashley AU - Moodley A AD - Department of Obstetrics and Gynaecology, Stellenbosch University and Tygerberg Academic Hospital, Cape Town, South Africa. FAU - Burke, Jonathan AU - Burke J AD - Department of Anaesthesiology and Critical Care, Stellenbosch University and Tygerberg Academic Hospital, Cape Town, South Africa. FAU - van Roosmalen, Jos AU - van Roosmalen J AD - Department of Obstetrics and Gynaecology, Leiden University Medical Centre, Leiden, The Netherlands. AD - Athena Institute, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. FAU - Gebhardt, Stefan AU - Gebhardt S AD - Department of Obstetrics and Gynaecology, Stellenbosch University and Tygerberg Academic Hospital, Cape Town, South Africa. FAU - Vollmer, Linda AU - Vollmer L AD - Department of Obstetrics and Gynaecology, Stellenbosch University and Tygerberg Academic Hospital, Cape Town, South Africa. FAU - de Vries, Johanna I AU - de Vries JI AD - Department of Obstetrics and Gynaecology, Amsterdam UMC, Vrije Universiteit Amsterdam and Research Institute Amsterdam Reproduction & Development, Amsterdam, The Netherlands. FAU - van den Akker, Thomas AU - van den Akker T AD - Department of Obstetrics and Gynaecology, Leiden University Medical Centre, Leiden, The Netherlands. AD - Athena Institute, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. FAU - Theron, Gerhard AU - Theron G AD - Department of Obstetrics and Gynaecology, Stellenbosch University and Tygerberg Academic Hospital, Cape Town, South Africa. LA - eng PT - Journal Article DEP - 20230621 PL - England TA - Trop Med Int Health JT - Tropical medicine & international health : TM & IH JID - 9610576 SB - IM MH - Pregnancy MH - Female MH - Humans MH - Male MH - *Pre-Eclampsia/epidemiology MH - Cohort Studies MH - *Pulmonary Edema/epidemiology/etiology MH - South Africa/epidemiology MH - Clinical Audit OTO - NOTNLM OT - South Africa OT - audit OT - high-risk pregnancy OT - obstetrics OT - pulmonary oedema OT - severe maternal outcome EDAT- 2023/06/21 06:42 MHDA- 2023/10/23 00:42 CRDT- 2023/06/21 05:28 PHST- 2023/10/23 00:42 [medline] PHST- 2023/06/21 06:42 [pubmed] PHST- 2023/06/21 05:28 [entrez] AID - 10.1111/tmi.13905 [doi] PST - ppublish SO - Trop Med Int Health. 2023 Aug;28(8):677-687. doi: 10.1111/tmi.13905. Epub 2023 Jun 21. PMID- 37337011 OWN - NLM STAT- MEDLINE DCOM- 20231023 LR - 20231103 IS - 1861-0692 (Electronic) IS - 1861-0684 (Print) IS - 1861-0684 (Linking) VI - 112 IP - 10 DP - 2023 Oct TI - Cardio-hepatic syndrome in patients undergoing transcatheter aortic valve replacement. PG - 1427-1435 LID - 10.1007/s00392-023-02245-w [doi] AB - BACKGROUND: Cardiohepatic syndrome (CHS) has been identified as an important but underrecognized survival predictor in multiple cardiovascular disease entities. The objectives of this study were to evaluate the prevalence and prognostic value of CHS in patients undergoing TAVR for severe aortic stenosis (AS). METHODS: The study included patients with available laboratory parameters of hepatic function who underwent TAVR from July 2013 until December 2019 at our center. CHS was defined as an elevation of at least two of three laboratory cholestasis parameters above the upper limit of normal (bilirubin, alkaline phosphatase, and gamma glutamyl transferase). Study endpoints were three-year survival, technical and device failure (VARC 3), as well as New York Heart Association (NYHA) functional class at follow-up. RESULTS: Among a total of 953 analyzed patients (47.6% females, median age 80.0 [76.0-85.0] years) CHS was present in 212 patients (22.4%). In patients with vs. without CHS, rates of technical (6.1% vs. 8.4%, p = 0.29) and device failure (18.9% vs. 17.3%, p = 0.59) were comparable. NYHA functional class at baseline and follow-up was more severe in patients with CHS. Nevertheless, heart failure symptoms improved from baseline to follow-up irrespective of hepatic function. Three-year survival rates were significantly lower in patients with CHS (49.4 vs. 65.4%, p < 0.001). The predictive value of CHS persisted after adjustment in a multivariable analysis (hazard ratio 1.58, p < 0.01). CONCLUSION: In patients undergoing TAVR, CHS is prevalent in 22% of patients and is associated with increased postinterventional mortality. Thus, CHS should be included in the decision-making process within the TAVR heart team. Cardiohepatic syndrome (CHS) as defined by an elevation of at least two of three laboratory cholestasis parameters above the upper limit of normal was prevalent in 22% of patients undergoing TAVR for severe AS. The presence of CHS was associated with more severe heart failure symptoms and worse three-year survival. CI - (c) 2023. The Author(s). FAU - Stolz, Lukas AU - Stolz L AUID- ORCID: 0000-0002-1362-1493 AD - Medizinische Klinik und Poliklinik I, Klinikum der Universitat Munchen, Marchioninistr. 15, 81377, Munich, Germany. FAU - Kirchner, Michael AU - Kirchner M AD - Medizinische Klinik und Poliklinik I, Klinikum der Universitat Munchen, Marchioninistr. 15, 81377, Munich, Germany. FAU - Steffen, Julius AU - Steffen J AD - Medizinische Klinik und Poliklinik I, Klinikum der Universitat Munchen, Marchioninistr. 15, 81377, Munich, Germany. FAU - Doldi, Philipp M AU - Doldi PM AD - Medizinische Klinik und Poliklinik I, Klinikum der Universitat Munchen, Marchioninistr. 15, 81377, Munich, Germany. AD - German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany. FAU - Braun, Daniel AU - Braun D AD - Medizinische Klinik und Poliklinik I, Klinikum der Universitat Munchen, Marchioninistr. 15, 81377, Munich, Germany. FAU - Weckbach, Ludwig T AU - Weckbach LT AD - Medizinische Klinik und Poliklinik I, Klinikum der Universitat Munchen, Marchioninistr. 15, 81377, Munich, Germany. FAU - Stocker, Thomas J AU - Stocker TJ AD - Medizinische Klinik und Poliklinik I, Klinikum der Universitat Munchen, Marchioninistr. 15, 81377, Munich, Germany. FAU - Low, Kornelia AU - Low K AD - Medizinische Klinik und Poliklinik I, Klinikum der Universitat Munchen, Marchioninistr. 15, 81377, Munich, Germany. FAU - Fischer, Julius AU - Fischer J AD - Medizinische Klinik und Poliklinik I, Klinikum der Universitat Munchen, Marchioninistr. 15, 81377, Munich, Germany. FAU - Haum, Magda AU - Haum M AD - Medizinische Klinik und Poliklinik I, Klinikum der Universitat Munchen, Marchioninistr. 15, 81377, Munich, Germany. FAU - Theiss, Hans D AU - Theiss HD AD - Medizinische Klinik und Poliklinik I, Klinikum der Universitat Munchen, Marchioninistr. 15, 81377, Munich, Germany. FAU - Rizas, Konstantinos AU - Rizas K AD - Medizinische Klinik und Poliklinik I, Klinikum der Universitat Munchen, Marchioninistr. 15, 81377, Munich, Germany. AD - German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany. FAU - Orban, Martin AU - Orban M AD - Medizinische Klinik und Poliklinik I, Klinikum der Universitat Munchen, Marchioninistr. 15, 81377, Munich, Germany. AD - German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany. FAU - Peterss, Sven AU - Peterss S AD - Herzchirurgische Klinik und Poliklinik, Klinikum der Universitat Munchen, Munich, Germany. FAU - Nabauer, Michael AU - Nabauer M AD - Medizinische Klinik und Poliklinik I, Klinikum der Universitat Munchen, Marchioninistr. 15, 81377, Munich, Germany. AD - German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany. FAU - Massberg, Steffen AU - Massberg S AD - Medizinische Klinik und Poliklinik I, Klinikum der Universitat Munchen, Marchioninistr. 15, 81377, Munich, Germany. AD - German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany. FAU - Hausleiter, Jorg AU - Hausleiter J AD - Medizinische Klinik und Poliklinik I, Klinikum der Universitat Munchen, Marchioninistr. 15, 81377, Munich, Germany. AD - German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany. FAU - Deseive, Simon AU - Deseive S AD - Medizinische Klinik und Poliklinik I, Klinikum der Universitat Munchen, Marchioninistr. 15, 81377, Munich, Germany. Simon.Deseive@med.uni-muenchen.de. AD - German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany. Simon.Deseive@med.uni-muenchen.de. LA - eng PT - Journal Article DEP - 20230619 PL - Germany TA - Clin Res Cardiol JT - Clinical research in cardiology : official journal of the German Cardiac Society JID - 101264123 SB - IM MH - Female MH - Humans MH - Aged, 80 and over MH - Male MH - *Transcatheter Aortic Valve Replacement/adverse effects MH - *Aortic Valve Stenosis/diagnosis/surgery MH - Treatment Outcome MH - *Heart Failure MH - *Cholestasis MH - Aortic Valve/surgery MH - Risk Factors PMC - PMC10562337 OTO - NOTNLM OT - Aortic stenosis OT - Cardiohepatic syndrome OT - Congestion OT - Heart failure OT - Liver function OT - TAVR COIS- JH has received speaker honoraria from and serves as consultant for Edwards Lifesciences. SD and JS received speaker honoraria from AstraZeneca. DB received speaker honoraria from Abbott Vascular. LW reports speaker honoraria from AstraZeneca and Bayer. MO received speaker honoraria from Abbott Medical, AstraZeneca, Abiomed, Bayer vital, BIOTRONIK, Bristol-Myers Squibb, CytoSorbents, Daiichi Sankyo Deutschland, Edwards Lifesciences Services and Sedana Medical. The other authors have no conflict of interest to declare. EDAT- 2023/06/20 01:08 MHDA- 2023/10/23 00:44 PMCR- 2023/06/19 CRDT- 2023/06/19 23:22 PHST- 2023/02/13 00:00 [received] PHST- 2023/06/05 00:00 [accepted] PHST- 2023/10/23 00:44 [medline] PHST- 2023/06/20 01:08 [pubmed] PHST- 2023/06/19 23:22 [entrez] PHST- 2023/06/19 00:00 [pmc-release] AID - 10.1007/s00392-023-02245-w [pii] AID - 2245 [pii] AID - 10.1007/s00392-023-02245-w [doi] PST - ppublish SO - Clin Res Cardiol. 2023 Oct;112(10):1427-1435. doi: 10.1007/s00392-023-02245-w. Epub 2023 Jun 19. PMID- 37336313 OWN - NLM STAT- MEDLINE DCOM- 20231216 LR - 20231216 IS - 1535-6280 (Electronic) IS - 0146-2806 (Linking) VI - 48 IP - 10 DP - 2023 Oct TI - Beyond the Prescription Pad: Clinical Pharmacists as Integral Members of Cardiology Care Teams, A Comprehensive Review of Their Expanding Roles and Contributions. PG - 101880 LID - S0146-2806(23)00297-9 [pii] LID - 10.1016/j.cpcardiol.2023.101880 [doi] AB - In recent years, the role of clinical pharmacists in cardiology care teams has evolved significantly. Traditionally known for their expertise in medication management, clinical pharmacists are now being recognized as integral members of interdisciplinary teams in cardiology settings. This review article aims to explore the expanding roles and contributions of clinical pharmacists in cardiac care, going beyond their traditional responsibilities. It examines their involvement in patient care, medication therapy management, collaborative decision-making, patient education, and research activities. By highlighting the value they bring to the table, this article emphasizes the need for incorporating clinical pharmacists as vital team members in cardiology care. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Suman, Satyam AU - Suman S AD - Department of Pharmacy Practice, Kakatiya University, Warangal, Telangana, India. Electronic address: satyamsatyasuman@gmial.com. FAU - Pravalika, Jakkula AU - Pravalika J AD - Department of Pharmacy Practice, Kakatiya University, Warangal, Telangana, India. LA - eng PT - Journal Article PT - Review DEP - 20230617 PL - Netherlands TA - Curr Probl Cardiol JT - Current problems in cardiology JID - 7701802 SB - IM MH - Humans MH - *Patient Care Team MH - Pharmacists MH - Medication Therapy Management MH - Prescriptions MH - *Cardiology COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2023/06/20 01:09 MHDA- 2023/12/17 09:44 CRDT- 2023/06/19 19:13 PHST- 2023/06/12 00:00 [received] PHST- 2023/06/13 00:00 [accepted] PHST- 2023/12/17 09:44 [medline] PHST- 2023/06/20 01:09 [pubmed] PHST- 2023/06/19 19:13 [entrez] AID - S0146-2806(23)00297-9 [pii] AID - 10.1016/j.cpcardiol.2023.101880 [doi] PST - ppublish SO - Curr Probl Cardiol. 2023 Oct;48(10):101880. doi: 10.1016/j.cpcardiol.2023.101880. Epub 2023 Jun 17. PMID- 37334215 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260920 IS - 2296-2360 (Print) IS - 2296-2360 (Electronic) IS - 2296-2360 (Linking) VI - 11 DP - 2023 TI - Core components of a rehabilitation program in pediatric cardiac disease. PG - 1104794 LID - 10.3389/fped.2023.1104794 [doi] LID - 1104794 AB - There is increasing effort in both the inpatient and outpatient setting to improve care, function, and quality of life for children with congenital heart disease, and to decrease complications. As the mortality rates of surgical procedures for congenital heart disease decrease, improvement in perioperative morbidity and quality of life have become key metrics of quality of care. Quality of life and function in patients with congenital heart disease can be affected by multiple factors: the underlying heart condition, cardiac surgery, complications, and medical treatment. Some of the functional areas affected are motor abilities, exercise capacity, feeding, speech, cognition, and psychosocial adjustment. Rehabilitation interventions aim to enhance and restore functional ability and quality of life for those with physical impairments or disabilities. Interventions such as exercise training have been extensively evaluated in adults with acquired heart disease, and rehabilitation interventions for pediatric patients with congenital heart disease have similar potential to improve perioperative morbidity and quality of life. However, literature regarding the pediatric population is limited. We have gathered a multidisciplinary team of experts from major institutions to create evidence- and practice-based guidelines for pediatric cardiac rehabilitation programs in both inpatient and outpatient settings. To improve the quality of life of pediatric patients with congenital heart disease, we propose the use of individualized multidisciplinary rehabilitation programs that include: medical management; neuropsychology; nursing care; rehabilitation equipment; physical, occupational, speech, and feeding therapies; and exercise training. CI - (c) 2023 Ubeda Tikkanen, Vova, Holman, Chrisman, Clarkson, Santiago, Schonberger, White, Badaly, Gauthier, Pham, Britt, Crouter, Giangregorio, Nathan and Akamagwuna. FAU - Ubeda Tikkanen, Ana AU - Ubeda Tikkanen A AD - Department of Pediatric Rehabilitation, Spaulding Rehabilitation Hospital, Boston, MA, United States. AD - Department of Cardiac Surgery, Boston Children's Hospital, Boston, MA, United States. AD - Department of Orthopedic Surgery, Boston Children's Hospital, Boston, MA, United States. AD - Department of Physical Medicine and Rehabilitation, Harvard Medical School, Boston, MA, United States. FAU - Vova, Joshua AU - Vova J AD - Department of Physiatry, Children's Healthcare of Atlanta, Atlanta, GA, United States. FAU - Holman, Lainie AU - Holman L AD - Department Pediatric Physical Medicine and Rehabilitation, Cleveland Clinic, Cleveland, OH, United States. FAU - Chrisman, Maddie AU - Chrisman M AD - Wolff Center, University of Pittsburgh Medical Center, Pittsburgh, PA, United States. FAU - Clarkson, Kristin AU - Clarkson K AD - Department of Pediatric Physical Medicine and Rehabilitation, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, United States. FAU - Santiago, Rachel AU - Santiago R AD - Department of Otolaryngology and Communication Enhancement, Boston Children's Hospital, Boston, MA, United States. FAU - Schonberger, Lisa AU - Schonberger L AD - Department of Otolaryngology and Communication Enhancement, Boston Children's Hospital, Boston, MA, United States. FAU - White, Kelsey AU - White K AD - Department of Otolaryngology and Communication Enhancement, Boston Children's Hospital, Boston, MA, United States. FAU - Badaly, Daryaneh AU - Badaly D AD - Learning and Development Center, Child Mind Institute, New York, NY, United States. FAU - Gauthier, Naomi AU - Gauthier N AD - Department of Cardiology, Boston Children's Hospital, Boston, MA, United States. FAU - Pham, Tam Dan N AU - Pham TDN AD - Department of Pediatric Cardiology, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, United States. FAU - Britt, Jolie J AU - Britt JJ AD - Department of Pediatric Cardiology, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, United States. FAU - Crouter, Scott E AU - Crouter SE AD - Department of Kinesiology, Recreation, and Sport Studies, The University of Tennessee Knoxville, Knoxville, IL, United States. FAU - Giangregorio, Maeve AU - Giangregorio M AD - Department of Cardiology, Boston Children's Hospital, Boston, MA, United States. FAU - Nathan, Meena AU - Nathan M AD - Department of Cardiac Surgery, Boston Children's Hospital, Boston, MA, United States. FAU - Akamagwuna, Unoma O AU - Akamagwuna UO AD - Department Pediatric Physical Medicine and Rehabilitation, Texas Children's Hospital, Houston, TX, United States. AD - Department of Physical Medicine and Rehabilitation, Baylor College of Medicine, TX, United States. LA - eng PT - Journal Article PT - Review DEP - 20230531 PL - Switzerland TA - Front Pediatr JT - Frontiers in pediatrics JID - 101615492 PMC - PMC10275574 OTO - NOTNLM OT - cardiac OT - children OT - function OT - heart OT - rehabilitation COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/06/19 06:42 MHDA- 2023/06/19 06:43 PMCR- 2023/05/31 CRDT- 2023/06/19 03:03 PHST- 2022/11/22 00:00 [received] PHST- 2023/04/17 00:00 [accepted] PHST- 2023/06/19 06:43 [medline] PHST- 2023/06/19 06:42 [pubmed] PHST- 2023/06/19 03:03 [entrez] PHST- 2023/05/31 00:00 [pmc-release] AID - 10.3389/fped.2023.1104794 [doi] PST - epublish SO - Front Pediatr. 2023 May 31;11:1104794. doi: 10.3389/fped.2023.1104794. eCollection 2023. PMID- 37332054 OWN - NLM STAT- MEDLINE DCOM- 20231130 LR - 20260120 IS - 2151-4658 (Electronic) IS - 2151-464X (Linking) VI - 75 IP - 12 DP - 2023 Dec TI - Proposed Response Parameters for Twelve-Month Drug Trial in Juvenile Systemic Sclerosis: Results of the Hamburg International Consensus Meetings. PG - 2453-2462 LID - 10.1002/acr.25171 [doi] AB - OBJECTIVE: Juvenile systemic sclerosis (SSc) is an orphan disease, associated with high morbidity and mortality. New treatment strategies are much needed, but clearly defining appropriate outcomes is necessary if successful therapies are to be developed. Our objective here was to propose such outcomes. METHODS: This proposal is the result of 4 face-to-face consensus meetings with a 27-member multidisciplinary team of pediatric rheumatologists, adult rheumatologists, dermatologists, pediatric cardiologists, pulmonologists, gastroenterologists, a statistician, and patients. Throughout the process, we reviewed the existing adult data in this field, the more limited pediatric literature for juvenile SSc outcomes, and data from 2 juvenile SSc patient cohorts to assist in making informed, data-driven decisions. The use of items for each domain as an outcome measure in an open label 12-month clinical trial of juvenile SSc was voted and agreed upon using a nominal group technique. RESULTS: After voting, the domains agreed on were global disease activity, skin, Raynaud's phenomenon, digital ulcers, musculoskeletal, cardiac, pulmonary, renal, and gastrointestinal involvement, and quality of life. Fourteen outcome measures had 100% agreement, 1 item had 91% agreement, and 1 item had 86% agreement. The domains of biomarkers and growth/development were moved to the research agenda. CONCLUSION: We reached consensus on multiple domains and items that should be assessed in an open label, 12-month clinical juvenile SSc trial as well as a research agenda for future development. CI - (c) 2023 American College of Rheumatology. FAU - Foeldvari, Ivan AU - Foeldvari I AUID- ORCID: 0000-0003-0659-5298 AD - Schon Klinik Hamburg Eilbek, Hamburg, Germany. FAU - Torok, Kathryn S AU - Torok KS AUID- ORCID: 0000-0002-1662-143X AD - University of Pittsburgh and Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania. FAU - Anton, Jordi AU - Anton J AUID- ORCID: 0000-0002-8792-4219 AD - Hospital Sant Joan de Deu and Universitat de Barcelona, Barcelona, Spain. FAU - Blakley, Michael AU - Blakley M AD - Indiana University School of Medicine and Riley Hospital for Children at IU Health, Indianapolis. FAU - Constantin, Tamas AU - Constantin T AD - Semmelweis University, Budapest, Hungary. FAU - Curran, Megan AU - Curran M AD - University of Colorado School of Medicine and Children's Hospital Colorado, Aurora. FAU - Cutolo, Maurizio AU - Cutolo M AUID- ORCID: 0000-0002-5396-0932 AD - University of Genoa and IRCCS San Martino Polyclinic Hospital, Genoa, Italy. FAU - Denton, Christopher AU - Denton C AUID- ORCID: 0000-0003-3975-8938 AD - Royal Free London NHS Foundation Trust, London, UK. FAU - Fligelstone, Kim AU - Fligelstone K AD - Scleroderma & Raynaud's United Kingdom, London, UK. FAU - Ingegnoli, Francesca AU - Ingegnoli F AD - University of Milan, ASST G. Pini, Milan, Italy. FAU - Li, Suzanne C AU - Li SC AD - Hackensack University Medical Center, Hackensack, New Jersey. FAU - Nemcova, Dana AU - Nemcova D AD - Charles University, Prague, Czech Republic. FAU - Orteu, Catherine AU - Orteu C AD - Royal Free London, London, UK. FAU - Pilkington, Clarissa AU - Pilkington C AD - Great Ormond Street Hospital, London, UK. FAU - Smith, Vanessa AU - Smith V AD - Ghent University, Ghent University Hospital, VIB Inflammation Research Center, and ERN ReCONNET, Ghent, Belgium. FAU - Stevens, Anne AU - Stevens A AD - Children's Hospital Research Institute and University of Washington, Seattle, and Janssen Pharmaceutical Companies of Johnson & Johnson, Spring House, Pennsylvania. FAU - Klotsche, Jens AU - Klotsche J AUID- ORCID: 0000-0002-2954-5755 AD - German Rheumatism Research Center, Berlin, Germany. FAU - Khanna, Dinesh AU - Khanna D AUID- ORCID: 0000-0003-1412-4453 AD - University of Michigan, Ann Arbor. FAU - Costa-Reis, Patricia AU - Costa-Reis P AD - Hospital de Santa Maria, Faculdade de Medicina, and Universidade de Lisboa, Lisbon, Portugal. FAU - Del Galdo, Francesco AU - Del Galdo F AUID- ORCID: 0000-0002-8528-2283 AD - University of Leeds and Leeds Teaching Hospital Trust, Leeds, UK. FAU - Hinrichs, Bernd AU - Hinrichs B AD - Asklepios Klinik Nord-Heidberg, Hamburg, Germany. FAU - Kasapcopur, Ozgur AU - Kasapcopur O AUID- ORCID: 0000-0002-1125-7720 AD - Cerrahpasa Medical School and Istanbul University-Cerrahpasa, Istanbul, Turkey. FAU - Pain, Clare AU - Pain C AD - Alder Hey Children's Foundation NHS Trust, Liverpool, UK. FAU - Ruperto, Nicolino AU - Ruperto N AUID- ORCID: 0000-0001-8407-7782 AD - IRCCSG Istituto G. Gaslini, Genoa, Italy. FAU - Zheng, Alison AU - Zheng A AD - Chinese Organization for Scleroderma, Chengdu City, Sichuan Province, China. FAU - Furst, Daniel E AU - Furst DE AUID- ORCID: 0000-0001-7857-2373 AD - University of California, Los Angeles, University of Washington, Seattle, and University of Florence, Florence, Italy. LA - eng PT - Consensus Statement PT - Journal Article PT - Review DEP - 20230912 PL - United States TA - Arthritis Care Res (Hoboken) JT - Arthritis care & research JID - 101518086 RN - digital ulcers RN - Juvenile systemic scleroderma RN - Juvenile-onset scleroderma SB - IM MH - Adult MH - Quality of Life MH - Child MH - Humans MH - *Raynaud Disease/drug therapy MH - *Scleroderma, Systemic/diagnosis/drug therapy/complications MH - Skin Ulcer MH - Scleroderma, Localized EDAT- 2023/06/19 00:42 MHDA- 2023/11/30 06:43 CRDT- 2023/06/18 23:37 PHST- 2023/04/03 00:00 [revised] PHST- 2022/11/24 00:00 [received] PHST- 2023/06/08 00:00 [accepted] PHST- 2023/11/30 06:43 [medline] PHST- 2023/06/19 00:42 [pubmed] PHST- 2023/06/18 23:37 [entrez] AID - 10.1002/acr.25171 [doi] PST - ppublish SO - Arthritis Care Res (Hoboken). 2023 Dec;75(12):2453-2462. doi: 10.1002/acr.25171. Epub 2023 Sep 12. PMID- 37324338 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230619 IS - 2666-2507 (Electronic) IS - 2666-2507 (Linking) VI - 19 DP - 2023 Jun TI - Eliminating sternal wound infections: Why every cardiac surgery program needs an I hate infections team. PG - 93-103 LID - 10.1016/j.xjtc.2023.03.019 [doi] AB - OBJECTIVES: The majority of studies examining deep sternal wound infection (DSWI) prevention focus on ameliorating 1 variable at a time. There is a paucity of data regarding the synergistic effects of combining clinical and environmental interventions. This article describes an interdisciplinary, multimodal approach to eliminate DSWIs at a large community hospital. METHODS: We developed a robust, multidisciplinary infection prevention team to evaluate and act in all phases of perioperative care to achieve a cardiac surgery DSWI rate of 0, named: the I hate infections team. The team identified opportunities for improved care and best practices and implemented changes on an ongoing basis. RESULTS: Patient-related interventions consisted of preoperative methicillin-resistant Staphylococcus aureus identification, individualized perioperative antibiotics, antimicrobial dosing strategies, and maintenance of normothermia. Operative-related interventions involved glycemic control, sternal adhesives, medications and hemostasis, rigid sternal fixation for high-risk patients, chlorhexidine gluconate dressings over invasive lines, and use of disposable health care equipment. Environment-related interventions included optimizing operating room ventilation and terminal cleaning, reducing airborne particle counts, and decreasing foot traffic. Together, these interventions reduced the DSWI incidence from 1.6% preintervention to 0% for 12 consecutive months after full bundle implementation. CONCLUSIONS: A multidisciplinary team focused on eliminating DSWI identified known risk factors and implemented evidence-based interventions in each phase of care to ameliorate risk. Although the influence of each individual intervention on DSWI remains unknown, use of the bundled infection prevention approach reduced the incidence to 0 for the first 12 months after implementation. CI - (c) 2023 The Author(s). FAU - Downing, Maren AU - Downing M AD - WakeMed Health and Hospitals, Raleigh, NC. AD - Campbell University School of Osteopathic Medicine, Lillington, NC. FAU - Modrow, Michael AU - Modrow M AD - WakeMed Health and Hospitals, Raleigh, NC. AD - Department of Cardiovascular and Thoracic Surgery, WakeMed Heart and Vascular, Raleigh, NC. FAU - Thompson-Brazill, Kelly A AU - Thompson-Brazill KA AD - WakeMed Health and Hospitals, Raleigh, NC. AD - Department of Cardiovascular and Thoracic Surgery, WakeMed Heart and Vascular, Raleigh, NC. FAU - Ledford, J Erin AU - Ledford JE AD - WakeMed Health and Hospitals, Raleigh, NC. AD - Department of Cardiovascular and Thoracic Surgery, WakeMed Heart and Vascular, Raleigh, NC. FAU - Harr, Charles D AU - Harr CD AD - WakeMed Health and Hospitals, Raleigh, NC. AD - Department of Cardiovascular and Thoracic Surgery, WakeMed Heart and Vascular, Raleigh, NC. FAU - Williams, Judson B AU - Williams JB AD - WakeMed Health and Hospitals, Raleigh, NC. AD - Department of Cardiovascular and Thoracic Surgery, WakeMed Heart and Vascular, Raleigh, NC. LA - eng PT - Journal Article DEP - 20230414 PL - United States TA - JTCVS Tech JT - JTCVS techniques JID - 101768546 PMC - PMC10268509 OTO - NOTNLM OT - cardiac surgery OT - enhanced recovery after surgery OT - mediastinitis OT - operating room airborne contaminants OT - operating room traffic OT - prevention OT - sternal wound infections EDAT- 2023/06/16 06:42 MHDA- 2023/06/16 06:43 PMCR- 2023/04/14 CRDT- 2023/06/16 04:09 PHST- 2022/10/03 00:00 [received] PHST- 2023/02/23 00:00 [revised] PHST- 2023/03/27 00:00 [accepted] PHST- 2023/06/16 06:43 [medline] PHST- 2023/06/16 06:42 [pubmed] PHST- 2023/06/16 04:09 [entrez] PHST- 2023/04/14 00:00 [pmc-release] AID - S2666-2507(23)00118-9 [pii] AID - 10.1016/j.xjtc.2023.03.019 [doi] PST - epublish SO - JTCVS Tech. 2023 Apr 14;19:93-103. doi: 10.1016/j.xjtc.2023.03.019. eCollection 2023 Jun. PMID- 37321830 OWN - NLM STAT- MEDLINE DCOM- 20231129 LR - 20250916 IS - 1468-201X (Electronic) IS - 1355-6037 (Linking) VI - 109 IP - 24 DP - 2023 Nov 27 TI - Burden and prognostic impact of cardiovascular disease in patients with cancer. PG - 1819-1826 LID - 10.1136/heartjnl-2022-321324 [doi] AB - The number of patients at the intersection of cancer and cardiovascular disease (CVD) is increasing, reflecting ageing global populations, rising burden of shared cardiometabolic risk factors, and improved cancer survival. Many cancer treatments carry a risk of cardiotoxicity. Baseline cardiovascular risk assessment is recommended in all patients with cancer and requires consideration of individual patient risk and the cardiotoxicity profile of proposed anticancer therapies. Patients with pre-existing CVD are potentially at high or very high risk of cancer-therapy related cardiovascular toxicity. The detection of pre-existing CVD should prompt cardiac optimisation and planning of surveillance during cancer treatment. In patients with severe CVD, the risk of certain cancer therapies may be prohibitively high. Such decisions require multidisciplinary discussion with consideration of alternative anti-cancer therapies, risk-benefit assessment, and patient preference. Current practice is primarily guided by expert opinion and data from select clinical cohorts. There is need for development of a stronger evidence base to guide clinical practice in cardio-oncology. The establishment of multicentre international registries and national-level healthcare data linkage projects are important steps towards facilitating enrichment of cardio-oncology research programmes. In this narrative review, we consider epidemiological trends of cancer and CVD comorbidities and the impact of their co-occurrence on clinical outcomes, current approach to supporting cancer patients with pre-existing CVD and gaps in existing knowledge. CI - (c) Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Raisi-Estabragh, Zahra AU - Raisi-Estabragh Z AD - William Harvey Research Institute, NIHR Barts Biomedical Research Centre, Centre for Advanced Cardiovascular Imaging, Queen Mary University London, London, UK. AD - Barts Heart Centre, Saint Bartholomew's Hospital, London, UK. FAU - Manisty, Charlotte H AU - Manisty CH AD - Barts Heart Centre, Saint Bartholomew's Hospital, London, UK. AD - Institute of Cardiovascular Science, University College London, London, London, UK. FAU - Cheng, Richard K AU - Cheng RK AUID- ORCID: 0000-0001-5994-5998 AD - Division of Cardiology, University of Washington Medical Center, Seattle, Washington, USA. FAU - Lopez Fernandez, Teresa AU - Lopez Fernandez T AD - Hospital Universitario La Paz, Instituto de Investigacion La Paz-IdiPaz, Madrid, Spain. FAU - Mamas, Mamas A AU - Mamas MA AUID- ORCID: 0000-0001-9241-8890 AD - Institute of Population Health, University of Manchester, Manchester, UK mamasmamas1@yahoo.co.uk. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20231127 PL - England TA - Heart JT - Heart (British Cardiac Society) JID - 9602087 SB - IM MH - Humans MH - *Cardiovascular Diseases/diagnosis/epidemiology/therapy MH - Cardiotoxicity/etiology MH - Prognosis MH - *Neoplasms/complications/diagnosis/epidemiology MH - Medical Oncology OTO - NOTNLM OT - Epidemiology OT - Health Services OT - Risk Factors COIS- Competing interests: MAM is an International Advisory Board Member of Heart. RKC is an Associate Editor for Heart. EDAT- 2023/06/16 01:08 MHDA- 2023/11/29 06:43 CRDT- 2023/06/15 21:12 PHST- 2023/02/04 00:00 [received] PHST- 2023/05/25 00:00 [accepted] PHST- 2023/11/29 06:43 [medline] PHST- 2023/06/16 01:08 [pubmed] PHST- 2023/06/15 21:12 [entrez] AID - heartjnl-2022-321324 [pii] AID - 10.1136/heartjnl-2022-321324 [doi] PST - epublish SO - Heart. 2023 Nov 27;109(24):1819-1826. doi: 10.1136/heartjnl-2022-321324. PMID- 37316813 OWN - NLM STAT- MEDLINE DCOM- 20230616 LR - 20231102 IS - 1472-6963 (Electronic) IS - 1472-6963 (Linking) VI - 23 IP - 1 DP - 2023 Jun 14 TI - Community pharmacists' perceptions on multidisciplinary heart failure care: an exploratory qualitative study. PG - 638 LID - 10.1186/s12913-023-09661-8 [doi] LID - 638 AB - BACKGROUND: Heart failure (HF) is an important health problem and guidelines recommend multidisciplinary management. The pharmacist is an important member of the multidisciplinary heart failure team, both in the hospital and community setting. This study aims to explore the perceptions of community pharmacists on their role in HF care. METHODS: We conducted a qualitative study based on face-to-face semi-structured interviews with 13 Belgian community pharmacists between September 2020 and December 2020. We used the Qualitative Analysis Guide of Leuven (QUAGOL) method as guidance for data analysis until data saturation was reached. We structured interview content into a thematic matrix. RESULTS: We identified two major themes: heart failure management and multidisciplinary management. Pharmacists feel responsible for the pharmacological and non-pharmacological management of heart failure, citing easy access and pharmacological expertise as important assets. Diagnostic uncertainty, lack of knowledge and time, disease complexity and difficulties in communication with patients and informal care providers are barriers to optimal management. General practitioners are the most important partners in multidisciplinary community heart failure management, although pharmacists perceive a lack of appreciation and cooperation and deplore communication difficulties. They feel intrinsically motivated to provide extended pharmaceutical care in HF but cite the lack of financial viability and information sharing structures as important barriers. CONCLUSION: The importance of pharmacist involvement in multidisciplinary heart failure teams is undisputed by Belgian pharmacists, who cite easy access and pharmacological expertise as important assets. They point out several barriers impeding evidence-based pharmacist care for outpatients with heart failure: diagnostic uncertainty and disease complexity, lack of multidisciplinary information technology and insufficient resources. We recommend that future policy should focus on improved medical data exchanges between primary and secondary care electronic health records as well as the reinforcement of interprofessional relationships between locally affiliated pharmacists and general practitioners. CI - (c) 2023. The Author(s). FAU - Raat, Willem AU - Raat W AD - Department of Public Health and Primary Care, KU Leuven, Kapucijnenvoer 7, blok D bus 7001 3000, Leuven, Belgium. willem.raat@kuleuven.be. FAU - Truyts, Pauline AU - Truyts P AD - Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium. FAU - Gaillaert, Justine AU - Gaillaert J AD - Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium. FAU - Van de Putte, Marie AU - Van de Putte M AD - Zorgzaam Leuven, Leuven, Belgium. FAU - Van der Linden, Lorenz AU - Van der Linden L AD - Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium. AD - Pharmacy Department, University Hospitals Leuven, KU Leuven, Leuven, Belgium. FAU - Janssens, Stefan AU - Janssens S AD - Department of Cardiovascular Diseases, University Hospitals Leuven, KU Leuven, Leuven, Belgium. FAU - Vaes, Bert AU - Vaes B AD - Department of Public Health and Primary Care, KU Leuven, Kapucijnenvoer 7, blok D bus 7001 3000, Leuven, Belgium. FAU - Smeets, Miek AU - Smeets M AD - Department of Public Health and Primary Care, KU Leuven, Kapucijnenvoer 7, blok D bus 7001 3000, Leuven, Belgium. LA - eng PT - Journal Article DEP - 20230614 PL - England TA - BMC Health Serv Res JT - BMC health services research JID - 101088677 SB - IM MH - Humans MH - Pharmacists MH - *Heart Failure/drug therapy MH - *Pharmacy MH - Communication MH - Data Analysis PMC - PMC10266313 OTO - NOTNLM OT - Heart failure OT - Multidisciplinary care OT - Pharmacologist OT - Qualitative design COIS- The authors declare no competing interests. EDAT- 2023/06/15 01:08 MHDA- 2023/06/16 06:42 PMCR- 2023/06/14 CRDT- 2023/06/14 23:34 PHST- 2023/01/30 00:00 [received] PHST- 2023/06/07 00:00 [accepted] PHST- 2023/06/16 06:42 [medline] PHST- 2023/06/15 01:08 [pubmed] PHST- 2023/06/14 23:34 [entrez] PHST- 2023/06/14 00:00 [pmc-release] AID - 10.1186/s12913-023-09661-8 [pii] AID - 9661 [pii] AID - 10.1186/s12913-023-09661-8 [doi] PST - epublish SO - BMC Health Serv Res. 2023 Jun 14;23(1):638. doi: 10.1186/s12913-023-09661-8. PMID- 37314025 OWN - NLM STAT- MEDLINE DCOM- 20230710 LR - 20230718 IS - 0310-057X (Print) IS - 0310-057X (Linking) VI - 51 IP - 4 DP - 2023 Jul TI - Triggers for medical emergency team activation after non-cardiac surgery. PG - 281-287 LID - 10.1177/0310057X221141107 [doi] AB - Deterioration after major surgery is common, with many patients experiencing a medical emergency team (MET) activation. Understanding the triggers for MET calls may help design interventions to prevent deterioration. We aimed to identify triggers for MET activation in non-cardiac surgical patients. A retrospective cohort study of adult patients who experienced a postoperative MET call at a single tertiary hospital was undertaken. The trigger and timing of each MET call and patient characteristics were collected.Four hundred and one MET calls occurred after 23,258 surgical procedures, a rate of 1.7% of all non-cardiac surgical procedures, accounting for 11.7% of all MET calls over the study period. Hypotension (41.4%) was the most common trigger, followed by tachycardia (18.5%), altered conscious state (11.0%), hypoxia (10.0%), tachypnoea (5.7%), 'other' (5.7%), clinical concern (4.0%), increased work of breathing (1.5%) and bradypnoea (0.7%). Cardiac and/or respiratory arrest triggered 1.2% of MET activations. Eighty-six percent of patients had a single MET call, 10.2% had two, 1.8% had three and one patient (0.3%) had four. The median interval between post-anaesthetic care unit (PACU) discharge and MET call was 14.7 h (95% confidence interval 4.2 to 28.9 h). MET calls resulted in intensive care unit (ICU) admission in 40 patients (10%), while 82% remained on the ward, 4% had a MET call shortly after ICU discharge and returned there, 2% returned to theatre, and 2% went to a high dependency unit.Hypotension was the most common trigger for MET calls after non-cardiac surgery. Deterioration frequently occurred within 24 h of PACU discharge. Future research should focus on prevention of hypotension and tachycardia after surgery. FAU - Douglas, Ned Wr AU - Douglas NW AUID- ORCID: 0000-0002-3085-5005 AD - Department of Anaesthesia and Pain Management, The Royal Melbourne Hospital, Parkville, Australia. AD - Department of Critical Care, The University of Melbourne, Parkville, Australia. FAU - Coleman, Olivia M AU - Coleman OM AD - Department of Anaesthesia and Pain Management, The Royal Melbourne Hospital, Parkville, Australia. FAU - Steel, Amelia Ca AU - Steel AC AD - Department of Anaesthesia and Pain Management, The Royal Melbourne Hospital, Parkville, Australia. FAU - Leslie, Kate AU - Leslie K AUID- ORCID: 0000-0001-8512-3517 AD - Department of Anaesthesia and Pain Management, The Royal Melbourne Hospital, Parkville, Australia. AD - Department of Critical Care, The University of Melbourne, Parkville, Australia. FAU - Darvall, Jai Nl AU - Darvall JN AUID- ORCID: 0000-0003-0579-8931 AD - Department of Anaesthesia and Pain Management, The Royal Melbourne Hospital, Parkville, Australia. AD - Department of Critical Care, The University of Melbourne, Parkville, Australia. LA - eng PT - Journal Article DEP - 20230614 PL - United States TA - Anaesth Intensive Care JT - Anaesthesia and intensive care JID - 0342017 SB - IM MH - Adult MH - Humans MH - Retrospective Studies MH - Hospitalization MH - Intensive Care Units MH - Tertiary Care Centers MH - *Hypotension/epidemiology MH - *Hospital Rapid Response Team MH - Hospital Mortality OTO - NOTNLM OT - Surgery OT - anaesthesia OT - deterioration OT - failure to rescue OT - medical emergency teams OT - rapid response teams EDAT- 2023/06/14 13:06 MHDA- 2023/07/10 06:42 CRDT- 2023/06/14 07:13 PHST- 2023/07/10 06:42 [medline] PHST- 2023/06/14 13:06 [pubmed] PHST- 2023/06/14 07:13 [entrez] AID - 10.1177/0310057X221141107 [doi] PST - ppublish SO - Anaesth Intensive Care. 2023 Jul;51(4):281-287. doi: 10.1177/0310057X221141107. Epub 2023 Jun 14. PMID- 37309178 OWN - NLM STAT- MEDLINE DCOM- 20240119 LR - 20240201 IS - 1467-1107 (Electronic) IS - 1047-9511 (Linking) VI - 34 IP - 1 DP - 2024 Jan TI - Evaluating variation in pre-operative evaluation and planning for children undergoing atrial or ventricular septal defect repair. PG - 164-170 LID - 10.1017/S1047951123001336 [doi] AB - BACKGROUND: CHD care is resource-intensive. Unwarranted variation in care may increase cost and result in poorer health outcomes. We hypothesise that process variation exists within the pre-operative evaluation and planning process for children undergoing repair of atrial septal defect or ventricular septal defect and that substantial variation occurs in a small number of care points. METHODS: From interviews with staff of an integrated congenital heart centre, an initial process map was constructed. A retrospective chart review of patients with isolated surgical atrial septal defect and ventricular septal defect repair from 7/1/2018 through 11/1/2020 informed revisions of the process map. The map was assessed for points of consistency and variability. RESULTS: Thirty-two surgical atrial septal defect/ventricular septal defect repair patients were identified. Ten (31%) were reviewed by interventional cardiology before surgical review. Of these, 6(60%) had a failed catheter-based closure and 4 (40%) were deemed inappropriate for catheter-based closure. Thirty (94%) were reviewed in case conference, all attended surgical clinic, and none were admitted prior to surgery. The process map from interviews alone identified surgery rescheduling as a point of major variability; however, chart review revealed this was not as prominent a source of variability as pre-operative interventional cardiology review. CONCLUSIONS: Significant variation in the pre-operative evaluation and planning process for surgical atrial septal defect/ventricular septal defect patients was identified. If such process variation is widespread through CHD care, it may contribute to variations in outcome and cost previously documented within CHD surgery. Future research will focus on determining whether the variation is warranted or unwarranted, associated health outcomes and cost variation attributed to these variations in care processes. FAU - Dawson-Gore, Catherine C AU - Dawson-Gore CC AUID- ORCID: 0000-0002-5020-9916 AD - Texas Center for Pediatric and Congenital Heart Disease, UT Health Austin / Dell Children's Medical Center, AustinTX, USA. AD - Department of Surgery School of Medicine, University of Colorado, Anschutz Medical Campus, AuroraCO, USA. FAU - Well, Andrew AU - Well A AUID- ORCID: 0000-0002-0725-2791 AD - Texas Center for Pediatric and Congenital Heart Disease, UT Health Austin / Dell Children's Medical Center, AustinTX, USA. AD - Department of Surgery and Perioperative Care, The University of Texas at Austin Dell Medical School, AustinTX, USA. AD - The Value Institute for Health and Care, The University of Texas at Austin Dell Medical School and McCombs School of Business, AustinTX, USA. FAU - Wallace, Scott AU - Wallace S AD - The Value Institute for Health and Care, The University of Texas at Austin Dell Medical School and McCombs School of Business, AustinTX, USA. FAU - Teisberg, Elizabeth AU - Teisberg E AD - The Value Institute for Health and Care, The University of Texas at Austin Dell Medical School and McCombs School of Business, AustinTX, USA. FAU - Born, Christopher AU - Born C AD - Administration, Dell Children's Medical Center, AustinTX, USA. FAU - Carberry, Kathleen AU - Carberry K AD - The Value Institute for Health and Care, The University of Texas at Austin Dell Medical School and McCombs School of Business, AustinTX, USA. FAU - Gottlieb, Erin AU - Gottlieb E AD - Texas Center for Pediatric and Congenital Heart Disease, UT Health Austin / Dell Children's Medical Center, AustinTX, USA. AD - Department of Surgery and Perioperative Care, The University of Texas at Austin Dell Medical School, AustinTX, USA. FAU - Holt, Dudley Byron AU - Holt DB AD - Texas Center for Pediatric and Congenital Heart Disease, UT Health Austin / Dell Children's Medical Center, AustinTX, USA. AD - Department of Pediatrics, The University of Texas at Austin Dell Medical School, AustinTX, USA. FAU - Fraser, Charles D Jr AU - Fraser CD Jr AD - Texas Center for Pediatric and Congenital Heart Disease, UT Health Austin / Dell Children's Medical Center, AustinTX, USA. AD - Department of Surgery and Perioperative Care, The University of Texas at Austin Dell Medical School, AustinTX, USA. FAU - Mery, Carlos M AU - Mery CM AD - Texas Center for Pediatric and Congenital Heart Disease, UT Health Austin / Dell Children's Medical Center, AustinTX, USA. AD - Department of Surgery and Perioperative Care, The University of Texas at Austin Dell Medical School, AustinTX, USA. LA - eng PT - Journal Article DEP - 20230613 PL - England TA - Cardiol Young JT - Cardiology in the young JID - 9200019 SB - IM MH - Child MH - Humans MH - Retrospective Studies MH - Treatment Outcome MH - *Heart Septal Defects, Ventricular/surgery MH - *Heart Septal Defects, Atrial/surgery MH - Heart Ventricles OTO - NOTNLM OT - Congenital heart surgery OT - atrial septal defect OT - preoperative care OT - ventricular septal defect EDAT- 2023/06/13 06:42 MHDA- 2024/01/19 06:42 CRDT- 2023/06/13 03:40 PHST- 2024/01/19 06:42 [medline] PHST- 2023/06/13 06:42 [pubmed] PHST- 2023/06/13 03:40 [entrez] AID - S1047951123001336 [pii] AID - 10.1017/S1047951123001336 [doi] PST - ppublish SO - Cardiol Young. 2024 Jan;34(1):164-170. doi: 10.1017/S1047951123001336. Epub 2023 Jun 13. PMID- 37309123 OWN - NLM STAT- MEDLINE DCOM- 20230710 LR - 20240611 IS - 2150-136X (Electronic) IS - 2150-1351 (Linking) VI - 14 IP - 4 DP - 2023 Jul TI - Perioperative Care Models for Neonates With Congenital Heart Disease: Evolving Role of Neonatology Within the Cardiac Intensive Care Unit. PG - 481-489 LID - 10.1177/21501351231170772 [doi] AB - A multidisciplinary team is needed to optimally care for infants with congenital heart disease (CHD). Different compositions of teams trained in cardiology, critical care, cardiothoracic surgery, anesthesia, and neonatology have been identified as being primarily responsible for perioperative care of this high-risk population in dedicated cardiac intensive care units (CICUs). Although the specific role of cardiac intensivists has become more well defined over the past two decades, the responsibilities of neonatologists remain highly variable in the CICU with neonatologists providing care along with a unique spectrum of primary, shared, or consultative care. The neonatologist can function as the primary physician and assume all or share responsibility with the cardiac intensivists for the management of infants with CHD. A neonatologist can provide care as a secondary consultant physician in a supportive role for the primary CICU team. Additionally, neonates with CHD can be mixed with older children in a CICU, cohorted in a dedicated space within the CICU or placed in a stand-alone infant CICU without older children. Although variations exist between centers on which model of care is deployed and the location within a CICU, characterization of current practice patterns represents the initial step required to determine optimal best practices to improve the quality of care for neonates with cardiac disease. In this manuscript, we present four models utilized in the United States in which the neonatologist provides neonatal-cardiac-focused care in a dedicated CICU. We also outline the different permutations of location where neonates can be cared for in dedicated pediatric/infant CICUs. FAU - Chaudhry, Paulomi M AU - Chaudhry PM AD - Division of Neonatology, Department of Pediatrics, Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, IN, USA. FAU - Sen, Shawn AU - Sen S AUID- ORCID: 0000-0001-5619-0905 AD - Division of Neonatology and Pediatric Cardiology, Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. FAU - Steurer, Martina AU - Steurer M AD - Department of Pediatrics, University of California San Francisco, San Francisco, CA, USA. AD - Department of Epidemiology and Biostatistics, California Preterm Birth Initiative, University of California San Francisco, San Francisco, CA, USA. FAU - Levy, Victor Y AU - Levy VY AD - Department of Pediatrics, Texas Tech University Health Sciences Center, Lubbock, TX, USA. FAU - Gowda, Sharada AU - Gowda S AD - Division of Neonatology, Department of Pediatrics, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA. FAU - Ball, Molly K AU - Ball MK AD - Division of Neonatology, Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH, USA. FAU - Ashrafi, Amir AU - Ashrafi A AD - Department of Pediatrics, CHOC Children's Hospital, Orange, CA, USA. AD - University of California Irvine, Orange, CA, USA. FAU - Emani, Sitaram M AU - Emani SM AD - Department of Cardiac Surgery, Boston Children's Hospital, Department of Surgery, Harvard Medical School Boston, Boston, MA, USA. FAU - Bacha, Emile A AU - Bacha EA AD - Division of Cardiac, Thoracic and Vascular Surgery, New York-Presbyterian/Morgan Stanley Children's Hospital, Columbia University Medical Center, Pediatric and Congenital Cardiac Surgery, New York, NY, USA. FAU - Checchia, Paul A AU - Checchia PA AD - Division of Critical Care Medicine, Department of Pediatrics, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA. FAU - Levy, Philip T AU - Levy PT AD - Division of Newborn Medicine, Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA. FAU - Krishnamurthy, Ganga AU - Krishnamurthy G AD - Division of Neonatology, Department of Pediatrics, New York-Presbyterian Morgan Stanley Children's Hospital, Columbia University Irving Medical Center, New York, NY, USA. LA - eng PT - Journal Article DEP - 20230612 PL - United States TA - World J Pediatr Congenit Heart Surg JT - World journal for pediatric & congenital heart surgery JID - 101518415 SB - IM MH - Infant MH - Infant, Newborn MH - Humans MH - Child MH - United States MH - Adolescent MH - *Neonatology MH - *Heart Defects, Congenital/surgery MH - Intensive Care Units MH - Critical Care MH - Perioperative Care OTO - NOTNLM OT - CICU OT - congenital heart disease OT - neonatology EDAT- 2023/06/13 06:42 MHDA- 2023/07/10 06:42 CRDT- 2023/06/13 03:38 PHST- 2023/07/10 06:42 [medline] PHST- 2023/06/13 06:42 [pubmed] PHST- 2023/06/13 03:38 [entrez] AID - 10.1177/21501351231170772 [doi] PST - ppublish SO - World J Pediatr Congenit Heart Surg. 2023 Jul;14(4):481-489. doi: 10.1177/21501351231170772. Epub 2023 Jun 12. PMID- 37309083 OWN - NLM STAT- MEDLINE DCOM- 20231023 LR - 20231023 IS - 1742-481X (Electronic) IS - 1742-4801 (Print) IS - 1742-4801 (Linking) VI - 20 IP - 9 DP - 2023 Nov TI - The application of MDT model for calciphylaxis management in patients with end-stage renal disease. PG - 3717-3723 LID - 10.1111/iwj.14265 [doi] AB - This study focuses on the application of nurse-led multidisciplinary collaborative therapy (MDT) management model for calciphylaxis prevention of patients with terminal renal disease. Through the establishment of a multidisciplinary management team spanning nephrology department, blood purification center, dermatology department, burn and plastic surgery department, infection department, stem cell platform, nutrition department, pain department, cardiology department, hydrotherapy group, dermatology group, and outpatient treatment room, the distribution of duties among team members were clarified to bring out the best advantages of a multidisciplinary teamwork during treatment and nursing. For patients with calciphylaxis symptoms in terminal renal disease, a case-by-case management model was carried out with the focus on personalised problem. We emphasised on personalised wound care, precise medication care, active pain management, psychological intervention and palliative care, the amelioration of calcium and phosphorus metabolism disorder, nutritional supplementation, and the therapeutic intervention based on human amniotic mesenchymal stem cell regeneration. The MDT model effectively compensates for traditional nursing mode and could serve as a novel clinical management modality for calciphylaxis prevention in patients with terminal renal disease. CI - (c) 2023 The Authors. International Wound Journal published by Medicalhelplines.com Inc and John Wiley & Sons Ltd. FAU - Pan, Yanyan AU - Pan Y AD - Department of Nephrology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Wang, Hui AU - Wang H AD - Department of Nephrology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Ye, Yajun AU - Ye Y AD - Department of Nephrology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Lv, Manman AU - Lv M AD - Department of Nephrology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Zhu, Yamei AU - Zhu Y AD - Blood Purification Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Wang, Ningning AU - Wang N AD - Department of Nephrology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Zhao, Jing AU - Zhao J AD - Outpatient Treatment Room, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Shi, Jingping AU - Shi J AD - Department of Plastic and Burn, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Lv, Xiaolin AU - Lv X AD - Department of Nephrology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. LA - eng GR - 81570666/National Natural Science Foundation of China/ GR - 81671447/National Natural Science Foundation of China/ GR - 81730041/National Natural Science Foundation of China/ GR - 2017YFC1001303/National key R&D projects/ PT - Journal Article DEP - 20230612 PL - England TA - Int Wound J JT - International wound journal JID - 101230907 SB - IM MH - Humans MH - *Calciphylaxis/etiology/therapy/diagnosis MH - *Kidney Failure, Chronic/complications/therapy MH - Renal Dialysis MH - Pain Management MH - Pain PMC - PMC10588363 OTO - NOTNLM OT - calciphylaxis OT - end-stage renal disease OT - human amniotic mesenchymal stem cells OT - multidisciplinary cooperative therapy OT - personalised medicine COIS- The authors declared that there are no conflicts of interest in this work. EDAT- 2023/06/13 06:42 MHDA- 2023/10/23 00:42 PMCR- 2023/06/12 CRDT- 2023/06/13 00:53 PHST- 2023/03/29 00:00 [received] PHST- 2023/05/20 00:00 [accepted] PHST- 2023/10/23 00:42 [medline] PHST- 2023/06/13 06:42 [pubmed] PHST- 2023/06/13 00:53 [entrez] PHST- 2023/06/12 00:00 [pmc-release] AID - IWJ14265 [pii] AID - 10.1111/iwj.14265 [doi] PST - ppublish SO - Int Wound J. 2023 Nov;20(9):3717-3723. doi: 10.1111/iwj.14265. Epub 2023 Jun 12. PMID- 37307564 OWN - NLM STAT- MEDLINE DCOM- 20231030 LR - 20231203 IS - 2047-2412 (Electronic) IS - 2047-2404 (Linking) VI - 24 IP - 11 DP - 2023 Oct 27 TI - Absence of infective endocarditis relapse when end-of-treatment fluorodeoxyglucose positron emission tomography/computed tomography is negative. PG - 1480-1488 LID - 10.1093/ehjci/jead138 [doi] AB - AIMS: In non-operated infective endocarditis (IE), relapse may impair the outcome of the disease. The aim of the study was to evaluate the relationship between end-of-treatment (EOT) fluorodeoxyglucose positron emission tomography/computed tomography FDG-PET/CT results and relapse in non-operated IE either on native or prosthetic valve. METHODS AND RESULTS: We included 62 patients who underwent an EOT FDG-PET/CT for non-operated IE performed between 30 and 180 days of antibiotic therapy initiation. Qualitative valve assessment categorized initial and EOT FDG-PET/CT as negative or positive. Quantitative analyses were also conducted. Clinical data from medical charts were collected, including endocarditis team decision for IE diagnosis and relapse. Forty-one (66%) patients were male with a median age of 68 years (57; 80) and 42 (68%) had prosthetic valve IE. End-of-treatment FDG-PET/CT was negative in 29 and positive in 33 patients. The proportion of positive scans decreased significantly compared with initial FDG-PET/CT (53% vs. 77%, respectively, P < 0.0001). All relapses (n = 7, 11%) occurred in patients with a positive EOT FDG-PET/CT with a median delay after EOT FDG-PET/CT of 10 days (0; 45). The relapse rate was significantly lower in negative (0/29) than in positive (7/33) EOT FDG-PET/CT (P = 0.01). CONCLUSION: In this series of 62 patients with non-operated IE who underwent EOT FDG-PET/CT, those with a negative scan (almost half of the study population) did not develop IE relapse after a median follow-up of 10 months. These findings need to be confirmed by prospective and larger studies. CI - (c) The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. FAU - Regis, Claudine AU - Regis C AUID- ORCID: 0000-0002-9333-8072 AD - Nuclear Medicine Department, Hopital Bichat-Claude Bernard, AP-HP, 46 rue Henri-Huchard, Paris 75018, France. AD - Department of Medical Imaging, Institut de cardiologie de Montreal, Universite de Montreal, 5000 rue Belanger, Montreal, Quebec H1T 1C8, Canada. FAU - Thy, Michael AU - Thy M AD - Infectious Disease Department, Hopital Bichat-Claude Bernard, AP-HP, 46 rue Henri-Huchard, Paris 75018, France. AD - Universite Paris Cite, 45 Rue des Saints-Peres, Paris 75006, France. FAU - Mahida, Besma AU - Mahida B AD - Nuclear Medicine Department, Hopital Bichat-Claude Bernard, AP-HP, 46 rue Henri-Huchard, Paris 75018, France. AD - Laboratory for Vascular Translational Science, Inserm U1148, 46 rue Henri-Huchard, Paris 75018, France. FAU - Deconinck, Laurene AU - Deconinck L AD - Infectious Disease Department, Hopital Bichat-Claude Bernard, AP-HP, 46 rue Henri-Huchard, Paris 75018, France. FAU - Tubiana, Sarah AU - Tubiana S AD - Universite Paris Cite, 45 Rue des Saints-Peres, Paris 75006, France. AD - Clinical Investigation Center, Hopital Bichat-Claude Bernard, AP-HP, 46 rue Henri-Huchard, Paris 75018, France. FAU - Iung, Bernard AU - Iung B AD - Universite Paris Cite, 45 Rue des Saints-Peres, Paris 75006, France. AD - Laboratory for Vascular Translational Science, Inserm U1148, 46 rue Henri-Huchard, Paris 75018, France. AD - Cardiology Department, Hopital Bichat-Claude Bernard, AP-HP, 46 rue Henri-Huchard, 75018, 46 rue Henri-Huchard, Paris 75018, France. FAU - Duval, Xavier AU - Duval X AD - Universite Paris Cite, 45 Rue des Saints-Peres, Paris 75006, France. AD - Clinical Investigation Center, Hopital Bichat-Claude Bernard, AP-HP, 46 rue Henri-Huchard, Paris 75018, France. FAU - Rouzet, Francois AU - Rouzet F AD - Nuclear Medicine Department, Hopital Bichat-Claude Bernard, AP-HP, 46 rue Henri-Huchard, Paris 75018, France. AD - Universite Paris Cite, 45 Rue des Saints-Peres, Paris 75006, France. AD - Laboratory for Vascular Translational Science, Inserm U1148, 46 rue Henri-Huchard, Paris 75018, France. LA - eng PT - Journal Article PL - England TA - Eur Heart J Cardiovasc Imaging JT - European heart journal. Cardiovascular Imaging JID - 101573788 RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18) RN - 0 (Radiopharmaceuticals) SB - IM CIN - Eur Heart J Cardiovasc Imaging. 2023 Oct 27;24(11):1489-1490. doi: 10.1093/ehjci/jead175. PMID: 37463273 MH - Humans MH - Male MH - Aged MH - Female MH - Positron Emission Tomography Computed Tomography/methods MH - Fluorodeoxyglucose F18 MH - Prospective Studies MH - Radiopharmaceuticals MH - *Endocarditis, Bacterial MH - *Endocarditis/diagnostic imaging MH - Chronic Disease MH - Recurrence OTO - NOTNLM OT - FDG OT - PET/CT OT - cardiovascular imaging OT - endocarditis COIS- Conflict of interest: None declared. EDAT- 2023/06/12 19:12 MHDA- 2023/10/30 06:46 CRDT- 2023/06/12 16:53 PHST- 2023/02/25 00:00 [received] PHST- 2023/04/19 00:00 [revised] PHST- 2023/05/14 00:00 [accepted] PHST- 2023/10/30 06:46 [medline] PHST- 2023/06/12 19:12 [pubmed] PHST- 2023/06/12 16:53 [entrez] AID - 7194662 [pii] AID - 10.1093/ehjci/jead138 [doi] PST - ppublish SO - Eur Heart J Cardiovasc Imaging. 2023 Oct 27;24(11):1480-1488. doi: 10.1093/ehjci/jead138. PMID- 37306641 OWN - NLM STAT- MEDLINE DCOM- 20230814 LR - 20260304 IS - 1097-685X (Electronic) IS - 0022-5223 (Linking) VI - 166 IP - 3 DP - 2023 Sep TI - The American Association for Thoracic Surgery (AATS) 2023 Expert Consensus Document: Staging and multidisciplinary management of patients with early-stage non-small cell lung cancer. PG - 637-654 LID - S0022-5223(23)00363-X [pii] LID - 10.1016/j.jtcvs.2023.04.039 [doi] AB - Novel targeted therapy and immunotherapy drugs have recently been approved for use in patients with surgically resectable lung cancer. Accurate staging, early molecular testing, and knowledge of recent trials are critical to optimize oncologic outcomes in these patients. CI - Copyright (c) 2023 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved. CN - Expert Consensus Panel FAU - Kidane, Biniam AU - Kidane B AD - University of Manitoba, Winnipeg, Manitoba, Canada. FAU - Bott, Matthew AU - Bott M AD - Memorial Sloan-Kettering Cancer Center, New York, NY. FAU - Spicer, Jonathan AU - Spicer J AD - McGill University, Montreal, Quebec, Canada. FAU - Backhus, Leah AU - Backhus L AD - Stanford University, Palo Alto, Calif. FAU - Chaft, Jamie AU - Chaft J AD - Memorial Sloan-Kettering Cancer Center, New York, NY. FAU - Chudgar, Neel AU - Chudgar N AD - Albert Einstein College of Medicine, Bronx, NY. FAU - Colson, Yolonda AU - Colson Y AD - Massachusetts General Hospital, Boston, Mass. FAU - D'Amico, Thomas A AU - D'Amico TA AD - Duke Cancer Institute, Durham, NC. FAU - David, Elizabeth AU - David E AD - University of Colorado, Denver, Colo. FAU - Lee, Jay AU - Lee J AD - University of California, Los Angeles, Los Angeles, Calif. FAU - Najmeh, Sara AU - Najmeh S AD - McGill University, Montreal, Quebec, Canada. FAU - Sepesi, Boris AU - Sepesi B AD - MD Anderson Cancer Center, Houston, Tex. FAU - Shu, Catherine AU - Shu C AD - Columbia University, New York, NY. FAU - Yang, Jeffrey AU - Yang J AD - Massachusetts General Hospital, Boston, Mass. FAU - Swanson, Scott AU - Swanson S AD - Brigham and Women's Hospital, Boston, Mass. FAU - Stiles, Brendon AU - Stiles B AD - Albert Einstein College of Medicine, Bronx, NY. Electronic address: brstiles@montefiore.org. LA - eng PT - Consensus Statement PT - Journal Article PT - Practice Guideline DEP - 20230610 PL - United States TA - J Thorac Cardiovasc Surg JT - The Journal of thoracic and cardiovascular surgery JID - 0376343 SB - IM MH - Humans MH - United States MH - *Lung Neoplasms/surgery/drug therapy MH - *Carcinoma, Non-Small-Cell Lung/surgery/drug therapy MH - *Thoracic Surgery MH - *Small Cell Lung Carcinoma MH - Neoplasm Staging MH - Neoadjuvant Therapy MH - Immunotherapy OTO - NOTNLM OT - adjuvant OT - clinical staging OT - immunotherapy OT - neoadjuvant OT - non-small cell lung cancer OT - surgery OT - targeted therapy EDAT- 2023/06/12 13:07 MHDA- 2023/08/14 06:43 CRDT- 2023/06/12 10:28 PHST- 2023/03/30 00:00 [received] PHST- 2023/04/27 00:00 [accepted] PHST- 2023/08/14 06:43 [medline] PHST- 2023/06/12 13:07 [pubmed] PHST- 2023/06/12 10:28 [entrez] AID - S0022-5223(23)00363-X [pii] AID - 10.1016/j.jtcvs.2023.04.039 [doi] PST - ppublish SO - J Thorac Cardiovasc Surg. 2023 Sep;166(3):637-654. doi: 10.1016/j.jtcvs.2023.04.039. Epub 2023 Jun 10. PMID- 37305005 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230613 IS - 2284-2594 (Electronic) IS - 2284-2594 (Linking) VI - 10 IP - 6 DP - 2023 TI - Remitting Seronegative Symmetrical Synovitis with Pitting Oedema Following Administration of the Chadox1-S/NCOV-19 Coronavirus Vaccine. PG - 003742 LID - 10.12890/2023_003742 [doi] LID - 003742 AB - INTRODUCTION: We describe a case of remitting seronegative symmetrical synovitis with pitting oedema (RS3PE) syndrome following administration of the ChAdOx1-S/nCoV-19 [recombinant] vaccine, suggesting a possible causal link. CASE DESCRIPTION: A 72-year-old man presented to his general practitioner with swollen, oedematous hands and legs 2 weeks after receiving a coronavirus vaccine. He had raised inflammatory markers but remained systemically well. He was initially presumed to have cellulitis, but his symptoms persisted despite several courses of antibiotics. Deep vein thromboses, cardiac failure, renal failure and hypoalbuminaemia were ruled out. Upon Rheumatology review, he was diagnosed as having RS3PE syndrome with the Covid vaccine suspected of being an immunogenic trigger. Following initiation of steroid therapy, his symptoms improved dramatically, as is characteristic of RS3PE syndrome. DISCUSSION: The pathophysiology of RS3PE is unclear. It is known to have various triggers and associations including infections, certain vaccines and malignancy. This case highlights that a coronavirus vaccine (ChAdOx1-S/nCoV-19 [recombinant] vaccine) is also a possible trigger. Factors that make the diagnosis likely include an acute onset of symptoms including pitting oedema in a typical distribution, age above 50, and unremarkable autoimmune serology. Other learning points from this case include the importance of antibiotic stewardship and the need to explore non-infectious causes of illness when antibiotics do not improve symptoms. CONCLUSION: The ChAdOx1-S/nCoV-19 [recombinant] vaccine is a possible trigger of RS3PE. However, the benefits of vaccines against coronavirus outweigh the risks in the majority of patients. LEARNING POINTS: This case demonstrates a possible link between the ChAdOx1-S/nCoV-19 [recombinant] vaccine and autoimmune conditions such as RS3PE.It is important to consider alternative diagnoses when antibiotic regimes fail to work.A barrier to accurate diagnosis includes an episodic approach, where a patient presents to multiple clinicians acutely rather than having a long-term, continuous relationship with a single multi-disciplinary team, where response to treatment can be monitored. CI - (c) EFIM 2023. FAU - Muhammad, Syed Aun AU - Muhammad SA AD - Southend University Hospital, Mid and South Essex NHS Foundation Trust, Essex, UK. FAU - Coath, Fiona AU - Coath F AD - Southend University Hospital, Mid and South Essex NHS Foundation Trust, Essex, UK. FAU - Jegard, James AU - Jegard J AD - Southend University Hospital, Mid and South Essex NHS Foundation Trust, Essex, UK. LA - eng PT - Journal Article DEP - 20230505 PL - Italy TA - Eur J Case Rep Intern Med JT - European journal of case reports in internal medicine JID - 101648453 PMC - PMC10253250 OTO - NOTNLM OT - ChAdOx1-S/nCoV-19 [recombinant] vaccine OT - RS3PE OT - coronavirus COIS- Conflicts of Interests: The Authors declare that there are no competing interests. EDAT- 2023/06/12 06:42 MHDA- 2023/06/12 06:43 PMCR- 2023/05/05 CRDT- 2023/06/12 04:17 PHST- 2022/12/29 00:00 [received] PHST- 2023/03/08 00:00 [accepted] PHST- 2023/06/12 06:43 [medline] PHST- 2023/06/12 06:42 [pubmed] PHST- 2023/06/12 04:17 [entrez] PHST- 2023/05/05 00:00 [pmc-release] AID - 3742 [pii] AID - 10.12890/2023_003742 [doi] PST - epublish SO - Eur J Case Rep Intern Med. 2023 May 5;10(6):003742. doi: 10.12890/2023_003742. eCollection 2023. PMID- 37302648 OWN - NLM STAT- MEDLINE DCOM- 20231216 LR - 20250422 IS - 1535-6280 (Electronic) IS - 0146-2806 (Print) IS - 0146-2806 (Linking) VI - 48 IP - 10 DP - 2023 Oct TI - Cardiovascular Manifestations of Human Monkeypox Virus: An Updated Review. PG - 101869 LID - S0146-2806(23)00286-4 [pii] LID - 10.1016/j.cpcardiol.2023.101869 [doi] LID - 101869 AB - Cardiovascular manifestations in human monkeypox virus (MPXV) infection has gained increasing recognition as significant complications with both social and clinical implications. Myocarditis, viral pericarditis, heart failure, and arrhythmias can occur, leading to adverse effects on individuals' health and quality of life. Understanding the detailed pathophysiology of these cardiovascular manifestations is essential for improved diagnosis and management. The social implications of these cardiovascular complications are multifaceted, ranging from public health concerns and the impact on individuals' quality of life to psychological distress and social stigma. Clinically, diagnosing, and managing these complications present challenges, requiring a multidisciplinary approach and specialized care. The burden on healthcare resources necessitates preparedness and resource allocation to effectively address these complications. We delve into the pathophysiological mechanisms involved, including viral-induced cardiac damage, immune response, and inflammatory processes. Additionally, we explore the types of cardiovascular manifestations and their clinical presentations. Addressing cardiovascular manifestations' social and clinical implications in MPXV infection requires a comprehensive approach involving healthcare professionals, public health authorities, and communities. By prioritizing research, enhancing diagnosis and treatment strategies, and promoting preventive measures, we can mitigate the impact of these complications, improve patient care, and protect public health. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Maqbool, Khawaja Usama AU - Maqbool KU AD - Department of Medicine, University Hospital Kerry, Tralee, Ireland. FAU - Arsh, Hina AU - Arsh H AD - Department of Medicine, THQ Hospital, Pasrur, Pakistan. FAU - Kumar, Deepak AU - Kumar D AD - Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan. FAU - Veena, Fnu AU - Veena F AD - Department of Medicine, Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan. FAU - Punshi, Ashish Kumar AU - Punshi AK AD - Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan. FAU - Payal, Fnu AU - Payal F AD - Department of Medicine, Shaheed Mohtarma Benazir Bhutto University, Larkana, Pakistan. FAU - Kumar, Sameet AU - Kumar S AD - Department of Medicine, Shaheed Mohtarma Benazir Bhutto University, Larkana, Pakistan. FAU - Kumar, Saroop AU - Kumar S AD - Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan. FAU - Rani, Deepa AU - Rani D AD - Department of Medicine, Shaheed Mohtarma Benazir Bhutto University, Larkana, Pakistan. FAU - Malik, Jahanzeb AU - Malik J AD - Department of Cardiovascular Research, Cardiovascular Analytics Group, Islamabad, Pakistan. Electronic address: heartdoc86@gmail.com. LA - eng PT - Journal Article PT - Review DEP - 20230609 PL - Netherlands TA - Curr Probl Cardiol JT - Current problems in cardiology JID - 7701802 SB - IM CIN - Curr Probl Cardiol. 2024 Feb;49(2):102240. doi: 10.1016/j.cpcardiol.2023.102240. PMID: 38043877 MH - Humans MH - *Monkeypox virus/physiology MH - Quality of Life MH - *Mpox, Monkeypox PMC - PMC10251728 COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2023/06/12 00:42 MHDA- 2023/12/17 09:42 PMCR- 2023/06/09 CRDT- 2023/06/11 19:16 PHST- 2023/06/02 00:00 [received] PHST- 2023/06/04 00:00 [accepted] PHST- 2023/12/17 09:42 [medline] PHST- 2023/06/12 00:42 [pubmed] PHST- 2023/06/11 19:16 [entrez] PHST- 2023/06/09 00:00 [pmc-release] AID - S0146-2806(23)00286-4 [pii] AID - 101869 [pii] AID - 10.1016/j.cpcardiol.2023.101869 [doi] PST - ppublish SO - Curr Probl Cardiol. 2023 Oct;48(10):101869. doi: 10.1016/j.cpcardiol.2023.101869. Epub 2023 Jun 9. PMID- 37302466 OWN - NLM STAT- MEDLINE DCOM- 20240713 LR - 20260327 IS - 1097-685X (Electronic) IS - 0022-5223 (Linking) VI - 168 IP - 2 DP - 2024 Aug TI - The association between preoperative multidisciplinary team care and patient outcome in frail patients undergoing cardiac surgery. PG - 608-616.e5 LID - S0022-5223(23)00462-2 [pii] LID - 10.1016/j.jtcvs.2023.05.037 [doi] AB - OBJECTIVE: To evaluate the influence of preoperative multidisciplinary team (MDT) care on perioperative management and outcomes of frail patients undergoing cardiac surgery. BACKGROUND: Frail patients are at increased risk for complications and poor functional outcome after cardiac surgery. In these patients, preoperative MDT care may improve outcomes. METHODS: Between 2018 and 2021, 1168 patients aged 70 years or older were scheduled for cardiac surgery, of whom 98 (8.4%) frail patients were referred for MDT care. The MDT discussed surgical risk, prehabilitation, and alternative treatment. Outcomes of MDT patients were compared with 183 frail patients (non-MDT group) from a historical study cohort (2015-2017). Inverse probability of treatment weighting was used to minimize bias from nonrandom allocation of MDT versus non-MDT care. Outcomes were severe postoperative complications, total days in hospital after 120 days, disability, and health-related quality of life after 120 days. RESULTS: This study included 281 patients (98 MDT and 183 non-MDT patients). Of the MDT patients, 67 (68%) had open surgery, 21 (21%) underwent minimally invasive procedures, and 10 (10%) received conservative treatment. In the non-MDT group, all patients had open surgery. Fourteen (14%) MDT patients experienced a severe complication versus 42 (23%) non-MDT patients (adjusted relative risk, 0.76; 95% CI, 0.51-0.99). Adjusted total days in hospital after 120 days was 8 days (interquartile range, 3-12 days) versus 11 days (interquartile range, 7-16 days) for MDT and non-MDT patients, respectively (P = .01). There was no difference in disability or health-related quality of life. CONCLUSIONS: Preoperative MDT care for frail patients undergoing cardiac surgery is associated with alterations in surgical management and with a lower risk for severe complications. CI - Copyright (c) 2023 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved. FAU - Smoor, Rosa M AU - Smoor RM AD - Department of Anesthesiology, Intensive Care, and Pain Medicine, St Antonius Hospital, Nieuwegein, The Netherlands; Department of Intensive Care Medicine, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands. FAU - van Dongen, Eric P A AU - van Dongen EPA AD - Department of Anesthesiology, Intensive Care, and Pain Medicine, St Antonius Hospital, Nieuwegein, The Netherlands. FAU - Daeter, Edgar J AU - Daeter EJ AD - Department of Cardiothoracic Surgery, St Antonius Hospital, Nieuwegein, The Netherlands. FAU - Emmelot-Vonk, Marielle H AU - Emmelot-Vonk MH AD - Department of Geriatric Medicine, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands. FAU - Cremer, Olaf L AU - Cremer OL AD - Department of Intensive Care Medicine, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands. FAU - Vernooij, Lisette M AU - Vernooij LM AD - Department of Anesthesiology, Intensive Care, and Pain Medicine, St Antonius Hospital, Nieuwegein, The Netherlands; Department of Intensive Care Medicine, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands. FAU - Noordzij, Peter G AU - Noordzij PG AD - Department of Anesthesiology, Intensive Care, and Pain Medicine, St Antonius Hospital, Nieuwegein, The Netherlands; Department of Intensive Care Medicine, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands. Electronic address: p.noordzij@antoniusziekenhuis.nl. LA - eng PT - Journal Article DEP - 20230610 PL - United States TA - J Thorac Cardiovasc Surg JT - The Journal of thoracic and cardiovascular surgery JID - 0376343 SB - IM MH - Humans MH - Aged MH - Female MH - Male MH - *Patient Care Team MH - *Cardiac Surgical Procedures/adverse effects MH - *Postoperative Complications/epidemiology/therapy/etiology MH - Aged, 80 and over MH - *Frail Elderly MH - *Quality of Life MH - Treatment Outcome MH - *Preoperative Care/methods MH - Frailty/diagnosis/complications MH - Risk Factors MH - Risk Assessment MH - Length of Stay/statistics & numerical data MH - Retrospective Studies MH - Time Factors MH - Functional Status OTO - NOTNLM OT - frailty OT - multidisciplinary team care OT - older patients OT - treatment decision making EDAT- 2023/06/12 00:42 MHDA- 2024/07/14 02:43 CRDT- 2023/06/11 19:13 PHST- 2022/12/30 00:00 [received] PHST- 2023/05/12 00:00 [revised] PHST- 2023/05/30 00:00 [accepted] PHST- 2024/07/14 02:43 [medline] PHST- 2023/06/12 00:42 [pubmed] PHST- 2023/06/11 19:13 [entrez] AID - S0022-5223(23)00462-2 [pii] AID - 10.1016/j.jtcvs.2023.05.037 [doi] PST - ppublish SO - J Thorac Cardiovasc Surg. 2024 Aug;168(2):608-616.e5. doi: 10.1016/j.jtcvs.2023.05.037. Epub 2023 Jun 10. PMID- 31751050 STAT- Publisher CTDT- 20230612 PB - StatPearls Publishing DP - 2023 Jan TI - NPH Insulin. BTI - StatPearls AB - NPH (neutral protamine Hagedorn) insulin is a medication used to treat and manage diabetes mellitus, which is a significant risk factor for coronary artery disease. Most cases are not attributable to any specific etiology. This activity reviews the indications, contraindications, activity, adverse events, and other key elements of NPH insulin therapy in the clinical setting as relates to the essential points needed by members of an interprofessional team managing the care of patients with diabetes mellitus and its related conditions and sequelae. CI - Copyright (c) 2023, StatPearls Publishing LLC. FAU - Saleem, Fatima AU - Saleem F AD - King Edward Medical University FAU - Sharma, Ashish AU - Sharma A AD - Yuma Regional Medical Center LA - eng PT - Study Guide PT - Book Chapter PL - Treasure Island (FL) COIS- Disclosure: Fatima Saleem declares no relevant financial relationships with ineligible companies. Disclosure: Ashish Sharma declares no relevant financial relationships with ineligible companies. EDAT- 2023/06/12 00:00 CRDT- 2023/06/12 00:00 AID - NBK549860 [bookaccession] PMID- 37298070 OWN - NLM STAT- MEDLINE DCOM- 20230612 LR - 20230612 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 24 IP - 11 DP - 2023 May 23 TI - Introducing and Implementing Genetic Assessment in Cardio-Obstetrics Clinical Practice: Clinical and Genetic Workup of Patients with Cardiomyopathy. LID - 10.3390/ijms24119119 [doi] LID - 9119 AB - Cardiovascular disease (CVD) during pregnancy varies significantly worldwide, influenced by factors such as access to healthcare, delayed diagnosis, causes, and risk factors. Our study sought to explore the spectrum of CVD present in pregnant women in the United Arab Emirates to better understand this population's unique needs and challenges. Central to our study is an emphasis on the importance of implementing a multidisciplinary approach that involves the collaboration of obstetricians, cardiologists, geneticists, and other healthcare professionals to ensure that patients receive comprehensive and coordinated care. This approach can also help identify high-risk patients and implement preventive measures to reduce the occurrence of adverse maternal outcomes. Furthermore, increasing awareness among women about the risk of CVD during pregnancy and obtaining detailed family histories can help in the early identification and management of these conditions. Genetic testing and family screening can also aid in identifying inherited CVD that can be passed down through families. To illustrate the significance of such an approach, we provide a comprehensive analysis of five women's cases from our retrospective study of 800 women. The findings from our study emphasize the importance of addressing maternal cardiac health in pregnancy and the need for targeted interventions and improvements in the existing healthcare system to reduce adverse maternal outcomes. FAU - Mansoori, Ghadeera Al AU - Mansoori GA AD - Department of Cardiology, Sheikh Shakhbout Medical City, Abu Dhabi 11001, United Arab Emirates. FAU - Mahmeed, Wael Al AU - Mahmeed WA AUID- ORCID: 0000-0003-0312-9910 AD - Heart, Vascular & Thoracic Institute, Cleveland Clinic, Abu Dhabi 112412, United Arab Emirates. FAU - Wani, Saleema AU - Wani S AD - Department of Obstetrics & Gynecology, Corniche Hospital, Abu Dhabi 3788, United Arab Emirates. FAU - Salih, Bashir Taha AU - Salih BT AD - Department of Obstetrics & Gynecology, Corniche Hospital, Abu Dhabi 3788, United Arab Emirates. FAU - Ansari, Tarek El AU - Ansari TE AUID- ORCID: 0009-0006-9129-2353 AD - Department of Obstetrics & Gynecology, Corniche Hospital, Abu Dhabi 3788, United Arab Emirates. FAU - Farook, Fathima AU - Farook F AD - Department of Obstetrics & Gynecology, Corniche Hospital, Abu Dhabi 3788, United Arab Emirates. FAU - Farooq, Zenab AU - Farooq Z AD - College of Medicine and Health Sciences, Khalifa University, Abu Dhabi 127788, United Arab Emirates. FAU - Khair, Howaida AU - Khair H AD - Department of Obstetrics & Gynecology, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain 15551, United Arab Emirates. FAU - Zareba, Kornelia AU - Zareba K AUID- ORCID: 0000-0002-8262-4380 AD - Department of Obstetrics & Gynecology, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain 15551, United Arab Emirates. FAU - Dhahouri, Nahid Al AU - Dhahouri NA AD - Department of Genetics and Genomics, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain 15551, United Arab Emirates. FAU - Raj, Anjana AU - Raj A AUID- ORCID: 0009-0006-6704-8350 AD - Department of Genetics and Genomics, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain 15551, United Arab Emirates. FAU - Foo, Roger S AU - Foo RS AD - Cardiovascular Research Institute, National University Healthcare Systems, Singapore 117599, Singapore. AD - Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore 138672, Singapore. FAU - Ali, Bassam R AU - Ali BR AUID- ORCID: 0000-0003-1306-6618 AD - Department of Genetics and Genomics, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain 15551, United Arab Emirates. FAU - Jasmi, Fatma Al AU - Jasmi FA AD - Department of Genetics and Genomics, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain 15551, United Arab Emirates. FAU - Akawi, Nadia AU - Akawi N AUID- ORCID: 0000-0001-6311-7028 AD - Department of Genetics and Genomics, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain 15551, United Arab Emirates. AD - Division of Cardiovascular Medicine, University of Oxford, Oxford OX3 9DU, UK. LA - eng GR - # 12M106 and 31M491/United Arab Emirates University/ PT - Journal Article DEP - 20230523 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 SB - IM MH - Humans MH - Pregnancy MH - Female MH - *Obstetrics MH - Retrospective Studies MH - Risk Assessment MH - *Cardiovascular Diseases/diagnosis/genetics MH - *Cardiomyopathies PMC - PMC10252198 OTO - NOTNLM OT - cardio-obstetrics clinic OT - cardiovascular disease OT - genetics OT - inherited cardiomyopathy OT - preconception counselling OT - pregnancy COIS- The authors declare no conflict of interest. EDAT- 2023/06/10 15:14 MHDA- 2023/06/12 06:43 PMCR- 2023/05/23 CRDT- 2023/06/10 01:10 PHST- 2023/03/31 00:00 [received] PHST- 2023/05/09 00:00 [revised] PHST- 2023/05/11 00:00 [accepted] PHST- 2023/06/12 06:43 [medline] PHST- 2023/06/10 15:14 [pubmed] PHST- 2023/06/10 01:10 [entrez] PHST- 2023/05/23 00:00 [pmc-release] AID - ijms24119119 [pii] AID - ijms-24-09119 [pii] AID - 10.3390/ijms24119119 [doi] PST - epublish SO - Int J Mol Sci. 2023 May 23;24(11):9119. doi: 10.3390/ijms24119119. PMID- 37297886 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230612 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 12 IP - 11 DP - 2023 May 26 TI - Benefits of Prehabilitation before Complex Aortic Surgery. LID - 10.3390/jcm12113691 [doi] LID - 3691 AB - The purpose of this narrative review was to detail and discuss the underlying principles and benefits of preoperative interventions addressing risk factors for perioperative adverse events in open aortic surgery (OAS). The term "complex aortic disease" encompasses juxta/pararenal aortic and thoraco-abdominal aneurysms, chronic aortic dissection and occlusive aorto-iliac pathology. Although endovascular surgery has been increasingly favored, OAS remains a durable option, but by necessity involves extensive surgical approaches and aortic cross-clamping and requires a trained multidisciplinary team. The physiological stress of OAS in a fragile and comorbid patient group mandates thoughtful preoperative risk assessment and the implementation of measures dedicated to improving outcomes. Cardiac and pulmonary complications are one of the most frequent adverse events following major OAS and their incidences are correlated to the patient's functional status and previous comorbidities. Prehabilitation should be considered in patients with risk factors for pulmonary complications including advanced age, previous chronic obstructive pulmonary disease, and congestive heart failure with the aid of pulmonary function tests. It should also be combined with other measures to improve postoperative course and be included in the more general concept of enhanced recovery after surgery (ERAS). Although the current level of evidence regarding the effectiveness of ERAS in the setting of OAS remains low, an increasing body of literature has promoted its implementation in other specialties. Consequently, vascular teams should commit to improving the current evidence through studies to make ERAS the standard of care for OAS. FAU - Mesnard, Thomas AU - Mesnard T AD - Service de Chirurgie Vasculaire, Centre de l'Aorte, CHU Lille, 59000 Lille, France. AD - Univ. Lille, INSERM U1008-Advanced Drug Delivery Systems and Biomaterials, 59000 Lille, France. FAU - Dubosq, Maxime AU - Dubosq M AUID- ORCID: 0000-0002-5457-8807 AD - Service de Chirurgie Vasculaire, Centre de l'Aorte, CHU Lille, 59000 Lille, France. FAU - Pruvot, Louis AU - Pruvot L AD - Service de Chirurgie Vasculaire, Centre de l'Aorte, CHU Lille, 59000 Lille, France. FAU - Azzaoui, Richard AU - Azzaoui R AD - Service de Chirurgie Vasculaire, Centre de l'Aorte, CHU Lille, 59000 Lille, France. FAU - Patterson, Benjamin O AU - Patterson BO AD - Department of Vascular Surgery, University Hospital Southampton, Southampton SO16 6YD, UK. FAU - Sobocinski, Jonathan AU - Sobocinski J AUID- ORCID: 0000-0003-2926-9225 AD - Service de Chirurgie Vasculaire, Centre de l'Aorte, CHU Lille, 59000 Lille, France. AD - Univ. Lille, INSERM U1008-Advanced Drug Delivery Systems and Biomaterials, 59000 Lille, France. LA - eng PT - Journal Article PT - Review DEP - 20230526 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC10253497 OTO - NOTNLM OT - enhanced recovery after surgery OT - open aortic repair OT - prehabilitation COIS- J.S. is a consultant for CookMedical and GE healthcare. The others declare no conflict of interest. EDAT- 2023/06/10 15:14 MHDA- 2023/06/10 15:15 PMCR- 2023/05/26 CRDT- 2023/06/10 01:09 PHST- 2023/03/26 00:00 [received] PHST- 2023/05/14 00:00 [revised] PHST- 2023/05/23 00:00 [accepted] PHST- 2023/06/10 15:15 [medline] PHST- 2023/06/10 15:14 [pubmed] PHST- 2023/06/10 01:09 [entrez] PHST- 2023/05/26 00:00 [pmc-release] AID - jcm12113691 [pii] AID - jcm-12-03691 [pii] AID - 10.3390/jcm12113691 [doi] PST - epublish SO - J Clin Med. 2023 May 26;12(11):3691. doi: 10.3390/jcm12113691. PMID- 37296764 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231102 IS - 2075-4418 (Print) IS - 2075-4418 (Electronic) IS - 2075-4418 (Linking) VI - 13 IP - 11 DP - 2023 May 30 TI - The Role of the Cardiac Biomarkers in the Renal Cell Carcinoma Multidisciplinary Management. LID - 10.3390/diagnostics13111912 [doi] LID - 1912 AB - Renal cell carcinoma, an aggressive malignancy, is often incidentally diagnosed. The patient remains asymptomatic to the late stage of the disease, when the local or distant metastases are already present. Surgical treatment remains the choice for these patients, although the plan must adapt to the characteristics of the patients and the extension of the neoplasm. Systemic therapy is sometimes needed. It includes immunotherapy, target therapy, or both, with a high level of toxicity. Cardiac biomarkers have prognosis and monitoring values in this setting. Their role in postoperative identification of myocardial injury and heart failure already have been demonstrated, as well as their importance in preoperative evaluation from the cardiac point of view and the progression of renal cancer. The cardiac biomarkers are also part of the new cardio-oncologic approach to establishing and monitoring systemic therapy. They are complementary tests for assessment of the baseline toxicity risk and tools to guide therapy. The goal must be to continue the treatment as long as possible with the initiation and optimisation of the cardiological treatment. Cardiac atrial biomarkers are reported to have also antitumoral and anti-inflammatory properties. This review aims to present the role of cardiac biomarkers in the multidisciplinary management of renal cell carcinoma patients. FAU - Dragan, Anca AU - Dragan A AUID- ORCID: 0000-0003-2944-6527 AD - Department of Cardiovascular Anaesthesiology and Intensive Care, Prof. C.C. Iliescu Emergency Institute for Cardiovascular Diseases, 258 Fundeni Road, 022328 Bucharest, Romania. FAU - Sinescu, Ioanel AU - Sinescu I AD - Department of Urological Surgery, Dialysis and Kidney Transplantation, Fundeni Clinical Institute, 258 Fundeni Road, 022328 Bucharest, Romania. AD - Department of Uronephrology, Carol Davila University of Medicine and Pharmacy, 8 Eroii Sanitari Blvd, 050474 Bucharest, Romania. LA - eng PT - Journal Article PT - Review DEP - 20230530 PL - Switzerland TA - Diagnostics (Basel) JT - Diagnostics (Basel, Switzerland) JID - 101658402 PMC - PMC10253077 OTO - NOTNLM OT - cardiac biomarkers OT - cardio-oncology OT - global longitudinal strain OT - renal cell carcinoma OT - risk assessment COIS- The authors declare no conflict of interest. EDAT- 2023/06/10 15:14 MHDA- 2023/06/10 15:15 PMCR- 2023/05/30 CRDT- 2023/06/10 01:02 PHST- 2023/04/03 00:00 [received] PHST- 2023/04/27 00:00 [revised] PHST- 2023/05/25 00:00 [accepted] PHST- 2023/06/10 15:15 [medline] PHST- 2023/06/10 15:14 [pubmed] PHST- 2023/06/10 01:02 [entrez] PHST- 2023/05/30 00:00 [pmc-release] AID - diagnostics13111912 [pii] AID - diagnostics-13-01912 [pii] AID - 10.3390/diagnostics13111912 [doi] PST - epublish SO - Diagnostics (Basel). 2023 May 30;13(11):1912. doi: 10.3390/diagnostics13111912. PMID- 37296026 OWN - NLM STAT- MEDLINE DCOM- 20230731 LR - 20230731 IS - 1532-8422 (Electronic) IS - 1053-0770 (Linking) VI - 37 IP - 9 DP - 2023 Sep TI - Quelling the Storm: A Review of the Management of Electrical Storm. PG - 1776-1784 LID - S1053-0770(23)00338-5 [pii] LID - 10.1053/j.jvca.2023.05.029 [doi] AB - Heightened sympathetic input to the myocardium potentiates cardiac electrical instability and may herald an electrical storm. An electrical storm is characterized by 3 or more episodes of ventricular tachycardia, ventricular fibrillation, or appropriate internal cardiac defibrillator shocks within 24 hours. Management of electrical storms is resource-intensive and inevitably requires careful coordination between multiple subspecialties. Anesthesiologists have an important role in acute, subacute, and long-term management. Identifying the phase of an electrical storm and understanding the characteristics of each morphology may help the anesthesiologist anticipate the management approach. In the acute phase, management of an electrical storm is aimed at providing advanced cardiac life support and identifying reversible causes. After initial stabilization, subacute management focuses on dampening the sympathetic surge with sedation, thoracic epidural, or stellate ganglion blockade. Definitive long-term management with surgical sympathectomy or catheter ablation also may be warranted. Our objective is to provide an overview of electrical storms and the anesthesiologist's role in management. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - McCabe, Melissa D AU - McCabe MD AD - Department of Anesthesiology, Loma Linda University School of Medicine, Loma Linda, California. Electronic address: mmccabe@llu.edu. FAU - Cervantes, Richard AU - Cervantes R AD - Department of Anesthesiology, Loma Linda University School of Medicine, Loma Linda, California. FAU - Kewcharoen, Jakrin AU - Kewcharoen J AD - Cardiac Arrhythmia Service, Loma Linda University School of Medicine, Loma Linda, California. FAU - Sran, Jasmine AU - Sran J AD - Department of Anesthesiology, Loma Linda University School of Medicine, Loma Linda, California. FAU - Garg, Jalaj AU - Garg J AD - Cardiac Arrhythmia Service, Loma Linda University School of Medicine, Loma Linda, California. LA - eng PT - Journal Article PT - Review DEP - 20230521 PL - United States TA - J Cardiothorac Vasc Anesth JT - Journal of cardiothoracic and vascular anesthesia JID - 9110208 SB - IM MH - Humans MH - Ventricular Fibrillation/etiology MH - Arrhythmias, Cardiac MH - *Tachycardia, Ventricular/surgery MH - *Defibrillators, Implantable/adverse effects MH - Heart MH - *Catheter Ablation/adverse effects MH - Treatment Outcome OTO - NOTNLM OT - catheter ablation OT - electrical storm OT - multidisciplinary approach OT - sympathectomy OT - ventricular arrhythmia OT - ventricular tachycardia COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2023/06/10 15:14 MHDA- 2023/07/31 06:42 CRDT- 2023/06/09 21:58 PHST- 2023/04/12 00:00 [received] PHST- 2023/05/17 00:00 [accepted] PHST- 2023/07/31 06:42 [medline] PHST- 2023/06/10 15:14 [pubmed] PHST- 2023/06/09 21:58 [entrez] AID - S1053-0770(23)00338-5 [pii] AID - 10.1053/j.jvca.2023.05.029 [doi] PST - ppublish SO - J Cardiothorac Vasc Anesth. 2023 Sep;37(9):1776-1784. doi: 10.1053/j.jvca.2023.05.029. Epub 2023 May 21. PMID- 37292224 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230611 IS - 1985-207X (Print) IS - 1985-2274 (Electronic) IS - 1985-2274 (Linking) VI - 18 DP - 2023 TI - Practical guide in using insulin degludec/insulin aspart: A multidisciplinary approach in Malaysia. PG - 31 LID - 10.51866/cpg.255 [doi] AB - Insulin degludec/insulin aspart (IDegAsp) co-formulation provides both basal and mealtime glycaemic control in a single injection. The glucose level-lowering efficacy of IDegAsp is reported to be superior or non-inferior to that of the currently available insulin therapies with a lower rate of overall hypoglycaemia and nocturnal hypoglycaemia. An expert panel from Malaysia aims to provide insights into the utilisation of IDegAsp across a broad range of patients with type 2 diabetes mellitus (i.e. treatment-naive or insulin-naive patients or patients receiving treatment intensification from basal-only regimens, premixed insulin and basal-bolus insulin therapy). IDegAsp can be initiated as once-daily dosing for the main meal with the largest carbohydrate content with weekly dose adjustments based on patient response. A lower starting dose is recommended for patients with cardiac or renal comorbidities. Dose intensification with IDegAsp may warrant splitting into twice-daily dosing. IDegAsp twice-daily dosing does not need to be split at a 50:50 ratio but should be adjusted to match the carbohydrate content of meals. The treatment of patients choosing to fast during Ramadan should be switched to IDegAsp early before Ramadan, as a longer duration of titration leads to better glycated haemoglobin level reductions. The pre-Ramadan breakfast/lunch insulin dose can be reduced by 30%-50% and taken during sahur, while the preRamadan dinner dose can be taken without any change during iftar. Education on the main meal concept is important, as carbohydrates are present in almost all meals. Patients should not have a misconception of consuming more carbohydrates while taking IDegAsp. CI - (c) Academy of Family Physicians of Malaysia. FAU - Chan, Siew Pheng AU - Chan SP AD - MBBS (Mal) FRCP (Edin), AM (Mal), Consultant Endocrinologist, University of Malaya, Jln Profesor Diraja Ungku Aziz, Kuala Lumpur, Selangor, Malaysia. Email: spchan88@hotmail.com. FAU - Mumtaz, Malik AU - Mumtaz M AD - MBBS (USM), MRCP (UK), FRCP (Edinburgh, Glasgow), Island Hospital Penang, 308, Jalan Macalister, George Town, Pulau, Pinang, Malaysia. FAU - Ratnasingam, Jeyakantha AU - Ratnasingam J AD - MMed (UM), Fellowship in Endocrinology (Australia), MD (UKM), University of Malaya, Jln Profesor, Diraja Ungku Aziz, Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia. FAU - Tan, Alexander Tong Boon AU - Tan ATB AD - MB ChB (Liverpool), MRCP (UK), FRCP (Edinburgh), Sunway Medical Centre, 5, Jalan Lagoon Selatan, Bandar Sunway, Petaling Jaya, Selangor, Malaysia. FAU - Lim, Siang Chin AU - Lim SC AD - DM (UKM), MRCP (UK), Fellowship in Endocrinology (Malaysia), Mahkota Medical Centre, No 3, Mahkota Melaka, Jln Merdeka, Melaka, Malaysia. FAU - Rosman, Azhari AU - Rosman A AD - MD (UM, Mal), MRCP (UK), FNHAM (MAl), FAPSIC (Asia Pacific), FAsCC (ASEAN), FESC (EU), FACC (US), Institut Jantung Negara,145, Jln Tun Razak, Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia. FAU - Chee, Kok Han AU - Chee KH AD - NHAM, MMed (Mal), MBBS (UM), University of Malaya, Jln Profesor, Diraja Ungku Aziz, Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia. FAU - Lim, Soo Kun AU - Lim SK AD - AM (MAL), FRCP(Edin), MBBS(MAL), MRCP(UK), University of Malaya, Jln Profesor, Diraja Ungku Aziz, Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia. FAU - Yew, Shiong Shiong AU - Yew SS AD - MBBS (UM), MRCP (UK), Mahkota Medical Centre, No 3, Mahkota Melaka, Jln Merdeka, Melaka, Malaysia. FAU - Mohd Yusof, Barakatun-Nisak AU - Mohd Yusof BN AD - BS (Diabetics; UKM), Ph.D (UKM), Universiti Putra Malaysia, Jalan, Universiti 1 Serdang, Seri Kembangan, Selangor, Malaysia. FAU - Lau, Bik Kui AU - Lau BK AD - MD (USM), MRCP (UK), KPJ Kuching Specialist Hospital, Lot 18807, Block 11 Muara Tebas, Land District, Jln Stutong, Kuching, Sarawak, Malaysia. FAU - Kassim, Saiful Bahari AU - Kassim SB AD - MB BCh BAO (NUIG), PGCMedEd (QUB), MRCP (U.K.), FRCP (Lon), FRCP (Glasg) FRCPI (Ire) FRCP (Edin), CCST (JRCPTB U.K. Endocrinology & Diabetes; Internal Medicine), Gleneagles Kuala Lumpur, Jalan Ampang, Kampung Berembang, Kuala Lumpur, Wilayah Persekutuan, Kuala Lumpur, Malaysia. FAU - Mohamed, Mafauzy AU - Mohamed M AD - MBBS (Adelaide), MRCP (UK), MMedSci (University of Sheffield), FRCP (Edinburgh), Universiti Sains Malaysia Hospital, Jalan Raja Perempuan Zainab II, Kubang Kerian, Kota Bharu, Kelantan, Malaysia. LA - eng PT - Journal Article DEP - 20230504 PL - Malaysia TA - Malays Fam Physician JT - Malaysian family physician : the official journal of the Academy of Family Physicians of Malaysia JID - 101466855 PMC - PMC10246713 OTO - NOTNLM OT - Glucose OT - Hypoglycaemia OT - Insulin aspart OT - Type 2 diabetes mellitus OT - insulin degludec COIS- The authors declare that they have no conflicts of interest related to the publication of this article. EDAT- 2023/06/09 06:41 MHDA- 2023/06/09 06:42 PMCR- 2023/05/04 CRDT- 2023/06/09 04:19 PHST- 2023/06/09 06:42 [medline] PHST- 2023/06/09 06:41 [pubmed] PHST- 2023/06/09 04:19 [entrez] PHST- 2023/05/04 00:00 [pmc-release] AID - 10.51866/cpg.255 [doi] PST - epublish SO - Malays Fam Physician. 2023 May 4;18:31. doi: 10.51866/cpg.255. eCollection 2023. PMID- 37291962 OWN - NLM STAT- MEDLINE DCOM- 20240405 LR - 20260921 IS - 1744-4136 (Electronic) IS - 0929-7049 (Linking) VI - 30 IP - 3 DP - 2024 Apr TI - The multifaceted role of neuropsychology in pediatric solid organ transplant: preliminary guidelines and strategies for clinical practice. PG - 503-537 LID - 10.1080/09297049.2023.2221759 [doi] AB - The incidence of pediatric solid organ transplantation (SOT) has increased in recent decades due to medical and surgical advances as well as improvements in organ procurement. Survival rates for pediatric kidney, liver, and heart transplantation are above 85% but patients continue to experience complex healthcare needs over their lifetime. Long-term developmental and neuropsychological sequelae are becoming increasingly recognized in this population, although preliminary work is limited and deserves further attention. Neuropsychological weaknesses are often present prior to transplantation and may be related to underlying congenital conditions as well as downstream impact of the indicating organ dysfunction on the central nervous system. Neuropsychological difficulties pose risk for functional complications, including disruption to adaptive skill development, social-emotional functioning, quality of life, and transition to adulthood. The impact of cognitive dysfunction on health management activities (e.g., medication adherence, medical decision-making) is also an important consideration given these patients' lifelong medical needs. The primary aim of this paper is to provide preliminary guidelines and clinical strategies for assessment of neuropsychological outcomes across SOT populations for pediatric neuropsychologists and the multidisciplinary medical team, including detailing unique and shared etiologies and risk factors for impairment across organ types, and functional implications. Recommendations for clinical neuropsychological monitoring as well as multidisciplinary collaboration within pediatric SOT teams are also provided. FAU - Turner, Elise M AU - Turner EM AUID- ORCID: 0000-0003-4461-8235 AD - Department of Pediatrics, Section of Neurology, Children's Hospital Colorado/University of Colorado School of Medicine, Aurora, CO, USA. FAU - Cassidy, Adam R AU - Cassidy AR AD - Departments of Psychiatry & Psychology and Pediatric & Adolescent Medicine, Mayo Clinic, Rochester, MN, USA. AD - Department of Psychiatry and Behavioral Sciences, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA. FAU - Rea, Kelly E AU - Rea KE AD - Division of Pediatric Psychology, Department of Pediatrics, C. S. Mott Children's Hospital, Michigan Medicine, Ann Arbor, MI, USA. FAU - Smith-Paine, Julia M AU - Smith-Paine JM AD - Division of Developmental-Behavioral Pediatrics & Psychology, Department of Pediatrics, Rainbow Babies & Children's Hospital, University Hospitals Cleveland Medical Center, Cleveland, OH, USA. FAU - Wolfe, Kelly R AU - Wolfe KR AD - Department of Pediatrics, Section of Neurology, Children's Hospital Colorado/University of Colorado School of Medicine, Aurora, CO, USA. LA - eng PT - Journal Article DEP - 20230608 PL - England TA - Child Neuropsychol JT - Child neuropsychology : a journal on normal and abnormal development in childhood and adolescence JID - 9512515 SB - IM MH - Child MH - Humans MH - Neuropsychology MH - Quality of Life/psychology MH - *Organ Transplantation/adverse effects/psychology MH - *Heart Transplantation MH - Social Adjustment OTO - NOTNLM OT - Pediatric solid organ transplantation OT - heart transplantation OT - kidney transplantation OT - liver transplantation OT - pediatric neuropsychology EDAT- 2023/06/09 06:41 MHDA- 2024/04/05 06:44 CRDT- 2023/06/09 04:03 PHST- 2024/04/05 06:44 [medline] PHST- 2023/06/09 06:41 [pubmed] PHST- 2023/06/09 04:03 [entrez] AID - 10.1080/09297049.2023.2221759 [doi] PST - ppublish SO - Child Neuropsychol. 2024 Apr;30(3):503-537. doi: 10.1080/09297049.2023.2221759. Epub 2023 Jun 8. PMID- 37290264 OWN - NLM STAT- MEDLINE DCOM- 20230711 LR - 20230718 IS - 1532-1932 (Electronic) IS - 1521-6934 (Linking) VI - 89 DP - 2023 Jul TI - Peri-operative anaesthetic management of women with obesity. PG - 102335 LID - S1521-6934(23)00035-4 [pii] LID - 10.1016/j.bpobgyn.2023.102335 [doi] AB - Obesity in women is prevalent and growing at an alarming pace worldwide, resulting in significant healthcare and socioeconomic consequences. Obesity is a multisystemic disease that is associated with numerous comorbidities, particularly sleep-disordered breathing, hypertension, coronary artery disease, pulmonary hypertension, thromboembolism, and diabetes mellitus. Additionally, obesity poses several peri-operative challenges including difficulty with airway management and mechanical ventilation, challenges with intravenous access or regional blocks, the need for modified anaesthetic drug dosing, the requirement for correctly sized and rated equipment, and appropriate post-operative monitoring. Therefore, early multidisciplinary planning is crucial to identify and address important peri-operative and clinical issues. Parturients with obesity are especially at high risk due to the additional physiological changes and obstetric comorbidities associated with obesity. Antenatal anaesthetic consultation along with close communication and collaboration within the multidisciplinary team are important to improve maternal and neonatal safety. CI - Copyright (c) 2023 Elsevier Ltd. All rights reserved. FAU - Tan, Hon Sen AU - Tan HS AD - Department of Women's Anaesthesia, KK Women's and Children's Hospital, 100 Bukit Timah Road, 229899, Singapore. FAU - Habib, Ashraf S AU - Habib AS AD - Department of Anesthesiology, Duke University Medical Center, Box 3094, Durham, NC, 27710, USA. Electronic address: https://twitter.com/ashrafhabib5. LA - eng PT - Journal Article PT - Review DEP - 20230408 PL - Netherlands TA - Best Pract Res Clin Obstet Gynaecol JT - Best practice & research. Clinical obstetrics & gynaecology JID - 101121582 RN - 0 (Anesthetics) SB - IM MH - Infant, Newborn MH - Pregnancy MH - Female MH - Humans MH - *Anesthesia, Obstetrical/methods MH - Obesity/complications MH - *Pregnancy Complications MH - *Anesthetics/therapeutic use MH - Referral and Consultation OTO - NOTNLM OT - Analgesia OT - Caesarean delivery OT - Labour OT - Obesity OT - Peri-partum OT - Pregnant COIS- Declaration of competing interest None. EDAT- 2023/06/09 01:09 MHDA- 2023/07/11 06:41 CRDT- 2023/06/08 18:05 PHST- 2023/01/22 00:00 [received] PHST- 2023/02/27 00:00 [revised] PHST- 2023/03/31 00:00 [accepted] PHST- 2023/07/11 06:41 [medline] PHST- 2023/06/09 01:09 [pubmed] PHST- 2023/06/08 18:05 [entrez] AID - S1521-6934(23)00035-4 [pii] AID - 10.1016/j.bpobgyn.2023.102335 [doi] PST - ppublish SO - Best Pract Res Clin Obstet Gynaecol. 2023 Jul;89:102335. doi: 10.1016/j.bpobgyn.2023.102335. Epub 2023 Apr 8. PMID- 37286186 OWN - NLM STAT- MEDLINE DCOM- 20240906 LR - 20250715 IS - 1439-1902 (Electronic) IS - 0171-6425 (Print) IS - 0171-6425 (Linking) VI - 72 IP - 6 DP - 2024 Sep TI - Follow-Up and Outcome after Coronary Bypass Surgery Preceded by Coronary Stent Implantation. PG - 423-434 LID - 10.1055/a-2107-0481 [doi] AB - BACKGROUND: Guidelines on myocardial revascularization define recommendations for percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) surgery. Only little information exists on long-term follow-up and quality of life (QoL) after CABG preceded by PCI. The aim of our study was to evaluate the impact of prior PCI on outcome and QoL in patients with stable coronary artery disease who underwent CABG. METHODS: In our retrospective study, CABG patients were divided in: CABG preceded by PCI: PCI-first (PCF), and CABG-only (CO) groups. The PCF group was further divided in guideline-conform (GCO) and guideline nonconform (GNC) subgroups, according to the SYNTAX score (2014 European Society of Cardiology [ESC]/European Association for Cardio-Thoracic Surgery [EACTS] guidelines). Thirty days mortality, major adverse cardiac events, and QoL using the European Quality-of-Life-5 Dimensions were evaluated. RESULTS: A total of 997 patients were analyzed, of which 784 underwent CABG without (CO), and 213 individuals with prior PCI (PCF). The latter group consisted of 67 patients being treated in accordance (GCO), and 24 in discordance (GNC) to the 2014 ESC/EACTS guidelines. Reinfarction (PCF: 3.8% vs. CO: 1.0%; p = 0.024), re-angiography (PCF: 17.6% vs. CO: 9.0%; p = 0.004), and re-PCI (PCF: 10.4% vs. CO: 3.0%; p < 0.001) were observed more frequently in PCF patients. Also, patients reported better health status in the CO compared to PCF group (CO: 72.48 +/- 19.31 vs. PCF: 68.20 +/- 17.86; p = 0.01). Patients from the guideline nonconform subgroup reported poorer health status compared to the guideline-conform group (GNC: 64.23 +/- 14.56 vs. GCO: 73.42 +/- 17.66; p = 0.041) and were more likely to require re-PCI (GNC: 18.8% vs. GCO: 2.4%; p = 0.03). Also, GNC patients were more likely to have left main stenosis (GCO: 19.7% vs. GNC: 37.5%; p < 0.001) and showed higher preinterventional SYNTAX score (GCO: 18.63 +/- 9.81 vs. GNC: 26.67 +/- 5.07; p < 0.001). CONCLUSION: PCI preceding CABG is associated with poorer outcomes such as reinfarction, re-angiography, and re-PCI, but also worse health status and higher rehospitalization. Nevertheless, results were better when PCI was guideline-conformant. This data should impact the Heart Team decision. CI - The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/). FAU - Hamiko, Marwan AU - Hamiko M AD - Department of Cardiac Surgery, Universitatsklinikum Bonn, Bonn, Nordrhein-Westfalen, Germany. FAU - Konrad, Nicole AU - Konrad N AD - Department of Cardiac Surgery, Universitatsklinikum Bonn, Bonn, Nordrhein-Westfalen, Germany. FAU - Lagemann, Doreen AU - Lagemann D AD - Department of Cardiac Surgery, Universitatsklinikum Bonn, Bonn, Nordrhein-Westfalen, Germany. FAU - Gestrich, Christopher AU - Gestrich C AD - Department of Cardiac Surgery, Universitatsklinikum Bonn, Bonn, Nordrhein-Westfalen, Germany. FAU - Masseli, Franz AU - Masseli F AD - Department of Cardiovascular Surgery, Universitatsmedizin der Johannes Gutenberg-Universitat Mainz, Mainz, Rheinland-Pfalz, Germany. FAU - Oezkur, Mehmet AU - Oezkur M AD - Department of Cardiovascular Surgery, Universitatsmedizin der Johannes Gutenberg-Universitat Mainz, Mainz, Rheinland-Pfalz, Germany. FAU - Velten, Markus AU - Velten M AD - Department of Anesthesiology and Intensive Care Medicine, Universitatsklinikum Bonn, Bonn, Nordrhein-Westfalen, Germany. FAU - Treede, Hendrik AU - Treede H AD - Department of Cardiovascular Surgery, Universitatsmedizin der Johannes Gutenberg-Universitat Mainz, Mainz, Rheinland-Pfalz, Germany. FAU - Duerr, Georg Daniel AU - Duerr GD AUID- ORCID: 0000-0002-0310-6236 AD - Department of Cardiovascular Surgery, Universitatsmedizin der Johannes Gutenberg-Universitat Mainz, Mainz, Rheinland-Pfalz, Germany. LA - eng PT - Comparative Study PT - Journal Article DEP - 20230607 PL - Germany TA - Thorac Cardiovasc Surg JT - The Thoracic and cardiovascular surgeon JID - 7903387 SB - IM MH - Humans MH - *Coronary Artery Bypass/adverse effects/mortality MH - *Quality of Life MH - Male MH - Female MH - Retrospective Studies MH - *Coronary Artery Disease/mortality/diagnostic imaging/surgery/therapy MH - Treatment Outcome MH - Aged MH - Middle Aged MH - Time Factors MH - *Percutaneous Coronary Intervention/adverse effects/mortality MH - *Stents MH - Risk Factors MH - Practice Guidelines as Topic MH - Guideline Adherence MH - Recurrence MH - Risk Assessment PMC - PMC11379534 COIS- None declared. EDAT- 2023/06/08 01:08 MHDA- 2024/09/07 14:42 PMCR- 2023/07/01 CRDT- 2023/06/07 19:33 PHST- 2024/09/07 14:42 [medline] PHST- 2023/06/08 01:08 [pubmed] PHST- 2023/06/07 19:33 [entrez] PHST- 2023/07/01 00:00 [pmc-release] AID - tcs-02-2023-6826-OC [pii] AID - 10.1055/a-2107-0481 [doi] PST - ppublish SO - Thorac Cardiovasc Surg. 2024 Sep;72(6):423-434. doi: 10.1055/a-2107-0481. Epub 2023 Jun 7. PMID- 37279732 OWN - NLM STAT- MEDLINE DCOM- 20230724 LR - 20230807 IS - 1873-734X (Electronic) IS - 1010-7940 (Linking) VI - 64 IP - 1 DP - 2023 Jul 3 TI - The impact of surgical learning curve on short-term outcomes after bilateral lung transplantation: results from a multidisciplinary surgical team. LID - ezad227 [pii] LID - 10.1093/ejcts/ezad227 [doi] AB - OBJECTIVES: The aim of this study was to examine the impact of surgical learning curve on short-term clinical outcomes of patients after bilateral lung transplantation (LTx) performed by a surgical multidisciplinary team (MDT). METHODS: Forty-two patients underwent double LTx from December 2016 to October 2021. All procedures were performed by a surgical MDT in a newly established LTx program. The time required for bronchial, left atrial cuff and pulmonary artery anastomoses was the main end point to assess surgical proficiency. The associations between the surgeon's experience and procedural duration were examined by linear regression analysis. We employed the simple moving average technique to generate learning curves and evaluated short-term outcomes before and after achieving surgical proficiency. RESULTS: Both total operating time and total anastomosis time were inversely associated with the surgeon's experience. On analysing the learning curve for bronchial, left atrial cuff and pulmonary artery anastomoses using moving averages, the inflection points occurred at 20, 15 and 10 cases, respectively. To assess the learning curve effect, the study cohort was divided into early (cases 1-20) and late (cases 21-42) groups. Short-term outcomes-including intensive care unit stay, in-hospital stay and severe complications-were significantly more favourable in the late group. Furthermore, there was a notable tendency for patients in the late group to experience a decreased duration of mechanical ventilation along with reduced instances of grade 3 primary graft dysfunction. CONCLUSIONS: A surgical MDT can perform double LTx safely after 20 procedures. CI - (c) The Author(s) 2023. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved. FAU - Chou, Pin-Li AU - Chou PL AUID- ORCID: 0000-0002-1344-1986 AD - Division of Thoracic Surgery, Chang Gung Memorial Hospital, Taoyuan, Taiwan. FAU - Liu, Kuo-Sheng AU - Liu KS AD - Division of Thoracic Surgery, Chang Gung Memorial Hospital, Taoyuan, Taiwan. FAU - Chao, Yin-Kai AU - Chao YK AD - Division of Thoracic Surgery, Chang Gung Memorial Hospital, Taoyuan, Taiwan. FAU - Wen, Yu-Wen AU - Wen YW AD - Clinical Informatics and Medical Statistics Research Center, Chang Gung University, Chang Gung Memorial Hospital, Taoyuan, Taiwan. FAU - Liu, Yun-Hen AU - Liu YH AD - Division of Thoracic Surgery, Chang Gung Memorial Hospital, Taoyuan, Taiwan. FAU - Hsieh, Ming-Ju AU - Hsieh MJ AD - Division of Thoracic Surgery, Chang Gung Memorial Hospital, Taoyuan, Taiwan. FAU - Chiu, Chien-Hung AU - Chiu CH AD - Division of Thoracic Surgery, Chang Gung Memorial Hospital, Taoyuan, Taiwan. FAU - Fang, Hsin-Yueh AU - Fang HY AD - Division of Thoracic Surgery, Chang Gung Memorial Hospital, Taoyuan, Taiwan. FAU - Cheng, Chia-Hui AU - Cheng CH AD - Transplantation Program, Chang Gung Memorial Hospital, Taoyuan, Taiwan. FAU - Hu, Han-Chung AU - Hu HC AD - Department of Chest Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan. FAU - Chen, Wei-Hsun AU - Chen WH AD - Division of Thoracic Surgery, Chang Gung Memorial Hospital, Taoyuan, Taiwan. LA - eng PT - Journal Article PL - Germany TA - Eur J Cardiothorac Surg JT - European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery JID - 8804069 SB - IM CIN - Eur J Cardiothorac Surg. 2023 Jul 3;64(1):ezad258. doi: 10.1093/ejcts/ezad258. PMID: 37432418 MH - Humans MH - Learning Curve MH - *Atrial Fibrillation MH - *Lung Transplantation MH - Bronchi MH - Anastomosis, Surgical/methods MH - Retrospective Studies OTO - NOTNLM OT - Learning curve OT - Lung transplantation OT - Multidisciplinary team EDAT- 2023/06/07 01:07 MHDA- 2023/07/24 06:42 CRDT- 2023/06/06 18:33 PHST- 2022/09/22 00:00 [received] PHST- 2023/05/09 00:00 [revised] PHST- 2023/06/03 00:00 [accepted] PHST- 2023/07/24 06:42 [medline] PHST- 2023/06/07 01:07 [pubmed] PHST- 2023/06/06 18:33 [entrez] AID - 7190372 [pii] AID - 10.1093/ejcts/ezad227 [doi] PST - ppublish SO - Eur J Cardiothorac Surg. 2023 Jul 3;64(1):ezad227. doi: 10.1093/ejcts/ezad227. PMID- 37277709 OWN - NLM STAT- MEDLINE DCOM- 20230607 LR - 20231102 IS - 1471-2318 (Electronic) IS - 1471-2318 (Linking) VI - 23 IP - 1 DP - 2023 Jun 5 TI - Comprehensive end-of-life care practices for older patients with heart failure provided by specialized nurses: a qualitative study. PG - 350 LID - 10.1186/s12877-023-04050-6 [doi] LID - 350 AB - BACKGROUND: The context of end-of-life care for older heart failure patients with a complex clinical course provided by certified nurse specialists in gerontology (GCNSs) and Certified nurses in chronic heart failure (CNCHFs) is unclear; therefore, this study aims to describe comprehensive nursing practice for older patients with heart failure at their end of life. METHODS: This study adopts a qualitative descriptive design using content analysis. Five GCNSs, and five CNCHFs were interviewed using a web app from January to March 2022. RESULTS: Thirteen categories of nursing practices for older patients with heart failure were generated: (1) Provide thorough acute care by a multidisciplinary team to alleviate dyspnea, (2) Assess psychiatric symptoms and use a suitable environment to perform treatment, (3) Explain the progression of heart failure with the doctor, (4) Build a trusting relationship with the patient and family and implement advance care planning (ACP) early during the patient's recovery, (5) Involve multiple professions to help patients to achieve their desired life, (6) Perform ACP always in collaboration with multiple professionals, (7) Provide lifestyle guidance according to patients' feelings so that they can continue living at home after discharge from the hospital, (8) Provide palliative and acute care in parallel with multiple professions, (9) Achieve end-of-life care at home through multidisciplinary cooperation, (10) Provide basic nursing care to the patient and family until the moment of death, (11) Provide concurrent acute and palliative care as well as psychological support to alleviate physical and mental symptoms, (12) Share the patient's prognosis and future wishes with multiple professionals, and (13) Engage in ACP from early stages, through several conversations with patients and their families. CONCLUSIONS: Specialized nurses provide acute care, palliative care, and psychological support to alleviate physical and mental symptoms throughout the different stages of chronic heart failure. In addition to nursing care by specialized nurses at each stage shown in this study, it is important to initiate ACP early in the end-of-life stage and to provide care for patients with multiple professionals. CI - (c) 2023. The Author(s). FAU - Doi, Mana AU - Doi M AD - Department of Gerontological Nursing, Nursing Course, School of Medicine, Yokohama City University, 3-9 Fukuura Kanazawa-Ku, Yokohama, Kanagawa, 236-0004, Japan. m-doi@thcu.ac.jp. AD - Tokyo Healthcare University, Chiba Faculty of Nursing, 1-1042-2 Kaijincho-Nishi, Funabashi, Chiba, 273-8710, Japan. m-doi@thcu.ac.jp. FAU - Maruyama, Yukie AU - Maruyama Y AD - Department of Gerontological Nursing, Nursing Course, School of Medicine, Yokohama City University, 3-9 Fukuura Kanazawa-Ku, Yokohama, Kanagawa, 236-0004, Japan. FAU - Kaneda, Akiko AU - Kaneda A AD - Department of Gerontological Nursing, Nursing Course, School of Medicine, Yokohama City University, 3-9 Fukuura Kanazawa-Ku, Yokohama, Kanagawa, 236-0004, Japan. FAU - Minamizaki, Maya AU - Minamizaki M AD - Department of Gerontological Nursing, Nursing Course, School of Medicine, Yokohama City University, 3-9 Fukuura Kanazawa-Ku, Yokohama, Kanagawa, 236-0004, Japan. FAU - Fukada, Masami AU - Fukada M AD - Department of Gerontological Nursing, Nursing Course, School of Medicine, Yokohama City University, 3-9 Fukuura Kanazawa-Ku, Yokohama, Kanagawa, 236-0004, Japan. FAU - Kanoya, Yuka AU - Kanoya Y AD - Department of Gerontological Nursing, Nursing Course, School of Medicine, Yokohama City University, 3-9 Fukuura Kanazawa-Ku, Yokohama, Kanagawa, 236-0004, Japan. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230605 PL - England TA - BMC Geriatr JT - BMC geriatrics JID - 100968548 SB - IM MH - Humans MH - *Terminal Care/psychology MH - Palliative Care MH - *Advance Care Planning MH - Qualitative Research MH - *Heart Failure/diagnosis/therapy MH - *Nurses PMC - PMC10240706 OTO - NOTNLM OT - End-of-life care OT - Heart failure OT - Nurse specialists OT - Older adults OT - Palliative care OT - Qualitative research COIS- The authors declare no competing interests. EDAT- 2023/06/06 01:11 MHDA- 2023/06/07 06:42 PMCR- 2023/06/05 CRDT- 2023/06/05 23:34 PHST- 2023/01/25 00:00 [received] PHST- 2023/05/18 00:00 [accepted] PHST- 2023/06/07 06:42 [medline] PHST- 2023/06/06 01:11 [pubmed] PHST- 2023/06/05 23:34 [entrez] PHST- 2023/06/05 00:00 [pmc-release] AID - 10.1186/s12877-023-04050-6 [pii] AID - 4050 [pii] AID - 10.1186/s12877-023-04050-6 [doi] PST - epublish SO - BMC Geriatr. 2023 Jun 5;23(1):350. doi: 10.1186/s12877-023-04050-6. PMID- 37273745 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230606 IS - 2474-8714 (Electronic) IS - 2474-8706 (Print) IS - 2474-8706 (Linking) VI - 6 IP - 2 DP - 2022 Jun TI - One-Year Outcomes of Early, Compassionate Use of the PASCAL Ace Implant System for Transcatheter Mitral Valve Repair. PG - 100030 LID - 10.1016/j.shj.2022.100030 [doi] LID - 100030 AB - BACKGROUND: Continued development of transcatheter mitral repair technologies is needed to address the large and diverse population of high-risk patients with symptomatic mitral regurgitation (MR). The new PASCAL Ace implant system, with its narrower profile, complements the original PASCAL transcatheter valve repair system. The aim of this study is to report 1-year outcomes from the early, compassionate-use observational experience with the novel PASCAL Ace implant system. METHODS: After heart team assessment, adults with symptomatic moderate-to-severe (3+) or severe (4+) MR despite optimal medical therapy were treated under compassionate use at 3 hospitals internationally. Data were prospectively collected, and outcomes were assessed over a 12-month follow-up period. RESULTS: Seventeen patients (mean age 76 years, 65% male, mean Society of Thoracic Surgeons Predicted Risk of Operative Mortality score 9.6) were treated. MR etiology was degenerative in 29%, functional in 65%, and mixed in 6%; 59% were in New York Heart Association (NYHA) class III-IV. Technical success was achieved in 100%, and procedural success in 94%. At 1 year, MR grade /=10% (mean change 17%+/-6%). There were no major adverse events reported, and the median Patient Satisfaction Score was 96% well above the institutional target of 90%. This shows a well-designed quality improvement programme is an appropriate strategy for implementing HCRP2-EP in a clinical setting, and HCRP2-EP is a feasible, effective and safe intervention in eligible male patients with cardiovascular disease. CI - (c) Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Loureiro Diaz, Javier AU - Loureiro Diaz J AUID- ORCID: 0000-0003-1727-9135 AD - Cardiac Rehabilitation Department, Heart Hospital, Hamad Medical Corporation, Doha, Qatar JLOUREIRODIAZ@GMAIL.COM. FAU - Foster, Liam David AU - Foster LD AD - Cardiac Rehabilitation Department, Cardiff and Vale University Health Board, Cardiff, UK. FAU - Surendran, Praveen Jayaprabha AU - Surendran PJ AUID- ORCID: 0000-0002-7417-3559 AD - Cardiac Rehabilitation Department, Heart Hospital, Hamad Medical Corporation, Doha, Qatar. FAU - Jacob, Prasobh AU - Jacob P AUID- ORCID: 0000-0003-1153-6305 AD - Cardiac Rehabilitation Department, Heart Hospital, Hamad Medical Corporation, Doha, Qatar. FAU - Ibrahim, Omar AU - Ibrahim O AD - Cardiac Rehabilitation Department, Heart Hospital, Hamad Medical Corporation, Doha, Qatar. FAU - Gupta, Poonam AU - Gupta P AUID- ORCID: 0000-0001-8737-8804 AD - Performance Improvement Department, Heart Hospital, Hamad Medical Corporation, Doha, Qatar. LA - eng PT - Clinical Trial, Phase II PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - BMJ Open Qual JT - BMJ open quality JID - 101710381 SB - IM MH - Humans MH - Male MH - *Cardiac Rehabilitation/methods MH - Pandemics MH - Quality Improvement MH - *COVID-19 MH - Exercise Therapy PMC - PMC10254689 OTO - NOTNLM OT - COVID-19 OT - Coronary Disease OT - Exercise OT - Healthcare quality improvement OT - Rehabilitation COIS- Competing interests: None declared. EDAT- 2023/06/01 01:08 MHDA- 2023/06/02 06:43 PMCR- 2023/05/31 CRDT- 2023/05/31 20:53 PHST- 2022/11/30 00:00 [received] PHST- 2023/04/25 00:00 [accepted] PHST- 2023/06/02 06:43 [medline] PHST- 2023/06/01 01:08 [pubmed] PHST- 2023/05/31 20:53 [entrez] PHST- 2023/05/31 00:00 [pmc-release] AID - bmjoq-2022-002202 [pii] AID - 10.1136/bmjoq-2022-002202 [doi] PST - ppublish SO - BMJ Open Qual. 2023 May;12(2):e002202. doi: 10.1136/bmjoq-2022-002202. PMID- 37257875 OWN - NLM STAT- MEDLINE DCOM- 20230602 LR - 20230602 IS - 1940-8250 (Electronic) IS - 0279-5442 (Linking) VI - 43 IP - 3 DP - 2023 Jun 1 TI - A Review of Thromboelastography for Nurses. PG - 29-37 LID - 10.4037/ccn2023371 [doi] AB - BACKGROUND: Thromboelastography is a viscoelastic test with multiple potential advantages over conventional coagulation tests in various disease states. Thromboelastography rapidly provides qualitative and quantitative information related to a patient's coagulation status. OBJECTIVE: To describe recent studies of the use of thromboelastography in various clinical states and how thromboelastography is used in coagulation management. METHODS: A literature review using the MEDLINE and PubMed databases was conducted. The updated methodology for integrated reviews by Whittemore and Knafl was followed. Coauthors evaluated separate areas that were independently reviewed by other coauthors to ensure appropriateness for inclusion. RESULTS: The use of thromboelastography for various clinical conditions with challenging hemostatic profiles has increased. This integrative review covers the use of thromboelastography in patients with trauma, medication-induced coagulopathy, acute and chronic liver failure, and cardiothoracic surgery. Potential future directions are also discussed. DISCUSSION: Thromboelastography has numerous potential benefits over conventional coagulation tests for assessing coagulation status in patients in various clinical states. Nurses can support clinical decisions to use the most appropriate test for their patients. CONCLUSIONS: Each team member should be involved in assessing the usefulness of thromboelastography. Critical care nurses and the multidisciplinary team must identify patients in whom its use is warranted, interpret the results, and provide appropriate interventions in response to the results and clinical status of the patient. CI - (c)2023 American Association of Critical-Care Nurses. FAU - Vollmer, Nicholas J AU - Vollmer NJ AD - Nicholas J. Vollmer is an emergency medicine and intensive care unit clinical pharmacy specialist at Mayo Clinic, Rochester, Minnesota. FAU - Leshko, Nicole A AU - Leshko NA AD - Nicole A. Leshko is a critical care pharmacist at Northwestern Memorial Hospital, Chicago, Illinois. FAU - Wilson, Charles S AU - Wilson CS AD - Charles S. Wilson Jr is a postgraduate year 2 critical care pharmacy resident at Wesley Medical Center, Wichita, Kansas. FAU - Gilbert, Brian W AU - Gilbert BW AD - Brian W. Gilbert is an emergency medicine clinical pharmacy specialist and Residency Program Director for the Postgraduate Year 2 Critical Care Pharmacy program at Wesley Medical Center. LA - eng PT - Journal Article PT - Review PL - United States TA - Crit Care Nurse JT - Critical care nurse JID - 8207799 RN - 0 (Hemostatics) MH - Humans MH - Thrombelastography/methods MH - *Blood Coagulation Disorders/diagnosis MH - *Hemostatics MH - Critical Care MH - *Nurses EDAT- 2023/06/01 01:08 MHDA- 2023/06/02 06:43 CRDT- 2023/05/31 20:13 PHST- 2023/06/02 06:43 [medline] PHST- 2023/06/01 01:08 [pubmed] PHST- 2023/05/31 20:13 [entrez] AID - 32102 [pii] AID - 10.4037/ccn2023371 [doi] PST - ppublish SO - Crit Care Nurse. 2023 Jun 1;43(3):29-37. doi: 10.4037/ccn2023371. PMID- 37257485 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230603 IS - 2325-4637 (Print) IS - 2325-4637 (Electronic) IS - 2325-4637 (Linking) VI - 11 IP - 2 DP - 2023 Apr TI - Early Thoracic Endovascular Aortic Repair of Uncomplicated Type B Thoracic Aortic Dissection: An Aorta Team Approach. PG - 50-56 LID - 10.1055/s-0043-1768201 [doi] AB - BACKGROUND: Although uncomplicated Type B aortic dissection (uTBAD) is traditionally treated with optimal medical therapy (OMT) as per guidelines, recent studies, performed primarily in interventional radiology or surgical operating rooms, suggest superiority of thoracic endovascular aortic repair (TEVAR) over OMT due to recent advancements in endovascular technologies. We report a large, single-center, case control study of TEVAR versus OMT in this population, undertaken solely in a cardiac catheterization laboratory (CCL) with a cardiologist and surgeon. We aimed to determine if TEVAR for uTBAD results in better outcomes compared with OMT. METHODS: This was a retrospective chart review of all patients with uTBAD during the last 13 years, with 46 cases (TEVAR group) and 56 controls (OMT group). RESULTS: In the TEVAR group, the procedure duration of 2.5 hours resulted in 100% procedural success for stent placement, with 63% undergoing protective left subclavian artery bypass, 0% mortality or stroke, and a lower readmission rate (1 vs. 2%; p = 0.04 in early TEVAR cases), but a longer length of stay (12.9 vs. 8.5 days: p = 0.006). The risk of all-cause long-term mortality was markedly reduced in the TEVAR group (RR = 0.38; p = 0.01), irrespective of early (<14 days) versus late intervention. On follow-up computed tomography imaging, the false lumen stabilized or decreased in 85% of cases, irrespective of intervention timing. CONCLUSION: TEVAR performed solely in the CCL is safe and effective, with lower all-cause mortality than OMT. These data, in collaboration with previous data on TEVAR in different settings, call for consideration of an update of practice guidelines. CI - The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/). FAU - Ammar, Khawaja A AU - Ammar KA AUID- ORCID: 0000-0001-7216-7051 AD - Aurora Cardiovascular and Thoracic Services, Aurora Sinai/Aurora St. Luke's Medical Centers, Milwaukee, Wisconsin. AD - Department of Cardiovascular Medicine, University of Wisconsin School of Medicine and Public Health, Milwaukee, Wisconsin. FAU - McDiarmid, Matthew AU - McDiarmid M AD - Aurora Cardiovascular and Thoracic Services, Aurora Sinai/Aurora St. Luke's Medical Centers, Milwaukee, Wisconsin. FAU - Richards, Lauren AU - Richards L AUID- ORCID: 0000-0002-7555-0571 AD - Aurora Cardiovascular and Thoracic Services, Aurora Sinai/Aurora St. Luke's Medical Centers, Milwaukee, Wisconsin. FAU - Mewissen, Mark W AU - Mewissen MW AUID- ORCID: 0000-0001-8141-8852 AD - Aurora Cardiovascular and Thoracic Services, Aurora Sinai/Aurora St. Luke's Medical Centers, Milwaukee, Wisconsin. AD - Department of Cardiovascular Medicine, University of Wisconsin School of Medicine and Public Health, Milwaukee, Wisconsin. FAU - Jan, M Fuad AU - Jan MF AUID- ORCID: 0000-0001-5072-710X AD - Aurora Cardiovascular and Thoracic Services, Aurora Sinai/Aurora St. Luke's Medical Centers, Milwaukee, Wisconsin. AD - Department of Cardiovascular Medicine, University of Wisconsin School of Medicine and Public Health, Milwaukee, Wisconsin. FAU - Weiss, Eric S AU - Weiss ES AUID- ORCID: 0000-0003-1253-2437 AD - Aurora Cardiovascular and Thoracic Services, Aurora Sinai/Aurora St. Luke's Medical Centers, Milwaukee, Wisconsin. AD - Department of Cardiovascular Medicine, University of Wisconsin School of Medicine and Public Health, Milwaukee, Wisconsin. FAU - Bajwa, Tanvir AU - Bajwa T AUID- ORCID: 0000-0002-0720-0879 AD - Aurora Cardiovascular and Thoracic Services, Aurora Sinai/Aurora St. Luke's Medical Centers, Milwaukee, Wisconsin. AD - Department of Cardiovascular Medicine, University of Wisconsin School of Medicine and Public Health, Milwaukee, Wisconsin. LA - eng PT - Journal Article DEP - 20230531 PL - Germany TA - Aorta (Stamford) JT - Aorta (Stamford, Conn.) JID - 101655549 PMC - PMC10232024 COIS- The authors declare no conflict of interest related to this article. EDAT- 2023/06/01 01:08 MHDA- 2023/06/01 01:09 PMCR- 2023/05/01 CRDT- 2023/05/31 19:03 PHST- 2023/06/01 01:09 [medline] PHST- 2023/06/01 01:08 [pubmed] PHST- 2023/05/31 19:03 [entrez] PHST- 2023/05/01 00:00 [pmc-release] AID - A-22-0028 [pii] AID - 10.1055/s-0043-1768201 [doi] PST - ppublish SO - Aorta (Stamford). 2023 Apr;11(2):50-56. doi: 10.1055/s-0043-1768201. Epub 2023 May 31. PMID- 37246286 OWN - NLM STAT- MEDLINE DCOM- 20230831 LR - 20250313 IS - 1536-3732 (Electronic) IS - 1049-2275 (Linking) VI - 34 IP - 6 DP - 2023 Sep 1 TI - Metopic and Sagittal Craniosynostosis in Williams Syndrome. PG - e564-e566 LID - 10.1097/SCS.0000000000009394 [doi] AB - Craniosynostosis has been previously reported in patients with Williams syndrome. Due to the associated significant cardiovascular anomalies, with an attendant increased risk of death under anaesthesia, most patients have been managed conservatively. Here we report the multidisciplinary approach in a 12-month-old female infant with Williams syndrome who has metopic and sagittal craniosynostosis. The child successfully underwent calvarial remodelling procedures, with the clinical outcome demonstrating dramatically improved global development after surgery. CI - Copyright (c) 2023 by Mutaz B. Habal, MD. FAU - Chaisrisawadisuk, Sarut AU - Chaisrisawadisuk S AUID- ORCID: 0000-0001-6040-0784 AD - Division of Plastic Surgery, Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. FAU - Khampalikit, Inthira AU - Khampalikit I AD - Division of Neurosurgery, Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. FAU - Moore, Mark H AU - Moore MH AD - Cleft and Craniofacial South Australia, Women's and Children's Hospital, North Adelaide, South Australia, Australia. FAU - Sathienkijkanchai, Achara AU - Sathienkijkanchai A AD - Division of Medical Genetics, Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. LA - eng PT - Journal Article DEP - 20230529 PL - United States TA - J Craniofac Surg JT - The Journal of craniofacial surgery JID - 9010410 SB - IM MH - Infant MH - Child MH - Humans MH - Female MH - *Williams Syndrome/complications/surgery MH - *Craniosynostoses/diagnostic imaging/surgery/complications MH - *Jaw Abnormalities MH - Retrospective Studies COIS- The authors report no conflicts of interest. EDAT- 2023/05/29 06:41 MHDA- 2023/08/31 06:42 CRDT- 2023/05/29 00:03 PHST- 2023/02/27 00:00 [received] PHST- 2023/03/06 00:00 [accepted] PHST- 2023/08/31 06:42 [medline] PHST- 2023/05/29 06:41 [pubmed] PHST- 2023/05/29 00:03 [entrez] AID - 00001665-202309000-00078 [pii] AID - 10.1097/SCS.0000000000009394 [doi] PST - ppublish SO - J Craniofac Surg. 2023 Sep 1;34(6):e564-e566. doi: 10.1097/SCS.0000000000009394. Epub 2023 May 29. PMID- 37246228 OWN - NLM STAT- MEDLINE DCOM- 20230530 LR - 20230601 IS - 1750-1172 (Electronic) IS - 1750-1172 (Linking) VI - 18 IP - 1 DP - 2023 May 29 TI - Healthcare resource utilization of patients with mitochondrial disease in an outpatient hospital setting. PG - 129 LID - 10.1186/s13023-023-02746-x [doi] LID - 129 AB - BACKGROUND AND OBJECTIVES: Mitochondrial diseases present as multi-system disorders requiring a comprehensive multidisciplinary approach. The data on healthcare resource utilization associated with mitochondrial diseases and the clinical drivers of these costs are limited including for the out-patient setting where the majority of the clinical care for mitochondrial disease patients occurs. We performed a cross-sectional retrospective study of out-patient healthcare resource utilization and costs for patients with a confirmed diagnosis of mitochondrial disease. METHODS: We recruited participants from the Mitochondrial Disease Clinic in Sydney and stratified them into three groups: those with mitochondrial DNA (mtDNA) mutations (Group 1), those with nuclear DNA (nDNA) mutations and the predominant phenotype of chronic progressive external ophthalmoplegia (CPEO) or optic atrophy (Group 2) and those without a confirmed genetic diagnosis but clinical criteria and muscle biopsy findings supportive of a diagnosis of mitochondrial disease (Group 3). Data was collected through retrospective chart review and out-patient costs were calculated using the Medicare Benefits Schedule. RESULTS: We analyzed the data from 91 participants and found that Group 1 had the greatest average out-patient costs per person per annum ($838.02; SD 809.72). Neurological investigations were the largest driver of outpatient healthcare costs in all groups (average costs per person per annum:-Group 1: $364.11; SD 340.93, Group 2: $247.83; SD 113.86 and Group 3: $239.57; SD 145.69) consistent with the high frequency (94.5%) of neurological symptoms. Gastroenterological and cardiac-related out-patient costs were also major contributors to out-patient healthcare resource utilization in Groups 1 and 3. In Group 2, ophthalmology was the second-most resource intensive specialty ($136.85; SD 173.35). The Group 3 had the greatest average healthcare resource utilization per person over the entire duration of out-patient clinic care ($5815.86; SD 3520.40) most likely due to the lack of a molecular diagnosis and a less customized management approach. CONCLUSION: The drivers of healthcare resource utilization are dependent on the phenotype-genotype characteristics. Neurological, cardiac, and gastroenterological costs were the top three drivers in the out-patient clinics unless the patient had nDNA mutations with predominant phenotype of CPEO and/or optic atrophy wherein ophthalmological-related costs were the second most resource intensive driver. CI - (c) 2023. Crown. FAU - Haque, Sameen AU - Haque S AUID- ORCID: 0000-0002-6204-6640 AD - Nepean Hospital, Derby Street, Kingswood, NSW, 2747, Australia. sameenhaque@hotmail.com. AD - The Kolling Institute, Royal North Shore Hospital, Reserve Road, St Leonards, NSW, 2065, Australia. sameenhaque@hotmail.com. FAU - Crawley, Karen AU - Crawley K AD - The Kolling Institute, Royal North Shore Hospital, Reserve Road, St Leonards, NSW, 2065, Australia. FAU - Shrestha, Rupendra AU - Shrestha R AD - Centre for Economic Impacts of Genomic Medicine (GenIMPACT), Macquarie Business School, Macquarie University, Eastern Rd, Macquarie Park, NSW, 2109, Australia. FAU - Schofield, Deborah AU - Schofield D AD - Centre for Economic Impacts of Genomic Medicine (GenIMPACT), Macquarie Business School, Macquarie University, Eastern Rd, Macquarie Park, NSW, 2109, Australia. FAU - Sue, Carolyn M AU - Sue CM AD - The Kolling Institute, Royal North Shore Hospital, Reserve Road, St Leonards, NSW, 2065, Australia. AD - Neuroscience Research Australia, University of New South Wales, Sydney, Australia. LA - eng PT - Journal Article DEP - 20230529 PL - England TA - Orphanet J Rare Dis JT - Orphanet journal of rare diseases JID - 101266602 SB - IM MH - Aged MH - Humans MH - United States MH - Retrospective Studies MH - *Outpatients MH - Cross-Sectional Studies MH - Medicare MH - Health Care Costs MH - *Ophthalmoplegia, Chronic Progressive External MH - Hospitals PMC - PMC10226231 OTO - NOTNLM OT - Health care costs OT - Health resources OT - Health services OT - Mitochondrial diseases OT - Mitochondrial disorders OT - Outpatients COIS- The authors report no disclosures relative to the manuscript. EDAT- 2023/05/29 00:42 MHDA- 2023/05/30 06:42 PMCR- 2023/05/29 CRDT- 2023/05/28 23:14 PHST- 2023/01/30 00:00 [received] PHST- 2023/05/18 00:00 [accepted] PHST- 2023/05/30 06:42 [medline] PHST- 2023/05/29 00:42 [pubmed] PHST- 2023/05/28 23:14 [entrez] PHST- 2023/05/29 00:00 [pmc-release] AID - 10.1186/s13023-023-02746-x [pii] AID - 2746 [pii] AID - 10.1186/s13023-023-02746-x [doi] PST - epublish SO - Orphanet J Rare Dis. 2023 May 29;18(1):129. doi: 10.1186/s13023-023-02746-x. PMID- 37241171 OWN - NLM STAT- MEDLINE DCOM- 20230529 LR - 20230530 IS - 1648-9144 (Electronic) IS - 1010-660X (Print) IS - 1010-660X (Linking) VI - 59 IP - 5 DP - 2023 May 12 TI - Infective Endocarditis during Pregnancy-Keep It Safe and Simple! LID - 10.3390/medicina59050939 [doi] LID - 939 AB - The diagnosis of infective endocarditis (IE) during pregnancy is accompanied by a poor prognosis for both mother and fetus in the absence of prompt management by multidisciplinary teams. We searched the electronic databases of PubMed, MEDLINE and EMBASE for clinical studies addressing the management of infective endocarditis during pregnancy, with the aim of realizing a literature review ranging from risk factors to diagnostic investigations to optimal therapeutic management for mother and fetus alike. The presence of previous cardiovascular pathologies such as rheumatic heart disease, congenital heart disease, prosthetic valves, hemodialysis, intravenous catheters or immunosuppression are the main risk factors predisposing patients to IE during pregnancy. The identification of modern risk factors such as intracardiac devices and intravenous drug administration as well as genetic diagnostic methods such as cell-free deoxyribonucleic acid (DNA) next-generation sequencing require that these cases be addressed in multidisciplinary teams. Guiding treatment to eradicate infection and protect the fetus simultaneously creates challenges for cardiologists and gynecologists alike. FAU - Onofrei, Viviana Aursulesei AU - Onofrei VA AD - Department of Medical Specialties I, II, III and Preventive Medicine and Interdisciplinary, "Grigore T. Popa" University of Medicine and Pharmacy, University Street No. 16, 700115 Iasi, Romania. AD - "St. Spiridon" Clinical Emergency Hospital, Independence Boulevard No. 1, 700111 Iasi, Romania. FAU - Adam, Cristina Andreea AU - Adam CA AUID- ORCID: 0000-0001-7313-3320 AD - Department of Medical Specialties I, II, III and Preventive Medicine and Interdisciplinary, "Grigore T. Popa" University of Medicine and Pharmacy, University Street No. 16, 700115 Iasi, Romania. AD - Cardiovascular Rehabilitation Clinic, Clinical Rehabilitation Hospital, Pantelimon Halipa Street No. 14, 700661 Iasi, Romania. FAU - Marcu, Dragos Traian Marius AU - Marcu DTM AUID- ORCID: 0000-0003-2334-9953 AD - Department of Medical Specialties I, II, III and Preventive Medicine and Interdisciplinary, "Grigore T. Popa" University of Medicine and Pharmacy, University Street No. 16, 700115 Iasi, Romania. AD - Clinical Hospital of Pneumophthisiology Iasi, Doctor Iosif Cihac Street No. 30, 700115 Iasi, Romania. FAU - Crisan Dabija, Radu AU - Crisan Dabija R AUID- ORCID: 0000-0003-3732-0350 AD - Department of Medical Specialties I, II, III and Preventive Medicine and Interdisciplinary, "Grigore T. Popa" University of Medicine and Pharmacy, University Street No. 16, 700115 Iasi, Romania. AD - Clinical Hospital of Pneumophthisiology Iasi, Doctor Iosif Cihac Street No. 30, 700115 Iasi, Romania. FAU - Ceasovschih, Alexandr AU - Ceasovschih A AUID- ORCID: 0000-0002-0043-9051 AD - Department of Medical Specialties I, II, III and Preventive Medicine and Interdisciplinary, "Grigore T. Popa" University of Medicine and Pharmacy, University Street No. 16, 700115 Iasi, Romania. AD - "St. Spiridon" Clinical Emergency Hospital, Independence Boulevard No. 1, 700111 Iasi, Romania. FAU - Constantin, Mihai AU - Constantin M AD - Department of Medical Specialties I, II, III and Preventive Medicine and Interdisciplinary, "Grigore T. Popa" University of Medicine and Pharmacy, University Street No. 16, 700115 Iasi, Romania. AD - "St. Spiridon" Clinical Emergency Hospital, Independence Boulevard No. 1, 700111 Iasi, Romania. FAU - Grigorescu, Elena-Daniela AU - Grigorescu ED AUID- ORCID: 0000-0002-7721-554X AD - Department of Medical Specialties I, II, III and Preventive Medicine and Interdisciplinary, "Grigore T. Popa" University of Medicine and Pharmacy, University Street No. 16, 700115 Iasi, Romania. FAU - Petroaie, Antoneta Dacia AU - Petroaie AD AUID- ORCID: 0000-0002-1239-8058 AD - Department of Medical Specialties I, II, III and Preventive Medicine and Interdisciplinary, "Grigore T. Popa" University of Medicine and Pharmacy, University Street No. 16, 700115 Iasi, Romania. FAU - Mitu, Florin AU - Mitu F AUID- ORCID: 0000-0003-1801-9327 AD - Department of Medical Specialties I, II, III and Preventive Medicine and Interdisciplinary, "Grigore T. Popa" University of Medicine and Pharmacy, University Street No. 16, 700115 Iasi, Romania. AD - Cardiovascular Rehabilitation Clinic, Clinical Rehabilitation Hospital, Pantelimon Halipa Street No. 14, 700661 Iasi, Romania. AD - Academy of Medical Sciences, Ion C. Bratianu Boulevard No. 1, 030167 Bucharest, Romania. AD - Academy of Romanian Scientists, Professor Dr. Doc. Dimitrie Mangeron Boulevard No. 433, 700050 Iasi, Romania. LA - eng PT - Journal Article PT - Review DEP - 20230512 PL - Switzerland TA - Medicina (Kaunas) JT - Medicina (Kaunas, Lithuania) JID - 9425208 SB - IM MH - Pregnancy MH - Female MH - Humans MH - *Endocarditis, Bacterial MH - *Endocarditis/diagnosis/etiology/therapy MH - *Heart Defects, Congenital/complications MH - Risk Factors MH - Heart PMC - PMC10223066 OTO - NOTNLM OT - cardiovascular maternal risk OT - heart team OT - infective endocarditis OT - multidisciplinary approach OT - pregnancy COIS- The authors declare no conflict of interest. EDAT- 2023/05/27 09:42 MHDA- 2023/05/29 06:42 PMCR- 2023/05/12 CRDT- 2023/05/27 01:21 PHST- 2023/02/12 00:00 [received] PHST- 2023/05/09 00:00 [revised] PHST- 2023/05/10 00:00 [accepted] PHST- 2023/05/29 06:42 [medline] PHST- 2023/05/27 09:42 [pubmed] PHST- 2023/05/27 01:21 [entrez] PHST- 2023/05/12 00:00 [pmc-release] AID - medicina59050939 [pii] AID - medicina-59-00939 [pii] AID - 10.3390/medicina59050939 [doi] PST - epublish SO - Medicina (Kaunas). 2023 May 12;59(5):939. doi: 10.3390/medicina59050939. PMID- 37240454 OWN - NLM STAT- MEDLINE DCOM- 20230529 LR - 20230529 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 24 IP - 10 DP - 2023 May 22 TI - Clinical, Genetic, and Histological Characterization of Patients with Rare Neuromuscular and Mitochondrial Diseases Presenting with Different Cardiomyopathy Phenotypes. LID - 10.3390/ijms24109108 [doi] LID - 9108 AB - Cardiomyopathies are mostly determined by genetic mutations affecting either cardiac muscle cell structure or function. Nevertheless, cardiomyopathies may also be part of complex clinical phenotypes in the spectrum of neuromuscular (NMD) or mitochondrial diseases (MD). The aim of this study is to describe the clinical, molecular, and histological characteristics of a consecutive cohort of patients with cardiomyopathy associated with NMDs or MDs referred to a tertiary cardiomyopathy clinic. Consecutive patients with a definitive diagnosis of NMDs and MDs presenting with a cardiomyopathy phenotype were described. Seven patients were identified: two patients with ACAD9 deficiency (Patient 1 carried the c.1240C>T (p.Arg414Cys) homozygous variant in ACAD9; Patient 2 carried the c.1240C>T (p.Arg414Cys) and the c.1646G>A (p.Ar549Gln) variants in ACAD9); two patients with MYH7-related myopathy (Patient 3 carried the c.1325G>A (p.Arg442His) variant in MYH7; Patient 4 carried the c.1357C>T (p.Arg453Cys) variant in MYH7); one patient with desminopathy (Patient 5 carried the c.46C>T (p.Arg16Cys) variant in DES); two patients with mitochondrial myopathy (Patient 6 carried the m.3243A>G variant in MT-TL1; Patient 7 carried the c.253G>A (p.Gly85Arg) and the c.1055C>T (p.Thr352Met) variants in MTO1). All patients underwent a comprehensive cardiovascular and neuromuscular evaluation, including muscle biopsy and genetic testing. This study described the clinical phenotype of rare NMDs and MDs presenting as cardiomyopathies. A multidisciplinary evaluation, combined with genetic testing, plays a main role in the diagnosis of these rare diseases, and provides information about clinical expectations, and guides management. FAU - Monda, Emanuele AU - Monda E AUID- ORCID: 0000-0001-9304-988X AD - Inherited and Rare Cardiovascular Disease Unit, Department of Translational Medical Sciences, University of Campania Luigi Vanvitelli, AORN dei Colli, Monaldi Hospital, 81031 Naples, Italy. FAU - Lioncino, Michele AU - Lioncino M AUID- ORCID: 0000-0003-0205-5235 AD - Inherited and Rare Cardiovascular Disease Unit, Department of Translational Medical Sciences, University of Campania Luigi Vanvitelli, AORN dei Colli, Monaldi Hospital, 81031 Naples, Italy. FAU - Caiazza, Martina AU - Caiazza M AUID- ORCID: 0000-0003-3805-4170 AD - Inherited and Rare Cardiovascular Disease Unit, Department of Translational Medical Sciences, University of Campania Luigi Vanvitelli, AORN dei Colli, Monaldi Hospital, 81031 Naples, Italy. FAU - Simonelli, Vincenzo AU - Simonelli V AD - Neurology Unit, AORN dei Colli, Monaldi Hospital, 81031 Naples, Italy. FAU - Nesti, Claudia AU - Nesti C AUID- ORCID: 0000-0001-5769-8655 AD - Molecular Medicine, IRCCS Stella Maris Foundation, 56128 Pisa, Italy. FAU - Rubino, Marta AU - Rubino M AD - Inherited and Rare Cardiovascular Disease Unit, Department of Translational Medical Sciences, University of Campania Luigi Vanvitelli, AORN dei Colli, Monaldi Hospital, 81031 Naples, Italy. FAU - Perna, Alessia AU - Perna A AD - Inherited and Rare Cardiovascular Disease Unit, Department of Translational Medical Sciences, University of Campania Luigi Vanvitelli, AORN dei Colli, Monaldi Hospital, 81031 Naples, Italy. FAU - Mauriello, Alfredo AU - Mauriello A AUID- ORCID: 0000-0001-7060-6938 AD - Inherited and Rare Cardiovascular Disease Unit, Department of Translational Medical Sciences, University of Campania Luigi Vanvitelli, AORN dei Colli, Monaldi Hospital, 81031 Naples, Italy. FAU - Budillon, Alberta AU - Budillon A AD - Department of Advanced Medical and Surgical Sciences, 2nd Division of Neurology, Center for Rare Diseases and InterUniversity Center for Research in Neurosciences, University of Campania Luigi Vanvitelli, Via Sergio Pansini, 5, 80131 Naples, Italy. FAU - Pota, Vincenzo AU - Pota V AD - NeuroMuscular Omnicentre (NEMO), AORN dei Colli, Monaldi Hospital, 80131 Naples, Italy. FAU - Bruno, Giorgia AU - Bruno G AUID- ORCID: 0000-0001-9388-9336 AD - Pediatric Neurology Unit, Department of Neurosciences, Santobono-Pausilipon Children's Hospital, 80122 Naples, Italy. FAU - Varone, Antonio AU - Varone A AD - Pediatric Neurology Unit, Department of Neurosciences, Santobono-Pausilipon Children's Hospital, 80122 Naples, Italy. FAU - Nigro, Vincenzo AU - Nigro V AD - Department of Precision Medicine, University of Campania Luigi Vanvitelli, Via Luigi De Crecchio 7, 80138 Naples, Italy. AD - Telethon Institute of Genetics and Medicine, Via Campi Flegrei 34, 80078 Pozzuoli, Italy. FAU - Santorelli, Filippo Maria AU - Santorelli FM AD - Molecular Medicine, IRCCS Stella Maris Foundation, 56128 Pisa, Italy. FAU - Pacileo, Giuseppe AU - Pacileo G AD - Heart Failure Unit, Department of Cardiology, AORN dei Colli, Monaldi Hospital, 80131 Naples, Italy. FAU - Russo, Maria Giovanna AU - Russo MG AD - Paediatric Cardiology Unit, University of Campania Luigi Vanvitelli, AORN dei Colli, Monaldi Hospital, 81100 Caserta, Italy. FAU - Frisso, Giulia AU - Frisso G AUID- ORCID: 0000-0003-3487-7743 AD - Department of Molecular Medicine and Medical Biotechnology, University of Naples "Federico II", 80138 Naples, Italy. FAU - Sampaolo, Simone AU - Sampaolo S AUID- ORCID: 0000-0002-1383-6638 AD - Department of Advanced Medical and Surgical Sciences, 2nd Division of Neurology, Center for Rare Diseases and InterUniversity Center for Research in Neurosciences, University of Campania Luigi Vanvitelli, Via Sergio Pansini, 5, 80131 Naples, Italy. FAU - Limongelli, Giuseppe AU - Limongelli G AUID- ORCID: 0000-0002-8291-9517 AD - Inherited and Rare Cardiovascular Disease Unit, Department of Translational Medical Sciences, University of Campania Luigi Vanvitelli, AORN dei Colli, Monaldi Hospital, 81031 Naples, Italy. AD - NeuroMuscular Omnicentre (NEMO), AORN dei Colli, Monaldi Hospital, 80131 Naples, Italy. AD - Institute of Cardiovascular Sciences, University College of London and St. Bartholomew's Hospital, Gower St, London WC1E 6DD, UK. LA - eng PT - Journal Article DEP - 20230522 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 SB - IM MH - Humans MH - *Cardiomyopathies/genetics/diagnosis MH - *Mitochondrial Diseases/diagnosis/genetics MH - *Cardiomyopathy, Hypertrophic MH - *Muscular Diseases/diagnosis/genetics MH - Mutation MH - Phenotype PMC - PMC10218839 OTO - NOTNLM OT - cardiomyopathy OT - genetic testing OT - neuromuscular disease COIS- The authors declare no conflict of interest. EDAT- 2023/05/27 09:42 MHDA- 2023/05/29 06:42 PMCR- 2023/05/22 CRDT- 2023/05/27 01:17 PHST- 2023/04/20 00:00 [received] PHST- 2023/05/15 00:00 [revised] PHST- 2023/05/20 00:00 [accepted] PHST- 2023/05/29 06:42 [medline] PHST- 2023/05/27 09:42 [pubmed] PHST- 2023/05/27 01:17 [entrez] PHST- 2023/05/22 00:00 [pmc-release] AID - ijms24109108 [pii] AID - ijms-24-09108 [pii] AID - 10.3390/ijms24109108 [doi] PST - epublish SO - Int J Mol Sci. 2023 May 22;24(10):9108. doi: 10.3390/ijms24109108. PMID- 38939605 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260922 IS - 2772-963X (Electronic) IS - 2772-963X (Linking) VI - 2 IP - 3 DP - 2023 May TI - Endocarditis Team as a Paradigm for Multidisciplinary Heart Team. PG - 100319 LID - 10.1016/j.jacadv.2023.100319 [doi] LID - 100319 FAU - Beraud, Guillaume AU - Beraud G FAU - Ternacle, Julien AU - Ternacle J FAU - Botelho-Nevers, Elisabeth AU - Botelho-Nevers E FAU - Selton-Suty, Christine AU - Selton-Suty C FAU - Habib, Gilbert AU - Habib G CN - Association pour l'Etude et la Prevention de l'Endocardite Infectieuse LA - eng PT - Journal Article DEP - 20230526 PL - United States TA - JACC Adv JT - JACC. Advances JID - 9918419284106676 PMC - PMC11198039 EDAT- 2023/05/26 00:00 MHDA- 2023/05/26 00:01 PMCR- 2023/05/26 CRDT- 2024/06/28 05:00 PHST- 2023/05/26 00:01 [medline] PHST- 2023/05/26 00:00 [pubmed] PHST- 2024/06/28 05:00 [entrez] PHST- 2023/05/26 00:00 [pmc-release] AID - S2772-963X(23)00090-X [pii] AID - 100319 [pii] AID - 10.1016/j.jacadv.2023.100319 [doi] PST - epublish SO - JACC Adv. 2023 May 26;2(3):100319. doi: 10.1016/j.jacadv.2023.100319. eCollection 2023 May. PMID- 37235670 OWN - NLM STAT- MEDLINE DCOM- 20230529 LR - 20230531 IS - 1759-7390 (Electronic) IS - 1750-8460 (Linking) VI - 84 IP - 5 DP - 2023 May 2 TI - Progressive pericardial echinococcosis with intra- and extra-cardiac complications: a multidisciplinary approach. PG - 1-3 LID - 10.12968/hmed.2022.0528 [doi] FAU - Walsh, Jason L AU - Walsh JL AD - Department of Medicine, Wexham Park Hospital, Frimley Health NHS Foundation Trust, Slough, UK. FAU - Moezinia, Carine J AU - Moezinia CJ AD - Department of Medicine, University College Hospital London, London, UK. FAU - Mandal, Amit Kj AU - Mandal AK AD - Department of Medicine, Wexham Park Hospital, Frimley Health NHS Foundation Trust, Slough, UK. FAU - Lawrence, David AU - Lawrence D AD - Department of Cardiothoracic Surgery, St Bartholomew's Hospital, London, UK. FAU - Missouris, Constantinos G AU - Missouris CG AD - Department of Medicine, Wexham Park Hospital, Frimley Health NHS Foundation Trust, Slough, UK. AD - University of Nicosia Medical School, Cyprus. LA - eng PT - Journal Article DEP - 20230508 PL - Singapore TA - Br J Hosp Med (Lond) JT - British journal of hospital medicine (London, England : 2005) JID - 101257109 SB - IM MH - Humans MH - *Pericardium/diagnostic imaging MH - *Echinococcosis/complications/diagnosis EDAT- 2023/05/26 19:14 MHDA- 2023/05/29 06:41 CRDT- 2023/05/26 14:03 PHST- 2023/05/29 06:41 [medline] PHST- 2023/05/26 19:14 [pubmed] PHST- 2023/05/26 14:03 [entrez] AID - 10.12968/hmed.2022.0528 [doi] PST - ppublish SO - Br J Hosp Med (Lond). 2023 May 2;84(5):1-3. doi: 10.12968/hmed.2022.0528. Epub 2023 May 8. PMID- 37234376 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241007 IS - 2297-055X (Print) IS - 2297-055X (Electronic) IS - 2297-055X (Linking) VI - 10 DP - 2023 TI - Cardiorenal syndrome and diabetes: an evil pairing. PG - 1185707 LID - 10.3389/fcvm.2023.1185707 [doi] LID - 1185707 AB - Cardiorenal syndrome (CRS) is a pathology where the heart and kidney are involved, and the deterioration of one of them leads to the malfunction of the other. Diabetes mellitus (DM) carries a higher risk of HF and a worse prognosis. Furthermore, almost half of people with DM will have chronic kidney disease (CKD), which means that DM is the main cause of kidney failure. The triad of cardiorenal syndrome and diabetes is known to be associated with increased risk of hospitalization and mortality. Cardiorenal units, with a multidisciplinary team (cardiologist, nephrologist, nursing), multiple tools for diagnosis, as well as new treatments that help to better control cardio-renal-metabolic patients, offer holistic management of patients with CRS. In recent years, the appearance of drugs such as sodium-glucose cotransporter type 2 inhibitors, have shown cardiovascular benefits, initially in patients with type 2 DM and later in CKD and heart failure with and without DM2, offering a new therapeutic opportunity, especially for cardiorenal patients. In addition, glucagon-like peptide-1 receptor agonists have shown CV benefits in patients with DM and CV disease in addition to a reduced risk of CKD progression. CI - (c) 2023 Mendez Fernandez, Vergara Arana, Olivella San Emeterio, Azancot Rivero, Soriano Colome and Soler Romeo. FAU - Mendez Fernandez, Ana Belen AU - Mendez Fernandez AB AD - Department of Cardiology, Hospital Universitario Vall d Hebron, Barcelona, Spain. FAU - Vergara Arana, Ander AU - Vergara Arana A AD - Department of Nephrology, Hospital Universitario Vall d Hebron, Barcelona, Spain. FAU - Olivella San Emeterio, Aleix AU - Olivella San Emeterio A AD - Department of Cardiology, Hospital Universitario Vall d Hebron, Barcelona, Spain. FAU - Azancot Rivero, Maria Antonieta AU - Azancot Rivero MA AD - Department of Nephrology, Hospital Universitario Vall d Hebron, Barcelona, Spain. FAU - Soriano Colome, Toni AU - Soriano Colome T AD - Department of Cardiology, Hospital Universitario Vall d Hebron, Barcelona, Spain. FAU - Soler Romeo, Maria Jose AU - Soler Romeo MJ AD - Department of Nephrology, Hospital Universitario Vall d Hebron, Barcelona, Spain. LA - eng PT - Journal Article PT - Review DEP - 20230510 PL - Switzerland TA - Front Cardiovasc Med JT - Frontiers in cardiovascular medicine JID - 101653388 PMC - PMC10206318 OTO - NOTNLM OT - cardiorenal syndrome OT - cardiorenal units OT - chronic kidney disease OT - diabetes mellitus OT - heart failure COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/05/26 13:09 MHDA- 2023/05/26 13:10 PMCR- 2023/01/01 CRDT- 2023/05/26 12:10 PHST- 2023/03/13 00:00 [received] PHST- 2023/04/24 00:00 [accepted] PHST- 2023/05/26 13:10 [medline] PHST- 2023/05/26 13:09 [pubmed] PHST- 2023/05/26 12:10 [entrez] PHST- 2023/01/01 00:00 [pmc-release] AID - 10.3389/fcvm.2023.1185707 [doi] PST - epublish SO - Front Cardiovasc Med. 2023 May 10;10:1185707. doi: 10.3389/fcvm.2023.1185707. eCollection 2023. PMID- 37233180 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230528 IS - 2308-3425 (Electronic) IS - 2308-3425 (Linking) VI - 10 IP - 5 DP - 2023 May 13 TI - The Positive Impact of Early Frailty Levels on Mortality in Elderly Patients with Severe Aortic Stenosis Undergoing Transcatheter/Surgical Aortic Valve Replacement. LID - 10.3390/jcdd10050212 [doi] LID - 212 AB - Background: Frailty is highly common in older patients (pts) undergoing transcatheter aortic valve replacement (TAVR), and it is associated with poor outcomes. The selection of patients who can benefit from this procedure is necessary and challenging. The aim of the present study is to evaluate outcomes in older severe aortic valve stenosis (AS) pts, selected by a multidisciplinary approach for surgical, clinical, and geriatric risk and referred to treatment, according to frailty levels. Methods: A total of 109 pts (83 +/- 5 years; females, 68%) with AS were classified by Fried's score in pre-frail, early frail, and frail and underwent surgical aortic valve replacement SAVR/TAVR, balloon aortic valvuloplasty, or medical therapy. We evaluated geriatric, clinical, and surgical features and detected periprocedural complications. The outcome was all-cause mortality. Results: Increasing frailty was associated with the worst clinical, surgical, geriatric conditions. By using Kaplan-Meier analysis, the survival rate was higher in pre-frail and TAVR groups (p < 0.001) (median follow-up = 20 months). By using the Cox regression model, frailty (p = 0.004), heart failure (p = 0.007), EF% (p = 0.043), albumin (p = 0.018) were associated with all-cause mortality. Conclusions: According to tailored frailty management, elderly AS pts with early frailty levels seem to be the most suitable candidates for TAVR/SAVR for positive outcomes because advanced frailty would make each treatment futile or palliative. FAU - Mazzone, Annamaria AU - Mazzone A AD - Diagnostic and Interventional Cardiology Department, Fondazione Toscana Gabriele Monasterio, 54100 Massa, Italy. FAU - Del Turco, Serena AU - Del Turco S AUID- ORCID: 0000-0003-3722-8861 AD - CNR Institute of Clinical Physiology, 56124 Pisa, Italy. FAU - Trianni, Giuseppe AU - Trianni G AD - Diagnostic and Interventional Cardiology Department, Fondazione Toscana Gabriele Monasterio, 54100 Massa, Italy. FAU - Quadrelli, Paola AU - Quadrelli P AD - Adult Cardiosurgery Department, Fondazione Toscana Gabriele Monasterio, 54100 Massa, Italy. FAU - Marotta, Marco AU - Marotta M AD - Adult Cardiosurgery Department, Fondazione Toscana Gabriele Monasterio, 54100 Massa, Italy. FAU - Bastiani, Luca AU - Bastiani L AD - CNR Institute of Clinical Physiology, 56124 Pisa, Italy. FAU - Gasbarri, Tommaso AU - Gasbarri T AUID- ORCID: 0000-0002-5181-7198 AD - Adult Cardiosurgery Department, Fondazione Toscana Gabriele Monasterio, 54100 Massa, Italy. FAU - D'Agostino, Andreina AU - D'Agostino A AD - Diagnostic and Interventional Cardiology Department, Fondazione Toscana Gabriele Monasterio, 54100 Massa, Italy. FAU - Mariani, Massimiliano AU - Mariani M AD - Diagnostic and Interventional Cardiology Department, Fondazione Toscana Gabriele Monasterio, 54100 Massa, Italy. FAU - Basta, Giuseppina AU - Basta G AD - CNR Institute of Clinical Physiology, 56124 Pisa, Italy. FAU - Foffa, Ilenia AU - Foffa I AUID- ORCID: 0000-0002-4604-0871 AD - CNR Institute of Clinical Physiology, 54100 Massa, Italy. FAU - Sbrana, Silverio AU - Sbrana S AUID- ORCID: 0000-0002-7811-4265 AD - CNR Institute of Clinical Physiology, 54100 Massa, Italy. FAU - Vassalle, Cristina AU - Vassalle C AUID- ORCID: 0000-0003-3438-6450 AD - Fondazione Toscana Gabriele Monasterio, 56124 Pisa, Italy. FAU - Ravani, Marcello AU - Ravani M AD - Diagnostic and Interventional Cardiology Department, Fondazione Toscana Gabriele Monasterio, 54100 Massa, Italy. FAU - Solinas, Marco AU - Solinas M AD - Adult Cardiosurgery Department, Fondazione Toscana Gabriele Monasterio, 54100 Massa, Italy. FAU - Berti, Sergio AU - Berti S AUID- ORCID: 0000-0002-5244-0556 AD - Diagnostic and Interventional Cardiology Department, Fondazione Toscana Gabriele Monasterio, 54100 Massa, Italy. LA - eng PT - Journal Article DEP - 20230513 PL - Switzerland TA - J Cardiovasc Dev Dis JT - Journal of cardiovascular development and disease JID - 101651414 PMC - PMC10218811 OTO - NOTNLM OT - aortic stenosis OT - frailty OT - mortality OT - pre-frailty OT - transcatheter aortic valve replacement COIS- The authors declare that they have no conflicts of interest. EDAT- 2023/05/26 13:09 MHDA- 2023/05/26 13:10 PMCR- 2023/05/13 CRDT- 2023/05/26 09:54 PHST- 2023/03/08 00:00 [received] PHST- 2023/05/08 00:00 [revised] PHST- 2023/05/10 00:00 [accepted] PHST- 2023/05/26 13:10 [medline] PHST- 2023/05/26 13:09 [pubmed] PHST- 2023/05/26 09:54 [entrez] PHST- 2023/05/13 00:00 [pmc-release] AID - jcdd10050212 [pii] AID - jcdd-10-00212 [pii] AID - 10.3390/jcdd10050212 [doi] PST - epublish SO - J Cardiovasc Dev Dis. 2023 May 13;10(5):212. doi: 10.3390/jcdd10050212. PMID- 37230556 OWN - NLM STAT- MEDLINE DCOM- 20230529 LR - 20230529 IS - 1557-8232 (Electronic) IS - 0749-0704 (Linking) VI - 39 IP - 3 DP - 2023 Jul TI - Development of the Modern Cardiothoracic Intensive Care Unit and Current Management. PG - 559-576 LID - S0749-0704(23)00021-0 [pii] LID - 10.1016/j.ccc.2023.03.008 [doi] AB - The modern cardiothoracic intensive care unit (CTICU) developed as a result of advances in critical care, cardiology, and cardiac surgery. Patients undergoing cardiac surgery today are sicker, frailer, and have more complex cardiac and noncardiac morbidities. CTICU providers need to understand postoperative implications of different surgical procedures, complications that can occur in CTICU patients, resuscitation protocols for cardiac arrest, and diagnostic and therapeutic interventions such as transesophageal echocardiography and mechanical circulatory support. Optimum CTICU care requires a multidisciplinary team with collaboration between cardiac surgeons and critical care physicians with training and experience in the care of CTICU patients. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Pearl, Ronald G AU - Pearl RG AD - Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University, Stanford University School of Medicine, 300 Pasteur Drive, Room H3589. Electronic address: rgp@stanford.edu. FAU - Cole, Sheela Pai AU - Cole SP AD - Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University, Stanford University School of Medicine, 300 Pasteur Drive, Room H3589. LA - eng PT - Journal Article PT - Review PL - United States TA - Crit Care Clin JT - Critical care clinics JID - 8507720 SB - IM MH - Humans MH - *Intensive Care Units MH - Critical Care MH - *Cardiac Surgical Procedures MH - Heart OTO - NOTNLM OT - Cardiac surgery OT - Echocardiography OT - Intensive care unit OT - Left ventricular failure OT - Low cardiac output syndrome OT - Mechanical circulatory support OT - Postoperative complications OT - Right ventricular failure EDAT- 2023/05/26 01:05 MHDA- 2023/05/29 06:42 CRDT- 2023/05/25 20:56 PHST- 2023/05/29 06:42 [medline] PHST- 2023/05/26 01:05 [pubmed] PHST- 2023/05/25 20:56 [entrez] AID - S0749-0704(23)00021-0 [pii] AID - 10.1016/j.ccc.2023.03.008 [doi] PST - ppublish SO - Crit Care Clin. 2023 Jul;39(3):559-576. doi: 10.1016/j.ccc.2023.03.008. PMID- 37230250 OWN - NLM STAT- MEDLINE DCOM- 20230724 LR - 20230724 IS - 1469-0691 (Electronic) IS - 1198-743X (Linking) VI - 29 IP - 8 DP - 2023 Aug TI - The role of early defervescence in ruling out infective endocarditis: a cohort study. PG - 1087.e5-1087.e8 LID - S1198-743X(23)00243-4 [pii] LID - 10.1016/j.cmi.2023.05.019 [doi] AB - OBJECTIVES: To evaluate the role of defervescence within 4 days from antibiotic treatment initiation in ruling out infective endocarditis (IE) among patients suspected of such diagnosis. METHODS: This study was conducted at the Lausanne University Hospital, Switzerland (January 2014 to May 2022). All patients with suspected IE being febrile upon presentation were included. IE was classified according to the modified Duke criteria proposed by the 2015 European Society of Cardiology guidelines, before or after applying the criterion 'resolution of symptoms suggesting IE within 4 days of the introduction of antibiotic therapy' based solely on early defervescence. RESULTS: Among 1022 episodes with suspected IE, 332 (37%) had IE according to Endocarditis-Team evaluation; 248 were classified by clinical Duke criteria as definite and 84 as possible IE. The rate of defervescence within 4 days from antibiotic treatment initiation was similar (p 0.547) among episodes without (606/690; 88%) and those with IE (287/332; 86%); among episodes classified as definite and possible IE by clinical Duke criteria, 211 of 248 (85%) and 76 of 84 (90%), respectively, defervesced within 4 days from antibiotic treatment initiation. By using early defervescence as a rejection criterion, the 76 episodes with final IE diagnosis classified as possible by clinical criteria could be reclassified as rejected. DISCUSSION: The majority of IE episodes defervesced within 4 days from antibiotic treatment initiation; thus, early defervescence should not be used to rule out the diagnosis of IE. CI - Copyright (c) 2023 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved. FAU - Stavropoulou, Elisavet AU - Stavropoulou E AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Guery, Benoit AU - Guery B AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Ianculescu, Nicoleta AU - Ianculescu N AD - Department of Cardiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Tozzi, Piergiorgio AU - Tozzi P AD - Department of Cardiac Surgery, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Kirsch, Matthias AU - Kirsch M AD - Department of Cardiac Surgery, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Monney, Pierre AU - Monney P AD - Department of Cardiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. FAU - Papadimitriou-Olivgeris, Matthaios AU - Papadimitriou-Olivgeris M AD - Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. Electronic address: Matthaios.Papadimitriou-Olivgeris@chuv.ch. LA - eng PT - Journal Article DEP - 20230523 PL - England TA - Clin Microbiol Infect JT - Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases JID - 9516420 RN - 0 (Anti-Bacterial Agents) SB - IM MH - Humans MH - Cohort Studies MH - *Endocarditis, Bacterial/diagnosis/drug therapy/microbiology MH - *Endocarditis/diagnosis/drug therapy MH - Echocardiography, Transesophageal MH - Anti-Bacterial Agents/therapeutic use OTO - NOTNLM OT - Duke criteria OT - Fever OT - Infective endocarditis OT - Persistent bacteraemia OT - Rejection criterion EDAT- 2023/05/26 01:05 MHDA- 2023/07/24 06:42 CRDT- 2023/05/25 19:25 PHST- 2023/03/29 00:00 [received] PHST- 2023/05/13 00:00 [revised] PHST- 2023/05/16 00:00 [accepted] PHST- 2023/07/24 06:42 [medline] PHST- 2023/05/26 01:05 [pubmed] PHST- 2023/05/25 19:25 [entrez] AID - S1198-743X(23)00243-4 [pii] AID - 10.1016/j.cmi.2023.05.019 [doi] PST - ppublish SO - Clin Microbiol Infect. 2023 Aug;29(8):1087.e5-1087.e8. doi: 10.1016/j.cmi.2023.05.019. Epub 2023 May 23. PMID- 39493942 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241105 IS - 1758-3896 (Electronic) IS - 1758-3896 (Print) IS - 1758-3896 (Linking) VI - 17 DP - 2023 TI - Pregnancy and Congenital Heart Disease: Moving Beyond the Current Risk Stratification Tools. PG - e06 LID - 10.15420/usc.2022.16 [doi] LID - e06 AB - Women with congenital heart disease have increased risks of complications during pregnancy. Several risk scoring tools have been developed to quantify the likelihood of adverse cardiac outcomes during pregnancy. This article describes how comprehensive pre-pregnancy or early pregnancy counseling needs to go well beyond these risk scores. Non-cardiac risk factors and adverse obstetric and fetal outcomes are vital components of the dialogue between the multidisciplinary team and the patient embarking on, or contemplating, pregnancy. CI - Copyright (c) The Author(s), 2023. Published by Radcliffe Group Ltd. FAU - Kulasekaran, Ajitha AU - Kulasekaran A AD - Department of Medicine, University of Glasgow Glasgow, UK. AD - Scottish Adult Congenital Cardiac Service, Golden Jubilee National Hospital Clydebank, UK. FAU - Swan, Lorna AU - Swan L AD - Department of Medicine, University of Glasgow Glasgow, UK. AD - Scottish Adult Congenital Cardiac Service, Golden Jubilee National Hospital Clydebank, UK. LA - eng PT - Journal Article PT - Review DEP - 20230525 PL - England TA - US Cardiol JT - US cardiology JID - 101574791 PMC - PMC11526489 OTO - NOTNLM OT - Adult congenital heart disease OT - maternal mortality OT - pregnancy OT - risk stratification COIS- Disclosure: The authors have no conflicts of interest to declare. EDAT- 2023/05/25 00:00 MHDA- 2023/05/25 00:01 PMCR- 2023/05/25 CRDT- 2024/11/04 05:12 PHST- 2022/07/04 00:00 [received] PHST- 2023/03/16 00:00 [accepted] PHST- 2023/05/25 00:01 [medline] PHST- 2023/05/25 00:00 [pubmed] PHST- 2024/11/04 05:12 [entrez] PHST- 2023/05/25 00:00 [pmc-release] AID - 10.15420/usc.2022.16 [doi] PST - epublish SO - US Cardiol. 2023 May 25;17:e06. doi: 10.15420/usc.2022.16. eCollection 2023. PMID- 37229152 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230528 IS - 2666-5778 (Electronic) IS - 2666-5778 (Linking) VI - 3 IP - 2 DP - 2023 May TI - Urgent robotic coronary revascularization in a pregnant woman. PG - 100183 LID - 10.1016/j.xagr.2023.100183 [doi] LID - 100183 AB - BACKGROUND: Outcomes of robotic-assisted coronary artery bypass grafting in pregnant women have not been assessed. OBJECTIVE: This study aimed to understand the importance of minimally invasive robotic-assisted coronary artery bypass grafting in pregnant woman with coronary artery disease. We describe the case of a G3P1011 woman at 19+6 weeks' gestation presenting with a non-ST myocardial infarction treated with off-pump hybrid robotic-assisted revascularization. STUDY DESIGN: This study describes the surgical approach for a pregnant woman presenting with non-ST myocardial infarction treated with hybrid robotic-assisted revascularization. RESULTS: A coronary angiography demonstrated a culprit lesion of 90% stenosis in the left anterior descending coronary artery and an 80% stenosis in the right coronary artery. Because of the high rate of complications with traditional coronary artery bypass grafting, the heart team opted for hybrid robotic-assisted revascularization and the postoperative recovery was uneventful. CONCLUSION: Robotic coronary artery bypass grafting can be the preferred surgical choice to decrease maternal and fetal mortality in patients undergoing coronary artery bypass grafting, and it is an important tool in the surgical armamentarium. CI - (c) 2023 The Authors. FAU - Hawthorne, Katie AU - Hawthorne K AD - Department of Cardiology, Lankenau Heart Center, Mainline Health, Wynnewood, PA (Drs Hawthorne, Drosou, and Shapiro). FAU - Drosou, Maria Eleni AU - Drosou ME AD - Department of Cardiology, Lankenau Heart Center, Mainline Health, Wynnewood, PA (Drs Hawthorne, Drosou, and Shapiro). FAU - Shapiro, Thomas A AU - Shapiro TA AD - Department of Cardiology, Lankenau Heart Center, Mainline Health, Wynnewood, PA (Drs Hawthorne, Drosou, and Shapiro). FAU - Sicouri, Serge AU - Sicouri S AD - Department of Cardiac Surgery Research, Lankenau Institute for Medical Research, Main Line Health, Wynnewood, PA (Drs Sicouri, Ramlawi, Erten, Dokollari, and Torregrossa). FAU - Gnall, Eric M AU - Gnall EM AD - Department of Cardiac Surgery, Lankenau Heart Center, Main Line Health, Wynnewood, PA (Drs Gnall, Ramlawi, Sutter, Dokollari, and Torregrossa). FAU - Ramlawi, Basel AU - Ramlawi B AD - Department of Cardiac Surgery Research, Lankenau Institute for Medical Research, Main Line Health, Wynnewood, PA (Drs Sicouri, Ramlawi, Erten, Dokollari, and Torregrossa). AD - Department of Cardiac Surgery, Lankenau Heart Center, Main Line Health, Wynnewood, PA (Drs Gnall, Ramlawi, Sutter, Dokollari, and Torregrossa). FAU - Erten, Ozgun AU - Erten O AD - Department of Cardiac Surgery Research, Lankenau Institute for Medical Research, Main Line Health, Wynnewood, PA (Drs Sicouri, Ramlawi, Erten, Dokollari, and Torregrossa). FAU - Sutter, Francis AU - Sutter F AD - Department of Cardiac Surgery, Lankenau Heart Center, Main Line Health, Wynnewood, PA (Drs Gnall, Ramlawi, Sutter, Dokollari, and Torregrossa). FAU - Dokollari, Aleksander AU - Dokollari A AD - Department of Cardiac Surgery Research, Lankenau Institute for Medical Research, Main Line Health, Wynnewood, PA (Drs Sicouri, Ramlawi, Erten, Dokollari, and Torregrossa). AD - Department of Cardiac Surgery, Lankenau Heart Center, Main Line Health, Wynnewood, PA (Drs Gnall, Ramlawi, Sutter, Dokollari, and Torregrossa). FAU - Torregrossa, Gianluca AU - Torregrossa G AD - Department of Cardiac Surgery Research, Lankenau Institute for Medical Research, Main Line Health, Wynnewood, PA (Drs Sicouri, Ramlawi, Erten, Dokollari, and Torregrossa). AD - Department of Cardiac Surgery, Lankenau Heart Center, Main Line Health, Wynnewood, PA (Drs Gnall, Ramlawi, Sutter, Dokollari, and Torregrossa). LA - eng PT - Journal Article DEP - 20230217 PL - United States TA - AJOG Glob Rep JT - AJOG global reports JID - 101777907 PMC - PMC10205483 OTO - NOTNLM OT - hybrid robotic-assisted revascularization OT - myocardial infarction OT - pregnancy OT - urgent coronary artery bypass grafting EDAT- 2023/05/25 19:12 MHDA- 2023/05/25 19:13 PMCR- 2023/02/17 CRDT- 2023/05/25 14:19 PHST- 2023/05/25 19:13 [medline] PHST- 2023/05/25 19:12 [pubmed] PHST- 2023/05/25 14:19 [entrez] PHST- 2023/02/17 00:00 [pmc-release] AID - S2666-5778(23)00024-2 [pii] AID - 100183 [pii] AID - 10.1016/j.xagr.2023.100183 [doi] PST - epublish SO - AJOG Glob Rep. 2023 Feb 17;3(2):100183. doi: 10.1016/j.xagr.2023.100183. eCollection 2023 May. PMID- 37227669 OWN - NLM STAT- MEDLINE DCOM- 20230814 LR - 20261010 IS - 1546-9549 (Electronic) IS - 1546-9530 (Linking) VI - 20 IP - 4 DP - 2023 Aug TI - Management of Ventricular Arrhythmias in Heart Failure. PG - 237-253 LID - 10.1007/s11897-023-00608-y [doi] AB - PURPOSE OF REVIEW: Despite substantial progress in medical and device-based heart failure (HF) therapy, ventricular arrhythmias (VA) and sudden cardiac death (SCD) remain a major challenge. Here we review contemporary management of VA in the context of HF with one particular focus on recent advances in imaging and catheter ablation. RECENT FINDINGS: Besides limited efficacy of antiarrhythmic drugs (AADs), their potentially life-threatening side effects are increasingly acknowledged. On the other hand, with tremendous advances in catheter technology, electroanatomical mapping, imaging, and understanding of arrhythmia mechanisms, catheter ablation has evolved into a safe, efficacious therapy. In fact, recent randomized trials support early catheter ablation, demonstrating superiority over AAD. Importantly, CMR imaging with gadolinium contrast has emerged as a central tool for the management of VA complicating HF: CMR is not only essential for an accurate diagnosis of the underlying entity and subsequent treatment decisions, but also improves risk stratification for SCD prevention and patient selection for ICD therapy. Finally, 3-dimensional characterization of arrhythmogenic substrate by CMR and imaging-guided ablation approaches substantially enhance procedural safety and efficacy. VA management in HF patients is highly complex and should be addressed in a multidisciplinary approach, preferably at specialized centers. While recent evidence supports early catheter ablation of VA, an impact on mortality remains to be demonstrated. Moreover, risk stratification for ICD therapy may have to be reconsidered, taking into account imaging, genetic testing, and other parameters beyond left ventricular function. CI - (c) 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Vazquez-Calvo, Sara AU - Vazquez-Calvo S AD - Arrhythmia Section, Cardiovascular Institute (ICCV), CLINIC Barcelona University Hospital, C/Villarroel N degrees 170, 08036, Barcelona, Catalonia, Spain. AD - Institut d'Investigacions Biomediques August Pi I Sunyer (IDIBAPS), Barcelona, Catalonia, Spain. FAU - Roca-Luque, Ivo AU - Roca-Luque I AD - Arrhythmia Section, Cardiovascular Institute (ICCV), CLINIC Barcelona University Hospital, C/Villarroel N degrees 170, 08036, Barcelona, Catalonia, Spain. AD - Institut d'Investigacions Biomediques August Pi I Sunyer (IDIBAPS), Barcelona, Catalonia, Spain. FAU - Althoff, Till F AU - Althoff TF AUID- ORCID: 0000-0002-3289-2985 AD - Arrhythmia Section, Cardiovascular Institute (ICCV), CLINIC Barcelona University Hospital, C/Villarroel N degrees 170, 08036, Barcelona, Catalonia, Spain. althoff.tf@gmail.com. AD - Institut d'Investigacions Biomediques August Pi I Sunyer (IDIBAPS), Barcelona, Catalonia, Spain. althoff.tf@gmail.com. LA - eng PT - Journal Article PT - Review DEP - 20230525 PL - United States TA - Curr Heart Fail Rep JT - Current heart failure reports JID - 101196487 RN - 0 (Anti-Arrhythmia Agents) SB - IM MH - Humans MH - *Heart Failure/therapy/drug therapy MH - Arrhythmias, Cardiac/etiology/therapy MH - Death, Sudden, Cardiac/etiology/prevention & control MH - Anti-Arrhythmia Agents/therapeutic use MH - *Catheter Ablation/methods MH - *Defibrillators, Implantable/adverse effects OTO - NOTNLM OT - Cardiac implantable electronic devices OT - Catheter ablation OT - Heart failure OT - Imaging OT - Sudden cardiac death OT - Ventricular tachycardia EDAT- 2023/05/25 13:07 MHDA- 2023/08/14 06:42 CRDT- 2023/05/25 11:42 PHST- 2023/05/08 00:00 [accepted] PHST- 2023/08/14 06:42 [medline] PHST- 2023/05/25 13:07 [pubmed] PHST- 2023/05/25 11:42 [entrez] AID - 10.1007/s11897-023-00608-y [pii] AID - 10.1007/s11897-023-00608-y [doi] PST - ppublish SO - Curr Heart Fail Rep. 2023 Aug;20(4):237-253. doi: 10.1007/s11897-023-00608-y. Epub 2023 May 25. PMID- 37226505 OWN - NLM STAT- MEDLINE DCOM- 20240119 LR - 20250104 IS - 1467-1107 (Electronic) IS - 1047-9511 (Print) IS - 1047-9511 (Linking) VI - 34 IP - 1 DP - 2024 Jan TI - Parent communication with care teams and preparation for family meetings in the paediatric cardiac ICU: a qualitative study. PG - 113-119 LID - 10.1017/S1047951123001282 [doi] AB - OBJECTIVE: The paediatric cardiac ICU presents unique challenges to optimal communication practices, which may impact participation in medical decision-making and long-term psychosocial outcomes for families. This study characterised parent perceptions of (1) team practices that impeded or facilitated communication and (2) preparation for family meetings with interprofessional care teams during extended cardiac ICU admissions. METHODS: A purposive sample of parents of children admitted to the cardiac ICU was selected to participate in interviews about their communication experiences. Data were analysed using a grounded theory approach. RESULTS: Twenty-three parents of 18 patients participated with an average length of stay of 55 days at the time of interview. Team practices that impeded communication included inaccurate/incomplete communication, inconsistent within team communication/coordination, and feeling overwhelmed by too many team members/questions. Team practices that facilitated communication included valuing parent preferences, provider continuity, explaining jargon, and eliciting questions. Preparation for family meetings included team practices, parental preferences, and experiences when learning about family meetings (including apprehension about meetings). Family meetings were described as valued opportunities to improve communication. CONCLUSION: Communication with medical teams represents a modifiable determinant of long-term outcomes for families of children in the cardiac ICU. When parents are included as valued members of their child's care team, they are more likely to feel a sense of control over their child's outcomes, even in the face of prognostic uncertainty. Family meetings represent an important opportunity to repair fractures in trust between families and care teams and overcome barriers to communication between parties. FAU - Gramszlo, Colette AU - Gramszlo C AUID- ORCID: 0000-0003-2644-936X AD - Department of Child and Adolescent Psychiatry and Behavioral Sciences, Children's Hospital of Philadelphia, Philadelphia, PA, USA. FAU - Girgis, Hannah AU - Girgis H AD - Northeast Ohio Medical School, Rootstown, OH, USA. FAU - Hill, Douglas AU - Hill D AD - Pediatric Advanced Care Team, Children's Hospital of Philadelphia, Philadelphia, PA, USA. AD - Center for Clinical Futures, Children's Hospital of Philadelphia, Philadelphia, PA, USA. FAU - Walter, Jennifer K AU - Walter JK AUID- ORCID: 0000-0003-0723-2464 AD - Pediatric Advanced Care Team, Children's Hospital of Philadelphia, Philadelphia, PA, USA. AD - Center for Clinical Futures, Children's Hospital of Philadelphia, Philadelphia, PA, USA. LA - eng GR - K23 HL141700/HL/NHLBI NIH HHS/United States PT - Journal Article DEP - 20230525 PL - England TA - Cardiol Young JT - Cardiology in the young JID - 9200019 SB - IM MH - Child MH - Humans MH - *Intensive Care Units, Pediatric MH - *Parents MH - Communication MH - Qualitative Research MH - Patient Care Team PMC - PMC10674036 MID - NIHMS1922835 OTO - NOTNLM OT - Team communication OT - cardiac ICU OT - paediatrics OT - psychosocial stress COIS- Conflict of interest. None. EDAT- 2023/05/25 06:42 MHDA- 2024/01/19 06:42 PMCR- 2025/01/01 CRDT- 2023/05/25 04:00 PHST- 2024/01/19 06:42 [medline] PHST- 2023/05/25 06:42 [pubmed] PHST- 2023/05/25 04:00 [entrez] PHST- 2025/01/01 00:00 [pmc-release] AID - S1047951123001282 [pii] AID - 10.1017/S1047951123001282 [doi] PST - ppublish SO - Cardiol Young. 2024 Jan;34(1):113-119. doi: 10.1017/S1047951123001282. Epub 2023 May 25. PMID- 37220832 OWN - NLM STAT- MEDLINE DCOM- 20241220 LR - 20261005 IS - 1555-7162 (Electronic) IS - 0002-9343 (Print) IS - 0002-9343 (Linking) VI - 138 IP - 1 DP - 2025 Jan TI - Multidisciplinary Center Care for Long COVID Syndrome-A Retrospective Cohort Study. PG - 108-120 LID - S0002-9343(23)00328-5 [pii] LID - 10.1016/j.amjmed.2023.05.002 [doi] AB - BACKGROUND: Persistent multi-organ symptoms after coronavirus disease 2019 (COVID-19) have been termed "long COVID" or "post-acute sequelae of SARS-CoV-2 infection." The complexity of these clinical manifestations posed challenges early in the pandemic as different ambulatory models formed out of necessity to manage the influx of patients. Little is known about the characteristics and outcomes of patients seeking care at multidisciplinary post-COVID centers. METHODS: We performed a retrospective cohort study of patients evaluated at our multidisciplinary comprehensive COVID-19 center in Chicago, Ill, between May 2020 and February 2022. We analyzed specialty clinic utilization and clinical test results according to severity of acute COVID-19. RESULTS: We evaluated 1802 patients a median of 8 months from acute COVID-19 onset, including 350 post-hospitalization and 1452 non-hospitalized patients. Patients were seen in 2361 initial visits in 12 specialty clinics, with 1151 (48.8%) in neurology, 591 (25%) in pulmonology, and 284 (12%) in cardiology. Among the patients tested, 742/916 (81%) reported decreased quality of life, 284/553 (51%) had cognitive impairment, 195/434 (44.9%) had alteration of lung function, 249/299 (83.3%) had abnormal computed tomography chest scans, and 14/116 (12.1%) had elevated heart rate on rhythm monitoring. Frequency of cognitive impairment and pulmonary dysfunction was associated with severity of acute COVID-19. Non-hospitalized patients with positive SARS-CoV-2 testing had findings similar to those with negative or no test results. CONCLUSIONS: The experience at our multidisciplinary comprehensive COVID-19 center shows common utilization of multiple specialists by long COVID patients, who harbor frequent neurologic, pulmonary, and cardiologic abnormalities. Differences in post-hospitalization and non-hospitalized groups suggest distinct pathogenic mechanisms of long COVID in these populations. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Bailey, Joseph AU - Bailey J AD - Division of Pulmonary and Critical Care Medicine, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Ill. Electronic address: joseph.bailey1@northwestern.edu. FAU - Lavelle, Bianca AU - Lavelle B AD - McGaw Medical Center, Northwestern University Feinberg School of Medicine, Chicago, Ill. FAU - Miller, Janet AU - Miller J AD - Division of Pulmonary and Critical Care Medicine, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Ill. FAU - Jimenez, Millenia AU - Jimenez M AD - Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Ill. FAU - Lim, Patrick H AU - Lim PH AD - Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Ill. FAU - Orban, Zachary S AU - Orban ZS AD - Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Ill. FAU - Clark, Jeffrey R AU - Clark JR AD - Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Ill. FAU - Tomar, Ria AU - Tomar R AD - Division of Pulmonary and Critical Care Medicine, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Ill. FAU - Ludwig, Amy AU - Ludwig A AD - Division of Pulmonary and Critical Care Medicine, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Ill. FAU - Ali, Sareen T AU - Ali ST AD - Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Ill. FAU - Lank, Grace K AU - Lank GK AD - Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Ill. FAU - Zielinski, Allison AU - Zielinski A AD - Division of Cardiology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Ill. FAU - Mylvaganam, Ruben AU - Mylvaganam R AD - Division of Pulmonary and Critical Care Medicine, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Ill. FAU - Kalhan, Ravi AU - Kalhan R AD - Division of Pulmonary and Critical Care Medicine, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Ill. FAU - El Muayed, Malek AU - El Muayed M AD - Division of Endocrinology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Ill. FAU - Mutharasan, R Kannan AU - Mutharasan RK AD - Division of Cardiology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Ill. FAU - Liotta, Eric M AU - Liotta EM AD - Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Ill. FAU - Sznajder, Jacob I AU - Sznajder JI AD - Division of Pulmonary and Critical Care Medicine, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Ill. FAU - Davidson, Charles AU - Davidson C AD - Division of Cardiology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Ill. FAU - Koralnik, Igor J AU - Koralnik IJ AD - Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Ill. FAU - Sala, Marc A AU - Sala MA AD - Division of Pulmonary and Critical Care Medicine, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Ill. CN - Northwestern Medicine Comprehensive COVID Center Investigators LA - eng GR - T32 HL076139/HL/NHLBI NIH HHS/United States GR - UL1 TR001422/TR/NCATS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20230522 PL - United States TA - Am J Med JT - The American journal of medicine JID - 0267200 SB - IM MH - Humans MH - *COVID-19/therapy/epidemiology/complications MH - Retrospective Studies MH - Female MH - Male MH - Middle Aged MH - *Post-Acute COVID-19 Syndrome MH - Aged MH - SARS-CoV-2 MH - Adult MH - Chicago/epidemiology MH - Quality of Life MH - Patient Care Team PMC - PMC10200714 OTO - NOTNLM OT - Health service delivery OT - Long COVID OT - Multidisciplinary care OT - PASC OT - Post-acute sequelae of SARS-CoV-2 infection COIS- The authors report no conflicts of interest. EDAT- 2023/05/24 01:06 MHDA- 2024/12/21 16:43 PMCR- 2023/05/22 CRDT- 2023/05/23 19:16 PHST- 2023/02/02 00:00 [received] PHST- 2023/04/17 00:00 [revised] PHST- 2023/05/17 00:00 [accepted] PHST- 2024/12/21 16:43 [medline] PHST- 2023/05/24 01:06 [pubmed] PHST- 2023/05/23 19:16 [entrez] PHST- 2023/05/22 00:00 [pmc-release] AID - S0002-9343(23)00328-5 [pii] AID - 10.1016/j.amjmed.2023.05.002 [doi] PST - ppublish SO - Am J Med. 2025 Jan;138(1):108-120. doi: 10.1016/j.amjmed.2023.05.002. Epub 2023 May 22. PMID- 37219851 OWN - NLM STAT- MEDLINE DCOM- 20230525 LR - 20250722 IS - 1557-2501 (Electronic) IS - 1042-3931 (Linking) VI - 35 IP - 5 DP - 2023 May TI - Transcatheter Aortic Valve Implantation With Balloon-Expandable Valve Prostheses in Patients With Pure Native Non- or Mildly Calcified Aortic Regurgitation: A Case-Series and Literature Review. PG - E254-E264 AB - OBJECTIVE: Transcatheter aortic valve implantation (TAVI) is an off-label procedure for selected patients at high surgical risk with native non- or mildly calcified aortic regurgitation (AR). Traditionally, self-expanding transcatheter heart valves (THV) have been favored over balloon-expandable THV's probably due to assumed better device fixation. We report a series of patients with native severe AR successfully treated with a balloon-expandable THV. METHODS: Between 2019 and 2022, 8 consecutive patients (5 male, 82 (interquartile range 80-85) years old, STS PROM 4.0 % (interquartile range 2.9-6.0), EuroSCORE II 5.5% (IQR 4.1-7.0) with non- or mildly calcified pure AR were treated with a balloon-expandable THV. All procedures were performed after heart team discussion and standardized diagnostic workup. Clinical endpoints were collected prospectively and included device success, procedural complications (according to VARC-2 definitions) and 1-month survival. RESULTS: Device success was 100% with no device embolization or migration. Two preprocedural nonfatal complications were reported (one access site complication that required stent implantation and one pericardial tamponade). Two patients required permanent pacemaker implantation for complete AV block. At discharge and at 30-day follow-up all patients were alive and no patient showed more than minimal AR. CONCLUSION: This series documents that treatment of native non- or mildly calcified AR with balloon-expandable THV is feasible, safe and offers favorable short-term clinical outcomes. Hence, TAVI with balloon-expandable THVs may offer a valuable treatment option in patients with native AR at high surgical risk. FAU - Oechslin, Luca AU - Oechslin L AD - Heart Clinic Zurich, Witellikerstrasse 40, Zurich, 8032 Switzerland. luca.oechslin@hirslanden.ch. FAU - Biaggi, Patric AU - Biaggi P FAU - Wenaweser, Peter AU - Wenaweser P FAU - Wyss, Christophe AU - Wyss C FAU - Fritschi, Daniel AU - Fritschi D FAU - Gaemperli, Oliver AU - Gaemperli O FAU - Corti, Roberto AU - Corti R LA - eng PT - Journal Article PT - Review PL - United States TA - J Invasive Cardiol JT - The Journal of invasive cardiology JID - 8917477 SB - IM MH - Humans MH - Male MH - Aged, 80 and over MH - *Aortic Valve Insufficiency MH - *Transcatheter Aortic Valve Replacement MH - *Heart Valve Prosthesis MH - Catheters MH - Heart OTO - NOTNLM OT - aortic regurgitation OT - balloon-expandable valve prostheses OT - native non- or mildly calcified aortic regurgitation OT - transcatheter aortic valve implantation OT - transcatheter aortic valve replacement OT - transcatheter heart valves EDAT- 2023/05/23 13:06 MHDA- 2023/05/25 06:42 CRDT- 2023/05/23 11:15 PHST- 2023/05/25 06:42 [medline] PHST- 2023/05/23 13:06 [pubmed] PHST- 2023/05/23 11:15 [entrez] AID - 10.25270/jic/23.00048 [doi] PST - ppublish SO - J Invasive Cardiol. 2023 May;35(5):E254-E264. doi: 10.25270/jic/23.00048. PMID- 37214245 OWN - NLM STAT- MEDLINE DCOM- 20230524 LR - 20230524 IS - 1664-2392 (Print) IS - 1664-2392 (Electronic) IS - 1664-2392 (Linking) VI - 14 DP - 2023 TI - Individuals with numerical and structural variations of sex chromosomes: interdisciplinary management with focus on fertility potential. PG - 1160884 LID - 10.3389/fendo.2023.1160884 [doi] LID - 1160884 AB - Diagnosis and management of individuals who have differences of sex development (DSD) due to numerical or structural variations of sex chromosomes (NSVSC) remains challenging. Girls who have Turner syndrome (45X) may present with varying phenotypic features, from classical/severe to minor, and some remain undiagnosed. Boys and girls who have 45,X/46,XY chromosomal mosaicism may have Turner syndrome-like features and short stature; therefore, unexplained short stature during childhood requires karyotype analysis in both sexes, particularly if characteristic features or atypical genitalia are present. Many individuals with Klinefelter syndrome (47XXY) remain undiagnosed or are only diagnosed as adults due to fertility problems. Newborn screening by heel prick tests could potentially identify sex chromosome variations but would have ethical and financial implications, and in-depth cost-benefit analyses are needed before nationwide screening can be introduced. Most individuals who have NSVSC have lifelong co-morbidities and healthcare should be holistic, personalized and centralized, with a focus on information, psychosocial support and shared decision-making. Fertility potential should be assessed individually and discussed at an appropriate age. Oocyte or ovarian tissue cryopreservation is possible in some women who have Turner syndrome and live births have been reported following assisted reproductive technology (ART). Testicular sperm cell extraction (TESE) is possible in some men who have 45,X/46,XY mosaicism, but there is no established protocol and no reported fathering of children. Some men with Klinefelter syndrome can now father a child following TESE and ART, with multiple reports of healthy live births. Children who have NSVSC, their parents and DSD team members need to address possibilities and ethical questions relating to potential fertility preservation, with guidelines and international studies still needed. CI - Copyright (c) 2023 Juul, Gravholt, De Vos, Koledova and Cools. FAU - Juul, Anders AU - Juul A AD - Department of Growth and Reproduction, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark. AD - Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. FAU - Gravholt, Claus H AU - Gravholt CH AD - Department of Endocrinology, Aarhus University Hospital, Aarhus, Denmark. AD - Institute for Clinical Medicine, Aarhus University, Aarhus, Denmark. AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark. FAU - De Vos, Michel AU - De Vos M AD - Brussels IVF, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium. FAU - Koledova, Ekaterina AU - Koledova E AD - Global Medical Affairs Cardiometabolic and Endocrinology, Merck Healthcare KGaA, Darmstadt, Germany. FAU - Cools, Martine AU - Cools M AD - Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium. AD - Pediatric Endocrinology Service, Department of Pediatrics, Ghent University Hospital, Ghent, Belgium. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20230505 PL - Switzerland TA - Front Endocrinol (Lausanne) JT - Frontiers in endocrinology JID - 101555782 SB - IM MH - Male MH - Female MH - Humans MH - *Turner Syndrome/diagnosis/genetics/therapy MH - *Klinefelter Syndrome/diagnosis/genetics/therapy MH - Semen MH - Mosaicism MH - Sex Chromosomes PMC - PMC10197804 OTO - NOTNLM OT - DSD OT - Klinefelter syndrome OT - NSVSC OT - Turner syndrome OT - sex chromosomes COIS- CG has received honoraria from Merck and Novo Nordisk. EK is an employee of Merck KGaA, Darmstadt, Germany and holds shares in the company. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declare that this study received funding from Merck KGaA, Darmstadt, Germany (CrossRef Funder ID: 10.13039/100009945). The funder had the following involvement with the study: Merck Healthcare KGaA was involved in organizing and selecting speakers for the meeting that formed the basis for this report, and the authors (except EK) were speakers at the meeting. Merck Healthcare KGaA was involved in the conceptualization of the publication and the decision to publish. There was no commercial influence on analysis or interpretation of any of the information described in the manuscript. EDAT- 2023/05/22 19:11 MHDA- 2023/05/24 06:42 PMCR- 2023/01/01 CRDT- 2023/05/22 12:09 PHST- 2023/02/07 00:00 [received] PHST- 2023/04/10 00:00 [accepted] PHST- 2023/05/24 06:42 [medline] PHST- 2023/05/22 19:11 [pubmed] PHST- 2023/05/22 12:09 [entrez] PHST- 2023/01/01 00:00 [pmc-release] AID - 10.3389/fendo.2023.1160884 [doi] PST - epublish SO - Front Endocrinol (Lausanne). 2023 May 5;14:1160884. doi: 10.3389/fendo.2023.1160884. eCollection 2023. PMID- 37211509 OWN - NLM STAT- MEDLINE DCOM- 20230725 LR - 20240802 IS - 1532-7361 (Electronic) IS - 0039-6060 (Print) IS - 0039-6060 (Linking) VI - 174 IP - 2 DP - 2023 Aug TI - A qualitative study of how team characteristics and leadership are associated with information sharing in multidisciplinary intensive care units. PG - 350-355 LID - S0039-6060(23)00163-0 [pii] LID - 10.1016/j.surg.2023.03.017 [doi] AB - BACKGROUND: Better information sharing in intensive care units has been associated with lower risk-adjusted mortality. This study explored how team characteristics and leadership are associated with information sharing in 4 intensive care units in a single large urban, academic medical center. METHODS: A qualitative study was conducted to understand how team characteristics and leadership are associated with information sharing. Qualitative data were conducted through ethnographic observations. One postdoctoral research fellow and one PhD qualitative researcher conducted nonparticipant observations of a Medical, Surgical, Neurological, and Cardiothoracic intensive care unit morning and afternoon rounds, as well as nurse and resident handoffs from May to September 2021. Field notes of observations were thematically analyzed using deductive reasoning anchored to the Edmondson Team Learning Model. This study included nurses, physicians (ie, intensivists, surgeons, fellows, and residents), medical students, pharmacists, respiratory therapists, dieticians, physical therapists, physician assistants, and nurse practitioners. RESULTS: We conducted 50 person-hours of observations involving 148 providers. Three themes emerged from the qualitative analysis: (1) team leaders used variable leadership techniques to involve team members in discussions for information sharing related to patient care, (2) predefined tasks for team members allowed them to prepare for effective information sharing during intensive care unit rounds, and (3) a psychologically safe environment allowed team members to participate in discussions for information sharing related to patient care. CONCLUSION: Inclusive team leadership is foundational in creating a psychologically safe environment for effective information sharing. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Abahuje, Egide AU - Abahuje E AD - Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL. Electronic address: abegid@gmail.com. FAU - Diaz, Carmen M AU - Diaz CM AD - Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL. FAU - Lin, Katherine A AU - Lin KA AD - Department of Surgery, Mayo Clinic, Rochester, MN. FAU - Tesorero, Kaithlyn AU - Tesorero K AD - Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL. FAU - Bushara, Omar AU - Bushara O AD - Department of Surgery, University of Pennsylvania, Philadelphia, PA. FAU - Yang, Sohae AU - Yang S AD - Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL. FAU - Berry, Andrew B L AU - Berry ABL AD - Department of Medical Social Sciences, Feinberg School of Medicine, Northwestern University, Chicago, IL. FAU - Rafferty, Miriam R AU - Rafferty MR AD - Shirley Ryan Ability Lab, Northwestern University, Chicago, IL. FAU - Johnson, Julie K AU - Johnson JK AD - Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL. FAU - Stey, Anne M AU - Stey AM AD - Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL. LA - eng GR - K23 HL157832/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230519 PL - United States TA - Surgery JT - Surgery JID - 0417347 SB - IM MH - Humans MH - *Leadership MH - Patient Care Team MH - Intensive Care Units MH - Qualitative Research MH - *Surgeons MH - Information Dissemination PMC - PMC11210940 MID - NIHMS2002542 COIS- Conflict of interest/Disclosure The authors have no conflicts of interests or disclosures to report. EDAT- 2023/05/22 00:41 MHDA- 2023/07/25 06:42 PMCR- 2024/08/01 CRDT- 2023/05/21 22:00 PHST- 2023/01/04 00:00 [received] PHST- 2023/03/14 00:00 [revised] PHST- 2023/03/17 00:00 [accepted] PHST- 2023/07/25 06:42 [medline] PHST- 2023/05/22 00:41 [pubmed] PHST- 2023/05/21 22:00 [entrez] PHST- 2024/08/01 00:00 [pmc-release] AID - S0039-6060(23)00163-0 [pii] AID - 10.1016/j.surg.2023.03.017 [doi] PST - ppublish SO - Surgery. 2023 Aug;174(2):350-355. doi: 10.1016/j.surg.2023.03.017. Epub 2023 May 19. PMID- 31194471 STAT- Publisher CTDT- 20230522 PB - StatPearls Publishing DP - 2023 Jan TI - Dipeptidyl Peptidase IV (DPP IV) Inhibitors. BTI - StatPearls AB - Dipeptidyl peptidase 4 (DPP-4) inhibitors are a group of antihyperglycemic medications used to manage type 2 diabetes mellitus, which is a significant risk factor for coronary disease, heart failure, stroke, and many other cardiovascular conditions. This activity reviews the various drugs in this group, indications, contraindications, activity, adverse events, and other key elements of DPP-4 inhibitors therapy in the clinical setting. It also elaborates on the essential information needed by any interprofessional team member managing the care of patients with diabetes. CI - Copyright (c) 2023, StatPearls Publishing LLC. FAU - Kasina, Srinivasa Venkata Siva Kumar AU - Kasina SVSK FAU - Baradhi, Krishna M AU - Baradhi KM AD - University of Oklahoma LA - eng PT - Study Guide PT - Book Chapter PL - Treasure Island (FL) COIS- Disclosure: Srinivasa Venkata Siva Kumar Kasina declares no relevant financial relationships with ineligible companies. Disclosure: Krishna M Baradhi declares no relevant financial relationships with ineligible companies. EDAT- 2023/05/22 00:00 CRDT- 2023/05/22 00:00 AID - NBK542331 [bookaccession] PMID- 37210333 OWN - NLM STAT- MEDLINE DCOM- 20231106 LR - 20231106 IS - 2588-994X (Electronic) IS - 2588-994X (Linking) VI - 26 IP - 4 DP - 2023 Dec TI - Impact of an emergency department rapid response system on inpatient clinical deterioration: A controlled pre-post study. PG - 333-340 LID - S2588-994X(23)00029-5 [pii] LID - 10.1016/j.auec.2023.05.001 [doi] AB - AIM: To determine the impact implementation of Emergency Department Clinical Emergency Response System (EDCERS) on inpatient deterioration events and identify contributing causal factors. METHODS: EDCERS was implemented in an Australian regional hospital, integrating a single parameter track and trigger criteria for escalation of care, and emergency, specialty and critical care clinician response to patient deterioration. In this controlled pre-post study, electronic medical records of patients who experienced a deterioration event (rapid response call, cardiac arrest or unplanned intensive care admission) on the ward within 72 h of admission from the emergency department (ED) were reviewed. Causal factors contributing to the deteriorating event were assessed using a validated human factors framework. RESULTS: Implementation of EDCERS reduced the number of inpatient deterioration events within 72 h of emergency admission with failure or delayed response to ED patient deterioration as a causal factor. There was no change in the overall rate of inpatient deterioration events. CONCLUSION: This study supports wider implementation of rapid response systems in the ED to improve management of deteriorating patients. Tailored implementation strategies should be used to achieve successful and sustainable uptake of ED rapid response systems and improve outcomes in deteriorating patients. CI - Crown Copyright (c) 2023. Published by Elsevier Ltd. All rights reserved. FAU - Munroe, Belinda AU - Munroe B AD - Emergency Services, Illawarra Shoalhaven Local Health District, Australia; Faculty of Science, Medicine and Health, University of Wollongong, Australia. Electronic address: Belinda.Munroe@health.nsw.gov.au. FAU - Curtis, Kate AU - Curtis K AD - Emergency Services, Illawarra Shoalhaven Local Health District, Australia; Faculty of Science, Medicine and Health, University of Wollongong, Australia; Susan Wakil School of Nursing and Midwifery, University of Sydney, Australia; George Institute for Global Health, Australia. FAU - Fry, Margaret AU - Fry M AD - Susan Wakil School of Nursing and Midwifery, University of Sydney, Australia; University of Technology Sydney, Australia; Northern Sydney Local Health District, Australia. FAU - Balzer, Sharyn AU - Balzer S AD - Emergency Services, Illawarra Shoalhaven Local Health District, Australia; Shoalhaven Hospital Group, Illawarra Shoalhaven Local Health District, Australia. FAU - Perara, Panchalee AU - Perara P AD - Wollongong Hospital, Illawarra Shoalhaven Local Health District, Australia. FAU - Couttie, Tracey AU - Couttie T AD - Division of Child and Families, Illawarra Shoalhaven Local Health District, Australia. FAU - Royston, Karlie AU - Royston K AD - Shoalhaven Hospital Group, Illawarra Shoalhaven Local Health District, Australia. FAU - Yu, Ping AU - Yu P AD - Centre for Digital Transformation, University of Wollongong, Australia. FAU - Tidswell, Natasha AU - Tidswell N AD - Emergency Services, Illawarra Shoalhaven Local Health District, Australia. FAU - Considine, Julie AU - Considine J AD - School of Nursing and Midwifery and Centre for Quality and Patient Safety Research in the Institute for Health Transformation, Deakin University, Geelong, Victoria, Australia; Centre for Quality and Patient Safety Research - Eastern Health, Box Hill, Victoria, Australia. LA - eng PT - Journal Article DEP - 20230518 PL - Australia TA - Australas Emerg Care JT - Australasian emergency care JID - 101727782 SB - IM MH - Humans MH - *Clinical Deterioration MH - Inpatients MH - Australia MH - *Hospital Rapid Response Team MH - Emergency Service, Hospital OTO - NOTNLM OT - Adverse events OT - Causal factors OT - Emergency Service, Hospital OT - Patient Deterioration OT - Rapid Response Systems COIS- Declaration of Competing Interest Professor Margaret Fry and Professor Julie Considine are senior editors for Australasian Emergency Care however were not involve in the peer review process. There are no other conflicts of interest. EDAT- 2023/05/21 01:05 MHDA- 2023/11/06 06:41 CRDT- 2023/05/20 22:02 PHST- 2023/02/01 00:00 [received] PHST- 2023/05/03 00:00 [revised] PHST- 2023/05/03 00:00 [accepted] PHST- 2023/11/06 06:41 [medline] PHST- 2023/05/21 01:05 [pubmed] PHST- 2023/05/20 22:02 [entrez] AID - S2588-994X(23)00029-5 [pii] AID - 10.1016/j.auec.2023.05.001 [doi] PST - ppublish SO - Australas Emerg Care. 2023 Dec;26(4):333-340. doi: 10.1016/j.auec.2023.05.001. Epub 2023 May 18. PMID- 37209415 OWN - NLM STAT- MEDLINE DCOM- 20230707 LR - 20230718 IS - 1549-490X (Electronic) IS - 1083-7159 (Print) IS - 1083-7159 (Linking) VI - 28 IP - 7 DP - 2023 Jul 5 TI - Carcinoid Heart Disease Management: A Multi-Disciplinary Collaboration. PG - 575-583 LID - 10.1093/oncolo/oyad126 [doi] AB - Carcinoid heart disease (CaHD) is an important complication among patients with metastatic neuroendocrine tumors and carcinoid syndrome (CS). CS patients (25%-65%) eventually develop CaHD; these patients face a significantly increased risk of morbidity and mortality. Guidance papers (eg, clinical practice guidelines, consensus guidelines, and expert statements) have been established by major organizations across the disciplines of cardiology and oncology; however, these recommendations are not routinely implemented. The aim of this article is to encourage the integration of current recommendations from national societies into clinical practice. Early screening upon recognition of CS and prior to the development of CaHD symptoms is paramount, as no existing therapies are approved to reverse the fibrotic damage to the heart once it occurs. Valvular replacement is the only definitive treatment for CaHD once it has developed. When patients are noted to have urinary 5-hydroxyindoleacetic acid (5-HIAA) levels >/=300 micromol/24 h and/or serum N-terminal pro B-type natriuretic peptide (NT-proBNP) levels >260 pg/mL, echocardiography is recommended. Systemic approaches to control tumor growth and hormonal secretion include somatostatin analogs (SSAs), followed by options including peptide receptor radiotherapy (PRRT), everolimus and liver embolization. Telotristat is the primary choice for control of diarrhea refractory to SSA. Diuretics are the mainstay of heart failure symptom management for patients who develop CaHD. Considerations for future research are discussed, including the ongoing TELEHEART (TELotristat Ethyl in a HEART biomarker study) trial involving telotristat and not yet activated CHARRT (Carcinoid Heart disease And peptide Receptor Radiotargetted Therapy) study involving PRRT with lutetium 177 (177Lu) dotatate. CI - (c) The Author(s) 2023. Published by Oxford University Press. FAU - Das, Satya AU - Das S AUID- ORCID: 0000-0002-7625-1039 AD - Late Development Oncology, GI, AstraZeneca, Gaithersburg, MD, USA. FAU - Stockton, Shannon S AU - Stockton SS AD - Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. FAU - Hassan, Saamir A AU - Hassan SA AD - Ascension Texas Cardiovascular, Cedar Park, TX, USA. LA - eng PT - Journal Article PL - England TA - Oncologist JT - The oncologist JID - 9607837 RN - 9HW64Q8G6G (Everolimus) SB - IM MH - Humans MH - *Carcinoid Heart Disease/diagnosis/therapy MH - *Carcinoid Tumor/drug therapy MH - *Malignant Carcinoid Syndrome/drug therapy MH - *Neuroendocrine Tumors/therapy/drug therapy MH - Everolimus/therapeutic use PMC - PMC10322126 OTO - NOTNLM OT - 5-hydroxyindoleacetic acid OT - N-terminal pro B-type natriuretic peptide OT - carcinoid heart disease OT - carcinoid syndrome OT - neuroendocrine tumors COIS- Satya Das has received consulting fees from AAA/Novartis, Ipsen, and TerSera and is now employed by AstraZeneca. Shannon S. Stockton and Saamir A. Hassan indicated no financial relationships. EDAT- 2023/05/20 19:13 MHDA- 2023/07/07 06:42 PMCR- 2023/05/20 CRDT- 2023/05/20 16:42 PHST- 2023/03/07 00:00 [received] PHST- 2023/04/17 00:00 [accepted] PHST- 2023/07/07 06:42 [medline] PHST- 2023/05/20 19:13 [pubmed] PHST- 2023/05/20 16:42 [entrez] PHST- 2023/05/20 00:00 [pmc-release] AID - 7174955 [pii] AID - oyad126 [pii] AID - 10.1093/oncolo/oyad126 [doi] PST - ppublish SO - Oncologist. 2023 Jul 5;28(7):575-583. doi: 10.1093/oncolo/oyad126. PMID- 37208096 OWN - NLM STAT- MEDLINE DCOM- 20230522 LR - 20250227 IS - 1600-0641 (Electronic) IS - 0168-8278 (Print) IS - 0168-8278 (Linking) VI - 78 IP - 6 DP - 2023 Jun TI - Evaluation of recipients with significant comorbidity - Patients with cardiovascular disease. PG - 1089-1104 LID - S0168-8278(23)00200-3 [pii] LID - 10.1016/j.jhep.2023.03.023 [doi] AB - Liver transplant(ation) (LT) is the most effective treatment for patients with decompensated liver disease. The increasing prevalence of obesity and type 2 diabetes and the growing number of patients with non-alcoholic fatty liver disease being evaluated for LT, have resulted in a greater proportion of LT candidates presenting with a higher risk of cardiovascular disease. As cardiovascular disease is a major cause of morbidity and mortality after LT, a thorough cardiovascular evaluation pre-LT is crucial. In this review, we discuss the latest evidence on the cardiovascular evaluation of LT candidates and we focus on the most prevalent conditions, namely ischaemic heart disease, atrial fibrillation and other arrhythmias, valvular heart disease, and cardiomyopathies. LT candidates undergo an electrocardiogram, a resting transthoracic echocardiography and an assessment of their cardiopulmonary functional ability as part of their standardised pre-LT work-up. Further diagnostic work-up is undertaken based on the results of the baseline evaluation and may include a coronary computed tomography angiography in patients with cardiovascular risk factors. The evaluation of potential LT candidates for cardiovascular disease requires a multidisciplinary approach, with input from anaesthetists, cardiologists, hepatologists and transplant surgeons. CI - Copyright (c) 2023 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. FAU - Tsochatzis, Emmanuel A AU - Tsochatzis EA AD - UCL Institute for Liver and Digestive Health, Royal Free Campus, London, UK; Sheila Sherlock Liver Unit, Royal Free Hospital, London, UK. Electronic address: e.tsochatzis@ucl.ac.uk. FAU - Watt, Kymberly D AU - Watt KD AD - Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA. FAU - VanWagner, Lisa B AU - VanWagner LB AD - Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, Dallas, Texas, USA. FAU - Verna, Elizabeth C AU - Verna EC AD - Center for Liver Disease and Transplantation, Columbia University Irving Medical Center, New York, New York, USA. FAU - Berzigotti, Annalisa AU - Berzigotti A AD - Department of Visceral Surgery and Medicine, Bern University Hospital, University of Bern, Bern, Switzerland. LA - eng GR - R56 HL155093/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Review PL - Netherlands TA - J Hepatol JT - Journal of hepatology JID - 8503886 SB - IM MH - Humans MH - *Cardiovascular Diseases/epidemiology MH - Risk Factors MH - *Diabetes Mellitus, Type 2/epidemiology MH - Comorbidity MH - *Non-alcoholic Fatty Liver Disease/complications/diagnosis/epidemiology PMC - PMC11856630 MID - NIHMS2055197 OTO - NOTNLM OT - MELD OT - NAFLD OT - cardiomyopathy OT - cardiopulmonary reserve OT - cirrhosis OT - ischaemic heart disease OT - liver transplantation OT - type II diabetes COIS- Conflicts of interest LBV receives grant support from W.L. Gore & Associates and Astra Zeneca, and consults for Novo Nordisk and Numares. Please refer to the accompanying ICMJE disclosure forms for further details. EDAT- 2023/05/20 09:42 MHDA- 2023/05/22 06:42 PMCR- 2025/02/25 CRDT- 2023/05/19 21:01 PHST- 2022/11/10 00:00 [received] PHST- 2023/03/24 00:00 [revised] PHST- 2023/03/26 00:00 [accepted] PHST- 2023/05/22 06:42 [medline] PHST- 2023/05/20 09:42 [pubmed] PHST- 2023/05/19 21:01 [entrez] PHST- 2025/02/25 00:00 [pmc-release] AID - S0168-8278(23)00200-3 [pii] AID - 10.1016/j.jhep.2023.03.023 [doi] PST - ppublish SO - J Hepatol. 2023 Jun;78(6):1089-1104. doi: 10.1016/j.jhep.2023.03.023. PMID- 37208057 OWN - NLM STAT- MEDLINE DCOM- 20230522 LR - 20230522 IS - 1556-228X (Electronic) IS - 0278-5919 (Linking) VI - 42 IP - 3 DP - 2023 Jul TI - General Medical Emergencies in Athletes. PG - 427-440 LID - S0278-5919(23)00032-7 [pii] LID - 10.1016/j.csm.2023.02.007 [doi] AB - This article focuses on the management of the most common on-field medical emergencies. As with any discipline in medicine, a well-defined plan and systematic approach is the cornerstone of quality health care delivery. In addition, the team-based collaboration is necessary for the safety of the athlete and the success of the treatment plan. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Verhey, Jens T AU - Verhey JT AD - Orthopaedic Surgery Residency, Department of Orthopaedic Surgery, Mayo Clinic Arizona, Phoenix, AZ, USA. FAU - Poon, Steven K AU - Poon SK AD - Sports Medicine Section, Department of Orthopaedic Surgery, Mayo Clinic Arizona, Phoenix, AZ, USA. Electronic address: poon.steven@mayo.edu. LA - eng PT - Journal Article PT - Review DEP - 20230406 PL - United States TA - Clin Sports Med JT - Clinics in sports medicine JID - 8112473 SB - IM MH - Humans MH - Death, Sudden, Cardiac MH - *Sports MH - Emergencies MH - Athletes MH - *Sports Medicine OTO - NOTNLM OT - Asthma OT - Emergency action plan OT - Sports medicine OT - Sudden cardiac arrest EDAT- 2023/05/20 09:42 MHDA- 2023/05/22 06:42 CRDT- 2023/05/19 20:59 PHST- 2023/05/22 06:42 [medline] PHST- 2023/05/20 09:42 [pubmed] PHST- 2023/05/19 20:59 [entrez] AID - S0278-5919(23)00032-7 [pii] AID - 10.1016/j.csm.2023.02.007 [doi] PST - ppublish SO - Clin Sports Med. 2023 Jul;42(3):427-440. doi: 10.1016/j.csm.2023.02.007. Epub 2023 Apr 6. PMID- 39131656 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240813 IS - 2772-9303 (Electronic) IS - 2772-9303 (Linking) VI - 2 IP - 4 DP - 2023 Jul-Aug TI - Predictors of Residual Severe Tricuspid Regurgitation After Transcatheter Mitral Valve Repair. PG - 100612 LID - 10.1016/j.jscai.2023.100612 [doi] LID - 100612 AB - BACKGROUND: Severe tricuspid regurgitation (TR) may persist after a mitral transcatheter edge-to-edge repair (M-TEER) and is associated with worsened clinical outcomes and survival. It is unclear which patients with concomitant mitral regurgitation (MR) and TR will have TR reduction after M-TEER. The aim of this study was to identify the predictors of residual TR after transcatheter edge-to-edge repair (TEER). METHODS: Data were collected from the Northwell TEER registry, a prospectively maintained mandatory database including 4 high-volume transcatheter aortic valve replacement/TEER centers. Transthoracic echocardiograms, both pre-TEER and post-TEER, were evaluated. Univariate and multivariate logistic regression analyses were performed to identify predictors of severe TR after M-TEER. Significant TR reduction was defined as a reduction in TR grade by at least 1+ with moderate (2+) or less TR at 1 month. RESULTS: Of the 479 patients who underwent M-TEER, 107 patients with concomitant severe MR/TR were included. Successful MR reduction occurred in 89 patients (84%) and a significant TR reduction in 45 (42%). On the univariate analysis, the only predictors of severe residual TR were right atrial area and unsuccessful M-TEER. On the multivariate logistic regression model, the only predictor variable for patients with a reduction in TR was MR reduction of >/=3+ with M-TEER. CONCLUSIONS: In patients with concomitant severe MR and TR, TR reduction after isolated M-TEER occurs in only approximately 40% of patients. MR grade reduction >/=3+ was the only independent predictor for TR reduction. Other clinical and echocardiographic variables (including pulmonary hypertension, right ventricular function, tricuspid annular dilation, atrial fibrillation, and presence of a cardiac implantable electrical device) were not associated with residual TR. Inability to predict TR reduction after M-TEER highlights the importance of establishing transcatheter tricuspid valve therapies and should factor in heart-team discussions. CI - (c) 2023 The Author(s). FAU - Basman, Craig AU - Basman C AD - Department of Cardiovascular and Thoracic Surgery, Lenox Hill Hospital/Northwell Health, New York, New York. FAU - Kodra, Arber AU - Kodra A AD - Department of Cardiovascular and Thoracic Surgery, Lenox Hill Hospital/Northwell Health, New York, New York. FAU - Pirelli, Luigi AU - Pirelli L AD - Department of Cardiovascular and Thoracic Surgery, Lenox Hill Hospital/Northwell Health, New York, New York. FAU - Mustafa, Ahmad AU - Mustafa A AD - Department of Cardiovascular and Thoracic Surgery, Staten Island/Northwell Health, New York, NY. FAU - Mehla, Priti AU - Mehla P AD - Department of Cardiovascular and Thoracic Surgery, Lenox Hill Hospital/Northwell Health, New York, New York. FAU - Trost, Biana AU - Trost B AD - Department of Cardiovascular and Thoracic Surgery, Lenox Hill Hospital/Northwell Health, New York, New York. FAU - Ong, Caroline AU - Ong C AD - Department of Cardiovascular and Thoracic Surgery, Lenox Hill Hospital/Northwell Health, New York, New York. FAU - Remillard, Taylor AU - Remillard T AD - Department of Cardiovascular and Thoracic Surgery, Lenox Hill Hospital/Northwell Health, New York, New York. FAU - Schultz, Emily AU - Schultz E AD - Department of Cardiovascular and Thoracic Surgery, Lenox Hill Hospital/Northwell Health, New York, New York. FAU - Wang, Denny AU - Wang D AD - Department of Cardiovascular and Thoracic Surgery, Lenox Hill Hospital/Northwell Health, New York, New York. FAU - Liu, Shangyi AU - Liu S AD - Department of Cardiovascular and Thoracic Surgery, Lenox Hill Hospital/Northwell Health, New York, New York. FAU - Mihelis, Efstathia AU - Mihelis E AD - Department of Cardiovascular and Thoracic Surgery, Lenox Hill Hospital/Northwell Health, New York, New York. FAU - Rutkin, Bruce AU - Rutkin B AD - Department of Cardiovascular and Thoracic Surgery, North Shore University/Northwell Health, New York, New York. FAU - Koss, Elana AU - Koss E AD - Department of Cardiovascular and Thoracic Surgery, North Shore University/Northwell Health, New York, New York. FAU - Kalimi, Robert AU - Kalimi R AD - Department of Cardiovascular and Thoracic Surgery, South Shore University/Northwell Health, New York, New York. FAU - Maniatis, Gregory AU - Maniatis G AD - Department of Cardiovascular and Thoracic Surgery, Staten Island/Northwell Health, New York, NY. FAU - Supariwala, Azhar AU - Supariwala A AD - Department of Cardiovascular and Thoracic Surgery, South Shore University/Northwell Health, New York, New York. FAU - Scheinerman, S Jacob AU - Scheinerman SJ AD - Department of Cardiovascular and Thoracic Surgery, Lenox Hill Hospital/Northwell Health, New York, New York. FAU - Kliger, Chad AU - Kliger C AD - Department of Cardiovascular and Thoracic Surgery, Lenox Hill Hospital/Northwell Health, New York, New York. LA - eng PT - Journal Article DEP - 20230519 PL - United States TA - J Soc Cardiovasc Angiogr Interv JT - Journal of the Society for Cardiovascular Angiography & Interventions JID - 9918419271306676 PMC - PMC11307626 OTO - NOTNLM OT - transcatheter edge-to-edge repair OT - transcatheter mitral valve repair OT - transcatheter mitral valve replacement OT - tricuspid regurgitation COIS- Chad A. Kliger is a consultant and receives speaking honoraria from Edwards Lifesciences and Medtronic. Luigi Pirelli is a consultant and receives speaking honoraria from Edwards Lifesciences and Medtronic. Azhar Supariwala is a consultant and receives speaking honoraria from Abbott. Bruce Rutkin is a consultant and receives speaking honoraria from Edwards Lifesciences and Medtronic. None of the other authors have anything to disclose. EDAT- 2023/05/19 00:00 MHDA- 2023/05/19 00:01 PMCR- 2023/05/19 CRDT- 2024/08/12 06:14 PHST- 2022/12/12 00:00 [received] PHST- 2023/02/05 00:00 [revised] PHST- 2023/02/22 00:00 [accepted] PHST- 2023/05/19 00:01 [medline] PHST- 2023/05/19 00:00 [pubmed] PHST- 2024/08/12 06:14 [entrez] PHST- 2023/05/19 00:00 [pmc-release] AID - S2772-9303(23)00039-X [pii] AID - 100612 [pii] AID - 10.1016/j.jscai.2023.100612 [doi] PST - epublish SO - J Soc Cardiovasc Angiogr Interv. 2023 May 19;2(4):100612. doi: 10.1016/j.jscai.2023.100612. eCollection 2023 Jul-Aug. PMID- 37204656 OWN - NLM STAT- MEDLINE DCOM- 20230731 LR - 20260304 IS - 1936-0541 (Electronic) IS - 1936-0533 (Print) IS - 1936-0533 (Linking) VI - 17 IP - 4 DP - 2023 Aug TI - An international multidisciplinary consensus statement on MAFLD and the risk of CVD. PG - 773-791 LID - 10.1007/s12072-023-10543-8 [doi] AB - BACKGROUND: Fatty liver disease in the absence of excessive alcohol consumption is an increasingly common condition with a global prevalence of ~ 25-30% and is also associated with cardiovascular disease (CVD). Since systemic metabolic dysfunction underlies its pathogenesis, the term metabolic (dysfunction)-associated fatty liver disease (MAFLD) has been proposed for this condition. MAFLD is closely intertwined with obesity, type 2 diabetes mellitus and atherogenic dyslipidemia, which are established cardiovascular risk factors. Unlike CVD, which has received attention in the literature on fatty liver disease, the CVD risk associated with MAFLD is often underestimated, especially among Cardiologists. METHODS AND RESULTS: A multidisciplinary panel of fifty-two international experts comprising Hepatologists, Endocrinologists, Diabetologists, Cardiologists and Family Physicians from six continents (Asia, Europe, North America, South America, Africa and Oceania) participated in a formal Delphi survey and developed consensus statements on the association between MAFLD and the risk of CVD. Statements were developed on different aspects of CVD risk, ranging from epidemiology to mechanisms, screening, and management. CONCULSIONS: The expert panel identified important clinical associations between MAFLD and the risk of CVD that could serve to increase awareness of the adverse metabolic and cardiovascular outcomes of MAFLD. Finally, the expert panel also suggests potential areas for future research. CI - (c) 2023. Asian Pacific Association for the Study of the Liver. FAU - Zhou, Xiao-Dong AU - Zhou XD AD - Department of Cardiovascular Medicine, The Heart Center, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. FAU - Targher, Giovanni AU - Targher G AD - Department of Medicine, Section of Endocrinology, Diabetes, and Metabolism, University of Verona, Verona, Italy. FAU - Byrne, Christopher D AU - Byrne CD AD - Southampton National Institute for Health and Care Research Biomedical Research Centre, University Hospital Southampton, and University of Southampton, Southampton General Hospital, Southampton, UK. FAU - Somers, Virend AU - Somers V AD - Department of Cardiovascular Medicine, Mayo Clinic College of Medicine, Rochester, USA. FAU - Kim, Seung Up AU - Kim SU AD - Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, South Korea. FAU - Chahal, C Anwar A AU - Chahal CAA AD - Department of Cardiovascular Medicine, Mayo Clinic College of Medicine, Rochester, USA. AD - Center for Inherited Cardiovascular Diseases, WellSpan Health, Lancaster, PA, USA. AD - Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, EC1A 7BE, West Smithfield, UK. FAU - Wong, Vincent Wai-Sun AU - Wong VW AD - State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China. FAU - Cai, Jingjing AU - Cai J AD - Department of Cardiology, The Third Xiangya Hospital, Central South University, Changsha, China. FAU - Shapiro, Michael D AU - Shapiro MD AD - Center for Prevention of Cardiovascular Disease, Section on Cardiovascular Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA. FAU - Eslam, Mohammed AU - Eslam M AD - Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital, University of Sydney, Sydney, NSW, 2145, Australia. FAU - Steg, Philippe Gabriel AU - Steg PG AD - Universite Paris -Cite, Assistance Publique-Hopitaux de Paris, Hopital Bichat, FACT (French Alliance for Cardiovascular Trials), INSERM U1148, Paris, France. FAU - Sung, Ki-Chul AU - Sung KC AD - Department of Internal Medicine, Division of Cardiology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Misra, Anoop AU - Misra A AD - Fortis C-DOC Centre of Excellence for Diabetes, Metabolic Diseases and Endocrinology, Chirag Enclave, National Diabetes Obesity and Cholesterol Foundation and Diabetes Foundation (India), New Delhi, India. FAU - Li, Jian-Jun AU - Li JJ AD - State Key Laboratory of Cardiovascular Diseases, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Brotons, Carlos AU - Brotons C AD - Biomedical Research Institute Sant Pau (IIB Sant Pau), Sardenya Primary Health Care Center, Barcelona, Spain. FAU - Huang, Yuli AU - Huang Y AD - Department of Cardiology, Shunde Hospital, Southern Medical University, Jiazi Road, Lunjiao Town, Shunde District, Foshan, China. FAU - Papatheodoridis, George V AU - Papatheodoridis GV AD - Department of Gastroenterology, Medical School of National and Kapodistrian University of Athens, General Hospital of Athens "Laiko", Athens, Greece. FAU - Sun, Aijun AU - Sun A AD - Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China. FAU - Yilmaz, Yusuf AU - Yilmaz Y AD - Institute of Gastroenterology, Marmara University, Istanbul, Turkey. AD - Department of Gastroenterology, School of Medicine, Recep Tayyip Erdogan University, Rize, Turkey. FAU - Chan, Wah Kheong AU - Chan WK AD - Gastroenterology and Hepatology Unit, Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. FAU - Huang, Hui AU - Huang H AD - Department of Cardiology, The Eighth Affiliated Hospital of Sun Yat-Sen University, 3025 Shennan Middle Road, Shenzhen, China. FAU - Mendez-Sanchez, Nahum AU - Mendez-Sanchez N AD - Liver Research Unit, Medica Sur Clinic and Foundation and Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico. FAU - Alqahtani, Saleh A AU - Alqahtani SA AD - Liver Transplantation Unit, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia. AD - Division of Gastroenterology and Hepatology, Johns Hopkins University School of Medicine, 720 Rutland Avenue, Baltimore, MD, USA. FAU - Cortez-Pinto, Helena AU - Cortez-Pinto H AD - Laboratorio de Nutricao e Metabolismo, Faculdade de Medicina, Clinica Universitaria de Gastrenterologia, Universidade de Lisboa, Lisbon, Portugal. FAU - Lip, Gregory Y H AU - Lip GYH AD - Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart and Chest Hospital, Liverpool, UK. AD - Danish Center for Clinical Health Services Research, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. FAU - de Knegt, Robert J AU - de Knegt RJ AD - Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, Gravendijkwal 230, Room Ha 206, Rotterdam, The Netherlands. FAU - Ocama, Ponsiano AU - Ocama P AD - Department of Internal Medicine, School of Medicine, Makerere University College of Health Sciences, Kampala, Uganda. FAU - Romero-Gomez, Manuel AU - Romero-Gomez M AD - Department of Digestive and Liver Diseases, Institute of Biomedicine of Seville, University Hospital Virgen del Rocio, University of Seville, Seville, Spain. FAU - Fudim, Marat AU - Fudim M AD - Department of Cardiology, Duke University School of Medicine, Durham, NC, USA. AD - Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA. FAU - Sebastiani, Giada AU - Sebastiani G AD - Division of Gastroenterology and Hepatology, Chronic Viral Illness Service, McGill University Health Centre, Royal Victoria Hospital, 1001 Blvd. Decarie, Montreal, Canada. FAU - Son, Jang Won AU - Son JW AD - Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea. FAU - Ryan, John D AU - Ryan JD AD - Department of Hepatology, RCSI School of Medicine and Medical Sciences, Dublin/Beaumont Hospital, Dublin, Ireland. FAU - Ikonomidis, Ignatios AU - Ikonomidis I AD - Preventive Cardiology Laboratory and Cardiometabolic Clinic, Second Cardiology Department, Attikon Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece. FAU - Treeprasertsuk, Sombat AU - Treeprasertsuk S AD - Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand. FAU - Pastori, Daniele AU - Pastori D AD - Department of Clinical, Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy. FAU - Lupsor-Platon, Monica AU - Lupsor-Platon M AD - Department of Medical Imaging, "Prof. Dr. Octavian Fodor" Regional Institute of Gastroenterology and Hepathology, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania. FAU - Tilg, Herbert AU - Tilg H AD - Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology and Metabolism, Medical University Innsbruck, Innsbruck, Austria. FAU - Ghazinyan, Hasmik AU - Ghazinyan H AD - Department of Hepatology, Nork Clinical Hospital of Infectious Disease, Yerevan, Armenia. FAU - Boursier, Jerome AU - Boursier J AD - Hepato-Gastroenterology Department, University Hospital, 4 Larrey Street, 49933, Angers Cedex 09, France. AD - HIFIH Laboratory, UPRES 3859, SFR 4208, LUNAM University, Angers, France. FAU - Hamaguchi, Masahide AU - Hamaguchi M AD - Department of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465, Kajii-Cho, Kawaramachi-Hirokoji, Kamigyo-Ku, Kyoto, Japan. FAU - Nguyen, Mindie H AU - Nguyen MH AD - Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, CA, USA. AD - Department of Epidemiology and Population Health, Stanford University Medical Center, Palo Alto, CA, USA. FAU - Fan, Jian-Gao AU - Fan JG AD - Center for Fatty Liver, Department of Gastroenterology, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Goh, George Boon-Bee AU - Goh GB AD - Department of Gastroenterology and Hepatology, Singapore General Hospital, Singapore, Singapore. FAU - Al Mahtab, Mamun AU - Al Mahtab M AD - Department of Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh. FAU - Hamid, Saeed AU - Hamid S AD - Department of Medicine, Aga Khan University, Stadium Road, Karachi, 74800, Pakistan. FAU - Perera, Nilanka AU - Perera N AD - Department of Medicine, University of Sri Jayewardenepura, Nugegoda, Sri Lanka. FAU - George, Jacob AU - George J AD - Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital, University of Sydney, Sydney, NSW, 2145, Australia. jacob.george@sydney.edu.au. FAU - Zheng, Ming-Hua AU - Zheng MH AUID- ORCID: 0000-0003-4984-2631 AD - MAFLD Research Center, Department of Hepatology, The First Affiliated Hospital of Wenzhou Medical University, No. 2 Fuxue Lane, Wenzhou, 325000, China. zhengmh@wmu.edu.cn. AD - Institute of Hepatology, Wenzhou Medical University, Wenzhou, China. zhengmh@wmu.edu.cn. AD - Key Laboratory of Diagnosis and Treatment for the Development of Chronic Liver Disease in Zhejiang Province, Wenzhou, China. zhengmh@wmu.edu.cn. LA - eng PT - Consensus Statement PT - Journal Article DEP - 20230519 PL - United States TA - Hepatol Int JT - Hepatology international JID - 101304009 SB - IM MH - Humans MH - *Cardiovascular Diseases/epidemiology/etiology MH - *Diabetes Mellitus, Type 2/complications/epidemiology MH - Asia MH - *Liver Diseases MH - *Non-alcoholic Fatty Liver Disease PMC - PMC10198034 OTO - NOTNLM OT - Cardiovascular disease OT - Consensus OT - Delphi survey OT - MAFLD OT - Metabolic (dysfunction)-associated fatty liver disease OT - Non-alcoholic fatty liver disease COIS- George V Papatheodoridis: Advisor: Abbvie, Albireo, Amgen, Dicerna, Gilead, GlaxoSmithKline, Ipsen, Janssen, Novo Nordisk, Roche and Takeda; Lectures: Abbvie, Gilead, GlaxoSmithKline, Ipsen, Novo Nordisk, Sobi; Research grants: Abbvie, Gilead; Investigator in clinical trials: Abbvie, Astellas, Bayer, Eiger, Gilead, GlaxoSmithKline, Janssen, Merck Sharp & Dohme, Noorik, Novartis, Novo Nordisk, Regulus, Roche, Takeda. Giada Sebastiani: Speaker: Merck, Gilead, Abbvie, Novonordisk, Novartis and Pfizer; Advisory board member: Pfizer, Merck, Novonordisk, Gilead and Intercept; Unrestricted research funding: Theratecnologies Inc. Gregory Y. H. Lip: Consultant and speaker for BMS/Pfizer, Boehringer Ingelheim, Daiichi-Sankyo, Anthem. No fees are received personally. GYHL is co-principal investigator of the AFFIRMO project on multimorbidity in AF, which has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 899871. Jian-Gao Fan: Speaker, a consultant and an advisory for Sanofi, Abbott, EchoSens, Novartis, Hisky, Gilead, Allergan, Terns and MADAUS GMBH. John D. Ryan: None related to MAFLD. Consulting: Bond Biosciences, Pfizer, Gilead; Lectures: Kyowa kirin, Falk. Marat Fudim: Dr Fudim was supported by Bayer. He receives consulting fees from Bayer, Merck, NovoNordisk. Michael D. Shapiro: Research Grants (paid to my institution): AHA, NIH, Amgen, Novartis, Ionis, Esperion; Consultant: Ionis, Novartis, Regeneron; Scientific Advisory Boards: Amgen, Novartis, Precision Bioscience. Mindie H. Nguyen: Last 36 months: Research support: Pfizer, Enanta, Astra Zeneca, Innogen, Exact Science, CurveBio, Delfi Biotech, Gilead, Exact Sciences, Vir Biotech, Helio Health, National Cancer Institute, Glycotest, B.K. Kee Foundation. Consulting and/or Advisory Board: Intercept, Exact Science, Gilead, GSK, Eli Lilly, Laboratory of Advanced Medicine, Exelixis Research grants. Ming-Hua Zheng: Lectures: Hisky Medical. Philippe Gabriel Steg: Research grants: Amarin, Bayer, Sanofi, and Servier; Clinical Trials (Steering committee, CEC, DSMB): Amarin, AstraZeneca, Bayer, Bristol-Myers Squibb, Idorsia, Novartis, PhaseBio, Pfizer, Sanofi, Servier; Consulting or speaking: Amarin, Amgen, BMS/Myokardia, Merck, Novo-Nordisk, Regeneron; Senior Associate Editor at Circulation. Seung Up Kim: He has served as an advisory committee member Gilead Sciences, Bayer, Eisai, and Novo Nordisk. He is a speaker for Gilead Sciences, GSK, Bayer, Eisai, Abbvie, EchoSens, MSD, Eisai, Otsuka, and Bristol-Myers Squibb. He has also received a research grant from Abbvie and Bristol-Myers Squibb. Vincent Wai-Sun Wong: Consultancy: AbbVie, Boehringer Ingelheim, Echosens, Gilead Sciences, Intercept, Inventiva, Novo Nordisk, Pfizer, Sagimet Biosciences, TARGET PharmaSolutions; Lectures: Abbott, AbbVie, Gilead Sciences, Novo Nordisk; Research grants: Gilead Sciences; Stock: Co-founder of Illuminatio Medical Technology Limited. Wah Kheong Chan: Consultant or advisory board member for Roche, Abbvie, Boehringer Ingelheim and Novo Nordisk; speaker for Viatris and Hisky Medical. Yusuf Yilmaz: He has served as consultant to Cymabay, Zydus, Novo Nordisk, and Echosens. The other authors have no conflicts of interest to declare. EDAT- 2023/05/19 13:05 MHDA- 2023/07/31 06:43 PMCR- 2023/05/19 CRDT- 2023/05/19 11:13 PHST- 2023/03/19 00:00 [received] PHST- 2023/04/18 00:00 [accepted] PHST- 2023/07/31 06:43 [medline] PHST- 2023/05/19 13:05 [pubmed] PHST- 2023/05/19 11:13 [entrez] PHST- 2023/05/19 00:00 [pmc-release] AID - 10.1007/s12072-023-10543-8 [pii] AID - 10543 [pii] AID - 10.1007/s12072-023-10543-8 [doi] PST - ppublish SO - Hepatol Int. 2023 Aug;17(4):773-791. doi: 10.1007/s12072-023-10543-8. Epub 2023 May 19. PMID- 37203747 OWN - NLM STAT- MEDLINE DCOM- 20230522 LR - 20230522 IS - 1879-8365 (Electronic) IS - 0926-9630 (Linking) VI - 302 DP - 2023 May 18 TI - Interdisciplinary Human-Centered AI for Hospital Readmission Prediction of Heart Failure Patients. PG - 556-560 LID - 10.3233/SHTI230204 [doi] AB - The evolution of clinical decision support (CDS) tools has been improved by usage of new technologies, yet there is an increased need to develop user-friendly, evidence-based, and expert-curated CDS solutions. In this paper, we show with a use-case how interdisciplinary expertise can be combined to develop CDS tool for hospital readmission prediction of heart failure patients. We also discuss how to make the tool integrated in clinical workflow by understanding end-user needs and have clinicians-in-the-loop during the different development stages. FAU - Soliman, Amira AU - Soliman A AD - Halmstad University, Halmstad, Sweden. FAU - Nair, Monika AU - Nair M AD - Halmstad University, Halmstad, Sweden. FAU - Petersson, Marcus AU - Petersson M AD - Cambio Healthcare Systems AB, Sweden. FAU - Lundgren, Lina AU - Lundgren L AD - Halmstad University, Halmstad, Sweden. FAU - Dryselius, Petra AU - Dryselius P AD - Cambio Healthcare Systems AB, Sweden. FAU - Fogelberg, Ebba AU - Fogelberg E AD - Cambio Healthcare Systems AB, Sweden. FAU - Hamed, Omar AU - Hamed O AD - Halmstad University, Halmstad, Sweden. FAU - Etminani, Kobra AU - Etminani K AD - Halmstad University, Halmstad, Sweden. FAU - Nygren, Jens AU - Nygren J AD - Halmstad University, Halmstad, Sweden. LA - eng PT - Journal Article PL - Netherlands TA - Stud Health Technol Inform JT - Studies in health technology and informatics JID - 9214582 MH - Humans MH - Patient Readmission MH - *Decision Support Systems, Clinical MH - Workflow MH - Artificial Intelligence MH - *Heart Failure/diagnosis/therapy OTO - NOTNLM OT - Hospital Readmission Prediction OT - Human-Centered AI OT - Interdisciplinary Healthcare EDAT- 2023/05/19 06:42 MHDA- 2023/05/22 06:42 CRDT- 2023/05/19 05:30 PHST- 2023/05/22 06:42 [medline] PHST- 2023/05/19 06:42 [pubmed] PHST- 2023/05/19 05:30 [entrez] AID - SHTI230204 [pii] AID - 10.3233/SHTI230204 [doi] PST - ppublish SO - Stud Health Technol Inform. 2023 May 18;302:556-560. doi: 10.3233/SHTI230204. PMID- 37201632 OWN - NLM STAT- MEDLINE DCOM- 20231102 LR - 20231102 IS - 2241-5955 (Electronic) IS - 1109-9666 (Linking) VI - 73 DP - 2023 Sep-Oct TI - The patient pathway in ATTR-CM in Greece and how to improve it: A multidisciplinary perspective. PG - 73-80 LID - S1109-9666(23)00071-4 [pii] LID - 10.1016/j.hjc.2023.05.004 [doi] AB - Transthyretin amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed disease associated with high mortality rates and the patient journey is characterized by increased complexities. Accurate and timely diagnosis and prompt initiation of disease-modifying treatment constitute the contemporary unmet need in ATTR-CM. ATTR-CM diagnosis is characterized by considerable delays and high rates of misdiagnosis. The majority of patients present themselves to primary care physicians, internists, and cardiologists, and many have undergone repeated medical evaluations before an accurate diagnosis has been made. The disease is diagnosed mainly after the development of heart failure symptoms, reflecting a long course of missed opportunities before diagnosis and disease-modifying treatment initiation. Early referral to experienced centers ensures prompt diagnosis and therapy. Early diagnosis, better care coordination, acceleration of digital transformation and reference networks, encouragement of patient engagement, and implementation of rare disease registries are the key pillars to improve the ATTR-CM patient pathway and achieve important benefits in ATTR-CM outcomes. CI - Copyright (c) 2023 Hellenic Society of Cardiology. Published by Elsevier B.V. All rights reserved. FAU - Apostolou, Efstratios A AU - Apostolou EA AD - Department of Health Policy and LSE Health, London School of Economics and Political Science, London, United Kingdom; Heart Failure Unit, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece. FAU - Fontrier, Anna-Maria AU - Fontrier AM AD - Department of Health Policy and LSE Health, London School of Economics and Political Science, London, United Kingdom. FAU - Efthimiadis, Georgios K AU - Efthimiadis GK AD - 1(st) Cardiology Department, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece. FAU - Kastritis, Efstathios AU - Kastritis E AD - Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece. FAU - Parissis, John AU - Parissis J AD - Heart Failure Unit, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece. FAU - Kanavos, Panos AU - Kanavos P AD - Department of Health Policy and LSE Health, London School of Economics and Political Science, London, United Kingdom. Electronic address: p.g.kanavos@lse.ac.uk. LA - eng PT - Journal Article PT - Review DEP - 20230516 PL - Netherlands TA - Hellenic J Cardiol JT - Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese JID - 101257381 SB - IM MH - Humans MH - *Amyloid Neuropathies, Familial/diagnosis/therapy MH - Greece/epidemiology MH - *Heart Failure/diagnosis/epidemiology/therapy MH - *Heart Diseases MH - Early Diagnosis MH - *Cardiomyopathies/diagnosis/therapy OTO - NOTNLM OT - Cardiomyopathy OT - Clinical pathway OT - Patient journey OT - Transthyretin amyloidosis COIS- Conflict of interest EAA has received honoraria, educational support, and consulting fees from AstraZeneca, Boehringer Ingelheim, Pfizer, Amgen, Novartis, and Winmedica. EK has received honoraria from Amgen, Genesis Pharma, Janssen, Takeda, Pfizer, and GSK and research support from Amgen, Janssen, and Pfizer. JP has received honoraria for lectures and advisory boards from AstraZeneca, Pfizer, Bayer, Novartis, Servier, and Genesis Pharma. AMF, GKE, and PK have no related conflict of interest to declare. Fig. 1 has been designed using free resources from Flaticon.com. EDAT- 2023/05/19 01:04 MHDA- 2023/05/19 01:05 CRDT- 2023/05/18 19:25 PHST- 2022/12/12 00:00 [received] PHST- 2023/04/07 00:00 [revised] PHST- 2023/05/12 00:00 [accepted] PHST- 2023/05/19 01:05 [medline] PHST- 2023/05/19 01:04 [pubmed] PHST- 2023/05/18 19:25 [entrez] AID - S1109-9666(23)00071-4 [pii] AID - 10.1016/j.hjc.2023.05.004 [doi] PST - ppublish SO - Hellenic J Cardiol. 2023 Sep-Oct;73:73-80. doi: 10.1016/j.hjc.2023.05.004. Epub 2023 May 16. PMID- 37200778 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230521 IS - 2521-3768 (Electronic) IS - 2521-3768 (Linking) VI - 7 DP - 2023 Jan 30 TI - Simultaneous minimally invasive uniportal atrial septal defect repair and pulmonary lobectomy: a case report. LID - 8 [pii] LID - 10.21037/shc-22-36 [doi] AB - BACKGROUND: Combination of non-oncological pulmonary and cardiac conditions is common entity in modern thoracic surgery, allowing concurrent surgical correction. Multiple publications in the literature address the success of simultaneous interventions for combined conditions, however almost all are performed with an open approach. CASE DESCRIPTION: A 49-year-old male with past medical history significant for bronchiectasis, complicated by fibrosis of the middle lobe, presented with dyspnea, recurrent hemoptysis, and nonproductive cough. Echocardiography revealed a large atrial septal defect (ASD), biventricular enlargement with severe mitral and tricuspid regurgitation. After multidisciplinary evaluation, patient was taken to the operating room for simultaneous cardiac intervention with right middle lobectomy. The total duration of surgery was 332 min, with cross-clamp time of 79 min. Estimated blood loss was 800 mL. Patient was extubated 3 h postoperatively, chest tube was removed on postoperative day 4 and the patient was discharged home on postoperative day 8 without postoperative complications. CONCLUSIONS: In this article, we describe the first case of simultaneous thoracoscopic uniportal intervention with cardiopulmonary bypass (CPB) in the treatment of multiple congenital heart defects and pulmonary complications of bronchiectasis. Presented case demonstrates potential advantage and feasibility of minimally invasive simultaneous procedures in patients with concurrent pulmonary and cardiac conditions. The described approach allowed radical surgical intervention to address both problems in the single setting, while retaining advantage of minimally invasive intervention. FAU - Bazarov, Dmitry V AU - Bazarov DV AD - Department of Thoracic Surgery and Oncology Petrovsky National Research Center of Surgery, Moscow, Russia. FAU - Gritsiuta, Andrei I AU - Gritsiuta AI AUID- ORCID: 0000-0003-2265-9992 AD - Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. FAU - Evseev, Evgeny P AU - Evseev EP AD - Department of Cardiac Surgery, Petrovsky National Research Center of Surgery, Moscow, Russia. FAU - Petrov, Roman V AU - Petrov RV AD - Division of Cardiothoracic Surgery, University of Texas Medical Branch (UTMB) John Sealy School of Medicine, Galveston, TX, USA. LA - eng GR - P30 CA006927/CA/NCI NIH HHS/United States PT - Journal Article DEP - 20221206 PL - China TA - Shanghai Chest JT - Shanghai chest JID - 101727866 PMC - PMC10191362 MID - NIHMS1872736 OTO - NOTNLM OT - Congenital heart defect OT - case report OT - fibroatelectasis OT - thoracoscopy OT - uniportal VATS COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://shc.amegroups.com/article/view/10.21037/shc-22-36/coif). The authors have no conflicts of interest to declare. EDAT- 2023/05/18 19:12 MHDA- 2023/05/18 19:13 PMCR- 2023/05/17 CRDT- 2023/05/18 16:46 PHST- 2023/05/18 19:13 [medline] PHST- 2023/05/18 19:12 [pubmed] PHST- 2023/05/18 16:46 [entrez] PHST- 2023/05/17 00:00 [pmc-release] AID - 8 [pii] AID - 10.21037/shc-22-36 [doi] PST - ppublish SO - Shanghai Chest. 2023 Jan 30;7:8. doi: 10.21037/shc-22-36. Epub 2022 Dec 6. PMID- 37196385 OWN - NLM STAT- MEDLINE DCOM- 20230718 LR - 20230719 IS - 1527-3288 (Electronic) IS - 0147-9563 (Linking) VI - 61 DP - 2023 Sep-Oct TI - Implementation of a multidisciplinary inpatient heart failure service and its association with hospitalized patient outcomes: First experience from the Middle East and North Africa region. PG - 92-97 LID - S0147-9563(23)00119-X [pii] LID - 10.1016/j.hrtlng.2023.05.004 [doi] AB - BACKGROUND: Multidisciplinary care models have been associated with improved clinical outcomes and an increase in adherence to guideline-directed medical therapy among patients hospitalized with heart failure (HF). OBJECTIVE: This study aims to evaluate the association between the creation of a multidisciplinary inpatient HF service and patient outcomes at a tertiary care center in the Middle East/ North Africa. METHODS: We used electronic health records to retrospectively identify patients hospitalized for acute HF between June-2015 and June-2018. Patients were categorized by whether they were hospitalized before (n = 71) or after (n = 86) the implementation of a multidisciplinary HF team (HF-MDT), starting on 1/1/2017. The groups were compared for optimal use of guideline-directed medical therapy, hospital length of stay, 30-day hospital readmission, and in-hospital mortality. RESULTS: The creation of the HF-MDT was associated with significantly better adherence to GDMT at discharge (27.5% vs. 55.4%, (OR 3.3, 95% CI [1.65-6.5]), P<0.001), shorter median hospital length of stay (8, IQR [4.8 - 19] vs. 5, IQR [3- 9], P = 0.02) and a reduction in 30-day hospital readmission (26.5% vs. 11%; OR 0.3, 95% CI [0.1-0.8], P = 0.02). However, there was no difference in-hospital mortality (10.5% vs. 3.5%; OR 0.3, 95% CI [0.1-1.2], P = 0.1). CONCLUSIONS: Implementing an HF-MDT in the care of patients hospitalized with HF is associated with better adherence to GDMT on discharge, reduced hospital length of stay, and lower 30-day readmission rates. The current data support the broader adoption of dedicated HF programs in the Middle East to improve outcomes of patients with HF. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Manla, Yosef AU - Manla Y AD - Heart, Vascular, and Thoracic Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates; Academic Office, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates. FAU - Ghalib, Hussam H AU - Ghalib HH AD - Heart, Vascular, and Thoracic Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates. FAU - Badarin, Firas Al AU - Badarin FA AD - Heart, Vascular, and Thoracic Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates. FAU - Ferrer, Richard AU - Ferrer R AD - Heart, Vascular, and Thoracic Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates. FAU - Lee-St John, Terrence AU - Lee-St John T AD - Academic Office, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates. FAU - Abdalla, Khalid AU - Abdalla K AD - Department of Internal Medicine, University of Missouri-Kansas City. FAU - Soliman, Medhat AU - Soliman M AD - Heart, Vascular, and Thoracic Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates. FAU - Gabra, Guirgis AU - Gabra G AD - Heart, Vascular, and Thoracic Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates. FAU - Bader, Feras AU - Bader F AD - Heart, Vascular, and Thoracic Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates. Electronic address: baderf@clevelandclinicabudhabi.ae. LA - eng PT - Journal Article DEP - 20230515 PL - United States TA - Heart Lung JT - Heart & lung : the journal of critical care JID - 0330057 SB - IM MH - Humans MH - *Inpatients MH - Retrospective Studies MH - Patient Readmission MH - *Heart Failure/therapy MH - Africa, Northern/epidemiology MH - Middle East/epidemiology MH - Hospitalization OTO - NOTNLM OT - Heart failure service OT - Inpatient OT - Middle East OT - Multidisciplinary COIS- Declaration of Competing Interest None EDAT- 2023/05/18 01:07 MHDA- 2023/07/18 13:10 CRDT- 2023/05/17 18:01 PHST- 2023/02/13 00:00 [received] PHST- 2023/05/05 00:00 [revised] PHST- 2023/05/06 00:00 [accepted] PHST- 2023/07/18 13:10 [medline] PHST- 2023/05/18 01:07 [pubmed] PHST- 2023/05/17 18:01 [entrez] AID - S0147-9563(23)00119-X [pii] AID - 10.1016/j.hrtlng.2023.05.004 [doi] PST - ppublish SO - Heart Lung. 2023 Sep-Oct;61:92-97. doi: 10.1016/j.hrtlng.2023.05.004. Epub 2023 May 15. PMID- 37186398 OWN - NLM STAT- MEDLINE DCOM- 20230719 LR - 20260120 IS - 1600-0609 (Electronic) IS - 0902-4441 (Linking) VI - 111 IP - 2 DP - 2023 Aug TI - Cardiovascular risk in chronic myeloid leukaemia: A multidisciplinary consensus on screening and management. PG - 201-210 LID - 10.1111/ejh.13983 [doi] AB - INTRODUCTION: Tyrosine kinase inhibitors (TKIs) have become the mainstay of treatment for chronic myeloid leukaemia (CML), but cardiovascular (CV) risk and exacerbation of underlying risk factors associated with TKIs have become widely debated. Real-world evidence reveals little application of CV risk factor screening or continued monitoring within UK CML management. This consensus paper presents practical recommendations to assist healthcare professionals in conducting CV screening/comorbidity management for patients receiving TKIs. METHODS: We conducted a multidisciplinary panel meeting and two iterative surveys involving 10 CML specialists: five haematologists, two cardio-oncologists, one vascular surgeon, one haemato-oncology pharmacist and one specialist nurse practitioner. RESULTS: The panel recommended that patients commencing second-/third-generation TKIs undergo formal CV risk assessment at baseline, with additional investigations and involvement of cardiologists/vascular surgeons for those with high CV risk. During treatment, patients should undergo CV monitoring, with the nature and frequency of testing dependent on TKI and baseline CV risk. For patients who develop CV adverse events, decision-making around TKI interruption, cessation or change should be multidisciplinary and balance CV and haematological risk. CONCLUSION: The panel anticipates these recommendations will support healthcare professionals in implementing CV risk screening and monitoring, broadly and consistently, and thereby help optimise TKI treatment for CML. CI - (c) 2023 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd. FAU - Milojkovic, Dragana AU - Milojkovic D AUID- ORCID: 0000-0002-0593-8220 AD - Hammersmith Hospital, London, UK. FAU - Lyon, Alexander R AU - Lyon AR AD - The Royal Brompton Hospital, London, UK. FAU - Mehta, Priyanka AU - Mehta P AD - University Hospital Bristol, Bristol, UK. FAU - Dimitriadou, Evangelia AU - Dimitriadou E AD - Maidstone & Tunbridge Wells, Tunbridge Wells, UK. FAU - Choudhuri, Satarupa AU - Choudhuri S AD - Northern Care Alliance, Manchester, UK. FAU - Manisty, Charlotte AU - Manisty C AD - Barts Health NHS Trust and University College London, London, UK. FAU - Cheshire, Nick AU - Cheshire N AD - The Royal Brompton Hospital, London, UK. FAU - Crozier, Kirsty AU - Crozier K AD - Churchill Hospital, Oxford, UK. FAU - Basker, Nanda AU - Basker N AD - Southampton General Hospital, Southampton, UK. FAU - Amer, Karim AU - Amer K AD - Pfizer Ltd., London, UK. FAU - Purcell, Simon AU - Purcell S AD - Pfizer Ltd., London, UK. FAU - Tan, Susan AU - Tan S AD - Envision Pharma Group, Sydney, Australia. FAU - Clark, Richard E AU - Clark RE AD - Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK. LA - eng PT - Consensus Statement PT - Journal Article DEP - 20230425 PL - England TA - Eur J Haematol JT - European journal of haematology JID - 8703985 RN - 0 (Antineoplastic Agents) RN - 0 (Protein Kinase Inhibitors) SB - IM MH - Humans MH - *Antineoplastic Agents/therapeutic use MH - *Cardiovascular Diseases/diagnosis/epidemiology/etiology MH - Protein Kinase Inhibitors/adverse effects MH - Risk Factors MH - *Leukemia, Myelogenous, Chronic, BCR-ABL Positive/complications/diagnosis/drug therapy MH - Heart Disease Risk Factors OTO - NOTNLM OT - cardiovascular OT - chronic myeloid leukaemia OT - consensus OT - tyrosine kinase inhibitor EDAT- 2023/05/15 19:12 MHDA- 2023/07/19 06:42 CRDT- 2023/05/15 14:27 PHST- 2023/04/06 00:00 [revised] PHST- 2022/10/11 00:00 [received] PHST- 2023/04/08 00:00 [accepted] PHST- 2023/07/19 06:42 [medline] PHST- 2023/05/15 19:12 [pubmed] PHST- 2023/05/15 14:27 [entrez] AID - 10.1111/ejh.13983 [doi] PST - ppublish SO - Eur J Haematol. 2023 Aug;111(2):201-210. doi: 10.1111/ejh.13983. Epub 2023 Apr 25. PMID- 37186174 OWN - NLM STAT- MEDLINE DCOM- 20230529 LR - 20261010 IS - 1432-1971 (Electronic) IS - 0172-0643 (Linking) VI - 44 IP - 5 DP - 2023 Jun TI - Prenatal Congenital Heart Disease-It Takes a Multidisciplinary Village. PG - 1050-1056 LID - 10.1007/s00246-023-03161-6 [doi] AB - Prenatal diagnosis of congenital heart disease (CHD) allows for thoughtful multidisciplinary planning about location, timing, and need for medical interventions at birth. We sought to assess the accuracy of our prenatal cardiac diagnosis, and postnatal needs for patients with CHD utilizing a multidisciplinary approach. We performed a retrospective chart review of fetal CHD patients between 1/1/18 and 4/30/19. Maternal and infant charts were reviewed for delivery planning, subspecialty care needs, genetic evaluation, prenatal and postnatal cardiac diagnoses, need for prostaglandin (PGE) and neonatal cardiac intervention. 82 maternal-fetal dyads met inclusion criteria during the study period and delivered at a median of 38w2d gestation. 32 (39%) dyads had CHD and other anomalies or genetic abnormalities. All dyads met with a genetic counselor and neonatologist. 11 patients delivered at outside hospitals as planned (all with isolated CHD not requiring neonatal intervention), and 5 chose a palliative delivery. 30 patients were counseled to expect a neonatal cardiac intervention and 25 (83%) underwent an intervention within the expected time period. No neonates required an uncounseled cardiac intervention. 29 patients planned for PGE at birth and 31 received PGE. Of the 79 postnatal echocardiograms, 60 (76%) were entirely consistent with the fetal diagnosis. A multidisciplinary approach to the prenatal diagnosis of CHD in maternal-fetal dyads is optimal and utilizing this method we were able to accurately predict postnatal physiology and ensure that patients delivered in the correct location with an appropriate supportive structure in place. CI - (c) 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Ronai, Christina AU - Ronai C AD - Department of Pediatrics, Oregon Health and Science University, Portland, OR, USA. christina.ronai@cardio.chboston.org. FAU - Kim, Amanda AU - Kim A AD - Department of Pediatrics, Oregon Health and Science University, Portland, OR, USA. FAU - Dukhovny, Stephanie AU - Dukhovny S AD - Department of Obstetrics and Gynecology, Oregon Health and Science University, Portland, OR, USA. FAU - Fisher, Christina R AU - Fisher CR AD - Department of Pediatrics, Oregon Health and Science University, Portland, OR, USA. FAU - Madriago, Erin AU - Madriago E AD - Department of Pediatrics, Oregon Health and Science University, Portland, OR, USA. LA - eng PT - Journal Article DEP - 20230425 PL - United States TA - Pediatr Cardiol JT - Pediatric cardiology JID - 8003849 SB - IM MH - Pregnancy MH - Infant MH - Female MH - Infant, Newborn MH - Humans MH - Retrospective Studies MH - Ultrasonography, Prenatal/methods MH - *Heart Defects, Congenital/diagnostic imaging/therapy MH - Prenatal Diagnosis MH - *Fetal Diseases OTO - NOTNLM OT - Antenatal counseling OT - Congenital heart disease OT - Fetal cardiology OT - Fetal care OT - Prenatal diagnosis EDAT- 2023/05/15 19:12 MHDA- 2023/05/29 06:42 CRDT- 2023/05/15 14:13 PHST- 2022/08/09 00:00 [received] PHST- 2023/04/10 00:00 [accepted] PHST- 2023/05/29 06:42 [medline] PHST- 2023/05/15 19:12 [pubmed] PHST- 2023/05/15 14:13 [entrez] AID - 10.1007/s00246-023-03161-6 [pii] AID - 10.1007/s00246-023-03161-6 [doi] PST - ppublish SO - Pediatr Cardiol. 2023 Jun;44(5):1050-1056. doi: 10.1007/s00246-023-03161-6. Epub 2023 Apr 25. PMID- 37185649 OWN - NLM STAT- MEDLINE DCOM- 20230517 LR - 20230525 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 13 IP - 4 DP - 2023 Apr 26 TI - Efficiency and effectiveness of intensive multidisciplinary follow-up of patients with stroke/TIA or myocardial infarction compared to usual monitoring: protocol of a pragmatic randomised clinical trial. DiVa (Dijon vascular) study. PG - e070197 LID - 10.1136/bmjopen-2022-070197 [doi] LID - e070197 AB - INTRODUCTION: The ongoing ageing population is associated with an increase in the number of patients suffering a stroke, transient ischaemic attack (TIA) or myocardial infarction (MI). In these patients, implementing secondary prevention is a critical challenge and new strategies need to be developed to close the gap between clinical practice and evidence-based recommendations. We describe the protocol of a randomised clinical trial that aims to evaluate the efficiency and effectiveness of an intensive multidisciplinary follow-up of patients compared with standard care. METHODS AND ANALYSIS: The DiVa study is a randomised, prospective, controlled, multicentre trial including patients >18 years old with a first or recurrent stroke (ischaemic or haemorrhagic) or TIA, or a type I or II MI, managed in one of the participating hospitals of the study area, with a survival expectancy >12 months. Patients will be randomised with an allocation ratio of 1:1 in two parallel groups: one group assigned to a multidisciplinary, nurse-based and pharmacist-based 2-year follow-up in association with general practitioners, neurologists and cardiologists versus one group with usual follow-up. In each group for each disease (stroke/TIA or MI), 430 patients will be enrolled (total of 1720 patients) over 3 years. The primary outcome will be the incremental cost-utility ratio at 24 months between intensive and standard follow-up in a society perspective. Secondary outcomes will include the incremental cost-utility ratio at 6 and 12 months, the incremental cost-effectiveness ratio at 24 months, reduction at 6, 12 and 24 months of the rates of death, unscheduled rehospitalisation and iatrogenic complications, changes in quality of life, net budgetary impact at 5 years of the intensive follow-up on the national health insurance perspective and analysis of factors having positive or negative effects on the implementation of the project in the study area. ETHICS AND DISSEMINATION: Ethical approval was obtained and all patients receive information about the study and give their consent to participate before randomisation. Results of the main trial and each of the secondary analyses will be submitted for publication in a peer-reviewed journal. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov Identifier: NCT04188457. Registered on 6 December 2019. CI - (c) Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Bejot, Yannick AU - Bejot Y AUID- ORCID: 0000-0001-7848-7072 AD - Neurology, University Hospital Centre Dijon Bourgogne, Dijon, France yannick.bejot@chu-dijon.fr. FAU - Soilly, Anne-Laure AU - Soilly AL AD - Department of Clinical Research and Innovation, Clinical Research Unit-Methodological Support Network (USMR), University Hospital Centre Dijon Bourgogne, Dijon, France. FAU - Bardou, Marc AU - Bardou M AD - Gastroenterology, University Hospital Centre Dijon Bourgogne, Dijon, France. AD - CIC-Inserm 1432, University of Burgundy, Dijon, France. FAU - Duloquin, Gauthier AU - Duloquin G AUID- ORCID: 0000-0002-5351-7869 AD - Neurology, University Hospital Centre Dijon Bourgogne, Dijon, France. FAU - Pommier, Thibaut AU - Pommier T AD - Cardiology, University Hospital Centre Dijon Bourgogne, Dijon, France. FAU - Laurent, Gabriel AU - Laurent G AD - Cardiology, University Hospital Centre Dijon Bourgogne, Dijon, France. FAU - Cottin, Yves AU - Cottin Y AUID- ORCID: 0000-0002-5176-5121 AD - Cardiology, University Hospital Centre Dijon Bourgogne, Dijon, France. FAU - Vadot, Lucie AU - Vadot L AD - Pharmacy, University Hospital Centre Dijon Bourgogne, Dijon, France. FAU - Adam, Heloise AU - Adam H AD - Pharmacy, University Hospital Centre Dijon Bourgogne, Dijon, France. FAU - Boulin, Mathieu AU - Boulin M AD - Pharmacy, University Hospital Centre Dijon Bourgogne, Dijon, France. FAU - Giroud, Maurice AU - Giroud M AD - Neurology, University Hospital Centre Dijon Bourgogne, Dijon, France. LA - eng SI - ClinicalTrials.gov/NCT04188457 PT - Clinical Trial Protocol PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230426 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 SB - IM MH - Adolescent MH - Humans MH - Follow-Up Studies MH - *Ischemic Attack, Transient/drug therapy MH - Multicenter Studies as Topic MH - *Myocardial Infarction/prevention & control MH - Prospective Studies MH - Quality of Life MH - Randomized Controlled Trials as Topic MH - *Stroke MH - Pragmatic Clinical Trials as Topic PMC - PMC10151851 OTO - NOTNLM OT - health economics OT - myocardial infarction OT - stroke COIS- Competing interests: YB received honoraria for lectures or consulting fees from BMS, Pfizer, Medtronic, Amgen, Servier, Boehringer-Ingelheim and NovoNordisk, outside the submitted work. GL received honoraria for lectures or consulting fees from Abbott, Biotronik, Boston, Medtronic, MicroPort, Novo Nordisk, BMS and Pfizer, outside the submitted work. YC received honoraria for lectures or consulting fees from Bayer, BMS, Pfizer, Boehringer-Ingelheim, Novartis, Sanofi and Servier, outside the submitted work. EDAT- 2023/05/15 19:12 MHDA- 2023/05/17 06:42 PMCR- 2023/04/26 CRDT- 2023/05/15 13:43 PHST- 2023/05/17 06:42 [medline] PHST- 2023/05/15 19:12 [pubmed] PHST- 2023/05/15 13:43 [entrez] PHST- 2023/04/26 00:00 [pmc-release] AID - bmjopen-2022-070197 [pii] AID - 10.1136/bmjopen-2022-070197 [doi] PST - epublish SO - BMJ Open. 2023 Apr 26;13(4):e070197. doi: 10.1136/bmjopen-2022-070197. PMID- 37184336 OWN - NLM STAT- MEDLINE DCOM- 20230818 LR - 20231003 IS - 1530-0293 (Electronic) IS - 0090-3493 (Linking) VI - 51 IP - 9 DP - 2023 Sep 1 TI - Advances in the Management of Cardiogenic Shock. PG - 1222-1233 LID - 10.1097/CCM.0000000000005919 [doi] AB - OBJECTIVES: To review a contemporary approach to the management of patients with cardiogenic shock (CS). DATA SOURCES: We reviewed salient medical literature regarding CS. STUDY SELECTION: We included professional society scientific statements and clinical studies examining outcomes in patients with CS, with a focus on randomized clinical trials. DATA EXTRACTION: We extracted salient study results and scientific statement recommendations regarding the management of CS. DATA SYNTHESIS: Professional society recommendations were integrated with evaluated studies. CONCLUSIONS: CS results in short-term mortality exceeding 30% despite standard therapy. While acute myocardial infarction (AMI) has been the focus of most CS research, heart failure-related CS now predominates at many centers. CS can present with a wide spectrum of shock severity, including patients who are normotensive despite ongoing hypoperfusion. The Society for Cardiovascular Angiography and Intervention Shock Classification categorizes patients with or at risk of CS according to shock severity, which predicts mortality. The CS population includes a heterogeneous mix of phenotypes defined by ventricular function, hemodynamic profile, biomarkers, and other clinical variables. Integrating the shock severity and CS phenotype with nonmodifiable risk factors for mortality can guide clinical decision-making and prognostication. Identifying and treating the cause of CS is crucial for success, including early culprit vessel revascularization for AMI. Vasopressors and inotropes titrated to restore arterial pressure and perfusion are the cornerstone of initial medical therapy for CS. Temporary mechanical circulatory support (MCS) is indicated for appropriately selected patients as a bridge to recovery, decision, durable MCS, or heart transplant. Randomized controlled trials have not demonstrated better survival with the routine use of temporary MCS in patients with CS. Accordingly, a multidisciplinary team-based approach should be used to tailor the type of hemodynamic support to each individual CS patient's needs based on shock severity, phenotype, and exit strategy. CI - Copyright (c) 2023 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved. FAU - Jentzer, Jacob C AU - Jentzer JC AD - Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN. FAU - Poss, Janine AU - Poss J AD - Department of Internal Medicine/Cardiology, Heart Center Leipzig at University of Leipzig, Leipzig, Germany. FAU - Schaubroeck, Hannah AU - Schaubroeck H AD - Department of Intensive Care Medicine, Intensive Care Unit, Ghent University Hospital, Ghent, Belgium. FAU - Morrow, David A AU - Morrow DA AD - TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA. FAU - Hollenberg, Steven M AU - Hollenberg SM AD - Division of Cardiology, Emory University School of Medicine, Atlanta, GA. FAU - Mebazaa, Alexandre AU - Mebazaa A AD - Department of Anesthesia & Critical Care, Universite Paris Cite, APHP, Inserm MASCOT, FHU PROMICE, Paris, France. LA - eng PT - Journal Article PT - Review DEP - 20230515 PL - United States TA - Crit Care Med JT - Critical care medicine JID - 0355501 SB - IM MH - Humans MH - Shock, Cardiogenic/etiology MH - Treatment Outcome MH - *Myocardial Infarction MH - *Heart Failure/etiology MH - *Heart-Assist Devices/adverse effects COIS- Dr. Poss receives research funding from the German Cardiac Society, German Heart Research Foundation, and Dr. Rolf M. Schwiete Foundation. Dr. Schaubroeck has received honoraria from Abiomed. Dr. Morrow's institution received funding from Abbott, Abiomed, and Amgen; he disclosed that he is a member of the Thrombolysis in Myocardial Infarction Study Group, which has received institutional research grant support through Brigham and Women's Hospital from: Abbott, Amgen, Anthos Therapeutics, ARCA Biopharma, AstraZeneca, Bayer HealthCare Pharmaceuticals, Daiichi-Sankyo, Eisai, Intarcia, Ionis Pharmaceuticals, Janssen Research and Development, LLC, Merck, Novartis, Pfizer, Quark Pharmaceuticals, Regeneron Pharmaceuticals, Roche, Siemens Healthcare Diagnostics, Softcell Medical Limited, and Zora Biosciences. He has received consulting fees from Abbott Laboratories, ARCA Biopharma, InCardia, Inflammatix, Merck & Co, Novartis, and Roche Diagnostics. Dr. Mebazaa received grant from Roche Diagnostics, Abbott Laboratories, 4TEEN4, and WIndtree Therapeutics; he received honoraria for lectures from Roche Diagnostics, Bayer, and MSD; he is a consultant for Corteria Pharmaceuticals, S-Form Pharma, FIRE-1, Implicity, 4TEEN4, and Adrenomed; he is coinventor of a patent on combination therapy for patients having acute and/or persistent dyspnea; and he disclosed the off-label product use of Vasopressors and specific mechanical circulatory support devices may not be labeled for use in shock. The remaining authors have disclosed that they do not have any potential conflicts of interest. EDAT- 2023/05/15 13:06 MHDA- 2023/08/18 06:43 CRDT- 2023/05/15 09:33 PHST- 2023/08/18 06:43 [medline] PHST- 2023/05/15 13:06 [pubmed] PHST- 2023/05/15 09:33 [entrez] AID - 00003246-202309000-00013 [pii] AID - 10.1097/CCM.0000000000005919 [doi] PST - ppublish SO - Crit Care Med. 2023 Sep 1;51(9):1222-1233. doi: 10.1097/CCM.0000000000005919. Epub 2023 May 15. PMID- 37178388 OWN - NLM STAT- MEDLINE DCOM- 20230704 LR - 20230807 IS - 1522-726X (Electronic) IS - 1522-1946 (Linking) VI - 102 IP - 1 DP - 2023 Jul TI - Three-year outcomes for transcatheter repair in patients with mitral regurgitation from the CLASP study. PG - 145-154 LID - 10.1002/ccd.30686 [doi] AB - BACKGROUND: Mitral valve transcatheter edge-to-edge repair (M-TEER) is an effective option for treatment of mitral regurgitation (MR). We previously reported favorable 2-year outcomes for the PASCAL transcatheter valve repair system. OBJECTIVES: We report 3-year outcomes from the multinational, prospective, single-arm CLASP study with analysis by functional MR (FMR) and degenerative MR (DMR). METHODS: Patients with core-lab determined MR >/= 3+ were deemed candidates for M-TEER by the local heart team. Major adverse events were assessed by an independent clinical events committee to 1 year and by sites thereafter. Echocardiographic outcomes were evaluated by the core laboratory to 3 years. RESULTS: The study enrolled 124 patients, 69% FMR; 31% DMR (60% NYHA class III-IVa, 100% MR >/= 3+). The 3-year Kaplan-Meier estimate for survival was 75% (66% FMR; 92% DMR) and freedom from heart failure hospitalization (HFH) was 73% (64% FMR; 91% DMR), with 85% reduction in annualized HFH rate (81% FMR; 96% DMR) (p < 0.001). MR /=4). Of the AHF patients, 20.5% had no NCC, 28.5% had 1 NCC, 23.1% had 2 NCC, 15.4% had 3 NCC, and 12.5% had >/=4 NCC. In-hospital and post-discharge mortality increased with number of NCCs from 3.0% and 18.5% for 1 NCC to 12.5% and 36% for >/=4 NCCs.Anaemia, COPD, PVD, sleep apnoea, rheumatoid arthritis, stroke/TIA, Parkinson, and depression were more prevalent in HF with preserved EF (HFpEF). The hazard ratio (95% confidence interval) for post-discharge death for each NCC was for anaemia 1.6 (1.4-1.8), diabetes 1.2 (1.1-1.4), kidney dysfunction 1.7 (1.5-1.9), COPD 1.4 (1.2-1.5), PVD 1.2 (1.1-1.4), stroke/TIA 1.3 (1.1-1.5), depression 1.2 (1.0-1.5), hepatic dysfunction 2.1 (1.8-2.5), malignancy 1.5 (1.2-1.8), sleep apnoea 1.2 (0.9-1.7), rheumatoid arthritis 1.5 (1.1-2.1), and Parkinson 1.4 (0.9-2.1). Anaemia, kidney dysfunction, COPD, and diabetes were associated with post-discharge mortality in all EF categories, PVD, stroke/TIA, and depression only in HF with reduced EF, and sleep apnoea and malignancy only in HFpEF. CONCLUSION: Multiple NCCs conferred poor in-hospital and post-discharge outcomes. Ejection fraction categories had different prevalence and risk profile associated with individual NCCs. CI - (c) The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. FAU - Chioncel, Ovidiu AU - Chioncel O AUID- ORCID: 0000-0002-3197-3628 AD - Emergency Institute for Cardiovascular Diseases 'Prof. C.C. Iliescu', Bucharest, Romania. AD - University of Medicine Carol Davila, Bucharest, Romania. FAU - Benson, Lina AU - Benson L AD - Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden. FAU - Crespo-Leiro, Maria G AU - Crespo-Leiro MG AD - Cardiology Department Complexo Hospitalario Universitario A Coruna, (CHUAC), CIBERCV, INIBIC, UDC, La Coruna, Spain. FAU - Anker, Stefan D AU - Anker SD AUID- ORCID: 0000-0002-0805-8683 AD - Department of Cardiology (CVK), Berlin Institute of Health Center for Regenerative Therapies (BCRT), German Centre for Cardiovascular Research (DZHK) partner site Berlin, Berlin, Germany. AD - Charite Universitatsmedizin, Berlin, Germany. FAU - Coats, Andrew J S AU - Coats AJS AD - Heart Research Institute, Sydney, Monash University, Sidney, Australia. FAU - Filippatos, Gerasimos AU - Filippatos G AUID- ORCID: 0000-0002-5640-0332 AD - Heart Failure Unit, Attikon University Hospital, University of Athens, Athens, Greece. AD - School of Medicine, University of Cyprus, Nicosia, Cyprus. FAU - McDonagh, Theresa AU - McDonagh T AD - Department of Cardiology, King's College Hospital London, London, UK. AD - School of Cardiovascular Medicine and Sciences, King's College London British Heart Foundation Centre of Excellence, London, UK. FAU - Margineanu, Cornelia AU - Margineanu C AD - Emergency Institute for Cardiovascular Diseases 'Prof. C.C. Iliescu', Bucharest, Romania. AD - University of Medicine Carol Davila, Bucharest, Romania. FAU - Mebazaa, Alexandre AU - Mebazaa A AD - University of Paris Diderot, Hopitaux Universitaires Saint Louis Lariboisiere, APHP, Paris, France. FAU - Metra, Marco AU - Metra M AD - Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy. FAU - Piepoli, Massimo F AU - Piepoli MF AD - Cardiology, IRCCS PoliclinicoSan Donato, San Donato Milanese, Milan, Italy. AD - Dipartimento di Scienze Biomediche per la Salute, University of Milan, Milan, Italy. FAU - Adamo, Marianna AU - Adamo M AUID- ORCID: 0000-0002-3855-1815 AD - Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy. FAU - Rosano, Giuseppe M C AU - Rosano GMC AD - Cardiology Clinical Academy Group, St Georges Hospital NHS Trust, University of London, London, UK. AD - Department of Medical Sciences, Centre for Clinical and Basic Research, IRCCS San Raffaele Pisana, Rome, Italy. FAU - Ruschitzka, Frank AU - Ruschitzka F AD - Department of Cardiology, University Hospital Zurich, Zurich, Switzerland. FAU - Savarese, Gianluigi AU - Savarese G AD - Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden. FAU - Seferovic, Petar AU - Seferovic P AD - Faculty of Medicine, University of Belgrade, Belgrade, Serbia. AD - Serbian Academy of Sciences and Arts, Belgrade, Serbia. FAU - Volterrani, Maurizio AU - Volterrani M AD - IRCCS San Raffaele Pisana, Rome, Italy. FAU - Ferrari, Roberto AU - Ferrari R AUID- ORCID: 0000-0003-2046-9175 AD - Scientific Department, MTA Group, Lugano, Switzerland. FAU - Maggioni, Aldo P AU - Maggioni AP AD - ANMCO Research Centre, Florence, Italy. FAU - Lund, Lars H AU - Lund LH AD - Department of Medicine, Karolinska Institute, Stockholm, Sweden. AD - Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Eur J Prev Cardiol JT - European journal of preventive cardiology JID - 101564430 SB - IM CIN - Eur J Prev Cardiol. 2023 Sep 20;30(13):1343-1345. doi: 10.1093/eurjpc/zwad170. PMID: 37219916 EIN - Eur J Prev Cardiol. 2024 Jan 25;31(2):274. doi: 10.1093/eurjpc/zwad396. PMID: 38195099 MH - Humans MH - *Heart Failure/diagnosis/epidemiology/complications MH - Stroke Volume MH - Aftercare MH - *Ischemic Attack, Transient MH - *Parkinson Disease/complications MH - Prognosis MH - Patient Discharge MH - *Anemia/diagnosis/epidemiology/complications MH - *Cardiology MH - *Arthritis, Rheumatoid/complications MH - *Sleep Apnea Syndromes/complications MH - Registries MH - *Stroke MH - *Pulmonary Disease, Chronic Obstructive/diagnosis/epidemiology/complications OAB - The current analysis from ESC-Heart Failure Long-Term Registry represents the largest and most comprehensive study in an acute heart failure (AHF) population with HF with reduced ejection fraction (HFrEF), HF with mildly reduced EF (HFmrEF), and HF with preserved EF (HFpEF), on prevalence and association with in-hospital and post-discharge outcomes of a large number of non-cardiac comorbidities.A greater number of non-cardiac comorbidities (CNNs) were associated at admission with older age, preserved EF, more severe NYHA class, and longer duration of HF. In-hospital and post-discharge mortality gradually increased with number of CNNs.The association between each individual comorbidity and post-discharge outcomes varied substantially in AHF patients with HFrEF, HFmrEF, and HFpEF, suggesting that an 'EF-specific' multidisciplinary approach with distinct comorbidity management programs should be applied in post-discharge phase. OABL- eng OTO - NOTNLM OT - Acute heart failure OT - Comorbidities OT - Prognosis COIS- Conflict of interest: O. Chioncel declare no conflict of interest related to present work; ESC meeting support from Servier. L. Benson declare no conflict of interest. M. Crespo-Leiro reports unrelated to the present work: consultancy or speaker's honoraria from Novartis, AstraZeneca, Boehringer Ingelheim, Abbott, Medtronic, CareDx, Astellas and Vifor Pharma. S.D. Anker reports unrelated to the present work: Grants or contracts: Vifor Int, Abbott Vascular; Consulting fees: CVRx, Amgen, Respicardia, Novo Nordisk, Brahms, Novartis, Sanofi, Cordio; Leadership or fiduciary role in other board: Abbott Vascular, Astra Zeneca, Bayer AG, Bioventrix, Boehringer Ingelheim, Cardiac Dimension, Cardior, Impulse Dynamics, Janssen, Occlutech, Servier, Vifor Int, and V-Wave. A.J.S. Coats reports unrelated to the present work: speaker's honoraria from: Astra Zeneca, Bayer, Boehringer Ingelheim, Edwards, Menarini, Novartis, Servier, Vifor, Abbott, Actimed, Arena, Cardiac Dimensions, Corvia, CVRx, Enopace, ESN Cleer, Faraday, Impulse Dynamics, Respicardia, and Viatris. G. Filippatos reports lecture fees and/or committee membership in trials sponsored by Bayer, Vifor, Medtronic, Novartis, Servier, Boehringer Ingelheim, and research support from the European Union. T. McDonagh reports unrelated to the present work: speaker's honoraria from Abbot, Astra Zeneca, Boeringher Ingelheim and Edwards. C. Margineanu none related to the present work. A. Mebazaa reports unrelated to the present work: Grants or contracts from and consulting fees from Roche, 4TEEN4, Corteria; speaker's honoraria from MSD; Patents: S-Form Pharma. M. Metra reports personal fees from Amgen, AstraZeneca, Abbott Vascular, Bayer, Edwards Therapeutics, Livanova, Vifor Pharma, as member of Trials' Committees or advisory boards or for speeches at sponsored meetings in the last 3 years. M. Piepoli reports unrelated to the present work: consultancy, speaker's, institutional fees from Astra-Zeneca, Boehringer- Ingelheim, CHF solution, Menarini, Novartis, Servier M. Adammo reports speaker fees from Abbott Vascular and Medtronic. G.M.C. Rosano declare no conflict of interest. F. Ruschitzka has not received personal payments by pharmaceutical companies or device manufacturers in the last 3 years (remuneration for the time spent in activities, such as participation as steering committee member of clinical trials and member of the Pfizer Research Award selection committee in Switzerland, were made directly to the University of Zurich). The Department of Cardiology (University Hospital of Zurich/University of Zurich) reports research-, educational- and/or travel grants from Abbott, Amgen, Astra Zeneca, Bayer, Berlin Heart, B. Braun, Biosense Webster, Biosensors Europe AG, Biotronik, BMS, Boehringer Ingelheim, Boston Scientific, Bracco, Cardinal Health Switzerland, Corteria, Daiichi, Diatools AG, Edwards Lifesciences, Guidant Europe NV (BS), Hamilton Health Sciences, Kaneka Corporation, Kantar, Labormedizinisches Zentrum, Medtronic, MSD, Mundipharma Medical Company, Novartis, Novo Nordisk, Orion, Pfizer, Quintiles Switzerland Sarl, Roche Diagnostics, Sahajanand IN, Sanofi, Sarstedt AG, Servier, SIS Medical, SSS International Clinical Research, Terumo Deutschland, Trama Solutions, V- Wave, Vascular Medical, Vifor, Wissens Plus, ZOLL. The research and educational grants do not impact on Prof. Ruschitzka;s personal remuneration. G. Savarese reports unrelated to the present work: Grants or contracts: Vifor Pharma, Boehringer Ingelheim, Astra Zeneca, Merck, Cytokinetics; Consulting fees: Societa' Prodotti Antibiotici, Medical Education Global Solutions, Genesis, Agence Recherche (ANR); speaker's honoraria: Servier, Cytokinetics, Medtronic, Dynamicom Education, Vifor Pharma; Support for attending meetings: Boehringer Ingelheim; Data Safety Monitoring Bord or Advisory Board: Astra Zeneca, Uppsala Clinical Research Center, Servier. P. Seferovic reports unrelated to the present work: speaker's honoraria from Servier, Astra Zeneca, Menarini, Boehringer Ingelheim, Novartis and Roche diagnostic. M. Volterrani: none related to the present work. R. Ferrari reports unrelated to the present work: speaker's honoraria and support for attending meetings: Servier International, Merck Serono, Lupin, Sunpharma, Reddys Ltd; leadership or fiduciary role in other board: Scientific Director of Medical Trial Analysis. A. Maggioni: personal fees from AstraZeneca, Bayer, Fresenius, Novartis, outside the submitted work. L.H. Lund is supported by Supported by Karolinska Institutet, the Swedish Research Council [grant 523-2014-2336], the Swedish Heart Lung Foundation [grants 20150557, 20190310], and the Stockholm County Council [grants 20170112, 20190525] and reports unrelated to the present work: Grants: AstraZeneca, Vifor, Boston Scientific, Boehringer Ingelheim, Novartis, MSD; Consulting: Vifor, AstraZeneca, Bayer, Pharmacosmos, MSD, MedScape, Sanofi, Lexicon, Myokardia, Boehringer Ingelheim, Servier, Edwards Life Sciences, Alleviant; Speaker's honoraria: Abbott, OrionPharma, MedScape, Radcliffe, AstraZeneca, Novartis, Boehringer Ingelheim, Bayer; Patent: AnaCardio; Stock ownership: AnaCardio. EDAT- 2023/05/12 19:07 MHDA- 2023/09/25 06:42 CRDT- 2023/05/12 17:12 PHST- 2023/01/26 00:00 [received] PHST- 2023/05/05 00:00 [revised] PHST- 2023/05/06 00:00 [accepted] PHST- 2023/09/25 06:42 [medline] PHST- 2023/05/12 19:07 [pubmed] PHST- 2023/05/12 17:12 [entrez] AID - 7161110 [pii] AID - 10.1093/eurjpc/zwad151 [doi] PST - ppublish SO - Eur J Prev Cardiol. 2023 Sep 20;30(13):1346-1358. doi: 10.1093/eurjpc/zwad151. PMID- 37171293 OWN - NLM STAT- MEDLINE DCOM- 20240531 LR - 20250804 IS - 1680-0745 (Electronic) IS - 1015-9657 (Linking) VI - 35 IP - 1 DP - 2024 Jan-Apr 23 TI - A strategy to improve adherence to guideline-directed medical therapy (GDMT) and the role of the multidisciplinary team in a heart-failure programme. PG - 12-15 LID - 10.5830/CVJA-2022-067 [doi] AB - BACKGROUND: Heart failure (HF) patients place a heavy burden on the healthcare system because of their frequent need for in-patient treatment, emergency room visits and subsequent hospital stays. To provide proper care and effective therapy, practitioners have streamlined delivery techniques such as clinical pathways, checklists and pocket manuals. However, a description of the establishment of a disease-management programme, including a multidisciplinary team of physicians, clinical pharmacists and nurse specialists is required. The aim of this study was to highlight the role of the multidisciplinary team in a heart-failure programme by assessing the improvement in adherence to guideline-directed medical therapy. METHODS: A retrospective, observational research was undertaken on patients with HF at a cardiac centre in Riyadh, to observe the HF patients' management before (January to December 2014) and after (January to December 2015) the establishment of a programme. RESULTS: The use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers was 75.59% in 2014 at discharge and 81.17% in 2015 (p = 0.249). Beta-blockers use at release increased from 87.83% in 2014 to 94.53% in 2015 (p = 0.021). The flu vaccine was given to 48.24% of patients in 2014 and 75.13% of the patients in 2015 (p < 0.001). The pneumococcal vaccine was administered to 44.22% of patients in 2014 and 75.13% of patients in 2015 (p < 0.001). The ejection fraction improved from 30.21% in the first month to 39.56% in the 12th month (p = 0.001) in patients managed in 2015. CONCLUSION: The multidisciplinary heart-failure programme resulted in a positive effect, in the form of improved patient care after including the clinical pharmacist and nurse specialist. FAU - AlHabeeb, Waleed AU - AlHabeeb W AD - King Saud University, Riyadh, Saudi Arabia. Email: walhabeeb@ksu.edu.sa. FAU - Alayoubi, Fakhr AU - Alayoubi F AD - King Saud University, Riyadh, Saudi Arabia. FAU - Hayajneh, Ahmed AU - Hayajneh A AD - King Saud University, Riyadh, Saudi Arabia. FAU - Ullah, Anhar AU - Ullah A AD - King Saud University, Riyadh, Saudi Arabia. FAU - Elshaer, Fayez AU - Elshaer F AD - King Saud University, Riyadh, Saudi Arabia. LA - eng PT - Journal Article PT - Observational Study DEP - 20230505 PL - South Africa TA - Cardiovasc J Afr JT - Cardiovascular journal of Africa JID - 101313864 RN - 0 (Angiotensin-Converting Enzyme Inhibitors) RN - 0 (Angiotensin Receptor Antagonists) RN - 0 (Adrenergic beta-Antagonists) RN - 0 (Cardiovascular Agents) SB - IM MH - Humans MH - Retrospective Studies MH - *Patient Care Team MH - *Guideline Adherence MH - Female MH - *Heart Failure/drug therapy/physiopathology/therapy/diagnosis MH - Male MH - Middle Aged MH - Aged MH - *Practice Guidelines as Topic MH - Saudi Arabia MH - Treatment Outcome MH - Angiotensin-Converting Enzyme Inhibitors/therapeutic use MH - Time Factors MH - Practice Patterns, Physicians'/standards MH - Program Evaluation MH - Interdisciplinary Communication MH - Angiotensin Receptor Antagonists/therapeutic use MH - Quality Improvement/standards MH - Quality Indicators, Health Care/standards MH - Adrenergic beta-Antagonists/therapeutic use MH - Cardiovascular Agents/therapeutic use MH - Pharmacists OTO - NOTNLM OT - angiotensin converting enzyme inhibitors OT - directed medical therapy OT - heart failure OT - immunisation OT - medical therapy EDAT- 2023/05/12 13:08 MHDA- 2024/05/31 12:44 CRDT- 2023/05/12 10:13 PHST- 2022/08/30 00:00 [received] PHST- 2022/12/01 00:00 [accepted] PHST- 2024/05/31 12:44 [medline] PHST- 2023/05/12 13:08 [pubmed] PHST- 2023/05/12 10:13 [entrez] AID - 10.5830/CVJA-2022-067 [doi] PST - ppublish SO - Cardiovasc J Afr. 2024 Jan-Apr 23;35(1):12-15. doi: 10.5830/CVJA-2022-067. Epub 2023 May 5. PMID- 37168648 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230514 IS - 2691-171X (Electronic) IS - 2691-171X (Linking) VI - 3 IP - 3 DP - 2022 Aug TI - Care Pattern for Fontan-Associated Liver Disease by Academic Pediatric Hepatologists in Canada. PG - e207 LID - 10.1097/PG9.0000000000000207 [doi] AB - Fontan-Associated Liver Disease (FALD) is a common extracardiac complication seen in patients following the Fontan procedure. There are no consensus guidelines on screening and management of children with FALD. OBJECTIVE: The current study aims to determine academic pediatric hepatologists' practices and identify variability in management provided to children with FALD in Canada. METHODS: Using the infrastructure of the Canadian Pediatric Hepatology Research Group, a nationwide survey was distributed electronically to all pediatric hepatologists practicing in university-affiliated hospitals. RESULTS: Twelve pediatric hepatologists from 12 of 13 academic centers (92%) responded to the survey. The institutions of only 2 (17%) physicians offer post-Fontan care with a multidisciplinary team, both from different provinces. The screening for other comorbidities, use of noninvasive modality, and timing of liver biopsy for estimation of liver fibrosis and screening for esophageal varices differ from program to program. The frequency of outpatient clinic follow-up varies significantly. Education and counseling concerning liver health are generally used as treatment; only 58% of academic centers have a formal adult care transition plan. CONCLUSIONS: Significant discrepancies exist in the care provided to children with FALD by hepatologists practicing in academic centers across Canada. Future study is needed to develop a standardized protocol for managing and following children and youth with FALD. CI - Copyright (c) 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. FAU - Kehar, Mohit AU - Kehar M AD - From the Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Children's Hospital of Eastern Ontario, Department of Pediatrics, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada. FAU - Jimenez-Rivera, Carolina AU - Jimenez-Rivera C AD - From the Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Children's Hospital of Eastern Ontario, Department of Pediatrics, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada. LA - eng PT - Journal Article DEP - 20220621 PL - United States TA - JPGN Rep JT - JPGN reports JID - 101773885 PMC - PMC10158345 OTO - NOTNLM OT - Canada OT - cardiac OT - congenital heart disease OT - hepatic disease OT - pediatric COIS- The authors report no conflicts of interest. EDAT- 2023/05/12 01:07 MHDA- 2023/05/12 01:08 PMCR- 2022/06/21 CRDT- 2023/05/11 19:24 PHST- 2022/01/22 00:00 [received] PHST- 2022/04/04 00:00 [accepted] PHST- 2023/05/12 01:08 [medline] PHST- 2023/05/12 01:07 [pubmed] PHST- 2023/05/11 19:24 [entrez] PHST- 2022/06/21 00:00 [pmc-release] AID - 10.1097/PG9.0000000000000207 [doi] PST - epublish SO - JPGN Rep. 2022 Jun 21;3(3):e207. doi: 10.1097/PG9.0000000000000207. eCollection 2022 Aug. PMID- 37168251 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230516 IS - 2572-9292 (Electronic) IS - 2572-9292 (Linking) VI - 7 IP - 2 DP - 2023 Mar 13 TI - Development of In-Hospital Outcomes in Patients undergoing Transcatheter Aortic Valve Implantation (TAVI) at an Interdisciplinary Heart Center: A Single-Center Experience of 489 Consecutive Cases. PG - 52-68 LID - 10.26502/fccm.92920309 [doi] AB - BACKGROUND: Transcatheter Aortic Valve Implantation (TAVI) has emerged over time, reflected in appropriate adjustments in the European Society of Cardiology (ESC) guidelines in 2007, 2012 and 2017. OBJECTIVE: The aim of this study was to analyze in-hospital outcomes after TAVI in the development within a single heart center over a period of 10 years depending on adjustments in the guidelines, infrastructural and procedural determinants. METHODS: 489 consecutive patients who underwent TAVI from 2010 and 2019 at our center were analyzed retrospectively. Patients were divided into 3 groups of different treatment circumstances depending on guidelines adjustments and local infrastructural progress (group 1: 2010-2015 (n = 132), group 2: 2016-2017 (n = 155), group 3: 2018-2019 (n = 202). The primary endpoint was defined as all-cause in-hospital mortality. Secondary endpoints were selected according to the Valve Academic Research Consortium (VARC)-2 definitions. Multivariate logistic regression analysis was performed to determine predictors of in-hospital mortality. Statistical significance was assumed for p < 0.05. RESULTS: 489 patients (346 (70.8 %) transfemoral and 143 (29.2 %) transapical) underwent TAVI. Comparing periods (group 1 vs. 2 vs. 3) age (82.1 +/- 6.2 vs. 82.5 +/- 4.8 vs. 81.1 +/- 5.1 years, p = 0.012) and EuroSCORE II (8.4 +/- 6.0 vs. 5.8 +/- 4.9 vs. 5.5 +/- 5.0 %, p < 0.001) declined over time. Rates of in-hospital mortality decreased significantly (9.1 % vs. 5.8 % vs. 2.5 %, p = 0.029), especially with observed-to-expected mortality ratios indicating a disproportionate decline of in-hospital mortality (1.08 vs. 1.00 vs. 0.45). Furthermore, post-procedural complications, such as acute kidney injury stage 3 (10.6 % vs. 3.2 % vs. 4.5 %, p = 0.016) and bleeding complications (14.4 % vs. 11.6 % vs 7.9 %, p = 0.165) decreased from group 1 to 3. However, rates of permanent pacemaker implantations (7.6 % vs. 11.0 % vs. 22.8 %, p < 0.001) increased, associated with a switch towards self-expanding valves (0.0 % vs. 61.3 % vs. 76.7 %, p < 0.001). Length of hospitalization as well as stay at intensive care and intermediate care unit could be reduced significantly during the observation period. In multivariate analysis age (OR: 1.103; 95 % CI: 1.013 - 1.202; p = 0.025), creatinine level before TAVI (OR: 1.497; 95 % CI: 1.013 - 2.212; p = 0.043), atrial fibrillation (OR: 2.956; 95 % CI: 1.127 - 7.749; p = 0.028) and procedure duration (OR: 1.017; 95 % CI: 1.009 - 1.025; p < 0.001) could be identified as independent predictors of in-hospital mortality. CONCLUSION: This study identified age, creatinine level before TAVI, the presence of atrial fibrillation and procedure duration as independent predictors for in-hospital mortality. Although these predictors decreased during the observation period, the decline in hospital-mortality was disproportionate, which was indicated by an observed-to-expected mortality ratio of 0.45 for the last observation period. However, it can be assumed that apart from patient-related factors, there were further institutional, technical and procedural developments, which ran in parallel and affected in-hospital mortality rates after TAVI. FAU - Rana, Mukaram AU - Rana M AD - Herz-Thorax-Zentrum Fulda, Medizinische Klinik I (Kardiologie, Angiologie, Intensivmedizin), Klinikum Fulda, Universitatsmedizin Marburg - Campus Fulda, Fulda. FAU - Niethammer, Margit AU - Niethammer M AD - Herz-Thorax-Zentrum Fulda, Medizinische Klinik I (Kardiologie, Angiologie, Intensivmedizin), Klinikum Fulda, Universitatsmedizin Marburg - Campus Fulda, Fulda. FAU - Sellin, Christian AU - Sellin C AD - Herz-Thorax-Zentrum Fulda, Klinik fur Herz- und Thoraxchirurgie, Klinikum Fulda, Universitatsmedizin Marburg - Campus Fulda, Fulda. FAU - Dorge, Hilmar AU - Dorge H AD - Herz-Thorax-Zentrum Fulda, Klinik fur Herz- und Thoraxchirurgie, Klinikum Fulda, Universitatsmedizin Marburg - Campus Fulda, Fulda. FAU - Eggebrecht, Holger AU - Eggebrecht H AD - Herz-Thorax-Zentrum Fulda, Medizinische Klinik I (Kardiologie, Angiologie, Intensivmedizin), Klinikum Fulda, Universitatsmedizin Marburg - Campus Fulda, Fulda. AD - Cardiologisches Centrum Bethanien (CCB), Frankfurt a. M. FAU - Schachinger, Volker AU - Schachinger V AD - Herz-Thorax-Zentrum Fulda, Medizinische Klinik I (Kardiologie, Angiologie, Intensivmedizin), Klinikum Fulda, Universitatsmedizin Marburg - Campus Fulda, Fulda. LA - eng GR - R01 HL147662/HL/NHLBI NIH HHS/United States PT - Journal Article PL - United States TA - Cardiol Cardiovasc Med JT - Cardiology and cardiovascular medicine JID - 101721428 PMC - PMC10167775 MID - NIHMS1883380 OTO - NOTNLM OT - Aortic stenosis (AS) OT - In-hospital outcomes OT - Transcatheter Aortic Valve Implantation (TAVI) COIS- Conflicts of Interest The authors state that they have no conflicts of interest. EDAT- 2023/05/12 01:07 MHDA- 2023/05/12 01:08 PMCR- 2023/05/09 CRDT- 2023/05/11 19:17 PHST- 2023/05/12 01:08 [medline] PHST- 2023/05/12 01:07 [pubmed] PHST- 2023/05/11 19:17 [entrez] PHST- 2023/05/09 00:00 [pmc-release] AID - 10.26502/fccm.92920309 [doi] PST - ppublish SO - Cardiol Cardiovasc Med. 2023 Mar 13;7(2):52-68. doi: 10.26502/fccm.92920309. PMID- 37163197 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250720 IS - 1178-2390 (Print) IS - 1178-2390 (Electronic) IS - 1178-2390 (Linking) VI - 16 DP - 2023 TI - Peripartum Cardiomyopathy: Risks Diagnosis and Management. PG - 1249-1258 LID - 10.2147/JMDH.S372747 [doi] AB - Peripartum cardiomyopathy is a rare cause of heart failure that occurs during late pregnancy or in the early postpartum period. Delays in diagnosis may occur as symptoms of heart failure mimic those of normal pregnancy. The diagnosis should be considered in any pregnant or postpartum woman with symptoms concerning for heart failure. If there are clinical concerns, labs including N-terminal pro-BNP should be checked, and an echocardiogram should be ordered to assess for systolic dysfunction. Prompt medical treatment tailored for pregnancy and lactation is essential to prevent adverse events. Outcomes are variable, including complete recovery, persistent myocardial dysfunction with heart failure symptoms, arrhythmias, thromboembolic events, and/or rapid deterioration requiring mechanical circulatory support and cardiac transplantation. It is essential that care is provided as part of a multidisciplinary cardio-obstetrics team including obstetrics, cardiology, maternal fetal medicine, anesthesiology, and nursing. All women with peripartum cardiomyopathy should have close follow-up with a cardiologist, although optimal duration of medical therapy following complete recovery is unknown. Women considering a subsequent pregnancy require preconception counseling and close collaboration between obstetrics and cardiology throughout pregnancy. CI - (c) 2023 Carlson et al. FAU - Carlson, Selma AU - Carlson S AD - Division of Cardiology, Department of Medicine, University of Minnesota, Minneapolis, MN, USA. AD - Division of Cardiology, Minneapolis VA Medical Center, Minneapolis, MN, USA. FAU - Schultz, Jessica AU - Schultz J AD - Division of Cardiology, Department of Medicine, University of Minnesota, Minneapolis, MN, USA. FAU - Ramu, Bhavadharini AU - Ramu B AD - Division of Cardiology, Department of Medicine, Medical University of South Carolina (MUSC), Charleston, SC, USA. FAU - Davis, Melinda B AU - Davis MB AUID- ORCID: 0000-0002-3676-1982 AD - Division of Cardiovascular Medicine, Department of Medicine, University of Michigan, Ann Arbor, MI, USA. LA - eng GR - IK2 CX002525/CX/CSRD VA/United States PT - Journal Article PT - Review DEP - 20230503 PL - New Zealand TA - J Multidiscip Healthc JT - Journal of multidisciplinary healthcare JID - 101512691 PMC - PMC10164389 OTO - NOTNLM OT - cardiomyopathy OT - heart failure OT - peripartum OT - pregnancy COIS- The authors report no conflicts of interest in this work. EDAT- 2023/05/10 12:42 MHDA- 2023/05/10 12:43 PMCR- 2023/05/03 CRDT- 2023/05/10 11:26 PHST- 2023/03/03 00:00 [received] PHST- 2023/04/27 00:00 [accepted] PHST- 2023/05/10 12:43 [medline] PHST- 2023/05/10 12:42 [pubmed] PHST- 2023/05/10 11:26 [entrez] PHST- 2023/05/03 00:00 [pmc-release] AID - 372747 [pii] AID - 10.2147/JMDH.S372747 [doi] PST - epublish SO - J Multidiscip Healthc. 2023 May 3;16:1249-1258. doi: 10.2147/JMDH.S372747. eCollection 2023. PMID- 39076751 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240731 IS - 2153-8174 (Electronic) IS - 2153-8174 (Print) IS - 1530-6550 (Linking) VI - 24 IP - 5 DP - 2023 May TI - Improved Endothelial and Autonomic Function after Transcatheter Aortic Valve Implantation. PG - 140 LID - 10.31083/j.rcm2405140 [doi] LID - 140 AB - BACKGROUND: Degenerative aortic stenosis is an atherosclerotic-like process associated with impaired endothelial and autonomic function. Transcatheter aortic valve implantation (TAVI) has become a treatment of choice for patient with severe degenerative aortic stenosis at high surgical risk. The effect of this procedure on endothelial function measured with flow mediated dilatation (FMD) and autonomic function measured with heart rate variability (HRV) at different time-points of disease management (early and late follow-up) remains unknown. METHODS: We prospectively included 50 patients with severe aortic stenosis who were deemed suitable for TAVI by the Heart Team. FMD and HRV parameters were collected at baseline ( < 24 h pre-TAVI), at early follow-up (up to 48 h post-TAVI) and at late follow-up (3-6 months post-TAVI). RESULTS: 43 patients (mean age 81 (75-85); 60% women) completed the study. FMD significantly improved from 2.8 +/- 1.5% before TAVI to 4.7 +/- 2.7% early after TAVI (p < 0.001) and was later maintained on late follow-up (4.8 +/- 2.7%, p = 0.936). Conversely, high-resolution ECG parameters remained preserved at early and improved at late follow-up after TAVI. Significant improvement was detected in a high frequency-domain parameter-HF (from 5231 +/- 1783 to 6507 +/- 1789 ms2 ; p = 0.029) and in two Poincare plot parameters: ratio of the short- and long-term R-R variability in the Poincare plot-SD1/SD2 (from 0.682 to 0.884 ms2 ; p = 0.003) and short-term R-R variability in the Poincare plot-SDRR (from 9.6 to 23.9 ms; p = 0.001). Echocardiographic parameters comprising baseline maximal aortic valve velocity (R = 0.415; p = 0.011), mean aortic gradient (R = 0.373; p = 0.018), indexed stroke volume (R = 0.503; p = 0.006), change in aortic valve maximal velocity (R = 0.365; p = 0.031), change in mean aortic gradient (R = 0.394; p = 0.019) and NT-proBNP (R = 0.491; p = 0.001) were found as significant predictors of change in FMD. CONCLUSIONS: Endothelial function measured with FMD and autonomic function obtained with HRV parameters significantly improve after TAVI. While endothelial function improves early and is maintained later after TAVI, autonomic function remains stable and improves on late follow-up. This is most likely caused by early hemodynamic changes after resolution of aortic valve obstruction and gradual left ventricular remodeling. CLINICAL TRIAL REGISTRATION: www.clinicaltrials.gov, identifier NCT04286893. CI - Copyright: (c) 2023 The Author(s). Published by IMR Press. FAU - Vitez, Luka AU - Vitez L AD - Department of Cardiology, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia. AD - Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia. FAU - Starc, Vito AU - Starc V AD - Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia. FAU - Jug, Borut AU - Jug B AD - Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia. AD - Department of Vascular Diseases, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia. FAU - Bunc, Matjaz AU - Bunc M AD - Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia. AD - Department of Vascular Diseases, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia. LA - eng SI - ClinicalTrials.gov/NCT04286893 PT - Journal Article DEP - 20230508 PL - Singapore TA - Rev Cardiovasc Med JT - Reviews in cardiovascular medicine JID - 100960007 PMC - PMC11273032 OTO - NOTNLM OT - aortic stenosis OT - autonomic function OT - endothelial function OT - flow mediated dilatation OT - heart rate variability OT - transcatheter aortic valve implantation COIS- The authors declare no conflict of interest. EDAT- 2023/05/08 00:00 MHDA- 2023/05/08 00:01 PMCR- 2023/05/08 CRDT- 2024/07/30 05:00 PHST- 2023/02/28 00:00 [received] PHST- 2023/03/20 00:00 [revised] PHST- 2023/03/24 00:00 [accepted] PHST- 2023/05/08 00:01 [medline] PHST- 2023/05/08 00:00 [pubmed] PHST- 2024/07/30 05:00 [entrez] PHST- 2023/05/08 00:00 [pmc-release] AID - S1530-6550(23)00960-2 [pii] AID - 10.31083/j.rcm2405140 [doi] PST - epublish SO - Rev Cardiovasc Med. 2023 May 8;24(5):140. doi: 10.31083/j.rcm2405140. eCollection 2023 May. PMID- 37146529 OWN - NLM STAT- MEDLINE DCOM- 20230605 LR - 20250313 IS - 1873-5134 (Electronic) IS - 0738-3991 (Linking) VI - 113 DP - 2023 Aug TI - Evaluation of counselling materials for hybrid cardiac rehabilitation in a low-resource setting: Perceptions of patients and providers. PG - 107772 LID - S0738-3991(23)00152-0 [pii] LID - 10.1016/j.pec.2023.107772 [doi] AB - OBJECTIVE: This study evaluated the usefulness of a booklet as support material for counseling focused on self-efficacy and therapist interaction in the course of counseling in a hybrid CR program (i.e., supervised and unsupervised sessions) developed for low-resource settings. METHODS: Counseling material was developed by a multidisciplinary team, with patient input. Using multi-methods, first input from patients from six centers in Chile was sought through a telephone survey (cross-sectional). Second, input from physiotherapists delivering the intervention at all centres was solicited qualitatively through a focus group on Zoom. Content analysis was performed using a deductive-thematic approach. RESULTS: Seventy-one patients were included. All (100 %) participants responded that the materials were easy to understand, contained suggestions applicable to daily life, captured their attention and was useful for future questions. The booklet overall was rated 6.7 +/- 0.6/7 %, and 98.2 % were satisfied with the counselling. Overall themes from the six deliverers related to the CR intervention (e.g., well manualized protocols for counselling), the deliverer (e.g., expertise to deliver) and patients (e.g., found information useful). CONCLUSION: The usefulness of the counseling together with the supporting booklet was established by patients and delivering professionals. PRACTICE IMPLICATIONS: Thus, with some final refinement, this resource can be disseminated for use by other Spanish CR programs. CI - Copyright (c) 2023 Elsevier B.V. All rights reserved. FAU - Gomez-Perez, Daniela AU - Gomez-Perez D AD - Universidad de La Frontera, Facultad de Educacion, Ciencias Sociales y Humanidades, Depto. de Psicologia & LEDSA, Temuco, Chile. FAU - Seron, Pamela AU - Seron P AD - Universidad de La Frontera, Facultad de Medicina, Depto. de Cs. de la Rehabilitacion, Temuco, Chile; Universidad de La Frontera, Centro de Excelencia CIGES, Temuco, Chile. Electronic address: pamela.seron@ufrontera.cl. FAU - Oliveros, Maria Jose AU - Oliveros MJ AD - Universidad de La Frontera, Facultad de Medicina, Depto. de Cs. de la Rehabilitacion, Temuco, Chile; Universidad de La Frontera, Centro de Excelencia CIGES, Temuco, Chile. FAU - Morales Illanes, Gladys AU - Morales Illanes G AD - Universidad de La Frontera, Facultad de Medicina, Depto. de Salud Publica & EPICYN, Temuco, Chile. FAU - Arancibia, Maria Jose AU - Arancibia MJ AD - Universidad de La Frontera, Facultad de Medicina, Depto. de Cs. de la Rehabilitacion, Temuco, Chile. FAU - Grace, Sherry L AU - Grace SL AD - Kinesiology & Health Science, York University, Toronto, Canada; KITE Research Institute & Peter Munk Cardiac Centre, University Health Network, University of Toronto, Canada. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230425 PL - Ireland TA - Patient Educ Couns JT - Patient education and counseling JID - 8406280 SB - IM MH - Humans MH - *Cardiac Rehabilitation/methods MH - Cross-Sectional Studies MH - Counseling/methods MH - Self Efficacy MH - Focus Groups OTO - NOTNLM OT - Behavior change OT - Cardiac rehabilitation OT - Counseling OT - Patient education OT - Self-efficacy OT - User-centred design COIS- Declaration of Competing Interest None. EDAT- 2023/05/06 09:42 MHDA- 2023/06/05 06:42 CRDT- 2023/05/05 18:08 PHST- 2023/01/23 00:00 [received] PHST- 2023/04/19 00:00 [revised] PHST- 2023/04/24 00:00 [accepted] PHST- 2023/06/05 06:42 [medline] PHST- 2023/05/06 09:42 [pubmed] PHST- 2023/05/05 18:08 [entrez] AID - S0738-3991(23)00152-0 [pii] AID - 10.1016/j.pec.2023.107772 [doi] PST - ppublish SO - Patient Educ Couns. 2023 Aug;113:107772. doi: 10.1016/j.pec.2023.107772. Epub 2023 Apr 25. PMID- 37145342 OWN - NLM STAT- MEDLINE DCOM- 20230710 LR - 20230718 IS - 1179-187X (Electronic) IS - 1175-3277 (Print) IS - 1175-3277 (Linking) VI - 23 IP - 4 DP - 2023 Jul TI - Management of Gastrointestinal Bleeding and Resumption of Oral Anticoagulant Therapy in Patients with Atrial Fibrillation: A Multidisciplinary Discussion. PG - 407-418 LID - 10.1007/s40256-023-00582-9 [doi] AB - Direct oral anticoagulants (DOACs) are recommended for the prevention of thromboembolism in patients with atrial fibrillation (AF), and are now preferred over vitamin K antagonists due to their beneficial efficacy and safety profile. However, all oral anticoagulants carry a risk of gastrointestinal (GI) bleeding. Although the risk is well documented and acute bleeding well codified, there is limited high-quality evidence and no guidelines to guide physicians on the optimal management of anticoagulation after a GI bleeding event. The aim of this review is to provide a multidisciplinary critical discussion of the optimal management of GI bleeding in patients with AF receiving oral anticoagulants to help physicians provide individualized treatment for each patient and optimize outcomes. It is important to perform endoscopy when a patient presents with bleeding manifestations or hemodynamic instability to determine the bleed location and severity of bleeding and then perform initial resuscitation. Administration of all anticoagulants and antiplatelets should be stopped and bleeding allowed to resolve with time; however, anticoagulant reversal should be considered for patients who have life-threatening bleeding or when the bleeding is not controlled by the initial resuscitation. Anticoagulation needs to be timely resumed considering that bleeding risk outweighs thrombotic risk when anticoagulation is resumed early after the bleeding event. To prevent further bleeding, physicians should prescribe anticoagulant therapy with the lowest risk of GI bleeding, avoid medications with GI toxicity, and consider the effect of concomitant medications on potentiating the bleeding risk. CI - (c) 2023. The Author(s). FAU - Martin, Anne-Celine AU - Martin AC AUID- ORCID: 0000-0002-6148-3523 AD - Advanced Heart Failure Unit, AP-HP, Cardiology Department, European Hospital Georges Pompidou, Paris, France. anne-celine.martin@aphp.fr. AD - INSERM UMRS_1140, Innovative Therapies in Haemostasis, Universite Paris Cite, 75006, Paris, France. anne-celine.martin@aphp.fr. FAU - Benamouzig, Robert AU - Benamouzig R AD - Service de Gastroenterologie, Hopital Avicenne, AP-HP, Universite Paris-Nord-La Sorbonne, Bobigny, France. FAU - Gouin-Thibault, Isabelle AU - Gouin-Thibault I AD - Laboratory of Hematology, IRSET-INSERM UMRS 1085, Rennes University Hospital, Rennes, France. FAU - Schmidt, Jeannot AU - Schmidt J AD - LaPSCo, Physiological and Psychosocial Stress, CNRS, Universite Clermont Auvergne, Clermont-Ferrand, France. AD - Emergency Department, CHU Clermont-Ferrand, University Hospital Gabriel Montpied, Clermont-Ferrand, France. LA - eng PT - Journal Article PT - Review DEP - 20230505 PL - New Zealand TA - Am J Cardiovasc Drugs JT - American journal of cardiovascular drugs : drugs, devices, and other interventions JID - 100967755 RN - 0 (Anticoagulants) SB - IM MH - Humans MH - *Atrial Fibrillation/complications/drug therapy MH - Anticoagulants/adverse effects MH - Gastrointestinal Hemorrhage/chemically induced/prevention & control MH - *Thromboembolism/drug therapy/prevention & control MH - Blood Coagulation MH - Administration, Oral MH - *Stroke/prevention & control PMC - PMC10329066 COIS- Anne-Celine Martin: BMS/Pfizer, Bayer, Boehringer Ingelheim, Astra Zeneca, Novartis. Robert Benamouzig: no relevant conflicts of interest to declare. Isabelle Gouin-Thibault: Alliance BMS/Pfizer, Bayer, Leo Pharma, Abbvie. Jeannot Schmidt: no relevant conflicts of interest to declare. EDAT- 2023/05/05 12:42 MHDA- 2023/07/10 06:42 PMCR- 2023/05/05 CRDT- 2023/05/05 11:15 PHST- 2023/04/05 00:00 [accepted] PHST- 2023/07/10 06:42 [medline] PHST- 2023/05/05 12:42 [pubmed] PHST- 2023/05/05 11:15 [entrez] PHST- 2023/05/05 00:00 [pmc-release] AID - 10.1007/s40256-023-00582-9 [pii] AID - 582 [pii] AID - 10.1007/s40256-023-00582-9 [doi] PST - ppublish SO - Am J Cardiovasc Drugs. 2023 Jul;23(4):407-418. doi: 10.1007/s40256-023-00582-9. Epub 2023 May 5. PMID- 37141594 OWN - NLM STAT- MEDLINE DCOM- 20230725 LR - 20230725 IS - 1873-233X (Electronic) IS - 0029-7844 (Print) IS - 0029-7844 (Linking) VI - 141 IP - 6 DP - 2023 Jun 1 TI - Confirmation of Heart Malformations in Fetuses in the First Trimester Using Three-Dimensional Histologic Autopsy. PG - 1209-1218 LID - 10.1097/AOG.0000000000005169 [doi] AB - BACKGROUND: We aimed to evaluate the usefulness of three-dimensional (3D) reconstruction of histology slides to confirm congenital heart disease (CHD) detected by first-trimester fetal cardiac ultrasonography. Conventional autopsy is hindered by the small size of the first-trimester fetal heart, and current CHD confirmation studies employ the use of highly specialized and expensive methods. TECHNIQUE: An extended first-trimester ultrasound examination protocol was used to diagnose fetal heart anomalies. Medical termination of pregnancies was followed by fetal heart extraction. The specimens were sliced, and the histology slides were stained and scanned. The resulting images were processed, and volume rendering was performed using 3D reconstruction software. The volumes were analyzed by a multidisciplinary team of maternal-fetal medicine subspecialists and pathologists and compared with ultrasound examination findings. EXPERIENCE: Six fetuses with heart malformations were evaluated using histologic 3D imaging: two with hypoplastic left heart syndrome, two with atrioventricular septal defects, one with an isolated ventricular septal defect, and one with transposition of the great arteries. The technique allowed us to confirm ultrasound-detected anomalies and also identified additional malformations. CONCLUSION: After pregnancy termination or loss, histologic 3D imaging can be used to confirm the presence of fetal cardiac malformations detected during first-trimester ultrasound examination. Additionally, this technique has the potential to refine the diagnosis for counseling regarding recurrence risk and retains the advantages of standard histology. CI - Copyright (c) 2023 The Author(s). Published by Wolters Kluwer Health, Inc. FAU - Ruican, Dan AU - Ruican D AD - Department of Obstetrics and Gynecology, University Emergency County Hospital, and the Doctoral School, the Department of Histology, the Research Centre for Microscopic Morphology and Immunology, and the Department of Obstetrics and Gynecology, University of Medicine and Pharmacy of Craiova, Craiova, Romania. FAU - Petrescu, Ana-Maria AU - Petrescu AM FAU - Istrate-Ofiteru, Anca-Maria AU - Istrate-Ofiteru AM FAU - Rosu, Gabriela Camelia AU - Rosu GC FAU - Zorila, George-Lucian AU - Zorila GL FAU - Dira, Laurentiu Mihai AU - Dira LM FAU - Nagy, Rodica Daniela AU - Nagy RD FAU - Mogoanta, Laurentiu AU - Mogoanta L FAU - Pirici, Daniel AU - Pirici D FAU - Iliescu, Dominic Gabriel AU - Iliescu DG LA - eng PT - Journal Article DEP - 20230503 PL - United States TA - Obstet Gynecol JT - Obstetrics and gynecology JID - 0401101 SB - IM MH - Pregnancy MH - Female MH - Humans MH - Pregnancy Trimester, First MH - Autopsy MH - *Transposition of Great Vessels MH - *Heart Defects, Congenital/diagnostic imaging MH - Ultrasonography, Prenatal/methods MH - Fetal Heart/diagnostic imaging PMC - PMC10184816 COIS- Financial Disclosure The authors did not report any potential conflicts of interest. EDAT- 2023/05/04 18:41 MHDA- 2023/07/25 06:43 PMCR- 2023/05/15 CRDT- 2023/05/04 17:03 PHST- 2022/12/27 00:00 [received] PHST- 2023/02/09 00:00 [accepted] PHST- 2023/07/25 06:43 [medline] PHST- 2023/05/04 18:41 [pubmed] PHST- 2023/05/04 17:03 [entrez] PHST- 2023/05/15 00:00 [pmc-release] AID - 00006250-990000000-00767 [pii] AID - ONG-22-2175 [pii] AID - 10.1097/AOG.0000000000005169 [doi] PST - ppublish SO - Obstet Gynecol. 2023 Jun 1;141(6):1209-1218. doi: 10.1097/AOG.0000000000005169. Epub 2023 May 3. PMID- 37141087 OWN - NLM STAT- MEDLINE DCOM- 20230508 LR - 20230517 IS - 1651-2006 (Electronic) IS - 1401-7431 (Linking) VI - 57 IP - 1 DP - 2023 Dec TI - Implementing screening for myocardial injury in non-cardiac surgery: perspectives of an ad-hoc interdisciplinary expert group. PG - 31-39 LID - 10.1080/14017431.2022.2112071 [doi] AB - Objectives. Perioperative myocardial injury (PMI) is increasingly recognised as an important complication of non-cardiac surgery, with often clinically silent presentation, but detrimental prognosis. Active screening for PMI, involving the detection of dynamic and elevated levels of cardiac troponin, has recently been advocated by an increasing number of guidelines; however, active PMI screening has not been reflected in clinical practice. Design. As consensus on a common screening and management pathway is lacking, we synthesise the current evidence to provide suggestions on the selection of patients for screening, organisation of a screening program, and a potential management pathway, building upon a recently published perioperative screening algorithm. Results. Screening should be performed using high-sensitivity assays both preoperatively and postoperatively (postoperative Days 1 and 2) in patients at high-risk of experiencing perioperative complications. Conclusion. This expert opinion piece by an interdisciplinary group of predominantly Norwegian clinicians aims to assist healthcare professionals planning to implement guideline-recommended PMI screening at a local level in order to improve patient outcomes following non-cardiac surgery. FAU - Atar, Dan AU - Atar D AUID- ORCID: 0000-0003-1513-8793 AD - Department of Cardiology, Oslo University Hospital Ulleval, Oslo, Norway. AD - Institute of Clinical Medicine, University of Oslo, Oslo, Norway. FAU - Rosseland, Leiv Arne AU - Rosseland LA AD - Institute of Clinical Medicine, University of Oslo, Oslo, Norway. AD - Department of Research and Development, Division of Emergencies and Critical Care, Oslo University Hospital, Oslo, Norway. FAU - Jammer, Ib AU - Jammer I AD - Department of Anaesthesia and Intensive Care, Haukeland University Hospital, Bergen, Norway. AD - Department of Clinical Medicine, University of Bergen, Bergen, Norway. FAU - Aakre, Kristin Moberg AU - Aakre KM AD - Department of Medical Biochemistry and Pharmacology, Haukeland University Hospital, Bergen, Norway. AD - Department of Heart Disease, Haukeland University Hospital, Bergen, Norway. AD - Department of Clinical Science, University of Bergen, Bergen, Norway. FAU - Wiseth, Rune AU - Wiseth R AD - Clinic of Cardiology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway. AD - Department of Circulation and Medical Imaging, NTNU, Norwegian University of Science and Technology, Trondheim, Norway. FAU - Molund, Marius AU - Molund M AD - Department of Orthopaedic Surgery, Ostfold Hospital Trust, Gralum, Norway. FAU - Gualandro, Danielle M AU - Gualandro DM AD - Department of Cardiology and Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, University of Basel, Switzerland. FAU - Omland, Torbjorn AU - Omland T AUID- ORCID: 0000-0002-6452-0369 AD - Institute of Clinical Medicine, University of Oslo, Oslo, Norway. AD - Department of Cardiology, Akershus University Hospital, Lorenskog, Norway. LA - eng PT - Journal Article PL - England TA - Scand Cardiovasc J JT - Scandinavian cardiovascular journal : SCJ JID - 9708377 SB - IM MH - Humans MH - *Myocardium/metabolism MH - Prognosis MH - *Postoperative Complications/diagnosis/etiology OTO - NOTNLM OT - PMI OT - Perioperative screening OT - cardiac troponin OT - myocardial infarction OT - myocardial injury EDAT- 2023/05/04 18:42 MHDA- 2023/05/08 06:42 CRDT- 2023/05/04 12:34 PHST- 2023/05/08 06:42 [medline] PHST- 2023/05/04 18:42 [pubmed] PHST- 2023/05/04 12:34 [entrez] AID - 10.1080/14017431.2022.2112071 [doi] PST - ppublish SO - Scand Cardiovasc J. 2023 Dec;57(1):31-39. doi: 10.1080/14017431.2022.2112071. PMID- 37139137 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240917 IS - 2297-055X (Print) IS - 2297-055X (Electronic) IS - 2297-055X (Linking) VI - 10 DP - 2023 TI - The role of the pregnancy heart team in clinical practice. PG - 1135294 LID - 10.3389/fcvm.2023.1135294 [doi] LID - 1135294 AB - Significant maternal and fetal morbidity and mortality risk has been shown to be associated with cardiovascular disease in pregnancy. Several determinants, such as the increasing number of females with corrected congenital heart disease in reproductive age, a more advanced maternal age associated with cardiovascular risk factors, and a greater prevalence of preexisting comorbidities related to cardiac disorders such as cancer and COVID-19), lead to a higher incidence of cardiac complications in pregnancy in the last few decades. However, adopting a multidisciplinary strategy may influence maternal and neonatal outcomes. This review aims at assessing the role of the Pregnancy Heart Team, which should ensure careful pre-pregnancy counseling, pregnancy monitoring, and delivery planning for both congenital and other cardiac or metabolic disorders, addressing several emerging aspects in the multidisciplinary team-based approach. CI - (c) 2023 Luca, Colivicchi, Parrini, Russo, Di Fusco, Ceravolo, Riccio, Favilli, Rossini, Gelsomino, Oliva and Gulizia. FAU - Luca, Fabiana AU - Luca F AD - Cardiology Department, Grande Ospedale Metropolitano, GOM, AO Bianchi Melacrino Morelli, Reggio Calabria, Italy. FAU - Colivicchi, Furio AU - Colivicchi F AD - Clinical and Rehabilitation Cardiology Department, San Filippo Neri Hospital, ASL Roma 1, Roma, Italy. FAU - Parrini, Iris AU - Parrini I AD - Cardiology Department, Mauriziano Hospital, Torino, Italy. FAU - Russo, Maria Giovanna AU - Russo MG AD - U.O.C. Cardiologia e UTIC Pediatrica, AORN dei Colli, Ospedale Monaldi, Universita Della Campania "L. Vanvitelli", Napoli, Italy. FAU - Di Fusco, Stefania Angela AU - Di Fusco SA AD - Clinical and Rehabilitation Cardiology Department, San Filippo Neri Hospital, ASL Roma 1, Roma, Italy. FAU - Ceravolo, Roberto AU - Ceravolo R AD - Cardiology Unit, Giovanni Paolo II Hospital, Lamezia, Italy. FAU - Riccio, Carmine AU - Riccio C AD - Cardiovascular Department, Sant'Anna e San Sebastiano Hospital, Caserta, Italy. FAU - Favilli, Silvia AU - Favilli S AD - Department of Pediatric Cardiology, Meyer Hospital, Florence, Italy. FAU - Rossini, Roberta AU - Rossini R AD - Cardiology Unit, Ospedale Santa Croce e Carle, Cuneo, Italy. FAU - Gelsomino, Sandro AU - Gelsomino S AD - Cardiothoracic Department, Maastricht University Hospital, Maastricht, Netherlands. FAU - Oliva, Fabrizio AU - Oliva F AD - Cardiology Unit, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy. FAU - Gulizia, Michele Massimo AU - Gulizia MM AD - Cardiology Department, Garibaldi Nesima Hospital, Catania, Italy. LA - eng PT - Journal Article PT - Review DEP - 20230417 PL - Switzerland TA - Front Cardiovasc Med JT - Frontiers in cardiovascular medicine JID - 101653388 PMC - PMC10150137 OTO - NOTNLM OT - acquired heart disease OT - cardio obstetric team OT - corrected congenital heart disease OT - multidisciplinary team-Based approach OT - postpartum followup OT - pre-conception counseling OT - pregnancy heart team COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/05/04 06:42 MHDA- 2023/05/04 06:43 PMCR- 2023/01/01 CRDT- 2023/05/04 02:13 PHST- 2022/12/31 00:00 [received] PHST- 2023/03/29 00:00 [accepted] PHST- 2023/05/04 06:43 [medline] PHST- 2023/05/04 06:42 [pubmed] PHST- 2023/05/04 02:13 [entrez] PHST- 2023/01/01 00:00 [pmc-release] AID - 10.3389/fcvm.2023.1135294 [doi] PST - epublish SO - Front Cardiovasc Med. 2023 Apr 17;10:1135294. doi: 10.3389/fcvm.2023.1135294. eCollection 2023. PMID- 37133483 OWN - NLM STAT- MEDLINE DCOM- 20230505 LR - 20230505 IS - 1545-9616 (Print) IS - 1545-9616 (Linking) VI - 22 IP - 5 DP - 2023 May 1 TI - A Review of Antithrombotic Agents in Dermatologic Surgery and Context for a Practical Approach, With Cardiology and Pharmacologic Input. PG - 496-501 LID - 10.36849/JDD.7456 [doi] AB - Dermatologic surgeons are encountering more patients on antithrombotic agents. There are no established consensus guidelines for managing antithrombotic agents in the perioperative period. We provide an updated overview of antithrombotic agents in dermatologic surgery and management of such agents in the perioperative period with additional unique perspectives from cardiology and pharmacy. A literature search of PubMed and Google Scholar was performed to review the English-language medical literature. The landscape of antithrombotic therapy is changing with a notable rise in the use of direct oral anticoagulants (DOACs.) While no consensus guidelines exist, most studies recommend continuing antithrombotic therapy in the perioperative period with appropriate lab monitoring, when applicable. However, recent data suggest it is safe to hold DOACs in the perioperative period. As antithrombotic therapy evolves, the dermatologic surgeon needs to remain current with the most recent available data. Where data are limited, a multidisciplinary approach to managing these agents in the perioperative period is essential. J Drugs Dermatol. 2023;22(5): doi:10.36849/JDD.7456. FAU - Rao, Elizabeth AU - Rao E FAU - Andrasik, Wyatt AU - Andrasik W FAU - Michalski, Basia AU - Michalski B FAU - Tarakji, Khaldoun AU - Tarakji K FAU - Militello, Michael AU - Militello M FAU - Lucas, Jennifer AU - Lucas J LA - eng PT - Journal Article PT - Review PL - United States TA - J Drugs Dermatol JT - Journal of drugs in dermatology : JDD JID - 101160020 RN - 0 (Fibrinolytic Agents) RN - 0 (Anticoagulants) SB - IM MH - Humans MH - *Fibrinolytic Agents/adverse effects MH - Anticoagulants/adverse effects MH - *Cardiology MH - Dermatologic Surgical Procedures/adverse effects EDAT- 2023/05/03 12:42 MHDA- 2023/05/05 06:42 CRDT- 2023/05/03 11:01 PHST- 2023/05/05 06:42 [medline] PHST- 2023/05/03 12:42 [pubmed] PHST- 2023/05/03 11:01 [entrez] AID - S1545961623P0496X [pii] AID - 10.36849/JDD.7456 [doi] PST - ppublish SO - J Drugs Dermatol. 2023 May 1;22(5):496-501. doi: 10.36849/JDD.7456. PMID- 37130695 OWN - NLM STAT- MEDLINE DCOM- 20230504 LR - 20230611 IS - 2399-6641 (Electronic) IS - 2399-6641 (Linking) VI - 12 IP - 2 DP - 2023 May TI - Preoperative and postoperative optimisation of patients undergoing thyroid surgery: a multicentre quality improvement project at Barts Health NHS Trust. LID - 10.1136/bmjoq-2020-001190 [doi] LID - e001190 AB - Hypocalcaemia following thyroid surgery can occur in up to 38% of patients. With over 7100 thyroid surgeries performed in 2018 in the UK, this is a common postoperative complication. Undertreated hypocalcaemia can result in cardiac arrhythmias and death. Preventing adverse events from hypocalcaemia requires preoperative identification and treatment of at-risk patients with vitamin D deficiency, timely recognition of postoperative hypocalcaemia and prompt appropriate treatment with calcium supplementation. This project aimed to design and implement a perioperative protocol for prevention, detection and management of post-thyroidectomy hypocalcaemia. A retrospective audit of thyroid surgeries (n=67; October 2017 to June 2018) was undertaken to establish baseline practice of (1) preoperative vitamin D levels assessment, (2) postoperative calcium checks and incidence of postoperative hypocalcaemia and (3) management of postoperative hypocalcaemia. A multidisciplinary team approach following quality improvement principles was then used to design a perioperative management protocol with all relevant stakeholders involved. After dissemination and implementation, the above measures were reassessed prospectively (n=23; April-July 2019). The percentage of patients having their preoperative vitamin D measured increased from 40.3% to 65.2%. Postoperative day-of-surgery calcium checks increased from 76.1% to 87.0%. Hypocalcaemia was detected in 26.8% of patients before and 30.43% of patients after protocol implementation. The postoperative component of the protocol was followed in 78.3% of patients. Limitations include low number of patients which precluded from analysis of the impact of the protocol on length of stay. Our protocol provides a foundation for preoperative risk stratification and prevention, early detection and subsequent management of hypocalcaemia in thyroidectomy patients. This aligns with enhanced recovery protocols. Moreover, we offer suggestions for others to build on this quality improvement project with the aim to further advance the perioperative care of thyroidectomy patients. CI - (c) Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Lechner, Matt AU - Lechner M AD - Division of Surgery and Interventional Science & Cancer Institute, University College London, London, UK m.lechner@ucl.ac.uk k.ghufoor@nhs.net. FAU - Moghul, Gulwish AU - Moghul G AD - Department of Otolaryngology - Head and Neck Surgery, Royal London Hospital, Barts Health NHS Trust, London, UK. FAU - Chandrasekharan, Deepak AU - Chandrasekharan D AD - Department of Otolaryngology - Head and Neck Surgery, Royal London Hospital, Barts Health NHS Trust, London, UK. AD - Department of Otolaryngology - Head and Neck Surgery, Whipps Cross University Hospitals, Barts Health NHS Trust, London, UK. FAU - Ashraf, Salman AU - Ashraf S AD - Department of Otolaryngology - Head and Neck Surgery, Whipps Cross University Hospitals, Barts Health NHS Trust, London, UK. FAU - Emanuel, Oscar AU - Emanuel O AD - Department of Otolaryngology - Head and Neck Surgery, Royal London Hospital, Barts Health NHS Trust, London, UK. FAU - Magos, Tiarnan AU - Magos T AD - Department of Otolaryngology - Head and Neck Surgery, Royal London Hospital, Barts Health NHS Trust, London, UK. FAU - Liu, Zi Wei AU - Liu ZW AD - Department of Otolaryngology-Head and Neck Surgery, Northwick Park Hospital, London North West Healthcare NHS Trust, London, UK. FAU - Crutchlow, Margaret AU - Crutchlow M AD - Pre-assessment Clinic, Whipps Cross University Hospital, Barts Health NHS Trust, London, UK. FAU - Kinghorn, Stephen AU - Kinghorn S AD - Pre-assessment Clinic, Whipps Cross University Hospital, Barts Health NHS Trust, London, UK. FAU - McDonnell, Gayle AU - McDonnell G AD - Pre-assessment Clinic, Royal London Hospital, Barts Health NHS Trust, London, UK. FAU - McArdle, Harry AU - McArdle H AD - Pre-assessment Clinic, Royal London Hospital, Barts Health NHS Trust, London, UK. FAU - Salem, Amr AU - Salem A AD - Department of Otolaryngology - Head and Neck Surgery, Whipps Cross University Hospitals, Barts Health NHS Trust, London, UK. FAU - Papesch, Mike AU - Papesch M AD - Department of Otolaryngology - Head and Neck Surgery, Whipps Cross University Hospitals, Barts Health NHS Trust, London, UK. AD - Department of Otorhinolaryngology and Maxillofacial Surgery, Zealand University Hospital, Koge, Denmark. FAU - Majumdar, Kalpita AU - Majumdar K AD - Division of Endocrinology, Department of Medicine, Whipps Cross University Hospital, Barts Health NHS Trust, London, UK. FAU - Lakhdar, Abdulfattah AU - Lakhdar A AD - Division of Endocrinology, Department of Medicine, Whipps Cross University Hospital, Barts Health NHS Trust, London, UK. FAU - Ali, Safina AU - Ali S AD - Department of Otolaryngology - Head and Neck Surgery, Royal London Hospital, Barts Health NHS Trust, London, UK. FAU - Ahmed, Jahangir AU - Ahmed J AD - Department of Otolaryngology - Head and Neck Surgery, Royal London Hospital, Barts Health NHS Trust, London, UK. FAU - Alusi, Ghassan AU - Alusi G AD - Department of Otolaryngology - Head and Neck Surgery, Royal London Hospital, Barts Health NHS Trust, London, UK. FAU - Stimpson, Paul AU - Stimpson P AD - Head and Neck Centre, University College London Hospitals NHS Trust, London, UK. FAU - Waterhouse, Mona AU - Waterhouse M AD - Department of Endocrinology, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK. FAU - Ghufoor, Khalid AU - Ghufoor K AD - Department of Otolaryngology - Head and Neck Surgery, Royal London Hospital, Barts Health NHS Trust, London, UK m.lechner@ucl.ac.uk k.ghufoor@nhs.net. LA - eng PT - Journal Article PT - Multicenter Study PL - England TA - BMJ Open Qual JT - BMJ open quality JID - 101710381 RN - SY7Q814VUP (Calcium) RN - 1406-16-2 (Vitamin D) SB - IM MH - Humans MH - *Hypocalcemia/etiology/prevention & control/diagnosis MH - Calcium MH - Thyroid Gland MH - Retrospective Studies MH - Quality Improvement MH - State Medicine MH - Vitamin D MH - Thyroidectomy/adverse effects/methods PMC - PMC10163442 OTO - NOTNLM OT - clinical audit OT - clinical protocols OT - critical care OT - postoperative care OT - preoperative care COIS- Competing interests: None declared. EDAT- 2023/05/03 00:41 MHDA- 2023/05/04 12:41 PMCR- 2023/05/02 CRDT- 2023/05/02 21:03 PHST- 2020/09/01 00:00 [received] PHST- 2021/08/11 00:00 [accepted] PHST- 2023/05/04 12:41 [medline] PHST- 2023/05/03 00:41 [pubmed] PHST- 2023/05/02 21:03 [entrez] PHST- 2023/05/02 00:00 [pmc-release] AID - bmjoq-2020-001190 [pii] AID - 10.1136/bmjoq-2020-001190 [doi] PST - ppublish SO - BMJ Open Qual. 2023 May;12(2):e001190. doi: 10.1136/bmjoq-2020-001190. PMID- 37130658 OWN - NLM STAT- MEDLINE DCOM- 20230504 LR - 20240918 IS - 2053-3624 (Print) IS - 2053-3624 (Electronic) IS - 2053-3624 (Linking) VI - 10 IP - 1 DP - 2023 May TI - Systematic coronary physiology improves level of agreement in diagnostic coronary angiography. LID - 10.1136/openhrt-2023-002258 [doi] LID - e002258 AB - OBJECTIVE: The training of interventional cardiologists (ICs), non-interventional cardiologists (NICs) and cardiac surgeons (CSs) differs, and this may be reflected in their interpretation of invasive coronary angiography (ICA) and management plan. Availability of systematic coronary physiology might result in more homogeneous interpretation and management strategy compared with ICA alone. METHODS: 150 coronary angiograms from patients with stable chest pain were presented independently to three NICs, three ICs and three CSs. By consensus, each group graded (1) coronary disease severity and (2) management plan, using options: (a) optimal medical therapy alone, (b) percutaneous coronary intervention, (c) coronary artery bypass graft or (d) more investigation required. Each group was then provided with fractional flow reserve (FFR) from all major vessels and asked to repeat the analysis. RESULTS: There was only 'fair' level of agreement of management plan among ICs, NICs and CSs (kappa 0.351, 95% CI 0.295-0.408, p<0.001) based on ICA alone (complete agreement in 35% of cases), which almost doubled to 'good' level (kappa 0.635, 95% CI 0.572-0.697, p<0.001) when comprehensive FFR was available (complete agreement in 66% of cases). Overall, the consensus management plan changed in 36.7%, 52% and 37.3% of cases for ICs, NICs and CSs, respectively, when FFR data were available. CONCLUSIONS: Compared with ICA alone, the availability of systematic FFR of all major coronary arteries produced a significantly more concordant interpretation and more homogeneous management plan among IC, NIC and CS specialists. Comprehensive physiological assessment may be of value in routine care for Heart Team decision-making. TRIAL REGISTRATION NUMBER: NCT01070771. CI - (c) Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Bashar, Hussein Ali Bashar AU - Bashar HAB AUID- ORCID: 0000-0001-8256-5168 AD - Wessex Cardiothoracic Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK. FAU - Saunders, Alec AU - Saunders A AD - Wessex Cardiothoracic Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK. AD - Faculty of Medicine, University of Southampton, Southampton, UK. FAU - Alaour, Bashir AU - Alaour B AD - Cardiovascular Research, King's College London, Southampton, UK. FAU - Gerontitis, Dimitrios AU - Gerontitis D AD - Bristol Heart Institute, Bristol Royal Infirmary, Bristol, UK. FAU - Hinton, Jonathan AU - Hinton J AD - Department of Cardiology, University Hospitals Dorset NHS Foundation Trust, Poole, UK. FAU - Karamanou, Danai AU - Karamanou D AD - Wessex Cardiothoracic Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK. FAU - Kechagioglou, Georgios AU - Kechagioglou G AD - Wessex Cardiothoracic Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK. FAU - Olsen, Sally AU - Olsen S AD - Wessex Cardiothoracic Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK. FAU - Onwordi, Eunice AU - Onwordi E AD - Wessex Cardiothoracic Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK. FAU - Pope, Michael AU - Pope M AD - Wessex Cardiothoracic Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK. AD - Faculty of Medicine, University of Southampton, Southampton, UK. FAU - Zingale, Anna AU - Zingale A AD - Wessex Cardiothoracic Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK. FAU - Nicholas, Zoe AU - Nicholas Z AD - Wessex Cardiothoracic Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK. FAU - Golledge, Peter AU - Golledge P AD - Royal Hampshire County Hospital, Winchester, UK. FAU - Escaned, Javier AU - Escaned J AD - Department of Cardiology, Hospital Clinico San Carlos, Madrid, Spain. FAU - Ali, Ziad AU - Ali Z AD - Interventional & Structural Cardiology, St Francis Hospital Heart Centre, New York, New York, USA. FAU - Curzen, Nick AU - Curzen N AUID- ORCID: 0000-0001-9651-7829 AD - Wessex Cardiothoracic Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK nick.curzen@uhs.nhs.uk. AD - Faculty of Medicine, University of Southampton, Southampton, UK. LA - eng SI - ClinicalTrials.gov/NCT01070771 PT - Journal Article PL - England TA - Open Heart JT - Open heart JID - 101631219 SB - IM MH - Humans MH - Coronary Angiography MH - *Fractional Flow Reserve, Myocardial/physiology MH - *Coronary Artery Disease/diagnostic imaging/therapy MH - Heart MH - Coronary Artery Bypass PMC - PMC10163596 OTO - NOTNLM OT - coronary angiography OT - coronary artery bypass OT - coronary artery disease OT - fractional flow reserve OT - percutaneous coronary intervention COIS- Competing interests: JE reports receiving consulting fees and lecture fees from Abbott, Philips and Boston Scientific, and lecture fees from Abiomed, Terumo, Medtronic and Biosensors. ZA reports institutional research grants to St Francis Hospital from Abbott, Philips, Boston Scientific, Abiomed, Acist Medical, Medtronic and Cardiovascular Systems; being a consultant to Amgen, AstraZeneca and Philips; and having equity in Shockwave Medical. NC reports unrestricted grants from Boston Scientific, HeartFlow, Haemonetics and Beckmann Coulter; speaker fees from Abbott, Boston and Edwards; and travel sponsorship from Abbott, Biosensors, Medtronic and Shockwave. All other authors declare no conflict of interest. EDAT- 2023/05/03 00:41 MHDA- 2023/05/04 12:42 PMCR- 2023/05/02 CRDT- 2023/05/02 21:03 PHST- 2023/01/12 00:00 [received] PHST- 2023/03/29 00:00 [accepted] PHST- 2023/05/04 12:42 [medline] PHST- 2023/05/03 00:41 [pubmed] PHST- 2023/05/02 21:03 [entrez] PHST- 2023/05/02 00:00 [pmc-release] AID - openhrt-2023-002258 [pii] AID - 10.1136/openhrt-2023-002258 [doi] PST - ppublish SO - Open Heart. 2023 May;10(1):e002258. doi: 10.1136/openhrt-2023-002258. PMID- 37126150 OWN - NLM STAT- MEDLINE DCOM- 20230911 LR - 20261010 IS - 1863-2491 (Electronic) IS - 1863-2483 (Linking) VI - 17 IP - 5 DP - 2023 Oct TI - Development of a high fidelity, multidisciplinary, crisis simulation model for robotic surgical teams. PG - 2019-2025 LID - 10.1007/s11701-023-01612-z [doi] AB - Immediate access to the patient in crisis situations, such as cardiac arrest during robotic surgery, can be challenging. We aimed to present a full immersion simulation module to train robotic surgical teams to manage a crisis scenario, enhance teamwork, establish clear lines of communication, improve coordination and speed of response. Start time of cardiopulmonary resuscitation (CPR), first defibrillator shock and robotic de-docking time from the first 'cardiac arrest call' were recorded. Observational Teamwork Assessment for Surgery (OTAS) scores were used in control and test simulations to assess performance along with a participant survey. Repeat scenarios and assessment were conducted at a 6-month interval for the same team to validate knowledge retention and an additional scenario was run with a new anaesthetic team to validate modular design. OTAS scores improved across all specialty teams after training with emergency algorithm and at retention validity re-test (p = 0.0181; p = 0.0063). There was an overall reduction in time to CPR (101-48 s), first defibrillator shock (> 302 s to 86 s) and robot de dock time (86-25 s) Improvement remained constant at retention validity re-test. Replacing the anaesthetic team showed improvement in time to CPR, first shock and robotic de-dock times and did not affect OTAS scores (p = 0.1588). The module was rated highly for realism and crisis training by all teams. This high-fidelity simulation training module is realistic and feasible to deliver. Its modular design allows for efficient assessment and feedback, optimising staff training time and making it a valuable addition to robotic team training. CI - (c) 2023. The Author(s), under exclusive licence to Springer-Verlag London Ltd., part of Springer Nature. FAU - Patki, Siddhant AU - Patki S AUID- ORCID: 0000-0002-3722-6308 AD - Imperial College London, London, UK. FAU - Nathan, Arjun AU - Nathan A AD - University College London, London, UK. AD - Royal Free Hospital, London, UK. FAU - Lyness, Craig AU - Lyness C AD - Royal Free Hospital, London, UK. FAU - Nadarajah, Premala AU - Nadarajah P AD - Royal Free Hospital, London, UK. FAU - Sevastru, Stefan AU - Sevastru S AD - Royal Free Hospital, London, UK. FAU - Mahrous, Ahmed AU - Mahrous A AD - Royal Free Hospital, London, UK. FAU - De-Silva, Pedro AU - De-Silva P AD - Royal Free Hospital, London, UK. FAU - Shoniwa, Angeline AU - Shoniwa A AD - Royal Free Hospital, London, UK. FAU - Undre, Shabnam AU - Undre S AD - Lister Hospital, Stevenage, UK. FAU - Patki, Prasad AU - Patki P AD - University College London, London, UK. prasad.patki@nhs.net. AD - Royal Free Hospital, London, UK. prasad.patki@nhs.net. LA - eng PT - Journal Article DEP - 20230501 PL - England TA - J Robot Surg JT - Journal of robotic surgery JID - 101300401 SB - IM MH - Humans MH - *Robotic Surgical Procedures/methods MH - *Robotics MH - Patient Care Team MH - *Heart Arrest/surgery MH - *Simulation Training MH - Clinical Competence OTO - NOTNLM OT - Crisis OT - Multidisciplinary OT - Robotics OT - Simulation OT - Surgery EDAT- 2023/05/01 12:43 MHDA- 2023/09/11 06:42 CRDT- 2023/05/01 11:06 PHST- 2023/02/10 00:00 [received] PHST- 2023/04/23 00:00 [accepted] PHST- 2023/09/11 06:42 [medline] PHST- 2023/05/01 12:43 [pubmed] PHST- 2023/05/01 11:06 [entrez] AID - 10.1007/s11701-023-01612-z [pii] AID - 10.1007/s11701-023-01612-z [doi] PST - ppublish SO - J Robot Surg. 2023 Oct;17(5):2019-2025. doi: 10.1007/s11701-023-01612-z. Epub 2023 May 1. PMID- 37125808 OWN - NLM STAT- MEDLINE DCOM- 20230804 LR - 20250502 IS - 1529-7535 (Print) IS - 1529-7535 (Linking) VI - 24 IP - 8 DP - 2023 Aug 1 TI - A Novel Comprehensive Algorithm for Evaluation of PICU Patients With New Fever or Instability. PG - 670-680 LID - 10.1097/PCC.0000000000003256 [doi] AB - OBJECTIVES: There is variation in microbiology testing among PICU patients with fever offering opportunities to reduce avoidable testing and treatment. Our objective is to describe the development and assess the impact of a novel comprehensive testing algorithm to support judicious testing practices and expanded diagnostic differentials for PICU patients with new fever or instability. DESIGN: A mixed-methods quality improvement study. SETTING: Single-center academic PICU and pediatric cardiac ICU. SUBJECTS: Admitted PICU patients and physicians. INTERVENTIONS: A multidisciplinary team developed a clinical decision-support algorithm. MEASUREMENTS AND MAIN RESULTS: We evaluated blood, endotracheal, and urine cultures, urinalyses, and broad-spectrum antibiotic use per 1,000 ICU patient-days using statistical process control charts and incident rate ratios (IRRs) and assessed clinical outcomes 24 months pre- and 18 months postimplementation. We surveyed physicians weekly for 12 months postimplementation. Blood cultures declined by 17% (IRR, 0.83; 95% CI, 0.77-0.89), endotracheal cultures by 26% (IRR, 0.74; 95% CI, 0.63-0.86), and urine cultures by 36% (IRR, 0.64; 95% CI, 0.56-0.73). There was an anticipated rise in urinalysis testing by 23% (IRR, 1.23; 95% CI, 1.14-1.33). Despite higher acuity and fewer brief hospitalizations, mortality, hospital, and PICU readmissions were stable, and PICU length of stay declined. Of the 108 physician surveys, 46 replied (43%), and 39 (85%) recently used the algorithm; 0 reported patient safety concerns, two (4%) provided constructive feedback, and 28 (61%) reported the algorithm improved patient care. CONCLUSIONS: A comprehensive fever algorithm was associated with reductions in blood, endotracheal, and urine cultures and anticipated increase in urinalyses. We detected no patient harm, and physicians reported improved patient care. CI - Copyright (c) 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies. FAU - Sick-Samuels, Anna C AU - Sick-Samuels AC AD - Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD. AD - Department of Hospital Epidemiology and Infection Control, Johns Hopkins Hospital, Baltimore, MD. AD - Armstrong Institute of Patient Safety and Quality, Johns Hopkins University School of Medicine, Baltimore, MD. AD - Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD. FAU - Booth, Lauren D AU - Booth LD AD - Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD. FAU - Milstone, Aaron M AU - Milstone AM AD - Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD. AD - Department of Hospital Epidemiology and Infection Control, Johns Hopkins Hospital, Baltimore, MD. AD - Armstrong Institute of Patient Safety and Quality, Johns Hopkins University School of Medicine, Baltimore, MD. AD - Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD. FAU - Schumacher, Christina AU - Schumacher C AD - Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD. FAU - Bergmann, Jules AU - Bergmann J AD - Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD. FAU - Stockwell, David C AU - Stockwell DC AD - Armstrong Institute of Patient Safety and Quality, Johns Hopkins University School of Medicine, Baltimore, MD. AD - Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD. LA - eng GR - K23 HL161449/HL/NHLBI NIH HHS/United States GR - K24 AI141580/AI/NIAID NIH HHS/United States GR - KL2 TR003099/TR/NCATS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20230501 PL - United States TA - Pediatr Crit Care Med JT - Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies JID - 100954653 SB - IM CIN - Pediatr Crit Care Med. 2023 Aug 1;24(8):705-707. doi: 10.1097/PCC.0000000000003279. PMID: 37534969 MH - Child MH - Humans MH - Infant MH - *Trachea MH - *Physicians MH - Surveys and Questionnaires MH - Hospitalization MH - Length of Stay MH - Intensive Care Units, Pediatric PMC - PMC10392890 MID - NIHMS1881267 COIS- Dr. Sick-Samuels' institution received funding from the National Institutes of Health (NIH) and the Thomas Willson Foundation. Drs. Sick-Samuels and Milstone received support for article research from the NIH. Dr. Milstone's institution received funding from Merck. The remaining authors have disclosed that they do not have any potential conflicts of interest. EDAT- 2023/05/01 12:43 MHDA- 2023/08/04 06:43 PMCR- 2023/08/01 CRDT- 2023/05/01 09:03 PHST- 2023/08/04 06:43 [medline] PHST- 2023/05/01 12:43 [pubmed] PHST- 2023/05/01 09:03 [entrez] PHST- 2023/08/01 00:00 [pmc-release] AID - 00130478-202308000-00006 [pii] AID - 10.1097/PCC.0000000000003256 [doi] PST - ppublish SO - Pediatr Crit Care Med. 2023 Aug 1;24(8):670-680. doi: 10.1097/PCC.0000000000003256. Epub 2023 May 1. PMID- 37125299 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230502 IS - 1520-765X (Print) IS - 1554-2815 (Electronic) IS - 1520-765X (Linking) VI - 25 IP - Suppl C DP - 2023 May TI - Autopsy and sudden death. PG - C118-C129 LID - 10.1093/eurheartjsupp/suad014 [doi] AB - Our story dates back in the late 70s, when a series of juvenile sudden death (SD) occurred in the Veneto region, north east of Italy. A successful application for a prospective study on young people dying suddenly (<35-year-old, sudden infant death syndrome excluded) was submitted to the regional health authorities, thus implementing a network of collaboration with local anatomic and forensic pathologists, to collect all such events and to gather demographic data. The project is still in progress, and since then, we studied hundreds of consecutive juvenile SD cases, allowing to identify the culprit diseases in the various organs and cardiac structures (aorta, coronary arteries, myocardium, valves, and conduction system). The long-standing Veneto region experience clearly shows that autopsy still plays a pivotal role in the study and prevention of SD and should be carried out regularly. With time, the investigation of SD moved from the classic post-mortem study to molecular autopsy, especially in cases of SD with structurally normal heart. Sudden death prevention in the young has to be faced by an interdisciplinary team, including pathologists, cardiologists, sport physicians, and geneticists, the clinicopathologic correlation method still being the polar star. The game in the fight against SD is still played in the anatomical theatre, the place where 'death enjoys to save lives'. CI - (c) The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. FAU - Thiene, Gaetano AU - Thiene G AUID- ORCID: 0000-0002-8814-2577 AD - Emeritus Professor of Cardiovascular Pathology, University of Padua and A.R.C.A. Via A. Gabelli 86 35121 Padua, Italy. LA - eng PT - Journal Article DEP - 20230426 PL - England TA - Eur Heart J Suppl JT - European heart journal supplements : journal of the European Society of Cardiology JID - 100886647 PMC - PMC10132616 OTO - NOTNLM OT - Molecular autopsy OT - Sudden death OT - Young people COIS- Conflict of interest: None declared. EDAT- 2023/05/01 06:42 MHDA- 2023/05/01 06:43 PMCR- 2023/04/26 CRDT- 2023/05/01 03:56 PHST- 2023/05/01 06:43 [medline] PHST- 2023/05/01 06:42 [pubmed] PHST- 2023/05/01 03:56 [entrez] PHST- 2023/04/26 00:00 [pmc-release] AID - suad014 [pii] AID - 10.1093/eurheartjsupp/suad014 [doi] PST - epublish SO - Eur Heart J Suppl. 2023 Apr 26;25(Suppl C):C118-C129. doi: 10.1093/eurheartjsupp/suad014. eCollection 2023 May. PMID- 37125296 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230502 IS - 1520-765X (Print) IS - 1554-2815 (Electronic) IS - 1520-765X (Linking) VI - 25 IP - Suppl C DP - 2023 May TI - Cardiovascular prevention: sometimes dreams can come true. PG - C44-C48 LID - 10.1093/eurheartjsupp/suad006 [doi] AB - Cardiovascular disease (CVD) is a chronic condition driven by the complex interaction of different risk factors including genetics, lifestyle, environment, etc. which, differently from other pathologies, can be prevented. Treatment of CVD has been inconceivably successful but now it seems that it has reached a plateau suggesting that prevention is the way forward. However, the COVID-19 pandemic has spotted all the limits of the actual health system regarding territorial and, particularly, of preventive medicine. To this end, recently, the SCORE2 risk prediction algorithms, a contemporary model to estimate 10 years risk of CVD in Europe and the new guidelines on prevention have been released. The present review article describes a dream: how prevention of CVD should be addressed in the future. New concepts and paradigms like early genetically personalized and imaging driven risk factors, cardiac risk cartography, measurements of the exposome, estimation of costs of a delayed outcome vs. healthy lifespan, are all addressed. We highlight the importance of technologies and the concept of being engaged in a 'healthy' and not just 'sick' system as it is today. The concept of 'clearing house' with a 'care health team' instead of a 'heart team' is described. Finally, we articulate the four points necessary for the dream to come true. CI - (c) The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. FAU - Ferrari, Roberto AU - Ferrari R AD - Cardiovascular Research Centre, Ferrara University, Via Aldo Moro 8, 44124 Ferrara, Italy. FAU - Cimaglia, Paolo AU - Cimaglia P AD - Cardiovascular Research Centre, Ferrara University, Via Aldo Moro 8, 44124 Ferrara, Italy. FAU - Cantone, Anna AU - Cantone A AD - Cardiovascular Research Centre, Ferrara University, Via Aldo Moro 8, 44124 Ferrara, Italy. FAU - Serenelli, Matteo AU - Serenelli M AD - Cardiovascular Research Centre, Ferrara University, Via Aldo Moro 8, 44124 Ferrara, Italy. FAU - Guardigli, Gabriele AU - Guardigli G AD - Cardiovascular Research Centre, Ferrara University, Via Aldo Moro 8, 44124 Ferrara, Italy. LA - eng PT - Journal Article DEP - 20230426 PL - England TA - Eur Heart J Suppl JT - European heart journal supplements : journal of the European Society of Cardiology JID - 100886647 PMC - PMC10132572 OTO - NOTNLM OT - Cardiovascular diseases OT - Health system OT - Prevention OT - Risk scores COIS- Conflict of interest: R.F. reports having received research grants and personal fees from Novartis and Servier personal fees from Merck Serono, Boehringer Ingelheim, Sunpharma, Lupin, Doc Generici, Pfizer, Spa Prodotti Antibiotici outside the submitted work. He is a director of Art Research and Science S.r.l (A.R.S.1). P.C. has no conflict of interest to disclose. A.C. has no conflict of interest to disclose. M.S. has no conflict of interest to disclose. G.G. has no conflict of interest to disclose. EDAT- 2023/05/01 06:42 MHDA- 2023/05/01 06:43 PMCR- 2023/04/26 CRDT- 2023/05/01 03:56 PHST- 2023/05/01 06:43 [medline] PHST- 2023/05/01 06:42 [pubmed] PHST- 2023/05/01 03:56 [entrez] PHST- 2023/04/26 00:00 [pmc-release] AID - suad006 [pii] AID - 10.1093/eurheartjsupp/suad006 [doi] PST - epublish SO - Eur Heart J Suppl. 2023 Apr 26;25(Suppl C):C44-C48. doi: 10.1093/eurheartjsupp/suad006. eCollection 2023 May. PMID- 37125278 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230502 IS - 1520-765X (Print) IS - 1554-2815 (Electronic) IS - 1520-765X (Linking) VI - 25 IP - Suppl C DP - 2023 May TI - Electrical storm management in structural heart disease. PG - C242-C248 LID - 10.1093/eurheartjsupp/suad048 [doi] AB - Electrical storm (ES) is a life-threatening condition characterized by at least three separate episodes of ventricular arrhythmias (VAs) over 24 h, each requiring therapeutic intervention, including implantable cardioverter defibrillator (ICD) therapies. Patients with ICDs in secondary prevention are at higher risk of ES and the most common presentation is that of scar-related monomorphic VAs. Electrical storm represents a major unfavourable prognostic marker in the history of patients with structural heart disease, with an associated two- to five-fold increase in mortality, heart transplant, and heart failure hospitalization. Early recognition and prompt treatment are crucial to improve the outcome. Yet, ES management is complex and requires a multidisciplinary approach and well-defined protocols and networks to guarantee a proper patient care. Acute phase stabilization should include a comprehensive clinical assessment, resuscitation and sedation management skills, ICD reprogramming, and acute sympathetic modulation, while the sub-acute/chronic phase requires a comprehensive heart team evaluation to define the better treatment option according to the haemodynamic and overall patient's condition and the type of VAs. Advanced anti-arrhythmic strategies, not mutually exclusive, include invasive ablation, cardiac sympathetic denervation, and, for very selected cases, stereotactic ablation. Each of these aspects, as well as the new European Society of Cardiology guidelines recommendations, will be discussed in the present review. CI - (c) The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. FAU - Dusi, Veronica AU - Dusi V AD - Division of Cardiology, Cardiovascular and Thoracic Department, Citta della Salute e della Scienza, Corso Bramante 88, 10126 Turin, Italy. AD - Department of Medical Sciences, University of Turin, Corso Achille Mario Dogliotti, 14, 10126 Turin, Italy. FAU - Angelini, Filippo AU - Angelini F AD - Division of Cardiology, Cardiovascular and Thoracic Department, Citta della Salute e della Scienza, Corso Bramante 88, 10126 Turin, Italy. FAU - Gravinese, Carol AU - Gravinese C AD - Division of Cardiology, Cardiovascular and Thoracic Department, Citta della Salute e della Scienza, Corso Bramante 88, 10126 Turin, Italy. FAU - Frea, Simone AU - Frea S AD - Division of Cardiology, Cardiovascular and Thoracic Department, Citta della Salute e della Scienza, Corso Bramante 88, 10126 Turin, Italy. FAU - De Ferrari, Gaetano Maria AU - De Ferrari GM AD - Division of Cardiology, Cardiovascular and Thoracic Department, Citta della Salute e della Scienza, Corso Bramante 88, 10126 Turin, Italy. AD - Department of Medical Sciences, University of Turin, Corso Achille Mario Dogliotti, 14, 10126 Turin, Italy. LA - eng PT - Journal Article DEP - 20230426 PL - England TA - Eur Heart J Suppl JT - European heart journal supplements : journal of the European Society of Cardiology JID - 100886647 PMC - PMC10132591 OTO - NOTNLM OT - Ablation OT - Electrical storm OT - Neuromodulation OT - Sedation OT - Ventricular arrhythmias COIS- Conflict of interest: None declared. EDAT- 2023/05/01 06:42 MHDA- 2023/05/01 06:43 PMCR- 2023/04/26 CRDT- 2023/05/01 03:56 PHST- 2023/05/01 06:43 [medline] PHST- 2023/05/01 06:42 [pubmed] PHST- 2023/05/01 03:56 [entrez] PHST- 2023/04/26 00:00 [pmc-release] AID - suad048 [pii] AID - 10.1093/eurheartjsupp/suad048 [doi] PST - epublish SO - Eur Heart J Suppl. 2023 Apr 26;25(Suppl C):C242-C248. doi: 10.1093/eurheartjsupp/suad048. eCollection 2023 May. PMID- 37125273 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230502 IS - 1520-765X (Print) IS - 1554-2815 (Electronic) IS - 1520-765X (Linking) VI - 25 IP - Suppl C DP - 2023 May TI - Optimal management of patients after acute coronary syndrome. PG - C84-C89 LID - 10.1093/eurheartjsupp/suad039 [doi] AB - Patients with clinically established atherosclerotic cardiovascular disease are at a very high risk of recurrent cardiovascular events. An adequate management of risk factors and the implementation of healthy behaviours significantly decrease the risk of unfavourable clinical outcomes and future cardiovascular events, including death. Patients discharged after an acute coronary syndrome should be managed according to their individual risk level in order to ensure the appropriate treatment. Nevertheless, care pathways should also take into consideration the available resources and the logistical/structural aspects. In this setting, cardiac rehabilitation is prosed as a multidisciplinary approach to improving daily function and reducing cardiovascular risk factors. The organization of a network with the involvement of different medical and non-medical figures is essential to ensure successful outcomes and expected cost-effectiveness. CI - (c) The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. FAU - Panattoni, Germana AU - Panattoni G AD - Division of Cardiology, Policlinico Casilino, Via Casilina 1049, 00169 Rome, Italy. FAU - Monzo, Luca AU - Monzo L AD - Division of Cardiology, Policlinico Casilino, Via Casilina 1049, 00169 Rome, Italy. AD - Centre d' Investigations Cliniques Plurithematique, Universite de Lorraine INSERM, 5 Rue du Morvan, 54500 Vandoeuvre-les-Nancy, Francia. FAU - Gugliotta, Maria AU - Gugliotta M AD - Division of Cardiology, Policlinico Casilino, Via Casilina 1049, 00169 Rome, Italy. FAU - Proietti, Giulia AU - Proietti G AD - Division of Cardiology, Policlinico Casilino, Via Casilina 1049, 00169 Rome, Italy. FAU - Tatangelo, Mario AU - Tatangelo M AD - Division of Cardiology, Policlinico Casilino, Via Casilina 1049, 00169 Rome, Italy. FAU - Jacomelli, Ilaria AU - Jacomelli I AD - Division of Cardiology, Policlinico Casilino, Via Casilina 1049, 00169 Rome, Italy. FAU - Zimbardo, Giuseppe AU - Zimbardo G AD - Division of Cardiology, Policlinico Casilino, Via Casilina 1049, 00169 Rome, Italy. FAU - Meringolo, Federica AU - Meringolo F AD - Division of Cardiology, Policlinico Casilino, Via Casilina 1049, 00169 Rome, Italy. AD - Department of Biomedical Sciences, Faculty of Medicine, Catholic University "Our Lady of Good Counsel", Rr. Dritan Hoxha 1000, Tirana, Albania. FAU - Fedele, Elisa AU - Fedele E AD - Division of Cardiology, Policlinico Casilino, Via Casilina 1049, 00169 Rome, Italy. FAU - Calo, Leonardo AU - Calo L AD - Division of Cardiology, Policlinico Casilino, Via Casilina 1049, 00169 Rome, Italy. LA - eng PT - Journal Article DEP - 20230426 PL - England TA - Eur Heart J Suppl JT - European heart journal supplements : journal of the European Society of Cardiology JID - 100886647 PMC - PMC10132559 OTO - NOTNLM OT - Acute coronary syndrome OT - Atherosclerotic cardiovascular disease OT - Cardiac rehabilitation OT - Healthy behaviours OT - Risk factor OT - Secondary prediction COIS- Conflict of interest: None declared. EDAT- 2023/05/01 06:42 MHDA- 2023/05/01 06:43 PMCR- 2023/04/26 CRDT- 2023/05/01 03:56 PHST- 2023/05/01 06:43 [medline] PHST- 2023/05/01 06:42 [pubmed] PHST- 2023/05/01 03:56 [entrez] PHST- 2023/04/26 00:00 [pmc-release] AID - suad039 [pii] AID - 10.1093/eurheartjsupp/suad039 [doi] PST - epublish SO - Eur Heart J Suppl. 2023 Apr 26;25(Suppl C):C84-C89. doi: 10.1093/eurheartjsupp/suad039. eCollection 2023 May. PMID- 37124976 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230502 IS - 1949-8462 (Print) IS - 1949-8462 (Electronic) VI - 15 IP - 4 DP - 2023 Apr 26 TI - Optimization of the pharmacological therapy in patients with poly-vascular disease: A multidisciplinary approach. PG - 142-153 LID - 10.4330/wjc.v15.i4.142 [doi] AB - The recent shift of the concept of cardiovascular disease as a chronic progressive condition, potentially involving multiple districts, has driven attention to the optimal management of patients with concomitant coronary and peripheral artery disease, representing a subset of patients with an increased risk of events and impaired survival. Recent pharmacological achievements in terms of antithrombotic therapy and lipid-lowering drugs allow multiple therapeutical combinations, thus requiring optimizing the treatment in a tailored fashion according to patients' risk profiles. Nevertheless, data dedicated to this specific subset of patients are still modest. We summarize currently available strategies and indications for the management of antithrombotic and lipid-lowering drugs in patients with the poly-vascular disease. CI - (c)The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. FAU - Gioscia, Rocco AU - Gioscia R AD - Department of Cardiology, Nuovo Ospedale Degli Infermi, Biella 13900, Italy. FAU - Castagno, Claudio AU - Castagno C AD - Department of Vascular Surgery, Nuovo Ospedale Degli Infermi, Biella 13900, Italy. FAU - Verdoia, Monica AU - Verdoia M AD - Department of Cardiology, Nuovo Ospedale Degli Infermi, Biella 13900, Italy. FAU - Conti, Barbara AU - Conti B AD - Department of Vascular Surgery, Nuovo Ospedale Degli Infermi, Biella 13900, Italy. FAU - Forliti, Enzo AU - Forliti E AD - Department of Vascular Surgery, Nuovo Ospedale Degli Infermi, Biella 13900, Italy. FAU - Rognoni, Andrea AU - Rognoni A AD - Department of Cardiology, Nuovo Ospedale Degli Infermi, Biella 13900, Italy. andrea.rognoni@aslbi.piemonte.it. LA - eng PT - Journal Article PT - Review PL - United States TA - World J Cardiol JT - World journal of cardiology JID - 101537090 PMC - PMC10130889 OTO - NOTNLM OT - Antitrombotic therapy OT - Atherosclerosis OT - Cholesterol OT - Coronary artery disease OT - PCSK9 OT - Poly-vascular disease OT - Statins COIS- Conflict-of-interest statement: All the authors declare that they have no conflict of interest. EDAT- 2023/05/01 06:42 MHDA- 2023/05/01 06:43 PMCR- 2023/04/26 CRDT- 2023/05/01 03:52 PHST- 2023/01/03 00:00 [received] PHST- 2023/03/27 00:00 [revised] PHST- 2023/04/07 00:00 [accepted] PHST- 2023/05/01 06:43 [medline] PHST- 2023/05/01 06:42 [pubmed] PHST- 2023/05/01 03:52 [entrez] PHST- 2023/04/26 00:00 [pmc-release] AID - 10.4330/wjc.v15.i4.142 [doi] PST - ppublish SO - World J Cardiol. 2023 Apr 26;15(4):142-153. doi: 10.4330/wjc.v15.i4.142. PMID- 37124180 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240929 IS - 2296-2360 (Print) IS - 2296-2360 (Electronic) IS - 2296-2360 (Linking) VI - 11 DP - 2023 TI - The safety of sports in children with inherited arrhythmia substrates. PG - 1151286 LID - 10.3389/fped.2023.1151286 [doi] LID - 1151286 AB - Sudden cardiac death (SCD) is a rare and devastating event in children and remains a leading cause of death in young athletes. Channelopathies and cardiomyopathies, in particular long QT syndrome (LQTS), catecholaminergic polymorphic ventricular tachycardia (CPVT), hypertrophic cardiomyopathy (HCM), and arrhythmogenic cardiomyopathy (ACM) are associated with exercise-related SCD. Implantable cardioverter-defibrillators (ICDs) are often placed for secondary prevention for athletes with cardiomyopathy or channelopathy. There remains concern regarding the safety of return to participation with an ICD in place. Guidelines have historically recommended that patients with inherited heart rhythm disorders be restricted from competitive sports participation. Increasing evidence suggests a lower risk of exercise-related cardiac events in young athletes with inherited heart rhythm disorders. In this review, we highlight current knowledge, evolving guidelines, and present a multidisciplinary approach involving shared decision-making and appropriate planning for safe sports participation of children with inherited heart rhythm disorders. CI - (c) 2023 Katyal, Li, Franciosi and Sanatani. FAU - Katyal, Abhay AU - Katyal A AD - British Columbia Children's Hospital Heart Center, Department of Pediatrics, University of British Columbia, Vancouver, BC, Canada. FAU - Li, Christopher O Y AU - Li COY AD - British Columbia Children's Hospital Heart Center, Department of Pediatrics, University of British Columbia, Vancouver, BC, Canada. FAU - Franciosi, Sonia AU - Franciosi S AD - British Columbia Children's Hospital Heart Center, Department of Pediatrics, University of British Columbia, Vancouver, BC, Canada. FAU - Sanatani, Shubhayan AU - Sanatani S AD - British Columbia Children's Hospital Heart Center, Department of Pediatrics, University of British Columbia, Vancouver, BC, Canada. LA - eng PT - Journal Article PT - Review DEP - 20230404 PL - Switzerland TA - Front Pediatr JT - Frontiers in pediatrics JID - 101615492 PMC - PMC10132466 OTO - NOTNLM OT - cardiomyopathy OT - channelopathy OT - exercise OT - implantable cardioverter-defibrillator OT - pediatrics OT - physical activity OT - sports OT - sudden cardiac death COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/05/01 06:42 MHDA- 2023/05/01 06:43 PMCR- 2023/04/04 CRDT- 2023/05/01 03:40 PHST- 2023/01/25 00:00 [received] PHST- 2023/03/22 00:00 [accepted] PHST- 2023/05/01 06:43 [medline] PHST- 2023/05/01 06:42 [pubmed] PHST- 2023/05/01 03:40 [entrez] PHST- 2023/04/04 00:00 [pmc-release] AID - 10.3389/fped.2023.1151286 [doi] PST - epublish SO - Front Pediatr. 2023 Apr 4;11:1151286. doi: 10.3389/fped.2023.1151286. eCollection 2023. PMID- 28722993 STAT- Publisher CTDT- 20230501 PB - StatPearls Publishing DP - 2023 Jan TI - Warfarin Drug Interactions. BTI - StatPearls AB - Warfarin has FDA approval for the prophylaxis and treatment of venous thrombosis and its complications, such as a pulmonary embolus. It is also indicated to prevent thromboembolic complications associated with conditions such as atrial fibrillation, cardiac valve replacement, and inherited genetic factors like C and S protein deficiency or Factor V Leiden. Additionally, warfarin is FDA approved as an adjunct to reduce the risk of myocardial infarction (MI) and other thromboembolic events in high-risk patients. However, warfarin falls in the narrow therapeutic index drug category and is subject to numerous interactions. This activity outlines the indications, mechanism of action, interactions, significant adverse effects, contraindications, toxicity, and warfarin monitoring so providers can direct patient therapy where anticoagulation is indicated as part of the interprofessional team. CI - Copyright (c) 2023, StatPearls Publishing LLC. FAU - Crader, Marsha F AU - Crader MF AD - Univ. of Arkansas for Medical Sciences FAU - Johns, Tracy AU - Johns T AD - USF-Morton Plant Mease Family Medicine Residency FAU - Arnold, Justin K AU - Arnold JK AD - University of South Florida LA - eng PT - Study Guide PT - Book Chapter PL - Treasure Island (FL) COIS- Disclosure: Marsha F Crader declares no relevant financial relationships with ineligible companies. Disclosure: Tracy Johns declares no relevant financial relationships with ineligible companies. Disclosure: Justin K Arnold declares no relevant financial relationships with ineligible companies. EDAT- 2023/05/01 00:00 CRDT- 2023/05/01 00:00 AID - NBK441964 [bookaccession] PMID- 37120515 OWN - NLM STAT- MEDLINE DCOM- 20230501 LR - 20230502 IS - 1471-2474 (Electronic) IS - 1471-2474 (Linking) VI - 24 IP - 1 DP - 2023 Apr 29 TI - Reducing complications of femoral neck fracture management: a retrospective study on the application of multidisciplinary team. PG - 338 LID - 10.1186/s12891-023-06455-1 [doi] LID - 338 AB - BACKGROUND: Femoral neck fractures are associated with substantial morbidity and mortality for older adults. Multi-system medical diseases and complications can lead to long-term care needs, functional decline and death, so patients sustaining hip fractures usually have comorbid conditions that may benefit from application of multidisciplinary team(MDT). METHODS: This is a retrospective cohort study that incorporates medical record review with an outcomes management database. 199 patients were included who had surgery for a new unilateral femoral neck fracture from January 2018 to December 2021 (96 patients in usual care (UC) model and 103 patients in MDT model. High-energy, pathological, old and periprosthetic femoral neck fracture were excluded. Age, gender, comorbidity status, time to surgery, and postoperative complication, length of stay, in-hospital mortality, 30-day readmission rate, 90-day mortality data were collected and analyzed. RESULTS: Preoperative general data of sex, age, community dwelling and charlson comorbidity score of MDT group (n = 103) have no statistically significant difference with that of usual care (UC) group. Patients treated in the MDT model had significantly shorter times to surgery (38.5 vs. 73.4 h;P = 0.028) and lower lengths of stay (11.5 vs. 15.2 days;P = 0.031). There were no significant differences between two models in In-hospital mortality (1.0% vs. 2.1%; P = 0.273), 30-day readmission rate (7.8% vs. 11.5%; P = 0.352) and 90-day mortality (2.9% vs. 3.1%; P = 0.782). The MDT model had fewer complications overall (16.5% vs. 31.3%; P = 0.039), with significantly lower risks of delirium, postoperative infection, bleeding, cardiac complication, hypoxia, and thromboembolism. CONCLUSION: Application of MDT can provide standardized protocols and a total quality management approach, leading to fewer complications for elderly patients with femoral neck fracture. TRIAL REGISTRATION: No. CI - (c) 2023. The Author(s). FAU - Liang, Weiming AU - Liang W AD - The First Affiliated Hospital of Guangxi University of Science and Technology, Guangxi University of Science and Technology, 124 Yuejin Road, Liuzhou, 545001, Guangxi Province, China. FAU - Qin, Gang AU - Qin G AD - The First Affiliated Hospital of Guangxi University of Science and Technology, Guangxi University of Science and Technology, 124 Yuejin Road, Liuzhou, 545001, Guangxi Province, China. FAU - Yu, Lizhi AU - Yu L AD - The First Affiliated Hospital of Guangxi University of Science and Technology, Guangxi University of Science and Technology, 124 Yuejin Road, Liuzhou, 545001, Guangxi Province, China. FAU - Wang, Yingying AU - Wang Y AD - The First Affiliated Hospital of Guangxi University of Science and Technology, Guangxi University of Science and Technology, 124 Yuejin Road, Liuzhou, 545001, Guangxi Province, China. WYY15652606080@126.com. LA - eng GR - AD19245017/the Guangxi Natural Science Foundation/ GR - AD19245017/the Guangxi Natural Science Foundation/ GR - 20Z13/the Scientific Research Foundation of Guangxi University of Science and Technology/ GR - 20Z13/the Scientific Research Foundation of Guangxi University of Science and Technology/ GR - Z20211376/the Scientific Research Foundation of Guangxi Health Commission/ GR - Z20190410/the Scientific Research Foundation of Guangxi Health Commission/ GR - Z20211376/the Scientific Research Foundation of Guangxi Health Commission/ PT - Journal Article DEP - 20230429 PL - England TA - BMC Musculoskelet Disord JT - BMC musculoskeletal disorders JID - 100968565 SB - IM MH - Humans MH - Aged MH - Retrospective Studies MH - *Femoral Neck Fractures/complications MH - *Hip Fractures/surgery MH - Postoperative Complications/epidemiology/etiology/prevention & control MH - Patient Care Team PMC - PMC10148526 OTO - NOTNLM OT - Complication OT - Femoral neck fracture OT - Multidisciplinary team COIS- The authors declare that they have no competing interests. EDAT- 2023/04/30 00:42 MHDA- 2023/05/01 06:42 PMCR- 2023/04/29 CRDT- 2023/04/29 23:13 PHST- 2022/12/13 00:00 [received] PHST- 2023/04/25 00:00 [accepted] PHST- 2023/05/01 06:42 [medline] PHST- 2023/04/30 00:42 [pubmed] PHST- 2023/04/29 23:13 [entrez] PHST- 2023/04/29 00:00 [pmc-release] AID - 10.1186/s12891-023-06455-1 [pii] AID - 6455 [pii] AID - 10.1186/s12891-023-06455-1 [doi] PST - epublish SO - BMC Musculoskelet Disord. 2023 Apr 29;24(1):338. doi: 10.1186/s12891-023-06455-1. PMID- 37115947 OWN - NLM STAT- MEDLINE DCOM- 20230822 LR - 20250806 IS - 1536-0237 (Electronic) IS - 0883-5993 (Linking) VI - 38 IP - 5 DP - 2023 Sep 1 TI - Cardiothoracic Radiologist Workload, Work Capacity, and Burnout Post-COVID: Results of a Survey From the Society of Thoracic Radiology. PG - 261-269 LID - 10.1097/RTI.0000000000000710 [doi] AB - In this report and analysis of the results of a late 2021 post-COVID pandemic survey of members of the Society of Thoracic Radiology, we compared cardiothoracic radiologist workloads and burnout rates with those obtained from a prepandemic survey of society members. The more recent survey also asked respondents to provide a subjective assessment of their individual workload capacity should they be required to read cases at a section average daily case work volume, and this assessment was correlated with burnout rates. To measure nonrelative value unit workload, we requested data on non-case-related work responsibilities including teaching and multidisciplinary conferences that were not assessed in the first survey. In addition, we asked respondents to provide information on the availability of support services, personnel, and hardware and software tools that could improve work efficiency and reduce radiologist stress levels thereby mitigating burnout. We found that postpandemic case workload and cardiothoracic radiologists' burnout rates were similarly high compared with prepandemic levels with an overall burnout rate of 88% including a 100% burnout rate among women which had significantly increased. The range of radiologists' workload capacity is broad, although 80% of respondents reported that reading at an average sectional case volume was at or above their capacity, and the perceived capacity correlated with burnout measures. The presence of fellows and computer-aided diagnosis/artificial intelligence tools were each associated with significant decreases in burnout, providing 2 potential strategies that could be employed to address high cardiothoracic radiologist burnout rates. CI - Copyright (c) 2023 Wolters Kluwer Health, Inc. All rights reserved. FAU - Meyer, Cristopher A AU - Meyer CA AD - Department of Radiology, University of Wisconsin School of Medicine, Madison, WI. FAU - Klein, Jeffrey S AU - Klein JS AUID- ORCID: 0000-0002-6099-4639 AD - Department of Radiology, University of Vermont Larner College of Medicine, Burlington, VT. FAU - Liubauskas, Rokas AU - Liubauskas R AD - Department of Radiology, Harvard University School of Medicine, Boston, MA. FAU - Bhalla, Sanjeev AU - Bhalla S AD - Department of Radiology, Mallinckrodt Institute of Radiology at Washington University School of Medicine, St. Louis, MO. FAU - Eisenberg, Ronald L AU - Eisenberg RL AD - Department of Radiology, Harvard University School of Medicine, Boston, MA. LA - eng PT - Journal Article DEP - 20230407 PL - United States TA - J Thorac Imaging JT - Journal of thoracic imaging JID - 8606160 SB - IM MH - Humans MH - Female MH - Workload MH - Artificial Intelligence MH - *COVID-19 MH - Radiologists MH - Surveys and Questionnaires MH - *Burnout, Professional MH - *Radiology/education COIS- The authors declare no conflicts of interest. EDAT- 2023/04/28 18:43 MHDA- 2023/08/22 06:42 CRDT- 2023/04/28 14:05 PHST- 2023/08/22 06:42 [medline] PHST- 2023/04/28 18:43 [pubmed] PHST- 2023/04/28 14:05 [entrez] AID - 00005382-202309000-00001 [pii] AID - 10.1097/RTI.0000000000000710 [doi] PST - ppublish SO - J Thorac Imaging. 2023 Sep 1;38(5):261-269. doi: 10.1097/RTI.0000000000000710. Epub 2023 Apr 7. PMID- 37109147 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230501 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 12 IP - 8 DP - 2023 Apr 11 TI - Alcohol Septal Ablation in Patients with Hypertrophic Obstructive Cardiomyopathy: A Contemporary Perspective. LID - 10.3390/jcm12082810 [doi] LID - 2810 AB - Alcohol septal ablation is a minimally invasive procedure for the treatment of left ventricular outflow tract (LVOT) obstruction in patients with hypertrophic obstructive cardiomyopathy (HOCM) who remain symptomatic despite optimal medical therapy. The procedure causes a controlled myocardial infarction of the basal portion of the interventricular septum by the injection of absolute alcohol with the aim of reducing LVOT obstruction and improving the patient's hemodynamics and symptoms. Numerous observations have demonstrated the efficacy and safety of the procedure, making it a valid alternative to surgical myectomy. In particular, the success of alcohol septal ablation depends on appropriate patient selection and the experience of the institution where the procedure is performed. In this review, we summarize the current evidence on alcohol septal ablation and highlight the importance of a multidisciplinary approach involving a team of clinical and interventional cardiologists and cardiac surgeons with high expertise in the management of HOCM patients-the Cardiomyopathy Team. FAU - Gragnano, Felice AU - Gragnano F AUID- ORCID: 0000-0002-6943-278X AD - Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", 83043 Naples, Italy. AD - Division of Clinical Cardiology, Azienda Ospedaliera di Rilievo Nazionale "Sant'Anna e San Sebastiano", 81100 Caserta, Italy. FAU - Pelliccia, Francesco AU - Pelliccia F AUID- ORCID: 0000-0003-1260-1308 AD - Department of Cardiovascular Sciences, University Sapienza, 00185 Rome, Italy. FAU - Guarnaccia, Natale AU - Guarnaccia N AD - Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", 83043 Naples, Italy. AD - Division of Clinical Cardiology, Azienda Ospedaliera di Rilievo Nazionale "Sant'Anna e San Sebastiano", 81100 Caserta, Italy. FAU - Niccoli, Giampaolo AU - Niccoli G AD - Department of Medicine and Surgery, University of Parma, 43121 Parma, Italy. FAU - De Rosa, Salvatore AU - De Rosa S AUID- ORCID: 0000-0001-5388-942X AD - Division of Cardiology, Department of Medical and Surgical Sciences, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy. FAU - Piccolo, Raffaele AU - Piccolo R AD - Department of Advanced Biomedical Sciences, University of Naples Federico II, 80138 Naples, Italy. FAU - Moscarella, Elisabetta AU - Moscarella E AD - Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", 83043 Naples, Italy. AD - Division of Clinical Cardiology, Azienda Ospedaliera di Rilievo Nazionale "Sant'Anna e San Sebastiano", 81100 Caserta, Italy. FAU - Fabris, Enrico AU - Fabris E AUID- ORCID: 0000-0001-9458-0736 AD - Cardiothoracovascular Department, Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), University of Trieste, 34127 Trieste, Italy. FAU - Montone, Rocco Antonio AU - Montone RA AUID- ORCID: 0000-0002-6439-1018 AD - Department of Cardiovascular Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy. FAU - Cesaro, Arturo AU - Cesaro A AUID- ORCID: 0000-0003-4435-1235 AD - Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", 83043 Naples, Italy. AD - Division of Clinical Cardiology, Azienda Ospedaliera di Rilievo Nazionale "Sant'Anna e San Sebastiano", 81100 Caserta, Italy. FAU - Porto, Italo AU - Porto I AD - Dipartimento CardioToracoVascolare, Ospedale Policlinico San Martino IRCCS, 16132 Genova, Italy. FAU - Indolfi, Ciro AU - Indolfi C AUID- ORCID: 0000-0003-1241-6487 AD - Division of Cardiology, Department of Medical and Surgical Sciences, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy. AD - Mediterranea Cardiocentro, 80122 Naples, Italy. FAU - Sinagra, Gianfranco AU - Sinagra G AD - Cardiothoracovascular Department, Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), University of Trieste, 34127 Trieste, Italy. FAU - Perrone Filardi, Pasquale AU - Perrone Filardi P AD - Department of Advanced Biomedical Sciences, University of Naples Federico II, 80138 Naples, Italy. FAU - Ando, Giuseppe AU - Ando G AUID- ORCID: 0000-0001-5552-6382 AD - Department of Clinical and Experimental Medicine, University of Messina, AOU Policlinic "G. Martino", 98122 Messina, Italy. FAU - Calabro, Paolo AU - Calabro P AUID- ORCID: 0000-0002-5018-830X AD - Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", 83043 Naples, Italy. AD - Division of Clinical Cardiology, Azienda Ospedaliera di Rilievo Nazionale "Sant'Anna e San Sebastiano", 81100 Caserta, Italy. CN - Working Group of Interventional Cardiology of the Italian Society of Cardiology LA - eng PT - Journal Article PT - Review DEP - 20230411 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC10142866 OTO - NOTNLM OT - alcohol septal ablation OT - hypertrophic cardiomyopathy OT - myectomy COIS- The authors declare no conflict of interest. EDAT- 2023/04/28 06:41 MHDA- 2023/04/28 06:42 PMCR- 2023/04/11 CRDT- 2023/04/28 01:32 PHST- 2023/03/02 00:00 [received] PHST- 2023/04/02 00:00 [revised] PHST- 2023/04/10 00:00 [accepted] PHST- 2023/04/28 06:42 [medline] PHST- 2023/04/28 06:41 [pubmed] PHST- 2023/04/28 01:32 [entrez] PHST- 2023/04/11 00:00 [pmc-release] AID - jcm12082810 [pii] AID - jcm-12-02810 [pii] AID - 10.3390/jcm12082810 [doi] PST - epublish SO - J Clin Med. 2023 Apr 11;12(8):2810. doi: 10.3390/jcm12082810. PMID- 37109125 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250530 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 12 IP - 8 DP - 2023 Apr 9 TI - Clinical and Genetic Screening for Hypertrophic Cardiomyopathy in Paediatric Relatives: Changing Paradigms in Clinical Practice. LID - 10.3390/jcm12082788 [doi] LID - 2788 AB - Hypertrophic cardiomyopathy (HCM) is an important cause of morbidity and mortality in children. While the aetiology is heterogeneous, most cases are caused by variants in the genes encoding components of the cardiac sarcomere, which are inherited as an autosomal dominant trait. In recent years, there has been a paradigm shift in the role of clinical screening and predictive genetic testing in children with a first-degree relative with HCM, with the recognition that phenotypic expression can, and often does, manifest in young children and that familial disease in the paediatric age group may not be benign. The care of the child and family affected by HCM relies on a multidisciplinary team, with a key role for genomics. This review article summarises current evidence in clinical and genetic screening for hypertrophic cardiomyopathy in paediatric relatives and highlights aspects that remain to be resolved. FAU - Lawley, Claire M AU - Lawley CM AD - Centre for Inherited Cardiovascular Diseases, Great Ormond Street Hospital, London WC1N 3JH, UK. AD - The University of Sydney Children's Hospital Westmead Clinical School, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW 2006, Australia. FAU - Kaski, Juan Pablo AU - Kaski JP AUID- ORCID: 0000-0002-0014-9927 AD - Centre for Inherited Cardiovascular Diseases, Great Ormond Street Hospital, London WC1N 3JH, UK. AD - Centre for Paediatric Inherited and Rare Cardiovascular Disease, University College London Institute of Cardiovascular Science, London WC1E 6DD, UK. LA - eng GR - MR/T024062/1/MRC_/Medical Research Council/United Kingdom PT - Journal Article PT - Review DEP - 20230409 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC10146293 OTO - NOTNLM OT - genetics OT - hypertrophic cardiomyopathy OT - paediatrics OT - precision medicine OT - screening OT - sudden death COIS- The authors declare no conflict of interest. EDAT- 2023/04/28 06:42 MHDA- 2023/04/28 06:43 PMCR- 2023/04/09 CRDT- 2023/04/28 01:32 PHST- 2023/03/12 00:00 [received] PHST- 2023/04/02 00:00 [revised] PHST- 2023/04/06 00:00 [accepted] PHST- 2023/04/28 06:43 [medline] PHST- 2023/04/28 06:42 [pubmed] PHST- 2023/04/28 01:32 [entrez] PHST- 2023/04/09 00:00 [pmc-release] AID - jcm12082788 [pii] AID - jcm-12-02788 [pii] AID - 10.3390/jcm12082788 [doi] PST - epublish SO - J Clin Med. 2023 Apr 9;12(8):2788. doi: 10.3390/jcm12082788. PMID- 37105303 OWN - NLM STAT- MEDLINE DCOM- 20230621 LR - 20230621 IS - 1879-0887 (Electronic) IS - 0167-8140 (Linking) VI - 184 DP - 2023 Jul TI - A pulmonary vein atlas for radiotherapy planning. PG - 109680 LID - S0167-8140(23)00218-9 [pii] LID - 10.1016/j.radonc.2023.109680 [doi] AB - BACKGROUND AND PURPOSE: Cardiac arrhythmia is a recognised potential complication of thoracic radiotherapy, but the responsible cardiac substructures for arrhythmogenesis have not been identified. Arrhythmogenic tissue is commonly located in the pulmonary veins (PVs) of cardiology patients with arrhythmia, however these structures are not currently considered organs-at-risk during radiotherapy planning. A standardised approach to their delineation was developed and evaluated. MATERIALS AND METHODS: The gross and radiological anatomy relevant to atrial fibrillation was derived from cardiology and radiology literature by a multidisciplinary team. A region of interest and contouring instructions for radiotherapy computed tomography scans were iteratively developed and subsequently evaluated. Radiation oncologists (n = 5) and radiation technologists (n = 2) contoured the PVs on the four-dimensional planning datasets of five patients with locally advanced lung cancer treated with 1.8-2.75 Gy fractions. Contours were compared to reference contours agreed by the researchers using geometric and dosimetric parameters. RESULTS: The mean dose to the PVs was 35% prescription dose. Geometric and dosimetric similarity of the observer contours with reference contours was fair, with an overall mean Dice of 0.80 +/- 0.02. The right superior PV (mean DSC 0.83 +/- 0.02) had better overlap than the left (mean DSC 0.80 +/- 0.03), but the inferior PVs were equivalent (mean DSC of 0.78). The mean difference in mean dose was 0.79 Gy +/- 0.71 (1.46% +/- 1.25). CONCLUSION: A PV atlas with multidisciplinary approval led to reproducible delineation for radiotherapy planning, supporting the utility of the atlas in future clinical radiotherapy cardiotoxicity research encompassing arrhythmia endpoints. CI - Copyright (c) 2023 The Authors. Published by Elsevier B.V. All rights reserved. FAU - Walls, Gerard M AU - Walls GM AD - Cancer Centre Belfast City Hospital, Belfast Health & Social Care Trust, Lisburn Road, Belfast, UK; Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Lisburn Road, Belfast, UK. Electronic address: g.walls@qub.ac.uk. FAU - McCann, Conor AU - McCann C AD - Department of Cardiology, Belfast City Hospital, Belfast Health & Social Care Trust, Lisburn Road, Belfast, UK. FAU - Ball, Peter AU - Ball P AD - Department of Radiology, Royal Victoria Hospital, Belfast Health & Social Care Trust, 274 Grosvenor Rd, Belfast, UK. FAU - Atkins, Katelyn M AU - Atkins KM AD - Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, California, USA. FAU - Mak, Raymond H AU - Mak RH AD - Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts, USA. FAU - Bedair, Ahmed AU - Bedair A AD - North West Cancer Centre, ltnagelvin Hospital, Glenshane Road, Derry, UK. FAU - O'Hare, Jolyne AU - O'Hare J AD - Cancer Centre Belfast City Hospital, Belfast Health & Social Care Trust, Lisburn Road, Belfast, UK. FAU - McAleese, Jonathan AU - McAleese J AD - Cancer Centre Belfast City Hospital, Belfast Health & Social Care Trust, Lisburn Road, Belfast, UK. FAU - Harrison, Claire AU - Harrison C AD - Cancer Centre Belfast City Hospital, Belfast Health & Social Care Trust, Lisburn Road, Belfast, UK. FAU - Tumelty, Karen A AU - Tumelty KA AD - Cancer Centre Belfast City Hospital, Belfast Health & Social Care Trust, Lisburn Road, Belfast, UK. FAU - Crockett, Cathryn AU - Crockett C AD - Cancer Centre Belfast City Hospital, Belfast Health & Social Care Trust, Lisburn Road, Belfast, UK. FAU - Black, Sarah-Louise AU - Black SL AD - Cancer Centre Belfast City Hospital, Belfast Health & Social Care Trust, Lisburn Road, Belfast, UK. FAU - Nelson, Catherine AU - Nelson C AD - Cancer Centre Belfast City Hospital, Belfast Health & Social Care Trust, Lisburn Road, Belfast, UK. FAU - O'Connor, John AU - O'Connor J AD - Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Lisburn Road, Belfast, UK. FAU - Hounsell, Alan R AU - Hounsell AR AD - Cancer Centre Belfast City Hospital, Belfast Health & Social Care Trust, Lisburn Road, Belfast, UK; Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Lisburn Road, Belfast, UK. FAU - McGarry, Conor K AU - McGarry CK AD - Cancer Centre Belfast City Hospital, Belfast Health & Social Care Trust, Lisburn Road, Belfast, UK; Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Lisburn Road, Belfast, UK. FAU - Butterworth, Karl T AU - Butterworth KT AD - Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Lisburn Road, Belfast, UK. FAU - Cole, Aidan J AU - Cole AJ AD - Cancer Centre Belfast City Hospital, Belfast Health & Social Care Trust, Lisburn Road, Belfast, UK; Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Lisburn Road, Belfast, UK. FAU - Jain, Suneil AU - Jain S AD - Cancer Centre Belfast City Hospital, Belfast Health & Social Care Trust, Lisburn Road, Belfast, UK; Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Lisburn Road, Belfast, UK. FAU - Hanna, Gerard G AU - Hanna GG AD - Cancer Centre Belfast City Hospital, Belfast Health & Social Care Trust, Lisburn Road, Belfast, UK; Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Lisburn Road, Belfast, UK. LA - eng GR - 203930/B/16/Z/WT_/Wellcome Trust/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230425 PL - Ireland TA - Radiother Oncol JT - Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology JID - 8407192 SB - IM MH - Humans MH - *Pulmonary Veins/diagnostic imaging MH - Radiotherapy Planning, Computer-Assisted/methods MH - Heart MH - Tomography, X-Ray Computed/methods MH - Arrhythmias, Cardiac MH - Organs at Risk OTO - NOTNLM OT - Atrial fibrillation OT - Cardio-oncology OT - Lung cancer OT - Oesophageal cancer OT - Pulmonary veins OT - Radiation cardiotoxicity COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2023/04/28 00:42 MHDA- 2023/06/21 06:42 CRDT- 2023/04/27 19:23 PHST- 2022/09/19 00:00 [received] PHST- 2023/04/10 00:00 [revised] PHST- 2023/04/19 00:00 [accepted] PHST- 2023/06/21 06:42 [medline] PHST- 2023/04/28 00:42 [pubmed] PHST- 2023/04/27 19:23 [entrez] AID - S0167-8140(23)00218-9 [pii] AID - 10.1016/j.radonc.2023.109680 [doi] PST - ppublish SO - Radiother Oncol. 2023 Jul;184:109680. doi: 10.1016/j.radonc.2023.109680. Epub 2023 Apr 25. PMID- 37104835 OWN - NLM STAT- MEDLINE DCOM- 20230501 LR - 20230503 IS - 1936-2692 (Electronic) IS - 1088-0224 (Linking) VI - 29 IP - 4 DP - 2023 Apr 1 TI - Effect of home care after cardiac surgery. PG - e96-e103 LID - 10.37765/ajmc.2023.89349 [doi] AB - OBJECTIVES: Home care that maintains continuity of health care services after cardiac surgery is considered a complementary component of clinical care. We estimated that effective home care given with a multidisciplinary approach would contribute to decreasing symptoms and readmissions to the hospital after cardiac surgery. STUDY DESIGN: This experimental study with a 6-week follow-up period and a 2-group repeated measures design with pretest, posttest, and interval tests was conducted in a public hospital in Turkey in 2016. METHODS: We identified the self-efficacy levels, symptoms, and readmissions to the hospital of 60 patients (30 in the experimental group and 30 in the control group) throughout the data collection process, and we estimated the effect of home care on self-efficacy, symptom management, and hospital readmissions by comparing the data of patients in the experimental and control groups. Each patient in the experimental group received 7 home visits along with 24/7 telephone counseling services throughout the first 6 weeks after discharge, and patients were provided physical care, training, and counseling services during these home visits with the collaboration of their physician. RESULTS: Home care resulted in better self-efficacy and fewer symptoms in the experimental group (P < .05), and it also reduced readmissions to the hospital in the experimental group (23.3%) compared with the control group (46.7%). CONCLUSIONS: This study's findings suggest that home care, with a focus on continuity of care, decreases symptoms and readmissions to the hospital and improves the self-efficacy of patients after cardiac surgery. FAU - Saglam Aksut, Rabia AU - Saglam Aksut R AD - Nursing Department, Faculty of Health Sciences, Fenerbahce University, 34758, Istanbul, Turkey. Email: rabia.saglam@fbu.edu.tr. FAU - Kilic, Dilek AU - Kilic D LA - eng PT - Journal Article DEP - 20230401 PL - United States TA - Am J Manag Care JT - The American journal of managed care JID - 9613960 MH - Humans MH - *Home Care Services MH - Patient Discharge MH - Patient Readmission MH - *Cardiac Surgical Procedures MH - Hospitals EDAT- 2023/04/27 18:41 MHDA- 2023/05/01 06:42 CRDT- 2023/04/27 17:02 PHST- 2023/05/01 06:42 [medline] PHST- 2023/04/27 18:41 [pubmed] PHST- 2023/04/27 17:02 [entrez] AID - 89349 [pii] AID - 10.37765/ajmc.2023.89349 [doi] PST - epublish SO - Am J Manag Care. 2023 Apr 1;29(4):e96-e103. doi: 10.37765/ajmc.2023.89349. PMID- 37104082 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230501 IS - 2226-4787 (Electronic) IS - 2226-4787 (Linking) VI - 11 IP - 2 DP - 2023 Apr 17 TI - An Integrated Multidisciplinary Circuit Led by Hospital and Community Pharmacists to Implement Clopidogrel Pharmacogenetics in Clinical Practice. LID - 10.3390/pharmacy11020076 [doi] LID - 76 AB - The use of pharmacogenetics to optimize pharmacotherapy is growing rapidly. This study evaluates the feasibility and operability of a collaborative circuit involving hospital and community pharmacists to implement clopidogrel pharmacogenetics in Barcelona, Catalonia, Spain. We aimed to enroll patients with a clopidogrel prescription from cardiologists at the collaborating hospital. Community pharmacists collected patients' pharmacotherapeutic profiles and saliva samples, which were then sent to the hospital for CYP2C19 genotyping. Hospital pharmacists collated the obtained data with patients' clinical records. Data were analyzed jointly with a cardiologist to assess the suitability of clopidogrel. The provincial pharmacists' association coordinated the project and provided IT and logistic support. The study began in January 2020. However, it was suspended in March 2020 due to the COVID-19 pandemic. At that moment, 120 patients had been assessed, 16 of whom met the inclusion criteria and were enrolled in the study. The processing of samples obtained before the pandemic had an average delay of 13.8 +/- 5.4 days. A total of 37.5% patients were intermediate metabolizers and 18.8% were ultrarapid metabolizers. No poor metabolizers were detected. Pharmacists rated their experience with a 7.3 +/- 2.7 likelihood of recommending that fellow pharmacists participate. The net promoter score among participating pharmacists was +10%. Our results show that the circuit is feasible and operable for further initiatives. FAU - Mir, Joan Francesc AU - Mir JF AUID- ORCID: 0000-0001-8501-0969 AD - Professional Projects and Research Area, Col.legi de Farmaceutics de Barcelona/Barcelona Pharmacists' Association, 08009 Barcelona, Spain. AD - Blanquerna School of Health Sciences, Universitat Ramon Llull, 08022 Barcelona, Spain. FAU - Rodriguez-Caba, Cristina AU - Rodriguez-Caba C AD - Professional Projects and Research Area, Col.legi de Farmaceutics de Barcelona/Barcelona Pharmacists' Association, 08009 Barcelona, Spain. FAU - Estrada-Campmany, Maria AU - Estrada-Campmany M AD - Professional Projects and Research Area, Col.legi de Farmaceutics de Barcelona/Barcelona Pharmacists' Association, 08009 Barcelona, Spain. FAU - Fernandez de Gamarra-Martinez, Edurne AU - Fernandez de Gamarra-Martinez E AD - Pharmacy Department, Institut d'Investigacio Biomedica Sant Pau (IIB-Sant Pau), Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain. FAU - Mangues, Maria Antonia AU - Mangues MA AUID- ORCID: 0000-0002-1438-8515 AD - Pharmacy Department, Institut d'Investigacio Biomedica Sant Pau (IIB-Sant Pau), Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain. FAU - Bagaria, Guillermo AU - Bagaria G AD - Professional Projects and Research Area, Col.legi de Farmaceutics de Barcelona/Barcelona Pharmacists' Association, 08009 Barcelona, Spain. FAU - Riera, Pau AU - Riera P AUID- ORCID: 0000-0002-3074-3927 AD - Pharmacy Department, Institut d'Investigacio Biomedica Sant Pau (IIB-Sant Pau), Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain. AD - CIBER de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, 28029 Madrid, Spain. LA - eng GR - Joaquim Bonal grant 2019-2021/Catalan Society of Clinical Pharmacy (SCFC)/ GR - Veroval - Laboratorios HARTMANN S.A./ GR - Grant JR20/00008 to Pau Riera/Instituto de Salud Carlos III/ PT - Journal Article DEP - 20230417 PL - Switzerland TA - Pharmacy (Basel) JT - Pharmacy (Basel, Switzerland) JID - 101678532 PMC - PMC10146470 OTO - NOTNLM OT - clinical pharmacy OT - clopidogrel OT - community pharmacy OT - hospital pharmacy OT - personalized medicine OT - pharmaceutical care OT - pharmacogenetics COIS- The authors declare no conflict of interest related to the study. The funders had no role in the design of the study, the collection, analyses, or interpretation of data, the writing of the manuscript or the decision to publish the results. EDAT- 2023/04/27 18:41 MHDA- 2023/04/27 18:42 PMCR- 2023/04/17 CRDT- 2023/04/27 12:32 PHST- 2023/03/17 00:00 [received] PHST- 2023/04/04 00:00 [revised] PHST- 2023/04/06 00:00 [accepted] PHST- 2023/04/27 18:42 [medline] PHST- 2023/04/27 18:41 [pubmed] PHST- 2023/04/27 12:32 [entrez] PHST- 2023/04/17 00:00 [pmc-release] AID - pharmacy11020076 [pii] AID - pharmacy-11-00076 [pii] AID - 10.3390/pharmacy11020076 [doi] PST - epublish SO - Pharmacy (Basel). 2023 Apr 17;11(2):76. doi: 10.3390/pharmacy11020076. PMID- 37103087 OWN - NLM STAT- MEDLINE DCOM- 20230501 LR - 20230519 IS - 1791-7549 (Electronic) IS - 0258-851X (Print) IS - 0258-851X (Linking) VI - 37 IP - 3 DP - 2023 May-Jun TI - Stereotactic Arrhythmia Radioablation (STAR): A Multidisciplinary Narrative Minireview of Preclinical Studies. PG - 963-971 LID - 10.21873/invivo.13170 [doi] AB - The aim of this narrative review of the literature was to collect and analyze the results of the published preclinical studies on stereotactic arrhythmia radioablation (STAR) in the treatment of refractory cardiac arrhythmias. A literature search was conducted on PubMed using the following terms: ("stereotactic" OR "SBRT" OR "SABR" OR "radioablation" OR "radiosurgery") AND ("arrhythmia" OR "tachycardia"). Preclinical and pathological reports published in English without time limit, comprising studies of STAR in animal models and histological analyzes of explanted animal and human hearts were included. The analyzed studies confirm that doses lower than 25 Gy seem to produce sub-optimal therapeutic results whereas doses >35 Gy are less safe in terms of radiation-induced toxicity. However, long-term results (>1 year) are still missing and reporting outcomes based on low dose irradiation (1 year) in animal models irradiated at doses similar to those used in the clinic; 3) define the optimal target. CI - Copyright (c) 2023, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. FAU - Galietta, Erika AU - Galietta E AD - Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; erika.galietta@studio.unibo.it. AD - Department of Medical and Surgical Sciences-DIMEC, Alma Mater Studiorum University of Bologna, Bologna, Italy. FAU - Strolin, Silvia AU - Strolin S AD - Medical Physics, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. FAU - Bisello, Silvia AU - Bisello S AD - Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. AD - Department of Medical and Surgical Sciences-DIMEC, Alma Mater Studiorum University of Bologna, Bologna, Italy. FAU - Cellini, Francesco AU - Cellini F AD - Dipartimento Universitario Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Universita Cattolica del Sacro Cuore, Rome, Italy. AD - Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy. FAU - Lovato, Luigi AU - Lovato L AD - Cardio-Thoracic-Vascular Department, Cardio-Thoracic Radiology, Cardiovascular Section, AOU Policlinico S.Orsola-Malpighi, Bologna, Italy. FAU - Ravegnini, Gloria AU - Ravegnini G AD - Department of Pharmacy and Biotechnology (FABIT), University of Bologna, Bologna, Italy. FAU - Martignani, Cristian AU - Martignani C AD - Cardio-Thoracic-Vascular Department, Cardio-Thoracic Radiology, Cardiovascular Section, AOU Policlinico S.Orsola-Malpighi, Bologna, Italy. FAU - Spadotto, Alberto AU - Spadotto A AD - Cardio-Thoracic-Vascular Department, Cardio-Thoracic Radiology, Cardiovascular Section, AOU Policlinico S.Orsola-Malpighi, Bologna, Italy. FAU - Buwenge, Milly AU - Buwenge M AD - Department of Medical and Surgical Sciences-DIMEC, Alma Mater Studiorum University of Bologna, Bologna, Italy. FAU - Cammelli, Silvia AU - Cammelli S AD - Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. AD - Department of Medical and Surgical Sciences-DIMEC, Alma Mater Studiorum University of Bologna, Bologna, Italy. FAU - Strigari, Lidia AU - Strigari L AD - Medical Physics, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. FAU - Morganti, Alessio G AU - Morganti AG AD - Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. AD - Department of Medical and Surgical Sciences-DIMEC, Alma Mater Studiorum University of Bologna, Bologna, Italy. FAU - Arcelli, Alessandra AU - Arcelli A AD - Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. LA - eng PT - Journal Article PT - Review PL - Greece TA - In Vivo JT - In vivo (Athens, Greece) JID - 8806809 SB - IM MH - Animals MH - Humans MH - *Arrhythmias, Cardiac/etiology/radiotherapy MH - *Radiosurgery/adverse effects/methods MH - Heart MH - Models, Animal MH - Time Factors PMC - PMC10188005 OTO - NOTNLM OT - Arrhythmia OT - literature review OT - narrative review OT - preclinical studies OT - radioablation OT - review OT - stereotactic radiotherapy COIS- The Authors declare no conflicts of interest in relation to this study. EDAT- 2023/04/27 12:41 MHDA- 2023/05/01 06:42 PMCR- 2023/05/03 CRDT- 2023/04/27 10:33 PHST- 2023/02/06 00:00 [received] PHST- 2023/02/18 00:00 [revised] PHST- 2023/02/22 00:00 [accepted] PHST- 2023/05/01 06:42 [medline] PHST- 2023/04/27 12:41 [pubmed] PHST- 2023/04/27 10:33 [entrez] PHST- 2023/05/03 00:00 [pmc-release] AID - 37/3/963 [pii] AID - 10.21873/invivo.13170 [doi] PST - ppublish SO - In Vivo. 2023 May-Jun;37(3):963-971. doi: 10.21873/invivo.13170. PMID- 37103032 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230501 IS - 2308-3425 (Electronic) IS - 2308-3425 (Linking) VI - 10 IP - 4 DP - 2023 Apr 1 TI - The Heart-Brain Interplay in Multiple Sclerosis from Pathophysiology to Clinical Practice: A Narrative Review. LID - 10.3390/jcdd10040153 [doi] LID - 153 AB - Multiple sclerosis (MS) is a chronic neurological disorder characterized by inflammation in the central nervous system (CNS) that leads to neurodegeneration. The clinical course is highly variable, but its prevalence is rising worldwide, partly thanks to novel disease-modifying therapies. Additionally, the lifespan of people with MS is increasing, and for this reason, it is fundamental to have a multidisciplinary approach to MS. MS may be associated with cardiovascular diseases (CVD), but there is scarce attention on this issue. In particular, CNS is essential in regulating the autonomic system and heart activity. Moreover, cardiovascular risk factors show a higher prevalence in MS patients. On the other hand, conditions like Takotsubo syndrome are rare complications of MS. The parallelism between MS and myocarditis is also interesting. Finally, cardiac toxicity represents a not infrequent adverse reaction to MS drugs. This narrative review aims to provide an overview of cardiovascular complications in MS and their management to prompt further clinical and pre-clinical research on this topic. FAU - Zavarella, Matteo AU - Zavarella M AD - Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy. AD - Faculty of Medicine and Surgery, Vita-Salute San Raffaele University, 20132 Milan, Italy. FAU - Villatore, Andrea AU - Villatore A AUID- ORCID: 0000-0002-2858-1404 AD - Faculty of Medicine and Surgery, Vita-Salute San Raffaele University, 20132 Milan, Italy. AD - Department of Cardiac Electrophysiology and Arrhythmology, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy. AD - Myocarditis Disease Unit, IRCCS San Raffaele Scientific Institute, 20019 Milan, Italy. FAU - Rocca, Maria Assunta AU - Rocca MA AD - Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy. AD - Faculty of Medicine and Surgery, Vita-Salute San Raffaele University, 20132 Milan, Italy. AD - Neurology Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy. FAU - Peretto, Giovanni AU - Peretto G AUID- ORCID: 0000-0003-1815-4000 AD - Faculty of Medicine and Surgery, Vita-Salute San Raffaele University, 20132 Milan, Italy. AD - Department of Cardiac Electrophysiology and Arrhythmology, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy. AD - Myocarditis Disease Unit, IRCCS San Raffaele Scientific Institute, 20019 Milan, Italy. FAU - Filippi, Massimo AU - Filippi M AUID- ORCID: 0000-0002-5485-0479 AD - Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy. AD - Faculty of Medicine and Surgery, Vita-Salute San Raffaele University, 20132 Milan, Italy. AD - Neurology Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy. AD - Neurorehabilitation Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy. AD - Neurophysiology Service, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy. LA - eng PT - Journal Article PT - Review DEP - 20230401 PL - Switzerland TA - J Cardiovasc Dev Dis JT - Journal of cardiovascular development and disease JID - 101651414 PMC - PMC10144916 OTO - NOTNLM OT - autoimmunity OT - autonomic dysfunction OT - cardiovascular disease OT - drug toxicity OT - multiple sclerosis OT - myocarditis COIS- The authors declare that M. Filippi is Editor-in-Chief of the Journal of Neurology, Associate Editor of Human Brain Mapping, Associate Editor of Radiology, and Associate Editor of Neurological Sciences; received compensation for consulting services from Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi; speaking activities from Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA; participation in Advisory Boards for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda; scientific direction of educational events for Biogen, Merck, Roche, Celgene, Bris-tol-Myers Squibb, Lilly, Novartis, Sanofi-Genzyme; he receives research support from Bio-gen Idec, Merck-Serono, Novartis, Roche, Italian Ministry of Health, and Fondazione Italiana Sclerosi Multipla. M.A. Rocca received consulting fees from Biogen, Bristol Myers Squibb, Eli Lilly, Janssen, Roche; and speaker honoraria from Bayer, Biogen, Bristol Myers Squibb, Bromatech, Celgene, Genzyme, Merck Healthcare Germany, Merck Serono SpA, Novartis, Roche, and Teva. She receives research support from the MS Society of Canada and Fondazione Italiana Sclerosi Multipla. She is Associate Editor for Multiple Sclerosis and Related Disorders. The other authors have no conflicts of interest. EDAT- 2023/04/27 12:42 MHDA- 2023/04/27 12:43 PMCR- 2023/04/01 CRDT- 2023/04/27 10:33 PHST- 2023/01/23 00:00 [received] PHST- 2023/03/06 00:00 [revised] PHST- 2023/03/29 00:00 [accepted] PHST- 2023/04/27 12:43 [medline] PHST- 2023/04/27 12:42 [pubmed] PHST- 2023/04/27 10:33 [entrez] PHST- 2023/04/01 00:00 [pmc-release] AID - jcdd10040153 [pii] AID - jcdd-10-00153 [pii] AID - 10.3390/jcdd10040153 [doi] PST - epublish SO - J Cardiovasc Dev Dis. 2023 Apr 1;10(4):153. doi: 10.3390/jcdd10040153. PMID- 37101848 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230428 IS - 2054-3581 (Print) IS - 2054-3581 (Electronic) IS - 2054-3581 (Linking) VI - 10 DP - 2023 TI - Amyloidoses in Onco-Nephrology Practice: A Multidisciplinary Case-Based Conference Report. PG - 20543581231165711 LID - 10.1177/20543581231165711 [doi] LID - 20543581231165711 AB - INTRODUCTION AND OBJECTIVE: Amyloidoses are a heterogeneous group of disorders resulting from deposition of amyloid fibrils into extracellular tissues. While the kidneys are one of the most frequent sites of amyloid deposition, amyloid deposits can also affect a wide range of organ systems, including the heart, liver, gastrointestinal tract, and peripheral nerves. The prognosis of amyloidosis, especially with cardiac involvement, remains poor; however, a collaborative approach applying new tools for diagnosis and management may improve outcomes. In September 2021, the Canadian Onco-Nephrology Interest Group hosted a symposium to discuss diagnostic challenges and recent advances in the management of amyloidosis from the perspectives of the nephrologist, cardiologist, and onco-hematologist. METHODS AND SOURCES OF INFORMATION: Through structured presentations, the group discussed a series of cases highlighting the varied clinical presentations of amyloidoses affecting the kidney and heart. Expert opinions, clinical trial findings, and publication summaries were used to illustrate patient-related and treatment-related considerations in the diagnosis and management of amyloidoses. KEY FINDINGS: (1) Overview of the clinical presentation of amyloidoses and the role of specialists in performing timely and accurate diagnostic workup; (2) review of best practices for multidisciplinary management of amyloidosis, including prognostic variables and determinants of treatment response; and (3) update on new and emerging treatments in the management of light chain and amyloid transthyretin amyloidoses. LIMITATIONS: This conference featured multidisciplinary discussion of cases, and learning points reflect the assessments by the involved experts/authors. IMPLICATIONS: Identification and management of amyloidoses can be facilitated with a multidisciplinary approach and higher index of suspicion from cardiologists, nephrologists, and hemato-oncologists. Increased awareness of clinical presentations and diagnostic algorithms for amyloidosis subtyping will lead to more timely interventions and improved clinical outcomes. CI - (c) The Author(s) 2023. FAU - Kitchlu, Abhijat AU - Kitchlu A AUID- ORCID: 0000-0002-4340-5046 AD - Department of Medicine, Division of Nephrology, University Health Network, University of Toronto, ON, Canada. FAU - Chan, Christopher T AU - Chan CT AD - Department of Medicine, Division of Nephrology, University Health Network, University of Toronto, ON, Canada. FAU - Jhaveri, Kenar D AU - Jhaveri KD AD - The Glomerular Disease Center at Northwell Health, Division of Kidney Diseases and Hypertension, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, USA. FAU - Delgado, Diego AU - Delgado D AD - Division of Cardiology, Heart Failure and Transplant Program, University Health Network, Toronto General Hospital, ON, Canada. FAU - Tam, Paul AU - Tam P AD - Division of Nephrology, The Scarborough Hospital, Toronto, ON, Canada. LA - eng PT - Journal Article DEP - 20230418 PL - England TA - Can J Kidney Health Dis JT - Canadian journal of kidney health and disease JID - 101640242 PMC - PMC10123889 OTO - NOTNLM OT - AL OT - ATTR OT - amyloid deposits OT - amyloidosis COIS- The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Abhijat Kitchlu: No relevant conflicts of interest to disclose. Christopher T. Chan: No relevant conflicts of interest to disclose. Kenar D. Jhaveri: Consultancy agreements with Secretome, George Clinicals, PMV pharmaceuticals, GSK, and Calliditas. K.D.J. reports honoraria from the American Society of Nephrology and UpToDate.com; reports serving on the editorial boards of American Journal of Kidney Diseases, CJASN, Clinical Kidney Journal, Journal of Onconephrology, Kidney International, and Nephrology Dialysis Transplantation; reports serving as Editor-in-Chief of ASN Kidney News and section editor for onconephrology for Nephrology Dialysis Transplantation. Diego Delgado: Consulting fees and speakers' honoraria from Akcea, Alnylam, Pfizer. Paul Tam: No relevant conflicts of interest to disclose EDAT- 2023/04/27 06:42 MHDA- 2023/04/27 06:43 PMCR- 2023/04/18 CRDT- 2023/04/27 02:12 PHST- 2022/12/08 00:00 [received] PHST- 2023/02/09 00:00 [accepted] PHST- 2023/04/27 06:43 [medline] PHST- 2023/04/27 06:42 [pubmed] PHST- 2023/04/27 02:12 [entrez] PHST- 2023/04/18 00:00 [pmc-release] AID - 10.1177_20543581231165711 [pii] AID - 10.1177/20543581231165711 [doi] PST - epublish SO - Can J Kidney Health Dis. 2023 Apr 18;10:20543581231165711. doi: 10.1177/20543581231165711. eCollection 2023. PMID- 37101328 OWN - NLM STAT- MEDLINE DCOM- 20230428 LR - 20230920 IS - 1539-0683 (Electronic) IS - 0361-929X (Linking) VI - 48 IP - 3 DP - 2023 May-Jun 01 TI - The Role of Nurses in Fetal Cardiology Programs: An Integrative Review. PG - 151-160 LID - 10.1097/NMC.0000000000000910 [doi] AB - BACKGROUND: Fetal cardiology programs are evolving quickly and include multiple interdisciplinary health care professionals whose roles could benefit from clear definition. Nurses provide an essential function in this field; however, descriptions or definitions of nursing practice, education and knowledge requirements, and responsibilities are limited and vary across institutions and disciplines. PURPOSE: To conduct an integrative review summarizing the literature to determine the role of nurses in fetal cardiology programs. METHODS: We conducted an integrative review as per Whittemore and Knafl's (2005) methodology of current literature to reveal strengths and opportunities in describing nursing practice as fetal cardiology nurses. The search strategy included five electronic databases: CINAHL, Medline, PsycINFO, Web of Science, and Google Scholar. Peer-reviewed English-language articles discussing nursing practices in fetal cardiology published between 2015 and 2022 were selected. Data extraction and analysis were completed on a final sample of 26 articles. RESULTS: Four themes were identified on fetal cardiac nursing practice from nursing and medical perspectives: multidisciplinary key team member, psychosocial family support and counselor, coordinator or navigator, and role description. CLINICAL IMPLICATIONS: More discussion in the literature is needed to better understand and define fetal cardiac nursing practice. Although most experts agree nurses are an important member of the interdisciplinary fetal cardiology team, their roles and educational requirements are poorly described and defined. Quality metrics and benchmarks are needed to ensure safe and effective fetal cardiology care. CI - Copyright (c) 2023 Wolters Kluwer Health, Inc. All rights reserved. FAU - Butler, Mary AU - Butler M FAU - McArthur, Erin C AU - McArthur EC LA - eng PT - Journal Article PT - Review PL - United States TA - MCN Am J Matern Child Nurs JT - MCN. The American journal of maternal child nursing JID - 7605941 SB - IM MH - Female MH - Pregnancy MH - Humans MH - Health Personnel MH - Prenatal Care MH - Social Behavior MH - *Cardiology MH - *Nurses EDAT- 2023/04/27 06:42 MHDA- 2023/04/28 06:41 CRDT- 2023/04/27 00:12 PHST- 2023/04/28 06:41 [medline] PHST- 2023/04/27 06:42 [pubmed] PHST- 2023/04/27 00:12 [entrez] AID - 00005721-202305000-00006 [pii] AID - 10.1097/NMC.0000000000000910 [doi] PST - ppublish SO - MCN Am J Matern Child Nurs. 2023 May-Jun 01;48(3):151-160. doi: 10.1097/NMC.0000000000000910. PMID- 37098833 OWN - NLM STAT- MEDLINE DCOM- 20230619 LR - 20250623 IS - 1099-0496 (Electronic) IS - 1099-0496 (Linking) VI - 58 IP - 7 DP - 2023 Jul TI - Safety study of moxifloxacin in children with severe refractory Mycoplasma pneumoniae pneumonia. PG - 2017-2024 LID - 10.1002/ppul.26426 [doi] AB - BACKGROUND: With the increase in macrolide-resistant M. pneumoniae infections, off-label use is difficult to avoid. This study assessed the safety of moxifloxacin in pediatric patients with severe refractory M. pneumoniae pneumonia (SRMPP). METHODS: We retrospectively reviewed the medical records of children with SRMPP between January 2017 and November 2020 at Beijing Children's Hospital. They were divided into the moxifloxacin group and azithromycin group according to whether or not moxifloxacin was used. The clinical symptoms, radiographs of both knees, and cardiac ultrasounds of the children were collected after drug withdrawal for at least 1 year. A multidisciplinary team reviewed all adverse events and determined their relationship with moxifloxacin. RESULTS: A total of 52 children with SRMPP were included in this study (31 in the moxifloxacin group and 21 in the azithromycin group). In the moxifloxacin group, four patients had arthralgia, one had joint effusion, and seven had heart valve regurgitation. In the azithromycin group, three patients had arthralgia, one had claudication, and one had heart valve regurgitation; no obvious knee abnormalities were observed in the radiographs. No statistically significant differences in clinical symptoms or imaging findings were found between the groups. As for the adverse events, 11 patients in moxifloxacin group were deemed to be doubtfully related and one possibly related to moxifloxacin; in the azithromycin group, four patients were regarded to be doubtfully related to azithromycin and one not related. CONCLUSION: Moxifloxacin was well tolerated and safe for treating SRMPP in children. CI - (c) 2023 The Authors. Pediatric Pulmonology published by Wiley Periodicals LLC. FAU - He, Yu-Shan AU - He YS AUID- ORCID: 0000-0003-3585-8579 AD - Pediatric Intensive Care Unit, Beijing Children's Hospital, National Center for Children's Health, Capital Medical University, Beijing, China. FAU - Yang, Mei AU - Yang M AD - Department of Pharmacy, Beijing Children's Hospital, National Center for Children's Health, Capital Medical University, Beijing, China. FAU - Liu, Gang AU - Liu G AD - Pediatric Intensive Care Unit, Beijing Children's Hospital, National Center for Children's Health, Capital Medical University, Beijing, China. FAU - Ji, Jian AU - Ji J AD - Pediatric Intensive Care Unit, Beijing Children's Hospital, National Center for Children's Health, Capital Medical University, Beijing, China. FAU - Qian, Su-Yun AU - Qian SY AD - Pediatric Intensive Care Unit, Beijing Children's Hospital, National Center for Children's Health, Capital Medical University, Beijing, China. LA - eng GR - Z211100002921063/Research and Application of Clinical Diagnosis and Treatment Technology in Capital/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230426 PL - United States TA - Pediatr Pulmonol JT - Pediatric pulmonology JID - 8510590 RN - 83905-01-5 (Azithromycin) RN - U188XYD42P (Moxifloxacin) RN - 0 (Anti-Bacterial Agents) SB - IM MH - Child MH - Humans MH - *Azithromycin/adverse effects MH - Moxifloxacin/therapeutic use MH - Mycoplasma pneumoniae MH - Retrospective Studies MH - *Pneumonia, Mycoplasma/diagnostic imaging/drug therapy MH - Anti-Bacterial Agents/adverse effects MH - Drug Resistance, Bacterial OTO - NOTNLM OT - Mycoplasma pneumoniae OT - heart valves OT - musculoskeletal diseases OT - quinolones OT - safety EDAT- 2023/04/26 12:42 MHDA- 2023/06/19 13:08 CRDT- 2023/04/26 09:33 PHST- 2023/03/28 00:00 [revised] PHST- 2022/08/29 00:00 [received] PHST- 2023/04/10 00:00 [accepted] PHST- 2023/06/19 13:08 [medline] PHST- 2023/04/26 12:42 [pubmed] PHST- 2023/04/26 09:33 [entrez] AID - 10.1002/ppul.26426 [doi] PST - ppublish SO - Pediatr Pulmonol. 2023 Jul;58(7):2017-2024. doi: 10.1002/ppul.26426. Epub 2023 Apr 26. PMID- 37092840 OWN - NLM STAT- MEDLINE DCOM- 20230426 LR - 20230508 IS - 1940-087X (Electronic) IS - 1940-087X (Linking) IP - 194 DP - 2023 Apr 7 TI - A Modified Sonographic Algorithm for Image Acquisition in Life-Threatening Emergencies in the Critically Ill Newborn. LID - 10.3791/64931 [doi] AB - The use of routine point-of-care ultrasound (POCUS) is increasing in neonatal intensive care units (NICUs), with several centers advocating for 24 h equipment availability. In 2018, the sonographic algorithm for life-threatening emergencies (SAFE) protocol was published, which allows the assessment of neonates with sudden decompensation to identify abnormal contractility, tamponade, pneumothorax, and pleural effusion. In the study unit (with a consulting neonatal hemodynamics and POCUS service), the algorithm was adapted by including consolidated core steps to support at-risk newborns, aiding clinicians in managing cardiac arrest, and adding views to verify correct intubation. This paper presents a protocol that can be applied in the NICU and the delivery room (DR) in relation to three scenarios: cardiac arrest, hemodynamic deterioration, or respiratory decompensation. This protocol can be performed with a state-of-the-art ultrasound machine or an affordable handheld device; the image acquisition protocol is carefully detailed. This method was designed to be learned as a general competence to obtain the timely diagnosis of life-threatening scenarios; the method aims to save time but does not represent a substitute for comprehensive and standardized hemodynamic and radiological analyses by a multidisciplinary team, which might not universally be on call but needs to be involved in the process. From January 2019 to July 2022, in our center, 1,045 hemodynamic consultation/POCUS consults were performed with 25 patients requiring the modified SAFE protocol (2.3%), and a total of 19 procedures were performed. In five cases, trained fellows on call resolved life-threatening situations. Clinical examples are provided that show the importance of including this technique in the care of critical newborns. FAU - Ibarra-Rios, Daniel AU - Ibarra-Rios D AD - Hemodynamic Consultation and Ultrasound in the Critically Ill Neonate, Hospital Infantil de Mexico Federico Gomez (HIMFG); ibarraneonato@gmail.com. FAU - Serpa-Maldonado, Eunice Valeria AU - Serpa-Maldonado EV AD - Hemodynamic Consultation and Ultrasound in the Critically Ill Neonate, Hospital Infantil de Mexico Federico Gomez (HIMFG). FAU - Mantilla-Uresti, Jose Guadalupe AU - Mantilla-Uresti JG AD - Hemodynamic Consultation and Ultrasound in the Critically Ill Neonate, Hospital Infantil de Mexico Federico Gomez (HIMFG). FAU - Guillen-Torres, Rogelio AU - Guillen-Torres R AD - Hemodynamic Consultation and Ultrasound in the Critically Ill Neonate, Hospital Infantil de Mexico Federico Gomez (HIMFG). FAU - Aguilar-Martinez, Naomi AU - Aguilar-Martinez N AD - Neonatology Department, HIMFG. FAU - Sanchez-Cruz, Alejandra AU - Sanchez-Cruz A AD - Neonatal Intensive Care Unit, Hospital de Ginecologia y Obstetricia Numero 4, Luis Castelazo Ayala, Instituto Mexicano del Seguro Social. FAU - Morales-Barquet, Deneb Algedi AU - Morales-Barquet DA AD - Head of Intermediate Care, Instituto Nacional de Perinatologia. FAU - Becerra-Becerra, Rosario AU - Becerra-Becerra R AD - Head of the Echocardiography Lab, HIMFG. FAU - Marquez-Gonzalez, Horacio AU - Marquez-Gonzalez H AD - Clinical Investigation Department, HIMFG. LA - eng PT - Journal Article PT - Video-Audio Media DEP - 20230407 PL - United States TA - J Vis Exp JT - Journal of visualized experiments : JoVE JID - 101313252 SB - IM MH - Humans MH - Infant, Newborn MH - *Emergencies MH - Critical Illness MH - Intensive Care Units, Neonatal MH - Ultrasonography MH - *Heart Arrest EDAT- 2023/04/24 12:42 MHDA- 2023/04/26 06:42 CRDT- 2023/04/24 09:03 PHST- 2023/04/26 06:42 [medline] PHST- 2023/04/24 12:42 [pubmed] PHST- 2023/04/24 09:03 [entrez] AID - 10.3791/64931 [doi] PST - epublish SO - J Vis Exp. 2023 Apr 7;(194). doi: 10.3791/64931. PMID- 37086835 OWN - NLM STAT- MEDLINE DCOM- 20230814 LR - 20230814 IS - 1916-7075 (Electronic) IS - 0828-282X (Linking) VI - 39 IP - 8 DP - 2023 Aug TI - Pericardial Diseases in Pregnancy. PG - 1067-1077 LID - S0828-282X(23)00311-2 [pii] LID - 10.1016/j.cjca.2023.04.010 [doi] AB - Pericardial effusion is the most common manifestation of pericardial diseases during pregnancy. This effusion is benign, mild, or moderate, well tolerated, with spontaneous resolution after delivery; no specific treatment is required. Acute pericarditis is the second most common condition, usually requiring medical therapy during pregnancy. Cardiac tamponade and constrictive pericarditis are rare in pregnancy. Pre-pregnancy counselling is essential in women of childbearing age with recurrent pericarditis to plan pregnancy in a phase of disease quiescence and to review therapy. High-dose aspirin or nonselective nonsteroidal anti-inflammatory drugs, such as ibuprofen and indomethacin, can be used up to the 20th week of gestation. Low-dose prednisone (2.5-10 mg/d) can be administered throughout pregnancy. All of these medications, apart from high-dose aspirin, may be used during lactation. Colchicine is compatible with pregnancy and breastfeeding, and it can be continued throughout pregnancy to prevent recurrences. Appropriate follow-up with a multidisciplinary team with experience in the field is recommended throughout pregnancy to ensure good maternal and fetal outcomes. CI - Copyright (c) 2023 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved. FAU - Serati, Lisa AU - Serati L AD - Department of Internal Medicine, Fatebenefratelli Hospital, Milan, Italy. Electronic address: lisa.serati@unimi.it. FAU - Mardigyan, Vartan AU - Mardigyan V AD - Department of Medicine, Jewish General Hospital, Montreal, Quebec, Canada. FAU - Dominioni, Costanza Caccia AU - Dominioni CC AD - Department of Internal Medicine, Fatebenefratelli Hospital, Milan, Italy. FAU - Agozzino, Francesco AU - Agozzino F AD - Department of Internal Medicine, Fatebenefratelli Hospital, Milan, Italy. FAU - Bizzi, Emanuele AU - Bizzi E AD - Department of Internal Medicine, Fatebenefratelli Hospital, Milan, Italy. FAU - Trotta, Lucia AU - Trotta L AD - Department of Internal Medicine, Fatebenefratelli Hospital, Milan, Italy. FAU - Nivuori, Mariangela AU - Nivuori M AD - Department of Internal Medicine, Fatebenefratelli Hospital, Milan, Italy. FAU - Maestroni, Silvia AU - Maestroni S AD - Department of Internal Medicine, Papa Giovanni XXIII Hospital, Bergamo, Italy. FAU - Negro, Enrica AU - Negro E AD - Department of Internal Medicine, Fatebenefratelli Hospital, Milan, Italy. FAU - Imazio, Massimo AU - Imazio M AD - Cardiology, Cardiothoracic Department, University Hospital "Santa Maria della Misericordia," Udine, Italy. FAU - Brucato, Antonio AU - Brucato A AD - Department of Biomedical and Clinical Sciences, University of Milan, Fatebenefratelli Hospital, Milan, Italy. LA - eng PT - Journal Article PT - Review DEP - 20230420 PL - England TA - Can J Cardiol JT - The Canadian journal of cardiology JID - 8510280 RN - R16CO5Y76E (Aspirin) RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) SB - IM MH - Pregnancy MH - Humans MH - Female MH - *Pericarditis/therapy/drug therapy MH - *Pericarditis, Constrictive MH - *Pericardial Effusion MH - Aspirin/therapeutic use MH - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use MH - *Cardiac Tamponade EDAT- 2023/04/23 00:41 MHDA- 2023/08/14 06:42 CRDT- 2023/04/22 19:25 PHST- 2022/12/15 00:00 [received] PHST- 2023/04/13 00:00 [revised] PHST- 2023/04/14 00:00 [accepted] PHST- 2023/08/14 06:42 [medline] PHST- 2023/04/23 00:41 [pubmed] PHST- 2023/04/22 19:25 [entrez] AID - S0828-282X(23)00311-2 [pii] AID - 10.1016/j.cjca.2023.04.010 [doi] PST - ppublish SO - Can J Cardiol. 2023 Aug;39(8):1067-1077. doi: 10.1016/j.cjca.2023.04.010. Epub 2023 Apr 20. PMID- 37079147 OWN - NLM STAT- MEDLINE DCOM- 20230424 LR - 20261010 IS - 1437-9813 (Electronic) IS - 0179-0358 (Linking) VI - 39 IP - 1 DP - 2023 Apr 20 TI - Multi-disciplinary care in patients with complex pediatric general and thoracic surgical pathology: lessons learned from a 20-year experience. PG - 184 LID - 10.1007/s00383-023-05456-4 [doi] AB - PURPOSE: Complex pediatric surgery patients with thoracic tumors invading the mediastinum and infradiaphragmatic tumors extending into the chest are at risk for surgical morbidity and mortality if the patient's care is not coordinated. We sought to identify areas of focus when managing these patients to improve care. METHODS: A 20-year, retrospective study of pediatric patients with complex surgical pathology was performed. Demographic data, pre-operative characteristics, intraoperative data, complications, and outcomes data were collected. Three index cases were highlighted to provide granularity in patient management. RESULTS: Twenty-six patients were identified. Common pathology included mediastinal teratomas, foregut duplications, advanced Wilms tumors, hepatoblastoma, and lung masses. All cases were performed in a multidisciplinary fashion. All cases were done with pediatric cardiothoracic surgery and three cases (11.5%) required pediatric otolaryngology. Eight patients (30.7%) required cardiopulmonary bypass. Operative and 30-day mortality was zero. CONCLUSIONS: Management of complex pediatric surgical patients requires a multidisciplinary approach throughout the patient's hospital course. This multidisciplinary team should meet in advance of a patient's procedure to create a customized care plan that may include pre-operative optimization. At the time of their procedure, all necessary and emergency equipment should available. This approach improves patient safety and has resulted in excellent outcomes. LEVEL OF EVIDENCE: IV. CI - (c) 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Keller, Benjamin A AU - Keller BA AD - Division of Pediatric Surgery, Department of Surgery, Rady Children's Hospital, University of California San Diego, 3030 Children's Way Medical Office Building 1st Floor South, San Diego, CA, 92123, USA. bakeller@health.ucsd.edu. FAU - Saenz, Nicholas C AU - Saenz NC AD - Division of Pediatric Surgery, Department of Surgery, Rady Children's Hospital, University of California San Diego, 3030 Children's Way Medical Office Building 1st Floor South, San Diego, CA, 92123, USA. LA - eng PT - Journal Article DEP - 20230420 PL - Germany TA - Pediatr Surg Int JT - Pediatric surgery international JID - 8609169 SB - IM MH - Humans MH - Child MH - Retrospective Studies MH - *Specialties, Surgical OTO - NOTNLM OT - Complex operative cases OT - Multidisciplinary care OT - Surgical optimization EDAT- 2023/04/20 13:41 MHDA- 2023/04/24 06:41 CRDT- 2023/04/20 11:18 PHST- 2023/04/03 00:00 [accepted] PHST- 2023/04/24 06:41 [medline] PHST- 2023/04/20 13:41 [pubmed] PHST- 2023/04/20 11:18 [entrez] AID - 10.1007/s00383-023-05456-4 [pii] AID - 10.1007/s00383-023-05456-4 [doi] PST - epublish SO - Pediatr Surg Int. 2023 Apr 20;39(1):184. doi: 10.1007/s00383-023-05456-4. PMID- 37077441 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230421 IS - 2666-0849 (Electronic) IS - 2666-0849 (Linking) VI - 11 DP - 2023 Apr 5 TI - Infective Endocarditis in Adults With Congenital Heart Disease: Never Stop Digging-The Role of Multimodality Imaging. PG - 101798 LID - 10.1016/j.jaccas.2023.101798 [doi] LID - 101798 AB - A challenging case of infective endocarditis in a young woman with repaired tetralogy of Fallot and a diagnosis of ankylosing spondylitis is described. Despite the presence of multiple confounding factors, a multidisciplinary approach with the use of multimodality cardiac imaging allowed a correct diagnosis and effective medical treatment. (Level of Difficulty: Intermediate.). CI - (c) 2023 The Authors. FAU - Roma, Anna Selvaggia AU - Roma AS AD - Adult Congenital Heart Disease Unit, AO dei Colli, Monaldi Hospital, Naples, Italy. FAU - Fusco, Flavia AU - Fusco F AD - Adult Congenital Heart Disease Unit, AO dei Colli, Monaldi Hospital, Naples, Italy. FAU - D'Arienzo, Davide AU - D'Arienzo D AD - Nuclear Medicine Unit, AO dei Colli, Monaldi Hospital, Naples, Italy. FAU - De Rimini, Maria Luisa AU - De Rimini ML AD - Nuclear Medicine Unit, AO dei Colli, Monaldi Hospital, Naples, Italy. FAU - Scognamiglio, Giancarlo AU - Scognamiglio G AD - Adult Congenital Heart Disease Unit, AO dei Colli, Monaldi Hospital, Naples, Italy. FAU - Sarubbi, Berardo AU - Sarubbi B AD - Adult Congenital Heart Disease Unit, AO dei Colli, Monaldi Hospital, Naples, Italy. LA - eng PT - Journal Article DEP - 20230302 PL - Netherlands TA - JACC Case Rep JT - JACC. Case reports JID - 101757292 PMC - PMC10107041 OTO - NOTNLM OT - FDG PET/CT OT - adult congenital heart disease OT - case report OT - infective endocarditis OT - multimodality imaging OT - pulmonary valve prosthesis OT - transcatheter pulmonary valve COIS- The authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2023/04/20 06:42 MHDA- 2023/04/20 06:43 PMCR- 2023/03/02 CRDT- 2023/04/20 02:19 PHST- 2023/01/05 00:00 [received] PHST- 2023/02/09 00:00 [accepted] PHST- 2023/04/20 06:43 [medline] PHST- 2023/04/20 06:42 [pubmed] PHST- 2023/04/20 02:19 [entrez] PHST- 2023/03/02 00:00 [pmc-release] AID - S2666-0849(23)00074-8 [pii] AID - 101798 [pii] AID - 10.1016/j.jaccas.2023.101798 [doi] PST - epublish SO - JACC Case Rep. 2023 Mar 2;11:101798. doi: 10.1016/j.jaccas.2023.101798. eCollection 2023 Apr 5. PMID- 37076226 OWN - NLM STAT- MEDLINE DCOM- 20230421 LR - 20230506 IS - 1877-9190 (Electronic) IS - 1877-9182 (Linking) VI - 15 IP - 2 DP - 2023 Jun TI - Pre-cath Laboratory Planning for Left Atrial Appendage Occlusion - Optional or Essential? PG - 141-150 LID - S1877-9182(23)00020-5 [pii] LID - 10.1016/j.ccep.2023.01.009 [doi] AB - In the wake of rapid advancement in cardiovascular procedural technologies, physician-led preprocedural planning utilizing multi-modality imaging training is increasingly recognized as invaluable for procedural accuracy. Left atrial appendage occlusion (LAAO) is one such procedure in which complications such as device leak, cardiac injury, and device embolization can be decreased substantially with incorporation of physician driven imaging and digital tools. We discuss the benefits of cardiac CT and 3D printing in preprocedural planning for the Heart Team, as well as novel applications by physicians of intraprocedural 3D angiography and dynamic fusion imaging. Furthermore, incorporation of computational modeling and artificial intelligence (AI) may yield promise. For optimal patient-centric procedural success, we advocate for standardized preprocedural imaging planning by physicians within the Heart Team as an essential part of LAAO. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Devgun, Jasneet AU - Devgun J AD - Division of Cardiology, Henry Ford Health System, 2799 West Grand Boulevard, Clara Ford Pavilion, Detroit, MI 48202, USA. FAU - De Potter, Tom AU - De Potter T AD - Cardiovascular Center, Onze-Lieve-Vrouwziekenhuis Hospital, Moorselbaan 164, Aalst 9300, Belgium. FAU - Fabbricatore, Davide AU - Fabbricatore D AD - Cardiovascular Center, Onze-Lieve-Vrouwziekenhuis Hospital, Moorselbaan 164, Aalst 9300, Belgium. FAU - Wang, Dee Dee AU - Wang DD AD - Division of Cardiology, Henry Ford Health System, 2799 West Grand Boulevard, Clara Ford Pavilion, Detroit, MI 48202, USA. Electronic address: dwang2@hfhs.org. LA - eng PT - Journal Article PT - Review PL - United States TA - Card Electrophysiol Clin JT - Cardiac electrophysiology clinics JID - 101549998 SB - IM MH - Humans MH - *Atrial Appendage/diagnostic imaging/surgery MH - Treatment Outcome MH - Artificial Intelligence MH - *Atrial Fibrillation/diagnostic imaging/surgery MH - Echocardiography, Transesophageal/methods MH - Cardiac Catheterization/methods OTO - NOTNLM OT - 3D printing OT - Atrial fibrillation OT - Cardiac CT OT - Imaging OT - Left atrial appendage OT - Left atrial appendage occlusion OT - Structural heart disease COIS- Disclosure Dr D.D. Wang is a consultant for Edwards Lifesciences, Boston Scientific, Abbott, and Neochord. Dr D.D. Wang receives a research grant from Boston Scientific assigned to employer Henry Ford Health System not associated with this article. Dr T. De Potter consults for and received research grants not associated with this article from Boston Scientific, for which all invoices and payments are made directly to nonprofit "Cardiovascular Research Institute Aalst." All other authors report no relevant financial disclosures. EDAT- 2023/04/20 00:41 MHDA- 2023/04/21 06:41 CRDT- 2023/04/19 20:57 PHST- 2023/04/21 06:41 [medline] PHST- 2023/04/20 00:41 [pubmed] PHST- 2023/04/19 20:57 [entrez] AID - S1877-9182(23)00020-5 [pii] AID - 10.1016/j.ccep.2023.01.009 [doi] PST - ppublish SO - Card Electrophysiol Clin. 2023 Jun;15(2):141-150. doi: 10.1016/j.ccep.2023.01.009. PMID- 37076225 OWN - NLM STAT- MEDLINE DCOM- 20230421 LR - 20230506 IS - 1877-9190 (Electronic) IS - 1877-9182 (Linking) VI - 15 IP - 2 DP - 2023 Jun TI - Left Atrial Appendage Occlusion-A Choice or a Last Resort? How to Approach the Patient. PG - 133-140 LID - S1877-9182(23)00017-5 [pii] LID - 10.1016/j.ccep.2023.01.006 [doi] AB - Left atrial appendage (LAA) occlusion is emerging as a viable alternative to oral anticoagulation in high-risk patients with atrial fibrillation. However, there remains limited evidence for this approach, especially in certain subgroups, and therefore patient selection is an important aspect of treatment. Here, the authors present arguments for LAA occlusion as either a last resort versus patient choice by evaluating contemporary studies on this topic and discuss practical steps in the approach of patients who may be suitable for LAA occlusion. Overall, an individualized and multidisciplinary team approach should be adopted in patients who are being considered for LAA occlusion. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Ding, Wern Yew AU - Ding WY AD - Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK. FAU - Lip, Gregory Y H AU - Lip GYH AD - Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK; Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. FAU - Gupta, Dhiraj AU - Gupta D AD - Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK. Electronic address: Dhiraj.Gupta@lhch.nhs.uk. LA - eng PT - Journal Article PT - Review PL - United States TA - Card Electrophysiol Clin JT - Cardiac electrophysiology clinics JID - 101549998 SB - IM MH - Humans MH - *Stroke MH - *Atrial Appendage MH - Treatment Outcome MH - *Atrial Fibrillation MH - Echocardiography, Transesophageal OTO - NOTNLM OT - Anticoagulation OT - Atrial fibrillation OT - Closure OT - Left atrial appendage OT - Occlusion OT - Patient choice COIS- Disclosure W.Y. Ding: none declared. G.Y.H. Lip: consultant and speaker for BMS/Pfizer, Boehringer Ingelheim, and Daiichi-Sankyo. No fees are directly received personally. D. Gupta: Speaker for Boehringer Ingelheim, Biosense Webster, and Boston Scientific; Proctor for Abbott. Research Grants from Medtronic, Biosense Webster, and Boston Scientific. All authors declare no conflict of interest. EDAT- 2023/04/20 00:41 MHDA- 2023/04/21 06:41 CRDT- 2023/04/19 20:57 PHST- 2023/04/21 06:41 [medline] PHST- 2023/04/20 00:41 [pubmed] PHST- 2023/04/19 20:57 [entrez] AID - S1877-9182(23)00017-5 [pii] AID - 10.1016/j.ccep.2023.01.006 [doi] PST - ppublish SO - Card Electrophysiol Clin. 2023 Jun;15(2):133-140. doi: 10.1016/j.ccep.2023.01.006. PMID- 37075805 OWN - NLM STAT- MEDLINE DCOM- 20230707 LR - 20230919 IS - 1869-0327 (Electronic) IS - 1869-0327 (Linking) VI - 14 IP - 3 DP - 2023 May TI - Implementation of 2D Barcode Medication Labels and Smart Pumps in Pediatric Acute Care: Lessons Learned. PG - 503-512 LID - 10.1055/a-2077-2457 [doi] AB - BACKGROUND: In pediatric intensive care, prescription, administration, and interpretation of drug doses are weight dependent. The use of standardized concentrations simplifies the preparation of drugs and increases safety. For safe administration as well as easy interpretation of intravenous drug dosing regimens with standardized concentrations, the display of weight-related dose rates on the infusion device is of pivotal significance. OBJECTIVES: We report on challenges in the implementation of a new information technology-supported medication workflow. The workflow was introduced on eight beds in the pediatric heart surgery intensive care unit as well as in the pediatric anesthesia at the University of Bonn Medical Center. The proposed workflow utilizes medication labels generated from prescription data from the electronic health record. The generated labels include a two-dimensional barcode to transfer data to the infusion devices. METHODS: Clinical and technical processes were agilely developed. The reliability of the system under real-life conditions was monitored. User satisfaction and potential for improvement were assessed. In addition, a structured survey among the nursing staff was performed. The questionnaire addressed usability as well as the end-users' perception of the effects on patient safety. RESULTS: The workflow has been applied 44,111 times during the pilot phase. A total of 114 known failures in the technical infrastructure were observed. The survey showed good ratings for usability and safety (median "school grade" 2 or B for patient safety, intelligibility, patient identification, and handling). The medical management of the involved acute care facilities rated the process as clearly beneficial regarding patient safety, suggesting a rollout to all pediatric intensive care areas. CONCLUSION: A medical information technology-supported medication workflow can increase user satisfaction and patient safety as perceived by the clinical end-users in pediatric acute care. The successful implementation benefits from an interdisciplinary team, active investigation of possible associated risks, and technical redundancy. CI - The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/). FAU - Erdfelder, Felix AU - Erdfelder F AD - Staff Unit for Medical and Scientific Technology Development and Coordination, University Hospital Bonn, Bonn, Germany. AD - Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn, Bonn, Germany. AD - Applied Mathematical Physiology (AMP) Lab, Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn, Bonn, Germany. AD - Applied Medical Informatics (AMI) Lab, Institute for Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, Bonn, Germany. FAU - Ebach, Fabian AU - Ebach F AD - Department of Neonatology and Pediatric Critical Care, University Hospital Bonn, Bonn, Germany. FAU - Zoller, Richard AU - Zoller R AD - Staff Unit for Medical and Scientific Technology Development and Coordination, University Hospital Bonn, Bonn, Germany. FAU - Walterscheid, Verena AU - Walterscheid V AD - Staff Unit for Medical and Scientific Technology Development and Coordination, University Hospital Bonn, Bonn, Germany. AD - Department of Neonatology and Pediatric Critical Care, University Hospital Bonn, Bonn, Germany. FAU - Weiss, Claudia AU - Weiss C AD - Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn, Bonn, Germany. FAU - Kappler, Jochen AU - Kappler J AD - Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn, Bonn, Germany. FAU - Gortzen-Patin, Jan AU - Gortzen-Patin J AD - Staff Unit for Medical and Scientific Technology Development and Coordination, University Hospital Bonn, Bonn, Germany. AD - Applied Medical Informatics (AMI) Lab, Institute for Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, Bonn, Germany. AD - Department of Internal Medicine I - Gastroenterology and Hepatology, Nephrology, Infectious Diseases, Endocrinology and Diabetology, University Hospital Bonn, Bonn, Germany. FAU - Schmitt, Joachim AU - Schmitt J AD - Department of Neonatology and Pediatric Critical Care, University Hospital Bonn, Bonn, Germany. FAU - Freudenthal, Noa J AU - Freudenthal NJ AD - Pediatric Cardiac Surgery at the German Pediatric Heart Centre in Bonn, University Hospital Bonn, Bonn, Germany. FAU - Muller, A AU - Muller A AD - Department of Neonatology and Pediatric Critical Care, University Hospital Bonn, Bonn, Germany. FAU - Ksellmann, Anne AU - Ksellmann A AD - Pediatric Cardiac Surgery at the German Pediatric Heart Centre in Bonn, University Hospital Bonn, Bonn, Germany. FAU - Grigutsch, Daniel AU - Grigutsch D AD - Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn, Bonn, Germany. AD - Applied Medical Informatics (AMI) Lab, Institute for Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, Bonn, Germany. FAU - Kulshammer, Manuel AU - Kulshammer M AD - Staff Unit for Medical and Scientific Technology Development and Coordination, University Hospital Bonn, Bonn, Germany. AD - Department of Neonatology and Pediatric Critical Care, University Hospital Bonn, Bonn, Germany. FAU - Fussel, Maike AU - Fussel M AD - Staff Unit for Medical and Scientific Technology Development and Coordination, University Hospital Bonn, Bonn, Germany. AD - Department of Neonatology and Pediatric Critical Care, University Hospital Bonn, Bonn, Germany. FAU - Zenker, Sven AU - Zenker S AD - Staff Unit for Medical and Scientific Technology Development and Coordination, University Hospital Bonn, Bonn, Germany. AD - Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn, Bonn, Germany. AD - Applied Mathematical Physiology (AMP) Lab, Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn, Bonn, Germany. AD - Applied Medical Informatics (AMI) Lab, Institute for Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, Bonn, Germany. LA - eng PT - Journal Article DEP - 20230419 PL - Germany TA - Appl Clin Inform JT - Applied clinical informatics JID - 101537732 SB - IM MH - Humans MH - Child MH - *Medication Errors/prevention & control MH - Reproducibility of Results MH - *Patient Safety MH - Intensive Care Units, Pediatric MH - Critical Care PMC - PMC10322227 COIS- None declared. EDAT- 2023/04/20 00:41 MHDA- 2023/07/07 06:42 PMCR- 2023/07/01 CRDT- 2023/04/19 19:13 PHST- 2023/07/07 06:42 [medline] PHST- 2023/04/20 00:41 [pubmed] PHST- 2023/04/19 19:13 [entrez] PHST- 2023/07/01 00:00 [pmc-release] AID - ACI-2022-08-RA-0207 [pii] AID - 10.1055/a-2077-2457 [doi] PST - ppublish SO - Appl Clin Inform. 2023 May;14(3):503-512. doi: 10.1055/a-2077-2457. Epub 2023 Apr 19. PMID- 37070401 OWN - NLM STAT- MEDLINE DCOM- 20230710 LR - 20230718 IS - 1535-2900 (Electronic) IS - 1079-2082 (Linking) VI - 80 IP - 14 DP - 2023 Jul 7 TI - Extracorporeal cardiopulmonary resuscitation: A primer for pharmacists. PG - 889-898 LID - 10.1093/ajhp/zxad077 [doi] AB - PURPOSE: To describe the use of mechanical circulatory support in the setting of cardiac arrest and summarize pharmacists' role in extracorporeal cardiopulmonary resuscitation (ECPR). SUMMARY: ECPR is increasingly used to reduce morbidity and improve mortality after cardiac arrest. ECPR employs venoarterial ECMO, which provides full circulatory perfusion and gas exchange in both adult and pediatric patients in cardiac arrest. After the emergency medicine team identifies potential candidates for ECPR, the ECMO team is consulted. If deemed a candidate for ECPR by the ECMO team, the patient is cannulated during ongoing standard cardiopulmonary resuscitation. A multidisciplinary team of physicians, nurses, perfusionists, pharmacists, and support staff is needed for successful ECPR. Pharmacists play a vital role in advanced cardiac life support (ACLS) prior to cannulation. Pharmacists intervene to make pharmacotherapy recommendations during ACLS, prepare medications, and administer medications as allowed by institutional and state regulations. Pharmacists also provide pharmacotherapy support in the selection of anticoagulation agents, ongoing vasopressor administration during ECMO cannulation, and the optimization of medication selection in the peri-ECPR period. CONCLUSION: With the growing use of ECPR, pharmacists should be aware of their role in medication optimization during ECPR. CI - (c) American Society of Health-System Pharmacists 2023. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. FAU - Brown, Caitlin S AU - Brown CS AD - Department of Pharmacy and Department of Emergency Medicine, Mayo Clinic, Rochester, MN, USA. FAU - Wieruszewski, Erin D AU - Wieruszewski ED AD - Department of Pharmacy and Department of Emergency Medicine, Mayo Clinic, Rochester, MN, USA. FAU - Nei, Scott D AU - Nei SD AD - Department of Pharmacy, Mayo Clinic, Rochester, MN, USA. FAU - Vollmer, Nicholas J AU - Vollmer NJ AD - Department of Pharmacy, Mayo Clinic, Rochester, MN, USA. FAU - Mattson, Alicia E AU - Mattson AE AD - Department of Pharmacy, Mayo Clinic, Rochester, MN, USA. FAU - Wieruszewski, Patrick M AU - Wieruszewski PM AD - Department of Pharmacy and Department of Anesthesiology, Mayo Clinic, Rochester, MN, USA. LA - eng PT - Journal Article PL - England TA - Am J Health Syst Pharm JT - American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists JID - 9503023 SB - IM MH - Adult MH - Humans MH - Child MH - Pharmacists MH - *Cardiopulmonary Resuscitation MH - *Heart Arrest/therapy MH - *Extracorporeal Membrane Oxygenation MH - Advanced Cardiac Life Support MH - Retrospective Studies OTO - NOTNLM OT - cardiac arrest OT - pharmacist services OT - resuscitation OT - shock EDAT- 2023/04/19 06:00 MHDA- 2023/07/10 06:42 CRDT- 2023/04/18 04:43 PHST- 2023/07/10 06:42 [medline] PHST- 2023/04/19 06:00 [pubmed] PHST- 2023/04/18 04:43 [entrez] AID - 7127414 [pii] AID - 10.1093/ajhp/zxad077 [doi] PST - ppublish SO - Am J Health Syst Pharm. 2023 Jul 7;80(14):889-898. doi: 10.1093/ajhp/zxad077. PMID- 37068854 OWN - NLM STAT- MEDLINE DCOM- 20230419 LR - 20230424 IS - 2399-6641 (Electronic) IS - 2399-6641 (Linking) VI - 12 IP - 2 DP - 2023 Apr TI - Developing a post-myocardial infarction medicines optimisation clinic: core competencies for upskilling pharmacists and initial patient feedback. LID - 10.1136/bmjoq-2022-002152 [doi] LID - e002152 AB - BACKGROUND: Medicines optimisation and adherence support are essential to secondary prevention after myocardial infarction (MI). Following successful implementation of a consultant pharmacist-led post-MI medicines optimisation clinic, the service was expanded by training advanced clinical pharmacists to manage clinics (with appropriate multidisciplinary team support). METHODS: Key steps in the development process were: definition of a key competency framework based on relevant qualifications and experience, knowledge, skills and clinic management practicalities; creation and enaction of trainee-specific development plans to address gaps (including independent learning, teaching from multidisciplinary colleagues and shadowing in clinics); establishment of relevant protocols and proformas to ensure consistent standards (eg, a patient self-reporting tool for identifying adherence barriers, consultation proforma, directory of clinical parameters and pathway for onward referral when needed); phased clinic roll-out, initially under supervision; and gathering of feedback from patients and colleagues. Clinic letters from 50 attending patients were reviewed to quantify resulting interventions; the first 50 anonymously completed patient feedback questionnaires were also analysed. RESULTS: Expansion of the service initially doubled capacity. A review of clinic letters from attending patients demonstrated that various interventions were recommended, including further investigations, medication changes, lifestyle adjustments and onward referrals. Most respondents to the patient feedback questionnaire thought the clinic was patient friendly and welcoming (n=48/50; 96%); felt listened to (n=48/50; 96%); considered that adequate explanation was given (n=47/50; 94%); and felt clear plans were provided (n=45/49; 92%). Most agreed that it was valuable (n=44/50; 88%), and the mean rating was 4.48 (on a scale of 1 (very poor) to 5 (excellent)). CONCLUSIONS: A person-centred post-MI medicines optimisation service was successfully delivered by appropriately trained advanced cardiology pharmacists. A structured competency framework and training programme were required, but once completed, the clinic was highly valued by patients. A similar model could be rolled out elsewhere with adaption to local requirements. CI - (c) Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Price, Ruth AU - Price R AUID- ORCID: 0000-0001-5781-2550 AD - Cardio-Respiratory Department, Leeds Teaching Hospitals NHS Trust, Leeds, UK. AD - Pharmacy Department, Leeds Teaching Hospitals NHS Trust, Leeds, UK. FAU - Wilson, Franki AU - Wilson F AD - Pharmacy Department, Leeds Teaching Hospitals NHS Trust, Leeds, UK. FAU - Hall, Alistair AU - Hall A AD - Cardio-Respiratory Department, Leeds Teaching Hospitals NHS Trust, Leeds, UK. AD - Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK. FAU - McGawley, Gina AU - McGawley G AD - Cardio-Respiratory Department, Leeds Teaching Hospitals NHS Trust, Leeds, UK. FAU - Laverty, Una AU - Laverty U AD - Pharmacy Department, Leeds Teaching Hospitals NHS Trust, Leeds, UK. FAU - Pepper, Chris AU - Pepper C AD - Cardio-Respiratory Department, Leeds Teaching Hospitals NHS Trust, Leeds, UK. FAU - Khatib, Rani AU - Khatib R AD - Cardio-Respiratory Department, Leeds Teaching Hospitals NHS Trust, Leeds, UK r.khatib@leeds.ac.uk. AD - Pharmacy Department, Leeds Teaching Hospitals NHS Trust, Leeds, UK. AD - Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review PL - England TA - BMJ Open Qual JT - BMJ open quality JID - 101710381 SB - IM MH - Humans MH - *Pharmacists MH - Feedback MH - Surveys and Questionnaires MH - Self Report MH - *Myocardial Infarction/drug therapy PMC - PMC10111893 OTO - NOTNLM OT - Health professions education OT - Healthcare quality improvement OT - Hospital medicine OT - Patient-centred care OT - Pharmacists COIS- Competing interests: None declared. EDAT- 2023/04/18 06:00 MHDA- 2023/04/19 06:42 PMCR- 2023/04/17 CRDT- 2023/04/17 20:53 PHST- 2022/10/12 00:00 [received] PHST- 2023/04/01 00:00 [accepted] PHST- 2023/04/19 06:42 [medline] PHST- 2023/04/17 20:53 [entrez] PHST- 2023/04/18 06:00 [pubmed] PHST- 2023/04/17 00:00 [pmc-release] AID - bmjoq-2022-002152 [pii] AID - 10.1136/bmjoq-2022-002152 [doi] PST - ppublish SO - BMJ Open Qual. 2023 Apr;12(2):e002152. doi: 10.1136/bmjoq-2022-002152. PMID- 37067856 OWN - NLM STAT- MEDLINE DCOM- 20230517 LR - 20230626 IS - 1573-2665 (Electronic) IS - 0141-8955 (Linking) VI - 46 IP - 3 DP - 2023 May TI - Safety, efficacy, and timing of transplantation(s) in propionic and methylmalonic aciduria. PG - 466-481 LID - 10.1002/jimd.12613 [doi] AB - Propionic (PA) and methylmalonic aciduria (MMA) share many clinical similarities, which include the risk of acute metabolic encephalopathies, and some long-term complications, such as optic neuropathy, pancreatic involvement, developmental disability, and similar management approaches, but they also represent distinct clinical and biochemical entities. In the severe forms of PA and MMA, most long-term complications cannot be prevented with conventional clinical management. Organ transplantation represents a form of partial enzyme replacement to improve the long-term outlook for these disorders. There is evidence that early liver transplant in both disorders greatly improves metabolic stability and reduces the risk of long-term complications. For MMA, early liver transplant reduces methylmalonic acid levels which in turns reduces its effects on kidneys, and therefore slows progression of chronic kidney disease. However, established organ damage cannot be reversed. For patients with MMA who present with chronic kidney disease, consideration should be given for combined liver and kidney transplants. Transplantation in PA and MMA carries a high risk of complications and requires highly specialised pre-operative and peri-operative management. Involvement of a multidisciplinary team is essential and should include metabolic team, nephrologist, hepatologist, hepatobiliary and renal transplant surgeons, anaesthesiologists, cardiologists, intensive care team, dieticians and specialist nurses. These patients require life-long multidisciplinary follow-up. There is increasing evidence in the literature on excellent short to medium-term patient and allograft survival following transplantation when patients are managed by a multidisciplinary team in a specialist centre. Improved early diagnosis and reductions in transplant-related mortality and morbidity have allowed early transplantation to be used electively to further improve the outcome. CI - (c) 2023 SSIEM. FAU - Chakrapani, Anupam AU - Chakrapani A AUID- ORCID: 0000-0002-0789-0945 AD - Department of Metabolic Medicine, Great Ormond Street Hospital NHS Foundation Trust, London, UK. AD - University College Hospital, London, UK. FAU - Stojanovic, Jelena AU - Stojanovic J AUID- ORCID: 0000-0001-9887-9081 AD - University College Hospital, London, UK. AD - Department of Paediatric Nephrology and Transplantation, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK. FAU - Vara, Roshni AU - Vara R AUID- ORCID: 0000-0002-4007-6558 AD - Department of Paediatric Inherited Metabolic Diseases, Evelina London Children's Hospital, St Thomas' Hospital, London, UK. FAU - De Nictolis, Francesca AU - De Nictolis F AUID- ORCID: 0000-0002-1723-9881 AD - Division of Metabolic Diseases, Bambino Gesu Children's Hospital IRCCS, Rome, Italy. FAU - Spada, Marco AU - Spada M AUID- ORCID: 0000-0003-0796-6847 AD - Unit of Hepato-biliary-pancreatic Surgery, Bambino Gesu Children's Hospital IRCCS, Rome, Italy. FAU - Dionisi-Vici, Carlo AU - Dionisi-Vici C AUID- ORCID: 0000-0002-0007-3379 AD - Division of Metabolic Diseases, Bambino Gesu Children's Hospital IRCCS, Rome, Italy. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20230424 PL - United States TA - J Inherit Metab Dis JT - Journal of inherited metabolic disease JID - 7910918 RN - 8LL8S712J7 (Methylmalonic Acid) RN - Methylmalonic acidemia SB - IM MH - Humans MH - *Amino Acid Metabolism, Inborn Errors/diagnosis MH - *Liver Transplantation MH - *Kidney Transplantation/adverse effects MH - *Renal Insufficiency, Chronic/complications MH - Methylmalonic Acid MH - *Propionic Acidemia/diagnosis OTO - NOTNLM OT - liver and kidney transplantation OT - liver transplantation OT - methylmalonic aciduria OT - propionic aciduria EDAT- 2023/04/18 06:00 MHDA- 2023/05/17 06:42 CRDT- 2023/04/17 11:53 PHST- 2023/04/12 00:00 [revised] PHST- 2022/12/27 00:00 [received] PHST- 2023/04/14 00:00 [accepted] PHST- 2023/05/17 06:42 [medline] PHST- 2023/04/18 06:00 [pubmed] PHST- 2023/04/17 11:53 [entrez] AID - 10.1002/jimd.12613 [doi] PST - ppublish SO - J Inherit Metab Dis. 2023 May;46(3):466-481. doi: 10.1002/jimd.12613. Epub 2023 Apr 24. PMID- 37066841 OWN - NLM STAT- MEDLINE DCOM- 20241016 LR - 20241016 IS - 2046-5556 (Electronic) IS - 0264-8725 (Linking) VI - 40 IP - 3 DP - 2024 Nov TI - Analysis of the effectiveness of multi-disciplinary team integrated management combined with full-media health education intervention in patients with coronary heart disease and diabetes mellitus. PG - 2745-2759 LID - 10.1080/02648725.2023.2202518 [doi] AB - OBJECTIVE: To study the effect of a multi-disciplinary team (MDT) integrated management combined with all-media health education intervention on patients with coronary heart disease (CHD) and diabetes mellitus (DM). METHODS: Fasting plasma glucose (FPG), systolic blood pressure (SBP), and total cholesterol (TC) were evaluated before and after the intervention. The general self-efficacy scale (GSES) was utilized to assess the self-efficacy. Self-rating anxiety scale (SAS) and self-rating depression scale (SDS) were used to evaluate depression and anxiety. The Seattle Angina Questionnaire (SAQ), a CHD-specific functional status and quality of life self-measurement tool, was employed to evaluate the quality of life. RESULTS: After the intervention, the levels of FPG, systolic blood pressure, SAS, SDS, and TC in the three groups all decreased (C>B>A,P<0.05). After the intervention, the self-efficacy scores of all three groups were improved (A>B>C, P < 0.05). After the intervention, the score of quality of life in group A and group B was higher than that in group C, and the score in group A was higher than that in group B (P<0.05). CONCLUSION: MDT integrated management combined with all-media health education intervention can effectively ameliorate blood glucose, blood pressure, and blood lipids of patients with CHD and DM, promote their healthy life, improve their self-efficacy, and improve their negative emotions and quality of life. FAU - Lu, Caiping AU - Lu C AD - Department of Medicine, Henan Vocational University of Science and Technology, Zhoukou, Henan, China. LA - eng PT - Journal Article DEP - 20230417 PL - England TA - Biotechnol Genet Eng Rev JT - Biotechnology & genetic engineering reviews JID - 8510274 RN - 0 (Blood Glucose) SB - IM MH - Humans MH - *Coronary Disease/therapy MH - *Quality of Life MH - Male MH - Female MH - *Diabetes Mellitus/therapy MH - Middle Aged MH - *Health Education/methods MH - Patient Care Team MH - Blood Glucose/analysis MH - Blood Pressure MH - Aged MH - Self Efficacy MH - Surveys and Questionnaires OTO - NOTNLM OT - all-media health education intervention OT - coronary heart disease (CHD) OT - diabetes mellitus (DM) OT - multi-disciplinary team EDAT- 2023/04/18 06:00 MHDA- 2024/10/16 12:24 CRDT- 2023/04/17 05:42 PHST- 2024/10/16 12:24 [medline] PHST- 2023/04/18 06:00 [pubmed] PHST- 2023/04/17 05:42 [entrez] AID - 10.1080/02648725.2023.2202518 [doi] PST - ppublish SO - Biotechnol Genet Eng Rev. 2024 Nov;40(3):2745-2759. doi: 10.1080/02648725.2023.2202518. Epub 2023 Apr 17. PMID- 37063675 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240413 IS - 2296-2360 (Print) IS - 2296-2360 (Electronic) IS - 2296-2360 (Linking) VI - 11 DP - 2023 TI - A multidisciplinary approach to severe bronchopulmonary dysplasia is associated with resolution of pulmonary hypertension. PG - 1077422 LID - 10.3389/fped.2023.1077422 [doi] LID - 1077422 AB - OBJECTIVE: To describe our multidisciplinary bronchopulmonary dysplasia (BPD) consult team's systematic approach to BPD associated pulmonary hypertension (PH), to report our center outcomes, and to evaluate clinical associations with outcomes. STUDY DESIGN: Retrospective cohort of 60 patients with BPD-PH who were referred to the Seattle Children's Hospital BPD team from 2018 to 2020. Patients with critical congenital heart disease were excluded. Demographics, comorbidities, treatments, closure of hemodynamically relevant intracardiac shunts, and clinical outcomes including time to BPD-PH resolution were reviewed. RESULTS: Median gestational age of the 60 patients was 25 weeks (IQR: 24-26). 20% were small for gestational age (SGA), 65% were male, and 25% received a tracheostomy. With aggressive cardiopulmonary management including respiratory support optimization, patent ductus arteriosus (PDA) and atrial septal defect (ASD) closure (40% PDA, 5% ASD, 3% both), and limited use of pulmonary vasodilators (8%), all infants demonstrated resolution of PH during the follow-up period, including three (5%) who later died from non-BPD-PH morbidities. Neither SGA status nor the timing of PH diagnosis (<36 vs. >/=36 weeks PMA) impacted the time to BPD-PH resolution in our cohort [median 72 days (IQR 30.5-166.5)]. CONCLUSION: Our multidisciplinary, systematic approach to BPD-PH management was associated with complete resolution of PH with lower mortality despite less sildenafil use than reported in comparable cohorts. Unique features of our approach included aggressive PDA and ASD device closure and rare initiation of sildenafil only after lack of BPD-PH improvement with respiratory support optimization and diagnostic confirmation by cardiac catheterization. CI - (c) 2023 Yung, Jackson, Blumenfeld, Redding, DiGeronimo, McGuire, Riker, Tressel, Berkelhamer and Eldredge. FAU - Yung, Delphine AU - Yung D AD - Division of Cardiology, Department of Pediatrics, University of Washington School of Medicine, Seattle, WA, United States. FAU - Jackson, Emma O AU - Jackson EO AD - Heart Center, Seattle Children's Hospital, Seattle, WA, United States. FAU - Blumenfeld, Alyssa AU - Blumenfeld A AD - Division of Pulmonary and Sleep Medicine, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States. FAU - Redding, Gregory AU - Redding G AD - Division of Pulmonology, Department of Pediatrics, University of Washington School of Medicine, Seattle, WA, United States. FAU - DiGeronimo, Robert AU - DiGeronimo R AD - Division of Neonatology, Department of Pediatrics, University of Washington School of Medicine, and Seattle Children's Hospital, Seattle, WA, United States. FAU - McGuire, John K AU - McGuire JK AD - Division of Critical Care Medicine, Department of Pediatrics, University of Washington School of Medicine, Seattle, WA, United States. FAU - Riker, Meredith AU - Riker M AD - Heart Center, Seattle Children's Hospital, Seattle, WA, United States. FAU - Tressel, William AU - Tressel W AD - Collaborative Health Studies Coordinating Center, Department of Biostatistics, University of Washington, Seattle, WA, United States. FAU - Berkelhamer, Sara AU - Berkelhamer S AD - Division of Neonatology, Department of Pediatrics, University of Washington School of Medicine, and Seattle Children's Hospital, Seattle, WA, United States. FAU - Eldredge, Laurie C AU - Eldredge LC AD - Division of Pulmonology, Department of Pediatrics, University of Washington School of Medicine, Seattle, WA, United States. LA - eng GR - K08 HL140104/HL/NHLBI NIH HHS/United States PT - Journal Article DEP - 20230330 PL - Switzerland TA - Front Pediatr JT - Frontiers in pediatrics JID - 101615492 PMC - PMC10098720 OTO - NOTNLM OT - bronchopulmonary dysplasia OT - miltidisciplinary care OT - neonate OT - pulmonary hypertension OT - sildenafil COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer SB declared a shared affiliation with the author AB to the handling editor at the time of review. EDAT- 2023/04/18 06:00 MHDA- 2023/04/18 06:01 PMCR- 2023/03/30 CRDT- 2023/04/17 03:32 PHST- 2022/10/23 00:00 [received] PHST- 2023/03/08 00:00 [accepted] PHST- 2023/04/18 06:01 [medline] PHST- 2023/04/17 03:32 [entrez] PHST- 2023/04/18 06:00 [pubmed] PHST- 2023/03/30 00:00 [pmc-release] AID - 10.3389/fped.2023.1077422 [doi] PST - epublish SO - Front Pediatr. 2023 Mar 30;11:1077422. doi: 10.3389/fped.2023.1077422. eCollection 2023. PMID- 32491434 STAT- Publisher CTDT- 20230417 PB - StatPearls Publishing DP - 2023 Jan TI - Rivaroxaban. BTI - StatPearls AB - Rivaroxaban is used to treat and manage venous thromboembolism as a postoperative thromboprophylaxis for patients undergoing orthopedic surgery to prevent stroke in patients with non-valvular atrial fibrillation and recently has received approval as an add-on drug for secondary prevention of acute coronary syndrome and peripheral arterial disease. It is a novel oral anticoagulant (NOAC) and is commonly referred to as a blood thinner agent. This activity reviews the indications, contraindications, activity, adverse events, and other key elements of rivaroxaban therapy in the clinical setting as relates to the essential points needed by members of an interprofessional team managing the care of patients with venous and arterial thromboembolism (VTE) and its related conditions and sequelae. CI - Copyright (c) 2023, StatPearls Publishing LLC. FAU - Singh, Rajshree AU - Singh R AD - Mercy Catholic Medical Center FAU - Emmady, Prabhu D AU - Emmady PD AD - UNC school of Medicine, Atrium Health LA - eng PT - Study Guide PT - Book Chapter PL - Treasure Island (FL) COIS- Disclosure: Rajshree Singh declares no relevant financial relationships with ineligible companies. Disclosure: Prabhu D Emmady declares no relevant financial relationships with ineligible companies. EDAT- 2023/04/17 00:00 CRDT- 2023/04/17 00:00 AID - NBK557502 [bookaccession] PMID- 37059640 OWN - NLM STAT- MEDLINE DCOM- 20230605 LR - 20230605 IS - 1532-8422 (Electronic) IS - 1053-0770 (Linking) VI - 37 IP - 7 DP - 2023 Jul TI - How Would We Treat Our Own Heart Transplantation Surgery: A Perioperative Look. PG - 1075-1085 LID - S1053-0770(23)00113-1 [pii] LID - 10.1053/j.jvca.2023.02.024 [doi] AB - Heart failure is a disease affecting 6.2 million adults in the United States, resulting in morbidity and mortality in the short and long terms. Although options such as mechanical circulatory support and transplantation are considered a solution when medical management is insufficient, heart transplantation (HTX) is regarded as the better option, with a lower incidence of multiorgan failure. A limiting step for HTX is the inadequate donor pool, so options like donation after circulatory death and xenotransplantation have emerged as alternatives. The cardiac anesthesiologist plays a pivotal role in the perioperative management of donors and recipients. A full understanding of the nature of the disease, pathophysiology, and perioperative management is paramount to the success of an HTX program. The authors include an index case to illustrate the multidisciplinary approach to the disease and the implications of managing these complex patients presenting to the operating room. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Aljure, Oscar D AU - Aljure OD AD - Division of Cardiovascular and Thoracic Anesthesiology, Department of Anesthesiology, University of Miami, Miami, FL. Electronic address: oaljure@med.miami.edu. FAU - Tan, Derek AU - Tan D AD - Division of Cardiovascular and Thoracic Anesthesiology, Department of Anesthesiology, University of Miami, Miami, FL. FAU - Loebe, Mathias AU - Loebe M AD - Division of Cardiothoracic Transplantation and Mechanical Support, Miami Transplant Institute, University of Miami, Miami, FL. FAU - Phancao, Anita AU - Phancao A AD - Division of Cardiothoracic Transplantation and Mechanical Support, Miami Transplant Institute, University of Miami, Miami, FL. FAU - Ram, Harish AU - Ram H AD - Division of Cardiovascular and Thoracic Anesthesiology, Department of Anesthesiology, University of Miami, Miami, FL. FAU - Mohammed, Neil AU - Mohammed N AD - Division of Cardiovascular and Thoracic Anesthesiology, Department of Anesthesiology, University of Miami, Miami, FL. FAU - Kukucka, Marian AU - Kukucka M AD - Department of Cardiac Anesthesiology and Intensive Care Medicine, Deutsches Herzzentrum der Charite, Berlin, Germany; Charite - Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany. LA - eng PT - Journal Article DEP - 20230220 PL - United States TA - J Cardiothorac Vasc Anesth JT - Journal of cardiothoracic and vascular anesthesia JID - 9110208 SB - IM CIN - J Cardiothorac Vasc Anesth. 2023 Jul;37(7):1086-1087. doi: 10.1053/j.jvca.2023.02.040. PMID: 36990802 MH - Adult MH - Humans MH - United States MH - *Heart Transplantation/methods MH - *Heart Failure/surgery MH - Tissue Donors MH - Morbidity COIS- Declaration of competing interest None. EDAT- 2023/04/15 06:00 MHDA- 2023/06/05 06:42 CRDT- 2023/04/14 21:59 PHST- 2022/06/30 00:00 [received] PHST- 2023/02/06 00:00 [revised] PHST- 2023/02/14 00:00 [accepted] PHST- 2023/06/05 06:42 [medline] PHST- 2023/04/15 06:00 [pubmed] PHST- 2023/04/14 21:59 [entrez] AID - S1053-0770(23)00113-1 [pii] AID - 10.1053/j.jvca.2023.02.024 [doi] PST - ppublish SO - J Cardiothorac Vasc Anesth. 2023 Jul;37(7):1075-1085. doi: 10.1053/j.jvca.2023.02.024. Epub 2023 Feb 20. PMID- 37058724 OWN - NLM STAT- MEDLINE DCOM- 20230418 LR - 20230721 IS - 1526-7598 (Electronic) IS - 0003-2999 (Linking) VI - 136 IP - 5 DP - 2023 May 1 TI - Comprehensive Management of the Patient With Traumatic Cardiac Injury. PG - 877-893 LID - 10.1213/ANE.0000000000006380 [doi] AB - Cardiac injuries are rare but potentially life-threatening, with a significant proportion of victims dying before arrival at the hospital. The in-hospital mortality among patients who arrive in-hospital alive also remains significantly high, despite major advancements in trauma care including the continuous updating of the Advanced Trauma Life Support (ATLS) program. Stab and gunshot wounds due to assault or self-inflicted injuries are the common causes of penetrating cardiac injuries, while motor vehicular accidents and fall from height are attributable causes of blunt cardiac injury. Rapid transport of victim to trauma care facility, prompt recognition of cardiac trauma by clinical evaluation and focused assessment with sonography for trauma (FAST) examination, quick decision-making to perform emergency department thoracotomy, and/or shifting the patient expeditiously to the operating room for operative intervention with ongoing resuscitation are the key components for a successful outcome in cardiac injury victims with cardiac tamponade or exsanguinating hemorrhage. Blunt cardiac injury with arrhythmias, myocardial dysfunction, or cardiac failure may need continuous cardiac monitoring or anesthetic care for operative procedure of other associated injuries. This mandates a multidisciplinary approach working in concert with agreed local protocols and shared goals. An anesthesiologist has a pivotal role to play as a team leader or member in the trauma pathway of severely injured patients. They are not only involved in in-hospital care as a perioperative physician but also participate in the organizational aspects of prehospital trauma systems and training of prehospital care providers/paramedics. There is sparse literature available on the anesthetic management of cardiac injury (penetrating as well as blunt) patients. This narrative review discusses the comprehensive management of cardiac injury patients, focusing on the anesthetic concerns and is guided by our experience in managing cardiac injury cases at Jai Prakash Narayan Apex Trauma Center (JPNATC), All India Institute of Medical Sciences, New Delhi. JPNATC is the only level 1 trauma center in north India, providing services to a population of approximately 30 million with around 9000 operations being performed annually. CI - Copyright (c) 2023 International Anesthesia Research Society. FAU - Gupta, Babita AU - Gupta B AD - From the Department of Anaesthesiology, Pain Medicine and Critical Care, Jai Prakash Narayan Apex Trauma Center, All India Institute of Medical Sciences, New Delhi, India. FAU - Singh, Yudhyavir AU - Singh Y AD - From the Department of Anaesthesiology, Pain Medicine and Critical Care, Jai Prakash Narayan Apex Trauma Center, All India Institute of Medical Sciences, New Delhi, India. FAU - Bagaria, Dinesh AU - Bagaria D AD - Division of Trauma Surgery and Critical Care, Jai Prakash Narayan Apex Trauma Center, All India Institute of Medical Sciences, New Delhi, India. FAU - Nagarajappa, Abhishek AU - Nagarajappa A AD - Department of Anaesthesiology, Pain Medicine and Critical Care, All India Institute of Medical Sciences, New Delhi, India. LA - eng PT - Journal Article PT - Review DEP - 20230414 PL - United States TA - Anesth Analg JT - Anesthesia and analgesia JID - 1310650 SB - IM MH - Humans MH - *Wounds, Gunshot/surgery MH - *Wounds, Penetrating/diagnosis/diagnostic imaging MH - *Heart Injuries/diagnostic imaging/etiology/therapy MH - Resuscitation MH - *Myocardial Contusions MH - Retrospective Studies COIS- The authors declare no conflicts of interest. EDAT- 2023/04/15 06:00 MHDA- 2023/04/18 10:16 CRDT- 2023/04/14 17:32 PHST- 2023/04/18 10:16 [medline] PHST- 2023/04/14 17:32 [entrez] PHST- 2023/04/15 06:00 [pubmed] AID - 00000539-202305000-00009 [pii] AID - 10.1213/ANE.0000000000006380 [doi] PST - ppublish SO - Anesth Analg. 2023 May 1;136(5):877-893. doi: 10.1213/ANE.0000000000006380. Epub 2023 Apr 14. PMID- 37052025 OWN - NLM STAT- MEDLINE DCOM- 20230414 LR - 20230414 IS - 0030-9982 (Print) IS - 0030-9982 (Linking) VI - 73 IP - 4 DP - 2023 Apr TI - Cardiac Rehabilitation for Visceral Obesity: A Multidisciplinary Approach. PG - 944-946 LID - 10.47391/JPMA.23-31 [doi] AB - World Health Organization data indicates a marked rise in global obesity, with approximately 30% of the world's population classified as overweight or obese. The contributory factors include unhealthy dietary habits, lack of physical activity, urbanization, and technology dependent sedentary lifestyle. Among the various management approaches, cardiac rehabilitation has evolved from an exercise-only programme for patients with cardiac diseases to a multi-disciplinary individualised intervention plan for risk factor modification, primary and secondary prevention of cardiometabolic diseases. Evidence suggests that visceral obesity is an independent risk factor of morbidity and mortality from cardiometabolic causes. There are multiple training programmes targeting visceral fat oxidation, one of which is high intensity interval training. It appears to be a promising regime, inducing metabolic adaptations in the body. This review summarizes the multidisciplinary cardiac rehabilitation services for the management of visceral adiposity and generalised obesity, its under-utilization and scarcity of local published data, highlighting the need for future research. FAU - Khalid, Zara AU - Khalid Z AD - Foundation University College of Physical Therapy, Foundation University Islamabad. FAU - Gul, Iram AU - Gul I AD - Department of Behavioral Sciences, Fatima Jinnah Women University Rawalpindi. FAU - Siddiqi, Furqan Ahmed AU - Siddiqi FA AD - Foundation University College of Physical Therapy, Foundation University Islamabad. FAU - Rathore, Farooq Azam AU - Rathore FA AD - Armed Forces Institute of Rehabilitation Medicine (AFIRM), Rawalpindi. LA - eng PT - Journal Article PT - Review PL - Pakistan TA - J Pak Med Assoc JT - JPMA. The Journal of the Pakistan Medical Association JID - 7501162 SB - IM MH - Humans MH - Obesity, Abdominal MH - *Cardiac Rehabilitation MH - Obesity/epidemiology MH - Overweight MH - *Heart Diseases OTO - NOTNLM OT - Adipose tissue, cardiac rehabilitation, cardiometabolic risk factors, high intensity interval training, visceral obesity. EDAT- 2023/04/14 06:00 MHDA- 2023/04/14 06:42 CRDT- 2023/04/13 05:23 PHST- 2023/04/14 06:42 [medline] PHST- 2023/04/13 05:23 [entrez] PHST- 2023/04/14 06:00 [pubmed] AID - 11984 [pii] AID - 10.47391/JPMA.23-31 [doi] PST - ppublish SO - J Pak Med Assoc. 2023 Apr;73(4):944-946. doi: 10.47391/JPMA.23-31. PMID- 37051480 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230415 IS - 2284-2594 (Electronic) IS - 2284-2594 (Linking) VI - 10 IP - 4 DP - 2023 TI - Hiatal Hernia: The Great Masquerade in the Emergency Department. PG - 003834 LID - 10.12890/2023_003834 [doi] LID - 003834 AB - Chest pain and dyspnoea are among the most common complaints seen in the emergency room and each symptom calls for a broad differential diagnosis. Large hiatal hernias are infrequent, but they can lead to atypical symptoms mimicking different cardiovascular, pulmonary and neoplastic diseases. We present two cases of older patients with an apparent left atrial mass on transthoracic echocardiography, which was subsequently identified as hiatal hernia by other imaging modalities. A multidisciplinary team with multimodality imaging is necessary for diagnostic work-up of chest pain and dyspnoea of non-cardiac origin and especially for a suspected mass compressing the heart, causing chest discomfort. LEARNING POINTS: Hiatal hernia (HH) can mimic different cardiovascular, pulmonary and neoplastic diseases.HH has a typical echocardiographic (2DE) presentation as an amorphous, echolucent mass with the appearance of a left atrial space-occupying lesion.Oral ingestion of a carbonated drink may help to distinguish between a large HH and an atrial mass by 2DE. CI - (c) EFIM 2023. FAU - Borizanova, Angelina AU - Borizanova A AD - Department of Emergency medicine, Medical university Sofia, Bulgaria. AD - Clinic of Cardiology, UMHAT "Tsaritsa Yoanna - ISUL" Sofia, Bulgaria. FAU - Kinova, Elena AU - Kinova E AD - Department of Emergency medicine, Medical university Sofia, Bulgaria. AD - Clinic of Cardiology, UMHAT "Tsaritsa Yoanna - ISUL" Sofia, Bulgaria. FAU - Getsov, Plamen AU - Getsov P AD - Department of Imaging diagnostics, Medical university Sofia, Bulgaria. FAU - Peichinov, Dimitar AU - Peichinov D AD - Department of Emergency medicine, Medical university Sofia, Bulgaria. AD - Surgery clinic, UMHAT "Tsaritsa Yoanna - ISUL" Sofia, Bulgaria. FAU - Goudev, Assen AU - Goudev A AD - Department of Emergency medicine, Medical university Sofia, Bulgaria. AD - Clinic of Cardiology, UMHAT "Tsaritsa Yoanna - ISUL" Sofia, Bulgaria. LA - eng PT - Journal Article DEP - 20230321 PL - Italy TA - Eur J Case Rep Intern Med JT - European journal of case reports in internal medicine JID - 101648453 PMC - PMC10084805 OTO - NOTNLM OT - Hiatal hernia OT - carbonated drink OT - echocardiography OT - left atrial mass COIS- Conflicts of Interests: The Authors declare that there are no competing interests. EDAT- 2023/04/14 06:00 MHDA- 2023/04/14 06:01 PMCR- 2023/03/21 CRDT- 2023/04/13 02:03 PHST- 2023/02/28 00:00 [received] PHST- 2023/03/04 00:00 [accepted] PHST- 2023/04/14 06:01 [medline] PHST- 2023/04/13 02:03 [entrez] PHST- 2023/04/14 06:00 [pubmed] PHST- 2023/03/21 00:00 [pmc-release] AID - 3834 [pii] AID - 10.12890/2023_003834 [doi] PST - epublish SO - Eur J Case Rep Intern Med. 2023 Mar 21;10(4):003834. doi: 10.12890/2023_003834. eCollection 2023. PMID- 37050929 OWN - NLM STAT- MEDLINE DCOM- 20230414 LR - 20230415 IS - 1178-2048 (Electronic) IS - 1176-6344 (Print) IS - 1176-6344 (Linking) VI - 19 DP - 2023 TI - Familial Hypertrophic Cardiomyopathy: Diagnosis and Management. PG - 211-221 LID - 10.2147/VHRM.S365001 [doi] AB - Hypertrophic cardiomyopathy (HCM) is widely recognized as one of the most common inheritable cardiac disorders. Since its initial description over 60 years ago, advances in multimodality imaging and translational genetics have revolutionized our understanding of the disorder. The diagnosis and management of patients with HCM are optimized with a multidisciplinary approach. This, along with increased safety and efficacy of medical, percutaneous, and surgical therapies for HCM, has afforded more personalized care and improved outcomes for this patient population. In this review, we will discuss our modern understanding of the molecular pathophysiology that underlies HCM. We will describe the range of clinical presentations and discuss the role of genetic testing in diagnosis. Finally, we will summarize management strategies for the hemodynamic subtypes of HCM with specific emphasis on the rationale and evidence for the use of implantable cardioverter defibrillators, septal reduction therapy, and cardiac myosin inhibitors. CI - (c) 2023 Litt et al. FAU - Litt, Michael J AU - Litt MJ AD - Division of Cardiovascular Medicine, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. FAU - Ali, Ayan AU - Ali A AD - Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. FAU - Reza, Nosheen AU - Reza N AUID- ORCID: 0000-0002-2942-3731 AD - Division of Cardiovascular Medicine, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. LA - eng PT - Journal Article PT - Review DEP - 20230406 PL - New Zealand TA - Vasc Health Risk Manag JT - Vascular health and risk management JID - 101273479 SB - IM MH - Humans MH - *Cardiomyopathy, Hypertrophic, Familial/diagnosis/genetics/therapy MH - *Cardiomyopathy, Hypertrophic/diagnosis/genetics/therapy MH - Diagnostic Imaging MH - *Defibrillators, Implantable PMC - PMC10084873 OTO - NOTNLM OT - genetics OT - heart failure OT - hypertrophic cardiomyopathy OT - mavacamten OT - myosin COIS- N.R. reports support from the National Center for Advancing Translational Sciences of the National Institutes of Health under award number KL2TR001879 and honoraria from Zoll. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The remaining authors report no conflicts of interest in this work. EDAT- 2023/04/14 06:00 MHDA- 2023/04/14 06:42 PMCR- 2023/04/06 CRDT- 2023/04/13 01:53 PHST- 2022/11/22 00:00 [received] PHST- 2023/03/28 00:00 [accepted] PHST- 2023/04/14 06:42 [medline] PHST- 2023/04/13 01:53 [entrez] PHST- 2023/04/14 06:00 [pubmed] PHST- 2023/04/06 00:00 [pmc-release] AID - 365001 [pii] AID - 10.2147/VHRM.S365001 [doi] PST - epublish SO - Vasc Health Risk Manag. 2023 Apr 6;19:211-221. doi: 10.2147/VHRM.S365001. eCollection 2023. PMID- 37048727 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240929 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 12 IP - 7 DP - 2023 Apr 1 TI - Early Recognition and Risk Stratification in Cardiogenic Shock: Well Begun Is Half Done. LID - 10.3390/jcm12072643 [doi] LID - 2643 AB - Cardiogenic shock is a complex syndrome manifesting with distinct phenotypes depending on the severity of the primary cardiac insult and the underlying status. As long as therapeutic interventions fail to divert its unopposed rapid evolution, poor outcomes will continue challenging health care systems. Thus, early recognition in the emergency setting is a priority, in order to avoid delays in appropriate management and to ensure immediate initial stabilization. Since advanced therapeutic strategies and specialized shock centers may provide beneficial support, it seems that directing patients towards the recently described shock network may improve survival rates. A multidisciplinary approach strategy commands the interconnections between the strategic role of the ED in affiliation with cardiac shock centers. This review outlines critical features of early recognition and initial therapeutic management, as well as the utility of diagnostic tools and risk stratification models regarding the facilitation of patient trajectories through the shock network. Further, it proposes the implementation of precise criteria for shock team activation and the establishment of definite exclusion criteria for streaming the right patient to the right place at the right time. FAU - Polyzogopoulou, Effie AU - Polyzogopoulou E AUID- ORCID: 0000-0001-7585-1203 AD - Emergency Department, Attikon University Hospital, National and Kapodistrian University of Athens, Rimini 1, Chaidari, 12462 Athens, Greece. FAU - Bezati, Sofia AU - Bezati S AUID- ORCID: 0000-0002-2038-844X AD - Emergency Department, Attikon University Hospital, National and Kapodistrian University of Athens, Rimini 1, Chaidari, 12462 Athens, Greece. FAU - Karamasis, Grigoris AU - Karamasis G AUID- ORCID: 0000-0002-4560-7629 AD - Second Department of Cardiology, Medical School, Attikon University Hospital, National and Kapodistrian University of Athens, 12462 Athens, Greece. FAU - Boultadakis, Antonios AU - Boultadakis A AD - Emergency Department, Attikon University Hospital, National and Kapodistrian University of Athens, Rimini 1, Chaidari, 12462 Athens, Greece. FAU - Parissis, John AU - Parissis J AD - Emergency Department, Attikon University Hospital, National and Kapodistrian University of Athens, Rimini 1, Chaidari, 12462 Athens, Greece. LA - eng PT - Journal Article PT - Review DEP - 20230401 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC10095596 OTO - NOTNLM OT - cardiogenic shock OT - management OT - risk scores OT - risk stratification OT - shock network OT - shock team COIS- S.B., G.K., A.B. and E.P. have no conflicts of interest or financial ties to disclose. J.P. received honoraria for lectures from Orion Pharma, Pfizer, Servier, Astra, AO Orphan and Roche Diagnostics. For the present study, the authors have no conflicts of interest to declare. EDAT- 2023/04/14 06:00 MHDA- 2023/04/14 06:01 PMCR- 2023/04/01 CRDT- 2023/04/13 01:20 PHST- 2023/02/21 00:00 [received] PHST- 2023/03/24 00:00 [revised] PHST- 2023/03/29 00:00 [accepted] PHST- 2023/04/14 06:01 [medline] PHST- 2023/04/13 01:20 [entrez] PHST- 2023/04/14 06:00 [pubmed] PHST- 2023/04/01 00:00 [pmc-release] AID - jcm12072643 [pii] AID - jcm-12-02643 [pii] AID - 10.3390/jcm12072643 [doi] PST - epublish SO - J Clin Med. 2023 Apr 1;12(7):2643. doi: 10.3390/jcm12072643. PMID- 37048573 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230415 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 12 IP - 7 DP - 2023 Mar 24 TI - Genetic Testing and Counselling in Hypertrophic Cardiomyopathy: Frequently Asked Questions. LID - 10.3390/jcm12072489 [doi] LID - 2489 AB - Genetic counselling and genetic testing in hypertrophic cardiomyopathy (HCM) represent an integral part of the diagnostic algorithm to confirm the diagnosis, distinguish it from phenocopies, and suggest tailored therapeutic intervention strategies. Additionally, they enable cascade genetic testing in the family. With the implementation of Next Generation Sequencing technologies (NGS), the interpretation of genetic data has become more complex. In this regard, cardiologists play a central role, aiding geneticists to correctly evaluate the pathogenicity of the identified genetic alterations. In the ideal setting, geneticists and cardiologists must work side by side to diagnose HCM as well as convey the correct information to patients in response to their many questions and concerns. After a brief overview of the role of genetics in the diagnosis of HCM, we present and discuss the frequently asked questions by HCM patients throughout our 20-year genetic counselling experience. Appropriate communication between the team and the families is key to the goal of delivering the full potential of genetic testing to our patients. FAU - Girolami, Francesca AU - Girolami F AUID- ORCID: 0000-0001-9143-3597 AD - Pediatric Cardiology Unit, Meyer Children's Hospital IRCCS, 50139 Florence, Italy. FAU - Gozzini, Alessia AU - Gozzini A AD - Pediatric Cardiology Unit, Meyer Children's Hospital IRCCS, 50139 Florence, Italy. FAU - Palinkas, Eszter Dalma AU - Palinkas ED AUID- ORCID: 0000-0003-0713-3909 AD - Doctoral School of Clinical Medicine, University of Szeged, 6720 Szeged, Hungary. AD - Cardiomyopathy Unit, Careggi University Hospital, 50134 Florence, Italy. FAU - Ballerini, Adelaide AU - Ballerini A AD - Pediatric Cardiology Unit, Meyer Children's Hospital IRCCS, 50139 Florence, Italy. FAU - Tomberli, Alessia AU - Tomberli A AD - Pediatric Cardiology Unit, Meyer Children's Hospital IRCCS, 50139 Florence, Italy. FAU - Baldini, Katia AU - Baldini K AD - Cardiomyopathy Unit, Careggi University Hospital, 50134 Florence, Italy. FAU - Marchi, Alberto AU - Marchi A AD - Pediatric Cardiology Unit, Meyer Children's Hospital IRCCS, 50139 Florence, Italy. FAU - Zampieri, Mattia AU - Zampieri M AUID- ORCID: 0000-0002-1140-134X AD - Pediatric Cardiology Unit, Meyer Children's Hospital IRCCS, 50139 Florence, Italy. FAU - Passantino, Silvia AU - Passantino S AD - Pediatric Cardiology Unit, Meyer Children's Hospital IRCCS, 50139 Florence, Italy. FAU - Porcedda, Giulio AU - Porcedda G AD - Pediatric Cardiology Unit, Meyer Children's Hospital IRCCS, 50139 Florence, Italy. FAU - Calabri, Giovanni Battista AU - Calabri GB AUID- ORCID: 0000-0002-7256-3916 AD - Pediatric Cardiology Unit, Meyer Children's Hospital IRCCS, 50139 Florence, Italy. FAU - Bennati, Elena AU - Bennati E AD - Pediatric Cardiology Unit, Meyer Children's Hospital IRCCS, 50139 Florence, Italy. FAU - Spaziani, Gaia AU - Spaziani G AUID- ORCID: 0000-0002-4697-6303 AD - Pediatric Cardiology Unit, Meyer Children's Hospital IRCCS, 50139 Florence, Italy. FAU - Crotti, Lia AU - Crotti L AUID- ORCID: 0000-0001-8739-6527 AD - Department of Cardiovascular, Neural and Metabolic Sciences, San Luca Hospital, Istituto Auxologico Italiano, IRCCS, 20100 Milan, Italy. AD - Department of Medicine and Surgery, University Milano Bicocca, 20126 Milan, Italy. FAU - Cecchi, Franco AU - Cecchi F AD - Department of Cardiovascular, Neural and Metabolic Sciences, San Luca Hospital, Istituto Auxologico Italiano, IRCCS, 20100 Milan, Italy. FAU - Favilli, Silvia AU - Favilli S AD - Pediatric Cardiology Unit, Meyer Children's Hospital IRCCS, 50139 Florence, Italy. FAU - Olivotto, Iacopo AU - Olivotto I AUID- ORCID: 0000-0003-1751-9266 AD - Pediatric Cardiology Unit, Meyer Children's Hospital IRCCS, 50139 Florence, Italy. AD - Department of Experimental and Clinical Medicine, University of Florence, 50121 Florence, Italy. LA - eng PT - Journal Article DEP - 20230324 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC10095452 OTO - NOTNLM OT - cascade testing OT - genetic counselling OT - genetic testing OT - hypertrophic cardiomyopathy OT - multidisciplinary team OT - next-generation sequencing COIS- The authors declare no conflict of interest. EDAT- 2023/04/14 06:00 MHDA- 2023/04/14 06:01 PMCR- 2023/03/24 CRDT- 2023/04/13 01:19 PHST- 2023/02/12 00:00 [received] PHST- 2023/03/13 00:00 [revised] PHST- 2023/03/24 00:00 [accepted] PHST- 2023/04/14 06:01 [medline] PHST- 2023/04/13 01:19 [entrez] PHST- 2023/04/14 06:00 [pubmed] PHST- 2023/03/24 00:00 [pmc-release] AID - jcm12072489 [pii] AID - jcm-12-02489 [pii] AID - 10.3390/jcm12072489 [doi] PST - epublish SO - J Clin Med. 2023 Mar 24;12(7):2489. doi: 10.3390/jcm12072489. PMID- 37046550 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230415 IS - 2075-4418 (Print) IS - 2075-4418 (Electronic) IS - 2075-4418 (Linking) VI - 13 IP - 7 DP - 2023 Apr 3 TI - Clinical Characteristics and Outcomes following Percutaneous Coronary Intervention in Unprotected Left Main Disease: A Single-Center Study. LID - 10.3390/diagnostics13071333 [doi] LID - 1333 AB - Background: Hemodynamically significant unprotected left main (LM) coronary artery disease is a high-risk clinical condition because of the large area of myocardium at risk, and it requires prompt revascularization. Percutaneous coronary intervention (PCI) is an appropriate alternative to coronary artery bypass grafting (CABG) for revascularization of unprotected LM disease in patients with low-to-intermediate anatomic complexity or when the patient refuses CABG after adequate counseling by the heart team. Methods: We retrospectively evaluated 201 patients receiving left main (LM) provisional one-stent or two-stent procedures, and we assessed the clinical characteristics and outcomes of patients undergoing unprotected LM PCI. Results: The mean age was 66.5 +/- 9.9 years, and 72% were male. The majority of the subjects presented several cardiovascular risk factors, among which arterial hypertension (179 patients, 89.5%) and dyslipidemia (173 patients, 86.5%) were the most frequent. Out of all patients, 162 (81.8%) underwent revascularization by using the one-stent technique, while the two-stent technique was used in 36 patients (18.2%). The median value of fractional flow reserve (FFR) of the side branch was 0.9 [0.85-0.95], and 135 patients (67.1%) showed a value of FFR > 0.8. One hundred nine patients (54.2%) had a stent enhancement side branch length (SESBL) > 2, with median values of 2.5 mm(2) [2.1-3]. Regarding angiographic parameters, the LM area as assessed by intravascular ultrasound (IVUS) or optical coherence tomography (OCT) and the grade of stenosis as assessed by quantitative coronary angiography (QCA) were similar between groups. However, patients who required revascularization by using the two-stent technique presented more frequently with intermediate rather than low SYNTAX scores (69.4% vs. 28.4%, p < 0.0001). Also, the same group required kissing balloon inflation (KBI) more frequently (69.4% vs. 30%, p < 0.001). There were no differences regarding the success of revascularization between the use of the one-stent or two-stent technique. FFR was able to predict a SESBL > 2 mm. The cut-off value for FFR to afford the highest degree of sensitivity (74.5%) and specificity (47%) for a SESBL > 2 was >0.86, indicating a moderate accuracy (AUC = 0.61, 95% CI 0.525-0.690, p = 0.036). Conclusions: Unprotected left main PCI is a safe and effective revascularization option amongst a complex and morbid population. There were no differences regarding the success of revascularization between the use of the one-stent or two-stent technique, and there was no significant impact of KBI on side branch FFR measurements but lower side branch FFR values were correlated with angiographic side branch compromise. FAU - Mot, Stefan Dan Cezar AU - Mot SDC AUID- ORCID: 0000-0003-0140-2194 AD - Cardiology Department, Heart Institute Niculae Stancioiu, 19-21 Motilor Street, 400001 Cluj-Napoca, Romania. AD - 5th Department of Internal Medicine, Faculty of Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania. FAU - Serban, Adela Mihaela AU - Serban AM AD - Cardiology Department, Heart Institute Niculae Stancioiu, 19-21 Motilor Street, 400001 Cluj-Napoca, Romania. AD - 5th Department of Internal Medicine, Faculty of Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania. FAU - Achim, Alexandru AU - Achim A AUID- ORCID: 0000-0002-5540-3478 AD - Cardiology Department, Heart Institute Niculae Stancioiu, 19-21 Motilor Street, 400001 Cluj-Napoca, Romania. AD - Cardiology Department, Kantonsspital Baselland, 4410 Liestal, Switzerland. FAU - Dadarlat-Pop, Alexandra AU - Dadarlat-Pop A AUID- ORCID: 0000-0003-3964-6995 AD - Cardiology Department, Heart Institute Niculae Stancioiu, 19-21 Motilor Street, 400001 Cluj-Napoca, Romania. AD - 5th Department of Internal Medicine, Faculty of Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania. FAU - Tomoaia, Raluca AU - Tomoaia R AUID- ORCID: 0000-0002-1944-4088 AD - 5th Department of Internal Medicine, Faculty of Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania. AD - Department of Cardiology, Clinical Rehabilitation Hospital, 400347 Cluj-Napoca, Romania. FAU - Pop, Dana AU - Pop D AD - 5th Department of Internal Medicine, Faculty of Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania. AD - Department of Cardiology, Clinical Rehabilitation Hospital, 400347 Cluj-Napoca, Romania. LA - eng PT - Journal Article DEP - 20230403 PL - Switzerland TA - Diagnostics (Basel) JT - Diagnostics (Basel, Switzerland) JID - 101658402 PMC - PMC10093002 OTO - NOTNLM OT - POT OT - bifurcation OT - kissing OT - left main OT - percutaneous coronary intervention OT - side branch OT - stent apposition OT - stent enhancement COIS- The authors declare no conflict of interest. EDAT- 2023/04/14 06:00 MHDA- 2023/04/14 06:01 PMCR- 2023/04/03 CRDT- 2023/04/13 01:06 PHST- 2023/02/20 00:00 [received] PHST- 2023/03/20 00:00 [revised] PHST- 2023/03/31 00:00 [accepted] PHST- 2023/04/14 06:01 [medline] PHST- 2023/04/13 01:06 [entrez] PHST- 2023/04/14 06:00 [pubmed] PHST- 2023/04/03 00:00 [pmc-release] AID - diagnostics13071333 [pii] AID - diagnostics-13-01333 [pii] AID - 10.3390/diagnostics13071333 [doi] PST - epublish SO - Diagnostics (Basel). 2023 Apr 3;13(7):1333. doi: 10.3390/diagnostics13071333. PMID- 37046545 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240916 IS - 2075-4418 (Print) IS - 2075-4418 (Electronic) IS - 2075-4418 (Linking) VI - 13 IP - 7 DP - 2023 Apr 3 TI - Combined CT Coronary Artery Assessment and TAVI Planning. LID - 10.3390/diagnostics13071327 [doi] LID - 1327 AB - Computed tomography angiography (CTA) of the aorta and the iliofemoral arteries is crucial for preprocedural planning of transcatheter aortic valve implantation (TAVI) in patients with severe aortic stenosis (AS), because it provides details on a variety of aspects required for heart team decision-making. In addition to providing relevant diagnostic information on the degree of aortic valve calcification, CTA allows for a customized choice of the transcatheter heart valve system and the TAVI access route. Furthermore, current guidelines recommend the exclusion of relevant coronary artery disease (CAD) prior to TAVI. The feasibility of coronary artery assessment with CTA in patients scheduled for TAVI has been established previously, and accumulating data support its value. In addition, fractional flow reserve determined from CTA (CT-FFR) and machine learning-based CT-FFR were recently shown to improve its diagnostic yield for this purpose. However, the utilization of CTA for coronary artery evaluation remains limited in this specific population of patients due to the relatively high risk of CAD coexistence with severe AS. Therefore, the current diagnostic work-up prior to TAVI routinely includes invasive catheter coronary angiography at most centers. In this article, the authors address technological prerequisites and CT protocol considerations, discuss pitfalls, review the current literature regarding combined CTA coronary artery assessment and preprocedural TAVI evaluation, and provide an overview of unanswered questions and future research goals within the field. FAU - Renker, Matthias AU - Renker M AUID- ORCID: 0000-0002-4756-5397 AD - Department of Cardiology, Campus Kerckhoff of the Justus Liebig University Giessen, 61231 Bad Nauheim, Germany. AD - Department of Cardiac Surgery, Campus Kerckhoff of the Justus Liebig University Giessen, 61231 Bad Nauheim, Germany. AD - German Centre for Cardiovascular Research (DZHK), Partner Site Rhine-Main, 61231 Bad Nauheim, Germany. FAU - Schoepf, U Joseph AU - Schoepf UJ AD - Heart & Vascular Center, Medical University of South Carolina, Charleston, SC 29425, USA. FAU - Kim, Won Keun AU - Kim WK AD - Department of Cardiology, Campus Kerckhoff of the Justus Liebig University Giessen, 61231 Bad Nauheim, Germany. AD - Department of Cardiac Surgery, Campus Kerckhoff of the Justus Liebig University Giessen, 61231 Bad Nauheim, Germany. AD - German Centre for Cardiovascular Research (DZHK), Partner Site Rhine-Main, 61231 Bad Nauheim, Germany. AD - Department of Cardiology, Justus Liebig University Giessen, 35392 Giessen, Germany. LA - eng PT - Journal Article PT - Review DEP - 20230403 PL - Switzerland TA - Diagnostics (Basel) JT - Diagnostics (Basel, Switzerland) JID - 101658402 PMC - PMC10093468 OTO - NOTNLM OT - aortic stenosis OT - chronic coronary syndrome OT - computed tomography OT - coronary artery disease OT - fractional flow reserve OT - transcatheter aortic valve implantation COIS- M.R. has no conflict of interest to declare. U.J.S.: institutional research support and/or honoraria for speaking and consulting from Bayer, ElucidBio, Guerbet, HeartFlow, Inc., Keya Medical, and Siemens Healthineers. W.K.: proctor/speaker fees from Abbott, Boston Scientific, Edwards Lifesciences, Medtronic, and Meril Life Sciences. EDAT- 2023/04/14 06:00 MHDA- 2023/04/14 06:01 PMCR- 2023/04/03 CRDT- 2023/04/13 01:06 PHST- 2023/01/14 00:00 [received] PHST- 2023/03/04 00:00 [revised] PHST- 2023/03/24 00:00 [accepted] PHST- 2023/04/14 06:01 [medline] PHST- 2023/04/13 01:06 [entrez] PHST- 2023/04/14 06:00 [pubmed] PHST- 2023/04/03 00:00 [pmc-release] AID - diagnostics13071327 [pii] AID - diagnostics-13-01327 [pii] AID - 10.3390/diagnostics13071327 [doi] PST - epublish SO - Diagnostics (Basel). 2023 Apr 3;13(7):1327. doi: 10.3390/diagnostics13071327. PMID- 37042605 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20261019 LR - 20261019 IS - 1467-1107 (Electronic) IS - 1047-9511 (Linking) VI - 33 IP - 12 DP - 2023 Dec TI - Implementation of the Cardiac Inpatient Neurodevelopmental Care Optimization (CINCO) programme: an interdisciplinary, generalisable approach to inpatient neurodevelopmental care. PG - 2581-2588 LID - 10.1017/S1047951123000562 [doi] AB - BACKGROUND: Children with CHD are at risk for neurodevelopmental delays, and length of hospitalisation is a predictor of poorer long-term outcomes. Multiple aspects of hospitalisation impact neurodevelopment, including sleep interruptions, limited holding, and reduced developmental stimulation. We aimed to address modifiable factors by creating and implementing an interdisciplinary inpatient neurodevelopmental care programme in our Heart Institute. METHODS: In this quality improvement study, we developed an empirically supported approach to neurodevelopmental care across the continuum of hospitalisation for patients with CHD using three plan-do-study-act cycles. With input from multi-level stakeholders including parents/caregivers, we co-designed interventions that comprised the Cardiac Inpatient Neurodevelopmental Care Optimization (CINCO) programme. These included medical/nursing orders for developmental care practices, developmental kits for patients, bedside developmental plans, caregiver education and support, developmental care rounds, and a specialised volunteer programme. We obtained data from the electronic health record for patients aged 0-2 years admitted for at least 7 days to track implementation. RESULTS: There were 619 admissions in 18 months. Utilisation of CINCO interventions increased over time, particularly for the medical/nursing orders and caregiver handouts. The volunteer programme launch was delayed but grew rapidly and within six months, provided over 500 hours of developmental interaction with patients. CONCLUSIONS: We created and implemented a low-cost programme that systematised and expanded upon existing neurodevelopmental care practices in the cardiac inpatient units. Feasibility was demonstrated through increasing implementation rates over time. Key takeaways include the importance of multi-level stakeholder buy-in and embedding processes in existing clinical workflows. CI - (c) The Author(s), 2023. Published by Cambridge University Press FAU - Wolfe, Kelly R AU - Wolfe KR AUID- ORCID: 0000-0003-4754-4577 AD - Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA. FAU - Caprarola, Sherrill D AU - Caprarola SD AUID- ORCID: 0000-0001-9523-6291 AD - Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA. FAU - Clark, Caelah AU - Clark C AD - Children's Hospital Colorado, Aurora, CO, USA. FAU - Davidson, Jesse AU - Davidson J AD - Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA. FAU - Everitt, Melanie D AU - Everitt MD AD - Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA. FAU - Faul, Laura AU - Faul L AD - Children's Hospital Colorado, Aurora, CO, USA. FAU - Hageman, Colton AU - Hageman C AD - Children's Hospital Colorado, Aurora, CO, USA. FAU - Kelly, Sarah L AU - Kelly SL AUID- ORCID: 0000-0002-6137-6824 AD - Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA. FAU - Maloney, Emily AU - Maloney E AD - Children's Hospital Colorado, Aurora, CO, USA. FAU - Patteson, Hilary AU - Patteson H AD - Children's Hospital Colorado, Aurora, CO, USA. FAU - Scott, Sarah AU - Scott S AD - Children's Hospital Colorado, Aurora, CO, USA. FAU - Talbot, Alyse AU - Talbot A AD - Children's Hospital Colorado, Aurora, CO, USA. FAU - Tong, Suhong AU - Tong S AD - Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA. FAU - DiMaria, Kimberly L AU - DiMaria KL AD - Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA. LA - eng PT - Journal Article DEP - 20230412 PL - England TA - Cardiol Young JT - Cardiology in the young JID - 9200019 SB - IM OTO - NOTNLM OT - Cardiac neurodevelopment OT - cardiac intensive care OT - inpatient neurodevelopmental care OT - quality improvement COIS- None. EDAT- 2023/04/13 06:00 MHDA- 2023/04/13 06:01 CRDT- 2023/04/12 08:32 PHST- 2022/12/20 00:00 [received] PHST- 2023/03/01 00:00 [accepted] PHST- 2023/04/13 06:01 [medline] PHST- 2023/04/12 08:32 [entrez] PHST- 2023/04/13 06:00 [pubmed] AID - S1047951123000562 [pii] AID - 10.1017/S1047951123000562 [doi] PST - ppublish SO - Cardiol Young. 2023 Dec;33(12):2581-2588. doi: 10.1017/S1047951123000562. Epub 2023 Apr 12. PMID- 37039249 OWN - NLM STAT- MEDLINE DCOM- 20230803 LR - 20230803 IS - 1471-0528 (Electronic) IS - 1470-0328 (Linking) VI - 130 IP - 10 DP - 2023 Sep TI - Management and outcomes of pulmonary artery hypertension and Eisenmenger syndrome during pregnancy: a prospective observational cohort study. PG - 1258-1268 LID - 10.1111/1471-0528.17474 [doi] AB - OBJECTIVES: Maternal-fetal morbidity and mortality among pregnant women with pulmonary artery hypertension (PAH) and Eisenmenger syndrome are unacceptable, and management decision-making in these clinical scenarios remains debatable. This study aimed to compare and analyse clinical characteristics, management and pregnancy outcomes in PAH and Eisenmenger syndrome. DESIGN: Prospective observational cohort study. SETTINGS: A large tertiary care university hospital. PATIENTS: Thirty patients with pulmonary artery hypertension and 20 patients with Eisenmenger syndrome. METHODS: Data pertaining to clinical characteristics, anaesthetic, medical and obstetric management, and outcomes in pregnancy complicated by PAH and Eisenmenger syndrome were collected between July 2020 and June 2022. Each treating unit followed its management protocol in consultation with the multidisciplinary team. MAIN OUTCOME MEASURES: Maternal mortality and morbidity. RESULTS: Maternal mortality was lower in the PAH group (6.6% versus 15%; p = 0.33). All mortalities were in the postpartum period. The incidence of new-onset or exacerbation of heart failure (23.3% versus 60%; p = 0.009) and hypoxaemia (13.3% versus 50%; p = 0.005) were significantly lower in the PAH group. In the Eisenmenger syndrome group, a significantly higher number of women received pulmonary hypertension and heart failure medications. Prematurity and neonatal intensive care unit admission were frequently noticed in Eisenmenger syndrome, whereas perinatal mortality, birthweight and APGAR score were comparable. CONCLUSIONS: Fetomaternal outcomes are inferior in Eisenmenger syndrome compared with PAH and are either lower or comparable to those reported from contemporary cohorts of developed nations. CI - (c) 2023 John Wiley & Sons Ltd. FAU - Jha, Nivedita AU - Jha N AUID- ORCID: 0000-0002-0183-0773 AD - Department of Obstetrics and Gynaecology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India. FAU - Divya, Mecheril Balachandran AU - Divya MB AD - Department of Obstetrics and Gynaecology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India. FAU - Jha, Ajay Kumar AU - Jha AK AUID- ORCID: 0000-0002-8968-9216 AD - Cardiothoracic Division, Department of Anaesthesiology and Critical Care, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, India. LA - eng PT - Journal Article PT - Observational Study DEP - 20230411 PL - England TA - BJOG JT - BJOG : an international journal of obstetrics and gynaecology JID - 100935741 SB - IM MH - Infant, Newborn MH - Female MH - Pregnancy MH - Humans MH - *Eisenmenger Complex/complications/therapy MH - Pulmonary Artery MH - Prospective Studies MH - Cesarean Section/adverse effects MH - *Hypertension, Pulmonary/etiology/therapy MH - Pregnancy Outcome MH - *Heart Failure OTO - NOTNLM OT - Eisenmenger syndrome OT - management OT - morbidity OT - mortality OT - outcomes OT - pregnancy OT - pulmonary hypertension EDAT- 2023/04/12 06:00 MHDA- 2023/08/03 06:42 CRDT- 2023/04/11 06:43 PHST- 2023/01/09 00:00 [revised] PHST- 2022/09/08 00:00 [received] PHST- 2023/01/18 00:00 [accepted] PHST- 2023/08/03 06:42 [medline] PHST- 2023/04/12 06:00 [pubmed] PHST- 2023/04/11 06:43 [entrez] AID - 10.1111/1471-0528.17474 [doi] PST - ppublish SO - BJOG. 2023 Sep;130(10):1258-1268. doi: 10.1111/1471-0528.17474. Epub 2023 Apr 11. PMID- 37035922 OWN - NLM STAT- MEDLINE DCOM- 20230519 LR - 20240603 IS - 1524-4563 (Electronic) IS - 0194-911X (Print) IS - 0194-911X (Linking) VI - 80 IP - 6 DP - 2023 Jun TI - Angiotensin II-Mediated Neuroinflammation in the Hippocampus Contributes to Neuronal Deficits and Cognitive Impairment in Heart Failure Rats. PG - 1258-1273 LID - 10.1161/HYPERTENSIONAHA.123.21070 [doi] AB - BACKGROUND: Heart failure (HF) is a debilitating disease affecting >64 million people worldwide. In addition to impaired cardiovascular performance and associated systemic complications, most patients with HF suffer from depression and substantial cognitive decline. Although neuroinflammation and brain hypoperfusion occur in humans and rodents with HF, the underlying neuronal substrates, mechanisms, and their relative contribution to cognitive deficits in HF remains unknown. METHODS: To address this critical gap in our knowledge, we used a well-established HF rat model that mimics clinical outcomes observed in the human population, along with a multidisciplinary approach combining behavioral, electrophysiological, neuroanatomical, molecular and systemic physiological approaches. RESULTS: Our studies support neuroinflammation, hypoperfusion/hypoxia, and neuronal deficits in the hippocampus of HF rats, which correlated with the progression and severity of the disease. An increased expression of AT1aRs (Ang II [angiotensin II] receptor type 1a) in hippocampal microglia preceded the onset of neuroinflammation. Importantly, blockade of AT1Rs with a clinically used therapeutic drug (Losartan), and delivered in a clinically relevant manner, efficiently reversed neuroinflammatory end points (but not hypoxia ones), resulting in turn in improved cognitive performance in HF rats. Finally, we show than circulating Ang II can leak and access the hippocampal parenchyma in HF rats, constituting a possible source of Ang II initiating the neuroinflammatory signaling cascade in HF. CONCLUSIONS: In this study, we identified a neuronal substrate (hippocampus), a mechanism (Ang II-driven neuroinflammation) and a potential neuroprotective therapeutic target (AT1aRs) for the treatment of cognitive deficits in HF. FAU - Althammer, Ferdinand AU - Althammer F AD - Center for Neuroinflammation and Cardiometabolic Diseases (F.A., R.K.R., M.K.K., E.C.-L., J.M., H.C.F.-N., U.Z., M.B.P., J.E.S.), Georgia State University, Atlanta. AD - Now with Institute of Human Genetics, University Hospital Heidelberg (F.A.). FAU - Roy, Ranjan K AU - Roy RK AUID- ORCID: 0000-0001-6234-8043 AD - Center for Neuroinflammation and Cardiometabolic Diseases (F.A., R.K.R., M.K.K., E.C.-L., J.M., H.C.F.-N., U.Z., M.B.P., J.E.S.), Georgia State University, Atlanta. FAU - Kirchner, Matthew K AU - Kirchner MK AUID- ORCID: 0000-0001-6960-7685 AD - Center for Neuroinflammation and Cardiometabolic Diseases (F.A., R.K.R., M.K.K., E.C.-L., J.M., H.C.F.-N., U.Z., M.B.P., J.E.S.), Georgia State University, Atlanta. FAU - Campos-Lira, Elba AU - Campos-Lira E AD - Center for Neuroinflammation and Cardiometabolic Diseases (F.A., R.K.R., M.K.K., E.C.-L., J.M., H.C.F.-N., U.Z., M.B.P., J.E.S.), Georgia State University, Atlanta. AD - Neuroscience Institute (E.C.-L., K.E.W., S.D., U.Z., M.B.P., J.E.S.), Georgia State University, Atlanta. FAU - Whitley, Kathryn E AU - Whitley KE AUID- ORCID: 0000-0002-0934-7655 AD - Neuroscience Institute (E.C.-L., K.E.W., S.D., U.Z., M.B.P., J.E.S.), Georgia State University, Atlanta. FAU - Davis, Steven AU - Davis S AD - Neuroscience Institute (E.C.-L., K.E.W., S.D., U.Z., M.B.P., J.E.S.), Georgia State University, Atlanta. FAU - Montanez, Juliana AU - Montanez J AD - Center for Neuroinflammation and Cardiometabolic Diseases (F.A., R.K.R., M.K.K., E.C.-L., J.M., H.C.F.-N., U.Z., M.B.P., J.E.S.), Georgia State University, Atlanta. FAU - Ferreira-Neto, Hildebrando Candido AU - Ferreira-Neto HC AD - Center for Neuroinflammation and Cardiometabolic Diseases (F.A., R.K.R., M.K.K., E.C.-L., J.M., H.C.F.-N., U.Z., M.B.P., J.E.S.), Georgia State University, Atlanta. FAU - Danh, Jessica AU - Danh J AUID- ORCID: 0000-0001-7739-0287 AD - Department of Nutrition (J.D., R.F.), Georgia State University, Atlanta. FAU - Feresin, Rafaela AU - Feresin R AUID- ORCID: 0000-0003-0649-2774 AD - Department of Nutrition (J.D., R.F.), Georgia State University, Atlanta. FAU - Biancardi, Vinicia Campana AU - Biancardi VC AUID- ORCID: 0000-0001-7301-1702 AD - Anatomy, Physiology, & Pharmacology, College of Veterinary Medicine, Auburn University, AL (V.C.B.). FAU - Zafar, Usama AU - Zafar U AD - Center for Neuroinflammation and Cardiometabolic Diseases (F.A., R.K.R., M.K.K., E.C.-L., J.M., H.C.F.-N., U.Z., M.B.P., J.E.S.), Georgia State University, Atlanta. AD - Neuroscience Institute (E.C.-L., K.E.W., S.D., U.Z., M.B.P., J.E.S.), Georgia State University, Atlanta. FAU - Parent, Marise B AU - Parent MB AUID- ORCID: 0000-0001-7862-5623 AD - Center for Neuroinflammation and Cardiometabolic Diseases (F.A., R.K.R., M.K.K., E.C.-L., J.M., H.C.F.-N., U.Z., M.B.P., J.E.S.), Georgia State University, Atlanta. AD - Neuroscience Institute (E.C.-L., K.E.W., S.D., U.Z., M.B.P., J.E.S.), Georgia State University, Atlanta. AD - Department of Psychology (M.B.P.), Georgia State University, Atlanta. FAU - Stern, Javier E AU - Stern JE AUID- ORCID: 0000-0002-9310-0486 AD - Center for Neuroinflammation and Cardiometabolic Diseases (F.A., R.K.R., M.K.K., E.C.-L., J.M., H.C.F.-N., U.Z., M.B.P., J.E.S.), Georgia State University, Atlanta. AD - Neuroscience Institute (E.C.-L., K.E.W., S.D., U.Z., M.B.P., J.E.S.), Georgia State University, Atlanta. LA - eng GR - R01 HL090948/HL/NHLBI NIH HHS/United States GR - R01 HL162575/HL/NHLBI NIH HHS/United States GR - R01 NS094640/NS/NINDS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20230410 PL - United States TA - Hypertension JT - Hypertension (Dallas, Tex. : 1979) JID - 7906255 RN - 11128-99-7 (Angiotensin II) SB - IM MH - Rats MH - Humans MH - Animals MH - Angiotensin II/pharmacology MH - Neuroinflammatory Diseases MH - *Heart Failure/metabolism MH - *Cognitive Dysfunction/etiology/metabolism MH - Hippocampus PMC - PMC10192104 MID - NIHMS1886876 OTO - NOTNLM OT - angiotensin II OT - depression OT - heart failure OT - hippocampus OT - microglia COIS- Disclosures None. EDAT- 2023/04/11 06:00 MHDA- 2023/05/19 06:42 PMCR- 2024/06/01 CRDT- 2023/04/10 05:03 PHST- 2023/05/19 06:42 [medline] PHST- 2023/04/11 06:00 [pubmed] PHST- 2023/04/10 05:03 [entrez] PHST- 2024/06/01 00:00 [pmc-release] AID - 10.1161/HYPERTENSIONAHA.123.21070 [doi] PST - ppublish SO - Hypertension. 2023 Jun;80(6):1258-1273. doi: 10.1161/HYPERTENSIONAHA.123.21070. Epub 2023 Apr 10. PMID- 37035105 OWN - NLM STAT- MEDLINE DCOM- 20230411 LR - 20231102 IS - 1432-2277 (Electronic) IS - 0934-0874 (Print) IS - 0934-0874 (Linking) VI - 36 DP - 2023 TI - Individual-Level Socioeconomic Position and Long-Term Prognosis in Danish Heart-Transplant Recipients. PG - 10976 LID - 10.3389/ti.2023.10976 [doi] LID - 10976 AB - Socioeconomic deprivation can limit access to healthcare. Important gaps persist in the understanding of how individual indicators of socioeconomic disadvantage may affect clinical outcomes after heart transplantation. We sought to examine the impact of individual-level socioeconomic position (SEP) on prognosis of heart-transplant recipients. A population-based study including all Danish first-time heart-transplant recipients (n = 649) was conducted. Data were linked across complete national health registers. Associations were evaluated between SEP and all-cause mortality and first-time major adverse cardiovascular event (MACE) during follow-up periods. The half-time survival was 15.6 years (20-year period). In total, 330 (51%) of recipients experienced a first-time cardiovascular event and the most frequent was graft failure (42%). Both acute myocardial infarction and cardiac arrest occurred in 90% of cases, particularly the tricuspid and pulmonary valves, which become thickened, retracted and immobile, resulting in regurgitation or stenosis. CHD represents a major diagnostic and therapeutic challenge for patients with NET and CS and is associated with increased risk of morbidity and mortality. CHD often occurs 2-5 years after the diagnosis of metastatic NET, but diagnosis of CHD can be delayed as patients are often asymptomatic for a long time despite severe heart valve involvement. Circulating biomarkers (5HIAA, NT-proBNP) are relevant tools but transthoracic echocardiography is the key examination for diagnosis and follow-up of CHD. However, there is no consensus on the optimal indications and frequency of TTE and biomarker dosing regarding screening and diagnosis. Treatment of CHD is complex and requires a multidisciplinary approach. It relies on antitumour treatment, control of CS and surgical valve replacement in cases of severe CHD. However, cardiac surgery is associated with a high risk of mortality, notably due to perioperative carcinoid crisis and right ventricular dysfunction. Timing of surgery is the most crucial point of CHD management and relies on the case-by-case determination of the optimal compromise between tumour progression, cardiac symptoms and CS control. CI - (c) 2023 The Authors. Journal of Neuroendocrinology published by John Wiley & Sons Ltd on behalf of British Society for Neuroendocrinology. FAU - Delhomme, Clemence AU - Delhomme C AUID- ORCID: 0000-0003-0746-8784 AD - Universite Paris-Cite, Department of Cardiology, Bichat/Beaujon Hospital (APHP.Nord), ENETS Centre of Excellence, Paris/Clichy, France. FAU - Walter, Thomas AU - Walter T AD - Hospices Civils de Lyon, Department of Medical Oncology, ENETS Centre of Excellence, Lyon, France. FAU - Arangalage, Dimitri AU - Arangalage D AD - Universite Paris-Cite, Department of Cardiology, Bichat/Beaujon Hospital (APHP.Nord), ENETS Centre of Excellence, Paris/Clichy, France. FAU - Suc, Gaspard AU - Suc G AD - Universite Paris-Cite, Department of Cardiology, Bichat/Beaujon Hospital (APHP.Nord), ENETS Centre of Excellence, Paris/Clichy, France. FAU - Hentic, Olivia AU - Hentic O AD - Universite Paris-Cite, Department of Pancreatology and Digestive Oncology, ENETS Centre of Excellence, Beaujon Hospital (APHP.Nord), Clichy, France. FAU - Cachier, Agnes AU - Cachier A AD - Universite Paris-Cite, Department of Cardiology, Bichat/Beaujon Hospital (APHP.Nord), ENETS Centre of Excellence, Paris/Clichy, France. FAU - Alkhoder, Soleiman AU - Alkhoder S AD - Universite Paris-Cite, Department of Cardiac Surgery, Bichat Hospital (APHP.Nord), ENETS Centre of Excellence, Paris, France. FAU - Francois, Laurent AU - Francois L AD - Hospices Civils de Lyon, Department of Cardiology, ENETS Centre of Excellence, Lyon, France. FAU - Lombard-Bohas, Catherine AU - Lombard-Bohas C AD - Hospices Civils de Lyon, Department of Medical Oncology, ENETS Centre of Excellence, Lyon, France. FAU - Iung, Bernard AU - Iung B AD - Universite Paris-Cite, Department of Cardiology, Bichat/Beaujon Hospital (APHP.Nord), ENETS Centre of Excellence, Paris/Clichy, France. FAU - Ruszniewski, Philippe AU - Ruszniewski P AD - Universite Paris-Cite, Department of Pancreatology and Digestive Oncology, ENETS Centre of Excellence, Beaujon Hospital (APHP.Nord), Clichy, France. FAU - de Mestier, Louis AU - de Mestier L AD - Universite Paris-Cite, Department of Pancreatology and Digestive Oncology, ENETS Centre of Excellence, Beaujon Hospital (APHP.Nord), Clichy, France. LA - eng PT - Journal Article PT - Review DEP - 20230402 PL - United States TA - J Neuroendocrinol JT - Journal of neuroendocrinology JID - 8913461 RN - 333DO1RDJY (Serotonin) SB - IM MH - Humans MH - *Carcinoid Heart Disease/diagnosis/etiology/therapy MH - *Neuroendocrine Tumors/complications/diagnosis/therapy MH - *Intestinal Neoplasms/therapy/complications MH - Morbidity MH - Serotonin OTO - NOTNLM OT - carcinoid heart disease OT - carcinoid syndrome OT - neuroendocrine tumours EDAT- 2023/04/03 06:00 MHDA- 2023/04/28 06:41 CRDT- 2023/04/02 22:05 PHST- 2022/12/29 00:00 [revised] PHST- 2022/06/13 00:00 [received] PHST- 2023/03/08 00:00 [accepted] PHST- 2023/04/28 06:41 [medline] PHST- 2023/04/03 06:00 [pubmed] PHST- 2023/04/02 22:05 [entrez] AID - 10.1111/jne.13262 [doi] PST - ppublish SO - J Neuroendocrinol. 2023 Apr;35(4):e13262. doi: 10.1111/jne.13262. Epub 2023 Apr 2. PMID- 37003680 OWN - NLM STAT- MEDLINE DCOM- 20230404 LR - 20230404 IS - 1558-2264 (Electronic) IS - 0733-8651 (Linking) VI - 41 IP - 2 DP - 2023 May TI - Radionuclide Imaging of Infective Endocarditis. PG - 233-249 LID - S0733-8651(23)00011-5 [pii] LID - 10.1016/j.ccl.2023.01.011 [doi] AB - Infective endocarditis (IE) is associated with high morbidity and mortality. Early diagnosis is crucial for adequate patient management. Due to difficulties in the diagnosis, a multidisciplinary discussion in addition to the integration of clinical signs, microbiology data, and imaging data is used. Imaging, including echocardiography, molecular imaging techniques, and coronary CT angiography (CTA) is central to detect infections involving heart valves and implanted cardiovascular devices, also allowing for early detection of septic emboli and metastatic. This article describes the main clinical application of white blood cell SPECT/CT and [(18)F]FDG-PET/CT and CTA in IE and infections associated with cardiovascular implantable electronic devices. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Ferro, Paola AU - Ferro P AD - Nuclear Medicine Department ASST Ospedale Papa Giovanni XXIII Bergamo (Italy), Piazza OMS 1, Bergamo 24127, Italy. FAU - Boni, Roberto AU - Boni R AD - Nuclear Medicine Department ASST Ospedale Papa Giovanni XXIII Bergamo (Italy), Piazza OMS 1, Bergamo 24127, Italy. FAU - Bartoli, Francesco AU - Bartoli F AD - Department of Translational Research and Advanced Technologies in Medicine and Surgery, Regional Center of Nuclear Medicine, University of Pisa, Via Roma 57, Pisa I-56126, Italy. FAU - Lazzeri, Francesca AU - Lazzeri F AD - Department of Translational Research and Advanced Technologies in Medicine and Surgery, Regional Center of Nuclear Medicine, University of Pisa, Via Roma 57, Pisa I-56126, Italy. FAU - Slart, Riemer H J A AU - Slart RHJA AD - Medical Imaging Center, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, the Netherlands. FAU - Erba, Paola A AU - Erba PA AD - Department of Medicine and Surgery, University of Milan Bicocca and Nuclear Medicine Unit ASST Ospedale Papa Giovanni XXIII Bergamo (Italy), Piazza OMS 1, Bergamo 24127, Italy. Electronic address: paolaanna.erba@unimib.it. LA - eng PT - Journal Article PT - Review DEP - 20230303 PL - Netherlands TA - Cardiol Clin JT - Cardiology clinics JID - 8300331 RN - 0 (Radiopharmaceuticals) RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18) SB - IM MH - Humans MH - Positron Emission Tomography Computed Tomography/methods MH - Radiopharmaceuticals MH - Fluorodeoxyglucose F18 MH - *Endocarditis/diagnostic imaging MH - Coronary Angiography MH - *Prosthesis-Related Infections/diagnostic imaging OTO - NOTNLM OT - Duke/ESC criteria OT - Echocardiography OT - Infections associated with cardiovascular implantable electronic devices (CIED) OT - Infectious endocarditis (IE) OT - Labeled leukocyte (WBC) imaging OT - PET/CT imaging OT - SPECT/CT imaging OT - diagnosis EDAT- 2023/04/02 06:00 MHDA- 2023/04/04 06:42 CRDT- 2023/04/01 20:59 PHST- 2023/04/04 06:42 [medline] PHST- 2023/04/01 20:59 [entrez] PHST- 2023/04/02 06:00 [pubmed] AID - S0733-8651(23)00011-5 [pii] AID - 10.1016/j.ccl.2023.01.011 [doi] PST - ppublish SO - Cardiol Clin. 2023 May;41(2):233-249. doi: 10.1016/j.ccl.2023.01.011. Epub 2023 Mar 3. PMID- 37001910 OWN - NLM STAT- MEDLINE DCOM- 20230404 LR - 20260127 IS - 2053-3624 (Print) IS - 2053-3624 (Electronic) IS - 2053-3624 (Linking) VI - 10 IP - 1 DP - 2023 Mar TI - Consensus statement on aortic valve replacement via an anterior right minithoracotomy in the UK healthcare setting. LID - 10.1136/openhrt-2022-002194 [doi] LID - e002194 AB - The wide uptake of anterior right thoracotomy (ART) as an approach for aortic valve replacement (AVR) has been limited despite initial reports of its use in 1993. Compared with median sternotomy, and even ministernotomy, ART is considered to be less traumatic to the chest wall and to help facilitate quicker patient recovery. In this statement, a consensus agreement is outlined that describes the potential benefits of the ART AVR. The technical considerations that require specific attention are described and the initiation of an ART programme at a UK centre is recommended through simulation and/or use of specialist instruments in conventional cases. The use of soft tissue retractors, peripheral cannulation, modified aortic clamping and the use of intraoperative adjuncts, such as sutureless valves and/or automated knot fasteners, are important to consider in order to circumvent the challenges of minimal the altered exposure via an ART.A coordinated team-based approach that encourages ownership of the programme by team members is critical. A designated proctor/mentor is also recommended. The organisation of structured training and simulation, as well as planning the initial cases are important steps to consider. CI - (c) Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Vohra, Hunaid A AU - Vohra HA AD - Bristol Royal Infirmary, Bristol, UK. FAU - Salmasi, M Yousuf AU - Salmasi MY AUID- ORCID: 0000-0002-4085-1294 AD - Surgery and Cancer, Imperial College London, London, UK y.salmasi@imperial.ac.uk. FAU - Mohamed, Fatemazahra AU - Mohamed F AD - Imperial College London, London, UK. FAU - Shehata, Monica AU - Shehata M AD - Royal Brompton and Harefield Hospitals, London, UK. FAU - Bahrami, Bardia AU - Bahrami B AD - Royal Brompton and Harefield Hospitals, London, UK. FAU - Caputo, Massimo AU - Caputo M AUID- ORCID: 0000-0001-7508-0891 AD - Bristol Royal Infirmary, Bristol, UK. FAU - Deshpande, Ranjit AU - Deshpande R AD - Cardiology, King's College Hospital, London, UK. FAU - Bapat, Vinayak AU - Bapat V AD - Cardiovascular Directorate, Guy's & St Thomas' Hospitals NHS Foundation Trust, London, UK. FAU - Bahrami, Toufan AU - Bahrami T AD - Royal Brompton and Harefield Hospitals, London, UK. FAU - Birdi, Inderpaul AU - Birdi I AD - Basildon and Thurrock University Hospitals NHS Foundation Trust, Basildon, UK. FAU - Zacharias, Joseph AU - Zacharias J AUID- ORCID: 0000-0003-1832-0638 AD - Lancashire Cardiac Centre, Blackpool Victoria Hospital, Blackpool, UK. LA - eng GR - CH/17/1/32804/BHF_/British Heart Foundation/United Kingdom PT - Consensus Statement PT - Journal Article PT - Review PL - England TA - Open Heart JT - Open heart JID - 101631219 SB - IM MH - Humans MH - *Aortic Valve/diagnostic imaging/surgery MH - Thoracotomy/adverse effects MH - *Heart Valve Prosthesis Implantation/adverse effects MH - Treatment Outcome MH - Delivery of Health Care MH - United Kingdom PMC - PMC10069572 OTO - NOTNLM OT - Aortic Valve Stenosis OT - Heart Valve Prosthesis Implantation OT - Outcome Assessment, Health Care COIS- Competing interests: None declared. EDAT- 2023/04/01 06:00 MHDA- 2023/04/04 06:42 PMCR- 2023/03/31 CRDT- 2023/03/31 20:42 PHST- 2022/11/29 00:00 [received] PHST- 2023/02/27 00:00 [accepted] PHST- 2023/04/04 06:42 [medline] PHST- 2023/03/31 20:42 [entrez] PHST- 2023/04/01 06:00 [pubmed] PHST- 2023/03/31 00:00 [pmc-release] AID - openhrt-2022-002194 [pii] AID - 10.1136/openhrt-2022-002194 [doi] PST - ppublish SO - Open Heart. 2023 Mar;10(1):e002194. doi: 10.1136/openhrt-2022-002194. PMID- 36996363 OWN - NLM STAT- MEDLINE DCOM- 20230403 LR - 20230403 IS - 1538-8646 (Electronic) IS - 0730-4625 (Linking) VI - 42 IP - 3 DP - 2023 May-Jun 01 TI - Implementing a Rapid Response Team: A Quality Improvement Project in a Low- to Middle-Income Country. PG - 171-178 LID - 10.1097/DCC.0000000000000584 [doi] AB - BACKGROUND: The benefits of rapid response teams (RRTs) have been controversial with few studies conducted in low- to middle-income countries. OBJECTIVE: The aim of this study was to investigate the effectiveness of implementing an RRT on 4 patient outcomes. METHODS: We conducted a quality improvement pre-and-post design using the Plan-Do-Study-Act model in a tertiary hospital in a low- to middle-income country. We collected data before and after implementing the RRT in 4 phases and over 4 years. RESULTS: Survival to discharge after cardiac arrest was 25.0% per 1000 discharges in 2016 and increased to 50% in 2019, a 50% increase. The rate of activations per 1000 discharges was 20.45% for the code team in 2016 and 33.6% for the RRT team in 2019. Thirty-one patients who arrested were transferred to a critical care unit before implementing the RRT, and 33% of such patients were transferred after. The time it took the code team to arrive at the bedside was 3.1 minutes in 2016 and decreased to 1.7 minutes for the RRT team to arrive in 2019, a 46% decrease. DISCUSSION AND CLINICAL IMPLICATIONS: Implementing an RTT led by nurses in a low- to middle-income country increased the survival rate of patients who had a cardiac arrest by 50%. The role of nurses in improving patient outcomes and saving lives is substantial and empowers nurses to call for assistance to save patient lives who show early signs of a cardiac arrest. Hospital administrators should continue to use strategies to improve nurses' timely response to the clinical deterioration of patients and to continue to collect data to assess the effect of the RRT over time. CI - Copyright (c) 2023 Wolters Kluwer Health, Inc. All rights reserved. FAU - Jamous, Sabat El AU - Jamous SE FAU - Kouatly, Iman AU - Kouatly I FAU - Irani, Joanna AU - Irani J FAU - Badr, Lina Kurdahi AU - Badr LK LA - eng PT - Journal Article PL - United States TA - Dimens Crit Care Nurs JT - Dimensions of critical care nursing : DCCN JID - 8211489 MH - Humans MH - *Hospital Rapid Response Team MH - Quality Improvement MH - Intensive Care Units MH - *Heart Arrest/therapy MH - Patient Discharge EDAT- 2023/03/31 06:00 MHDA- 2023/04/03 06:42 CRDT- 2023/03/30 16:01 PHST- 2023/04/03 06:42 [medline] PHST- 2023/03/30 16:01 [entrez] PHST- 2023/03/31 06:00 [pubmed] AID - 00003465-202305000-00008 [pii] AID - 10.1097/DCC.0000000000000584 [doi] PST - ppublish SO - Dimens Crit Care Nurs. 2023 May-Jun 01;42(3):171-178. doi: 10.1097/DCC.0000000000000584. PMID- 36995405 OWN - NLM STAT- MEDLINE DCOM- 20240226 LR - 20261010 IS - 1432-1971 (Electronic) IS - 0172-0643 (Linking) VI - 45 IP - 3 DP - 2024 Mar TI - Is There a Role for Alcohol Septal Ablation in Young Patients with Medically Refractory Hypertrophic Obstructive Cardiomyopathy? PG - 648-659 LID - 10.1007/s00246-023-03145-6 [doi] AB - Surgical myectomy is recommended for symptomatic hypertrophic obstructive cardiomyopathy (HOCM) after optimal pharmacological therapy. Percutaneous transluminal septal myocardial ablation (PTSMA) is reserved for high-risk adults. Symptomatic patients below 25 years underwent either surgery or PTSMA after heart-team discussion and informed consent. Echocardiography assessed gradients in surgical group. PTSMA group underwent invasive transseptal hemodynamic assessment, selective coronary angiography and super-selective cannulation of septal perforators using microcatheters. Contrast echocardiography through the microcatheter identified the myocardial target for PTSMA. Hemodynamic and electrocardiographic monitoring guided alcohol injection. Both groups were continued on beta-blockers. Symptoms, echocardiographic gradients and Brain natriuretic peptide (NTproBNP) measurements were assessed on follow-up. Twelve patients aged 5-23 years (11-98 kg) formed the study group. Indications for PTSMA in 8 patients included abnormal mitral valve anatomy warranting replacement (n = 3), Jehovah's witness (n = 2), severe neurodevelopmental and growth retardation (n = 1) and refusal of surgery (n = 2). PTSMA targeted first perforator (n = 5), second perforator (n = 2) and anomalous septal artery from left main trunk (n = 1). Outflow gradient reduced from 92.5 +/- 19.7 to 33.1 +/- 13.5 mmHg. At a median follow-up of 38 months (range 3-120 weeks), the peak instantaneous echocardiographic gradient was 32 +/- 16.5 mmHg. Gradient reduced in four surgical patients from 86.5 +/- 16.3 mmHg to 42 +/- 14.7 mm Hg. All patients were in NYHA class I/II on follow-up. The mean NTproBNP in PTSMA group reduced from 6084 +/- 3628 pg/ml to 3081 +/- 2019 pg/ml; it was 1396 and 1795 pg/ml in surgery. PTSMA may be considered in medically refractory high-risk young patients. It relieves symptoms and reduces gradient. Though surgery is preferred in young patients, PTSMA may have a role in selected patients. CI - (c) 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Sivakumar, Kothandam AU - Sivakumar K AD - Department of Pediatric Cardiology, Institute of Cardio Vascular Diseases, Madras Medical Mission, 4A, Dr J J Nagar, Mogappair, Chennai, 600089, India. drkumarsiva@hotmail.com. FAU - Jain, Gaurav AU - Jain G AD - Department of Pediatric Cardiology, Institute of Cardio Vascular Diseases, Madras Medical Mission, 4A, Dr J J Nagar, Mogappair, Chennai, 600089, India. LA - eng PT - Journal Article DEP - 20230330 PL - United States TA - Pediatr Cardiol JT - Pediatric cardiology JID - 8003849 SB - IM MH - Adult MH - Humans MH - *Cardiac Surgical Procedures MH - *Cardiomyopathy, Hypertrophic/diagnostic imaging/surgery MH - Heart MH - Vascular Surgical Procedures MH - Myocardium OTO - NOTNLM OT - Dynamic outflow obstruction OT - Ethyl alcohol OT - Extended septal myectomy OT - Noonan syndrome OT - Percutaneous transluminal septal myocardial ablation OT - Subvalvar left ventricular outflow obstruction EDAT- 2023/03/31 06:00 MHDA- 2024/02/26 06:45 CRDT- 2023/03/30 11:14 PHST- 2022/12/21 00:00 [received] PHST- 2023/03/11 00:00 [accepted] PHST- 2024/02/26 06:45 [medline] PHST- 2023/03/31 06:00 [pubmed] PHST- 2023/03/30 11:14 [entrez] AID - 10.1007/s00246-023-03145-6 [pii] AID - 10.1007/s00246-023-03145-6 [doi] PST - ppublish SO - Pediatr Cardiol. 2024 Mar;45(3):648-659. doi: 10.1007/s00246-023-03145-6. Epub 2023 Mar 30. PMID- 36993787 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230331 IS - 2451-8654 (Electronic) IS - 2451-8654 (Linking) VI - 33 DP - 2023 Jun TI - The feasibility and acceptability of an early tele-palliative care intervention to improve quality of life in heart failure patients in Iran: A protocol for a randomized controlled trial. PG - 101114 LID - 10.1016/j.conctc.2023.101114 [doi] LID - 101114 AB - BACKGROUND: Heart failure (HF) has become a global health problem that has affected the quality of life of millions of people. One approach to improving patients' quality of life (QoL) with chronic diseases such as HF is palliative care. In Iran, the bulk of palliative care research is directed to patients with cancer, with the primary focus on the physical aspect rather than the psychosocial and spiritual aspects of palliative care. To address this gap, this study aims to determine the feasibility and acceptability of this early tele-palliative care intervention to improve quality of life in heart failure patients in Iran. METHODS: The early tele-palliative care versus usual care study is designed as a single-centre, randomised, feasibility trial of 50 patients with heart failure aged 18 to 65 and clinician-determined New York Heart Association class II/III or American College of Cardiology stage B/C HF, recruited in Imam Khomeini Hospital Complex, Tehran, Iran. This intervention contains 6 weekly educational webinars and concurrent WhatsApp(R) group activities. Program feasibility and acceptability will be assessed by measuring the recruitment, attrition, and questionnaire completion rates; satisfaction and attitudes about the intervention will be measured via a telephone-based interviews. Secondary outcomes of Qol, mood status and number of emergency department visits will be measured with validated instruments. Participants in both groups will be followed up for 6 weeks, and the measures will be re-administered. Appropriate statistical tests will be used to analyse the data. CONCLUSION: This is the first early tele-palliative care intervention designed for heart failure patients in Iran. The intervention has been developed by a multidisciplinary team of academic and clinical professionals with patient stakeholder input to create a rigorous and culturally responsive approach for palliative care delivery for heart failure patients in Iran. TRIAL REGISTRATION: IRCT registration number - IRCT20100725004443N29. CI - (c) 2023 The Authors. FAU - Mirshahi, Arvin AU - Mirshahi A AD - Department of Medical-Surgical Nursing, School of Nursing and Midwifery, Tehran University of Medical Sciences, Tehran, Iran. AD - USERN Care (TUMS) Office, School of Nursing and Midwifery, Tehran University of Medical Sciences, Tehran, Iran. FAU - Ghiasvandian, Shahrzad AU - Ghiasvandian S AD - Department of Medical-Surgical Nursing, School of Nursing and Midwifery, Tehran University of Medical Sciences, Tehran, Iran. FAU - Khoshavi, Meysam AU - Khoshavi M AD - Department of Cardiology, School of Medicine, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran. FAU - Riahi, Seyed Mohammad AU - Riahi SM AD - School of Medicine, Cardiovascular Diseases Research Center, Birjand University of Medical Sciences, Tehran, Iran. FAU - Khanipour-Kencha, Ali AU - Khanipour-Kencha A AD - Department of Medical-Surgical Nursing, School of Nursing and Midwifery, Tehran University of Medical Sciences, Tehran, Iran. AD - USERN Care (TUMS) Office, School of Nursing and Midwifery, Tehran University of Medical Sciences, Tehran, Iran. FAU - Bakitas, Marie AU - Bakitas M AD - School of Nursing, and Department of Medicine, Division of Gerontology, Geriatrics, and Palliative Care, University of Alabama at Birmingham, Birmingham, AL, USA. FAU - Dionne-Odom, J Nicholas AU - Dionne-Odom JN AD - School of Nursing, University of Alabama at Birmingham (UAB) and UAB Center for Palliative and Supportive Care, USA. FAU - Wells, Rachel AU - Wells R AD - School of Nursing, University of Alabama at Birmingham, Birmingham, AL, USA. FAU - Zakerimoghadam, Masoumeh AU - Zakerimoghadam M AD - Department of Medical-Surgical Nursing, School of Nursing and Midwifery, Tehran University of Medical Sciences, Tehran, Iran. LA - eng PT - Journal Article DEP - 20230320 PL - Netherlands TA - Contemp Clin Trials Commun JT - Contemporary clinical trials communications JID - 101671157 PMC - PMC10041464 OTO - NOTNLM OT - Clinical trial protocol OT - Feasibility studies OT - Heart failure OT - Iran OT - Palliative care OT - Telemedicine COIS- None declared. EDAT- 2023/03/31 06:00 MHDA- 2023/03/31 06:01 PMCR- 2023/03/20 CRDT- 2023/03/30 02:55 PHST- 2022/12/05 00:00 [received] PHST- 2023/02/27 00:00 [revised] PHST- 2023/03/10 00:00 [accepted] PHST- 2023/03/31 06:01 [medline] PHST- 2023/03/30 02:55 [entrez] PHST- 2023/03/31 06:00 [pubmed] PHST- 2023/03/20 00:00 [pmc-release] AID - S2451-8654(23)00060-1 [pii] AID - 101114 [pii] AID - 10.1016/j.conctc.2023.101114 [doi] PST - epublish SO - Contemp Clin Trials Commun. 2023 Mar 20;33:101114. doi: 10.1016/j.conctc.2023.101114. eCollection 2023 Jun. PMID- 36991137 OWN - NLM STAT- MEDLINE DCOM- 20230626 LR - 20230919 IS - 1615-2573 (Electronic) IS - 0910-8327 (Print) IS - 0910-8327 (Linking) VI - 38 IP - 8 DP - 2023 Aug TI - Predictors of physical frailty improvement in older patients enrolled in a multidisciplinary cardiac rehabilitation program. PG - 1056-1064 LID - 10.1007/s00380-023-02254-9 [doi] AB - Cardiac rehabilitation (CR) improves clinical and functional recovery in older patients after acute cardiac syndromes, whose outcome is influenced by cardiac disease severity, but also by comorbidity and frailty. The aim of the study was to analyze the predictors of physical frailty improvement during the CR program. Data were collected in all patients aged > 75 years consecutively admitted from 1 January to December 2017 to our CR, consisting of 5-day-per-week of 30-min session of biking or calisthenics on alternate days for 4 weeks. Physical frailty was measured with short physical performance battery (SPPB) at the entry and the end of CR. Outcome was represented by an increase of at least 1 point in the SPPB score from baseline to the end of the CR program. In our study population of 100 patients, mean age 81 years, we demonstrated that a strong predictor of improvement in SPPB score was the poorer performance in the test at baseline; for Delta-1 point of score, we registered an OR 2.50 (95% CI = 1.64-3.85; p = 0.001) of probability to improve the physical performance at the end of CR. Interestingly those patients with worse performance at SPPB balance and chair standing task showed greater probability of ameliorating their physical frailty profile at the end of CR. Our data strongly suggest that CR program after acute cardiac syndrome produces a significant physical frailty improvement in those patients with worse frailty phenotype with an impairment in chair standing or balance at entry. CI - (c) 2023. The Author(s). FAU - Baldasseroni, Samuele AU - Baldasseroni S AD - Department of Experimental and Clinical Medicine, University of Florence and Cardiac Rehabilitation Unit, Azienda Ospedaliero-Universitaria Careggi, Largo Brambilla 3, 50134, Florence, Italy. FAU - Silverii, Maria Vittoria AU - Silverii MV AD - Department of Experimental and Clinical Medicine, University of Florence and Cardiac Rehabilitation Unit, Azienda Ospedaliero-Universitaria Careggi, Largo Brambilla 3, 50134, Florence, Italy. FAU - Herbst, Andrea AU - Herbst A AD - Department of Experimental and Clinical Medicine, University of Florence and Cardiac Rehabilitation Unit, Azienda Ospedaliero-Universitaria Careggi, Largo Brambilla 3, 50134, Florence, Italy. FAU - Orso, Francesco AU - Orso F AD - Department of Experimental and Clinical Medicine, University of Florence and Cardiac Rehabilitation Unit, Azienda Ospedaliero-Universitaria Careggi, Largo Brambilla 3, 50134, Florence, Italy. FAU - Di Bari, Mauro AU - Di Bari M AD - Department of Experimental and Clinical Medicine, University of Florence and Cardiac Rehabilitation Unit, Azienda Ospedaliero-Universitaria Careggi, Largo Brambilla 3, 50134, Florence, Italy. FAU - Pratesi, Alessandra AU - Pratesi A AD - Department of Experimental and Clinical Medicine, University of Florence and Cardiac Rehabilitation Unit, Azienda Ospedaliero-Universitaria Careggi, Largo Brambilla 3, 50134, Florence, Italy. FAU - Burgisser, Costanza AU - Burgisser C AD - Department of Experimental and Clinical Medicine, University of Florence and Cardiac Rehabilitation Unit, Azienda Ospedaliero-Universitaria Careggi, Largo Brambilla 3, 50134, Florence, Italy. FAU - Ungar, Andrea AU - Ungar A AD - Department of Experimental and Clinical Medicine, University of Florence and Cardiac Rehabilitation Unit, Azienda Ospedaliero-Universitaria Careggi, Largo Brambilla 3, 50134, Florence, Italy. FAU - Marchionni, Niccolo AU - Marchionni N AD - Department of Experimental and Clinical Medicine, University of Florence and Cardiac Rehabilitation Unit, Azienda Ospedaliero-Universitaria Careggi, Largo Brambilla 3, 50134, Florence, Italy. FAU - Fattirolli, Francesco AU - Fattirolli F AD - Department of Experimental and Clinical Medicine, University of Florence and Cardiac Rehabilitation Unit, Azienda Ospedaliero-Universitaria Careggi, Largo Brambilla 3, 50134, Florence, Italy. francesco.fattirolli@unifi.it. LA - eng PT - Journal Article DEP - 20230330 PL - Japan TA - Heart Vessels JT - Heart and vessels JID - 8511258 SB - IM MH - Humans MH - *Frailty/diagnosis MH - *Cardiac Rehabilitation MH - Recovery of Function MH - Hospitalization MH - Physical Functional Performance PMC - PMC10289976 OTO - NOTNLM OT - Acute coronary syndrome OT - Cardiac rehabilitation OT - Elderly OT - Short physical performance battery COIS- The authors declare that they have no conflict of interest. EDAT- 2023/03/30 06:00 MHDA- 2023/06/26 06:42 PMCR- 2023/03/30 CRDT- 2023/03/29 23:21 PHST- 2022/05/09 00:00 [received] PHST- 2023/02/16 00:00 [accepted] PHST- 2023/06/26 06:42 [medline] PHST- 2023/03/30 06:00 [pubmed] PHST- 2023/03/29 23:21 [entrez] PHST- 2023/03/30 00:00 [pmc-release] AID - 10.1007/s00380-023-02254-9 [pii] AID - 2254 [pii] AID - 10.1007/s00380-023-02254-9 [doi] PST - ppublish SO - Heart Vessels. 2023 Aug;38(8):1056-1064. doi: 10.1007/s00380-023-02254-9. Epub 2023 Mar 30. PMID- 36990441 OWN - NLM STAT- MEDLINE DCOM- 20240620 LR - 20241122 IS - 1477-111X (Electronic) IS - 0267-6591 (Linking) VI - 39 IP - 5 DP - 2024 Jul TI - Mechanical life support algorithm for emergency management of patient receiving extracorporeal membrane oxygenation. PG - 896-901 LID - 10.1177/02676591231168291 [doi] AB - BACKGROUND: There are limited practical advanced life support algorithms to aid teams in the management of cardiac arrest in patients on extracorporeal membrane oxygenation (ECMO). METHODS: In our specialist tertiary referral centre we developed, by iteration, a novel resuscitation algorithm for ECMO emergencies which we validated through simulation and assessment of our multi-disciplinary team. A Mechanical Life Support course was established to provide theoretical and practical education combined with simulation to consolidate knowledge and confidence in algorithm use. We assessed these measures using confidence scoring, a key performance indicator (the time taken to resolve gas line disconnection) and a multiple choice question (MCQ) examination. RESULTS: Following this intervention the median confidence scores increased from 2 (Interquartile range IQR 2, 3) to 4 (IQR 4, 4) out of maximum 5 (n = 53, p < 0.0001). Theoretical knowledge assessed by median MCQ score increased from 8 (6, 9) to 9 (7, 10) out of maximum 11 (n = 53, p0.0001). The use of the ECMO algorithm reduced the time taken by teams in a simulated emergency to identify a gas line disconnection and resolve the problem from median 128 s (65, 180) to 44 s (31, 59) (n = 36, p 0.001) and by a mean of 81.5 s (CI 34, 116, p = 0.001). CONCLUSIONS: We present an evidence based practical ECMO resuscitation algorithm that provides guidance to clinical teams responding to cardiac arrest in ECMO patients covering both patient and ECMO troubleshooting. FAU - Akhtar, Waqas AU - Akhtar W AUID- ORCID: 0000-0001-7563-7346 AD - Harefield Hospital, Royal Brompton and Harefield Hospitals, Guys and St Thomas' NHS Foundation Trust, London, UK. FAU - Pinto, Sofia AU - Pinto S AD - Harefield Hospital, Royal Brompton and Harefield Hospitals, Guys and St Thomas' NHS Foundation Trust, London, UK. FAU - Gerlando, Emanuele AU - Gerlando E AD - Harefield Hospital, Royal Brompton and Harefield Hospitals, Guys and St Thomas' NHS Foundation Trust, London, UK. FAU - Pitt, Timothy AU - Pitt T AD - Harefield Hospital, Royal Brompton and Harefield Hospitals, Guys and St Thomas' NHS Foundation Trust, London, UK. FAU - Banya, Winston AU - Banya W AD - Harefield Hospital, Royal Brompton and Harefield Hospitals, Guys and St Thomas' NHS Foundation Trust, London, UK. FAU - Dunning, John AU - Dunning J AD - Harefield Hospital, Royal Brompton and Harefield Hospitals, Guys and St Thomas' NHS Foundation Trust, London, UK. FAU - Bowles, Christopher T AU - Bowles CT AD - Harefield Hospital, Royal Brompton and Harefield Hospitals, Guys and St Thomas' NHS Foundation Trust, London, UK. FAU - Rosenberg, Alex AU - Rosenberg A AD - Harefield Hospital, Royal Brompton and Harefield Hospitals, Guys and St Thomas' NHS Foundation Trust, London, UK. LA - eng PT - Journal Article DEP - 20230329 PL - England TA - Perfusion JT - Perfusion JID - 8700166 SB - IM MH - *Extracorporeal Membrane Oxygenation/methods MH - Humans MH - *Algorithms MH - Heart Arrest/therapy MH - Male MH - Female OTO - NOTNLM OT - algorithm OT - cardiac arrest OT - emergency OT - extracorporeal membrane oxygenation OT - resuscitation COIS- Declaration of conflicting interestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: WA Abbott/Medtronic/Abiomed Educational Grant, AR Abiomed Honoraria, SP Abiomed Honoraria. EDAT- 2023/03/30 06:00 MHDA- 2024/06/20 12:42 CRDT- 2023/03/29 19:42 PHST- 2024/06/20 12:42 [medline] PHST- 2023/03/30 06:00 [pubmed] PHST- 2023/03/29 19:42 [entrez] AID - 10.1177/02676591231168291 [doi] PST - ppublish SO - Perfusion. 2024 Jul;39(5):896-901. doi: 10.1177/02676591231168291. Epub 2023 Mar 29. PMID- 36989524 OWN - NLM STAT- MEDLINE DCOM- 20230403 LR - 20260127 IS - 1945-0257 (Electronic) IS - 1945-0257 (Linking) VI - 27 IP - 3 DP - 2023 Mar TI - Differential Expression of Caveolin-3, Suppression of Tumorigenicity 2, and Growth Differentiation Factor-15 Genes and Their Association with Acute Myocardial Infarction: A Cross-Sectional Study in a Multi-Specialty Hospital in Tamil Nadu. PG - 109-119 LID - 10.1089/gtmb.2022.0162 [doi] AB - Background: Acute myocardial infarction (AMI) is one of the world's leading causes of cardiovascular death. Recent studies have reported the influence of the genes caveolin-3 (CAV3), suppression of tumorigenicity 2, and growth differentiating factor-15 in cardiovascular diseases, especially myocardial infarction, but their role and function remain unclear. Hence, this study was designed to evaluate the expression levels of these three genes in AMI and understanding the role of CAV-3 in the pathogenesis of AMI. Methods and Results: Blood samples were collected from 50 AMI patients and 50 non-AMI controls in this cross-sectional study. Relative expression levels of the three genes were performed using real-time PCR. Bioinformatics tools were used for functional gene enrichment and protein-protein interactions. CAV-3 was significantly upregulated among AMI patients compared to controls. In silico analyses identified CAV-3 as playing critical roles in smooth muscle contraction, cardiac conduction, and calcium-mediated transport via binding with essential proteins including dysferlin and annexins Conclusion: This study is a first of its kind, reporting an upregulation of CAV-3 in AMI patients. The expression of all three genes significantly influenced the systolic function of the heart in AMI patients. A more in-depth understanding of CAV-3 in the pathophysiology of AMI is essential and it may prove to be a novel. FAU - Venugopal, Priyanka AU - Venugopal P AUID- ORCID: 0000-0003-1830-4419 AD - Clinical Research, Hindu Mission Hospital, Chennai, India. FAU - Logu, Kannika AU - Logu K AD - Cardiology, Hindu Mission Hospital, Chennai, India. FAU - Balakrishnan, Karthikeyan AU - Balakrishnan K AD - Cardiology, Hindu Mission Hospital, Chennai, India. FAU - Subbaih, Usha AU - Subbaih U AD - Human Genetics Research Centre, Sree Balaji Dental College and Hospital, Bharath Institute of Higher Education and Research (BIHER), Chennai, India. FAU - Damal Kandadai, Sriram AU - Damal Kandadai S AD - Diabetology and Endocrinology, Hindu Mission Hospital, Chennai, India. FAU - George, Melvin AU - George M AUID- ORCID: 0000-0001-7101-8513 AD - Clinical Research, Hindu Mission Hospital, Chennai, India. LA - eng PT - Journal Article PL - United States TA - Genet Test Mol Biomarkers JT - Genetic testing and molecular biomarkers JID - 101494210 RN - 0 (Caveolin 3) RN - 0 (Growth Differentiation Factors) RN - 0 (GDF15 protein, human) RN - 0 (Growth Differentiation Factor 15) RN - 0 (IL1RL1 protein, human) RN - 0 (Interleukin-1 Receptor-Like 1 Protein) SB - IM MH - Humans MH - *Caveolin 3/genetics MH - Cross-Sectional Studies MH - Growth Differentiation Factors MH - Hospitals MH - India MH - *Myocardial Infarction/genetics MH - Growth Differentiation Factor 15 MH - Interleukin-1 Receptor-Like 1 Protein OTO - NOTNLM OT - caveolin-3 OT - fibrosis OT - markers OT - myocardial infarction OT - pathogenesis EDAT- 2023/03/30 06:00 MHDA- 2023/03/31 06:41 CRDT- 2023/03/29 17:22 PHST- 2023/03/31 06:41 [medline] PHST- 2023/03/29 17:22 [entrez] PHST- 2023/03/30 06:00 [pubmed] AID - 10.1089/gtmb.2022.0162 [doi] PST - ppublish SO - Genet Test Mol Biomarkers. 2023 Mar;27(3):109-119. doi: 10.1089/gtmb.2022.0162. PMID- 36984587 OWN - NLM STAT- MEDLINE DCOM- 20230330 LR - 20230331 IS - 1648-9144 (Electronic) IS - 1010-660X (Print) IS - 1010-660X (Linking) VI - 59 IP - 3 DP - 2023 Mar 16 TI - Management of Coronary Artery Disease in CADASIL Patients: Review of Current Literature. LID - 10.3390/medicina59030586 [doi] LID - 586 AB - Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is the most common heritable form of vascular dementia in adults. It is well-established that CADASIL results in neurocognitive dysfunction and mood disturbance. There is also cumulative evidence that CADASIL patients are more susceptible to ischemic heart disease. The aim of this study is to review the current literature regarding the incidence of coronary artery disease in CADASIL patients with a focus on the various management options and the clinical challenges associated with each of these treatment strategies. We conducted a literature search using Cochrane, MEDLINE, and EMBASE for papers that reported the occurrence of coronary artery disease in patients with CADASIL. We supplemented the search with a manual search in Google Scholar. Only case reports, case series, and original articles were included. The search resulted in six reports indicating the association between coronary artery disease and CADASIL and its management. Evidence suggests that extracranial manifestations of CADASIL may include coronary artery disease, presenting as a more extensive burden of disease in younger patients. Surgical and percutaneous revascularization strategies are feasible, but the incidence of peri-procedural stroke remains significant and should be weighed against the potential benefit derived from either of these strategies. A multidisciplinary approach to therapy, with perspectives from neurologists, cardiologists, and cardiac surgeons, is needed to provide the appropriate treatment to the CADASIL patient with severe coronary artery disease. Future studies should be directed toward the development of targeted therapies that may help with the early detection and prevention of disease progress in these patients. FAU - Servito, Maria AU - Servito M AD - Department of Cardiac Surgery, University of Manitoba, Winnipeg, MB R2H 2A6, Canada. FAU - Gill, Isha AU - Gill I AD - Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON K7L 2V7, Canada. FAU - Durbin, Joshua AU - Durbin J AUID- ORCID: 0009-0000-0698-8636 AD - Division of Cardiology, Department of Medicine, Queen's University, Kingston, ON K7L 2V7, Canada. FAU - Ghasemlou, Nader AU - Ghasemlou N AD - Department of Anaesthesiology, Queen's University, Kingston, ON K7L 2V7, Canada. FAU - Popov, Aron-Frederik AU - Popov AF AUID- ORCID: 0000-0003-4226-3004 AD - Department of Cardiothoracic Surgery, Helios Clinic, 53721 Siegburg, Germany. FAU - Stephen, Christopher D AU - Stephen CD AD - Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. FAU - El-Diasty, Mohammad AU - El-Diasty M AUID- ORCID: 0000-0002-1807-8397 AD - Division of Cardiac Surgery, Department of Surgery, Queen's University, Kingston, ON K7L 2V7, Canada. LA - eng PT - Journal Article PT - Review DEP - 20230316 PL - Switzerland TA - Medicina (Kaunas) JT - Medicina (Kaunas, Lithuania) JID - 9425208 SB - IM MH - Adult MH - Humans MH - *CADASIL/complications/therapy MH - *Coronary Artery Disease/complications/therapy MH - Cerebral Infarction MH - *Stroke/complications MH - *Myocardial Ischemia/complications MH - Magnetic Resonance Imaging PMC - PMC10059795 OTO - NOTNLM OT - CADASIL OT - cerebral microbleeds OT - coronary artery disease OT - stroke COIS- The authors declare no conflict of interest. EDAT- 2023/03/30 06:00 MHDA- 2023/03/30 06:11 PMCR- 2023/03/16 CRDT- 2023/03/29 01:50 PHST- 2022/12/28 00:00 [received] PHST- 2023/02/27 00:00 [revised] PHST- 2023/03/06 00:00 [accepted] PHST- 2023/03/30 06:11 [medline] PHST- 2023/03/29 01:50 [entrez] PHST- 2023/03/30 06:00 [pubmed] PHST- 2023/03/16 00:00 [pmc-release] AID - medicina59030586 [pii] AID - medicina-59-00586 [pii] AID - 10.3390/medicina59030586 [doi] PST - epublish SO - Medicina (Kaunas). 2023 Mar 16;59(3):586. doi: 10.3390/medicina59030586. PMID- 36984479 OWN - NLM STAT- MEDLINE DCOM- 20230330 LR - 20230331 IS - 1648-9144 (Electronic) IS - 1010-660X (Print) IS - 1010-660X (Linking) VI - 59 IP - 3 DP - 2023 Feb 28 TI - Optimization of Therapy and the Risk of Probiotic Use during Antibiotherapy in Septic Critically Ill Patients: A Narrative Review. LID - 10.3390/medicina59030478 [doi] LID - 478 AB - Optimizing the entire therapeutic regimen in septic critically ill patients should be based not only on improving antibiotic use but also on optimizing the entire therapeutic regimen by considering possible drug-drug or drug-nutrient interactions. The aim of this narrative review is to provide a comprehensive overview on recent advances to optimize the therapeutic regimen in septic critically ill patients based on a pharmacokinetics and pharmacodynamic approach. Studies on recent advances on TDM-guided drug therapy optimization based on PK and/or PD results were included. Studies on patients <18 years old or with classical TDM-guided therapy were excluded. New approaches in TDM-guided therapy in septic critically ill patients based on PK and/or PD parameters are presented for cefiderocol, carbapenems, combinations beta-lactams/beta-lactamase inhibitors (piperacillin/tazobactam, ceftolozane/tazobactam, ceftazidime/avibactam), plazomicin, oxazolidinones and polymyxins. Increased midazolam toxicity in combination with fluconazole, nephrotoxic synergism between furosemide and aminoglycosides, life-threatening hypoglycemia after fluoroquinolone and insulin, prolonged muscle weakness and/or paralysis after neuromuscular blocking agents and high-dose corticosteroids combinations are of interest in critically ill patients. In the real-world practice, the use of probiotics with antibiotics is common; even data about the risk and benefits of probiotics are currently spares and inconclusive. According to current legislation, probiotic use does not require safety monitoring, but there are reports of endocarditis, meningitis, peritonitis, or pneumonia associated with probiotics in critically ill patients. In addition, probiotics are associated with risk of the spread of antimicrobial resistance. The TDM-guided method ensures a true optimization of antibiotic therapy, and particular efforts should be applied globally. In addition, multidrug and drug-nutrient interactions in critically ill patients may increase the likelihood of adverse events and risk of death; therefore, the PK and PD particularities of the critically ill patient require a multidisciplinary approach in which knowledge of clinical pharmacology is essential. FAU - Onofrei, Maria Ioana AU - Onofrei MI AD - Clinic of Infectious Diseases, "Sf. Parascheva" Clinical Hospital of Infectious Diseases, 700116 Iasi, Romania. AD - Department of Infectious Diseases, Grigore T. Popa University of Medicine and Pharmacy of Iasi, 16 Universitatii Street, 700115 Iasi, Romania. FAU - Ghiciuc, Cristina Mihaela AU - Ghiciuc CM AUID- ORCID: 0000-0003-1791-0425 AD - Pharmacology, Clinical Pharmacology and Algeziology, Department of Morpho-Functional Sciences II, Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy of Iasi, 16 Universitatii Street, 700115 Iasi, Romania. FAU - Luca, Catalina Mihaela AU - Luca CM AD - Clinic of Infectious Diseases, "Sf. Parascheva" Clinical Hospital of Infectious Diseases, 700116 Iasi, Romania. AD - Department of Infectious Diseases, Grigore T. Popa University of Medicine and Pharmacy of Iasi, 16 Universitatii Street, 700115 Iasi, Romania. FAU - Postolache, Paraschiva AU - Postolache P AD - Department of Medicine I-Pulmonary Rehabilitation Clinic, Grigore T. Popa University of Medicine and Pharmacy of Iasi, 16 Universitatii Street, 700115 Iasi, Romania. FAU - Sapaniuc, Cristina AU - Sapaniuc C AD - Clinic of Infectious Diseases, "Sf. Parascheva" Clinical Hospital of Infectious Diseases, 700116 Iasi, Romania. AD - Department of Infectious Diseases, Grigore T. Popa University of Medicine and Pharmacy of Iasi, 16 Universitatii Street, 700115 Iasi, Romania. FAU - Enache Leonte, Georgiana AU - Enache Leonte G AD - Clinic of Infectious Diseases, "Sf. Parascheva" Clinical Hospital of Infectious Diseases, 700116 Iasi, Romania. AD - Department of Infectious Diseases, Grigore T. Popa University of Medicine and Pharmacy of Iasi, 16 Universitatii Street, 700115 Iasi, Romania. FAU - Rosu, Florin Manuel AU - Rosu FM AD - Clinic of Infectious Diseases, "Sf. Parascheva" Clinical Hospital of Infectious Diseases, 700116 Iasi, Romania. AD - Department of Infectious Diseases, Grigore T. Popa University of Medicine and Pharmacy of Iasi, 16 Universitatii Street, 700115 Iasi, Romania. LA - eng PT - Journal Article PT - Review DEP - 20230228 PL - Switzerland TA - Medicina (Kaunas) JT - Medicina (Kaunas, Lithuania) JID - 9425208 RN - 0 (Anti-Bacterial Agents) RN - SE10G96M8W (Tazobactam) RN - 157044-21-8 (Piperacillin, Tazobactam Drug Combination) SB - IM MH - Humans MH - Adolescent MH - *Critical Illness/therapy MH - *Anti-Bacterial Agents/adverse effects MH - Tazobactam MH - Piperacillin, Tazobactam Drug Combination/pharmacokinetics PMC - PMC10056847 OTO - NOTNLM OT - PK/PD relationship OT - critically ill OT - pharmacodynamic OT - pharmacokinetics OT - probiotics OT - septic patients OT - septic stress OT - synbiotics OT - therapeutic drug monitoring COIS- The authors declare no conflict of interest. EDAT- 2023/03/30 06:00 MHDA- 2023/03/30 06:11 PMCR- 2023/02/28 CRDT- 2023/03/29 01:49 PHST- 2023/02/01 00:00 [received] PHST- 2023/02/24 00:00 [revised] PHST- 2023/02/25 00:00 [accepted] PHST- 2023/03/30 06:11 [medline] PHST- 2023/03/29 01:49 [entrez] PHST- 2023/03/30 06:00 [pubmed] PHST- 2023/02/28 00:00 [pmc-release] AID - medicina59030478 [pii] AID - medicina-59-00478 [pii] AID - 10.3390/medicina59030478 [doi] PST - epublish SO - Medicina (Kaunas). 2023 Feb 28;59(3):478. doi: 10.3390/medicina59030478. PMID- 36983180 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231102 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 12 IP - 6 DP - 2023 Mar 10 TI - The Global Burden of Valvular Heart Disease: From Clinical Epidemiology to Management. LID - 10.3390/jcm12062178 [doi] LID - 2178 AB - Valvular heart disease is a leading cause of cardiovascular morbidity and mortality and a major contributor of symptoms and functional disability. Knowledge of valvular heart disease epidemiology and a deep comprehension of the geographical and temporal trends are crucial for clinical advances and the formulation of effective health policy for primary and secondary prevention. This review mainly focuses on the epidemiology of primary (organic, related to the valve itself) valvular disease and its management, especially emphasizing the importance of heart valve centers in ensuring the best care of patients through a multidisciplinary team. FAU - Santangelo, Gloria AU - Santangelo G AD - Department of Cardio-Thoracic-Vascular Diseases, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy. FAU - Bursi, Francesca AU - Bursi F AD - Division of Cardiology, Department of Health Sciences, San Paolo Hospital, University of Milan, 20122 Milan, Italy. FAU - Faggiano, Andrea AU - Faggiano A AUID- ORCID: 0000-0002-3247-3203 AD - Department of Cardio-Thoracic-Vascular Diseases, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy. AD - Department of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy. FAU - Moscardelli, Silvia AU - Moscardelli S AD - Division of Cardiology, Department of Health Sciences, San Paolo Hospital, University of Milan, 20122 Milan, Italy. FAU - Simeoli, Pasquale Simone AU - Simeoli PS AD - Division of Cardiology, Department of Health Sciences, San Paolo Hospital, University of Milan, 20122 Milan, Italy. FAU - Guazzi, Marco AU - Guazzi M AD - Division of Cardiology, Department of Health Sciences, San Paolo Hospital, University of Milan, 20122 Milan, Italy. FAU - Lorusso, Roberto AU - Lorusso R AUID- ORCID: 0000-0002-1777-2045 AD - Cardiothoracic Surgery Department, Heart and Vascular Centre, Maastricht University Medical Centre (MUMC), The Cardiovascular Research Institute Maastricht (CARIM), 6229 ER Maastricht, The Netherlands. FAU - Carugo, Stefano AU - Carugo S AUID- ORCID: 0000-0002-5166-0899 AD - Department of Cardio-Thoracic-Vascular Diseases, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy. AD - Department of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy. FAU - Faggiano, Pompilio AU - Faggiano P AUID- ORCID: 0000-0002-7997-6908 AD - Cardiothoracic Department Unit, Fondazione Poliambulanza, Via Leonida Bissolati 57, 25100 Brescia, Italy. LA - eng PT - Journal Article PT - Review DEP - 20230310 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC10054046 OTO - NOTNLM OT - aortic regurgitation OT - aortic stenosis OT - epidemiology OT - heart team OT - heart valve center OT - heart valve disease OT - mitral annular disjunction OT - mitral annulus calcification COIS- The authors state that they have no conflict of interest. EDAT- 2023/03/30 06:00 MHDA- 2023/03/30 06:01 PMCR- 2023/03/10 CRDT- 2023/03/29 01:42 PHST- 2023/01/25 00:00 [received] PHST- 2023/02/23 00:00 [revised] PHST- 2023/03/08 00:00 [accepted] PHST- 2023/03/30 06:01 [medline] PHST- 2023/03/29 01:42 [entrez] PHST- 2023/03/30 06:00 [pubmed] PHST- 2023/03/10 00:00 [pmc-release] AID - jcm12062178 [pii] AID - jcm-12-02178 [pii] AID - 10.3390/jcm12062178 [doi] PST - epublish SO - J Clin Med. 2023 Mar 10;12(6):2178. doi: 10.3390/jcm12062178. PMID- 36983179 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240915 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 12 IP - 6 DP - 2023 Mar 10 TI - Cardiac Surgery in Nonagenarians Following the TAVI/TMVI Era: A Multicenter 23-Year Comparative Analysis. LID - 10.3390/jcm12062177 [doi] LID - 2177 AB - BACKGROUND: Studies reporting on the outcome of 90-year-old patients undergoing cardiac surgery are scant in literature; and currently, those regarding the implementation of trans-catheter techniques number even fewer. METHODS: We compared patients aged >89 years operated on between 1998 and 2008 at 8 Italian cardiac surgery centers, with patients of the same age operated on between 2009 and 2021. All of the patients were operated on with "open" surgery, with the exclusion of percutaneous valve repair/implantation procedures. RESULTS: The patients of the two groups (group 98-08-127 patients, and group 09-21-101 patients) had comparable preoperative risk factors in terms of the LogEuroSCORE (98-08: 21.3 +/- 6.1 vs. 09-21: 20.9 +/- 11.1, p = 0.12). There was a considerable difference in the type of surgery (isolated valve, isolated coronary, and combined surgery, 46.5, 38.5, and 15% vs. 52, 13, and 35% in 98-08 and 09-21, respectively, p = 0.01). Analogous operating durations were recorded (cross-clamp time: 98-08: 46 +/- 28 min vs. 09-21: 51 +/- 28 min, p = 0.06). The number of packed bypasses was lower in 09-21 (1.3 +/- 0.6 vs. 2.4 +/- 1.2, p = 0.001). In the postoperative period, there was a statistically significant difference in the 30-day survival in favor of the "more recent" patients (98-08: 17 deaths (13.4%) versus 09-21: 6(5.9%); p = 0.001), also confirmed in the subgroups (12.2% vs. 0% in isolated coronary surgery, p < 0.001; and 12.3% vs. 0% in isolated valve surgery, p < 0.001). CONCLUSIONS: Accurate pre-, intra-, and post-operative evaluation/management to reduce biological impacts facilitate significant improvements in the outcomes in nonagenarian patients when compared to the results recorded in previous years. FAU - Nasso, Giuseppe AU - Nasso G AUID- ORCID: 0000-0002-3519-770X AD - Department of Cardiac Surgery, Anthea Hospital, GVM Care & Research, 70100 Bari, Italy. FAU - Santarpino, Giuseppe AU - Santarpino G AD - Department of Cardiac Surgery, Citta di Lecce Hospital, GVM Care & Research, 73100 Lecce, Italy. AD - Department of Cardiac Surgery, Paracelsus Medical University, 40100 Nuremberg, Germany. AD - Department of Experimental and Clinical Medicine, "Magna Graecia" University, 88100 Catanzaro, Italy. FAU - Di Bari, Nicola AU - Di Bari N AD - Department of Cardiac Surgery, "Aldo Moro" University, 70100 Bari, Italy. FAU - Fattouch, Khalil AU - Fattouch K AD - Department of Cardiac Surgery, Maria Eleonora Hospital, GVM Care & Research, 90121 Palermo, Italy. FAU - Condello, Ignazio AU - Condello I AD - Department of Cardiac Surgery, Anthea Hospital, GVM Care & Research, 70100 Bari, Italy. FAU - Moscarelli, Marco AU - Moscarelli M AD - Department of Cardiac Surgery, Maria Eleonora Hospital, GVM Care & Research, 90121 Palermo, Italy. FAU - Del Giglio, Mauro AU - Del Giglio M AD - Department of Cardiac Surgery, Maria Pia Hospital, GVM Care & Research, 10024 Torino, Italy. FAU - Paparella, Domenico AU - Paparella D AD - Department of Cardiac Surgery, Santa Maria Hospital, GVM Care & Research, 70100 Bari, Italy. AD - Department of Cardiac Surgery, University of Foggia, 71121 Foggia, Italy. FAU - Lamarra, Mauro AU - Lamarra M AD - Department of Cardiac Surgery, Maria Cecilia Hospital, GVM Care & Research, 40100 Cotignola, Italy. AD - Department of Cardiac Surgery, Villa Torri Hospital, GVM Care & Research, 40100 Bologna, Italy. FAU - Savini, Carlo AU - Savini C AUID- ORCID: 0000-0003-4197-7486 AD - Department of Cardiac Surgery, Maria Cecilia Hospital, GVM Care & Research, 40100 Cotignola, Italy. FAU - Coppola, Roberto AU - Coppola R AD - Department of Cardiac Surgery, ICLAS Hospital, GVM Care & Research, 16135 Rapallo, Italy. FAU - Fiorani, Vinicio AU - Fiorani V AD - Department of Cardiac Surgery, Salus Hospital, GVM Care & Research, 40100 Reggio Emilia, Italy. FAU - Speziale, Giuseppe AU - Speziale G AD - Department of Cardiac Surgery, Anthea Hospital, GVM Care & Research, 70100 Bari, Italy. AD - Department of Cardiac Surgery, San Carlo di Nancy Hospital, GVM Care & Research, 00042 Rome, Italy. LA - eng PT - Journal Article DEP - 20230310 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC10054800 OTO - NOTNLM OT - cardiac surgery OT - elderly OT - heart team OT - nonagenarians COIS- The authors declare no conflict of interest. EDAT- 2023/03/30 06:00 MHDA- 2023/03/30 06:01 PMCR- 2023/03/10 CRDT- 2023/03/29 01:42 PHST- 2022/12/26 00:00 [received] PHST- 2023/02/27 00:00 [revised] PHST- 2023/03/03 00:00 [accepted] PHST- 2023/03/30 06:01 [medline] PHST- 2023/03/29 01:42 [entrez] PHST- 2023/03/30 06:00 [pubmed] PHST- 2023/03/10 00:00 [pmc-release] AID - jcm12062177 [pii] AID - jcm-12-02177 [pii] AID - 10.3390/jcm12062177 [doi] PST - epublish SO - J Clin Med. 2023 Mar 10;12(6):2177. doi: 10.3390/jcm12062177. PMID- 36983126 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231103 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 12 IP - 6 DP - 2023 Mar 8 TI - Cardiovascular Side Effects of Anthracyclines and HER2 Inhibitors among Patients with Breast Cancer: A Multidisciplinary Stepwise Approach for Prevention, Early Detection, and Treatment. LID - 10.3390/jcm12062121 [doi] LID - 2121 AB - Cardiovascular (CV) diseases (CVD) are a major cause of long-term morbidity and mortality affecting life expectancy amongst cancer survivors. In recent years, because of the possibility of early diagnosis and the increased efficacy of neo-adjuvant and adjuvant systemic treatments (targeting specific molecular pathways), the high percentage of survival from breast cancer led CVD to become the first cause of death among survivors. Therefore, it is mandatory to adopt cardioprotective strategies to minimize CV side effects and CVD in general in breast cancer patients. Cancer therapeutics-related cardiac dysfunction (CTRCD) is a common group of side effects of chemotherapeutics widely employed in breast cancer (e.g., anthracycline and human epidermal growth factor receptor 2 inhibitors). The aim of the present manuscript is to propose a pragmatic multidisciplinary stepwise approach for prevention, early detection, and treatment of cardiotoxicity in patients with breast cancer. FAU - Mauro, Ciro AU - Mauro C AD - Cardiology Division, Antonio Cardarelli Hospital, Via Cardarelli 9, 80131 Naples, Italy. FAU - Capone, Valentina AU - Capone V AUID- ORCID: 0000-0002-0080-9948 AD - Cardiology Division, Antonio Cardarelli Hospital, Via Cardarelli 9, 80131 Naples, Italy. AD - Department of Advanced Biomedical Sciences, University of Naples Federico II, Via Sergio Pansini 5, 80131 Naples, Italy. FAU - Cocchia, Rosangela AU - Cocchia R AD - Cardiology Division, Antonio Cardarelli Hospital, Via Cardarelli 9, 80131 Naples, Italy. FAU - Cademartiri, Filippo AU - Cademartiri F AUID- ORCID: 0000-0002-0579-3279 AD - Department of Radiology, Fondazione G. Monasterio CNR-Regione Toscana, Via Moruzzi 1, 56124 Pisa, Italy. FAU - Riccardi, Ferdinando AU - Riccardi F AD - Oncology Unit, Antonio Cardarelli Hospital, Via Cardarelli 9, 80131 Naples, Italy. FAU - Arcopinto, Michele AU - Arcopinto M AD - Department of Translational Medical Sciences, Federico II University, 80138 Naples, Italy. FAU - Alshahid, Maie AU - Alshahid M AD - The Heart Centre, King Faisal Specialist Hospital & Research Centre, Riyadh 11564, Saudi Arabia. FAU - Anwar, Kashif AU - Anwar K AD - The Heart Centre, King Faisal Specialist Hospital & Research Centre, Riyadh 11564, Saudi Arabia. FAU - Carafa, Mariano AU - Carafa M AD - Emergency Medicine Division, Antonio Cardarelli Hospital, Via Cardarelli 9, 80131 Naples, Italy. FAU - Carbone, Andreina AU - Carbone A AUID- ORCID: 0000-0002-2190-7010 AD - Unit of Cardiology, Department of Translational Medical Sciences, Monaldi Hospital, University of Campania Luigi Vanvitelli, 80131 Naples, Italy. FAU - Castaldo, Rossana AU - Castaldo R AUID- ORCID: 0000-0003-4143-1678 AD - IRCCS SYNLAB SDN, Via Emanuele Gianturco 113, 80143 Naples, Italy. FAU - Chianese, Salvatore AU - Chianese S AD - Cardiology Division, Antonio Cardarelli Hospital, Via Cardarelli 9, 80131 Naples, Italy. AD - Department of Advanced Biomedical Sciences, University of Naples Federico II, Via Sergio Pansini 5, 80131 Naples, Italy. FAU - Crisci, Giulia AU - Crisci G AD - Department of Translational Medical Sciences, Federico II University, 80138 Naples, Italy. FAU - D'Assante, Roberta AU - D'Assante R AUID- ORCID: 0000-0001-6729-374X AD - Department of Translational Medical Sciences, Federico II University, 80138 Naples, Italy. FAU - De Luca, Mariarosaria AU - De Luca M AUID- ORCID: 0000-0002-6727-5725 AD - Department of Translational Medical Sciences, Federico II University, 80138 Naples, Italy. FAU - Franzese, Monica AU - Franzese M AUID- ORCID: 0000-0002-6490-7694 AD - IRCCS SYNLAB SDN, Via Emanuele Gianturco 113, 80143 Naples, Italy. FAU - Galzerano, Domenico AU - Galzerano D AUID- ORCID: 0000-0002-9682-3815 AD - The Heart Centre, King Faisal Specialist Hospital & Research Centre, Riyadh 11564, Saudi Arabia. FAU - Maffei, Vincenzo AU - Maffei V AD - Post Operative Intensive Care Division, Antonio Cardarelli Hospital, 80131 Naples, Italy. FAU - Marra, Alberto M AU - Marra AM AD - Department of Translational Medical Sciences, Federico II University, 80138 Naples, Italy. FAU - Valente, Valeria AU - Valente V AD - Department of Translational Medical Sciences, Federico II University, 80138 Naples, Italy. FAU - Giardino, Federica AU - Giardino F AD - Department of Translational Medical Sciences, Federico II University, 80138 Naples, Italy. FAU - Mazza, Alfredo AU - Mazza A AD - Unit of Cardiology, Camerino Hospital, 62032 Macerata, Italy. FAU - Ranieri, Brigida AU - Ranieri B AUID- ORCID: 0000-0003-4880-5679 AD - IRCCS SYNLAB SDN, Via Emanuele Gianturco 113, 80143 Naples, Italy. FAU - D'Agostino, Anna AU - D'Agostino A AUID- ORCID: 0000-0002-1394-4786 AD - IRCCS SYNLAB SDN, Via Emanuele Gianturco 113, 80143 Naples, Italy. FAU - Rega, Salvatore AU - Rega S AD - Department of Public Health, University Federico II of Naples, Via Sergio Pansini 5, 80131 Naples, Italy. FAU - Romano, Luigia AU - Romano L AD - Department of General and Emergency Radiology, Antonio Cardarelli Hospital, Via Cardarelli 9, 80131 Naples, Italy. FAU - Scagliarini, Sarah AU - Scagliarini S AD - Oncology Unit, Antonio Cardarelli Hospital, Via Cardarelli 9, 80131 Naples, Italy. FAU - Sepe, Chiara AU - Sepe C AD - Technical Nursing and Rehabilitation Service (SITR) Department, Cardarelli Hospital, 80131 Naples, Italy. FAU - Vriz, Olga AU - Vriz O AD - The Heart Centre, King Faisal Specialist Hospital & Research Centre, Riyadh 11564, Saudi Arabia. FAU - Izzo, Raffaele AU - Izzo R AD - Department of Advanced Biomedical Sciences, University of Naples Federico II, Via Sergio Pansini 5, 80131 Naples, Italy. FAU - Cittadini, Antonio AU - Cittadini A AD - Department of Translational Medical Sciences, Federico II University, 80138 Naples, Italy. FAU - Bossone, Eduardo AU - Bossone E AUID- ORCID: 0000-0003-2769-9950 AD - Department of Public Health, University Federico II of Naples, Via Sergio Pansini 5, 80131 Naples, Italy. FAU - Salzano, Andrea AU - Salzano A AUID- ORCID: 0000-0003-2352-2103 AD - Cardiology Division, Antonio Cardarelli Hospital, Via Cardarelli 9, 80131 Naples, Italy. AD - Department of Cardiovascular Sciences, University of Leicester, Leicester LE2 7TG, UK. LA - eng PT - Journal Article PT - Review DEP - 20230308 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC10056500 OTO - NOTNLM OT - breast cancer OT - cardio-oncology OT - cardiotoxicity OT - prevention COIS- The authors declare no conflict of interest. EDAT- 2023/03/30 06:00 MHDA- 2023/03/30 06:01 PMCR- 2023/03/08 CRDT- 2023/03/29 01:42 PHST- 2022/12/29 00:00 [received] PHST- 2023/02/25 00:00 [revised] PHST- 2023/03/03 00:00 [accepted] PHST- 2023/03/30 06:01 [medline] PHST- 2023/03/29 01:42 [entrez] PHST- 2023/03/30 06:00 [pubmed] PHST- 2023/03/08 00:00 [pmc-release] AID - jcm12062121 [pii] AID - jcm-12-02121 [pii] AID - 10.3390/jcm12062121 [doi] PST - epublish SO - J Clin Med. 2023 Mar 8;12(6):2121. doi: 10.3390/jcm12062121. PMID- 36981559 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230331 IS - 2227-9032 (Print) IS - 2227-9032 (Electronic) IS - 2227-9032 (Linking) VI - 11 IP - 6 DP - 2023 Mar 21 TI - Obesity and Cardiovascular Risk: Systematic Intervention Is the Key for Prevention. LID - 10.3390/healthcare11060902 [doi] LID - 902 AB - Obesity is a serious public health issue and associated with an increased risk of cardiovascular disease events and mortality. The risk of cardiovascular complications is directly related to excess body fat mass and ectopic fat deposition, but also other obesity-related complications such as pre-type 2 diabetes, obstructive sleep apnoea, and non-alcoholic fatty liver diseases. Body mass index and waist circumference are used to classify a patient as overweight or obese and to stratify cardiovascular risk. Physical activity and diet, despite being key points in preventing adverse events and reducing cardiovascular risk, are not always successful strategies. Pharmacological treatments for weight reduction are promising strategies, but are restricted by possible safety issues and cost. Nonetheless, these treatments are associated with improvements in cardiovascular risk factors, and studies are ongoing to better evaluate cardiovascular outcomes. Bariatric surgery is effective in reducing the incidence of death and cardiovascular events such as myocardial infarction and stroke. Cardiac rehabilitation programs in obese patients improve cardiovascular disease risk factors, quality of life, and exercise capacity. The aim of this review was to critically analyze the current role and future aspects of lifestyle changes, medical and surgical treatments, and cardiac rehabilitation in obese patients, to reduce cardiovascular disease risk and mortality, and to highlight the need for a multidisciplinary approach to improving cardiovascular outcomes. FAU - Perone, Francesco AU - Perone F AUID- ORCID: 0000-0002-1418-7908 AD - Cardiac Rehabilitation Unit, Rehabilitation Clinic "Villa delle Magnolie", 81020 Castel Morrone, Caserta, Italy. FAU - Pingitore, Annachiara AU - Pingitore A AUID- ORCID: 0000-0002-9419-0858 AD - Department of General and Specialistic Surgery "Paride Stefanini", Sapienza University of Rome, 00161 Rome, Italy. FAU - Conte, Edoardo AU - Conte E AD - Department of Clinical Cardiology and Cardiovascular Imaging, Galeazzi-Sant'Ambrogio Hospital IRCCS, 20100 Milan, Lombardy, Italy. FAU - Halasz, Geza AU - Halasz G AD - Cardiology Department, Azienda Ospedaliera San Camillo Forlanini, 00152 Rome, Italy. FAU - Ambrosetti, Marco AU - Ambrosetti M AD - Cardiovascular Rehabilitation Unit, ASST Crema Santa Marta Hospital, 26027 Rivolta D'Adda, Cremona, Italy. FAU - Peruzzi, Mariangela AU - Peruzzi M AD - Department of Clinical Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, 00161 Rome, Italy. AD - Mediterranea Cardiocentro, 80122 Naples, Campania, Italy. FAU - Cavarretta, Elena AU - Cavarretta E AUID- ORCID: 0000-0003-0221-6000 AD - Mediterranea Cardiocentro, 80122 Naples, Campania, Italy. AD - Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, 04100 Latina, Latina, Italy. LA - eng PT - Journal Article PT - Review DEP - 20230321 PL - Switzerland TA - Healthcare (Basel) JT - Healthcare (Basel, Switzerland) JID - 101666525 PMC - PMC10048800 OTO - NOTNLM OT - bariatric surgery OT - cardiac rehabilitation OT - cardiovascular disease risk OT - cardiovascular mortality OT - lifestyle interventions OT - obesity OT - pharmacologic treatment OT - physical activity COIS- The authors declare no conflict of interest. EDAT- 2023/03/30 06:00 MHDA- 2023/03/30 06:01 PMCR- 2023/03/21 CRDT- 2023/03/29 01:31 PHST- 2023/01/29 00:00 [received] PHST- 2023/03/09 00:00 [revised] PHST- 2023/03/16 00:00 [accepted] PHST- 2023/03/30 06:01 [medline] PHST- 2023/03/29 01:31 [entrez] PHST- 2023/03/30 06:00 [pubmed] PHST- 2023/03/21 00:00 [pmc-release] AID - healthcare11060902 [pii] AID - healthcare-11-00902 [pii] AID - 10.3390/healthcare11060902 [doi] PST - epublish SO - Healthcare (Basel). 2023 Mar 21;11(6):902. doi: 10.3390/healthcare11060902. PMID- 36979658 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230331 IS - 2227-9059 (Print) IS - 2227-9059 (Electronic) IS - 2227-9059 (Linking) VI - 11 IP - 3 DP - 2023 Feb 23 TI - Pituitary Apoplexy in Patients with Pituitary Neuroendocrine Tumors (PitNET). LID - 10.3390/biomedicines11030680 [doi] LID - 680 AB - Various complications of pituitary neuroendocrine tumors (PitNET) are reported, and an intratumor hemorrhage or infarct underlying pituitary apoplexy (PA) represents an uncommon, yet potentially life-threatening, feature, and thus early recognition and prompt intervention are important. Our purpose is to overview PA from clinical presentation to management and outcome. This is a narrative review of the English-language, PubMed-based original articles from 2012 to 2022 concerning PA, with the exception of pregnancy- and COVID-19-associated PA, and non-spontaneous PA (prior specific therapy for PitNET). We identified 194 original papers including 1452 patients with PA (926 males, 525 females, and one transgender male; a male-to-female ratio of 1.76; mean age at PA diagnostic of 50.52 years, the youngest being 9, the oldest being 85). Clinical presentation included severe headache in the majority of cases (but some exceptions are registered, as well); neuro-ophthalmic panel with nausea and vomiting, meningism, and cerebral ischemia; respectively, decreased visual acuity to complete blindness in two cases; visual field defects: hemianopia, cranial nerve palsies manifesting as diplopia in the majority, followed by ptosis and ophthalmoplegia (most frequent cranial nerve affected was the oculomotor nerve, and, rarely, abducens and trochlear); proptosis (N = 2 cases). Risk factors are high blood pressure followed by diabetes mellitus as the main elements. Qualitative analysis also pointed out infections, trauma, hematologic conditions (thrombocytopenia, polycythemia), Takotsubo cardiomyopathy, and T3 thyrotoxicosis. Iatrogenic elements may be classified into three main categories: medication, diagnostic tests and techniques, and surgical procedures. The first group is dominated by anticoagulant and antiplatelet drugs; additionally, at a low level of statistical evidence, we mention androgen deprivation therapy for prostate cancer, chemotherapy, thyroxine therapy, oral contraceptives, and phosphodiesterase 5 inhibitors. The second category includes a dexamethasone suppression test, clomiphene use, combined endocrine stimulation tests, and a regadenoson myocardial perfusion scan. The third category involves major surgery, laparoscopic surgery, coronary artery bypass surgery, mitral valvuloplasty, endonasal surgery, and lumbar fusion surgery in a prone position. PA in PitNETs still represents a challenging condition requiring a multidisciplinary team from first presentation to short- and long-term management. Controversies involve the specific panel of risk factors and adequate protocols with concern to neurosurgical decisions and their timing versus conservative approach. The present decade-based analysis, to our knowledge the largest so far on published cases, confirms a lack of unanimous approach and criteria of intervention, a large panel of circumstantial events, and potential triggers with different levels of statistical significance, in addition to a heterogeneous clinical picture (if any, as seen in subacute PA) and a spectrum of evolution that varies from spontaneous remission and control of PitNET-associated hormonal excess to exitus. Awareness is mandatory. A total of 25 cohorts have been published so far with more than 10 PA cases/studies, whereas the largest cohorts enrolled around 100 patients. Further studies are necessary. FAU - Gheorghe, Ana-Maria AU - Gheorghe AM AD - Department of Endocrinology, "C.I. Parhon" National Institute of Endocrinology, 011683 Bucharest, Romania. FAU - Trandafir, Alexandra Ioana AU - Trandafir AI AD - Department of Endocrinology, "C.I. Parhon" National Institute of Endocrinology, 011683 Bucharest, Romania. FAU - Ionovici, Nina AU - Ionovici N AD - Department of Occupational Medicine, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania. FAU - Carsote, Mara AU - Carsote M AUID- ORCID: 0000-0001-8585-3835 AD - Department of Endocrinology, "Carol Davila" University of Medicine and Pharmacy & "C.I. Parhon" National Institute of Endocrinology, 011683 Bucharest, Romania. FAU - Nistor, Claudiu AU - Nistor C AUID- ORCID: 0000-0002-2274-5666 AD - Department 4-Cardio-Thoracic Pathology, Thoracic Surgery II Discipline, Faculty of Medicine, "Carol Davila" University of Medicine and Pharmacy & Thoracic Surgery Department, "Carol Davila" Central Emergency University Military Hospital, 013058 Bucharest, Romania. FAU - Popa, Florina Ligia AU - Popa FL AUID- ORCID: 0000-0002-9834-3380 AD - Department of Physical Medicine and Rehabilitation, Faculty of Medicine, "Lucian Blaga" University of Sibiu, 550024 Sibiu, Romania. FAU - Stanciu, Mihaela AU - Stanciu M AD - Department of Endocrinology, Faculty of Medicine, "Lucian Blaga" University of Sibiu, 550169 Sibiu, Romania. LA - eng PT - Journal Article PT - Review DEP - 20230223 PL - Switzerland TA - Biomedicines JT - Biomedicines JID - 101691304 PMC - PMC10044830 OTO - NOTNLM OT - anticoagulant OT - computed tomography OT - headache OT - hormone OT - neurosurgery OT - pituitary apoplexy OT - pituitary neuroendocrine tumors OT - surgery COIS- The authors declare no conflict of interest. EDAT- 2023/03/30 06:00 MHDA- 2023/03/30 06:01 PMCR- 2023/02/23 CRDT- 2023/03/29 01:20 PHST- 2023/01/26 00:00 [received] PHST- 2023/02/17 00:00 [revised] PHST- 2023/02/21 00:00 [accepted] PHST- 2023/03/30 06:01 [medline] PHST- 2023/03/29 01:20 [entrez] PHST- 2023/03/30 06:00 [pubmed] PHST- 2023/02/23 00:00 [pmc-release] AID - biomedicines11030680 [pii] AID - biomedicines-11-00680 [pii] AID - 10.3390/biomedicines11030680 [doi] PST - epublish SO - Biomedicines. 2023 Feb 23;11(3):680. doi: 10.3390/biomedicines11030680. PMID- 36975864 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240915 IS - 2308-3425 (Electronic) IS - 2308-3425 (Linking) VI - 10 IP - 3 DP - 2023 Feb 25 TI - Acute and Chronic Changes in Myocardial Work Parameters in Patients with Severe Primary Mitral Regurgitation Undergoing Transcatheter Edge-to-Edge Repair. LID - 10.3390/jcdd10030100 [doi] LID - 100 AB - BACKGROUND: The noninvasive assessment of myocardial work (MW) allows for the evaluation of left ventricular (LV) performance by considering the effect of LV afterload. This study aims to evaluate the acute and chronic impact of transcatheter edge-to-edge repair (TEER) on MW parameters and LV remodeling in patients with severe primary mitral regurgitation (PMR). METHODS: A total of 71 patients (age: 77 +/- 9 years, females: 44%) with moderate-to-severe or severe PMR (effective regurgitant orifice: 0.57 +/- 0.31 cm(2); regurgitant volume: 80 +/- 34 mL; LV end-systolic diameter: 42 +/- 12 mm) underwent TEER after a global assessment by the heart team. MW indices were evaluated before the procedure, at hospital discharge, and at 1-year follow-up. LV remodeling was described as the percentage variation in LVEDV between baseline and 1-year follow-up. RESULTS: TEER caused an acute reduction in LVEF, global longitudinal strain (GLS), global MW index (GWI), work efficiency (GWE), and mechanical dispersion (MD) and a significant increase in wasted work (GWW). One year after the procedure, GLS, GWI, GWE, and MD recovered, whereas GWW remained significantly impaired. Baseline GWW (beta = -0.29, p = 0.03) was an independent predictor of LV reverse remodeling at 1-year follow-up. CONCLUSIONS: In patients with severe PMR undergoing TEER, the acute reduction in LV preload causes significant impairment to all the parameters of LV performance. Baseline GWW was the only independent predictor of LV reverse remodeling, suggesting that a lower myocardial energetic efficiency in the context of chronic preload increase might impact the left ventricular response to mitral regurgitation correction. FAU - Galli, Elena AU - Galli E AUID- ORCID: 0000-0001-9584-5505 AD - Cardiology Department, University Hospital of Rennes, University of Rennes, LTSI-INSEMR, 35000 Rennes, France. FAU - Hubert, Pierre AU - Hubert P AD - Cardiology Department, University Hospital of Rennes, University of Rennes, LTSI-INSEMR, 35000 Rennes, France. FAU - Leurent, Guillaume AU - Leurent G AUID- ORCID: 0000-0001-9940-3843 AD - Cardiology Department, University Hospital of Rennes, University of Rennes, LTSI-INSEMR, 35000 Rennes, France. FAU - Auffret, Vincent AU - Auffret V AUID- ORCID: 0000-0003-0535-2120 AD - Cardiology Department, University Hospital of Rennes, University of Rennes, LTSI-INSEMR, 35000 Rennes, France. FAU - Panis, Vasileios AU - Panis V AUID- ORCID: 0000-0001-7158-4187 AD - Cardiology Department, University Hospital of Rennes, University of Rennes, LTSI-INSEMR, 35000 Rennes, France. FAU - L'Official, Guillaume AU - L'Official G AUID- ORCID: 0000-0002-6379-0156 AD - Cardiology Department, University Hospital of Rennes, University of Rennes, LTSI-INSEMR, 35000 Rennes, France. FAU - Donal, Erwan AU - Donal E AUID- ORCID: 0000-0003-2677-3389 AD - Cardiology Department, University Hospital of Rennes, University of Rennes, LTSI-INSEMR, 35000 Rennes, France. LA - eng PT - Journal Article DEP - 20230225 PL - Switzerland TA - J Cardiovasc Dev Dis JT - Journal of cardiovascular development and disease JID - 101651414 PMC - PMC10051684 OTO - NOTNLM OT - left ventricular remodeling OT - myocardial work OT - percutaneous mitral valve repair OT - primary mitral regurgitation COIS- The authors declare no conflict of interest. EDAT- 2023/03/29 06:00 MHDA- 2023/03/29 06:01 PMCR- 2023/02/25 CRDT- 2023/03/28 10:08 PHST- 2023/02/02 00:00 [received] PHST- 2023/02/21 00:00 [revised] PHST- 2023/02/24 00:00 [accepted] PHST- 2023/03/29 06:01 [medline] PHST- 2023/03/28 10:08 [entrez] PHST- 2023/03/29 06:00 [pubmed] PHST- 2023/02/25 00:00 [pmc-release] AID - jcdd10030100 [pii] AID - jcdd-10-00100 [pii] AID - 10.3390/jcdd10030100 [doi] PST - epublish SO - J Cardiovasc Dev Dis. 2023 Feb 25;10(3):100. doi: 10.3390/jcdd10030100. PMID- 36974357 OWN - NLM STAT- MEDLINE DCOM- 20230925 LR - 20250530 IS - 2047-4881 (Electronic) IS - 2047-4873 (Linking) VI - 30 IP - 13 DP - 2023 Sep 20 TI - Advanced heart failure in adult congenital heart disease: the role of renal dysfunction in management and outcomes. PG - 1335-1342 LID - 10.1093/eurjpc/zwad094 [doi] AB - AIMS: Previous studies in adult congenital heart disease (CHD) have demonstrated a link between renal dysfunction and mortality. However, the prognostic significance of renal dysfunction in CHD and decompensated heart failure (HF) remains unclear. We sought to assess the association between renal dysfunction and outcomes in adults with CHD presenting to our centre with acute HF between 2010 and 2021. METHODS AND RESULTS: This retrospective analysis focused on the association between renal dysfunction, pre-existing and on admission, and outcomes during and after the index hospitalization. Chronic kidney disease (CKD) was defined as an estimated glomerular filtration rate <60 mL/min/1.73 m2. Cox regression analysis was used to identify the predictors of death post-discharge. In total, 176 HF admissions were included (mean age 47.7 +/- 14.5 years, 43.2% females). One-half of patients had a CHD of great complexity, 22.2% had a systemic right ventricle, and 18.8% had Eisenmenger syndrome. Chronic kidney disease was present in one-quarter of patients. The median length of intravenous diuretic therapy was 7 (4-12) days, with a maximum dose of 120 (80-160) mg furosemide equivalents/day, and 15.3% required inotropic support. The in-hospital mortality rate was 4.5%. The 1- and 5-year survival rates free of transplant or ventricular assist device (VAD) post-discharge were 75.4% [95% confidence interval (CI): 69.2-82.3%] and 43.3% (95% CI: 36-52%), respectively. On multivariable Cox analysis, CKD was the strongest predictor of mortality or transplantation/VAD. Highly complex CHD and inpatient requirement of inotropes also remained predictive of an adverse outcome. CONCLUSION: Adult patients with CHD admitted with acute HF are a high-risk cohort. CKD is common and triples the risk of death/transplantation/VAD. An expert multidisciplinary approach is essential for optimizing outcomes. CI - (c) The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. FAU - Krishnathasan, Kaushiga AU - Krishnathasan K AUID- ORCID: 0000-0002-7097-6012 AD - Adult Congenital Heart Centre and Centre for Pulmonary Hypertension, Royal Brompton Hospital, Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, Sydney Street, London SW3 6NP, UK. FAU - Dimopoulos, Konstantinos AU - Dimopoulos K AUID- ORCID: 0000-0003-1300-0504 AD - Adult Congenital Heart Centre and Centre for Pulmonary Hypertension, Royal Brompton Hospital, Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, Sydney Street, London SW3 6NP, UK. AD - National Heart and Lung Institute, Imperial College London, London, UK. FAU - Duncan, Neill AU - Duncan N AUID- ORCID: 0000-0003-3820-6859 AD - Renal and Transplant Centre, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK. AD - Department of Immunology and Inflammation, Imperial College London, London, UK. FAU - Ricci, Piera AU - Ricci P AD - Adult Congenital Heart Centre and Centre for Pulmonary Hypertension, Royal Brompton Hospital, Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, Sydney Street, London SW3 6NP, UK. FAU - Kempny, Alexander AU - Kempny A AD - Adult Congenital Heart Centre and Centre for Pulmonary Hypertension, Royal Brompton Hospital, Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, Sydney Street, London SW3 6NP, UK. AD - National Heart and Lung Institute, Imperial College London, London, UK. FAU - Rafiq, Isma AU - Rafiq I AUID- ORCID: 0000-0002-0107-7996 AD - Adult Congenital Heart Centre and Centre for Pulmonary Hypertension, Royal Brompton Hospital, Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, Sydney Street, London SW3 6NP, UK. AD - National Heart and Lung Institute, Imperial College London, London, UK. FAU - Gatzoulis, Michael A AU - Gatzoulis MA AUID- ORCID: 0000-0002-2700-7232 AD - Adult Congenital Heart Centre and Centre for Pulmonary Hypertension, Royal Brompton Hospital, Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, Sydney Street, London SW3 6NP, UK. AD - National Heart and Lung Institute, Imperial College London, London, UK. FAU - Heng, Ee Ling AU - Heng EL AD - Adult Congenital Heart Centre and Centre for Pulmonary Hypertension, Royal Brompton Hospital, Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, Sydney Street, London SW3 6NP, UK. AD - National Heart and Lung Institute, Imperial College London, London, UK. FAU - Blakey, Sarah AU - Blakey S AD - Renal and Transplant Centre, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK. AD - Department of Immunology and Inflammation, Imperial College London, London, UK. FAU - Montanaro, Claudia AU - Montanaro C AD - Adult Congenital Heart Centre and Centre for Pulmonary Hypertension, Royal Brompton Hospital, Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, Sydney Street, London SW3 6NP, UK. AD - National Heart and Lung Institute, Imperial College London, London, UK. FAU - Babu-Narayan, Sonya V AU - Babu-Narayan SV AUID- ORCID: 0000-0002-1558-8447 AD - Adult Congenital Heart Centre and Centre for Pulmonary Hypertension, Royal Brompton Hospital, Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, Sydney Street, London SW3 6NP, UK. AD - National Heart and Lung Institute, Imperial College London, London, UK. FAU - Francis, Darrel P AU - Francis DP AD - National Heart and Lung Institute, Imperial College London, London, UK. AD - Hammersmith Hospital, Imperial College Healthcare NHS Trust, Imperial College London, London, UK. FAU - Li, Wei AU - Li W AUID- ORCID: 0000-0002-3394-5559 AD - Adult Congenital Heart Centre and Centre for Pulmonary Hypertension, Royal Brompton Hospital, Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, Sydney Street, London SW3 6NP, UK. AD - National Heart and Lung Institute, Imperial College London, London, UK. FAU - Constantine, Andrew AU - Constantine A AUID- ORCID: 0000-0001-7899-463X AD - Adult Congenital Heart Centre and Centre for Pulmonary Hypertension, Royal Brompton Hospital, Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, Sydney Street, London SW3 6NP, UK. AD - National Heart and Lung Institute, Imperial College London, London, UK. LA - eng GR - FS/11/38/28864/BHF_/British Heart Foundation/United Kingdom PT - Journal Article PL - England TA - Eur J Prev Cardiol JT - European journal of preventive cardiology JID - 101564430 SB - IM CIN - Eur J Prev Cardiol. 2023 Sep 20;30(13):1333-1334. doi: 10.1093/eurjpc/zwad136. PMID: 37210588 MH - Female MH - Humans MH - Adult MH - Middle Aged MH - Male MH - *Heart Defects, Congenital/complications/diagnosis/therapy MH - Retrospective Studies MH - Aftercare MH - Patient Discharge MH - *Heart Failure/diagnosis/etiology/therapy MH - *Renal Insufficiency, Chronic/complications/diagnosis/therapy OAB - Renal dysfunction was associated with more advanced disease, higher diuretic doses, and a longer hospital inpatient stay. Chronic kidney disease was common and tripled the risk of death, transplantation, or ventricular assist device. Renal dysfunction in adults with congenital heart disease and heart failure should prompt intensified monitoring, optimization of medical therapy, and collaborative management with renal physicians. OABL- eng OTO - NOTNLM OT - Adult congenital heart disease OT - Bayesian analysis OT - Chronic kidney disease OT - Heart failure OT - Renal failure COIS- Conflict of interest: K.K. and A.C. have received educational grants, personal fees, and non-financial support from Janssen-Cilag Limited. K.D. has received non-financial support from Janssen-Cilag Limited and has been a consultant to, and received grants and personal fees from, Janssen-Cilag Limited, Pfizer, GlaxoSmithKline, and Bayer/MSD. S.V.B.-N. is supported by the British Heart Foundation, London, UK (EX/18/1/34296). All of the remaining authors have no relationships with the industry to declare. EDAT- 2023/03/29 06:00 MHDA- 2023/09/25 06:42 CRDT- 2023/03/28 02:22 PHST- 2022/12/23 00:00 [received] PHST- 2023/03/13 00:00 [revised] PHST- 2023/03/23 00:00 [accepted] PHST- 2023/09/25 06:42 [medline] PHST- 2023/03/29 06:00 [pubmed] PHST- 2023/03/28 02:22 [entrez] AID - 7088575 [pii] AID - 10.1093/eurjpc/zwad094 [doi] PST - ppublish SO - Eur J Prev Cardiol. 2023 Sep 20;30(13):1335-1342. doi: 10.1093/eurjpc/zwad094. PMID- 36974111 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230329 IS - 1735-1995 (Print) IS - 1735-7136 (Electronic) IS - 1735-1995 (Linking) VI - 28 DP - 2023 TI - Availability and nature of cardiac rehabilitation by province in Iran: A 2018 update of ICCPR's global audit. PG - 1 LID - 1 AB - BACKGROUND: Cardiac rehabilitation (CR) is scantly available in Iran, although it is the cost-benefit strategy in cardiac patients, It has not been established how CR is delivered within Iran. This study aimed to determine: (a) availability, density and unmet need for CR, and (b) nature of CR services in Iran by province. MATERIALS AND METHODS: In this cross-sectional sub-study of the global CR audit, program availability was determined through cardiovascular networks. An online survey was then disseminated to these programs in June 2016-2017 which assessed capacity and characteristics; a paper-based survey was disseminated in 2018 to nonresponding and any new programs. CR density and need was computed based on annual incidence of acute myocardial infarction (AMI) in each province. RESULTS: Of the 31 provinces, 12 (38.7%) had CR services. There were 30 programs nationally, all in capital cities; of these, programs in 9 (75.0%) provinces, specifically 22 (73.3%) programs, participated. The national CR density is 1 spot per 7 incident AMI patients/year. Unmet need is greatest in Khuzestan, Tehran and west Azerbaijan, with 44,816 more spots needed/year. Most programs assessed cardiovascular risk factors, and offered comprehensive services, delivered by a multi-disciplinary team, comprised chiefly of nurses, dietitians and cardiologists. Median dose is 14 sessions/program in supervised programs. A third of programs offered home-based services. CONCLUSION: Where programs do exist in IRAN, they are generally delivered in accordance with guidelines. Therefore, we must increase capacity in CR services in all provinces to improve secondary prevention services. CI - Copyright: (c) 2023 Journal of Research in Medical Sciences. FAU - Sadeghi, Masoumeh AU - Sadeghi M AD - Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran. FAU - Turk-Adawi, Karam AU - Turk-Adawi K AD - Department of Public Health, QU-Health, Qatar University, Doha, Qatar. FAU - Supervia, Marta AU - Supervia M AD - Medicina Fisica y Rehabilitacion, Gregorio Maranon Health Research Institute, Gregorio Maranon General University Hospital, Madrid, Spain. AD - Department of Cardiovascular Medicine, Division of Preventive Cardiology, Mayo Clinic, Rochester, Minnesota, USA. FAU - Fard, Mohammad Rafati AU - Fard MR AD - Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran. FAU - Noohi, Fereydoun AU - Noohi F AD - Rajaie Cardiovascular, Medical and Research Center, Iranian Network of Cardiovascular Research, Tehran, Iran. FAU - Roohafza, Hamidreza AU - Roohafza H AD - Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran. FAU - Sarrafzadegan, Nizal AU - Sarrafzadegan N AD - Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran. AD - School of Population and Public Health, University of British Columbia, Vancouver, Canada. FAU - Grace, Sherry L AU - Grace SL AD - Faculty of Health, York University, Toronto, Canada. AD - KITE-Toronto Rehabilitation Institute and Peter Munk Cardiac Centre, University Health Network, University of Toronto, Toronto, Canada. LA - eng PT - Journal Article DEP - 20230131 PL - India TA - J Res Med Sci JT - Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences JID - 101235599 PMC - PMC10039098 OTO - NOTNLM OT - Capacity building OT - Iran OT - cardiac rehabilitation OT - international health OT - quality of health care COIS- There are no conflicts of interest. EDAT- 2023/03/29 06:00 MHDA- 2023/03/29 06:01 PMCR- 2023/01/31 CRDT- 2023/03/28 01:54 PHST- 2021/01/22 00:00 [received] PHST- 2022/06/28 00:00 [revised] PHST- 2022/07/19 00:00 [accepted] PHST- 2023/03/29 06:01 [medline] PHST- 2023/03/28 01:54 [entrez] PHST- 2023/03/29 06:00 [pubmed] PHST- 2023/01/31 00:00 [pmc-release] AID - JRMS-28-1 [pii] AID - 10.4103/jrms.jrms_68_21 [doi] PST - epublish SO - J Res Med Sci. 2023 Jan 31;28:1. doi: 10.4103/jrms.jrms_68_21. eCollection 2023. PMID- 36970980 OWN - NLM STAT- MEDLINE DCOM- 20230420 LR - 20260127 IS - 2574-8300 (Electronic) IS - 2574-8300 (Linking) VI - 16 IP - 2 DP - 2023 Apr TI - Interpreting Incidentally Identified Variants in Genes Associated With Heritable Cardiovascular Disease: A Scientific Statement From the American Heart Association. PG - e000092 LID - 10.1161/HCG.0000000000000092 [doi] AB - Rapid advances in genetic technologies have led to expanding use of diagnostic, research, and direct-to-consumer exome and genome sequencing. Incidentally identified variants from this sequencing represent a significant and growing challenge to interpret and translate into clinical care and include variants in genes associated with heritable cardiovascular disease such as cardiac ion channelopathies, cardiomyopathies, thoracic aortic disease, dyslipidemias, and congenital/structural heart disease. These variants need to be properly reported, the risk of associated disease accurately assessed, and clinical management implemented to prevent or lessen the disease so that cardiovascular genomic medicine can become both predictive and preventive. The goal of this American Heart Association consensus statement is to provide guidance to clinicians who are called on to evaluate patients with incidentally identified genetic variants in monogenic cardiovascular disease genes and to assist them in the interpretation and clinical application of variants. This scientific statement outlines a framework through which clinicians can assess the pathogenicity of an incidental variant, which includes a clinical evaluation of the patient and the patient's family and re-evaluation of the genetic variant in question. Furthermore, this guidance underscores the importance of a multidisciplinary team to address these challenging clinical evaluations and highlights how clinicians can effectively interface with specialty centers. FAU - Landstrom, Andrew P AU - Landstrom AP AUID- ORCID: 0000-0002-1878-9631 FAU - Chahal, Anwar A AU - Chahal AA FAU - Ackerman, Michael J AU - Ackerman MJ FAU - Cresci, Sharon AU - Cresci S FAU - Milewicz, Dianna M AU - Milewicz DM FAU - Morris, Alanna A AU - Morris AA FAU - Sarquella-Brugada, Georgia AU - Sarquella-Brugada G FAU - Semsarian, Christopher AU - Semsarian C FAU - Shah, Svati H AU - Shah SH FAU - Sturm, Amy C AU - Sturm AC CN - American Heart Association Data Science and Precision Medicine Committee of the Council on Genomic and Precision Medicine and Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Hypertension; Council on Lifelong Congenital Heart Disease and Heart Health in the Young; Council on Peripheral Vascular Disease; and Stroke Council LA - eng PT - Consensus Statement PT - Journal Article PT - Review DEP - 20230327 PL - United States TA - Circ Genom Precis Med JT - Circulation. Genomic and precision medicine JID - 101714113 SB - IM EIN - Circ Genom Precis Med. 2023 Apr;16(2):e000093. doi: 10.1161/HCG.0000000000000093. PMID: 37071727 MH - *Genetic Predisposition to Disease MH - American Heart Association MH - *Cardiovascular Diseases/genetics MH - Humans MH - Genetic Variation MH - Genetic Counseling MH - United States OTO - NOTNLM OT - AHA Scientific Statements OT - aortic diseases OT - cardiomyopathies OT - cardiovascular diseases OT - channelopathies OT - dyslipidemias OT - genomics OT - patient care team EDAT- 2023/03/28 06:00 MHDA- 2023/04/20 10:17 CRDT- 2023/03/27 05:02 PHST- 2023/04/20 10:17 [medline] PHST- 2023/03/28 06:00 [pubmed] PHST- 2023/03/27 05:02 [entrez] AID - 10.1161/HCG.0000000000000092 [doi] PST - ppublish SO - Circ Genom Precis Med. 2023 Apr;16(2):e000092. doi: 10.1161/HCG.0000000000000092. Epub 2023 Mar 27. PMID- 36968940 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230328 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 15 IP - 2 DP - 2023 Feb TI - Cardiopulmonary Arrest During Pregnancy: A Review Article. PG - e35219 LID - 10.7759/cureus.35219 [doi] LID - e35219 AB - Massive pulmonary embolism (PE) is an uncommon but severe complication of pregnancy or during the first few weeks after giving birth. Our intention was to thoroughly analyze the information available to its management methods. Significant bleeding of mother survival and early deliveries in fetal survivals were having hemorrhage and were having key outcomes. We found 127 severe PE cases that have had at least one form of treatment (at least 83% big; 23% with cardiac arrest). The 83 women who received thrombolysis had a 94% (95%) survival rate. Cardiac arrest in pregnancy is uncommon, although maintaining current competency can be challenging. While maternal mortality rates have decreased globally over the past 25 years, they have increased in the United States. The intricacy of the maternal mortality issue is a result of a number of clinical and socioeconomic problems such as unequal healthcare access, racial and ethnic disparities, maternal comorbidities, and bias in epidemiologic ascertainment. The importance of doctors being prepared to react to a potential maternal cardiac arrest in any situation where they are providing treatment for pregnant women is highlighted by the rise in maternal mortality. For the treatment of maternal cardiac arrest, an interdisciplinary team with expertise in both the maternal resuscitation procedure and the physiological changes that take place during pregnancy is necessary. Additionally offered are basic and advanced cardiac life support protocols. Techniques to remove obstacles like aortocaval compression that could impair the effectiveness of resuscitation should be used. CI - Copyright (c) 2023, Pawar et al. FAU - Pawar, Sujeet J AU - Pawar SJ AD - Anatomy, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Wardha, IND. FAU - Anjankar, Vaibhav P AU - Anjankar VP AD - Anatomy, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Wardha, IND. FAU - Anjankar, Ashish AU - Anjankar A AD - Biochemistry, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Wardha, IND. FAU - Adnan, Mohammad AU - Adnan M AD - Anatomy, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Wardha, IND. LA - eng PT - Journal Article PT - Review DEP - 20230220 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC10032350 OTO - NOTNLM OT - cardiac arrest OT - foetal survival OT - haemorrhage OT - maternal mortality OT - pulmonary embolism COIS- The authors have declared that no competing interests exist. EDAT- 2023/03/28 06:00 MHDA- 2023/03/28 06:01 PMCR- 2023/02/20 CRDT- 2023/03/27 03:31 PHST- 2022/09/16 00:00 [received] PHST- 2023/02/20 00:00 [accepted] PHST- 2023/03/27 03:31 [entrez] PHST- 2023/03/28 06:00 [pubmed] PHST- 2023/03/28 06:01 [medline] PHST- 2023/02/20 00:00 [pmc-release] AID - 10.7759/cureus.35219 [doi] PST - epublish SO - Cureus. 2023 Feb 20;15(2):e35219. doi: 10.7759/cureus.35219. eCollection 2023 Feb. PMID- 36966758 OWN - NLM STAT- MEDLINE DCOM- 20230501 LR - 20230916 IS - 1473-5687 (Electronic) IS - 0954-691X (Linking) VI - 35 IP - 5 DP - 2023 May 1 TI - Alcoholic cardiomyopathy in patients with alcoholic liver cirrhosis: a study across 10 years. PG - 600-603 LID - 10.1097/MEG.0000000000002541 [doi] AB - BACKGROUND AND OBJECTIVES: Available data regarding cardiomyopathy in patients with alcoholic liver cirrhosis (ALC) are very limited because it often requires multidisciplinary assessments. The study aims to evaluate the prevalence of alcoholic cardiomyopathy in ALC and their clinical correlations. METHODS: Adult ALC patients without a previous diagnosis of cardiovascular diseases between January 2010 and December 2019 were included in the study. The prevalence rate of alcoholic cardiomyopathy in patients with ALC was calculated together with a 95% confidence interval (CI) using the Clopper-Pearson exact method. RESULTS: A total of 1022 ALC patients were included. Male patients predominated (90.5%). ECG abnormalities were observed in 353 patients (34.5%). Prolonged QT interval was most common in ALC patients with ECG abnormalities, which occurred in 109. Thirty-five ALC patients underwent the cardiac MRI examination and only one patient was found with cardiomyopathy. The estimated prevalence rate of alcoholic cardiomyopathy in all the ALC patients was 0.0286 (95% CI, 0.0007-0.1492). There was no statistical difference regarding the prevalence rate between the group of patients with ECG abnormalities and the group without ECG abnormalities (0.0400 vs. 0.0000, P = 1.000). CONCLUSION: Although ECG abnormalities, especially QT prolongation, existed in a proportion of ALC patients, cardiomyopathy in the patient population was not common. Further larger-sample studies based on cardiac MRI are needed to verify our results. CI - Copyright (c) 2023 Wolters Kluwer Health, Inc. All rights reserved. FAU - Wang, Chunya AU - Wang C AD - Coronary Heart Disease Center, Beijing Anzhen Hospital, Capital Medical University. FAU - Gao, Hai AU - Gao H AD - Coronary Heart Disease Center, Beijing Anzhen Hospital, Capital Medical University. FAU - Liu, Weibin AU - Liu W AD - Department of Interventional Radiology, Beijing Anzhen Hospital, Capital Medical University. FAU - Chen, Jing AU - Chen J AD - The Fifth Medical Center (formerly Beijing 302 Hospital), Chinese PLA General Hospital, Beijing. FAU - Guo, Yupeng AU - Guo Y AD - College of Public Health, Mudanjiang Medical University, Mudanjiang, Heilongjiang, China. FAU - Zhao, Pan AU - Zhao P AD - The Fifth Medical Center (formerly Beijing 302 Hospital), Chinese PLA General Hospital, Beijing. LA - eng PT - Journal Article DEP - 20230318 PL - England TA - Eur J Gastroenterol Hepatol JT - European journal of gastroenterology & hepatology JID - 9000874 SB - IM MH - Adult MH - Humans MH - Male MH - *Liver Cirrhosis, Alcoholic/complications/diagnosis/epidemiology MH - *Cardiomyopathy, Alcoholic/diagnosis/epidemiology/complications MH - Liver Cirrhosis/diagnostic imaging/epidemiology EDAT- 2023/03/27 06:00 MHDA- 2023/05/01 06:42 CRDT- 2023/03/26 19:53 PHST- 2023/05/01 06:42 [medline] PHST- 2023/03/27 06:00 [pubmed] PHST- 2023/03/26 19:53 [entrez] AID - 00042737-202305000-00012 [pii] AID - 10.1097/MEG.0000000000002541 [doi] PST - ppublish SO - Eur J Gastroenterol Hepatol. 2023 May 1;35(5):600-603. doi: 10.1097/MEG.0000000000002541. Epub 2023 Mar 18. PMID- 36963130 OWN - NLM STAT- MEDLINE DCOM- 20230425 LR - 20230425 IS - 1872-6283 (Electronic) IS - 0379-0738 (Linking) VI - 346 DP - 2023 May TI - Black box of diving accidents: Contribution of forensic underwater experts to three fatal cases. PG - 111642 LID - S0379-0738(23)00092-0 [pii] LID - 10.1016/j.forsciint.2023.111642 [doi] AB - Diving is a popular activity, largely practiced worldwide. Diving fatalities are not rare events, with drowning being the most common cause of death, followed by cardiac-related natural causes, immersion pulmonary edema and arterial gas embolism. In such cases, positive signs of drowning are not specific, depending also on the time of submersion of corpses. Moreover, drowning can be the terminal event. Over the years, measures to perform appropriate post-mortem examination in cases of diving fatalities were suggested, including the execution of post-mortem CT-scan, the use of a decompression chamber and the adoption of specific autoptic techniques. Although a multidisciplinary approach in forensic investigations concerning diving fatalities is discussed, poor cases focus on how the analysis of diving computer records and equipment can contribute to determining the cause of death. The present study shows how the cooperation between a forensic underwater expert and a forensic pathologist played a crucial role in interpreting radiological findings, guiding the autopsy and confirming/denying circumstantial data emerging from the investigations. Technical analysis of dive computer records and diving equipment is a fundamental step in the definition of the cause of death in diving fatalities. All diving computer data, not only those related to maximum depth and ascent's profile, should be considered in detail, and the immersion graph carefully studied by both the forensic pathologist and the forensic underwater experts. The diving technical data can often play a crucial role in explaining any legal issue related to the circumstances of death, possibly leading the prosecutor to further investigation. CI - Copyright (c) 2023 Elsevier B.V. All rights reserved. FAU - Tarozzi, Ilaria AU - Tarozzi I AD - Modena Local Health Unit, Department of Legal Medicine and Risk Management, Modena, Italy. FAU - Franceschetti, Lorenzo AU - Franceschetti L AD - Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy; Sezione di Medicina Legale e delle Assicurazioni, Dipartimento di Scienze Biomediche per la Salute, Universita degli Studi di Milano, Via Luigi Mangiagalli, 37, 20133 Milano, Italy. Electronic address: lorenzofranceschetti@gmail.com. FAU - Simonini, Gianfranco AU - Simonini G AD - Technical Diving Center of Polignano a Mare, Bari, Italy. FAU - Raddi, Silvia AU - Raddi S AD - Health Science Department, Forensic Pathology Section, University of Florence, Florence, Italy. FAU - Machado, Davide AU - Machado D AD - South-East Tuscany Local Health Unit, Department of Neuroradiology, Grosseto, Italy. FAU - Bugelli, Valentina AU - Bugelli V AD - South-East Tuscany Local Health Unit, Department of Legal Medicine, Grosseto, Italy. LA - eng PT - Journal Article DEP - 20230315 PL - Ireland TA - Forensic Sci Int JT - Forensic science international JID - 7902034 SB - IM MH - Humans MH - *Diving/adverse effects MH - *Drowning/diagnosis MH - Accidents MH - Forensic Medicine/methods MH - *Pulmonary Edema OTO - NOTNLM OT - Diving fatalities OT - Diving technical data OT - SCUBA diving OT - Underwater expert EDAT- 2023/03/25 06:00 MHDA- 2023/04/25 10:20 CRDT- 2023/03/24 19:01 PHST- 2022/12/07 00:00 [received] PHST- 2023/03/04 00:00 [revised] PHST- 2023/03/08 00:00 [accepted] PHST- 2023/04/25 10:20 [medline] PHST- 2023/03/25 06:00 [pubmed] PHST- 2023/03/24 19:01 [entrez] AID - S0379-0738(23)00092-0 [pii] AID - 10.1016/j.forsciint.2023.111642 [doi] PST - ppublish SO - Forensic Sci Int. 2023 May;346:111642. doi: 10.1016/j.forsciint.2023.111642. Epub 2023 Mar 15. PMID- 36949510 OWN - NLM STAT- MEDLINE DCOM- 20230324 LR - 20240914 IS - 2047-2994 (Electronic) IS - 2047-2994 (Linking) VI - 12 IP - 1 DP - 2023 Mar 22 TI - Patient and ward related risk factors in a multi-ward nosocomial outbreak of COVID-19: Outbreak investigation and matched case-control study. PG - 21 LID - 10.1186/s13756-023-01215-1 [doi] LID - 21 AB - BACKGROUND: Risk factors for nosocomial COVID-19 outbreaks continue to evolve. The aim of this study was to investigate a multi-ward nosocomial outbreak of COVID-19 between 1st September and 15th November 2020, occurring in a setting without vaccination for any healthcare workers or patients. METHODS: Outbreak report and retrospective, matched case-control study using incidence density sampling in three cardiac wards in an 1100-bed tertiary teaching hospital in Calgary, Alberta, Canada. Patients were confirmed/probable COVID-19 cases and contemporaneous control patients without COVID-19. COVID-19 outbreak definitions were based on Public Health guidelines. Clinical and environmental specimens were tested by RT-PCR and as applicable quantitative viral cultures and whole genome sequencing were conducted. Controls were inpatients on the cardiac wards during the study period confirmed to be without COVID-19, matched to outbreak cases by time of symptom onset dates, age within +/- 15 years and were admitted in hospital for at least 2 days. Demographics, Braden Score, baseline medications, laboratory measures, co-morbidities, and hospitalization characteristics were collected on cases and controls. Univariate and multivariate conditional logistical regression was used to identify independent risk factors for nosocomial COVID-19. RESULTS: The outbreak involved 42 healthcare workers and 39 patients. The strongest independent risk factor for nosocomial COVID-19 (IRR 3.21, 95% CI 1.47-7.02) was exposure in a multi-bedded room. Of 45 strains successfully sequenced, 44 (97.8%) were B.1.128 and differed from the most common circulating community lineages. SARS-CoV-2 positive cultures were detected in 56.7% (34/60) of clinical and environmental specimens. The multidisciplinary outbreak team observed eleven contributing events to transmission during the outbreak. CONCLUSIONS: Transmission routes of SARS-CoV-2 in hospital outbreaks are complex; however multi-bedded rooms play a significant role in the transmission of SARS-CoV-2. CI - (c) 2023. The Author(s). FAU - Leal, Jenine AU - Leal J AD - Infection Prevention and Control, Alberta Health Services, Calgary, AB, Canada. AD - Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. AD - O'Brien Institute for Public Health, University of Calgary and Alberta Health Services, Calgary, AB, Canada. AD - Department of Microbiology, Immunology and Infectious Diseases, University of Calgary, Calgary, AB, Canada. FAU - O'Grady, Heidi M AU - O'Grady HM AD - Infection Prevention and Control, Alberta Health Services, Calgary, AB, Canada. FAU - Armstrong, Logan AU - Armstrong L AD - Infection Prevention and Control, Alberta Health Services, Edmonton, AB, Canada. FAU - Dixit, Devika AU - Dixit D AD - Department of Pediatrics, Division of Infectious Diseases, University of Calgary and Alberta Health Services, Calgary, AB, Canada. FAU - Khawaja, Zoha AU - Khawaja Z AD - W21C, Department of Medicine, University of Calgary, Calgary, AB, Canada. FAU - Snedeker, Kate AU - Snedeker K AD - Provincial Population and Public Health, Alberta Health Services, Calgary, AB, Canada. FAU - Ellison, Jennifer AU - Ellison J AD - Infection Prevention and Control, Alberta Health Services, Lethbridge, AB, Canada. FAU - Erebor, Joyce AU - Erebor J AD - Infection Prevention and Control, Alberta Health Services, Calgary, AB, Canada. FAU - Jamieson, Peter AU - Jamieson P AD - Department of Family Medicine, University of Calgary and Alberta Health Services, Calgary, AB, Canada. FAU - Weiss, Amanda AU - Weiss A AD - Cardiac Sciences, Foothills Medical Centre, Alberta Health Services, Calgary, AB, Canada. FAU - Salcedo, Daniel AU - Salcedo D AD - Cardiac Sciences, Foothills Medical Centre, Alberta Health Services, Calgary, AB, Canada. FAU - Roberts, Kimberley AU - Roberts K AD - Cardiac Sciences, Foothills Medical Centre, Alberta Health Services, Calgary, AB, Canada. FAU - Wiens, Karen AU - Wiens K AD - Cardiac Sciences, Foothills Medical Centre, Alberta Health Services, Calgary, AB, Canada. FAU - Croxen, Matthew A AU - Croxen MA AD - Li Ka Shing Institute of Virology, University of Alberta, Edmonton, AB, Canada. AD - Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada. AD - Women and Children's Health Research Institute, University of Alberta, Edmonton, AB, Canada. AD - Alberta Public Health Laboratory, Alberta Precision Laboratories, Edmonton, AB, Canada. FAU - Berenger, Byron M AU - Berenger BM AD - Department of Pathology and Laboratory Medicine, University of Calgary and Alberta Health Services, Calgary, AB, Canada. AD - Alberta Public Health Laboratory, Alberta Precision Laboratories, Calgary, AB, Canada. FAU - Pabbaraju, Kanti AU - Pabbaraju K AD - Alberta Public Health Laboratory, Alberta Precision Laboratories, Calgary, AB, Canada. FAU - Lin, Yi-Chan AU - Lin YC AD - Li Ka Shing Institute of Virology, University of Alberta, Edmonton, AB, Canada. AD - Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, AB, Canada. FAU - Evans, David AU - Evans D AD - Li Ka Shing Institute of Virology, University of Alberta, Edmonton, AB, Canada. AD - Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, AB, Canada. FAU - Conly, John M AU - Conly JM AD - Infection Prevention and Control, Alberta Health Services, Calgary, AB, Canada. John.Conly@albertahealthservices.ca. AD - Department of Medicine, Cumming School of Medicine, University of Calgary and Alberta Health Services, Calgary, AB, Canada. John.Conly@albertahealthservices.ca. AD - O'Brien Institute for Public Health, University of Calgary and Alberta Health Services, Calgary, AB, Canada. John.Conly@albertahealthservices.ca. AD - Department of Microbiology, Immunology and Infectious Diseases, University of Calgary, Calgary, AB, Canada. John.Conly@albertahealthservices.ca. AD - Department of Pathology and Laboratory Medicine, University of Calgary and Alberta Health Services, Calgary, AB, Canada. John.Conly@albertahealthservices.ca. AD - Synder Institute for Chronic Diseases, University of Calgary and Alberta Health Services, Calgary, AB, Canada. John.Conly@albertahealthservices.ca. AD - W21C, Department of Medicine, University of Calgary, Calgary, AB, Canada. John.Conly@albertahealthservices.ca. AD - Foothills Medical Centre, AGW5 - Special Services Bldg, 1403 29Th Street Nw, Calgary, AB, T2N 2T9, Canada. John.Conly@albertahealthservices.ca. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230322 PL - England TA - Antimicrob Resist Infect Control JT - Antimicrobial resistance and infection control JID - 101585411 SB - IM MH - Humans MH - *COVID-19/epidemiology MH - SARS-CoV-2/genetics MH - *Cross Infection/epidemiology/prevention & control MH - Case-Control Studies MH - Retrospective Studies MH - Disease Outbreaks MH - Risk Factors MH - Tertiary Care Centers MH - Alberta PMC - PMC10031162 OTO - NOTNLM OT - COVID-19 OT - Case-control OT - Environment OT - Incidence density sampling OT - Nosocomial OT - Outbreak OT - Rate ratio OT - Risk factors OT - Viral culture COIS- All authors will have filled out an ICMJE Disclosure form. JL reports Program funds from the Centre of Health Informatics at the University of Calgary used to provide in-Kind analytical support for her COVID-19 research, not related to this manuscript and funds paid to the University of Calgary to support professional development, specifically IPAC Canada 2022 Virtual conference fees were reimbursed by the Public Health Agency of Canada's Canadian Nosocomial Infection Surveillance Program. All other authors do not have relevant conflicts of interest to declare related to any aspect of the submitted manuscript. All authors have reviewed the version of the manuscript which has been submitted. EDAT- 2023/03/24 06:00 MHDA- 2023/03/25 06:00 PMCR- 2023/03/22 CRDT- 2023/03/23 00:37 PHST- 2022/10/05 00:00 [received] PHST- 2023/02/10 00:00 [accepted] PHST- 2023/03/23 00:37 [entrez] PHST- 2023/03/24 06:00 [pubmed] PHST- 2023/03/25 06:00 [medline] PHST- 2023/03/22 00:00 [pmc-release] AID - 10.1186/s13756-023-01215-1 [pii] AID - 1215 [pii] AID - 10.1186/s13756-023-01215-1 [doi] PST - epublish SO - Antimicrob Resist Infect Control. 2023 Mar 22;12(1):21. doi: 10.1186/s13756-023-01215-1. PMID- 36946812 OWN - NLM STAT- MEDLINE DCOM- 20230324 LR - 20230324 IS - 1984-0446 (Electronic) IS - 0034-7167 (Print) IS - 0034-7167 (Linking) VI - 76 IP - 2 DP - 2023 TI - Features of the triggering of the yellow code and factors associated with the occurrence of adverse events. PG - e20220181 LID - S0034-71672023000200158 [pii] LID - 10.1590/0034-7167-2022-0181 [doi] LID - e20220181 AB - OBJECTIVE: to analyze the characteristics of the activation of the yellow code in wards and identify the factors associated with adverse events after the Rapid Response Team. METHODS: a cross-sectional study with retrospective analysis of medical records of adults admitted to medical or surgical clinic wards of the University Hospital of Sao Paulo. RESULTS: among the 91 patients, the most frequent signs of triggers (n=107) were peripheral oxygen saturation of less than 90% (40.2%) and hypotension (30.8%). Regarding the associated factors the research identified each minute of attendance of the Rapid Response Team in the wards increased by 1.2% odds of adverse events (twenty-four unplanned admission in the ICU and one cardiac arrest) in the sample (p=0.014). CONCLUSIONS: decreased oxygen saturation and hypotension were the main reasons for the triggering, and the length of care was associated with the frequency of adverse events. FAU - Santos, Pollyana Karine Lopes Dos AU - Santos PKLD AUID- ORCID: 0000-0002-6923-6519 AD - Universidade de Sao Paulo. Sao Paulo, Sao Paulo, Brazil. FAU - Oliveira, Gabriella Novelli AU - Oliveira GN AUID- ORCID: 0000-0003-2100-1937 AD - Universidade de Sao Paulo, Hospital Universitario. Sao Paulo, Sao Paulo, Brazil. FAU - Sichieri, Karina AU - Sichieri K AUID- ORCID: 0000-0002-5074-4636 AD - Universidade de Sao Paulo, Hospital Universitario. Sao Paulo, Sao Paulo, Brazil. FAU - Cruz, Dina de Almeida Lopes Monteiro da AU - Cruz DALMD AUID- ORCID: 0000-0003-1373-409X AD - Universidade de Sao Paulo. Sao Paulo, Sao Paulo, Brazil. FAU - Nogueira, Lilia de Souza AU - Nogueira LS AUID- ORCID: 0000-0001-5387-3807 AD - Universidade de Sao Paulo. Sao Paulo, Sao Paulo, Brazil. LA - eng LA - por PT - Journal Article DEP - 20230317 PL - Brazil TA - Rev Bras Enferm JT - Revista brasileira de enfermagem JID - 7910105 MH - Adult MH - Humans MH - Retrospective Studies MH - Cross-Sectional Studies MH - Intensive Care Units MH - Brazil MH - *Hospital Rapid Response Team MH - Hospitals, University MH - *Hypotension/epidemiology/etiology MH - Hospital Mortality PMC - PMC10021946 EDAT- 2023/03/23 06:00 MHDA- 2023/03/25 06:00 PMCR- 2023/03/17 CRDT- 2023/03/22 10:24 PHST- 2022/05/21 00:00 [received] PHST- 2022/11/17 00:00 [accepted] PHST- 2023/03/22 10:24 [entrez] PHST- 2023/03/23 06:00 [pubmed] PHST- 2023/03/25 06:00 [medline] PHST- 2023/03/17 00:00 [pmc-release] AID - S0034-71672023000200158 [pii] AID - 10.1590/0034-7167-2022-0181 [doi] PST - epublish SO - Rev Bras Enferm. 2023 Mar 17;76(2):e20220181. doi: 10.1590/0034-7167-2022-0181. eCollection 2023. PMID- 36938616 OWN - NLM STAT- MEDLINE DCOM- 20230404 LR - 20230414 IS - 1098-4275 (Electronic) IS - 0031-4005 (Linking) VI - 151 IP - 4 DP - 2023 Apr 1 TI - Health Supervision for Children and Adolescents With Marfan Syndrome. LID - e2023061450 [pii] LID - 10.1542/peds.2023-061450 [doi] AB - Marfan syndrome is a heritable connective tissue disorder that affects many different organ systems. In some cases, features of Marfan syndrome can be recognized at birth, but the majority will have manifestations that emerge throughout childhood and into adulthood. Significant morbidity and mortality are associated with this syndrome, and its features are best managed using a multidisciplinary approach. This clinical report is designed to assist the pediatrician in recognizing the features of Marfan syndrome as well as caring for the individual with Marfan syndrome to maximize their health and quality of life. CI - Copyright (c) 2023 by the American Academy of Pediatrics. FAU - Tinkle, Brad T AU - Tinkle BT AD - Peyton Manning Children's Hospital, Ascension Healthcare, Indianapolis, Indiana. FAU - Lacro, Ronald V AU - Lacro RV AD - Cardiovascular Genetics Clinic for Connective Tissue Disorders and Aortopathies, Department of Cardiology, Boston Children's Hospital, Boston, Massachusetts. FAU - Burke, Leah W AU - Burke LW AD - University of Vermont, Burlington, Vermont. CN - COUNCIL ON GENETICS LA - eng PT - Journal Article PL - United States TA - Pediatrics JT - Pediatrics JID - 0376422 SB - IM MH - Infant, Newborn MH - Humans MH - Child MH - Adolescent MH - *Marfan Syndrome/diagnosis/therapy/complications MH - Quality of Life MH - Pediatricians EDAT- 2023/03/21 06:00 MHDA- 2023/04/04 06:42 CRDT- 2023/03/20 04:22 PHST- 2023/01/25 00:00 [accepted] PHST- 2023/04/04 06:42 [medline] PHST- 2023/03/21 06:00 [pubmed] PHST- 2023/03/20 04:22 [entrez] AID - 190852 [pii] AID - 10.1542/peds.2023-061450 [doi] PST - ppublish SO - Pediatrics. 2023 Apr 1;151(4):e2023061450. doi: 10.1542/peds.2023-061450. PMID- 36938226 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240914 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 15 IP - 2 DP - 2023 Feb TI - Management of Heart Failure With Preserved Ejection Fraction in Elderly Patients: Effectiveness and Safety. PG - e35030 LID - 10.7759/cureus.35030 [doi] LID - e35030 AB - The proportion of the elderly population continues to increase due to the global increase in longevity. Heart failure with preserved ejection fraction (HFpEF) is common in the elderly due to cellular aging, myocardial stiffness, and multiple comorbidities. This age group is often under-represented in clinical trials. In this narrative review, we looked into the latest evidence-based lines of management of HFpEF in this vulnerable cohort. In this narrative review, we brought the latest evidence on the treatment of HFpEf in the elderly. We searched the largest three scientific databases (Pubmed, Google Scholar, and EMBASE) using the search words (elderly, HFpEF, heart failure with preserved ejection fraction, guidelines, treatment, and management) in different combinations. To date, screening for and treatment of the causes of HFpEF (such as hypertension, coronary artery disease [CAD], valvular heart disease, and cardiac amyloidosis) and associated comorbidities (such as diabetes mellitus [DM], iron deficiency, obesity, and thyroid dysfunction) are the main line of management of HFpEF. A multidisciplinary team, including an HF specialist cardiologist, an HF nurse, a geriatrician, a dietician, a psychologist, a physiotherapist, and an occupational therapist, should manage HFpEF elderly patients. Other specialist input may be needed according to the patient's requirements. The evidence on the effective management of HFpEF in the elderly age group is scarce and controversial. Some studied non-pharmacological approaches include supervised exercise training, pulmonary artery pressure monitoring, and the interatrial shunt device (an emerging modality that includes a small percutaneously inserted interatrial left to right valve aiming to reduce the left atrial and pulmonary wedge pressures). These modalities can only improve the symptoms and HF hospitalizations without robustly impacting cardiovascular (CV) death. Among the pharmacological approaches to treat HFpEF, only the sodium-glucose cotransporter 2 (SGLT-2) inhibitors proved efficacy in reducing the hard outcomes of CV death, HF hospitalizations, and urgent visits for HF when used in elderly HFpEF patients, irrespective of the presence of diabetes mellitus. Diuretics are only beneficial to alleviate the symptoms of fluid overload, with a risk of renal impairment in volume-depleted patients. The evidence on the effectiveness of other HF-specific disease-modifying agents in elderly HFpEF patients is controversial. Elderly patients have a higher risk of having side effects from HF medications due to the higher prevalence of polypharmacy, cognitive decline, and impairment of kidney and liver functions. Therefore, cautious initiation of HF treatment with a close follow-up of the blood pressure, liver functions, kidney functions, and electrolytes are of utmost importance. CI - Copyright (c) 2023, Elkammash et al. FAU - Elkammash, Amr AU - Elkammash A AD - Department of Cardiology, The Royal Papworth Hospital NHS Foundation Trust, Cambridge, GBR. FAU - Tam, Simpson Shiu Chung AU - Tam SSC AD - School of Clinical Medicine, University of Cambridge, Cambridge, GBR. FAU - Yogarajah, Geethana AU - Yogarajah G AD - School of Clinical Medicine, University of Cambridge, Cambridge, GBR. FAU - You, Jianing AU - You J AD - School of Clinical Medicine, University of Cambridge, Cambridge, GBR. LA - eng PT - Journal Article PT - Review DEP - 20230215 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC10023169 OTO - NOTNLM OT - beta-blockers OT - cardiomems OT - elderly OT - heart failure with preserved ejection fraction OT - mineralocorticoid receptor antagonist OT - renin-angiotensin-aldosterone system (raas) OT - sacubitril-valsartan OT - side-effects OT - sodium-glucose cotransporter 2 (sglt-2) inhibitors COIS- The authors have declared that no competing interests exist. EDAT- 2023/03/21 06:00 MHDA- 2023/03/21 06:01 PMCR- 2023/02/15 CRDT- 2023/03/20 04:15 PHST- 2023/02/14 00:00 [accepted] PHST- 2023/03/20 04:15 [entrez] PHST- 2023/03/21 06:00 [pubmed] PHST- 2023/03/21 06:01 [medline] PHST- 2023/02/15 00:00 [pmc-release] AID - 10.7759/cureus.35030 [doi] PST - epublish SO - Cureus. 2023 Feb 15;15(2):e35030. doi: 10.7759/cureus.35030. eCollection 2023 Feb. PMID- 36937979 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240914 IS - 2296-2360 (Print) IS - 2296-2360 (Electronic) IS - 2296-2360 (Linking) VI - 11 DP - 2023 TI - Fontan-associated liver disease: Diagnosis, surveillance, and management. PG - 1100514 LID - 10.3389/fped.2023.1100514 [doi] LID - 1100514 AB - The Fontan operation is a lifesaving procedure for patients with functional single-ventricle congenital heart disease, where hypoplastic left heart syndrome is the most frequent anomaly. Hemodynamic changes following Fontan circulation creation are now increasingly recognized to cause multiorgan affection, where the development of a chronic liver disease, Fontan-associated liver disease (FALD), is one of the most important morbidities. Virtually, all patients with a Fontan circulation develop liver congestion, resulting in fibrosis and cirrhosis, and most patients experience childhood onset. FALD is a distinctive type of congestive hepatopathy, and its pathogenesis is thought to be a multifactorial process driven by increased nonpulsatile central venous pressure and decreased cardiac output, both of which are inherent in the Fontan circulation. In the advanced stage of liver injury, complications of portal hypertension often occur, and there is a risk of developing secondary liver cancer, reported at young age. However, FALD develops with few clinical symptoms, a surprisingly variable degree of severity in liver disease, and with little relation to poor cardiac function. The disease mechanisms and modifying factors of its development are still not fully understood. As one of the more important noncardiac complications of the Fontan circulation, FALD needs to be diagnosed in a timely manner with a structured monitoring scheme of disease development, early detection of malignancy, and determination of the optimal time point for transplantation. There is also a clear need for consensus on the best surveillance strategy for FALD. In this regard, imaging plays an important role together with clinical scoring systems, biochemical workups, and histology. Patients operated on with a Fontan circulation are generally followed up in cardiology units. Ultimately, the resulting multiorgan affection requires a multidisciplinary team of healthcare personnel to address the different organ complications. This article discusses the current concepts, diagnosis, and management of FALD, with special emphasis on the role of different imaging techniques in the diagnosis and monitoring of disease progression, as well as current recommendations for liver disease surveillance. CI - (c) 2023 de Lange, Moller and Hebelka. FAU - de Lange, Charlotte AU - de Lange C AD - Department of Pediatric Radiology, Queen Silvia Children's Hospital, Sahlgrenska University Hospital, Gothenburg, Sweden. AD - Institution of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. FAU - Moller, Thomas AU - Moller T AD - Department of Pediatric Cardiology, Oslo University Hospital, Oslo, Norway. FAU - Hebelka, Hanna AU - Hebelka H AD - Department of Pediatric Radiology, Queen Silvia Children's Hospital, Sahlgrenska University Hospital, Gothenburg, Sweden. AD - Institution of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. LA - eng PT - Journal Article PT - Review DEP - 20230303 PL - Switzerland TA - Front Pediatr JT - Frontiers in pediatrics JID - 101615492 PMC - PMC10020358 OTO - NOTNLM OT - Fontan procedure OT - chronic liver disease OT - congestion OT - imaging OT - surveillance COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/03/21 06:00 MHDA- 2023/03/21 06:01 PMCR- 2023/03/03 CRDT- 2023/03/20 04:11 PHST- 2022/11/16 00:00 [received] PHST- 2023/02/09 00:00 [accepted] PHST- 2023/03/20 04:11 [entrez] PHST- 2023/03/21 06:00 [pubmed] PHST- 2023/03/21 06:01 [medline] PHST- 2023/03/03 00:00 [pmc-release] AID - 10.3389/fped.2023.1100514 [doi] PST - epublish SO - Front Pediatr. 2023 Mar 3;11:1100514. doi: 10.3389/fped.2023.1100514. eCollection 2023. PMID- 31082038 STAT- Publisher CTDT- 20230320 PB - StatPearls Publishing DP - 2023 Jan TI - Lovastatin. BTI - StatPearls AB - Lovastatin is a lipid-lowering medication in the statin drug class used to treat and prevent coronary heart disease, hypercholesterolemia, and adolescent patients with heterozygous familial hypercholesterolemia. This activity will review the mechanism of action, adverse effects, and other key factors (eg, off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions) pertinent to the interprofessional team members in treating patients with hypercholesterolemia. CI - Copyright (c) 2023, StatPearls Publishing LLC. FAU - Duong, Hanh AU - Duong H FAU - Bajaj, Tushar AU - Bajaj T AD - US Acute Care Solutions LA - eng PT - Study Guide PT - Book Chapter PL - Treasure Island (FL) COIS- Disclosure: Hanh Duong declares no relevant financial relationships with ineligible companies. Disclosure: Tushar Bajaj declares no relevant financial relationships with ineligible companies. EDAT- 2023/03/20 00:00 CRDT- 2023/03/20 00:00 AID - NBK540994 [bookaccession] PMID- 36930487 OWN - NLM STAT- MEDLINE DCOM- 20230321 LR - 20230503 IS - 2284-0729 (Electronic) IS - 1128-3602 (Linking) VI - 27 IP - 5 DP - 2023 Mar TI - Predictive effect of nutritional scores assessment for 1-year mortality in patients with severe aortic stenosis treated with SAVR or TAVR. PG - 1904-1911 LID - 31556 [pii] LID - 10.26355/eurrev_202303_31556 [doi] AB - OBJECTIVE: As treatment modalities of severe AS, interventional treatments such as SAVR or TAVR with the decision of the heart team have been performed recently. Controlling nutritional status (CONUT) score and prognostic nutritional index (PNI) have a very important place among the scores that provide a simple, effective, and objective evaluation of prognosis. In our study, we aimed to investigate the short-term prognostic results of severe AS patients who underwent TAVR or SAVR by comparing the CONUT and PNI results of the patients. PATIENTS AND METHODS: 258 patients who underwent percutaneous TAVR or SAVR in our clinic between December 2012 and December 2020 were included in the study in a randomized retrospective manner. The primary endpoint of the study was in-hospital and 1-year all-cause death. The results of all patient groups were compared by dividing them into 2 groups as all-cause death group (deceased group) and non-all-cause death group (survived group) within 1 year. RESULTS: All-cause mortality occurred in 57 (29%) patients within 1 year. As nutritional status scores, the PNI score (39.9+/-7.4 vs. 46.5+/-6.9, p<0.001) was lower in the deceased group and the median CONUT score [4(4) vs. 1(3) p<0.001] was found significantly higher. NLR score was also found to be significantly higher in the deceased group (p<0.001). They were divided into 3 tertiles containing an equal number of patients and compared according to the nutritional scores. Significantly higher 1-year mortality was observed in the high CONUT [10 (12%) deaths in T1, 12 (14%) in T2, and 35 (41%) deaths in T3, respectively, p<0.001] and low PNI [37 (43%) deaths in T1, 13 (15%) in T2, and 7 (8%) deaths in T3, respectively, p<0.001] groups, which can be considered as the worse nutritional group. CONCLUSIONS: In the surgical or transarterial treatment of symptomatic severe aortic stenosis, we found that a high CONUT score and a low PNI score were predictors of all-cause mortality at 1-year follow-up, regardless of the type of treatment. We think that checking patients with scores like the abovementioned procedure and making the necessary corrections will lead to positive results in terms of prognosis. FAU - Karacalilar, M AU - Karacalilar M AD - Department of Cardiovascular Surgery, Department of Cardiology, Faculty of Medicine, Dicle University, Diyarbakir, Turkey. m.karacalilar@gmail.com. FAU - Ozbek, M AU - Ozbek M LA - eng PT - Journal Article PL - United States TA - Eur Rev Med Pharmacol Sci JT - European review for medical and pharmacological sciences JID - 9717360 SB - IM MH - Humans MH - Nutrition Assessment MH - *Transcatheter Aortic Valve Replacement/adverse effects MH - Retrospective Studies MH - *Aortic Valve Stenosis/diagnosis/surgery MH - Nutritional Status MH - Risk Factors EDAT- 2023/03/18 06:00 MHDA- 2023/03/22 06:00 CRDT- 2023/03/17 12:25 PHST- 2023/03/17 12:25 [entrez] PHST- 2023/03/18 06:00 [pubmed] PHST- 2023/03/22 06:00 [medline] AID - 31556 [pii] AID - 10.26355/eurrev_202303_31556 [doi] PST - ppublish SO - Eur Rev Med Pharmacol Sci. 2023 Mar;27(5):1904-1911. doi: 10.26355/eurrev_202303_31556. PMID- 36927986 OWN - NLM STAT- MEDLINE DCOM- 20230406 LR - 20230511 IS - 1531-7080 (Electronic) IS - 0268-4705 (Linking) VI - 38 IP - 3 DP - 2023 May 1 TI - Management of pregnancy in left ventricular assist device and heart transplant recipients: a concise review. PG - 257-265 LID - 10.1097/HCO.0000000000001036 [doi] AB - PURPOSE OF REVIEW: Women of reproductive age are increasingly undergoing heart transplantation (HT) or left ventricular assist device (LVAD) implantation for advanced heart failure. This review is intended to give an overview of the current state of the art management of pregnancy in patients with LVAD or HT recipients. RECENT FINDINGS: Heart transplant recipients are at increased risk for graft rejection, renal dysfunction, preeclampsia and worsening of comorbidities (hypertension and diabetes). Patients with LVAD are at higher risk of thromboembolic events, infections, right ventricular failure and require close surveillance during pregnancy. Preconception counseling must be offered to all women of reproductive age group with HT or LVAD to avoid unplanned pregnancies. SUMMARY: A multidisciplinary approach with close antepartum and postpartum surveillance is recommended. CI - Copyright (c) 2023 Wolters Kluwer Health, Inc. All rights reserved. FAU - Marek-Iannucci, Stefanie AU - Marek-Iannucci S AD - Division of Cardiology, Jefferson Heart Institute, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA. FAU - Uber, Patricia AU - Uber P FAU - Rajapreyar, Indranee AU - Rajapreyar I LA - eng PT - Journal Article PT - Review DEP - 20230302 PL - United States TA - Curr Opin Cardiol JT - Current opinion in cardiology JID - 8608087 SB - IM MH - Humans MH - Female MH - Pregnancy MH - *Heart-Assist Devices MH - Treatment Outcome MH - Retrospective Studies MH - *Heart Transplantation MH - *Heart Failure/surgery/etiology EDAT- 2023/03/18 06:00 MHDA- 2023/04/06 06:41 CRDT- 2023/03/17 08:46 PHST- 2023/04/06 06:41 [medline] PHST- 2023/03/18 06:00 [pubmed] PHST- 2023/03/17 08:46 [entrez] AID - 00001573-202305000-00015 [pii] AID - 10.1097/HCO.0000000000001036 [doi] PST - ppublish SO - Curr Opin Cardiol. 2023 May 1;38(3):257-265. doi: 10.1097/HCO.0000000000001036. Epub 2023 Mar 2. PMID- 36927866 OWN - NLM STAT- MEDLINE DCOM- 20230320 LR - 20230423 IS - 2053-3624 (Print) IS - 2053-3624 (Electronic) IS - 2053-3624 (Linking) VI - 10 IP - 1 DP - 2023 Mar TI - Harnessing digital health to optimise the delivery of guideline-based cardiac rehabilitation during COVID-19: an observational study. LID - 10.1136/openhrt-2022-002211 [doi] LID - e002211 AB - BACKGROUND: The COVID-19 pandemic accelerated the uptake of digital health interventions for the delivery of cardiac rehabilitation (CR). However, there is a need to evaluate these interventions. METHODS: We examined the impact of an evidence-based, digital CR programme on medical, lifestyle and psychosocial outcomes. Delivered by an interdisciplinary team of healthcare professionals, the core components of this 12-week programme included lifestyle modification, medical risk factor management, psychosocial and behavioural change support. To support self-management, patients were provided with a Fitbit, a home blood pressure (BP) monitor and an interactive workbook. Patients received access to a bespoke web-based platform and were invited to attend weekly, online group-based supervised exercise sessions and educational workshops. Outcomes were assessed at baseline, end of programme and at 6-month follow-up. RESULTS: Over a 3-month period, 105 patients (88% with coronary heart disease) were referred with 74% (n=77) attending initial assessment. Of these, 97% (n=75) enrolled in the programme, with 85% (n=64) completing the programme, 86% (n=55) of completers attended 6-month follow-up. Comparing baseline to end of programme, we observed significant improvements in the proportion of patients meeting guideline-recommended targets for physical activity (+68%, p<0.001), BP (+44%, p<0.001) and low-density lipoprotein cholesterol (+27%, p<0.001). There were significant reductions in mean weight (-2.6 kg, p<0.001). Adherence to the Mediterranean diet score improved from 5.2 to 7.3 (p<0.001). Anxiety and depression levels (Hospital Anxiety and Depression score) both reduced by more than 50% (p<0.001). The majority of these improvements were sustained at 6-month follow-up. CONCLUSION: Outcomes from this study suggest that interdisciplinary digital CR programmes can be successfully implemented and help patients achieve guideline recommended lifestyle, medical and therapeutic targets. CI - (c) Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Gibson, Irene AU - Gibson I AUID- ORCID: 0000-0002-5700-2280 AD - School of Medicine, University of Galway, Galway, Ireland irene.gibson@universityofgalway.ie. AD - National Institute for Prevention and Cardiovascular Health, Galway, Ireland. FAU - McCrudden, Zoe AU - McCrudden Z AD - Sligo University Hospital, Sligo, Ireland. FAU - Dunne, Denise AU - Dunne D AD - Community Healthcare West, Health Service Executive West, Galway, Ireland. FAU - Harris, Aisling AU - Harris A AD - Croi, West of Ireland Cardiac and Stroke Foundation, Galway, Ireland. FAU - Hynes, Lisa AU - Hynes L AD - Croi, West of Ireland Cardiac and Stroke Foundation, Galway, Ireland. FAU - Murphy, Ella AU - Murphy E AD - School of Medicine, University of Galway, Galway, Ireland. FAU - Murphy, Andrew William AU - Murphy AW AD - Discipline of General Practice, University of Galway, Galway, Ireland. FAU - Byrne, Molly AU - Byrne M AD - Health Behaviour Change Research Group, University of Galway, Galway, Ireland. FAU - McEvoy, John William AU - McEvoy JW AD - School of Medicine, University of Galway, Galway, Ireland. AD - National Institute for Prevention and Cardiovascular Health, Galway, Ireland. LA - eng PT - Journal Article PT - Observational Study PT - Research Support, Non-U.S. Gov't PL - England TA - Open Heart JT - Open heart JID - 101631219 SB - IM MH - Humans MH - *Cardiac Rehabilitation MH - Pandemics MH - *COVID-19 MH - Risk Factors MH - Exercise PMC - PMC10030287 OTO - NOTNLM OT - COVID-19 OT - cardiac rehabilitation OT - telemedicine COIS- Competing interests: None declared. EDAT- 2023/03/18 06:00 MHDA- 2023/03/21 06:00 PMCR- 2023/03/16 CRDT- 2023/03/17 08:44 PHST- 2022/11/16 00:00 [received] PHST- 2023/02/09 00:00 [accepted] PHST- 2023/03/17 08:44 [entrez] PHST- 2023/03/18 06:00 [pubmed] PHST- 2023/03/21 06:00 [medline] PHST- 2023/03/16 00:00 [pmc-release] AID - openhrt-2022-002211 [pii] AID - 10.1136/openhrt-2022-002211 [doi] PST - ppublish SO - Open Heart. 2023 Mar;10(1):e002211. doi: 10.1136/openhrt-2022-002211. PMID- 36922827 OWN - NLM STAT- MEDLINE DCOM- 20230320 LR - 20260108 IS - 1745-6215 (Electronic) IS - 1745-6215 (Linking) VI - 24 IP - 1 DP - 2023 Mar 15 TI - The protocol for the prehabilitation for thoracic surgery study: a randomized pragmatic trial comparing a short home-based multimodal program to aerobic training in patients undergoing video-assisted thoracoscopic surgery lobectomy. PG - 194 LID - 10.1186/s13063-023-07220-4 [doi] LID - 194 AB - BACKGROUND: Prehabilitation has been shown to have a positive effect on the postoperative recovery of functional capacity in patients undergoing video-assisted thoracoscopic surgery (VATS) lobectomy. The optimal way to implement prehabilitation programs, such as the optimal forms of prehabilitation, duration, intensity, and methods to improve compliance, remained to be studied. This Prehabilitation for Thoracic Surgery Study will compare the effectiveness of multimodal and aerobic training-only programs in patients undergoing thoracoscopic lobectomy. METHODS: This randomized pragmatic trial will be conducted in Peking Union Medical College Hospital (PUMCH) and include 100 patients who are eligible to undergo VATS lobectomy. Patients will be randomized to a multimodal or aerobic training group. Prehabilitation training guidance will be provided by a multidisciplinary care team. The patients in the multimodal group will perform aerobic exercises, resistance exercises, breathing exercises, psychological improvement strategies, and nutritional supplementation. Meanwhile, the patients in the aerobic group will conduct only aerobic exercises. The interventions will be home-based and supervised by medical providers. The patients will be followed up until 30 days after surgery to investigate whether the multimodal prehabilitation program differs from the aerobic training program in terms of the magnitude of improvement in functional capability pre- to postoperatively. The primary outcome will be the perioperative 6-min walk distance (6MWD). The secondary outcomes will include the postoperative pulmonary functional recovery status, health-related quality of life score, incidence of postoperative complications, and clinical outcomes. DISCUSSION: Prehabilitation remains a relatively new approach that is not widely performed by thoracic surgery patients. The existing studies mainly focus on unimodal interventions. While multimodal prehabilitation strategies have been shown to be preferable to unimodal strategies in a few studies, the evidence remains scarce for thoracic surgery patients. The results of this study will contribute to the understanding of methods for thoracoscopic lobectomy patients. TRIAL REGISTRATION: ClinicalTrials.gov NCT04049942 . Registered on August 8, 2019. CI - (c) 2023. The Author(s). FAU - Liu, Yuchao AU - Liu Y AD - Department of Anesthesiology, Chinese Academy of Medical Sciences & Peking Union Medical College Hospital, Beijing, 100730, China. FAU - Liu, Zijia AU - Liu Z AUID- ORCID: 0000-0002-1866-4337 AD - Department of Anesthesiology, Chinese Academy of Medical Sciences & Peking Union Medical College Hospital, Beijing, 100730, China. liu-zj02@126.com. FAU - Zhang, Yuelun AU - Zhang Y AD - Department of Medical Research Center, Chinese Academy of Medical Sciences & Peking Union Medical College Hospital, Beijing, 100730, China. FAU - Cui, Yushang AU - Cui Y AD - Department of Thoracic Surgery, Chinese Academy of Medical Sciences & Peking Union Medical College Hospital, Beijing, 100730, China. FAU - Pei, Lijian AU - Pei L AD - Department of Anesthesiology, Chinese Academy of Medical Sciences & Peking Union Medical College Hospital, Beijing, 100730, China. FAU - Huang, Yuguang AU - Huang Y AD - Department of Anesthesiology, Chinese Academy of Medical Sciences & Peking Union Medical College Hospital, Beijing, 100730, China. LA - eng SI - ClinicalTrials.gov/NCT04049942 GR - 2019XK320023/Chinese Academy of Medical Sciences/ PT - Clinical Trial Protocol PT - Journal Article DEP - 20230315 PL - England TA - Trials JT - Trials JID - 101263253 SB - IM MH - Humans MH - *Thoracic Surgery, Video-Assisted/adverse effects MH - *Thoracic Surgery MH - Preoperative Exercise MH - Quality of Life MH - Exercise Therapy/adverse effects MH - Postoperative Complications/etiology/prevention & control/epidemiology MH - Randomized Controlled Trials as Topic MH - Pragmatic Clinical Trials as Topic PMC - PMC10017060 OTO - NOTNLM OT - 6-min walk distance OT - Aerobic training OT - Functional capacity OT - Lobectomy OT - Multimodal prehabilitation OT - Pragmatic trial OT - Video-assisted thoracoscopic surgeries COIS- The authors declare that they have no competing interests. EDAT- 2023/03/17 06:00 MHDA- 2023/03/21 06:00 PMCR- 2023/03/15 CRDT- 2023/03/16 01:56 PHST- 2021/06/23 00:00 [received] PHST- 2023/03/06 00:00 [accepted] PHST- 2023/03/16 01:56 [entrez] PHST- 2023/03/17 06:00 [pubmed] PHST- 2023/03/21 06:00 [medline] PHST- 2023/03/15 00:00 [pmc-release] AID - 10.1186/s13063-023-07220-4 [pii] AID - 7220 [pii] AID - 10.1186/s13063-023-07220-4 [doi] PST - epublish SO - Trials. 2023 Mar 15;24(1):194. doi: 10.1186/s13063-023-07220-4. PMID- 36921955 OWN - NLM STAT- MEDLINE DCOM- 20230320 LR - 20250130 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 13 IP - 3 DP - 2023 Mar 15 TI - Methods for assessing guideline adherence for invasive procedures in the care of chronic coronary artery disease: a scoping review. PG - e069832 LID - 10.1136/bmjopen-2022-069832 [doi] LID - e069832 AB - OBJECTIVES: In the care of coronary artery disease (CAD), evidence questions the adequate application of guidelines for cardiovascular procedures, particularly coronary angiographies (CA) and myocardial revascularisation. This review aims to examine how care providers' guideline adherence for CA and myocardial revascularisation in the care of chronic CAD was assessed in the literature. DESIGN: Scoping review. DATA SOURCES: PubMed and EMBASE were searched through in June 2021 (rerun in September 2022). ELIGIBILITY CRITERIA: We included studies assessing care providers' adherence to evidence-based guidelines for CA or myocardial revascularisation in the care of chronic CAD. Studies had to list the evaluation of guideline adherence as study objective, describe the evaluation methods used and report the underlying guidelines and recommendations. DATA EXTRACTION AND SYNTHESIS: Two independent reviewers used standardised forms to extract study characteristics, methodological aspects such as data sources and variables, definitions of guideline adherence and quantification methods and the extent of guideline adherence. To elucidate the measurement of guideline adherence, the main steps were described. RESULTS: Twelve studies (311 869 participants) were included, which evaluated guideline adherence by (1) defining guideline adherence, (2) specifying the study population, (3) assigning (classes of) recommendations and (4) quantifying adherence. Thereby, primarily secondary data were used. Studies differed in their definitions of guideline adherence, where six studies each considered only recommendation class I/grade A/strong recommendations as adherent or additionally recommendation classes IIa/IIb. Furthermore, some of the studies reported a priori definitions and allocation rules for the assignment of recommendation classes. Guideline adherence results ranged from 10% for percutaneous coronary intervention with prior heart team discussion to 98% for coronary artery bypass grafting. CONCLUSION: Due to remarkable inconsistencies in the assessment, a cautious interpretation of the guideline adherence results is required. Future efforts should endeavour to establish a consistent understanding of the concept of guideline adherence. CI - (c) Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Kentenich, Hannah AU - Kentenich H AUID- ORCID: 0000-0002-5331-9256 AD - Institute for Health Economics and Clinical Epidemiology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany hannah.kentenich@uk-koeln.de. FAU - Muller, Dirk AU - Muller D AUID- ORCID: 0000-0002-5576-0192 AD - Institute for Health Economics and Clinical Epidemiology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany. FAU - Wein, Bastian AU - Wein B AUID- ORCID: 0000-0003-1146-6757 AD - Department of Cardiology and Angiology, Contilia Heart and Vascular Center, Elisabeth-Hospital Essen, Essen, Germany. AD - Department of Cardiology, Faculty of Medicine, University of Augsburg, Augsburg, Germany. FAU - Stock, Stephanie AU - Stock S AUID- ORCID: 0000-0002-1726-9300 AD - Institute for Health Economics and Clinical Epidemiology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany. FAU - Seleznova, Yana AU - Seleznova Y AUID- ORCID: 0000-0001-7260-6384 AD - Institute for Health Economics and Clinical Epidemiology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Scoping Review DEP - 20230315 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 SB - IM MH - Humans MH - *Coronary Artery Disease/surgery MH - Guideline Adherence MH - Coronary Artery Bypass MH - Myocardial Revascularization MH - Coronary Angiography PMC - PMC10030787 OTO - NOTNLM OT - cardiology OT - coronary heart disease OT - coronary intervention OT - quality in health care COIS- Competing interests: None declared. EDAT- 2023/03/16 06:00 MHDA- 2023/03/21 06:00 PMCR- 2023/03/14 CRDT- 2023/03/15 20:43 PHST- 2023/03/15 20:43 [entrez] PHST- 2023/03/16 06:00 [pubmed] PHST- 2023/03/21 06:00 [medline] PHST- 2023/03/14 00:00 [pmc-release] AID - bmjopen-2022-069832 [pii] AID - 10.1136/bmjopen-2022-069832 [doi] PST - epublish SO - BMJ Open. 2023 Mar 15;13(3):e069832. doi: 10.1136/bmjopen-2022-069832. PMID- 36921886 OWN - NLM STAT- MEDLINE DCOM- 20230619 LR - 20231120 IS - 1532-8414 (Electronic) IS - 1071-9164 (Linking) VI - 29 IP - 6 DP - 2023 Jun TI - Multidisciplinary Care in Heart Failure Services. PG - 943-958 LID - S1071-9164(23)00067-2 [pii] LID - 10.1016/j.cardfail.2023.02.011 [doi] AB - The American College of Cardiology/American Heart Association/Heart Failure Society of American 2022 guidelines for heart failure (HF) recommend a multidisciplinary team approach for patients with HF. The multidisciplinary HF team-based approach decreases the hospitalization rate for HF and health care costs and improves adherence to self-care and the use of guideline-directed medical therapy. This article proposes the optimal multidisciplinary team structure and each team member's delineated role to achieve institutional goals and metrics for HF care. The proposed HF-specific multidisciplinary team comprises cardiologists, surgeons, advanced practice providers, clinical pharmacists, specialty nurses, dieticians, physical therapists, psychologists, social workers, immunologists, and palliative care clinicians. A standardized multidisciplinary HF team-based approach should be incorporated to optimize the structure, minimize the redundancy of clinical responsibilities among team members, and improve clinical outcomes and patient satisfaction in their HF care. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Sokos, George AU - Sokos G AD - Department of Cardiology, West Virginia University School of Medicine, Morgantown, West Virginia. FAU - Kido, Kazuhiko AU - Kido K AD - Department of Clinical Pharmacy, West Virginia University School of Pharmacy, Morgantown, West Virginia. Electronic address: kazuhiko.kido0322@gmail.com. FAU - Panjrath, Gurusher AU - Panjrath G AD - School of Medicine and Health Sciences, George Washington University, North Englewood, Maryland. FAU - Benton, Emily AU - Benton E AD - Department of Medicine, University of Colorado, Boulder, Colorado. FAU - Page, Robert 2nd AU - Page R 2nd AD - Department of Clinical Pharmacy, at the University of Colorado Denver Skaggs School of Pharmacy, Denver, Colorado. FAU - Patel, Jignesh AU - Patel J AD - Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California. FAU - Smith, Patrick J AU - Smith PJ AD - Psychiatry, University of North Carolina School of Medicine, Chapel Hill, North Carolina. FAU - Korous, Shelly AU - Korous S AD - Advanced Heart Failure Program, Indiana University Health, Indianapolis, Indiana. FAU - Guglin, Maya AU - Guglin M AD - Department of Medicine, Indiana University Health, Indianapolis, Indiana. LA - eng PT - Journal Article PT - Review DEP - 20230314 PL - United States TA - J Card Fail JT - Journal of cardiac failure JID - 9442138 SB - IM MH - Humans MH - *Heart Failure/therapy MH - Hospitalization MH - *Cardiology MH - Benchmarking OTO - NOTNLM OT - Heart failure OT - LVAD OT - interdisciplinary OT - multidisciplinary OT - team-based OT - transplant COIS- Disclosure The authors have no relationships with the industry and nothing to disclose. EDAT- 2023/03/16 06:00 MHDA- 2023/06/19 13:08 CRDT- 2023/03/15 20:30 PHST- 2022/09/15 00:00 [received] PHST- 2023/02/01 00:00 [revised] PHST- 2023/02/05 00:00 [accepted] PHST- 2023/06/19 13:08 [medline] PHST- 2023/03/16 06:00 [pubmed] PHST- 2023/03/15 20:30 [entrez] AID - S1071-9164(23)00067-2 [pii] AID - 10.1016/j.cardfail.2023.02.011 [doi] PST - ppublish SO - J Card Fail. 2023 Jun;29(6):943-958. doi: 10.1016/j.cardfail.2023.02.011. Epub 2023 Mar 14. PMID- 36921548 OWN - NLM STAT- MEDLINE DCOM- 20230502 LR - 20230502 IS - 1527-3288 (Electronic) IS - 0147-9563 (Linking) VI - 60 DP - 2023 Jul-Aug TI - Discharge optimization tool to decrease length of stay and improve satisfaction related to advanced practice provider communication. PG - 59-65 LID - S0147-9563(23)00058-4 [pii] LID - 10.1016/j.hrtlng.2023.02.026 [doi] AB - BACKGROUND: Prolonged length of stay (LOS) due to delayed hospital discharge is associated with increased patient morbidity and mortality and other poor outcomes. The length of stay (LOS) in patients undergoing elective, isolated coronary artery bypass grafting (CABG) at an urban, level 1 trauma center is 8.73 days, compared to the 7.0-day benchmark reported by the Society of Thoracic Surgeons (STS). Improving and reducing length of stay (LOS) can improve clinical, financial, and operational outcomes and decrease the costs of care for patients and the healthcare system. OBJECTIVE: The purpose of this quality improvement project was to implement an evidence-based discharge optimization tool (DOT) within the Electronic Health Record to reduce LOS in patients undergoing isolated CABG and enhance communication satisfaction in cardiothoracic surgery advanced practice providers (APP). METHODS: We used a DOT to communicate anticipated time to discharge in CABG patients to the multidisciplinary team. Outcomes included postoperative LOS and APP communication satisfaction. Data was obtained via chart review and statistically analyzed using a one sample T-test. RESULTS: 177 patients (mean age 64 years, 72% male, 66% Caucasian) were studied. The mean postoperative LOS decreased by 16% from 8.73 days to 7.31 days (p = 0.007; Standard deviation of 3.20). Cardiothoracic surgery APP communication satisfaction improved by 33%. CONCLUSIONS: Utilization of a discharge optimization tool to communicate anticipated time to discharge can significantly decrease LOS and improve APP communication satisfaction. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Kelly, Sean T AU - Kelly ST AD - Tampa General Hospital: Cardiothoracic Surgery Department, Tampa, FL, 33606. Electronic address: seantkelly@usf.edu. FAU - Cardy, Christina AU - Cardy C AD - University of South Florida College of Nursing, 12912 USF Health Dr, Tampa, FL 33612. LA - eng PT - Journal Article DEP - 20230313 PL - United States TA - Heart Lung JT - Heart & lung : the journal of critical care JID - 0330057 SB - IM MH - Humans MH - Male MH - Middle Aged MH - Female MH - Length of Stay MH - *Patient Discharge MH - *Coronary Artery Bypass MH - Postoperative Period MH - Personal Satisfaction MH - Retrospective Studies OTO - NOTNLM OT - Advanced Practice Provider (APP) Satisfaction OT - Cardiothoracic Surgery OT - Communication OT - Coronary Artery Bypass Grafting (CABG) OT - Discharge Optimization OT - Length of Stay (LOS) COIS- Conflict of Interest This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. EDAT- 2023/03/16 06:00 MHDA- 2023/05/02 06:41 CRDT- 2023/03/15 19:16 PHST- 2022/11/26 00:00 [received] PHST- 2023/02/26 00:00 [revised] PHST- 2023/02/28 00:00 [accepted] PHST- 2023/05/02 06:41 [medline] PHST- 2023/03/16 06:00 [pubmed] PHST- 2023/03/15 19:16 [entrez] AID - S0147-9563(23)00058-4 [pii] AID - 10.1016/j.hrtlng.2023.02.026 [doi] PST - ppublish SO - Heart Lung. 2023 Jul-Aug;60:59-65. doi: 10.1016/j.hrtlng.2023.02.026. Epub 2023 Mar 13. PMID- 36920426 OWN - NLM STAT- MEDLINE DCOM- 20230406 LR - 20230407 IS - 1538-3598 (Electronic) IS - 0098-7484 (Linking) VI - 329 IP - 13 DP - 2023 Apr 4 TI - Virtual Care Teams Improved Guideline Adoption for Heart Failure. PG - 1054 LID - 10.1001/jama.2023.3315 [doi] FAU - Harris, Emily AU - Harris E LA - eng PT - Journal Article PL - United States TA - JAMA JT - JAMA JID - 7501160 SB - IM MH - Humans MH - *Guideline Adherence/standards MH - *Heart Failure/therapy MH - *Patient Care Team/standards MH - *Practice Guidelines as Topic/standards MH - *Telemedicine/standards EDAT- 2023/03/16 06:00 MHDA- 2023/04/06 06:42 CRDT- 2023/03/15 11:43 PHST- 2023/04/06 06:42 [medline] PHST- 2023/03/16 06:00 [pubmed] PHST- 2023/03/15 11:43 [entrez] AID - 2802701 [pii] AID - 10.1001/jama.2023.3315 [doi] PST - ppublish SO - JAMA. 2023 Apr 4;329(13):1054. doi: 10.1001/jama.2023.3315. PMID- 36917842 OWN - NLM STAT- MEDLINE DCOM- 20230403 LR - 20230418 IS - 1538-943X (Electronic) IS - 1058-2916 (Linking) VI - 69 IP - 4 DP - 2023 Apr 1 TI - Multidisciplinary Stroke Pathway for Children Supported With Ventricular Assist Devices. PG - 402-410 LID - 10.1097/MAT.0000000000001822 [doi] AB - Mechanical circulatory support (MCS), including ventricular assist device (VAD) support, is a leading cause of stroke in children; however, existing pediatric stroke recommendations do not apply to many pediatric VAD patients. We sought to develop a multidisciplinary pathway to improve timely and effective acute stroke care and examine the early performance of the pathway in expediting stroke care. Stakeholders from pediatric heart failure, cardiac intensive care, neurology, interventional radiology, neuroradiology, neurosurgery, pharmacy, and adult VAD care convened at Stanford University in August 2017 to discuss the challenges of providing high-quality acute stroke care to children on VAD support, and to develop multidisciplinary acute stroke pathways. Stakeholders identified multiple barriers to providing timely acute stroke care to pediatric VAD patients. These include delayed recognition of stroke, and lack of clarity related to the optimal imaging technique, when to emergently reverse antithrombotic therapy (AT), pediatric indications for thrombectomy and cranial decompression, and strategies to avoid unnecessary serial CTS. Four stroke pathways were created including evaluation and management of the pediatric patient with (1) an acute neurologic change before an imaging diagnosis; (2) an arterial ischemic stroke (AIS); (3) an intracerebral hemorrhage (ICH); and (4) a subdural hematoma (SDH). With the implementation of the stroke pathway, the median time-to-first-CT image decreased by 43 minutes from 66 to 23 minutes ( P < 0.001) while the proportion with a CT within 30 minutes increased from 0% to 67% ( P < 0.001). Despite a variety of challenges, multidisciplinary consensus can be achieved on a rapid stroke management pathway for children on VAD support that addresses important barriers to timely stroke care. Although too few stoke events occurred to differentiate clinical outcomes, the time-to-first-CT image was significantly shorter after pathway implementation. CI - Copyright (c) ASAIO 2023. FAU - Lee, Sarah AU - Lee S AD - From the Department of Neurology & Neurological Sciences, Division of Child Neurology, Stanford University School of Medicine, Stanford, CA. FAU - Ryan, Kathleen R AU - Ryan KR AD - Department of Pediatrics, Division of Cardiology, Stanford University School of Medicine, Stanford, CA. FAU - Murray, Jenna AU - Murray J AD - Department of Pediatrics, Division of Cardiology, Stanford University School of Medicine, Stanford, CA. FAU - Chen, Sharon AU - Chen S AD - Department of Pediatrics, Division of Cardiology, Stanford University School of Medicine, Stanford, CA. FAU - Grant, Gerald A AU - Grant GA AD - Department of Neurosurgery, Division of Pediatric Neurosurgery, Stanford University School of Medicine, Stanford, CA. FAU - Wilkins, Sarah AU - Wilkins S AD - Department of Pediatrics, Division of Cardiology, Stanford University School of Medicine, Stanford, CA. FAU - Yarlagadda, Vamsi V AU - Yarlagadda VV AD - Department of Pediatrics, Division of Cardiology, Stanford University School of Medicine, Stanford, CA. FAU - Wintermark, Max AU - Wintermark M AD - Department of Radiology, Division of Neuroimaging & Neuro-intervention, Stanford University School of Medicine, Stanford, CA. FAU - Dodd, Robert AU - Dodd R AD - Department of Radiology, Division of Neuroimaging & Neuro-intervention, Stanford University School of Medicine, Stanford, CA. AD - Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA. FAU - Rosenthal, David AU - Rosenthal D AD - Department of Pediatrics, Division of Cardiology, Stanford University School of Medicine, Stanford, CA. FAU - Teuteburg, Jeffrey AU - Teuteburg J AD - Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, CA. FAU - Navaratnam, Manchula AU - Navaratnam M AD - Department of Anesthesiology, Perioperative and Pain Management, Division of Pediatric Anesthesia, Stanford University School of Medicine, Stanford, CA. FAU - Lee, Joanne AU - Lee J AD - Departments of Pharmacy and Pediatrics (Cardiology), Stanford University School of Medicine, Stanford, CA. FAU - Jordan, Lori C AU - Jordan LC AD - Department of Pediatrics, Division of Pediatric Neurology, Vanderbilt University Medical Center, Nashville, TN. FAU - Almond, Christopher S AU - Almond CS AD - Department of Neurosurgery, Division of Pediatric Neurosurgery, Stanford University School of Medicine, Stanford, CA. LA - eng PT - Journal Article DEP - 20220330 PL - United States TA - ASAIO J JT - ASAIO journal (American Society for Artificial Internal Organs : 1992) JID - 9204109 SB - IM MH - Adult MH - Humans MH - Child MH - *Heart-Assist Devices/adverse effects MH - Treatment Outcome MH - *Stroke/surgery/etiology MH - *Heart Failure/surgery MH - *Heart Transplantation/adverse effects MH - Retrospective Studies COIS- Disclosure: The authors have no conflicts of interest. EDAT- 2023/03/15 06:00 MHDA- 2023/04/03 06:41 CRDT- 2023/03/14 18:22 PHST- 2023/04/03 06:41 [medline] PHST- 2023/03/15 06:00 [pubmed] PHST- 2023/03/14 18:22 [entrez] AID - 00002480-202304000-00012 [pii] AID - 10.1097/MAT.0000000000001822 [doi] PST - ppublish SO - ASAIO J. 2023 Apr 1;69(4):402-410. doi: 10.1097/MAT.0000000000001822. Epub 2022 Mar 30. PMID- 36912004 OWN - NLM STAT- MEDLINE DCOM- 20240402 LR - 20240611 IS - 2005-7563 (Electronic) IS - 2005-6419 (Print) IS - 2005-6419 (Linking) VI - 77 IP - 2 DP - 2024 Apr TI - Anesthetic management for non-cardiac surgery in patients with left ventricular assist devices. PG - 175-184 LID - 10.4097/kja.23169 [doi] AB - With the growing number of patients undergoing left ventricular assist device (LVAD) implantation and improved survival in this population, more patients with LVADs are presenting for various types of non-cardiac surgery. Therefore, anesthesiologists need to understand the physiology and adequately prepare for the perioperative management of this unique patient population. This review addresses perioperative considerations and intraoperative management for the safe and successful management of patients with an LVAD undergoing non-cardiac surgery. Understanding the basic physiology of preload dependency and afterload sensitivity in these patients is essential. The main considerations include a collaborative preoperative multidisciplinary approach, perioperative care aimed at optimizing the intravascular volume and right ventricular function, and maintaining the afterload within recommended ranges for optimal LVAD function. FAU - Min, Jeong-Jin AU - Min JJ AD - Department of Anesthesiology and Pain Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Cho, Yang Hyun AU - Cho YH AD - Department of Thoracic & Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Lee, Sangmin M AU - Lee SM AD - Department of Anesthesiology and Pain Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Lee, Jong-Hwan AU - Lee JH AD - Department of Anesthesiology and Pain Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. LA - eng PT - Journal Article PT - Review DEP - 20230310 PL - Korea (South) TA - Korean J Anesthesiol JT - Korean journal of anesthesiology JID - 101502451 RN - 0 (Anesthetics) SB - IM MH - Humans MH - *Heart-Assist Devices MH - Perioperative Care MH - *Thoracic Surgical Procedures MH - Anesthesiologists MH - *Anesthetics PMC - PMC10982535 OTO - NOTNLM OT - Anesthesia OT - General anesthesia OT - Heart-assist devices OT - Intraoperative monitoring OT - Surgical procedures OT - Ventricle-assist device. COIS- Conflicts of Interest No potential conflict of interest relevant to this article was reported. EDAT- 2023/03/14 06:00 MHDA- 2024/04/02 06:46 PMCR- 2024/04/01 CRDT- 2023/03/13 04:38 PHST- 2023/03/08 00:00 [received] PHST- 2023/03/10 00:00 [accepted] PHST- 2024/04/02 06:46 [medline] PHST- 2023/03/14 06:00 [pubmed] PHST- 2023/03/13 04:38 [entrez] PHST- 2024/04/01 00:00 [pmc-release] AID - kja.23169 [pii] AID - kja-23169 [pii] AID - 10.4097/kja.23169 [doi] PST - ppublish SO - Korean J Anesthesiol. 2024 Apr;77(2):175-184. doi: 10.4097/kja.23169. Epub 2023 Mar 10. PMID- 36909146 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240923 IS - 2772-9931 (Electronic) IS - 2772-9931 (Linking) VI - 1 IP - 1 DP - 2023 Mar TI - Physical Simulation of Transcatheter Edge-to-Edge Repair using Image-Derived 3D Printed Heart Models. PG - 40-45 LID - 10.1016/j.atssr.2022.09.008 [doi] AB - BACKGROUND: Transcatheter edge-to-edge valve repair (TEER) is a complex procedure requiring delivery and alignment of the device to the target valve, which can be challenging in atypical or surgically palliated anatomy. We demonstrate application of virtual and physical simulation to plan optimal TEER access and catheter path in normal and congenitally abnormal cardiac anatomy. METHODS: Three heart models were created from three-dimensional (3D) images and 3D printed, including two with congenital heart disease. TEER catheter course was simulated both virtually and physically using a commercial TEER system. RESULTS: We demonstrate application of modeling in three patients, including two with congenital heart disease and a Fontan circulation. Access site and pathway to device delivery was simulated by members of a multidisciplinary valve team. Virtual and physical simulation were compared. CONCLUSIONS: Virtual and physical simulation of TEER using 3D printed heart models is feasible and may be beneficial for planning and simulation, particularly in patients with complex anatomy. Future work is required to demonstrate application in the clinical setting. FAU - Ching, Stephen AU - Ching S AD - Children's Hospital of Philadelphia, Department of Anesthesia and Critical Care, Philadelphia, PA. FAU - Cianciulli, Alana R AU - Cianciulli AR AD - Children's Hospital of Philadelphia, Department of Anesthesia and Critical Care, Philadelphia, PA. FAU - Flynn, Maura AU - Flynn M AD - Children's Hospital of Philadelphia, Department of Anesthesia and Critical Care, Philadelphia, PA. FAU - Silvestro, Elizabeth AU - Silvestro E AD - Children's Hospital of Philadelphia, Department of Radiology, Philadelphia, PA. FAU - Sabin, Patricia AU - Sabin P AD - Children's Hospital of Philadelphia, Department of Anesthesia and Critical Care, Philadelphia, PA. FAU - Lasso, Andras AU - Lasso A AD - Queen's University, Kingston, ON, Canada. FAU - Ghosh, Reena M AU - Ghosh RM AD - Children's Hospital of Philadelphia, Division of Pediatric Cardiology, Philadelphia, PA. FAU - Gillespie, Matthew J AU - Gillespie MJ AD - Children's Hospital of Philadelphia, Division of Pediatric Cardiology, Philadelphia, PA. FAU - Jolley, Matthew A AU - Jolley MA AD - Children's Hospital of Philadelphia, Department of Anesthesia and Critical Care, Philadelphia, PA. AD - Children's Hospital of Philadelphia, Division of Pediatric Cardiology, Philadelphia, PA. LA - eng GR - R01 HL153166/HL/NHLBI NIH HHS/United States GR - T32 GM008562/GM/NIGMS NIH HHS/United States PT - Journal Article DEP - 20220923 PL - United States TA - Ann Thorac Surg Short Rep JT - Annals of thoracic surgery short reports JID - 9918506088006676 PMC - PMC9996204 MID - NIHMS1852401 OTO - NOTNLM OT - Congenital heart disease OT - Valve repair OT - transcatheter valve repair EDAT- 2023/03/14 06:00 MHDA- 2023/03/14 06:01 PMCR- 2022/09/23 CRDT- 2023/03/13 03:55 PHST- 2023/03/13 03:55 [entrez] PHST- 2023/03/14 06:00 [pubmed] PHST- 2023/03/14 06:01 [medline] PHST- 2022/09/23 00:00 [pmc-release] AID - S2772-9931(22)00020-1 [pii] AID - 10.1016/j.atssr.2022.09.008 [doi] PST - ppublish SO - Ann Thorac Surg Short Rep. 2023 Mar;1(1):40-45. doi: 10.1016/j.atssr.2022.09.008. Epub 2022 Sep 23. PMID- 36906932 OWN - NLM STAT- MEDLINE DCOM- 20230424 LR - 20250313 IS - 1873-5134 (Electronic) IS - 0738-3991 (Linking) VI - 111 DP - 2023 Jun TI - The WeChat platform-based health education improves health outcomes among patients with stable coronary artery disease. PG - 107704 LID - S0738-3991(23)00084-8 [pii] LID - 10.1016/j.pec.2023.107704 [doi] AB - OBJECTIVE: The aim of this study was to evaluate the effect of the WeChat platform-based health education on patients with stable coronary artery disease (CAD) compared with usual care. METHODS: We conducted a randomized controlled trial that included patients with stable CAD who were admitted to the Bin Hai Wan Central Hospital of Dongguan between January 2020 and December 2020. Participants in the control group received a standard regimen of care. In the WeChat group, the patients were provided with the WeChat platform-based health education by multidisciplinary team members in addition to usual care. The coprimary outcome of the study was the blood pressure, lipid profile, fasting blood glucose, Hamilton Anxiety Scale (HAMA) scores, Hamilton Depression Scale (HAMD) scores and Seattle Angina Questionnaire (SAQ) scores at 12 months, relative to baseline levels. RESULTS: Between January 2020 and December 2020, 200 eligible CAD patients were randomly assigned to WeChat group (n = 100) or usual care group (n = 100). After 12 months, the number of participants who knew the risk factors, symptoms, diagnostic criteria, management methods and treating target of CAD was significantly larger in the WeChat group than at baseline (P < 0.05) and also larger than the post-intervention level of the control group (P < 0.05). The systolic blood pressure after intervention of the WeChat group significantly decreased compared to those of the control group (132.06 +/- 8.87 mmHg vs 140.32 +/- 9.42 mmHg; P < 0.05). After intervention, the triglycerides, total cholesterol, and low-density lipoprotein cholesterol of the WeChat group significantly decreased compared to those at baseline and significantly decreased than those in the control group (all P < 0.05). After the intervention, scores of HAMA and HAMD both significantly decreased in the two groups. Moreover, the decreases were more significant in the WeChat group than in the control group (5.78 +/- 0.98 vs 8.54 +/- 1.24; 6.27 +/- 1.03 vs 8.63 +/- 1.66; P < 0.05). The SAQ scores of WeChat group were significantly higher than those of the control group in all 5 dimensions at the 1-year follow-up (72.71 +/- 10.83 vs 59.32 +/- 9.86; 80.01 +/- 11.56 vs 61.98 +/- 11.02; 76.76 +/- 12.64 vs 65.22 +/- 10.72; 83.17 +/- 13.06 vs 67.01 +/- 12.86; 71.82 +/- 12.78 vs 55.79 +/- 11.90; all P < 0.05). CONCLUSION: This study showed the high efficacy of the WeChat platform-based health education in improving health outcomes in patients with CAD. PRACTICE IMPLICATIONS: This study highlighted the potential of social media as a helpful tool for health education among patients with CAD. CI - Copyright (c) 2023 Elsevier B.V. All rights reserved. FAU - Kang, GuanYang AU - Kang G AD - Department of Cardiology, Bin Hai Wan Central Hospital of Dongguan, The Dongguan Affiliated Hospital of Jinan University (also called The Fifth People's Hospital of Dongguan, Taiping People's Hospital of Dongguan), Dongguan, Guangdong, China. Electronic address: gykang2008@126.com. FAU - Zhang, HuiQing AU - Zhang H AD - Department of Clinical Pharmacy, Bin Hai Wan Central Hospital of Dongguan, The Dongguan Affiliated Hospital of Jinan University (also called The Fifth People's Hospital of Dongguan, Taiping People's Hospital of Dongguan), Dongguan, Guangdong, China. FAU - Zhou, Jian AU - Zhou J AD - Department of Cardiovascular Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200123, China. FAU - Wan, DeLi AU - Wan D AD - Department of Cardiology, Bin Hai Wan Central Hospital of Dongguan, The Dongguan Affiliated Hospital of Jinan University (also called The Fifth People's Hospital of Dongguan, Taiping People's Hospital of Dongguan), Dongguan, Guangdong, China. LA - eng PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20230307 PL - Ireland TA - Patient Educ Couns JT - Patient education and counseling JID - 8406280 RN - 0 (Cholesterol, LDL) SB - IM MH - Humans MH - *Coronary Artery Disease MH - Health Education MH - Risk Factors MH - Cholesterol, LDL MH - Outcome Assessment, Health Care OTO - NOTNLM OT - Coronary artery disease OT - Health education OT - Mobile health OT - Public health OT - WeChat COIS- Conflict of interest The Authors declare that there is no conflict of interest. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2023/03/13 06:00 MHDA- 2023/04/24 06:41 CRDT- 2023/03/12 19:01 PHST- 2022/11/10 00:00 [received] PHST- 2023/02/03 00:00 [revised] PHST- 2023/03/04 00:00 [accepted] PHST- 2023/04/24 06:41 [medline] PHST- 2023/03/13 06:00 [pubmed] PHST- 2023/03/12 19:01 [entrez] AID - S0738-3991(23)00084-8 [pii] AID - 10.1016/j.pec.2023.107704 [doi] PST - ppublish SO - Patient Educ Couns. 2023 Jun;111:107704. doi: 10.1016/j.pec.2023.107704. Epub 2023 Mar 7. PMID- 32644607 STAT- Publisher CTDT- 20230313 PB - StatPearls Publishing DP - 2023 Jan TI - Bumetanide. BTI - StatPearls AB - Bumetanide is FDA-approved for managing various edematous conditions secondary to cardiac failure or hepatic or renal disease, including nephrotic syndrome. It is a member of the loop diuretic class of drugs. This activity reviews bumetanide's indications, action, and contraindications as a valuable agent in treating and managing various edematous conditions secondary to cardiac failure or hepatic or renal disease. This activity will highlight the mechanism of action, adverse effects, and other key factors such as dosing, pharmacodynamics, pharmacokinetics, monitoring, and relevant interactions pertinent for interprofessional team members in treating and caring for patients with edematous conditions. CI - Copyright (c) 2023, StatPearls Publishing LLC. FAU - Sidhu, Gursharan AU - Sidhu G AD - Avalon University School of Medicine FAU - Puckett, Yana AU - Puckett Y AD - Orlando Health Cancer Institute, Orlando, Florida LA - eng PT - Study Guide PT - Book Chapter PL - Treasure Island (FL) COIS- Disclosure: Gursharan Sidhu declares no relevant financial relationships with ineligible companies. Disclosure: Yana Puckett declares no relevant financial relationships with ineligible companies. EDAT- 2023/03/13 00:00 CRDT- 2023/03/13 00:00 AID - NBK559181 [bookaccession] PMID- 36906104 OWN - NLM STAT- MEDLINE DCOM- 20230619 LR - 20250918 IS - 2213-3348 (Electronic) IS - 2213-333X (Print) IS - 2213-333X (Linking) VI - 11 IP - 4 DP - 2023 Jul TI - Pulmonary embolism response team for hospitalized patients with submassive and massive pulmonary embolism: A single-center experience. PG - 741-747.e2 LID - S2213-333X(23)00069-0 [pii] LID - 10.1016/j.jvsv.2023.03.002 [doi] AB - BACKGROUND: Pulmonary embolism (PE) is a major cause of mortality with presentation varying between few or no symptoms to sudden death. This makes timely and appropriate treatment extremely important. Multidisciplinary PE response teams (PERT) have emerged to improve the management of acute PE. This study aims to describe the experience of a large multihospital single-network institution with PERT. METHODS: A retrospective cohort study of patients admitted for submassive and massive PE between 2012 and 2019 was conducted. The cohort was divided based on time of diagnosis and hospital into two groups: non-PERT included patients treated at hospitals that did not initiate PERT and patients diagnosed before the introduction of PERT (June 1, 2014); and the PERT group included those admitted after June 1, 2014, to a hospital with PERT. Patients with low-risk PE and those who had admissions in both time periods were excluded. Primary outcomes included all-cause mortality at 30, 60, and 90 days. Secondary outcomes included causes of death, intensive care unit (ICU) admission, ICU length of stay (LOS), total hospital LOS, type of treatment, and specialty consultations. RESULTS: We analyzed 5190 patients, with 819 (15.8%) being in the PERT group. Patients in the PERT group were more likely to receive extensive workup that included troponin-I (66.3% vs 42.3%; P < .001) and brain natriuretic peptide (50.4% vs 20.3%; P < .001). They also more often received catheter-directed interventions (12% vs 6.2%; P < .001) rather than anticoagulation monotherapy. Mortality outcomes were similar between both groups at all measured timepoints. Rates of ICU admission (65.2% vs 29.7%; P < .001), ICU LOS (median, 64.7 hours; interquartile range [IQR], 41.9-89.1 hours vs median, 38 hours; IQR, 22-66.4 hours; P < .001), and total hospital LOS (median, 5 days; IQR, 3-8 days vs median, 4 days; IQR, 2-6 days; P < .001) were all higher among the PERT group. Patients in the PERT group were more likely to receive vascular surgery consultation (5.3% vs 0.8%; P < .001) and the consultation occurred earlier in the admission when compared with the non-PERT group (median, 0 days; IQR, 0-1 days vs median, 1 day; IQR, 0-1; P = .04). CONCLUSIONS: The data presented here showed that there was no difference in mortality after PERT implementation. These results suggest that the presence of PERT increases the number of patients receiving a full PE workup with cardiac biomarkers. PERT also leads to more specialty consultations and more advanced therapies such as catheter-directed interventions. Further research is needed to assess the effect of PERT on long-term survival of patients with massive and submassive PE. CI - Copyright (c) 2023 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved. FAU - Hussein, Emad A AU - Hussein EA AD - Department of Vascular Surgery, Ain Shams University, Cairo, Egypt. Electronic address: emad.hussein52@hotmail.com. FAU - Semaan, Dana B AU - Semaan DB AD - Division of Vascular Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA. FAU - Phillips, Amanda R AU - Phillips AR AD - Division of Vascular Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA. FAU - Andraska, Elizabeth A AU - Andraska EA AD - Division of Vascular Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA. FAU - Rivera-Lebron, Belinda N AU - Rivera-Lebron BN AD - Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA. FAU - Chaer, Rabih A AU - Chaer RA AD - Division of Vascular Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA. FAU - Eslami, Mohammad H AU - Eslami MH AD - Division of Vascular Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA. FAU - Sridharan, Natalie AU - Sridharan N AD - Division of Vascular Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA. LA - eng GR - T32 HL098036/HL/NHLBI NIH HHS/United States PT - Journal Article DEP - 20230310 PL - United States TA - J Vasc Surg Venous Lymphat Disord JT - Journal of vascular surgery. Venous and lymphatic disorders JID - 101607771 SB - IM MH - Humans MH - Retrospective Studies MH - *Patient Care Team MH - *Pulmonary Embolism/diagnostic imaging/therapy MH - Hospitalization MH - Length of Stay MH - Thrombolytic Therapy/adverse effects/methods PMC - PMC12433811 OTO - NOTNLM OT - Anticoagulation OT - Catheter-directed interventions OT - Outcomes OT - Pulmonary embolism OT - Pulmonary embolism response team EDAT- 2023/03/12 06:00 MHDA- 2023/06/19 13:08 PMCR- 2023/03/10 CRDT- 2023/03/11 19:29 PHST- 2022/12/16 00:00 [received] PHST- 2023/01/30 00:00 [revised] PHST- 2023/03/01 00:00 [accepted] PHST- 2023/06/19 13:08 [medline] PHST- 2023/03/12 06:00 [pubmed] PHST- 2023/03/11 19:29 [entrez] PHST- 2023/03/10 00:00 [pmc-release] AID - S2213-333X(23)00069-0 [pii] AID - 10.1016/j.jvsv.2023.03.002 [doi] PST - ppublish SO - J Vasc Surg Venous Lymphat Disord. 2023 Jul;11(4):741-747.e2. doi: 10.1016/j.jvsv.2023.03.002. Epub 2023 Mar 10. PMID- 36904269 OWN - NLM STAT- MEDLINE DCOM- 20230314 LR - 20230314 IS - 2072-6643 (Electronic) IS - 2072-6643 (Linking) VI - 15 IP - 5 DP - 2023 Mar 3 TI - Key Strategies for Optimizing Pediatric Perioperative Nutrition-Insight from a Multidisciplinary Expert Panel. LID - 10.3390/nu15051270 [doi] LID - 1270 AB - Adequate nutrition is an essential factor in healing and immune support in pediatric patients undergoing surgery, but its importance in this setting is not consistently recognized. Standardized institutional nutrition protocols are rarely available, and some clinicians may be unaware of the importance of assessing and optimizing nutritional status. Moreover, some clinicians may be unaware of updated recommendations that call for limited perioperative fasting. Enhanced recovery protocols have been used in adult patients undergoing surgery to ensure consistent attention to nutrition and other support strategies in adult patients before and after surgery, and these are now under evaluation for use in pediatric patients as well. To support better adoption of ideal nutrition delivery, a multidisciplinary panel of experts in the fields of pediatric anesthesiology, surgery, gastroenterology, cardiology, nutrition, and research have gathered and reviewed current evidence and best practices to support nutrition goals in this setting. FAU - Raval, Mehul V AU - Raval MV AUID- ORCID: 0000-0002-1527-2661 AD - Division of Pediatric Surgery, Department of Surgery, Northwestern University Feinberg School of Medicine, 225 E. Chicago Avenue, Box 63, Chicago, IL 60611, USA. FAU - Brockel, Megan A AU - Brockel MA AD - Department of Anesthesiology, Children's Hospital Colorado, Aurora, CO 80045, USA. FAU - Kolacek, Sanja AU - Kolacek S AD - Referral Centre for Pediatric Gastroenterology and Nutrition, University Children's Hospital Zagreb, 10000 Zagreb, Croatia. FAU - Simpson, Kathleen E AU - Simpson KE AD - Department of Pediatrics, University of Colorado, Denver, CO 80204, USA. FAU - Spoede, Elizabeth AU - Spoede E AD - Pediatric Clinical Dietitian, Texas Children's Hospital, Houston, TX 77030, USA. FAU - Starr, Kathryn N Porter AU - Starr KNP AD - Division of Geriatrics, Department of Medicine, Duke University School of Medicine, Durham, NC 27708, USA. AD - Durham VA Health Care System, Durham, NC 27705, USA. FAU - Wulf, Karyn L AU - Wulf KL AD - Abbott Nutrition, Abbott Laboratories, Columbus, OH 43219, USA. LA - eng PT - Journal Article PT - Review DEP - 20230303 PL - Switzerland TA - Nutrients JT - Nutrients JID - 101521595 SB - IM MH - Humans MH - Child MH - *Nutritional Status MH - *Child Nutritional Physiological Phenomena MH - Fasting MH - Gastrointestinal Tract MH - Nutritional Support/methods MH - Perioperative Care/methods PMC - PMC10005187 OTO - NOTNLM OT - nutrition therapy OT - nutritional assessment OT - nutritional status COIS- This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. EDAT- 2023/03/12 06:00 MHDA- 2023/03/15 06:00 PMCR- 2023/03/03 CRDT- 2023/03/11 01:30 PHST- 2023/01/18 00:00 [received] PHST- 2023/02/25 00:00 [revised] PHST- 2023/03/02 00:00 [accepted] PHST- 2023/03/11 01:30 [entrez] PHST- 2023/03/12 06:00 [pubmed] PHST- 2023/03/15 06:00 [medline] PHST- 2023/03/03 00:00 [pmc-release] AID - nu15051270 [pii] AID - nutrients-15-01270 [pii] AID - 10.3390/nu15051270 [doi] PST - epublish SO - Nutrients. 2023 Mar 3;15(5):1270. doi: 10.3390/nu15051270. PMID- 36897689 OWN - NLM STAT- MEDLINE DCOM- 20230314 LR - 20230916 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 102 IP - 10 DP - 2023 Mar 10 TI - Perinatal outcomes of intrauterine fetal arrhythmias: A 10-year retrospective cohort study. PG - e33244 LID - 10.1097/MD.0000000000033244 [doi] LID - e33244 AB - Sustained fetal arrhythmia can produce life-threatening fetal distress, fetal hemodynamic compromise, hydrops fetalis, or even fetal death. Survivors may subsequently possess severe neurologic deficits. We conducted a retrospective observational study of pregnant women hospitalized with fetal arrhythmias from January 2011 to May 2020 at West China Second University Hospital, and fetal arrhythmias were diagnosed by specialists in cardiac ultrasonography. Of 90 cases of fetal arrhythmias, 14 (15.6%) were complicated by fetal congenital heart disease (CHD), 21 (23.33%) by fetal-hydrops, 15 (16.67%) cases by intrauterine therapy, and 6 (6.67%) by maternal auto-immune disease. In the fetal-hydrops group, the intrauterine therapy rate was significantly higher (47.62% vs 7.24%, P < .001) and the survival rate significantly lower (47.62% vs 92.75%, P < .001) than in the nonfetal hydrops group. A fetus whose arrhythmia was complicated by fetal-hydrops and CHD was delivered earlier and exhibited a lower cardiovascular profile score at diagnosis and birth, lower birth weight, and a higher rate of pregnancy termination than cases without hydrops and CHD (P < .05). Among the cases with maternal auto-immune disease, 71.43% (5/7) manifested fetal atrioventricular block. Multiple linear regression analysis revealed that 3 variables - fetal-hydrops (P < .001), body mass index (P = .014), and gestational age at diagnosis of fetal arrhythmia (P = .047) - were correlated with the gestational delivery age of arrhythmic fetuses. Parents should be counseled by the multidisciplinary team regarding the individualized management and prognosis of the arrhythmic fetus, and individualized fetal intrauterine therapy should be performed if necessary. CI - Copyright (c) 2023 the Author(s). Published by Wolters Kluwer Health, Inc. FAU - Hu, Qing AU - Hu Q AD - Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, China. AD - Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, China. FAU - Liao, Hua AU - Liao H AD - Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, China. AD - Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, China. FAU - Xu, Tingting AU - Xu T AD - Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, China. AD - Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, China. FAU - Liu, Hongyan AU - Liu H AD - Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, China. AD - Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, China. FAU - Wang, Xiaodong AU - Wang X AD - Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, China. AD - Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, China. FAU - Yu, Haiyan AU - Yu H AD - Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, China. AD - Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, China. LA - eng PT - Journal Article PT - Observational Study PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R SB - IM MH - Pregnancy MH - Female MH - Humans MH - Retrospective Studies MH - Ultrasonography, Prenatal MH - Arrhythmias, Cardiac/diagnosis MH - *Fetal Diseases MH - Hydrops Fetalis/therapy MH - *Heart Defects, Congenital/complications MH - Gestational Age PMC - PMC9997811 COIS- The authors have no conflicts of interest to disclose. EDAT- 2023/03/11 06:00 MHDA- 2023/03/15 06:00 PMCR- 2023/03/10 CRDT- 2023/03/10 12:04 PHST- 2023/03/10 12:04 [entrez] PHST- 2023/03/11 06:00 [pubmed] PHST- 2023/03/15 06:00 [medline] PHST- 2023/03/10 00:00 [pmc-release] AID - 00005792-202303100-00024 [pii] AID - 10.1097/MD.0000000000033244 [doi] PST - ppublish SO - Medicine (Baltimore). 2023 Mar 10;102(10):e33244. doi: 10.1097/MD.0000000000033244. PMID- 36896230 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230311 IS - 1923-2829 (Print) IS - 1923-2837 (Electronic) IS - 1923-2829 (Linking) VI - 14 IP - 1 DP - 2023 Feb TI - Potential Association of Holidays on Internationalized Normalized Ratio in Warfarin-Users at a Multidisciplinary Clinic. PG - 38-44 LID - 10.14740/cr1448 [doi] AB - BACKGROUND: Warfarin is approved by the United States Food and Drug Administration for numerous clinical indications. The effectiveness of warfarin is highly dependent on the time-in-therapeutic range based on the international normalized ratio (INR) goal, which may be altered by changes in diet, alcohol intake, concomitant drugs, and travel, all of which are prevalent during the holidays. At this time, there are no published studies assessing the impact of holidays on INR in warfarin-users. METHODS: A retrospective chart review was conducted on all adult patients taking warfarin and managed at a multidisciplinary clinic. Patients were included if they were taking warfarin at home regardless of indication for anticoagulation. The INR pre- and post-holiday was assessed. RESULTS: Of a total of 92 patients, the mean age was 71.5 +/- 14.3 years, and most patients were on warfarin with an INR goal of 2 - 3 (89%). There were significant differences in INR before and after Independence Day (2.55 vs. 2.81, P = 0.043) and Columbus Day (2.39 vs. 2.82, P < 0.001). The remaining holidays showed no significant differences in INR before and after each respective holiday. CONCLUSIONS: There may be factors related to Independence and Columbus Day that are increasing the level of anticoagulation in warfarin-users. Although the mean post-holiday INR values, in essence, maintained within the typical target of 2 - 3, our study underscores the specialized care that is warranted in higher risk patients to prevent a continued increase in INR and subsequent toxicities. We hope our results would be hypothesis-generating and aid in the development of larger, prospective evaluations to validate the findings of our present study. CI - Copyright 2023, Ryu et al. FAU - Ryu, Rachel AU - Ryu R AUID- ORCID: 0000-0002-9593-8928 AD - Western University of Health Sciences College of Pharmacy, Pomona, CA 91766, USA. FAU - Bahjri, Khaled AU - Bahjri K AD - Loma Linda University School of Pharmacy, Loma Linda, CA 92350, USA. FAU - Tran, Huyentran AU - Tran H AD - Loma Linda University School of Pharmacy, Loma Linda, CA 92350, USA. LA - eng PT - Journal Article DEP - 20230225 PL - Canada TA - Cardiol Res JT - Cardiology research JID - 101557543 PMC - PMC9990547 OTO - NOTNLM OT - Anticoagulation OT - Cardiology OT - International normalized ratio OT - Warfarin COIS- The authors declare no conflict of interest. EDAT- 2023/03/11 06:00 MHDA- 2023/03/11 06:01 PMCR- 2023/02/25 CRDT- 2023/03/10 02:39 PHST- 2022/11/08 00:00 [received] PHST- 2023/01/06 00:00 [accepted] PHST- 2023/03/10 02:39 [entrez] PHST- 2023/03/11 06:00 [pubmed] PHST- 2023/03/11 06:01 [medline] PHST- 2023/02/25 00:00 [pmc-release] AID - 10.14740/cr1448 [doi] PST - ppublish SO - Cardiol Res. 2023 Feb;14(1):38-44. doi: 10.14740/cr1448. Epub 2023 Feb 25. PMID- 36890671 OWN - NLM STAT- MEDLINE DCOM- 20230410 LR - 20230622 IS - 1477-0377 (Electronic) IS - 1358-863X (Linking) VI - 28 IP - 2 DP - 2023 Apr TI - Multidisciplinary coordinated care of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease). PG - 153-165 LID - 10.1177/1358863X231151731 [doi] AB - Hereditary hemorrhagic telangiectasia (HHT), also known as Osler-Weber-Rendu disease, is a rare disorder with a case prevalence as high as one in 5000, causing arteriovenous malformations in multiple organ systems. HHT is familial with autosomal dominant inheritance, with genetic testing allowing confirmation of the diagnosis in asymptomatic kindreds. Common clinical manifestations are epistaxis and intestinal lesions causing anemia and requiring transfusions. Pulmonary vascular malformations predispose to ischemic stroke and brain abscess and may cause dyspnea and cardiac failure. Brain vascular malformations can cause hemorrhagic stroke and seizures. Rarely, liver arteriovenous malformations can cause hepatic failure. A form of HHT can cause juvenile polyposis syndrome and colon cancer. Specialists in multiple fields may be called to care for one or more aspects of HHT, but few are familiar with evidence-based guidelines for HHT management or see a sufficient number of patients to gain experience with the unique characteristics of the disease. Primary care physicians and specialists are often unaware of the important manifestations of HHT in multiple systems and the thresholds for their screening and appropriate management. To improve familiarity, experience, and coordinated multisystem care for patients with HHT, the Cure HHT Foundation, which advocates for patients and families with this disease, has accredited 29 centers in North America with designated specialists for the evaluation and care of patients with HHT. Team assembly and current screening and management protocols are described as a model for evidence-based, multidisciplinary care in this disease. FAU - Alkhalid, Yasmine AU - Alkhalid Y AD - Department of Neurological Surgery, University of Chicago Medicine, Chicago, IL, USA. FAU - Darji, Zeena AU - Darji Z AD - Department of Neurological Surgery, University of Chicago Medicine, Chicago, IL, USA. FAU - Shenkar, Robert AU - Shenkar R AUID- ORCID: 0000-0002-1300-6845 AD - Department of Neurological Surgery, University of Chicago Medicine, Chicago, IL, USA. FAU - Clancy, Marianne AU - Clancy M AD - Cure HHT Foundation, Monkton, MD, USA. FAU - Dyamenahalli, Umesh AU - Dyamenahalli U AUID- ORCID: 0000-0003-1300-8012 AD - Department of Pediatrics, Section of Pediatric Cardiology, University of Chicago Medicine, Chicago, IL, USA. FAU - Awad, Issam A AU - Awad IA AD - Department of Neurological Surgery, University of Chicago Medicine, Chicago, IL, USA. AD - Multidisciplinary faculty of the HHT Center of Excellence at University of Chicago Medicine, Chicago, IL, USA includes: Remzi Bag, Section of Pulmonary Medicine; Fuad Baroody, Section of Otolaryngology and Head and Neck Surgery; Elizabeth Blair, Section of Otolaryngology and Head and Neck Surgery; Diana Bolotin, Section of Dermatology; James R Brorson, Department of Neurology; Kenneth S Cohen, Section of Hematology and Oncology; Brian Funaki, Section of Interventional Radiology; Hilary Jericho, Section of Pediatric Gastroenterology; Tarek Kass-Hout: Department of Neurology; Sonia Kupfer, Section of Gastroenterology; James K Liao, Section of Cardiology; Anjana Pillai, Section of Gastroenterology; Jayant Pinto, Section of Otolaryngology and Head and Neck Surgery; Christopher Roxbury, Section of Otolaryngology and Head and Neck Surgery; Carol E Semrad, Section of Gastroenterology; Sarah Stein, Section of Dermatology; Mary E Strek: Section of Pulmonary Medicine; Darrel J Waggoner, Department of Human Genetics; Steven Zangan, Section of Interventional Radiology. CN - the multidisciplinary faculty of the HHT Center of Excellence at University of Chicago Medicine AD - Multidisciplinary faculty of the HHT Center of Excellence at University of Chicago Medicine, Chicago, IL, USA includes: Remzi Bag, Section of Pulmonary Medicine; Fuad Baroody, Section of Otolaryngology and Head and Neck Surgery; Elizabeth Blair, Section of Otolaryngology and Head and Neck Surgery; Diana Bolotin, Section of Dermatology; James R Brorson, Department of Neurology; Kenneth S Cohen, Section of Hematology and Oncology; Brian Funaki, Section of Interventional Radiology; Hilary Jericho, Section of Pediatric Gastroenterology; Tarek Kass-Hout: Department of Neurology; Sonia Kupfer, Section of Gastroenterology; James K Liao, Section of Cardiology; Anjana Pillai, Section of Gastroenterology; Jayant Pinto, Section of Otolaryngology and Head and Neck Surgery; Christopher Roxbury, Section of Otolaryngology and Head and Neck Surgery; Carol E Semrad, Section of Gastroenterology; Sarah Stein, Section of Dermatology; Mary E Strek: Section of Pulmonary Medicine; Darrel J Waggoner, Department of Human Genetics; Steven Zangan, Section of Interventional Radiology. LA - eng PT - Journal Article DEP - 20230308 PL - England TA - Vasc Med JT - Vascular medicine (London, England) JID - 9610930 SB - IM MH - Humans MH - *Telangiectasia, Hereditary Hemorrhagic/diagnosis/genetics/therapy MH - *Arteriovenous Malformations/diagnostic imaging/therapy MH - Lung MH - *Central Nervous System Vascular Malformations MH - Prevalence OTO - NOTNLM OT - Osler-Weber-Rendu OT - arteriovenous malformation (AVM) OT - hereditary hemorrhagic telangiectasia (HHT) OT - vascular malformation OT - vascular medicine EDAT- 2023/03/10 06:00 MHDA- 2023/04/10 06:42 CRDT- 2023/03/09 00:32 PHST- 2023/04/10 06:42 [medline] PHST- 2023/03/10 06:00 [pubmed] PHST- 2023/03/09 00:32 [entrez] AID - 10.1177/1358863X231151731 [doi] PST - ppublish SO - Vasc Med. 2023 Apr;28(2):153-165. doi: 10.1177/1358863X231151731. Epub 2023 Mar 8. PMID- 36889877 OWN - NLM STAT- MEDLINE DCOM- 20230310 LR - 20230403 IS - 1558-3597 (Electronic) IS - 0735-1097 (Linking) VI - 81 IP - 10 DP - 2023 Mar 14 TI - Prevalence and Complications of Aberrant Subclavian Artery in Patients With Heritable and Nonheritable Arteriopathies. PG - 979-991 LID - S0735-1097(23)00081-5 [pii] LID - 10.1016/j.jacc.2023.01.005 [doi] AB - BACKGROUND: An aberrant subclavian artery (ASA) (or lusoria) is the most common congenital anomaly of the aortic arch (0.5%-2.2%; female-to-male ratio 2:1 to 3:1). ASA can become aneurysmal and result in dissection, involving Kommerell's diverticulum when present and the aorta. Data of its significance in genetic arteriopathies are not available. OBJECTIVES: The purpose of this study was to assess the prevalence and complications of ASA in gene-positive and -negative nonatherosclerotic arteriopathies. MATERIALS: The series includes 1,418 consecutive patients with gene-positive (n = 854) and gene-negative arteriopathies (n = 564) diagnosed as part of institutional work-up for nonatherosclerotic syndromic and nonsyndromic arteriopathies. Comprehensive evaluation includes genetic counseling, next-generation sequencing multigene testing, cardiovascular and multidisciplinary assessment, and whole-body computed tomography angiography. RESULTS: ASA was found in 34 of 1,418 cases (2.4%), with a similar prevalence in gene-positive (n = 21 of 854, 2.5%) and gene-negative (n = 13 of 564, 2.3%) arteriopathies. Of the former 21 patients, 14 had Marfan syndrome, 5 had Loeys-Dietz syndrome, 1 had type-IV Ehlers-Danlos syndrome, and 1 had periventricular heterotopia type 1. ASA did not segregate with genetic defects. Dissection occurred in 5 of 21 patients with genetic arteriopathies (23.8%; 2 Marfan syndrome and 3 Loeys-Dietz syndrome), all with associated Kommerell's diverticulum. No dissections occurred in gene-negative patients. At baseline, none of the 5 patients with ASA dissection fulfilled criteria for elective repair according to guidelines. CONCLUSIONS: The risk of complications of ASA is higher in patients with genetic arteriopathies and is difficult to predict. In these diseases, imaging of the supra-aortic trunks should enter baseline investigations. Determination of precise indications for repair can prevent unexpected acute events such as those described. CI - Copyright (c) 2023 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. FAU - Giuliani, Lorenzo AU - Giuliani L AD - Transplant Research Area and Centre for Inherited Cardiovascular Diseases, Fondazione IRCCS Policlinico San Matteo, VASCERN HTAD European Reference Centre, Pavia, Italy. FAU - Di Toro, Alessandro AU - Di Toro A AD - Transplant Research Area and Centre for Inherited Cardiovascular Diseases, Fondazione IRCCS Policlinico San Matteo, VASCERN HTAD European Reference Centre, Pavia, Italy. FAU - Urtis, Mario AU - Urtis M AD - Transplant Research Area and Centre for Inherited Cardiovascular Diseases, Fondazione IRCCS Policlinico San Matteo, VASCERN HTAD European Reference Centre, Pavia, Italy. FAU - Narula, Nupoor AU - Narula N AD - Division of Cardiology and Weill Cornell Women's Heart Program, Weill Cornell Medicine, New York, New York, USA. FAU - Grasso, Maurizia AU - Grasso M AD - Transplant Research Area and Centre for Inherited Cardiovascular Diseases, Fondazione IRCCS Policlinico San Matteo, VASCERN HTAD European Reference Centre, Pavia, Italy. FAU - Pelenghi, Stefano AU - Pelenghi S AD - Cardiac 1 Surgery Unit, Cardiothorax and Vascular Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. FAU - Belliato, Mirko AU - Belliato M AD - AR2-Cardiothoracic ICU, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. FAU - Bozzani, Antonio AU - Bozzani A AD - Vascular and Endovascular Surgery Unit, Department of Surgical Science, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. FAU - Arici, Vittorio AU - Arici V AD - Vascular and Endovascular Surgery Unit, Department of Surgical Science, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. FAU - Pellegrini, Carlo AU - Pellegrini C AD - Cardiac 1 Surgery Unit, Cardiothorax and Vascular Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, Universita degli Studi di Pavia, Pavia, Italy. FAU - Serio, Alessandra AU - Serio A AD - Transplant Research Area and Centre for Inherited Cardiovascular Diseases, Fondazione IRCCS Policlinico San Matteo, VASCERN HTAD European Reference Centre, Pavia, Italy. FAU - Pilotto, Andrea AU - Pilotto A AD - Transplant Research Area and Centre for Inherited Cardiovascular Diseases, Fondazione IRCCS Policlinico San Matteo, VASCERN HTAD European Reference Centre, Pavia, Italy. FAU - Fergnani, Viola AU - Fergnani V AD - Transplant Research Area and Centre for Inherited Cardiovascular Diseases, Fondazione IRCCS Policlinico San Matteo, VASCERN HTAD European Reference Centre, Pavia, Italy. FAU - Antoniazzi, Elena AU - Antoniazzi E AD - Ophthalmology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. FAU - Magrassi, Lorenzo AU - Magrassi L AD - Neurosurgery, Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, Universita degli Studi di Pavia, Pavia, Italy. FAU - Dore, Roberto AU - Dore R AD - Unit of Radiology, Clinical Institute, Citta di Pavia, Pavia, Italy. FAU - Valentini, Adele AU - Valentini A AD - Department of Radiology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. FAU - Preda, Lorenzo AU - Preda L AD - Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, Universita degli Studi di Pavia, Pavia, Italy; Department of Radiology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. FAU - Calliada, Fabrizio AU - Calliada F AD - Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, Universita degli Studi di Pavia, Pavia, Italy. FAU - Quaretti, Pietro AU - Quaretti P AD - Unit of Interventional Radiology-Department of Radiology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. FAU - Pirrelli, Stefano AU - Pirrelli S AD - Division of Vascular Surgery-Cardiovascular Department, ASST Papa Giovanni XXIII, Bergamo, Italy. FAU - Kodama, Takaide AU - Kodama T AD - Department of Cardiology, Toranomon Hospital, Tokyo, Japan. FAU - Vricella, Luca AU - Vricella L AD - The Heart Institute for Children, Advocate Children's Hospital, Oak Lawn, Illinois, USA; Department of Surgery, University of Chicago Medicine, Chicago, Illinois, USA. FAU - Cameron, Duke AU - Cameron D AD - Division of Cardiac Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. FAU - Arbustini, Eloisa AU - Arbustini E AD - Transplant Research Area and Centre for Inherited Cardiovascular Diseases, Fondazione IRCCS Policlinico San Matteo, VASCERN HTAD European Reference Centre, Pavia, Italy. Electronic address: e.arbustini@smatteo.pv.it. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - J Am Coll Cardiol JT - Journal of the American College of Cardiology JID - 8301365 RN - Aberrant subclavian artery SB - IM CIN - J Am Coll Cardiol. 2023 Mar 14;81(10):992-993. doi: 10.1016/j.jacc.2023.01.020. PMID: 36889878 MH - Prevalence MH - *Diverticulum/complications MH - Male MH - *Loeys-Dietz Syndrome MH - Female MH - Humans MH - Subclavian Artery/diagnostic imaging/abnormalities MH - *Vascular Diseases/complications MH - *Heart Defects, Congenital/complications MH - Aorta, Thoracic MH - *Marfan Syndrome/complications MH - Cardiovascular Abnormalities OTO - NOTNLM OT - Loeys-Dietz syndrome OT - Lusoria OT - Marfan syndrome OT - aberrant subclavian artery OT - dissection OT - genetic arteriopathies COIS- Funding Support and Author Disclosures The study was supported by continuous RC funds on heritable connective tissue diseases from the Italian Ministry of Health to the Fondazione IRCCS Policlinico San Matteo, n. 221-rcr2000b-8 and n. 888-rcr2017i-71 projects; project RCR-2019-23669116_001 (CV-PREVITAL) from the Italian Ministry of Health; Telethon grant n.GGP08238 for Marfan Syndrome; and FRRB grant n.CP2_14/2018 for monogenic arteriopathies. The authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2023/03/09 06:00 MHDA- 2023/03/11 06:00 CRDT- 2023/03/08 20:56 PHST- 2022/10/27 00:00 [received] PHST- 2022/12/27 00:00 [revised] PHST- 2023/01/03 00:00 [accepted] PHST- 2023/03/08 20:56 [entrez] PHST- 2023/03/09 06:00 [pubmed] PHST- 2023/03/11 06:00 [medline] AID - S0735-1097(23)00081-5 [pii] AID - 10.1016/j.jacc.2023.01.005 [doi] PST - ppublish SO - J Am Coll Cardiol. 2023 Mar 14;81(10):979-991. doi: 10.1016/j.jacc.2023.01.005. PMID- 36889612 OWN - NLM STAT- MEDLINE DCOM- 20230428 LR - 20240319 IS - 1558-3597 (Electronic) IS - 0735-1097 (Print) IS - 0735-1097 (Linking) VI - 81 IP - 17 DP - 2023 May 2 TI - Virtual Care Team Guided Management of Patients With Heart Failure During Hospitalization. PG - 1680-1693 LID - S0735-1097(23)04471-6 [pii] LID - 10.1016/j.jacc.2023.02.029 [doi] AB - BACKGROUND: Scalable and safe approaches for heart failure guideline-directed medical therapy (GDMT) optimization are needed. OBJECTIVES: The authors assessed the safety and effectiveness of a virtual care team guided strategy on GDMT optimization in hospitalized patients with heart failure with reduced ejection fraction (HFrEF). METHODS: In a multicenter implementation trial, we allocated 252 hospital encounters in patients with left ventricular ejection fraction /= 20 ann.) and stereotactic body radiotherapy (59% > 200 ann.) was adequate, and 84 STAR treatments were performed until project launch, while 8/22 centres already recruited VT patients in national clinical trials. The majority currently base their target definition on mapping during VT (96%) and/or pace mapping (75%), reduced voltage areas (63%), or late ventricular potentials (75%) during sinus rhythm. The majority currently apply a single-fraction dose of 25 Gy while planning techniques and dose prescription methods vary greatly. The current clinical STAR practice in the STOPSTORM consortium highlights potential areas of optimization and harmonization for substrate mapping, target delineation, motion management, dosimetry, and QA, which will be addressed in the various WPs. CI - (c) The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. FAU - Grehn, Melanie AU - Grehn M AUID- ORCID: 0000-0002-6170-5122 AD - Department of Radiation Oncology, University Medical Center Schleswig-Holstein, Arnold-Heller-Strasse 3, Kiel 24105, Germany. FAU - Mandija, Stefano AU - Mandija S AUID- ORCID: 0000-0002-4612-5509 AD - Department of Radiotherapy, University Medical Center Utrecht, Heidelberglaan 100, Utrecht 3584 CX, The Netherlands. FAU - Miszczyk, Marcin AU - Miszczyk M AUID- ORCID: 0000-0002-4375-0827 AD - IIIrd Radiotherapy and Chemotherapy Department, Maria Sklodowska-Curie National Research Institute of Oncology, Ul. Wybrzeze Armii Krajowej, Gliwice 44102, Poland. FAU - Krug, David AU - Krug D AUID- ORCID: 0000-0001-8811-5416 AD - Department of Radiation Oncology, University Medical Center Schleswig-Holstein, Arnold-Heller-Strasse 3, Kiel 24105, Germany. FAU - Tomasik, Bartlomiej AU - Tomasik B AUID- ORCID: 0000-0001-5648-345X AD - Department of Radiotherapy, Maria Sklodowska-Curie National Research Institute of Oncology, Ul. Wybrzeze Armii Krajowej, Gliwice 44102, Poland. AD - Department of Oncology and Radiotherapy, Faculty of Medicine, Medical University of Gdansk, M. Sklodowskiel-Curie 3a, Gdansk 80210, Poland. FAU - Stickney, Kristine E AU - Stickney KE AD - Research Support Office, University Medical Center Utrecht, Heidelberglaan 100, Utrecht 3584 CX, The Netherlands. FAU - Alcantara, Pino AU - Alcantara P AUID- ORCID: 0000-0001-5744-9480 AD - Department of Radiation Oncology, Hospital Clinico San Carlos, Faculty of Medicine, University Complutense of Madrid, Profesor Martin Lagos, Madrid 28040, Spain. FAU - Alongi, Filippo AU - Alongi F AD - Department of Advanced Radiation Oncology, IRCCS Sacro Cuore Don Calabria Hospital, University of Brescia, Via San Zeno in Monte 23, Verona 37129, Italy. FAU - Anselmino, Matteo AU - Anselmino M AUID- ORCID: 0000-0002-6311-4270 AD - Division of Cardiology, Cardiovascular and Thoracic Department, 'Citta della Salute e della Scienza' Hospital, Via Giuseppe Verdi 8, Torino 10124, Italy. AD - Department of Medical Sciences, University of Turin, Via Verdi 8, Torino 10124, Italy. FAU - Aranda, Ricardo Salgado AU - Aranda RS AUID- ORCID: 0000-0002-2627-8436 AD - Electrophysiology Unit, Department of Cardiology, Hospital Clinico San Carlos Madrid, Professor Martin Lagos, Madrid 28040, Spain. FAU - Balgobind, Brian V AU - Balgobind BV AD - Department of Radiation Oncology, Amsterdam UMC, University of Amsterdam, Meibergdreef 15, Amsterdam 1105AZ, The Netherlands. FAU - Boda-Heggemann, Judit AU - Boda-Heggemann J AD - Department of Radiation Oncology, University Medical Center Mannheim, Medical Faculty Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, Mannheim 68167, Germany. FAU - Boldt, Leif-Hendrik AU - Boldt LH AD - Department of Rhythmology, Charite-University Medicine Berlin, Chariteplatz 1, 10117 Berlin, Germany. FAU - Bottoni, Nicola AU - Bottoni N AD - Cardiology Arrhythmology Center, AUSL-IRCCS di Reggio Emilia, Via Amendola 2, Reggio Emilia 42100, Italy. FAU - Cvek, Jakub AU - Cvek J AUID- ORCID: 0000-0003-1579-1792 AD - Department of Oncology, University Hospital and Faculty of Medicine, Listopadu 1790, Ostrava Poruba 70852, Czech Republic. FAU - Elicin, Olgun AU - Elicin O AUID- ORCID: 0000-0002-6996-0646 AD - Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 18, Bern 3010, Switzerland. FAU - De Ferrari, Gaetano Maria AU - De Ferrari GM AUID- ORCID: 0000-0003-4940-0876 AD - Division of Cardiology, Cardiovascular and Thoracic Department, 'Citta della Salute e della Scienza' Hospital, Via Giuseppe Verdi 8, Torino 10124, Italy. FAU - Hassink, Rutger J AU - Hassink RJ AUID- ORCID: 0000-0003-0237-7867 AD - Department of Cardiology, Division of Heart and Lungs, University Medical Center Utrecht, Utrecht University, Heidelberglaan 100, Utrecht 3584 CX, The Netherlands. FAU - Hazelaar, Colien AU - Hazelaar C AD - Department of Radiation Oncology (Maastro), GROW School for Oncology and Reproduction, Maastricht University Medical Centre+, P. Debyelaan 25, Maastricht 6229 HX, The Netherlands. FAU - Hindricks, Gerhard AU - Hindricks G AUID- ORCID: 0000-0002-0132-0773 AD - Department of Electrophysiology, Heart Center Leipzig, University of Leipzig, Struempellstrasse 39, Leipzig 04289, Germany. FAU - Hurkmans, Coen AU - Hurkmans C AUID- ORCID: 0000-0003-2268-0492 AD - Department of Radiation Oncology, Catharina Hospital, Michelangelolaan 2, Eindhoven 5623 EJ, The Netherlands. FAU - Iotti, Cinzia AU - Iotti C AUID- ORCID: 0000-0001-9686-7298 AD - Radiation Oncology Unit, Clinical Cancer Centre, AUSL-IRCCS di Reggio Emilia, Via Amendola 2, Reggio Emilia 42100, Italy. FAU - Jadczyk, Tomasz AU - Jadczyk T AUID- ORCID: 0000-0002-7955-9100 AD - Division of Cardiology and Structural Heart Diseases, Medical University of Silesia, Ul. Poniatowskiego 15, Katowice 40055, Poland. AD - Interventional Cardiac Electrophysiology Group, International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic. FAU - Jiravsky, Otakar AU - Jiravsky O AUID- ORCID: 0000-0001-9334-5734 AD - Cardiocenter, Hospital Agel Trinec Podlesi and Masaryk University, Konska 453, Trinec 73961, Czech Republic. FAU - Jumeau, Raphael AU - Jumeau R AUID- ORCID: 0000-0002-0098-8835 AD - Department of Radio-Oncology, Lausanne University Hospital, Rue du Bugnon 21, Lausanne 1011, Switzerland. FAU - Kristiansen, Steen Buus AU - Kristiansen SB AD - Department of Cardiology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, Aarhus 8200, Denmark. FAU - Levis, Mario AU - Levis M AUID- ORCID: 0000-0002-7668-3296 AD - Department of Oncology, University of Torino, Via Giuseppe Verdi 8, Torino 10124, Italy. FAU - Lopez, Manuel Algara AU - Lopez MA AUID- ORCID: 0000-0002-0500-9202 AD - Department of Radiation Oncology, Hospital del Mar, Universitat Pompeu Fabra, Institut Hospital del Mar d'Investigacions Mediques, Paseo Maritim 25-29, Barcelona 08003, Spain. FAU - Marti-Almor, Julio AU - Marti-Almor J AUID- ORCID: 0000-0001-9927-1190 AD - Department of Cardiology, Hospital del Mar, Universitat Pompeu Fabra, Institut Hospital del Mar d'Investigacions Mediques, Paseo Maritim 25-29, Barcelona 08003, Spain. FAU - Mehrhof, Felix AU - Mehrhof F AUID- ORCID: 0000-0003-0553-4290 AD - Department for Radiation Oncology, Charite-Universitatsmedizin Berlin, Chariteplatz 1, 10117 Berlin, Germany. FAU - Moller, Ditte Sloth AU - Moller DS AUID- ORCID: 0000-0001-9910-515X AD - Department of Oncology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, Aarhus 8200, Denmark. FAU - Molon, Giulio AU - Molon G AUID- ORCID: 0000-0001-8287-0461 AD - Department of Cardiology, IRCCS Sacro Cuore Don Calabria Hospital, Via San Zeno in Monte 23, Verona 37129, Italy. FAU - Ouss, Alexandre AU - Ouss A AUID- ORCID: 0000-0001-7405-822X AD - Department of Cardiology, Catharina Hospital, Michelangelolaan 2, Eindhoven 5623 EJ, The Netherlands. FAU - Peichl, Petr AU - Peichl P AUID- ORCID: 0000-0002-5625-0071 AD - Department of Cardiology, Institute for Clinical and Experimental Medicine, Videnska 9, Prague 14000, Czech Republic. FAU - Plasek, Jiri AU - Plasek J AD - Department of Cardiovascular Medicine, University Hospital Ostrava, Listopadu 1790. Ostrava Poruba 70852, Czech Republic. FAU - Postema, Pieter G AU - Postema PG AUID- ORCID: 0000-0003-2863-9159 AD - Department of Cardiology, Amsterdam UMC, University of Amsterdam, Meibergdreef 15, Amsterdam 1105AZ, The Netherlands. FAU - Quesada, Aurelio AU - Quesada A AUID- ORCID: 0000-0003-4709-1993 AD - Arrhythmia Unit, Department of Cardiology, Consorcio Hospital General Universitario de Valencia, Av Tres Cruces 2, Valencia 46014, Spain. FAU - Reichlin, Tobias AU - Reichlin T AUID- ORCID: 0000-0002-7197-8415 AD - Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 18, Bern 3010, Switzerland. FAU - Rordorf, Roberto AU - Rordorf R AUID- ORCID: 0000-0003-4111-1690 AD - Cardiac Intensive Care Unit, Arrhythmia and Electrophysiology and Experimental Cardiology, Fondazione IRCCS Policlinico San Matteo, Camillo Golgi Avenue 5, Pavia 27100, Italy. FAU - Rudic, Boris AU - Rudic B AUID- ORCID: 0000-0002-2275-7149 AD - Department of Medicine I, University Medical Center Mannheim, Medical Faculty Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, Mannheim 68167, Germany. FAU - Saguner, Ardan M AU - Saguner AM AD - Arrhythmia Unit, Department of Cardiology, University Hospital Zurich, Ramistrasse 71, Zurich 8006, Switzerland. FAU - Ter Bekke, Rachel M A AU - Ter Bekke RMA AUID- ORCID: 0000-0003-4278-0132 AD - Department of Cardiology, Maastricht University Medical Center, P. Debyelaan 25, Maastricht 6229 HX, The Netherlands. FAU - Torrecilla, Jose Lopez AU - Torrecilla JL AUID- ORCID: 0000-0002-6012-1694 AD - Department of Radiation Oncology, Hospital General Valencia, Av Tres Cruces 2, Valencia 46014, Spain. FAU - Troost, Esther G C AU - Troost EGC AD - Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universitat Dresden, Fetscherstrasse 74, Dresden 01307, Germany. AD - OncoRay-National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus. Technische Universitat Dresden, Helmholtz-Zentrum Dresden-Rossendorf, Fetscherstrasse 74, Dresden 01307, Germany. AD - Institute of Radiooncology - OncoRay, Helmholtz-Zentrum Dresden-Rossendorf, Bautzner Landstr. 400, Dresden 01328, Germany. FAU - Vitolo, Viviana AU - Vitolo V AUID- ORCID: 0000-0001-7833-827X AD - National Center of Oncological Hadrontherapy (Fondazione CNAO), Strada Campeggi 53, Pavia PV27100, Italy. FAU - Andratschke, Nicolaus AU - Andratschke N AUID- ORCID: 0000-0003-3647-5916 AD - Department of Radiation Oncology, University Hospital of Zurich, Ramistrasse 71, Zurich 8006, Switzerland. FAU - Zeppenfeld, Katja AU - Zeppenfeld K AUID- ORCID: 0000-0001-6645-082X AD - Unit of Clinical Electrophysiology, Leiden University Medical Center, Albinusdreef 2, Leiden 2333 ZA, The Netherlands. FAU - Blamek, Slawomir AU - Blamek S AUID- ORCID: 0000-0002-0585-9100 AD - Department of Radiotherapy, Maria Sklodowska-Curie National Research Institute of Oncology, Ul. Wybrzeze Armii Krajowej, Gliwice 44102, Poland. FAU - Fast, Martin AU - Fast M AUID- ORCID: 0000-0001-9107-4627 AD - Department of Radiotherapy, University Medical Center Utrecht, Heidelberglaan 100, Utrecht 3584 CX, The Netherlands. FAU - de Panfilis, Ludovica AU - de Panfilis L AUID- ORCID: 0000-0002-5509-7626 AD - Bioethics Unit, Azienda Unita Sanitaria Locale-IRCCS, Via Amendola 2, Reggio Emilia 42100, Italy. FAU - Blanck, Oliver AU - Blanck O AD - Department of Radiation Oncology, University Medical Center Schleswig-Holstein, Arnold-Heller-Strasse 3, Kiel 24105, Germany. FAU - Pruvot, Etienne AU - Pruvot E AUID- ORCID: 0000-0003-1386-9285 AD - Heart and Vessel Department, Service of Cardiology, Lausanne University Hospital and University of Lausanne, Rue du Bugnon 21, Lausanne 1011, Switzerland. FAU - Verhoeff, Joost J C AU - Verhoeff JJC AUID- ORCID: 0000-0001-9673-0793 AD - Department of Radiotherapy, University Medical Center Utrecht, Heidelberglaan 100, Utrecht 3584 CX, The Netherlands. LA - eng PT - Journal Article PT - Review PL - England TA - Europace JT - Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology JID - 100883649 SB - IM MH - Humans MH - Prospective Studies MH - Arrhythmias, Cardiac MH - *Tachycardia, Ventricular MH - Heart Ventricles MH - *Catheter Ablation/adverse effects/methods MH - Treatment Outcome PMC - PMC10105846 OTO - NOTNLM OT - Cardiac arrhythmias OT - Consortium OT - EU Horizon 2020 OT - Stereotactic arrhythmia radioablation OT - Stereotactic body radiotherapy OT - Ventricular tachycardia COIS- Conflict of interests: D.K. has received honoraria from Merck Sharp & Dohme and Pfizer, as well as research funding from Merck KGaA, all outside of the submitted work. M.A. is a consultant for Biosense Webster and Boston Scientific, has received educational grants from Abbott, and is a proctor for Medtronic. J.B.-H. received personal fees from EBAMed SA, Switzerland, outside the submitted work. O.E. received honoraries for participation on advisory board meetings from Merck Serono, MSD, and AstraZeneca concerning oncologic treatments and also received project funding for clinical trials from non-profit organizations, all outside of the submitted work. T.R. gets research grants from the Swiss National Science Foundation, the Swiss Heart Foundation, and the Sitem Insel support fund. Speaker/consulting honoraria or travel support from Abbott/SJM, Bayer, Biosense Webster, Biotronik, Boston Scientific, Daiichi Sankyo, Farapulse, Medtronic, and Pfizer-BMS. Support for the institution's fellowship programme from Abbott/SJM, Biosense Webster, Biotronik, Boston Scientific and Medtronic. A.S. received educational grants through his institution from Abbott, Bayer Healthcare, Biosense Webster, Biotronik, Boston Scientific, BMS/Pfizer, and Medtronic; and speaker/advisory board fees from Abbott, Bayer Healthcare, Daiichi Sankyo, Medtronic and Novartis. All other authors declare no conflict of interests. EDAT- 2023/03/08 06:00 MHDA- 2023/04/18 10:16 PMCR- 2023/03/06 CRDT- 2023/03/07 00:42 PHST- 2022/08/04 00:00 [received] PHST- 2022/11/18 00:00 [accepted] PHST- 2023/04/18 10:16 [medline] PHST- 2023/03/08 06:00 [pubmed] PHST- 2023/03/07 00:42 [entrez] PHST- 2023/03/06 00:00 [pmc-release] AID - 7069964 [pii] AID - euac238 [pii] AID - 10.1093/europace/euac238 [doi] PST - ppublish SO - Europace. 2023 Apr 15;25(4):1284-1295. doi: 10.1093/europace/euac238. PMID- 36879082 OWN - NLM STAT- MEDLINE DCOM- 20230529 LR - 20230529 IS - 1875-8312 (Electronic) IS - 1569-5794 (Print) IS - 1569-5794 (Linking) VI - 39 IP - 6 DP - 2023 Jun TI - Functional outcomes in post Covid-19 patients with persistent dyspnea: multidisciplinary approach. PG - 1115-1122 LID - 10.1007/s10554-023-02819-9 [doi] AB - BACKGROUND: Post-acute sequelae of SARS-CoV-2 (PASC) have emerged as a major health issue in patients who have previously been infected with Covid-19 virus. PURPOSE: we aimed at the assessment of functional outcomes in post Covid-19 patients with persistent dyspnea using a multidisciplinary approach including clinical assessment, laboratory investigations, exercise ECG, and different echo-Doppler modalities, including left atrial functions. METHODS: The current observational randomized controlled study conducted on 60- patients one month after recovery from Covid-19 infection presented with persistent dyspnea compared to 30 healthy volunteers. All participants were subjected to evaluation of dyspnea by different scores, laboratory investigations, stress ECG, and echo-Doppler examination to measure LV dimensions, volumes, systolic and diastolic functions by M-mode, 2D, and tissue Doppler imaging in addition to 2-D speckle tacking LA strain. RESULTS: Post Covid-19 patients had persistent elevation of inflammatory markers, low functional capacity (evidenced by a higher NYHA class, m MRC score, PCFS scale) and decreased METs by stress ECG compared to control group. Post Covid-19 patients showed LV diastolic dysfunction and impairment of 2D-STE LA functions compared to control group. We found negative correlations between LA strain with NYHA class, mMRC scale, LAVI, ESR and CRP; meanwhile, there were significant positive correlations between LA strain with exercise duration and METs. CONCLUSION: post Covid patients presented with persistent dyspnea demonstrated low functional capacity evidenced by different scores and stress ECG. Moreover, patients with post Covid syndrome showed elevated inflammatory biomarkers, LV diastolic dysfunction in addition to impaired LA strain functions. Impairment of LA strain was closely correlated to different functional scores, inflammatory biomarkers, exercise duration, and METs suggesting that these could to be the possible etiologies for the persistence of post Covid symptoms. CI - (c) 2023. The Author(s). FAU - Hamdy, Rehab M AU - Hamdy RM AUID- ORCID: 0000-0002-8188-6792 AD - Department of cardiology, Faculty of Medicine (for Girls), Al-Azhar University, Cairo, Egypt. rehabmohamed.8@azhar.edu.eg. FAU - Abdelaziz, Ola Hassan AU - Abdelaziz OH AD - Department of cardiology, Faculty of Medicine (for Girls), Al-Azhar University, Cairo, Egypt. FAU - Shamsseldain, Hager Elsayed AU - Shamsseldain HE AD - Department of cardiology, Faculty of Medicine (for Girls), Al-Azhar University, Cairo, Egypt. FAU - Eltrawy, Heba H AU - Eltrawy HH AD - Department of Chest, Faculty of Medicine (for Girls), Al-Azhar University, Cairo, Egypt. LA - eng PT - Journal Article DEP - 20230306 PL - United States TA - Int J Cardiovasc Imaging JT - The international journal of cardiovascular imaging JID - 100969716 SB - IM MH - Humans MH - Predictive Value of Tests MH - *COVID-19/complications MH - SARS-CoV-2 MH - *Ventricular Dysfunction, Left MH - Atrial Function, Left MH - Heart Atria PMC - PMC9988204 OTO - NOTNLM OT - 2D-STE-LA strain OT - Persistent dyspnea OT - Post Covid-19 syndrome COIS- The authors declare no competing interests. EDAT- 2023/03/07 06:00 MHDA- 2023/05/29 06:41 PMCR- 2023/03/06 CRDT- 2023/03/06 23:22 PHST- 2023/01/02 00:00 [received] PHST- 2023/02/16 00:00 [accepted] PHST- 2023/05/29 06:41 [medline] PHST- 2023/03/07 06:00 [pubmed] PHST- 2023/03/06 23:22 [entrez] PHST- 2023/03/06 00:00 [pmc-release] AID - 10.1007/s10554-023-02819-9 [pii] AID - 2819 [pii] AID - 10.1007/s10554-023-02819-9 [doi] PST - ppublish SO - Int J Cardiovasc Imaging. 2023 Jun;39(6):1115-1122. doi: 10.1007/s10554-023-02819-9. Epub 2023 Mar 6. PMID- 36877689 OWN - NLM STAT- MEDLINE DCOM- 20231130 LR - 20250816 IS - 1559-713X (Electronic) IS - 1559-2332 (Linking) VI - 18 IP - 6 DP - 2023 Dec 1 TI - Crisis Scenarios for Simulation-Based Nontechnical Skills Training for Cardiac Surgery Teams: A National Survey Among Cardiac Anesthesiologists, Cardiac Surgeons, Clinical Perfusionists, and Cardiac Operating Room Nurses. PG - 367-374 LID - 10.1097/SIH.0000000000000715 [doi] AB - BACKGROUND: Nontechnical skills in cardiac surgery are vital in ensuring patient safety in the operating room (OR). To train these skills in a simulation-based scenario, a collection of commonly accepted crisis scenarios is needed to serve as a framework for a simulation-based training program. OBJECTIVE: The objective of this study was to identify and reach consensus on a collection of relevant crisis scenarios in cardiac surgery suitable for simulation-based team training focusing on nontechnical skills. METHODS: Using the Delphi method, a national assessment was performed among cardiac surgeons, cardiac anesthesiologists, clinical perfusionists, and cardiac OR nurses in the Netherlands. In the first Delphi round, potential crisis scenarios for simulation-based team training in cardiac surgery were identified. In the second round, the identified scenarios were rated using a 5-point Likert scale. Finally, based on consensus (two-thirds majority), scenarios were prioritized and explored for feasibility. RESULTS: One hundred fourteen experts participated in the study (26 cardiac anesthesiologists, 24 cardiac surgeons, 25 clinical perfusionists, and 39 OR nurses), representing all 16 cardiac surgical centers in the Netherlands. In the first round, 237 scenarios were identified. After eliminating duplicates and grouping similar scenarios, 44 scenarios were scored in round 2, which finally resulted in 13 relevant crisis scenarios with an expert consensus higher than 67%. CONCLUSIONS: Thirteen crisis scenarios relevant to simulation-based team training were identified by an expert panel consisting of all members of the cardiac surgical team. Further research is needed to evaluate the educational value of the respective scenarios. CI - Copyright (c) 2023 Society for Simulation in Healthcare. FAU - Kemper, Tom AU - Kemper T AD - From the Department of Anesthesiology (T.K., M.v.H., S.E., E.W., B.P.), Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands; Department of Cardiothoracic Surgery (T.W.), Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands; Department of Extracorporeal Circulation (S.M.v.D.), St. Antonius Hospital, Nieuwegein, Netherlands; and Center for Simulation-Based Education (T.K., M.v.H., E.W.), Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands. FAU - van Haperen, Maartje AU - van Haperen M FAU - Eberl, Susanne AU - Eberl S FAU - Winkelman, Toon AU - Winkelman T FAU - van Deventer, San-Mari AU - van Deventer SM FAU - Waller, Elbert AU - Waller E FAU - Preckel, Benedikt AU - Preckel B LA - eng PT - Journal Article DEP - 20230503 PL - United States TA - Simul Healthc JT - Simulation in healthcare : journal of the Society for Simulation in Healthcare JID - 101264408 SB - IM MH - Humans MH - Anesthesiologists MH - Operating Rooms MH - Clinical Competence MH - *Simulation Training MH - *Surgeons MH - Patient Care Team COIS- The authors declare no conflict of interest. EDAT- 2023/03/07 06:00 MHDA- 2023/11/30 06:43 CRDT- 2023/03/06 13:33 PHST- 2023/11/30 06:43 [medline] PHST- 2023/03/07 06:00 [pubmed] PHST- 2023/03/06 13:33 [entrez] AID - 01266021-202312000-00003 [pii] AID - 10.1097/SIH.0000000000000715 [doi] PST - ppublish SO - Simul Healthc. 2023 Dec 1;18(6):367-374. doi: 10.1097/SIH.0000000000000715. Epub 2023 May 3. PMID- 36874173 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230307 IS - 2452-1094 (Print) IS - 2452-1094 (Electronic) IS - 2452-1094 (Linking) VI - 8 IP - 4 DP - 2023 Jul-Aug TI - Management of Patients with Cardiovascular Implantable Electronic Devices Undergoing Radiation Therapy: A National Survey of Canadian Multidisciplinary Radiation Oncology Professionals. PG - 101184 LID - 10.1016/j.adro.2023.101184 [doi] LID - 101184 AB - PURPOSE: This study aimed to characterize contemporary management of Canadian patients with cardiovascular implantable electronic devices (CIEDs) undergoing radiation therapy (RT) in light of updated American Association of Physicists in Medicine guidelines. METHODS AND MATERIALS: A 22-question web-based survey was distributed to members of the Canadian Association of Radiation Oncology, Canadian Organization of Medical Physicists, and Canadian Association of Medical Radiation Technologists from January to February 2020. Respondent demographics, knowledge, and management practices were elicited. Statistical comparisons by respondent demographics were performed using chi(2) and Fisher exact tests. RESULTS: In total, 155 surveys were completed by 54 radiation oncologists, 26 medical physicists, and 75 radiation therapists in academic (51%) and community (49%) practices across all provinces. The majority of respondents (77%) had managed >10 patients with CIEDs in their career. Most respondents (70%) reported using risk-stratified institutional management protocols. Respondents used manufacturer recommendations, rather than American Association of Physicists in Medicine or institutionally recommended dose limits, when the manufacturer limit was 0 Gy (44%), 0 to 2 Gy (45%), or >2 Gy (34%). The majority of respondents (86%) reported institutional policies to refer to a cardiologist for CIED evaluation both before and after completion of RT. Cumulative dose to CIED, pacing dependence, and neutron production were considered during risk stratification by 86%, 74%, and 50% of participants, respectively. Dose and energy thresholds for high-risk management were not known by 45% and 52% of respondents, with radiation oncologists and radiation therapists significantly less likely to report thresholds than medical physicists (P < .001). Although 59% of respondents felt comfortable managing patients with CIEDs, community respondents were less likely to feel comfortable than academic respondents (P = .037). CONCLUSIONS: The management of Canadian patients with CIEDs undergoing RT is characterized by variability and uncertainty. National consensus guidelines may have a role in improving provider knowledge and confidence in caring for this growing population. CI - (c) 2023 The Author(s). FAU - Safavi, Amir H AU - Safavi AH AD - Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada. FAU - Louie, Alexander V AU - Louie AV AD - Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada. AD - Odette Cancer Centre - Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. FAU - Elzibak, Alyaa H AU - Elzibak AH AD - Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada. AD - Odette Cancer Centre - Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. FAU - Warner, Andrew AU - Warner A AD - Department of Radiation Oncology, London Health Sciences Centre, London, Ontario, Canada. FAU - Donovan, Elysia K AU - Donovan EK AD - Department of Oncology, McMaster University, Hamilton, Ontario, Canada. FAU - Detsky, Jay S AU - Detsky JS AD - Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada. AD - Odette Cancer Centre - Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. LA - eng PT - Journal Article DEP - 20230125 PL - United States TA - Adv Radiat Oncol JT - Advances in radiation oncology JID - 101677247 PMC - PMC9975614 EDAT- 2023/03/07 06:00 MHDA- 2023/03/07 06:01 PMCR- 2023/01/25 CRDT- 2023/03/06 03:51 PHST- 2022/11/09 00:00 [received] PHST- 2023/01/11 00:00 [accepted] PHST- 2023/03/06 03:51 [entrez] PHST- 2023/03/07 06:00 [pubmed] PHST- 2023/03/07 06:01 [medline] PHST- 2023/01/25 00:00 [pmc-release] AID - S2452-1094(23)00013-1 [pii] AID - 101184 [pii] AID - 10.1016/j.adro.2023.101184 [doi] PST - epublish SO - Adv Radiat Oncol. 2023 Jan 25;8(4):101184. doi: 10.1016/j.adro.2023.101184. eCollection 2023 Jul-Aug. PMID- 36873720 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230307 IS - 1753-4313 (Electronic) IS - 0969-6113 (Print) IS - 0969-6113 (Linking) VI - 29 IP - 3 DP - 2022 TI - High-output heart failure due to arteriovenous malformation treated by endovascular embolisation. PG - 26 LID - 10.5837/bjc.2022.026 [doi] LID - 26 AB - High-output heart failure (HF) is an uncommon condition. This occurs when HF syndrome patients have a cardiac output higher than eight litres per minute. Shunts, such as fistulas and arteriovenous malformations are an important reversible cause. We present the case of a 30-year-old man who presented to the emergency department due to decompensated HF. Echocardiogram showed dilated myocardiopathy with high cardiac output (19.5 L/min calculated on long-axis view). He was diagnosed with arteriovenous malformation by computed tomography (CT) and subsequent angiography, and a multi-disciplinary team decided to perform endovascular embolisation with ethylene vinyl alcohol/dimethyl sulfoxide at different times. The transthoracic echocardiogram showed a significant decrease in cardiac output (9.8 L/min) and his general condition improved significantly. CI - Copyright (c) 2022 Medinews (Cardiology) Limited. FAU - Liberman, Federico AU - Liberman F AD - Resident, Cardiology Residency Program at Cardiovascular Unit Sanatorium Allende, Obispo Oro 42, Cordoba, X5000BFB, Argentina. FAU - Cooke, Roberto AU - Cooke R AD - Coordinator, Critical Care Unit, Cardiovascular Unit Sanatorium Allende, Obispo Oro 42, Cordoba, X5000BFB, Argentina. FAU - Cabrera, Maria J AU - Cabrera MJ AD - Head of Interventional Cardiology Service Sanatorium Allende, Obispo Oro 42, Cordoba, X5000BFB, Argentina. FAU - Vigo, Santiago AU - Vigo S AD - Head of Service, Echocardiography Laboratory Sanatorium Allende, Obispo Oro 42, Cordoba, X5000BFB, Argentina. FAU - Allende, Guillermo AU - Allende G AD - Coordinator, Cardiac Magnetic Resonance Imaging Department Sanatorium Allende, Obispo Oro 42, Cordoba, X5000BFB, Argentina. FAU - Auad, Luciana AU - Auad L AD - Staff, Vascular Ultrasound and Angiology Unit Sanatorium Allende, Obispo Oro 42, Cordoba, X5000BFB, Argentina. FAU - Ricarte-Bratti, Juan P AU - Ricarte-Bratti JP AD - Coordinator, Critical Care Unit, Cardiovascular Unit Sanatorium Allende, Obispo Oro 42, Cordoba, X5000BFB, Argentina. LA - eng PT - Journal Article DEP - 20220719 PL - England TA - Br J Cardiol JT - The British journal of cardiology JID - 9503762 PMC - PMC9982658 OTO - NOTNLM OT - dilated cardiomyopathy OT - high-output heart failure OT - therapeutic embolisation OT - thyroid carcinoma COIS- Conflicts of interest None declared. EDAT- 2023/03/07 06:00 MHDA- 2023/03/07 06:01 PMCR- 2022/07/19 CRDT- 2023/03/06 03:45 PHST- 2023/03/06 03:45 [entrez] PHST- 2023/03/07 06:00 [pubmed] PHST- 2023/03/07 06:01 [medline] PHST- 2022/07/19 00:00 [pmc-release] AID - bjc.2022.026 [pii] AID - 10.5837/bjc.2022.026 [doi] PST - epublish SO - Br J Cardiol. 2022 Jul 19;29(3):26. doi: 10.5837/bjc.2022.026. eCollection 2022. PMID- 36872581 OWN - NLM STAT- MEDLINE DCOM- 20230503 LR - 20230507 IS - 1559-0879 (Electronic) IS - 1556-9845 (Print) IS - 1556-9845 (Linking) VI - 18 IP - 2 DP - 2023 Mar-Apr TI - Urgent Combination of Robotic and MIDCAB Coronary Revascularization in a Morbidly Obese Patient. PG - 193-195 LID - 10.1177/15569845231157745 [doi] AB - In this article, we focus on the important role of robot-assisted coronary surgery by reporting the successful case of a morbidly obese male (body mass index = 58 kg/m(2)) who presented to our center with severe coronary disease. A 54-year-old morbidly obese male presented with acute chest pain and was diagnosed with coronary artery disease. The culprit lesion was the left anterior descending (LAD) coronary artery. A percutaneous coronary intervention angiography attempted in a university hospital was not successful. Our heart team chose a hybrid robot-assisted revascularization (HCR) strategy based on the patient's body size. The patient underwent left internal thoracic mammary artery to LAD bypass with uneventful postoperative recovery. Robotic HCR is a valuable strategy in morbidly obese patients undergoing coronary artery bypass grafting. FAU - Torregrossa, Gianluca AU - Torregrossa G AD - Department of Cardiac Surgery Research, Lankenau Institute for Medical Research, Main Line Health, Wynnewood, PA, USA. AD - Department of Cardiac Surgery, Lankenau Heart Center, Main Line Health, Wynnewood, PA, USA. FAU - Sicouri, Serge AU - Sicouri S AUID- ORCID: 0000-0002-1822-768X AD - Department of Cardiac Surgery Research, Lankenau Institute for Medical Research, Main Line Health, Wynnewood, PA, USA. AD - Department of Cardiac Surgery, Lankenau Heart Center, Main Line Health, Wynnewood, PA, USA. FAU - Hosseinian, Leila AU - Hosseinian L AD - Department of Cardiac Surgery Research, Lankenau Institute for Medical Research, Main Line Health, Wynnewood, PA, USA. FAU - Sutter, Francis AU - Sutter F AD - Department of Cardiac Surgery Research, Lankenau Institute for Medical Research, Main Line Health, Wynnewood, PA, USA. FAU - Folesani, Gianluca AU - Folesani G AD - Department of Cardiac Surgery, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant' Orsola, Italy. FAU - Ramlawi, Basel AU - Ramlawi B AD - Department of Cardiac Surgery Research, Lankenau Institute for Medical Research, Main Line Health, Wynnewood, PA, USA. AD - Department of Cardiac Surgery, Lankenau Heart Center, Main Line Health, Wynnewood, PA, USA. FAU - Dokollari, Aleksander AU - Dokollari A AD - Department of Cardiac Surgery Research, Lankenau Institute for Medical Research, Main Line Health, Wynnewood, PA, USA. AD - Department of Cardiac Surgery, Lankenau Heart Center, Main Line Health, Wynnewood, PA, USA. LA - eng PT - Journal Article DEP - 20230305 PL - United States TA - Innovations (Phila) JT - Innovations (Philadelphia, Pa.) JID - 101257528 SB - IM MH - Humans MH - Male MH - Middle Aged MH - *Robotics MH - *Robotic Surgical Procedures MH - *Obesity, Morbid MH - Treatment Outcome MH - *Coronary Artery Disease/surgery MH - *Percutaneous Coronary Intervention PMC - PMC10160794 OTO - NOTNLM OT - hybrid robot-assisted CABG OT - myocardial infarction OT - obesity OT - urgent CABG COIS- The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2023/03/07 06:00 MHDA- 2023/05/03 06:42 PMCR- 2023/05/05 CRDT- 2023/03/06 01:12 PHST- 2023/05/03 06:42 [medline] PHST- 2023/03/07 06:00 [pubmed] PHST- 2023/03/06 01:12 [entrez] PHST- 2023/05/05 00:00 [pmc-release] AID - 10.1177_15569845231157745 [pii] AID - 10.1177/15569845231157745 [doi] PST - ppublish SO - Innovations (Phila). 2023 Mar-Apr;18(2):193-195. doi: 10.1177/15569845231157745. Epub 2023 Mar 5. PMID- 36867368 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230718 IS - 2193-8261 (Print) IS - 2193-6544 (Electronic) IS - 2193-6544 (Linking) VI - 12 IP - 2 DP - 2023 Jun TI - TAVI in Patient Suffering from Niemann-Pick Disease (Acid Sphingomyelinase Deficiency) with Concomitant Situs Inversus and Dextrocardia. PG - 409-414 LID - 10.1007/s40119-023-00308-7 [doi] AB - Acid sphingomyelinase deficiency (ASMD)-also known as Niemann-Pick (NP) disease-is a rare, autosomal recessive disorder which is characterized by deficiency of the lysosomal enzyme acid sphingomyelinase (ASM), resulting in excessive storage of lipids in organs (i.e., spleen, liver, lung, bone marrow, lymph nodes, and vascular system). Only a few cases of moderate-to-severe valvular heart disease due to ASMD are described in the literature, mostly in adulthood. We report here the case of a patient with NP disease subtype B that was diagnosed during adulthood. NP disease in this patient was found to be associated with situs inversus. Specifically, a severe, symptomatic aortic stenosis was identified, and the need for surgical or percutaneous intervention was discussed. The heart team chose transcatheter aortic valvular implantation (TAVI), which was successfully performed with no complications on follow-up. CI - (c) 2023. The Author(s). FAU - De Feo, Daniele AU - De Feo D AD - Division of University Cardiology, Cardiothoracic Department, Policlinico University Hospital, 70124, Bari, Italy. FAU - D'Anzi, Anna AU - D'Anzi A AD - Division of University Cardiology, Cardiothoracic Department, Policlinico University Hospital, 70124, Bari, Italy. FAU - Pestrichella, Vincenzo AU - Pestrichella V AD - Interventional Cardiology Service, "Mater Dei" Hospital, 70125, Bari, Italy. FAU - Scicchitano, Pietro AU - Scicchitano P AUID- ORCID: 0000-0003-0471-0053 AD - Division of Cardiology, "F. Perinei" Hospital, Azienda Sanitaria Locale Bari (ASL Bari) , SS 96 Altamura-Gravina Km 73.800, 70022, Altamura, BA, Italy. piero.sc@hotmail.it. FAU - Lafranceschina, Carlo AU - Lafranceschina C AD - Interventional Cardiology Service, "Mater Dei" Hospital, 70125, Bari, Italy. FAU - Caragnano, Vito AU - Caragnano V AD - Interventional Cardiology Service, "Mater Dei" Hospital, 70125, Bari, Italy. FAU - Tiecco, Fabio AU - Tiecco F AD - Interventional Cardiology Service, "Mater Dei" Hospital, 70125, Bari, Italy. FAU - Scialpi, Antonella AU - Scialpi A AD - Interventional Cardiology Service, "Mater Dei" Hospital, 70125, Bari, Italy. FAU - Laronga, Giuliana AU - Laronga G AD - Interventional Cardiology Service, "Mater Dei" Hospital, 70125, Bari, Italy. FAU - Ciccone, Marco Matteo AU - Ciccone MM AD - Division of University Cardiology, Cardiothoracic Department, Policlinico University Hospital, 70124, Bari, Italy. FAU - Iliceto, Sabino AU - Iliceto S AD - Interventional Cardiology Service, "Mater Dei" Hospital, 70125, Bari, Italy. LA - eng PT - Journal Article DEP - 20230303 PL - England TA - Cardiol Ther JT - Cardiology and therapy JID - 101634495 PMC - PMC10209358 OTO - NOTNLM OT - Acid sphingomyelinase deficiency disease OT - Aortic stenosis OT - Niemann-Pick OT - Risk scores OT - Situs inversus OT - Transcatheter aortic valve implantation COIS- Daniele De Feo, Anna D'Anzi, Vincenzo Pestrichella, Pietro Scicchitano, Carlo Lafranceschina, Vito Caragnano, Fabio Tiecco, Antonella Scialpi, Giuliana Laronga, Marco Matteo Ciccone, and Sabino Iliceto have nothing to disclose. EDAT- 2023/03/04 06:00 MHDA- 2023/03/04 06:01 PMCR- 2023/03/03 CRDT- 2023/03/03 11:21 PHST- 2023/01/18 00:00 [received] PHST- 2023/02/20 00:00 [accepted] PHST- 2023/03/04 06:01 [medline] PHST- 2023/03/04 06:00 [pubmed] PHST- 2023/03/03 11:21 [entrez] PHST- 2023/03/03 00:00 [pmc-release] AID - 10.1007/s40119-023-00308-7 [pii] AID - 308 [pii] AID - 10.1007/s40119-023-00308-7 [doi] PST - ppublish SO - Cardiol Ther. 2023 Jun;12(2):409-414. doi: 10.1007/s40119-023-00308-7. Epub 2023 Mar 3. PMID- 36867048 OWN - NLM STAT- MEDLINE DCOM- 20230509 LR - 20230510 IS - 1651-2227 (Electronic) IS - 0803-5253 (Linking) VI - 112 IP - 6 DP - 2023 Jun TI - Childhood manifestations of 22q11.2 deletion syndrome: A Finnish nationwide register-based cohort study. PG - 1312-1318 LID - 10.1111/apa.16737 [doi] AB - AIM: The aim of the study was to describe the clinical manifestations of 22q11.2 deletion syndrome patients in the Finnish paediatric population. METHODS: Nationwide registry data including all diagnoses and procedures of every public hospital in Finland between 2004 and 2018 along with mortality and cancer registry data were retrieved. Patients born during the study period and with an ICD-10 code of D82.1 or Q87.06 were included as having 22q11.2 deletion syndrome. A control group was formed with patients born during the study period and with benign cardiac murmur diagnosed under the age of 1 year. RESULTS: We identified 100 pediatric patients with 22q11.2 deletion syndrome (54% males, median age at diagnosis <1 year, median follow-up 9 years). Cumulative mortality was 7.1%. Among patients with 22q11.2 deletion syndrome, 73.8% had congenital heart defects, 21.8% had cleft palate, 13.6% had hypocalcaemia, and 7.2% had immunodeficiencies. Furthermore, 29.6% were diagnosed with autoimmune diseases, 92.9% had infections, and 93.2% had neuropsychiatric and developmental issues during follow-up. Malignancy was found in 2.1% of the patients. CONCLUSION: The 22q11.2 deletion syndrome is associated with increased mortality and substantial multimorbidity in children. A structured multidisciplinary approach is necessary for managing patients with 22q11.2 deletion syndrome. CI - (c) 2023 Foundation Acta Paediatrica. Published by John Wiley & Sons Ltd. FAU - Wahrmann, Sakari AU - Wahrmann S AUID- ORCID: 0000-0001-8692-6610 AD - Department of Pediatrics, Turku University Hospital, University of Turku, Turku, Finland. FAU - Kainulainen, Leena AU - Kainulainen L AD - Department of Pediatrics, Turku University Hospital, University of Turku, Turku, Finland. FAU - Kyto, Ville AU - Kyto V AD - Heart Center, Turku University Hospital, University of Turku, Turku, Finland. AD - Research Center of Applied and Preventive Cardiovascular Medicine, University of Turku, Turku, Finland. AD - Center for Population Health Research, Turku University Hospital, University of Turku, Turku, Finland. AD - Administrative Center, Hospital District of Southwest Finland, Turku, Finland. AD - Department of Public Health, University of Helsinki, Helsinki, Finland. FAU - Lempainen, Johanna AU - Lempainen J AUID- ORCID: 0000-0001-9893-1468 AD - Department of Pediatrics, Turku University Hospital, University of Turku, Turku, Finland. AD - Immunogenetics Laboratory, University of Turku, Turku, Finland. AD - Clinical Microbiology, Turku University Hospital, Turku, Finland. LA - eng GR - Finnish Foundation for Cardiovascular Research sr/ GR - Paavo Nurmi Foundation sr/ PT - Journal Article DEP - 20230307 PL - Norway TA - Acta Paediatr JT - Acta paediatrica (Oslo, Norway : 1992) JID - 9205968 SB - IM MH - Male MH - Child MH - Humans MH - Infant MH - Female MH - *DiGeorge Syndrome/complications/epidemiology/diagnosis MH - Cohort Studies MH - Finland/epidemiology MH - *Heart Defects, Congenital/diagnosis OTO - NOTNLM OT - 22q11.2 microdeletion OT - DiGeorge syndrome OT - congenital anomaly OT - immunodeficiency OT - velocardiofacial syndrome EDAT- 2023/03/04 06:00 MHDA- 2023/05/09 06:42 CRDT- 2023/03/03 09:02 PHST- 2023/02/25 00:00 [revised] PHST- 2022/11/15 00:00 [received] PHST- 2023/02/28 00:00 [accepted] PHST- 2023/05/09 06:42 [medline] PHST- 2023/03/04 06:00 [pubmed] PHST- 2023/03/03 09:02 [entrez] AID - 10.1111/apa.16737 [doi] PST - ppublish SO - Acta Paediatr. 2023 Jun;112(6):1312-1318. doi: 10.1111/apa.16737. Epub 2023 Mar 7. PMID- 36864956 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230304 IS - 2223-3652 (Print) IS - 2223-3660 (Electronic) IS - 2223-3652 (Linking) VI - 13 IP - 1 DP - 2023 Feb 28 TI - Clinical aspects and targeted inspiratory muscle training in children and adolescents with Fontan circulation: a randomized controlled trial. PG - 11-24 LID - 10.21037/cdt-22-308 [doi] AB - BACKGROUND: Since 1968, thousands of patients with a morphologically or functionally univentricular heart have been treated with a total cavopulmonary connection/Fontan operation. Because of the resulting passive pulmonary perfusion, blood flow is assisted by the pressure shift during respiration. Respiratory training is known to improve exercise capacity and cardiopulmonary function. However, there are limited data on whether respiratory training can also improve physical performance after Fontan surgery. The aim of the present study was to clarify the effects of six months of daily home-based inspiratory muscle training (IMT) aimed at increasing physical performance by strengthening respiratory muscles, improving lung function and peripheral oxygenation. METHODS: In this non-blinded randomized controlled trial, the effects of IMT on lung capacity and exercise capacity were measured in a large cohort of 40 Fontan patients (25% female; 12.3+/-2.2 years) who were under regular follow-up by the outpatient clinic of the Department of Congenital Heart Defects and Pediatric Cardiology of the German Heart Center Munich. After a lung function test and a cardiopulmonary exercise test, patients were randomly assigned in a parallel arm design to either an intervention group (IG) or a control group (CG) via stratified and computer-generated letter randomization from May 2014 to May 2015. The IG completed a daily, telephone-monitored IMT of three sets of 30 repetitions for six months with an inspiratory resistive training device (POWERbreathe medic((R))), the CG continued their usual daily activities without an IMT until the second examination within the timeframe of November 2014 until November 2015. RESULTS: After six months of IMT, lung capacity values in the IG (n=18) did not increase significantly compared to the CG [n=19; DeltaFVC: IG: 0.21+/-0.16 l vs. CG 0.22+/-0.31 l; P=0.946 (CI: -0.16, 0.17); DeltaFEV1: CG: 0.14+/-0.30 vs. IG: 0.17+/-0.20 P=0.707 (CI: -0.20, 0.14)]. Exercise capacity did not improve significantly, yet the maximum workload achieved trended to improve with an increase of 14% in the IG vs. 6.5% in the CG [P=0.113 (CI: -15.8, 1.76)]. There was a significant increase of oxygen saturation at rest in the IG compared to the CG [IG: 3.31%+/-4.09% vs. CG: 0.17%+/-2.92%, P=0.014 (CI: -5.60, -0.68)]. Compared to the CG, the mean oxygen saturation at peak exercise no longer dropped below 90% in the IG. This observation is thus not statistically significant, yet of clinical relevance. CONCLUSIONS: The results of this study show benefits of an IMT in young Fontan patients. Even if some data are not statistically significant, they may still be clinically relevant and may contribute to a multidisciplinary approach in patient care. IMT should therefore be an additional target and integrated into the training program to improve the prognosis of Fontan patients. TRIAL REGISTRATION: German Clinical Trials Register; DRKS.de; registration ID: DRKS00030340. CI - 2023 Cardiovascular Diagnosis and Therapy. All rights reserved. FAU - Neidenbach, Rhoia AU - Neidenbach R AD - Department of Congenital Heart Disease and Pediatric Cardiology, German Heart Centre Munich, Technical University Munich, Munich, Germany. AD - Chair of Preventive Pediatrics, Department of Sport and Health Sciences, Technical University of Munich, Munich, Germany. AD - Department of Sports Medicine, Exercise Physiology and Prevention, Institute of Sport Science, University of Vienna, Vienna, Austria. FAU - Freilinger, Sebastian AU - Freilinger S AD - Department of Congenital Heart Disease and Pediatric Cardiology, German Heart Centre Munich, Technical University Munich, Munich, Germany. AD - Chair of Preventive Pediatrics, Department of Sport and Health Sciences, Technical University of Munich, Munich, Germany. FAU - Stocker, Fabian AU - Stocker F AD - Chair of Preventive Pediatrics, Department of Sport and Health Sciences, Technical University of Munich, Munich, Germany. FAU - Ewert, Peter AU - Ewert P AD - Department of Congenital Heart Disease and Pediatric Cardiology, German Heart Centre Munich, Technical University Munich, Munich, Germany. FAU - Nagdyman, Nicole AU - Nagdyman N AD - Department of Congenital Heart Disease and Pediatric Cardiology, German Heart Centre Munich, Technical University Munich, Munich, Germany. FAU - Oberhoffer-Fritz, Renate AU - Oberhoffer-Fritz R AD - Department of Congenital Heart Disease and Pediatric Cardiology, German Heart Centre Munich, Technical University Munich, Munich, Germany. AD - Chair of Preventive Pediatrics, Department of Sport and Health Sciences, Technical University of Munich, Munich, Germany. FAU - Pieper, Lars AU - Pieper L AD - Department of Congenital Heart Disease and Pediatric Cardiology, German Heart Centre Munich, Technical University Munich, Munich, Germany. FAU - Kaemmerer, Harald AU - Kaemmerer H AD - Department of Congenital Heart Disease and Pediatric Cardiology, German Heart Centre Munich, Technical University Munich, Munich, Germany. FAU - Hager, Alfred AU - Hager A AD - Department of Congenital Heart Disease and Pediatric Cardiology, German Heart Centre Munich, Technical University Munich, Munich, Germany. LA - eng PT - Journal Article DEP - 20230115 PL - China TA - Cardiovasc Diagn Ther JT - Cardiovascular diagnosis and therapy JID - 101601613 PMC - PMC9971296 OTO - NOTNLM OT - Fontan operation OT - exercise capacity OT - inspiratory muscle training COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (https://cdt.amegroups.com/article/view/10.21037/cdt-22-308/coif). The series "Current Management Aspects in Adult Congenital Heart Disease (ACHD): Part V" was commissioned by the editorial office without any funding or sponsorship. HK served as the unpaid Guest Editor of the series. HK has the following potential conflicts of interest to report: Sponsorship/Honoraria: Actelion/Janssen, Bristol-Myers Squibb, Steering Board: COMPERA International Steering Board and Research grant/support: Patient organizations: Deutsche Herzstiftung and Herzkind e.V. The authors have no other conflicts of interest to declare. EDAT- 2023/03/04 06:00 MHDA- 2023/03/04 06:01 PMCR- 2023/02/28 CRDT- 2023/03/03 02:26 PHST- 2022/06/18 00:00 [received] PHST- 2022/12/23 00:00 [accepted] PHST- 2023/03/03 02:26 [entrez] PHST- 2023/03/04 06:00 [pubmed] PHST- 2023/03/04 06:01 [medline] PHST- 2023/02/28 00:00 [pmc-release] AID - cdt-13-01-11 [pii] AID - 10.21037/cdt-22-308 [doi] PST - ppublish SO - Cardiovasc Diagn Ther. 2023 Feb 28;13(1):11-24. doi: 10.21037/cdt-22-308. Epub 2023 Jan 15. PMID- 36857967 OWN - NLM STAT- MEDLINE DCOM- 20230418 LR - 20230418 IS - 2352-3964 (Electronic) IS - 2352-3964 (Linking) VI - 90 DP - 2023 Apr TI - Development and validation of echocardiography-based machine-learning models to predict mortality. PG - 104479 LID - S2352-3964(23)00044-0 [pii] LID - 10.1016/j.ebiom.2023.104479 [doi] LID - 104479 AB - BACKGROUND: Echocardiography (echo) based machine learning (ML) models may be useful in identifying patients at high-risk of all-cause mortality. METHODS: We developed ML models (ResNet deep learning using echo videos and CatBoost gradient boosting using echo measurements) to predict 1-year, 3-year, and 5-year mortality. Models were trained on the Mackay dataset, Taiwan (6083 echos, 3626 patients) and validated in the Alberta HEART dataset, Canada (997 echos, 595 patients). We examined the performance of the models overall, and in subgroups (healthy controls, at risk of heart failure (HF), HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF)). We compared the models' performance to the MAGGIC risk score, and examined the correlation between the models' predicted probability of death and baseline quality of life as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ). FINDINGS: Mortality rates at 1-, 3- and 5-years were 14.9%, 28.6%, and 42.5% in the Mackay cohort, and 3.0%, 10.3%, and 18.7%, in the Alberta HEART cohort. The ResNet and CatBoost models achieved area under the receiver-operating curve (AUROC) between 85% and 92% in internal validation. In external validation, the AUROCs for the ResNet (82%, 82%, and 78%) were significantly better than CatBoost (78%, 73%, and 75%), for 1-, 3- and 5-year mortality prediction respectively, with better or comparable performance to the MAGGIC score. ResNet models predicted higher probability of death in the HFpEF and HFrEF (30%-50%) subgroups than in controls and at risk patients (5%-20%). The predicted probabilities of death correlated with KCCQ scores (all p < 0.05). INTERPRETATION: Echo-based ML models to predict mortality had good internal and external validity, were generalizable, correlated with patients' quality of life, and are comparable to an established HF risk score. These models can be leveraged for automated risk stratification at point-of-care. FUNDING: Funding for Alberta HEART was provided by an Alberta Innovates - Health Solutions Interdisciplinary Team Grant no. AHFMRITG 200801018. P.K. holds a Canadian Institutes of Health Research (CIHR) Sex and Gender Science Chair and a Heart & Stroke Foundation Chair in Cardiovascular Research. A.V. and V.S. received funding from the Mitacs Globalink Research Internship. CI - Copyright (c) 2023 The Author(s). Published by Elsevier B.V. All rights reserved. FAU - Valsaraj, Akshay AU - Valsaraj A AD - Bits Pilani KK Birla Goa Campus, Goa, India. FAU - Kalmady, Sunil Vasu AU - Kalmady SV AD - Canadian VIGOUR Centre, University of Alberta, Alberta, Canada; Department of Computing Science, University of Alberta, Edmonton, Alberta, Canada; Faculty of Medicine & Dentistry, University of Alberta, Alberta, Canada. FAU - Sharma, Vaibhav AU - Sharma V AD - Aligarh Muslim University, Uttar Pradesh, India. FAU - Frost, Matthew AU - Frost M AD - US2.ai, Singapore. FAU - Sun, Weijie AU - Sun W AD - Canadian VIGOUR Centre, University of Alberta, Alberta, Canada; Department of Computing Science, University of Alberta, Edmonton, Alberta, Canada. FAU - Sepehrvand, Nariman AU - Sepehrvand N AD - Canadian VIGOUR Centre, University of Alberta, Alberta, Canada; Faculty of Medicine & Dentistry, University of Alberta, Alberta, Canada. FAU - Ong, Marcus AU - Ong M AD - US2.ai, Singapore. FAU - Equilbec, Cyril AU - Equilbec C AD - US2.ai, Singapore. FAU - Dyck, Jason R B AU - Dyck JRB AD - Faculty of Medicine & Dentistry, University of Alberta, Alberta, Canada. FAU - Anderson, Todd AU - Anderson T AD - Libin Cardiovascular Institute, Cumming School of Medicine, University of Calgary, Alberta, Canada. FAU - Becher, Harald AU - Becher H AD - Faculty of Medicine & Dentistry, University of Alberta, Alberta, Canada. FAU - Weeks, Sarah AU - Weeks S AD - Libin Cardiovascular Institute, Cumming School of Medicine, University of Calgary, Alberta, Canada. FAU - Tromp, Jasper AU - Tromp J AD - Saw Swee Hock School of Public Health, National University of Singapore & National University Health System, Singapore; Duke-NUS Medical School, Singapore. FAU - Hung, Chung-Lieh AU - Hung CL AD - MacKay Memorial Hospital, Taipei City, Taiwan. FAU - Ezekowitz, Justin A AU - Ezekowitz JA AD - Canadian VIGOUR Centre, University of Alberta, Alberta, Canada; Faculty of Medicine & Dentistry, University of Alberta, Alberta, Canada. FAU - Kaul, Padma AU - Kaul P AD - Canadian VIGOUR Centre, University of Alberta, Alberta, Canada; Faculty of Medicine & Dentistry, University of Alberta, Alberta, Canada. Electronic address: pkaul@ualberta.ca. LA - eng PT - Journal Article DEP - 20230228 PL - Netherlands TA - EBioMedicine JT - EBioMedicine JID - 101647039 SB - IM MH - Male MH - Female MH - Humans MH - *Heart Failure/diagnostic imaging MH - Quality of Life MH - Stroke Volume MH - Canada MH - Machine Learning MH - Echocardiography MH - Prognosis PMC - PMC10006431 OTO - NOTNLM OT - Deep learning OT - Echocardiography OT - Functional status OT - Heart failure OT - Machine learning OT - Mortality OT - Prognostic models COIS- Declaration of interests J.T. reports consulting or speaker fees from Daiichi-Sankyo, Boehringer Ingelheim, Roche Diagnostics and Us2.ai, owns patent US-10702247-B2 unrelated to the present work. M.F., M.O. and C.E. report owning stock or stock options from Us2.ai. J.E. reports research grants from Bayer, Merck & Co, Novo Nordisk, Cytokinetics, Applied Therapeutics, American Regent, US2.ai, Canadian Institutes of Health Research, Heart and Stroke Foundation, Weston Foundation; consulting fees from AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Otsuka, Bayer, Novartis; participation on a Data Safety Monitoring Board or Advisory Board for Cardiac Sarcoidosis Randomized Trial (CHASM-CS-RCT); leadership or fiduciary role in the Canadian Heart Failure Society. C-L.H. reports honoraria for lectures or presentations as a speaker with AstraZeneca, Boehringer Ingelheim, Sanofi and Bayer Pharma; participation in Advisory Board activity in AstraZeneca, Boehringer Ingelheim, Sanofi and Bayer Pharma. All other authors report no conflicts of interest. EDAT- 2023/03/02 06:00 MHDA- 2023/04/18 06:41 PMCR- 2023/02/28 CRDT- 2023/03/01 18:14 PHST- 2022/10/03 00:00 [received] PHST- 2023/02/01 00:00 [revised] PHST- 2023/02/01 00:00 [accepted] PHST- 2023/04/18 06:41 [medline] PHST- 2023/03/02 06:00 [pubmed] PHST- 2023/03/01 18:14 [entrez] PHST- 2023/02/28 00:00 [pmc-release] AID - S2352-3964(23)00044-0 [pii] AID - 104479 [pii] AID - 10.1016/j.ebiom.2023.104479 [doi] PST - ppublish SO - EBioMedicine. 2023 Apr;90:104479. doi: 10.1016/j.ebiom.2023.104479. Epub 2023 Feb 28. PMID- 36847990 OWN - NLM STAT- MEDLINE DCOM- 20230329 LR - 20261010 IS - 1534-3170 (Electronic) IS - 1523-3782 (Linking) VI - 25 IP - 4 DP - 2023 Apr TI - Review of Pathophysiology of Cardiogenic Shock and Escalation of Mechanical Circulatory Support Devices. PG - 213-227 LID - 10.1007/s11886-023-01843-4 [doi] AB - PURPOSE OF REVIEW: Cardiogenic shock (CS) is a complex clinical entity that continues to carry a high risk of mortality. The landscape of CS management has changed with the advent of several temporary mechanical circulatory support (MCS) devices designed to provide hemodynamic support. It remains challenging to understand the role of different temporary MCS devices in patients with CS, as many of these patients are critically ill, requiring complex care with multiple MCS device options. Each temporary MCS device can provide different types and levels of hemodynamic support. It is important to understand the risk/benefit profile of each one of them for appropriate device selection in patients with CS. RECENT FINDINGS: MCS may be beneficial in CS patients through augmentation of cardiac output with subsequent improvement of systemic perfusion. Selecting the optimal MCS device depends on several variables including the underlying etiology of CS, clinical strategy of MCS use (bridge to recovery, bridge to transplant or durable MCS, or abridge to decision), amount of hemodynamic support needed, associated respiratory failure, and institutional preference. Furthermore, it is even more challenging to determine the appropriate time to escalate from one MCS device to another or combine different MCS devices. In this review, we discuss the current available data published in the literature on the management of CS and propose a standardized approach for escalation of MCS devices in patients with CS. Shock teams can play an important role to help in hemodynamic-guided management and algorithm-based step-by-step approach in early initiation and escalation of temporary MCS devices at different stages of CS. It is important to define the etiology of CS, and stage of shock and recognize univentricular vs biventricular shock for appropriate device selection and escalation of therapy. CI - (c) 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Pahuja, Mohit AU - Pahuja M AD - Department of Cardiology, MedStar Georgetown University/Washington Hospital Center, 110 Irving St., NW, Suite 4B-1, Washington D.C., 20010, USA. FAU - Yerasi, Charan AU - Yerasi C AD - Department of Cardiology, MedStar Georgetown University/Washington Hospital Center, 110 Irving St., NW, Suite 4B-1, Washington D.C., 20010, USA. FAU - Lam, Phillip H AU - Lam PH AD - Department of Cardiology, MedStar Georgetown University/Washington Hospital Center, 110 Irving St., NW, Suite 4B-1, Washington D.C., 20010, USA. FAU - Hashim, Hayder AU - Hashim H AD - Department of Cardiology, MedStar Georgetown University/Washington Hospital Center, 110 Irving St., NW, Suite 4B-1, Washington D.C., 20010, USA. FAU - Ben-Dor, Itsik AU - Ben-Dor I AD - Department of Cardiology, MedStar Georgetown University/Washington Hospital Center, 110 Irving St., NW, Suite 4B-1, Washington D.C., 20010, USA. FAU - Bernardo, Nelson L AU - Bernardo NL AD - Department of Cardiology, MedStar Georgetown University/Washington Hospital Center, 110 Irving St., NW, Suite 4B-1, Washington D.C., 20010, USA. FAU - Satler, Lowell F AU - Satler LF AD - Department of Cardiology, MedStar Georgetown University/Washington Hospital Center, 110 Irving St., NW, Suite 4B-1, Washington D.C., 20010, USA. FAU - Sheikh, Farooq H AU - Sheikh FH AD - Department of Cardiology, MedStar Georgetown University/Washington Hospital Center, 110 Irving St., NW, Suite 4B-1, Washington D.C., 20010, USA. FAU - Najjar, Samer S AU - Najjar SS AD - Department of Cardiology, MedStar Georgetown University/Washington Hospital Center, 110 Irving St., NW, Suite 4B-1, Washington D.C., 20010, USA. FAU - Molina, Ezequiel J AU - Molina EJ AD - Department of Cardiac Surgery, MedStar Georgetown University/Washington Hospital Center, Washington D.C., USA. FAU - Waksman, Ron AU - Waksman R AUID- ORCID: 0000-0002-4063-9226 AD - Department of Cardiology, MedStar Georgetown University/Washington Hospital Center, 110 Irving St., NW, Suite 4B-1, Washington D.C., 20010, USA. ron.waksman@medstar.net. LA - eng PT - Journal Article PT - Review DEP - 20230227 PL - United States TA - Curr Cardiol Rep JT - Current cardiology reports JID - 100888969 SB - IM MH - Humans MH - Shock, Cardiogenic/therapy MH - *Heart-Assist Devices MH - *Extracorporeal Membrane Oxygenation MH - Risk Assessment MH - Hemodynamics OTO - NOTNLM OT - Cardiogenic shock OT - Heart failure OT - Hemodynamic support OT - Mechanical circulatory support OT - Shock team EDAT- 2023/02/28 06:00 MHDA- 2023/03/29 06:04 CRDT- 2023/02/27 11:37 PHST- 2023/01/30 00:00 [accepted] PHST- 2023/03/29 06:04 [medline] PHST- 2023/02/28 06:00 [pubmed] PHST- 2023/02/27 11:37 [entrez] AID - 10.1007/s11886-023-01843-4 [pii] AID - 10.1007/s11886-023-01843-4 [doi] PST - ppublish SO - Curr Cardiol Rep. 2023 Apr;25(4):213-227. doi: 10.1007/s11886-023-01843-4. Epub 2023 Feb 27. PMID- 36846957 OWN - NLM STAT- MEDLINE DCOM- 20230403 LR - 20230403 IS - 1744-8344 (Electronic) IS - 1477-9072 (Linking) VI - 21 IP - 3 DP - 2023 Mar TI - Decision making in anomalous aortic origin of a coronary artery. PG - 177-191 LID - 10.1080/14779072.2023.2184799 [doi] AB - INTRODUCTION: There are many uncertainties surrounding anomalous aortic origin of a coronary artery (AAOCA) including the pathophysiology of sudden cardiac death, how to best risk stratify patients, how to best evaluate patients, who would benefit from exercise restriction, who should undergo surgical intervention, and which operation to perform. AREAS COVERED: The goal of this review is to provide a comprehensive but succinct overview of AAOCA to help clinicians with the difficult task of navigating optimal evaluation and treatment of an individual patient with AAOCA. EXPERT OPINION: Beginning in year 2012, some of our authors proposed an integrated, multi-disciplinary working group which has become the standard management strategy for patients diagnosed with AAOCA. A multi-disciplinary team with a focus on shared decision-making with the patients/families is likely necessary to optimize outcomes. Long-term follow-up and research are needed to improve our understanding of AAOCA. FAU - Agrawal, Hitesh AU - Agrawal H AUID- ORCID: 0000-0001-9272-6949 AD - Department of Pediatrics, Texas Center for Pediatric and Congenital Heart Disease, University of Texas Dell Medical School/Dell Children's Medical Center, Austin, TX, USA. FAU - Lamari-Fisher, Alexandra AU - Lamari-Fisher A AD - Department of Pediatrics, Texas Center for Pediatric and Congenital Heart Disease, University of Texas Dell Medical School/Dell Children's Medical Center, Austin, TX, USA. FAU - Hasbani, Keren AU - Hasbani K AD - Department of Pediatrics, Texas Center for Pediatric and Congenital Heart Disease, University of Texas Dell Medical School/Dell Children's Medical Center, Austin, TX, USA. FAU - Philip, Stephanie AU - Philip S AUID- ORCID: 0000-0003-2051-276X AD - Department of Pediatrics, Texas Center for Pediatric and Congenital Heart Disease, University of Texas Dell Medical School/Dell Children's Medical Center, Austin, TX, USA. FAU - Fraser, Charles D AU - Fraser CD AD - Department of Pediatrics, Texas Center for Pediatric and Congenital Heart Disease, University of Texas Dell Medical School/Dell Children's Medical Center, Austin, TX, USA. FAU - Mery, Carlos M AU - Mery CM AD - Department of Pediatrics, Texas Center for Pediatric and Congenital Heart Disease, University of Texas Dell Medical School/Dell Children's Medical Center, Austin, TX, USA. LA - eng PT - Journal Article PT - Review DEP - 20230228 PL - England TA - Expert Rev Cardiovasc Ther JT - Expert review of cardiovascular therapy JID - 101182328 SB - IM MH - Humans MH - *Coronary Vessels MH - *Coronary Vessel Anomalies/complications/therapy/diagnosis MH - Aorta MH - Death, Sudden, Cardiac/etiology/prevention & control MH - Decision Making OTO - NOTNLM OT - AAOCA OT - Anomalous coronary artery OT - coronary artery anomalies OT - exercise OT - myocardial ischemia OT - risk stratification OT - sudden cardiac death OT - surgery EDAT- 2023/02/28 06:00 MHDA- 2023/04/03 06:41 CRDT- 2023/02/27 06:26 PHST- 2023/04/03 06:41 [medline] PHST- 2023/02/28 06:00 [pubmed] PHST- 2023/02/27 06:26 [entrez] AID - 10.1080/14779072.2023.2184799 [doi] PST - ppublish SO - Expert Rev Cardiovasc Ther. 2023 Mar;21(3):177-191. doi: 10.1080/14779072.2023.2184799. Epub 2023 Feb 28. PMID- 36842677 OWN - NLM STAT- MEDLINE DCOM- 20230522 LR - 20230607 IS - 1873-1570 (Electronic) IS - 0300-9572 (Linking) VI - 187 DP - 2023 Jun TI - Feasibility of accelerated code team activation with code button triggered smartphone notification. PG - 109752 LID - S0300-9572(23)00065-5 [pii] LID - 10.1016/j.resuscitation.2023.109752 [doi] AB - INTRODUCTION: Studies support rapid interventions to improve outcomes in patients with in-hospital cardiac arrest. We sought to decrease the time to code team activation and improve dissemination of patient-specific data to facilitate targeted treatments. METHODS: We mapped code blue buttons behind each bed to patients through the electronic medical record. Pushing the button sent patient-specific data (admitting diagnosis, presence of difficult airway, and recent laboratory values) through a secure messaging system to the responding teams' smartphones. The code button also activated a hospital-wide alert through the operator. We piloted the system on seven medicine inpatient units from November 2019 through May 2022. We compared the time from code blue button press to smartphone message receipt vs traditional operator-sent overhead page. RESULTS: The code button was the primary mode of code team activation for 12/35 (34.3%) cardiac arrest events. The code team received smartphone notifications a median of 78 s (IQR = 47-127 s) before overhead page. The median time to adrenaline administration for codes activated with the code button was not significantly different (240 s (IQR 142-300 s for code button) vs 148 s (IQR = 34-367 s) for overhead page, p = 0.89). Survival to discharge was 3/12 (25.0%) for codes activated with the code button vs 4/23 (17.4%) when activated by calling the operator (p = 0.67). CONCLUSION: Implementation of a smartphone-based code button notification system reduced time to code team activation by 78 s. Larger cohorts are necessary to assess effects on patient outcomes. CI - Copyright (c) 2023 Elsevier B.V. All rights reserved. FAU - Morris, Nicholas A AU - Morris NA AD - Department of Neurology, Program in Trauma, University of Maryland School of Medicine, Baltimore, MD, USA. Electronic address: nicholas.morris@som.umaryland.edu. FAU - Couperus, Cody AU - Couperus C AD - Department of Emergency Medicine, University of Maryland School of Medicine, Baltimore, MD, USA; Department of Internal Medicine, University of Maryland School of Medicine, Baltimore, MD, USA. FAU - Dezman, Zach AU - Dezman Z AD - Department of Emergency Medicine, University of Maryland School of Medicine, Baltimore, MD, USA; Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD, USA. FAU - Rubinson, Lewis AU - Rubinson L AD - Robert Wood Johnson Hospital, New Brunswick, NJ, USA. FAU - Friedrich, Rebekah AU - Friedrich R AD - Center for Technology Innovation, University of Maryland Medical System, Baltimore, MD, USA. FAU - Gurmu, Samuel AU - Gurmu S AD - Center for Technology Innovation, University of Maryland Medical System, Baltimore, MD, USA. FAU - Lemkin, Dan AU - Lemkin D AD - Department of Emergency Medicine, University of Maryland School of Medicine, Baltimore, MD, USA; Center for Technology Innovation, University of Maryland Medical System, Baltimore, MD, USA. LA - eng PT - Journal Article DEP - 20230225 PL - Ireland TA - Resuscitation JT - Resuscitation JID - 0332173 SB - IM CIN - Resuscitation. 2023 Jun;187:109814. doi: 10.1016/j.resuscitation.2023.109814. PMID: 37121463 MH - Humans MH - *Hospital Rapid Response Team MH - Smartphone MH - Feasibility Studies MH - *Cardiopulmonary Resuscitation MH - *Heart Arrest/therapy OTO - NOTNLM OT - Cardiopulmonary resuscitation OT - Electronic health records OT - Epinephrine OT - Heart Arrest OT - Hospitals OT - Humans EDAT- 2023/02/27 06:00 MHDA- 2023/05/22 06:42 CRDT- 2023/02/26 19:31 PHST- 2022/12/13 00:00 [received] PHST- 2023/01/30 00:00 [revised] PHST- 2023/02/20 00:00 [accepted] PHST- 2023/05/22 06:42 [medline] PHST- 2023/02/27 06:00 [pubmed] PHST- 2023/02/26 19:31 [entrez] AID - S0300-9572(23)00065-5 [pii] AID - 10.1016/j.resuscitation.2023.109752 [doi] PST - ppublish SO - Resuscitation. 2023 Jun;187:109752. doi: 10.1016/j.resuscitation.2023.109752. Epub 2023 Feb 25. PMID- 36840752 OWN - NLM STAT- MEDLINE DCOM- 20230804 LR - 20240820 IS - 1432-198X (Electronic) IS - 0931-041X (Print) IS - 0931-041X (Linking) VI - 38 IP - 8 DP - 2023 Aug TI - Transplantation in paediatric patients with MMA requires multidisciplinary approach for achievement of good clinical outcomes. PG - 2887-2896 LID - 10.1007/s00467-023-05906-0 [doi] AB - BACKGROUND: As modern medicine is advancing, younger, small, and more complex children are becoming multi-organ transplant candidates. This brings up new challenges in all aspects of their care. METHODS: We describe the first report of a small child receiving a simultaneous liver and kidney transplant and abdominal rectus sheath fascia transplant on the background of Williams syndrome and methylmalonic acidaemia. At the time of transplantation, the child was 3 years old, weighed 14.0 kg, had chronic kidney disease stage V, and had not yet started any other form of kidney replacement therapy. RESULTS: There were many anaesthetic, medical, metabolic, and surgical challenges to consider in this case. A long general anaesthetic time increased the risk of cardiac complications and metabolic decompensation. Additionally, the small size of the patient and the organ size mis-match meant that primary abdominal closure was not possible. The patient's recovery was further complicated by sepsis, transient CNI toxicity, and de novo DSAs. CONCLUSIONS: Through a multidisciplinary approach between 9 specialties in 4 hospitals across England and Wales, and detailed pre-operative planning, a good outcome was achieved for this child. An hour by hour management protocol was drafted to facilitate transplant and included five domains: 1. management at the time of organ offer; 2. before the admission; 3. at admission and before theatre time; 4. intra-operative management; and 5. post-operative management in the first 24 h. Importantly, gaining a clear and in depth understanding of the metabolic state of the patient pre- and peri-operatively was crucial in avoiding metabolic decompensation. Furthermore, an abdominal rectus sheath fascia transplant was required to achieve abdominal closure, which to our knowledge, had never been done before for this indication. Using our experience of this complex case, as well as our experience in transplanting other children with MMA, and through a literature review, we propose a new perioperative management pathway for this complex cohort of transplant recipients. CI - (c) 2023. The Author(s). FAU - Paessler, Alicia AU - Paessler A AUID- ORCID: 0000-0003-3891-904X AD - Great Ormond Street Hospital for Children NHS Foundation Trust, Great Ormond Street, WC1N 3JH, London, UK. AD - University College London Great Ormond Street Institute of Child Health, London, UK. FAU - Cortes-Cerisuelo, Miriam AU - Cortes-Cerisuelo M AD - King's College Hospital NHS Foundation Trust, London, UK. FAU - Jassem, Wayel AU - Jassem W AD - King's College Hospital NHS Foundation Trust, London, UK. FAU - Vilca-Melendez, Hector AU - Vilca-Melendez H AD - King's College Hospital NHS Foundation Trust, London, UK. FAU - Deep, Akash AU - Deep A AD - King's College Hospital NHS Foundation Trust, London, UK. FAU - Jain, Vandana AU - Jain V AD - King's College Hospital NHS Foundation Trust, London, UK. FAU - Pool, Andrew AU - Pool A AD - King's College Hospital NHS Foundation Trust, London, UK. FAU - Grunewald, Stephanie AU - Grunewald S AD - Great Ormond Street Hospital for Children NHS Foundation Trust, Great Ormond Street, WC1N 3JH, London, UK. FAU - Kessaris, Nicos AU - Kessaris N AD - Guys and St Thomas' NHS Foundation Trust, London, UK. FAU - Stojanovic, Jelena AU - Stojanovic J AD - Great Ormond Street Hospital for Children NHS Foundation Trust, Great Ormond Street, WC1N 3JH, London, UK. jelena.stojanovic@gosh.nhs.uk. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20230225 PL - Germany TA - Pediatr Nephrol JT - Pediatric nephrology (Berlin, Germany) JID - 8708728 SB - IM MH - Child MH - Humans MH - Child, Preschool MH - *Liver Transplantation/adverse effects/methods MH - *Amino Acid Metabolism, Inborn Errors/complications MH - *Kidney Failure, Chronic/complications MH - Liver MH - *Kidney Transplantation/adverse effects/methods PMC - PMC10393894 OTO - NOTNLM OT - Abdominal wall transplantation OT - Kidney transplantation OT - Liver transplantation OT - Methylmalonic acidaemia OT - Paediatrics OT - Williams syndrome COIS- The authors declare no competing interests. EDAT- 2023/02/26 06:00 MHDA- 2023/08/04 06:43 PMCR- 2023/02/25 CRDT- 2023/02/25 11:13 PHST- 2022/11/28 00:00 [received] PHST- 2023/02/06 00:00 [accepted] PHST- 2023/02/06 00:00 [revised] PHST- 2023/08/04 06:43 [medline] PHST- 2023/02/26 06:00 [pubmed] PHST- 2023/02/25 11:13 [entrez] PHST- 2023/02/25 00:00 [pmc-release] AID - 10.1007/s00467-023-05906-0 [pii] AID - 5906 [pii] AID - 10.1007/s00467-023-05906-0 [doi] PST - ppublish SO - Pediatr Nephrol. 2023 Aug;38(8):2887-2896. doi: 10.1007/s00467-023-05906-0. Epub 2023 Feb 25. PMID- 36838359 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230228 IS - 2076-2607 (Print) IS - 2076-2607 (Electronic) IS - 2076-2607 (Linking) VI - 11 IP - 2 DP - 2023 Feb 3 TI - Targeted Therapy of Severe Infections Caused by Staphylococcus aureus in Critically Ill Adult Patients: A Multidisciplinary Proposal of Therapeutic Algorithms Based on Real-World Evidence. LID - 10.3390/microorganisms11020394 [doi] LID - 394 AB - (1) Introduction: To develop evidence-based algorithms for targeted antibiotic therapy of infections caused by Staphylococcus aureus in critically ill adult patients. (2) Methods: A multidisciplinary team of four experts had several rounds of assessment for developing algorithms concerning targeted antimicrobial therapy of severe infections caused by Staphylococcus aureus in critically ill patients. The literature search was performed by a researcher on PubMed-MEDLINE (until August 2022) to provide evidence for supporting therapeutic choices. Quality and strength of evidence was established according to a hierarchical scale of the study design. Two different algorithms were created, one for methicillin-susceptible Staphylococcus aureus (MSSA) and the other for methicillin-resistant Staphylococcus aureus (MRSA). The therapeutic options were categorized for each different site of infection and were selected also on the basis of pharmacokinetic/pharmacodynamic features. (3) Results: Cefazolin or oxacillin were the agents proposed for all of the different types of severe MSSA infections. The proposed targeted therapies for severe MRSA infections were different according to the infection site: daptomycin plus fosfomycin or ceftaroline or ceftobiprole for bloodstream infections, infective endocarditis, and/or infections associated with intracardiac/intravascular devices; ceftaroline or ceftobiprole for community-acquired pneumonia; linezolid alone or plus fosfomycin for infection-related ventilator-associated complications or for central nervous system infections; daptomycin alone or plus clindamycin for necrotizing skin and soft tissue infections. (4) Conclusions: We are confident that targeted therapies based on scientific evidence and optimization of the pharmacokinetic/pharmacodynamic features of antibiotic monotherapy or combo therapy may represent valuable strategies for treating MSSA and MRSA infections. FAU - Gatti, Milo AU - Gatti M AUID- ORCID: 0000-0003-3018-3779 AD - Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, 40138 Bologna, Italy. AD - Clinical Pharmacology Unit, Department for Integrated Infectious Risk Management, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy. FAU - Viaggi, Bruno AU - Viaggi B AD - Neurointensive Care Unit, Department of Anesthesiology, Careggi, University Hospital, 50134 Florence, Italy. FAU - Rossolini, Gian Maria AU - Rossolini GM AD - Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy. AD - Microbiology and Virology Unit, Florence Careggi University Hospital, 50134 Florence, Italy. AD - IRCCS Fondazione Don Carlo Gnocchi, 50143 Florence, Italy. FAU - Pea, Federico AU - Pea F AUID- ORCID: 0000-0002-6966-7167 AD - Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, 40138 Bologna, Italy. AD - Clinical Pharmacology Unit, Department for Integrated Infectious Risk Management, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy. FAU - Viale, Pierluigi AU - Viale P AD - Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, 40138 Bologna, Italy. AD - Infectious Diseases Unit, Department for Integrated Infectious Risk Management, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40126 Bologna, Italy. LA - eng PT - Journal Article DEP - 20230203 PL - Switzerland TA - Microorganisms JT - Microorganisms JID - 101625893 PMC - PMC9960997 OTO - NOTNLM OT - MRSA OT - MSSA OT - critically ill patients OT - multidisciplinary taskforce OT - targeted antibiotic therapy COIS- M.G. received personal fees from Angelini; B.V participated in advisory boards and in the speaker's bureau for and received research contracts, contributions, and study events from Abbott, Accelerate Diagnostics, Ada, Alifax, Angelini, Becton Dickinson, Bellco, Biomerieux, Biotest, Cepheid, Correvio, Gilead, Menarini, MSD Italia, Nordic Pharma, Pfizer, Shionogi, and Thermo Fisher Scientific; G.M.R participated in advisory boards and the speaker's bureau for and received research contracts, contributions, and travel grants from Accelerate, Angelini, Arrow, Beckman Biomedical Service, Coulter, Becton-Dickinson, bioMerieux, Cepheid, Hain Life Sciences, Menarini, Meridian, MSD, Nordic Pharma, Pfizer, Qiagen, Q-linea, Qpex, Quidel, Qvella, Roche, Seegene, Set-Lance, Shionogi, Symcel, ThermoFisher, VenatorX, and Zambon; F.P participated in the speaker's bureau for Angelini, Basilea Pharmaceutica, Gilead, Hikma, Merck Sharp & Dohme, Nordic Pharma, Pfizer, and Sanofi Aventis and participated in the advisory board for Angelini, Basilea Pharmaceutica, Correvio, Gilead, Merck Sharp & Dohme, Nordic Pharma, Novartis, Pfizer, and Thermo-Fisher. P.V has served as a consultant for Biomerieux, Gilead, Merck Sharp & Dohme, Nabriva, Nordic Pharma, Pfizer, Thermo-Fisher, and Venatorx and received payment for serving on the speaker's bureau for Correvio, Gilead, Merck Sharp & Dohme, Nordic Pharma, and Pfizer. The authors report no other conflicts of interest in this work. EDAT- 2023/02/26 06:00 MHDA- 2023/02/26 06:01 PMCR- 2023/02/03 CRDT- 2023/02/25 03:48 PHST- 2023/01/13 00:00 [received] PHST- 2023/01/30 00:00 [revised] PHST- 2023/02/01 00:00 [accepted] PHST- 2023/02/25 03:48 [entrez] PHST- 2023/02/26 06:00 [pubmed] PHST- 2023/02/26 06:01 [medline] PHST- 2023/02/03 00:00 [pmc-release] AID - microorganisms11020394 [pii] AID - microorganisms-11-00394 [pii] AID - 10.3390/microorganisms11020394 [doi] PST - epublish SO - Microorganisms. 2023 Feb 3;11(2):394. doi: 10.3390/microorganisms11020394. PMID- 36836734 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230301 IS - 2075-1729 (Print) IS - 2075-1729 (Electronic) IS - 2075-1729 (Linking) VI - 13 IP - 2 DP - 2023 Jan 30 TI - Current Views on Infective Endocarditis: Changing Epidemiology, Improving Diagnostic Tools and Centering the Patient for Up-to-Date Management. LID - 10.3390/life13020377 [doi] LID - 377 AB - Infective endocarditis (IE) is a rare but potentially life-threatening disease, sometimes with longstanding sequels among surviving patients. The population at high risk of IE is represented by patients with underlying structural heart disease and/or intravascular prosthetic material. Taking into account the increasing number of intravascular and intracardiac procedures associated with device implantation, the number of patients at risk is growing too. If bacteremia develops, infected vegetation on the native/prosthetic valve or any intracardiac/intravascular device may occur as the final result of invading microorganisms/host immune system interaction. In the case of IE suspicion, all efforts must be focused on the diagnosis as IE can spread to almost any organ in the body. Unfortunately, the diagnosis of IE might be difficult and require a combination of clinical examination, microbiological assessment and echocardiographic evaluation. There is a need of novel microbiological and imaging techniques, especially in cases of blood culture-negative. In the last few years, the management of IE has changed. A multidisciplinary care team, including experts in infectious diseases, cardiology and cardiac surgery, namely, the Endocarditis Team, is highly recommended by the current guidelines. FAU - Cimmino, Giovanni AU - Cimmino G AUID- ORCID: 0000-0002-3802-7052 AD - Department of Translational Medical Sciences, Section of Cardiology, University of Campania Luigi Vanvitelli, 80131 Naples, Italy. FAU - Bottino, Roberta AU - Bottino R AD - Cardiology Unit, Azienda Ospedaliera Universitaria Luigi Vanvitelli, 80138 Napoli, Italy. FAU - Formisano, Tiziana AU - Formisano T AD - Cardiology Unit, Azienda Ospedaliera Universitaria Luigi Vanvitelli, 80138 Napoli, Italy. FAU - Orlandi, Massimiliano AU - Orlandi M AD - Cardiology Unit, Azienda Ospedaliera Universitaria Luigi Vanvitelli, 80138 Napoli, Italy. FAU - Molinari, Daniele AU - Molinari D AD - Cardiology Unit, Azienda Ospedaliera Universitaria Luigi Vanvitelli, 80138 Napoli, Italy. FAU - Sperlongano, Simona AU - Sperlongano S AD - Department of Translational Medical Sciences, Section of Cardiology, University of Campania Luigi Vanvitelli, 80131 Naples, Italy. FAU - Castaldo, Pasquale AU - Castaldo P AD - Cardiology Unit, Azienda Ospedaliera Universitaria Luigi Vanvitelli, 80138 Napoli, Italy. FAU - D'Elia, Saverio AU - D'Elia S AUID- ORCID: 0000-0001-5415-1953 AD - Cardiology Unit, Azienda Ospedaliera Universitaria Luigi Vanvitelli, 80138 Napoli, Italy. FAU - Carbone, Andreina AU - Carbone A AUID- ORCID: 0000-0002-2190-7010 AD - Cardiology Unit, Azienda Ospedaliera Universitaria Luigi Vanvitelli, 80138 Napoli, Italy. FAU - Palladino, Alberto AU - Palladino A AD - Cardiology Unit, Azienda Ospedaliera Universitaria Luigi Vanvitelli, 80138 Napoli, Italy. FAU - Forte, Lavinia AU - Forte L AD - Cardiology Unit, Azienda Ospedaliera Universitaria Luigi Vanvitelli, 80138 Napoli, Italy. FAU - Coppolino, Francesco AU - Coppolino F AUID- ORCID: 0000-0002-1362-7393 AD - Department of Women, Child and General and Specialized Surgery, Section of Anaesthesiology, University of Campania Luigi Vanvitelli, Piazza Miraglia 2, 80138 Naples, Italy. FAU - Torella, Michele AU - Torella M AD - Department of Translational Medical Sciences, Section of Cardiac Surgery and Heart Transplant, University of Campania Luigi Vanvitelli, 81100 Caserta, Italy. FAU - Coppola, Nicola AU - Coppola N AUID- ORCID: 0000-0001-5897-4949 AD - Department of Mental Health and Public Medicine, Section of Infectious Diseases, University of Campania Luigi Vanvitelli, 81100 Caserta, Italy. LA - eng PT - Journal Article PT - Review DEP - 20230130 PL - Switzerland TA - Life (Basel) JT - Life (Basel, Switzerland) JID - 101580444 PMC - PMC9965398 OTO - NOTNLM OT - antibiotics OT - imaging technique OT - infection OT - multidisciplinary team COIS- The authors declare no conflict of interest. EDAT- 2023/02/26 06:00 MHDA- 2023/02/26 06:01 PMCR- 2023/01/30 CRDT- 2023/02/25 03:18 PHST- 2022/12/10 00:00 [received] PHST- 2023/01/08 00:00 [revised] PHST- 2023/01/23 00:00 [accepted] PHST- 2023/02/25 03:18 [entrez] PHST- 2023/02/26 06:00 [pubmed] PHST- 2023/02/26 06:01 [medline] PHST- 2023/01/30 00:00 [pmc-release] AID - life13020377 [pii] AID - life-13-00377 [pii] AID - 10.3390/life13020377 [doi] PST - epublish SO - Life (Basel). 2023 Jan 30;13(2):377. doi: 10.3390/life13020377. PMID- 36836527 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230227 IS - 2075-4426 (Print) IS - 2075-4426 (Electronic) IS - 2075-4426 (Linking) VI - 13 IP - 2 DP - 2023 Feb 6 TI - Management of Vascular Access in the Setting of Percutaneous Mechanical Circulatory Support (pMCS): Sheaths, Vascular Access and Closure Systems. LID - 10.3390/jpm13020293 [doi] LID - 293 AB - The use of percutaneous mechanical circulatory support (pMCS), such as intra-aortic balloon pump, Impella, TandemHeart and VA-ECMO, in the setting of cardiogenic shock or in protect percutaneous coronary intervention (protect-PCI) is rapidly increasing in clinical practice. The major problem related to the use of pMCS is the management of all the device-related complications and of any vascular injury. MCS often requires large-bore access, if compared with common PCI, and for this reason the correct management of vascular access is a crucial point. The correct use of these devices in catheterization laboratories requires specific knowledge such as the correct evaluation of the vascular access performed, when possible, with advance imaging techniques in order to choose a percutaneous or a surgical approach. In addition to conventional transfemoral access, other types of access, such as transaxillary/subclavial access and the transcaval approach, have emerged over the years. These other approaches require advanced skills of the operators and a multidisciplinary team with dedicated physicians. Another important part of the management of vascular access is the closure systems used for hemostasis. Currently, two types of devices are typically used in the lab: suture-based or plug-based ones. In this review we want to describe all these aspects related to the management of vascular access in pMCS and describe, finally, a case report from our center's experience. FAU - Sardone, Andrea AU - Sardone A AD - Division of Cardiology, San Giovanni Bosco Hospital, ASL Citta di Torino, 10100 Turin, Italy. FAU - Franchin, Luca AU - Franchin L AUID- ORCID: 0000-0001-6221-482X AD - Division of Cardiology, San Giovanni Bosco Hospital, ASL Citta di Torino, 10100 Turin, Italy. FAU - Moniaci, Diego AU - Moniaci D AUID- ORCID: 0000-0003-4324-6126 AD - Division of Vascular Surgery, San Giovanni Bosco Hospital, ASL Citta di Torino, 10100 Turin, Italy. FAU - Colangelo, Salvatore AU - Colangelo S AD - Division of Cardiology, San Giovanni Bosco Hospital, ASL Citta di Torino, 10100 Turin, Italy. FAU - Colombo, Francesco AU - Colombo F AD - Division of Cardiology, San Giovanni Bosco Hospital, ASL Citta di Torino, 10100 Turin, Italy. FAU - Boccuzzi, Giacomo AU - Boccuzzi G AD - Division of Cardiology, San Giovanni Bosco Hospital, ASL Citta di Torino, 10100 Turin, Italy. FAU - Iannaccone, Mario AU - Iannaccone M AUID- ORCID: 0000-0003-0571-3918 AD - Division of Cardiology, San Giovanni Bosco Hospital, ASL Citta di Torino, 10100 Turin, Italy. LA - eng PT - Journal Article PT - Review DEP - 20230206 PL - Switzerland TA - J Pers Med JT - Journal of personalized medicine JID - 101602269 PMC - PMC9960206 OTO - NOTNLM OT - cardiogenic shock OT - mechanical circulatory support OT - protect-PCI OT - vascular management COIS- The authors declare no conflict of interest. EDAT- 2023/02/26 06:00 MHDA- 2023/02/26 06:01 PMCR- 2023/02/06 CRDT- 2023/02/25 03:14 PHST- 2022/11/17 00:00 [received] PHST- 2023/01/30 00:00 [revised] PHST- 2023/01/31 00:00 [accepted] PHST- 2023/02/25 03:14 [entrez] PHST- 2023/02/26 06:00 [pubmed] PHST- 2023/02/26 06:01 [medline] PHST- 2023/02/06 00:00 [pmc-release] AID - jpm13020293 [pii] AID - jpm-13-00293 [pii] AID - 10.3390/jpm13020293 [doi] PST - epublish SO - J Pers Med. 2023 Feb 6;13(2):293. doi: 10.3390/jpm13020293. PMID- 36836147 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250104 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 12 IP - 4 DP - 2023 Feb 17 TI - Exploring the Cardiotoxicity Spectrum of Anti-Cancer Treatments: Definition, Classification, and Diagnostic Pathways. LID - 10.3390/jcm12041612 [doi] LID - 1612 AB - Early detection and treatment of cancer have led to a noticeable reduction in both mortality and morbidity. However, chemotherapy and radiotherapy could exert cardiovascular (CV) side effects, impacting survival and quality of life, independent of the oncologic prognosis. In this regard, a high clinical index of suspicion is required by the multidisciplinary care team in order to trigger specific laboratory tests (namely natriuretic peptides and high-sensitivity cardiac troponin) and appropriate imaging techniques (transthoracic echocardiography along with cardiac magnetic resonance, cardiac computed tomography, and nuclear testing (if clinically indicated)), leading to timely diagnosis. In the near future, we do expect a more tailored approach to patient care within the respective community along with the widespread implementation of digital health tools. FAU - Mauro, Ciro AU - Mauro C AD - Cardiology Division, Antonio Cardarelli Hospital, Via Cardarelli, 9, 80131 Naples, Italy. FAU - Capone, Valentina AU - Capone V AUID- ORCID: 0000-0002-0080-9948 AD - Cardiology Division, Antonio Cardarelli Hospital, Via Cardarelli, 9, 80131 Naples, Italy. AD - Department of Advanced Biomedical Sciences, University of Naples Federico II, Via Sergio Pansini, 5, 80131 Naples, Italy. FAU - Cocchia, Rosangela AU - Cocchia R AD - Cardiology Division, Antonio Cardarelli Hospital, Via Cardarelli, 9, 80131 Naples, Italy. FAU - Cademartiri, Filippo AU - Cademartiri F AUID- ORCID: 0000-0002-0579-3279 AD - Department of Radiology, Fondazione G. Monasterio CNR-Regione Toscana, Via Moruzzi, 1, 56124 Pisa, Italy. FAU - Riccardi, Ferdinando AU - Riccardi F AD - Oncology Unit, Antonio Cardarelli Hospital, Via Cardarelli, 9, 80131 Naples, Italy. FAU - Arcopinto, Michele AU - Arcopinto M AD - Department of Translational Medical Sciences, Federico II University, 80138 Naples, Italy. FAU - Alshahid, Maie AU - Alshahid M AD - The Heart Centre, King Faisal Specialist Hospital & Research Centre, Riyadh 11564, Saudi Arabia. FAU - Anwar, Kashif AU - Anwar K AD - The Heart Centre, King Faisal Specialist Hospital & Research Centre, Riyadh 11564, Saudi Arabia. FAU - Carafa, Mariano AU - Carafa M AD - Emergency Medicine Division, Antonio Cardarelli Hospital, Via Cardarelli, 9, 80131 Naples, Italy. FAU - Carbone, Andreina AU - Carbone A AUID- ORCID: 0000-0002-2190-7010 AD - Unit of Cardiology, Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", Monaldi Hospital, 80131 Naples, Italy. FAU - Castaldo, Rossana AU - Castaldo R AUID- ORCID: 0000-0003-4143-1678 AD - IRCCS SYNLAB SDN, Via Emanuele Gianturco, 113, 80143 Naples, Italy. FAU - Chianese, Salvatore AU - Chianese S AD - Cardiology Division, Antonio Cardarelli Hospital, Via Cardarelli, 9, 80131 Naples, Italy. AD - Department of Advanced Biomedical Sciences, University of Naples Federico II, Via Sergio Pansini, 5, 80131 Naples, Italy. FAU - Crisci, Giulia AU - Crisci G AD - Department of Translational Medical Sciences, Federico II University, 80138 Naples, Italy. FAU - D'Assante, Roberta AU - D'Assante R AUID- ORCID: 0000-0001-6729-374X AD - Department of Translational Medical Sciences, Federico II University, 80138 Naples, Italy. FAU - De Luca, Mariarosaria AU - De Luca M AUID- ORCID: 0000-0002-6727-5725 AD - Department of Translational Medical Sciences, Federico II University, 80138 Naples, Italy. FAU - Franzese, Monica AU - Franzese M AUID- ORCID: 0000-0002-6490-7694 AD - IRCCS SYNLAB SDN, Via Emanuele Gianturco, 113, 80143 Naples, Italy. FAU - Galzerano, Domenico AU - Galzerano D AUID- ORCID: 0000-0002-9682-3815 AD - The Heart Centre, King Faisal Specialist Hospital & Research Centre, Riyadh 11564, Saudi Arabia. FAU - Maffei, Vincenzo AU - Maffei V AD - Post Operative Intensive Care Division, Antonio Cardarelli Hospital, 9, 80131 Naples, Italy. FAU - Marra, Alberto Maria AU - Marra AM AD - Department of Translational Medical Sciences, Federico II University, 80138 Naples, Italy. FAU - Mazza, Alfredo AU - Mazza A AD - Unit of Cardiology, Camerino Hospital, 62032 Macerata, Italy. FAU - Ranieri, Brigida AU - Ranieri B AUID- ORCID: 0000-0003-4880-5679 AD - IRCCS SYNLAB SDN, Via Emanuele Gianturco, 113, 80143 Naples, Italy. FAU - D'Agostino, Anna AU - D'Agostino A AUID- ORCID: 0000-0002-1394-4786 AD - IRCCS SYNLAB SDN, Via Emanuele Gianturco, 113, 80143 Naples, Italy. FAU - Rega, Salvatore AU - Rega S AD - Department of Public Health, University Federico II of Naples, Via Sergio Pansini, 5, 80131 Naples, Italy. FAU - Romano, Luigia AU - Romano L AD - Department of General and Emergency Radiology, Antonio Cardarelli Hospital, Via Cardarelli, 9, 80131 Naples, Italy. FAU - Scagliarini, Sarah AU - Scagliarini S AUID- ORCID: 0000-0001-5814-2296 AD - Oncology Unit, Antonio Cardarelli Hospital, Via Cardarelli, 9, 80131 Naples, Italy. FAU - Sepe, Chiara AU - Sepe C AD - Technical Nursing and Rehabilitation Service (SITR) Department, Cardarelli Hospital, 80131 Naples, Italy. FAU - Vriz, Olga AU - Vriz O AD - The Heart Centre, King Faisal Specialist Hospital & Research Centre, Riyadh 11564, Saudi Arabia. FAU - Izzo, Raffaele AU - Izzo R AUID- ORCID: 0000-0002-0308-2836 AD - Department of Advanced Biomedical Sciences, University of Naples Federico II, Via Sergio Pansini, 5, 80131 Naples, Italy. FAU - Cittadini, Antonio AU - Cittadini A AD - Department of Translational Medical Sciences, Federico II University, 80138 Naples, Italy. FAU - Bossone, Eduardo AU - Bossone E AUID- ORCID: 0000-0003-2769-9950 AD - Department of Public Health, University Federico II of Naples, Via Sergio Pansini, 5, 80131 Naples, Italy. FAU - Salzano, Andrea AU - Salzano A AUID- ORCID: 0000-0003-2352-2103 AD - IRCCS SYNLAB SDN, Via Emanuele Gianturco, 113, 80143 Naples, Italy. LA - eng PT - Journal Article PT - Review DEP - 20230217 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC9962102 OTO - NOTNLM OT - cancer therapy-related cardiovascular toxicity OT - cardio-oncology OT - chemotherapy COIS- The authors declare that there is no conflict of interest. EDAT- 2023/02/26 06:00 MHDA- 2023/02/26 06:01 PMCR- 2023/02/17 CRDT- 2023/02/25 03:07 PHST- 2022/12/28 00:00 [received] PHST- 2023/02/14 00:00 [revised] PHST- 2023/02/15 00:00 [accepted] PHST- 2023/02/25 03:07 [entrez] PHST- 2023/02/26 06:00 [pubmed] PHST- 2023/02/26 06:01 [medline] PHST- 2023/02/17 00:00 [pmc-release] AID - jcm12041612 [pii] AID - jcm-12-01612 [pii] AID - 10.3390/jcm12041612 [doi] PST - epublish SO - J Clin Med. 2023 Feb 17;12(4):1612. doi: 10.3390/jcm12041612. PMID- 36830266 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240913 IS - 2079-6382 (Print) IS - 2079-6382 (Electronic) IS - 2079-6382 (Linking) VI - 12 IP - 2 DP - 2023 Feb 8 TI - Outpatient Parenteral Antimicrobial Therapy for Infective Endocarditis-Model of Care. LID - 10.3390/antibiotics12020355 [doi] LID - 355 AB - Infective endocarditis (IE) is a serious infectious disease with significant mortality and morbidity placing a burden on healthcare systems. Outpatient antimicrobial therapy in selected patients has been shown to be safe and beneficial to both patients and the healthcare system. In this article, we review the literature on the model of care for outpatient parenteral antimicrobial therapy in infective endocarditis and propose that systems of care be developed based on local resources and all patients admitted with infective endocarditis be screened appropriately for outpatient antimicrobial therapy. FAU - Rajaratnam, Dylan AU - Rajaratnam D AD - Liverpool Hospital, Sydney, NSW 2170, Australia. FAU - Rajaratnam, Rohan AU - Rajaratnam R AUID- ORCID: 0000-0002-7643-0221 AD - Liverpool Hospital, Sydney, NSW 2170, Australia. AD - School of Medicine, Western Sydney University, Campbelltown Campus, Sydney, NSW 2560, Australia. AD - School of Medicine, Southwest Clinical School, The University of New South Wales, Sydney, NSW 2170, Australia. LA - eng PT - Journal Article DEP - 20230208 PL - Switzerland TA - Antibiotics (Basel) JT - Antibiotics (Basel, Switzerland) JID - 101637404 PMC - PMC9952299 OTO - NOTNLM OT - OPAT OT - infective endocarditis OT - multidisciplinary team COIS- The authors declare no conflict of interest. EDAT- 2023/02/26 06:00 MHDA- 2023/02/26 06:01 PMCR- 2023/02/08 CRDT- 2023/02/25 01:15 PHST- 2022/12/28 00:00 [received] PHST- 2023/02/01 00:00 [revised] PHST- 2023/02/06 00:00 [accepted] PHST- 2023/02/25 01:15 [entrez] PHST- 2023/02/26 06:00 [pubmed] PHST- 2023/02/26 06:01 [medline] PHST- 2023/02/08 00:00 [pmc-release] AID - antibiotics12020355 [pii] AID - antibiotics-12-00355 [pii] AID - 10.3390/antibiotics12020355 [doi] PST - epublish SO - Antibiotics (Basel). 2023 Feb 8;12(2):355. doi: 10.3390/antibiotics12020355. PMID- 36821026 OWN - NLM STAT- MEDLINE DCOM- 20230406 LR - 20250103 IS - 1865-8652 (Electronic) IS - 0741-238X (Print) IS - 0741-238X (Linking) VI - 40 IP - 4 DP - 2023 Apr TI - GLP-1 RAs in Spain: A Short Narrative Review of Their Use in Real Clinical Practice. PG - 1418-1429 LID - 10.1007/s12325-023-02442-z [doi] AB - Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are a class of drugs with potent glucose-lowering activity. Additionally, some GLP-1 RAs have demonstrated cardiovascular and renal benefits. Current guidelines recommend their use in patients with type 2 diabetes (T2D) at high risk of or with established cardiovascular disease (CVD), regardless of glycaemic control, with lifestyle modification and metformin. However, several studies have recently highlighted the limited number of patients with T2D benefiting from these medications worldwide. Given the huge burden of CVD among patients with T2D, efforts should be made to bring clinical practice closer to expert guidelines. This review describes the current situation of GLP-1 RA use in Spain and the reasons behind the gap between guidelines and real-world practice and suggests possible solutions. Administrative issues, lack of awareness of the cardiovascular benefits, clinical inertia, rejection of injectable medication and costs could be some of the reasons for the current situation. Possible strategies that could help to close the gap include encouraging a multidisciplinary approach to the treatment of diabetes which involves cardiologists, endocrinologists, nephrologists, primary care providers and pharmacists; improved awareness of comorbidities and earlier evaluation and treatment or risks; and better education of healthcare providers regarding the cardioprotective benefits of these drugs. CI - (c) 2023. The Author(s). FAU - Romera, Irene AU - Romera I AUID- ORCID: 0000-0002-1345-9799 AD - Eli Lilly and Company, Avda. de la Industria 30, 28108, Alcobendas, Madrid, Spain. romera_irene@lilly.com. FAU - Rubio-de Santos, Miriam AU - Rubio-de Santos M AUID- ORCID: 0000-0001-7393-6334 AD - Eli Lilly and Company, Avda. de la Industria 30, 28108, Alcobendas, Madrid, Spain. FAU - Artola, Sara AU - Artola S AUID- ORCID: 0000-0002-6713-7197 AD - Centro de Salud Jose Marva, Madrid, Spain. FAU - Suarez Fernandez, Carmen AU - Suarez Fernandez C AUID- ORCID: 0000-0002-6008-0693 AD - Hospital de La Princesa, Madrid, Spain. FAU - Conget, Ignacio AU - Conget I AUID- ORCID: 0000-0002-5532-5449 AD - Hospital Clinic Barcelona, Barcelona, Spain. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20230223 PL - United States TA - Adv Ther JT - Advances in therapy JID - 8611864 RN - 89750-14-1 (Glucagon-Like Peptide 1) RN - 0 (Hypoglycemic Agents) RN - 0 (Glucagon-Like Peptide-1 Receptor Agonists) MH - Humans MH - *Cardiovascular Diseases/drug therapy/chemically induced MH - *Diabetes Mellitus, Type 2/complications/drug therapy MH - Glucagon-Like Peptide 1/antagonists & inhibitors MH - Hypoglycemic Agents/therapeutic use MH - Spain MH - Glucagon-Like Peptide-1 Receptor Agonists PMC - PMC10070220 OAB - The glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are a class of drugs that can be beneficial for patients with type 2 diabetes who are at high risk of cardiovascular complications, such as heart attacks. For this reason, the current clinical guidelines strongly recommend their use in these patients. Unfortunately, many patients with type 2 diabetes and high cardiovascular risk still do not benefit from these drugs. This review analyses the reasons for this situation in Spain, and proposes some possible solutions. The reasons for the low use of GLP-1 RAs could be related to doctors not updating a patient's diabetes medicine as often as they should, lack of awareness about the cardiovascular benefits of these drugs, fear of medicines that involve needles, administrative issues, and costs. Some of the possible strategies to improve the use of GLP-1 RAs among patients with type 2 diabetes with high cardiovascular risk could be to foster greater cooperation among specialists, increase awareness of the need to treat cardiovascular risk in patients with diabetes, and better education of doctors regarding the benefits of these drugs. OABL- eng OTO - NOTNLM OT - Cardiovascular disease OT - Clinical inertia OT - Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) OT - Type 2 diabetes mellitus EDAT- 2023/02/24 06:00 MHDA- 2023/04/05 06:42 PMCR- 2023/02/23 CRDT- 2023/02/23 11:34 PHST- 2022/11/22 00:00 [received] PHST- 2023/01/24 00:00 [accepted] PHST- 2023/04/05 06:42 [medline] PHST- 2023/02/24 06:00 [pubmed] PHST- 2023/02/23 11:34 [entrez] PHST- 2023/02/23 00:00 [pmc-release] AID - 10.1007/s12325-023-02442-z [pii] AID - 2442 [pii] AID - 10.1007/s12325-023-02442-z [doi] PST - ppublish SO - Adv Ther. 2023 Apr;40(4):1418-1429. doi: 10.1007/s12325-023-02442-z. Epub 2023 Feb 23. PMID- 36820361 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230224 IS - 2666-2507 (Electronic) IS - 2666-2507 (Linking) VI - 17 DP - 2023 Feb TI - Three-dimensional printing and virtual reconstruction in surgical planning of double-outlet right ventricle repair. PG - 138-150 LID - 10.1016/j.xjtc.2022.11.005 [doi] AB - OBJECTIVES: For more than a decade, 3-dimensional (3D) printing has been identified as an innovative tool for the surgical planning of double-outlet right ventricle (DORV). Nevertheless, lack of evidence concerning its benefits encourages us to identify valuable criteria for future prospective trials. METHODS: We conducted a retrospective study involving 10 patients with DORV operated between 2015 and 2019 in our center. During a preoperative multidisciplinary heart team meeting, we harvested surgical decisions following a 3-increment step process: (1) multimodal imaging; (2) 3D virtual valvular reconstruction (3DVVR); and (3) 3D-printed heart model (3DPHM). The primary outcome was the proportion of predicted surgical strategy following each of the 3 steps, compared with the institutional retrospective surgical strategy. The secondary outcome was the change of surgical strategy through 3D modalities compared with multimodal imaging. The incremental benefit of the 3DVVR and 3DPHM over multimodal imaging was then assessed. RESULTS: The operative strategy was predicted in 5 cases after multimodal imaging, in 9 cases after 3DVVR, and the 10 cases after 3DPHM. Compared with multimodal imaging, 3DVVR modified the strategy for 4 cases. One case was correctly predicted only after 3DPHM inspection. CONCLUSIONS: 3DVVR and 3DPHM improved multimodal imaging in the surgical planning of patients with DORV. 3DVVR allowed a better appreciation of the relationships between great vessels, valves, and ventricular septal defects. 3DPHM offers a realistic preoperative view at patient scale and enhances the evaluation of outflow tract obstruction. Our retrospective study demonstrates benefits of preoperative 3D modalities and supports future prospective trials to assess their impact on postoperative outcomes. CI - (c) 2022 The Author(s). FAU - Ponchant, Kevin AU - Ponchant K AD - Cardiovascular Radiology Unit, Geneva University Hospitals and University of Geneva, Geneva, Switzerland. FAU - Nguyen, Duy-Anh AU - Nguyen DA AD - Pediatric Cardiology Unit, Children's University Hospital, Geneva, Switzerland. FAU - Prsa, Milan AU - Prsa M AD - Division of Pediatric Cardiology, Woman-Mother-Child Department, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. AD - Centre Universitaire Romand de Cardiologie et Chirurgie Cardiaque Pediatrique, Geneva University Hospitals/Lausanne University Hospital, Geneva/Lausanne, Switzerland. FAU - Beghetti, Maurice AU - Beghetti M AD - Pediatric Cardiology Unit, Children's University Hospital, Geneva, Switzerland. AD - Centre Universitaire Romand de Cardiologie et Chirurgie Cardiaque Pediatrique, Geneva University Hospitals/Lausanne University Hospital, Geneva/Lausanne, Switzerland. FAU - Sologashvili, Tornike AU - Sologashvili T AD - Centre Universitaire Romand de Cardiologie et Chirurgie Cardiaque Pediatrique, Geneva University Hospitals/Lausanne University Hospital, Geneva/Lausanne, Switzerland. AD - Division of Cardiac Surgery, Geneva University Hospitals, Geneva, Switzerland. FAU - Vallee, Jean-Paul AU - Vallee JP AD - Cardiovascular Radiology Unit, Geneva University Hospitals and University of Geneva, Geneva, Switzerland. LA - eng PT - Journal Article DEP - 20221126 PL - United States TA - JTCVS Tech JT - JTCVS techniques JID - 101768546 PMC - PMC9938382 OTO - NOTNLM OT - 3D modality in surgical planning OT - 3D printed heart model OT - 3D printing OT - 3D virtual valvular reconstruction OT - 3D, 3-dimensional OT - 3DPHM, 3D-printed heart model OT - 3DVVR, 3D virtual valvular annulus reconstruction OT - CTA, computed tomography angiogram OT - DORV, double-outlet right ventricle OT - LV, left ventricle OT - PA, pulmonary artery OT - PV, pulmonary valve OT - TGA, transposition of the great arteries OT - TTE, transthoracic echocardiography OT - VSD, ventricular septal defect OT - double-outlet right ventricle EDAT- 2023/02/24 06:00 MHDA- 2023/02/24 06:01 PMCR- 2022/11/26 CRDT- 2023/02/23 10:36 PHST- 2022/07/22 00:00 [received] PHST- 2022/10/12 00:00 [revised] PHST- 2022/10/31 00:00 [accepted] PHST- 2023/02/23 10:36 [entrez] PHST- 2023/02/24 06:00 [pubmed] PHST- 2023/02/24 06:01 [medline] PHST- 2022/11/26 00:00 [pmc-release] AID - S2666-2507(22)00585-5 [pii] AID - 10.1016/j.xjtc.2022.11.005 [doi] PST - epublish SO - JTCVS Tech. 2022 Nov 26;17:138-150. doi: 10.1016/j.xjtc.2022.11.005. eCollection 2023 Feb. PMID- 36807306 OWN - NLM STAT- MEDLINE DCOM- 20230605 LR - 20260920 IS - 1529-7535 (Print) IS - 1529-7535 (Linking) VI - 24 IP - 6 DP - 2023 Jun 1 TI - Structured Multidisciplinary Follow-Up After Pediatric Intensive Care: A Model for Continuous Data-Driven Health Care Innovation. PG - 484-498 LID - 10.1097/PCC.0000000000003213 [doi] AB - OBJECTIVES: Morbidity after PICU admission for critical illness is a growing concern. Sequelae may occur in various domains of functioning and can only appropriately be determined through structured follow-up. Here, we describe the process of designing and implementing a structured multidisciplinary follow-up program for patients and their parents after PICU admission and show the first results illustrating the significance of our program. DESIGN: Prospective observational cohort study. SETTING: Outpatient PICU follow-up clinic. PATIENTS: Patients 0-18 years old admitted to our PICU. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: In our structured multidisciplinary follow-up program, follow-up care is provided by a pediatric intensivist and psychologist and in addition, depending on patient's critical illness and received PICU treatment(s), by a pediatric pulmonologist, cardiologist, neurologist, and/or neuropsychologist. All consultations are scheduled consecutively. Collected data are stored in a hospital-wide data warehouse and used for yearly health care evaluation sessions as well as scientific research. Challenges in organizing this follow-up program include technological challenges, providing time-efficient care, participation rate, and completeness of questionnaires. In our experience, a dedicated team is essential to tackle these challenges. Our first results, obtained in 307 of 388 referred patients (79.1%), showed the diversity of problems arising after PICU discharge, including physical, neurocognitive, and psychosocial sequelae. In addition, our data also reflected the risk of psychosocial problems among parents. Within the limited operation time of our follow-up program, the program has evolved based on our experiences and the data collected. CONCLUSIONS: We successfully developed and implemented a structured multidisciplinary follow-up program for patients and their parents after PICU admission. This program may help to timely initiate appropriate interventions, improve the standard of care during and after PICU admission, and facilitate scientific research on outcome and prognosis after PICU admission. CI - Copyright (c) 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies. FAU - de Sonnaville, Eleonore S V AU - de Sonnaville ESV AD - Amsterdam UMC, University of Amsterdam, Emma Children's Hospital, Department of Pediatric Intensive Care, Amsterdam Reproduction and Development Research Institute, Meibergdreef 9, Amsterdam, The Netherlands. AD - Amsterdam UMC, University of Amsterdam, Emma Children's Hospital, Department of Pediatrics, Emma Children's Hospital Amsterdam UMC Follow Me Program & Emma Neuroscience Group, Amsterdam Reproduction and Development Research Institute, Meibergdreef 9, Amsterdam, The Netherlands. FAU - van Woensel, Job B M AU - van Woensel JBM AD - Amsterdam UMC, University of Amsterdam, Emma Children's Hospital, Department of Pediatric Intensive Care, Amsterdam Reproduction and Development Research Institute, Meibergdreef 9, Amsterdam, The Netherlands. FAU - van Goudoever, Johannes B AU - van Goudoever JB AD - Amsterdam UMC, University of Amsterdam & Vrije Universiteit, Emma Children's Hospital, Department of Pediatrics, Amsterdam Reproduction and Development Research Institute, Meibergdreef 9, Amsterdam, The Netherlands. FAU - Otten, Marieke H AU - Otten MH AD - Amsterdam UMC, University of Amsterdam, Emma Children's Hospital, Department of Pediatric Intensive Care, Amsterdam Reproduction and Development Research Institute, Meibergdreef 9, Amsterdam, The Netherlands. FAU - Teela, Lorynn AU - Teela L AD - Amsterdam UMC, University of Amsterdam, Emma Children's Hospital, Department of Child and Adolescent Psychiatry & Psychosocial Care, Amsterdam Reproduction and Development & Amsterdam Public Health Research Institutes, Meibergdreef 9, Amsterdam, The Netherlands. FAU - Aarnoudse-Moens, Cornelieke S H AU - Aarnoudse-Moens CSH AD - Amsterdam UMC, University of Amsterdam, Emma Children's Hospital, Department of Pediatrics, Emma Children's Hospital Amsterdam UMC Follow Me Program & Emma Neuroscience Group, Amsterdam Reproduction and Development Research Institute, Meibergdreef 9, Amsterdam, The Netherlands. AD - Amsterdam UMC, University of Amsterdam, Emma Children's Hospital, Department of Child and Adolescent Psychiatry & Psychosocial Care, Amsterdam Reproduction and Development & Amsterdam Public Health Research Institutes, Meibergdreef 9, Amsterdam, The Netherlands. FAU - Terheggen-Lagro, Suzanne W J AU - Terheggen-Lagro SWJ AD - Amsterdam UMC, University of Amsterdam, Emma Children's Hospital, Department of Pediatric Pulmonology and Allergy, Amsterdam Reproduction and Development & Infection and Immunity Research Institutes, Meibergdreef 9, Amsterdam, The Netherlands. FAU - van der Hulst, Annelies E AU - van der Hulst AE AD - Amsterdam UMC, University of Amsterdam, Emma Children's Hospital, Department of Pediatric Cardiology, Meibergdreef 9, Amsterdam, The Netherlands. FAU - Engelen, Marc AU - Engelen M AD - Amsterdam UMC, University of Amsterdam, Emma Children's Hospital, Department of Pediatric Neurology, Amsterdam Leukodystrophy Center, Amsterdam Neuroscience & Amsterdam Gastroenterology Endocrinology Metabolism Research Institutes, Meibergdreef 9, Amsterdam, The Netherlands. FAU - Kӧnigs, Marsh AU - Kӧnigs M AD - Amsterdam UMC, University of Amsterdam, Emma Children's Hospital, Department of Pediatrics, Emma Children's Hospital Amsterdam UMC Follow Me Program & Emma Neuroscience Group, Amsterdam Reproduction and Development Research Institute, Meibergdreef 9, Amsterdam, The Netherlands. FAU - Oosterlaan, Jaap AU - Oosterlaan J AD - Amsterdam UMC, University of Amsterdam, Emma Children's Hospital, Department of Pediatrics, Emma Children's Hospital Amsterdam UMC Follow Me Program & Emma Neuroscience Group, Amsterdam Reproduction and Development Research Institute, Meibergdreef 9, Amsterdam, The Netherlands. FAU - Knoester, Hennie AU - Knoester H AD - Amsterdam UMC, University of Amsterdam, Emma Children's Hospital, Department of Pediatric Intensive Care, Amsterdam Reproduction and Development Research Institute, Meibergdreef 9, Amsterdam, The Netherlands. CN - Emma Children's Hospital Amsterdam UMC Follow Me Program Consortium LA - eng PT - Journal Article PT - Observational Study PT - Research Support, Non-U.S. Gov't DEP - 20230217 PL - United States TA - Pediatr Crit Care Med JT - Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies JID - 100954653 SB - IM MH - Child MH - Humans MH - Infant MH - Infant, Newborn MH - Child, Preschool MH - Adolescent MH - Follow-Up Studies MH - Prospective Studies MH - *Critical Illness MH - *Critical Care MH - Delivery of Health Care MH - Intensive Care Units, Pediatric PMC - PMC10226472 COIS- Dr. de Sonnaville's institution received funding from Janivo and C.J. Vaillant. Dr. Konigs disclosed work for hire. The remaining authors have disclosed that they do not have any potential conflicts of interest. EDAT- 2023/02/23 06:00 MHDA- 2023/06/05 06:42 PMCR- 2023/05/29 CRDT- 2023/02/22 11:32 PHST- 2023/06/05 06:42 [medline] PHST- 2023/02/23 06:00 [pubmed] PHST- 2023/02/22 11:32 [entrez] PHST- 2023/05/29 00:00 [pmc-release] AID - 00130478-202306000-00007 [pii] AID - 10.1097/PCC.0000000000003213 [doi] PST - ppublish SO - Pediatr Crit Care Med. 2023 Jun 1;24(6):484-498. doi: 10.1097/PCC.0000000000003213. Epub 2023 Feb 17. PMID- 36804342 OWN - NLM STAT- MEDLINE DCOM- 20230606 LR - 20230823 IS - 1529-7535 (Print) IS - 1529-7535 (Linking) VI - 24 IP - 6 DP - 2023 Jun 1 TI - Improvement in Multidisciplinary Provider Rounding (Surgical Rounds) in the Pediatric Cardiac ICU: An Application of Lean Methodology. PG - e282-e291 LID - 10.1097/PCC.0000000000003218 [doi] AB - OBJECTIVES: Provider-only, combined surgical, and medical multidisciplinary rounds ("surgical rounds") are essential to achieve optimal outcomes in large pediatric cardiac ICUs. Lean methodology was applied with the aims of identifying areas of waste and nonvalue-added work within the surgical rounds process. Thereby, the goals were to improve rounding efficiency and reduce rounding duration while not sacrificing critical patient care discussion nor delaying bedside rounds or surgical start times. DESIGN: Single-center improvement science study with observational and interventional phases from February 2, 2021, to July 31, 2021. SETTING: Tertiary pediatric cardiac ICU. PARTICIPANTS: Cardiothoracic surgery and cardiac intensive care team members participating in daily "surgical" rounds. INTERVENTIONS: Implementation of technology automation, creation of work instructions, standardization of patient presentation content and order, provider training, and novel role assignment. MEASUREMENTS AND MAIN RESULTS: Sixty-one multidisciplinary rounds were observed (30 pre, 31 postintervention). During the preintervention period, identified inefficiencies included prolonged preparation time, redundant work, presentation variability and extraneous information, and frequent provider transitions. Application of targeted interventions resulted in a 26% decrease in indexed rounds duration (2.42 vs 1.8 min; p = 0.0003), 50% decrease in indexed rounds preparation time (0.53 vs 0.27 min; p < 0.0001), and 66% decrease in transition time between patients (0.09 vs 0.03 min; p < 0.0001). The number of presenting provider changes also decreased (9 vs 4; p < 0.0001). Indexed discussion duration did not change (1 vs 0.98 min; p = 0.08) nor did balancing measures (bedside rounds and surgical start times) change (8.5 vs 9 min; p = 0.89 and 38 vs 22 min; p = 0.09). CONCLUSIONS: Lean methodology can be effectively applied to multidisciplinary rounds in a joint cardiothoracic surgery/cardiac intensive care setting to decrease waste and inefficiency. Interventions resulted in decreased preparation time, transition time, presenting provider changes, total rounds duration indexed to patient census, and anecdotal improvements in provider satisfaction. CI - Copyright (c) 2023 by the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies. FAU - Brown, Tyler N AU - Brown TN AD - The Heart Institute, Division of Cardiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH. FAU - Justice, Lindsey AU - Justice L AD - The Heart Institute, Division of Cardiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH. FAU - Malik, Farhan AU - Malik F AD - The Heart Institute, Division of Cardiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH. AD - Department of Pediatrics, Johns Hopkins All Children's Hospital, St. Petersburg, FL. FAU - Lehenbauer, David AU - Lehenbauer D AD - The Heart Institute, Division of Cardiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH. FAU - O'Donnell, Alan AU - O'Donnell A AD - The Heart Institute, Division of Cardiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH. FAU - Brown, James M AU - Brown JM AD - James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH. FAU - Powers, Tricia AU - Powers T AD - James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH. FAU - Neogi, Smriti AU - Neogi S AD - James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH. FAU - Cooper, David S AU - Cooper DS AD - The Heart Institute, Division of Cardiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH. AD - Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH. FAU - Mah, Kenneth E AU - Mah KE AD - The Heart Institute, Division of Cardiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH. AD - Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH. AD - Department of Pediatrics, Stanford University School of Medicine, Palo Alto, CA. LA - eng PT - Journal Article PT - Observational Study PT - Research Support, Non-U.S. Gov't DEP - 20230217 PL - United States TA - Pediatr Crit Care Med JT - Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies JID - 100954653 SB - IM CIN - Pediatr Crit Care Med. 2023 Jun 1;24(6):531-533. doi: 10.1097/PCC.0000000000003230. PMID: 37260340 MH - Child MH - Humans MH - Critical Care MH - Intensive Care Units, Pediatric MH - *Patient Care Team MH - *Teaching Rounds/methods MH - Time Factors COIS- The authors have disclosed that they do not have any potential conflicts of interest. EDAT- 2023/02/23 06:00 MHDA- 2023/06/05 06:42 CRDT- 2023/02/22 08:39 PHST- 2023/06/05 06:42 [medline] PHST- 2023/02/23 06:00 [pubmed] PHST- 2023/02/22 08:39 [entrez] AID - 00130478-202306000-00020 [pii] AID - 10.1097/PCC.0000000000003218 [doi] PST - ppublish SO - Pediatr Crit Care Med. 2023 Jun 1;24(6):e282-e291. doi: 10.1097/PCC.0000000000003218. Epub 2023 Feb 17. PMID- 36803216 OWN - NLM STAT- MEDLINE DCOM- 20230327 LR - 20240523 IS - 2150-136X (Electronic) IS - 2150-1351 (Linking) VI - 14 IP - 2 DP - 2023 Mar TI - A Multidisciplinary Surgical Approach to Mediastinal Masses in Children. PG - 180-184 LID - 10.1177/21501351221133753 [doi] AB - The aim of this study is to demonstrate the safety and advantages of a multidisciplinary approach to surgical resection of mediastinal masses in children. Eight patients underwent resection of a mediastinal mass by a team involving both a pediatric general surgeon and pediatric cardiothoracic surgeon. One patient required rapid initiation of cardiopulmonary bypass to complete the tumor resection and repair an aortic injury that occurred when removing adherent tumor from the structure. Perioperative outcomes were excellent for all patients. This series shows that a multidisciplinary surgical approach can be potentially life saving. FAU - Miller, Vanessa M AU - Miller VM AUID- ORCID: 0000-0002-2673-2571 AD - Division of Cardiothoracic Surgery, Department of Surgery, 22078University of Alabama at Birmingham, Birmingham, AL, USA. FAU - Disharoon, Mitchell AU - Disharoon M AD - Division of Cardiothoracic Surgery, Department of Surgery, 22078University of Alabama at Birmingham, Birmingham, AL, USA. FAU - Padilla, Luz A AU - Padilla LA AD - Division of Cardiothoracic Surgery, Department of Surgery, 22078University of Alabama at Birmingham, Birmingham, AL, USA. FAU - Beierle, Elizabeth A AU - Beierle EA AD - Division of Pediatric Surgery, Department of Surgery, 22078University of Alabama at Birmingham, Birmingham, AL, USA. FAU - Dabal, Robert J AU - Dabal RJ AD - Division of Cardiothoracic Surgery, Department of Surgery, 22078University of Alabama at Birmingham, Birmingham, AL, USA. LA - eng PT - Journal Article DEP - 20230219 PL - United States TA - World J Pediatr Congenit Heart Surg JT - World journal for pediatric & congenital heart surgery JID - 101518415 SB - IM MH - Humans MH - Child MH - *Mediastinal Neoplasms/surgery MH - Cardiopulmonary Bypass OTO - NOTNLM OT - cardiopulmonary bypass OT - mediastinal tumor OT - mediastinum OT - outcomes OT - patient safety EDAT- 2023/02/22 06:00 MHDA- 2023/03/28 06:00 CRDT- 2023/02/21 17:51 PHST- 2023/02/22 06:00 [pubmed] PHST- 2023/03/28 06:00 [medline] PHST- 2023/02/21 17:51 [entrez] AID - 10.1177/21501351221133753 [doi] PST - ppublish SO - World J Pediatr Congenit Heart Surg. 2023 Mar;14(2):180-184. doi: 10.1177/21501351221133753. Epub 2023 Feb 19. PMID- 36796574 OWN - NLM STAT- MEDLINE DCOM- 20230411 LR - 20260105 IS - 1097-6744 (Electronic) IS - 0002-8703 (Print) IS - 0002-8703 (Linking) VI - 259 DP - 2023 May TI - Design and rationale of re-energize fontan: Randomized exercise intervention designed to maximize fitness in fontan patients. PG - 68-78 LID - S0002-8703(23)00040-6 [pii] LID - 10.1016/j.ahj.2023.02.006 [doi] AB - In this manuscript, we describe the design and rationale of a randomized controlled trial in pediatric Fontan patients to test the hypothesis that a live-video-supervised exercise (aerobic+resistance) intervention will improve cardiac and physical capacity; muscle mass, strength, and function; and endothelial function. Survival of children with single ventricles beyond the neonatal period has increased dramatically with the staged Fontan palliation. Yet, long-term morbidity remains high. By age 40, 50% of Fontan patients will have died or undergone heart transplantation. Factors that contribute to onset and progression of heart failure in Fontan patients remain incompletely understood. However, it is established that Fontan patients have poor exercise capacity which is associated with a greater risk of morbidity and mortality. Furthermore, decreased muscle mass, abnormal muscle function, and endothelial dysfunction in this patient population is known to contribute to disease progression. In adult patients with 2 ventricles and heart failure, reduced exercise capacity, muscle mass, and muscle strength are powerful predictors of poor outcomes, and exercise interventions can not only improve exercise capacity and muscle mass, but also reverse endothelial dysfunction. Despite these known benefits of exercise, pediatric Fontan patients do not exercise routinely due to their chronic condition, perceived restrictions to exercise, and parental overprotection. Limited exercise interventions in children with congenital heart disease have demonstrated that exercise is safe and effective; however, these studies have been conducted in small, heterogeneous groups, and most had few Fontan patients. Critically, adherence is a major limitation in pediatric exercise interventions delivered on-site, with adherence rates as low as 10%, due to distance from site, transportation difficulties, and missed school or workdays. To overcome these challenges, we utilize live-video conferencing to deliver the supervised exercise sessions. Our multidisciplinary team of experts will assess the effectiveness of a live-video-supervised exercise intervention, rigorously designed to maximize adherence, and improve key and novel measures of health in pediatric Fontan patients associated with poor long-term outcomes. Our ultimate goal is the translation of this model to clinical application as an "exercise prescription" to intervene early in pediatric Fontan patients and decrease long-term morbidity and mortality. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Selamet Tierney, Elif Seda AU - Selamet Tierney ES AD - Department of Pediatrics, Division of Pediatric Cardiology, Stanford University, School of Medicine, Palo Alto, CA, USA. Electronic address: tierneys@stanford.edu. FAU - Palaniappan, Latha AU - Palaniappan L AD - Department of Medicine, Stanford University, School of Medicine, Palo Alto, CA, USA. FAU - Leonard, Mary AU - Leonard M AD - Department of Pediatrics, Division of Pediatric Nephrology, Stanford University, School of Medicine, Palo Alto, CA, USA. FAU - Long, Jin AU - Long J AD - Department of Pediatrics, Division of Pediatric Nephrology, Stanford University, School of Medicine, Palo Alto, CA, USA. FAU - Myers, Jonathan AU - Myers J AD - Department of Medicine, Health Research Science, Palo Alto VA Health Care System, Palo Alto, CA, USA. FAU - Davila, Tania AU - Davila T AD - Department of Pediatrics, Division of Pediatric Cardiology, Stanford University, School of Medicine, Palo Alto, CA, USA. FAU - Lui, Mavis C AU - Lui MC AD - Department of Pediatrics, Division of Pediatric Cardiology, Stanford University, School of Medicine, Palo Alto, CA, USA. FAU - Kogan, Feliks AU - Kogan F AD - Department of Radiology, Stanford University, School of Medicine, Palo Alto, CA, USA. FAU - Olson, Inger AU - Olson I AD - Department of Pediatrics, Division of Pediatric Cardiology, Stanford University, School of Medicine, Palo Alto, CA, USA. FAU - Punn, Rajesh AU - Punn R AD - Department of Pediatrics, Division of Pediatric Cardiology, Stanford University, School of Medicine, Palo Alto, CA, USA. FAU - Desai, Manisha AU - Desai M AD - Department of Biomedical Data Science, Stanford University, School of Medicine, Palo Alto, CA, USA. FAU - Schneider, Lauren M AU - Schneider LM AD - Psychiatry and Behavioral Sciences - Child & Adolescent Psychiatry and Child Development, Palo Alto, CA, USA. FAU - Wang, Chih-Hung AU - Wang CH AD - Department of Pediatrics, Health Policy, Stanford University, School of Medicine, Palo Alto, CA, USA. FAU - Cooke, John P AU - Cooke JP AD - Houston Methodist Research Institute Houston Methodist Hospital & Research Institute, Houston, Texas, USA. FAU - Bernstein, Daniel AU - Bernstein D AD - Department of Pediatrics, Division of Pediatric Cardiology, Stanford University, School of Medicine, Palo Alto, CA, USA. LA - eng SI - ClinicalTrials.gov/NCT04195451 GR - K24 HL150476/HL/NHLBI NIH HHS/United States GR - R33 HL146775/HL/NHLBI NIH HHS/United States GR - R61 HL146775/HL/NHLBI NIH HHS/United States PT - Clinical Trial Protocol PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20230214 PL - United States TA - Am Heart J JT - American heart journal JID - 0370465 SB - IM MH - Adult MH - Infant, Newborn MH - Humans MH - Child MH - Exercise/physiology MH - Exercise Therapy MH - *Heart Transplantation MH - Muscle Strength MH - Exercise Test MH - *Heart Failure MH - *Heart Defects, Congenital MH - *Fontan Procedure MH - Randomized Controlled Trials as Topic PMC - PMC10085861 MID - NIHMS1874449 COIS- Conflict of Interest: none EDAT- 2023/02/17 06:00 MHDA- 2023/04/11 06:42 PMCR- 2024/05/01 CRDT- 2023/02/16 19:25 PHST- 2022/12/06 00:00 [received] PHST- 2023/01/22 00:00 [revised] PHST- 2023/02/05 00:00 [accepted] PHST- 2023/04/11 06:42 [medline] PHST- 2023/02/17 06:00 [pubmed] PHST- 2023/02/16 19:25 [entrez] PHST- 2024/05/01 00:00 [pmc-release] AID - S0002-8703(23)00040-6 [pii] AID - 10.1016/j.ahj.2023.02.006 [doi] PST - ppublish SO - Am Heart J. 2023 May;259:68-78. doi: 10.1016/j.ahj.2023.02.006. Epub 2023 Feb 14. PMID- 36793669 OWN - NLM STAT- MEDLINE DCOM- 20230217 LR - 20240912 IS - 1540-8183 (Electronic) IS - 0896-4327 (Print) IS - 0896-4327 (Linking) VI - 2023 DP - 2023 TI - Prophylactic ECMO Support during Elective Coronary Percutaneous Interventions in High-Risk Patients: A Single-Center Experience. PG - 5332038 LID - 10.1155/2023/5332038 [doi] LID - 5332038 AB - INTRODUCTION: Evidence regarding the impact of prophylactic implantation of venoarterial extracorporeal membrane oxygenation (VA-ECMO) for elective high-risk percutaneous coronary intervention (PCI) is limited. The purpose of this paper is to evaluate the outcome during index hospitalization and 3 years after interventions. METHODS: This is an observational retrospective study including all patients undergoing elective, high-risk PCI and receiving VA-ECMO for cardiopulmonary support. Primary endpoints were in-hospital and 3- year major adverse cardiovascular and cerebrovascular event (MACCE) rates. Secondary endpoints were vascular complications, bleeding, and procedural success. RESULTS: Nine patients were included in total. All patients were considered inoperable by the local heart team, and 1 patient had a previous coronary artery bypass graft (CABG). All patients were hospitalized for an acute heart failure episode 30 days before the index procedure. Severe left ventricular dysfunction was present in 8 patients. The main target vessel was the left main coronary artery in 5 cases. Complex PCI techniques were used: bifurcations with 2 stents in 8 patients, rotational atherectomy was performed in 3, and coronary lithoplasty in 1 case. PCI was successful in all of the patients with revascularization of all target and additional lesions. Eight of the 9 patients survived for at least 30 days after the procedure, and 7 patients survived for 3 years after the procedure. Regarding the complication rate, 2 patients suffered from limb ischemia and were treated by an antegrade perfusion, 1 patient had a femoral perforation that needed surgical repair, 6 patients had a hematoma, 5 patients had a significant drop in hemoglobin of more than 2 g/dl and received blood transfusions, 2 patients were treated for septicemia, and 2 patients needed hemodialysis. CONCLUSIONS: Prophylactic use of VA-ECMO in elective patients is an acceptable strategy for revascularization by high-risk coronary percutaneous interventions with good long-term outcomes for patients considered inoperable when a clear clinical benefit is expected. Regarding the potential risk of complications due to a VA-ECMO system, the selection of candidates in our series was based on a multiparameter analysis. The two main triggers in favor of prophylactic VA-ECMO in our studies were the presence of a recent heart failure episode and the high probability of periprocedural prolonged impairment of the coronary flow through the major epicardial artery. CI - Copyright (c) 2023 Claudiu Ungureanu et al. FAU - Ungureanu, Claudiu AU - Ungureanu C AUID- ORCID: 0000-0002-1583-5882 AD - Cardiovascular Department, Jolimont Hospital, La Louviere, Belgium. FAU - Blaimont, Marc AU - Blaimont M AD - Cardiovascular Department, Jolimont Hospital, La Louviere, Belgium. FAU - Trine, Hugues AU - Trine H AD - Intensive Care Department, Jolimont Hospital, La Louviere, Belgium. FAU - Henin, Pierre AU - Henin P AD - Intensive Care Department, Jolimont Hospital, La Louviere, Belgium. FAU - Courcelle, Romain AU - Courcelle R AD - Intensive Care Department, Jolimont Hospital, La Louviere, Belgium. FAU - Laurent, Yves AU - Laurent Y AD - Intensive Care Department, Jolimont Hospital, La Louviere, Belgium. FAU - Van Ruyssevelt, Patrick AU - Van Ruyssevelt P AD - Cardiothoracic Surgery Department, Jolimont Hospital, La Louviere, Belgium. FAU - Lepiece, Caroline AU - Lepiece C AD - Cardiovascular Department, Jolimont Hospital, La Louviere, Belgium. FAU - Huberlant, Vincent AU - Huberlant V AD - Intensive Care Department, Jolimont Hospital, La Louviere, Belgium. LA - eng PT - Journal Article PT - Observational Study DEP - 20230204 PL - United States TA - J Interv Cardiol JT - Journal of interventional cardiology JID - 8907826 SB - IM MH - Humans MH - *Percutaneous Coronary Intervention/adverse effects/methods MH - *Extracorporeal Membrane Oxygenation/adverse effects/methods MH - Retrospective Studies MH - Coronary Artery Bypass/methods MH - *Heart Failure MH - Treatment Outcome PMC - PMC9922177 COIS- The authors declare that they have no conflicts of interest. EDAT- 2023/02/17 06:00 MHDA- 2023/02/18 06:00 PMCR- 2023/02/04 CRDT- 2023/02/16 02:19 PHST- 2022/07/06 00:00 [received] PHST- 2022/10/17 00:00 [revised] PHST- 2022/11/25 00:00 [accepted] PHST- 2023/02/16 02:19 [entrez] PHST- 2023/02/17 06:00 [pubmed] PHST- 2023/02/18 06:00 [medline] PHST- 2023/02/04 00:00 [pmc-release] AID - 10.1155/2023/5332038 [doi] PST - epublish SO - J Interv Cardiol. 2023 Feb 4;2023:5332038. doi: 10.1155/2023/5332038. eCollection 2023. PMID- 36791329 OWN - NLM STAT- MEDLINE DCOM- 20230907 LR - 20240902 IS - 1557-7740 (Electronic) IS - 1096-6218 (Print) IS - 1557-7740 (Linking) VI - 26 IP - 9 DP - 2023 Sep TI - Top Ten Tips Palliative Care Clinicians Should Know About Working With Adults Receiving Extracorporeal Membrane Oxygenation. PG - 1270-1276 LID - 10.1089/jpm.2023.0017 [doi] AB - Extracorporeal membrane oxygenation (ECMO) is an invasive intervention that is both resource- and labor-intensive. It can also be emotionally challenging for all involved. Palliative care (PC) clinicians can support adult patients, families, surrogate decision makers, and the interdisciplinary team (IDT) throughout ECMO, starting at the time of ECMO initiation through discontinuation and to bereavement in the event of a patient's death. In addition to knowing the basics of ECMO circuitry, indications to start ECMO, and the complex decision points throughout treatment, PC clinicians must understand the critical need for specialist and IDT coordination when discussing prognosis and resuscitation, clarifying goals of care, and identifying future treatment options. Not only are PC clinicians' skills needed to manage symptoms and psychosocial needs but also during end-of-life care, which can often be rapid and requires team consensus to ensure a smooth clinical process with continuous family support. While using their expert communication skills to conduct frequent family meetings, ideally starting within one week of ECMO initiation and weekly thereafter, PC clinicians offer a consistent presence and "big picture" perspective for patients and families, while other members of the IDT may rotate regularly. PC clinicians will also be called on to assist members of the IDT to debrief about the understandable moral and emotional distress they may experience while providing care for patients receiving ECMO and their families. FAU - Grouls, Astrid AU - Grouls A AD - Department of Medicine, Section of Geriatrics and Palliative Medicine, Baylor College of Medicine, Houston, Texas, USA. FAU - Dobbie, Krista AU - Dobbie K AD - Department of Palliative and Supportive Care, Cleveland Clinic, Cleveland, Ohio, USA. FAU - Neuendorf, Kathleen AU - Neuendorf K AD - Department of Palliative and Supportive Care, Cleveland Clinic, Cleveland, Ohio, USA. FAU - Nakagawa, Shunichi AU - Nakagawa S AD - Adult Palliative Care Service, Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA. FAU - Young, Alisha AU - Young A AUID- ORCID: 0000-0003-2812-0517 AD - Division of Pulmonary and Critical Care Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas, USA. AD - Division of Geriatric and Palliative Care Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas, USA. FAU - Rosa, William E AU - Rosa WE AUID- ORCID: 0000-0002-0680-8911 AD - Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York, USA. FAU - Akkanti, Bindu AU - Akkanti B AD - Division of Pulmonary and Critical Care Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas, USA. AD - Advanced Cardio-Pulmonary Therapeutics and Transplantation, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas, USA. LA - eng GR - P30 CA008748/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20230215 PL - United States TA - J Palliat Med JT - Journal of palliative medicine JID - 9808462 SB - IM MH - Humans MH - Adult MH - *Extracorporeal Membrane Oxygenation MH - Palliative Care MH - *Terminal Care MH - Prognosis MH - Resuscitation PMC - PMC10701507 OTO - NOTNLM OT - cardiac conditions OT - critical illness OT - extracorporeal membrane oxygenation OT - mechanical circulatory support OT - palliative care OT - pulmonary conditions OT - symptom control COIS- No competing financial interests exist. EDAT- 2023/02/16 06:00 MHDA- 2023/09/07 06:42 PMCR- 2024/09/01 CRDT- 2023/02/15 15:43 PHST- 2023/09/07 06:42 [medline] PHST- 2023/02/16 06:00 [pubmed] PHST- 2023/02/15 15:43 [entrez] PHST- 2024/09/01 00:00 [pmc-release] AID - 10.1089/jpm.2023.0017 [pii] AID - 10.1089/jpm.2023.0017 [doi] PST - ppublish SO - J Palliat Med. 2023 Sep;26(9):1270-1276. doi: 10.1089/jpm.2023.0017. Epub 2023 Feb 15. PMID- 36790508 OWN - NLM STAT- MEDLINE DCOM- 20240716 LR - 20240716 IS - 1432-1971 (Electronic) IS - 0172-0643 (Print) IS - 0172-0643 (Linking) VI - 45 IP - 6 DP - 2024 Aug TI - Cardiac Point-of-Care Ultrasound and Multi-Disciplinary Improvement Opportunities in Acute Systolic Heart Failure Management in a Pediatric Emergency Center. PG - 1353-1358 LID - 10.1007/s00246-023-03125-w [doi] AB - Cardiac point-of-care ultrasound (POCUS) has the ability to rapidly assess function and identify systolic heart failure (HF), an often-missed diagnosis. POCUS has the potential to expedite medical intervention, improving overall outcomes. There have been limited studies describing pediatric emergency center (EC) utilization of cardiac POCUS and its impact on outcomes in pediatric patients. Authors performed a retrospective chart review at a tertiary children's hospital to identify all patients admitted from the EC to the Cardiac Intensive Care Unit (CICU) with acute systolic HF between January 2017 and August 2019. Outcome measures included EC length of stay (LOS), CICU LOS, and time until first IV HF medicine was administered. A total of 21 patients and 24 encounters meeting criteria were identified. Cardiac POCUS agreed with standard echocardiography in 8 of 9 cases. Patients who had a cardiac POCUS in the EC seemed more likely to receive their first dose of intravenous heart failure medication while in the Emergency Center (70% vs 43%). There was a trend toward significance, but it did not reach statistical significance (p = 0.1). EC and CICU LOS were not significantly different between POCUS and non-POCUS groups. Cardiac POCUS has the potential to have a valuable role in the early diagnosis of acute systolic HF in children. However, early diagnosis by POCUS did not translate into shorter EC or CICU LOS. This pilot data serves as a baseline for efforts to promote earlier clinical recognition of acute HF and more efficient collaboration between clinical services. CI - (c) 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Scott, Camille AU - Scott C AD - Department of Pediatrics, Section of Emergency Medicine, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA. camille.scott@bcm.edu. AD - Department of Pediatrics, Section of Cardiology, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA. camille.scott@bcm.edu. FAU - Alade, Kiyetta AU - Alade K AD - Department of Pediatrics, Section of Emergency Medicine, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA. AD - Department of Pediatrics, Section of Cardiology, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA. FAU - Leung, Stephanie K AU - Leung SK AD - Department of Pediatrics, Section of Emergency Medicine, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA. AD - Department of Pediatrics, Section of Cardiology, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA. FAU - Vaughan, Ruth Morrison AU - Vaughan RM AD - Department of Pediatrics, Section of Emergency Medicine, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA. AD - Department of Pediatrics, Section of Cardiology, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA. FAU - Riley, Alan F AU - Riley AF AD - Department of Pediatrics, Section of Emergency Medicine, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA. AD - Department of Pediatrics, Section of Cardiology, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA. LA - eng PT - Journal Article DEP - 20230215 PL - United States TA - Pediatr Cardiol JT - Pediatric cardiology JID - 8003849 SB - IM MH - Humans MH - Retrospective Studies MH - Female MH - Male MH - *Heart Failure, Systolic/diagnostic imaging/therapy MH - Child, Preschool MH - Child MH - *Point-of-Care Systems MH - *Emergency Service, Hospital MH - *Echocardiography/methods MH - Infant MH - *Length of Stay/statistics & numerical data MH - Adolescent MH - Acute Disease PMC - PMC9930710 OTO - NOTNLM OT - Acute decompensated heart failure OT - Echocardiography OT - Emergency center OT - Point-of-care ultrasound COIS- The authors declare that they have no relevant financial or non-financial conflicts of interest to disclose. EDAT- 2023/02/16 06:00 MHDA- 2024/07/16 12:44 PMCR- 2023/02/15 CRDT- 2023/02/15 11:15 PHST- 2022/10/18 00:00 [received] PHST- 2023/02/02 00:00 [accepted] PHST- 2024/07/16 12:44 [medline] PHST- 2023/02/16 06:00 [pubmed] PHST- 2023/02/15 11:15 [entrez] PHST- 2023/02/15 00:00 [pmc-release] AID - 10.1007/s00246-023-03125-w [pii] AID - 3125 [pii] AID - 10.1007/s00246-023-03125-w [doi] PST - ppublish SO - Pediatr Cardiol. 2024 Aug;45(6):1353-1358. doi: 10.1007/s00246-023-03125-w. Epub 2023 Feb 15. PMID- 36788008 OWN - NLM STAT- MEDLINE DCOM- 20240621 LR - 20250702 IS - 2047-9956 (Print) IS - 2047-9964 (Electronic) IS - 2047-9956 (Linking) VI - 31 IP - 4 DP - 2024 Jun 21 TI - Drug-related problems at the heart of cardiac surgery. PG - 332-338 LID - 10.1136/ejhpharm-2022-003669 [doi] AB - OBJECTIVES: Optimal perioperative success in cardiac surgery requires precise management of drug treatment. This study aimed to determine the prevalence, types and associated factors of drug-related problems (DRPs) during the entire hospital stay. METHODS: A prospective observational study was conducted at the department of cardiovascular surgery in a university hospital between November 2019 and March 2020. Patients with planned elective cardiac surgery, aged >/=18 years, were included. A clinical pharmacist collaboratively reviewed medications on a daily basis and identified DRPs. RESULTS: A total of 100 patients (60 male) were included; median (range) age was 62 (19-86) years, and median (IQR) length of stay in hospital was 15 (9) days. A total of 275 DRPs were identified (median (IQR) 3 (2-4)). The number of patients who had at least one DRP was 47 preoperatively, 55 in the postoperative intensive care unit, 100 in the postoperative ward, and 16 at discharge. In order to reduce bias because of the small sample size, Firth's logistic regression analysis was conducted. Statistically significant variables according to univariate analysis were included into a logistic regression model. Therefore the length of hospital stay (OR 1.14, 95% CI 1.03 to 1.26, p=0.008), living arrangements (living alone) (OR 4.24, 95% CI 1.41 to 12.73, p=0.009), number of medications at admission (OR 1.32, 95% CI 1.09 to 1.59, p=0.002), and having coronary artery bypass graft surgery (OR 2.87, 95% CI 1.07 to 7.70, p=0.03) were associated with an increased risk for DRPs in the final model. CONCLUSION: Hospital stay carries an increased risk for DRPs, especially at the postoperative stage. Modifiable risk factors for DRPs can be managed by required interventions performed by a multidisciplinary healthcare team. CI - (c) European Association of Hospital Pharmacists 2024. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Kelleci Cakir, Burcu AU - Kelleci Cakir B AUID- ORCID: 0000-0003-2547-8919 AD - Department of Clinical Pharmacy, Hacettepe University Faculty of Pharmacy, Ankara, Turkey burcukelleci@hacettepe.edu.tr. FAU - Aydin, Ahmet AU - Aydin A AD - Department of Cardiovascular Surgery, Hacettepe University Faculty of Medicine, Ankara, Turkey. FAU - Yilmaz, Mustafa AU - Yilmaz M AD - Department of Cardiovascular Surgery, Hacettepe University Faculty of Medicine, Ankara, Turkey. FAU - Bayraktar-Ekincioglu, Aygin AU - Bayraktar-Ekincioglu A AUID- ORCID: 0000-0002-3481-0074 AD - Department of Clinical Pharmacy, Hacettepe University Faculty of Pharmacy, Ankara, Turkey. LA - eng PT - Journal Article PT - Observational Study DEP - 20240621 PL - England TA - Eur J Hosp Pharm JT - European journal of hospital pharmacy : science and practice JID - 101578294 SB - IM MH - Humans MH - Male MH - Aged MH - Female MH - Middle Aged MH - *Cardiac Surgical Procedures/adverse effects/trends/methods MH - Prospective Studies MH - Aged, 80 and over MH - *Length of Stay MH - Adult MH - *Drug-Related Side Effects and Adverse Reactions/epidemiology MH - Young Adult MH - Pharmacy Service, Hospital/methods MH - Pharmacists/trends MH - Hospitals, University PMC - PMC11265555 OTO - NOTNLM OT - CLINICAL PHARMACY OT - DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS OT - PHARMACY SERVICE, HOSPITAL OT - Safety OT - Vascular Surgical Procedures COIS- Competing interests: None declared. EDAT- 2023/02/15 06:00 MHDA- 2024/06/22 05:43 PMCR- 2025/07/01 CRDT- 2023/02/14 21:22 PHST- 2022/12/23 00:00 [received] PHST- 2023/02/05 00:00 [accepted] PHST- 2024/06/22 05:43 [medline] PHST- 2023/02/15 06:00 [pubmed] PHST- 2023/02/14 21:22 [entrez] PHST- 2025/07/01 00:00 [pmc-release] AID - ejhpharm-2022-003669 [pii] AID - 10.1136/ejhpharm-2022-003669 [doi] PST - epublish SO - Eur J Hosp Pharm. 2024 Jun 21;31(4):332-338. doi: 10.1136/ejhpharm-2022-003669. PMID- 36787125 OWN - NLM STAT- MEDLINE DCOM- 20230310 LR - 20240302 IS - 1555-905X (Electronic) IS - 1555-9041 (Print) IS - 1555-9041 (Linking) VI - 18 IP - 3 DP - 2023 Mar 1 TI - Team-Based Coaching Intervention to Improve Contrast-Associated Acute Kidney Injury: A Cluster-Randomized Trial. PG - 315-326 LID - 10.2215/CJN.0000000000000067 [doi] AB - BACKGROUND: Up to 14% of patients in the United States undergoing cardiac catheterization each year experience AKI. Consistent use of risk minimization preventive strategies may improve outcomes. We hypothesized that team-based coaching in a Virtual Learning Collaborative (Collaborative) would reduce postprocedural AKI compared with Technical Assistance (Assistance), both with and without Automated Surveillance Reporting (Surveillance). METHODS: The IMPROVE AKI trial was a 2x2 factorial cluster-randomized trial across 20 Veterans Affairs medical centers (VAMCs). Participating VAMCs received Assistance, Assistance with Surveillance, Collaborative, or Collaborative with Surveillance for 18 months to implement AKI prevention strategies. The Assistance and Collaborative approaches promoted hydration and limited NPO and contrast dye dosing. We fit logistic regression models for AKI with site-level random effects accounting for the clustering of patients within medical centers with a prespecified interest in exploring differences across the four intervention arms. RESULTS: Among VAMCs' 4517 patients, 510 experienced AKI (235 AKI events among 1314 patients with preexisting CKD). AKI events in each intervention cluster were 110 (13%) in Assistance, 122 (11%) in Assistance with Surveillance, 190 (13%) in Collaborative, and 88 (8%) in Collaborative with Surveillance. Compared with sites receiving Assistance alone, case-mix-adjusted differences in AKI event proportions were -3% (95% confidence interval [CI], -4 to -3) for Assistance with Surveillance, -3% (95% CI, -3 to -2) for Collaborative, and -5% (95% CI, -6 to -5) for Collaborative with Surveillance. The Collaborative with Surveillance intervention cluster had a substantial 46% reduction in AKI compared with Assistance alone (adjusted odds ratio=0.54; 0.40-0.74). CONCLUSIONS: This implementation trial estimates that the combination of Collaborative with Surveillance reduced the odds of AKI by 46% at VAMCs and is suggestive of a reduction among patients with CKD. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: IMPROVE AKI Cluster-Randomized Trial (IMPROVE-AKI), NCT03556293. CI - Copyright (c) 2023 by the American Society of Nephrology. FAU - Brown, Jeremiah R AU - Brown JR AD - Department of Epidemiology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire. AD - Biomedical Data Science, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire. FAU - Solomon, Richard AU - Solomon R AUID- ORCID: 0000-0002-5943-4378 AD - University of Vermont Larner College of Medicine, Burlington, Vermont. FAU - Stabler, Meagan E AU - Stabler ME AUID- ORCID: 0000-0002-3706-2622 AD - Department of Epidemiology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire. FAU - Davis, Sharon AU - Davis S AD - Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee. FAU - Carpenter-Song, Elizabeth AU - Carpenter-Song E AD - Department of Psychiatry and Center for Technology and Behavioral Health, Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire. FAU - Zubkoff, Lisa AU - Zubkoff L AD - Department of Medicine, University of Alabama at Birmingham and VA Birmingham Health Care, Birmingham, Alabama. FAU - Westerman, Dax M AU - Westerman DM AD - Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee. FAU - Dorn, Chad AU - Dorn C AD - Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee. FAU - Cox, Kevin C AU - Cox KC AD - Department of Epidemiology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire. FAU - Minter, Freneka AU - Minter F AD - Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee. FAU - Jneid, Hani AU - Jneid H AD - Section of Cardiology, Baylor College of Medicine, Houston, Texas. FAU - Currier, Jesse W AU - Currier JW AD - Division of Cardiology, Department of Medicine, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California. AD - Division of Cardiology, Department of Medicine, University of California Los Angeles David Geffen School of Medicine, Los Angeles, California. FAU - Athar, S Ahmed AU - Athar SA AUID- ORCID: 0000-0002-8993-1367 AD - Section of Cardiology, Loma Linda VA Medical Center, Loma Linda, California. AD - Department of Medicine, Division of Cardiology, Loma Linda University School of Medicine, Loma Linda, California. FAU - Girotra, Saket AU - Girotra S AD - Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas. FAU - Leung, Calvin AU - Leung C AD - Orlando VA Medical Center, Orlando, Florida. FAU - Helton, Thomas J AU - Helton TJ AD - East Tennessee State University, Johnson City, Tennessee. FAU - Agarwal, Ajay AU - Agarwal A AD - Wright State University Dayton VA Medical Center, Dayton, Ohio. FAU - Vidovich, Mladen I AU - Vidovich MI AD - Section of Cardiology, Jesse Brown VA Medical Center and Department of Medicine, University of Illinois at Chicago, Chicago, Illinois. FAU - Plomondon, Mary E AU - Plomondon ME AD - CART Program, VHA Office of Quality and Safety, Washington, DC. FAU - Waldo, Stephen W AU - Waldo SW AD - CART Program, VHA Office of Quality and Safety, Washington, DC. AD - Department of Medicine, Cardiology Section, Rocky Mountain Regional VA Medical Center, Aurora, Colorado. AD - Department of Medicine, Division of Cardiology, University of Colorado School of Medicine, Aurora, Colorado. FAU - Aschbrenner, Kelly A AU - Aschbrenner KA AD - Department of Psychiatry and Center for Technology and Behavioral Health, Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire. FAU - O'Malley, A James AU - O'Malley AJ AD - Biomedical Data Science, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire. AD - The Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, New Hampshire. FAU - Matheny, Michael E AU - Matheny ME AUID- ORCID: 0000-0003-3217-4147 AD - Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee. AD - Geriatric Research Education and Clinical Care Center, Tennessee Valley Healthcare System VA, Nashville, Tennessee. LA - eng SI - ClinicalTrials.gov/NCT03556293 GR - R01 DK113201/DK/NIDDK NIH HHS/United States PT - Journal Article PT - Randomized Controlled Trial DEP - 20230208 PL - United States TA - Clin J Am Soc Nephrol JT - Clinical journal of the American Society of Nephrology : CJASN JID - 101271570 RN - 0 (Contrast Media) SB - IM CIN - Clin J Am Soc Nephrol. 2023 Mar 1;18(3):300-302. doi: 10.2215/CJN.0000000000000082. PMID: 36888886 MH - Humans MH - United States MH - *Mentoring MH - Contrast Media/adverse effects MH - United States Department of Veterans Affairs MH - *Renal Insufficiency, Chronic/chemically induced MH - *Acute Kidney Injury/chemically induced/prevention & control PMC - PMC10103221 COIS- A. Agarwal reports employment with VA Medical Center, Wright State University, and an advisory or leadership role for the American College of Cardiology Board of Trustees-Ohio Chapter (an unpaid position). S.A. Athar reports employment with Loma Linda VA Medical Center. E. Carpenter-Song served as a consultant for Westat during 2022 to support the use of qualitative methods in two studies: (1) a study examining an employment program for Veterans transitioning to civilian life and (2) a study examining evidence-based supported employment for young adults with serious mental illnesses. E. Carpenter-Song was part of a research team that received funding in 2020 from the Bristol Meyers Squibb Foundation to conduct research examining the impact of COVID-19 on rural health systems and communities. S. Girotra reports research funding from National Heart, Lung, and Blood Institute (R01HL160734 and R56HL158803). T.J. Helton reports employment with James H. Quillen VA Medical Center and ownership interest in Apple, AirBNB, ASML holding, Confluent, Crowdstrike, Microsoft, Shopify, and Upstart. C. Leung reports employment with Orlando Veterans Affairs Medical Center. M.E. Matheny reports employment with Department of Veterans Affairs and consultancy agreements with NIH-VA-DoD Pain Management Grant Consortium (PMC3). M. Matheny reports advisory or leadership roles for Informatics & Methods Section, SMRB Study Section, VA HSR&D; Steering Committee-Indianapolis VA HSR&D COIN Center; and Steering Committee-VA HSR&D VIREC. A.J. O'Malley reports consultancy agreements with JB Associates and an advisory or leadership role for Statistics in Medicine and Observational Studies. M.E. Plomondon reports employment with Veterans Health Administration, Washington, DC. R. Solomon reports consultancy agreements with MediBeacon, Inc., PLC Inc., and Sonogenix, Inc.; research funding from REATA and Vera Pharmaceuticals; and advisory or leadership roles for MediBeacon, PLC Med, Inc., and Sonogenix. M.I. Vidovich reports consultancy agreements with Boston Scientific, research funding from Boston Scientific, patents or royalties from Merit Medical, and an advisory or leadership role for Intersocietal Accreditation Commission. S.W. Waldo reports employment with Rocky Mountain Regional VA Medical Center and research funding from Cardiovascular Systems Incorporated and Janssen Pharmaceuticals. L. Zubkoff reports employment with Birmingham VA Healthcare System. All remaining authors have nothing to disclose. EDAT- 2023/02/15 06:00 MHDA- 2023/03/11 06:00 PMCR- 2024/03/01 CRDT- 2023/02/14 11:26 PHST- 2022/09/01 00:00 [received] PHST- 2022/12/19 00:00 [accepted] PHST- 2023/02/15 06:00 [pubmed] PHST- 2023/03/11 06:00 [medline] PHST- 2023/02/14 11:26 [entrez] PHST- 2024/03/01 00:00 [pmc-release] AID - 01277230-202303000-00008 [pii] AID - CJASN-2022-001279 [pii] AID - 10.2215/CJN.0000000000000067 [doi] PST - ppublish SO - Clin J Am Soc Nephrol. 2023 Mar 1;18(3):315-326. doi: 10.2215/CJN.0000000000000067. Epub 2023 Feb 8. PMID- 36780387 OWN - NLM STAT- MEDLINE DCOM- 20230215 LR - 20250103 IS - 1524-4539 (Electronic) IS - 0009-7322 (Linking) VI - 147 IP - 7 DP - 2023 Feb 14 TI - Maternal Outcomes Among Pregnant Women With Congenital Heart Disease-Associated Pulmonary Hypertension. PG - 549-561 LID - 10.1161/CIRCULATIONAHA.122.057987 [doi] AB - BACKGROUND: Studies focused on pregnant women with congenital heart disease (CHD)-associated pulmonary hypertension (PH) are scarce and limited by small sample sizes and single-center design. This study sought to describe the pregnancy outcomes in women with CHD with and without PH. METHODS: Outcomes for pregnant women with CHD were evaluated retrospectively from 1993 to 2016 and prospectively from 2017 to 2019 from 7 tertiary hospitals. PH was diagnosed on the basis of echocardiogram or catheterization. The incidence of maternal death, cardiac complications, and obstetric and offspring complications was compared for women with CHD and no PH, mild, and moderate-to-severe PH. RESULTS: A total of 2220 pregnant women with CHD had completed pregnancies. PH associated with CHD was identified in 729 women, including 398 with mild PH (right ventricle to right atrium gradient 30-50 mm Hg) and 331 with moderate-to-severe PH (right ventricle to right atrium gradient >50 mm Hg). Maternal mortality occurred in 1 (0.1%), 0, and 19 (5.7%) women with CHD and no, mild, or moderate-to-severe PH, respectively. Of the 729 patients with PH, 619 (85%) had CHD-associated pulmonary arterial hypertension, and 110 (15%) had other forms of PH. Overall, patients with mild PH had better maternal outcomes than those with moderate-to-severe PH, including the incidence of maternal mortality or heart failure (7.8% versus 39.6%; P<0.001), other cardiac complications (9.0% versus 32.3%; P<0.001), and obstetric complications (5.3% versus 15.7%; P<0.001). Brain natriuretic peptide >100 ng/L (odds ratio, 1.9 [95% CI, 1.0-3.4], P=0.04) and New York Heart Association class III to IV (odds ratio, 2.9 [95% CI, 1.6-5.3], P<0.001) were independently associated with adverse maternal cardiac events in pregnancy with PH, whereas follow-up with a multidisciplinary team (odds ratio, 0.4 [95% CI, 0.2-0.6], P<0.001) and strict antenatal supervision (odds ratio, 0.5 [95% CI, 0.3-0.7], P=0.001) were protective. CONCLUSIONS: Women with CHD-associated mild PH appear to have better outcomes compared with women with CHD-associated moderate-to-severe PH, and with event rates similar for most outcomes with women with CHD and no PH. Multimodality risk assessment, including PH severity, brain natriuretic peptide level, and New York Heart Association class, may be useful in risk stratification in pregnancy with PH. Follow-up with a multidisciplinary team and strict antenatal supervision during pregnancy may also help to mitigate the risk of adverse maternal cardiac events. FAU - Zhang, Qian AU - Zhang Q AUID- ORCID: 0000-0002-3880-2020 AD - Department of Cardiothoracic Surgery, Heart Center (Q.Z., F.Z., G.S., C.H., R.M., Y.Y., Z.Z., H.Z., Huiwen Chen), China. FAU - Zhu, Fang AU - Zhu F AUID- ORCID: 0000-0002-7116-8797 AD - Department of Cardiothoracic Surgery, Heart Center (Q.Z., F.Z., G.S., C.H., R.M., Y.Y., Z.Z., H.Z., Huiwen Chen), China. AD - Shanghai Children's Medical Center, Department of Surgical Oncology, Shanghai Lung Cancer Center, Shanghai Chest Hospital (F.Z.), China. FAU - Shi, Guocheng AU - Shi G AD - Department of Cardiothoracic Surgery, Heart Center (Q.Z., F.Z., G.S., C.H., R.M., Y.Y., Z.Z., H.Z., Huiwen Chen), China. FAU - Hu, Chen AU - Hu C AD - Department of Cardiothoracic Surgery, Heart Center (Q.Z., F.Z., G.S., C.H., R.M., Y.Y., Z.Z., H.Z., Huiwen Chen), China. AD - Department of Cardiovascular Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China (C.H.). FAU - Zhang, Weituo AU - Zhang W AD - Clinical Research Center (W.Z.), China. FAU - Huang, Puzhen AU - Huang P AD - Shanghai Jiao Tong University School of Medicine (P.H., Z.P.), China. FAU - Zhu, Chunfeng AU - Zhu C AUID- ORCID: 0000-0002-0496-2157 AD - Department of Obstetrics and Gynecology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, China (C.Z., F.H.). FAU - Gu, Hong AU - Gu H AD - Department of Pediatric Cardiology (H.G., Q.L.), Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung, and Blood Vessel Diseases, China. FAU - Yang, Dong AU - Yang D AD - Department of Obstetrics and Gynecology (D.Y., X.Z., Y.L.), Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung, and Blood Vessel Diseases, China. FAU - Li, Qiangqiang AU - Li Q AD - Department of Pediatric Cardiology (H.G., Q.L.), Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung, and Blood Vessel Diseases, China. FAU - Niu, Yonghua AU - Niu Y AD - Department of Ultrasound (Y.N.), Renji Hospital, Shanghai Jiao Tong University School of Medicine, China. FAU - Chen, Hao AU - Chen H AUID- ORCID: 0000-0002-9577-2091 AD - Department of Cardiology, Heart Center (Hao Chen), China. FAU - Ma, Ruixiang AU - Ma R AD - Department of Cardiothoracic Surgery, Heart Center (Q.Z., F.Z., G.S., C.H., R.M., Y.Y., Z.Z., H.Z., Huiwen Chen), China. FAU - Pan, Ziyi AU - Pan Z AD - Shanghai Jiao Tong University School of Medicine (P.H., Z.P.), China. FAU - Miao, Huixian AU - Miao H AD - Department of Obstetrics and Gynecology (J.L., H.M.), Renji Hospital, Shanghai Jiao Tong University School of Medicine, China. AD - Department of Gynecology, Jiangsu Province Hospital, The First Affiliated Hospital with Nanjing First Medical University, China (H.M.). FAU - Zhang, Xin AU - Zhang X AD - Department of Obstetrics and Gynecology (D.Y., X.Z., Y.L.), Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung, and Blood Vessel Diseases, China. FAU - Li, Genxia AU - Li G AD - Department of Obstetrics, Third Affiliated Hospital of Zhengzhou University, Henan, China (G.L.). FAU - Tang, Yabing AU - Tang Y AD - Department of Obstetrics Section 3, Hunan Provincial Maternal and Child Health Care Hospital, China (Y.T.). FAU - Qiao, Guyuan AU - Qiao G AD - Department of Obstetrics and Gynecology, Xijing Hospital, Fourth Military Medical University, Xi'an, China (G.Q.). FAU - Yan, Yichen AU - Yan Y AUID- ORCID: 0000-0002-0717-3962 AD - Department of Cardiothoracic Surgery, Heart Center (Q.Z., F.Z., G.S., C.H., R.M., Y.Y., Z.Z., H.Z., Huiwen Chen), China. FAU - Zhu, Zhongqun AU - Zhu Z AD - Department of Cardiothoracic Surgery, Heart Center (Q.Z., F.Z., G.S., C.H., R.M., Y.Y., Z.Z., H.Z., Huiwen Chen), China. FAU - Zhang, Hao AU - Zhang H AUID- ORCID: 0000-0002-0206-9066 AD - Department of Cardiothoracic Surgery, Heart Center (Q.Z., F.Z., G.S., C.H., R.M., Y.Y., Z.Z., H.Z., Huiwen Chen), China. FAU - Han, Fengzhen AU - Han F AUID- ORCID: 0000-0001-7378-2021 AD - Department of Obstetrics and Gynecology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, China (C.Z., F.H.). FAU - Li, Yanna AU - Li Y AD - Department of Obstetrics and Gynecology (D.Y., X.Z., Y.L.), Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung, and Blood Vessel Diseases, China. FAU - Lin, Jianhua AU - Lin J AD - Department of Obstetrics and Gynecology (J.L., H.M.), Renji Hospital, Shanghai Jiao Tong University School of Medicine, China. FAU - Chen, Huiwen AU - Chen H AUID- ORCID: 0000-0001-5269-2334 AD - Department of Cardiothoracic Surgery, Heart Center (Q.Z., F.Z., G.S., C.H., R.M., Y.Y., Z.Z., H.Z., Huiwen Chen), China. AD - Clinical Research Center (Huiwen Chen), China. AD - Guizhou Branch (Huiwen Chen), China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230213 PL - United States TA - Circulation JT - Circulation JID - 0147763 RN - 114471-18-0 (Natriuretic Peptide, Brain) SB - IM CIN - Circulation. 2023 Feb 14;147(7):562-564. doi: 10.1161/CIRCULATIONAHA.122.063191. PMID: 36780392 MH - Pregnancy MH - Female MH - Humans MH - *Hypertension, Pulmonary/etiology/complications MH - Pregnant People MH - Retrospective Studies MH - Natriuretic Peptide, Brain MH - *Pregnancy Complications, Cardiovascular/diagnosis MH - Pregnancy Outcome MH - *Pulmonary Arterial Hypertension MH - *Heart Defects, Congenital/diagnosis OTO - NOTNLM OT - brain natriuretic peptide OT - congenital heart disease OT - gender OT - multimodality risk assessment OT - pregnancy OT - pulmonary hypertension EDAT- 2023/02/14 06:00 MHDA- 2023/02/16 06:00 CRDT- 2023/02/13 14:04 PHST- 2023/02/13 14:04 [entrez] PHST- 2023/02/14 06:00 [pubmed] PHST- 2023/02/16 06:00 [medline] AID - 10.1161/CIRCULATIONAHA.122.057987 [doi] PST - ppublish SO - Circulation. 2023 Feb 14;147(7):549-561. doi: 10.1161/CIRCULATIONAHA.122.057987. Epub 2023 Feb 13. PMID- 36780370 OWN - NLM STAT- MEDLINE DCOM- 20230315 LR - 20230507 IS - 1524-4539 (Electronic) IS - 0009-7322 (Linking) VI - 147 IP - 11 DP - 2023 Mar 14 TI - Anesthetic Care of the Pregnant Patient With Cardiovascular Disease: A Scientific Statement From the American Heart Association. PG - e657-e673 LID - 10.1161/CIR.0000000000001121 [doi] AB - The pregnancy-related mortality rate in the United States is excessively high. The American Heart Association is dedicated to fighting heart disease and recognizes that cardiovascular disease, preexisting or acquired during pregnancy, is the leading cause of maternal mortality in the United States. Comprehensive scientific statements from cardiology and obstetrics experts guide the treatment of cardio-obstetric patients before, during, and after pregnancy. This scientific statement aims to highlight the role of specialized cardio-obstetric anesthesiology care, presenting a systematic approach to the care of these patients from the anesthesiology perspective. The anesthesiologist is a critical part of the pregnancy heart team as the perioperative physician who is trained to prevent or promptly recognize and treat patients with peripartum cardiovascular decompensation. Maternal morbidity is attenuated with expert anesthesiology peripartum care, which includes the management of neuraxial anesthesia, inotrope and vasopressor support, transthoracic echocardiography, optimization of delivery location, and consideration of advanced critical care and mechanical support when needed. Standardizing the anesthesiology approach to patients with high peripartum cardiovascular risk and ensuring that cardio-obstetrics patients have access to the appropriate care team, facilities, and advanced cardiovascular therapies will contribute to improving peripartum morbidity and mortality. FAU - Meng, Marie-Louise AU - Meng ML FAU - Arendt, Katherine W AU - Arendt KW FAU - Banayan, Jennifer M AU - Banayan JM FAU - Bradley, Elisa A AU - Bradley EA FAU - Vaught, Arthur J AU - Vaught AJ FAU - Hameed, Afshan B AU - Hameed AB FAU - Harris, Jade AU - Harris J FAU - Bryner, Benjamin AU - Bryner B FAU - Mehta, Laxmi S AU - Mehta LS CN - American Heart Association Council on Cardiovascular Surgery and Anesthesia; Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; and Council on Peripheral Vascular Disease LA - eng PT - Journal Article PT - Review DEP - 20230213 PL - United States TA - Circulation JT - Circulation JID - 0147763 RN - 0 (Anesthetics) SB - IM MH - Pregnancy MH - Female MH - Humans MH - United States MH - *Cardiovascular Diseases/diagnosis/therapy MH - American Heart Association MH - *Heart Diseases/therapy MH - *Anesthetics MH - *Cardiology OTO - NOTNLM OT - AHA Scientific Statements OT - anesthesiology OT - cardiovascular disease OT - maternal mortality OT - obstetrics OT - patient care team OT - peripartum period EDAT- 2023/02/14 06:00 MHDA- 2023/03/16 06:00 CRDT- 2023/02/13 14:03 PHST- 2023/02/14 06:00 [pubmed] PHST- 2023/03/16 06:00 [medline] PHST- 2023/02/13 14:03 [entrez] AID - 10.1161/CIR.0000000000001121 [doi] PST - ppublish SO - Circulation. 2023 Mar 14;147(11):e657-e673. doi: 10.1161/CIR.0000000000001121. Epub 2023 Feb 13. PMID- 36776681 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240912 IS - 2296-2360 (Print) IS - 2296-2360 (Electronic) IS - 2296-2360 (Linking) VI - 10 DP - 2022 TI - Six-month multidisciplinary follow-up in multisystem inflammatory syndrome in children: An Italian single-center experience. PG - 1080654 LID - 10.3389/fped.2022.1080654 [doi] LID - 1080654 AB - BACKGROUND: A severe multisystem inflammatory syndrome in children (MIS-C) related to SARS-CoV-2 has been described after infection. A limited number of reports have analyzed the long-term complications related to pro-inflammatory status in MIS-C. We evaluated multiorgan impairment at the 6-month follow-up in MIS-C. METHODS: We enrolled 33 pediatric patients consecutively hospitalized for MIS-C and monitored for almost 6 months. The inter-relationship of patient's features and disease severity at admission with long term complications was studied by multivariate analysis. RESULTS: Endo-metabolic derangement, cardiac injury, respiratory, renal and gastrointestinal manifestations and neurological involvement are part of the initial presentation. The most abnormalities appear to resolve within the first few weeks, without significant long term dysfunction at the 6-months follow-up, except for endocrine (non-thyroidal illness syndrome in 12.1%, insulin resistance in 21.2%) and neurological system (27.3% cognitive or psychological, behavioral, adaptive difficulties). Endocrine and heart involvement at admission represent a significant factor on the long term sequelae; however no association between severity score and long-term outcome was noted. CONCLUSIONS: The severity of initial clinical presentation may be associated to organ domain, however it is not related to long term sequelae. The prevalent organ restoration supports a predominant indirect immune-mediated injury triggered by a systemic inflammatory response; however a direct damage due to the viral entry could be not excluded. Eventhought our preliminary results seem to suggest that MIS-C is not a long-term risk condition for children health, a longer follow-up is mandatory to confirm this hypothesis. CI - (c) 2023 Zuccotti, Calcaterra, Mannarino, D'Auria, Bova, Fiori, Verduci, Milanese, Marano, Garbin, Zirpoli, Fabiano, Carlucci, Olivotto, Gianolio, De Santis, Pelizzo, Zoia, Dilillo and Biganzoli. FAU - Zuccotti, Gianvincenzo AU - Zuccotti G AD - Department of Biomedical and Clinical Science, University of Milan, Milan, Italy. AD - Pediatric Department, Buzzi Children's Hospital, Milan, Italy. FAU - Calcaterra, Valeria AU - Calcaterra V AD - Pediatric Department, Buzzi Children's Hospital, Milan, Italy. AD - Department of Internal Medicine, University of Pavia, Pavia, Italy. FAU - Mannarino, Savina AU - Mannarino S AD - Pediatric Cardiology Unit, Buzzi Children's Hospital, Milan, Italy. FAU - D'Auria, Enza AU - D'Auria E AD - Pediatric Department, Buzzi Children's Hospital, Milan, Italy. FAU - Bova, Stefania Maria AU - Bova SM AD - Pediatric Neurology Unit, Buzzi Children's Hospital, Milan, Italy. FAU - Fiori, Laura AU - Fiori L AD - Pediatric Department, Buzzi Children's Hospital, Milan, Italy. FAU - Verduci, Elvira AU - Verduci E AD - Pediatric Department, Buzzi Children's Hospital, Milan, Italy. AD - Department of Health Sciences, University of Milano, Milano, Italy. FAU - Milanese, Alberto AU - Milanese A AD - Medical Statistics Unit, Department of Biomedical and Clinical Sciences, "Luigi Sacco" University Hospital, University of Milan, Milan, Italy. FAU - Marano, Giuseppe AU - Marano G AD - Medical Statistics Unit, Department of Biomedical and Clinical Sciences, "Luigi Sacco" University Hospital, University of Milan, Milan, Italy. FAU - Garbin, Massimo AU - Garbin M AD - Pediatric Cardiology Unit, Buzzi Children's Hospital, Milan, Italy. FAU - Zirpoli, Salvatore AU - Zirpoli S AD - Pediatric Radiology Unit, Buzzi Children's Hospital, Milan, Italy. FAU - Fabiano, Valentina AU - Fabiano V AD - Department of Biomedical and Clinical Science, University of Milan, Milan, Italy. AD - Pediatric Department, Buzzi Children's Hospital, Milan, Italy. FAU - Carlucci, Patrizia AU - Carlucci P AD - Pediatric Department, Buzzi Children's Hospital, Milan, Italy. FAU - Olivotto, Sara AU - Olivotto S AD - Pediatric Neurology Unit, Buzzi Children's Hospital, Milan, Italy. FAU - Gianolio, Laura AU - Gianolio L AD - Pediatric Department, Buzzi Children's Hospital, Milan, Italy. FAU - De Santis, Raffaella AU - De Santis R AD - Pediatric Department, Buzzi Children's Hospital, Milan, Italy. FAU - Pelizzo, Gloria AU - Pelizzo G AD - Pediatric Surgery Department, Buzzi Children's Hospital, Milan, Italy. FAU - Zoia, Elena AU - Zoia E AD - Intensive Care Unit, Buzzi Children's Hospital, Milan, Italy. FAU - Dilillo, Dario AU - Dilillo D AD - Pediatric Department, Buzzi Children's Hospital, Milan, Italy. FAU - Biganzoli, Elia Mario AU - Biganzoli EM AD - Medical Statistics Unit, Department of Biomedical and Clinical Sciences, "Luigi Sacco" University Hospital, University of Milan, Milan, Italy. LA - eng PT - Journal Article DEP - 20230126 PL - Switzerland TA - Front Pediatr JT - Frontiers in pediatrics JID - 101615492 PMC - PMC9909209 OTO - NOTNLM OT - COVID-19 OT - SARS-CoV2 OT - children OT - complications OT - follow-up OT - multisystem inflammatory syndrome COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/02/14 06:00 MHDA- 2023/02/14 06:01 PMCR- 2023/01/26 CRDT- 2023/02/13 03:23 PHST- 2022/11/04 00:00 [received] PHST- 2022/12/30 00:00 [accepted] PHST- 2023/02/13 03:23 [entrez] PHST- 2023/02/14 06:00 [pubmed] PHST- 2023/02/14 06:01 [medline] PHST- 2023/01/26 00:00 [pmc-release] AID - 10.3389/fped.2022.1080654 [doi] PST - epublish SO - Front Pediatr. 2023 Jan 26;10:1080654. doi: 10.3389/fped.2022.1080654. eCollection 2022. PMID- 31424850 STAT- Publisher CTDT- 20230213 PB - StatPearls Publishing DP - 2023 Jan TI - Gemfibrozil. BTI - StatPearls AB - Gemfibrozil is an FDA-approved fibric acid agent (fibrate) to manage hypertriglyceridemia (particularly in type IV and V hyperlipidemia). Diet and exercise constitute the first-line treatment for mild and moderate hypertriglyceridemia. However, patients with no adequate therapeutic response to dietary measurements will benefit from the initiation of this medication. Very high levels of triglycerides represent a risk factor for the development of acute pancreatitis. Gemfibrozil is a useful medication for the reduction of triglycerides in patients with very high triglycerides serum levels. This drug is also approved for decreasing the risk of developing coronary heart disease (Type IIb), particularly in patients without a history of subsisting coronary heart disease symptoms. This activity outlines the indications, contraindications, interactions, monitoring, and other therapeutic information pertinent to members of the interprofessional healthcare team caring for patients with hyperlipidemia (particularly hypertriglyceridemia) with gemfibrozil. CI - Copyright (c) 2023, StatPearls Publishing LLC. FAU - Quintanilla Rodriguez, Bryan S AU - Quintanilla Rodriguez BS AD - New York Medical College - Metropolitan Hospital Center FAU - Patel, Preeti AU - Patel P FAU - Correa, Ricardo AU - Correa R AD - University of Arizona LA - eng PT - Study Guide PT - Book Chapter PL - Treasure Island (FL) COIS- Disclosure: Bryan S Quintanilla Rodriguez declares no relevant financial relationships with ineligible companies. Disclosure: Preeti Patel declares no relevant financial relationships with ineligible companies. Disclosure: Ricardo Correa declares no relevant financial relationships with ineligible companies. EDAT- 2023/02/13 00:00 CRDT- 2023/02/13 00:00 AID - NBK545266 [bookaccession] PMID- 36769531 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230325 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 12 IP - 3 DP - 2023 Jan 22 TI - Multidisciplinary Management of Opioid Use-Related Infective Endocarditis: Treatment, QTc Values, and Cardiac Arrests due to Ventricular Fibrillation. LID - 10.3390/jcm12030882 [doi] LID - 882 AB - (1) Background: The opioid epidemic has led to an increase in cardiac surgery for infective endocarditis (IE-CS) related to injection use of opioids (OUD) and other substances and a call for a coordinated approach to initiate substance use disorder treatment, including medication for OUD (MOUD), during IE-CS hospitalizations. We sought to determine the effects of the initiation of a multi-disciplinary endocarditis evaluation team (MEET) on MOUD use, electrocardiographic QTc measurements and cardiac arrests due to ventricular fibrillation (VF) in patients with OUD. (2) Methods and Results: A historical group undergoing IE-CS at Yale-New Haven Hospital prior to MEET initiation, Group I (43 episodes of IE-CS, 38 patients) was compared to 24 patients undergoing IE-CS after MEET involvement (Group II). Compared to Group l, Group II patients were more likely to receive MOUD (41.9 vs. 95.8%, p < 0.0001), predominantly methadone (41.9 vs. 79.2%, p = 0.0035) at discharge. Both groups had similar QTcs: approximately 30% of reviewed electrocardiograms had QTcs >/= 470 ms and 17%, QTcs >/= 500 ms. Cardiac arrests due to VF were not uncommon: Group I: 9.3% vs. Group II: 8.3%, p = 0.8914. Half occurred in the 1-2 months after surgery and were contributed to by pacemaker malfunction/ management and half were related to opioid use. (3) Conclusions: MEET was associated with increased MOUD (predominantly methadone) use during IE-CS hospitalizations without an increase in QTc prolongation or cardiac arrest due to VF compared to Group I, but events occurred in both groups. These arrests were associated with pacemaker issues or a return to opioid use. Robust follow-up of IE-CS patients is essential, as is further research to clarify the longer-term effects of MEET on outcomes. FAU - Rosenfeld, Lynda E AU - Rosenfeld LE AD - Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, CT 06510, USA. FAU - Jain, Shashank AU - Jain S AD - Section of Cardiovascular Medicine, Case Western Reserve School of Medicine, Cleveland, OH 44106, USA. FAU - Amabile, Andrea AU - Amabile A AUID- ORCID: 0000-0003-4689-3871 AD - Division of Cardiac Surgery, Yale School of Medicine, New Haven, CT 06510, USA. FAU - Geirsson, Arnar AU - Geirsson A AD - Division of Cardiac Surgery, Yale School of Medicine, New Haven, CT 06510, USA. FAU - Krane, Markus AU - Krane M AD - Division of Cardiac Surgery, Yale School of Medicine, New Haven, CT 06510, USA. FAU - Weimer, Melissa B AU - Weimer MB AUID- ORCID: 0000-0002-5624-2434 AD - Division of General Medicine, Program in Addiction Medicine, Yale School of Medicine, New Haven, CT 06510, USA. LA - eng GR - UL1 TR001863/TR/NCATS NIH HHS/United States PT - Journal Article DEP - 20230122 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC9917424 OTO - NOTNLM OT - infective endocarditis OT - methadone OT - opioid use disorder COIS- The authors declare no conflict of interest. EDAT- 2023/02/12 06:00 MHDA- 2023/02/12 06:01 PMCR- 2023/01/22 CRDT- 2023/02/11 01:27 PHST- 2022/11/30 00:00 [received] PHST- 2023/01/15 00:00 [revised] PHST- 2023/01/18 00:00 [accepted] PHST- 2023/02/11 01:27 [entrez] PHST- 2023/02/12 06:00 [pubmed] PHST- 2023/02/12 06:01 [medline] PHST- 2023/01/22 00:00 [pmc-release] AID - jcm12030882 [pii] AID - jcm-12-00882 [pii] AID - 10.3390/jcm12030882 [doi] PST - epublish SO - J Clin Med. 2023 Jan 22;12(3):882. doi: 10.3390/jcm12030882. PMID- 36765334 OWN - NLM STAT- MEDLINE DCOM- 20230214 LR - 20250103 IS - 1471-2466 (Electronic) IS - 1471-2466 (Linking) VI - 23 IP - 1 DP - 2023 Feb 11 TI - Effect of multidisciplinary team (MDT) centred on pregnant women with pulmonary hypertension on treatment and outcomes of pregnancy. PG - 62 LID - 10.1186/s12890-023-02355-1 [doi] LID - 62 AB - BACKGROUND: The importance of multidisciplinary team (MDT) centred on pregnant women with pulmonary hypertension (PH) has been highlighted. However, rare studies have explored its effects on pregnancy outcomes. This study seeks to investigate whether and how the MDT has an effect on the treatment and outcomes of PH pregnant women. METHODS: A pre- and post-intervention study was conducted based on an interrupted time series design to compare the treatment and outcomes of patients with PH before (pre-MDT) and after (post-MDT) implementation of the MDT. PH was defined as pulmonary artery systolic pressure (sPAP) >/= 35 mmHg measured by echocardiography or right heart catheterization and sPAP at 35-60 mmHg and over 60 mmHg was defined as mild and severe PH, respectively. All results were analyzed by T-tests, Chi square tests or Fisher exact test and two-sided p value < 0.05 was set to be statistically significant. RESULTS: 149 pregnancies were found in 143 women with PH. Overall, 46 pregnancies were elective abortions, remaining 49 and 54 pregnancies completing delivery in the pre-MDT group and post-MDT group, respectively. Five (10.2%) mother and seven (8.6%) neonatal died in the former, while no maternal deaths but 1.9% neonatal death occurred in the latter. In subgroup analysis, maternal and fetal/neonatal complications were higher in patients with severe PH and World Health Organization functional class (WHO FC) III/IV and all maternal deaths occurred in class III/IV women. In pre-MDT and post-MDT groups, there were 8 and 22 pregnant women receiving the pulmonary-specific therapy and completing delivery, respectively. The percentage of heart failure and urgent cesarean of pre-MDT group was higher than the post-MDT group (30.6% vs. 12.9%, p = 0.02; 40.8% vs. 14.8%, p = 0.01, respectively). CONCLUSION: Implementing the MDT decreased the rate of urgent caesarean section and heart failure in patients with PH and no maternal deaths occurred in the post-MDT group. Pregnant women with severe PH and WHO FC III/IV might have a poor prognosis, whereas the use of pulmonary-specific therapy might improve outcomes of pregnancy. CI - (c) 2023. The Author(s). FAU - Chen, Wenjie AU - Chen W AD - Department of Cardiovascular Medicine, The Second Xiangya Hospital of Central South University, No. 139 Middle Renmin Road, Furong District, Changsha City, 410011, Hunan Province, China. FAU - Luo, Jun AU - Luo J AD - Department of Cardiovascular Medicine, The Second Xiangya Hospital of Central South University, No. 139 Middle Renmin Road, Furong District, Changsha City, 410011, Hunan Province, China. FAU - Chen, Jingyuan AU - Chen J AD - Department of Cardiovascular Medicine, The Second Xiangya Hospital of Central South University, No. 139 Middle Renmin Road, Furong District, Changsha City, 410011, Hunan Province, China. FAU - Chen, Yusi AU - Chen Y AD - Department of Cardiovascular Medicine, The Second Xiangya Hospital of Central South University, No. 139 Middle Renmin Road, Furong District, Changsha City, 410011, Hunan Province, China. FAU - Li, Zilu AU - Li Z AD - Department of Cardiovascular Medicine, The Second Xiangya Hospital of Central South University, No. 139 Middle Renmin Road, Furong District, Changsha City, 410011, Hunan Province, China. FAU - Qiu, Haihua AU - Qiu H AD - Department of Cardiovascular Medicine, The Second Xiangya Hospital of Central South University, No. 139 Middle Renmin Road, Furong District, Changsha City, 410011, Hunan Province, China. FAU - Li, Jiang AU - Li J AUID- ORCID: 0000-0003-4904-6635 AD - Department of Cardiovascular Medicine, The Second Xiangya Hospital of Central South University, No. 139 Middle Renmin Road, Furong District, Changsha City, 410011, Hunan Province, China. lijiangcs@csu.edu.cn. LA - eng PT - Journal Article DEP - 20230211 PL - England TA - BMC Pulm Med JT - BMC pulmonary medicine JID - 100968563 SB - IM MH - Infant, Newborn MH - Pregnancy MH - Female MH - Humans MH - *Hypertension, Pulmonary/complications MH - Cesarean Section/adverse effects MH - Pregnant People MH - Pregnancy Outcome MH - *Heart Failure/complications/therapy MH - Treatment Outcome MH - Patient Care Team MH - Retrospective Studies PMC - PMC9921663 OTO - NOTNLM OT - Multidisciplinary team OT - Pregnant outcomes OT - Pulmonary hypertension OT - Targeted therapy COIS- The authors declare that they have no competing interests. EDAT- 2023/02/12 06:00 MHDA- 2023/02/15 06:00 PMCR- 2023/02/11 CRDT- 2023/02/11 00:03 PHST- 2022/05/26 00:00 [received] PHST- 2023/02/06 00:00 [accepted] PHST- 2023/02/11 00:03 [entrez] PHST- 2023/02/12 06:00 [pubmed] PHST- 2023/02/15 06:00 [medline] PHST- 2023/02/11 00:00 [pmc-release] AID - 10.1186/s12890-023-02355-1 [pii] AID - 2355 [pii] AID - 10.1186/s12890-023-02355-1 [doi] PST - epublish SO - BMC Pulm Med. 2023 Feb 11;23(1):62. doi: 10.1186/s12890-023-02355-1. PMID- 36763070 OWN - NLM STAT- MEDLINE DCOM- 20230214 LR - 20230214 IS - 1827-191X (Electronic) IS - 0021-9509 (Linking) VI - 64 IP - 1 DP - 2023 Feb TI - Technical tips and clinical experience with the Nexus Endospan arch branch stent-graft. PG - 33-40 LID - 10.23736/S0021-9509.22.12577-2 [doi] AB - Aortic arch pathologies are commonly treated by open surgery which is still the gold standard. Patients that are unfit for surgery can be effectively treated mini-invasively with novel endovascular endograft specifically designed for the arch. Endovascular technology has remarkably improved in recent years and is a valid alternative option for the treatment of aortic arch. Available endografts on the market include fenestrated and branched (single, double, or triple). Most endograft designed for the aortic arch are custom-made and production time could be limiting. The aim of this study is to report our experience with the only single branch bi-modular off-the shelf device available on the market specifically designed for aortic arch aneurysms and dissections. We perform endovascular treatment of the arch in a multidisciplinary team together with dedicated anesthesiologist team, interventional cardiologists, and cardiac surgeons. Prior to the implantation of the endograft, a debranching procedure must be made to redirect the blood from brachiocephalic trunk (BCT) to the left common carotid artery and left subclavian artery. A through and through system from the right axillary artery to the femoral artery is required to deploy the main module. The ascending module is delivered over an extra stiff guidewire placed in the left ventricle. Molding of the endografts is performed with kissing balloon in rapid pacing. We performed 8 cases. Six of them came to our attention for residual dissection and has already been treated with ascending aorta replacement. Mean aortic diameter was 63 mm. All patients required complete debranching of the supra-aortic vessel and received a right common carotid -left subclavian artery bypass with reimplantation of the left common carotid artery on the graft. Timing of the debranching was a few days before the endovascular procedure in 76% of cases. Technical success of the endovascular intervention occurred in 100% of cases. In 2 cases the target supra-aortic trunk for the deployment of the main module BCT branch was the left subclavian artery with no adverse event related to this variation. No intraoperative adjunctive maneuvers have been registered, left subclavian artery have been embolized during the procedure in 5 cases. No access complications have been reported. We experienced 1 case of major stroke with permanent neurological impairments that lead to worsening of clinical condition and death at 6 months. No cardiological adverse event have been registered. Two cases of type 2 endoleak have been reported and required reintervention with embolization of the LSA. At 1 year follow-up no aorta-related adverse event has been reported. The use of this off-the-shelf device for the treatment of aortic arch pathologies requiring total debranching of the supra-aortic vessels seems to be safe and effective. Preliminary results are promising despite available data are insufficient and further data collection is mandatory. FAU - Squizzato, Francesco AU - Squizzato F AD - Unit of Vascular and Endovascular Surgery, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy. FAU - Spertino, Andrea AU - Spertino A AD - Unit of Vascular and Endovascular Surgery, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy. FAU - Grego, Franco AU - Grego F AD - Unit of Vascular and Endovascular Surgery, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy. FAU - D'Onofrio, Augusto AU - D'Onofrio A AD - Unit of Cardiac Surgery, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy. FAU - Piazza, Michele AU - Piazza M AD - Unit of Vascular and Endovascular Surgery, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy. FAU - Antonello, Michele AU - Antonello M AD - Unit of Vascular and Endovascular Surgery, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy - michele.antonello.1@unipd.it. LA - eng PT - Journal Article PL - Italy TA - J Cardiovasc Surg (Torino) JT - The Journal of cardiovascular surgery JID - 0066127 SB - IM MH - Humans MH - Blood Vessel Prosthesis MH - *Blood Vessel Prosthesis Implantation MH - *Aortic Aneurysm, Thoracic/diagnostic imaging/surgery MH - *Aortic Dissection MH - Prosthesis Design MH - Treatment Outcome MH - Aorta, Thoracic/diagnostic imaging/surgery MH - Stents MH - *Endovascular Procedures/adverse effects MH - Retrospective Studies EDAT- 2023/02/11 06:00 MHDA- 2023/02/15 06:00 CRDT- 2023/02/10 10:33 PHST- 2023/02/10 10:33 [entrez] PHST- 2023/02/11 06:00 [pubmed] PHST- 2023/02/15 06:00 [medline] AID - S0021-9509.22.12577-2 [pii] AID - 10.23736/S0021-9509.22.12577-2 [doi] PST - ppublish SO - J Cardiovasc Surg (Torino). 2023 Feb;64(1):33-40. doi: 10.23736/S0021-9509.22.12577-2. PMID- 36754525 OWN - NLM STAT- MEDLINE DCOM- 20230210 LR - 20230519 IS - 2213-1787 (Electronic) IS - 2213-1779 (Print) IS - 2213-1779 (Linking) VI - 11 IP - 2 DP - 2023 Feb TI - Approaches to Genetic Screening in Cardiomyopathies: Practical Guidance for Clinicians. PG - 133-142 LID - S2213-1779(22)00720-X [pii] LID - 10.1016/j.jchf.2022.11.025 [doi] AB - Patients and families benefit when the genetic etiology of cardiomyopathy is elucidated through a multidisciplinary approach including genetic counseling and judicious use of genetic testing. The yield of genetic testing is optimized when performed on a proband with a clear phenotype, and interrogates genes that are validated in association with that specific form of cardiomyopathy. Variants of uncertain significance are frequently uncovered and should not be overinterpreted. Identifying an impactful genetic variant as the cause of a patient's cardiomyopathy can have important prognostic impact, and enable streamlined cascade testing to highlight at risk relatives. Certain genotypes are associated with unique potential cardiac and noncardiac risk factors and may dictate personalized approaches to treatment. CI - Copyright (c) 2023 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. FAU - Kontorovich, Amy R AU - Kontorovich AR AD - Center for Inherited Cardiovascular Diseases, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Electronic address: amy.kontorovich@mountsinai.org. LA - eng GR - K23 HL140083/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Review PL - United States TA - JACC Heart Fail JT - JACC. Heart failure JID - 101598241 SB - IM MH - Humans MH - Genetic Predisposition to Disease MH - *Heart Failure/genetics MH - Genetic Testing MH - *Cardiomyopathies/diagnosis/genetics MH - Genetic Counseling MH - Phenotype PMC - PMC10191168 MID - NIHMS1873279 OTO - NOTNLM OT - cardiomyopathy OT - genetic counseling OT - genetic testing OT - genetics COIS- Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2023/02/09 06:00 MHDA- 2023/02/11 06:00 PMCR- 2023/05/17 CRDT- 2023/02/08 20:59 PHST- 2022/08/15 00:00 [received] PHST- 2022/11/28 00:00 [revised] PHST- 2022/11/29 00:00 [accepted] PHST- 2023/02/08 20:59 [entrez] PHST- 2023/02/09 06:00 [pubmed] PHST- 2023/02/11 06:00 [medline] PHST- 2023/05/17 00:00 [pmc-release] AID - S2213-1779(22)00720-X [pii] AID - 10.1016/j.jchf.2022.11.025 [doi] PST - ppublish SO - JACC Heart Fail. 2023 Feb;11(2):133-142. doi: 10.1016/j.jchf.2022.11.025. PMID- 36754512 OWN - NLM STAT- MEDLINE DCOM- 20230210 LR - 20240206 IS - 1558-3597 (Electronic) IS - 0735-1097 (Print) IS - 0735-1097 (Linking) VI - 81 IP - 6 DP - 2023 Feb 14 TI - Impact of Transcatheter Mitral Valve Repair Availability on Volume and Outcomes of Surgical Repair. PG - 521-532 LID - S0735-1097(22)07556-8 [pii] LID - 10.1016/j.jacc.2022.11.043 [doi] AB - BACKGROUND: The impact of transcatheter edge-to-edge repair (TEER) on national surgical mitral valve repair (MVr) volume and outcomes is unknown. OBJECTIVES: This study aims to assess the impact of TEER availability on MVr volumes and outcomes for degenerative mitral regurgitation. METHODS: MVr volume, 30-day and 5-year outcomes, including mortality, heart failure rehospitalization and mitral valve reintervention, were obtained from the Society of Thoracic Surgeons database linked with Medicare administrative claims and were compared within TEER centers before and after the first institutional TEER procedure. A difference-in-difference approach comparing parallel trends in coronary artery bypass grafting outcomes was used to account for temporal improvements in perioperative care. RESULTS: From July 2011 through December 2018, 13,959 patients underwent MVr at 278 institutions, which became TEER-capable during the study period. There was no significant change in median annualized institutional MVr volume before (32 [IQR: 17-54]) vs after (29 [IQR: 16-54]) the first TEER (P = 0.06). However, higher-risk (Society of Thoracic Surgeons predicted risk of mortality >/=2%) MVr procedures declined over the study period (P < 0.001 for trend). The introduction of TEER was associated with reduced risk-adjusted odds of mortality after MVr at 30 days (adjusted OR: 0.73; 95% CI: 0.54-0.99) and over 5 years (adjusted HR: 0.75; 95% CI: 0.66-0.86). These improvements in 30-day and 5-year mortality were significantly greater than equivalent trends in coronary artery bypass grafting. CONCLUSIONS: The introduction of TEER has not significantly changed overall MVr case volumes for degenerative mitral regurgitation but is associated with a decrease in higher-risk surgical operations and improved 30-day and 5-year outcomes within institutions adopting the technology. CI - Copyright (c) 2023 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. FAU - Lowenstern, Angela M AU - Lowenstern AM AD - Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA. Electronic address: https://twitter.com/A_Lowenstern. FAU - Vekstein, Andrew M AU - Vekstein AM AD - Division of Cardiovascular and Thoracic Surgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA; Duke Clinical Research Institute, Durham, North Carolina, USA. Electronic address: andrew.vekstein@duke.edu. FAU - Grau-Sepulveda, Maria AU - Grau-Sepulveda M AD - Duke Clinical Research Institute, Durham, North Carolina, USA. FAU - Badhwar, Vinay AU - Badhwar V AD - Department of Cardiovascular and Thoracic Surgery, West Virginia University, Morgantown, West Virginia, USA. FAU - Thourani, Vinod H AU - Thourani VH AD - Department of Cardiovascular Surgery, Marcus Heart and Vascular Center, Piedmont Heart and Vascular Institute, Atlanta, Georgia, USA. FAU - Cohen, David J AU - Cohen DJ AD - Cardiovascular Research Foundation, New York, New York, USA; St Francis Hospital and Heart Center, Roslyn, New York, USA. FAU - Sorajja, Paul AU - Sorajja P AD - Valve Science Center, Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA. FAU - Goel, Kashish AU - Goel K AD - Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA. FAU - Barker, Colin M AU - Barker CM AD - Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA. FAU - Lindman, Brian R AU - Lindman BR AD - Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA. FAU - Glower, Donald G AU - Glower DG AD - Division of Cardiovascular and Thoracic Surgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA. FAU - Wang, Andrew AU - Wang A AD - Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA. FAU - Vemulapalli, Sreekanth AU - Vemulapalli S AD - Duke Clinical Research Institute, Durham, North Carolina, USA; Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA; Duke-Margolis Center for Health Policy, Duke University, Durham, North Carolina, USA. LA - eng GR - T32 HL069749/HL/NHLBI NIH HHS/United States GR - UM1 HL088925/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PL - United States TA - J Am Coll Cardiol JT - Journal of the American College of Cardiology JID - 8301365 SB - IM CIN - J Am Coll Cardiol. 2023 Feb 14;81(6):533-536. doi: 10.1016/j.jacc.2022.12.004. PMID: 36754513 MH - Humans MH - Aged MH - United States/epidemiology MH - *Mitral Valve Insufficiency/surgery MH - Mitral Valve/diagnostic imaging/surgery MH - *Heart Valve Prosthesis Implantation MH - Treatment Outcome MH - Medicare PMC - PMC10464889 MID - NIHMS1922549 OTO - NOTNLM OT - heart team OT - mitral regurgitation OT - mitral valve repair OT - transcatheter COIS- Funding Support and Author Disclosures This work was supported by an internal grant to Duke University (AD-STAR program) by Abbott. The authors are responsible for the study design, analysis, interpretation, and manuscript. This work was also supported in part by the National Institutes of Health (5T32HL069749-17 to Dr Vekstein). Dr Lowenstern has received consulting fees from Edwards Lifesciences. Dr Thourani has received consulting or research fees from Abbott Vascular, Boston Scientific, CryoLife/Artivion, Edwards Lifesciences, Jenavalve, Medtronic, and Shockwave. Dr Cohen has received research grant support from Edwards Lifesciences, Abbott, Boston Scientific, and Medtronic; and has received consulting fees from Edwards Lifesciences, Abbott, Boston Scientific, and Medtronic. Mr Lindman is a member of the Scientific Advisory Board for Roche Diagnostics; and has received grants and/or research support from Edwards Lifesciences and Roche Diagnostics. Dr Vemulapalli has received grants/contracts from the American College of Cardiology, Society of Thoracic Surgeons, Cytokinetics, Abbott Vascular, National Institutes of Health (R01 and SBIR), and Boston Scientific; and has received consulting fees/been on advisory board with Janssen, American College of Physicians, HeartFlow, and Edwards LifeSciences. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2023/02/09 06:00 MHDA- 2023/02/11 06:00 PMCR- 2023/08/29 CRDT- 2023/02/08 20:58 PHST- 2022/07/20 00:00 [received] PHST- 2022/10/31 00:00 [revised] PHST- 2022/11/07 00:00 [accepted] PHST- 2023/02/08 20:58 [entrez] PHST- 2023/02/09 06:00 [pubmed] PHST- 2023/02/11 06:00 [medline] PHST- 2023/08/29 00:00 [pmc-release] AID - S0735-1097(22)07556-8 [pii] AID - 10.1016/j.jacc.2022.11.043 [doi] PST - ppublish SO - J Am Coll Cardiol. 2023 Feb 14;81(6):521-532. doi: 10.1016/j.jacc.2022.11.043. PMID- 36752228 OWN - NLM STAT- MEDLINE DCOM- 20230223 LR - 20230421 IS - 2047-9980 (Electronic) IS - 2047-9980 (Linking) VI - 12 IP - 4 DP - 2023 Feb 21 TI - Informing Use of Telehealth for Managing Chronic Conditions: Mixed-Methods Evaluation of Telehealth Use to Manage Heart Failure During COVID-19. PG - e027362 LID - 10.1161/JAHA.122.027362 [doi] LID - e027362 AB - Background The COVID-19 pandemic forced Veterans Health Administration facilities to rapidly adopt and deploy telehealth alternatives to provide continuity of care to veterans while minimizing physical contact. The impact of moving to virtual visits on patients with congestive heart failure (HF) is unknown. The goal of this study was to understand how patients with HF and their providers experienced the shift to telehealth for managing a chronic condition, and to inform best practices for continued telehealth use. Methods and Results We identified Veterans Health Administration Medical Centers with high telehealth use before COVID-19 and sites that were forced to adopt telehealth in response to COVID-19, and interviewed cardiology providers and veterans with HF about their experiences using telehealth. Interviews were recorded, transcribed, and analyzed using team-based rapid content analysis. We identified 3 trajectory patterns for cardiology telehealth use before and during COVID-19. They were the low-use class (low to low), high-use class (relatively high to higher), and increased-use class (low to high). The high-use and increased-use classes fit the criteria for sites that had high telehealth use before COVID-19 and sites that rapidly adopted telehealth in response to COVID-19. There were 12 sites in the high-use class and 4 sites in the increased-use class. To match with the number of sites in the increased-use class, we selected the top 4 sites by looking at the months before COVID-19. We identified 3 themes related to telehealth use among patients with HF and cardiology providers: (1) technology was the primary barrier for both patients and providers; (2) infrastructural support was the primary facilitator for providers; and (3) both patients and providers had largely neutral opinions on how telehealth compares to in-person care but described situations in which telehealth is not appropriate. Conclusions Only 12 sites fit the criteria of high telehealth use in cardiology before COVID-19, and 4 fit the criteria of low use that increased in response to COVID-19. Patients and providers at both site types were largely satisfied using telehealth to manage HF. Understanding best practices for managing ambulatory care-sensitive conditions through virtual visits can help the Veterans Health Administration prepare for long-term impacts of COVID-19 on in-person visits, as well as improve access to care for veterans who live remotely or who have difficulty traveling to in-person appointments. FAU - Leonard, Chelsea AU - Leonard C AUID- ORCID: 0000-0002-4865-4658 AD - Denver Seattle Center of Innovation (COIN) Aurora Colorado. AD - Division of Health Care Policy and Research University of Colorado Medical Campus Aurora Colorado. FAU - Liu, Wenhui AU - Liu W AD - Denver Seattle Center of Innovation (COIN) Aurora Colorado. FAU - Holstein, Ariel AU - Holstein A AUID- ORCID: 0000-0002-8150-8820 AD - Denver Seattle Center of Innovation (COIN) Aurora Colorado. FAU - Alliance, Slande AU - Alliance S AUID- ORCID: 0000-0003-1290-8422 AD - Malcom Randall VA Medical Center Gainesville Florida. FAU - Nunnery, Mary AU - Nunnery M AD - Denver Seattle Center of Innovation (COIN) Aurora Colorado. FAU - Rohs, Carly AU - Rohs C AUID- ORCID: 0000-0003-2902-1836 AD - Denver Seattle Center of Innovation (COIN) Aurora Colorado. FAU - Sloan, Marilyn AU - Sloan M AUID- ORCID: 0000-0003-4023-7750 AD - Denver Seattle Center of Innovation (COIN) Aurora Colorado. FAU - Winchester, David E AU - Winchester DE AUID- ORCID: 0000-0002-5224-2891 AD - Malcom Randall VA Medical Center Gainesville Florida. LA - eng PT - Journal Article PT - Research Support, U.S. Gov't, Non-P.H.S. DEP - 20230208 PL - England TA - J Am Heart Assoc JT - Journal of the American Heart Association JID - 101580524 SB - IM MH - Humans MH - *COVID-19 MH - Pandemics MH - *Telemedicine MH - *Veterans MH - *Heart Failure/epidemiology/therapy PMC - PMC10111499 OTO - NOTNLM OT - COVID-19 OT - ambulatory care sensitive conditions OT - congestive heart failure OT - mixed-methods research OT - telehealth EDAT- 2023/02/09 06:00 MHDA- 2023/02/25 06:00 PMCR- 2023/02/21 CRDT- 2023/02/08 06:23 PHST- 2023/02/09 06:00 [pubmed] PHST- 2023/02/25 06:00 [medline] PHST- 2023/02/08 06:23 [entrez] PHST- 2023/02/21 00:00 [pmc-release] AID - JAH38161 [pii] AID - 10.1161/JAHA.122.027362 [doi] PST - ppublish SO - J Am Heart Assoc. 2023 Feb 21;12(4):e027362. doi: 10.1161/JAHA.122.027362. Epub 2023 Feb 8. PMID- 36750232 OWN - NLM STAT- MEDLINE DCOM- 20230209 LR - 20230209 IS - 1476-4954 (Electronic) IS - 1476-4954 (Linking) VI - 36 IP - 1 DP - 2023 Dec TI - Pregnancy-related maternal deaths due to cardiovascular diseases in Japan from 2010 to 2019: an analysis of maternal death exploratory committee data. PG - 2175207 LID - 10.1080/14767058.2023.2175207 [doi] AB - OBJECTIVE: Cardiovascular disease (CVD) is the leading cause of maternal deaths in high-income countries. This study aimed to assess the characteristics of maternal deaths due to CVDs and the quality of care provided to patients, and to identify elements to improve maternal care in Japan. METHODS: This descriptive study used the maternal death registration data of the Maternal Deaths Exploratory Committee of Japan between 2010 and 2019. RESULTS: Of 445 eligible pregnancy-related maternal deaths, 44 (9.9%) were attributed to CVD. The most frequent cause was aortic dissection (18 patients, 40.9%), followed by peripartum cardiomyopathy (8 patients, 18.2%), and pulmonary hypertension (5 patients, 11.4%). In 31.8% of cases, cardiopulmonary arrest occurred within 30 min after initial symptoms. Frequent symptoms included pain (27.3%) and respiratory symptoms (27.3%), with 61.4% having initial symptoms during the prenatal period. 63.6% of the patients had known risk factors, with age >/=35 years (38.6％), hypertensive disorder (15.9%), and obesity (15.9%) being the most common. Quality of care was assessed as suboptimal in 16 (36.4%) patients. Cardiac risk assessment was insufficient in three patients with preexisting cardiac disease, while 13 patients had symptoms and risk factors warranting intensive monitoring and evaluation. CONCLUSION: Aortic dissection was the leading cause of maternal death due to CVDs. Obstetrics care providers need to be familiar with cardiac risk factors and clinical warning signs that may lead to impending fatal cardiac events. Timely risk assessment, patient awareness, and a multidisciplinary team approach are key to improving maternal care in Japan. FAU - Matsushita, Tomomi AU - Matsushita T AD - Department of Obstetrics and Gynecology, Showa University School of Medicine, Tokyo, Japan. FAU - Arakaki, Tatsuya AU - Arakaki T AD - Department of Obstetrics and Gynecology, Showa University School of Medicine, Tokyo, Japan. FAU - Sekizawa, Akihiko AU - Sekizawa A AD - Department of Obstetrics and Gynecology, Showa University School of Medicine, Tokyo, Japan. FAU - Hasegawa, Junichi AU - Hasegawa J AD - Department of Obstetrics and Gynecology, Showa University School of Medicine, Tokyo, Japan. AD - Department of Obstetrics and Gynecology, St. Marianna University School of Medicine, Kanagawa, Japan. FAU - Tanaka, Hiroaki AU - Tanaka H AD - Department of Obstetrics and Gynecology, Mie University School of Medicine, Mie, Japan. FAU - Katsuragi, Shinji AU - Katsuragi S AD - Department of Obstetrics and Gynecology, University of Miyazaki, Miyazaki, Japan. FAU - Nakata, Masahiko AU - Nakata M AD - Department of Obstetrics and Gynecology, Toho University, Tokyo, Japan. FAU - Murakoshi, Takeshi AU - Murakoshi T AD - Obstetrics and Gynecology, Maternal and Perinatal Care Center, Seirei Hamamatsu General Hospital, Hamamatsu, Japan. FAU - Ikeda, Tomoaki AU - Ikeda T AD - Department of Obstetrics and Gynecology, Mie University School of Medicine, Mie, Japan. FAU - Ishiwata, Isamu AU - Ishiwata I AD - Ishiwata Obstetrics and Gynecology Hospital, Ibaraki, Japan. LA - eng PT - Journal Article PL - England TA - J Matern Fetal Neonatal Med JT - The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians JID - 101136916 SB - IM MH - Pregnancy MH - Female MH - Humans MH - Adult MH - *Maternal Death MH - *Cardiovascular Diseases/complications MH - Japan MH - Maternal Mortality MH - *Aortic Dissection OTO - NOTNLM OT - Maternal death OT - aortic dissection OT - cardiovascular disease OT - cardiovascular risk assessment OT - pregnancy-related cardiovascular disease EDAT- 2023/02/08 06:00 MHDA- 2023/02/10 06:00 CRDT- 2023/02/07 20:12 PHST- 2023/02/07 20:12 [entrez] PHST- 2023/02/08 06:00 [pubmed] PHST- 2023/02/10 06:00 [medline] AID - 10.1080/14767058.2023.2175207 [doi] PST - ppublish SO - J Matern Fetal Neonatal Med. 2023 Dec;36(1):2175207. doi: 10.1080/14767058.2023.2175207. PMID- 36745007 OWN - NLM STAT- MEDLINE DCOM- 20240531 LR - 20250804 IS - 1680-0745 (Electronic) IS - 1015-9657 (Linking) VI - 35 IP - 1 DP - 2024 Jan-Apr 23 TI - Characteristics and immediate outcomes of patients who underwent percutaneous balloon mitral valvuloplasty at the Jakaya Kikwete Cardiac Institute, Tanzania. PG - 16-26 LID - 10.5830/CVJA-2022-068 [doi] AB - BACKGROUND: For rheumatic mitral stenosis (MS), a multidisciplinary evaluation is mandatory to determine the optimal treatment: medical, percutaneous balloon mitral valvuloplasty (PBMV) or valve surgery. Clinical and imaging evaluations are essential for procedural risk assessment and outcomes. PBMV interventions are increasingly available in Africa and are feasible options for selected candidates. Enhancing PBMV training/skills transfer across most of African countries is possible. OBJECTIVES: The aim of this study was to provide insight into the clinical practice of patients with rheumatic MS evaluated for PBMV in a Tanzanian teaching hospital and to define the role of imaging, and evaluate the heart team and training/skills transfer in PBMV interventions. METHODS: From August 2019 to May 2022, 290 patients with rheumatic MS were recruited consecutively in the Tanzania Mitral Stenosis study. In total, 43 (14.8%) patients were initially evaluated for eligibility for PBMV by a heart team. We carried out the clinical assessment, laboratory investigations, transthoracic/oesophageal echocardiography (TTE/TEE) and electrocardiography. RESULTS: The median age was 31 years (range 11-68), and two-thirds of the patients were female (four diagnosed during pregnancy). Two patients had symptomatic MS at six and eight years. Nine patients had atrial fibrillation with left atrial thrombus in three, and two were detected by TEE. Nine patients in normal sinus rhythm had spontaneous echo contrast. The mean Wilkins score was 8.6 (range 8-12). With re-evaluation by the local and visiting team, 17 patients were found to have unfavourable characteristics: Bi-commissural calcification (four), >/= grade 2/4 mitral regurgitation (six), high scores and left atrial thrombus (three), left atrial thrombus (two), and severe pulmonary hypertension (two). Three patients died before the planned PBMV. Eleven patients were on a waiting list. We performed PBMV in 12 patients, with success in 10 of these, and good short-term outcomes [mean pre-PBMV (16.03 +/- 5.52 mmHg) and post-PBMV gradients (3.08 +/- 0.44 mmHg, p < 0.001)]. There were no complications. CONCLUSIONS: PBMV had good outcomes for selected candidates. TEE is mandatory in pre-PBMV screening and for procedural guidance. In our cohort, patients with Wilkins score of up to 11 underwent successful PBMV. We encourage PBMV skills expansion in low- and middle-income countries, concentrating on expertise centres. FAU - Mutagaywa, Reuben K AU - Mutagaywa RK AD - Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania; Jakaya Kikwete Cardiac Institute, Dar es Salaam, Tanzania; Department of Cardiology, Division of Heart and Lung, University Medical Centre Utrecht, Utrecht, The Netherlands. Email: reubenmutagaywa@yahoo.com. FAU - Cramer, Maarten J AU - Cramer MJ AD - Department of Cardiology, Division of Heart and Lung, University Medical Centre Utrecht, Utrecht, The Netherlands. FAU - Chillo, Pilly AU - Chillo P AD - Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania; Jakaya Kikwete Cardiac Institute, Dar es Salaam, Tanzania. FAU - Barongo, Aileen AU - Barongo A AD - Department of Paediatric and Child Health, Mwananyamala Regional Hospital, Dar es Salaam, Tanzania. FAU - Kifai, Engerasiya AU - Kifai E AD - Jakaya Kikwete Cardiac Institute, Dar es Salaam, Tanzania. FAU - Chamuleau, Steven AU - Chamuleau S AD - Amsterdam Heart Centre, Department of Cardiology, Amsterdam University Medical Centre, Amsterdam, The Netherlands. FAU - Eze-Nliam, Chete AU - Eze-Nliam C AD - Department of Clinical and Interventional Cardiology, Cleveland Clinic; Heart, Vascular, and Thoracic Institute, Cleveland, USA. FAU - Vera, Nelson B AU - Vera NB AD - Department of Clinical and Interventional Cardiology, Cleveland Clinic; Heart, Vascular, and Thoracic Institute, Cleveland, USA. FAU - Nkya, Deogratias AU - Nkya D AD - Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania; Jakaya Kikwete Cardiac Institute, Dar es Salaam, Tanzania. FAU - Loth, Alex AU - Loth A AD - Jakaya Kikwete Cardiac Institute, Dar es Salaam, Tanzania. FAU - Alencherry, Ben AU - Alencherry B AD - Jakaya Kikwete Cardiac Institute, Dar es Salaam, Tanzania; Department of Clinical and Interventional Cardiology, Cleveland Clinic; Heart, Vascular, and Thoracic Institute, Cleveland, USA. FAU - Mongella, Stella AU - Mongella S AD - Jakaya Kikwete Cardiac Institute, Dar es Salaam, Tanzania. FAU - Mayala, Henry AU - Mayala H AD - Jakaya Kikwete Cardiac Institute, Dar es Salaam, Tanzania. FAU - Kisenge, Peter AU - Kisenge P AD - Jakaya Kikwete Cardiac Institute, Dar es Salaam, Tanzania. FAU - Mwinchete, Salehe AU - Mwinchete S AD - Jakaya Kikwete Cardiac Institute, Dar es Salaam, Tanzania. FAU - Joseph, Alex B AU - Joseph AB AD - Jakaya Kikwete Cardiac Institute, Dar es Salaam, Tanzania. FAU - Kwesigabo, Gideon AU - Kwesigabo G AD - Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania. FAU - Kamuhabwa, Appolinary AU - Kamuhabwa A AD - Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania. FAU - Albaghdadi, Mazen AU - Albaghdadi M AD - NCH Heart Institute - NCH Healthcare System, Florida, USA. FAU - Ghobrial, Joanna AU - Ghobrial J AD - Department of Clinical and Interventional Cardiology, Cleveland Clinic; Heart, Vascular, and Thoracic Institute, Cleveland, USA. FAU - Janabi, Mohamed AU - Janabi M AD - Jakaya Kikwete Cardiac Institute, Dar es Salaam, Tanzania. LA - eng PT - Journal Article DEP - 20230206 PL - South Africa TA - Cardiovasc J Afr JT - Cardiovascular journal of Africa JID - 101313864 SB - IM MH - Humans MH - *Mitral Valve Stenosis/diagnostic imaging/therapy/physiopathology/surgery MH - Female MH - *Balloon Valvuloplasty/adverse effects MH - *Rheumatic Heart Disease/therapy/diagnostic imaging/diagnosis MH - Male MH - Adult MH - Young Adult MH - Treatment Outcome MH - Tanzania MH - Adolescent MH - Middle Aged MH - Aged MH - Child MH - *Mitral Valve/diagnostic imaging/surgery/physiopathology MH - Time Factors MH - Risk Factors MH - Recovery of Function MH - Echocardiography, Transesophageal OTO - NOTNLM OT - Wilkins score OT - outcome OT - percutaneous mitral valvuloplasty OT - rheumatic heart disease OT - thrombus EDAT- 2023/02/07 06:00 MHDA- 2024/05/31 12:43 CRDT- 2023/02/06 09:42 PHST- 2021/10/05 00:00 [received] PHST- 2022/12/06 00:00 [accepted] PHST- 2024/05/31 12:43 [medline] PHST- 2023/02/07 06:00 [pubmed] PHST- 2023/02/06 09:42 [entrez] AID - 10.5830/CVJA-2022-068 [doi] PST - ppublish SO - Cardiovasc J Afr. 2024 Jan-Apr 23;35(1):16-26. doi: 10.5830/CVJA-2022-068. Epub 2023 Feb 6. PMID- 36740551 OWN - NLM STAT- MEDLINE DCOM- 20230531 LR - 20230606 IS - 1878-0938 (Electronic) IS - 1878-0938 (Linking) VI - 51 DP - 2023 Jun TI - Ongoing Experience With Patient-Specific Computer Simulation of Transcatheter Aortic Valve Replacement in Bicuspid Aortic Valve. PG - 31-37 LID - S1553-8389(23)00016-7 [pii] LID - 10.1016/j.carrev.2023.01.015 [doi] AB - BACKGROUND: Transcatheter aortic valve replacement (TAVR) is increasingly being used to treat younger, lower-risk patients with bicuspid aortic valve (BAV). Patient-specific computer simulation may identify patients at risk for developing paravalvular regurgitation (PVR) and major conduction disturbance. Only limited prospective experience of this technology exist. We wished to describe our ongoing experience with patient-specific computer simulation. METHODS: Patients who were referred for consideration of TAVR with a self-expanding transcatheter heart valve (THV) and had BAV identified on pre-procedural cardiac computed tomography imaging underwent patient-specific computer simulation. The computer simulations were reviewed by the Heart Team and used to guide surgical or transcatheter treatment approaches and to aid in THV sizing and positioning. Clinical outcomes were recorded. RESULTS: Between May 2019 and May 2021, 16 patients with BAV were referred for consideration of TAVR with a self-expanding THV. Sievers Type 1 morphology was present in 15 patients and Type 0 in the remaining patient. Two patients were predicted to develop moderate-to-severe PVR with a TAVR procedure and these patients underwent successful surgical aortic valve replacement. In the remaining 14 patients, computer simulation was used to optimize THV sizing and positioning to minimise PVR and conduction disturbance. One patient with a low valve implantation depth developed moderate PVR and this complication was correctly predicted by the computer simulations. No patient required insertion of a new permanent pacemaker. CONCLUSION: Patient-specific computer simulation may be used to guide the most appropriate treatment modality for patients with BAV. The usage of computer simulation to guide THV sizing and positioning was associated with favourable clinical outcomes. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Dowling, Cameron AU - Dowling C AD - Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, USA; MonashHeart, Monash Health and Monash Cardiovascular Research Centre, Monash University, Melbourne, Australia. Electronic address: cameron.dowling@stanford.edu. FAU - Gooley, Robert AU - Gooley R AD - MonashHeart, Monash Health and Monash Cardiovascular Research Centre, Monash University, Melbourne, Australia. FAU - McCormick, Liam AU - McCormick L AD - MonashHeart, Monash Health and Monash Cardiovascular Research Centre, Monash University, Melbourne, Australia. FAU - Sharma, Rahul P AU - Sharma RP AD - Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, USA. FAU - Yeung, Alan C AU - Yeung AC AD - Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, USA. FAU - Fearon, William F AU - Fearon WF AD - Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, USA. FAU - Dargan, James AU - Dargan J AD - Cardiology Clinical Academic Group, St. George's University of London and St. George's University Hospitals NHS Foundation Trust, London, United Kingdom. FAU - Khan, Faisal AU - Khan F AD - Cardiology Clinical Academic Group, St. George's University of London and St. George's University Hospitals NHS Foundation Trust, London, United Kingdom. FAU - Firoozi, Sami AU - Firoozi S AD - Cardiology Clinical Academic Group, St. George's University of London and St. George's University Hospitals NHS Foundation Trust, London, United Kingdom. FAU - Brecker, Stephen J AU - Brecker SJ AD - Cardiology Clinical Academic Group, St. George's University of London and St. George's University Hospitals NHS Foundation Trust, London, United Kingdom. LA - eng PT - Journal Article DEP - 20230124 PL - United States TA - Cardiovasc Revasc Med JT - Cardiovascular revascularization medicine : including molecular interventions JID - 101238551 SB - IM MH - Humans MH - *Transcatheter Aortic Valve Replacement/adverse effects/methods MH - *Bicuspid Aortic Valve Disease/etiology/surgery MH - *Heart Valve Diseases/diagnostic imaging/surgery MH - *Aortic Valve Stenosis/diagnostic imaging/surgery/etiology MH - Computer Simulation MH - Prospective Studies MH - Multidetector Computed Tomography MH - Aortic Valve/diagnostic imaging/surgery MH - *Heart Valve Prosthesis MH - Treatment Outcome MH - Prosthesis Design OTO - NOTNLM OT - Aortic valve stenosis OT - Bicuspid aortic valve OT - Computer simulation OT - Finite element analysis OT - Heart valve prosthesis implantation OT - Transcatheter aortic valve replacement COIS- Declaration of competing interest Dr. Dowling reports grants from Medtronic, outside the submitted work. A/Prof. Gooley reports personal fees from Boston Scientific, outside the submitted work. Dr. McCormick reports personal fees from Boston Scientific, outside the submitted work. Prof. Brecker reports grants and personal fees from Medtronic, outside the submitted work. All other authors have nothing to disclose. EDAT- 2023/02/06 06:00 MHDA- 2023/05/31 06:42 CRDT- 2023/02/05 22:02 PHST- 2022/11/07 00:00 [received] PHST- 2022/12/23 00:00 [revised] PHST- 2023/01/18 00:00 [accepted] PHST- 2023/05/31 06:42 [medline] PHST- 2023/02/06 06:00 [pubmed] PHST- 2023/02/05 22:02 [entrez] AID - S1553-8389(23)00016-7 [pii] AID - 10.1016/j.carrev.2023.01.015 [doi] PST - ppublish SO - Cardiovasc Revasc Med. 2023 Jun;51:31-37. doi: 10.1016/j.carrev.2023.01.015. Epub 2023 Jan 24. PMID- 36740487 OWN - NLM STAT- MEDLINE DCOM- 20230307 LR - 20230310 IS - 1558-4623 (Electronic) IS - 0001-2998 (Linking) VI - 53 IP - 2 DP - 2023 Mar TI - Imaging of Endocarditis and Cardiac Device-Related Infections: An Update. PG - 184-198 LID - S0001-2998(23)00001-6 [pii] LID - 10.1053/j.semnuclmed.2023.01.001 [doi] AB - IE is a deadly disease requiring prompt diagnosis for adequate patient's management. The diagnosis requires the integration of clinical signs, microbiology data and imaging data and proper discussion within a multidisciplinary team, the endocarditis team. Since the introduction of (18)F-FDG-PET/CT and WBC SPECT/CT in the diagnostic algorithm of PVE the nuclear medicine imaging specialists is active part of the Endocarditis Team, requiring proper knowledge of dedicated imaging acquisition protocols, expertise for imaging reading and interpretations to select the best test or combination of tests for each specific clinical situation. In this manuscript, we will review the main technical aspects of each imaging procedure, the most recent literature with specific regards to special challenging populations and provide clinical examples. CI - Copyright (c) 2023. Published by Elsevier Inc. FAU - Ferro, Paola AU - Ferro P AD - Nuclear Medicine Unit, ASST Ospedale Papa Giovanni XXIII, Bergamo, Italy. Electronic address: paolaanna.erba@unimib.it. FAU - Boni, Roberto AU - Boni R AD - Nuclear Medicine Unit, ASST Ospedale Papa Giovanni XXIII, Bergamo, Italy. FAU - Slart, Riemer Hja AU - Slart RH AD - Medical Imaging Center, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; Faculty of Science and Technology, Biomedical Photonic Imaging, University of Twente, Enschede, The Netherlands. FAU - Erba, Paola Anna AU - Erba PA AD - Medical Imaging Center, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; Department of Medicine and Surgery, University of Milan Bicocca and Nuclear Medicine Unit ASST Ospedale Papa Giovanni XXIII, Bergamo, Italy. LA - eng PT - Journal Article PT - Review DEP - 20230204 PL - United States TA - Semin Nucl Med JT - Seminars in nuclear medicine JID - 1264464 RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18) RN - 0 (Radiopharmaceuticals) SB - IM MH - Humans MH - Positron Emission Tomography Computed Tomography/methods MH - *Defibrillators, Implantable MH - Fluorodeoxyglucose F18 MH - *Endocarditis MH - Positron-Emission Tomography MH - *Prosthesis-Related Infections MH - Radiopharmaceuticals EDAT- 2023/02/06 06:00 MHDA- 2023/03/08 06:00 CRDT- 2023/02/05 21:59 PHST- 2023/01/03 00:00 [received] PHST- 2023/01/04 00:00 [accepted] PHST- 2023/02/06 06:00 [pubmed] PHST- 2023/03/08 06:00 [medline] PHST- 2023/02/05 21:59 [entrez] AID - S0001-2998(23)00001-6 [pii] AID - 10.1053/j.semnuclmed.2023.01.001 [doi] PST - ppublish SO - Semin Nucl Med. 2023 Mar;53(2):184-198. doi: 10.1053/j.semnuclmed.2023.01.001. Epub 2023 Feb 4. PMID- 32119448 STAT- Publisher CTDT- 20230205 PB - StatPearls Publishing DP - 2023 Jan TI - Laryngotracheal Stenosis. BTI - StatPearls AB - Laryngotracheal stenosis (LTS) is a narrowing of the upper airway between the larynx and the trachea with potentially devastating consequences, including respiratory failure, cardiopulmonary arrest, and death. The upper airway is comprised of the larynx, glottis, subglottic region, and trachea. The trachea is a cylindrical-shaped tube with an anterior cartilaginous wall formed by C-shaped rings and a posterior membranous wall. The trachea branches off into the right and left mainstem bronchi at the carina, which is at the level of the 4th thoracic vertebra (T4). Laryngeal stenosis may occur as a result of trauma, related to endotracheal intubation, or due to a neoplasm, autoimmune, or infectious process. It can be asymptomatic or can lead to symptoms of upper airway obstruction. Laryngeal narrowing from any cause requires a multidisciplinary approach to management, including, but not limited to, pulmonologists, intensivists, otolaryngologists, and gastroenterologists, as well as speech-language pathologists and cardiothoracic surgeons. Determining the etiology of LTS is critical, as it informs management and provides prognostic information for the patient. CI - Copyright (c) 2023, StatPearls Publishing LLC. FAU - Almanzar, Aimee AU - Almanzar A AD - Aventura Hospital and Medical Center FAU - Danckers, Mauricio AU - Danckers M AD - Aventura Hospital and Medical Center LA - eng PT - Study Guide PT - Book Chapter PL - Treasure Island (FL) COIS- Disclosure: Aimee Almanzar declares no relevant financial relationships with ineligible companies. Disclosure: Mauricio Danckers declares no relevant financial relationships with ineligible companies. EDAT- 2023/02/05 00:00 CRDT- 2023/02/05 00:00 AID - NBK554561 [bookaccession] PMID- 36735917 OWN - NLM STAT- MEDLINE DCOM- 20230207 LR - 20250103 IS - 1526-6702 (Electronic) IS - 0730-2347 (Print) IS - 0730-2347 (Linking) VI - 50 IP - 1 DP - 2023 Jan 1 TI - Aortic Dissection and COVID-19 Pneumonia in a Pregnant Woman at 34 Weeks of Gestation. LID - 10.14503/THIJ-22-7854 [doi] LID - e227854 AB - Between 0.1% and 0.3% of all aortic dissections occur during pregnancy. Arterial hypertension, connective tissue disorders, and congenital cardiovascular anomalies-including bicuspid aortic valves-are well-known risk factors. The causality between pregnancy and aortic dissection is unclear, but there have been some observations that COVID-19 illness may increase the risk. This report describes a pregnant woman at 34 weeks of gestation who had a bicuspid aortic valve and experienced an acute aortic dissection while ill with COVID-19 pneumonia. Computed tomography confirmed a type A aortic dissection and bilateral patchy pulmonary opacities. Cesarean delivery was performed, followed by replacement of the aortic valve with a mechanical aortic prosthesis and reconstruction of the ascending aorta and hemiarch. The intraoperative course was uneventful, and the patient was successfully weaned from mechanical ventilation after 51 hours. COVID-19 during pregnancy seems to increase the risk for aortic dissection, although there is no evidence base for an association. Because guidelines for diagnosis and treatment in such complex cases are lacking, care from a multidisciplinary team is crucial for successful outcomes. CI - (c) 2023 by the Texas Heart(R) Institute, Houston. FAU - Krzelj, Kristina AU - Krzelj K AD - Department of Cardiac Surgery, University Hospital Centre Zagreb, Zagreb, Croatia. FAU - Anic, Darko AU - Anic D AD - Department of Cardiac Surgery, University Hospital Centre Zagreb, Zagreb, Croatia. LA - eng PT - Journal Article PL - United States TA - Tex Heart Inst J JT - Texas Heart Institute journal JID - 8214622 SB - IM MH - Pregnancy MH - Female MH - Humans MH - Pregnant People MH - *COVID-19/complications MH - *Aortic Dissection/diagnosis/etiology/surgery MH - Aorta MH - Aortic Valve/surgery MH - *Pregnancy Complications, Cardiovascular/diagnosis/surgery PMC - PMC9969779 OTO - NOTNLM OT - Aortic dissection OT - COVID-19 OT - interdisciplinary communication OT - pregnancy COIS- Conflicts of Interest Disclosures: The authors certify there is no conflict of interest with any financial organization regarding the material discussed in this article. EDAT- 2023/02/04 06:00 MHDA- 2023/02/08 06:00 PMCR- 2023/01/01 CRDT- 2023/02/03 16:32 PHST- 2023/02/03 16:32 [entrez] PHST- 2023/02/04 06:00 [pubmed] PHST- 2023/02/08 06:00 [medline] PHST- 2023/01/01 00:00 [pmc-release] AID - 490619 [pii] AID - 10.14503/THIJ-22-7854 [doi] PST - ppublish SO - Tex Heart Inst J. 2023 Jan 1;50(1):e227854. doi: 10.14503/THIJ-22-7854. PMID- 36731605 OWN - NLM STAT- MEDLINE DCOM- 20230411 LR - 20230411 IS - 1916-7075 (Electronic) IS - 0828-282X (Linking) VI - 39 IP - 4 DP - 2023 Apr TI - Management of Cardiogenic Shock Unrelated to Acute Myocardial Infarction. PG - 406-419 LID - S0828-282X(23)00069-7 [pii] LID - 10.1016/j.cjca.2023.01.023 [doi] AB - Cardiogenic shock is an extreme manifestation of acute decompensated heart failure. Cardiogenic shock is often caused by-and has traditionally been studied in the setting of-acute myocardial infarction (AMI CS); however, there is increasing incidence and recognition of cardiogenic shock not associated with acute myocardial infarction (non-AMI CS) as a distinct entity. Despite decades of study and technologic advancements, cardiogenic shock mortality remains as high as 50%, regardless of etiology. New approaches to shock phenotyping and classification have emerged, with a focus on appropriately matching patient physiology to a growing list of available interventions. Further study is needed to determine whether these efforts will lead to more nuanced use of mechanical circulatory support and improved patient outcomes, especially in non-AMI CS. In the meantime, models of care incorporating multidisciplinary decision making, such as shock teams, may improve patient selection and outcomes. CI - Copyright (c) 2023 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved. FAU - Barnett, Christopher F AU - Barnett CF AD - Division of Cardiology, University of California, San Francisco, San Francisco, California, USA. FAU - Brusca, Samuel B AU - Brusca SB AD - Division of Cardiology, University of California, San Francisco, San Francisco, California, USA. FAU - Hanff, Thomas C AU - Hanff TC AD - Division of Cardiovascular Medicine, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA. FAU - Blumer, Vanessa AU - Blumer V AD - Department of Cardiovascular Medicine, Heart and Vascular Institute, Kaufman Center for Heart Failure, Cleveland Clinic, Cleveland, Ohio, USA. FAU - Kalif, Adnan AU - Kalif A AD - Cardiovascular Institute at Allegheny Health Network, Pittsburgh, Pennsylvania, USA. FAU - Kanwar, Manreet AU - Kanwar M AD - Cardiovascular Institute at Allegheny Health Network, Pittsburgh, Pennsylvania, USA. Electronic address: manreet.kanwar@ahn.org. LA - eng PT - Journal Article PT - Review DEP - 20230131 PL - England TA - Can J Cardiol JT - The Canadian journal of cardiology JID - 8510280 SB - IM MH - Humans MH - Shock, Cardiogenic/therapy/complications MH - *Myocardial Infarction/complications/therapy MH - *Heart Failure/complications MH - Treatment Outcome EDAT- 2023/02/03 06:00 MHDA- 2023/04/11 06:41 CRDT- 2023/02/02 19:22 PHST- 2022/11/19 00:00 [received] PHST- 2023/01/18 00:00 [revised] PHST- 2023/01/19 00:00 [accepted] PHST- 2023/04/11 06:41 [medline] PHST- 2023/02/03 06:00 [pubmed] PHST- 2023/02/02 19:22 [entrez] AID - S0828-282X(23)00069-7 [pii] AID - 10.1016/j.cjca.2023.01.023 [doi] PST - ppublish SO - Can J Cardiol. 2023 Apr;39(4):406-419. doi: 10.1016/j.cjca.2023.01.023. Epub 2023 Jan 31. PMID- 36730494 OWN - NLM STAT- MEDLINE DCOM- 20240202 LR - 20250619 IS - 1538-4683 (Electronic) IS - 1061-5377 (Linking) VI - 32 IP - 2 DP - 2024 Mar-Apr 01 TI - Cardiac Rehabilitation Programs: Content, Effectiveness, Limitations, and Gaps in Knowledge. PG - 157-161 LID - 10.1097/CRD.0000000000000492 [doi] AB - Cardiac rehabilitation (CR) constitutes a valuable therapeutic approach for patients with a broad spectrum of cardiovascular diseases facilitating the development and maintenance of a desirable level of physical, social, and psychological functioning following the onset of cardiovascular disease. Nowadays, cardiac rehabilitation programs emphasize the use of a multidisciplinary approach. The current review aims at presenting the state-of-the-art knowledge on the indications of patients entering cardiac rehabilitation programs, including their core components, duration, and effectiveness. Following a careful review of the international literature, we conclude that there are significant differences between the most commonly cited international CR guidelines as well as additional limitations and gaps in knowledge. Despite the benefits associated with CR and despite their widespread acceptance, CR referrals and program attendance remains low, while many questions have not been so far addressed through scientific research. Overall, the findings of our study suggest a critical need for the development of robust and evidence-based standardized CR interventions to increase their use and effectiveness throughout the world. CI - Copyright (c) 2022 Wolters Kluwer Health, Inc. All rights reserved. FAU - Economidou, Eleftheria C AU - Economidou EC AD - From the Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece. FAU - Lianopoulou, Barbara AU - Lianopoulou B AD - Management Organization Unit of Development Programs, Human Resource Management, Ministry of Development and Investments, Republic of Greece, Athens, Greece. FAU - Soteriades, Soteris AU - Soteriades S AD - Hull Royal Infirmary, Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom. FAU - Soteriades, Elpidoforos S AU - Soteriades ES AD - Healthcare Management Program, School of Economics and Management, Open University of Cyprus, Nicosia, Cyprus. AD - Environmental and Occupational Medicine and Epidemiology (EOME), Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA. LA - eng PT - Journal Article PT - Review DEP - 20221121 PL - United States TA - Cardiol Rev JT - Cardiology in review JID - 9304686 SB - IM MH - Humans MH - *Cardiac Rehabilitation MH - *Cardiovascular Diseases/psychology COIS- Disclosure: The authors have no conflicts of interest to report. EDAT- 2023/02/03 06:00 MHDA- 2024/02/02 06:43 CRDT- 2023/02/02 14:13 PHST- 2024/02/02 06:43 [medline] PHST- 2023/02/03 06:00 [pubmed] PHST- 2023/02/02 14:13 [entrez] AID - 00045415-202403000-00011 [pii] AID - 10.1097/CRD.0000000000000492 [doi] PST - ppublish SO - Cardiol Rev. 2024 Mar-Apr 01;32(2):157-161. doi: 10.1097/CRD.0000000000000492. Epub 2022 Nov 21. PMID- 36729965 OWN - NLM STAT- MEDLINE DCOM- 20230224 LR - 20230920 IS - 1550-5065 (Electronic) IS - 1057-3631 (Linking) VI - 38 IP - 2 DP - 2023 Apr-Jun 01 TI - Use of the Modified Early Warning Score by Medical-Surgical Nurses to Initiate the Rapid Response Team: Impact on Patient Outcomes. PG - 171-176 LID - 10.1097/NCQ.0000000000000680 [doi] AB - BACKGROUND: Cardiac arrests are often preceded by several hours of physiological deterioration that may go undetected. LOCAL PROBLEM: Cardiac arrests frequently occurred on medical-surgical units without prior rapid response team intervention. METHODS: A pre/postintervention design was used to evaluate a protocol to guide the use of the Modified Early Warning Score (MEWS) by medical-surgical nurses to escalate the care of deteriorating adult patients. INTERVENTIONS: Following staff education, the MEWS protocol was implemented across 8 medical-surgical units. RESULTS: There was a significant increase in patients experiencing a rapid response prior to a cardiac arrest after implementing the MEWS protocol ( P < .0001). CONCLUSION: Implementing a consistent review of MEWS values allows medical-surgical nurses to initiate assistance from a rapid response team that may prevent an inpatient cardiac arrest. CI - Copyright (c) 2022 Wolters Kluwer Health, Inc. All rights reserved. FAU - Miles, Iman AU - Miles I AD - WellStar Cobb Hospital, Austell, Georgia (Dr Miles); University of Pittsburgh School of Nursing; Pittsburgh, Pennsylvania (Drs Anderson, Ren, and Fennimore); and WellStar Center for Nursing Excellence, Austell, Georgia (Ms Coker). FAU - Anderson, Maighdlin AU - Anderson M FAU - Ren, Dianxu AU - Ren D FAU - Coker, Tamara AU - Coker T FAU - Fennimore, Laura AU - Fennimore L LA - eng PT - Journal Article DEP - 20221203 PL - United States TA - J Nurs Care Qual JT - Journal of nursing care quality JID - 9200672 SB - IM MH - Adult MH - Humans MH - *Early Warning Score MH - *Hospital Rapid Response Team MH - *Heart Arrest MH - *Nurses COIS- The authors declare no conflicts of interest. EDAT- 2023/02/03 06:00 MHDA- 2023/02/25 06:00 CRDT- 2023/02/02 13:03 PHST- 2023/02/03 06:00 [pubmed] PHST- 2023/02/25 06:00 [medline] PHST- 2023/02/02 13:03 [entrez] AID - 00001786-202304000-00013 [pii] AID - 10.1097/NCQ.0000000000000680 [doi] PST - ppublish SO - J Nurs Care Qual. 2023 Apr-Jun 01;38(2):171-176. doi: 10.1097/NCQ.0000000000000680. Epub 2022 Dec 3. PMID- 36729479 OWN - NLM STAT- MEDLINE DCOM- 20230224 LR - 20230302 IS - 1549-8425 (Electronic) IS - 1549-8417 (Linking) VI - 19 IP - 2 DP - 2023 Mar 1 TI - Closed-Loop Communication in Interprofessional Emergency Teams: A Cross-Sectional Observation Study on the Use of Closed-Loop Communication Among Anesthesia Personnel. PG - 93-98 LID - 10.1097/PTS.0000000000001098 [doi] AB - OBJECTIVES: Communication failure is one of the most common causes of adverse events in hospitals and poses a direct threat to patient safety. Research recommends the use of closed-loop communication in interprofessional emergency teams to prevent such events. Multiple studies have examined closed-loop communication during simulation training, but few have investigated its use in clinical practice. The aim of the study was to explore the use of closed-loop communication by anesthesia personnel in real-life interprofessional emergency teams. METHODS: This study had a descriptive, cross-sectional design where structured field observations were used to assess anesthesia personnel's use of closed-loop communication in real-life interprofessional emergency teams. A total of 60 interprofessional teams were observed, including 120 anesthesia personnel at a hospital in South-Eastern Norway. Data were analyzed using descriptive statistics. RESULTS: A total of 1626 call outs were registered, in which closed-loop communication was applied in 45%. Closed-loop communication was used more frequently when call outs were directed using eye contact and when the call outs were medication orders. There was no difference in the use of closed-loop communication between nurse anesthetists and anesthesiologists. Closed-loop communication was used more frequently in cardiac arrest teams than in trauma teams. CONCLUSIONS: The findings in this study have contributed knowledge about anesthesia personnel's use of closed-loop communication in real-life interprofessional emergency teams and indicate a potential for improvement. Further research is needed about real-life interprofessional emergency teams' communication patterns and potential barriers from using closed-loop communication, with the aim to improve patient safety. CI - Copyright (c) 2022 Wolters Kluwer Health, Inc. All rights reserved. FAU - Gjovikli, Kristin AU - Gjovikli K AD - From the Oslo University Hospital. FAU - Valeberg, Berit T AU - Valeberg BT AD - OsloMet University, Oslo Metropolitan University, Oslo, Norway. LA - eng PT - Journal Article DEP - 20221219 PL - United States TA - J Patient Saf JT - Journal of patient safety JID - 101233393 SB - IM MH - Humans MH - *Interprofessional Relations MH - Teach-Back Communication MH - Cross-Sectional Studies MH - Communication MH - *Anesthesia MH - Patient Care Team COIS- The authors disclose no conflict of interest. EDAT- 2023/02/03 06:00 MHDA- 2023/02/25 06:00 CRDT- 2023/02/02 11:36 PHST- 2023/02/03 06:00 [pubmed] PHST- 2023/02/25 06:00 [medline] PHST- 2023/02/02 11:36 [entrez] AID - 01209203-202303000-00006 [pii] AID - 10.1097/PTS.0000000000001098 [doi] PST - ppublish SO - J Patient Saf. 2023 Mar 1;19(2):93-98. doi: 10.1097/PTS.0000000000001098. Epub 2022 Dec 19. PMID- 36725213 OWN - NLM STAT- MEDLINE DCOM- 20230328 LR - 20240502 IS - 1532-8651 (Electronic) IS - 1098-7339 (Print) IS - 1098-7339 (Linking) VI - 48 IP - 5 DP - 2023 May TI - Stellate ganglion block catheters for refractory electrical storm: a retrospective cohort and care pathway. PG - 224-228 LID - 10.1136/rapm-2022-104172 [doi] AB - BACKGROUND: Electrical storm can be challenging to treat, requiring a multidisciplinary team to coordinate medical management and invasive procedures. As the stellate ganglion provides efferent sympathetic outflow to the myocardium, stellate ganglion blocks (SGB) can be used to combat ventricular arrhythmias that arise from sympathetic overactivity. Data are scarce regarding SGB catheters as a treatment for electrical storm. We reviewed our use of SGB catheters for refractory electrical storm using our pathway collaboratively developed by critical care, cardiology, and regional anesthesia teams. METHODS: We conducted a retrospective cohort study of patients who underwent an SGB for electrical storm between January 2020 and April 2022 in our cardiovascular intensive care unit. The primary outcome was the sustained cessation of electrical storm for 24 hours. RESULTS: Upon chart review, 27 patients were identified and 11 met inclusion criteria. Cessation of electrical storm for 24 hours was achieved in 90% (n=10) of patients after left SGB. Similarly, 90% (n=10) had no documented episodes of ventricular arrhythmias requiring intervention within 6 hours after SGB. CONCLUSIONS: SGBs can interrupt or treat electrical storm. SGB catheters allow for prolonged arrhythmia cessation without repeated blocks and decrease the risk of repeat episodes of ventricular arrhythmias. CI - (c) American Society of Regional Anesthesia & Pain Medicine 2023. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Patel, Rishi Ashok AU - Patel RA AUID- ORCID: 0000-0002-2604-6061 AD - Department of Anesthesia and Perioperative Medicine, Medical University of South Carolina, Charleston, South Carolina, USA patris@musc.edu. FAU - Condrey, Jackson M AU - Condrey JM AUID- ORCID: 0000-0003-3062-9590 AD - Department of Anesthesia and Perioperative Medicine, Medical University of South Carolina, Charleston, South Carolina, USA. FAU - George, Renuka M AU - George RM AUID- ORCID: 0000-0001-5184-5677 AD - Department of Anesthesia and Perioperative Medicine, Medical University of South Carolina, Charleston, South Carolina, USA. FAU - Wolf, Bethany J AU - Wolf BJ AUID- ORCID: 0000-0002-7124-5158 AD - Department of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina, USA. FAU - Wilson, Sylvia H AU - Wilson SH AUID- ORCID: 0000-0003-4747-6009 AD - Department of Anesthesia and Perioperative Medicine, Medical University of South Carolina, Charleston, South Carolina, USA. LA - eng GR - UL1 TR001450/TR/NCATS NIH HHS/United States PT - Journal Article PT - Review DEP - 20230201 PL - England TA - Reg Anesth Pain Med JT - Regional anesthesia and pain medicine JID - 9804508 SB - IM MH - Humans MH - Retrospective Studies MH - *Stellate Ganglion MH - Critical Pathways MH - Arrhythmias, Cardiac/diagnosis/therapy MH - Heart MH - *Autonomic Nerve Block/methods PMC - PMC10251217 MID - NIHMS1902463 OTO - NOTNLM OT - Autonomic Nerve Block OT - Critical Care OT - Outcome Assessment, Health Care COIS- Competing interests: None declared. EDAT- 2023/02/02 06:00 MHDA- 2023/03/28 17:13 PMCR- 2024/05/01 CRDT- 2023/02/01 21:03 PHST- 2022/11/07 00:00 [received] PHST- 2023/01/24 00:00 [accepted] PHST- 2023/03/28 17:13 [medline] PHST- 2023/02/02 06:00 [pubmed] PHST- 2023/02/01 21:03 [entrez] PHST- 2024/05/01 00:00 [pmc-release] AID - rapm-2022-104172 [pii] AID - 10.1136/rapm-2022-104172 [doi] PST - ppublish SO - Reg Anesth Pain Med. 2023 May;48(5):224-228. doi: 10.1136/rapm-2022-104172. Epub 2023 Feb 1. PMID- 36723969 OWN - NLM STAT- MEDLINE DCOM- 20230612 LR - 20230612 IS - 2724-5438 (Electronic) IS - 2724-5691 (Linking) VI - 78 IP - 3 DP - 2023 Jun TI - Surgical repair of postinfarction ventricular septal rupture: current state of the art. PG - 293-299 LID - 10.23736/S2724-5691.22.09832-X [doi] AB - The incidence of postacute myocardial infarction ventricular septal rupture (post-AMI VSR) has decreased over the past two decades. Nevertheless, individuals who suffer from post-AMI VSR continue to represent a subgroup of patients with high morbidity and mortality. The care for these patients is complex and requires a multidisciplinary approach. However, because of the small number of reports that exist to guide clinical practice, there is a significant variability in care among centers. This review summarizes information on post-AMI VSR diagnosis and outline contemporary best management and practice consideration. FAU - Matteucci, Matteo AU - Matteucci M AD - Unit of Cardiac Surgery, Department of Medicine, and Surgery, ASST dei Sette Laghi, University of Insubria, Varese, Italy - matteomatteucci87@gmail.com. AD - Thoracic Research Center, Collegium Medicum Nicolaus Copernicus University, Innovative Medical Forum, Bydgoszcz, Poland - matteomatteucci87@gmail.com. AD - Department of Cardiothoracic Surgery, Heart and Vascular Center, Maastricht University Medical Centre (MUMC), Maastricht, the Netherlands - matteomatteucci87@gmail.com. FAU - Ferrarese, Sandro AU - Ferrarese S AD - Unit of Cardiac Surgery, Department of Medicine, and Surgery, ASST dei Sette Laghi, University of Insubria, Varese, Italy. FAU - Kowalewski, Mariusz AU - Kowalewski M AD - Thoracic Research Center, Collegium Medicum Nicolaus Copernicus University, Innovative Medical Forum, Bydgoszcz, Poland. AD - Department of Cardiothoracic Surgery, Heart and Vascular Center, Maastricht University Medical Centre (MUMC), Maastricht, the Netherlands. AD - Department of Cardiac Surgery, Center of Postgraduate Medical Education, Central Clinical Hospital of the Ministry of Interior, Warsaw, Poland. FAU - Meani, Paolo AU - Meani P AD - Thoracic Research Center, Collegium Medicum Nicolaus Copernicus University, Innovative Medical Forum, Bydgoszcz, Poland. AD - Department of Cardiothoracic Surgery, Heart and Vascular Center, Maastricht University Medical Centre (MUMC), Maastricht, the Netherlands. FAU - Messina, Corinne AU - Messina C AD - Unit of Cardiac Surgery, Department of Medicine, and Surgery, ASST dei Sette Laghi, University of Insubria, Varese, Italy. FAU - Giusti, Rosa AU - Giusti R AD - Unit of Cardiac Surgery, Department of Medicine, and Surgery, ASST dei Sette Laghi, University of Insubria, Varese, Italy. FAU - Velasco, Maria AU - Velasco M AD - Unit of Cardiac Surgery, Department of Medicine, and Surgery, ASST dei Sette Laghi, University of Insubria, Varese, Italy. FAU - Scarantino, Arianna AU - Scarantino A AD - Unit of Cardiac Surgery, Department of Medicine, and Surgery, ASST dei Sette Laghi, University of Insubria, Varese, Italy. FAU - Garis, Sara AU - Garis S AD - Unit of Cardiac Surgery, Department of Medicine, and Surgery, ASST dei Sette Laghi, University of Insubria, Varese, Italy. FAU - Borsani, Paolo AU - Borsani P AD - Unit of Cardiac Surgery, Department of Medicine, and Surgery, ASST dei Sette Laghi, University of Insubria, Varese, Italy. FAU - Corazzari, Claudio AU - Corazzari C AD - Unit of Cardiac Surgery, Department of Medicine, and Surgery, ASST dei Sette Laghi, University of Insubria, Varese, Italy. FAU - Ronco, Daniele AU - Ronco D AD - Department of Cardiothoracic Surgery, Heart and Vascular Center, Maastricht University Medical Centre (MUMC), Maastricht, the Netherlands. FAU - Lorusso, Roberto AU - Lorusso R AD - Department of Cardiothoracic Surgery, Heart and Vascular Center, Maastricht University Medical Centre (MUMC), Maastricht, the Netherlands. FAU - Severgnini, Paolo AU - Severgnini P AD - Cardiac Surgery Intensive Care Unit, Department of Biotechnology and Life Sciences, ASST dei Sette Laghi, University of Insubria, Varese, Italy. FAU - Musazzi, Andrea AU - Musazzi A AD - Unit of Cardiac Surgery, Department of Medicine, and Surgery, ASST dei Sette Laghi, University of Insubria, Varese, Italy. LA - eng PT - Journal Article PT - Review DEP - 20230201 PL - Italy TA - Minerva Surg JT - Minerva surgery JID - 101777295 SB - IM MH - Humans MH - *Ventricular Septal Rupture/etiology/surgery/diagnosis MH - Treatment Outcome MH - Risk Factors MH - *Myocardial Infarction/complications/epidemiology MH - Incidence EDAT- 2023/02/02 06:00 MHDA- 2023/06/12 06:42 CRDT- 2023/02/01 11:42 PHST- 2023/06/12 06:42 [medline] PHST- 2023/02/02 06:00 [pubmed] PHST- 2023/02/01 11:42 [entrez] AID - S2724-5691.22.09832-X [pii] AID - 10.23736/S2724-5691.22.09832-X [doi] PST - ppublish SO - Minerva Surg. 2023 Jun;78(3):293-299. doi: 10.23736/S2724-5691.22.09832-X. Epub 2023 Feb 1. PMID- 20301783 STAT- Publisher DRDT- 20230202 CTDT- 20100126 PB - University of Washington, Seattle DP - 1993 TI - Koolen-de Vries Syndrome. BTI - GeneReviews((R)) AB - CLINICAL CHARACTERISTICS: Koolen-de Vries syndrome (KdVS) is characterized by congenital malformations, developmental delay / intellectual disability, neonatal/childhood hypotonia, epilepsy, dysmorphisms, and behavioral features. Psychomotor developmental delay is noted in all individuals from an early age. The majority of individuals with KdVS function in the mild-to-moderate range of intellectual disability. Other findings include speech and language delay (100%), epilepsy (~33%), congenital heart defects (25%-50%), renal and urologic anomalies (25%-50%), and cryptorchidism. Behavior in most is described as friendly, amiable, and cooperative. DIAGNOSIS/TESTING: The diagnosis of KdVS is established in a proband who has either a heterozygous 500- to 650-kb deletion at chromosome 17q21.31 that includes KANSL1 or a heterozygous intragenic pathogenic variant in KANSL1. Note: The 17q21.31 deletion cannot be identified by analysis of G-banded chromosomes or other cytogenetic banding techniques. MANAGEMENT: Treatment of manifestations: Supportive care, ideally through a multidisciplinary team of specialists, to improve quality of life, maximize function, and reduce complications is recommended. Speech therapy to support early feeding challenges and communication development; physiotherapy for gross and fine motor delays; educational programs directed to specific disabilities identified. Growth hormone therapy is indicated for those with growth hormone deficiency. Routine treatment of vision issues / strabismus; hearing loss; cardiac, renal, and urologic issues; epilepsy; scoliosis, hip dislocation, and positional deformities of the feet; multiple nevi. Surveillance: At each visit: measurement of growth parameters; evaluation of nutritional status and safety of oral intake; monitoring of developmental progress and educational needs; assessment for new manifestations, such as seizures and changes in tone; behavioral assessment; assessment of mobility and self-help skills. Annual full skin examination in those with lighter skin tones or skin types who are at greater risk for developing melanoma. Ophthalmology and hearing evaluations annually or as clinically indicated. GENETIC COUNSELING: KdVS, caused by a heterozygous deletion at chromosome 17q21.31 or a heterozygous intragenic KANSL1 pathogenic variant, is an autosomal dominant disorder. Almost all affected individuals represent simplex cases (i.e., a single affected individual in the family).The recurrence risk for future pregnancies is slightly greater than that of the general population because of the possibility of germline mosaicism in one of the parents. Once the KdVS-related genetic alteration has been identified in an affected family member, prenatal and preimplantation genetic testing are possible. CI - Copyright (c) 1993-2026, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved. FED - Adam, Margaret P ED - Adam MP FED - Bick, Sarah ED - Bick S FED - Mirzaa, Ghayda M ED - Mirzaa GM FED - Wallace, Stephanie E ED - Wallace SE FED - Amemiya, Anne ED - Amemiya A FAU - Koolen, David A AU - Koolen DA AD - Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands FAU - Morgan, Angela AU - Morgan A AD - Murdoch Children's Research Institute, Victoria, Australia AD - Department of Audiology and Speech Pathology, University of Melbourne, Melbourne, Australia FAU - de Vries, Bert BA AU - de Vries BBA AD - Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands LA - eng PT - Review PT - Book Chapter PL - Seattle (WA) OTO - NLM OT - KdVS OT - KAT8 regulatory NSL complex subunit 1 OT - Not applicable OT - KANSL1 OT - Not applicable OT - Koolen-de Vries Syndrome OT - KdVS EDAT- 2023/02/02 00:00 CRDT- 2023/02/02 00:00 AID - NBK24676 [bookaccession] PMID- 36718620 OWN - NLM STAT- MEDLINE DCOM- 20230201 LR - 20230911 IS - 1531-7080 (Electronic) IS - 0268-4705 (Linking) VI - 38 IP - 2 DP - 2023 Mar 1 TI - Update on cardiogenic shock: from detection to team management. PG - 108-115 LID - 10.1097/HCO.0000000000001017 [doi] AB - PURPOSE OF REVIEW: The following review is intended to provide a summary of contemporary cardiogenic shock (CS) profiling and diagnostic strategies, including biomarker and hemodynamic-based (invasive and noninvasive) monitoring, discuss clinical differences in presentation and trajectory between acute myocardial infarction (AMI)-CS and heart failure (HF)-CS, describe transitions to native heart recovery and heart replacement therapies with a focus on tailored management and emerging real-world data, and emphasize trends in team-based initiatives and interventions for cardiogenic shock including the integration of protocol-driven care. RECENT FINDINGS: This document provides a broad overview of contemporary scientific consensus statements as well as data derived from randomized controlled clinical trials and observational registry working groups focused on cardiogenic shock management. SUMMARY: This review highlights the increasingly important role of pulmonary artery catheterization in AMI-CS and HF-CS cardiogenic shock and advocates for routine application of algorithmic approaches with interdisciplinary care pathways. Cardiogenic shock algorithms facilitate the integration of clinical, hemodynamic, and imaging data to determine the most appropriate patient hemodynamic support platform to achieve adequate organ perfusion and decongestion. CI - Copyright (c) 2022 Wolters Kluwer Health, Inc. All rights reserved. FAU - Khariton, Yevgeniy AU - Khariton Y AD - Baylor Scott and White Health - Temple, Texas, USA. FAU - Hassan, Ossama Abou AU - Hassan OA FAU - Hernandez-Montfort, Jaime A AU - Hernandez-Montfort JA LA - eng PT - Journal Article PT - Review DEP - 20230116 PL - United States TA - Curr Opin Cardiol JT - Current opinion in cardiology JID - 8608087 RN - 0 (Cardiotonic Agents) SB - IM MH - Humans MH - Shock, Cardiogenic/diagnosis/therapy MH - *Myocardial Infarction/therapy MH - *Heart Failure MH - Cardiotonic Agents MH - Hemodynamics EDAT- 2023/02/01 06:00 MHDA- 2023/02/02 06:00 CRDT- 2023/01/31 03:43 PHST- 2023/01/31 03:43 [entrez] PHST- 2023/02/01 06:00 [pubmed] PHST- 2023/02/02 06:00 [medline] AID - 00001573-202303000-00010 [pii] AID - 10.1097/HCO.0000000000001017 [doi] PST - ppublish SO - Curr Opin Cardiol. 2023 Mar 1;38(2):108-115. doi: 10.1097/HCO.0000000000001017. Epub 2023 Jan 16. PMID- 36714240 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230202 IS - 1178-2390 (Print) IS - 1178-2390 (Electronic) IS - 1178-2390 (Linking) VI - 16 DP - 2023 TI - Development of a Multidisciplinary Clinic for Patients with Ehlers Danlos Syndromes: Considerations and Strategies. PG - 191-195 LID - 10.2147/JMDH.S396221 [doi] AB - Ehlers-Danlos Syndromes (EDS) is a group of connective tissue disorders often encountered within rheumatology clinics and is associated with several overlapping symptoms, which may require attention from other medical subspecialities. Barriers exist to implementing multidisciplinary care for EDS, including a lack of knowledge, comfort, and time managing EDS. In the absence of multidisciplinary care, patients are often forced to self-coordinate care. This can lead to gaps in care and a lack of clarity of medical ownership over the patient's care. Integrated multidisciplinary clinics are sorely needed, but the development and implementation of such clinics is limited by resources and personnel. As such, the development of a multidisciplinary clinic can be daunting and may serve to discourage providers with competencies in EDS from attempting to develop this service. In this editorial, we share our experiences in developing a multidisciplinary clinic for EDS at a moderately-sized children's hospital, relying on several core disciplines with established EDS clinical loads (ie, rheumatology, cardiology, genetics, and psychology). We discuss considerations for the expansion of this service, pitfalls, and barriers throughout the development of the clinic, and our rationale underlying our process-related decisions. Development of a greater number of multidisciplinary EDS clinics, even in the potential absence of larger institutional support, is both possible and imperative for improving EDS care globally. CI - (c) 2023 Black et al. FAU - Black, William R AU - Black WR AUID- ORCID: 0000-0002-1060-0187 AD - Department of Pediatrics, University of Kansas School of Medicine, Kansas City, KS, USA. AD - Center for Children's Healthy Lifestyles and Nutrition, Children's Mercy Kansas City, Kansas City, MO, USA. FAU - Jones, Jordan T AU - Jones JT AUID- ORCID: 0000-0003-0986-4991 AD - Department of Pediatrics, University of Kansas School of Medicine, Kansas City, KS, USA. AD - Department of Pediatrics, Children's Mercy Kansas City, Kansas City, MO, USA. AD - University of Missouri-Kansas City School of Medicine, Kansas City, MO, USA. FAU - Rush, Eric T AU - Rush ET AD - Department of Pediatrics, University of Kansas School of Medicine, Kansas City, KS, USA. AD - Department of Pediatrics, Children's Mercy Kansas City, Kansas City, MO, USA. AD - University of Missouri-Kansas City School of Medicine, Kansas City, MO, USA. FAU - Malloy Walton, Lindsey AU - Malloy Walton L AD - Department of Pediatrics, University of Kansas School of Medicine, Kansas City, KS, USA. AD - Department of Pediatrics, Children's Mercy Kansas City, Kansas City, MO, USA. AD - University of Missouri-Kansas City School of Medicine, Kansas City, MO, USA. FAU - Harding, Ashley AU - Harding A AD - Children's Mercy Kansas City, Kansas City, KS, USA. LA - eng PT - Journal Article DEP - 20230121 PL - New Zealand TA - J Multidiscip Healthc JT - Journal of multidisciplinary healthcare JID - 101512691 PMC - PMC9875570 OTO - NOTNLM OT - Ehlers-Danlos OT - hypermobility OT - multidisciplinary OT - pediatrics COIS- Dr Eric T Rush reports grants and/or personal fees from Alexion AstraZeneca Rare Disease, Ultragenyx Pharmaceuticals, BioMarin Pharmaceuticals, Inozyme Pharma, Ascendis Pharma, Kyowa Kirin Pharmaceuticals, and Angitia Bio, outside the submitted work. The authors declared no other potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2023/01/31 06:00 MHDA- 2023/01/31 06:01 PMCR- 2023/01/21 CRDT- 2023/01/30 04:27 PHST- 2022/11/05 00:00 [received] PHST- 2023/01/08 00:00 [accepted] PHST- 2023/01/30 04:27 [entrez] PHST- 2023/01/31 06:00 [pubmed] PHST- 2023/01/31 06:01 [medline] PHST- 2023/01/21 00:00 [pmc-release] AID - 396221 [pii] AID - 10.2147/JMDH.S396221 [doi] PST - epublish SO - J Multidiscip Healthc. 2023 Jan 21;16:191-195. doi: 10.2147/JMDH.S396221. eCollection 2023. PMID- 36713753 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230202 IS - 2772-3747 (Electronic) IS - 2772-3747 (Linking) VI - 2 IP - 7 DP - 2022 Dec TI - Outcome of Nonagenarians Undergoing Transfemoral Transcatheter Aortic Valve Replacement: A Nationwide Registry Analysis From Japan. PG - 856-864 LID - 10.1016/j.jacasi.2022.08.007 [doi] AB - BACKGROUND: Nonagenarians are a growing age group in patients undergoing transcatheter aortic valve replacement (TAVR); however, the appropriate use of TAVR in this population remains discussed because of their limited life expectancy and worse outcome reported. OBJECTIVES: The authors aimed to evaluate clinical characteristics and the prognostic impact of nonagenarians. METHODS: We analyzed consecutive patients undergoing transfemoral TAVR and were registered in the nationwide registry for TAVR in Japan (Japanese Transcatheter Valvular Therapies registry) between 2013 and 2018. The rate of 30-day and 1-year mortality and composite adverse event, comprising all-cause death, all stroke, and life-threatening/major bleeding, were assessed. RESULTS: Of the 15,028 registered patients during the study period, 2,215 (14.7%) were nonagenarians. Although the nonagenarians were less likely to have comorbid conditions (eg, diabetes mellitus and malignancy) than patients aged <90 y, they had a higher Society of Thoracic Surgeons risk score (8.8% vs 5.6%), mainly owing to their advanced age. The procedural characteristics were identical between 2 groups. The rate of 30-day mortality and composite endpoint was similar, whereas 1-year mortality and composite adverse events were increased among nonagenarians (10.3% vs 6.8% and 13.5% vs 9.2%, respectively), and nonagenarians were independently associated with these endpoints (HR: 1.21; 95% CI: 1.03-1.42; P = 0.023; HR: 1.24; 95% CI: 1.07-1.42; P = 0.004). CONCLUSIONS: Of the 15,028 TAVR procedures performed in Japan between 2013 and 2018, 14.7% were performed in nonagenarians. These patients were carefully selected by a multidisciplinary heart team and showed 21% and 24% increase of 1-year mortality and composite adverse outcome. CI - (c) 2022 The Authors. FAU - Higuchi, Ryosuke AU - Higuchi R AD - Department of Cardiology, Sakakibara Heart Institute, Tokyo, Japan. FAU - Kumamaru, Hiraku AU - Kumamaru H AD - Department of Healthcare Quality Assessment, Graduate School of Medicine, University of Tokyo, Tokyo, Japan. FAU - Kohsaka, Shun AU - Kohsaka S AD - Department of Cardiology, Keio University, Tokyo, Japan. FAU - Saji, Mike AU - Saji M AD - Department of Cardiology, Sakakibara Heart Institute, Tokyo, Japan. FAU - Takamisawa, Itaru AU - Takamisawa I AD - Department of Cardiology, Sakakibara Heart Institute, Tokyo, Japan. FAU - Nanasato, Mamoru AU - Nanasato M AD - Department of Cardiology, Sakakibara Heart Institute, Tokyo, Japan. FAU - Shimokawa, Tomoki AU - Shimokawa T AD - Department of Cardiovascular Surgery, Sakakibara Heart Institute, Tokyo, Japan. FAU - Shimizu, Hideyuki AU - Shimizu H AD - Department of Cardiovascular Surgery, Keio University, Tokyo, Japan. FAU - Takayama, Morimasa AU - Takayama M AD - Department of Cardiology, Sakakibara Heart Institute, Tokyo, Japan. LA - eng PT - Journal Article DEP - 20221129 PL - United States TA - JACC Asia JT - JACC. Asia JID - 9918452380106676 PMC - PMC9876954 OTO - NOTNLM OT - J-TVT registry OT - Japan OT - TAVR OT - TAVR, transcatheter aortic valve replacement OT - elderly COIS- Dr Kumamaru is affiliated with the department of Healthcare Quality Assessment, which is a social collaboration department supported by National Clinical Database, Johnson & Johnson K.K., and Nipro Corporation. Dr Kohsaka has received unrestricted grants from Daiichi Sankyo and Novartis and lecture fees from Bayer, Bristol-Myers Squibb, and Pfizer outside of the submitted work. Dr Takamisawa is a technical proctor of Edwards Lifesciences and Medtronic. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2023/01/31 06:00 MHDA- 2023/01/31 06:01 PMCR- 2022/11/29 CRDT- 2023/01/30 04:18 PHST- 2022/03/21 00:00 [received] PHST- 2022/07/27 00:00 [revised] PHST- 2022/08/08 00:00 [accepted] PHST- 2023/01/30 04:18 [entrez] PHST- 2023/01/31 06:00 [pubmed] PHST- 2023/01/31 06:01 [medline] PHST- 2022/11/29 00:00 [pmc-release] AID - S2772-3747(22)00220-4 [pii] AID - 10.1016/j.jacasi.2022.08.007 [doi] PST - epublish SO - JACC Asia. 2022 Nov 29;2(7):856-864. doi: 10.1016/j.jacasi.2022.08.007. eCollection 2022 Dec. PMID- 36709638 OWN - NLM STAT- MEDLINE DCOM- 20230328 LR - 20230328 IS - 1090-2147 (Electronic) IS - 0278-2626 (Linking) VI - 166 DP - 2023 Mar TI - Counting on random number generation: Uncovering mild executive dysfunction in congenital heart disease. PG - 105955 LID - S0278-2626(23)00012-X [pii] LID - 10.1016/j.bandc.2023.105955 [doi] AB - Congenital heart disease (CHD) is associated with various neurocognitive deficits, particularly targeting executive functions (EFs), of which random number generation (RNG) is one indicator. RNG has, however, never been investigated in CHD. We administered the Mental Dice Task (MDT) to 67 young adults with CHD and 55 healthy controls. This 1-minute-task requires the generation of numbers 1 to 6 in a random sequence. RNG performance was correlated with a global EF score. Participants underwent MRI to examine structural-volumetric correlates of RNG. Compared to controls, CHD patients showed increased backward counting, reflecting deficient inhibition of automatized behavior. They also lacked a small-number bias (higher frequency of small relative to large numbers). RNG performance was associated with global EF scores in both groups. In CHD patients, MRI revealed an inverse association of counting bias with most of the volumetric measurements and the amount of small numbers was positively associated with corpus callosum volume, suggesting callosal involvement in the "pseudoneglect in number space". In conclusion, we found an impaired RNG performance in CHD patients, which is associated with brain volumetric measures. RNG, reportedly resistant to learning effects, may be an ideal task for the longitudinal assessment of EFs in patients with CHD. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Schlosser, Ladina AU - Schlosser L AD - Child Development Centre, University Children's Hospital Zurich, Steinwiesstrasse 75, 8032 Zurich, Switzerland; University Heart Center, Department of Cardiology, University Hospital Zurich, University of Zurich, Ramistrasse 100, 8091 Zurich, Switzerland. Electronic address: ladina.schlosser@usz.ch. FAU - Naef, Nadja AU - Naef N AD - Child Development Centre, University Children's Hospital Zurich, Steinwiesstrasse 75, 8032 Zurich, Switzerland. FAU - Ehrler, Melanie AU - Ehrler M AD - Child Development Centre, University Children's Hospital Zurich, Steinwiesstrasse 75, 8032 Zurich, Switzerland. FAU - Wehrle, Flavia AU - Wehrle F AD - Child Development Centre, University Children's Hospital Zurich, Steinwiesstrasse 75, 8032 Zurich, Switzerland; Department of Neonatology and Intensive Care, University Children's Hospital Zurich, Zurich, Switzerland. FAU - Greutmann, Matthias AU - Greutmann M AD - University Heart Center, Department of Cardiology, University Hospital Zurich, University of Zurich, Ramistrasse 100, 8091 Zurich, Switzerland. FAU - Oxenius, Angela AU - Oxenius A AD - University Heart Center, Department of Cardiology, University Hospital Zurich, University of Zurich, Ramistrasse 100, 8091 Zurich, Switzerland. FAU - Tuura, Ruth AU - Tuura R AD - Children's Research Center, University Children's Hospital Zurich, University of Zurich, Zurich, Switzerland. FAU - Latal, Beatrice AU - Latal B AD - Child Development Centre, University Children's Hospital Zurich, Steinwiesstrasse 75, 8032 Zurich, Switzerland. FAU - Brugger, Peter AU - Brugger P AD - Psychiatric University Clinic PUK, University Hospital Zurich, Lenggstrasse 31, PO Box 1931, 8032 Zurich, Switzerland; Neuropsychology Unit, Valens Rehabilitation Centre, Taminaplatz 1, 7317 Valens, Switzerland. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230127 PL - United States TA - Brain Cogn JT - Brain and cognition JID - 8218014 SB - IM MH - Humans MH - Brain/diagnostic imaging MH - Brain Mapping MH - *Cognitive Dysfunction MH - Executive Function MH - *Heart Defects, Congenital MH - Case-Control Studies OTO - NOTNLM OT - Congenital heart disease OT - Executive functions OT - Mental Dice Task OT - Neural correlates of nonrandomness OT - Random number generation COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2023/01/30 06:00 MHDA- 2023/03/21 06:00 CRDT- 2023/01/29 18:13 PHST- 2022/10/28 00:00 [received] PHST- 2023/01/09 00:00 [revised] PHST- 2023/01/12 00:00 [accepted] PHST- 2023/01/30 06:00 [pubmed] PHST- 2023/03/21 06:00 [medline] PHST- 2023/01/29 18:13 [entrez] AID - S0278-2626(23)00012-X [pii] AID - 10.1016/j.bandc.2023.105955 [doi] PST - ppublish SO - Brain Cogn. 2023 Mar;166:105955. doi: 10.1016/j.bandc.2023.105955. Epub 2023 Jan 27. PMID- 29763157 STAT- Publisher CTDT- 20230130 PB - StatPearls Publishing DP - 2023 Jan TI - Selective Beta-1 Blockers. BTI - StatPearls AB - The cardio-selective beta-1-blockers include atenolol, betaxolol, bisoprolol, esmolol, acebutolol, metoprolol, and nebivolol. FDA-approved uses of beta-1-selective blockers include hypertension, chronic stable angina, heart failure, post-myocardial infarction, and decreased left ventricular function after a recent myocardial infarction. Non-FDA-approved uses include migraine prophylaxis, treatment of arrhythmias, tremor reduction, and the symptomatic treatment of anxiety disorders. Their use is associated with decreased morbidity and mortality post-myocardial infarction. Treatment with beta-1 blockers reduces the risk of stroke, coronary artery disease, and congestive heart failure. This activity outlines the indications, mechanisms of action, methods of administration, important adverse effects, contraindications, and monitoring of selective beta-1 antagonists so providers can direct patient therapy in treating indicated disorders as part of the interprofessional team, with a basis on the current knowledge for optimal utilization. CI - Copyright (c) 2023, StatPearls Publishing LLC. FAU - Tucker, William D AU - Tucker WD AD - ETSU Quillen College of Medicine FAU - Sankar, Parvathy AU - Sankar P AD - Michigan State University College of Osteopathic Medicine FAU - Theetha Kariyanna, Pramod AU - Theetha Kariyanna P AD - State Un of New York - Downstate MC LA - eng PT - Study Guide PT - Book Chapter PL - Treasure Island (FL) COIS- Disclosure: William D Tucker declares no relevant financial relationships with ineligible companies. Disclosure: Parvathy Sankar declares no relevant financial relationships with ineligible companies. Disclosure: Pramod Theetha Kariyanna declares no relevant financial relationships with ineligible companies. EDAT- 2023/01/30 00:00 CRDT- 2023/01/30 00:00 AID - NBK499982 [bookaccession] PMID- 36707122 OWN - NLM STAT- MEDLINE DCOM- 20230131 LR - 20240911 IS - 2399-6641 (Electronic) IS - 2399-6641 (Linking) VI - 12 IP - 1 DP - 2023 Jan TI - Quality and process improvement of the multidisciplinary Heart Team meeting using Lean Six Sigma. LID - 10.1136/bmjoq-2022-002050 [doi] LID - e002050 AB - INTRODUCTION: The Heart Team is a multidisciplinary meeting for shared decision-making in cardiology and cardiothoracic surgery. A quality improvement project to optimise the Heart Team was initiated after the merger of the cardiac centres of Amsterdam University Medical Centre. METHODS: Lean Six Sigma was applied with the purpose of improving efficiency and quality of care. Qualitative and quantitative analyses supported the multidisciplinary team during quality improvement sessions. Lean Six Sigma tools included process mapping, gemba walks, root cause analysis, line balancing, first time right, standardised work and poka-yoke. INTERVENTIONS: Seven areas of improvement were introduced. Key elements were the improvement of the patient referral process, introduction of a structured agenda, task division and balanced planning of patients, better exchange of information, improved availability of diagnostics and supportive tools and information technology. Work agreements were introduced to support a positive work culture and mutual respect. RESULTS: Lean Six Sigma designed an optimised Heart Team to improve efficiency by better resource utilisation, first time right decision-making, patient selection, complete and better access to information and elimination of waste. It leads to higher quality of decision-making by involving physicians in a more structured preparation, attendance of an imaging cardiologist, meeting duration within limits, installation of standard operating procedures, increased involvement of the referring cardiologists and a better engaged team. CONCLUSIONS: Heart Teams are essential to make evidence-based, patient-centred treatment plans for optimal patient outcomes. However, clinical practice and experience showed that it is challenging to have an efficient and effective discussion with complete patient information and to bring together healthcare professionals. The application of Lean Six Sigma resulted in an optimised Heart Team and created a best practice design for patient-centred, evidence-based decision-making. After implementation and process stability, a postintervention analysis could clarify long-term success and sustainability. CI - (c) Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Hoefsmit, Paulien C AU - Hoefsmit PC AUID- ORCID: 0000-0003-4019-7197 AD - Cardiothoracic Surgery, Amsterdam UMC, Amsterdam, Netherlands p.hoefsmit@amsterdamumc.nl. AD - Cardiothoracic Surgery, Amsterdam UMC Locatie AMC, Amsterdam, Netherlands. FAU - Schretlen, Stijn AU - Schretlen S AD - Integrated Health Solutions, Medtronic Europe, Eindhoven, Netherlands. FAU - Does, Ronald J M M AU - Does RJMM AD - Business Analytics, Amsterdam Business School, University of Amsterdam, Amsterdam, Netherlands. FAU - Verouden, Niels J AU - Verouden NJ AD - Cardiology, Amsterdam UMC, Amsterdam, Netherlands. AD - Cardiology, Amsterdam UMC Locatie AMC, Amsterdam, Netherlands. FAU - Zandbergen, H Reinier AU - Zandbergen HR AD - Cardiothoracic Surgery, Amsterdam UMC, Amsterdam, Netherlands. AD - Cardiothoracic Surgery, Amsterdam UMC Locatie AMC, Amsterdam, Netherlands. LA - eng PT - Journal Article PL - England TA - BMJ Open Qual JT - BMJ open quality JID - 101710381 SB - IM MH - Humans MH - *Total Quality Management MH - *Efficiency, Organizational MH - Quality Improvement PMC - PMC9884867 OTO - NOTNLM OT - Lean management OT - Quality improvement OT - Shared decision making OT - Six Sigma OT - Teamwork COIS- Competing interests: SS is an employee at Medtronic. EDAT- 2023/01/28 06:00 MHDA- 2023/02/01 06:00 PMCR- 2023/01/26 CRDT- 2023/01/27 20:52 PHST- 2022/07/14 00:00 [received] PHST- 2023/01/11 00:00 [accepted] PHST- 2023/01/27 20:52 [entrez] PHST- 2023/01/28 06:00 [pubmed] PHST- 2023/02/01 06:00 [medline] PHST- 2023/01/26 00:00 [pmc-release] AID - bmjoq-2022-002050 [pii] AID - 10.1136/bmjoq-2022-002050 [doi] PST - ppublish SO - BMJ Open Qual. 2023 Jan;12(1):e002050. doi: 10.1136/bmjoq-2022-002050. PMID- 36700182 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260419 IS - 2589-790X (Electronic) IS - 2589-790X (Linking) VI - 5 IP - 1 DP - 2023 Jan TI - Outcomes in Patients Undergoing Surgical Aortic Valve Replacement With vs Without a Preoperative Heart Team Assessment. PG - 24-34 LID - 10.1016/j.cjco.2022.10.003 [doi] AB - BACKGROUND: This study sought to compare characteristics and outcomes of patients who underwent surgical aortic valve replacement (SAVR) after being referred to a heart team (HT), to those of patients referred directly for SAVR. METHODS: An analysis of patients who underwent SAVR from 2015 to 2020 was conducted. Patients were categorized into 3 groups, as follows: (i) H-HT: patients referred to the HT from 2015 to 2017 (historical cohort); (ii) C-HT: patients referred to the HT from 2018 to 2020 (contemporary cohort); and (iii) No-HT: patients referred directly to cardiac surgery from 2018 to 2020. Two subanalyses were performed: H-HT vs C-HT patients, and C-HT vs No-HT patients. The primary outcome was a composite of in-hospital mortality, prolonged intubation, reoperation, sternal wound infection, and stroke. RESULTS: This study consisted of 288 patients, distributed as follows: H-HT (n = 45); C-HT (n = 51); and No-HT (n = 192). The mean ages of H-HT, C-HT, and No-HT patients was 76.3 +/- 6.9 years, 73.3 +/- 7.6 years, and 69.6 +/- 9.7 years, respectively (P = 0.0001). H-HT, C-HT, and No-HT patients had average Society of Thoracic Surgeons scores of 4.8 +/- 2.2, 3.2 +/- 1.6, and 4.2 +/- 2 (P = 0.002), respectively. The composite outcome rate was more than 5 times higher among H-HT patients compared to that among the C-HT patients (20.0 vs 3.9%, P = 0.02), and was numerically higher in No-HT compared to C-HT patients (13.0 vs 3.9%, P = 0.07). CONCLUSIONS: Referral to an HT appears to be primarily driven by higher chronological age rather than overall risk profile. Patients assessed by the HT prior to undergoing SAVR have a low incidence of complications, comparable to that among patients referred directly to cardiac surgery. CI - (c) 2022 The Authors. FAU - Rodighiero, Julia AU - Rodighiero J AD - Division of Cardiology, McGill University Health Centre, Montreal, Quebec, Canada. FAU - Alakhtar, Ali M AU - Alakhtar AM AD - Division of Cardiac Surgery, McGill University Health Centre, Montreal, Quebec, Canada. AD - Division of Surgery, Qassim University, Qassim, Kingdom of Saudi Arabia. FAU - Baker, Nouf AU - Baker N AD - Division of Cardiac Surgery, McGill University Health Centre, Montreal, Quebec, Canada. FAU - Zgheib, Ali AU - Zgheib A AD - Division of Cardiology, McGill University Health Centre, Montreal, Quebec, Canada. FAU - de Varennes, Benoit AU - de Varennes B AD - Division of Cardiac Surgery, McGill University Health Centre, Montreal, Quebec, Canada. FAU - Lachapelle, Kevin AU - Lachapelle K AD - Division of Cardiac Surgery, McGill University Health Centre, Montreal, Quebec, Canada. FAU - Cecere, Renzo AU - Cecere R AD - Division of Cardiac Surgery, McGill University Health Centre, Montreal, Quebec, Canada. FAU - Ergina, Patrick AU - Ergina P AD - Division of Cardiac Surgery, McGill University Health Centre, Montreal, Quebec, Canada. FAU - Tchervenkov, Christo AU - Tchervenkov C AD - Division of Cardiac Surgery, McGill University Health Centre, Montreal, Quebec, Canada. FAU - Shum-Tim, Dominique AU - Shum-Tim D AD - Division of Cardiac Surgery, McGill University Health Centre, Montreal, Quebec, Canada. FAU - Martucci, Giuseppe AU - Martucci G AD - Division of Cardiology, McGill University Health Centre, Montreal, Quebec, Canada. FAU - Piazza, Nicolo AU - Piazza N AD - Division of Cardiology, McGill University Health Centre, Montreal, Quebec, Canada. FAU - Afilalo, Jonathan AU - Afilalo J AD - Division of Cardiology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada. FAU - Spaziano, Marco AU - Spaziano M AD - Division of Cardiology, McGill University Health Centre, Montreal, Quebec, Canada. LA - eng PT - Journal Article DEP - 20221013 PL - United States TA - CJC Open JT - CJC open JID - 101763635 PMC - PMC9869348 EDAT- 2023/01/27 06:00 MHDA- 2023/01/27 06:01 PMCR- 2022/10/13 CRDT- 2023/01/26 02:54 PHST- 2022/06/24 00:00 [received] PHST- 2022/10/07 00:00 [accepted] PHST- 2023/01/26 02:54 [entrez] PHST- 2023/01/27 06:00 [pubmed] PHST- 2023/01/27 06:01 [medline] PHST- 2022/10/13 00:00 [pmc-release] AID - S2589-790X(22)00204-9 [pii] AID - 10.1016/j.cjco.2022.10.003 [doi] PST - epublish SO - CJC Open. 2022 Oct 13;5(1):24-34. doi: 10.1016/j.cjco.2022.10.003. eCollection 2023 Jan. PMID- 36700060 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230202 IS - 2373-8731 (Print) IS - 2373-8731 (Electronic) IS - 2373-8731 (Linking) VI - 9 IP - 2 DP - 2023 Feb TI - Cardiologist Evaluation and Approval Was the Primary Predictor of Kidney Transplant Candidacy and Transplantation Among Patients With Reduced Left Ventricular Ejection Fraction. PG - e1421 LID - 10.1097/TXD.0000000000001421 [doi] LID - e1421 AB - End-stage kidney disease patients with concomitant heart failure (HF) with reduced ejection fraction are often denied kidney transplantation. The aims of this study were to explore factors predictive of suitability for kidney transplant and to assess cardiovascular outcomes in patients with impaired left ventricular ejection fraction (LVEF) after transplant. METHODS: We evaluated 109 consecutive adults with LVEF 3% estimated risk of mortality. CONCLUSIONS: This etiologic and procedure-specific risk model establishes that the contemporary mortality risk of MV repair for primary MR is <1% for the vast majority of patients. CI - Copyright (c) 2023 American College of Cardiology and The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved. FAU - Badhwar, Vinay AU - Badhwar V AD - Department of Cardiovascular and Thoracic Surgery, West Virginia University, Morgantown, West Virginia. Electronic address: vinay.badhwar@wvumedicine.org. FAU - Chikwe, Joanna AU - Chikwe J AD - Department of Cardiac Surgery, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California. FAU - Gillinov, A Marc AU - Gillinov AM AD - Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, Ohio. FAU - Vemulapalli, Sreek AU - Vemulapalli S AD - Department of Medicine, Duke University, Durham, North Carolina. FAU - O'Gara, Patrick T AU - O'Gara PT AD - Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. FAU - Mehaffey, J Hunter AU - Mehaffey JH AD - Department of Cardiovascular and Thoracic Surgery, West Virginia University, Morgantown, West Virginia. FAU - Wyler von Ballmoos, Moritz AU - Wyler von Ballmoos M AD - Department of Cardiac Surgery, University Hospital Zurich, Zurich, Switzerland. FAU - Bowdish, Michael E AU - Bowdish ME AD - Department of Cardiac Surgery, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California. FAU - Gray, Elizabeth L AU - Gray EL AD - STS Analytic and Research Center, Society of Thoracic Surgeons, Chicago, Illinois. FAU - O'Brien, Sean M AU - O'Brien SM AD - Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina. FAU - Thourani, Vinod H AU - Thourani VH AD - Department of Cardiac Surgery, Piedmont Heart Institute, Atlanta, Georgia. FAU - Shahian, David M AU - Shahian DM AD - Division of Cardiac Surgery, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. FAU - Habib, Robert H AU - Habib RH AD - STS Analytic and Research Center, Society of Thoracic Surgeons, Chicago, Illinois. LA - eng PT - Journal Article DEP - 20230118 PL - Netherlands TA - Ann Thorac Surg JT - The Annals of thoracic surgery JID - 15030100R SB - IM MH - Adult MH - Humans MH - Aged MH - *Mitral Valve Insufficiency/surgery MH - Mitral Valve/surgery MH - Treatment Outcome MH - *Heart Valve Prosthesis Implantation/methods MH - *Cardiac Surgical Procedures EDAT- 2023/01/21 06:00 MHDA- 2023/02/25 06:00 CRDT- 2023/01/20 22:02 PHST- 2022/11/10 00:00 [accepted] PHST- 2023/01/21 06:00 [pubmed] PHST- 2023/02/25 06:00 [medline] PHST- 2023/01/20 22:02 [entrez] AID - S0003-4975(22)01611-3 [pii] AID - 10.1016/j.athoracsur.2022.12.024 [doi] PST - ppublish SO - Ann Thorac Surg. 2023 Mar;115(3):600-610. doi: 10.1016/j.athoracsur.2022.12.024. Epub 2023 Jan 18. PMID- 36669958 OWN - NLM STAT- MEDLINE DCOM- 20230217 LR - 20230804 IS - 1558-3597 (Electronic) IS - 0735-1097 (Linking) VI - 81 IP - 7 DP - 2023 Feb 21 TI - Risk of Surgical Mitral Valve Repair for Primary Mitral Regurgitation. PG - 636-648 LID - S0735-1097(22)07418-6 [pii] LID - 10.1016/j.jacc.2022.11.017 [doi] AB - BACKGROUND: Risk estimation for surgical intervention is an essential component of heart team shared decision-making. However, current mitral valve (MV) surgery risk models used in practice lack etiologic or procedural specificity. OBJECTIVES: The purpose of this study was to establish a comprehensive method for assessment of operative risk of MV repair of primary mitral regurgitation (MR). METHODS: A novel etiology and procedure-specific algorithm identified 53,462 consecutive (July 2014 to June 2020) intention-to-treat MV repair patients with primary MR from The Society of Thoracic Surgeons Adult Cardiac Surgery Database. Risk models were fit for 30-day operative mortality, mortality and/or major morbidity, and conversion-to-replacement (CONV). As-treated mortality and morbidity models were derived separately. RESULTS: Event rates for mortality (n = 619; 1.16%), mortality plus morbidity (n = 4,746; 8.88%), and CONV (n = 3,399; 6.36%) were low. Mortality was higher in CONV patients vs repair (3.18% vs 1.02%). All event rates were lower with increasing program volumes. The mortality risk model had excellent discrimination (AUC: 0.807) and calibration and confirmed very low mortality risk for isolated MV repair for primary MR, with mean mortality risk of 1.16% and median of 0.55% (IQR: 0.30%-1.17%) with 90th and 95th percentiles 2.48% and 3.99%, respectively. The mortality risk was <0.5% in patients <65 years of age, with 97% of the total population across age groups having a risk of <3%. Only 1 in 4 patients age 75 or older had >3% estimated risk of mortality. CONCLUSIONS: This etiologic and procedure-specific risk model establishes that the contemporary mortality risk of MV repair for primary MR is <1% for the vast majority of patients. CI - Copyright (c) 2023 American College of Cardiology and the society of thoracic surgeons. Published by Elsevier Inc. All rights reserved. FAU - Badhwar, Vinay AU - Badhwar V AD - Department of Cardiovascular and Thoracic Surgery, West Virginia University, Morgantown, West Virginia, USA. Electronic address: vinay.badhwar@wvumedicine.org. FAU - Chikwe, Joanna AU - Chikwe J AD - Department of Cardiac Surgery, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA. FAU - Gillinov, A Marc AU - Gillinov AM AD - Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, Ohio, USA. FAU - Vemulapalli, Sreek AU - Vemulapalli S AD - Department of Medicine, Duke University, Durham, North Carolina, USA. FAU - O'Gara, Patrick T AU - O'Gara PT AD - Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA. FAU - Mehaffey, J Hunter AU - Mehaffey JH AD - Department of Cardiovascular and Thoracic Surgery, West Virginia University, Morgantown, West Virginia, USA. FAU - Wyler von Ballmoos, Moritz AU - Wyler von Ballmoos M AD - Department of Cardiac Surgery, University Hospital Zurich, Zurich, Switzerland. FAU - Bowdish, Michael E AU - Bowdish ME AD - Department of Cardiac Surgery, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA. FAU - Gray, Elizabeth L AU - Gray EL AD - STS Analytic and Research Center, The Society of Thoracic Surgeons, Chicago, Illinois, USA. FAU - O'Brien, Sean M AU - O'Brien SM AD - Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina, USA. FAU - Thourani, Vinod H AU - Thourani VH AD - Department of Cardiac Surgery, Piedmont Heart Institute, Atlanta, Georgia, USA. FAU - Shahian, David M AU - Shahian DM AD - Division of Cardiac Surgery, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. FAU - Habib, Robert H AU - Habib RH AD - STS Analytic and Research Center, The Society of Thoracic Surgeons, Chicago, Illinois, USA. LA - eng GR - UM1 HL088925/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20230118 PL - United States TA - J Am Coll Cardiol JT - Journal of the American College of Cardiology JID - 8301365 SB - IM CIN - J Am Coll Cardiol. 2023 Feb 21;81(7):649-652. doi: 10.1016/j.jacc.2023.01.001. PMID: 36792279 CIN - J Am Coll Cardiol. 2023 Aug 8;82(6):e43. doi: 10.1016/j.jacc.2023.02.054. PMID: 37532428 CIN - J Am Coll Cardiol. 2023 Aug 8;82(6):e45. doi: 10.1016/j.jacc.2023.04.058. PMID: 37532429 CIN - J Am Coll Cardiol. 2023 Aug 8;82(6):e47-e48. doi: 10.1016/j.jacc.2023.06.004. PMID: 37532430 MH - Adult MH - Humans MH - Aged MH - *Mitral Valve Insufficiency MH - Mitral Valve/diagnostic imaging/surgery MH - Treatment Outcome MH - *Heart Valve Prosthesis Implantation/methods MH - *Cardiac Surgical Procedures OTO - NOTNLM OT - mitral regurgitation OT - mitral valve repair OT - primary degenerative OT - risk model COIS- Funding Support and Author Disclosures This work was supported by The Society of Thoracic Surgeons and National Institutes of Health National Heart, Lung, and Blood Institute # 2UM1 HL088925 12 (to Drs Badhwar and Mehaffey). Dr Badhwar is a consultant to Abbott (uncompensated). Dr Gillinov is a consultant to Edwards Lifesciences, Medtronic, Abbott, AtriCure, CryoLife, and ClearFlow. Dr Vemulapalli is a consultant to Janssen, American College of Physicians, and Edwards Lifesciences. Dr Wyler von Ballmoos is a consultant to Medtronic, Boston Scientific, Teleflex, and Corcym. Dr Thourani is a consultant to Abbott, Edwards Lifesciences, CryoLife, and Boston Scientific. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2023/01/21 06:00 MHDA- 2023/02/18 06:00 CRDT- 2023/01/20 22:02 PHST- 2022/06/29 00:00 [received] PHST- 2022/10/31 00:00 [revised] PHST- 2022/11/10 00:00 [accepted] PHST- 2023/01/21 06:00 [pubmed] PHST- 2023/02/18 06:00 [medline] PHST- 2023/01/20 22:02 [entrez] AID - S0735-1097(22)07418-6 [pii] AID - 10.1016/j.jacc.2022.11.017 [doi] PST - ppublish SO - J Am Coll Cardiol. 2023 Feb 21;81(7):636-648. doi: 10.1016/j.jacc.2022.11.017. Epub 2023 Jan 18. PMID- 36669644 OWN - NLM STAT- MEDLINE DCOM- 20230227 LR - 20230227 IS - 2468-7847 (Electronic) IS - 2468-7847 (Linking) VI - 52 IP - 3 DP - 2023 Mar TI - Obstetrical outcomes in cases of maternal heart disease with a risk of cardiac decompensation: A retrospective study since the establishment of a multidisciplinary consultation meeting "heart and pregnancy". PG - 102537 LID - S2468-7847(23)00005-3 [pii] LID - 10.1016/j.jogoh.2023.102537 [doi] AB - BACKGROUND: Pregnant women with chronic heart failure (CHF) are at increased risk for cardiac complications. However, the frequency of obstetrical and neonatal complications in pregnant women with CHF remains unclear. OBJECTIVE: The objective of our study was to describe obstetrical and neonatal outcomes in pregnant with CHF. METHOD: This single-center retrospective cohort study involves pregnant women with a CHF who delivered at Jeanne de Flandre, the Lille's university hospital, from 2017 to 2021. The frequency of obstetrical, neonatal, and cardiovascular complications was collected. RESULT: During this period, we identified 26 pregnant women with a CHF. The main cardiac diseases responsible for CHF were cardiomyopathies (53.8%) and congenital heart disease (46.2%). Acute heart failure occurred in 30.8% of the cases and mainly concerned patients with no follow-up of their heart disease. The main obstetrical complications were fetal growth restriction (38.5%) and premature rupture of fetal membranes (19.2%). The 26 pregnancies comprised 25 live births and 1 stillbirth. Newborn infants were delivered via cesarean in 69.2%. Of the live births, 60% were preterm at a median gestational age of 36 (34-38) weeks. CONCLUSION: Pregnant women with CHF had a higher risk for obstetrical and neonatal outcomes. CI - Copyright (c) 2023 Elsevier Masson SAS. All rights reserved. FAU - Demeyere, Mathilde AU - Demeyere M AD - Pole Femme Mere Nouveau-ne, obstetrics clinic, Hopital Jeanne de Flandre, Universite Nord de France, Lille, France. FAU - Richardson, Marjorie AU - Richardson M AD - Department of Cardiovascular Functional Explorations, Heart-Lung Institute, University Hospital of Lille, Lille, France. FAU - Deken, Valerie AU - Deken V AD - Biostatistics Department, Lille University Hospital, Lille, France. FAU - Estevez, Max Gonzalez AU - Estevez MG AD - Department of Anesthesiology and Intensive Care, Jeanne de Flandre Hospital, University Hospital of Lille, Lille, France. FAU - Domanski, Olivia AU - Domanski O AD - Department of Pediatric Cardiology, Heart-Lung Institute, University Hospital of Lille, Lille, France. FAU - Gautier, Sophie AU - Gautier S AD - Centre Regional de Pharmacovigilance, CHRU de Lille, 1, place de Verdun, 59045 Lille Cedex, France. FAU - Marsili, Luisa AU - Marsili L AD - Genetics Clinic, CHU Lille, Lille, France. FAU - Constans, Benjamin AU - Constans B AD - Department of Anesthesiology and Intensive Care, Jeanne de Flandre Hospital, University Hospital of Lille, Lille, France. FAU - Hamoud, Yasmine AU - Hamoud Y AD - Pole Femme Mere Nouveau-ne, obstetrics clinic, Hopital Jeanne de Flandre, Universite Nord de France, Lille, France. FAU - Ghesquiere, Louise AU - Ghesquiere L AD - Pole Femme Mere Nouveau-ne, obstetrics clinic, Hopital Jeanne de Flandre, Universite Nord de France, Lille, France; University of Lille, CHU de Lille, ULR2694 METRICS, Health Technology and Medical Practice Assessment, F-59000 Lille, France. Electronic address: louise.ghesquiere@chu-lille.fr. LA - eng PT - Journal Article DEP - 20230117 PL - France TA - J Gynecol Obstet Hum Reprod JT - Journal of gynecology obstetrics and human reproduction JID - 101701588 SB - IM MH - Infant, Newborn MH - Infant MH - Pregnancy MH - Humans MH - Female MH - Retrospective Studies MH - *Premature Birth MH - *Heart Defects, Congenital MH - *Heart Failure/complications MH - Stillbirth OTO - NOTNLM OT - Maternal heart disease OT - Obstetrical outcomes EDAT- 2023/01/21 06:00 MHDA- 2023/03/03 06:00 CRDT- 2023/01/20 19:24 PHST- 2022/10/09 00:00 [received] PHST- 2022/12/27 00:00 [revised] PHST- 2023/01/16 00:00 [accepted] PHST- 2023/01/21 06:00 [pubmed] PHST- 2023/03/03 06:00 [medline] PHST- 2023/01/20 19:24 [entrez] AID - S2468-7847(23)00005-3 [pii] AID - 10.1016/j.jogoh.2023.102537 [doi] PST - ppublish SO - J Gynecol Obstet Hum Reprod. 2023 Mar;52(3):102537. doi: 10.1016/j.jogoh.2023.102537. Epub 2023 Jan 17. PMID- 36656289 OWN - NLM STAT- MEDLINE DCOM- 20230201 LR - 20230911 IS - 1531-7080 (Electronic) IS - 0268-4705 (Linking) VI - 38 IP - 2 DP - 2023 Mar 1 TI - Engaging medical students in cardiac surgery: a focus on equity, diversity, and inclusion. PG - 94-102 LID - 10.1097/HCO.0000000000001010 [doi] AB - PURPOSE OF REVIEW: The Coronavirus Disease 2019 pandemic prohibited Canadian medical students from in-person observerships. This may be particularly detrimental to under-represented groups that may consider surgical subspecialties. To address the unprecedented need for alternative surgical career exploration and diversity within the profession, The University of Toronto Cardiac Surgery Interest Group and Division of Cardiac Surgery collaborated on virtual experiential programming. RECENT FINDINGS: Medical students were invited to virtual (1) observerships of a cardiac bypass case, (2) mentorship sessions with surgeons, (3) resident teaching sessions, (4) multidisciplinary case-based Heart Team discussions to further their understanding of the scope of Cardiac surgery, and (5) a virtual coronary anastomosis training program. Additionally, a comprehensive virtual program was spearheaded to increase interest in Cardiac surgery among low-income Black high school students. SUMMARY: Trainee response to the virtual education, mentorship, and skill acquisition was positive. Trainees reported high levels of interest in the profession, particularly among females and under-represented minorities, supporting the principles of equity diversity, and inclusion in Cardiac surgery. CI - Copyright (c) 2023 Wolters Kluwer Health, Inc. All rights reserved. FAU - Elfaki, Lina AU - Elfaki L AD - Temerty Faculty of Medicine, University of Toronto. FAU - Nwakoby, Akachukwu AU - Nwakoby A AD - Temerty Faculty of Medicine, University of Toronto. FAU - Lia, Hillary AU - Lia H AD - Temerty Faculty of Medicine, University of Toronto. FAU - Zhao, George AU - Zhao G AD - Temerty Faculty of Medicine, University of Toronto. FAU - Sicila, Amanda AU - Sicila A AD - Division of Cardiac Surgery, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada. FAU - Yoshida, Nao AU - Yoshida N AD - Division of Cardiac Surgery, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada. FAU - Yanagawa, Bobby AU - Yanagawa B AD - Temerty Faculty of Medicine, University of Toronto. AD - Division of Cardiac Surgery, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20230119 PL - United States TA - Curr Opin Cardiol JT - Current opinion in cardiology JID - 8608087 SB - IM MH - Female MH - Humans MH - Curriculum MH - *Students, Medical MH - Diversity, Equity, Inclusion MH - Canada MH - *Education, Medical, Undergraduate MH - Career Choice MH - *COVID-19/epidemiology MH - *Cardiac Surgical Procedures/education EDAT- 2023/01/20 06:00 MHDA- 2023/02/02 06:00 CRDT- 2023/01/19 10:54 PHST- 2023/01/20 06:00 [pubmed] PHST- 2023/02/02 06:00 [medline] PHST- 2023/01/19 10:54 [entrez] AID - 00001573-202303000-00008 [pii] AID - 10.1097/HCO.0000000000001010 [doi] PST - ppublish SO - Curr Opin Cardiol. 2023 Mar 1;38(2):94-102. doi: 10.1097/HCO.0000000000001010. Epub 2023 Jan 19. PMID- 36655573 OWN - NLM STAT- MEDLINE DCOM- 20240527 LR - 20240527 IS - 1708-539X (Electronic) IS - 1708-5381 (Linking) VI - 32 IP - 3 DP - 2024 Jun TI - Effectiveness of carotid council in the treatment of carotid artery disease: Early-term outcomes of the multidisciplinary approach. PG - 573-578 LID - 10.1177/17085381231153222 [doi] AB - OBJECTIVES: Carotid arterial stenosis could be treated by surgical or percutaneous stenting. In this study, we aimed to investigate the effectiveness of the carotid council on the outcomes of patients with carotid artery disease. METHODS: In this retrospective study, we analyzed the patients who had undergone carotid arterial revascularization from April 2014 to July 2022 in our hospital. All patients were evaluated in carotid council, which is constituted by neurologist, cardiologist and cardiovascular surgeon. Patient-specific treatment procedure was decided in the council. Demographics and early-term follow-up results of the patients were evaluated. RESULTS: Totally 95 procedures in 85 patients were analyzed during the study period. 27.4 % of the patients had significant contralateral carotid arterial stenosis. In 88 (92.6%) procedures, patients were treated by carotid endarterectomy, and 5 procedures were performed under regional anesthesia. Shunt usage was 6.0% during the surgery, and arteriotomy was repaired with primary sutures in 87.3%. Stent implantation was performed in 7 patients. There were 5 neurological adverse events after the carotid endarterectomy and 2 neurological events were after carotid arterial stenting. In each treatment group, one patient died after the procedure. In the follow-up period, restenosis was observed just in a patient who was treated with carotid endarterectomy and primary repair. CONCLUSION: Although carotid artery disease could be treated in accordance with the guidelines, treatment procedures should be patient-specific. Carotid councils might be helpful in giving patient-specific decisions, thereby providing the patient-based treatment procedure and improving the outcomes of the patients with carotid artery disease. FAU - Ozbek, Ismail C AU - Ozbek IC AD - Department of Cardiovascular Surgery, Sancaktepe Sehit Professor Doctor Ilhan Varank Education and Research Hospital, University of Health Sciences, Istanbul, Turkey. FAU - Durmaz, Aysegul AU - Durmaz A AD - Department of Cardiovascular Surgery, Sancaktepe Sehit Professor Doctor Ilhan Varank Education and Research Hospital, University of Health Sciences, Istanbul, Turkey. FAU - Ozen, Yucel AU - Ozen Y AD - Department of Cardiovascular Surgery, Sancaktepe Sehit Professor Doctor Ilhan Varank Education and Research Hospital, University of Health Sciences, Istanbul, Turkey. FAU - Demir, Serkan AU - Demir S AD - Department of Neurology, Sancaktepe Sehit Professor Doctor Ilhan Varank Education and Research Hospital, University of Health Sciences, Istanbul, Turkey. FAU - Celik, Didem AU - Celik D AD - Department of Neurology, Sancaktepe Sehit Professor Doctor Ilhan Varank Education and Research Hospital, University of Health Sciences, Istanbul, Turkey. FAU - Yalcinkaya, Emre AU - Yalcinkaya E AD - Department of Cardiology, Sancaktepe Sehit Professor Doctor Ilhan Varank Education and Research Hospital, University of Health Sciences, Istanbul, Turkey. FAU - Cunurlu, Merve AU - Cunurlu M AD - Department of Cardiovascular Surgery, Sancaktepe Sehit Professor Doctor Ilhan Varank Education and Research Hospital, University of Health Sciences, Istanbul, Turkey. FAU - Ugur, Murat AU - Ugur M AUID- ORCID: 0000-0002-1714-7813 AD - Department of Cardiovascular Surgery, Sancaktepe Sehit Professor Doctor Ilhan Varank Education and Research Hospital, University of Health Sciences, Istanbul, Turkey. LA - eng PT - Journal Article DEP - 20230119 PL - England TA - Vascular JT - Vascular JID - 101196722 SB - IM MH - Humans MH - Male MH - Female MH - Retrospective Studies MH - Aged MH - *Endarterectomy, Carotid/adverse effects/mortality MH - Treatment Outcome MH - *Stents MH - Time Factors MH - Middle Aged MH - *Carotid Stenosis/diagnostic imaging/therapy/surgery/mortality MH - Risk Factors MH - *Patient Care Team MH - Endovascular Procedures/adverse effects/mortality MH - Aged, 80 and over MH - Recurrence OTO - NOTNLM OT - Carotid arterial disease OT - carotid council OT - carotid stenting OT - endarterectomy COIS- Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2023/01/20 06:00 MHDA- 2024/05/27 06:44 CRDT- 2023/01/19 05:03 PHST- 2024/05/27 06:44 [medline] PHST- 2023/01/20 06:00 [pubmed] PHST- 2023/01/19 05:03 [entrez] AID - 10.1177/17085381231153222 [doi] PST - ppublish SO - Vascular. 2024 Jun;32(3):573-578. doi: 10.1177/17085381231153222. Epub 2023 Jan 19. PMID- 36653205 OWN - NLM STAT- MEDLINE DCOM- 20230228 LR - 20230320 IS - 2152-2669 (Electronic) IS - 2152-2669 (Linking) VI - 23 IP - 3 DP - 2023 Mar TI - A Comprehensive Multidisciplinary Diagnostic Algorithm for the Early and Efficient Detection of Amyloidosis. PG - 194-202 LID - S2152-2650(22)01777-3 [pii] LID - 10.1016/j.clml.2022.12.013 [doi] AB - Amyloidosis is a rare protein misfolding disease caused by the accumulation of amyloid fibrils in various tissues and organs. There are different subtypes of amyloidosis, with light chain (AL) amyloidosis being the most common. Amyloidosis is notoriously difficult to diagnose because it is clinically heterogeneous, no single test is diagnostic for the disease, and diagnosis typically involves multiple specialists. Here, we propose an integrated, multidisciplinary algorithm for efficiently diagnosing amyloidosis. Drawing on research from several medical disciplines, we have combined clinical decisions and best practices into a comprehensive algorithm to facilitate the early detection of amyloidosis. Currently, many patients are diagnosed more than 6 months after symptom onset, yet early diagnosis is the major predictor of survival. Our algorithm aims to shorten the time to diagnosis with efficient sequencing of tests and minimizing uninformative investigations. We also recommend typing and staging of confirmed amyloidosis to guide treatment. By reducing time to diagnosis, our algorithm could lead to earlier and more targeted treatment, ultimately improving prognosis and survival. CI - Copyright (c) 2022 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Jimenez-Zepeda, Victor AU - Jimenez-Zepeda V AD - Department of Hematology, University of Calgary and Arnie Charbonneau Cancer Institute, Calgary, Alberta, Canada. Electronic address: victor.zepeda@ahs.ca. FAU - Bril, Vera AU - Bril V AD - Division of Neurology, Department of Medicine, University of Toronto and University Health Network, Toranto, Ontario, Canada. FAU - Lemieux-Blanchard, Emilie AU - Lemieux-Blanchard E AD - Department of Hematology, Service d'hematologie-oncologie du Centre hospitalier de l'Universite de Montreal and Centre de recherche du CHUM, Montreal, Quebec, Canada. FAU - Royal, Virginie AU - Royal V AD - Department of Pathology, Hopital Maisonneuve-Rosemont, Universite de Montreal, Montreal, Quebec, Canada. FAU - McCurdy, Arleigh AU - McCurdy A AD - Division of Hematology, The Ottawa Hospital and University of Ottawa, Ottawa, Ontario, Canada. FAU - Schwartz, Daniel AU - Schwartz D AD - Faculty of Medicine, Division of Nephrology, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Davis, Margot K AU - Davis MK AD - Division of Cardiology, University of British Columbia, Vancouver, British Columbia, Canada. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20221224 PL - United States TA - Clin Lymphoma Myeloma Leuk JT - Clinical lymphoma, myeloma & leukemia JID - 101525386 RN - 0 (Amyloid) SB - IM MH - Humans MH - *Amyloid Neuropathies, Familial/diagnosis/metabolism/therapy MH - *Immunoglobulin Light-chain Amyloidosis MH - Amyloid MH - Prognosis MH - Algorithms OTO - NOTNLM OT - AA Amyloidosis OT - ATTR amyloidosis OT - Cardiac amyloidosis OT - Hereditary amyloidosis OT - Light Chain Amyloidosis EDAT- 2023/01/19 06:00 MHDA- 2023/03/03 06:00 CRDT- 2023/01/18 21:58 PHST- 2022/04/20 00:00 [received] PHST- 2022/12/16 00:00 [revised] PHST- 2022/12/21 00:00 [accepted] PHST- 2023/01/19 06:00 [pubmed] PHST- 2023/03/03 06:00 [medline] PHST- 2023/01/18 21:58 [entrez] AID - S2152-2650(22)01777-3 [pii] AID - 10.1016/j.clml.2022.12.013 [doi] PST - ppublish SO - Clin Lymphoma Myeloma Leuk. 2023 Mar;23(3):194-202. doi: 10.1016/j.clml.2022.12.013. Epub 2022 Dec 24. PMID- 36646584 OWN - NLM STAT- MEDLINE DCOM- 20240703 LR - 20250716 IS - 1531-6564 (Electronic) IS - 0363-5023 (Linking) VI - 49 IP - 7 DP - 2024 Jul TI - Results of Implementation of Amyloidosis Screening for Patients Undergoing Carpal Tunnel Release. PG - 675-680 LID - S0363-5023(22)00540-8 [pii] LID - 10.1016/j.jhsa.2022.09.005 [doi] AB - PURPOSE: Many patients with amyloidosis undergo carpal tunnel release (CTR) before amyloidosis diagnosis and before developing cardiac or other serious disease manifestations. The purposes of this study were to examine if our patient population had a similar prevalence of positive amyloidosis diagnoses to that in prior studies and to describe the results of implementing a screening program for amyloidosis. METHODS: We retrospectively reviewed the biopsy results and subsequent interventions for all patients who underwent screening tenosynovial biopsy during CTR from March 2020 through December 2021. Amyloid screening was offered to patients who met the criteria for increased risk of disease using an appropriateness screening algorithm. RESULTS: Seventy-five (48%) of 156 patients who underwent CTR met the eligibility criteria for amyloidosis testing. Of the 62 patients who agreed to undergo tenosynovial biopsy, 14 had amyloid-positive biopsy specimens (10 men and 4 women). All patients with positive tenosynovial biopsies had bilateral carpal tunnel syndrome and wild-type transthyretin amyloid subtype. One patient was diagnosed and started treatment for otherwise asymptomatic cardiac amyloidosis. CONCLUSIONS: The incidence of amyloid-positive tenosynovial biopsy results from CTR was 22.5% in patients using the criteria from an appropriateness screening algorithm, which was higher than previously reported. Implementation of a screening program for patients undergoing CTR requires a multidisciplinary approach and may result in early diagnosis and lifesaving interventions for patients with amyloidosis. TYPE OF STUDY/LEVEL OF EVIDENCE: Differential diagnosis/symptom prevalence study, II. CI - Copyright (c) 2024 American Society for Surgery of the Hand. Published by Elsevier Inc. All rights reserved. FAU - Gannon, Nicholas P AU - Gannon NP AD - Department of Orthopaedic Surgery, University of Minnesota, Minneapolis, MN. FAU - Ward, Christina M AU - Ward CM AD - Department of Orthopaedic Surgery, University of Minnesota, Minneapolis, MN; Department of Orthopaedic Surgery, Regions Hospital, Saint Paul, MN. Electronic address: Christina.M.Ward@healthpartners.com. LA - eng PT - Journal Article DEP - 20230114 PL - United States TA - J Hand Surg Am JT - The Journal of hand surgery JID - 7609631 SB - IM MH - Humans MH - *Carpal Tunnel Syndrome/surgery/diagnosis MH - Male MH - Female MH - Retrospective Studies MH - *Amyloidosis/diagnosis/surgery MH - Aged MH - Biopsy MH - Middle Aged MH - Mass Screening MH - Algorithms MH - Synovial Membrane/pathology MH - Decompression, Surgical MH - Aged, 80 and over OTO - NOTNLM OT - Amyloidosis OT - carpal tunnel release OT - carpal tunnel syndrome OT - screening OT - tenosynovial EDAT- 2023/01/17 06:00 MHDA- 2024/07/04 01:18 CRDT- 2023/01/16 21:58 PHST- 2022/04/25 00:00 [received] PHST- 2022/07/16 00:00 [revised] PHST- 2022/09/12 00:00 [accepted] PHST- 2024/07/04 01:18 [medline] PHST- 2023/01/17 06:00 [pubmed] PHST- 2023/01/16 21:58 [entrez] AID - S0363-5023(22)00540-8 [pii] AID - 10.1016/j.jhsa.2022.09.005 [doi] PST - ppublish SO - J Hand Surg Am. 2024 Jul;49(7):675-680. doi: 10.1016/j.jhsa.2022.09.005. Epub 2023 Jan 14. PMID- 36645078 OWN - NLM STAT- MEDLINE DCOM- 20230119 LR - 20240912 IS - 2047-9980 (Electronic) IS - 2047-9980 (Linking) VI - 12 IP - 2 DP - 2023 Jan 17 TI - Heart-Brain Team Approach of Acute Myocardial Infarction Complicating Acute Stroke: Characteristics of Guideline-Recommended Coronary Revascularization and Antithrombotic Therapy and Cardiovascular and Bleeding Outcomes. PG - e027156 LID - 10.1161/JAHA.122.027156 [doi] LID - e027156 AB - Background Acute myocardial infarction (AMI) infrequently occurs after acute stroke. The Heart-brain team approach has a potential to appropriately manage this poststroke cardiovascular complication. However, clinical outcomes of AMI complicating acute stroke (AMI-CAS) with the heart-brain team approach have not been characterized. The current study investigated cardiovascular outcomes in patients with AMI-CAS managed by a heart-brain team. Methods and Results We retrospectively analyzed 2390 patients with AMI at our institute (January 1, 2007-September 30, 2020). AMI-CAS was defined as the occurrence of AMI within 14 days after acute stroke. Major adverse cerebral/cardiovascular events (cardiac-cause death, nonfatal myocardial infarction, and nonfatal stroke) and major bleeding events were compared in subjects with AMI-CAS and those without acute stroke. AMI-CAS was identified in 1.6% of the subjects. Most AMI-CASs (37/39=94.9%) presented ischemic stroke. Median duration of AMI from the onset of acute stroke was 2 days. Patients with AMI-CAS less frequently received primary percutaneous coronary intervention (43.6% versus 84.7%; P<0.001) and dual-antiplatelet therapy (38.5% versus 85.7%; P<0.001), and 33.3% of them did not receive any antithrombotic agents (versus 1.3%; P<0.001). During the observational period (median, 2.4 years [interquartile range, 1.1-4.4 years]), patients with AMI-CAS exhibited a greater likelihood of experiencing major adverse cerebral/cardiovascular events (hazard ratio [HR], 3.47 [95% CI, 1.99-6.05]; P<0.001) and major bleeding events (HR, 3.30 [95% CI, 1.34-8.10]; P=0.009). These relationships still existed even after adjusting for clinical characteristics and medication use (major adverse cerebral/cardiovascular event: HR, 1.87 [95% CI, 1.02-3.42]; P=0.04; major bleeding: HR, 2.67 [95% CI, 1.03-6.93]; P=0.04). Conclusions Under the heart-brain team approach, AMI-CAS was still a challenging disease, reflected by less adoption of primary percutaneous coronary intervention and antithrombotic therapies, with substantially elevated cardiovascular and major bleeding risks. Our findings underscore the need for a further refined approach to mitigate their ischemic/bleeding risks. FAU - Suzuki, Toshiaki AU - Suzuki T AUID- ORCID: 0000-0001-9386-2432 AD - Department of Cardiovascular Medicine National Cerebral and Cardiovascular Center Suita, Osaka Japan. AD - Department of Advanced Cardiovascular Medicine, Graduate School of Medical Sciences Kumamoto University Kumamoto Japan. FAU - Kataoka, Yu AU - Kataoka Y AUID- ORCID: 0000-0001-6307-5593 AD - Department of Cardiovascular Medicine National Cerebral and Cardiovascular Center Suita, Osaka Japan. AD - Department of Advanced Cardiovascular Medicine, Graduate School of Medical Sciences Kumamoto University Kumamoto Japan. FAU - Shiozawa, Masayuki AU - Shiozawa M AUID- ORCID: 0000-0002-8071-7284 AD - Department of Cerebrovascular Medicine National Cerebral and Cardiovascular Center Suita, Osaka Japan. FAU - Morris, Kensuke AU - Morris K AUID- ORCID: 0000-0003-0535-5532 AD - Department of Preventive Cardiology National Cerebral and Cardiovascular Center Suita, Osaka Japan. FAU - Kiyoshige, Eri AU - Kiyoshige E AUID- ORCID: 0000-0002-0558-9323 AD - Department of Preventive Cardiology National Cerebral and Cardiovascular Center Suita, Osaka Japan. FAU - Nishimura, Kunihiro AU - Nishimura K AUID- ORCID: 0000-0002-0639-0949 AD - Department of Preventive Cardiology National Cerebral and Cardiovascular Center Suita, Osaka Japan. FAU - Murai, Kota AU - Murai K AUID- ORCID: 0000-0002-5162-4783 AD - Department of Cardiovascular Medicine National Cerebral and Cardiovascular Center Suita, Osaka Japan. AD - Department of Advanced Cardiovascular Medicine, Graduate School of Medical Sciences Kumamoto University Kumamoto Japan. FAU - Sawada, Kenichiro AU - Sawada K AD - Department of Cardiovascular Medicine National Cerebral and Cardiovascular Center Suita, Osaka Japan. AD - Department of Advanced Cardiovascular Medicine, Graduate School of Medical Sciences Kumamoto University Kumamoto Japan. FAU - Iwai, Takamasa AU - Iwai T AD - Department of Cardiovascular Medicine National Cerebral and Cardiovascular Center Suita, Osaka Japan. FAU - Matama, Hideo AU - Matama H AD - Department of Cardiovascular Medicine National Cerebral and Cardiovascular Center Suita, Osaka Japan. AD - Department of Advanced Cardiovascular Medicine, Graduate School of Medical Sciences Kumamoto University Kumamoto Japan. FAU - Honda, Satoshi AU - Honda S AUID- ORCID: 0000-0002-1393-4270 AD - Department of Cardiovascular Medicine National Cerebral and Cardiovascular Center Suita, Osaka Japan. FAU - Fujino, Masashi AU - Fujino M AUID- ORCID: 0000-0002-2706-4317 AD - Department of Cardiovascular Medicine National Cerebral and Cardiovascular Center Suita, Osaka Japan. FAU - Yoneda, Shuichi AU - Yoneda S AD - Department of Cardiovascular Medicine National Cerebral and Cardiovascular Center Suita, Osaka Japan. FAU - Takagi, Kensuke AU - Takagi K AD - Department of Cardiovascular Medicine National Cerebral and Cardiovascular Center Suita, Osaka Japan. FAU - Otsuka, Fumiyuki AU - Otsuka F AUID- ORCID: 0000-0003-4162-2036 AD - Department of Cardiovascular Medicine National Cerebral and Cardiovascular Center Suita, Osaka Japan. FAU - Asaumi, Yasuhide AU - Asaumi Y AUID- ORCID: 0000-0002-9009-7234 AD - Department of Cardiovascular Medicine National Cerebral and Cardiovascular Center Suita, Osaka Japan. FAU - Koga, Masatoshi AU - Koga M AUID- ORCID: 0000-0002-6758-4026 AD - Department of Cerebrovascular Medicine National Cerebral and Cardiovascular Center Suita, Osaka Japan. FAU - Ihara, Masafumi AU - Ihara M AUID- ORCID: 0000-0002-7102-4048 AD - Department of Neurology National Cerebral and Cardiovascular Center Suita, Osaka Japan. FAU - Toyoda, Kazunori AU - Toyoda K AUID- ORCID: 0000-0002-8346-9845 AD - Department of Cerebrovascular Medicine National Cerebral and Cardiovascular Center Suita, Osaka Japan. FAU - Tsujita, Kenichi AU - Tsujita K AD - Department of Cardiovascular Medicine, Graduate School of Medical Sciences Kumamoto University Kumamoto Japan. FAU - Noguchi, Teruo AU - Noguchi T AUID- ORCID: 0000-0001-5372-4932 AD - Department of Cardiovascular Medicine National Cerebral and Cardiovascular Center Suita, Osaka Japan. AD - Department of Advanced Cardiovascular Medicine, Graduate School of Medical Sciences Kumamoto University Kumamoto Japan. LA - eng PT - Journal Article DEP - 20230116 PL - England TA - J Am Heart Assoc JT - Journal of the American Heart Association JID - 101580524 RN - 0 (Fibrinolytic Agents) SB - IM MH - Humans MH - *Fibrinolytic Agents/adverse effects MH - Hemorrhage/chemically induced/epidemiology MH - *Myocardial Infarction/complications/therapy/epidemiology MH - *Percutaneous Coronary Intervention/adverse effects MH - Retrospective Studies MH - Risk Factors MH - *Stroke/epidemiology/therapy MH - Treatment Outcome PMC - PMC9939076 OTO - NOTNLM OT - acute myocardial infarction OT - acute stroke OT - antithrombotic therapy OT - bleeding OT - heart-brain team approach EDAT- 2023/01/17 06:00 MHDA- 2023/01/19 06:00 PMCR- 2023/01/17 CRDT- 2023/01/16 06:22 PHST- 2023/01/17 06:00 [pubmed] PHST- 2023/01/19 06:00 [medline] PHST- 2023/01/16 06:22 [entrez] PHST- 2023/01/17 00:00 [pmc-release] AID - JAH38140 [pii] AID - 10.1161/JAHA.122.027156 [doi] PST - ppublish SO - J Am Heart Assoc. 2023 Jan 17;12(2):e027156. doi: 10.1161/JAHA.122.027156. Epub 2023 Jan 16. PMID- 36643082 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230117 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 15 IP - 1 DP - 2023 Jan TI - Nicorandil, Novel Potassium Adenosine Triphosphate Channel (K+ ATP) Opener in Ischemia With Non-Obstructive Coronary Arteries (INOCA) and Atherosclerotic Cardiovascular Disease (ASCVD): Delphi Consensus Statement. PG - e33624 LID - 10.7759/cureus.33624 [doi] LID - e33624 AB - BACKGROUND: Coronary artery disease (CAD) is a significant health concern today that has assumed epidemic proportions worldwide and in India. OBJECTIVE: The pathobiology of CAD or ischemia with non-obstructive coronary arteries disease (INOCA) in most cases involves coronary microvascular dysfunction (CMD) that often requires personalized pheno-approach based on the risk stratification and diagnostic yield, especially in patients with recurrent angina episodes. Chronic therapy with anti-anginal is often fraught with challenges of unipolar action, tolerance, and oxidative stress that precludes consistent benefits in clinical cases of CMD represented by microvascular angina (MVA). To further elucidate the clinical role and relevance of long-term vasodilator therapy, including nicorandil, a Knowledge, Attitude, and Perception (KAP) survey was planned to be conducted. METHODS: Based on responses to the KAP survey questionnaire, Delphi-mediated graded recommendations were developed by a specialist panel as per Agency of Health Care and Quality Systems (AHRQ) criteria. RESULTS: Management of INOCA with MVA requires a multidisciplinary approach involving non- or invasive procedures that may be relevant for persistent or refractory angina before instituting symptomatic and long-term use of nicorandil for beta-blocker intolerant and associated clinical phenotypes. CONCLUSION: The analyses provide a real-life approach to the management of INOCA and angina non-obstructive coronary artery disease (ANOCA) with underlying CMD that may be relevant in outpatient settings in India. CI - Copyright (c) 2023, Chakraborty et al. FAU - Chakraborty, Rabin AU - Chakraborty R AD - Cardiology, Medica Superspecialty Hospital, Kolkata, IND. LA - eng PT - Journal Article DEP - 20230110 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC9835851 OTO - NOTNLM OT - angina non-obstructive coronary artery disease OT - coronary artery disease OT - ischemic non-obstructive coronary artery disease OT - microvascular angina OT - nicorandil OT - type 2 diabetes COIS- The authors have declared that no competing interests exist. EDAT- 2023/01/17 06:00 MHDA- 2023/01/17 06:01 PMCR- 2023/01/10 CRDT- 2023/01/16 02:36 PHST- 2023/01/05 00:00 [accepted] PHST- 2023/01/16 02:36 [entrez] PHST- 2023/01/17 06:00 [pubmed] PHST- 2023/01/17 06:01 [medline] PHST- 2023/01/10 00:00 [pmc-release] AID - 10.7759/cureus.33624 [doi] PST - epublish SO - Cureus. 2023 Jan 10;15(1):e33624. doi: 10.7759/cureus.33624. eCollection 2023 Jan. PMID- 36642302 OWN - NLM STAT- MEDLINE DCOM- 20230828 LR - 20230831 IS - 1556-5653 (Electronic) IS - 0015-0282 (Linking) VI - 120 IP - 3 Pt 1 DP - 2023 Sep TI - Reproduction as a window for health in men. PG - 429-437 LID - S0015-0282(23)00052-3 [pii] LID - 10.1016/j.fertnstert.2023.01.014 [doi] AB - Male factor infertility is widely considered a harbinger for a man's general health. Failure of reproduction often accompanies other underlying processes, with growing evidence suggesting that a diagnosis of infertility increases the likelihood of developing future cardiac, metabolic, and oncologic diseases. The goal of this review is to provide a comprehensive overview of the research on male fertility as a marker for current and future health. A multidisciplinary approach is essential, and there is growing consensus that the male fertility evaluation offers an opportunity to better men's wellness beyond their immediate reproductive ambitions. CI - Copyright (c) 2023 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved. FAU - Belladelli, Federico AU - Belladelli F AD - Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; University Vita-Salute San Raffaele, Milan, Italy; Department of Urology, School of Medicine, Stanford University, Stanford, California. FAU - Muncey, Wade AU - Muncey W AD - Department of Urology, School of Medicine, Stanford University, Stanford, California. FAU - Eisenberg, Michael L AU - Eisenberg ML AD - Department of Urology, School of Medicine, Stanford University, Stanford, California. Electronic address: eisenberg@stanford.edu. LA - eng PT - Journal Article PT - Review DEP - 20230112 PL - United States TA - Fertil Steril JT - Fertility and sterility JID - 0372772 SB - IM MH - Humans MH - Male MH - *Reproduction MH - *Infertility, Male/diagnosis/etiology OTO - NOTNLM OT - Andrology OT - biomarker OT - infertility OT - men's health EDAT- 2023/01/16 06:00 MHDA- 2023/08/28 06:43 CRDT- 2023/01/15 19:26 PHST- 2022/08/24 00:00 [received] PHST- 2022/11/29 00:00 [revised] PHST- 2023/01/09 00:00 [accepted] PHST- 2023/08/28 06:43 [medline] PHST- 2023/01/16 06:00 [pubmed] PHST- 2023/01/15 19:26 [entrez] AID - S0015-0282(23)00052-3 [pii] AID - 10.1016/j.fertnstert.2023.01.014 [doi] PST - ppublish SO - Fertil Steril. 2023 Sep;120(3 Pt 1):429-437. doi: 10.1016/j.fertnstert.2023.01.014. Epub 2023 Jan 12. PMID- 36641646 OWN - NLM STAT- MEDLINE DCOM- 20230208 LR - 20241219 IS - 1897-4279 (Electronic) IS - 0022-9032 (Linking) VI - 81 IP - 1 DP - 2023 TI - Management of valvular heart disease in patients with cancer: Multidisciplinary team, cancer-therapy related cardiotoxicity, diagnosis, transcatheter intervention, and cardiac surgery. Expert opinion of the Association on Valvular Heart Disease, Association of Cardiovascular Interventions, and Working Group on Cardiac Surgery of the Polish Cardiac Society. PG - 82-101 LID - 10.33963/KP.a2023.0023 [doi] AB - The Association on Valvular Heart Disease, Association of Cardiovascular Interventions, and the Working Group on CardiacSurgery of the Polish Cardiac Society have released a position statement on risk factors, diagnosis, and management of patients with cancer and valvular heart disease (VHD). VHD can occur in patients with cancer in several ways, for example, it can exist or be diagnosed before cancer treatment, after cancer treatment, be an incidental finding during imaging tests, endocarditis related to immunosuppression, prolonged intravenous catheter use, or combination treatment, and nonbacterial thrombotic endocarditis. It is recommended to employ close cardiac surveillance for patients at high risk of complications during and after cancer treatment and for cancer treatments that may be cardiotoxic to be discussed by a multidisciplinary team. Patients with cancer and pre-existing severe VHD should be managed according to the 2021 European Society of Cardiology (ESC) and European Association for Cardio-Thoracic Surgery (EACTS) guidelines for VHD management, taking into consideration cancer prognosis and patient preferences. FAU - Plonska-Gosciniak, Edyta AU - Plonska-Gosciniak E AD - Department of Cardiology, Pomeranian Medical University, Szczecin, Poland. FAU - Piotrowski, Grzegorz AU - Piotrowski G AD - Department of Cardiology, Nicolaus Copernicus Memorial Hospital Lodz, Poland & Cardio-oncology Department, Medical University of Lodz, Lodz, Poland. FAU - Wojakowski, Wojciech AU - Wojakowski W AD - Department of Cardiology and Structural Heart Diseases Medical University of Silesia, Katowice, Poland. FAU - Gosciniak, Piotr AU - Gosciniak P AD - Laboratory of Non-Invasive Cardiac Imaging and Cardiooncology & Department of Endocrinology, Metabolic and Internal Diseases, Pomeranian Medical University, Szczecin, Poland. piotrgosciniak1@gmail.com. FAU - Olszowska, Maria AU - Olszowska M AD - Department of Cardiac and Vascular Diseases, Institute of Cardiology & Department of Social Cardiology Institute of Cardiology, Jagiellonian University Medical College, Krakow. AD - John Paul II Hospital, Krakow, Poland. FAU - Lesiak, Maciej AU - Lesiak M AD - 1st Department of Cardiology, Poznan University of Medical Sciences, Poznan, Poland. FAU - Klotzka, Aneta AU - Klotzka A AD - 1st Department of Cardiology, Poznan University of Medical Sciences, Poznan, Poland. FAU - Grygier, Marek AU - Grygier M AD - 1st Department of Cardiology, Poznan University of Medical Sciences, Poznan, Poland. FAU - Deja, Marek AU - Deja M AD - Department of Cardiac Surgery, Medical University of Silesia, Katowice, Poland. FAU - Kasprzak, Jaroslaw D AU - Kasprzak JD AD - 1st Department of Cardiology, Medical University of Lodz, Lodz, Poland. FAU - Kukulski, Tomasz AU - Kukulski T AD - 2nd Department of Cardiology, Medical University of Silesia, Katowice Poland, Spec. Hospital, Zabrze, Poland. FAU - Kosmala, Wojciech AU - Kosmala W AD - Department of Cardiovascular Imaging, Institute of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland. FAU - Suwalski, Piotr AU - Suwalski P AD - Clinical Department of Cardiac Surgery, Central Clinical Hospital of the Ministry of Interior and Administration, Warszawa, Poland. FAU - Kolowca, Maciej AU - Kolowca M AD - Department of Cardiac Surgery, University of Rzeszow, Rzeszow, Poland. FAU - Widenka, Kazimierz AU - Widenka K AD - Department of Cardiac Surgery, University of Rzeszow, Rzeszow, Poland. FAU - Hryniewiecki, Tomasz AU - Hryniewiecki T AD - Department of Valvular Heart Disease, National Institute of Cardiology, Warszawa, Poland. LA - eng PT - Journal Article DEP - 20230115 PL - Poland TA - Kardiol Pol JT - Kardiologia polska JID - 0376352 SB - IM MH - Humans MH - Poland MH - *Thoracic Surgery MH - Cardiotoxicity MH - *Heart Valve Diseases/diagnosis/surgery MH - *Cardiac Surgical Procedures MH - *Endocarditis MH - Patient Care Team MH - *Neoplasms/complications OTO - NOTNLM OT - cancer OT - cancer therapy related cardiotoxicity OT - cardiooncology OT - cardiovascular imaging OT - valvular heart disease EDAT- 2023/01/16 06:00 MHDA- 2023/02/09 06:00 CRDT- 2023/01/15 04:42 PHST- 2023/01/14 00:00 [received] PHST- 2023/01/14 00:00 [accepted] PHST- 2023/01/16 06:00 [pubmed] PHST- 2023/02/09 06:00 [medline] PHST- 2023/01/15 04:42 [entrez] AID - VM/OJS/J/93692 [pii] AID - 10.33963/KP.a2023.0023 [doi] PST - ppublish SO - Kardiol Pol. 2023;81(1):82-101. doi: 10.33963/KP.a2023.0023. Epub 2023 Jan 15. PMID- 36639338 OWN - NLM STAT- MEDLINE DCOM- 20230501 LR - 20230503 IS - 1878-0938 (Electronic) IS - 1878-0938 (Linking) VI - 50 DP - 2023 May TI - Appropriateness of the Modality of Revascularization According to the SYNTAX Score II 2020 in the FASTTRACK CABG Study: An Interim Report on Patient Selection. PG - 34-40 LID - S1553-8389(23)00001-5 [pii] LID - 10.1016/j.carrev.2023.01.001 [doi] AB - BACKGROUND: Personalized long term vital prognosis plays a key role in deciding between percutaneous coronary intervention (PCI) and CABG in patients with complex coronary artery disease. The FASTTRACK CABG trial enrolls patients with the sole guidance of coronary computed tomographic angiography (CCTA) and fractional flow reserve CCTA (FFR(CT)). The feasibility/non-feasibility of this approach is determined by the surgeon request to have access to the invasive coronary angiography. METHODS: This interim analysis, which was requested by the Data and Safety Monitoring Board (DSMB), compared the treatment decision of the "on site" Heart team to the recommended treatment as per the SYNTAX Score II 2020 (SS-2020), which was prospectively assessed by the central core laboratory in the first 57 consecutive patients (half of the planned population) enrolled in this First in Man study. RESULTS: The average anatomical SYTAX Score is 35.6 +/- 11.5. The SS-2020 predicted 5-year MACE and 10-year all-cause mortality are 14.7 % and 21.6 % following CABG, and 23.0 % and 30.4 % following PCI. Among the enrolled patients the SS-2020 predicts long-term PCI outcomes similar to CABG (absolute risk difference /= 0.70 for both relevance and adequacy, except for 2 screens. The CVI Average Method of the app was 0.851. CONCLUSIONS: mICardiApp is presented as an application to improve health literacy and self-management of patients with multimorbidity and heart failure, with proven validation. CI - Copyright (c) 2023 The Authors. Published by Elsevier B.V. All rights reserved. FAU - Fernandez-Gutierrez, Martina AU - Fernandez-Gutierrez M AD - Department of Nursing and Physiotherapy, University of Cadiz, Cadiz, Spain; Instituto de Investigacion e Innovacion Biomedica de Cadiz (INiBICA), Cadiz, Spain. FAU - Bas-Sarmiento, Pilar AU - Bas-Sarmiento P AD - Department of Nursing and Physiotherapy, University of Cadiz, Cadiz, Spain; Instituto de Investigacion e Innovacion Biomedica de Cadiz (INiBICA), Cadiz, Spain. Electronic address: pilar.bas@uca.es. FAU - Jesus Marin-Paz, Antonio AU - Jesus Marin-Paz A AD - Department of Nursing and Physiotherapy, University of Cadiz, Cadiz, Spain; The University Research Institute for Sustainable Social Development, INDESS, Spain. FAU - Castro-Yuste, Cristina AU - Castro-Yuste C AD - Department of Nursing and Physiotherapy, University of Cadiz, Cadiz, Spain; Instituto de Investigacion e Innovacion Biomedica de Cadiz (INiBICA), Cadiz, Spain. FAU - Sanchez-Sanchez, Eduardo AU - Sanchez-Sanchez E AD - Department of Nursing and Physiotherapy, University of Cadiz, Cadiz, Spain; Instituto de Investigacion e Innovacion Biomedica de Cadiz (INiBICA), Cadiz, Spain. FAU - Hernandez-Encuentra, Eulalia AU - Hernandez-Encuentra E AD - Department of Psychology and Education, Universitat Oberta de Catalunya, Spain. FAU - Jesus Vinolo-Gil, Maria AU - Jesus Vinolo-Gil M AD - Department of Nursing and Physiotherapy, University of Cadiz, Cadiz, Spain; Instituto de Investigacion e Innovacion Biomedica de Cadiz (INiBICA), Cadiz, Spain. FAU - Carmona-Barrientos, Ines AU - Carmona-Barrientos I AD - Department of Nursing and Physiotherapy, University of Cadiz, Cadiz, Spain; Instituto de Investigacion e Innovacion Biomedica de Cadiz (INiBICA), Cadiz, Spain. FAU - Poza-Mendez, Miriam AU - Poza-Mendez M AD - Department of Nursing and Physiotherapy, University of Cadiz, Cadiz, Spain; The University Research Institute for Sustainable Social Development, INDESS, Spain. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230106 PL - Ireland TA - Int J Med Inform JT - International journal of medical informatics JID - 9711057 SB - IM MH - Humans MH - *Self-Management MH - *Heart Failure/therapy MH - *Telemedicine MH - Exercise MH - Health Facilities MH - *Mobile Applications OTO - NOTNLM OT - App OT - Content validity OT - Heart failure OT - Mobile application OT - Multimorbidity OT - mHealth COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2023/01/14 06:00 MHDA- 2023/02/07 06:00 CRDT- 2023/01/13 18:06 PHST- 2022/11/08 00:00 [received] PHST- 2022/12/22 00:00 [revised] PHST- 2023/01/04 00:00 [accepted] PHST- 2023/01/14 06:00 [pubmed] PHST- 2023/02/07 06:00 [medline] PHST- 2023/01/13 18:06 [entrez] AID - S1386-5056(23)00003-5 [pii] AID - 10.1016/j.ijmedinf.2023.104986 [doi] PST - ppublish SO - Int J Med Inform. 2023 Mar;171:104986. doi: 10.1016/j.ijmedinf.2023.104986. Epub 2023 Jan 6. PMID- 36635661 OWN - NLM STAT- MEDLINE DCOM- 20230116 LR - 20240910 IS - 1471-2369 (Electronic) IS - 1471-2369 (Linking) VI - 24 IP - 1 DP - 2023 Jan 12 TI - UK prescribing practice of anticoagulants in patients with chronic kidney disease: a nephrology and haematology-based survey. PG - 9 LID - 10.1186/s12882-022-03041-w [doi] LID - 9 AB - A survey to gain insight into anticoagulant prescribing practice in the setting of chronic kidney disease (CKD) across the UK was disseminated via renal and haematology networks. Areas of anticoagulant use included patients with venous thromboembolism (VTE), requiring thromboprophylaxis for VTE, Atrial Fibrillation (AF) and nephrotic syndrome.An online-survey was disseminated via British Haematology Society, UK Kidney Association, and Renal Pharmacy Group over a five month period. All responses were voluntary and anonymous.Among 117 responses there were 49 nephrology doctors, 47 renal pharmacists and 20 haematology clinicians. A specialist multidisciplinary team to discuss the specific anticoagulant management of these patients was only available to 3% (4/117) respondents. Renal function estimate used for anticoagulant dosing was mainly Cockcroft-Gault for pharmacists and haematology but lab-based estimates were used by nephrology doctors. Therapeutic dose of Low Molecular Weight Heparin was mostly likely to be reduced by one-third when used for VTE treatment, with the majority of units undertaking anti-Xa monitoring in CKD stage 5 and dialysis. Direct-acting Oral Anticoagulants are being used in patients with nephrotic syndrome, those with CKD stage 5 and on dialysis for VTE and AF in the absence of license in these indications.This survey highlighted the significant differences between anticoagulant prescribing in CKD between two professional specialties and marked variation between centres in anticoagulant management strategies employed for these patients. With gaps still existing in the evidence base and answers to these not expected within the next few years, development of a best-practice guideline would be warranted to support clinicians in this field. CI - (c) 2023. The Author(s). FAU - Parker, Kathrine AU - Parker K AUID- ORCID: 0000-0001-9908-5160 AD - Manchester Institute of Nephrology and Transplantation, Manchester University NHS Foundation Trust, Oxford Road, M13 9WL, Manchester, UK. Kathrine.parker@postgrad.manchester.ac.uk. AD - Division of pharmacy and optometry, School of health sciences, Manchester Academic Health Science Centre, The University of Manchester, University of Manchester, M13 9PT, Manchester, UK. Kathrine.parker@postgrad.manchester.ac.uk. FAU - Choudhuri, Satarupa AU - Choudhuri S AD - Department of Haematology, Northern Care Alliance NHS Foundation Trust, Royal Oldham hospital, Rochdale Rd, OL1 2JH, Oldham, UK. FAU - Lewis, Penny AU - Lewis P AD - Division of pharmacy and optometry, School of health sciences, Manchester Academic Health Science Centre, The University of Manchester, University of Manchester, M13 9PT, Manchester, UK. FAU - Thachil, Jecko AU - Thachil J AD - Department of Haematology, Manchester University NHS Foundation Trust, Oxford Road, M13 9WL, Manchester, UK. FAU - Mitra, Sandip AU - Mitra S AD - Manchester Institute of Nephrology and Transplantation, Manchester University NHS Foundation Trust, Oxford Road, M13 9WL, Manchester, UK. AD - Division of cardiovascular sciences, School of medical sciences, The University of Manchester, M13 9NT, Manchester, UK. LA - eng GR - NIHR300545/National Institute of Healthcare Research/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230112 PL - England TA - BMC Nephrol JT - BMC nephrology JID - 100967793 RN - 0 (Anticoagulants) RN - 0 (Heparin, Low-Molecular-Weight) SB - IM MH - Humans MH - Anticoagulants/therapeutic use MH - *Venous Thromboembolism/drug therapy/prevention & control MH - *Nephrology MH - *Nephrotic Syndrome/drug therapy MH - Renal Dialysis MH - *Renal Insufficiency, Chronic/complications/drug therapy/epidemiology MH - *Atrial Fibrillation/drug therapy MH - Heparin, Low-Molecular-Weight/therapeutic use MH - *Kidney Failure, Chronic/drug therapy MH - Surveys and Questionnaires MH - *Hematology MH - United Kingdom/epidemiology MH - Administration, Oral PMC - PMC9837988 OTO - NOTNLM OT - Anticoagulation OT - Atrial fibrillation OT - Chronic kidney disease OT - Nephrotic syndrome OT - Venous thromboembolism COIS- Within the last 3 years KP has received honoraria from Bayer. JT has received honoraria from Bayer, Boehringer Ingelheim, BMS-Pfizer, Daichi-Sankyo, Octapharma, Leo Pharma. SC, PL and SM have no competing interests to declare that are relevant to the content of this article. EDAT- 2023/01/13 06:00 MHDA- 2023/01/17 06:00 PMCR- 2023/01/12 CRDT- 2023/01/12 23:35 PHST- 2022/10/04 00:00 [received] PHST- 2022/12/15 00:00 [accepted] PHST- 2023/01/12 23:35 [entrez] PHST- 2023/01/13 06:00 [pubmed] PHST- 2023/01/17 06:00 [medline] PHST- 2023/01/12 00:00 [pmc-release] AID - 10.1186/s12882-022-03041-w [pii] AID - 3041 [pii] AID - 10.1186/s12882-022-03041-w [doi] PST - epublish SO - BMC Nephrol. 2023 Jan 12;24(1):9. doi: 10.1186/s12882-022-03041-w. PMID- 36634931 OWN - NLM STAT- MEDLINE DCOM- 20230407 LR - 20250130 IS - 1449-8944 (Electronic) IS - 0156-5788 (Linking) VI - 47 IP - 2 DP - 2023 Apr TI - Exploring the delivery of phase II cardiac rehabilitation services in rural and remote Australia: a scoping review. PG - 239-245 LID - 10.1071/AH22204 [doi] AB - Objective Phase II cardiac rehabilitation (CR) reduces cardiovascular risk factors, morbidity and mortality after a cardiac event. Traditional Australian CR programs are located in metropolitan areas and delivered by an expert, multidisciplinary team. Referral and uptake barriers for people living in rural and remote locations are significantly affected by geographical isolation. This scoping review aimed to explore how phase II CR services in rural and remote Australia are being delivered. Methods A scoping review was conducted to obtain all published literature relating to CR service delivery for people living in rural and remote Australia. A literature search of the following databases was performed in December 2021: Cumulative Index to Nursing and Allied Health Literature, Embase, the Physiotherapy Evidence Database, and PubMed. Results Six articles met the inclusion criteria. Study designs varied and included mixed methods, cross-sectional design and narrative review. Overall, literature relating to CR programs in rural and remote Australia was limited. Three themes were apparent: (1) barriers to the delivery of phase II CR in rural and remote Australia remain; (2) community centre-based programs do not reach all people in rural and remote Australia; and (3) alternative models of CR are underutilised. Conclusions Phase II CR programs in rural and remote Australia do not align with current recommendations for service delivery. The use of technology as a primary or adjunct model of delivery to support people living in rural and remote Australia needs to be further developed and implemented. Further research exploring barriers to the uptake of alternative models of CR delivery is recommended. FAU - Corones-Watkins, Katina AU - Corones-Watkins K AD - School of Nursing and Midwifery, Faculty of Health, Griffith University, Nathan Campus, Brisbane, Qld 4111, Australia. FAU - Cooke, Marie AU - Cooke M AD - School of Nursing and Midwifery, Faculty of Health, Griffith University, Nathan Campus, Brisbane, Qld 4111, Australia. FAU - Butland, Michelle AU - Butland M AD - School of Nursing and Midwifery, Faculty of Health, Griffith University, Nathan Campus, Brisbane, Qld 4111, Australia. FAU - McGuire, Amanda AU - McGuire A AD - School of Nursing and Midwifery, Faculty of Health, Griffith University, Gold Coast Campus, Southport, Qld 4215, Australia. LA - eng PT - Journal Article PT - Scoping Review PL - Australia TA - Aust Health Rev JT - Australian health review : a publication of the Australian Hospital Association JID - 8214381 MH - Humans MH - Australia MH - *Cardiac Rehabilitation MH - Cross-Sectional Studies MH - *Medicine MH - *Rural Health Services MH - Rural Population MH - Clinical Trials, Phase II as Topic EDAT- 2023/01/13 06:00 MHDA- 2023/04/07 06:41 CRDT- 2023/01/12 20:43 PHST- 2022/09/09 00:00 [received] PHST- 2022/12/13 00:00 [accepted] PHST- 2023/04/07 06:41 [medline] PHST- 2023/01/13 06:00 [pubmed] PHST- 2023/01/12 20:43 [entrez] AID - AH22204 [pii] AID - 10.1071/AH22204 [doi] PST - ppublish SO - Aust Health Rev. 2023 Apr;47(2):239-245. doi: 10.1071/AH22204. PMID- 38939019 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250907 IS - 2772-963X (Electronic) IS - 2772-963X (Linking) VI - 2 IP - 1 DP - 2023 Jan TI - The Multidisciplinary Heart Team in Cardiovascular Medicine: Current Role and Future Challenges. PG - 100160 LID - S2772-963X(22)00238-1 [pii] LID - 10.1016/j.jacadv.2022.100160 [doi] LID - 100160 AB - Cardiovascular multidisciplinary heart teams (MDHTs) have evolved significantly over the past decade. These teams play a central role in the treatment of a wide array of cardiovascular diseases affecting interventional cardiology, cardiac surgery, interventional imaging, advanced heart failure, adult congenital heart disease, cardio-oncology, and cardio-obstetrics. To meet the specific needs of both patients and heart programs, the composition and function of cardiovascular MDHTs have had to adapt and evolve. Although lessons have been learned from multidisciplinary cancer care, best practices for the operation of cardiovascular MDHTs have yet to be defined, and the evidence base supporting their effectiveness is limited. This expert panel review discusses the history and evolution of cardiovascular MDHTs, their composition and role in treating patients across a broad spectrum of disciplines, basic tenets for successful operation, and the future challenges facing them. CI - (c) 2023 The Authors. FAU - Batchelor, Wayne B AU - Batchelor WB AD - ACC Interventional Cardiology Section Leadership Council, Inova Heart and Vascular Institute, Falls Church, Virginia, USA. Electronic address: Wayne.Batchelor@inova.org. FAU - Anwaruddin, Saif AU - Anwaruddin S AD - Division of Cardiology, ACC Interventional Section Leadership Council, St. Vincent Hospital, Worcester, Massachusetts, USA. FAU - Wang, Dee Dee AU - Wang DD AD - ACC Cardiovascular Imaging Section Leadership Council, Center for Structural Heart Disease, Henry Ford Hospital, Detroit, Michigan, USA. FAU - Perpetua, Elizabeth M AU - Perpetua EM AD - ACC Cardiovascular Team Section Leadership Council, Empath Health Services, Seattle, Washington, USA; Seattle Pacific University, School of Health Sciences and School of Nursing, Seattle, Washington, USA. FAU - Krishnaswami, Ashok AU - Krishnaswami A AD - Division of Cardiology, ACC Geriatric Cardiology Section Leadership Council, Kaiser Permanente San Jose Medical Center, San Jose, California, USA; Division of Geriatrics, Stanford University School of Medicine, Stanford, California, USA. FAU - Velagapudi, Poonam AU - Velagapudi P AD - Division of Cardiology, ACC Early Career Professionals Section Leadership Council, University of Nebraska Medical Center, Omaha, Nebraska, USA. FAU - Wyman, Janet F AU - Wyman JF AD - ACC Cardiovascular Team Section Leadership Council, Center for Structural Heart Disease, Henry Ford Health System, Detroit, Michigan, USA. FAU - Fullerton, David AU - Fullerton D AD - Division of Cardiothoracic Surgery, Department of Surgery, ACC Cardiac Surgery Team Section Leadership Council, University of Colorado School of Medicine, Aurora, Colorado, USA. FAU - Keegan, Patricia AU - Keegan P AD - Division of Cardiology, ACC Cardiovascular Team Section Leadership Council, Emory Structural Heart and Valve Center, Emory University Hospital Midtown, Atlanta, Georgia, USA. FAU - Phillips, Alistair AU - Phillips A AD - ACC Cardiac Surgery Team Section Leadership Council, The Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA. FAU - Ross, Laura AU - Ross L AD - ACC Interventional Cardiology Section Leadership Council, Park Nicollet Heart and Vascular Center, St. Louis Park, Massachusetts, USA. FAU - Maini, Brij AU - Maini B AD - Charles E. Schmidt College of Medicine, Florida Atlantic University, Delray Medical Center, Delray Beach, Florida, USA. FAU - Bernacki, Gwen AU - Bernacki G AD - Cardiovascular Division, Department of Medicine, ACC Geriatric Section Leadership Council, Cambia Palliative Care Center of Excellence, University of Washington, Seattle, Washington, USA; Veterans Administration of Puget Sound, University of Washington School of Medicine, Seattle, Washington, USA. FAU - Panjrath, Gurusher S AU - Panjrath GS AD - ACC Heart Failure and Transplant Section Leadership Council, George Washington University School of Medicine and Health Sciences, Washington, DC, USA. FAU - Lee, James AU - Lee J AD - ACC Cardiovascular Imaging Section Leadership Council, Center for Structural Heart Disease, Henry Ford Hospital, Detroit, Michigan, USA. FAU - Geske, Jeffrey B AU - Geske JB AD - Department of Cardiovascular Medicine, ACC Cardiovascular Imaging Section Leadership Council, Mayo Clinic, Rochester, Minnesota, USA. FAU - Welt, Fred AU - Welt F AD - Division of Cardiovascular Medicine, ACC Interventional Cardiology Leadership Council, University of Utah Health Sciences Center, Salt Lake City, Utah, USA. FAU - Thakker, Prashanth D AU - Thakker PD AD - Cardiovascular Division, Department of Medicine, ACC Fellows in Training Section Leadership Council, Washington University, Saint Louis, Missouri, USA. FAU - Deswal, Anita AU - Deswal A AD - Division of Internal Medicine, Department of Cardiology, ACC Cardio-Oncology Leadership Council, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. FAU - Park, Ki AU - Park K AD - Division of Cardiovascular Medicine, ACC Interventional Cardiology Section Leadership Council, University of Florida College of Medicine, Malcom Randall VA Medical Center, Gainesville, Florida, USA. FAU - Mack, Michael J AU - Mack MJ AD - Division of Cardiothoracic Surgery, Department of Surgery, ACC Cardiac Surgery Team Section Leadership Council, Baylor Scott and White Health, Dallas, Texas, USA. FAU - Leon, Martin AU - Leon M AD - Division of Cardiology, Department of Medicine, ACC Leon Center Leadership Council, Columbia University Irving Medical Center, New York, New York, USA. FAU - Lewis, Sandra AU - Lewis S AD - ACC Section Steering Committee, Legacy Medical Group Cardiology, Portland, Oregon, USA. FAU - Holmes, David AU - Holmes D AD - Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA. LA - eng PT - Journal Article PT - Review DEP - 20230111 PL - United States TA - JACC Adv JT - JACC. Advances JID - 9918419284106676 PMC - PMC11198656 OTO - NOTNLM OT - multidisciplinary heart team OT - structural heart disease OT - team-based care COIS- Dr Batchelor has received institutional research grant support from Abbott and Boston Scientific; and is a consultant for Abbott, Medtronic, Edwards, V-Wave Medical, and Boston Scientific. Dr Anwaruddin is a consultant/proctor/advisory board member at Medtronic; proctor at Edwards; on the steering committee of Boston Scientific; on the advisory board of OpSens; and has equity in East End Medical. Dr Wang is a consultant at Edwards Lifesciences, Boston Scientific, Abbott, and Neochord; and has received institutional research grant support from Boston scientific. Dr Velugapudi is on the Speakers Bureau of Abiomed and Opsens; and is on the advisory board of Women's Health Initiative. Ms Wyman is a consultant at Edwards Lifesciences and Boston Scientific. Ms Perpetua is a consultant at Abbott and Edwards; and is on the advisory board of Abbott. Dr Maini has equity in East End Medical; is on the advisory board of Boston Scientific, Abbott, and Medtronic; is on the Speakers Bureau of Boston Scientific, Abbott, and Medtronic; and has received proctorship honoraria from Boston Scientific, Abbott, and Medtronic. Dr Mack is a co-principal investigator/study chair (no renumeration) for Abbott, Edwards Lifesciences, and Medtronic. Dr Leon is on the advisory board (no renumeration) of Abbott, BSC, MDT, Edwards, Gore, and Venus Medtech. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2023/01/11 00:00 MHDA- 2023/01/11 00:01 PMCR- 2023/01/11 CRDT- 2024/06/28 04:53 PHST- 2022/08/23 00:00 [received] PHST- 2022/10/17 00:00 [accepted] PHST- 2023/01/11 00:01 [medline] PHST- 2023/01/11 00:00 [pubmed] PHST- 2024/06/28 04:53 [entrez] PHST- 2023/01/11 00:00 [pmc-release] AID - S2772-963X(22)00238-1 [pii] AID - 100160 [pii] AID - 10.1016/j.jacadv.2022.100160 [doi] PST - epublish SO - JACC Adv. 2023 Jan 11;2(1):100160. doi: 10.1016/j.jacadv.2022.100160. eCollection 2023 Jan. PMID- 36621456 OWN - NLM STAT- MEDLINE DCOM- 20230717 LR - 20231227 IS - 1097-685X (Electronic) IS - 0022-5223 (Linking) VI - 166 IP - 2 DP - 2023 Aug TI - Operative mortality after Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery Mortality Category 1 to 3 procedures: Deficiencies and opportunities for quality improvement. PG - 325-333.e3 LID - S0022-5223(22)01265-X [pii] LID - 10.1016/j.jtcvs.2022.11.022 [doi] AB - OBJECTIVES: We examined cases of operative mortality at a single quaternary academic center for patients undergoing relatively lower-risk (Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery Mortality Category 1-3) procedures, as a means of identifying systemic weaknesses and opportunities for quality improvement. METHODS: A retrospective review of all operative mortality events for patients who underwent a Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery Mortality Category 1, 2, or 3 index procedure (2009-2020) at our institution was performed. After a detailed chart review was performed by 2 independent faculty for each case, factors and system deficiencies that contributed to mortality were identified. RESULTS: A total of 42 mortalities were identified. A total of 37 patients (88%) had at least 1 Society of Thoracic Surgeons-designated risk factor, including prior cardiac operations (48%), extracardiac malformations (43%), and preoperative ventilation (33%). Eight patients (19%) had non-Society of Thoracic Surgeons-designated preoperative patient-level variables considered as at potential risk, including severe ventricular dysfunction, pulmonary hypertension, lung hypoplasia, and undiagnosed severe coronary abnormalities. Four patients (10%) had no identified preoperative risk factors. After detailed chart review, 5 broad categories were identified: patient-related factors (n = 33; 78%), postoperative infection (n = 13; 31%), postoperative residual lesions (n = 7; 17%), Fontan physiology failure (n = 4; 10%), and unexplained left ventricular failure after tetralogy of Fallot repair (n = 3; 7%). A total of 74% of patients had at least 1 preoperative, intraoperative, or postoperative system deficiency. A total of 50% of surgeries were urgent or emergency. CONCLUSIONS: Operative mortality after Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery Mortality Category 1 to 3 procedures is related to the presence of multifactorial risk patterns (Society of Thoracic Surgeons and non-Society of Thoracic Surgeons-designated patient-level risk factors and variables, broad risk categories, system deficiencies, emergency surgery). A multidisciplinary approach to care, with early recognition and treatment of modifiable additional burdens, could reduce this risk. CI - Copyright (c) 2022 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved. FAU - Kalfa, David AU - Kalfa D AD - Section of Pediatric and Congenital and Cardiac Surgery, Division of Cardiac, Thoracic and Vascular Surgery, Department of Surgery, Morgan Stanley Children's Hospital-New York Presbyterian Hospital, Columbia University Vagelos College of Physicians and Surgeons, New York, NY. Electronic address: dk2757@cumc.columbia.edu. FAU - Karamichalis, John M AU - Karamichalis JM AD - Section of Pediatric and Congenital and Cardiac Surgery, Division of Cardiac, Thoracic and Vascular Surgery, Department of Surgery, Morgan Stanley Children's Hospital-New York Presbyterian Hospital, Columbia University Vagelos College of Physicians and Surgeons, New York, NY. FAU - Singh, Sameer K AU - Singh SK AD - Section of Pediatric and Congenital and Cardiac Surgery, Division of Cardiac, Thoracic and Vascular Surgery, Department of Surgery, Morgan Stanley Children's Hospital-New York Presbyterian Hospital, Columbia University Vagelos College of Physicians and Surgeons, New York, NY. FAU - Jiang, Pengfei AU - Jiang P AD - Division of Pediatric Cardiology, Morgan Stanley Children's Hospital-New York Presbyterian Hospital, Columbia University Vagelos College of Physicians and Surgeons, New York, NY. FAU - Anderson, Brett R AU - Anderson BR AD - Division of Pediatric Cardiology, Morgan Stanley Children's Hospital-New York Presbyterian Hospital, Columbia University Vagelos College of Physicians and Surgeons, New York, NY. FAU - Vargas, Diana AU - Vargas D AD - Division of Pediatrics, Morgan Stanley Children's Hospital-New York Presbyterian Hospital, Columbia University Vagelos College of Physicians and Surgeons, New York, NY. FAU - Choudhury, Tarif AU - Choudhury T AD - Division of Pediatric Cardiology, Morgan Stanley Children's Hospital-New York Presbyterian Hospital, Columbia University Vagelos College of Physicians and Surgeons, New York, NY. FAU - Habib, Anthony AU - Habib A AD - Division of Anesthesiology, Morgan Stanley Children's Hospital-New York Presbyterian Hospital, Columbia University Vagelos College of Physicians and Surgeons, New York, NY. FAU - Bacha, Emile AU - Bacha E AD - Section of Pediatric and Congenital and Cardiac Surgery, Division of Cardiac, Thoracic and Vascular Surgery, Department of Surgery, Morgan Stanley Children's Hospital-New York Presbyterian Hospital, Columbia University Vagelos College of Physicians and Surgeons, New York, NY. LA - eng PT - Journal Article DEP - 20221130 PL - United States TA - J Thorac Cardiovasc Surg JT - The Journal of thoracic and cardiovascular surgery JID - 0376343 SB - IM CIN - J Thorac Cardiovasc Surg. 2023 Aug;166(2):334-335. doi: 10.1016/j.jtcvs.2023.01.009. PMID: 36803551 MH - Humans MH - *Thoracic Surgery MH - Quality Improvement MH - *Cardiac Surgical Procedures/adverse effects MH - *Heart Defects, Congenital/surgery MH - *Surgeons MH - Databases, Factual OTO - NOTNLM OT - STAT category 1-3 OT - mortality risk model OT - quality improvement OT - risk factors OT - system deficiencies EDAT- 2023/01/10 06:00 MHDA- 2023/07/17 06:42 CRDT- 2023/01/09 04:54 PHST- 2022/05/15 00:00 [received] PHST- 2022/11/08 00:00 [revised] PHST- 2022/11/12 00:00 [accepted] PHST- 2023/07/17 06:42 [medline] PHST- 2023/01/10 06:00 [pubmed] PHST- 2023/01/09 04:54 [entrez] AID - S0022-5223(22)01265-X [pii] AID - 10.1016/j.jtcvs.2022.11.022 [doi] PST - ppublish SO - J Thorac Cardiovasc Surg. 2023 Aug;166(2):325-333.e3. doi: 10.1016/j.jtcvs.2022.11.022. Epub 2022 Nov 30. PMID- 36620388 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230111 IS - 2214-4269 (Print) IS - 2214-4269 (Electronic) IS - 2214-4269 (Linking) VI - 33 IP - Suppl 1 DP - 2022 Dec TI - Variable disease manifestations and metabolic management within a single family affected by ornithine transcarbamylase deficiency. PG - 100906 LID - 10.1016/j.ymgmr.2022.100906 [doi] LID - 100906 AB - We report on a family with ornithine transcarbamylase (OTC) deficiency, an X-linked urea cycle disorder, with variable disease severity and tailored management strategies based on each family member's biochemical profile and clinical presentation. Our primary patient is a female monozygotic twin who presented to medical care at 10 months of age with acute liver failure, gastrointestinal symptoms, altered mental status, hypoglycemia, and hyperammonemia. The patient's older brother, known to have hemizygous OTC deficiency, died at 8 months of age from cardiac arrest after complications secondary to his diagnosis. Despite her family history, manifestation of symptoms of heterozygous (partial) OTC deficiency went unrecognized by multiple providers based on misconceptions regarding a female's risk for X-linked disease. Despite barriers related to the family's low socioeconomic status, follow-up care by a multidisciplinary metabolic care team, including moderate protein restriction and nitrogen scavenger therapy, led to positive outcomes for the patient. Her twin sister and mother are also heterozygous for variants in OTC and remain controlled on moderate protein restriction. This case illustrates the importance of genotyping all individuals with genetic risk factors for OTC deficiency and the variability in disease manifestation that necessitates tailored treatment approaches for individuals with partial OTC deficiency. CI - (c) 2022 The Authors. FAU - Baker, Joshua AU - Baker J AD - Division of Genetics, Birth Defects & Metabolism, Ann & Robert H. Lurie Children's Hospital of Chicago, 225 E Chicago Ave, Chicago, IL 60611, USA. AD - Department of Pediatrics (Genetics, Birth Defects, and Metabolism), Northwestern University Feinberg School of Medicine, 420 E Superior St, Chicago, IL 60611, USA. FAU - Hitchins, Lauren AU - Hitchins L AD - Division of Genetics, Birth Defects & Metabolism, Ann & Robert H. Lurie Children's Hospital of Chicago, 225 E Chicago Ave, Chicago, IL 60611, USA. FAU - Vucko, Erika AU - Vucko E AD - Division of Genetics, Birth Defects & Metabolism, Ann & Robert H. Lurie Children's Hospital of Chicago, 225 E Chicago Ave, Chicago, IL 60611, USA. FAU - Havens, Kirsten AU - Havens K AD - Division of Genetics, Birth Defects & Metabolism, Ann & Robert H. Lurie Children's Hospital of Chicago, 225 E Chicago Ave, Chicago, IL 60611, USA. FAU - Becker, Karen AU - Becker K AD - Division of Genetics, Birth Defects & Metabolism, Ann & Robert H. Lurie Children's Hospital of Chicago, 225 E Chicago Ave, Chicago, IL 60611, USA. FAU - Arduini, Katherine AU - Arduini K AD - Division of Genetics, Birth Defects & Metabolism, Ann & Robert H. Lurie Children's Hospital of Chicago, 225 E Chicago Ave, Chicago, IL 60611, USA. LA - eng PT - Journal Article DEP - 20220730 PL - United States TA - Mol Genet Metab Rep JT - Molecular genetics and metabolism reports JID - 101624422 PMC - PMC9817479 OTO - NOTNLM OT - ALT, alanine aminotransferase OT - AST, aspartate transaminase OT - CVS, chorionic villus sampling OT - DOL, day of life OT - EAA, essential amino acid OT - GPB, glycerol phenylbutyrate OT - HC, head circumference OT - IV, intravenous OT - Late onset OT - Manifesting heterozygote OT - NBS, newborn screen OT - NORD, National Organization for Rare Disorders OT - NaPB, sodium phenylbutyrate OT - OTC, ornithine transcarbamylase OT - Ornithine transcarbamylase deficiency OT - PO, per os, by mouth OT - Partial ornithine transcarbamylase deficiency OT - UCD, urea cycle disorder OT - Urea cycle disorder OT - X-linked COIS- Joshua Baker, Lauren Hitchins, Erika Vucko, and Katherine Arduini have participated in advisory boards and received honoraria from Horizon Therapeutics plc. Joshua Baker is PI for a clinical trial sponsored by Ultragenyx. He has received consulting fees/honoraria from Biomarin, Horizon, Takeda, and Ultragenyx. Lauren Hitchins has received consulting fees/honoraria from Amicus and Acer Therapeutics. Erika Vucko has received consulting fees/honoraria from Takeda, BioMarin, and Sanofi Genzyme. Katherine Arduini has been involved in clinical trials sponsored by Ultragenyx, and has received consulting fees/honoraria from Acer Therapeutics. Kirsten Havens and Karen Becker have no conflicts to disclose. No authors received compensation for involvement with this manuscript. The authors confirm independence from the sponsor; the content of the article has not been influenced by the sponsor. EDAT- 2023/01/10 06:00 MHDA- 2023/01/10 06:01 PMCR- 2022/07/30 CRDT- 2023/01/09 04:10 PHST- 2022/05/13 00:00 [received] PHST- 2022/07/25 00:00 [revised] PHST- 2022/07/25 00:00 [accepted] PHST- 2023/01/09 04:10 [entrez] PHST- 2023/01/10 06:00 [pubmed] PHST- 2023/01/10 06:01 [medline] PHST- 2022/07/30 00:00 [pmc-release] AID - S2214-4269(22)00066-0 [pii] AID - 100906 [pii] AID - 10.1016/j.ymgmr.2022.100906 [doi] PST - epublish SO - Mol Genet Metab Rep. 2022 Jul 30;33(Suppl 1):100906. doi: 10.1016/j.ymgmr.2022.100906. eCollection 2022 Dec. PMID- 36615178 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230111 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 12 IP - 1 DP - 2023 Jan 3 TI - Gliflozins: From Antidiabetic Drugs to Cornerstone in Heart Failure Therapy-A Boost to Their Utilization and Multidisciplinary Approach in the Management of Heart Failure. LID - 10.3390/jcm12010379 [doi] LID - 379 AB - Heart failure (HF) is a complex, multifactorial, progressive clinical condition affecting 64.3 million people worldwide, with a strong impact in terms of morbidity, mortality and public health costs. In the last 50 years, along with a better understanding of HF physiopathology and in agreement with the four main models of HF, many therapeutic options have been developed. Recently, the European Society of Cardiology (ESC) HF guidelines enthusiastically introduced inhibitors of the sodium-glucose cotransporter (SGLT2i) as first line therapy for HF with reduced ejection fraction (HFrEF) in order to reduce hospitalizations and mortality. Despite drugs developed as hypoglycemic agents, data from the EMPA-REG OUTCOME trial encouraged the evaluation of the possible cardiovascular effects, showing SGLT2i beneficial effects on loading conditions, neurohormonal axes, heart cells' biochemistry and vascular stiffness, determining an improvement of each HF model. We want to give a boost to their use by increasing the knowledge of SGLT2-I and understanding the probable mechanisms of this new class of drugs, highlighting strengths and weaknesses, and providing a brief comment on major trials that made Gliflozins a cornerstone in HF therapy. Finally, aspects that may hinder SGLT2-i widespread utilization among different types of specialists, despite the guidelines' indications, will be discussed. FAU - Pistelli, Lorenzo AU - Pistelli L AD - Department of Biomedical and Dental Sciences and Morphofunctional Imaging, Section of Cardiology, University of Messina, 98122 Messina, Italy. FAU - Parisi, Francesca AU - Parisi F AD - Department of Biomedical and Dental Sciences and Morphofunctional Imaging, Section of Cardiology, University of Messina, 98122 Messina, Italy. FAU - Correale, Michele AU - Correale M AUID- ORCID: 0000-0002-7863-253X AD - Cardiothoracic Department, University Hospital Policlinico Riuniti, 71100 Foggia, Italy. FAU - Cocuzza, Federica AU - Cocuzza F AD - Department of Biomedical and Dental Sciences and Morphofunctional Imaging, Section of Cardiology, University of Messina, 98122 Messina, Italy. FAU - Campanella, Francesca AU - Campanella F AD - Department of Biomedical and Dental Sciences and Morphofunctional Imaging, Section of Cardiology, University of Messina, 98122 Messina, Italy. FAU - de Ferrari, Tommaso AU - de Ferrari T AD - Department of Biomedical and Dental Sciences and Morphofunctional Imaging, Section of Cardiology, University of Messina, 98122 Messina, Italy. FAU - Crea, Pasquale AU - Crea P AD - Department of Biomedical and Dental Sciences and Morphofunctional Imaging, Section of Cardiology, University of Messina, 98122 Messina, Italy. FAU - De Sarro, Rosalba AU - De Sarro R AD - Department of Biomedical and Dental Sciences and Morphofunctional Imaging, Section of Cardiology, University of Messina, 98122 Messina, Italy. FAU - La Cognata, Olga AU - La Cognata O AD - Department of Biomedical and Dental Sciences and Morphofunctional Imaging, Section of Cardiology, University of Messina, 98122 Messina, Italy. FAU - Ceratti, Simona AU - Ceratti S AD - Department of Biomedical and Dental Sciences and Morphofunctional Imaging, Section of Cardiology, University of Messina, 98122 Messina, Italy. FAU - Recupero, Tonino AU - Recupero T AD - Department of Biomedical and Dental Sciences and Morphofunctional Imaging, Section of Cardiology, University of Messina, 98122 Messina, Italy. FAU - Ruocco, Gaetano AU - Ruocco G AD - Cardiology Unit, Riuniti of Valdichiana Hospitals, USL-SUD-EST Toscana, 53045 Montepulciano, Italy. FAU - Palazzuoli, Alberto AU - Palazzuoli A AUID- ORCID: 0000-0002-6235-984X AD - Cardiovascular Diseases Unit, Cardio Thoracic and Vascular Department, S. Maria alle Scotte Hospital, University of Siena, 53018 Siena, Italy. FAU - Imbalzano, Egidio AU - Imbalzano E AUID- ORCID: 0000-0003-2656-5467 AD - Department of Biomedical and Dental Sciences and Morphofunctional Imaging, Section of Cardiology, University of Messina, 98122 Messina, Italy. FAU - Dattilo, Giuseppe AU - Dattilo G AD - Department of Biomedical and Dental Sciences and Morphofunctional Imaging, Section of Cardiology, University of Messina, 98122 Messina, Italy. LA - eng PT - Journal Article PT - Review DEP - 20230103 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC9820867 OTO - NOTNLM OT - SGLT-2 inhibitors OT - chronic heart failure OT - gliflozins OT - heart failure OT - pharmacological therapy COIS- The authors declare no conflict of interest. EDAT- 2023/01/09 06:00 MHDA- 2023/01/09 06:01 PMCR- 2023/01/03 CRDT- 2023/01/08 01:32 PHST- 2022/10/26 00:00 [received] PHST- 2022/12/11 00:00 [revised] PHST- 2022/12/30 00:00 [accepted] PHST- 2023/01/08 01:32 [entrez] PHST- 2023/01/09 06:00 [pubmed] PHST- 2023/01/09 06:01 [medline] PHST- 2023/01/03 00:00 [pmc-release] AID - jcm12010379 [pii] AID - jcm-12-00379 [pii] AID - 10.3390/jcm12010379 [doi] PST - epublish SO - J Clin Med. 2023 Jan 3;12(1):379. doi: 10.3390/jcm12010379. PMID- 36614945 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230111 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 12 IP - 1 DP - 2022 Dec 24 TI - Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus. LID - 10.3390/jcm12010145 [doi] LID - 145 AB - Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are indicated in type 2 diabetes and obesity for their high efficacy in controlling glycaemia and inducing body weight loss, respectively. Patients may develop gastrointestinal adverse events (GI AEs), namely nausea, vomiting, diarrhoea and/or constipation. To minimize their severity and duration, healthcare providers (HCPs) and patients must be aware of appropriate measures to follow while undergoing treatment. An expert panel comprising endocrinologists, nephrologists, primary care physicians, cardiologists, internists and diabetes nurse educators convened across virtual meetings to reach a consensus regarding these compelling recommendations. Firstly, specific guidelines are provided about how to reach the maintenance dose and how to proceed if GI AEs develop during dose-escalation. Secondly, specific directions are set about how to avoid/minimize nausea, vomiting, diarrhoea and constipation symptoms. Clinical scenarios representing common situations in daily practice, and infographics useful to guide both HCPs and patients, are included. These recommendations may prevent people with T2D and/or obesity from withdrawing from GLP-1 RAs treatment, thus benefitting from their superior effect on glycaemic control and weight loss. FAU - Gorgojo-Martinez, Juan J AU - Gorgojo-Martinez JJ AD - Department of Endocrinology and Nutrition, Hospital Universitario Fundacion Alcorcon, 28922 Madrid, Spain. FAU - Mezquita-Raya, Pedro AU - Mezquita-Raya P AD - Department of Endocrinology and Nutrition, Hospital Universitario Torrecardenas, 04009 Almeria, Spain. FAU - Carretero-Gomez, Juana AU - Carretero-Gomez J AUID- ORCID: 0000-0002-7754-6090 AD - Department of Internal Medicine, University Hospital of Badajoz, 06080 Badajoz, Spain. FAU - Castro, Almudena AU - Castro A AD - Department of Cardiology, University Hospital la Paz, IdiPAZ, Biomedical Research Center-Cardiovascular Diseases (CIBERCV-ISCIII), 28046 Madrid, Spain. FAU - Cebrian-Cuenca, Ana AU - Cebrian-Cuenca A AUID- ORCID: 0000-0003-3710-6370 AD - Health Centre Casco Antiguo Cartagena, Primary Care Research Group, Biomedical Research Institute of Murcia (IMIB), 30201 Cartagena, Spain. FAU - de Torres-Sanchez, Alejandra AU - de Torres-Sanchez A AD - Department of Endocrinology and Nutrition, Hospital Universitario Torrecardenas, 04009 Almeria, Spain. FAU - Garcia-de-Lucas, Maria Dolores AU - Garcia-de-Lucas MD AD - Department of Internal Medicine, Costa del Sol Hospital, 29603 Marbella, Spain. FAU - Nunez, Julio AU - Nunez J AUID- ORCID: 0000-0003-1672-7119 AD - Department of Cardiology, Valencia Clinic University Hospital, Instituto de Investigacion Sanitaria (INCLIVA), 46010 Valencia, Spain. FAU - Obaya, Juan Carlos AU - Obaya JC AD - Health Centre la Chopera, 28100 Madrid, Spain. FAU - Soler, Maria Jose AU - Soler MJ AD - Nephrology and Kidney Transplantation Research Group, Nephrology Department, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, 08035 Barcelona, Spain. FAU - Gorriz, Jose Luis AU - Gorriz JL AUID- ORCID: 0000-0002-1134-9051 AD - Nephrology Department, Valencia Clinic University Hospital, Instituto de Investigacion Sanitaria (INCLIVA), Universitat de Valencia, 46010 Valencia, Spain. FAU - Rubio-Herrera, Miguel Angel AU - Rubio-Herrera MA AUID- ORCID: 0000-0002-0495-6240 AD - Department of Endocrinology and Nutrition, San Carlos Clinical Hospital, Health Research Institute of the San Carlos Clinical Hospital (IDISSC), 28040 Madrid, Spain. LA - eng GR - n.a./Novo Nordisk (Spain)./ PT - Journal Article DEP - 20221224 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC9821052 OTO - NOTNLM OT - gastrointestinal adverse events OT - glucagon-like peptide-1 receptor agonists OT - guidelines OT - obesity OT - type 2 diabetes COIS- Juan J. Gorgojo-Martinez has the following financial relationships: advisor on scientific boards for Astra-Zeneca, Janssen Pharmaceuticals, Eli Lilly and Company, Merck Sharp & Dohme and Novo-Nordisk; lectures for Abbott, AbbVie Inc, Amarin, Astra-Zeneca, Boehringer Ingelheim Pharmaceuticals Inc, Esteve, Janssen Pharmaceuticals, Eli Lilly and Company, Merck Sharp & Dohme, Mundipharma, Novo-Nordisk and Roche Pharma, and research activities for Astra-Zeneca, Mundipharma, Novo-Nordisk and Eli Lilly and Company. Pedro Mezquita-Raya has the following financial relationships: advisor on scientific boards for Abbott, Astra-Zeneca, FAES and Novo-Nordisk; lectures for Astra-Zeneca, Eli Lilly and Company, FAES, Fresenius and Novo-Nordisk and research activities for Eli Lilly and Company and Novo Nordisk. Juana Carretero-Gomez reported receiving consulting fees and/or speaker from Astra Zeneca, Boehringer-Ingelheim, Janssen, MSD, Abbot, Nestle, Sanofi-Aventis and Novo-Nordisk. Almudena Castro has consulting fees from Astra Zeneca, Novartis, Boehringer-Ingelheim, Lilly, Novo-Nordisk, Bayer, Pfizer, Amgen, Sanofi, Organon, Daichii Sankyo and Vifor Pharma. Ana Cebrian-Cuenca has the following financial relationships: advisor on scientific boards for Astra-Zeneca, Boehringer Ingelheim Pharmaceuticals Inc, Eli Lilly and Company, Merck Sharp & Dohme and Novo-Nordisk; lectures for Astra-Zeneca, Boehringer Ingelheim Pharmaceuticals Inc, Esteve, Janssen Pharmaceuticals, Eli Lilly and Company, Merck Sharp & Dohme, Mundipharma and Novo-Nordisk, and research activities for Astra-Zeneca, Merck Sharp & Dohme, Mundipharma, Novo-Nordisk and Eli Lilly and Company. Alejandra de Torres has the following financial relationships: lectures for Novo-Nordisk, received grant support from Abbott, and research activities from Novo-Nordisk and Eli Lilly and Company. Maria Dolores Garcia de Lucas has the following financial relationships: advisor on scientific boards for Boehringer Ingelheim Pharmaceuticals Inc and Novo-Nordisk; lectures for Astra-Zeneca, Boehringer Ingelheim Pharmaceuticals Inc, Janssen Pharmaceuticals, Eli Lilly and Company, Merck Sharp & Dohme, Mundipharma and Novo-Nordisk. Julio Nunez reports personal and consulting fees from Astra Zeneca, Novartis, Boehringer-Ingelheim, Eli Lilly, Rovi, Novo-Nordisk, Bayer, Pfizer, and Vifor Pharma. Juan Carlos Obaya has the following financial relationships: advisor on scientific boards for, Astra-Zeneca, Novo-Nordisk and Novartis; lectures for Astra-Zeneca, Eli Lilly and Company, Ferrer, Sanofi and Novo-Nordisk. Maria Jose Soler is the CKJ Editor-in-Chief and reports honorarium for conferences, consulting fees and advisory boards from AstraZeneca, Novo-Nordsik, Esteve, Vifor, Travere Therapeutics, Bayer, Mundipharma, Ingelheim Lilly, Jansen, ICU Medical and Boehringer. Jose Luis Gorriz has the following financial relationships: advisor on scientific boards for Astra-Zeneca, Bayer and Novo-Nordisk; lectures for Astra-Zeneca, Boehringuer-Ingelnheim, Esteve, Bayer, Eli Lilly and Company, Mundipharma, Astrazeneca, Novartis, Bayer, Astellas and Novo-Nordisk and research activities for Astra-Zeneca. Miguel Angel Rubio-Herrera reported receiving consulting fees and/or speaker from Amgen, Astra Zeneca, Boehringer-Ingelheim, Eli Lilly, Janssen, Merck, Mundipharma, Rubio, and Sanofi-Aventis; and is an advisory board member and speaker for Novo-Nordisk. EDAT- 2023/01/09 06:00 MHDA- 2023/01/09 06:01 PMCR- 2022/12/24 CRDT- 2023/01/08 01:31 PHST- 2022/11/25 00:00 [received] PHST- 2022/12/21 00:00 [revised] PHST- 2022/12/23 00:00 [accepted] PHST- 2023/01/08 01:31 [entrez] PHST- 2023/01/09 06:00 [pubmed] PHST- 2023/01/09 06:01 [medline] PHST- 2022/12/24 00:00 [pmc-release] AID - jcm12010145 [pii] AID - jcm-12-00145 [pii] AID - 10.3390/jcm12010145 [doi] PST - epublish SO - J Clin Med. 2022 Dec 24;12(1):145. doi: 10.3390/jcm12010145. PMID- 36611389 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230111 IS - 2075-4418 (Print) IS - 2075-4418 (Electronic) IS - 2075-4418 (Linking) VI - 13 IP - 1 DP - 2022 Dec 29 TI - Cor Triatriatum Sinister Presenting as Cardioembolic Stroke in a Young Woman. LID - 10.3390/diagnostics13010097 [doi] LID - 97 AB - Cor triatriatum sinister is a rare congenital heart disease characterized by an additional fibromuscular membrane in the left atrium. Cardioembolic stroke is a rare complication of cor triatriatum sinister, especially among women. We hereby describe the case of an 18-year-old female patient, without a past medical history, presenting with cardioembolic stroke in the territory of the right posterior cerebral artery. During extensive diagnostic work-up, nonrestrictive cor triatriatum sinister and patent foramen ovale were diagnosed using transthoracic and transesophageal echocardiography. In clinical practice, it is important to identify congenital cardiac defects as potential substrates for cardioembolism in young patients. In our case, cor triatriatum sinister presenting as ischemic stroke was diagnosed, which is an uncommon finding, especially in young females. Determining the optimal management strategy for patients with cor triatriatum sinister complicated by cardioembolic stroke requires a multidisciplinary approach. FAU - Szabo, Timea Magdolna AU - Szabo TM AD - Department of Biochemistry and Environmental Chemistry, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540142 Targu Mures, Romania. FAU - Heidenhoffer, Erhard AU - Heidenhoffer E AD - Department of Cardiology, Clinical County Hospital Mures, 540103 Targu Mures, Romania. FAU - Kirchmaier, Adam AU - Kirchmaier A AD - Department of Cardiology, Clinical County Hospital Mures, 540103 Targu Mures, Romania. FAU - Pelok, Benedek AU - Pelok B AD - Department of Neurology, Municipal Hospital Odorheiu Secuiesc, 535600 Odorheiu Secuiesc, Romania. FAU - Frigy, Attila AU - Frigy A AUID- ORCID: 0000-0003-3346-4082 AD - Department of Cardiology, Clinical County Hospital Mures, 540103 Targu Mures, Romania. AD - Department of Internal Medicine IV, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540103 Targu Mures, Romania. LA - eng PT - Journal Article DEP - 20221229 PL - Switzerland TA - Diagnostics (Basel) JT - Diagnostics (Basel, Switzerland) JID - 101658402 PMC - PMC9818967 OTO - NOTNLM OT - cardioembolic stroke OT - congenital heart disease OT - cor triatriatum sinister COIS- The authors declare no conflict of interest. EDAT- 2023/01/09 06:00 MHDA- 2023/01/09 06:01 PMCR- 2022/12/29 CRDT- 2023/01/08 01:02 PHST- 2022/11/06 00:00 [received] PHST- 2022/12/27 00:00 [accepted] PHST- 2023/01/08 01:02 [entrez] PHST- 2023/01/09 06:00 [pubmed] PHST- 2023/01/09 06:01 [medline] PHST- 2022/12/29 00:00 [pmc-release] AID - diagnostics13010097 [pii] AID - diagnostics-13-00097 [pii] AID - 10.3390/diagnostics13010097 [doi] PST - epublish SO - Diagnostics (Basel). 2022 Dec 29;13(1):97. doi: 10.3390/diagnostics13010097. PMID- 39076883 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240731 IS - 2153-8174 (Electronic) IS - 2153-8174 (Print) IS - 1530-6550 (Linking) VI - 24 IP - 1 DP - 2023 Jan TI - Prevention of Sudden Death in Sports: A Global and Multidisciplinary Observatory for Scientific Research and Knowledge Transfer (PREMUBID). PG - 12 LID - 10.31083/j.rcm2401012 [doi] LID - 12 AB - BACKGROUND: The health benefits of sports and exercise training are well known. However, an acute bout of exercise transiently increases the risk of sudden cardiac death (SCD). To minimize the cardiovascular risks of exercise, more insight into the prevention and causes of SCD is needed. METHODS: The observatory for the prevention of sudden death in sports, PREMUBID, was created with the aim of fostering research to assess the benefits and risks of exercise at different volumes and intensities and to get insight into the underlying mechanisms of potentially cardiac (mal) adaptations. RESULTS: The observatory gathers researchers from a wide range of disciplines working at institutions in Europe and North America. The guiding principles of PREMUBID are to broaden the understanding of SCD in sports, strengthening collaborative research across the globe, and to develop, implement and evaluate robust pre-participation screening and emergency care strategies to further reduce the number of fatal cardiac events in sport events. During the inaugural meeting of the observatory, members and affiliated researchers discussed possibilities to initiate collaborative research projects and to exchange staff and students to share information and practices to prevent SCD. The final goal is to translate the obtained knowledge to understandable messages for the general population and healthcare workers to ensure that the population at large benefits from it. CONCLUSIONS: The PREMUBID consortium aims to produce novel knowledge and insights in SCD prevention, in order to maximize the health benefits associated with acute and long-term exercise training. CI - Copyright: (c) 2023 The Author(s). Published by IMR Press. FAU - Garatachea, Nuria AU - Garatachea N AD - Growth, Exercise, NUtrition and Development (GENUD) Research Group, University of Zaragoza, 50009 Zaragoza, Spain. AD - Department of Physiatry and Nursing, Faculty of Health and Sport Science (FCSD), University of Zaragoza, 22002 Huesca, Spain. AD - Instituto Agroalimentario de Aragon (IA2), Centro de Investigacion y Tecnologia Agroalimentaria de Aragon (CITA), Universidad de Zaragoza, 50013 Zaragoza, Spain. FAU - Pueyo, Esther AU - Pueyo E AD - Biomedical Signal Interpretation and Computational Simulation (BSICoS), Aragon Institute for Engineering Research (I3A), IIS Aragon, University of Zaragoza, 50018 Zaragoza, Spain. AD - CIBER de Bioingenieria, Biomateriales y Nanomedicina, CIBER-BBN, 28029 Madrid, Spain. FAU - Eijsvogels, Thijs M H AU - Eijsvogels TMH AD - Radboud Institute for Health Sciences, Department of Physiology, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands. LA - eng PT - Journal Article DEP - 20230106 PL - Singapore TA - Rev Cardiovasc Med JT - Reviews in cardiovascular medicine JID - 100960007 PMC - PMC11270393 OTO - NOTNLM OT - network OT - research OT - sport OT - sudden cardiac death COIS- The authors declare no conflict of interest. EDAT- 2023/01/06 00:00 MHDA- 2023/01/06 00:01 PMCR- 2023/01/06 CRDT- 2024/07/30 05:01 PHST- 2022/10/18 00:00 [received] PHST- 2022/11/17 00:00 [revised] PHST- 2022/11/28 00:00 [accepted] PHST- 2023/01/06 00:01 [medline] PHST- 2023/01/06 00:00 [pubmed] PHST- 2024/07/30 05:01 [entrez] PHST- 2023/01/06 00:00 [pmc-release] AID - S1530-6550(22)00792-X [pii] AID - 10.31083/j.rcm2401012 [doi] PST - epublish SO - Rev Cardiovasc Med. 2023 Jan 6;24(1):12. doi: 10.31083/j.rcm2401012. eCollection 2023 Jan. PMID- 36598208 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230131 IS - 2757-6256 (Print) IS - 2757-6256 (Electronic) IS - 2757-6256 (Linking) VI - 58 IP - 1 DP - 2023 Jan TI - Evaluation of Clinical Findings in Children with Chylothorax: A Descriptive Study. PG - 28-33 LID - 10.5152/TurkArchPediatr.2022.22182 [doi] AB - OBJECTIVE: Chylothorax refers to the presence of chyle in the pleural space. There are multiple etiologies of chylothorax. Our aim in this study was to evaluate the clinical manifestations, causes, and treatment of chylothorax in childhood and also to show the differences between the 2 age groups admitted to a tertiary care children's hospital. The second aim was to evaluate the clinical and radiologic features of patients diagnosed as having Gorham-Stout disease via chylothorax. MATERIALS AND METHODS: The archives were reviewed for chylothorax documented in the last 31 years. Twenty-two patients (11 girls and 11 boys) were included. Patients were divided into 2 groups: the younger group aged under 24 months and the older group aged over 24 months. RESULTS: A total of 22 patients had chylothorax, and 10 were aged younger than 24 months. In the younger group, etiologies were in order congenital heart surgery, congenital chylothorax, and Gorham-Stout disease. In the older group, etiologies were Gorham-Stout disease, congenital heart surgery, heart failure, heart transplantation, thrombus, intestinal lymphangiectasia, and idiopathic. The most common treatment in the younger group was the medium-chain triglyceride diet (70%), and in the older group, it was sirolimus (50%). CONCLUSION: There is a wide variety of underlying etiologies in childhood, so a multidisciplinary approach is important to identify the underlying diagnosis. The common etiologies were postoperative and Gorham-Stout disease in our study. All patients with Gorham-Stout disease had a good prognosis. Gorham-Stout disease should be considered in patients of any age with a diagnosis of chylothorax who have bone lesions. FAU - Nayir Buyuksahin, Halime AU - Nayir Buyuksahin H AD - Department of Pediatric Pulmonology, Hacettepe University, School of Medicine, Ihsan Dogramaci Children's Hospital, Ankara, Turkey. FAU - Emiralioglu, Nagehan AU - Emiralioglu N AD - Department of Pediatric Pulmonology, Hacettepe University, School of Medicine, Ihsan Dogramaci Children's Hospital, Ankara, Turkey. FAU - Ozcan, H Nursun AU - Ozcan HN AD - Division of Pediatric Radiology, Department of Radiology, Hacettepe University, School of Medicine, Ankara, Turkey. FAU - Sunman, Birce AU - Sunman B AD - Department of Pediatric Pulmonology, Hacettepe University, School of Medicine, Ihsan Dogramaci Children's Hospital, Ankara, Turkey. FAU - Guzelkas, Ismail AU - Guzelkas I AD - Department of Pediatric Pulmonology, Hacettepe University, School of Medicine, Ihsan Dogramaci Children's Hospital, Ankara, Turkey. FAU - Alboga, Didem AU - Alboga D AD - Department of Pediatric Pulmonology, Hacettepe University, School of Medicine, Ihsan Dogramaci Children's Hospital, Ankara, Turkey. FAU - Akgul Erdal, Meltem AU - Akgul Erdal M AD - Department of Pediatric Pulmonology, Hacettepe University, School of Medicine, Ihsan Dogramaci Children's Hospital, Ankara, Turkey. FAU - Kutluk, Tezer AU - Kutluk T AD - Department of Pediatric Oncology, Hacettepe University Cancer Institute, Ankara, Turkey. FAU - Kurucu, Nilgun AU - Kurucu N AD - Department of Pediatric Oncology, Hacettepe University Cancer Institute, Ankara, Turkey. FAU - Yalcin, Ebru AU - Yalcin E AD - Department of Pediatric Pulmonology, Hacettepe University, School of Medicine, Ihsan Dogramaci Children's Hospital, Ankara, Turkey. FAU - Dogru, Deniz AU - Dogru D AD - Department of Pediatric Pulmonology, Hacettepe University, School of Medicine, Ihsan Dogramaci Children's Hospital, Ankara, Turkey. FAU - Ozcelik, Ugur AU - Ozcelik U AD - Department of Pediatric Pulmonology, Hacettepe University, School of Medicine, Ihsan Dogramaci Children's Hospital, Ankara, Turkey. FAU - Kiper, Nural AU - Kiper N AD - Department of Pediatric Pulmonology, Hacettepe University, School of Medicine, Ihsan Dogramaci Children's Hospital, Ankara, Turkey. LA - eng PT - Journal Article PL - Turkey TA - Turk Arch Pediatr JT - Turkish archives of pediatrics JID - 101776822 PMC - PMC9885784 EDAT- 2023/01/05 06:00 MHDA- 2023/01/05 06:01 PMCR- 2023/01/01 CRDT- 2023/01/04 09:04 PHST- 2023/01/04 09:04 [entrez] PHST- 2023/01/05 06:00 [pubmed] PHST- 2023/01/05 06:01 [medline] PHST- 2023/01/01 00:00 [pmc-release] AID - tap-58-1-28 [pii] AID - 10.5152/TurkArchPediatr.2022.22182 [doi] PST - ppublish SO - Turk Arch Pediatr. 2023 Jan;58(1):28-33. doi: 10.5152/TurkArchPediatr.2022.22182. PMID- 36598073 OWN - NLM STAT- MEDLINE DCOM- 20230809 LR - 20230814 IS - 1468-201X (Electronic) IS - 1355-6037 (Linking) VI - 109 IP - 8 DP - 2023 Mar 27 TI - Outcomes in patients with moderate and asymptomatic severe aortic stenosis followed up in heart valve clinics. PG - 634-642 LID - 10.1136/heartjnl-2022-321874 [doi] AB - BACKGROUND: Heart valve clinics (HVC) have been introduced to manage patients with valvular heart disease within a multidisciplinary team. OBJECTIVE: To determine the outcome benefit of HVC approach compared with standard of care (SOC) for patients with moderate and asymptomatic severe aortic stenosis (mAS and asAS). METHODS: Single-centre, observational registry of patients with mAS and asAS with at least one cardiac ambulatory consultation at our Cardiovascular Centre. Based on the outpatient strategy, patients were divided into HVC group, if receiving at least one visit at HVC, and SOC group, if followed by routine cardiac consultations. RESULTS: 2129 patients with mAS and asAS were divided into those followed in HVC (n=251) versus SOC group (n=1878). The mean age was 76.5+/-12.4 years; 919 (43.2%) had asAS. During a follow-up of 4.8+/-1.8 years, 822 patients (38.6%) died, 307 (14.4%) were hospitalised for heart failure and 596 (28%) underwent aortic valve replacement (AVR). After propensity score matching, the number of consultations per year, exercise stress tests, brain natriuretic peptide (BNP) determinations and CTs were higher in the HVC cohort (p<0.05 for all). A shorter time between indication of AVR and less advanced New York Heart Association class was reported in the HVC cohort (p<0.001 and p=0.032). Compared with SOC, the HVC approach was associated with reduced all-cause mortality (HR=0.63, 95% CI 0.40 to 0.98, p=0.038) and cardiovascular death (p=0.030). At multivariable analysis, the HVC remained an independent predictor of all-cause mortality (HR=0.54, 95% CI 0.34 to 0.85, p=0.007). CONCLUSIONS: In patients with mAS and asAS, the HVC approach was associated with more efficient management and outcome benefit compared with SOC. CI - (c) Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Paolisso, Pasquale AU - Paolisso P AD - Cardiology Department, Hartcentrum OLV Aalst, Aalst, Belgium. AD - Department of Advanced Biomedical Sciences, Federico II University Hospital, Napoli, Campania, Italy. FAU - Beles, Monika AU - Beles M AD - Cardiology Department, Hartcentrum OLV Aalst, Aalst, Belgium. FAU - Belmonte, Marta AU - Belmonte M AD - Cardiology Department, Hartcentrum OLV Aalst, Aalst, Belgium. AD - Department of Advanced Biomedical Sciences, Federico II University Hospital, Napoli, Campania, Italy. FAU - Gallinoro, Emanuele AU - Gallinoro E AUID- ORCID: 0000-0002-5519-2818 AD - Cardiology Department, Hartcentrum OLV Aalst, Aalst, Belgium. FAU - De Colle, Cristina AU - De Colle C AD - Cardiology Department, Hartcentrum OLV Aalst, Aalst, Belgium. AD - Department of Advanced Biomedical Sciences, Federico II University Hospital, Napoli, Campania, Italy. FAU - Mileva, Niya AU - Mileva N AD - Cardiology Department, Hartcentrum OLV Aalst, Aalst, Belgium. FAU - Bertolone, Dario Tino AU - Bertolone DT AD - Cardiology Department, Hartcentrum OLV Aalst, Aalst, Belgium. AD - Department of Advanced Biomedical Sciences, Federico II University Hospital, Napoli, Campania, Italy. FAU - Deschepper, Celine AU - Deschepper C AD - Cardiology Department, Hartcentrum OLV Aalst, Aalst, Belgium. FAU - Spapen, Jerrold AU - Spapen J AD - Cardiology Department, Hartcentrum OLV Aalst, Aalst, Belgium. FAU - Brouwers, Sofie AU - Brouwers S AD - Cardiology Department, Hartcentrum OLV Aalst, Aalst, Belgium. AD - Department of Experimental Pharmacology, Vrije Universiteit Brussel, Brussel, Belgium. FAU - Degrieck, Ivan AU - Degrieck I AD - Department of Cardiovascular Surgery, Hartcentrum OLV Aalst, Aalst, Belgium. FAU - Casselman, Filip AU - Casselman F AD - Department of Cardiovascular Surgery, Hartcentrum OLV Aalst, Aalst, Belgium. FAU - Stockman, Bernard AU - Stockman B AD - Department of Cardiovascular Surgery, Hartcentrum OLV Aalst, Aalst, Belgium. FAU - Van Praet, Frank AU - Van Praet F AD - Department of Cardiovascular Surgery, Hartcentrum OLV Aalst, Aalst, Belgium. FAU - Penicka, Martin AU - Penicka M AD - Cardiology Department, Hartcentrum OLV Aalst, Aalst, Belgium. FAU - Collet, Carlos AU - Collet C AD - Cardiology Department, Hartcentrum OLV Aalst, Aalst, Belgium. FAU - Wyffels, Eric AU - Wyffels E AD - Cardiology Department, Hartcentrum OLV Aalst, Aalst, Belgium. FAU - Vanderheyden, Marc AU - Vanderheyden M AD - Cardiology Department, Hartcentrum OLV Aalst, Aalst, Belgium. FAU - Barbato, Emanuele AU - Barbato E AUID- ORCID: 0000-0002-0050-5178 AD - Cardiology Department, Hartcentrum OLV Aalst, Aalst, Belgium. AD - Department of Advanced Biomedical Sciences, Federico II University Hospital, Napoli, Campania, Italy. FAU - Bartunek, Jozef AU - Bartunek J AD - Cardiology Department, Hartcentrum OLV Aalst, Aalst, Belgium. FAU - Van Camp, Guy AU - Van Camp G AUID- ORCID: 0000-0002-9815-8337 AD - Cardiology Department, Hartcentrum OLV Aalst, Aalst, Belgium guy_vancamp@outlook.com. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230327 PL - England TA - Heart JT - Heart (British Cardiac Society) JID - 9602087 SB - IM CIN - Heart. 2023 Mar 27;109(8):581-582. doi: 10.1136/heartjnl-2022-322101. PMID: 36702541 CIN - Heart. 2023 Aug 11;109(17):1338. doi: 10.1136/heartjnl-2023-322845. PMID: 37137677 CIN - Heart. 2023 Aug 11;109(17):1338. doi: 10.1136/heartjnl-2023-322844. PMID: 37137679 MH - Humans MH - Middle Aged MH - Aged MH - Aged, 80 and over MH - *Aortic Valve Stenosis/diagnosis/surgery/etiology MH - Aortic Valve/surgery MH - *Transcatheter Aortic Valve Replacement/adverse effects MH - *Heart Valve Prosthesis Implantation MH - *Heart Valve Prosthesis MH - Treatment Outcome MH - Severity of Illness Index OTO - NOTNLM OT - aortic valve stenosis OT - heart valve diseases OT - outcome assessment, health care OT - transcatheter aortic valve replacement COIS- Competing interests: None declared. EDAT- 2023/01/05 06:00 MHDA- 2023/08/09 06:43 CRDT- 2023/01/04 07:03 PHST- 2022/09/12 00:00 [received] PHST- 2022/11/17 00:00 [accepted] PHST- 2023/08/09 06:43 [medline] PHST- 2023/01/05 06:00 [pubmed] PHST- 2023/01/04 07:03 [entrez] AID - heartjnl-2022-321874 [pii] AID - 10.1136/heartjnl-2022-321874 [doi] PST - epublish SO - Heart. 2023 Mar 27;109(8):634-642. doi: 10.1136/heartjnl-2022-321874. PMID- 36596742 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230805 IS - 2713-4148 (Electronic) IS - 2713-4148 (Linking) VI - 66 IP - 8 DP - 2023 Aug TI - Environmental changes surrounding congenital heart disease. PG - 332-338 LID - 10.3345/cep.2022.00976 [doi] AB - As the outcomes of patients with congenital heart disease (CHD) improve, the number of patients is accumulating and the proportion of adult CHD patients is gradually increasing. Accordingly, the proportion of typical adult diseases such as coronary arterial disease, diabetes, dyslipidemia, and hypertension among patients with CHD is increasing, as is the medical burden due to residual cardiac problems, heart failure, and arrhythmias. Due to increasing genetic knowledge, efforts are being made to provide active medical support through risk stratification. Surgical techniques and prostheses are also developing, the instruments used for transcatheter intervention are diversifying, and the range of therapeutic options is expanding. In addition, owing to the development of electronic devices, heart rhythm and blood pressure monitoring instruments have been miniaturized and diversified. In this process, a vast amount of information is collected; therefore, the current systematic review examined their clinical usefulness. A team approach consisting of experts from various fields is essential for the treatment of patients with CHD and advanced heart failure. FAU - Choi, Eun-Young AU - Choi EY AD - Department of Pediatrics, Bucheon Sejong Hospital, Bucheon, Korea. LA - eng PT - Journal Article DEP - 20230102 PL - Korea (South) TA - Clin Exp Pediatr JT - Clinical and experimental pediatrics JID - 101761234 PMC - PMC10397998 OTO - NOTNLM OT - Adult congenital heart disease OT - Arrhythmia OT - Congenital heart disease OT - Heart failure OT - Medical burden COIS- Conflicts of interest No potential conflict of interest relevant to this article was reported. EDAT- 2023/01/04 06:00 MHDA- 2023/01/04 06:01 PMCR- 2023/01/02 CRDT- 2023/01/03 22:36 PHST- 2022/07/24 00:00 [received] PHST- 2022/11/28 00:00 [accepted] PHST- 2023/01/04 06:01 [medline] PHST- 2023/01/04 06:00 [pubmed] PHST- 2023/01/03 22:36 [entrez] PHST- 2023/01/02 00:00 [pmc-release] AID - cep.2022.00976 [pii] AID - cep-2022-00976 [pii] AID - 10.3345/cep.2022.00976 [doi] PST - ppublish SO - Clin Exp Pediatr. 2023 Aug;66(8):332-338. doi: 10.3345/cep.2022.00976. Epub 2023 Jan 2. PMID- 36594762 OWN - NLM STAT- MEDLINE DCOM- 20230105 LR - 20230111 IS - 1759-7390 (Electronic) IS - 1750-8460 (Linking) VI - 83 IP - 12 DP - 2022 Dec 2 TI - Maternal collapse in pregnancy. PG - 1-12 LID - 10.12968/hmed.2022.0259 [doi] AB - Maternal collapse is a rare life-threatening event that can occur at any stage of pregnancy or up to 6 weeks postpartum. Prompt identification and timely intervention by a multidisciplinary team that includes an obstetrician, midwifery staff and an obstetric anaesthetist are essential to improve maternal and fetal outcomes. Standard adult resuscitation guidelines need to be followed with some modifications, taking into account the maternal-fetal physiology, which clinicians should be familiar with. During cardiac arrest, the emphasis is on advanced airway management, manual uterine displacement to relieve aortocaval compression and performing a resuscitative hysterotomy (peri-mortem caesarean delivery) swiftly in patients who are more than 20 weeks gestation to improve maternal survival. Annual multidisciplinary simulation training is recommended for all professionals involved in maternity care; this can improve teamwork, communication and emergency preparedness during maternal collapse. FAU - Knapp, C AU - Knapp C AD - North West School of Anaesthesia, Health Education England North West, Manchester, UK. FAU - Bhatia, K AU - Bhatia K AD - Department of Anaesthesia, St Mary's Hospital, Manchester University NHS Foundation Trust, University of Manchester, Manchester, UK. LA - eng PT - Journal Article PT - Review DEP - 20221209 PL - Singapore TA - Br J Hosp Med (Lond) JT - British journal of hospital medicine (London, England : 2005) JID - 101257109 SB - IM MH - Adult MH - Pregnancy MH - Humans MH - Female MH - *Maternal Health Services MH - *Heart Arrest/therapy MH - Cesarean Section MH - Resuscitation MH - *Pregnancy Complications, Cardiovascular/diagnosis/therapy OTO - NOTNLM OT - Aortic dissection OT - Cardiac arrest OT - Haemorrhage OT - Pregnancy OT - Pulmonary embolism OT - Resuscitation EDAT- 2023/01/04 06:00 MHDA- 2023/01/06 06:00 CRDT- 2023/01/03 09:22 PHST- 2023/01/03 09:22 [entrez] PHST- 2023/01/04 06:00 [pubmed] PHST- 2023/01/06 06:00 [medline] AID - 10.12968/hmed.2022.0259 [doi] PST - ppublish SO - Br J Hosp Med (Lond). 2022 Dec 2;83(12):1-12. doi: 10.12968/hmed.2022.0259. Epub 2022 Dec 9. PMID- 36590043 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240910 IS - 0970-9134 (Print) IS - 0973-7723 (Electronic) IS - 0970-9134 (Linking) VI - 39 IP - 1 DP - 2023 Jan TI - Nature always sides with the hidden flaw: importance of the 'aortic team' approach. PG - 3-5 LID - 10.1007/s12055-022-01415-1 [doi] AB - Blunt thoracic aortic injuries (BTAI) are highly lethal, though their incidence is < 1%. The treatment options for BTAI have evolved over the years, where non-operative management is advised even in grade II injuries. In patients undergoing thoracic endovascular aortic repair, it is of vital importance that the left subclavian artery is revascularized. Many authors have opted for selective revascularization of the left subclavian artery in case of an emergency situation where the clinical condition of the patient is unstable. A joint team effort involving the diagnostic radiologist, cardiologist, interventional cardiologist/radiologist/vascular surgeon, cardiac surgeon and anaesthesiologist, referred to as the 'aortic team', is vital in complex aortic interventions. CI - (c) Indian Association of Cardiovascular-Thoracic Surgeons 2022. FAU - Idhrees, Mohammed AU - Idhrees M AUID- ORCID: 0000-0001-5981-9705 AD - Institute of Cardiac and Aortic Disorders, SRM Institutes for Medical Science (SIMS Hospitals), Chennai, India 600 026. GRID: grid.513026.3. ISNI: 0000 0004 1781 5054 LA - eng PT - Journal Article DEP - 20221012 PL - India TA - Indian J Thorac Cardiovasc Surg JT - Indian journal of thoracic and cardiovascular surgery JID - 8700105 PMC - PMC9794658 OTO - NOTNLM OT - Aortic team OT - Aortic trauma OT - Endoleak OT - TEVAR COIS- Conflict of interestThe author declares that he has no conflict of interest. EDAT- 2023/01/03 06:00 MHDA- 2023/01/03 06:01 PMCR- 2024/01/01 CRDT- 2023/01/02 04:14 PHST- 2022/08/09 00:00 [received] PHST- 2022/08/25 00:00 [revised] PHST- 2022/08/31 00:00 [accepted] PHST- 2023/01/02 04:14 [entrez] PHST- 2023/01/03 06:00 [pubmed] PHST- 2023/01/03 06:01 [medline] PHST- 2024/01/01 00:00 [pmc-release] AID - 1415 [pii] AID - 10.1007/s12055-022-01415-1 [doi] PST - ppublish SO - Indian J Thorac Cardiovasc Surg. 2023 Jan;39(1):3-5. doi: 10.1007/s12055-022-01415-1. Epub 2022 Oct 12. PMID- 36585272 OWN - NLM STAT- MEDLINE DCOM- 20231023 LR - 20231028 IS - 2212-1692 (Electronic) IS - 1875-9572 (Linking) VI - 64 IP - 4 DP - 2023 Jul TI - Associated factors with parental pregnancy decision-making and use of consultation after a prenatal congenital heart disease diagnosis. PG - 371-380 LID - S1875-9572(22)00261-3 [pii] LID - 10.1016/j.pedneo.2022.07.015 [doi] AB - BACKGROUND: Prenatal diagnosis of congenital heart disease (CHD) often leads affected families to experience psychological stress. Pediatric cardiology consultation is important in providing parents with sufficient information and reducing their anxiety to make an informed pregnancy decision. Involving a fetal nurse coordinator may optimize fetal anomaly care. Our study aimed to identify factors associated with parental decision-making for choosing to use pediatric cardiology consultations and pregnancy termination. METHODS: From September 2017 to December 2018, all fetal CHD cases diagnosed in the second trimester from a primary screening clinic in Taiwan were included (n = 145). Univariate and multivariate logistic regression were performed to analyze maternal, fetal, and medical factors for predictors of parental decisions for consultation use and pregnancy termination. RESULTS: Acceptance for fetal nurse coordinator care and pediatric cardiology consultation were 84.8% (n = 123) and 83.4% (n = 121), respectively. Predictors for termination of pregnancy included the following: multiple anomalies (OR: 10.6; 95% CI: 3.6-35.7), chromosomal/genetic abnormalities (OR: 20.2; 95% CI: 3.1-395.8), severe CHDs (OR: 9.8; 95% CI: 4.3-23.4), CHDs that required surgery (OR: 32.4; 95% CI: 11.4-117.8), and physiological single-ventricle (OR: 47.3; 95% CI: 12.4-312.5). Parents who had pediatric cardiology counseling were less likely to terminate the pregnancy (OR: 0.1; 95% CI: 0.0-0.7). Parents with fetal diagnosis having multiple anomalies (OR: 0.2; 95% CI: 0.1-0.7) or chromosomal/genetic abnormalities (OR: 0.1; 95% CI: 0.03-0.9) were less likely to make use of cardiology consultation. Parents who accepted fetal nurse coordinator care were more likely to have pediatric cardiology consultation before pregnancy decision (OR: 149.5, 95% CI: 37.8-821.5). CONCLUSIONS: Anomaly complexity appeared to be a strong predictor for termination of pregnancy beyond non-acceptability of prenatal cardiology consultation. Prenatal cardiology counseling may help support the parental decision to continue with the pregnancy. Incorporation of a fetal nurse coordinator care into the multidisciplinary fetal medicine team improved the acceptability of prenatal consultation. CI - Copyright (c) 2022 Taiwan Pediatric Association. Published by Elsevier B.V. All rights reserved. FAU - Chih, Wan-Ling AU - Chih WL AD - Taiji Clinic, Taipei, Taiwan; Department of Pediatrics, MacKay Memorial Hospital, Taipei, Taiwan. FAU - Tung, Yu-Hsuan AU - Tung YH AD - Taiji Clinic, Taipei, Taiwan. FAU - Lussier, Eric C AU - Lussier EC AD - Taiji Clinic, Taipei, Taiwan. FAU - Sung, Chan-Yu AU - Sung CY AD - Taiji Clinic, Taipei, Taiwan. FAU - Huang, Yi-Ling AU - Huang YL AD - Taiji Clinic, Taipei, Taiwan. FAU - Hung, Wei-Li AU - Hung WL AD - Department of Pediatrics, MacKay Memorial Hospital, Taipei, Taiwan. FAU - Hsu, Kang-Hong AU - Hsu KH AD - Division of Cardiovascular Surgery, Department of Surgery, MacKay Memorial Hospital, Taipei, Taiwan. FAU - Chang, Chung-I AU - Chang CI AD - Division of Cardiovascular Surgery, Department of Surgery, MacKay Memorial Hospital, Taipei, Taiwan. FAU - Chang, Tung Yao AU - Chang TY AD - Taiji Clinic, Taipei, Taiwan. FAU - Chen, Ming-Ren AU - Chen MR AD - Department of Pediatrics, MacKay Memorial Hospital, Taipei, Taiwan. Electronic address: mingren44@gmail.com. LA - eng PT - Journal Article DEP - 20221214 PL - Singapore TA - Pediatr Neonatol JT - Pediatrics and neonatology JID - 101484755 SB - IM MH - Pregnancy MH - Female MH - Child MH - Humans MH - Prenatal Diagnosis MH - *Heart Defects, Congenital/diagnosis MH - *Abortion, Induced MH - Chromosome Aberrations MH - Parents/psychology MH - Referral and Consultation MH - Ultrasonography, Prenatal OTO - NOTNLM OT - Congenital heart disease OT - Prenatal consultation OT - Prenatal counseling OT - Prenatal diagnosis OT - Termination of pregnancy COIS- Declaration of competing interest The authors state that they do not have any conflict of interests. EDAT- 2022/12/31 06:00 MHDA- 2023/10/23 00:42 CRDT- 2022/12/30 21:52 PHST- 2022/01/06 00:00 [received] PHST- 2022/07/12 00:00 [revised] PHST- 2022/07/18 00:00 [accepted] PHST- 2023/10/23 00:42 [medline] PHST- 2022/12/31 06:00 [pubmed] PHST- 2022/12/30 21:52 [entrez] AID - S1875-9572(22)00261-3 [pii] AID - 10.1016/j.pedneo.2022.07.015 [doi] PST - ppublish SO - Pediatr Neonatol. 2023 Jul;64(4):371-380. doi: 10.1016/j.pedneo.2022.07.015. Epub 2022 Dec 14. PMID- 36581397 OWN - NLM STAT- MEDLINE DCOM- 20230102 LR - 20230209 IS - 1554-6179 (Electronic) IS - 1539-4182 (Print) IS - 1539-4182 (Linking) VI - 20 IP - 4 DP - 2022 Dec TI - Multidisciplinary Integrated Care in Atrial Fibrillation (MICAF): A Systematic Review and Meta-Analysis. PG - 219-230 LID - 10.3121/cmr.2022.1702 [doi] AB - Objective: To assess the effectiveness of multidisciplinary integrated care in the clinical outcomes of atrial fibrillation patients.Methods: Medline, EMBASE, and the CENTRAL trials registry of the Cochrane Collaboration were searched for articles on multidisciplinary integrated care in atrial fibrillation patients. The systematic review and meta-analysis included six and five articles, respectively, that compared the outcomes between the integrated care group and control group.Results: Multidisciplinary integrated care was concomitant with a decrease in all-cause mortality (OR 0.52, 95%CI 0.36-0.74, P=0.0003) and cardiovascular hospitalization (OR 0.66, 95%CI 0.49-0.89, P=0.007). Multidisciplinary integrated care had no significant impact on major adverse cardiovascular event (MACE) (OR 0.76, 95%CI 0.37-1.53, P=0.44), cardiovascular deaths (OR 0.49, 95% CI 0.21-1.17, P=0.11), atrial fibrillation (AF)-related hospitalization (OR 0.76, 95%CI 0.53-1.09, P=0.14), major bleeding (OR 1.02, 95%CI 0.59-1.75, P=0.94), minor bleeding (OR 1.12, 95%CI 0.55-2.26, P=0.76), and cerebrovascular events (OR 0.72, 95%CI 0.45-1.18, P=0.19).Conclusion: In comparison to usual care, a multidisciplinary integrated care approach (i.e., nurse-led care along with usual specialist care) in AF patients is associated with reduced all-cause mortality and cardiovascular hospitalization. CI - Copyright (c) 2022 Marshfield Clinic Health System. FAU - Khan, Adnan AU - Khan A AD - Sharif Medical City, Lahore, Pakistan, and London School of Economics and Political Science, London, UK adnan.khan@outlook.com. FAU - Cereda, Alberto AU - Cereda A AD - HPG XXII Hospital, Bergamo Italy. FAU - Walther, Claudia AU - Walther C AD - University Hospital of Theodor-Stern-Kai 7, Frankfurt Germany. FAU - Aslam, Aqsa AU - Aslam A AD - Sharif Medical City, Lahore, Pakistan, and London School of Economics and Political Science, London, UK. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review PL - United States TA - Clin Med Res JT - Clinical medicine & research JID - 101175887 SB - IM MH - Humans MH - *Atrial Fibrillation/therapy/complications MH - Hemorrhage/complications MH - Heart MH - *Delivery of Health Care, Integrated PMC - PMC9799227 OTO - NOTNLM OT - Atrial fibrillation OT - Clinical outcomes OT - Multidisciplinary integrated care COIS- Disclosure: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The authors have reported no conflicts of interest. EDAT- 2022/12/30 06:00 MHDA- 2023/01/03 06:00 PMCR- 2022/12/01 CRDT- 2022/12/29 21:02 PHST- 2021/06/20 00:00 [received] PHST- 2022/03/12 00:00 [revised] PHST- 2022/07/22 00:00 [revised] PHST- 2022/08/09 00:00 [accepted] PHST- 2022/12/29 21:02 [entrez] PHST- 2022/12/30 06:00 [pubmed] PHST- 2023/01/03 06:00 [medline] PHST- 2022/12/01 00:00 [pmc-release] AID - cmr.2022.1702 [pii] AID - 10.3121/cmr.2022.1702 [doi] PST - ppublish SO - Clin Med Res. 2022 Dec;20(4):219-230. doi: 10.3121/cmr.2022.1702. PMID- 36578770 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240909 IS - 1016-7315 (Print) IS - 2212-5043 (Electronic) IS - 1016-7315 (Linking) VI - 34 IP - 3 DP - 2022 TI - Saudi Heart Association Guidelines on Best Practices in the Management of Chronic Coronary Syndromes. PG - 182-211 LID - 10.37616/2212-5043.1320 [doi] AB - BACKGROUND: The prevalence of both chronic coronary syndrome (CCS) and its risk factors is alarming in Saudi Arabia and only a minority of patients achieve optimal medical management. Context-specific CCS guidelines outlining best clinical practices are therefore needed to address local gaps and challenges. CONSENSUS PANEL: A panel of experts representing the Saudi Heart Association (SHA) reviewed existing evidence and formulated guidance relevant to local clinical practice considering the characteristics of the Saudi population, the Saudi healthcare system, its resources and medical expertise. They were reviewed by external experts to ensure scientific and medical accuracy. CONSENSUS FINDINGS: Recommendations are provided on the clinical assessment and management of CCS, along with supporting evidence. Risk reduction through non-pharmacological therapy (lifestyle modifications) remains at the core of CCS management. Great emphasis should be placed on the use of available pharmacological options (anti-anginal therapy and event prevention) only as appropriate and necessary. Lifestyle counseling and pharmacological strategy must be optimized before considering revascularization, unless otherwise indicated. Revascularization strategies should be carefully considered by the Heart Team to ensure the appropriate choice is made in accordance to current guidelines and patient preference. CONCLUSION: Conscientious, multidisciplinary, and personalized clinical management is necessary to navigate the complex landscape of CCS in Saudi Arabia considering its population and resource differences. The reconciliation of international evidence and local characteristics is critical for the improvement of healthcare outcomes among CCS patients in Saudi Arabia. CI - (c) 2022 Saudi Heart Association. FAU - AlShammeri, Owayed AU - AlShammeri O AD - Dr. Sulaiman Al-Habib Hospital, Riyadh, Saudi Arabia. FAU - Al Saif, Shukri AU - Al Saif S AD - Saud Albabtain Cardiac Center, Dammam, Saudi Arabia. FAU - Al Shehri, Halia AU - Al Shehri H AD - King Salman Heart Centre, King Fahad Medical City, Riyadh, Saudi Arabia. FAU - Alasng, Mirvat AU - Alasng M AD - Cardiac Center, King Fahd Armed Forces Hospital, Jeddah, Saudi Arabia. FAU - Qaddoura, Fatema AU - Qaddoura F AD - Dr. Suliman AL-Habib Hospital, Al-khobar, Saudi Arabia. FAU - Al Shehri, Mohammad AU - Al Shehri M AD - Armed Forces Hospitals Southern Region, Saudi Arabia. FAU - Turkistani, Yosra AU - Turkistani Y AD - Umm AlQura University, Makkah, Saudi Arabia. FAU - Tash, Adel AU - Tash A AD - National Heart Center, Saudi Health Council, Saudi Arabia. FAU - Alharbi, Walid AU - Alharbi W AD - King Fahad Cardiac Center, King Saud University, Riyadh, Saudi Arabia. FAU - Al Qahtani, Fahad AU - Al Qahtani F AD - King Salman Heart Centre, King Fahad Medical City, Riyadh, Saudi Arabia. FAU - Diaz, Rafael AU - Diaz R AD - ECLA (Estudios Clinicos Latino America), Instituto Cardiovascular de Rosario, Rosario, Argentina. FAU - Mahaimeed, Wael AU - Mahaimeed W AD - Heart and Vascular Institute, Cleveland Clinic, Abu Dhabi, United Arab Emirates. FAU - Al Habeeb, Waleed AU - Al Habeeb W AD - Saudi Heart Association, Department of Cardiac Sciences, King Saud University Riyadh, Saudi Arabia. FAU - Alfaraidy, Khalid AU - Alfaraidy K AD - King Fahad Military Medical Complex, Dhahran, Saudi Arabia. LA - eng PT - Journal Article DEP - 20221118 PL - Saudi Arabia TA - J Saudi Heart Assoc JT - Journal of the Saudi Heart Association JID - 9887261 PMC - PMC9762239 OTO - NOTNLM OT - Chronic coronary syndrome OT - Guidelines OT - Saudi Arabia COIS- Conflict of interest None declared. EDAT- 2022/12/30 06:00 MHDA- 2022/12/30 06:01 PMCR- 2022/11/18 CRDT- 2022/12/29 02:33 PHST- 2022/08/10 00:00 [received] PHST- 2022/10/05 00:00 [revised] PHST- 2022/10/09 00:00 [accepted] PHST- 2022/12/29 02:33 [entrez] PHST- 2022/12/30 06:00 [pubmed] PHST- 2022/12/30 06:01 [medline] PHST- 2022/11/18 00:00 [pmc-release] AID - sha182-211 [pii] AID - 10.37616/2212-5043.1320 [doi] PST - epublish SO - J Saudi Heart Assoc. 2022 Nov 18;34(3):182-211. doi: 10.37616/2212-5043.1320. eCollection 2022. PMID- 36578016 OWN - NLM STAT- MEDLINE DCOM- 20221230 LR - 20240910 IS - 1756-994X (Electronic) IS - 1756-994X (Linking) VI - 14 IP - 1 DP - 2022 Dec 28 TI - The role of genetic testing in diagnosis and care of inherited cardiac conditions in a specialised multidisciplinary clinic. PG - 145 LID - 10.1186/s13073-022-01149-0 [doi] LID - 145 AB - BACKGROUND: The diagnostic yield of genetic testing for inherited cardiac diseases is up to 40% and is primarily indicated for screening of at-risk relatives. Here, we evaluate the role of genomics in diagnosis and management among consecutive individuals attending a specialised clinic and identify those with the highest likelihood of having a monogenic disease. METHODS: A retrospective audit of 1697 consecutive, unrelated probands referred to a specialised, multidisciplinary clinic between 2002 and 2020 was performed. A concordant clinical and genetic diagnosis was considered solved. Cases were classified as likely monogenic based on a score comprising a positive family history, young age at onset, and severe phenotype, whereas low-scoring cases were considered to have a likely complex aetiology. The impact of a genetic diagnosis was evaluated. RESULTS: A total of 888 probands fulfilled the inclusion criteria, and genetic testing identified likely pathogenic or pathogenic (LP/P) variants in 330 individuals (37%) and suspicious variants of uncertain significance (VUS) in 73 (8%). Research-focused efforts identified 46 (5%) variants, missed by conventional genetic testing. Where a variant was identified, this changed or clarified the final diagnosis in a clinically useful way for 51 (13%). The yield of suspicious VUS across ancestry groups ranged from 15 to 20%, compared to only 10% among Europeans. Even when the clinical diagnosis was uncertain, those with the most monogenic disease features had the greatest diagnostic yield from genetic testing. CONCLUSIONS: Research-focused efforts can increase the diagnostic yield by up to 5%. Where a variant is identified, this will have clinical utility beyond family screening in 13%. We demonstrate the value of genomics in reaching an overall diagnosis and highlight inequities based on ancestry. Acknowledging our incomplete understanding of disease phenotypes, we propose a framework for prioritising likely monogenic cases to solve their underlying cause of disease. CI - (c) 2022. The Author(s). FAU - Stafford, Fergus AU - Stafford F AD - Cardio Genomics Program at Centenary Institute, The University of Sydney, Sydney, Australia. AD - Centre for Population Genomics, Garvan Institute of Medical Research, and UNSW Sydney, 384 Victoria Street, Darlinghurst, NSW, 2010, Australia. AD - Centre for Population Genomics, Murdoch Children's Research Institute, Melbourne, Australia. FAU - Krishnan, Neesha AU - Krishnan N AD - Cardio Genomics Program at Centenary Institute, The University of Sydney, Sydney, Australia. AD - Centre for Population Genomics, Garvan Institute of Medical Research, and UNSW Sydney, 384 Victoria Street, Darlinghurst, NSW, 2010, Australia. AD - Centre for Population Genomics, Murdoch Children's Research Institute, Melbourne, Australia. FAU - Richardson, Ebony AU - Richardson E AD - Cardio Genomics Program at Centenary Institute, The University of Sydney, Sydney, Australia. AD - Centre for Population Genomics, Garvan Institute of Medical Research, and UNSW Sydney, 384 Victoria Street, Darlinghurst, NSW, 2010, Australia. AD - Centre for Population Genomics, Murdoch Children's Research Institute, Melbourne, Australia. FAU - Butters, Alexandra AU - Butters A AD - Cardio Genomics Program at Centenary Institute, The University of Sydney, Sydney, Australia. AD - Centre for Population Genomics, Garvan Institute of Medical Research, and UNSW Sydney, 384 Victoria Street, Darlinghurst, NSW, 2010, Australia. AD - Centre for Population Genomics, Murdoch Children's Research Institute, Melbourne, Australia. AD - Faculty of Medicine and Health, The University of Sydney, Sydney, Australia. FAU - Hespe, Sophie AU - Hespe S AD - Centre for Population Genomics, Garvan Institute of Medical Research, and UNSW Sydney, 384 Victoria Street, Darlinghurst, NSW, 2010, Australia. AD - Centre for Population Genomics, Murdoch Children's Research Institute, Melbourne, Australia. AD - Faculty of Medicine and Health, The University of Sydney, Sydney, Australia. FAU - Burns, Charlotte AU - Burns C AD - Faculty of Medicine and Health, The University of Sydney, Sydney, Australia. AD - Agnes Ginges Centre for Molecular Cardiology at Centenary Institute, The University of Sydney, Sydney, Australia. FAU - Gray, Belinda AU - Gray B AD - Faculty of Medicine and Health, The University of Sydney, Sydney, Australia. AD - Department of Cardiology, Royal Prince Alfred Hospital, Sydney, Australia. FAU - Medi, Caroline AU - Medi C AD - Department of Cardiology, Royal Prince Alfred Hospital, Sydney, Australia. FAU - Nowak, Natalie AU - Nowak N AD - Faculty of Medicine and Health, The University of Sydney, Sydney, Australia. AD - Agnes Ginges Centre for Molecular Cardiology at Centenary Institute, The University of Sydney, Sydney, Australia. FAU - Isbister, Julia C AU - Isbister JC AD - Faculty of Medicine and Health, The University of Sydney, Sydney, Australia. AD - Agnes Ginges Centre for Molecular Cardiology at Centenary Institute, The University of Sydney, Sydney, Australia. AD - Department of Cardiology, Royal Prince Alfred Hospital, Sydney, Australia. FAU - Raju, Hariharan AU - Raju H AD - Department of Cardiology, Royal Prince Alfred Hospital, Sydney, Australia. AD - Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, Australia. FAU - Richmond, David AU - Richmond D AD - Faculty of Medicine and Health, The University of Sydney, Sydney, Australia. AD - Department of Cardiology, Royal Prince Alfred Hospital, Sydney, Australia. FAU - Ryan, Mark P AU - Ryan MP AD - Department of Cardiology, Royal Prince Alfred Hospital, Sydney, Australia. FAU - Singer, Emma S AU - Singer ES AD - Faculty of Medicine and Health, The University of Sydney, Sydney, Australia. AD - Agnes Ginges Centre for Molecular Cardiology at Centenary Institute, The University of Sydney, Sydney, Australia. FAU - Sy, Raymond W AU - Sy RW AD - Faculty of Medicine and Health, The University of Sydney, Sydney, Australia. AD - Agnes Ginges Centre for Molecular Cardiology at Centenary Institute, The University of Sydney, Sydney, Australia. FAU - Yeates, Laura AU - Yeates L AD - Cardio Genomics Program at Centenary Institute, The University of Sydney, Sydney, Australia. AD - Centre for Population Genomics, Garvan Institute of Medical Research, and UNSW Sydney, 384 Victoria Street, Darlinghurst, NSW, 2010, Australia. AD - Centre for Population Genomics, Murdoch Children's Research Institute, Melbourne, Australia. AD - Faculty of Medicine and Health, The University of Sydney, Sydney, Australia. AD - Agnes Ginges Centre for Molecular Cardiology at Centenary Institute, The University of Sydney, Sydney, Australia. AD - Department of Cardiology, Royal Prince Alfred Hospital, Sydney, Australia. FAU - Bagnall, Richard D AU - Bagnall RD AD - Faculty of Medicine and Health, The University of Sydney, Sydney, Australia. AD - Agnes Ginges Centre for Molecular Cardiology at Centenary Institute, The University of Sydney, Sydney, Australia. FAU - Semsarian, Christopher AU - Semsarian C AD - Faculty of Medicine and Health, The University of Sydney, Sydney, Australia. AD - Agnes Ginges Centre for Molecular Cardiology at Centenary Institute, The University of Sydney, Sydney, Australia. AD - Department of Cardiology, Royal Prince Alfred Hospital, Sydney, Australia. FAU - Ingles, Jodie AU - Ingles J AUID- ORCID: 0000-0002-4846-7676 AD - Cardio Genomics Program at Centenary Institute, The University of Sydney, Sydney, Australia. jodie.ingles@populationgenomics.org.au. AD - Centre for Population Genomics, Garvan Institute of Medical Research, and UNSW Sydney, 384 Victoria Street, Darlinghurst, NSW, 2010, Australia. jodie.ingles@populationgenomics.org.au. AD - Centre for Population Genomics, Murdoch Children's Research Institute, Melbourne, Australia. jodie.ingles@populationgenomics.org.au. AD - Agnes Ginges Centre for Molecular Cardiology at Centenary Institute, The University of Sydney, Sydney, Australia. jodie.ingles@populationgenomics.org.au. AD - Department of Cardiology, Royal Prince Alfred Hospital, Sydney, Australia. jodie.ingles@populationgenomics.org.au. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20221228 PL - England TA - Genome Med JT - Genome medicine JID - 101475844 SB - IM MH - Humans MH - Retrospective Studies MH - *Genetic Testing MH - Phenotype MH - *Heart Diseases/diagnosis/genetics/therapy PMC - PMC9795753 OTO - NOTNLM OT - Genetic testing OT - Inherited cardiac conditions OT - Sudden cardiac death COIS- J. Ingles receives research grant support from Bristol Myers Squibb. The remaining authors declare that they have no competing interests. EDAT- 2022/12/29 06:00 MHDA- 2022/12/31 06:00 PMCR- 2022/12/28 CRDT- 2022/12/28 23:43 PHST- 2022/06/21 00:00 [received] PHST- 2022/12/12 00:00 [accepted] PHST- 2022/12/28 23:43 [entrez] PHST- 2022/12/29 06:00 [pubmed] PHST- 2022/12/31 06:00 [medline] PHST- 2022/12/28 00:00 [pmc-release] AID - 10.1186/s13073-022-01149-0 [pii] AID - 1149 [pii] AID - 10.1186/s13073-022-01149-0 [doi] PST - epublish SO - Genome Med. 2022 Dec 28;14(1):145. doi: 10.1186/s13073-022-01149-0. PMID- 36567108 OWN - NLM STAT- MEDLINE DCOM- 20231226 LR - 20250117 IS - 1347-4820 (Electronic) IS - 1346-9843 (Linking) VI - 88 IP - 1 DP - 2023 Dec 25 TI - Developing Multidisciplinary Management of Heart Failure in the Super-Aging Society of Japan. PG - 2-9 LID - 10.1253/circj.CJ-22-0675 [doi] AB - The Japanese population is rapidly aging because of its long life expectancy and low birth rate; additionally, the number of patients with heart failure (HF) is increasing to the extent that HF is now considered a pandemic. According to a recent HF registry study, Japanese patients with HF have both medical and care-related problems. Although hospitalization is used to provide medical services, and institutionalization is used to provide care for frail older adults, it can be difficult to distinguish between them. In this context, multidisciplinary management of HF has become increasingly important in preventing hospital readmissions and maintaining a patient's quality of life. Academia has promoted an increase in the number of certified HF nurses and educators. Researchers have issued numerous guidelines or statements on topics such as cardiac rehabilitation, nutrition, and palliative care, in addition to the diagnosis and treatment of acute and chronic HF. Moreover, the Japanese government has created incentives through various medical and long-term care systems adjustments to increase collaboration between these two fields. This review summarizes current epidemiological registries that focus not only on medical but also care-related problems and the 10 years of multidisciplinary management experience in Japanese medical and long-term care systems. FAU - Sato, Yukihito AU - Sato Y AD - Department of Cardiology, Hyogo Prefectural Amagasaki General Medical Center. FAU - Kuragaichi, Takashi AU - Kuragaichi T AD - Department of Cardiology, Hyogo Prefectural Amagasaki General Medical Center. FAU - Nakayama, Hiroyuki AU - Nakayama H AD - Department of Cardiology, Hyogo Prefectural Amagasaki General Medical Center. FAU - Hotta, Kozo AU - Hotta K AD - Department of Cardiology, Hyogo Prefectural Amagasaki General Medical Center. FAU - Nishimoto, Yuji AU - Nishimoto Y AD - Department of Cardiology, Hyogo Prefectural Amagasaki General Medical Center. FAU - Kato, Takao AU - Kato T AD - Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine. FAU - Taniguchi, Ryoji AU - Taniguchi R AD - Department of Cardiology, Hyogo Prefectural Amagasaki General Medical Center. FAU - Washida, Koichi AU - Washida K AD - Department of Nursing, Hyogo Prefectural Amagasaki General Medical Center. AD - Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine. LA - eng PT - Journal Article PT - Review DEP - 20221223 PL - Japan TA - Circ J JT - Circulation journal : official journal of the Japanese Circulation Society JID - 101137683 SB - IM MH - Humans MH - Aged MH - Japan/epidemiology MH - Quality of Life MH - *Heart Failure/diagnosis/epidemiology/therapy MH - Aging MH - *Cardiac Rehabilitation OTO - NOTNLM OT - Cardiac rehabilitation OT - Heart failure OT - Long-term care OT - Nutritional support OT - Palliative care EDAT- 2022/12/26 06:00 MHDA- 2023/12/26 06:41 CRDT- 2022/12/25 21:02 PHST- 2023/12/26 06:41 [medline] PHST- 2022/12/26 06:00 [pubmed] PHST- 2022/12/25 21:02 [entrez] AID - 10.1253/circj.CJ-22-0675 [doi] PST - ppublish SO - Circ J. 2023 Dec 25;88(1):2-9. doi: 10.1253/circj.CJ-22-0675. Epub 2022 Dec 23. PMID- 36565750 OWN - NLM STAT- MEDLINE DCOM- 20230329 LR - 20230329 IS - 1885-5857 (Electronic) IS - 1885-5857 (Linking) VI - 76 IP - 4 DP - 2023 Apr TI - Cardiogenic shock code 2023. Expert document for a multidisciplinary organization that allows quality care. PG - 261-269 LID - S1885-5857(22)00330-9 [pii] LID - 10.1016/j.rec.2022.10.014 [doi] AB - Despite the efforts made to improve the care of cardiogenic shock (CS) patients, including the development of mechanical circulatory support (MCS), the prognosis of these patients continues to be poor. In this context, CS code initiatives arise, based on providing adequate, rapid, and quality care to these patients. In this multidisciplinary document we try to justify the need to implement the SC code, defining its structure/organization, activation criteria, patient flow according to care level, and quality indicators. Our specific purposes are: a) to present the peculiarities of this condition and the lessons of infarction code and previous experiences in CS; b) to detail the structure of the teams, their logistics and the bases for the management of these patients, the choice of the type of MCS, and the moment of its implantation, and c) to address challenges to SC code implementation, including the uniqueness of the pediatric SC code. There is an urgent need to develop protocolized, multidisciplinary, and centralized care in hospitals with a large volume and experience that will minimize inequity in access to the MCS and improve the survival of these patients. Only institutional and structural support from the different administrations will allow optimizing care for CS. CI - Copyright (c) 2022 Sociedad Espanola de Cardiologia. Published by Elsevier Espana, S.L.U. All rights reserved. FAU - Martinez-Selles, Manuel AU - Martinez-Selles M AD - Servicio de Cardiologia, Hospital General Universitario Gregorio Maranon, Madrid, Spain; Centro de Investigacion Biomedica en Red Enfermedades Cardiovasculares (CIBERCV), Spain; Universidad Europea, Madrid, Spain; Universidad Complutense, Madrid, Spain. Electronic address: mmselles@secardiologia.es. FAU - Hernandez-Perez, Francisco Jose AU - Hernandez-Perez FJ AD - Servicio de Cardiologia, Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Madrid, Spain. FAU - Uribarri, Aitor AU - Uribarri A AD - Servicio de Cardiologia, Hospital Universitario Vall d'Hebron, Universidad Autonoma de Barcelona, Barcelona, Spain. FAU - Martin Villen, Luis AU - Martin Villen L AD - Unidad de Gestion Clinica de Cuidados Intensivos, Hospital Universitario Virgen del Rocio, Seville, Spain. FAU - Zapata, Luis AU - Zapata L AD - Servicio de Medicina Intensiva, Hospital de la Santa Creu i Sant Pau, Universidad Autonoma de Barcelona, Barcelona, Spain. FAU - Alonso, Joaquin J AU - Alonso JJ AD - Universidad Europea, Madrid, Spain; Servicio Cardiologia, Hospital Universitario de Getafe, Getafe, Madrid, Spain. FAU - Amat-Santos, Ignacio J AU - Amat-Santos IJ AD - Servicio de Cardiologia, Hospital Clinico Universitario de Valladolid, Valladolid, Spain. FAU - Ariza-Sole, Albert AU - Ariza-Sole A AD - Unidad de Cuidados Intensivos Cardiologicos, Servicio de Cardiologia, Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain. FAU - Barrabes, Jose A AU - Barrabes JA AD - Centro de Investigacion Biomedica en Red Enfermedades Cardiovasculares (CIBERCV), Spain; Servicio de Cardiologia, Hospital Universitario Vall d'Hebron, Universidad Autonoma de Barcelona, Barcelona, Spain. FAU - Barrio, Jose Maria AU - Barrio JM AD - Seccion de Anestesia Cardiaca-Unidad de Cuidados Posquirurgicos Cardiacos, Servicio de Anestesiologia, Hospital General Universitario Gregorio Maranon, CIBERES, Madrid, Spain. FAU - Canteli, Angela AU - Canteli A AD - Servicio de Cardiologia, Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain. FAU - Alonso-Fernandez-Gatta, Marta AU - Alonso-Fernandez-Gatta M AD - Centro de Investigacion Biomedica en Red Enfermedades Cardiovasculares (CIBERCV), Spain; Servicio de Cardiologia, Hospital Clinico Universitario de Salamanca, Salamanca, Spain. FAU - Corbi Pascual, Miguel J AU - Corbi Pascual MJ AD - Unidad de Cuidados Intensivos Cardiologicos, Servicio de Cardiologia, Hospital General de Albacete, Albacete, Spain. FAU - Diaz, Domingo AU - Diaz D AD - Servicio de Cuidados Intensivos, Hospital Universitario Infanta Leonor, Madrid, Spain. FAU - Crespo-Leiro, Maria G AU - Crespo-Leiro MG AD - Centro de Investigacion Biomedica en Red Enfermedades Cardiovasculares (CIBERCV), Spain; Servicio de Cardiologia, Complexo Hospitalario Universitario A Coruna, Universidad de A Coruna (UDC), A Coruna, Spain. FAU - de la Torre-Hernandez, Jose Maria AU - de la Torre-Hernandez JM AD - Servicio de Cardiologia, Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain. FAU - Ferrera, Carlos AU - Ferrera C AD - Unidad de Cuidados Agudos Cardiologicos, Instituto Cardiovascular, Hospital Clinico San Carlos, Madrid, Spain. FAU - Garcia Gonzalez, Martin J AU - Garcia Gonzalez MJ AD - Unidad de Cuidados Intensivos Cardiologicos, Servicio de Cardiologia, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain. FAU - Garcia-Carreno, Jorge AU - Garcia-Carreno J AD - Servicio de Cardiologia, Hospital General Universitario Gregorio Maranon, Madrid, Spain; Centro de Investigacion Biomedica en Red Enfermedades Cardiovasculares (CIBERCV), Spain. FAU - Garcia-Guereta, Luis AU - Garcia-Guereta L AD - Servicio de Cardiologia Pediatrica, Hospital Universitario La Paz, Madrid, Spain. FAU - Garcia Quintana, Antonio AU - Garcia Quintana A AD - Servicio de Cardiologia, Hospital Universitario de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain. FAU - Jorge Perez, Pablo AU - Jorge Perez P AD - Unidad de Cuidados Intensivos Cardiologicos, Servicio de Cardiologia, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain. FAU - Gonzalez-Juanatey, Jose R AU - Gonzalez-Juanatey JR AD - Centro de Investigacion Biomedica en Red Enfermedades Cardiovasculares (CIBERCV), Spain; Servicio de Cardiologia y Unidad Coronaria, Hospital Clinico Universitario de Santiago de Compostela, Santiago de Compostela, A Coruna, Spain. FAU - Lopez de Sa, Esteban AU - Lopez de Sa E AD - Servicio de Cardiologia, Hospital Universitario La Paz, Madrid, Spain. FAU - Sanchez, Pedro Luis AU - Sanchez PL AD - Centro de Investigacion Biomedica en Red Enfermedades Cardiovasculares (CIBERCV), Spain; Servicio de Cardiologia, Hospital Clinico Universitario de Salamanca, Salamanca, Spain. FAU - Monteagudo, Maria AU - Monteagudo M AD - Servicio de Cirugia Cardiaca, Hospital Universitario de La Princesa, Universidad Autonoma de Madrid, Madrid, Spain. FAU - Palomo Lopez, Nora AU - Palomo Lopez N AD - Unidad de Gestion Clinica de Cuidados Intensivos, Hospital Universitario Virgen del Rocio, Seville, Spain. FAU - Reyes, Guillermo AU - Reyes G AD - Servicio de Cirugia Cardiaca, Hospital Universitario de La Princesa, Universidad Autonoma de Madrid, Madrid, Spain. FAU - Rosell, Fernando AU - Rosell F AD - Servicio de Emergencias Sanitarias (061), La Rioja Salud, La Rioja, Spain. FAU - Solla Buceta, Miguel Antonio AU - Solla Buceta MA AD - Servicio de Medicina Intensiva, Complejo Hospitalario Universitario A Coruna (CHUAC), Instituto de Investigacion Biomedica de A Coruna (INIBIC), A Coruna, Spain. FAU - Segovia-Cubero, Javier AU - Segovia-Cubero J AD - Centro de Investigacion Biomedica en Red Enfermedades Cardiovasculares (CIBERCV), Spain; Servicio de Cardiologia, Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Madrid, Spain. FAU - Sionis Green, Alessandro AU - Sionis Green A AD - Centro de Investigacion Biomedica en Red Enfermedades Cardiovasculares (CIBERCV), Spain; Unidad de Cuidados Agudos Cardiologicos, Servicio de Cardiologia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. FAU - Stepanenko, Alexander AU - Stepanenko A AD - Servicio de Cardiologia, Hospital Clinico Universitario de Valladolid, Valladolid, Spain. FAU - Iglesias Alvarez, Diego AU - Iglesias Alvarez D AD - Centro de Investigacion Biomedica en Red Enfermedades Cardiovasculares (CIBERCV), Spain; Servicio de Cardiologia y Unidad Coronaria, Hospital Clinico Universitario de Santiago de Compostela, Santiago de Compostela, A Coruna, Spain. FAU - Viana Tejedor, Ana AU - Viana Tejedor A AD - Universidad Complutense, Madrid, Spain; Unidad de Cuidados Agudos Cardiologicos, Instituto Cardiovascular, Hospital Clinico San Carlos, Madrid, Spain. FAU - Voces, Roberto AU - Voces R AD - Grupo ECMO, Hospital Universitario de Cruces, Bilbao, Vizcaya, Spain. FAU - Fuset Cabanes, Maria Paz AU - Fuset Cabanes MP AD - Servicio de Medicina Intensiva, Hospital Universitario de Bellvitge, Servicio de Emergencias Sanitarias de Cataluna, L'Hospitalet de Llobregat, Barcelona, Spain. FAU - Gimeno Costa, Jose Ricardo AU - Gimeno Costa JR AD - Servicio de Medicina Intensiva, Hospital Universitario y Politecnico La Fe, Valencia, Spain. FAU - Diaz, Jose AU - Diaz J AD - Servicio de Cardiologia, Hospital Universitario Virgen del Rocio, Seville, Spain. FAU - Fernandez-Aviles, Francisco AU - Fernandez-Aviles F AD - Servicio de Cardiologia, Hospital General Universitario Gregorio Maranon, Madrid, Spain; Centro de Investigacion Biomedica en Red Enfermedades Cardiovasculares (CIBERCV), Spain; Universidad Complutense, Madrid, Spain. LA - eng LA - spa PT - Journal Article DEP - 20221221 PL - Spain TA - Rev Esp Cardiol (Engl Ed) JT - Revista espanola de cardiologia (English ed.) JID - 101587954 SB - IM MH - Humans MH - Child MH - Shock, Cardiogenic/therapy MH - *Heart-Assist Devices MH - *Extracorporeal Membrane Oxygenation MH - Intra-Aortic Balloon Pumping MH - Treatment Outcome OTO - NOTNLM OT - Atencion de calidad OT - Cardiogenic shock OT - Logistics OT - Logistica OT - Multidisciplinary organization OT - Organizacion multidisciplinaria OT - Quality of care OT - Shock cardiogenico EDAT- 2022/12/25 06:00 MHDA- 2023/03/29 06:05 CRDT- 2022/12/24 19:12 PHST- 2022/09/26 00:00 [received] PHST- 2022/10/14 00:00 [accepted] PHST- 2023/03/29 06:05 [medline] PHST- 2022/12/25 06:00 [pubmed] PHST- 2022/12/24 19:12 [entrez] AID - S1885-5857(22)00330-9 [pii] AID - 10.1016/j.rec.2022.10.014 [doi] PST - ppublish SO - Rev Esp Cardiol (Engl Ed). 2023 Apr;76(4):261-269. doi: 10.1016/j.rec.2022.10.014. Epub 2022 Dec 21. PMID- 36561256 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221224 IS - 2251-6093 (Electronic) IS - 2251-6085 (Print) IS - 2251-6085 (Linking) VI - 51 IP - 11 DP - 2022 Nov TI - Effect of Early Multidisciplinary Collaboration Combined with Cluster Strategy on Acquired Debilitating Syndrome in ICU of Patients with Acute Myocardial Infarction. PG - 2519-2527 LID - 10.18502/ijph.v51i11.11169 [doi] AB - BACKGROUND: To investigate the preventive effect of early multidisciplinary collaboration combined with cluster strategy on acquired frailty syndrome in ICU of patients with acute myocardial infarction (AMI). METHODS: A total of 240 patients with myocardial infarction (MI) admitted to ICU in The Third Affiliated Hospital of Qiqihar Medical University, Qiqihar, China from March 2018 to March 2020 were selected. The patients were randomly divided into experiment group and control group equally according to random number method. The experimental group was treated with early multidisciplinary collaboration and cluster strategy, while the control group was treated with routine nursing mode. Duration of ventilation, total length of stay, length of ICU stay, New York College of Cardiology cardiac function classification, MRC-Score, BI and complications during hospitalization were recorded. RESULTS: After intervention, there were statistically significant differences in ventilation duration, total length of stay, length of stay in ICU, Heart function classification of New York Cardiology Society, MRC-Score, BI index, SF-36 score and complications during hospitalization in 2 groups (P < 0.05), and the above indicators in the experimental group were better than those in the control group. CONCLUSION: Early multidisciplinary collaboration combined with cluster strategy can significantly reduce the incidence of AMI in ICU of MI patients. CI - Copyright (c) 2022 Zhao et al. Published by Tehran University of Medical Sciences. FAU - Zhao, Teng AU - Zhao T AD - Department of Intensive Care Medicine, The Third Affiliated Hospital of Qiqihar Medical University, Qiqihar 161000, China. FAU - Zhao, Mingyu AU - Zhao M AD - Department of Vascular Surgery, The Third Affiliated Hospital of Qiqihar Medical University, Qiqihar 161000, China. FAU - Li, Qiang AU - Li Q AD - Department of Cardiology, The Third Affiliated Hospital of Qiqihar Medical University, Qiqihar 161000, China. FAU - Guan, Zhanjiang AU - Guan Z AD - Department of Intensive Care Medicine, The Third Affiliated Hospital of Qiqihar Medical University, Qiqihar 161000, China. FAU - Zhang, Xu AU - Zhang X AD - Department of Clinical Pharmacy, The Third Affiliated Hospital of Qiqihar Medical University, Qiqihar 161000, China. FAU - Li, Li AU - Li L AD - Department of Nursing, The Third Affiliated Hospital of Qiqihar Medical University, Qiqihar 161000, China. LA - eng PT - Journal Article PL - Iran TA - Iran J Public Health JT - Iranian journal of public health JID - 7505531 PMC - PMC9745402 OTO - NOTNLM OT - Acute myocardial infarction OT - Bunching strategy OT - Multidisciplinary collaboration COIS- Conflict of Interest The authors declare that there is no conflict of interest. EDAT- 2022/12/24 06:00 MHDA- 2022/12/24 06:01 PMCR- 2022/11/01 CRDT- 2022/12/23 02:20 PHST- 2022/03/09 00:00 [received] PHST- 2022/05/18 00:00 [accepted] PHST- 2022/12/23 02:20 [entrez] PHST- 2022/12/24 06:00 [pubmed] PHST- 2022/12/24 06:01 [medline] PHST- 2022/11/01 00:00 [pmc-release] AID - IJPH-51-2519 [pii] AID - 10.18502/ijph.v51i11.11169 [doi] PST - ppublish SO - Iran J Public Health. 2022 Nov;51(11):2519-2527. doi: 10.18502/ijph.v51i11.11169. PMID- 36556163 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240909 IS - 2075-4426 (Print) IS - 2075-4426 (Electronic) IS - 2075-4426 (Linking) VI - 12 IP - 12 DP - 2022 Nov 22 TI - Biosensors for the Rapid Detection of Cardiovascular Biomarkers of Vital Interest: Needs, Analysis and Perspectives. LID - 10.3390/jpm12121942 [doi] LID - 1942 AB - We have previously surveyed a panel of 508 physicians from around the world about which biomarkers would be relevant if obtained in a very short time frame, corresponding to emergency situations (life-threatening or not). The biomarkers that emerged from this study were markers of cardiovascular disease: troponin, D-dimers, and brain natriuretic peptide (BNP). Cardiovascular disease is a group of disorders affecting the heart and blood vessels. At the intersection of medicine, basic research and engineering, biosensors that address the need for rapid biological analysis could find a place of choice in the hospital or primary care ecosystem. Rapid, reliable, and inexpensive analysis with a multi-marker approach, including machine learning analysis for patient risk analysis, could meet the demand of medical teams. The objective of this opinion review, proposed by a multidisciplinary team of experts (physicians, biologists, market access experts, and engineers), is to present cases where a rapid biological response is indeed valuable, to provide a short overview of current biosensor technologies for cardiac biomarkers designed for a short result time, and to discuss existing market access issues. FAU - Abensur Vuillaume, Laure AU - Abensur Vuillaume L AUID- ORCID: 0000-0003-2527-8458 AD - Emergency Department CHR Metz-Thionville, 57000 Metz, France. AD - IRL 2958 Georgia Tech CNRS, 57000 Metz, France. FAU - Frija-Masson, Justine AU - Frija-Masson J AD - Digital Medical Hub, AP-HP, 75000 Paris, France. AD - Service de Physiologie Clinique-Explorations Fonctionnelles, Hopital Bichat, AP-HP, F-75018 Paris, France. AD - UFR de Medecine, Universite Paris Cite, NeuroDiderot, INSERM, F-75019 Paris, France. FAU - Hadjiat, Meriem AU - Hadjiat M AD - Biology Department, CHR Metz-Thionville, 57000 Metz, France. FAU - Riquier, Thomas AU - Riquier T AD - Digital Medical Hub, AP-HP, 75000 Paris, France. FAU - d'Ortho, Marie-Pia AU - d'Ortho MP AD - Digital Medical Hub, AP-HP, 75000 Paris, France. AD - Service de Physiologie Clinique-Explorations Fonctionnelles, Hopital Bichat, AP-HP, F-75018 Paris, France. AD - UFR de Medecine, Universite Paris Cite, NeuroDiderot, INSERM, F-75019 Paris, France. FAU - Le Borgne, Pierrick AU - Le Borgne P AD - Emergency Department, Hopitaux Universitaires de Strasbourg, 67000 Strasbourg, France. AD - INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative NanoMedicine (RNM), Federation de Medecine Translationnelle (FMTS), University of Strasbourg, 67000 Strasbourg, France. FAU - Goetz, Christophe AU - Goetz C AD - Clinical Research Support, CHR Metz-Thionville, 57000 Metz, France. FAU - Voss, Paul L AU - Voss PL AD - IRL 2958 Georgia Tech CNRS, 57000 Metz, France. AD - Georgia Institute of Technology, School of Electrical and Computer Engineering, Atlanta, GA 30332-0250, USA. FAU - Ougazzaden, Abdallah AU - Ougazzaden A AUID- ORCID: 0000-0002-9959-5280 AD - IRL 2958 Georgia Tech CNRS, 57000 Metz, France. AD - Georgia Institute of Technology, School of Electrical and Computer Engineering, Atlanta, GA 30332-0250, USA. FAU - Salvestrini, Jean-Paul AU - Salvestrini JP AUID- ORCID: 0000-0002-0482-1178 AD - IRL 2958 Georgia Tech CNRS, 57000 Metz, France. AD - Georgia Institute of Technology, School of Electrical and Computer Engineering, Atlanta, GA 30332-0250, USA. FAU - Leichle, Thierry AU - Leichle T AD - IRL 2958 Georgia Tech CNRS, 57000 Metz, France. AD - LAAS-CNRS, 31400 Toulouse, France. LA - eng PT - Journal Article PT - Review DEP - 20221122 PL - Switzerland TA - J Pers Med JT - Journal of personalized medicine JID - 101602269 PMC - PMC9781598 OTO - NOTNLM OT - BNP OT - D-dimers OT - biosensors OT - cardiac biomarkers OT - troponin COIS- The authors declare no conflict of interest. EDAT- 2022/12/24 06:00 MHDA- 2022/12/24 06:01 PMCR- 2022/11/22 CRDT- 2022/12/23 01:39 PHST- 2022/09/19 00:00 [received] PHST- 2022/11/09 00:00 [revised] PHST- 2022/11/11 00:00 [accepted] PHST- 2022/12/23 01:39 [entrez] PHST- 2022/12/24 06:00 [pubmed] PHST- 2022/12/24 06:01 [medline] PHST- 2022/11/22 00:00 [pmc-release] AID - jpm12121942 [pii] AID - jpm-12-01942 [pii] AID - 10.3390/jpm12121942 [doi] PST - epublish SO - J Pers Med. 2022 Nov 22;12(12):1942. doi: 10.3390/jpm12121942. PMID- 36553289 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20261001 IS - 2227-9067 (Print) IS - 2227-9067 (Electronic) IS - 2227-9067 (Linking) VI - 9 IP - 12 DP - 2022 Nov 28 TI - Quality Improvement in a Pediatric Echocardiography Laboratory: A Collaborative Process. LID - 10.3390/children9121845 [doi] LID - 1845 AB - Transthoracic echocardiography (TTE) is an essential tool for diagnosis and management of congenital heart disease. Pediatric echocardiography presents unique challenges including complex anatomy, variable patient cooperation and provider expertise. Diagnostic errors inevitably occur. We designed a collaborative and stepwise quality improvement (QI) process to address diagnostic errors within our laboratory. We retrospectively reviewed medical records to identify diagnostic TTE errors in 100 consecutive cardiac surgery patients 60 mm Hg), urgent intervention should be considered in eligible newborns. The second parameter was the left ventricular end-systolic eccentricity index (EI), a newly emerging echocardiographic marker and indirect correlate of PH. As an alternative to the TR gradient, an increased eccentricity index (>1.6) suggests severe right heart compromise, requiring emergency catheter embolization of the malformation. Postoperatively, the progressive reduction of both the TR gradient and the EI correlated with recovery. LESSONS: In eligible newborns, urgent embolization of a VoGM is recommended in the presence of suprasystemic TR gradients and/or increased EI >1.6. FAU - Yarden, Jeremy A AU - Yarden JA AD - Departments of1Neurosurgery. FAU - Hauck, Lily I AU - Hauck LI AD - Departments of1Neurosurgery. FAU - Athavale, Kamlesh V AU - Athavale KV AD - 2Pediatrics/Neonatology, and. FAU - McCrary, Andrew W AU - McCrary AW AD - 3Pediatric Cardiology, Duke University, Durham, North Carolina. FAU - Campbell, M Jay AU - Campbell MJ AD - 3Pediatric Cardiology, Duke University, Durham, North Carolina. FAU - Hauck, Erik F AU - Hauck EF AD - Departments of1Neurosurgery. LA - eng PT - Journal Article DEP - 20221010 PL - United States TA - J Neurosurg Case Lessons JT - Journal of neurosurgery. Case lessons JID - 9918227275606676 PMC - PMC9552681 OTO - NOTNLM OT - TR gradient OT - eccentricity index OT - embolization OT - newborn OT - vein of Galen malformation COIS- Disclosures The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper. EDAT- 2022/12/04 06:00 MHDA- 2022/12/04 06:01 PMCR- 2022/10/10 CRDT- 2022/12/03 05:42 PHST- 2022/07/29 00:00 [received] PHST- 2022/08/31 00:00 [accepted] PHST- 2022/12/03 05:42 [entrez] PHST- 2022/12/04 06:00 [pubmed] PHST- 2022/12/04 06:01 [medline] PHST- 2022/10/10 00:00 [pmc-release] AID - CASE22323 [pii] AID - 10.3171/CASE22323 [doi] PST - epublish SO - J Neurosurg Case Lessons. 2022 Oct 10;4(15):CASE22323. doi: 10.3171/CASE22323. Print 2022 Oct 10. PMID- 36460550 OWN - NLM STAT- MEDLINE DCOM- 20230613 LR - 20230613 IS - 1878-7886 (Electronic) IS - 1878-7886 (Linking) VI - 160 IP - 3 DP - 2023 Jun TI - Postoperative morbidity and mortality in patients with diabetes after colorectal surgery with an enhanced recovery program: A monocentric retrospective study. PG - 180-187 LID - S1878-7886(22)00157-6 [pii] LID - 10.1016/j.jviscsurg.2022.11.001 [doi] AB - BACKGROUND: Diabetes mellitus may increase the risk of adverse perioperative outcomes and prolong hospital stay. An enhanced recovery program (ERP) reduces surgical stress and its metabolic consequences, so attenuating the impact of preoperative risk factors. We tested the hypothesis that diabetes would have only a minor impact on outcome after colorectal surgery with an ERP. METHODS: The data for patients scheduled for colorectal surgery between 2015 and 2021, were analyzed (n=769). All the patients were managed with the same protocol. Demographic data, preoperative risk factors, postoperative complications, and length of stay were compared between patients with and without diabetes. RESULTS: In all, 124 patients (16.1%) had diabetes, of whom 30 (24.1%) required insulin. The following preoperative risk factors for postoperative complications were significantly more frequent in the patients with diabetes: age>70 years, ASA score >/= III, renal failure, cardiac disease, BMI>30 kg/m(2), anemia, and cancer as indication for surgery. Despite more risk factors, patients with diabetes did not experience more overall postoperative complications than controls (OR (95%IC): 0.9 [0.6-1.5], p=0.85). Length of hospital stay was not significantly longer in patients with diabetes than in those without (4 [2-7] vs. 3 [2-7] days; p=0.45). CONCLUSIONS: Despite more risk factors, patients with diabetes did not experience more complications or longer length of stay after colorectal surgery with an ERP. The multimodal, multidisciplinary approach of ERP to reducing surgical stress may thus help mitigate the reported deleterious effects of diabetes. CI - Copyright (c) 2022 Elsevier Masson SAS. All rights reserved. FAU - Lejeune, D AU - Lejeune D AD - Department of Anesthesiology and Reanimation, CHU Liege, University of Liege, domaine universitaire du Sart Tilman, Liege, Belgium. FAU - Hardy, P-Y AU - Hardy PY AD - Department of Anesthesiology and Reanimation, CHU Liege, University of Liege, domaine universitaire du Sart Tilman, Liege, Belgium; Groupe francophone de rehabilitation amelioree apres chirurgie (GRACE; Francophone Group for Enhanced Recovery after Surgery), Beaumont, France. Electronic address: pyhardy@chuliege.be. FAU - Kaba, A AU - Kaba A AD - Department of Anesthesiology and Reanimation, CHU Liege, University of Liege, domaine universitaire du Sart Tilman, Liege, Belgium. FAU - Joris, J AU - Joris J AD - Department of Anesthesiology and Reanimation, CHU Liege, University of Liege, domaine universitaire du Sart Tilman, Liege, Belgium; Groupe francophone de rehabilitation amelioree apres chirurgie (GRACE; Francophone Group for Enhanced Recovery after Surgery), Beaumont, France. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20221129 PL - France TA - J Visc Surg JT - Journal of visceral surgery JID - 101532664 SB - IM MH - Humans MH - Aged MH - Retrospective Studies MH - *Colorectal Surgery/adverse effects MH - *Digestive System Surgical Procedures/adverse effects MH - Postoperative Complications/etiology MH - *Diabetes Mellitus/epidemiology/etiology MH - Length of Stay OTO - NOTNLM OT - Colorectal OT - Diabetes OT - Enhanced recovery program OT - Length of hospital stay OT - Postoperative complications OT - Surgery EDAT- 2022/12/03 06:00 MHDA- 2023/06/13 06:42 CRDT- 2022/12/02 22:04 PHST- 2023/06/13 06:42 [medline] PHST- 2022/12/03 06:00 [pubmed] PHST- 2022/12/02 22:04 [entrez] AID - S1878-7886(22)00157-6 [pii] AID - 10.1016/j.jviscsurg.2022.11.001 [doi] PST - ppublish SO - J Visc Surg. 2023 Jun;160(3):180-187. doi: 10.1016/j.jviscsurg.2022.11.001. Epub 2022 Nov 29. PMID- 36460051 OWN - NLM STAT- MEDLINE DCOM- 20231108 LR - 20231114 IS - 2058-1742 (Electronic) IS - 2058-1742 (Linking) VI - 9 IP - 7 DP - 2023 Nov 2 TI - Waiting times of women vs. men undergoing transcatheter aortic valve implantation. PG - 691-698 LID - 10.1093/ehjqcco/qcac081 [doi] AB - AIMS: Increasing transcatheter aortic valve implantation (TAVI) rates have resulted in prolonged waiting times. These have been associated with heart failure hospitalizations (HFH) and mortality yet sex differences have not yet been reported. METHODS AND RESULTS: All patients who underwent TAVI for severe aortic stenosis at a tertiary referral hospital in Australia were prospectively included. Total waiting time was divided into 'work-up' waiting time (period from referral date until heart team approval) and, 'procedural' waiting time (period from heart team approval until procedure date). Patients were analysed according to sex. Cohorts were matched to correct for differences in baseline and procedural variables. The primary endpoints were waiting times. Secondary outcomes included a composite of 30-day mortality and HFH, quality of life, and mobility. A total of 407 patients (42% women) were included. After matching of the two cohorts (345 patients), women had significantly longer total waiting times than men: median 156 [interquartile range (IQR) 114-220] days in women vs. 147 [IQR 92-204] days in men (P = 0.037) including longer work-up (83 [IQR 50-128] vs. 71 [IQR 36-119], P = 0.15) and procedural waiting times (65 [IQR 44-100] vs. 58 [IQR 30-93], P = 0.042). Increasing waiting times were associated with higher 30-day mortality and HFH (P = 0.01 for work-up waiting time, P = 0.02 for procedural waiting time) and decreased 30-day mobility (P = 0.044 for procedural waiting time) in women, but not in men. CONCLUSION: TAVI waiting times are significantly longer in women compared to men and are associated with increased mortality and HFH and reduced mobility at 30-days. CI - (c) The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology. FAU - Stehli, Julia AU - Stehli J AUID- ORCID: 0000-0003-3089-1062 AD - Monash University, Faculty of Medicine, Nursing and Health Sciences, Clayton, VIC 3800, Australia. FAU - Johnston, Rozanne AU - Johnston R AD - Department of Cardiology, Alfred Hospital, Melbourne, VIC 3004, Australia. FAU - Duffy, Stephen J AU - Duffy SJ AUID- ORCID: 0000-0003-4255-9155 AD - Centre of Cardiovascular Research and Education in Therapeutics, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC 3004, Australia. FAU - Zaman, Sarah AU - Zaman S AUID- ORCID: 0000-0002-7698-0397 AD - Department of Cardiology, Westmead Hospital, Sydney, Westmead, NSW 2145, Australia. AD - Westmead Applied Research Centre, University of Sydney, Sydney, Westmead, NSW 2145, Australia. FAU - Gusberti, Tomoe D H AU - Gusberti TDH AD - Freelance data scientist, Kolabtree.com. FAU - Dagan, Misha AU - Dagan M AUID- ORCID: 0000-0002-2353-9776 AD - Department of Cardiology, Alfred Hospital, Melbourne, VIC 3004, Australia. FAU - Stub, Dion AU - Stub D AUID- ORCID: 0000-0001-8686-2709 AD - Department of Cardiology, Alfred Hospital, Melbourne, VIC 3004, Australia. FAU - Walton, Antony AU - Walton A AUID- ORCID: 0000-0002-9173-5904 AD - Department of Cardiology, Alfred Hospital, Melbourne, VIC 3004, Australia. LA - eng PT - Journal Article PL - England TA - Eur Heart J Qual Care Clin Outcomes JT - European heart journal. Quality of care & clinical outcomes JID - 101677796 SB - IM MH - Humans MH - Male MH - Female MH - *Transcatheter Aortic Valve Replacement MH - Waiting Lists MH - *Aortic Valve Stenosis/surgery MH - Quality of Life MH - Treatment Outcome OTO - NOTNLM OT - Sex discrepancies OT - TAVI OT - Wait times OT - Waiting times EDAT- 2022/12/03 06:00 MHDA- 2023/11/08 06:42 CRDT- 2022/12/02 19:13 PHST- 2022/09/29 00:00 [received] PHST- 2022/11/26 00:00 [revised] PHST- 2022/11/30 00:00 [accepted] PHST- 2023/11/08 06:42 [medline] PHST- 2022/12/03 06:00 [pubmed] PHST- 2022/12/02 19:13 [entrez] AID - 6865356 [pii] AID - 10.1093/ehjqcco/qcac081 [doi] PST - ppublish SO - Eur Heart J Qual Care Clin Outcomes. 2023 Nov 2;9(7):691-698. doi: 10.1093/ehjqcco/qcac081. PMID- 36456053 OWN - NLM STAT- MEDLINE DCOM- 20221205 LR - 20221210 IS - 1558-3597 (Electronic) IS - 0735-1097 (Linking) VI - 80 IP - 23 DP - 2022 Dec 6 TI - Management of Heart Failure With Arrhythmia in Adults With Congenital Heart Disease: JACC State-of-the-Art Review. PG - 2224-2238 LID - S0735-1097(22)07033-4 [pii] LID - 10.1016/j.jacc.2022.09.038 [doi] AB - Together, heart failure and arrhythmia represent the most important cardiovascular sources of morbidity and mortality among adults with congenital heart disease (ACHDs). Although traditionally conceptualized as operating within 2 distinct clinical silos, these scenarios frequently coexist within the same individual; consequently the mechanistic, therapeutic, and prognostic overlap between them demands increased recognition. In fact, given the near ubiquity of heart failure and arrhythmia among ACHDs, there is perhaps no other arena within cardiology where this critical intersection is more frequently observed. Optimal care for ACHDs therefore requires a heightened awareness of the relevant interactions as well as the pharmacologic and interventional resources that are increasingly available to the treating cardiologist. This review explores and highlights the overlap between these 2 fields to recommend a parallel, yet interactive, multidisciplinary approach to clinical management. Congenital heart disease categories are broken down into their archetypal subtypes to highlight subtleties of the pathophysiology, evaluation, and therapeutic approach. CI - Published by Elsevier Inc. FAU - Moore, Jeremy P AU - Moore JP AD - Division of Cardiology, Department of Medicine, University of California Los Angeles (UCLA) Medical Center, Ahmanson/UCLA Adult Congenital Heart Disease Center, Los Angeles, California, USA; UCLA Cardiac Arrhythmia Center, UCLA Health System, David Geffen School of Medicine at UCLA, Los Angeles, California, USA; Division of Cardiology, Department of Pediatrics, UCLA Medical Center, Los Angeles, California, USA. Electronic address: jpmoore@mednet.ucla.edu. FAU - Marelli, Ariane AU - Marelli A AD - McGill Adult Unit for Congenital Heart Disease Excellence, Division of Cardiology, McGill University, Montreal, Quebec, Canada. FAU - Burchill, Luke J AU - Burchill LJ AD - Department of Cardiovascular Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota, USA; Department of Medicine, Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, Australia. FAU - Chubb, Henry AU - Chubb H AD - Division of Pediatric Cardiology, Department of Pediatrics, Stanford University, Stanford, California, USA. FAU - Roche, S Lucy AU - Roche SL AD - Division of Cardiology, Peter Munk Cardiac Centre, University Health Network and University of Toronto, Toronto, Ontario, Canada. FAU - Cedars, Ari M AU - Cedars AM AD - Department of Internal Medicine and Pediatrics, Johns Hopkins University, Baltimore, Maryland, USA. FAU - Khairy, Paul AU - Khairy P AD - Montreal Heart Institute, Universite de Montreal, Montreal, Quebec, Canada. FAU - Zaidi, Ali N AU - Zaidi AN AD - Mount Sinai Adult Congenital Heart Disease Center, Mount Sinai Cardiovascular Institute and The Children's Heart Center, Mount Sinai Kravis Children's Hospital, New York, New York, USA. FAU - Janousek, Jan AU - Janousek J AD - Children's Heart Centre, 2nd Faculty of Medicine Charles University in Prague and Motol University Hospital, Prague, Czech Republic. FAU - Crossland, David S AU - Crossland DS AD - Freeman Hospital Cardiothoracic Centre, Newcastle upon Tyne, Tyne and Wear, United Kingdom. FAU - Pass, Robert H AU - Pass RH AD - Division of Pediatric Cardiology and Pediatric Critical Care Medicine, Department of Pediatrics, Icahn School of Medicine at Mount Sinai and Kravis Children's Hospital at Mount Sinai, Mount Sinai Medical Center, New York, New York, USA. FAU - Jacobs, Jeffrey P AU - Jacobs JP AD - Division of Cardiovascular Surgery, Departments of Surgery and Pediatrics, University of Florida, Gainesville, Florida, USA. FAU - Menachem, Jonathan N AU - Menachem JN AD - Vanderbilt University Medical Center, Nashville, Tennessee, USA. FAU - Frankel, David S AU - Frankel DS AD - Cardiovascular Division, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA. FAU - Ernst, Sabine AU - Ernst S AD - Department of Cardiology, Royal Brompton and Harefield Hospital, Royal Brompton and Harefield NHS Trust, Imperial College London, London, United Kingdom. FAU - Vehmeijer, Jim T AU - Vehmeijer JT AD - Department of Cardiology, Heart Center, Amsterdam University Medical Centers/University of Amsterdam, Amsterdam, the Netherlands. FAU - Cohen, Mitchell I AU - Cohen MI AD - Division of Cardiology, Inova Children's Hospital, Fairfax, Virginia, USA. LA - eng PT - Journal Article PT - Review PL - United States TA - J Am Coll Cardiol JT - Journal of the American College of Cardiology JID - 8301365 SB - IM MH - Adult MH - Humans MH - Arrhythmias, Cardiac/etiology/therapy MH - *Heart Defects, Congenital/complications/therapy MH - *Heart Failure/complications/therapy MH - *Cardiology MH - *Cardiologists OTO - NOTNLM OT - adults with congenital heart disease OT - arrhythmia OT - heart failure COIS- Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2022/12/02 06:00 MHDA- 2022/12/06 06:00 CRDT- 2022/12/01 21:03 PHST- 2022/08/29 00:00 [received] PHST- 2022/09/08 00:00 [accepted] PHST- 2022/12/01 21:03 [entrez] PHST- 2022/12/02 06:00 [pubmed] PHST- 2022/12/06 06:00 [medline] AID - S0735-1097(22)07033-4 [pii] AID - 10.1016/j.jacc.2022.09.038 [doi] PST - ppublish SO - J Am Coll Cardiol. 2022 Dec 6;80(23):2224-2238. doi: 10.1016/j.jacc.2022.09.038. PMID- 36456006 OWN - NLM STAT- MEDLINE DCOM- 20221205 LR - 20240908 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 12 IP - 12 DP - 2022 Dec 1 TI - Effect of a standardised heart team protocol versus a guideline-based protocol on revascularisation decision stability in stable complex coronary artery disease: rationale and design of a randomised trial of cardiology specialists using historic cases. PG - e064761 LID - 10.1136/bmjopen-2022-064761 [doi] LID - e064761 AB - INTRODUCTION: A multidisciplinary heart team approach has been recommended by revascularisation guidelines, but how to organise and implement the heart team in a standardised way has not been validated. Inter-team and intra-team decision instability existed in the guideline-based heart team protocol, and our standardised heart team protocol based on a mixed method study may improve decision stability. The objective of this study is to evaluate the effect of the standardised heart team protocol versus the guideline-based protocol on decision-making stability in stable complex coronary artery disease (CAD). METHODS AND ANALYSIS: Eighty-four eligible interventional cardiologists, cardiac surgeons or non-interventional cardiologists from 26 hospitals in China have been enrolled. They will be randomised to a standardised heart team protocol group or a guideline-based protocol group to make revascularisation decisions for 480 historic cases (from a prospective registry) with stable complex CAD. In the standardised group, we will establish 12 heart teams based on an evidence-based protocol, including specialist selection, specialist training, team composition, team training and a standardised meeting process. In the guideline-based group, we will organise 12 heart teams according to the guideline principles, including team composition and standardised meeting process. The primary outcome is the overall percent agreement in revascularisation decisions between heart teams within a group. To demonstrate the clinical implication of decision-making stability, we will further explore the association between decision stability and 1-year clinical outcomes. ETHICS AND DISSEMINATION: The study was approved by the Institutional Review Board (IRB) of Fuwai Hospital (No. 2019-1303). All participants have provided informed consent and all patients included as historic cases provided written informed consent at the time of entry to the prospective registry. The results of this trial will be disseminated through manuscript publication and national/international conferences, and reported in the trial registry entry. TRIAL REGISTRATION NUMBER: NCT05039567. CI - (c) Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Ma, Hanping AU - Ma H AUID- ORCID: 0000-0002-9465-1060 AD - National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China. FAU - Lin, Shen AU - Lin S AD - National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China. AD - Department of Cardiovascular Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China. FAU - Li, Xi AU - Li X AUID- ORCID: 0000-0003-2249-688X AD - National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China. AD - Central China Sub-center of the National Center for Cardiovascular Diseases, Zhengzhou, People's Republic of China. FAU - Wang, Yang AU - Wang Y AD - Medical Research and Biometrics Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China. FAU - Xu, Bo AU - Xu B AD - Catheterization Laboratories, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China. FAU - Zheng, Zhe AU - Zheng Z AUID- ORCID: 0000-0002-9162-6492 AD - National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China zhengzhe@fuwai.com. AD - Department of Cardiovascular Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China. AD - National Health Commission Key Laboratory of Cardiovascular Regenerative Medicine, Fuwai Central-China Hospital, Central-China Branch of National Center for Cardiovascular Diseases, Zhengzhou, People's Republic of China. LA - eng SI - ClinicalTrials.gov/NCT05039567 PT - Clinical Trial Protocol PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20221201 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 SB - IM MH - Humans MH - *Coronary Artery Disease/surgery MH - Heart MH - *Cardiovascular System MH - *Cardiology MH - Vascular Surgical Procedures MH - Randomized Controlled Trials as Topic PMC - PMC9716884 OTO - NOTNLM OT - coronary heart disease OT - coronary intervention OT - protocols & guidelines COIS- Competing interests: None declared. EDAT- 2022/12/02 06:00 MHDA- 2022/12/06 06:00 PMCR- 2022/12/01 CRDT- 2022/12/01 20:53 PHST- 2022/12/01 20:53 [entrez] PHST- 2022/12/02 06:00 [pubmed] PHST- 2022/12/06 06:00 [medline] PHST- 2022/12/01 00:00 [pmc-release] AID - bmjopen-2022-064761 [pii] AID - 10.1136/bmjopen-2022-064761 [doi] PST - epublish SO - BMJ Open. 2022 Dec 1;12(12):e064761. doi: 10.1136/bmjopen-2022-064761. PMID- 39790549 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250111 IS - 2772-9931 (Electronic) IS - 2772-9931 (Linking) VI - 1 IP - 1 DP - 2023 Mar TI - Results of a Multimodal Approach for the Launch of a Ross Program. PG - 210-213 LID - 10.1016/j.atssr.2022.11.015 [doi] AB - BACKGROUND: There has been renewed interest in the Ross procedure in young patients with aortic valve disease. We describe the details and results of a systematic strategy to launch a new Ross program. METHODS: Our department developed a multidisciplinary educational program that involved all practitioners involved in the care of potential Ross patients. A core group of surgeons underwent extensive hands-on technical preparation. Selection of patients was reviewed by a multidisciplinary team. Patient characteristics, operative details, and postoperative outcomes were analyzed. RESULTS: Between March 2021 and March 2022, 22 consecutive patients underwent Ross procedure at our institution. The mean age of the patients at time of operation was 40.4 +/- 10.2 years, and most patients had no medical comorbidities (12/22). The most common indication for operation was aortic stenosis (13/22), followed by mixed aortic stenosis and aortic insufficiency (7/22). There were no deaths. Postoperatively, no patient required blood transfusion or reexploration for hemorrhage. All patients were discharged home on mean hospital day 5.9 +/- 1.1. On predischarge echocardiography, there was a significant reduction in mean aortic gradients preoperatively to postoperatively (49 +/- 20 mm Hg vs 4 +/- 1 mm Hg; P < .01) without aortic insufficiency or a change in left or right ventricular function. CONCLUSIONS: We demonstrate that with multidisciplinary education and extensive hands-on surgical preparation under proctored supervision, a Ross program can be initiated safely with excellent short-term results and perioperative risk that mimics that of conventional surgical aortic valve replacement. CI - (c) 2022 Published by Elsevier Inc. on behalf of The Society of Thoracic Surgeons. FAU - Ibrahim, Michael E AU - Ibrahim ME AD - Division of Cardiovascular Surgery, University of Pennsylvania, Philadelphia, Pennsylvania. FAU - Lawrence, Kendall M AU - Lawrence KM AD - Division of Cardiovascular Surgery, University of Pennsylvania, Philadelphia, Pennsylvania. FAU - Bavaria, Joseph E AU - Bavaria JE AD - Division of Cardiovascular Surgery, University of Pennsylvania, Philadelphia, Pennsylvania. FAU - Grimm, Joshua AU - Grimm J AD - Division of Cardiovascular Surgery, University of Pennsylvania, Philadelphia, Pennsylvania. FAU - Acker, Michael AU - Acker M AD - Division of Cardiovascular Surgery, University of Pennsylvania, Philadelphia, Pennsylvania. FAU - El-Hamamsy, Ismail AU - El-Hamamsy I AD - Department of Cardiovascular Surgery, Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, New York. FAU - Szeto, Wilson Y AU - Szeto WY AD - Division of Cardiovascular Surgery, University of Pennsylvania, Philadelphia, Pennsylvania. FAU - Desai, Nimesh AU - Desai N AD - Division of Cardiovascular Surgery, University of Pennsylvania, Philadelphia, Pennsylvania. LA - eng PT - Journal Article DEP - 20221201 PL - United States TA - Ann Thorac Surg Short Rep JT - Annals of thoracic surgery short reports JID - 9918506088006676 PMC - PMC11708624 EDAT- 2022/12/01 00:00 MHDA- 2022/12/01 00:01 PMCR- 2022/12/01 CRDT- 2025/01/10 04:19 PHST- 2022/11/21 00:00 [accepted] PHST- 2022/12/01 00:01 [medline] PHST- 2022/12/01 00:00 [pubmed] PHST- 2025/01/10 04:19 [entrez] PHST- 2022/12/01 00:00 [pmc-release] AID - S2772-9931(22)00060-2 [pii] AID - 10.1016/j.atssr.2022.11.015 [doi] PST - epublish SO - Ann Thorac Surg Short Rep. 2022 Dec 1;1(1):210-213. doi: 10.1016/j.atssr.2022.11.015. eCollection 2023 Mar. PMID- 36448467 OWN - NLM STAT- MEDLINE DCOM- 20230105 LR - 20230111 IS - 1540-8191 (Electronic) IS - 0886-0440 (Linking) VI - 37 IP - 12 DP - 2022 Dec TI - Multicenter experience with valve-in-valve transcatheter aortic valve replacement compared with primary, native valve transcatheter aortic valve replacement. PG - 4382-4388 LID - 10.1111/jocs.17084 [doi] AB - BACKGROUND: Valve-in-valve (ViV) transcatheter aortic valve replacement (TAVR) offers an alternative to reoperative surgical aortic valve replacement. The short- and intermediate-term outcomes after ViV TAVR in the real world are not entirely clear. PATIENTS AND METHODS: A multicenter, retrospective analysis of a consecutive series of 121 ViV TAVR patients and 2200 patients undergoing primary native valve TAVR from 2012 to 2017 at six medical centers. The main outcome measures were in-hospital mortality, 30-day mortality, stroke, myocardial infarction, acute kidney injury, and pacemaker implantation. RESULTS: ViV patients were more likely male, younger, prior coronary artery bypass graft, "hostile chest," and urgent. 30% of the patients had Society of Thoracic Surgeons risk score <4%, 36.3% were 4%-8% and 33.8% were >8%. In both groups many patients had concomitant coronary artery disease. Median time to prosthetic failure was 9.6 years (interquartile range: 5.5-13.5 years). 82% of failed surgical valves were size 21, 23, or 25 mm. Access was 91% femoral. After ViV, 87% had none or trivial aortic regurgitation. Mean gradients were <20 mmHg in 54.6%, 20-29 mmHg in 30.6%, 30-39 mmHg in 8.3% and >/=40 mmHg in 5.87%. Median length of stay was 4 days. In-hospital mortality was 0%. 30-day mortality was 0% in ViV and 3.7% in native TAVR. There was no difference in in-hospital mortality, postprocedure myocardial infarction, stroke, or acute kidney injury. CONCLUSION: Compared to native TAVR, ViV TAVR has similar peri-procedural morbidity with relatively high postprocedure mean gradients. A multidisciplinary approach will help ensure patients receive the ideal therapy in the setting of structural bioprosthetic valve degeneration. CI - (c) 2022 Wiley Periodicals LLC. FAU - Robich, Michael P AU - Robich MP AD - Department of Surgery and Medicine, Cardiovascular Institute, Maine Medical Center, Portland, Maine, USA. FAU - Iribarne, Alexander AU - Iribarne A AD - Department of Surgery, Section of Cardiac Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA. FAU - Butzel, David AU - Butzel D AD - Department of Surgery and Medicine, Cardiovascular Institute, Maine Medical Center, Portland, Maine, USA. FAU - DiScipio, Anthony W AU - DiScipio AW AD - Department of Surgery, Section of Cardiac Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA. FAU - Dauerman, Harold L AU - Dauerman HL AD - Department of Medicine, Section of Cardiology, University of Vermont Medical Center, Burlington, Vermont, USA. FAU - Leavitt, Bruce J AU - Leavitt BJ AD - Department of Surgery, Section of Cardiac Surgery, University of Vermont Medical Center, Burlington, Vermont, USA. FAU - DeSimone, Joseph P AU - DeSimone JP AD - Department of Surgery, Section of Cardiac Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA. FAU - Coylewright, Megan AU - Coylewright M AD - Department of Internal Medicine, Section of Cardiovascular Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA. FAU - Flynn, James M AU - Flynn JM AD - New England Heart Institute, Catholic Medical Center, Manchester, New Hampshire, USA. FAU - Westbrook, Benjamin M AU - Westbrook BM AD - New England Heart Institute, Catholic Medical Center, Manchester, New Hampshire, USA. FAU - Ver Lee, Peter N AU - Ver Lee PN AD - Northern Light Cardiology, Northern Light Eastern Maine Medical Center, Bangor, Maine, USA. FAU - Zaky, Mina AU - Zaky M AD - Tufts University School of Medicine, Boston, Massachusetts, USA. FAU - Quinn, Reed AU - Quinn R AD - Department of Surgery and Medicine, Cardiovascular Institute, Maine Medical Center, Portland, Maine, USA. FAU - Malenka, David J AU - Malenka DJ AD - Department of Internal Medicine, Section of Cardiovascular Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA. LA - eng GR - The member centers of the Northern New England Cardiovascular Disease Study Group/ PT - Journal Article PT - Multicenter Study DEP - 20221130 PL - United States TA - J Card Surg JT - Journal of cardiac surgery JID - 8908809 SB - IM CIN - J Card Surg. 2022 Dec;37(12):4389-4390. doi: 10.1111/jocs.17083. PMID: 36321723 MH - Humans MH - Male MH - *Transcatheter Aortic Valve Replacement/methods MH - Retrospective Studies MH - *Aortic Valve Stenosis/etiology MH - Treatment Outcome MH - *Bioprosthesis/adverse effects MH - Aortic Valve/surgery MH - *Heart Valve Prosthesis Implantation/methods MH - *Heart Valve Prosthesis MH - Risk Factors OTO - NOTNLM OT - aortic valve replacement OT - cardiac catheterization/intervention OT - heart valve replacement OT - percutaneous OT - transapical OT - transcatheter EDAT- 2022/12/01 06:00 MHDA- 2023/01/06 06:00 CRDT- 2022/11/30 05:12 PHST- 2022/06/01 00:00 [received] PHST- 2022/08/31 00:00 [accepted] PHST- 2022/12/01 06:00 [pubmed] PHST- 2023/01/06 06:00 [medline] PHST- 2022/11/30 05:12 [entrez] AID - 10.1111/jocs.17084 [doi] PST - ppublish SO - J Card Surg. 2022 Dec;37(12):4382-4388. doi: 10.1111/jocs.17084. Epub 2022 Nov 30. PMID- 36447936 OWN - NLM STAT- MEDLINE DCOM- 20221201 LR - 20221202 IS - 1540-8183 (Electronic) IS - 0896-4327 (Print) IS - 0896-4327 (Linking) VI - 2022 DP - 2022 TI - Prophylactic Impella CP versus VA-ECMO in Patients Undergoing Complex High-Risk Indicated PCI. PG - 8167011 LID - 10.1155/2022/8167011 [doi] LID - 8167011 AB - OBJECTIVES: To compare two different forms of mechanical circulatory support (MCS) in patients with complex high-risk indicated PCI (CHIP): the Impella CP system and veno-arterial extracorporeal membrane oxygenation (VA-ECMO). BACKGROUND: To prevent hemodynamic instability in CHIP, various MCS systems are available. However, comparable data on different forms of MCS are not at hand. METHODS: In this multicenter observational study, we retrospectively evaluated all CHIP procedures with the support of an Impella CP or VA-ECMO, who were declined surgery by the heart team. Major adverse cardiac events (MACE), mortality at discharge, and 30-day mortality were evaluated. RESULTS: A total of 41 patients were included, of which 27 patients were supported with Impella CP and 14 patients with VA-ECMO. Baseline characteristics were well-balanced in both groups. No significant difference in periprocedural hemodynamic instability was observed between both groups (3.7% vs. 14.3%; p = 0.22). The composite outcome of MACE showed no significant difference (30.7% vs. 21.4%; p = 0.59). Bleeding complications were higher in the Impella CP group, but showed no significant difference (22.2% vs. 7.1%; p = 0.22) and occurred more at the non-Impella access site. In-hospital mortality was 7.4% in the Impella CP group versus 14.3% in the VA-ECMO group and showed no significant difference (p = 0.48). 30-Day mortality showed no significant difference (7.4% vs. 21.4%; p = 0.09). CONCLUSIONS: In patients with CHIP, there were no significant differences in hemodynamic instability and overall MACE between VA-ECMO or Impella CP device as mechanical circulatory support. Based on this study, the choice of either VA-ECMO or Impella CP does not alter the outcome. CI - Copyright (c) 2022 Deborah M.F. van den Buijs et al. FAU - van den Buijs, Deborah M F AU - van den Buijs DMF AUID- ORCID: 0000-0002-1613-5829 AD - Amsterdam Universitair Medisch Centrum, Vrije Universiteit Medisch Centrum, Amsterdam, Netherlands. AD - Ziekenhuis Oost-Limburg, Genk, Belgium. FAU - Wilgenhof, Adriaan AU - Wilgenhof A AUID- ORCID: 0000-0002-3263-7394 AD - Ziekenhuis Netwerk Antwerpen Middelheim, Antwerpen, Belgium. FAU - Knaapen, Paul AU - Knaapen P AUID- ORCID: 0000-0001-8038-7898 AD - Amsterdam Universitair Medisch Centrum, Vrije Universiteit Medisch Centrum, Amsterdam, Netherlands. FAU - Zivelonghi, Carlo AU - Zivelonghi C AUID- ORCID: 0000-0001-9825-6589 AD - Ziekenhuis Netwerk Antwerpen Middelheim, Antwerpen, Belgium. FAU - Meijers, Tom AU - Meijers T AUID- ORCID: 0000-0002-4298-1607 AD - Isala Ziekenhuis, Zwolle, Netherlands. FAU - Vermeersch, Paul AU - Vermeersch P AUID- ORCID: 0000-0002-3290-3453 AD - Ziekenhuis Netwerk Antwerpen Middelheim, Antwerpen, Belgium. FAU - Arslan, Fatih AU - Arslan F AUID- ORCID: 0000-0001-6598-8599 AD - Vivantes Netzwerk fur Gesundheit GmbH, Klinikum am Urban Berlin, Germany (present Leids Universitair Medisch Centrum), Leiden, Netherlands. FAU - Verouden, Niels AU - Verouden N AD - Amsterdam Universitair Medisch Centrum, Vrije Universiteit Medisch Centrum, Amsterdam, Netherlands. FAU - Nap, Alex AU - Nap A AUID- ORCID: 0000-0001-9184-3561 AD - Amsterdam Universitair Medisch Centrum, Vrije Universiteit Medisch Centrum, Amsterdam, Netherlands. FAU - Sjauw, Krischan AU - Sjauw K AUID- ORCID: 0000-0001-8354-8511 AD - Medisch Centrum Leeuwarden, Leeuwarden, Netherlands. FAU - van den Brink, Floris S AU - van den Brink FS AUID- ORCID: 0000-0003-4998-4373 AD - Leids Universitair Medisch Centrum, Leiden, Netherlands. LA - eng PT - Journal Article PT - Multicenter Study PT - Observational Study DEP - 20221107 PL - United States TA - J Interv Cardiol JT - Journal of interventional cardiology JID - 8907826 SB - IM MH - Humans MH - *Extracorporeal Membrane Oxygenation MH - *Percutaneous Coronary Intervention MH - Retrospective Studies MH - Hospital Mortality MH - Hand MH - *Vascular Diseases PMC - PMC9663242 COIS- The authors declare that they have no conflicts of interest. EDAT- 2022/12/01 06:00 MHDA- 2022/12/02 06:00 PMCR- 2022/11/07 CRDT- 2022/11/30 02:01 PHST- 2022/07/19 00:00 [received] PHST- 2022/10/20 00:00 [revised] PHST- 2022/10/31 00:00 [accepted] PHST- 2022/11/30 02:01 [entrez] PHST- 2022/12/01 06:00 [pubmed] PHST- 2022/12/02 06:00 [medline] PHST- 2022/11/07 00:00 [pmc-release] AID - 10.1155/2022/8167011 [doi] PST - epublish SO - J Interv Cardiol. 2022 Nov 7;2022:8167011. doi: 10.1155/2022/8167011. eCollection 2022. PMID- 36446625 OWN - NLM STAT- MEDLINE DCOM- 20230313 LR - 20230313 IS - 1439-1902 (Electronic) IS - 0171-6425 (Linking) VI - 71 IP - 2 DP - 2023 Mar TI - Valve-Related Complications in TAVI Leading to Emergent Cardiac Surgery. PG - 107-117 LID - 10.1055/s-0042-1758073 [doi] AB - Transcatheter aortic valve implantation (TAVI) is now a standard procedure for the treatment of symptomatic aortic valve stenosis in many patients. In Germany, according to the annual reports from the German Institute for Quality Assurance and Transparency in Healthcare (Institut fur Qualitatssicherung und Transparenz im Gesundheitswesen), the rate of serious intraprocedural complications, such as valve malpositioning or embolization, coronary obstruction, aortic dissection, annular rupture, pericardial tamponade, or severe aortic regurgitation requiring emergency cardiac surgery has decreased markedly in recent years from more than 5.5% in 2012 to 2.0% in 2019. However, with increased use, the total number of adverse events remains about 500 per year, about 100 of which require conversion to sternotomy. These, sometimes, fatal events can occur at any time and are still challenging. Therefore, the interdisciplinary TAVI heart team should be prepared and aware of possible rescue strategies. CI - Thieme. All rights reserved. FAU - Conzelmann, Lars AU - Conzelmann L AD - Department of Cardiac Surgery, HELIOS Clinic for Cardiac Surgery Karlsruhe, Karlsruhe, Germany. FAU - Grotherr, Philipp AU - Grotherr P AD - Department of Cardiology, Medical Clinic IV, Municipal Hospital Karlsruhe, Karlsruhe, Germany. FAU - Dapeng, Lu AU - Dapeng L AD - Department of Cardiology, Intensive Care Medicine and Angiology, Vincentius-Diakonissen Hospital Karlsruhe, Karlsruhe, Germany. FAU - Wurth, Alexander AU - Wurth A AD - Department of Cardiology, Medical Clinic IV, Municipal Hospital Karlsruhe, Karlsruhe, Germany. FAU - Widder, Julian AU - Widder J AD - Department of Cardiology, Medical Clinic IV, Municipal Hospital Karlsruhe, Karlsruhe, Germany. FAU - Jacobshagen, Claudius AU - Jacobshagen C AD - Department of Cardiology, Intensive Care Medicine and Angiology, Vincentius-Diakonissen Hospital Karlsruhe, Karlsruhe, Germany. FAU - Mehlhorn, Uwe AU - Mehlhorn U AD - Department of Cardiac Surgery, HELIOS Clinic for Cardiac Surgery Karlsruhe, Karlsruhe, Germany. LA - eng PT - Journal Article DEP - 20221129 PL - Germany TA - Thorac Cardiovasc Surg JT - The Thoracic and cardiovascular surgeon JID - 7903387 SB - IM MH - Humans MH - *Transcatheter Aortic Valve Replacement/adverse effects MH - *Aortic Valve Stenosis/diagnostic imaging/surgery MH - Treatment Outcome MH - Aortic Valve/diagnostic imaging/surgery MH - *Thoracic Surgery MH - *Heart Valve Prosthesis MH - *Heart Valve Prosthesis Implantation/adverse effects COIS- None declared. EDAT- 2022/11/30 06:00 MHDA- 2023/03/14 06:00 CRDT- 2022/11/29 21:45 PHST- 2022/11/30 06:00 [pubmed] PHST- 2023/03/14 06:00 [medline] PHST- 2022/11/29 21:45 [entrez] AID - 10.1055/s-0042-1758073 [doi] PST - ppublish SO - Thorac Cardiovasc Surg. 2023 Mar;71(2):107-117. doi: 10.1055/s-0042-1758073. Epub 2022 Nov 29. PMID- 36444365 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221202 IS - 2589-790X (Electronic) IS - 2589-790X (Linking) VI - 4 IP - 11 DP - 2022 Nov TI - Extended Myectomy for Hypertrophic Cardiomyopathy: Early Outcomes From a Nascent Centre of Excellence in Canada. PG - 921-928 LID - 10.1016/j.cjco.2022.06.012 [doi] AB - Hypertrophic cardiomyopathy (HCM) is one of the commonest inherited cardiac abnormalities. The disorder is clinically and genetically heterogeneous and is characterized by left ventricular wall thickening that is not explained by abnormal loading conditions. HCM is estimated to affect between 1 in 200 and 1 in 500 people in the general population. In the majority of cases, HCM patients have a relatively benign course; however, if left untreated, this abnormality can lead to sudden cardiac death, especially in young adults and athletes. Therefore, early diagnosis is crucial to help implement the proper management for patients with HCM. In response to the growing need for more HCM centres of excellence in Canada, we developed one such centre at the University of Ottawa Heart Institute from the start of 2018. This centre will help in the early diagnosis and management of HCM patients, especially those with left ventricular outflow tract obstruction who might benefit from myectomy surgery. This paper describes our early experience with surgical myectomy in adult HCM patients between January 2018 and December 2020. We report the results of 27 patients with HCM who underwent myectomy surgery during the study period. All 27 patients survived to discharge, and all were still alive at 6 months postdischarge. Our experience highlights the crucial role that preoperative and perioperative imaging play in the management of this condition, in addition to the vital role of having a committed "heart team" of cardiologists, surgeons, and anesthesiologists. CI - (c) 2022 The Authors. FAU - Crean, Andrew M AU - Crean AM AD - Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada. FAU - Gharibeh, Lara AU - Gharibeh L AD - Division of Cardiac Surgery, University of Ottawa Heart Institute, Ottawa, Ontario, Canada. AD - Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada. FAU - Saleem, Zain AU - Saleem Z AD - Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada. FAU - Glineur, David AU - Glineur D AD - Division of Cardiac Surgery, University of Ottawa Heart Institute, Ottawa, Ontario, Canada. FAU - Maharaj, Gyaandeo AU - Maharaj G AD - Division of Cardiovascular Surgery, Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada. FAU - Grau, Juan B AU - Grau JB AD - Division of Cardiac Surgery, University of Ottawa Heart Institute, Ottawa, Ontario, Canada. AD - Division of Cardiothoracic Surgery, The Valley Hospital, Ridgewood, New Jersey, USA. LA - eng PT - Journal Article DEP - 20220805 PL - United States TA - CJC Open JT - CJC open JID - 101763635 PMC - PMC9700218 EDAT- 2022/11/30 06:00 MHDA- 2022/11/30 06:01 PMCR- 2022/08/05 CRDT- 2022/11/29 01:51 PHST- 2022/03/28 00:00 [received] PHST- 2022/06/21 00:00 [accepted] PHST- 2022/11/29 01:51 [entrez] PHST- 2022/11/30 06:00 [pubmed] PHST- 2022/11/30 06:01 [medline] PHST- 2022/08/05 00:00 [pmc-release] AID - S2589-790X(22)00137-8 [pii] AID - 10.1016/j.cjco.2022.06.012 [doi] PST - epublish SO - CJC Open. 2022 Aug 5;4(11):921-928. doi: 10.1016/j.cjco.2022.06.012. eCollection 2022 Nov. PMID- 36442889 OWN - NLM STAT- MEDLINE DCOM- 20240724 LR - 20240801 IS - 2633-3775 (Electronic) IS - 2633-3767 (Print) IS - 2633-3767 (Linking) VI - 170 IP - 4 DP - 2024 Jul 24 TI - Cardiopulmonary exercise testing excludes significant disease in patients recovering from COVID-19. PG - 308-314 LID - 10.1136/military-2022-002193 [doi] AB - OBJECTIVE: Post-COVID-19 syndrome presents a health and economic challenge affecting ~10% of patients recovering from COVID-19. Accurate assessment of patients with post-COVID-19 syndrome is complicated by health anxiety and coincident symptomatic autonomic dysfunction. We sought to determine whether either symptoms or objective cardiopulmonary exercise testing could predict clinically significant findings. METHODS: 113 consecutive military patients were assessed in a comprehensive clinical pathway. This included symptom reporting, history, examination, spirometry, echocardiography and cardiopulmonary exercise testing (CPET) in all, with chest CT, dual-energy CT pulmonary angiography and cardiac MRI where indicated. Symptoms, CPET findings and presence/absence of significant pathology were reviewed. Data were analysed to identify diagnostic strategies that may be used to exclude significant disease. RESULTS: 7/113 (6%) patients had clinically significant disease adjudicated by cardiothoracic multidisciplinary team (MDT). These patients had reduced fitness (V̇O(2) 26.7 (+/-5.1) vs 34.6 (+/-7.0) mL/kg/min; p=0.002) and functional capacity (peak power 200 (+/-36) vs 247 (+/-55) W; p=0.026) compared with those without significant disease. Simple CPET criteria (oxygen uptake (V̇O(2)) >100% predicted and minute ventilation (VE)/carbon dioxide elimination (V̇CO(2)) slope <30.0 or VE/V̇CO(2) slope <35.0 in isolation) excluded significant disease with sensitivity and specificity of 86% and 83%, respectively (area under the receiver operating characteristic curve (AUC) 0.89). The addition of capillary blood gases to estimate alveolar-arterial gradient improved diagnostic performance to 100% sensitivity and 78% specificity (AUC 0.92). Symptoms and spirometry did not discriminate significant disease. CONCLUSIONS: In a population recovering from SARS-CoV-2, there is reassuringly little organ pathology. CPET and functional capacity testing, but not reported symptoms, permit the exclusion of clinically significant disease. CI - (c) Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY. Published by BMJ. FAU - Holdsworth, D A AU - Holdsworth DA AUID- ORCID: 0000-0003-2465-1521 AD - Oxford University Hospitals NHS Foundation Trust, Oxford, UK david.holdsworth@ouh.nhs.uk. AD - Royal Centre for Defence Medicine, Birmingham, UK. FAU - Barker-Davies, R M AU - Barker-Davies RM AD - Academic Department of Military Rehabilitation, Defence Medical Rehabilitation Centre, Loughborough, UK. FAU - Chamley, R R AU - Chamley RR AD - Oxford University Hospitals NHS Foundation Trust, Oxford, UK. AD - Oxford Centre for Clincal Magnetic Resonance Research, University of Oxford, Oxford, UK. FAU - O'Sullivan, O AU - O'Sullivan O AD - Academic Department of Military Rehabilitation, Defence Medical Rehabilitation Centre, Loughborough, UK. FAU - Ladlow, P AU - Ladlow P AD - Academic Department of Military Rehabilitation, Defence Medical Rehabilitation Centre, Loughborough, UK. FAU - May, S AU - May S AD - Defence Medical Rehabilitation Centre Stanford Hall, Loughborough, UK. FAU - Houston, A D AU - Houston AD AUID- ORCID: 0000-0001-9973-3818 AD - Academic Department of Military Rehabilitation, Defence Medical Services, Loughborough, UK. FAU - Mulae, J AU - Mulae J AD - Royal Centre for Defence Medicine, Birmingham, UK. FAU - Xie, C AU - Xie C AD - Oxford University Hospitals NHS Foundation Trust, Oxford, UK. FAU - Cranley, M AU - Cranley M AD - Defence Medical Rehabilitation Centre Stanford Hall, Loughborough, UK. FAU - Sellon, E AU - Sellon E AD - Oxford University Hospitals NHS Foundation Trust, Oxford, UK. AD - Royal Centre for Defence Medicine, Birmingham, UK. FAU - Naylor, J AU - Naylor J AD - Royal Centre for Defence Medicine, Birmingham, UK. FAU - Halle, M AU - Halle M AD - Klinikum rechts der Isar der Technischen Universitat Munchen, Munchen, Germany. FAU - Parati, G AU - Parati G AD - Universita degli Studi di Milano-Bicocca, Milano, Italy. FAU - Davos, C AU - Davos C AD - Academy of Athens Biomedical Research Foundation, Athens, Greece. FAU - Rider, O J AU - Rider OJ AD - Oxford University Hospitals NHS Foundation Trust, Oxford, UK. AD - Oxford Centre for Clincal Magnetic Resonance Research, University of Oxford, Oxford, UK. FAU - Bennett, A B AU - Bennett AB AD - Academic Department of Military Rehabilitation, Defence Medical Rehabilitation Centre, Loughborough, UK. AD - Defence Medical Rehabilitation Centre Stanford Hall, Loughborough, UK. FAU - Nicol, E D AU - Nicol ED AD - School of Biomedical Engineering and Imaging Sciences, King's College, London, UK. LA - eng PT - Journal Article DEP - 20240724 PL - England TA - BMJ Mil Health JT - BMJ military health JID - 101761581 SB - IM MH - Humans MH - *COVID-19/complications/physiopathology/diagnosis MH - Male MH - *Exercise Test/methods/statistics & numerical data MH - Female MH - Adult MH - Middle Aged MH - SARS-CoV-2 MH - Military Personnel/statistics & numerical data MH - Post-Acute COVID-19 Syndrome PMC - PMC11287624 OTO - NOTNLM OT - COVID-19 OT - Respiratory physiology OT - adult cardiology OT - rehabilitation medicine COIS- Competing interests: None declared. EDAT- 2022/11/29 06:00 MHDA- 2024/07/26 12:36 PMCR- 2024/07/30 CRDT- 2022/11/28 20:43 PHST- 2022/06/30 00:00 [received] PHST- 2022/09/19 00:00 [accepted] PHST- 2024/07/26 12:36 [medline] PHST- 2022/11/29 06:00 [pubmed] PHST- 2022/11/28 20:43 [entrez] PHST- 2024/07/30 00:00 [pmc-release] AID - military-2022-002193 [pii] AID - 10.1136/military-2022-002193 [doi] PST - epublish SO - BMJ Mil Health. 2024 Jul 24;170(4):308-314. doi: 10.1136/military-2022-002193. PMID- 36441043 OWN - NLM STAT- MEDLINE DCOM- 20221227 LR - 20230209 IS - 1873-5894 (Electronic) IS - 0730-725X (Linking) VI - 96 DP - 2023 Feb TI - An algorithm for pacing and cardioverting electronic devices undergoing magnetic resonance imaging: The PACED-MRI protocol. PG - 44-49 LID - S0730-725X(22)00193-X [pii] LID - 10.1016/j.mri.2022.10.012 [doi] AB - OBJECTIVE: Cardiac implantable electronic devices (CIEDs) have traditionally been a contraindication for magnetic resonance imaging (MRI). However, there is an increasing amount of literature to suggest that MRI can be safely performed in select patients with pacemakers and implantable cardioverter defibrillators by following a standardized protocol. We created an institutional protocol, made accessible as an online form, that is primarily technologist-driven and does not require direct electrophysiologist supervision. The purpose of this study was to evaluate the PACEDMRI protocol for screening and completing MRI in patients with MR conditional CIEDs. SUBJECTS AND METHODS: After the implementation of our standardized PACED-MRI protocol, patients with MR conditional CIEDs who were referred for MRI were included in the study. On the day of the MRI, the device company representative utilized our protocol accessed through PACEDMRI.com. If all parameters and criteria within the protocol were met, the examination proceeded. The device representative programed the CIED to the appropriate mode for MRI as instructed by the PACED-MRI protocol. CIED interrogation was performed immediately before and after MRI. The on-call electrophysiology nurse practitioner was notified only if the protocol instructed the team to not proceed with MRI. CIED programming changes, malfunctions, and intraprocedural events were documented. Additionally, any adverse outcomes were recorded including peri-MRI symptom onset, arrhythmia, and death. RESULTS: One hundred thirty-eight MRI examinations were performed on patients with MR conditional CIEDs (100 pacemakers: 38 implantable cardiac defibrillators). There was no incidence of symptom onset requiring early termination of the MRI, death, or arrhythmic events during or after MRI. No significant changes in lead parameters, including sensing amplitudes, lead thresholds, or lead impedances were noted on post-MRI device interrogation. Out of the 138 completed MRIs, the on-call electrophysiology provider was notified on one, non-urgent occasion. CONCLUSION: The implementation of the standardized, technologists-driven PACED-MRI protocol allowed for a multidisciplinary approach to MRI for patients with MR conditional CIEDs. This study demonstrates that the PACED-MRI protocol can be used for patients with MR conditional CIEDs undergoing MRI without the need for direct electrophysiologist supervision. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Goodwin, Elliott AU - Goodwin E AD - Department of Cardiology, University of Tennessee Graduate School of Medicine, Knoxville, TN, USA. Electronic address: emgoodwin@utmck.edu. FAU - Fogelson, Benjamin AU - Fogelson B AD - Department of Cardiology, University of Tennessee Graduate School of Medicine, Knoxville, TN, USA. FAU - Cox, James W Jr AU - Cox JW Jr AD - Department of Cardiology, University of Tennessee Graduate School of Medicine, Knoxville, TN, USA. FAU - Mahlow, William J AU - Mahlow WJ AD - Department of Cardiology, University of Tennessee Graduate School of Medicine, Knoxville, TN, USA. LA - eng PT - Journal Article DEP - 20221027 PL - Netherlands TA - Magn Reson Imaging JT - Magnetic resonance imaging JID - 8214883 SB - IM MH - Humans MH - *Pacemaker, Artificial MH - Magnetic Resonance Imaging/methods MH - *Defibrillators, Implantable MH - Algorithms MH - Magnetic Resonance Spectroscopy OTO - NOTNLM OT - Cardiac implantable electronic device OT - Magnetic resonance imaging COIS- Declaration of Competing Interest The Authors declare that there are no conflicts of interest. EDAT- 2022/11/29 06:00 MHDA- 2022/12/28 06:00 CRDT- 2022/11/28 09:56 PHST- 2022/05/05 00:00 [received] PHST- 2022/10/18 00:00 [revised] PHST- 2022/10/23 00:00 [accepted] PHST- 2022/11/29 06:00 [pubmed] PHST- 2022/12/28 06:00 [medline] PHST- 2022/11/28 09:56 [entrez] AID - S0730-725X(22)00193-X [pii] AID - 10.1016/j.mri.2022.10.012 [doi] PST - ppublish SO - Magn Reson Imaging. 2023 Feb;96:44-49. doi: 10.1016/j.mri.2022.10.012. Epub 2022 Oct 27. PMID- 36436004 OWN - NLM STAT- MEDLINE DCOM- 20230403 LR - 20261010 IS - 1432-1971 (Electronic) IS - 0172-0643 (Linking) VI - 44 IP - 4 DP - 2023 Apr TI - Team Communication and Expectations Following Pediatric Cardiac Surgery: A Multi-Disciplinary Survey. PG - 908-914 LID - 10.1007/s00246-022-03059-9 [doi] AB - Patients and families desire an accurate understanding of the expected recovery following congenital cardiac surgery. Variation in knowledge and expectations within the care team may be under-recognized and impact communication and care delivery. Our objective was to assess knowledge of common postoperative milestones and perceived efficacy of communication with patients and families and within the care team. An 18-question survey measuring knowledge of expected milestones for recovery after four index operations and team communication in the postoperative period was distributed electronically to multidisciplinary care team members at 16 academic pediatric heart centers. Answers were compared to local median data for each respondent's heart center to assess accuracy and stratified by heart center role and years of experience. We obtained 874 responses with broad representation of disciplines. More than half of all respondent predictions (55.3%) did not match their local median data. Percent matching did not vary by care team role but improved with increasing experience (35.8% < 2 years vs. 46.4% > 10 years, p = 0.2133). Of all respondents, 62.7% expressed confidence discussing the anticipated postoperative course, 78.6% denoted confidence discussing postoperative complications, and 55.3% conveyed that not all members of their care team share a common expectation for typical postoperative recovery. Most respondents (94.6%) stated that increased knowledge of local data would positively impact communication. Confidence in communication exceeded accuracy in predicting the timing of postoperative milestones. Important variation in knowledge and expectations for postoperative recovery in pediatric cardiac surgery exists and may impact communication and clinical effectiveness. CI - (c) 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Bushnell, Julie AU - Bushnell J AD - Department of Pediatrics, University of California San Francisco School of Medicine, San Francisco, CA, USA. FAU - Connelly, Chloe AU - Connelly C AD - University of Cincinnati School of Medicine, Cincinnati Children's Hospital and James M. Anderson Center for Health Systems Excellence, Cincinnati, OH, USA. FAU - Algaze, Claudia A AU - Algaze CA AD - Department of Pediatrics, Stanford University School of Medicine, Palo Alto, CA, USA. FAU - Bailly, David K AU - Bailly DK AD - Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, UT, USA. FAU - Koth, Andrew AU - Koth A AD - Department of Pediatrics, University of Washington School of Medicine, Seattle, WA, USA. FAU - Mafla, Monica AU - Mafla M AD - Department of Pediatrics, Stanford University School of Medicine, Palo Alto, CA, USA. FAU - Presnell, Laura AU - Presnell L AD - Department of Pediatrics, Stanford University School of Medicine, Palo Alto, CA, USA. FAU - Shin, Andrew Y AU - Shin AY AD - Department of Pediatrics, Stanford University School of Medicine, Palo Alto, CA, USA. FAU - McCammond, Amy N AU - McCammond AN AD - Department of Pediatrics, University of California San Francisco School of Medicine, San Francisco, CA, USA. amy.mccammond@ucsf.edu. LA - eng PT - Journal Article DEP - 20221127 PL - United States TA - Pediatr Cardiol JT - Pediatric cardiology JID - 8003849 SB - IM MH - Child MH - Humans MH - *Motivation MH - Surveys and Questionnaires MH - *Cardiac Surgical Procedures MH - Delivery of Health Care MH - Communication MH - Patient Care Team OTO - NOTNLM OT - Communication OT - Length of Stay OT - Pediatric cardiac surgery EDAT- 2022/11/28 06:00 MHDA- 2023/04/03 06:41 CRDT- 2022/11/27 14:02 PHST- 2022/04/12 00:00 [received] PHST- 2022/11/16 00:00 [accepted] PHST- 2023/04/03 06:41 [medline] PHST- 2022/11/28 06:00 [pubmed] PHST- 2022/11/27 14:02 [entrez] AID - 10.1007/s00246-022-03059-9 [pii] AID - 10.1007/s00246-022-03059-9 [doi] PST - ppublish SO - Pediatr Cardiol. 2023 Apr;44(4):908-914. doi: 10.1007/s00246-022-03059-9. Epub 2022 Nov 27. PMID- 36426901 OWN - NLM STAT- MEDLINE DCOM- 20230929 LR - 20230929 IS - 2532-5264 (Electronic) IS - 1122-0643 (Linking) VI - 93 IP - 4 DP - 2022 Nov 24 TI - Three-dimensional printing in integrated multi-modality imaging approach for management of prosthetic valves infective endocarditis. LID - 10.4081/monaldi.2022.2479 [doi] AB - After heart failure, infectious endocarditis is the second leading cause of death in patients with prosthetic valves. Aortic pseudoaneurysms are a serious complication of infective endocarditis in mechanical or bioprosthetic aortic prostheses. Diagnostic and management challenges are posed by aortic pseudoaneurysms. In these cases, a multi-modality imaging approach with a heart team is recommended. We described two cases of aortic pseudoaneurysms that developed as a result of infective endocarditis. The first case involved a TAVI patient who developed infective endocarditis as a result of diabetic foot complications. Because traditional echocardiography and computed tomography failed to show the anatomy of the lesion, we used 3D printing to show the anatomy, extension of the pseudoaneurysm, and proximity to the right coronary artery. The second case involved a patient who underwent Bentall's surgery with an aortic root and mechanical aortic valve and later developed infective endocarditis complicated by pseudoaneurysms. In this case, 3D printing was used for preoperative surgical planning. FAU - Eltayeb, Abdalla AU - Eltayeb A AD - Heart Centre Department, King Faisal Specialist Hospital and Research Center, Riyadh. abdullaheltayeb2002@gmail.com. FAU - Khan, Shahid AU - Khan S AD - Heart Centre Department, King Faisal Specialist Hospital and Research Center, Riyadh. shahidkhan@kfshrc.edu.sa. FAU - Dib, Salam AU - Dib S AD - Heart Centre Department, King Faisal Specialist Hospital and Research Center, Riyadh. salamdib@gmail.com. FAU - Musthaq, Ali AU - Musthaq A AD - College of Medicine, Alfaisal University, Riyadh. amushtaq@alfaisal.edu. FAU - Elshaer, Ahmed AU - Elshaer A AD - College of Medicine, Alfaisal University, Riyadh. anelshaer@alfaisal.edu. FAU - Shaik, Abdullah AU - Shaik A AD - College of Medicine, Alfaisal University, Riyadh. ashaik@alfaisal.edu. FAU - Galzerano, Domenico AU - Galzerano D AD - Heart Centre Department, King Faisal Specialist Hospital and Research Center, Riyadh. domenicogalzerano@libero.it. FAU - Fadel, Bahaa AU - Fadel B AD - Heart Centre Department, King Faisal Specialist Hospital and Research Center, Riyadh. bfadel@kfshrc.edu.sa. FAU - Aladmawi, Mohamed AU - Aladmawi M AD - Heart Centre Department, King Faisal Specialist Hospital and Research Center, Riyadh. madmawi@kfshrc.edu.sa. FAU - Vriz, Olga AU - Vriz O AD - Heart Centre Department, King Faisal Specialist Hospital and Research Center, Riyadh. Olgavriz@yahoo.com. LA - eng PT - Journal Article DEP - 20221124 PL - Italy TA - Monaldi Arch Chest Dis JT - Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace JID - 9307314 SB - IM MH - Humans MH - Aortic Valve/diagnostic imaging/surgery MH - *Aneurysm, False/diagnostic imaging/etiology/surgery MH - *Endocarditis/diagnosis/diagnostic imaging MH - *Endocarditis, Bacterial/complications/diagnostic imaging/surgery MH - Printing, Three-Dimensional MH - Multimodal Imaging/adverse effects MH - *Heart Valve Prosthesis/adverse effects EDAT- 2022/11/26 06:00 MHDA- 2023/09/29 06:44 CRDT- 2022/11/25 08:57 PHST- 2022/11/11 00:00 [received] PHST- 2022/11/17 00:00 [accepted] PHST- 2023/09/29 06:44 [medline] PHST- 2022/11/26 06:00 [pubmed] PHST- 2022/11/25 08:57 [entrez] AID - 10.4081/monaldi.2022.2479 [doi] PST - epublish SO - Monaldi Arch Chest Dis. 2022 Nov 24;93(4). doi: 10.4081/monaldi.2022.2479. PMID- 36423996 OWN - NLM STAT- MEDLINE DCOM- 20221129 LR - 20221201 IS - 1558-3597 (Electronic) IS - 0735-1097 (Linking) VI - 80 IP - 22 DP - 2022 Nov 29 TI - A Practical Approach to Left Main Coronary Artery Disease: JACC State-of-the-Art Review. PG - 2119-2134 LID - S0735-1097(22)07026-7 [pii] LID - 10.1016/j.jacc.2022.09.034 [doi] AB - The treatment of left main (LM) coronary artery disease (CAD) requires complex decision-making. Recent clinical practice guidelines provide clinicians with guidance; however, decisions regarding treatment for individual patients can still be difficult. The American College of Cardiology's Cardiac Surgery Team and Interventional Council joined together to develop a practical approach to the treatment of LM CAD, taking into account randomized clinical trial, meta-analyses, and clinical practice guidelines. The various presentations of LM CAD based on anatomy and physiology are presented. Recognizing the complexity of LM CAD, which rarely presents isolated and is often in combination with multivessel disease, a treatment algorithm with medical therapy alone or in conjunction with percutaneous coronary intervention or coronary artery bypass grafting is proposed. A heart team approach is recommended that accounts for clinical, procedural, operator, and institutional factors, and features shared decision-making that meets the needs and preferences of each patient and their specific clinical situation. CI - Copyright (c) 2022. Published by Elsevier Inc. FAU - Davidson, Laura J AU - Davidson LJ AD - Divisions of Cardiology and Cardiac Surgery, Northwestern University, Chicago, Illinois, USA. FAU - Cleveland, Joseph C AU - Cleveland JC AD - Department of Cardiothoracic Surgery, University of Colorado, Aurora, Colorado, USA. FAU - Welt, Frederick G AU - Welt FG AD - Department of Cardiovascular Medicine, University of Utah, Salt Lake City, Utah, USA. FAU - Anwaruddin, Saif AU - Anwaruddin S AD - Department of Cardiology & Interventional Cardiology, St. Vincent Hospital, Worcester, Massachusetts, USA. FAU - Bonow, Robert O AU - Bonow RO AD - Divisions of Cardiology and Cardiac Surgery, Northwestern University, Chicago, Illinois, USA. FAU - Firstenberg, Michael S AU - Firstenberg MS AD - Department of Cardiothoracic Surgery, St. Elizabeth Medical Center, Appleton, Wisconsin, USA. FAU - Gaudino, Mario F AU - Gaudino MF AD - Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, New York, USA. FAU - Gersh, Bernard J AU - Gersh BJ AD - Department of Cardiovascular Medicine, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA. FAU - Grubb, Kendra J AU - Grubb KJ AD - Department of Surgery, Division of Cardiothoracic Surgery, Emory University, Atlanta, Georgia, USA. FAU - Kirtane, Ajay J AU - Kirtane AJ AD - Division of Cardiology and the Cardiovascular Research Foundation, Columbia University Irving Medical Center/NewYork-Presbyterian Hospital, New York, New York, USA. FAU - Tamis-Holland, Jacqueline E AU - Tamis-Holland JE AD - Department of Cardiology, Mount Sinai, New York, New York, USA. FAU - Truesdell, Alexander G AU - Truesdell AG AD - Department of Interventional Cardiology, Virginia Heart and the Inova Heart and Vascular Institute, Falls Church, Virginia, USA. FAU - Windecker, Stephan AU - Windecker S AD - Department of Cardiology, Bern University Hospital, Inselspital, Bern, Switzerland. FAU - Taha, Roza A AU - Taha RA AD - Divisions of Cardiology and Cardiac Surgery, Northwestern University, Chicago, Illinois, USA. FAU - Malaisrie, S Chris AU - Malaisrie SC AD - Divisions of Cardiology and Cardiac Surgery, Northwestern University, Chicago, Illinois, USA. Electronic address: chris.malaisrie@nm.org. LA - eng PT - Journal Article PT - Review PL - United States TA - J Am Coll Cardiol JT - Journal of the American College of Cardiology JID - 8301365 SB - IM MH - Humans MH - Coronary Artery Bypass MH - *Coronary Artery Disease/diagnosis/surgery MH - Meta-Analysis as Topic MH - *Percutaneous Coronary Intervention MH - Randomized Controlled Trials as Topic MH - Practice Guidelines as Topic OTO - NOTNLM OT - coronary artery bypass grafting OT - coronary artery disease OT - left main coronary artery disease OT - myocardial revascularization OT - percutaneous coronary intervention COIS- Funding Support and Author Disclosures Dr Davidson is a co-investigator for Edwards Lifesciences and Abbott clinical trials. Dr Cleveland has received research grants from Medtronic and Abbott; has served on research committees for Abbott; has been a consultant for and received honoraria from ConneX Biomedical and Medtronic; and has received honoraria from Edwards Lifesciences. Dr Welt has been a consultant for and received honoraria from Medtronic; and holds stock in Xenter, Inc. Dr Anwaruddin has been a consultant and proctor for Edwards Lifesciences and Medtronic; has served on a steering committee for Boston Scientific; and holds equity in East End Medical. Dr Grubb has been a speaker for Edwards Lifesciences, Boston Scientific, and Medtronic; has been a proctor for Edwards Lifesciences and Medtronic; has served on advisory boards for Medtronic and Abbott; has been a principal investigator for trials sponsored by Edwards Lifesciences and Medtronic; and has been a consultant for Gore. Dr Kirtane has been a consultant for IMDS; has received travel expenses/meals from Medtronic, Boston Scientific, Abbott Vascular, CSI, Siemens, Philips, ReCor Medical, Chiesi, OpSens, Zoll, and Regeneron; and has received research grants from, been a consultant for, an/or received speaker fees from Medtronic, Boston Scientific, Abbott Vascular, Amgen, CSI, Philips, ReCor Medical, Neurotronic, Biotronik, Chiesi, Bolt Medical, Magenta Medical, Canon, and SoniVie, paid to his institution. Dr Truesdell has received consultant and speaker fees, paid to his institution, from Abiomed Inc. Dr Windecker has received research and educational grants paid to employer from Abbott, Abiomed, Amgen, AstraZeneca, Bayer, Biotronik, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cardinal Health, CardioValve, Corflow Therapeutics, CSL Behring, Daiichi-Sankyo, Edwards Lifesciences, Guerbet, InfraRedx, Janssen-Cilag, Johnson & Johnson, Medicure, Medtronic, Merck Sharp & Dohm, Miracor Medical, Novartis, Novo Nordisk, Organon, OrPha Suisse, Pfizer, Polares, Regeneron, Sanofi, Servier, Sinomed, Terumo, Vifor, V-Wave; has served as advisory board member and/or member of the steering/executive group of trials funded by Abbott, Abiomed, Amgen, AstraZeneca, Bayer, Boston Scientific, Biotronik, Bristol Myers Squibb, Edwards Lifesciences, Janssen, MedAlliance, Medtronic, Novartis, Polares, Recardio, Sinomed, Terumo, V-Wave, and Xeltis with payments to employer but no personal payments; and has been a member of the steering/executive committee group of several investigator-initiated trials that receive funding by industry without impact on his personal remuneration. Dr Malaisrie has been a consultant for and received research funding from Edwards Lifesciences, Medtronic, Terumo Aortic, and Artivion. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2022/11/25 06:00 MHDA- 2022/11/29 06:00 CRDT- 2022/11/24 21:04 PHST- 2022/08/10 00:00 [received] PHST- 2022/09/07 00:00 [accepted] PHST- 2022/11/24 21:04 [entrez] PHST- 2022/11/25 06:00 [pubmed] PHST- 2022/11/29 06:00 [medline] AID - S0735-1097(22)07026-7 [pii] AID - 10.1016/j.jacc.2022.09.034 [doi] PST - ppublish SO - J Am Coll Cardiol. 2022 Nov 29;80(22):2119-2134. doi: 10.1016/j.jacc.2022.09.034. PMID- 36423902 OWN - NLM STAT- MEDLINE DCOM- 20230322 LR - 20230324 IS - 1465-3362 (Electronic) IS - 0959-5236 (Linking) VI - 42 IP - 3 DP - 2023 Mar TI - Clinical characteristics of fatal cocaine toxicity in Australia, 2000-2021. PG - 582-591 LID - 10.1111/dar.13581 [doi] AB - INTRODUCTION: With increased use, the number of cocaine-related deaths has increased. We aimed to determine: (i) the toxicological profile of cocaine, metabolites and adulterants amongst three groups of cocaine-related fatalities in which cocaine and/or metabolites were present in blood: (a) fatal toxicity, where cocaine only (CO) was present (n = 48), (b) multiple drug toxicity (MDT) where other drugs were present (n = 604), and (c) a comparison group of death from traumatic injury (TI, n = 232); (ii) the acute clinical presentation by group; and (iii) cardiovascular disease by group. METHODS: Retrospective study of cocaine-related deaths in Australia, 2000-2021, from the National Coronial Information System. RESULTS: The parent drug cocaine was significantly more common, and had a higher median concentration, amongst the CO group (97.9%, 1.550 mg/L) than the MDT (68.9%, 0.09 mg/L) and TI (70.7%, 0.05 mg/L) groups respectively. Similarly large ratios between CO, MDT and TI were seen for benzoylecgonine (2.100, 0.510, 0.240 mg/L), methylecgonine (1.350, 0.140, 0.070 mg/L), lignocaine (1.200, 0.200, 0.150 mg/L) and levamisole (0.230, 0.045, 0.025 mg/L). The two toxicity groups had significantly higher proportions than the TI group for reports of sudden collapse, seizure, acute psychosis, hyperthermia and vomiting. In addition, CO had higher proportions than MDT and TI of sudden collapse. CO had significantly higher proportions of cardiomegaly and coronary artery disease than the TI group. DISCUSSION AND CONCLUSIONS: Compared to MDT and TI cases, CO cases had higher cocaine concentrations, higher concentrations of adulterants, higher levels of cardiovascular disease and were more likely to suddenly collapse. CI - (c) 2022 Australasian Professional Society on Alcohol and other Drugs. FAU - Darke, Shane AU - Darke S AUID- ORCID: 0000-0001-8718-7055 AD - National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, Australia. FAU - Duflou, Johan AU - Duflou J AD - National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, Australia. AD - Sydney Medical School, The University of Sydney, Sydney, Australia. FAU - Peacock, Amy AU - Peacock A AUID- ORCID: 0000-0002-5705-2026 AD - National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, Australia. FAU - Chrzanowska, Agata AU - Chrzanowska A AD - National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, Australia. FAU - Farrell, Michael AU - Farrell M AD - National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, Australia. FAU - Lappin, Julia AU - Lappin J AD - National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, Australia. AD - School of Psychiatry, UNSW Sydney, Sydney, Australia. LA - eng GR - National Drug and Alcohol Research Centre/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20221124 PL - Australia TA - Drug Alcohol Rev JT - Drug and alcohol review JID - 9015440 RN - I5Y540LHVR (Cocaine) SB - IM MH - Humans MH - Retrospective Studies MH - *Cardiovascular Diseases MH - *Cocaine MH - *Cocaine-Related Disorders/complications/epidemiology MH - Australia/epidemiology OTO - NOTNLM OT - Australia OT - clinical OT - cocaine OT - mortality OT - toxicology EDAT- 2022/11/25 06:00 MHDA- 2023/03/23 06:00 CRDT- 2022/11/24 20:23 PHST- 2022/09/27 00:00 [revised] PHST- 2022/07/19 00:00 [received] PHST- 2022/11/02 00:00 [accepted] PHST- 2022/11/25 06:00 [pubmed] PHST- 2023/03/23 06:00 [medline] PHST- 2022/11/24 20:23 [entrez] AID - 10.1111/dar.13581 [doi] PST - ppublish SO - Drug Alcohol Rev. 2023 Mar;42(3):582-591. doi: 10.1111/dar.13581. Epub 2022 Nov 24. PMID- 36417147 OWN - NLM STAT- MEDLINE DCOM- 20221222 LR - 20230128 IS - 1534-6277 (Electronic) IS - 1534-6277 (Linking) VI - 23 IP - 12 DP - 2022 Dec TI - Current Practice in Carcinoid Heart Disease and Burgeoning Opportunities. PG - 1793-1803 LID - 10.1007/s11864-022-01023-6 [doi] AB - Cardiac surgery with tricuspid valve and potentially pulmonic valve replacement at an experienced center is currently the most effective strategy available for the treatment of carcinoid heart disease. Cardiac surgery for carcinoid heart disease requires a multidisciplinary team including cardiology, medical oncology, cardiothoracic anesthesia, and cardiac surgery. Without cardiac surgery, morbidity and mortality from carcinoid heart disease is high. Aggressive management of carcinoid before and after cardiac surgery is critical. Over time, though, circulating carcinoid hormones can lead to destruction of prosthetic valves as well, resulting in recurrent right heart failure. Percutaneous options for valve repair may be on the horizon for management of carcinoid heart disease. CI - (c) 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Lenneman, Carrie AU - Lenneman C AD - Division of Cardiology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. FAU - Harrison, David AU - Harrison D AD - Division of Cardiology, Department of Medicine, University of Colorado, 12631 E. 17th Avenue Mail Stop B130, Aurora, CO, 80045, USA. FAU - Davis, S Lindsey AU - Davis SL AD - Division of Medical Oncology, Department of Medicine, University of Colorado, Aurora, CO, USA. FAU - Kondapalli, Lavanya AU - Kondapalli L AUID- ORCID: 0000-0002-3507-2296 AD - Division of Cardiology, Department of Medicine, University of Colorado, 12631 E. 17th Avenue Mail Stop B130, Aurora, CO, 80045, USA. lavanya.kondapalli@cuanschutz.edu. LA - eng PT - Journal Article PT - Review DEP - 20221122 PL - United States TA - Curr Treat Options Oncol JT - Current treatment options in oncology JID - 100900946 SB - IM MH - Humans MH - *Carcinoid Heart Disease/diagnosis/etiology/therapy MH - Morbidity OTO - NOTNLM OT - Carcinoid crisis OT - Carcinoid heart disease OT - Carcinoid syndrome OT - Cardiac surgery OT - Neuroendocrine tumor OT - Pulmonic valve disease OT - Somatostatin analogs OT - Tricuspid valve disease OT - Valvular heart disease EDAT- 2022/11/24 06:00 MHDA- 2022/12/23 06:00 CRDT- 2022/11/23 12:14 PHST- 2022/09/20 00:00 [accepted] PHST- 2022/11/24 06:00 [pubmed] PHST- 2022/12/23 06:00 [medline] PHST- 2022/11/23 12:14 [entrez] AID - 10.1007/s11864-022-01023-6 [pii] AID - 10.1007/s11864-022-01023-6 [doi] PST - ppublish SO - Curr Treat Options Oncol. 2022 Dec;23(12):1793-1803. doi: 10.1007/s11864-022-01023-6. Epub 2022 Nov 22. PMID- 36417136 OWN - NLM STAT- MEDLINE DCOM- 20230206 LR - 20230206 IS - 1720-8319 (Electronic) IS - 1594-0667 (Linking) VI - 35 IP - 2 DP - 2023 Feb TI - Functional continuum: independent predictor of one-year mortality and key decision-making element in older adults with severe aortic stenosis amenable to aortic valve replacement. PG - 323-331 LID - 10.1007/s40520-022-02300-y [doi] AB - OBJECTIVES: The impact of functional capacity over the entire functional continuum in older adults undergoing aortic valve replacement (AVR) has not been studied to date. This study aims to analyze 1.- the distribution of a cohort of older adults presenting severe aortic stenosis (AS) amenable to AVR in the different categories of the Functional Continuum Scale (FCS); 2.- its association with decision-making regarding valve disease; and 3.- its impact upon the one-year mortality rate of surgical (SAVR), transcatheter (TAVR) aortic valve replacement, or the decision to provide conservative management (OMT). METHODS: This prospective study included patients from the FRESAS (FRailty-Evaluation-in-Severe-Aortic-Stenosis) registry evaluated by the reference Heart-Team of a region in northern Spain. All the patients underwent comprehensive geriatric assessment. RESULTS: The study comprised 257 patients aged 84.0 +/- 3.9 years. MANAGEMENT: SAVR: 25.3%, TAVR: 58.0% and OMT: 16.7%. Increased patient functional capacity was associated with an increased tendency to perform more invasive valve disease treatment. The overall one-year survival rate was 81.3%. One-year all-cause mortality: FCS-1 to FCS-2 "robust" 11.5%, FCS-3 to FCS-4 "prefrail" 14.7%, FCS-5 "frail" 19.2% and FCS-6 to FCS-8 "dependent" 45.0%; p < 0.001. Adjusted mortality analysis: FCS with HR = 1.206 [95%CI, 0.999-1.451 (p = 0.051)]; EuroSCORE-II with HR = 1.071 [95%CI, 1.006-1.161 (p = 0.033)]; and OMT with HR = 2.840 [95%CI, 1.409-5.772 (p = 0.004)] were retained in the final multivariable logistic regression model. CONCLUSIONS: In older AS patients amenable to AVR, the FCS is a useful predictive tool that may aid clinical decision-making. CI - (c) 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG. FAU - Solla-Suarez, Pablo AU - Solla-Suarez P AUID- ORCID: 0000-0003-0412-6578 AD - Geriatrics Department, Geriatrics Clinical Management Area, Hospital Monte Naranco, HMN, Oviedo, Spain. pasosu@gmail.com. AD - Health Research Institute of Asturias, ISPA, Oviedo, Spain. pasosu@gmail.com. FAU - Avanzas, Pablo AU - Avanzas P AD - Cardiology Department, Cardiac Area, Hospital Universitario Central de Asturias, HUCA, Oviedo, Spain. AD - Health Research Institute of Asturias, ISPA, Oviedo, Spain. AD - University of Oviedo, UOV, Oviedo, Spain. FAU - Fernandez-Fernandez, Marta AU - Fernandez-Fernandez M AD - Geriatrics Department, Geriatrics Clinical Management Area, Hospital Monte Naranco, HMN, Oviedo, Spain. FAU - Pascual, Isaac AU - Pascual I AD - Cardiology Department, Cardiac Area, Hospital Universitario Central de Asturias, HUCA, Oviedo, Spain. AD - Health Research Institute of Asturias, ISPA, Oviedo, Spain. AD - University of Oviedo, UOV, Oviedo, Spain. FAU - Moreno-Planillo, Carmen AU - Moreno-Planillo C AD - Geriatrics Department, Geriatrics Clinical Management Area, Hospital Monte Naranco, HMN, Oviedo, Spain. FAU - Almendarez, Marcel AU - Almendarez M AD - Cardiology Department, Cardiac Area, Hospital Universitario Central de Asturias, HUCA, Oviedo, Spain. AD - Health Research Institute of Asturias, ISPA, Oviedo, Spain. FAU - Lopez-Alvarez, Eva AU - Lopez-Alvarez E AD - Geriatrics Department, Geriatrics Clinical Management Area, Hospital Monte Naranco, HMN, Oviedo, Spain. FAU - Alvarez, Rut AU - Alvarez R AD - Cardiology Department, Cardiac Area, Hospital Universitario Central de Asturias, HUCA, Oviedo, Spain. AD - Health Research Institute of Asturias, ISPA, Oviedo, Spain. FAU - Coto-Montes, Ana AU - Coto-Montes A AD - Health Research Institute of Asturias, ISPA, Oviedo, Spain. AD - University of Oviedo, UOV, Oviedo, Spain. AD - Institute of Neurosciences of the Principality of Asturias, INEUROPA, Oviedo, Spain. FAU - Moris, Cesar AU - Moris C AD - Cardiology Department, Cardiac Area, Hospital Universitario Central de Asturias, HUCA, Oviedo, Spain. AD - Health Research Institute of Asturias, ISPA, Oviedo, Spain. AD - University of Oviedo, UOV, Oviedo, Spain. FAU - Gutierrez-Rodriguez, Jose AU - Gutierrez-Rodriguez J AD - Geriatrics Department, Geriatrics Clinical Management Area, Hospital Monte Naranco, HMN, Oviedo, Spain. AD - Health Research Institute of Asturias, ISPA, Oviedo, Spain. LA - eng PT - Journal Article DEP - 20221122 PL - Germany TA - Aging Clin Exp Res JT - Aging clinical and experimental research JID - 101132995 SB - IM MH - Aged MH - Humans MH - Aortic Valve/surgery MH - *Transcatheter Aortic Valve Replacement MH - Prospective Studies MH - *Aortic Valve Stenosis MH - Risk Factors MH - Treatment Outcome MH - *Heart Valve Prosthesis Implantation OTO - NOTNLM OT - Aortic stenosis OT - Aortic valve replacement OT - Frailty OT - Functional continuum OT - Mortality EDAT- 2022/11/24 06:00 MHDA- 2023/02/07 06:00 CRDT- 2022/11/23 12:13 PHST- 2022/10/06 00:00 [received] PHST- 2022/11/02 00:00 [accepted] PHST- 2022/11/24 06:00 [pubmed] PHST- 2023/02/07 06:00 [medline] PHST- 2022/11/23 12:13 [entrez] AID - 10.1007/s40520-022-02300-y [pii] AID - 10.1007/s40520-022-02300-y [doi] PST - ppublish SO - Aging Clin Exp Res. 2023 Feb;35(2):323-331. doi: 10.1007/s40520-022-02300-y. Epub 2022 Nov 22. PMID- 36410442 OWN - NLM STAT- MEDLINE DCOM- 20230214 LR - 20260105 IS - 1097-6744 (Electronic) IS - 0002-8703 (Linking) VI - 257 DP - 2023 Mar TI - Percutaneous coronary intervention of native coronary artery versus saphenous vein graft in patients with prior coronary artery bypass graft surgery: Rationale and design of the multicenter, randomized PROCTOR trial. PG - 20-29 LID - S0002-8703(22)00296-4 [pii] LID - 10.1016/j.ahj.2022.11.014 [doi] AB - BACKGROUND: Patients with prior coronary artery bypass grafting (CABG) frequently require repeat percutaneous revascularization due to advanced age, progressive coronary artery disease and bypass graft failure. Percutaneous coronary intervention (PCI) of either the bypass graft or the native coronary artery may be performed. Randomized trials comparing native vessel PCI with bypass graft PCI are lacking and long-term outcomes have not been reported. METHODS: PROCTOR (NCT03805048) is a prospective, multicenter, randomized controlled trial, that will include 584 patients presenting with saphenous vein graft (SVG) failure and a clinical indication for revascularization, as determined by the local Heart Team. The trial is designed to compare the clinical and angiographic outcomes in patients randomly allocated in a 1:1 fashion to either a strategy of native vessel PCI or SVG PCI. The primary study endpoint is a 3-year composite of major adverse cardiac events (MACE: all-cause mortality, non-fatal target coronary territory myocardial infarction [MI], or clinically driven target coronary territory revascularization). At 3-years, after evaluation of the primary endpoint, follow-up invasive coronary angiography will be performed. Secondary endpoints comprise individual components of MACE at 1, 3 and 5 years follow-up, PCI-related MI, MI >48 hours after index PCI, target vessel failure, target lesion revascularization, renal failure requiring renal-replacement therapy, angiographic outcomes at 3-years and quality of life (delta Seattle Angina Questionnaire, Canadian Cardiovascular Society Grading Scale and Rose Dyspnea Scale). CONCLUSION: PROCTOR is the first randomized trial comparing an invasive strategy of native coronary artery PCI with SVG PCI in post-CABG patients presenting with SVG failure. CI - Copyright (c) 2022 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - de Winter, Ruben W AU - de Winter RW AD - Department of Cardiology, Heart Center Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands. FAU - Walsh, Simon J AU - Walsh SJ AD - Department of Cardiology, Belfast Health and Social Care Trust, Royal Victoria Hospital, Belfast, United Kingdom. FAU - Hanratty, Colm G AU - Hanratty CG AD - Heart & Vascular Centre, Mater Private Day Hospital, Dublin, Ireland. FAU - Spratt, James C AU - Spratt JC AD - Department of Cardiology, St George's University Hospital NHS Trust, London, United Kingdom. FAU - Sprengers, Ralf W AU - Sprengers RW AD - Department of Radiology & Nuclear Medicine, Amsterdam UMC, Amsterdam, the Netherlands. FAU - Twisk, Jos W R AU - Twisk JWR AD - Department of Epidemiology & Data Science, Amsterdam UMC, Amsterdam, the Netherlands. FAU - Vegting, Iris AU - Vegting I AD - Department of Cardiology, Heart Center Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands. FAU - Schumacher, Stefan P AU - Schumacher SP AD - Department of Cardiology, Heart Center Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands. FAU - Bom, Michiel J AU - Bom MJ AD - Department of Cardiology, Heart Center Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands. FAU - Hoek, Roel AU - Hoek R AD - Department of Cardiology, Heart Center Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands. FAU - Verouden, Niels J AU - Verouden NJ AD - Department of Cardiology, Heart Center Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands. FAU - Delewi, Ronak AU - Delewi R AD - Department of Cardiology, Heart Center Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands. FAU - Nap, Alexander AU - Nap A AD - Department of Cardiology, Heart Center Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands. FAU - Knaapen, Paul AU - Knaapen P AD - Department of Cardiology, Heart Center Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands. Electronic address: p.knaapen@amsterdamumc.nl. CN - PROCTOR Trial Research Group LA - eng PT - Clinical Trial Protocol PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20221119 PL - United States TA - Am Heart J JT - American heart journal JID - 0370465 SB - IM MH - Humans MH - Prospective Studies MH - *Percutaneous Coronary Intervention/adverse effects MH - Saphenous Vein/transplantation MH - Quality of Life MH - Treatment Outcome MH - *Drug-Eluting Stents/adverse effects MH - Canada MH - Coronary Artery Bypass/adverse effects MH - *Coronary Artery Disease MH - *Myocardial Infarction/etiology MH - Multicenter Studies as Topic MH - Randomized Controlled Trials as Topic EDAT- 2022/11/22 06:00 MHDA- 2023/02/15 06:00 CRDT- 2022/11/21 19:33 PHST- 2022/07/12 00:00 [received] PHST- 2022/10/26 00:00 [revised] PHST- 2022/11/15 00:00 [accepted] PHST- 2022/11/22 06:00 [pubmed] PHST- 2023/02/15 06:00 [medline] PHST- 2022/11/21 19:33 [entrez] AID - S0002-8703(22)00296-4 [pii] AID - 10.1016/j.ahj.2022.11.014 [doi] PST - ppublish SO - Am Heart J. 2023 Mar;257:20-29. doi: 10.1016/j.ahj.2022.11.014. Epub 2022 Nov 19. PMID- 36407439 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221122 IS - 2297-055X (Print) IS - 2297-055X (Electronic) IS - 2297-055X (Linking) VI - 9 DP - 2022 TI - The association between implementation of multidisciplinary rounds and clinical outcomes. PG - 1005150 LID - 10.3389/fcvm.2022.1005150 [doi] LID - 1005150 AB - BACKGROUND: Multidisciplinary rounds (MDR) consisting of social workers, dietitians, pharmacists, physical therapists, nurses, and physicians have been implemented at many healthcare institutions to address the complex components of inpatient care. However, little is known on the association of MDR on clinical outcomes across cardiovascular pathologies. This study aimed to investigate the impact of MDR on cardiovascular patients. METHODS: Hospital admissions to inpatient cardiology were evaluated prior to (November 2017 to November 2018) and after implementation of MDR (December 2018 to August 2020) at a metropolitan academic medical center. The following outcomes were evaluated: clinical complications (incidence of stroke, gastrointestinal bleed, myocardial infarction, or systemic infection during hospitalization), Length of Stay (LOS), 30-day readmissions and all-cause in-hospital mortality. Secondary outcomes included utilization of physical therapy and dietary services. RESULTS: Admissions were evaluated prior to (N = 1054) and after (N = 1659) MDR implementation. All-cause in-hospital mortality after MDR implementation decreased significantly from 2.8 to 1.6% (P = 0.03). Although the number of complications and LOS decreased, these differences were not statistically significant. No significant change was observed in 30-day readmissions. Significant increase in the utilization of physical therapy (34.2 to 53.5%; P < 0.01) and dietary services (7.2 to 19.3%; P < 0.01) were observed. CONCLUSION: Multidisciplinary rounds implementation was associated with significantly decreased mortality and positively impacted resource utilization with increased consultations for ancillary services. MDR is a high impact intervention that utilizes existing resources to improve mortality and should be implemented especially for cardiovascular patients. Further investigation into the benefit of MDR across different patient populations and care settings is warranted. CI - Copyright (c) 2022 Sreepathy, Kim, Ahuja, Shroff and Nazir. FAU - Sreepathy, Pranati AU - Sreepathy P AD - Department of Medicine, University of Illinois at Chicago, Chicago, IL, United States. FAU - Kim, Yoo Jin AU - Kim YJ AD - The Johns Hopkins Hospital, Johns Hopkins Medicine, Baltimore, MD, United States. AD - College of Medicine, University of Illinois at Chicago, Chicago, IL, United States. FAU - Ahuja, Zaneta AU - Ahuja Z AD - Health Sciences System, University of Illinois Hospital, Chicago, IL, United States. FAU - Shroff, Adhir R AU - Shroff AR AD - Division of Cardiology, Department of Medicine, University of Illinois at Chicago, Chicago, IL, United States. FAU - Nazir, Noreen T AU - Nazir NT AD - Division of Cardiology, Department of Medicine, University of Illinois at Chicago, Chicago, IL, United States. LA - eng PT - Journal Article DEP - 20221104 PL - Switzerland TA - Front Cardiovasc Med JT - Frontiers in cardiovascular medicine JID - 101653388 PMC - PMC9671934 OTO - NOTNLM OT - cardiovascular care and outcomes OT - cardiovascular care coordination OT - care strategies OT - mortality benefit OT - multidisciplinary team COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/11/22 06:00 MHDA- 2022/11/22 06:01 PMCR- 2022/01/01 CRDT- 2022/11/21 04:32 PHST- 2022/07/28 00:00 [received] PHST- 2022/10/19 00:00 [accepted] PHST- 2022/11/21 04:32 [entrez] PHST- 2022/11/22 06:00 [pubmed] PHST- 2022/11/22 06:01 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.3389/fcvm.2022.1005150 [doi] PST - epublish SO - Front Cardiovasc Med. 2022 Nov 4;9:1005150. doi: 10.3389/fcvm.2022.1005150. eCollection 2022. PMID- 36404271 OWN - NLM STAT- MEDLINE DCOM- 20230831 LR - 20230918 IS - 1478-5153 (Electronic) IS - 1362-1017 (Linking) VI - 28 IP - 5 DP - 2023 Sep TI - Association between preoperative on-site CCU visits and postoperative delirium in patients undergoing cardiac surgery: A retrospective cohort study. PG - 689-697 LID - 10.1111/nicc.12862 [doi] AB - BACKGROUND: Postoperative delirium (POD) is a common complication after cardiac surgery (CS), with symptoms like attention disorders and even delays patients' recovery. AIMS: To evaluate the impact of preoperative on-site visits in the cardiac care unit (CCU) on POD after CS. STUDY DESIGN: Patients admitted to the CCU with extracorporeal CS were included in the visiting or non-visiting group according to whether they were on visiting week. The visiting group received a preoperative visit from a nurse-led multidisciplinary visiting team (including CCU nurses and physicians) 1 week before surgery in addition to standard care. The non-visiting group received standard care like unstructured information from the CS team and anesthesiologists and so on. The Confusion Assessment Method for the ICU (CAM-ICU) and the Intensive Care Delirium Screening Checklist (ICDSC) were used to evaluate the POD severity. The incidence, occurrence and duration of POD, as well as the CCU length of stay, postoperative mechanical ventilation duration and length of hospital stay were compared between the two groups. RESULTS: A total of 735 participants (369 in the visited group and 366 in the unvisited group) were included in this study. Preoperative on-site visits were associated with a decreased POD incidence (odds ratio [OR]: 0.524, 95% CI: 0.336-0.817), an improved POD severity (OR: 0.578, 95% CI: 0.359-0.932) and a shortening POD duration (OR: 0.972, 95% CI: 0.951-0.994). There was a significant difference between the visiting and non-visiting groups in the mechanical ventilation duration (OR: 0.987, 95% CI: 0.978-0.996). CONCLUSIONS: Preoperative on-site visits are associated with a reduction in the incidence, duration, and severity of POD, as well as the mechanical ventilation duration of patients. RELEVANCE TO CLINICAL PRACTICE: This study found that preoperative on-site visits were associated with the onset, duration, severity and duration of mechanical ventilation of POD. Although many factors influence the occurrence of POD, a multidisciplinary visiting team led by a nurse (including CCU nurses and physicians) can provide early nursing interventions through preoperative visits, better obtain postoperative cooperation from patients, establish a good nurse-patient relationship and provide better health services to patients. In a realistic CCU setting, nurses and physicians can act as educators, assessing patients before surgery, enhancing preoperative education, improving patient familiarity with the CCU environment and teaching sign language communication skills when patients are mechanically ventilated. These findings can therefore provide the basis for effective clinical care to prevent postoperative POD. CI - (c) 2022 British Association of Critical Care Nurses. FAU - Chen, Beibei AU - Chen B AD - Department of Cardiac Care Unit, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. FAU - Wu, Lina AU - Wu L AD - Department of Cardiac Care Unit, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. FAU - Fang, Zhenhong AU - Fang Z AD - Department of Cardiac Care Unit, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. FAU - Zheng, Jing AU - Zheng J AD - Department of Cardiac Care Unit, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. FAU - Dong, Weihua AU - Dong W AD - Department of Cardiac Care Unit, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. FAU - Hong, Xia AU - Hong X AD - Department of Cardiac Care Unit, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. FAU - Jin, Peifeng AU - Jin P AUID- ORCID: 0000-0002-4933-9406 AD - Department of Cardiac Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. LA - eng GR - Y20210557/Basic scientific research projects in Wenzhou/ GR - 81500220/National Natural Science Foundation of China/ GR - Y2020019/Wenzhou Municipal Science and Technology Bureau of China/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20221120 PL - England TA - Nurs Crit Care JT - Nursing in critical care JID - 9808649 MH - Humans MH - *Emergence Delirium/complications MH - Retrospective Studies MH - *Delirium/epidemiology/etiology/diagnosis MH - Postoperative Complications/epidemiology/etiology/therapy MH - Risk Factors MH - *Cardiac Surgical Procedures/adverse effects OTO - NOTNLM OT - cardiac surgery OT - delirium duration OT - intensive care unit OT - postoperative delirium OT - preoperative visit EDAT- 2022/11/21 06:00 MHDA- 2023/08/31 06:41 CRDT- 2022/11/20 22:12 PHST- 2022/11/04 00:00 [revised] PHST- 2022/01/24 00:00 [received] PHST- 2022/11/05 00:00 [accepted] PHST- 2023/08/31 06:41 [medline] PHST- 2022/11/21 06:00 [pubmed] PHST- 2022/11/20 22:12 [entrez] AID - 10.1111/nicc.12862 [doi] PST - ppublish SO - Nurs Crit Care. 2023 Sep;28(5):689-697. doi: 10.1111/nicc.12862. Epub 2022 Nov 20. PMID- 36402217 OWN - NLM STAT- MEDLINE DCOM- 20230103 LR - 20230111 IS - 1535-6280 (Electronic) IS - 0146-2806 (Linking) VI - 48 IP - 2 DP - 2023 Feb TI - Outcome of Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting for Patients With Intermediate SYNTAX II Score. PG - 101512 LID - S0146-2806(22)00409-1 [pii] LID - 10.1016/j.cpcardiol.2022.101512 [doi] AB - Patients with intermediate SYNTAX II score have been representing a confusion in our daily practice for interventional cardiologists whether to treat them by percutaneous coronary intervention (PCI) using second generation drug eluting stents or by coronary artery bypass grafting (CABG). We enrolled 214 consecutive patients with intermediate SYNTAX II score to undergo revascularization (109 patients underwent PCI and 105 patients underwent CABG) after Heart Team discussion. We compared both procedures with respect to the primary composite end point of major adverse cardiac or cerebrovascular events (all-cause mortality, myocardial infarction, target vessel revascularization or stroke) at 40 months post procedure. At 40 months post revascularization procedure, the primary end-point occurred in 22 patients and 15 patients in the PCI and CABG groups, respectively (hazard ratio, 1.65; 95% confidence interval, 0.87-3.14; P = 0.13). No significant differences were detected between both groups regarding the composite incidence of all-cause mortality, myocardial infarction, target vessel revascularization, and stroke. CABG significantly provided better quality of life than PCI for patients with intermediate SYNTAX II score. In patients with intermediate SYNTAX II score, there was no statistically significant difference between the PCI using second generation drug eluting stents and CABG with respect to the incidence of MACCE at 40 months post revascularization procedure. CI - Copyright (c) 2022 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Etman, Waleed AU - Etman W AD - Medical Research Institute, Alexandria University, Alexandria, Egypt. Electronic address: etman.waleed@hotmail.com. FAU - Loutfi, Mohamed AU - Loutfi M AD - Faculty of Medicine, Alexandria University, Alexandria, Egypt. FAU - Ahmed, Kamal AU - Ahmed K AD - Medical Research Institute, Alexandria University, Alexandria, Egypt. FAU - Eltahan, Salah AU - Eltahan S AD - Faculty of Medicine, Alexandria University, Alexandria, Egypt. FAU - Rayan, Amr AU - Rayan A AD - Faculty of Medicine, Alexandria University, Alexandria, Egypt. LA - eng PT - Journal Article PT - Review DEP - 20221117 PL - Netherlands TA - Curr Probl Cardiol JT - Current problems in cardiology JID - 7701802 SB - IM MH - Humans MH - *Coronary Artery Disease/therapy MH - *Percutaneous Coronary Intervention/methods MH - Quality of Life MH - Coronary Artery Bypass/adverse effects/methods MH - *Myocardial Infarction/etiology MH - *Stroke/epidemiology/etiology MH - Treatment Outcome EDAT- 2022/11/20 06:00 MHDA- 2023/01/04 06:00 CRDT- 2022/11/19 19:24 PHST- 2022/11/11 00:00 [received] PHST- 2022/11/11 00:00 [accepted] PHST- 2022/11/20 06:00 [pubmed] PHST- 2023/01/04 06:00 [medline] PHST- 2022/11/19 19:24 [entrez] AID - S0146-2806(22)00409-1 [pii] AID - 10.1016/j.cpcardiol.2022.101512 [doi] PST - ppublish SO - Curr Probl Cardiol. 2023 Feb;48(2):101512. doi: 10.1016/j.cpcardiol.2022.101512. Epub 2022 Nov 17. PMID- 36385102 OWN - NLM STAT- MEDLINE DCOM- 20230605 LR - 20231130 IS - 2691-3321 (Electronic) IS - 2691-3321 (Linking) VI - 21 IP - 2 DP - 2023 Jun 1 TI - Preprocedure care for outpatients in the cardiac catheterization lab in an acute care hospital in central Mississippi: a best practice implementation project. PG - 167-177 LID - 10.1097/XEB.0000000000000358 [doi] AB - OBJECTIVES: The objective of this implementation project was to improve the cardiac catheterization lab multidisciplinary team's compliance with best practices regarding preprocedural care. INTRODUCTION: The cardiac catheterization lab performs numerous diagnostic and interventional outpatient procedures. Preprocedural care is a crucial step in preparing patients and clinical staff. METHODS: The JBI Evidence Implementation framework was used for this project. The baseline audit for the project included a review of 30 electronic health records for best practice adherence. The Getting Research into Practice tool guided leadership to increase awareness and compliance to evidence-based practice. A follow-up audit of 30 electronic health records followed implementation of strategies. RESULTS: Baseline audit data suggested all best practices combined were only followed at 79%, and revealed the need for improvement in preprocedural phone calls to patients and documentation related to patient education regarding the procedure and expectations for procedure recovery. Four barriers were identified and multiple strategies were implemented in an attempt to improve compliance with evidence-based practices. Follow-up audits showed an overall improvement to 81% after project implementation. CONCLUSIONS: The project showed improvements with best practices for preprocedural care in the outpatient setting. However, more work remains to obtain sustainability of best practices, including preprocedural assessment undertaken prior to the cardiac catheterization procedure, information provided to the patient prior to the cardiac catheterization procedure explaining the test and expected recovery, and patients receiving a phone call prior to the procedure for reminders of procedural details. CI - Copyright (c) 2022 JBI. Unauthorized reproduction of this article is prohibited. FAU - McGregor, Christy AU - McGregor C AD - School of Nursing, University of Mississippi Medical Center. AD - Mississippi Centre for Evidence-Based Practice: A JBI Centre of Excellence, Jackson, Mississippi, USA. FAU - Palokas, Michelle J AU - Palokas MJ AD - School of Nursing, University of Mississippi Medical Center. AD - Mississippi Centre for Evidence-Based Practice: A JBI Centre of Excellence, Jackson, Mississippi, USA. LA - eng PT - Journal Article PT - Review DEP - 20230601 PL - United States TA - JBI Evid Implement JT - JBI evidence implementation JID - 101772772 SB - IM MH - Humans MH - *Outpatients MH - Mississippi MH - *Hospitals EDAT- 2022/11/18 06:00 MHDA- 2023/06/05 06:42 CRDT- 2022/11/17 10:17 PHST- 2023/06/05 06:42 [medline] PHST- 2022/11/18 06:00 [pubmed] PHST- 2022/11/17 10:17 [entrez] AID - 02205615-202306000-00008 [pii] AID - 10.1097/XEB.0000000000000358 [doi] PST - epublish SO - JBI Evid Implement. 2023 Jun 1;21(2):167-177. doi: 10.1097/XEB.0000000000000358. PMID- 36382008 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240907 IS - 1520-765X (Print) IS - 1554-2815 (Electronic) IS - 1520-765X (Linking) VI - 24 IP - Suppl H DP - 2022 Nov TI - Cardiovascular prevention: sometimes dreams can come true. PG - H3-H7 LID - 10.1093/eurheartjsupp/suac057 [doi] AB - Cardiovascular disease (CVD) is a chronic condition driven by the complex interaction of different risk factors including genetics, lifestyle, environment, etc. which, differently from other pathologies, can be prevented. Treatment of CVD has been inconceivably successful but now it seems that it has reached a plateau suggesting that prevention is the way forward. However, the COVID-19 pandemic has spotted all the limits of the actual health system regarding territorial and, particularly, of preventive medicine. To this end, recently, the SCORE2 risk prediction algorithms, a contemporary model to estimate 10-years risk of CVD in Europe and the new guidelines on prevention have been released. The present review article describes a dream: how prevention of CVD should be addressed in the future. New concepts and paradigms like early genetically personalized and imaging driven risk factors, cardiac risk cartography, measurements of the exposome, estimation of costs of a delayed outcome vs. healthy lifespan, are all addressed. We highlight the importance of technologies and the concept of being engaged in a 'healthy' and not just 'sick' system as it is today. The concept of 'clearing house' with a 'healthcare team' instead of a 'heart team' is described. Finally, we articulate the four points necessary for the dream to come true. CI - (c) The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology. FAU - Ferrari, Roberto AU - Ferrari R AD - Cardiovascular Research Centre, Ferrara University, Via Aldo Moro 8, Ferrara 44124, Italy. FAU - Cimaglia, Paolo AU - Cimaglia P AD - Cardiovascular Department, GVM Care and Research, Maria Cecilia Hospital, Via Corriera 1, Cotignola, RA 48033, Italy. FAU - Rapezzi, Claudio AU - Rapezzi C AD - Cardiovascular Research Centre, Ferrara University, Via Aldo Moro 8, Ferrara 44124, Italy. AD - Cardiovascular Department, GVM Care and Research, Maria Cecilia Hospital, Via Corriera 1, Cotignola, RA 48033, Italy. FAU - Tavazzi, Luigi AU - Tavazzi L AD - Cardiovascular Department, GVM Care and Research, Maria Cecilia Hospital, Via Corriera 1, Cotignola, RA 48033, Italy. FAU - Guardigli, Gabriele AU - Guardigli G AD - Cardiovascular Research Centre, Ferrara University, Via Aldo Moro 8, Ferrara 44124, Italy. LA - eng PT - Journal Article DEP - 20221111 PL - England TA - Eur Heart J Suppl JT - European heart journal supplements : journal of the European Society of Cardiology JID - 100886647 PMC - PMC9650456 OTO - NOTNLM OT - CVD OT - Health system OT - Prevention OT - Risk scores COIS- Conflict of interest: R.F. reports having received research grants and personal fees from Novartis and Servier personal fees from Merck Serono, Boehringer Ingelheim, Sunpharma, Lupin, Doc Generici, Pfizer, Spa Prodotti Antibiotici outside the submitted work. He is a director of Art Research and Science S.r.l (A.R.S.1). P.C. has no conflict of interest to disclose. C.R. reports grants and personal fees from Pfizer, personal fees from Sanofi, personal fees from Novartis, personal fees from Alnylam Pharmaceuticals, outside the submitted work. L.T. reports personal fees from SERVIER, personal fees from CVIE THERAPEUTICS outside the submitted work. G.G. has no conflict of interest to disclose. EDAT- 2022/11/17 06:00 MHDA- 2022/11/17 06:01 PMCR- 2022/11/11 CRDT- 2022/11/16 02:59 PHST- 2022/11/16 02:59 [entrez] PHST- 2022/11/17 06:00 [pubmed] PHST- 2022/11/17 06:01 [medline] PHST- 2022/11/11 00:00 [pmc-release] AID - suac057 [pii] AID - 10.1093/eurheartjsupp/suac057 [doi] PST - epublish SO - Eur Heart J Suppl. 2022 Nov 11;24(Suppl H):H3-H7. doi: 10.1093/eurheartjsupp/suac057. eCollection 2022 Nov. PMID- 36380984 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221117 IS - 2572-9292 (Electronic) IS - 2572-9292 (Linking) VI - 6 IP - 5 DP - 2022 TI - A Case of Multidisciplinary Approach to Post-Radiotherapy Dilative Cardiomyopathy Undergoing Elective Cesarean Delivery: Anesthetic and Intensive Care Management. PG - 493-496 LID - 10.26502/fccm.92920288 [doi] AB - BACKGROUND: Cardiovascular diseases are the most common non-obstetric cause of maternal death. These cases became more common thanks to the improvement in cardiovascular therapies. A multidisciplinary team is necessary to manage these pregnancies. CASE REPORT: A 32 years old women at the 25(th) week of gestation for acute heart failure in pre-existing left ventricular dysfunction induced by radio-chemotherapy admitted to the Coronary Unit of IRCCS Policlinico Universitario Agostino Gemelli for worsening of dyspneic symptoms and anuria not responding to diuretic therapy. At the echocardiogram: ejection fraction 30%, enlarged left atrium, systolic pulmonary arterial pressure 38 mmHg, bilateral pleural effusion, bilateral diffused pulmonary B lines. A multidisciplinary team composed by cardiologists, gynecologists, anesthesiologists, cardiac surgeons, neonatologists and bioethicists decided for an elective cesarean delivery at the 27(th) week of gestation in the hybrid cardio-thoracic operating theater. Anesthesia was provided by combined spinal-epidural technique under invasive continuous hemodynamic monitoring with the Edwards Lifesciences HemoSphere with Hypotension Prediction Index (HPI) and ForeSight technology (Edwards Lifesciences, Irvine, USA) through catheterization of the left radial artery. The femoral arteries were left available for extracorporeal circulation. Continuous norepinephrine infusion was started once liquor was collected in the spinal needle at a 0.1 mcg/kg/minute through a central line and was continued until the end of surgery. Fluid management consisted of a total of 200 ml of crystalloids. HPI values never reached alarm values (maximum value =10). The patient was discharged home on the 5(th) day after delivery with good hemodynamic compensation. The baby was intubated at birth and then gradually weaned from mechanical ventilation, then discharged. FAU - Sonnino, Chiara AU - Sonnino C AD - Unit of Obstetric and Gynecologic Anesthesia, IRCCS Fondazione Policlinico Universitario Agostino Gemelli, Italy. FAU - Frassanito, Luciano AU - Frassanito L AD - Unit of Obstetric and Gynecologic Anesthesia, IRCCS Fondazione Policlinico Universitario Agostino Gemelli, Italy. FAU - Zanfini, Bruno Antonio AU - Zanfini BA AD - Unit of Obstetric and Gynecologic Anesthesia, IRCCS Fondazione Policlinico Universitario Agostino Gemelli, Italy. FAU - Catarci, Stefano AU - Catarci S AD - Unit of Obstetric and Gynecologic Anesthesia, IRCCS Fondazione Policlinico Universitario Agostino Gemelli, Italy. FAU - Olivieri, Cristina AU - Olivieri C AD - Unit of Obstetric and Gynecologic Anesthesia, IRCCS Fondazione Policlinico Universitario Agostino Gemelli, Italy. FAU - Ciancia, Mariano AU - Ciancia M AD - Unit of Obstetric and Gynecologic Anesthesia, IRCCS Fondazione Policlinico Universitario Agostino Gemelli, Italy. FAU - Santantonio, Maria Teresa AU - Santantonio MT AD - Unit of Obstetric and Gynecologic Anesthesia, IRCCS Fondazione Policlinico Universitario Agostino Gemelli, Italy. FAU - Draisci, Gaetano AU - Draisci G AD - Unit of Obstetric and Gynecologic Anesthesia, IRCCS Fondazione Policlinico Universitario Agostino Gemelli, Italy. LA - eng GR - R01 HL147662/HL/NHLBI NIH HHS/United States PT - Journal Article DEP - 20220908 PL - United States TA - Cardiol Cardiovasc Med JT - Cardiology and cardiovascular medicine JID - 101721428 PMC - PMC9648409 MID - NIHMS1845258 OTO - NOTNLM OT - Cardiovascular Diseases OT - Coronary Unit OT - Hypotension Prediction Index OT - Radio-Chemotherapy EDAT- 2022/11/17 06:00 MHDA- 2022/11/17 06:01 PMCR- 2022/11/14 CRDT- 2022/11/16 02:46 PHST- 2022/11/16 02:46 [entrez] PHST- 2022/11/17 06:00 [pubmed] PHST- 2022/11/17 06:01 [medline] PHST- 2022/11/14 00:00 [pmc-release] AID - 10.26502/fccm.92920288 [doi] PST - ppublish SO - Cardiol Cardiovasc Med. 2022;6(5):493-496. doi: 10.26502/fccm.92920288. Epub 2022 Sep 8. PMID- 36380807 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221117 IS - 1520-765X (Print) IS - 1554-2815 (Electronic) IS - 1520-765X (Linking) VI - 24 IP - Suppl I DP - 2022 Nov TI - Surgical approach to combined mitral and tricuspid valve disease: good neighbourhood rules. PG - I1-I8 LID - 10.1093/eurheartjsupp/suac096 [doi] AB - Tricuspid regurgitation afflicts more than one-third of patients with mitral valve disease during their clinical history, and negatively affects their outcomes, increasing mortality and hospitalizations for heart failure and reducing the quality of life. A renewed interest in the 'neglected valve' has increased the frequency of the combined treatment of these two diseases. Undoubtedly necessary in patients with degenerative mitral valve disease in the presence of two severe valve defects, tricuspid annuloplasty has proven to be safe and effective even if performed prophylactically, when tricuspid annular dilation coexists with primary mitral dysfunction. In the absence of survival benefits, however, this additional surgical procedure increases the risk of high-grade atrio-ventricular blocks and the need for a definitive pacemaker. On the other hand, the role of surgery has been scaled down in patients with functional mitral and tricuspid regurgitation. In this context, a multidisciplinary approach is needed and transcatheter alternatives are increasingly the chosen treatment option. A new therapeutic algorithm is therefore looming on the horizon. In the future, the treatment of tricuspid and mitral valve disease may be considered two potentially distinct and successive phases of an integrated heart failure patients care process. CI - (c) The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology. FAU - Ascione, Guido AU - Ascione G AUID- ORCID: 0000-0002-7727-0573 AD - Cardiac Surgery Unit, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy. FAU - Carino, Davide AU - Carino D AD - Cardiac Surgery Unit, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy. FAU - Alfieri, Ottavio AU - Alfieri O AD - Cardiac Surgery Unit, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy. AD - Alfieri Heart Foundation, Milan, Italy. LA - eng PT - Journal Article DEP - 20221112 PL - England TA - Eur Heart J Suppl JT - European heart journal supplements : journal of the European Society of Cardiology JID - 100886647 PMC - PMC9653119 OTO - NOTNLM OT - Mitraclip OT - Mitral regurgitation OT - Mitral valve surgery OT - Tricuspid regurgitation OT - Tricuspid valve surgery COIS- Conflict of interest: None declared. EDAT- 2022/11/17 06:00 MHDA- 2022/11/17 06:01 PMCR- 2022/11/12 CRDT- 2022/11/16 02:44 PHST- 2022/11/16 02:44 [entrez] PHST- 2022/11/17 06:00 [pubmed] PHST- 2022/11/17 06:01 [medline] PHST- 2022/11/12 00:00 [pmc-release] AID - suac096 [pii] AID - 10.1093/eurheartjsupp/suac096 [doi] PST - epublish SO - Eur Heart J Suppl. 2022 Nov 12;24(Suppl I):I1-I8. doi: 10.1093/eurheartjsupp/suac096. eCollection 2022 Nov. PMID- 39076200 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240731 IS - 2153-8174 (Electronic) IS - 2153-8174 (Print) IS - 1530-6550 (Linking) VI - 23 IP - 11 DP - 2022 Nov TI - A Review of Cardiovascular Complications among Pregnant Patients with COVID-19. PG - 383 LID - 10.31083/j.rcm2311383 [doi] LID - 383 AB - Cardiovascular complications of severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) infection are well-described in the general population but remain limited among pregnant patients. This review summarizes data from case reports, case series, and observational studies of cardiovascular manifestations of corona virus disease 2019 (COVID-19) in pregnant patients and provides recommendations to the cardiovascular clinician regarding management considerations in this vulnerable population. Pregna is an immunocompromised state in which cardiovascular demands are increased. Cardiovascular complications of COVID-19 that have been described in pregnancy include myocardial injury, cardiomyopathy, thromboembolism, pre-eclampsia and arrhythmia. Physiologic and cardiovascular changes in pregnancy predispose pregnant patients with COVID-19 to more severe illness than the general population. Black or Hispanic race, obesity, diabetes, hypertension and lung disease are risk factors for more severe infection, maternal death and adverse perinatal outcomes. Pregnant patients with severe COVID-19 disease compared with non-pregnant age-matched women with COVID infection are more likely to be admitted to the intensive care unit (ICU), receive mechanical ventilation and require advanced mechanical circulatory support. Cardiovascular complications of COVID-19 in pregnant patients requires further attention, particularly given the anticipated increase in birth volume and ongoing nature of COVID-19 pandemic with novel variants. Clinicians should have a lower threshold for cardiac testing and multidisciplinary management in pregnant women with severe COVID-19 disease. Given the persistence of COVID-19 within our communities, diagnostic laboratory and imaging testing for high-risk pregnant patients hospitalized with COVID-19 infection should be routine. We strongly urge the implementation of a cardio-obstetric multidisciplinary team in individually managing these high-risk patients in an effort to improve maternal and fetal outcomes. CI - Copyright: (c) 2022 The Author(s). Published by IMR Press. FAU - Pruzansky, Alix J AU - Pruzansky AJ AD - Department of Cardiology, Kaiser Permanente, Santa Clara, CA 95051, USA. FAU - Slade, Justin J AU - Slade JJ AD - Department of Cardiology, Kaiser Permanente, San Francisco, CA 94115, USA. FAU - Stephenson, Megan AU - Stephenson M AD - Department of Maternal Fetal Medicine, Kaiser Permanente, Santa Clara, CA 95051, USA. FAU - Pursnani, Seema AU - Pursnani S AD - Department of Cardiology, Kaiser Permanente, Santa Clara, CA 95051, USA. LA - eng PT - Journal Article PT - Review DEP - 20221116 PL - Singapore TA - Rev Cardiovasc Med JT - Reviews in cardiovascular medicine JID - 100960007 PMC - PMC11269075 OTO - NOTNLM OT - COVID-19 OT - cardiovascular complications OT - pregnancy COIS- The authors declare no conflict of interest. EDAT- 2022/11/16 00:00 MHDA- 2022/11/16 00:01 PMCR- 2022/11/16 CRDT- 2024/07/30 04:54 PHST- 2022/06/02 00:00 [received] PHST- 2022/08/15 00:00 [revised] PHST- 2022/08/25 00:00 [accepted] PHST- 2022/11/16 00:01 [medline] PHST- 2022/11/16 00:00 [pubmed] PHST- 2024/07/30 04:54 [entrez] PHST- 2022/11/16 00:00 [pmc-release] AID - S1530-6550(22)00679-2 [pii] AID - 10.31083/j.rcm2311383 [doi] PST - epublish SO - Rev Cardiovasc Med. 2022 Nov 16;23(11):383. doi: 10.31083/j.rcm2311383. eCollection 2022 Nov. PMID- 36380126 OWN - NLM STAT- MEDLINE DCOM- 20230607 LR - 20261010 IS - 1556-0961 (Electronic) IS - 1541-6933 (Linking) VI - 38 IP - 3 DP - 2023 Jun TI - Factors Associated with Early Withdrawal of Life-Sustaining Treatments After Out-of-Hospital Cardiac Arrest: A Subanalysis of a Randomized Trial of Prehospital Therapeutic Hypothermia. PG - 676-687 LID - 10.1007/s12028-022-01636-7 [doi] AB - BACKGROUND: The objective of this study is to describe incidence and factors associated with early withdrawal of life-sustaining therapies based on presumed poor neurologic prognosis (WLST-N) and practices around multimodal prognostication after out-of-hospital cardiac arrest (OHCA). METHODS: We performed a subanalysis of a randomized controlled trial assessing prehospital therapeutic hypothermia in adult patients admitted to nine hospitals in King County with nontraumatic OHCA between 2007 and 2012. Patients who underwent tracheal intubation and were unconscious following return of spontaneous circulation were included. Our outcomes were (1) incidence of early WLST-N (WLST-N within < 72 h from return of spontaneous circulation), (2) factors associated with early WLST-N compared with patients who remained comatose at 72 h without WLST-N, (3) institutional variation in early WLST-N, (4) use of multimodal prognostication, and (5) use of sedative medications in patients with early WLST-N. Analysis included descriptive statistics and multivariable logistic regression. RESULTS: We included 1,040 patients (mean age was 65 years, 37% were female, 41% were White, and 44% presented with arrest due to ventricular fibrillation) admitted to nine hospitals. Early WLST-N accounted for 24% (n = 154) of patient deaths and occurred in half (51%) of patients with WLST-N. Factors associated with early WLST-N in multivariate regressions were older age (odds ratio [OR] 1.02, 95% confidence interval [CI]: 1.01-1.03), preexisting do-not-attempt-resuscitation orders (OR 4.67, 95% CI: 1.55-14.01), bilateral absent pupillary reflexes (OR 2.4, 95% CI: 1.42-4.10), and lack of neurological consultation (OR 2.60, 95% CI: 1.52-4.46). The proportion of patients with early WLST-N among all OHCA admissions ranged from 19-60% between institutions. A head computed tomography scan was obtained in 54% (n = 84) of patients with early WLST-N; 22% (n = 34) and 5% (n = 8) underwent >/= 1 and >/= 2 additional prognostic tests, respectively. Prognostic tests were more frequently performed when neurological consultation occurred. Most patients received sedating medications (90%) within 24 h before early WLST-N; the median time from last sedation to early WLST-N was 4.2 h (interquartile range 0.4-15). CONCLUSIONS: Nearly one quarter of deaths after OHCA were due to early WLST-N. The presence of concerning neurological examination findings appeared to impact early WLST-N decisions, even though these are not fully reliable in this time frame. Lack of neurological consultation was associated with early WLST-N and resulted in underuse of guideline-concordant multimodal prognostication. Sedating medications were often coadministered prior to early WLST-N and may have further confounded the neurological examination. Standardizing prognostication, restricting early WLST-N, and a multidisciplinary approach including neurological consultation might improve outcomes after OHCA. CI - (c) 2022. Springer Science+Business Media, LLC, part of Springer Nature and Neurocritical Care Society. FAU - Wahlster, Sarah AU - Wahlster S AUID- ORCID: 0000-0002-1744-1166 AD - Department of Neurology, Harborview Medical Center, University of Washington, 325 9th Avenue, Box 359702, Seattle, WA, USA. wahlster@uw.edu. AD - Department of Anesthesiology, University of Washington, Seattle, WA, USA. wahlster@uw.edu. AD - Department of Neurological Surgery, University of Washington, Seattle, WA, USA. wahlster@uw.edu. FAU - Danielson, Kyle AU - Danielson K AD - Airlift Northwest, University of Washington Medicine, Seattle, WA, USA. FAU - Craft, Lindy AU - Craft L AD - Department of Anesthesiology, University of Washington, Seattle, WA, USA. FAU - Matin, Nassim AU - Matin N AD - Department of Neurology, Harborview Medical Center, University of Washington, 325 9th Avenue, Box 359702, Seattle, WA, USA. FAU - Town, James A AU - Town JA AD - Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Washington, Seattle, WA, USA. FAU - Srinivasan, Vasisht AU - Srinivasan V AD - Department of Emergency Medicine, University of Washington, Seattle, WA, USA. FAU - Schubert, Glenn AU - Schubert G AD - Department of Neurology, Harborview Medical Center, University of Washington, 325 9th Avenue, Box 359702, Seattle, WA, USA. FAU - Carlbom, David AU - Carlbom D AD - Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Washington, Seattle, WA, USA. FAU - Kim, Francis AU - Kim F AD - Division of Cardiology, Department of Medicine, University of Washington, Seattle, WA, USA. FAU - Johnson, Nicholas J AU - Johnson NJ AD - Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Washington, Seattle, WA, USA. AD - Department of Emergency Medicine, University of Washington, Seattle, WA, USA. FAU - Tirschwell, David AU - Tirschwell D AD - Department of Neurology, Harborview Medical Center, University of Washington, 325 9th Avenue, Box 359702, Seattle, WA, USA. LA - eng PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, Non-P.H.S. PT - Research Support, U.S. Gov't, P.H.S. DEP - 20221115 PL - United States TA - Neurocrit Care JT - Neurocritical care JID - 101156086 SB - IM MH - Adult MH - Humans MH - Female MH - Aged MH - Male MH - *Out-of-Hospital Cardiac Arrest/therapy/complications MH - Coma/etiology MH - Prognosis MH - *Cardiopulmonary Resuscitation/adverse effects MH - *Hypothermia, Induced/methods MH - *Emergency Medical Services OTO - NOTNLM OT - Cardiac arrest OT - Neurological prognostication OT - Out-of-hospital cardiac arrest OT - Withdrawal of life-sustaining treatments EDAT- 2022/11/16 06:00 MHDA- 2023/06/07 06:42 CRDT- 2022/11/15 23:46 PHST- 2022/05/28 00:00 [received] PHST- 2022/10/25 00:00 [accepted] PHST- 2023/06/07 06:42 [medline] PHST- 2022/11/16 06:00 [pubmed] PHST- 2022/11/15 23:46 [entrez] AID - 10.1007/s12028-022-01636-7 [pii] AID - 10.1007/s12028-022-01636-7 [doi] PST - ppublish SO - Neurocrit Care. 2023 Jun;38(3):676-687. doi: 10.1007/s12028-022-01636-7. Epub 2022 Nov 15. PMID- 36378861 OWN - NLM STAT- MEDLINE DCOM- 20230105 LR - 20230111 IS - 1540-8191 (Electronic) IS - 0886-0440 (Linking) VI - 37 IP - 12 DP - 2022 Dec TI - The ability of the logistic EuroSCORE to predict long-term outcomes after coronary artery bypass graft surgery. PG - 4962-4966 LID - 10.1111/jocs.17186 [doi] AB - OBJECTIVES: The European System for Cardiac Operative Risk Evaluation (EuroSCORE) predicts in-hospital mortality for patients undergoing cardiac surgery. Many variables associated with increased surgical mortality persist postoperatively. The aim of this study was to investigate the predictive value of the logistic EuroSCORE to long-term survival after coronary artery bypass surgery. METHODS: Data were collected retrospectively for all patients undergoing coronary artery bypass graft (CABG) at a single center between January 1, 2009 and December 31, 2009. Data submitted to NICOR were used for EuroSCORE and in-hospital outcomes; longer-term, all-cause mortality from NHS digital Personal Demographic Service. Low (<3), intermediate (3-6), and high-risk (>6) logistic EuroSCORE groups were identified and analyzed using the appropriate statistical methodology, with p values less than .05 being taken as significant. RESULTS: Six hundred and sixty-three patients underwent isolated CABG procedures during the study. The 1-, 3-, 5-, and 10-year survival rates were 97.6%, 94.3%, 89.3%, and 73.5%, respectively. Comparing survival outcomes between low-, intermediate-, and high-risk groups showed that the logistic EuroSCORE was able to predict long-term outcomes (p < .05). In addition, poor left ventricular ejection fraction, serum creatinine above 200 ml, chronic pulmonary disease, extracardiac arteriopathy, and pulmonary hypertension were identified as independent predictors of long-term mortality. CONCLUSIONS: Our study demonstrates the logistic EuroSCORE predicted long-term outcomes following CABG surgery. This finding can inform patients of the long-term risks of CABG surgery and guide MDT decision-making. CI - (c) 2022 Wiley Periodicals LLC. FAU - Fleet, Benjamin G AU - Fleet BG AUID- ORCID: 0000-0002-8832-8531 AD - Lancaster Medical School, Lancaster, UK. FAU - Walker, Antony H AU - Walker AH AD - Department of Cardiothoracic Surgery, Blackpool Victoria Hospital, Blackpool, UK. LA - eng PT - Journal Article DEP - 20221115 PL - United States TA - J Card Surg JT - Journal of cardiac surgery JID - 8908809 SB - IM MH - Humans MH - Retrospective Studies MH - Stroke Volume MH - *Ventricular Function, Left MH - Coronary Artery Bypass MH - *Cardiac Surgical Procedures MH - Hospital Mortality MH - Risk Assessment OTO - NOTNLM OT - cardiovascular research OT - coronary artery disease EDAT- 2022/11/16 06:00 MHDA- 2023/01/06 06:00 CRDT- 2022/11/15 14:43 PHST- 2022/09/07 00:00 [received] PHST- 2022/10/27 00:00 [accepted] PHST- 2022/11/16 06:00 [pubmed] PHST- 2023/01/06 06:00 [medline] PHST- 2022/11/15 14:43 [entrez] AID - 10.1111/jocs.17186 [doi] PST - ppublish SO - J Card Surg. 2022 Dec;37(12):4962-4966. doi: 10.1111/jocs.17186. Epub 2022 Nov 15. PMID- 36377402 OWN - NLM STAT- MEDLINE DCOM- 20221202 LR - 20230123 IS - 2154-1671 (Electronic) IS - 2154-1671 (Linking) VI - 12 IP - 12 DP - 2022 Dec 1 TI - Characteristics of Adult Rapid Response Events in a Freestanding Children's Hospital. PG - 1058-1065 LID - 10.1542/hpeds.2022-006748 [doi] AB - OBJECTIVES: To describe nonhospitalized adult rapid response events (adult RREs) in a freestanding children's hospital and examine the relationship between various demographic and clinical factors with the final patient disposition. METHODS: We retrospectively reviewed records for nonhospitalized patients >/=18 years of age from events that occurred in a freestanding pediatric hospital between January 2011 through December 2020. We examined the relationship between adult RREs and patient demographic information, medical history, interventions, and patient disposition following an adult RRE. RESULTS: Four hundred twenty-nine events met inclusion criteria for analysis. Most events (69%) occurred in females, 49% of events occurred in family members of patients, and 47% occurred on inpatient floor and ICU areas. The most common presenting complaint was syncope or dizziness (36%). Delivery of bad news or grief response was associated with 14% of adult RREs. Overall, 46% (n = 196) of patients were transferred to the pediatric emergency department (ED). Patients requiring acute intervention or with cardiac or neurologic past medical histories were more likely to be transferred to the pediatric ED. Acute advanced cardiac life support interventions were infrequent but, of the patients taken to the pediatric ED, 1 died, and 3 were admitted to the ICU. CONCLUSIONS: Adult RREs are common in freestanding children's hospitals and, although rare, some patients required critical care. Expertise in adult critical care management should be available to the rapid response team and additional training for the pediatric rapid response team in caring for adult nonpatients may be warranted. CI - Copyright (c) 2022 by the American Academy of Pediatrics. FAU - Chalam, Jennifer N AU - Chalam JN AD - Division of Emergency Medicine, Department of Pediatrics, Children's Hospital of Michigan, Detroit, Michigan. FAU - Noble, Jennifer AU - Noble J AD - Division of Emergency Medicine, Department of Pediatrics, Children's Hospital of Michigan, Detroit, Michigan. AD - Central Michigan University School of Medicine, Mount Pleasant, Michigan. FAU - DeLaroche, Amy M AU - DeLaroche AM AD - Division of Emergency Medicine, Department of Pediatrics, Children's Hospital of Michigan, Detroit, Michigan. AD - Central Michigan University School of Medicine, Mount Pleasant, Michigan. FAU - Ehrman, Robert R AU - Ehrman RR AD - Department of Emergency Medicine, Wayne State University School of Medicine, Detroit Medical Center, Sinai-Grace Hospital, Detroit, Michigan. FAU - Cashen, Katherine AU - Cashen K AD - Division of Pediatric Critical Care Medicine, Department of Pediatrics, Duke University Children's Hospital, Duke University School of Medicine, Durham, North Carolina. LA - eng PT - Journal Article PL - United States TA - Hosp Pediatr JT - Hospital pediatrics JID - 101585349 SB - IM MH - Adult MH - Female MH - Child MH - Humans MH - *Hospitals, Pediatric MH - Retrospective Studies MH - *Hospital Rapid Response Team MH - Hospitalization MH - Emergency Service, Hospital EDAT- 2022/11/16 06:00 MHDA- 2022/12/03 06:00 CRDT- 2022/11/15 03:24 PHST- 2022/11/16 06:00 [pubmed] PHST- 2022/12/03 06:00 [medline] PHST- 2022/11/15 03:24 [entrez] AID - 189947 [pii] AID - 10.1542/hpeds.2022-006748 [doi] PST - ppublish SO - Hosp Pediatr. 2022 Dec 1;12(12):1058-1065. doi: 10.1542/hpeds.2022-006748. PMID- 36374361 OWN - NLM STAT- MEDLINE DCOM- 20221116 LR - 20230103 IS - 1573-689X (Electronic) IS - 0148-5598 (Print) IS - 0148-5598 (Linking) VI - 46 IP - 12 DP - 2022 Nov 14 TI - Effects of the Multidisciplinary Preoperative Clinic on the Incidence of Elective Surgery Cancellation. PG - 95 LID - 10.1007/s10916-022-01883-3 [doi] LID - 95 AB - To evaluate effects of the multidisciplinary preoperative clinic (POC) consisting of anesthesiologists, dentists, pharmacists, and nurses on elective surgery cancellation, we retrospectively investigated patients who underwent elective non-cardiac, non-obstetric surgeries between October, 2018 and March, 2019 (before the POC establishment: Group 1) and between October, 2019 and March, 2020 (after the POC establishment: Group 2). Among reasons for surgery cancellation allocated into eight categories, three reasons for cancellation (related to consent authorization, medication, and significant comorbidities) were considered preventable. We compared incidences of overall and preventable cancellations of surgeries between 4,198 patients in Group 1 and 4,664 patients in Group 2, who had significantly different clinical backgrounds, including the ASA-PS class. There was no significant difference in the incidence of overall cancellation between Group 1 and Group 2 (4.1% vs. 4.1%, p = 0.96). However, the incidence of preventable cancellation was significantly lower in Group 2 than in Group 1 (0.4% vs. 0.7%, p = 0.045). In addition, the incidence of overall cancellation was significantly lower in 3,741 Group 2 patients visiting the POC than in 5,121 patients not visiting the POC in both Groups (3.2% vs. 4.7%, p < 0.001). Further, in 3,423 pairs of patients with comparable clinical backgrounds created from both Groups using propensity score matching, incidences of overall cancellation (2.2% vs. 3.1%) and preventable cancellation (0.1% vs. 0.6%) were significantly lower in Group 2 than in Group 1 (p = 0.036 and 0.008, respectively). In conclusion, the multidisciplinary POC was effective in reducing elective surgery cancellation. CI - (c) 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Umeno, Yuki AU - Umeno Y AD - Department of Anesthesiology and Pain Medicine, Graduate School of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-Ku, Tokyo, 113-8421, Japan. FAU - Ishikawa, Seiji AU - Ishikawa S AD - Department of Anesthesiology and Pain Medicine, Graduate School of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-Ku, Tokyo, 113-8421, Japan. seiji.ishikawa.juntendo@gmail.com. AD - Department of Anesthesiology and Pain Medicine, Faculty of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-Ku, Tokyo, 113-8421, Japan. seiji.ishikawa.juntendo@gmail.com. FAU - Kudoh, Osamu AU - Kudoh O AD - Department of Anesthesiology and Pain Medicine, Faculty of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-Ku, Tokyo, 113-8421, Japan. FAU - Hayashida, Masakazu AU - Hayashida M AD - Department of Anesthesiology and Pain Medicine, Graduate School of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-Ku, Tokyo, 113-8421, Japan. AD - Department of Anesthesiology and Pain Medicine, Faculty of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-Ku, Tokyo, 113-8421, Japan. LA - eng PT - Journal Article DEP - 20221114 PL - United States TA - J Med Syst JT - Journal of medical systems JID - 7806056 SB - IM MH - Humans MH - *Appointments and Schedules MH - Incidence MH - Retrospective Studies MH - *Operating Rooms MH - Elective Surgical Procedures PMC - PMC9660193 OTO - NOTNLM OT - Cancellation of surgery OT - Multidisciplinary team OT - Operational efficiency OT - Preoperative clinic COIS- The authors declare no conflict of interest associated with this study. EDAT- 2022/11/15 06:00 MHDA- 2022/11/18 06:00 PMCR- 2022/11/14 CRDT- 2022/11/14 11:29 PHST- 2022/09/16 00:00 [received] PHST- 2022/10/25 00:00 [accepted] PHST- 2022/11/14 11:29 [entrez] PHST- 2022/11/15 06:00 [pubmed] PHST- 2022/11/18 06:00 [medline] PHST- 2022/11/14 00:00 [pmc-release] AID - 10.1007/s10916-022-01883-3 [pii] AID - 1883 [pii] AID - 10.1007/s10916-022-01883-3 [doi] PST - epublish SO - J Med Syst. 2022 Nov 14;46(12):95. doi: 10.1007/s10916-022-01883-3. PMID- 36360185 OWN - NLM STAT- MEDLINE DCOM- 20221114 LR - 20221126 IS - 2073-4425 (Electronic) IS - 2073-4425 (Linking) VI - 13 IP - 11 DP - 2022 Oct 26 TI - The Unique Experience of a New Multidisciplinary Program for 22q Deletion and Duplication Syndromes in a Community Hospital in Florida: A Reaffirmation That Multidisciplinary Care Is Essential for Best Outcomes in These Patients. LID - 10.3390/genes13111949 [doi] LID - 1949 AB - In 2018, the first 22q11.2 multidisciplinary program in the state of Florida was created at Joe DiMaggio Children's Hospital following the new paradigm for best care of 22q11.2 deletion patients. Since inauguration, the clinic flourished despite challenges. Our 22q clinic has 149 patients ranging from ages 0-21. From that total, 138 are 22q11.2DS: 74 females and 64 males (44% Hispanics, 35% Caucasians, 11% African American, 3% Asian and 7% multiracial). Eleven patients are in the 22q11.2 duplication group; 7 females and 4 males (50% Hispanics, 30% Caucasians 10% Asian and 10% multiracial). Our multidisciplinary team has grown to include twelve different specialties to better serve our growing patient population and has adapted to the pandemic by offering virtual clinics. Although there are many 22q multidisciplinary clinics worldwide, our clinic has special characteristics. We have an ethnically diverse group of patients and a large team of mostly bilingual providers who are passionate about and have expertise on 22q Deletion/Duplication Syndromes. Our 22q clinic is based at a community hospital and counts on the partnership of local 22q patient support groups. The program is also unique in that it is now expanding to care for adult 22q patients. Our clinic is another live example of how multidisciplinary care is the best way to achieve the most optimal outcomes in 22q patients, and that if there is a passionate and dedicated team of providers willing to collaborate for these patients, a 22q multidisciplinary program can thrive, succeed and grow at a community hospital. FAU - Meneses, Zaimary AU - Meneses Z AD - Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL 33431, USA. FAU - Durant, Jenna AU - Durant J AUID- ORCID: 0000-0002-7278-3142 AD - Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL 33431, USA. FAU - Ale, Hanadys AU - Ale H AD - Department of Allergy and Immunology, Joe DiMaggio Children's Hospital, Hollywood, FL 33021, USA. LA - eng PT - Journal Article DEP - 20221026 PL - Switzerland TA - Genes (Basel) JT - Genes JID - 101551097 SB - IM MH - Adult MH - Child MH - Male MH - Female MH - Humans MH - Infant, Newborn MH - Infant MH - Child, Preschool MH - Adolescent MH - Young Adult MH - Syndrome MH - *Hospitals, Community MH - Florida MH - *DiGeorge Syndrome/genetics MH - Chromosome Duplication PMC - PMC9690475 OTO - NOTNLM OT - 22q11.2 deletion syndrome OT - 22q11.2 duplication syndrome OT - chromosomal microdeletion OT - multidisciplinary care OT - multidisciplinary clinic COIS- The authors declare no conflict of interest. EDAT- 2022/11/12 06:00 MHDA- 2022/11/15 06:00 PMCR- 2022/10/26 CRDT- 2022/11/11 01:15 PHST- 2022/09/24 00:00 [received] PHST- 2022/10/19 00:00 [revised] PHST- 2022/10/24 00:00 [accepted] PHST- 2022/11/11 01:15 [entrez] PHST- 2022/11/12 06:00 [pubmed] PHST- 2022/11/15 06:00 [medline] PHST- 2022/10/26 00:00 [pmc-release] AID - genes13111949 [pii] AID - genes-13-01949 [pii] AID - 10.3390/genes13111949 [doi] PST - epublish SO - Genes (Basel). 2022 Oct 26;13(11):1949. doi: 10.3390/genes13111949. PMID- 36355270 OWN - NLM STAT- MEDLINE DCOM- 20230525 LR - 20230526 IS - 1439-0973 (Electronic) IS - 0300-8126 (Print) IS - 0300-8126 (Linking) VI - 51 IP - 3 DP - 2023 Jun TI - Value of diagnosing immunological phenomena in patients with suspected endocarditis. PG - 705-713 LID - 10.1007/s15010-022-01954-0 [doi] AB - PURPOSE: Immunological phenomena are a minor criteria in the modified Duke Criteria for endocarditis. Given the changes in epidemiology and diagnostics, the added value of determining these phenomena in today's patients with suspected endocarditis is unknown. METHODS: In a retrospective cohort study of all patients with suspected endocarditis admitted to our hospital and discussed in our endocarditis team, we determined the proportion of patients classified as definite endocarditis because of either positive IgM rheumatoid factor (IgM RF), haematuria, or Roth's spots on ophthalmology consultation. We also determined diagnostic accuracy of each of these immunological phenomena separately and combined. RESULTS: Of 285 patients included, 138 (48%) had definite endocarditis and at least one immunological test was performed in 222 patients (78%). Elevated IgM RF was found in 22 of 126 patients tested (17%), haematuria in 78 of 196 tested (40%) and Roth's spots in six of 120 tested (5%). Eighteen of 138 patients with definite IE (13%) were classified as such because of a positive IgM RF, haematuria or Roth's spots. Haematuria had the highest sensitivity: 50.5% (95% CI 40.4-60.6) and Roth's spots the highest specificity: 98.3% (95% CI 90.8-99.9). The diagnostic accuracy results were robust in a sensitivity analysis aimed at avoiding incorporation bias. CONCLUSION: Among patients with a clinical suspicion of endocarditis, recommended systematic testing for immunological phenomena helped classify more patients as definite IE and is useful to confirm the diagnosis of endocarditis. CI - (c) 2022. The Author(s). FAU - van der Vaart, Thomas W AU - van der Vaart TW AUID- ORCID: 0000-0002-5873-0474 AD - Department of Internal Medicine, Division of Infectious Diseases, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. t.w.vandervaart@amsterdamumc.nl. AD - Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands. t.w.vandervaart@amsterdamumc.nl. FAU - Heerschop, Luca L AU - Heerschop LL AD - Department of Internal Medicine, Division of Infectious Diseases, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. FAU - Bouma, Berto J AU - Bouma BJ AD - Department of Cardiology, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. FAU - Freudenburg, Wieke AU - Freudenburg W AD - Department of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. FAU - Bonten, Marc J M AU - Bonten MJM AD - Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands. FAU - Prins, Jan M AU - Prins JM AD - Department of Internal Medicine, Division of Infectious Diseases, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. FAU - van der Meer, Jan T M AU - van der Meer JTM AD - Department of Internal Medicine, Division of Infectious Diseases, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. LA - eng PT - Journal Article DEP - 20221110 PL - Germany TA - Infection JT - Infection JID - 0365307 RN - 0 (Immunoglobulin M) SB - IM MH - Humans MH - Retrospective Studies MH - Hematuria MH - *Endocarditis MH - Hospitalization MH - Immunoglobulin M MH - *Endocarditis, Bacterial/diagnosis PMC - PMC10205820 OTO - NOTNLM OT - Diagnosis OT - Duke Criteria OT - Endocarditis OT - Immunological phenomena OT - Rheumatoid factor OT - Roth's spots COIS- The authors have no relevant financial or non-financial interests to disclose. EDAT- 2022/11/11 06:00 MHDA- 2023/05/25 06:42 PMCR- 2022/11/10 CRDT- 2022/11/10 11:21 PHST- 2022/05/04 00:00 [received] PHST- 2022/11/02 00:00 [accepted] PHST- 2023/05/25 06:42 [medline] PHST- 2022/11/11 06:00 [pubmed] PHST- 2022/11/10 11:21 [entrez] PHST- 2022/11/10 00:00 [pmc-release] AID - 10.1007/s15010-022-01954-0 [pii] AID - 1954 [pii] AID - 10.1007/s15010-022-01954-0 [doi] PST - ppublish SO - Infection. 2023 Jun;51(3):705-713. doi: 10.1007/s15010-022-01954-0. Epub 2022 Nov 10. PMID- 36354772 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250511 IS - 2308-3425 (Electronic) IS - 2308-3425 (Linking) VI - 9 IP - 11 DP - 2022 Oct 31 TI - Maternal Cardiovascular Outcomes of Pregnancy in Childhood, Adolescent, and Young Adult Cancer Survivors. LID - 10.3390/jcdd9110373 [doi] LID - 373 AB - This review focuses on the maternal cardiovascular risk and outcomes of pregnancy in childhood, adolescent, and young adult cancer survivors who are achieving survival to their prime reproductive years. Childhood, adolescent, and young adult cancer survivors are a growing population and have increasing needs for reproductive care over decades of life. Female cancer survivors have an overall higher risk of maternal cardiovascular events compared to those without a history of cancer. In female cancer survivors with normal cardiac function before pregnancy, the incidence of new heart failure during pregnancy is low. In survivors with cardiotoxicity prior to pregnancy, the risk of heart failure during and immediately after pregnancy is much higher. We recommend cardiomyopathy surveillance with echocardiography before pregnancy for all female survivors treated with anthracyclines and chest radiation. Survivors with cardiotoxicity prior to pregnancy should be cared for by an expert multidisciplinary team, including obstetrics, cardiology, anesthesia, and specialized nursing, among others. FAU - Bansal, Neha AU - Bansal N AD - The Children's Heart Center, Kravis Children's Hospital, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. FAU - Hazim, Carol Fernandez AU - Hazim CF AD - Department of Medicine, Montefiore Medical Center, Bronx, New York, NY 10467, USA. FAU - Badillo, Sergio AU - Badillo S AD - Cardiology, CEDIMAT Cardiovascular Center, Santo Domingo 10514, Dominican Republic. FAU - Shyam, Sharvari AU - Shyam S AD - Department of Pediatrics, St. Barnabas Hospital, Bronx, New York, NY 10457, USA. FAU - Wolfe, Diana AU - Wolfe D AUID- ORCID: 0000-0002-5698-3347 AD - Department of Obstetrics & Gynecology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, NY 10461, USA. AD - Women's Health, MFM-Cardiology Joint Program, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, NY 10461, USA. FAU - Bortnick, Anna E AU - Bortnick AE AUID- ORCID: 0000-0001-7983-5243 AD - Department of Medicine, Division of Geriatrics, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, NY 10461, USA. AD - Department of Medicine, Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, 111 E 210th St, Bronx, New York, NY 10467, USA. FAU - Garcia, Mario J AU - Garcia MJ AD - Department of Medicine, Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, 111 E 210th St, Bronx, New York, NY 10467, USA. FAU - Rodriguez, Carols J AU - Rodriguez CJ AD - Department of Medicine, Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, 111 E 210th St, Bronx, New York, NY 10467, USA. FAU - Zhang, Lili AU - Zhang L AD - Department of Medicine, Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, 111 E 210th St, Bronx, New York, NY 10467, USA. LA - eng GR - K23 HL146982/HL/NHLBI NIH HHS/United States GR - The Glorney-Raisbeck Junior Faculty Research Award In Cardiovascular Diseases/New York Academy of Medicine/ PT - Journal Article PT - Review DEP - 20221031 PL - Switzerland TA - J Cardiovasc Dev Dis JT - Journal of cardiovascular development and disease JID - 101651414 PMC - PMC9695103 OTO - NOTNLM OT - cancer survivors OT - cardiotoxicity cardiovascular outcomes OT - pregnancy COIS- The authors declare no conflict of interest. EDAT- 2022/11/11 06:00 MHDA- 2022/11/11 06:01 PMCR- 2022/10/31 CRDT- 2022/11/10 10:22 PHST- 2022/07/14 00:00 [received] PHST- 2022/08/13 00:00 [revised] PHST- 2022/08/15 00:00 [accepted] PHST- 2022/11/10 10:22 [entrez] PHST- 2022/11/11 06:00 [pubmed] PHST- 2022/11/11 06:01 [medline] PHST- 2022/10/31 00:00 [pmc-release] AID - jcdd9110373 [pii] AID - jcdd-09-00373 [pii] AID - 10.3390/jcdd9110373 [doi] PST - epublish SO - J Cardiovasc Dev Dis. 2022 Oct 31;9(11):373. doi: 10.3390/jcdd9110373. PMID- 36375007 STAT- Publisher CTDT- 20221110 PB - University of Washington, Seattle DP - 1993 TI - Stromme Syndrome. BTI - GeneReviews((R)) AB - CLINICAL CHARACTERISTICS: Stromme syndrome is a clinically variable disorder characterized primarily by small bowel intestinal atresia (including apple peel intestinal atresia), microcephaly, developmental delay and/or intellectual disability, structural brain anomalies, and ocular, genitourinary, and cardiac anomalies. A highly variable clinical presentation is observed among affected individuals that may range from mid-gestation lethality, to multisystem involvement with features implicated in the ciliopathies, to nonsyndromic microcephaly with developmental delay. Apple peel intestinal atresia, a rare form of small bowel atresia involving the proximal jejunum near the ligament of Treitz, occurs in some individuals. Intestinal atresia in individuals with Stromme syndrome can involve the duodenum, jejunum, or multiple segments. DIAGNOSIS/TESTING: The diagnosis of Stromme syndrome is established in a proband with characteristic features and biallelic CENPF pathogenic variants identified by molecular genetic testing. MANAGEMENT: Treatment: Individualized care by a multidisciplinary team; surgical treatment of gastrointestinal atresia; developmental and educational support; standard treatment for ocular anomalies, vision issues, renal anomalies, and cardiac anomalies; social work involvement and care coordination as needed. Surveillance: Assess growth, feeding, and development at each visit. Follow up for ophthalmologic manifestations and vision issues as recommended by ophthalmologist and low-vision clinic. GENETIC COUNSELING: Stromme syndrome is inherited in an autosomal recessive manner. If both parents are known to be heterozygous for a CENPF pathogenic variant, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Once the CENPF pathogenic variants have been identified in an affected family member, carrier testing for at-risk relatives and prenatal/preimplantation genetic testing are possible. CI - Copyright (c) 1993-2026, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved. FED - Adam, Margaret P ED - Adam MP FED - Bick, Sarah ED - Bick S FED - Mirzaa, Ghayda M ED - Mirzaa GM FED - Wallace, Stephanie E ED - Wallace SE FED - Amemiya, Anne ED - Amemiya A FAU - Ho, Stephanie KL AU - Ho SKL AD - Clinical Genetic Service, Department of Health, Hong Kong Special Administrative Region, China FAU - Leung, Lai Ting AU - Leung LT AD - Clinical Genetic Service, Department of Health, Hong Kong Special Administrative Region, China FAU - Luk, Ho-ming AU - Luk HM AD - Clinical Genetics Service Unit, Hong Kong Children's Hospital, Hong Kong Special Administrative Region, China FAU - Lo, Ivan FM AU - Lo IFM AD - Clinical Genetic Service, Department of Health, Hong Kong Special Administrative Region, China LA - eng PT - Review PT - Book Chapter PL - Seattle (WA) OTO - NLM OT - Apple Peel Syndrome with Microcephaly and Ocular Anomalies OT - Jejunal Atresia with Microcephaly and Ocular Anomalies OT - Centromere protein F OT - CENPF OT - Stromme Syndrome OT - Apple Peel Syndrome with Microcephaly and Ocular Anomalies OT - Jejunal Atresia with Microcephaly and Ocular Anomalies EDAT- 2022/11/10 00:00 CRDT- 2022/11/10 00:00 AID - NBK586170 [bookaccession] PMID- 36352318 OWN - NLM STAT- MEDLINE DCOM- 20221215 LR - 20221221 IS - 2662-4737 (Electronic) IS - 2662-4729 (Print) IS - 2662-4729 (Linking) VI - 45 IP - 4 DP - 2022 Dec TI - Combined clustered scan-based metal artifact reduction algorithm (CCS-MAR) for ultrasound-guided cardiac radioablation. PG - 1273-1287 LID - 10.1007/s13246-022-01192-6 [doi] AB - Cardiac radioablation is a promising treatment for cardiac arrhythmias, but accurate dose delivery can be affected by heart motion. For this reason, real-time cardiac motion monitoring during radioablation is of paramount importance. Real-time ultrasound (US) guidance can be a solution. The US-guided cardiac radioablation workflow can be simplified by the simultaneous US and planning computed tomography (CT) acquisition, which can result in US transducer-induced metal artifacts on the planning CT scans. To reduce the impact of these artifacts, a new metal artifact reduction (MAR) algorithm (named: Combined Clustered Scan-based MAR [CCS-MAR]) has been developed and compared with iMAR (Siemens), O-MAR (Philips) and MDT (ReVision Radiology) algorithms. CCS-MAR is a fully automated sinogram inpainting-based MAR algorithm, which uses a two-stage correction process based on a normalized MAR method. The second stage aims to correct errors remaining from the first stage to create an artifact-free combined clustered scan for the process of metal artifact reduction. To evaluate the robustness of CCS-MAR, conventional CT scans and/or dual-energy CT scans from three anthropomorphic phantoms and transducers with different sizes were used. The performance of CCS-MAR for metal artifact reduction was compared with other algorithms through visual comparison, image quality metrics analysis, and HU value restoration evaluation. The results of this study show that CCS-MAR effectively reduced the US transducer-induced metal artifacts and that it improved HU value accuracy more or comparably to other MAR algorithms. These promising results justify future research into US transducer-induced metal artifact reduction for the US-guided cardiac radioablation purposes. CI - (c) 2022. The Author(s). FAU - Puvanasunthararajah, Sathyathas AU - Puvanasunthararajah S AUID- ORCID: 0000-0002-0752-4953 AD - School of Clinical Sciences, Queensland University of Technology, Brisbane, QLD, Australia. sathyathas.puvanasunthararajah@hdr.qut.edu.au. AD - Centre for Biomedical Technologies, Queensland University of Technology, Brisbane, QLD, Australia. sathyathas.puvanasunthararajah@hdr.qut.edu.au. FAU - Camps, Saskia M AU - Camps SM AD - EBAMed SA, Geneva, Switzerland. FAU - Wille, Marie-Luise AU - Wille ML AD - Centre for Biomedical Technologies, Queensland University of Technology, Brisbane, QLD, Australia. AD - School of Mechanical, Medical & Process Engineering, Faculty of Engineering, Queensland University of Technology, Brisbane, QLD, Australia. AD - ARC ITTC for Multiscale 3D Imaging, Modelling, and Manufacturing, Queensland University of Technology, Brisbane, QLD, Australia. FAU - Fontanarosa, Davide AU - Fontanarosa D AD - School of Clinical Sciences, Queensland University of Technology, Brisbane, QLD, Australia. AD - Centre for Biomedical Technologies, Queensland University of Technology, Brisbane, QLD, Australia. LA - eng GR - 954783/HORIZON EUROPE European Research Council/ GR - 40854/Innosuisse - Schweizerische Agentur fur Innovationsforderung/ PT - Journal Article DEP - 20221109 PL - Switzerland TA - Phys Eng Sci Med JT - Physical and engineering sciences in medicine JID - 101760671 RN - 0 (Metals) SB - IM MH - *Metals MH - *Artifacts MH - Algorithms MH - Phantoms, Imaging MH - Ultrasonography, Interventional PMC - PMC9747859 OTO - NOTNLM OT - And cardiac radioablation OT - Cardiac arrhythmias OT - Computed tomography OT - Metal artifact reduction OT - Ultrasound guidance COIS- The authors have no relevant financial or non-financial interests to disclose. EDAT- 2022/11/10 06:00 MHDA- 2022/12/16 06:00 PMCR- 2022/11/09 CRDT- 2022/11/09 23:59 PHST- 2022/06/02 00:00 [received] PHST- 2022/10/20 00:00 [accepted] PHST- 2022/11/10 06:00 [pubmed] PHST- 2022/12/16 06:00 [medline] PHST- 2022/11/09 23:59 [entrez] PHST- 2022/11/09 00:00 [pmc-release] AID - 10.1007/s13246-022-01192-6 [pii] AID - 1192 [pii] AID - 10.1007/s13246-022-01192-6 [doi] PST - ppublish SO - Phys Eng Sci Med. 2022 Dec;45(4):1273-1287. doi: 10.1007/s13246-022-01192-6. Epub 2022 Nov 9. PMID- 36351064 OWN - NLM STAT- MEDLINE DCOM- 20221111 LR - 20260901 IS - 1982-4335 (Electronic) IS - 0103-507X (Print) IS - 0103-507X (Linking) VI - 34 IP - 3 DP - 2022 TI - Automated documentation of vital parameters in wards using portable stations - Effect on proper triggering of the rapid response team: a study protocol of a cluster randomized clinical trial. PG - 319-326 LID - S0103-507X2022000300319 [pii] LID - 10.5935/0103-507X.20220101-pt [doi] AB - OBJECTIVE: To evaluate the effectiveness of the Welch Allyn Connex(R) Spot Monitor/Hillrom Connecta solution in activating the rapid response team in a timely manner compared to manual activation. METHODS: The Hillrom study is a single-center, open-label, superiority, cluster-randomized, parallel-group (1:1 allocation ratio) clinical trial that will be conducted in a tertiary hospital. Two sets of three wards with 28 beds will be included (one as the intervention cluster and the other as the control). The wards will be randomly assigned to use the Welch Allyn Connex(R) Spot Monitor/Hillrom Connecta automated solution (intervention cluster) or to maintain the usual routine (control cluster) regarding rapid response team activation. The primary outcome will be the absolute number of episodes of rapid response team triggering in an appropriate time; as secondary outcomes, clinical features (mortality, cardiac arrest, need for intensive care unit admission and duration of hospitalization) will be assessed according to clusters in an exploratory way. A sample size of 216 rapid response team activations was estimated to identify a possible difference between the groups. The protocol has been approved by the institutional Research Ethics Committee. EXPECTED RESULTS: The Welch Allyn Connex(R) Spot Monitor/Hillrom Connecta automated solution is expected to be more effective in triggering the nurse call system to activate the rapid response team in a timely and adequate manner compared to manual triggering (usual practice). CLINICALTRIALS.GOV: NCT04648579. FAU - Ribeiro, Jose Cesar AU - Ribeiro JC AUID- ORCID: 0000-0003-4787-0962 AD - Departamento de Enfermagem, HCor-Hospital do Coracao - Sao Paulo (SP), Brasil. FAU - Sgorbissa, Cristina AU - Sgorbissa C AUID- ORCID: 0000-0002-4283-3268 AD - Departamento de Enfermagem, HCor-Hospital do Coracao - Sao Paulo (SP), Brasil. FAU - Silva, Karla Aparecida AU - Silva KA AD - Departamento de Enfermagem, HCor-Hospital do Coracao - Sao Paulo (SP), Brasil. FAU - Braz, Maria de Lourdes Dias AU - Braz MLD AUID- ORCID: 0000-0001-8797-5983 AD - Departamento de Enfermagem, HCor-Hospital do Coracao - Sao Paulo (SP), Brasil. FAU - Horak, Ana Clara Peneluppi AU - Horak ACP AUID- ORCID: 0000-0002-9119-5987 AD - Instituto de Pesquisa, HCor-Hospital do Coracao - Sao Paulo (SP), Brasil. FAU - Nicola, Marina Lazzari AU - Nicola ML AUID- ORCID: 0000-0003-1711-2431 AD - Instituto de Pesquisa, HCor-Hospital do Coracao - Sao Paulo (SP), Brasil. FAU - Gurgel, Rodrigo Magalhaes AU - Gurgel RM AUID- ORCID: 0000-0002-3901-2768 AD - Instituto de Pesquisa, HCor-Hospital do Coracao - Sao Paulo (SP), Brasil. FAU - Tokunaga, Samira Martins AU - Tokunaga SM AUID- ORCID: 0000-0003-3350-6481 AD - Instituto de Pesquisa, HCor-Hospital do Coracao - Sao Paulo (SP), Brasil. FAU - Negrelli, Karina Leal AU - Negrelli KL AUID- ORCID: 0000-0002-0259-3116 AD - Instituto de Pesquisa, HCor-Hospital do Coracao - Sao Paulo (SP), Brasil. FAU - Murizine, Gabriela Souza AU - Murizine GS AUID- ORCID: 0000-0003-2147-9906 AD - Instituto de Pesquisa, HCor-Hospital do Coracao - Sao Paulo (SP), Brasil. FAU - Medrado Junior, Fernando AU - Medrado Junior F AUID- ORCID: 0000-0002-8049-9213 AD - Instituto de Pesquisa, HCor-Hospital do Coracao - Sao Paulo (SP), Brasil. FAU - Coli, Rita de Cassia Pires AU - Coli RCP AUID- ORCID: 0000-0002-0948-0325 AD - Departamento de Enfermagem, HCor-Hospital do Coracao - Sao Paulo (SP), Brasil. FAU - Cavalcanti, Alexandre Biasi AU - Cavalcanti AB AUID- ORCID: 0000-0003-2798-6263 AD - Instituto de Pesquisa, HCor-Hospital do Coracao - Sao Paulo (SP), Brasil. FAU - Marcadenti, Aline AU - Marcadenti A AUID- ORCID: 0000-0003-1994-4610 AD - Instituto de Pesquisa, HCor-Hospital do Coracao - Sao Paulo (SP), Brasil. LA - por LA - eng SI - ClinicalTrials.gov/NCT04648579 PT - Clinical Trial Protocol PT - Journal Article TT - Documentacao automatizada de parametros vitais em enfermarias utilizando estacoes portateis - Efeito no acionamento adequado do time de resposta rapida: um protocolo de um ensaio clinico randomizado em clusters. DEP - 20221104 PL - Brazil TA - Rev Bras Ter Intensiva JT - Revista Brasileira de terapia intensiva JID - 9506692 SB - IM MH - Humans MH - *Hospital Rapid Response Team MH - *COVID-19 MH - Hospitalization MH - Documentation MH - Randomized Controlled Trials as Topic MH - Equivalence Trials as Topic PMC - PMC9749098 COIS- Conflicts of interest: None. EDAT- 2022/11/10 06:00 MHDA- 2022/11/15 06:00 PMCR- 2022/07/01 CRDT- 2022/11/09 14:23 PHST- 2022/03/11 00:00 [received] PHST- 2022/07/08 00:00 [accepted] PHST- 2022/11/09 14:23 [entrez] PHST- 2022/11/10 06:00 [pubmed] PHST- 2022/11/15 06:00 [medline] PHST- 2022/07/01 00:00 [pmc-release] AID - S0103-507X2022000300319 [pii] AID - 10.5935/0103-507X.20220101-pt [doi] PST - epublish SO - Rev Bras Ter Intensiva. 2022 Nov 4;34(3):319-326. doi: 10.5935/0103-507X.20220101-pt. eCollection 2022. PMID- 36346471 OWN - NLM STAT- MEDLINE DCOM- 20230109 LR - 20230111 IS - 1435-4373 (Electronic) IS - 0934-9723 (Print) IS - 0934-9723 (Linking) VI - 42 IP - 1 DP - 2023 Jan TI - Risk scores' performance and their impact on operative decision-making in left-sided endocarditis: a cohort study. PG - 33-42 LID - 10.1007/s10096-022-04516-2 [doi] AB - The accuracy of contemporary risk scores in predicting perioperative mortality in infective endocarditis (IE) remains controversial. The aim is to evaluate the performance of existent mortality risk scores for cardiovascular surgery in IE and the impact on operability at high-risk thresholds. A single-center retrospective review of adult patients diagnosed with acute left-sided IE undergoing surgery from May 2014 to August 2019 (n = 142) was done. Individualized risk calculation was obtained according to the available mortality risk scores: EuroScore I and II, PALSUSE, Risk-E, Costa, De Feo-Cotrufo, AEPEI, STS-risk, STS-IE, APORTEI, and ICE-PCS scores. A cross-validation analysis was performed on the score with the best area under the curve (AUC). The 30-day survival was 96.5% (95%CI 91-98%). The score with worse area under the curve (AUC = 0.6) was the STS-IE score, while the higher was for the RISK-E score (AUC = 0.89). The AUC of the majority of risk scores suggested acceptable performance; however, statistically significant differences in expected versus observed mortalities were common. The cross-validation analysis showed that a large number of survivors (> 75%) would not have been operated if arbitrary high-risk threshold estimates had been used to deny surgery. The observed mortality in our cohort is significantly lower than is predicted by contemporary risk scores. Despite the reasonable numeric performance of the analyzed scores, their utility in judging the operability of a given patient remains questionable, as demonstrated in the cross-validation analysis. Future guidelines may advise that denial of surgery should only follow a highly experienced Endocarditis Team evaluation. CI - (c) 2022. The Author(s). FAU - Fernandez-Cisneros, A AU - Fernandez-Cisneros A AD - Cardiovascular Surgery Department, Hospital Clinic - IDIBAPS, University of Barcelona, C/Villarroel 170, 08036, Barcelona, CP, Spain. FAU - Hernandez-Meneses, M AU - Hernandez-Meneses M AD - Infectious Diseases Service, Hospital Clinic - IDIBAPS, University of Barcelona, Barcelona, Spain. FAU - Llopis, J AU - Llopis J AD - Department of Genetics, Microbiology and Statistics, University of Barcelona, Barcelona, Spain. FAU - Sandoval, E AU - Sandoval E AD - Cardiovascular Surgery Department, Hospital Clinic - IDIBAPS, University of Barcelona, C/Villarroel 170, 08036, Barcelona, CP, Spain. AD - Departament de Cirurgia i Especialitats Medicoquirurgiques, Facultat de Medicina i Ciencies de la Salut, Universitat de Barcelona, Barcelona, Spain. FAU - Pereda, D AU - Pereda D AD - Cardiovascular Surgery Department, Hospital Clinic - IDIBAPS, University of Barcelona, C/Villarroel 170, 08036, Barcelona, CP, Spain. AD - Departament de Cirurgia i Especialitats Medicoquirurgiques, Facultat de Medicina i Ciencies de la Salut, Universitat de Barcelona, Barcelona, Spain. FAU - Alcocer, J AU - Alcocer J AD - Cardiovascular Surgery Department, Hospital Clinic - IDIBAPS, University of Barcelona, C/Villarroel 170, 08036, Barcelona, CP, Spain. FAU - Barriuso, C AU - Barriuso C AD - Cardiovascular Surgery Department, Hospital Clinic - IDIBAPS, University of Barcelona, C/Villarroel 170, 08036, Barcelona, CP, Spain. FAU - Castella, M AU - Castella M AD - Cardiovascular Surgery Department, Hospital Clinic - IDIBAPS, University of Barcelona, C/Villarroel 170, 08036, Barcelona, CP, Spain. AD - Departament de Cirurgia i Especialitats Medicoquirurgiques, Facultat de Medicina i Ciencies de la Salut, Universitat de Barcelona, Barcelona, Spain. FAU - Ambrosioni, J AU - Ambrosioni J AD - Infectious Diseases Service, Hospital Clinic - IDIBAPS, University of Barcelona, Barcelona, Spain. FAU - Pericas, J M AU - Pericas JM AD - Infectious Diseases Service, Hospital Clinic - IDIBAPS, University of Barcelona, Barcelona, Spain. AD - Liver Unit, Internal Medicine Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Research, CIBERehd, Barcelona, Spain. FAU - Vidal, B AU - Vidal B AD - Cardiology Department, Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain. FAU - Falces, C AU - Falces C AD - Cardiology Department, Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain. FAU - Ibanez, C AU - Ibanez C AD - Anesthesiology Department, Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain. FAU - Perdomo, J AU - Perdomo J AD - Anesthesiology Department, Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain. FAU - Rovira, I AU - Rovira I AD - Departament de Cirurgia i Especialitats Medicoquirurgiques, Facultat de Medicina i Ciencies de la Salut, Universitat de Barcelona, Barcelona, Spain. AD - Anesthesiology Department, Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain. FAU - Garcia-de-la-Maria, C AU - Garcia-de-la-Maria C AD - Infectious Diseases Service, Hospital Clinic - IDIBAPS, University of Barcelona, Barcelona, Spain. FAU - Moreno, A AU - Moreno A AD - Infectious Diseases Service, Hospital Clinic - IDIBAPS, University of Barcelona, Barcelona, Spain. FAU - Almela, M AU - Almela M AD - Microbiology Department, Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain. FAU - Perisinotti, A AU - Perisinotti A AD - Nuclear Medicine Department, Biomaterials and Nanomedicine (CIBER-BBN), Hospital Clinic-IDIBAPS, University of Barcelona & Biomedical Research Networking Center of Bioengineering, Barcelona, Spain. FAU - Dahl, A AU - Dahl A AD - Infectious Diseases Service, Hospital Clinic - IDIBAPS, University of Barcelona, Barcelona, Spain. FAU - Castro, P AU - Castro P AD - Internal Medicine Department, Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain. FAU - Miro, J M AU - Miro JM AD - Infectious Diseases Service, Hospital Clinic - IDIBAPS, University of Barcelona, Barcelona, Spain. jmmiro@ub.edu. FAU - Quintana, E AU - Quintana E AUID- ORCID: 0000-0002-5386-7463 AD - Cardiovascular Surgery Department, Hospital Clinic - IDIBAPS, University of Barcelona, C/Villarroel 170, 08036, Barcelona, CP, Spain. eduquintana@ub.edu. AD - Departament de Cirurgia i Especialitats Medicoquirurgiques, Facultat de Medicina i Ciencies de la Salut, Universitat de Barcelona, Barcelona, Spain. eduquintana@ub.edu. CN - Equip d'Endocarditis de l'Hospital Clinic de Barcelona LA - eng PT - Journal Article DEP - 20221108 PL - Germany TA - Eur J Clin Microbiol Infect Dis JT - European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology JID - 8804297 SB - IM MH - Adult MH - Humans MH - Cohort Studies MH - Risk Assessment MH - *Cardiac Surgical Procedures MH - Risk Factors MH - *Endocarditis/diagnosis/surgery MH - *Endocarditis, Bacterial MH - Retrospective Studies PMC - PMC9816251 OTO - NOTNLM OT - Infective endocarditis OT - Postoperative outcomes OT - Risk scores OT - Risk stratification COIS- JMM has received consulting honoraria and/or research grants from Angelini, Bristol-Myers Squibb, Contrafect, Genentech, Gilead Sciences, MSD, Medtronic, Novartis, Pfizer, and ViiV. All other authors: no conflicts. EDAT- 2022/11/09 06:00 MHDA- 2023/01/10 06:00 PMCR- 2022/11/08 CRDT- 2022/11/08 11:14 PHST- 2022/06/30 00:00 [received] PHST- 2022/10/20 00:00 [accepted] PHST- 2022/11/09 06:00 [pubmed] PHST- 2023/01/10 06:00 [medline] PHST- 2022/11/08 11:14 [entrez] PHST- 2022/11/08 00:00 [pmc-release] AID - 10.1007/s10096-022-04516-2 [pii] AID - 4516 [pii] AID - 10.1007/s10096-022-04516-2 [doi] PST - ppublish SO - Eur J Clin Microbiol Infect Dis. 2023 Jan;42(1):33-42. doi: 10.1007/s10096-022-04516-2. Epub 2022 Nov 8. PMID- 36346276 OWN - NLM STAT- MEDLINE DCOM- 20221222 LR - 20221222 IS - 1557-8674 (Electronic) IS - 1096-2964 (Linking) VI - 23 IP - 10 DP - 2022 Dec TI - Co-Management Reduces Mortality in Post-Sternotomy Mediastinitis. PG - 873-879 LID - 10.1089/sur.2022.176 [doi] AB - Background: Post-sternotomy mediastinitis (PSM) is one of the most feared complications of cardiac surgery. The impact of a multidisciplinary management approach on this pathology is yet unknown. Patients and Methods: A multidisciplinary approach based on a co-management model (CMM) of care was initiated in January 2018 because of the incorporation of a hospitalist unit on a cardiac surgery department. An observational retrospective cohort study was designed to evaluate the impact of the CMM of care compared to the standard model (SM) of care in patients diagnosed with PSM. Our primary and secondary outcomes were survival time and treatment failure rate (two or more surgical procedures needed to solve PSM or PSM-related death), respectively. Data related to patient death date were collected from the Spanish National Death Index. A multivariable Cox regression model was created using those variables believed to be clinically relevant. Results: Ninety-one patients developed PSM from January 2010 to June 2020. Regarding the pre-operative clinical status, surgical procedure, and PSM severity, both groups had similar baseline characteristics. Patients were followed for a mean of 27.54 +/- 30.5 months. A total of 60.3% of the SM group and 11.1% of the CMM group (p < 0.001) died. Treatment failure occurred in 53 patients (72.6%) in the SM group versus 7 (38.6%) in the CMM group (p = 0.007). The CMM independently reduced overall mortality (hazard ratio [HR], 0.11; 95% confidence interval [CI]. 0.01-0.83) and treatment failure rate (HR, 0.01; 95% CI, 0.001-0.183). Gram-positive bacterial infection (HR, 3.73; 95% CI, .6-8.3), and complete osteosynthesis material removal (HR, 0.47; 95% CI, 0.24-0.91) also influenced mortality in our model. Conclusions: A co-management care model reduced overall mortality in patients diagnosed with post-sternotomy mediastinitis. FAU - Fernandez-de-Velasco, David AU - Fernandez-de-Velasco D AD - Department of Hospital Medicine, Hospital Clinico San Carlos, Universidad Complutense, Madrid, Spain. FAU - Villamor-Jimenez, Cristina AU - Villamor-Jimenez C AD - Department of Hospital Medicine, Hospital Clinico San Carlos, Universidad Complutense, Madrid, Spain. FAU - Carnero-Alcazar, Manuel AU - Carnero-Alcazar M AD - Department of Cardiac Surgery, Hospital Clinico San Carlos, Universidad Complutense, Madrid, Spain. FAU - Sanchez-Del-Hoyo, Rafael AU - Sanchez-Del-Hoyo R AD - Department of Methodological and Preventive Health Medicine and IdISSC of Hospital Clinico San Carlos, Madrid, Spain. FAU - Perez-Camargo, Daniel AU - Perez-Camargo D AD - Department of Cardiac Surgery, Hospital Clinico San Carlos, Universidad Complutense, Madrid, Spain. FAU - Montero-Cruces, Lourdes AU - Montero-Cruces L AD - Department of Cardiac Surgery, Hospital Clinico San Carlos, Universidad Complutense, Madrid, Spain. FAU - Torres-Maestro, Blanca AU - Torres-Maestro B AD - Department of Cardiac Surgery, Hospital Clinico San Carlos, Universidad Complutense, Madrid, Spain. FAU - Giraldo, Maria Alejandra AU - Giraldo MA AD - Department of Cardiac Surgery, Hospital Clinico San Carlos, Universidad Complutense, Madrid, Spain. FAU - Reguillo-Lacruz, Fernando Jose AU - Reguillo-Lacruz FJ AD - Department of Cardiac Surgery, Hospital Clinico San Carlos, Universidad Complutense, Madrid, Spain. FAU - Campelos-Fernandez, Paula AU - Campelos-Fernandez P AD - Department of Cardiac Surgery, Hospital Clinico San Carlos, Universidad Complutense, Madrid, Spain. FAU - Villagran-Medinilla, Enrique AU - Villagran-Medinilla E AD - Department of Cardiac Surgery, Hospital La Paz, Madrid, Spain. FAU - Kisuule, Flora AU - Kisuule F AD - Division of Hospital Medicine, The Johns Hopkins Bayview Medical Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. FAU - Calleja-Sanz, Jorge AU - Calleja-Sanz J AD - Department of Hospital Medicine, Hospital Clinico San Carlos, Universidad Complutense, Madrid, Spain. FAU - Maroto-Castellanos, Luis AU - Maroto-Castellanos L AD - Department of Cardiac Surgery, Hospital Clinico San Carlos, Universidad Complutense, Madrid, Spain. FAU - Alvarez-de-Arcaya, Arantzazu AU - Alvarez-de-Arcaya A AD - Department of Hospital Medicine, Hospital Clinico San Carlos, Universidad Complutense, Madrid, Spain. LA - eng PT - Journal Article PT - Observational Study DEP - 20221107 PL - United States TA - Surg Infect (Larchmt) JT - Surgical infections JID - 9815642 SB - IM MH - Humans MH - Retrospective Studies MH - Sternotomy/adverse effects MH - *Mediastinitis/surgery MH - *Cross Infection MH - *Thoracic Surgical Procedures/adverse effects OTO - NOTNLM OT - cardiothoracic surgery OT - co-management OT - health-care associated infection OT - hospitalist OT - mediastinitis OT - surgical site infection EDAT- 2022/11/09 06:00 MHDA- 2022/12/15 06:00 CRDT- 2022/11/08 09:48 PHST- 2022/11/09 06:00 [pubmed] PHST- 2022/12/15 06:00 [medline] PHST- 2022/11/08 09:48 [entrez] AID - 10.1089/sur.2022.176 [doi] PST - ppublish SO - Surg Infect (Larchmt). 2022 Dec;23(10):873-879. doi: 10.1089/sur.2022.176. Epub 2022 Nov 7. PMID- 36345986 OWN - NLM STAT- MEDLINE DCOM- 20230918 LR - 20250623 IS - 1784-973X (Electronic) IS - 0001-5385 (Linking) VI - 78 IP - 7 DP - 2023 Sep TI - The role of invasive cardiopulmonary exercise testing in patients with unexplained dyspnea: a systemic review. PG - 754-760 LID - 10.1080/00015385.2022.2141434 [doi] AB - BACKGROUND: Dyspnoea is a common complaint that often remains unexplained with no diagnosis and poor management despite extensive, repetitive and costly testing. Invasive cardiopulmonary testing has been used in the evaluation of dyspnoea, however, its role is not yet well defined. We sought to perform a systematic review of the literature looking at the role of invasive cardiopulmonary testing in the evaluation of chronic dyspnoea and/or exercise intolerance. METHODS AND RESULTS: We performed a literature review in accordance with PRISMA, analysing articles published in peer-reviewed journals between January 1st 1985 and January 31st 2020, available in 3 databases. The aim was to identify randomised and non-randomised clinical studies that focussed on the utility of invasive cardiopulmonary exercise test in the evaluation of dyspnoea. Emphasis was placed on studies that noted the use of exercise stress testing with the concomitant use of right heart catheterisation to evaluate hemodynamics as part of the work up for dyspnoea. We identified 6 retrospective studies that assessed the use of exercise hemodynamics to identify the aetiology of dyspnoea. CONCLUSION: Invasive cardiopulmonary exercise test is a useful tool for identifying the cause of unexplained dyspnoea. It can be helpful in early recognition and prognostication of patients with heart failure with preserved ejection fraction and pulmonary hypertension. It has also shown to be beneficial for constructing a multidisciplinary approach to chronic dyspnoea. FAU - Behrooz, Leili AU - Behrooz L AUID- ORCID: 0000-0003-3971-9226 AD - Department of Medicine, Division of Cardiovascular Medicine, Boston University School of Medicine, Boston, MA, USA. FAU - Barillas-Lara, Maria AU - Barillas-Lara M AD - Department of Medicine, Division of Internal Medicine, Boston University School of Medicine, Boston, MA, USA. FAU - Fattouh, Michael AU - Fattouh M AD - Department of Medicine, Division of Internal Medicine, Monte Fiore Medical Center, Bronx, NY, USA. FAU - Loubeau, Berenice AU - Loubeau B AD - Centro de Diagnostico Medicina Avanzada y Telemedicina, Santo Domingo, Dominican Republic. FAU - Ibrahim, Michel AU - Ibrahim M AD - Department of Medicine, Division of Cardiovascular Medicine, Temple University Hospital, Philadelphia, PA, USA. LA - eng PT - Journal Article PT - Systematic Review DEP - 20221108 PL - England TA - Acta Cardiol JT - Acta cardiologica JID - 0370570 SB - IM MH - Humans MH - Exercise Test/methods MH - Retrospective Studies MH - Dyspnea/diagnosis/etiology MH - *Hypertension, Pulmonary/complications MH - Cardiac Catheterization/adverse effects MH - *Heart Failure MH - Exercise Tolerance OTO - NOTNLM OT - Dyspnoea OT - exercise hemodynamics OT - invasive cardiopulmonary exercise test EDAT- 2022/11/09 06:00 MHDA- 2023/09/18 12:43 CRDT- 2022/11/08 06:33 PHST- 2023/09/18 12:43 [medline] PHST- 2022/11/09 06:00 [pubmed] PHST- 2022/11/08 06:33 [entrez] AID - 10.1080/00015385.2022.2141434 [doi] PST - ppublish SO - Acta Cardiol. 2023 Sep;78(7):754-760. doi: 10.1080/00015385.2022.2141434. Epub 2022 Nov 8. PMID- 36345687 OWN - NLM STAT- MEDLINE DCOM- 20230105 LR - 20230111 IS - 1540-8191 (Electronic) IS - 0886-0440 (Linking) VI - 37 IP - 12 DP - 2022 Dec TI - Cardiothoracic surgery leadership and learning are indispensable to each other. PG - 4204-4206 LID - 10.1111/jocs.17116 [doi] AB - Cardiothoracic surgery is facing a multitude of challenges in leadership and training on the global scale, these being a complex and aging patient population, shortage of cardiac surgeons, diminishing student interest and trainee enthusiasm, increasingly challenging training obstacles and work-life imbalances, suboptimal job prospects, reports of discrimination and bullying and lack of diversity as well as gap between innovation and technology, clinical application, and training of future surgeons. The survival of cardiac surgery hinges on the leadership attracting and retaining young surgeons into the specialty. Mentoring, leading through example, recognizing the work-life imbalances, adapting to diverse and modern training models and embracing diversity with respect to gender and race, will ultimately be required to create and cultivate a nurturing environment of training and preparing future leaders. The vision for training future generations of cardiothoracic surgeons must rely heavily on strengthening the unity of the heart team. In doing so we can provide the best possible care for our patients and a most fulfilling career for the future generation of cardiac surgeons. CI - (c) 2022 Wiley Periodicals LLC. FAU - Bashir, Mohamad AU - Bashir M AUID- ORCID: 0000-0002-2605-538X AD - Department of Vascular and Endovascular Surgery, Velindre University NHS Trust, Health Education and Improvement Wales (HEIW), Cardiff, UK. AD - Neurovascular Research Laboratory, Faculty of Life Sciences and Education, University of South Wales, Pontypridd, UK. FAU - Jubouri, Matti AU - Jubouri M AUID- ORCID: 0000-0001-6725-6164 AD - Hull York Medical School, University of York, York, UK. FAU - Chen, Edward P AU - Chen EP AD - Division of Cardiovascular and Thoracic Surgery, Duke University Medical Center, Durham, North Carolina, USA. FAU - Mariscalco, Giovanni AU - Mariscalco G AD - Department of Cardiac Surgery, Glenfield Hospital, University Hospitals of Leicester NHS Trust, Leicester, UK. FAU - Narayan, Pradeep AU - Narayan P AUID- ORCID: 0000-0002-3843-1338 AD - Department of Cardiac Surgery, Rabindranath Tagore International Institute of Cardiac Sciences, Narayana Health, Kolkata, West Bengal, India. FAU - Bailey, Damian M AU - Bailey DM AD - Neurovascular Research Laboratory, Faculty of Life Sciences and Education, University of South Wales, Pontypridd, UK. FAU - Awad, Wael I AU - Awad WI AUID- ORCID: 0000-0003-3380-9554 AD - Department of Cardiothoracic Surgery, Barts Heart Centre, St Bartholomew's Hospital, London, UK. FAU - Williams, Ian M AU - Williams IM AD - Department of Vascular Surgery, University Hospital of Wales, Cardiff, UK. FAU - Velayudhan, Bashi AU - Velayudhan B AUID- ORCID: 0000-0002-3634-4134 AD - Institute of Cardiac and Aortic Disorders (ICAD), SRM Institutes for Medical Science (SIMS Hospital), Chennai, Tamil Nadu, India. FAU - Mohammed, Idhrees AU - Mohammed I AUID- ORCID: 0000-0001-5981-9705 AD - Institute of Cardiac and Aortic Disorders (ICAD), SRM Institutes for Medical Science (SIMS Hospital), Chennai, Tamil Nadu, India. LA - eng GR - Royal Society Wolfson Research Fellowship (#WM170007)/ PT - Journal Article DEP - 20221108 PL - United States TA - J Card Surg JT - Journal of cardiac surgery JID - 8908809 SB - IM MH - Humans MH - Leadership MH - *Thoracic Surgery/education MH - *Cardiac Surgical Procedures MH - *Surgeons OTO - NOTNLM OT - cardiothoracic surgery OT - education OT - training EDAT- 2022/11/09 06:00 MHDA- 2023/01/06 06:00 CRDT- 2022/11/08 03:13 PHST- 2022/10/11 00:00 [received] PHST- 2022/10/17 00:00 [accepted] PHST- 2022/11/09 06:00 [pubmed] PHST- 2023/01/06 06:00 [medline] PHST- 2022/11/08 03:13 [entrez] AID - 10.1111/jocs.17116 [doi] PST - ppublish SO - J Card Surg. 2022 Dec;37(12):4204-4206. doi: 10.1111/jocs.17116. Epub 2022 Nov 8. PMID- 36341218 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240906 IS - 2772-3747 (Electronic) IS - 2772-3747 (Linking) VI - 1 IP - 3 DP - 2021 Dec TI - Transcatheter Aortic Valve Replacement in Asia: Present Status and Future Perspectives. PG - 279-293 LID - 10.1016/j.jacasi.2021.10.006 [doi] AB - Over the last decade, based on evidence from multiple randomized clinical trials, transcatheter aortic valve replacement (TAVR) has become the established treatment for patients with symptomatic severe aortic stenosis. Despite the overwhelming expansion of TAVR in Western countries, the initial uptake and widespread adoption of this procedure have been relatively delayed in Asian countries, owing to the high cost of devices; limited local health and reimbursement policies; and lack of specific training/proctoring program, specialized heart team, or dedicated infrastructure. Furthermore, it has not yet been determined whether there are substantial interracial and ethnic differences in the clinical characteristics, comorbidities, and anatomic features, as well as procedural and long-term outcomes, in patients receiving TAVR. In this review, we provide not only a comprehensive look at the current status and outcomes of TAVR in Asian populations compared with those of Western populations but also a perspective on the future of TAVR in Asia. CI - (c) 2021 The Authors. FAU - Lee, Cheol Hyun AU - Lee CH AD - Division of Cardiology, Department of Internal Medicine, Keimyung University Dongsan Hospital, Deagu, South Korea. FAU - Inohara, Taku AU - Inohara T AD - Department of Cardiology, Keio University School of Medicine, Tokyo, Japan. FAU - Hayashida, Kentaro AU - Hayashida K AD - Department of Cardiology, Keio University School of Medicine, Tokyo, Japan. FAU - Park, Duk-Woo AU - Park DW AD - Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. LA - eng PT - Journal Article PT - Review DEP - 20211207 PL - United States TA - JACC Asia JT - JACC. Asia JID - 9918452380106676 PMC - PMC9627874 OTO - NOTNLM OT - AR, aortic regurgitation OT - AS, aortic stenosis OT - BAV, bicuspid aortic valve OT - BSA, body surface area OT - PPI, permanent pacemaker insertion OT - PPM, patient-prosthesis mismatch OT - PVL, paravalvular leak OT - RCT, randomized clinical trial OT - SAVR, surgical aortic valve replacement OT - STS, Society of Thoracic Surgeons OT - TAVR, transcatheter aortic valve replacement OT - VHD, valvular heart disease OT - aortic stenosis OT - outcomes OT - race and ethnicity OT - valvular disease COIS- Dr Hayashida has served as a clinical proctor for Edwards Lifesciences and Medtronic. Dr Park has served as a clinical proctor for Edwards Lifesciences and Medtronic. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2022/11/08 06:00 MHDA- 2022/11/08 06:01 PMCR- 2021/12/07 CRDT- 2022/11/07 05:13 PHST- 2021/07/01 00:00 [received] PHST- 2021/09/01 00:00 [revised] PHST- 2021/10/07 00:00 [accepted] PHST- 2022/11/07 05:13 [entrez] PHST- 2022/11/08 06:00 [pubmed] PHST- 2022/11/08 06:01 [medline] PHST- 2021/12/07 00:00 [pmc-release] AID - S2772-3747(21)00129-0 [pii] AID - 10.1016/j.jacasi.2021.10.006 [doi] PST - epublish SO - JACC Asia. 2021 Dec 7;1(3):279-293. doi: 10.1016/j.jacasi.2021.10.006. eCollection 2021 Dec. PMID- 36336873 OWN - NLM STAT- MEDLINE DCOM- 20230216 LR - 20230228 IS - 1097-0223 (Electronic) IS - 0197-3851 (Linking) VI - 43 IP - 2 DP - 2023 Feb TI - Reproductive health in Turner syndrome: A narrative review. PG - 261-271 LID - 10.1002/pd.6261 [doi] AB - Turner syndrome (TS), a common chromosomal abnormality affecting females, is associated with partial or complete loss of the second sex chromosome. Although the classic karyotype is 45, X, the detection of mosaic TS is increasing. TS is a multi-system disorder with significant endocrine, cardiovascular and reproductive impacts. Accelerated ovarian follicular loss leads to primary amenorrhoea or premature ovarian insufficiency and infertility. Early diagnosis and counselling regarding hormone replacement therapy and future reproductive capacity, including fertility preservation, are essential to improve reproductive outcomes. Pubertal induction or estrogen replacement is usually required to optimise long-term health outcomes; however, initiation may be delayed due to delayed diagnosis. Spontaneous pregnancy occurs in a small number of women; however, many require donor oocytes and assisted reproductive technology to achieve a pregnancy. Pregnancy is a high risk especially when associated with congenital heart disease. Prepregnancy counselling by the multidisciplinary team (MDT) to identify contraindications and optimise pre-existing health issues is essential. Pregnancy management should be led by a maternal-fetal medicine unit with input from the MDT. This review examines reproductive health outcomes in women with TS and how best to manage them to reduce health risks and improve maternal and neonatal outcomes. CI - (c) 2022 The Authors. Prenatal Diagnosis published by John Wiley & Sons Ltd. FAU - Whigham, Carole-Anne AU - Whigham CA AUID- ORCID: 0000-0003-3205-0400 AD - Women's and Newborn Program, Monash Health, Clayton, Victoria, Australia. AD - Department of Obstetrics and Gynaecology, Monash University, Clayton, Victoria, Australia. FAU - Vollenhoven, Beverley AU - Vollenhoven B AD - Women's and Newborn Program, Monash Health, Clayton, Victoria, Australia. AD - Department of Obstetrics and Gynaecology, Monash University, Clayton, Victoria, Australia. AD - Monash IVF, Clayton, Victoria, Australia. FAU - Vincent, Amanda J AU - Vincent AJ AD - Department of Endocrinology, Monash Health, Clayton, Victoria, Australia. AD - Monash Centre for Health Research and Implementation, School of Public Health and Preventive Medicine, Monash University, Clayton, Victoria, Australia. LA - eng PT - Journal Article PT - Review DEP - 20221112 PL - England TA - Prenat Diagn JT - Prenatal diagnosis JID - 8106540 SB - IM MH - Pregnancy MH - Humans MH - Female MH - *Turner Syndrome/complications/diagnosis/genetics MH - Reproductive Health MH - *Primary Ovarian Insufficiency/complications MH - Chromosome Aberrations MH - Reproductive Techniques, Assisted EDAT- 2022/11/08 06:00 MHDA- 2023/02/17 06:00 CRDT- 2022/11/07 01:02 PHST- 2022/10/30 00:00 [revised] PHST- 2022/06/23 00:00 [received] PHST- 2022/11/03 00:00 [accepted] PHST- 2022/11/08 06:00 [pubmed] PHST- 2023/02/17 06:00 [medline] PHST- 2022/11/07 01:02 [entrez] AID - 10.1002/pd.6261 [doi] PST - ppublish SO - Prenat Diagn. 2023 Feb;43(2):261-271. doi: 10.1002/pd.6261. Epub 2022 Nov 12. PMID- 36336572 OWN - NLM STAT- MEDLINE DCOM- 20240803 LR - 20250806 IS - 1531-6564 (Electronic) IS - 0363-5023 (Linking) VI - 49 IP - 8 DP - 2024 Aug TI - Classic Timothy Syndrome Associated With Bilateral Border Digit Syndactyly: A Case Series. PG - 794.e1-794.e6 LID - S0363-5023(22)00538-X [pii] LID - 10.1016/j.jhsa.2022.09.003 [doi] AB - PURPOSE: Timothy syndrome (TS) is characterized by congenital long-QT arrhythmia and limb syndactyly. Patients who undergo syndactyly repair with undiagnosed TS may have their abnormal cardiac electrical activity unmasked during surgery. The purpose of this study was to detail the extremity phenotype seen in patients with TS, which may help hand surgeons in their preoperative assessment. METHODS: This was a retrospective review of all patients with TS seen at our institution from 1998 to 2022. Descriptive statistics regarding their demographics, medical and surgical histories, and syndactyly phenotypes were obtained. RESULTS: Seven patients (5 males and 2 females) with TS were seen at our institution for multidisciplinary evaluation (median age at presentation was 23 months). Six patients had finger syndactyly and 5 had toe syndactyly. One patient did not have any extremity syndactyly and was noted to have a specific TS mutation known to lack musculoskeletal abnormalities. All patients with finger syndactyly had border digit involvement, with 5 out of 6 patients displaying syndactyly of the middle-ring and ring-little finger web spaces. Toe syndactyly was more heterogeneous, with 1 patient lacking any lower extremity syndactyly and others having variable involvement of the second-third, third-fourth, and fourth-little toe web spaces. Complexity ranged from simple to complete. Four patients had intraoperative cardiac events leading to TS diagnoses after surgery. CONCLUSIONS: Bilateral border digit hand syndactyly, with or without bilateral toe syndactyly, should raise concerns for TS and prompt further investigation into potential cardiac disease to avoid perioperative cardiac morbidity and mortality. TYPE OF STUDY/LEVEL OF EVIDENCE: Therapeutic V. CI - Copyright (c) 2024 American Society for Surgery of the Hand. Published by Elsevier Inc. All rights reserved. FAU - Zheng, Eugene E AU - Zheng EE AD - Division of Plastic Surgery, Mayo Clinic, Rochester, MN. Electronic address: zheng.eugene@mayo.edu. FAU - Avila, Francisco R AU - Avila FR AD - Division of Plastic Surgery, Mayo Clinic, Jacksonville, FL. FAU - Ackerman, Michael J AU - Ackerman MJ AD - Division of Pediatric Cardiology, Mayo Clinic, Rochester, MN. FAU - Moran, Steven L AU - Moran SL AD - Division of Plastic Surgery, Mayo Clinic, Rochester, MN. LA - eng PT - Journal Article DEP - 20221103 PL - United States TA - J Hand Surg Am JT - The Journal of hand surgery JID - 7609631 RN - Timothy syndrome SB - IM MH - Humans MH - *Syndactyly/surgery MH - Male MH - Female MH - Retrospective Studies MH - Infant MH - *Long QT Syndrome/congenital/complications MH - Autistic Disorder/complications MH - Phenotype MH - Child, Preschool MH - Toes/abnormalities/surgery OTO - NOTNLM OT - Congenital hand OT - Timothy syndrome OT - heart arrhythmias OT - long-QT syndrome OT - syndactyly EDAT- 2022/11/07 06:00 MHDA- 2024/08/04 13:44 CRDT- 2022/11/06 22:07 PHST- 2022/06/04 00:00 [received] PHST- 2022/08/02 00:00 [revised] PHST- 2022/09/12 00:00 [accepted] PHST- 2024/08/04 13:44 [medline] PHST- 2022/11/07 06:00 [pubmed] PHST- 2022/11/06 22:07 [entrez] AID - S0363-5023(22)00538-X [pii] AID - 10.1016/j.jhsa.2022.09.003 [doi] PST - ppublish SO - J Hand Surg Am. 2024 Aug;49(8):794.e1-794.e6. doi: 10.1016/j.jhsa.2022.09.003. Epub 2022 Nov 3. PMID- 36336119 OWN - NLM STAT- MEDLINE DCOM- 20230103 LR - 20230111 IS - 1535-6280 (Electronic) IS - 0146-2806 (Linking) VI - 48 IP - 2 DP - 2023 Feb TI - Therapy of ATTR Cardiac Amyloidosis: Current Indications. PG - 101487 LID - S0146-2806(22)00384-X [pii] LID - 10.1016/j.cpcardiol.2022.101487 [doi] AB - Transthyretin cardiac amyloidosis is a restrictive cardiomyopathy caused by extracellular deposition in the heart of amyloid fibrils derived from plasma transthyretin (ATTR), either in its hereditary (ATTRh) or acquired (ATTRwt) forms. Cardiac amyloidosis has a very poor prognosis if therapy is not started promptly. Therefore, it is very important to recognize cardiac amyloidosis early in order to immediately start a treatment capable of modifying the prognosis. Treatment of cardiac amyloidosis is not easy, often requiring a multidisciplinary team. New RNA-interfering drugs (such as patisiran) have been devised and are effective in the treatment of ATTRh amyloidosis. Tafamidis (a stabilizer of the native tetramer structure of TTR) is recommended to treat patients with genetic testing-proven hereditary hTTR-cardiomyopathy or wild-type TTR cardiomyopathy and NYHA Class I or II to reduce symptoms, CV hospitalization and mortality (Class I, level of evidence B). Patisiran should be considered in ATTRh cardiomyopathy with polyneuropathy. Thus, this review is intended to be a simple practical guide for the treatment of ATTR cardiac amyloidosis. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Di Lisi, Daniela AU - Di Lisi D AD - Division of Cardiology, University Hospital Paolo Giaccone, Palermo, Italy; Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE) "G. D'Alessandro", University of Palermo, Palermo, Italy.. Electronic address: danydilis@hotmail.it. FAU - Di Stefano, Vincenzo AU - Di Stefano V AD - Section of Neurology, Department of Biomedicine, Neurosciences and Advanced Diagnostics (BiND), University of Palermo, Palermo, Italy. FAU - Brighina, Filippo AU - Brighina F AD - Section of Neurology, Department of Biomedicine, Neurosciences and Advanced Diagnostics (BiND), University of Palermo, Palermo, Italy. FAU - Galassi, Alfredo Ruggero AU - Galassi AR AD - Division of Cardiology, University Hospital Paolo Giaccone, Palermo, Italy; Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE) "G. D'Alessandro", University of Palermo, Palermo, Italy. FAU - Novo, Giuseppina AU - Novo G AD - Division of Cardiology, University Hospital Paolo Giaccone, Palermo, Italy; Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE) "G. D'Alessandro", University of Palermo, Palermo, Italy. LA - eng PT - Journal Article PT - Review DEP - 20221104 PL - Netherlands TA - Curr Probl Cardiol JT - Current problems in cardiology JID - 7701802 RN - 0 (Prealbumin) RN - 0 (Amyloid) SB - IM MH - Humans MH - *Amyloid Neuropathies, Familial/therapy/drug therapy MH - Prealbumin/genetics/therapeutic use MH - *Cardiomyopathies/diagnosis/drug therapy/etiology MH - Amyloid EDAT- 2022/11/07 06:00 MHDA- 2023/01/04 06:00 CRDT- 2022/11/06 19:34 PHST- 2022/10/29 00:00 [received] PHST- 2022/10/31 00:00 [accepted] PHST- 2022/11/07 06:00 [pubmed] PHST- 2023/01/04 06:00 [medline] PHST- 2022/11/06 19:34 [entrez] AID - S0146-2806(22)00384-X [pii] AID - 10.1016/j.cpcardiol.2022.101487 [doi] PST - ppublish SO - Curr Probl Cardiol. 2023 Feb;48(2):101487. doi: 10.1016/j.cpcardiol.2022.101487. Epub 2022 Nov 4. PMID- 36334952 OWN - NLM STAT- MEDLINE DCOM- 20221215 LR - 20260702 IS - 1558-3597 (Electronic) IS - 0735-1097 (Print) IS - 0735-1097 (Linking) VI - 80 IP - 24 DP - 2022 Dec 13 TI - 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. PG - e223-e393 LID - S0735-1097(22)05769-2 [pii] LID - 10.1016/j.jacc.2022.08.004 [doi] AB - AIM: The "2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease" provides recommendations to guide clinicians in the diagnosis, genetic evaluation and family screening, medical therapy, endovascular and surgical treatment, and long-term surveillance of patients with aortic disease across its multiple clinical presentation subsets (ie, asymptomatic, stable symptomatic, and acute aortic syndromes). METHODS: A comprehensive literature search was conducted from January 2021 to April 2021, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from PubMed, EMBASE, the Cochrane Library, CINHL Complete, and other selected databases relevant to this guideline. Additional relevant studies, published through June 2022 during the guideline writing process, were also considered by the writing committee, where appropriate. STRUCTURE: Recommendations from previously published AHA/ACC guidelines on thoracic aortic disease, peripheral artery disease, and bicuspid aortic valve disease have been updated with new evidence to guide clinicians. In addition, new recommendations addressing comprehensive care for patients with aortic disease have been developed. There is added emphasis on the role of shared decision making, especially in the management of patients with aortic disease both before and during pregnancy. The is also an increased emphasis on the importance of institutional interventional volume and multidisciplinary aortic team expertise in the care of patients with aortic disease. CI - Copyright (c) 2022 American College of Cardiology Foundation and the American Heart Association, Inc. Published by Elsevier Inc. All rights reserved. CN - Writing Committee Members FAU - Isselbacher, Eric M AU - Isselbacher EM FAU - Preventza, Ourania AU - Preventza O FAU - Hamilton Black Iii, James AU - Hamilton Black Iii J FAU - Augoustides, John G AU - Augoustides JG FAU - Beck, Adam W AU - Beck AW FAU - Bolen, Michael A AU - Bolen MA FAU - Braverman, Alan C AU - Braverman AC FAU - Bray, Bruce E AU - Bray BE FAU - Brown-Zimmerman, Maya M AU - Brown-Zimmerman MM FAU - Chen, Edward P AU - Chen EP FAU - Collins, Tyrone J AU - Collins TJ FAU - DeAnda, Abe Jr AU - DeAnda A Jr FAU - Fanola, Christina L AU - Fanola CL FAU - Girardi, Leonard N AU - Girardi LN FAU - Hicks, Caitlin W AU - Hicks CW FAU - Hui, Dawn S AU - Hui DS FAU - Jones, William Schuyler AU - Jones WS FAU - Kalahasti, Vidyasagar AU - Kalahasti V FAU - Kim, Karen M AU - Kim KM FAU - Milewicz, Dianna M AU - Milewicz DM FAU - Oderich, Gustavo S AU - Oderich GS FAU - Ogbechie, Laura AU - Ogbechie L FAU - Promes, Susan B AU - Promes SB FAU - Ross, Elsie Gyang AU - Ross EG FAU - Schermerhorn, Marc L AU - Schermerhorn ML FAU - Times, Sabrina Singleton AU - Times SS FAU - Tseng, Elaine E AU - Tseng EE FAU - Wang, Grace J AU - Wang GJ FAU - Woo, Y Joseph AU - Woo YJ LA - eng GR - K01 HL148639/HL/NHLBI NIH HHS/United States GR - K23 DK124515/DK/NIDDK NIH HHS/United States GR - R25 HL145817/HL/NHLBI NIH HHS/United States GR - T32 HL007444/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Practice Guideline DEP - 20221102 PL - United States TA - J Am Coll Cardiol JT - Journal of the American College of Cardiology JID - 8301365 SB - IM CIN - J Am Coll Cardiol. 2022 Dec 13;80(24):2348-2352. doi: 10.1016/j.jacc.2022.10.001. PMID: 36334953 MH - United States MH - Humans MH - *American Heart Association MH - Universities MH - *Aortic Diseases/diagnosis/therapy PMC - PMC9860464 MID - NIHMS1860836 OTO - NOTNLM OT - ACC/AHA Clinical Practice Guidelines OT - abdominal aortic aneurysm OT - aortic dissection OT - aortitis OT - aortopathy OT - bicuspid aortic valve OT - blunt traumatic aortic injury OT - cardiac surgery OT - endovascular aortic repair OT - guidelines OT - heritable thoracic aortic disease OT - intramural hematoma OT - loeys-dietz syndrome OT - malperfusion syndrome OT - marfan syndrome OT - penetrating atherosclerotic ulcer OT - thoracic aortic aneurysm OT - thoracic endovascular aortic repair OT - thoracoabdominal aortic aneurysm OT - vascular surgery EDAT- 2022/11/06 06:00 MHDA- 2022/12/15 06:00 PMCR- 2023/12/13 CRDT- 2022/11/05 23:03 PHST- 2022/11/06 06:00 [pubmed] PHST- 2022/12/15 06:00 [medline] PHST- 2022/11/05 23:03 [entrez] PHST- 2023/12/13 00:00 [pmc-release] AID - S0735-1097(22)05769-2 [pii] AID - 10.1016/j.jacc.2022.08.004 [doi] PST - ppublish SO - J Am Coll Cardiol. 2022 Dec 13;80(24):e223-e393. doi: 10.1016/j.jacc.2022.08.004. Epub 2022 Nov 2. PMID- 36332941 OWN - NLM STAT- MEDLINE DCOM- 20221108 LR - 20221129 IS - 2053-3624 (Print) IS - 2053-3624 (Electronic) IS - 2053-3624 (Linking) VI - 9 IP - 2 DP - 2022 Nov TI - Developing a contemporary community clinic for patients with heart failure with preserved ejection fraction within the current National Health Service model. LID - 10.1136/openhrt-2022-002101 [doi] LID - e002101 AB - INTRODUCTION: The diagnostic and therapeutic arsenal for heart failure with preserved ejection (HFpEF) has expanded. With novel therapies (eg, sodium-glucose co-transporter 2 inhibitors) and firmer recommendations to optimise non-cardiac comorbidities, it is unclear if outpatient HFpEF models can adequately deliver this. We; therefore, evaluated the efficacy of an existing dedicated HFpEF clinic to find innovative ways to design a more comprehensive model tailored to the modern era of HFpEF. METHODS: A single-centre retrospective analysis of 202 HFpEF outpatients was performed over 12 months before the COVID-19 pandemic. Baseline characteristics, clinic activities (eg, medication changes, lifestyle modifications, management of comorbidities) and follow-up arrangements were compared between a HFpEF and general cardiology clinic to assess their impact on mortality and morbidity at 6 and 12 months. RESULTS: Between the two clinic groups, the sample population was evenly matched with a typical HFpEF profile (mean age 79+/-9.6 years, 55% female and a high prevalence of cardiometabolic comorbidities). While follow-up practices were similar, the HFpEF clinic delivered significantly more interventions on lifestyle changes, blood pressure and heart rate control (p<0.0001) compared with the general clinic. Despite this, no significant differences in all-cause hospitalisation and mortality were observed. This may be attributed to the fact that clinic activities were primarily cardiology-focused. Importantly, non-cardiovascular admissions accounted for >60% of hospitalisation, including causes of recurrent admissions. CONCLUSION: This study suggests that existing general and emerging dedicated HFpEF clinics may not be adequate in addressing the multifaceted aspects of HFpEF as clinic activities concentrated primarily on cardiological measures. Although the small cohort and short follow-up period are important limitations, this study reminds clinicians that HFpEF patients are more at risk of non-cardiac than HF-related events. We have therefore proposed a pragmatic framework that can comprehensively deliver the modern guideline-directed recommendations and management of non-cardiac comorbidities through a multidisciplinary approach. CI - (c) Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Tran, Patrick AU - Tran P AUID- ORCID: 0000-0001-9304-9521 AD - Cardiology Department, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK. AD - Centre for Sport, Exercise & Life Sciences, Faculty of Health and Life Sciences, Coventry University, Coventry, UK. FAU - Long, Thomas AU - Long T AD - Cardiology Department, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK. FAU - Smith, Jessica AU - Smith J AD - Cardiology Department, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK. FAU - Kuehl, Michael AU - Kuehl M AD - Cardiology Department, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK. AD - Warwick Medical School, University of Warwick, Coventry, UK. FAU - Mahdy, Tarek AU - Mahdy T AD - Cardiology Department, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK. FAU - Banerjee, Prithwish AU - Banerjee P AUID- ORCID: 0000-0001-7793-1733 AD - Centre for Sport, Exercise & Life Sciences, Faculty of Health and Life Sciences, Coventry University, Coventry, UK Prithwish.Banerjee@uhcw.nhs.uk. AD - Warwick Medical School, University of Warwick, Coventry, UK. AD - Department of Cardiology, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK. LA - eng PT - Journal Article PL - England TA - Open Heart JT - Open heart JID - 101631219 SB - IM MH - Humans MH - Female MH - Aged MH - Aged, 80 and over MH - Male MH - Stroke Volume/physiology MH - *Heart Failure/diagnosis/epidemiology/therapy MH - State Medicine MH - Retrospective Studies MH - Pandemics MH - *COVID-19/therapy MH - Ambulatory Care Facilities PMC - PMC9639156 OTO - NOTNLM OT - cardiac rehabilitation OT - health services OT - heart failure OT - palliative care OT - risk factors COIS- Competing interests: None declared. EDAT- 2022/11/05 06:00 MHDA- 2022/11/09 06:00 PMCR- 2022/11/04 CRDT- 2022/11/04 20:52 PHST- 2022/07/25 00:00 [received] PHST- 2022/10/13 00:00 [accepted] PHST- 2022/11/04 20:52 [entrez] PHST- 2022/11/05 06:00 [pubmed] PHST- 2022/11/09 06:00 [medline] PHST- 2022/11/04 00:00 [pmc-release] AID - openhrt-2022-002101 [pii] AID - 10.1136/openhrt-2022-002101 [doi] PST - ppublish SO - Open Heart. 2022 Nov;9(2):e002101. doi: 10.1136/openhrt-2022-002101. PMID- 36329396 OWN - NLM STAT- MEDLINE DCOM- 20221107 LR - 20221112 IS - 1471-2261 (Electronic) IS - 1471-2261 (Linking) VI - 22 IP - 1 DP - 2022 Nov 3 TI - The cardiac distress inventory: A new measure of psychosocial distress associated with an acute cardiac event. PG - 460 LID - 10.1186/s12872-022-02897-y [doi] LID - 460 AB - BACKGROUND: Many challenges are posed by the experience of a heart attack or heart surgery which can be characterised as 'cardiac distress'. It spans multiple psychosocial domains incorporating patients' responses to physical, affective, cognitive, behavioural and social symptoms and experiences related to their cardiac event and their recovery. Although some measures of the psychological and emotional impacts of a cardiac event exist, none provides a comprehensive assessment of cardiac distress. To address this gap, the study aimed to develop a Cardiac Distress Inventory (CDI) using best practice in instrument design. METHOD: An item pool was generated through analysis of cognate measures, mostly in relation to other health conditions and through focus group and individual review by a multidisciplinary development team, cardiac patients, and end-users including cardiac rehabilitation co-ordinators. The resulting 144 items were reduced through further reviews to 74 for testing. The testing was carried out with 405 people recruited from three hospitals, through social media and by direct enrolment on the study website. A two-stage psychometric evaluation of the 74 items used exploratory factor analysis to extract the factors followed by Rasch analysis to confirm dimensionality within factors. RESULTS: Psychometric analysis resulted in the identification of 55 items comprising eight subscales, to form the CDI. The subscales assess fear and uncertainty, disconnection and hopelessness, changes to roles and relationships, overwhelm and depletion, cognitive challenges, physical challenges, health system challenges, and death concerns. Validation against the Kessler 6 supports the criterion validity of the CDI. CONCLUSION: The CDI reflects a nuanced understanding of cardiac distress and should prove to be a useful clinical assessment tool, as well as a research instrument. Individual subscales or the complete CDI could be used to assess or monitor specific areas of distress in clinical practice. Development of a short form screening version for use in primary care, cardiac rehabilitation and counselling services is warranted. CI - (c) 2022. The Author(s). FAU - Jackson, Alun C AU - Jackson AC AD - Australian Centre for Heart Health, Melbourne, VIC, Australia. alun.jackson@australianhearthealth.org.au. AD - Centre on Behavioral Health, University of Hong Kong, Hong Kong SAR, China. alun.jackson@australianhearthealth.org.au. FAU - Grande, Michael R Le AU - Grande MRL AD - Australian Centre for Heart Health, Melbourne, VIC, Australia. AD - Melbourne Centre for Behaviour Change, School of Psychological Sciences, University of Melbourne, Melbourne, VIC, Australia. FAU - Rogerson, Michelle C AU - Rogerson MC AD - Australian Centre for Heart Health, Melbourne, VIC, Australia. FAU - Ski, Chantal F AU - Ski CF AD - Australian Centre for Heart Health, Melbourne, VIC, Australia. AD - Integrated Care Academy, University of Suffolk, Ipswich, UK. AD - Department of Psychiatry, University of Melbourne, Melbourne, VIC, Australia. FAU - Amerena, John AU - Amerena J AD - Barwon Health, Geelong, VIC, Australia. AD - Deakin School of Medicine, University Hospital Geelong, Geelong, VIC, Australia. FAU - Smith, Julian A AU - Smith JA AD - Department of Cardiothoracic Surgery, Monash Health, Clayton, VIC, Australia. AD - Department of Surgery, School of Clinical Sciences at Monash Health), Monash University, Clayton, VIC, Australia. FAU - Hoover, Valerie AU - Hoover V AD - Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, USA. FAU - Alvarenga, Marlies E AU - Alvarenga ME AD - Australian Centre for Heart Health, Melbourne, VIC, Australia. AD - Institute of Health and Wellbeing, Federation University, Berwick, VIC, Australia. AD - Victorian Heart Institute, Clayton, VIC, Australia. AD - Monash Health & Department of Medicine, Monash University, Clayton, VIC, Australia. FAU - Higgins, Rosemary O AU - Higgins RO AD - Australian Centre for Heart Health, Melbourne, VIC, Australia. AD - Department of Physiotherapy, University of Melbourne, Parkville, VIC, Australia. FAU - Thompson, David R AU - Thompson DR AD - Australian Centre for Heart Health, Melbourne, VIC, Australia. AD - Department of Psychiatry, University of Melbourne, Melbourne, VIC, Australia. AD - School of Nursing and Midwifery, Queen's University Belfast, Belfast, UK. FAU - Murphy, Barbara M AU - Murphy BM AD - Australian Centre for Heart Health, Melbourne, VIC, Australia. AD - Melbourne School of Psychological Sciences, University of Melbourne, Parkville, VIC, Australia. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20221103 PL - England TA - BMC Cardiovasc Disord JT - BMC cardiovascular disorders JID - 100968539 SB - IM MH - Humans MH - Surveys and Questionnaires MH - *Stress, Psychological/diagnosis/psychology MH - Psychometrics MH - Reproducibility of Results PMC - PMC9633013 OTO - NOTNLM OT - Cardiovascular disease OT - Measurement OT - Mental health OT - Psychological distress OT - Psychometric analysis OT - Scale development COIS- The authors declare no competing interests. EDAT- 2022/11/05 06:00 MHDA- 2022/11/08 06:00 PMCR- 2022/11/03 CRDT- 2022/11/04 00:45 PHST- 2022/07/22 00:00 [received] PHST- 2022/10/10 00:00 [accepted] PHST- 2022/11/04 00:45 [entrez] PHST- 2022/11/05 06:00 [pubmed] PHST- 2022/11/08 06:00 [medline] PHST- 2022/11/03 00:00 [pmc-release] AID - 10.1186/s12872-022-02897-y [pii] AID - 2897 [pii] AID - 10.1186/s12872-022-02897-y [doi] PST - epublish SO - BMC Cardiovasc Disord. 2022 Nov 3;22(1):460. doi: 10.1186/s12872-022-02897-y. PMID- 36328338 OWN - NLM STAT- MEDLINE DCOM- 20230103 LR - 20230103 IS - 1535-6280 (Electronic) IS - 0146-2806 (Linking) VI - 48 IP - 2 DP - 2023 Feb TI - Integrating Cardiac MRI Imaging and Multidisciplinary Clinical Care is Associated With Improved Outcomes in Patients With Fabry Disease. PG - 101476 LID - S0146-2806(22)00373-5 [pii] LID - 10.1016/j.cpcardiol.2022.101476 [doi] AB - Given the inherent complexities of Fabry disease (FD) and evolving landscape of cardiovascular clinical management, there is no established ideal clinical care model for these patients. We identified clinical factors predictive of increased risk of major adverse cardiac events (MACE) in patients with FD targeted to improve clinical outcomes. Ninety-five patients studied over a median follow-up time of 6.3 years, and 26 patients reached the composite endpoint with a high prevalence of heart failure and cerebrovascular events and no cardiac-related mortality. Patients with MACE had worse health-related quality of life scores. Hypertrophy and presence of myocardial fibrosis increase risk of MACE by 4-5 times, and dyslipidemia increases risk of MACE by 3 times. Early Fabry-specific treatment and close monitoring of comorbidities reduce cardiac complications and mortality. These findings highlight the importance of comprehensive multidisciplinary management to help improve outcomes in FD patients. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Perera, Kevin AU - Perera K AD - Department of Medicine, University of Alberta, Edmonton, Alberta, Canada; Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta, Canada. FAU - Kashyap, Niharika AU - Kashyap N AD - Department of Medicine, University of Alberta, Edmonton, Alberta, Canada; Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta, Canada. FAU - Wang, Kaiming AU - Wang K AD - Department of Medicine, University of Alberta, Edmonton, Alberta, Canada; Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta, Canada. FAU - Omar, Fadya AU - Omar F AD - School of Health and Public Safety, Southern Alberta Institute of Technology, Calgary, Alberta, Canada; Metabolics and Genetics in Canada (M.A.G.I.C.) Clinic Ltd., Calgary, Alberta, Canada. FAU - Prosia, Easter AU - Prosia E AD - Department of Cardiac Sciences, Cumming School of Medicine, University of Calgary, Calgary Alberta, Canada. FAU - Thompson, Richard B AU - Thompson RB AD - Department of Biomedical Engineering, University of Alberta, Edmonton, Alberta, Canada. FAU - Paterson, D Ian AU - Paterson DI AD - Department of Medicine, University of Alberta, Edmonton, Alberta, Canada; Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta, Canada. FAU - Fine, Nowell M AU - Fine NM AD - Department of Cardiac Sciences, Cumming School of Medicine, University of Calgary, Calgary Alberta, Canada. FAU - White, James A AU - White JA AD - Department of Cardiac Sciences, Cumming School of Medicine, University of Calgary, Calgary Alberta, Canada. FAU - Khan, Aneal AU - Khan A AD - Metabolics and Genetics in Canada (M.A.G.I.C.) Clinic Ltd., Calgary, Alberta, Canada; Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. FAU - Oudit, Gavin Y AU - Oudit GY AD - Department of Medicine, University of Alberta, Edmonton, Alberta, Canada; Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta, Canada. Electronic address: gavin.oudit@ualberta.ca. LA - eng PT - Journal Article PT - Review DEP - 20221101 PL - Netherlands TA - Curr Probl Cardiol JT - Current problems in cardiology JID - 7701802 SB - IM MH - Humans MH - *Fabry Disease/complications/therapy/epidemiology MH - Quality of Life MH - Magnetic Resonance Imaging MH - *Heart Diseases MH - *Heart Failure/complications EDAT- 2022/11/04 06:00 MHDA- 2023/01/04 06:00 CRDT- 2022/11/03 20:35 PHST- 2022/10/14 00:00 [received] PHST- 2022/10/26 00:00 [accepted] PHST- 2022/11/04 06:00 [pubmed] PHST- 2023/01/04 06:00 [medline] PHST- 2022/11/03 20:35 [entrez] AID - S0146-2806(22)00373-5 [pii] AID - 10.1016/j.cpcardiol.2022.101476 [doi] PST - ppublish SO - Curr Probl Cardiol. 2023 Feb;48(2):101476. doi: 10.1016/j.cpcardiol.2022.101476. Epub 2022 Nov 1. PMID- 36327054 OWN - NLM STAT- MEDLINE DCOM- 20221215 LR - 20230109 IS - 1534-3170 (Electronic) IS - 1523-3782 (Linking) VI - 24 IP - 12 DP - 2022 Dec TI - Optimal, Early Postoperative Management of Cardiac Transplant and Durable Left Ventricular Assist Recipients. PG - 2023-2029 LID - 10.1007/s11886-022-01823-0 [doi] AB - PURPOSE OF REVIEW: Summarize developments in the early postoperative care of patients undergoing cardiac transplantation or left ventricular assist device implantation. Provide a practical approach with personal insights to highly complex patients at risk for prolonged hospitalization. RECENT FINDINGS: Advancements in technology allow for percutaneous mechanical circulatory support of both the right and left ventricles either isolated or combined via subclavian and neck vessels. Since the adult heart allocation system has been changed to reduce waitlist mortality, the use of temporary mechanical circulatory support has increased. This has influenced preoperative optimization by enabling ambulation and majorly changed postoperative strategy. New doors have been opened for a multidisciplinary approach to facilitate rapid weaning of inotropic medications, limitation of sedation, early liberation from mechanical ventilation, and mobilization. Individualized percutaneous mechanical circulatory support offers new possibilities for the early postoperative management of highly complex patients undergoing cardiac transplantation or durable left ventricular assist device implantation. CI - (c) 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Freundt, Miriam AU - Freundt M AUID- ORCID: 0000-0001-9189-5759 AD - Heart and Vascular Institute Critical Care Unit and Adult ECMO and Mechanical Circulatory Support Program, Penn State University College of Medicine, Hershey, PA, 17033, USA. mfreundt@pennstatehealth.psu.edu. FAU - Lavanga, Elizabeth AU - Lavanga E AD - Penn State College of Medicine, Hershey, USA. FAU - Brehm, Christoph AU - Brehm C AD - Heart and Vascular Institute Critical Care Unit and Adult ECMO and Mechanical Circulatory Support Program, Penn State University College of Medicine, Hershey, PA, 17033, USA. LA - eng PT - Journal Article PT - Review DEP - 20221103 PL - United States TA - Curr Cardiol Rep JT - Current cardiology reports JID - 100888969 SB - IM MH - Adult MH - Humans MH - *Heart-Assist Devices MH - Prosthesis Implantation MH - Heart Ventricles MH - Treatment Outcome MH - *Heart Transplantation MH - *Heart Failure/surgery/etiology MH - Retrospective Studies MH - Shock, Cardiogenic OTO - NOTNLM OT - Acute postoperative cardiogenic shock OT - Cardiac transplantation OT - Fast-track surgery OT - Left ventricular assist device implantation OT - Postoperative management OT - Vasoplegia EDAT- 2022/11/04 06:00 MHDA- 2022/12/16 06:00 CRDT- 2022/11/03 12:23 PHST- 2022/10/19 00:00 [accepted] PHST- 2022/11/04 06:00 [pubmed] PHST- 2022/12/16 06:00 [medline] PHST- 2022/11/03 12:23 [entrez] AID - 10.1007/s11886-022-01823-0 [pii] AID - 10.1007/s11886-022-01823-0 [doi] PST - ppublish SO - Curr Cardiol Rep. 2022 Dec;24(12):2023-2029. doi: 10.1007/s11886-022-01823-0. Epub 2022 Nov 3. PMID- 36325943 OWN - NLM STAT- MEDLINE DCOM- 20230823 LR - 20230823 IS - 1467-1107 (Electronic) IS - 1047-9511 (Linking) VI - 33 IP - 7 DP - 2023 Jul TI - Impact of interdisciplinary counselling for parental decision-making in cases of pregnancies with prenatally diagnosed CHD - ERRATUM. PG - 1274 LID - 10.1017/S1047951122003377 [doi] FAU - Schneider, Katja AU - Schneider K FAU - Bousi, Dafni AU - Bousi D FAU - Stressig, Rudiger AU - Stressig R LA - eng PT - Journal Article DEP - 20221103 PL - England TA - Cardiol Young JT - Cardiology in the young JID - 9200019 SB - IM MH - Pregnancy MH - Female MH - Humans MH - *Prenatal Diagnosis MH - Genetic Counseling MH - Counseling MH - Parents MH - *Heart Defects, Congenital/diagnostic imaging EDAT- 2022/11/04 06:00 MHDA- 2023/08/23 06:42 CRDT- 2022/11/03 05:13 PHST- 2023/08/23 06:42 [medline] PHST- 2022/11/04 06:00 [pubmed] PHST- 2022/11/03 05:13 [entrez] AID - S1047951122003377 [pii] AID - 10.1017/S1047951122003377 [doi] PST - ppublish SO - Cardiol Young. 2023 Jul;33(7):1274. doi: 10.1017/S1047951122003377. Epub 2022 Nov 3. PMID- 36324527 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240906 IS - 1176-6336 (Print) IS - 1178-203X (Electronic) IS - 1176-6336 (Linking) VI - 18 DP - 2022 TI - Clinical Perspectives on Cardiac Rehabilitation After Heart Failure in Elderly Patients with Frailty: A Narrative Review. PG - 1009-1028 LID - 10.2147/TCRM.S350748 [doi] AB - The purpose of this narrative review is to examine rehabilitation modalities for patients with heart failure and Frailty who require comprehensive intervention. Ischemic heart disease is the leading cause of death worldwide, accounting for 16% of global mortality. Due to population growing and aging, the total number of heart failure patients continues to rise, a condition known as the heart failure pandemic. Furthermore, frailty has been associated with an increased risk for heart failure and increased morbidity and mortality. The 2021 update of the 2017 ACC expert consensus decision pathway for optimization of HF treatment has become more concerning, citing frailty as one of the 10 most important issues associated with heart failure with reduced ejection fraction (HFrEF). Frailty and heart failure share common pathological mechanisms and are associated with poor clinical outcomes. Most studies of frailty in patients with heart failure primarily focus on physical frailty, and associations between psycho-psychological and social factors such as cognitive dysfunction and social isolation have also been reported. These results suggest that a more comprehensive assessment of frailty is important to determine the risk in patients with heart failure. Therefore, mechanisms of the three domains, including not only physical frailty but also cognitive, psychological, spiritual, and social aspects, should be understood. In addition to interventions in these three domains, nutritional and pharmacological interventions are also important and require tailor-made interventions for the widely varied conditions associated with heart failure and frailty. Although several studies have shown a relationship between frailty and prognosis in patients with heart failure, interventions to improve the prognosis have not yet been established. Further information is needed on frailty intervention by a multidisciplinary team to improve the prognosis. CI - (c) 2022 Tsukakoshi et al. FAU - Tsukakoshi, Daichi AU - Tsukakoshi D AUID- ORCID: 0000-0003-0771-325X AD - Department of Rehabilitation, Shinshu University Hospital, Matsumoto, Japan. FAU - Yamamoto, Shuhei AU - Yamamoto S AUID- ORCID: 0000-0003-0257-633X AD - Department of Rehabilitation, Shinshu University Hospital, Matsumoto, Japan. FAU - Takeda, Shuhei AU - Takeda S AD - Department of Rehabilitation, Shinshu University Hospital, Matsumoto, Japan. FAU - Furuhashi, Keisuke AU - Furuhashi K AD - Department of Rehabilitation, Shinshu University Hospital, Matsumoto, Japan. FAU - Sato, Masaaki AU - Sato M AUID- ORCID: 0000-0003-3267-5371 AD - Division of Occupational Therapy, School of Health Sciences, Shinshu University, Matsumoto, Nagano, Japan. LA - eng PT - Journal Article PT - Review DEP - 20221027 PL - New Zealand TA - Ther Clin Risk Manag JT - Therapeutics and clinical risk management JID - 101253281 PMC - PMC9620837 OTO - NOTNLM OT - cardiovascular diseases OT - frailty OT - heart failure OT - rehabilitation COIS- The authors report no conflicts of interest in this work. EDAT- 2022/11/04 06:00 MHDA- 2022/11/04 06:01 PMCR- 2022/10/27 CRDT- 2022/11/03 02:28 PHST- 2022/06/09 00:00 [received] PHST- 2022/09/11 00:00 [accepted] PHST- 2022/11/03 02:28 [entrez] PHST- 2022/11/04 06:00 [pubmed] PHST- 2022/11/04 06:01 [medline] PHST- 2022/10/27 00:00 [pmc-release] AID - 350748 [pii] AID - 10.2147/TCRM.S350748 [doi] PST - epublish SO - Ther Clin Risk Manag. 2022 Oct 27;18:1009-1028. doi: 10.2147/TCRM.S350748. eCollection 2022. PMID- 36322642 OWN - NLM STAT- MEDLINE DCOM- 20221215 LR - 20260518 IS - 1524-4539 (Electronic) IS - 0009-7322 (Print) IS - 0009-7322 (Linking) VI - 146 IP - 24 DP - 2022 Dec 13 TI - 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. PG - e334-e482 LID - 10.1161/CIR.0000000000001106 [doi] AB - AIM: The "2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease" provides recommendations to guide clinicians in the diagnosis, genetic evaluation and family screening, medical therapy, endovascular and surgical treatment, and long-term surveillance of patients with aortic disease across its multiple clinical presentation subsets (ie, asymptomatic, stable symptomatic, and acute aortic syndromes). METHODS: A comprehensive literature search was conducted from January 2021 to April 2021, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from PubMed, EMBASE, the Cochrane Library, CINHL Complete, and other selected databases relevant to this guideline. Additional relevant studies, published through June 2022 during the guideline writing process, were also considered by the writing committee, where appropriate. Structure: Recommendations from previously published AHA/ACC guidelines on thoracic aortic disease, peripheral artery disease, and bicuspid aortic valve disease have been updated with new evidence to guide clinicians. In addition, new recommendations addressing comprehensive care for patients with aortic disease have been developed. There is added emphasis on the role of shared decision making, especially in the management of patients with aortic disease both before and during pregnancy. The is also an increased emphasis on the importance of institutional interventional volume and multidisciplinary aortic team expertise in the care of patients with aortic disease. FAU - Isselbacher, Eric M AU - Isselbacher EM FAU - Preventza, Ourania AU - Preventza O FAU - Hamilton Black, James 3rd AU - Hamilton Black J 3rd FAU - Augoustides, John G AU - Augoustides JG AD - SCA representative. FAU - Beck, Adam W AU - Beck AW FAU - Bolen, Michael A AU - Bolen MA AD - ACR representative. FAU - Braverman, Alan C AU - Braverman AC FAU - Bray, Bruce E AU - Bray BE AD - AHA/ACC Joint Committee on Clinical Data Standards liaison. FAU - Brown-Zimmerman, Maya M AU - Brown-Zimmerman MM AD - Lay stakeholder representative. FAU - Chen, Edward P AU - Chen EP FAU - Collins, Tyrone J AU - Collins TJ AD - SCAI representative. FAU - DeAnda, Abe Jr AU - DeAnda A Jr FAU - Fanola, Christina L AU - Fanola CL FAU - Girardi, Leonard N AU - Girardi LN AD - AATS representative. FAU - Hicks, Caitlin W AU - Hicks CW AD - ACC/AHA Joint Committee on Performance Measures liaison. FAU - Hui, Dawn S AU - Hui DS FAU - Schuyler Jones, William AU - Schuyler Jones W AD - AHA/ACC Joint Committee on Clinical Practice Guidelines liaison. FAU - Kalahasti, Vidyasagar AU - Kalahasti V FAU - Kim, Karen M AU - Kim KM AD - STS representative. FAU - Milewicz, Dianna M AU - Milewicz DM FAU - Oderich, Gustavo S AU - Oderich GS FAU - Ogbechie, Laura AU - Ogbechie L FAU - Promes, Susan B AU - Promes SB FAU - Gyang Ross, Elsie AU - Gyang Ross E FAU - Schermerhorn, Marc L AU - Schermerhorn ML AD - SVS representative. FAU - Singleton Times, Sabrina AU - Singleton Times S AD - AHA/ACC staff representative. FAU - Tseng, Elaine E AU - Tseng EE FAU - Wang, Grace J AU - Wang GJ FAU - Woo, Y Joseph AU - Woo YJ AD - AHA/ACC Joint Committee on Clinical Practice Guidelines liaison. CN - Peer Review Committee Members LA - eng GR - K23 DK124515/DK/NIDDK NIH HHS/United States PT - Journal Article PT - Practice Guideline DEP - 20221102 PL - United States TA - Circulation JT - Circulation JID - 0147763 SB - IM MH - Female MH - Humans MH - Pregnancy MH - American Heart Association MH - *Aortic Diseases/diagnosis/therapy MH - *Bicuspid Aortic Valve Disease MH - *Cardiology MH - Research Report MH - United States PMC - PMC9876736 MID - NIHMS1860835 OTO - NOTNLM OT - AHA Scientific Statements OT - Loeys-Dietz syndrome OT - Marfan syndrome OT - abdominal aortic aneurysm OT - aortic dissection OT - aortitis OT - aortopathy OT - bicuspid aortic valve OT - blunt traumatic aortic injury OT - cardiac surgery OT - endovascular aortic repair OT - guidelines OT - heritable thoracic aortic disease OT - intramural hematoma OT - malperfusion syndrome OT - penetrating atherosclerotic ulcer OT - thoracic aortic aneurysm OT - thoracic endovascular aortic repair OT - thoracoabdominal aortic aneurysm OT - vascular surgery FIR - Faxon, David P IR - Faxon DP FIR - Upchurch Jr, Gilbert R IR - Upchurch Jr GR FIR - Aday, Aaron W IR - Aday AW FIR - Azizzadeh, Ali IR - Azizzadeh A FIR - Boisen, Michael IR - Boisen M FIR - Hawkins, Beau IR - Hawkins B FIR - Kramer, Christopher M IR - Kramer CM FIR - Luc, Jessica GY IR - Luc JG FIR - MacGillivray, Thomas E IR - MacGillivray TE FIR - Malaisrie, S Christopher IR - Malaisrie SC FIR - Osteen, Kathryn IR - Osteen K FIR - Patel, Himanshu J IR - Patel HJ FIR - Patel, Parag J IR - Patel PJ FIR - Popescu, Wanda M IR - Popescu WM FIR - Rodriguez, Evelio IR - Rodriguez E FIR - Sorber, Rebecca IR - Sorber R FIR - Tsao, Philip S IR - Tsao PS FIR - Volgman, Annabelle Santos IR - Volgman AS EDAT- 2022/11/03 06:00 MHDA- 2022/12/15 06:00 PMCR- 2023/12/13 CRDT- 2022/11/02 14:05 PHST- 2022/11/03 06:00 [pubmed] PHST- 2022/12/15 06:00 [medline] PHST- 2022/11/02 14:05 [entrez] PHST- 2023/12/13 00:00 [pmc-release] AID - 10.1161/CIR.0000000000001106 [doi] PST - ppublish SO - Circulation. 2022 Dec 13;146(24):e334-e482. doi: 10.1161/CIR.0000000000001106. Epub 2022 Nov 2. PMID- 36322202 OWN - NLM STAT- MEDLINE DCOM- 20230227 LR - 20230227 IS - 1432-1971 (Electronic) IS - 0172-0643 (Print) IS - 0172-0643 (Linking) VI - 44 IP - 3 DP - 2023 Mar TI - Organizational Culture as a Determinant of Outcome in Teams: Implications for the Pediatric Cardiac Specialist. PG - 530-539 LID - 10.1007/s00246-022-03041-5 [doi] AB - Although enormous effort has focussed on how to build an effective culture in the business community, relatively little effort has addressed how to achieve this in the hospital environment, specifically related to the field of congenital heart disease teams. The examination of culture in pediatric cardiac care is particularly important for several key reasons: first, it represents high-stakes medicine, second, there are multiple stakeholders requiring collaboration between cardiologists, surgeons, anaesthesiologists, perfusionists, nursing staff, and allied health care professionals, and finally, both the patient and the family are intimately involved in the care pathway. This review article investigates some of the critical components to building an effective culture, drawing upon similarities in other disciplines, thereby fostering high performance multidisciplinary teams in congenital cardiology care. Strategies to change culture such as Kotter's model of change are also discussed. High performance teams share one common vital characteristic: psychological safety for team members to speak their minds, thereby fostering an open culture, in which creativity can flourish to facilitate major breakthroughs. Adoption of the "Flight Plan" review promotes patient centric care and champions a psychologically safe culture. CI - (c) 2022. The Author(s). FAU - McMahon, Colin J AU - McMahon CJ AD - Department of Paediatric Cardiology, Children's Health Ireland, Crumlin, Dublin 12, Ireland. cmcmahon992004@yahoo.com. AD - School of Medicine, University College Dublin, Belfield, Dublin 4, Ireland. cmcmahon992004@yahoo.com. AD - School of Health Professions Education, Maastricht University, Maastricht, Netherlands. cmcmahon992004@yahoo.com. FAU - Hickey, Edward J AU - Hickey EJ AD - Department of Cardiothoracic Surgery, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, 77030, USA. FAU - Nolke, Lars AU - Nolke L AD - Department of Cardiothoracic Surgery, Children's Health Ireland, Crumlin, Dublin 12, Ireland. FAU - Penny, Daniel J AU - Penny DJ AD - Department of Pediatrics, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, 77030, USA. LA - eng PT - Journal Article PT - Review DEP - 20221102 PL - United States TA - Pediatr Cardiol JT - Pediatric cardiology JID - 8003849 SB - IM MH - Humans MH - Child MH - Organizational Culture MH - Patient Care Team MH - Leadership MH - *Heart Defects, Congenital/therapy MH - *Cardiology PMC - PMC9950153 OTO - NOTNLM OT - Congenital heart disease OT - Culture OT - Leadership OT - Organizational behaviour OT - Organizational culture OT - Pediatric cardiology OT - Psychological safety OT - Teams COIS- The authors declare that they have no conflict of interest. EDAT- 2022/11/03 06:00 MHDA- 2023/03/03 06:00 PMCR- 2022/11/02 CRDT- 2022/11/02 12:15 PHST- 2022/08/01 00:00 [received] PHST- 2022/10/24 00:00 [accepted] PHST- 2022/11/03 06:00 [pubmed] PHST- 2023/03/03 06:00 [medline] PHST- 2022/11/02 12:15 [entrez] PHST- 2022/11/02 00:00 [pmc-release] AID - 10.1007/s00246-022-03041-5 [pii] AID - 3041 [pii] AID - 10.1007/s00246-022-03041-5 [doi] PST - ppublish SO - Pediatr Cardiol. 2023 Mar;44(3):530-539. doi: 10.1007/s00246-022-03041-5. Epub 2022 Nov 2. PMID- 36320966 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221104 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 14 IP - 9 DP - 2022 Sep TI - A Multidisciplinary Approach and Current Perspective of Nonalcoholic Fatty Liver Disease: A Systematic Review. PG - e29657 LID - 10.7759/cureus.29657 [doi] LID - e29657 AB - In recent times, nonalcoholic fatty liver disease (NAFLD) has been considered one of the major causes of liver disease across the world. NAFLD is defined as the deposition of triglycerides in the liver and is associated with obesity and metabolic syndrome. Hyperinsulinemia, insulin resistance (IR), fatty liver, hepatocyte injury, unbalanced proinflammatory cytokines, mitochondrial dysfunction, oxidative stress, liver inflammation, and fibrosis are the main pathogenesis in NAFLD. Recent studies suggest that the action of intestinal microbiota through chronic inflammation, increased intestinal permeability, and energy uptake plays a vital role in NAFLD. Moreover, polycystic ovarian syndrome also causes NAFLD development through IR. Age, gender, race, ethnicity, sleep, diet, sedentary lifestyle, and genetic and epigenetic pathways are some contributing factors of NAFLD that can exacerbate the risk of liver cirrhosis and hepatocellular carcinoma (HCC) and eventually lead to death. NAFLD has various presentations, including fatigue, unexplained weight loss, bloating, upper abdominal pain, decreased appetite, headache, anxiety, poor sleep, increased thirst, palpitation, and a feeling of warmth. Some studies have shown that NAFLD with severe coronavirus disease 2019 (COVID-19) has poor outcomes. The gold standard for NAFLD diagnosis is liver biopsy. Other diagnostic tools are imaging tests, serum biomarkers, microbiota markers, and tests for extrahepatic complications. There are no specific treatments for NAFLD. Therefore, the main concern for NAFLD is treating the comorbid conditions such as anti-diabetic agents for type 2 diabetes mellitus, statins to reduce HCC progression, antioxidants to prevent hepatocellular damage, and bariatric surgery for patients with a BMI of >40 kg/m(2) and >35 kg/m(2) with comorbidities. Lifestyle and dietary changes are considered preventive strategies against NAFLD advancement. Inadequate treatment of NAFLD further leads to cardiac consequences, sleep apnea, chronic kidney disease, and inflammatory bowel disease. In this systematic review, we have briefly discussed the risk factors, pathogenesis, clinical features, and numerous consequences of NAFLD. We have also reviewed various guidelines for NAFLD diagnosis along with existing therapeutic strategies for the management and prevention of the disease. CI - Copyright (c) 2022, Zaman et al. FAU - Zaman, Chowdhury F AU - Zaman CF AD - Medicine and Surgery, Jahurul Islam Medical College and Hospital, Kishoreganj, BGD. FAU - Sultana, Jakia AU - Sultana J AD - Medicine, Comilla Medical College, Cumilla, BGD. FAU - Dey, Proma AU - Dey P AD - Internal Medicine, Chittagong Medical College, Chattogram, BGD. FAU - Dutta, Jui AU - Dutta J AD - Medicine, Comilla Medical College, Cumilla, BGD. FAU - Mustarin, Sadia AU - Mustarin S AD - Medicine, Mymensingh Medical College, Mymensingh, BGD. FAU - Tamanna, Nuzhat AU - Tamanna N AD - Medicine, Rangpur Medical College and Hospital, Rangpur, BGD. FAU - Roy, Aditi AU - Roy A AD - Medicine, Sher-e-Bangla Medical College, Barisal, BGD. FAU - Bhowmick, Nisha AU - Bhowmick N AD - Medicine, Shaheed Ziaur Rahman Medical College, Bogra, BGD. FAU - Khanam, Mousumi AU - Khanam M AD - Internal Medicine, Dhaka Medical College, Dhaka, BGD. FAU - Sultana, Sadia AU - Sultana S AD - Medicine, Anwer Khan Modern Medical College, Dhaka, BGD. FAU - Chowdhury, Selia AU - Chowdhury S AD - Internal Medicine, Dhaka Medical College, Dhaka, BGD. FAU - Khanam, Farjana AU - Khanam F AD - Medicine, Central Medical College, Cumilla, BGD. FAU - Sakibuzzaman, Md AU - Sakibuzzaman M AD - Neurology, The University of Toledo, Toledo, USA. AD - Internal Medicine, University of Mississippi Medical Center, Jackson, USA. AD - Internal Medicine, Sir Salimullah Medical College, Dhaka, BGD. AD - Experimental Pathology (Cancer Biology), Mayo Clinic, Rochester, USA. FAU - Dutta, Priyata AU - Dutta P AD - Internal Medicine, Trinity Health, St. Joseph Mercy Ann Arbor, Ann Arbor, USA. LA - eng PT - Journal Article PT - Review DEP - 20220927 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC9612896 OTO - NOTNLM OT - covid-19 OT - gut microbiota OT - hepatocellular carcinoma (hcc) OT - metabolic syndrome OT - nafld OT - nonalcoholic fatty liver disease OT - nonalcoholic fatty liver disease (nafld) OT - obesity COIS- The authors have declared that no competing interests exist. EDAT- 2022/11/03 06:00 MHDA- 2022/11/03 06:01 PMCR- 2022/09/27 CRDT- 2022/11/02 02:21 PHST- 2022/09/27 00:00 [accepted] PHST- 2022/11/02 02:21 [entrez] PHST- 2022/11/03 06:00 [pubmed] PHST- 2022/11/03 06:01 [medline] PHST- 2022/09/27 00:00 [pmc-release] AID - 10.7759/cureus.29657 [doi] PST - epublish SO - Cureus. 2022 Sep 27;14(9):e29657. doi: 10.7759/cureus.29657. eCollection 2022 Sep. PMID- 36318462 OWN - NLM STAT- MEDLINE DCOM- 20221103 LR - 20250617 IS - 1557-2501 (Electronic) IS - 1042-3931 (Linking) VI - 34 IP - 11 DP - 2022 Nov TI - Emergent Off-Label TAVR for Native Aortic Valve Endocarditis. PG - E820-E821 AB - A 76-year-old-male transferred to our center with severe breathlessness (New York Heart Association class III-IV). He was afebrile, hypoxic, and tachycardic with a wide pulse-pressure. Chest auscultation revealed a systolic and early diastolic murmur. Two weeks prior to admission, he reported severe cellulitis treated with intravenous antibiotics. Transthoracic echocardiogram demonstrated severe aortic valve (AoV) stenosis and evidence of AoV disruption with mobile vegetations and severe aortic regurgitation (AR) in keeping with plausible infectious endocarditis (IE). Following 3 sets of blood cultures, we treated the patient with intravenous antibiotics and diuretics. Blood cultures were negative, likely due to previous antibiotics treatment. Due to the acute decompensation, he underwent early heart team discussion with a view to urgent surgical AoV replacement. This case example suggests that TAVR with cerebral protection might be a safe treatment option in inoperable patients with AoV IE. FAU - Kalogeropoulos, Andreas S AU - Kalogeropoulos AS AD - Andreas Kalogeropoulos, MD, PhD, FRCP, FESC, Department of Cardiology, Mitera General Hospital Hygeia Healthcare Group, Athens, Greece. andkalog@gmail.com. FAU - Redwood, Simon R AU - Redwood SR FAU - Klein, John AU - Klein J FAU - Prendergast, Bernard AU - Prendergast B FAU - Patterson, Tiffany AU - Patterson T LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - J Invasive Cardiol JT - The Journal of invasive cardiology JID - 8917477 RN - 0 (Anti-Bacterial Agents) SB - IM MH - Humans MH - Male MH - Aged MH - Aortic Valve/surgery MH - *Transcatheter Aortic Valve Replacement MH - Off-Label Use MH - *Endocarditis MH - *Aortic Valve Stenosis/surgery MH - Anti-Bacterial Agents/therapeutic use OTO - NOTNLM OT - TAVR OT - aortic valve endocarditis EDAT- 2022/11/02 06:00 MHDA- 2022/11/04 06:00 CRDT- 2022/11/01 12:32 PHST- 2022/11/01 12:32 [entrez] PHST- 2022/11/02 06:00 [pubmed] PHST- 2022/11/04 06:00 [medline] AID - 10.25270/jic/22.00089 [doi] PST - ppublish SO - J Invasive Cardiol. 2022 Nov;34(11):E820-E821. doi: 10.25270/jic/22.00089. PMID- 36317978 OWN - NLM STAT- MEDLINE DCOM- 20221103 LR - 20260127 IS - 1098-4275 (Electronic) IS - 0031-4005 (Linking) VI - 150 IP - Suppl 2 DP - 2022 Nov 1 TI - Analgesia, Sedation, and Anesthesia for Neonates With Cardiac Disease. LID - e2022056415K [pii] LID - 10.1542/peds.2022-056415K [doi] AB - Analgesia, sedation, and anesthesia are a continuum. Diagnostic and/or therapeutic procedures in newborns often require analgesia, sedation, and/or anesthesia. Newborns, in general, and, particularly, those with heart disease, have an increased risk of serious adverse events, including mortality under anesthesia. In this section, we discuss the assessment and management of pain and discomfort during interventions, review the doses and side effects of commonly used medications, and provide recommendations for their use in newborns with heart disease. For procedures requiring deeper levels of sedation and anesthesia, airway and hemodynamic support might be necessary. Although associations of long-term deleterious neurocognitive effects of anesthetic agents have received considerable attention in both scientific and lay press, causality is not established. Nonetheless, an early multimodal, multidisciplinary approach is beneficial for safe management before, during, and after interventional procedures and surgery to avoid problems of tolerance and delirium, which can contribute to long-term cognitive dysfunction. CI - Copyright (c) 2022 by the American Academy of Pediatrics. FAU - Smith-Parrish, Melissa AU - Smith-Parrish M AD - Monroe Carell Jr. Children's Hospital at Vanderbilt, Vanderbilt University School of Medicine, Nashville, Tennessee. FAU - Vargas Chaves, Dianna P AU - Vargas Chaves DP AD - Columbia Presbyterian Hospital, New York City, New York. FAU - Taylor, Katherine AU - Taylor K AD - Hospital for Sick Children, Toronto, Canada. FAU - Achuff, Barbara-Jo AU - Achuff BJ AD - Texas Children's Hospital, Baylor College of Medicine, Houston, Texas. FAU - Lasa, Javier J AU - Lasa JJ AD - Texas Children's Hospital, Baylor College of Medicine, Houston, Texas. FAU - Hopper, Andrew AU - Hopper A AD - Loma Linda University Children's Hospital, Loma Linda, California. FAU - Ramamoorthy, Chandra AU - Ramamoorthy C AD - Stanford Children's Hospital, Stanford University, California. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Pediatrics JT - Pediatrics JID - 0376422 SB - IM MH - Infant, Newborn MH - Humans MH - *Analgesia/methods MH - *Anesthesia MH - Pain MH - Pain Management MH - *Heart Diseases MH - Procedural Sedation EDAT- 2022/11/02 06:00 MHDA- 2022/11/04 06:00 CRDT- 2022/11/01 09:53 PHST- 2022/08/29 00:00 [accepted] PHST- 2022/11/01 09:53 [entrez] PHST- 2022/11/02 06:00 [pubmed] PHST- 2022/11/04 06:00 [medline] AID - 189889 [pii] AID - 10.1542/peds.2022-056415K [doi] PST - ppublish SO - Pediatrics. 2022 Nov 1;150(Suppl 2):e2022056415K. doi: 10.1542/peds.2022-056415K. PMID- 36317971 OWN - NLM STAT- MEDLINE DCOM- 20221103 LR - 20221115 IS - 1098-4275 (Electronic) IS - 0031-4005 (Linking) VI - 150 IP - Suppl 2 DP - 2022 Nov 1 TI - Acute Cardiac Care for Neonatal Heart Disease. LID - e2022056415J [pii] LID - 10.1542/peds.2022-056415J [doi] AB - This manuscript is one component of a larger series of articles produced by the Neonatal Cardiac Care Collaborative that are published in this supplement of Pediatrics. In this review article, we summarize the contemporary physiologic principles, evaluation, and management of acute care issues for neonates with complex congenital heart disease. A multidisciplinary team of authors was created by the Collaborative's Executive Committee. The authors developed a detailed outline of the manuscript, and small teams of authors were assigned to draft specific sections. The authors reviewed the literature, with a focus on original manuscripts published in the last decade, and drafted preliminary content and recommendations. All authors subsequently reviewed and edited the entire manuscript until a consensus was achieved. Topics addressed include cardiopulmonary interactions, the pathophysiology of and strategies to minimize the development of ventilator-induced low cardiac output syndrome, common postoperative physiologies, perioperative bleeding and coagulation, and common postoperative complications. CI - Copyright (c) 2022 by the American Academy of Pediatrics. FAU - Cooper, David S AU - Cooper DS AD - Department of Pediatrics, University of Cincinnati College of Medicine, The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. FAU - Hill, Kevin D AU - Hill KD AD - Division of Cardiology, Duke Children's Hospital, Durham, North Carolina. FAU - Krishnamurthy, Ganga AU - Krishnamurthy G AD - Division of Neonatology, Columbia University Medical Center, New York, New York. FAU - Sen, Shawn AU - Sen S AD - Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois. FAU - Costello, John M AU - Costello JM AD - Division of Cardiology, Medical University of South Carolina, Charleston, South Carolina. FAU - Lehenbauer, David AU - Lehenbauer D AD - Department of Pediatrics, University of Cincinnati College of Medicine, The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. FAU - Twite, Mark AU - Twite M AD - Department of Anesthesia, Colorado Children's Hospital, Aurora, Colorado. FAU - James, Lorraine AU - James L AD - Department of Pediatrics, Children's Hospital of Los Angeles, Los Angeles, California. FAU - Mah, Kenneth E AU - Mah KE AD - Department of Pediatrics, University of Cincinnati College of Medicine, The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. FAU - Taylor, Carmen AU - Taylor C AD - Department of Pediatric Cardiothoracic Surgery, The Children's Hospital, Oklahoma City, Oklahoma. FAU - McBride, Mary E AU - McBride ME AD - Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review PL - United States TA - Pediatrics JT - Pediatrics JID - 0376422 SB - IM MH - Infant, Newborn MH - Child MH - Humans MH - *Cardiac Output, Low MH - *Critical Care MH - Consensus MH - Postoperative Complications EDAT- 2022/11/02 06:00 MHDA- 2022/11/04 06:00 CRDT- 2022/11/01 09:53 PHST- 2022/08/29 00:00 [accepted] PHST- 2022/11/01 09:53 [entrez] PHST- 2022/11/02 06:00 [pubmed] PHST- 2022/11/04 06:00 [medline] AID - 189882 [pii] AID - 10.1542/peds.2022-056415J [doi] PST - ppublish SO - Pediatrics. 2022 Nov 1;150(Suppl 2):e2022056415J. doi: 10.1542/peds.2022-056415J. PMID- 36316173 OWN - NLM STAT- MEDLINE DCOM- 20221102 LR - 20230129 IS - 1937-710X (Electronic) IS - 1062-3264 (Linking) VI - 31 IP - 6 DP - 2022 Nov 1 TI - Implementation and Modification of Developmental Care Rounds in the Cardiac Intensive Care Unit. PG - 494-498 LID - 10.4037/ajcc2022941 [doi] AB - In 2019, an interprofessional team at Texas Children's Hospital designed and instituted developmental care rounds to better coordinate developmentally appropriate care within the cardiac intensive care unit. During the first 2 years, we conducted 230 developmental care rounds on 169 patients; for these rounds, family participation was greater than 85%. Since their inception, these rounds have undergone several modifications, including changes to the patient selection criteria and team role delegation. Importantly, the structure of these rounds has evolved to prominently integrate family members' perspectives and experiences. Lessons learned through developmental care rounds have formed a foundation for implementing other developmentally appropriate practices and initiatives throughout the hospital's Heart Center. CI - (c)2022 American Association of Critical-Care Nurses. FAU - Elhoff, Justin J AU - Elhoff JJ AD - Justin J. Elhoff is an assistant professor of pediatrics, Baylor College of Medicine and a cardiac intensivist at Texas Children's Hospital, Houston, Texas. FAU - Zender, Jill AU - Zender J AD - Jill Zender is a nurse practitioner, University of Texas Southwestern, Children's Health, Dallas, Texas. FAU - Davis, Kelly L R AU - Davis KLR AD - Kelly L. R. Davis is an occupational therapist, Texas Children's Hospital. FAU - Rizk, Claire M AU - Rizk CM AD - Claire M. Rizk is an instructor, Baylor College of Medicine and a nurse practitioner, Texas Children's Hospital. FAU - Salinas, Lauren H AU - Salinas LH AD - Lauren H. Salinas is a clinical nurse specialist, Texas Children's Hospital. FAU - Tsang, Rocky AU - Tsang R AD - Rocky Tsang is an assistant professor of pediatrics, Baylor College of Medicine and a cardiac intensivist, Texas Children's Hospital. FAU - Schlosser, Robin R AU - Schlosser RR AD - Robin R. Schlosser is a physical therapist, Texas Children's Hospital. LA - eng PT - Journal Article PL - United States TA - Am J Crit Care JT - American journal of critical care : an official publication, American Association of Critical-Care Nurses JID - 9211547 SB - IM MH - Child MH - Humans MH - *Teaching Rounds MH - Intensive Care Units MH - Professional-Family Relations MH - Family MH - Hospitals, Pediatric MH - Patient Care Team EDAT- 2022/11/01 06:00 MHDA- 2022/11/03 06:00 CRDT- 2022/10/31 22:12 PHST- 2022/10/31 22:12 [entrez] PHST- 2022/11/01 06:00 [pubmed] PHST- 2022/11/03 06:00 [medline] AID - 31873 [pii] AID - 10.4037/ajcc2022941 [doi] PST - ppublish SO - Am J Crit Care. 2022 Nov 1;31(6):494-498. doi: 10.4037/ajcc2022941. PMID- 36312259 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221102 IS - 2297-055X (Print) IS - 2297-055X (Electronic) IS - 2297-055X (Linking) VI - 9 DP - 2022 TI - Women in mechanical circulatory support: She persisted! PG - 961404 LID - 10.3389/fcvm.2022.961404 [doi] LID - 961404 AB - Many women physicians have blazed trails and played instrumental roles in advancing the field of Advanced Heart Failure (AHF), Mechanical Circulatory Support (MCS), and cardiac transplantation to its current recognition and glory. In contrast to other areas of cardiology, women have played an integral role in the evolution and emergence of this sub-specialty. Although the ceiling had been broken much later for women cardiothoracic (CT) surgeons in the field of AHF, the ingress of women into surgical fields particularly CT surgery was stonewalled due to pervasive stereotyping. The constancy, commitment, and contributions of women to the field of AHF and MCS cannot be minimized in bringing this field to the forefront of innovation both from technological aspect as well as in redesigning of healthcare delivery models. Integrated team-based approach is a necessity for the optimal care of MCS patients and forced institutions to develop this approach when patients with durable left ventricular assist devices (LVAD) began discharging from the hospitals to local communities. Women in various roles in this field played a pivotal role in developing and designing patient centered care and coordination of care in a multidisciplinary manner. While embracing the challenges and turning them to opportunities, establishing partnerships and finding solutions with expectations to egalitarianism, women in this field continue to push boundaries and subscribe to the continued evolution of the field of AHF and advanced cardiac therapies. CI - Copyright (c) 2022 Benck, Khan and Munagala. FAU - Benck, Kelley N AU - Benck KN AD - Division of Cardiology, University of Miami Miller School of Medicine, Miami, FL, United States. FAU - Khan, Fatima A AU - Khan FA AD - Department of Cardiology, University of Texas Medical Branch, Galveston, TX, United States. FAU - Munagala, Mrudula R AU - Munagala MR AD - Division of Cardiology, University of Miami Miller School of Medicine, Miami, FL, United States. LA - eng PT - Journal Article PT - Review DEP - 20221013 PL - Switzerland TA - Front Cardiovasc Med JT - Frontiers in cardiovascular medicine JID - 101653388 PMC - PMC9606210 OTO - NOTNLM OT - CT surgeons OT - cardiologist OT - heart failure OT - left ventricular assist device (LVAD) OT - mechanical circulatory support (MCS) OT - women in MCS OT - women in medicine COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/11/01 06:00 MHDA- 2022/11/01 06:01 PMCR- 2022/01/01 CRDT- 2022/10/31 04:37 PHST- 2022/06/04 00:00 [received] PHST- 2022/09/07 00:00 [accepted] PHST- 2022/10/31 04:37 [entrez] PHST- 2022/11/01 06:00 [pubmed] PHST- 2022/11/01 06:01 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.3389/fcvm.2022.961404 [doi] PST - epublish SO - Front Cardiovasc Med. 2022 Oct 13;9:961404. doi: 10.3389/fcvm.2022.961404. eCollection 2022. PMID- 36308680 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20221215 LR - 20240524 IS - 1534-6315 (Electronic) IS - 1529-7322 (Linking) VI - 22 IP - 12 DP - 2022 Dec TI - Cardiac Sarcoidosis: Current Approaches to Diagnosis and Management. PG - 171-182 LID - 10.1007/s11882-022-01046-x [doi] AB - PURPOSE OF REVIEW: Cardiac sarcoidosis (CS) is an important cause of non-ischemic cardiomyopathy and has specific diagnostic and therapeutic considerations. With advances in imaging techniques and treatment approaches, the approach to monitoring disease progression and management of CS continues to evolve. The purpose of this review is to highlight advances in CS diagnosis and treatment and present a center's multidisciplinary approach to CS care. RECENT FINDINGS: In this review, we highlight advances in granuloma biology along with contemporary diagnostic approaches. Moreover, we expand on current targets of immunosuppression focused on granuloma biology and concurrent advances in the cardiovascular care of CS in light of recent guideline recommendations. Here, we review advances in the understanding of the sarcoidosis granuloma along with contemporary diagnostic and therapeutic considerations for CS. Additionally, we highlight knowledge gaps and areas for future research in CS treatment. CI - (c) 2022. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply. FAU - Rosario, Karen Flores AU - Rosario KF AD - Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC, 27710, USA. FAU - Brezitski, Kyla AU - Brezitski K AD - Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC, 27710, USA. FAU - Arps, Kelly AU - Arps K AD - Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC, 27710, USA. FAU - Milne, Megan AU - Milne M AD - Division of Rheumatology, Department of Medicine, Duke University Medical Center, Durham, NC, 27710, USA. FAU - Doss, Jayanth AU - Doss J AD - Division of Rheumatology, Department of Medicine, Duke University Medical Center, Durham, NC, 27710, USA. FAU - Karra, Ravi AU - Karra R AUID- ORCID: 0000-0001-6741-285X AD - Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC, 27710, USA. ravi.karra@duke.edu. AD - Department of Pathology, Duke University Medical Center, Box 102152 DUMC, Durham, NC, 27710, USA. ravi.karra@duke.edu. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20221029 PL - United States TA - Curr Allergy Asthma Rep JT - Current allergy and asthma reports JID - 101096440 SB - IM OTO - NOTNLM OT - Biomarkers OT - Cardiac sarcoidosis OT - Immunosuppression OT - Non-caseating granulomas EDAT- 2022/10/30 06:00 MHDA- 2022/10/30 06:01 CRDT- 2022/10/29 11:21 PHST- 2022/10/04 00:00 [accepted] PHST- 2022/10/30 06:00 [pubmed] PHST- 2022/10/30 06:01 [medline] PHST- 2022/10/29 11:21 [entrez] AID - 10.1007/s11882-022-01046-x [pii] AID - 10.1007/s11882-022-01046-x [doi] PST - ppublish SO - Curr Allergy Asthma Rep. 2022 Dec;22(12):171-182. doi: 10.1007/s11882-022-01046-x. Epub 2022 Oct 29. PMID- 36300657 OWN - NLM STAT- MEDLINE DCOM- 20221102 LR - 20221209 IS - 2047-9980 (Electronic) IS - 2047-9980 (Linking) VI - 11 IP - 21 DP - 2022 Nov TI - Social Isolation and Implementation of Advanced Care Planning Among Hospitalized Patients With Heart Failure. PG - e026645 LID - 10.1161/JAHA.122.026645 [doi] LID - e026645 AB - Background The implementation of advance care planning (ACP) in heart failure management is insufficient. Social isolation (SI) could be a barrier to ACP initiation, albeit the relationship between SI and patients' preference for ACP or end-of-life care remains unknown. Methods and Results We conducted a questionnaire survey, including assessments of SI using the 6-item Lubben Social Network Scale as well as patients' perspectives on ACP and end-of-life care. Of the 160 patients approached by our multidisciplinary heart failure team during admission, 120 patients (75.0%) completed the survey (median age, 73.0 years; men, 74.2%). A Cox proportional hazard model was constructed to elucidate the short-term (180-day) prognostic impact of SI. Overall, 28.3% of participants were at high risk for SI (6-item Lubben Social Network Scale score <12). High-risk patients had more negative attitudes toward ACP than those without (61.8% versus 80.2%; P=0.035). The actual performance of ACP conversation in patients with and without high risk were 20.6% and 30.2%, respectively. Regarding preference in end-of-life care, "Saying what one wants to tell loved ones" (73.5% versus 90.6%; P=0.016) and "Spending enough time with family" (58.8% versus 77.9%; P=0.035) were less important in high-risk patients. High risk for SI was associated with higher 180-day risk-adjusted all-cause mortality (hazard ratio, 7.89 [95% CI, 1.53-40.75]). Conclusions In hospitalized patients with heart failure, high risk for SI was frequently observed. High-risk patients were associated with a negative attitude toward ACP, despite higher mortality. Further research is required to establish an ideal approach to provide ACP in socially vulnerable patients. FAU - Kitakata, Hiroki AU - Kitakata H AD - Department of Cardiology Keio University School of Medicine Tokyo Japan. FAU - Kohno, Takashi AU - Kohno T AUID- ORCID: 0000-0003-2604-1284 AD - Department of Cardiology Keio University School of Medicine Tokyo Japan. AD - Department of Cardiovascular Medicine Kyorin University Faculty of Medicine Tokyo Japan. FAU - Kohsaka, Shun AU - Kohsaka S AUID- ORCID: 0000-0003-3779-2972 AD - Department of Cardiology Keio University School of Medicine Tokyo Japan. FAU - Fujisawa, Daisuke AU - Fujisawa D AUID- ORCID: 0000-0003-1913-6955 AD - Department of Neuropsychiatry Keio University School of Medicine Tokyo Japan. FAU - Nakano, Naomi AU - Nakano N AD - Department of Cardiology Keio University School of Medicine Tokyo Japan. FAU - Sekine, Otoya AU - Sekine O AD - Department of Cardiology Keio University School of Medicine Tokyo Japan. FAU - Shiraishi, Yasuyuki AU - Shiraishi Y AD - Department of Cardiology Keio University School of Medicine Tokyo Japan. FAU - Kishino, Yoshikazu AU - Kishino Y AUID- ORCID: 0000-0003-3291-2795 AD - Department of Cardiology Keio University School of Medicine Tokyo Japan. FAU - Katsumata, Yoshinori AU - Katsumata Y AUID- ORCID: 0000-0001-5576-5789 AD - Department of Cardiology Keio University School of Medicine Tokyo Japan. FAU - Yuasa, Shinsuke AU - Yuasa S AUID- ORCID: 0000-0001-5593-7552 AD - Department of Cardiology Keio University School of Medicine Tokyo Japan. FAU - Fukuda, Keiichi AU - Fukuda K AUID- ORCID: 0000-0003-1413-0482 AD - Department of Cardiology Keio University School of Medicine Tokyo Japan. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20221027 PL - England TA - J Am Heart Assoc JT - Journal of the American Heart Association JID - 101580524 SB - IM MH - Male MH - Humans MH - Aged MH - *Advance Care Planning MH - *Terminal Care MH - Patients MH - *Heart Failure/diagnosis/therapy MH - Social Isolation PMC - PMC9673637 OTO - NOTNLM OT - advance care planning OT - heart failure OT - patient perspective OT - social isolation EDAT- 2022/10/28 06:00 MHDA- 2022/11/03 06:00 PMCR- 2022/11/01 CRDT- 2022/10/27 07:03 PHST- 2022/10/28 06:00 [pubmed] PHST- 2022/11/03 06:00 [medline] PHST- 2022/10/27 07:03 [entrez] PHST- 2022/11/01 00:00 [pmc-release] AID - JAH37901 [pii] AID - 10.1161/JAHA.122.026645 [doi] PST - ppublish SO - J Am Heart Assoc. 2022 Nov;11(21):e026645. doi: 10.1161/JAHA.122.026645. Epub 2022 Oct 27. PMID- 36299648 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230131 IS - 2666-0849 (Electronic) IS - 2666-0849 (Linking) VI - 4 IP - 20 DP - 2022 Oct 19 TI - A First Suspected Case of Fibrosing Mediastinitis After Anti-PD-1 Therapy. PG - 1363-1365 LID - 10.1016/j.jaccas.2022.09.002 [doi] AB - We describe a first suspected case of fibrosing mediastinitis following anti-programmed death (PD)-1 therapy, pembrolizumab. Multimodality imaging, including cardiac magnetic resonance imaging, and a multidisciplinary team approach were integral to the diagnosis. If further substantiated, systematic surveillance after anti-PD-1 therapy for fibrosing mediastinitis may be warranted. (Level of Difficulty: Intermediate.). CI - (c) 2022 The Authors. FAU - Park, Carolyn J AU - Park CJ AD - Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA. FAU - Vasu, Sujethra AU - Vasu S AD - Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA. FAU - Urbain, Jean L AU - Urbain JL AD - Section on Cardiovascular Medicine, Department of Internal Medicine and the Department of Radiology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA. FAU - Triozzi, Pierre L AU - Triozzi PL AD - Section on Hematology and Oncology, Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA. FAU - Pokharel, Yashashwi AU - Pokharel Y AD - Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA. LA - eng GR - T32 HL076132/HL/NHLBI NIH HHS/United States PT - Journal Article DEP - 20221019 PL - Netherlands TA - JACC Case Rep JT - JACC. Case reports JID - 101757292 PMC - PMC9588595 OTO - NOTNLM OT - CHF, congestive heart failure OT - CMR, cardiac magnetic resonance OT - FDG, fluorodeoxyglucose OT - LGE, late gadolinium enhancement OT - PD-1, programmed death-1 OT - PET, positron emission tomography OT - anti-programmed death-1 OT - cardiac magnetic resonance OT - fibrosing mediastinitis OT - fibrosis OT - immunotherapy OT - positron emission tomography COIS- The authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2022/10/28 06:00 MHDA- 2022/10/28 06:01 PMCR- 2022/10/19 CRDT- 2022/10/27 02:29 PHST- 2022/05/16 00:00 [received] PHST- 2022/08/23 00:00 [revised] PHST- 2022/09/05 00:00 [accepted] PHST- 2022/10/27 02:29 [entrez] PHST- 2022/10/28 06:00 [pubmed] PHST- 2022/10/28 06:01 [medline] PHST- 2022/10/19 00:00 [pmc-release] AID - S2666-0849(22)00685-4 [pii] AID - 10.1016/j.jaccas.2022.09.002 [doi] PST - epublish SO - JACC Case Rep. 2022 Oct 19;4(20):1363-1365. doi: 10.1016/j.jaccas.2022.09.002. eCollection 2022 Oct 19. PMID- 36294165 OWN - NLM STAT- MEDLINE DCOM- 20221028 LR - 20230117 IS - 1660-4601 (Electronic) IS - 1661-7827 (Print) IS - 1660-4601 (Linking) VI - 19 IP - 20 DP - 2022 Oct 20 TI - Nurses' Perception of, and Barriers to, Delivering Cardiopulmonary Rehabilitation for Heart Failure Patients: A National Survey in Saudi Arabia. LID - 10.3390/ijerph192013586 [doi] LID - 13586 AB - BACKGROUND: Heart failure (HF) patients require a holistic management approach to improve their clinical outcomes. Cardiopulmonary rehabilitation (CR) is a core component of HF patients' management and is supervised by a multidisciplinary team including nurses. Nursing attitudes regarding CR delivery for patients with HF and the possible barriers and factors that potentially affect referral have not been explored. Therefore, this study seeks to evaluate nurses' attitudes towards the delivery of CR programs and the possible barriers and factors that potentially influence the decision for a referral. METHODS: An online survey with eight multiple-choice items was disseminated to all nurses between February and July 2022 in Saudi Arabia. The characteristics of the respondents were described using descriptive statistics. Percentages and frequencies were used to report categorical variables. RESULTS: Overall, 1056 nurses completed the online survey, of which 395 (37.40%) were male. Out of 1056 nurses, 414 (39.20%) strongly agreed that CR would improve patients' physical fitness, and 392 (37.10%) strongly agreed that CR would reduce breathlessness in patients with HF. In total, 381 nurses strongly agreed (36.10%) that CR would improve HF patients' palpitation and fatigue. Out of 1056 nurses, 396 (37.50%) strongly agreed that CR would improve HF patients' ability to perform daily activities, and 326 (30.90%) strongly agreed that CPR would reduce the rate of hospital readmission. The at-home program was the preferred mode of delivering CR programs among 607 (57.50%) nurses. Apart from the exercise component, symptom management was perceived by 704 (66.70%) nurses as the fundamental component of CR programs. The most common patient-related factor that strongly affected the decisions regarding referral was "mobility affected by breathlessness" (57%). A lack of CR centers (46%) was the most common barrier. CONCLUSION: Nurses perceived CR as an effective management strategy for HF patients. Although a home-based program, with symptom management being an essential component, in addition to the exercise component, was perceived as the preferred mode of delivery, CR centers are lacking, which represented a significant barrier to CR referral from the nurses' perspective. FAU - Aldhahir, Abdulelah M AU - Aldhahir AM AUID- ORCID: 0000-0002-4270-9494 AD - Respiratory Therapy Department, Faculty of Applied Medical Sciences, Jazan University, Jazan 45142, Saudi Arabia. LA - eng PT - Journal Article DEP - 20221020 PL - Switzerland TA - Int J Environ Res Public Health JT - International journal of environmental research and public health JID - 101238455 SB - IM MH - Humans MH - Male MH - Female MH - Saudi Arabia MH - *Heart Failure MH - Dyspnea MH - Perception MH - *Nurses PMC - PMC9602745 OTO - NOTNLM OT - CR OT - Saudi Arabia OT - cardiopulmonary rehabilitation OT - heart failure OT - nursing COIS- The author declares no conflict of interest. EDAT- 2022/10/28 06:00 MHDA- 2022/10/29 06:00 PMCR- 2022/10/20 CRDT- 2022/10/27 01:29 PHST- 2022/09/13 00:00 [received] PHST- 2022/10/16 00:00 [revised] PHST- 2022/10/17 00:00 [accepted] PHST- 2022/10/27 01:29 [entrez] PHST- 2022/10/28 06:00 [pubmed] PHST- 2022/10/29 06:00 [medline] PHST- 2022/10/20 00:00 [pmc-release] AID - ijerph192013586 [pii] AID - ijerph-19-13586 [pii] AID - 10.3390/ijerph192013586 [doi] PST - epublish SO - Int J Environ Res Public Health. 2022 Oct 20;19(20):13586. doi: 10.3390/ijerph192013586. PMID- 36292657 OWN - NLM STAT- MEDLINE DCOM- 20221028 LR - 20231103 IS - 2073-4425 (Electronic) IS - 2073-4425 (Linking) VI - 13 IP - 10 DP - 2022 Sep 30 TI - Multidisciplinary Progress in Obesity Research. LID - 10.3390/genes13101772 [doi] LID - 1772 AB - Obesity is a chronic disease that endangers human health. In recent years, the phenomenon of obesity has become more and more common, and it has become a global epidemic. Obesity is closely associated with many adverse metabolic changes and diseases, such as insulin resistance, type 2 diabetes mellitus, coronary heart disease, nervous system diseases and some malignant tumors, which have caused a huge burden on the country's medical finance. In most countries of the world, the incidence of cancer caused by obesity is increasing year on year. Diabetes associated with obesity can lead to secondary neuropathy. How to treat obesity and its secondary diseases has become an urgent problem for patients, doctors and society. This article will summarize the multidisciplinary research on obesity and its complications. FAU - Lu, Xiaoqing AU - Lu X AD - Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing 100191, China. AD - Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing 100191, China. AD - Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing 100191, China. AD - Beijing Laboratory of Integrative Microangiopathy, Beijing 100191, China. AD - State Key Laboratory of Core Technology in Innovative Chinese Medicine, Beijing 100191, China. FAU - Jin, Yuxin AU - Jin Y AUID- ORCID: 0000-0002-5677-1133 AD - Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing 100191, China. AD - Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing 100191, China. AD - Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing 100191, China. AD - Beijing Laboratory of Integrative Microangiopathy, Beijing 100191, China. AD - State Key Laboratory of Core Technology in Innovative Chinese Medicine, Beijing 100191, China. FAU - Li, Dexin AU - Li D AD - Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing 100191, China. AD - Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing 100191, China. AD - Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing 100191, China. AD - Beijing Laboratory of Integrative Microangiopathy, Beijing 100191, China. AD - State Key Laboratory of Core Technology in Innovative Chinese Medicine, Beijing 100191, China. FAU - Zhang, Jingxin AU - Zhang J AD - Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing 100191, China. AD - Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing 100191, China. AD - Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing 100191, China. AD - Beijing Laboratory of Integrative Microangiopathy, Beijing 100191, China. AD - State Key Laboratory of Core Technology in Innovative Chinese Medicine, Beijing 100191, China. FAU - Han, Jingyan AU - Han J AD - Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing 100191, China. AD - Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing 100191, China. AD - Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing 100191, China. AD - Beijing Laboratory of Integrative Microangiopathy, Beijing 100191, China. AD - State Key Laboratory of Core Technology in Innovative Chinese Medicine, Beijing 100191, China. FAU - Li, Yin AU - Li Y AUID- ORCID: 0000-0002-4019-3391 AD - Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing 100191, China. AD - Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing 100191, China. AD - Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing 100191, China. AD - Beijing Laboratory of Integrative Microangiopathy, Beijing 100191, China. AD - State Key Laboratory of Core Technology in Innovative Chinese Medicine, Beijing 100191, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20220930 PL - Switzerland TA - Genes (Basel) JT - Genes JID - 101551097 SB - IM MH - Humans MH - *Diabetes Mellitus, Type 2/metabolism MH - Obesity/complications/epidemiology/metabolism MH - *Insulin Resistance PMC - PMC9601416 OTO - NOTNLM OT - cancer OT - metabolic diseases OT - multidisciplinary treatment of obesity OT - nervous system diseases OT - obesity COIS- The authors declare no conflict of interest. EDAT- 2022/10/28 06:00 MHDA- 2022/10/29 06:00 PMCR- 2022/09/30 CRDT- 2022/10/27 01:19 PHST- 2022/08/25 00:00 [received] PHST- 2022/09/20 00:00 [revised] PHST- 2022/09/27 00:00 [accepted] PHST- 2022/10/27 01:19 [entrez] PHST- 2022/10/28 06:00 [pubmed] PHST- 2022/10/29 06:00 [medline] PHST- 2022/09/30 00:00 [pmc-release] AID - genes13101772 [pii] AID - genes-13-01772 [pii] AID - 10.3390/genes13101772 [doi] PST - epublish SO - Genes (Basel). 2022 Sep 30;13(10):1772. doi: 10.3390/genes13101772. PMID- 36288923 OWN - NLM STAT- MEDLINE DCOM- 20230809 LR - 20230810 IS - 1468-201X (Electronic) IS - 1355-6037 (Linking) VI - 109 IP - 8 DP - 2023 Mar 27 TI - Inflammatory and thrombotic valvulopathies in autoimmune disease. PG - 583-588 LID - 10.1136/heartjnl-2021-319603 [doi] AB - Rheumatologic diseases are characterised by loss of immune tolerance, resulting in systemic inflammation. Inflammation and scarring of the endocardium, which lines the inner surface of the heart chambers and valves, can result in valvular thickening and dysfunction. Estimates of prevalence vary depending on the sensitivity of the screening methodology used and range from 30%-50% in systemic lupus and rheumatoid arthritis to 10%-30% in ankylosing spondylitis. Progression of valve disease is a slow process but can result in haemodynamically significant complications. Thromboembolic complications such as cerebrovascular occlusions pose a serious risk of morbidity. The presence of antiphospholipid antibodies increases the risk of valvular disease and thrombotic complications. Anticoagulation is recommended in the presence of antiphospholipid antibodies, but the guidance on the role of immunosuppressive therapy to treat valvular disease is lacking. Surgical valve therapy may be considered in severe disease, but there is increased risk in patients with an autoimmune disease which includes a higher risk of infection, thromboembolic and bleeding complications, as well as cardiovascular events in the setting of premature atherosclerotic heart disease. Therefore, management should be provided in a multidisciplinary team that includes a rheumatologist, a cardiologist and a cardiothoracic surgeon; medical therapy should be optimised before considering a high-risk valve surgery. CI - (c) Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Gartshteyn, Yevgeniya AU - Gartshteyn Y AUID- ORCID: 0000-0001-5547-4658 AD - Medicine, Columbia University Irving Medical Center, New York, New York, USA yg2372@cumc.columbia.edu. FAU - Bhave, Nicole AU - Bhave N AD - Medicine, University of Michigan Michigan Medicine, Ann Arbor, Michigan, USA. FAU - Joseph, Megan Shetty AU - Joseph MS AD - Medicine, University of Michigan Michigan Medicine, Ann Arbor, Michigan, USA. FAU - Askanase, Anca AU - Askanase A AD - Medicine, Columbia University Irving Medical Center, New York, New York, USA. FAU - Bernstein, Elana J AU - Bernstein EJ AD - Medicine, Columbia University Irving Medical Center, New York, New York, USA. LA - eng PT - Journal Article PT - Review DEP - 20230327 PL - England TA - Heart JT - Heart (British Cardiac Society) JID - 9602087 RN - 0 (Antibodies, Antiphospholipid) SB - IM MH - Humans MH - *Antiphospholipid Syndrome/complications/diagnosis/therapy MH - *Heart Valve Diseases/diagnosis MH - *Autoimmune Diseases/complications/diagnosis/therapy MH - *Thrombosis/complications MH - Antibodies, Antiphospholipid MH - *Thromboembolism/etiology/prevention & control MH - Inflammation OTO - NOTNLM OT - Heart Valve Diseases COIS- Competing interests: None declared. EDAT- 2022/10/27 06:00 MHDA- 2023/08/09 06:42 CRDT- 2022/10/26 21:03 PHST- 2022/06/14 00:00 [received] PHST- 2022/10/12 00:00 [accepted] PHST- 2023/08/09 06:42 [medline] PHST- 2022/10/27 06:00 [pubmed] PHST- 2022/10/26 21:03 [entrez] AID - heartjnl-2021-319603 [pii] AID - 10.1136/heartjnl-2021-319603 [doi] PST - epublish SO - Heart. 2023 Mar 27;109(8):583-588. doi: 10.1136/heartjnl-2021-319603. PMID- 36273431 OWN - NLM STAT- MEDLINE DCOM- 20230105 LR - 20230111 IS - 1540-8191 (Electronic) IS - 0886-0440 (Linking) VI - 37 IP - 12 DP - 2022 Dec TI - Talk like a duck, walk like a duck: A cardiac surgeon's understanding of complex imaging in the management of atrial fibrillation. PG - 4178-4185 LID - 10.1111/jocs.17045 [doi] AB - The treatment of atrial fibrillation continues to evolve. The Heart Team Hybrid Ablation Approach is the latest iteration of Electrophysiology and Arrythmia surgeon collaboration that is focused on the treatment of complex (persistent and long-standing persistent) atrial fibrillation patients. Critical to this team approach is the ability to converse regarding atrial anatomy, atrial substrate and transmurality of ablation lesions. The cornerstone of these dialogs is advanced imaging techniques including; transesophageal echocardiography, enhanced magnetic resonance imaging, endocardial voltage mapping, and epicardial electrogram mapping. We herein review these techniques and their clinic implications. CI - (c) 2022 Wiley Periodicals LLC. FAU - Kiankhooy, Armin AU - Kiankhooy A AUID- ORCID: 0000-0001-7610-9406 AD - Department of Cardiothoracic Surgery, Adventist Health-Saint Helena, Saint Helena, California, USA. LA - eng PT - Journal Article PT - Review DEP - 20221023 PL - United States TA - J Card Surg JT - Journal of cardiac surgery JID - 8908809 SB - IM MH - Humans MH - *Atrial Fibrillation/diagnostic imaging/surgery MH - Heart Atria/diagnostic imaging/surgery MH - Endocardium/surgery MH - Diagnostic Imaging MH - *Catheter Ablation/methods MH - Treatment Outcome OTO - NOTNLM OT - arrythmia surgery OT - enhanced MRI OT - hybrid ablation OT - surgical ablation OT - voltage mapping EDAT- 2022/10/24 06:00 MHDA- 2023/01/06 06:00 CRDT- 2022/10/23 17:01 PHST- 2022/10/02 00:00 [received] PHST- 2022/10/03 00:00 [accepted] PHST- 2022/10/24 06:00 [pubmed] PHST- 2023/01/06 06:00 [medline] PHST- 2022/10/23 17:01 [entrez] AID - 10.1111/jocs.17045 [doi] PST - ppublish SO - J Card Surg. 2022 Dec;37(12):4178-4185. doi: 10.1111/jocs.17045. Epub 2022 Oct 23. PMID- 36270966 OWN - NLM STAT- MEDLINE DCOM- 20230124 LR - 20230201 IS - 1878-0938 (Electronic) IS - 1878-0938 (Linking) VI - 47 DP - 2023 Feb TI - Comparison of American and European Guidelines for the Management of Patients With Valvular Heart Disease. PG - 76-85 LID - S1553-8389(22)00822-3 [pii] LID - 10.1016/j.carrev.2022.10.005 [doi] AB - This review compares the recommendations of the recent 2020 American College of Cardiology (ACC)/American Heart Association (AHA) and 2021 European Society of Cardiology (ESC)/European Association for Cardio-Thoracic Surgery (EACTS) guidelines on the management of patients with valvular heart disease (VHD). ACC/AHA and ESC/EACTS guidelines are both the updated versions of previous 2017 documents. Both guidelines fundamentally agree on the extended indications of percutaneous valve interventions, the optimal use of imaging modalities other than 2D echocardiography, the importance of a multidisciplinary Heart Team as well as active patient participation in clinical decision making, more widespread use of NOACs and earlier intervention with lower left ventricular dilatation thresholds to decrease long-term mortality. The differences between the guidelines are mainly related to the classification of the severity of valve pathologies and frequency of follow-up, level of recommendations of valve intervention indications in special patient groups such as frail patients and the left ventricular diameter and ejection fraction thresholds for intervention. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Inanc, Ibrahim Halil AU - Inanc IH AD - Kirikkale Yuksek Ihtisas Hospital, Department of Cardiology, Kirikkale, Turkey. Electronic address: ihinanc@yahoo.com. FAU - Cilingiroglu, Mehmet AU - Cilingiroglu M AD - University of Texas in Houston, MD Anderson Cancer Center, Houston, TX, United States of America. FAU - Iliescu, Cezar AU - Iliescu C AD - University of Texas in Houston, MD Anderson Cancer Center, Houston, TX, United States of America. Electronic address: ciliescu@mdanderson.org. FAU - NInios, Vlasis AU - NInios V AD - Department of Cardiology, Interbalkan European Medical Center, Thessaloniki, Greece. FAU - Matar, Fadi AU - Matar F AD - Department of Cardiology, University of South Florida, Tampa, FL, United States of America. Electronic address: fmatar@health.usf.edu. FAU - Ates, Ismail AU - Ates I AD - Department of Cardiology, Sisli Kolan International Hospital, Istanbul, Turkey. FAU - Toutouzas, Konstantinos AU - Toutouzas K AD - Hippocrateion Athens General Hospital, Athens Medical School, National and Kapodistrian University of Athens, Athens, Greece. Electronic address: ktoutouz@otenet.gr. FAU - Hermiller, James AU - Hermiller J AD - Department of Cardiology, St Vincent Heart Center, Indianapolis, IN, United States of America. FAU - Marmagkiolis, Kostas AU - Marmagkiolis K AD - University of Texas in Houston, MD Anderson Cancer Center, Houston, TX, United States of America; Department of Cardiology, University of South Florida, Tampa, FL, United States of America. LA - eng PT - Journal Article PT - Review DEP - 20221017 PL - United States TA - Cardiovasc Revasc Med JT - Cardiovascular revascularization medicine : including molecular interventions JID - 101238551 RN - 0 (Anticoagulants) SB - IM MH - Humans MH - United States MH - Administration, Oral MH - Anticoagulants MH - *Heart Valve Diseases/therapy/surgery MH - *Cardiology MH - Echocardiography OTO - NOTNLM OT - ACC/AHA OT - ESC OT - Valvular heart disease COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2022/10/22 06:00 MHDA- 2023/01/25 06:00 CRDT- 2022/10/21 22:13 PHST- 2022/08/22 00:00 [received] PHST- 2022/10/11 00:00 [revised] PHST- 2022/10/12 00:00 [accepted] PHST- 2022/10/22 06:00 [pubmed] PHST- 2023/01/25 06:00 [medline] PHST- 2022/10/21 22:13 [entrez] AID - S1553-8389(22)00822-3 [pii] AID - 10.1016/j.carrev.2022.10.005 [doi] PST - ppublish SO - Cardiovasc Revasc Med. 2023 Feb;47:76-85. doi: 10.1016/j.carrev.2022.10.005. Epub 2022 Oct 17. PMID- 36267910 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221022 IS - 2542-4548 (Electronic) IS - 2542-4548 (Linking) VI - 6 IP - 6 DP - 2022 Dec TI - The Sports Cardiology Team: Personalizing Athlete Care Through a Comprehensive, Multidisciplinary Approach. PG - 525-535 LID - 10.1016/j.mayocpiqo.2022.08.006 [doi] AB - OBJECTIVE: To systematically investigate and document the infrastructure, practices, recommendations, and clinical consequences of a structured, organized sports cardiology multidisciplinary team (MDT) for athletes and patients who wish to engage in sports and exercise. PATIENTS AND METHODS: We established bimonthly sports cardiology MDT meetings, with a permanent panel of experts in sports cardiology, genetics, pediatric cardiology, cardiovascular imaging, electrophysiology, and sports and exercise medicine. Cases were referred nationally or internationally by cardiologists/sports physicians. We retrospectively analyzed all MDT cases (April 10, 2019 through May 13, 2020) and collected clinical follow-up data up to 1 year after the initial review. RESULTS: A total of 115 athletes underwent MDT review; of them, 11% were women, 65% were recreational athletes, and 54% were performing "mixed" type of sports; the mean age was 32+/-16 years. An MDT review led to a diagnosis revision of "suspected cardiac pathology" to "no cardiac pathology" in 38% of the athletes and increased the number of definitive diagnoses (from 77 to 109; P=.03). We observed fewer "total sports restrictions" (from 6 to 0; P=.04) and more tailored sports advice concerning "no peak load/specific maximum load" (from 10 to 26; P=.02). At the 14+/-6-month follow-up, 112 (97%) athletes reported no cardiovascular events, 111 (97%) athletes reported no (new) cardiac symptoms, 113 (98%) athletes reported adherence to the MDT sports advice, and no diagnoses were revised. CONCLUSION: Our experiences with a comprehensive sports cardiology MDT demonstrate that this approach leads to higher percentages of definitive diagnoses and fewer cardiac pathology diagnoses, more tailored sports advice with excellent rates of adherence, and fewer total sports restrictions. Our findings highlight the added value of sports cardiology MDTs for patient and athlete care. CI - (c) 2022 The Authors. FAU - van Hattum, Juliette C AU - van Hattum JC AD - Department of Cardiology, University of Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands. FAU - Verwijs, Sjoerd M AU - Verwijs SM AD - Department of Cardiology, University of Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands. FAU - Senden, P Jeff AU - Senden PJ AD - Department of Cardiology, Meander Medical Center, Amersfoort, the Netherlands. FAU - Spies, Jessica L AU - Spies JL AD - Department of Cardiology, University of Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands. FAU - Boekholdt, S Matthijs AU - Boekholdt SM AD - Department of Cardiology, University of Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands. FAU - Groenink, Maarten AU - Groenink M AD - Department of Cardiology, University of Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands. FAU - Panhuyzen-Goedkoop, Nicole M AU - Panhuyzen-Goedkoop NM AD - Department of Cardiology, University of Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands. AD - Department of Cardiology, Sports Medical Centre Papendal, Arnhem, the Netherlands. FAU - Willems, Albert R AU - Willems AR AD - Department of Cardiology and Hospital Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands. FAU - Knobbe, Ingmar AU - Knobbe I AD - Department of Paediatric Cardiology, and University of Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands. FAU - Blom, Nicolaas A AU - Blom NA AD - Department of Paediatric Cardiology, and University of Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands. FAU - Wijne, Cornelis A C M AU - Wijne CACM AD - Department of Sports Medicine, Hospital Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands. FAU - Reurink, Gustaaf AU - Reurink G AD - Department of Sports Medicine, Hospital Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands. FAU - van der Crabben, Saskia N AU - van der Crabben SN AD - Department of Clinical Genetics, University of Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands. FAU - Bijsterveld, Nick R AU - Bijsterveld NR AD - Department of Cardiology, University of Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands. AD - Department of Cardiology, Flevoziekenhuis, Almere, the Netherlands. FAU - Verhagen, Evert A L M AU - Verhagen EALM AD - Department of Epidemiology of Sports, Exercise & Health, Amsterdam UMC, Amsterdam, the Netherland. FAU - Pinto, Yigal M AU - Pinto YM AD - Department of Cardiology, University of Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands. FAU - Wilde, Arthur A M AU - Wilde AAM AD - Department of Cardiology, University of Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands. FAU - Jorstad, Harald T AU - Jorstad HT AD - Department of Cardiology, University of Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands. AD - Department of Cardiology, Sports Medical Centre Papendal, Arnhem, the Netherlands. LA - eng PT - Journal Article DEP - 20221012 PL - Netherlands TA - Mayo Clin Proc Innov Qual Outcomes JT - Mayo Clinic proceedings. Innovations, quality & outcomes JID - 101728275 PMC - PMC9576626 OTO - NOTNLM OT - Amsterdam UMC, Amsterdam University Medical Centers OT - CVD, cardiovascular disease OT - ICD, implantable cardioverter-defibrillator OT - MDT, multidisciplinary team OT - SEM, sports and exercise medicine EDAT- 2022/10/22 06:00 MHDA- 2022/10/22 06:01 PMCR- 2022/10/12 CRDT- 2022/10/21 03:03 PHST- 2022/10/21 03:03 [entrez] PHST- 2022/10/22 06:00 [pubmed] PHST- 2022/10/22 06:01 [medline] PHST- 2022/10/12 00:00 [pmc-release] AID - S2542-4548(22)00059-5 [pii] AID - 10.1016/j.mayocpiqo.2022.08.006 [doi] PST - epublish SO - Mayo Clin Proc Innov Qual Outcomes. 2022 Oct 12;6(6):525-535. doi: 10.1016/j.mayocpiqo.2022.08.006. eCollection 2022 Dec. PMID- 36264696 OWN - NLM STAT- MEDLINE DCOM- 20221024 LR - 20221203 IS - 2216-0280 (Electronic) IS - 0120-5307 (Print) IS - 0120-5307 (Linking) VI - 40 IP - 2 DP - 2022 Jun TI - Effect of the Implementation of Interdisciplinary Discharge Planning on Treatment Adherence and Readmission in Patients Undergoing Coronary Artery Angioplasty. LID - 10.17533/udea.iee.v40n2e08 [doi] LID - e08 AB - OBJECTIVES: To determine the effect of interdisciplinary discharge planning on treatment adherence and readmission in the patients undergoing coronary artery angioplasty in the south of Iran in 2020. METHODS: This experimental study had an intervention group and a control group with pre-test and post-test. 70 patients participated in the study who were randomly divided into the groups (intervention group (n=35) and control group (n=35)). In the intervention group, discharge planning was performed based on an interdisciplinary approach. Treatment adherence before, immediately, and one month after the intervention was evaluated with a 10-question survey scored from 1 to 5 (maximum score = 50), as well as readmission three months after the discharge was examined in both groups. RESULTS: Before the intervention, there was no statistically significant difference between the intervention and the control groups in the treatment adherence score (18.22 versus 17.37; p=0.84) but immediately and one month after the intervention statistically significant differences between the groups were showed (21.51 versus 46.14 and 23.28 versus 43.12, respectively; p<0.001). Within three months after discharge, the readmission rate was 11.4% in the control group, while no readmission was reported in the intervention group. Within three months after discharge, the readmission rate was 11.4% in the control group, while no readmission was reported in the intervention group. CONCLUSIONS: The implementation of interdisciplinary discharge planning had positive effects on treatment adherence and readmission rate in patients undergoing coronary artery angioplasty; therefore, it is suggested that health care system managers make the necessary plans to institutionalize this new educational approach for other patients discharge planning. CI - Copyright� by the Universidad de Antioquia. FAU - Rahpeima, Elaheh AU - Rahpeima E AD - Fasa University of Medical Sciences, Fasa, Iran,rahpeima.elahe@gmail.com. FAU - Bijani, Mostafa AU - Bijani M AD - Fasa University of Medical Sciences, Fasa, Iran,bizhani_mostafa@yahoo.com. FAU - Karimi, Shahnaz AU - Karimi S AD - Department of Medical Education, Medical Education Research Center, Email: shahkar20022002@yahoo.com. FAU - Alkamel, Abdulhakim AU - Alkamel A AD - Fasa University of Medical Sciences, Fasa, Iran,aalkamel@yahoo.com. FAU - Dehghan, Azizallah AU - Dehghan A AD - Fasa University of Medical Sciences, Fasa, Iran,dehghanaz@gmail.com. LA - eng PT - Journal Article PT - Randomized Controlled Trial PL - Colombia TA - Invest Educ Enferm JT - Investigacion y educacion en enfermeria JID - 9108180 SB - IM MH - Humans MH - *Patient Discharge MH - *Patient Readmission MH - Coronary Vessels MH - Treatment Adherence and Compliance MH - Angioplasty PMC - PMC9714981 OTO - NOTNLM OT - angioplasty OT - interprofessional relations OT - patient compliance OT - patient discharge OT - patient readmission COIS- The authors of this article and the planning committee members and staff have no relevant financial relationships with commercial interests to disclose. EDAT- 2022/10/21 06:00 MHDA- 2022/10/25 06:00 PMCR- 2022/09/19 CRDT- 2022/10/20 13:12 PHST- 2021/10/10 00:00 [received] PHST- 2022/06/06 00:00 [accepted] PHST- 2022/10/20 13:12 [entrez] PHST- 2022/10/21 06:00 [pubmed] PHST- 2022/10/25 06:00 [medline] PHST- 2022/09/19 00:00 [pmc-release] AID - 10.17533/udea.iee.v40n2e08 [doi] PST - ppublish SO - Invest Educ Enferm. 2022 Jun;40(2):e08. doi: 10.17533/udea.iee.v40n2e08. PMID- 36264386 OWN - NLM STAT- MEDLINE DCOM- 20230712 LR - 20261010 IS - 1572-8595 (Electronic) IS - 1383-875X (Linking) VI - 66 IP - 5 DP - 2023 Aug TI - High rates of oral anticoagulation in atrial fibrillation patients observed in a large multi-specialty health system in the Northeast. PG - 1119-1124 LID - 10.1007/s10840-022-01395-7 [doi] AB - BACKGROUND: Anticoagulation is a cornerstone in atrial fibrillation (AF) management for stroke prevention. Studies showed that oral anticoagulants (OAC), previously limited to warfarin, were underused. Recently, non-vitamin K oral anticoagulants (NOACs) have seen widespread adoption, but it has not been well studied whether there has been a subsequent increase in OAC usage in AF patients. METHODS: We quantified OAC rates in AF patients in a large multispecialty health system in the Northeast United States. A total of 351,795 patients seen in the network over the preceding 18 months were reviewed. RESULTS: Of these patients, 8727 (2.5%) carried a diagnosis of AF, and, of the 6933 patients with a CHA(2)DS(2)-VASc score of 2 or higher, 5576 (80.4%) had an OAC listed as an active medication or had received a left atrial appendage occlusion device. Of the 6605 patients treated with an OAC, 5308 (80.4%) were treated with a NOAC and 1295 (19.6%) were prescribed warfarin. A higher percentage of patients with CHA(2)DS(2)-VASc >/= 2 who had seen a cardiologist were treated with an OAC vs. those who had not seen a cardiologist in the prior 18 months (83.95% vs. 67.43%, p < 0.01). CONCLUSIONS: We show dramatically increased OAC usage among patients with AF and that NOACs comprise the large majority of OACs compared with previous studies. This suggests an association between widespread adoption of NOACs and increased oral anticoagulation rates. Future directions include assessing barriers to oral anticoagulation and developing interventions to reduce disparity in OAC use between clinics. CI - (c) 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Dutta, Roop AU - Dutta R AD - St. Elizabeth's Medical Center, Boston, MA, USA. FAU - Hurley, Sally AU - Hurley S AD - Steward Medical Group, Dallas, TX, USA. FAU - Atkins, David AU - Atkins D AD - Steward Medical Group, Dallas, TX, USA. FAU - Weinstein, Joseph AU - Weinstein J AD - Steward Medical Group, Dallas, TX, USA. FAU - Wylie, John AU - Wylie J AUID- ORCID: 0000-0001-6584-0535 AD - St. Elizabeth's Medical Center, Boston, MA, USA. john.wylie@steward.org. LA - eng PT - Journal Article DEP - 20221020 PL - Netherlands TA - J Interv Card Electrophysiol JT - Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing JID - 9708966 RN - 5Q7ZVV76EI (Warfarin) RN - 0 (Anticoagulants) SB - IM MH - Humans MH - *Atrial Fibrillation/complications/drug therapy MH - Warfarin/therapeutic use MH - Anticoagulants MH - *Stroke/etiology/prevention & control MH - Administration, Oral OTO - NOTNLM OT - Anticoagulation OT - Atrial fibrillation OT - DOAC OT - Quality improvement EDAT- 2022/10/21 06:00 MHDA- 2023/07/12 06:42 CRDT- 2022/10/20 11:16 PHST- 2022/08/03 00:00 [received] PHST- 2022/10/05 00:00 [accepted] PHST- 2023/07/12 06:42 [medline] PHST- 2022/10/21 06:00 [pubmed] PHST- 2022/10/20 11:16 [entrez] AID - 10.1007/s10840-022-01395-7 [pii] AID - 10.1007/s10840-022-01395-7 [doi] PST - ppublish SO - J Interv Card Electrophysiol. 2023 Aug;66(5):1119-1124. doi: 10.1007/s10840-022-01395-7. Epub 2022 Oct 20. PMID- 36259577 OWN - NLM STAT- MEDLINE DCOM- 20230622 LR - 20230622 IS - 2532-5264 (Electronic) IS - 1122-0643 (Linking) VI - 93 IP - 3 DP - 2022 Oct 14 TI - Adherence to Mediterranean diet among patients with acute cardiovascular events admitted in Cardiac Rehabilitation unit. LID - 10.4081/monaldi.2022.2391 [doi] AB - The Mediterranean Diet plays a critical role in the prevention of primary cardiovascular disease (CVD). Actually, there is a scarcity of evidence for secondary prevention. The current study aims to assess adherence to the Mediterranean diet (MD) in patients recently admitted to the Cardiac Rehabilitation Unit following acute cardiovascular disease. Adherence to MD was assessed in 111 patients admitted to the Cardiac Rehabilitation Unit of the Federico II Hospital in Naples. The Medi-Lite score was used to assess adherence to MD. The main determinant of reduced MD compliance was assessed using Pearson's correlation analysis and a multivariable regression model. The population had a median MD adherence score of 11 and a mean score of 10.9. The lowest possible score was 5 (indicating poor adherence), and the highest possible score was 15 (excellent adherence index). There were 3 participants with a poor score (<7), 82 with a good score (7-12), and 26 with an excellent score ((3)13). Lower Medi-Lite score was associated with younger age and being an active worker in a multivariate regression model (both p<0.05). Our findings show that among patients admitted to the Cardiac Rehabilitation Unit after a major CV event, young active workers have the lowest adherence to MD, requiring an individualized and multidisciplinary approach to improve their adherence to MD for secondary CV prevention. FAU - Lubrano, Fortuna AU - Lubrano F AD - Cardiac Rehabilitation Unit, Federico II University Hospital, Naples. fo.lubrano@studenti.unina.it. FAU - Fucile, Ilaria AU - Fucile I AD - Cardiac Rehabilitation Unit, Federico II University Hospital, Naples. fucile.ilaria@gmail.com. FAU - Conte, Maurizio AU - Conte M AD - . maurizio.conte89@gmail.com. FAU - Santoro, Ciro AU - Santoro C AD - Cardiac Rehabilitation Unit, Federico II University Hospital, Naples. ciro.santoro@unina.it. FAU - Rozza, Francesco AU - Rozza F AD - Cardiac Rehabilitation Unit, Federico II University Hospital, Naples. francesco.rozza@unina.it. FAU - De Luca, Nicola AU - De Luca N AD - . nicola.deluca@unina.it. FAU - Mancusi, Costantino AU - Mancusi C AD - Cardiac Rehabilitation Unit, Federico II University Hospital, Naples. costantino.mancusi@unina.it. LA - eng PT - Journal Article DEP - 20221014 PL - Italy TA - Monaldi Arch Chest Dis JT - Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace JID - 9307314 SB - IM MH - Humans MH - *Cardiovascular Diseases/epidemiology/prevention & control MH - *Cardiac Rehabilitation MH - *Diet, Mediterranean MH - Patient Compliance MH - Hospitalization EDAT- 2022/10/20 06:00 MHDA- 2023/06/22 06:42 CRDT- 2022/10/19 07:22 PHST- 2022/07/29 00:00 [received] PHST- 2022/10/08 00:00 [accepted] PHST- 2023/06/22 06:42 [medline] PHST- 2022/10/20 06:00 [pubmed] PHST- 2022/10/19 07:22 [entrez] AID - 10.4081/monaldi.2022.2391 [doi] PST - epublish SO - Monaldi Arch Chest Dis. 2022 Oct 14;93(3). doi: 10.4081/monaldi.2022.2391. PMID- 36258817 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231102 IS - 0970-9134 (Print) IS - 0973-7723 (Electronic) IS - 0970-9134 (Linking) VI - 38 IP - 6 DP - 2022 Nov TI - The motivators and barriers to a career in cardiothoracic surgery: a cross-sectional study among surgical residents in India. PG - 613-623 LID - 10.1007/s12055-022-01406-2 [doi] AB - INTRODUCTION: A consistent decline in the number of applicants to cardiothoracic and vascular surgery (CTVS) training programs has been observed across the country over the last few years. This disenchantment with the speciality will lead to a shortage of trained CTVS surgeons at a time when incidence of cardiovascular diseases is continuously rising in India. AIMS/OBJECTIVES: The aim of the study was to reflect on the reasons that averted applicants from pursuing a career in CTVS and measures that would make CTVS a more attractive option to future applicants. METHODS: An online nationwide prospective cross-sectional survey was conducted. The participants were from a pool of general surgery residents/residents who had just completed the training. A 5-point Likert scale was utilized to rate and evaluate the factors influencing CTVS as the primary choice, factors influencing any super-speciality, and factors that would aid in decision-making and encourage an interest in CTVS. RESULTS: A total of 618 responses were obtained, 25.6% (N = 158) of the responses were from female residents. Only 10.7% (N = 66) of the respondents wanted to pursue CTVS as their primary choice. While interest in CTVS among the 1(st) year residents was 26%, it was further observed to decline to 18.72% after completion of training. The main disincentives for pursuing CTVS were the need for a hospital with required infrastructure and the dependence on a multi-disciplinary team. The perception of the participants that the cardiologist will take over CTVS procedures was another misguided but important factor. Those residents interested in pursuing CTVS identified the dynamic nature of the speciality as well as the thrills of being a cardiac surgeon as important motivators. Participants felt that adding catheter-based technology to the CTVS curriculum, mandatory CTVS rotation during surgical training, and closer interaction with CTVS residents will generate more interest in CTVS. CONCLUSION: Although surgical residents report early interest in CTVS, a lack of adequate exposure to the speciality leads to a decline in interest in CTVS. An overhaul of the surgical training that mandates rotating to CTVS, increased interactions with medical students and surgical trainees by CTVS faculty, and incorporation of catheter-based training in the CTVS syllabus is urgently required to increase the number of applicants to CTVS. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12055-022-01406-2. CI - (c) Indian Association of Cardiovascular-Thoracic Surgeons 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. FAU - Idhrees, Mohammed AU - Idhrees M AUID- ORCID: 0000-0001-5981-9705 AD - Institute of Cardiac and Aortic Disorders (ICAD), SRM Institutes of Medical Science (SIMS Hospital), 600026 Vadapalani, Chennai, India. GRID: grid.513026.3. ISNI: 0000 0004 1781 5054 FAU - Narayan, Pradeep AU - Narayan P AD - Department of Cardiac Surgery, Rabindranath Tagore International Institute of Cardiac Sciences, Narayana Health, 124, EM Bypass, Mukundapur, Kolkata India. GRID: grid.496646.f. ISNI: 0000 0004 1806 0407 FAU - George, Melvin AU - George M AD - Department of Clinical Pharmacology, SRM Medical College Hospital & Research Centre, Kattankulathur, Chengalpet, India. GRID: grid.412742.6. ISNI: 0000 0004 0635 5080 FAU - Radhakrishna, Patta AU - Radhakrishna P AD - Department of Gastrointestinal Surgery, SRM Institutes of Medical Science (SIMS Hospital), Chennai Vadapalani, India. GRID: grid.513026.3. ISNI: 0000 0004 1781 5054 FAU - Abraham, Santhosh John AU - Abraham SJ AD - Department of Surgery, Lourdes Hospital, Kochi, India. GRID: grid.416130.1. ISNI: 0000 0004 1804 8758 FAU - Velayudhan, Bashi AU - Velayudhan B AD - Institute of Cardiac and Aortic Disorders (ICAD), SRM Institutes of Medical Science (SIMS Hospital), 600026 Vadapalani, Chennai, India. GRID: grid.513026.3. ISNI: 0000 0004 1781 5054 LA - eng PT - Journal Article DEP - 20220924 PL - India TA - Indian J Thorac Cardiovasc Surg JT - Indian journal of thoracic and cardiovascular surgery JID - 8700105 CIN - Indian J Thorac Cardiovasc Surg. 2023 Mar;39(2):209-210. doi: 10.1007/s12055-022-01444-w. PMID: 36785607 PMC - PMC9569278 OTO - NOTNLM OT - Cardiothoracic and vascular surgery OT - Career OT - Postgraduates OT - Residents OT - Surgical education OT - Surgical training COIS- Conflict of interestThe authors declare that they have no conflict of interest. EDAT- 2022/10/20 06:00 MHDA- 2022/10/20 06:01 PMCR- 2023/11/01 CRDT- 2022/10/19 01:46 PHST- 2022/03/07 00:00 [received] PHST- 2022/08/05 00:00 [revised] PHST- 2022/08/11 00:00 [accepted] PHST- 2022/10/19 01:46 [entrez] PHST- 2022/10/20 06:00 [pubmed] PHST- 2022/10/20 06:01 [medline] PHST- 2023/11/01 00:00 [pmc-release] AID - 1406 [pii] AID - 10.1007/s12055-022-01406-2 [doi] PST - ppublish SO - Indian J Thorac Cardiovasc Surg. 2022 Nov;38(6):613-623. doi: 10.1007/s12055-022-01406-2. Epub 2022 Sep 24. PMID- 36257543 OWN - NLM STAT- MEDLINE DCOM- 20241126 LR - 20250715 IS - 1439-1902 (Electronic) IS - 0171-6425 (Linking) VI - 72 IP - 8 DP - 2024 Dec TI - Invasive Coronary Angiography in Patients with Native or Prosthetic Aortic Valve Endocarditis. PG - 579-586 LID - 10.1055/s-0042-1757600 [doi] AB - BACKGROUND: Invasive coronary angiography (ICA) is essential to detect significant coronary artery disease (CAD) but is generally not recommended in patients with infective aortic valve endocarditis. This study aimed to evaluate the risks and benefits of preoperative ICA in patients before aortic valve replacement. METHODS: Between March 2008 and September 2020, 232 patients were surgically treated for infectious endocarditis of the aortic valve. Sixty-seven (29%) of them underwent preoperative diagnostic ICA and were compared with the patients without preoperative ICA. We collected their baseline characteristics, including the neurological status, previous cardiac surgical procedures, and reviewed the preoperative echocardiograms and the ICA data. The intraoperative data and clinical outcomes after ICA and after surgery were evaluated. RESULTS: ICA revealed a CAD in the majority of our patients (n = 36; 54%): One-vessel disease n = 19 (28%), two-vessel disease n = 6 (9%), and three-vessel disease n = 11 (16%). We observed no adverse events following preoperative diagnostic ICA, particularly no thromboembolic complications, including stroke, visceral, or lower body ischemia were detected. During surgical aortic valve replacement, concomitant coronary artery bypass grafting was performed in 20 patients (30%). In patients with preoperative ICA, postoperative in-hospital mortality was significantly lower (n = 8 [12%] vs. n = 30 [18%]; p < 0.001), while the incidence of postoperative bleeding was higher (n = 18 [27%] vs. n = 22 [13%]; p = 0.022). The new-onset stroke incidence was 5% in each group. CONCLUSION: Taking a multidisciplinary team approach, ICA is safe in selected patients with aortic valve infectious endocarditis with no adverse clinical outcomes, but significant clinical implications. CI - Thieme. All rights reserved. FAU - Berger, Tim AU - Berger T AUID- ORCID: 0000-0001-6263-9123 AD - Department of Cardiovascular Surgery, University Hospital Freiburg, Heart Centre, Faculty of Medicine, University of Freiburg, Freiburg, Germany. FAU - Dees, Dominik AU - Dees D AD - Department of Cardiology and Angiology, University Hospital Freiburg, Heart Centre, Faculty of Medicine, University of Freiburg, Freiburg, Germany. FAU - Siepe, Matthias AU - Siepe M AD - Department of Cardiovascular Surgery, University Hospital Freiburg, Heart Centre, Faculty of Medicine, University of Freiburg, Freiburg, Germany. FAU - Pingpoh, Clarence AU - Pingpoh C AD - Department of Cardiovascular Surgery, University Hospital Freiburg, Heart Centre, Faculty of Medicine, University of Freiburg, Freiburg, Germany. FAU - Fagu, Albi AU - Fagu A AD - Department of Cardiovascular Surgery, University Hospital Freiburg, Heart Centre, Faculty of Medicine, University of Freiburg, Freiburg, Germany. FAU - Zeh, Wolfgang AU - Zeh W AD - Department of Cardiology and Angiology, University Hospital Freiburg, Heart Centre, Faculty of Medicine, University of Freiburg, Freiburg, Germany. FAU - Beyersdorf, Friedhelm AU - Beyersdorf F AD - Department of Cardiovascular Surgery, University Hospital Freiburg, Heart Centre, Faculty of Medicine, University of Freiburg, Freiburg, Germany. FAU - Neumann, Franz-Josef AU - Neumann FJ AD - Department of Cardiology and Angiology, University Hospital Freiburg, Heart Centre, Faculty of Medicine, University of Freiburg, Freiburg, Germany. FAU - Czerny, Martin AU - Czerny M AD - Department of Cardiovascular Surgery, University Hospital Freiburg, Heart Centre, Faculty of Medicine, University of Freiburg, Freiburg, Germany. FAU - Kreibich, Maximilian AU - Kreibich M AD - Department of Cardiovascular Surgery, University Hospital Freiburg, Heart Centre, Faculty of Medicine, University of Freiburg, Freiburg, Germany. LA - eng PT - Journal Article DEP - 20221018 PL - Germany TA - Thorac Cardiovasc Surg JT - The Thoracic and cardiovascular surgeon JID - 7903387 SB - IM MH - Humans MH - Male MH - Female MH - Middle Aged MH - Aged MH - *Aortic Valve/surgery/diagnostic imaging/microbiology MH - *Heart Valve Prosthesis Implantation/adverse effects/mortality/instrumentation MH - *Heart Valve Prosthesis/adverse effects MH - *Predictive Value of Tests MH - *Coronary Artery Disease/diagnostic imaging/mortality/surgery/complications MH - Retrospective Studies MH - Treatment Outcome MH - Risk Factors MH - *Coronary Angiography MH - Risk Assessment MH - *Hospital Mortality MH - *Prosthesis-Related Infections/diagnostic imaging/microbiology/mortality/surgery MH - Endocarditis/mortality/surgery/diagnostic imaging MH - Time Factors MH - Endocarditis, Bacterial/mortality/microbiology/diagnostic imaging/surgery/diagnosis COIS- M.C. is consultant to Terumo Aortic, Medtronic, Endospan, and NEOS and shareholder of Ascense Medical, received speaking honoraria from Cryolife-Jotec and Bentley and is shareholder of TEVAR Ltd. EDAT- 2022/10/19 06:00 MHDA- 2024/11/27 00:20 CRDT- 2022/10/18 19:26 PHST- 2024/11/27 00:20 [medline] PHST- 2022/10/19 06:00 [pubmed] PHST- 2022/10/18 19:26 [entrez] AID - 10.1055/s-0042-1757600 [doi] PST - ppublish SO - Thorac Cardiovasc Surg. 2024 Dec;72(8):579-586. doi: 10.1055/s-0042-1757600. Epub 2022 Oct 18. PMID- 36255711 OWN - NLM STAT- MEDLINE DCOM- 20230614 LR - 20230614 IS - 1827-1669 (Electronic) IS - 0026-4806 (Linking) VI - 114 IP - 3 DP - 2023 Jun TI - New paradigm for the management of cardio-nephro-metabolic syndrome: multidisciplinary approach and role of telemedicine. PG - 345-356 LID - 10.23736/S0026-4806.22.08165-4 [doi] AB - Heart failure (HF), type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) are some of the most important health problems of this century, and these three conditions often coexist, one worsening the prognosis of the other two. No disease is more important than the others in the composition of risk, which is significantly increased by their overlap. Thus, it would be more appropriate to refer to this cluster as cardio-nephro-metabolic syndrome. The aim of this review is to promote the development of an integrated multidisciplinary approach to the treatment of HF, T2DM and CKD in a perspective of paradigm shift from an individual management among different specialists to a shared one. Nowadays, this is achievable thanks to telemedicine and optimized therapy consisting in the new drugs with pleiotropic effect available today. The need is to have technological solutions, which also include telemedicine, for the management of patients affected by all three diseases to consider their fragility, sometimes due to a wrong, partial, or incomplete treatment. Multicentric, multidisciplinary trials on cardio-nephro-metabolic syndrome and new telemedicine/telemonitoring technologies could help place the chronic and fragile patient at the center of such multidimensionally integrated care. FAU - Giallauria, Francesco AU - Giallauria F AD - Unit of Internal Medicine and Cardiac Rehabilitation, Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy. FAU - Baratta, Roberto AU - Baratta R AD - Unit of Endocrinology, ARNAS Garibaldi, Catania, Italy. FAU - Costa, Francesco AU - Costa F AD - Unit of Interventional Cardiology, G. Martino University Hospital, University of Messina, Messina, Italy. FAU - D'Amario, Domenico AU - D'Amario D AD - Department of Cardiovascular and Thoracic Sciences, IRCCS A. Gemelli University Polyclinic Foundation, Rome, Italy. FAU - DE Gennaro, Luisa AU - DE Gennaro L AD - Unit of Cardiology and Coronary Care Unit, San Paolo Hospital, E. Cannizzaro Hospital, Catania, Italy. FAU - Giubilato, Simona AU - Giubilato S AD - Cardiology, Coronary Care Unit and Hemodynamics, E. Cannizzaro Hospital, Catania, Italy. FAU - Mattina, Alessandro AU - Mattina A AD - Unit of Diabetes and Islet Transplantation, Department of Diagnostic and Therapeutic Services, Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione (IRCCS-ISMETT), University of Pittsburgh Medical Center (UPMC) Italy, Palermo, Italy. FAU - Provenzano, Michele AU - Provenzano M AD - Department of Specialized, Diagnostic and Experimental Medicine (DIMES), University of Bologna, Bologna, Italy. FAU - Santoro, Domenico AU - Santoro D AD - Unit of Nephrology and Dialysis, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy. FAU - Versaci, Francesco AU - Versaci F AD - Department of Cardiology, Santa Maria Goretti Hospital, Latina, Italy - francescoversaci2022@gmail.com. AD - Department of Systems Medicine, Tor Vergata University, Rome, Italy. LA - eng PT - Journal Article PT - Review DEP - 20221018 PL - Italy TA - Minerva Med JT - Minerva medica JID - 0400732 SB - IM MH - Humans MH - *Diabetes Mellitus, Type 2 MH - *Metabolic Syndrome MH - *Telemedicine MH - *Heart Failure/therapy MH - *Renal Insufficiency, Chronic/therapy EDAT- 2022/10/19 06:00 MHDA- 2023/06/14 06:42 CRDT- 2022/10/18 11:22 PHST- 2023/06/14 06:42 [medline] PHST- 2022/10/19 06:00 [pubmed] PHST- 2022/10/18 11:22 [entrez] AID - S0026-4806.22.08165-4 [pii] AID - 10.23736/S0026-4806.22.08165-4 [doi] PST - ppublish SO - Minerva Med. 2023 Jun;114(3):345-356. doi: 10.23736/S0026-4806.22.08165-4. Epub 2022 Oct 18. PMID- 36255709 OWN - NLM STAT- MEDLINE DCOM- 20230614 LR - 20230614 IS - 1827-1669 (Electronic) IS - 0026-4806 (Linking) VI - 114 IP - 3 DP - 2023 Jun TI - Risk stratification and long-term outcome of patients receiving in-hospital medical emergency team critical care: experience from Austria's largest medical center. PG - 307-315 LID - 10.23736/S0026-4806.22.07780-1 [doi] AB - BACKGROUND: We aimed to investigate predictors for long-term survival of in-hospital patients with medical emergency team (MET) consultation with or without in-hospital cardiac arrest (IHCA) in Austria's largest medical center. METHODS: Data of patients, who needed an intervention of a MET between 01/2014 and 03/2020 were reviewed for this retrospective analysis. RESULTS: In total, 708 MET calls were analyzed. The minimum follow-up was 7 months, the maximum 6.2 years. The main MET indications were circulatory failure (63%) followed by respiratory failure (27.1%), and bleeding events (3.5%). IHCA with subsequent cardiopulmonary resuscitation (CPR) was experienced by 425 (60%) patients. Of those, 274 (64%) reached return of spontaneous circulation (ROSC), and 221 (52%) survived the first 24-hours (median survival: 146 days) and 22.1% the first year. After adjustment for potential confounders, age (P<0.001), time to ROSC (P<0.001), a non-shockable rhythm (P=0.041), chronic kidney disease (CKD, P=0.041), peak lactate levels (P<0.001), and C-reactive protein (P=0.001) were associated with long-term all-cause mortality in IHCA patients in Cox regression analysis. The 283 MET calls (40%) which were due to other reasons than IHCA were associated with a much better 24-hours (93%) and 1-year survival (61.8%). Beside age (P<0.001), the main risk factors associated with mortality in MET patients without IHCA were comorbidities such as chronic obstructive pulmonary disease (COPD, P=0.008), CKD (P=0.001), pulmonary hypertension/chronic thromboembolic pulmonary hypertension (PH/CTEPH, P=0.024), and cancer (P=0.040). CONCLUSIONS: Patients triggering MET calls have an increased mortality, especially those with IHCA. Predictors of mortality comprise age, comorbidities, and cardiac arrest-related parameters. A better characterization of MET call populations and their outcome might help to improve clinical decision making. FAU - Sheikh Rezaei, Safoura AU - Sheikh Rezaei S AD - Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria. FAU - Gatterer, Constantin AU - Gatterer C AD - Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria. FAU - Sulzgruber, Patrick AU - Sulzgruber P AD - Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria. FAU - Hofer, Felix AU - Hofer F AD - Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria. FAU - Mittlboeck, Helene AU - Mittlboeck H AD - Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria. FAU - Gavrilovic, Stefan AU - Gavrilovic S AD - Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria. FAU - Loyoddin, Yannick AU - Loyoddin Y AD - Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria. FAU - Wolzt, Michael AU - Wolzt M AD - Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria. FAU - Schonbauer, Robert AU - Schonbauer R AD - Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria. FAU - Speidl, Walter AU - Speidl W AD - Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria. FAU - Richter, Bernhard AU - Richter B AD - Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria. FAU - Heinz, Gottfried AU - Heinz G AD - Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria - gottfried.heinz@meduniwien.ac.at. FAU - Sponder, Michael AU - Sponder M AD - Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria. LA - eng PT - Journal Article DEP - 20221018 PL - Italy TA - Minerva Med JT - Minerva medica JID - 0400732 SB - IM MH - Humans MH - Retrospective Studies MH - *Hospital Rapid Response Team MH - Austria MH - *Hypertension, Pulmonary MH - *Heart Arrest MH - Hospitals MH - *Pulmonary Disease, Chronic Obstructive MH - Risk Assessment EDAT- 2022/10/19 06:00 MHDA- 2023/06/14 06:42 CRDT- 2022/10/18 11:22 PHST- 2023/06/14 06:42 [medline] PHST- 2022/10/19 06:00 [pubmed] PHST- 2022/10/18 11:22 [entrez] AID - S0026-4806.22.07780-1 [pii] AID - 10.23736/S0026-4806.22.07780-1 [doi] PST - ppublish SO - Minerva Med. 2023 Jun;114(3):307-315. doi: 10.23736/S0026-4806.22.07780-1. Epub 2022 Oct 18. PMID- 36254905 OWN - NLM STAT- MEDLINE DCOM- 20221019 LR - 20221212 IS - 0974-5181 (Electronic) IS - 0971-9784 (Print) IS - 0971-9784 (Linking) VI - 25 IP - 4 DP - 2022 Oct-Dec TI - One-year experience after adoption of an on-table extubation protocol following pediatric cardiac surgery. PG - 422-428 LID - 10.4103/aca.aca_58_21 [doi] AB - OBJECTIVE: To report our initial experience with on-table extubation following cardiac surgery for congenital heart disease, assessing its efficacy and safety, and the potential for fast-tracking these patients through the intensive care unit (ICU). METHODS: We decided to implement a multidisciplinary protocol aiming toward on-table extubation following congenital cardiac surgery at our hospital. Between December 2018 and January 2020, 376 patients underwent congenital cardiac surgery. The management strategy involved choosing the patients preoperatively, a specific anesthetic technique, application of a standard extubation protocol, multidisciplinary team approach, and perioperative echocardiogram for assessment of surgical repair. Relevant data were collected and analyzed. RESULTS: Out of the 376 patients who underwent congenital cardiac surgery during the study period, 44 patients were extubated on-table. Although a majority of these patients belonged to Risk Adjustment for Congenital Heart Surgery-1 score (RACHS-1) 1 and 2 categories, 18% of the patients who were extubated on-table were of RACHS-3 category. This included a wide spectrum of anatomical substrates such as endocardial cushion defects, pulmonary venous anomalies, single ventricle physiology, valvular defects, and others such as cor triatriatum and sinus of Valsalva aneurysm. There was no in-hospital mortality related to on-table extubation. Only one patient was reintubated following on-table extubation resulting in a reintubation rate of 2.27% among those patients extubated on-table. The patients extubated on-table had a shorter ICU stay (25.89 +/- 7.20 h) compared with those patients who underwent delayed extubation (59.30 +/- 6.80 h). The duration of the hospital stay was also significantly reduced in these patients (91.09 +/- 20.40 h) leading to an earlier discharge compared with those patients who underwent delayed extubation (134.40 +/- 16.20 h). CONCLUSION: On-table extubation is an attractive alternative in limited-resource environments to enhance recovery in patients following congenital cardiac malformations. Owing to the lack of significant comorbidities such as Chronic Obstructive Pulmonary Disease (COPD) in this patient population, corrective surgery for cardiac malformation usually optimizes the cardiorespiratory status. This results in more chances of successful extubation immediately following surgery. However, this requires proper perioperative planning, a careful discussion about the choice of patients, adoption of an extubation protocol, and most importantly, a multidisciplinary team approach. It is associated with low morbidity and mortality, with reduced length of stay in the ICU and hospital. This preliminary study demonstrated that on-table extubation is feasible following congenital cardiac surgery at our center and greatly reduces the intensive care requirements. This article focuses mainly on the decision-making process which determines the ideal candidates for on-table extubation and the anesthetic protocol implemented in a low-resource environment to enable the same. FAU - Kaushik, Jothinath AU - Kaushik J AD - Department of Cardiac Anesthesiology, G Kuppuswamy Naidu Memorial Hospital, Coimbatore, Tamil Nadu, India. FAU - Vijayakumar, Raju AU - Vijayakumar R AD - Department of Cardiac Anesthesiology, G Kuppuswamy Naidu Memorial Hospital, Coimbatore, Tamil Nadu, India. FAU - Soundaravalli, Balakrishnan AU - Soundaravalli B AD - Department of Cardiac Surgery, G Kuppuswamy Naidu Memorial Hospital, Coimbatore, Tamil Nadu, India. FAU - Shoba, Menon AU - Shoba M AD - Department of Cardiac Surgery, G Kuppuswamy Naidu Memorial Hospital, Coimbatore, Tamil Nadu, India. FAU - Jenit, Osborn AU - Jenit O AD - Department of Community Medicine, PSG Institute of Medical Sciences and Research, Coimbatore, Tamil Nadu, India. FAU - Anisha, Shajan AU - Anisha S AD - Department of Cardiac Surgery, G Kuppuswamy Naidu Memorial Hospital, Coimbatore, Tamil Nadu, India. LA - eng PT - Journal Article PL - India TA - Ann Card Anaesth JT - Annals of cardiac anaesthesia JID - 9815987 SB - IM MH - Airway Extubation/methods MH - *Cardiac Surgical Procedures/methods MH - Child MH - *Heart Defects, Congenital/surgery MH - Humans MH - Intubation, Intratracheal MH - Length of Stay MH - Retrospective Studies PMC - PMC9732950 OTO - NOTNLM OT - Fast-tracking OT - On-table extubation OT - pediatric cardiac surgery COIS- There are no conflicts of interest. EDAT- 2022/10/19 06:00 MHDA- 2022/10/20 06:00 PMCR- 2022/10/01 CRDT- 2022/10/18 07:13 PHST- 2022/10/18 07:13 [entrez] PHST- 2022/10/19 06:00 [pubmed] PHST- 2022/10/20 06:00 [medline] PHST- 2022/10/01 00:00 [pmc-release] AID - AnnCardAnaesth_2022_25_4_422_358136 [pii] AID - ACA-25-422 [pii] AID - 10.4103/aca.aca_58_21 [doi] PST - ppublish SO - Ann Card Anaesth. 2022 Oct-Dec;25(4):422-428. doi: 10.4103/aca.aca_58_21. PMID- 36247485 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240905 IS - 2297-055X (Print) IS - 2297-055X (Electronic) IS - 2297-055X (Linking) VI - 9 DP - 2022 TI - Cardiovascular drug interventions in the cardio-oncology clinic by a cardiology pharmacist: ICOP-Pharm study. PG - 972455 LID - 10.3389/fcvm.2022.972455 [doi] LID - 972455 AB - BACKGROUND: Cardio-oncology is a rapidly growing field that requires a novel service design to deal with the increasing number of patients. It is reported that the volume of patients at the cardio-oncology clinic in the United Kingdom is 535 patients/5 years and in Canada is 779 patients/7 years. The pharmacist has a role in reducing the consultation time of physicians. OBJECTIVE: To identify the role of a qualified cardiology pharmacist at the cardio-oncology clinic using a new paradigm based on complementary interventions with the cardiologist for the management of patients with cancer and cardiovascular risk factors and/or cardiovascular diseases (CVRF/CVD). METHODS: A prospective observational study was conducted at the cardio-oncology clinic in the Medical City in Baghdad, Iraq between December 2020 and December 2021. Patients with CVRF/CVD were registered. The Iraqi Cardio-Oncology Program-Pharmacist (ICOP-Pharm) paradigm was designed to involve a qualified cardiology pharmacist for initial cardiovascular (CV) drug interventions. RESULTS: Among 333 patients who attended our clinic over the 1-year interval, 200 (60%) CVRF/CVD cases were enrolled in the study, and of them 79 (40%) patients had CV drug interventions. A total of 196 interventions were done, including 147 (75%) cases performed by the cardiology pharmacist, and 92 (63%) of the latter were CV drug initiations. Among the total CVRF/CVD treated initially by the cardiology pharmacist, hypertension 32 (26%) and cancer therapy-related cardiac dysfunction 29 (24%) were the main types. CONCLUSION: The qualified cardiology pharmacist was responsible for three-quarters of the initial CV drug interventions at the cardio-oncology clinic in a complementary approach to the cardiologist. The role of the cardiology pharmacist in the ICOP-Pharm paradigm may be one of the reasons for the ability of the heart team to manage 3-fold of the patient volume when compared with those in the United Kingdom or Canada. CI - Copyright (c) 2022 Yaseen and Farhan. FAU - Yaseen, Israa Fadhil AU - Yaseen IF AD - Baghdad Heart Center, Medical City, Baghdad, Iraq. AD - Scientific Council of Cardiology, Iraqi Board for Medical Specializations, Baghdad, Iraq. FAU - Farhan, Hasan Ali AU - Farhan HA AD - Baghdad Heart Center, Medical City, Baghdad, Iraq. AD - Scientific Council of Cardiology, Iraqi Board for Medical Specializations, Baghdad, Iraq. LA - eng PT - Journal Article DEP - 20220929 PL - Switzerland TA - Front Cardiovasc Med JT - Frontiers in cardiovascular medicine JID - 101653388 PMC - PMC9556995 OTO - NOTNLM OT - breast cancer OT - care delivery model OT - heart failure OT - hypertension OT - risk factor (RF) OT - treatment COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/10/18 06:00 MHDA- 2022/10/18 06:01 PMCR- 2022/01/01 CRDT- 2022/10/17 04:50 PHST- 2022/06/18 00:00 [received] PHST- 2022/09/06 00:00 [accepted] PHST- 2022/10/17 04:50 [entrez] PHST- 2022/10/18 06:00 [pubmed] PHST- 2022/10/18 06:01 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.3389/fcvm.2022.972455 [doi] PST - epublish SO - Front Cardiovasc Med. 2022 Sep 29;9:972455. doi: 10.3389/fcvm.2022.972455. eCollection 2022. PMID- 36246970 OWN - NLM STAT- MEDLINE DCOM- 20221018 LR - 20230721 IS - 2314-6141 (Electronic) IS - 2314-6133 (Print) VI - 2022 DP - 2022 TI - Effect Analysis of Nursing Method Based on Stratified Emergency Knowledge in Emergency Myocardial Infarction. PG - 3505228 LID - 10.1155/2022/3505228 [doi] LID - 3505228 AB - First aid is to give immediate first aid to patients who have suffered accidental injuries or sudden diseases before the emergency medical personnel arrive at the scene or are sent to the hospital for treatment; myocardial infarction is a severe and emergency of coronary heart disease. It is often because of coronary atherosclerosis, plaque rupture, bleeding, or thrombosis, which leads to the acute and complete occlusion of the coronary arteries and acute necrosis of the myocardium. This article aims to investigate the effectiveness of a stratified emergency care team assisted by multidisciplinary first aid knowledge in acute myocardial infarction first aid, hoping to reduce the probability of acute myocardial infarction through first aid and nursing care. Business process reengineering is a management idea that reached its heyday in the 1990s and is usually defined as achieving workflow and productivity through the reorganization and optimization of corporate strategies, value-added operational processes, and the systems, policies, organizations, and structures that support them. This article first outlines the concepts and steps of medical image registration, analyzes the characteristics of current medical image registration methods, and uses the two most commonly used medical registration methods today; in this study, the BPR theory was used to construct the AMI emergency care process in the hospital, which effectively reduced the emergency delay time of AMI patients, improved the patient's emergency response, and increased the efficiency of emergency nurses' rescue work. The experimental results in this paper show that the sensitivities of the first four groups of ST upward arrowIII > II, ST downward arrow aVL > I, STV3 downward arrow /STIII upward arrow/=0.05 mV are 82.1%, 80%, 75.3%, and 60.3%, respectively. Their sensitivities are relatively close, both are greater than 50%; among them, ST upward arrowIII > II has the highest sensitivity, which is 80%. In terms of specificity, ST upward arrowIII > II, ST downward arrow aVL > I, STV3 downward arrow /STIII upward arrow/=0.05 mV were 82.1%, 89.2%, 82.7%, and 65.2%, respectively. ST downward arrow >/=0.05 mV has the lowest specificity, and ST downward arrow aVL > I has the highest specificity. CI - Copyright (c) 2022 Junxia Yu and Jie Mu. FAU - Yu, Junxia AU - Yu J AUID- ORCID: 0000-0002-1905-5226 AD - Kaifeng Central Hospital, Kaifeng, 475000 Henan, China. FAU - Mu, Jie AU - Mu J AD - Kaifeng Vocational College of Culture and Art, Kaifeng, 475000 Henan, China. LA - eng PT - Journal Article PT - Retracted Publication DEP - 20220930 PL - United States TA - Biomed Res Int JT - BioMed research international JID - 101600173 SB - IM RIN - Biomed Res Int. 2023 Jul 12;2023:9861430. doi: 10.1155/2023/9861430. PMID: 37475801 MH - *Coronary Disease MH - Electrocardiography/methods MH - *Emergency Medical Services MH - Humans MH - *Myocardial Infarction/therapy PMC - PMC9553482 COIS- The authors declare that they have no conflicts of interest. EDAT- 2022/10/18 06:00 MHDA- 2022/10/19 06:00 PMCR- 2022/09/30 CRDT- 2022/10/17 04:41 PHST- 2022/08/02 00:00 [received] PHST- 2022/08/25 00:00 [revised] PHST- 2022/09/08 00:00 [accepted] PHST- 2022/10/17 04:41 [entrez] PHST- 2022/10/18 06:00 [pubmed] PHST- 2022/10/19 06:00 [medline] PHST- 2022/09/30 00:00 [pmc-release] AID - 10.1155/2022/3505228 [doi] PST - epublish SO - Biomed Res Int. 2022 Sep 30;2022:3505228. doi: 10.1155/2022/3505228. eCollection 2022. PMID- 36245386 OWN - NLM STAT- MEDLINE DCOM- 20221115 LR - 20221209 IS - 2214-3602 (Electronic) IS - 2214-3599 (Print) IS - 2214-3599 (Linking) VI - 9 IP - 6 DP - 2022 TI - Gene Therapy for Duchenne Muscular Dystrophy: Unlocking the Opportunities in Countries in the Middle East and Beyond. PG - 787-801 LID - 10.3233/JND-221528 [doi] AB - BACKGROUND: Duchenne muscular dystrophy (DMD) is a severe neuromuscular disorder which leads to progressive muscle degeneration and weakness. Most patients die from cardiac or respiratory failure. Gene transfer therapy offers a promising approach to treating this disorder. OBJECTIVE: Given the genetic disease burden, family size, and the high consanguinity rates in the Middle East, our objective is to address current practices and challenges of DMD patient care within two countries in this region, namely the United Arab Emirates and Kuwait, and to outline readiness for gene therapy. METHODS: An expert panel meeting was held to discuss the DMD patient journey, disease awareness, current management of DMD, challenges faced and recommendations for improvement. Opportunities and challenges for gene therapy in both countries were also deliberated. A pre-meeting survey was conducted, and the results were used to guide the discussion during the meeting. RESULTS: DMD awareness is poor resulting in a delay in referral and diagnosis of patients. Awareness and education initiatives, along with an interconnected referral system could improve early diagnosis. Genetic testing is available in both countries although coverage varies. Corticosteroid therapy is the standard of care however there is often a delay in treatment initiation. Patients with DMD should be diagnosed and managed by a multi-disciplinary team in centers of excellence for neuromuscular disorders. Key success factors to support the introduction of gene therapy include education and training, timely and accessible genetic testing and resolution of reimbursement and cost issues. CONCLUSION: There are many challenges facing the management of DMD patients in the United Arab Emirates and Kuwait and most likely other countries within the Middle East. Successful introduction of gene therapy to treat DMD will require careful planning, education, capacity building and prioritization of core initiatives. FAU - Elbashir, Haitham AU - Elbashir H AD - Neurosciences Center of Excellence, Al Jalila Children's Hospital, Dubai, United Arab Emirates. FAU - Fathalla, Waseem AU - Fathalla W AD - Sheikh Shakhbout Medical City, Abu Dhabi, United Arab Emirates. FAU - Mundada, Vivek AU - Mundada V AD - Medcare Women and Children Hospital, Dubai, United Arab Emirates. FAU - Iqbal, Mehtab AU - Iqbal M AD - Tawam Hospital, Al Ain, Abu Dhabi, United Arab Emirates. FAU - Al Tawari, Asmaa A AU - Al Tawari AA AD - Al Sabah Hospital, Kuwait. FAU - Chandratre, Saleel AU - Chandratre S AD - Sheikh Khalifa Medical City, Ajman, United Arab Emirates. FAU - Bastaki, Laila AU - Bastaki L AD - Kuwait Medical Genetic Centre, Kuwait. FAU - Romany, Ingy AU - Romany I AD - Pfizer Gulf FZ LLC, Dubai, United Arab Emirates. FAU - Ismayl, Omar AU - Ismayl O AD - Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates. FAU - Abou Tayoun, Ahmad AU - Abou Tayoun A AD - Genomic Center of Excellence, Al Jalila Children's Hospital, Dubai, United Arab Emirates. LA - eng PT - Journal Article PL - United States TA - J Neuromuscul Dis JT - Journal of neuromuscular diseases JID - 101649948 SB - IM MH - Humans MH - *Muscular Dystrophy, Duchenne/genetics/therapy/diagnosis MH - Genetic Testing MH - Middle East MH - Genetic Therapy/methods PMC - PMC9697043 OTO - NOTNLM OT - Duchenne muscular dystrophy OT - gene therapy OT - genetic disorders OT - multidisciplinary care OT - muscle degeneration COIS- HE, WF, VM, MI, AAAT, SC, LB, OI and AT received an honorarium for participating in the Advisory Board Meeting and other work outside of the submitted manuscript. Neither honoraria nor payments were made for authorship. IR is a full-time employee of Pfizer Gulf FZ LLC. EDAT- 2022/10/18 06:00 MHDA- 2022/11/16 06:00 PMCR- 2022/11/25 CRDT- 2022/10/17 04:03 PHST- 2022/10/18 06:00 [pubmed] PHST- 2022/11/16 06:00 [medline] PHST- 2022/10/17 04:03 [entrez] PHST- 2022/11/25 00:00 [pmc-release] AID - JND221528 [pii] AID - 10.3233/JND-221528 [doi] PST - ppublish SO - J Neuromuscul Dis. 2022;9(6):787-801. doi: 10.3233/JND-221528. PMID- 36243686 OWN - NLM STAT- MEDLINE DCOM- 20221018 LR - 20221031 IS - 2731-4553 (Electronic) IS - 2731-4553 (Linking) VI - 23 IP - 1 DP - 2022 Oct 15 TI - What GPs do to meet accreditation standards - implementation activities and perceived improvements attributed to general practice accreditation. PG - 265 LID - 10.1186/s12875-022-01864-y [doi] LID - 265 AB - BACKGROUND: Healthcare accreditation is a widely implemented tool used to enhance the quality of care and underpin quality control. However, research is sparse on the accreditation process in general practice. The aim of this study was to explore how team-based implementation activities preceding accreditation were associated with self-perceived improvements in emergency preparedness (preparedness for urgent disease and cardiac arrest) and handling of prescription renewals in Danish general practice. METHODS: GPs (general practitioners) completed a questionnaire exploring practice-team activities conducted to implement two specific accreditation standards and the related improvements as perceived by the GPs. The following implementation activities were selected, inspired by Normalization Process Theory: Common understanding (obtaining a common understanding of the purpose of implementing changes according to the accreditation standard), key person (assigning a key person responsible for working with the standard), and easy integration (finding it easy to integrate changes into existing working procedures). Data were analysed with logistic regression, and adjusted analyses included practice type, number of GP partners, number of staff, training site for junior GPs and administrative region. RESULTS: The total response rate was 74% (n = 920). Around 80% of the clinics reported having conducted team-based implementation activities. Almost half of the clinics (48%) reported perceived improvements in the emergency preparedness, and 30% reported perceived improvements in the handling of prescription renewals. Obtaining a common understanding was found to have a strong, significant association with perceived improvements in the emergency preparedness (OR = 5.07 (3.06-8.40)) and handling of prescription renewals (OR = 3.66 (2.07-6.46)). Easy integration of changes was also significantly associated with improvements in both emergency preparedness (OR = 1.88 (1.24-2.85)) and handling of prescription renewals (OR = 2.34 (1.44-3.79)), whereas assigning a key person was only significantly associated with improved emergency preparedness (OR = 1.95 (1.19-3.19)). CONCLUSION: Clinical quality initiatives that involve collaboration within a practice team are more likely to cause improvements if specific team-based implementation activities are conducted. It is particularly important to facilitate a common understanding of the purpose of the initiative. Therefore, external support for quality initiatives aiming at the practice level in general practice should facilitate such team-based activities. CI - (c) 2022. The Author(s). FAU - Molgaard, Cecilie AU - Molgaard C AD - Department of Public Health, Aarhus University, Bartholins Alle 2, DK-8000, Aarhus C, Denmark. Ceciliemlgaard@gmail.com. AD - , Grangardsvej 58, 9530, Stovring, Denmark. Ceciliemlgaard@gmail.com. FAU - Bro, Flemming AU - Bro F AD - Department of Public Health, Aarhus University, Bartholins Alle 2, DK-8000, Aarhus C, Denmark. AD - Research Unit for General Practice, Bartholins Alle 2, DK-8000, Aarhus C, Denmark. FAU - Mygind, Anna AU - Mygind A AD - Research Unit for General Practice, Bartholins Alle 2, DK-8000, Aarhus C, Denmark. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20221015 PL - England TA - BMC Prim Care JT - BMC primary care JID - 9918300889006676 SB - IM MH - Accreditation MH - Family Practice MH - *General Practice MH - *General Practitioners MH - Humans MH - Surveys and Questionnaires PMC - PMC9571477 OTO - NOTNLM OT - Accreditation OT - Cross-sectional studies OT - Denmark. OT - Emergency treatment OT - General practitioners OT - Implementation science OT - Normalization process theory OT - Prescriptions OT - Primary care OT - Quality improvement COIS- The authors declare that they have no competing interests. EDAT- 2022/10/16 06:00 MHDA- 2022/10/19 06:00 PMCR- 2022/10/15 CRDT- 2022/10/15 23:13 PHST- 2021/10/28 00:00 [received] PHST- 2022/09/16 00:00 [accepted] PHST- 2022/10/15 23:13 [entrez] PHST- 2022/10/16 06:00 [pubmed] PHST- 2022/10/19 06:00 [medline] PHST- 2022/10/15 00:00 [pmc-release] AID - 10.1186/s12875-022-01864-y [pii] AID - 1864 [pii] AID - 10.1186/s12875-022-01864-y [doi] PST - epublish SO - BMC Prim Care. 2022 Oct 15;23(1):265. doi: 10.1186/s12875-022-01864-y. PMID- 36241582 OWN - NLM STAT- MEDLINE DCOM- 20230606 LR - 20240422 IS - 2588-994X (Electronic) IS - 2588-994X (Linking) VI - 26 IP - 2 DP - 2023 Jun TI - Effect of a specific training intervention with task interruptions on the quality of simulated advance life support: A randomized multi centered controlled simulation study. PG - 153-157 LID - S2588-994X(22)00084-7 [pii] LID - 10.1016/j.auec.2022.10.001 [doi] AB - PURPOSE: Task interruptions (TI) are frequent disturbances for emergency professionals performing advanced life support (ALS). The aim of our study was to evaluate a specific training intervention with TI on the quality of simulated ALS. METHODS: During this multi centered randomized controlled trial, each team included one resident, one nurse and one emergency physician. The teams were randomized for the nature of their training session: control (without interruption) or intervention (with TI). The primary outcome was non-technical skills assessed with the TEAM score. We also measured the no flow time, the Cardiff score and chest compression depth and rate. RESULTS: On a total of 21 included teams, 11 were randomized to a control training session and 10 to the specific TI training. During training, teams' characteristics and skills were similar between the two groups. During the evaluation session, the TEAM score was not different between groups: median score for control group 33,5 vs 31,5 for intervention group. We also report similar no flow time and Cardiff score. CONCLUSION: In this simulated ALS study, a specific training intervention with TI did not improve technical and non-technical skills. Further research is required to limit the impact of TI in emergency settings. CI - Copyright (c) 2022 College of Emergency Nursing Australasia. Published by Elsevier Ltd. All rights reserved. FAU - Truchot, Jennifer AU - Truchot J AD - ILumens Platform of Medical Simulation Paris University, 45 rue des Saint Peres, 75006 Paris, France; ILumens Platform of Medical Simulation Paris University, 20 rue du departement, 75010 Paris, France; Department of Emergency Medicine, Lariboisiere University Hospital, APHP, Universite de Paris, 2 rue Ambroise Pare, Paris, France; Emergency department - SAMU 75, Cochin University Hospital- University of Paris, 27 Rue du Faubourg Saint-Jacques, 75014 Paris, France. Electronic address: contact@ilumens.org. FAU - Michelet, Daphne AU - Michelet D AD - ILumens Platform of Medical Simulation Paris University, 45 rue des Saint Peres, 75006 Paris, France; Department of Anesthesia and Intensive Care, American Memorial University Hospital, Reims, France. FAU - Philippon, Anne Laure AU - Philippon AL AD - Emergency Department, Pitie-Salpetriere hospital, Sorbonne Universite, APHP, Paris, France. FAU - Drummond, David AU - Drummond D AD - ILumens Platform of Medical Simulation Paris University, 45 rue des Saint Peres, 75006 Paris, France; Pediatric Pulmonology, Necker-Enfants Malades University Hospital, APHP, France. FAU - Freund, Yonathan AU - Freund Y AD - Emergency Department, Pitie-Salpetriere hospital, Sorbonne Universite, APHP, Paris, France. FAU - Plaisance, Patrick AU - Plaisance P AD - ILumens Platform of Medical Simulation Paris University, 45 rue des Saint Peres, 75006 Paris, France; ILumens Platform of Medical Simulation Paris University, 20 rue du departement, 75010 Paris, France; Department of Emergency Medicine, Lariboisiere University Hospital, APHP, Universite de Paris, 2 rue Ambroise Pare, Paris, France. LA - eng PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial DEP - 20221012 PL - Australia TA - Australas Emerg Care JT - Australasian emergency care JID - 101727782 SB - IM MH - Humans MH - *Advanced Cardiac Life Support/education MH - Patient Care Team MH - Research Design MH - *Simulation Training OTO - NOTNLM OT - Advanced life support OT - Cardiac arrest OT - Emergency medicine OT - Simulation OT - Stress OT - Task interruptions COIS- Conflict of interest The authors declare that they have no conflict of interest. EDAT- 2022/10/15 06:00 MHDA- 2023/06/06 06:42 CRDT- 2022/10/14 22:13 PHST- 2022/09/21 00:00 [received] PHST- 2022/09/28 00:00 [revised] PHST- 2022/10/01 00:00 [accepted] PHST- 2023/06/06 06:42 [medline] PHST- 2022/10/15 06:00 [pubmed] PHST- 2022/10/14 22:13 [entrez] AID - S2588-994X(22)00084-7 [pii] AID - 10.1016/j.auec.2022.10.001 [doi] PST - ppublish SO - Australas Emerg Care. 2023 Jun;26(2):153-157. doi: 10.1016/j.auec.2022.10.001. Epub 2022 Oct 12. PMID- 36241194 OWN - NLM STAT- MEDLINE DCOM- 20221206 LR - 20221213 IS - 1098-8971 (Electronic) IS - 0272-8087 (Linking) VI - 42 IP - 4 DP - 2022 Nov TI - NAFLD in Cardiovascular Diseases: A Contributor or Comorbidity? PG - 465-474 LID - 10.1055/s-0042-1757712 [doi] AB - Nonalcoholic fatty liver disease (NAFLD) and cardiovascular diseases are both highly prevalent conditions around the world, and emerging data have shown an association between them. This review found several longitudinal and cross-sectional studies showing that NAFLD was associated with coronary artery disease, cardiac remodeling, aortic valve remodeling, mitral annulus valve calcifications, diabetic cardiomyopathy, diastolic cardiac dysfunction, arrhythmias, and stroke. Although the specific underlying mechanisms are not clear, many hypotheses have been suggested, including that metabolic syndrome might act as an upstream metabolic defect, leading to end-organ manifestations in both the heart and liver. Management of NAFLD includes weight loss through lifestyle interventions or bariatric surgery, and pharmacological interventions, often targeting comorbidities. Although there are no Food and Drug Administration-approved nonalcoholic steatohepatitis-specific therapies, several drug candidates have demonstrated effect in the improvement in fibrosis or nonalcoholic steatohepatitis resolution. Further studies are needed to assess the effect of those interventions on cardiovascular outcomes, the major cause of mortality in patients with NAFLD. In conclusion, a more comprehensive, multidisciplinary approach to diagnosis and management of patients with NAFLD and cardiovascular diseases is needed to optimize clinical outcomes. CI - Thieme. All rights reserved. FAU - Chen, Bing AU - Chen B AD - Department of Gastroenterology and Nutrition, Geisinger Medical Center, Danville, Pennsylvania. FAU - Tang, W H Wilson AU - Tang WHW AD - Heart Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio. FAU - Rodriguez, Mario AU - Rodriguez M AD - John T. Milliken Department of Medicine, Division of Cardiovascular disease, Barnes-Jewish Hospital/Washington University in St. Louis School of Medicine, St. Louis, Missouri. FAU - Corey, Kathleen E AU - Corey KE AD - Liver Center, Gastroenterology Division, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. FAU - Sanyal, Arun J AU - Sanyal AJ AD - Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia. FAU - Kamath, Patrick S AU - Kamath PS AD - Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, Rochester, Minnesota. FAU - Bozkurt, Biykem AU - Bozkurt B AD - Winters Center for Heart Failure Research, Cardiovascular Research Institute (B.B.), Baylor College of Medicine, DeBakey VA Medical Center, Houston, Texas. FAU - Virk, Hafeez Ul Hassan AU - Virk HUH AD - Harrington Heart & Vascular Institute, Case Western Reserve University, University Hospitals Cleveland Medical Center, Cleveland, Ohio. FAU - Pressman, Gregg S AU - Pressman GS AD - Division of Cardiovascular Diseases, Einstein Medical Center, Thomas Jefferson University, Philadelphia, Pennsylvania. FAU - Lazarus, Jeffrey V AU - Lazarus JV AD - Barcelona Institute for Global Health (ISGlobal), Hospital Clinic, University of Barcelona, Barcelona, Spain. AD - Faculty of Medicine, University of Barcelona, Barcelona, Spain. FAU - El-Serag, Hashem B AU - El-Serag HB AD - Section of Gastroenterology and Hepatology, Michael E. DeBakey Veterans Affairs Medical Center, Baylor College of Medicine, Houston, Texas. AD - Veterans Affairs Health Services Research and Development Center for Innovations in Quality, Effectiveness, and Safety, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas. FAU - Krittanawong, Chayakrit AU - Krittanawong C AD - Cardiology Division, NYU Langone Health and NYU School of Medicine, New York, New York. LA - eng PT - Journal Article PT - Review DEP - 20221014 PL - United States TA - Semin Liver Dis JT - Seminars in liver disease JID - 8110297 SB - IM MH - Humans MH - *Non-alcoholic Fatty Liver Disease/complications/diagnosis/epidemiology MH - *Cardiovascular Diseases/epidemiology/therapy/complications MH - Cross-Sectional Studies MH - *Metabolic Syndrome/complications MH - Comorbidity COIS- J.V.L. acknowledges grants and speaker fees from Gilead Sciences and MSD and speaker fees from AbbVie, Genfit, Intercept and ViiV, outside of the submitted work. CK discloses the following relationships - Member of the American College of Cardiology Solution Set Oversight Committee, The American College of Cardiology/American Heart Association (ACC/AHA) Joint Committee on Clinical Data Standards, the American Heart Association Committee of the Council on Genomic and Precision Medicine, and the American College of Cardiology/American Heart Association (ACC/AHA) Task Force on Performance Measures, The Lancet Digital Health (Advisory Board), European Heart Journal Digital Health (Editorial board), Journal of the American Heart Association (Editorial board), JACC: Asia (Section Editor), The Journal of Scientific Innovation in Medicine (Associate Editor), and Frontiers in Cardiovascular Medicine (Associate Editor). Other authors have no disclosure. EDAT- 2022/10/15 06:00 MHDA- 2022/12/07 06:00 CRDT- 2022/10/14 20:32 PHST- 2022/10/15 06:00 [pubmed] PHST- 2022/12/07 06:00 [medline] PHST- 2022/10/14 20:32 [entrez] AID - 10.1055/s-0042-1757712 [doi] PST - ppublish SO - Semin Liver Dis. 2022 Nov;42(4):465-474. doi: 10.1055/s-0042-1757712. Epub 2022 Oct 14. PMID- 36240517 OWN - NLM STAT- MEDLINE DCOM- 20230224 LR - 20230920 IS - 1550-5065 (Electronic) IS - 1057-3631 (Linking) VI - 38 IP - 2 DP - 2023 Apr-Jun 01 TI - Ensuring Rapid Response Team Care Aligns With Patients' Limitations of Medical Therapy: A Quality Improvement Project. PG - 134-140 LID - 10.1097/NCQ.0000000000000669 [doi] AB - BACKGROUND: Rapid response teams (RRTs) are designed to improve patient care during deterioration in clinical condition. LOCAL PROBLEM: Patients' desired limitations of medical therapy (LOMTs) were not documented or communicated to the RRT, and patients received care not aligned with their wishes. METHODS: A multidisciplinary team developed a process for improving documentation, communication of LOMTs, and care delivery on 3 medical cardiology units. The team implemented 3 Plan-Do-Study-Act (PDSA) cycles over 6 months. INTERVENTIONS: In cycle 1, team members taught the unit nurses, RRT members, and physicians to share LOMTs during handoff communications. Cycle 2 engaged case managers in LOMT documentation. In cycle 3, unit-based RRT simulation was conducted. RESULTS: All care delivered by the RRT aligned with the documented LOMTs. Documentation of LOMTs increased from 76% to 82.5% ( P = .014). CONCLUSIONS: Education, scripting, and simulation were successful strategies to ensure that care given during RRT events aligned with patients' wishes. CI - Copyright (c) 2022 Wolters Kluwer Health, Inc. All rights reserved. FAU - Mininni, Nicolette C AU - Mininni NC AD - University of Pittsburg Medical Center (UPMC) Shadyside, Pittsburgh, Pennsylvania (Drs Mininni and George); and Waynesburg University, Waynesburg, Pennsylvania (Drs Whiteman, Stephens, and Swanson-Biearman). FAU - Whiteman, Kimberly AU - Whiteman K FAU - Stephens, Kimberly AU - Stephens K FAU - George, Elisabeth AU - George E FAU - Swanson-Biearman, Brenda AU - Swanson-Biearman B LA - eng PT - Journal Article DEP - 20221012 PL - United States TA - J Nurs Care Qual JT - Journal of nursing care quality JID - 9200672 SB - IM MH - Humans MH - *Hospital Rapid Response Team MH - Quality Improvement COIS- The authors declare no conflict of interest. EDAT- 2022/10/15 06:00 MHDA- 2023/02/25 06:00 CRDT- 2022/10/14 17:52 PHST- 2022/10/15 06:00 [pubmed] PHST- 2023/02/25 06:00 [medline] PHST- 2022/10/14 17:52 [entrez] AID - 00001786-202304000-00007 [pii] AID - 10.1097/NCQ.0000000000000669 [doi] PST - ppublish SO - J Nurs Care Qual. 2023 Apr-Jun 01;38(2):134-140. doi: 10.1097/NCQ.0000000000000669. Epub 2022 Oct 12. PMID- 36231926 OWN - NLM STAT- MEDLINE DCOM- 20221017 LR - 20230117 IS - 1660-4601 (Electronic) IS - 1661-7827 (Print) IS - 1660-4601 (Linking) VI - 19 IP - 19 DP - 2022 Oct 3 TI - National Survey: How Do We Approach the Patient at Risk of Clinical Deterioration outside the ICU in the Spanish Context? LID - 10.3390/ijerph191912627 [doi] LID - 12627 AB - BACKGROUND: Anticipating and avoiding preventable intrahospital cardiac arrest and clinical deterioration are important priorities for international healthcare systems and institutions. One of the internationally followed strategies to improve this matter is the introduction of the Rapid Response Systems (RRS). Although there is vast evidence from the international community, the evidence reported in a Spanish context is scarce. METHODS: A nationwide cross-sectional research consisting of a voluntary 31-question online survey was performed. The Spanish Society of Intensive, Critical and Coronary Care Medicine (SEMICYUC) supported the research. RESULTS: We received 62 fully completed surveys distributed within 13 of the 17 regions and two autonomous cities of Spain. Thirty-two of the participants had an established Rapid Response Team (RRT). Common frequency on measuring vital signs was at least once per shift but other frequencies were contemplated (48.4%), usually based on professional criteria (69.4%), as only 12 (19.4%) centers used Early Warning Scores (EWS) or automated alarms on abnormal parameters. In the sample, doctors, nurses (55%), and other healthcare professionals (39%) could activate the RRT via telephone, but only 11.3% of the sample enacted this at early signs of deterioration. The responders on the RRT are the Intensive Care Unit (ICU), doctors, and nurses, who are available 24/7 most of the time. Concerning the education and training of general ward staff and RRT members, this varies from basic to advanced and specific-specialized level, simulating a growing educational methodology among participants. A great number of participants have emergency resuscitation equipment (drugs, airway adjuncts, and defibrillators) in their general wards. In terms of quality improvement, only half of the sample registered RRT activity indicators. In terms of the use of communication and teamwork techniques, the most used is clinical debriefing in 29 centers. CONCLUSIONS: In terms of the concept of RRS, we found in our context that we are in the early stages of the establishment process, as it is not yet a generalized concept in most of our hospitals. The centers that have it are in still in the process of maturing the system and adapting themselves to our context. FAU - Clemente Vivancos, Alvaro AU - Clemente Vivancos A AD - Health Sciences Doctoral Program, Universidad Catolica de Murcia (UCAM), 30107 Murcia, Spain. AD - Advanced Nursing Practice, Hospital del Mar, 08003 Barcelona, Spain. AD - IMIM (Hospital del Mar Medical Research Institute), 08003 Barcelona, Spain. FAU - Leon Castelao, Esther AU - Leon Castelao E AUID- ORCID: 0000-0003-1209-6401 AD - Simulation Laboratory, School of Medicine and Health Sciences, 08036 Barcelona, Spain. AD - Clinical Simulation Lab, University of Barcelona, 08036 Barcelona, Spain. FAU - Castellanos Ortega, Alvaro AU - Castellanos Ortega A AD - Intensive Care Unit Medical Director, University Hospital La Fe, 46026 Valencia, Spain. AD - Associate Lecturer, University of Valencia, 46010 Valencia, Spain. FAU - Bodi Saera, Maria AU - Bodi Saera M AD - Intensive Care Unit, University Hospital Joan XIII, 43005 Tarragona, Spain. AD - Pere I Virgili Health Research Institute, Rovira I Virgili University, 43003 Tarragona, Spain. AD - Center for Biomedical Research in Respiratory Diseases Network (CIEBERES), Carlos III Health Institute, 28029 Madrid, Spain. FAU - Gordo Vidal, Federico AU - Gordo Vidal F AUID- ORCID: 0000-0001-9605-1918 AD - Intensive Care Unit, University Hospital of Henares, 28822 Madrid, Spain. AD - Critical Pathology Research Group, Francisco de Vitoria University, 28223 Madrid, Spain. FAU - Martin Delgado, Maria Cruz AU - Martin Delgado MC AUID- ORCID: 0000-0002-7468-4594 AD - Intensive Care Unit, Hospital 12th of October, 28041 Madrid, Spain. AD - Facultad de Medicina, Francisco de Vitoria University, 28223 Madrid, Spain. FAU - Jorge-Soto, Cristina AU - Jorge-Soto C AD - CLINURSID Research Group, Psychiatry, Radiology, Public Health, Nursing and Medicine Department, Universidad de Santiago de Compostela, 15705 Galicia, Spain. AD - Simulation and Intensive Care Unit of Santiago (SICRUS) Research Group, Health Research Institute of Santiago, University Hospital of Santiago de Compostela-CHUS, 15705 Santiago de Compostela, Spain. AD - Faculty of Nursing, Universidade de Santiago de Compostela, 15705 Santiago de Compostela, Spain. FAU - Fernandez Mendez, Felipe AU - Fernandez Mendez F AD - School of Nursing, Universidade de Vigo, 36310 Pontevedra, Spain. AD - REMOSS Research Group, Universidade de Vigo, 36310 Pontevedra, Spain. FAU - Igeno Cano, Jose Carlos AU - Igeno Cano JC AUID- ORCID: 0000-0001-6013-0972 AD - Intensive Care Unit, San Juan de Dios Hospital, 14012 Cordoba, Spain. FAU - Trenado Alvarez, Josep AU - Trenado Alvarez J AUID- ORCID: 0000-0002-2930-0766 AD - Intensive Care and High Dependency Unit, Mutua Terrassa Hospital, 08221 Terrasa, Spain. AD - Department of Medicine, University of Barcelona, 08036 Barcelona, Spain. FAU - Caballero Lopez, Jesus AU - Caballero Lopez J AUID- ORCID: 0000-0001-9005-9687 AD - Intensive Care Unit, University Hospital Arnau de Vilanova, 25198 Lleida, Spain. AD - IRBLleida, 25198 Lleida, Spain. FAU - Parraga Ramirez, Manuel Jose AU - Parraga Ramirez MJ AD - Intensive Care Unit, JM Morales Meseguer, 30008 Murcia, Spain. AD - Simulation and Clinical Skills Director, UCAM, 30107 Murcia, Spain. AD - Medical Degree Direction Team, UCAM, 30107 Murcia, Spain. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20221003 PL - Switzerland TA - Int J Environ Res Public Health JT - International journal of environmental research and public health JID - 101238455 SB - IM MH - *Clinical Deterioration MH - Cross-Sectional Studies MH - *Hospital Rapid Response Team MH - Humans MH - Intensive Care Units MH - Quality Improvement PMC - PMC9565925 OTO - NOTNLM OT - early warning score OT - hospital medical emergency team OT - rapid response team COIS- The authors declare no conflict of interest. EDAT- 2022/10/15 06:00 MHDA- 2022/10/18 06:00 PMCR- 2022/10/03 CRDT- 2022/10/14 02:02 PHST- 2022/09/12 00:00 [received] PHST- 2022/09/26 00:00 [revised] PHST- 2022/09/30 00:00 [accepted] PHST- 2022/10/14 02:02 [entrez] PHST- 2022/10/15 06:00 [pubmed] PHST- 2022/10/18 06:00 [medline] PHST- 2022/10/03 00:00 [pmc-release] AID - ijerph191912627 [pii] AID - ijerph-19-12627 [pii] AID - 10.3390/ijerph191912627 [doi] PST - epublish SO - Int J Environ Res Public Health. 2022 Oct 3;19(19):12627. doi: 10.3390/ijerph191912627. PMID- 36229301 OWN - NLM STAT- MEDLINE DCOM- 20230711 LR - 20230711 IS - 1876-4738 (Electronic) IS - 0914-5087 (Linking) VI - 81 IP - 1 DP - 2023 Jan TI - Surgical extraction of cardiac implantable electronic device leads based on a heart team approach. PG - 111-116 LID - S0914-5087(22)00221-0 [pii] LID - 10.1016/j.jjcc.2022.08.013 [doi] AB - BACKGROUND: As cardiac implantable electronic devices, such as pacemakers, cardioverter defibrillators, and cardiac resynchronization therapies, have become more popular, device extraction has become more frequent. At our institution, individual treatment strategies are discussed at a heart team meeting. Transvenous lead extraction (TVLE) is a first-line treatment; however, surgical lead extraction (SLE) is sometimes selected as a primary choice to provide optimal treatment and maintain the medical safety policy. This study aimed to investigate the validity of this heart team decision-making. METHODS: From 2013 to 2021, 384 consecutive patients underwent lead extraction at our institution. RESULTS: SLE was proposed as the primary intervention for 21 patients who had high risk of bleeding, difficult TVLE conditions, large vegetations, and other concomitant cardiac diseases. Of the 363 TVLE patients, 10 patients required surgical intervention; 5 had TVLE difficulty followed by SLE and 5 had excessive bleeding. SLE was performed in 26 patients, 19 of whom required valve surgery, and 8 required plication of the great veins. In 4 of the 17 hybrid procedures with SLE and TVLE, excessive bleeding occurred due to laceration of the superior vena cava and innominate vein. Operative mortality was not observed in SLE patients but was observed in 1 of the 4 TVLE patients who required emergent open-chest hemostasis. CONCLUSIONS: The heart team discussion was essential to provide optimal treatment and maintain medical safety policies for each patient. SLE should be selected for patients with high risk of TVLE or other cardiac complications such as tricuspid valve incompetence. CI - Copyright (c) 2022. Published by Elsevier Ltd. FAU - Mizuno, Tomohiro AU - Mizuno T AD - Department of Cardiovascular Surgery, Graduate School of Medical and Dental Science, Tokyo Medical and Dental University, Tokyo, Japan; Arrhythmia Center, Tokyo Medical and Dental University Hospital, Tokyo, Japan. Electronic address: mizuno.cvsg@tmd.ac.jp. FAU - Goya, Masahiko AU - Goya M AD - Arrhythmia Center, Tokyo Medical and Dental University Hospital, Tokyo, Japan; Department of Cardiovascular Medicine, Graduate School of Medical and Dental Science, Tokyo Medical and Dental University, Tokyo, Japan. FAU - Fujiwara, Tatsuki AU - Fujiwara T AD - Department of Cardiovascular Surgery, Graduate School of Medical and Dental Science, Tokyo Medical and Dental University, Tokyo, Japan. FAU - Oishi, Kiyotoshi AU - Oishi K AD - Department of Cardiovascular Surgery, Graduate School of Medical and Dental Science, Tokyo Medical and Dental University, Tokyo, Japan. FAU - Takeshita, Masashi AU - Takeshita M AD - Department of Cardiovascular Surgery, Graduate School of Medical and Dental Science, Tokyo Medical and Dental University, Tokyo, Japan. FAU - Yashima, Masafumi AU - Yashima M AD - Department of Cardiovascular Surgery, Graduate School of Medical and Dental Science, Tokyo Medical and Dental University, Tokyo, Japan. FAU - Nagaoka, Eiki AU - Nagaoka E AD - Department of Cardiovascular Surgery, Graduate School of Medical and Dental Science, Tokyo Medical and Dental University, Tokyo, Japan. FAU - Oi, Keiji AU - Oi K AD - Department of Cardiovascular Surgery, Graduate School of Medical and Dental Science, Tokyo Medical and Dental University, Tokyo, Japan. FAU - Sasano, Tetsuo AU - Sasano T AD - Arrhythmia Center, Tokyo Medical and Dental University Hospital, Tokyo, Japan; Department of Cardiovascular Medicine, Graduate School of Medical and Dental Science, Tokyo Medical and Dental University, Tokyo, Japan. LA - eng PT - Journal Article DEP - 20221011 PL - Netherlands TA - J Cardiol JT - Journal of cardiology JID - 8804703 SB - IM MH - Humans MH - *Defibrillators, Implantable/adverse effects MH - Device Removal/methods MH - Electronics MH - *Pacemaker, Artificial/adverse effects MH - Retrospective Studies MH - Treatment Outcome MH - Vena Cava, Superior OTO - NOTNLM OT - Arrhythmia OT - Heart team OT - Implantable electronic device OT - Infection OT - Pacemaker EDAT- 2022/10/14 06:00 MHDA- 2022/12/06 06:00 CRDT- 2022/10/13 22:05 PHST- 2022/05/23 00:00 [received] PHST- 2022/07/30 00:00 [revised] PHST- 2022/08/22 00:00 [accepted] PHST- 2022/10/14 06:00 [pubmed] PHST- 2022/12/06 06:00 [medline] PHST- 2022/10/13 22:05 [entrez] AID - S0914-5087(22)00221-0 [pii] AID - 10.1016/j.jjcc.2022.08.013 [doi] PST - ppublish SO - J Cardiol. 2023 Jan;81(1):111-116. doi: 10.1016/j.jjcc.2022.08.013. Epub 2022 Oct 11. PMID- 36226746 OWN - NLM STAT- MEDLINE DCOM- 20221201 LR - 20260127 IS - 2048-8734 (Electronic) IS - 2048-8726 (Linking) VI - 11 IP - 11 DP - 2022 Nov 30 TI - Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Clinical Consensus Statement of the Acute CardioVascular Care Association (ACVC) and the ESC council of Cardio-Oncology-part 2: acute heart failure, acute myocardial diseases, acute venous thromboembolic diseases, and acute arrhythmias. PG - 865-874 LID - 10.1093/ehjacc/zuac107 [doi] AB - Advances in treatment, common cardiovascular (CV) risk factors and the ageing of the population have led to an increasing number of cancer patients presenting with acute CV diseases. These events may be related to cancer itself or cancer treatment. Acute cardiac care specialists must be aware of these acute CV complications and be able to manage them. This may require an individualized and multidisciplinary approach. The management of acute coronary syndromes and acute pericardial diseases in cancer patients was covered in part 1 of a clinical consensus document. This second part focusses on acute heart failure, acute myocardial diseases, venous thromboembolic diseases and acute arrhythmias. CI - (c) The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please email: journals.permissions@oup.com. FAU - Gevaert, Sofie A AU - Gevaert SA AUID- ORCID: 0000-0002-8721-3003 AD - Department of Cardiology, Ghent University Hospital, Gent, Belgium. FAU - Halvorsen, Sigrun AU - Halvorsen S AD - Department of Cardiology, Oslo University Hospital Ulleval, and University of Oslo, Oslo, Norway. FAU - Sinnaeve, Peter R AU - Sinnaeve PR AD - Department of Cardiology, University Hospital Leuven, Leuven, Belgium. FAU - Sambola, Antonia AU - Sambola A AD - Department of Cardiology, University Hospital Vall d'Hebron, Universitat Autonoma, CIBER-CV, Barcelona, Spain. FAU - Gulati, Geeta AU - Gulati G AUID- ORCID: 0000-0002-1316-8676 AD - Department of Cardiology, Oslo University Hospital Ulleval, and University of Oslo, Oslo, Norway. FAU - Lancellotti, Patrizio AU - Lancellotti P AUID- ORCID: 0000-0002-0804-8194 AD - University of Liege Hospital, GIGA Cardiovascular Science, Department of Cardiology, CHU Sart Tilman, Liege, Belgium. FAU - Van Der Meer, Peter AU - Van Der Meer P AD - Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. FAU - Lyon, Alexander R AU - Lyon AR AD - Cardio-Oncology Clinic at Royal Brompton Hospital and Imperial College London, London, UK. FAU - Farmakis, Dimitrios AU - Farmakis D AUID- ORCID: 0000-0001-8364-3447 AD - University of Cyprus Medical School, Nicosia, Cyprus. FAU - Lee, Geraldine AU - Lee G AD - Florence Nightingale Faculty of Nursing, Midwifery and Palliative Care, King's College, London, UK. FAU - Boriani, Giuseppe AU - Boriani G AUID- ORCID: 0000-0002-9820-4815 AD - Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico Di Modena, Modena, Italy. FAU - Wechalekar, Ashutosh AU - Wechalekar A AUID- ORCID: 0000-0002-4406-7237 AD - Department of Haematology, University College London/University College London Hospitals, London, UK. FAU - Okines, Alicia AU - Okines A AD - Department of Medicine, The Royal Marsden NHS Foundation Trust, London, UK. FAU - Asteggiano, Riccardo AU - Asteggiano R AUID- ORCID: 0000-0002-2273-7228 AD - Insubria University, Varese, Italy. AD - LARC (Laboratorio Analisi e Ricerca Clinica), Turin, Italy. FAU - Combes, Alain AU - Combes A AD - Medical-Surgical ICU, Hopital Pitie-Salpetriere, Paris, France. AD - Sorbonne University, Institute of Cardiometabolism and Nutrition, Paris, France. FAU - Pfister, Roman AU - Pfister R AD - Department III of Internal Medicine, Heart Center, University of Cologne, Cologne, Germany. FAU - Bergler-Klein, Jutta AU - Bergler-Klein J AD - Department of Cardiology, University Clinic of Internal Medicine II, Medical University of Vienna, Vienna, Austria. FAU - Lettino, Maddalena AU - Lettino M AD - Department of Cardiology, San Gerardo Hospital, ASST-Monza, Monza, Italy. LA - eng GR - Fondation Leducq Network of Excellence in Cardio-Oncology/ GR - Pfizer/ GR - Roche/ GR - Vifor Pharma/ GR - AstraZeneca/ GR - Fondation Leducq Network of Excellence/ PT - Consensus Statement PT - Journal Article PL - England TA - Eur Heart J Acute Cardiovasc Care JT - European heart journal. Acute cardiovascular care JID - 101591369 SB - IM MH - Humans MH - *Cardiovascular Diseases/complications/epidemiology/therapy MH - Risk Factors MH - *Neoplasms/complications/epidemiology/therapy MH - Arrhythmias, Cardiac/therapy/complications MH - *Acute Coronary Syndrome/complications/diagnosis/epidemiology MH - *Heart Failure/complications/therapy MH - *Cardiomyopathies/complications OTO - NOTNLM OT - Acute heart failure OT - Acute toxicity OT - Arrhythmia OT - Cancer OT - Cardiac implanted electronic devices (CIED) OT - Cardiotoxicity OT - Myocarditis OT - Pulmonary embolism OT - Takotsubo syndrome OT - Venous thromboembolic disease COIS- Conflict of interest: P.L.: nothing in relation to this work. A.S.: nothing in relation to this work. G.G.: has received speaker honoraria from Novartis, Orion Pharma, AstraZeneca, and Bristol-Myers Squibb. R.A.: nothing in relation to this work. G.B.: nothing in relation to this work. S.H.: nothing in relation to this work. G.L.: nothing in relation to this work. D.F.: speaker's honoraria or advisory board fees from Abbott Laboratories, Bayer, Boehringer Ingelheim, Leo Pharmaceuticals, Menarini, Novartis, Orion Pharma, Roche Diagnostics. S.G.: speaker's and advisory fees (all institutional) from AstraZeneca, Daiichi-Sankyo, Boehringer. P.S.: speaker's and advisory fees (all institutional) from AstraZeneca, Daiichi-Sankyo, Bayer, Boehringer, Pfizer, BMS, Amgen, Sanofi. P.V.D.M.: consultancy and/or Servier, Novartis, Pfizer, Pharmacosmos, Ionis. Supported by the ERC (StG 715732). A.R.L.: speaker, advisory board, or consultancy fees and/or research grants from Pfizer, Novartis, Servier, Amgen, Takeda, Roche, Janssens-Cilag Ltd., Clinigen, Eli Lily, Eisai, Bristol-Myers Squibb, Ferring Pharmaceuticals, Boehringer Ingelheim, Myocardial Solutions, iOWNA, and Heartfelt Technologies Ltd. A.O.: speaker's and advisory fees from Seagen, Roche, Diaichi-Sankyo, and Astra Zeneca. Travel support from Lilly, Astra Zeneca, and Leo Pharmaceuticals. A.W.: honorarium, advisory board or consultancy fees: Janssen Cilag, GSK, Alexion, Caelum, Takeda, Celgene. EDAT- 2022/10/14 06:00 MHDA- 2022/12/02 06:00 CRDT- 2022/10/13 07:02 PHST- 2022/08/19 00:00 [received] PHST- 2022/08/29 00:00 [accepted] PHST- 2022/10/14 06:00 [pubmed] PHST- 2022/12/02 06:00 [medline] PHST- 2022/10/13 07:02 [entrez] AID - 6759859 [pii] AID - 10.1093/ehjacc/zuac107 [doi] PST - ppublish SO - Eur Heart J Acute Cardiovasc Care. 2022 Nov 30;11(11):865-874. doi: 10.1093/ehjacc/zuac107. PMID- 36221937 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221020 IS - 2287-6391 (Print) IS - 2287-6405 (Electronic) IS - 2287-6391 (Linking) VI - 24 IP - 3 DP - 2022 Sep TI - Establishment of the Heart and Brain Team for Patent Foramen Ovale Closure in Stroke Patients: An Expert Opinion. PG - 345-351 LID - 10.5853/jos.2022.02103 [doi] AB - The online 2021 Asian-Pacific Heart and Brain Summit was organized to present and discuss experiences within leading Asian-Pacific centers with regard to institutional heart and brain teams managing the diagnosis, treatment, and follow-up of cryptogenic stroke (CS) patients with patent foramen ovale (PFO). This manuscript presents a narrative review of presentations and discussions during the summit meeting. Percutaneous PFO closure is an established therapy for CS patients in whom PFO is considered to be causal. Guidelines and consensus statements emphasize the importance of multidisciplinary clinical decision-making regarding PFO closure with the involvement of several clinical specialties, including neurology, cardiology, and hematology. It is also recommended that the patient be closely involved in this process. The heart and brain team is a collaborative platform that facilitates such a multidisciplinary decision-making process and patient involvement. It also creates opportunities for education and evaluation of the healthcare provided to patients with CS. This review provides insights into the implementation, composition, organization, and operation of a heart and brain team. Methods and metrics are suggested to evaluate the team's role. We suggest that an efficient heart and brain team can implement guideline-recommended multidisciplinary clinical decision-making with regard to PFO closure in CS patients and play an important role in the management of these patients. FAU - Kim, Jong S AU - Kim JS AD - Department of Neurology, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Korea. FAU - Thijs, Vincent AU - Thijs V AD - Stroke Theme, Florey Institute of Neuroscience and Mental Health, Heidelberg, Australia. FAU - Yudi, Matias AU - Yudi M AD - Department of Cardiology, Austin Health, Heidelberg, Australia. FAU - Toyoda, Kazunori AU - Toyoda K AD - Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan. FAU - Shiozawa, Masayuki AU - Shiozawa M AD - Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan. FAU - Zening, Jin AU - Zening J AD - Department of Neurology, Beijing Tiantan Hospital, Beijing, China. FAU - Clapp, Brian AU - Clapp B AD - Interventional Cardiology, St. Thomas' Hospital, London, UK. FAU - Albers, Bert AU - Albers B AD - Albers Clinical Evidence Consultancy, Winterswijk Woold, The Netherlands. FAU - Diener, Hans-Christoph AU - Diener HC AD - Department of Neuroepidemiology, Institute for Medical Informatics, Biometry and Epidemiology (IMIBE), Medical Faculty of the University Duisburg-Essen, Essen, Germany. LA - eng GR - Boehringer Ingelheim/ PT - Journal Article PT - Review DEP - 20220930 PL - Korea (South) TA - J Stroke JT - Journal of stroke JID - 101602023 PMC - PMC9561221 OTO - NOTNLM OT - Clinical decision-making OT - Patent foramen ovale OT - Secondary prevention OT - Stroke EDAT- 2022/10/13 06:00 MHDA- 2022/10/13 06:01 PMCR- 2022/09/01 CRDT- 2022/10/12 02:59 PHST- 2022/06/29 00:00 [received] PHST- 2022/08/03 00:00 [accepted] PHST- 2022/10/12 02:59 [entrez] PHST- 2022/10/13 06:00 [pubmed] PHST- 2022/10/13 06:01 [medline] PHST- 2022/09/01 00:00 [pmc-release] AID - jos.2022.02103 [pii] AID - jos-2022-02103 [pii] AID - 10.5853/jos.2022.02103 [doi] PST - ppublish SO - J Stroke. 2022 Sep;24(3):345-351. doi: 10.5853/jos.2022.02103. Epub 2022 Sep 30. PMID- 36216499 OWN - NLM STAT- MEDLINE DCOM- 20230118 LR - 20230331 IS - 1742-6723 (Electronic) IS - 1742-6723 (Linking) VI - 35 IP - 1 DP - 2023 Feb TI - Role of the emergency department in implementing an extracorporeal membrane oxygenation cardiopulmonary resuscitation. PG - 173-175 LID - 10.1111/1742-6723.14100 [doi] AB - The Royal Brisbane and Women's Hospital has introduced an extracorporeal membrane oxygenation (ECMO) cardiopulmonary resuscitation (E-CPR) service with collaboration between ED and ICU teams for refractory cardiac arrest patients. E-CPR is potentially beneficial to patients who do not gain return of spontaneous circulation after conventional advanced cardiac life support treatments, provided specific demographic and biochemical inclusion criteria are met. A joint ICU and ED decision is reached to commence ECMO flow. We discuss our rationale to use the ED and the emergency physician role in leading the multidisciplinary team, with ICU leading the cannulation team. The development of ED processes and the increased availability of this intervention can significantly impact the survivability of refractory cardiac arrest with good neurological outcomes. CI - (c) 2022 Australasian College for Emergency Medicine. FAU - Gilbert, Felicity AU - Gilbert F AUID- ORCID: 0000-0002-0487-8828 AD - Emergency and Trauma Centre, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia. AD - Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia. FAU - Mitchell, Gary AU - Mitchell G AUID- ORCID: 0000-0001-6440-3683 AD - Emergency and Trauma Centre, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia. AD - Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia. AD - Jamieson Trauma Institute, Brisbane, Queensland, Australia. FAU - Townsend, Shane AU - Townsend S AD - Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia. AD - Department of Intensive Care Medicine, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia. FAU - Dhanani, Jayesh AU - Dhanani J AD - Department of Intensive Care Medicine, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia. AD - Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia. AD - School of Nursing, Queensland University of Technology, Brisbane, Queensland, Australia. FAU - Sng, Nicole AU - Sng N AD - Emergency and Trauma Centre, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia. AD - Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia. LA - eng PT - Journal Article DEP - 20221010 PL - Australia TA - Emerg Med Australas JT - Emergency medicine Australasia : EMA JID - 101199824 SB - IM MH - Humans MH - Female MH - *Cardiopulmonary Resuscitation MH - *Extracorporeal Membrane Oxygenation MH - *Heart Arrest/therapy MH - Emergency Service, Hospital MH - *Out-of-Hospital Cardiac Arrest/therapy OTO - NOTNLM OT - cardiac arrest OT - emergency medicine OT - extracorporeal membrane oxygenation EDAT- 2022/10/11 06:00 MHDA- 2023/01/19 06:00 CRDT- 2022/10/10 21:12 PHST- 2022/09/21 00:00 [received] PHST- 2022/09/21 00:00 [accepted] PHST- 2022/10/11 06:00 [pubmed] PHST- 2023/01/19 06:00 [medline] PHST- 2022/10/10 21:12 [entrez] AID - 10.1111/1742-6723.14100 [doi] PST - ppublish SO - Emerg Med Australas. 2023 Feb;35(1):173-175. doi: 10.1111/1742-6723.14100. Epub 2022 Oct 10. PMID- 36212569 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221011 IS - 2666-3341 (Electronic) IS - 2666-3341 (Linking) VI - 3 IP - 3 DP - 2022 Sep TI - In vitro fertilization outcomes in VACTERL association (vertebral defects, anal atresia, cardiac defects, tracheoesophageal fistula, renal anomalies and limb anomalies): report of 2 cases. PG - 280-284 LID - 10.1016/j.xfre.2022.06.006 [doi] AB - OBJECTIVE: To report 2 cases of women with vertebral defects, anal atresia, cardiac defects, tracheaesophageal fistula, renal anomalies, and/or limb anomalies (VACTERL association) and the outcomes of their in vitro fertilization (IVF) cycles. DESIGN: A case report. We obtained informed consent from both the patients for this case report. SETTING: Outpatient clinic at an academic hospital. PATIENTS: Patient 1 was a 23-year-old woman with scoliosis, tethered spinal cord, tracheaesophageal fistula, duodenal atresia, and a common cloaca at birth. Patient 2 was a 36-year-old woman with dextrocardia, congenital heart disease, scoliosis, and an imperforate anus at birth. INTERVENTIONS: Both the patients underwent IVF. MAIN OUTCOME MEASURES: Oocyte yield, oocyte quality, and number of embryos. RESULTS: Patient 1 underwent 1 IVF cycle, with 16 oocytes retrieved, of which 6 were mature. However, during intracytoplasmic sperm injection, the oocytes were noted to be extremely fragile and degenerated immediately after sperm injection. No oocyte was fertilized. Patient 2 underwent 3 IVF cycles, and 2 oocyte retrievals, with a total of 7 oocytes under cryopreservation. CONCLUSIONS: Both the patients' cases presented challenges due to aberrations in pelvic anatomy and poor IVF outcomes. There is a paucity of data regarding fertility outcomes and, specifically, oocyte quality in patients with vertebral defects, anal atresia, cardiac defects, tracheaesophageal fistula, renal anomalies, and/or limb anomalies association. Their care requires a multidisciplinary assessment, an individualized approach, and continued investigation of their IVF and fertility outcomes. CI - (c) 2022 The Authors. FAU - LePoidevin, Lindsey AU - LePoidevin L AD - Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, Texas. FAU - Dunn, Timothy AU - Dunn T AD - Department of Reproductive Endocrinology and Infertility, Baylor College of Medicine, Houston, Texas. FAU - Arian, Sara E AU - Arian SE AD - Department of Reproductive Endocrinology and Infertility, Baylor College of Medicine, Houston, Texas. FAU - Kaskar, Khalied AU - Kaskar K AD - Department of Reproductive Endocrinology and Infertility, Baylor College of Medicine, Houston, Texas. FAU - Schutt, Amy AU - Schutt A AD - Department of Reproductive Endocrinology and Infertility, Baylor College of Medicine, Houston, Texas. LA - eng PT - Journal Article DEP - 20220702 PL - United States TA - F S Rep JT - F&S reports JID - 101766618 PMC - PMC9532890 OTO - NOTNLM OT - IVF OT - VACTERL OT - egg quality OT - fertility OT - mullerian OT - oocyte EDAT- 2022/10/11 06:00 MHDA- 2022/10/11 06:01 PMCR- 2022/07/02 CRDT- 2022/10/10 04:14 PHST- 2022/04/06 00:00 [received] PHST- 2022/06/29 00:00 [revised] PHST- 2022/06/29 00:00 [accepted] PHST- 2022/10/10 04:14 [entrez] PHST- 2022/10/11 06:00 [pubmed] PHST- 2022/10/11 06:01 [medline] PHST- 2022/07/02 00:00 [pmc-release] AID - S2666-3341(22)00069-1 [pii] AID - 10.1016/j.xfre.2022.06.006 [doi] PST - epublish SO - F S Rep. 2022 Jul 2;3(3):280-284. doi: 10.1016/j.xfre.2022.06.006. eCollection 2022 Sep. PMID- 36210551 OWN - NLM STAT- MEDLINE DCOM- 20221011 LR - 20221104 IS - 1879-2472 (Electronic) IS - 0049-3848 (Linking) VI - 213 Suppl 1 DP - 2022 May TI - Optimizing antithrombotic therapy for atrial fibrillation in cancer. PG - S103-S106 LID - S0049-3848(22)00001-9 [pii] LID - 10.1016/j.thromres.2022.01.001 [doi] AB - Atrial fibrillation (AF) may be a pre-existing disease before cancer diagnosis, may be a direct effect of the neoplasm or, more often, appears as a post-surgical complication, especially after thoracic surgery. AF may also develop as a consequence of chemotherapy or radiotherapy. The management of the anticoagulation in cancer patients with AF is challenging, and data on these patients are lacking. The use of vitamin K antagonists (VKAs) may be problematic because of the unpredictable therapeutic response and high bleeding risk in patients with active cancer who are undergoing chemotherapy and who may experience thrombocytopenia and/or changes in renal or hepatic function. Low molecular weight heparins and direct oral anticoagulants (DOACs) could be preferred. However, the possible pharmacological interactions of DOACs with anti-cancer and anti-arrhythmic drugs and the bleeding risks in thrombocytopenic patients should be considered. Based on these considerations, a careful evaluation of the antithrombotic strategy with the best efficacy/safety ratio is always needed in cancer patients and anticoagulation for AF should be tailored individually. An ongoing consultation of oncologists/hematologists with cardiologists and coagulation experts in a multidisciplinary approach, with a periodic re-assessment of the benefits of anticoagulation with changes in cancer status/advancement and treatment plans is needed. CI - Copyright (c) 2022 Elsevier Ltd. All rights reserved. FAU - Tufano, Antonella AU - Tufano A AD - Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy. Electronic address: atufano@unina.it. LA - eng PT - Journal Article DEP - 20220526 PL - United States TA - Thromb Res JT - Thrombosis research JID - 0326377 RN - 0 (Anti-Arrhythmia Agents) RN - 0 (Anticoagulants) RN - 0 (Fibrinolytic Agents) RN - 0 (Heparin, Low-Molecular-Weight) RN - 12001-79-5 (Vitamin K) SB - IM MH - Administration, Oral MH - Anti-Arrhythmia Agents/therapeutic use MH - Anticoagulants/therapeutic use MH - *Atrial Fibrillation/complications/diagnosis/drug therapy MH - Fibrinolytic Agents/therapeutic use MH - Heparin, Low-Molecular-Weight/therapeutic use MH - Humans MH - *Neoplasms/complications/drug therapy MH - *Stroke/drug therapy MH - Vitamin K OTO - NOTNLM OT - Anticoagulants OT - Atrial fibrillation OT - Chemotherapy OT - Thrombocytopenia OT - cancer EDAT- 2022/10/11 06:00 MHDA- 2022/10/12 06:00 CRDT- 2022/10/10 01:53 PHST- 2021/10/19 00:00 [received] PHST- 2022/01/03 00:00 [revised] PHST- 2022/01/03 00:00 [accepted] PHST- 2022/10/10 01:53 [entrez] PHST- 2022/10/11 06:00 [pubmed] PHST- 2022/10/12 06:00 [medline] AID - S0049-3848(22)00001-9 [pii] AID - 10.1016/j.thromres.2022.01.001 [doi] PST - ppublish SO - Thromb Res. 2022 May;213 Suppl 1:S103-S106. doi: 10.1016/j.thromres.2022.01.001. Epub 2022 May 26. PMID- 36207759 OWN - NLM STAT- MEDLINE DCOM- 20221011 LR - 20221011 IS - 1476-7120 (Electronic) IS - 1476-7120 (Linking) VI - 20 IP - 1 DP - 2022 Oct 7 TI - Evaluation of left ventricular systolic function in patients with systemic lupus erythematosus using ultrasonic layer-specific strain technology and its association with cardiovascular events: a long-term follow-up study. PG - 25 LID - 10.1186/s12947-022-00295-0 [doi] LID - 25 AB - BACKGROUND: Systemic lupus erythematosus (SLE) is a multisystem, autoimmune disease with potential cardiovascular involvement. Layer-specific strain (LSS) analysis is a new method that allows early detection of subtle left ventricular (LV) systolic dysfunction. The aim of this study was to evaluate LV systolic function in patients with SLE using conventional echocardiographic measurements and longitudinal strain (LS) and circumferential strain (CS) by LSS. Furthermore, the association between echocardiographic parameters and the occurrence of cardiovascular events was assessed. METHODS: A total of 162 patients with SLE (the SLE group) who underwent a dedicated multidisciplinary assessment, including echocardiography, were analyzed at the time of their first visits. The control group consisted of 68 age- and sex-matched healthy subjects. LS and CS on endocardial, mid-myocardial, and epicardial layers at 17 cardiac segments were measured. Transmural strain gradient was calculated as the differences in systolic strain between the endocardial and epicardial layers. RESULTS: Compared with control subjects, patients with SLE had significantly lower LV ejection fraction, LS, and CS values in all layers (P < 0.05); LV LS and CS gradient were all lower than control subjects (P < 0.05). During a median follow-up period of 83 months (interquartile range: 64-95 months), 59 patients (36.4%) developed cardiovascular events. Using multivariate Cox regression analysis, we found that LV endocardial LS (hazard ratio, 1.014; 95% CI, 1.002-1.035; P = 0.025) and CS (hazard ratio, 1.051; 95% CI, 1.027-1.077; P < 0.001) demonstrated independent associations with cardiovascular events; whereas LV ejection fraction was not significantly associated with cardiovascular events. The Kaplan-Meier survival curves showed that patients with SLE with lower LV endocardial LS and CS (based on the cutoff values of -21.5% and -29.0%, respectively) experienced higher cumulative rates of cardiovascular events compared with those with higher LV endocardial LS and CS. CONCLUSIONS: In patients with SLE, LV systolic function measured by LV endocardial LS and CS were significantly lower than that of the control group and were associated with cardiovascular events, potentially representing a new technology to improve risk stratification in these patients. CI - (c) 2022. The Author(s). FAU - Zhang, Hebin AU - Zhang H AD - Department of Ultrasound, the Affiliated Hospital of Hangzhou Normal University, Zhejiang Province, Hangzhou, 310015, China. FAU - Yang, Cunxin AU - Yang C AD - Department of Ultrasound, the Affiliated Hospital of Hangzhou Normal University, Zhejiang Province, Hangzhou, 310015, China. FAU - Gao, Feng AU - Gao F AD - Department of Ultrasound, the Affiliated Hospital of Hangzhou Normal University, Zhejiang Province, Hangzhou, 310015, China. z632023@163.com. FAU - Hu, Shanting AU - Hu S AD - Department of Ultrasound, the Affiliated Hospital of Hangzhou Normal University, Zhejiang Province, Hangzhou, 310015, China. FAU - Ma, Hui AU - Ma H AD - Department of Ultrasound, the Affiliated Hospital of Hangzhou Normal University, Zhejiang Province, Hangzhou, 310015, China. LA - eng GR - No. 2022KY972/Medical and Health Research Program of Zhejiang Province/ PT - Journal Article DEP - 20221007 PL - England TA - Cardiovasc Ultrasound JT - Cardiovascular ultrasound JID - 101159952 SB - IM MH - Follow-Up Studies MH - Humans MH - *Lupus Erythematosus, Systemic/complications/diagnosis MH - Technology MH - Ultrasonics MH - *Ventricular Dysfunction, Left/diagnostic imaging/etiology MH - Ventricular Function, Left PMC - PMC9541079 OTO - NOTNLM OT - Cardiovascular outcome OT - Layer-specific strain OT - Left ventricle function OT - Myocardium OT - Speckle-tracking OT - Systemic lupus erythematosus COIS- The authors declare that they have no competing interests. EDAT- 2022/10/08 06:00 MHDA- 2022/10/12 06:00 PMCR- 2022/10/07 CRDT- 2022/10/07 23:51 PHST- 2021/10/18 00:00 [received] PHST- 2022/10/03 00:00 [accepted] PHST- 2022/10/07 23:51 [entrez] PHST- 2022/10/08 06:00 [pubmed] PHST- 2022/10/12 06:00 [medline] PHST- 2022/10/07 00:00 [pmc-release] AID - 10.1186/s12947-022-00295-0 [pii] AID - 295 [pii] AID - 10.1186/s12947-022-00295-0 [doi] PST - epublish SO - Cardiovasc Ultrasound. 2022 Oct 7;20(1):25. doi: 10.1186/s12947-022-00295-0. PMID- 36204994 OWN - NLM STAT- MEDLINE DCOM- 20221103 LR - 20230911 IS - 1473-5598 (Electronic) IS - 0263-6352 (Linking) VI - 40 IP - 12 DP - 2022 Dec 1 TI - Hypertension and atrial fibrillation. PG - 2337-2352 LID - 10.1097/HJH.0000000000003278 [doi] AB - Hypertension is the most prevalent cardiovascular risk factor underlying atrial fibrillation and is present in up to 40% of patients with atrial fibrillation. Furthermore, attributable risk studies have shown that a history of hypertension contributes to up to 24% of incident atrial fibrillation. New data suggest that even early forms of hypertension (prehypertension and aortic stiffness) are associated with an increased risk of atrial fibrillation development. Hypertension and prehypertension are therefore critical mediators for the development of atrial fibrillation. Mechanisms for the association between hypertension and atrial fibrillation include diffuse electro-structural changes to the left atrium, driven by the haemodynamic and neurohormonal influences of hypertension and other, frequently coexisting, cardiovascular risk factors. Management of hypertension in atrial fibrillation should focus not only on blood pressure reduction but also on a comprehensive risk factor modification strategy. Such strategies have been shown to be associated with significant improvements in atrial fibrillation symptom burden as well as improved arrhythmia-free survival and reversal of the progression of atrial fibrillation. These strategies should focus on dietary modifications as well as prescribed exercise programmes involving a multidisciplinary team and patient-centred atrial fibrillation care. Risk factor management, supplemented by antihypertensive medications as needed, provides the optimum strategy for improving outcomes and even reversing the natural progression of atrial fibrillation in patients with hypertension. CI - Copyright (c) 2022 Wolters Kluwer Health, Inc. All rights reserved. FAU - Middeldorp, Melissa E AU - Middeldorp ME AD - Centre for Heart Rhythm Disorder, University of Adelaide and the Royal Adelaide Hospital, Adelaide, South Australia, Australia. AD - Department of Cardiology, Smidt Heart institute, Cedars Sinai Medical Center (CMA), Los Angeles, California, USA. FAU - Ariyaratnam, Jonathan P AU - Ariyaratnam JP AD - Centre for Heart Rhythm Disorder, University of Adelaide and the Royal Adelaide Hospital, Adelaide, South Australia, Australia. FAU - Kamsani, Suraya H AU - Kamsani SH AD - Centre for Heart Rhythm Disorder, University of Adelaide and the Royal Adelaide Hospital, Adelaide, South Australia, Australia. FAU - Albert, Christine M AU - Albert CM AD - Department of Cardiology, Smidt Heart institute, Cedars Sinai Medical Center (CMA), Los Angeles, California, USA. FAU - Sanders, Prashanthan AU - Sanders P AD - Centre for Heart Rhythm Disorder, University of Adelaide and the Royal Adelaide Hospital, Adelaide, South Australia, Australia. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20221004 PL - Netherlands TA - J Hypertens JT - Journal of hypertension JID - 8306882 RN - 0 (Antihypertensive Agents) SB - IM MH - Humans MH - *Atrial Fibrillation/etiology MH - *Prehypertension/complications MH - *Hypertension MH - Antihypertensive Agents/therapeutic use MH - Heart Atria MH - Risk Factors EDAT- 2022/10/08 06:00 MHDA- 2022/11/04 06:00 CRDT- 2022/10/07 03:12 PHST- 2022/10/08 06:00 [pubmed] PHST- 2022/11/04 06:00 [medline] PHST- 2022/10/07 03:12 [entrez] AID - 00004872-202212000-00002 [pii] AID - 10.1097/HJH.0000000000003278 [doi] PST - ppublish SO - J Hypertens. 2022 Dec 1;40(12):2337-2352. doi: 10.1097/HJH.0000000000003278. Epub 2022 Oct 4. PMID- 36203036 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221202 IS - 1868-310X (Print) IS - 1868-6001 (Electronic) IS - 1868-310X (Linking) VI - 13 IP - 6 DP - 2022 Dec TI - Genetic screening of relatives of decedents experiencing sudden unexpected death: medical examiner's office referrals to a multi-disciplinary cardiogenetics program. PG - 629-639 LID - 10.1007/s12687-022-00611-1 [doi] AB - Currently, no standardized system exists for evaluating and testing at-risk family members of decedents with abnormal post-mortem genetic testing in cases of sudden unexpected death (SUD). The goal of this study was to evaluate the outcomes of referrals made by an urban medical examiner's office to a multi-disciplinary cardiogenetics clinic. Relatives of decedents with pathogenic/likely pathogenic (P/LP) variants or variants of unknown significance (VUS) in genes known to be associated with cardiomyopathies and/or arrhythmias were identified by the New York City Office of Chief Medical Examiner and referred to the Cardiogenetics Clinic at Montefiore Medical Center. Familial referrals of 15 decedents (median 15 years, range 2 days to 57 years) were evaluated. Variants in 13 genes were identified among decedents (9 arrhythmia, 5 cardiomyopathy). P/LP variants were identified in both arrhythmia (RYR2, SCN5A) and cardiomyopathy syndrome (MYBPC3 (2), MYH7) genes. Thirty-two family members were referred, and 14 variants were detected. One pathogenic (MYBPC3) and two likely pathogenic (RYR2, MYH7) mutations were identified. Referral of at-risk family members of decedents who experienced SUD based on informative post-mortem genetic testing for cardiac and genetic evaluation is warranted, as family studies help to reclassify variants and prevent additional sudden death. CI - (c) 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Siskind, Tamar AU - Siskind T AD - Department of Pediatrics, Children's Hospital at Montefiore, Bronx, New York, NY, USA. FAU - Williams, Nori AU - Williams N AD - New York City Office of Chief Medical Examiner, New York, NY, USA. FAU - Sebastin, Monisha AU - Sebastin M AD - Division of Genetics, Children's Hospital at Montefiore, Bronx, New York, NY, USA. FAU - Marion, Robert AU - Marion R AD - Division of Genetics, Children's Hospital at Montefiore, Bronx, New York, NY, USA. AD - Department of Pediatrics, Albert Einstein College of Medicine, Bronx, New York, NY, USA. FAU - McDonald, Thomas V AU - McDonald TV AD - Division of Cardiology, Albert Einstein College of Medicine, Bronx, New York, NY, USA. FAU - Walsh, Christine AU - Walsh C AD - Division of Cardiology, Children's Hospital at Montefiore, Bronx, New York, NY, USA. FAU - Sampson, Barbara AU - Sampson B AD - New York City Office of Chief Medical Examiner, New York, NY, USA. FAU - Tang, Yingying AU - Tang Y AD - New York City Office of Chief Medical Examiner, New York, NY, USA. FAU - Clark, Bradley C AU - Clark BC AD - Department of Pediatrics, Albert Einstein College of Medicine, Bronx, New York, NY, USA. bradleyclarkep@gmail.com. AD - Division of Cardiology, Children's Hospital at Montefiore, Bronx, New York, NY, USA. bradleyclarkep@gmail.com. LA - eng PT - Journal Article DEP - 20221007 PL - Germany TA - J Community Genet JT - Journal of community genetics JID - 101551501 PMC - PMC9681958 OTO - NOTNLM OT - Cardiogenetics OT - Cascade genetic screening OT - Molecular autopsy OT - Sudden cardiac death COIS- The authors declare no competing interests. The authors declare no competing interests. EDAT- 2022/10/07 06:00 MHDA- 2022/10/07 06:01 PMCR- 2022/12/01 CRDT- 2022/10/06 23:36 PHST- 2022/07/07 00:00 [received] PHST- 2022/09/30 00:00 [accepted] PHST- 2022/10/07 06:00 [pubmed] PHST- 2022/10/07 06:01 [medline] PHST- 2022/10/06 23:36 [entrez] PHST- 2022/12/01 00:00 [pmc-release] AID - 10.1007/s12687-022-00611-1 [pii] AID - 611 [pii] AID - 10.1007/s12687-022-00611-1 [doi] PST - ppublish SO - J Community Genet. 2022 Dec;13(6):629-639. doi: 10.1007/s12687-022-00611-1. Epub 2022 Oct 7. PMID- 36202533 OWN - NLM STAT- MEDLINE DCOM- 20221010 LR - 20221026 IS - 1558-3597 (Electronic) IS - 0735-1097 (Linking) VI - 80 IP - 15 DP - 2022 Oct 11 TI - Impediments to Heart Transplantation in Adults With MELAS(MT-TL1:m.3243A>G) Cardiomyopathy. PG - 1431-1443 LID - S0735-1097(22)06530-5 [pii] LID - 10.1016/j.jacc.2022.04.067 [doi] AB - BACKGROUND: The heart is commonly involved in maternally inherited mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome caused by the MT-TL1 m.3243A>G mutation of the mitochondrial DNA. Heart transplantation (HTx) is controversial and has rarely been performed with conflicting results. OBJECTIVES: We analyzed factors preventing HTx in consecutive adult patients with MELAS(MT-TL1:m.3243A>G) cardiomyopathy diagnosed and followed during the last 23 years in our HTx referral center. METHODS: The series consists of 14 unrelated adult probands who were referred for evaluation of cardiomyopathy from 1998 to 2021. None had a suspected diagnosis of MELAS before referral. All patients underwent clinical and genetic visit and counseling, mitochondrial DNA sequencing, cardiovascular investigation (including right heart catheterization and endomyocardial biopsy in 10), multidisciplinary assessment, and biochemical tests. Family screening identified 2 affected relatives. RESULTS: The cardiac phenotype was characterized by hypertrophic, concentric, nonobstructive cardiomyopathy that often evolved into a dilated cardiomyopathy-like phenotype. Of the 14 probands, 7 were potential candidates for HTx, 2 for heart and kidney Tx, and 1 was on the active HTx list for 3 years. None of the 10 probands underwent HTx. One is currently being evaluated for HTx. All had diabetes, hearing loss, and myopathy, and 10 had chronic kidney disease and progressive encephalomyopathy. During follow-up, 10 died from heart failure associated with multiorgan failure within 5 years of the genetic diagnosis. CONCLUSIONS: High risk of stroke-like episodes, chronic kidney disease, and wasting myopathy in MELAS(MT-TL1:m.3243A>G) patients prevents activation of plans for HTx. As a result, the management of their cardiomyopathy in this syndromic context remains an unmet clinical need. CI - Copyright (c) 2022 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. FAU - Di Toro, Alessandro AU - Di Toro A AD - Transplant Research Area and Centre for Inherited Cardiovascular Diseases, Department of Medical Sciences and Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. FAU - Urtis, Mario AU - Urtis M AD - Transplant Research Area and Centre for Inherited Cardiovascular Diseases, Department of Medical Sciences and Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Electrical, Computer and Biomedical Engineering, University of Pavia, Pavia, Italy. FAU - Narula, Nupoor AU - Narula N AD - Transplant Research Area and Centre for Inherited Cardiovascular Diseases, Department of Medical Sciences and Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Division of Cardiology, Department of Medicine, Weill Cornell Medicine, New York, New York, USA. FAU - Giuliani, Lorenzo AU - Giuliani L AD - Transplant Research Area and Centre for Inherited Cardiovascular Diseases, Department of Medical Sciences and Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. FAU - Grasso, Maurizia AU - Grasso M AD - Transplant Research Area and Centre for Inherited Cardiovascular Diseases, Department of Medical Sciences and Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. FAU - Pasotti, Michele AU - Pasotti M AD - Department of Cardiology, Ospedale Civile di Voghera, Voghera, Italy. FAU - Pellegrini, Carlo AU - Pellegrini C AD - Cardiac Surgery Division, Department of Intensive Medicine, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy. FAU - Serio, Alessandra AU - Serio A AD - Transplant Research Area and Centre for Inherited Cardiovascular Diseases, Department of Medical Sciences and Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. FAU - Pilotto, Andrea AU - Pilotto A AD - Transplant Research Area and Centre for Inherited Cardiovascular Diseases, Department of Medical Sciences and Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. FAU - Antoniazzi, Elena AU - Antoniazzi E AD - Ophthalmology Division, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. FAU - Rampino, Teresa AU - Rampino T AD - Unit of Nephrology, Dialysis and Transplantation, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. FAU - Magrassi, Lorenzo AU - Magrassi L AD - Neurosurgery Division, Department of Clinical Surgical Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy. FAU - Valentini, Adele AU - Valentini A AD - Radiology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. FAU - Cavallini, Anna AU - Cavallini A AD - Stroke Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. FAU - Scelsi, Laura AU - Scelsi L AD - Division of Cardiology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. FAU - Ghio, Stefano AU - Ghio S AD - Division of Cardiology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. FAU - Abelli, Massimo AU - Abelli M AD - Renal Transplantation Division, Department of Surgery, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. FAU - Olivotto, Iacopo AU - Olivotto I AD - Cardiomyopathy Unit, University of Florence, Florence, Italy. FAU - Porcu, Maurizio AU - Porcu M AD - Cardiology Service, Mater Olbia Hospital, Olbia, Italy. FAU - Gavazzi, Antonello AU - Gavazzi A AD - FROM Research Foundation, Bergamo, Italy. FAU - Kodama, Takahide AU - Kodama T AD - Department of Cardiovascular Center, Toranomon Hospital, Tokyo, Japan. FAU - Arbustini, Eloisa AU - Arbustini E AD - Transplant Research Area and Centre for Inherited Cardiovascular Diseases, Department of Medical Sciences and Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. Electronic address: e.arbustini@smatteo.pv.it. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - J Am Coll Cardiol JT - Journal of the American College of Cardiology JID - 8301365 RN - 0 (DNA, Mitochondrial) SB - IM CIN - J Am Coll Cardiol. 2022 Oct 11;80(15):1444-1446. doi: 10.1016/j.jacc.2022.08.719. PMID: 36202534 MH - *Cardiomyopathies/complications/genetics/surgery MH - DNA, Mitochondrial/genetics MH - *Heart Transplantation MH - Humans MH - *MELAS Syndrome/diagnosis/genetics/pathology MH - *Muscular Diseases MH - Mutation MH - *Renal Insufficiency, Chronic/complications OTO - NOTNLM OT - MELAS OT - MT-TL1:m.3243A>G OT - heart transplantation OT - mitochondrial cardiomyopathy COIS- Funding Support and Author Disclosures The study was supported by continuous funds on cardiomyopathies and heart transplantation from the Ministry of Health to the IRCCS Foundation Policlinico San Matteo by project numbers 888-rcr2017i-71 and RCR-2019-23669116_001 CV-PREVITAL (Genetic Section). The authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2022/10/07 06:00 MHDA- 2022/10/12 06:00 CRDT- 2022/10/06 21:05 PHST- 2022/02/23 00:00 [received] PHST- 2022/04/12 00:00 [revised] PHST- 2022/04/19 00:00 [accepted] PHST- 2022/10/06 21:05 [entrez] PHST- 2022/10/07 06:00 [pubmed] PHST- 2022/10/12 06:00 [medline] AID - S0735-1097(22)06530-5 [pii] AID - 10.1016/j.jacc.2022.04.067 [doi] PST - ppublish SO - J Am Coll Cardiol. 2022 Oct 11;80(15):1431-1443. doi: 10.1016/j.jacc.2022.04.067. PMID- 36200768 OWN - NLM STAT- MEDLINE DCOM- 20221205 LR - 20260127 IS - 1529-7535 (Print) IS - 1529-7535 (Linking) VI - 23 IP - 12 DP - 2022 Dec 1 TI - Routine Perioperative Esmolol After Infant Tetralogy of Fallot Repair: Single-Center Retrospective Study of Hemodynamics. PG - e583-e589 LID - 10.1097/PCC.0000000000003088 [doi] AB - OBJECTIVES: Currently, surgical repair of tetralogy of Fallot (TOF) is associated with an 1.1% 30-day mortality rate. Those with junctional ectopic tachycardia (JET) and restrictive right ventricular physiology have poorer outcomes. Routine postoperative adrenergic or inodilator therapy has been reported, while beta-blockade following cardiopulmonary bypass has not. This study evaluated routine perioperative treatment with esmolol in infants undergoing TOF repair. DESIGN: Retrospective chart review of the perioperative course following TOF repair. SETTING: Single-center case series describing perioperative management of TOF in a cardiac ICU. PATIENTS: This study reviewed all patients less than 18 months old who underwent TOF repair, excluding cases of TOF with absent pulmonary valve or atrioventricular septal defect, at our institution from June 2018 to April 2021. INTERVENTIONS: This review investigates the hemodynamic effects of esmolol following cardiopulmonary bypass for TOF repair. MEASUREMENTS AND MAIN RESULTS: Preoperative clinical characteristics and perioperative course were extracted from the medical record. Descriptive statistics were used. Twenty-six patients receiving perioperative esmolol after TOF repair were identified and included. Postoperative hemodynamic parameters were within a narrow range with minimal vasoactive support in most patients. Three of 26 patients experienced JET, and one of 26 of whom had a brief cardiac arrest. Median and interquartile range (IQR) for hospital and postoperative length of stay was 7 days (IQR, 6-9 d) and 6 days (IQR, 5-8 d), respectively. There were no 30-day or 1-year mortalities. CONCLUSIONS: In this infant cohort, our experience is that the routine use of postoperative esmolol is associated with good cardiac output with minimal requirement for vasoactive support in most patients. We believe optimal postoperative management of infant TOF repair requires a meticulous multidisciplinary approach, which in our experience is enhanced with routine postoperative esmolol treatment. CI - Copyright (c) 2022 by the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies. FAU - Affolter, Jeremy T AU - Affolter JT AD - Texas Center for Pediatric and Congenital Heart Disease, UT Health Austin and Dell Children's Medical Center, Austin, TX. AD - Department of Pediatrics, University of Texas at Austin Dell Medical School, Austin, TX. FAU - Well, Andrew AU - Well A AD - Texas Center for Pediatric and Congenital Heart Disease, UT Health Austin and Dell Children's Medical Center, Austin, TX. AD - Department of Surgery and Perioperative Care, University of Texas at Austin Dell Medical School, Austin, TX. FAU - Gottlieb, Erin A AU - Gottlieb EA AD - Texas Center for Pediatric and Congenital Heart Disease, UT Health Austin and Dell Children's Medical Center, Austin, TX. AD - Department of Surgery and Perioperative Care, University of Texas at Austin Dell Medical School, Austin, TX. FAU - Fraser, Charles D Jr AU - Fraser CD Jr AD - Texas Center for Pediatric and Congenital Heart Disease, UT Health Austin and Dell Children's Medical Center, Austin, TX. AD - Department of Surgery and Perioperative Care, University of Texas at Austin Dell Medical School, Austin, TX. LA - eng PT - Journal Article PT - Review DEP - 20221005 PL - United States TA - Pediatr Crit Care Med JT - Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies JID - 100954653 RN - MDY902UXSR (esmolol) RN - 0 (Propanolamines) SB - IM MH - Infant MH - Humans MH - *Tetralogy of Fallot/surgery MH - Retrospective Studies MH - *Cardiac Surgical Procedures MH - *Tachycardia, Ectopic Junctional MH - Hemodynamics MH - Treatment Outcome MH - Propanolamines COIS- The authors have disclosed that they do not have any potential conflicts of interest. EDAT- 2022/10/07 06:00 MHDA- 2022/12/06 06:00 CRDT- 2022/10/06 09:04 PHST- 2022/10/07 06:00 [pubmed] PHST- 2022/12/06 06:00 [medline] PHST- 2022/10/06 09:04 [entrez] AID - 00130478-202212000-00022 [pii] AID - 10.1097/PCC.0000000000003088 [doi] PST - ppublish SO - Pediatr Crit Care Med. 2022 Dec 1;23(12):e583-e589. doi: 10.1097/PCC.0000000000003088. Epub 2022 Oct 5. PMID- 36199124 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221009 IS - 1745-6215 (Electronic) IS - 1745-6215 (Linking) VI - 23 IP - 1 DP - 2022 Oct 5 TI - Correction: Interdisciplinary and cross-sectoral perioperative care model in cardiac surgery: implementation in the setting of minimally invasive heart valve surgery (INCREASE)-study protocol for a randomized controlled trial. PG - 853 LID - 10.1186/s13063-022-06813-9 [doi] LID - 853 FAU - Klotz, Susanne G R AU - Klotz SGR AD - Department of Physiotherapy, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany. FAU - Ketels, Gesche AU - Ketels G AD - Department of Physiotherapy, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany. FAU - Behrendt, Christian A AU - Behrendt CA AD - Research Group GermanVasc, Department of Vascular Medicine, University Heart and Vascular Center, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany. FAU - Konig, Hans-Helmut AU - Konig HH AD - Department of Health Economics and Health Services Research, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany. FAU - Kohlmann, Sebastian AU - Kohlmann S AD - Department of Psychosomatic Medicine and Psychotherapy, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany. FAU - Lowe, Bernd AU - Lowe B AD - Department of Psychosomatic Medicine and Psychotherapy, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany. FAU - Petersen, Johannes AU - Petersen J AD - Department of Cardiovascular Surgery, University Heart and Vascular Center, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany. FAU - Stock, Sina AU - Stock S AD - Department of Cardiothoracic Surgery, University Hospital Augsburg, Stenglinstr. 2, 86156, Augsburg, Germany. FAU - Vettorazzi, Eik AU - Vettorazzi E AD - Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany. FAU - Zapf, Antonia AU - Zapf A AD - Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany. FAU - Zastrow, Inke AU - Zastrow I AD - Department of Patient and Care Management, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany. FAU - Zollner, Christian AU - Zollner C AD - Department of Anesthesiology, Center of Anesthesiology and Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany. FAU - Reichenspurner, Hermann AU - Reichenspurner H AD - Department of Cardiovascular Surgery, University Heart and Vascular Center, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany. FAU - Girdauskas, Evaldas AU - Girdauskas E AD - Department of Cardiothoracic Surgery, University Hospital Augsburg, Stenglinstr. 2, 86156, Augsburg, Germany. evaldas.girdauskas@uk-augsburg.de. LA - eng PT - Published Erratum DEP - 20221005 PL - England TA - Trials JT - Trials JID - 101263253 SB - IM EFR - Trials. 2022 Jun 23;23(1):528. doi: 10.1186/s13063-022-06455-x. PMID: 35739541 PMC - PMC9535991 EDAT- 2022/10/06 06:00 MHDA- 2022/10/06 06:01 PMCR- 2022/10/05 CRDT- 2022/10/05 23:44 PHST- 2022/10/05 23:44 [entrez] PHST- 2022/10/06 06:00 [pubmed] PHST- 2022/10/06 06:01 [medline] PHST- 2022/10/05 00:00 [pmc-release] AID - 10.1186/s13063-022-06813-9 [pii] AID - 6813 [pii] AID - 10.1186/s13063-022-06813-9 [doi] PST - epublish SO - Trials. 2022 Oct 5;23(1):853. doi: 10.1186/s13063-022-06813-9. PMID- 36197184 OWN - NLM STAT- MEDLINE DCOM- 20221007 LR - 20221011 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 101 IP - 38 DP - 2022 Sep 23 TI - Correlation between diminished vagal tone and somatic dysfunction severity in very and extremely low birth weight preterm infants assessed with frequency spectrum heart rate variability and salivary cortisol. PG - e30565 LID - 10.1097/MD.0000000000030565 [doi] LID - e30565 AB - Osteopathic manipulative treatment (OMT) is evolving in the neonatal intensive care unit (NICU) setting. Studies showed its efficacy in length of stay and hospitalization costs reduction. Moreover, it was suggested that OMT has a modulatory effect on the preterm infants' autonomic nervous system (ANS), influencing saturation and heart rate. Even if OMT is based on the palpatory examination of the somatic dysfunctions (SD), there are controversies about its identification and clinical relevance. The objective of this study was to evaluate the inter-rater reliability, clinical characteristics, and functional correlation of the SD Grade score with the heart rate variability (HRV) and the salivary cortisol (sCor) using a multivariate linear model approach. To evaluate those features, we implemented an ad hoc SD examination for preterm infants that was performed by 2 trained osteopaths. It was based on the new variability model of SD that includes an SD Grade assessment procedure. The ANS features were assessed by frequency parameters of HRV studying high frequency (HF), low frequency (LF), and HF/LF, whereas sCor was tested with a radioimmunoassay. The ANS assessment was standardized and performed before SD testing. Sixty-nine premature infants were eligible. SD Grade showed excellent concordance between the blinded raters. Using SD Grade as a grouping variable, the infants presented differences in GA, Apgar, pathological findings, length of stay, and ventilatory assistance. In our multivariate model, HF, LF, and LF/HF resulted linearly correlated with SD Grade. Instead, sCor presented a linear correlation with 5' Apgar and respiratory distress syndrome but not with SD Grade. SD Grade was in line with the natural history of the underdevelopment due to prematurity. Our models indicate that the cardiac vagal tone is linearly related with SD Grade. This finding may improve the multidisciplinary decision making inside NICU and the management of modifiable factors, like SD, for cardiac vagal tone regulation. CI - Copyright (c) 2022 the Author(s). Published by Wolters Kluwer Health, Inc. FAU - Vismara, Luca AU - Vismara L AUID- ORCID: 0000-0001-9034-7101 AD - Division of Neurology and Neurorehabilitation, IRCCS Istituto Auxologico Italiano, Piancavallo-Verbania, Italy. AD - Department of Neurosciences, University of Torino, Torino, Italy. AD - Division of Paediatric, Manima Non-Profit Organization Social Assistance and Healthcare, Milan, Italy. FAU - Gianmaria Tarantino, Andrea AU - Gianmaria Tarantino A AD - Division of Paediatric, Manima Non-Profit Organization Social Assistance and Healthcare, Milan, Italy. AD - Department of Research, SOMA - Istituto Osteopatia Milano, Milan, Italy. FAU - Bergna, Andrea AU - Bergna A AD - Department of Research, SOMA - Istituto Osteopatia Milano, Milan, Italy. FAU - Bianchi, Giuliana AU - Bianchi G AD - Neonatal Intensive Care Unit, Woman and Child Department, Del Ponte Hospital, Varese, Italy. FAU - Bragalini, Cristina AU - Bragalini C AD - Division of Paediatric, Manima Non-Profit Organization Social Assistance and Healthcare, Milan, Italy. FAU - Billo, Elisa AU - Billo E AD - Division of Paediatric, Manima Non-Profit Organization Social Assistance and Healthcare, Milan, Italy. FAU - Dal Farra, Fulvio AU - Dal Farra F AD - Department of Research, SOMA - Istituto Osteopatia Milano, Milan, Italy. FAU - Buffone, Francesca AU - Buffone F AD - Division of Paediatric, Manima Non-Profit Organization Social Assistance and Healthcare, Milan, Italy. AD - Department of Research, SOMA - Istituto Osteopatia Milano, Milan, Italy. AD - PPCR, Harvard T.H. Chan School of Public Health - ECPE, Boston, MA, USA. FAU - Agosti, Massimo AU - Agosti M AD - Neonatal Intensive Care Unit, Woman and Child Department, Del Ponte Hospital, Varese, Italy. LA - eng PT - Journal Article PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R RN - WI4X0X7BPJ (Hydrocortisone) SB - IM MH - Heart Rate/physiology MH - Humans MH - *Hydrocortisone MH - Infant MH - Infant, Extremely Low Birth Weight MH - Infant, Newborn MH - *Infant, Premature/physiology MH - Reproducibility of Results PMC - PMC9509086 COIS- The authors have no funding and conflicts of interest to disclose. EDAT- 2022/10/06 06:00 MHDA- 2022/10/12 06:00 PMCR- 2022/09/23 CRDT- 2022/10/05 10:01 PHST- 2022/10/05 10:01 [entrez] PHST- 2022/10/06 06:00 [pubmed] PHST- 2022/10/12 06:00 [medline] PHST- 2022/09/23 00:00 [pmc-release] AID - 00005792-202209230-00030 [pii] AID - 10.1097/MD.0000000000030565 [doi] PST - ppublish SO - Medicine (Baltimore). 2022 Sep 23;101(38):e30565. doi: 10.1097/MD.0000000000030565. PMID- 36194025 OWN - NLM STAT- MEDLINE DCOM- 20221205 LR - 20230420 IS - 1529-7535 (Print) IS - 1529-7535 (Linking) VI - 23 IP - 12 DP - 2022 Dec 1 TI - Bereaved Caregiver Perspectives on the End of Life in Pediatric Patients With Ventricular Assist Devices. PG - e601-e606 LID - 10.1097/PCC.0000000000003089 [doi] AB - OBJECTIVES: Ventricular assist devices (VADs) are increasingly used in pediatric heart failure as bridges to heart transplantation, although 25% will die with VADs. Family experiences in this population are not well-described. The objective is to understand bereaved families' perspectives on VAD and end-of-life decision-making. DESIGN: Semistructured interviews with bereaved caregivers of pediatric VAD patients. SETTING: Tertiary children's hospital. PATIENTS: Families of six pediatric VAD patients who died from 2014 to 2020. INTERVENTIONS: Not available. MEASUREMENTS AND MAIN RESULTS: Applying a grounded theory framework, interviews were coded by two independent readers using qualitative software. Themes were discussed in iterative multidisciplinary meetings. Participants were interviewed at a median 2.4 years after their child died. Three major themes emerged: 1) "lack of regret" for VAD implantation despite the outcome; 2) "caregiver-child accord" (via patient's verbal assent or physical cues) at implantation and end-of-life was important in family decision-making; and 3) development of a "local surrogate family" (medical team and peer families) provided powerful support. CONCLUSIONS: Bereaved families' perspectives provide insight into quality decision-making for major interventions and end-of-life care in pediatric patients with chronic illness who face decisions regarding technology dependence. CI - Copyright (c) 2022 by the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies. FAU - Bui, Christine M AU - Bui CM AD - Department of Pediatrics, Division of Cardiology, Stanford University, Palo Alto, CA. FAU - Schneider, Lauren M AU - Schneider LM AD - Department of Psychiatry, Division of Child Psychiatry, Stanford University, Palo Alto, CA. FAU - Brown, Michelle R AU - Brown MR AD - Department of Psychiatry, Division of Child Psychiatry, Stanford University, Palo Alto, CA. FAU - Char, Danton S AU - Char DS AD - Department of Pediatrics, Division of Cardiology, Stanford University, Palo Alto, CA. AD - Department of Anesthesiology, Stanford University, Palo Alto, CA. FAU - McIlvennan, Colleen K AU - McIlvennan CK AD - Department of Medicine, Division of Cardiology, University of Colorado, Denver, CO. FAU - Hollander, Seth A AU - Hollander SA AD - Department of Pediatrics, Division of Cardiology, Stanford University, Palo Alto, CA. LA - eng PT - Journal Article DEP - 20221004 PL - United States TA - Pediatr Crit Care Med JT - Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies JID - 100954653 SB - IM MH - Child MH - Humans MH - *Heart-Assist Devices MH - Caregivers MH - *Terminal Care MH - *Heart Failure/surgery MH - Death COIS- Dr. Bui received funding from the Maggie Adalyn Otto Pediatric Palliative Fellowship. Dr. Schneider's institution received funding from the Maggie Adalyn Otto Pediatric Palliative Fellowship. The remaining authors have disclosed that they do not have any potential conflicts of interest. EDAT- 2022/10/05 06:00 MHDA- 2022/12/06 06:00 CRDT- 2022/10/04 09:04 PHST- 2022/10/05 06:00 [pubmed] PHST- 2022/12/06 06:00 [medline] PHST- 2022/10/04 09:04 [entrez] AID - 00130478-202212000-00025 [pii] AID - 10.1097/PCC.0000000000003089 [doi] PST - ppublish SO - Pediatr Crit Care Med. 2022 Dec 1;23(12):e601-e606. doi: 10.1097/PCC.0000000000003089. Epub 2022 Oct 4. PMID- 36192311 OWN - NLM STAT- MEDLINE DCOM- 20221205 LR - 20221229 IS - 1938-131X (Electronic) IS - 1553-7250 (Linking) VI - 48 IP - 12 DP - 2022 Dec TI - Intraoperative Code Blue: Improving Teamwork and Code Response Through Interprofessional, In Situ Simulation. PG - 665-673 LID - S1553-7250(22)00190-8 [pii] LID - 10.1016/j.jcjq.2022.08.011 [doi] AB - INTRODUCTION: An intraoperative cardiac arrest requires perioperative teams to be equipped with the technical skills, nontechnical skills, and confidence to provide the best resuscitative measures for the patient. In situ simulation (simulation conducted in health professionals' work environment, such as a patient care unit, and not in an off-site location) has the potential to improve team performance. The research team assessed the effects of in situ simulation on code response, teamwork, communication, and comfort in intraoperative resuscitations. METHODS: This study included seven interprofessional teams consisting of RNs, anesthesiologists, surgical technologists, and patient care technicians working in the operating room of a community hospital in New Jersey. The hour-long interdisciplinary simulation training sessions consisted of a code blue scenario run twice; both times video recorded, retrospectively reviewed, and compared to each other. Technical skills were measured by "time-to-tasks"; nontechnical skills were assessed using the Team Emergency Assessment Measure (TEAM) instrument. Self-reported comfort in skills was collected before the simulation program and after completion of the training. RESULTS: A total of 21 perioperative nurses, 7 anesthesiologists, 7 surgical technologists, and 4 patient care technicians participated from January to April 2021. There was a significant (p < 0.05) decrease in time to compressions (by 14 seconds, 53.5% improvement) and in time to defibrillation (by 49 seconds) between the two simulations. Significant improvements were noted in confidence levels of certain CPR-related technical skills. There were statistically significant improvements in TEAM scores in the two teams that performed lowest in the pre-debrief simulation (p < 0.05). CONCLUSION: In the operative setting, where time and space for training are limited, in situ simulation training was associated with improvement in technical skills of individuals and teams, with significantly improved teamwork in teams that required the most training. The long-term effects of such training and its effects on patient outcomes require additional research. CI - Copyright (c) 2022 The Joint Commission. Published by Elsevier Inc. All rights reserved. FAU - Wu, Gregory AU - Wu G FAU - Podlinski, Lori AU - Podlinski L FAU - Wang, Cedar AU - Wang C FAU - Dunn, Debra AU - Dunn D FAU - Buldo, Deborah AU - Buldo D FAU - Mazza, Benedict AU - Mazza B FAU - Fox, James AU - Fox J FAU - Kostelnik, Matthew AU - Kostelnik M FAU - Defenza, Giuseppe AU - Defenza G LA - eng PT - Journal Article DEP - 20220905 PL - Netherlands TA - Jt Comm J Qual Patient Saf JT - Joint Commission journal on quality and patient safety JID - 101238023 SB - IM MH - Humans MH - Patient Care Team MH - Retrospective Studies MH - *Simulation Training MH - *Cardiopulmonary Resuscitation MH - Operating Rooms EDAT- 2022/10/04 06:00 MHDA- 2022/12/06 06:00 CRDT- 2022/10/03 22:07 PHST- 2022/03/26 00:00 [received] PHST- 2022/08/28 00:00 [revised] PHST- 2022/08/30 00:00 [accepted] PHST- 2022/10/04 06:00 [pubmed] PHST- 2022/12/06 06:00 [medline] PHST- 2022/10/03 22:07 [entrez] AID - S1553-7250(22)00190-8 [pii] AID - 10.1016/j.jcjq.2022.08.011 [doi] PST - ppublish SO - Jt Comm J Qual Patient Saf. 2022 Dec;48(12):665-673. doi: 10.1016/j.jcjq.2022.08.011. Epub 2022 Sep 5. PMID- 36191325 OWN - NLM STAT- MEDLINE DCOM- 20221005 LR - 20221005 IS - 2327-6924 (Electronic) IS - 2327-6886 (Linking) VI - 34 IP - 10 DP - 2022 Oct 1 TI - Health care utilization in a nurse practitioner-led atrial fibrillation clinic. PG - 1139-1148 LID - 10.1097/JXX.0000000000000779 [doi] AB - BACKGROUND: Atrial fibrillation (AF) is the most common cardiac arrhythmia and is emerging in prevalence with an increasingly aging population. The complex nature of the disease and its association with significant morbidity and mortality has resulted in a call for a new integrative, multidisciplinary approach to AF management. PURPOSE: Determine if the use of a nurse practitioner (NP)-led AF clinic (NPAFC) can improve care for patients. METHODOLOGY: An NPAFC was designed to serve as an independent clinic for standardizing patient care and improving access to care. Baseline patient demographics, care pathway, and interventions were characterized in clinic. Primary outcomes were hospitalizations and emergency department (ER) visits, before and after clinic implementation. RESULTS: Overall, 1,442 patients were enrolled in the AF clinic between January 2016 and June 2018. The mean age at the first AF clinic visit was 68.7 +/- 12.6 years, 54% were male, and the mean body mass index was 31 +/- 7 kg/m2. Among the patients, 45.2% had paroxysmal AF, 43.6% persistent AF, and 5.5% permanent AF. With an average of 3 +/- 3 clinic visits per patient, the number of patients with >/=1 hospitalization decreased by 78% after clinic implementation. Similarly, the number of patients with >/=1 ER visit decreased by 79%, and 22.7% of patients avoided at least one ER visit. CONCLUSIONS: The number of patients with >/=1 hospitalization or >/=1ER visit decreased within two years after the implementation of an NPAFC. IMPLICATIONS: Implementation of an NP-led AF clinic in the United States may reduce hospitalizations and ER visits if implemented in an integrative model. CI - Copyright (c) 2022 American Association of Nurse Practitioners. FAU - Meyer, David B AU - Meyer DB AD - East Carolina University Brody School of Medicine, Department of Internal Medicine, Greenville, NC. FAU - Larkins, Michael C AU - Larkins MC AD - East Carolina University Brody School of Medicine, Department of Internal Medicine, Greenville, NC. FAU - Taha, Omar AU - Taha O AD - East Carolina University Brody School of Medicine, Department of Internal Medicine, Greenville, NC. FAU - Seiler, Amber AU - Seiler A AD - Cone Health, LeBauer Research Foundation, Cone Health, LeBauer Research Foundation, Department of Cardiovascular Research, Greensboro, NC. FAU - Booth, Sheryl AU - Booth S AD - Cone Health, LeBauer Research Foundation, Cone Health, LeBauer Research Foundation, Department of Cardiovascular Research, Greensboro, NC. FAU - Hokanson, Robert B AU - Hokanson RB AD - Medtronic, Inc, Minneapolis, MN. FAU - Allred, James AU - Allred J AD - Cone Health, LeBauer Research Foundation, Cone Health, LeBauer Research Foundation, Department of Cardiovascular Research, Greensboro, NC. LA - eng PT - Journal Article DEP - 20221001 PL - United States TA - J Am Assoc Nurse Pract JT - Journal of the American Association of Nurse Practitioners JID - 101600770 MH - Aged MH - *Atrial Fibrillation/therapy MH - Emergency Service, Hospital MH - Female MH - Hospitalization MH - Humans MH - Male MH - *Nurse Practitioners MH - Patient Acceptance of Health Care MH - United States EDAT- 2022/10/04 06:00 MHDA- 2022/10/06 06:00 CRDT- 2022/10/03 17:04 PHST- 2022/05/23 00:00 [received] PHST- 2022/08/09 00:00 [accepted] PHST- 2022/10/03 17:04 [entrez] PHST- 2022/10/04 06:00 [pubmed] PHST- 2022/10/06 06:00 [medline] AID - 01741002-202210000-00006 [pii] AID - 10.1097/JXX.0000000000000779 [doi] PST - epublish SO - J Am Assoc Nurse Pract. 2022 Oct 1;34(10):1139-1148. doi: 10.1097/JXX.0000000000000779. PMID- 36190861 OWN - NLM STAT- MEDLINE DCOM- 20221005 LR - 20221005 IS - 1527-1323 (Electronic) IS - 0271-5333 (Linking) VI - 42 IP - 6 DP - 2022 Oct TI - Contemporary Management of Acute Pulmonary Embolism: Evolution of Catheter-based Therapy. PG - 1861-1880 LID - 10.1148/rg.220026 [doi] AB - Acute pulmonary embolism (PE) affects more than 100 000 people in the United States annually and is the third leading cardiovascular cause of death. The standard management for PE is systemic anticoagulation therapy. However, a subset of patients experience hemodynamic decompensation, despite conservative measures. Traditionally, these patients have been treated with systemic administration of thrombolytic agents or open cardiac surgery, although attempts at endovascular treatment have a long history that dates back to the 1960s. The technology for catheter-based therapy for acute PE is rapidly evolving, with multiple devices approved over the past decade. Currently available devices fall into two broad categories of treatment methods: catheter-directed thrombolysis and percutaneous suction thrombectomy. Catheter-directed thrombolysis is the infusion of thrombolytic agents directly into the occluded pulmonary arteries to increase local delivery and decrease the total dose. Suction thrombectomy involves the use of small- or large-bore catheters to mechanically aspirate a clot from the pulmonary arteries without the need for a thrombolytic agent. A thorough understanding of the various risk stratification schemes and the available evidence for each device is critical for optimal treatment of this complex entity. Multiple ongoing studies will improve our understanding of the role of catheter-based therapy for acute PE in the next 5-10 years. A multidisciplinary approach through PE response teams has become the management standard at most institutions. An invited commentary by Bulman and Weinstein is available online. Online supplemental material is available for this article. ((c))RSNA, 2022. FAU - Carlon, Timothy A AU - Carlon TA AUID- ORCID: 0000-0001-5591-8482 AD - From the Department of Diagnostic, Molecular, and Interventional Radiology (T.A.C., D.T.G., B.S.M., R.A.K., J.M.W., R.S.P., V.L.B., R.A.L.) and Department of Anesthesiology (S.D.L.), Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1234, New York, NY 10029. FAU - Goldman, Daryl T AU - Goldman DT AD - From the Department of Diagnostic, Molecular, and Interventional Radiology (T.A.C., D.T.G., B.S.M., R.A.K., J.M.W., R.S.P., V.L.B., R.A.L.) and Department of Anesthesiology (S.D.L.), Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1234, New York, NY 10029. FAU - Marinelli, Brett S AU - Marinelli BS AD - From the Department of Diagnostic, Molecular, and Interventional Radiology (T.A.C., D.T.G., B.S.M., R.A.K., J.M.W., R.S.P., V.L.B., R.A.L.) and Department of Anesthesiology (S.D.L.), Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1234, New York, NY 10029. FAU - Korff, Ricki A AU - Korff RA AD - From the Department of Diagnostic, Molecular, and Interventional Radiology (T.A.C., D.T.G., B.S.M., R.A.K., J.M.W., R.S.P., V.L.B., R.A.L.) and Department of Anesthesiology (S.D.L.), Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1234, New York, NY 10029. FAU - Watchmaker, Jennifer M AU - Watchmaker JM AD - From the Department of Diagnostic, Molecular, and Interventional Radiology (T.A.C., D.T.G., B.S.M., R.A.K., J.M.W., R.S.P., V.L.B., R.A.L.) and Department of Anesthesiology (S.D.L.), Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1234, New York, NY 10029. FAU - Patel, Rahul S AU - Patel RS AD - From the Department of Diagnostic, Molecular, and Interventional Radiology (T.A.C., D.T.G., B.S.M., R.A.K., J.M.W., R.S.P., V.L.B., R.A.L.) and Department of Anesthesiology (S.D.L.), Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1234, New York, NY 10029. FAU - Lipson, Scott D AU - Lipson SD AUID- ORCID: 0000-0003-0196-7814 AD - From the Department of Diagnostic, Molecular, and Interventional Radiology (T.A.C., D.T.G., B.S.M., R.A.K., J.M.W., R.S.P., V.L.B., R.A.L.) and Department of Anesthesiology (S.D.L.), Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1234, New York, NY 10029. FAU - Bishay, Vivian L AU - Bishay VL AD - From the Department of Diagnostic, Molecular, and Interventional Radiology (T.A.C., D.T.G., B.S.M., R.A.K., J.M.W., R.S.P., V.L.B., R.A.L.) and Department of Anesthesiology (S.D.L.), Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1234, New York, NY 10029. FAU - Lookstein, Robert A AU - Lookstein RA AD - From the Department of Diagnostic, Molecular, and Interventional Radiology (T.A.C., D.T.G., B.S.M., R.A.K., J.M.W., R.S.P., V.L.B., R.A.L.) and Department of Anesthesiology (S.D.L.), Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1234, New York, NY 10029. LA - eng PT - Journal Article PL - United States TA - Radiographics JT - Radiographics : a review publication of the Radiological Society of North America, Inc JID - 8302501 RN - 0 (Anticoagulants) RN - 0 (Fibrinolytic Agents) SB - IM CIN - Radiographics. 2022 Oct;42(6):E186-E187. doi: 10.1148/rg.220174. PMID: 36190875 MH - Acute Disease MH - Anticoagulants MH - Catheters MH - *Fibrinolytic Agents MH - Humans MH - *Pulmonary Embolism/diagnostic imaging/therapy MH - Thrombolytic Therapy MH - Treatment Outcome MH - United States EDAT- 2022/10/04 06:00 MHDA- 2022/10/06 06:00 CRDT- 2022/10/03 13:03 PHST- 2022/10/03 13:03 [entrez] PHST- 2022/10/04 06:00 [pubmed] PHST- 2022/10/06 06:00 [medline] AID - 10.1148/rg.220026 [doi] PST - ppublish SO - Radiographics. 2022 Oct;42(6):1861-1880. doi: 10.1148/rg.220026. PMID- 36187899 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221209 IS - 1523-3847 (Print) IS - 1534-3146 (Electronic) IS - 1523-3847 (Linking) VI - 24 IP - 11 DP - 2022 TI - Nosocomial Extracardiac Infections After Cardiac Surgery. PG - 159-171 LID - 10.1007/s11908-022-00787-0 [doi] AB - PURPOSE OF REVIEW: Nosocomial extracardiac infections after cardiac surgery are a major public health issue affecting 3-8.2% of patients within 30-60 days following the intervention. RECENT FINDINGS: Here, we have considered the most important postoperative infective complications that, in order of frequency, are pneumonia, surgical site infection, urinary tract infection, and bloodstream infection. The overall picture that emerges shows that they cause a greater perioperative morbidity and mortality with a longer hospitalization time and excess costs. Preventive interventions and corrective measures, diminishing the burden of nosocomial extracardiac infections, may reduce the global costs. A multidisciplinary team may assure a more appropriate management of nosocomial extracardiac infections leading to a reduction of hospitalization time and mortality rate. SUMMARY: The main and most current data on epidemiology, prevention, microbiology, diagnosis, and management for each one of the most important postoperative infective complications are reported. The establishment of an antimicrobial stewardship in each hospital seems to be, at the moment, the more valid strategy to counteract the challenging problems. CI - (c) The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022, corrected publication 2022Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. FAU - Zardi, Enrico Maria AU - Zardi EM AUID- ORCID: 0000-0002-2476-1213 AD - Internistic Ultrasound Service, Department of Medicine and Surgery, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo 200, 00128 Rome, Italy. GRID: grid.488514.4. ISNI: 0000000417684285 FAU - Chello, Massimo AU - Chello M AD - Unit of Cardiovascular Surgery, Department of Medicine and Surgery, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo 200, 00128 Rome, Italy. GRID: grid.488514.4. ISNI: 0000000417684285 FAU - Zardi, Domenico Maria AU - Zardi DM AD - Interventional Cardiology Unit, Castelli Hospital (NOC), RM 00040 Ariccia, Italy. FAU - Barbato, Raffaele AU - Barbato R AD - Unit of Cardiovascular Surgery, Department of Medicine and Surgery, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo 200, 00128 Rome, Italy. GRID: grid.488514.4. ISNI: 0000000417684285 FAU - Giacinto, Omar AU - Giacinto O AD - Unit of Cardiovascular Surgery, Department of Medicine and Surgery, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo 200, 00128 Rome, Italy. GRID: grid.488514.4. ISNI: 0000000417684285 FAU - Mastroianni, Ciro AU - Mastroianni C AD - Unit of Cardiovascular Surgery, Department of Medicine and Surgery, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo 200, 00128 Rome, Italy. GRID: grid.488514.4. ISNI: 0000000417684285 FAU - Lusini, Mario AU - Lusini M AD - Unit of Cardiovascular Surgery, Department of Medicine and Surgery, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo 200, 00128 Rome, Italy. GRID: grid.488514.4. ISNI: 0000000417684285 LA - eng PT - Journal Article PT - Review DEP - 20220924 PL - United States TA - Curr Infect Dis Rep JT - Current infectious disease reports JID - 100888983 PMC - PMC9510267 OTO - NOTNLM OT - Cardiac surgery OT - Epidemiology OT - Nosocomial complications OT - Postsurgical infections OT - Stewardship OT - Treatment COIS- Conflict of InterestEnrico M Zardi, Massimo Chello, Domenico M Zardi, Raffaele Barbato, Omar Giacinto, Ciro Mastroianni, and Mario Lusini declare that they have no conflict of interest. EDAT- 2022/10/04 06:00 MHDA- 2022/10/04 06:01 PMCR- 2022/09/26 CRDT- 2022/10/03 04:59 PHST- 2022/08/02 00:00 [accepted] PHST- 2022/10/04 06:00 [pubmed] PHST- 2022/10/04 06:01 [medline] PHST- 2022/10/03 04:59 [entrez] PHST- 2022/09/26 00:00 [pmc-release] AID - 787 [pii] AID - 10.1007/s11908-022-00787-0 [doi] PST - ppublish SO - Curr Infect Dis Rep. 2022;24(11):159-171. doi: 10.1007/s11908-022-00787-0. Epub 2022 Sep 24. PMID- 36185369 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221003 IS - 2589-0042 (Electronic) IS - 2589-0042 (Linking) VI - 25 IP - 10 DP - 2022 Oct 21 TI - Building an interdisciplinary program of cardiovascular research at the Swiss Federal Institute of Technology- the ETHeart story. PG - 105157 LID - 10.1016/j.isci.2022.105157 [doi] LID - 105157 AB - In this backstory, researchers from Swiss Federal Institute of Technology (ETH Zurich) who initiated an interdisciplinary program to generate innovative solutions for different cardiovascular diseases, such as myocardial infarction, valvular replacement, and movement-based rehabilitation therapy, discuss the benefits and challenges of interdisciplinary research. CI - (c) 2022 The Author(s). FAU - Kourouklis, Andreas P AU - Kourouklis AP AD - Institute for Mechanical Systems, Department of Mechanical and Process Engineering, ETH Zurich, Zurich, Switzerland. FAU - Wu, Xi AU - Wu X AD - Institute for Mechanical Systems, Department of Mechanical and Process Engineering, ETH Zurich, Zurich, Switzerland. FAU - Geyer, Robin C AU - Geyer RC AD - Department of Computer Science, Institute for Machine Learning, ETH Zurich, Zurich, Switzerland. FAU - Exarchos, Vasileios AU - Exarchos V AD - Department of Cardiothoracic and Vascular Surgery, German Heart Center Berlin, Berlin, Germany. FAU - Nazari, Timo AU - Nazari T AD - Department of Cardiothoracic and Vascular Surgery, German Heart Center Berlin, Berlin, Germany. FAU - Kaemmel, Julius AU - Kaemmel J AD - Department of Cardiothoracic and Vascular Surgery, German Heart Center Berlin, Berlin, Germany. FAU - Magkoutas, Konstantinos AU - Magkoutas K AD - Product Development Group Zurich, Material and Fabrication, Department of Mechanical and Process Engineering, ETH Zurich, Zurich, Switzerland. FAU - Daners, Marianne Schmid AU - Daners MS AD - Product Development Group Zurich, Material and Fabrication, Department of Mechanical and Process Engineering, ETH Zurich, Zurich, Switzerland. FAU - Weisskopf, Miriam AU - Weisskopf M AD - Hochschulmedizin Zurich, University of Zurich, Zurich, Switzerland. FAU - Maini, Lucrezia AU - Maini L AD - Micro- and Nanosystems, Department of Mechanical and Process Engineering, ETH Zurich, Zurich, Switzerland. FAU - Roman, Cosmin AU - Roman C AD - Micro- and Nanosystems, Department of Mechanical and Process Engineering, ETH Zurich, Zurich, Switzerland. FAU - Iske, Jasper AU - Iske J AD - Department of Cardiothoracic and Vascular Surgery, German Heart Center Berlin, Berlin, Germany. FAU - Pappas, Georgios A AU - Pappas GA AD - Laboratory of Composite Materials and Adaptive Structures, Department of Mechanical and Process Engineering, ETH Zurich, Zurich, Switzerland. FAU - Chen, Mary Jialu AU - Chen MJ AD - Laboratory of Composite Materials and Adaptive Structures, Department of Mechanical and Process Engineering, ETH Zurich, Zurich, Switzerland. FAU - Smid, Caroline AU - Smid C AD - Laboratory of Composite Materials and Adaptive Structures, Department of Mechanical and Process Engineering, ETH Zurich, Zurich, Switzerland. FAU - Unbehaun, Axel AU - Unbehaun A AD - Department of Cardiothoracic and Vascular Surgery, German Heart Center Berlin, Berlin, Germany. AD - Translational Cardiovascular Technologies, Department of Health Sciences and Technology, ETH Zurich, 8093 Zurich, Switzerland. FAU - Meyer, Alexander AU - Meyer A AD - Department of Cardiothoracic and Vascular Surgery, German Heart Center Berlin, Berlin, Germany. FAU - Emmert, Maximilian AU - Emmert M AD - Department of Cardiothoracic and Vascular Surgery, German Heart Center Berlin, Berlin, Germany. FAU - Ferrari, Aldo AU - Ferrari A AD - Institute for Mechanical Systems, Department of Mechanical and Process Engineering, ETH Zurich, Zurich, Switzerland. AD - EMPA, Swiss Federal Laboratories for Material Science and Technology, Dubendorf, Switzerland. AD - Laboratory of Thermodynamics in Emerging Technologies, Department of Mechanical and Process Engineering, ETH Zurich, Zurich, Switzerland. FAU - Schuett, Corina AU - Schuett C AD - Institute for Mechanical Systems, Department of Mechanical and Process Engineering, ETH Zurich, Zurich, Switzerland. FAU - Poulikakos, Dimos AU - Poulikakos D AD - Laboratory of Thermodynamics in Emerging Technologies, Department of Mechanical and Process Engineering, ETH Zurich, Zurich, Switzerland. FAU - Mazza, Edoardo AU - Mazza E AD - Institute for Mechanical Systems, Department of Mechanical and Process Engineering, ETH Zurich, Zurich, Switzerland. AD - EMPA, Swiss Federal Laboratories for Material Science and Technology, Dubendorf, Switzerland. FAU - Falk, Volkmar AU - Falk V AD - Department of Cardiothoracic and Vascular Surgery, German Heart Center Berlin, Berlin, Germany. AD - Translational Cardiovascular Technologies, Department of Health Sciences and Technology, ETH Zurich, 8093 Zurich, Switzerland. FAU - Cesarovic, Nikola AU - Cesarovic N AD - Department of Cardiothoracic and Vascular Surgery, German Heart Center Berlin, Berlin, Germany. AD - Translational Cardiovascular Technologies, Department of Health Sciences and Technology, ETH Zurich, 8093 Zurich, Switzerland. LA - eng PT - News DEP - 20220927 PL - United States TA - iScience JT - iScience JID - 101724038 PMC - PMC9520014 EDAT- 2022/10/04 06:00 MHDA- 2022/10/04 06:01 PMCR- 2022/09/27 CRDT- 2022/10/03 04:18 PHST- 2022/10/03 04:18 [entrez] PHST- 2022/10/04 06:00 [pubmed] PHST- 2022/10/04 06:01 [medline] PHST- 2022/09/27 00:00 [pmc-release] AID - S2589-0042(22)01429-8 [pii] AID - 105157 [pii] AID - 10.1016/j.isci.2022.105157 [doi] PST - epublish SO - iScience. 2022 Sep 27;25(10):105157. doi: 10.1016/j.isci.2022.105157. eCollection 2022 Oct 21. PMID- 36184546 OWN - NLM STAT- MEDLINE DCOM- 20221004 LR - 20221004 IS - 1349-3299 (Electronic) IS - 1349-2365 (Linking) VI - 63 IP - 5 DP - 2022 TI - Combination Use of Inoue-Balloon and Self-Expandable Transcatheter Valves in Managing Aortic Stenosis Not Amenable to Balloon-Expandable Valves. PG - 843-851 LID - 10.1536/ihj.22-220 [doi] AB - Data on the combined use of aortic Inoue-Balloon catheter and self-expandable transcatheter valve for patients undergoing transcatheter aortic valve replacement (TAVR) are lacking. This study aimed to assess the feasibility and safety of this combination, particularly in patients who cannot be safely managed with balloon-expandable valves.Between 2018 and 2021, 140 consecutive patients who had Inoue-Balloon catheters with self-expandable valves were retrospectively examined. Self-expandable transcatheter valves were deployed using the heart team approach in patients with calcification on the left ventricular outflow tract, which could not be safely addressed with the current-generation balloon-expandable valves.The 20- and 22 mm Inoue-Balloon catheters were used with the 26- and 29 mm Evolut valves, respectively. According to the Valve Academic Research Consortium-2 criteria, the procedural success rate was 95.0%, with an early safety at 30 days rate of 6.5%. A total of 27 patients required post-dilation with the same Inoue-Balloon catheter used for pre-dilation after adjustment to appropriate sizes. Post-dilation, with balloon size adjusted to be 1.4 +/- 0.9 mm larger than that in pre-dilation, was effective in 19 out of 27 patients (70.3%) for decreasing paravalvular leak after transcatheter valve deployment. The procedural complication rates between patients with and without post-dilation were not different.The combined use of the size-adjustable Inoue-Balloon catheter and self-expandable valve is safe, particularly in patients who cannot be safely managed with balloon-expandable valves. However, further studies are warranted to elucidate concerns regarding the durability of self-expandable transcatheter valves after post-dilation using the Inoue-Balloon catheter. FAU - Saji, Mike AU - Saji M AD - Department of Cardiology, Sakakibara Heart Institute. FAU - Highchi, Ryosuke AU - Highchi R AD - Department of Cardiology, Sakakibara Heart Institute. FAU - Iguchi, Nobuo AU - Iguchi N AD - Department of Cardiology, Sakakibara Heart Institute. FAU - Takamisawa, Itaru AU - Takamisawa I AD - Department of Cardiology, Sakakibara Heart Institute. FAU - Shimizu, Jun AU - Shimizu J AD - Department of Anesthesiology, Sakakibara Heart Institute. FAU - Shimokawa, Tomoki AU - Shimokawa T AD - Department of Cardiovascular Surgery, Sakakibara Heart Institute. FAU - Nanasato, Mamoru AU - Nanasato M AD - Department of Cardiology, Sakakibara Heart Institute. FAU - Takayama, Morimasa AU - Takayama M AD - Department of Cardiology, Sakakibara Heart Institute. FAU - Isobe, Mitsuaki AU - Isobe M AD - Sakakibara Heart Institute. LA - eng PT - Journal Article PL - Japan TA - Int Heart J JT - International heart journal JID - 101244240 SB - IM MH - Aortic Valve/surgery MH - *Aortic Valve Stenosis MH - *Heart Valve Prosthesis MH - Humans MH - Prosthesis Design MH - Retrospective Studies MH - *Transcatheter Aortic Valve Replacement/adverse effects MH - Treatment Outcome OTO - NOTNLM OT - Calcified valve OT - Complications OT - Transcatheter aortic valve implantation (TAVI) OT - Transcatheter aortic valve replacement (TAVR) EDAT- 2022/10/03 06:00 MHDA- 2022/10/05 06:00 CRDT- 2022/10/02 22:20 PHST- 2022/10/02 22:20 [entrez] PHST- 2022/10/03 06:00 [pubmed] PHST- 2022/10/05 06:00 [medline] AID - 10.1536/ihj.22-220 [doi] PST - ppublish SO - Int Heart J. 2022;63(5):843-851. doi: 10.1536/ihj.22-220. PMID- 36183703 OWN - NLM STAT- MEDLINE DCOM- 20221109 LR - 20221109 IS - 1473-0804 (Electronic) IS - 1369-7137 (Linking) VI - 25 IP - 6 DP - 2022 Dec TI - An interprofessional clinic for adults with Turner syndrome: the patient perspective. PG - 609-614 LID - 10.1080/13697137.2022.2122428 [doi] AB - OBJECTIVES: This qualitative study assessed the value of a primary care-based interprofessional clinical team for adults with Turner syndrome (TS) utilizing patient perspectives. METHODS: Ten patients within one institution's interprofessional adult TS clinic participated in one of two semi-structured focus groups. Content analysis was used to classify content provided by participants into themes and sub-themes using Dedoose software. RESULTS: Participants found that their quality of care and life were both improved due to the presence of the interprofessional Adults with TS Clinic. Specifically, participants reported that the clinic helped address problems with finding knowledgeable providers and care gaps, made appointments more convenient and improved interprofessional communication. Participants also reported that the clinic helped them find a sense of community and increased personal confidence. Study participants suggested improvements to the clinic by expanding the scope of practice further, simplifying processes to schedule appointments, and potentially creating interprofessional clinics for other rare diseases as well. CONCLUSION: Pursuing avenues to create interprofessional clinics for adults with rare diseases has value from the patient perspective. This value can translate to improved patient outcomes through improvements in patient knowledge of their diagnosis, adherence to evidence-based care and quality of life. FAU - Younger, K AU - Younger K AD - Department of Family Medicine and Community Health, University of Kansas Medical Center, Kansas City, KS, USA. FAU - Malhotra, K AU - Malhotra K AD - Department of Family Medicine and Community Health, Northwestern University, Chicago, IL, USA. FAU - Clark, H D AU - Clark HD AD - Department of Psychology, University of Kansas, Lawrence, KS, USA. FAU - Kelly, K AU - Kelly K AD - Department of Family Medicine and Community Health, University of Kansas Medical Center, Kansas City, KS, USA. LA - eng PT - Journal Article DEP - 20221002 PL - England TA - Climacteric JT - Climacteric : the journal of the International Menopause Society JID - 9810959 SB - IM MH - Adult MH - Humans MH - *Interprofessional Relations MH - Patient Care Team MH - *Turner Syndrome/therapy MH - Rare Diseases MH - Quality of Life OTO - NOTNLM OT - Turner syndrome OT - interprofessional OT - patient perspective OT - qualitative study OT - rare diseases EDAT- 2022/10/03 06:00 MHDA- 2022/11/10 06:00 CRDT- 2022/10/02 19:02 PHST- 2022/10/03 06:00 [pubmed] PHST- 2022/11/10 06:00 [medline] PHST- 2022/10/02 19:02 [entrez] AID - 10.1080/13697137.2022.2122428 [doi] PST - ppublish SO - Climacteric. 2022 Dec;25(6):609-614. doi: 10.1080/13697137.2022.2122428. Epub 2022 Oct 2. PMID- 36181948 OWN - NLM STAT- MEDLINE DCOM- 20221216 LR - 20221221 IS - 1874-1754 (Electronic) IS - 0167-5273 (Linking) VI - 371 DP - 2023 Jan 15 TI - Looking for optimal antithrombotic strategy after transcatheter left atrial appendage occlusion: a real-world comparison of different antiplatelet regimens. PG - 92-99 LID - S0167-5273(22)01416-4 [pii] LID - 10.1016/j.ijcard.2022.09.066 [doi] AB - BACKGROUND: Transcatheter left atrial appendage occlusion (LAAO) has emerged as an effective procedure for the prevention of thromboembolic events in non-valvular atrial fibrillation (AF) patients with contraindications to oral anticoagulation. After the procedure, different antithrombotic regimens have been used, in order to prevent device-related thrombus and trying to minimize bleedings. The search for the optimal antithrombotic strategy is still ongoing. We sought to assess efficacy and safety of different antiplatelet therapy (APT) regimens. METHODS: We enrolled non-randomized consecutive patients who underwent LAAO at the University Hospital of Parma between 2010 and 2021. Three study groups were identified according to post-procedural APT: long (>1, /=65 years (HR, 1.78), congestive heart failure (HR, 1.87), and enterococcus endocarditis (HR, 1.54). The 5-year rate of reoperation was similar between IVDU and non-IVDU groups (2.4% vs 2.7%). CONCLUSIONS: IVDU is a significant risk factor for long-term mortality. A multidisciplinary approach was preferred for IVDU patients to treat both endocarditis and substance use disorder and improve long-term survival. CI - (c) 2022 The Author(s). FAU - Caceres, Juan AU - Caceres J AD - University of Michigan Medical School, Ann Arbor, Mich. FAU - Malik, Aroosa AU - Malik A AD - University of Michigan Medical School, Ann Arbor, Mich. FAU - Ren, Tom AU - Ren T AD - Department of Cardiac Surgery, Michigan Medicine, Ann Arbor, Mich. FAU - Naeem, Aroma AU - Naeem A AD - Department of Cardiac Surgery, Michigan Medicine, Ann Arbor, Mich. FAU - Clemence, Jeffrey AU - Clemence J AD - Department of Cardiac Surgery, Michigan Medicine, Ann Arbor, Mich. FAU - Makkinejad, Alexander AU - Makkinejad A AD - Department of Cardiac Surgery, Michigan Medicine, Ann Arbor, Mich. FAU - Wu, Xiaoting AU - Wu X AD - Department of Cardiac Surgery, Michigan Medicine, Ann Arbor, Mich. FAU - Yang, Bo AU - Yang B AD - Department of Cardiac Surgery, Michigan Medicine, Ann Arbor, Mich. LA - eng GR - K08 HL130614/HL/NHLBI NIH HHS/United States GR - R01 HL141891/HL/NHLBI NIH HHS/United States GR - R01 HL151776/HL/NHLBI NIH HHS/United States PT - Journal Article DEP - 20220531 PL - Netherlands TA - JTCVS Open JT - JTCVS open JID - 101768541 PMC - PMC9510881 OTO - NOTNLM OT - CHF, congestive heart failure OT - HR, hazard ratio OT - IVDU, intravenous drug use OT - MET, multidisciplinary endocarditis team OT - aortic valve surgery OT - cardiac surgery OT - endocarditis OT - outcomes OT - tricuspid valve surgery EDAT- 2022/09/30 06:00 MHDA- 2022/09/30 06:01 PMCR- 2022/05/31 CRDT- 2022/09/29 02:18 PHST- 2021/09/28 00:00 [received] PHST- 2022/04/08 00:00 [revised] PHST- 2022/05/24 00:00 [accepted] PHST- 2022/09/29 02:18 [entrez] PHST- 2022/09/30 06:00 [pubmed] PHST- 2022/09/30 06:01 [medline] PHST- 2022/05/31 00:00 [pmc-release] AID - S2666-2736(22)00239-X [pii] AID - 10.1016/j.xjon.2022.05.013 [doi] PST - epublish SO - JTCVS Open. 2022 May 31;11:92-104. doi: 10.1016/j.xjon.2022.05.013. eCollection 2022 Sep. PMID- 36169219 OWN - NLM STAT- MEDLINE DCOM- 20221223 LR - 20221223 IS - 1399-3062 (Electronic) IS - 1398-2273 (Linking) VI - 24 IP - 6 DP - 2022 Dec TI - Vancomycin-resistant Enterococcus outbreak in a pre- and post-cardiothoracic transplant population: Impact of discontinuing multidrug-resistant organism surveillance during the coronavirus disease 2019 pandemic. PG - e13972 LID - 10.1111/tid.13972 [doi] AB - INTRODUCTION: Many institutions suspended surveillance and contact precautions for multidrug-resistant organisms (MDROs) at the outset of the coronavirus disease 2019 (COVID-19) pandemic due to a lack of resources. Once our institution reinstated surveillance in September 2020, a vancomycin-resistant Enterococcus (VRE) faecium outbreak was detected in the cardiothoracic transplant units, a population in which we had not previously detected outbreaks. METHODS: An outbreak investigation was conducted using pulsed-field gel electrophoresis for strain typing and electronic medical record review to determine the clinical characteristics of involved patients. The infection prevention (IP) team convened a multidisciplinary process improvement team comprised of IP, cardiothoracic transplant nursing and medical leadership, environmental services, and the microbiology laboratory. RESULTS: Between December 2020 and March 2021, the outbreak involved thirteen patients in the cardiothoracic transplant units, four index cases, and nine transmissions. Of the 13, seven (54%) were on the transplant service, including heart and lung transplant recipients, patients with ventricular assist devices, and a patient on extracorporeal membrane oxygenation as a bridge to lung transplantation. Four of 13 (31%) developed a clinical infection. DISCUSSION: Cardiothoracic surgery/transplant patients may have a similar risk for VRE-associated morbidity as abdominal solid organ transplant and stem cell transplant patients, highlighting the need for aggressive outbreak management when VRE transmission is detected. Our experience demonstrates an unintended consequence of discontinuing MDRO surveillance in this population and highlights a need for education, monitoring, and reinforcement of foundational infection prevention measures to ensure optimal outcomes. CI - (c) 2022 Wiley Periodicals LLC. FAU - Rathod, Shardul N AU - Rathod SN AUID- ORCID: 0000-0002-9768-4095 AD - Department of Healthcare Epidemiology and Infection Prevention, Northwestern Memorial Hospital, Chicago, Illinois, USA. FAU - Bardowski, Laura AU - Bardowski L AD - Department of Healthcare Epidemiology and Infection Prevention, Northwestern Memorial Hospital, Chicago, Illinois, USA. FAU - Tse, Isabella AU - Tse I AD - Cardiac, Vascular, and Thoracic Stepdown, Northwestern Memorial Hospital, Chicago, Illinois, USA. FAU - Churyla, Andrei AU - Churyla A AD - Division of Cardiac Surgery, Department of Surgery, Bluhm Cardiovascular Institute, Northwestern University Feinberg School of Medicine and Northwestern Medicine, Chicago, Illinois, USA. FAU - Fiehler, Monica AU - Fiehler M AD - Division of Cardiac Surgery, Department of Surgery, Bluhm Cardiovascular Institute, Northwestern University Feinberg School of Medicine and Northwestern Medicine, Chicago, Illinois, USA. FAU - Malczynski, Michael AU - Malczynski M AD - Department of Pathology, Northwestern University Feinberg School of Medicine, Clinical Microbiology Laboratory, Northwestern Memorial Hospital and Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. FAU - Qi, Chao AU - Qi C AD - Department of Pathology, Northwestern University Feinberg School of Medicine, Clinical Microbiology Laboratory, Northwestern Memorial Hospital and Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. FAU - Tanna, Sajal D AU - Tanna SD AUID- ORCID: 0000-0003-2641-5004 AD - Department of Medicine, Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. FAU - Bulger, Christine AU - Bulger C AD - Department of Environmental Services and Patient Escort, Northwestern Memorial Hospital, Chicago, Illinois, USA. FAU - Al-Qamari, Abbas AU - Al-Qamari A AD - Division of Cardiac Surgery, Department of Surgery, Bluhm Cardiovascular Institute, Northwestern University Feinberg School of Medicine and Northwestern Medicine, Chicago, Illinois, USA. AD - Department of Anesthesiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. FAU - Oakley, Robin AU - Oakley R AD - Cardiac Transplant Intensive Care Unit, Northwestern Memorial Hospital, Chicago, Illinois, USA. FAU - Zembower, Teresa R AU - Zembower TR AD - Department of Healthcare Epidemiology and Infection Prevention, Northwestern Memorial Hospital, Chicago, Illinois, USA. AD - Department of Pathology, Northwestern University Feinberg School of Medicine, Clinical Microbiology Laboratory, Northwestern Memorial Hospital and Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. AD - Department of Medicine, Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. LA - eng PT - Journal Article DEP - 20221103 PL - Denmark TA - Transpl Infect Dis JT - Transplant infectious disease : an official journal of the Transplantation Society JID - 100883688 RN - 6Q205EH1VU (Vancomycin) RN - 0 (Anti-Bacterial Agents) SB - IM MH - Humans MH - Vancomycin/therapeutic use MH - Anti-Bacterial Agents/therapeutic use/pharmacology MH - Pandemics/prevention & control MH - Drug Resistance, Multiple, Bacterial MH - *COVID-19/epidemiology/prevention & control MH - *Enterococcus faecium MH - *Vancomycin-Resistant Enterococci MH - Disease Outbreaks MH - *Gram-Positive Bacterial Infections/epidemiology/prevention & control/drug therapy MH - *Cross Infection/epidemiology/prevention & control OTO - NOTNLM OT - COVID-19 pandemic OT - VRE outbreak OT - extracorporeal membrane oxygenation OT - heart transplant OT - lung transplant OT - ventricular assist device EDAT- 2022/09/29 06:00 MHDA- 2022/12/24 06:00 CRDT- 2022/09/28 08:22 PHST- 2022/08/31 00:00 [revised] PHST- 2021/12/17 00:00 [received] PHST- 2022/09/16 00:00 [accepted] PHST- 2022/09/29 06:00 [pubmed] PHST- 2022/12/24 06:00 [medline] PHST- 2022/09/28 08:22 [entrez] AID - 10.1111/tid.13972 [doi] PST - ppublish SO - Transpl Infect Dis. 2022 Dec;24(6):e13972. doi: 10.1111/tid.13972. Epub 2022 Nov 3. PMID- 36167227 OWN - NLM STAT- MEDLINE DCOM- 20221123 LR - 20221123 IS - 1535-6280 (Electronic) IS - 0146-2806 (Linking) VI - 48 IP - 1 DP - 2023 Jan TI - Multidisciplinary Heart Failure Care Program: An Experience From Colombia. PG - 101431 LID - S0146-2806(22)00328-0 [pii] LID - 10.1016/j.cpcardiol.2022.101431 [doi] AB - The prevalence of Heart Failure is growing alarmingly; its treatment consumes health resources and affects the quality of life of patients. To describe the changes in NYHA functional Class, ejection fraction, hospitalizations, and mortality after 8 years of follow up in a multidisciplinary heart failure program in Colombia as a model for lower and middle income countries. An observational study was performed with the retrospective analysis of the information. 1757 patients were included, The NYHA functional class at the beginning of the program was: NYHA I 23.5%, NYHA II 50.3%, NYHA class Improvement was observed at the end of the follow-up with an increase in the percentage of patients in Functional Class NYHA I and II. The reduction in hospitalizations were 35% less (mean: 0.68 +/- 0.95, P < 0.0001), a reduction in the length of stay in the hospital was 13.2% (before: 4.46 +/- 7.16, after 3.87 +/- 8.1 days, P < 0.001). The total mortality after eight years of follow-up was 6.6 % (n = 116). Multidisciplinary follow-up in Heart Failure (HF) programs improves Functional Class and EF, decreases hospital admissions as well as hospitalization and the length of stay. This is a very simple and successful model of care for this disease that can be implemented for countries of lower- and middle-income countries. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Saldarriaga, Clara AU - Saldarriaga C AD - University of Antioquia, Pontificia Bolivariana University, Medellin, Colombia; Cardio VID Clinic, Medellin, Colombia. FAU - Gallego, Catalina AU - Gallego C AD - Cardio VID Clinic, Medellin, Colombia. FAU - Fajardo, Luis Alfonso AU - Fajardo LA AD - Cardio VID Clinic, Medellin, Colombia. FAU - Agudelo, Adriana Maria AU - Agudelo AM AD - Cardio VID Clinic, Medellin, Colombia. FAU - Sanchez Zapata, Paola AU - Sanchez Zapata P AD - Cardio VID Clinic, Medellin, Colombia. Electronic address: paola.sanchez.zapata@gmail.com. FAU - Perez, Luz Eugenia AU - Perez LE AD - CES University, Medellin, Colombia. FAU - Valencia, Juan E AU - Valencia JE AD - Medtronic Latin America, Antioquia, Medellin, Colombia. LA - eng PT - Journal Article PT - Review DEP - 20220924 PL - Netherlands TA - Curr Probl Cardiol JT - Current problems in cardiology JID - 7701802 SB - IM MH - Humans MH - *Quality of Life MH - Retrospective Studies MH - Colombia/epidemiology MH - *Heart Failure/epidemiology/therapy MH - Stroke Volume MH - Observational Studies as Topic EDAT- 2022/09/28 06:00 MHDA- 2022/11/24 06:00 CRDT- 2022/09/27 19:25 PHST- 2022/09/21 00:00 [received] PHST- 2022/09/21 00:00 [accepted] PHST- 2022/09/28 06:00 [pubmed] PHST- 2022/11/24 06:00 [medline] PHST- 2022/09/27 19:25 [entrez] AID - S0146-2806(22)00328-0 [pii] AID - 10.1016/j.cpcardiol.2022.101431 [doi] PST - ppublish SO - Curr Probl Cardiol. 2023 Jan;48(1):101431. doi: 10.1016/j.cpcardiol.2022.101431. Epub 2022 Sep 24. PMID- 36166324 OWN - NLM STAT- MEDLINE DCOM- 20221018 LR - 20221206 IS - 1558-2035 (Electronic) IS - 1558-2027 (Linking) VI - 23 IP - 11 DP - 2022 Nov 1 TI - A 20-year experience in cardiac tumors: a single center surgical experience and a review of literature. PG - 722-727 LID - 10.2459/JCM.0000000000001375 [doi] AB - INTRODUCTION: Cardiac tumors are rare and heterogeneous entities which still remain a diagnostic and therapeutic challenge. The treatment for most cardiac tumors is prompt surgical resection. We sought to provide an overview of surgical results from a series of consecutive patients treated at our tertiary care center during almost a 20-year experience. METHODS AND RESULTS: In this single center study, 55 consecutive patients with diagnosis of cardiac tumor underwent surgical treatment from January 2002 to April 2021. Of these, 23 (42%) were male and the mean age was 62 +/- 12 years. Fifteen (27%) patients were symptomatic at the time of the diagnosis, mostly for dyspnea and palpitations. The most frequent benign cardiac tumor was myxoma (32; 58%), occurring mainly in the left atrium (31; 97%). Pleomorphic sarcoma was the most frequent primary malignant cardiac tumor (4; 7%), mainly located in the ventricles (1; 25% in the left ventricle; 2; 50% in the right ventricle). In all cases of benign tumors surgery was successful with no relapses. Two (50%) pleomorphic sarcomas showed subsequent relapses. After a median follow-up of 44 months, 15 (27%) patients died. Although malignant tumors presented a limited survival, benign tumors showed a very good prognosis. CONCLUSION: Cardiac tumors require a multidisciplinary approach to guarantee a prompt diagnosis and appropriate treatment. In our surgical experience, outcome after surgery of benign tumors was excellent, while malignant tumors had poor prognosis despite radical surgery. CI - Copyright (c) 2022 Italian Federation of Cardiology - I.F.C. All rights reserved. FAU - Restivo, Luca AU - Restivo L AD - Cardiothoracovascular Department, Division of Cardiology, Azienda Sanitaria Universitaria Giuliano Isontina and University of Trieste. FAU - De Luca, Antonio AU - De Luca A AD - Cardiothoracovascular Department, Division of Cardiology, Azienda Sanitaria Universitaria Giuliano Isontina and University of Trieste. FAU - Fabris, Enrico AU - Fabris E AD - Cardiothoracovascular Department, Division of Cardiology, Azienda Sanitaria Universitaria Giuliano Isontina and University of Trieste. FAU - Pagura, Linda AU - Pagura L AD - Cardiothoracovascular Department, Division of Cardiology, Azienda Sanitaria Universitaria Giuliano Isontina and University of Trieste. FAU - Pierri, Alessandro AU - Pierri A AD - Cardiothoracovascular Department, Division of Cardiology, Azienda Sanitaria Universitaria Giuliano Isontina and University of Trieste. FAU - Korcova, Renata AU - Korcova R AD - Cardiothoracovascular Department, Division of Cardiology, Azienda Sanitaria Universitaria Giuliano Isontina and University of Trieste. FAU - Franzese, Ilaria AU - Franzese I AD - Cardiothoracovascular Department, Division of Cardiac Surgery, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste. FAU - Fiocco, Alessandro AU - Fiocco A AD - Cardiothoracovascular Department, Division of Cardiac Surgery, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste. AD - Department of Surgical, Medical and Molecular Pathology and Critical Care, Division of Cardiac Surgery, University of Pisa, Pisa. FAU - Rauber, Elisabetta AU - Rauber E AD - Cardiothoracovascular Department, Division of Cardiac Surgery, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste. FAU - Mazzaro, Enzo AU - Mazzaro E AD - Cardiothoracovascular Department, Division of Cardiac Surgery, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste. FAU - Bussani, Rossana AU - Bussani R AD - Pathology Department, Azienda Sanitaria Universitaria Giuliano Isontina and University of Trieste. FAU - Belgrano, Manuel AU - Belgrano M AD - Department of Radiology, Azienda Sanitaria Universitaria Integrata and University of Trieste, Trieste, Italy. FAU - Pappalardo, Aniello AU - Pappalardo A AD - Cardiothoracovascular Department, Division of Cardiac Surgery, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste. FAU - Sinagra, Gianfranco AU - Sinagra G AD - Cardiothoracovascular Department, Division of Cardiology, Azienda Sanitaria Universitaria Giuliano Isontina and University of Trieste. LA - eng PT - Journal Article PT - Review DEP - 20220831 PL - United States TA - J Cardiovasc Med (Hagerstown) JT - Journal of cardiovascular medicine (Hagerstown, Md.) JID - 101259752 SB - IM MH - Aged MH - Female MH - Heart Atria/pathology MH - *Heart Neoplasms/diagnostic imaging/surgery MH - Humans MH - Male MH - Middle Aged MH - *Myxoma/pathology/surgery MH - Neoplasm Recurrence, Local MH - Retrospective Studies MH - *Sarcoma/pathology/surgery EDAT- 2022/09/28 06:00 MHDA- 2022/10/19 06:00 CRDT- 2022/09/27 12:22 PHST- 2022/09/28 06:00 [pubmed] PHST- 2022/10/19 06:00 [medline] PHST- 2022/09/27 12:22 [entrez] AID - 01244665-202211000-00004 [pii] AID - 10.2459/JCM.0000000000001375 [doi] PST - ppublish SO - J Cardiovasc Med (Hagerstown). 2022 Nov 1;23(11):722-727. doi: 10.2459/JCM.0000000000001375. Epub 2022 Aug 31. PMID- 36165269 OWN - NLM STAT- MEDLINE DCOM- 20230605 LR - 20260921 IS - 1741-2889 (Electronic) IS - 1367-4935 (Print) IS - 1367-4935 (Linking) VI - 27 IP - 2 DP - 2023 Jun TI - Children's understanding and consent to heart surgery: Multidisciplinary teamwork and moral experiences. PG - 197-211 LID - 10.1177/13674935221100419 [doi] AB - Mainstream law and ethics literature on consent to children's surgery contrasts with moral experiences of children and adults observed in two heart surgery centres. Research interviews were conducted with 45 practitioners and related experts, and with 16 families of children aged 6 to 15, admitted for non-urgent surgery, as well as an online survey. Thematic data analysis was informed by critical realism and childhood studies.Impersonal adult-centric mainstream literature assumes young children cannot consent. It is based on dichotomies: adult/child, competent/incompetent, respect or protect children, inform or distract them, use time swiftly or flexibly, verbal/non-verbal communication, respect or control children and reason/emotion.Through their moral experiences, adults and children resolve these seeming dichotomies. Through understanding young children's reasoning and emotions about complex distressing decisions related to heart surgery, adults share knowledge, control, trust and respect with them. They see children's consent or refusal before non-urgent surgery as a shared personal moral experience within the child's life course, beyond mere legal compliance. Adults help children to understand and 'want' the surgery that offers things they value: better health or to 'be more like their friends'. If children are not convinced, sometimes surgery is postponed or occasionally cancelled. FAU - Alderson, Priscilla AU - Alderson P AUID- ORCID: 0000-0003-4002-4501 AD - Social Research Institute, University College London, London, UK. FAU - Bellsham-Revell, Hannah AU - Bellsham-Revell H AD - Evelina Children's Hospital, Guy's and St Thomas NHS Trust, London, UK. FAU - Dedieu, Nathalie AU - Dedieu N AD - Great Ormond Street Hospital NHS Trust, London, UK. FAU - King, Liz AU - King L AD - School of Health, Wellbeing and Social Care Open University, Milton Keynes, UK. FAU - Mendizabal, Rosa AU - Mendizabal R AD - Social Research Institute, University College London, London, UK. FAU - Sutcliffe, Katy AU - Sutcliffe K AD - Social Research Institute, University College London, London, UK. LA - eng GR - PG/18/22/33604/BHF_/British Heart Foundation/United Kingdom GR - 176835/BHF_/British Heart Foundation/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220927 PL - England TA - J Child Health Care JT - Journal of child health care : for professionals working with children in the hospital and community JID - 9806360 MH - Adult MH - Child MH - Humans MH - Child, Preschool MH - *Morals MH - *Cardiac Surgical Procedures PMC - PMC10240628 OTO - NOTNLM OT - Childhood illness OT - Children's rights OT - consent OT - critical thinking OT - ethics COIS- The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2022/09/28 06:00 MHDA- 2023/06/05 06:43 PMCR- 2023/06/05 CRDT- 2022/09/27 06:33 PHST- 2023/06/05 06:43 [medline] PHST- 2022/09/28 06:00 [pubmed] PHST- 2022/09/27 06:33 [entrez] PHST- 2023/06/05 00:00 [pmc-release] AID - 10.1177_13674935221100419 [pii] AID - 10.1177/13674935221100419 [doi] PST - ppublish SO - J Child Health Care. 2023 Jun;27(2):197-211. doi: 10.1177/13674935221100419. Epub 2022 Sep 27. PMID- 36159207 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240923 IS - 1932-9520 (Print) IS - 1932-9563 (Electronic) IS - 1932-9520 (Linking) VI - 16 IP - 12 DP - 2022 TI - The Fourth Trimester: a Time for Enhancing Transitions in Cardiovascular Care. PG - 219-229 LID - 10.1007/s12170-022-00706-x [doi] AB - PURPOSE OF REVIEW: The "fourth trimester" concept, defined as the first 12 weeks after delivery (and beyond), is a critical window of time for clinicians to intervene to optimize women's cardiovascular health after pregnancy. A timely and comprehensive postpartum cardiovascular assessment should be performed in all women following delivery in order to (1) follow up medical conditions present prior to conception, (2) evaluate symptoms and signs of common postpartum complications, and (3) identify risk factors and prevent future adverse cardiovascular outcomes. In this review, we aim to discuss major maternal cardiovascular risk factors such as hypertensive disorders of pregnancy, gestational diabetes mellitus, postpartum weight retention, and postpartum depression, as well as lactation as a potential protective risk modifying factor. Additionally, we will review effectiveness of outpatient interventions to enhance transitions in cardiovascular care during the fourth trimester. RECENT FINDINGS: A seamless hand-off from obstetric to primary care, and potentially cardiology, is needed for early detection and management of hypertension, weight, glycemic control, stress and mood, and long-term cardiovascular risk. Additionally, the use of telemedicine, blood pressure self-monitoring, remote activity monitoring, and behavioral health coaches are potentially feasible modalities to augment clinic-based care for cardiovascular risk factors and weight management, but additional studies are needed to study their long-term effectiveness. SUMMARY: Development of a comprehensive postpartum care plan with careful consideration of each patient's risk profile and access to resources is critical to improve maternal morbidity and mortality, reduce health disparities, and achieve long-term cardiovascular health for women. Supporting postpartum well-being of women during this transition period requires a multidisciplinary approach, especially primary care engagement, and planning should start before delivery. CI - (c) The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. FAU - Choi, Eunjung AU - Choi E AD - Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD 21287 USA. GRID: grid.21107.35. ISNI: 0000 0001 2171 9311 FAU - Kazzi, Brigitte AU - Kazzi B AD - Department of Medicine, Johns Hopkins University School of Medicine, MD 21287 Baltimore, USA. GRID: grid.21107.35. ISNI: 0000 0001 2171 9311 FAU - Varma, Bhavya AU - Varma B AD - Department of Medicine, Johns Hopkins University School of Medicine, MD 21287 Baltimore, USA. GRID: grid.21107.35. ISNI: 0000 0001 2171 9311 FAU - Ortengren, Alexandra R AU - Ortengren AR AD - Heart and Vascular Center, Dartmouth-Hitchcock Medical Center, NH Lebanon, USA. GRID: grid.413480.a. ISNI: 0000 0004 0440 749X FAU - Minhas, Anum S AU - Minhas AS AD - Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD 21287 USA. GRID: grid.21107.35. ISNI: 0000 0001 2171 9311 FAU - Vaught, Arthur Jason AU - Vaught AJ AD - Division of Maternal Fetal Medicine, Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD 21287 USA. GRID: grid.21107.35. ISNI: 0000 0001 2171 9311 FAU - Bennett, Wendy L AU - Bennett WL AD - Division of General Internal Medicine, Johns Hopkins School of Medicine, Baltimore, MD 21287 USA. GRID: grid.21107.35. ISNI: 0000 0001 2171 9311 FAU - Lewey, Jennifer AU - Lewey J AD - Division of Cardiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA USA. GRID: grid.25879.31. ISNI: 0000 0004 1936 8972 FAU - Michos, Erin D AU - Michos ED AD - Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD 21287 USA. GRID: grid.21107.35. ISNI: 0000 0001 2171 9311 AD - Division of Cardiology, Johns Hopkins Hospital, 600 N. Wolfe Street, Blalock 524-B, Baltimore, MD 21287 USA. GRID: grid.411935.b. ISNI: 0000 0001 2192 2723 LA - eng GR - K23 HL153667/HL/NHLBI NIH HHS/United States GR - R18 DK122416/DK/NIDDK NIH HHS/United States PT - Journal Article PT - Review DEP - 20220921 PL - United States TA - Curr Cardiovasc Risk Rep JT - Current cardiovascular risk reports JID - 101463024 PMC - PMC9490714 OTO - NOTNLM OT - Adverse pregnancy outcomes OT - Blood pressure control OT - Cardiovascular disease OT - Fourth trimester OT - Prevention OT - Weight management COIS- Conflict of InterestDr. Michos reports Advisory Board participation for AstraZeneca, Bayer, Boehringer Ingelheim, Esperion, Novartis, Novo Nordisk, and Pfizer. No other authors report any disclosures. EDAT- 2022/09/27 06:00 MHDA- 2022/09/27 06:01 PMCR- 2022/09/21 CRDT- 2022/09/26 17:32 PHST- 2022/08/25 00:00 [accepted] PHST- 2022/09/27 06:00 [pubmed] PHST- 2022/09/27 06:01 [medline] PHST- 2022/09/26 17:32 [entrez] PHST- 2022/09/21 00:00 [pmc-release] AID - 706 [pii] AID - 10.1007/s12170-022-00706-x [doi] PST - ppublish SO - Curr Cardiovasc Risk Rep. 2022;16(12):219-229. doi: 10.1007/s12170-022-00706-x. Epub 2022 Sep 21. PMID- 36157095 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230826 IS - 1061-1711 (Print) IS - 1615-5939 (Electronic) IS - 1061-1711 (Linking) VI - 31 IP - 3 DP - 2022 Sep TI - The Pulmonary Embolism Response Team: Rationale, Operation, and Outcomes. PG - 198-202 LID - 10.1055/s-0042-1750328 [doi] AB - The pulmonary embolism response team (PERT) is an institutionally based multidisciplinary team that is able to rapidly assess and provide treatment for patients with acute pulmonary embolism (PE). Intrinsic to the team's structure is a formal mechanism to execute a full range of medical, endovascular, and surgical therapies. In addition, the PERT provides appropriate multidisciplinary follow-up of patients. In the 10 years since the PERT was first introduced, it has gained acceptance in many centers in the United States and around the world. These PERTs have joined together to form an international association, called the PERT Consortium. The mission of this consortium is to advance the diagnosis, treatment, and outcomes of patients with PE. There is considerable evidence that the PERT model improves delivery and standardization of care of PE patients, particularly those patients with massive and submassive PE. However, it is not yet clear whether PERTs improve clinical outcomes. A large prospective database is currently being compiled by the PERT Consortium. Analysis of this database will likely further delineate the role of PERTs in the management of intermediate-to-high risk PE patients and, importantly, help determine in which PE patients PERT may improve clinical outcomes. CI - International College of Angiology. This article is published by Thieme. FAU - Glazier, James J AU - Glazier JJ AUID- ORCID: 0000-0001-5239-3692 AD - Department of Medicine, Wayne State University School of Medicine, Detroit, Michigan. AD - Department of Cardiology, Oakland University William Beaumont School of Medicine, Rochester, Michigan. FAU - Patino-Velasquez, Skarlet AU - Patino-Velasquez S AD - Department of Medicine, Wayne State University School of Medicine, Detroit, Michigan. FAU - Oviedo, Carlos AU - Oviedo C AD - Department of Medicine, Wayne State University School of Medicine, Detroit, Michigan. LA - eng PT - Journal Article DEP - 20220825 PL - United States TA - Int J Angiol JT - The International journal of angiology : official publication of the International College of Angiology, Inc JID - 9504821 PMC - PMC9507552 OTO - NOTNLM OT - interventional cardiology OT - interventional radiology OT - multidisciplinary approach OT - pulmonary embolism response team OT - pulmonary embolus OT - rapid response team COIS- Conflict of Interest None declared. EDAT- 2022/09/27 06:00 MHDA- 2022/09/27 06:01 PMCR- 2023/08/25 CRDT- 2022/09/26 17:03 PHST- 2022/09/26 17:03 [entrez] PHST- 2022/09/27 06:00 [pubmed] PHST- 2022/09/27 06:01 [medline] PHST- 2023/08/25 00:00 [pmc-release] AID - 220025 [pii] AID - 10.1055/s-0042-1750328 [doi] PST - epublish SO - Int J Angiol. 2022 Aug 25;31(3):198-202. doi: 10.1055/s-0042-1750328. eCollection 2022 Sep. PMID- 36155176 OWN - NLM STAT- MEDLINE DCOM- 20221031 LR - 20221229 IS - 1938-131X (Electronic) IS - 1553-7250 (Linking) VI - 48 IP - 11 DP - 2022 Nov TI - Variations in Code Team Composition During Different Times of Day and Week and by Level of Hospital Complexity. PG - 564-571 LID - S1553-7250(22)00172-6 [pii] LID - 10.1016/j.jcjq.2022.07.003 [doi] AB - BACKGROUND: Previous data demonstrated lower survival rates of in-hospital cardiac arrests during nights and weekends compared to weekday daytime. This study aimed to evaluate variations of personnel attending to codes based on day/night/weekend conditions within the US Veterans Affairs (VA) system, as well as variations of personnel responsible for intubations during codes. METHODS: Hospital leaders were surveyed regarding code team membership, leadership, and intubations during four time periods (weekday daytime, weekday nighttime, weekend daytime, and weekend nighttime). RESULTS: Surveys were completed for 93 of 123 eligible VA hospitals (response rate of 75.6%). Code teams were significantly smaller during "off-hours." Membership in code teams during regular vs. off-hours was significantly greater for ICU physicians (44.1% vs. 7.5%-15.0%, p < 0.001), anesthesiologists (34.4% vs. 12.9%, p < 0.001), and pharmacists (46.2% vs. 23.7%-26.9%, p < 0.01). Significant differences were found for codes led by ICU attendings (20.4% vs. 5.4%-7.5%, p < 0.05) and intubations performed by ICU attendings (21.5% vs. 6.5%-10.8%, p < 0.05). ICU-based physicians were team leaders more often in high-complexity hospitals (19.7%-50.0% vs. 0%-14.8%), while hospitalists led the majority in the low-complexity hospitals (28.8%-39.4% vs. 63.0%-70.4%). ICU physicians had significantly less involvement in code intubations in low-complexity hospitals (6.1%-22.7% vs. 3.7%-18.5%), while respiratory therapists took on most of this responsibility in low-complexity hospitals and particularly at night. CONCLUSION: This study found significant differences in code team composition, leadership, and intubation responsibilities between regular and off-hours. Low-complexity hospitals, which are generally rural, had team compositions and responsibilities that were visibly different from higher-complexity hospitals. CI - Published by Elsevier Inc. FAU - Li, Yi AU - Li Y FAU - Lighthall, Geoffrey K AU - Lighthall GK LA - eng PT - Journal Article DEP - 20220728 PL - Netherlands TA - Jt Comm J Qual Patient Saf JT - Joint Commission journal on quality and patient safety JID - 101238023 SB - IM MH - Humans MH - *Hospital Rapid Response Team MH - Hospital Mortality MH - *Heart Arrest MH - Hospitals MH - *Hospitalists EDAT- 2022/09/27 06:00 MHDA- 2022/11/01 06:00 CRDT- 2022/09/26 15:23 PHST- 2022/03/02 00:00 [received] PHST- 2022/07/23 00:00 [revised] PHST- 2022/07/25 00:00 [accepted] PHST- 2022/09/27 06:00 [pubmed] PHST- 2022/11/01 06:00 [medline] PHST- 2022/09/26 15:23 [entrez] AID - S1553-7250(22)00172-6 [pii] AID - 10.1016/j.jcjq.2022.07.003 [doi] PST - ppublish SO - Jt Comm J Qual Patient Saf. 2022 Nov;48(11):564-571. doi: 10.1016/j.jcjq.2022.07.003. Epub 2022 Jul 28. PMID- 36152075 OWN - NLM STAT- MEDLINE DCOM- 20221115 LR - 20221115 IS - 1437-9813 (Electronic) IS - 0179-0358 (Linking) VI - 38 IP - 12 DP - 2022 Dec TI - Perioperative management and outcomes of neonates undergoing anaesthesia for congenital tracheo-oesophageal fistula repair at Charlotte Maxeke Johannesburg academic hospital. PG - 1909-1917 LID - 10.1007/s00383-022-05251-7 [doi] AB - PURPOSE: Congenital tracheo-oesophageal fistula (TOF) occurs in 1 in 3000 births. Perioperative management for TOF repair requires co-ordination with a multi-disciplinary team, support from critical care units, and expertise in neonatal and cardiothoracic anaesthesia. Charlotte Maxeke Johannesburg academic hospital (CMJAH) is a quaternary referral centre that serves the regional community of Johannesburg, in Gauteng, South Africa. The aim of this research was to describe the perioperative outcomes of neonates undergoing surgical TOF repair at CMJAH. Factors in the preoperative, intra-operative, and postoperative management were considered to find relationships with the perioperative outcomes. METHOD: A retrospective single institution study was conducted with a population of 38 neonates who underwent congenital TOF repair from 1 January 2015 to 31 March 2020 at CMJAH. Descriptive statistics were used to describe the biodata using percentages, median, and inter-quartile ranges. An in-depth description of neonates that died was performed. RESULTS: A total of 38 neonates diagnosed with TOF/OA were operated on during the study period. The mortality rate was 15.8%. No deaths occurred intraoperatively. In addition, 52.6% of the neonates had a prolonged stay in ICU, 44% had a delay in the initiation of feeds, 65% developed sepsis, and 36.8% had surgical related complications. CPR was required in 1 neonate, hypoxia leading to bradycardia in 10, and hyperlactataemia in 9 neonates. Inotropic support was required in 6 neonates, and vasopressor support in 4. Blood product transfusion were necessary for 9 neonates. CONCLUSION: The in-hospital mortality of TOF repair was better than that reported in other African countries and worse than international findings. In-hospital morbidity was burdened by respiratory illness and sepsis. Areas where management could be improved include widespread foetal anomaly scanning, incorporation of bronchoscopy, and preoperative respiratory optimisation. CI - (c) 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Waghmarae, Sweeka AU - Waghmarae S AD - Department of Anaesthesia, University of Witwatersrand, Johannesburg, Gauteng, South Africa. sweekaw@hotmail.co.za. FAU - Manitshana, Nontsikelelo AU - Manitshana N AUID- ORCID: 0000-0002-8264-9916 AD - Department of Anaesthesia, University of Witwatersrand, Johannesburg, Gauteng, South Africa. FAU - Motshabi Chakane, Palesa AU - Motshabi Chakane P AUID- ORCID: 0000-0001-9990-6336 AD - Department of Anaesthesia, University of Witwatersrand, Johannesburg, Gauteng, South Africa. LA - eng PT - Journal Article DEP - 20220924 PL - Germany TA - Pediatr Surg Int JT - Pediatric surgery international JID - 8609169 SB - IM MH - Infant, Newborn MH - Humans MH - Retrospective Studies MH - South Africa/epidemiology MH - *Tracheoesophageal Fistula/diagnosis MH - *Anesthesia MH - Hospitals MH - *Sepsis MH - *Esophageal Atresia/surgery OTO - NOTNLM OT - Morbidity OT - Mortality OT - Neonate OT - Tracheo-oesophageal fistula EDAT- 2022/09/25 06:00 MHDA- 2022/11/16 06:00 CRDT- 2022/09/24 11:24 PHST- 2022/09/16 00:00 [accepted] PHST- 2022/09/25 06:00 [pubmed] PHST- 2022/11/16 06:00 [medline] PHST- 2022/09/24 11:24 [entrez] AID - 10.1007/s00383-022-05251-7 [pii] AID - 10.1007/s00383-022-05251-7 [doi] PST - ppublish SO - Pediatr Surg Int. 2022 Dec;38(12):1909-1917. doi: 10.1007/s00383-022-05251-7. Epub 2022 Sep 24. PMID- 36151850 OWN - NLM STAT- MEDLINE DCOM- 20221115 LR - 20240907 IS - 2324-9269 (Electronic) IS - 2324-9269 (Linking) VI - 10 IP - 11 DP - 2022 Nov TI - Resource utilization and multidisciplinary care needs for patients with Ehlers-Danlos syndrome. PG - e2057 LID - 10.1002/mgg3.2057 [doi] LID - e2057 AB - BACKGROUND: Ehlers-Danlos syndrome (EDS) represents a family of heritable connective tissue disorders with overlapping phenotypic features, frequently including joint hypermobility, tissue fragility, and skin hyperextensibility. Comorbid symptoms are common for patients with EDS and include multiple body systems marked by neurologic, cardiovascular, gastrointestinal, musculoskeletal issues, chronic pain, headaches, and anxiety and depression. The many comorbidities lead to high disease burden, which requires greater healthcare utilization. METHODS: This survey of families examines healthcare utilization, of adults and minors, through evaluation of subspecialty care appointments across many healthcare systems in one region. RESULTS: There were 155 adults and 83 minors with a diagnosis of EDS with a total of 693 unique visits across 27 different specialties at over 20 different hospitals or clinics in the surveyed area. Cardiology, neurology, and gastroenterology were the most utilized subspecialties for adults, while rheumatology, cardiology, and neurology were most utilized by minors. Many respondents (67%) reported their medical care needs are not being met, and 87% reported interest in a multidisciplinary clinic for EDS with the most interest in pain management, physical and occupational therapy, and rheumatology. CONCLUSION: Understanding healthcare utilization and needs of those with EDS can provide the foundation for improved care for those with EDS through a coordinated multidisciplinary care model. CI - (c) 2022 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals LLC. FAU - Jones, Jordan T AU - Jones JT AUID- ORCID: 0000-0003-0986-4991 AD - Department of Pediatrics, Children's Mercy Kansas City, Kansas City, Missouri, USA. AD - Department of Pediatrics, University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, USA. AD - Department of Pediatrics, University of Kansas School of Medicine, Kansas City, Kansas, USA. FAU - Black, William R AU - Black WR AD - Department of Pediatrics, University of Kansas School of Medicine, Kansas City, Kansas, USA. AD - Center for Children's Healthy Lifestyles and Nutrition, Children's Mercy Kansas City, Kansas City, Missouri, USA. FAU - Cogan, Wendy AU - Cogan W AD - EDSKC Collaboration Inc, A Non-Profit Patient Advocacy Organization, Kansas City, Missouri, USA. FAU - Callen, Elisabeth AU - Callen E AD - American Academy of Family Physicians, Leawood, Kansas, USA. LA - eng PT - Journal Article DEP - 20220924 PL - United States TA - Mol Genet Genomic Med JT - Molecular genetics & genomic medicine JID - 101603758 SB - IM MH - Adult MH - Humans MH - *Ehlers-Danlos Syndrome/epidemiology/therapy/diagnosis MH - *Connective Tissue Diseases MH - *Skin Abnormalities MH - *Joint Instability/diagnosis MH - Surveys and Questionnaires PMC - PMC9651604 OTO - NOTNLM OT - Ehlers-Danlos syndrome OT - adults OT - health care utilization OT - multidisciplinary care OT - pediatrics COIS- The authors have no conflicts of interest to disclose. No honorarium, grant, or payment was given to any author to produce this work. EDAT- 2022/09/25 06:00 MHDA- 2022/11/16 06:00 PMCR- 2022/09/24 CRDT- 2022/09/24 03:43 PHST- 2022/08/23 00:00 [revised] PHST- 2022/06/07 00:00 [received] PHST- 2022/09/05 00:00 [accepted] PHST- 2022/09/25 06:00 [pubmed] PHST- 2022/11/16 06:00 [medline] PHST- 2022/09/24 03:43 [entrez] PHST- 2022/09/24 00:00 [pmc-release] AID - MGG32057 [pii] AID - 10.1002/mgg3.2057 [doi] PST - ppublish SO - Mol Genet Genomic Med. 2022 Nov;10(11):e2057. doi: 10.1002/mgg3.2057. Epub 2022 Sep 24. PMID- 36150940 OWN - NLM STAT- MEDLINE DCOM- 20240807 LR - 20250505 IS - 1097-685X (Electronic) IS - 0022-5223 (Linking) VI - 167 IP - 4 DP - 2024 Apr TI - Complete transcatheter versus surgical approach to aortic stenosis with coronary artery disease: A systematic review and meta-analysis. PG - 1305-1313.e9 LID - S0022-5223(22)00893-5 [pii] LID - 10.1016/j.jtcvs.2022.08.006 [doi] AB - OBJECTIVE: This meta-analysis aimed to evaluate outcomes of transcatheter aortic valve replacement (TAVR) with percutaneous coronary intervention (PCI) versus surgical aortic valve replacement (SAVR) with coronary artery bypass grafting (CABG). METHODS: The MEDLINE, EMBASE, and Cochrane Library databases were searched through November 2021 to identify studies comparing TAVR + PCI and SAVR + CABG for severe aortic stenosis with concurrent coronary artery disease. Outcomes of interest were all-cause mortality, repeat coronary intervention, rehospitalization, myocardial infarction, and stroke during follow-up, and 30-day periprocedural outcomes. RESULTS: Two randomized controlled trials and 6 observational studies including a total of 104,220 patients (TAVR + PCI, n = 5004; SAVR + CABG, n = 99,216) were included. The weighted mean follow-up period was 30.2 months. TAVR + PCI was associated with greater all-cause mortality and coronary reintervention during follow-up period (hazard ratio, 1.35; 95% confidence interval [CI], 1.11-1.65; P = .003, hazard ratio, 4.14; 95% CI, 1.74-9.86; P = .001, respectively), 30-day permanent pacemaker implantation rate (odds ratio [OR], 3.79; 95% CI, 1.61-8.95; P = .002), and periprocedural vascular complications (OR, 6.97; 95% CI, 1.85-26.30; P = .004). In contrast, TAVR + PCI was associated with a lower rate of 30-day acute kidney injury (OR, 0.32; 95% CI, 0.20-0.50; P = .0001). Rehospitalization, myocardial infarction, stroke during follow-up, and other periprocedural outcomes including 30-day mortality were similar in both groups. CONCLUSIONS: In patients with severe aortic stenosis and coronary artery disease, TAVR + PCI was associated with greater all-cause mortality at follow-up compared with SAVR + CABG. Heart Team approach to assess TAVR candidacy remains imperative. CI - Copyright (c) 2022 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved. FAU - Sakurai, Yosuke AU - Sakurai Y AD - Department of Surgery, Marshall University Joan Edwards School of Medicine, WVa. FAU - Yokoyama, Yujiro AU - Yokoyama Y AD - Department of Surgery, St Luke's University Health Network, Pa. FAU - Fukuhara, Shinichi AU - Fukuhara S AD - Department of Cardiothoracic Surgery, University of Michigan, Ann Arbor, Mich. FAU - Takagi, Hisato AU - Takagi H AD - Department of Cardiovascular Surgery, Shizuoka Medical Center, Shizuoka, Japan. FAU - Kuno, Toshiki AU - Kuno T AD - Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY. Electronic address: tkuno@montefiore.org. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20220818 PL - United States TA - J Thorac Cardiovasc Surg JT - The Journal of thoracic and cardiovascular surgery JID - 0376343 CIN - J Thorac Cardiovasc Surg. 2024 Apr;167(4):1314-1315. doi: 10.1016/j.jtcvs.2022.09.012. PMID: 36243602 MH - Humans MH - *Aortic Valve Stenosis/surgery/mortality/complications/diagnostic imaging MH - *Transcatheter Aortic Valve Replacement/mortality/adverse effects/methods MH - *Coronary Artery Disease/mortality/surgery/complications MH - *Percutaneous Coronary Intervention/mortality/adverse effects/methods MH - *Coronary Artery Bypass/mortality/adverse effects MH - Treatment Outcome MH - Risk Factors MH - Postoperative Complications/mortality/etiology MH - Heart Valve Prosthesis Implantation/adverse effects/mortality MH - Male MH - Female MH - Aged MH - Risk Assessment MH - Aortic Valve/surgery/diagnostic imaging MH - Aged, 80 and over OTO - NOTNLM OT - aortic stenosis OT - coronary artery disease OT - transcatheter aortic valve replacement EDAT- 2022/09/24 06:00 MHDA- 2024/03/15 06:44 CRDT- 2022/09/23 22:04 PHST- 2022/04/14 00:00 [received] PHST- 2022/07/24 00:00 [revised] PHST- 2022/08/15 00:00 [accepted] PHST- 2024/03/15 06:44 [medline] PHST- 2022/09/24 06:00 [pubmed] PHST- 2022/09/23 22:04 [entrez] AID - S0022-5223(22)00893-5 [pii] AID - 10.1016/j.jtcvs.2022.08.006 [doi] PST - ppublish SO - J Thorac Cardiovasc Surg. 2024 Apr;167(4):1305-1313.e9. doi: 10.1016/j.jtcvs.2022.08.006. Epub 2022 Aug 18. PMID- 36142997 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220928 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 11 IP - 18 DP - 2022 Sep 12 TI - Can Quality Improvement Methodologies Derived from Manufacturing Industry Improve Care in Cardiac Surgery? A Systematic Review. LID - 10.3390/jcm11185350 [doi] LID - 5350 AB - OBJECTIVES: Healthcare is required to be effectively organised to ensure that growing, aging and medically more complex populations have timely access to high-quality, affordable care. Cardiac surgery is no exception to this, especially due to the competition for and demand on hospital resources, such as operating rooms and intensive care capacity. This is challenged more since the COVID-19 pandemic led to postponed care and prolonged waiting lists. In other sectors, Quality Improvement Methodologies (QIM) derived from the manufacturing industry have proven effective in enabling more efficient utilisation of existing capacity and resources and in improving the quality of care. We performed a systematic review to evaluate the ability of such QIM to improve care in cardiac surgery. METHODS: A literature search was performed in PubMed, Embase, Clarivate Analytics/Web of Science Core Collection and Wiley/the Cochrane Library according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis methodology. RESULTS: Ten articles were identified. The following QIM were used: Lean, Toyota Production System, Six Sigma, Lean Six Sigma, Root Cause Analysis, Kaizen and Plan-Do-Study-Act. All reported one or more relevant improvements in patient-related (e.g., infection rates, ventilation time, mortality, adverse events, glycaemic control) and process-related outcomes (e.g., shorter waiting times, shorter transfer time and productivity). Elements to enhance the success included: multidisciplinary team engagement, a patient-oriented, data-driven approach, a sense of urgency and a focus on sustainability. CONCLUSIONS: In all ten papers describing the application of QIM initiatives to cardiac surgery, positive results, of varying magnitude, were reported. While the consistency of the available data is encouraging, the limited quantity and heterogenous quality of the evidence base highlights that more rigorous evaluation, including how best to employ manufacturing industry-derived QIM in cardiac surgery is warranted. FAU - Hoefsmit, Paulien Christine AU - Hoefsmit PC AD - Department of Cardiothoracic Surgery, Amsterdam University Medical Centre, 1081 HV Amsterdam, The Netherlands. FAU - Schretlen, Stijn AU - Schretlen S AUID- ORCID: 0000-0001-9190-2269 AD - Integrated Health Solutions, Medtronic Inc., 5616 VB Eindhoven, The Netherlands. FAU - Burchell, George AU - Burchell G AD - Medical Library, Vrije Universiteit, 1081 HV Amsterdam, The Netherlands. FAU - van den Heuvel, Jaap AU - van den Heuvel J AD - Department of Healthcare Management, University of Amsterdam Business School, 1018 TV Amsterdam, The Netherlands. FAU - Bonjer, Jaap AU - Bonjer J AD - Department of Surgery, Amsterdam University Medical Centre, 1081 HV Amsterdam, The Netherlands. FAU - Dahele, Max AU - Dahele M AD - Department of Radiation Oncology, Amsterdam University Medical Centre, 1081 HV Amsterdam, The Netherlands. FAU - Zandbergen, Reinier AU - Zandbergen R AD - Department of Cardiothoracic Surgery, Amsterdam University Medical Centre, 1081 HV Amsterdam, The Netherlands. AD - Department of Surgery, Amsterdam University Medical Centre, 1081 HV Amsterdam, The Netherlands. LA - eng PT - Journal Article PT - Review DEP - 20220912 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC9502537 OTO - NOTNLM OT - Lean OT - Quality Improvement Methodologies OT - Six Sigma OT - Toyota Production System OT - cardiac surgery COIS- The authors declare no conflict of interest with respect to the research, authorship, and/or publication of this article. Outside of this work: MD declares research funding and honoraria from Varian Medical Systems. EDAT- 2022/09/24 06:00 MHDA- 2022/09/24 06:01 PMCR- 2022/09/12 CRDT- 2022/09/23 01:27 PHST- 2022/08/18 00:00 [received] PHST- 2022/09/05 00:00 [revised] PHST- 2022/09/07 00:00 [accepted] PHST- 2022/09/23 01:27 [entrez] PHST- 2022/09/24 06:00 [pubmed] PHST- 2022/09/24 06:01 [medline] PHST- 2022/09/12 00:00 [pmc-release] AID - jcm11185350 [pii] AID - jcm-11-05350 [pii] AID - 10.3390/jcm11185350 [doi] PST - epublish SO - J Clin Med. 2022 Sep 12;11(18):5350. doi: 10.3390/jcm11185350. PMID- 36136036 OWN - NLM STAT- MEDLINE DCOM- 20221115 LR - 20221130 IS - 1897-4279 (Electronic) IS - 0022-9032 (Linking) VI - 80 IP - 10 DP - 2022 TI - What do we know about carcinoid heart disease in the present era? PG - 990-1001 LID - 10.33963/KP.a2022.0222 [doi] AB - Carcinoid heart disease (CHD) is a severe complication of carcinoid syndrome (CS) found primarily in patients with small intestine neuroendocrine neoplasms (SI-NENs). Patients who develop CHD have significantly worse morbidity and mortality outcomes, highlighting the importance of clinical practice recommendations for CHD screening, diagnosis, and treatment that are both consistent and practical. CHD is characterized by white plaque-like deposits on the endocardial surface of heart structures, generally affecting the right heart valves, causing tricuspid and pulmonary regurgitation and, less commonly, valve stenosis. Cardiac imaging is essential for both the diagnosis and management of CHD. Previously, imaging for CHD was mostly achieved by echocardiography, but more recently, imaging has become multimodal. N-terminal pro-B-type natriuretic peptide (NT-proBNP) and 5-hydroxyindoleacetic acid in the urine (u5-HIAA) are currently the most effective markers used in screening CS patients and evaluating CHD severity. Managing patients with CHD is challenging since both systemic malignant disease and cardiac involvement must be treated concurrently. Early diagnosis and surgical intervention when required are critical to patient prognosis, especially in those without primary tumor resection. Valve replacement surgery is the most effective treatment for patients with advanced carcinoid heart disease for alleviating cardiac symptoms and contributing to survival outcomes. To deliver effective patient treatment, multidisciplinary team collaboration is needed. This review summarizes current research findings on CHD pathogenesis, clinical and epidemiological features, useful biomarkers and imaging modalities, and treatment strategies. FAU - Peczkowska, Mariola AU - Peczkowska M AD - National Institute of Cardiology, Warszawa, Poland. mpeczkowska@ikard.pl. FAU - Konsek-Komorowska, Sonia J AU - Konsek-Komorowska SJ AD - Department of Cardiology and Internal Medicine, School of Medicine, Collegium Medicum, University of Warmia and Mazury in Olsztyn, Olsztyn, Poland. FAU - Kolasinska-Cwikla, Agnieszka D AU - Kolasinska-Cwikla AD AD - Maria Sklodowska-Curie National Research Institute of Oncology, Warszawa, Poland. FAU - Konka, Marek AU - Konka M AD - National Institute of Cardiology, Warszawa, Poland. FAU - Michalowska, Ilona AU - Michalowska I AD - National Institute of Cardiology, Warszawa, Poland. FAU - Cwikla, Jaroslaw B AU - Cwikla JB AD - Department of Cardiology and Internal Medicine, School of Medicine, Collegium Medicum, University of Warmia and Mazury in Olsztyn, Olsztyn, Poland. LA - eng PT - Journal Article PT - Review DEP - 20220922 PL - Poland TA - Kardiol Pol JT - Kardiologia polska JID - 0376352 RN - 0 (Biomarkers) SB - IM MH - Humans MH - *Carcinoid Heart Disease/diagnosis/therapy/pathology MH - Heart Valves/surgery MH - Prognosis MH - Echocardiography MH - *Neuroendocrine Tumors/pathology MH - Biomarkers OTO - NOTNLM OT - carcinoid heart disease OT - carcinoid syndrome OT - neuroendocrine neoplasms of the small intestine EDAT- 2022/09/23 06:00 MHDA- 2022/11/16 06:00 CRDT- 2022/09/22 10:33 PHST- 2022/06/17 00:00 [received] PHST- 2022/06/17 00:00 [accepted] PHST- 2022/09/23 06:00 [pubmed] PHST- 2022/11/16 06:00 [medline] PHST- 2022/09/22 10:33 [entrez] AID - VM/OJS/J/90585 [pii] AID - 10.33963/KP.a2022.0222 [doi] PST - ppublish SO - Kardiol Pol. 2022;80(10):990-1001. doi: 10.33963/KP.a2022.0222. Epub 2022 Sep 22. PMID- 36126131 OWN - NLM STAT- MEDLINE DCOM- 20220923 LR - 20221013 IS - 1941-7632 (Electronic) IS - 1941-7640 (Linking) VI - 15 IP - 9 DP - 2022 Sep TI - Association Between Peripheral Versus Central Access for Alternative Access Transcatheter Aortic Valve Replacement and Mortality and Stroke: A Report From the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. PG - e011756 LID - 10.1161/CIRCINTERVENTIONS.121.011756 [doi] AB - BACKGROUND: In some patients, the alternative access route for transcatheter aortic valve replacement (TAVR) is utilized because the conventional transfemoral approach is not felt to be either feasible or optimal. However, accurate prognostication of patient risks is not well established. This study examines the associations between peripheral (transsubclavian/transaxillary, and transcarotid) versus central access (transapical and transaortic) in alternative access TAVR and 30-day and 1-year end points of mortality and stroke for all valve platforms. METHODS: Using data from The Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry with linkage to Medicare claims, patients who underwent alternative access TAVR from June 1, 2015 to June 30, 2018 were identified. Adjusted and unadjusted Cox proportional hazards modeling were performed to determine the association between alternate access TAVR site and 30-day and 1-year end points of mortality and stroke. RESULTS: Of 7187 alternative access TAVR patients, 3725 (52%) had peripheral access and 3462 (48%) had central access. All-cause mortality was significantly lower in peripheral access versus central access group at in-hospital and 1 year (2.9% versus 6.3% and 20.3% versus 26.6%, respectively), but stroke rates were higher (5.0% versus 2.8% and 7.3% versus 5.5%, respectively; all P<0.001). These results persisted after 1-year adjustment (death adjusted hazard ratio, 0.72 [95% CI, 0.62-0.85] and stroke adjusted hazard ratio, 2.92 [95% CI, 2.21-3.85]). When broken down by individual subtypes, compared with transaxillary/subclavian access patients, transapical, and transaortic access patients had higher all-cause mortality but less stroke (P<0.05). CONCLUSIONS: In this real-world, contemporary, nationally representative benchmarking study of alternate access TAVR sites, peripheral access was associated with favorable mortality and morbidity outcomes compared with central access, at the expense of higher stroke. These findings may allow for accurate prognostication of risk for patient counseling and decision-making for the heart team with regard to alternative access TAVR. FAU - Kaneko, Tsuyoshi AU - Kaneko T AUID- ORCID: 0000-0001-6500-7471 AD - Division of Thoracic and Cardiac Surgery (T.K., S.H., F.Y.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA. FAU - Hirji, Sameer A AU - Hirji SA AD - Division of Thoracic and Cardiac Surgery (T.K., S.H., F.Y.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA. FAU - Yazdchi, Farhang AU - Yazdchi F AD - Division of Thoracic and Cardiac Surgery (T.K., S.H., F.Y.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA. FAU - Sun, Yee-Ping AU - Sun YP AUID- ORCID: 0000-0003-1320-1875 AD - Division of Cardiovascular Medicine (Y.P.S., P.S., P.O.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA. FAU - Nyman, Charles AU - Nyman C AD - Division of Cardiac Anesthesia (C.N., D.S.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA. FAU - Shook, Douglas AU - Shook D AD - Division of Cardiac Anesthesia (C.N., D.S.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA. FAU - Cohen, David J AU - Cohen DJ AUID- ORCID: 0000-0001-9163-724X AD - Cardiovascular Research Foundation, New York, NY (D.J.C.). AD - Duke Clinical Research Institute, Durham, NC (D.J.C.). FAU - Stebbins, Amanda AU - Stebbins A AUID- ORCID: 0000-0002-0808-9025 FAU - Zeitouni, Michel AU - Zeitouni M AUID- ORCID: 0000-0001-9562-3128 FAU - Vemulapalli, Sreekanth AU - Vemulapalli S AUID- ORCID: 0000-0003-1599-2957 FAU - Thourani, Vinod H AU - Thourani VH AD - Piedmont Heart Institute, Atlanta, GA (V.H.T.). FAU - Shah, Pinak B AU - Shah PB AUID- ORCID: 0000-0002-1642-7557 AD - Division of Cardiovascular Medicine (Y.P.S., P.S., P.O.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA. FAU - O'Gara, Patrick AU - O'Gara P AUID- ORCID: 0000-0003-0601-1088 AD - Division of Cardiovascular Medicine (Y.P.S., P.S., P.O.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA. LA - eng PT - Journal Article DEP - 20220920 PL - United States TA - Circ Cardiovasc Interv JT - Circulation. Cardiovascular interventions JID - 101499602 SB - IM MH - Aged MH - *Aortic Valve Stenosis MH - *Cardiology MH - Humans MH - Medicare MH - Registries MH - *Stroke/etiology MH - *Surgeons MH - *Transcatheter Aortic Valve Replacement MH - Treatment Outcome MH - United States OTO - NOTNLM OT - Medicare OT - counseling OT - hospitals OT - morbidity OT - transcatheter aortic valve replacement EDAT- 2022/09/21 06:00 MHDA- 2022/09/24 06:00 CRDT- 2022/09/20 14:04 PHST- 2022/09/20 14:04 [entrez] PHST- 2022/09/21 06:00 [pubmed] PHST- 2022/09/24 06:00 [medline] AID - 10.1161/CIRCINTERVENTIONS.121.011756 [doi] PST - ppublish SO - Circ Cardiovasc Interv. 2022 Sep;15(9):e011756. doi: 10.1161/CIRCINTERVENTIONS.121.011756. Epub 2022 Sep 20. PMID- 36124729 OWN - NLM STAT- MEDLINE DCOM- 20221223 LR - 20230111 IS - 1522-9645 (Electronic) IS - 0195-668X (Linking) VI - 43 IP - 48 DP - 2022 Dec 21 TI - Post-infarction ventricular septal defect: percutaneous or surgical management in the UK national registry. PG - 5020-5032 LID - 10.1093/eurheartj/ehac511 [doi] AB - AIMS: Post-infarction ventricular septal defect (PIVSD) is a mechanical complication of acute myocardial infarction (AMI) with a poor prognosis. Surgical repair is the mainstay of treatment, although percutaneous closure is increasingly undertaken. METHODS AND RESUTS: Patients treated with surgical or percutaneous repair of PIVSD (2010-2021) were identified at 16 UK centres. Case note review was undertaken. The primary outcome was long-term mortality. Patient groups were allocated based upon initial management (percutaneous or surgical). Three-hundred sixty-two patients received 416 procedures (131 percutaneous, 231 surgery). 16.1% of percutaneous patients subsequently had surgery. 7.8% of surgical patients subsequently had percutaneous treatment. Times from AMI to treatment were similar [percutaneous 9 (6-14) vs. surgical 9 (4-22) days, P = 0.18]. Surgical patients were more likely to have cardiogenic shock (62.8% vs. 51.9%, P = 0.044). Percutaneous patients were substantially older [72 (64-77) vs. 67 (61-73) years, P < 0.001] and more likely to be discussed in a heart team setting. There was no difference in long-term mortality between patients (61.1% vs. 53.7%, P = 0.17). In-hospital mortality was lower in the surgical group (55.0% vs. 44.2%, P = 0.048) with no difference in mortality after hospital discharge (P = 0.65). Cardiogenic shock [adjusted hazard ratio (aHR) 1.97 (95% confidence interval 1.37-2.84), P < 0.001), percutaneous approach [aHR 1.44 (1.01-2.05), P = 0.042], and number of vessels with coronary artery disease [aHR 1.22 (1.01-1.47), P = 0.043] were independently associated with long-term mortality. CONCLUSION: Surgical and percutaneous repair are viable options for management of PIVSD. There was no difference in post-discharge long-term mortality between patients, although in-hospital mortality was lower for surgery. CI - (c) The Author(s) 2022. Published by Oxford University Press on behalf of European Society of Cardiology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. FAU - Giblett, Joel P AU - Giblett JP AUID- ORCID: 0000-0001-8020-5433 AD - Liverpool Centre for Cardiovascular Science, Liverpool Heart and Chest Hospital, Liverpool, UK. AD - Department of Cardiology, Royal Papworth Hospital, Cambridge, UK. FAU - Matetic, Andrija AU - Matetic A AUID- ORCID: 0000-0001-9272-6906 AD - Keele Cardiovascular Research Group, Keele University, Stoke-on-Trent, UK. AD - Department of Cardiology, University Hospital of Split, Split, Croatia. FAU - Jenkins, David AU - Jenkins D AD - Department of Cardiothoracic Surgery, Royal Papworth Hospital, Cambridge, UK. FAU - Ng, Choo Y AU - Ng CY AD - Department of Cardiothoracic Surgery, Royal Papworth Hospital, Cambridge, UK. FAU - Venuraju, Shreenidhi AU - Venuraju S AD - Department of Cardiology, Royal Papworth Hospital, Cambridge, UK. FAU - MacCarthy, Tobias AU - MacCarthy T AD - Department of Cardiology, Royal Papworth Hospital, Cambridge, UK. AD - University of Cambridge, Cambridge, UK. FAU - Vibhishanan, Jonathan AU - Vibhishanan J AD - Department of Cardiology, Royal Papworth Hospital, Cambridge, UK. AD - University of Cambridge, Cambridge, UK. FAU - O'Neill, John P AU - O'Neill JP AD - University of Liverpool, Liverpool, UK. FAU - Kirmani, Bilal H AU - Kirmani BH AD - Liverpool Centre for Cardiovascular Science, Liverpool Heart and Chest Hospital, Liverpool, UK. AD - Department of Cardiothoracic Surgery, Liverpool Heart and Chest Hospital, Liverpool, UK. FAU - Pullan, D Mark AU - Pullan DM AD - Department of Cardiothoracic Surgery, Liverpool Heart and Chest Hospital, Liverpool, UK. FAU - Stables, Rod H AU - Stables RH AD - Liverpool Centre for Cardiovascular Science, Liverpool Heart and Chest Hospital, Liverpool, UK. FAU - Andrews, Jack AU - Andrews J AD - Royal Infirmary of Edinburgh, Edinburgh, UK. FAU - Buttinger, Nicolas AU - Buttinger N AD - University Hospitals Sussex NHS Foundation Trust, Brighton, UK. FAU - Kim, Wan Cheol AU - Kim WC AD - University Hospital Bristol and Weston, Bristol, UK. FAU - Kanyal, Ritesh AU - Kanyal R AD - King's College Hospital, London, UK. FAU - Butler, Megan A AU - Butler MA AD - University of Bristol, Bristol, UK. FAU - Butler, Robert AU - Butler R AD - Royal Stoke University Hospital, Stoke-upon-Trent, UK. FAU - George, Sudhakar AU - George S AD - University Hospitals Birmingham, Birmingham, UK. FAU - Khurana, Ayush AU - Khurana A AD - Morriston Hospital, Swansea, UK. FAU - Crossland, David S AU - Crossland DS AD - Freeman Hospital, Newcastle-upon-Tyne, UK. FAU - Marczak, Jakub AU - Marczak J AD - Nottingham University Hospital, Nottingham, UK. FAU - Smith, William H T AU - Smith WHT AD - Nottingham University Hospital, Nottingham, UK. FAU - Thomson, John D R AU - Thomson JDR AD - Leeds General Infirmary, Leeds, UK. FAU - Bentham, James R AU - Bentham JR AD - Leeds General Infirmary, Leeds, UK. FAU - Clapp, Brian R AU - Clapp BR AD - Guys and St. Thomas' Hospital, London, UK. FAU - Buch, Mamta AU - Buch M AD - Wythenshawe Hospital, Manchester, UK. FAU - Hayes, Nicholas AU - Hayes N AUID- ORCID: 0000-0001-5768-486X AD - Southampton Children's Hospital, Southampton, UK. FAU - Byrne, Jonathan AU - Byrne J AD - King's College Hospital, London, UK. FAU - MacCarthy, Philip AU - MacCarthy P AD - King's College Hospital, London, UK. FAU - Aggarwal, Suneil K AU - Aggarwal SK AD - Liverpool Centre for Cardiovascular Science, Liverpool Heart and Chest Hospital, Liverpool, UK. FAU - Shapiro, Leonard M AU - Shapiro LM AD - Department of Cardiology, Royal Papworth Hospital, Cambridge, UK. FAU - Turner, Mark S AU - Turner MS AD - University Hospital Bristol and Weston, Bristol, UK. FAU - de Giovanni, Joe AU - de Giovanni J AD - University Hospitals Birmingham, Birmingham, UK. FAU - Northridge, David B AU - Northridge DB AD - Royal Infirmary of Edinburgh, Edinburgh, UK. FAU - Hildick-Smith, David AU - Hildick-Smith D AUID- ORCID: 0000-0002-1147-1436 AD - University Hospitals Sussex NHS Foundation Trust, Brighton, UK. FAU - Mamas, Mamas A AU - Mamas MA AD - Keele Cardiovascular Research Group, Keele University, Stoke-on-Trent, UK. AD - University of Bristol, Bristol, UK. FAU - Calvert, Patrick A AU - Calvert PA AUID- ORCID: 0000-0002-0292-0578 AD - Department of Cardiology, Royal Papworth Hospital, Cambridge, UK. AD - University of Cambridge, Cambridge, UK. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Eur Heart J JT - European heart journal JID - 8006263 SB - IM CIN - Eur Heart J. 2022 Dec 21;43(48):5033-5036. doi: 10.1093/eurheartj/ehac532. PMID: 36124726 MH - Humans MH - Shock, Cardiogenic/etiology MH - Aftercare MH - Treatment Outcome MH - Patient Discharge MH - *Heart Septal Defects, Ventricular/surgery MH - *Myocardial Infarction MH - *Anterior Wall Myocardial Infarction MH - Registries MH - United Kingdom/epidemiology MH - Retrospective Studies OTO - NOTNLM OT - Percutaneous ventricular septal defect repair OT - Post-infarction ventricular septal defect OT - Ventricular septal rupture COIS- Conflict of interest: B.R.C. has received speaking fees from Abbott Vascular. P.M. has provided expert testimony and worked as a speaker for Edwards Lifesciences. J.B. has worked as a proctor for Abbott Vascular. M.S.T. has worked as a consultant and received educational grants from Occlutech. He has worked as a consultant and proctor for Abbott Vascular. D.B.N. has worked as a proctor for Abbott Vascular. D.H.-S. has received travel support and worked as a proctor for Abbott Vascular and Boston Scientific; he has received consulting fees and participated in a data and safety monitoring board for Abbott Vascular. M.A.M. has received non-restrictive educational grants from Abbott Vascular and Terumo, and worked as a consultant for Daiichi Sankyo and Terumo. P.A.C. has worked as a proctor for Abbott Vascular, Gore Medical and Occlutech. EDAT- 2022/09/21 06:00 MHDA- 2022/12/24 06:00 CRDT- 2022/09/20 04:53 PHST- 2022/04/07 00:00 [received] PHST- 2022/08/16 00:00 [revised] PHST- 2022/09/01 00:00 [accepted] PHST- 2022/09/21 06:00 [pubmed] PHST- 2022/12/24 06:00 [medline] PHST- 2022/09/20 04:53 [entrez] AID - 6696034 [pii] AID - 10.1093/eurheartj/ehac511 [doi] PST - ppublish SO - Eur Heart J. 2022 Dec 21;43(48):5020-5032. doi: 10.1093/eurheartj/ehac511. PMID- 36122994 OWN - NLM STAT- MEDLINE DCOM- 20220922 LR - 20240904 IS - 2399-6641 (Electronic) IS - 2399-6641 (Linking) VI - 11 IP - 3 DP - 2022 Sep TI - Interventions to prevent hypothermia in extremely preterm low-weight infants undergoing cardiac catheterisation. LID - 10.1136/bmjoq-2021-001773 [doi] LID - e001773 AB - BACKGROUND: In January 2019, a new device called the Amplatzer Piccolo Occluder was approved by the US Food and Drug Administration for percutaneous closure of patent ductus arteriosus in infants weighing more than 700 g and of postnatal age more than 3 days. Premature low-weight infants are predisposed to hypothermia when transported outside of the thermo-neutral environment. At our institution, 90% of extremely preterm low-weight infants developed transient moderate hypothermia in the cardiac catheterisation suite. METHODS: We conducted a study testing multiple hypotheses aimed at preventing hypothermia in the cardiac catheterisation suite. Interventions included increasing ambient room temperature, reducing exposure to cold environment and reducing overall time spent in the remote location. The primary outcome was the proportion of patients who developed transient hypothermia at the start of the procedure in the cardiac catheterisation suite. The secondary measures included mean core body temperature at four different instances, as well as anaesthesia time, procedure time and radiation exposure. RESULTS: During the study period, 10 patients were enrolled in each group. The postintervention group saw a reduction in transient hypothermia from 90% to 40% (absolute risk reduction 50%, p=0.02). Data analysis showed an improvement in mean core body temperature (35.4 degrees C vs 36.4 degrees C, p<0.01) as well as a smaller percentage drop in temperature (4% vs 1.3%, p<0.01) between the two groups, both of which were statistically significant. The anaesthesia time, procedure time and radiation exposure reduced between the two groups. CONCLUSION: The application of the interventions reduced hypothermia in this high-risk population. The implementation of a protocol with collaboration of a multidisciplinary team is indispensable in providing optimal care to extremely preterm infants. CI - (c) Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Alhalabi, Eliane AU - Alhalabi E AUID- ORCID: 0000-0002-9035-2207 AD - Anesthesiology, Henry Ford Health System, Detroit, Michigan, USA. FAU - Zestos, Maria AU - Zestos M AD - Children's Hospital of Michigan, Detroit, Michigan, USA mzestos@med.wayne.edu. AD - Department of Anesthesiology, Wayne State University School of Medicine, Detroit, MI, USA. FAU - Kobayashi, Daisuke AU - Kobayashi D AD - Department of Cardiology, Children's Hospital of Michigan, Detroit, Michigan, USA. FAU - Mckelvey, George M AU - Mckelvey GM AD - Department of Anesthesiology, Detroit Medical Center, Detroit, MI, USA. FAU - Taylor, Rachel A AU - Taylor RA AD - Department of Cardiology, Children's Hospital and Medical Center, Omaha, Nebraska, USA. LA - eng PT - Journal Article PL - England TA - BMJ Open Qual JT - BMJ open quality JID - 101710381 SB - IM MH - *Cardiac Catheterization/adverse effects MH - *Ductus Arteriosus, Patent/etiology MH - Humans MH - *Hypothermia/epidemiology/etiology/prevention & control MH - Infant MH - Infant, Extremely Premature MH - Infant, Newborn MH - *Septal Occluder Device MH - United States PMC - PMC9486285 OTO - NOTNLM OT - Clinical Protocols OT - Healthcare quality improvement OT - Paediatrics COIS- Competing interests: None declared. EDAT- 2022/09/20 06:00 MHDA- 2022/09/23 06:00 PMCR- 2022/09/19 CRDT- 2022/09/19 21:04 PHST- 2021/12/03 00:00 [received] PHST- 2022/09/01 00:00 [accepted] PHST- 2022/09/19 21:04 [entrez] PHST- 2022/09/20 06:00 [pubmed] PHST- 2022/09/23 06:00 [medline] PHST- 2022/09/19 00:00 [pmc-release] AID - bmjoq-2021-001773 [pii] AID - 10.1136/bmjoq-2021-001773 [doi] PST - ppublish SO - BMJ Open Qual. 2022 Sep;11(3):e001773. doi: 10.1136/bmjoq-2021-001773. PMID- 36117426 OWN - NLM STAT- MEDLINE DCOM- 20230321 LR - 20240402 IS - 1527-6473 (Electronic) IS - 1527-6465 (Print) IS - 1527-6465 (Linking) VI - 29 IP - 4 DP - 2023 Apr 1 TI - Portopulmonary hypertension practice patterns after liver transplantation. PG - 365-376 LID - 10.1002/lt.26575 [doi] AB - Portopulmonary hypertension (POPH) is a type of pulmonary arterial hypertension occurring exclusively in those with portal hypertensive liver disease. Liver transplantation (LT) can significantly improve outcomes. Current guidelines counsel against immediate adjustments to targeted therapy after LT and suggest routine echocardiography as sufficiently informative to guide therapeutic adjustments. Current practice patterns for adjusting targeted therapy after LT in POPH, and how they compare with guidelines, are not well established. To answer this question, we performed an institutional review board-approved, cross-sectional mixed-methods survey-based study of US POPH providers. Anonymized requests to complete the survey were sent through professional networks between January 20, 2022, and April 20, 2022. Responses were compared between cardiologists and pulmonologists using Fisher's exact tests, at a significance of 0.05. A total of 85 POPH physicians were included in the final analysis (66% pulmonologists and 34% cardiologists). Following LT, the majority of respondents routinely used a combination of standard cardiopulmonary assessment modalities to guide adjustment of targeted therapy following LT. Most respondents (69%) started by adjusting parenteral prostacyclins with small titrations and frequent reassessments within 3 months of LT, but some (19.7%) adjusted targeted therapy immediately after LT. Our results showed that the majority of respondents favored serial integrated cardiopulmonary testing (including routine right heart catheterization) to guide the adjustment of targeted therapy in POPH after LT, and almost one-fifth of respondents weaned therapy immediately after LT. Our study demonstrates heterogeneity in POPH practice patterns after LT, highlights differences between current practice patterns and the most recent guidelines, emphasizes the need for additional research, and supports a team-based approach to standardize care for these high-risk patients and optimize post-LT outcomes. CI - Copyright (c) 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Association for the Study of Liver Diseases. FAU - Jose, Arun AU - Jose A AUID- ORCID: 0000-0001-7109-2692 AD - Division of Pulmonary, Critical Care, and Sleep Medicine , University of Cincinnati , Cincinnati , Ohio , USA. FAU - Kopras, Elizabeth J AU - Kopras EJ AUID- ORCID: 0000-0001-5429-2609 AD - Division of Pulmonary, Critical Care, and Sleep Medicine , University of Cincinnati , Cincinnati , Ohio , USA. FAU - Shah, Shimul A AU - Shah SA AUID- ORCID: 0000-0003-3406-7310 AD - Department of Surgery , University of Cincinnati , Cincinnati , Ohio , USA. FAU - Elwing, Jean M AU - Elwing JM AUID- ORCID: 0000-0001-6199-1707 AD - Division of Pulmonary, Critical Care, and Sleep Medicine , University of Cincinnati , Cincinnati , Ohio , USA. LA - eng GR - K23 HL164971/HL/NHLBI NIH HHS/United States GR - KL2 TR001426/TR/NCATS NIH HHS/United States GR - UL1 TR001425/TR/NCATS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20220905 PL - United States TA - Liver Transpl JT - Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society JID - 100909185 SB - IM CIN - Liver Transpl. 2023 Apr 1;29(4):349-350. doi: 10.1097/LVT.0000000000000078. PMID: 36724441 MH - Humans MH - *Liver Transplantation/adverse effects MH - *Pulmonary Arterial Hypertension/diagnosis/etiology/surgery MH - *Hypertension, Pulmonary/etiology/surgery MH - Cross-Sectional Studies MH - *Hypertension, Portal/etiology/therapy PMC - PMC9985659 MID - NIHMS1838570 COIS- Conflicts of Interest - EK and SAS have no financial relationships to disclose. EDAT- 2022/09/20 06:00 MHDA- 2023/03/22 06:00 PMCR- 2024/04/01 CRDT- 2022/09/19 03:13 PHST- 2022/07/14 00:00 [received] PHST- 2022/09/08 00:00 [accepted] PHST- 2022/09/20 06:00 [pubmed] PHST- 2023/03/22 06:00 [medline] PHST- 2022/09/19 03:13 [entrez] PHST- 2024/04/01 00:00 [pmc-release] AID - 01445473-202304000-00006 [pii] AID - 10.1002/lt.26575 [doi] PST - ppublish SO - Liver Transpl. 2023 Apr 1;29(4):365-376. doi: 10.1002/lt.26575. Epub 2022 Sep 5. PMID- 36116812 OWN - NLM STAT- MEDLINE DCOM- 20220920 LR - 20220926 IS - 1557-8216 (Electronic) IS - 0272-5231 (Linking) VI - 43 IP - 3 DP - 2022 Sep TI - Management of the Critically Ill Patient with Pulmonary Arterial Hypertension and Right Heart Failure. PG - 425-439 LID - S0272-5231(22)00032-6 [pii] LID - 10.1016/j.ccm.2022.04.005 [doi] AB - Right ventricular (RV) failure is a recognized complication of pulmonary hypertension (PH). Pregnancy and surgery represent unique challenges to the patient with PH and require input from an interprofessional team. Approach to treatment must embrace sound physiologic principles that are based on optimization of RV preload, contractility, and afterload to improve cardiac function and tissue perfusion before the onset of multiorgan dysfunction. Failure of medical therapy needs to be recognized before the onset of irreversible shock. When appropriate, eligible patients should be considered for mechanical circulatory support as a bridge to recovery or transplantation. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Granton, John AU - Granton J AD - University of Toronto, Pulmonary and Critical Care Medicine, University Health Network, 9-9023 MARS Building, 585 University Avenue, Toronto, Ontario M5G 2N2, Canada. Electronic address: John.granton@uhn.ca. FAU - Teijeiro-Paradis, Ricardo AU - Teijeiro-Paradis R AD - Interdepartmental Division of Critical Care, University of Toronto, University Health Network, 585 University Avenue, Toronto, Ontario M5G 2N2, Canada. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review PL - United States TA - Clin Chest Med JT - Clinics in chest medicine JID - 7907612 SB - IM MH - Critical Illness/therapy MH - *Heart Failure/complications/therapy MH - Humans MH - *Hypertension, Pulmonary/complications/therapy MH - *Pulmonary Arterial Hypertension MH - *Ventricular Dysfunction, Right/complications/therapy OTO - NOTNLM OT - Echocardiography OT - Extracorporeal support OT - Heart failure OT - Pulmonary hypertension OT - Right ventricle EDAT- 2022/09/19 06:00 MHDA- 2022/09/21 06:00 CRDT- 2022/09/18 21:03 PHST- 2022/09/18 21:03 [entrez] PHST- 2022/09/19 06:00 [pubmed] PHST- 2022/09/21 06:00 [medline] AID - S0272-5231(22)00032-6 [pii] AID - 10.1016/j.ccm.2022.04.005 [doi] PST - ppublish SO - Clin Chest Med. 2022 Sep;43(3):425-439. doi: 10.1016/j.ccm.2022.04.005. PMID- 36114022 OWN - NLM STAT- MEDLINE DCOM- 20221018 LR - 20221122 IS - 1879-1913 (Electronic) IS - 0002-9149 (Linking) VI - 183 DP - 2022 Nov 15 TI - In-Hospital Outcomes of Surgical Aortic Valve Replacement at Transcatheter Valve Implantation Centers. PG - 78-84 LID - S0002-9149(22)00841-4 [pii] LID - 10.1016/j.amjcard.2022.08.003 [doi] AB - The availability of transcatheter aortic valve implantation (TAVI) has led to the development of a multidisciplinary team, the "heart team," at institutions offering both TAVI and surgical aortic valve replacement (SAVR). Whether this approach has improved in-hospital outcomes in patients who underwent SAVR at institutions offering TAVI versus those not offering TAVI is largely unknown. The National Inpatient Sample (2011 to 2018) was used to study trends in visits for SAVR and in-hospital outcomes at TAVI and non-TAVI centers. Survey estimation commands were used to determine weighted national estimates. There were 559,365 inpatient visits during 2011 to 2018 for aortic valve replacement, with 65.9 +/- 0.8% and 34.0 +/- 0.8% at TAVI and non-TAVI centers, respectively. Patients who underwent SAVR at TAVI hospitals had more co-morbidities and were less likely to receive mechanical prosthesis (24.7 +/- 0.5% vs 35.5 +/- 0.6%). Adjusted in-hospital mortality was lower among any SAVR (odds ratio 0.84, 95% confidence interval 0.75 to 0.94) and isolated SAVR (odds ratio 0.83, 95% confidence interval 0.70 to 0.98) recipients at TAVI centers. There was no difference in the incidence of stroke, permanent pacemaker placement, and acute kidney injury after SAVR in TAVI and non-TAVI centers. Although patients who underwent SAVR at TAVI centers had more co-morbidities, in-hospital mortality was lower at TAVI centers than non-TAVI centers. This may be attributable to several factors, including but not limited to experience, resource availability, and operative volumes and the use of the heart team. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Hiltner, Emily AU - Hiltner E AD - Division of Cardiology, Department of Medicine, Robert Wood Johnson University Hospital, New Brunswick, New Jersey. FAU - Erinne, Ikenna AU - Erinne I AD - Division of Cardiology, Department of Medicine, Robert Wood Johnson University Hospital, New Brunswick, New Jersey. FAU - Singh, Anjuli AU - Singh A AD - Department of Family Medicine Robert Wood Johnson University Hospital Somerset, Somerville, New Jersey. FAU - Chen, Chunguang AU - Chen C AD - Department of Cardiology, Deborah Heart and Lung Center, Browns Mills, Burlington County, New Jersey. FAU - Kassotis, John AU - Kassotis J AD - Division of Cardiology, Department of Medicine, Robert Wood Johnson University Hospital, New Brunswick, New Jersey. FAU - Russo, Mark AU - Russo M AD - Division of Cardiothoracic Surgery, Department of Surgery, Robert Wood Johnson University Hospital, New Brunswick, New Jersey. FAU - Sethi, Ankur AU - Sethi A AD - Division of Cardiology, Department of Medicine, Robert Wood Johnson University Hospital, New Brunswick, New Jersey. Electronic address: drankursethi@gmail.com. LA - eng PT - Journal Article DEP - 20220914 PL - United States TA - Am J Cardiol JT - The American journal of cardiology JID - 0207277 SB - IM MH - Aortic Valve/surgery MH - *Aortic Valve Stenosis/surgery MH - *Heart Valve Prosthesis MH - *Heart Valve Prosthesis Implantation MH - Hospitals MH - Humans MH - Postoperative Complications/epidemiology/surgery MH - Risk Factors MH - *Transcatheter Aortic Valve Replacement MH - Treatment Outcome EDAT- 2022/09/17 06:00 MHDA- 2022/10/19 06:00 CRDT- 2022/09/16 22:02 PHST- 2022/04/19 00:00 [received] PHST- 2022/08/02 00:00 [revised] PHST- 2022/08/06 00:00 [accepted] PHST- 2022/09/17 06:00 [pubmed] PHST- 2022/10/19 06:00 [medline] PHST- 2022/09/16 22:02 [entrez] AID - S0002-9149(22)00841-4 [pii] AID - 10.1016/j.amjcard.2022.08.003 [doi] PST - ppublish SO - Am J Cardiol. 2022 Nov 15;183:78-84. doi: 10.1016/j.amjcard.2022.08.003. Epub 2022 Sep 14. PMID- 36111640 OWN - NLM STAT- MEDLINE DCOM- 20221124 LR - 20221217 IS - 1532-2092 (Electronic) IS - 1099-5129 (Linking) VI - 24 IP - 11 DP - 2022 Nov 22 TI - Thoracoscopic hybrid ablation in a patient with drug refractory arrhythmogenic right ventricular cardiomyopathy combined with non-invasive electrocardiographic imaging: a multidisciplinary approach. PG - 1808 LID - 10.1093/europace/euac127 [doi] FAU - Monaco, Cinzia AU - Monaco C AD - Heart Rhythm Management Centre, Postgraduate Program in Cardiac Electrophysiology and Pacing, European Reference Networks Guard-Heart, Vrije Universiteit Brussel, Universitair Ziekenhuis, Belgium. FAU - Pannone, Luigi AU - Pannone L AUID- ORCID: 0000-0001-9769-1511 AD - Heart Rhythm Management Centre, Postgraduate Program in Cardiac Electrophysiology and Pacing, European Reference Networks Guard-Heart, Vrije Universiteit Brussel, Universitair Ziekenhuis, Belgium. FAU - Bisignani, Antonio AU - Bisignani A AUID- ORCID: 0000-0003-3938-4948 AD - Heart Rhythm Management Centre, Postgraduate Program in Cardiac Electrophysiology and Pacing, European Reference Networks Guard-Heart, Vrije Universiteit Brussel, Universitair Ziekenhuis, Belgium. FAU - Chierchia, Gian Battista AU - Chierchia GB AD - Heart Rhythm Management Centre, Postgraduate Program in Cardiac Electrophysiology and Pacing, European Reference Networks Guard-Heart, Vrije Universiteit Brussel, Universitair Ziekenhuis, Belgium. FAU - La Meir, Mark AU - La Meir M AD - Department of Cardiac Surgery, Vrije Universiteit Brussel, Universitair Ziekenhuis, Brussel, Belgium. FAU - de Asmundis, Carlo AU - de Asmundis C AUID- ORCID: 0000-0001-9351-0760 AD - Heart Rhythm Management Centre, Postgraduate Program in Cardiac Electrophysiology and Pacing, European Reference Networks Guard-Heart, Vrije Universiteit Brussel, Universitair Ziekenhuis, Belgium. LA - eng PT - Journal Article PL - England TA - Europace JT - Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology JID - 100883649 SB - IM MH - Humans MH - *Arrhythmogenic Right Ventricular Dysplasia/diagnosis/diagnostic imaging MH - Electrocardiography MH - *Tachycardia, Ventricular/diagnostic imaging/surgery MH - *Catheter Ablation EDAT- 2022/09/17 06:00 MHDA- 2022/11/25 06:00 CRDT- 2022/09/16 06:23 PHST- 2022/09/17 06:00 [pubmed] PHST- 2022/11/25 06:00 [medline] PHST- 2022/09/16 06:23 [entrez] AID - 6701892 [pii] AID - 10.1093/europace/euac127 [doi] PST - ppublish SO - Europace. 2022 Nov 22;24(11):1808. doi: 10.1093/europace/euac127. PMID- 36104027 OWN - NLM STAT- MEDLINE DCOM- 20220916 LR - 20221003 IS - 1098-9048 (Electronic) IS - 1069-3424 (Linking) VI - 43 IP - 4 DP - 2022 Aug TI - Nonmalignant Pleural Effusions. PG - 570-582 LID - 10.1055/s-0042-1748186 [doi] AB - Although the potential causes of nonmalignant pleural effusions are many, the management of a few, including complicated pleural infections and refractory heart failure and hepatic hydrothoraces, can be challenging and requires the assistance of interventional pulmonologists. A pragmatic approach to complicated parapneumonic effusions or empyemas is the insertion of a small-bore chest tube (e.g., 14-16 Fr) through which fibrinolytics (e.g., urokinase and alteplase) and DNase are administered in combination. Therapeutic thoracenteses are usually reserved for small to moderate effusions that are expected to be completely aspirated at a single time, whereas video-assisted thoracic surgery should be considered after failure of intrapleural enzyme therapy. Refractory cardiac and liver-induced pleural effusions portend a poor prognosis. In cases of heart failure-related effusions, therapeutic thoracentesis is the first-line palliative therapy. However, if it is frequently needed, an indwelling pleural catheter (IPC) is recommended. In patients with hepatic hydrothorax, repeated therapeutic thoracenteses are commonly performed while a multidisciplinary decision on the most appropriate definitive management is taken. The percutaneous creation of a portosystemic shunt may be used as a bridge to liver transplantation or as a potential definitive therapy in nontransplant candidates. In general, an IPC should be avoided because of the high risk of complications, particularly infections, that may jeopardize candidacy for liver transplantation. Even so, in noncandidates for liver transplant or surgical correction of diaphragmatic defects, IPC is a therapeutic option as valid as serial thoracenteses. CI - Thieme. All rights reserved. FAU - Porcel, Jose M AU - Porcel JM AD - Pleural Medicine Unit, Department of Internal Medicine, Arnau de Vilanova University Hospital, IRBLleida, University of Lleida, Lleida, Spain. LA - eng PT - Journal Article DEP - 20220914 PL - United States TA - Semin Respir Crit Care Med JT - Seminars in respiratory and critical care medicine JID - 9431858 SB - IM MH - Catheters, Indwelling/adverse effects MH - *Heart Failure/complications/therapy MH - Humans MH - *Hydrothorax/etiology MH - *Pleural Effusion/etiology/therapy MH - Thoracentesis/adverse effects COIS- None declared. EDAT- 2022/09/15 06:00 MHDA- 2022/09/17 06:00 CRDT- 2022/09/14 20:33 PHST- 2022/09/14 20:33 [entrez] PHST- 2022/09/15 06:00 [pubmed] PHST- 2022/09/17 06:00 [medline] AID - 10.1055/s-0042-1748186 [doi] PST - ppublish SO - Semin Respir Crit Care Med. 2022 Aug;43(4):570-582. doi: 10.1055/s-0042-1748186. Epub 2022 Sep 14. PMID- 36098413 OWN - NLM STAT- MEDLINE DCOM- 20221219 LR - 20230123 IS - 1875-6212 (Electronic) IS - 1570-1611 (Linking) VI - 20 IP - 6 DP - 2022 TI - Patients with Polyvascular Disease: A Very High-risk Group. PG - 475-490 LID - 10.2174/1570161120666220912103321 [doi] AB - Polyvascular disease (PolyvascDis) with atherosclerosis occurring in >2 vascular beds (coronary, carotid, aortic, visceral and/or peripheral arteries) is encountered in 15-30% of patients who experience greater rates of major adverse cardiovascular (CV) events. Every patient with multiple CV risk factors or presenting with CV disease in one arterial bed should be assessed for PolyvascDis clinically and noninvasively prior to invasive angiography. Peripheral arterial disease (PAD) can be readily diagnosed in routine practice by measuring the ankle-brachial index. Carotid disease can be diagnosed by duplex ultrasound showing % stenosis and/or presence of plaques. Coronary artery disease (CAD) can be screened by determining coronary artery calcium score using coronary computed tomography angiography; further, non-invasive testing includes exercise stress and/or myocardial perfusion imaging or dobutamine stress test, prior to coronary angiography. Abdominal ultrasound can reveal an abdominal aortic aneurysm. Computed tomography angiography will be needed in patients with suspected mesenteric ischemia to assess the mesenteric arteries. Patients with the acute coronary syndrome and concomitant other arterial diseases have more extensive CAD and poorer CV outcomes. Similarly, PolyvascDis in patients with carotid disease and/or other PAD is independently associated with an increased risk for all-cause and CV mortality during long-term follow-up. Treatment of patients with PolyvascDis should include aggressive management of all modifiable risk factors by lifestyle changes and drug therapy, with particular attention to patients who are commonly undertreated, such as those with PAD. Revascularization should be reserved for symptomatic vascular beds, using the least aggressive strategy in a multidisciplinary vascular team approach. CI - Copyright(c) Bentham Science Publishers; For any queries, please email at epub@benthamscience.net. FAU - Manolis, Antonis A AU - Manolis AA AD - School of Medicine, Patras University, Patras, Greece. FAU - Manolis, Theodora A AU - Manolis TA AD - School of Medicine, Athens University, Athens, Greece. FAU - Manolis, Antonis S AU - Manolis AS AD - School of Medicine, Athens University, Athens, Greece. LA - eng PT - Journal Article PL - United Arab Emirates TA - Curr Vasc Pharmacol JT - Current vascular pharmacology JID - 101157208 SB - IM MH - Humans MH - *Coronary Artery Disease/diagnostic imaging/therapy MH - Coronary Angiography MH - *Peripheral Arterial Disease/diagnosis MH - *Acute Coronary Syndrome/therapy MH - Risk Factors OTO - NOTNLM OT - Polyvascular disease OT - abdominal aortic aneurysm OT - atherosclerosis OT - cardiovascular outcomes OT - carotid disease OT - coronary artery disease OT - major adverse cardiovascular events OT - peripheral artery disease EDAT- 2022/09/14 06:00 MHDA- 2022/12/20 06:00 CRDT- 2022/09/13 08:03 PHST- 2022/05/16 00:00 [received] PHST- 2022/08/04 00:00 [revised] PHST- 2022/08/04 00:00 [accepted] PHST- 2022/09/14 06:00 [pubmed] PHST- 2022/12/20 06:00 [medline] PHST- 2022/09/13 08:03 [entrez] AID - CVP-EPUB-126272 [pii] AID - 10.2174/1570161120666220912103321 [doi] PST - ppublish SO - Curr Vasc Pharmacol. 2022;20(6):475-490. doi: 10.2174/1570161120666220912103321. PMID- 36094465 OWN - NLM STAT- MEDLINE DCOM- 20221007 LR - 20230316 IS - 1531-7080 (Electronic) IS - 0268-4705 (Linking) VI - 37 IP - 6 DP - 2022 Nov 1 TI - How to deal with nonsevere stenoses in coronary artery bypass grafting - a critical perspective on competitive flow and surgical precision. PG - 468-473 LID - 10.1097/HCO.0000000000000993 [doi] AB - PURPOSE OF REVIEW: For invasive treatment of coronary artery disease (CAD), we assess anatomical complexity, analyse surgical risk and make heart-team decisions for percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG). With PCI, treating flow-relevant lesions is recommended, and reintervention easily treats disease progression. For CABG, some stenoses may only be borderline or nonsevere despite a clear surgical indication. As reoperations are not easy, the question on how to address these lesions has been around from the start, but has never satisfactorily been answered. RECENT FINDINGS: With a new mechanistic perspective, we had suggested that infarct-prevention by surgical collateralization is the main prognostic mechanism of CABG in chronic coronary syndrome. Importantly, the majority of infarctions arise from nonsevere coronary lesions. Thus, surgical collateralization may be a valid treatment option for nonsevere lesions, but graft patency moves more into focus here, because graft patency directly correlates with the severity of coronary stenoses. In addition, CABG may even accelerate native disease progression. SUMMARY: We here review the evidence for and against grafting nonsevere CAD lesions, suggesting that patency of grafts (to moderate lesions) may be improved by increasing surgical precision. In addition, we must improve our ability to predict future myocardial infarctions. CI - Copyright (c) 2022 Wolters Kluwer Health, Inc. All rights reserved. FAU - Doenst, Torsten AU - Doenst T AD - Department of Cardiothoracic Surgery, Jena University Hospital, Friedrich Schiller University of Jena, Jena, Germany. FAU - Sousa-Uva, Miguel AU - Sousa-Uva M AD - Department of Cardiothoracic Surgery, Hospital de Santa Cruz, Carnaxide. AD - Department of Physiology, Porto University Medical School, Porto, Portugal. LA - eng PT - Journal Article PT - Review DEP - 20220912 PL - United States TA - Curr Opin Cardiol JT - Current opinion in cardiology JID - 8608087 SB - IM MH - Constriction, Pathologic MH - Coronary Artery Bypass MH - *Coronary Artery Disease/complications/surgery MH - Disease Progression MH - Humans MH - *Percutaneous Coronary Intervention MH - Treatment Outcome EDAT- 2022/09/13 06:00 MHDA- 2022/10/12 06:00 CRDT- 2022/09/12 11:39 PHST- 2022/09/13 06:00 [pubmed] PHST- 2022/10/12 06:00 [medline] PHST- 2022/09/12 11:39 [entrez] AID - 00001573-202211000-00006 [pii] AID - 10.1097/HCO.0000000000000993 [doi] PST - ppublish SO - Curr Opin Cardiol. 2022 Nov 1;37(6):468-473. doi: 10.1097/HCO.0000000000000993. Epub 2022 Sep 12. PMID- 36094460 OWN - NLM STAT- MEDLINE DCOM- 20221007 LR - 20230316 IS - 1531-7080 (Electronic) IS - 0268-4705 (Linking) VI - 37 IP - 6 DP - 2022 Nov 1 TI - It's not all about ISCHEMIA: the case for coronary artery bypass grafting in stable coronary artery disease. PG - 459-467 LID - 10.1097/HCO.0000000000000994 [doi] AB - PURPOSE OF REVIEW: The recent American College of Cardiology/American Heart Association/Society for Cardiovascular Angiography and Interventions Guidelines for Coronary Artery Revascularization have raised concerns on the survival benefits of coronary artery bypass grafting (CABG) over guideline-directed medical therapy (GDMT) in stable coronary artery disease (CAD) and appropriate conduit selection for CABG. This review summarizes the evidence supporting CABG for stable CAD and use of the radial artery as a conduit for CABG. RECENT FINDINGS: CABG has consistently demonstrated a survival benefit over GDMT for patients with stable multivessel CAD. These benefits were more pronounced in patients with diabetes and/or anatomically complex coronary artery disease. The recently published International Study of Comparative Health Effectiveness with Medical and Invasive Approaches trial was not designed to and did not include an appropriate patient population to compare revascularization with CABG to GDMT. These results should thus be viewed in the context of previously published studies. Furthermore, increasing evidence suggests that use of a radial artery in CABG is associated with reduced myocardial infarction and repeat revascularization. This should be considered when selecting the appropriate conduits based on underlying patient factors. SUMMARY: Readers should be cautious when applying these guidelines broadly. Appropriate consideration of patient and anatomic factors, and in consultation with a multidisciplinary heart team, is important to achieve the best outcomes for patients. CI - Copyright (c) 2022 Wolters Kluwer Health, Inc. All rights reserved. FAU - Yan, Weiang AU - Yan W AD - Section of Cardiac Surgery, Department of Surgery, Max Rady College of Medicine. AD - Cardiac Sciences Program. FAU - Eikelboom, Rachel AU - Eikelboom R AD - Section of Cardiac Surgery, Department of Surgery, Max Rady College of Medicine. AD - Cardiac Sciences Program. FAU - Muller Moran, Hellmuth R AU - Muller Moran HR AD - Section of Cardiac Surgery, Department of Surgery, Max Rady College of Medicine. AD - Cardiac Sciences Program. FAU - Arora, Rakesh C AU - Arora RC AD - Section of Cardiac Surgery, Department of Surgery, Max Rady College of Medicine. AD - Cardiac Sciences Program. AD - Department of Anesthesiology, Perioperative and Pain Medicine, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada. LA - eng GR - MEF-171305/CIHR/Canada PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20220912 PL - United States TA - Curr Opin Cardiol JT - Current opinion in cardiology JID - 8608087 SB - IM MH - Coronary Artery Bypass/adverse effects MH - *Coronary Artery Disease/therapy MH - Humans MH - *Myocardial Infarction/surgery MH - *Percutaneous Coronary Intervention/adverse effects MH - Treatment Outcome EDAT- 2022/09/13 06:00 MHDA- 2022/10/12 06:00 CRDT- 2022/09/12 11:39 PHST- 2022/09/13 06:00 [pubmed] PHST- 2022/10/12 06:00 [medline] PHST- 2022/09/12 11:39 [entrez] AID - 00001573-202211000-00005 [pii] AID - 10.1097/HCO.0000000000000994 [doi] PST - ppublish SO - Curr Opin Cardiol. 2022 Nov 1;37(6):459-467. doi: 10.1097/HCO.0000000000000994. Epub 2022 Sep 12. PMID- 36090574 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220913 IS - 2296-2360 (Print) IS - 2296-2360 (Electronic) IS - 2296-2360 (Linking) VI - 10 DP - 2022 TI - Long-term management of Fontan patients: The importance of a multidisciplinary approach. PG - 886208 LID - 10.3389/fped.2022.886208 [doi] LID - 886208 AB - The Fontan operation is a palliative procedure that leads to increased survival of patients with a functional single ventricle (SV). Starting from 1967 when the first operation was performed by Francis Fontan, more and more patients have reached adulthood. Furthermore, it is expected that in the next 20 years, the population with Fontan circulation will reach 150,000 subjects. The absence of right ventricular propulsion and the inability to improve cardiac output because of the low cardiac reserve are the main issues with the Fontan circulation; however, potential complications may also involve multiple organ systems, such as the liver, lungs, brain, bones, and the lymphatic system. As these patients were initially managed mainly by pediatric cardiologists, it was important to assure the appropriate transition to adult care with the involvement of a multidisciplinary team, including adult congenital cardiologists and multiple subspecialists, many of whom are neither yet familiar with the pathophysiology nor the end-organ consequences of the Fontan circulation. Therefore, the aim of our work was to collect all the best available evidence on Fontan's complications management to provide "simple and immediate" information sources for practitioners looking for state of the art evidence to guide their decision-making and work practices. Moreover, we suggest a model of follow-up of patients with Fontan based on a patient-centered multidisciplinary approach. CI - Copyright (c) 2022 Martino, Rizzardi, Vigezzi, Guariento, Sturniolo, Tesser and Salvo. FAU - Martino, Diletta AU - Martino D AD - Pediatric Unit, Department for Women's and Children's Health, University Hospital of Padova, Padua, Italy. FAU - Rizzardi, Caterina AU - Rizzardi C AD - Pediatric Unit, Department for Women's and Children's Health, University Hospital of Padova, Padua, Italy. FAU - Vigezzi, Serena AU - Vigezzi S AD - Pediatric Unit, Department for Women's and Children's Health, University Hospital of Padova, Padua, Italy. FAU - Guariento, Chiara AU - Guariento C AD - Pediatric Unit, Department for Women's and Children's Health, University Hospital of Padova, Padua, Italy. FAU - Sturniolo, Giulia AU - Sturniolo G AD - Pediatric Unit, Department for Women's and Children's Health, University Hospital of Padova, Padua, Italy. FAU - Tesser, Francesca AU - Tesser F AD - Pediatric Unit, Department for Women's and Children's Health, University Hospital of Padova, Padua, Italy. FAU - Salvo, Giovanni di AU - Salvo GD AD - Pediatric and Congenital Cardiology Unit, Department for Women's and Children's Health, University Hospital of Padova, Padua, Italy. LA - eng PT - Journal Article PT - Review DEP - 20220825 PL - Switzerland TA - Front Pediatr JT - Frontiers in pediatrics JID - 101615492 PMC - PMC9452819 OTO - NOTNLM OT - Fontan OT - Fontan circuit OT - complications OT - failure Fontan OT - multidisciplinary COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/09/13 06:00 MHDA- 2022/09/13 06:01 PMCR- 2022/08/25 CRDT- 2022/09/12 03:45 PHST- 2022/02/28 00:00 [received] PHST- 2022/07/11 00:00 [accepted] PHST- 2022/09/12 03:45 [entrez] PHST- 2022/09/13 06:00 [pubmed] PHST- 2022/09/13 06:01 [medline] PHST- 2022/08/25 00:00 [pmc-release] AID - 10.3389/fped.2022.886208 [doi] PST - epublish SO - Front Pediatr. 2022 Aug 25;10:886208. doi: 10.3389/fped.2022.886208. eCollection 2022. PMID- 36088681 OWN - NLM STAT- MEDLINE DCOM- 20221207 LR - 20230227 IS - 1527-3288 (Electronic) IS - 0147-9563 (Linking) VI - 57 DP - 2023 Jan-Feb TI - The role of a multidisciplinary heart failure clinic in optimization of guideline-directed medical therapy: HF-optimize. PG - 95-101 LID - S0147-9563(22)00189-3 [pii] LID - 10.1016/j.hrtlng.2022.08.010 [doi] AB - BACKGROUND: Guideline-directed medical therapy (GDMT) reduces mortality and hospitalizations in adults with heart failure with reduced ejection fraction (HFrEF); however, few are receiving GDMT. National registries show as few as 1% of patients are receiving appropriate GDMT. Development of heart failure clinics achieving optimal GDMT are crucial to improve outcomes for HFrEF patients. OBJECTIVE: We developed a multidisciplinary HF-Optimize clinic aimed at improving GDMT use along with providing education, resources, and comorbidity screening for adults with HFrEF. METHODS: We targeted patients with newly diagnosed HFrEF and/or recent or multiple admissions for 6 visits over 12 weeks. We measured medication use, ejection fraction, 6-minute walk test distance, and health-related quality of life (EuroQol Visual Analog Scale) at visits 1 and 6. RESULTS: One-hundred ten patients completed all visits. Patients were a mean age of 58 (+/-14) years, 37% were female, and 42% were of non-White race. From visit 1 to visit 6, utilization of GDMT increased from 35.5% to 85.5% (p < 0.001) and significant improvements in ejection fraction (25.9% to 35.5%, p < 0.001), 6-minute walk distance (1032 feet to 1121.7 feet, p = 0.001), and quality of life (63.8/100 vs 70.8/100, p = 0.002). Only 2 patients (1.8%) that completed HF-Optimize had a 30-day heart failure readmission. CONCLUSION: Our multidisciplinary HF-Optimize clinic improved medication usage and clinical outcomes. Further studies are needed to validate outcomes of multidisciplinary GDMT clinics. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Diederich, Theresa AU - Diederich T AD - Nebraska Medicine, Cardiology, United States. Electronic address: tdiederich@nebraskamed.com. FAU - Burdorf, Adam AU - Burdorf A AD - University of Nebraska Medical Center, Cardiology, United States. FAU - Pozehl, Bunny AU - Pozehl B AD - University of Nebraska Medical Center, College of Nursing, United States. FAU - Bowman, Stephanie AU - Bowman S AD - Nebraska Medicine, Pharmacy, United States. FAU - Ferguson, Kelly AU - Ferguson K AD - Nebraska Medicine, Cardiology, United States. FAU - Holder, Kyana AU - Holder K AD - Nebraska Medicine, Cardiology, United States. Electronic address: kholder@nebraskamed.com. FAU - Alonso, Windy AU - Alonso W AD - University of Nebraska Medical Center, College of Nursing, United States. FAU - Stoller, Douglas AU - Stoller D AD - University of Nebraska Medical Center, Cardiology, United States. FAU - Lundgren, Scott AU - Lundgren S AD - University of Nebraska Medical Center, Cardiology, United States. LA - eng PT - Journal Article DEP - 20220908 PL - United States TA - Heart Lung JT - Heart & lung : the journal of critical care JID - 0330057 SB - IM MH - Adult MH - Humans MH - Female MH - Middle Aged MH - Male MH - *Heart Failure/drug therapy/diagnosis MH - Stroke Volume MH - Quality of Life MH - Ventricular Function, Left MH - Patient Readmission OTO - NOTNLM OT - Guideline-directed medical therapy OT - Health related quality of life OT - Heart failure outcomes OT - Multidisciplinary heart failure clinic COIS- Declaration of Competing Interest No authors have conflicts of interest to disclose for our article, The Role of a Multidisciplinary Heart Failure Clinic in Optimization of Guideline-Directed Medical Therapy: HF-Optimize EDAT- 2022/09/12 06:00 MHDA- 2023/03/03 06:00 CRDT- 2022/09/11 18:07 PHST- 2022/04/15 00:00 [received] PHST- 2022/07/26 00:00 [revised] PHST- 2022/08/20 00:00 [accepted] PHST- 2022/09/12 06:00 [pubmed] PHST- 2023/03/03 06:00 [medline] PHST- 2022/09/11 18:07 [entrez] AID - S0147-9563(22)00189-3 [pii] AID - 10.1016/j.hrtlng.2022.08.010 [doi] PST - ppublish SO - Heart Lung. 2023 Jan-Feb;57:95-101. doi: 10.1016/j.hrtlng.2022.08.010. Epub 2022 Sep 8. PMID- 36084397 OWN - NLM STAT- MEDLINE DCOM- 20221207 LR - 20230313 IS - 1527-3288 (Electronic) IS - 0147-9563 (Linking) VI - 57 DP - 2023 Jan-Feb TI - Correlation between severity of obesity and mortality in cardiogenic shock. PG - 66-68 LID - S0147-9563(22)00198-4 [pii] LID - 10.1016/j.hrtlng.2022.08.022 [doi] AB - INTRODUCTION: Cardiogenic shock (CS) is associated with high mortality despite the development of risk stratification tools and new treatment strategies. Obesity, although a risk factor for cardiovascular disease, is not included in current risk stratification tools for CS. A relationship between mortality and obesity has only been shown in subsets populations of CS; there is not yet a clear relationship between severity of obesity and all-cause CS. OBJECTIVES: In this study we evaluate the relationship between rising body mass index (BMI) and mortality in all-cause CS. METHODS: All patients with BMI measurements and hospitalizations complicated by CS from 2014 to 2019 at a single quaternary care institution were identified. Patients were grouped by obesity classification. Multivariate logistic regression was performed to determine a relationship between higher obesity classifications with 30-day mortality in patients with CS. RESULTS: Seventy-two patients were available for analysis. Mean BMI for those who survived compared to those who did not was 29.7 +/- 8 kg/m2 vs 33.7 +/- 7.6 kg/m2 (p = 0.04). The odds ratio for mortality with incremental increase in obesity classification was 1.6 (95% CI 1.1 - 2.6, p = 0.03) after adjusting for etiology of CS and other common associations with CS mortality. CONCLUSION: This study suggests that the higher mortality risk with incremental increases in BMI should be taken into account when risk stratifying these patients. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Delfiner, Matthew S AU - Delfiner MS AD - Division of Cardiovascular Disease, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA. Electronic address: matthew.delfiner@tuhs.temple.edu. FAU - Romero, Carlos Manuel AU - Romero CM AD - Department of Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA. FAU - Dillane, Catherine AU - Dillane C AD - Division of Cardiovascular Medicine, Atlanticare, Atlantic City, NJ, USA. FAU - Feldman, Elizabeth AU - Feldman E AD - Department of Medicine, Johns Hopkins Hospital, Baltimore, MD, USA. FAU - Hamad, Eman AU - Hamad E AD - Division of Cardiovascular Disease, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA. LA - eng PT - Journal Article DEP - 20220906 PL - United States TA - Heart Lung JT - Heart & lung : the journal of critical care JID - 0330057 SB - IM CIN - Heart Lung. 2023 Mar-Apr;58:250-251. doi: 10.1016/j.hrtlng.2022.11.007. PMID: 36456378 MH - Humans MH - *Shock, Cardiogenic/therapy MH - Hospital Mortality MH - Odds Ratio MH - *Obesity/complications/epidemiology MH - Logistic Models OTO - NOTNLM OT - Body mass index OT - Cardiogenic shock OT - Obesity OT - Shock team COIS- Declaration of Competing Interest Not Applicable. EDAT- 2022/09/10 06:00 MHDA- 2023/03/03 06:00 CRDT- 2022/09/09 18:17 PHST- 2022/05/01 00:00 [received] PHST- 2022/08/13 00:00 [revised] PHST- 2022/08/28 00:00 [accepted] PHST- 2022/09/10 06:00 [pubmed] PHST- 2023/03/03 06:00 [medline] PHST- 2022/09/09 18:17 [entrez] AID - S0147-9563(22)00198-4 [pii] AID - 10.1016/j.hrtlng.2022.08.022 [doi] PST - ppublish SO - Heart Lung. 2023 Jan-Feb;57:66-68. doi: 10.1016/j.hrtlng.2022.08.022. Epub 2022 Sep 6. PMID- 36084315 OWN - NLM STAT- MEDLINE DCOM- 20221123 LR - 20230920 IS - 1550-5065 (Electronic) IS - 1057-3631 (Linking) VI - 38 IP - 1 DP - 2023 Jan-Mar 01 TI - The Five-4-Life Quality Improvement Program: Improving Frontline Nurses' Cardiopulmonary Resuscitation Leadership and Team Management Skills. PG - 40-46 LID - 10.1097/NCQ.0000000000000648 [doi] AB - BACKGROUND: Poor leadership and teamwork in cardiopulmonary resuscitation (CPR) are associated with poor patient outcomes. PROBLEM: Frontline nursing staff frequently identify patients in cardiac arrest but may not have the initial leadership and teamwork skills to organize their initial rescue response. APPROACH: The Five-4-Life Quality Improvement (QI) program was pilot tested in a pediatric unit within a 510-bed acute care hospital in 2 phases: first, an educational program focused on leadership, team dynamics, and CPR skills, followed by sustaining interventions in the unit. Video recordings of 12 mock codes (4 pre-, 4 post-, 4 follow-up) were analyzed by trained observers. OUTCOMES: Descriptive statistical tests indicated a significant improvement in leadership, teamwork, and task management scores pre- and post-program, and sustained after the program. CONCLUSION: Implementing the Five-4-Life QI program is feasible in improving leadership, teamwork, and task management of first responding frontline nurses. CI - Copyright (c) 2022 Wolters Kluwer Health, Inc. All rights reserved. FAU - Bala-Kerr, Ruth AU - Bala-Kerr R AD - Department of Nursing, Harbor-UCLA Medical Center, Torrance, California. FAU - Sullivan, Brittany AU - Sullivan B FAU - Martin, Shelley AU - Martin S LA - eng PT - Journal Article DEP - 20220908 PL - United States TA - J Nurs Care Qual JT - Journal of nursing care quality JID - 9200672 SB - IM MH - Child MH - Humans MH - Leadership MH - Quality Improvement MH - *Cardiopulmonary Resuscitation MH - *Nurses MH - Patient Care Team MH - Clinical Competence COIS- The authors declare no conflicts of interest. EDAT- 2022/09/10 06:00 MHDA- 2022/11/24 06:00 CRDT- 2022/09/09 17:02 PHST- 2022/09/10 06:00 [pubmed] PHST- 2022/11/24 06:00 [medline] PHST- 2022/09/09 17:02 [entrez] AID - 00001786-202301000-00011 [pii] AID - 10.1097/NCQ.0000000000000648 [doi] PST - ppublish SO - J Nurs Care Qual. 2023 Jan-Mar 01;38(1):40-46. doi: 10.1097/NCQ.0000000000000648. Epub 2022 Sep 8. PMID- 36079121 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230308 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 11 IP - 17 DP - 2022 Sep 1 TI - Effects of on-Table Extubation after Pediatric Cardiac Surgery. LID - 10.3390/jcm11175186 [doi] LID - 5186 AB - Background: Enhanced recovery after surgery (ERAS) protocols are utilizing a multidisciplinary approach, reassessing physiology to improve clinical outcomes, reducing length of hospital stay (LOS) stay, resulting in cost reduction. Since its introduction in colorectal surgery. the concept has been utilized in various fields and benefits have been recognized also in adult cardiac surgery. However, ERAS concepts in pediatric cardiac surgery are not yet widely established. Therefore, the aim of the present study was to assess the effects of on-table extubation (OTE) after pediatric cardiac surgery compared to the standard approach of delayed extubation (DET) during intensive care treatment. Study Design and Methods: We performed a retrospective analysis of all pediatric cardiac surgery cases performed in children below the age of two years using cardiopulmonary bypass at our institution in 2021. Exclusion criteria were emergency and off pump surgeries as well as children already ventilated preoperatively. Results: OTE children were older (267.3 days vs. 126.7 days, p < 0.001), had a higher body weight (7.0 +/- 1.6 kg vs. 4.9 +/- 1.9 kg, p < 0.001), showed significantly reduced duration of ICU treatment (75.9 +/- 56.8 h vs. 217.2 +/- 211.4 h, p < 0.001) and LOS (11.1 +/- 10.2 days vs. 20.1 +/- 23.4 days; p = 0.001) compared to DET group. Furthermore, OTE children had significantly fewer catecholamine dependencies at 12-, 24-, 48-, and 72-h post-surgery, while DET children showed a significantly increased intrafluid shift relative to body weight (109.1 +/- 82.0 mL/kg body weight vs. 63.0 +/- 63.0 mL/kg body weight, p < 0.001). After propensity score matching considering age, weight, bypass duration, Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery Mortality (STATS)-Score, and the outcome variables, including duration of ICU treatment, catecholamine dependencies, and hospital LOS, findings significantly favored the OTE group. Conclusion: Our results suggest that on-table extubation after pediatric cardiac surgery is feasible and in our cohort was associated with a favorable postoperative course. FAU - Baehner, Torsten AU - Baehner T AUID- ORCID: 0000-0003-3044-2275 AD - Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn, 53127 Bonn, Germany. AD - Department of Anesthesiology and Intensive Care Medicine, Stiftshospital Andernach, 56626 Andernach, Germany. FAU - Pruemm, Philipp AU - Pruemm P AD - Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn, 53127 Bonn, Germany. FAU - Vergnat, Mathieu AU - Vergnat M AD - Department of Congenital Cardiac Surgery, University Hospital Bonn, 53127 Bonn, Germany. FAU - Asfour, Boulos AU - Asfour B AD - Department of Congenital Cardiac Surgery, University Hospital Bonn, 53127 Bonn, Germany. FAU - Strassberger-Nerschbach, Nadine AU - Strassberger-Nerschbach N AD - Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn, 53127 Bonn, Germany. FAU - Kirfel, Andrea AU - Kirfel A AUID- ORCID: 0000-0003-3503-4705 AD - Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn, 53127 Bonn, Germany. FAU - Hamann, Michael AU - Hamann M AD - Section of Pediatric Cardiac Intensive Care Medicine, University Hospital Bonn, 53127 Bonn, Germany. FAU - Mayr, Andreas AU - Mayr A AUID- ORCID: 0000-0001-7106-9732 AD - Institute for Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, 53127 Bonn, Germany. FAU - Schindler, Ehrenfried AU - Schindler E AUID- ORCID: 0000-0002-2377-3327 AD - Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn, 53127 Bonn, Germany. FAU - Velten, Markus AU - Velten M AUID- ORCID: 0000-0001-5439-4648 AD - Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn, 53127 Bonn, Germany. FAU - Wittmann, Maria AU - Wittmann M AUID- ORCID: 0000-0003-4786-7712 AD - Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn, 53127 Bonn, Germany. LA - eng PT - Journal Article DEP - 20220901 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC9457288 OTO - NOTNLM OT - enhanced recovery after surgery (ERAS) OT - on table extubation OT - pediatric cardiac anesthesia COIS- The authors declare no conflict of interest. EDAT- 2022/09/10 06:00 MHDA- 2022/09/10 06:01 PMCR- 2022/09/01 CRDT- 2022/09/09 01:20 PHST- 2022/07/23 00:00 [received] PHST- 2022/08/20 00:00 [revised] PHST- 2022/08/22 00:00 [accepted] PHST- 2022/09/09 01:20 [entrez] PHST- 2022/09/10 06:00 [pubmed] PHST- 2022/09/10 06:01 [medline] PHST- 2022/09/01 00:00 [pmc-release] AID - jcm11175186 [pii] AID - jcm-11-05186 [pii] AID - 10.3390/jcm11175186 [doi] PST - epublish SO - J Clin Med. 2022 Sep 1;11(17):5186. doi: 10.3390/jcm11175186. PMID- 36078921 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220913 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 11 IP - 17 DP - 2022 Aug 25 TI - Patients with Cardiac Implantable Electronic Device Undergoing Radiation Therapy: Insights from a Ten-Year Tertiary Center Experience. LID - 10.3390/jcm11174990 [doi] LID - 4990 AB - BACKGROUND: The number of patients with cardiac implantable electronic devices (CIEDs) receiving radiotherapy (RT) is increasing. The management of CIED-carriers undergoing RT is challenging and requires a collaborative multidisciplinary approach. AIM: The aim of the study is to report the real-world, ten-year experience of a tertiary multidisciplinary teaching hospital. METHODS: We conducted an observational, real-world, retrospective, single-center study, enrolling all CIED-carriers who underwent RT at the San Raffaele University Hospital, between June 2010 and December 2021. All devices were MRI-conditional. The devices were programmed to an asynchronous pacing mode for patients who had an intrinsic heart rate of less than 40 beats per minute. An inhibited pacing mode was used for all other patients. All tachyarrhythmia device functions were temporarily disabled. After each RT session, the CIED were reprogrammed to the original settings. Outcomes included adverse events and changes in the variables that indicate lead and device functions. RESULTS: Between June 2010 and December 2021, 107 patients were enrolled, among which 63 (58.9%) were pacemaker carriers and 44 (41.1%) were ICD carriers. Patients were subjected to a mean of 16.4 (+/-10.7) RT sessions. The most represented tumors in our cohort were prostate cancer (12; 11%), breast cancer (10; 9%) and lung cancer (28; 26%). No statistically significant changes in device parameters were recorded before and after radiotherapy. Generator failures, power-on resets, changes in pacing threshold or sensing requiring system revision or programming changes, battery depletions, pacing inhibitions and inappropriate therapies did not occur in our cohort of patients during a ten-year time span period. Atrial arrhythmias were recorded during RT session in 14 patients (13.1%) and ventricular arrhythmias were observed at device interrogation in 10 patients (9.9%). CONCLUSIONS: Changes in device parameters and arrhythmia occurrence were infrequent, and none resulted in a clinically significant adverse event. FAU - Gulletta, Simone AU - Gulletta S AD - Department of Arrhythmology and Cardiac Electrophysiology, San Raffaele Hospital, Via Olgettina 60, 20132 Milan, Italy. FAU - Falasconi, Giulio AU - Falasconi G AUID- ORCID: 0000-0001-7128-9911 AD - Department of Arrhythmology and Cardiac Electrophysiology, San Raffaele Hospital, Via Olgettina 60, 20132 Milan, Italy. FAU - Cianfanelli, Lorenzo AU - Cianfanelli L AD - Department of Arrhythmology and Cardiac Electrophysiology, San Raffaele Hospital, Via Olgettina 60, 20132 Milan, Italy. FAU - Centola, Alice AU - Centola A AD - Centro Cardiologico Monzino, Via Carlo Parea 4, 20138 Milan, Italy. FAU - Paglino, Gabriele AU - Paglino G AD - Department of Arrhythmology and Cardiac Electrophysiology, San Raffaele Hospital, Via Olgettina 60, 20132 Milan, Italy. FAU - Cireddu, Manuela AU - Cireddu M AD - Department of Arrhythmology and Cardiac Electrophysiology, San Raffaele Hospital, Via Olgettina 60, 20132 Milan, Italy. FAU - Radinovic, Andrea AU - Radinovic A AD - Department of Arrhythmology and Cardiac Electrophysiology, San Raffaele Hospital, Via Olgettina 60, 20132 Milan, Italy. FAU - D'Angelo, Giuseppe AU - D'Angelo G AUID- ORCID: 0000-0002-1198-9745 AD - Department of Arrhythmology and Cardiac Electrophysiology, San Raffaele Hospital, Via Olgettina 60, 20132 Milan, Italy. FAU - Marzi, Alessandra AU - Marzi A AD - Department of Arrhythmology and Cardiac Electrophysiology, San Raffaele Hospital, Via Olgettina 60, 20132 Milan, Italy. FAU - Sala, Simone AU - Sala S AUID- ORCID: 0000-0003-3303-8892 AD - Department of Arrhythmology and Cardiac Electrophysiology, San Raffaele Hospital, Via Olgettina 60, 20132 Milan, Italy. FAU - Fierro, Nicolai AU - Fierro N AD - Department of Arrhythmology and Cardiac Electrophysiology, San Raffaele Hospital, Via Olgettina 60, 20132 Milan, Italy. FAU - Bisceglia, Caterina AU - Bisceglia C AD - Department of Arrhythmology and Cardiac Electrophysiology, San Raffaele Hospital, Via Olgettina 60, 20132 Milan, Italy. FAU - Peretto, Giovanni AU - Peretto G AUID- ORCID: 0000-0003-1815-4000 AD - Department of Arrhythmology and Cardiac Electrophysiology, San Raffaele Hospital, Via Olgettina 60, 20132 Milan, Italy. FAU - Di Muzio, Nadia AU - Di Muzio N AD - Department of Arrhythmology and Cardiac Electrophysiology, San Raffaele Hospital, Via Olgettina 60, 20132 Milan, Italy. FAU - Della Bella, Paolo AU - Della Bella P AD - Department of Arrhythmology and Cardiac Electrophysiology, San Raffaele Hospital, Via Olgettina 60, 20132 Milan, Italy. FAU - Vergara, Pasquale AU - Vergara P AUID- ORCID: 0000-0001-7751-6871 AD - Department of Arrhythmology and Cardiac Electrophysiology, San Raffaele Hospital, Via Olgettina 60, 20132 Milan, Italy. FAU - Dell'Oca, Italo AU - Dell'Oca I AD - Department of Arrhythmology and Cardiac Electrophysiology, San Raffaele Hospital, Via Olgettina 60, 20132 Milan, Italy. LA - eng PT - Journal Article DEP - 20220825 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC9457044 OTO - NOTNLM OT - cancer OT - cardiac implantable electronic device OT - implantable cardioverter defibrillator OT - pacemaker OT - radiotherapy COIS- The authors declare no conflict of interest. EDAT- 2022/09/10 06:00 MHDA- 2022/09/10 06:01 PMCR- 2022/08/25 CRDT- 2022/09/09 01:19 PHST- 2022/07/12 00:00 [received] PHST- 2022/08/19 00:00 [revised] PHST- 2022/08/22 00:00 [accepted] PHST- 2022/09/09 01:19 [entrez] PHST- 2022/09/10 06:00 [pubmed] PHST- 2022/09/10 06:01 [medline] PHST- 2022/08/25 00:00 [pmc-release] AID - jcm11174990 [pii] AID - jcm-11-04990 [pii] AID - 10.3390/jcm11174990 [doi] PST - epublish SO - J Clin Med. 2022 Aug 25;11(17):4990. doi: 10.3390/jcm11174990. PMID- 36075533 OWN - NLM STAT- MEDLINE DCOM- 20230109 LR - 20230206 IS - 1556-3871 (Electronic) IS - 1547-5271 (Linking) VI - 20 IP - 1 DP - 2023 Jan TI - Outcomes of a PAINESD score-guided multidisciplinary management approach for patients with ventricular tachycardia storm and advanced heart failure: A pilot study. PG - 134-139 LID - S1547-5271(22)02384-0 [pii] LID - 10.1016/j.hrthm.2022.08.037 [doi] FAU - Pothineni, Naga Venkata K AU - Pothineni NVK AD - Section of Electrophysiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania. FAU - Enriquez, Andres AU - Enriquez A AD - Section of Electrophysiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania. FAU - Kumareswaran, Ramanan AU - Kumareswaran R AD - Section of Electrophysiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania. FAU - Garcia, Fermin AU - Garcia F AD - Section of Electrophysiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania. FAU - Shah, Ronak AU - Shah R AD - Section of Anesthesiology and Critical Care, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania. FAU - Wald, Joyce AU - Wald J AD - Section of Heart Failure, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania. FAU - Bermudez, Christian AU - Bermudez C AD - Division of Cardiovascular Surgery, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania. FAU - Muser, Daniele AU - Muser D AD - Section of Electrophysiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania. FAU - Marchlinski, Francis E AU - Marchlinski FE AD - Section of Electrophysiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania. FAU - Santangeli, Pasquale AU - Santangeli P AD - Section of Electrophysiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: pasquale.santangeli@pennmedicine.upenn.edu. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220906 PL - United States TA - Heart Rhythm JT - Heart rhythm JID - 101200317 SB - IM MH - Humans MH - Pilot Projects MH - *Heart Failure/complications/therapy MH - *Tachycardia, Ventricular MH - *Catheter Ablation MH - Treatment Outcome OTO - NOTNLM OT - Catheter ablation OT - Electrical storm OT - Heart failure OT - Mechanical support OT - Ventricular tachycardia EDAT- 2022/09/09 06:00 MHDA- 2023/01/10 06:00 CRDT- 2022/09/08 19:35 PHST- 2022/06/21 00:00 [received] PHST- 2022/08/26 00:00 [revised] PHST- 2022/08/30 00:00 [accepted] PHST- 2022/09/09 06:00 [pubmed] PHST- 2023/01/10 06:00 [medline] PHST- 2022/09/08 19:35 [entrez] AID - S1547-5271(22)02384-0 [pii] AID - 10.1016/j.hrthm.2022.08.037 [doi] PST - ppublish SO - Heart Rhythm. 2023 Jan;20(1):134-139. doi: 10.1016/j.hrthm.2022.08.037. Epub 2022 Sep 6. PMID- 36074973 OWN - NLM STAT- MEDLINE DCOM- 20220923 LR - 20260726 IS - 1941-3084 (Electronic) IS - 1941-3149 (Print) IS - 1941-3084 (Linking) VI - 15 IP - 9 DP - 2022 Sep TI - Sinus Tachycardia: a Multidisciplinary Expert Focused Review. PG - e007960 LID - 10.1161/CIRCEP.121.007960 [doi] AB - Sinus tachycardia (ST) is ubiquitous, but its presence outside of normal physiological triggers in otherwise healthy individuals remains a commonly encountered phenomenon in medical practice. In many cases, ST can be readily explained by a current medical condition that precipitates an increase in the sinus rate, but ST at rest without physiological triggers may also represent a spectrum of normal. In other cases, ST may not have an easily explainable cause but may represent serious underlying pathology and can be associated with intolerable symptoms. The classification of ST, consideration of possible etiologies, as well as the decisions of when and how to intervene can be difficult. ST can be classified as secondary to a specific, usually treatable, medical condition (eg, pulmonary embolism, anemia, infection, or hyperthyroidism) or be related to several incompletely defined conditions (eg, inappropriate ST, postural tachycardia syndrome, mast cell disorder, or post-COVID syndrome). While cardiologists and cardiac electrophysiologists often evaluate patients with symptoms associated with persistent or paroxysmal ST, an optimal approach remains uncertain. Due to the many possible conditions associated with ST, and an overlap in medical specialists who see these patients, the inclusion of experts in different fields is essential for a more comprehensive understanding. This article is unique in that it was composed by international experts in Neurology, Psychology, Autonomic Medicine, Allergy and Immunology, Exercise Physiology, Pulmonology and Critical Care Medicine, Endocrinology, Cardiology, and Cardiac Electrophysiology in the hope that it will facilitate a more complete understanding and thereby result in the better care of patients with ST. FAU - Mayuga, Kenneth A AU - Mayuga KA AUID- ORCID: 0000-0002-3434-9599 AD - Section of Cardiac Electrophysiology and Pacing, Department of Cardiovascular Medicine, Cleveland Clinic, OH (K.A.M.). FAU - Fedorowski, Artur AU - Fedorowski A AUID- ORCID: 0000-0002-5352-6327 AD - Karolinska Institutet & Karolinska University Hospital, Stockholm, Sweden (A.F.). FAU - Ricci, Fabrizio AU - Ricci F AUID- ORCID: 0000-0002-1401-6623 AD - Department of Neuroscience, Imaging and Clinical Sciences, "G.d'Annunzio" University of Chieti-Pescara, Chieti Scalo, Italy (F.R.). FAU - Gopinathannair, Rakesh AU - Gopinathannair R AUID- ORCID: 0000-0003-4611-3687 AD - Kansas City Heart Rhythm Institute, Overland Park (R.G.). FAU - Dukes, Jonathan Walter AU - Dukes JW AD - Community Memorial Hospital, Ventura, CA (J.W.D.). FAU - Gibbons, Christopher AU - Gibbons C AD - Beth Israel Deaconess Medical Center, Boston, MA (C.G.). FAU - Hanna, Peter AU - Hanna P AUID- ORCID: 0000-0003-3092-5090 AD - University of California, Los Angeles (P.H.). FAU - Sorajja, Dan AU - Sorajja D AUID- ORCID: 0000-0003-1976-6420 AD - Mayo Clinic Arizona (D.S.). FAU - Chung, Mina AU - Chung M AUID- ORCID: 0000-0002-7835-6045 AD - Section of Cardiac Electrophysiology and Pacing, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH (M.C.). FAU - Benditt, David AU - Benditt D AUID- ORCID: 0000-0002-8511-6920 AD - University of Minnesota Medical School, Minneapolis (D.B.). FAU - Sheldon, Robert AU - Sheldon R AUID- ORCID: 0000-0002-3463-4082 AD - University of Calgary, Canada (R.S.). FAU - Ayache, Mirna B AU - Ayache MB AD - MetroHealth Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH (M.B.A.). FAU - AbouAssi, Hiba AU - AbouAssi H AD - Division of Endocrinology, Metabolism, and Nutrition, Duke University Medical Center, Durham, NC (H.A.A.). FAU - Shivkumar, Kalyanam AU - Shivkumar K AUID- ORCID: 0000-0002-4121-1766 AD - University of California, Los Angeles (K.S.). FAU - Grubb, Blair P AU - Grubb BP AD - The University of Toledo Medical Center, OH (B.P.G.). FAU - Hamdan, Mohamed H AU - Hamdan MH AD - University of Wisconsin, Madison (M.H.H.). FAU - Stavrakis, Stavros AU - Stavrakis S AUID- ORCID: 0000-0002-4370-8135 AD - University of Oklahoma Health Science Center, Oklahoma City (S.S.). FAU - Singh, Tamanna AU - Singh T AUID- ORCID: 0000-0002-9591-7860 AD - Department of Cardiovascular Medicine, Cleveland Clinic, OH (T.S.). FAU - Goldberger, Jeffrey J AU - Goldberger JJ AUID- ORCID: 0000-0001-9802-1851 AD - Division of Cardiology, Department of Medicine, University of Miami, FL (J.J.G.). FAU - Muldowney, James A S 3rd AU - Muldowney JAS 3rd AUID- ORCID: 0000-0001-7449-5868 AD - Vanderbilt University Medical Center &Tennessee Valley Healthcare System, Nashville Campus, Department of Veterans Affairs, TN (J.A.S.M.). FAU - Belham, Mark AU - Belham M AUID- ORCID: 0000-0002-8572-3501 AD - Cambridge University Hospitals NHS FT, United Kingdom (M.B.). FAU - Kem, David C AU - Kem DC AUID- ORCID: 0000-0001-8142-7767 AD - University of Oklahoma Health Sciences Center, Oklahoma City (D.C.K.). FAU - Akin, Cem AU - Akin C AUID- ORCID: 0000-0001-6301-4520 AD - University of Michigan, Ann Arbor (C.A.). FAU - Bruce, Barbara K AU - Bruce BK AUID- ORCID: 0000-0003-2502-2428 AD - Mayo Clinic, Jacksonville, FL (B.K.B.). FAU - Zahka, Nicole E AU - Zahka NE AUID- ORCID: 0000-0003-3545-0370 AD - Cincinnati Children's Hospital Medical Center, OH (N.E.Z.). FAU - Fu, Qi AU - Fu Q AUID- ORCID: 0000-0002-4218-9126 AD - Institute for Exercise and Environmental Medicine at Texas Health Presbyterian Hospital Dallas & University of Texas Southwestern Medical Center (Q.F.). FAU - Van Iterson, Erik H AU - Van Iterson EH AUID- ORCID: 0000-0003-0576-3229 AD - Section of Preventive Cardiology & Rehabilitation, Robert and Suzanne Tomsich Department of Cardiovascular Medicine, Miller Family Heart, Vascular & Thoracic Institute, Cleveland Clinic, OH (E.H.V.I.). FAU - Raj, Satish R AU - Raj SR AUID- ORCID: 0000-0002-5890-3785 AD - Department of Cardiac Sciences, Libin Cardiovascular Institute, Cumming School of Medicine, University of Calgary, Canada (S.R.R.). FAU - Fouad-Tarazi, Fetnat AU - Fouad-Tarazi F AD - Cleveland Clinic, OH (F.F.-T.). FAU - Goldstein, David S AU - Goldstein DS AD - CNP/DIR/NINDS/NIH, Bethesda, MD (D.S.G.). FAU - Stewart, Julian AU - Stewart J AUID- ORCID: 0000-0002-6082-359X AD - New York Medical College, Hawthorne (J.S.). FAU - Olshansky, Brian AU - Olshansky B AUID- ORCID: 0000-0002-6044-045X AD - University of Iowa (B.O.). LA - eng GR - ZIA NS003033/ImNIH/Intramural NIH HHS/United States GR - IK6 BX006185/BX/BLRD VA/United States GR - P01 HL158502/HL/NHLBI NIH HHS/United States GR - R01 HL111314/HL/NHLBI NIH HHS/United States GR - R01 HL158071/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Review DEP - 20220908 PL - United States TA - Circ Arrhythm Electrophysiol JT - Circulation. Arrhythmia and electrophysiology JID - 101474365 SB - IM MH - *COVID-19 MH - Humans MH - *Postural Orthostatic Tachycardia Syndrome MH - Tachycardia, Sinus/diagnosis/therapy PMC - PMC9523592 MID - NIHMS1830947 OTO - NOTNLM OT - autonomic dysfunction OT - hyperthyroidism OT - inappropriate sinus tachycardia OT - post-COVID syndrome OT - postural orthostatic tachycardia syndrome OT - sinus tachycardia EDAT- 2022/09/09 06:00 MHDA- 2022/09/24 06:00 PMCR- 2023/09/08 CRDT- 2022/09/08 15:13 PHST- 2022/09/09 06:00 [pubmed] PHST- 2022/09/24 06:00 [medline] PHST- 2022/09/08 15:13 [entrez] PHST- 2023/09/08 00:00 [pmc-release] AID - 10.1161/CIRCEP.121.007960 [doi] PST - ppublish SO - Circ Arrhythm Electrophysiol. 2022 Sep;15(9):e007960. doi: 10.1161/CIRCEP.121.007960. Epub 2022 Sep 8. PMID- 36074270 OWN - NLM STAT- MEDLINE DCOM- 20221124 LR - 20240907 IS - 1861-0692 (Electronic) IS - 1861-0684 (Print) IS - 1861-0684 (Linking) VI - 111 IP - 12 DP - 2022 Dec TI - Propensity matched comparison of TAVI and SAVR in intermediate-risk patients with severe aortic stenosis and moderate-to-severe chronic kidney disease: a subgroup analysis from the German Aortic Valve Registry. PG - 1387-1395 LID - 10.1007/s00392-022-02083-2 [doi] AB - OBJECTIVE: We compared TAVI vs. SAVR in patients with moderate-to-severe chronic kidney disease (eGFR 15-60 ml/min/1.73 m(2)) for whom both procedures could possibly be considered (age /=1 complication): 3 pregnancy losses, 9 urgent Caesarean sections, 2 emergency Caesarean sections, 1 fetal death, and 11 preterm births. Two patients presented a relapse during a median follow-up of 3.1 years (IQR 0.6-7.4). CONCLUSIONS: Strict medical surveillance of pregnant women with IE is required and must involve a multidisciplinary team including obstetricians and neonatologists. Furthermore, the potential risk of IE during pregnancy should never be underestimated in women with previously known underlying heart disease. CI - (c) The Author(s) 2022. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. FAU - Escola-Verge, Laura AU - Escola-Verge L AUID- ORCID: 0000-0002-5608-3090 AD - Servei de Malalties Infeccioses, Hospital Universitari Vall d'Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain. AD - CIBERINFEC, ISCIII-CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain. FAU - Rello, Pau AU - Rello P AUID- ORCID: 0000-0001-9800-7152 AD - Department of Cardiology, Hospital Universitari Vall d'Hebron, Barcelona, Spain. FAU - Declerck, Charles AU - Declerck C AD - Infectious Diseases Department, Angers University Hospital, Angers, France. FAU - Dubee, Vincent AU - Dubee V AUID- ORCID: 0000-0002-9982-4741 AD - Infectious Diseases Department, Angers University Hospital, Angers, France. FAU - Rouleau, Frederic AU - Rouleau F AD - Department of Cardiology, Angers University Hospital, Angers, France. FAU - Duval, Xavier AU - Duval X AUID- ORCID: 0000-0003-1079-4230 AD - Infectious Diseases, CIC Inserm 1425, IAME, Bichat Hospital, APHP, Paris Cite University, Paris, France. FAU - Habib, Gilbert AU - Habib G AUID- ORCID: 0000-0003-3899-9983 AD - Cardiology Department, La Timone Hospital, Aix Marseille University, IRD, APHM, Marseille, France. FAU - Lavie-Badie, Yoan AU - Lavie-Badie Y AUID- ORCID: 0000-0002-8310-4512 AD - Heart Valve Center, Toulouse University Hospital, Toulouse, France. FAU - Martin-Blondel, Guillaume AU - Martin-Blondel G AUID- ORCID: 0000-0002-8363-7028 AD - Department of Infectious and Tropical Diseases, Toulouse University Hospital, Toulouse, France. FAU - Porte, Lydie AU - Porte L AD - Department of Infectious and Tropical Diseases, Toulouse University Hospital, Toulouse, France. FAU - Bouiller, Kevin AU - Bouiller K AUID- ORCID: 0000-0002-2177-4318 AD - Infectious Diseases, CHU Besancon, Besancon, France. FAU - Goehringer, Francois AU - Goehringer F AUID- ORCID: 0000-0001-6997-598X AD - Infectious Diseases Department, Nancy University Hospital, Nancy, France. FAU - Selton-Suty, Christine AU - Selton-Suty C AUID- ORCID: 0000-0003-4129-5784 AD - Cardiology Department, CHU Nancy, Nancy, France. FAU - Lamas, Cristiane da Cruz AU - Lamas CDC AUID- ORCID: 0000-0002-5561-999X AD - Infectious Diseases, Instituto Nacional de Cardiologia. Unigranrio. Instituto Nacional de Infectologia Evandro Chagas, Fiocruz, Rio de Janeiro, Brazil. FAU - Nacinovich, Francisco AU - Nacinovich F AD - Infectious Diseases, Instituto Cardiovascular Buenos Aires, Buenos Aires, Argentina. FAU - Issa, Nahema AU - Issa N AUID- ORCID: 0000-0002-3443-6115 AD - Infectious Diseases and ICU, Groupe Saint-Andre Hospital, University Hospital, Bordeaux, France. FAU - Richaud, Clemence AU - Richaud C AUID- ORCID: 0000-0001-8100-6057 AD - Internal Medecine, Institut Mutualiste Montsouris, Paris, France. FAU - Hammoudi, Nadjib AU - Hammoudi N AUID- ORCID: 0000-0003-2085-8525 AD - Sorbonne Universite, ACTION Study Group, INSERM UMR_S 1166, and Hopital Pitie-Salpetriere (AP-HP), Paris, France. FAU - Barranco, Francisco Jose AU - Barranco FJ AUID- ORCID: 0000-0001-9156-7739 AD - Maternal Fetal Medicine Unit, Department of Obstetrics, Vall d'Hebron Barcelona Hospital Campus, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Almirante, Benito AU - Almirante B AUID- ORCID: 0000-0002-1189-2361 AD - Servei de Malalties Infeccioses, Hospital Universitari Vall d'Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain. AD - CIBERINFEC, ISCIII-CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain. FAU - Tattevin, Pierre AU - Tattevin P AUID- ORCID: 0000-0003-3617-5411 AD - Infectious Diseases and ICU, Pontchaillou University Hospital, Rennes, France. FAU - Fernandez-Hidalgo, Nuria AU - Fernandez-Hidalgo N AUID- ORCID: 0000-0002-2115-344X AD - Servei de Malalties Infeccioses, Hospital Universitari Vall d'Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain. AD - CIBERINFEC, ISCIII-CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain. LA - eng GR - Instituto de Salud Carlos III/ PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't PL - England TA - J Antimicrob Chemother JT - The Journal of antimicrobial chemotherapy JID - 7513617 SB - IM MH - *Endocarditis/drug therapy/epidemiology MH - *Endocarditis, Bacterial/drug therapy/epidemiology MH - Female MH - Humans MH - Infant MH - Infant, Newborn MH - Pregnancy MH - Pregnant People MH - Retrospective Studies MH - Staphylococcus EDAT- 2022/08/14 06:00 MHDA- 2022/10/05 06:00 CRDT- 2022/08/13 02:42 PHST- 2022/04/04 00:00 [received] PHST- 2022/06/29 00:00 [accepted] PHST- 2022/08/14 06:00 [pubmed] PHST- 2022/10/05 06:00 [medline] PHST- 2022/08/13 02:42 [entrez] AID - 6664295 [pii] AID - 10.1093/jac/dkac258 [doi] PST - ppublish SO - J Antimicrob Chemother. 2022 Sep 30;77(10):2701-2705. doi: 10.1093/jac/dkac258. PMID- 35960664 OWN - NLM STAT- MEDLINE DCOM- 20220908 LR - 20250728 IS - 1527-1323 (Electronic) IS - 0271-5333 (Linking) VI - 42 IP - 5 DP - 2022 Sep-Oct TI - Imaging of Genetic Thoracic Aortopathy. PG - 1283-1302 LID - 10.1148/rg.220033 [doi] AB - Aortopathy is a term most commonly used to describe a group of genetic diseases that predispose patients to an elevated risk of aortic events including aneurysm and acute aortic syndrome. Types of genetic aortopathy are classified as either heritable or congenital, with heritable thoracic aortic disease (HTAD) further subclassified into syndromic HTAD or nonsyndromic HTAD, the former of which is associated with specific phenotypic features. Radiologists may be the first physicians to encounter features of genetic aortopathy, either incidentally or at the time of an acute aortic event. Identifying patients with genetic aortopathy is of substantial importance to clinicians who manage thoracic aortic disease, because aortic diameter thresholds for surgical intervention are often lower than those for nongenetic aortopathy related to aging and hypertension. In addition, when reparative surgery is performed, the approach and extent of the repair may differ in patients with genetic aortopathy. The radiologist should also be familiar with competing diagnoses that can result in acute aortic events, mainly acquired inflammatory and noninflammatory thoracic aortic disease, because these conditions may be associated with increased risks of similar pathologic endpoints. Because many imaging and phenotypic features of various types of genetic aortopathy overlap, diagnosis and determination of appropriate follow-up recommendations can be challenging. A multidisciplinary approach with the use of imaging is often required and, once the diagnosis is made, imaging has additional importance because of the need for lifelong follow-up. ((c))RSNA, 2022. FAU - Steinbrecher, Kacie L AU - Steinbrecher KL AUID- ORCID: 0000-0001-8795-5827 AD - From the Mallinckrodt Institute of Radiology (K.L.S., K.M.M., S.B., C.A.R.), Department of Internal Medicine, Cardiovascular Division (A.C.B.), Department of Surgery (J.W.O.), and Department of Pathology (C.Y.L.), Washington University School of Medicine, 510 S Kingshighway Blvd, St Louis, MO 63110; and Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, Ga (M.N.). FAU - Marquis, Kaitlin M AU - Marquis KM AUID- ORCID: 0000-0002-8540-2361 AD - From the Mallinckrodt Institute of Radiology (K.L.S., K.M.M., S.B., C.A.R.), Department of Internal Medicine, Cardiovascular Division (A.C.B.), Department of Surgery (J.W.O.), and Department of Pathology (C.Y.L.), Washington University School of Medicine, 510 S Kingshighway Blvd, St Louis, MO 63110; and Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, Ga (M.N.). FAU - Braverman, Alan C AU - Braverman AC AUID- ORCID: 0000-0003-1859-310X AD - From the Mallinckrodt Institute of Radiology (K.L.S., K.M.M., S.B., C.A.R.), Department of Internal Medicine, Cardiovascular Division (A.C.B.), Department of Surgery (J.W.O.), and Department of Pathology (C.Y.L.), Washington University School of Medicine, 510 S Kingshighway Blvd, St Louis, MO 63110; and Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, Ga (M.N.). FAU - Ohman, J Westley AU - Ohman JW AUID- ORCID: 0000-0002-6996-8912 AD - From the Mallinckrodt Institute of Radiology (K.L.S., K.M.M., S.B., C.A.R.), Department of Internal Medicine, Cardiovascular Division (A.C.B.), Department of Surgery (J.W.O.), and Department of Pathology (C.Y.L.), Washington University School of Medicine, 510 S Kingshighway Blvd, St Louis, MO 63110; and Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, Ga (M.N.). FAU - Bhalla, Sanjeev AU - Bhalla S AUID- ORCID: 0000-0002-1262-8925 AD - From the Mallinckrodt Institute of Radiology (K.L.S., K.M.M., S.B., C.A.R.), Department of Internal Medicine, Cardiovascular Division (A.C.B.), Department of Surgery (J.W.O.), and Department of Pathology (C.Y.L.), Washington University School of Medicine, 510 S Kingshighway Blvd, St Louis, MO 63110; and Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, Ga (M.N.). FAU - Lin, Chieh-Yu AU - Lin CY AD - From the Mallinckrodt Institute of Radiology (K.L.S., K.M.M., S.B., C.A.R.), Department of Internal Medicine, Cardiovascular Division (A.C.B.), Department of Surgery (J.W.O.), and Department of Pathology (C.Y.L.), Washington University School of Medicine, 510 S Kingshighway Blvd, St Louis, MO 63110; and Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, Ga (M.N.). FAU - Naeem, Muhammad AU - Naeem M AD - From the Mallinckrodt Institute of Radiology (K.L.S., K.M.M., S.B., C.A.R.), Department of Internal Medicine, Cardiovascular Division (A.C.B.), Department of Surgery (J.W.O.), and Department of Pathology (C.Y.L.), Washington University School of Medicine, 510 S Kingshighway Blvd, St Louis, MO 63110; and Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, Ga (M.N.). FAU - Raptis, Constantine A AU - Raptis CA AUID- ORCID: 0000-0003-0924-2447 AD - From the Mallinckrodt Institute of Radiology (K.L.S., K.M.M., S.B., C.A.R.), Department of Internal Medicine, Cardiovascular Division (A.C.B.), Department of Surgery (J.W.O.), and Department of Pathology (C.Y.L.), Washington University School of Medicine, 510 S Kingshighway Blvd, St Louis, MO 63110; and Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, Ga (M.N.). LA - eng PT - Journal Article DEP - 20220812 PL - United States TA - Radiographics JT - Radiographics : a review publication of the Radiological Society of North America, Inc JID - 8302501 SB - IM MH - Aorta MH - Aorta, Thoracic/diagnostic imaging MH - *Aortic Diseases/complications/diagnostic imaging/genetics MH - Aortic Valve/abnormalities/pathology/surgery MH - Diagnostic Imaging MH - Humans MH - Syndrome EDAT- 2022/08/13 06:00 MHDA- 2022/09/09 06:00 CRDT- 2022/08/12 13:02 PHST- 2022/08/13 06:00 [pubmed] PHST- 2022/09/09 06:00 [medline] PHST- 2022/08/12 13:02 [entrez] AID - 10.1148/rg.220033 [doi] PST - ppublish SO - Radiographics. 2022 Sep-Oct;42(5):1283-1302. doi: 10.1148/rg.220033. Epub 2022 Aug 12. PMID- 35958531 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220813 IS - 2225-319X (Print) IS - 2304-1021 (Electronic) IS - 2225-319X (Linking) VI - 11 IP - 4 DP - 2022 Jul TI - The need for comprehensive multidisciplinary programs, complex interventions, and precision medicine for bicuspid aortic valve disease. PG - 369-379 LID - 10.21037/acs-2021-bav-207 [doi] AB - Patients with bicuspid aortic valves commonly require an intervention on their valve and/or aorta. Because of their heterogeneous presentations, recommendations for imaging surveillance and surgery timing are highly individualized. Critical points in care include time of diagnosis, transition from adolescent to adult medicine, and surgery referral. To better support patients with bicuspid aortic valves, we developed a comprehensive program that utilizes the multidisciplinary care team, complex interventions, and translational research protocols. We describe our program structure and experience with this common and sometimes challenging diagnosis. CI - 2022 Annals of Cardiothoracic Surgery. All rights reserved. FAU - Crawford, Erin E AU - Crawford EE AD - Division of Cardiac Surgery, Northwestern Medicine, Chicago, IL, USA. FAU - McCarthy, Patrick M AU - McCarthy PM AD - Division of Cardiac Surgery, Northwestern Medicine, Chicago, IL, USA. AD - Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. FAU - Malaisrie, S Chris AU - Malaisrie SC AD - Division of Cardiac Surgery, Northwestern Medicine, Chicago, IL, USA. AD - Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. FAU - Mehta, Christopher K AU - Mehta CK AD - Division of Cardiac Surgery, Northwestern Medicine, Chicago, IL, USA. AD - Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. FAU - Puthumana, Jyothy J AU - Puthumana JJ AD - Division of Cardiology, Northwestern Medicine, Chicago, IL, USA. AD - Department of Internal Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. FAU - Robinson, Joshua D AU - Robinson JD AD - Division of Cardiology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA. AD - Department of Pediatrics, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. AD - Department of Radiology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. FAU - Markl, Michael AU - Markl M AD - Department of Radiology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. AD - McCormick School of Engineering, Northwestern University, Evanston, IL, USA. FAU - Bonow, Robert O AU - Bonow RO AD - Division of Cardiology, Northwestern Medicine, Chicago, IL, USA. AD - Department of Internal Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. FAU - Fedak, Paul W M AU - Fedak PWM AD - Division of Cardiac Surgery, Northwestern Medicine, Chicago, IL, USA. AD - Section of Cardiac Surgery, Department of Cardiac Sciences, Cumming School of Medicine, University of Calgary, Calgary, Canada. AD - Libin Cardiovascular Institute, Calgary, Canada. LA - eng PT - Journal Article PT - Review PL - China TA - Ann Cardiothorac Surg JT - Annals of cardiothoracic surgery JID - 101605877 PMC - PMC9357958 OTO - NOTNLM OT - Bicuspid aortic valve (BAV) OT - aortic surgery OT - congenital COIS- Conflicts of Interest: PMM: Royalties: Edwards Lifesciences, Inc.; Speaker fees: Atricure, Inc.; Medtronic, Inc.; Edwards Lifesciences, Inc. SCM: Consultant: Edwards Lifesciences, Inc., Medtronic, Inc.; Cryolife; Terumo Aortic. MM: Research support: Siemens; Grant: Circle Cardiovascular Imaging ROB: Editor-in-Chief, JAMA Cardiology. PWMF: Consultant: Aziyo Biologics Inc., Abyrx Inc. The other authors have no conflicts of interest to declare. EDAT- 2022/08/13 06:00 MHDA- 2022/08/13 06:01 PMCR- 2022/07/01 CRDT- 2022/08/12 02:59 PHST- 2021/11/25 00:00 [received] PHST- 2022/02/08 00:00 [accepted] PHST- 2022/08/12 02:59 [entrez] PHST- 2022/08/13 06:00 [pubmed] PHST- 2022/08/13 06:01 [medline] PHST- 2022/07/01 00:00 [pmc-release] AID - acs-11-04-369 [pii] AID - 10.21037/acs-2021-bav-207 [doi] PST - ppublish SO - Ann Cardiothorac Surg. 2022 Jul;11(4):369-379. doi: 10.21037/acs-2021-bav-207. PMID- 35953138 OWN - NLM STAT- MEDLINE DCOM- 20220815 LR - 20260728 IS - 1558-3597 (Electronic) IS - 0735-1097 (Linking) VI - 80 IP - 7 DP - 2022 Aug 16 TI - Management of Patients With Severe Mitral Annular Calcification: JACC State-of-the-Art Review. PG - 722-738 LID - S0735-1097(22)05346-3 [pii] LID - 10.1016/j.jacc.2022.06.009 [doi] AB - Mitral annular calcification (MAC) is a common and challenging pathologic condition, especially in the context of an aging society. Surgical mitral valve intervention in patients with MAC is difficult, with varying approaches to the calcified annular anatomy, and the advent of transcatheter valve interventions has provided additional treatment options. Advanced imaging provides the foundation for heart team discussions and management decisions concerning individual patients. This review focuses on the prognosis of, preoperative planning for, and management strategies for patients with MAC. CI - Copyright (c) 2022 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. FAU - Chehab, Omar AU - Chehab O AD - Departments of Cardiology and Cardiac Surgery, St Thomas' Hospital, Westminster Bridge Road, London, United Kingdom. FAU - Roberts-Thomson, Ross AU - Roberts-Thomson R AD - Departments of Cardiology and Cardiac Surgery, St Thomas' Hospital, Westminster Bridge Road, London, United Kingdom; Department of Cardiology, Royal Adelaide Hospital, Adelaide, South Australia, Australia. FAU - Bivona, Antonio AU - Bivona A AD - Departments of Cardiology and Cardiac Surgery, St Thomas' Hospital, Westminster Bridge Road, London, United Kingdom. FAU - Gill, Harminder AU - Gill H AD - School of Biomedical Engineering and Imaging Sciences, King's College London, London, United Kingdom. FAU - Patterson, Tiffany AU - Patterson T AD - Departments of Cardiology and Cardiac Surgery, St Thomas' Hospital, Westminster Bridge Road, London, United Kingdom; School of Cardiovascular Medicine and Sciences, King's College London, London, United Kingdom. FAU - Pursnani, Amit AU - Pursnani A AD - Division of Cardiology, Evanston Hospital, Northshore University Health System, Evanston, Illinois, USA. FAU - Grigoryan, Karine AU - Grigoryan K AD - Departments of Cardiology and Cardiac Surgery, St Thomas' Hospital, Westminster Bridge Road, London, United Kingdom. FAU - Vargas, Bernardo AU - Vargas B AD - Division of Cardiology, Evanston Hospital, Northshore University Health System, Evanston, Illinois, USA. FAU - Bokhary, Ujala AU - Bokhary U AD - Division of Cardiology, Evanston Hospital, Northshore University Health System, Evanston, Illinois, USA. FAU - Blauth, Christopher AU - Blauth C AD - Departments of Cardiology and Cardiac Surgery, St Thomas' Hospital, Westminster Bridge Road, London, United Kingdom. FAU - Lucchese, Gianluca AU - Lucchese G AD - Departments of Cardiology and Cardiac Surgery, St Thomas' Hospital, Westminster Bridge Road, London, United Kingdom. FAU - Bapat, Vinayak AU - Bapat V AD - Center for Valve and Structural Heart Disease, Minneapolis Heart Institute, Minneapolis, Minnesota, USA. FAU - Guerrero, Mayra AU - Guerrero M AD - Department of Cardiology, Mayo Clinic, Rochester, Minnesota, USA. FAU - Redwood, Simon AU - Redwood S AD - Departments of Cardiology and Cardiac Surgery, St Thomas' Hospital, Westminster Bridge Road, London, United Kingdom; School of Cardiovascular Medicine and Sciences, King's College London, London, United Kingdom. FAU - Prendergast, Bernard AU - Prendergast B AD - Departments of Cardiology and Cardiac Surgery, St Thomas' Hospital, Westminster Bridge Road, London, United Kingdom. Electronic address: bernard.prendergast@gstt.nhs.uk. FAU - Rajani, Ronak AU - Rajani R AD - Departments of Cardiology and Cardiac Surgery, St Thomas' Hospital, Westminster Bridge Road, London, United Kingdom; School of Biomedical Engineering and Imaging Sciences, King's College London, London, United Kingdom. LA - eng GR - FS/CRTF/22/24312/BHF_/British Heart Foundation/United Kingdom PT - Journal Article PT - Review PL - United States TA - J Am Coll Cardiol JT - Journal of the American College of Cardiology JID - 8301365 SB - IM MH - *Calcinosis/diagnostic imaging/surgery MH - *Heart Valve Diseases/diagnostic imaging/surgery MH - *Heart Valve Prosthesis Implantation/methods MH - Humans MH - Mitral Valve/diagnostic imaging/pathology/surgery MH - *Mitral Valve Insufficiency/diagnostic imaging/surgery MH - Treatment Outcome OTO - NOTNLM OT - mitral annular calcification OT - mitral valve OT - surgery OT - valve-in-MAC COIS- Funding Support and Author Disclosures Dr Lucchese has been a consultant for and received speaker fees from Edwards Lifesciences, Cryolife, and Bard-DB. Dr Bapat has received speaker/consultancy fees and research grant support from Edwards Lifesciences, Medtronic, Boston Scientific, and Abbott. Dr Guerrero has received research grant support from Abbott Structural Heart and Edwards Lifesciences. Dr Redwood has received speaker fees from Edwards Lifesciences. Dr Prendergast has received unrestricted research and educational grants from Edwards Lifesciences; and has received speaker/consultancy fees from Abbott, Medtronic, Microport, Anteris, and Edwards Lifesciences. Dr Rajani has received speaker/consultancy fees from Siemens Healthineers, GE Healthcare, Medtronic, and Edwards Lifesciences. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2022/08/12 06:00 MHDA- 2022/08/16 06:00 CRDT- 2022/08/11 21:04 PHST- 2022/03/14 00:00 [received] PHST- 2022/06/17 00:00 [revised] PHST- 2022/06/21 00:00 [accepted] PHST- 2022/08/11 21:04 [entrez] PHST- 2022/08/12 06:00 [pubmed] PHST- 2022/08/16 06:00 [medline] AID - S0735-1097(22)05346-3 [pii] AID - 10.1016/j.jacc.2022.06.009 [doi] PST - ppublish SO - J Am Coll Cardiol. 2022 Aug 16;80(7):722-738. doi: 10.1016/j.jacc.2022.06.009. PMID- 39076619 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240731 IS - 2153-8174 (Electronic) IS - 2153-8174 (Print) IS - 1530-6550 (Linking) VI - 23 IP - 8 DP - 2022 Aug TI - Long-Term Outcomes of Conservative Versus Invasive Approach of Coronary Aneurysm. PG - 281 LID - 10.31083/j.rcm2308281 [doi] LID - 281 AB - INTRODUCTION: Up to date, the management of coronary artery aneurysm (CAA) is not well defined and depends on local heart team decision. Data reported in literature are scarce and controversial. We aim to compare the long-term outcomes of different therapeutic strategies of CAA (medical vs percutaneous coronary intervention (PCI) vs coronary artery bypass graft(CABG)). MATERIALS AND METHODS: A retrospective cohort study was conducted on 100 consecutive patients who underwent coronary angiography at Toulouse University Hospital, Toulouse France and fulfilled the diagnostic criteria of CAA. Coronary angiograms were reviewed, and all necessary data were collected. CAA was defined by a coronary dilation exceedingly at least 50% of reference coronary diameter. RESULTS: We identified 100 patients with CAA with a mean age of 67.9 +/- 12 years. The left anterior descending coronary artery was most affected (36%). CAA is associated with significant coronary artery disease in 78% of cases. The incidence of major adverse cardiovascular and cerebrovascular events (MACCE) was 13% during a median follow-up period of 46.2 +/- 24 months. A 53% of patients underwent PCI or CABG. The rate of MACCE was lower in CABG group (9.1%) compared to PCI (14.3%) and medical (12.8%) groups, but without reaching statistically significant level. Longitudinal aneurysm diameter was positively linked to MACCE [OR = 1.109, 95% CI (1.014-1.214), p = 0.024]. No benefits have been attributed to anticoagulant regimen over antiplatelet therapy. CONCLUSIONS: In our retrospective observational study, there seems to be no significant differences in MACCE-free survival between all groups (Medical vs PCI vs CABG). Larger longitudinal aneurysm diameter was identified as a predictor of poor prognosis during follow-up. CI - Copyright: (c) 2022 The Author(s). Published by IMR Press. FAU - Matta, Anthony AU - Matta A AD - Department of Cardiology, Toulouse University Hospital (Hopital Rangeuil), 31400 Toulouse, France. AD - Department of Cardiology, Centre Hospitalier Intercommunal Castres-Mazamet, 81108 Castres, France. AD - Faculty of Sciences, Paul-Sabatier Toulouse III University, 31062 Toulouse, France. AD - Faculty of Medicine, Holy Spirit University of Kaslik, 446 Jounieh, Lebanon. FAU - Campelo-Parada, Francisco AU - Campelo-Parada F AD - Department of Cardiology, Toulouse University Hospital (Hopital Rangeuil), 31400 Toulouse, France. FAU - Nader, Vanessa AU - Nader V AD - Department of Cardiology, Toulouse University Hospital (Hopital Rangeuil), 31400 Toulouse, France. AD - Faculty of Sciences, Paul-Sabatier Toulouse III University, 31062 Toulouse, France. FAU - Lhermusier, Thibault AU - Lhermusier T AD - Department of Cardiology, Toulouse University Hospital (Hopital Rangeuil), 31400 Toulouse, France. FAU - Bouisset, Frederic AU - Bouisset F AD - Department of Cardiology, Toulouse University Hospital (Hopital Rangeuil), 31400 Toulouse, France. FAU - Blanco, Stephanie AU - Blanco S AD - Department of Cardiology, Toulouse University Hospital (Hopital Rangeuil), 31400 Toulouse, France. FAU - Elbaz, Meyer AU - Elbaz M AD - Department of Cardiology, Toulouse University Hospital (Hopital Rangeuil), 31400 Toulouse, France. AD - Faculty of Sciences, Paul-Sabatier Toulouse III University, 31062 Toulouse, France. FAU - Roncalli, Jerome AU - Roncalli J AD - Department of Cardiology, Toulouse University Hospital (Hopital Rangeuil), 31400 Toulouse, France. AD - Faculty of Sciences, Paul-Sabatier Toulouse III University, 31062 Toulouse, France. FAU - Carrie, Didier AU - Carrie D AD - Department of Cardiology, Toulouse University Hospital (Hopital Rangeuil), 31400 Toulouse, France. AD - Faculty of Sciences, Paul-Sabatier Toulouse III University, 31062 Toulouse, France. LA - eng PT - Journal Article DEP - 20220810 PL - Singapore TA - Rev Cardiovasc Med JT - Reviews in cardiovascular medicine JID - 100960007 PMC - PMC11266970 OTO - NOTNLM OT - cardiac surgery OT - coronary artery aneurysm OT - coronary artery disease OT - medical OT - percutaneous coronary intervention COIS- The authors declare no conflict of interest. Anthony Matta and Jerome Roncalli are serving as the Guest editors of this journal. We declare that Anthony Matta and Jerome Roncalli had no involvement in the peer review of this article and has no access to information regarding its peer review. Full responsibility for the editorial process for this article was delegated to Daniel I. Simon and Teruo Inoue. EDAT- 2022/08/10 00:00 MHDA- 2022/08/10 00:01 PMCR- 2022/08/10 CRDT- 2024/07/30 04:58 PHST- 2022/06/06 00:00 [received] PHST- 2022/06/19 00:00 [revised] PHST- 2022/07/07 00:00 [accepted] PHST- 2022/08/10 00:01 [medline] PHST- 2022/08/10 00:00 [pubmed] PHST- 2024/07/30 04:58 [entrez] PHST- 2022/08/10 00:00 [pmc-release] AID - S1530-6550(22)00622-6 [pii] AID - 10.31083/j.rcm2308281 [doi] PST - epublish SO - Rev Cardiovasc Med. 2022 Aug 10;23(8):281. doi: 10.31083/j.rcm2308281. eCollection 2022 Aug. PMID- 35943565 OWN - NLM STAT- MEDLINE DCOM- 20220912 LR - 20261029 IS - 1437-9813 (Electronic) IS - 0179-0358 (Linking) VI - 38 IP - 10 DP - 2022 Oct TI - Continence management in children with severe caudal regression syndrome: role of multidisciplinary team and long-term follow-up. PG - 1461-1472 LID - 10.1007/s00383-022-05168-1 [doi] AB - PURPOSE: Caudal regression syndrome (CRS) is a rare congenital abnormality including orthopedic deformities, urological, anorectal, and cardiac malformations. The clinical spectrum of CRS varies in severity, therefore multiple surgeries and complex medical care may be required with the efforts and support of a multidisciplinary team to ensure the most accurate treatment and the best outcome. The aim of our retrospective study was to evaluate the role of a multidisciplinary treatment and the long-term outcome in patients with severe CRS. METHODS: Clinical, surgical and psychological data were collected for all patients with diagnosis of CRS, treated at our Pediatric Hospital from January 1995 to December 2020. Patients with a severe form of CRS according to Pang's classification were included in the study. All patients have been followed by a multidisciplinary team composed by urologists, neurosurgeons, neonatal and digestive surgeons, orthopedic surgeon, physiatrists and psychologists. On admission, patients were screened for CRS with sacrum, spine and legs X-ray, spine MRI, renal ultrasound, voiding cystography and urodynamic, and renography. Clinical data about bowel function were evaluated. RESULTS: During the study period, 55 patients with CRS were treated at our Institution. Six out of 55 (10.9%), presented with severe form of CRS (5 pts with type 1; 1 pt, with type 2) and represent our study group. Diagnosis of severe CRS was made at birth because of the typical deformities of the pelvis (fusion of the iliac wings), and of the lower extremities (undeveloped legs with flexion of the knees, clubfoot). All patients presented with neurogenic bladder, 4/6 (66.6%) with vesicoureteral reflux (VUR) and 2/6 (33.3%) with renal agenesia and contralateral ectopic hypoplastic kidney. Bowel symptoms occurred in 5/6 pts (83.3%). All patients were started with an earlier clean intermittent catheterization (CIC) regimen. In 3 patients oxybutynin has been effective or well tolerated, while in other 3 onabotulinumtoxin A has been used. Vesicoureteral reimplantation has been performed in 1 patient, 2 required endoscopic treatment of VUR. On long-term, 2 patients required bladder augmentation with ileum and appendicostomy (Mitrofanoff). Low adherences in CIC have been observed in three patients, mainly at puberty. Two patients presented with chronic renal failure. One patient reported suicide proposal. Regarding social life, only one is regularly performing sport activity. CONCLUSION: CRS is characterized by maldevelopment of the caudal half of the body with variable involvement of the gastrointestinal, genitourinary, skeletal, and nervous systems. Management of CRS includes a wide variety of interventions to address the full spectrum of possible anatomical abnormalities. Hence, a multidisciplinary team is also mandatory for a correct bladder and bowel management, in order to maintain continence and preserve renal function, improve quality of life and increase self-esteem. CI - (c) 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Esposito, Giacomo AU - Esposito G AUID- ORCID: 0000-0002-6384-1371 AD - Department of Neuroscience, Neurosurgery Unit, Bambino Gesu Children's Hospital, IRCCS, Rome, Italy. giacomo.esposito@opbg.net. FAU - Totonelli, Giorgia AU - Totonelli G AD - Medical and Surgical Department of the Fetus-Newborn-Infant, Newborn Surgery Unit, Bambino Gesu Children's Hospital, IRCCS, Rome, Italy. FAU - Iacobelli, Barbara Daniela AU - Iacobelli BD AD - Medical and Surgical Department of the Fetus-Newborn-Infant, Newborn Surgery Unit, Bambino Gesu Children's Hospital, IRCCS, Rome, Italy. FAU - Longo, Daniela AU - Longo D AD - Imaging Department, Neuroradiology Unit, Bambino Gesu Children's Hospital, IRCCS, Rome, Italy. FAU - Caldaro, Tamara AU - Caldaro T AD - Division of Digestive Surgery and Endoscopy, Bambino Gesu Children's Hospital, IRCCS, Rome, Italy. FAU - Blasetti, Giulia AU - Blasetti G AD - Department of Neuro-Rehabilitation, Bambino Gesu Children's Hospital, IRCCS, Rome, Italy. FAU - Bevilacqua, Francesca AU - Bevilacqua F AD - Department of Neuroscience, Unit of Clinical Psychology, Bambino Gesu Children's Hospital, IRCSS, Rome, Italy. FAU - Santato, Francesca AU - Santato F AD - Department of Neuroscience, Unit of Clinical Psychology, Bambino Gesu Children's Hospital, IRCSS, Rome, Italy. FAU - Lucignani, Giulia AU - Lucignani G AD - Imaging Department, Neuroradiology Unit, Bambino Gesu Children's Hospital, IRCCS, Rome, Italy. FAU - Sollini, Maria Laura AU - Sollini ML AD - Division of Neuro-Urology, Bambino Gesu Children's Hospital, IRCCS, Rome, Italy. FAU - Marras, Carlo Efisio AU - Marras CE AD - Department of Neuroscience, Neurosurgery Unit, Bambino Gesu Children's Hospital, IRCCS, Rome, Italy. FAU - Bagolan, Pietro AU - Bagolan P AD - Medical and Surgical Department of the Fetus-Newborn-Infant, Newborn Surgery Unit, Bambino Gesu Children's Hospital, IRCCS, Rome, Italy. AD - Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy. FAU - Mosiello, Giovanni AU - Mosiello G AD - Division of Neuro-Urology, Bambino Gesu Children's Hospital, IRCCS, Rome, Italy. LA - eng PT - Journal Article DEP - 20220809 PL - Germany TA - Pediatr Surg Int JT - Pediatric surgery international JID - 8609169 SB - IM MH - *Abnormalities, Multiple MH - Child MH - Follow-Up Studies MH - Humans MH - Infant, Newborn MH - Patient Care Team MH - Quality of Life MH - Retrospective Studies MH - *Urinary Bladder, Neurogenic/etiology MH - *Vesico-Ureteral Reflux OTO - NOTNLM OT - Bladder OT - Bowel OT - Caudal regression syndrome OT - Neurological deficit EDAT- 2022/08/10 06:00 MHDA- 2022/09/14 06:00 CRDT- 2022/08/09 11:14 PHST- 2022/06/28 00:00 [accepted] PHST- 2022/08/10 06:00 [pubmed] PHST- 2022/09/14 06:00 [medline] PHST- 2022/08/09 11:14 [entrez] AID - 10.1007/s00383-022-05168-1 [pii] AID - 10.1007/s00383-022-05168-1 [doi] PST - ppublish SO - Pediatr Surg Int. 2022 Oct;38(10):1461-1472. doi: 10.1007/s00383-022-05168-1. Epub 2022 Aug 9. PMID- 35942691 OWN - NLM STAT- MEDLINE DCOM- 20220908 LR - 20250728 IS - 1531-7072 (Electronic) IS - 1070-5295 (Linking) VI - 28 IP - 5 DP - 2022 Oct 1 TI - Endocarditis in the intensive care unit: an update. PG - 503-512 LID - 10.1097/MCC.0000000000000973 [doi] AB - PURPOSE OF REVIEW: The incidence of infective endocarditis (IE) is increasing worldwide, resulting in a higher number of patients with IE being admitted to intensive care units (ICU). Nearly half of patients with IE develop a complication during their clinical course. However, few well conducted studies or reviews are devoted to critically ill IE patients. This review discusses the contemporary perioperative and intensive care literature. RECENT FINDINGS: IE epidemiology is changing towards elderly and frail patients. ICU patients are at risk of risk of developing IE because they are often in a pro-inflammatory state and many also have several indwelling catheters, which favors infection. Increased performance and recent advances in cardiac imaging allow for easier diagnosis of EI, but the applicability of these techniques to ICU patients is still relatively limited. New developments in antibiotic treatment and adjunctive therapies are explored further in this review. SUMMARY: The lack of evidence on ICU patients with IE highlights the critical importance of multidisciplinary decision-making and the need for further research. CI - Copyright (c) 2022 Wolters Kluwer Health, Inc. All rights reserved. FAU - Lakbar, Ines AU - Lakbar I AD - Department of Anesthesiology and Intensive Care Unit, Aix Marseille University, Assistance Publique Hopitaux Universitaires de Marseille, Nord Hospital, Marseille, France. FAU - Delamarre, Louis AU - Delamarre L AD - Department of Anesthesiology and Intensive Care Unit, Aix Marseille University, Assistance Publique Hopitaux Universitaires de Marseille, Nord Hospital, Marseille, France. FAU - Einav, Sharon AU - Einav S AD - General Intensive Care Unit of the Shaare Zedek Medical Centre and the Hebrew University Faculty of Medicine, Jerusalem, Israel. FAU - Leone, Marc AU - Leone M AD - Department of Anesthesiology and Intensive Care Unit, Aix Marseille University, Assistance Publique Hopitaux Universitaires de Marseille, Nord Hospital, Marseille, France. LA - eng PT - Journal Article PT - Review DEP - 20220804 PL - United States TA - Curr Opin Crit Care JT - Current opinion in critical care JID - 9504454 SB - IM MH - Aged MH - Critical Care MH - Critical Illness MH - *Endocarditis/diagnosis/epidemiology/therapy MH - *Endocarditis, Bacterial/diagnosis/drug therapy/surgery MH - Humans MH - Intensive Care Units EDAT- 2022/08/10 06:00 MHDA- 2022/09/09 06:00 CRDT- 2022/08/09 03:54 PHST- 2022/08/10 06:00 [pubmed] PHST- 2022/09/09 06:00 [medline] PHST- 2022/08/09 03:54 [entrez] AID - 00075198-202210000-00008 [pii] AID - 10.1097/MCC.0000000000000973 [doi] PST - ppublish SO - Curr Opin Crit Care. 2022 Oct 1;28(5):503-512. doi: 10.1097/MCC.0000000000000973. Epub 2022 Aug 4. PMID- 35942377 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230728 IS - 1741-427X (Print) IS - 1741-4288 (Electronic) IS - 1741-427X (Linking) VI - 2022 DP - 2022 TI - Effect of Paclitaxel Combined with Doxorubicin Hydrochloride Liposome Injection in the Treatment of Osteosarcoma and MRI Changes before and after Treatment. PG - 5651793 LID - 10.1155/2022/5651793 [doi] LID - 5651793 AB - OBJECTIVE: The aim of this study is to investigate the effect of paclitaxel combined with doxorubicin hydrochloride liposome injection (DHLI) in the treatment of osteosarcoma and the MRI changes before and after treatment. METHODS: A total of 108 osteosarcoma patients treated in our hospital (January 2020-April 2022) were selected to carry out a single-center retrospective study. Among them, 54 patients receiving the combination chemotherapy (MDT) with high-dose methotrexate, ifosfamide, cisplatin, and ADM were selected as the control group (COG), while 54 patients receiving MDT with high-dose methotrexate, ifosfamide, cisplatin, paclitaxel, and DHLI were chosen as the study group (STG). The COG and STG had the same dose intensity and chemotherapy cycles, and clinical and MRI evaluations were performed after treatment. RESULTS: The evaluation of postoperative clinical efficacy showed that the disease control rate (DCR) of the STG was markedly higher than that of the COG (P < 0.05). The incidence of cardiac toxicity was remarkably lower in the STG than that in the COG (P < 0.05), with no between-group differences in the incidence of fever, abnormal liver function, myelosuppression, stomatitis, and alopecia (P > 0.05). Obvious differences were found in the semiquantitative parameters of MRI in the STG before and after chemotherapy (P < 0.05) and were also found in the SI(max), TTP, SEE, PPE, WOR, and R values in the COG before and after chemotherapy (P < 0.05). After chemotherapy, statistical differences were observed in the semiquantitative parameters of MRI between the two groups, with lower parameters such as Slope, SI(max), SEE, and R values and higher parameters such as TTP, PPE, and WOR values in the STG than those in the COG (P < 0.05). CONCLUSION: Paclitaxel combined with DHLI has definite efficacy in osteosarcoma chemotherapy, which is conducive to narrowing the lesion, controlling the disease, and reducing the occurrence of cardiac-related risk events. In addition, the semiquantitative parameters of dynamic contrast-enhanced MRI (DCE-MRI) have a high predictive value for the efficacy of chemotherapy, which can reflect the degree of tumor necrosis and contribute to a timely and objective assessment of the efficacy of osteosarcoma chemotherapy. CI - Copyright (c) 2022 Ning Tian et al. FAU - Tian, Ning AU - Tian N AD - Department of Medical Imaging, Shandong Provincial Third Hospital, Jinan 250031, Shandong, China. FAU - Wang, Dongmei AU - Wang D AD - Department of Medical Imaging, Shandong Provincial Third Hospital, Jinan 250031, Shandong, China. FAU - Li, Xiaobao AU - Li X AD - Department of Medical Imaging, Shandong Provincial Third Hospital, Jinan 250031, Shandong, China. FAU - Xue, Minghua AU - Xue M AD - Department of Ultrasonography, Shandong Provincial Qianfoshan Hospital, The First Affiliated Hospital of Shandong First Medical University, Jinan 250014, Shandong, China. FAU - Zheng, Bo AU - Zheng B AUID- ORCID: 0000-0002-3842-0698 AD - Department of Medical Imaging, Shandong Provincial Third Hospital, Jinan 250031, Shandong, China. LA - eng PT - Journal Article PT - Retracted Publication DEP - 20220730 PL - United States TA - Evid Based Complement Alternat Med JT - Evidence-based complementary and alternative medicine : eCAM JID - 101215021 RIN - Evid Based Complement Alternat Med. 2023 Jul 19;2023:9816837. doi: 10.1155/2023/9816837. PMID: 37501833 PMC - PMC9356788 COIS- The authors declare that they have no conflicts of interest. EDAT- 2022/08/10 06:00 MHDA- 2022/08/10 06:01 PMCR- 2022/07/30 CRDT- 2022/08/09 02:10 PHST- 2022/06/22 00:00 [received] PHST- 2022/07/07 00:00 [revised] PHST- 2022/07/12 00:00 [accepted] PHST- 2022/08/09 02:10 [entrez] PHST- 2022/08/10 06:00 [pubmed] PHST- 2022/08/10 06:01 [medline] PHST- 2022/07/30 00:00 [pmc-release] AID - 10.1155/2022/5651793 [doi] PST - epublish SO - Evid Based Complement Alternat Med. 2022 Jul 30;2022:5651793. doi: 10.1155/2022/5651793. eCollection 2022. PMID- 35935922 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240902 IS - 1078-4497 (Print) IS - 1945-337X (Electronic) IS - 1078-4497 (Linking) VI - 39 IP - 5 DP - 2022 May TI - Natriuretic Peptide Screening for Primary Prevention or Early Detection of Heart Failure: A Pharmacist-Driven Team-Based Approach. PG - 212-217 LID - 10.12788/fp.0255 [doi] AB - BACKGROUND: Emerging data indicates that natriuretic peptide biomarker-based screening and early intervention could prevent left ventricular dysfunction or new-onset heart failure (HF). The 2017 update of the American College of Cardiology/ American Heart Association/Heart Failure Society of America guideline for managing HF provides a IIa recommendation for natriuretic peptide biomarker screening followed by a team-based approach for preventing HF. OBSERVATIONS: Clinical pharmacists worked collaboratively with a cardiology specialist and primary care practitioners to establish a protocol to identify patients at risk for HF. Patients with hypertension and/or type 2 diabetes mellitus (T2DM) and without a history of HF with N-terminal pro-B-type natriuretic peptide > 125 pg/mL received follow-up from clinical pharmacists, including initiation and/or adjustment of reninangiotensin system inhibitors, discussion of echocardiogram, and comprehensive disease state management of hypertension, T2DM, atherosclerotic cardiovascular disease risk reduction, oral nonsteroidal anti-inflammatory drug reduction, and tobacco cessation. CONCLUSIONS: By using natriuretic peptide screening, clinical pharmacists were able to identify patients with hypertension and/or T2DM who were at higher risk for HF and provide comprehensive medication management. CI - Copyright (c) 2022 Frontline Medical Communications Inc., Parsippany, NJ, USA. FAU - Martin, Meghan AU - Martin M AD - Charlie Norwood Veterans Affairs Medical Center, Augusta, Georgia. FAU - Peterson, Daisy AU - Peterson D AD - Clement J. Zablocki Veterans Affairs Medical Center, Milwaukee, Wisconsin. FAU - Yentz, Casie AU - Yentz C AD - Clement J. Zablocki Veterans Affairs Medical Center, Milwaukee, Wisconsin. FAU - Charlson, Kristen AU - Charlson K AD - Clement J. Zablocki Veterans Affairs Medical Center, Milwaukee, Wisconsin. LA - eng PT - Journal Article DEP - 20220512 PL - United States TA - Fed Pract JT - Federal practitioner : for the health care professionals of the VA, DoD, and PHS JID - 9500574 PMC - PMC9351738 COIS- Author disclosures The authors report no actual or potential conflicts of interest or outside sources of finding with regard to this article. EDAT- 2022/08/09 06:00 MHDA- 2022/08/09 06:01 PMCR- 2022/05/01 CRDT- 2022/08/08 03:41 PHST- 2022/08/08 03:41 [entrez] PHST- 2022/08/09 06:00 [pubmed] PHST- 2022/08/09 06:01 [medline] PHST- 2022/05/01 00:00 [pmc-release] AID - fp-39-05-212 [pii] AID - 10.12788/fp.0255 [doi] PST - ppublish SO - Fed Pract. 2022 May;39(5):212-217. doi: 10.12788/fp.0255. Epub 2022 May 12. PMID- 35934320 OWN - NLM STAT- MEDLINE DCOM- 20220809 LR - 20250728 IS - 1468-2834 (Electronic) IS - 0002-0729 (Linking) VI - 51 IP - 8 DP - 2022 Aug 2 TI - Age and ageing cardiovascular collection: blood pressure, coronary heart disease and heart failure. LID - afac179 [pii] LID - 10.1093/ageing/afac179 [doi] AB - As people age they are at increased risk of cardiovascular disease, the leading cause of mortality and morbidity worldwide. Understanding cardiovascular ageing is essential to preserving healthy ageing and preventing serious health outcomes. This collection of papers published in Age and Ageing since 2011 cover key themes in cardiovascular ageing, with a separate collection on stroke and atrial fibrillation planned. Treating high blood pressure remains important as people age and reduces strokes and heart attacks. That said, a more personalised approach to blood pressure may be even more important as people age to lower blood pressure to tight targets where appropriate but avoid overtreatment in vulnerable groups. As people age, more people experience blood pressure drops on standing (orthostatic hypotension), particularly as they become frail. This can predispose them to falls. The papers in this collection provide an insight into blood pressure and orthostatic hypotension. They highlight areas for further research to understand blood pressure changes and management in the ageing population. Inpatient clinical care of older people with heart attacks differs from younger people in UK national audit data. People aged over 80 had improved outcomes in survival after heart attack over time, but had lower rates of specialist input from cardiology compared with younger people. This may partly reflect different clinical presentations, with heart attacks occurring in the context of other health conditions, frailty and multimorbidity. The care and outcomes of acute and chronic cardiovascular disease are impacted by the frailty and health status of an individual at baseline. The research included in this collection reinforces the wide variations in the ageing population and the necessity to focus on the individual needs and priorities, and provide a person-centred multidisciplinary approach to care. CI - (c) The Author(s) 2022. Published by Oxford University Press on behalf of the British Geriatrics Society. All rights reserved. For permissions, please email: journals.permissions@oup.com. FAU - Masoli, Jane A H AU - Masoli JAH AUID- ORCID: 0000-0003-3794-7065 AD - Healthcare for Older People, Royal Devon University Healthcare NHS Foundation Trust, Exeter, UK. AD - Institute of Biomedical and Clinical Science, University of Exeter, Exeter UK. FAU - Mensah, Ekow AU - Mensah E AD - Department of Elderly Care and Stroke Medicine, Brighton and Sussex University Hospitals Trust, Brighton, UK. FAU - Rajkumar, Chakravarthi AU - Rajkumar C AD - Department of Elderly Care and Stroke Medicine, Brighton and Sussex University Hospitals Trust, Brighton, UK. AD - Department of Medicine, Brighton and Sussex Medical School, Brighton, UK. LA - eng PT - Journal Article PL - England TA - Age Ageing JT - Age and ageing JID - 0375655 SB - IM MH - Aged MH - Aged, 80 and over MH - Blood Pressure/physiology MH - *Coronary Disease MH - *Frailty/diagnosis/epidemiology/therapy MH - *Heart Failure/diagnosis/epidemiology/therapy MH - Humans MH - *Hypotension, Orthostatic/diagnosis/epidemiology/therapy MH - *Myocardial Infarction MH - *Stroke/prevention & control OTO - NOTNLM OT - blood pressure OT - coronary heart disease OT - hypertension OT - hypotension OT - older people OT - orthostatic EDAT- 2022/08/08 06:00 MHDA- 2022/08/10 06:00 CRDT- 2022/08/07 20:12 PHST- 2022/06/03 00:00 [received] PHST- 2022/08/07 20:12 [entrez] PHST- 2022/08/08 06:00 [pubmed] PHST- 2022/08/10 06:00 [medline] AID - 6657798 [pii] AID - 10.1093/ageing/afac179 [doi] PST - ppublish SO - Age Ageing. 2022 Aug 2;51(8):afac179. doi: 10.1093/ageing/afac179. PMID- 35931208 OWN - NLM STAT- MEDLINE DCOM- 20221017 LR - 20221224 IS - 1874-1754 (Electronic) IS - 0167-5273 (Print) IS - 0167-5273 (Linking) VI - 369 DP - 2022 Dec 15 TI - How does protocolization improve outcomes in cardiogenic shock due to end-stage heart failure? PG - 33-36 LID - S0167-5273(22)01115-9 [pii] LID - 10.1016/j.ijcard.2022.07.045 [doi] AB - BACKGROUND: Protocolized team-based care has been shown to improve outcomes in cardiogenic shock (CS) in patients with end-stage heart failure (ESHF). This study tested the hypothesis that protocolized care improves survival by reducing multi-organ dysfunction prior to orthotopic heart transplantation (OHT) or durable left ventricular assist device (LVAD). METHODS: We developed a protocolized Recognize/rescue-Optimization-Stabilization-Exit/de-Escalation (ROSE) framework for CS due to ESHF. Six-month survival pre-ROSE (2014-2018) and post-ROSE (2018-2021) were compared. The Sequential Organ Failure Assessment (SOFA) score was calculated as a measure of multi-organ dysfunction pre-MCS and pre-"Exit" therapy (OHT, LVAD or recovery). RESULTS: 101 consecutive patients with CS due to ESHF who were deteriorating on inotropes (INTERMACS 1 or 2) were included (63 in Pre-ROSE and 38 in Post-ROSE). The proportions of patients who died on support (26 (41%) vs 11 (29%), p = 0.213) or bridged to "Exit" therapy were comparable between Pre- and Post-ROSE: OHT (28 (44%) vs 21 (55%), p = 0.292); durable LVAD (8 (13%) vs 5 (13%), p = 0.947); or recovery (1 (2%) vs 1 (3%), p = 0.715). SOFA score prior to "Exit" therapy was higher Pre-ROSE compared to Post-ROSE (4 (2-7) vs 2 (1-5), p = 0.012). Six-month survival from initial MCS (71% vs 41%, p = 0.004) and in patients who underwent "Exit" therapy (100% vs 71%, p = 0.001) were higher Post-ROSE vs Pre-ROSE, respectively. Higher pre-"Exit" SOFA score was associated with 6-month survival. None of the patients with Pre-"Exit" SOFA score >/= 9 survived at 6 months. CONCLUSION: Protocolization of CS care in ESHF improved six-month survival by improving multi-organ dysfunction (SOFA score) prior to OHT and LVAD implant. CI - Copyright (c) 2022 Elsevier B.V. All rights reserved. FAU - Lim, Hoong Sern AU - Lim HS AD - University Hospital Birmingham NHS Foundation Trust, Birmingham B15 2TH, UK. Electronic address: sern.lim@uhb.nhs.uk. LA - eng PT - Journal Article DEP - 20220802 PL - Netherlands TA - Int J Cardiol JT - International journal of cardiology JID - 8200291 SB - IM MH - *Heart Failure/diagnosis/therapy MH - *Heart Transplantation MH - *Heart-Assist Devices/adverse effects MH - Humans MH - Multiple Organ Failure/diagnosis/etiology MH - Retrospective Studies MH - Shock, Cardiogenic/diagnosis/etiology/therapy MH - Treatment Outcome PMC - PMC9771587 OTO - NOTNLM OT - Cardiogenic shock OT - Heart failure OT - Mechanical circulatory support EDAT- 2022/08/06 06:00 MHDA- 2022/10/18 06:00 PMCR- 2022/12/22 CRDT- 2022/08/05 19:24 PHST- 2022/01/24 00:00 [received] PHST- 2022/07/04 00:00 [revised] PHST- 2022/07/29 00:00 [accepted] PHST- 2022/08/06 06:00 [pubmed] PHST- 2022/10/18 06:00 [medline] PHST- 2022/08/05 19:24 [entrez] PHST- 2022/12/22 00:00 [pmc-release] AID - S0167-5273(22)01115-9 [pii] AID - 10.1016/j.ijcard.2022.07.045 [doi] PST - ppublish SO - Int J Cardiol. 2022 Dec 15;369:33-36. doi: 10.1016/j.ijcard.2022.07.045. Epub 2022 Aug 2. PMID- 35930815 OWN - NLM STAT- MEDLINE DCOM- 20220831 LR - 20250728 IS - 1872-7654 (Electronic) IS - 0301-2115 (Linking) VI - 276 DP - 2022 Sep TI - Assisted reproduction in patients with cardiac disease: A retrospective review. PG - 199-203 LID - S0301-2115(22)00442-0 [pii] LID - 10.1016/j.ejogrb.2022.07.020 [doi] AB - OBJECTIVE: To assess risks of assisted reproduction in patients with cardiac disease. STUDY DESIGN: Retrospective case note review of patients with cardiac disease undergoing ART over a 10 year period in the obstetric cardiac services of three UK tertiary centres. Assessment of maternal, obstetric and fetal complications during ART and resultant pregnancies. RESULTS: 34 patients with cardiac disease underwent 51 cycles of assisted reproduction. 24 patients (71%) received pre-pregnancy counselling. Mean age at the start of an assisted reproduction cycle was 32 years. Modified WHO (mWHO) risk category for the 34 patients was mWHO I, n = 3; mWHO II, n = 13; mWHO II- III, n = 10; mWHO III, n = 7; mWHO IV, n = 1. The 51 assisted reproduction cycles resulted in 31 pregnancies in 29 patients, and 31 live births, including two sets of twins. Live birth rate per cycle was 60.8%. Twin pregnancy rate per cycle was 5.8%. Four patients experienced complications during assisted reproduction treatment (7.8% per cycle); one major intra-abdominal haemorrhage following egg collection in a patient with a mechanical aortic valve, one endocarditis, one mild ovarian hyperstimulation syndrome and one vagal syncope during egg collection. Four other patients experienced cardiac complications during resultant pregnancies (12.9%). 43% of mWHO class III patients experienced cardiac, obstetric or neonatal complications. Five babies were delivered pre-term (<37/40). CONCLUSIONS: This small study demonstrates that assisted reproduction carries increased risks of complications in patients with cardiac disease, but can be undertaken without major complication in the majority, as long as appropriate adjustments to treatment pathways are made, and they are managed through a multi-disciplinary team. CI - Crown Copyright (c) 2022. Published by Elsevier B.V. All rights reserved. FAU - Skorupskaite, Karolina AU - Skorupskaite K AD - Leeds Fertility, Seacroft Hospital, York Road, Leeds LS14 6UH, UK. Electronic address: karolina.skorupskaite@nhs.net. FAU - Joy, Eleanor AU - Joy E AD - Department of Adult Congenital Heart Disease, Leeds General Infirmary, LS1 3EX, UK. Electronic address: eleanor.joy@nhs.net. FAU - Balen, Adam AU - Balen A AD - Leeds Fertility, Seacroft Hospital, York Road, Leeds LS14 6UH, UK. Electronic address: a.balen@nhs.net. FAU - Agarwal, Kavita AU - Agarwal K AD - Department of Obstetrics, Nottingham City Hospital, Derby Road, Nottingham NG5 1PB, UK. FAU - Cauldwell, Matthew AU - Cauldwell M AD - Department of Obstetrics, Maternal Medicine Service, St George's Hospital, Blackshaw Road, London SW17 0QT, UK. Electronic address: matthew.cauldwell@nhs.net. FAU - English, Kate AU - English K AD - Department of Adult Congenital Heart Disease, Leeds General Infirmary, LS1 3EX, UK. Electronic address: kateenglish@nhs.net. LA - eng PT - Journal Article DEP - 20220729 PL - Ireland TA - Eur J Obstet Gynecol Reprod Biol JT - European journal of obstetrics, gynecology, and reproductive biology JID - 0375672 SB - IM MH - Female MH - *Heart Diseases MH - Humans MH - Infant, Newborn MH - Live Birth MH - Pregnancy MH - *Pregnancy Outcome MH - Pregnancy, Twin MH - Reproductive Techniques, Assisted/adverse effects MH - Retrospective Studies OTO - NOTNLM OT - Cardiac disease OT - Medically assisted reproduction EDAT- 2022/08/06 06:00 MHDA- 2022/09/01 06:00 CRDT- 2022/08/05 18:13 PHST- 2022/05/06 00:00 [received] PHST- 2022/07/07 00:00 [revised] PHST- 2022/07/26 00:00 [accepted] PHST- 2022/08/06 06:00 [pubmed] PHST- 2022/09/01 06:00 [medline] PHST- 2022/08/05 18:13 [entrez] AID - S0301-2115(22)00442-0 [pii] AID - 10.1016/j.ejogrb.2022.07.020 [doi] PST - ppublish SO - Eur J Obstet Gynecol Reprod Biol. 2022 Sep;276:199-203. doi: 10.1016/j.ejogrb.2022.07.020. Epub 2022 Jul 29. PMID- 35927629 OWN - NLM STAT- MEDLINE DCOM- 20220808 LR - 20250728 IS - 1471-2318 (Electronic) IS - 1471-2318 (Linking) VI - 22 IP - 1 DP - 2022 Aug 4 TI - Comprehensive geriatric assessment for older orthopedic patients and analysis of risk factors for postoperative complications. PG - 644 LID - 10.1186/s12877-022-03328-5 [doi] LID - 644 AB - BACKGROUND: The comprehensive geriatric assessment (CGA) has been proposed as a supplementary tool to reduce perioperative complications of geriatric patients, however there is no universally accepted standardization of CGA for orthopedic surgery. In this study, a novel CGA strategy was applied to evaluate the conditions of older patients undergoing orthopedic surgery from a broad view and to identify potential risk factors for postoperative complications. METHODS: A prospective cohort study was conducted from March 2019 to December 2020.The study enrolled patients (age > 75 years) for elective or confined orthopedic surgery. All patients were treated by a multidisciplinary team. A structured CGA was conducted to identify high-risk older patients and to facilitate coordinated multidisciplinary team care by a geriatric team. The basic patient characteristics, CGA results, postoperative complication and mortality rates were collected. Multivariate logistic regression analysis was used to identify risk factors for postoperative complications. RESULTS: A total of 214 patients with an age of 81.07 +/- 4.78 (range, 75-100) years were prospectively enrolled in this study. In total, 66 (30.8%) complications were registered, including one death from myocardial infarction (mortality rate, 0.5%). Poor Activities of Daily Living (ADL) and Instrumental Activities of Daily Living (IADL) were accompanied by frailty, worse perioperative risk, pain, and nutritional status. Poor ADL was also associated with higher risks of falling, polypharmacy, and cardiac and respiration complications. Poor IADL was associated with a higher risk of cardiac and respiration complications. Higher stroke risk was accompanied by higher risks of cardiac complications, delirium, and hemorrhage. Worse American Society of Anesthesiologists (ASA) score was associated with worse ADL, IADL, frailty, and higher delirium risk. Multivariate logistic regression analysis showed that spinal fusion (odds ratio [OR], 0.73; 95% confidence interval [CI], 0.65 to 0.83; p = 0.0214), blood loss(OR, 1.68; 95% CI, 1.31 to 2.01; p = 0.0168), ADL (severe dysfunction or worse) (OR, 1.45; 95% CI, 1.16 to 1.81; p = 0.0413), IADL (serious dependence) (OR, 1.08; 95% CI, 1.33 to 1.63; p = 0.0436), renal function (chronic kidney disease (CKD) >/= stage 3a) (OR, 2.01; 95% CI, 1.54 to 2.55; p = 0.0133), and malnutrition(OR, 2.11; 95% CI, 1.74 to 2.56; p = 0.0101) were independent risk factors for postoperative complications. CONCLUSION: The CGA process reduces patient mortality and increases safety in older orthopedic surgery patients. Spinal fusion, blood loss, ADL (severe dysfunction or worse), IADL (serious dependence), renal function (CKD >/= stage 3a) and nutrition mini nutritional assessment (MNA) (malnourished) were independent risk factors of postoperative complications following orthopaedic surgery in older patients. CI - (c) 2022. The Author(s). FAU - Kong, Chao AU - Kong C AD - Department of Orthopedics, Xuanwu Hospital of Capital Medical University, 45 Changchun Street, Xicheng, Beijing, 100053, People's Republic of China. AD - National Geriatric Disease Research Center, Xuanwu Hospital of Capital Medical University, 45 Changchun Street, Xicheng, Beijing, 100053, People's Republic of China. AD - Beijing Municipal Geriatric Medical Research Center, Xuanwu Hospital of Capital Medical University, 45 Changchun Street, Xicheng, Beijing, 100053, People's Republic of China. FAU - Zhang, Yanhong AU - Zhang Y AD - Department of Orthopedics, Xuanwu Hospital of Capital Medical University, 45 Changchun Street, Xicheng, Beijing, 100053, People's Republic of China. AD - National Geriatric Disease Research Center, Xuanwu Hospital of Capital Medical University, 45 Changchun Street, Xicheng, Beijing, 100053, People's Republic of China. AD - Beijing Municipal Geriatric Medical Research Center, Xuanwu Hospital of Capital Medical University, 45 Changchun Street, Xicheng, Beijing, 100053, People's Republic of China. FAU - Wang, Chaodong AU - Wang C AD - Department of Orthopedics, Xuanwu Hospital of Capital Medical University, 45 Changchun Street, Xicheng, Beijing, 100053, People's Republic of China. AD - National Geriatric Disease Research Center, Xuanwu Hospital of Capital Medical University, 45 Changchun Street, Xicheng, Beijing, 100053, People's Republic of China. AD - Beijing Municipal Geriatric Medical Research Center, Xuanwu Hospital of Capital Medical University, 45 Changchun Street, Xicheng, Beijing, 100053, People's Republic of China. FAU - Wang, Peng AU - Wang P AD - Department of Orthopedics, Xuanwu Hospital of Capital Medical University, 45 Changchun Street, Xicheng, Beijing, 100053, People's Republic of China. AD - National Geriatric Disease Research Center, Xuanwu Hospital of Capital Medical University, 45 Changchun Street, Xicheng, Beijing, 100053, People's Republic of China. AD - Beijing Municipal Geriatric Medical Research Center, Xuanwu Hospital of Capital Medical University, 45 Changchun Street, Xicheng, Beijing, 100053, People's Republic of China. FAU - Li, Xiangyu AU - Li X AD - Department of Orthopedics, Xuanwu Hospital of Capital Medical University, 45 Changchun Street, Xicheng, Beijing, 100053, People's Republic of China. AD - National Geriatric Disease Research Center, Xuanwu Hospital of Capital Medical University, 45 Changchun Street, Xicheng, Beijing, 100053, People's Republic of China. AD - Beijing Municipal Geriatric Medical Research Center, Xuanwu Hospital of Capital Medical University, 45 Changchun Street, Xicheng, Beijing, 100053, People's Republic of China. FAU - Wang, Wei AU - Wang W AD - Department of Orthopedics, Xuanwu Hospital of Capital Medical University, 45 Changchun Street, Xicheng, Beijing, 100053, People's Republic of China. AD - National Geriatric Disease Research Center, Xuanwu Hospital of Capital Medical University, 45 Changchun Street, Xicheng, Beijing, 100053, People's Republic of China. AD - Beijing Municipal Geriatric Medical Research Center, Xuanwu Hospital of Capital Medical University, 45 Changchun Street, Xicheng, Beijing, 100053, People's Republic of China. FAU - Wang, Yu AU - Wang Y AD - Department of Orthopedics, Xuanwu Hospital of Capital Medical University, 45 Changchun Street, Xicheng, Beijing, 100053, People's Republic of China. AD - National Geriatric Disease Research Center, Xuanwu Hospital of Capital Medical University, 45 Changchun Street, Xicheng, Beijing, 100053, People's Republic of China. AD - Beijing Municipal Geriatric Medical Research Center, Xuanwu Hospital of Capital Medical University, 45 Changchun Street, Xicheng, Beijing, 100053, People's Republic of China. FAU - Shen, Jianghua AU - Shen J AD - Department of Orthopedics, Xuanwu Hospital of Capital Medical University, 45 Changchun Street, Xicheng, Beijing, 100053, People's Republic of China. AD - National Geriatric Disease Research Center, Xuanwu Hospital of Capital Medical University, 45 Changchun Street, Xicheng, Beijing, 100053, People's Republic of China. AD - Beijing Municipal Geriatric Medical Research Center, Xuanwu Hospital of Capital Medical University, 45 Changchun Street, Xicheng, Beijing, 100053, People's Republic of China. FAU - Ren, Xiaoyi AU - Ren X AD - Department of Orthopedics, Xuanwu Hospital of Capital Medical University, 45 Changchun Street, Xicheng, Beijing, 100053, People's Republic of China. AD - National Geriatric Disease Research Center, Xuanwu Hospital of Capital Medical University, 45 Changchun Street, Xicheng, Beijing, 100053, People's Republic of China. AD - Beijing Municipal Geriatric Medical Research Center, Xuanwu Hospital of Capital Medical University, 45 Changchun Street, Xicheng, Beijing, 100053, People's Republic of China. FAU - Wang, Tianlong AU - Wang T AD - Department of Orthopedics, Xuanwu Hospital of Capital Medical University, 45 Changchun Street, Xicheng, Beijing, 100053, People's Republic of China. w_tl5595@hotmail.com. AD - National Geriatric Disease Research Center, Xuanwu Hospital of Capital Medical University, 45 Changchun Street, Xicheng, Beijing, 100053, People's Republic of China. w_tl5595@hotmail.com. AD - Beijing Municipal Geriatric Medical Research Center, Xuanwu Hospital of Capital Medical University, 45 Changchun Street, Xicheng, Beijing, 100053, People's Republic of China. w_tl5595@hotmail.com. FAU - Zhao, Guoguang AU - Zhao G AD - Department of Orthopedics, Xuanwu Hospital of Capital Medical University, 45 Changchun Street, Xicheng, Beijing, 100053, People's Republic of China. cmuzhaogg@163.com. AD - National Geriatric Disease Research Center, Xuanwu Hospital of Capital Medical University, 45 Changchun Street, Xicheng, Beijing, 100053, People's Republic of China. cmuzhaogg@163.com. AD - Beijing Municipal Geriatric Medical Research Center, Xuanwu Hospital of Capital Medical University, 45 Changchun Street, Xicheng, Beijing, 100053, People's Republic of China. cmuzhaogg@163.com. FAU - Lu, Shibao AU - Lu S AD - Department of Orthopedics, Xuanwu Hospital of Capital Medical University, 45 Changchun Street, Xicheng, Beijing, 100053, People's Republic of China. shibaoluspine@sina.com. AD - National Geriatric Disease Research Center, Xuanwu Hospital of Capital Medical University, 45 Changchun Street, Xicheng, Beijing, 100053, People's Republic of China. shibaoluspine@sina.com. AD - Beijing Municipal Geriatric Medical Research Center, Xuanwu Hospital of Capital Medical University, 45 Changchun Street, Xicheng, Beijing, 100053, People's Republic of China. shibaoluspine@sina.com. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220804 PL - England TA - BMC Geriatr JT - BMC geriatrics JID - 100968548 SB - IM MH - Activities of Daily Living MH - Aged MH - Aged, 80 and over MH - *Delirium/etiology MH - *Frailty/complications MH - Geriatric Assessment/methods MH - Humans MH - *Malnutrition/complications MH - Postoperative Complications/diagnosis/epidemiology MH - Prospective Studies MH - *Renal Insufficiency, Chronic MH - Risk Factors PMC - PMC9354431 OTO - NOTNLM OT - Comprehensive geriatric assessment OT - Older people; risk factor; Postoperative complication OT - Orthopedic surgery COIS- The authors declare no financial and non-financial competing interests. EDAT- 2022/08/05 06:00 MHDA- 2022/08/09 06:00 PMCR- 2022/08/04 CRDT- 2022/08/04 23:42 PHST- 2022/02/11 00:00 [received] PHST- 2022/07/20 00:00 [accepted] PHST- 2022/08/04 23:42 [entrez] PHST- 2022/08/05 06:00 [pubmed] PHST- 2022/08/09 06:00 [medline] PHST- 2022/08/04 00:00 [pmc-release] AID - 10.1186/s12877-022-03328-5 [pii] AID - 3328 [pii] AID - 10.1186/s12877-022-03328-5 [doi] PST - epublish SO - BMC Geriatr. 2022 Aug 4;22(1):644. doi: 10.1186/s12877-022-03328-5. PMID- 35925981 OWN - NLM STAT- MEDLINE DCOM- 20220808 LR - 20240902 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 17 IP - 8 DP - 2022 TI - Cognitive impairment, frailty and rehabilitation outcome in older cardiorespiratory patients. DEC_FRAinRIAB: Study protocol. PG - e0272132 LID - 10.1371/journal.pone.0272132 [doi] LID - e0272132 AB - BACKGROUND: Chronic heart failure (CHF) and chronic obstructive pulmonary disease (COPD) are two clinical conditions often associated with functional worsening, cognitive dysfunctions, treatment non-adherence, psychological distress and poor quality of life (QoL). In addition, since patients suffering from these conditions are often older adults, the presence of frailty syndrome could worsen the clinical situation. METHODS AND DESIGN: This study protocol of a prospective multi-center clinical trial, will be conducted at two hospitals of the Istituti Clinici Scientifici Maugeri IRCCS group, from July 2020 until December 2022. CHF and COPD older patients (age >/=65) will undergo a multidisciplinary assessment at admission, discharge and at 6 months follow-up, from an inpatient rehabilitation program: disease-related clinical characteristics, functional variables, cognitive screening, treatment adherence, anxiety, depression, QoL and frailty. The estimated sample size will consist of 300 patients. DISCUSSION: The expected results are related to the possibility of an improvement in the areas of intervention after the rehabilitative program and the maintenance of these improvements over time. The assessment of clinical and functional status, cognitive impairment, treatment adherence, psychosocial characteristics, and frailty could provide more specific and useful information about the main features to be considered in the evaluation and treatment of older patients suffering from CHF and COPD undergoing a rehabilitative pathway. TRIAL REGISTRATION: The study has been registered on January 28, 2022 with the ClinicalTrials.gov NCT05230927 registration number (clinicaltrials.gov/ct2/show/NCT05230927). FAU - Vigore, Martina AU - Vigore M AD - Istituti Clinici Scientifici Maugeri, IRCCS, Psychology Unit of Montescano Institute, Pavia, Italy. FAU - Granata, Nicolo AU - Granata N AUID- ORCID: 0000-0001-9743-6684 AD - Istituti Clinici Scientifici Maugeri, IRCCS, Cardiac Rehabilitation Division of Tradate Institute, Varese, Italy. FAU - Braga, Simona Sarzi AU - Braga SS AD - Istituti Clinici Scientifici Maugeri, IRCCS, Cardiac Rehabilitation Division of Tradate Institute, Varese, Italy. FAU - Piaggi, Giancarlo AU - Piaggi G AUID- ORCID: 0000-0003-0896-6136 AD - Istituti Clinici Scientifici Maugeri, IRCCS, Respiratory Rehabilitation Division of Montescano Institute, Pavia, Italy. FAU - Audifreddi, Silvia AU - Audifreddi S AD - Istituti Clinici Scientifici Maugeri, IRCCS, Health Direction of Tradate Institute, Varese, Italy. FAU - Ferrari, Marina AU - Ferrari M AD - Istituti Clinici Scientifici Maugeri, IRCCS, Cardiac Rehabilitation Division of Montescano Institute, Pavia, Italy. FAU - La Rovere, Maria Teresa AU - La Rovere MT AD - Istituti Clinici Scientifici Maugeri, IRCCS, Cardiac Rehabilitation Division of Montescano Institute, Pavia, Italy. FAU - Pierobon, Antonia AU - Pierobon A AD - Istituti Clinici Scientifici Maugeri, IRCCS, Psychology Unit of Montescano Institute, Pavia, Italy. LA - eng SI - ClinicalTrials.gov/NCT05230927 PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220804 PL - United States TA - PLoS One JT - PloS one JID - 101285081 SB - IM MH - Aged MH - Humans MH - Chronic Disease MH - *Cognitive Dysfunction/complications MH - Frail Elderly MH - *Frailty/complications MH - *Heart Failure/complications MH - Prospective Studies MH - *Pulmonary Disease, Chronic Obstructive MH - Quality of Life MH - Treatment Outcome PMC - PMC9351997 COIS- The authors have no competing interests to report. EDAT- 2022/08/05 06:00 MHDA- 2022/08/09 06:00 PMCR- 2022/08/04 CRDT- 2022/08/04 13:53 PHST- 2022/04/26 00:00 [received] PHST- 2022/07/08 00:00 [accepted] PHST- 2022/08/04 13:53 [entrez] PHST- 2022/08/05 06:00 [pubmed] PHST- 2022/08/09 06:00 [medline] PHST- 2022/08/04 00:00 [pmc-release] AID - PONE-D-22-11167 [pii] AID - 10.1371/journal.pone.0272132 [doi] PST - epublish SO - PLoS One. 2022 Aug 4;17(8):e0272132. doi: 10.1371/journal.pone.0272132. eCollection 2022. PMID- 35920514 OWN - NLM STAT- MEDLINE DCOM- 20220804 LR - 20260728 IS - 1984-0446 (Electronic) IS - 0034-7167 (Linking) VI - 75 IP - 5 DP - 2022 TI - Technologies used by nursing to predict clinical deterioration in hospitalized adults: a scoping review. PG - e20210570 LID - S0034-71672022000600303 [pii] LID - 10.1590/0034-7167-2021-0570 [doi] AB - OBJECTIVE: to map the early clinical deterioration technologies used in nurses' professional practice in the care of hospitalized adult patients. METHODS: this is a scoping review, according to Joanna Briggs Institute Reviewer's Manual, which seeks to map the main technologies for detecting early clinical deterioration of hospitalized patients available for use by nurses, summarizing them and indicating gaps in knowledge to be investigated. RESULTS: twenty-seven studies were found. The most present variables in the technologies were vital signs, urinary output, awareness and risk scales, clinical examination and nurses' judgment. The main outcomes were activation of rapid response teams, death, cardiac arrest and admission to critical care units. FINAL CONSIDERATIONS: the study emphasizes the most accurate variables in patient clinical assessment, so that indicative signs of potential severity can be prioritized to guide health conducts aiming to intervene early in the face of ongoing clinical deterioration. FAU - Gondim, Erica Sobral AU - Gondim ES AUID- ORCID: 0000-0001-5257-6245 AD - Universidade Regional do Cariri. Crato, Ceara, Brazil. FAU - Gomes, Emiliana Bezerra AU - Gomes EB AUID- ORCID: 0000-0002-7135-512X AD - Universidade Regional do Cariri. Crato, Ceara, Brazil. FAU - Matos, Jose Hiago Feitosa de AU - Matos JHF AUID- ORCID: 0000-0001-8473-7269 AD - Universidade Regional do Cariri. Crato, Ceara, Brazil. FAU - Pinto, Sarah de Lima AU - Pinto SL AUID- ORCID: 0000-0002-9020-5610 AD - Universidade Regional do Cariri. Crato, Ceara, Brazil. FAU - Oliveira, Celida Juliana de AU - Oliveira CJ AUID- ORCID: 0000-0002-8900-6833 AD - Universidade Regional do Cariri. Crato, Ceara, Brazil. FAU - Alencar, Ana Maria Parente Garcia AU - Alencar AMPG AUID- ORCID: 0000-0003-0459-4291 AD - Universidade Regional do Cariri. Crato, Ceara, Brazil. LA - eng LA - por PT - Journal Article PT - Scoping Review DEP - 20220729 PL - Brazil TA - Rev Bras Enferm JT - Revista brasileira de enfermagem JID - 7910105 MH - Adult MH - *Clinical Deterioration MH - *Hospital Rapid Response Team MH - Hospitalization MH - Humans MH - Intensive Care Units MH - Vital Signs EDAT- 2022/08/04 06:00 MHDA- 2022/08/05 06:00 CRDT- 2022/08/03 07:54 PHST- 2021/09/16 00:00 [received] PHST- 2022/04/12 00:00 [accepted] PHST- 2022/08/03 07:54 [entrez] PHST- 2022/08/04 06:00 [pubmed] PHST- 2022/08/05 06:00 [medline] AID - S0034-71672022000600303 [pii] AID - 10.1590/0034-7167-2021-0570 [doi] PST - epublish SO - Rev Bras Enferm. 2022 Jul 29;75(5):e20210570. doi: 10.1590/0034-7167-2021-0570. eCollection 2022. PMID- 35919661 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250130 IS - 2752-4191 (Electronic) IS - 2752-4191 (Linking) VI - 2 IP - 1 DP - 2022 Jan TI - Inflammatory bowel disease and cardiovascular diseases: a concise review. PG - oeab029 LID - 10.1093/ehjopen/oeab029 [doi] LID - oeab029 AB - Cardiovascular diseases (CVDs) remain the leading cause of morbidity and mortality despite aggressive treatment of traditional risk factors. Chronic inflammation plays an important role in the initiation and progression of CVDs. Inflammatory bowel disease (IBD) is a systemic state of inflammation exhibiting increased levels of pro-inflammatory cytokines including tumour necrosis factor-alpha (TNF-alpha), interleukin (IL)-1beta, and IL-6. Importantly, IBD is associated with increased risk for CVDs especially in women and young adults, including coronary artery disease, stroke, thromboembolic diseases, and arrhythmias. Potential mechanisms underlying the increased risk for CVDs in IBD patients include increased levels of inflammatory cytokines and oxidative stress, altered platelet function, hypercoagulability, decreased numbers of circulating endothelial progenitor cells, endothelial dysfunction, and possible interruption of gut microbiota. Although IBD does not appear to exacerbate the traditional risk factors for CVDs, including hypertension, hyperlipidaemia, diabetes mellitus, and obesity, aggressive risk stratifications are important for primary and secondary prevention of CVDs for IBD patients. Compared to 5-aminosalicylates and corticosteroids, anti-TNF-alpha therapy in IBD patients was consistently associated with decreasing cardiovascular events. In the absence of contraindications, low-dose aspirin and statins appear to be beneficial for IBD patients. Low-molecular-weight heparin is also recommended for patients who are hospitalized with acute IBD flares without major bleeding risk. A multidisciplinary team approach should be considered for the management of IBD patients. CI - (c) The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology. FAU - Wu, Hao AU - Wu H AUID- ORCID: 0000-0001-6154-9759 AD - Center for Precision Medicine and Division of Cardiovascular Medicine, Department of Medicine, University of Missouri School of Medicine, One Hospital Drive, Columbia, MO 65212, USA. AD - Department of Gastroenterology, The Third Xiangya Hospital, Central South University, 138 Tongzipo Road, Changsha 410013, China. FAU - Hu, Tingzi AU - Hu T AD - Center for Precision Medicine and Division of Cardiovascular Medicine, Department of Medicine, University of Missouri School of Medicine, One Hospital Drive, Columbia, MO 65212, USA. FAU - Hao, Hong AU - Hao H AD - Center for Precision Medicine and Division of Cardiovascular Medicine, Department of Medicine, University of Missouri School of Medicine, One Hospital Drive, Columbia, MO 65212, USA. FAU - Hill, Michael A AU - Hill MA AD - Dalton Cardiovascular Research Center, University of Missouri, 134 Research Park Drive, Columbia, MO 65211, USA. FAU - Xu, Canxia AU - Xu C AD - Department of Gastroenterology, The Third Xiangya Hospital, Central South University, 138 Tongzipo Road, Changsha 410013, China. FAU - Liu, Zhenguo AU - Liu Z AD - Center for Precision Medicine and Division of Cardiovascular Medicine, Department of Medicine, University of Missouri School of Medicine, One Hospital Drive, Columbia, MO 65212, USA. LA - eng PT - Journal Article DEP - 20211014 PL - England TA - Eur Heart J Open JT - European heart journal open JID - 9918282081406676 PMC - PMC9242064 OTO - NOTNLM OT - Cardiovascular medications OT - Inflammatory bowel disease OT - Ischaemic arterial disease OT - Venous thromboembolism EDAT- 2022/08/04 06:00 MHDA- 2022/08/04 06:01 PMCR- 2021/10/14 CRDT- 2022/08/03 02:11 PHST- 2021/06/03 00:00 [received] PHST- 2021/08/26 00:00 [revised] PHST- 2021/10/12 00:00 [accepted] PHST- 2022/08/03 02:11 [entrez] PHST- 2022/08/04 06:00 [pubmed] PHST- 2022/08/04 06:01 [medline] PHST- 2021/10/14 00:00 [pmc-release] AID - oeab029 [pii] AID - 10.1093/ehjopen/oeab029 [doi] PST - epublish SO - Eur Heart J Open. 2021 Oct 14;2(1):oeab029. doi: 10.1093/ehjopen/oeab029. eCollection 2022 Jan. PMID- 35919348 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220805 IS - 2752-4191 (Electronic) IS - 2752-4191 (Linking) VI - 2 IP - 3 DP - 2022 May TI - Autoimmune connective tissue diseases and aortic valve replacement outcomes: a population-based study. PG - oeac024 LID - 10.1093/ehjopen/oeac024 [doi] LID - oeac024 AB - AIMS: Patients with autoimmune connective tissue diseases (CTDs) have a high burden of valvular heart disease and are often thought of as high surgical risk patients. METHODS AND RESULTS: Patients undergoing aortic valve replacement (AVR) were identified in the Nationwide Readmissions Database between January 2012 and December 2018. Patients with a history of systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, mixed C, Sjogren syndrome, polymyositis, and dermatomyositis were included in the CTD cohort. Patients undergoing coronary artery bypass grafting concomitantly with AVR were excluded. A total of 569 600 hospitalizations were included, of which16 531 (2.9%) had CTD. CTD patients were more likely to be females, with higher rates of heart failure, pulmonary hypertension, and more likely to be insured by Medicare. CTD patients had lower mortality than non-CTD patients [odds ratio (OR) 0.66; 95% confidence interval (CI): 0.59-0.74] and stroke [OR 0.87; 95% (CI): 0.79-0.97]. CTD patients undergoing SAVR had lower mortality [OR 0.69; 95% (CI): 0.60-0.80] and stroke [OR 0.86; 95% (CI): 0.75-0.98). CTD patients undergoing TAVR had lower mortality outcomes [OR 0.67; 95% (CI): 0.56-0.80]; however, they had comparable stroke outcomes [OR 0.97; 95% (CI): 0.83-1.13, P = 0.69]. CONCLUSIONS: Outcomes for patients with CTD requiring AVR are not inferior to their non-CTD counterparts. A comprehensive heart team selection of patients undergoing AVR approaches should place CTD history under consideration; however, pre-existing CTD should not be prohibitive of AVR interventions. CI - (c) The Author(s) 2022. Published by Oxford University Press on behalf of European Society of Cardiology. FAU - Gad, Mohamed M AU - Gad MM AUID- ORCID: 0000-0003-0218-3317 AD - Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Heart and Vascular Institute, 9500 Euclid Avenue, J2-3, Cleveland, OH 44195, USA. FAU - Lichtman, Devora AU - Lichtman D AD - Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Heart and Vascular Institute, 9500 Euclid Avenue, J2-3, Cleveland, OH 44195, USA. FAU - Saad, Anas M AU - Saad AM AD - Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Heart and Vascular Institute, 9500 Euclid Avenue, J2-3, Cleveland, OH 44195, USA. FAU - Isogai, Toshiaki AU - Isogai T AD - Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Heart and Vascular Institute, 9500 Euclid Avenue, J2-3, Cleveland, OH 44195, USA. FAU - Bansal, Agam AU - Bansal A AD - Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Heart and Vascular Institute, 9500 Euclid Avenue, J2-3, Cleveland, OH 44195, USA. FAU - Abdallah, Mouin S AU - Abdallah MS AD - Department of Cardiology, Medstar Heart and Vascular Institute, Fairfax, VA 22031, USA. FAU - Roselli, Eric AU - Roselli E AD - Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Heart and Vascular Institute, 9500 Euclid Avenue, J2-3, Cleveland, OH 44195, USA. FAU - Chatterjee, Soumya AU - Chatterjee S AD - Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Heart and Vascular Institute, 9500 Euclid Avenue, J2-3, Cleveland, OH 44195, USA. FAU - Reed, Grant W AU - Reed GW AD - Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Heart and Vascular Institute, 9500 Euclid Avenue, J2-3, Cleveland, OH 44195, USA. FAU - Kapadia, Samir R AU - Kapadia SR AD - Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Heart and Vascular Institute, 9500 Euclid Avenue, J2-3, Cleveland, OH 44195, USA. FAU - Menon, Venu AU - Menon V AD - Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Heart and Vascular Institute, 9500 Euclid Avenue, J2-3, Cleveland, OH 44195, USA. FAU - Wassif, Heba AU - Wassif H AD - Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Heart and Vascular Institute, 9500 Euclid Avenue, J2-3, Cleveland, OH 44195, USA. LA - eng PT - Journal Article DEP - 20220406 PL - England TA - Eur Heart J Open JT - European heart journal open JID - 9918282081406676 PMC - PMC9242052 OTO - NOTNLM OT - Aortic valve replacement OT - Autoimmune connective tissue diseases OT - Valvular heart disease EDAT- 2022/08/04 06:00 MHDA- 2022/08/04 06:01 PMCR- 2022/04/06 CRDT- 2022/08/03 02:07 PHST- 2022/01/06 00:00 [received] PHST- 2022/03/26 00:00 [revised] PHST- 2022/08/03 02:07 [entrez] PHST- 2022/08/04 06:00 [pubmed] PHST- 2022/08/04 06:01 [medline] PHST- 2022/04/06 00:00 [pmc-release] AID - oeac024 [pii] AID - 10.1093/ehjopen/oeac024 [doi] PST - epublish SO - Eur Heart J Open. 2022 Apr 6;2(3):oeac024. doi: 10.1093/ehjopen/oeac024. eCollection 2022 May. PMID- 35916923 OWN - NLM STAT- MEDLINE DCOM- 20220913 LR - 20260728 IS - 1557-2501 (Electronic) IS - 1042-3931 (Linking) VI - 34 IP - 9 DP - 2022 Sep TI - The Impact of a Dedicated Chronic Total Occlusion PCI Program on Heart Team Decision Making. PG - E660-E664 LID - JIC20220727-2 [pii] AB - BACKGROUND: Guidelines endorse a heart team (HT) approach to standardize the decision-making process for patients with complex coronary artery disease (CAD). With percutaneous treatment options for complex CAD increasing, we hypothesized that practice had changed over the past decade-and that more individuals, previously deemed too high risk for intervention, would now be referred for either surgical or percutaneous revascularization. METHODS: This observational study was conducted at St Thomas' Hospital (London, United Kingdom). All patients discussed at HT meetings were recorded and treatment recommendations audited. A subset of historic cases was selected for blinded, repeat discussion. RESULTS: From April 2018 to 2019, a total of 52 HT meetings discussing 375 cases were held. Patients tended to be male, with a majority demonstrating multivessel CAD in the context of preserved left ventricular function. SYNTAX scores were balanced across the tertiles. Thirty-five percent of patients had at least 1 chronic total occlusion (mean J-CTO, 3 [interquartile range, 2-3]), affecting the right coronary artery in 60%. Fifteen historic patients with isolated CTOs were re-presented an average of 8 years later; only 3 patients received the same outcome, with 80% now receiving a recommendation for revascularization over medical therapy. CONCLUSIONS: A dedicated program supporting complex coronary intervention is associated with a change in treatment recommendations issued by the local HT. In line with international guidelines, this might indicate that any complex or multivessel CAD should be discussed at HT meetings with, ideally, the presence of CTO operators. FAU - Kaier, Thomas E AU - Kaier TE FAU - Hurrell, Harriet AU - Hurrell H FAU - Patterson, Tiffany AU - Patterson T FAU - Li Kam Wa, Matthew AU - Li Kam Wa M FAU - Fisk, Gracie AU - Fisk G FAU - Stewart, Jack AU - Stewart J FAU - Baig, Kamran AU - Baig K FAU - Ghosh-Dastidar, Michael AU - Ghosh-Dastidar M FAU - Young, Christopher P AU - Young CP FAU - Redwood, Simon R AU - Redwood SR FAU - De Silva, Kalpa AU - De Silva K FAU - Clapp, Brian AU - Clapp B FAU - Perera, Divaka AU - Perera D FAU - Pavlidis, Antonis N AU - Pavlidis AN AD - St Thomas' Hospital, Guy's and St Thomas' NHS Foundation Trust, Westminster Bridge Road, London SE1 7EH, United Kingdom. antonis.pavlidis@gstt.nhs.uk. LA - eng PT - Journal Article PT - Observational Study PT - Research Support, Non-U.S. Gov't DEP - 20220727 PL - United States TA - J Invasive Cardiol JT - The Journal of invasive cardiology JID - 8917477 SB - IM MH - Chronic Disease MH - Coronary Artery Bypass MH - *Coronary Artery Disease/diagnosis/surgery MH - *Coronary Occlusion/diagnosis/surgery MH - Decision Making MH - Humans MH - Male MH - *Percutaneous Coronary Intervention/adverse effects MH - Risk Factors MH - Treatment Outcome MH - United Kingdom OTO - NOTNLM OT - coronary artery disease OT - health outcomes OT - heart team OT - revascularization EDAT- 2022/08/03 06:00 MHDA- 2022/09/14 06:00 CRDT- 2022/08/02 11:14 PHST- 2022/08/03 06:00 [pubmed] PHST- 2022/09/14 06:00 [medline] PHST- 2022/08/02 11:14 [entrez] AID - JIC20220727-2 [pii] AID - 10.25270/jic/21.00447 [doi] PST - ppublish SO - J Invasive Cardiol. 2022 Sep;34(9):E660-E664. doi: 10.25270/jic/21.00447. Epub 2022 Jul 27. PMID- 35915979 OWN - NLM STAT- MEDLINE DCOM- 20230823 LR - 20230823 IS - 1467-1107 (Electronic) IS - 1047-9511 (Linking) VI - 33 IP - 7 DP - 2023 Jul TI - Impact of interdisciplinary counselling for parental decision-making in cases of pregnancies with prenatally diagnosed CHD. PG - 1172-1176 LID - 10.1017/S104795112200213X [doi] AB - INTRODUCTION: Parental counselling after antenatal diagnosis of a congenital heart defect requires a high degree of professional and emotional competence and ultimately a sense of responsibility on the part of the consulting physicians. However, little is known about parents; perceptions and evaluation of these consultations. MATERIAL/METHODS: Survey on 425 women who received interdisciplinary counselling after antenatal diagnosis of a complex fetal congenital heart defect in a specialized prenatal outpatient clinic with an affiliated paediatric heart centre. Two questionnaires were used to retrospectively evaluate the parental perception and impact on counselling, particularly on decision-making. Questionnaires differed between women conceiving the child and women who terminated the pregnancy. RESULTS: 400 women continued, 25 women terminated the pregnancy after diagnosis and counselling. Good quality of life was reported for 68% of the children, 15% died postnatally in the further course. 95% rated the counselling as good or very good regardless of the child s outcome. 73% described the counselling as highly important for their subsequent decision. The possibility of termination of pregnancy was discussed with 37% of the respondents, 22% of them found it outrageous or very distressing. Of all respondents, one woman would have made a different decision regarding continuation of the pregnancy in retrospect. CONCLUSION: Retrospectively, parents rate prenatal counselling extremely positively, irrespective of the severity of the child s heart defect. It can be assumed that the consistent joint interdisciplinary consultation and the high reputation of the cooperating heart centre have had an influence on the below-average rate of termination of pregnancy. FAU - Schneider, Katja AU - Schneider K AUID- ORCID: 0000-0002-4273-6855 AD - Department of Neonatology, GFO Kliniken, Bonn, Germany. FAU - Bousi, Dafni AU - Bousi D AD - Department of Gynaecology and Obstetrics, Stadtische Kliniken, Cologne, Germany. FAU - Stressig, Rudiger AU - Stressig R AD - Department of Fetal Diagnostics, Pranatal Plus, Cologne, Germany. LA - eng PT - Journal Article DEP - 20220802 PL - England TA - Cardiol Young JT - Cardiology in the young JID - 9200019 SB - IM MH - Child MH - Pregnancy MH - Female MH - Humans MH - Retrospective Studies MH - *Quality of Life MH - Prenatal Diagnosis MH - *Heart Defects, Congenital/diagnosis MH - Counseling MH - Ultrasonography, Prenatal EDAT- 2022/08/03 06:00 MHDA- 2023/08/23 06:42 CRDT- 2022/08/02 03:03 PHST- 2023/08/23 06:42 [medline] PHST- 2022/08/03 06:00 [pubmed] PHST- 2022/08/02 03:03 [entrez] AID - S104795112200213X [pii] AID - 10.1017/S104795112200213X [doi] PST - ppublish SO - Cardiol Young. 2023 Jul;33(7):1172-1176. doi: 10.1017/S104795112200213X. Epub 2022 Aug 2. PMID- 35915596 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220803 IS - 1177-889X (Print) IS - 1177-889X (Electronic) IS - 1177-889X (Linking) VI - 16 DP - 2022 TI - Do Patients Seek Women-Centered Cardiac Care? Patient Experience of an All-Female Multidisciplinary Heart Center for Women. PG - 1749-1758 LID - 10.2147/PPA.S363325 [doi] AB - PURPOSE: Cardiovascular disease in women is frequently under-diagnosed and under-treated. Numerous heart centers for women have opened throughout the world to address these disparities; however, there is a paucity of data regarding participants' perspectives. The current study assesses motivation to participate and perceived benefits in attending a heart center for women (HCW) in Jerusalem, Israel. METHODS: This study utilized qualitative methods to assess patients' motivation and perceived benefits to attending a women's heart center, particularly as they relate to gender medicine and single-sex staffing. A random sample of 42 clinic patients were asked to participate in interviews. Inclusionary criteria consisted of previous cardiovascular event, active cardiac symptom or three or more cardiovascular disease risk factors. Exclusionary criteria consisted of pregnancy, type 1 diabetes requiring insulin, psychiatric diagnosis that precluded participation, dementia, or other multidisciplinary clinic participation. Interviews were audio recorded and transcribed verbatim. Qualitative data analysis followed Braun and Clarke's methodology of thematic analysis. RESULTS: The single-sex and gender medicine aspects did not motivate women to attend the HCW, although some participants perceived this as beneficial in retrospect. Women reported that the clinic visit enhanced their knowledge and awareness of issues related to heart disease in women as well as personal health benefits. They reported benefitting from the holistic approach, consideration of their lifestyle, the staff's expression of concern, personalized attention, common language, and feeling understood. CONCLUSION: This study describes the patient experience in an all-female HCW, highlighting their motivation for attendance and perceived benefits. While they did not actively seek women-centered care, women reported educational and care provision benefits to their attendance. The care attributes that women identified as beneficial typify the person-centered approach to care. These findings may inform both the design and evaluation of medical care facilities that aim to address the sex and gender disparities in cardiology as well as other medical specialties. CI - (c) 2022 Finkelstein et al. FAU - Finkelstein, Adi AU - Finkelstein A AD - Department of Nursing, Faculty of Life and Health Sciences, Jerusalem College of Technology, Jerusalem, Israel. FAU - Leiter, Elisheva AU - Leiter E AUID- ORCID: 0000-0002-6072-6431 AD - Linda Joy Pollin Cardiovascular Wellness Center for Women, Hadassah University Medical Center, Jerusalem, Israel. FAU - Reinfeld, Tanya AU - Reinfeld T AD - Linda Joy Pollin Cardiovascular Wellness Center for Women, Hadassah University Medical Center, Jerusalem, Israel. FAU - Levy, Ora AU - Levy O AD - Linda Joy Pollin Cardiovascular Wellness Center for Women, Hadassah University Medical Center, Jerusalem, Israel. FAU - Hoss, Sara AU - Hoss S AD - Linda Joy Pollin Cardiovascular Wellness Center for Women, Hadassah University Medical Center, Jerusalem, Israel. FAU - Sloman, Lori AU - Sloman L AD - Linda Joy Pollin Cardiovascular Wellness Center for Women, Hadassah University Medical Center, Jerusalem, Israel. FAU - Zwas, Donna R AU - Zwas DR AD - Linda Joy Pollin Cardiovascular Wellness Center for Women, Hadassah University Medical Center, Jerusalem, Israel. LA - eng PT - Journal Article DEP - 20220725 PL - New Zealand TA - Patient Prefer Adherence JT - Patient preference and adherence JID - 101475748 PMC - PMC9338434 OTO - NOTNLM OT - cardiovascular disease OT - gender medicine OT - patient experience OT - person-centered care COIS- The authors report no conflicts of interest in this work. EDAT- 2022/08/03 06:00 MHDA- 2022/08/03 06:01 PMCR- 2022/07/25 CRDT- 2022/08/02 01:43 PHST- 2022/02/22 00:00 [received] PHST- 2022/06/24 00:00 [accepted] PHST- 2022/08/02 01:43 [entrez] PHST- 2022/08/03 06:00 [pubmed] PHST- 2022/08/03 06:01 [medline] PHST- 2022/07/25 00:00 [pmc-release] AID - 363325 [pii] AID - 10.2147/PPA.S363325 [doi] PST - epublish SO - Patient Prefer Adherence. 2022 Jul 25;16:1749-1758. doi: 10.2147/PPA.S363325. eCollection 2022. PMID- 35912470 OWN - NLM STAT- MEDLINE DCOM- 20220802 LR - 20250728 IS - 1087-2981 (Electronic) IS - 1087-2981 (Linking) VI - 27 IP - 1 DP - 2022 Dec TI - Pediatic code blue event anaylsis: Performance of non-acute health-care providers. PG - 2106811 LID - 10.1080/10872981.2022.2106811 [doi] LID - 2106811 AB - In-hospital pediatric cardiopulmonary arrest is rare. With more than 50% of patients not surviving to discharge following cardiopulmonary arrest, it is important that health-care providers (HCPs) respond appropriately to deteriorating patients. Our study evaluated the performance of basic life support skills using non-acute HCPs during pediatric inpatient resuscitation events. We conducted a retrospective chart review of all code blue team (CBT) activations in non-acute care areas of a tertiary care children's hospital from 2008 to 2017. The main outcomes were frequency of life support algorithmic assessments and interventions (critical actions) performed by non-acute HCPs prior to the arrival of CBT. CBT activation and outcome data were summarized descriptively. Logistic regression was used to assess for an association of outcomes with the presence of established leadership. A total of 60 CBT activations were retrieved, 48 of which had data available on isolated non-acute HCP performance. Most children (93%) survived to discharge. Critical action performance review revealed that an airway, breathing and pulse assessment was documented to have occurred in 33%, 69% and 29% of cases, respectively. A full primary assessment was documented in 6% of cases. The presence of established leadership was associated with the performance of a partial ABC assessment. Our results suggest that resuscitation performance of pediatric inpatient non-acute HCPs often does not adhere to standard life support guidelines. These results highlight the need to reconsider the current approaches used for non-acute HCP resuscitation training. FAU - Chamberlain, Graham AU - Chamberlain G AD - Department of Pediatrics CHEO, Ottawa, Ontario, Canada. FAU - Gupta, Ronish AU - Gupta R AD - Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada. AD - School of Education, Johns Hopkins University, Baltimore, MD, USA. FAU - Lobos, Anna-Theresa AU - Lobos AT AD - Division of Critical Care, Department of Pediatrics, CHEO, Ottawa, Ontario, Canada. LA - eng PT - Journal Article PL - United States TA - Med Educ Online JT - Medical education online JID - 9806550 SB - IM MH - *Cardiopulmonary Resuscitation/methods MH - Child MH - Health Personnel MH - *Heart Arrest/diagnosis/therapy MH - *Hospital Rapid Response Team MH - Humans MH - Retrospective Studies PMC - PMC9347468 OTO - NOTNLM OT - In-Hospital arrest OT - Medical education OT - basic life support OT - cardiopulmonary arrest OT - critical care OT - hospital medicine OT - pediatrics OT - resuscitation COIS- No potential conflict of interest was reported by the author(s). EDAT- 2022/08/02 06:00 MHDA- 2022/08/03 06:00 PMCR- 2022/08/01 CRDT- 2022/08/01 04:06 PHST- 2022/08/01 04:06 [entrez] PHST- 2022/08/02 06:00 [pubmed] PHST- 2022/08/03 06:00 [medline] PHST- 2022/08/01 00:00 [pmc-release] AID - 2106811 [pii] AID - 10.1080/10872981.2022.2106811 [doi] PST - ppublish SO - Med Educ Online. 2022 Dec;27(1):2106811. doi: 10.1080/10872981.2022.2106811. PMID- 35911539 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240901 IS - 2297-055X (Print) IS - 2297-055X (Electronic) IS - 2297-055X (Linking) VI - 9 DP - 2022 TI - Gender Differences in Cardiogenic Shock Patients: Clinical Features, Risk Prediction, and Outcomes in a Hub Center. PG - 912802 LID - 10.3389/fcvm.2022.912802 [doi] LID - 912802 AB - INTRODUCTION: There is scarce knowledge about gender differences in clinical presentation, management, use of risk stratification tools and prognosis in cardiogenic shock (CS) patients. PURPOSE: The primary endpoint was to investigate the differences in characteristics, management, and in-hospital mortality according to gender in a cohort of CS patients admitted to a tertiary hub center. The secondary endpoint was to evaluate the prognostic performance of the Society of Cardiovascular Angiography and Interventions (SCAI) classification in predicting in-hospital mortality according to sex. METHODS: This is a retrospective single-Center cohort study of CS patients treated by a multidisciplinary shock team between September 2014 and December 2020. Baseline characteristics and clinical outcomes according to gender were registered. Discrimination of SCAI classification was assessed using the area under the receiver operating characteristic curve (AUC). RESULTS: Overall, 163 patients were included, 39 of them female (24%). Mean age of the overall cohort was 55 years (44-62), similar between groups. Compared with men, women were less likely to be smokers and the prevalence of COPD and diabetes mellitus was significantly lower in this group (p < 0.05). Postcardiotomy (44 vs. 31%) and fulminant myocarditis (13 vs. 2%) were more frequent etiologies in females than in males (p = 0.01), whereas acute myocardial infarction was less common among females (13 vs. 33%). Regarding management, the use of temporary mechanical circulatory support, mechanical ventilation, or renal replacement therapy was frequent and no different between the groups (88, 87, and 49%, respectively, in females vs. 42, 91, and 41% in males, p > 0.05). In-hospital survival in the overall cohort was 53%, without differences between groups (52% in females vs. 55% in males, p = 0.76). Most of the patients (60.7%) were in SCAIE at presentation without differences between sexes. The SCAI classification showed a moderate ability for predicting in-hospital mortality (overall, AUC: 0.653, 95% CI 0.582-0.725). The AUC was 0.636 for women (95% CI 0.491-0.780) and 0.658 for men (95% CI 0.575-0.740). CONCLUSIONS: Only one in four of patients treated at a dedicated CS team were female. This may reflect differences in prevalence of severe heart disease at young (<65) ages, although a patient-selection bias cannot be ruled out. In this very high-risk CS population of multiple etiologies, overall, in-hospital survival was slightly above 50% and showed no differences between sexes. Treatment approaches, procedures, and SCAI risk stratification performance did not show gender disparities among treated patients. CI - Copyright (c) 2022 Lozano-Jimenez, Iranzo-Valero, Segovia-Cubero, Gomez-Bueno, Rivas-Lasarte, Mitroi, Escudier-Villa, Oteo-Dominguez, Vieitez-Florez, Villar-Garcia and Hernandez-Perez. FAU - Lozano-Jimenez, Sara AU - Lozano-Jimenez S AD - Department of Cardiology, Hospital Puerta de Hierro, Madrid, Spain. AD - Centre of Biomedical Research in Cardiovascular Diseases (CIBERCV), Carlos III, Madrid, Spain. FAU - Iranzo-Valero, Reyes AU - Iranzo-Valero R AD - Department of Anesthesiology, Hospital Puerta de Hierro, Madrid, Spain. FAU - Segovia-Cubero, Javier AU - Segovia-Cubero J AD - Department of Cardiology, Hospital Puerta de Hierro, Madrid, Spain. FAU - Gomez-Bueno, Manuel AU - Gomez-Bueno M AD - Department of Cardiology, Hospital Puerta de Hierro, Madrid, Spain. FAU - Rivas-Lasarte, Mercedes AU - Rivas-Lasarte M AD - Department of Cardiology, Hospital Puerta de Hierro, Madrid, Spain. FAU - Mitroi, Cristina AU - Mitroi C AD - Department of Cardiology, Hospital Puerta de Hierro, Madrid, Spain. FAU - Escudier-Villa, Juan Manuel AU - Escudier-Villa JM AD - Department of Cardiology, Hospital Puerta de Hierro, Madrid, Spain. FAU - Oteo-Dominguez, Juan Francisco AU - Oteo-Dominguez JF AD - Department of Cardiology, Hospital Puerta de Hierro, Madrid, Spain. FAU - Vieitez-Florez, Jose Maria AU - Vieitez-Florez JM AD - Department of Cardiology, Hospital Puerta de Hierro, Madrid, Spain. FAU - Villar-Garcia, Susana AU - Villar-Garcia S AD - Department of Cardiovascular Surgery, Hospital Puerta de Hierro, Madrid, Spain. FAU - Hernandez-Perez, Francisco Jose AU - Hernandez-Perez FJ AD - Department of Cardiology, Hospital Puerta de Hierro, Madrid, Spain. LA - eng PT - Journal Article DEP - 20220713 PL - Switzerland TA - Front Cardiovasc Med JT - Frontiers in cardiovascular medicine JID - 101653388 PMC - PMC9326060 OTO - NOTNLM OT - SCAI classification OT - cardiogenic shock OT - gender OT - heart failure OT - mortality OT - prognosis COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/08/02 06:00 MHDA- 2022/08/02 06:01 PMCR- 2022/01/01 CRDT- 2022/08/01 03:47 PHST- 2022/04/04 00:00 [received] PHST- 2022/06/22 00:00 [accepted] PHST- 2022/08/01 03:47 [entrez] PHST- 2022/08/02 06:00 [pubmed] PHST- 2022/08/02 06:01 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.3389/fcvm.2022.912802 [doi] PST - epublish SO - Front Cardiovasc Med. 2022 Jul 13;9:912802. doi: 10.3389/fcvm.2022.912802. eCollection 2022. PMID- 37800118 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240330 IS - 2666-6022 (Electronic) IS - 2666-6022 (Linking) VI - 20 DP - 2022 Aug TI - Connected Health Innovation Research Program (C.H.I.R.P.): A bridge for digital health and wellness in cardiology and oncology. LID - 100192 [pii] LID - 10.1016/j.ahjo.2022.100192 [doi] AB - STUDY OBJECTIVE: Cancer and heart disease are leading causes of mortality, and cardio-oncology is emerging as a new field addressing the cardiovascular toxicities related to cancer and cancer therapy. Interdisciplinary research platforms that incorporate digital health to optimize cardiovascular health and wellness in cancer survivors are therefore needed as we advance in the digital era. Our goal was to develop the Connected Health Innovation Research Program (C.H.I.R.P.) to serve as a foundation for future integration and assessments of adoption and clinical efficacy of digital health tools for cardiovascular health and wellness in the general population and in oncology patients. DESIGN/SETTING/PARTICIPANTS: Partner companies were identified through the American Medical Association innovation platform, as well as LinkedIn and direct contact by our team. Company leaders met with our team to discuss features of their technology or software. Non-disclosure agreements were signed and data were discussed and obtained for descriptive or statistical analysis. RESULTS: A suite of companies with technologies focused on wellness, biometrics tracking, audio companions, oxygen saturation, weight trends, sleep patterns, heart rate variability, electrocardiogram patterns, blood pressure patterns, real-time metabolism tracking, instructional video modules, or integration of these technologies into electronic health records was collated. We formed an interdisciplinary research team and established an academia-industry collaborative foundation for connecting patients with wellness digital health technologies. CONCLUSIONS: A suite of software and device technologies accessible to the cardiology and oncology population has been established and will facilitate retrospective, prospective, and case research studies assessing adoption and clinical efficacy of digital health tools in cardiology/oncology. FAU - Maddula, Ragasnehith AU - Maddula R AD - Medical College of Wisconsin, Milwaukee, WI, USA. FAU - MacLeod, James AU - MacLeod J AD - Medical College of Wisconsin, Milwaukee, WI, USA. FAU - Painter, Sabrina AU - Painter S AD - University of Wisconsin-Milwaukee, Milwaukee, WI, USA. FAU - McLeish, Tyson AU - McLeish T AD - Medical College of Wisconsin, Milwaukee, WI, USA. FAU - Steward, Austin AU - Steward A AD - Medical College of Wisconsin, Milwaukee, WI, USA. FAU - Rossman, Andrea AU - Rossman A AD - Medical College of Wisconsin, Milwaukee, WI, USA. FAU - Hamid, Abdulaziz AU - Hamid A AD - Medical College of Wisconsin, Milwaukee, WI, USA. FAU - Ashwath, Mahi AU - Ashwath M AD - University of Iowa, Iowa City, IA, USA. FAU - Martinez, Hugo R AU - Martinez HR AD - The Heart Institute at Le Bonheur Children's Hospital, Memphis, TN, USA. AD - St. Jude Children's Research Hospital, Memphis, TN, USA. FAU - Guha, Avirup AU - Guha A AD - Cardio-Oncology Program, Medical College of Georgia at Augusta University, Augusta, GA, USA. FAU - Patel, Brijesh AU - Patel B AD - West Virginia University, Morgantown, MI, USA. FAU - Addison, Daniel AU - Addison D AD - Cardio-Oncology Program, Ohio State University, Columbus, OH, USA. FAU - Blaes, Anne AU - Blaes A AD - Division of Hematology, Oncology and Transplantation, University of Minnesota Medical School, MN, USA. FAU - Choudhuri, Indrajit AU - Choudhuri I AD - Froedtert South Hospital, Kenosha, WI, USA. FAU - Brown, Sherry-Ann AU - Brown SA AD - Cardio-Oncology Program, Division of Cardiovascular Medicine, Medical College of Wisconsin, Milwaukee, WI, USA. AD - Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA. LA - eng GR - KL2 TR001438/TR/NCATS NIH HHS/United States GR - UL1 TR001436/TR/NCATS NIH HHS/United States PT - Journal Article DEP - 20220809 PL - United States TA - Am Heart J Plus JT - American heart journal plus : cardiology research and practice JID - 101779333 PMC - PMC10552440 MID - NIHMS1907649 OTO - NOTNLM OT - Cardio-oncology OT - Connected health OT - Digital health OT - Digital transformation OT - Innovation OT - Learning Health System COIS- Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: All of our authors work closely with several health technology companies, none of whom inappropriately restrict or limit our analyses or publications. Dr. Brown serves as an advisor for two of the companies and has not been paid for any work related to this manuscript. EDAT- 2022/08/01 00:00 MHDA- 2022/08/01 00:01 PMCR- 2022/08/09 CRDT- 2023/10/06 04:01 PHST- 2022/08/01 00:01 [medline] PHST- 2022/08/01 00:00 [pubmed] PHST- 2023/10/06 04:01 [entrez] PHST- 2022/08/09 00:00 [pmc-release] AID - 100192 [pii] AID - 10.1016/j.ahjo.2022.100192 [doi] PST - ppublish SO - Am Heart J Plus. 2022 Aug;20:100192. doi: 10.1016/j.ahjo.2022.100192. Epub 2022 Aug 9. PMID- 35909151 OWN - NLM STAT- MEDLINE DCOM- 20220802 LR - 20250728 IS - 1098-4275 (Electronic) IS - 0031-4005 (Linking) VI - 150 IP - 2 DP - 2022 Aug 1 TI - Implementation of a Pediatric Emergency Department Cardiopulmonary Resuscitation Quality Bundle. LID - e2021055462 [pii] LID - 10.1542/peds.2021-055462 [doi] AB - BACKGROUND AND OBJECTIVES: We have previously demonstrated that standardized handoff from prehospital to hospital clinicians can improve cardiopulmonary resuscitation performance for out-of-hospital cardiac arrest (OHCA) patients in a pediatric emergency department (ED). We leveraged our previous quality improvement initiative to standardize performance of a bundle of 5 discrete aspects of resuscitation for OHCA patients: intravenous or intraosseous catheter (IV/IO) access, epinephrine administration, advanced airway placement, end-tidal capnography (ETCO2) application, and cardiac rhythm verbalization. We aimed to reduce time to completion of the bundle from 302 seconds at baseline to less than 120 seconds within 1 year. METHODS: A multidisciplinary team performed video-based review of actual OHCA resuscitations in our pediatric ED. We designed interventions aimed at key drivers of bundle performance. Interventions included specific roles and responsibilities and a standardized choreography for each bundle element. To assess the effect of the interventions, time to performance of each bundle element was measured by standardized review of video recordings from our resuscitation bay. Balancing measures were time off the chest and time to defibrillator pad placement. RESULTS: We analyzed 56 cases of OHCA from May 2019 through May 2021. Time to bundle completion improved from a baseline of 302 seconds to 147 seconds. Four of 5 individual bundle elements also demonstrated significant improvement. These improvements were sustained without any negative impact on balancing measures. CONCLUSIONS: Standardized choreography for the initial minutes of ED cardiac arrest resuscitation shows promise to decrease time to crucial interventions in children presenting to the pediatric ED with OHCA. CI - Copyright (c) 2022 by the American Academy of Pediatrics. FAU - Runkle, Anne P AU - Runkle AP AD - Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. FAU - Gray, James AU - Gray J AD - Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. FAU - Cabrera-Thurman, Mary K AU - Cabrera-Thurman MK AD - Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. FAU - Frey, Mary AU - Frey M AD - Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. FAU - Hoehn, Erin F AU - Hoehn EF AD - Rainbow Babies and Children's Hospital, Cleveland, Ohio. FAU - Kerrey, Benjamin T AU - Kerrey BT AD - Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. FAU - Vukovic, Adam A AU - Vukovic AA AD - Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. LA - eng PT - Journal Article PL - United States TA - Pediatrics JT - Pediatrics JID - 0376422 SB - IM MH - *Cardiopulmonary Resuscitation MH - Child MH - *Emergency Medical Services MH - Emergency Service, Hospital MH - Humans MH - *Out-of-Hospital Cardiac Arrest/therapy MH - Quality Improvement EDAT- 2022/08/01 06:00 MHDA- 2022/08/03 06:00 CRDT- 2022/07/31 23:16 PHST- 2022/04/29 00:00 [accepted] PHST- 2022/07/31 23:16 [entrez] PHST- 2022/08/01 06:00 [pubmed] PHST- 2022/08/03 06:00 [medline] AID - 188524 [pii] AID - 10.1542/peds.2021-055462 [doi] PST - ppublish SO - Pediatrics. 2022 Aug 1;150(2):e2021055462. doi: 10.1542/peds.2021-055462. PMID- 35908767 OWN - NLM STAT- MEDLINE DCOM- 20220802 LR - 20250728 IS - 1940-8250 (Electronic) IS - 0279-5442 (Linking) VI - 42 IP - 4 DP - 2022 Aug 1 TI - Decreasing 30-Day Readmission Rates in Patients With Heart Failure. PG - 13-19 LID - 10.4037/ccn2022417 [doi] AB - BACKGROUND: Heart failure affects approximately 6.2 million adults in the United States and has an estimated national cost of $30.7 billion annually. Despite advances in treatment, heart failure is a leading cause of hospital readmissions. Nonadherence to treatment plans, lack of education, and lack of access to care contribute to poorer outcomes. LOCAL PROBLEM: For patients with heart failure, the mean readmission rate is 21% nationally and 23% in New York State. Before the pilot heart failure program began, the 30-day readmission rate in the study institution was 28.6%. METHODS: A multidisciplinary team created a heart failure self-care pilot program that was implemented on a hospital telemetry unit with 47 patients. Patients received education on their disease process, medications, diet, exercise, and early symptom recognition. Patients received a follow-up telephone call 48 to 72 hours after discharge and were seen by a cardiologist within a week of discharge. RESULTS: The 30-day readmission rate for heart failure decreased by 16.6% after implementation of the pilot program, which improved patient adherence to their medication and treatment plan and resulted in a reduction of readmissions. DISCUSSION: Patients in the pilot program represented diverse backgrounds. Socioeconomic factors such as the lack of affordable, healthy food choices and easy access to resources were associated with worse outcomes. CONCLUSIONS: The evidence-based heart failure program improved knowledge, early symptom recognition, lifestyle modification, and adherence to medication, treatment plan, and follow-up appointments. The multidisciplinary team approach to the heart failure program reduced gaps in care and improved coordination and transition of care. CI - (c)2022 American Association of Critical-Care Nurses. FAU - Rizzuto, Nancy AU - Rizzuto N AD - Nancy Rizzuto is an adult nurse practitioner and the Director of Nursing, Critical Care, and Cardiology Services, Brookdale University Hospital, Brooklyn, New York. FAU - Charles, Greg AU - Charles G AD - Greg Charles is a program director for Cardiology Services and an angioplasty specialist, Brookdale University Hospital. FAU - Knobf, M Tish AU - Knobf MT AD - M. Tish Knobf is a professor of nursing, Yale University School of Nursing, Orange, Connecticut. LA - eng PT - Journal Article PL - United States TA - Crit Care Nurse JT - Critical care nurse JID - 8207799 EIN - Crit Care Nurse. 2022 Oct 1;42(5):7. doi: 10.4037/ccn2022699. PMID: 36180053 MH - Adult MH - *Heart Failure/diagnosis MH - Humans MH - Patient Discharge MH - *Patient Readmission MH - Self Care MH - Telemetry MH - United States EDAT- 2022/08/01 06:00 MHDA- 2022/08/03 06:00 CRDT- 2022/07/31 20:12 PHST- 2022/07/31 20:12 [entrez] PHST- 2022/08/01 06:00 [pubmed] PHST- 2022/08/03 06:00 [medline] AID - 31804 [pii] AID - 10.4037/ccn2022417 [doi] PST - ppublish SO - Crit Care Nurse. 2022 Aug 1;42(4):13-19. doi: 10.4037/ccn2022417. PMID- 35904213 OWN - NLM STAT- MEDLINE DCOM- 20220803 LR - 20250728 IS - 2047-9980 (Electronic) IS - 2047-9980 (Linking) VI - 11 IP - 15 DP - 2022 Aug 2 TI - Patient-Reported Outcomes in a Multidisciplinary Electrophysiology-Psychology Ventricular Arrhythmia Clinic. PG - e025301 LID - 10.1161/JAHA.122.025301 [doi] LID - e025301 AB - Background Ventricular arrhythmias (VAs) and their treatment have been associated with psychological distress and diminished quality of life (QOL). We administered a battery of patient-reported outcome measures (PROMs) to patients seeing an electrophysiologist and psychologist in a multidisciplinary VA clinic for patients referred for consideration of catheter ablation for sustained VAs or implantable cardioverter-defibrillator therapies. Methods and Results In this retrospective study of the initial VA clinic visit, we analyzed PROMs of: anxiety and depression symptoms, visual analog scales for physical health status and quality of life, cardiac anxiety, implantable cardioverter-defibrillator acceptance, and implantable cardioverter-defibrillator shock anxiety. We quantitated baseline PROM score means and performed correlation analysis with clinical makers of cardiac and VA disease severity. We also performed an item-level analysis of each PROM question to quantify most frequent patient concerns. A total of 66 patients (56+/-15 years; 77% men) were included; 70% had prior implantable cardioverter-defibrillator shock, and 44% with prior VA ablation. Elevated symptoms of anxiety (53%) and depression (20%) were common. Younger patients had greater symptom burden of general health anxiety, cardiac anxiety, and shock anxiety, and lower device acceptance, but indices of VA burden such as number of ICD shocks and time since last ICD shock did not predict anxiety or depression. Item-level review of cardiac-specific PROMs revealed that >40% of patients expressed concern regarding resumption of physical activity, sex and employment. Conclusions Clinicians can expect elevated symptoms of depression, and cardiac and device-related anxiety among patients with VAs. Routine use of PROMs may elicit these symptoms, which were otherwise not predicted by arrhythmia burden. Review of individual PROM items can facilitate targeting specific patient concerns, which commonly involved physical activity. FAU - Sandhu, Uday AU - Sandhu U AD - Knight Cardiovascular Institute Oregon Health & Science University Portland OR. FAU - Nguyen, Andrew T AU - Nguyen AT AD - Knight Cardiovascular Institute Oregon Health & Science University Portland OR. FAU - Dornblaser, John AU - Dornblaser J AD - Knight Cardiovascular Institute Oregon Health & Science University Portland OR. FAU - Gray, Andrew AU - Gray A AD - Knight Cardiovascular Institute Oregon Health & Science University Portland OR. FAU - Paladino, Karen AU - Paladino K AD - Knight Cardiovascular Institute Oregon Health & Science University Portland OR. FAU - Henrikson, Charles A AU - Henrikson CA AUID- ORCID: 0000-0002-3381-8437 AD - Knight Cardiovascular Institute Oregon Health & Science University Portland OR. FAU - Kovacs, Adrienne H AU - Kovacs AH AD - Knight Cardiovascular Institute Oregon Health & Science University Portland OR. FAU - Nazer, Babak AU - Nazer B AUID- ORCID: 0000-0002-4078-9064 AD - Knight Cardiovascular Institute Oregon Health & Science University Portland OR. LA - eng GR - K08 HL138156/HL/NHLBI NIH HHS/United States GR - R01 HL160712/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20220729 PL - England TA - J Am Heart Assoc JT - Journal of the American Heart Association JID - 101580524 SB - IM MH - Arrhythmias, Cardiac/diagnosis/etiology/therapy MH - Cardiac Electrophysiology MH - *Defibrillators, Implantable/adverse effects MH - Female MH - Humans MH - Male MH - Patient Reported Outcome Measures MH - *Quality of Life MH - Retrospective Studies PMC - PMC9375498 OTO - NOTNLM OT - implantable cardioverter-defibrillator OT - patient-reported outcomes OT - quality of life OT - ventricular arrythmia OT - ventricular tachycardia EDAT- 2022/07/30 06:00 MHDA- 2022/08/04 06:00 PMCR- 2022/08/02 CRDT- 2022/07/29 07:33 PHST- 2022/07/30 06:00 [pubmed] PHST- 2022/08/04 06:00 [medline] PHST- 2022/07/29 07:33 [entrez] PHST- 2022/08/02 00:00 [pmc-release] AID - JAH37712 [pii] AID - 10.1161/JAHA.122.025301 [doi] PST - ppublish SO - J Am Heart Assoc. 2022 Aug 2;11(15):e025301. doi: 10.1161/JAHA.122.025301. Epub 2022 Jul 29. PMID- 35904203 OWN - NLM STAT- MEDLINE DCOM- 20220803 LR - 20250103 IS - 2047-9980 (Electronic) IS - 2047-9980 (Linking) VI - 11 IP - 15 DP - 2022 Aug 2 TI - Lessons Learned From a Patient-Centered, Team-Based Intervention for Patients With Type 2 Diabetes at High Cardiovascular Risk: Year 1 Results From the CINEMA Program. PG - e024482 LID - 10.1161/JAHA.120.024482 [doi] LID - e024482 AB - Background The care for patients with type 2 diabetes necessitates a multidisciplinary team approach to reduce cardiovascular risk, but implementation of effective integrated strategies has been limited. Methods and Results We conceptualized and initiated a patient-centered, team-based intervention called Center for Integrated and Novel Approaches in Vascular-Metabolic Disease (CINEMA) at University Hospitals Cleveland Medical Center. Patients with type 2 diabetes at high risk for cardiovascular events, including those with established atherosclerotic cardiovascular disease, elevated coronary artery calcium score >100, chronic heart failure with reduced ejection fraction, and/or chronic kidney disease stages 2 to 4 were included. Herein, we present the year 1 results for the program. From May 2020 through August 2021, there were 417 referrals. Among 206 eligible patients, 113 (55%) completed a baseline and >/=1 follow-up visit through December 2021, with mean (SD) time of 105 (34) days between baseline and first follow-up visits. Mean age was 59 years, with 49% women and 37% Black patients. Patients had significant reductions from baseline in glycosylated hemoglobin (-10.8%), total cholesterol (-7.9%), low-density lipoprotein cholesterol (-13.5%), systolic blood pressure (-4.0%), and body mass index (-2.7%) (P/=3 months, 27% 4 to 12 weeks, and 30% <4 weeks. Two reported no duration requirement, 6 stated an indefinite 24/7 commitment was necessary. Across 22 interviews, SWs mirrored that caregiving plans were the most common psychosocial contraindication. How caregiving is operationalized varied. Participants voiced a tension between extended caregiving improving outcomes and the sense that some people of color, women, or low socioeconomic status patients struggle to meet stringent requirements. CONCLUSIONS: Policies regarding adequate duration of 24/7 caregiving vary, but inadequate caregiving plans are the most common psychosocial contraindication. Participants worry about patients' ability to meet restrictive requirements, particularly from historically undertreated groups. This highlights a need to operationalize quality caregiving, standardize assessment, and support medically appropriate patients with strained social resources. FAU - Knoepke, Christopher E AU - Knoepke CE AUID- ORCID: 0000-0003-3521-7157 AD - Division of Cardiology (C.E.K., L.A.A., S.L.D., C.K.M., P.K.), University of Colorado Anschutz Medical Campus, Aurora. AD - Adult and Child Center for Outcomes Research and Delivery Science (C.E.K., L.A.A., S.L.D.), University of Colorado Anschutz Medical Campus, Aurora. FAU - Siry-Bove, Bonnie AU - Siry-Bove B AUID- ORCID: 0000-0001-9665-0611 AD - Department of Emergency Medicine (B.S.-B.), University of Colorado Anschutz Medical Campus, Aurora. FAU - Mayton, Caitlin AU - Mayton C AUID- ORCID: 0000-0002-2854-7353 AD - School of Social Work, Virginia Commonwealth University, Richmond (C.M.). FAU - Latimer, Abigail AU - Latimer A AUID- ORCID: 0000-0002-5252-2199 AD - College of Nursing, University of Kentucky, Lexington (A.L.). FAU - Hart, Jan AU - Hart J AD - Ascension St. Vincent Medical Center, Indianapolis, IN (J.H.). FAU - Allen, Larry A AU - Allen LA AUID- ORCID: 0000-0003-2540-3095 AD - Division of Cardiology (C.E.K., L.A.A., S.L.D., C.K.M., P.K.), University of Colorado Anschutz Medical Campus, Aurora. AD - Adult and Child Center for Outcomes Research and Delivery Science (C.E.K., L.A.A., S.L.D.), University of Colorado Anschutz Medical Campus, Aurora. FAU - Daugherty, Stacie L AU - Daugherty SL AUID- ORCID: 0000-0001-8969-566X AD - Division of Cardiology (C.E.K., L.A.A., S.L.D., C.K.M., P.K.), University of Colorado Anschutz Medical Campus, Aurora. AD - Adult and Child Center for Outcomes Research and Delivery Science (C.E.K., L.A.A., S.L.D.), University of Colorado Anschutz Medical Campus, Aurora. AD - Institute for Health Research, Kaiser Permanente Colorado, Aurora (S.L.D.). FAU - McIlvennan, Colleen K AU - McIlvennan CK AUID- ORCID: 0000-0003-2131-9910 AD - Division of Cardiology (C.E.K., L.A.A., S.L.D., C.K.M., P.K.), University of Colorado Anschutz Medical Campus, Aurora. FAU - Matlock, Daniel D AU - Matlock DD AUID- ORCID: 0000-0001-9597-9642 AD - Division of Geriatric Medicine (D.D.M.), University of Colorado Anschutz Medical Campus, Aurora. FAU - Khazanie, Prateeti AU - Khazanie P AUID- ORCID: 0000-0001-8959-1609 AD - Division of Cardiology (C.E.K., L.A.A., S.L.D., C.K.M., P.K.), University of Colorado Anschutz Medical Campus, Aurora. LA - eng GR - K23 HL145122/HL/NHLBI NIH HHS/United States GR - K23 HL153892/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20220707 PL - United States TA - Circ Heart Fail JT - Circulation. Heart failure JID - 101479941 SB - IM MH - Aftercare MH - Caregivers/psychology MH - Female MH - *Heart Failure/diagnosis/therapy MH - *Heart-Assist Devices/psychology MH - Humans MH - Patient Discharge PMC - PMC9388601 MID - NIHMS1815123 OTO - NOTNLM OT - caregivers OT - contraindications OT - health equity OT - heart failure OT - social workers EDAT- 2022/07/22 06:00 MHDA- 2022/08/19 06:00 PMCR- 2023/08/01 CRDT- 2022/07/21 11:33 PHST- 2022/07/22 06:00 [pubmed] PHST- 2022/08/19 06:00 [medline] PHST- 2022/07/21 11:33 [entrez] PHST- 2023/08/01 00:00 [pmc-release] AID - 10.1161/CIRCHEARTFAILURE.122.009583 [doi] PST - ppublish SO - Circ Heart Fail. 2022 Aug;15(8):e009583. doi: 10.1161/CIRCHEARTFAILURE.122.009583. Epub 2022 Jul 7. PMID- 35860884 OWN - NLM STAT- MEDLINE DCOM- 20220722 LR - 20250728 IS - 1308-4488 (Electronic) IS - 1016-5169 (Linking) VI - 50 IP - 5 DP - 2022 Jul TI - The Role of Prophylactic Ipsilateral Distal Femoral Artery Cannulation in Preventing Periprocedural Peripheral Complications During Transcatheter Aortic Valve Implantation. PG - 327-333 LID - 10.5543/tkda.2022.21276 [doi] AB - OBJECTIVE: Access site-related vascular complications are common complications of trans- catheter aortic valve replacement. In this study, we aimed to investigate the efficacy and safety of prophylactic cannulation of the ipsilateral distal femoral artery in the management of access site-related vascular complications. METHODS: One hundred sixty-four patients, who were evaluated by the Heart Team of our institution and found eligible for transcatheter aortic valve replacement procedure between January 2016 and August 2019, were included in this retrospective study. Patients were divided into two groups according to the management of peripheral complications. The antegrade crossover was used as bailout treatment in the first 70 patients. Prophylactic cannulation of the ipsilateral distal femoral artery was performed in the last 94 patients. These 2 groups were compared. RESULTS: Peripheral complications developed in 15 of the first 70 patients included in the study. The percutaneous intervention was unsuccessful in 4 of the patients who underwent bailout antegrade crossover. Peripheral complications developed in 14 of the last 94 patients in whom prophylactic cannulation of the ipsilateral distal femoral artery was performed, and all these patients were managed successfully with percutaneous intervention. CONCLUSION: Prophylactic cannulation of the ipsilateral distal femoral artery is a simple, effec- tive, and safe method in the management of access site-related vascular complications. FAU - Avci, Ilhan Ilker AU - Avci II AD - Dr. Siyami Ersek Egitim ve Arastirma Hastanesi, Kardiyoloji Bolumu, Istanbul, Turkiye. FAU - Zeren, Gonul AU - Zeren G AD - Dr. Siyami Ersek Egitim ve Arastirma Hastanesi, Kardiyoloji Bolumu, Istanbul, Turkiye. FAU - Sungur, Mustafa Azmi AU - Sungur MA AD - Dr. Siyami Ersek Egitim ve Arastirma Hastanesi, Kardiyoloji Bolumu, Istanbul, Turkiye. FAU - Simsek, Baris AU - Simsek B AD - Dr. Siyami Ersek Egitim ve Arastirma Hastanesi, Kardiyoloji Bolumu, Istanbul, Turkiye. FAU - Can, Fatma AU - Can F AD - Dr. Siyami Ersek Egitim ve Arastirma Hastanesi, Kardiyoloji Bolumu, Istanbul, Turkiye. FAU - Yilmaz, Mehmet Fatih AU - Yilmaz MF AD - Dr. Siyami Ersek Egitim ve Arastirma Hastanesi, Kardiyoloji Bolumu, Istanbul, Turkiye. FAU - Yilmaz, Sahin AU - Yilmaz S AD - Dr. Siyami Ersek Egitim ve Arastirma Hastanesi, Anestezi ve Reanimasyon Bolumu, Istanbul, Turkiye. FAU - Gurkan, Ufuk AU - Gurkan U AD - Dr. Siyami Ersek Egitim ve Arastirma Hastanesi, Kardiyoloji Bolumu, Istanbul, Turkiye. FAU - Karabay, Can Yucel AU - Karabay CY AD - Dr. Siyami Ersek Egitim ve Arastirma Hastanesi, Kardiyoloji Bolumu, Istanbul, Turkiye. LA - eng PT - Journal Article PL - Turkey TA - Turk Kardiyol Dern Ars JT - Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir JID - 9426239 SB - IM MH - *Catheterization, Peripheral/adverse effects/methods MH - Femoral Artery/surgery MH - Humans MH - Retrospective Studies MH - *Transcatheter Aortic Valve Replacement/adverse effects/methods EDAT- 2022/07/22 06:00 MHDA- 2022/07/23 06:00 CRDT- 2022/07/21 03:02 PHST- 2022/07/21 03:02 [entrez] PHST- 2022/07/22 06:00 [pubmed] PHST- 2022/07/23 06:00 [medline] AID - 10.5543/tkda.2022.21276 [doi] PST - ppublish SO - Turk Kardiyol Dern Ars. 2022 Jul;50(5):327-333. doi: 10.5543/tkda.2022.21276. PMID- 39600837 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241128 IS - 1758-3896 (Electronic) IS - 1758-3896 (Print) IS - 1758-3896 (Linking) VI - 16 DP - 2022 TI - Transcatheter Versus Surgical Aortic Valve Replacement in Young, Low-risk Patients with Severe Aortic Stenosis. PG - e18 LID - 10.15420/usc.2022.08 [doi] LID - e18 AB - Aortic stenosis is a common form of acquired degenerative valvular disease associated with poor survival after the onset of symptoms. Treatment options for patients with aortic stenosis in addition to medical therapy include surgical aortic valve replacement (SAVR) with either tissue or mechanical valves, or transcatheter aortic valve replacement (TAVR) with either balloon-expandable or self-expanding valves via either transfemoral or alternative access routes. In this review, the authors discuss the current evidence and special considerations regarding the use of TAVR versus SAVR in the management of severe aortic stenosis in young (<65 years of age), low-risk patients, highlighting the history of aortic stenosis treatment, the current guidelines and recommendations, and important issues that remain to be addressed. Ultimately, until ongoing clinical trials with long-term follow-up data shed light on whether interventions for aortic stenosis can be broadened to a low-risk population, TAVR in young, low-risk patients should be undertaken with caution and with guidance from a multidisciplinary heart team. CI - Copyright (c) The Author(s), 2022. Published by Radcliffe Group Ltd. FAU - Nguyen, Quynh AU - Nguyen Q AD - Faculty of Medicine and Dentistry, University of Alberta Edmonton, Canada. FAU - Luc, Jessica Gy AU - Luc JG AD - Division of Cardiovascular Surgery, Department of Surgery, University of British Columbia Vancouver, Canada. FAU - MacGillivray, Thomas E AU - MacGillivray TE AD - Division of Cardiac Surgery and Thoracic Transplantation Surgery, Houston Methodist DeBakey Heart and Vascular Center Houston, TX. FAU - Preventza, Ourania A AU - Preventza OA AD - Division of Cardiothoracic Surgery, Michael E DeBakey Department of Surgery, Baylor College of Medicine Houston, TX. AD - Department of Cardiovascular Surgery, Texas Heart Institute Houston, TX. LA - eng PT - Journal Article PT - Review DEP - 20220721 PL - England TA - US Cardiol JT - US cardiology JID - 101574791 PMC - PMC11588169 OTO - NOTNLM OT - Aortic stenosis OT - surgical aortic valve replacement OT - transcatheter aortic valve replacement COIS- Disclosure: OAP is a consultant for Terumo Aortic and WL Gore and Associates. All other authors have no conflicts of interest to declare. EDAT- 2022/07/21 00:00 MHDA- 2022/07/21 00:01 PMCR- 2022/07/21 CRDT- 2024/11/27 04:13 PHST- 2022/02/18 00:00 [received] PHST- 2022/04/13 00:00 [accepted] PHST- 2022/07/21 00:01 [medline] PHST- 2022/07/21 00:00 [pubmed] PHST- 2024/11/27 04:13 [entrez] PHST- 2022/07/21 00:00 [pmc-release] AID - 10.15420/usc.2022.08 [doi] PST - epublish SO - US Cardiol. 2022 Jul 21;16:e18. doi: 10.15420/usc.2022.08. eCollection 2022. PMID- 35858706 OWN - NLM STAT- MEDLINE DCOM- 20220722 LR - 20250728 IS - 2053-3624 (Print) IS - 2053-3624 (Electronic) IS - 2053-3624 (Linking) VI - 9 IP - 2 DP - 2022 Jul TI - Multispecialty multidisciplinary input into comorbidities along with treatment optimisation in heart failure reduces hospitalisation and clinic attendance. LID - 10.1136/openhrt-2022-001979 [doi] LID - e001979 AB - AIMS: Heart failure (HF) is associated with comorbidities which independently influence treatment response and outcomes. This retrospective observational study (January 2020-June 2021) analysed the impact of monthly HF multispecialty multidisciplinary team (MDT) meetings to address management of HF comorbidities and thereby on provision, cost of care and HF outcomes. METHODS: Patients acted as their own controls, with outcomes compared for equal periods (for each patient) pre (HF MDT) versus post-MDT (multispecialty) meeting. The multispecialty MDT comprised HF cardiologists (primary, secondary, tertiary care), HF nurses, nephrologist, endocrinologist, palliative care, chest physician, pharmacist, clinical pharmacologist and geriatrician. Outcome measures were (1) all-cause hospitalisations, (2) outpatient clinic attendances and (3) cost. RESULTS: 334 patients (mean age 72.5+/-11 years) were discussed virtually through MDT meetings and follow-up duration was 13.9+/-4 months. Mean age-adjusted Charlson Comorbidity Index was 7.6+/-2.1 and Rockwood Frailty Score 5.5+/-1.6. Multispecialty interventions included optimising diabetes therapy (haemoglobin A1c-HbA1c pre-MDT 68+/-11 mmol/mol vs post-MDT 61+/-9 mmol/mol; p<0.001), deprescribing to reduce anticholinergic burden (pre-MDT 1.85+/-0.4 vs 1.5+/-0.3 post-MDT; p<0.001), initiation of renin-angiotensin aldosterone system inhibitors in HF with reduced ejection fraction (HFrEF) with advanced chronic kidney disease (9% pre vs 71% post-MDT; p<0.001). Other interventions included potassium binders, treatment of anaemia, falls assessment, management of chest conditions, day-case ascitic, pleural drains and palliative support. Total cost of funding monthly multispecialty meetings was pound32 400 and resultant 64 clinic appointments cost pound9600. The post-MDT study period was associated with reduction in 481 clinic appointments (cost saving pound72150) and reduced all-cause hospitalisations (pre-MDT 1.1+/-0.4 vs 0.6+/-0.1 post-MDT; p<0.001), reduction of 1586 hospital bed-days and cost savings of pound634 400. Total cost saving to the healthcare system was pound664 550. CONCLUSION: HF multispecialty virtual MDT model provides integrated, holistic care across all healthcare tiers for management of HF and associated comorbidities. This approach is associated with reduced clinic attendances and all-cause hospitalisations, leading to significant cost savings. CI - (c) Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Essa, Hani AU - Essa H AUID- ORCID: 0000-0001-9445-2582 AD - Cardiology, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK. AD - Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool, UK. FAU - Walker, Lauren AU - Walker L AD - Pharmacology, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK. AD - Clinical Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK. FAU - Mohee, Kevin AU - Mohee K AUID- ORCID: 0000-0002-7409-7197 AD - Cardiology, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK. FAU - Oguguo, Chukwuemeka AU - Oguguo C AD - Cardiology, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK. FAU - Douglas, Homeyra AU - Douglas H AD - Cardiology, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK. FAU - Kahn, Matthew AU - Kahn M AD - Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool, UK. AD - Cardiology, Liverpool Heart and Chest Hospital, Liverpool, UK. FAU - Rao, Archana AU - Rao A AD - Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool, UK. AD - Cardiology, Liverpool Heart and Chest Hospital, Liverpool, UK. FAU - Bellieu, Julie AU - Bellieu J AD - Palliative Medicine, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK. FAU - Hadcroft, Justine AU - Hadcroft J AD - Respiratory Medicine, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK. FAU - Hartshorne-Evans, Nick AU - Hartshorne-Evans N AD - CEO and Founder, The Pumping Marvellous Foundation (Patient-Led Heart Failure Charity), Preston, UK. FAU - Bliss, Janet AU - Bliss J AD - Chair, NHS Liverpool Clinical Commissioning Group, Liverpool, UK. AD - GP Senior Partner, Grey Road Surgery, Liverpool, UK. FAU - Akpan, Asangaedem AU - Akpan A AD - Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool, UK. AD - Institute of Health, University of Cumbria, Cumbria, UK. AD - Geriatrics, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK. AD - Faculty of Health and Life Science, University of Liverpool, Liverpool, UK. FAU - Wong, Christopher AU - Wong C AD - Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool, UK. AD - Nephrology, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK. AD - School of Health and Sport Sciences, Liverpool Hope University, Liverpool, UK. FAU - Cuthbertson, Daniel J AU - Cuthbertson DJ AUID- ORCID: 0000-0002-6128-0822 AD - Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool, UK. AD - Faculty of Health and Life Science, University of Liverpool, Liverpool, UK. AD - Diabetes and Endocrinology, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK. FAU - Sankaranarayanan, Rajiv AU - Sankaranarayanan R AUID- ORCID: 0000-0003-2355-2011 AD - Cardiology, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK Rajiv.Sankaranarayanan@liverpoolft.nhs.uk. AD - Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool, UK. AD - NIHR Research Scholar, NIHR CRN North West Coast, National Institute for Health and Care Research (NIHR), Liverpool, UK. LA - eng PT - Journal Article PT - Observational Study PT - Research Support, Non-U.S. Gov't PL - England TA - Open Heart JT - Open heart JID - 101631219 SB - IM MH - Aged MH - Aged, 80 and over MH - Ambulatory Care Facilities MH - Comorbidity MH - *Heart Failure/diagnosis/epidemiology/therapy MH - Hospitalization MH - Humans MH - Middle Aged MH - Stroke Volume PMC - PMC9305818 OTO - NOTNLM OT - Health Care Economics and Organizations OT - Heart Failure OT - Outcome Assessment, Health Care OT - Pharmacology OT - Quality of Health Care COIS- Competing interests: None declared. EDAT- 2022/07/21 06:00 MHDA- 2022/07/23 06:00 PMCR- 2022/07/20 CRDT- 2022/07/20 20:42 PHST- 2022/02/01 00:00 [received] PHST- 2022/06/20 00:00 [accepted] PHST- 2022/07/20 20:42 [entrez] PHST- 2022/07/21 06:00 [pubmed] PHST- 2022/07/23 06:00 [medline] PHST- 2022/07/20 00:00 [pmc-release] AID - openhrt-2022-001979 [pii] AID - 10.1136/openhrt-2022-001979 [doi] PST - ppublish SO - Open Heart. 2022 Jul;9(2):e001979. doi: 10.1136/openhrt-2022-001979. PMID- 35857271 OWN - NLM STAT- MEDLINE DCOM- 20221024 LR - 20260524 IS - 1559-0100 (Electronic) IS - 1355-008X (Print) IS - 1355-008X (Linking) VI - 78 IP - 2 DP - 2022 Nov TI - The osteo-metabolic phenotype of COVID-19: an update. PG - 247-254 LID - 10.1007/s12020-022-03135-3 [doi] AB - CONTEXT: In the multifaceted COVID-19 clinical scenario characterized by a multi-system disorder with negative implications not only on respiratory function but also on cardiac, hematological, neurological and endocrine-metabolic systems, a distinctive osteo-metabolic phenotype with an independent influence on disease severity and recovery of patients affected was early reported. AIM: To summarize and update the main evidences regarding the distinct components of this phenotype in acute and Long COVID-19, reinforcing its clinical relevance and discussing the main pathophysiological and clinical-therapeutic implications of the most recent reported findings. RESULTS: This emerging phenotype is characterized by a widespread acute hypocalcemia and hypovitaminosis D with an impaired compensatory parathyroid hormone response, and a high prevalence of skeletal complications such as vertebral fractures. The clinical relevance of this osteo-metabolic phenotype on acute COVID-19 is well characterized, and novel seminal evidences are progressively highlighting its importance also in predicting patient's long-term outcomes and Long COVID-19 occurrence. CONCLUSIONS: These findings reinforced the central role of a multidisciplinary team, including endocrinologists, in evaluating these patients for a proactive search of each aspect of the osteo-metabolic phenotype components since they may represent suitable therapeutic targets to prevent SARS-CoV-2 infection, poor COVID-19 outcomes, Long COVID-19 occurrence and even possibly better responses to COVID-19 vaccination. CI - (c) 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - di Filippo, Luigi AU - di Filippo L AD - Institute of Endocrine and Metabolic Sciences, Universita Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy. FAU - Frara, Stefano AU - Frara S AD - Institute of Endocrine and Metabolic Sciences, Universita Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy. FAU - Doga, Mauro AU - Doga M AD - Institute of Endocrine and Metabolic Sciences, Universita Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy. FAU - Giustina, Andrea AU - Giustina A AUID- ORCID: 0000-0001-6783-3398 AD - Institute of Endocrine and Metabolic Sciences, Universita Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy. giustina.andrea@hsr.it. LA - eng PT - Journal Article PT - Review DEP - 20220720 PL - United States TA - Endocrine JT - Endocrine JID - 9434444 RN - 0 (COVID-19 Vaccines) RN - 0 (Parathyroid Hormone) SB - IM MH - Humans MH - *COVID-19 MH - SARS-CoV-2 MH - COVID-19 Vaccines MH - Parathyroid Hormone MH - Phenotype MH - Post-Acute COVID-19 Syndrome PMC - PMC9297261 OTO - NOTNLM OT - COVID-19 OT - Hypocalcemia OT - Long-COVID OT - Osteo-metabolic phenotype OT - Vertebral fractures OT - Vitamin D COIS- The authors declare no competing interests. EDAT- 2022/07/21 06:00 MHDA- 2022/10/25 06:00 PMCR- 2022/07/20 CRDT- 2022/07/20 11:25 PHST- 2022/05/30 00:00 [received] PHST- 2022/07/03 00:00 [accepted] PHST- 2022/07/21 06:00 [pubmed] PHST- 2022/10/25 06:00 [medline] PHST- 2022/07/20 11:25 [entrez] PHST- 2022/07/20 00:00 [pmc-release] AID - 10.1007/s12020-022-03135-3 [pii] AID - 3135 [pii] AID - 10.1007/s12020-022-03135-3 [doi] PST - ppublish SO - Endocrine. 2022 Nov;78(2):247-254. doi: 10.1007/s12020-022-03135-3. Epub 2022 Jul 20. PMID- 39076626 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240731 IS - 2153-8174 (Electronic) IS - 2153-8174 (Print) IS - 1530-6550 (Linking) VI - 23 IP - 8 DP - 2022 Aug TI - Dental Management Considerations for Patients with Cardiovascular Disease-A Narrative Review. PG - 261 LID - 10.31083/j.rcm2308261 [doi] LID - 261 AB - Dental therapists encounter patients with various systemic diseases of which cardiovascular disease (CVD) patients form a significant segment. Relation between oral health and cardiac diseases has been well established. Common cardiac disorders encountered in a dental practice include arterial hypertension, heart failure, ischemic heart disease, cardiac arrhythmias, infective endocarditis, stroke, and cardiac pacemaker. Patients with CVDs pose a significant challenge to dental therapy. These patients need special considerations and an adequate understanding of the underlying cardiovascular condition to provide safe and effective dental treatment. Based on the cardiac condition, an appropriate modification in dental care is crucial. A multidisciplinary approach including the patient's cardiologist can potentially reduce complications and improve dental treatment results. This review aims at unfolding the risks associated with the dental management of a cardiac patient and outlines the measures to be undertaken for optimum dental treatment. CI - Copyright: (c) 2022 The Author(s). Published by IMR Press. FAU - Gupta, Kanishk AU - Gupta K AD - Department of Periodontology, Dentistry Program, Batterjee Medical College, 21442 Jeddah, Saudi Arabia. FAU - Kumar, Santhosh AU - Kumar S AD - Department of Periodontology, Manipal College of Dental Sciences, Manipal, Manipal Academy of Higher Education, 576104 Manipal, Karnataka, India. FAU - Anand Kukkamalla, Meena AU - Anand Kukkamalla M AD - Department of Periodontology, Faculty of Dentistry, Manipal University College Malaysia (MUCM), 75150 Melaka, Malaysia. FAU - Taneja, Vani AU - Taneja V AD - Department of Pediatric Dentistry, Dentistry Program, Batterjee Medical College, 21442 Jeddah, Saudi Arabia. FAU - Syed, Gufaran Ali AU - Syed GA AD - Department of Endodontics, Dentistry Program, Batterjee Medical College, 21442 Jeddah, Saudi Arabia. FAU - Pullishery, Fawaz AU - Pullishery F AD - Division of Dental Public Health, Dentistry Program, Batterjee Medical College, 21442 Jeddah, Saudi Arabia. FAU - Zarbah, Mohammad A AU - Zarbah MA AD - Department of Prosthetic Dental Science, College of Dentistry, King Khalid University, 62529 Abha, Saudi Arabia. FAU - Alqahtani, Saeed M AU - Alqahtani SM AD - Department of Prosthetic Dentistry, College of Dentistry, King Khalid University, 62529 Abha, Saudi Arabia. FAU - Alobaoid, Mohammed A AU - Alobaoid MA AD - Department of Restorative Dental Sciences and Department of Dental Education, King Khalid University College of Dentistry, 61471 Abha, Saudi Arabia. FAU - Chaturvedi, Saurabh AU - Chaturvedi S AD - Department of Prosthetic Dental Science, College of Dentistry, King Khalid University, 62529 Abha, Saudi Arabia. LA - eng PT - Journal Article PT - Review DEP - 20220720 PL - Singapore TA - Rev Cardiovasc Med JT - Reviews in cardiovascular medicine JID - 100960007 PMC - PMC11266964 OTO - NOTNLM OT - anticoagulants OT - cardiac arrhythmias OT - dental care OT - hypertension OT - myocardial ischemia OT - vasoconstrictor COIS- The authors declare no conflict of interest. EDAT- 2022/07/20 00:00 MHDA- 2022/07/20 00:01 PMCR- 2022/07/20 CRDT- 2024/07/30 04:58 PHST- 2022/02/18 00:00 [received] PHST- 2022/06/08 00:00 [revised] PHST- 2022/06/13 00:00 [accepted] PHST- 2022/07/20 00:01 [medline] PHST- 2022/07/20 00:00 [pubmed] PHST- 2024/07/30 04:58 [entrez] PHST- 2022/07/20 00:00 [pmc-release] AID - S1530-6550(22)00637-8 [pii] AID - 10.31083/j.rcm2308261 [doi] PST - epublish SO - Rev Cardiovasc Med. 2022 Jul 20;23(8):261. doi: 10.31083/j.rcm2308261. eCollection 2022 Aug. PMID- 35851025 OWN - NLM STAT- MEDLINE DCOM- 20220721 LR - 20240901 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 12 IP - 7 DP - 2022 Jul 18 TI - Real-world, feasibility study to investigate the use of a multidisciplinary app (Pulsara) to improve prehospital communication and timelines for acute stroke/STEMI care. PG - e052332 LID - 10.1136/bmjopen-2021-052332 [doi] LID - e052332 AB - OBJECTIVES: To determine if a digital communication app improves care timelines for patients with suspected acute stroke/ST-elevation myocardial infarction (STEMI). DESIGN: Real-world feasibility study, quasi-experimental design. SETTING: Prehospital (25 Ambulance Victoria branches) and within-hospital (2 hospitals) in regional Victoria, Australia. PARTICIPANTS: Paramedics or emergency department (ED) clinicians identified patients with suspected acute stroke (onset <4.5 hours; n=604) or STEMI (n=247). INTERVENTION: The Pulsara communication app provides secure, two-way, real-time communication. Assessment and treatment times were recorded for 12 months (May 2017-April 2018), with timelines compared between 'Pulsara initiated' (Pulsara) and 'not initiated' (no Pulsara). PRIMARY OUTCOME MEASURE: Door-to-treatment (needle for stroke, balloon for STEMI) Secondary outcome measures: ambulance and hospital processes. RESULTS: Stroke (no Pulsara n=215, Pulsara n=389) and STEMI (no Pulsara n=76, Pulsara n=171) groups were of similar age and sex (stroke: 76 vs 75 years; both groups 50% male; STEMI: 66 vs 63 years; 68% and 72% male). When Pulsara was used, patients were off ambulance stretcher faster for stroke (11(7, 17) vs 19(11, 29); p=0.0001) and STEMI (14(7, 23) vs 19(10, 32); p=0.0014). ED door-to-first medical review was faster (6(2, 14) vs 23(8, 67); p=0.0001) for stroke but only by 1 min for STEMI (3 (0, 7) vs 4 (0, 14); p=0.25). Door-to-CT times were 44 min faster (27(18, 44) vs 71(43, 147); p=0.0001) for stroke, and percutaneous intervention door-to-balloon times improved by 17 min, but non-significant (56 (34, 88) vs 73 (49, 110); p=0.41) for STEMI. There were improvements in the proportions of patients treated within 60 min for stroke (12%-26%, p=0.15) and 90 min for STEMI (50%-78%, p=0.20). CONCLUSIONS: In this Australian-first study, uptake of the digital communication app was strong, patient-centred care timelines improved, although door-to-treatment times remained similar. CI - (c) Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Bladin, Chris F AU - Bladin CF AUID- ORCID: 0000-0002-1729-0855 AD - Ambulance Victoria, Doncaster, Victoria, Australia chris.bladin@ambulance.vic.gov.au. AD - The Florey Institute of Neuroscience and Mental Health, Heidelberg, Victoria, Australia. AD - Eastern Health Clinical School, Monash University, Box Hill, Victoria, Australia. FAU - Bagot, Kathleen L AU - Bagot KL AUID- ORCID: 0000-0003-2895-4327 AD - The Florey Institute of Neuroscience and Mental Health, Heidelberg, Victoria, Australia. AD - Stroke and Ageing Research, Department of Medicine, Monash University, Clayton, Victoria, Australia. FAU - Vu, Michelle AU - Vu M AD - Epworth Hospital, Richmond, Victoria, Australia. FAU - Kim, Joosup AU - Kim J AUID- ORCID: 0000-0002-4079-0428 AD - The Florey Institute of Neuroscience and Mental Health, Heidelberg, Victoria, Australia. AD - Stroke and Ageing Research, Department of Medicine, Monash University, Clayton, Victoria, Australia. FAU - Bernard, Stephen AU - Bernard S AD - Ambulance Victoria, Doncaster, Victoria, Australia. FAU - Smith, Karen AU - Smith K AUID- ORCID: 0000-0002-9057-0685 AD - Centre for Research and Evaluation, Ambulance Victoria, Doncaster, Victoria, Australia. AD - School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia. FAU - Hocking, Grant AU - Hocking G AD - Ambulance Victoria, Doncaster, Victoria, Australia. FAU - Coupland, Tessa AU - Coupland T AD - Bendigo Health, Bendigo, Victoria, Australia. FAU - Pearce, Debra AU - Pearce D AD - Ballarat Health Services, Ballarat, Victoria, Australia. FAU - Badcock, Diane AU - Badcock D AD - Bendigo Health, Bendigo, Victoria, Australia. FAU - Budge, Marc AU - Budge M AD - Bendigo Health, Bendigo, Victoria, Australia. FAU - Nadurata, Voltaire AU - Nadurata V AUID- ORCID: 0000-0002-0312-3140 AD - Bendigo Health, Bendigo, Victoria, Australia. FAU - Pearce, Wayne AU - Pearce W AD - Ambulance Victoria, Doncaster, Victoria, Australia. FAU - Hall, Howard AU - Hall H AD - Ambulance Victoria, Doncaster, Victoria, Australia. FAU - Kelly, Ben AU - Kelly B AD - Ballarat Health Services, Ballarat, Victoria, Australia. FAU - Spencer, Angie AU - Spencer A AD - Ballarat Health Services, Ballarat, Victoria, Australia. FAU - Chapman, Pauline AU - Chapman P AD - Ballarat Health Services, Ballarat, Victoria, Australia. FAU - Oqueli, Ernesto AU - Oqueli E AD - Ballarat Health Services, Ballarat, Victoria, Australia. AD - Department of Medicine, Deakin University, Burwood, Sydney, Australia. FAU - Sahathevan, Ramesh AU - Sahathevan R AUID- ORCID: 0000-0001-7643-0961 AD - Ballarat Health Services, Ballarat, Victoria, Australia. AD - Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Victoria, Australia. FAU - Kraemer, Thomas AU - Kraemer T AD - Ballarat Health Services, Ballarat, Victoria, Australia. FAU - Hair, Casey AU - Hair C AD - Ballarat Health Services, Ballarat, Victoria, Australia. FAU - Stub, Dion AU - Stub D AUID- ORCID: 0000-0001-8686-2709 AD - Ambulance Victoria, Doncaster, Victoria, Australia. AD - School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia. FAU - Cadilhac, Dominique A AU - Cadilhac DA AUID- ORCID: 0000-0001-8162-682X AD - The Florey Institute of Neuroscience and Mental Health, Heidelberg, Victoria, Australia. AD - Stroke and Ageing Research, Department of Medicine, Monash University, Clayton, Victoria, Australia. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220718 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 SB - IM MH - Ambulances MH - Arrhythmias, Cardiac MH - Communication MH - Electrocardiography MH - *Emergency Medical Services MH - Feasibility Studies MH - Female MH - Humans MH - Male MH - *Mobile Applications MH - *Myocardial Infarction/therapy MH - *ST Elevation Myocardial Infarction/therapy MH - *Stroke/therapy MH - Time Factors MH - Treatment Outcome MH - Victoria PMC - PMC9297229 OTO - NOTNLM OT - ACCIDENT & EMERGENCY MEDICINE OT - CARDIOLOGY OT - Organisation of health services OT - Stroke COIS- Competing interests: None of the authors have a financial interest in the Pulsara app or Pulsara Communicare Technology. KB and DAC received a travel grant paid to their institution from Pulsara Communicare Technology. This grant was a contribution to defray the costs of attending an international conference to present the final results. The peer-reviewed abstract submission was accepted prior to receiving the travel grant. The company had no input to the content of the abstracts or the presentations (nor this manuscript). EDAT- 2022/07/20 06:00 MHDA- 2022/07/22 06:00 PMCR- 2022/07/18 CRDT- 2022/07/19 07:59 PHST- 2022/07/19 07:59 [entrez] PHST- 2022/07/20 06:00 [pubmed] PHST- 2022/07/22 06:00 [medline] PHST- 2022/07/18 00:00 [pmc-release] AID - bmjopen-2021-052332 [pii] AID - 10.1136/bmjopen-2021-052332 [doi] PST - epublish SO - BMJ Open. 2022 Jul 18;12(7):e052332. doi: 10.1136/bmjopen-2021-052332. PMID- 35845142 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250130 IS - 2688-1152 (Electronic) IS - 2688-1152 (Linking) VI - 3 IP - 4 DP - 2022 Aug TI - Cardiac arrest: An interdisciplinary scoping review of clinical literature from 2020. PG - e12773 LID - 10.1002/emp2.12773 [doi] LID - e12773 AB - OBJECTIVES: The Interdisciplinary Cardiac Arrest Research Review (ICARE) group was formed in 2018 to conduct an annual search of peer-reviewed literature relevant to cardiac arrest. Now in its third year, the goals of the review are to highlight annual updates in the interdisciplinary world of clinical cardiac arrest research with a focus on clinically relevant and impactful clinical and population-level studies from 2020. METHODS: A search of PubMed using keywords related to clinical research in cardiac arrest was conducted. Titles and abstracts were screened for relevance and sorted into 7 categories: Epidemiology & Public Health Initiatives; Prehospital Resuscitation, Technology & Care; In-Hospital Resuscitation & Post-Arrest Care; Prognostication & Outcomes; Pediatrics; Interdisciplinary Guidelines & Reviews; and a new section dedicated to the coronavirus disease 2019 (COVID-19) pandemic. Screened manuscripts underwent standardized scoring of methodological quality and impact on the respective fields by reviewer teams lead by a subject matter expert editor. Articles scoring higher than 99 percentiles by category were selected for full critique. Systematic differences between editors' and reviewers' scores were assessed using Wilcoxon signed-rank test. RESULTS: A total of 3594 articles were identified on initial search; of these, 1026 were scored after screening for relevance and deduplication, and 51 underwent full critique. The leading category was Prehospital Resuscitation, Technology & Care representing 35% (18/51) of fully reviewed articles. Four COVID-19 related articles were included for formal review that was attributed to a relative lack of high-quality data concerning cardiac arrest and COVID-19 specifically by the end of the 2020 calendar year. No significant differences between editor and reviewer scoring were found among review articles (P = 0.697). Among original research articles, section editors scored a median 1 point (interquartile range, 0-3; P < 0.01) less than reviewers. CONCLUSIONS: Several clinically relevant studies have added to the evidence base for the management of cardiac arrest patients including methods for prognostication of neurologic outcome following arrest, airway management strategy, timing of coronary intervention, and methods to improve expeditious performance of key components of resuscitation such as chest compressions in adults and children. CI - (c) 2022 The Authors. JACEP Open published by Wiley Periodicals LLC on behalf of American College of Emergency Physicians. FAU - Murphy, Travis W AU - Murphy TW AD - Division of Critical Care Medicine Department of Emergency Medicine University of Florida Gainesville Florida USA. AD - Cardiothoracic Critical Care Miami Transplant Institute University of Miami Miami Florida USA. AD - Department of Emergency Medicine University of Florida Gainesville Florida USA. FAU - Cohen, Scott A AU - Cohen SA AD - Department of Emergency Medicine University of Florida Gainesville Florida USA. FAU - Hwang, Charles W AU - Hwang CW AD - Department of Emergency Medicine University of Florida Gainesville Florida USA. FAU - Avery, K Leslie AU - Avery KL AD - Division of Pediatric Critical Care Department of Pediatrics University of Florida Gainesville Florida USA. FAU - Balakrishnan, Meenakshi P AU - Balakrishnan MP AD - Department of Emergency Medicine University of Florida Gainesville Florida USA. FAU - Balu, Ramani AU - Balu R AD - Division of Neurocritical Care Department of Neurology University of Pennsylvania Philadelphia Pennsylvania USA. FAU - Chowdhury, Muhammad Abdul Baker AU - Chowdhury MAB AD - Department of Emergency Medicine University of Florida Gainesville Florida USA. FAU - Crabb, David B AU - Crabb DB AD - Department of Emergency Medicine University of Florida Gainesville Florida USA. FAU - Elmelige, Yasmeen AU - Elmelige Y AD - Department of Emergency Medicine University of Florida Gainesville Florida USA. FAU - Maciel, Carolina B AU - Maciel CB AD - Division of Neurocritical Care Department of Neurology University of Pennsylvania Philadelphia Pennsylvania USA. AD - Department of Neurology Yale University New Haven Connecticut USA. AD - Division of Neurocritical Care Department of Neurology University of Florida Gainesville Florida USA. FAU - Gul, Sarah S AU - Gul SS AD - Department of Surgery Yale University New Haven Connecticut USA. FAU - Han, Francis AU - Han F AD - Department of Emergency Medicine University of Florida Gainesville Florida USA. AD - Lake Erie College of Osteopathic Medicine Bradenton Florida USA. FAU - Becker, Torben K AU - Becker TK AD - Division of Critical Care Medicine Department of Emergency Medicine University of Florida Gainesville Florida USA. AD - Department of Emergency Medicine University of Florida Gainesville Florida USA. CN - Interdisciplinary Cardiac Arrest Research Review (ICARE) group LA - eng GR - UL1 TR001863/TR/NCATS NIH HHS/United States PT - Journal Article PT - Scoping Review DEP - 20220714 PL - United States TA - J Am Coll Emerg Physicians Open JT - Journal of the American College of Emergency Physicians open JID - 101764779 PMC - PMC9282171 OTO - NOTNLM OT - cardiopulmonary resuscitation OT - emergency medical services OT - epidemiology OT - heart arrest OT - out-of-hospital cardiac arrest OT - sudden cardiac death EDAT- 2022/07/19 06:00 MHDA- 2022/07/19 06:01 PMCR- 2022/07/14 CRDT- 2022/07/18 03:46 PHST- 2021/11/11 00:00 [received] PHST- 2022/05/15 00:00 [revised] PHST- 2022/06/02 00:00 [accepted] PHST- 2022/07/18 03:46 [entrez] PHST- 2022/07/19 06:00 [pubmed] PHST- 2022/07/19 06:01 [medline] PHST- 2022/07/14 00:00 [pmc-release] AID - EMP212773 [pii] AID - 10.1002/emp2.12773 [doi] PST - epublish SO - J Am Coll Emerg Physicians Open. 2022 Jul 14;3(4):e12773. doi: 10.1002/emp2.12773. eCollection 2022 Aug. PMID- 35843489 OWN - NLM STAT- MEDLINE DCOM- 20221219 LR - 20230306 IS - 1532-8414 (Electronic) IS - 1071-9164 (Linking) VI - 28 IP - 12 DP - 2022 Dec TI - The Intersection Between Heart Failure and Critical Care Cardiology: An International Perspective on Structure, Staffing, and Design Considerations. PG - 1703-1716 LID - S1071-9164(22)00579-6 [pii] LID - 10.1016/j.cardfail.2022.06.007 [doi] AB - The overall patient population in contemporary cardiac intensive care units (CICUs) has only increased with respect to patient acuity, complexity, and illness severity. The current population has more cardiac and noncardiac comorbidities, a higher prevalence of multiorgan injury, and consumes more critical care resources than previously. Patients with heart failure (HF) now occupy a large portion of contemporary tertiary or quaternary care CICU beds around the world. In this review, we discuss the core issues that relate to the care of critically ill patients with HF, including global perspectives on the organization, designation, and collaboration of CICUs regionally and across institutions, as well as unique models for provisioning care for patients with HF within a health care setting. The latter includes a discussion of traditional and emerging models, specialized HF units, the makeup and implementation of multidisciplinary team-based decision-making, and cardiac critical care admission and triage practices. This article illustrates the ways in which critically ill patients with HF have helped to shape contemporary CICUs throughout the world and explores how these very patients will similarly help to inform the future maturation of these specialized critical care units. Finally, we will critically examine broad, contemporary, international models of HF and cardiac critical care delivery in North America, Europe, South America, and Asia, and conclude with opportunities for the further investigation and generation of evidence for care delivery. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Sinha, Shashank S AU - Sinha SS AD - Inova Heart and Vascular Institute, Inova Fairfax Medical Campus, Falls Church, Virginia. FAU - Bohula, Erin A AU - Bohula EA AD - Levine Cardiac Intensive Care Unit, TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. FAU - Diepen, Sean VAN AU - Diepen SV AD - Department of Critical Care Medicine and Division of Cardiology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada. FAU - Leonardi, Sergio AU - Leonardi S AD - Fondazione IRCCS Policlinico San Matteo, Pavia and University of Pavia, Pavia, Italy. FAU - Mebazaa, Alexandre AU - Mebazaa A AD - Universite de Paris, Inserm 942 MASCOT, APHP Hopitaux Universitaires Saint-Louis-Lariboisiere, Paris, France. FAU - Proudfoot, Alastair G AU - Proudfoot AG AD - Perioperative Medicine Department, Barts Heart Centre, St Bartholomew's Hospital, London, UK; Clinic For Anaesthesiology & Intensive Care, Charite-Universitatsmedizin Berlin corporate member of Freie Universitat Berlin and Humboldt Univesitat zu, Berlin, Germany. FAU - Sionis, Alessandro AU - Sionis A AD - Intensive Cardiac Care Unit, Cardiology Department, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Spain; Centro de Investigacion Biomedica en Red de Enfermedades Cardiovasculares (CIBER-CV), Madrid, Spain. FAU - Chia, Yew Woon AU - Chia YW AD - Cardiac Intensive Care Unit, Department of Cardiology, Tan Tock Seng Hospital, Singapore. FAU - Zampieri, Fernando G AU - Zampieri FG AD - HCor Research Institute, Sao Paulo, Brazil Intensive Care Unit, Federal University of Sao Paulo, Brazil. FAU - Lopes, Renato D AU - Lopes RD AD - Division of Cardiology, Duke University School of Medicine, Durham, North Carolina; Brazilian Clinical Research Institute (BCRI), Sao Paulo, Brazil. FAU - Katz, Jason N AU - Katz JN AD - Division of Cardiology, Duke University School of Medicine, Durham, North Carolina. LA - eng PT - Journal Article PT - Review DEP - 20220714 PL - United States TA - J Card Fail JT - Journal of cardiac failure JID - 9442138 SB - IM MH - Humans MH - *Heart Failure/diagnosis/epidemiology/therapy MH - Critical Illness MH - Critical Care MH - *Cardiology MH - Internationality MH - Workforce OTO - NOTNLM OT - Cardiac critical care OT - heart failure OT - organizational structure OT - staffing EDAT- 2022/07/18 06:00 MHDA- 2022/12/20 06:00 CRDT- 2022/07/17 19:27 PHST- 2021/06/09 00:00 [received] PHST- 2022/06/16 00:00 [revised] PHST- 2022/06/24 00:00 [accepted] PHST- 2022/07/18 06:00 [pubmed] PHST- 2022/12/20 06:00 [medline] PHST- 2022/07/17 19:27 [entrez] AID - S1071-9164(22)00579-6 [pii] AID - 10.1016/j.cardfail.2022.06.007 [doi] PST - ppublish SO - J Card Fail. 2022 Dec;28(12):1703-1716. doi: 10.1016/j.cardfail.2022.06.007. Epub 2022 Jul 14. PMID- 35842812 OWN - NLM STAT- MEDLINE DCOM- 20220907 LR - 20250728 IS - 1540-8191 (Electronic) IS - 0886-0440 (Linking) VI - 37 IP - 10 DP - 2022 Oct TI - Standardization of operative start times for non-emergent cardiac surgical procedures. PG - 3092-3098 LID - 10.1111/jocs.16756 [doi] AB - OBJECTIVE: Late surgical start times have been associated with a multitude of adverse consequences such as increased cost, delay in treatment, increase in medical errors, and patient complications. From October 1, 2018 to September 30, 2019, 47% (67/144) of non-emergent cardiac cases in our institution had a late start by our institutional standard. Our objective was to decrease the percentage of late start non-emergent cardiac cases from 47% to 37% by October 2020. METHODS: All non-emergent cardiac surgical procedures as first start cases in a single institution were included in our study. Preintervention cardiac surgical cases were reviewed from October 1, 2018 to February 28, 2020 to determine key drivers contributing to late start times. A multidisciplinary team was formed and utilized A3 process and problem-solving strategies to address our objective. A multipronged intervention approach was used to address key drivers contributing to late start times. RESULTS: All interventions were implemented in March 2020. Postintervention data was collected from March 1, 2020 to February 28, 2021, on all non-emergent cardiac surgical procedures. The percentage of non-emergent cardiac cases starting after 8:00 a.m. decreased to 27% (17/62). The decrease in late start cases translated into saving an average of 45min of operating room (OR) time (average cost savings of ~$5,000/case). Additionally, staff reported improved job satisfaction. CONCLUSIONS: Delayed surgical case start times can have negative effects on patients, employees, and lead to increase costs of medical care. Our research has shown adherence to on-time surgical start can improve OR efficiency, decrease cost, and improve employee satisfaction. CI - (c) 2022 Wiley Periodicals LLC. FAU - Burton, Elan AU - Burton E AUID- ORCID: 0000-0001-6062-709X AD - Department of Cardiothoracic Surgery, Stanford University School of Medicine, Palo Alto, California, USA. FAU - Medina, Melissa AU - Medina M AD - Department of Cardiothoracic Surgery, Stanford University School of Medicine, Palo Alto, California, USA. FAU - Antonio, Honeylet AU - Antonio H AD - Santa Clara County Medical Center, San Jose, California, USA. LA - eng PT - Journal Article DEP - 20220717 PL - United States TA - J Card Surg JT - Journal of cardiac surgery JID - 8908809 SB - IM CIN - J Card Surg. 2022 Oct;37(10):3099-3100. doi: 10.1111/jocs.16755. PMID: 35842820 MH - *Cardiac Surgical Procedures MH - Cost Savings MH - Humans MH - Operating Rooms MH - Reference Standards MH - Time Factors OTO - NOTNLM OT - efficiency OT - healthcare cost OT - operating room OT - quality improvement EDAT- 2022/07/18 06:00 MHDA- 2022/09/08 06:00 CRDT- 2022/07/17 03:12 PHST- 2022/05/10 00:00 [revised] PHST- 2022/03/31 00:00 [received] PHST- 2022/06/04 00:00 [accepted] PHST- 2022/07/18 06:00 [pubmed] PHST- 2022/09/08 06:00 [medline] PHST- 2022/07/17 03:12 [entrez] AID - 10.1111/jocs.16756 [doi] PST - ppublish SO - J Card Surg. 2022 Oct;37(10):3092-3098. doi: 10.1111/jocs.16756. Epub 2022 Jul 17. PMID- 35835511 OWN - NLM STAT- MEDLINE DCOM- 20220718 LR - 20220718 IS - 1092-9126 (Print) IS - 1092-9126 (Linking) VI - 25 DP - 2022 TI - Considerations for Biventricular Conversion of Fontan Circulation. PG - 11-18 LID - S1092-9126(22)00004-7 [pii] LID - 10.1053/j.pcsu.2022.04.003 [doi] AB - Despite significant improvements in the management of Fontan circulation in patients with single ventricle physiology, long-term outcomes continue to be suboptimal. Conversion to biventricular circulation is increasingly gaining popularity, particularly in the subset of patients who are not ideal Fontan candidates. Meticulous image-guided planning, extensive preoperative discussions, and a team-based approach are required for successful execution of complex biventricular conversion. A segmental approach to the anatomy of the heart defect allows methodical planning of the technique of biventricular conversion. Ventricular size and function continue to be the Achilles heel of successful biventricular repair. Long-term studies comparing outcomes in patients converted to biventricular circulation to those in patients with Fontan physiology are required to appropriately tailor management approaches to an individual patient. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Kumar, S Ram AU - Kumar SR AD - Division of Cardiothoracic Surgery, Department of Surgery, University of Southern California, Los Angeles, California; Department of Pediatrics, University of Southern California, Los Angeles, California; Heart Institute, Children's Hospital of Los Angeles, Los Angeles, California. Electronic address: rsubramanyan@surgery.usc.edu. FAU - Detterich, Jon AU - Detterich J AD - Division of Cardiology, University of Southern California, Los Angeles, California; Department of Pediatrics, University of Southern California, Los Angeles, California; Heart Institute, Children's Hospital of Los Angeles, Los Angeles, California. LA - eng PT - Journal Article PT - Review PL - United States TA - Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu JT - Seminars in thoracic and cardiovascular surgery. Pediatric cardiac surgery annual JID - 9815944 SB - IM MH - *Fontan Procedure/adverse effects MH - *Heart Defects, Congenital/surgery MH - Heart Ventricles/surgery MH - Humans MH - Palliative Care/methods OTO - NOTNLM OT - Advanced imaging OT - Biventricular circulation OT - Fontan physiology OT - Ventricular recruitment EDAT- 2022/07/15 06:00 MHDA- 2022/07/19 06:00 CRDT- 2022/07/14 21:04 PHST- 2022/03/02 00:00 [received] PHST- 2022/04/26 00:00 [revised] PHST- 2022/04/29 00:00 [accepted] PHST- 2022/07/14 21:04 [entrez] PHST- 2022/07/15 06:00 [pubmed] PHST- 2022/07/19 06:00 [medline] AID - S1092-9126(22)00004-7 [pii] AID - 10.1053/j.pcsu.2022.04.003 [doi] PST - ppublish SO - Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu. 2022;25:11-18. doi: 10.1053/j.pcsu.2022.04.003. PMID- 35832154 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220716 IS - 2234-6163 (Print) IS - 2234-6171 (Electronic) IS - 2234-6163 (Linking) VI - 49 IP - 3 DP - 2022 May TI - Gigantomastia as a Cause of Pulmonary Hypertension. PG - 369-372 LID - 10.1055/s-0042-1748651 [doi] AB - Reduction mammaplasty is the gold standard treatment for gigantomastia. We report one female patient with juvenile gigantomastia associated with severe pulmonary hypertension where her pulmonary pressure decreased significantly after the surgery, improving her quality of life. A 22-year-old female patient with gigantomastia since 10 years old, tricuspid regurgitation, and pulmonary thromboembolism antecedent was admitted to the emergency department. Her oxygen saturation was 89%. Acute heart failure management was initiated. An echocardiogram reported left ventricle ejection fraction (LVEF) of 70% with severe right heart dilation, contractile dysfunction, and arterial pulmonary pressure (PASP) of 110 mm Hg. A multidisciplinary team considered gigantomastia could generate a restrictive pattern, so a Thorek reduction mammoplasty with Wise pattern was performed. Presurgical measurements were: sternal notch to nipple-areola complex, right 59 cm, left 56 cm. Three days after surgery, the patient could breathe without oxygen support. In the outpatient follow-up, patient referred reduction of her respiratory symptoms and marked improvement in her quality of life. Six months after surgery, a control echocardiogram showed a LVEF of 62% and PASP of 85 mm Hg. Pulmonary hypertension may be present in patients with gigantomastia. Reduction mammoplasty may be a feasible alternative to improve the cardiac signs and symptoms in patients with medical refractory management. CI - The Korean Society of Plastic and Reconstructive Surgeons. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ). FAU - Castillo, Juan Pablo AU - Castillo JP AD - Facultad de Ciencias de la Salud, Grupo de investigacion PLASTICUV Cali, Universidad del Valle, Cali, Colombia. FAU - Robledo, Ana Maria AU - Robledo AM AD - Facultad de Ciencias de la Salud, Grupo de investigacion PLASTICUV Cali, Universidad del Valle, Cali, Colombia. AD - Plastic Surgery Service, Hospital Universitario del Valle, Cali, Colombia. FAU - Torres-Canchala, Laura AU - Torres-Canchala L AD - Facultad de Ciencias de la Salud, Universidad Icesi, Cali, Colombia. FAU - Roa-Saldarriaga, Lady AU - Roa-Saldarriaga L AD - Facultad de Ciencias de la Salud, Grupo de investigacion PLASTICUV Cali, Universidad del Valle, Cali, Colombia. AD - Plastic Surgery Service, Hospital Universitario del Valle, Cali, Colombia. LA - eng PT - Journal Article DEP - 20220527 PL - Korea (South) TA - Arch Plast Surg JT - Archives of plastic surgery JID - 101577999 PMC - PMC9142248 OTO - NOTNLM OT - gigantomastia OT - mammoplasty reduction OT - pulmonary hypertension COIS- Conflict of Interest None declared. EDAT- 2022/07/15 06:00 MHDA- 2022/07/15 06:01 PMCR- 2022/05/01 CRDT- 2022/07/14 02:15 PHST- 2022/07/14 02:15 [entrez] PHST- 2022/07/15 06:00 [pubmed] PHST- 2022/07/15 06:01 [medline] PHST- 2022/05/01 00:00 [pmc-release] AID - 21228 [pii] AID - 10.1055/s-0042-1748651 [doi] PST - epublish SO - Arch Plast Surg. 2022 May 27;49(3):369-372. doi: 10.1055/s-0042-1748651. eCollection 2022 May. PMID- 35821795 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220716 IS - 1933-6586 (Print) IS - 1933-6594 (Electronic) IS - 1933-6586 (Linking) VI - 34 IP - 3 DP - 2022 Jun 1 TI - Acupuncture in Multidisciplinary Treatment for Post-COVID-19 Syndrome. PG - 177-183 LID - 10.1089/acu.2021.0086 [doi] AB - BACKGROUND: Post-COVID syndrome (PCS) is a complex, multisystem illness that may follow SARS-CoV-2/COVID-19 infection. As there is limited evidence for individual therapies and no singular treatment for PCS, guidelines endorse a multidisciplinary approach. This is a case report of a patient with PCS benefiting from a comprehensive approach including acupuncture with symptom-titrated physical activity (STPA). CASE: A 50-year-old woman presented from a Long-COVID Clinic referral to an outpatient hospital-affiliated acupuncturist. She had 8 months of fatigue, anosmia, chest pressure, palpitations, and other symptoms following mild assay-confirmed COVID-19. Prior/concurrent medical testing revealed multisystem-inflammatory involvement (pericardial effusion, thyroid dysfunction, and elevated d-dimers). Cardiology/pulmonology cleared the patient for exercise to tolerance considering that serious pathology was absent. The acupuncturist's Traditional Chinese Medicine impression was of Qi Deficiency of the Heart, Lung, Spleen, and Kidney. This patient received 7 sessions of scalp, auricular, and body acupuncture. Physical-therapist (PT)-led STPA began 1-week post-acupuncture, involving 6 30-minute exercise sessions while monitoring her heart rate, with as-needed rest. RESULTS: The patient's chest pressure and palpitations resolved after 1 acupuncture treatment. With 6 additional treatments, spanning 9 weeks, overlapping with PT-led SPTA, she recovered completely and resumed her normal exercise. CONCLUSIONS: Acupuncture appeared to facilitate PCS recovery. However, the independent effects of acupuncture are less clear, given the concurrent STPA/exercise therapy, and should be explored using large study designs. Acupuncture is an attractive potential PCS therapy, considering its holistic approach and that it may be added to a multidisciplinary, guideline-concordant regimen. CI - (c) Robert J. Trager et al., 2022; Published by Mary Ann Liebert, Inc. FAU - Trager, Robert J AU - Trager RJ AUID- ORCID: 0000-0002-4714-1076 AD - Connor Whole Health, University Hospitals Cleveland Medical Center, Cleveland, OH, USA. FAU - Brewka, Elise C AU - Brewka EC AD - Connor Whole Health, University Hospitals Cleveland Medical Center, Cleveland, OH, USA. FAU - Kaiser, Christine M AU - Kaiser CM AD - Connor Whole Health, University Hospitals Cleveland Medical Center, Cleveland, OH, USA. AD - Department of Reproductive Endocrinology, School of Medicine, Case Western Reserve University, Cleveland, OH, USA. FAU - Patterson, Andrew J AU - Patterson AJ AD - University Hospitals Harrington Heart and Vascular Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA. FAU - Dusek, Jeffery A AU - Dusek JA AUID- ORCID: 0000-0001-9581-0564 AD - Connor Whole Health, University Hospitals Cleveland Medical Center, Cleveland, OH, USA. AD - Department of Family Medicine and Community Health, School of Medicine, Case Western Reserve University, Cleveland, OH, USA. LA - eng PT - Journal Article DEP - 20220616 PL - United States TA - Med Acupunct JT - Medical acupuncture JID - 100899009 PMC - PMC9248328 OTO - NOTNLM OT - COVID-19 OT - Traditional Chinese Medicine OT - acupuncture OT - complementary therapies OT - exercise OT - pericardial effusion COIS- No financial conflicts of interest exist. EDAT- 2022/07/14 06:00 MHDA- 2022/07/14 06:01 PMCR- 2022/06/16 CRDT- 2022/07/13 02:07 PHST- 2022/07/13 02:07 [entrez] PHST- 2022/07/14 06:00 [pubmed] PHST- 2022/07/14 06:01 [medline] PHST- 2022/06/16 00:00 [pmc-release] AID - 10.1089/acu.2021.0086 [pii] AID - 10.1089/acu.2021.0086 [doi] PST - ppublish SO - Med Acupunct. 2022 Jun 1;34(3):177-183. doi: 10.1089/acu.2021.0086. Epub 2022 Jun 16. PMID- 35817739 OWN - NLM STAT- MEDLINE DCOM- 20220713 LR - 20220713 IS - 2224-5839 (Electronic) IS - 2224-5820 (Linking) VI - 11 IP - 6 DP - 2022 Jun TI - Competency expectations of nurses in rapid response teams: an interview-based qualitative study. PG - 2043-2049 LID - 10.21037/apm-22-566 [doi] AB - BACKGROUND: The rapid response teams (RRTs) are early intervention Teams made up of physicians, nurses, and/or other designated personnel that conduct early assessment and intervention of patients with changing conditions outside the intensive care unit (ICU) in order to reduce ICU admissions and prevent further deterioration or promote early admission to the ICU in critically ill patients. Numerous studies have shown that RRT can effectively reduce the incidence of cardiac arrest and accidental death in patients. Nurses are the most indispensable members of multidisciplinary teams (MDT), and their ability is closely related to the success rate of RRT. METHODS: Using the phenomenological method of qualitative research, we conducted semi-structured interviews with 16 non-nurse members of RRT, including 6 doctors, 5 anesthesiologists and 5 respiratory therapists, in a third class a general hospital in Shanghai. Colaizzi content analysis was used for data analysis. RESULTS: After analysis and collation, three themes were extracted: professional theoretical knowledge, professional practical skills, and personality traits. Professional theoretical knowledge includes basic medical knowledge and knowledge of rapid response system. Professional practical skills include quick reaction capability, ability to assess illness, first aid skills and communication skills; Personality traits include imperturbable and cooperative spirit of group. CONCLUSIONS: Non-nurse members of the RRT expect the response team nurses to possess solid professional theoretical knowledge, skilled professional practical skills, and good personality qualities. Nursing managers should pay attention to the training of professional theoretical knowledge, professional practical skills and personality quality when carrying out the training practice of nurses' competency in RRT, so as to truly improve the success rate of RRT operation and further promote patient safety. FAU - Yuan, Xia AU - Yuan X AD - School of Nursing, Fudan University, Shanghai, China; Zhongshan Hospital Affiliated to Fudan University, Shanghai, China. FAU - Wan, Shenmin AU - Wan S AD - Zhongshan Hospital Affiliated to Fudan University, Shanghai, China. FAU - Chen, Yihong AU - Chen Y AD - Zhongshan Hospital Affiliated to Fudan University, Shanghai, China. FAU - Qin, Wei AU - Qin W AD - Zhongshan Hospital Affiliated to Fudan University, Shanghai, China. LA - eng PT - Journal Article PL - China TA - Ann Palliat Med JT - Annals of palliative medicine JID - 101585484 SB - IM MH - China MH - *Hospital Rapid Response Team MH - Humans MH - Motivation MH - Patient Safety MH - Qualitative Research OTO - NOTNLM OT - Rapid response team (RRT) OT - competency OT - qualitative research EDAT- 2022/07/12 06:00 MHDA- 2022/07/14 06:00 CRDT- 2022/07/11 22:22 PHST- 2022/04/13 00:00 [received] PHST- 2022/06/16 00:00 [accepted] PHST- 2022/07/11 22:22 [entrez] PHST- 2022/07/12 06:00 [pubmed] PHST- 2022/07/14 06:00 [medline] AID - 10.21037/apm-22-566 [doi] PST - ppublish SO - Ann Palliat Med. 2022 Jun;11(6):2043-2049. doi: 10.21037/apm-22-566. PMID- 35817063 OWN - NLM STAT- MEDLINE DCOM- 20220914 LR - 20250807 IS - 1439-1902 (Electronic) IS - 0171-6425 (Linking) VI - 70 IP - 6 DP - 2022 Sep TI - Rationale and Initiative of the Impella in Cardiac Surgery (ImCarS) Register Platform. PG - 458-466 LID - 10.1055/s-0042-1749686 [doi] AB - OBJECTIVES: Cardiac support systems are being used increasingly more due to the growing prevalence of heart failure and cardiogenic shock. Reducing cardiac afterload, intracardiac pressure, and flow support are important factors. Extracorporeal membrane oxygenation (ECMO) and intracardiac microaxial pump systems (Impella) as non-permanent MCS (mechanical circulatory support) are being used increasingly. METHODS: We reviewed the recent literature and developed an international European registry for non-permanent MCS. RESULTS: Life-threatening conditions that are observed preoperatively often include reduced left ventricular function, systemic hypoperfusion, myocardial infarction, acute and chronic heart failure, myocarditis, and valve vitia. Postoperative complications that are commonly observed include severe systemic inflammatory response, ischemia-reperfusion injury, trauma-related disorders, which ultimately may lead to low cardiac output (CO) syndrome and organ dysfunctions, which necessitates a prolonged ICU stay. Choosing the appropriate device for support is critical. The management strategies and complications differ by system. The "heart-team" approach is inevitably needed.However despite previous efforts to elucidate these topics, it remains largely unclear which patients benefit from certain systems, when is the right time to initiate (MCS), which support system is appropriate, what is the optimal level and type of support, which therapeutic additive and supportive strategies should be considered and ultimately, what are the future prospects and therapeutic developments. CONCLUSION: The European cardiac surgical register ImCarS has been established as an IIT with the overall aim to evaluate data received from the daily clinical practice in cardiac surgery. Interested colleagues are cordially invited to join the register. CLINICAL REGISTRATION NUMBER: DRKS00024560. POSITIVE ETHICS VOTE: AZ 246/20 Faculty of Medicine, Justus-Liebig-University-Giessen. CI - Thieme. All rights reserved. FAU - Niemann, Bernd AU - Niemann B AD - Department of Cardiovascular Surgery, University Hospital Giessen, Germany. FAU - Stoppe, Christian AU - Stoppe C AD - Department of Anesthesiology and Intensive Care Medicine, University Hospital Wurzburg, Wurzburg, Bavaria, Germany. AD - Abiomed, Abiomed, Danvers, Massachusetts, United States. FAU - Wittenberg, Michael AU - Wittenberg M AD - Coordinating Center for Clinical Trials, Philipps-University of Marburg, Marburg, Hessia, Germany. FAU - Rohrbach, Susanne AU - Rohrbach S AD - Institute of Physiology, Justus-Liebig-University Giessen, Giessen, Hessen, Germany. FAU - Saeed, Diyar AU - Saeed D AD - Department for Cardiac Surgery, Leipzig Heart Center, Leipzig, Germany. FAU - Billion, Michael AU - Billion M AD - Department of Cardiac Surgery, Schuchtermann Hospital Bad Rothenfelde, Bad Rothenfelde, Niedersachsen, Germany. FAU - Potapov, Evgenij AU - Potapov E AD - Department of Cardiac Surgery, Deutsches Herzzentrum Berlin Ringgold Standard Institution, Berlin, Berlin, Germany. FAU - Oezkur, Mehmet AU - Oezkur M AD - Department of Cardiac and Vascular Surgery, University of Mainz, Mainz, Germany. FAU - Akhyari, Payam AU - Akhyari P AUID- ORCID: 0000-0002-6452-8678 AD - Department of Cardiac Surgery, Medical Faculty, Heinrich Heine University, Dusseldorf, Germany. FAU - Schmack, Bastian AU - Schmack B AD - Department of Cardiac Surgery, University of Essen, Essen, Germany. FAU - Schibilsky, David AU - Schibilsky D AD - Department of Cardiac Surgery, University of Freiburg, Freiburg, Germany. FAU - Bernhardt, Alexander M AU - Bernhardt AM AUID- ORCID: 0000-0001-9974-8091 AD - Department of Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany. FAU - Schmitto, Jan D AU - Schmitto JD AD - Department of Cardiac-, Thoracic-, Transplantation- and Vascular Surgery, Hannover Medical School, Hannover, Germany. FAU - Hagl, Christian AU - Hagl C AD - Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Munchen, Germany. FAU - Masiello, Paolo AU - Masiello P AD - Department of Cardiac Surgery, San Giovanni di Dio e R.A. Hospital, Salerno, Salerno, Italy. FAU - Boning, Andreas AU - Boning A AD - Department of Cardiovascular Surgery, University Hospital Giessen, Germany. LA - eng PT - Journal Article PT - Review DEP - 20220711 PL - Germany TA - Thorac Cardiovasc Surg JT - The Thoracic and cardiovascular surgeon JID - 7903387 SB - IM EIN - Thorac Cardiovasc Surg. 2022 Sep;70(6):e1. doi: 10.1055/s-0042-1755310. PMID: 35973777 MH - *Cardiac Surgical Procedures/adverse effects MH - *Heart Failure/diagnosis/therapy MH - *Heart-Assist Devices/adverse effects MH - Humans MH - Shock, Cardiogenic/diagnosis/etiology/therapy MH - Treatment Outcome COIS- None declared. EDAT- 2022/07/12 06:00 MHDA- 2022/09/15 06:00 CRDT- 2022/07/11 18:52 PHST- 2022/07/12 06:00 [pubmed] PHST- 2022/09/15 06:00 [medline] PHST- 2022/07/11 18:52 [entrez] AID - 10.1055/s-0042-1749686 [doi] PST - ppublish SO - Thorac Cardiovasc Surg. 2022 Sep;70(6):458-466. doi: 10.1055/s-0042-1749686. Epub 2022 Jul 11. PMID- 35814505 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230703 IS - 0973-6883 (Print) IS - 2213-3453 (Electronic) IS - 0973-6883 (Linking) VI - 12 IP - 4 DP - 2022 Jul-Aug TI - Surgical Risk Assessment in Patients with Chronic Liver Diseases. PG - 1175-1183 LID - 10.1016/j.jceh.2022.03.004 [doi] AB - Chronic liver diseases (CLD) is one of the leading causes of morbidity and mortality. The overall life span of patients with CLD has increased and so is the number of surgical procedures these patients undergo. Pathophysiological and hemodynamic changes in cirrhosis make these patients more susceptible to hypotension and hypoxia during surgery. They also have a high risk of drug induced liver injury, renal dysfunction and post-operative liver decompensation. Patients with CLD planned for elective or semi-elective surgery should undergo detailed preoperative risk assessment. Patients should be evaluated for the presence of clinically significant portal hypertension and cirrhosis. In the absence of both cirrhosis and clinically significant portal hypertension, patients with CLD can undergo surgery with minimal or low risk. Various risk assessment tools available for patients with advanced CLD are-CTP score, MELD Score, Mayo risk score, VOCAL-Penn score. A Child class C and/or Mayo risk score >15 in general is associated with high risk of post-operative mortality and elective surgery should be deferred in these patients. In patients with Child class, A and MELD 10-15 surgery is permissible with caution (except liver resection and cardiac surgery) while in Child A and MELD <10 surgery is well tolerated. VOCAL-Penn score is a new promising tool and can be the better alternative of CTP, MELD, and Mayo risk score models but more prospective studies with large patients' population are warranted. Certain surgeries like Hepatic resection, intraabdominal, and cardiothoracic have higher risk than abdominal wall hernia repair and orthopedic surgery. Laparoscopic approaches have better outcomes and less risk of liver failure than open surgery. Minimally invasive alternatives like colonic stent placement in case of obstruction can be considered in high-risk cases. Perioperative optimization and management of ascites, HE, bleeding, liver decompensation, and nutrition should be done with multidisciplinary approach. Patients with cirrhosis undergoing high risk elective surgery can develop liver failure in post-operative period and should be evaluated and counseled for liver transplantation if not contraindicated. CI - (c) 2022 Indian National Association for Study of the Liver. Published by Elsevier B.V. All rights reserved. FAU - Jadaun, Shekhar S AU - Jadaun SS AD - Department of Gastroenterology and Hepatology, Centre for Liver and Biliary Sciences, Max Super Speciality Hospital, Saket, New Delhi, India. FAU - Saigal, Sanjiv AU - Saigal S AD - Department of Gastroenterology and Hepatology, Centre for Liver and Biliary Sciences, Max Super Speciality Hospital, Saket, New Delhi, India. LA - eng PT - Journal Article PT - Review DEP - 20220323 PL - India TA - J Clin Exp Hepatol JT - Journal of clinical and experimental hepatology JID - 101574137 PMC - PMC9257927 OTO - NOTNLM OT - ASA, American Society of Anaesthesiologists OT - CLD, Chronic liver disease OT - CTP, Child-Turcotte-Pugh OT - Cirrhosis OT - HCC, Hepatocellular carcinoma OT - HVPG, hepatic venous pressure gradient OT - MELD, Model for end stage liver disease OT - NASH, Non-alcoholic steatohepatitis OT - ROTEM, rotational thromboelastometry OT - Surgery in cirrhosis OT - Surgical risk assessment OT - TEG, Thromboelastography OT - VOCAL-Penn score, Veterans Outcomes and Costs Associated with Liver Disease-Penn score EDAT- 2022/07/12 06:00 MHDA- 2022/07/12 06:01 PMCR- 2023/07/01 CRDT- 2022/07/11 04:18 PHST- 2022/01/10 00:00 [received] PHST- 2022/03/16 00:00 [accepted] PHST- 2022/07/11 04:18 [entrez] PHST- 2022/07/12 06:00 [pubmed] PHST- 2022/07/12 06:01 [medline] PHST- 2023/07/01 00:00 [pmc-release] AID - S0973-6883(22)00051-2 [pii] AID - 10.1016/j.jceh.2022.03.004 [doi] PST - ppublish SO - J Clin Exp Hepatol. 2022 Jul-Aug;12(4):1175-1183. doi: 10.1016/j.jceh.2022.03.004. Epub 2022 Mar 23. PMID- 35798525 OWN - NLM STAT- MEDLINE DCOM- 20220711 LR - 20220716 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 12 IP - 7 DP - 2022 Jul 7 TI - Impact of a nurse-led teleconsultation strategy for cardiovascular disease management during COVID-19 pandemic in India: a pyramid model feasibility study. PG - e056408 LID - 10.1136/bmjopen-2021-056408 [doi] LID - e056408 AB - OBJECTIVE: The COVID-19 pandemic necessitated the use of telemedicine to maintain continuity of care for patients with cardiovascular diseases (CVDs). This study aimed to demonstrate the feasibility of implementing a nurse-led teleconsultation strategy for CVD management during the COVID-19 pandemic in India and evaluated the impact of nurse-led teleconsultations on patient treatment satisfaction. DESIGN, SETTING AND PARTICIPANTS: We developed a two-stage teleconsultation strategy and tested the feasibility of implementing a nurse-led teleconsultation strategy to manage CVD in a northern state (Punjab) in India. A multidisciplinary team of experts developed the treatment protocol used for teleconsultations to manage CVD. Nurses were trained to provide teleconsultation, triaging of patients and referrals to the physicians. Patients with CVD who had an outpatient visit or hospitalisation between September 2019 and March 2020 at the Dayanand Medical College Hospital, Ludhiana, India, were contacted by phone and offered teleconsultations. Telemedicine strategy comprised: stage 1 nurse-led teleconsultations and stage 2 physician-led teleconsultations. Descriptive analysis was performed to report the proportion of patients triaged by the two-stage telemedicine strategy, and patient's clinical characteristics, and treatment satisfaction between the nurse-led versus physician-led teleconsultations. RESULTS: Overall, nurse-led stage 1 teleconsultations were provided to 12 042 patients with CVD. The mean (SD) age of the participants was 58.9 years (12.8), and men were 65.4%. A relatively small proportion of patients (6.3%) were referred for the stage-2 physician-led teleconsultations and of these only 8.4% required hospitalisations. During stage 1 nurse-led teleconsultations, patients were referred to the physicians due to uncontrolled diabetes (24.9%), uncontrolled hypertension (18.7%) and congestive heart failure (16.2%). The patient's treatment satisfaction was similar between the nurse-led versus physician-led teleconsultations (p=0.07). CONCLUSION: This study showed that a nurse-led telemedicine strategy is feasible to implement in a resource-constraint setting for triaging patients with CVD and reduces physician's burden. CI - (c) Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Mohan, Bishav AU - Mohan B AUID- ORCID: 0000-0002-4337-3603 AD - Department of Cardiology, Dayanand Medical College and Hospital, Ludhiana, India. FAU - Singh, Bhupinder AU - Singh B AD - Department of Cardiology, Dayanand Medical College and Hospital, Ludhiana, India. FAU - Singh, Kavita AU - Singh K AUID- ORCID: 0000-0003-4330-666X AD - Centre for Chronic Conditions and Injuries, Public Health Foundation, Gurugram, India kavita.singh@phfi.org. AD - Heidelberg Institute of Global Health, Heidelberg University, Heidelberg, Germany. FAU - Naik, Nitish AU - Naik N AD - Department of Cardiology, All India Institute of Medical Sciences, New Delhi, India. FAU - Roy, Ambuj AU - Roy A AD - Department of Cardiology, All India Institute of Medical Sciences, New Delhi, India. FAU - Goyal, Abhishek AU - Goyal A AD - Department of Cardiology, Dayanand Medical College and Hospital, Ludhiana, India. FAU - SIngh, Gurbhej AU - SIngh G AD - Department of Cardiology, Dayanand Medical College and Hospital, Ludhiana, India. FAU - Aggarwal, Shivaansh AU - Aggarwal S AD - Department of Cardiology, Dayanand Medical College and Hospital, Ludhiana, India. FAU - Saini, Aftabh AU - Saini A AD - Department of Cardiology, Dayanand Medical College and Hospital, Ludhiana, India. FAU - Tandon, Rohit AU - Tandon R AD - Department of Cardiology, Dayanand Medical College and Hospital, Ludhiana, India. FAU - Chhabra, Shibba Takkar AU - Chhabra ST AD - Department of Cardiology, Dayanand Medical College and Hospital, Ludhiana, India. FAU - Aslam, Naved AU - Aslam N AD - Department of Cardiology, Dayanand Medical College and Hospital, Ludhiana, India. FAU - Wander, Gurpreet Singh AU - Wander GS AUID- ORCID: 0000-0002-4596-4247 AD - Department of Cardiology, Dayanand Medical College and Hospital, Ludhiana, India. FAU - Prabhakaran, Dorairaj AU - Prabhakaran D AD - Centre for Chronic Conditions and Injuries, Public Health Foundation, Gurugram, India. LA - eng GR - K43 TW011164/TW/FIC NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20220707 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 SB - IM MH - *COVID-19 MH - *Cardiovascular Diseases/therapy MH - Feasibility Studies MH - Humans MH - Male MH - Middle Aged MH - Nurse's Role MH - Pandemics MH - *Remote Consultation/methods MH - *Telemedicine/methods PMC - PMC9263376 OTO - NOTNLM OT - adult cardiology OT - coronary heart disease OT - organisation of health services OT - telemedicine COIS- Competing interests: None declared. EDAT- 2022/07/08 06:00 MHDA- 2022/07/12 06:00 PMCR- 2022/07/07 CRDT- 2022/07/07 21:12 PHST- 2022/07/07 21:12 [entrez] PHST- 2022/07/08 06:00 [pubmed] PHST- 2022/07/12 06:00 [medline] PHST- 2022/07/07 00:00 [pmc-release] AID - bmjopen-2021-056408 [pii] AID - 10.1136/bmjopen-2021-056408 [doi] PST - epublish SO - BMJ Open. 2022 Jul 7;12(7):e056408. doi: 10.1136/bmjopen-2021-056408. PMID- 35798181 OWN - NLM STAT- MEDLINE DCOM- 20220928 LR - 20221227 IS - 2241-5955 (Electronic) IS - 1109-9666 (Print) IS - 1109-9666 (Linking) VI - 67 DP - 2022 Sep-Oct TI - Changes to transcatheter aortic valve replacement (TAVR) services during the first wave of the COVID-19 pandemic: A single centre experience from United Kingdom tertiary hospital. PG - 36-41 LID - S1109-9666(22)00094-X [pii] LID - 10.1016/j.hjc.2022.07.001 [doi] AB - AIMS: COVID-19 had a devastating impact on patients with severe aortic stenosis (AS). Like many cardiac procedures, transcatheter aortic valve replacement (TAVR) services were suspended during the first wave of COVID-19. We took the opportunity to evaluate the clinical outcomes and identify any delays at different stages of the TAVR pathway during the COVID-19 pandemic. METHODS: Prospectively collected data on 210 consecutive TAVR patients between March 2019 and March 2021 were analysed. We compared the clinical outcomes and 30-day mortality rates of TAVR cases pre-pandemic and during the pandemic. We also looked to identify any time lags from the initial referral to respective stages of the TAVR workup. RESULTS: A total of 134 patients underwent TAVR prior to the national lockdown (March 2019-March 2020), compared to 76 patients during COVID-19 (April 2020-April 2021). Success rates of TAVR were similar (99% prior to the pandemic and 97.4% during COVID-19). The 30-day survival rates were 98.6% and 94.7%, respectively. Median length of stay post TAVR was 2 days during COVID-19 and 2.5 days prior to the pandemic (p = 0.064). Patients were seen quicker in clinic (median of 33 days) during COVID-19, compared to 51 days before COVID-19 (p = 0.044). No significant difference in times from referral to discussion at TAVR multidisciplinary team (MDT) meetings, CT Aortogram and TAVR implantation, in both groups. CONCLUSIONS: Reconfiguring the patient pathway during COVID-19 allowed TAVR to be performed safely, with a similar success rate and no excess complications or increased 30-day mortality. There proved to be no delay in the respective stages of patient TAVR workup, during the pandemic. CI - Copyright (c) 2022 Hellenic Society of Cardiology. All rights reserved. FAU - Tan, Joon Heng AU - Tan JH AD - Trent Cardiac Centre, Nottingham City Hospital, Nottingham University Hospitals NHS Trust, United Kingdom. Electronic address: joon.tan@nhs.net. FAU - Teoh, Tsu Kuan AU - Teoh TK AD - Trent Cardiac Centre, Nottingham City Hospital, Nottingham University Hospitals NHS Trust, United Kingdom. FAU - Ivanova, Julia AU - Ivanova J AD - Trent Cardiac Centre, Nottingham City Hospital, Nottingham University Hospitals NHS Trust, United Kingdom. FAU - Varcoe, Richard AU - Varcoe R AD - Trent Cardiac Centre, Nottingham City Hospital, Nottingham University Hospitals NHS Trust, United Kingdom. FAU - Jadhav, Sachin AU - Jadhav S AD - Trent Cardiac Centre, Nottingham City Hospital, Nottingham University Hospitals NHS Trust, United Kingdom. FAU - Baig, Kamran AU - Baig K AD - Trent Cardiac Centre, Nottingham City Hospital, Nottingham University Hospitals NHS Trust, United Kingdom. FAU - Gunarathne, Ashan AU - Gunarathne A AD - Trent Cardiac Centre, Nottingham City Hospital, Nottingham University Hospitals NHS Trust, United Kingdom. LA - eng PT - Journal Article DEP - 20220704 PL - Netherlands TA - Hellenic J Cardiol JT - Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese JID - 101257381 SB - IM MH - Aortic Valve/surgery MH - *Aortic Valve Stenosis/surgery MH - *COVID-19/epidemiology MH - Communicable Disease Control MH - *Heart Valve Prosthesis Implantation/methods MH - Humans MH - Pandemics MH - Risk Factors MH - Tertiary Care Centers MH - *Transcatheter Aortic Valve Replacement/methods MH - Treatment Outcome MH - United Kingdom/epidemiology PMC - PMC9251899 OTO - NOTNLM OT - Aortic stenosis OT - COVID-19 OT - TAVR COIS- Conflicts of interest None declared. EDAT- 2022/07/08 06:00 MHDA- 2022/09/28 06:00 PMCR- 2022/07/04 CRDT- 2022/07/07 19:25 PHST- 2022/03/30 00:00 [received] PHST- 2022/06/19 00:00 [revised] PHST- 2022/07/01 00:00 [accepted] PHST- 2022/07/08 06:00 [pubmed] PHST- 2022/09/28 06:00 [medline] PHST- 2022/07/07 19:25 [entrez] PHST- 2022/07/04 00:00 [pmc-release] AID - S1109-9666(22)00094-X [pii] AID - 10.1016/j.hjc.2022.07.001 [doi] PST - ppublish SO - Hellenic J Cardiol. 2022 Sep-Oct;67:36-41. doi: 10.1016/j.hjc.2022.07.001. Epub 2022 Jul 4. PMID- 35797046 OWN - NLM STAT- MEDLINE DCOM- 20220711 LR - 20250318 IS - 2574-3805 (Electronic) IS - 2574-3805 (Linking) VI - 5 IP - 7 DP - 2022 Jul 1 TI - Comparison of Radiation Exposure Among Interventional Echocardiographers, Interventional Cardiologists, and Sonographers During Percutaneous Structural Heart Interventions. PG - e2220597 LID - 10.1001/jamanetworkopen.2022.20597 [doi] LID - e2220597 AB - IMPORTANCE: Transesophageal echocardiography during percutaneous left atrial appendage closure (LAAO) and transcatheter edge-to-edge mitral valve repair (TEER) require an interventional echocardiographer to stand near the radiation source and patient, the primary source of scatter radiation. Despite previous work demonstrating high radiation exposure for interventional cardiologists performing percutaneous coronary and structural heart interventions, similar data for interventional echocardiographers are lacking. OBJECTIVE: To assess whether interventional echocardiographers are exposed to greater radiation doses than interventional cardiologists and sonographers during structural heart procedures. DESIGN, SETTING, AND PARTICIPANTS: In this single-center cross-sectional study, radiation doses were collected from interventional echocardiographers, interventional cardiologists, and sonographers at a quaternary care center during 30 sequential LAAO and 30 sequential TEER procedures from July 1, 2016, to January 31, 2018. Participants and study personnel were blinded to radiation doses through data analysis (January 1, 2020, to October 12, 2021). EXPOSURES: Occupation defined as interventional echocardiographers, interventional cardiologists, and sonographers. MAIN OUTCOMES AND MEASURES: Measured personal dose equivalents per case were recorded using real-time radiation dosimeters. RESULTS: A total of 60 (30 TEER and 30 LAAO) procedures were performed in 60 patients (mean [SD] age, 79 [8] years; 32 [53.3%] male) with a high cardiovascular risk factor burden. The median radiation dose per case was higher for interventional echocardiographers (10.6 muSv; IQR, 4.2-22.4 muSv) than for interventional cardiologists (2.1 muSv; IQR, 0.2-8.3 muSv; P < .001). During TEER, interventional echocardiographers received a median radiation dose of 10.5 muSv (IQR, 3.1-20.5 muSv), which was higher than the median radiation dose received by interventional cardiologists (0.9 muSv; IQR, 0.1-12.2 muSv; P < .001). During LAAO procedures, the median radiation dose was 10.6 muSv (IQR, 5.8-24.1 muSv) among interventional echocardiographers and 3.5 (IQR, 1.3-6.3 muSv) among interventional cardiologists (P < .001). Compared with interventional echocardiographers, sonographers exhibited low median radiation doses during both LAAO (0.2 muSv; IQR, 0.0-1.6 muSv; P < .001) and TEER (0.0 muSv; IQR, 0.0-0.1 muSv; P < .001). CONCLUSIONS AND RELEVANCE: In this cross-sectional study, interventional echocardiographers were exposed to higher radiation doses than interventional cardiologists during LAAO and TEER procedures, whereas sonographers demonstrated comparatively lower radiation doses. Higher radiation doses indicate a previously underappreciated occupational risk faced by interventional echocardiographers, which has implications for the rapidly expanding structural heart team. FAU - McNamara, David A AU - McNamara DA AD - Frederik Meijer Heart & Vascular Institute, Spectrum Health, Grand Rapids, Michigan. FAU - Chopra, Rajus AU - Chopra R AD - Frederik Meijer Heart & Vascular Institute, Spectrum Health, Grand Rapids, Michigan. FAU - Decker, Jeffrey M AU - Decker JM AD - Frederik Meijer Heart & Vascular Institute, Spectrum Health, Grand Rapids, Michigan. FAU - McNamara, Michael W AU - McNamara MW AD - Frederik Meijer Heart & Vascular Institute, Spectrum Health, Grand Rapids, Michigan. FAU - VanOosterhout, Stacie M AU - VanOosterhout SM AD - Frederik Meijer Heart & Vascular Institute, Spectrum Health, Grand Rapids, Michigan. FAU - Berkompas, Duane C AU - Berkompas DC AD - Frederik Meijer Heart & Vascular Institute, Spectrum Health, Grand Rapids, Michigan. FAU - Dahu, Musa I AU - Dahu MI AD - Frederik Meijer Heart & Vascular Institute, Spectrum Health, Grand Rapids, Michigan. FAU - Kenaan, Mohamad A AU - Kenaan MA AD - Frederik Meijer Heart & Vascular Institute, Spectrum Health, Grand Rapids, Michigan. FAU - Jawad, Wassim I AU - Jawad WI AD - Frederik Meijer Heart & Vascular Institute, Spectrum Health, Grand Rapids, Michigan. FAU - Merhi, William M AU - Merhi WM AD - Frederik Meijer Heart & Vascular Institute, Spectrum Health, Grand Rapids, Michigan. FAU - Parker, Jessica L AU - Parker JL AD - Frederik Meijer Heart & Vascular Institute, Spectrum Health, Grand Rapids, Michigan. FAU - Madder, Ryan D AU - Madder RD AD - Frederik Meijer Heart & Vascular Institute, Spectrum Health, Grand Rapids, Michigan. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220701 PL - United States TA - JAMA Netw Open JT - JAMA network open JID - 101729235 SB - IM CIN - Rev Esp Cardiol (Engl Ed). 2023 Dec;76(12):956-960. doi: 10.1016/j.rec.2023.05.010. PMID: 37572774 MH - Aged MH - *Cardiologists MH - Cross-Sectional Studies MH - Female MH - Humans MH - Male MH - *Occupational Exposure/adverse effects/prevention & control MH - Radiation Dosage MH - *Radiation Exposure PMC - PMC9264035 COIS- Conflict of Interest Disclosures: Dr Madder reported receiving research support and speaker honoraria and serving on the advisory board of Corindus, A Siemens Healthineers Company, and grants from Corindus, A Siemens Healthineers Company, outside the submitted work. No other disclosures were reported. EDAT- 2022/07/08 06:00 MHDA- 2022/07/12 06:00 PMCR- 2022/07/07 CRDT- 2022/07/07 11:34 PHST- 2022/07/07 11:34 [entrez] PHST- 2022/07/08 06:00 [pubmed] PHST- 2022/07/12 06:00 [medline] PHST- 2022/07/07 00:00 [pmc-release] AID - 2793929 [pii] AID - zoi220589 [pii] AID - 10.1001/jamanetworkopen.2022.20597 [doi] PST - epublish SO - JAMA Netw Open. 2022 Jul 1;5(7):e2220597. doi: 10.1001/jamanetworkopen.2022.20597. PMID- 35796644 OWN - NLM STAT- MEDLINE DCOM- 20230612 LR - 20230923 IS - 1528-1140 (Electronic) IS - 0003-4932 (Linking) VI - 278 IP - 1 DP - 2023 Jul 1 TI - Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting for Patients With Three Vessel Coronary Artery Disease: A Comparison of Centers in the Same Jurisdiction With Differing Multidisciplinary Heart Team Approaches. PG - e190-e195 LID - 10.1097/SLA.0000000000005513 [doi] AB - OBJECTIVES: Referral patterns and outcomes of percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) were compared between 2 centers within 1 jurisdiction wherein only 1 center utilizes multidisciplinary review for all patients. BACKGROUND: Management of advanced coronary artery disease often involves PCI and CABG for improvements in quality of life and survival. Indications exist for PCI and CABG, with CABG demonstrating benefit in three-vessel disease (TVD). METHODS: A total of 27,961 patients underwent cardiac catheterization in 2 centers within the same single-payer health jurisdiction (Center A and B) from 2017 to 2018. Rates of PCI, CABG, and outcomes of 1-year mortality, rehospitalization, myocardial infarction, and stroke were compared. RESULTS: More patients in Center A received PCI and less received CABG compared with Center B even among patients with TVD ( P <0.001). Multivariable logistic regression identified Center B as protective for mortality for TVD patients ( P <0.001) and those undergoing PCI ( P =0.004), but not CABG ( P =0.06). Center A's 1-year mortality was increased for all patients ( P =0.004) and those with TVD ( P =0.011). CONCLUSION: Discordant outcomes exist between these 2 centers. While patients in Center A were more likely to undergo PCI than Center B and experienced decreased 1-year survival, the difference was not significant for CABG. In part, the differences are attributable to contrasting referral practices and the discrepant rates of PCI and CABG between centers. Review of all coronary artery disease patients with a multidisciplinary Heart Team including a surgical opinion may lead to a more evidence-based referral practice aligned with current clinical guidelines. CI - Copyright (c) 2022 Wolters Kluwer Health, Inc. All rights reserved. FAU - El-Andari, Ryaan AU - El-Andari R AD - Department of Surgery, Division of Cardiac Surgery, University of Alberta, Edmonton, AB, Canada. FAU - Nagendran, Jeevan AU - Nagendran J AD - Department of Cardiac Sciences, Section of Cardiac Surgery, Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, AB, Canada. FAU - Hong, Yongzhe AU - Hong Y AD - Department of Cardiac Sciences, Section of Cardiac Surgery, Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, AB, Canada. FAU - Ali, Imtiaz AU - Ali I AD - Department of Cardiac Sciences, Section of Cardiac Surgery, Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, AB, Canada. FAU - Nagendran, Jayan AU - Nagendran J AD - Department of Cardiac Sciences, Section of Cardiac Surgery, Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, AB, Canada. LA - eng PT - Journal Article DEP - 20220706 PL - United States TA - Ann Surg JT - Annals of surgery JID - 0372354 SB - IM MH - Humans MH - *Coronary Artery Disease/surgery MH - *Percutaneous Coronary Intervention MH - Quality of Life MH - Treatment Outcome MH - Coronary Artery Bypass COIS- The authors report no conflicts of interest. EDAT- 2022/07/08 06:00 MHDA- 2023/06/12 06:42 CRDT- 2022/07/07 09:43 PHST- 2023/06/12 06:42 [medline] PHST- 2022/07/08 06:00 [pubmed] PHST- 2022/07/07 09:43 [entrez] AID - 00000658-202307000-00048 [pii] AID - 10.1097/SLA.0000000000005513 [doi] PST - ppublish SO - Ann Surg. 2023 Jul 1;278(1):e190-e195. doi: 10.1097/SLA.0000000000005513. Epub 2022 Jul 6. PMID- 35795491 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240831 IS - 2045-8932 (Print) IS - 2045-8940 (Electronic) IS - 2045-8932 (Linking) VI - 12 IP - 2 DP - 2022 Apr TI - The exercise in pulmonary arterial hypertension (ExPAH) study: A randomized controlled pilot of exercise training and multidisciplinary rehabilitation in pulmonary arterial hypertension. PG - e12069 LID - 10.1002/pul2.12069 [doi] LID - e12069 AB - Pulmonary hypertension (PH) is characterized by progressive dyspnea, fatigue, and reduced exercise capacity. Despite medical treatment, outcomes remain poor. While exercise training is well established in patients with heart failure, it is less established in patients with PH. This single-blind, randomized controlled pilot study examined the feasibility and effect of 12-week outpatient exercise (multidisciplinary rehabilitation or home walking program) on hemodynamics using cardiac magnetic resonance imaging (cMRI) and right heart catheterization (RHC) in patients with pulmonary arterial hypertension (PAH), a subset of PH. Sixteen participants were randomized to either multidisciplinary outpatient rehabilitation or a home walking program for 12 weeks. Primary outcome measures were changes in right ventricular ejection fraction and stroke volume index on cMRI. Secondary outcome measures included hemodynamics on RHC, quality of life (QOL), muscle strength (handgrip and vital capacity) and 6-min walk test. This preliminary, pilot study suggests that outpatient exercise interventions may be associated with improved hemodynamic function (mean pulmonary artery wedge pressure, stroke volume, and stroke volume index), QOL (PH symptoms, depression, and anxiety), and muscular strength (vital capacity and handgrip strength) for people with PAH, but was not adequately powered to make any formal conclusions. However, our outpatient programs were feasible, safe, and acceptable to participants. Future studies are required to further explore the potential hemodynamic benefits of exercise in PAH. CI - (c) 2022 The Authors. Pulmonary Circulation published by John Wiley & Sons Ltd on behalf of Pulmonary Vascular Research Institute. FAU - Chia, Karen S W AU - Chia KSW AD - Department of Medicine, St Vincent's Clinical School University of New South Wales Sydney Australia. AD - Department of Rehabiliation Medicine St Vincent's Hospital Sydney New South Wales Australia. AD - UNSW Rural Clinical School Coffs Harbour New South Wales Australia. FAU - Shiner, Christine T AU - Shiner CT AD - Department of Medicine, St Vincent's Clinical School University of New South Wales Sydney Australia. AD - Department of Rehabiliation Medicine St Vincent's Hospital Sydney New South Wales Australia. FAU - Brown, Karen AU - Brown K AD - Department of Cardiology St Vincent's Hospital Sydney New South Wales Australia. FAU - Holloway, Cameron J AU - Holloway CJ AD - Department of Cardiology St Vincent's Hospital Sydney New South Wales Australia. FAU - Moreyra, Camila AU - Moreyra C AD - Department of Cardiology St Vincent's Hospital Sydney New South Wales Australia. FAU - Bart, Nicole AU - Bart N AD - Department of Cardiology St Vincent's Hospital Sydney New South Wales Australia. FAU - Wong, Peter K K AU - Wong PKK AD - UNSW Rural Clinical School Coffs Harbour New South Wales Australia. FAU - Faux, Steven G AU - Faux SG AD - Department of Medicine, St Vincent's Clinical School University of New South Wales Sydney Australia. AD - Department of Rehabiliation Medicine St Vincent's Hospital Sydney New South Wales Australia. FAU - Kotlyar, Eugene AU - Kotlyar E AD - Department of Cardiology St Vincent's Hospital Sydney New South Wales Australia. LA - eng PT - Journal Article DEP - 20220511 PL - United States TA - Pulm Circ JT - Pulmonary circulation JID - 101557243 PMC - PMC9248794 OTO - NOTNLM OT - exercise OT - pulmonary hypertension OT - rehabilitation COIS- The authors declare no conflicts of interest. EDAT- 2022/07/08 06:00 MHDA- 2022/07/08 06:01 PMCR- 2022/05/11 CRDT- 2022/07/07 02:30 PHST- 2022/01/15 00:00 [received] PHST- 2022/03/18 00:00 [revised] PHST- 2022/03/23 00:00 [accepted] PHST- 2022/07/07 02:30 [entrez] PHST- 2022/07/08 06:00 [pubmed] PHST- 2022/07/08 06:01 [medline] PHST- 2022/05/11 00:00 [pmc-release] AID - PUL212069 [pii] AID - 10.1002/pul2.12069 [doi] PST - epublish SO - Pulm Circ. 2022 May 11;12(2):e12069. doi: 10.1002/pul2.12069. eCollection 2022 Apr. PMID- 35790105 OWN - NLM STAT- MEDLINE DCOM- 20220929 LR - 20260127 IS - 2473-9537 (Electronic) IS - 2473-9529 (Print) IS - 2473-9529 (Linking) VI - 6 IP - 18 DP - 2022 Sep 27 TI - International consensus statement on the management of cardiovascular risk of Bruton's tyrosine kinase inhibitors in CLL. PG - 5516-5525 LID - 10.1182/bloodadvances.2022007938 [doi] AB - Bruton's tyrosine kinase inhibitors (BTKis) have altered the treatment landscape for chronic lymphocytic leukemia (CLL) by offering effective and well-tolerated therapeutic options. However, since the approval of ibrutinib, concern has risen regarding the risk of cardiovascular (CV) adverse events, including atrial fibrillation (AF), hypertension, and heart failure. Newer BTKis appear to have lower CV risks, but data are limited. It is important to understand the risks posed by BTKis and how those risks interact with individual patients, and we convened a panel of physicians with expertise in CLL and CV toxicities in oncology to develop evidence-based consensus recommendations for community hematologists and oncologists. Care providers should thoroughly assess a patient's CV risk level before treatment initiation, including established CV diseases and risk factors, and perform investigations dependent on preexisting diseases and risk factors, including an electrocardiogram (ECG). For patients with high CV risk, BTKi treatment is often appropriate in consultation with a multidisciplinary team (MDT), and more selective BTKis, including acalabrutinib and zanubrutinib, are preferred. BTKi treatment should generally be avoided in patients with a history of heart failure. Ibrutinib should be avoided in patients with a history of ventricular arrhythmias, but the risk of newer drugs is not yet known. Finally, an MDT is crucial to help manage emerging toxicities with the goal of maintaining BTKi therapy, if possible. Optimizing heart failure, arrhythmia, and hypertension control will likely improve tolerance and maintenance of BTKi therapy. However, additional studies are needed to identify the most optimal strategy for these drugs. CI - (c) 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. FAU - Awan, Farrukh T AU - Awan FT AUID- ORCID: 0000-0003-1813-9812 AD - Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX. FAU - Addison, Daniel AU - Addison D AUID- ORCID: 0000-0002-9113-8333 AD - Cardio-Oncology Program, Division of Cardiology, The Ohio State University Medical Center, Columbus, OH. FAU - Alfraih, Feras AU - Alfraih F AD - Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia. FAU - Baratta, Sergio J AU - Baratta SJ AD - Hospital Universitario Austral, Buenos Aires, Argentina. FAU - Campos, Rodrigo Noronha AU - Campos RN AD - Benefieciencia Portuguesa Hospital, Sao Paulo, Brazil. FAU - Cugliari, Maria Silvana AU - Cugliari MS AD - Hematology Department, Angel Roffo Institute of Oncology University of Buenos Aires, Buenos Aires, Argentina. FAU - Goh, Yeow Tee AU - Goh YT AD - Singapore General Hospital, Duke-National University of Singapore Graduate Medical School, Singapore, Singapore. FAU - Ionin, Valery Alexandrovich AU - Ionin VA AUID- ORCID: 0000-0001-7293-1144 AD - Almazov National Medical Research Centre and Pavlov University, St. Petersburg, Russia. FAU - Mundnich, Stefanie AU - Mundnich S AUID- ORCID: 0000-0002-8796-2207 AD - Clinica Red Salud Vitacura y Providencia, Santiago, Chile. FAU - Sverdlov, Aaron L AU - Sverdlov AL AUID- ORCID: 0000-0003-2539-8038 AD - Cardiovascular Department, John Hunter Hospital, Hunter New England Local Health District and University of Newcastle, Callaghan, NSW, Australia. FAU - Tam, Constantine AU - Tam C AUID- ORCID: 0000-0002-9759-5017 AD - Alfred Health and Monash University, Melbourne, Australia; and. FAU - Ysebaert, Loic AU - Ysebaert L AD - Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France. LA - eng GR - K23 HL155890/HL/NHLBI NIH HHS/United States GR - L30 HL149063/HL/NHLBI NIH HHS/United States PT - Consensus Statement PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Blood Adv JT - Blood advances JID - 101698425 RN - 0 (Protein Kinase Inhibitors) RN - EC 2.7.10.2 (Agammaglobulinaemia Tyrosine Kinase) SB - IM MH - Agammaglobulinaemia Tyrosine Kinase MH - *Cardiovascular Diseases/chemically induced MH - Heart Disease Risk Factors MH - *Heart Failure/chemically induced/drug therapy MH - Humans MH - *Hypertension/chemically induced MH - *Leukemia, Lymphocytic, Chronic, B-Cell/complications/drug therapy MH - Protein Kinase Inhibitors/adverse effects MH - Risk Factors PMC - PMC9631706 EDAT- 2022/07/06 06:00 MHDA- 2022/09/30 06:00 PMCR- 2022/09/27 CRDT- 2022/07/05 20:15 PHST- 2022/04/28 00:00 [received] PHST- 2022/06/01 00:00 [accepted] PHST- 2022/07/06 06:00 [pubmed] PHST- 2022/09/30 06:00 [medline] PHST- 2022/07/05 20:15 [entrez] PHST- 2022/09/27 00:00 [pmc-release] AID - 485792 [pii] AID - 2022/ADV2022007938 [pii] AID - 10.1182/bloodadvances.2022007938 [doi] PST - ppublish SO - Blood Adv. 2022 Sep 27;6(18):5516-5525. doi: 10.1182/bloodadvances.2022007938. PMID- 35783339 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240915 IS - 2405-6030 (Electronic) IS - 2405-6030 (Linking) VI - 28 DP - 2022 Sep TI - COVID-19 in the perioperative setting: A review of the literature and the clinical landscape. PG - 100272 LID - 10.1016/j.pcorm.2022.100272 [doi] AB - The COVID-19 pandemic has dramatically affected societies and healthcare systems around the globe. The perioperative care continuum has also been under significant strain due to the pandemic-tasked with simultaneously addressing surgical strains and backlogs, infection prevention strategies, and emerging data regarding significantly higher perioperative risk for COVID-19 patients and survivors. Many uncertainties persist regarding the perioperative risk, assessment, and management of COVID-19 survivors-and the energy to catch up on surgical backlogs must be tempered with strategies to continue to mitigate COVID-19 related perioperative risk. Here, we review the available data for COVID-19-related perioperative risk, discuss areas of persistent uncertainty, and empower the perioperative teams to pursue evidence-based strategies for high quality, patient-centered, team-based care as we enter the third year of the COVID-19 pandemic. CI - (c) 2022 Elsevier Inc. All rights reserved. FAU - O'Glasser, Avital Y AU - O'Glasser AY AD - Division of Hospital Medicine, Department of Medicine, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, CHH2 8008, Portland, OR 97239, United States. AD - Department of Anesthesiology & Perioperative Medicine, Oregon Health & Science University, United States. FAU - Schenning, Katie J AU - Schenning KJ AD - Department of Anesthesiology & Perioperative Medicine, Oregon Health & Science University, United States. LA - eng PT - Journal Article PT - Review DEP - 20220627 PL - Netherlands TA - Perioper Care Oper Room Manag JT - Perioperative care and operating room management JID - 101672954 PMC - PMC9236621 OTO - NOTNLM OT - APSF, anesthesia patient safety foundation OT - ARDS, acute respiratory distress syndrome OT - ASA PS, American society of anesthesiologists physical status OT - ASA, American society of anesthesiologists OT - ASC, ambulatory surgery center OT - Anesthesiology OT - COVID-19 OT - ECMO, extracorporeal membrane oxygenation OT - NNV, number needed to vaccinate OT - PASC, post-acute sequelae of SARS-CoV-2 OT - PEM, post-exertional malaise OT - PICS, post-intensive care syndrome OT - POTS, postural orthostatic tachycardia syndrome OT - PPE, personal protective equipment OT - PTSD, post-traumatic stress disorder OT - Perioperative medicine OT - RCRI, revised cardiac risk index OT - SARS-CoV-2 OT - Surgical risk OT - VTE, venous thromboembolism COIS- The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2022/07/06 06:00 MHDA- 2022/07/06 06:01 PMCR- 2022/06/27 CRDT- 2022/07/05 10:07 PHST- 2022/05/24 00:00 [received] PHST- 2022/06/21 00:00 [revised] PHST- 2022/06/23 00:00 [accepted] PHST- 2022/07/06 06:00 [pubmed] PHST- 2022/07/06 06:01 [medline] PHST- 2022/07/05 10:07 [entrez] PHST- 2022/06/27 00:00 [pmc-release] AID - S2405-6030(22)00034-6 [pii] AID - 100272 [pii] AID - 10.1016/j.pcorm.2022.100272 [doi] PST - ppublish SO - Perioper Care Oper Room Manag. 2022 Sep;28:100272. doi: 10.1016/j.pcorm.2022.100272. Epub 2022 Jun 27. PMID- 35781784 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230111 IS - 1568-5888 (Print) IS - 1876-6250 (Electronic) IS - 1568-5888 (Linking) VI - 31 IP - 1 DP - 2023 Jan TI - The impact of the multidisciplinary Endocarditis Team on the management of infective endocarditis. PG - 29-35 LID - 10.1007/s12471-022-01707-6 [doi] AB - BACKGROUND: In their latest guidelines for infective endocarditis (IE) (2015), the European Society of Cardiology (ESC) introduced the implementation of the Endocarditis Team (ET) to facilitate the management of IE. This study presents our experiences and the diagnostic and therapeutic impact of the ET on the management of IE. METHODS: From 2016-2020, data of all patients with suspected IE referred to the ET were prospectively collected. The final diagnosis was defined by the ET as either rejected, possible or definite IE. Diagnostic impact was scored as any change in initial diagnosis, the frequency of additional diagnostic tests advised by the ET and any change in diagnosis after these tests. Therapeutic impact was scored as any change in antibiotic therapy or change from conservative to invasive therapy or vice versa. RESULTS: A total of 321 patients (median age 67 [55-77] years, 71% male) were enrolled. The final diagnosis was rejected IE in 47 (15%), possible IE in 34 (11%) and definite IE in 240 (75%) patients. A change of initial diagnosis was seen in 53/321(17%) patients. Additional microbiological tests were advised in 69/321 (21%) patients, and additional imaging tests in 136/321 (42%) patients, which resulted in subsequent change in diagnosis in 23/321 (7%) patients. Any change in antibiotic treatment was advised in 135/321 (42%) patients, and change from initial conservative to additional surgical treatment in 15/321 (5%) patients. CONCLUSION: The ET had a clear impact on the therapeutic policy for patients with suspected IE and is useful in the management of this life-threatening disease. Broad implementation is warranted. CI - (c) 2022. The Author(s). FAU - Wahadat, A R AU - Wahadat AR AD - Department of Cardiology, Erasmus Medical Centre, Rotterdam, The Netherlands. AD - Department of Radiology and Nuclear Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands. AD - Department of Cardiology, Haga Teaching Hospital, The Hague, The Netherlands. FAU - Tanis, W AU - Tanis W AD - Department of Cardiology, Haga Teaching Hospital, The Hague, The Netherlands. FAU - Galema, T W AU - Galema TW AD - Department of Cardiology, Erasmus Medical Centre, Rotterdam, The Netherlands. FAU - Swart, L E AU - Swart LE AD - Department of Cardiology, Erasmus Medical Centre, Rotterdam, The Netherlands. AD - Department of Radiology and Nuclear Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands. FAU - van Leeuwen, W J AU - van Leeuwen WJ AD - Department of Cardiothoracic Surgery, Erasmus Medical Centre, Rotterdam, The Netherlands. FAU - Verkaik, N J AU - Verkaik NJ AD - Department of Medical Microbiology and Infectious Diseases, Erasmus Medical Centre, Rotterdam, The Netherlands. FAU - Schurink, C A M AU - Schurink CAM AD - Department of Medical Microbiology and Infectious Diseases, Erasmus Medical Centre, Rotterdam, The Netherlands. AD - Department of Internal Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands. FAU - van Dalen, B AU - van Dalen B AD - Department of Cardiology, Franciscus Gasthuis & Vlietland Hospital, Rotterdam, The Netherlands. FAU - Zoet-Nugteren, S AU - Zoet-Nugteren S AD - Department of Cardiology, Ikazia Hospital, Rotterdam, The Netherlands. FAU - Gurlek, C AU - Gurlek C AD - Department of Cardiology, Admiral de Ruyter Hospital, Goes, The Netherlands. FAU - Budde, R P J AU - Budde RPJ AD - Department of Radiology and Nuclear Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands. FAU - Roos-Hesselink, J W AU - Roos-Hesselink JW AUID- ORCID: 0000-0002-6770-3830 AD - Department of Cardiology, Erasmus Medical Centre, Rotterdam, The Netherlands. j.roos@erasmusmc.nl. LA - eng PT - Journal Article DEP - 20220704 PL - Netherlands TA - Neth Heart J JT - Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation JID - 101095458 PMC - PMC9807728 OTO - NOTNLM OT - Infection OT - Infective endocarditis OT - Multidisciplinary care COIS- A.R. Wahadat, W. Tanis, T.W. Galema, L.E. Swart, W.J. van Leeuwen, N.J. Verkaik, C.A.M. Schurink, B. van Dalen, S. Zoet-Nugteren, C. Gurlek, R.P.J. Budde and J.W. Roos-Hesselink declare that they have no competing interests. EDAT- 2022/07/06 06:00 MHDA- 2022/07/06 06:01 PMCR- 2022/07/04 CRDT- 2022/07/05 09:31 PHST- 2022/05/24 00:00 [accepted] PHST- 2022/07/06 06:00 [pubmed] PHST- 2022/07/06 06:01 [medline] PHST- 2022/07/05 09:31 [entrez] PHST- 2022/07/04 00:00 [pmc-release] AID - 10.1007/s12471-022-01707-6 [pii] AID - 1707 [pii] AID - 10.1007/s12471-022-01707-6 [doi] PST - ppublish SO - Neth Heart J. 2023 Jan;31(1):29-35. doi: 10.1007/s12471-022-01707-6. Epub 2022 Jul 4. PMID- 35773192 OWN - NLM STAT- MEDLINE DCOM- 20220704 LR - 20230129 IS - 1937-710X (Electronic) IS - 1062-3264 (Linking) VI - 31 IP - 4 DP - 2022 Jul 1 TI - The Sky's the Limit: Expanding Nursing's Contribution to Acute Stroke Science. PG - 266-274 LID - 10.4037/ajcc2022109 [doi] AB - Stroke is the number one cause of preventable disability in adults in the United States. Significant advances have occurred in medications and technology supporting rapid stroke diagnosis and treatment during the past 30 years, along with blurring of the lines of what traditionally constituted nursing or medical research. Ischemic stroke is a disease of vascular insufficiency that mirrors myocardial infarction more than any other neurologic diagnosis. My primary program of research is focused on exploration of methods to improve intracranial blood flow in patients with hyperacute ischemic stroke who have viable, yet vulnerable, brain tissue to prevent worsening or enable improvement of stroke symptoms. I am also examining augmentation of recombinant tissue plasminogen activator treatment and stimulation of both arteriogenesis and angiogenesis with external counter-pulsation in patients with intracranial atherosclerosis. My secondary program of research focuses on methods to improve stroke systems of care, including improvement of advance practice providers' contributions to acute stroke care, use of innovative mobile stroke units, and improvement of quality core measure processes. Lessons learned along the way are highlighted, along with the value of interdisciplinary "team science" to build knowledge and enhance the care of highly vulnerable patients with acute stroke. CI - (c)2022 American Association of Critical-Care Nurses. FAU - Alexandrov, Anne W AU - Alexandrov AW AD - Anne W. Alexandrov is a professor of nursing and neurology and chief nurse practitioner, Acute Stroke Team and Mobile Stroke Unit, University of Tennessee Health Science Center, Memphis, Tennessee; a principal partner at Health Outcomes Institute, LLC, and a professor, NET SMART Program, Fountain Hills, Arizona. LA - eng PT - Journal Article PL - United States TA - Am J Crit Care JT - American journal of critical care : an official publication, American Association of Critical-Care Nurses JID - 9211547 RN - EC 3.4.21.68 (Tissue Plasminogen Activator) SB - IM MH - Adult MH - *Brain Ischemia/complications/drug therapy MH - Humans MH - *Ischemic Stroke MH - *Myocardial Infarction/complications MH - *Stroke/complications/therapy MH - Tissue Plasminogen Activator/therapeutic use MH - Treatment Outcome MH - United States EDAT- 2022/07/01 06:00 MHDA- 2022/07/06 06:00 CRDT- 2022/06/30 22:13 PHST- 2022/06/30 22:13 [entrez] PHST- 2022/07/01 06:00 [pubmed] PHST- 2022/07/06 06:00 [medline] AID - 31783 [pii] AID - 10.4037/ajcc2022109 [doi] PST - ppublish SO - Am J Crit Care. 2022 Jul 1;31(4):266-274. doi: 10.4037/ajcc2022109. PMID- 35772176 OWN - NLM STAT- MEDLINE DCOM- 20221004 LR - 20260127 IS - 1205-7541 (Electronic) IS - 0008-4212 (Linking) VI - 100 IP - 10 DP - 2022 Oct 1 TI - Cardiodiabetology: newer pharmacologic strategies for reducing cardiovascular disease risks. PG - 956-967 LID - 10.1139/cjpp-2022-0065 [doi] AB - Globally, nearly 500 million adults currently have diabetes, which is expected to increase to approximately 700 million by 2040. Cardiovascular diseases (CVD), including coronary heart disease, stroke, heart failure, and peripheral arterial disease, are the principal causes of death in persons with diabetes. Key to the prevention of CVD is optimization of associated risk factors. However, few persons with diabetes are at recommended targets for key CVD risk factors including low-density lipoprotein-cholesterol (LDL-C), blood pressure, glycated hemoglobin, nonsmoking status, and body mass index. While lifestyle management forms the basis for the prevention and control of these risk factors, newer and existing pharmacologic approaches are available to optimize the potential for CVD risk reduction, particularly for the management of lipids, blood pressure, and blood glucose. For higher-risk patients, antiplatelet therapy is recommended. Medication for blood pressure, statins, and most recently, icosapent ethyl, have evidence for reducing CVD events in persons with diabetes. Newer medications for diabetes, including sodium glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists, also reduce CVD and SGLT2 inhibitors in particular also reduce progression of kidney disease and reduce heart failure hospitalizations (HFHs). Most importantly, a multidisciplinary team is required to address the polypharmaceutical options to best reduce CVD risks persons with diabetes. FAU - Wong, Nathan D AU - Wong ND AUID- ORCID: 0000-0003-1102-7324 AD - Heart Disease Prevention Program, Division of Cardiology, University of California, Irvine, CA 92697 USA. LA - eng PT - Journal Article PT - Review DEP - 20220630 PL - Canada TA - Can J Physiol Pharmacol JT - Canadian journal of physiology and pharmacology JID - 0372712 RN - 0 (Blood Glucose) RN - 0 (Cholesterol, LDL) RN - 0 (Glucagon-Like Peptide-1 Receptor) RN - 0 (Glycated Hemoglobin) RN - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors) RN - 0 (Hypoglycemic Agents) RN - 0 (Platelet Aggregation Inhibitors) RN - 0 (Sodium-Glucose Transporter 2) RN - 0 (Sodium-Glucose Transporter 2 Inhibitors) RN - 0 (Glucagon-Like Peptide-1 Receptor Agonists) SB - IM MH - Adult MH - Blood Glucose MH - *Cardiovascular Diseases/drug therapy/etiology/prevention & control MH - Cholesterol, LDL/therapeutic use MH - *Diabetes Mellitus, Type 2/drug therapy MH - Glucagon-Like Peptide-1 Receptor/metabolism/therapeutic use MH - Glycated Hemoglobin/metabolism MH - *Heart Failure/drug therapy MH - Humans MH - *Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use MH - Hypoglycemic Agents/pharmacology/therapeutic use MH - Platelet Aggregation Inhibitors/therapeutic use MH - Sodium-Glucose Transporter 2 MH - *Sodium-Glucose Transporter 2 Inhibitors/pharmacology MH - Glucagon-Like Peptide-1 Receptor Agonists OTO - NOTNLM OT - GLP1 receptor agonists OT - SGLT2 inhibitors OT - agoniste des recepteurs du GLP1 OT - cardiovascular disease OT - diabetes OT - diabete OT - facteurs de risque OT - inhibiteurs du SGLT2 OT - maladies cardiovasculaires OT - risk assessment OT - risk factors OT - statines OT - statins OT - evaluation du risque EDAT- 2022/07/01 06:00 MHDA- 2022/10/05 06:00 CRDT- 2022/06/30 17:42 PHST- 2022/07/01 06:00 [pubmed] PHST- 2022/10/05 06:00 [medline] PHST- 2022/06/30 17:42 [entrez] AID - 10.1139/cjpp-2022-0065 [doi] PST - ppublish SO - Can J Physiol Pharmacol. 2022 Oct 1;100(10):956-967. doi: 10.1139/cjpp-2022-0065. Epub 2022 Jun 30. PMID- 35768716 OWN - NLM STAT- MEDLINE DCOM- 20220908 LR - 20261029 IS - 1873-4626 (Electronic) IS - 1091-255X (Linking) VI - 26 IP - 8 DP - 2022 Aug TI - Outcomes of Stable Lung Colorectal Metastases on Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. PG - 1724-1731 LID - 10.1007/s11605-022-05390-1 [doi] AB - BACKGROUND: Cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) have demonstrated benefit in patients with colorectal peritoneal metastases (CRPM). Traditionally, extraperitoneal disease is considered a contraindication to CRS/HIPEC. Stable lung metastases in patients with colorectal cancer often have an indolent course, while the presence of untreated peritoneal metastases poorly affects short-term survival. We sought to evaluate the outcomes of patients undergoing CRS/HIPEC for peritoneal disease with known stable lung metastases. METHODS: We retrospectively reviewed our prospectively maintained CRS/HIPEC database. In 2017, we adopted a policy of considering patients with stable lung metastases for CRS/HIPEC as part of multidisciplinary treatment. We compared the oncologic outcome and safety of CRS/HIPEC with peritoneal only (PM) against patients with peritoneal and lung metastases (PLM). RESULTS: Our database includes 570 patients with CRS/HIPEC of which 174 with CRPM that underwent CRS/HIPEC, 18 with preoperatively diagnosed peritoneal and lung metastases. The demographics of the PM and PLM group were similar with the exception of operative time that was longer in the PLM group. Median PCI of the cohort was 7, similar in both groups (p = 0.89). Three-year overall survival (OS) of PLM patients was 68%, compared to 71% in PM (p = 0.277). Three-year progression-free survival (PFS) rate was 20% in PLM and 23% in PM (p = 0.688). CONCLUSIONS: Presence of stable lung metastases from colorectal cancer in patients with CRPM does not appear to affect the outcomes of CRS/HIPEC. Patients with stable lung disease should be considered for CRS/HIPEC after multidisciplinary discussion. CI - (c) 2022. The Society for Surgery of the Alimentary Tract. FAU - Pantelis, Arnos AU - Pantelis A AD - The Department of General and Oncological Surgery - Surgery C, Sheba Medical Center, Affiliated With the Sackler School of Medicine, Tel Aviv University, 52621, Tel Hashomer, Israel. FAU - Ben-Yaacov, Almog AU - Ben-Yaacov A AD - The Department of General and Oncological Surgery - Surgery C, Sheba Medical Center, Affiliated With the Sackler School of Medicine, Tel Aviv University, 52621, Tel Hashomer, Israel. FAU - Adileh, Mohammad AU - Adileh M AD - The Department of General and Oncological Surgery - Surgery C, Sheba Medical Center, Affiliated With the Sackler School of Medicine, Tel Aviv University, 52621, Tel Hashomer, Israel. FAU - Schtrechman, Gal AU - Schtrechman G AD - The Department of General and Oncological Surgery - Surgery C, Sheba Medical Center, Affiliated With the Sackler School of Medicine, Tel Aviv University, 52621, Tel Hashomer, Israel. FAU - Shacham-Shmueli, Einat AU - Shacham-Shmueli E AD - The Department of Oncology, Sheba Medical Center, Affiliated With the Sackler School of Medicine, Tel Aviv University, Tel Hashomer, Israel. FAU - Boursi, Ben AU - Boursi B AD - The Department of Oncology, Sheba Medical Center, Affiliated With the Sackler School of Medicine, Tel Aviv University, Tel Hashomer, Israel. FAU - Margalit, Ofer AU - Margalit O AD - The Department of Oncology, Sheba Medical Center, Affiliated With the Sackler School of Medicine, Tel Aviv University, Tel Hashomer, Israel. FAU - Halpern, Naama AU - Halpern N AD - The Department of Oncology, Sheba Medical Center, Affiliated With the Sackler School of Medicine, Tel Aviv University, Tel Hashomer, Israel. FAU - Mor, Eyal AU - Mor E AD - The Department of General and Oncological Surgery - Surgery C, Sheba Medical Center, Affiliated With the Sackler School of Medicine, Tel Aviv University, 52621, Tel Hashomer, Israel. FAU - Assaf, Dan AU - Assaf D AD - The Department of General and Oncological Surgery - Surgery C, Sheba Medical Center, Affiliated With the Sackler School of Medicine, Tel Aviv University, 52621, Tel Hashomer, Israel. FAU - Maximiliano, Klug AU - Maximiliano K AD - The Department of Radiology - Sheba Medical Center, Affiliated With the Sackler School of Medicine, Tel Aviv University, Tel Hashomer, Israel. FAU - Nissan, Aviram AU - Nissan A AD - The Department of General and Oncological Surgery - Surgery C, Sheba Medical Center, Affiliated With the Sackler School of Medicine, Tel Aviv University, 52621, Tel Hashomer, Israel. FAU - Laks, Shachar AU - Laks S AUID- ORCID: 0000-0001-6629-453X AD - The Department of General and Oncological Surgery - Surgery C, Sheba Medical Center, Affiliated With the Sackler School of Medicine, Tel Aviv University, 52621, Tel Hashomer, Israel. Shachar.laks@sheba.health.gov.il. LA - eng PT - Journal Article DEP - 20220629 PL - Netherlands TA - J Gastrointest Surg JT - Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract JID - 9706084 SB - IM MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - *Colorectal Neoplasms/pathology MH - Combined Modality Therapy MH - Cytoreduction Surgical Procedures MH - Humans MH - *Hyperthermia, Induced MH - Hyperthermic Intraperitoneal Chemotherapy MH - Lung MH - *Lung Neoplasms/therapy MH - *Percutaneous Coronary Intervention MH - *Peritoneal Neoplasms/secondary MH - Retrospective Studies MH - Survival Rate OTO - NOTNLM OT - Colon cancer OT - Cytoreductive surgery OT - Hyperthermic intraperitoneal chemotherapy OT - Lung neoplasm OT - Neoplasm metastasis EDAT- 2022/06/30 06:00 MHDA- 2022/09/09 06:00 CRDT- 2022/06/29 23:35 PHST- 2022/03/08 00:00 [received] PHST- 2022/04/30 00:00 [accepted] PHST- 2022/06/30 06:00 [pubmed] PHST- 2022/09/09 06:00 [medline] PHST- 2022/06/29 23:35 [entrez] AID - S1091-255X(23)05740-2 [pii] AID - 10.1007/s11605-022-05390-1 [doi] PST - ppublish SO - J Gastrointest Surg. 2022 Aug;26(8):1724-1731. doi: 10.1007/s11605-022-05390-1. Epub 2022 Jun 29. PMID- 35748908 OWN - NLM STAT- MEDLINE DCOM- 20221020 LR - 20261029 IS - 1615-2573 (Electronic) IS - 0910-8327 (Linking) VI - 37 IP - 12 DP - 2022 Dec TI - Trends in prognosis after hospitalization for acute heart failure in Kurashiki Central hospital 2015-2018: single-center prospective study. PG - 2014-2028 LID - 10.1007/s00380-022-02116-w [doi] AB - Recently, we have been working on enhancing the effectiveness of treatment for acute heart failure (HF) through team-based care. This study was designed to assess the benefits of this initiative by quantifying the prognostic impact on HF patients receiving treatment at our hospital. We identified 1977 consecutive HF patients (mean age 78.3 +/- 11.9 years) being discharged from our hospital between February 2015 and December 2018, divided them by admission year, and tracked changes over time, with 2015 as a reference. The postdischarge clinical outcome measures were defined as a composite of all-cause death or rehospitalization for HF, all-cause death, and rehospitalization for HF. The risk of a composite of all-cause death or rehospitalization for HF was lower in 2017 (adjusted hazard ratio, 0.72; 95% confidence interval: 0.57 to 0.91; p = 0.005) and 2018 (adjusted hazard ratio, 0.78; 95% confidence interval: 0.61 to 0.99; p = 0.045) than in 2015, and that of all-cause death was lower in 2017 (adjusted hazard ratio, 0.72; 95% confidence interval: 0.53 to 0.98; p = 0.04) and 2018 (adjusted hazard ratio, 0.60; 95% confidence interval: 0.43 to 0.85; p = 0.004) than in 2015, but that of rehospitalization for HF was not significantly different through the study period. The mortality rate decreased at the end of the study period, but the rate of rehospitalization for HF did not. The benefits of team-based care were difficult to evaluate by quantification. CI - (c) 2022. Springer Japan KK, part of Springer Nature. FAU - Kawase, Yuichi AU - Kawase Y AUID- ORCID: 0000-0001-8762-2918 AD - Department of Cardiovascular Medicine, Kurashiki Central Hospital, 1-1-1 Miwa, Kurashiki, 710-8602, Japan. yk13983@kchnet.or.jp. FAU - Yoshida, Kenta AU - Yoshida K AD - Department of Cardiovascular Medicine, Kurashiki Central Hospital, 1-1-1 Miwa, Kurashiki, 710-8602, Japan. FAU - Matsushita, Shunsuke AU - Matsushita S AD - Department of Cardiovascular Medicine, Kurashiki Central Hospital, 1-1-1 Miwa, Kurashiki, 710-8602, Japan. FAU - Tada, Takeshi AU - Tada T AD - Department of Cardiovascular Medicine, Kurashiki Central Hospital, 1-1-1 Miwa, Kurashiki, 710-8602, Japan. FAU - Yamamoto, Hiromi AU - Yamamoto H AD - Department of Cardiovascular Medicine, Kurashiki Central Hospital, 1-1-1 Miwa, Kurashiki, 710-8602, Japan. FAU - Katoh, Harumi AU - Katoh H AD - Department of Cardiovascular Medicine, Kurashiki Central Hospital, 1-1-1 Miwa, Kurashiki, 710-8602, Japan. FAU - Kadota, Kazushige AU - Kadota K AD - Department of Cardiovascular Medicine, Kurashiki Central Hospital, 1-1-1 Miwa, Kurashiki, 710-8602, Japan. LA - eng PT - Journal Article DEP - 20220624 PL - Japan TA - Heart Vessels JT - Heart and vessels JID - 8511258 SB - IM MH - Humans MH - Aged MH - Aged, 80 and over MH - Prospective Studies MH - *Aftercare MH - Patient Discharge MH - Hospitalization MH - *Heart Failure/therapy/drug therapy MH - Prognosis MH - Hospitals MH - Patient Readmission OTO - NOTNLM OT - Acute heart failure OT - In-hospital treatment OT - Prognosis OT - Team-based care EDAT- 2022/06/25 06:00 MHDA- 2022/10/21 06:00 CRDT- 2022/06/24 11:13 PHST- 2022/03/24 00:00 [received] PHST- 2022/06/03 00:00 [accepted] PHST- 2022/06/25 06:00 [pubmed] PHST- 2022/10/21 06:00 [medline] PHST- 2022/06/24 11:13 [entrez] AID - 10.1007/s00380-022-02116-w [pii] AID - 10.1007/s00380-022-02116-w [doi] PST - ppublish SO - Heart Vessels. 2022 Dec;37(12):2014-2028. doi: 10.1007/s00380-022-02116-w. Epub 2022 Jun 24. PMID- 35739541 OWN - NLM STAT- MEDLINE DCOM- 20220627 LR - 20221006 IS - 1745-6215 (Electronic) IS - 1745-6215 (Linking) VI - 23 IP - 1 DP - 2022 Jun 23 TI - Interdisciplinary and cross-sectoral perioperative care model in cardiac surgery: implementation in the setting of minimally invasive heart valve surgery (INCREASE)-study protocol for a randomized controlled trial. PG - 528 LID - 10.1186/s13063-022-06455-x [doi] LID - 528 AB - BACKGROUND: Valvular heart diseases are frequent and increasing in prevalence. Minimally invasive heart valve surgery embedded in an interdisciplinary enhanced recovery after surgery (ERAS) program may have potential benefits with regard to reduced length of stay and improved patient reported outcomes. However, no prospective randomized data exist regarding the superiority of ERAS program for the patients' outcome. METHODS: We aim to randomize (1:1) a total of 186 eligible patients with minimally invasive heart valve surgery to an ERAS program vs. standard treatment at two centers including the University Medical Center Hamburg-Eppendorf, Germany, and the University Hospital Augsburg, Germany. The intervention is composed out of pre-, peri-, and postoperative components. The preoperative protocol aims at better preparation for the operation with regard to physical activity, nutrition, and psychological preparedness. Intraoperative anesthesiologic and surgical management are trimmed to enable an early extubation. Patients will be transferred to a specialized postoperative anesthesia care unit, where first mobilization occurs 3 h after surgery. Transfer to low care ward will be at the next day and discharge at the fifth day. Participants in the control group will receive treatment as usual. Primary endpoints include functional discharge at discharge and duration of in-hospital care during the first 12 months after index surgery. Secondary outcomes include health-related quality of life, health literacy, and level of physical activity. DISCUSSION: This is the first randomized controlled trial evaluating the effectiveness of an ERAS process after minimally invasive heart valve surgery. Interprofessional approach is the key factor of the ERAS process and includes in particular surgical, anesthesiological, physiotherapeutic, advanced nursing, and psychosocial components. A clinical implication guideline will be developed facilitating the adoption of ERAS model in other heart teams. TRIAL REGISTRATION: The study has been registered in ClinicalTrials.gov ( NCT04977362 assigned July 27, 2021). CI - (c) 2022. The Author(s). FAU - Klotz, Susanne G R AU - Klotz SGR AD - Department of Physiotherapy, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany. FAU - Ketels, Gesche AU - Ketels G AD - Department of Physiotherapy, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany. FAU - Behrendt, Christian A AU - Behrendt CA AD - Research Group GermanVasc, Department of Vascular Medicine, University Heart and Vascular Center, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany. FAU - Konig, Hans-Helmut AU - Konig HH AD - Department of Health Economics and Health Services Research, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany. FAU - Kohlmann, Sebastian AU - Kohlmann S AD - Department of Psychosomatic Medicine and Psychotherapy, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany. FAU - Lowe, Bernd AU - Lowe B AD - Department of Psychosomatic Medicine and Psychotherapy, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany. FAU - Petersen, Johannes AU - Petersen J AD - Department of Cardiovascular Surgery, University Heart and Vascular Center, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany. FAU - Stock, Sina AU - Stock S AD - Department of Cardiothoracic Surgery, University Hospital Augsburg, Stenglinstr. 2, 86156, Augsburg, Germany. FAU - Vettorazzi, Eik AU - Vettorazzi E AD - Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany. FAU - Zapf, Antonia AU - Zapf A AD - Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany. FAU - Zastrow, Inke AU - Zastrow I AD - Department of Patient and Care Management, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany. FAU - Zollner, Christian AU - Zollner C AD - Department of Anesthesiology, Center of Anesthesiology and Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany. FAU - Reichenspurner, Hermann AU - Reichenspurner H AD - Department of Cardiovascular Surgery, University Heart and Vascular Center, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany. FAU - Girdauskas, Evaldas AU - Girdauskas E AD - Department of Cardiothoracic Surgery, University Hospital Augsburg, Stenglinstr. 2, 86156, Augsburg, Germany. evaldas.girdauskas@uk-augsburg.de. LA - eng SI - ClinicalTrials.gov/NCT04977362 GR - 01NVF19028/Gemeinsamer Bundesausschuss/ PT - Clinical Trial Protocol PT - Journal Article DEP - 20220623 PL - England TA - Trials JT - Trials JID - 101263253 SB - IM EIN - Trials. 2022 Oct 5;23(1):853. doi: 10.1186/s13063-022-06813-9. PMID: 36199124 MH - *Cardiac Surgical Procedures MH - Heart Valves/surgery MH - Humans MH - *Perioperative Care/methods MH - Quality of Life MH - Randomized Controlled Trials as Topic MH - Treatment Outcome PMC - PMC9229105 OTO - NOTNLM OT - Advanced practice nurse OT - ERAS OT - Enhanced recovery after surgery OT - Fast track OT - Interdisciplinary OT - Minimally invasive heart valve surgery OT - Physiotherapy OT - Psychosomatic medicine COIS- The authors declare that they have no competing interests. EDAT- 2022/06/24 06:00 MHDA- 2022/06/28 06:00 PMCR- 2022/06/23 CRDT- 2022/06/23 23:43 PHST- 2022/03/18 00:00 [received] PHST- 2022/06/08 00:00 [accepted] PHST- 2022/06/23 23:43 [entrez] PHST- 2022/06/24 06:00 [pubmed] PHST- 2022/06/28 06:00 [medline] PHST- 2022/06/23 00:00 [pmc-release] AID - 10.1186/s13063-022-06455-x [pii] AID - 6455 [pii] AID - 10.1186/s13063-022-06455-x [doi] PST - epublish SO - Trials. 2022 Jun 23;23(1):528. doi: 10.1186/s13063-022-06455-x. PMID- 35735823 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220716 IS - 2308-3425 (Electronic) IS - 2308-3425 (Linking) VI - 9 IP - 6 DP - 2022 Jun 18 TI - Management of Pulmonary Arterial Hypertension in Pregnancy: Experience from a Nationally Accredited Center. LID - 10.3390/jcdd9060195 [doi] LID - 195 AB - (1) Background: In pulmonary arterial hypertension (PAH), pregnancy is regarded a contraindication due to high maternal and fetal morbidity and mortality. We report our experience in the management of pregnancies in PAH. (2) Methods: retrospective observational study in a nationally accredited pulmonary hypertension (PH) center from 2013 to 2021. (3) Results: seven pregnancies in six women with PAH, ranging from low to high risk and 21 to 37 years old. Half had known pre-existing PAH before pregnancy. One had a multifetal gestation, and one was pregnant twice under our care. PH medical therapy and serial clinical assessment throughout pregnancy were implemented with focused attention on optimizing right heart function. Delivery was planned by a multidisciplinary team involving PH cardiology, maternal fetal medicine, and obstetric anesthesiology. Patients delivered between 31 and 40 weeks of gestation; five of the seven were via cesarean section. All received regional anesthesia and were monitored in the PH intermediate step-down unit after delivery until discharge. In all cases, delivery was without complications with excellent outcomes for the mother and child. (4) Conclusions: Multidisciplinary and tailored management of PAH in pregnancy, emphasizing optimized right heart function prior to delivery, can result in excellent clinical outcomes in a referral PH center. FAU - Vaidya, Anjali AU - Vaidya A AUID- ORCID: 0000-0001-6513-4112 AD - Pulmonary Hypertension, Right Heart Failure, CTEPH Program, Temple Heart and Vascular Institute, Department of Medicine, Temple University Hospital, Philadelphia, PA 19197, USA. FAU - Oliveros, Estefania AU - Oliveros E AD - Pulmonary Hypertension, Right Heart Failure, CTEPH Program, Temple Heart and Vascular Institute, Department of Medicine, Temple University Hospital, Philadelphia, PA 19197, USA. FAU - Mulla, Wadia AU - Mulla W AD - Division of Maternal Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, Temple University Hospital, Philadelphia, PA 19197, USA. FAU - Feinstein, Diana AU - Feinstein D AD - Obstetric Anesthesiology, Department of Anesthesiology, Temple University Hospital, Philadelphia, PA 19197, USA. FAU - Hart, Laura AU - Hart L AD - Division of Maternal Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, Temple University Hospital, Philadelphia, PA 19197, USA. FAU - Forfia, Paul AU - Forfia P AD - Pulmonary Hypertension, Right Heart Failure, CTEPH Program, Temple Heart and Vascular Institute, Department of Medicine, Temple University Hospital, Philadelphia, PA 19197, USA. LA - eng PT - Journal Article DEP - 20220618 PL - Switzerland TA - J Cardiovasc Dev Dis JT - Journal of cardiovascular development and disease JID - 101651414 PMC - PMC9224797 OTO - NOTNLM OT - cardio-obstetrics OT - maternal fetal medicine OT - pregnancy OT - pulmonary hypertension OT - right heart failure OT - right ventricular dysfunction COIS- The authors declare no conflict of interest. EDAT- 2022/06/24 06:00 MHDA- 2022/06/24 06:01 PMCR- 2022/06/18 CRDT- 2022/06/23 08:53 PHST- 2022/05/14 00:00 [received] PHST- 2022/06/10 00:00 [revised] PHST- 2022/06/16 00:00 [accepted] PHST- 2022/06/23 08:53 [entrez] PHST- 2022/06/24 06:00 [pubmed] PHST- 2022/06/24 06:01 [medline] PHST- 2022/06/18 00:00 [pmc-release] AID - jcdd9060195 [pii] AID - jcdd-09-00195 [pii] AID - 10.3390/jcdd9060195 [doi] PST - epublish SO - J Cardiovasc Dev Dis. 2022 Jun 18;9(6):195. doi: 10.3390/jcdd9060195. PMID- 35734150 OWN - NLM STAT- MEDLINE DCOM- 20220624 LR - 20231101 IS - 1947-6108 (Electronic) IS - 1947-6094 (Print) IS - 1947-6108 (Linking) VI - 18 IP - 3 DP - 2022 TI - Instituting a Curriculum for Cardio-Obstetrics Subspecialty Fellowship Training. PG - 14-23 LID - 10.14797/mdcvj.1101 [doi] AB - Maternal mortality is rising in the United States, and cardiovascular disease is the leading cause. Adverse pregnancy outcomes such as preeclampsia and gestational diabetes heighten the risk of cardiovascular complications during pregnancy and the peripartum period and are associated with long-term cardiovascular risks. The field of cardio-obstetrics is a subspecialty within adult cardiology that focuses on the management of women with or at high risk for heart disease who are considering pregnancy or have become pregnant. There is growing recognition of the need for more specialists with dedicated expertise in cardio-obstetrics to improve the cardiovascular care of this high-risk patient population. Current recommendations for cardiovascular fellowship training programs accredited by the Accreditation Council for Graduate Medical Education involve establishing core competency in the knowledge of managing heart disease in pregnancy. However, little granular detail is available of what such training should entail, which can lead to knowledge gaps. Additionally, dedicated advanced subspecialty training in this area is not commonly offered. Multidisciplinary collaborative teams have been shown to improve outcomes in cardiac patients during pregnancy, and cardiovascular fellows-in-training interested in cardio-obstetrics should have the opportunity to participate in and contribute to a pregnancy heart team. In this document, we describe a proposed specialized cardio-obstetrics training pathway that could serve to adequately prepare trainees to competently and comprehensively care for women with cardiovascular disease before, during, and after pregnancy. CI - Copyright: (c) 2022 The Author(s). FAU - Minhas, Anum S AU - Minhas AS AUID- ORCID: 0000-0001-6680-0404 AD - Johns Hopkins University School of Medicine, Baltimore, Maryland, US. FAU - Goldstein, Sarah A AU - Goldstein SA AUID- ORCID: 0000-0002-7789-4773 AD - Duke University School of Medicine, Durham, North Carolina, US. FAU - Vaught, Arthur Jason AU - Vaught AJ AUID- ORCID: 0000-0002-2370-3716 AD - Johns Hopkins University School of Medicine, Baltimore, Maryland, US. FAU - Lewey, Jennifer AU - Lewey J AUID- ORCID: 0000-0003-3483-5527 AD - University of Pennsylvania, Philadelphia, Pennsylvania, US. FAU - Ward, Cary AU - Ward C AUID- ORCID: 0000-0002-5283-0490 AD - Duke University School of Medicine, Durham, North Carolina, US. FAU - Schulman, Steven P AU - Schulman SP AUID- ORCID: 0000-0003-3964-8886 AD - Johns Hopkins University School of Medicine, Baltimore, Maryland, US. FAU - Michos, Erin D AU - Michos ED AUID- ORCID: 0000-0002-5547-5084 AD - Johns Hopkins University School of Medicine, Baltimore, Maryland, US. AD - Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, US. LA - eng GR - K23 HL153667/HL/NHLBI NIH HHS/United States GR - T32 HL007024/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Review DEP - 20220603 PL - United States TA - Methodist Debakey Cardiovasc J JT - Methodist DeBakey cardiovascular journal JID - 101508600 SB - IM MH - Adult MH - *Cardiovascular Diseases/diagnosis/therapy MH - Curriculum MH - Education, Medical, Graduate MH - Fellowships and Scholarships MH - Female MH - *Heart Diseases MH - Humans MH - *Obstetrics MH - Pregnancy MH - United States PMC - PMC9165665 OTO - NOTNLM OT - cardio-obstetrics OT - curriculum OT - education OT - training COIS- Dr. Minhas was supported by the National Heart, Lung, and Blood Institute training grant T32HL007024, the Lou and Nancy Grasmick Research Fellowship, and the Marie-Josee and Henry R. Kravis Endowed Fellowship at the Johns Hopkins University. Dr. Goldstein is supported by The Thomas Anstrom Fellowship in Congenital Heart Disease Fund. Dr. Michos is funded by the Amato Fund in Women's Cardiovascular Health Research at Johns Hopkins University. Dr. Lewey is funded by a grant from the National Heart, Lung, and Blood Institute (K23HL153667). Unrelated to this work, Dr. Michos serves on the advisory boards for AstraZeneca, Amarin, Bayer, Boehringer Ingelheim, Esperion, Novartis, Novo Nordisk, and Pfizer. EDAT- 2022/06/24 06:00 MHDA- 2022/06/25 06:00 PMCR- 2022/06/03 CRDT- 2022/06/23 02:35 PHST- 2022/02/16 00:00 [received] PHST- 2022/03/24 00:00 [accepted] PHST- 2022/06/23 02:35 [entrez] PHST- 2022/06/24 06:00 [pubmed] PHST- 2022/06/25 06:00 [medline] PHST- 2022/06/03 00:00 [pmc-release] AID - 10.14797/mdcvj.1101 [doi] PST - epublish SO - Methodist Debakey Cardiovasc J. 2022 Jun 3;18(3):14-23. doi: 10.14797/mdcvj.1101. eCollection 2022. PMID- 35733722 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220716 IS - 2225-319X (Print) IS - 2304-1021 (Electronic) IS - 2225-319X (Linking) VI - 11 IP - 3 DP - 2022 May TI - Mitral valve repair in papillary muscle rupture. PG - 281-289 LID - 10.21037/acs-2021-ami-23 [doi] AB - Papillary muscle rupture (PMR) is a significant mechanical complication following myocardial infarction (MI), a condition associated with a high mortality. It results in severe mitral valve regurgitation (MR), often accompanied by cardiogenic shock and pulmonary edema, requiring both emergent medical treatment and surgical intervention. Surgical treatment includes either chordal sparing mitral valve replacement or mitral valve repair, which is associated with a high mortality. Mitral valve repair is believed to be superior to mitral valve replacement with respect to improving left ventricular function, albeit with risk of repair failure and resulting in increased cross clamp times. Concomitant coronary revascularization may improve both short- and long-term outcomes after surgery. With advances in medical innovations in the field of transcatheter devices, these devices may serve as a bridge to recovery or treatment in the setting of acute MR due to PMR. However, long-term data will be required to establish the non-inferiority of one treatment modality over the other. Management of these patients should be guided by a dedicated mitral heart team. CI - 2022 Annals of Cardiothoracic Surgery. All rights reserved. FAU - Hamid, Umar Imran AU - Hamid UI AD - Department of Cardiothoracic Surgery, Maastricht University Medical Centre, Maastricht, The Netherlands. FAU - Aksoy, Rezan AU - Aksoy R AD - Department of Cardiothoracic Surgery, Maastricht University Medical Centre, Maastricht, The Netherlands. FAU - Sardari Nia, Peyman AU - Sardari Nia P AD - Department of Cardiothoracic Surgery, Maastricht University Medical Centre, Maastricht, The Netherlands. LA - eng PT - Journal Article PT - Review PL - China TA - Ann Cardiothorac Surg JT - Annals of cardiothoracic surgery JID - 101605877 PMC - PMC9207695 OTO - NOTNLM OT - Papillary muscle rupture (PMR) OT - mitral clip OT - mitral valve repair OT - myocardial infarction (MI) OT - neochordae COIS- Conflicts of Interest: The authors have no conflicts of interest to declare. EDAT- 2022/06/24 06:00 MHDA- 2022/06/24 06:01 PMCR- 2022/05/01 CRDT- 2022/06/23 02:28 PHST- 2021/12/18 00:00 [received] PHST- 2022/03/11 00:00 [accepted] PHST- 2022/06/23 02:28 [entrez] PHST- 2022/06/24 06:00 [pubmed] PHST- 2022/06/24 06:01 [medline] PHST- 2022/05/01 00:00 [pmc-release] AID - acs-11-03-281 [pii] AID - 10.21037/acs-2021-ami-23 [doi] PST - ppublish SO - Ann Cardiothorac Surg. 2022 May;11(3):281-289. doi: 10.21037/acs-2021-ami-23. PMID- 35733711 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220716 IS - 2225-319X (Print) IS - 2304-1021 (Electronic) IS - 2225-319X (Linking) VI - 11 IP - 3 DP - 2022 May TI - Pre- and post-operative mechanical circulatory support in surgical repair of post-acute myocardial infarction mechanical complications. PG - 304-309 LID - 10.21037/acs-2021-ami-206 [doi] AB - The outcomes of patients with acute myocardial infarctions (AMI) have significantly improved with advances in early reperfusion strategies; however, patients with massive infarcts or those who do not receive timely revascularization may develop mechanical complications of AMI. The most common mechanical complications are ventricular septal rupture (VSR), acute mitral regurgitation (MR) due to papillary muscle rupture, and free-wall rupture. Each complication is associated with a high risk of morbidity and mortality, and requires a multidisciplinary approach for prompt diagnosis and hemodynamic stabilization. Surgery is the mainstay of therapy but is associated with poor outcomes if performed too early during the treatment course for VSR or if performed too late with MR and free wall rupture. Optimal timing for surgery in combination with temporary circulatory support may be a feasible strategy for better results. CI - 2022 Annals of Cardiothoracic Surgery. All rights reserved. FAU - Bhardwaj, Anju AU - Bhardwaj A AD - The University of Texas Health Science Center at Houston, Houston, TX, USA. FAU - Kumar, Sachin AU - Kumar S AD - The University of Texas Health Science Center at Houston, Houston, TX, USA. FAU - Salas de Armas, Ismael A AU - Salas de Armas IA AD - The University of Texas Health Science Center at Houston, Houston, TX, USA. FAU - Nascimbene, Angelo AU - Nascimbene A AD - The University of Texas Health Science Center at Houston, Houston, TX, USA. FAU - Nathan, Sriram AU - Nathan S AD - The University of Texas Health Science Center at Houston, Houston, TX, USA. FAU - Kar, Biswajit AU - Kar B AD - The University of Texas Health Science Center at Houston, Houston, TX, USA. FAU - Gregoric, Igor D AU - Gregoric ID AD - The University of Texas Health Science Center at Houston, Houston, TX, USA. LA - eng PT - Journal Article PT - Review PL - China TA - Ann Cardiothorac Surg JT - Annals of cardiothoracic surgery JID - 101605877 PMC - PMC9207699 OTO - NOTNLM OT - Mechanical circulatory support (MCS) OT - left ventricular assist device OT - mechanical complication OT - ventricular septal rupture (VSR) COIS- Conflicts of Interest: The authors have no conflicts of interest to declare. EDAT- 2022/06/24 06:00 MHDA- 2022/06/24 06:01 PMCR- 2022/05/01 CRDT- 2022/06/23 02:27 PHST- 2021/11/25 00:00 [received] PHST- 2022/03/22 00:00 [accepted] PHST- 2022/06/23 02:27 [entrez] PHST- 2022/06/24 06:00 [pubmed] PHST- 2022/06/24 06:01 [medline] PHST- 2022/05/01 00:00 [pmc-release] AID - acs-11-03-304 [pii] AID - 10.21037/acs-2021-ami-206 [doi] PST - ppublish SO - Ann Cardiothorac Surg. 2022 May;11(3):304-309. doi: 10.21037/acs-2021-ami-206. PMID- 35723783 OWN - NLM STAT- MEDLINE DCOM- 20221007 LR - 20261029 IS - 1546-9549 (Electronic) IS - 1546-9530 (Linking) VI - 19 IP - 5 DP - 2022 Oct TI - Polypharmacy in Older Heart Failure Patients: a Multidisciplinary Approach. PG - 290-302 LID - 10.1007/s11897-022-00559-w [doi] AB - PURPOSE OF REVIEW: We provide a review of considerations when applying principles of optimal pharmacotherapy to older adults with heart failure (HF), an analysis on the pivotal clinical trials focusing on applicability to older adults, and multi-disciplinary strategies to optimize the health of HF patients with polypharmacy. RECENT FINDINGS: Polypharmacy is very common among patients with HF, due to medications for both HF and non-HF comorbidities. Definitions of polypharmacy were not developed specifically for older adults with HF and may need to be modified in order to meaningfully describe medication burden and promote appropriate medical therapy. This is because clinical practice guidelines for multi-drug HF regimens have unique considerations, given that they improve outcomes and symptoms of HF. Adults older than 65 years are well represented in contemporary clinical trials for HF with preserved ejection fraction (HFpEF) and guideline directed medical therapy (GDMT) for HF with reduced ejection fraction (HFrEF). While these trials did not have significant heterogeneity in safety or efficacy across a broad age spectrum, some may have limited representation of adults >/= 80 years old, the sickest older adults, or those with decreased functional status. There is also a lack of data on the safety and efficacy of deprescribing HF medications, and deprescription in otherwise stable patients may lead to clinical destabilization or disease progression. There is therefore innate tension between the well-studied benefits of optimized HF therapy for older adults that must be weighed against the risks of polypharmacy and many unknowns that still exist. Given the strong evidence that optimized HF therapies confer symptomatic and mortality benefits for older adults, it is clear that polypharmacy in this context can be appropriate. A shift in paradigm is therefore needed when evaluating polypharmacy in patients with HF. Instead of assuming all polypharmacy is "good" or "bad," we propose a concerted move, using a multidisciplinary approach, to focus on the "appropriateness" of specific medications, in order to optimize HF medical therapy. Clinicians of all specialties caring for complex older adults with HF must consider goals of care, functional status, and new evidence-based therapies, in order to optimize this polypharmacy for older adults. CI - (c) 2022. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply. FAU - Sukumar, Smrithi AU - Sukumar S AD - Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. FAU - Orkaby, Ariela R AU - Orkaby AR AD - Department of Medicine, VA Boston Healthcare System, Boston, MA, USA. AD - New England Geriatric Research, Education, and Clinical Center (GRECC), VA Boston Healthcare System, Boston, MA, USA. AD - Division of Aging, Brigham & Women's Hospital, Boston, MA, USA. FAU - Schwartz, Janice B AU - Schwartz JB AD - Department of Medicine, UC San Francisco, San Francisco, CA, USA. FAU - Marcum, Zachary AU - Marcum Z AD - UW School of Pharmacy, University of Washington, Seattle, WA, USA. FAU - Januzzi, James L AU - Januzzi JL AD - Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. FAU - Vaduganathan, Muthiah AU - Vaduganathan M AD - Department of Medicine, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA. FAU - Warraich, Haider J AU - Warraich HJ AUID- ORCID: 0000-0001-9493-1372 AD - Department of Medicine, VA Boston Healthcare System, Boston, MA, USA. AD - Department of Medicine, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA. AD - , Boston, MA, USA. LA - eng GR - IK2 CX001800/CX/CSRD VA/United States GR - R03 AG060169/AG/NIA NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, U.S. Gov't, Non-P.H.S. PT - Review DEP - 20220620 PL - United States TA - Curr Heart Fail Rep JT - Current heart failure reports JID - 101196487 SB - IM MH - Aged MH - Aged, 80 and over MH - *Heart Failure/therapy MH - Humans MH - Polypharmacy MH - Stroke Volume MH - *Ventricular Dysfunction, Left MH - Ventricular Function, Left OTO - NOTNLM OT - Guideline-directed medical therapy OT - Heart failure OT - Multi-disciplinary OT - Older adults OT - Polypharmacy EDAT- 2022/06/21 06:00 MHDA- 2022/10/12 06:00 CRDT- 2022/06/20 11:17 PHST- 2022/06/02 00:00 [accepted] PHST- 2022/06/21 06:00 [pubmed] PHST- 2022/10/12 06:00 [medline] PHST- 2022/06/20 11:17 [entrez] AID - 10.1007/s11897-022-00559-w [pii] AID - 10.1007/s11897-022-00559-w [doi] PST - ppublish SO - Curr Heart Fail Rep. 2022 Oct;19(5):290-302. doi: 10.1007/s11897-022-00559-w. Epub 2022 Jun 20. PMID- 35722034 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221104 IS - 1671-5411 (Print) IS - 1671-5411 (Linking) VI - 19 IP - 5 DP - 2022 May 28 TI - Multidisciplinary team management and long-term prognosis of an elderly patient with severe cardiac amyloidosis complicated with multiple myeloma. PG - 398-402 LID - 10.11909/j.issn.1671-5411.2022.05.006 [doi] FAU - Shang, Zhi AU - Shang Z AD - Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, Beijing, China. FAU - Zhao, Meng-Lin AU - Zhao ML AD - Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, Beijing, China. FAU - Wang, Xin-Yu AU - Wang XY AD - Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, Beijing, China. FAU - Gao, Wei AU - Gao W AD - Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, Beijing, China. LA - eng PT - Journal Article PL - China TA - J Geriatr Cardiol JT - Journal of geriatric cardiology : JGC JID - 101237881 PMC - PMC9170903 COIS- None EDAT- 2022/06/21 06:00 MHDA- 2022/06/21 06:01 PMCR- 2022/05/28 CRDT- 2022/06/20 04:02 PHST- 2022/06/20 04:02 [entrez] PHST- 2022/06/21 06:00 [pubmed] PHST- 2022/06/21 06:01 [medline] PHST- 2022/05/28 00:00 [pmc-release] AID - jgc-19-5-398 [pii] AID - 10.11909/j.issn.1671-5411.2022.05.006 [doi] PST - ppublish SO - J Geriatr Cardiol. 2022 May 28;19(5):398-402. doi: 10.11909/j.issn.1671-5411.2022.05.006. PMID- 35718422 OWN - NLM STAT- MEDLINE DCOM- 20220621 LR - 20241003 IS - 1551-7136 (Print) IS - 1551-7136 (Linking) VI - 18 IP - 3 DP - 2022 Jul TI - Training and Career Development in Cardio-Oncology Translational and Implementation Science. PG - 503-514 LID - S1551-7136(22)00015-0 [pii] LID - 10.1016/j.hfc.2022.02.014 [doi] AB - Cardiovascular disease is a leading cause of death in cancer survivors, after recurrence of the primary tumor or occurrence of a secondary malignancy. Consequently, the interdisciplinary field of cardio-oncology has grown rapidly in recent years to address the cardiovascular care needs of this unique population through clinical care and research initiatives. Here, the authors discuss the ideal infrastructure for training and career development in cardio-oncology translational and implementation science and emphasize the importance of the multidisciplinary cardiovascular team for both research and patient care. Cardio-oncology training opportunities in general cardiology, hematology/oncology, and specialized cardio-oncology clinical and research fellowships are also considered. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Brown, Sherry-Ann AU - Brown SA AD - Cardio-Oncology Program, Division of Cardiovascular Medicine, Medical College of Wisconsin, 8701 West Watertown Plank Road, Milwaukee, WI 53226, USA. Electronic address: drbrowncares@gmail.com. FAU - Yang, Eric H AU - Yang EH AD - UCLA Cardio-Oncology Program, Division of Cardiology, Department of Medicine, University of California at Los Angeles, UCLA Cardiovascular Center, 100 Medical Plaza, Suite 630, Los Angeles, CA 90095, USA. Electronic address: https://twitter.com/datsunian. FAU - Branch, Mary AU - Branch M AD - Section of Cardiovascular Medicine, Wake Forest University, 1834 Wake Forest Road, Winston- Salem, NC 27109, USA. Electronic address: https://twitter.com/DocBanks84. FAU - Beavers, Craig AU - Beavers C AD - University of Kentucky College of Pharmacy, 40506, 789 South Limestone, Lexington, KY 40508, USA. Electronic address: https://twitter.com/beaverspharmd. FAU - Blaes, Anne AU - Blaes A AD - Division of Hematology/Oncology, University of Minnesota, 3 Morrill Hall, 100 Church Street Southeast, Minneapolis, MN 55455, USA. Electronic address: https://twitter.com/BlaesAnne. FAU - Fradley, Michael G AU - Fradley MG AD - Division of Cardiology, Department of Medicine, Cardio-Oncology Center of Excellence, Perelman School of Medicine at the University of Pennsylvania, 3400 Civic Center Boulevard, Philadelphia, PA 19104, USA. FAU - Cheng, Richard K AU - Cheng RK AD - Cardio-oncology Program, Division of Cardiology, University of Washington, 1959 Northeast Pacific Street, Seattle, WA 98195, USA. Electronic address: https://twitter.com/Richardkcheng2. LA - eng GR - K24 HL152143/HL/NHLBI NIH HHS/United States GR - KL2 TR001438/TR/NCATS NIH HHS/United States GR - UL1 TR001436/TR/NCATS NIH HHS/United States PT - Journal Article PT - Review PL - United States TA - Heart Fail Clin JT - Heart failure clinics JID - 101231934 SB - IM MH - *Cardiology/education MH - *Cardiovascular Diseases/epidemiology MH - Humans MH - Implementation Science MH - Medical Oncology/education MH - *Neoplasms/complications/therapy PMC - PMC9236555 MID - NIHMS1812933 OTO - NOTNLM OT - Cardio-oncology OT - Cardiology OT - Education OT - Oncology OT - Trainees COIS- Disclosure This publication was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant Numbers UL1TR001436 and KL2TR001438. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. The authors have no other relevant disclosures. EDAT- 2022/06/20 06:00 MHDA- 2022/06/22 06:00 PMCR- 2023/07/01 CRDT- 2022/06/19 21:07 PHST- 2022/06/19 21:07 [entrez] PHST- 2022/06/20 06:00 [pubmed] PHST- 2022/06/22 06:00 [medline] PHST- 2023/07/01 00:00 [pmc-release] AID - S1551-7136(22)00015-0 [pii] AID - 10.1016/j.hfc.2022.02.014 [doi] PST - ppublish SO - Heart Fail Clin. 2022 Jul;18(3):503-514. doi: 10.1016/j.hfc.2022.02.014. PMID- 35716933 OWN - NLM STAT- MEDLINE DCOM- 20220809 LR - 20250728 IS - 1874-1754 (Electronic) IS - 0167-5273 (Linking) VI - 364 DP - 2022 Oct 1 TI - Predictors of antiplatelet cessation in a real-world patient population undergoing non-cardiac surgery after PCI. PG - 27-30 LID - S0167-5273(22)00921-4 [pii] LID - 10.1016/j.ijcard.2022.06.023 [doi] AB - BACKGROUND: The optimal perioperative management of antiplatelet therapy (APT) therapy in patients undergoing noncardiac surgery (NCS) following percutaneous coronary intervention (PCI) is unclear. We sought to identify predictors of APT cessation in a real-world cohort of patients undergoing NCS within 1 year of PCI. METHODS: Consecutive patients undergoing PCI at a tertiary center between 2011 and 2018 were prospectively enrolled. Perioperative interruption of APT was defined as cessation of either aspirin or P2Y(12) inhibitor between 1 and 14 days prior to NCS. Predictors of APT discontinuation were identified by multivariable Cox regression with stepwise selection of candidate variables. RESULTS: A total of 1092 surgeries corresponding to 747 patients were identified. Overall, there were 487 (44.6%) preoperative antiplatelet interruptions: discontinuation of either P2Y(12) inhibitors only (47.4%), aspirin only (7.9%), or both agents (44.7%). Both patient-specific risk factors (prior stroke, lower BMI, anemia, MI) and procedure specific risk factors (chronic total occlusions, multivessel disease, drug-eluting stent use) affected decisions regarding APT cessation. Likelihood of APT cessation increased in higher-risk surgeries and in patients on more potent P2Y(12) inhibitors (ticagrelor/prasugrel vs clopidogrel) whereas those undergoing NCS <90 days post PCI were less likely to have cessation of APT. CONCLUSION: In this contemporary cohort of post-PCI patients undergoing NCS, patient-, angiographic- and surgery-specific factors all affected decision-making regarding APT cessation. Our findings reflective of real-world practice, highlight the importance of a multidisciplinary team approach to individualize decision making in these patients. CI - Copyright (c) 2022 Elsevier B.V. All rights reserved. FAU - Koshy, Anoop N AU - Koshy AN AD - The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Cardiology and The University of Melbourne, Austin Health, Melbourne, Australia. FAU - Cao, Davide AU - Cao D AD - The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Cardiovascular Department, Humanitas Gavazzeni, Bergamo, Italy. FAU - Levin, Matthew A AU - Levin MA AD - Department of Anesthesiology, Perioperative and Pain Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Sartori, Samantha AU - Sartori S AD - The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Giustino, Gennaro AU - Giustino G AD - The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Kyaw, Htoo AU - Kyaw H AD - The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Claessen, Bimmer AU - Claessen B AD - The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Zhang, Zhongjie AU - Zhang Z AD - The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Nicolas, Johny AU - Nicolas J AD - The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Camaj, Anton AU - Camaj A AD - The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Roumeliotis, Anastasios AU - Roumeliotis A AD - The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Chandiramani, Rishi AU - Chandiramani R AD - The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Bedekar, Rashi AU - Bedekar R AD - The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Waseem, Zaha AU - Waseem Z AD - The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Bagga, Shiv AU - Bagga S AD - The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Kini, Annapoorna AU - Kini A AD - The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Sharma, Samin K AU - Sharma SK AD - The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Mehran, Roxana AU - Mehran R AD - The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Center for Interventional Cardiovascular Research and Clinical Trials, The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574, USA. Electronic address: roxana.mehran@mountsinai.org. LA - eng PT - Journal Article DEP - 20220615 PL - Netherlands TA - Int J Cardiol JT - International journal of cardiology JID - 8200291 RN - 0 (Platelet Aggregation Inhibitors) RN - G89JQ59I13 (Prasugrel Hydrochloride) RN - R16CO5Y76E (Aspirin) SB - IM MH - Aspirin/therapeutic use MH - *Drug-Eluting Stents MH - Humans MH - *Percutaneous Coronary Intervention/methods MH - Platelet Aggregation Inhibitors MH - Prasugrel Hydrochloride MH - Treatment Outcome OTO - NOTNLM OT - Antiplatelet therapy OT - Non-cardiac surgery OT - Percutaneous coronary intervention EDAT- 2022/06/19 06:00 MHDA- 2022/08/10 06:00 CRDT- 2022/06/18 19:36 PHST- 2022/03/26 00:00 [received] PHST- 2022/05/17 00:00 [revised] PHST- 2022/06/10 00:00 [accepted] PHST- 2022/06/19 06:00 [pubmed] PHST- 2022/08/10 06:00 [medline] PHST- 2022/06/18 19:36 [entrez] AID - S0167-5273(22)00921-4 [pii] AID - 10.1016/j.ijcard.2022.06.023 [doi] PST - ppublish SO - Int J Cardiol. 2022 Oct 1;364:27-30. doi: 10.1016/j.ijcard.2022.06.023. Epub 2022 Jun 15. PMID- 35714761 OWN - NLM STAT- MEDLINE DCOM- 20220809 LR - 20250728 IS - 1751-486X (Electronic) IS - 1751-4851 (Linking) VI - 26 IP - 4 DP - 2022 Aug TI - Early Recognition and Treatment for the Optimal Care of Individuals With Peripartum Cardiomyopathy. PG - 308-317 LID - S1751-4851(22)00130-1 [pii] LID - 10.1016/j.nwh.2022.05.004 [doi] AB - Peripartum cardiomyopathy (PPCM) is a life-threatening pregnancy-associated condition that often develops within the last month of pregnancy and up to 5 months postpartum. Although it is uncommon, the incidence in the United States is on the rise, especially among Black individuals. Early recognition and treatment are crucial for long-term health and the recovery of left ventricular ejection fraction. Most people with PPCM will recover with time, but a multidisciplinary team is needed to help with long-term treatment. Informed contraception counseling is also needed to minimize the incidence of subsequent pregnancy before recovery, which could worsen conditions. The purpose of this article is to review PPCM and discuss early recognition and management options, which may minimize complications and improve outcomes. CI - Copyright (c) 2022 AWHONN. Published by Elsevier Inc. All rights reserved. FAU - LeBlanc, Courtney A AU - LeBlanc CA FAU - Johnson, Kathryn AU - Johnson K LA - eng PT - Journal Article PT - Review DEP - 20220615 PL - United States TA - Nurs Womens Health JT - Nursing for women's health JID - 101304602 MH - *Cardiomyopathies/complications/diagnosis/therapy MH - Female MH - Humans MH - Peripartum Period MH - Pregnancy MH - *Pregnancy Complications, Cardiovascular/diagnosis/etiology/therapy MH - *Puerperal Disorders MH - Stroke Volume MH - Ventricular Function, Left OTO - NOTNLM OT - Black OT - cardiovascular OT - health equity OT - heart failure OT - left ventricular ejection fraction OT - peripartum cardiomyopathy OT - pregnancy EDAT- 2022/06/18 06:00 MHDA- 2022/08/10 06:00 CRDT- 2022/06/17 19:24 PHST- 2021/11/28 00:00 [received] PHST- 2022/02/08 00:00 [revised] PHST- 2022/05/18 00:00 [accepted] PHST- 2022/06/18 06:00 [pubmed] PHST- 2022/08/10 06:00 [medline] PHST- 2022/06/17 19:24 [entrez] AID - S1751-4851(22)00130-1 [pii] AID - 10.1016/j.nwh.2022.05.004 [doi] PST - ppublish SO - Nurs Womens Health. 2022 Aug;26(4):308-317. doi: 10.1016/j.nwh.2022.05.004. Epub 2022 Jun 15. PMID- 35710280 OWN - NLM STAT- MEDLINE DCOM- 20220620 LR - 20220824 IS - 2211-7466 (Electronic) IS - 2211-7458 (Linking) VI - 11 IP - 3 DP - 2022 Jul TI - Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy. PG - 245-255 LID - S2211-7458(22)00026-8 [pii] LID - 10.1016/j.iccl.2022.03.001 [doi] AB - Over the past several decades, alcohol septal ablation has become an established therapy for selected patients, in whom there is clinical improvement in symptoms as well as objective functional capacity. Patient selection is essential to success, with continued emphasis on the procedure being performed by experienced operators as part of a multidisciplinary team. In many patients, the outcomes of alcohol septal ablation are comparable to the standard of surgical myectomy. The optimization of the outcomes of alcohol septal ablation is essential for the longitudinal care of patients with hypertrophic cardiomyopathy. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Sorajja, Paul AU - Sorajja P AD - Center for Valve and Structural Heart Disease, Minneapolis Heart Institute at Abbott Northwestern Hospital, 920 East, 28th Street, Minneapolis, MN 55417, USA; Valve Science Center, Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, 800 East 28th Street, Minneapolis, MN 55401, USA; Hypertrophic Cardiomyopathy Center, Minneapolis Heart Institute Foundation, 920 East, 28th Street, Minneapolis, MN 55417, USA. Electronic address: paul.sorajja@allina.com. FAU - Fraser, Robert AU - Fraser R AD - Center for Valve and Structural Heart Disease, Minneapolis Heart Institute at Abbott Northwestern Hospital, 920 East, 28th Street, Minneapolis, MN 55417, USA; Hypertrophic Cardiomyopathy Center, Minneapolis Heart Institute Foundation, 920 East, 28th Street, Minneapolis, MN 55417, USA. FAU - Steffen, Robert AU - Steffen R AD - Center for Valve and Structural Heart Disease, Minneapolis Heart Institute at Abbott Northwestern Hospital, 920 East, 28th Street, Minneapolis, MN 55417, USA; Hypertrophic Cardiomyopathy Center, Minneapolis Heart Institute Foundation, 920 East, 28th Street, Minneapolis, MN 55417, USA. FAU - Harris, Kevin M AU - Harris KM AD - Center for Valve and Structural Heart Disease, Minneapolis Heart Institute at Abbott Northwestern Hospital, 920 East, 28th Street, Minneapolis, MN 55417, USA; Hypertrophic Cardiomyopathy Center, Minneapolis Heart Institute Foundation, 920 East, 28th Street, Minneapolis, MN 55417, USA. LA - eng PT - Journal Article PT - Review PL - Netherlands TA - Interv Cardiol Clin JT - Interventional cardiology clinics JID - 101615153 RN - 3K9958V90M (Ethanol) SB - IM MH - *Cardiac Surgical Procedures/methods MH - *Cardiomyopathy, Hypertrophic/diagnosis MH - Ethanol/therapeutic use MH - Heart Septum/surgery MH - Humans MH - Vascular Surgical Procedures OTO - NOTNLM OT - Alcohol septal ablation OT - Hypertrophic obstructive cardiomyopathy OT - Myomectomy OT - Percutaneous EDAT- 2022/06/17 06:00 MHDA- 2022/06/22 06:00 CRDT- 2022/06/16 21:10 PHST- 2022/06/16 21:10 [entrez] PHST- 2022/06/17 06:00 [pubmed] PHST- 2022/06/22 06:00 [medline] AID - S2211-7458(22)00026-8 [pii] AID - 10.1016/j.iccl.2022.03.001 [doi] PST - ppublish SO - Interv Cardiol Clin. 2022 Jul;11(3):245-255. doi: 10.1016/j.iccl.2022.03.001. PMID- 35710196 OWN - NLM STAT- MEDLINE DCOM- 20220620 LR - 20220727 IS - 1558-3597 (Electronic) IS - 0735-1097 (Linking) VI - 79 IP - 24 DP - 2022 Jun 21 TI - Inappropriate Sinus Tachycardia: Etiology, Pathophysiology, and Management: JACC Review Topic of the Week. PG - 2450-2462 LID - S0735-1097(22)04825-2 [pii] LID - 10.1016/j.jacc.2022.04.019 [doi] AB - Inappropriate sinus tachycardia (IST) is a clinical syndrome that generally affects young patients and is associated with distressing symptoms. Although the most common symptom is palpitations, it can be accompanied by a myriad of symptoms, including anxiety, dizziness, presyncope, and syncope. The pathogenesis of IST is not well understood and considered multifactorial, with autonomic dysfunction being the central abnormality. IST is a diagnosis of exclusion. Management presents a clinical challenge. The overall efficacy of lifestyle modifications and medical therapy may be limited. Recent advances in catheter and surgical sinus node sparing ablation techniques have led to improvement in outcomes. In addition, increased focus has led to development of multimodality team-based interventions to improve outcomes in this group of patients. In this review, we discuss the mechanistic basis of IST, review current approaches to diagnosis, and outline contemporary therapeutic approaches. CI - Copyright (c) 2022 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Ahmed, Adnan AU - Ahmed A AD - Kansas City Heart Rhythm Institute, Overland Park, Kansas, USA. FAU - Pothineni, Naga Venkata K AU - Pothineni NVK AD - Kansas City Heart Rhythm Institute, Overland Park, Kansas, USA. FAU - Charate, Rishi AU - Charate R AD - Kansas City Heart Rhythm Institute, Overland Park, Kansas, USA. FAU - Garg, Jalaj AU - Garg J AD - Loma Linda University Hospital, Heart Arrythmia and Electrophysiology, Loma Linda, California, USA. FAU - Elbey, Mehmet AU - Elbey M AD - Kansas City Heart Rhythm Institute, Overland Park, Kansas, USA. FAU - de Asmundis, Carlo AU - de Asmundis C AD - Heart Rhythm Management Centre, Postgraduate Program in Cardiac Electrophysiology and Pacing, Universitair Ziekenhuis Brussel-Vrije Universiteit Brussel, European Reference Networks Guard-Heart, Brussels, Belgium. FAU - LaMeir, Mark AU - LaMeir M AD - Heart Rhythm Management Centre, Postgraduate Program in Cardiac Electrophysiology and Pacing, Universitair Ziekenhuis Brussel-Vrije Universiteit Brussel, European Reference Networks Guard-Heart, Brussels, Belgium. FAU - Romeya, Ahmed AU - Romeya A AD - Kansas City Heart Rhythm Institute, Overland Park, Kansas, USA. FAU - Shivamurthy, Poojita AU - Shivamurthy P AD - Kansas City Heart Rhythm Institute, Overland Park, Kansas, USA. FAU - Olshansky, Brian AU - Olshansky B AD - The University of Iowa, Iowa City, Iowa, USA. FAU - Russo, Andrea AU - Russo A AD - Copper University Health Care, Camden, New Jersey, USA. FAU - Gopinathannair, Rakesh AU - Gopinathannair R AD - Kansas City Heart Rhythm Institute, Overland Park, Kansas, USA. FAU - Lakkireddy, Dhanunjaya AU - Lakkireddy D AD - Kansas City Heart Rhythm Institute, Overland Park, Kansas, USA. Electronic address: dlakkireddy@kchri.org. LA - eng PT - Journal Article PT - Review PL - United States TA - J Am Coll Cardiol JT - Journal of the American College of Cardiology JID - 8301365 SB - IM MH - *Catheter Ablation/methods MH - Heart Rate MH - Humans MH - Sinoatrial Node/surgery MH - Syndrome MH - *Tachycardia, Sinus/diagnosis/etiology/therapy OTO - NOTNLM OT - cardiac dysautonomia OT - inappropriate sinus tachycardia OT - sinus node modification COIS- Funding Support and Author Disclosures Dr Lakkireddy has been a consultant for Johnson & Johnson, Abbott, Biotronik, Pfizer, and Boston Scientific. Dr Gopinathannair has been a consultant/speaker for Abbott Medical, Boston Scientific, and Biosense Webster. Dr Olshansky has been a consultant for Sanofi; Chair of DSMB REDUCE IT-Amarin; and U.S. coordinator of GLORIA AF at Boehringer Ingelheim. Dr Russo has provided research support at Boston Scientific, Kestra, Medilynx, and Medtronic; has been a consultant for Abbott, Atricure, Biosense Webster, Boston Scientific, Medtronic, and PaceMate; has received honoraria from Biotronik, Bristol Myers Squibb/Pfizer, and Medtronic; and has received royalties from Up-to-Date. Dr LaMeier has been a consultant at Atricure. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2022/06/17 06:00 MHDA- 2022/06/22 06:00 CRDT- 2022/06/16 21:05 PHST- 2022/02/03 00:00 [received] PHST- 2022/03/31 00:00 [revised] PHST- 2022/04/01 00:00 [accepted] PHST- 2022/06/16 21:05 [entrez] PHST- 2022/06/17 06:00 [pubmed] PHST- 2022/06/22 06:00 [medline] AID - S0735-1097(22)04825-2 [pii] AID - 10.1016/j.jacc.2022.04.019 [doi] PST - ppublish SO - J Am Coll Cardiol. 2022 Jun 21;79(24):2450-2462. doi: 10.1016/j.jacc.2022.04.019. PMID- 35709974 OWN - NLM STAT- MEDLINE DCOM- 20220908 LR - 20250728 IS - 2213-3763 (Electronic) IS - 0019-4832 (Print) IS - 0019-4832 (Linking) VI - 74 IP - 4 DP - 2022 Jul-Aug TI - Outcomes with heart failure management in a multidisciplinary clinic - A randomized controlled trial. PG - 327-331 LID - S0019-4832(22)00101-8 [pii] LID - 10.1016/j.ihj.2022.06.005 [doi] FAU - Pant, Bhagwati Prasad AU - Pant BP AD - Department of Cardiology, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, India. Electronic address: drbhagwatipant@gmail.com. FAU - Satheesh, Santhosh AU - Satheesh S AD - Department of Cardiology, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, India. FAU - Pillai, Ajith Ananthakrishna AU - Pillai AA AD - Department of Cardiology, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, India. FAU - Anantharaj, Avinash AU - Anantharaj A AD - Department of Cardiology, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, India. FAU - Ramamoorthy, Lakshmi AU - Ramamoorthy L AD - Department of Nursing, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, India. FAU - Selvaraj, Raja AU - Selvaraj R AD - Department of Cardiology, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, India. LA - eng PT - Journal Article PT - Randomized Controlled Trial DEP - 20220614 PL - India TA - Indian Heart J JT - Indian heart journal JID - 0374675 SB - IM MH - Ambulatory Care Facilities MH - *Heart Failure/therapy MH - Humans PMC - PMC9453057 COIS- Declaration of competing interest None. EDAT- 2022/06/17 06:00 MHDA- 2022/09/09 06:00 PMCR- 2022/07/01 CRDT- 2022/06/16 19:32 PHST- 2022/01/23 00:00 [received] PHST- 2022/04/30 00:00 [revised] PHST- 2022/06/10 00:00 [accepted] PHST- 2022/06/17 06:00 [pubmed] PHST- 2022/09/09 06:00 [medline] PHST- 2022/06/16 19:32 [entrez] PHST- 2022/07/01 00:00 [pmc-release] AID - S0019-4832(22)00101-8 [pii] AID - 10.1016/j.ihj.2022.06.005 [doi] PST - ppublish SO - Indian Heart J. 2022 Jul-Aug;74(4):327-331. doi: 10.1016/j.ihj.2022.06.005. Epub 2022 Jun 14. PMID- 35709725 OWN - NLM STAT- MEDLINE DCOM- 20240514 LR - 20250722 IS - 1098-8785 (Electronic) IS - 0735-1631 (Print) IS - 0735-1631 (Linking) VI - 41 IP - S 01 DP - 2024 May TI - Infective Endocarditis in Pregnancy: A Contemporary Cohort. PG - e230-e235 LID - 10.1055/a-1877-5763 [doi] AB - OBJECTIVE: Pregnancy-related infective endocarditis (IE) caries a high risk of morbidity and mortality. With increasing intravenous drug abuse (IVDA) amid the opioid epidemic, the risk factor profile may be shifting. In this case series, we aimed to describe risk factors and outcomes for peripartum IE in a contemporary cohort. STUDY DESIGN: We identified patients with IE diagnosed during pregnancy or up to 6 weeks' postpartum from 2015 through 2018 at a single tertiary care center. We abstracted detailed medical history and clinical outcome measures from the electronic medical record. The diagnosis of IE was supported by the modified Duke Criteria. RESULTS: Nine patients had peripartum IE: eight (89%) with a history of IVDA, one with an indwelling central venous catheter (11%), and one with prior IE (11%). None had preexisting congenital or valvular heart disease. Six (67%) had comorbid hepatitis C. Eight cases (89%) had gram-positive cocci with vegetations involving the tricuspid valve (56%) and both mitral and tricuspid valves (22%). Major complications included shock (33%), mechanical ventilation (44%), septic emboli (67%), and noncardiac abscesses (33%). Two patients underwent valve surgery, and there were two cases of postpartum maternal mortality (22%), one from septic shock and one from intracerebral hemorrhage. While four patients (44%) delivered preterm (average gestational age 35 weeks), most delivered vaginally (89%) with only one requiring an emergent caesarean section. There was no fetal mortality, although three newborns (43%) required admission to the neonatal intensive care unit. Two patients were initiated on medication-assisted treatment for opioid use disorder. Consultants included infectious disease, cardiology, cardiac surgery, maternal-fetal medicine, and psychiatry. CONCLUSION: These findings confirm that IVDA is a growing risk factor for pregnancy-related IE. Peripartum IE carries a high risk of complications, including maternal mortality, and warrants management with a multidisciplinary care team at a tertiary center. KEY POINTS: . Intravenous drug use was the most common risk factor for IE in pregnancy.. . IE in pregnancy carries a high morbidity and mortality with complications including septic emboli, septic shock, and need for mechanical ventilation.. . A multidisciplinary team approach can assure the best possible maternal and fetal outcomes.. CI - Thieme. All rights reserved. FAU - Countouris, Malamo E AU - Countouris ME AUID- ORCID: 0000-0003-2535-0309 AD - University of Pittsburgh Medical Center, Heart and Vascular Institute, University of Pittsburgh, Pittsburgh, Pennsylvania. FAU - Marino, Amy L AU - Marino AL AD - University of Pittsburgh Medical Center, Heart and Vascular Institute, University of Pittsburgh, Pittsburgh, Pennsylvania. FAU - Raymond, Megan AU - Raymond M AD - Department of Obstetrics and Gynecology, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania. FAU - Hauspurg, Alisse AU - Hauspurg A AD - Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, University of Pittsburgh Medical Center University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. FAU - Berlacher, Kathryn L AU - Berlacher KL AD - University of Pittsburgh Medical Center, Heart and Vascular Institute, University of Pittsburgh, Pittsburgh, Pennsylvania. LA - eng GR - K12 HD043441/HD/NICHD NIH HHS/United States GR - K23 HL168356/HL/NHLBI NIH HHS/United States PT - Journal Article DEP - 20220616 PL - United States TA - Am J Perinatol JT - American journal of perinatology JID - 8405212 SB - IM MH - Humans MH - Female MH - Pregnancy MH - Adult MH - *Pregnancy Complications, Infectious/epidemiology MH - Risk Factors MH - Substance Abuse, Intravenous/complications MH - Endocarditis/epidemiology MH - Retrospective Studies MH - Cohort Studies MH - Young Adult MH - Infant, Newborn PMC - PMC9943787 MID - NIHMS1866390 COIS- None declared. EDAT- 2022/06/17 06:00 MHDA- 2024/05/15 05:44 PMCR- 2025/05/01 CRDT- 2022/06/16 18:42 PHST- 2024/05/15 05:44 [medline] PHST- 2022/06/17 06:00 [pubmed] PHST- 2022/06/16 18:42 [entrez] PHST- 2025/05/01 00:00 [pmc-release] AID - 10.1055/a-1877-5763 [doi] PST - ppublish SO - Am J Perinatol. 2024 May;41(S 01):e230-e235. doi: 10.1055/a-1877-5763. Epub 2022 Jun 16. PMID- 35703196 OWN - NLM STAT- MEDLINE DCOM- 20220824 LR - 20250728 IS - 1536-3708 (Electronic) IS - 0148-7043 (Linking) VI - 89 IP - 3 DP - 2022 Sep 1 TI - Breast Implant-Related Outcomes After Cardiothoracic Surgeries and Electrophysiologic Procedures. PG - 267-273 LID - 10.1097/SAP.0000000000003213 [doi] AB - BACKGROUND: Outcomes related to preexisting breast implants after cardiothoracic procedures are poorly characterized. This study evaluated complications after minimally invasive cardiac surgery (MICS), median sternotomy (MS), and electrophysiologic procedures (EP) in patients with preexisting breast implants. METHODS: A retrospective review of patients with prior breast implants who underwent MICS, MS, or EP from 1994 to 2019 was performed. Demographic, treatment, and outcome characteristics were recorded. chi 2 Test and analysis of variance were used to perform statistical comparisons. RESULTS: In total, 78 patients (37 MICS, 21 MS, and 20 EP) were identified. Mean breast implant age was 13.3, 11.7, and 10.2 years, respectively ( P = 0.235). Intraoperative plastic surgeon involvement was present in 26 (70.3%) MICS cases, compared with 2 (9.5%) MS and 0% EP ( P < 0.001). Intraoperative rupture occurred in 5 (13.5%) MICS cases and no MS or EP cases ( P < 0.001). Postoperative implant complications occurred in 6 (16.2%) MICS, 8 (38.1%) MS, and 5 (25.0%) EP ( P = 0.350) cases, with median time to complication of 5.9, 5.4, and 38.9 months, respectively ( P = 0.596). Revision surgery was performed in 5 (13.5%) MICS, 7 (33.3%) MS, and 5 (25.0%) EP ( P = 0.246) cases. On multivariate analysis, lack of intraoperative plastic surgeon involvement ( P = 0.034) and breast implant age ( P = 0.001) were significant predictors of postoperative complications. CONCLUSIONS: Long-term complication rates are highest among patients with breast implants undergoing MS. Plastic surgeon involvement was significantly associated with fewer postoperative complications. Our results support a multidisciplinary approach to managing breast implants during cardiothoracic procedures. CI - Copyright (c) 2022 Wolters Kluwer Health, Inc. All rights reserved. FAU - Coombs, Demetrius M AU - Coombs DM AD - From the Department of Plastic Surgery, The Cleveland Clinic. FAU - Wu, Shannon S AU - Wu SS FAU - Bernard, Steven AU - Bernard S AD - From the Department of Plastic Surgery, The Cleveland Clinic. FAU - Djohan, Risal AU - Djohan R AD - From the Department of Plastic Surgery, The Cleveland Clinic. FAU - Isakov, Raymond AU - Isakov R AD - From the Department of Plastic Surgery, The Cleveland Clinic. FAU - Schwarz, Graham AU - Schwarz G AD - From the Department of Plastic Surgery, The Cleveland Clinic. FAU - Bassiri Gharb, Bahar AU - Bassiri Gharb B AD - From the Department of Plastic Surgery, The Cleveland Clinic. FAU - Rampazzo, Antonio AU - Rampazzo A AD - From the Department of Plastic Surgery, The Cleveland Clinic. LA - eng PT - Journal Article DEP - 20220528 PL - United States TA - Ann Plast Surg JT - Annals of plastic surgery JID - 7805336 SB - IM MH - *Breast Implantation/methods MH - *Breast Implants/adverse effects MH - Humans MH - Minimally Invasive Surgical Procedures/methods MH - Postoperative Complications/epidemiology/etiology/surgery MH - Retrospective Studies MH - Treatment Outcome COIS- Conflicts of interest and sources of funding: none declared. EDAT- 2022/06/16 06:00 MHDA- 2022/08/25 06:00 CRDT- 2022/06/15 06:13 PHST- 2022/06/16 06:00 [pubmed] PHST- 2022/08/25 06:00 [medline] PHST- 2022/06/15 06:13 [entrez] AID - 00000637-202209000-00006 [pii] AID - 10.1097/SAP.0000000000003213 [doi] PST - ppublish SO - Ann Plast Surg. 2022 Sep 1;89(3):267-273. doi: 10.1097/SAP.0000000000003213. Epub 2022 May 28. PMID- 35696046 OWN - NLM STAT- MEDLINE DCOM- 20220719 LR - 20250728 IS - 1534-3170 (Electronic) IS - 1523-3782 (Print) IS - 1523-3782 (Linking) VI - 24 IP - 7 DP - 2022 Jul TI - Alternative Nuclear Imaging Tools for Infection Imaging. PG - 879-891 LID - 10.1007/s11886-022-01708-2 [doi] AB - PURPOSE OF REVIEW: Cardiovascular infections are serious disease associated with high morbidity and mortality. Their diagnosis is challenging, requiring a proper management for a prompt recognition of the clinical manifestations, and a multidisciplinary approach involving cardiologists, cardiothoracic surgeons, infectious diseases specialist, imagers, and microbiologists. Imaging plays a central role in the diagnostic workout, including molecular imaging techniques. In this setting, two different strategies might be used to image infections: the first is based on the use of agents targeting the microorganism responsible for the infection. Alternatively, we can target the components of the pathophysiological changes of the inflammatory process and/or the host response to the infectious pathogen can be considered. Understanding the strength and limitations of each strategy is crucial to select the most appropriate imaging tool. RECENT FINDINGS: Currently, multislice computed tomography (MSCT) and nuclear imaging ((18)F-fluorodeoxyglucose positron emission tomography/computed tomography, and leucocyte scintigraphy) are part of the diagnostic strategies. The main role of nuclear medicine imaging (PET/CT and SPECT/CT) is the confirmation of valve/CIED involvement and/or associated perivalvular infection and the detection of distant septic embolism. Proper patients' preparation, imaging acquisition, and reconstruction as well as imaging reading are crucial to maximize the diagnostic information. In this manuscript, we described the use of molecular imaging techniques, in particular WBC imaging, in patients with infective endocarditis, cardiovascular implantable electronic device infections, and infections of composite aortic graft, underlying the strength and limitations of such approached as compared to the other imaging modalities. CI - (c) 2022. The Author(s). FAU - Erba, Paola Anna AU - Erba PA AUID- ORCID: 0000-0003-0058-7377 AD - Regional Center of Nuclear Medicine, Department of Translational Research and Advanced Technologies in Medicine and Surgery, University of Pisa, Via Roma 57, 56126, Pisa, Italy. paola.erba@unipi.it. AD - Medical Imaging Center, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. paola.erba@unipi.it. FAU - Bartoli, Francesco AU - Bartoli F AD - Regional Center of Nuclear Medicine, Department of Translational Research and Advanced Technologies in Medicine and Surgery, University of Pisa, Via Roma 57, 56126, Pisa, Italy. FAU - Sollini, Martina AU - Sollini M AD - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy. AD - IRCCS Humanitas Research Hospital, Rozzano, Italy. FAU - Raffaella, Berchiolli AU - Raffaella B AD - Vascular Surgery Unit, Department of Translational Research and Advanced Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy. FAU - Zanca, Roberta AU - Zanca R AD - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy. AD - IRCCS Humanitas Research Hospital, Rozzano, Italy. FAU - Enrica, Esposito AU - Enrica E AD - Regional Center of Nuclear Medicine, Department of Translational Research and Advanced Technologies in Medicine and Surgery, University of Pisa, Via Roma 57, 56126, Pisa, Italy. FAU - Lazzeri, Elena AU - Lazzeri E AD - Regional Center of Nuclear Medicine, Department of Translational Research and Advanced Technologies in Medicine and Surgery, University of Pisa, Via Roma 57, 56126, Pisa, Italy. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20220613 PL - United States TA - Curr Cardiol Rep JT - Current cardiology reports JID - 100888969 RN - 0 (Radiopharmaceuticals) RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18) SB - IM MH - *Endocarditis/diagnostic imaging MH - Fluorodeoxyglucose F18 MH - Humans MH - Positron Emission Tomography Computed Tomography/methods MH - *Prosthesis-Related Infections/diagnostic imaging MH - Radiopharmaceuticals PMC - PMC9288362 OTO - NOTNLM OT - CIED infections OT - CVS infections OT - Infective endocarditis OT - SPECT/CT embolic burden OT - WBC scan COIS- Dr. Bartoli reports grants, personal fees, and non-financial support from gammaservizi, and grants from Philogen SpA, outside the submitted work. Dr. Lazzeri reports personal fees from Springer, outside the submitted work. Dr. Erba reports grants and non-financial support from gammaservizi, personal fees from GE Healthcare, grants and personal fees from Philogen SpA, other from AAA, and personal fees from Springer, outside the submitted work. The other authors declare that they have no conflict of interest. EDAT- 2022/06/14 06:00 MHDA- 2022/07/20 06:00 PMCR- 2022/06/13 CRDT- 2022/06/13 11:22 PHST- 2022/04/21 00:00 [accepted] PHST- 2022/06/14 06:00 [pubmed] PHST- 2022/07/20 06:00 [medline] PHST- 2022/06/13 11:22 [entrez] PHST- 2022/06/13 00:00 [pmc-release] AID - 10.1007/s11886-022-01708-2 [pii] AID - 1708 [pii] AID - 10.1007/s11886-022-01708-2 [doi] PST - ppublish SO - Curr Cardiol Rep. 2022 Jul;24(7):879-891. doi: 10.1007/s11886-022-01708-2. Epub 2022 Jun 13. PMID- 35695792 OWN - NLM STAT- MEDLINE DCOM- 20220823 LR - 20250728 IS - 1540-8167 (Electronic) IS - 1045-3873 (Print) IS - 1045-3873 (Linking) VI - 33 IP - 8 DP - 2022 Aug TI - Staged hybrid totally thoracoscopic maze and catheter ablation for atrial fibrillation. PG - 1961-1965 LID - 10.1111/jce.15594 [doi] AB - INTRODUCTION: Atrial fibrillation (AF) is a growing health problem and is associated with increased risk of stroke. The Cox-Maze surgical procedure has offered the highest success rate, but utilization of this technique is low due to procedure invasiveness and complexity. Advances in catheter ablation and minimally invasive surgical techniques offer new options for AF treatment. METHODS: In this review, we describe current trends and outcomes of minimally invasive treatment of persistent and long-standing persistent AF. RESULTS: Treatment of persistent and long-standing persistent AF can be successfully treated using a team approach combining cardiac surgery and electrophysiology procedures. With this approach, the 1-year freedom from AF off antiarrhythmic drugs was 85%. DISCUSSION: There are a variety of techniques and approaches used around the world as technology evolves to help develop new treatment strategies for AF. Our report will focus on a hybrid treatment approach using surgical and electrophysiology approaches providing enhanced treatment options by replicating Cox-Maze IV lesions using skills from each specialty. Closure of the left atrial appendage as part of these procedures enhances protection from late stroke. A team approach provides a cohesive evaluation, treatment, and monitoring plan for patients. Development of successful, less invasive treatment options will help address the growing population of patients with AF. CI - (c) 2022 The Authors. Journal of Cardiovascular Electrophysiology published by Wiley Periodicals LLC. FAU - Churyla, Andrei AU - Churyla A AUID- ORCID: 0000-0003-1439-6010 AD - Department of Surgery, Division of Cardiac Surgery, Northwestern Medicine, Northwestern University, Chicago, Illinois, USA. FAU - Passman, Rod AU - Passman R AD - Department of Medicine, Division of Cardiology, Northwestern Medicine, Northwestern University, Chicago, Illinois, USA. FAU - McCarthy, Patrick M AU - McCarthy PM AD - Department of Surgery, Division of Cardiac Surgery, Northwestern Medicine, Northwestern University, Chicago, Illinois, USA. FAU - Kislitsina, Olga N AU - Kislitsina ON AD - Department of Medicine, Division of Cardiology, Northwestern Medicine, Northwestern University, Chicago, Illinois, USA. FAU - Kruse, Jane AU - Kruse J AUID- ORCID: 0000-0002-8833-9847 AD - Department of Surgery, Division of Cardiac Surgery, Northwestern Medicine, Northwestern University, Chicago, Illinois, USA. FAU - Cox, James L AU - Cox JL AD - Department of Surgery, Division of Cardiac Surgery, Northwestern Medicine, Northwestern University, Chicago, Illinois, USA. LA - eng PT - Journal Article PT - Review DEP - 20220624 PL - United States TA - J Cardiovasc Electrophysiol JT - Journal of cardiovascular electrophysiology JID - 9010756 SB - IM MH - *Atrial Fibrillation/diagnosis/etiology/surgery MH - *Catheter Ablation/adverse effects/methods MH - Humans MH - *Stroke/etiology/prevention & control MH - Thoracoscopy/adverse effects/methods MH - Treatment Outcome PMC - PMC9544946 OTO - NOTNLM OT - atrial fibrillation OT - catheter ablation OT - thoracoscopic hybrid maze procedure EDAT- 2022/06/14 06:00 MHDA- 2022/08/24 06:00 PMCR- 2022/10/07 CRDT- 2022/06/13 10:22 PHST- 2022/05/31 00:00 [revised] PHST- 2022/03/08 00:00 [received] PHST- 2022/06/01 00:00 [accepted] PHST- 2022/06/14 06:00 [pubmed] PHST- 2022/08/24 06:00 [medline] PHST- 2022/06/13 10:22 [entrez] PHST- 2022/10/07 00:00 [pmc-release] AID - JCE15594 [pii] AID - 10.1111/jce.15594 [doi] PST - ppublish SO - J Cardiovasc Electrophysiol. 2022 Aug;33(8):1961-1965. doi: 10.1111/jce.15594. Epub 2022 Jun 24. PMID- 35695718 OWN - NLM STAT- MEDLINE DCOM- 20220803 LR - 20250728 IS - 1540-8191 (Electronic) IS - 0886-0440 (Linking) VI - 37 IP - 9 DP - 2022 Sep TI - The management of paravalvular leaks post aortic valve replacement. PG - 2786-2798 LID - 10.1111/jocs.16672 [doi] AB - BACKGROUND: Paravalvular leak (PVL) is uncommon but can lead to severe complications after surgical or transcatheter aortic valve implantation. Conditions associated with PVLs such as heart failure, hemolysis, and infective endocarditis can lead to catastrophic results if not treated promptly; the therapeutic goals differ according to the presentation. It is vital that PVLs are diagnosed early using various imaging modalities. Different approaches have been studied in managing PVLs; there is an increased interest in the transcatheter aortic valve closure procedure as it is minimally invasive and decreases the occurrence of further reinterventions. AIM: To discuss the classification of PVLs, diagnostic approaches, and available management options. METHOD: A literature review was performed using 28 studies. RESULTS: This review evaluated the relationship between the time of diagnosis, management of PVL and the resulting outcomes. DISCUSSION: Patients with PVL should be assessed through a multidisciplinary team approach and a patient-selective plan should be in place. CONCLUSION: Open surgical intervention is reserved for complex cases where minimally invasive techniques cannot be utilized. CI - (c) 2022 Wiley Periodicals LLC. FAU - Kananathan, Shalini AU - Kananathan S AUID- ORCID: 0000-0003-4394-0708 AD - Dnipro Medical Institute of Traditional and Non-Traditional Medicine, Dnipro, Ukraine. FAU - Perera, Lakshini Anuruddika AU - Perera LA AUID- ORCID: 0000-0002-6937-1067 AD - Dnipro Medical Institute of Traditional and Non-Traditional Medicine, Dnipro, Ukraine. FAU - Mohanarajan, Maneeshaa AU - Mohanarajan M AUID- ORCID: 0000-0002-7019-9305 AD - Dnipro Medical Institute of Traditional and Non-Traditional Medicine, Dnipro, Ukraine. FAU - Sherif, Mohamed AU - Sherif M AUID- ORCID: 0000-0001-5544-3528 AD - Department of Cardiothoracic Surgery, Northern General Hospital, Sheffield, UK. FAU - Harky, Amer AU - Harky A AUID- ORCID: 0000-0001-5507-5841 AD - Department of Cardiothoracic Surgery, Liverpool Heart and Chest Hospital, Liverpool, UK. LA - eng PT - Journal Article PT - Review DEP - 20220613 PL - United States TA - J Card Surg JT - Journal of cardiac surgery JID - 8908809 SB - IM CIN - J Card Surg. 2022 Sep;37(9):2607-2609. doi: 10.1111/jocs.16671. PMID: 35661261 MH - Aortic Valve/surgery MH - *Aortic Valve Insufficiency/surgery MH - *Heart Valve Prosthesis/adverse effects MH - *Heart Valve Prosthesis Implantation/adverse effects/methods MH - Humans MH - *Transcatheter Aortic Valve Replacement/adverse effects MH - Treatment Outcome OTO - NOTNLM OT - TAVR OT - aortic valve replacement OT - paravalvular leak EDAT- 2022/06/14 06:00 MHDA- 2022/08/04 06:00 CRDT- 2022/06/13 09:52 PHST- 2022/04/04 00:00 [revised] PHST- 2021/08/05 00:00 [received] PHST- 2022/04/08 00:00 [accepted] PHST- 2022/06/14 06:00 [pubmed] PHST- 2022/08/04 06:00 [medline] PHST- 2022/06/13 09:52 [entrez] AID - 10.1111/jocs.16672 [doi] PST - ppublish SO - J Card Surg. 2022 Sep;37(9):2786-2798. doi: 10.1111/jocs.16672. Epub 2022 Jun 13. PMID- 35695701 OWN - NLM STAT- MEDLINE DCOM- 20230119 LR - 20230223 IS - 1945-7189 (Electronic) IS - 0163-769X (Linking) VI - 44 IP - 1 DP - 2023 Jan 12 TI - The Changing Face of Turner Syndrome. PG - 33-69 LID - 10.1210/endrev/bnac016 [doi] AB - Turner syndrome (TS) is a condition in females missing the second sex chromosome (45,X) or parts thereof. It is considered a rare genetic condition and is associated with a wide range of clinical stigmata, such as short stature, ovarian dysgenesis, delayed puberty and infertility, congenital malformations, endocrine disorders, including a range of autoimmune conditions and type 2 diabetes, and neurocognitive deficits. Morbidity and mortality are clearly increased compared with the general population and the average age at diagnosis is quite delayed. During recent years it has become clear that a multidisciplinary approach is necessary toward the patient with TS. A number of clinical advances has been implemented, and these are reviewed. Our understanding of the genomic architecture of TS is advancing rapidly, and these latest developments are reviewed and discussed. Several candidate genes, genomic pathways and mechanisms, including an altered transcriptome and epigenome, are also presented. CI - (c) The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. FAU - Gravholt, Claus H AU - Gravholt CH AUID- ORCID: 0000-0001-5924-1720 AD - Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus 8200 N, Denmark. AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus 8200 N, Denmark. FAU - Viuff, Mette AU - Viuff M AUID- ORCID: 0000-0001-6574-4893 AD - Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus 8200 N, Denmark. AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus 8200 N, Denmark. FAU - Just, Jesper AU - Just J AUID- ORCID: 0000-0002-3825-0000 AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus 8200 N, Denmark. FAU - Sandahl, Kristian AU - Sandahl K AUID- ORCID: 0000-0002-0071-3575 AD - Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus 8200 N, Denmark. FAU - Brun, Sara AU - Brun S AUID- ORCID: 0000-0002-3708-2949 AD - Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus 8200 N, Denmark. FAU - van der Velden, Janielle AU - van der Velden J AUID- ORCID: 0000-0001-9421-9289 AD - Department of Pediatrics, Radboud University Medical Centre, Amalia Children's Hospital, 6525 Nijmegen, the Netherlands. FAU - Andersen, Niels H AU - Andersen NH AUID- ORCID: 0000-0002-5394-3016 AD - Department of Cardiology, Aalborg University Hospital, Aalborg 9000, Denmark. FAU - Skakkebaek, Anne AU - Skakkebaek A AUID- ORCID: 0000-0001-9178-4901 AD - Department of Molecular Medicine, Aarhus University Hospital, Aarhus 8200 N, Denmark. AD - Department of Clinical Genetics, Aarhus University Hospital, Aarhus 8200 N, Denmark. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review PL - United States TA - Endocr Rev JT - Endocrine reviews JID - 8006258 SB - IM MH - Female MH - Humans MH - *Diabetes Mellitus, Type 2/complications MH - *Endocrine System Diseases MH - *Infertility MH - *Turner Syndrome/diagnosis/genetics/complications OTO - NOTNLM OT - congenital heart malformations OT - epidemiology OT - estradiol OT - genomics OT - hormone replacement therapy OT - hypergonadotropic hypogonadism OT - infertility OT - quality of life EDAT- 2022/06/14 06:00 MHDA- 2023/01/14 06:00 CRDT- 2022/06/13 09:43 PHST- 2021/07/02 00:00 [received] PHST- 2022/06/14 06:00 [pubmed] PHST- 2023/01/14 06:00 [medline] PHST- 2022/06/13 09:43 [entrez] AID - 6607573 [pii] AID - 10.1210/endrev/bnac016 [doi] PST - ppublish SO - Endocr Rev. 2023 Jan 12;44(1):33-69. doi: 10.1210/endrev/bnac016. PMID- 35694661 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220716 IS - 2297-055X (Print) IS - 2297-055X (Electronic) IS - 2297-055X (Linking) VI - 9 DP - 2022 TI - Alcohol Septal Ablation or Septal Myectomy? An Updated Systematic Review and Meta-Analysis of Septal Reduction Therapy for Hypertrophic Obstructive Cardiomyopathy. PG - 900469 LID - 10.3389/fcvm.2022.900469 [doi] LID - 900469 AB - OBJECTIVE: To evaluate the safety and effectiveness of alcohol septal ablation (ASA) and septal myectomy (SM) for the treatment of hypertrophic obstructive cardiomyopathy. METHODS: We searched the PubMed, MEDLINE, EMBASE, and CBM databases for observational research articles related to ASA and SM published from the establishment of the databases to November 2021. All ultimate selected articles were highly related to our target. The Newcastle-Ottawa Scale was used to evaluate the literature quality. A fixed or random effect model was performed in the meta-analysis depending on the heterogeneity of the included studies. The Mantel-Haenszelt test with relative risk ratio (RR) and 95% confidence interval (CI) was used to measure the effect indicator of binary data, while the inverse variance method with weighted mean difference (WMD) and 95% CI was used to measure the effect indicator of continuous data. RESULTS: A totally of 3,647 cases (1,555 cases treated with ASA and 2,092 cases treated with SM) were included. The results of the systematic review indicated no statistically significant difference in postoperative all-cause mortality (RR = 0.82; 95% CI: 0.65-1.04; P = 0.10) between patients treated with ASA and SM, but both the reduction in the postoperative left ventricular outflow tract pressure gradient (WMD = 9.35 mmHg, 95% CI: 5.38-13.31, P < 0.00001) and the post-operative improvement on cardiac function, assessed by the grade of New York Heart Association (NYHA), compared to pre-operative measurements (WMD = 0.13; 95% CI: 0.00-0.26; P < 0.04) in the ASA group were slightly inferior to those in the SM group. In addition, both the risk of pacemaker implantation (RR = 2.83, 95% CI: 2.06-3.88; P < 0.00001) and the risk of reoperation (RR = 11.23, 95% CI: 6.21-20.31; P < 0.00001) are recorded at a higher level after ASA procedure. CONCLUSION: Both ASA and SM have a high degree of safety, but the reduction in the postoperative left ventricular outflow tract pressure gradient and the improvement on cardiac function are slightly inferior to SM. In addition, both the risk of pacemaker implantation and the risk of reoperation are recorded at a higher level after ASA procedure. The operative plan should be chosen through multidisciplinary discussions in combination with the wishes of the patients and the actual clinical situation. CI - Copyright (c) 2022 Zheng, Yang, Hui, Lu and Feng. FAU - Zheng, Xifeng AU - Zheng X AD - Department of Geriatrics, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China. FAU - Yang, Bin AU - Yang B AD - Department of Geriatrics, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China. FAU - Hui, Haosheng AU - Hui H AD - Department of Cardiology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China. FAU - Lu, Bing AU - Lu B AD - Department of Geriatrics, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China. FAU - Feng, Yinhui AU - Feng Y AD - Department of Nuclear Medicine, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China. LA - eng PT - Journal Article PT - Systematic Review DEP - 20220525 PL - Switzerland TA - Front Cardiovasc Med JT - Frontiers in cardiovascular medicine JID - 101653388 PMC - PMC9178179 OTO - NOTNLM OT - alcohol septal ablation OT - hypertrophic obstructive cardiomyopathy OT - meta-analysis OT - septal myectomy OT - systematic review COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/06/14 06:00 MHDA- 2022/06/14 06:01 PMCR- 2022/01/01 CRDT- 2022/06/13 03:35 PHST- 2022/03/20 00:00 [received] PHST- 2022/04/11 00:00 [accepted] PHST- 2022/06/13 03:35 [entrez] PHST- 2022/06/14 06:00 [pubmed] PHST- 2022/06/14 06:01 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.3389/fcvm.2022.900469 [doi] PST - epublish SO - Front Cardiovasc Med. 2022 May 25;9:900469. doi: 10.3389/fcvm.2022.900469. eCollection 2022. PMID- 35691294 OWN - NLM STAT- MEDLINE DCOM- 20240515 LR - 20240729 IS - 1098-8785 (Electronic) IS - 0735-1631 (Linking) VI - 41 IP - S 01 DP - 2024 May TI - Implementation of a Bedside Point-of-Care Ultrasound Program in a Large Academic Neonatal Intensive Care Unit. PG - e76-e84 LID - 10.1055/s-0042-1750118 [doi] AB - OBJECTIVES: In the adult and pediatric critical care population, point-of-care ultrasound (POCUS) can aid in diagnosis, patient management, and procedural accuracy. For neonatal providers, training in ultrasound and the use of ultrasound for diagnosis and management is increasing, but use in the neonatal intensive care unit (NICU) is still uncommon compared with other critical care fields. Our objective was to describe the process of implementing a POCUS program in a large academic NICU and evaluate the role of ultrasound in neonatal care during early adaption of this program. STUDY DESIGN: A POCUS program established in December 2018 included regular bedside scanning, educational sessions, and quality assurance, in collaboration with members of the cardiology, radiology, and pediatric critical care divisions. Core applications were determined, and protocols outlined guidelines for image acquisition. An online database included images and descriptive logs for each ultrasound. RESULTS: A total of 508 bedside ultrasounds (76.8% diagnostic and 23.2% procedural) were performed by 23 providers from December 2018 to December 2020 in five core diagnostic applications: umbilical line visualization, cardiac, lung, abdomen (including bladder), and cranial as well as procedural applications. POCUS guided therapy and influenced clinical management in all applications: umbilical line assessment (26%), cardiac (33%), lung (14%), abdomen (53%), and cranial (43%). With regard to procedural ultrasound, 74% of ultrasound-guided arterial access and 89% of ultrasound-guided lumbar punctures were successful. CONCLUSIONS: Implementation of a POCUS program is feasible in a large academic NICU and can benefit from a team approach. Establishing a program in any NICU requires didactic opportunities, a defined scope of practice, and imaging review with quality assurance. Bedside clinician performed ultrasound findings can provide valuable information in the NICU and impact clinical management. KEY POINTS: . Use of point-of-care ultrasound is increasing in neonatology and has been shown to improve patient care.. . Implementation of a point-of-care ultrasound program requires the definition of scope of practice and can benefit from the support of other critical care and imaging departments and providers.. . Opportunities for point-of-care ultrasound didactics, imaging review, and quality assurance can enhance the utilization of bedside ultrasound.. CI - Thieme. All rights reserved. FAU - Pai, Vidya V AU - Pai VV AD - Division of Neonatology, UCSF Benioff Children's Hospital Oakland, Oakland, California. FAU - Noh, Caroline Y AU - Noh CY AUID- ORCID: 0000-0002-4462-3811 AD - Division of Neonatal and Developmental Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, California. FAU - Dasani, Reedhi AU - Dasani R AD - Division of Neonatal and Developmental Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, California. FAU - Vallandingham, Shelby AU - Vallandingham S AD - Division of Neonatal and Developmental Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, California. FAU - Manipon, Christine AU - Manipon C AD - Division of Neonatal and Developmental Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, California. FAU - Haileselassie, Bereketeab AU - Haileselassie B AD - Division of Pediatric Critical Care, Department of Pediatrics, Stanford University School of Medicine, Stanford, California. FAU - Profit, Jochen AU - Profit J AD - Division of Neonatal and Developmental Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, California. AD - California Perinatal Quality Care Collaborative, Stanford, California. FAU - Balasundaram, Malathi AU - Balasundaram M AD - Division of Neonatal and Developmental Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, California. FAU - Davis, Alexis S AU - Davis AS AD - Division of Neonatal and Developmental Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, California. FAU - Bhombal, Shazia AU - Bhombal S AD - Division of Neonatal and Developmental Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, California. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220612 PL - United States TA - Am J Perinatol JT - American journal of perinatology JID - 8405212 SB - IM MH - Humans MH - *Intensive Care Units, Neonatal MH - Infant, Newborn MH - *Ultrasonography/methods MH - *Point-of-Care Systems MH - Neonatology/education MH - Academic Medical Centers COIS- None declared. EDAT- 2022/06/13 06:00 MHDA- 2024/05/16 00:43 CRDT- 2022/06/12 18:42 PHST- 2024/05/16 00:43 [medline] PHST- 2022/06/13 06:00 [pubmed] PHST- 2022/06/12 18:42 [entrez] AID - 10.1055/s-0042-1750118 [doi] PST - ppublish SO - Am J Perinatol. 2024 May;41(S 01):e76-e84. doi: 10.1055/s-0042-1750118. Epub 2022 Jun 12. PMID- 35688758 OWN - NLM STAT- MEDLINE DCOM- 20220804 LR - 20250728 IS - 1532-8422 (Electronic) IS - 1053-0770 (Linking) VI - 36 IP - 9 DP - 2022 Sep TI - Curriculum for Subspecialty Anesthesia Training in Adult Structural Heart Disease Imaging: A Single-Center Experience. PG - 3469-3474 LID - S1053-0770(22)00321-4 [pii] LID - 10.1053/j.jvca.2022.04.047 [doi] AB - Intraprocedural transesophageal echocardiography imaging is an integral part of percutaneous structural heart disease (SHD) interventions. The rapid growth in the number, scope, and complexity of SHD interventions has outpaced the efforts to develop training and proficiency standards in periprocedural imaging. At the Beth Israel Deaconess Medical Center in Boston, Massachusetts, the authors have developed a 6-month duration fellowship in interventional echocardiography for SHD to address this issue. The purpose of this fellowship is to train cardiac anesthesiologists to address the unique challenges of interventional echocardiography. In this paper, the authors describe the rationale for and specific features of this training program. Their fellowship curriculum follows a multimodal integrative approach to training in SHD imaging, which includes simulation sessions, online modules, deliberate practice in the clinical setting, and interdisciplinary team-based training. In the next several years, there will be an increased need for echocardiographers who are proficient in intraprocedural SHD imaging. In this article, the authors describe their experience with a competency-based curriculum for subspecialty anesthesia training in SHD imaging. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Bose, Ruma AU - Bose R AD - Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA. FAU - Montealegre-Gallegos, Mario AU - Montealegre-Gallegos M AD - Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA. Electronic address: mmonteal@bidmc.harvard.edu. FAU - Mitchell, John D AU - Mitchell JD AD - Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA. FAU - Sharkey, Aidan AU - Sharkey A AD - Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA. FAU - Sehgal, Sankalp AU - Sehgal S AD - Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA. FAU - Krajewski, Megan L AU - Krajewski ML AD - Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA. FAU - Robitaille, Mark J AU - Robitaille MJ AD - Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA. FAU - Katsiampoura, Anastasia AU - Katsiampoura A AD - Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA. FAU - Haering, James Michael AU - Haering JM AD - Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA. FAU - Laham, Roger AU - Laham R AD - Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA. FAU - Mahmood, Feroze AU - Mahmood F AD - Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA. LA - eng PT - Journal Article DEP - 20220507 PL - United States TA - J Cardiothorac Vasc Anesth JT - Journal of cardiothoracic and vascular anesthesia JID - 9110208 SB - IM MH - Adult MH - *Anesthesia MH - Curriculum MH - Echocardiography, Transesophageal MH - *Heart Diseases/diagnostic imaging MH - Humans MH - *Internship and Residency OTO - NOTNLM OT - fellowship training OT - structural heart disease OT - three-dimensional echocardiography OT - transesophageal echocardiography EDAT- 2022/06/11 06:00 MHDA- 2022/08/05 06:00 CRDT- 2022/06/10 22:14 PHST- 2021/10/28 00:00 [received] PHST- 2022/04/22 00:00 [revised] PHST- 2022/04/30 00:00 [accepted] PHST- 2022/06/11 06:00 [pubmed] PHST- 2022/08/05 06:00 [medline] PHST- 2022/06/10 22:14 [entrez] AID - S1053-0770(22)00321-4 [pii] AID - 10.1053/j.jvca.2022.04.047 [doi] PST - ppublish SO - J Cardiothorac Vasc Anesth. 2022 Sep;36(9):3469-3474. doi: 10.1053/j.jvca.2022.04.047. Epub 2022 May 7. PMID- 35687317 OWN - NLM STAT- MEDLINE DCOM- 20240411 LR - 20240429 IS - 2724-5772 (Electronic) IS - 2724-5683 (Linking) VI - 72 IP - 2 DP - 2024 Apr TI - Transcatheter aortic valve intervention in hospitals without cardiac surgery departments: a future scenario? PG - 204-211 LID - 10.23736/S2724-5683.22.06076-8 [doi] AB - Transcatheter aortic valve intervention (TAVI) was introduced in early 2000 to offer treatment to inoperable patients with severe aortic valve stenosis. In a couple of decades, the procedure resulted effective and safe also in patients with intermediate to low risk for surgery; therefore, due to the progressive ageing of the population, the clinical need for TAVI is continuously increasing and is hardly met by the availability of the procedure, the so-called "TAVI capacity". As a result, many patients encounter difficulties in being referred to TAVI centers or face long waiting list times, thus risking severe adverse events (including death) before the procedure is performed. Although contemporary guidelines and consensus documents recommend that TAVI should only be performed in hospitals with active cardiac surgery departments, starting TAVI programs also in interventional cardiac laboratories without on-site cardiac surgery could represent a way to increase TAVI capacity, thus leading to a greater number of patients being treated in less time. On the other side of the coin, such a strategy may jeopardize patient safety in case of periprocedural complications needing bailout surgery and may lead to a suboptimal multidisciplinary Heart Team evaluation. This review aims to assess and discuss available clinical data and implementation of TAVI programs in hospitals without on-site active cardiac surgery departments considering the growing unmet clinical need and technical advancement of TAVI platforms, yet not overlooking the recommendations of international scientific societies. FAU - Rigattieri, Stefano AU - Rigattieri S AD - Interventional Cardiology Unit, Sant'Andrea University Hospital, Rome, Italy - stefanorigattieri@yahoo.it. FAU - Bernelli, Chiara AU - Bernelli C AD - Department of Cardiology, Santa Corona Hospital, Pietra Ligure, Savona, Italy. FAU - Tomassini, Francesco AU - Tomassini F AD - Interventional Cardiology Unit, Ospedale degli Infermi, Rivoli, Turin, Italy. FAU - Caretta, Giorgio AU - Caretta G AD - Section of Cardiology, Sant'Andrea Hospital, ASL 5, La Spezia, Italy. FAU - Moshiri, Shahram AU - Moshiri S AD - Department of Cardiology, Santa Corona Hospital, Pietra Ligure, Savona, Italy. FAU - Berni, Andrea AU - Berni A AD - Interventional Cardiology Unit, Sant'Andrea University Hospital, Rome, Italy. FAU - Varbella, Ferdinando AU - Varbella F AD - Interventional Cardiology Unit, Ospedale degli Infermi, Rivoli, Turin, Italy. FAU - Menozzi, Alberto AU - Menozzi A AD - Section of Cardiology, Sant'Andrea Hospital, ASL 5, La Spezia, Italy. LA - eng PT - Journal Article PT - Review DEP - 20220610 PL - Italy TA - Minerva Cardiol Angiol JT - Minerva cardiology and angiology JID - 101776555 SB - IM MH - Humans MH - Aortic Valve/surgery MH - *Transcatheter Aortic Valve Replacement/adverse effects/methods MH - *Aortic Valve Stenosis/surgery/etiology MH - Consensus MH - Hospitals EDAT- 2022/06/11 06:00 MHDA- 2024/04/11 06:43 CRDT- 2022/06/10 11:21 PHST- 2024/04/11 06:43 [medline] PHST- 2022/06/11 06:00 [pubmed] PHST- 2022/06/10 11:21 [entrez] AID - S2724-5683.22.06076-8 [pii] AID - 10.23736/S2724-5683.22.06076-8 [doi] PST - ppublish SO - Minerva Cardiol Angiol. 2024 Apr;72(2):204-211. doi: 10.23736/S2724-5683.22.06076-8. Epub 2022 Jun 10. PMID- 35687315 OWN - NLM STAT- MEDLINE DCOM- 20230329 LR - 20230329 IS - 2724-5772 (Electronic) IS - 2724-5683 (Linking) VI - 71 IP - 2 DP - 2023 Apr TI - Performance, clinical outcomes and implementation of an original heart valve clinic model. PG - 189-198 LID - 10.23736/S2724-5683.22.05998-1 [doi] AB - BACKGROUND: Valvular heart disease (VHD) requires optimized outpatient management that is generally considered to be best delivered by a dedicated, multidisciplinary team (Heart Valve Clinic [HVC]). Although HVC is promoted by clinical guidelines and organized in many centers, real world outcome assessments are limited. Thus, we evaluated the performance, clinical and management outcomes during a 6-year experience with an original HVC model. METHODS: By interrogating the local database, 1047 consecutive patients admitted to the HVC from January 2015 to October 2020 were found. Management and mortality were checked for all patients. After 3 years of HVC activity, in order to improve appropriateness and efficiency, access priority criteria were introduced. Thus, the study population was divided in two period subgroups (before and after access criteria introduction) that were compared. RESULTS: A total of 1047 consecutive patients admitted to the HVC constituted the study population; 346 patients (33%) were recommended for invasive treatment. After a mean follow-up of 25.7+/-3.1 months, 37 patients (3.5%) died. When comparing study periods, statistically significant increase inpatients' complexity and VHD severity was noticed in Period 2, also translating into higher rate of referral to intervention (39.0% vs. 29.4% in Period 1; P=0.001). Finally, despite higher rate of elderly and frail patients, operative mortality was not jeopardized. CONCLUSIONS: The present study reports a comprehensive assessment of the characteristics and outcomes achieved through an original HVC model. Standardization of access criteria supports the HVC improvement. FAU - Pavone, Natalia AU - Pavone N AD - Department of Cardiovascular Sciences, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy. FAU - Manfredonia, Laura AU - Manfredonia L AD - Department of Cardiovascular Sciences, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy. FAU - Burzotta, Francesco AU - Burzotta F AD - Department of Cardiovascular Sciences, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy - francesco.burzotta@unicatt.it. AD - Universita Cattolica del Sacro Cuore, Rome, Italy. FAU - Cammertoni, Federico AU - Cammertoni F AD - Department of Cardiovascular Sciences, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy. FAU - Vicchio, Luisa AU - Vicchio L AD - Department of Cardiovascular Sciences, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy. FAU - Spalletta, Claudio AU - Spalletta C AD - Department of Cardiovascular Sciences, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy. FAU - Graziani, Francesca AU - Graziani F AD - Department of Cardiovascular Sciences, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy. FAU - Locorotondo, Gabriella AU - Locorotondo G AD - Department of Cardiovascular Sciences, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy. FAU - Aurigemma, Cristina AU - Aurigemma C AD - Department of Cardiovascular Sciences, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy. FAU - Romagnoli, Enrico AU - Romagnoli E AD - Department of Cardiovascular Sciences, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy. FAU - Bruno, Piergiorgio AU - Bruno P AD - Department of Cardiovascular Sciences, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy. AD - Universita Cattolica del Sacro Cuore, Rome, Italy. FAU - Del Zanna, Niccolo AU - Del Zanna N AD - Department of Cardiovascular Sciences, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy. FAU - Marzetti, Emanuele AU - Marzetti E AD - Department of Cardiovascular Sciences, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy. AD - Universita Cattolica del Sacro Cuore, Rome, Italy. FAU - Calabrese, Maria AU - Calabrese M AD - Department of Cardiovascular Sciences, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy. FAU - Grandinetti, Maria AU - Grandinetti M AD - Department of Cardiovascular Sciences, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy. FAU - Nesta, Marialisa AU - Nesta M AD - Department of Cardiovascular Sciences, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy. FAU - Lombardo, Antonella AU - Lombardo A AD - Department of Cardiovascular Sciences, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy. AD - Universita Cattolica del Sacro Cuore, Rome, Italy. FAU - Trani, Carlo AU - Trani C AD - Department of Cardiovascular Sciences, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy. AD - Universita Cattolica del Sacro Cuore, Rome, Italy. FAU - Massetti, Massimo AU - Massetti M AD - Department of Cardiovascular Sciences, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy. AD - Universita Cattolica del Sacro Cuore, Rome, Italy. LA - eng PT - Journal Article DEP - 20220610 PL - Italy TA - Minerva Cardiol Angiol JT - Minerva cardiology and angiology JID - 101776555 SB - IM MH - Humans MH - Aged MH - *Heart Valve Diseases/surgery/epidemiology MH - Heart Valves MH - Ambulatory Care Facilities MH - Referral and Consultation EDAT- 2022/06/11 06:00 MHDA- 2023/03/29 06:05 CRDT- 2022/06/10 11:21 PHST- 2023/03/29 06:05 [medline] PHST- 2022/06/11 06:00 [pubmed] PHST- 2022/06/10 11:21 [entrez] AID - S2724-5683.22.05998-1 [pii] AID - 10.23736/S2724-5683.22.05998-1 [doi] PST - ppublish SO - Minerva Cardiol Angiol. 2023 Apr;71(2):189-198. doi: 10.23736/S2724-5683.22.05998-1. Epub 2022 Jun 10. PMID- 35686043 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240829 IS - 2297-055X (Print) IS - 2297-055X (Electronic) IS - 2297-055X (Linking) VI - 9 DP - 2022 TI - Transcatheter Aortic Valve Implantation: A Report on Serbia's First Systematic Program. PG - 882854 LID - 10.3389/fcvm.2022.882854 [doi] LID - 882854 AB - INTRODUCTION: Severe aortic stenosis, a highly-common valve disease in the elderly, has a poor prognosis if left untreated. To address the concern of effective procedures for severe aortic stenosis, a systematic TAVI program was established at the Dedinje Cardiovascular Institute (Belgrade, Serbia). METHODS: Our cohort was composed of 56 patients (74+/-15 years old). The mean logistic EuroScore was 10.17%; the mean Society of Thoracic Surgeons score was 3.22%. One third of the patients were categorized as class III or IV of the New York Heart Association (NYHA). The valves selected for use were either self-expandable or balloon expandable (Evolut R, Medtronic; Acurate Neo, Boston Scientific and Myval, Meril). The choice of valve type was made by the Institute's Structural Heart Team, in accordance with the patient's native aortic valve, size and calcification of ilio-femoral vessels, as well as the need for alternative access. TAVI procedure was conducted according to current guidelines provided by the European Society of Cardiology. RESULTS: The procedure success rate was 100%. Trans-femoral approach was achieved in 100% of patients; percutaneously in 87.5%, while a surgical cut was necessary in 12.5%. No patient showed moderate or severe aortic regurgitation after the procedure, although trace or mild regurgitation was recorded in 30.3%. Permanent pacemaker was implanted in one patient (1.78%), contrast induced acute kidney injury occured in one patient (1.78%), no stroke was recorded, and three pseudo-aneurysms which required surgical intervention occurred. Three patients required blood transfusions (5.33%). A 30-day all-cause mortality rate was 1.78%. CONCLUSION: The Dedinje Cardiovascular Institute spearheaded all efforts to establish a TAVI program in Serbia. Our initial TAVI results are promising, encouraging, and comparable with the results of previous large randomized trials. This initial experience opens the door for further development with a goal of our Institute to become a high-volume TAVI center. CI - Copyright (c) 2022 Boljevic, Bojic, Farkic, Sagic, Topic, Kovacevic, Lakcevic, Veljkovic, Dobric, Hinic, Ilijevski, Nikolic, Kaludjerovic, Bunc and Nikolic. FAU - Boljevic, Darko AU - Boljevic D AD - Dedinje Cardiovascular Institute, Belgrade, Serbia. FAU - Bojic, Milovan AU - Bojic M AD - Dedinje Cardiovascular Institute, Belgrade, Serbia. AD - School of Medicine, University of Banja Luka, Banja Luka, Bosnia and Herzegovina. FAU - Farkic, Mihajlo AU - Farkic M AD - Dedinje Cardiovascular Institute, Belgrade, Serbia. FAU - Sagic, Dragan AU - Sagic D AD - Dedinje Cardiovascular Institute, Belgrade, Serbia. AD - School of Medicine, University of Belgrade, Belgrade, Serbia. FAU - Topic, Dragan AU - Topic D AD - Dedinje Cardiovascular Institute, Belgrade, Serbia. FAU - Kovacevic, Vladimir AU - Kovacevic V AD - Dedinje Cardiovascular Institute, Belgrade, Serbia. FAU - Lakcevic, Jovana AU - Lakcevic J AD - Dedinje Cardiovascular Institute, Belgrade, Serbia. FAU - Veljkovic, Stefan AU - Veljkovic S AD - Dedinje Cardiovascular Institute, Belgrade, Serbia. FAU - Dobric, Milan AU - Dobric M AD - Dedinje Cardiovascular Institute, Belgrade, Serbia. AD - School of Medicine, University of Belgrade, Belgrade, Serbia. FAU - Hinic, Sasa AU - Hinic S AD - Dedinje Cardiovascular Institute, Belgrade, Serbia. FAU - Ilijevski, Nenad AU - Ilijevski N AD - Dedinje Cardiovascular Institute, Belgrade, Serbia. AD - School of Medicine, University of Belgrade, Belgrade, Serbia. FAU - Nikolic, Marko AU - Nikolic M AD - Dedinje Cardiovascular Institute, Belgrade, Serbia. FAU - Kaludjerovic, Aleksandra AU - Kaludjerovic A AD - Dedinje Cardiovascular Institute, Belgrade, Serbia. FAU - Bunc, Matjaz AU - Bunc M AD - University Clinical Center Ljubljana, University of Ljubljana, Ljubljana, Slovenia. FAU - Nikolic, Aleksandra AU - Nikolic A AD - Dedinje Cardiovascular Institute, Belgrade, Serbia. AD - School of Medicine, University of Belgrade, Belgrade, Serbia. LA - eng PT - Journal Article DEP - 20220524 PL - Switzerland TA - Front Cardiovasc Med JT - Frontiers in cardiovascular medicine JID - 101653388 PMC - PMC9170914 OTO - NOTNLM OT - TAVI OT - TAVI in Serbia OT - aortic stenosis OT - aortic valve OT - structural heart disease interventions COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/06/11 06:00 MHDA- 2022/06/11 06:01 PMCR- 2022/01/01 CRDT- 2022/06/10 02:40 PHST- 2022/02/24 00:00 [received] PHST- 2022/04/26 00:00 [accepted] PHST- 2022/06/10 02:40 [entrez] PHST- 2022/06/11 06:00 [pubmed] PHST- 2022/06/11 06:01 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.3389/fcvm.2022.882854 [doi] PST - epublish SO - Front Cardiovasc Med. 2022 May 24;9:882854. doi: 10.3389/fcvm.2022.882854. eCollection 2022. PMID- 35678200 OWN - NLM STAT- MEDLINE DCOM- 20220610 LR - 20220719 IS - 1477-1128 (Electronic) IS - 1463-4236 (Print) IS - 1463-4236 (Linking) VI - 23 DP - 2022 Jun 9 TI - Understanding healthcare providers' experiences with video recording of patient consultations. PG - e35 LID - 10.1017/S1463423622000214 [doi] LID - e35 AB - AIM: To understand healthcare providers' experiences with video recording of patient consultations. BACKGROUND: Video recordings have been recognised to be an effective method to evaluate in situ interactions in clinical practice. The video recordings are often conducted by researchers, but active involvement of healthcare providers into the process of recording is evolving. Still, little is known of how video recordings by healthcare providers may influence daily clinical practice and potentials for direct use to guide practice development. METHODS: A qualitative design was used, conducting two focus group interviews including 12 healthcare providers representing eight different healthcare services who provide municipal cardiac rehabilitation. Interpretive description was used as the methodological framework, and symbolic interactionism served as the theoretical lens. FINDINGS: Three themes were identified reflecting healthcare providers' experiences with video recording of patient consultations: 'Concerns of compromising primary work tasks', 'Exposing professional and personal skills' and 'A new learning dimension'. Overall, the three themes represent the process of video recording own practices attached to patient consultations and the personal investment attached to the video data. Also, how the recordings may provide new insights for practice development in terms of individual and team-based performance in patient consultations. CONCLUSION: Video recordings by healthcaref providers may be a useful source to provide information and learning about patient consultation practice to use in research and supervision, keeping in mind their challenges of implementation into daily clinical practice. FAU - Pedersen, Charlotte Gjorup AU - Pedersen CG AUID- ORCID: 0000-0003-1116-8389 AD - DEFACTUM, Central Denmark Region, Aarhus, Denmark. AD - Department of Public Health, Aarhus University, Aarhus, Denmark. AD - REHPA, The Danish Knowledge Centre for Rehabilitation and Palliative Care, Odense University Hospital, Nyborg, Denmark. AD - Department of Clinical Research, University of Southern Denmark, Odense, Denmark. FAU - Hostrup, Lea Hoj AU - Hostrup LH AD - DEFACTUM, Central Denmark Region, Aarhus, Denmark. FAU - Gadager, Birgitte Bitsch AU - Gadager BB AUID- ORCID: 0000-0002-1184-7579 AD - DEFACTUM, Central Denmark Region, Aarhus, Denmark. FAU - Nielsen, Claus Vinther AU - Nielsen CV AUID- ORCID: 0000-0002-2467-1103 AD - DEFACTUM, Central Denmark Region, Aarhus, Denmark. AD - Department of Public Health, Aarhus University, Aarhus, Denmark. AD - Department of Clinical Social Medicine and Rehabilitation, Godstrup Hospital, Herning, Denmark. FAU - Maribo, Thomas AU - Maribo T AUID- ORCID: 0000-0003-0856-6837 AD - DEFACTUM, Central Denmark Region, Aarhus, Denmark. AD - Department of Public Health, Aarhus University, Aarhus, Denmark. FAU - Madsen, Louise Sofia AU - Madsen LS AUID- ORCID: 0000-0002-0919-2454 AD - DEFACTUM, Central Denmark Region, Aarhus, Denmark. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220609 PL - England TA - Prim Health Care Res Dev JT - Primary health care research & development JID - 100897390 SB - IM MH - Focus Groups MH - *Health Personnel MH - Humans MH - Qualitative Research MH - *Referral and Consultation MH - Video Recording PMC - PMC9247682 OTO - NOTNLM OT - focus-group interviews OT - healthcare providers OT - patient consultations OT - video recording EDAT- 2022/06/10 06:00 MHDA- 2022/06/11 06:00 PMCR- 2022/06/09 CRDT- 2022/06/09 05:13 PHST- 2022/06/09 05:13 [entrez] PHST- 2022/06/10 06:00 [pubmed] PHST- 2022/06/11 06:00 [medline] PHST- 2022/06/09 00:00 [pmc-release] AID - S1463423622000214 [pii] AID - 10.1017/S1463423622000214 [doi] PST - epublish SO - Prim Health Care Res Dev. 2022 Jun 9;23:e35. doi: 10.1017/S1463423622000214. PMID- 35677617 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240830 IS - 1178-2390 (Print) IS - 1178-2390 (Electronic) IS - 1178-2390 (Linking) VI - 15 DP - 2022 TI - Multidisciplinary Management of Costello Syndrome: Current Perspectives. PG - 1277-1296 LID - 10.2147/JMDH.S291757 [doi] AB - Costello syndrome (CS) is a rare neurodevelopmental disorder caused by germline mutations in HRAS. It belongs among the RASopathies, a group of syndromes characterized by alterations in components of the RAS/MAPK signaling pathway and sharing overlapping phenotypes. Its typical features include a distinctive facial appearance, growth delay, intellectual disability, ectodermal, cardiac, and musculoskeletal abnormalities, and cancer predisposition. Due to the several comorbidities having a strong impact on the quality of life, a multidisciplinary team is essential in the management of such a condition from infancy to adult age, to promptly address any detected issue and to develop appropriate personalized follow-up protocols and treatment strategies. With the present paper we aim to highlight the core and ancillary medical disciplines involved in managing the health challenges characterizing CS from pediatric to adult age, according to literature and to our large clinical experience. CI - (c) 2022 Leoni et al. FAU - Leoni, Chiara AU - Leoni C AUID- ORCID: 0000-0002-4089-637X AD - Center for Rare Diseases and Birth Defects, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy. FAU - Viscogliosi, Germana AU - Viscogliosi G AUID- ORCID: 0000-0002-1697-6337 AD - Center for Rare Diseases and Birth Defects, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy. FAU - Tartaglia, Marco AU - Tartaglia M AD - Genetics and Rare Diseases Research Division, Ospedale Pediatrico Bambino Gesu, IRCCS, Rome, Italy. FAU - Aoki, Yoko AU - Aoki Y AD - Department of Medical Genetics, Tohoku University School of Medicine, Sendai, Japan. FAU - Zampino, Giuseppe AU - Zampino G AD - Center for Rare Diseases and Birth Defects, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy. AD - Universita Cattolica del Sacro Cuore, Rome, Italy. LA - eng PT - Journal Article PT - Review DEP - 20220602 PL - New Zealand TA - J Multidiscip Healthc JT - Journal of multidisciplinary healthcare JID - 101512691 PMC - PMC9169840 OTO - NOTNLM OT - Costello syndrome OT - HRAS OT - RASopathies OT - multidisciplinary team OT - personalized medicine COIS- The authors report no conflict of interest in this work. EDAT- 2022/06/10 06:00 MHDA- 2022/06/10 06:01 PMCR- 2022/06/02 CRDT- 2022/06/09 02:18 PHST- 2022/02/01 00:00 [received] PHST- 2022/05/10 00:00 [accepted] PHST- 2022/06/09 02:18 [entrez] PHST- 2022/06/10 06:00 [pubmed] PHST- 2022/06/10 06:01 [medline] PHST- 2022/06/02 00:00 [pmc-release] AID - 291757 [pii] AID - 10.2147/JMDH.S291757 [doi] PST - epublish SO - J Multidiscip Healthc. 2022 Jun 2;15:1277-1296. doi: 10.2147/JMDH.S291757. eCollection 2022. PMID- 35677616 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220716 IS - 1178-2390 (Print) IS - 1178-2390 (Electronic) IS - 1178-2390 (Linking) VI - 15 DP - 2022 TI - Generalized Arterial Calcification of Infancy (GACI): Optimizing Care with a Multidisciplinary Approach. PG - 1261-1276 LID - 10.2147/JMDH.S251861 [doi] AB - It is very unusual to see evidence of arterial calcification in infants and children, and when detected, genetic disorders of calcium metabolism should be suspected. Generalized arterial calcification of infancy (GACI) is a hereditary disease, which is characterized by severe arterial calcification of medium sized arteries, mostly involving the media with marked intimal proliferation and ectopic mineralization of the extravascular tissues. It is caused by inactivating variants in genes encoding either ENPP1, in a majority of cases (70-75%), or ABCC6, in a minority (9-10%). Despite similar histologic appearances between ENPP1 and ABCC6 deficiencies, including arterial calcification, organ calcification, and cardiovascular calcification, mortality is higher in subjects carrying the ENPP1 versus ABCC6 variants (40% vs 10%, respectively). Overall mortality in individuals with GACI is high (55%) before the age of 6 months, with 24.4% dying in utero or being stillborn. Rare cases show spontaneous regression with age, while others who survive into adulthood often manifest musculoskeletal complications (osteoarthritis and interosseous membrane ossification), enthesis mineralization, and cervical spine fusion. Despite recent advances in the understanding of the genetic mechanisms underlying this disease, there is still no ideal therapy for the resolution of vascular calcification in GACI. Although bisphosphonates with anti-calcification properties have been commonly used for the treatment of CAGI, their benefit is controversial, with favorable results reported at one year and questionable benefit with delayed initiation of treatment. Enzyme replacement therapy with administration of recombinant form of ENPP1 prevents calcification and mortality, improves hypertension and cardiac function, and prevents intimal proliferation and osteomalacia in mouse models of ENPP1 deficiency. Therefore, newer treatments targeting genes are on the horizon. In this article, we review up to date knowledge of the understanding of GACI, its clinical, pathologic, and etiologic understanding and treatment in support of more comprehensive care of GACI patients. CI - (c) 2022 Kawai et al. FAU - Kawai, Kenji AU - Kawai K AD - CVPath Institute, Gaithersburg, MD, USA. FAU - Sato, Yu AU - Sato Y AD - CVPath Institute, Gaithersburg, MD, USA. FAU - Kawakami, Rika AU - Kawakami R AD - CVPath Institute, Gaithersburg, MD, USA. FAU - Sakamoto, Atsushi AU - Sakamoto A AD - CVPath Institute, Gaithersburg, MD, USA. FAU - Cornelissen, Anne AU - Cornelissen A AD - CVPath Institute, Gaithersburg, MD, USA. FAU - Mori, Masayuki AU - Mori M AD - CVPath Institute, Gaithersburg, MD, USA. FAU - Ghosh, Saikat AU - Ghosh S AD - CVPath Institute, Gaithersburg, MD, USA. FAU - Kutys, Robert AU - Kutys R AD - CVPath Institute, Gaithersburg, MD, USA. FAU - Virmani, Renu AU - Virmani R AD - CVPath Institute, Gaithersburg, MD, USA. FAU - Finn, Aloke V AU - Finn AV AD - CVPath Institute, Gaithersburg, MD, USA. AD - University of Maryland, School of Medicine, Baltimore, MD, USA. LA - eng GR - R01 HL141425/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Review DEP - 20220601 PL - New Zealand TA - J Multidiscip Healthc JT - Journal of multidisciplinary healthcare JID - 101512691 PMC - PMC9167688 OTO - NOTNLM OT - ATP binding cassette subfamily C member 6 OT - ectonucleotide pyrophosphatase/phosphodiesterase 1 OT - generalized arterial calcification of infancy OT - vascular calcification COIS- Dr. Aloke V. Finn received consultant fees/honoraria from Abbott Vascular, Amgen, Biosensors, Boston Scientific, Celonova, Cook Medical, CSI, Lutonix Bard, Sinomed, and Terumo Corporation. Dr. Renu Virmani is a consultant of Abbott Vascular, Boston Scientific, Celonova, OrbusNeich Medical, Terumo Corporation, W. L. Gore, Edwards Lifesciences, Cook Medical, CSI, ReCor Medical, SinoMedical Sciences Technology, Surmodics, Bard BD and a scientific Advisory Board Member of Medtronic and Xeltis. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or any other conflict with the subject matter or materials discussed. EDAT- 2022/06/10 06:00 MHDA- 2022/06/10 06:01 PMCR- 2022/06/01 CRDT- 2022/06/09 02:18 PHST- 2021/12/31 00:00 [received] PHST- 2022/04/22 00:00 [accepted] PHST- 2022/06/09 02:18 [entrez] PHST- 2022/06/10 06:00 [pubmed] PHST- 2022/06/10 06:01 [medline] PHST- 2022/06/01 00:00 [pmc-release] AID - 251861 [pii] AID - 10.2147/JMDH.S251861 [doi] PST - epublish SO - J Multidiscip Healthc. 2022 Jun 1;15:1261-1276. doi: 10.2147/JMDH.S251861. eCollection 2022. PMID- 35675493 OWN - NLM STAT- MEDLINE DCOM- 20220819 LR - 20250728 IS - 1678-9741 (Electronic) IS - 0102-7638 (Print) IS - 0102-7638 (Linking) VI - 37 IP - 4 DP - 2022 Aug 16 TI - Surgical Approach and Management Strategies in a Pediatric Cardiovascular Surgery Clinic During the COVID-19 Outbreak. PG - 466-471 LID - 10.21470/1678-9741-2020-0614 [doi] AB - INTRODUCTION: The coronavirus disease 2019 (COVID-19) pandemic has required changes in the management of pediatric cardiac surgery. We would like to share the patient treatment and surgical management strategies employed in our Pediatric Cardiovascular Surgery Clinic during the COVID-19 pandemic. METHODS: A total of 112 patients were followed up in our clinic between 11.03.2020 and 02.07.2020. Their mean age was 1,118 (4-5,740) days. Management and treatment were performed by our pediatric heart team (pediatric cardiac anesthetists, general pediatricians, pediatric cardiologists, pediatric cardiac surgeons, and an infectious diseases specialist). We prepared new protocols and a surveillance system specific to the pandemic to prevent in-hospital transmission and reduce postoperative mortality and morbidity; our operations were performed according to these protocols. All decisions pertaining to the operation timing and treatment strategy of our COVID-19-positive patients were made by the same team. RESULTS: During the study period, a total of 112 patients, 69 boys and 43 girls, were hospitalized in our clinic. A total of 333 COVID-19 real-time polymerase chain reaction tests were performed on patients and accompanying persons; positive results were found in three patients and two accompanying individuals. CONCLUSION: By employing new protocols and a surveillance system throughout the healthcare system, we think that early diagnosis and treatment of the pediatric congenital heart disease population, which is susceptible to infections, can continue unperturbed. This and similar approaches can increase postoperative success and prevent transmission in the pediatric population - which are frequently COVID-19 asymptomatic. FAU - Arslanoglu, Ergin AU - Arslanoglu E AD - Department of Pediatric Cardiovascular Surgery, Kartal Kosuyolu Yuksek Ihtisas Egitim ve Arastirma Hastanesi, Istanbul, Turkey. FAU - Isik, Mehmet Emirhan AU - Isik ME AD - Department of Infectious Disease, Kartal Kosuyolu Yuksek Ihtisas Egitim ve Arastirma Hastanesi, Istanbul, Turkey. FAU - Kara, Kenan Abdurrahman AU - Kara KA AUID- ORCID: 0000-0003-1295-7689 AD - Department of Pediatric Cardiovascular Surgery, Kartal Kosuyolu Yuksek Ihtisas Egitim ve Arastirma Hastanesi, Istanbul, Turkey. FAU - Cine, Nihat AU - Cine N AD - Department of Infectious Disease, Kartal Kosuyolu Yuksek Ihtisas Egitim ve Arastirma Hastanesi, Istanbul, Turkey. FAU - Tuncer, Eylem AU - Tuncer E AD - Department of Infectious Disease, Kartal Kosuyolu Yuksek Ihtisas Egitim ve Arastirma Hastanesi, Istanbul, Turkey. FAU - Ceyran, Hakan AU - Ceyran H AD - Department of Infectious Disease, Kartal Kosuyolu Yuksek Ihtisas Egitim ve Arastirma Hastanesi, Istanbul, Turkey. LA - eng PT - Journal Article DEP - 20220816 PL - Brazil TA - Braz J Cardiovasc Surg JT - Brazilian journal of cardiovascular surgery JID - 101677045 SB - IM MH - *COVID-19 MH - Child MH - Disease Outbreaks MH - Female MH - Humans MH - Male MH - Pandemics/prevention & control MH - SARS-CoV-2 MH - *Thoracic Surgery PMC - PMC9423802 OTO - NOTNLM OT - Cardiac Surgical Procedures OT - Child OT - Congenital Heart Disease OT - Covid-19 OT - Delivery of Health Care OT - Early Diagnosis OT - Real Time Polymerase Chain Reaction COIS- No conflict of interest. EDAT- 2022/06/09 06:00 MHDA- 2022/08/20 06:00 PMCR- 2022/07/01 CRDT- 2022/06/08 14:24 PHST- 2022/06/09 06:00 [pubmed] PHST- 2022/08/20 06:00 [medline] PHST- 2022/06/08 14:24 [entrez] PHST- 2022/07/01 00:00 [pmc-release] AID - 10.21470/1678-9741-2020-0614 [doi] PST - epublish SO - Braz J Cardiovasc Surg. 2022 Aug 16;37(4):466-471. doi: 10.21470/1678-9741-2020-0614. PMID- 35674775 OWN - NLM STAT- MEDLINE DCOM- 20220809 LR - 20261010 IS - 1615-6692 (Electronic) IS - 0340-9937 (Linking) VI - 47 IP - 4 DP - 2022 Aug TI - Cardiac amyloidosis-interdisciplinary approach to diagnosis and therapy. PG - 324-331 LID - 10.1007/s00059-022-05122-w [doi] AB - The vast majority of cardiac amyloidosis (CA) cases are caused by light chain (AL) or transthyretin (ATTR) amyloidosis. The latter is divided into hereditary (ATTRv) and wild-type forms (ATTRwt). The incidence of ATTRwt amyloidosis has significantly increased, particularly due to the improved diagnosis of cardiac manifestations, with relevant proportions in patient populations with heart failure (HF) and preserved ejection fraction (HFpEF). Cardiac amyloidosis should be suspected in HF with indicative clinical scenarios/"red flags" with typical signs of CA in echocardiography. Further noninvasive imaging (cardiovascular magnetic resonance imaging, scintigraphy) and specific laboratory diagnostics are important for the diagnosis and typing of CA into the underlying main forms of ATTR and AL amyloidosis. The histopathologic analysis of an endomyocardial biopsy is necessary if noninvasive diagnostic methods do not enable reliable typing of CA. This is crucial for initiating specific therapy. Therapy of HF in CA is largely limited to the use of diuretics in the absence of evidence on the benefit of classic HF therapy with neurohormonal modulators. Innovative therapies have been developed for amyloidosis with improvement in organ protection, prognosis, and quality of life. These include specific cytoreductive therapies for monoclonal light-chain disease in AL amyloidosis and pharmacologic stabilization or inhibition of transthyretin expression in ATTR amyloidosis. Since the CA underlying amyloidosis is a systemic disease also affecting other organ systems, close interdisciplinary cooperation is crucial for rapid and effective diagnosis and therapy. CI - (c) 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature. FAU - Hanselmann, A AU - Hanselmann A AD - Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany. FAU - Berliner, D AU - Berliner D AD - Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany. FAU - Bauersachs, J AU - Bauersachs J AD - Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany. FAU - Bavendiek, U AU - Bavendiek U AD - Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany. bavendiek.udo@mh-hannover.de. AD - Amyloidosezentrum Niedersachsen, Hannover Medical School, Hannover, Germany. bavendiek.udo@mh-hannover.de. LA - eng PT - Journal Article PT - Review TT - Kardiale Amyloidose - interdisziplinarer Ansatz bei Diagnose und Therapie. DEP - 20220608 PL - Germany TA - Herz JT - Herz JID - 7801231 RN - 0 (Prealbumin) SB - IM MH - *Amyloid Neuropathies, Familial/diagnosis/therapy MH - *Cardiomyopathies/diagnosis/therapy MH - *Heart Failure/epidemiology MH - Humans MH - *Immunoglobulin Light-chain Amyloidosis/complications/epidemiology MH - Prealbumin/metabolism MH - Quality of Life MH - Stroke Volume OTO - NOTNLM OT - Amyloidosis OT - Diagnostics OT - Heart failure OT - Light-chain OT - Transthyretin EDAT- 2022/06/09 06:00 MHDA- 2022/08/10 06:00 CRDT- 2022/06/08 11:12 PHST- 2022/04/27 00:00 [accepted] PHST- 2022/06/09 06:00 [pubmed] PHST- 2022/08/10 06:00 [medline] PHST- 2022/06/08 11:12 [entrez] AID - 10.1007/s00059-022-05122-w [pii] AID - 10.1007/s00059-022-05122-w [doi] PST - ppublish SO - Herz. 2022 Aug;47(4):324-331. doi: 10.1007/s00059-022-05122-w. Epub 2022 Jun 8. PMID- 35671766 OWN - NLM STAT- MEDLINE DCOM- 20220609 LR - 20220609 IS - 1558-3171 (Electronic) IS - 0039-6109 (Linking) VI - 102 IP - 3 DP - 2022 Jun TI - Management of Coronary Artery Disease. PG - 449-464 LID - S0039-6109(22)00005-6 [pii] LID - 10.1016/j.suc.2022.01.005 [doi] AB - This article reviews the surgical management of coronary artery disease (CAD). The authors cover the background, presentation, diagnosis, heart team evaluation, and development of treatment strategies tailored to individual patients with significant CAD. Special attention is given to conduit selection and configuration as well as alternative revascularization approaches that differ from traditional coronary artery bypass grafting. CI - Published by Elsevier Inc. FAU - Sulava, Eric Francis AU - Sulava EF AD - Department of Emergency Medicine, Naval Medical Readiness & Training Center Portsmouth, 620 John Paul Jones Circle, Portsmouth, VA 23708, USA. FAU - Johnson, Jeffery Chad AU - Johnson JC AD - Department of Surgery, Division of Cardiothoracic Surgery, Naval Medical Readiness & Training Center Portsmouth, 620 John Paul Jones Circle, Portsmouth, VA 23708, USA. Electronic address: jchadjohnson@gmail.com. LA - eng PT - Journal Article PT - Review DEP - 20220421 PL - United States TA - Surg Clin North Am JT - The Surgical clinics of North America JID - 0074243 SB - IM MH - Coronary Artery Bypass MH - *Coronary Artery Disease/diagnosis/surgery MH - Humans MH - Treatment Outcome OTO - NOTNLM OT - Coronary artery bypass grafting (CABG) OT - Heart team OT - Hybrid revascularization OT - Minimally invasive CABG COIS- Disclosure The authors have nothing to disclose. EDAT- 2022/06/08 06:00 MHDA- 2022/06/10 06:00 CRDT- 2022/06/07 18:52 PHST- 2022/06/07 18:52 [entrez] PHST- 2022/06/08 06:00 [pubmed] PHST- 2022/06/10 06:00 [medline] AID - S0039-6109(22)00005-6 [pii] AID - 10.1016/j.suc.2022.01.005 [doi] PST - ppublish SO - Surg Clin North Am. 2022 Jun;102(3):449-464. doi: 10.1016/j.suc.2022.01.005. Epub 2022 Apr 21. PMID- 35669936 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220716 IS - 2542-4548 (Electronic) IS - 2542-4548 (Linking) VI - 6 IP - 4 DP - 2022 Aug TI - Postacute Sequelae of SARS-CoV-2 Infection-Lessons Learned From a Coordinated Health System Response. PG - 311-319 LID - 10.1016/j.mayocpiqo.2022.05.007 [doi] AB - OBJECTIVE: To outline a consensus-designed process for triaging and managing patients with post-coronavirus disease (COVID-19) syndrome at Mayo Clinic. PATIENTS AND METHODS: We convened a central multidisciplinary team including members from the departments of general internal medicine, occupational medicine, physical medicine and rehabilitation, psychology, allergy and immunology, infectious disease, pulmonology, neurology, cardiology, and pediatrics and otorhinolaryngology with membership from all Mayo Clinic sites in Arizona, Florida, Iowa, Minnesota, and Wisconsin. RESULTS: Consensus recommendations were made for the best practice guidelines on triaging and managing patients. Several innovations were agreed upon, including a postacute sequelae of COVID-19-specific appointment request form for data collection, a bioregistry, a biorepository, and a postacute sequelae of COVID-19-specific treatment program. CONCLUSION: Given that each clinical site had individual clinical practices, these recommendations were implemented using different models, which may provide broad applicability to other clinical settings. CI - (c) 2022 The Authors. FAU - Ganesh, Ravindra AU - Ganesh R AD - Division of General Internal Medicine, Mayo Clinic, Rochester, MN. FAU - Vanichkachorn, Greg S AU - Vanichkachorn GS AD - Division of Preventative Medicine, Mayo Clinic, Rochester, MN. FAU - Munipalli, Bala AU - Munipalli B AD - Division of General Internal Medicine, Mayo Clinic, Jacksonville, FL. FAU - Hanson, Sara N AU - Hanson SN AD - Mayo Clinic Health Systems, Mankato, MN. FAU - Abu Dabrh, Abd Moain AU - Abu Dabrh AM AD - Division of General Internal Medicine, Mayo Clinic, Jacksonville, FL. FAU - Croghan, Ivana T AU - Croghan IT AD - Division of General Internal Medicine, Mayo Clinic, Rochester, MN. FAU - Dawson, Nancy L AU - Dawson NL AD - Division of General Internal Medicine, Mayo Clinic, Jacksonville, FL. FAU - Hurt, Ryan T AU - Hurt RT AD - Division of General Internal Medicine, Mayo Clinic, Rochester, MN. LA - eng PT - Journal Article DEP - 20220601 PL - Netherlands TA - Mayo Clin Proc Innov Qual Outcomes JT - Mayo Clinic proceedings. Innovations, quality & outcomes JID - 101728275 PMC - PMC9156955 OTO - NOTNLM OT - ARF, appointment request form OT - CARP, Coronavirus Disease 2019 Activity Rehabilitation Program OT - CFS, chronic fatigue syndrome OT - COVID-19, coronavirus disease 2019 OT - FMS, fibromyalgia OT - GIM, general internal medicine OT - MC, Mayo Clinic OT - MCA, Mayo Clinic Arizona OT - MCF, Mayo Clinic Florida OT - MCHS, Mayo Clinic Health System OT - MCR, Mayo Clinic Rochester OT - NIH, National Institutes of Health OT - PASC, postacute sequelae of coronavirus disease 2019 OT - PCOCC, post-COVID-19 care clinic OT - POTS, postural orthostatic tachycardia syndrome OT - PoCOS, post-COVID-19 syndrome OT - Prev Med, Preventative Medicine OT - SARS-CoV-2, severe acute respiratory syndrome coronavirus 2 EDAT- 2022/06/08 06:00 MHDA- 2022/06/08 06:01 PMCR- 2022/06/01 CRDT- 2022/06/07 02:49 PHST- 2022/06/08 06:00 [pubmed] PHST- 2022/06/08 06:01 [medline] PHST- 2022/06/07 02:49 [entrez] PHST- 2022/06/01 00:00 [pmc-release] AID - S2542-4548(22)00033-9 [pii] AID - 10.1016/j.mayocpiqo.2022.05.007 [doi] PST - ppublish SO - Mayo Clin Proc Innov Qual Outcomes. 2022 Aug;6(4):311-319. doi: 10.1016/j.mayocpiqo.2022.05.007. Epub 2022 Jun 1. PMID- 35669886 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220716 IS - 1178-6981 (Print) IS - 1178-6981 (Electronic) IS - 1178-6981 (Linking) VI - 14 DP - 2022 TI - Cost-Effectiveness and Budget Impact of Comprehensive Anemia Management, The First Pillar of Patient Blood Management, on the Turkish Healthcare System. PG - 415-426 LID - 10.2147/CEOR.S360944 [doi] AB - PURPOSE: Patient blood management (PBM) is a patient-centered, evidence-based, multidisciplinary approach aimed at optimizing hemoglobin concentration, ensuring the continuity of hemostasis and minimizing blood loss in patients undergoing surgery. The aims of this study were: (1) to explore the cost-effectiveness of comprehensive anemia management, the first pillar of PBM, in non-cardiac and cardiac surgery from the Turkish Social Security Institution's (SSI's) perspective; and (2) to explore the potential budget impact of PBM for coronary artery bypass grafting (CABG) and hip and knee arthroplasty to the SSI. METHODS: Cost-effectiveness and budget impact models were developed based on the avoided postoperative adverse events following implementation of the first pillar of PBM for non-cardiac and cardiac surgical patients. The probabilities of adverse events (sepsis with and without pneumonia, renal failure, myocardial infarction and stroke) were taken from a recent meta-analysis and the costs of treating these adverse events to the SSI were estimated through expert views and the use of SSI guidelines. RESULTS: The PBM arm dominated the control arm for both non-cardiac and cardiac surgeries in terms of cost-effectiveness in the simulated cohort of patients and was associated with improved outcomes and lower costs (1768 and 1244 avoided adverse events, and incremental cost reductions for non-cardiac and cardiac surgery of 7504 Turkish lira [TRY] and 6102 TRY, respectively). The budget impact analysis showed that PBM is a potential cost-saving option for the SSI, with savings of up to 196,937,705 TRY (euro12,841,697) for hip and knee arthroplasty and 24,642,504 TRY (euro1,606,861) for CABG surgery. CONCLUSION: PBM is a cost-effective option with a potential of cost-saving for cardiac and non-cardiac surgery in Turkey. CI - (c) 2022 Tatar et al. FAU - Tatar, Mehtap AU - Tatar M AUID- ORCID: 0000-0001-9189-9178 AD - Polar Health Economics and Policy, Ankara, Turkey. FAU - Alkis, Neslihan AU - Alkis N AD - Department of Anesthesiology and Intensive Care Unit, Faculty of Medicine, Ankara University, Ankara, Turkey. FAU - Yildirim Guclu, Cigdem AU - Yildirim Guclu C AUID- ORCID: 0000-0002-8416-3418 AD - Department of Anesthesiology and Intensive Care Unit, Faculty of Medicine, Ankara University, Ankara, Turkey. FAU - Bermede, Onat AU - Bermede O AUID- ORCID: 0000-0002-8598-6264 AD - Department of Anesthesiology and Intensive Care Unit, Faculty of Medicine, Ankara University, Ankara, Turkey. FAU - Erdemli, Bulent AU - Erdemli B AD - Department of Orthopaedic Surgery and Traumatology, Faculty of Medicine, Ankara University, Ankara, Turkey. FAU - Gunaydin, Serdar AU - Gunaydin S AUID- ORCID: 0000-0002-9717-9793 AD - Department of Cardiovascular Surgery, University of Health Sciences, Ankara City Hospital Campus, Ankara, Turkey. LA - eng PT - Journal Article DEP - 20220530 PL - New Zealand TA - Clinicoecon Outcomes Res JT - ClinicoEconomics and outcomes research : CEOR JID - 101560564 PMC - PMC9166278 OTO - NOTNLM OT - Turkey; Turkish healthcare system OT - budget impact OT - cost-effectiveness analysis OT - patient blood management COIS- MT provides consultancy to Vifor Pharma. OB, BE, SG, CYG and NA report no conflicts of interest in this work. EDAT- 2022/06/08 06:00 MHDA- 2022/06/08 06:01 PMCR- 2022/05/30 CRDT- 2022/06/07 02:47 PHST- 2022/02/16 00:00 [received] PHST- 2022/05/07 00:00 [accepted] PHST- 2022/06/07 02:47 [entrez] PHST- 2022/06/08 06:00 [pubmed] PHST- 2022/06/08 06:01 [medline] PHST- 2022/05/30 00:00 [pmc-release] AID - 360944 [pii] AID - 10.2147/CEOR.S360944 [doi] PST - epublish SO - Clinicoecon Outcomes Res. 2022 May 30;14:415-426. doi: 10.2147/CEOR.S360944. eCollection 2022. PMID- 35669526 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220716 IS - 2666-5204 (Electronic) IS - 2666-5204 (Linking) VI - 10 DP - 2022 Jun TI - Mechanical life support algorithm developed by simulation for inpatient emergency management of recipients of implantable left ventricular assist devices. PG - 100254 LID - 10.1016/j.resplu.2022.100254 [doi] LID - 100254 AB - BACKGROUND: Published guidance concerning emergency management of left ventricular assist device (LVAD) recipients is both limited and lacking in consensus which increases the risk of delayed and/or inappropriate actions. METHODS: In our specialist tertiary referral centre we developed, by iteration, a novel in-hospital resuscitation algorithm for LVAD emergencies which we validated through simulation and assessment of our multi-disciplinary team. A Mechanical Life Support course was established to provide theoretical and practical education combined with simulation to consolidate knowledge and confidence in algorithm use. We assessed these measures using confidence scoring, a key performance indicator (the time taken to restart LVAD function) and a multiple-choice question (MCQ) examination. RESULTS: The mean baseline staff confidence score in management of LVAD emergencies was 2.4 +/- 1.2 out of a maximum of 5 (n = 29). After training with simulation, mean confidence score increased to 3.5 +/- 0.8 (n = 13).Clinical personnel who were provided with the novel resuscitation algorithm were able to reduce time taken to restart LVAD function from a mean value of 49 +/- 8.2 seconds (pre-training) to 20.4 +/- 5 seconds (post-training) (n = 42, p < 0.0001).The Mechanical Life Support course increased mean confidence from 2.5 +/- 1.2 to 4 +/- 0.6 (n = 44, p < 0.0001) and mean MCQ score from 18.7 +/- 3.4 to 22.8 +/- 2.6, out of a maximum of 28 (n = 44, p < 0.0001). CONCLUSION: We present a simplified LVAD Advanced Life Support algorithm to aid the crucial first minutes of resuscitation where basic interventions are likely to be critical in assuring good patient outcomes. CI - (c) 2022 The Author(s). FAU - Akhtar, Waqas AU - Akhtar W AD - Harefield Hospital, Hill End Road, Harefield, Uxbridge UB96JH, United Kingdom. FAU - Gamble, Brigitte AU - Gamble B AD - Harefield Hospital, Hill End Road, Harefield, Uxbridge UB96JH, United Kingdom. FAU - Kiff, Kristine AU - Kiff K AD - Harefield Hospital, Hill End Road, Harefield, Uxbridge UB96JH, United Kingdom. FAU - Wypych-Zych, Agnieszka AU - Wypych-Zych A AD - Harefield Hospital, Hill End Road, Harefield, Uxbridge UB96JH, United Kingdom. FAU - Raj, Binu AU - Raj B AD - Harefield Hospital, Hill End Road, Harefield, Uxbridge UB96JH, United Kingdom. FAU - Takata, Junko AU - Takata J AD - Harefield Hospital, Hill End Road, Harefield, Uxbridge UB96JH, United Kingdom. FAU - Gil, Fernando Riesgo AU - Gil FR AD - Harefield Hospital, Hill End Road, Harefield, Uxbridge UB96JH, United Kingdom. FAU - Hurtado, Ana AU - Hurtado A AD - Harefield Hospital, Hill End Road, Harefield, Uxbridge UB96JH, United Kingdom. FAU - Rosenberg, Alex AU - Rosenberg A AD - Harefield Hospital, Hill End Road, Harefield, Uxbridge UB96JH, United Kingdom. FAU - Bowles, Christopher T AU - Bowles CT AD - Harefield Hospital, Hill End Road, Harefield, Uxbridge UB96JH, United Kingdom. LA - eng PT - Journal Article DEP - 20220531 PL - Netherlands TA - Resusc Plus JT - Resuscitation plus JID - 101774410 PMC - PMC9162943 OTO - NOTNLM OT - ALS, Advanced Life Support OT - Advanced life support OT - CALS, Cardiac Advanced Life Support OT - CPR, Cardio-Pulmonary Resuscitation OT - Cardiac arrest OT - DNAR, do not attempt resuscitation order OT - ECMO, Extracorporeal Membrane Oxygenation OT - ETCO2, End Tidal Carbon Dioxide, kPa Kilopascal OT - LVAD OT - LVAD, Left Ventricular Assist Device OT - Left ventricular assist device OT - MAP, Mean Arterial Pressure OT - MCQ, multiple-choice exam OT - MDT, multi-disciplinary team OT - MLS, Mechanical Life Support OT - Mechanical circulatory support OT - Resuscitation OT - VF, Ventricular Fibrillation OT - VT, Ventricular Tachycardia EDAT- 2022/06/08 06:00 MHDA- 2022/06/08 06:01 PMCR- 2022/05/31 CRDT- 2022/06/07 02:38 PHST- 2022/03/31 00:00 [received] PHST- 2022/04/23 00:00 [revised] PHST- 2022/05/16 00:00 [accepted] PHST- 2022/06/07 02:38 [entrez] PHST- 2022/06/08 06:00 [pubmed] PHST- 2022/06/08 06:01 [medline] PHST- 2022/05/31 00:00 [pmc-release] AID - S2666-5204(22)00054-6 [pii] AID - 100254 [pii] AID - 10.1016/j.resplu.2022.100254 [doi] PST - epublish SO - Resusc Plus. 2022 May 31;10:100254. doi: 10.1016/j.resplu.2022.100254. eCollection 2022 Jun. PMID- 35668532 OWN - NLM STAT- MEDLINE DCOM- 20220608 LR - 20260518 IS - 1745-6215 (Electronic) IS - 1745-6215 (Linking) VI - 23 IP - 1 DP - 2022 Jun 6 TI - Prehabilitation of elderly frail or pre-frail patients prior to elective surgery (PRAEP-GO): study protocol for a randomized, controlled, outcome assessor-blinded trial. PG - 468 LID - 10.1186/s13063-022-06401-x [doi] LID - 468 AB - BACKGROUND: Frailty is expressed by a reduction in physical capacity, mobility, muscle strength, and endurance. (Pre-)frailty is present in up to 42% of the older surgical population, with an increased risk for peri- and postoperative complications. Consequently, these patients often suffer from a delayed or limited recovery, loss of autonomy and quality of life, and a decrease in functional and cognitive capacities. Since frailty is modifiable, prehabilitation may improve the physiological reserves of patients and reduce the care dependency 12 months after surgery. METHODS: Patients >/= 70 years old scheduled for elective surgery or intervention will be recruited in this multicenter, randomized controlled study, with a target of 1400 participants with an allocation ratio of 1:1. The intervention consists of (1) a shared decision-making process with the patient, relatives, and an interdisciplinary and interprofessional team and (2) a 3-week multimodal, individualized prehabilitation program including exercise therapy, nutritional intervention, mobility or balance training, and psychosocial interventions and medical assessment. The frequency of the supervised prehabilitation is 5 times/week for 3 weeks. The primary endpoint is defined as the level of care dependency 12 months after surgery or intervention. DISCUSSION: Prehabilitation has been proven to be effective for different populations, including colorectal, transplant, and cardiac surgery patients. In contrast, evidence for prehabilitation in older, frail patients has not been clearly established. To the best of our knowledge, this is currently the largest prehabilitation study on older people with frailty undergoing general elective surgery. TRIAL REGISTRATION: ClinicalTrials.gov NCT04418271 . Registered on 5 June 2020. Universal Trial Number (UTN): U1111-1253-4820. CI - (c) 2022. The Author(s). FAU - Schaller, Stefan J AU - Schaller SJ AD - Department of Anesthesiology and Operative Intensive Care Medicine (CVK/CCM), Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Chariteplatz 1, 10117, Berlin, Germany. FAU - Kiselev, Jorn AU - Kiselev J AD - Department of Anesthesiology and Operative Intensive Care Medicine (CVK/CCM), Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Chariteplatz 1, 10117, Berlin, Germany. FAU - Loidl, Verena AU - Loidl V AD - Institute for Medical Information Processing, Biometry, and Epidemiology - IBE, Ludwig-Maximilians-Universitat Munchen, Munich, Germany. FAU - Quentin, Wilm AU - Quentin W AD - Department of Health Care Management, Technische Universitat Berlin, Berlin, Germany. FAU - Schmidt, Katrin AU - Schmidt K AD - Department of Anesthesiology and Operative Intensive Care Medicine (CVK/CCM), Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Chariteplatz 1, 10117, Berlin, Germany. FAU - Morgeli, Rudolf AU - Morgeli R AD - Department of Anesthesiology and Operative Intensive Care Medicine (CVK/CCM), Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Chariteplatz 1, 10117, Berlin, Germany. FAU - Rombey, Tanja AU - Rombey T AD - Department of Health Care Management, Technische Universitat Berlin, Berlin, Germany. FAU - Busse, Reinhard AU - Busse R AD - Department of Health Care Management, Technische Universitat Berlin, Berlin, Germany. FAU - Mansmann, Ulrich AU - Mansmann U AD - Institute for Medical Information Processing, Biometry, and Epidemiology - IBE, Ludwig-Maximilians-Universitat Munchen, Munich, Germany. FAU - Spies, Claudia AU - Spies C AUID- ORCID: 0000-0002-1062-0495 AD - Department of Anesthesiology and Operative Intensive Care Medicine (CVK/CCM), Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Chariteplatz 1, 10117, Berlin, Germany. claudia.spies@charite.de. CN - PRAEP-GO consortium, CN - PRAEP-GO investigators LA - eng SI - ClinicalTrials.gov/NCT04418271 GR - 01NVF18024/Gemeinsame Bundesausschuss/ PT - Clinical Trial Protocol PT - Journal Article DEP - 20220606 PL - England TA - Trials JT - Trials JID - 101263253 SB - IM EIN - Trials. 2023 Feb 14;24(1):111. doi: 10.1186/s13063-023-07106-5. PMID: 36788584 MH - Aged MH - Elective Surgical Procedures MH - *Frail Elderly MH - *Frailty/diagnosis MH - Humans MH - Multicenter Studies as Topic MH - Postoperative Complications/epidemiology/etiology/prevention & control MH - Preoperative Exercise MH - Quality of Life MH - Randomized Controlled Trials as Topic PMC - PMC9167908 OTO - NOTNLM OT - Decision-making, Shared OT - Frail elderly OT - Frailty OT - Health services research OT - Perioperative care OT - Preoperative exercise OT - Randomized controlled trial COIS- SJS received grants from Reactive Robotics GmbH (Munich, Germany); grants and non-financial support from STIMIT AG (Biel, Switzerland), Liberate Medical LLC (Crestwood USA), and ESICM (Geneva, Switzerland); grants, personal fees, and non-financial support from Fresenius Kabi Deutschland GmbH (Bad Homburg, Germany); personal fees from Springer Verlag GmbH (Vienna, Austria) for educational purposes; and non-financial support from Technical University of Munich (Munich, Germany) and from national and international societies (and their congress organizers) in the field of anesthesiology and intensive care medicine, outside the submitted work. Dr. Schaller held stocks in small amounts from Rhon-Klinikum AG and holds stocks in small amounts from Alphabeth Inc., Bayer AG, and Siemens AG; these holdings have not affected any decisions regarding his research or this study. J Kiselev declares no competing interests. V Loidl declares no competing interests. W Quentin declares no competing interests. K Schmidt declares no competing interests. R Morgeli declares no competing interests. T Rombey received honorary fees for commissioned research by the Statutory Health Insurance Medical Review Board. R Busse declares no competing interests. U Mannsmann declares no competing interests. C Spies reports grants from Gemeinsamer Bundesausschuss/Federal Joint Committee (G-BA) during the conduct of the study, grants from BMG/RKI, grants from Deutsche Forschungsgemeinschaft/German Research Society, grants from Deutsches Zentrum fur Luft- und Raumfahrt e. V. (DLR)/German Aerospace Center, grants from Einstein Stiftung Berlin/Einstein Foundation Berlin, grants from Inneruniversitare Forschungsforderung/Inner University Grants, grants from Projekttrager im DLR/Project Management Agency, grants from Stifterverband/Non-Profit Society Promoting Science and Education, grants from European Society of Anaesthesiology and Intensive Care, grants from Baxter Deutschland GmbH, grants from Cytosorbents Europe GmbH, grants from Edwards Lifesciences Germany GmbH, grants from Fresenius Medical Care, grants from Grunenthal GmbH, grants from Masimo Europe Ltd., grants from Pfizer Pharma PFE GmbH, personal fees from Georg Thieme Verlag, grants from Dr. F. Kohler Chemie GmbH, grants from Sintetica GmbH, grants from Stifterverband fur die deutsche Wissenschaft Thorn.V./PhilipsEth grants from Stiftung Charite, grants from AGUETTANT Deutschland GmbH, grants from AbbVie Deutschland GmbH & Co. KG, grants from Amomed Pharma GmbH, grants from InTouch Health, grants from Copra System GmbH, grants from Correvio GmbH, grants from Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V., grants from Deutsche Gesellschaft fur Anasthesiologie & Intensivmedizin (DGAI, grants from Stifterverband fur die deutsche Wissenschaft e.V./Metronic, grants from Philips Electronics Nederland BV, grants from BMG/RKI, grants from BMBF, grants from Deutsche Forschungsgemeinschaft/German Research Society, and grants from Dragerwerk AG & Co. KGaA, outside the submitted work. In addition, Dr. Spies has a patent 10 2014 215 211.9 licensed, a patent 10 2018 114 364.8 licensed, a patent 10 2018 110 275.5 licensed, a patent 50 2015 010 534.8Eth licensed, a patent 50 2015 010 347.7 licensed, and a patent 10 2014 215 212.7 licensed. FIR - Spies, Claudia IR - Spies C FIR - Marschall, Ursula IR - Marschall U FIR - Eckardt-Felmberg, Rahel IR - Eckardt-Felmberg R FIR - Landgraf, Irmgard IR - Landgraf I FIR - Schwantes, Ulrich IR - Schwantes U FIR - Busse, Reinhard IR - Busse R FIR - Mansmann, Ulrich IR - Mansmann U FIR - Borchers, Friedrich IR - Borchers F FIR - Morgeli, Rudolf IR - Morgeli R FIR - Schonenberger, Eva IR - Schonenberger E FIR - Klassen, Philipp IR - Klassen P FIR - Kleikamp, Bernadette IR - Kleikamp B FIR - Brandhorst, Philipp IR - Brandhorst P FIR - Spiegel, Anna-Lena H IR - Spiegel AH FIR - Papenfuss, Bernhard IR - Papenfuss B FIR - Dowideit, Jens IR - Dowideit J FIR - Oefele, Caroline IR - Oefele C FIR - Gebhardt, Volker IR - Gebhardt V FIR - Zappel, Kristina IR - Zappel K FIR - Govercin, Mehmet IR - Govercin M FIR - Konig, Thomas IR - Konig T FIR - Chesi, Claudio IR - Chesi C FIR - Reisshauer, Anett IR - Reisshauer A FIR - Rosada, Adrian IR - Rosada A FIR - Muller-Werdan, Ursula IR - Muller-Werdan U FIR - Heymann, Anja IR - Heymann A FIR - Hanke, Marion IR - Hanke M FIR - Leymann, Jens IR - Leymann J FIR - Saller, Thomas IR - Saller T FIR - Bischof, Ann-Cathrin IR - Bischof AC FIR - Reisner, Angelika IR - Reisner A FIR - Albrecht, Wolf Leopold IR - Albrecht WL FIR - Wojciechowski, Julia IR - Wojciechowski J FIR - Schuldt, Martina IR - Schuldt M FIR - Baum, Michael IR - Baum M FIR - Brnabic, Dijana IR - Brnabic D FIR - von Pickardt, Bjorn IR - von Pickardt B FIR - Deutschmann, Agnieszka IR - Deutschmann A FIR - Scholz, Carsten IR - Scholz C FIR - May, Lars IR - May L FIR - Eckardt-Felmberg, Rahel IR - Eckardt-Felmberg R FIR - Wenghofer, Isabell IR - Wenghofer I FIR - Blobner, Manfred IR - Blobner M FIR - Sattari, Sima IR - Sattari S FIR - Dummert, Michael IR - Dummert M FIR - Nau, Carla IR - Nau C FIR - Otto, Mareike IR - Otto M FIR - Voss-Lumers, Ute IR - Voss-Lumers U FIR - Lang, Danny IR - Lang D FIR - Wiggert, Daniel IR - Wiggert D EDAT- 2022/06/07 06:00 MHDA- 2022/06/09 06:00 PMCR- 2022/06/06 CRDT- 2022/06/06 23:38 PHST- 2022/04/11 00:00 [received] PHST- 2022/05/12 00:00 [accepted] PHST- 2022/06/06 23:38 [entrez] PHST- 2022/06/07 06:00 [pubmed] PHST- 2022/06/09 06:00 [medline] PHST- 2022/06/06 00:00 [pmc-release] AID - 10.1186/s13063-022-06401-x [pii] AID - 6401 [pii] AID - 10.1186/s13063-022-06401-x [doi] PST - epublish SO - Trials. 2022 Jun 6;23(1):468. doi: 10.1186/s13063-022-06401-x. PMID- 35665906 OWN - NLM STAT- MEDLINE DCOM- 20220704 LR - 20241219 IS - 1897-4279 (Electronic) IS - 0022-9032 (Linking) VI - 80 IP - 6 DP - 2022 TI - An expert opinion of the Polish Cardiac Society Working Group on Pulmonary Circulation on screening for chronic thromboembolic pulmonary hypertension patients after acute pulmonary embolism: Update. PG - 723-732 LID - 10.33963/KP.a2022.0141 [doi] AB - Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare complication of acute pulmonary embolism (APE). Both pharmacological and invasive treatments for CTEPH are available in Poland, and awareness of the disease among physicians is growing. It has been suggested that the COVID-19 pandemic may increase the incidence of CTEPH and facilitate disease detection during more advanced stages of the illness. Thus, the Polish Cardiac Society's Working Group on Pulmonary Circulation, in cooperation with independent experts in this field, launched the updated statement on the algorithm to guide a CTEPH diagnosis in patients with previous APE. CTEPH should be suspected in individuals after APE with dyspnea, despite at least 3 months of effective anticoagulation, particularly when specific risk factors are present. Echocardiography is the main screening tool for CTEPH. A diagnostic workup of patients with significant clinical suspicion of CTEPH and right ventricular overload evident on echocardiography should be performed in reference centers. Pulmonary scintigraphy is a safe and highly sensitive screening test for CTEPH. Computed tomography pulmonary angiography with precise detection of thromboembolic residues in the pulmonary circulation is important for the planning of a pulmonary thromboendarterectomy. Right heart catheterization definitively confirms the presence of pulmonary hypertension and direct pulmonary angiography allows for the identification of lesions suitable for thromboendarterectomy or balloon pulmonary angioplasty. In this document, we propose a diagnostic algorithm for patients with suspected CTEPH. With an individualized and sequential diagnostic strategy, each patient can be provided with suitable and tailored therapy provided by a dedicated CTEPH Heart Team. FAU - Ciurzynski, Michal AU - Ciurzynski M AD - Department of Internal Medicine and Cardiology with the Center for Diagnosis and Treatment of Venous Thromboembolism, Medical University of Warsaw, Warszawa, Poland. michal.ciurzynski@wum.edu.pl. FAU - Kurzyna, Marcin AU - Kurzyna M AD - Department of Pulmonary Circulation, Thromboembolism and Cardiology, Medical Center for Postgraduate Education in Warsaw, European Health Center, Otwock, Poland. FAU - Kopec, Grzegorz AU - Kopec G AD - Pulmonary Circulation Center, Department of Cardiac and Vascular Diseases, Jagiellonian University Medical College, Krakow, Poland. AD - Department of Cardiovascular Diseases with Cardiac Intensive Care Unit, John Paul II Hospital, Krakow, Poland. FAU - Blaszczak, Piotr AU - Blaszczak P AD - Department of Cardiology and Intensive Cardiac Care, Stefan Cardinal Wyszynski Provincial Specialist Hospital, Lublin, Poland. FAU - Chrzanowski, Lukasz AU - Chrzanowski L AD - Department of Cardiology, Medical University of Lodz, Lodz, Poland. FAU - Kaminski, Karol AU - Kaminski K AD - Department of Population Medicine and Lifestyle Diseases Prevention, Medical University of Bialystok, Bialystok, Poland. AD - Department of Cardiology, University Hospital in Bialystok, Bialystok, Poland. FAU - Mizia-Stec, Katarzyna AU - Mizia-Stec K AD - 1st Department of Cardiology, Faculty of Medicine, Medical University of Silesia in Katowice, Katowice, Poland. AD - European Reference Network for Rare, Low Prevalence, or Complex Diseases of the Heart (ERN GUARD Heart). FAU - Mularek-Kubzdela, Tatiana AU - Mularek-Kubzdela T AD - 1st Department of Cardiology, Poznan University of Medical Sciences, Poznan, Poland. FAU - Biederman, Andrzej AU - Biederman A AD - Department of Cardiac Surgery, Medicover Hospital, Warszawa, Poland. FAU - Zielinski, Dariusz AU - Zielinski D AD - Department of Cardiac Surgery, Medicover Hospital, Warszawa, Poland. FAU - Pruszczyk, Piotr AU - Pruszczyk P AD - Department of Internal Medicine and Cardiology with the Center for Diagnosis and Treatment of Venous Thromboembolism, Medical University of Warsaw, Warszawa, Poland. FAU - Torbicki, Adam AU - Torbicki A AD - Department of Pulmonary Circulation, Thromboembolism and Cardiology, Medical Center for Postgraduate Education in Warsaw, European Health Center, Otwock, Poland. FAU - Mroczek, Ewa AU - Mroczek E AD - Department of Cardiology, University Clinical Hospital, Institute of Heart Diseases, Wroclaw, Poland. LA - eng PT - Journal Article DEP - 20220606 PL - Poland TA - Kardiol Pol JT - Kardiologia polska JID - 0376352 SB - IM MH - Acute Disease MH - *COVID-19 MH - Chronic Disease MH - Humans MH - *Hypertension, Pulmonary/diagnosis/etiology/therapy MH - Pandemics MH - Poland MH - Pulmonary Circulation MH - *Pulmonary Embolism/complications/diagnosis/therapy OTO - NOTNLM OT - acute pulmonary embolism OT - chronic thromboembolic pulmonary hypertension OT - computed tomography pulmonary angiography OT - diagnostic algorithm OT - echocardiography EDAT- 2022/06/07 06:00 MHDA- 2022/07/06 06:00 CRDT- 2022/06/06 15:03 PHST- 2022/06/06 00:00 [received] PHST- 2022/06/06 00:00 [accepted] PHST- 2022/06/07 06:00 [pubmed] PHST- 2022/07/06 06:00 [medline] PHST- 2022/06/06 15:03 [entrez] AID - VM/OJS/J/90401 [pii] AID - 10.33963/KP.a2022.0141 [doi] PST - ppublish SO - Kardiol Pol. 2022;80(6):723-732. doi: 10.33963/KP.a2022.0141. Epub 2022 Jun 6. PMID- 35662825 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220716 IS - 2296-875X (Print) IS - 2296-875X (Electronic) IS - 2296-875X (Linking) VI - 9 DP - 2022 TI - Evaluation of Whether Emergency Physicians Should Join the Multidisciplinary Team for Older Hip Fracture Patients. PG - 842978 LID - 10.3389/fsurg.2022.842978 [doi] LID - 842978 AB - BACKGROUND: Geriatric hip fracture is one of the most common end-stage events in older patients with osteoporosis. We aimed to improve the original co-management process by engaging emergency physicians in the preoperative multidisciplinary management team (MDT). We evaluated this intervention in terms of reducing patient waiting time before surgery. METHODS: Emergency Department data and hospitalization data for patients diagnosed with geriatric hip fractures in Beijing Jishuitan Hospital (JSTH) were collected and sorted into the intervention group, for whom the MDT included emergency physicians (from January 2019 to December 2019), and the control group (from January 2017 to December 2017). The percentage of patients treated with surgery within 48 h of admission was used as the primary outcome. The secondary outcomes included the time from emergency visit to admission (hours), the time from admission to discharge (days), the percentage of patients receiving surgical treatment after admission, the rate of perioperative medical complications during hospitalization, postoperative admission to the Intensive Care Unit, and total deaths during hospitalization. RESULTS: A total of 2,152 patients were enrolled. The rate of hypertension (58.5% vs 52.1%), coronary heart disease (24.6% vs 19.9%), and cerebrovascular disease (19.4% vs 15.5%) was higher in the intervention group than in the control group. The percentage of patients receiving surgical treatment in the intervention group (98.3%) was significantly higher than in the control group (96.3%, p = 0.004). The proportion of patients receiving surgical treatment within 48 h of admission was significantly higher in the intervention group (82.4%) than in the control group (60.4%, p < 0.001). The hospital stay was significantly shorter in the intervention group compared with the control group (p < 0.001). The incidence of perioperative medical complications and mortality during hospitalization was similar in the two groups. CONCLUSIONS: Involving emergency physicians in the MDT can reduce the waiting time before surgery and the hospital stay for older hip fracture patients. CI - Copyright (c) 2022 Guan, Wang, Zhao, Yang, Zhu and Wu. FAU - Guan, Lan AU - Guan L AD - Department of Emergency, Beijing Jishuitan Hospital, Beijing, China. FAU - Wang, Cong AU - Wang C AD - Department of Emergency, Beijing Jishuitan Hospital, Beijing, China. FAU - Zhao, Bin AU - Zhao B AD - Department of Emergency, Beijing Jishuitan Hospital, Beijing, China. FAU - Yang, Minghui AU - Yang M AD - Department of Orthopedics and Traumatology, Beijing Jishuitan Hospital, Beijing, China. FAU - Zhu, Shiwen AU - Zhu S AD - Department of Orthopedics and Traumatology, Beijing Jishuitan Hospital, Beijing, China. FAU - Wu, Xinbao AU - Wu X AD - Department of Orthopedics and Traumatology, Beijing Jishuitan Hospital, Beijing, China. LA - eng PT - Journal Article DEP - 20220518 PL - Switzerland TA - Front Surg JT - Frontiers in surgery JID - 101645127 PMC - PMC9157767 OTO - NOTNLM OT - China OT - emergency physician OT - hip fracture OT - multidisciplinary co-management OT - older people COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declare that this study received funding from Capital's Funds for Health Improvement and Research (2022-1-2071). The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication. EDAT- 2022/06/07 06:00 MHDA- 2022/06/07 06:01 PMCR- 2022/05/18 CRDT- 2022/06/06 13:48 PHST- 2021/12/24 00:00 [received] PHST- 2022/04/29 00:00 [accepted] PHST- 2022/06/06 13:48 [entrez] PHST- 2022/06/07 06:00 [pubmed] PHST- 2022/06/07 06:01 [medline] PHST- 2022/05/18 00:00 [pmc-release] AID - 10.3389/fsurg.2022.842978 [doi] PST - epublish SO - Front Surg. 2022 May 18;9:842978. doi: 10.3389/fsurg.2022.842978. eCollection 2022. PMID- 35662564 OWN - NLM STAT- MEDLINE DCOM- 20220623 LR - 20250623 IS - 1874-1754 (Electronic) IS - 0167-5273 (Linking) VI - 362 DP - 2022 Sep 1 TI - Clinical features and complications of Loeys-Dietz syndrome: A systematic review. PG - 158-167 LID - S0167-5273(22)00813-0 [pii] LID - 10.1016/j.ijcard.2022.05.065 [doi] AB - INTRODUCTION: Loeys-Dietz syndrome (LDS) is a connective tissue disorder that arises from mutations altering the transforming growth factor beta signalling pathway. Due to the recent discovery of the underlying genetic mutations leading to LDS, the spectrum of characteristics and complications is not fully understood. METHODS: Our search included five databases (Pubmed, SCOPUS, Web of Science, EMBASE and google scholar) and included variations of "Loeys-Dietz Syndrome" as search terms, using all available data until February 2021. All study types were included. Three reviewers screened 1394 abstracts, of which 418 underwent full-text review and 392 were included in the final analysis. RESULTS: We identified 3896 reported cases of LDS with the most commonly reported features and complications being: aortic aneurysms and dissections, arterial tortuosity, high arched palate, abnormal uvula and hypertelorism. LDS Types 1 and 2 share many clinical features, LDS Type 2 appears to have a more aggressive aortic disease. LDS Type 3 demonstrated an increased prevalence of mitral valve prolapse and arthritis. LDS Type 4 and 5 demonstrated a lower prevalence of musculoskeletal and cardiovascular involvement. Amongst 222 women who underwent 522 pregnancies, 4% experienced an aortic dissection and the peripartum mortality rate was 1%. CONCLUSION: We observed that LDS is a multisystem connective tissue disorder that is associated with a high burden of complications, requiring a multidisciplinary approach. Ongoing attempts to better characterise these features will allow clinicians to appropriately screen and manage these complications. CI - Copyright (c) 2022 The Author(s). Published by Elsevier B.V. All rights reserved. FAU - Gouda, Pishoy AU - Gouda P AD - University of Alberta, Division of Cariology, Edmonton, Alberta, Canada. FAU - Kay, Robert AU - Kay R AD - University of Alberta, Division of Cariology, Edmonton, Alberta, Canada. FAU - Habib, Marina AU - Habib M AD - Flinders University, School of Medicine, Adelaide, Australia. FAU - Aziz, Amir AU - Aziz A AD - University of Alberta, Division of Cariology, Edmonton, Alberta, Canada. FAU - Aziza, Eitan AU - Aziza E AD - University of Alberta, Division of Cariology, Edmonton, Alberta, Canada. FAU - Welsh, Robert AU - Welsh R AD - University of Alberta, Division of Cariology, Edmonton, Alberta, Canada; Canadian VIGOUR Centre, University of Alberta, Edmonton, Alberta, Canada. Electronic address: Robert.Welsh@ahs.ca. LA - eng PT - Journal Article PT - Systematic Review DEP - 20220601 PL - Netherlands TA - Int J Cardiol JT - International journal of cardiology JID - 8200291 SB - IM MH - *Aortic Dissection/diagnosis/epidemiology MH - Arteries MH - *Connective Tissue Diseases MH - Female MH - Humans MH - *Loeys-Dietz Syndrome/diagnosis/genetics MH - Mutation MH - Pregnancy OTO - NOTNLM OT - Connective tissue disease OT - Loeys-Dietz syndrome OT - SMAD3 OT - TGFB2 OT - TGFB3 OT - TGFBR1 OT - TGFBR2 EDAT- 2022/06/07 06:00 MHDA- 2022/06/24 06:00 CRDT- 2022/06/06 13:40 PHST- 2022/02/28 00:00 [received] PHST- 2022/05/23 00:00 [revised] PHST- 2022/05/29 00:00 [accepted] PHST- 2022/06/07 06:00 [pubmed] PHST- 2022/06/24 06:00 [medline] PHST- 2022/06/06 13:40 [entrez] AID - S0167-5273(22)00813-0 [pii] AID - 10.1016/j.ijcard.2022.05.065 [doi] PST - ppublish SO - Int J Cardiol. 2022 Sep 1;362:158-167. doi: 10.1016/j.ijcard.2022.05.065. Epub 2022 Jun 1. PMID- 35660234 OWN - NLM STAT- MEDLINE DCOM- 20220608 LR - 20220608 IS - 1558-3481 (Electronic) IS - 0899-5885 (Linking) VI - 34 IP - 2 DP - 2022 Jun TI - Transcatheter Aortic Valve Replacement Patient Care Improvements; It Takes a Team. PG - 205-214 LID - S0899-5885(22)00021-1 [pii] LID - 10.1016/j.cnc.2022.02.008 [doi] AB - Team-based care has been recommended by numerous cardiovascular organizations involving the treatment of valvular heart disease. Utilization of the cardiovascular team (CVT) in valvular programs has been discussed but there is a paucity of data involving team roles, backgrounds, or expectations. This article will describe a single health system and the roles of the CVT involved in the transcatheter aortic valve replacement (TAVR) program. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Keegan, Patricia A AU - Keegan PA AD - Emory Healthcare, 550 Peachtree Street Northeast, Atlanta, GA 30308, USA. Electronic address: patricia.keegan@emoryhealthcare.org. FAU - Mitchell, Rae AU - Mitchell R AD - Emory Healthcare, 550 Peachtree Street Northeast, Atlanta, GA 30308, USA. FAU - Stoneman, Christine AU - Stoneman C AD - Emory Healthcare, 550 Peachtree Street Northeast, Atlanta, GA 30308, USA. FAU - Arrington, William Shane AU - Arrington WS AD - Emory Healthcare, 550 Peachtree Street Northeast, Atlanta, GA 30308, USA. FAU - Spahr, Angela AU - Spahr A AD - Emory Healthcare, 550 Peachtree Street Northeast, Atlanta, GA 30308, USA. FAU - Brown, Thomas AU - Brown T AD - Emory Healthcare, 550 Peachtree Street Northeast, Atlanta, GA 30308, USA. FAU - Biven, Kelby AU - Biven K AD - Emory Healthcare, 550 Peachtree Street Northeast, Atlanta, GA 30308, USA. FAU - Donovan, Emily AU - Donovan E AD - Emory Healthcare, 550 Peachtree Street Northeast, Atlanta, GA 30308, USA. FAU - Kalinke, Louisa AU - Kalinke L AD - Emory Healthcare, 550 Peachtree Street Northeast, Atlanta, GA 30308, USA. FAU - Mathew, Preethy AU - Mathew P AD - Emory Healthcare, 550 Peachtree Street Northeast, Atlanta, GA 30308, USA. FAU - Harrison, Morgan AU - Harrison M AD - Emory Healthcare, 550 Peachtree Street Northeast, Atlanta, GA 30308, USA. FAU - Jones, Emily AU - Jones E AD - Emory Healthcare, 550 Peachtree Street Northeast, Atlanta, GA 30308, USA. FAU - Higgins, Mary AU - Higgins M AD - Emory Healthcare, 550 Peachtree Street Northeast, Atlanta, GA 30308, USA. FAU - Hester, Kenya AU - Hester K AD - Emory Healthcare, 550 Peachtree Street Northeast, Atlanta, GA 30308, USA. FAU - Gaston, Jeanette AU - Gaston J AD - Emory Healthcare, 550 Peachtree Street Northeast, Atlanta, GA 30308, USA. FAU - Mortorano, Cecilia AU - Mortorano C AD - Emory Healthcare, 550 Peachtree Street Northeast, Atlanta, GA 30308, USA. LA - eng PT - Journal Article PT - Review DEP - 20220428 PL - United States TA - Crit Care Nurs Clin North Am JT - Critical care nursing clinics of North America JID - 8912620 MH - *Aortic Valve Stenosis/surgery MH - Humans MH - Patient Care MH - Patient Care Team MH - Risk Factors MH - *Transcatheter Aortic Valve Replacement MH - Treatment Outcome OTO - NOTNLM OT - Heart team OT - Nursing OT - Pathway OT - Structural heart OT - TAVR EDAT- 2022/06/07 06:00 MHDA- 2022/06/09 06:00 CRDT- 2022/06/06 11:26 PHST- 2022/06/06 11:26 [entrez] PHST- 2022/06/07 06:00 [pubmed] PHST- 2022/06/09 06:00 [medline] AID - S0899-5885(22)00021-1 [pii] AID - 10.1016/j.cnc.2022.02.008 [doi] PST - ppublish SO - Crit Care Nurs Clin North Am. 2022 Jun;34(2):205-214. doi: 10.1016/j.cnc.2022.02.008. Epub 2022 Apr 28. PMID- 35660233 OWN - NLM STAT- MEDLINE DCOM- 20220608 LR - 20220608 IS - 1558-3481 (Electronic) IS - 0899-5885 (Linking) VI - 34 IP - 2 DP - 2022 Jun TI - Implementing Evidence-Based Motivational Interviewing Strategies in the Care of Patients with Heart Failure. PG - 191-204 LID - S0899-5885(22)00024-7 [pii] LID - 10.1016/j.cnc.2022.02.011 [doi] AB - Motivational interviewing (MI) has positive effects on heart failure patient outcomes related to self-care. MI can be effectively used by the interprofessional team in the hospital and clinic settings, and it can be effective even in brief patient interactions. The spirit of MI uses collaboration, evocation, and honoring the patient's autonomy. Open-ended questions, affirmations, reflective listening, and summarization are skills used to build empathy and elicit change talk with the MI framework. Clinicians can consider obtaining feedback to improve their practice of MI techniques for enhanced efficacy in helping heart failure patients improve self-care behaviors. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Judice Jones, Nicole AU - Judice Jones N AD - East Jefferson General Hospital, 4200 Houma Boulevard, Metairie, LA 70006, USA. Electronic address: Nicole.jones4@lcmchealth.org. FAU - Richard, Ana AU - Richard A AD - East Jefferson General Hospital, 4200 Houma Boulevard, Metairie, LA 70006, USA. LA - eng PT - Journal Article PT - Review PL - United States TA - Crit Care Nurs Clin North Am JT - Critical care nursing clinics of North America JID - 8912620 MH - Empathy MH - *Heart Failure/therapy MH - Humans MH - *Motivational Interviewing/methods MH - Self Care OTO - NOTNLM OT - Care of patients OT - Heart failure OT - Heart failure self-care OT - Motivational interviewing COIS- Disclosure The authors have nothing to disclose. EDAT- 2022/06/07 06:00 MHDA- 2022/06/09 06:00 CRDT- 2022/06/06 11:26 PHST- 2022/06/06 11:26 [entrez] PHST- 2022/06/07 06:00 [pubmed] PHST- 2022/06/09 06:00 [medline] AID - S0899-5885(22)00024-7 [pii] AID - 10.1016/j.cnc.2022.02.011 [doi] PST - ppublish SO - Crit Care Nurs Clin North Am. 2022 Jun;34(2):191-204. doi: 10.1016/j.cnc.2022.02.011. PMID- 35660232 OWN - NLM STAT- MEDLINE DCOM- 20230209 LR - 20230209 IS - 1558-3481 (Electronic) IS - 0899-5885 (Linking) VI - 34 IP - 2 DP - 2022 Jun TI - Prevention of Pressure Injury in Patients Hospitalized with Heart Failure. PG - 181-189 LID - S0899-5885(22)00023-5 [pii] LID - 10.1016/j.cnc.2022.02.010 [doi] AB - Hospital-acquired pressure injuries are problematic within organizations. The Centers for Medicare and Medicaid Services counts hospital-acquired pressure injuries as a patient safety event and encourages hospitals to reduce or eliminate them in part by reducing payments to the hospital. Individuals who are admitted to hospitals with acute heart failure are usually elderly with comorbidities that increase their risk of developing a pressure injury. Therefore, evidence-based protocols should be made, implemented, and analyzed by an interprofessional team to combat the development of pressure injuries to maintain the best quality of life for patients hospitalized with heart failure. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Johnson, Victoria Facquet AU - Johnson VF AD - Traction Department, East Jefferson General Hospital, Metairie, LA, USA. Electronic address: Victoria.Johnson@lcmchealth.org. FAU - Raphael, Krystal AU - Raphael K AD - Wound and Ostomy Care, Diabetes Management, East Jefferson General Hospital, Metairie, LA, USA. LA - eng PT - Journal Article PT - Review PL - United States TA - Crit Care Nurs Clin North Am JT - Critical care nursing clinics of North America JID - 8912620 MH - Aged MH - Humans MH - *Heart Failure/complications MH - Hospitalization MH - Hospitals MH - *Medicare MH - Quality of Life MH - United States/epidemiology MH - *Pressure Ulcer OTO - NOTNLM OT - Cardiac surgical patients OT - Heart failure patients OT - Pressure injuries OT - Prevention OT - Preventive dressings COIS- Disclosure The authors have nothing to disclose. EDAT- 2022/06/07 06:00 MHDA- 2022/06/09 06:00 CRDT- 2022/06/06 11:26 PHST- 2022/06/06 11:26 [entrez] PHST- 2022/06/07 06:00 [pubmed] PHST- 2022/06/09 06:00 [medline] AID - S0899-5885(22)00023-5 [pii] AID - 10.1016/j.cnc.2022.02.010 [doi] PST - ppublish SO - Crit Care Nurs Clin North Am. 2022 Jun;34(2):181-189. doi: 10.1016/j.cnc.2022.02.010. PMID- 35659955 OWN - NLM STAT- MEDLINE DCOM- 20220608 LR - 20220608 IS - 1878-1608 (Electronic) IS - 1753-3740 (Linking) VI - 36 IP - 1 DP - 2022 May TI - Cardiac disease in pregnancy. PG - 191-208 LID - S1521-6896(22)00009-X [pii] LID - 10.1016/j.bpa.2022.02.005 [doi] AB - In the developed world, cardiovascular disease has become the most frequent cause of death during pregnancy and postpartum, outnumbering by far obstetric causes of death such as bleeding or thromboembolism. Many factors contribute to this phenomenon, including an increasing age of pregnant women, co-morbidities, and an unhealthy lifestyle. The cardiovascular system is not only significantly challenged by physiological alterations in pregnancy but also by obstetric medication. Depending upon the severity of the underlying condition, pregnant women with cardiovascular disease should be managed by a multidisciplinary heart team in which anaesthesiologists play an important role. Profound knowledge of the cardiac pathophysiology is a prerequisite for the successful anaesthesiologic management of pregnant patients with cardiovascular disease. As there is no difference in general and regional anaesthesia regarding maternal outcomes, neuraxial anaesthesia using incremental techniques should be preferred for labour and (caesarean) delivery if not contraindicated by non-cardiac issues. CI - Copyright (c) 2022 Elsevier Ltd. All rights reserved. FAU - Rex, Steffen AU - Rex S AD - Department of Anaesthesiology, University Hospitals Leuven (BE), Department of Cardiovascular Sciences, KU Leuven (BE), Herestraat 49, B-3000 Leuven, Belgium. Electronic address: steffen.rex@uzleuven.be. FAU - Devroe, Sarah AU - Devroe S AD - Department of Anaesthesiology, University Hospitals Leuven (BE), Department of Cardiovascular Sciences, KU Leuven (BE), Herestraat 49, B-3000 Leuven, Belgium. Electronic address: sarah.devroe@uzleuven.be. LA - eng PT - Journal Article PT - Review DEP - 20220224 PL - Netherlands TA - Best Pract Res Clin Anaesthesiol JT - Best practice & research. Clinical anaesthesiology JID - 101121446 SB - IM MH - *Anesthesia, Conduction/methods MH - *Anesthesia, Obstetrical/methods MH - *Cardiovascular Diseases MH - Cesarean Section/methods MH - Female MH - *Heart Diseases/diagnosis/therapy MH - Humans MH - Pregnancy OTO - NOTNLM OT - anaesthesia OT - cardiovascular diseases OT - pregnancy COIS- Declaration of competing interest The authors declare no conflicts of interest. EDAT- 2022/06/07 06:00 MHDA- 2022/06/09 06:00 CRDT- 2022/06/06 11:15 PHST- 2022/02/01 00:00 [received] PHST- 2022/02/16 00:00 [accepted] PHST- 2022/06/06 11:15 [entrez] PHST- 2022/06/07 06:00 [pubmed] PHST- 2022/06/09 06:00 [medline] AID - S1521-6896(22)00009-X [pii] AID - 10.1016/j.bpa.2022.02.005 [doi] PST - ppublish SO - Best Pract Res Clin Anaesthesiol. 2022 May;36(1):191-208. doi: 10.1016/j.bpa.2022.02.005. Epub 2022 Feb 24. PMID- 35658810 OWN - NLM STAT- MEDLINE DCOM- 20220803 LR - 20250728 IS - 2154-8331 (Print) IS - 2154-8331 (Linking) VI - 50 IP - 3 DP - 2022 Aug TI - A multidisciplinary approach to heart failure care in the hospital: improving the patient journey. PG - 170-182 LID - 10.1080/21548331.2022.2082776 [doi] AB - BACKGROUND: Despite advancements in care for patients with heart failure (HF), morbidity and mortality remain high. Hospitalizations and readmissions for HF have been the focus of significant attention among health care providers and payers, with an eye toward reducing health care costs. However, considerable variability exists with regard to inpatient workflows and management for patients with HF, which represents a significant opportunity to improve care. OBJECTIVE: Here we provide a summary of optimal inpatient management strategies for HF, focusing on the multidisciplinary team of emergency medicine providers, admitting hospitalists, cardiovascular consultants, pharmacists, nurses, and social workers. METHODS: The patient journey serves as the template for this review article, from the initial presentation in the emergency department, to decongestion and stabilization, optimization of guideline-directed medical therapy, and discharge and appropriate disposition. CONCLUSION: This review aims not to be proscriptive but rather to provide best practices that are clinically relevant and actionable, with the goal of improving care for patients during the sentinel hospitalization for HF. FAU - Rao, Vijay U AU - Rao VU AD - Indiana Heart Physicians, Franciscan Health, Indianapolis, IN, USA. FAU - Bhasin, Atul AU - Bhasin A AD - Department of Internal Medicine, CentraState Medical Center, Freehold, and Hackensack Meridian Health Hospice, Wall, NJ, USA. FAU - Vargas, Jesus Jr AU - Vargas J Jr AD - Heart Failure Program, University of Pennsylvania Medical Center Harrisburg Hospital, Harrisburg, PA, USA. FAU - Arun Kumar, Vijaya AU - Arun Kumar V AUID- ORCID: 0000-0002-1699-1414 AD - Department of Emergency Medicine, Wayne State University, School of Medicine, Detroit, MI, USA. LA - eng PT - Journal Article PT - Review DEP - 20220704 PL - England TA - Hosp Pract (1995) JT - Hospital practice (1995) JID - 101268948 SB - IM MH - *Heart Failure/therapy MH - Hospitalization MH - Hospitals MH - Humans MH - Patient Discharge MH - Pharmacists OTO - NOTNLM OT - Cardiology OT - emergency medicine OT - heart failure OT - hospitalists OT - hospitalization EDAT- 2022/06/07 06:00 MHDA- 2022/08/04 06:00 CRDT- 2022/06/06 10:06 PHST- 2022/06/07 06:00 [pubmed] PHST- 2022/08/04 06:00 [medline] PHST- 2022/06/06 10:06 [entrez] AID - 10.1080/21548331.2022.2082776 [doi] PST - ppublish SO - Hosp Pract (1995). 2022 Aug;50(3):170-182. doi: 10.1080/21548331.2022.2082776. Epub 2022 Jul 4. PMID- 35645250 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230916 IS - 2079-9721 (Print) IS - 2079-9721 (Electronic) IS - 2079-9721 (Linking) VI - 10 IP - 2 DP - 2022 May 17 TI - When a Multidisciplinary Approach Is Life-Saving: A Case Report of Cardiogenic Shock Induced by a Large Pheochromocytoma. LID - 10.3390/diseases10020029 [doi] LID - 29 AB - BACKGROUND: Pheochromocytoma is known for its instantaneous presentation, especially in the younger population. Hemodynamic instability may be the cause of severe complications and impede patients' ability to undergo surgical treatment. These tumours are surgically difficult to treat due to the risk of catecholamine release during their manipulations, and when they are large, the tumour size represents an additional challenge. In our report, cardiogenic shock developed due to increases in systemic vascular resistance, and the lesion's size induced surgeons to perform open surgery. CASE PRESENTATION: A 46-year-old female patient was admitted to our intensive care unit with hypertension and later cardiogenic shock. Systolic dysfunction was noted, along with severely increased systemic vascular resistance. A CT scan showed a left-sided 8.5 cm adrenal mass, which was confirmed as pheochromocytoma using meta-iodobenzylguanidine scintigraphy. Anaesthesiologists and the surgical team planned an effective strategy of treatment. Given the lesion's size and its apparent invasion of the neighbouring organs, open adrenalectomy (after prolonged hemodynamic stabilisation) was considered safer. The surgery was successful, and the patient remains free from disease two years after the initial event. CONCLUSIONS: Large pheochromocytoma can be safely and effectively treated with open surgery by experienced hands but only by seeking to reach hemodynamic stabilisation and minimising the release of catecholamine before and during surgery. FAU - Baio, Raffaele AU - Baio R AUID- ORCID: 0000-0002-3157-0845 AD - Department of Medicine and Surgery "Scuola Medica Salernitana", University of Salerno, I-84081 Salerno, Italy. FAU - Pagano, Tommaso AU - Pagano T AUID- ORCID: 0000-0002-3962-5572 AD - Departments of Anesthesiology, Umberto I Hospital, I-84014 Salerno, Italy. FAU - Molisso, Giovanni AU - Molisso G AD - Department of Urology, Umberto I Hospital, I-84014 Salerno, Italy. FAU - Di Mauro, Umberto AU - Di Mauro U AD - Department of Urology, Umberto I Hospital, I-84014 Salerno, Italy. FAU - Intilla, Olivier AU - Intilla O AD - Department of Urology, Umberto I Hospital, I-84014 Salerno, Italy. FAU - Albano, Francesco AU - Albano F AD - Departments of Anesthesiology, Umberto I Hospital, I-84014 Salerno, Italy. FAU - Scarpato, Fulvio AU - Scarpato F AD - Departments of Anesthesiology, Umberto I Hospital, I-84014 Salerno, Italy. FAU - Giacometti, Stefania AU - Giacometti S AD - Departments of Anesthesiology, Umberto I Hospital, I-84014 Salerno, Italy. FAU - Sanseverino, Roberto AU - Sanseverino R AD - Department of Urology, Umberto I Hospital, I-84014 Salerno, Italy. LA - eng PT - Journal Article DEP - 20220517 PL - Switzerland TA - Diseases JT - Diseases (Basel, Switzerland) JID - 101636232 PMC - PMC9149903 OTO - NOTNLM OT - cardiogenic shock OT - open adrenalectomy OT - pheochromocytoma COIS- The authors declare that they have no competing interests. EDAT- 2022/06/02 06:00 MHDA- 2022/06/02 06:01 PMCR- 2022/05/17 CRDT- 2022/06/01 11:17 PHST- 2022/04/02 00:00 [received] PHST- 2022/05/06 00:00 [revised] PHST- 2022/05/11 00:00 [accepted] PHST- 2022/06/01 11:17 [entrez] PHST- 2022/06/02 06:00 [pubmed] PHST- 2022/06/02 06:01 [medline] PHST- 2022/05/17 00:00 [pmc-release] AID - diseases10020029 [pii] AID - diseases-10-00029 [pii] AID - 10.3390/diseases10020029 [doi] PST - epublish SO - Diseases. 2022 May 17;10(2):29. doi: 10.3390/diseases10020029. PMID- 35641327 OWN - NLM STAT- MEDLINE DCOM- 20220908 LR - 20260506 IS - 1879-1484 (Electronic) IS - 0021-9150 (Linking) VI - 355 DP - 2022 Aug TI - Outcome after percutaneous coronary intervention with contemporary stents in patients with concomitant peripheral arterial disease: A patient-level pooled analysis of four randomized trials. PG - 52-59 LID - S0021-9150(22)00238-6 [pii] LID - 10.1016/j.atherosclerosis.2022.05.002 [doi] AB - BACKGROUND AND AIMS: A considerable number of patients who undergo percutaneous coronary intervention (PCI) also have peripheral arterial disease (PAD) - a signal of more advanced atherosclerosis. After bare metal and early-generation drug-eluting coronary stent implantation, PAD patients showed inferior outcome. As stents and medical treatment were further improved, we aimed to assess the impact of PAD on outcome of PCI with contemporary new-generation stents. METHODS: We analyzed 3-year pooled patient-level data from 4 large-scale randomized new-generation stent trials to compare all-comer patients with and without (core lab-verified) history of symptomatic PAD, defined as obstructive lesions in peripheral locations including lower and upper extremities, carotid, vertebral, mesenteric and renal arteries. Main endpoint was target vessel failure: cardiac death, target vessel-related myocardial infarction, or clinically indicated target vessel revascularization. RESULTS: Of all 9204 patients, 695 (7.6%) had a history of symptomatic PAD. They were older and had more often diabetes, renal failure, hypertension, hypercholesterolemia, and prior stroke. PAD was an independent risk factor for target vessel failure (adjusted-HR:1.42, 95%-CI:1.12-1.73, p = 0.001). Target vessel revascularization (adjusted-HR:1.37, 95%-CI:1.04-1.80, p = 0.026), death (adjusted-HR:1.52, 95%-CI:1.17-1.99, p = 0.002), and major adverse cardiovascular event risks (adjusted-HR:1.36, 95%-CI:1.13-1.64, p = 0.001) were also substantially higher. CONCLUSIONS: A history of symptomatic PAD still allows to simply identify patients with increased risk of unfavorable clinical outcome after PCI, including a higher risk of repeated coronary revascularization, despite using contemporary stents. In clinical practice, this knowledge about higher event risks of PAD patients is helpful both during Heart Team discussions and when informing patients about the procedural risk. CI - Copyright (c) 2022 The Authors. Published by Elsevier B.V. All rights reserved. FAU - Pinxterhuis, Tineke H AU - Pinxterhuis TH AD - Department of Cardiology, Thoraxcentrum Twente, Medisch Spectrum Twente, Enschede, the Netherlands; Department of Health Technology and Services Research, Faculty BMS, Technical Medical Centre, University of Twente, Enschede, the Netherlands. FAU - Ploumen, Eline H AU - Ploumen EH AD - Department of Cardiology, Thoraxcentrum Twente, Medisch Spectrum Twente, Enschede, the Netherlands; Department of Health Technology and Services Research, Faculty BMS, Technical Medical Centre, University of Twente, Enschede, the Netherlands. FAU - Zocca, Paolo AU - Zocca P AD - Department of Cardiology, Thoraxcentrum Twente, Medisch Spectrum Twente, Enschede, the Netherlands. FAU - Doggen, Carine J M AU - Doggen CJM AD - Department of Health Technology and Services Research, Faculty BMS, Technical Medical Centre, University of Twente, Enschede, the Netherlands. FAU - Schotborgh, Carl E AU - Schotborgh CE AD - Department of Cardiology, Haga Hospital, The Hague, the Netherlands. FAU - Anthonio, Rutger L AU - Anthonio RL AD - Department of Cardiology, Treant Zorggroep, Scheper Hospital, Emmen, the Netherlands. FAU - Roguin, Ariel AU - Roguin A AD - Department of Cardiology, Hillel Yaffe Medical Center, Hadera and B. Rappaport-Faculty of Medicine, Israel, Institute of Technology, Haifa, Israel. FAU - Danse, Peter W AU - Danse PW AD - Department of Cardiology, Rijnstate Hospital, Arnhem, the Netherlands. FAU - Benit, Edouard AU - Benit E AD - Department of Cardiology, Jessa Hospital, Hasselt, Belgium. FAU - Aminian, Adel AU - Aminian A AD - Department of Cardiology, Centre Hospitalier Universitaire de Charleroi, Charleroi, Belgium. FAU - Stoel, Martin G AU - Stoel MG AD - Department of Cardiology, Thoraxcentrum Twente, Medisch Spectrum Twente, Enschede, the Netherlands. FAU - Linssen, Gerard C M AU - Linssen GCM AD - Department of Cardiology, Ziekenhuisgroep Twente, Almelo Hengelo, the Netherlands. FAU - Geelkerken, Robert H AU - Geelkerken RH AD - Department of Vascular Surgery, Medisch Spectrum Twente, Enschede, the Netherlands; Department of Multi-modality Medical Imaging (M3I) Group, Faculty of Science and Technology, Technical Medical Centre, University of Twente, Enschede, the Netherlands. FAU - von Birgelen, Clemens AU - von Birgelen C AD - Department of Cardiology, Thoraxcentrum Twente, Medisch Spectrum Twente, Enschede, the Netherlands; Department of Health Technology and Services Research, Faculty BMS, Technical Medical Centre, University of Twente, Enschede, the Netherlands. Electronic address: c.vonbirgelen@mst.nl. LA - eng SI - ClinicalTrials.gov/NCT01066650 SI - ClinicalTrials.gov/NCT01331707 SI - ClinicalTrials.gov/NCT01674803 SI - ClinicalTrials.gov/NCT02508714 PT - Journal Article DEP - 20220520 PL - Ireland TA - Atherosclerosis JT - Atherosclerosis JID - 0242543 SB - IM CIN - Atherosclerosis. 2022 Aug;355:45-47. doi: 10.1016/j.atherosclerosis.2022.06.1022. PMID: 35817601 MH - Humans MH - *Coronary Artery Disease/complications/surgery MH - *Drug-Eluting Stents MH - *Percutaneous Coronary Intervention/adverse effects MH - *Peripheral Arterial Disease/complications/diagnosis/therapy MH - Randomized Controlled Trials as Topic MH - Risk Factors MH - Stents MH - Treatment Outcome OTO - NOTNLM OT - Coronary artery disease OT - Drug-eluting stent OT - Percutaneous coronary intervention OT - Peripheral arterial disease EDAT- 2022/06/01 06:00 MHDA- 2022/09/09 06:00 CRDT- 2022/05/31 22:03 PHST- 2022/02/25 00:00 [received] PHST- 2022/04/29 00:00 [revised] PHST- 2022/05/05 00:00 [accepted] PHST- 2022/06/01 06:00 [pubmed] PHST- 2022/09/09 06:00 [medline] PHST- 2022/05/31 22:03 [entrez] AID - S0021-9150(22)00238-6 [pii] AID - 10.1016/j.atherosclerosis.2022.05.002 [doi] PST - ppublish SO - Atherosclerosis. 2022 Aug;355:52-59. doi: 10.1016/j.atherosclerosis.2022.05.002. Epub 2022 May 20. PMID- 35636519 OWN - NLM STAT- MEDLINE DCOM- 20220809 LR - 20250728 IS - 1535-6280 (Electronic) IS - 0146-2806 (Linking) VI - 47 IP - 9 DP - 2022 Sep TI - Challenges and Updates in the Diagnosis and Treatment of Infective Endocarditis. PG - 101267 LID - S0146-2806(22)00164-5 [pii] LID - 10.1016/j.cpcardiol.2022.101267 [doi] AB - Infective endocarditis is a life-threatening disease of the endocardium of the heart and cardiac valves, caused by several infectious agents, ranging from Streptococci to rickettsia. It has continued to be a serious cause of cardiac infection, with a rise in the incidence globally over the last 5 years. Despite diagnostic and therapeutic advances, its prognosis remains poor, and a surge in morbidity and hospital mortality highlights the significance of the swift diagnosis of this disease. Given its complexity, patients with infective endocarditis need rapid response and prompt diagnosis from a multidisciplinary team with a timely diagnostic protocol and treatment in the critical phase. Still, there is a lack of evidence regarding the timing of surgery or the role of antibiotic prophylaxis in the management. In this review, we detail the epidemiological transition, challenges in the diagnosis, and the newer avenues in the medical and surgical management of infective endocarditis. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Sebastian, Sneha A AU - Sebastian SA AD - Department of Internal Medicine, Azeezia Medical College, Kollam, Kerala, India. Electronic address: snehaann991@gmail.com. FAU - Co, Edzel L AU - Co EL AD - Department of Internal Medicine, University of Santo Tomas Faculty of Medicine and Surgery, Manila, Philippines. FAU - Mehendale, Meghana AU - Mehendale M AD - Department of Internal Medicine, Smolensk State Medical University, Smolensk Oblast, Russia. FAU - Sudan, Sourav AU - Sudan S AD - Department of Internal Medicine, Government Medical College, Jammu, India. FAU - Manchanda, Kshitij AU - Manchanda K AD - Department of Internal Medicine, Government Medical College Surat, Surat, India. FAU - Khan, Samina AU - Khan S AD - Department of Internal Medicine, University of Alberta, Alberta, Canada. LA - eng PT - Journal Article PT - Review DEP - 20220528 PL - Netherlands TA - Curr Probl Cardiol JT - Current problems in cardiology JID - 7701802 SB - IM MH - *Endocarditis/diagnosis/epidemiology/therapy MH - *Endocarditis, Bacterial/diagnosis/drug therapy MH - Hospital Mortality MH - Humans MH - Incidence MH - Prognosis EDAT- 2022/06/01 06:00 MHDA- 2022/08/10 06:00 CRDT- 2022/05/31 13:24 PHST- 2022/05/16 00:00 [received] PHST- 2022/05/23 00:00 [accepted] PHST- 2022/06/01 06:00 [pubmed] PHST- 2022/08/10 06:00 [medline] PHST- 2022/05/31 13:24 [entrez] AID - S0146-2806(22)00164-5 [pii] AID - 10.1016/j.cpcardiol.2022.101267 [doi] PST - ppublish SO - Curr Probl Cardiol. 2022 Sep;47(9):101267. doi: 10.1016/j.cpcardiol.2022.101267. Epub 2022 May 28. PMID- 35633822 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220716 IS - 1735-5370 (Print) IS - 2008-2371 (Electronic) IS - 1735-5370 (Linking) VI - 16 IP - 3 DP - 2021 Jul TI - Cardiac Manifestations in Iranian Patients with Behcet's Disease. PG - 109-112 LID - 10.18502/jthc.v16i3.8187 [doi] AB - Background: Behcet's disease (BD) is a vasculitis with multisystem and multiorgan involvement. Cardiac involvement in BD is a rare complication with a poor outcome that manifests itself in different forms. In this study, we aimed to investigate cardiac involvement in BD. Methods: This is a retrospective study based on cardiac manifestations in BD according to the data of the Behcet's Disease Unit, the Rheumatology Research Center, Tehran University of Medical Sciences, from registered patients from 1975 until June 2017. Cardiac manifestations consisted of pericarditis, myocardiopathy, myocardial infarction, stable ischemic heart disease, endomyocardial fibrosis, thrombosis, and valvular and coronary involvement. All the patients' baseline and demographic data were recorded in a designed questionnaire. The laboratory workups, imaging, and pathological tests were also performed. Results: We studied 7650 patients with BD, of whom 51% were male. In the entire study population, 47 patients manifested cardiac involvement: valvular involvement in 6.1%, myocardial infarction in 23.4%, stable ischemic heart disease in 20%, pericarditis in 21.3%, intracardiac thrombosis in 2.1%, coronary aneurysm in 2.1%, heart failure in 12.8%, and dilated cardiomyopathy in 4.3%. Conclusion: The prevalence of cardiac involvement in our patients with BD was 0.6%. A multidisciplinary approach can reduce mortality and morbidity rates. Consequently, we suggest that echocardiography and other cardiac diagnostic tests be routinely considered for early diagnosis and subsequent treatment. CI - Copyright (c) 2021 Tehran University of Medical Sciences. Published by Tehran University of Medical Sciences. FAU - Shadmanfar, Soraya AU - Shadmanfar S AD - Health Research Center, Lifestyle Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran. AD - Rheumatology Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran. FAU - Masoumi, Maryam AU - Masoumi M AD - Clinical Research Development Center, Shahid Beheshti Hospital, Qom University of Medical Sciences, Qom, Iran. AD - Rheumatology Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran. FAU - Davatchi, Fereydoun AU - Davatchi F AD - Rheumatology Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran. AD - Iran National Elite Foundation, Tehran, Iran. FAU - Akhlaghi, Massoomeh AU - Akhlaghi M AD - Rheumatology Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran. FAU - Faezi, Seyedeh Tahereh AU - Faezi ST AD - Rheumatology Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran. FAU - Kavosi, Hoda AU - Kavosi H AD - Rheumatology Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran. FAU - Balasi, Javad AU - Balasi J AD - School of Medicine, Iran University of Medical Sciences, Tehran, Iran. FAU - Deravi, Niloofar AU - Deravi N AD - School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. FAU - Montazeri, Seyed Mohammad Hashem AU - Montazeri SMH AD - School of Medicine, Qom University of Medical Sciences, Qom, Iran. FAU - Namazi, Mansoor AU - Namazi M AD - Clinical Research Development Center, Shahid Beheshti Hospital, Qom University of Medical Sciences, Qom, Iran. AD - Shahid Beheshti Hospital, Qom University of Medical Sciences, Qom, Iran. LA - eng PT - Journal Article PL - Iran TA - J Tehran Heart Cent JT - The journal of Tehran Heart Center JID - 101289255 PMC - PMC9108474 OTO - NOTNLM OT - Behcet's syndrome OT - Cardiovascular diseases OT - Iran EDAT- 2022/06/01 06:00 MHDA- 2022/06/01 06:01 PMCR- 2021/07/01 CRDT- 2022/05/31 09:46 PHST- 2020/12/06 00:00 [revised] PHST- 2021/06/25 00:00 [accepted] PHST- 2022/05/31 09:46 [entrez] PHST- 2022/06/01 06:00 [pubmed] PHST- 2022/06/01 06:01 [medline] PHST- 2021/07/01 00:00 [pmc-release] AID - JTHC-16-109 [pii] AID - 10.18502/jthc.v16i3.8187 [doi] PST - ppublish SO - J Tehran Heart Cent. 2021 Jul;16(3):109-112. doi: 10.18502/jthc.v16i3.8187. PMID- 35629130 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220716 IS - 2075-4426 (Print) IS - 2075-4426 (Electronic) IS - 2075-4426 (Linking) VI - 12 IP - 5 DP - 2022 Apr 28 TI - An Individualized Approach of Multidisciplinary Heart Team for Myocardial Revascularization and Valvular Heart Disease-State of Art. LID - 10.3390/jpm12050705 [doi] LID - 705 AB - The multidisciplinary Heart Team (HT) remains the standard of care for highly-burdened patients with coronary artery disease (CAD) and valvular heart disease (VHD) and is widely adopted in the medical community and supported by European and American guidelines. An approach of highly-experienced specialists, taking into account numerous clinical factors, risk assessment, long-term prognosis and patients preferences seems to be the most rational option for individuals with. Some studies suggest that HT management may positively impact adherence to current recommendations and encourage the incorporation of patient preferences through the use of shared-decision making. Evidence from randomized-controlled trials are scarce and we still have to satisfy with observational studies. Furthermore, we still do not know how HT should cooperate, what goals are desired and most importantly, how HT decisions affect long-term outcomes and patient's satisfaction. This review aimed to comprehensively discuss the available evidence establishing the role of HT for providing optimal care for patients with CAD and VHD. We believe that the need for research to recognize the HT definition and range of its functioning is an important issue for further exploration. Improved techniques of interventional cardiology, minimally-invasive surgeries and new drugs determine future perspectives of HT conceptualization, but also add new issues to the complexity of HT cooperation. Regardless of which direction HT has evolved, its concept should be continued and refined to improve healthcare standards. FAU - Jonik, Szymon AU - Jonik S AUID- ORCID: 0000-0002-9230-5455 AD - 1st Department of Cardiology, Medical University of Warsaw, Banacha 1a Str., 01-267 Warsaw, Poland. FAU - Marchel, Michal AU - Marchel M AD - 1st Department of Cardiology, Medical University of Warsaw, Banacha 1a Str., 01-267 Warsaw, Poland. FAU - Huczek, Zenon AU - Huczek Z AD - 1st Department of Cardiology, Medical University of Warsaw, Banacha 1a Str., 01-267 Warsaw, Poland. FAU - Kochman, Janusz AU - Kochman J AD - 1st Department of Cardiology, Medical University of Warsaw, Banacha 1a Str., 01-267 Warsaw, Poland. FAU - Wilimski, Radoslaw AU - Wilimski R AD - Department of Cardiac Surgery, Medical University of Warsaw, Banacha 1a Str., 01-267 Warsaw, Poland. FAU - Kusmierczyk, Mariusz AU - Kusmierczyk M AD - Department of Cardiac Surgery, Medical University of Warsaw, Banacha 1a Str., 01-267 Warsaw, Poland. FAU - Grabowski, Marcin AU - Grabowski M AUID- ORCID: 0000-0003-3306-0301 AD - 1st Department of Cardiology, Medical University of Warsaw, Banacha 1a Str., 01-267 Warsaw, Poland. FAU - Opolski, Grzegorz AU - Opolski G AD - 1st Department of Cardiology, Medical University of Warsaw, Banacha 1a Str., 01-267 Warsaw, Poland. FAU - Mazurek, Tomasz AU - Mazurek T AUID- ORCID: 0000-0002-3693-8741 AD - 1st Department of Cardiology, Medical University of Warsaw, Banacha 1a Str., 01-267 Warsaw, Poland. LA - eng PT - Journal Article PT - Review DEP - 20220428 PL - Switzerland TA - J Pers Med JT - Journal of personalized medicine JID - 101602269 PMC - PMC9144508 OTO - NOTNLM OT - aortic stenosis OT - coronary artery disease OT - decision-making OT - heart team OT - interventions OT - mitral regurgitation COIS- The authors declare no conflict of interest. EDAT- 2022/05/29 06:00 MHDA- 2022/05/29 06:01 PMCR- 2022/04/28 CRDT- 2022/05/28 01:26 PHST- 2022/03/26 00:00 [received] PHST- 2022/04/24 00:00 [revised] PHST- 2022/04/27 00:00 [accepted] PHST- 2022/05/28 01:26 [entrez] PHST- 2022/05/29 06:00 [pubmed] PHST- 2022/05/29 06:01 [medline] PHST- 2022/04/28 00:00 [pmc-release] AID - jpm12050705 [pii] AID - jpm-12-00705 [pii] AID - 10.3390/jpm12050705 [doi] PST - epublish SO - J Pers Med. 2022 Apr 28;12(5):705. doi: 10.3390/jpm12050705. PMID- 35622220 OWN - NLM STAT- MEDLINE DCOM- 20221025 LR - 20221025 IS - 1863-6713 (Electronic) IS - 1863-6705 (Linking) VI - 70 IP - 11 DP - 2022 Nov TI - Transcatheter tricuspid valve-in-valve implantation with bioprosthetic balloon expandable valve. PG - 947-953 LID - 10.1007/s11748-022-01829-z [doi] AB - OBJECTIVES: This study was conducted to evaluate the outcome of the transcatheter valve-in-valve implantation for degenerated tricuspid bioprosthetic valves with transcatheter aortic valves. METHODS: This retrospective study enrolled all consecutive patients who were considered high risk for reoperations by the heart team and who underwent transcatheter valve-in-valve implantation for degenerated tricuspid bioprosthetic valves in Tehran Heart Center, Tehran, Iran. All the procedures were performed via the transfemoral venous route under echocardiography and fluoroscopy guidance with Edwards SAPIEN transcatheter heart valves (Edwards Lifesciences, Irvine, CA). RESULTS: Ten patients underwent successful transcatheter valve-in-valve implantation in the tricuspid position without any major complications or need for emergency surgical interventions. The mean age was 54.1 +/- 17.1 years, and 8 patients were female. The median follow-up was 19.5 months (16-32.25 mon). The mean period between the last tricuspid valve replacement and transcatheter valve-in-valve implantation was 4.9 +/- 2.2 years. The bioprosthetic valves were Hancock in three patients, Mosaic in the other three patients, and Biocor, Pericarbon, Perimount, and Epic in the other patients. After the procedure, the clinical and functional status improved significantly in all the patients. The mean transvalvular gradient decreased from 6.75 +/- 2.66 mm Hg to 2.85 +/- 0.89 (P < 0.001), and the postoperative tricuspid regurgitation severity decreased significantly in almost all the patients. The hospitalization period after the procedure was 4.4 +/- 1.7 days. CONCLUSIONS: In high-risk patients, transcatheter valve-in-valve implantation seems to be a safe and minimally invasive alternative to reoperations for degenerated tricuspid bioprosthetic valves. CI - (c) 2022. The Author(s), under exclusive licence to The Japanese Association for Thoracic Surgery. FAU - Haji-Zeinali, Ali-Mohammad AU - Haji-Zeinali AM AD - Interventional Cardiology, Head of the Endovascular and Structural Heart Intervention Department, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran. ali_zeinali_cardio@yahoo.com. FAU - Etesamifard, Nasrin AU - Etesamifard N AD - Interventional Cardiology, Head of the Endovascular and Structural Heart Intervention Department, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran. FAU - Mohammadi, Zohre AU - Mohammadi Z AD - Department of Cardiology, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran. FAU - Haji-Zeinali, Mohammad-Mohsen AU - Haji-Zeinali MM AD - Research Department, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran. FAU - Sahebjam, Mohammad AU - Sahebjam M AD - Department of Echocardiography, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran. FAU - Abbasi, Kiomars AU - Abbasi K AD - Department of Cardiac Surgery, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran. LA - eng PT - Journal Article DEP - 20220527 PL - Japan TA - Gen Thorac Cardiovasc Surg JT - General thoracic and cardiovascular surgery JID - 101303952 SB - IM MH - Humans MH - Female MH - Adult MH - Middle Aged MH - Aged MH - Male MH - *Heart Valve Prosthesis MH - Tricuspid Valve/diagnostic imaging/surgery MH - *Bioprosthesis MH - *Heart Valve Prosthesis Implantation/adverse effects/methods MH - Cardiac Catheterization/methods MH - *Transcatheter Aortic Valve Replacement MH - Retrospective Studies MH - Prosthesis Failure MH - Prosthesis Design MH - Treatment Outcome MH - Iran OTO - NOTNLM OT - Balloon expandable valve OT - Bioprosthetic valve OT - Transcatheter tricuspid valve in valve OT - Tricuspid valve disease EDAT- 2022/05/28 06:00 MHDA- 2022/10/26 06:00 CRDT- 2022/05/27 11:18 PHST- 2021/11/23 00:00 [received] PHST- 2022/05/02 00:00 [accepted] PHST- 2022/05/28 06:00 [pubmed] PHST- 2022/10/26 06:00 [medline] PHST- 2022/05/27 11:18 [entrez] AID - 10.1007/s11748-022-01829-z [pii] AID - 10.1007/s11748-022-01829-z [doi] PST - ppublish SO - Gen Thorac Cardiovasc Surg. 2022 Nov;70(11):947-953. doi: 10.1007/s11748-022-01829-z. Epub 2022 May 27. PMID- 35621200 OWN - NLM STAT- MEDLINE DCOM- 20220608 LR - 20220805 IS - 2047-9980 (Electronic) IS - 2047-9980 (Linking) VI - 11 IP - 11 DP - 2022 Jun 7 TI - Clinical Impact of Heart Team Decisions for Patients With Complex Valvular Heart Disease: A Large, Single-Center Experience. PG - e024404 LID - 10.1161/JAHA.121.024404 [doi] LID - e024404 AB - Background A multidisciplinary approach might be pivotal for the management of patients with valvular heart disease (VHD), but clinical outcome data are lacking. Methods and Results At our institution, since 2014, internal guidelines recommended heart team consultations for patients with VHD. The clinical/echocardiographic characteristics, treatment recommendations, performed treatment, and early clinical outcomes of consecutive, hospitalized patients with VHD undergoing heart team evaluation were collected. Surgical risk was prospectively assessed by the EuroSCORE II and STS-PROM. The primary end point of the study was early mortality. A total of 1004 patients with VHD with high clinical complexity (mean age, 75 years; mean EuroSCORE II, 9.4%; mean STS-PROM, 5.6%; 48% ischemic heart disease; 29% chronic kidney disease, 9% oncologic/hematologic diseases) were enrolled. The heart team recommended an interventional treatment for 807 (80%) patients and conservative management for 197 (20%) patients. Management crossovers occurred in only 5% of patients. The recommended intervention was cardiac surgery for 230 (23%) patients, percutaneous treatment in 516 (51%) patients, and hybrid treatment in 61 (6%) patients. Early mortality occurred in 24 patients (2.4%) and was independently predicted by aortic stenosis, left ventricular ejection fraction, pulmonary artery systolic pressure, and conservative management recommendation. In patients referred to treatment, observed early mortality (1.7%) was significantly lower (P<0.001) than expected on the bases of both the STS-PROM (5.2%) and EuroSCORE II (9.7%). Conclusions Within the limitations of its single-center and observational design, the present study suggests that heart team-based management of patients with complex VHD is feasible and allows referral to a wide spectrum of interventions with promising early clinical results. FAU - Burzotta, Francesco AU - Burzotta F AUID- ORCID: 0000-0002-6569-9401 AD - Fondazione Policlinico Universitario A. Gemelli IRCCS Roma Italia. AD - Universita Cattolica del Sacro Cuore Roma Italia. FAU - Graziani, Francesca AU - Graziani F AUID- ORCID: 0000-0002-4520-5689 AD - Fondazione Policlinico Universitario A. Gemelli IRCCS Roma Italia. FAU - Trani, Carlo AU - Trani C AD - Fondazione Policlinico Universitario A. Gemelli IRCCS Roma Italia. AD - Universita Cattolica del Sacro Cuore Roma Italia. FAU - Aurigemma, Cristina AU - Aurigemma C AD - Fondazione Policlinico Universitario A. Gemelli IRCCS Roma Italia. FAU - Bruno, Piergiorgio AU - Bruno P AD - Fondazione Policlinico Universitario A. Gemelli IRCCS Roma Italia. AD - Universita Cattolica del Sacro Cuore Roma Italia. FAU - Lombardo, Antonella AU - Lombardo A AUID- ORCID: 0000-0003-3162-1830 AD - Fondazione Policlinico Universitario A. Gemelli IRCCS Roma Italia. AD - Universita Cattolica del Sacro Cuore Roma Italia. FAU - Liuzzo, Giovanna AU - Liuzzo G AD - Fondazione Policlinico Universitario A. Gemelli IRCCS Roma Italia. AD - Universita Cattolica del Sacro Cuore Roma Italia. FAU - Nesta, Marialisa AU - Nesta M AD - Fondazione Policlinico Universitario A. Gemelli IRCCS Roma Italia. FAU - Lanza, Gaetano Antonio AU - Lanza GA AUID- ORCID: 0000-0003-2187-6653 AD - Fondazione Policlinico Universitario A. Gemelli IRCCS Roma Italia. AD - Universita Cattolica del Sacro Cuore Roma Italia. FAU - Romagnoli, Enrico AU - Romagnoli E AUID- ORCID: 0000-0003-1611-7708 AD - Fondazione Policlinico Universitario A. Gemelli IRCCS Roma Italia. FAU - Locorotondo, Gabriella AU - Locorotondo G AUID- ORCID: 0000-0001-8589-7328 AD - Fondazione Policlinico Universitario A. Gemelli IRCCS Roma Italia. FAU - Leone, Antonio Maria AU - Leone AM AD - Fondazione Policlinico Universitario A. Gemelli IRCCS Roma Italia. FAU - Pavone, Natalia AU - Pavone N AD - Fondazione Policlinico Universitario A. Gemelli IRCCS Roma Italia. AD - Universita Cattolica del Sacro Cuore Roma Italia. FAU - Spalletta, Claudio AU - Spalletta C AD - Fondazione Policlinico Universitario A. Gemelli IRCCS Roma Italia. FAU - Pelargonio, Gemma AU - Pelargonio G AD - Fondazione Policlinico Universitario A. Gemelli IRCCS Roma Italia. AD - Universita Cattolica del Sacro Cuore Roma Italia. FAU - Sanna, Tommaso AU - Sanna T AUID- ORCID: 0000-0002-5760-6885 AD - Fondazione Policlinico Universitario A. Gemelli IRCCS Roma Italia. AD - Universita Cattolica del Sacro Cuore Roma Italia. FAU - Aspromonte, Nadia AU - Aspromonte N AUID- ORCID: 0000-0002-0369-2052 AD - Fondazione Policlinico Universitario A. Gemelli IRCCS Roma Italia. AD - Universita Cattolica del Sacro Cuore Roma Italia. FAU - Cavaliere, Franco AU - Cavaliere F AD - Fondazione Policlinico Universitario A. Gemelli IRCCS Roma Italia. AD - Universita Cattolica del Sacro Cuore Roma Italia. FAU - Crea, Filippo AU - Crea F AD - Fondazione Policlinico Universitario A. Gemelli IRCCS Roma Italia. AD - Universita Cattolica del Sacro Cuore Roma Italia. FAU - Massetti, Massimo AU - Massetti M AD - Fondazione Policlinico Universitario A. Gemelli IRCCS Roma Italia. AD - Universita Cattolica del Sacro Cuore Roma Italia. LA - eng PT - Journal Article DEP - 20220527 PL - England TA - J Am Heart Assoc JT - Journal of the American Heart Association JID - 101580524 SB - IM MH - Aged MH - *Aortic Valve Stenosis MH - Echocardiography MH - *Heart Valve Diseases/surgery/therapy MH - Humans MH - Risk Factors MH - Stroke Volume MH - Ventricular Function, Left PMC - PMC9238748 OTO - NOTNLM OT - TAVI OT - cardiac surgery OT - heart team OT - hybrid interventions OT - mortality OT - precision medicine OT - valvular heart disease EDAT- 2022/05/28 06:00 MHDA- 2022/06/09 06:00 PMCR- 2022/06/07 CRDT- 2022/05/27 07:12 PHST- 2022/05/28 06:00 [pubmed] PHST- 2022/06/09 06:00 [medline] PHST- 2022/05/27 07:12 [entrez] PHST- 2022/06/07 00:00 [pmc-release] AID - JAH37436 [pii] AID - 10.1161/JAHA.121.024404 [doi] PST - ppublish SO - J Am Heart Assoc. 2022 Jun 7;11(11):e024404. doi: 10.1161/JAHA.121.024404. Epub 2022 May 27. PMID- 35620558 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260518 IS - 1205-7088 (Print) IS - 1918-1485 (Electronic) IS - 1205-7088 (Linking) VI - 27 IP - Suppl 1 DP - 2022 Jun TI - All hands on deck: A multidisciplinary approach to SARS-CoV-2-associated MIS-C. PG - S53-S58 LID - 10.1093/pch/pxab110 [doi] AB - BACKGROUND: Multisystem Inflammatory Syndrome in Children (MIS-C) is a post-infectious complication of SARS-CoV-2 infection with overlapping features of Kawasaki disease and toxic shock syndrome. In May 2020, a provincial multidisciplinary working group was established in anticipation of emerging cases following the first wave of SARS-CoV-2 infections. METHODOLOGY: Our centre established a multidisciplinary working group for MIS-C cases in British Columbia. The group developed guidelines using the World Health Organization MIS-C case definition. Guidelines were updated using quality improvement methods as new reports and our local experience evolved. We included all children who were evaluated in person or had samples sent to our centre for MIS-C evaluation from May 2020 to April 2021. We prospectively collected patient demographics, clinical and laboratory characteristics, and treatment. RESULTS: Fifty-two children were included. Eleven were diagnosed as confirmed MIS-C. Ten of the 11 MIS-C cases presented with shock. Gastrointestinal and mucocutaneous involvement were also prominent. Common laboratory features included elevated C-reactive protein, D-dimer, troponin, and brain natriuretic peptide. Four out of 11 (36%) had myocardial dysfunction and 3/11 (27%) had coronary artery abnormalities. All 11 patients had evidence of SARS-CoV-2 infection. Ten out of 11 (91%) received intravenous (IV) immunoglobulin and IV corticosteroids. CONCLUSION: Our provincial cohort of MIS-C patients were more likely to present with shock and cardiac dysfunction, require ICU admission, and be treated with corticosteroids compared to ruled out cases. Our working group's evolving process ensured children with features of MIS-C were rapidly identified, had standardized evaluation, and received appropriate treatment in our province. CI - (c) The Author(s) 2022. Published by Oxford University Press on behalf of the Canadian Paediatric Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. FAU - Lopez, Alison A AU - Lopez AA AD - Division of Infectious Diseases, BC Children's Hospital, Vancouver, British Columbia, Canada. FAU - Patel, Mona AU - Patel M AD - Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada. AD - Division of Critical Care, BC Children's Hospital, Vancouver, British Columbia, Canada. FAU - Rayment, Jonathan H AU - Rayment JH AD - Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada. AD - Division of Respiratory Medicine, BC Children's Hospital, Vancouver, British Columbia, Canada. FAU - Tam, Herman AU - Tam H AUID- ORCID: 0000-0002-5805-0639 AD - Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada. AD - Division of Rheumatology, BC Children's Hospital, Vancouver, British Columbia, Canada. FAU - Roberts, Ashley AU - Roberts A AD - Division of Infectious Diseases, BC Children's Hospital, Vancouver, British Columbia, Canada. AD - Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Laskin, Samara AU - Laskin S AD - Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada. AD - Division of General Pediatrics, BC Children's Hospital, Vancouver, British Columbia, Canada. FAU - Tucker, Lori AU - Tucker L AD - Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada. AD - Division of Rheumatology, BC Children's Hospital, Vancouver, British Columbia, Canada. FAU - Biggs, Catherine M AU - Biggs CM AD - Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada. AD - Division of Allergy and Immunology, BC Children's Hospital, Vancouver, British Columbia, Canada. CN - BMWG LA - eng PT - Journal Article DEP - 20220428 PL - England TA - Paediatr Child Health JT - Paediatrics & child health JID - 9815960 PMC - PMC9126281 OTO - NOTNLM OT - COVID-19 OT - Critical illness OT - MIS-C OT - Sepsis OT - Surveillance FIR - Ahmed, May A IR - Ahmed MA FIR - Barakauskas, Vilte IR - Barakauskas V FIR - Galanis, Eleni IR - Galanis E FIR - Goldfarb, David IR - Goldfarb D FIR - Halparin, Jessica IR - Halparin J FIR - Harris, Kevin C IR - Harris KC FIR - Kissoon, Niranjan IR - Kissoon N FIR - Lawrence, Sally IR - Lawrence S FIR - McGuffin, Dominique IR - McGuffin D FIR - Meckler, Garth IR - Meckler G FIR - Noel, Kirsten IR - Noel K FIR - Schrader, Dewi IR - Schrader D FIR - Sherwood, Michelle IR - Sherwood M FIR - Singh, Avash IR - Singh A FIR - Vercauteren, Suzanne IR - Vercauteren S EDAT- 2022/05/28 06:00 MHDA- 2022/05/28 06:01 PMCR- 2023/04/28 CRDT- 2022/05/27 02:31 PHST- 2021/07/26 00:00 [received] PHST- 2022/01/24 00:00 [accepted] PHST- 2022/05/27 02:31 [entrez] PHST- 2022/05/28 06:00 [pubmed] PHST- 2022/05/28 06:01 [medline] PHST- 2023/04/28 00:00 [pmc-release] AID - pxab110 [pii] AID - 10.1093/pch/pxab110 [doi] PST - epublish SO - Paediatr Child Health. 2022 Apr 28;27(Suppl 1):S53-S58. doi: 10.1093/pch/pxab110. eCollection 2022 Jun. PMID- 35619983 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240828 IS - 2639-6378 (Electronic) IS - 2639-6378 (Linking) VI - 7 IP - 5 DP - 2021 Dec TI - Team Up For Quality Care:: The Role of Primary Care Teams in Prevention Of Cardiovascular Disease. PG - 80-90 LID - 10.32481/djph.2021.12.017 [doi] AB - Healthcare providers appreciate the value of evidence-based guidelines such as the American College of Cardiology/American Heart Association Guideline on the Primary Prevention of Cardiovascular Disease (Guideline). In a busy clinical practice, however, many competing demands can create barriers to full implementation of these protocols. A solution is to embrace a newer model of practice that engages the interdisciplinary care team with all staff working at the top of their licensure/training. The care team approach is backed by strong evidence supporting improved patient outcomes, such as hypertension control. By appropriately sharing responsibilities, the practice delivers a unified health promotion message, and physicians are able to focus on the care requiring their medical expertise. When all staff members have clear roles and responsibilities, the practice can more easily implement the Guideline fully and work together to deliver high-quality, evidence-based primary prevention of cardiovascular disease. FAU - Biederman, Cindy AU - Biederman C AD - Practice Transformation Specialist, Quality Insights. LA - eng PT - Journal Article DEP - 20211215 PL - United States TA - Dela J Public Health JT - Delaware journal of public health JID - 101769648 PMC - PMC9124550 EDAT- 2022/05/28 06:00 MHDA- 2022/05/28 06:01 PMCR- 2021/12/15 CRDT- 2022/05/27 02:19 PHST- 2022/05/27 02:19 [entrez] PHST- 2022/05/28 06:00 [pubmed] PHST- 2022/05/28 06:01 [medline] PHST- 2021/12/15 00:00 [pmc-release] AID - djph-75-017 [pii] AID - 10.32481/djph.2021.12.017 [doi] PST - epublish SO - Dela J Public Health. 2021 Dec 15;7(5):80-90. doi: 10.32481/djph.2021.12.017. eCollection 2021 Dec. PMID- 35616212 OWN - NLM STAT- MEDLINE DCOM- 20220608 LR - 20240830 IS - 2047-9980 (Electronic) IS - 2047-9980 (Linking) VI - 11 IP - 11 DP - 2022 Jun 7 TI - Cardiorenal Nexus: A Review With Focus on Combined Chronic Heart and Kidney Failure, and Insights From Recent Clinical Trials. PG - e024139 LID - 10.1161/JAHA.121.024139 [doi] LID - e024139 AB - The cardiorenal nexus encompasses a bidirectional relationship between the heart and the kidneys. Chronic abnormalities in cardiac function can lead to progressive kidney disease, and chronic kidney disease can lead to progressively decreasing cardiac function and increasing risk of cardiovascular disease, including heart failure. About 15% of US adults have chronic kidney disease, 2% have heart failure, and 9% have cardiovascular disease. Prevalence rates of chronic kidney disease, cardiovascular disease, and associated morbidities such as type 2 diabetes are expected to increase with an aging population. Observational studies provide evidence for the cardiorenal nexus. Follow-up data from placebo arms of clinical trials in chronic kidney disease or cardiovascular disease show higher rates of renal and cardiovascular outcome events in patient subgroups with type 2 diabetes than in those without type 2 diabetes. The cardiorenal syndromes develop along an interlinked pathophysiological trajectory that requires a holistic, collaborative approach involving a multidisciplinary team. There is now a compendium of treatment options. Greater understanding of the underlying pathophysiology of the cardiorenal nexus will support optimization of the management of these interlinked disease states. FAU - McCullough, Peter A AU - McCullough PA AUID- ORCID: 0000-0002-0997-6355 AD - Truth for Health Foundation Tucson AZ. FAU - Amin, Alpesh AU - Amin A AD - Department of Medicine University of California Irvine School of Medicine Orange CA. FAU - Pantalone, Kevin M AU - Pantalone KM AD - Endocrinology and Metabolism Institute Cleveland Clinic Cleveland OH. FAU - Ronco, Claudio AU - Ronco C AD - International Renal Research Institute of Vicenza Italy. AD - Department of Nephrology, Dialysis and Transplantation San Bortolo Hospital Vicenza Italy. AD - Department of Medicine (DIMED) Universita di Padova Padua Italy. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20220526 PL - England TA - J Am Heart Assoc JT - Journal of the American Heart Association JID - 101580524 SB - IM MH - Aged MH - *Cardio-Renal Syndrome/diagnosis/epidemiology/therapy MH - *Cardiovascular Diseases/complications MH - *Diabetes Mellitus, Type 2/complications/diagnosis/epidemiology MH - *Heart Failure/complications/epidemiology/therapy MH - Humans MH - *Renal Insufficiency, Chronic/diagnosis/epidemiology/therapy PMC - PMC9238695 OTO - NOTNLM OT - cardiorenal nexus OT - cardiorenal syndromes OT - cardiovascular disease OT - chronic kidney disease OT - heart failure OT - type 2 diabetes EDAT- 2022/05/27 06:00 MHDA- 2022/06/09 06:00 PMCR- 2022/06/07 CRDT- 2022/05/26 06:42 PHST- 2022/05/27 06:00 [pubmed] PHST- 2022/06/09 06:00 [medline] PHST- 2022/05/26 06:42 [entrez] PHST- 2022/06/07 00:00 [pmc-release] AID - JAH37475 [pii] AID - 10.1161/JAHA.121.024139 [doi] PST - ppublish SO - J Am Heart Assoc. 2022 Jun 7;11(11):e024139. doi: 10.1161/JAHA.121.024139. Epub 2022 May 26. PMID- 35615233 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240828 IS - 1751-1437 (Print) IS - 2057-360X (Electronic) IS - 1751-1437 (Linking) VI - 23 IP - 2 DP - 2022 May TI - Echocardiographic assessment and critical care management of peri-partum women with unexpected left ventricular failure. PG - 210-221 LID - 10.1177/1751143720978862 [doi] AB - INTRODUCTION: Cardiac disease remains the largest single cause of maternal death. Whilst uncommon, left ventricular failure during pregnancy and delivery can be devastating to both mother and child. Echocardiography can play a significant role in rapidly establishing a diagnosis, guiding initial therapy and then monitoring response. CLINICAL VIGNETTES: The history, presentation and management of three cases of peri-partum left ventricular failure is examined: stress cardiomyopathy in a 34 year old with twins, left ventricular dysfunction secondary to pre-eclampsia in a 22 year old with a singleton pregnancy and a true peri-partum cardiomyopathy in a 42 year old with IVF twins. The defining risk factors, presenting characteristics and echocardiographical findings for each pathology are highlighted. CONCLUSION: Echocardiography is playing an increasingly important role in the immediate assessment and management of left ventricular failure. This is especially true in the peri-partum woman, where establishing the correct therapy is both challenging and crucial due to the significant cardiovascular changes that occur around the time of delivery. To this end we believe that echocardiography should be rapidly available to guide the management of these patients by a multidisciplinary team made up of obstetricians, cardiologists, anaesthetists and intensive care physicians. CI - (c) The Intensive Care Society 2021. FAU - Greatorex, Ben AU - Greatorex B AUID- ORCID: 0000-0001-6736-2426 AD - Department of Anaesthesia and Intensive Care, Raigmore Hospital, NHS Highlands, Inverness, UK. FAU - Colebourn, Claire AU - Colebourn C AD - Oxford University Hospitals, Oxford, UK. FAU - Ormerod, Oliver AU - Ormerod O AD - Oxford University Hospitals, Oxford, UK. LA - eng PT - Journal Article PT - Review DEP - 20210105 PL - England TA - J Intensive Care Soc JT - Journal of the Intensive Care Society JID - 101538668 PMC - PMC9125437 OTO - NOTNLM OT - Echocardiography OT - cardiomyopathy OT - heart failure OT - peri-partum OT - pre-eclampsia COIS- Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2022/05/27 06:00 MHDA- 2022/05/27 06:01 PMCR- 2021/01/05 CRDT- 2022/05/26 02:19 PHST- 2022/05/26 02:19 [entrez] PHST- 2022/05/27 06:00 [pubmed] PHST- 2022/05/27 06:01 [medline] PHST- 2021/01/05 00:00 [pmc-release] AID - 10.1177_1751143720978862 [pii] AID - 10.1177/1751143720978862 [doi] PST - ppublish SO - J Intensive Care Soc. 2022 May;23(2):210-221. doi: 10.1177/1751143720978862. Epub 2021 Jan 5. PMID- 35613946 OWN - NLM STAT- MEDLINE DCOM- 20230828 LR - 20230907 IS - 1477-111X (Electronic) IS - 0267-6591 (Linking) VI - 38 IP - 6 DP - 2023 Sep TI - Development of pediatric multidisciplinary extracorporeal membrane oxygenation simulations: A novel educational program to enhance team communication and emergency preparedness. PG - 1142-1152 LID - 10.1177/02676591221105408 [doi] AB - INTRODUCTION: Pediatric extracorporeal membrane oxygenation (ECMO) is a high risk, low-volume technology. Infrequency of this technology and associated complications may translate to unfamiliarity of identification and management of potentially life-threatening events, which may require knowledge and procedural skills to be performed quickly. Providers involved in managing ECMO must be able to promptly identify and initiate management for such events, particularly when surgical colleagues are not readily available. METHODS: A multidisciplinary ECMO simulation program was implemented in a tertiary children's hospital. Over 18 months, a prospective, observational study was conducted evaluating simulations involving circuit and patient emergencies, teamwork and communication behaviors and technical skills. An on-line survey was sent to participants following sessions to evaluate post-simulation confidence, lessons learned and potential barriers to implementation of necessary skills and behaviors. RESULTS: Ten simulation sessions occurred during implementation. Mean participants per session was 7 (range: 5-11). Eight Pediatric Cardiac Intensive Care Unit attendings, four Advance Practice Nurses, 54 pediatric intensive care unit registered nurses, and 55 pediatric respiratory therapists attended. Tasks with highest self-reported increase in confidence were related to (1) diagnosis (tension pneumothorax, oxygenator failure, and ventricular tachycardia), (2) fluid administration and (3) early and efficient mobilization for ECPR, with less reported confidence increase with technical skills More than 90% of participants provided a task or behavior they would implement if a specific emergency was encountered in real-life following simulation training. Real-life application occurred following simulations with participants reporting direct impact of training on their ability to perform the skill efficiently and correctly. CONCLUSIONS: Implementation of ECMO multidisciplinary simulations provides structured opportunities for the team to learn and practice ECMO skills together in scenarios they may encounter without surgical presence. Ensuring competency of providers through implementation of such a program may improve patient safety through enhanced team communication, knowledge, and hands-on experience. FAU - Nater, Melissa AU - Nater M AUID- ORCID: 0000-0001-5310-4792 AD - Advocate Children's Heart Institute, Advocate Children's Hospital, Oak Lawn, IL, USA. FAU - Nelson-McMillan, Kristen AU - Nelson-McMillan K AD - Advocate Children's Heart Institute, Advocate Children's Hospital, Oak Lawn, IL, USA. AD - Department of Pediatrics, Division of Critical Care, University of Chicago, Chicago, IL, USA. FAU - Elzein, Chawki AU - Elzein C AD - Advocate Children's Heart Institute, Advocate Children's Hospital, Oak Lawn, IL, USA. AD - Department of Surgery, University of Illinois at Chicago, Chicago, IL, USA. FAU - Boone, Alison AU - Boone A AD - Advocate Christ Medical Center Simulation Center, Oak Lawn, IL, USA. FAU - Urbas, Cynthia AU - Urbas C AD - Department of Surgery, Advocate Children's Hospital, Oak Lawn, IL, USA. LA - eng PT - Journal Article PT - Observational Study DEP - 20220525 PL - England TA - Perfusion JT - Perfusion JID - 8700166 SB - IM MH - Humans MH - Child MH - *Extracorporeal Membrane Oxygenation/education MH - *Civil Defense MH - Prospective Studies MH - Communication MH - *Simulation Training MH - Clinical Competence OTO - NOTNLM OT - ECMO OT - extracorporeal membrane oxygenation OT - extracorporeal membrane oxygenation curriculum OT - multidisciplinary simulation OT - neonatal OT - pediatric OT - simulation EDAT- 2022/05/26 06:00 MHDA- 2023/08/28 06:42 CRDT- 2022/05/25 21:52 PHST- 2023/08/28 06:42 [medline] PHST- 2022/05/26 06:00 [pubmed] PHST- 2022/05/25 21:52 [entrez] AID - 10.1177/02676591221105408 [doi] PST - ppublish SO - Perfusion. 2023 Sep;38(6):1142-1152. doi: 10.1177/02676591221105408. Epub 2022 May 25. PMID- 35613307 OWN - NLM STAT- MEDLINE DCOM- 20220527 LR - 20251022 IS - 2329-9185 (Electronic) IS - 2329-9185 (Linking) VI - 10 IP - 5 DP - 2022 May 1 TI - Team Approach: Management of Geriatric Acetabular Fractures. LID - 10.2106/JBJS.RVW.22.00017 [doi] AB - >>: Geriatric acetabular fractures are defined as fractures sustained by patients who are >/=60 years old. With the rapidly aging American populace and its increasingly active lifestyle, the prevalence of these injuries will continue to increase. >>: An interdisciplinary approach is necessary to ensure successful outcomes. This begins in the emergency department with hemodynamic stabilization, diagnosis of the fracture, identification of comorbidities and concomitant injuries, as well as early consultation with the orthopaedic surgery service. This multifaceted approach is continued when patients are admitted, and trauma surgery, geriatrics, and cardiology teams are consulted. These teams are responsible for the optimization of complex medical conditions and risk stratification prior to operative intervention. >>: Treatment varies depending on a patient's preinjury functional status, the characteristics of the fracture, and the patient's ability to withstand surgery. Nonoperative management is recommended for patients with minimally displaced fractures who cannot tolerate the physiologic stress of surgery. Percutaneous fixation is a treatment option most suited for patients with minimally displaced fractures who are at risk for displacing the fracture or are having difficulty mobilizing because of pain. Open reduction and internal fixation is recommended for patients with displaced acetabular fractures who are medically fit for surgery and have a displaced fracture pattern that would do poorly without operative intervention. Fixation in combination with arthroplasty can be done acutely or in delayed fashion. Acute fixation combined with arthroplasty benefits patients who have poorer bone quality and fracture characteristics that make healing unlikely. Delayed arthroplasty is recommended for patients who have had failure of nonoperative management, have a fracture pattern that is not favorable to primary total hip arthroplasty, or have developed posttraumatic arthritis. CI - Copyright (c) 2022 by The Journal of Bone and Joint Surgery, Incorporated. FAU - Villacres Mori, Benjamin AU - Villacres Mori B AUID- ORCID: 0000-0001-6969-7879 AD - Division of Orthopaedic Surgery, Albany Medical Center, Albany, New York. FAU - Young, Joseph R AU - Young JR AUID- ORCID: 0000-0002-4624-3556 FAU - Lakra, Akshay AU - Lakra A FAU - Chisena, Ernest AU - Chisena E LA - eng PT - Journal Article DEP - 20220501 PL - United States TA - JBJS Rev JT - JBJS reviews JID - 101674872 SB - IM MH - Acetabulum/injuries/surgery MH - Aged MH - *Arthroplasty, Replacement, Hip MH - Fracture Fixation, Internal MH - *Hip Fractures/surgery MH - Humans MH - Middle Aged MH - Open Fracture Reduction MH - *Spinal Fractures/surgery COIS- Disclosure: The Disclosure of Potential Conflicts of Interest forms are provided with the online version of the article (http://links.lww.com/JBJSREV/A839). EDAT- 2022/05/26 06:00 MHDA- 2022/05/28 06:00 CRDT- 2022/05/25 14:13 PHST- 2022/05/25 14:13 [entrez] PHST- 2022/05/26 06:00 [pubmed] PHST- 2022/05/28 06:00 [medline] AID - 01874474-202205000-00009 [pii] AID - 10.2106/JBJS.RVW.22.00017 [doi] PST - epublish SO - JBJS Rev. 2022 May 1;10(5). doi: 10.2106/JBJS.RVW.22.00017. PMID- 35613200 OWN - NLM STAT- MEDLINE DCOM- 20220527 LR - 20240902 IS - 1678-4170 (Electronic) IS - 0066-782X (Print) IS - 0066-782X (Linking) VI - 118 IP - 5 DP - 2022 May TI - Infective Endocarditis: Still More Challenges Than Convictions. PG - 976-988 LID - S0066-782X2022000500976 [pii] LID - 10.36660/abc.20200798 [doi] AB - After fourteen decades of medical and technological evolution, infective endocarditis continues to challenge physicians in its daily diagnosis and management. Its increasing incidence, demographic shifts (affecting older patients), microbiology with higher rates of Staphylococcus infection, still frequent serious complications and substantial mortality make endocarditis a very complex disease. Despite this, innovations in the diagnosis, involving microbiology and imaging, and improvements in intensive care and cardiac surgical techniques, materials and timing can impact the prognosis of this disease. Ongoing challenges persist, including rethinking prophylaxis, improving the diagnosis criteria comprising blood culture-negative endocarditis and prosthetic valve endocarditis, timing of surgical intervention, and whether to perform surgery in the presence of ischemic stroke or in intravenous drug users. A combined strategy on infective endocarditis is crucial, involving advanced clinical decisions and protocols, a multidisciplinary approach, national healthcare organization and health policies to achieve better results for our patients. FAU - Sousa, Catarina AU - Sousa C AUID- ORCID: 0000-0003-1709-6283 AD - Centro Cardiovascular Universidade de Lisboa (CCUL), Faculdade de Medicina, Universidade de Lisboa, Lisboa - Portugal. AD - Servico de Cardiologia, Centro Hospitalar Barreiro Montijo (CHBM), Barreiro - Portugal. FAU - Pinto, Fausto J AU - Pinto FJ AUID- ORCID: 0000-0002-8034-4529 AD - Centro Cardiovascular Universidade de Lisboa (CCUL), Faculdade de Medicina, Universidade de Lisboa, Lisboa - Portugal. AD - Departamento Coracao e Vasos, Centro Hospitalar e Universitario Lisboa Norte (CHULN), Lisboa - Portugal. LA - eng LA - por PT - Journal Article TT - Endocardite Infecciosa: Ainda mais Desafios que Certezas. PL - Brazil TA - Arq Bras Cardiol JT - Arquivos brasileiros de cardiologia JID - 0421031 SB - IM MH - *Cardiac Surgical Procedures MH - *Endocarditis/complications/diagnosis/therapy MH - *Endocarditis, Bacterial/complications/diagnosis/therapy MH - *Heart Valve Prosthesis/adverse effects MH - Humans MH - *Staphylococcal Infections PMC - PMC9368884 OAB - After fourteen decades of medical and technological evolution, infective endocarditis continues to challenge physicians in its daily diagnosis and management. Its increasing incidence, demographic shifts (affecting older patients), microbiology with higher rates of Staphylococcus infection, still frequent serious complications and substantial mortality make endocarditis a very complex disease. Despite this, innovations in the diagnosis, involving microbiology and imaging, and improvements in intensive care and cardiac surgical techniques, materials and timing can impact the prognosis of this disease. Ongoing challenges persist, including rethinking prophylaxis, improving the diagnosis criteria comprising blood culture-negative endocarditis and prosthetic valve endocarditis, timing of surgical intervention, and whether to perform surgery in the presence of ischemic stroke or in intravenous drug users. A combined strategy on infective endocarditis is crucial, involving advanced clinical decisions and protocols, a multidisciplinary approach, national healthcare organization and health policies to achieve better results for our patients. OABL- eng COIS- Potencial conflito de interesse Nao ha conflito com o presente artigo EDAT- 2022/05/26 06:00 MHDA- 2022/05/28 06:00 PMCR- 2022/05/04 CRDT- 2022/05/25 13:53 PHST- 2020/07/21 00:00 [received] PHST- 2021/03/24 00:00 [accepted] PHST- 2022/05/25 13:53 [entrez] PHST- 2022/05/26 06:00 [pubmed] PHST- 2022/05/28 06:00 [medline] PHST- 2022/05/04 00:00 [pmc-release] AID - S0066-782X2022000500976 [pii] AID - abc.20200798 [pii] AID - 10.36660/abc.20200798 [doi] PST - ppublish SO - Arq Bras Cardiol. 2022 May;118(5):976-988. doi: 10.36660/abc.20200798. PMID- 35612941 OWN - NLM STAT- MEDLINE DCOM- 20220527 LR - 20220607 IS - 1531-7080 (Electronic) IS - 0268-4705 (Linking) VI - 37 IP - 3 DP - 2022 May 1 TI - The use of multidisciplinary teams, electronic health records tools, and technology to optimize heart failure population health. PG - 302-306 LID - 10.1097/HCO.0000000000000968 [doi] AB - PURPOSE OF REVIEW: Given the limited population level, adoption of optimal therapy that has been shown in recent clinical trials and heart failure registries, efforts to rapidly and safely improve adoption of guideline-directed medical therapy for heart failure should be prioritized. Opportunities to leverage remote monitoring technology, the electronic health record (EHR), and multidisciplinary teams to improve heart failure care merit review. RECENT FINDINGS: Dedicated multidisciplinary teams employing algorithmic medication titration schema have shown better efficacy than clinician alerts or quality initiatives that focus on education and audit-feedback processes alone. Technology that enables invasive pressure monitoring and wearable devices that transmit physiologic data have the potential to predict decompensation and allow for early intervention by alerting clinicians to signs of congestion/clinical worsening but further real-world data is needed to prove efficacy and develop effective treatment protocols. SUMMARY: The combination of technology, multidisciplinary teams, and identification of populations for intervention using the EHR will be central to impactful innovation in heart failure population health and prevention of avoidable morbidity. Novel approaches to study implementation efforts including cluster randomized trials are needed. CI - Copyright (c) 2022 Wolters Kluwer Health, Inc. All rights reserved. FAU - Martyn, Trejeeve AU - Martyn T AD - Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Kaufman Center for Heart Failure Treatment and Recovery, Cleveland Clinic, Cleveland, Ohio, USA. FAU - Montgomery, Robert A AU - Montgomery RA AD - Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Kaufman Center for Heart Failure Treatment and Recovery, Cleveland Clinic, Cleveland, Ohio, USA. FAU - Estep, Jerry D AU - Estep JD AD - Department of Cardiovascular Medicine, Cleveland Clinic Florida, Weston, Florida, USA. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review PL - United States TA - Curr Opin Cardiol JT - Current opinion in cardiology JID - 8608087 SB - IM MH - Electronic Health Records MH - *Heart Failure/therapy MH - Humans MH - Patient Care Team MH - *Population Health MH - Technology EDAT- 2022/05/26 06:00 MHDA- 2022/05/28 06:00 CRDT- 2022/05/25 12:12 PHST- 2022/05/25 12:12 [entrez] PHST- 2022/05/26 06:00 [pubmed] PHST- 2022/05/28 06:00 [medline] AID - 00001573-202205000-00014 [pii] AID - 10.1097/HCO.0000000000000968 [doi] PST - ppublish SO - Curr Opin Cardiol. 2022 May 1;37(3):302-306. doi: 10.1097/HCO.0000000000000968. PMID- 35612936 OWN - NLM STAT- MEDLINE DCOM- 20220527 LR - 20220607 IS - 1531-7080 (Electronic) IS - 0268-4705 (Linking) VI - 37 IP - 3 DP - 2022 May 1 TI - The shock team: a multidisciplinary approach to early patient phenotyping and appropriate care escalation in cardiogenic shock. PG - 241-249 LID - 10.1097/HCO.0000000000000967 [doi] AB - PURPOSE OF REVIEW: Cardiogenic shock (CS) is a highly morbid condition with mortality remaining greater than 30% despite improved pathophysiologic understanding and access to mechanical circulatory support (MCS). In response, shock teams modeled on successful multidisciplinary care structures for other diseases are being implemented nationwide. RECENT FINDINGS: Primary data supporting a benefit of shock team implementation on patient outcomes are relatively limited and entirely observational. Four single-center before-and-after studies and one multicenter registry study have demonstrated improved outcomes in patients with CS, potentially driven by increased pulmonary artery catheter (PAC) utilization and earlier (and more appropriate) initiation of MCS. Shock teams are also supported by a growing body of literature recognizing the independent benefit of the interventions they seek to implement, including patient phenotyping with PAC use and an algorithmic approach to CS care. Though debated, MCS is also highly likely to improve CS outcomes when applied appropriately, which further supports a multidisciplinary shock team approach to patient and device selection. SUMMARY: Shock teams likely improve patient outcomes by facilitating early patient phenotyping and appropriate intervention. Institutions should strongly consider adopting a multidisciplinary shock team approach to CS care, though additional data supporting these interventions are needed. CI - Copyright (c) 2022 Wolters Kluwer Health, Inc. All rights reserved. FAU - Brusca, Samuel B AU - Brusca SB AD - Division of Cardiology, Department of Internal Medicine, University of California, San Francisco, California, USA. FAU - Caughron, Hope AU - Caughron H FAU - Njoroge, Joyce N AU - Njoroge JN FAU - Cheng, Richard AU - Cheng R FAU - O'Brien, Connor G AU - O'Brien CG FAU - Barnett, Christopher F AU - Barnett CF LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review PL - United States TA - Curr Opin Cardiol JT - Current opinion in cardiology JID - 8608087 SB - IM MH - *Heart-Assist Devices MH - Humans MH - Multicenter Studies as Topic MH - Registries MH - *Shock, Cardiogenic/therapy EDAT- 2022/05/26 06:00 MHDA- 2022/05/28 06:00 CRDT- 2022/05/25 12:12 PHST- 2022/05/25 12:12 [entrez] PHST- 2022/05/26 06:00 [pubmed] PHST- 2022/05/28 06:00 [medline] AID - 00001573-202205000-00008 [pii] AID - 10.1097/HCO.0000000000000967 [doi] PST - ppublish SO - Curr Opin Cardiol. 2022 May 1;37(3):241-249. doi: 10.1097/HCO.0000000000000967. PMID- 35605219 OWN - NLM STAT- MEDLINE DCOM- 20220525 LR - 20220716 IS - 1678-9741 (Electronic) IS - 0102-7638 (Print) IS - 0102-7638 (Linking) VI - 37 IP - 3 DP - 2022 May 23 TI - Impact of COVID-19 on Cardiothoracic Surgery: Experience of Alexandria (Egypt) Main University Hospital. PG - 380-384 LID - 10.21470/1678-9741-2020-0551 [doi] AB - INTRODUCTION: The current coronavirus pandemic has greatly strained the limited resources that had previously maintained the sustainability of the high-cost cardiothoracic surgeries in low-income countries like Egypt. METHODS: Hospital databases and patients' records were reviewed to evaluate the impact of the pandemic on the workflow and waiting lists. Postoperative patients were contacted by telephone for follow-up, as well as preoperative patients whose operations were cancelled. Regular virtual meetings were held, and residents were asked to discuss the stresses, challenges, and their suggestions for the gradual resumption of services. Residents' logbooks were evaluated to assess the disruption of the surgical exposure compared to 2019. RESULTS: While thoracic surgeries have continued to thrive, cardiac surgeries have witnessed the worst consequences, including cancellation of all surgeries, expansion of waiting lists, patients' non-compliance with follow-up, and impaired surgical exposure of junior residents. CONCLUSION: The gradual recovery of cardiac surgery services in Alexandria (Egypt) is being carefully planned, taking into consideration the backlog of cases and the shortage of screening kits. Careful tiering and triaging of patients by a multidisciplinary team, as well as seeking alternative assessment tools for trainees, are the main lines of our action plan. FAU - Hemead, Hanan M AU - Hemead HM AUID- ORCID: 0000-0001-9790-1021 AD - Department of Cardiothoracic Surgery, Alexandria University of Medicine, Alexandria, Egypt. FAU - Elsayed, Mohamed H AU - Elsayed MH AD - Department of Cardiothoracic Surgery, Alexandria University of Medicine, Alexandria, Egypt. FAU - Hassanein, Wael AU - Hassanein W AD - Department of Cardiothoracic Surgery, Alexandria University of Medicine, Alexandria, Egypt. LA - eng PT - Journal Article DEP - 20220523 PL - Brazil TA - Braz J Cardiovasc Surg JT - Brazilian journal of cardiovascular surgery JID - 101677045 SB - IM MH - *COVID-19 MH - Egypt/epidemiology MH - Elective Surgical Procedures MH - Hospitals, University MH - Humans MH - Pandemics PMC - PMC9162409 OTO - NOTNLM OT - Cardiac Surgical Procedures OT - Coronavirus OT - Egypt OT - Pandemics OT - Patient Care Team OT - Thoracic Surgery COIS- No conflict of interest. EDAT- 2022/05/24 06:00 MHDA- 2022/05/26 06:00 PMCR- 2022/05/01 CRDT- 2022/05/23 16:23 PHST- 2022/05/23 16:23 [entrez] PHST- 2022/05/24 06:00 [pubmed] PHST- 2022/05/26 06:00 [medline] PHST- 2022/05/01 00:00 [pmc-release] AID - 10.21470/1678-9741-2020-0551 [doi] PST - epublish SO - Braz J Cardiovasc Surg. 2022 May 23;37(3):380-384. doi: 10.21470/1678-9741-2020-0551. PMID- 35604474 OWN - NLM STAT- MEDLINE DCOM- 20220720 LR - 20220920 IS - 1432-1971 (Electronic) IS - 0172-0643 (Print) IS - 0172-0643 (Linking) VI - 43 IP - 6 DP - 2022 Aug TI - A Path FORWARD: Development of a Comprehensive Multidisciplinary Clinic to Create Health and Wellness for the Child and Adolescent with a Fontan Circulation. PG - 1175-1192 LID - 10.1007/s00246-022-02930-z [doi] AB - Today, it is anticipated most individuals diagnosed with single-ventricle malformation will survive surgical reconstruction through a successful Fontan operation. As greater numbers of patients survive, so has the recognition that individuals with Fontan circulation face a variety of challenges. The goal of a normal quality and duration of life will not be reached by all. The hurdles fall into a variety of domains. From a cardiovascular perspective, the Fontan circulation is fundamentally flawed by its inherent nature of creating a state of chronically elevated venous pressure and congestion, accompanied by a relatively low cardiac output. Ventricular dysfunction, atrioventricular valve regurgitation, and arrhythmia may directly impact cardiac performance and can progress with time. Problems are not limited to the cardiovascular system. Fontan circulatory physiology impacts a multitude of biological processes and health parameters outside the heart. The lymphatic circulation is under strain manifesting as variable degrees of protein-rich lymph loss and immune system dysregulation. Organ system dysfunction develops through altered perfusion profiles. Liver fibrosis is ubiquitous, and a process of systemic fibrogenesis in response to circulatory stressors may affect other organs as well. Somatic growth and development can be delayed. Behavioral and mental health problems are common, presenting as clinically important levels of anxiety and depression. Most striking is the high variability in prevalence and magnitude of these complications within the population, indicating the likelihood of additional factors enhancing or mitigating their emergence. We propose that optimal care for the individual with single ventricle and a Fontan circulation is ideally offered in a comprehensive multidisciplinary manner, with attention to elements that are beyond cardiac management alone. In this report, we share the concepts, our experiences, and perspectives on development of a clinic model-the "Fontan rehabilitation, wellness and resilience development" or FORWARD program. We provide insights into the mechanics of our multidisciplinary model of care and the benefits offered serving our growing population of individuals with a Fontan circulation and their families. CI - (c) 2022. The Author(s). FAU - Rychik, Jack AU - Rychik J AUID- ORCID: 0000-0001-8625-6565 AD - Division of Cardiology, Children's Hospital of Philadelphia, Philadelphia, USA. rychik@chop.edu. AD - Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA. rychik@chop.edu. AD - Fontan FORWARD Program, Cardiac Center at the Children's Hospital of Philadelphia, 3401 Civic Center Boulevard, Philadelphia, PA, 19104, USA. rychik@chop.edu. FAU - Goldberg, David J AU - Goldberg DJ AD - Division of Cardiology, Children's Hospital of Philadelphia, Philadelphia, USA. AD - Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA. FAU - Rand, Elizabeth AU - Rand E AD - Division of Gastroenterology, Hepatology and Nutrition, Children's Hospital of Philadelphia, Philadelphia, USA. AD - Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA. FAU - Mancilla, Edna E AU - Mancilla EE AD - Division of Endocrinology and Diabetes, Children's Hospital of Philadelphia, Philadelphia, USA. AD - Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA. FAU - Heimall, Jennifer AU - Heimall J AD - Division of Allergy and Immunology, Children's Hospital of Philadelphia, Philadelphia, USA. AD - Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA. FAU - Seivert, Nicholas AU - Seivert N AD - Department of Child and Adolescent Psychiatry, and Behavioral Sciences, Children's Hospital of Philadelphia, Philadelphia, USA. AD - Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA. FAU - Campbell, Danielle AU - Campbell D AD - Clinical Nutrition, Children's Hospital of Philadelphia, Philadelphia, USA. FAU - O'Malley, Shannon AU - O'Malley S AD - Division of Cardiology, Children's Hospital of Philadelphia, Philadelphia, USA. FAU - Dodds, Kathryn M AU - Dodds KM AD - Division of Cardiology, Children's Hospital of Philadelphia, Philadelphia, USA. AD - Department of Nursing at the University of Pennsylvania, Philadelphia, USA. AD - Fontan FORWARD Program, Cardiac Center at the Children's Hospital of Philadelphia, 3401 Civic Center Boulevard, Philadelphia, PA, 19104, USA. LA - eng PT - Journal Article PT - Review DEP - 20220523 PL - United States TA - Pediatr Cardiol JT - Pediatric cardiology JID - 8003849 SB - IM EIN - Pediatr Cardiol. 2022 Oct;43(7):1678. doi: 10.1007/s00246-022-02952-7. PMID: 35695923 MH - Adolescent MH - Cardiac Output, Low MH - Child MH - *Fontan Procedure/adverse effects MH - *Heart Defects, Congenital/complications MH - Heart Ventricles MH - Humans MH - *Ventricular Dysfunction/complications PMC - PMC9125546 OTO - NOTNLM OT - Fontan circulation OT - Fontan-associated liver disease OT - Multidisciplinary care OT - Single ventricle COIS- Dr. Goldberg is a named inventor on method of use patents regarding the use of udenafil in patients who have undergone Fontan palliation. Dr. Rychik is a consultant for Mezzion Pharmaceuticals, a company in search of solutions for challenges in the single ventricle population. EDAT- 2022/05/24 06:00 MHDA- 2022/07/22 06:00 PMCR- 2022/05/23 CRDT- 2022/05/23 11:15 PHST- 2022/01/22 00:00 [received] PHST- 2022/04/28 00:00 [accepted] PHST- 2022/05/24 06:00 [pubmed] PHST- 2022/07/22 06:00 [medline] PHST- 2022/05/23 11:15 [entrez] PHST- 2022/05/23 00:00 [pmc-release] AID - 10.1007/s00246-022-02930-z [pii] AID - 2930 [pii] AID - 10.1007/s00246-022-02930-z [doi] PST - ppublish SO - Pediatr Cardiol. 2022 Aug;43(6):1175-1192. doi: 10.1007/s00246-022-02930-z. Epub 2022 May 23. PMID- 35597853 OWN - NLM STAT- MEDLINE DCOM- 20220524 LR - 20220718 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 12 IP - 1 DP - 2022 May 21 TI - Telephone-based reminder to improve safety after percutaneous coronary intervention. PG - 8597 LID - 10.1038/s41598-022-12722-3 [doi] LID - 8597 AB - Dual antiplatelet therapy (DAPT) is a class I guideline indication after percutaneous coronary intervention (PCI). Our population is high-risk for low medication adherence. With a multidisciplinary team we developed a telephone-based intervention to improve DAPT adherence post-PCI. Patients undergoing PCI at our center were contacted by nursing staff via telephone at 1 week, 30 days, and 60 days post-procedure. Calls included a reminder of the importance of DAPT and elicited any patient concerns. Concerns were relayed to the team who could take appropriate action. For patients filling their medications at any pharmacies within our closed system the proportion of days covered (PDC) was calculated. These were compared to data for patients undergoing PCI in the seven months prior to program initiation. Information on interventions performed as a result of calls was also collected. During the study period, 452 patients underwent PCI. Of these, 70% were contacted and 244 filled their prescription at our system pharmacies. Twelve-month median PDC was 74%, with 45% of patients having PDC > 80%. There was no significant difference when compared to the group prior to the intervention, median PDC 79% and 50% of patients having PDC > 80%. In 26 patients calls led to interventions, removing barriers that would have otherwise prevented continued adherence. A telephone-based reminder system led to directed interventions in nearly 1 in 10 patients contacted. It was not able to significantly improve PDC when compared to a contemporary sample. This highlights the difficulty in using PDC to detect barriers to adherence. CI - (c) 2022. The Author(s). FAU - Chidester, Jeffrey AU - Chidester J AD - University of Texas Southwestern, 6939 Patricia Avenue, Dallas, TX, 75223, USA. jeffrey.chidester@phhs.org. FAU - Bennett, Daniel AU - Bennett D AD - University of Texas Southwestern, 6939 Patricia Avenue, Dallas, TX, 75223, USA. AD - Revere Health, Provo, USA. FAU - Mathew, Chris AU - Mathew C AD - Parkland Health and Hospital System, Dallas, USA. FAU - Denkins, Tiffany AU - Denkins T AD - Parkland Health and Hospital System, Dallas, USA. FAU - Vigen, Rebecca AU - Vigen R AD - University of Texas Southwestern, 6939 Patricia Avenue, Dallas, TX, 75223, USA. FAU - Addo, Tayo AU - Addo T AD - University of Texas Southwestern, 6939 Patricia Avenue, Dallas, TX, 75223, USA. FAU - Das, Sandeep AU - Das S AD - University of Texas Southwestern, 6939 Patricia Avenue, Dallas, TX, 75223, USA. LA - eng PT - Journal Article DEP - 20220521 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 0 (Platelet Aggregation Inhibitors) SB - IM MH - Humans MH - Medication Adherence MH - *Percutaneous Coronary Intervention MH - Platelet Aggregation Inhibitors/therapeutic use MH - Reminder Systems MH - Telephone PMC - PMC9124185 COIS- The authors declare no competing interests. EDAT- 2022/05/22 06:00 MHDA- 2022/05/25 06:00 PMCR- 2022/05/21 CRDT- 2022/05/21 23:19 PHST- 2021/08/30 00:00 [received] PHST- 2022/05/12 00:00 [accepted] PHST- 2022/05/21 23:19 [entrez] PHST- 2022/05/22 06:00 [pubmed] PHST- 2022/05/25 06:00 [medline] PHST- 2022/05/21 00:00 [pmc-release] AID - 10.1038/s41598-022-12722-3 [pii] AID - 12722 [pii] AID - 10.1038/s41598-022-12722-3 [doi] PST - epublish SO - Sci Rep. 2022 May 21;12(1):8597. doi: 10.1038/s41598-022-12722-3. PMID- 35595919 OWN - NLM STAT- MEDLINE DCOM- 20221011 LR - 20261029 IS - 1573-7322 (Electronic) IS - 1382-4147 (Linking) VI - 27 IP - 6 DP - 2022 Nov TI - Outcomes of heart transplantation in cardiac amyloidosis: an updated systematic review. PG - 2201-2209 LID - 10.1007/s10741-022-10252-8 [doi] AB - Cardiac amyloidosis is one of the most common infiltrative cardiomyopathies that is characterized by the extracellular deposition of misfolded fibrillar protein. Several studies have previously found that patients with amyloid in the past have performed poorly after heart transplantation. Recent advancements in treatments have been made that have significantly improved outcomes in these patients. The study aimed to evaluate the outcomes of heart transplantation in cardiac amyloidosis. We systematically searched EMBASE, PubMed/MEDLINE, and Cochrane Library databases on 30 December 2021 following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. We identified 22 studies that examined 42,951 patients with cardiac amyloidosis of which only 1,329 patients underwent isolated heart transplantation. Seven studies reported individual patient data. The results of 123 patients have been pooled for analysis. There were 70 male patients, 45 female patients, and eight patients who did not report their gender. Among the types of amyloids, 63 (51%) patients were found to have light chain amyloidosis (AL) and 33 (27%) patients had transthyretin amyloidosis (ATTR). Only 41 patients (33.3%) reported a monoclonal component. There were 30 patients with AL that underwent autologous hematopoietic stem cell transplant (ASCT). The mean survival of 24 out of 30 patients was 4.33 years. In addition, the reported data include 13 patients requiring intra-aortic balloon pump (IABP), six with cardiac resynchronization therapy (CRT), and four with implantable cardioverter defibrillator (ICD). With the current advancements in treatments in combination with a multidisciplinary approach and careful patient selection, patients undergoing heart transplantation for amyloidosis may have encouraging results in the current era. Further studies will be needed to evaluate the outcomes of heart transplantation in amyloidosis patients now that several advances have been made in the field. CI - (c) 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Lakhdar, Sofia AU - Lakhdar S AUID- ORCID: 0000-0001-5320-2990 AD - Department of Medicine, Icahn School of Medicine at Mount Sinai/NYC H+H/Queens, 82-68 164th St. Queens, New York, NY, 11432, USA. sofia.lakhdar@mssm.edu. FAU - Buttar, Chandan AU - Buttar C AD - Department of Cardiology, Ochsner Medical Center, New Orleans, LA, USA. FAU - Nassar, Mahmood AU - Nassar M AD - Department of Medicine, Icahn School of Medicine at Mount Sinai/NYC H+H/Queens, 82-68 164th St. Queens, New York, NY, 11432, USA. FAU - Ciobanu, Camelia AU - Ciobanu C AD - St. Barnabas Hospital/Albert Einstein College of Medicine, New York, NY, USA. FAU - Patel, Rima AU - Patel R AD - Division of Cardiology, Icahn School of Medicine at Mount Sinai/NYC H+H/Queens, New York, NY, USA. FAU - Munira, Most Sirajum AU - Munira MS AD - Division of Cardiology, Icahn School of Medicine at Mount Sinai/NYC H+H/Queens, New York, NY, USA. AD - Division of Cardiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. LA - eng PT - Journal Article PT - Systematic Review DEP - 20220520 PL - United States TA - Heart Fail Rev JT - Heart failure reviews JID - 9612481 SB - IM MH - *Amyloid Neuropathies, Familial MH - *Cardiac Resynchronization Therapy MH - *Cardiomyopathies/surgery MH - Female MH - *Heart Transplantation MH - *Hematopoietic Stem Cell Transplantation/methods MH - Humans MH - Male OTO - NOTNLM OT - Cardiac amyloidosis OT - Heart failure OT - Heart transplantation OT - Infiltrative cardiomyopathy EDAT- 2022/05/21 06:00 MHDA- 2022/10/12 06:00 CRDT- 2022/05/20 23:25 PHST- 2022/05/16 00:00 [accepted] PHST- 2022/05/21 06:00 [pubmed] PHST- 2022/10/12 06:00 [medline] PHST- 2022/05/20 23:25 [entrez] AID - 10.1007/s10741-022-10252-8 [pii] AID - 10.1007/s10741-022-10252-8 [doi] PST - ppublish SO - Heart Fail Rev. 2022 Nov;27(6):2201-2209. doi: 10.1007/s10741-022-10252-8. Epub 2022 May 20. PMID- 35595676 OWN - NLM STAT- MEDLINE DCOM- 20220627 LR - 20220706 IS - 1876-7605 (Electronic) IS - 1936-8798 (Linking) VI - 15 IP - 12 DP - 2022 Jun 27 TI - Predicted and Observed Mortality at 10 Years in Patients With Bifurcation Lesions in the SYNTAX Trial. PG - 1231-1242 LID - S1936-8798(22)00847-0 [pii] LID - 10.1016/j.jcin.2022.04.025 [doi] AB - BACKGROUND: Percutaneous coronary intervention (PCI) of bifurcation lesions is associated with higher rates of adverse events, and currently it is unclear whether PCI or coronary artery bypass grafting (CABG) is the safer treatment for these patients at very long-term follow-up. OBJECTIVES: The aim of this study was to investigate the impact of bifurcation lesions on individual predicted and observed all-cause 10-year mortality in the SYNTAX (Synergy Between PCI With Taxus and Cardiac Surgery) trial. METHODS: In the SYNTAXES (SYNTAX Extended Survival) study, 10-year observed and individual predicted mortality derived from the SYNTAX score 2020 (SS-2020) was compared between patients with >/=1 bifurcation (n = 1,300) and those with no bifurcations (n = 487). RESULTS: Among patients treated with PCI, patients with >1 bifurcation lesion compared with those without bifurcation lesions had a significantly higher risk for all-cause death (19.8% vs 30.1%; HR: 1.55; 95% CI: 1.12-2.14; P = 0.007), whereas following CABG, mortality was similar in patients with and those without bifurcation lesions (23.3% vs 23.0%; HR: 0.81; 95% CI: 0.59-1.12; P = 0.207; P(interaction) = 0.006). In PCI patients, a 2-stent vs a 1-stent technique was associated with higher mortality (33.3% vs 25.9%; HR: 1.51; 95% CI: 1.06-2.14; P = 0.021). According to the SS-2020, among those with >/=1 bifurcation, there was equipoise for all-cause mortality between PCI and CABG in 2 quartiles of the population, whereas CABG was superior to PCI in the 2 remaining quartiles. CONCLUSIONS: Bifurcation lesions require special attention from the heart team, considering the higher 10-year all-cause mortality associated with PCI. Careful evaluation of bifurcation lesion complexity and calculation of individualized 10-year prognosis using the SS-2020 may therefore be helpful in decision making. (Synergy Between PCI With TAXUS and Cardiac Surgery: SYNTAX Extended Survival [SYNTAXES], NCT03417050; Taxus Drug-Eluting Stent Versus Coronary Artery Bypass Surgery for the Treatment of Narrowed Arteries [SYNTAX], NCT00114972). CI - Copyright (c) 2022 American College of Cardiology Foundation. All rights reserved. FAU - Ninomiya, Kai AU - Ninomiya K AD - Department of Cardiology, National University of Ireland, Galway, Galway, Ireland. FAU - Serruys, Patrick W AU - Serruys PW AD - Department of Cardiology, National University of Ireland, Galway, Galway, Ireland; National Heart and Lung Institute, Imperial College London, London, United Kingdom. Electronic address: patrick.serruys@nuigalway.ie. FAU - Garg, Scot AU - Garg S AD - Department of Cardiology, Royal Blackburn Hospital, Blackburn, United Kingdom. FAU - Gao, Chao AU - Gao C AD - Department of Cardiology, Xijing Hospital, Xi'an, China; Department of Cardiology, Radboud University, Nijmegen, the Netherlands. FAU - Masuda, Shinichiro AU - Masuda S AD - Department of Cardiology, National University of Ireland, Galway, Galway, Ireland. FAU - Lunardi, Mattia AU - Lunardi M AD - Department of Cardiology, National University of Ireland, Galway, Galway, Ireland. FAU - Lassen, Jens F AU - Lassen JF AD - Department of Cardiology, Odense University Hospital, Odense, Denmark. FAU - Banning, Adrian P AU - Banning AP AD - Department of Cardiology, John Radcliffe Hospital, Oxford University Hospitals, Oxford, United Kingdom. FAU - Colombo, Antonio AU - Colombo A AD - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele-Milan, Italy; Humanitas Clinical and Research Center IRCCS, Rozzano-Milan, Italy. FAU - Burzotta, Francesco AU - Burzotta F AD - Institute of Cardiology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Universita Cattolica del Sacro Cuore, Rome, Italy. FAU - Morice, Marie-Claude AU - Morice MC AD - Departement of Cardiologie, Hopital Prive Jacques Cartier, Generale de Sante Massy, France. FAU - Mack, Michael J AU - Mack MJ AD - Department of Cardiothoracic Surgery, Baylor University Medical Center, Dallas, Texas, USA. FAU - Holmes, David R AU - Holmes DR AD - Department of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA. FAU - Davierwala, Piroze M AU - Davierwala PM AD - University Department of Cardiac Surgery, Heart Centre Leipzig, Leipzig, Germany; Division of Cardiovascular Surgery, Peter Munk Cardiac Centre, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada; Department of Surgery, University of Toronto, Toronto, Ontario, Canada. FAU - Thuijs, Daniel J F M AU - Thuijs DJFM AD - Department of Cardiothoracic Surgery, Erasmus University Medical Centre, Rotterdam, the Netherlands. FAU - van Klaveren, David AU - van Klaveren D AD - Department of Public Health, Erasmus University Medical Center, Rotterdam, the Netherlands. FAU - Onuma, Yoshinobu AU - Onuma Y AD - Department of Cardiology, National University of Ireland, Galway, Galway, Ireland. CN - SYNTAX Extended Survival Investigators LA - eng SI - ClinicalTrials.gov/NCT00114972 PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220517 PL - United States TA - JACC Cardiovasc Interv JT - JACC. Cardiovascular interventions JID - 101467004 SB - IM CIN - JACC Cardiovasc Interv. 2022 Jun 27;15(12):1243-1248. doi: 10.1016/j.jcin.2022.05.011. PMID: 35583361 MH - Coronary Artery Bypass MH - *Coronary Artery Disease/diagnostic imaging/therapy MH - *Drug-Eluting Stents MH - Humans MH - *Percutaneous Coronary Intervention MH - Risk Factors MH - Treatment Outcome OTO - NOTNLM OT - CABG OT - PCI OT - SYNTAX OT - bifurcation lesion OT - long-term clinical outcomes COIS- Funding Support and Author Disclosures SYNTAXES was supported by the German Foundation of Heart Research. The SYNTAX trial, during 0- to 5-year follow-up, was funded by Boston Scientific. Both sponsors had no role in study design, data collection, data analyses, and interpretation of the study data and were not involved in the decision to publish the final manuscript. The principal investigators and authors had complete scientific freedom. Dr Ninomiya has received a grant from Abbott Medical Japan, outside the submitted work. Dr Serruys has received institutional grants from Sinomedical Sciences Technology, Sahajanand Medical Technological, Philips/Volcano, Xeltis, and HeartFlow, outside the submitted work. Dr Masuda has received a grant from Terumo, outside the submitted work. Dr Morice is the CEO and a shareholder of CERC, a contract research organization based in Paris, which had no role in this trial. Dr Burzotta has received speaker fees from Abbott, Abiomed, Medtronic, and Terumo. Dr Banning has received an institutional educational grant for a fellowship from Boston Scientific; and has received speaker fees from Boston Scientific, Medtronic, and Abbott Vascular. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2022/05/21 06:00 MHDA- 2022/06/28 06:00 CRDT- 2022/05/20 22:11 PHST- 2022/01/24 00:00 [received] PHST- 2022/04/13 00:00 [revised] PHST- 2022/04/19 00:00 [accepted] PHST- 2022/05/21 06:00 [pubmed] PHST- 2022/06/28 06:00 [medline] PHST- 2022/05/20 22:11 [entrez] AID - S1936-8798(22)00847-0 [pii] AID - 10.1016/j.jcin.2022.04.025 [doi] PST - ppublish SO - JACC Cardiovasc Interv. 2022 Jun 27;15(12):1231-1242. doi: 10.1016/j.jcin.2022.04.025. Epub 2022 May 17. PMID- 35593003 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220716 IS - 2287-979X (Print) IS - 2288-0011 (Electronic) IS - 2287-979X (Linking) VI - 57 IP - 2 DP - 2022 Jun 30 TI - Multidisciplinary supportive care in systemic light chain amyloidosis. PG - 106-116 LID - 10.5045/br.2022.2021227 [doi] AB - The immunoglobulin light-chain amyloidosis is a multisystemic disease which manifests by damage to the vital organs by light chain-derived amyloid fibril. Traditionally, the treatment has been directed to the underlying plasma cell clone with or without high dose chemotherapy followed by autologous stem cell transplantation using melphalan based conditioning. Now with the approval of highly tolerable anti-CD38 monoclonal antibody daratumumab based anti-plasma cell therapy in 2021, high rates of hematologic complete responses are possible even in patients who are otherwise deemed not a candidate for autologous stem cell transplantation. However, despite the progress, there remains a limitation in the strategies to improve symptoms particularly in patients with advanced cardiac involvement, those with nephrotic syndrome and autonomic dysfunction due to underlying systemic AL amyloidosis. The symptoms can be an ordeal for the patients and their caregivers and effective strategies are urgently needed to address them. The supportive care is aimed to counteract the symptoms of the disease and the effects of the treatment on involved organs' function and preserve patients' quality of life. Here we discuss multidisciplinary approach in a system-based fashion to address the symptom management in this dreadful disease. In addition to achieving excellent anti-plasma cell disease control, using treatment directed to remove amyloid from the vital organs can theoretically hasten recovery of the involved organs thereby improving symptoms at a faster pace. Ongoing phase III clinical trials of CAEL-101 and Birtamimab will address this question. FAU - Maroun, Bou Zerdan AU - Maroun BZ AD - Department of Hematology-Oncology, Myeloma and Amyloidosis Program, Maroone Cancer Center, Cleveland Clinic Florida, Weston, FL, USA. FAU - Allam, Sabine AU - Allam S AD - Department of Medicine, Faculty of Medicine, University of Balamand, Beirut, Lebanon. FAU - Chaulagain, Chakra P AU - Chaulagain CP AD - Department of Hematology-Oncology, Myeloma and Amyloidosis Program, Maroone Cancer Center, Cleveland Clinic Florida, Weston, FL, USA. LA - eng PT - Journal Article PT - Review DEP - 20220520 PL - Switzerland TA - Blood Res JT - Blood research JID - 101605247 PMC - PMC9242830 OTO - NOTNLM OT - Amyloidosis OT - Hematology OT - Light chain OT - Multidisciplinary approach OT - Supportive care COIS- Authors' Disclosures of Potential Conflicts of Interest No potential conflicts of interest relevant to this article were reported. EDAT- 2022/05/21 06:00 MHDA- 2022/05/21 06:01 PMCR- 2022/06/30 CRDT- 2022/05/20 03:33 PHST- 2021/12/29 00:00 [received] PHST- 2022/04/30 00:00 [revised] PHST- 2022/05/04 00:00 [accepted] PHST- 2022/05/21 06:00 [pubmed] PHST- 2022/05/21 06:01 [medline] PHST- 2022/05/20 03:33 [entrez] PHST- 2022/06/30 00:00 [pmc-release] AID - br.2022.2021227 [pii] AID - br-57-2-106 [pii] AID - 10.5045/br.2022.2021227 [doi] PST - ppublish SO - Blood Res. 2022 Jun 30;57(2):106-116. doi: 10.5045/br.2022.2021227. Epub 2022 May 20. PMID- 35590088 OWN - NLM STAT- MEDLINE DCOM- 20220804 LR - 20250728 IS - 1481-8043 (Electronic) IS - 1481-8035 (Print) IS - 1481-8035 (Linking) VI - 24 IP - 5 DP - 2022 Aug TI - The impact of clinical result acquisition and interpretation on task performance during a simulated pediatric cardiac arrest: a multicentre observational study. PG - 529-534 LID - 10.1007/s43678-022-00313-0 [doi] AB - PURPOSE: The acquisition and interpretation of clinical results during resuscitations is common; however, this can delay critical clinical tasks, resulting in increased morbidity and mortality. This study aims to determine the impact of clinical result acquisition and interpretation by the team leader on critical task completion during simulated pediatric cardiac arrest before and after team training. METHODS: This is a secondary data analysis of video-recorded simulated resuscitation scenarios conducted during Teams4Kids (T4K) study (June 2011-January 2015); scenarios included cardiac arrest before and after team training. The scenario included either a scripted paper or a phone call delivery of results concurrently with a clinical transition to pulseless ventricular tachycardia. Descriptive statistics and non-parametric tests were used to compare team performance before and after training. RESULTS: Performance from 40 teams was analyzed. Although the time taken to initiate CPR and defibrillation varied depending on the type of interruption and whether the scenario was before or after team training, these findings were not significantly associated with the leader's behaviour [Kruskal-Wallis test (p > 0.05)]. An exact McNemar's test determined no statistically significant difference in the proportion of leaders involved or not in interpreting results between and after the training (exact p value = 0.096). CONCLUSIONS: Team training was successful in reducing time to perform key clinical tasks. Although team training modified the way leaders behaved toward the results, this behaviour change did not impact the time taken to start CPR or defibrillate. Further understanding the elements that influence time to critical clinical tasks provides guidance in designing future simulated educational activities, subsequently improving clinical team performance and patient outcomes. CI - (c) 2022. The Author(s). FAU - Rizkalla, Carol AU - Rizkalla C AUID- ORCID: 0000-0002-7243-7784 AD - Royal College of Surgeons in Ireland, 123 St Stephens Green, Dublin, Ireland. carol1rizkalla@gmail.com. FAU - Garcia-Jorda, Dailys AU - Garcia-Jorda D AD - University of Calgary, Calgary, AB, Canada. FAU - Cheng, Adam AU - Cheng A AD - Pediatric Emergency Medicine, Alberta Children's Hospital, Calgary, AB, Canada. FAU - Duff, Jonathan P AU - Duff JP AD - Pediatrics, Stollery Children's Hospital, Edmonton, AB, Canada. FAU - Gottesman, Ronald AU - Gottesman R AD - Pediatrics, McGill University, Montreal, QC, Canada. FAU - Weiss, Matthew J AU - Weiss MJ AD - Pediatrics, Universite Laval Faculte de Medecine, Quebec, QC, Canada. FAU - Koot, Deanna A AU - Koot DA AD - KidSIM Pediatric Simulation Program, Alberta Children's Hospital, Calgary, AB, Canada. FAU - Gilfoyle, Elaine AU - Gilfoyle E AD - Pediatrics, University of Toronto, Toronto, ON, Canada. LA - eng PT - Journal Article PT - Multicenter Study PT - Observational Study DEP - 20220519 PL - England TA - CJEM JT - CJEM JID - 100893237 SB - IM MH - *Cardiopulmonary Resuscitation/methods MH - Child MH - *Heart Arrest/therapy MH - Humans MH - Patient Care Team MH - Resuscitation/education MH - Task Performance and Analysis PMC - PMC9345827 OTO - NOTNLM OT - Arret cardiaque OT - Cardiac arrest OT - Interruptions OT - Patient simulation OT - Pediatric resuscitation OT - Performance d'equipe OT - Reanimation pediatrique OT - Simulation de patient OT - Team performance COIS- The authors declare that they have no conflict of interest. EDAT- 2022/05/20 06:00 MHDA- 2022/08/05 06:00 PMCR- 2022/05/19 CRDT- 2022/05/19 23:38 PHST- 2021/07/31 00:00 [received] PHST- 2022/04/06 00:00 [accepted] PHST- 2022/05/20 06:00 [pubmed] PHST- 2022/08/05 06:00 [medline] PHST- 2022/05/19 23:38 [entrez] PHST- 2022/05/19 00:00 [pmc-release] AID - 10.1007/s43678-022-00313-0 [pii] AID - 313 [pii] AID - 10.1007/s43678-022-00313-0 [doi] PST - ppublish SO - CJEM. 2022 Aug;24(5):529-534. doi: 10.1007/s43678-022-00313-0. Epub 2022 May 19. PMID- 35588949 OWN - NLM STAT- MEDLINE DCOM- 20220720 LR - 20220811 IS - 1916-7075 (Electronic) IS - 0828-282X (Linking) VI - 38 IP - 7 DP - 2022 Jul TI - Cardiac Implantable Electronic Devices in the Fontan Patient. PG - 1048-1058 LID - S0828-282X(22)00281-1 [pii] LID - 10.1016/j.cjca.2022.04.024 [doi] AB - As a result of remarkable progress in operative techniques and cardiology care during childhood, Fontan patients continue to age and require team-based multidisciplinary expertise to manage complications encountered in adulthood. They face particular challenges in terms of altered hemodynamic stressors, cardiac and hepatic failure, and arrhythmias. Arrhythmias in Fontan patients are highly prevalent and associated with underlying anatomy, surgical technique, and postoperative sequelae. Diagnostic tools, treatments, and device strategies for arrhythmias in Fontan patients should be adapted to the specific anatomy, type of surgical repair, and clinical status. Great strides in our understanding of arrhythmia mechanisms, options and techniques to obtain access to relevant cardiac structures, and application of both old and new technologies have contributed to improving cardiac implantable electronic device (CIED) therapies for this unique population. In this state-of-the-art review, we discuss the various arrhythmias encountered in Fontan patients, their diagnosis, and options for treatment and prevention, with a focus on CIEDs. Throughout, access challenges particular to the Fontan circulation are considered. Recently developed technologies, such as the subcutaneous implantable cardioverter defibrillator, carry the potential to be transformative but require awareness of Fontan-specific issues. Moreover, new leadless pacing technology represents a promising strategy that may soon become applicable to Fontan patients with sinus-node dysfunction. CIEDs are essential tools in managing Fontan patients, but the complex clinical scenarios that arise in this patient population are among the most challenging for the electrophysiologist treating patients with congenital heart disease. CI - Copyright (c) 2022 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved. FAU - Mondesert, Blandine AU - Mondesert B AD - Adult Congenital Heart Disease Center, Montreal Heart Institute, Medicine Department, Universite de Montreal, Montreal, Quebec, Canada. Electronic address: Blandine.mondesert@icm-mhi.org. FAU - Moore, Jeremy P AU - Moore JP AD - Division of Cardiology, Department of Medicine, Ahmanson/UCLA Adult Congenital Heart Disease Center, Los Angeles, California, USA; UCLA Cardiac Arrhythmia Center, UCLA Health System, Los Angeles, California, USA; Division of Cardiology, Department of Pediatrics, UCLA Health System, Los Angeles, California, USA. FAU - Khairy, Paul AU - Khairy P AD - Adult Congenital Heart Disease Center, Montreal Heart Institute, Medicine Department, Universite de Montreal, Montreal, Quebec, Canada. LA - eng PT - Journal Article PT - Review DEP - 20220517 PL - England TA - Can J Cardiol JT - The Canadian journal of cardiology JID - 8510280 SB - IM MH - Adult MH - Arrhythmias, Cardiac/etiology/therapy MH - *Defibrillators, Implantable/adverse effects MH - Electronics MH - *Fontan Procedure/adverse effects MH - *Heart Defects, Congenital/diagnosis MH - Humans EDAT- 2022/05/20 06:00 MHDA- 2022/07/22 06:00 CRDT- 2022/05/19 20:05 PHST- 2022/01/09 00:00 [received] PHST- 2022/04/18 00:00 [revised] PHST- 2022/04/19 00:00 [accepted] PHST- 2022/05/20 06:00 [pubmed] PHST- 2022/07/22 06:00 [medline] PHST- 2022/05/19 20:05 [entrez] AID - S0828-282X(22)00281-1 [pii] AID - 10.1016/j.cjca.2022.04.024 [doi] PST - ppublish SO - Can J Cardiol. 2022 Jul;38(7):1048-1058. doi: 10.1016/j.cjca.2022.04.024. Epub 2022 May 17. PMID- 35584528 OWN - NLM STAT- MEDLINE DCOM- 20220520 LR - 20220716 IS - 1806-3756 (Electronic) IS - 1806-3713 (Print) IS - 1806-3713 (Linking) VI - 48 IP - 4 DP - 2022 TI - Incidental chest findings on coronary CT angiography: a pictorial essay and management proposal. PG - e20220015 LID - S1806-37132022000400700 [pii] LID - 10.36416/1806-3756/e20220015 [doi] LID - e20220015 AB - Many health systems have been using coronary CT angiography (CCTA) as a first-line examination for ischaemic heart disease patients in various countries. The rising number of CCTA examinations has led to a significant increase in the number of reported incidental extracardiac findings, mainly in the chest. Pulmonary nodules are the most common incidental findings on CCTA scans, as there is a substantial overlap of risk factors between the population seeking to exclude ischaemic heart disease and those at risk of developing lung cancer (i.e., advanced age and smoking habits). However, most incidental findings are clinically insignificant and actively pursuing them could be cost-prohibitive and submit the patient to unnecessary and potentially harmful examinations. Furthermore, there is little consensus regarding when to report or actively exclude these findings and how to manage them, that is, when to trigger an alert or to immediately refer the patient to a pulmonologist, a thoracic surgeon or a multidisciplinary team. This pictorial essay discusses the current literature on this topic and is illustrated with a review of CCTA scans. We also propose a checklist organised by organ and system, recommending actions to raise awareness of pulmonologists, thoracic surgeons, cardiologists and radiologists regarding the most significant and actionable incidental findings on CCTA scans. FAU - Pinto, Erique AU - Pinto E AUID- ORCID: 0000-0002-6648-9270 AD - . Faculdade de Ciencias da Saude, Universidade da Beira Interior, Covilha, Portugal. FAU - Penha, Diana AU - Penha D AUID- ORCID: 0000-0002-3358-6875 AD - . Faculdade de Ciencias da Saude, Universidade da Beira Interior, Covilha, Portugal. AD - . Imaging Department, Liverpool Heart and Chest Hospital NHS Foundation Trust, Liverpool, United Kingdom. FAU - Hochhegger, Bruno AU - Hochhegger B AUID- ORCID: 0000-0003-1984-4636 AD - . Pontificia Universidade Catolica do Rio Grande do Sul, Porto Alegre (RS) Brasil. FAU - Monaghan, Colin AU - Monaghan C AUID- ORCID: 0000-0002-5300-0229 AD - . Imaging Department, Liverpool Heart and Chest Hospital NHS Foundation Trust, Liverpool, United Kingdom. FAU - Marchiori, Edson AU - Marchiori E AUID- ORCID: 0000-0001-8797-7380 AD - . Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro (RJ) Brasil. AD - . Faculdade de Medicina, Universidade Federal Fluminense, Niteroi (RJ) Brasil. FAU - Taborda-Barata, Luis AU - Taborda-Barata L AUID- ORCID: 0000-0001-6649-8890 AD - . Faculdade de Ciencias da Saude, Universidade da Beira Interior, Covilha, Portugal. FAU - Irion, Klaus AU - Irion K AUID- ORCID: 0000-0002-7860-7879 AD - . Imaging Department, Liverpool Heart and Chest Hospital NHS Foundation Trust, Liverpool, United Kingdom. LA - eng LA - por PT - Journal Article PT - Review DEP - 20220513 PL - Brazil TA - J Bras Pneumol JT - Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia JID - 101222274 SB - IM MH - *Computed Tomography Angiography MH - Coronary Angiography MH - *Coronary Artery Disease/diagnostic imaging MH - Humans MH - Incidental Findings MH - Tomography, X-Ray Computed PMC - PMC9064655 COIS- CONFLICT OF INTEREST: None declared. EDAT- 2022/05/19 06:00 MHDA- 2022/05/21 06:00 PMCR- 2022/05/03 CRDT- 2022/05/18 17:04 PHST- 2022/01/18 00:00 [received] PHST- 2022/03/07 00:00 [accepted] PHST- 2022/05/18 17:04 [entrez] PHST- 2022/05/19 06:00 [pubmed] PHST- 2022/05/21 06:00 [medline] PHST- 2022/05/03 00:00 [pmc-release] AID - S1806-37132022000400700 [pii] AID - 10.36416/1806-3756/e20220015 [doi] PST - epublish SO - J Bras Pneumol. 2022 May 13;48(4):e20220015. doi: 10.36416/1806-3756/e20220015. eCollection 2022. PMID- 35584520 OWN - NLM STAT- MEDLINE DCOM- 20220520 LR - 20220531 IS - 1984-0446 (Electronic) IS - 0034-7167 (Linking) VI - 75 IP - 4 DP - 2022 TI - Requirements for building educational and care technology on heart failure. PG - e20210465 LID - S0034-71672022000500179 [pii] LID - 10.1590/0034-7167-2021-0465 [doi] AB - OBJECTIVES: to investigate the requirements for building an educational and care application about heart failure. METHODS: exploratory study, carried out with 15 people with heart failure and 19 family members/caregivers, assisted in a tertiary unit in the Brazilian Northeast. Individual semi-structured interviews were carried out between November and December 2020. Hannah Arendt's theoretical framework was adopted. RESULTS: two units of meaning emerged: "The plurality of care in heart failure" and "Expectations on the construction and use of educational and care technology for heart failure". The requirements involved the need to know the disease and its nuances, as well as the health network, through an application that can minimize individual and social precariousness; and highlighted the importance of the participation of the multidisciplinary team in the development and dissemination of the application. CONCLUSIONS: requirements on educational and care technology were identified and will support the creation of an application that promotes care, aiming to obtain positive health outcomes. FAU - Cestari, Virna Ribeiro Feitosa AU - Cestari VRF AUID- ORCID: 0000-0002-7955-0894 AD - Universidade Estadual do Ceara. Fortaleza, Ceara, Brazil. FAU - Florencio, Raquel Sampaio AU - Florencio RS AUID- ORCID: 0000-0003-3119-7187 AD - Universidade Estadual do Ceara. Fortaleza, Ceara, Brazil. FAU - Garces, Thiago Santos AU - Garces TS AUID- ORCID: 0000-0002-1670-725X AD - Universidade Estadual do Ceara. Fortaleza, Ceara, Brazil. FAU - Souza, Lorena Campos de AU - Souza LC AUID- ORCID: 0000-0002-3338-9425 AD - Universidade Estadual do Ceara. Fortaleza, Ceara, Brazil. FAU - Silva, Jessica Naiane Gama da AU - Silva JNGD AUID- ORCID: 0000-0003-0262-6763 AD - Universidade Estadual do Ceara. Fortaleza, Ceara, Brazil. FAU - Pessoa, Vera Lucia Mendes de Paula AU - Pessoa VLMP AUID- ORCID: 0000-0002-5441-5311 AD - Universidade Estadual do Ceara. Fortaleza, Ceara, Brazil. FAU - Moreira, Thereza Maria Magalhaes AU - Moreira TMM AUID- ORCID: 0000-0003-1424-0649 AD - Universidade Estadual do Ceara. Fortaleza, Ceara, Brazil. LA - eng LA - por PT - Journal Article DEP - 20220518 PL - Brazil TA - Rev Bras Enferm JT - Revista brasileira de enfermagem JID - 7910105 MH - *Biomedical Technology MH - Brazil MH - *Caregivers/education MH - *Heart Failure/therapy MH - Humans EDAT- 2022/05/19 06:00 MHDA- 2022/05/21 06:00 CRDT- 2022/05/18 17:04 PHST- 2021/08/02 00:00 [received] PHST- 2022/01/30 00:00 [accepted] PHST- 2022/05/18 17:04 [entrez] PHST- 2022/05/19 06:00 [pubmed] PHST- 2022/05/21 06:00 [medline] AID - S0034-71672022000500179 [pii] AID - 10.1590/0034-7167-2021-0465 [doi] PST - epublish SO - Rev Bras Enferm. 2022 May 18;75(4):e20210465. doi: 10.1590/0034-7167-2021-0465. eCollection 2022. PMID- 35581014 OWN - NLM STAT- MEDLINE DCOM- 20220816 LR - 20250728 IS - 1873-2623 (Electronic) IS - 0041-1345 (Linking) VI - 54 IP - 4 DP - 2022 May TI - Standards of Psychological Care for Pediatric Patients Awaiting Heart Transplantation and Those Requiring Mechanical Circulatory Support. PG - 1058-1059 LID - S0041-1345(22)00315-3 [pii] LID - 10.1016/j.transproceed.2022.03.029 [doi] AB - Children waiting for a heart transplant who require mechanical circulatory support often experience many months of hospitalization. This has a significant impact on their mental health and their development. Additional risk factors for these disorders are neurologic complications associated with the used treatment. To counteract developmental dysfunctions (despite successful heart transplantation) and possible disability in the sphere of mental health as well as to improve executive functions of children after a neurologic incident, there is a need for comprehensive care provided by a clinical psychologist who is a member of a multidisciplinary medical team taking care of the patient. Based on our own experience, standards of psychological care were developed for pediatric patients awaiting heart transplantation and those requiring mechanical circulatory support. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Rojewska, Katarzyna AU - Rojewska K AD - Central Laboratory of Clinical Psychology, Clinical Hospital No.1 in Zabrze Named after Professor S. Szyszko of the Medical University of Silesia, Katowice, Poland; Department of Cardiac Surgery, Transplantology and Mechanical Circulatory Support in Children, Silesian Center for Heart Diseases, Zabrze, Poland. FAU - Sliwka, Joanna E AU - Sliwka JE AD - Department of Cardiac Surgery, Transplantology and Mechanical Circulatory Support in Children, Silesian Center for Heart Diseases, Zabrze, Poland. Electronic address: jsliwka@sccs.pl. FAU - Pawlak, Szymon AU - Pawlak S AD - Department of Cardiac, Vascular and Endovascular Surgery and Transplantology, Medical University of Silesia, Silesian Center for Heart Diseases, Zabrze, Poland. LA - eng PT - Journal Article DEP - 20220514 PL - United States TA - Transplant Proc JT - Transplantation proceedings JID - 0243532 SB - IM MH - Child MH - *Extracorporeal Membrane Oxygenation/adverse effects MH - *Heart Failure/etiology/surgery MH - *Heart Transplantation/adverse effects MH - *Heart-Assist Devices/adverse effects MH - Humans MH - Risk Factors MH - Treatment Outcome EDAT- 2022/05/18 06:00 MHDA- 2022/08/17 06:00 CRDT- 2022/05/17 22:02 PHST- 2022/02/11 00:00 [received] PHST- 2022/03/08 00:00 [revised] PHST- 2022/03/14 00:00 [accepted] PHST- 2022/05/18 06:00 [pubmed] PHST- 2022/08/17 06:00 [medline] PHST- 2022/05/17 22:02 [entrez] AID - S0041-1345(22)00315-3 [pii] AID - 10.1016/j.transproceed.2022.03.029 [doi] PST - ppublish SO - Transplant Proc. 2022 May;54(4):1058-1059. doi: 10.1016/j.transproceed.2022.03.029. Epub 2022 May 14. PMID- 39077618 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240731 IS - 2153-8174 (Electronic) IS - 2153-8174 (Print) IS - 1530-6550 (Linking) VI - 23 IP - 5 DP - 2022 May TI - Insight from International Guidelines: do We Have Satisfactory Recommendations for Secondary Mitral Regurgitation? PG - 180 LID - 10.31083/j.rcm2305180 [doi] LID - 180 AB - Both the European Society of Cardiology (ESC) and the American College of Cardiology (ACC/AHA) have recently released guidelines on the management of patients with secondary mitral regurgitation. This includes defining, classifying, and assessing the severity of secondary mitral regurgitation. These guidelines are also the first to incorporate the use of transcatheter edge-to-edge repair in decision-making based on recent studies. The review highlights the strengths and shortcomings of these studies and the applicability and generalisability of these results to assist in decision-making for the heart time. It also emphasises the importance of shared decision-making via the heart team. Echocardiography plays an important role in the assessment of these patients although these may be specifically for primary mitral insufficiency. The optimal guideline-directed medical therapy should be the first line of treatment followed by mechanical intervention. The choice of intervention is best directed by a specialist multidisciplinary team. Concomitant revascularization should be performed in a subgroup of patients with severe secondary mitral regurgitation given the role of adverse LV remodelling in propagation of the dynamic secondary MR. The guidelines need further confirmation from high-quality studies in the near future to decision-making towards either TEER, mitral valve replacement, or mitral valve repair with or without a subvalvular procedure. CI - Copyright: (c) 2022 The Author(s). Published by IMR Press. FAU - Nappi, Francesco AU - Nappi F AD - Department of Cardiac Surgery, Centre Cardiologique du Nord, 93200 Saint-Denis, France. FAU - Avtaar Singh, Sanjeet Singh AU - Avtaar Singh SS AD - Department of Cardiothoracic Surgery, Golden Jubilee National Hospital, G81 4DY Glasgow, UK. FAU - Fiore, Antonio AU - Fiore A AD - Department of Cardiac Surgery, Hopitaux Universitaires Henri Mondor, Assistance Publique-Hopitaux de Paris, 94000 Creteil, France. FAU - Ellouze, Omar AU - Ellouze O AD - Department of Anesthesia, Centre Cardiologique du Nord, 93200 Saint-Denis, France. LA - eng PT - Journal Article PT - Review DEP - 20220517 PL - Singapore TA - Rev Cardiovasc Med JT - Reviews in cardiovascular medicine JID - 100960007 PMC - PMC11273860 OTO - NOTNLM OT - international guidelines OT - mitral valve surgery OT - secondary mitral regurgitation OT - transcatheter edge to edge valve repair COIS- The authors declare no conflict of interest. Francesco Nappi is serving as one of the Guest editors of this journal. We declare that Francesco Nappi had no involvement in the peer review of this article and has no access to information regarding its peer review. Full responsibility for the editorial process for this article was delegated to Antonio Mangieri and Alan Maisel. EDAT- 2022/05/17 00:00 MHDA- 2022/05/17 00:01 PMCR- 2022/05/17 CRDT- 2024/07/30 05:08 PHST- 2021/12/14 00:00 [received] PHST- 2022/02/04 00:00 [revised] PHST- 2022/02/16 00:00 [accepted] PHST- 2022/05/17 00:01 [medline] PHST- 2022/05/17 00:00 [pubmed] PHST- 2024/07/30 05:08 [entrez] PHST- 2022/05/17 00:00 [pmc-release] AID - S1530-6550(22)00523-3 [pii] AID - 10.31083/j.rcm2305180 [doi] PST - epublish SO - Rev Cardiovasc Med. 2022 May 17;23(5):180. doi: 10.31083/j.rcm2305180. eCollection 2022 May. PMID- 35569526 OWN - NLM STAT- MEDLINE DCOM- 20220808 LR - 20251031 IS - 1531-5053 (Electronic) IS - 0278-2391 (Linking) VI - 80 IP - 8 DP - 2022 Aug TI - Intraoperative Flap Warming: The Novel Use of a Sterile Cardiac Forced Warm Air Blanket for Maintaining Optimal Flap Perfusion. PG - 1451-1452 LID - S0278-2391(22)00299-3 [pii] LID - 10.1016/j.joms.2022.04.005 [doi] AB - The 2-team approach in major head and neck/reconstructive surgery can occasionally lead to delays between flap harvest and detachment, due to the complexity and length of the ablative procedure. In order to minimize the potential for flap cooling and the adverse impact on microcirculation, active warming can be beneficial. We present an inexpensive, readily available method of active flap warming, that can be easily introduced into practice. CI - Copyright (c) 2022 American Association of Oral and Maxillofacial Surgeons. Published by Elsevier Inc. All rights reserved. FAU - Subramaniam, Shiva S AU - Subramaniam SS AD - Oral and Maxillofacial Surgeon, The Royal Melbourne Hospital, Melbourne, Victoria; Townsville University Hospital, Townsville, Queensland, Australia. Electronic address: shiva@ofrs.com.au. LA - eng PT - Journal Article DEP - 20220414 PL - United States TA - J Oral Maxillofac Surg JT - Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons JID - 8206428 SB - IM MH - Bedding and Linens MH - Humans MH - Hypothermia MH - *Perfusion MH - *Plastic Surgery Procedures MH - *Surgical Flaps EDAT- 2022/05/16 06:00 MHDA- 2022/08/09 06:00 CRDT- 2022/05/15 19:23 PHST- 2022/02/10 00:00 [received] PHST- 2022/04/06 00:00 [revised] PHST- 2022/04/07 00:00 [accepted] PHST- 2022/05/16 06:00 [pubmed] PHST- 2022/08/09 06:00 [medline] PHST- 2022/05/15 19:23 [entrez] AID - S0278-2391(22)00299-3 [pii] AID - 10.1016/j.joms.2022.04.005 [doi] PST - ppublish SO - J Oral Maxillofac Surg. 2022 Aug;80(8):1451-1452. doi: 10.1016/j.joms.2022.04.005. Epub 2022 Apr 14. PMID- 35568645 OWN - NLM STAT- MEDLINE DCOM- 20220613 LR - 20220706 IS - 1876-7605 (Electronic) IS - 1936-8798 (Linking) VI - 15 IP - 11 DP - 2022 Jun 13 TI - Novel Transfemoral TAVR System to Treat Aortic Regurgitation in Degenerated Surgical Aortic Valve Replacement Even in Unfavorable Anatomy. PG - e135-e136 LID - S1936-8798(22)00540-4 [pii] LID - 10.1016/j.jcin.2022.02.043 [doi] FAU - Geyer, Martin AU - Geyer M AD - Department of Cardiology, Cardiology I, University Medical Center Mainz of the Johannes Gutenberg-University Mainz, Mainz, Germany. Electronic address: martin.geyer@unimedizin-mainz.de. FAU - Tamm, Alexander R AU - Tamm AR AD - Department of Cardiology, Cardiology I, University Medical Center Mainz of the Johannes Gutenberg-University Mainz, Mainz, Germany. FAU - Munzel, Thomas AU - Munzel T AD - Department of Cardiology, Cardiology I, University Medical Center Mainz of the Johannes Gutenberg-University Mainz, Mainz, Germany. FAU - Treede, Hendrik AU - Treede H AD - Department for Cardiac and Vascular Surgery, University Medical Center Mainz of the Johannes Gutenberg-University Mainz, Mainz, Germany. FAU - von Bardeleben, Ralph Stephan AU - von Bardeleben RS AD - Department of Cardiology, Cardiology I, University Medical Center Mainz of the Johannes Gutenberg-University Mainz, Mainz, Germany. LA - eng PT - Journal Article DEP - 20220511 PL - United States TA - JACC Cardiovasc Interv JT - JACC. Cardiovascular interventions JID - 101467004 SB - IM MH - Aortic Valve/diagnostic imaging/surgery MH - *Aortic Valve Insufficiency/diagnostic imaging/etiology/surgery MH - *Aortic Valve Stenosis/diagnostic imaging/surgery MH - *Heart Valve Prosthesis MH - *Heart Valve Prosthesis Implantation/adverse effects MH - Humans MH - Risk Factors MH - *Transcatheter Aortic Valve Replacement/adverse effects MH - Treatment Outcome OTO - NOTNLM OT - TAVR OT - aortic regurgitation OT - degenerated surgical aortic valve repair OT - interdisciplinary heart team OT - valve-in-valve replacement COIS- Funding Support and Author Disclosures Dr Tamm has received lecture honoraria from Edwards Lifesciences, Medtronic, and JenaValve Technology. Dr Treede has been a proctor and consultant for JenaValve Technology. Dr von Bardeleben has received research grants and honoraria from Abbott Structural Heart, Edwards Lifesciences, NeoChord; all trial activity is without personal reimbursement. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2022/05/15 06:00 MHDA- 2022/06/14 06:00 CRDT- 2022/05/14 22:06 PHST- 2022/01/14 00:00 [received] PHST- 2022/02/10 00:00 [revised] PHST- 2022/02/22 00:00 [accepted] PHST- 2022/05/15 06:00 [pubmed] PHST- 2022/06/14 06:00 [medline] PHST- 2022/05/14 22:06 [entrez] AID - S1936-8798(22)00540-4 [pii] AID - 10.1016/j.jcin.2022.02.043 [doi] PST - ppublish SO - JACC Cardiovasc Interv. 2022 Jun 13;15(11):e135-e136. doi: 10.1016/j.jcin.2022.02.043. Epub 2022 May 11. PMID- 35566553 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240312 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 11 IP - 9 DP - 2022 Apr 26 TI - Impella to Treat Acute Myocardial Infarct-Related Cardiogenic Shock. LID - 10.3390/jcm11092427 [doi] LID - 2427 AB - Acute myocardial infarction complicated by cardiogenic shock (AMICS), is characterized by critically low cardiac output and decreased myocardial contractility. In this situation, a treatment that unloads the myocardium and restores CO without increasing the myocardial oxygen demand is theoretically appealing. Axial flow pumps offer hemodynamic support without increasing myocardial oxygen consumption. Consequently, the use of axial flow pumps, especially the Impella devices, is increasing. It is likely that the SCAI C patient with predominantly left ventricular failure and without prolonged cardiac arrest is the best candidate for these devices. Registry data suggest that pre-PCI Impella may be advantageous to post-PCI placement. However, several gaps in knowledge exist regarding optimal patient selection, futility criteria, timing, weaning and escalation strategy, and until data from adequately sized randomized trials are available, immediate individual evaluation for mechanical circulatory support by a shock team is warranted when a patient is diagnosed with AMICS. FAU - Moller, Jacob Eifer AU - Moller JE AD - Department of Cardiology, Odense University Hospital, 5000 Odense, Denmark. AD - Heart Center, Copenhagen University Hospital Rigshospitalet, 2100 Copenhagen, Denmark. FAU - Kjaergaard, Jesper AU - Kjaergaard J AD - Heart Center, Copenhagen University Hospital Rigshospitalet, 2100 Copenhagen, Denmark. FAU - Terkelsen, Christian Juhl AU - Terkelsen CJ AD - Department of Cardiology, Aarhus University Hospital, 8000 Aarhus, Denmark. FAU - Hassager, Christian AU - Hassager C AD - Heart Center, Copenhagen University Hospital Rigshospitalet, 2100 Copenhagen, Denmark. LA - eng PT - Journal Article PT - Review DEP - 20220426 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC9101440 OTO - NOTNLM OT - acute myocardial infarction OT - cardiogenic shock OT - mechanical circulatory support COIS- J.E.M. has received a research grant and speakers fee from Abiomed, C.H. reports a speakers fee from Abiomed. No other conflict of interest exists for the submitted work. EDAT- 2022/05/15 06:00 MHDA- 2022/05/15 06:01 PMCR- 2022/04/26 CRDT- 2022/05/14 01:25 PHST- 2022/01/16 00:00 [received] PHST- 2022/04/08 00:00 [revised] PHST- 2022/04/21 00:00 [accepted] PHST- 2022/05/14 01:25 [entrez] PHST- 2022/05/15 06:00 [pubmed] PHST- 2022/05/15 06:01 [medline] PHST- 2022/04/26 00:00 [pmc-release] AID - jcm11092427 [pii] AID - jcm-11-02427 [pii] AID - 10.3390/jcm11092427 [doi] PST - epublish SO - J Clin Med. 2022 Apr 26;11(9):2427. doi: 10.3390/jcm11092427. PMID- 35564663 OWN - NLM STAT- MEDLINE DCOM- 20220518 LR - 20240827 IS - 1660-4601 (Electronic) IS - 1661-7827 (Print) IS - 1660-4601 (Linking) VI - 19 IP - 9 DP - 2022 Apr 26 TI - Telemonitoring in Long-COVID Patients-Preliminary Findings. LID - 10.3390/ijerph19095268 [doi] LID - 5268 AB - The COVID-19 pandemic has revealed the high usefulness of telemedicine. To date, no uniform recommendations or diagnostic protocols for long-COVID patients have been developed. This article presents the preliminary results of the examination of patients after SARS-CoV-2 infection who were provided with medical telemonitoring devices in order to oversee their pulmonological and cardiological health. Three cases have been analyzed. Each patient underwent a 10-day registration of basic vital signs, in three 15-min sessions daily: RR (respiratory rate), ECG (electrocardiogram), HR (pulse), SPO(2) (saturation), body temperature and cough. Rule methods and machine learning were employed to automatically detect events. As a result, serious disorders of all the three patients were detected: cardiological and respiratory disorders that required extended diagnostics. Furthermore, average values of the selected parameters (RR, HR, SPO(2)) were calculated for every patient, including an indication of how often they exceeded the alarm thresholds. In conclusion, monitoring parameters in patients using telemedicine, especially in a time of limited access to the healthcare system, is a valuable clinical instrument. It enables medical professionals to recognize conditions which may endanger a patient's health or life. Telemedicine provides a reliable assessment of a patient's health status made over a distance, which can alleviate a patient's stress caused by long-COVID syndrome. Telemedicine allows identification of disorders and performing further diagnosis, which is possible owing to the implementation of advanced analysis. Telemedicine, however, requires flexibility and the engagement of a multidisciplinary team, who will respond to patients' problems on an ongoing basis. FAU - Romaszko-Wojtowicz, Anna AU - Romaszko-Wojtowicz A AUID- ORCID: 0000-0003-2042-1382 AD - Department of Pulmonology, School of Public Health, Collegium Medicum of the University of Warmia and Mazury, ul. Jagiellonska 78, 10-357 Olsztyn, Poland. FAU - Maksymowicz, Stanislaw AU - Maksymowicz S AUID- ORCID: 0000-0002-6606-9575 AD - Department of Psychology and Sociology of Health and Public Health, School of Public Health, Collegium Medicum of the University of Warmia and Mazury, al. Warszawska 30, 10-082 Olsztyn, Poland. FAU - Jarynowski, Andrzej AU - Jarynowski A AUID- ORCID: 0000-0003-0949-6674 AD - Aidmed Sp. z o.o., ul. Uphagena 27, 80-237 Gdansk, Poland. FAU - Jaskiewicz, Lukasz AU - Jaskiewicz L AUID- ORCID: 0000-0002-0035-4314 AD - Department of Human Physiology and Pathophysiology, School of Medicine, Collegium Medicum of the University of Warmia and Mazury, al. Warszawska 30, 10-082 Olsztyn, Poland. FAU - Czekaj, Lukasz AU - Czekaj L AD - Aidmed Sp. z o.o., ul. Uphagena 27, 80-237 Gdansk, Poland. FAU - Doboszynska, Anna AU - Doboszynska A AD - Department of Pulmonology, School of Public Health, Collegium Medicum of the University of Warmia and Mazury, ul. Jagiellonska 78, 10-357 Olsztyn, Poland. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220426 PL - Switzerland TA - Int J Environ Res Public Health JT - International journal of environmental research and public health JID - 101238455 SB - IM MH - *COVID-19/complications/diagnosis MH - Humans MH - Pandemics MH - SARS-CoV-2 MH - *Telemedicine/methods MH - Post-Acute COVID-19 Syndrome PMC - PMC9103243 OTO - NOTNLM OT - cardiological and respiratory disorders OT - long-COVID OT - telemedicine COIS- The authors declare no conflict of interest. EDAT- 2022/05/15 06:00 MHDA- 2022/05/18 06:00 PMCR- 2022/04/26 CRDT- 2022/05/14 01:13 PHST- 2022/03/04 00:00 [received] PHST- 2022/04/04 00:00 [revised] PHST- 2022/04/14 00:00 [accepted] PHST- 2022/05/14 01:13 [entrez] PHST- 2022/05/15 06:00 [pubmed] PHST- 2022/05/18 06:00 [medline] PHST- 2022/04/26 00:00 [pmc-release] AID - ijerph19095268 [pii] AID - ijerph-19-05268 [pii] AID - 10.3390/ijerph19095268 [doi] PST - epublish SO - Int J Environ Res Public Health. 2022 Apr 26;19(9):5268. doi: 10.3390/ijerph19095268. PMID- 35564653 OWN - NLM STAT- MEDLINE DCOM- 20220517 LR - 20220528 IS - 1660-4601 (Electronic) IS - 1661-7827 (Print) IS - 1660-4601 (Linking) VI - 19 IP - 9 DP - 2022 Apr 26 TI - AvaLife-A New Multi-Disciplinary Approach Supported by Accident and Field Test Data to Optimize Survival Chances in Rescue and First Aid of Avalanche Patients. LID - 10.3390/ijerph19095257 [doi] LID - 5257 AB - Snow sports in the backcountry have seen a steep increase in popularity, and therefore preparedness for efficient companion and organized rescue is important. While technical rescue skills are widely taught, there is a lack of knowledge regarding first aid for avalanche patients. The stressful and time-critical situation for first responders requires a rule-based decision support tool. AvaLife has been designed from scratch, applying mathematical and statistical approaches including Monte Carlo simulations. New analysis of retrospective data and large prospective field test datasets were used to develop evidence-based algorithms exclusively for the avalanche rescue environment. AvaLife differs from other algorithms as it is not just a general-purpose CPR algorithm which has been slightly adapted for the avalanche patient. The sequence of actions, inclusion of the >/=150 cm burial depth triage criterion, advice to limit CPR duration for normothermic patients to 6 min in case of multiple burials and shortage of resources, criteria for using recovered subjects as a resource in the ongoing rescue, the adapted definition of "injuries incompatible with life", reasoning behind the utmost importance of rescue breaths, as well as the updated BLS-iCPR algorithm make AvaLife useful in single and multiple burial rescue. AvaLife is available as a companion rescue basic life support (BLS) version for the recreational user and an advanced companion and organized rescue BLS version for guides, ski patrols and mountain rescuers. AvaLife allows seamless interoperability with advanced life support (ALS) qualified medical personnel arriving on site. FAU - Genswein, Manuel AU - Genswein M AD - MountainSafety.info, 7260 Davos, Switzerland. FAU - Macias, Darryl AU - Macias D AD - Department of Emergency Medicine, University of New Mexico, International Mountain Medicine Center, Albuquerque, NM 87131, USA. FAU - McIntosh, Scott AU - McIntosh S AD - Department of Emergency Medicine, University of Utah Health, AirMed, Salt Lake City, UT 84132, USA. FAU - Reiweger, Ingrid AU - Reiweger I AD - Institute of Mountain Risk Engineering, University of Natural Resources and Life Sciences, 1190 Vienna, Austria. FAU - Hetland, Audun AU - Hetland A AD - CARE Center for Avalanche Research and Education, UiT The Arctic University of Norway, 9010 Tromso, Norway. FAU - Paal, Peter AU - Paal P AUID- ORCID: 0000-0002-2939-4782 AD - Department of Anesthesiology and Intensive Care Medicine, St. John of God Hospital, Paracelsus Medical University, 5010 Salzburg, Austria. LA - eng PT - Journal Article DEP - 20220426 PL - Switzerland TA - Int J Environ Res Public Health JT - International journal of environmental research and public health JID - 101238455 SB - IM MH - Accidents MH - Asphyxia MH - *Avalanches MH - First Aid MH - Humans MH - Prospective Studies MH - Retrospective Studies PMC - PMC9104102 OTO - NOTNLM OT - accidental OT - asphyxia OT - avalanche OT - basic life support OT - cardiac arrest OT - emergency medical services OT - hypothermia OT - mountain rescue COIS- The authors declare no conflict of interest. EDAT- 2022/05/15 06:00 MHDA- 2022/05/18 06:00 PMCR- 2022/04/26 CRDT- 2022/05/14 01:13 PHST- 2022/01/30 00:00 [received] PHST- 2022/03/10 00:00 [revised] PHST- 2022/03/16 00:00 [accepted] PHST- 2022/05/14 01:13 [entrez] PHST- 2022/05/15 06:00 [pubmed] PHST- 2022/05/18 06:00 [medline] PHST- 2022/04/26 00:00 [pmc-release] AID - ijerph19095257 [pii] AID - ijerph-19-05257 [pii] AID - 10.3390/ijerph19095257 [doi] PST - epublish SO - Int J Environ Res Public Health. 2022 Apr 26;19(9):5257. doi: 10.3390/ijerph19095257. PMID- 35552401 OWN - NLM STAT- MEDLINE DCOM- 20220708 LR - 20260127 IS - 1522-9645 (Electronic) IS - 0195-668X (Print) IS - 0195-668X (Linking) VI - 43 IP - 26 DP - 2022 Jul 7 TI - Integrated care for optimizing the management of stroke and associated heart disease: a position paper of the European Society of Cardiology Council on Stroke. PG - 2442-2460 LID - 10.1093/eurheartj/ehac245 [doi] AB - The management of patients with stroke is often multidisciplinary, involving various specialties and healthcare professionals. Given the common shared risk factors for stroke and cardiovascular disease, input may also be required from the cardiovascular teams, as well as patient caregivers and next-of-kin. Ultimately, the patient is central to all this, requiring a coordinated and uniform approach to the priorities of post-stroke management, which can be consistently implemented by different multidisciplinary healthcare professionals, as part of the patient 'journey' or 'patient pathway,' supported by appropriate education and tele-medicine approaches. All these aspects would ultimately aid delivery of care and improve patient (and caregiver) engagement and empowerment. Given the need to address the multidisciplinary approach to holistic or integrated care of patients with heart disease and stroke, the European Society of Cardiology Council on Stroke convened a Task Force, with the remit to propose a consensus on Integrated care management for optimizing the management of stroke and associated heart disease. The present position paper summarizes the available evidence and proposes consensus statements that may help to define evidence gaps and simple practical approaches to assist in everyday clinical practice. A post-stroke ABC pathway is proposed, as a more holistic approach to integrated stroke care, would include three pillars of management: A: Appropriate Antithrombotic therapy.B: Better functional and psychological status.C: Cardiovascular risk factors and Comorbidity optimization (including lifestyle changes). CI - (c) The Author(s) 2022. Published by Oxford University Press on behalf of European Society of Cardiology. FAU - Lip, Gregory Y H AU - Lip GYH AUID- ORCID: 0000-0002-7566-1626 AD - Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK. AD - Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. AD - Division of Medical Sciences in Zabrze, Department of Cardiology, Congenital Heart Diseases and Electrotherapy, The Medical University of Silesia, Silesian Center of Heart Diseases, Curie-Sklodowska Str 9, 41-800 Zabrze, Poland. AD - School of Medicine, Belgrade University, Belgrade, Serbia. FAU - Lane, Deirdre A AU - Lane DA AD - Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK. AD - Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. FAU - Lenarczyk, Radoslaw AU - Lenarczyk R AD - Division of Medical Sciences in Zabrze, Department of Cardiology, Congenital Heart Diseases and Electrotherapy, The Medical University of Silesia, Silesian Center of Heart Diseases, Curie-Sklodowska Str 9, 41-800 Zabrze, Poland. FAU - Boriani, Giuseppe AU - Boriani G AUID- ORCID: 0000-0002-9820-4815 AD - Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy. FAU - Doehner, Wolfram AU - Doehner W AUID- ORCID: 0000-0001-7598-708X AD - BIH Center for Regenerative Therapies (BCRT) and Department of Internal Medicine and Cardiology (Virchow Klinikum), German Centre for Cardiovascular Research (DZHK) partner site Berlin and Center for Stroke Research Berlin, Charite Universitatsmedizin Berlin, Berlin, Germany. FAU - Benjamin, Laura A AU - Benjamin LA AD - Laboratory of Molecular and Cell Biology, University College London National Hospital for Neurology and Neurosurgery, Queen Square, London. FAU - Fisher, Marc AU - Fisher M AD - Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. FAU - Lowe, Deborah AU - Lowe D AD - Wirral University Teaching Hospital NHS Foundation Trust, Wirral CH49 5PE, UK. FAU - Sacco, Ralph L AU - Sacco RL AD - UM Clinical & Translational Science Institute, University of Miami, Miller School of Medicine, Miami, FL, USA. FAU - Schnabel, Renate AU - Schnabel R AD - University Heart & Vascular Center Hamburg Eppendorf, German Center for Cardiovascular Research (DZHK) partner site Hamburg/Kiel/Lubeck, Hamburg, Germany. FAU - Watkins, Caroline AU - Watkins C AD - Faculty of Health and Care, University of Central Lancashire, Preston PR1 2HE, UK. FAU - Ntaios, George AU - Ntaios G AUID- ORCID: 0000-0002-0629-9248 AD - Department of Internal Medicine, School of Health Sciences, Faculty of Medicine, University of Thessaly, Larissa, Greece. FAU - Potpara, Tatjana AU - Potpara T AUID- ORCID: 0000-0001-6285-6902 AD - School of Medicine, Belgrade University, Belgrade, Serbia. AD - Cardiology Clinic, Clinical Centre of Serbia, Belgrade, Serbia. LA - eng PT - Consensus Statement PT - Journal Article PL - England TA - Eur Heart J JT - European heart journal JID - 8006263 SB - IM MH - *Atrial Fibrillation/drug therapy MH - *Cardiology MH - *Delivery of Health Care, Integrated MH - *Heart Diseases MH - Humans MH - *Stroke/therapy PMC - PMC9259378 OTO - NOTNLM OT - Delivery of care OT - Heart disease OT - Integrated care OT - Patient pathways OT - Stroke EDAT- 2022/05/14 06:00 MHDA- 2022/07/09 06:00 PMCR- 2022/05/11 CRDT- 2022/05/13 14:15 PHST- 2021/12/17 00:00 [received] PHST- 2022/03/11 00:00 [revised] PHST- 2022/04/27 00:00 [accepted] PHST- 2022/05/14 06:00 [pubmed] PHST- 2022/07/09 06:00 [medline] PHST- 2022/05/13 14:15 [entrez] PHST- 2022/05/11 00:00 [pmc-release] AID - 6583481 [pii] AID - ehac245 [pii] AID - 10.1093/eurheartj/ehac245 [doi] PST - ppublish SO - Eur Heart J. 2022 Jul 7;43(26):2442-2460. doi: 10.1093/eurheartj/ehac245. PMID- 35550435 OWN - NLM STAT- MEDLINE DCOM- 20220701 LR - 20221207 IS - 1539-0705 (Electronic) IS - 1522-2179 (Linking) VI - 24 IP - 4 DP - 2022 Aug 1 TI - Case Study of an African American Woman With Heart Failure: Ethical and Palliative Care Considerations. PG - 225-231 LID - 10.1097/NJH.0000000000000865 [doi] AB - Heart failure affects an estimated 6.2 million adults in the United States. African Americans have a higher incidence of heart failure at an earlier age and more rapid disease progression than other ethnicities. African Americans also often receive lower-quality, end-of-life care and less often receive palliative and advanced-care planning than Whites. Several barriers exist for effective heart failure evaluation and treatment among African Americans, including ineffective patient-provider communication, mistrust, health care providers' lack of understanding of palliative care services, and potential downstream effects of social determinants of health (eg, access barriers to healthy food and community health promotion resources). Despite the recognized benefits of palliative care, few adults with heart failure are receiving early discussions about palliative and advanced care planning to ensure delivery of goal-concordant care. This article presents a fictitious case study focused on an African American woman, Ms T, with heart failure who has been given 6 months to live. Racial inequities are presented surrounding Ms T's inadequate access to necessary health care resources and in receiving delayed communication about palliative and advanced care services. The case study also highlights ethical principles of concern, the role of an interdisciplinary team approach for patients with heart failure, and the advocacy role of nurses. CI - Copyright (c) 2022 by The Hospice and Palliative Nurses Association. All rights reserved. FAU - Hendricks-Ferguson, Verna L AU - Hendricks-Ferguson VL FAU - Stallings, Devita T AU - Stallings DT LA - eng PT - Journal Article DEP - 20220506 PL - United States TA - J Hosp Palliat Nurs JT - Journal of hospice and palliative nursing : JHPN : the official journal of the Hospice and Palliative Nurses Association JID - 100887419 SB - IM MH - Adult MH - Black or African American MH - Female MH - *Heart Failure/complications/therapy MH - *Hospice Care MH - Humans MH - Palliative Care MH - *Terminal Care MH - United States COIS- The authors have no conflict of interests to disclose. EDAT- 2022/05/14 06:00 MHDA- 2022/07/02 06:00 CRDT- 2022/05/13 12:39 PHST- 2022/05/14 06:00 [pubmed] PHST- 2022/07/02 06:00 [medline] PHST- 2022/05/13 12:39 [entrez] AID - 00129191-202208000-00004 [pii] AID - 10.1097/NJH.0000000000000865 [doi] PST - ppublish SO - J Hosp Palliat Nurs. 2022 Aug 1;24(4):225-231. doi: 10.1097/NJH.0000000000000865. Epub 2022 May 6. PMID- 35550231 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250801 LR - 20250801 IS - 1467-1107 (Electronic) IS - 1047-9511 (Linking) VI - 32 IP - 9 DP - 2022 Sep TI - Management of post-operative ventilator dependency in an operated case of tetralogy of Fallot with absent pulmonary valve: a team approach involving cardiac surgeon, cardiologist, intensivist, and radiologist. PG - 1527-1529 LID - 10.1017/S1047951122000026 [doi] AB - Tetralogy of Fallot with absent pulmonary valve syndrome is commonly associated with trachea-bronchial anomalies, possibly due to airway compression caused by massively dilated pulmonary arteries secondary to severe pulmonary regurgitation. This airway obstruction may persist post-operatively also. We report a case of an infant who required a series of management strategies including bronchial stenting to manage his obstructive symptoms. FAU - Pota, Abhay AU - Pota A AUID- ORCID: 0000-0003-3658-9841 AD - Department of Paediatric Cardiology, Medanta-The Medicity, Gurgaon, India. FAU - Biyani, Garima AU - Biyani G AUID- ORCID: 0000-0003-0179-4175 AD - Department of Paediatric Cardiology, Medanta-The Medicity, Gurgaon, India. FAU - Misri, Amit AU - Misri A AD - Department of Paediatric Cardiology, Medanta-The Medicity, Gurgaon, India. LA - eng PT - Journal Article DEP - 20220513 PL - England TA - Cardiol Young JT - Cardiology in the young JID - 9200019 SB - IM OTO - NOTNLM OT - Tetralogy of Fallot OT - absent pulmonary valve syndrome OT - biodegradable stent OT - bronchial stenting OT - medela suction EDAT- 2022/05/14 06:00 MHDA- 2022/05/14 06:01 CRDT- 2022/05/13 12:30 PHST- 2022/05/14 06:01 [medline] PHST- 2022/05/14 06:00 [pubmed] PHST- 2022/05/13 12:30 [entrez] AID - S1047951122000026 [pii] AID - 10.1017/S1047951122000026 [doi] PST - ppublish SO - Cardiol Young. 2022 Sep;32(9):1527-1529. doi: 10.1017/S1047951122000026. Epub 2022 May 13. PMID- 35549709 OWN - NLM STAT- MEDLINE DCOM- 20220726 LR - 20250728 IS - 1744-8298 (Electronic) IS - 1479-6678 (Linking) VI - 18 IP - 8 DP - 2022 Aug TI - Pregnancy in women with dilated cardiomyopathy. PG - 661-667 LID - 10.2217/fca-2021-0153 [doi] AB - Only a few studies describe the pathophysiology and outcomes of dilated cardiomyopathy (DCM) in pregnancy, which the authors aim to review here. DCM causes enlargement of the ventricles and reduced systolic function. Fluid overload and raised cardiac output in pregnancy may contribute to cardiac complications that lead to cardiac remodeling and heart failure, a common cause of maternal mortality. The risk of cardiac complications is higher in women with New York Heart Association class III and IV. Fetal and neonatal complications are common with coexisting obstetric risk factors. Hence, prepregnancy counseling and a multi-disciplinary approach are essential. Renin-angiotensin-aldosterone system blockers prevent cardiac remodeling but are teratogenic. Drugs, such as beta-blockers to control cardiac remodeling, thiazide diuretics to reduce preload, hydralazine and nitrates to reduce afterload and digoxin to increase inotropy, are safe and should be used to manage DCM in pregnancy. FAU - Bangi, Eera Fatima AU - Bangi EF AUID- ORCID: 0000-0003-3916-9738 AD - Seth Gordhandas Sunderdas Medical College & King Edward Memorial Hospital, Mumbai, India 400012. FAU - Maikawa, Nicolle AU - Maikawa N AD - Saint James School of Medicine, C/o Human Resource Development Services (HRDS) Inc., 1480 Renaissance Drive, Suite 300, Park Ridge, IL 60068, USA. FAU - Kaur, Amandeep AU - Kaur A AUID- ORCID: 0000-0002-7394-7727 AD - American University of Integrative Sciences School of Medicine, Barbados. FAU - Jain, Rahul AU - Jain R AD - University of Indiana, Department of Internal Medicine, Division of Cardiology, IN 46202, USA. FAU - Jain, Rohit AU - Jain R AD - Penn State Milton S Hershey Medical Center, Hershey, PA 17033, USA. LA - eng PT - Journal Article PT - Review DEP - 20220513 PL - England TA - Future Cardiol JT - Future cardiology JID - 101239345 RN - 0 (Adrenergic beta-Antagonists) SB - IM MH - Adrenergic beta-Antagonists/therapeutic use MH - *Cardiomyopathy, Dilated MH - Female MH - *Heart Failure/etiology MH - Humans MH - Infant, Newborn MH - Pregnancy MH - Renin-Angiotensin System MH - Ventricular Remodeling OAB - Dilated cardiomyopathy (DCM) is a rare disease of the heart associated with the enlargement of its chambers and subsequent reduction in its pumping ability. The authors aim to describe the disease process, presentation and treatment of DCM in pregnancy in this review article. A physiological change in pregnancy is an increase in the total blood volume to ensure blood supply to the fetus. This can, however, have a negative impact on the already diseased heart in DCM and present as heart failure in pregnancy. The clinical outcomes of DCM in pregnancy depend on heart health prior to pregnancy. During pregnancy, the mother can suffer from cardiac events, such as heart failure, arrhythmias and sudden death, whereas the fetus may be born prematurely and be small for gestational age. Drugs useful in slowing the progression of DCM, such as angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, are contraindicated in pregnancy. Hence, such women require careful monitoring throughout pregnancy by a multi-disciplinary team. Drugs that can be safely used to manage DCM include beta-blockers, thiazide diuretics and digoxin. More comprehensive studies on DCM in pregnancy are needed to better understand the disease process and accordingly counsel and treat women with this condition in pregnancy. OABL- eng OTO - NOTNLM OT - B-type natriuretic peptide OT - arrhythmia OT - dilated cardiomyopathy OT - echocardiography OT - heart failure OT - pregnancy OT - premature birth OT - renin-angiotensin-aldosterone system OT - small for gestational age OT - beta-blockers EDAT- 2022/05/14 06:00 MHDA- 2022/07/27 06:00 CRDT- 2022/05/13 12:02 PHST- 2022/05/14 06:00 [pubmed] PHST- 2022/07/27 06:00 [medline] PHST- 2022/05/13 12:02 [entrez] AID - 10.2217/fca-2021-0153 [doi] PST - ppublish SO - Future Cardiol. 2022 Aug;18(8):661-667. doi: 10.2217/fca-2021-0153. Epub 2022 May 13. PMID- 35546743 OWN - NLM STAT- MEDLINE DCOM- 20230816 LR - 20231119 IS - 1875-6557 (Electronic) IS - 1573-403X (Print) IS - 1573-403X (Linking) VI - 18 IP - 6 DP - 2022 TI - Paravalvular Leak: A Systemic Review. PG - e110522204571 LID - 10.2174/1573403X18666220511113310 [doi] LID - e110522204571 AB - BACKGROUND: Paravalvular Leak (PVL) refers to the retrograde flow of blood in the space between an implanted cardiac valve and native tissue. These are unfortunately but luckily relatively uncommon complications of prosthetic valve replacement that, especially when moderate or severe, have important clinical consequences. OBJECTIVE: Addressing PVL requires a multidisciplinary team to properly diagnose this process and choose the corrective option most likely to result in success. METHODS: A comprehensive literature search was undertaken to formulate this narrative review. RESULTS: This review highlights the complex nature of PVL and the promising contemporary treatments available. CONCLUSION: Clinicians should be adept at recognizing PVL and characterizing it using multimodality imaging. Using the many available tools and a multidisciplinary approach should lead to favorable outcomes in patients with PVL. CI - Copyright(c) Bentham Science Publishers; For any queries, please email at epub@benthamscience.net. FAU - Randall, Morgan AU - Randall M AD - Division of Cardiovascular Medicine, Department of Medicine, University of Florida, Gainesville, FL 32611, USA. FAU - Betageri, Omkar AU - Betageri O AD - Department of Medicine, University of Florida, Gainesville, FL 32611, USA. FAU - Hanayneh, Seri AU - Hanayneh S AD - Department of Medicine, University of Florida, Gainesville, FL 32611, USA. FAU - Anderson, R David AU - Anderson RD AD - Division of Cardiovascular Medicine, Department of Medicine, University of Florida, Gainesville, FL 32611, USA. LA - eng PT - Journal Article PT - Systematic Review PL - United Arab Emirates TA - Curr Cardiol Rev JT - Current cardiology reviews JID - 101261935 SB - IM MH - Humans MH - Aortic Valve/surgery MH - *Aortic Valve Insufficiency/etiology/surgery MH - *Heart Valve Prosthesis/adverse effects MH - *Heart Valve Prosthesis Implantation/adverse effects/methods MH - Retrospective Studies MH - *Transcatheter Aortic Valve Replacement MH - Treatment Outcome PMC - PMC9893144 OTO - NOTNLM OT - Paravalvular leak OT - interventional cardiology OT - surgical aortic valve replacement OT - surgical mitral valve replacement OT - transcatheter aortic valve replacement OT - transcatheter mitral valve replacement EDAT- 2022/05/14 06:00 MHDA- 2022/11/25 06:00 PMCR- 2023/11/18 CRDT- 2022/05/13 11:03 PHST- 2022/03/08 00:00 [received] PHST- 2022/03/10 00:00 [revised] PHST- 2022/03/15 00:00 [accepted] PHST- 2022/05/14 06:00 [pubmed] PHST- 2022/11/25 06:00 [medline] PHST- 2022/05/13 11:03 [entrez] PHST- 2023/11/18 00:00 [pmc-release] AID - CCR-EPUB-123358 [pii] AID - CCR-18-6-E110522204571 [pii] AID - 10.2174/1573403X18666220511113310 [doi] PST - ppublish SO - Curr Cardiol Rev. 2022;18(6):e110522204571. doi: 10.2174/1573403X18666220511113310. PMID- 35545796 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220716 IS - 2055-7426 (Electronic) IS - 2055-7426 (Linking) VI - 7 IP - 1 DP - 2022 May 11 TI - Unmet need for contraception and associated factors among women with cardiovascular disease having follow-up at Saint Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia: a cross-sectional study. PG - 6 LID - 10.1186/s40834-022-00173-0 [doi] LID - 6 AB - BACKGROUND: Unmet need for contraception refers to the proportion of women who want to postpone or stop childbearing but are not using a contraceptive method. Addressing unmet need is especially important for women with medical conditions such as cardiovascular disease (CVD). Preventing unintended pregnancy is crucial to improve pregnancy outcomes and minimize complications of CVD during pregnancy. However, unmet need for contraceptives continues to undermine the potential benefits of contraceptive use. This research aimed to determine the rate of unmet need for contraceptives and associated factors among women with cardiovascular disease having follow-up at Saint Paul's Hospital Millennium Medical College (SPHMMC), Addis Ababa, Ethiopia. METHODS: A facility-based cross-sectional study was conducted from February 1 to May 31/2020. A total of 284 reproductive age women with cardiovascular disease having follow-up at the cardiac clinic of SPHMMC were enrolled consecutively until the desired sample size was reached. Data was collected through an exit interview using a structured and pretested questionnaire. Descriptive, bivariate, and multivariable methods were used to analyze the level of unmet need and its associated factors. RESULTS: The overall unmet need for contraception was 36.0% (95% CI: 30.4-41.5). The majority of the respondents lack counseling on contraception use. The most common reasons for non-use of a contraceptive method were fear of drug side effects and drug interaction. Unmet need for contraception was found to be more likely among those who have not been counseled on contraceptive utilization (AOR 6.7, CI 1.8-24.7) and those who lack partner support on contraception use (AOR = 6.2, CI: 1.91-19.8). Unmet need was also found to be more likely among women who have never used contraception before (AOR = 3.2, CI 1.12-8.92). CONCLUSION: Unmet need for contraception was high in this high-risk population group. The cardiac follow-up clinic should implement client-centered counseling by a multidisciplinary team to address the needs of women and prevent consequences of unintended pregnancy. Furthermore, there is a need to initiate interventions that encourage communication between couples and increase male partner involvement through a renewed focus on couples counseling. CI - (c) 2022. The Author(s). FAU - Mechal, Negalign AU - Mechal N AD - Department of Obstetrics and Gynecology, Saint Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia. FAU - Negash, Mustefa AU - Negash M AD - Department of Obstetrics and Gynecology, Saint Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia. FAU - Bizuneh, Hailemichael AU - Bizuneh H AD - Epidemiology Unit, Department of Public Health, Saint Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia. FAU - Abubeker, Ferid A AU - Abubeker FA AD - Department of Obstetrics and Gynecology, Saint Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia. ferid.abas@sphmmc.edu.et. LA - eng PT - Journal Article DEP - 20220511 PL - England TA - Contracept Reprod Med JT - Contraception and reproductive medicine JID - 101703414 PMC - PMC9092812 OTO - NOTNLM OT - Cardiovascular disease OT - Chronic medical disease OT - Contraception OT - Ethiopia OT - Unmet need COIS- The authors declare that they have no competing interests. EDAT- 2022/05/12 06:00 MHDA- 2022/05/12 06:01 PMCR- 2022/05/11 CRDT- 2022/05/11 23:35 PHST- 2021/01/22 00:00 [received] PHST- 2022/04/28 00:00 [accepted] PHST- 2022/05/11 23:35 [entrez] PHST- 2022/05/12 06:00 [pubmed] PHST- 2022/05/12 06:01 [medline] PHST- 2022/05/11 00:00 [pmc-release] AID - 10.1186/s40834-022-00173-0 [pii] AID - 173 [pii] AID - 10.1186/s40834-022-00173-0 [doi] PST - epublish SO - Contracept Reprod Med. 2022 May 11;7(1):6. doi: 10.1186/s40834-022-00173-0. PMID- 35545459 OWN - NLM STAT- MEDLINE DCOM- 20220615 LR - 20221207 IS - 1532-8422 (Electronic) IS - 1053-0770 (Linking) VI - 36 IP - 8 Pt A DP - 2022 Aug TI - Type A Aortic Dissection After a Transcatheter Aortic Valve Replacement in a Prohibitive Surgical Risk Candidate. PG - 2803-2810 LID - S1053-0770(22)00268-3 [pii] LID - 10.1053/j.jvca.2022.04.009 [doi] FAU - Fried, Eric A AU - Fried EA AD - Department of Anesthesiology, Perioperative, and Pain Medicine, Icahn School of Medicine at Mount Sinai, New York, NY. FAU - Salter, Benjamin S AU - Salter BS AD - Department of Anesthesiology, Perioperative, and Pain Medicine, Icahn School of Medicine at Mount Sinai, New York, NY. FAU - Weiner, Menachem M AU - Weiner MM AD - Department of Anesthesiology, Perioperative, and Pain Medicine, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: menachem.weiner@mountsinai.org. FAU - Faloye, Abimbola O AU - Faloye AO AD - Department of Anesthesiology, Emory University, Atlanta, GA. FAU - Richter, Ellen W AU - Richter EW AD - Department of Anesthesiology, Emory University, Atlanta, GA. FAU - Pineda, Andres M AU - Pineda AM AD - Division of Cardiology, Department of Medicine, University of Florida College of Medicine, Gainesville, FL. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220414 PL - United States TA - J Cardiothorac Vasc Anesth JT - Journal of cardiothoracic and vascular anesthesia JID - 9110208 SB - IM MH - *Aortic Dissection/diagnostic imaging/etiology/surgery MH - Aortic Valve/diagnostic imaging/surgery MH - *Aortic Valve Stenosis/diagnostic imaging/surgery MH - *Heart Valve Prosthesis MH - *Heart Valve Prosthesis Implantation MH - Humans MH - Risk Factors MH - Severity of Illness Index MH - *Transcatheter Aortic Valve Replacement/adverse effects MH - Treatment Outcome OTO - NOTNLM OT - Aortic stenosis OT - Multidisciplinary approach OT - TAVR COIS- Conflict of Interest None. EDAT- 2022/05/12 06:00 MHDA- 2022/06/16 06:00 CRDT- 2022/05/11 22:02 PHST- 2022/04/05 00:00 [received] PHST- 2022/04/07 00:00 [accepted] PHST- 2022/05/12 06:00 [pubmed] PHST- 2022/06/16 06:00 [medline] PHST- 2022/05/11 22:02 [entrez] AID - S1053-0770(22)00268-3 [pii] AID - 10.1053/j.jvca.2022.04.009 [doi] PST - ppublish SO - J Cardiothorac Vasc Anesth. 2022 Aug;36(8 Pt A):2803-2810. doi: 10.1053/j.jvca.2022.04.009. Epub 2022 Apr 14. PMID- 35541286 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220512 IS - 2057-7540 (Print) IS - 2057-7559 (Electronic) IS - 2057-7540 (Linking) VI - 8 DP - 2022 Jan TI - Pulmonary Artery Catheter Monitoring in Patients with Cardiogenic Shock: Time for a Reappraisal? PG - e15 LID - 10.15420/cfr.2021.32 [doi] LID - e15 AB - Cardiogenic shock represents one of the most dramatic scenarios to deal with in intensive cardiology care and is burdened by substantial short-term mortality. An integrated approach, including timely diagnosis and phenotyping, along with a well-established shock team and management protocol, may improve survival. The use of the Swan-Ganz catheter could play a pivotal role in various phases of cardiogenic shock management, encompassing diagnosis and haemodynamic characterisation to treatment selection, titration and weaning. Moreover, it is essential in the evaluation of patients who might be candidates for long-term heart-replacement strategies. This review provides a historical background on the use of the Swan-Ganz catheter in the intensive care unit and an analysis of the available evidence in terms of potential prognostic implications in this setting. CI - Copyright (c) 2022, Radcliffe Cardiology. FAU - Bertaina, Maurizio AU - Bertaina M AD - Department of Cardiology, San Giovanni Bosco Hospital, ASL Citta di Torino Turin, Italy. FAU - Galluzzo, Alessandro AU - Galluzzo A AD - Department of Cardiology, Sant'Andrea Hospital Vercelli, Italy. FAU - Morici, Nuccia AU - Morici N AD - Intensive Cardiac Care Unit and De Gasperis Cardio Center, ASST Grande Ospedale Metropolitano Niguarda Milan, Italy. AD - IRCCS S. Maria Nascente - Fondazione Don Carlo Gnocchi ONLUS Milan, Italy. FAU - Sacco, Alice AU - Sacco A AD - Intensive Cardiac Care Unit and De Gasperis Cardio Center, ASST Grande Ospedale Metropolitano Niguarda Milan, Italy. FAU - Oliva, Fabrizio AU - Oliva F AD - Intensive Cardiac Care Unit and De Gasperis Cardio Center, ASST Grande Ospedale Metropolitano Niguarda Milan, Italy. FAU - Valente, Serafina AU - Valente S AD - Department of Cardiovascular Diseases, University of Siena Siena, Italy. FAU - D'Ascenzo, Fabrizio AU - D'Ascenzo F AD - Division of Cardiology, Department of Medical Sciences, University of Turin, Citta della Salute e della Scienza Hospital Turin, Italy. FAU - Frea, Simone AU - Frea S AD - Division of Cardiology, Department of Medical Sciences, University of Turin, Citta della Salute e della Scienza Hospital Turin, Italy. FAU - Sbarra, Pierluigi AU - Sbarra P AD - Department of Cardiology, San Giovanni Bosco Hospital, ASL Citta di Torino Turin, Italy. FAU - Petitti, Elisabetta AU - Petitti E AD - Department of Cardiology, San Giovanni Bosco Hospital, ASL Citta di Torino Turin, Italy. FAU - Prever, Silvia Brach AU - Prever SB AD - Department of Cardiology, San Giovanni Bosco Hospital, ASL Citta di Torino Turin, Italy. FAU - Boccuzzi, Giacomo AU - Boccuzzi G AD - Department of Cardiology, San Giovanni Bosco Hospital, ASL Citta di Torino Turin, Italy. FAU - Zanini, Paola AU - Zanini P AD - Department of Cardiology, San Giovanni Bosco Hospital, ASL Citta di Torino Turin, Italy. FAU - Attisani, Matteo AU - Attisani M AD - Department of Cardiac Surgery, San Giovanni Bosco Hospital, ASL Citta di Torino Turin, Italy. FAU - Rametta, Francesco AU - Rametta F AD - Department of Cardiology, Sant'Andrea Hospital Vercelli, Italy. FAU - De Ferrari, Gaetano Maria AU - De Ferrari GM AD - Division of Cardiology, Department of Medical Sciences, University of Turin, Citta della Salute e della Scienza Hospital Turin, Italy. FAU - Noussan, Patrizia AU - Noussan P AD - Department of Cardiology, San Giovanni Bosco Hospital, ASL Citta di Torino Turin, Italy. FAU - Iannaccone, Mario AU - Iannaccone M AD - Department of Cardiology, San Giovanni Bosco Hospital, ASL Citta di Torino Turin, Italy. LA - eng PT - Journal Article PT - Review DEP - 20220426 PL - England TA - Card Fail Rev JT - Cardiac failure review JID - 101696210 PMC - PMC9069264 OTO - NOTNLM OT - Swan-Ganz catheter OT - cardiogenic shock OT - invasive monitoring OT - pulmonary artery catheter OT - review COIS- Disclosure: The authors have no conflicts of interest to declare. EDAT- 2022/05/12 06:00 MHDA- 2022/05/12 06:01 PMCR- 2022/04/26 CRDT- 2022/05/11 04:01 PHST- 2021/11/16 00:00 [received] PHST- 2022/01/19 00:00 [accepted] PHST- 2022/05/11 04:01 [entrez] PHST- 2022/05/12 06:00 [pubmed] PHST- 2022/05/12 06:01 [medline] PHST- 2022/04/26 00:00 [pmc-release] AID - 10.15420/cfr.2021.32 [doi] PST - epublish SO - Card Fail Rev. 2022 Apr 26;8:e15. doi: 10.15420/cfr.2021.32. eCollection 2022 Jan. PMID- 27413799 STAT- Publisher DRDT- 20220512 CTDT- 20160714 PB - University of Washington, Seattle DP - 1993 TI - TXNL4A-Related Craniofacial Disorders. BTI - GeneReviews((R)) AB - CLINICAL CHARACTERISTICS: TXNL4A-related craniofacial disorders comprise a range of phenotypes that includes: isolated choanal atresia; choanal atresia with minor anomalies; and Burn-McKeown syndrome (BMKS), which is characterized by typical craniofacial features (bilateral choanal atresia/stenosis, short palpebral fissures, coloboma of the lower eyelids, prominent nasal bridge with widely spaced eyes, short philtrum, thin vermilion of the upper lip, and prominent ears). Hearing loss is common and cardiac defects and short stature have been reported. Intellectual disability is rare. DIAGNOSIS/TESTING: The diagnosis of a TXNL4A-related craniofacial disorder is established in a proband with suggestive findings and biallelic pathogenic variants in TXNL4A identified by molecular genetic testing. All probands described to date have had at least one copy of one of the two partially overlapping 34-bp deletions in the TXNL4A promoter. MANAGEMENT: Treatment of manifestations: Neonates with airway compromise at delivery may require intubation or surgical correction of choanal stenosis/atresia. Defects of the lower eyelids that can result in corneal exposure require care by an ophthalmologist to reduce the risk of corneal scarring. Treatment of hearing loss is individualized and may involve hearing aids. Treatment of craniofacial manifestations (e.g., cleft lip and/or palate, preauricular tags, prominent ears) is individualized and managed by a multidisciplinary team. Cardiac defects are managed in a routine manner. Surveillance: Monitoring by an ophthalmologist, audiologist, and craniofacial team is recommended. GENETIC COUNSELING: TXNL4A-related craniofacial disorders are inherited in an autosomal recessive manner. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance inheriting neither of the familial TXNL4A pathogenic variants. Once the TXNL4A pathogenic variants have been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic testing are possible. CI - Copyright (c) 1993-2026, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved. FED - Adam, Margaret P ED - Adam MP FED - Bick, Sarah ED - Bick S FED - Mirzaa, Ghayda M ED - Mirzaa GM FED - Wallace, Stephanie E ED - Wallace SE FED - Amemiya, Anne ED - Amemiya A FAU - Ludecke, Hermann-Josef AU - Ludecke HJ AD - Institut fur Humangenetik Universitatsklinikum Dusseldorf Heinrich-Heine-Universitat Dusseldorf, Germany FAU - Wieczorek, Dagmar AU - Wieczorek D AD - Institut fur Humangenetik Universitatsklinikum Dusseldorf Heinrich-Heine-Universitat Dusseldorf, Germany LA - eng PT - Review PT - Book Chapter PL - Seattle (WA) OTO - NLM OT - Burn-McKeown Syndrome (BMKS) OT - TXNL4A-Related Choanal Atresia with Minor Anomalies OT - TXNL4A-Related Isolated Choanal Atresia OT - Thioredoxin-like protein 4A OT - TXNL4A OT - TXNL4A-Related Craniofacial Disorders EDAT- 2022/05/12 00:00 CRDT- 2022/05/12 00:00 AID - NBK373577 [bookaccession] PMID- 35537892 OWN - NLM STAT- MEDLINE DCOM- 20221216 LR - 20221221 IS - 1097-685X (Electronic) IS - 0022-5223 (Linking) VI - 165 IP - 1 DP - 2023 Jan TI - Surgical outcomes of infective endocarditis in pediatrics: Moving the needle to a contemporary, multidisciplinary approach. PG - 275-284 LID - S0022-5223(22)00389-0 [pii] LID - 10.1016/j.jtcvs.2022.03.031 [doi] AB - BACKGROUND: Infective endocarditis (IE) is an uncommon disease in children that, when present, is accompanied by significant morbidity and mortality. The presence of congenital heart disease often complicates management. The aim of the present study is to describe the characteristics and outcomes of children undergoing surgery for IE. METHODS: A retrospective chart review from 2004 to 2020 was conducted to identify consecutive patients younger than age 20 years with IE undergoing surgery. RESULTS: A total of 94 patients with IE were identified, of whom 47 underwent surgery at a median age of 16.7 years. Thirty-one patients (65.95%) had congenital heart disease. Vegetation and embolic phenomena occurred in 41 and 29 patients (87.23% and 61.7%), respectively, with the brain as most common location (57.1%). Native valve involvement had a greater tendency to embolize (P < .001). Staphylococcus spp was the most common organism (49%). The mitral valve was the most affected (31.9%). Seven (14.9%) patients had multivalvar involvement and valve replacement was the most common procedure performed (37 patients; 78.7%). There were 3 operative deaths (6.4%). Median length of hospital stay was 21 days. Risk factors for prolonged hospital stay were time to surgery in days (P < .001) and native valvar involvement (P = .05). Five patients (10.6%) had postoperative recurrent IE. Survival at 1 and 5 years was 93.6% and 89.4%, respectively. CONCLUSIONS: Children with IE can undergo surgery with acceptable results. The morbidity, but not mortality, is driven by embolic complications. Staphylococcus spp and native valve involvement are significant risk factors. VIDEO ABSTRACT. CI - Copyright (c) 2022 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved. FAU - Carrillo, Sergio A AU - Carrillo SA AD - Department of Cardiothoracic Surgery, Nationwide Children's Hospital, Columbus, Ohio; The Ohio State University, Columbus, Ohio. Electronic address: sergio.carrillo@nationwidechildrens.org. FAU - Duenas, Helen AU - Duenas H AD - Department of Cardiothoracic Surgery, Nationwide Children's Hospital, Columbus, Ohio; The Ohio State University, Columbus, Ohio. FAU - Blaney, Cristin AU - Blaney C AD - The Ohio State University, Columbus, Ohio; Division of Cardiology, The Heart Center, Nationwide Children's Hospital, Columbus, Ohio. FAU - Eisner, Mariah AU - Eisner M AD - The Ohio State University, Columbus, Ohio; Biostatistics Resource, Nationwide Children's Hospital, Columbus, Ohio. FAU - Nandi, Deipanjan AU - Nandi D AD - The Ohio State University, Columbus, Ohio; Division of Cardiology, The Heart Center, Nationwide Children's Hospital, Columbus, Ohio. FAU - McConnell, Patrick I AU - McConnell PI AD - Department of Cardiothoracic Surgery, Nationwide Children's Hospital, Columbus, Ohio; The Ohio State University, Columbus, Ohio. LA - eng PT - Journal Article PT - Video-Audio Media DEP - 20220409 PL - United States TA - J Thorac Cardiovasc Surg JT - The Journal of thoracic and cardiovascular surgery JID - 0376343 SB - IM CIN - J Thorac Cardiovasc Surg. 2023 Jan;165(1):285-286. doi: 10.1016/j.jtcvs.2022.04.025. PMID: 35610071 MH - Humans MH - Child MH - Adolescent MH - Young Adult MH - Adult MH - Retrospective Studies MH - *Endocarditis, Bacterial/diagnosis/surgery MH - *Endocarditis/diagnosis/surgery MH - *Heart Defects, Congenital MH - Treatment Outcome OTO - NOTNLM OT - embolization OT - endocarditis team OT - infective endocarditis OT - pediatric OT - surgery EDAT- 2022/05/11 06:00 MHDA- 2022/12/17 06:00 CRDT- 2022/05/10 22:03 PHST- 2021/09/28 00:00 [received] PHST- 2022/03/09 00:00 [revised] PHST- 2022/03/21 00:00 [accepted] PHST- 2022/05/11 06:00 [pubmed] PHST- 2022/12/17 06:00 [medline] PHST- 2022/05/10 22:03 [entrez] AID - S0022-5223(22)00389-0 [pii] AID - 10.1016/j.jtcvs.2022.03.031 [doi] PST - ppublish SO - J Thorac Cardiovasc Surg. 2023 Jan;165(1):275-284. doi: 10.1016/j.jtcvs.2022.03.031. Epub 2022 Apr 9. PMID- 35537447 OWN - NLM STAT- MEDLINE DCOM- 20220628 LR - 20220708 IS - 1439-1902 (Electronic) IS - 0171-6425 (Linking) VI - 70 IP - 4 DP - 2022 Jun TI - Cardiac Surgery 2021 Reviewed. PG - 278-288 LID - 10.1055/s-0042-1744264 [doi] AB - PubMed displayed more than 35,000 hits for the search term "cardiac surgery AND 2021." We used the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) approach and selected relevant publications for a results-oriented summary. As in recent years, we reviewed the fields of coronary and conventional valve surgery and their overlap with their interventional alternatives. COVID reduced cardiac surgical activity around the world. In the coronary field, the FAME 3 trial dominated publications by practically repeating SYNTAX, but with modern stents and fractional flow reserve (FFR)-guided percutaneous coronary interventions (PCIs). PCI was again unable to achieve non-inferiority compared with coronary artery bypass graft surgery (CABG) in patients with triple-vessel disease. Survival advantages of CABG over PCI could be linked to a reduction in myocardial infarctions and current terminology was criticized because the term "myocardial revascularization" is not precise and does not reflect the infarct-preventing collateralization effect of CABG. In structural heart disease, new guidelines were published, providing upgrades of interventional treatments of both aortic and mitral valve disease. While for aortic stenosis, transcatheter aortic valve implantation (TAVI) received a primary recommendation in older and high-risk patients; recommendations for transcatheter mitral edge-to-edge treatment were upgraded for patients considered inappropriate for surgery. For heart team discussions it is important to know that classic aortic valve replacement currently provides strong signals (from registry and randomized evidence) for a survival advantage over TAVI after 5 years. This article summarizes publications perceived as important by us. It can neither be complete nor free of individual interpretation, but provides up-to-date information for decision-making and patient information. CI - Thieme. All rights reserved. FAU - Doenst, Torsten AU - Doenst T AD - Department of Cardiothoracic Surgery, Friedrich-Schiller-University of Jena, Jena, Germany. FAU - Schneider, Ulrich AU - Schneider U AD - Department of Cardiothoracic Surgery, Friedrich-Schiller-University of Jena, Jena, Germany. FAU - Can, Tolga AU - Can T AD - Department of Cardiothoracic Surgery, Friedrich-Schiller-University of Jena, Jena, Germany. FAU - Caldonazo, Tulio AU - Caldonazo T AD - Department of Cardiothoracic Surgery, Friedrich-Schiller-University of Jena, Jena, Germany. FAU - Diab, Mahmoud AU - Diab M AD - Department of Cardiothoracic Surgery, Friedrich-Schiller-University of Jena, Jena, Germany. FAU - Siemeni, Thierry AU - Siemeni T AD - Department of Cardiothoracic Surgery, Friedrich-Schiller-University of Jena, Jena, Germany. FAU - Farber, Gloria AU - Farber G AD - Department of Cardiothoracic Surgery, Friedrich-Schiller-University of Jena, Jena, Germany. FAU - Kirov, Hristo AU - Kirov H AD - Department of Cardiothoracic Surgery, Friedrich-Schiller-University of Jena, Jena, Germany. LA - eng PT - Journal Article PT - Review DEP - 20220510 PL - Germany TA - Thorac Cardiovasc Surg JT - The Thoracic and cardiovascular surgeon JID - 7903387 SB - IM MH - Aged MH - Aortic Valve Stenosis/surgery MH - COVID-19 MH - *Cardiac Surgical Procedures MH - Coronary Artery Disease/surgery MH - Fractional Flow Reserve, Myocardial MH - Humans MH - Percutaneous Coronary Intervention MH - Transcatheter Aortic Valve Replacement MH - Treatment Outcome COIS- None declared. EDAT- 2022/05/11 06:00 MHDA- 2022/06/29 06:00 CRDT- 2022/05/10 18:42 PHST- 2022/05/11 06:00 [pubmed] PHST- 2022/06/29 06:00 [medline] PHST- 2022/05/10 18:42 [entrez] AID - 10.1055/s-0042-1744264 [doi] PST - ppublish SO - Thorac Cardiovasc Surg. 2022 Jun;70(4):278-288. doi: 10.1055/s-0042-1744264. Epub 2022 May 10. PMID- 35534638 OWN - NLM STAT- MEDLINE DCOM- 20230426 LR - 20261010 IS - 1432-1068 (Electronic) IS - 1633-8065 (Linking) VI - 33 IP - 4 DP - 2023 May TI - Evaluating the association between pulmonary abnormalities and complications following pediatric hip dysplasia surgery. PG - 1193-1199 LID - 10.1007/s00590-022-03276-1 [doi] AB - PURPOSE: Developmental dysplasia of the hip (DDH) encompasses a wide range of abnormal hip development and is a common condition in the pediatric population. Congenital pulmonary abnormalities are typically mild in the pediatric population but can be associated with severe comorbid conditions. The purpose of this study was to analyze the effect of structural pulmonary/airway abnormalities on the incidence of postoperative complications following surgical management of DDH. METHODS: From 2012 to 2019, the National Surgical Quality Improvement Program-Pediatric database was utilized to identify pediatric patients undergoing surgical treatment for hip dysplasia. Patients were stratified into two groups: patients with a structural pulmonary/airway abnormality and patients without a pulmonary abnormality. Patient demographics, comorbidities, and postoperative complications were compared between the two cohorts with the use of various statistical analyses, including bivariate and multivariate analyses. RESULTS: Of the 10,853 patients who underwent surgical treatment for hip dysplasia, 10,157 patients (93.6%) did not have a structural pulmonary/airway abnormality whereas 696 (6.4%) had an airway abnormality. Following adjustment on multivariate analysis, patients with a structural pulmonary abnormality had an increased risk of cardiac arrest requiring cardiopulmonary resuscitation (OR 2.342; p = 0.045). CONCLUSION: The results indicated that patients with a structural pulmonary abnormality had an increased risk of cardiac arrest requiring cardiopulmonary resuscitation compared to those without a pulmonary abnormality. Ensuring appropriate preoperative evaluation with a multidisciplinary team and close monitoring postoperatively is important to prevent the risk of severe outcomes in this vulnerable patient population. CI - (c) 2022. The Author(s), under exclusive licence to Springer-Verlag France SAS, part of Springer Nature. FAU - Pizzarro, Jordan AU - Pizzarro J AD - Department of Orthopaedic Surgery, George Washington University School of Medicine and Health Sciences, 2300 Eye St NW, Washington, DC, 20037, USA. FAU - Quan, Theodore AU - Quan T AD - Department of Orthopaedic Surgery, George Washington University School of Medicine and Health Sciences, 2300 Eye St NW, Washington, DC, 20037, USA. teddyquan@gwu.edu. FAU - Manzi, Joseph E AU - Manzi JE AD - Weill Cornell Medical College, 1300 York Avenue, New York, NY, 10021, USA. FAU - Chen, Frank R AU - Chen FR AD - Department of Anesthesiology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA. FAU - Gu, Alex AU - Gu A AD - Department of Orthopaedic Surgery, George Washington University School of Medicine and Health Sciences, 2300 Eye St NW, Washington, DC, 20037, USA. FAU - Tabaie, Sean AU - Tabaie S AD - Department of Orthopaedic Surgery, Children's National Health System, Washington, DC, USA. LA - eng PT - Journal Article DEP - 20220509 PL - France TA - Eur J Orthop Surg Traumatol JT - European journal of orthopaedic surgery & traumatology : orthopedie traumatologie JID - 9518037 SB - IM MH - Humans MH - Child MH - *Hip Dislocation/complications MH - *Hip Dislocation, Congenital/surgery MH - Postoperative Complications/etiology MH - Thorax MH - Databases, Factual MH - Retrospective Studies OTO - NOTNLM OT - Airway abnormality OT - Complications OT - Hip dysplasia OT - Structural pulmonary abnormality OT - Surgical treatment EDAT- 2022/05/10 06:00 MHDA- 2023/04/26 06:42 CRDT- 2022/05/09 23:25 PHST- 2022/03/13 00:00 [received] PHST- 2022/04/20 00:00 [accepted] PHST- 2023/04/26 06:42 [medline] PHST- 2022/05/10 06:00 [pubmed] PHST- 2022/05/09 23:25 [entrez] AID - 10.1007/s00590-022-03276-1 [pii] AID - 10.1007/s00590-022-03276-1 [doi] PST - ppublish SO - Eur J Orthop Surg Traumatol. 2023 May;33(4):1193-1199. doi: 10.1007/s00590-022-03276-1. Epub 2022 May 9. PMID- 35534094 OWN - NLM STAT- MEDLINE DCOM- 20220511 LR - 20240827 IS - 2053-3624 (Print) IS - 2053-3624 (Electronic) IS - 2053-3624 (Linking) VI - 9 IP - 1 DP - 2022 May TI - Modified Duke/European Society of Cardiology 2015 clinical criteria for infective endocarditis: time for an update? LID - 10.1136/openhrt-2021-001856 [doi] LID - e001856 AB - BACKGROUND: The diagnosis of infective endocarditis (IE) is based on the modified Duke/European Society of Cardiology (ESC) 2015 clinical criteria. The sensitivity of the criteria is unknown in South Africa, but high rates of blood culture negative endocarditis (BCNIE), coupled with a change in the clinical features of IE, may limit the sensitivity. METHODS: The Tygerberg Endocarditis Cohort study prospectively enrolled patients with IE between November 2019 and June 2021. A standardised protocol for organism detection, with management of patients by an Endocarditis Team, was employed. Patients with definite IE by pathological criteria were analysed to determine the sensitivity of the current clinical criteria. RESULTS: Eighty consecutive patients with IE were included of which 45 (56.3%) had definite IE by pathological criteria. In patients with definite IE by pathological criteria, 26/45 (57.8%) of patients were classified as definite IE by clinical criteria. BCNIE was present in 25/45 (55.6%) of patients and less than three minor clinical criteria were present in 32/45 (75.6%) of patients. The elevation of Bartonella serology to a major microbiological criterion of the modified Duke/ESC 2015 clinical criteria would increase the sensitivity (57.8% vs 77.8%; p=0.07). CONCLUSION: The sensitivity of the modified Duke/ESC 2015 clinical criteria is lower than expected in patients with IE in South Africa, primarily due to the high rates of Bartonella-associated BCNIE. The elevation of Bartonella serology to a major microbiological criterion, similar to the status of Coxiella burnetii in the current criteria, would increase the sensitivity. The majority of patients with definite IE by pathological criteria had less than three minor criteria present. CI - (c) Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Pecoraro, Alfonso Jan Kemp AU - Pecoraro AJK AUID- ORCID: 0000-0001-6549-9402 AD - Division of Cardiology, Department of Medicine, Stellenbosch University Faculty of Medicine and Health Sciences, Cape Town, Western Cape, South Africa pecoraro@sun.ac.za. FAU - Herbst, Philipus George AU - Herbst PG AD - Division of Cardiology, Department of Medicine, Stellenbosch University Faculty of Medicine and Health Sciences, Cape Town, Western Cape, South Africa. FAU - Pienaar, Colette AU - Pienaar C AD - Division of Medical Microbiology, Department of Pathology, Stellenbusch University Faculty of Medicine and Health Sceinces, Cape Town, Western Cape, South Africa. AD - National Health Laboratory Service, Johannesburg, Gauteng, South Africa. FAU - Taljaard, Jantjie AU - Taljaard J AD - Division of Infectious Diseases, Department of Medicine, Stellenbosch University Faculty of Medicine and Health Sciences, Cape Town, Western Cape, South Africa. FAU - Prozesky, Hans AU - Prozesky H AUID- ORCID: 0000-0001-9715-3449 AD - Department of Medicine, Stellenbosch University Faculty of Medicine and Health Sciences, Cape Town, Western Cape, South Africa. FAU - Janson, Jacques AU - Janson J AD - Division of Cardiothoracic Surgery, Department of Surgery, Stellenbosch University Faculty of Medicine and Health Sciences, Cape Town, Western Cape, South Africa. FAU - Doubell, Anton Frans AU - Doubell AF AD - Division of Cardiology, Department of Medicine, Stellenbosch University Faculty of Medicine and Health Sciences, Cape Town, Western Cape, South Africa. LA - eng PT - Journal Article PL - England TA - Open Heart JT - Open heart JID - 101631219 SB - IM MH - *Cardiology MH - Cohort Studies MH - *Endocarditis MH - *Endocarditis, Bacterial/diagnosis/microbiology/therapy MH - Humans MH - South Africa/epidemiology PMC - PMC9086646 OTO - NOTNLM OT - Delivery of Health Care OT - Echocardiography OT - Endocarditis COIS- Competing interests: None declared. EDAT- 2022/05/10 06:00 MHDA- 2022/05/12 06:00 PMCR- 2022/05/09 CRDT- 2022/05/09 20:53 PHST- 2021/09/14 00:00 [received] PHST- 2022/04/21 00:00 [accepted] PHST- 2022/05/09 20:53 [entrez] PHST- 2022/05/10 06:00 [pubmed] PHST- 2022/05/12 06:00 [medline] PHST- 2022/05/09 00:00 [pmc-release] AID - openhrt-2021-001856 [pii] AID - 10.1136/openhrt-2021-001856 [doi] PST - ppublish SO - Open Heart. 2022 May;9(1):e001856. doi: 10.1136/openhrt-2021-001856. PMID- 35525635 OWN - NLM STAT- MEDLINE DCOM- 20220623 LR - 20220830 IS - 1879-0828 (Electronic) IS - 0953-6205 (Linking) VI - 101 DP - 2022 Jul TI - Comparing atrial fibrillation guidelines: Focus on stroke prevention, bleeding risk assessment and oral anticoagulant recommendations. PG - 1-7 LID - S0953-6205(22)00166-2 [pii] LID - 10.1016/j.ejim.2022.04.023 [doi] AB - Clinical practice in atrial fibrillation (AF) patient management is constantly evolving. In the past 3 years, various new AF guidelines or focused updates have been published, given this rapidly evolving field. In 2019, the American College of Cardiology/American Heart Association published a focused update of the 2014 guidelines. In 2020, both the European Society of Cardiology and the Canadian Cardiovascular Society released their new guidelines. Finally, the most recent guidelines were those published in 2021 by the Asian Pacific Heart Rhythm Society, which updates their 2017 version and the 2021 National Institute for Health and Care Excellence (NICE) guidelines. In the present narrative review, we compare these guidelines, emphasizing similarities and differences in the following mainstay elements of patient care: thromboembolic risk assessment, oral anticoagulants (OACs) prescription, bleeding risk evaluation, and integrated patient management. A formal evaluation of baseline thromboembolic and bleeding risks and their reassessment during follow-up is evenly recommended, although some differences in using risk stratification scores. OACs prescription is highly encouraged where appropriate, and prescription algorithms are broadly similar. The importance of an integrated and multidisciplinary approach to patient care is emerging, aiming to address several different aspects of a multifaceted disease. CI - Copyright (c) 2022. Published by Elsevier B.V. FAU - Imberti, Jacopo Francesco AU - Imberti JF AD - Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, Policlinico di Modena, University of Modena and Reggio Emilia, Via del Pozzo, 71, Modena 41124, Italy; Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy; Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK. FAU - Mei, Davide Antonio AU - Mei DA AD - Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, Policlinico di Modena, University of Modena and Reggio Emilia, Via del Pozzo, 71, Modena 41124, Italy. FAU - Vitolo, Marco AU - Vitolo M AD - Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, Policlinico di Modena, University of Modena and Reggio Emilia, Via del Pozzo, 71, Modena 41124, Italy; Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy; Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK. FAU - Bonini, Niccolo AU - Bonini N AD - Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, Policlinico di Modena, University of Modena and Reggio Emilia, Via del Pozzo, 71, Modena 41124, Italy; Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK. FAU - Proietti, Marco AU - Proietti M AD - Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK; Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy; Geriatric Unit, IRCCS Istituti Clinici Scientifici Maugeri, Milan, Italy. FAU - Potpara, Tatjana AU - Potpara T AD - School of Medicine, Belgrade University, dr Subotica 8, Belgrade 11000, Serbia; Cardiology Clinic, Clinical Centre of Serbia, Visegradska 26, Belgrade 11000, Serbia. FAU - Lip, Gregory Y H AU - Lip GYH AD - Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK. FAU - Boriani, Giuseppe AU - Boriani G AD - Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, Policlinico di Modena, University of Modena and Reggio Emilia, Via del Pozzo, 71, Modena 41124, Italy. Electronic address: giuseppe.boriani@unimore.it. LA - eng PT - Journal Article PT - Review DEP - 20220505 PL - Netherlands TA - Eur J Intern Med JT - European journal of internal medicine JID - 9003220 RN - 0 (Anticoagulants) SB - IM MH - Administration, Oral MH - Anticoagulants/adverse effects MH - *Atrial Fibrillation/complications/drug therapy MH - Canada MH - Hemorrhage/chemically induced/prevention & control MH - Humans MH - Risk Assessment MH - Risk Factors MH - *Stroke/drug therapy/prevention & control MH - *Thromboembolism/prevention & control OTO - NOTNLM OT - Atrial fibrillation OT - Bleeding OT - Guidelines OT - Oral anticoagulants OT - Stroke OT - Thromboembolism EDAT- 2022/05/08 06:00 MHDA- 2022/06/24 06:00 CRDT- 2022/05/07 22:03 PHST- 2022/04/09 00:00 [received] PHST- 2022/04/27 00:00 [accepted] PHST- 2022/05/08 06:00 [pubmed] PHST- 2022/06/24 06:00 [medline] PHST- 2022/05/07 22:03 [entrez] AID - S0953-6205(22)00166-2 [pii] AID - 10.1016/j.ejim.2022.04.023 [doi] PST - ppublish SO - Eur J Intern Med. 2022 Jul;101:1-7. doi: 10.1016/j.ejim.2022.04.023. Epub 2022 May 5. PMID- 35523426 OWN - NLM STAT- MEDLINE DCOM- 20220510 LR - 20250530 IS - 1522-9645 (Electronic) IS - 0195-668X (Print) IS - 0195-668X (Linking) VI - 43 IP - 18 DP - 2022 May 7 TI - The Atrial Fibrillation Heart Team-guiding therapy in left atrial appendage occlusion with increasingly complex patients and little evidence. PG - 1691-1692 LID - 10.1093/eurheartj/ehab744 [doi] FAU - Kany, Shinwan AU - Kany S AD - Department of Cardiology, University Heart and Vascular Centre Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Metzner, Andreas AU - Metzner A AD - Department of Cardiology, University Heart and Vascular Centre Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Lubos, Edith AU - Lubos E AD - Department of Cardiology, University Heart and Vascular Centre Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Kirchhof, Paulus AU - Kirchhof P AUID- ORCID: 0000-0002-1881-0197 AD - Department of Cardiology, University Heart and Vascular Centre Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. AD - German Centre for Cardiovascular Research (DZHK), Partner Site Hamburg/Lubeck/Kiel, Hamburg, Germany. AD - Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK. LA - eng GR - AA/18/2/34218/BHF_/British Heart Foundation/United Kingdom GR - FS/13/43/30324/BHF_/British Heart Foundation/United Kingdom GR - PG/17/30/32961/BHF_/British Heart Foundation/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Eur Heart J JT - European heart journal JID - 8006263 RN - 0 (Anti-Arrhythmia Agents) RN - 0 (Anticoagulants) SB - IM MH - Anti-Arrhythmia Agents MH - Anticoagulants/therapeutic use MH - *Atrial Appendage/diagnostic imaging/surgery MH - *Atrial Fibrillation/complications/therapy MH - Echocardiography, Transesophageal MH - Humans MH - *Stroke/etiology/prevention & control MH - Treatment Outcome PMC - PMC9076393 EDAT- 2022/05/07 06:00 MHDA- 2022/05/11 06:00 PMCR- 2022/11/22 CRDT- 2022/05/06 20:24 PHST- 2022/05/06 20:24 [entrez] PHST- 2022/05/07 06:00 [pubmed] PHST- 2022/05/11 06:00 [medline] PHST- 2022/11/22 00:00 [pmc-release] AID - 6433264 [pii] AID - ehab744 [pii] AID - 10.1093/eurheartj/ehab744 [doi] PST - ppublish SO - Eur Heart J. 2022 May 7;43(18):1691-1692. doi: 10.1093/eurheartj/ehab744. PMID- 35522421 OWN - NLM STAT- MEDLINE DCOM- 20220614 LR - 20261010 IS - 1534-3170 (Electronic) IS - 1523-3782 (Linking) VI - 24 IP - 6 DP - 2022 Jun TI - Role of Myocardial Strain Imaging in Cancer Therapy-Related Cardiac Dysfunction. PG - 739-748 LID - 10.1007/s11886-022-01692-7 [doi] AB - PURPOSE OF REVIEW: This review aims to provide a contemporary perspective on the role of myocardial strain imaging in the management of patients on cardiotoxic therapy. RECENT FINDINGS: Risk/benefit evaluation of cardiotoxic cancer treatment remains challenging, weighing life-saving cancer therapy with fatal cardiac dysfunction potentially caused by cancer therapy. The serial change in left ventricular ejection fraction (LVEF) was conventionally used for the detection of cancer therapy-related cardiac dysfunction (CTRCD). Peak systolic global longitudinal strain (GLS) by speckle-tracking echocardiography has turned into a vital pre- and post-chemotherapy assessment for the early detection of cardiotoxicity. Complexity in cardiotoxic therapy regimen, different definition of CTRCD by LVEF, variations in GLS values, timings, and variable cutoffs make it challenging to standardize the protocol for the detection of CTRCD. GLS > 15% relative reduction from baseline has been widely used. Evidence suggests that GLS could predict early subclinical LV dysfunction, and initiation of cardioprotective therapy led to less decline of LV function. Most of the studies used an echocardiographic endpoint, and the impact of GLS on the long-term clinical outcome is not established. GLS has emerged as a reliable measure to identify early subclinical LV dysfunction by detecting myocardial deformation in patients on cardiotoxic chemotherapy. To date, a significant decline in GLS suggests the initiation of cardioprotective therapy with close monitoring. Interruption of prognostically important cardiotoxic chemotherapies requires a multidisciplinary team approach guided mainly by LVEF and other clinical factors. Further randomized control trials with hard clinical endpoints and longer follow-ups may help to determine the role of GLS in CTRCD. CI - (c) 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Chaganti, Bhanu T AU - Chaganti BT AD - Department of Cardiovascular Medicine, Texas Tech University Health Science Center El Paso, 4800 Alberta Avenue, El Paso, TX, USA. FAU - Negishi, Kazuaki AU - Negishi K AD - Sydney Medical School Nepean, Faculty of Medicine and Health, Charles Perkins Centre, The University of Sydney, Nepean, NSW, Australia. AD - Department of Cardiology, Nepean Hospital, Sydney, NSW, Australia. FAU - Okajima, Kazue AU - Okajima K AUID- ORCID: 0000-0002-3286-1361 AD - Department of Cardiovascular Medicine, Texas Tech University Health Science Center El Paso, 4800 Alberta Avenue, El Paso, TX, USA. kazue.okajima@ttuhsc.edu. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20220506 PL - United States TA - Curr Cardiol Rep JT - Current cardiology reports JID - 100888969 SB - IM MH - Cardiotoxicity/diagnostic imaging/etiology MH - Early Detection of Cancer MH - *Heart Diseases/chemically induced/diagnostic imaging MH - Humans MH - *Neoplasms/drug therapy MH - Stroke Volume MH - *Ventricular Dysfunction, Left/chemically induced/diagnostic imaging MH - Ventricular Function, Left OTO - NOTNLM OT - Anthracyclines OT - Cardiotoxicity OT - Global longitudinal strain OT - HER-2 OT - Myocardial strain EDAT- 2022/05/07 06:00 MHDA- 2022/06/15 06:00 CRDT- 2022/05/06 11:40 PHST- 2022/03/02 00:00 [accepted] PHST- 2022/05/07 06:00 [pubmed] PHST- 2022/06/15 06:00 [medline] PHST- 2022/05/06 11:40 [entrez] AID - 10.1007/s11886-022-01692-7 [pii] AID - 10.1007/s11886-022-01692-7 [doi] PST - ppublish SO - Curr Cardiol Rep. 2022 Jun;24(6):739-748. doi: 10.1007/s11886-022-01692-7. Epub 2022 May 6. PMID- 35522280 OWN - NLM STAT- MEDLINE DCOM- 20220510 LR - 20250118 IS - 2574-3805 (Electronic) IS - 2574-3805 (Linking) VI - 5 IP - 5 DP - 2022 May 2 TI - Assessment of an Instrument to Measure Interdisciplinary Staff Perceptions of Quality of Dying and Death in a Pediatric Cardiac Intensive Care Unit. PG - e2210762 LID - 10.1001/jamanetworkopen.2022.10762 [doi] LID - e2210762 AB - IMPORTANCE: Lack of pediatric end-of-life care quality indicators and challenges ascertaining family perspectives make staff perceptions valuable. Cardiac intensive care unit (CICU) interdisciplinary staff play an integral role supporting children and families at end of life. OBJECTIVES: To evaluate the Pediatric Intensive Care Unit Quality of Dying and Death (PICU-QODD) instrument and examine differences between disciplines and end-of-life circumstances. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional survey included staff at a single center involved in pediatric CICU deaths from July 1, 2019, to June 30, 2021. EXPOSURES: Staff demographic characteristics, intensity of end-of-life care (mechanical support, open chest, or cardiopulmonary resuscitation [CPR]), mode of death (discontinuation of life-sustaining therapy, treatment limitation, comfort care, CPR, and brain death), and palliative care involvement. MAIN OUTCOMES AND MEASURES: PICU-QODD instrument standardized score (maximum, 100, with higher scores indicating higher quality); global rating of quality of the moment of death and 7 days prior (Likert 11-point scale, with 0 indicating terrible and 10, ideal) and mode-of-death alignment with family wishes. RESULTS: Of 60 patient deaths (31 [52%] female; median [IQR] age, 4.9 months [10 days to 7.5 years]), 33 (55%) received intense care. Of 713 surveys (72% response rate), 246 (35%) were from nurses, 208 (29%) from medical practitioners, and 259 (36%) from allied health professionals. Clinical experience varied (298 [42%] 15 y: 91, P = .002). Mean PICU-QODD scores were lower for patients with comorbidities, surgical admissions, death following treatment limitation, or death misaligned with family wishes. No difference was observed with palliative care involvement. High-intensity care, compared with low-intensity care, was associated with lower median (IQR) rating of the quality of the 7 days prior to death (4 [2-6] vs 6 [4-8]; P = .001) and of the moment of death (8 [4-10] vs 9 [8-10]; P =.001). CONCLUSIONS AND RELEVANCE: In this cross-sectional survey study of CICU staff, the PICU-QODD showed promise as a reliable and valid clinician measure of quality of dying and death in the CICU. Overall QODD was positively perceived, with lower rated quality of 7 days prior to death and variation by staff and patient characteristics. Our data could guide strategies to meaningfully improve CICU staff well-being and end-of-life experiences for patients and families. FAU - Bailey, Valerie AU - Bailey V AD - Cardiovascular and Critical Care Nursing Patient Services, Boston Children's Hospital, Boston, Massachusetts. FAU - Beke, Dorothy M AU - Beke DM AD - Cardiovascular and Critical Care Nursing Patient Services, Boston Children's Hospital, Boston, Massachusetts. FAU - Snaman, Jennifer M AU - Snaman JM AD - Department of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute, Boston, Massachusetts. AD - Department of Pediatrics, Boston Children's Hospital, Boston, Massachusetts. FAU - Alizadeh, Faraz AU - Alizadeh F AD - Department of Cardiology, Boston Children's Hospital, Boston, Massachusetts. AD - Department of Pediatrics, Harvard Medical School, Boston, Massachusetts. FAU - Goldberg, Sarah AU - Goldberg S AD - Department of Cardiology, Boston Children's Hospital, Boston, Massachusetts. AD - Department of Pediatrics, Harvard Medical School, Boston, Massachusetts. FAU - Smith-Parrish, Melissa AU - Smith-Parrish M AD - Department of Critical Care Medicine, Vanderbilt, Nashville, Tennessee. FAU - Gauvreau, Kimberlee AU - Gauvreau K AD - Department of Cardiology, Boston Children's Hospital, Boston, Massachusetts. AD - Department of Pediatrics, Harvard Medical School, Boston, Massachusetts. FAU - Blume, Elizabeth D AU - Blume ED AD - Department of Cardiology, Boston Children's Hospital, Boston, Massachusetts. AD - Department of Pediatrics, Harvard Medical School, Boston, Massachusetts. FAU - Moynihan, Katie M AU - Moynihan KM AD - Department of Cardiology, Boston Children's Hospital, Boston, Massachusetts. AD - Department of Pediatrics, Harvard Medical School, Boston, Massachusetts. AD - Sydney Medical School, University of Sydney, Sydney, Australia. LA - eng GR - T32 HL007572/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220502 PL - United States TA - JAMA Netw Open JT - JAMA network open JID - 101729235 SB - IM MH - Child MH - Cross-Sectional Studies MH - Death MH - *Family MH - Female MH - Humans MH - Infant MH - Intensive Care Units, Pediatric MH - Male MH - *Terminal Care PMC - PMC9077481 COIS- Conflict of Interest Disclosures: None reported. EDAT- 2022/05/07 06:00 MHDA- 2022/05/11 06:00 PMCR- 2022/05/06 CRDT- 2022/05/06 11:33 PHST- 2022/05/06 11:33 [entrez] PHST- 2022/05/07 06:00 [pubmed] PHST- 2022/05/11 06:00 [medline] PHST- 2022/05/06 00:00 [pmc-release] AID - 2791967 [pii] AID - zoi220323 [pii] AID - 10.1001/jamanetworkopen.2022.10762 [doi] PST - epublish SO - JAMA Netw Open. 2022 May 2;5(5):e2210762. doi: 10.1001/jamanetworkopen.2022.10762. PMID- 35513174 OWN - NLM STAT- MEDLINE DCOM- 20220720 LR - 20250728 IS - 1916-7075 (Electronic) IS - 0828-282X (Linking) VI - 38 IP - 7 DP - 2022 Jul TI - Surgical Strategies in Single Ventricle Management of Neonates and Infants. PG - 909-920 LID - S0828-282X(22)00278-1 [pii] LID - 10.1016/j.cjca.2022.04.021 [doi] AB - No area of congenital heart disease has undergone greater change and innovation than single ventricle management over the past 20 years. Surgical and catheterisation laboratory interventions have transformed outcomes such that in some subgroups more than 80% of the patients can survive into adulthood. Driven by parallel development in diagnostic imaging and cardiac intensive care, surgical management is focused on the neonatal period as the key time to creating a balanced circulation and limiting pulmonary blood flow. Different configurations of the circulation, including new types of surgical shunts, and the role of "hybrid" circulations provide greater options and better physiology. This overview focuses on these changes in surgical management and timing, but also looks at the exciting areas of regenerative therapies to improve ventricular function, and the concept of ventricular rehabilitation to achieve biventricular circulations in certain groups of patients. The importance of early (neonatal) intervention and multidisciplinary approach to management is emphasised, as well as looking beyond simply survival to also improving neurodevelopmental outcomes. CI - Crown Copyright (c) 2022. Published by Elsevier Inc. All rights reserved. FAU - Haller, Christoph AU - Haller C AD - Department of Cardiovascular Surgery, Labatt Family Heart Centre, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada. FAU - Barron, David J AU - Barron DJ AD - Department of Cardiovascular Surgery, Labatt Family Heart Centre, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada. Electronic address: david.barron@sickkids.ca. LA - eng PT - Journal Article PT - Review DEP - 20220502 PL - England TA - Can J Cardiol JT - The Canadian journal of cardiology JID - 8510280 SB - IM MH - *Heart Defects, Congenital/surgery MH - Heart Ventricles/abnormalities/diagnostic imaging/surgery MH - Humans MH - Infant MH - Infant, Newborn MH - Pulmonary Circulation/physiology MH - Treatment Outcome EDAT- 2022/05/06 06:00 MHDA- 2022/07/22 06:00 CRDT- 2022/05/05 21:47 PHST- 2022/02/15 00:00 [received] PHST- 2022/04/25 00:00 [revised] PHST- 2022/04/26 00:00 [accepted] PHST- 2022/05/06 06:00 [pubmed] PHST- 2022/07/22 06:00 [medline] PHST- 2022/05/05 21:47 [entrez] AID - S0828-282X(22)00278-1 [pii] AID - 10.1016/j.cjca.2022.04.021 [doi] PST - ppublish SO - Can J Cardiol. 2022 Jul;38(7):909-920. doi: 10.1016/j.cjca.2022.04.021. Epub 2022 May 2. PMID- 35512885 OWN - NLM STAT- MEDLINE DCOM- 20220509 LR - 20230112 IS - 1942-5546 (Electronic) IS - 0025-6196 (Print) IS - 0025-6196 (Linking) VI - 97 IP - 5 DP - 2022 May TI - Mental Stress and Its Effects on Vascular Health. PG - 951-990 LID - S0025-6196(22)00104-5 [pii] LID - 10.1016/j.mayocp.2022.02.004 [doi] AB - Coronary artery disease continues to be a major cause of morbidity and mortality despite significant advances in risk stratification and management. This has prompted the search for alternative nonconventional risk factors that may provide novel therapeutic targets. Psychosocial stress, or mental stress, has emerged as an important risk factor implicated in a higher incidence of cardiovascular events, and although our understanding of this far ranging and interesting phenomenon has developed greatly over recent times, there is still much to be learned regarding how to measure mental stress and how it may impact physical health. With the current coronavirus disease 2019 global pandemic and its incumbent lockdowns and social distancing, understanding the potentially harmful biological effects of stress related to life-changing events and social isolation has become even more important. In the current review our multidisciplinary team discusses stress from a psychosocial perspective and aims to define psychological stress as rigorously as possible; discuss the pathophysiologic mechanisms by which stress may mediate cardiovascular disease, with a particular focus to its effects on vascular health; outline existing methods and approaches to quantify stress by means of a vascular biomarker; outline the mechanisms whereby psychosocial stressors may have their pathologic effects ultimately transduced to the vasculature through the neuroendocrine immunologic axis; highlight areas for improvement to refine existing approaches in clinical research when studying the consequences of psychological stress on cardiovascular health; and discuss evidence-based therapies directed at reducing the deleterious effects of mental stress including those that target endothelial dysfunction. To this end we searched PubMed and Google Scholar to identify studies evaluating the relationship between mental or psychosocial stress and cardiovascular disease with a particular focus on vascular health. Search terms included "myocardial ischemia," "coronary artery disease," "mental stress," "psychological stress," "mental * stress *," "psychologic * stress *," and "cardiovascular disease *." The search was limited to studies published in English in peer-reviewed journals between 1990 and the present day. To identify potential studies not captured by our database search strategy, we also searched studies listed in the bibliography of relevant publications and reviews. CI - Copyright (c) 2022 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Sara, Jaskanwal Deep Singh AU - Sara JDS AD - Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA. FAU - Toya, Takumi AU - Toya T AD - Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA. FAU - Ahmad, Ali AU - Ahmad A AD - Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA. FAU - Clark, Matthew M AU - Clark MM AD - Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA. FAU - Gilliam, Wesley P AU - Gilliam WP AD - Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA. FAU - Lerman, Lliach O AU - Lerman LO AD - Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA. FAU - Lerman, Amir AU - Lerman A AD - Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA. Electronic address: lerman.amir@mayo.edu. LA - eng PT - Journal Article PT - Review PL - England TA - Mayo Clin Proc JT - Mayo Clinic proceedings JID - 0405543 SB - IM MH - *COVID-19 MH - *Cardiovascular Diseases/etiology MH - Communicable Disease Control MH - *Coronary Artery Disease MH - Humans MH - Stress, Psychological/complications PMC - PMC9058928 EDAT- 2022/05/06 06:00 MHDA- 2022/05/10 06:00 PMCR- 2022/05/02 CRDT- 2022/05/05 21:04 PHST- 2021/08/17 00:00 [received] PHST- 2022/01/24 00:00 [revised] PHST- 2022/02/08 00:00 [accepted] PHST- 2022/05/05 21:04 [entrez] PHST- 2022/05/06 06:00 [pubmed] PHST- 2022/05/10 06:00 [medline] PHST- 2022/05/02 00:00 [pmc-release] AID - S0025-6196(22)00104-5 [pii] AID - 10.1016/j.mayocp.2022.02.004 [doi] PST - ppublish SO - Mayo Clin Proc. 2022 May;97(5):951-990. doi: 10.1016/j.mayocp.2022.02.004. PMID- 35506944 OWN - NLM STAT- MEDLINE DCOM- 20220609 LR - 20221207 IS - 1524-4040 (Electronic) IS - 0148-396X (Linking) VI - 91 IP - 1 DP - 2022 Jul 1 TI - A Century With Craniopagus Twin Separation Surgeries: Nihilism to Optimism. PG - 27-42 LID - 10.1227/neu.0000000000001962 [doi] AB - Craniopagus conjoined twins are extremely rare, reported 1 in 2.5 million live births. To date, 62 separation attempts in 69 well-documented cases of craniopagus twins have been made. Of these, 34 were performed in a single-stage approach, and 28 were attempted in a multistage approach. One or both twins died of massive intraoperative blood loss and cardiac arrest in 14 cases. We report our surgical experience with conjoined craniopagus twins (JB) with type III total vertical joining and shared circumferential/circular sinus with left-sided dominance. A brief review of the literature is also provided. In our twins, the meticulous preoperative study and planning by the multidisciplinary team consisting of 125-member, first-staged surgical separation consisted of creation of venous conduit to bypass part of shared circumferential sinus and partial hemispheric disconnection. Six weeks later, twin J manifested acute cardiac overload because of one-way fistula development from blocked venous bypass graft necessitating emergency final separation surgery. Unique perioperative issues were abnormal anatomy, hemodynamic sequelae from one-way fistula development after venous bypass graft thrombosis, cardiac arrest after massive venous air embolism requiring prolonged cardiopulmonary resuscitation, and return of spontaneous circulation at 15 minutes immediately after separation. This is the first Indian craniopagus separation surgery in a complex total vertical craniopagus twin reported by a single-center multidisciplinary team. Both twins could be sent home, but one remained severely handicapped. Adequate perioperative planning and multidisciplinary team approach are vital in craniopagus twin separation surgeries. CI - Copyright (c) Congress of Neurological Surgeons 2022. All rights reserved. FAU - Gupta, Deepak AU - Gupta D AUID- ORCID: 0000-0001-7698-5668 AD - Department of Neurosurgery, All India Institute of Medical Sciences, New Delhi, India. FAU - Kedia, Shweta AU - Kedia S AD - Department of Neurosurgery, All India Institute of Medical Sciences, New Delhi, India. FAU - Rath, Girija Prasad AU - Rath GP AD - Department of Neuroanesthesia, All India Institute of Medical Sciences, New Delhi, India. FAU - Pandia, Mihir Prakash AU - Pandia MP AD - Department of Neuroanesthesia, All India Institute of Medical Sciences, New Delhi, India. FAU - Chauhan, Sandeep AU - Chauhan S AD - Department of Cardiac Anesthesia, All India Institute of Medical Sciences, New Delhi, India. FAU - Sharma, Rajeev AU - Sharma R AD - Department of Neurosurgery, All India Institute of Medical Sciences, New Delhi, India. FAU - Raheja, Amol AU - Raheja A AD - Department of Neurosurgery, All India Institute of Medical Sciences, New Delhi, India. FAU - Darbari, Shaurya AU - Darbari S AD - Department of Neurosurgery, All India Institute of Medical Sciences, New Delhi, India. FAU - Kamra, Devasheesh AU - Kamra D AD - Department of Neurosurgery, All India Institute of Medical Sciences, New Delhi, India. FAU - Malik, Vishwas AU - Malik V AD - Department of Cardiac Anesthesia, All India Institute of Medical Sciences, New Delhi, India. FAU - Saxena, Anita AU - Saxena A AD - Department of Cardiology, All India Institute of Medical Sciences, New Delhi, India. FAU - Hote, Milind AU - Hote M AD - Department of Cardiothoracic and Vascular Surgery, All India Institute of Medical Sciences, New Delhi, India. FAU - Lodha, Rakesh AU - Lodha R AD - Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India. FAU - Gulati, Sheffali AU - Gulati S AD - Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India. FAU - Jauhari, Prashant AU - Jauhari P AD - Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India. FAU - Sankar, Jhuma AU - Sankar J AD - Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India. FAU - Sinha, Aditi AU - Sinha A AD - Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India. FAU - Bagga, Arvind AU - Bagga A AD - Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India. FAU - Kapil, Arti AU - Kapil A AD - Department of Microbiology, All India Institute of Medical Sciences, New Delhi, India. FAU - Singhal, Maneesh AU - Singhal M AD - Department of Plastic and Reconstructive Surgery, All India Institute of Medical Sciences, New Delhi, India. FAU - Chauhan, Shashank AU - Chauhan S AD - Department of Plastic and Reconstructive Surgery, All India Institute of Medical Sciences, New Delhi, India. FAU - Tiwari, Raja AU - Tiwari R AD - Department of Plastic and Reconstructive Surgery, All India Institute of Medical Sciences, New Delhi, India. FAU - Prabhakar, Anuj AU - Prabhakar A AD - Department of Neuroimaging and Interventional Neuroradiology, All India Institute of Medical Sciences, New Delhi, India. FAU - Gaikwad, Shailesh B AU - Gaikwad SB AD - Department of Neuroimaging and Interventional Neuroradiology, All India Institute of Medical Sciences, New Delhi, India. FAU - Takizawa, Katsumi AU - Takizawa K AD - Department of Neurosurgery, Asahikawa Red Cross Hospital, Asahikawa, Japan. FAU - Sabapathy, S Raja AU - Sabapathy SR AD - Division of Plastic Surgery, Hand Surgery, Reconstructive Surgery and Burns, Ganga Hospital, Coimbatore, India. FAU - Mazzeo, Anna Teresa AU - Mazzeo AT AD - Department of Adult and Pediatric Pathology, University of Messina, Messina, Italy. FAU - Jaryal, Ashok AU - Jaryal A AD - Department of Physiology, All India Institute of Medical Sciences, New Delhi, India. FAU - Kale, Shashank Sharad AU - Kale SS AD - Department of Neurosurgery, All India Institute of Medical Sciences, New Delhi, India. FAU - Mahapatra, Ashok Kumar AU - Mahapatra AK AD - Department of Neurosurgery, All India Institute of Medical Sciences, New Delhi, India. LA - eng PT - Journal Article PT - Review DEP - 20220506 PL - United States TA - Neurosurgery JT - Neurosurgery JID - 7802914 SB - IM MH - Cranial Sinuses/surgery MH - *Fistula MH - *Heart Arrest/surgery MH - Humans MH - *Plastic Surgery Procedures MH - *Twins, Conjoined/surgery EDAT- 2022/05/05 06:00 MHDA- 2022/06/10 06:00 CRDT- 2022/05/04 10:43 PHST- 2021/06/30 00:00 [received] PHST- 2022/01/08 00:00 [accepted] PHST- 2022/05/05 06:00 [pubmed] PHST- 2022/06/10 06:00 [medline] PHST- 2022/05/04 10:43 [entrez] AID - 00006123-202207000-00003 [pii] AID - 10.1227/neu.0000000000001962 [doi] PST - ppublish SO - Neurosurgery. 2022 Jul 1;91(1):27-42. doi: 10.1227/neu.0000000000001962. Epub 2022 May 6. PMID- 35505360 OWN - NLM STAT- MEDLINE DCOM- 20220505 LR - 20220716 IS - 1749-8090 (Electronic) IS - 1749-8090 (Linking) VI - 17 IP - 1 DP - 2022 May 3 TI - Preoperative Master's double two-step test may predict survival after lobectomy in patients with lung cancer. PG - 91 LID - 10.1186/s13019-022-01850-6 [doi] LID - 91 AB - BACKGROUND: The Master's double two-step test (MDT), which is used to screen for coronary heart disease, is difficult for physically impaired patients to complete. The purpose of this study was to clarify the relationship between the results of the MDT and prognosis after lung cancer surgery. METHODS: Between May 2004 and September 2019, 1,434 patients underwent complete resection for lung cancer at our hospital. Among them, 418 with pathological stage I disease who underwent lobectomy were evaluated. We defined patients who could accomplish the MDT as the complete MDT group and those who could not as the incomplete MDT group. Patients who could not perform the MDT due to physical problems were included in the incomplete MDT group. We explored the prognostic impact of the MDT results in these patients. RESULTS: Fifty-three patients (12.7%) were in the incomplete MDT group; compared with the complete MDT group, they were older and had poorer performance status and respiratory function. However, the incidence of postoperative complications and 90-day mortality did not differ significantly between groups. Multivariate analyses revealed that age (p < 0.001), Charlson comorbidity index (p = 0.013), incomplete MDT (p = 0.049) and carcinoembryonic antigen (CEA) level (p = 0.003) were prognostic factors for worse overall survival; age (p < 0.001) and incomplete MDT (p = 0.022) were prognostic factors for worse non-cancer-specific survival. CONCLUSIONS: Although incomplete MDT was not associated with postoperative complications, 90-day mortality or cancer-specific survival, MDT results may be significantly associated with non-cancer-specific survival. CI - (c) 2022. The Author(s). FAU - Shiono, Satoshi AU - Shiono S AUID- ORCID: 0000-0003-4087-635X AD - Department of Thoracic Surgery, Yamagata Prefectural Central Hospital, 1800, Oazaaoyagi, Yamagata, 990-2292, Japan. sshiono@ypch.gr.jp. FAU - Endo, Makoto AU - Endo M AD - Department of Thoracic Surgery, Yamagata Prefectural Central Hospital, 1800, Oazaaoyagi, Yamagata, 990-2292, Japan. FAU - Nakahashi, Kenta AU - Nakahashi K AD - Department of Thoracic Surgery, Yamagata Prefectural Central Hospital, 1800, Oazaaoyagi, Yamagata, 990-2292, Japan. FAU - Nakatsuka, Marina AU - Nakatsuka M AD - Department of Thoracic Surgery, Yamagata Prefectural Central Hospital, 1800, Oazaaoyagi, Yamagata, 990-2292, Japan. LA - eng PT - Journal Article DEP - 20220503 PL - England TA - J Cardiothorac Surg JT - Journal of cardiothoracic surgery JID - 101265113 SB - IM MH - *Exercise Test MH - Humans MH - *Lung Neoplasms/surgery MH - Multivariate Analysis MH - Postoperative Complications/epidemiology MH - Prognosis PMC - PMC9066765 OTO - NOTNLM OT - Lung cancer OT - Master's double two-step test OT - Thoracic surgery COIS- The authors declare that they have no competing interests. EDAT- 2022/05/04 06:00 MHDA- 2022/05/06 06:00 PMCR- 2022/05/03 CRDT- 2022/05/03 23:48 PHST- 2021/11/03 00:00 [received] PHST- 2022/04/20 00:00 [accepted] PHST- 2022/05/03 23:48 [entrez] PHST- 2022/05/04 06:00 [pubmed] PHST- 2022/05/06 06:00 [medline] PHST- 2022/05/03 00:00 [pmc-release] AID - 10.1186/s13019-022-01850-6 [pii] AID - 1850 [pii] AID - 10.1186/s13019-022-01850-6 [doi] PST - epublish SO - J Cardiothorac Surg. 2022 May 3;17(1):91. doi: 10.1186/s13019-022-01850-6. PMID- 35503699 OWN - NLM STAT- MEDLINE DCOM- 20220505 LR - 20220716 IS - 1678-9741 (Electronic) IS - 0102-7638 (Print) IS - 0102-7638 (Linking) VI - 37 IP - 2 DP - 2022 May 2 TI - Combined Heart and Kidney Transplantation: Initial Clinical Experience. PG - 263-267 LID - 10.21470/1678-9741-2020-0720 [doi] AB - INTRODUCTION: Combined solid organ transplantation is infrequently performed in Brazil. The objective of this article is to present our initial experience with combined heart and kidney transplantation. METHODS: From January 2007 to December 2019, four patients were submitted to combined heart and kidney transplantation. Their mean age was 55.7+/-4.4 years, and three (75%) patients were males. All patients had Chagas cardiomyopathy, two were hospitalized and inotrope dependent, and all patients were on preoperative dialysis (median of 12 months prior to transplant). RESULTS: All patients survived and were in New York Heart Association functional class I at the latest follow-up (mean 34.7+/-17.5 months). Mean retarded kidney graft function was 22.9+/-9.7 days. One patient lost the kidney graft two years after the transplant due to Polyomavirus infection. CONCLUSION: Our initial experience of combined heart and kidney transplantation was favorable in selected patients with advanced heart failure and end-stage kidney disease. It requires involvement of a dedicated multispecialty team throughout all the diagnostics and treatment steps. FAU - Atik, Fernando Antibas AU - Atik FA AUID- ORCID: 0000-0003-3394-9493 AD - Department of Cardiovascular Surgery, Instituto de Cardiologia do Distrito Federal, Brasilia, Federal District, Brazil. FAU - Borges, Carolina de Castro AU - Borges CC AD - Transplant Unit, Instituto de Cardiologia do Distrito Federal, Brasilia, Federal District, Brazil. FAU - Ulhoa, Marcelo Botelho AU - Ulhoa MB AD - Transplant Unit, Instituto de Cardiologia do Distrito Federal, Brasilia, Federal District, Brazil. FAU - Chaves, Renato Bueno AU - Chaves RB AD - Transplant Unit, Instituto de Cardiologia do Distrito Federal, Brasilia, Federal District, Brazil. FAU - Barzilai, Vitor Salvatore AU - Barzilai VS AD - Transplant Unit, Instituto de Cardiologia do Distrito Federal, Brasilia, Federal District, Brazil. FAU - Biondi, Rodrigo Santos AU - Biondi RS AD - Transplant Unit, Instituto de Cardiologia do Distrito Federal, Brasilia, Federal District, Brazil. FAU - Almeida, Tiago Martins de AU - Almeida TM AD - Transplant Unit, Instituto de Cardiologia do Distrito Federal, Brasilia, Federal District, Brazil. FAU - Medeiros, Isabela Novais AU - Medeiros IN AD - Transplant Unit, Instituto de Cardiologia do Distrito Federal, Brasilia, Federal District, Brazil. FAU - Cardoso, Helen Souto Siqueira AU - Cardoso HSS AD - Transplant Unit, Instituto de Cardiologia do Distrito Federal, Brasilia, Federal District, Brazil. LA - eng PT - Journal Article DEP - 20220502 PL - Brazil TA - Braz J Cardiovasc Surg JT - Brazilian journal of cardiovascular surgery JID - 101677045 SB - IM MH - Female MH - *Heart Failure/surgery MH - *Heart Transplantation MH - Humans MH - *Kidney Transplantation MH - Male MH - Middle Aged MH - Renal Dialysis MH - *Transplants PMC - PMC9054141 OTO - NOTNLM OT - Cardiomyopathies OT - Chagas Disease OT - Heart Failure OT - Heart Transplantation OT - Kidney Transplantation COIS- No conflict of interest. EDAT- 2022/05/04 06:00 MHDA- 2022/05/06 06:00 PMCR- 2022/03/01 CRDT- 2022/05/03 12:59 PHST- 2022/05/03 12:59 [entrez] PHST- 2022/05/04 06:00 [pubmed] PHST- 2022/05/06 06:00 [medline] PHST- 2022/03/01 00:00 [pmc-release] AID - 10.21470/1678-9741-2020-0720 [doi] PST - epublish SO - Braz J Cardiovasc Surg. 2022 May 2;37(2):263-267. doi: 10.21470/1678-9741-2020-0720. PMID- 35498011 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230916 IS - 2297-055X (Print) IS - 2297-055X (Electronic) IS - 2297-055X (Linking) VI - 9 DP - 2022 TI - Outcomes With Multidisciplinary Cardiac Rehabilitation in Post-acute Systolic Heart Failure Patients-A Retrospective Propensity Score-Matched Study. PG - 763217 LID - 10.3389/fcvm.2022.763217 [doi] LID - 763217 AB - BACKGROUND: Cardiac rehabilitation (CR) is recommended for patients with acute heart failure (HF). However, the results of outcome studies and meta-analyses on CR in post-acute care are varied. We aimed to assess the medium- to long-term impact of CR and ascertain the predictors of successful CR. METHODS: In this propensity score-matched retrospective cohort study, records of consecutive patients who survived acute HF (left ventricular ejection fraction <40) and participated in a multidisciplinary HF rehabilitation program post-discharge between May 2014 and July 2019 were reviewed. Patients in the CR group had at least one exercise session within 3 months of discharge; the others were in the non-CR group. After propensity score matching, the primary (all-cause mortality) and secondary (HF readmission and life quality assessment) outcomes were analyzed. RESULTS: Among 792 patients, 142 attended at least one session of phase II CR. After propensity score matching for covariates related to HF prognosis, 518 patients were included in the study (CR group, 137 patients). The all-cause mortality rate was 24.9% and the HF rehospitalization rate was 34.6% in the median 3.04-year follow-up. Cox proportional hazard analysis revealed that the CR group had a significant reduction in all-cause mortality compared to the non-CR group (hazard ratio [HR]: 0.490, 95% confidence interval [CI]: 0.308-0.778). A lower risk of the primary outcome with CR was observed in patients on renin-angiotensin-aldosterone system (RAAS) inhibitors, but was not seen in patients who were not prescribed this class of medications (interaction p = 0.014). CONCLUSIONS: Cardiac rehabilitation participation was associated with reduced all-cause mortality after acute systolic heart failure hospital discharge. Our finding that the benefit of CR was decreased in patients not prescribed RAAS inhibitors warrants further evaluation. CI - Copyright (c) 2022 Chen, Wang, Liaw, Wu, Wu, Wei, Chen, Su, Chang, Yang, Chen, Cheng, Chen and Chen. FAU - Chen, Shyh-Ming AU - Chen SM AD - Section of Cardiology, Department of Internal Medicine, Heart Failure Center, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Wang, Lin-Yi AU - Wang LY AD - Department of Physical Medicine and Rehabilitation, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Liaw, Mei-Yun AU - Liaw MY AD - Department of Physical Medicine and Rehabilitation, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Wu, Ming-Kung AU - Wu MK AD - Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Wu, Po-Jui AU - Wu PJ AD - Section of Cardiology, Department of Internal Medicine, Heart Failure Center, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Wei, Chin-Ling AU - Wei CL AD - Department of Nursing, Heart Failure Center, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan. FAU - Chen, An-Ni AU - Chen AN AD - Department of Physical Therapy, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan. FAU - Su, Tsui-Ling AU - Su TL AD - Department of Physical Therapy, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan. FAU - Chang, Jui-Kun AU - Chang JK AD - Department of Occupational Therapy, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan. FAU - Yang, Tsung-Hsun AU - Yang TH AD - Department of Physical Medicine and Rehabilitation, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Chen, Ching AU - Chen C AD - Clinical Psychologist, Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Cheng, Cheng-I AU - Cheng CI AD - Section of Cardiology, Department of Internal Medicine, Heart Failure Center, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Chen, Po-Cheng AU - Chen PC AD - Department of Physical Medicine and Rehabilitation, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Chen, Yung-Lung AU - Chen YL AD - Section of Cardiology, Department of Internal Medicine, Heart Failure Center, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. LA - eng PT - Journal Article DEP - 20220412 PL - Switzerland TA - Front Cardiovasc Med JT - Frontiers in cardiovascular medicine JID - 101653388 PMC - PMC9039246 OTO - NOTNLM OT - cardiac rehabilitation OT - heart failure OT - mortality OT - multidisciplinary program OT - renin-angiotensin-aldosterone system COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/05/03 06:00 MHDA- 2022/05/03 06:01 PMCR- 2022/01/01 CRDT- 2022/05/02 07:06 PHST- 2021/08/23 00:00 [received] PHST- 2022/03/18 00:00 [accepted] PHST- 2022/05/02 07:06 [entrez] PHST- 2022/05/03 06:00 [pubmed] PHST- 2022/05/03 06:01 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.3389/fcvm.2022.763217 [doi] PST - epublish SO - Front Cardiovasc Med. 2022 Apr 12;9:763217. doi: 10.3389/fcvm.2022.763217. eCollection 2022. PMID- 35497993 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250530 IS - 2297-055X (Print) IS - 2297-055X (Electronic) IS - 2297-055X (Linking) VI - 9 DP - 2022 TI - Anatomy of a Transcatheter Mitral Valve Service. PG - 862471 LID - 10.3389/fcvm.2022.862471 [doi] LID - 862471 AB - Transcatheter mitral therapies offer treatment options to selected patients who are unable to undergo open procedures due to prohibitive surgical risk. Data detailing the design and structure of transcatheter mitral services to ensure appropriate patient selection and tailored management strategies is lacking. We report our initial experience of developing and running a purpose-built transcatheter mitral service. The nature and number of referral sources, the multi-disciplinary make-up of the dedicated Mitral Heart Team and the use of integrative imaging assessment with incorporation of computational solutions are discussed. In addition, a summary of the clinical decision-making process is presented. This report sets out a framework from which future clinics can evolve to improve and streamline the delivery of transcatheter mitral therapies. CI - Copyright (c) 2022 Gill, Adams, Chehab, Allen, Hancock, Lamata, Lucchese, Prendergast, Redwood, Patterson and Rajani. FAU - Gill, Harminder AU - Gill H AD - Cardiovascuar Directorate, Guy's and St Thomas' Hospitals, London, United Kingdom. AD - School of Biomedical Engineering and Imaging Sciences Engineering, King's College London, London, United Kingdom. FAU - Adams, Heath S L AU - Adams HSL AD - Cardiovascuar Directorate, Guy's and St Thomas' Hospitals, London, United Kingdom. FAU - Chehab, Omar AU - Chehab O AD - Cardiovascuar Directorate, Guy's and St Thomas' Hospitals, London, United Kingdom. FAU - Allen, Christopher AU - Allen C AD - Cardiovascuar Directorate, Guy's and St Thomas' Hospitals, London, United Kingdom. FAU - Hancock, Jane AU - Hancock J AD - Cardiovascuar Directorate, Guy's and St Thomas' Hospitals, London, United Kingdom. FAU - Lamata, Pablo AU - Lamata P AD - School of Biomedical Engineering and Imaging Sciences Engineering, King's College London, London, United Kingdom. FAU - Lucchese, Gianluca AU - Lucchese G AD - Cardiovascuar Directorate, Guy's and St Thomas' Hospitals, London, United Kingdom. FAU - Prendergast, Bernard AU - Prendergast B AD - Cardiovascuar Directorate, Guy's and St Thomas' Hospitals, London, United Kingdom. FAU - Redwood, Simon AU - Redwood S AD - Cardiovascuar Directorate, Guy's and St Thomas' Hospitals, London, United Kingdom. FAU - Patterson, Tiffany AU - Patterson T AD - Cardiovascuar Directorate, Guy's and St Thomas' Hospitals, London, United Kingdom. FAU - Rajani, Ronak AU - Rajani R AD - Cardiovascuar Directorate, Guy's and St Thomas' Hospitals, London, United Kingdom. AD - School of Biomedical Engineering and Imaging Sciences Engineering, King's College London, London, United Kingdom. LA - eng GR - FS/CRTF/22/24312/BHF_/British Heart Foundation/United Kingdom PT - Journal Article DEP - 20220415 PL - Switzerland TA - Front Cardiovasc Med JT - Frontiers in cardiovascular medicine JID - 101653388 PMC - PMC9051038 OTO - NOTNLM OT - Heart Team OT - indirect annuloplasty OT - mitral edge-to-edge repair OT - mitral regurgitation OT - mitral stenosis OT - transcatheter mitral valve replacement COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/05/03 06:00 MHDA- 2022/05/03 06:01 PMCR- 2022/01/01 CRDT- 2022/05/02 07:06 PHST- 2022/01/25 00:00 [received] PHST- 2022/03/22 00:00 [accepted] PHST- 2022/05/02 07:06 [entrez] PHST- 2022/05/03 06:00 [pubmed] PHST- 2022/05/03 06:01 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.3389/fcvm.2022.862471 [doi] PST - epublish SO - Front Cardiovasc Med. 2022 Apr 15;9:862471. doi: 10.3389/fcvm.2022.862471. eCollection 2022. PMID- 35497985 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220503 IS - 2297-055X (Print) IS - 2297-055X (Electronic) IS - 2297-055X (Linking) VI - 9 DP - 2022 TI - The Presence of Calcified Raphe Is an Independent Predictor of Adverse Long-Term Clinical Outcomes in Patients With Bicuspid Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement. PG - 767906 LID - 10.3389/fcvm.2022.767906 [doi] LID - 767906 AB - OBJECTIVE: Current guidelines recommend that transcatheter aortic valve replacement (TAVR) for bicuspid aortic valve (BAV) with aortic stenosis (AS) should only be performed in selected patients. However, we consider it even more crucial to identify what the really important factors are while determining long-term outcomes in patients with BAV undergoing TAVR, which is precisely the aim of this study. METHODS: We retrospectively evaluated consecutive patients who underwent TAVR with balloon-expandable Sapien XT or Sapien 3 valves (Edwards Lifesciences, Irvine, CA) for the treatment of severe bicuspid AS. The primary end points were major adverse cardiac and cerebral events (MACCE), that is, mortality, non-fatal myocardial infarction (MI), disabling stroke, valve failure needing reintervention, or clinically relevant valve thrombosis during follow-up. RESULTS: A total of 56 patients who underwent TAVR with Sapien XT (n = 20) or Sapien 3 (n = 36) were included. The device and procedural success rates were similar between the two TAVR valves; however, the newer-generation Sapien 3 yielded a trend toward better long-term clinical outcomes than the early-generation Sapien XT did (MACCE rates 35 vs. 11%, p = 0.071). In the multivariate Cox proportional hazards analyses, the presence of calcified raphe > 4 mm was the only independent predictor of long-term MACCE (hazard ratio: 6.76; 95% confidence interval: 1.21-37.67, p = 0.029). CONCLUSION: TAVR performed by a skilled heart team, while using newer-generation balloon-expandable Sapien 3 valve, may yield better long-term clinical outcomes compared to TAVR using early-generation Sapien XT valve. Moreover, the presence of calcified raphe >4 mm is an independent determinant of adverse clinical outcomes. CI - Copyright (c) 2022 Lee, Yin, Tsao, Lee, Hsiung, Tzeng and Wei. FAU - Lee, Yung-Tsai AU - Lee YT AD - Heart Center, Cheng Hsin General Hospital, Taipei, Taiwan. AD - Institute of Microbiology and Immunology, National Yang Ming Chiao Tung University, Taipei, Taiwan. FAU - Yin, Wei-Hsian AU - Yin WH AD - Heart Center, Cheng Hsin General Hospital, Taipei, Taiwan. AD - Faculty of Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan. FAU - Tsao, Tien-Ping AU - Tsao TP AD - Heart Center, Cheng Hsin General Hospital, Taipei, Taiwan. AD - Faculty of Medicine, National Defense Medical Center, Taipei, Taiwan. FAU - Lee, Kuo-Chen AU - Lee KC AD - Heart Center, Cheng Hsin General Hospital, Taipei, Taiwan. AD - Faculty of Medicine, National Defense Medical Center, Taipei, Taiwan. FAU - Hsiung, Ming-Chon AU - Hsiung MC AD - Heart Center, Cheng Hsin General Hospital, Taipei, Taiwan. FAU - Tzeng, Yun-Hsuan AU - Tzeng YH AD - Faculty of Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan. AD - Division of Medical Imaging, Health Management Center, Cheng Hsin General Hospital, Taipei, Taiwan. FAU - Wei, Jeng AU - Wei J AD - Heart Center, Cheng Hsin General Hospital, Taipei, Taiwan. AD - Faculty of Medicine, National Defense Medical Center, Taipei, Taiwan. LA - eng PT - Journal Article DEP - 20220413 PL - Switzerland TA - Front Cardiovasc Med JT - Frontiers in cardiovascular medicine JID - 101653388 PMC - PMC9043529 OTO - NOTNLM OT - aortic stenosis OT - balloon-expandable valve OT - bicuspid aortic valve OT - calcified raphe OT - clinical outcomes OT - transcatheter aortic valve replacement OT - valve calcification COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/05/03 06:00 MHDA- 2022/05/03 06:01 PMCR- 2022/01/01 CRDT- 2022/05/02 07:06 PHST- 2021/08/31 00:00 [received] PHST- 2022/03/10 00:00 [accepted] PHST- 2022/05/02 07:06 [entrez] PHST- 2022/05/03 06:00 [pubmed] PHST- 2022/05/03 06:01 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.3389/fcvm.2022.767906 [doi] PST - epublish SO - Front Cardiovasc Med. 2022 Apr 13;9:767906. doi: 10.3389/fcvm.2022.767906. eCollection 2022. PMID- 35490924 OWN - NLM STAT- MEDLINE DCOM- 20220720 LR - 20250728 IS - 1916-7075 (Electronic) IS - 0828-282X (Linking) VI - 38 IP - 7 DP - 2022 Jul TI - Reproductive Issues in Patients With the Fontan Operation. PG - 921-929 LID - S0828-282X(22)00270-7 [pii] LID - 10.1016/j.cjca.2022.04.020 [doi] AB - Patients with the Fontan operation have a unique circulation, with a limited ability to increase cardiac output, and high central venous pressure. They may have diastolic and/or systolic ventricular dysfunction, arrhythmias, thromboembolic complications, or multiorgan dysfunction. All of these factors contribute to reproductive issues, including menstrual irregularities, infertility, recurrent miscarriage, and complications during pregnancy. Although atrial arrhythmias are the most common cardiac complications during pregnancy, patients can develop heart failure and thromboembolic events. Obstetric bleeding, including postpartum hemorrhage, is common. In addition to maternal complications, adverse fetal and neonatal events, such as prematurity and low birthweight, are very common. Counselling about these reproductive issues should begin early. For those who become pregnant, care should be provided by a multidisciplinary cardio-obstetric team familiar with the specific issues and needs of the Fontan population. In this review, we discuss infertility, contraception, and pregnancy in patients with the Fontan operation. CI - Copyright (c) 2022 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved. FAU - Wichert-Schmitt, Barbara AU - Wichert-Schmitt B AD - Department of Cardiology and Medical Intensive Care, Kepler University Hospital, Medical Faculty, Johannes Kepler University, Linz, Austria. Electronic address: Barbara.Wichert-Schmitt@kepleruniklinikum.at. FAU - D'Souza, Rohan AU - D'Souza R AD - Departments of Obstetrics & Gynaecology and Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada. FAU - Silversides, Candice K AU - Silversides CK AD - Division of Cardiology, University of Toronto, Pregnancy and Heart Disease Program, Mount Sinai and Toronto General Hospitals, Toronto, Ontario, Canada. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20220428 PL - England TA - Can J Cardiol JT - The Canadian journal of cardiology JID - 8510280 SB - IM CIN - Can J Cardiol. 2024 Feb;40(2):182-184. doi: 10.1016/j.cjca.2023.05.004. PMID: 37178759 MH - Arrhythmias, Cardiac/etiology MH - Female MH - *Fontan Procedure/adverse effects MH - *Heart Defects, Congenital MH - Humans MH - Infant, Low Birth Weight MH - Infant, Newborn MH - *Infertility/complications MH - Pregnancy MH - Retrospective Studies MH - *Thromboembolism/etiology/prevention & control EDAT- 2022/05/02 06:00 MHDA- 2022/07/22 06:00 CRDT- 2022/05/01 19:27 PHST- 2022/03/04 00:00 [received] PHST- 2022/04/25 00:00 [revised] PHST- 2022/04/25 00:00 [accepted] PHST- 2022/05/02 06:00 [pubmed] PHST- 2022/07/22 06:00 [medline] PHST- 2022/05/01 19:27 [entrez] AID - S0828-282X(22)00270-7 [pii] AID - 10.1016/j.cjca.2022.04.020 [doi] PST - ppublish SO - Can J Cardiol. 2022 Jul;38(7):921-929. doi: 10.1016/j.cjca.2022.04.020. Epub 2022 Apr 28. PMID- 35490288 OWN - NLM STAT- MEDLINE DCOM- 20220503 LR - 20220510 IS - 1098-4275 (Electronic) IS - 0031-4005 (Linking) VI - 149 IP - 5 DP - 2022 May 1 TI - Identifying Food Insecurity in Cardiology Clinic and Connecting Families to Resources. LID - e2020011718 [pii] LID - 10.1542/peds.2020-011718 [doi] AB - BACKGROUND: Food insecurity (FI) increases children's risk for illness and developmental and behavioral problems, which are ongoing concerns for congenital heart disease (CHD) patients. In 2020, 14.8% of households with children suffered from FI. The Hunger Vital Signs (HVS) asks 2 questions to assess FI. The global aim of the project is to implement HVS and connect FI families to resources. METHODS: Stakeholders identified 6 critical drivers in implementing FI screening at an outpatient cardiology clinic and conducted plan-do-study-act (PDSA) cycles to implement HVS. Over the 13-month study period, time series analyses were performed to assess our process measure (FI screening) and outcome measure (connection of FI families to resources). Demographics and severity of CHD were analyzed for FI families. RESULTS: Screening rates increased from 0% to >85%, screening 5064 families. Process evaluations revealed roadblocks including screening discomfort. FI families were more likely to identify as Black or multiple or other ethnicity. Severe CHD patients were at higher risk for FI (n = 106, odds ratio [OR] 1.67 [1.21-2.29], P = .002). Face-to-face meetings with social work and community partnerships reduced loss to follow-up and our ability to offer all FI families individualized FI resources. CONCLUSION: HVS screening can be implemented in a cardiology clinic to improve identification of FI families. A written tool can combat screening discomfort and improve identification of FI families. Children with severe CHD may be at increased risk for FI. A multidisciplinary team and community partnerships can improve individualized resource distribution. CI - Copyright (c) 2022 by the American Academy of Pediatrics. FAU - Black, Allison K AU - Black AK AD - Norton Children's Hospital and School of Medicine, University of Louisville, Louisville, Kentucky. FAU - Pantalone, Julia AU - Pantalone J AD - University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. FAU - Marrone, Anna-Claire AU - Marrone AC AD - Children's Healthcare of Atlanta, Atlanta, Georgia. FAU - Morell, Evonne AU - Morell E AD - University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. AD - Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania. FAU - Telles, Robin AU - Telles R AD - Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania. FAU - DeBrunner, Mark AU - DeBrunner M AD - University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. AD - Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania. LA - eng PT - Journal Article PL - United States TA - Pediatrics JT - Pediatrics JID - 0376422 SB - IM MH - Ambulatory Care Facilities MH - *Cardiology MH - Child MH - Food Insecurity MH - *Food Supply MH - Humans MH - Mass Screening EDAT- 2022/05/02 06:00 MHDA- 2022/05/04 06:00 CRDT- 2022/05/01 00:02 PHST- 2021/11/29 00:00 [accepted] PHST- 2022/05/01 00:02 [entrez] PHST- 2022/05/02 06:00 [pubmed] PHST- 2022/05/04 06:00 [medline] AID - 186904 [pii] AID - 10.1542/peds.2020-011718 [doi] PST - ppublish SO - Pediatrics. 2022 May 1;149(5):e2020011718. doi: 10.1542/peds.2020-011718. PMID- 35490283 OWN - NLM STAT- MEDLINE DCOM- 20220503 LR - 20220510 IS - 1098-4275 (Electronic) IS - 0031-4005 (Linking) VI - 149 IP - 5 DP - 2022 May 1 TI - Reducing Pediatric Unplanned Extubation Across Multiple ICUs Using Quality Improvement. LID - e2021052259 [pii] LID - 10.1542/peds.2021-052259 [doi] AB - OBJECTIVES: Unplanned extubation (UE) in pediatric patients can result in significant harm or mortality. In our institution, efforts to reduce UE in the ICU were siloed and learnings were not shared. Our goal was to implement shared initiatives across ICUs in a pediatric institution using quality improvement methodology, with the global aim of reducing serious harm caused by UEs. METHODS: The study was conducted as a single-center prospective quality improvement initiative in the pediatric, neonatal, and cardiac ICUs of a large, freestanding academic pediatric hospital. Using the model for improvement and plan-do-study-act cycles, our multidisciplinary team implemented multiple interventions to reduce UEs. The primary measure monitored was the monthly UE rate, defined as the number of UEs per 100 ventilator days, which was tracked over time using statistical control charts. RESULTS: The overall monthly institutional UE rate was reduced from 1.22 UE per 100 ventilator days to 0.2 UE per 100 ventilator days, representing an 84% improvement in rate and reduction of harm. Sixteen percent to 21% of UEs required additional resources because of a difficult airway, and 10% to 22% of UEs resulted in cardiovascular collapse requiring resuscitation. CONCLUSIONS: Significant harm is associated with UEs in pediatric patients. We implemented a bundle for UE reduction across all ICU populations in a pediatric hospital and significantly reduced the rate of UE within our institution and within each individual unit. Allowing variation for implementation of interventions by unit, although targeting a common goal, contributed to overall success and sustainability. CI - Copyright (c) 2022 by the American Academy of Pediatrics. FAU - Melton, Kristin AU - Melton K AD - Department of Pediatrics, Division of Neonatology, Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, Ohio. FAU - Ryan, Caitlin AU - Ryan C AD - James M. Anderson Center for Health Systems Excellence. FAU - Saunders, Angela AU - Saunders A AD - Division of Respiratory Care. FAU - Zix, Julie AU - Zix J AD - Newborn ICU, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. LA - eng PT - Journal Article PL - United States TA - Pediatrics JT - Pediatrics JID - 0376422 SB - IM MH - *Airway Extubation/methods MH - Child MH - Humans MH - Infant, Newborn MH - Intensive Care Units MH - Prospective Studies MH - *Quality Improvement MH - Risk Factors EDAT- 2022/05/02 06:00 MHDA- 2022/05/04 06:00 CRDT- 2022/05/01 00:02 PHST- 2021/11/29 00:00 [accepted] PHST- 2022/05/01 00:02 [entrez] PHST- 2022/05/02 06:00 [pubmed] PHST- 2022/05/04 06:00 [medline] AID - 186762 [pii] AID - 10.1542/peds.2021-052259 [doi] PST - ppublish SO - Pediatrics. 2022 May 1;149(5):e2021052259. doi: 10.1542/peds.2021-052259. PMID- 35486435 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220716 IS - 2561-326X (Electronic) IS - 2561-326X (Linking) VI - 6 IP - 4 DP - 2022 Apr 29 TI - Adherence to a Multidisciplinary Lifestyle Program for Patients With Atrial Fibrillation and Obesity: Feasibility Study. PG - e32625 LID - 10.2196/32625 [doi] LID - e32625 AB - BACKGROUND: Atrial fibrillation is commonly associated with obesity. Observational studies have shown that weight loss is associated with improved prognosis and a decrease in atrial fibrillation frequency and severity. However, despite these benefits, nonadherence to lifestyle programs is common. OBJECTIVE: In this study, we evaluated adherence to and feasibility of a multidisciplinary lifestyle program focusing on behavior change in patients with atrial fibrillation and obesity. METHODS: Patients with atrial fibrillation and obesity participated in a 1-year goal-oriented cardiac rehabilitation program. After baseline assessment, the first 3 months included a cardiac rehabilitation intervention with 4 fixed modules: lifestyle counseling (with an advanced nurse practitioner), exercise training, dietary consultation, and psychosocial therapy; relaxation sessions were an additional optional treatment module. An advanced nurse practitioner monitored the personal lifestyle of each individual patient, with assessments and consultations at 3 months (ie, immediately after the intervention) and at the end of the year (ie, 9 months after the intervention). At each timepoint, level of physical activity, personal goals and progress, atrial fibrillation symptoms and frequency (Atrial Fibrillation Severity Scale), psychosocial stress (Generalized Anxiety Disorder-7), and depression (Patient Health Questionnaire-9) were assessed. The primary endpoints were adherence (defined as the number of visits attended as percentage of the number of planned visits) and completion rates of the cardiac rehabilitation intervention (defined as performing at least of 80% of the prescribed sessions). In addition, we performed an exploratory analysis of effects of the cardiac rehabilitation program on weight and atrial fibrillation symptom frequency and severity. RESULTS: Patients with atrial fibrillation and obesity (male: n=8; female: n=2; age: mean 57.2 years, SD 9.0; baseline weight: mean 107.2 kg, SD 11.8; baseline BMI: mean 32.4 kg/m2, SD 3.5) were recruited. Of the 10 participants, 8 participants completed the 3-month cardiac rehabilitation intervention, and 2 participants did not complete the cardiac rehabilitation intervention (both because of personal issues). Adherence to the fixed treatment modules was 95% (mean 3.8 sessions attended out of mean 4 planned) for lifestyle counseling, 86% (mean 15.2 sessions attended out of mean 17.6 planned) for physiotherapy sessions, 88% (mean 3.7 sessions attended out of mean 4.1 planned) for dietician consultations, and 60% (mean 0.6 sessions attended out of mean 1.0 planned) for psychosocial therapy; 70% of participants (7/10) were referred to the optional relaxation sessions, for which adherence was 86% (mean 2 sessions attended out of mean 2.4 planned). The frequency of atrial fibrillation symptoms was reduced immediately after the intervention (before: mean 35.6, SD 3.8; after: mean 31.2, SD 3.3), and this was sustained at 12 months (mean 24.8, SD 3.2). The severity of atrial fibrillation complaints immediately after the intervention (mean 20.0, SD 3.7) and at 12 months (mean 9.3, SD 3.6) were comparable to that at baseline (mean 16.6, SD 3.3). CONCLUSIONS: A 1-year multidisciplinary lifestyle program for obese patients with atrial fibrillation was found to be feasible, with high adherence and completion rates. Exploratory analysis revealed a sustained reduction in atrial fibrillation symptoms; however, these results remain to be confirmed in large-scale studies. CI - (c)Nicole Tenbult, Jos Kraal, Rutger Brouwers, Ruud Spee, Sabine Eijsbouts, Hareld Kemps. Originally published in JMIR Formative Research (https://formative.jmir.org), 29.04.2022. FAU - Tenbult, Nicole AU - Tenbult N AUID- ORCID: 0000-0002-9021-9895 AD - Telemedicine and Rehabilitation in Chronic Disease, Flow, Center for Prevention, Maxima MC, Veldhoven/Eindhoven, Netherlands. FAU - Kraal, Jos AU - Kraal J AUID- ORCID: 0000-0001-9667-6926 AD - Telemedicine and Rehabilitation in Chronic Disease, Flow, Center for Prevention, Maxima MC, Veldhoven/Eindhoven, Netherlands. AD - Faculty Industrial Design Engineering, Delft, Netherlands. FAU - Brouwers, Rutger AU - Brouwers R AUID- ORCID: 0000-0002-8409-2357 AD - Telemedicine and Rehabilitation in Chronic Disease, Flow, Center for Prevention, Maxima MC, Veldhoven/Eindhoven, Netherlands. FAU - Spee, Ruud AU - Spee R AUID- ORCID: 0000-0003-2885-8538 AD - Telemedicine and Rehabilitation in Chronic Disease, Flow, Center for Prevention, Maxima MC, Veldhoven/Eindhoven, Netherlands. AD - Department of Cardiology, Maxima MC, Veldhoven/Eindhoven, Netherlands. FAU - Eijsbouts, Sabine AU - Eijsbouts S AUID- ORCID: 0000-0001-9277-8255 AD - Department of Cardiology, Maxima MC, Veldhoven/Eindhoven, Netherlands. FAU - Kemps, Hareld AU - Kemps H AUID- ORCID: 0000-0003-0272-4355 AD - Telemedicine and Rehabilitation in Chronic Disease, Flow, Center for Prevention, Maxima MC, Veldhoven/Eindhoven, Netherlands. AD - Department of Cardiology, Maxima MC, Veldhoven/Eindhoven, Netherlands. AD - Department of Industrial Design, University of Technology Eindhoven, Eindhoven, Netherlands. LA - eng PT - Journal Article DEP - 20220429 PL - Canada TA - JMIR Form Res JT - JMIR formative research JID - 101726394 PMC - PMC9107041 OTO - NOTNLM OT - adherence OT - atrial fibrillation OT - cardiac rehabilitation OT - completion OT - lifestyle OT - obesity OT - participation COIS- Conflicts of Interest: None declared. EDAT- 2022/04/30 06:00 MHDA- 2022/04/30 06:01 PMCR- 2022/04/29 CRDT- 2022/04/29 11:53 PHST- 2021/08/30 00:00 [received] PHST- 2022/01/13 00:00 [accepted] PHST- 2021/12/23 00:00 [revised] PHST- 2022/04/29 11:53 [entrez] PHST- 2022/04/30 06:00 [pubmed] PHST- 2022/04/30 06:01 [medline] PHST- 2022/04/29 00:00 [pmc-release] AID - v6i4e32625 [pii] AID - 10.2196/32625 [doi] PST - epublish SO - JMIR Form Res. 2022 Apr 29;6(4):e32625. doi: 10.2196/32625. PMID- 35476085 OWN - NLM STAT- MEDLINE DCOM- 20220429 LR - 20220430 IS - 2317-6385 (Electronic) IS - 1679-4508 (Print) IS - 1679-4508 (Linking) VI - 20 DP - 2022 TI - Lung nodule localization in hybrid room before minimally invasive thoracic surgery: series of 20 cases and literature review. PG - eAO6665 LID - S1679-45082022000100230 [pii] LID - 10.31744/einstein_journal/2022AO6665 [doi] LID - eAO6665 AB - OBJECTIVE: To describe an experience in the preoperative localization of small pulmonary nodules and ground-glass lesions to guide minimally invasive thoracic surgery; in addition, a literature review was conducted, including the main advantages and disadvantages of the different agents used, and site marking in a hybrid operating room. METHODS: A retrospective search was conducted in a Interventional Radiology Department database, between March 2015 and May 2019, to identify patients undergoing preoperative percutaneous marking of lung injuries measuring up to 25mm. RESULTS: A total of 20 patients were included and submitted to descriptive analysis. All patients were marked in a hybrid room, at the same surgical-anesthetic time. Most often used markers were guidewire, Lipiodol(R) and microcoils. Despite one case of coil displacement, two cases of pneumothorax, and one case of hypotension after marking, all lesions were identified and resected accordingly from all patients. CONCLUSION: Preoperative percutaneous localization of lung injuries in hybrid room is an effective and a safe technique, which can have decisive impact on surgical resection. The choice of marker and of the operating room scenario should be based on availability and experience of service. Multidisciplinary discussions with surgical teams, pathologists, and interventional radiologists are crucial to improve outcome of patients. FAU - Gilberto, Guilherme Moratti AU - Gilberto GM AUID- ORCID: 0000-0002-8923-2996 AD - Hospital Israelita Albert Einstein, Sao Paulo, SP, Brazil. FAU - Falsarella, Priscila Mina AU - Falsarella PM AUID- ORCID: 0000-0003-3063-9174 AD - Hospital Israelita Albert Einstein, Sao Paulo, SP, Brazil. FAU - Andrade, Juliano Ribeiro de AU - Andrade JR AUID- ORCID: 0000-0002-8274-1034 AD - Hospital Israelita Albert Einstein, Sao Paulo, SP, Brazil. FAU - Schmid, Bruno Pagnin AU - Schmid BP AUID- ORCID: 0000-0002-2297-504X AD - Hospital Israelita Albert Einstein, Sao Paulo, SP, Brazil. FAU - Mariotti, Guilherme Cayres AU - Mariotti GC AUID- ORCID: 0000-0002-8052-6912 AD - Hospital Israelita Albert Einstein, Sao Paulo, SP, Brazil. FAU - Terra, Ricardo Mingarini AU - Terra RM AUID- ORCID: 0000-0001-8577-8708 AD - Hospital Israelita Albert Einstein, Sao Paulo, SP, Brazil. FAU - Campos, Jose Ribas Milanez de AU - Campos JRM AUID- ORCID: 0000-0002-2385-7707 AD - Hospital Israelita Albert Einstein, Sao Paulo, SP, Brazil. FAU - Succi, Jose Ernesto AU - Succi JE AUID- ORCID: 0000-0001-7810-1600 AD - Hospital Israelita Albert Einstein, Sao Paulo, SP, Brazil. FAU - Garcia, Rodrigo Gobbo AU - Garcia RG AUID- ORCID: 0000-0002-1968-9595 AD - Hospital Israelita Albert Einstein, Sao Paulo, SP, Brazil. LA - eng PT - Journal Article PT - Review DEP - 20220420 PL - Brazil TA - Einstein (Sao Paulo) JT - Einstein (Sao Paulo, Brazil) JID - 101281800 SB - IM MH - Humans MH - Lung/pathology MH - *Lung Injury MH - *Lung Neoplasms MH - Retrospective Studies MH - *Thoracic Surgery MH - Thoracic Surgery, Video-Assisted/methods MH - Tomography, X-Ray Computed/methods PMC - PMC9000983 COIS- Conflict of interest: none. EDAT- 2022/04/28 06:00 MHDA- 2022/04/30 06:00 PMCR- 2022/04/07 CRDT- 2022/04/27 12:17 PHST- 2021/04/08 00:00 [received] PHST- 2021/07/12 00:00 [accepted] PHST- 2022/04/27 12:17 [entrez] PHST- 2022/04/28 06:00 [pubmed] PHST- 2022/04/30 06:00 [medline] PHST- 2022/04/07 00:00 [pmc-release] AID - S1679-45082022000100230 [pii] AID - 10.31744/einstein_journal/2022AO6665 [doi] PST - epublish SO - Einstein (Sao Paulo). 2022 Apr 20;20:eAO6665. doi: 10.31744/einstein_journal/2022AO6665. eCollection 2022. PMID- 35472192 OWN - NLM STAT- MEDLINE DCOM- 20220608 LR - 20231116 IS - 2327-6924 (Electronic) IS - 2327-6886 (Linking) VI - 34 IP - 6 DP - 2022 Jun 1 TI - Reducing length of stay for patients undergoing transcatheter aortic valve replacement using a prescreening approach. PG - 844-849 LID - 10.1097/JXX.0000000000000719 [doi] AB - BACKGROUND: As transcatheter aortic valve replacement (TAVR) becomes a preferred treatment option for patients with aortic valve stenosis, and demand for TAVR increases, it is imperative that length of stay (LOS) is reduced while maintaining safety and effectiveness. LOCAL PROBLEM: As TAVR procedures have become less invasive and more streamlined, current protocols have not been updated to reflect today's postprocedure requirements. METHODS: The next-day discharge (NDD) protocol was established using available literature. A convenience sample was evaluated for NDD protocol inclusion during aortic multidisciplinary team conference using predetermined inclusion and exclusion criteria. Length of stay for NDD protocol participants was compared with LOS from a retrospective convenience sample of patients undergoing TAVR in the time frame mirroring NDD protocol initiation of the year prior. INTERVENTIONS: Patients meeting inclusion criteria were enrolled in the NDD protocol with a goal of discharge to home on postprocedural day 1 by 2:00 p.m. The NDD protocol included preprocedure expectation setting, prescheduled same-day postprocedure imaging, and discharge priority on postprocedure day 1. RESULTS: There is a significant difference in LOS between the NDD eligible retrospective and prospective groups. The prospective group has a significantly lower LOS than the retrospective group (M = 1.6 vs 2.1, respectively; p = .0454). CONCLUSIONS: An NDD protocol can help reduce LOS after TAVR in appropriately selected patients. Further protocol revision will be required to optimize LOS outcomes. CI - Copyright (c) 2022 American Association of Nurse Practitioners. FAU - Cusin, Crystal N AU - Cusin CN AD - Henry Ford Hospital, Madonna University. FAU - Clark, Patricia A AU - Clark PA FAU - Lauderbach, Claude W Jr AU - Lauderbach CW Jr FAU - Wyman, Janet AU - Wyman J LA - eng PT - Journal Article DEP - 20220601 PL - United States TA - J Am Assoc Nurse Pract JT - Journal of the American Association of Nurse Practitioners JID - 101600770 MH - Aortic Valve/surgery MH - *Aortic Valve Stenosis/surgery MH - Humans MH - Length of Stay MH - Prospective Studies MH - Retrospective Studies MH - Risk Factors MH - Time Factors MH - *Transcatheter Aortic Valve Replacement/methods MH - Treatment Outcome COIS- Competing interest: The authors report no conflicts of interest. EDAT- 2022/04/27 06:00 MHDA- 2022/06/09 06:00 CRDT- 2022/04/26 17:17 PHST- 2021/12/10 00:00 [received] PHST- 2022/03/04 00:00 [accepted] PHST- 2022/04/27 06:00 [pubmed] PHST- 2022/06/09 06:00 [medline] PHST- 2022/04/26 17:17 [entrez] AID - 01741002-202206000-00010 [pii] AID - 10.1097/JXX.0000000000000719 [doi] PST - epublish SO - J Am Assoc Nurse Pract. 2022 Jun 1;34(6):844-849. doi: 10.1097/JXX.0000000000000719. PMID- 35466896 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250731 LR - 20250731 IS - 1467-1107 (Electronic) IS - 1047-9511 (Linking) VI - 32 IP - 4 DP - 2022 Apr TI - Repeated extracorporeal membrane oxygenation for support of an Adult with Congenital Heart Disease and reperfusion pulmonary oedema. PG - 636-640 LID - 10.1017/S104795112200021X [doi] AB - We present the case of 28-year-old woman with a history of complex congenital cardiac surgery who developed cardiovascular collapse with reperfusion pulmonary oedema and right ventricular failure after surgical replacement of a severely stenosed right ventricle to pulmonary artery conduit. She required two separate episodes of support with extracorporeal membrane oxygenation and is alive and well 6 months after her initial cardiorespiratory crisis. We believe that consideration of a second period of support with extracorporeal membrane oxygenation is appropriate for select adults with CHD, provided they have a potentially reversible cause of postoperative cardiorespiratory collapse.Our case provides several important lessons: (1) adults with CHD with severe postcardiotomy cardiorespiratory failure may potentially be salvaged even if they require multiple runs of extracorporeal membrane oxygenation; (2) adults with CHD with severe postcardiotomy respiratory failure with adequate cardiac function may potentially be salvaged with veno-venous extracorporeal membrane oxygenation; and (3) patients supported with extracorporeal membrane oxygenation will benefit from care from a skilled multidisciplinary team who are able to focus on the support of the function of the organs of the patient whilst providing nutrition and mobilisation. FAU - Stukov, Yuriy AU - Stukov Y AD - Congenital Heart Center, Division of Cardiovascular Surgery, Departments of Surgery and Pediatrics, University of Florida, Gainesville, FL, USA. FAU - Jacobs, Jeffery P AU - Jacobs JP AUID- ORCID: 0000-0002-9916-929X AD - Congenital Heart Center, Division of Cardiovascular Surgery, Departments of Surgery and Pediatrics, University of Florida, Gainesville, FL, USA. FAU - Cornman, Jessica AU - Cornman J AD - Congenital Heart Center, Physical Therapy, University of Florida, Gainesville, FL, USA. FAU - Cruz Beltran, Susanna AU - Cruz Beltran S AD - Congenital Heart Center, Department of Anesthesia, University of Florida, Gainesville, FL, USA. FAU - Moguillansky, Diego AU - Moguillansky D AD - Congenital Heart Center, Division of Pediatric Cardiology, Department of Pediatrics, University of Florida, Gainesville, FL, USA. FAU - Bleiweis, Mark S AU - Bleiweis MS AD - Congenital Heart Center, Division of Cardiovascular Surgery, Departments of Surgery and Pediatrics, University of Florida, Gainesville, FL, USA. FAU - Peek, Giles J AU - Peek GJ AUID- ORCID: 0000-0002-1313-6498 AD - Congenital Heart Center, Division of Cardiovascular Surgery, Departments of Surgery and Pediatrics, University of Florida, Gainesville, FL, USA. LA - eng PT - Journal Article DEP - 20220425 PL - England TA - Cardiol Young JT - Cardiology in the young JID - 9200019 SB - IM OTO - NOTNLM OT - ACHD OT - CHD OT - Lung reperfusion injury OT - adults with CHD OT - extracorporeal membrane oxygenation EDAT- 2022/04/26 06:00 MHDA- 2022/04/26 06:01 CRDT- 2022/04/25 08:57 PHST- 2022/04/26 06:01 [medline] PHST- 2022/04/26 06:00 [pubmed] PHST- 2022/04/25 08:57 [entrez] AID - S104795112200021X [pii] AID - 10.1017/S104795112200021X [doi] PST - ppublish SO - Cardiol Young. 2022 Apr;32(4):636-640. doi: 10.1017/S104795112200021X. Epub 2022 Apr 25. PMID- 35466727 OWN - NLM STAT- MEDLINE DCOM- 20220908 LR - 20250728 IS - 1552-3799 (Electronic) IS - 1054-7738 (Linking) VI - 31 IP - 7 DP - 2022 Sep TI - Identifying Feasible Heart Failure Interventions Suitable for the Jordan Healthcare system: A Delphi Study. PG - 1263-1275 LID - 10.1177/10547738221091875 [doi] AB - Interventions and strategies should align with the context and capacity of the health system. Identifying the most feasible and appropriate heart failure interventions in Jordan will improve heart failure management and clinical outcomes. Therefore, this study aimed to derive consensus from clinicians (using the Delphi method) regarding the most feasible and appropriate heart failure interventions in Jordan. A two-round Delphi study involving seven clinicians and policy makers were conducted. The Delphi results found consensus for the feasibility of the educational materials, follow up phone call, cardiac rehabilitation, group session, and training courses for staff. The components that were not feasible were: multidisciplinary team, individual session, and telemonitoring devices. The present study demonstrates the importance of utilizing interventions tailored to patients' characteristics and aligned with the capacity of healthcare system. FAU - Alkouri, Osama AU - Alkouri O AUID- ORCID: 0000-0002-3268-2259 AD - Al-Ahliyya Amman University, Jordan. FAU - Hendriks, Jeroen M AU - Hendriks JM AD - Flinders University, Adelaide, SA, Australia. FAU - Magarey, Judy AU - Magarey J AD - University of Adelaide, SA, Australia. FAU - Schultz, Tim AU - Schultz T AD - Flinders University, Adelaide, SA, Australia. LA - eng PT - Journal Article DEP - 20220425 PL - United States TA - Clin Nurs Res JT - Clinical nursing research JID - 9208508 MH - Consensus MH - Delivery of Health Care MH - Delphi Technique MH - *Heart Failure/therapy MH - Humans MH - Jordan OTO - NOTNLM OT - Delphi OT - feasible interventions OT - heart failure interventions EDAT- 2022/04/26 06:00 MHDA- 2022/09/09 06:00 CRDT- 2022/04/25 08:56 PHST- 2022/04/26 06:00 [pubmed] PHST- 2022/09/09 06:00 [medline] PHST- 2022/04/25 08:56 [entrez] AID - 10.1177/10547738221091875 [doi] PST - ppublish SO - Clin Nurs Res. 2022 Sep;31(7):1263-1275. doi: 10.1177/10547738221091875. Epub 2022 Apr 25. PMID- 35466382 OWN - NLM STAT- MEDLINE DCOM- 20220802 LR - 20250728 IS - 1522-9645 (Electronic) IS - 0195-668X (Linking) VI - 43 IP - 29 DP - 2022 Aug 1 TI - Which patients with aortic stenosis should be referred to surgery rather than transcatheter aortic valve implantation? PG - 2729-2750 LID - 10.1093/eurheartj/ehac105 [doi] AB - Transcatheter aortic valve implantation (TAVI) has matured into a standard treatment option for patients with severe symptomatic aortic valve stenosis (AS) across the whole spectrum of risk. The advances in the interventional treatment of AS raise the question of which patients with severe AS should be referred to surgery. The myriad of clinical permutations does not allow providing a single, uniform treatment strategy. Rather, the advent of TAVI along with established surgical aortic valve replacement (SAVR) fundamentally enforces the role of the multidisciplinary heart team for decision-making recommending the best individual choice of the two options based on a thorough review of clinical and anatomical factors as well as lifetime management considerations. Involvement of the informed patient expressing treatment preferences is a key for a shared decision-making process. Herein, we provide an in-depth review of evidence informing the decision-making process between TAVI and SAVR and key elements for treatment selection. Special attention is given to the populations that have been excluded from randomized clinical trials, and also lifetime management strategies of patients with severe AS are proposed. CI - (c) The Author(s) 2022. Published by Oxford University Press on behalf of European Society of Cardiology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. FAU - Windecker, Stephan AU - Windecker S AUID- ORCID: 0000-0003-2653-6762 AD - Department of Cardiology, Inselspital, Bern University Hospital, Bern, Switzerland. FAU - Okuno, Taishi AU - Okuno T AUID- ORCID: 0000-0001-7831-2934 AD - Department of Cardiology, Inselspital, Bern University Hospital, Bern, Switzerland. FAU - Unbehaun, Axel AU - Unbehaun A AUID- ORCID: 0000-0003-2851-695X AD - Department of Cardiothoracic and Vascular Surgery, German Heart Centre Berlin, Berlin, Germany. AD - DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Berlin, Germany. FAU - Mack, Michael AU - Mack M AD - Baylor Scott & White Health, Baylor Scott & White Research Institute, Dallas, TX, USA. FAU - Kapadia, Samir AU - Kapadia S AUID- ORCID: 0000-0002-0026-3391 AD - Department of Cardiovascular Medicine, Heart, Vascular, and Thoracic Institute, Cleveland Clinic, OH, USA. FAU - Falk, Volkmar AU - Falk V AUID- ORCID: 0000-0002-7911-8620 AD - Department of Cardiothoracic and Vascular Surgery, German Heart Centre Berlin, Berlin, Germany. AD - DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Berlin, Germany. AD - Department of Cardiovascular Surgery, Charite University Hospital Berlin, Berlin, Germany. AD - ETH Zurich, Department of Health Sciences and Technology, Translational Cardiovascular Technology, Zurich, Switzerland. LA - eng PT - Journal Article PL - England TA - Eur Heart J JT - European heart journal JID - 8006263 SB - IM CIN - Eur Heart J. 2022 Aug 1;43(29):2751-2752. doi: 10.1093/eurheartj/ehac131. PMID: 35466365 CIN - Eur Heart J. 2022 Aug 1;43(29):2753-2755. doi: 10.1093/eurheartj/ehac154. PMID: 35466368 MH - Aortic Valve/surgery MH - *Aortic Valve Stenosis/etiology/surgery MH - *Heart Valve Prosthesis MH - *Heart Valve Prosthesis Implantation/adverse effects MH - Humans MH - Risk Factors MH - *Transcatheter Aortic Valve Replacement/adverse effects MH - Treatment Outcome OTO - NOTNLM OT - Lifetime management OT - Surgical aortic valve replacement OT - Transcatheter aortic valve implantation EDAT- 2022/04/26 06:00 MHDA- 2022/08/03 06:00 CRDT- 2022/04/25 06:15 PHST- 2021/10/13 00:00 [received] PHST- 2022/02/22 00:00 [revised] PHST- 2022/02/01 00:00 [accepted] PHST- 2022/04/26 06:00 [pubmed] PHST- 2022/08/03 06:00 [medline] PHST- 2022/04/25 06:15 [entrez] AID - 6572863 [pii] AID - 10.1093/eurheartj/ehac105 [doi] PST - ppublish SO - Eur Heart J. 2022 Aug 1;43(29):2729-2750. doi: 10.1093/eurheartj/ehac105. PMID- 35463150 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220429 IS - 1664-2295 (Print) IS - 1664-2295 (Electronic) IS - 1664-2295 (Linking) VI - 13 DP - 2022 TI - Seven Years of Selective Genetic Screening Program and Follow-Up of Asymptomatic Carriers With Hereditary Transthyretin Amyloidosis in Bulgaria. PG - 844595 LID - 10.3389/fneur.2022.844595 [doi] LID - 844595 AB - Hereditary transthyretin amyloidosis (ATTRv amyloidosis) is a rare, autosomal-dominant (AD) multisystem disorder resulting from the extracellular deposition of amyloid fibrils formed by a destabilized mutant form of transthyretin (TTR), a transport protein predominantly produced by the liver. AIM: The aims of the current study are to demonstrate the Bulgarian experience with the screening programs among the high-risk patient population over the last 7 years, to present the results from the therapy with TTR stabilizer in our cohort, as well as to stress on the importance of a follow-up of asymptomatic carriers with TTR pathogenic variants by a multidisciplinary team of specialists. MATERIALS AND METHODS: In 2014, a screening program among the high-risk patient population for ATTRv was initiated in Bulgaria. On one hand, it was conducted to identify new patients and families among people with "red flag" clinical features, while on the other hand, the program aimed to identify TTR mutation carriers among the families with already genetically proven diagnoses. Sanger sequencing methodology was used to make fast target testing for mutations in the TTR gene in the suspected individuals. All of the identified carriers underwent subsequent evaluation for neurological, cardiac, gastroenterological, and neuro-ophthalmological involvement. Those considered affected were provided with multidisciplinary treatment and a follow-up. RESULTS: As a result of a 7-year selective screening program among the high-risk patient population and relatives of genetically verified affected individuals, 340 carriers of TTR mutations were identified in Bulgaria with the following gene defects: 78.53% with Glu89Gln, 10.29% with Val30Met, 8.24% with Ser77Phe, 2.06% with Gly47Glu, and 0.59% with Ser52Pro. All of these affected displayed a mixed phenotype with variable ages at onset and rate of progression, according to their mutation. From the 150 patients treated with TTR stabilizer, 84 remained stable, while in other 66 patients the treatment was terminated either because of polyneuropathy progression or due to death. A program for a regular follow-up of asymptomatic carriers in the last 3 years enabled us to detect the transition of 39/65 to symptomatic patients and to initiate treatment in a timely manner. CONCLUSION: Bulgarian ATTRv patients display a mixed phenotype with some clinical peculiarities for each mutation that should be considered when treating the affected and the follow-up of the asymptomatic carriers of a specific gene defect. CI - Copyright (c) 2022 Chamova, Gospodinova, Asenov, Todorov, Pavlova, Kirov, Cherninkova, Kastreva, Taneva, Blagoeva, Zhelyazkova, Antimov, Chobanov, Todorova and Tournev. FAU - Chamova, Teodora AU - Chamova T AD - Department of Neurology, Expert Centre for Hereditary Neurologic and Metabolic Disorders, University Hospital "Alexandrovska", Medical University-Sofia, Sofia, Bulgaria. FAU - Gospodinova, Mariana AU - Gospodinova M AD - Expert Center for Transthyretin Cardiac Amyloidosis, University Hospital "St Ivan Rilski", Sofia, Bulgaria. FAU - Asenov, Ognian AU - Asenov O AD - Department of Neurology, Expert Centre for Hereditary Neurologic and Metabolic Disorders, University Hospital "Alexandrovska", Medical University-Sofia, Sofia, Bulgaria. FAU - Todorov, Tihomir AU - Todorov T AD - Independent Medico-Diagnostic Laboratory Genome Center "Bulgaria", Sofia, Bulgaria. AD - Genetic Medico-Diagnostic Laboratory Genica, Sofia, Bulgaria. FAU - Pavlova, Zornitsa AU - Pavlova Z AD - Independent Medico-Diagnostic Laboratory Genome Center "Bulgaria", Sofia, Bulgaria. AD - Genetic Medico-Diagnostic Laboratory Genica, Sofia, Bulgaria. AD - Department of Medical Chemistry and Biochemistry, Medical University Sofia, Sofia, Bulgaria. FAU - Kirov, Andrey AU - Kirov A AD - Independent Medico-Diagnostic Laboratory Genome Center "Bulgaria", Sofia, Bulgaria. AD - Genetic Medico-Diagnostic Laboratory Genica, Sofia, Bulgaria. FAU - Cherninkova, Sylvia AU - Cherninkova S AD - Department of Neurology, Expert Centre for Hereditary Neurologic and Metabolic Disorders, University Hospital "Alexandrovska", Medical University-Sofia, Sofia, Bulgaria. FAU - Kastreva, Kristina AU - Kastreva K AD - Department of Neurology, Expert Centre for Hereditary Neurologic and Metabolic Disorders, University Hospital "Alexandrovska", Medical University-Sofia, Sofia, Bulgaria. FAU - Taneva, Ani AU - Taneva A AD - Department of Neurology, Expert Centre for Hereditary Neurologic and Metabolic Disorders, University Hospital "Alexandrovska", Medical University-Sofia, Sofia, Bulgaria. FAU - Blagoeva, Stanislava AU - Blagoeva S AD - Department of Neurology, Expert Centre for Hereditary Neurologic and Metabolic Disorders, University Hospital "Alexandrovska", Medical University-Sofia, Sofia, Bulgaria. FAU - Zhelyazkova, Sashka AU - Zhelyazkova S AD - Department of Neurology, Expert Centre for Hereditary Neurologic and Metabolic Disorders, University Hospital "Alexandrovska", Medical University-Sofia, Sofia, Bulgaria. FAU - Antimov, Plamen AU - Antimov P AD - Department of Neurology, Expert Centre for Hereditary Neurologic and Metabolic Disorders, University Hospital "Alexandrovska", Medical University-Sofia, Sofia, Bulgaria. FAU - Chobanov, Kaloian AU - Chobanov K AD - Department of Neurology, Expert Centre for Hereditary Neurologic and Metabolic Disorders, University Hospital "Alexandrovska", Medical University-Sofia, Sofia, Bulgaria. FAU - Todorova, Albena AU - Todorova A AD - Independent Medico-Diagnostic Laboratory Genome Center "Bulgaria", Sofia, Bulgaria. AD - Genetic Medico-Diagnostic Laboratory Genica, Sofia, Bulgaria. AD - Department of Medical Chemistry and Biochemistry, Medical University Sofia, Sofia, Bulgaria. FAU - Tournev, Ivailo AU - Tournev I AD - Department of Neurology, Expert Centre for Hereditary Neurologic and Metabolic Disorders, University Hospital "Alexandrovska", Medical University-Sofia, Sofia, Bulgaria. AD - Department of Cognitive Science and Psychology, New Bulgarian University, Sofia, Bulgaria. LA - eng PT - Journal Article DEP - 20220408 PL - Switzerland TA - Front Neurol JT - Frontiers in neurology JID - 101546899 PMC - PMC9024406 OTO - NOTNLM OT - ATTRv OT - asymptomatic carrier OT - follow up OT - phenotype OT - screening COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/04/26 06:00 MHDA- 2022/04/26 06:01 PMCR- 2022/04/08 CRDT- 2022/04/25 05:17 PHST- 2021/12/28 00:00 [received] PHST- 2022/02/28 00:00 [accepted] PHST- 2022/04/25 05:17 [entrez] PHST- 2022/04/26 06:00 [pubmed] PHST- 2022/04/26 06:01 [medline] PHST- 2022/04/08 00:00 [pmc-release] AID - 10.3389/fneur.2022.844595 [doi] PST - epublish SO - Front Neurol. 2022 Apr 8;13:844595. doi: 10.3389/fneur.2022.844595. eCollection 2022. PMID- 35462033 OWN - NLM STAT- MEDLINE DCOM- 20220816 LR - 20251031 IS - 1532-8414 (Electronic) IS - 1071-9164 (Linking) VI - 28 IP - 8 DP - 2022 Aug TI - Health System-Level Performance in Prescribing Guideline-Directed Medical Therapy for Patients With Heart Failure With Reduced Ejection Fraction: Results From the CONNECT-HF Trial. PG - 1355-1361 LID - S1071-9164(22)00489-4 [pii] LID - 10.1016/j.cardfail.2022.03.356 [doi] AB - BACKGROUND: Health system-level interventions to improve use of guideline-directed medical therapy (GDMT) often fail in the acute care setting. We sought to identify factors associated with high performance in adoption of GDMT among health systems in CONNECT-HF. METHODS AND RESULTS: Site-level composite quality scores were calculated at discharge and last follow-up. Site performance was defined as the average change in score from baseline to last follow-up and analyzed by performance tertile using a mixed-effects model with baseline performance as a fixed effect and site as a random effect. Among 150 randomized sites, the mean 12-month improvement in GDMT was 1.8% (-26.4% to 60.0%). Achievement of 50% or more of the target dose for angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, angiotensin receptor-neprilysin inhibitors, and beta-blockers at 12 months was modest, even at the highest performing sites (median 29.6% [23%, 41%] and 41.2% [29%, 50%]). Sites achieving higher GDMT scores had care teams that included social workers and pharmacists, as well as patients who were able to afford medications and access medication lists in the electronic health record. CONCLUSIONS: Substantial gaps in site-level use of GDMT were found, even among the highest performing sites. The failure of hospital-level interventions to improve quality metrics suggests that a team-based approach to care and improved patient access to medications are needed for postdischarge success. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Granger, Bradi B AU - Granger BB AD - Duke Clinical Research Institute, Durham, NC; Duke University School of Nursing, Durham, NC; Duke University School of Medicine, Durham, NC. Electronic address: Bradi.granger@duke.edu. FAU - Kaltenbach, Lisa A AU - Kaltenbach LA AD - Duke Clinical Research Institute, Durham, NC. FAU - Fonarow, Gregg C AU - Fonarow GC AD - Ahmanson-UCLA Cardiomyopathy Center, Los Angeles, CA. FAU - Allen, Larry A AU - Allen LA AD - University of Colorado School of Medicine, Aurora, CO. FAU - Lanfear, David E AU - Lanfear DE AD - Henry Ford Heart and Vascular Institute, Detroit, MI. FAU - Albert, Nancy M AU - Albert NM AD - Cleveland Clinic, Cleveland, OH. FAU - Al-Khalidi, Hussein R AU - Al-Khalidi HR AD - Duke Clinical Research Institute, Durham, NC. FAU - Butler, Javed AU - Butler J AD - University of Mississippi Medical Center, Jackson, MS. FAU - Cooper, Lauren B AU - Cooper LB AD - Inova Heart and Vascular Institute, Falls Church, VA. FAU - Dewald, Tracy AU - Dewald T AD - Department of Medicine, Duke University School of Medicine, Durham, NC. FAU - Felker, G Michael AU - Felker GM AD - Duke Clinical Research Institute, Durham, NC; Duke University School of Medicine, Durham, NC. FAU - Heidenreich, Paul AU - Heidenreich P AD - Stanford University, Palo Alto, CA. FAU - Kottam, Anupama AU - Kottam A AD - Wayne State University and Detroit Medical Center, Detroit, MI. FAU - Lewis, Eldrin F AU - Lewis EF AD - Stanford Healthcare, San Francisco, CA. FAU - Pina, Ileana L AU - Pina IL AD - Wayne State University and Detroit Medical Center, Detroit, MI. FAU - Yancy, Clyde W AU - Yancy CW AD - Northwestern University, Chicago, IL. FAU - Granger, Christopher B AU - Granger CB AD - Duke Clinical Research Institute, Durham, NC; Duke University School of Medicine, Durham, NC. FAU - Hernandez, Adrian F AU - Hernandez AF AD - Duke Clinical Research Institute, Durham, NC; Duke University School of Medicine, Durham, NC. FAU - Devore, Adam D AU - Devore AD AD - Duke Clinical Research Institute, Durham, NC; Duke University School of Medicine, Durham, NC. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220422 PL - United States TA - J Card Fail JT - Journal of cardiac failure JID - 9442138 RN - 0 (Angiotensin Receptor Antagonists) SB - IM MH - Aftercare MH - Angiotensin Receptor Antagonists/pharmacology/therapeutic use MH - *Heart Failure/drug therapy MH - Humans MH - Patient Discharge MH - Stroke Volume OTO - NOTNLM OT - Heart failure OT - care transitions OT - guideline-directed medical therapy OT - implementation science EDAT- 2022/04/25 06:00 MHDA- 2022/08/17 06:00 CRDT- 2022/04/24 20:22 PHST- 2022/02/02 00:00 [received] PHST- 2022/03/10 00:00 [revised] PHST- 2022/03/25 00:00 [accepted] PHST- 2022/04/25 06:00 [pubmed] PHST- 2022/08/17 06:00 [medline] PHST- 2022/04/24 20:22 [entrez] AID - S1071-9164(22)00489-4 [pii] AID - 10.1016/j.cardfail.2022.03.356 [doi] PST - ppublish SO - J Card Fail. 2022 Aug;28(8):1355-1361. doi: 10.1016/j.cardfail.2022.03.356. Epub 2022 Apr 22. PMID- 35460366 OWN - NLM STAT- MEDLINE DCOM- 20220923 LR - 20261029 IS - 1432-1971 (Electronic) IS - 0172-0643 (Linking) VI - 43 IP - 7 DP - 2022 Oct TI - Ebstein's Anomaly: From Fetus to Adult-Literature Review and Pathway for Patient Care. PG - 1409-1428 LID - 10.1007/s00246-022-02908-x [doi] AB - Ebstein's anomaly, first described in 1866 by Dr William Ebstein, accounts for 0.3-0.5% of congenital heart defects and represents 40% of congenital tricuspid valve abnormalities. Ebstein's anomaly affects the development of the tricuspid valve with widely varying morphology and, therefore, clinical presentation. Associated congenital cardiac lesions tend to be found more often in younger patients and may even be the reason for presentation. Presentation can vary from the most extreme form in fetal life, to asymptomatic diagnosis late in adult life. The most symptomatic patients need intensive care support in the neonatal period. This article summarizes and analyzes the literature on Ebstein's anomaly and provides a framework for the investigation, management, and follow-up of these patients, whether they present via fetal detection or late in adult life. For each age group, the clinical presentation, required diagnostic investigations, natural history, and management are described. The surgical options available for patients with Ebstein's anomaly are detailed and analyzed, starting from the initial mono-leaflet repairs to the most recent cone repair and its modifications. The review also assesses the effects of pregnancy on the Ebstein's circulation, and vice versa, the effects of Ebstein's on pregnancy outcomes. Finally, two attached appendices are provided for a structured echocardiogram protocol and key information useful for comprehensive Multi-Disciplinary Team discussion. CI - (c) 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Ramcharan, Tristan K W AU - Ramcharan TKW AUID- ORCID: 0000-0003-0197-0722 AD - Department of Cardiology, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK. tristanramcharan@doctors.org.uk. FAU - Goff, Donna A AU - Goff DA AD - McGovern Medical School, Children's Heart Institute, University of Texas Health, Houston, TX, USA. FAU - Greenleaf, Christopher E AU - Greenleaf CE AD - McGovern Medical School, Children's Heart Institute, University of Texas Health, Houston, TX, USA. FAU - Shebani, Suhair O AU - Shebani SO AD - East Midlands Congenital Heart Centre, Glenfield Hospital, University Hospitals of Leicester, Leicester, UK. FAU - Salazar, Jorge D AU - Salazar JD AD - McGovern Medical School, Children's Heart Institute, University of Texas Health, Houston, TX, USA. FAU - Corno, Antonio F AU - Corno AF AD - McGovern Medical School, Children's Heart Institute, University of Texas Health, Houston, TX, USA. LA - eng PT - Journal Article PT - Review DEP - 20220423 PL - United States TA - Pediatr Cardiol JT - Pediatric cardiology JID - 8003849 SB - IM MH - Adult MH - *Ebstein Anomaly/diagnostic imaging/surgery MH - Echocardiography MH - Fetus MH - *Heart Defects, Congenital/diagnostic imaging/therapy MH - Humans MH - Infant, Newborn MH - Patient Care MH - Tricuspid Valve/diagnostic imaging OTO - NOTNLM OT - Cone procedure OT - Ebstein's anomaly OT - Tricuspid valve EDAT- 2022/04/24 06:00 MHDA- 2022/09/24 06:00 CRDT- 2022/04/23 12:01 PHST- 2022/01/17 00:00 [received] PHST- 2022/04/04 00:00 [accepted] PHST- 2022/04/24 06:00 [pubmed] PHST- 2022/09/24 06:00 [medline] PHST- 2022/04/23 12:01 [entrez] AID - 10.1007/s00246-022-02908-x [pii] AID - 10.1007/s00246-022-02908-x [doi] PST - ppublish SO - Pediatr Cardiol. 2022 Oct;43(7):1409-1428. doi: 10.1007/s00246-022-02908-x. Epub 2022 Apr 23. PMID- 35460200 OWN - NLM STAT- MEDLINE DCOM- 20220719 LR - 20250728 IS - 2055-5822 (Electronic) IS - 2055-5822 (Linking) VI - 9 IP - 4 DP - 2022 Aug TI - Comparing short-term/long-term outcomes of heart transplants that occur inside and outside of normal working hours. PG - 2484-2490 LID - 10.1002/ehf2.13947 [doi] AB - AIMS: Heart transplantation involves many factors such as donor selection, recipient management, multidisciplinary assessment, coordination with other organ teams, and transportation. Because of some unpredictable factors, heart transplantation can be conducted at any time of day. The purpose of this study is to investigate if outcomes differ between heart transplants taking place inside or outside of normal working hours. METHODS AND RESULTS: We reviewed patients who underwent heart transplantation at our institution from January 2010 to July 2020 (n = 329). Based on the documented start time of the recipient surgeries, the cohort was divided into two groups: working hours (Group A: 7:30 to 17:00; n = 92) and after hours (Group B: 17:00 to 7:30; n = 237). We compared these groups using propensity score matching analysis. After propensity score matching, 78 pairs of patients were successfully matched. We reviewed early and late clinical outcomes including survival. Long-term survival was compared using the Kaplan-Meier method. In the propensity-score matched patients, there were no significant differences in the baseline characteristics between two groups. In-hospital mortality was not significantly different between the two groups (Group A: 6.4% vs. Group B: 2.6%, P = 0.44). Ischaemic time and cross-clamp time did not differ between the groups. In terms of postoperative complications, there were no significant differences between two groups in stroke (6.4% vs. 3.9%, P = 0.72), primary graft dysfunction requiring extracorporeal membrane oxygenation (5.1% vs. 7.7%, P = 0.75), re-exploration for bleeding (9.0% vs. 12.8%, P = 0.44), and newly required haemodialysis (7.7% vs. 6.4%, P = 0.75). The survival rate in Group A (88.1% at 1 year, 81.3% at 3 years) was not significantly different from Group B (90.5% at 1 year, 82.3% at 3 years, log rank = 0.96). CONCLUSION: There was no significant difference in clinical outcomes between heart transplants taking place inside or outside of working hours. A high quality of care can be provided for heart transplant patients even during after hours. CI - (c) 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. FAU - Nishida, Hidefumi AU - Nishida H AD - Department of Surgery, The University of Chicago Medicine, Chicago, IL, USA. FAU - Salerno, Christopher AU - Salerno C AD - Department of Surgery, The University of Chicago Medicine, Chicago, IL, USA. FAU - Onsager, David AU - Onsager D AD - Department of Surgery, The University of Chicago Medicine, Chicago, IL, USA. FAU - Song, Tae AU - Song T AD - Department of Surgery, The University of Chicago Medicine, Chicago, IL, USA. FAU - Nguyen, Ann AU - Nguyen A AD - Department of Medicine, The University of Chicago Medicine, Chicago, IL, USA. FAU - Grinstein, Jonathan AU - Grinstein J AD - Department of Medicine, The University of Chicago Medicine, Chicago, IL, USA. FAU - Chung, Bow AU - Chung B AD - Department of Medicine, The University of Chicago Medicine, Chicago, IL, USA. FAU - Smith, Bryan AU - Smith B AD - Department of Medicine, The University of Chicago Medicine, Chicago, IL, USA. FAU - Kalantari, Sara AU - Kalantari S AD - Department of Medicine, The University of Chicago Medicine, Chicago, IL, USA. FAU - Sarswat, Nitasha AU - Sarswat N AD - Department of Medicine, The University of Chicago Medicine, Chicago, IL, USA. FAU - Kim, Gene AU - Kim G AD - Department of Medicine, The University of Chicago Medicine, Chicago, IL, USA. FAU - Pinney, Sean AU - Pinney S AD - Department of Medicine, The University of Chicago Medicine, Chicago, IL, USA. FAU - Jeevanandam, Valluvan AU - Jeevanandam V AD - Department of Surgery, The University of Chicago Medicine, Chicago, IL, USA. FAU - Ota, Takeyoshi AU - Ota T AD - Department of Surgery, The University of Chicago Medicine, Chicago, IL, USA. LA - eng PT - Journal Article PT - Review DEP - 20220423 PL - England TA - ESC Heart Fail JT - ESC heart failure JID - 101669191 SB - IM MH - Cohort Studies MH - Extracorporeal Membrane Oxygenation MH - *Heart Transplantation/methods MH - Humans MH - *Personnel Staffing and Scheduling MH - Postoperative Complications/epidemiology MH - Retrospective Studies PMC - PMC9288785 OTO - NOTNLM OT - Circadian rhythm OT - Heart OT - Outcome OT - Transplantation OT - Working hours COIS- None declared. EDAT- 2022/04/24 06:00 MHDA- 2022/07/20 06:00 PMCR- 2022/04/23 CRDT- 2022/04/23 05:26 PHST- 2022/03/10 00:00 [revised] PHST- 2022/01/07 00:00 [received] PHST- 2022/04/06 00:00 [accepted] PHST- 2022/04/24 06:00 [pubmed] PHST- 2022/07/20 06:00 [medline] PHST- 2022/04/23 05:26 [entrez] PHST- 2022/04/23 00:00 [pmc-release] AID - EHF213947 [pii] AID - 10.1002/ehf2.13947 [doi] PST - ppublish SO - ESC Heart Fail. 2022 Aug;9(4):2484-2490. doi: 10.1002/ehf2.13947. Epub 2022 Apr 23. PMID- 35456164 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230308 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 11 IP - 8 DP - 2022 Apr 7 TI - Chest Compression-Related Flail Chest Is Associated with Prolonged Ventilator Weaning in Cardiac Arrest Survivors. LID - 10.3390/jcm11082071 [doi] LID - 2071 AB - Chest compressions during cardiopulmonary resuscitation (CPR) may be associated with iatrogenic chest wall injuries. The extent to which these CPR-associated chest wall injuries contribute to a delay in the respiratory recovery of cardiac arrest survivors has not been sufficiently explored. In a single-center retrospective cohort study, surviving intensive care unit (ICU) patients, who had undergone CPR due to medical reasons between 1 January 2018 and 30 June 2019, were analyzed regarding CPR-associated chest wall injuries, detected by chest radiography and computed tomography. Among 109 included patients, 38 (34.8%) presented with chest wall injuries, including 10 (9.2%) with flail chest. The multivariable logistic regression analysis identified flail chest to be independently associated with the need for tracheostomy (OR 15.5; 95% CI 2.77-86.27; p = 0.002). The linear regression analysis identified pneumonia (beta 11.34; 95% CI 6.70-15.99; p < 0.001) and the presence of rib fractures (beta 5.97; 95% CI 1.01-10.93; p = 0.019) to be associated with an increase in the length of ICU stay, whereas flail chest (beta 10.45; 95% CI 3.57-17.33; p = 0.003) and pneumonia (beta 6.12; 95% CI 0.94-11.31; p = 0.021) were associated with a prolonged duration of mechanical ventilation. Four patients with flail chest underwent surgical rib stabilization and were successfully weaned from the ventilator. The results of this study suggest that CPR-associated chest wall injuries, flail chest in particular, may impair the respiratory recovery of cardiac arrest survivors in the ICU. A multidisciplinary assessment may help to identify patients who could benefit from a surgical treatment approach. FAU - Kunz, Kevin AU - Kunz K AD - Medical Intensive Care Unit, University Hospital Leipzig, 04103 Leipzig, Germany. FAU - Petros, Sirak AU - Petros S AUID- ORCID: 0000-0002-2345-756X AD - Medical Intensive Care Unit, University Hospital Leipzig, 04103 Leipzig, Germany. FAU - Ewens, Sebastian AU - Ewens S AD - Department of Diagnostic and Interventional Radiology, University Hospital Leipzig, 04103 Leipzig, Germany. FAU - Yahiaoui-Doktor, Maryam AU - Yahiaoui-Doktor M AUID- ORCID: 0000-0002-3321-1598 AD - Medical Faculty, Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, 04107 Leipzig, Germany. FAU - Denecke, Timm AU - Denecke T AD - Department of Diagnostic and Interventional Radiology, University Hospital Leipzig, 04103 Leipzig, Germany. FAU - Struck, Manuel Florian AU - Struck MF AUID- ORCID: 0000-0002-0070-3406 AD - Department of Anesthesiology and Intensive Care Medicine, University Hospital Leipzig, 04103 Leipzig, Germany. FAU - Kramer, Sebastian AU - Kramer S AUID- ORCID: 0000-0003-4867-8884 AD - Department of Visceral, Transplant, Thoracic and Vascular Surgery, Division of Thoracic Surgery, University Hospital Leipzig, 04103 Leipzig, Germany. LA - eng PT - Journal Article DEP - 20220407 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC9024943 OTO - NOTNLM OT - cardiopulmonary resuscitation OT - chest wall injury OT - flail chest OT - surgical rib stabilization OT - ventilator weaning COIS- The authors declare no conflict of interest. EDAT- 2022/04/24 06:00 MHDA- 2022/04/24 06:01 PMCR- 2022/04/07 CRDT- 2022/04/23 01:08 PHST- 2022/03/10 00:00 [received] PHST- 2022/03/24 00:00 [revised] PHST- 2022/04/04 00:00 [accepted] PHST- 2022/04/23 01:08 [entrez] PHST- 2022/04/24 06:00 [pubmed] PHST- 2022/04/24 06:01 [medline] PHST- 2022/04/07 00:00 [pmc-release] AID - jcm11082071 [pii] AID - jcm-11-02071 [pii] AID - 10.3390/jcm11082071 [doi] PST - epublish SO - J Clin Med. 2022 Apr 7;11(8):2071. doi: 10.3390/jcm11082071. PMID- 35454315 OWN - NLM STAT- MEDLINE DCOM- 20220426 LR - 20250103 IS - 1648-9144 (Electronic) IS - 1010-660X (Print) IS - 1010-660X (Linking) VI - 58 IP - 4 DP - 2022 Mar 25 TI - Pregnancy in Congenital Heart Disease, Complicated by Pulmonary Arterial Hypertension-A Challenging Issue for the Pregnant Woman, the Foetus, and Healthcare Professionals. LID - 10.3390/medicina58040476 [doi] LID - 476 AB - Background and Objectives: Pregnancy and delivery in patients with congenital heart disease (CHD) and pulmonary arterial hypertension (PAH) carry a very high risk for maternal and foetal complications and are contraindicated according to the guidelines. In the last decades, when an available modern PAH-targeted medication therapy and a new management concept improved patients' well-being and survival, some PAH-CHD females decided to conceive. Of note, despite advanced treatment and modern healthcare system possibilities, dealing with pregnancy in a diverse PAH-CHD population is still challenging. The study aimed to share our experience with PAH-CHD pregnancies and discuss the risk assessment and current management of these patients with the combination of two rare diseases. Materials and Methods: The retrospective search of pulmonary hypertension and adult CHD registries in our hospital was performed, selecting all patients with CHD and PAH who conceived pregnancy from 2013 to 2021. Baseline demographic, clinical, and functional characteristics and clinical outcomes were collected. Results: Thirteen pregnancies in eight patients with PAH-CHD resulted in seven live births, three miscarriages, and three terminations. Five women were diagnosed with Eisenmenger syndrome (ES) and three with residual PAH after CHD repair. Before pregnancy, half of them were in WHO functional class III. Seven (87.5%) patients received targeted PAH treatment with sildenafil during pregnancy. In addition, the two most severe cases were administered with iloprost during peripartum. Three ES patients delivered preterm by Caesarean section under general anaesthesia. No neonatal mortality was reported. Maternal complications were observed in half of our cases. One patient died 12 days after the delivery in another hospital due to deterioration of heart failure. Conclusions: On the basis of our clinical experience, we conclude that pregnancy and delivery carry a high risk for maternal complications and should be avoided in women with PAH-CHD. The individualised approach of multidisciplinary care and appropriate monitoring are mandatory in reducing the risk of adverse outcomes. FAU - Rudiene, Virginija AU - Rudiene V AD - Clinic of Cardiac and Vascular Diseases, Faculty of Medicine, Institute of Clinical Medicine, Vilnius University, LT-08661 Vilnius, Lithuania. AD - Faculty of Medicine, Vilnius University, LT-03101 Vilnius, Lithuania. FAU - Kapleriene, Lina AU - Kapleriene L AD - Clinic of Cardiac and Vascular Diseases, Faculty of Medicine, Institute of Clinical Medicine, Vilnius University, LT-08661 Vilnius, Lithuania. AD - Faculty of Medicine, Vilnius University, LT-03101 Vilnius, Lithuania. FAU - Jancauskaite, Dovile AU - Jancauskaite D AD - Clinic of Cardiac and Vascular Diseases, Faculty of Medicine, Institute of Clinical Medicine, Vilnius University, LT-08661 Vilnius, Lithuania. AD - Faculty of Medicine, Vilnius University, LT-03101 Vilnius, Lithuania. FAU - Meskene, Emilija AU - Meskene E AD - Clinic of Cardiac and Vascular Diseases, Faculty of Medicine, Institute of Clinical Medicine, Vilnius University, LT-08661 Vilnius, Lithuania. AD - Faculty of Medicine, Vilnius University, LT-03101 Vilnius, Lithuania. FAU - Paleviciute, Egle AU - Paleviciute E AD - Clinic of Cardiac and Vascular Diseases, Faculty of Medicine, Institute of Clinical Medicine, Vilnius University, LT-08661 Vilnius, Lithuania. AD - Faculty of Medicine, Vilnius University, LT-03101 Vilnius, Lithuania. FAU - Laukyte-Sleniene, Monika AU - Laukyte-Sleniene M AD - Clinic of Cardiac and Vascular Diseases, Faculty of Medicine, Institute of Clinical Medicine, Vilnius University, LT-08661 Vilnius, Lithuania. FAU - Gasiunaite, Diana AU - Gasiunaite D AD - Centre of Anaesthesiology, Intensive Therapy and Pain Management, Faculty of Medicine, Vilnius University, LT-08661 Vilnius, Lithuania. FAU - Ramasauskaite, Diana AU - Ramasauskaite D AD - Faculty of Medicine, Vilnius University, LT-03101 Vilnius, Lithuania. AD - Centre of Obstetrics and Gynaecology, Faculty of Medicine, Vilnius University, LT-08661 Vilnius, Lithuania. FAU - Jureviciene, Elena AU - Jureviciene E AUID- ORCID: 0000-0003-4331-5179 AD - Faculty of Medicine, Vilnius University, LT-03101 Vilnius, Lithuania. AD - Centre of Pulmonology and Allergology, Faculty of Medicine, Vilnius University, LT-08661 Vilnius, Lithuania. FAU - Gumbiene, Lina AU - Gumbiene L AD - Clinic of Cardiac and Vascular Diseases, Faculty of Medicine, Institute of Clinical Medicine, Vilnius University, LT-08661 Vilnius, Lithuania. AD - Faculty of Medicine, Vilnius University, LT-03101 Vilnius, Lithuania. AD - Centre of Heart and Chest Surgery, Faculty of Medicine, Vilnius University, LT-08661 Vilnius, Lithuania. LA - eng PT - Journal Article DEP - 20220325 PL - Switzerland TA - Medicina (Kaunas) JT - Medicina (Kaunas, Lithuania) JID - 9425208 SB - IM MH - *Abortion, Spontaneous MH - Adult MH - Cesarean Section/methods MH - Delivery of Health Care MH - *Eisenmenger Complex/complications MH - Familial Primary Pulmonary Hypertension/complications MH - Female MH - Fetus MH - *Heart Defects, Congenital/diagnosis MH - Humans MH - Infant, Newborn MH - Pregnancy MH - Pregnant People MH - *Pulmonary Arterial Hypertension/complications/drug therapy MH - Retrospective Studies PMC - PMC9033133 OTO - NOTNLM OT - congenital heart disease OT - multidisciplinary team OT - pregnancy OT - pulmonary arterial hypertension OT - rare diseases COIS- The authors have declared that no competing interests exist. EDAT- 2022/04/24 06:00 MHDA- 2022/04/27 06:00 PMCR- 2022/03/25 CRDT- 2022/04/23 01:03 PHST- 2022/01/31 00:00 [received] PHST- 2022/03/09 00:00 [revised] PHST- 2022/03/23 00:00 [accepted] PHST- 2022/04/23 01:03 [entrez] PHST- 2022/04/24 06:00 [pubmed] PHST- 2022/04/27 06:00 [medline] PHST- 2022/03/25 00:00 [pmc-release] AID - medicina58040476 [pii] AID - medicina-58-00476 [pii] AID - 10.3390/medicina58040476 [doi] PST - epublish SO - Medicina (Kaunas). 2022 Mar 25;58(4):476. doi: 10.3390/medicina58040476. PMID- 39713547 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250104 IS - 2666-6685 (Electronic) IS - 2666-6685 (Linking) VI - 9 DP - 2022 Sep TI - Development of delivery plans for pregnant women with complex heart disease. PG - 100375 LID - 10.1016/j.ijcchd.2022.100375 [doi] LID - 100375 AB - The population of pregnant patients with complex cardiac disorders is increasing. The overarching goal of guidelines and best practices revolve around optimal patient outcome and experience. This is achieved through collaborative practice models focused on the goal of the management of these high-risk patients. A coordinated multidisciplinary delivery plan is a centerfold of this iterative collaborative team approach to safe pregnancy care of the pregnant person and her neonate. Here, we provide an overview of how the delivery plan is developed and integrated into the clinical management of pregnant women with complex cardiac disease. CI - (c) 2022 Published by Elsevier B.V. FAU - Canobbio, Mary M AU - Canobbio MM AD - UCLA Ahmanson Adult Congenital Heart Center, UCLA School of Nursing. Los Angeles, CA, USA. FAU - Afshar, Yalda AU - Afshar Y AD - Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, David Geffen, UCLA School of Medicine, USA. LA - eng PT - Journal Article PT - Review DEP - 20220423 PL - Netherlands TA - Int J Cardiol Congenit Heart Dis JT - International journal of cardiology. Congenital heart disease JID - 9918367981006676 PMC - PMC11657793 OTO - NOTNLM OT - Cardiac disease OT - Cardio-obstetrics OT - Congenital heart disease OT - Delivery plan OT - Pregnancy COIS- The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2022/04/23 00:00 MHDA- 2022/04/23 00:01 PMCR- 2022/04/23 CRDT- 2024/12/23 06:25 PHST- 2021/07/01 00:00 [received] PHST- 2022/04/10 00:00 [accepted] PHST- 2022/04/23 00:01 [medline] PHST- 2022/04/23 00:00 [pubmed] PHST- 2024/12/23 06:25 [entrez] PHST- 2022/04/23 00:00 [pmc-release] AID - S2666-6685(22)00058-1 [pii] AID - 100375 [pii] AID - 10.1016/j.ijcchd.2022.100375 [doi] PST - epublish SO - Int J Cardiol Congenit Heart Dis. 2022 Apr 23;9:100375. doi: 10.1016/j.ijcchd.2022.100375. eCollection 2022 Sep. PMID- 35450810 OWN - NLM STAT- MEDLINE DCOM- 20220928 LR - 20220928 IS - 1878-0938 (Electronic) IS - 1878-0938 (Linking) VI - 43 DP - 2022 Oct TI - A Heart Team Approach to Assessing Frailty in the Cardiac Catheterization Laboratory. PG - 38-42 LID - S1553-8389(22)00174-9 [pii] LID - 10.1016/j.carrev.2022.04.001 [doi] AB - INTRODUCTION: Frailty is a well-documented risk factor for increased morbidity and mortality among patients undergoing percutaneous coronary intervention (PCI). There remains a lack of knowledge regarding the impact of patient frailty in cardiac patient management and outcomes. Thus, this study examined whether the Heart Team, without using frailty assessments, made decisions regarding coronary interventions [medical management (MM) vs. PCI vs. coronary artery bypass grafting (CABG)] that aligned with formally quantified frailty status. MATERIAL AND METHODS: This cross-sectional quality-improvement (QI) study was performed at a single, large, urban Veterans Affairs Hospital. From September 2019 to November 2020, heart team nurses approached patients prior to coronary angiograms and assessed for frailty using the Risk Analysis Index Questionnaire (RAIC). Interventional cardiologists were blinded to the results. This study's independent variable was RAI-C score. The outcome variables were "intervention performed" (MM, PCI, or CABG) and presence of a "reduced invasiveness intervention" (RI). RESULTS: Ninety-five of the 182 participants had obstructive coronary artery disease. Among them, there were 69 PCIs, 10 CABGs, and 16 MMs. 26 received RIs. The primary outcomes demonstrated that frailty score was positively associated with receiving RI [adjusted OR = 1.13, 95% CI = 1.02-1.24, p = 0.02] and MM [adjusted OR = 1.13, CI = 1.02-1.25, p = 0.02], and negatively associated with receiving PCI [adjusted OR = 0.94, CI = 0.88-0.998, p = 0.04]. There was no significant association between frailty and the likelihood of undergoing CABG [AOR = 0.95, CI = 0.81-1.10, p = 0.47]. CONCLUSION: This study demonstrated that the Heart Team and patients at baseline reduced high-risk interventions in frailer patients. A Heart Team, shared-decision-making model utilizing the RAI-C was found to be efficient and effective at measuring frailty in coronary angiogram patients and should be considered for use in the clinical setting. CI - Published by Elsevier Inc. FAU - Bricknell, Ryan A T AU - Bricknell RAT AD - Division of Cardiology, University of Illinois at Chicago, Chicago, IL, United States of America. FAU - Schwarzman, Logan S AU - Schwarzman LS AD - Division of Cardiology, University of Illinois at Chicago, Chicago, IL, United States of America. FAU - Taylor, Jeffrey AU - Taylor J AD - Division of Cardiology, University of Illinois at Chicago, Chicago, IL, United States of America. FAU - Soltes, Tiago AU - Soltes T AD - Jesse Brown Veterans Affairs Medical Center, Chicago, IL, United States of America. FAU - Vidovich, Mladen I AU - Vidovich MI AD - Division of Cardiology, University of Illinois at Chicago, Chicago, IL, United States of America; Jesse Brown Veterans Affairs Medical Center, Chicago, IL, United States of America. Electronic address: miv@uic.edu. LA - eng PT - Journal Article DEP - 20220409 PL - United States TA - Cardiovasc Revasc Med JT - Cardiovascular revascularization medicine : including molecular interventions JID - 101238551 SB - IM MH - Cardiac Catheterization/adverse effects MH - Coronary Artery Bypass/adverse effects MH - *Coronary Artery Disease/diagnostic imaging/etiology/therapy MH - Cross-Sectional Studies MH - *Frailty/diagnosis MH - Humans MH - *Percutaneous Coronary Intervention MH - Risk Factors MH - Treatment Outcome OTO - NOTNLM OT - Frailty OT - Heart team OT - Percutaneous coronary intervention COIS- Declaration of competing interest MV-Research grant, Boston Scientific. Royalty payments, Merit Medical. RB, LS, JT, TS - None. EDAT- 2022/04/23 06:00 MHDA- 2022/09/28 06:00 CRDT- 2022/04/22 07:03 PHST- 2022/01/04 00:00 [received] PHST- 2022/04/02 00:00 [revised] PHST- 2022/04/05 00:00 [accepted] PHST- 2022/04/23 06:00 [pubmed] PHST- 2022/09/28 06:00 [medline] PHST- 2022/04/22 07:03 [entrez] AID - S1553-8389(22)00174-9 [pii] AID - 10.1016/j.carrev.2022.04.001 [doi] PST - ppublish SO - Cardiovasc Revasc Med. 2022 Oct;43:38-42. doi: 10.1016/j.carrev.2022.04.001. Epub 2022 Apr 9. PMID- 35450510 OWN - NLM STAT- MEDLINE DCOM- 20220602 LR - 20250728 IS - 1744-8328 (Electronic) IS - 1473-7140 (Linking) VI - 22 IP - 5 DP - 2022 May TI - Unmet needs in the management of unresectable stage III non-small cell lung cancer: a review after the 'radio talk' webinars. PG - 549-559 LID - 10.1080/14737140.2022.2069098 [doi] AB - INTRODUCTION: Stage III non-small cell lung cancer (NSCLC) is a variable entity, encompassing bulky primary tumors, nodal involvement, or both. Multidisciplinary evaluation is essential to discuss multiple treatment options, to outline optimal management, and to examine the main debated topics and critical issues not addressed by current trials and guidelines that influence daily clinical practice. AREAS COVERED: From March to 5 May 2021 ,meetings were scheduled in a webinar format titled 'Radio Talk' due to the COVID-19 pandemic; the faculty was composed of 6 radiation oncologists from 6 different Institutions of Italy, all of them were the referring radiation oncologist for lung cancer treatment at their respective departments and were or had been members of AIRO (Italian Association of Radiation Oncology) Thoracic Oncology Study Group. The topics covered included: pulmonary toxicity, cardiac toxicity, radiotherapy dose, fractionation and volumes, unfit/elderly patients, multidisciplinary management. EXPERT OPINION: The debate was focused on the unmet needs triggered by case reports, personal experiences and questions; the answers were often not univocal; however, the exchange of opinion and the contribution of different centers confirmed the role of multidisciplinary management and the necessity that the most critical issues should be investigated in clinical trials. FAU - Borghetti, Paolo AU - Borghetti P AD - Department of Radiation Oncology, University and Spedali Civili Hospital, Piazzale Spedali Civili 1, 25123, Brescia, Italy. FAU - Guerini, Andrea Emanuele AU - Guerini AE AD - Department of Radiation Oncology, University and Spedali Civili Hospital, Piazzale Spedali Civili 1, 25123, Brescia, Italy. FAU - Sangalli, Claudia AU - Sangalli C AD - Department of Radiation Oncology 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. FAU - Piperno, Gaia AU - Piperno G AD - Division of Radiotherapy, IEO European Institute of Oncology IRCCS, Milan, Italy. FAU - Franceschini, Davide AU - Franceschini D AD - Department of Radiotherapy and Radiosurgery, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. FAU - La Mattina, Salvatore AU - La Mattina S AD - Department of Radiation Oncology, University and Spedali Civili Hospital, Piazzale Spedali Civili 1, 25123, Brescia, Italy. FAU - Arcangeli, Stefano AU - Arcangeli S AD - Department of Radiation Oncology, School of Medicine and Surgery, University of Milan Bicocca, Milan, Italy. FAU - Filippi, Andrea Riccardo AU - Filippi AR AD - Department of Radiation Oncology, Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20220425 PL - England TA - Expert Rev Anticancer Ther JT - Expert review of anticancer therapy JID - 101123358 SB - IM MH - Aged MH - *COVID-19 MH - *Carcinoma, Non-Small-Cell Lung/pathology/radiotherapy MH - Humans MH - *Lung Neoplasms/pathology/radiotherapy MH - Neoplasm Staging MH - Pandemics MH - Radiation Oncologists OTO - NOTNLM OT - Chemo-radiotherapy OT - immunotherapy OT - lung cancer OT - multidisciplinary evaluation OT - patient management OT - stage III NSCLC EDAT- 2022/04/23 06:00 MHDA- 2022/06/03 06:00 CRDT- 2022/04/22 07:01 PHST- 2022/04/23 06:00 [pubmed] PHST- 2022/06/03 06:00 [medline] PHST- 2022/04/22 07:01 [entrez] AID - 10.1080/14737140.2022.2069098 [doi] PST - ppublish SO - Expert Rev Anticancer Ther. 2022 May;22(5):549-559. doi: 10.1080/14737140.2022.2069098. Epub 2022 Apr 25. PMID- 35447745 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220716 IS - 2254-9625 (Electronic) IS - 2174-8144 (Print) IS - 2174-8144 (Linking) VI - 12 IP - 4 DP - 2022 Mar 27 TI - The Contribution of Exercise in Telemedicine Monitoring in Reducing the Modifiable Factors of Hypertension-A Multidisciplinary Approach. PG - 363-386 LID - 10.3390/ejihpe12040027 [doi] AB - The aim of this review was to explore the contribution of physical activity and exercise in the control and reduction of modifiable factors of arterial hypertension in telemedicine programs, assuming a multidisciplinary perspective. Searches were carried out following the PRISMA guidelines (Preferred Reporting Items for Systematic Reviews and Meta-analyses), and the research question defined using the PICOS approach (Population, Intervention, Comparator, Outcomes, Study design). The search strategy applied the following terms: blood pressure OR hypertension AND exercise OR physical activity AND telemedicine. The initial search identified 2190 records, but only 19 studies were considered eligible after checking for the inclusion and exclusion criteria. The following training variables were generally included: heart rate and heart rate reserve, respiratory rate, rate of perceived exertion and oxygen consumption, but no resistance training variables were found. The significant improvements on blood pressure parameters of participants diagnosed with hypertension tended to be transient. The exercise prescription was commonly based on general instructions and recommendations for exercise and hypertension. On the other hand, most of the studies including patients in cardiac rehabilitation programs used a personalized training program based on a baseline assessment, particularly following a cardiopulmonary exercise test. The inclusion of exercise professionals in multidisciplinary teams could provide a more person-oriented approach and the long-term maintenance of a healthy lifestyle. FAU - Viana, Silvane AU - Viana S AUID- ORCID: 0000-0001-8861-3095 AD - School of Education and Social Sciences, Polytechnic of Leiria, 2411 Leiria, Portugal. FAU - Salvador, Rogerio AU - Salvador R AD - School of Education and Social Sciences, Polytechnic of Leiria, 2411 Leiria, Portugal. AD - Life Quality Research Centre (CIEQV), 2411 Leiria, Portugal. FAU - Morouco, Pedro AU - Morouco P AUID- ORCID: 0000-0002-5956-9790 AD - School of Education and Social Sciences, Polytechnic of Leiria, 2411 Leiria, Portugal. AD - Center for Innovative Care and Health Technology (ciTechCare), Polytechnic of Leiria, 2411 Leiria, Portugal. FAU - Rebelo-Goncalves, Ricardo AU - Rebelo-Goncalves R AUID- ORCID: 0000-0003-0441-4668 AD - School of Education and Social Sciences, Polytechnic of Leiria, 2411 Leiria, Portugal. AD - Life Quality Research Centre (CIEQV), 2411 Leiria, Portugal. AD - Research Unit for Sport and Physical Activity (CIDAF-uid/dtp04213/2020), University of Coimbra, 3040 Coimbra, Portugal. LA - eng PT - Journal Article PT - Review DEP - 20220327 PL - Switzerland TA - Eur J Investig Health Psychol Educ JT - European journal of investigation in health, psychology and education JID - 101751466 PMC - PMC9028822 OTO - NOTNLM OT - blood pressure OT - e-health OT - home-based OT - physical activity OT - training COIS- The authors declare no conflict of interest. EDAT- 2022/04/22 06:00 MHDA- 2022/04/22 06:01 PMCR- 2022/03/27 CRDT- 2022/04/21 20:18 PHST- 2022/03/10 00:00 [received] PHST- 2022/03/21 00:00 [revised] PHST- 2022/03/24 00:00 [accepted] PHST- 2022/04/21 20:18 [entrez] PHST- 2022/04/22 06:00 [pubmed] PHST- 2022/04/22 06:01 [medline] PHST- 2022/03/27 00:00 [pmc-release] AID - ejihpe12040027 [pii] AID - ejihpe-12-00027 [pii] AID - 10.3390/ejihpe12040027 [doi] PST - epublish SO - Eur J Investig Health Psychol Educ. 2022 Mar 27;12(4):363-386. doi: 10.3390/ejihpe12040027. PMID- 35445896 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220716 IS - 2365-6271 (Electronic) IS - 2365-6271 (Linking) VI - 8 IP - 1 DP - 2022 Apr 21 TI - Clinical 3D modeling to guide pediatric cardiothoracic surgery and intervention using 3D printed anatomic models, computer aided design and virtual reality. PG - 11 LID - 10.1186/s41205-022-00137-9 [doi] LID - 11 AB - BACKGROUND: Surgical and catheter-based interventions for congenital heart disease require precise understanding of complex anatomy. The use of three-dimensional (3D) printing and virtual reality to enhance visuospatial understanding has been well documented, but integration of these methods into routine clinical practice has not been well described. We review the growth and development of a clinical 3D modeling service to inform procedural planning within a high-volume pediatric heart center. METHODS: Clinical 3D modeling was performed using cardiac magnetic resonance (CMR) or computed tomography (CT) derived data. Image segmentation and post-processing was performed using FDA-approved software. Patient-specific anatomy was visualized using 3D printed models, digital flat screen models and virtual reality. Surgical repair options were digitally designed using proprietary and open-source computer aided design (CAD) based modeling tools. RESULTS: From 2018 to 2020 there were 112 individual 3D modeling cases performed, 16 for educational purposes and 96 clinically utilized for procedural planning. Over the 3-year period, demand for clinical modeling tripled and in 2020, 3D modeling was requested in more than one-quarter of STAT category 3, 4 and 5 cases. The most common indications for modeling were complex biventricular repair (n = 30, 31%) and repair of multiple ventricular septal defects (VSD) (n = 11, 12%). CONCLUSIONS: Using a multidisciplinary approach, clinical application of 3D modeling can be seamlessly integrated into pre-procedural care for patients with congenital heart disease. Rapid expansion and increased demand for utilization of these tools within a high-volume center demonstrate the high value conferred on these techniques by surgeons and interventionalists alike. CI - (c) 2022. The Author(s). FAU - Ghosh, Reena M AU - Ghosh RM AD - Division of Pediatric Cardiology, Children's Hospital of Philadelphia, 3401 Civic Center Blvd, Philadelphia, 19104, PA, USA. reena.maria@gmail.com. FAU - Jolley, Matthew A AU - Jolley MA AD - Division of Pediatric Cardiology, Children's Hospital of Philadelphia, 3401 Civic Center Blvd, Philadelphia, 19104, PA, USA. AD - Department of Anesthesia and Critical Care, Children's Hospital of Philadelphia, Philadelphia, PA, USA. FAU - Mascio, Christopher E AU - Mascio CE AD - Division of Cardiothoracic Surgery, Children's Hospital of Philadelphia, Philadelphia, PA, USA. AD - Division of Cardiovascular and Thoracic Surgery, West Virginia University School of Medicine, Morgantown, WV, USA. FAU - Chen, Jonathan M AU - Chen JM AD - Division of Cardiothoracic Surgery, Children's Hospital of Philadelphia, Philadelphia, PA, USA. FAU - Fuller, Stephanie AU - Fuller S AD - Division of Cardiothoracic Surgery, Children's Hospital of Philadelphia, Philadelphia, PA, USA. FAU - Rome, Jonathan J AU - Rome JJ AD - Division of Pediatric Cardiology, Children's Hospital of Philadelphia, 3401 Civic Center Blvd, Philadelphia, 19104, PA, USA. FAU - Silvestro, Elizabeth AU - Silvestro E AD - Department of Radiology, Children's Hospital of Philadelphia, Philadelphia, PA, USA. FAU - Whitehead, Kevin K AU - Whitehead KK AD - Division of Pediatric Cardiology, Children's Hospital of Philadelphia, 3401 Civic Center Blvd, Philadelphia, 19104, PA, USA. LA - eng GR - R01 HL153166/HL/NHLBI NIH HHS/United States PT - Journal Article DEP - 20220421 PL - England TA - 3D Print Med JT - 3D printing in medicine JID - 101721758 PMC - PMC9027072 OTO - NOTNLM OT - 3D printing OT - Cardiac catheterization OT - Cardiothoracic surgery OT - Computer aided design OT - Congenital heart disease OT - Imaging OT - Magnetic resonance imaging OT - Pediatric cardiology OT - Surgical planning OT - Virtual reality COIS- The authors have no conflicts of interest to disclose. EDAT- 2022/04/22 06:00 MHDA- 2022/04/22 06:01 PMCR- 2022/04/21 CRDT- 2022/04/21 12:04 PHST- 2022/03/03 00:00 [received] PHST- 2022/03/12 00:00 [accepted] PHST- 2022/04/21 12:04 [entrez] PHST- 2022/04/22 06:00 [pubmed] PHST- 2022/04/22 06:01 [medline] PHST- 2022/04/21 00:00 [pmc-release] AID - 10.1186/s41205-022-00137-9 [pii] AID - 137 [pii] AID - 10.1186/s41205-022-00137-9 [doi] PST - epublish SO - 3D Print Med. 2022 Apr 21;8(1):11. doi: 10.1186/s41205-022-00137-9. PMID- 35445089 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220716 IS - 2297-055X (Print) IS - 2297-055X (Electronic) IS - 2297-055X (Linking) VI - 9 DP - 2022 TI - Pre-operative Considerations in Adult Mucopolysaccharidosis Patients Planned for Cardiac Intervention. PG - 851016 LID - 10.3389/fcvm.2022.851016 [doi] LID - 851016 AB - Mucopolysaccharidoses (MPS) are rare lysosomal storage diseases characterized by multiorgan involvement and shortened longevity. Due to advances in therapies such as enzyme replacement therapy and haematopoietic stem cell therapy, life expectancy has increased posing newer challenges to patients and health professionals. One such challenge is cardiovascular manifestations of MPS, which can be life limiting and cause reduction in quality of life. Any cardiovascular intervention mandates comprehensive, multi-systemic work-up by specialist teams to optimize outcome. We highlight the importance of multidisciplinary evaluation of adult MPS patients requiring cardiovascular intervention. Clinical assessments and investigations are discussed, with a focus on the cardiac, anesthetic, airway, respiratory, radiological and psychosocial factors. CI - Copyright (c) 2022 Cross, Stepien, Gadepalli, Kharabish, Woolfson, Tol and Jenkins. FAU - Cross, Benjamin AU - Cross B AD - Adult Congenital Heart Disease Department, Liverpool Heart and Chest Hospital, Liverpool, United Kingdom. FAU - Stepien, Karolina M AU - Stepien KM AD - Adult Inherited Metabolic Diseases Department, Salford Royal NHS Foundation Trust, Salford, United Kingdom. FAU - Gadepalli, Chaitanya AU - Gadepalli C AD - Ear Nose and Throat Department, Salford Royal NHS Foundation Trust, Salford, United Kingdom. FAU - Kharabish, Ahmed AU - Kharabish A AD - Radiology Department, Liverpool Heart and Chest Hospital, Liverpool, United Kingdom. AD - Radiology Department, Cairo University, Giza, Egypt. FAU - Woolfson, Peter AU - Woolfson P AD - Cardiology Department, Salford Royal NHS Foundation Trust, Salford, United Kingdom. FAU - Tol, Govind AU - Tol G AD - Anaesthetics Department, Salford Royal NHS Foundation Trust, Salford, United Kingdom. FAU - Jenkins, Petra AU - Jenkins P AD - Adult Congenital Heart Disease Department, Liverpool Heart and Chest Hospital, Liverpool, United Kingdom. LA - eng PT - Journal Article PT - Review DEP - 20220404 PL - Switzerland TA - Front Cardiovasc Med JT - Frontiers in cardiovascular medicine JID - 101653388 PMC - PMC9013828 OTO - NOTNLM OT - adult MPS OT - cardiac surgery OT - glycosaminoglycans OT - heart disease OT - pre-operative assessment COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/04/22 06:00 MHDA- 2022/04/22 06:01 PMCR- 2022/01/01 CRDT- 2022/04/21 05:45 PHST- 2022/01/08 00:00 [received] PHST- 2022/02/28 00:00 [accepted] PHST- 2022/04/21 05:45 [entrez] PHST- 2022/04/22 06:00 [pubmed] PHST- 2022/04/22 06:01 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.3389/fcvm.2022.851016 [doi] PST - epublish SO - Front Cardiovasc Med. 2022 Apr 4;9:851016. doi: 10.3389/fcvm.2022.851016. eCollection 2022. PMID- 35439177 OWN - NLM STAT- MEDLINE DCOM- 20221006 LR - 20230203 IS - 1538-943X (Electronic) IS - 1058-2916 (Linking) VI - 68 IP - 10 DP - 2022 Oct 1 TI - Key Considerations in Establishing a Pediatric Rescue Extracorporeal Life Support Program: A Multi Methods Review. PG - 1297-1304 LID - 10.1097/MAT.0000000000001734 [doi] AB - Extracorporeal life support (ECLS) is generally limited to centers with cardiac surgery. However, pediatric centers without cardiac surgery can still provide potentially lifesaving ECLS through a Rescue Program, allowing a local team to cannulate and stabilize patients before they are transported to a center with cardiac surgery support for ongoing care. This multimethod study provides an exploration of pediatric ECLS team insights regarding program implementation and offers recommendations for other centers wishing to develop a similar program. We performed surveys and semi-structured interviews to gather perspectives from ECLS team members. Demographics and preliminary perspectives were obtained from surveys. Interviews were transcribed and coded using thematic analysis to identify key considerations, facilitators, and barriers related to rescue program implementation. Our multidisciplinary ECLS team perceived great value in the rescue program and identified elements critical to successful program development and implementation, including barriers that might exist for any center wishing to set up a similar program. Participants emphasized that the initial design and continued maintenance of any Rescue ECLS Program be a comprehensive, multidisciplinary initiative. Clear communication, a mechanism for debriefing and feedback, and a strategy allowing for flexible program evolution are essential. CI - Copyright (c) ASAIO 2022. FAU - Blackwood, Jaime AU - Blackwood J AUID- ORCID: 0000-0002-9287-3890 AD - From the Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. AD - Department of Pediatrics, Alberta Children's Hospital, Calgary, AB, Canada. FAU - Zadunayski, Anna AU - Zadunayski A AD - From the Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. FAU - Spence, Tanya AU - Spence T AD - Department of Pediatrics, Alberta Children's Hospital, Calgary, AB, Canada. AD - Faculty of Nursing, University of Calgary, Calgary, AB, Canada. FAU - Nikitovic, Dejana AU - Nikitovic D AD - From the Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. FAU - Brindle, Mary E AU - Brindle ME AUID- ORCID: 0000-0003-3695-3447 AD - Department of Pediatrics, Alberta Children's Hospital, Calgary, AB, Canada. AD - Department of Surgery, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20220419 PL - United States TA - ASAIO J JT - ASAIO journal (American Society for Artificial Internal Organs : 1992) JID - 9204109 SB - IM MH - Child MH - *Extracorporeal Membrane Oxygenation MH - Humans MH - *Program Development COIS- Disclosure: The authors have no conflicts of interest to report. EDAT- 2022/04/20 06:00 MHDA- 2022/10/07 06:00 CRDT- 2022/04/19 17:11 PHST- 2022/04/20 06:00 [pubmed] PHST- 2022/10/07 06:00 [medline] PHST- 2022/04/19 17:11 [entrez] AID - 00002480-202210000-00013 [pii] AID - 10.1097/MAT.0000000000001734 [doi] PST - ppublish SO - ASAIO J. 2022 Oct 1;68(10):1297-1304. doi: 10.1097/MAT.0000000000001734. Epub 2022 Apr 19. PMID- 35435011 OWN - NLM STAT- MEDLINE DCOM- 20220421 LR - 20230222 IS - 2047-9980 (Electronic) IS - 2047-9980 (Linking) VI - 11 IP - 8 DP - 2022 Apr 19 TI - Need for Better and Broader Training in Cardio-Obstetrics: A National Survey of Cardiologists, Cardiovascular Team Members, and Cardiology Fellows in Training. PG - e024229 LID - 10.1161/JAHA.121.024229 [doi] LID - e024229 AB - Background Team-based models of cardio-obstetrics care have been developed to address the increasing rate of maternal mortality from cardiovascular diseases. Cardiovascular clinician and trainee knowledge and comfort with this topic, and the extent of implementation of an interdisciplinary approach to cardio-obstetrics, are unknown. Methods and Results We aimed to assess the current state of cardio-obstetrics knowledge, practices, and services provided by US cardiovascular clinicians and trainees. A survey developed in conjunction with the American College of Cardiology was circulated to a representative sample of cardiologists (N=311), cardiovascular team members (N=51), and fellows in training (N=139) from June 18, 2020, to July 29, 2020. Knowledge and attitudes about the provision of cardiovascular care to pregnant patients and the prevalence and composition of cardio-obstetrics teams were assessed. The widest knowledge gaps on the care of pregnant compared with nonpregnant patients were reported for medication safety (42%), acute coronary syndromes (39%), aortopathies (40%), and valvular heart disease (30%). Most respondents (76%) lack access to a dedicated cardio-obstetrics team, and only 29% of practicing cardiologists received cardio-obstetrics didactics during training. One third of fellows in training reported seeing pregnant women 0 to 1 time per year, and 12% of fellows in training report formal training in cardio-obstetrics. Conclusions Formalized training in cardio-obstetrics is uncommon, and limited access to multidisciplinary cardio-obstetrics teams and large knowledge gaps exist among cardiovascular clinicians. Augmentation of cardio-obstetrics education across career stages is needed to reduce these deficits. These survey results are an initial step toward developing a standard expectation for clinicians' training in cardio-obstetrics. FAU - Bello, Natalie A AU - Bello NA AUID- ORCID: 0000-0003-3257-3623 AD - Department of Cardiology Smidt Heart Institute Cedars-Sinai Medical Center Los Angeles CA. FAU - Agrawal, Akanksha AU - Agrawal A AD - Emory Heart and Vascular Center Emory Women's Heart Center Emory University School of Medicine Atlanta GA. FAU - Davis, Melinda B AU - Davis MB AUID- ORCID: 0000-0002-3676-1982 AD - Division of Cardiovascular Medicine University of Michigan Ann Arbor MI. FAU - Harrington, Colleen M AU - Harrington CM AUID- ORCID: 0000-0002-2830-9953 AD - Division of Cardiovascular Medicine Department of Medicine University of Massachusetts School of Medicine Worcester MA. FAU - Lindley, Kathryn J AU - Lindley KJ AUID- ORCID: 0000-0002-8504-0006 AD - Cardiovascular Division Department of Medicine Washington University in St Louis MO. FAU - Minissian, Margo B AU - Minissian MB AD - Barbra Streisand Women's Heart Center Cedars-Sinai Smidt Heart Institute and the Geri and Richard Brawerman Nursing Institute Cedars-Sinai Medical Center Los Angeles CA. FAU - Sharma, Garima AU - Sharma G AUID- ORCID: 0000-0001-7254-2077 AD - Ciccarone Center for the Prevention of Cardiovascular Disease Johns Hopkins University School of Medicine Baltimore MD. FAU - Walsh, Mary Norine AU - Walsh MN AD - Division of Cardiology St. Vincent Heart Center Indianapolis IN. FAU - Park, Ki AU - Park K AD - Division of Cardiovascular Medicine University of Florida College of Medicine Gainesville FL. LA - eng GR - K23 HL136853/HL/NHLBI NIH HHS/United States GR - R01 HL153382/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20220418 PL - England TA - J Am Heart Assoc JT - Journal of the American Heart Association JID - 101580524 SB - IM MH - *Cardiologists MH - *Cardiology/education MH - *Cardiovascular Diseases/epidemiology/therapy MH - Female MH - Humans MH - Maternal Mortality MH - *Obstetrics MH - Pregnancy MH - United States PMC - PMC9238459 OTO - NOTNLM OT - cardio-obstetrics OT - continuing medical education OT - medical knowledge OT - pregnancy EDAT- 2022/04/19 06:00 MHDA- 2022/04/22 06:00 PMCR- 2022/04/19 CRDT- 2022/04/18 08:40 PHST- 2022/04/19 06:00 [pubmed] PHST- 2022/04/22 06:00 [medline] PHST- 2022/04/18 08:40 [entrez] PHST- 2022/04/19 00:00 [pmc-release] AID - JAH37389 [pii] AID - 10.1161/JAHA.121.024229 [doi] PST - ppublish SO - J Am Heart Assoc. 2022 Apr 19;11(8):e024229. doi: 10.1161/JAHA.121.024229. Epub 2022 Apr 18. PMID- 35433371 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220716 IS - 2225-319X (Print) IS - 2304-1021 (Electronic) IS - 2225-319X (Linking) VI - 11 IP - 2 DP - 2022 Mar TI - Pulmonary thromboendarterectomy in chronic thromboembolic pulmonary hypertension: the Spanish experience. PG - 151-160 LID - 10.21037/acs-2021-pte-18 [doi] AB - BACKGROUND: Chronic thromboembolic pulmonary hypertension (CTEPH) can be cured by pulmonary endarterectomy (PEA). It is considered the best and only curable treatment option for patients with accessible lesions evaluated as optimal candidates. We describe the experience of the two reference centers in Spain, in order to reinforce the need for referring CTEPH patients to a specialized center to be assessed by a Multidisciplinary Expert Team. METHODS: We included a population of 338 patients who met the definition for CTEPH and underwent PEA between January 2007 and December 2019. The surgery was indicated in almost 60% of patients assessed. Demographic, anthropometric, hemodynamic and echocardiographic features are listed for PEA patients. Immediate and one-year postoperative outcomes as well as overall mortality were analyzed. RESULTS: Mean age was 53.5+/-15.0 years, 53.8% were men; a total of 68.5% were in WHO functional class III-IV; and most of them were in a preoperative hemodynamic condition: mean pulmonary arterial pressure (mPAP) was 46.5+/-13.1 mmHg and mean pulmonary vascular resistance (PVR) was 764.5+/-392.8 dyn.s.cm(-5). PEA surgery was performed with cardiopulmonary bypass (CBP) and circulatory arrest, with very few complications [including neurological, postoperative reperfusion edema, extracorporeal membrane oxygenation (ECMO) implant and cardiac failure] and optimal postoperative results, where exercise capacity increased and mPAP and PVR values decreased significantly. Presence of persistent pulmonary hypertension (PH) at the six-month right heart catheterization was evaluated. A 3.3% perioperative mortality was achieved. Overall, one-, three- and five-year survival rates were analyzed by Kaplan-Meier's method (94.8%, 93.3% and 90.5% respectively), as well as for residual PH patients. Mortality risk factors were assessed. CONCLUSIONS: Outstanding PEA results were seen in the immediate, one-year and long-term outcomes. The incidence of complications, including in-hospital mortality and long-term mortality were also below European rates. CI - 2022 Annals of Cardiothoracic Surgery. All rights reserved. FAU - Lopez-Gude, Maria Jesus AU - Lopez-Gude MJ AD - Department of Cardiac Surgery, Unidad Multidisciplinar de Hipertension Pulmonar, European Reference Network for Respiratory Diseases (ERN-lung), Hospital Universitario 12 de Octubre, Madrid, Spain. FAU - Blanco, Isabel AU - Blanco I AD - Department of Pulmonary Medicine, Hospital Clinic, Barcelona, Spain. AD - Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), University of Barcelona; Barcelona, Spain. AD - Biomedical Research Networking Center in Respiratory Diseases (CIBERES), Madrid, Spain. FAU - Benito-Arnaiz, Victoria AU - Benito-Arnaiz V AD - Department of Cardiac Surgery, Unidad Multidisciplinar de Hipertension Pulmonar, European Reference Network for Respiratory Diseases (ERN-lung), Hospital Universitario 12 de Octubre, Madrid, Spain. FAU - Castella, Manel AU - Castella M AD - Department of Cardiovascular Surgery, Cardiovascular Institute, Hospital Clinic, University of Barcelona, Barcelona, Spain. FAU - Escribano-Subias, Pilar AU - Escribano-Subias P AD - Department of Cardiology, Unidad Multidisciplinar de Hipertension Pulmonar, European Reference Network for Respiratory Diseases (ERN-lung), Hospital Universitario 12 de Octubre, Madrid, Spain. AD - Biomedical Research Networking Center in Cardiovascular Diseases (CIBERCV), Madrid, Spain. FAU - Martin, Clara AU - Martin C AD - Department of Pulmonary Medicine, Hospital Clinic, Barcelona, Spain. AD - Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), University of Barcelona; Barcelona, Spain. FAU - Barbera, Joan Albert AU - Barbera JA AD - Department of Pulmonary Medicine, Hospital Clinic, Barcelona, Spain. AD - Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), University of Barcelona; Barcelona, Spain. AD - Biomedical Research Networking Center in Respiratory Diseases (CIBERES), Madrid, Spain. FAU - Cortina-Romero, Jose Maria AU - Cortina-Romero JM AD - Department of Cardiac Surgery, Unidad Multidisciplinar de Hipertension Pulmonar, European Reference Network for Respiratory Diseases (ERN-lung), Hospital Universitario 12 de Octubre, Madrid, Spain. LA - eng PT - Journal Article PL - China TA - Ann Cardiothorac Surg JT - Annals of cardiothoracic surgery JID - 101605877 PMC - PMC9012199 OTO - NOTNLM OT - Pulmonary thromboendarterectomy OT - pulmonary hypertension (PH) OT - pulmonary vascular resistance (PVR) OT - residual pulmonary hypertension, operability COIS- Conflicts of Interest: The authors have no conflicts of interest to declare. EDAT- 2022/04/19 06:00 MHDA- 2022/04/19 06:01 PMCR- 2022/03/01 CRDT- 2022/04/18 06:38 PHST- 2021/10/16 00:00 [received] PHST- 2022/01/10 00:00 [accepted] PHST- 2022/04/18 06:38 [entrez] PHST- 2022/04/19 06:00 [pubmed] PHST- 2022/04/19 06:01 [medline] PHST- 2022/03/01 00:00 [pmc-release] AID - acs-11-02-151 [pii] AID - 10.21037/acs-2021-pte-18 [doi] PST - ppublish SO - Ann Cardiothorac Surg. 2022 Mar;11(2):151-160. doi: 10.21037/acs-2021-pte-18. PMID- 35432759 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220419 IS - 1948-9358 (Print) IS - 1948-9358 (Electronic) IS - 1948-9358 (Linking) VI - 13 IP - 3 DP - 2022 Mar 15 TI - Can the management of depression in type 2 diabetes be democratized? PG - 203-212 LID - 10.4239/wjd.v13.i3.203 [doi] AB - Both type 2 diabetes and depression are common and are projected to increase. There is increasing evidence for a bidirectional relationship between the two. Diabetes is a risk factor for depression; contrariwise, individuals with depression are at greater risk of developing diabetes. They are a burden for both the individual and the society. Co-existent depression worsens diabetic control because of obesity, insulin resistance and the adverse metabolic effects of anti-diabetes medicines. In addition, compliance to lifestyle measures required for diabetes is also compromised such as following a specific diet, taking proper medications on time, getting metabolic parameters assessed and maintaining a sleep cycle. Depression occurs in many grades; mild depression is more common in diabetes than frank or full-blown depression leading to suicide. Unfortunately, there are not enough trained and accessible mental health professionals such as psychologists or psychiatrists to deal with the increasing burden of depression in diabetes. Therefore, alternate models for management of mild to moderate depression are required. There is evidence that a team-approach by employing health care assistants can lower the risk of cardiac risk factors. INtegrating DEPrEssioN and Diabetes treatmENT study was carried out to determine whether the team-approach using non-health care professionals could be effective in managing mild to moderate depression and to study its effects on metabolic parameters among subjects with type 2 diabetes mellitus. The international study, carried out in four independent centers in India assessed the impact of a trained but not qualified non-psychiatrist in coordinating and forming a fulcrum between the patient, the family and the consultant endocrinologist/diabetologist. The interventions were fine-tuned to be culturally appropriate by qualitative interviews before they began. It was shown that the outcomes of both depression and diabetes could be improved by the employment of a clinical care coordinator. It is possible to scale up the studies to wider geographical areas and health-care organizations. CI - (c)The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. FAU - Sridhar, Gumpeny R AU - Sridhar GR AD - Department of Endocrinology, Endocrine & Diabet Ctr, Visakhapatnam 530002, India. sridharvizag@gmail.com. LA - eng PT - Journal Article PT - Review PL - United States TA - World J Diabetes JT - World journal of diabetes JID - 101547524 PMC - PMC8984566 OTO - NOTNLM OT - Antidepressants OT - Bidirectional OT - Care-coordinator OT - Insulin resistance OT - Integrating DEPrEssioN and Diabetes treatmENT study OT - Non-professional OT - Patient health questionnaire-9 COIS- Conflict-of-interest statement: Gumpeny R Sridhar has no conflicts of interest. He has not received fees for serving as a speaker, nor has he received research funding. He does not own stocks and/or shares. EDAT- 2022/04/19 06:00 MHDA- 2022/04/19 06:01 PMCR- 2022/03/15 CRDT- 2022/04/18 06:35 PHST- 2021/10/29 00:00 [received] PHST- 2022/01/07 00:00 [revised] PHST- 2022/02/22 00:00 [accepted] PHST- 2022/04/18 06:35 [entrez] PHST- 2022/04/19 06:00 [pubmed] PHST- 2022/04/19 06:01 [medline] PHST- 2022/03/15 00:00 [pmc-release] AID - 10.4239/wjd.v13.i3.203 [doi] PST - ppublish SO - World J Diabetes. 2022 Mar 15;13(3):203-212. doi: 10.4239/wjd.v13.i3.203. PMID- 35429589 OWN - NLM STAT- MEDLINE DCOM- 20220721 LR - 20220811 IS - 1916-7075 (Electronic) IS - 0828-282X (Linking) VI - 38 IP - 7 DP - 2022 Jul TI - Prenatal Diagnosis and Management of Single-Ventricle Heart Disease. PG - 897-908 LID - S0828-282X(22)00219-7 [pii] LID - 10.1016/j.cjca.2022.04.003 [doi] AB - In the current era, most single-ventricle heart disease (SVHD) is diagnosed prenatally by means of fetal echocardiography. Disparities exist, however, by socioeconomic status and remote location, which require further attention. Prenatal diagnosis affords the opportunity to counsel expectant parents regarding the life-long course of children with SVHD, including the stages of single-ventricle palliation and challenges of the Fontan circulation; to discuss pregnancy management options; and to optimise delivery planning and perinatal care. Prognosis may be refined by specific features on the fetal echocardiogram, such as ventricular morphology, total anomalous pulmonary venous return, and atrioventricular valve regurgitation. Expectant mothers should be referred for evaluation of extracardiac anomalies and/or a genetic syndrome, which also significantly affect outcome. Fetuses with SVHD should be cared for by a multidisciplinary team and ideally delivered at term at or near a cardiac surgical center. Serial echocardiograms refine the anticipated postnatal physiology to optimise transitional care, including the need for prostaglandin or urgent atrial septal intervention in fetuses with hypoplastic left heart syndrome. In selected patients, there may be a role for fetal cardiac intervention to improve mortality or achieve a biventricular circulation after birth. Together, these strategies enhance the preoperative status of the neonate. Recent advances in fetal cardiovascular magnetic resonance imaging have focused on studying the relationships between cardiovascular physiology and fetal growth and development. These novel techniques allow for the exploration of the physiologic effects of SVHD on the brain and open avenues for the investigation of neuroprotective therapies. CI - Copyright (c) 2022 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved. FAU - Freud, Lindsay R AU - Freud LR AD - Division of Paediatric Cardiology, Department of Paediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada. FAU - Seed, Mike AU - Seed M AD - Division of Paediatric Cardiology, Department of Paediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada. Electronic address: mike.seed@sickkids.ca. LA - eng PT - Journal Article PT - Review DEP - 20220413 PL - England TA - Can J Cardiol JT - The Canadian journal of cardiology JID - 8510280 SB - IM MH - Child MH - Echocardiography MH - Female MH - Fetal Heart MH - Fetus MH - *Fontan Procedure MH - Humans MH - *Hypoplastic Left Heart Syndrome/diagnostic imaging/surgery MH - Infant, Newborn MH - Pregnancy MH - Prenatal Diagnosis/methods MH - Retrospective Studies MH - Ultrasonography, Prenatal EDAT- 2022/04/17 06:00 MHDA- 2022/07/22 06:00 CRDT- 2022/04/16 20:09 PHST- 2022/01/08 00:00 [received] PHST- 2022/03/27 00:00 [revised] PHST- 2022/04/04 00:00 [accepted] PHST- 2022/04/17 06:00 [pubmed] PHST- 2022/07/22 06:00 [medline] PHST- 2022/04/16 20:09 [entrez] AID - S0828-282X(22)00219-7 [pii] AID - 10.1016/j.cjca.2022.04.003 [doi] PST - ppublish SO - Can J Cardiol. 2022 Jul;38(7):897-908. doi: 10.1016/j.cjca.2022.04.003. Epub 2022 Apr 13. PMID- 35429509 OWN - NLM STAT- MEDLINE DCOM- 20220603 LR - 20250623 IS - 1874-1754 (Electronic) IS - 0167-5273 (Linking) VI - 359 DP - 2022 Jul 15 TI - Hybrid coronary revascularization versus coronary artery bypass grafting for multivessel coronary artery disease: A systematic review and meta-analysis. PG - 20-27 LID - S0167-5273(22)00510-1 [pii] LID - 10.1016/j.ijcard.2022.04.030 [doi] AB - BACKGROUND: Hybrid coronary revascularization (HCR) combines the benefits of a left internal mammary artery to left anterior descending artery anastomosis, via a mini thoracotomy, with percutaneous coronary intervention (PCI) for other diseased coronaries. AIMS: The aim of this meta-analysis is to compare the short- and long-term outcomes of HCR with those of coronary artery bypass grafting (CABG) for multi-vessel coronary artery disease (MCAD). METHODS: We performed a meta-analysis with a primary outcome of short-term mortality and secondary outcomes of mid-term survival, length of hospital stay, stroke, renal failure and mid-term MACE rate. RESULTS: 3399 patients (HCR = 1164, CABG = 2235) were included, with no significant difference in short-term mortality between groups (OR = 1.50, 95% CI = [0.90,2.49], p = 0.11), although a higher mortality rate was seen in the HCR group (0.73% vs 0.64%). The average length of stay in intensive care unit was significantly shorter following HCR than CABG (mean difference = -15.52 h, CI = [-22.47,-8.59], p<0.001) and overall hospital stay was also shorter in this group, although not statistically significant (mean difference = -3.15 days, 95% CI = [-6.55, 0.25], p = 0.07). HCR was associated with a reduced odds of blood transfusion (OR = 0.34, 95% CI = [0.22,0.54], p < 0.001). There was not a significant difference in mid-term survival (OR = 0.86, 95% CI = [0.62,1.21], p = 0.39) or MACE rate (OR = 0.82, 95% CI = [0.55,1.23], p = 0.34). No differences were found between HCR and CABG for post-operative stroke (OR = 1.36, 95% CI = [0.87, 2.13], p = 0.16) or renal failure (OR = 0.71, 95% CI = [0.43,1.16], p = 0.14). CONCLUSIONS: HCR has a higher incidence of short-term mortality compared to CABG in patients with MCAD, although this difference is not statistically significant. Similar rates of mid-term survival and other short term post-operative complications were found between the two groups. HCR has a shorter ICU stays and reduced requirement for blood transfusion. CI - Copyright (c) 2022 Elsevier B.V. All rights reserved. FAU - Dixon, Lauren Kari AU - Dixon LK AD - Bristol Medical School, Public Health Science, University of Bristol, Bristol, UK. FAU - Akberali, Umme AU - Akberali U AD - Bristol Medical School, Translational Health Science, University of Bristol, Bristol, UK. FAU - Di Tommaso, Ettorino AU - Di Tommaso E AD - Bristol Medical School, Translational Health Science, University of Bristol, Bristol, UK. FAU - George, Sarah J AU - George SJ AD - Bristol Medical School, Translational Health Science, University of Bristol, Bristol, UK. FAU - Johnson, Thomas W AU - Johnson TW AD - Bristol Medical School, Translational Health Science, University of Bristol, Bristol, UK; Bristol Heart Institute, University Hospitals of Bristol and Weston NHS Foundation Trust, Bristol, UK. FAU - Bruno, Vito Domenico AU - Bruno VD AD - Bristol Medical School, Translational Health Science, University of Bristol, Bristol, UK; Bristol Heart Institute, University Hospitals of Bristol and Weston NHS Foundation Trust, Bristol, UK. Electronic address: vito.d.bruno@bristol.ac.uk. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20220413 PL - Netherlands TA - Int J Cardiol JT - International journal of cardiology JID - 8200291 SB - IM MH - Coronary Artery Bypass MH - *Coronary Artery Disease/diagnosis/surgery MH - Humans MH - *Percutaneous Coronary Intervention MH - *Renal Insufficiency MH - *Stroke MH - Treatment Outcome OTO - NOTNLM OT - Coronary bypass OT - Coronary disease OT - Heart team OT - Hybrid OT - Minimal invasive OT - Percutaneous coronary intervention EDAT- 2022/04/17 06:00 MHDA- 2022/06/07 06:00 CRDT- 2022/04/16 20:09 PHST- 2022/02/18 00:00 [received] PHST- 2022/03/23 00:00 [revised] PHST- 2022/04/10 00:00 [accepted] PHST- 2022/04/17 06:00 [pubmed] PHST- 2022/06/07 06:00 [medline] PHST- 2022/04/16 20:09 [entrez] AID - S0167-5273(22)00510-1 [pii] AID - 10.1016/j.ijcard.2022.04.030 [doi] PST - ppublish SO - Int J Cardiol. 2022 Jul 15;359:20-27. doi: 10.1016/j.ijcard.2022.04.030. Epub 2022 Apr 13. PMID- 35420730 OWN - NLM STAT- MEDLINE DCOM- 20220823 LR - 20250728 IS - 1540-8167 (Electronic) IS - 1045-3873 (Linking) VI - 33 IP - 8 DP - 2022 Aug TI - The hybrid convergent procedure for persistent and long-standing persistent atrial fibrillation from an electrophysiologist's perspective. PG - 1954-1960 LID - 10.1111/jce.15492 [doi] AB - In atrial fibrillation (AF), the pulmonary veins (PVs) are central to arrhythmogenicity and are targeted by PV isolation (PVI). As AF progresses, triggers become more prevalent in non-PV areas including the left atrial posterior wall (LAPW). Reported benefits of LAPW isolation in Cox-maze IV led to exploration of ablation strategies using endocardial catheters. However, no single approach to endocardial LAPW isolation exists. Relative success in comparison to PVI alone has been mixed. The hybrid convergent procedure was developed to combine minimally invasive surgical and electrophysiology techniques to accomplish effective PVI and LAPW isolation. Epicardial LAPW isolation is performed by a cardiothoracic surgeon followed by endocardial ablation by an electrophysiologist who ensures PVI completion and targets any remaining gaps. Safety and effectiveness of hybrid convergent were evaluated in the prospective, multicenter, randomized controlled trial, Convergence of Epicardial and Endocardial Ablation for the Treatment of Symptomatic Persistent AF (CONVERGE). CONVERGE compared the effectiveness of the hybrid convergent procedure to endocardial catheter ablation for treatment of drug-refractory persistent and long-standing persistent AF and demonstrated primary effectiveness of higher freedom from atrial arrhythmias absent new/increased dose previously failed/intolerant antiarrhythmic drugs through 12 months compared to endocardial catheter ablation. Greater freedom from AF and proportion of patients experiencing >/=90% burden reduction with hybrid convergent ablation were seen through 18 months of follow-up. Improved electrophysiology lab efficiency was demonstrated by the reduction in endocardial ablation time with addition of epicardial ablation. This multidisciplinary heart team procedure may improve outcomes in difficult-to-treat patients with advanced AF. CI - (c) 2022 Wiley Periodicals LLC. FAU - DeLurgio, David B AU - DeLurgio DB AUID- ORCID: 0000-0002-3272-7234 AD - School of Medicine, Emory University, Atlanta, Georgia, USA. LA - eng GR - Writing support, under my direction was provided by Atricure, Inc/ GR - The CONVERGE Trial, the subject of this review, was funded by Atricure, Inc/ PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20220504 PL - United States TA - J Cardiovasc Electrophysiol JT - Journal of cardiovascular electrophysiology JID - 9010756 SB - IM MH - *Atrial Fibrillation/diagnosis/etiology/surgery MH - *Catheter Ablation/adverse effects/methods MH - Humans MH - Multicenter Studies as Topic MH - Prospective Studies MH - *Pulmonary Veins/surgery MH - Recurrence MH - Treatment Outcome OTO - NOTNLM OT - atrial arrhythmias OT - atrial fibrillation OT - catheter ablation OT - electrophysiology EDAT- 2022/04/15 06:00 MHDA- 2022/08/24 06:00 CRDT- 2022/04/14 12:09 PHST- 2022/02/20 00:00 [revised] PHST- 2022/01/22 00:00 [received] PHST- 2022/03/10 00:00 [accepted] PHST- 2022/04/15 06:00 [pubmed] PHST- 2022/08/24 06:00 [medline] PHST- 2022/04/14 12:09 [entrez] AID - 10.1111/jce.15492 [doi] PST - ppublish SO - J Cardiovasc Electrophysiol. 2022 Aug;33(8):1954-1960. doi: 10.1111/jce.15492. Epub 2022 May 4. PMID- 35419100 OWN - NLM STAT- MEDLINE DCOM- 20220415 LR - 20220415 IS - 1844-3117 (Electronic) IS - 1844-122X (Print) IS - 1844-122X (Linking) VI - 15 IP - 2 DP - 2022 Feb TI - Simultaneous bilateral angioplasty and stenting for carotid stenosis - a single center experience. PG - 252-257 LID - 10.25122/jml-2021-0274 [doi] AB - Carotid artery stenosis is responsible for up to 12% of all ischemic strokes. The prevalence of bilateral carotid artery stenosis is nearly 8-39% among patients with stroke, and its management is still controversial. This study aimed to report the treatment results of bilateral carotid artery stenosis with simultaneous bilateral angioplasty and stenting (sbCAS) in a single institution during the last 10 years. 315 patients underwent carotid stenting in the Scientific-Practical Center of Endovascular Neuroradiology, NAMS of Ukraine during 2010-2020. 39 (12.4%) patients (mean age 57.9+/-2.1 - 28 men) underwent sbCAS. Primary clinical endpoints (stroke, myocardial infarction, or death) and secondary endpoints (hemodynamic depression (HD) - hypotension (<90 mmHg) or bradycardia (<60 bpm) and hyperperfusion syndrome (HPS) were evaluated. All sbCAS were technically successful, and a reduction of stenosis was noted in each case. There were two periprocedural neurological complications, one transient ischemic attack (TIA), and one minor stroke with the Modified Rankin Scale (mRS) - 3 at discharge. No myocardial infarction (MI) or death during hospitalization was noted. 28 patients (71.8%) had HD, and 2 (5.1%) had HPS. All patients except those with periprocedural stroke were discharged or transferred to another hospital without neurological deterioration. sbCAS is an effective and relatively safe procedure for carefully selected patients with bilateral carotid stenosis. Patients with bilateral carotid stenosis should be carefully examined, and the best treatment strategy should be assessed using a multidisciplinary approach taking into account the possibility of sbCAS. CI - (c)2022 JOURNAL of MEDICINE and LIFE. FAU - Shchehlov, Dmytro Viktorovych AU - Shchehlov DV AUID- ORCID: 0000-0003-1465-8738 AD - State Organization Scientific-Practical Center of Endovascular Neuroradiology, National Academy of Medical Sciences of Ukraine (NAMS), Kyiv, Ukraine. FAU - Svyrydiuk, Oleg Yevgenovych AU - Svyrydiuk OY AUID- ORCID: 0000-0001-7455-0396 AD - State Organization Scientific-Practical Center of Endovascular Neuroradiology, National Academy of Medical Sciences of Ukraine (NAMS), Kyiv, Ukraine. FAU - Vyval, Mykola Bohdanovych AU - Vyval MB AUID- ORCID: 0000-0002-9428-4678 AD - State Organization Scientific-Practical Center of Endovascular Neuroradiology, National Academy of Medical Sciences of Ukraine (NAMS), Kyiv, Ukraine. FAU - Sydorenko, Olena Fedorivna AU - Sydorenko OF AUID- ORCID: 0000-0002-0642-9583 AD - State Organization Scientific-Practical Center of Endovascular Neuroradiology, National Academy of Medical Sciences of Ukraine (NAMS), Kyiv, Ukraine. FAU - Nosenko, Nataliia Mykolayivna AU - Nosenko NM AUID- ORCID: 0000-0001-7040-7672 AD - State Organization Scientific-Practical Center of Endovascular Neuroradiology, National Academy of Medical Sciences of Ukraine (NAMS), Kyiv, Ukraine. FAU - Gudym, Maxym Stepanovych AU - Gudym MS AUID- ORCID: 0000-0001-8224-8314 AD - State Organization Scientific-Practical Center of Endovascular Neuroradiology, National Academy of Medical Sciences of Ukraine (NAMS), Kyiv, Ukraine. LA - eng PT - Journal Article PL - Romania TA - J Med Life JT - Journal of medicine and life JID - 101477617 SB - IM MH - Angioplasty/adverse effects/methods MH - *Carotid Stenosis/complications/surgery MH - Female MH - Humans MH - Male MH - Middle Aged MH - *Myocardial Infarction/complications MH - Retrospective Studies MH - Risk Factors MH - Stents/adverse effects MH - *Stroke/complications MH - Treatment Outcome PMC - PMC8999088 OTO - NOTNLM OT - bilateral carotid artery stenosis OT - simultaneous bilateral angioplasty OT - stenting EDAT- 2022/04/15 06:00 MHDA- 2022/04/16 06:00 PMCR- 2022/04/01 CRDT- 2022/04/14 05:21 PHST- 2021/09/16 00:00 [received] PHST- 2022/01/10 00:00 [accepted] PHST- 2022/04/14 05:21 [entrez] PHST- 2022/04/15 06:00 [pubmed] PHST- 2022/04/16 06:00 [medline] PHST- 2022/04/01 00:00 [pmc-release] AID - JMedLife-15-252 [pii] AID - 10.25122/jml-2021-0274 [doi] PST - ppublish SO - J Med Life. 2022 Feb;15(2):252-257. doi: 10.25122/jml-2021-0274. PMID- 35414823 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220414 IS - 1731-5530 (Print) IS - 1897-4252 (Electronic) IS - 1731-5530 (Linking) VI - 19 IP - 1 DP - 2022 Mar TI - Multidisciplinary aortic arch procedures within the "Aortic Team". PG - 11-15 LID - 10.5114/kitp.2022.114549 [doi] AB - INTRODUCTION AND AIM: The European societies EACTS (European Association for Cardio-Thoracic Surgery) and ESVS (European Society for Vascular Surgery) recommend the establishment of "Aortic Teams" from 2019. In Poland, the first such team was officially established in Specialist University Hospital no. 2 in Szczecin in 2021. MATERIAL AND METHODS: Sixty-four patients were treated for aortic arch pathology using frozen elephant trunk (n = 3), branch custom made devices (n = 12), physician-modified endo-grafts (PMEG; n = 30) and the thoracic endovascular aortic repair "plus" technique (n = 19). RESULTS: Among thoracic endovascular aortic repair (TEVAR) plus (chimneys/periscopes, n = 7, extra-anatomical bypasses, n = 12) there was 100% technical success and 4% bad outcomes (stroke or death). Among "customized" stent grafts there were Bolton Relay (n = 8), Brail Endo-Branch (n = 1) and Castor branched stent graft (n = 3) with 91% technical success and 18% bad outcomes. In the group of PMEG there were 14 cases with one fenestration, 5 cases with two fenestrations and 11 cases with triple fenestration to all vessels of the aortic arch. In this group, technical success was achieved in 91% and poor outcome ended treatment in 11%. In total we noted a 91% technical success rate and a good treatment outcome was achieved in 89%. The cooperation of cardiac surgeons and vascular surgeons in one team brought competence benefits for both specialties. It allowed for good clinical and economic results despite new logistical complexities and fits into the currently changing perspective of cardiac surgery development worldwide. CONCLUSIONS: Implementation of the recommendation to create aortic teams within cardiac surgery departments is possible and may be cost-effective in Polish conditions. CI - Copyright: (c) 2022 Polish Society of Cardiothoracic Surgeons (Polskie Towarzystwo KardioTorakochirurgow) and the editors of the Polish Journal of Cardio-Thoracic Surgery (Kardiochirurgia i Torakochirurgia Polska). FAU - Jedrzejczak, Tomasz AU - Jedrzejczak T AD - Cardiac Surgery Department, Pomeranian Medical University, Szczecin, Poland. FAU - Rynio, Pawel AU - Rynio P AD - Vascular Surgery Department, Pomeranian Medical University, Szczecin, Poland. FAU - Lewandowski, Maciej AU - Lewandowski M AD - Cardiology Department, Pomeranian Medical University, Szczecin, Poland. FAU - Zych, Andrzej AU - Zych A AD - Cardiac Surgery Department, Pomeranian Medical University, Szczecin, Poland. FAU - Rybicka, Anita AU - Rybicka A AD - Faculty and Department of Nursing, Pomeranian Medical University, Szczecin, Poland. FAU - Zukowski, Maciej AU - Zukowski M AD - Department of Anaesthesiology, Intensive Care and Acute Poisoning, Pomeranian Medical University, Szczecin, Poland. FAU - Kazimierczak, Arkadiusz AU - Kazimierczak A AD - Cardiac Surgery Department, Pomeranian Medical University, Szczecin, Poland. LA - eng PT - Journal Article DEP - 20220324 PL - Poland TA - Kardiochir Torakochirurgia Pol JT - Kardiochirurgia i torakochirurgia polska = Polish journal of cardio-thoracic surgery JID - 101279148 PMC - PMC8981135 OTO - NOTNLM OT - aortic team OT - f/bTEVAR OT - frozen elephant trunk COIS- The authors report no conflict of interest. EDAT- 2022/04/14 06:00 MHDA- 2022/04/14 06:01 PMCR- 2022/03/01 CRDT- 2022/04/13 05:35 PHST- 2021/09/23 00:00 [received] PHST- 2021/11/06 00:00 [accepted] PHST- 2022/04/13 05:35 [entrez] PHST- 2022/04/14 06:00 [pubmed] PHST- 2022/04/14 06:01 [medline] PHST- 2022/03/01 00:00 [pmc-release] AID - 46602 [pii] AID - 10.5114/kitp.2022.114549 [doi] PST - ppublish SO - Kardiochir Torakochirurgia Pol. 2022 Mar;19(1):11-15. doi: 10.5114/kitp.2022.114549. Epub 2022 Mar 24. PMID- 35414263 OWN - NLM STAT- MEDLINE DCOM- 20221215 LR - 20221222 IS - 1938-2715 (Electronic) IS - 1049-9091 (Linking) VI - 40 IP - 1 DP - 2023 Jan TI - Palliative Care in Heart Failure: An Integrative Review of Nurse Practice. PG - 96-105 LID - 10.1177/10499091221085276 [doi] AB - Introduction: Because it is a chronic disease of progressive evolution, heart failure requires nursing attitudes and practices that are articulated with palliative care, implemented in an interdisciplinary team along with patients and their families. Objective: Identifying nurses' attitudes and practices in palliative care in cardiology. Method: Integrative literature review. The searches were carried out in the following bases: Google Scholar, Virtual Health Library, LILACS, SciELO, Embase, MEDLINE, CINAHL, and Scopus; through the terms Palliative Care AND Cardiology AND Nursing. Results: We identified 1298 studies published in the last five years, 14 of which have been selected for the scope of this review. Nurse attitudes and practices were characterized as: approach to symptom control; promotion of comfort and well-being; integrality of care and family orientation; effective communication among patients, family members and nursing team; timely evaluation for palliative care. Most of the studies included in this review have evidence level 2C (n = 7) and 2B (n = 4). Therefore, the results can be interpreted as reliable. Conclusions: This study makes important contributions to the practice of nurses in palliative care for heart failure. Based on the evidence collected, nurses can develop actions with the nursing team and with the interdisciplinary team related to direct patient and family care, as well as professional training. However, the field lacks studies showing the practices and actions implemented by the nursing team. FAU - Nunciaroni, Andressa T AU - Nunciaroni AT AUID- ORCID: 0000-0001-6469-592X AD - Alfredo Pinto Nursing School, 89111Federal University of the State of Rio de Janeiro, Rio de Janeiro, RJ, Brazil. FAU - Neves, Izabella F AU - Neves IF AD - Registered Nurse, Federal University of the State of Rio de Janeiro, Rio de Janeiro, RJ, Brazil. FAU - Marques, Caroline S G AU - Marques CSG AD - Cardiology Nursing specialist, Federal University of the State of Rio de Janeiro, Rio de Janeiro, RJ, Brazil. FAU - Santos, Noemi D AU - Santos ND AD - Registered Nurse at 219784National Institute of Cardiology, Rio de Janeiro, RJ, Brazil. FAU - Correa, Vanessa F A AU - Correa VFA AD - Alfredo Pinto Nursing School, 89111Federal University of the State of Rio de Janeiro, Rio de Janeiro, RJ, Brazil. FAU - Silva, Renata Flavia A AU - Silva RFA AUID- ORCID: 0000-0003-1776-021X AD - Alfredo Pinto Nursing School, 89111Federal University of the State of Rio de Janeiro, Rio de Janeiro, RJ, Brazil. LA - eng PT - Journal Article PT - Review DEP - 20220413 PL - United States TA - Am J Hosp Palliat Care JT - The American journal of hospice & palliative care JID - 9008229 SB - IM MH - Humans MH - Palliative Care MH - *Hospice and Palliative Care Nursing MH - Family MH - *Heart Failure/therapy MH - *Nurses OTO - NOTNLM OT - attitudes OT - cardiology OT - health knowledge OT - heart failure OT - nursing OT - palliative care OT - practice OT - quality of life OT - review EDAT- 2022/04/14 06:00 MHDA- 2022/12/16 06:00 CRDT- 2022/04/13 05:27 PHST- 2022/04/14 06:00 [pubmed] PHST- 2022/12/16 06:00 [medline] PHST- 2022/04/13 05:27 [entrez] AID - 10.1177/10499091221085276 [doi] PST - ppublish SO - Am J Hosp Palliat Care. 2023 Jan;40(1):96-105. doi: 10.1177/10499091221085276. Epub 2022 Apr 13. PMID- 35411495 OWN - NLM STAT- MEDLINE DCOM- 20220503 LR - 20261010 IS - 1437-9813 (Electronic) IS - 0179-0358 (Linking) VI - 38 IP - 6 DP - 2022 Jun TI - Surgical insights and management in patients with the 22q11.2 deletion syndrome. PG - 899-905 LID - 10.1007/s00383-022-05123-0 [doi] AB - PURPOSE: 22q11.2 deletion syndrome (22q11.2DS) can present with a variety challenges to patients and their caregivers, many of which require surgical evaluation and intervention. Surgical needs can also extend long into adulthood, prompting evaluation and intervention throughout development and beyond. Here, we identify common concerns and patient needs associated with the 22q11.2DS from a general surgery perspective, their management, and typical management based on our institution's experience with 1263 patients. METHODS: 1263 patients evaluated and treated at the 22q And You Center at the Children's Hospital of Philadelphia were enrolled and included in the study, from January 1992 to May 2017 Co-morbidities, procedures, and imaging studies performed were quantified and assessed via descriptive analysis. RESULTS: Gastroesophageal reflux disease (GERD) and feeding difficulties were the most common surgical issues identified, while gastrostomy tube placement, anorectal procedures, and hernia repairs were the most common surgical interventions performed by general surgeons. CONCLUSIONS: General surgical procedures are commonly needed in this population and are part of the complex needs these patients and their surgeons may encounter in the setting of a 22q11.2DS diagnosis. These findings will help to inform a well-coordinated, multidisciplinary approach to care. CI - (c) 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - McGovern, Patrick E AU - McGovern PE AUID- ORCID: 0000-0003-0804-8212 AD - Division of General, Thoracic, and Fetal Surgery, The Children's Hospital of Philadelphia, 3401 Civic Center Blvd., Philadelphia, PA, 19104, USA. mcgovernp@chop.edu. FAU - Crowley, T Blaine AU - Crowley TB AD - Division of Human Genetics - 22q and You Center, The Children's Hospital of Philadelphia, 3401 Civic Center Blvd., Philadelphia, PA, 19104, USA. FAU - Zackai, Elaine H AU - Zackai EH AD - Division of Human Genetics - 22q and You Center, The Children's Hospital of Philadelphia, 3401 Civic Center Blvd., Philadelphia, PA, 19104, USA. AD - Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, 3401 Civic Center Blvd., Philadelphia, PA, 19104, USA. FAU - Burrows, Evanette AU - Burrows E AD - Roberts Center for Pediatric Research, The Children's Hospital of Philadelphia, 2716 South St, Philadelphia, PA, 19146, USA. FAU - McDonald-McGinn, Donna M AU - McDonald-McGinn DM AD - Division of Human Genetics - 22q and You Center, The Children's Hospital of Philadelphia, 3401 Civic Center Blvd., Philadelphia, PA, 19104, USA. AD - Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, 3401 Civic Center Blvd., Philadelphia, PA, 19104, USA. FAU - Nance, Michael L AU - Nance ML AD - Division of General, Thoracic, and Fetal Surgery, The Children's Hospital of Philadelphia, 3401 Civic Center Blvd., Philadelphia, PA, 19104, USA. AD - Department of Surgery, Perelman School of Medicine at the University of Pennsylvania, 3400 Spruce St # 4, Philadelphia, PA, 19104, USA. LA - eng PT - Journal Article DEP - 20220412 PL - Germany TA - Pediatr Surg Int JT - Pediatric surgery international JID - 8609169 SB - IM MH - Adult MH - Caregivers MH - Child MH - Comorbidity MH - *DiGeorge Syndrome/complications/genetics/surgery MH - Hospitals, Pediatric MH - Humans MH - *Surgeons OTO - NOTNLM OT - 22q OT - General surgery OT - Genetics OT - Multidisciplinary care EDAT- 2022/04/13 06:00 MHDA- 2022/05/04 06:00 CRDT- 2022/04/12 05:32 PHST- 2022/03/30 00:00 [accepted] PHST- 2022/04/13 06:00 [pubmed] PHST- 2022/05/04 06:00 [medline] PHST- 2022/04/12 05:32 [entrez] AID - 10.1007/s00383-022-05123-0 [pii] AID - 10.1007/s00383-022-05123-0 [doi] PST - ppublish SO - Pediatr Surg Int. 2022 Jun;38(6):899-905. doi: 10.1007/s00383-022-05123-0. Epub 2022 Apr 12. PMID- 35409613 OWN - NLM STAT- MEDLINE DCOM- 20220413 LR - 20240826 IS - 1660-4601 (Electronic) IS - 1661-7827 (Print) IS - 1660-4601 (Linking) VI - 19 IP - 7 DP - 2022 Mar 25 TI - Optimal Management of Patients with Severe Coronary Artery Disease following Multidisciplinary Heart Team Approach-Insights from Tertiary Cardiovascular Care Center. LID - 10.3390/ijerph19073933 [doi] LID - 3933 AB - Background: The purpose of this retrospective study was to investigate outcomes of patients with severe coronary artery disease (CAD) after implementing various treatment strategies following multidisciplinary Heart Team (MHT) discussion. Methods Primary and secondary endpoints and quality of life during a mean (SD) follow-up of 37 (14) months of patients with severe CAD (three-vessel [3-VD] or/and left main [LM] disease) qualified after MHT discussion to optimal medical treatment (OMT) alone, OMT and coronary artery bypass grafting (CABG), or OMT and percutaneous coronary intervention (PCI) were evaluated. As the primary endpoint, major adverse cardiac or cerebrovascular events (MACCE) (i.e., death from any cause, stroke, myocardial infarction, or repeat/need for revascularization) were considered. Result: From 2016 to 2019, 176 MHT meetings were held, and a total of 1286 participants with severe CAD and completely implemented MHT decisions (OMT, CABG, or PCI for 251, 356, and 679 patients, respectively) were included. The occurrence of the primary endpoint was significantly increased in OMT-group (154 (61.4%) vs. CABG and PCI groups-110 (30.9%) and 302 (44.5%) patients, respectively (p < 0.05). For interventional strategies only-CABG was associated with reduced rates of MACCE and repeat revascularization, while the superiority of PCI for stroke and disabling stroke was observed (p < 0.05). The general health status assessed at the end of the follow-up was significantly better for patients who underwent CABG or PCI than in the OMT group (p < 0.05). Conclusions: In this real-life study, we presented a single-center experience of providing optimal medical care for patients with severe CAD following MHT discussion. FAU - Jonik, Szymon AU - Jonik S AUID- ORCID: 0000-0002-9230-5455 AD - Department of Cardiology, Medical University of Warsaw, Banacha 1a Str., 01-267 Warsaw, Poland. FAU - Marchel, Michal AU - Marchel M AUID- ORCID: 0000-0003-4099-6247 AD - Department of Cardiology, Medical University of Warsaw, Banacha 1a Str., 01-267 Warsaw, Poland. FAU - Pedzich-Placha, Ewa AU - Pedzich-Placha E AUID- ORCID: 0000-0001-8965-0736 AD - Department of Cardiology, Medical University of Warsaw, Banacha 1a Str., 01-267 Warsaw, Poland. FAU - Pietrasik, Arkadiusz AU - Pietrasik A AD - Department of Cardiology, Medical University of Warsaw, Banacha 1a Str., 01-267 Warsaw, Poland. FAU - Rdzanek, Adam AU - Rdzanek A AD - Department of Cardiology, Medical University of Warsaw, Banacha 1a Str., 01-267 Warsaw, Poland. FAU - Huczek, Zenon AU - Huczek Z AD - Department of Cardiology, Medical University of Warsaw, Banacha 1a Str., 01-267 Warsaw, Poland. FAU - Kochman, Janusz AU - Kochman J AD - Department of Cardiology, Medical University of Warsaw, Banacha 1a Str., 01-267 Warsaw, Poland. FAU - Budnik, Monika AU - Budnik M AD - Department of Cardiology, Medical University of Warsaw, Banacha 1a Str., 01-267 Warsaw, Poland. FAU - Piatkowski, Radoslaw AU - Piatkowski R AUID- ORCID: 0000-0003-1344-3348 AD - Department of Cardiology, Medical University of Warsaw, Banacha 1a Str., 01-267 Warsaw, Poland. FAU - Scislo, Piotr AU - Scislo P AD - Department of Cardiology, Medical University of Warsaw, Banacha 1a Str., 01-267 Warsaw, Poland. FAU - Czub, Pawel AU - Czub P AD - Department of Cardiac Surgery, Medical University of Warsaw, Banacha 1a Str., 01-267 Warsaw, Poland. FAU - Wilimski, Radoslaw AU - Wilimski R AD - Department of Cardiac Surgery, Medical University of Warsaw, Banacha 1a Str., 01-267 Warsaw, Poland. FAU - Maksym, Jakub AU - Maksym J AD - Department of Cardiology, Medical University of Warsaw, Banacha 1a Str., 01-267 Warsaw, Poland. FAU - Grabowski, Marcin AU - Grabowski M AD - Department of Cardiology, Medical University of Warsaw, Banacha 1a Str., 01-267 Warsaw, Poland. FAU - Opolski, Grzegorz AU - Opolski G AD - Department of Cardiology, Medical University of Warsaw, Banacha 1a Str., 01-267 Warsaw, Poland. FAU - Mazurek, Tomasz AU - Mazurek T AUID- ORCID: 0000-0002-3693-8741 AD - Department of Cardiology, Medical University of Warsaw, Banacha 1a Str., 01-267 Warsaw, Poland. LA - eng PT - Journal Article DEP - 20220325 PL - Switzerland TA - Int J Environ Res Public Health JT - International journal of environmental research and public health JID - 101238455 SB - IM MH - *Coronary Artery Disease/complications/surgery MH - Humans MH - *Percutaneous Coronary Intervention/methods MH - Quality of Life MH - Retrospective Studies MH - *Stroke/complications MH - Treatment Outcome PMC - PMC8997622 OTO - NOTNLM OT - coronary artery bypass grafting OT - multidisciplinary heart team OT - multivessel coronary artery disease OT - optimal medical therapy OT - percutaneous coronary intervention COIS- The authors declare no conflict of interest. EDAT- 2022/04/13 06:00 MHDA- 2022/04/14 06:00 PMCR- 2022/03/25 CRDT- 2022/04/12 01:14 PHST- 2022/02/01 00:00 [received] PHST- 2022/03/19 00:00 [revised] PHST- 2022/03/23 00:00 [accepted] PHST- 2022/04/12 01:14 [entrez] PHST- 2022/04/13 06:00 [pubmed] PHST- 2022/04/14 06:00 [medline] PHST- 2022/03/25 00:00 [pmc-release] AID - ijerph19073933 [pii] AID - ijerph-19-03933 [pii] AID - 10.3390/ijerph19073933 [doi] PST - epublish SO - Int J Environ Res Public Health. 2022 Mar 25;19(7):3933. doi: 10.3390/ijerph19073933. PMID- 35407927 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220423 IS - 1996-1944 (Print) IS - 1996-1944 (Electronic) IS - 1996-1944 (Linking) VI - 15 IP - 7 DP - 2022 Apr 1 TI - Interdisciplinary Methods for Zoonotic Tissue Acellularization for Natural Heart Valve Substitute of Biomimetic Materials. LID - 10.3390/ma15072594 [doi] LID - 2594 AB - The goal of this work was to create a bioactive tissue-based scaffold using multi-disciplinary engineering materials and tissue engineering techniques. Materials & methods: Physical techniques such as direct laser interference lithography and proton radiation were selected as alternative methods of enzymatic and chemical decellularization to remove cells from a tissue without degradation of the extracellular matrix nor its protein structure. This study was an attempt to prepare a functional scaffold for cell culture from tissue of animal origin using new physical methods that have not been considered before. The work was carried out under full control of the histological and molecular analysis. Results & conclusions: The most important finding was that the physical methods used to obtain the decellularized tissue scaffold differed in the efficiency of cell removal from the tissue in favour of the laser method. Both the laser method and the proton method exhibited a destructive effect on tissue structure and the genetic material in cell nuclei. This effect was visible on histology images as blurred areas within the cell nucleus. The finite element 3D simulation of decellularization process of the three-layer tissue of animal origin sample reflected well the mechanical response of tissue described by hyperelastic material models and provided results comparable to the experimental ones. FAU - Major, Roman AU - Major R AUID- ORCID: 0000-0003-3809-1908 AD - Institute of Metallurgy and Materials Science, Polish Academy of Sciences, 25 Reymonta st., 30-059 Cracow, Poland. FAU - Kopernik, Magdalena AU - Kopernik M AUID- ORCID: 0000-0001-8705-6506 AD - AGH University of Science and Technology, Al. Mickiewicza 30, 30-059 Cracow, Poland. FAU - Ostrowski, Roman AU - Ostrowski R AD - Institute of Optoelectronics, Military University of Technology, Gen. S. Kaliskiego st. 2, 00-908 Warsaw, Poland. FAU - Wilczek, Piotr AU - Wilczek P AUID- ORCID: 0000-0002-4968-6512 AD - The President Stanislaw Wojciechowski Calisia University, Nowy Swiat 4 st., 62-800 Kalisz, Poland. FAU - Bartkowiak, Amanda AU - Bartkowiak A AUID- ORCID: 0000-0002-7890-5665 AD - Institute of Nuclear Physics Polish Academy of Sciences, PL-31342 Krakow, Poland. FAU - Szawiraacz, Karolina AU - Szawiraacz K AD - Institute of Metallurgy and Materials Science, Polish Academy of Sciences, 25 Reymonta st., 30-059 Cracow, Poland. FAU - Lis, Grzegorz AU - Lis G AUID- ORCID: 0000-0002-0467-8519 AD - Department of Histology, Jagiellonian University Medical College, Kopernika 7, 31-034 Krakow, Poland. FAU - Lekki, Janusz AU - Lekki J AUID- ORCID: 0000-0001-9848-6448 AD - Institute of Nuclear Physics Polish Academy of Sciences, PL-31342 Krakow, Poland. FAU - Gawlikowski, Maciej AU - Gawlikowski M AUID- ORCID: 0000-0002-6526-2656 AD - Department of Biosensors and Processing of Biomedical Signals, Faculty of Biomedical Engineering, Silesian University of Technology, Roosevelt Str. 40, 41-800 Zabrze, Poland. FAU - Major, Lukasz AU - Major L AD - Institute of Metallurgy and Materials Science, Polish Academy of Sciences, 25 Reymonta st., 30-059 Cracow, Poland. LA - eng GR - 2016/23/B/ST8/01481/National Science Center/ GR - 07/040/RGH20/1005/Silesian University of Technology/ GR - UGB/22-833/2021/WAT/Military University of Technology in Warsaw/ PT - Journal Article DEP - 20220401 PL - Switzerland TA - Materials (Basel) JT - Materials (Basel, Switzerland) JID - 101555929 PMC - PMC9000896 OTO - NOTNLM OT - aortic valve tissue OT - decellularized tissue scaffold OT - elastic fibers OT - hyperelastic material model OT - laser-tissue interaction OT - pericardium OT - proton microbeam irradiation OT - tissue autofluorescence COIS- The authors declare no conflict of interest. EDAT- 2022/04/13 06:00 MHDA- 2022/04/13 06:01 PMCR- 2022/04/01 CRDT- 2022/04/12 01:08 PHST- 2022/02/22 00:00 [received] PHST- 2022/03/14 00:00 [revised] PHST- 2022/03/29 00:00 [accepted] PHST- 2022/04/12 01:08 [entrez] PHST- 2022/04/13 06:00 [pubmed] PHST- 2022/04/13 06:01 [medline] PHST- 2022/04/01 00:00 [pmc-release] AID - ma15072594 [pii] AID - materials-15-02594 [pii] AID - 10.3390/ma15072594 [doi] PST - epublish SO - Materials (Basel). 2022 Apr 1;15(7):2594. doi: 10.3390/ma15072594. PMID- 35407540 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220421 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 11 IP - 7 DP - 2022 Mar 30 TI - Randomized Controlled Trial Comparing a Multidisciplinary Intervention by a Geriatrician and a Cardiologist to Usual Care after a Heart Failure Hospitalization in Older Patients: The SENECOR Study. LID - 10.3390/jcm11071932 [doi] LID - 1932 AB - BACKGROUND: The prognosis of older patients after a heart failure (HF) hospitalization is poor. METHODS: In this randomized trial, we consecutively assigned 150 patients 75 years old or older with a recent heart failure hospitalization to follow-up by a cardiologist (control) or follow-up by a cardiologist and a geriatrician (intervention). The primary outcome was all-cause hospitalization at a one-year follow-up. RESULTS: All-cause hospitalization occurred in 47 of 75 patients (62.7%) in the intervention group and in 58 of 75 patients (77.3%) in the control group (hazard ratio, 0.67; 95% confidence interval, 0.46 to 0.99; p = 0.046). The number of patients with at least one HF hospitalization was similar in both groups (34.7% in the intervention group vs. 40% in the control group, p = 0.5). There were a total of 236 hospitalizations during the study period. The main reasons for hospitalization were heart failure (38.1%) and infection (14.8%). Mortality was 24.7%. Heart failure was the leading cause of mortality (54.1% of all deaths), without differences between groups. CONCLUSIONS: A follow-up by a cardiologist and geriatrician in older patients after an HF hospitalization was superior to a cardiologist's follow-up in reducing all-cause hospitalization in older patients. (Funded by Beca Primitivo de la Vega, Fundacion MAPFRE. CLINICALTRIALS: gov number, NCT03555318). FAU - Herrero-Torrus, Marta AU - Herrero-Torrus M AD - Geriatrics Department, Hospital del Mar, 08003 Barcelona, Spain. FAU - Badosa, Neus AU - Badosa N AD - Heart Failure Unit, Cardiology Department, Hospital del Mar, 08003 Barcelona, Spain. AD - Biomedical Research Group on Heart Disease, Hospital del Mar Medical Research Group (IMIM), 08003 Barcelona, Spain. FAU - Roqueta, Cristina AU - Roqueta C AD - Geriatrics Department, Hospital del Mar, 08003 Barcelona, Spain. AD - Department of Medicine, Universitat Autonoma de Barcelona, 08193 Barcelona, Spain. FAU - Ruiz-Bustillo, Sonia AU - Ruiz-Bustillo S AUID- ORCID: 0000-0002-6074-914X AD - Heart Failure Unit, Cardiology Department, Hospital del Mar, 08003 Barcelona, Spain. AD - Biomedical Research Group on Heart Disease, Hospital del Mar Medical Research Group (IMIM), 08003 Barcelona, Spain. AD - Department of Experimental and Health Sciences, Universitat Pompeu Fabra, 08002 Barcelona, Spain. FAU - Sole-Gonzalez, Eduard AU - Sole-Gonzalez E AD - Heart Failure Unit, Cardiology Department, Hospital del Mar, 08003 Barcelona, Spain. FAU - Belarte-Tornero, Laia C AU - Belarte-Tornero LC AUID- ORCID: 0000-0003-2774-1290 AD - Heart Failure Unit, Cardiology Department, Hospital del Mar, 08003 Barcelona, Spain. AD - Biomedical Research Group on Heart Disease, Hospital del Mar Medical Research Group (IMIM), 08003 Barcelona, Spain. FAU - Valdivielso-More, Sandra AU - Valdivielso-More S AUID- ORCID: 0000-0002-0400-3247 AD - Heart Failure Unit, Cardiology Department, Hospital del Mar, 08003 Barcelona, Spain. AD - Biomedical Research Group on Heart Disease, Hospital del Mar Medical Research Group (IMIM), 08003 Barcelona, Spain. FAU - Vazquez, Olga AU - Vazquez O AD - Geriatrics Department, Hospital del Mar, 08003 Barcelona, Spain. FAU - Farre, Nuria AU - Farre N AUID- ORCID: 0000-0003-3110-6572 AD - Heart Failure Unit, Cardiology Department, Hospital del Mar, 08003 Barcelona, Spain. AD - Biomedical Research Group on Heart Disease, Hospital del Mar Medical Research Group (IMIM), 08003 Barcelona, Spain. AD - Department of Medicine, Universitat Autonoma de Barcelona, 08193 Barcelona, Spain. LA - eng SI - ClinicalTrials.gov/NCT03555318 GR - Beca Primitivo de la Vega/Fundacion Mapfre/ PT - Journal Article DEP - 20220330 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC8999953 OTO - NOTNLM OT - all-cause hospitalization OT - cardiologist OT - frailty OT - geriatrician OT - heart failure OT - prognosis COIS- The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. EDAT- 2022/04/13 06:00 MHDA- 2022/04/13 06:01 PMCR- 2022/03/30 CRDT- 2022/04/12 01:07 PHST- 2022/02/20 00:00 [received] PHST- 2022/03/25 00:00 [revised] PHST- 2022/03/28 00:00 [accepted] PHST- 2022/04/12 01:07 [entrez] PHST- 2022/04/13 06:00 [pubmed] PHST- 2022/04/13 06:01 [medline] PHST- 2022/03/30 00:00 [pmc-release] AID - jcm11071932 [pii] AID - jcm-11-01932 [pii] AID - 10.3390/jcm11071932 [doi] PST - epublish SO - J Clin Med. 2022 Mar 30;11(7):1932. doi: 10.3390/jcm11071932. PMID- 35407451 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220421 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 11 IP - 7 DP - 2022 Mar 26 TI - Current Strategies to Optimize Nutrition and Growth in Newborns and Infants with Congenital Heart Disease: A Narrative Review. LID - 10.3390/jcm11071841 [doi] LID - 1841 AB - (1) Objective: This review aims to identify the clinical and practical barriers to optimizing nutrition in newborn infants with congenital heart disease (CHD) and to describe updated evidence-based recommendations for clinical and nutritional management of these patients in a narrative review. (2) Research Methods and Procedures: We conducted a search of the relevant literature published from 2000 to December 2021. (3) Results: CHD patients undergo several nutritional challenges related to the underlying cardiac disease anomaly, the potential increased risk of NEC, and delayed enteral feeding, resulting in inadequate energy intake and sub-optimal growth, increased morbidity and mortality. (4) Conclusions: To optimize nutrition and growth in newborn infants with CHD, standardized protocols should be implemented. Regular nutritional and growth assessment with a multi-disciplinary team is essential. We propose a decisional algorithm that may represent a potentially useful tool to guide clinicians to optimize growth and nutrition. FAU - Salvatori, Guglielmo AU - Salvatori G AUID- ORCID: 0000-0001-8761-8732 AD - Neonatal Intensive Care Unit, Medical and Surgical Department of Fetus-Newborn-Infant, "Bambino Gesu" Children's Hospital, IRCCS, 00165 Rome, Italy. AD - Human Milk Bank, Medical and Surgical Department of Fetus-Newborn-Infant, "Bambino Gesu" Children's Hospital, IRCCS, 00165 Rome, Italy. FAU - De Rose, Domenico Umberto AU - De Rose DU AUID- ORCID: 0000-0002-9076-9838 AD - Neonatal Intensive Care Unit, Medical and Surgical Department of Fetus-Newborn-Infant, "Bambino Gesu" Children's Hospital, IRCCS, 00165 Rome, Italy. AD - PhD Course in Microbiology, Immunology, Infectious Diseases, and Transplants (MIMIT), Faculty of Medicine and Surgery, University of Rome "Tor Vergata", 00133 Rome, Italy. FAU - Massolo, Anna Claudia AU - Massolo AC AUID- ORCID: 0000-0002-1731-3068 AD - Neonatal Intensive Care Unit, Medical and Surgical Department of Fetus-Newborn-Infant, "Bambino Gesu" Children's Hospital, IRCCS, 00165 Rome, Italy. AD - Human Milk Bank, Medical and Surgical Department of Fetus-Newborn-Infant, "Bambino Gesu" Children's Hospital, IRCCS, 00165 Rome, Italy. FAU - Patel, Neil AU - Patel N AD - Department of Neonatology, Royal Hospital for Children, Glasgow G51 4TF, UK. FAU - Capolupo, Irma AU - Capolupo I AUID- ORCID: 0000-0002-3090-2887 AD - Neonatal Intensive Care Unit, Medical and Surgical Department of Fetus-Newborn-Infant, "Bambino Gesu" Children's Hospital, IRCCS, 00165 Rome, Italy. AD - Human Milk Bank, Medical and Surgical Department of Fetus-Newborn-Infant, "Bambino Gesu" Children's Hospital, IRCCS, 00165 Rome, Italy. FAU - Giliberti, Paola AU - Giliberti P AD - Neonatal Intensive Care Unit, Medical and Surgical Department of Fetus-Newborn-Infant, "Bambino Gesu" Children's Hospital, IRCCS, 00165 Rome, Italy. AD - Human Milk Bank, Medical and Surgical Department of Fetus-Newborn-Infant, "Bambino Gesu" Children's Hospital, IRCCS, 00165 Rome, Italy. FAU - Evangelisti, Melania AU - Evangelisti M AD - NESMOS Department, Chair of Pediatrics, Faculty of Medicine and Psychology, Sapienza University of Rome, Sant'Andrea University Hospital, 00189 Rome, Italy. FAU - Parisi, Pasquale AU - Parisi P AUID- ORCID: 0000-0001-9042-8120 AD - NESMOS Department, Chair of Pediatrics, Faculty of Medicine and Psychology, Sapienza University of Rome, Sant'Andrea University Hospital, 00189 Rome, Italy. FAU - Toscano, Alessandra AU - Toscano A AD - Perinatal Cardiology Unit, Medical and Surgical Department of Fetus-Newborn-Infant, "Bambino Gesu" Children's Hospital, IRCCS, 00165 Rome, Italy. FAU - Dotta, Andrea AU - Dotta A AUID- ORCID: 0000-0002-1260-6427 AD - Neonatal Intensive Care Unit, Medical and Surgical Department of Fetus-Newborn-Infant, "Bambino Gesu" Children's Hospital, IRCCS, 00165 Rome, Italy. AD - Human Milk Bank, Medical and Surgical Department of Fetus-Newborn-Infant, "Bambino Gesu" Children's Hospital, IRCCS, 00165 Rome, Italy. FAU - Di Nardo, Giovanni AU - Di Nardo G AUID- ORCID: 0000-0002-9026-7758 AD - NESMOS Department, Chair of Pediatrics, Faculty of Medicine and Psychology, Sapienza University of Rome, Sant'Andrea University Hospital, 00189 Rome, Italy. LA - eng PT - Journal Article PT - Review DEP - 20220326 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC8999967 OTO - NOTNLM OT - congenital heart disease OT - enteral feed OT - growth OT - necrotizing enterocolitis OT - nutrition OT - parenteral nutrition COIS- The authors declare no conflict of interest. EDAT- 2022/04/13 06:00 MHDA- 2022/04/13 06:01 PMCR- 2022/03/26 CRDT- 2022/04/12 01:07 PHST- 2022/01/29 00:00 [received] PHST- 2022/03/22 00:00 [revised] PHST- 2022/03/24 00:00 [accepted] PHST- 2022/04/12 01:07 [entrez] PHST- 2022/04/13 06:00 [pubmed] PHST- 2022/04/13 06:01 [medline] PHST- 2022/03/26 00:00 [pmc-release] AID - jcm11071841 [pii] AID - jcm-11-01841 [pii] AID - 10.3390/jcm11071841 [doi] PST - epublish SO - J Clin Med. 2022 Mar 26;11(7):1841. doi: 10.3390/jcm11071841. PMID- 35404945 OWN - NLM STAT- MEDLINE DCOM- 20220413 LR - 20220616 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 17 IP - 4 DP - 2022 TI - Outcome of adult cardiac surgery following COVID-19 infection in unvaccinated population in a national tertiary centre. PG - e0266056 LID - 10.1371/journal.pone.0266056 [doi] LID - e0266056 AB - BACKGROUND: Ever since COVID-19 was declared a pandemic, the world medical landscape has changed dramatically. As cardiac surgeons we not only have the duty to protect our patients and staff from COVID-19 infection, but we are also tasked with the responsibility to ensure those cardiovascular patients awaiting surgery are not harmed from an extended delay in surgery as the world comes to a halt from COVID-19. Currently there is limited literature on the outcome of cardiac surgery in the pre-operative Covid positive group. In this study we aim to assess the safety and outcome of patients undergoing cardiac surgery following Covid-19 infection. PATIENTS AND METHODS: This was a single centre retrospective observational study. All patients undergoing open heart surgery at Institut Jantung Negara from June 2020 to July 2021 were included in this study. Patients who were Covid positive pre-operatively were identified. Data from patient medical records collected contemporaneously were reviewed and analysed, supplemented by telephone call interviews after discharge. RESULTS: 2368 patients underwent open heart surgery from June 2020 until July 2021 in our centre. Of these, 0.5% (12 patients) were identified as Covid positive pre-operatively. Mean age of patients were 59.1 +/- 14.8 years old. Mean Ejection Fraction was 46.4 +/- 12.9. Most patients (75%) were asymptomatic with covid infection and only one patient were admitted to hospital for Covid infection. Mean duration from Covid PCR positive swab to surgery were 46.3 +/- 32.7days. Most of the patients (66.7%) underwent operation on an emergency or urgent basis. Median time to extubation was 1 day. Median ICU length of stay was 1 day. 25% patients required non-invasive ventilation post-operatively and one patient was discharged home on long term oxygen therapy. There were 2 deaths- none of which were covid related mortality. CONCLUSION: Cardiac surgery could be performed safely in patients with pre-operative Covid-19 infection after a period of recovery, especially in the asymptomatic to mild category of infection. Multi-disciplinary team approach may be useful in deciding the timing of surgery for complex cases. FAU - Ismail, Nur Aziah AU - Ismail NA AUID- ORCID: 0000-0003-0022-9545 AD - Department of Cardiothoracic Surgery, Institut Jantung Negara, Kuala Lumpur, Malaysia. FAU - Jaapar, Ahmad Nazrin AU - Jaapar AN AD - Department of Cardiothoracic Surgery, Institut Jantung Negara, Kuala Lumpur, Malaysia. FAU - Yunus, Alwi Mohamed AU - Yunus AM AD - Department of Cardiothoracic Surgery, Institut Jantung Negara, Kuala Lumpur, Malaysia. FAU - Sanusi, Abdul Rais AU - Sanusi AR AD - Department of Cardiothoracic Surgery, Institut Jantung Negara, Kuala Lumpur, Malaysia. FAU - Taib, Mohamed Ezani AU - Taib ME AD - Department of Cardiothoracic Surgery, Institut Jantung Negara, Kuala Lumpur, Malaysia. FAU - Yakub, Mohd Azhari AU - Yakub MA AD - Department of Cardiothoracic Surgery, Institut Jantung Negara, Kuala Lumpur, Malaysia. LA - eng SI - figshare/10.6084/m9.figshare.19538236 PT - Journal Article PT - Observational Study DEP - 20220411 PL - United States TA - PLoS One JT - PloS one JID - 101285081 SB - IM MH - Adult MH - Aged MH - *COVID-19/epidemiology MH - *Cardiac Surgical Procedures/adverse effects MH - Humans MH - Middle Aged MH - Pandemics MH - SARS-CoV-2 MH - Treatment Outcome PMC - PMC9000966 COIS- The authors have declared that no competing interests exist. EDAT- 2022/04/12 06:00 MHDA- 2022/04/14 06:00 PMCR- 2022/04/11 CRDT- 2022/04/11 17:40 PHST- 2021/10/19 00:00 [received] PHST- 2022/03/11 00:00 [accepted] PHST- 2022/04/11 17:40 [entrez] PHST- 2022/04/12 06:00 [pubmed] PHST- 2022/04/14 06:00 [medline] PHST- 2022/04/11 00:00 [pmc-release] AID - PONE-D-21-33226 [pii] AID - 10.1371/journal.pone.0266056 [doi] PST - epublish SO - PLoS One. 2022 Apr 11;17(4):e0266056. doi: 10.1371/journal.pone.0266056. eCollection 2022. PMID- 35403216 OWN - NLM STAT- MEDLINE DCOM- 20220713 LR - 20240905 IS - 1365-2362 (Electronic) IS - 0014-2972 (Print) IS - 0014-2972 (Linking) VI - 52 IP - 8 DP - 2022 Aug TI - Revascularization strategies for patients with established chronic coronary syndrome. PG - e13787 LID - 10.1111/eci.13787 [doi] LID - e13787 AB - Coronary artery disease is the most common type of cardiovascular disease, leading to high mortality rates worldwide. Although the vast majority can be treated effectively and safely by medical therapy, revascularization strategies remain essential for numerous patients. Outcomes of both percutaneous coronary intervention and coronary artery bypass grafting improve in a rapid pace, resulting from technical innovation and ongoing research. Progress has been achieved by technical improvements in coronary stents, optimal coronary target and graft selection, and the availability of minimally invasive surgical strategies. Besides technical progress, evidence-based patient-tailored decision-making by the Heart Team is the basic precondition for optimal outcome. The combination of fast innovation and long-term clinical evaluations creates a dynamic field. Research outcomes should be carefully interpreted according to the techniques used and the trial's design. Therefore, more and more trial outcomes suggest that revascularization strategies should be tailored towards the specific patient. Although the European Society of Cardiology/European Association for Cardio-Thoracic Surgery guidelines on myocardial revascularization date from 2018 and a large variety of trial outcomes on revascularization strategies in chronic coronary syndrome have been published since, we aim to provide an updated overview within this review. CI - (c) 2022 The Authors. European Journal of Clinical Investigation published by John Wiley & Sons Ltd on behalf of Stichting European Society for Clinical Investigation Journal Foundation. FAU - Coerkamp, Casper F AU - Coerkamp CF AUID- ORCID: 0000-0002-7237-9473 AD - Department of Cardiology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. FAU - Hoogewerf, Marieke AU - Hoogewerf M AD - Department of Cardiothoracic Surgery, St. Antonius Hospital, Nieuwegein, The Netherlands. AD - Department of Cardiology, University Medical Centre Utrecht, Utrecht, The Netherlands. FAU - van Putte, Bart P AU - van Putte BP AD - Department of Cardiothoracic Surgery, St. Antonius Hospital, Nieuwegein, The Netherlands. FAU - Appelman, Yolande AU - Appelman Y AD - Department of Cardiology, Amsterdam UMC, Amsterdam Cardiovascular Sciences, University of Amsterdam, Amsterdam, The Netherlands. FAU - Doevendans, Pieter A AU - Doevendans PA AD - Department of Cardiology, University Medical Centre Utrecht, Utrecht, The Netherlands. AD - Netherlands Heart Institute, Utrecht, The Netherlands. LA - eng PT - Journal Article PT - Review DEP - 20220429 PL - England TA - Eur J Clin Invest JT - European journal of clinical investigation JID - 0245331 SB - IM MH - Coronary Artery Bypass MH - *Coronary Artery Disease/surgery MH - Humans MH - Myocardial Revascularization MH - *Percutaneous Coronary Intervention MH - Stents MH - Treatment Outcome PMC - PMC9539712 OTO - NOTNLM OT - chronic coronary syndrome OT - coronary revascularization OT - patient-tailored COIS- We have no conflicts of interest to disclose. EDAT- 2022/04/12 06:00 MHDA- 2022/07/14 06:00 PMCR- 2022/10/07 CRDT- 2022/04/11 05:34 PHST- 2022/04/03 00:00 [revised] PHST- 2022/02/21 00:00 [received] PHST- 2022/04/04 00:00 [accepted] PHST- 2022/04/12 06:00 [pubmed] PHST- 2022/07/14 06:00 [medline] PHST- 2022/04/11 05:34 [entrez] PHST- 2022/10/07 00:00 [pmc-release] AID - ECI13787 [pii] AID - 10.1111/eci.13787 [doi] PST - ppublish SO - Eur J Clin Invest. 2022 Aug;52(8):e13787. doi: 10.1111/eci.13787. Epub 2022 Apr 29. PMID- 35401791 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220413 IS - 1756-1485 (Electronic) IS - 1756-1477 (Print) IS - 1756-1485 (Linking) VI - 17 DP - 2022 Jan TI - Trends in Transcatheter Aortic Valve Implantation in Australia. PG - e03 LID - 10.15420/icr.2021.27 [doi] LID - e03 AB - Aortic valve stenosis is the most common valvular lesion in Australia, with a rising prevalence in line with the ageing population. Recent trials have demonstrated the efficacy of transcatheter aortic valve implantation (TAVI) versus surgical aortic valve replacement in consecutively lower surgical risk patient cohorts. Despite this, the current indication for TAVI in Australia is for the treatment of severe symptomatic aortic stenosis in patients who are of prohibitive or high surgical risk and ultimately deemed suitable by a heart team. This article summarises the trends in TAVI in Australia over the last 5 years in terms of funding, accreditation and service delivery, as well as advances in technique, technology, patient selection and local outcomes. CI - Copyright (c) 2022, Radcliffe Cardiology. FAU - Gray, Rhys AU - Gray R AD - Department of Cardiology, Prince of Wales Hospital Sydney, Australia. AD - Prince of Wales Clinical School, University of New South Wales Medicine Sydney, Australia. AD - Eastern Heart Clinic Sydney, Australia. FAU - Sarathy, Kiran AU - Sarathy K AD - Department of Cardiology, Prince of Wales Hospital Sydney, Australia. AD - Prince of Wales Clinical School, University of New South Wales Medicine Sydney, Australia. AD - Eastern Heart Clinic Sydney, Australia. LA - eng PT - Journal Article PT - Review DEP - 20220321 PL - England TA - Interv Cardiol JT - Interventional cardiology (London, England) JID - 101559687 PMC - PMC8977994 OTO - NOTNLM OT - Aortic stenosis OT - Australia OT - review OT - surgical aortic valve replacement OT - transcatheter aortic valve implantation COIS- Disclosure: The authors have no conflicts of interest to declare. EDAT- 2022/04/12 06:00 MHDA- 2022/04/12 06:01 PMCR- 2022/03/21 CRDT- 2022/04/11 05:29 PHST- 2021/09/20 00:00 [received] PHST- 2021/12/05 00:00 [accepted] PHST- 2022/04/11 05:29 [entrez] PHST- 2022/04/12 06:00 [pubmed] PHST- 2022/04/12 06:01 [medline] PHST- 2022/03/21 00:00 [pmc-release] AID - 10.15420/icr.2021.27 [doi] PST - epublish SO - Interv Cardiol. 2022 Mar 21;17:e03. doi: 10.15420/icr.2021.27. eCollection 2022 Jan. PMID- 35399072 OWN - NLM STAT- MEDLINE DCOM- 20220412 LR - 20220414 IS - 1471-2393 (Electronic) IS - 1471-2393 (Linking) VI - 22 IP - 1 DP - 2022 Apr 10 TI - Pregnancy maternal fetal outcomes among pregnancies complicated with atrioventricular block. PG - 307 LID - 10.1186/s12884-022-04650-x [doi] LID - 307 AB - BACKGROUND: Atrioventricular block (AVB) during pregnancy is rare. Case study for pregnancy with AVB have been reported but a consensus guideline for peripartum management has not been established. This study aimed to investigate cardiac and obstetric complications and outcomes in our pregnant women with AVB and share our management experience. METHODS: This was a retrospective study. We reviewed a total of 74 pregnant women with AVB who delivered at our tertiary care center in the past 10 years. The patients were categorized into four groups according to the degree of block. The data were analyzed and compared among the four groups of patients. RESULTS: Regarding the cardiac complications, the cardiac function level showed significant difference among patient groups. The higher NYHA class were observed in patients with higher degree AVB. Pacemaker was placed before delivery in 32/33 patients with III degrees AVB, 8/25 patients with II degrees AVB, and 0/16 patient with I degrees AVB. Other types of arrhythmias except AVB were present in all groups of patients but more frequently observed in type I patients with II degrees AVB. No other heart abnormalities were observed among the patient groups. Obstetric complications were found in 21 women (28.4%), including premature labor, premature rupture of membranes (PROM), gestational diabetes mellitus (GDM), preeclampsia, etc. The incidence rate of fetal cardiac abnormalities was 6.58%. But no statistical difference was detected among four groups of patients for fetal and maternal complications and fetal cardiac abnormalities (P>0.05). Caesarean section was performed more in patients with high-degree AVB than in patients with low-degree AVB. No maternal or neonatal death in our cases. CONCLUSIONS: Most women with AVB could achieve successful pregnancy and delivery. Patients with II degrees AVB type II and III degrees AVB should be monitored vigilantly during pregnancy and post-partum. Temporary pacing before delivery appeared to be beneficial for women with III degrees AVB, and accurate diagnosis and care by a multidisciplinary team was recommended. CI - (c) 2022. The Author(s). FAU - Wang, Kana AU - Wang K AD - Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, No. 20, 3rd section, South Renmin Road, Chengdu, 610041, Sichuan, China. AD - Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Sichuan University, No. 20, 3rd section, South Renmin Road, Chengdu, 610041, Sichuan, China. FAU - Xin, Junguo AU - Xin J AD - School of Public Heath, Chengdu Medical College, Chengdu, China. FAU - Huang, Guiqiong AU - Huang G AD - Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, No. 20, 3rd section, South Renmin Road, Chengdu, 610041, Sichuan, China. AD - Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Sichuan University, No. 20, 3rd section, South Renmin Road, Chengdu, 610041, Sichuan, China. FAU - Wang, Xiaodong AU - Wang X AD - Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, No. 20, 3rd section, South Renmin Road, Chengdu, 610041, Sichuan, China. AD - Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Sichuan University, No. 20, 3rd section, South Renmin Road, Chengdu, 610041, Sichuan, China. FAU - Yu, Haiyan AU - Yu H AD - Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, No. 20, 3rd section, South Renmin Road, Chengdu, 610041, Sichuan, China. fanjy422@163.com. AD - Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Sichuan University, No. 20, 3rd section, South Renmin Road, Chengdu, 610041, Sichuan, China. fanjy422@163.com. LA - eng GR - No.2017-919-25/Academic and Technical Leader's Foundation of Sichuan Province/ PT - Journal Article DEP - 20220410 PL - England TA - BMC Pregnancy Childbirth JT - BMC pregnancy and childbirth JID - 100967799 SB - IM MH - *Atrioventricular Block/epidemiology/etiology/therapy MH - Cesarean Section MH - Female MH - Fetus MH - Humans MH - Infant, Newborn MH - Pregnancy MH - Pregnancy Outcome/epidemiology MH - Retrospective Studies PMC - PMC8994888 OTO - NOTNLM OT - Atrioventricular block OT - Cardiac arrhythmias OT - Gestation OT - Pacemaker COIS- The authors report no conflict of interest about this paper. EDAT- 2022/04/12 06:00 MHDA- 2022/04/13 06:00 PMCR- 2022/04/10 CRDT- 2022/04/11 05:04 PHST- 2021/09/08 00:00 [received] PHST- 2022/04/04 00:00 [accepted] PHST- 2022/04/11 05:04 [entrez] PHST- 2022/04/12 06:00 [pubmed] PHST- 2022/04/13 06:00 [medline] PHST- 2022/04/10 00:00 [pmc-release] AID - 10.1186/s12884-022-04650-x [pii] AID - 4650 [pii] AID - 10.1186/s12884-022-04650-x [doi] PST - epublish SO - BMC Pregnancy Childbirth. 2022 Apr 10;22(1):307. doi: 10.1186/s12884-022-04650-x. PMID- 39132569 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240813 IS - 2772-9303 (Electronic) IS - 2772-9303 (Linking) VI - 1 IP - 2 DP - 2022 Mar-Apr TI - Impact of Decision Aid on Decision-making of Patients With Severe Aortic Stenosis: Randomized Pilot Study. PG - 100025 LID - 10.1016/j.jscai.2022.100025 [doi] LID - 100025 AB - BACKGROUND: Clinical guidelines recommend patients with aortic stenosis (AS) being considered for transcatheter aortic valve implantation or surgical aortic valve replacement to participate in shared decision-making (SDM) with a heart valve team (HVT). Data supporting these recommendations are limited. This project gathered data on feasibility and preliminary efficacy of a decision aid (DA) in decision-making for patients with severe AS deciding between transcatheter aortic valve implantation and surgical aortic valve replacement. METHODS: This institutional review board-approved randomized pilot trial assigned eligible patients to receive either the American College of Cardiology's DA for patients with AS or usual care. Patients were surveyed after their visit regarding knowledge, treatment-preference concordance, SDM (SDM process and CollaboRATE Scales), and decisional conflict. Patients were followed for 3 months to collect data on treatment received. RESULTS: Of 62 patients approached, 59 (95%) consented and participated. The average age of participants was 72 years, they were 100% white, and 32% of them were female. Intervention patients had higher knowledge scores (75.6 vs 65.5) and more frequently reported CollaboRATE top scores (67% vs 33%) than usual care patients. No other group comparisons reached significance. Patients who saw both members of the HVT before survey completion reported higher SDM process scores than those who saw only 1 specialist (3.1 vs 2.4). CONCLUSIONS: The study exceeded enrollment targets, indicating feasibility. Results suggest the American College of Cardiology's DA improved patient knowledge and communication scores. Patients who met with both members of the HVT reported higher SDM. These observations highlight the importance of SDM and multidisciplinary HVT assessment in the management of severe AS. CI - (c) 2022 The Authors. FAU - Valentine, K D AU - Valentine KD AD - Department of General Internal Medicine, Massachusetts General Hospital, Boston, Massachusetts. FAU - Marques, Felisha AU - Marques F AD - Department of General Internal Medicine, Massachusetts General Hospital, Boston, Massachusetts. FAU - Selberg, Alexandra AU - Selberg A AD - Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts. FAU - Flannery, Laura AU - Flannery L AD - Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts. FAU - Langer, Nathaniel AU - Langer N AD - Division of Cardiac Surgery, Massachusetts General Hospital, Boston, Massachusetts. FAU - Inglessis, Ignacio AU - Inglessis I AD - Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts. FAU - Passeri, Jonathan AU - Passeri J AD - Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts. FAU - Sundt, Thoralf AU - Sundt T AD - Division of Cardiac Surgery, Massachusetts General Hospital, Boston, Massachusetts. FAU - Sepucha, Karen AU - Sepucha K AD - Department of General Internal Medicine, Massachusetts General Hospital, Boston, Massachusetts. FAU - Elmariah, Sammy AU - Elmariah S AD - Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts. LA - eng PT - Journal Article DEP - 20220411 PL - United States TA - J Soc Cardiovasc Angiogr Interv JT - Journal of the Society for Cardiovascular Angiography & Interventions JID - 9918419271306676 PMC - PMC11308039 OTO - NOTNLM OT - Aortic stenosis OT - aortic valve replacement OT - decision aid implementation OT - shared decision-making EDAT- 2022/04/11 00:00 MHDA- 2022/04/11 00:01 PMCR- 2022/04/11 CRDT- 2024/08/12 06:25 PHST- 2021/12/20 00:00 [received] PHST- 2022/01/27 00:00 [revised] PHST- 2022/01/28 00:00 [accepted] PHST- 2022/04/11 00:01 [medline] PHST- 2022/04/11 00:00 [pubmed] PHST- 2024/08/12 06:25 [entrez] PHST- 2022/04/11 00:00 [pmc-release] AID - S2772-9303(22)00008-4 [pii] AID - 100025 [pii] AID - 10.1016/j.jscai.2022.100025 [doi] PST - epublish SO - J Soc Cardiovasc Angiogr Interv. 2022 Apr 11;1(2):100025. doi: 10.1016/j.jscai.2022.100025. eCollection 2022 Mar-Apr. PMID- 35396217 OWN - NLM STAT- MEDLINE DCOM- 20220517 LR - 20220518 IS - 1468-201X (Electronic) IS - 1355-6037 (Linking) VI - 108 IP - 11 DP - 2022 May 12 TI - Getting the best from the Heart Team: guidance for cardiac multidisciplinary meetings. PG - e2 LID - 10.1136/heartjnl-2021-320510 [doi] AB - The purpose of this document is to update the existing joint British Societies recommendations on multidisciplinary meetings (MDMs) published in 2015 to reflect changes in practice. We aim to provide guidance on the structure and function of MDMs which should be taking place in every cardiac surgical centre. Out of scope are MDMs that do not require the routine presence of a cardiac surgeon such as electrophysiology MDMs and those which are not provided in every centre, such as complex aortic surgery. CI - (c) Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Archbold, Andrew AU - Archbold A AD - Cardiology, Barts Health NHS Trust, London, UK. FAU - Akowuah, Enoch AU - Akowuah E AD - Cardiac Surgery, South Tees Hospitals NHS Foundation Trust, Middlesbrough, UK. FAU - Banning, Adrian P AU - Banning AP AD - Cardiology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. FAU - Baumbach, Andreas AU - Baumbach A AD - Cardiology, Queen Mary University of London, London, UK. AD - Barts Heart Centre, Barts Health NHS Trust, London, UK. FAU - Braidley, Peter AU - Braidley P AD - Cardiac Surgery, Northern General Hospital, Sheffield, UK. FAU - Cooper, Graham AU - Cooper G AD - Cardiac Surgery, Northern General Hospital, Sheffield, UK. FAU - Kendall, Simon AU - Kendall S AD - Cardiac Surgery, South Tees Hospitals NHS Foundation Trust, Middlesbrough, UK. FAU - MacCarthy, Philip AU - MacCarthy P AUID- ORCID: 0000-0002-5963-0109 AD - Cardiology, King's College Hospital NHS Foundation Trust, London, UK. FAU - O'Kane, Peter AU - O'Kane P AD - Cardiology, University Hospitals Dorset NHS Foundation Trust, Poole, UK. FAU - O'Keeffe, Niall AU - O'Keeffe N AD - Cardiothoracic Anaesthesia and Critical Care, Manchester University NHS Foundation Trust, Manchester, UK. FAU - Shah, Benoy Nalin AU - Shah BN AUID- ORCID: 0000-0001-9681-7311 AD - Cardiology, Wessex Cardiothoracic Centre, University Hospital Southampton, Southampton, UK. FAU - Watt, Victoria AU - Watt V AD - Cardiology, Manchester University Hospitals NHS Foundation Trust, Manchester, UK. FAU - Ray, Simon AU - Ray S AUID- ORCID: 0000-0001-7775-1900 AD - Cardiology, Manchester University Hospitals NHS Foundation Trust, Manchester, UK simon.ray@nhs.net. LA - eng PT - Journal Article DEP - 20220512 PL - England TA - Heart JT - Heart (British Cardiac Society) JID - 9602087 SB - IM MH - Humans MH - *Interdisciplinary Communication MH - *Patient Care Team COIS- Competing interests: APB: unrestricted educational grant from Boston Scientific, speaker fees from Boston Scientific, Abbott Vascular, Medtronic, Miracor and Shockwave. AB: research support from Abbott Vascular, speaker fees from Microport, AstraZeneca, Sinomed, Medtronic, Terumo, Pi-cardia. GC: payment for expert testimony, Cambridgeshire Coroner, Trustee, The Aortic Dissection Charitable Trust. PMacC: speaker fees and expert testimony, Edwards Life Sciences. SR: fee for chairing advisory board and speaker fee paid to Manchester University Hospitals, Novartis; reimbursement of travel expenses as speaker (no fee), Abbott. Trustee, Heart Valve Voice. EDAT- 2022/04/10 06:00 MHDA- 2022/05/18 06:00 CRDT- 2022/04/09 05:17 PHST- 2022/04/10 06:00 [pubmed] PHST- 2022/05/18 06:00 [medline] PHST- 2022/04/09 05:17 [entrez] AID - heartjnl-2021-320510 [pii] AID - 10.1136/heartjnl-2021-320510 [doi] PST - epublish SO - Heart. 2022 May 12;108(11):e2. doi: 10.1136/heartjnl-2021-320510. PMID- 35394457 OWN - NLM STAT- MEDLINE DCOM- 20220503 LR - 20230821 IS - 2327-6924 (Electronic) IS - 2327-6886 (Print) IS - 2327-6886 (Linking) VI - 34 IP - 5 DP - 2022 May 1 TI - Exploring experiences associated with aortic stenosis diagnosis, treatment and life impact among middle-aged and older adults. PG - 748-754 LID - 10.1097/JXX.0000000000000714 [doi] AB - BACKGROUND AND PURPOSE: Although multiple studies have examined the clinical aspects of diagnosis, treatment, and management of patients with aortic stenosis (AS), limited data exist regarding patient experiences related to symptoms, diagnosis, treatment, and personal impacts of living with AS. METHODOLOGY: Adults aged >/=40 years diagnosed with AS were recruited and separated into three cohorts: medically managed, surgical aortic valve replacement (SAVR), and transcatheter aortic valve implantation (TAVI). Forty-five semi-structured interviews were conducted (15 per treatment group) via teleconference using open-ended questions and probes. Interview recordings were transcribed, and inductive thematic analyses were conducted. RESULTS: The majority of participants were male (55.6%), White (95.6%), and non-Hispanic (93.3%). Participants noting longer times to diagnosis also reported mild symptom onset and experiences of misdiagnoses. Participants described a strong reliance on their health care professionals (HCPs) to guide them through their treatment decisions, which were influenced by the effects of anticoagulation, future valve interventions, and recovery. Medically managed participants reported having to make lifestyle modifications to manage symptoms, while participants who underwent TAVI or SAVR reported positive sentiments in their ability to return to normal life following their treatment. CONCLUSIONS AND IMPLICATIONS: Due to the varied experiences of AS patients, there is a need to improve patient resources to advance patient understanding and facilitate informed treatment decisions. Reported experiences also indicate a need for additional HCP education on early referral to a multidisciplinary heart valve team. CI - Copyright (c) 2022 American Association of Nurse Practitioners. FAU - Picou, Kylie AU - Picou K AD - Data Science and Evaluation, American Heart Association , Dallas , Texas. FAU - Heard, Debra G AU - Heard DG AD - Data Science and Evaluation, American Heart Association , Dallas , Texas. FAU - Shah, Pinak B AU - Shah PB AD - Brigham and Women's Hospital, Heart and Vascular Center , Boston , Massachusetts. FAU - Arnold, Suzanne V AU - Arnold SV AD - Saint Luke's Mid America Heart Institute and University of Missouri , Kansas City , Missouri. LA - eng PT - Journal Article DEP - 20220501 PL - United States TA - J Am Assoc Nurse Pract JT - Journal of the American Association of Nurse Practitioners JID - 101600770 MH - Aged MH - *Aortic Valve Stenosis/diagnosis/surgery MH - Female MH - *Heart Valve Prosthesis Implantation MH - Humans MH - Male MH - Middle Aged MH - Risk Factors MH - *Transcatheter Aortic Valve Replacement MH - Treatment Outcome PMC - PMC9048624 COIS- Competing interests: K. Picou and D. Heard are employed by the American Heart Association. P. Shah is a proctor/consultant for Edwards Lifesciences, and has received educational grants from Edwards Lifesciences, Medtronic, and Abbott. The remaining authors report no conflicts of interest. EDAT- 2022/04/09 06:00 MHDA- 2022/05/04 06:00 PMCR- 2022/04/28 CRDT- 2022/04/08 12:11 PHST- 2021/07/14 00:00 [received] PHST- 2022/02/24 00:00 [accepted] PHST- 2022/04/09 06:00 [pubmed] PHST- 2022/05/04 06:00 [medline] PHST- 2022/04/08 12:11 [entrez] PHST- 2022/04/28 00:00 [pmc-release] AID - 01741002-202205000-00009 [pii] AID - JAANP-D-21-00159 [pii] AID - 10.1097/JXX.0000000000000714 [doi] PST - epublish SO - J Am Assoc Nurse Pract. 2022 May 1;34(5):748-754. doi: 10.1097/JXX.0000000000000714. PMID- 35393087 OWN - NLM STAT- MEDLINE DCOM- 20220411 LR - 20220411 IS - 2542-4513 (Electronic) IS - 2542-4513 (Linking) VI - 47 IP - 1 DP - 2022 Feb TI - Incident cardiovascular events and early mortality in patients with revascularized critical limb ischemia. PG - 19-26 LID - S2542-4513(22)00159-6 [pii] LID - 10.1016/j.jdmv.2022.02.001 [doi] AB - OBJECTIVES: Patients with critical limb ischemia (CLI) present a high risk of cardiovascular events and death. This study aimed to investigate the incidence of major adverse cardiovascular events (MACE) and one-year mortality in patients undergoing percutaneous revascularization procedure for CLI. METHODS: This investigation is a retrospective analysis of an ongoing cohort study in patients with CLI undergoing endovascular revascularization, hospitalized in the vascular medicine department from November 2013 to December 2018. Major cardiovascular events were collected during the first year after revascularization procedure and were defined as heart failure, acute coronary syndrome, ischemic stroke and sudden death. Mortality and major limb amputations, defined as above-the-ankle amputation, were determined during the one-year follow-up period. Multivariate logistic regression analyses were performed to identify factors independently associated with the occurrence of MACE and one-year mortality after revascularization procedure. A P 4.5%), only 19 received it. CONCLUSIONS: Despite the robustness of the risk models proposed for screening, several deviations from the recommended mode of revascularization were observed by the core laboratory among the first 200 patients with 3VD screened in the Multivessel TALENT trial. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov reference: NCT04390672. CI - Copyright: (c) 2022 The Author(s). Published by IMR Press. FAU - Ninomiya, Kai AU - Ninomiya K AD - Department of Cardiology, National University of Ireland, Galway (NUIG), H91 TK33 Galway, Ireland. FAU - Serruys, Patrick W AU - Serruys PW AD - Department of Cardiology, National University of Ireland, Galway (NUIG), H91 TK33 Galway, Ireland. AD - Department of Cardiology, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands. FAU - Garg, Scot AU - Garg S AD - Department of Cardiology, Royal Blackburn Hospital, BB2 3HH Blackburn, UK. FAU - Hara, Hironori AU - Hara H AD - Department of Cardiology, National University of Ireland, Galway (NUIG), H91 TK33 Galway, Ireland. FAU - Masuda, Shinichiro AU - Masuda S AD - Department of Cardiology, National University of Ireland, Galway (NUIG), H91 TK33 Galway, Ireland. FAU - Kageyama, Shigetaka AU - Kageyama S AD - Department of Cardiology, National University of Ireland, Galway (NUIG), H91 TK33 Galway, Ireland. FAU - Kotoku, Nozomi AU - Kotoku N AD - Department of Cardiology, National University of Ireland, Galway (NUIG), H91 TK33 Galway, Ireland. FAU - Sevestre, Emelyne AU - Sevestre E AD - Department of Cardiology, National University of Ireland, Galway (NUIG), H91 TK33 Galway, Ireland. FAU - Kumar, Abhishek AU - Kumar A AD - Department of Cardiology, Wrightington, Wigan and Leigh NHS Foundation Trust, WN1 2NN Wigan, UK. FAU - O'Kane, Peter AU - O'Kane P AD - Department of Cardiology, Royal Bournemouth Hospital, BH7 7DW Bournemouth, UK. FAU - Zaman, Azfar AU - Zaman A AD - Department of Cardiology, Freeman Hospital, NE7 7DN Newcastle, UK. FAU - Farah, Bruno AU - Farah B AD - Department of Interventional Cardiology, Clinique Pasteur, 31300 Toulouse, France. FAU - Magro, Michael AU - Magro M AD - Department of Cardiology, Elisabeth-TweeSteden Ziekenhuis, 5042AD Tilburg, The Netherlands. FAU - Oemrawsingh, Rohit M AU - Oemrawsingh RM AD - Department of Cardiology, Albert Schweitzer Hospital, 3318 AT Dordrecht, The Netherlands. FAU - Mollmann, Helge AU - Mollmann H AD - Department of Cardiology, St. Johannes Hospital, 44137 Dortmund, Germany. FAU - Meneveau, Nicolas AU - Meneveau N AD - Department of Cardiology, University Hospital Jean Minjoz, 25000 Besancon, France. FAU - Achenbach, Stephan AU - Achenbach S AD - Department of Cardiology, Friedrich-Alexander University Erlangen-Nurnberg, 91054 Erlangen, Germany. FAU - Lemoine, Julien AU - Lemoine J AD - Department of Cardiology, Clinique Louis Pasteur, 54270 Nancy, France. FAU - Allali, Abdelhakim AU - Allali A AD - Department of Cardiology, Heart Center, Segeberger Kliniken, 23795 Bad Segeberg, Germany. FAU - Gallagher, Sean AU - Gallagher S AD - Department of Cardiology, University Hospital of Wales, CF14 4XW Cardiff, UK. FAU - Wykrzykowska, Joanna AU - Wykrzykowska J AD - Department of Cardiology, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands. FAU - Lesiak, Maciej AU - Lesiak M AD - Department of Cardiology, Poznan University of Medical Sciences, 61-701 Poznan, Poland. FAU - Silvestri, Marc AU - Silvestri M AD - Department of Cardiology, GCS ES-Axium-Rambot, 13090 Aix-en-Provence, France. FAU - Wijns, William AU - Wijns W AD - Department of Cardiology, National University of Ireland, Galway (NUIG), H91 TK33 Galway, Ireland. FAU - Sharif, Faisal AU - Sharif F AD - Department of Cardiology, National University of Ireland, Galway (NUIG), H91 TK33 Galway, Ireland. FAU - Onuma, Yoshinobu AU - Onuma Y AD - Department of Cardiology, National University of Ireland, Galway (NUIG), H91 TK33 Galway, Ireland. LA - eng SI - ClinicalTrials.gov/NCT04390672 PT - Journal Article DEP - 20220408 PL - Singapore TA - Rev Cardiovasc Med JT - Reviews in cardiovascular medicine JID - 100960007 PMC - PMC11273643 OTO - NOTNLM OT - SYNTAX score OT - coronary artery bypass grafts (CABG) OT - percutaneous coronary intervention (PCI) OT - risk stratification COIS- The authors declare no conflict of interest. Patrick W. Serruys is serving as one of the Editorial Board members of this journal. We declare that Patrick W. Serruys had no involvement in the peer review of this article and has no access to information regarding its peer review. Full responsibility for the editorial process for this article was delegated to Peter A. McCullough and Federico Ronco. K. Ninomiya reports a grant from Abbott Medical Japan outside the submitted work. P.W. Serruys reports institutional grants from Sinomedical Sciences Technology, SMT (Sahajanand Medical technological), Philips/Volcano, Xeltis, and HeartFlow, outside the submitted work. EDAT- 2022/04/08 00:00 MHDA- 2022/04/08 00:01 PMCR- 2022/04/08 CRDT- 2024/07/30 04:54 PHST- 2022/01/28 00:00 [received] PHST- 2022/03/10 00:00 [revised] PHST- 2022/03/21 00:00 [accepted] PHST- 2022/04/08 00:01 [medline] PHST- 2022/04/08 00:00 [pubmed] PHST- 2024/07/30 04:54 [entrez] PHST- 2022/04/08 00:00 [pmc-release] AID - S1530-6550(22)00457-4 [pii] AID - 10.31083/j.rcm2304133 [doi] PST - epublish SO - Rev Cardiovasc Med. 2022 Apr 8;23(4):133. doi: 10.31083/j.rcm2304133. eCollection 2022 Apr. PMID- 35380417 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220827 IS - 1568-5888 (Print) IS - 1876-6250 (Electronic) IS - 1568-5888 (Linking) VI - 30 IP - 9 DP - 2022 Sep TI - Decision making in treatment of symptomatic severe aortic stenosis: a survey study in Dutch heart centres. PG - 423-428 LID - 10.1007/s12471-022-01676-w [doi] AB - AIM: To provide insight into the basic characteristics of decision making in the treatment of symptomatic severe aortic stenosis (SSAS) in Dutch heart centres with specific emphasis on the evaluation of frailty, cognition, nutritional status and physical functioning/functionality in (instrumental) activities of daily living [(I)ADL]. METHODS: A questionnaire was used that is based on the European and American guidelines for SSAS treatment. The survey was administered to physicians and non-physicians in Dutch heart centres involved in the decision-making pathway for SSAS treatment. RESULTS: All 16 Dutch heart centres participated. Before a patient case is discussed by the heart team, heart centres rarely request data from the referring hospital regarding patients' functionality (n = 5), frailty scores (n = 0) and geriatric consultation (n = 1) as a standard procedure. Most heart centres 'often to always' do their own screening for frailty (n = 10), cognition/mood (n = 9), nutritional status (n = 10) and physical functioning/functionality in (I)ADL (n = 10). During heart team meetings data are 'sometimes to regularly' available regarding frailty (n = 5), cognition/mood (n = 11), nutritional status (n = 8) and physical functioning/functionality in (I)ADL (n = 10). After assessment in the outpatient clinic patient cases are re-discussed 'sometimes to regularly' in heart team meetings (n = 10). CONCLUSIONS: Dutch heart centres make an effort to evaluate frailty, cognition, nutritional status and physical functioning/functionality in (I)ADL for decision making regarding SSAS treatment. However, these patient data are not routinely requested from the referring hospital and are not always available for heart team meetings. Incorporation of these important data in a structured manner early in the decision-making process may provide additional useful information for decision making in the heart team meeting. CI - (c) 2022. The Author(s). FAU - van Beek-Peeters, J J A M AU - van Beek-Peeters JJAM AD - Department of Cardiothoracic Surgery, Amphia Hospital, Breda, The Netherlands. jvanbeek1@amphia.nl. FAU - van den Ende, Z AU - van den Ende Z AD - Department of Geriatrics, Amphia Hospital, Breda, The Netherlands. FAU - Faes, M C AU - Faes MC AD - Department of Geriatrics, Amphia Hospital, Breda, The Netherlands. FAU - de Vos, A J B M AU - de Vos AJBM AD - Amphia Academy, Amphia Hospital, Breda, The Netherlands. FAU - van Geldorp, M W A AU - van Geldorp MWA AD - Department of Cardiothoracic Surgery, Amphia Hospital, Breda, The Netherlands. FAU - Van den Branden, B J L AU - Van den Branden BJL AD - Department of Interventional Cardiology, Amphia Hospital, Breda, The Netherlands. FAU - van der Meer, B J M AU - van der Meer BJM AD - TIAS School for Business and Society, Tilburg University, Tilburg, The Netherlands. AD - Board of Directors, Catharina Hospital, Eindhoven, The Netherlands. FAU - Minkman, M M N AU - Minkman MMN AD - TIAS School for Business and Society, Tilburg University, Tilburg, The Netherlands. AD - Vilans, Centre of Expertise for Long-term Care, Utrecht, The Netherlands. LA - eng PT - Journal Article DEP - 20220405 PL - Netherlands TA - Neth Heart J JT - Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation JID - 101095458 PMC - PMC9402830 OTO - NOTNLM OT - Aortic valve replacement OT - Decision making OT - Frailty OT - Heart team COIS- J.J.A.M. van Beek-Peeters, Z. van den Ende, M.C. Faes, A.J.B.M. de Vos, M.W.A. van Geldorp, B.J.L. Van den Branden, B.J.M. van der Meer and M.M.N. Minkman declare that they have no competing interests. EDAT- 2022/04/06 06:00 MHDA- 2022/04/06 06:01 PMCR- 2022/04/05 CRDT- 2022/04/05 12:09 PHST- 2022/02/17 00:00 [accepted] PHST- 2022/04/06 06:00 [pubmed] PHST- 2022/04/06 06:01 [medline] PHST- 2022/04/05 12:09 [entrez] PHST- 2022/04/05 00:00 [pmc-release] AID - 10.1007/s12471-022-01676-w [pii] AID - 1676 [pii] AID - 10.1007/s12471-022-01676-w [doi] PST - ppublish SO - Neth Heart J. 2022 Sep;30(9):423-428. doi: 10.1007/s12471-022-01676-w. Epub 2022 Apr 5. PMID- 35379889 OWN - NLM STAT- MEDLINE DCOM- 20220406 LR - 20220517 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 12 IP - 1 DP - 2022 Apr 4 TI - Effect of post-ICU follow-up by a rapid response team after congenital heart surgery. PG - 5633 LID - 10.1038/s41598-022-09683-y [doi] LID - 5633 AB - Patients with congenital heart disease who have a variety of cardiac/extracardiac problems are at high risk for deterioration. This study aimed to determine the effectiveness of post-intensive care unit (ICU) follow-up by a rapid response team (RRT) after congenital heart surgery. This before-and-after study was conducted at an urban regional tertiary hospital. We enrolled 572 consecutive patients who underwent congenital heart surgery and were transferred alive from the paediatric ICU (PICU) between April 2015 and March 2020. Post-ICU follow-up for 48 h was started in April 2018. The primary and secondary endpoints were unplanned ICU readmission and clinical outcomes at ICU readmission, respectively. Overall, 346 and 226 patients were analysed pre- and post-intervention, respectively. Patient demographics were similar between groups, but in the post-intervention group, patients tended to have had more complicated surgery. Unplanned ICU readmission rates within 30 days were similar between groups. Regarding the demographics and outcomes at ICU readmission, patients in the post-intervention group had lower predicted mortality rates (1.7% vs 5.3%, P = 0.001), required less ventilator days (median, 0.5 days [interquartile range (IQR) 0-1] vs median, 3 days [IQR 0.5-4], P = 0.02), and had a shorter ICU stay (median, 3 days [IQR 2-4] vs median, 6 days [IQR 3-9], P = 0.03), but there was no significant between-group difference in ICU mortality. Post-ICU follow-up by a RRT after congenital heart surgery did not decrease unplanned ICU readmission but improved several outcomes at ICU readmission. CI - (c) 2022. The Author(s). FAU - Haga, Taiki AU - Haga T AD - Department of Paediatric Critical Care Medicine, Osaka City General Hospital, 2-13-22, Miyakojima-hondori, Miyakojima-ku, Osaka, Osaka, 534-0021, Japan. taiki-haga@umin.ac.jp. FAU - Sakaguchi, Takaaki AU - Sakaguchi T AD - Department of Paediatric Critical Care Medicine, Osaka City General Hospital, 2-13-22, Miyakojima-hondori, Miyakojima-ku, Osaka, Osaka, 534-0021, Japan. FAU - Kazuta, Takao AU - Kazuta T AD - Department of Paediatric Critical Care Medicine, Osaka City General Hospital, 2-13-22, Miyakojima-hondori, Miyakojima-ku, Osaka, Osaka, 534-0021, Japan. FAU - Morooka, Takaya AU - Morooka T AD - Department of Emergency and Critical Care Medical Centre, Osaka City General Hospital, 2-13-22, Miyakojima-hondori, Miyakojima-ku, Osaka, Osaka, 534-0021, Japan. FAU - Maruyama, Junji AU - Maruyama J AD - Nursing Department, Intensive Care Centre, Osaka City General Hospital, 2-13-22, Miyakojima-hondori, Miyakojima-ku, Osaka, Osaka, 534-0021, Japan. FAU - Yamaoka, Naoko AU - Yamaoka N AD - Nursing Department, Intensive Care Centre, Osaka City General Hospital, 2-13-22, Miyakojima-hondori, Miyakojima-ku, Osaka, Osaka, 534-0021, Japan. FAU - Miyahara, Satoko AU - Miyahara S AD - Department of Medical Security and Patient Safety, Osaka City General Hospital, 2-13-22, Miyakojima-hondori, Miyakojima-ku, Osaka, Osaka, 534-0021, Japan. LA - eng PT - Journal Article DEP - 20220404 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 SB - IM MH - Child MH - Follow-Up Studies MH - *Hospital Rapid Response Team MH - Humans MH - Intensive Care Units MH - Patient Readmission MH - Tertiary Care Centers PMC - PMC8980095 COIS- The authors declare no competing interests. EDAT- 2022/04/06 06:00 MHDA- 2022/04/07 06:00 PMCR- 2022/04/04 CRDT- 2022/04/05 05:32 PHST- 2021/09/06 00:00 [received] PHST- 2022/03/28 00:00 [accepted] PHST- 2022/04/05 05:32 [entrez] PHST- 2022/04/06 06:00 [pubmed] PHST- 2022/04/07 06:00 [medline] PHST- 2022/04/04 00:00 [pmc-release] AID - 10.1038/s41598-022-09683-y [pii] AID - 9683 [pii] AID - 10.1038/s41598-022-09683-y [doi] PST - epublish SO - Sci Rep. 2022 Apr 4;12(1):5633. doi: 10.1038/s41598-022-09683-y. PMID- 35379622 OWN - NLM STAT- MEDLINE DCOM- 20220406 LR - 20240826 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 12 IP - 4 DP - 2022 Apr 4 TI - Three-dimensional QCA-based vessel fractional flow reserve (vFFR) in Heart Team decision-making: a multicentre, retrospective, cohort study. PG - e054202 LID - 10.1136/bmjopen-2021-054202 [doi] LID - e054202 AB - OBJECTIVES: To evaluate the feasibility of three-vessel three-dimensional (3D) quantitative coronary angiography (QCA)-based fractional flow reserve (FFR) computation in patients discussed within the Heart Team in whom the treatment decision was based on angiography alone, and to evaluate the concordance between 3D QCA-based vessel FFR (vFFR)-confirmed functional lesion significance and revascularisation strategy as proposed by the Heart Team. DESIGN: Retrospective, cohort. SETTING: 3D QCA-based FFR indices have not yet been evaluated in the context of Heart Team decision-making; consecutive patients from six institutions were screened for eligibility and three-vessel vFFR was computed by blinded analysts. PARTICIPANTS: Consecutive patients with chronic coronary syndrome or unstable angina referred for Heart Team consultation. Exclusion criteria involved: presentation with acute myocardial infarction (MI), significant valve disease, left ventricle ejection fraction <30%, inadequate quality of angiogram precluding vFFR computation in all three epicardial coronary arteries (ie, absence of a minimum of two angiographic projections with views of at least 30 degrees apart, substantial foreshortening/overlap of the vessel, poor contrast medium injection, ostial lesions, chronic total occlusions). PRIMARY AND SECONDARY OUTCOME MEASURES: Discordance between vFFR-confirmed lesion significance and revascularisation was assessed as the primary outcome measure. Rates of major adverse cardiac events (MACE) defined as cardiac death, MI and clinically driven revascularisation were reported. RESULTS: Of a total of 1003 patients were screened for eligibility, 416 patients (age 65.6+/-10.6, 71.2% male, 53% stable angina) were included. The most important reason for screening failure was insufficient quality of the angiogram (43%). Discordance between vFFR confirmed lesion significance and revascularisation was found in 124/416 patients (29.8%) corresponding to 149 vessels (46/149 vessels (30.9%) were reclassified as significant and 103/149 vessels (69.1%) as non-significant by vFFR). Over a median of 962 days, the cumulative incidence of MACE was 29.7% versus 18.5% in discordant versus concordant patients (p=0.031). CONCLUSIONS: vFFR computation is feasible in around 40% of the patients referred for Heart Team discussion, a limitation that is mostly based on insufficient quality of the angiogram. Three vessel vFFR screening indicated discordance between vFFR confirmed lesion significance and revascularisation in 29.8% of the patients. CI - (c) Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Tomaniak, Mariusz AU - Tomaniak M AUID- ORCID: 0000-0003-0966-3313 AD - Department of Cardiology, Erasmus University Medical Center, Thorax Center, Rotterdam, the Netherlands. AD - First Department of Cardiology, Medical University of Warsaw, Warsaw, Poland. FAU - Masdjedi, Kaneshka AU - Masdjedi K AD - Department of Cardiology, Erasmus University Medical Center, Thorax Center, Rotterdam, the Netherlands. FAU - Neleman, Tara AU - Neleman T AD - Department of Cardiology, Erasmus University Medical Center, Thorax Center, Rotterdam, the Netherlands. FAU - Kucuk, Ibrahim T AU - Kucuk IT AD - Department of Cardiology, Erasmus University Medical Center, Thorax Center, Rotterdam, the Netherlands. FAU - Vermaire, Alise AU - Vermaire A AD - Department of Cardiology, Erasmus University Medical Center, Thorax Center, Rotterdam, the Netherlands. FAU - van Zandvoort, Laurens J C AU - van Zandvoort LJC AD - Department of Cardiology, Erasmus University Medical Center, Thorax Center, Rotterdam, the Netherlands. FAU - Van Boven, Nick AU - Van Boven N AD - Department of Cardiology, Erasmus University Medical Center, Thorax Center, Rotterdam, the Netherlands. FAU - van Dalen, Bas M AU - van Dalen BM AD - Sint Franciscus Gasthuis & Vlietland Hospital, Rotterdam, the Netherlands. FAU - Soei, Loe Kie AU - Soei LK AD - Sint Franciscus Gasthuis & Vlietland Hospital, Rotterdam, the Netherlands. FAU - den Dekker, Wijnand K AU - den Dekker WK AD - Department of Cardiology, Erasmus University Medical Center, Thorax Center, Rotterdam, the Netherlands. FAU - Kardys, Isabella AU - Kardys I AD - Department of Cardiology, Erasmus University Medical Center, Thorax Center, Rotterdam, the Netherlands. FAU - Wilschut, Jeroen M AU - Wilschut JM AD - Department of Cardiology, Erasmus University Medical Center, Thorax Center, Rotterdam, the Netherlands. FAU - Diletti, Roberto AU - Diletti R AD - Department of Cardiology, Erasmus University Medical Center, Thorax Center, Rotterdam, the Netherlands. FAU - Zijlstra, Felix AU - Zijlstra F AD - Department of Cardiology, Erasmus University Medical Center, Thorax Center, Rotterdam, the Netherlands. FAU - Van Mieghem, Nicolas M AU - Van Mieghem NM AD - Department of Cardiology, Erasmus University Medical Center, Thorax Center, Rotterdam, the Netherlands. FAU - Daemen, Joost AU - Daemen J AUID- ORCID: 0000-0001-8628-1410 AD - Department of Cardiology, Erasmus University Medical Center, Thorax Center, Rotterdam, the Netherlands j.daemen@erasmusmc.nl. LA - eng PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't DEP - 20220404 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 SB - IM MH - Cohort Studies MH - Coronary Angiography/methods MH - Coronary Vessels/diagnostic imaging MH - Female MH - *Fractional Flow Reserve, Myocardial MH - Humans MH - Male MH - Retrospective Studies PMC - PMC8981358 OTO - NOTNLM OT - cardiology OT - coronary heart disease OT - coronary intervention OT - ischaemic heart disease COIS- Competing interests: MT acknowledges funding as the laureate of the European Society of Cardiology Research and Training Program in the form of the ESC 2018 Grant. KM received institutional grant support from Acist Medical. LJCvZ received institutional research grant support from Acist Medical. NMVM received research grant support from Edwards, Medtronic, Abbott, Boston Scientific, Pulse Cath, Acist Medical and Essential Medical. JD received institutional grant/research support from Abbott Vascular, Boston Scientific, Acist Medical, Medtronic and PulseCath, and consultancy and speaker fees from Acist medical, Boston Scientific, ReCor Medical, Medtronic and Pulse Cath. The remaining authors have nothing to disclose. EDAT- 2022/04/06 06:00 MHDA- 2022/04/07 06:00 PMCR- 2022/04/03 CRDT- 2022/04/05 05:30 PHST- 2022/04/05 05:30 [entrez] PHST- 2022/04/06 06:00 [pubmed] PHST- 2022/04/07 06:00 [medline] PHST- 2022/04/03 00:00 [pmc-release] AID - bmjopen-2021-054202 [pii] AID - 10.1136/bmjopen-2021-054202 [doi] PST - epublish SO - BMJ Open. 2022 Apr 4;12(4):e054202. doi: 10.1136/bmjopen-2021-054202. PMID- 35378800 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230621 IS - 2474-8714 (Electronic) IS - 2474-8706 (Print) IS - 2474-8706 (Linking) VI - 5 IP - 2 DP - 2021 Mar-Apr TI - Best Practice Recommendations for Optimizing Care in Structural Heart Programs: Planning Efficient and Resource Leveraging Systems (PEARLS). PG - 168-179 LID - 10.1080/24748706.2021.1877858 [doi] AB - The COVID19 pandemic brought unprecedented disruption to healthcare. Staggering morbidity, mortality, and economic losses prompted the review and refinement of care for structural heart disease (SHD). To mitigate negative impacts in the face of crisis or capacity constraints, this paper offers best practice recommendations for Planning Efficient and Resource Leveraging Systems (PEARLS) in structural heart programs. A systematic assessment is recommended for hospital capacity, Heart Team roles and functions, and patient and procedural risks associated with increased resource utilization. Strategies, tactics, and pathways are provided for the delivery of patient-centered, efficient and resource-leveraging care from referral to follow-up. Through the optimal use of capacity and resources, paired with dynamic triage, forecasting, and surveillance, Heart Teams may aspire to plan and implement an optimized system of care for SHD. Abbreviations: AS: aortic stenosis; ASD: atrioseptal defect; COVID19: Coronavirus disease 19; LAAO: left atrial appendage occlusion; MI: myocardial infarction; MR: mitral regurgitation; PFO: patent foramen ovale; PVL: paravalvular leak; SHD: structural heart disease; SAVR: surgical aortic valve replacement; SDM: shared decision-making; TAVR: transcatheter aortic valve replacement; TMVr: transcatheter mitral valve repair; TMVR: transcatheter mitral valve replacement; TEE: transesophageal echocardiography; TTE: transthoracic echocardiography. CI - Copyright (c) 2021 The Authors. Published by Elsevier Inc. on behalf of Cardiovascular Research Foundation. Published by Elsevier Inc. FAU - Perpetua, Elizabeth M AU - Perpetua EM AD - Empath Health Services, Seattle, Washington, USA. AD - School of Health Sciences, School of Nursing, Seattle Pacific University, Seattle, Washington, USA. FAU - Guibone, Kimberly A AU - Guibone KA AD - Department of Medicine, Division of Cardiology, Beth-Israel Deaconess Medical Center, Boston, Massachusetts, USA. FAU - Keegan, Patricia A AU - Keegan PA AD - Emory Healthcare, Atlanta, Georgia, USA. FAU - Palmer, Roseanne AU - Palmer R AD - Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, USA. FAU - Speight, Martina K AU - Speight MK AD - Stanford Healthcare, Stanford, California, USA. FAU - Jagnic, Kornelija AU - Jagnic K AD - University of Washington, Seattle, Washington, USA. FAU - Michaels, Joan AU - Michaels J AD - American College of Cardiology, Washington, DC, USA. FAU - Nguyen, Rosemarie A AU - Nguyen RA AD - Iora Healthcare, Seattle, Washington, USA. FAU - Pickett, Emily S AU - Pickett ES AD - Multicare Health, Seattle, Washington, USA. FAU - Ramsey, Dianna AU - Ramsey D AD - Virginia Mason Hospital and Medical Center, Seattle, Washington, USA. FAU - Schnell, Susan J AU - Schnell SJ AD - Columbia University Medical Center: HeartSource, New York, New York, USA. FAU - Wong, Shing-Chiu AU - Wong SC AD - Weil Cornell Medicine, New York Presbyterian Hospital - Cornell Campus, New York, USA. FAU - Reisman, Mark AU - Reisman M AD - Weil Cornell Medicine, New York Presbyterian Hospital - Cornell Campus, New York, USA. LA - eng PT - Journal Article DEP - 20220321 PL - United States TA - Struct Heart JT - Structural heart : the journal of the Heart Team JID - 101743256 PMC - PMC8968322 OTO - NOTNLM OT - COVID19, heart valve diseases OT - capacity building OT - continuum of care OT - patient care management OT - structural heart OT - transcatheter aortic valve replacement OT - transcatheter mitral valve repair OT - triage EDAT- 2022/04/06 06:00 MHDA- 2022/04/06 06:01 PMCR- 2022/03/21 CRDT- 2022/04/05 05:11 PHST- 2021/01/04 00:00 [received] PHST- 2021/01/11 00:00 [revised] PHST- 2021/09/26 00:00 [accepted] PHST- 2022/04/05 05:11 [entrez] PHST- 2022/04/06 06:00 [pubmed] PHST- 2022/04/06 06:01 [medline] PHST- 2022/03/21 00:00 [pmc-release] AID - S2474-8706(22)00808-9 [pii] AID - 10.1080/24748706.2021.1877858 [doi] PST - ppublish SO - Struct Heart. 2021 Mar-Apr;5(2):168-179. doi: 10.1080/24748706.2021.1877858. Epub 2022 Mar 21. PMID- 35377207 OWN - NLM STAT- MEDLINE DCOM- 20220406 LR - 20220406 IS - 1759-7390 (Electronic) IS - 1750-8460 (Linking) VI - 83 IP - 3 DP - 2022 Mar 2 TI - Changes and advances in the field of infective endocarditis. PG - 1-11 LID - 10.12968/hmed.2021.0510 [doi] AB - Infective endocarditis is a rare but deadly disease, with a highly variable presentation. The clinical manifestations of the condition are often multisystemic, ranging from dermatological to ophthalmic, and cardiovascular to renal. Thus, patients with infective endocarditis may first present to the acute or general physician, who may have a variable knowledge of the condition. The diagnosis of infective endocarditis can be challenging, relying on clinical, imaging and microbiological features. Recent decades have seen a transformation in the epidemiology and microbiology of infective endocarditis and yet, despite advances in diagnostics and therapeutics, mortality rates remain high. This review outlines the emerging studies and guidelines on the assessment and management of infective endocarditis, focusing on the evolving epidemiology of the condition, the role of new imaging modalities, updated diagnostic criteria, the latest on antimicrobial and surgical management, and the role of a multidisciplinary approach in the management of patients with infective endocarditis. FAU - Mills, Mark T AU - Mills MT AD - Department of Infection, Immunity and Cardiovascular Disease, The University of Sheffield, Sheffield, UK. AD - Department of Cardiology, Northern General Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. FAU - Al-Mohammad, Abdallah AU - Al-Mohammad A AD - Department of Infection, Immunity and Cardiovascular Disease, The University of Sheffield, Sheffield, UK. AD - Department of Cardiology, Northern General Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. FAU - Warriner, David R AU - Warriner DR AD - Department of Infection, Immunity and Cardiovascular Disease, The University of Sheffield, Sheffield, UK. AD - Department of Cardiology, Doncaster and Bassetlaw Teaching Hospitals NHS Foundation Trust, Doncaster, UK. AD - Department of Congenital Cardiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK. LA - eng PT - Journal Article PT - Review DEP - 20220317 PL - Singapore TA - Br J Hosp Med (Lond) JT - British journal of hospital medicine (London, England : 2005) JID - 101257109 RN - 0 (Anti-Bacterial Agents) RN - 0 (Anti-Infective Agents) SB - IM MH - Anti-Bacterial Agents/therapeutic use MH - *Anti-Infective Agents MH - *Endocarditis/diagnosis/epidemiology/therapy MH - *Endocarditis, Bacterial/diagnosis/epidemiology/therapy MH - Heart MH - Humans OTO - NOTNLM OT - Echocardiography OT - Embolism OT - Heart failure OT - Infection OT - Infective endocarditis EDAT- 2022/04/05 06:00 MHDA- 2022/04/07 06:00 CRDT- 2022/04/04 12:14 PHST- 2022/04/04 12:14 [entrez] PHST- 2022/04/05 06:00 [pubmed] PHST- 2022/04/07 06:00 [medline] AID - 10.12968/hmed.2021.0510 [doi] PST - ppublish SO - Br J Hosp Med (Lond). 2022 Mar 2;83(3):1-11. doi: 10.12968/hmed.2021.0510. Epub 2022 Mar 17. PMID- 35362378 OWN - NLM STAT- MEDLINE DCOM- 20221202 LR - 20221202 IS - 2212-3873 (Electronic) IS - 1871-5303 (Linking) VI - 22 IP - 13 DP - 2022 TI - Nurse-led and Interdisciplinary Secondary Cardiovascular Prevention Programmes: Spanish Cohort of the EUROACTION Project. PG - 1319-1329 LID - 10.2174/1871530322666220331154354 [doi] AB - BACKGROUND: Cardiovascular prevention and rehabilitation programmes (CVPRP) are a preventive tool, which can reverse unhealthy behaviours and improve risk factor management. They have been successfully implemented in a variety of settings in patients with coronary heart disease (CHD). OBJECTIVE: The objective of this study is to evaluate an interdisciplinary and nurse-led cardiovascular prevention and rehabilitation programme in patients with coronary heart disease. METHODS: Six pairs of hospitals were randomised between intervention (INT) and usual care (UC) patients. The interdisciplinary team in the intervention hospital carried out a 16-week CVPRP to reach European risk factor goals. The trial is registered as ISRCTN 71715857. RESULTS: The proportion of patients achieving European cardiovascular recommendations in Spain increased in the intervention hospital, mainly regarding fruit and vegetable consumption (INT 98% vs. UC 53%, p<0.001), oily fish consumption (INT 42% vs. UC 19.5%, p<0.001), self-reported physical activity (INT 31% vs. UC 12.4%, p=0.04), blood pressure (INT 69% vs. UC 47.1%) p< 0.05) and LDL concentrations (INT 86.1% vs. UC 67.6%, p=0.04). CONCLUSION: The EUROACTION nurse-led model of CVPR programme has shown that therapeutic goals in cardiovascular disease prevention are affordable and sustainable in everyday clinical practice. EUROACTION model adapted in Spain has produced a healthier lifestyle. CI - Copyright(c) Bentham Science Publishers; For any queries, please email at epub@benthamscience.net. FAU - Buigues, Cristina AU - Buigues C AD - Department of Nursing, University of Valencia, Valencia, Spain. AD - Frailty and Cognitive Impairment Group (FROG), University of Valencia, Valencia, Spain. FAU - Trapero, Isabel AU - Trapero I AD - Department of Nursing, University of Valencia, Valencia, Spain. FAU - Velasco, Jose Antonio AU - Velasco JA AD - Cardiology Service, Hospital General Universitario, Valencia, Spain. FAU - Salvador-Sanz, Antonio AU - Salvador-Sanz A AD - Cardiology Department, Valencian Institute of Oncology Foundation, Valencia, Spain. FAU - Jennings, Catriona AU - Jennings C AD - National Institute for Prevention and Cardiovascular Health, National University of Ireland - Galway, Ireland. FAU - Wood, David AU - Wood D AD - National Institute for Prevention and Cardiovascular Health, National University of Ireland - Galway, Ireland. AD - Cardiovascular Medicine, National Heart and Lung Institute, Imperial College London (Hammersmith Campus), International Centre for Circulatory Health, London, UK. FAU - Queralt, Ana AU - Queralt A AD - Department of Nursing, University of Valencia, Valencia, Spain. AD - AFIPS Research Group, University of Valencia, Valencia, Spain. LA - eng PT - Journal Article PT - Randomized Controlled Trial PL - United Arab Emirates TA - Endocr Metab Immune Disord Drug Targets JT - Endocrine, metabolic & immune disorders drug targets JID - 101269157 SB - IM MH - Humans MH - *Cardiovascular Diseases/epidemiology/prevention & control MH - Nurse's Role MH - Secondary Prevention MH - Risk Factors MH - *Coronary Disease/complications OTO - NOTNLM OT - EUROACTION OT - LDL OT - Nursing OT - cardiovascular prevention and rehabilitation programme OT - healthier lifestyle OT - interdisciplinary coronary heart disease EDAT- 2022/04/02 06:00 MHDA- 2022/12/03 06:00 CRDT- 2022/04/01 08:38 PHST- 2021/07/23 00:00 [received] PHST- 2022/01/05 00:00 [revised] PHST- 2022/01/05 00:00 [accepted] PHST- 2022/04/02 06:00 [pubmed] PHST- 2022/12/03 06:00 [medline] PHST- 2022/04/01 08:38 [entrez] AID - EMIDDT-EPUB-122102 [pii] AID - 10.2174/1871530322666220331154354 [doi] PST - ppublish SO - Endocr Metab Immune Disord Drug Targets. 2022;22(13):1319-1329. doi: 10.2174/1871530322666220331154354. PMID- 35362109 OWN - NLM STAT- MEDLINE DCOM- 20220609 LR - 20260105 IS - 1932-8737 (Electronic) IS - 0160-9289 (Print) IS - 0160-9289 (Linking) VI - 45 IP - 6 DP - 2022 Jun TI - Heart Team risk assessment with angiography-derived fractional flow reserve determining the optimal revascularization strategy in patients with multivessel disease: Trial design and rationale for the DECISION QFR randomized trial. PG - 605-613 LID - 10.1002/clc.23821 [doi] AB - In patients with multivessel disease (MVD), functional information on lesions improves the prognostic capability of the SYNTAX score. Quantitative flow ratio (QFR(R)) is an angiography-derived fractional flow reserve (FFR) that does not require a pressure wire or pharmacological hyperemia. We aimed to investigate the feasibility of QFR-based patient information in Heart Teams' discussions to determine the optimal revascularization strategy for patients with MVD. We hypothesized that there is an acceptable agreement between treatment recommendations based on the QFR approach and recommendation based on the FFR approach. The DECISION QFR study is a prospective, multicenter, randomized controlled trial that will include patients with MVD who require revascularization. Two Heart Teams comprising cardiologists and cardiac surgeons will be randomized to select a revascularization strategy (percutaneous coronary intervention or coronary artery bypass graft) according to patient information either based on QFR or on FFR. All 260 patients will be assessed by both teams with reference to the anatomical and functional SYNTAX score/SYNTAX score II 2020 derived from the allocated physiological index (QFR or FFR). The primary endpoint of the trial is the level of agreement between the treatment recommendations of both teams, assessed using Cohen's kappa. As of March 2022, the patient enrollment has been completed and 230 patients have been discussed in both Heart Teams. The current trial will indicate the usefulness of QFR, which enables a wireless multivessel physiological interrogation, in the discussions of Heart Teams to determine the optimal revascularization strategy for MVD. CI - (c) 2022 The Authors. Clinical Cardiology published by Wiley Periodicals, LLC. FAU - Miyata, Kotaro AU - Miyata K AD - Department of Cardiovascular Medicine, St. Luke's International Hospital, St. Luke's International University, Tokyo, Japan. FAU - Asano, Taku AU - Asano T AUID- ORCID: 0000-0001-5733-3381 AD - Department of Cardiovascular Medicine, St. Luke's International Hospital, St. Luke's International University, Tokyo, Japan. FAU - Saito, Akira AU - Saito A AD - Department of Cardiovascular Medicine, St. Luke's International Hospital, St. Luke's International University, Tokyo, Japan. FAU - Abe, Kohei AU - Abe K AD - Department of Cardiovascular Surgery, St. Luke's International Hospital, St. Luke's International University, Tokyo, Japan. FAU - Tanigaki, Toru AU - Tanigaki T AD - Department of Cardiovascular Medicine, Gifu Heart Center, Gifu, Japan. FAU - Hoshino, Masahiro AU - Hoshino M AD - Division of Cardiovascular Medicine, Tsuchiura Kyodo General Hospital, Ibaraki, Japan. FAU - Kobayashi, Tomoaki AU - Kobayashi T AD - Department of Cardiology, Osaka Police Hospital, Osaka, Japan. FAU - Takaoka, Yoshimitsu AU - Takaoka Y AD - Department of Cardiovascular Medicine, St. Luke's International Hospital, St. Luke's International University, Tokyo, Japan. FAU - Kanie, Takayoshi AU - Kanie T AUID- ORCID: 0000-0002-6955-0671 AD - Department of Cardiovascular Medicine, St. Luke's International Hospital, St. Luke's International University, Tokyo, Japan. FAU - Yamasaki, Manabu AU - Yamasaki M AD - Department of Cardiovascular Surgery, St. Luke's International Hospital, St. Luke's International University, Tokyo, Japan. FAU - Yoshino, Kunihiko AU - Yoshino K AD - Department of Cardiovascular Surgery, St. Luke's International Hospital, St. Luke's International University, Tokyo, Japan. FAU - Wakabayashi, Naoki AU - Wakabayashi N AD - Department of Radiology, St. Luke's International Hospital, St. Luke's International University, Tokyo, Japan. FAU - Ouchi, Koki AU - Ouchi K AD - Department of Radiology, St. Luke's International Hospital, St. Luke's International University, Tokyo, Japan. FAU - Kodama, Hiroyuki AU - Kodama H AD - Department of Cardiovascular Medicine, St. Luke's International Hospital, St. Luke's International University, Tokyo, Japan. FAU - Shiina, Yumi AU - Shiina Y AD - Department of Cardiovascular Medicine, St. Luke's International Hospital, St. Luke's International University, Tokyo, Japan. FAU - Tamaki, Rihito AU - Tamaki R AD - Department of Cardiovascular Surgery, St. Luke's International Hospital, St. Luke's International University, Tokyo, Japan. FAU - Nishihata, Yosuke AU - Nishihata Y AD - Department of Cardiovascular Medicine, St. Luke's International Hospital, St. Luke's International University, Tokyo, Japan. FAU - Masuda, Keita AU - Masuda K AD - Department of Cardiovascular Medicine, St. Luke's International Hospital, St. Luke's International University, Tokyo, Japan. FAU - Suzuki, Takahiro AU - Suzuki T AD - Department of Cardiovascular Medicine, St. Luke's International Hospital, St. Luke's International University, Tokyo, Japan. FAU - Nonaka, Hideaki AU - Nonaka H AD - Division of Cardiology, Mitsui Memorial Hospital, Tokyo, Japan. FAU - Emori, Hiroki AU - Emori H AD - Department of Cardiovascular Medicine, Wakayama Medical University, Wakayama, Japan. FAU - Katagiri, Yuki AU - Katagiri Y AD - Department of Cardiovascular Medicine, Sapporo Higashi Tokushukai Hospital, Sapporo, Japan. FAU - Miyazaki, Yosuke AU - Miyazaki Y AD - Division of Cardiology, Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan. FAU - Sotomi, Yohei AU - Sotomi Y AD - Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan. FAU - Yasunaga, Motoki AU - Yasunaga M AD - Department of Cardiology, Osaka Police Hospital, Osaka, Japan. FAU - Kogame, Norihiro AU - Kogame N AD - Division of Cardiovascular Medicine, Toho University Ohashi Medical Center, Meguro, Tokyo, Japan. FAU - Kuramitsu, Shoichi AU - Kuramitsu S AD - Department of Cardiology, Kokura Memorial Hospital, Kitakyushu, Japan. FAU - Reiber, Johan H C AU - Reiber JHC AD - Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands. FAU - Okamura, Takayuki AU - Okamura T AD - Division of Cardiology, Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan. FAU - Higuchi, Yoshiharu AU - Higuchi Y AD - Department of Cardiology, Osaka Police Hospital, Osaka, Japan. FAU - Kakuta, Tsunekazu AU - Kakuta T AD - Division of Cardiovascular Medicine, Tsuchiura Kyodo General Hospital, Ibaraki, Japan. FAU - Misumi, Hiroyasu AU - Misumi H AD - Department of Cardiovascular Surgery, St. Luke's International Hospital, St. Luke's International University, Tokyo, Japan. FAU - Komiyama, Nobuyuki AU - Komiyama N AD - Department of Cardiovascular Medicine, St. Luke's International Hospital, St. Luke's International University, Tokyo, Japan. FAU - Matsuo, Hitoshi AU - Matsuo H AD - Department of Cardiovascular Medicine, Gifu Heart Center, Gifu, Japan. FAU - Tanabe, Kengo AU - Tanabe K AD - Division of Cardiology, Mitsui Memorial Hospital, Tokyo, Japan. CN - DECISION QFR investigators LA - eng GR - 19K17617/Japanese National Grants-in-Aid for Scientific Research/ PT - Clinical Trial Protocol PT - Journal Article DEP - 20220331 PL - United States TA - Clin Cardiol JT - Clinical cardiology JID - 7903272 SB - IM MH - Coronary Angiography MH - *Coronary Artery Disease/diagnostic imaging/surgery MH - *Coronary Stenosis MH - Coronary Vessels MH - *Fractional Flow Reserve, Myocardial/physiology MH - Humans MH - Predictive Value of Tests MH - Prospective Studies MH - Risk Assessment MH - Multicenter Studies as Topic MH - Randomized Controlled Trials as Topic PMC - PMC9175249 OTO - NOTNLM OT - Heart Team OT - SYNTAX score II 2020 OT - decision-making OT - functional SYNTAX score OT - quantitative flow ratio COIS- Prof. Reiber is the CSO of Medis Medical Imaging Systems and has a part-time appointment at Leiden University Medical Center as a professor of medical imaging. All other authors have no conflict of interest to disclose. The authors declare no conflicts of interest. EDAT- 2022/04/02 06:00 MHDA- 2022/06/10 06:00 PMCR- 2022/03/31 CRDT- 2022/04/01 05:38 PHST- 2022/03/14 00:00 [revised] PHST- 2021/10/03 00:00 [received] PHST- 2022/03/16 00:00 [accepted] PHST- 2022/04/02 06:00 [pubmed] PHST- 2022/06/10 06:00 [medline] PHST- 2022/04/01 05:38 [entrez] PHST- 2022/03/31 00:00 [pmc-release] AID - CLC23821 [pii] AID - 10.1002/clc.23821 [doi] PST - ppublish SO - Clin Cardiol. 2022 Jun;45(6):605-613. doi: 10.1002/clc.23821. Epub 2022 Mar 31. PMID- 35361459 OWN - NLM STAT- MEDLINE DCOM- 20220405 LR - 20220518 IS - 2211-7466 (Electronic) IS - 2211-7458 (Linking) VI - 11 IP - 2 DP - 2022 Apr TI - Pre-cath Laboratory Planning for Left Atrial Appendage Occlusion - Optional or Essential? PG - 143-152 LID - S2211-7458(21)00107-3 [pii] LID - 10.1016/j.iccl.2021.11.003 [doi] AB - In the wake of rapid advancement in cardiovascular procedural technologies, physician-led preprocedural planning utilizing multi-modality imaging training is increasingly recognized as invaluable for procedural accuracy. Left atrial appendage occlusion (LAAO) is one such procedure in which complications such as device leak, cardiac injury, and device embolization can be decreased substantially with incorporation of physician driven imaging and digital tools. We discuss the benefits of cardiac CT and 3D printing in preprocedural planning for the Heart Team, as well as novel applications by physicians of intraprocedural 3D angiography and dynamic fusion imaging. Furthermore, incorporation of computational modeling and artificial intelligence (AI) may yield promise. For optimal patient-centric procedural success, we advocate for standardized preprocedural imaging planning by physicians within the Heart Team as an essential part of LAAO. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - Devgun, Jasneet AU - Devgun J AD - Division of Cardiology, Henry Ford Health System, 2799 West Grand Boulevard, Clara Ford Pavilion, Detroit, MI 48202, USA. FAU - De Potter, Tom AU - De Potter T AD - Cardiovascular Center, Onze-Lieve-Vrouwziekenhuis Hospital, Moorselbaan 164, Aalst 9300, Belgium. FAU - Fabbricatore, Davide AU - Fabbricatore D AD - Cardiovascular Center, Onze-Lieve-Vrouwziekenhuis Hospital, Moorselbaan 164, Aalst 9300, Belgium. FAU - Wang, Dee Dee AU - Wang DD AD - Division of Cardiology, Henry Ford Health System, 2799 West Grand Boulevard, Clara Ford Pavilion, Detroit, MI 48202, USA. Electronic address: dwang2@hfhs.org. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20220310 PL - Netherlands TA - Interv Cardiol Clin JT - Interventional cardiology clinics JID - 101615153 SB - IM MH - Artificial Intelligence MH - *Atrial Appendage/diagnostic imaging/surgery MH - *Atrial Fibrillation/surgery MH - Echocardiography, Transesophageal/methods MH - Humans MH - Treatment Outcome OTO - NOTNLM OT - 3D printing OT - Atrial fibrillation OT - Cardiac CT OT - Imaging OT - Left atrial appendage OT - Left atrial appendage occlusion OT - Structural heart disease COIS- Disclosure Dr D.D. Wang is a consultant for Edwards Lifesciences, Boston Scientific, Abbott, and Neochord. Dr D.D. Wang receives a research grant from Boston Scientific assigned to employer Henry Ford Health System not associated with this article. Dr T. De Potter consults for and received research grants not associated with this article from Boston Scientific, for which all invoices and payments are made directly to nonprofit "Cardiovascular Research Institute Aalst." All other authors report no relevant financial disclosures. EDAT- 2022/04/02 06:00 MHDA- 2022/04/05 06:00 CRDT- 2022/04/01 05:33 PHST- 2022/04/01 05:33 [entrez] PHST- 2022/04/02 06:00 [pubmed] PHST- 2022/04/05 06:00 [medline] AID - S2211-7458(21)00107-3 [pii] AID - 10.1016/j.iccl.2021.11.003 [doi] PST - ppublish SO - Interv Cardiol Clin. 2022 Apr;11(2):143-152. doi: 10.1016/j.iccl.2021.11.003. Epub 2022 Mar 10. PMID- 35361458 OWN - NLM STAT- MEDLINE DCOM- 20220404 LR - 20220518 IS - 2211-7466 (Electronic) IS - 2211-7458 (Linking) VI - 11 IP - 2 DP - 2022 Apr TI - Left Atrial Appendage Occlusion-A Choice or a Last Resort? How to Approach the Patient. PG - 135-142 LID - S2211-7458(21)00110-3 [pii] LID - 10.1016/j.iccl.2021.11.006 [doi] AB - Left atrial appendage (LAA) occlusion is emerging as a viable alternative to oral anticoagulation in high-risk patients with atrial fibrillation. However, there remains limited evidence for this approach, especially in certain subgroups, and therefore patient selection is an important aspect of treatment. Here, the authors present arguments for LAA occlusion as either a last resort versus patient choice by evaluating contemporary studies on this topic and discuss practical steps in the approach of patients who may be suitable for LAA occlusion. Overall, an individualized and multidisciplinary team approach should be adopted in patients who are being considered for LAA occlusion. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Ding, Wern Yew AU - Ding WY AD - Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK. FAU - Lip, Gregory Y H AU - Lip GYH AD - Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK; Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. FAU - Gupta, Dhiraj AU - Gupta D AD - Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK. Electronic address: Dhiraj.Gupta@lhch.nhs.uk. LA - eng PT - Journal Article PT - Review DEP - 20220310 PL - Netherlands TA - Interv Cardiol Clin JT - Interventional cardiology clinics JID - 101615153 SB - IM MH - *Atrial Appendage/surgery MH - *Atrial Fibrillation/complications/surgery MH - Humans MH - Patient Selection MH - *Stroke/etiology/prevention & control OTO - NOTNLM OT - Anticoagulation OT - Atrial fibrillation OT - Closure OT - Left atrial appendage OT - Occlusion OT - Patient choice COIS- Disclosure W.Y. Ding: none declared. G.Y.H. Lip: consultant and speaker for BMS/Pfizer, Boehringer Ingelheim, and Daiichi-Sankyo. No fees are directly received personally. D. Gupta: Speaker for Boehringer Ingelheim, Biosense Webster, and Boston Scientific; Proctor for Abbott. Research Grants from Medtronic, Biosense Webster, and Boston Scientific. All authors declare no conflict of interest. EDAT- 2022/04/02 06:00 MHDA- 2022/04/05 06:00 CRDT- 2022/04/01 05:33 PHST- 2022/04/01 05:33 [entrez] PHST- 2022/04/02 06:00 [pubmed] PHST- 2022/04/05 06:00 [medline] AID - S2211-7458(21)00110-3 [pii] AID - 10.1016/j.iccl.2021.11.006 [doi] PST - ppublish SO - Interv Cardiol Clin. 2022 Apr;11(2):135-142. doi: 10.1016/j.iccl.2021.11.006. Epub 2022 Mar 10. PMID- 35360554 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220402 IS - 1178-2390 (Print) IS - 1178-2390 (Electronic) IS - 1178-2390 (Linking) VI - 15 DP - 2022 TI - Congenital Central Hypoventilation Syndrome: Optimizing Care with a Multidisciplinary Approach. PG - 455-469 LID - 10.2147/JMDH.S284782 [doi] AB - Congenital central hypoventilation syndrome (CCHS) is a rare genetic disorder affecting respiratory control and autonomic nervous system function caused by variants in the paired-like homeobox 2B (PHOX2B) gene. Although most patients are diagnosed in the newborn period, an increasing number of patients are presenting later in childhood, adolescence, and adulthood. Despite hypoxemia and hypercapnia, patients do not manifest clinical features of respiratory distress during sleep and wakefulness. CCHS is a lifelong disorder. Patients require assisted ventilation throughout their life delivered by positive pressure ventilation via tracheostomy, noninvasive positive pressure ventilation, and/or diaphragm pacing. At different ages, patients may prefer to change their modality of assisted ventilation. This requires an individualized and coordinated multidisciplinary approach. Additional clinical features of CCHS that may present at different ages and require periodic evaluations or interventions include Hirschsprung's disease, gastrointestinal dysmotility, neural crest tumors, cardiac arrhythmias, and neurodevelopmental delays. Despite an established PHOX2B genotype and phenotype correlation, patients have variable and heterogeneous clinical manifestations requiring the formulation of an individualized plan of care based on collaboration between the pulmonologist, otolaryngologist, cardiologist, anesthesiologist, gastroenterologist, sleep medicine physician, geneticist, surgeon, oncologist, and respiratory therapist. A comprehensive multidisciplinary approach may optimize care and improve patient outcomes. With advances in CCHS management strategies, there is prolongation of survival necessitating high-quality multidisciplinary care for adults with CCHS. CI - (c) 2022 Kasi et al. FAU - Kasi, Ajay S AU - Kasi AS AUID- ORCID: 0000-0003-0435-2807 AD - Department of Pediatrics, Division of Pediatric Pulmonology and Sleep Medicine, Emory University, Children's Healthcare of Atlanta, Atlanta, GA, USA. FAU - Li, Hong AU - Li H AD - Department of Human Genetics, Emory University, Children's Healthcare of Atlanta, Atlanta, GA, USA. FAU - Harford, Kelli-Lee AU - Harford KL AD - Department of Pediatrics, Division of Pediatric Pulmonology and Sleep Medicine, Emory University, Children's Healthcare of Atlanta, Atlanta, GA, USA. FAU - Lam, Humphrey V AU - Lam HV AD - Division of Pediatric Anesthesiology, Emory University, Children's Healthcare of Atlanta, Atlanta, GA, USA. FAU - Mao, Chad AU - Mao C AD - Department of Pediatrics, Division of Pediatric Cardiology, Emory University, Children's Healthcare of Atlanta, Atlanta, GA, USA. FAU - Landry, April M AU - Landry AM AD - Division of Pediatric Otorhinolaryngology, Emory University, Children's Healthcare of Atlanta, Atlanta, GA, USA. FAU - Mitchell, Sarah G AU - Mitchell SG AUID- ORCID: 0000-0003-1656-2799 AD - Department of Pediatrics, Division of Pediatric Hematology and Oncology, Emory University, Children's Healthcare of Atlanta, Atlanta, GA, USA. FAU - Clifton, Matthew S AU - Clifton MS AD - Division of Pediatric Surgery, Emory University, Children's Healthcare of Atlanta, Atlanta, GA, USA. FAU - Leu, Roberta M AU - Leu RM AD - Department of Pediatrics, Division of Pediatric Pulmonology and Sleep Medicine, Emory University, Children's Healthcare of Atlanta, Atlanta, GA, USA. LA - eng PT - Journal Article PT - Review DEP - 20220308 PL - New Zealand TA - J Multidiscip Healthc JT - Journal of multidisciplinary healthcare JID - 101512691 PMC - PMC8963195 OTO - NOTNLM OT - CCHS OT - congenital central hypoventilation syndrome OT - diaphragm pacing OT - multidisciplinary care OT - noninvasive ventilation OT - tracheostomy COIS- The authors report no conflicts of interest in this work. EDAT- 2022/04/02 06:00 MHDA- 2022/04/02 06:01 PMCR- 2022/03/08 CRDT- 2022/04/01 05:24 PHST- 2022/01/02 00:00 [received] PHST- 2022/02/15 00:00 [accepted] PHST- 2022/04/01 05:24 [entrez] PHST- 2022/04/02 06:00 [pubmed] PHST- 2022/04/02 06:01 [medline] PHST- 2022/03/08 00:00 [pmc-release] AID - 284782 [pii] AID - 10.2147/JMDH.S284782 [doi] PST - epublish SO - J Multidiscip Healthc. 2022 Mar 8;15:455-469. doi: 10.2147/JMDH.S284782. eCollection 2022. PMID- 35360040 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220402 IS - 2297-055X (Print) IS - 2297-055X (Electronic) IS - 2297-055X (Linking) VI - 9 DP - 2022 TI - Hypertrophic Obstructive Cardiomyopathy: Comparison of Outcomes After Myectomy or Alcohol Ablation. PG - 755376 LID - 10.3389/fcvm.2022.755376 [doi] LID - 755376 AB - INTRODUCTION AND OBJECTIVES: The risk of ventricular arrhythmia and heart failure in patients with hypertrophic obstructive cardiomyopathy (HOCM) is much higher than that in the general population. More and more pieces of evidence showed that HOCM is the leading cause of sudden cardiac death in young people. We reported our experience in a study, comparing surgical myectomy, alcohol septal ablation (ASA), and medical therapy. METHODS: The original cohort included 965 consecutive patients with HOCM. The patients were divided into three groups according to treatment strategies: myectomy group (n = 502), ASA group (n = 138), and medical treatment group (n = 325). The median follow-up duration was 42.99 +/- 18.32 months, and the primary endpoints were all-cause mortality and heart transplantation. RESULTS: Both in short- and long-term observations, surgical myectomy reduced the left ventricular outflow tract (LVOT) gradients more effectively (7 days, 16.15 +/- 12.07 mmHg vs. 42.33 +/- 27.76 mmHg, p < 0.05; 1 year, 14.65 +/- 13.18 mmHg vs. 41.17 +/- 30.76 mmHg, p < 0.05). Among the three groups, the patients in the medical treatment group were at a higher risk of mortality and cardiac transplantation (vs. the myectomy group, p < 0.001 by log-rank test; vs. the alcohol septal ablation group, p = 0.017 by log-rank test), and the myectomy group shows a lower risk of reaching the primary endpoint than the two other groups. In the multivariate Cox regression analysis, previous atrial fibrillation (AF), N terminal pro B type natriuretic peptide (NT-pro-BNP), and surgical myectomy predicted an HOCM prognosis. However, the impact of surgical myectomy on HOCM prognosis seems to be limited to the <56 years group. CONCLUSIONS: The patients with medical treatments seemed to suffer from the highest risk of achieving an all-cause mortality and the endpoint of heart transplantation. In the long-term survival and clinical outcome, myectomy seemed better than alcohol septal ablation, especially the younger patients. Due to the less-controllable degree, periprocedural complication frequency after alcohol septal ablation was higher, compared with myectomy. Furthermore, gradients after myectomy are lower at late follow-up. To sum up, when selecting treatment strategies, the patients should be individually evaluated by a multidisciplinary team of cardiologists and surgeons. CI - Copyright (c) 2022 Meng, Wang, Gao, Zhang, Zheng, Wang, Liu, Shao and Tang. FAU - Meng, Xiangbin AU - Meng X AD - Key Laboratory of Molecular Cardiovascular Science, Ministry of Education, Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, Beijing, China. FAU - Wang, Wen-Yao AU - Wang WY AD - Key Laboratory of Molecular Cardiovascular Science, Ministry of Education, Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, Beijing, China. FAU - Gao, Jun AU - Gao J AD - Key Laboratory of Molecular Cardiovascular Science, Ministry of Education, Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, Beijing, China. FAU - Zhang, Kuo AU - Zhang K AD - State Key Laboratory of Cardiovascular Disease, Department of Cardiology, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Zheng, Jilin AU - Zheng J AD - State Key Laboratory of Cardiovascular Disease, Department of Cardiology, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Wang, Jing-Jia AU - Wang JJ AD - State Key Laboratory of Cardiovascular Disease, Department of Cardiology, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Liu, YuPeng AU - Liu Y AD - State Key Laboratory of Cardiovascular Disease, Department of Cardiology, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Shao, Chunli AU - Shao C AD - Key Laboratory of Molecular Cardiovascular Science, Ministry of Education, Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, Beijing, China. FAU - Tang, Yi-Da AU - Tang YD AD - Key Laboratory of Molecular Cardiovascular Science, Ministry of Education, Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, Beijing, China. AD - State Key Laboratory of Cardiovascular Disease, Department of Cardiology, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. LA - eng PT - Journal Article DEP - 20220314 PL - Switzerland TA - Front Cardiovasc Med JT - Frontiers in cardiovascular medicine JID - 101653388 PMC - PMC8964041 OTO - NOTNLM OT - LVOT OT - alcohol septal ablation OT - hypertrophic obstructive cardiomyopathy OT - myectomy OT - prognosis COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/04/02 06:00 MHDA- 2022/04/02 06:01 PMCR- 2022/01/01 CRDT- 2022/04/01 05:16 PHST- 2021/08/08 00:00 [received] PHST- 2022/01/21 00:00 [accepted] PHST- 2022/04/01 05:16 [entrez] PHST- 2022/04/02 06:00 [pubmed] PHST- 2022/04/02 06:01 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.3389/fcvm.2022.755376 [doi] PST - epublish SO - Front Cardiovasc Med. 2022 Mar 14;9:755376. doi: 10.3389/fcvm.2022.755376. eCollection 2022. PMID- 35359027 OWN - NLM STAT- MEDLINE DCOM- 20221205 LR - 20231202 IS - 1600-6143 (Electronic) IS - 1600-6135 (Print) IS - 1600-6135 (Linking) VI - 22 IP - 12 DP - 2022 Dec TI - Management of cardiac diseases in liver transplant recipients: Comprehensive review and multidisciplinary practice-based recommendations. PG - 2740-2758 LID - 10.1111/ajt.17049 [doi] AB - Cardiac diseases are one of the most common causes of morbidity and mortality following liver transplantation (LT). Prior studies have shown that cardiac diseases affect close to one-third of liver transplant recipients (LTRs) long term and that their incidence has been on the rise. This rise is expected to continue as more patients with advanced age and/or non-alcoholic steatohepatitis undergo LT. In view of the increasing disease burden, a multidisciplinary initiative was developed to critically review the existing literature (between January 1, 1990 and March 17, 2021) surrounding epidemiology, risk assessment, and risk mitigation of coronary heart disease, arrhythmia, heart failure, and valvular heart disease and formulate practice-based recommendations accordingly. In this review, the expert panel emphasizes the importance of optimizing management of metabolic syndrome and its components in LTRs and highlights the cardioprotective potential for the newer diabetes medications (e.g., sodium glucose transporter-2 inhibitors) in this high-risk population. Tailoring the multidisciplinary management of cardiac diseases in LTRs to the cardiometabolic risk profile of the individual patient is critical. The review also outlines numerous knowledge gaps to pave the road for future research in this sphere with the ultimate goal of improving clinical outcomes. CI - Darshana M. Dadhania and Lisa B. VanWagner contributed equally.(c) 2022 The American Society of Transplantation and the American Society of Transplant Surgeons. FAU - Izzy, Manhal AU - Izzy M AUID- ORCID: 0000-0002-6402-5333 AD - Department of Medicine, Division of Gastroenterology, Hepatology, and Nutrition, Vanderbilt University, Nashville, Tennessee, USA. FAU - Fortune, Brett E AU - Fortune BE AD - Department of Medicine, Division of Gastroenterology and Hepatology, Weill Cornell Medical College, New York, New York, USA. FAU - Serper, Marina AU - Serper M AUID- ORCID: 0000-0003-4899-2160 AD - Department of Medicine, Division of Gastroenterology, University of Pennsylvania, Philadelphia, Pennsylvania, USA. FAU - Bhave, Nicole AU - Bhave N AD - Department of Medicine, Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, Michigan, USA. FAU - deLemos, Andrew AU - deLemos A AD - Department of Medicine, Division of Hepatology, Atrium Health, Charlotte, North Carolina, USA. FAU - Gallegos-Orozco, Juan F AU - Gallegos-Orozco JF AD - Department of Medicine, Division of Gastroenterology, Hepatology and Nutrition, University of Utah School, Salt Lake City, Utah, USA. FAU - Guerrero-Miranda, Cesar AU - Guerrero-Miranda C AD - Center for Advanced Heart and Lung Disease, Baylor University Medical Center, Dallas, Texas, USA. FAU - Hall, Shelley AU - Hall S AUID- ORCID: 0000-0002-4894-396X AD - Center for Advanced Heart and Lung Disease, Baylor University Medical Center, Dallas, Texas, USA. FAU - Harinstein, Matthew E AU - Harinstein ME AD - Department of Medicine, Division of Cardiology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. FAU - Karas, Maria G AU - Karas MG AD - Department of Medicine, Division of Cardiology, Weill Cornell Medical College, New York, New York, USA. FAU - Kriss, Michael AU - Kriss M AUID- ORCID: 0000-0002-4229-4858 AD - Department of Medicine, Division of Gastroenterology and Hepatology, University of Colorado, Aurora, Colorado, USA. FAU - Lim, Nicholas AU - Lim N AUID- ORCID: 0000-0001-9740-8923 AD - Department of Medicine, Division of Gastroenterology, Hepatology, and Nutrition, University of Minnesota, Minneapolis, Minnesota, USA. FAU - Palardy, Maryse AU - Palardy M AD - Department of Medicine, Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, Michigan, USA. FAU - Sawinski, Deirdre AU - Sawinski D AD - Department of Medicine, Division of Nephrology and Hypertension, Weill Cornell Medical College, New York, New York, USA. FAU - Schonfeld, Emily AU - Schonfeld E AD - Department of Medicine, Division of Gastroenterology and Hepatology, Weill Cornell Medical College, New York, New York, USA. FAU - Seetharam, Anil AU - Seetharam A AD - Department of Medicine, Division of Gastroenterology and Hepatology, Banner - University Medical Center Phoenix, Phoenix, Arizona, USA. FAU - Sharma, Pratima AU - Sharma P AUID- ORCID: 0000-0002-1182-0579 AD - Department of Medicine, Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA. FAU - Tallaj, Jose AU - Tallaj J AD - Department of Medicine, Division of Cardiovascular Disease, University of Alabama, Birmingham, Alabama, USA. FAU - Dadhania, Darshana M AU - Dadhania DM AUID- ORCID: 0000-0002-7973-1521 AD - Department of Medicine, Division of Nephrology and Hypertension, Weill Cornell Medical College, New York, New York, USA. FAU - VanWagner, Lisa B AU - VanWagner LB AUID- ORCID: 0000-0002-6264-2573 AD - Department of Medicine, Division of Gastroenterology & Hepatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. AD - Department of Preventive Medicine, Division of Epidemiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. LA - eng GR - K23 HL136891/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Review DEP - 20220422 PL - United States TA - Am J Transplant JT - American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons JID - 100968638 SB - IM MH - Humans MH - *Liver Transplantation/adverse effects MH - Risk Factors MH - Risk Assessment MH - *Non-alcoholic Fatty Liver Disease/etiology/surgery MH - *Heart Failure MH - Transplant Recipients PMC - PMC9522925 MID - NIHMS1794303 OTO - NOTNLM OT - cardiac outcomes OT - cirrhotic cardiomyopathy OT - coronary artery disease OT - liver transplant COIS- Disclosure: B.E.F. is a consultant for W.L. Gore & Associates and Cook Medical. L.B.V. receives investigator-initiated grant support from W.L. Gore & Associates, grant support from Intercept Pharmaceuticals, and grant support from AMRA Medical outside the scope of this work. All other authors declare no conflicts of interest. EDAT- 2022/04/01 06:00 MHDA- 2022/12/06 06:00 PMCR- 2023/12/01 CRDT- 2022/03/31 20:17 PHST- 2022/03/10 00:00 [revised] PHST- 2022/01/17 00:00 [received] PHST- 2022/03/27 00:00 [accepted] PHST- 2022/04/01 06:00 [pubmed] PHST- 2022/12/06 06:00 [medline] PHST- 2022/03/31 20:17 [entrez] PHST- 2023/12/01 00:00 [pmc-release] AID - S1600-6135(23)00028-X [pii] AID - 10.1111/ajt.17049 [doi] PST - ppublish SO - Am J Transplant. 2022 Dec;22(12):2740-2758. doi: 10.1111/ajt.17049. Epub 2022 Apr 22. PMID- 35358113 OWN - NLM STAT- MEDLINE DCOM- 20220701 LR - 20230822 IS - 1539-0705 (Electronic) IS - 1522-2179 (Print) IS - 1522-2179 (Linking) VI - 24 IP - 4 DP - 2022 Aug 1 TI - Palliative Care for Patients With Heart Failure: An Integrative Review. PG - E151-E158 LID - 10.1097/NJH.0000000000000869 [doi] AB - Palliative care should be integrated into routine disease management for all patients with serious illness, regardless of settings or prognosis. The purposes of this integrative review were to identify the features of randomized controlled trials for adult patients with heart failure and to provide basic references for the development of future trials. Using Whittemore and Knafl's integrative literature review method, comprehensive searches of the PubMed, Cochrane Library, CINAHL, EMBASE, and Korean databases were conducted, integrating keywords about heart failure and palliative care interventions. Quality appraisal was assessed using Cochrane risk-of-bias tools. In total, there were 6 trials providing palliative care interventions integrating team-based approaches between palliative care specialists and nonpalliative clinicians, such as a cardiologist, cardiac nurse, and advanced practice nurse across inpatient and outpatient settings. The different types of interventions included home visits, symptom management via phone calls or referral to a specialist team, and the establishment of treatment planning. Patient-reported outcome measures included positive effects of palliative interventions on symptom burden and quality of life. Given that most of the selected studies were conducted in Western countries, palliative care should be culturally tailored to assist heart failure patients worldwide. CI - Copyright (c) 2022 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of The Hospice and Palliative Nurses Association. FAU - Kim, Changhwan AU - Kim C FAU - Kim, Sanghee AU - Kim S FAU - Lee, Kyunghwa AU - Lee K FAU - Choi, Jahyun AU - Choi J FAU - Kim, Sookyung AU - Kim S LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20220330 PL - United States TA - J Hosp Palliat Nurs JT - Journal of hospice and palliative nursing : JHPN : the official journal of the Hospice and Palliative Nurses Association JID - 100887419 SB - IM MH - Adult MH - *Heart Failure/therapy MH - *Hospice and Palliative Care Nursing MH - Humans MH - Palliative Care/methods MH - Quality of Life PMC - PMC9245551 COIS- The authors have no conflicts of interest to disclose. EDAT- 2022/04/01 06:00 MHDA- 2022/07/02 06:00 PMCR- 2022/06/30 CRDT- 2022/03/31 17:14 PHST- 2022/04/01 06:00 [pubmed] PHST- 2022/07/02 06:00 [medline] PHST- 2022/03/31 17:14 [entrez] PHST- 2022/06/30 00:00 [pmc-release] AID - 00129191-202208000-00012 [pii] AID - JHPN_220142 [pii] AID - 10.1097/NJH.0000000000000869 [doi] PST - ppublish SO - J Hosp Palliat Nurs. 2022 Aug 1;24(4):E151-E158. doi: 10.1097/NJH.0000000000000869. Epub 2022 Mar 30. PMID- 35357734 OWN - NLM STAT- MEDLINE DCOM- 20220617 LR - 20220808 IS - 1464-5491 (Electronic) IS - 0742-3071 (Print) IS - 0742-3071 (Linking) VI - 39 IP - 7 DP - 2022 Jul TI - The Pro-Diab Melbourne Perioperative Study: A structured pre-admission perioperative diabetes management plan to improve medication usage in elective surgery. PG - e14838 LID - 10.1111/dme.14838 [doi] LID - e14838 AB - BACKGROUND: Perioperative diabetes management has become increasingly complex; management is often inconsistent resulting in dysglycaemia and associated morbidity. AIM: To evaluate a structured pre-admission perioperative diabetes management plan (PDMP) for safe and appropriate recommendation, prescription and administration of diabetes medications in the perioperative period for people with diabetes undergoing elective, non-cardiac surgery. METHODS: A multidisciplinary team developed the intervention, a structured PDMP (including diabetes medication reconciliation, management guide, individualised plan) to standardise optimal perioperative diabetes management. A single centre prospective pre- and post-intervention pilot study was performed, including all individuals with diabetes medications attending the pre-admissions clinic during two 4-month periods (February to May) in 2016 (control period) and 2017 (intervention period). The primary outcome was appropriate recommendation, prescription and administration of diabetes medications (including insulin), according to the PDMP, in the perioperative period. Secondary outcomes measures were glycaemia. Analysis was by intention to treat. RESULTS: Control and intervention groups included 131 and 133 participants, respectively; they were well matched in clinical characteristics. The PDMP was completed correctly in 100 (75%) individuals in the intervention group. The appropriate use of diabetes medications increased from 30% in the control group to 71% in the intervention group (p < 0.001). Following the PDMP implementations, glycaemia improved in the overall perioperative period (8.7 +/- 2.9 vs. 9.8 +/- 3.3 mmol/L, p = 0.005) and at all time points (from admission and over entire hospital stay). CONCLUSION: A structured pre-admission perioperative diabetes management plan for elective surgery improved safe and appropriate diabetes medication use and glycaemia in the perioperative period. CI - (c) 2022 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK. FAU - Qi, Qi Yang Damien AU - Qi QYD AD - Department of Diabetes and Endocrinology, Royal Melbourne Hospital, Parkville, Victoria, Australia. AD - Department of Medicine, Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, Australia. FAU - Kyi, Mervyn AU - Kyi M AUID- ORCID: 0000-0002-4341-8250 AD - Department of Diabetes and Endocrinology, Royal Melbourne Hospital, Parkville, Victoria, Australia. AD - Department of Medicine, Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, Australia. AD - Department of General Medicine, Royal Melbourne Hospital, Parkville, Victoria, Australia. FAU - Pemberton, Elizabeth AU - Pemberton E AD - Department of Anaesthesia and Pain Management, Royal Melbourne Hospital, Parkville, Victoria, Australia. FAU - Colman, Peter Grahame AU - Colman PG AD - Department of Diabetes and Endocrinology, Royal Melbourne Hospital, Parkville, Victoria, Australia. AD - Department of Medicine, Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, Australia. FAU - Fourlanos, Spiros AU - Fourlanos S AUID- ORCID: 0000-0002-5153-8324 AD - Department of Diabetes and Endocrinology, Royal Melbourne Hospital, Parkville, Victoria, Australia. AD - Department of Medicine, Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, Australia. LA - eng SI - ANZCTR/ACTRN12617000827336 PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220408 PL - England TA - Diabet Med JT - Diabetic medicine : a journal of the British Diabetic Association JID - 8500858 RN - 0 (Blood Glucose) SB - IM MH - Blood Glucose MH - *Diabetes Mellitus/drug therapy MH - *Elective Surgical Procedures/methods MH - Humans MH - Pilot Projects MH - Prospective Studies PMC - PMC9325050 OTO - NOTNLM OT - diabetes OT - glucose OT - perioperative OT - pre-admission OT - structured plan COIS- There are no relevant conflicts of interest to disclose. EDAT- 2022/04/01 06:00 MHDA- 2022/06/18 06:00 PMCR- 2022/07/26 CRDT- 2022/03/31 12:07 PHST- 2021/10/26 00:00 [received] PHST- 2022/03/29 00:00 [accepted] PHST- 2022/04/01 06:00 [pubmed] PHST- 2022/06/18 06:00 [medline] PHST- 2022/03/31 12:07 [entrez] PHST- 2022/07/26 00:00 [pmc-release] AID - DME14838 [pii] AID - 10.1111/dme.14838 [doi] PST - ppublish SO - Diabet Med. 2022 Jul;39(7):e14838. doi: 10.1111/dme.14838. Epub 2022 Apr 8. PMID- 35356933 OWN - NLM STAT- MEDLINE DCOM- 20220406 LR - 20231130 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 101 IP - 11 DP - 2022 Mar 18 TI - Diversity of academic general medicine: A cross-sectional bibliometric study of original English-language research articles in general medicine and cardiology in Japan. LID - 10.1097/MD.0000000000029072 [doi] LID - e29072 AB - Although research in general medicine is diverse, it has not been compared with research in a different medical specialty. The study aim was to understand the characteristics of research produced at Japanese university departments of general medicine and published in English-language journals, via comparison with another academic specialty, cardiology.In this cross-sectional study, a nationwide survey of the official websites of 82 university-affiliated medical schools in Japan was conducted in April 2020 to identify the heads of general medicine departments. We then surveyed the research output of these individuals in terms of original article output and research field diversity for journals listed in the Web of Science Core Collection of journals from 2010 to 2019. A similar survey of cardiology department publications was also conducted to provide a reference for intergroup comparisons and analysis of covariance.The analysis included 128 researchers from 78 general medicine departments and 96 researchers from 81 cardiology departments. The dominant research field of general medicine was general and internal medicine; that of cardiology was cardiac/cardiovascular systems. Data stratification by research field showed that general medicine researchers published significantly more articles than researchers in cardiology, a field that contains relatively few researchers. Furthermore, a comparison of individual researchers with the same number of published articles showed that researchers in general medicine departments published across a significantly wider range of fields than those in cardiology.This is the first study to describe the research characteristics of general medicine university departments in Japan through comparison with research in a different academic specialty. General medicine researchers in Japan comprise a heterogeneous group that mainly publishes research on general and internal medicine. Some general medicine researchers take a multidisciplinary approach to research and publishing. CI - Copyright (c) 2022 the Author(s). Published by Wolters Kluwer Health, Inc. FAU - Takahashi, Noriyuki AU - Takahashi N AUID- ORCID: 0000-0003-1982-7019 AD - Department of Education for Community Oriented Medicine, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan,Department of General Medicine/Family & Community Medicine, Nagoya University Hospital, Nagoya, Aichi, Japan,M & D Data Science Center, Tokyo Medical and Dental University, Tokyo, Japan,Department of Biostatistics, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan,Medical Education Center, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan. FAU - Matsuhisa, Takaharu AU - Matsuhisa T AUID- ORCID: 0000-0003-4572-3758 FAU - Takahashi, Kunihiko AU - Takahashi K AUID- ORCID: 0000-0003-2387-7772 FAU - Ban, Nobutaro AU - Ban N LA - eng PT - Journal Article PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R SB - IM MH - *Cardiology MH - *Cardiovascular System MH - Cross-Sectional Studies MH - Humans MH - Japan MH - Language PMC - PMC10684137 COIS- The remaining authors have no conflicts of interest to disclose. EDAT- 2022/04/01 06:00 MHDA- 2022/04/07 06:00 PMCR- 2022/03/18 CRDT- 2022/03/31 08:37 PHST- 2020/11/09 00:00 [received] PHST- 2022/02/16 00:00 [received] PHST- 2022/02/25 00:00 [accepted] PHST- 2022/03/31 08:37 [entrez] PHST- 2022/04/01 06:00 [pubmed] PHST- 2022/04/07 06:00 [medline] PHST- 2022/03/18 00:00 [pmc-release] AID - 00005792-202203180-00036 [pii] AID - MD-D-20-11050 [pii] AID - 10.1097/MD.0000000000029072 [doi] PST - ppublish SO - Medicine (Baltimore). 2022 Mar 18;101(11):e29072. doi: 10.1097/MD.0000000000029072. PMID- 35353757 OWN - NLM STAT- MEDLINE DCOM- 20230222 LR - 20240102 IS - 1538-9804 (Electronic) IS - 0162-220X (Print) IS - 0162-220X (Linking) VI - 46 IP - 2 DP - 2023 Mar-Apr 01 TI - Association Between Cardiovascular Disease and Cognitive Dysfunction in Breast Cancer Survivors. PG - E122-E128 LID - 10.1097/NCC.0000000000001083 [doi] AB - BACKGROUND: Breast cancer survivors (BCSs) may have a greater risk for cardiovascular disease (congestive heart failure and hypertension), which in turn, can affect cognitive dysfunction, a frequent, bothersome, and potentially debilitating symptom. OBJECTIVE: The purpose of this study was to examine the relationship of cardiovascular disease on cognitive function in BCSs. METHODS: Baseline data from a double-blind randomized controlled trial for cognitive training of BCSs were examined. Early-stage BCS (stages I-IIIA) who were 21 years or older, completed adjuvant therapy (>/=6 months), and reported cognitive concerns completed questionnaires and a brief neuropsychological assessment, including tests of memory, attention and working memory, speed of processing, and verbal fluency. Descriptive statistics, Pearson correlation coefficient, and separate linear regression models for each cognitive domain were conducted. RESULTS: Forty-seven BCSs, who were on average 57.3 (SD, 8.1) years old, were 58% White, and had some college education (75%), completed the study. Furthermore, 44.7% of the BCS had cardiovascular disease (congestive heart failure or hypertension). In linear regression models, cardiovascular disease was significantly related to immediate and delayed memory and attention and working memory ( P < .01-.05). CONCLUSION: Breast cancer survivors who have cardiovascular disease may also be at a greater risk for cognitive dysfunction post treatment. Results from this study inform both clinical practice and future research, specifically by examining the intersection between cancer, cardiovascular disease (cardiotoxicity), and cognition. IMPLICATIONS FOR PRACTICE: Nurses should be aware that BCSs with co-occurring cardiovascular disease are at a higher risk for cognitive dysfunction and work within the multidisciplinary team to optimize BCS health and function. CI - Copyright (c) 2022 Wolters Kluwer Health, Inc. All rights reserved. FAU - Von Ah, Diane AU - Von Ah D AD - Author Affiliations: College of Nursing, The Ohio State University, Columbus (Drs Von Ah and Nolan); NewCourtland Center for Transitions and Health, University of Pennsylvania School of Nursing, Philadelphia (Dr Crouch); and The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus (Drs Arthur and Yang). FAU - Crouch, Adele AU - Crouch A FAU - Arthur, Elizabeth AU - Arthur E FAU - Yang, Yesol AU - Yang Y FAU - Nolan, Timiya AU - Nolan T LA - eng GR - K08 CA245208/CA/NCI NIH HHS/United States GR - R25 CA117865/CA/NCI NIH HHS/United States GR - T32 CA229114/CA/NCI NIH HHS/United States PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20221211 PL - United States TA - Cancer Nurs JT - Cancer nursing JID - 7805358 SB - IM MH - Humans MH - Child MH - Female MH - *Breast Neoplasms/psychology MH - *Cancer Survivors MH - *Cardiovascular Diseases/complications MH - *Cognitive Dysfunction/etiology MH - Cognition MH - *Hypertension MH - Neuropsychological Tests MH - *Heart Failure PMC - PMC9519810 MID - NIHMS1774404 COIS- The authors have no conflicts of interest to disclose. EDAT- 2022/03/31 06:00 MHDA- 2023/02/22 06:00 PMCR- 2024/01/01 CRDT- 2022/03/30 17:05 PHST- 2022/03/31 06:00 [pubmed] PHST- 2023/02/22 06:00 [medline] PHST- 2022/03/30 17:05 [entrez] PHST- 2024/01/01 00:00 [pmc-release] AID - 00002820-990000000-00003 [pii] AID - 10.1097/NCC.0000000000001083 [doi] PST - ppublish SO - Cancer Nurs. 2023 Mar-Apr 01;46(2):E122-E128. doi: 10.1097/NCC.0000000000001083. Epub 2022 Dec 11. PMID- 35353129 OWN - NLM STAT- MEDLINE DCOM- 20220517 LR - 20230331 IS - 2380-6591 (Electronic) IS - 2380-6583 (Print) VI - 7 IP - 5 DP - 2022 May 1 TI - Percutaneous Intramyocardial Septal Radiofrequency Ablation in Patients With Drug-Refractory Hypertrophic Obstructive Cardiomyopathy. PG - 529-538 LID - 10.1001/jamacardio.2022.0259 [doi] AB - IMPORTANCE: Patients with hypertrophic obstructive cardiomyopathy (HOCM) and drug-refractory symptoms and outflow gradients have limited nonsurgical treatment options. The feasibility of percutaneous intramyocardial septal radiofrequency ablation (PIMSRA) has been reported previously; however, procedural and medium-term outcomes are unknown. OBJECTIVE: To describe the safety and medium-term outcomes of PIMSRA in a large patient cohort with drug-refractory HOCM. DESIGN, SETTING, AND PARTICIPANTS: This was a single-arm, open-label study of PIMSRA in patients with drug-refractory HOCM. Patients presenting to the Xijing Hospital in Xi'an, China, between October 2016 to June 2020 with hypertrophic cardiomyopathy. Of 1314 patients presenting with HOCM, 244 fulfilled inclusion criteria of severe resting/provoked outflow gradients of 50 mm Hg or higher, and symptoms of New York Heart Association functional class of II or higher refractory to maximum tolerated medications. After discussion among the heart team, 40 patients underwent surgical or alcohol septal reduction therapy and 4 required treatment of significant coronary artery disease. INTERVENTIONS: PIMSRA performed in patients. MAIN OUTCOMES AND MEASURES: The primary outcome was 30-day major adverse clinical events: death, emergency surgery, severe effusion requiring intervention, procedure-related stroke, bleeding, and stroke. Secondary outcomes included 30-day technical success and 90-day improvement in outflow obstruction. RESULTS: The mean (SD) age of 200 patients was 46.9 (14.0) years, and 125 (62.5%) were men. Resting or provoked left ventricular outflow tract gradients were 50 mm Hg or higher. The median (IQR) follow-up for all patients was 19 (6-50) months. Thirty-day major adverse clinical events rate was 10.5% (n = 21): there were 2 in-hospital/30-day deaths (1.0%), 7 patients (3.5%) with pericardial effusion requiring mini-thoracotomy, 12 patients (6%) with pericardial effusion requiring pericardiocentesis, and no bleeding or strokes. Other periprocedural complications included permanent right bundle branch block in 5 patients (2.5%), resuscitated ventricular fibrillation in 2 (1.0%), and septal branch aneurysm in 2 (1.0%). There were no permanent pacemaker implantations. At follow-up, maximum septal thickness was reduced from a mean (SD) of 24.0 (5.1) mm to 17.3 (4.4) mm (P < .001), and left ventricular outflow tract gradient was decreased from a mean (SD) of 79.0 (53.0) mm Hg to 14.0 (24.0) mm Hg (P < .001). Overall, 190 patients (96%) with HOCM were in New York Heart Association functional class I or II at last follow-up. CONCLUSIONS AND RELEVANCE: This study found that PIMSRA in patients with drug-refractory HOCM may be an effective procedure for relief of left ventricular outflow tract obstruction and symptoms with acceptable complication rates. These results are encouraging and support the design of a randomized clinical trial against well-established septal reduction therapies. FAU - Zhou, Mengyao AU - Zhou M AD - Xijing Hypertrophic Cardiomyopathy Center, Department of Ultrasound, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China. FAU - Ta, Shengjun AU - Ta S AD - Xijing Hypertrophic Cardiomyopathy Center, Department of Ultrasound, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China. FAU - Hahn, Rebecca T AU - Hahn RT AD - Columbia University Medical Center/New York Presbyterian Hospital, University of Columbia College of Physicians and Surgeons, New York. FAU - Hsi, David H AU - Hsi DH AD - Heart & Vascular Institute, Stamford Hospital, Stamford, Connecticut. AD - University of Columbia College of Physicians and Surgeons, New York, New York. FAU - Leon, Martin B AU - Leon MB AD - Columbia University Medical Center/New York Presbyterian Hospital, University of Columbia College of Physicians and Surgeons, New York. FAU - Hu, Rui AU - Hu R AD - Xijing Hypertrophic Cardiomyopathy Center, Department of Ultrasound, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China. FAU - Zhang, Jun AU - Zhang J AD - Xijing Hypertrophic Cardiomyopathy Center, Department of Ultrasound, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China. AD - Department of Ultrasound, Xi'an New Changan Maternity Hospital, Xi'an, Shaanxi, China. FAU - Zuo, Lei AU - Zuo L AD - Xijing Hypertrophic Cardiomyopathy Center, Department of Ultrasound, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China. FAU - Li, Jing AU - Li J AD - Xijing Hypertrophic Cardiomyopathy Center, Department of Ultrasound, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China. FAU - Wang, Jing AU - Wang J AD - Xijing Hypertrophic Cardiomyopathy Center, Department of Ultrasound, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China. FAU - Wang, Bo AU - Wang B AD - Xijing Hypertrophic Cardiomyopathy Center, Department of Ultrasound, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China. FAU - Zhu, Xiaoli AU - Zhu X AD - Xijing Hypertrophic Cardiomyopathy Center, Department of Ultrasound, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China. FAU - Liu, Jiani AU - Liu J AD - Xijing Hypertrophic Cardiomyopathy Center, Department of Ultrasound, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China. FAU - Han, Yupeng AU - Han Y AD - Xijing Hypertrophic Cardiomyopathy Center, Department of Ultrasound, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China. FAU - Li, Xiaojuan AU - Li X AD - Xijing Hypertrophic Cardiomyopathy Center, Department of Ultrasound, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China. FAU - Xu, Bo AU - Xu B AD - Xijing Hypertrophic Cardiomyopathy Center, Department of Cardiac Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China. FAU - Zhang, Lei AU - Zhang L AD - Xijing Hypertrophic Cardiomyopathy Center, Department of Ultrasound, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China. AD - Department of Cardiology, Xi'an No. 3 Hospital, Northwest University, Xi'an, Shaanxi, China. FAU - Hou, Lihong AU - Hou L AD - Xijing Hypertrophic Cardiomyopathy Center, Department of Anesthesiology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China. FAU - Han, Chao AU - Han C AD - Xijing Hypertrophic Cardiomyopathy Center, Department of Ultrasound, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China. FAU - Liu, Jincheng AU - Liu J AD - Xijing Hypertrophic Cardiomyopathy Center, Department of Cardiac Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China. FAU - Liu, Liwen AU - Liu L AD - Xijing Hypertrophic Cardiomyopathy Center, Department of Ultrasound, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China. LA - eng PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't PL - United States TA - JAMA Cardiol JT - JAMA cardiology JID - 101676033 SB - IM CIN - JAMA Cardiol. 2022 May 1;7(5):538-539. doi: 10.1001/jamacardio.2022.0289. PMID: 35353117 MH - *Cardiomyopathy, Hypertrophic MH - Female MH - Humans MH - Male MH - Middle Aged MH - *Pericardial Effusion MH - *Radiofrequency Ablation MH - *Stroke MH - Treatment Outcome PMC - PMC9096597 COIS- Conflict of Interest Disclosures: Drs L. Liu and Zhou reported grants from National Natural Science Foundation of China and Shaanxi Province Key Project during the conduct of the study. Dr Hahn reported personal fees from Abbott, Baylis Medical, Edwards Lifesciences, and Philips Healthcare outside the submitted work; institutional consulting contracts for which she receives no direct compensation with Abbott Structural, Boston Scientific, Edwards Lifesciences, Medtronic, and Novartis; and has equity with Navigate. Dr Leon reports institutional research support from Edwards Lifesciences, Medtronic, Boston Scientific, and Abbott and consulting/advisory board participation for Medtronic, Boston Scientific, Gore, Meril Lifesciences, and Abbott. No other disclosures were reported. EDAT- 2022/03/31 06:00 MHDA- 2022/05/18 06:00 PMCR- 2023/03/30 CRDT- 2022/03/30 12:14 PHST- 2022/03/31 06:00 [pubmed] PHST- 2022/05/18 06:00 [medline] PHST- 2022/03/30 12:14 [entrez] PHST- 2023/03/30 00:00 [pmc-release] AID - 2790716 [pii] AID - hoi220007 [pii] AID - 10.1001/jamacardio.2022.0259 [doi] PST - ppublish SO - JAMA Cardiol. 2022 May 1;7(5):529-538. doi: 10.1001/jamacardio.2022.0259. PMID- 35352499 OWN - NLM STAT- MEDLINE DCOM- 20220505 LR - 20220716 IS - 2055-5822 (Electronic) IS - 2055-5822 (Linking) VI - 9 IP - 3 DP - 2022 Jun TI - Advanced heart failure: guideline-directed medical therapy, diuretics, inotropes, and palliative care. PG - 1507-1523 LID - 10.1002/ehf2.13859 [doi] AB - Heart failure (HF) is a major cause of mortality, hospitalizations, and reduced quality of life and a major burden for the healthcare system. The number of patients that progress to an advanced stage of HF is growing. Only a limited proportion of these patients can undergo heart transplantation or mechanical circulatory support. The purpose of this review is to summarize medical management of patients with advanced HF. First, evidence-based oral treatment must be implemented although it is often not tolerated. New therapeutic options may soon become possible for these patients. The second goal is to lessen the symptomatic burden through both decongestion and haemodynamic improvement. Some new treatments acting on cardiac function may fulfil both these needs. Inotropic agents acting through an increase in intracellular calcium have often increased risk of death. However, in the recent Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure (GALACTIC-HF) trial, omecamtiv mecarbil was safe and effective in the reduction of the primary outcome of cardiovascular death or HF event compared with placebo (hazard ratio, 0.92; 95% confidence interval, 0.86-0.99; P = 0.03) and its effects were larger in those patients with more severe left ventricular dysfunction. Patients with severe HF who received omecamtiv mecarbil experienced a significant treatment benefit, whereas patients without severe HF did not (P = 0.005 for interaction). Lastly, clinicians should take care of the end of life with an appropriate multidisciplinary approach. Medical treatment of advanced HF therefore remains a major challenge and a wide open area for further research. CI - (c) 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. FAU - Tomasoni, Daniela AU - Tomasoni D AD - Cardiology, Cardio-thoracic Department, Civil Hospitals and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy. FAU - Vishram-Nielsen, Julie K K AU - Vishram-Nielsen JKK AD - Department of Cardiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. FAU - Pagnesi, Matteo AU - Pagnesi M AD - Cardiology, Cardio-thoracic Department, Civil Hospitals and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy. FAU - Adamo, Marianna AU - Adamo M AD - Cardiology, Cardio-thoracic Department, Civil Hospitals and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy. FAU - Lombardi, Carlo Mario AU - Lombardi CM AD - Cardiology, Cardio-thoracic Department, Civil Hospitals and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy. FAU - Gustafsson, Finn AU - Gustafsson F AD - Department of Cardiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. AD - Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. FAU - Metra, Marco AU - Metra M AUID- ORCID: 0000-0001-6691-8568 AD - Cardiology, Cardio-thoracic Department, Civil Hospitals and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy. LA - eng PT - Journal Article PT - Review DEP - 20220330 PL - England TA - ESC Heart Fail JT - ESC heart failure JID - 101669191 RN - 0 (Diuretics) SB - IM MH - *Diuretics/therapeutic use MH - *Heart Failure/drug therapy MH - Humans MH - Palliative Care MH - Quality of Life MH - Stroke Volume PMC - PMC9065830 OTO - NOTNLM OT - Advanced heart failure OT - Diuretic therapy OT - Heart failure with reduced ejection fraction OT - Inotropes OT - Medical management OT - Omecamtiv mecarbil OT - Palliative care COIS- F.G. reports consulting fees from Abbott, Pfizer, Bayer, Ionis, Alnylam, and Boehringer-Ingelheim and speakers fees from Novartis, AstraZeneca, and Orion Pharma. M.M. reports consulting fees from Actelion, Amgen, AstraZeneca, Abbott vascular, Bayer, Servier, Edwards Therapeutics, Livanova, Vifor Pharma, and WindTree Therapeutics, as member of Trials' Committees or Advisory Boards or for speeches at sponsored meetings in the last 3 years. Other authors declare that they have no conflict of interest. EDAT- 2022/03/31 06:00 MHDA- 2022/05/06 06:00 PMCR- 2022/03/30 CRDT- 2022/03/30 05:46 PHST- 2022/01/16 00:00 [revised] PHST- 2021/11/23 00:00 [received] PHST- 2022/02/09 00:00 [accepted] PHST- 2022/03/31 06:00 [pubmed] PHST- 2022/05/06 06:00 [medline] PHST- 2022/03/30 05:46 [entrez] PHST- 2022/03/30 00:00 [pmc-release] AID - EHF213859 [pii] AID - 10.1002/ehf2.13859 [doi] PST - ppublish SO - ESC Heart Fail. 2022 Jun;9(3):1507-1523. doi: 10.1002/ehf2.13859. Epub 2022 Mar 30. PMID- 35352396 OWN - NLM STAT- MEDLINE DCOM- 20220420 LR - 20221207 IS - 1540-8191 (Electronic) IS - 0886-0440 (Linking) VI - 37 IP - 6 DP - 2022 Jun TI - Aortic dissection in the first trimester; is it a dead end? A narrative review of recent articles. PG - 1705-1711 LID - 10.1111/jocs.16451 [doi] AB - INTRODUCTION: Acute-type aortic dissection (AD) during pregnancy is considered a rare and potentially fatal complication for both mother and fetus. Although the definite treatment for an acute-type AD is considered to be open-heart surgery, the decision to perform such a surgery during pregnancy requires a multidisciplinary approach and carries significant risks. METHODS: In the present review of the literature, we have discussed various challenges in the management of acute-type AD during pregnancy, including therapeutic approaches, choosing the preferred imaging modalities, surgical techniques, and medication challenges. We have also reported an 8-week pregnant woman with Marfan syndrome who presented with chest pain and was diagnosed with acute AD. RESULTS: The patient underwent a Bentall operation and was discharged in good condition with her fetus alive. The medical team's various decisions during preoperative, operative, and postoperative treatments were discussed. CONCLUSIONS: Type A AD is considered infrequent in the second and third trimester of pregnancy and rare in the first trimester. Performing a CMR study without contrast in stable patients can help evaluate the extension of the flap. Urgent surgery in the hands of a skilled surgeon may prove lifesaving for the mother while maximizing the likelihood of preserving the fetus. CI - (c) 2022 Wiley Periodicals LLC. FAU - Ayati, Aryan AU - Ayati A AUID- ORCID: 0000-0002-0241-6865 AD - Tehran Heart Center, Tehran Heart Center Research Institute, Tehran University of Medical Sciences, Tehran, Iran. FAU - Sarraf, Syna AU - Sarraf S AD - Tehran Heart Center, Tehran Heart Center Research Institute, Tehran University of Medical Sciences, Tehran, Iran. FAU - Asl Fallah, Sahar AU - Asl Fallah S AD - Rajaie Cardiovascular Medical And Research Center, Iran University of Medical Sciences, Tehran, Iran. FAU - Bagheri, Jamshid AU - Bagheri J AD - Tehran Heart Center, Tehran Heart Center Research Institute, Tehran University of Medical Sciences, Tehran, Iran. FAU - Ahmadi Tafti, Hossein AU - Ahmadi Tafti H AD - Tehran Heart Center, Tehran Heart Center Research Institute, Tehran University of Medical Sciences, Tehran, Iran. AD - Research Center for Advanced Technologies in Cardiovascular Medicine, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran. FAU - Same, Kaveh AU - Same K AD - Tehran Heart Center, Tehran Heart Center Research Institute, Tehran University of Medical Sciences, Tehran, Iran. FAU - Hosseini, Kaveh AU - Hosseini K AUID- ORCID: 0000-0001-5676-3099 AD - Tehran Heart Center, Tehran Heart Center Research Institute, Tehran University of Medical Sciences, Tehran, Iran. LA - eng PT - Journal Article PT - Review DEP - 20220329 PL - United States TA - J Card Surg JT - Journal of cardiac surgery JID - 8908809 SB - IM MH - *Aortic Dissection/diagnosis MH - *Aortic Aneurysm/surgery MH - Female MH - Humans MH - *Marfan Syndrome/complications/diagnosis/surgery MH - Pregnancy MH - *Pregnancy Complications, Cardiovascular/surgery MH - Pregnancy Trimester, First OTO - NOTNLM OT - aorta and great vessels OT - cardiovascular research OT - valve repair/replacement EDAT- 2022/03/31 06:00 MHDA- 2022/04/21 06:00 CRDT- 2022/03/30 05:45 PHST- 2022/02/13 00:00 [revised] PHST- 2021/12/29 00:00 [received] PHST- 2022/02/17 00:00 [accepted] PHST- 2022/03/31 06:00 [pubmed] PHST- 2022/04/21 06:00 [medline] PHST- 2022/03/30 05:45 [entrez] AID - 10.1111/jocs.16451 [doi] PST - ppublish SO - J Card Surg. 2022 Jun;37(6):1705-1711. doi: 10.1111/jocs.16451. Epub 2022 Mar 29. PMID- 35351671 OWN - NLM STAT- MEDLINE DCOM- 20220606 LR - 20220624 IS - 2589-9333 (Electronic) IS - 2589-9333 (Linking) VI - 4 IP - 4 DP - 2022 Jul TI - Correlation between medical management and teamwork in multidisciplinary high-fidelity obstetrics simulations. PG - 100626 LID - S2589-9333(22)00068-4 [pii] LID - 10.1016/j.ajogmf.2022.100626 [doi] AB - BACKGROUND: Teamwork and communication gaps are consistently cited as contributors to adverse outcomes in obstetrics. The Critical Care in Obstetrics Course provides an innovative experience by combining brief interactive didactics with the opportunity to practice and implement the knowledge gained with hands-on simulation. Most participants have never worked together, which creates a unique environment to evaluate the importance of teamwork and communication. OBJECTIVE: This study aimed to evaluate the association between teamwork and medical management in high-fidelity critical care simulations. STUDY DESIGN: The participants were separated into multidisciplinary teams and taken through simulations, including placental abruption, hypertensive emergency, eclampsia, sepsis, cardiac arrest, venous thromboembolism, diabetic ketoacidosis, and thyroid storm. Facilitators completed a validated checklist assessment for each group's performance in medical care and teamwork. Each element was rated on a scale from 1 to 5, with 1 being unacceptable and 5 being perfect. We evaluated 5 communication measures, including the use of closed-loop communication and orientation of new team members. A Spearman correlation was used to evaluate the relationship between total medical management and total teamwork scores and specific measures of team communication. Receiver operating characteristic curves were created for total teamwork score as a predictor of good or perfect medical management. RESULTS: A total of 354 multidisciplinary teams participated in 1564 high-fidelity simulations. There was a significant correlation between medical management and teamwork and communication scores for all scenarios. The strongest correlation was for the total teamwork score for all simulations (rho=0.84). Teamwork scores were highly predictive of medical management scores with an area under the curve of at least 0.88 for all simulations, although this was not significant for diabetic ketoacidosis. CONCLUSION: The quality of teamwork and communication correlated with the quality of clinical performance in newly formed multidisciplinary teams. This demonstrates the importance of teamwork training, with a focus on key communication tools and strategies, among medical providers to optimize the management of complex and emergent obstetrical conditions. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Detlefs, Sarah E AU - Detlefs SE AD - Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, TX (Dr Detlefs). FAU - Goffman, Dena AU - Goffman D AD - Department of Obstetrics and Gynecology, Columbia University Irving Medical Center, New York, NY (Dr Goffman). FAU - Buttle, Rae A AU - Buttle RA AD - University of the Incarnate Word School of Osteopathic Medicine, San Antonio, TX (Ms Buttle). FAU - Crump, Cade M AU - Crump CM AD - Baylor University, Waco, TX (Mr Crump). FAU - Thornburg, Loralei L AU - Thornburg LL AD - Department of Obstetrics and Gynecology, University of Rochester Medical Center, Rochester, NY (Dr Thornburg). FAU - Foley, Michael R AU - Foley MR AD - Banner-University Medical Center Phoenix, The University of Arizona College of Medicine-Phoenix, Phoenix, AZ (Dr Foley). FAU - Deering, Shad AU - Deering S AD - Department of Obstetrics and Gynecology, Christus Health, Baylor College of Medicine, San Antonio, TX (Dr Deering). Electronic address: shad.deering@christushealth.org. LA - eng PT - Journal Article DEP - 20220326 PL - United States TA - Am J Obstet Gynecol MFM JT - American journal of obstetrics & gynecology MFM JID - 101746609 SB - IM MH - Clinical Competence MH - *Diabetic Ketoacidosis MH - Female MH - Humans MH - *Obstetrics MH - Patient Care Team MH - Placenta MH - Pregnancy OTO - NOTNLM OT - communication OT - crisis resource management OT - medical simulation OT - obstetrical emergency OT - teamwork EDAT- 2022/03/31 06:00 MHDA- 2022/06/07 06:00 CRDT- 2022/03/30 05:40 PHST- 2022/03/14 00:00 [received] PHST- 2022/03/23 00:00 [accepted] PHST- 2022/03/31 06:00 [pubmed] PHST- 2022/06/07 06:00 [medline] PHST- 2022/03/30 05:40 [entrez] AID - S2589-9333(22)00068-4 [pii] AID - 10.1016/j.ajogmf.2022.100626 [doi] PST - ppublish SO - Am J Obstet Gynecol MFM. 2022 Jul;4(4):100626. doi: 10.1016/j.ajogmf.2022.100626. Epub 2022 Mar 26. PMID- 35347997 OWN - NLM STAT- MEDLINE DCOM- 20220407 LR - 20220606 IS - 2047-9980 (Electronic) IS - 2047-9980 (Linking) VI - 11 IP - 7 DP - 2022 Apr 5 TI - Wearable Smartwatch Facilitated Remote Health Management for Patients Undergoing Transcatheter Aortic Valve Replacement. PG - e023219 LID - 10.1161/JAHA.121.023219 [doi] LID - e023219 AB - Background In the recent decades, the development of novel digital health technologies enables doctors to monitor ECG and vital signs remotely. But the data on applying the noninvasive wearable smartwatch on patients with transcatheter aortic valve replacement (TAVR) are unknown. Methods and Results We performed a prospective, observational cohort study to evaluate the feasibility of a novel, virtual, and remote health care strategy for patients with TAVR discharged to home with smart wearable devices. A total of 100 consecutive patients with severe aortic stenosis who underwent elective transfemoral TAVR were enrolled and received the Huawei smartwatch at least 1 day before TAVR. Vital signs, including heart rate, rhythm, oxygen saturation, and activity, were continuously recorded. Single-lead ECG was recorded twice per day in the week following TAVR discharge and at least 2 days a week for the subsequent month after TAVR discharge. A designated heart team member provided remote health care with the data from the smartwatch when the patient had a need. Thirty-eight cardiac events were reported in 34 patients after discharge, with most of the events (76.0%) detected and confirmed by the smartwatch. Six patients were advised and readmitted to the hospital for arrhythmia events detected by the smartwatch, of whom 4 patients received pacemaker implantation. The remaining 28 (82.4%) patients received telemedicine monitoring instead of face-to-face clinical visits, and 3 of them received new medication treatment under the online guidance of doctors. New-onset left branch bundle block was found in 48 patients, with transient characteristics, and recovered spontaneously in 30 patients, and new-onset atrial fibrillation was detected in 4 patients. There were no significant differences in the average weekly heart rates or the ratio of abnormal or low oxygen saturation when compared with the baseline. The average daily steps increased over time significantly (baseline, 870+/-1353 steps; first week, 1986+/-2406 steps; second week, 2707+/-2716 steps; third week, 3059+/-3036 steps; fourth week, 3678+/-3485 steps, P<0.001). Conclusions Smartwatches can facilitate remote health care for patients discharged to home after undergoing TAVR and enable a novel remote follow-up strategy. The majority of cardiac clinical events that occurred within 30-day follow-up were detected by the smartwatch, mainly because of the record of conduction abnormality. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT04454177. FAU - Liu, Xianbao AU - Liu X AD - Department of Cardiology Second Affiliated Hospital Zhejiang University School of Medicine Hangzhou People's Republic of China. AD - Zhejiang University School of Medicine Hangzhou People's Republic of China. FAU - Fan, Jiaqi AU - Fan J AUID- ORCID: 0000-0002-1909-9026 AD - Department of Cardiology Second Affiliated Hospital Zhejiang University School of Medicine Hangzhou People's Republic of China. FAU - Guo, Yuchao AU - Guo Y AUID- ORCID: 0000-0002-8206-6323 AD - Department of Cardiology Second Affiliated Hospital Zhejiang University School of Medicine Hangzhou People's Republic of China. FAU - Dai, Hanyi AU - Dai H AUID- ORCID: 0000-0002-7782-891X AD - Zhejiang University School of Medicine Hangzhou People's Republic of China. FAU - Xu, Jianguo AU - Xu J AD - Department of Electrocardiogram Second Affiliated Hospital Zhejiang University School of Medicine Hangzhou People's Republic of China. FAU - Wang, Lihan AU - Wang L AD - Department of Cardiology Second Affiliated Hospital Zhejiang University School of Medicine Hangzhou People's Republic of China. FAU - Hu, Po AU - Hu P AD - Department of Cardiology Second Affiliated Hospital Zhejiang University School of Medicine Hangzhou People's Republic of China. FAU - Lin, Xinping AU - Lin X AD - Department of Cardiology Second Affiliated Hospital Zhejiang University School of Medicine Hangzhou People's Republic of China. FAU - Li, Cheng AU - Li C AD - Department of Nursing Second Affiliated Hospital Zhejiang University School of Medicine Hangzhou People's Republic of China. FAU - Zhou, Dao AU - Zhou D AUID- ORCID: 0000-0001-7815-9490 AD - Zhejiang University School of Medicine Hangzhou People's Republic of China. FAU - Li, Huajun AU - Li H AD - Department of Cardiology Second Affiliated Hospital Zhejiang University School of Medicine Hangzhou People's Republic of China. FAU - Wang, Jian'an AU - Wang J AUID- ORCID: 0000-0002-4583-3204 AD - Department of Cardiology Second Affiliated Hospital Zhejiang University School of Medicine Hangzhou People's Republic of China. AD - Zhejiang University School of Medicine Hangzhou People's Republic of China. LA - eng SI - ClinicalTrials.gov/NCT04454177 PT - Journal Article PT - Observational Study PT - Research Support, Non-U.S. Gov't DEP - 20220329 PL - England TA - J Am Heart Assoc JT - Journal of the American Heart Association JID - 101580524 SB - IM MH - Aortic Valve/surgery MH - *Aortic Valve Stenosis/diagnosis/etiology/surgery MH - Humans MH - Prospective Studies MH - Risk Factors MH - *Transcatheter Aortic Valve Replacement/adverse effects/methods MH - Treatment Outcome MH - *Wearable Electronic Devices PMC - PMC9075450 OTO - NOTNLM OT - arrhythmias OT - remote health care OT - smartwatch OT - transcatheter aortic valve replacement EDAT- 2022/03/30 06:00 MHDA- 2022/04/08 06:00 PMCR- 2022/04/05 CRDT- 2022/03/29 08:50 PHST- 2022/03/30 06:00 [pubmed] PHST- 2022/04/08 06:00 [medline] PHST- 2022/03/29 08:50 [entrez] PHST- 2022/04/05 00:00 [pmc-release] AID - JAH36994 [pii] AID - 10.1161/JAHA.121.023219 [doi] PST - ppublish SO - J Am Heart Assoc. 2022 Apr 5;11(7):e023219. doi: 10.1161/JAHA.121.023219. Epub 2022 Mar 29. PMID- 35347973 OWN - NLM STAT- MEDLINE DCOM- 20221005 LR - 20221005 IS - 2532-5264 (Electronic) IS - 1122-0643 (Linking) VI - 92 IP - 4 DP - 2022 Mar 24 TI - A 12-year experience in endobronchial intervention using rigid bronchoscopy - account of a tertiary referral centre. LID - 10.4081/monaldi.2022.2161 [doi] AB - We describe our experience of rigid bronchoscopy and endobronchial intervention at a single tertiary centre over a 12-year period. All rigid bronchoscopy procedures between July 2008 and July 2020 (inclusive) were reviewed. All procedures were performed in cardiothoracic theatres by a designated team under general anaesthesia. 2135 rigid bronchoscopies were performed on 1301 patients aged between 18 and 93 years. Complications occurred in 24 (1.12%) procedures. There was one fatality (0.05%). Haemorrhage >100mls occurred in seven (0.33%) all of which were successfully managed endobronchially. Ten procedures (0.5%) were complicated by pneumothorax and an intercostal drain was required for eight. Five patients required intensive care admission post operatively, all of whom were subsequently discharged from hospital. One patient had stent migration. To the best of our knowledge, this is amongst the largest single centre collection of data available for endobronchial intervention using rigid bronchoscopy. We show that rigid bronchoscopy is a safe and effective procedure when performed in a high-volume specialist centre with designated lists involving a specialist multidisciplinary team. FAU - Bartlett-Pestell, Sam AU - Bartlett-Pestell S AD - Department of Cardiothoracic Surgery, St George's University Hospital NHS Foundation Trust, London. sam.bartlett2@nhs.net. FAU - May, James AU - May J AD - Department of Cardiothoracic Surgery, St. George's Hospital, Department of Cardiothoracic Surgery, St George's University Hospital NHS Foundation Trust, London. james.may4@nhs.net. FAU - Sharma, Ashutosh AU - Sharma A AD - Department of Cardiothoracic Surgery, St George's University Hospital NHS Foundation Trust, London. ashutosh_sharma@icloud.com. FAU - Alonzo, Sunshine AU - Alonzo S AD - Department of Cardiothoracic Surgery, St George's University Hospital NHS Foundation Trust, London. sunshine.alonzo@stgeorges.nhs.uk. FAU - Barnes, Natalie AU - Barnes N AD - Department of Cardiothoracic Surgery, St George's University Hospital NHS Foundation Trust, London. natalie.barnes@stgeorges.nhs.uk. FAU - Madden, Brendan P AU - Madden BP AD - Department of Cardiothoracic Surgery, St George's University Hospital NHS Foundation Trust, London. brendan.madden@stgeorges.nhs.uk. LA - eng PT - Journal Article DEP - 20220324 PL - Italy TA - Monaldi Arch Chest Dis JT - Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace JID - 9307314 SB - IM MH - Adolescent MH - Adult MH - Aged MH - Aged, 80 and over MH - *Bronchoscopy/methods MH - Critical Care MH - Humans MH - Middle Aged MH - *Pneumothorax/etiology MH - Retrospective Studies MH - Stents MH - Tertiary Care Centers MH - Young Adult EDAT- 2022/03/30 06:00 MHDA- 2022/10/06 06:00 CRDT- 2022/03/29 05:55 PHST- 2021/12/07 00:00 [received] PHST- 2022/03/03 00:00 [accepted] PHST- 2022/03/30 06:00 [pubmed] PHST- 2022/10/06 06:00 [medline] PHST- 2022/03/29 05:55 [entrez] AID - 10.4081/monaldi.2022.2161 [doi] PST - epublish SO - Monaldi Arch Chest Dis. 2022 Mar 24;92(4). doi: 10.4081/monaldi.2022.2161. PMID- 35345715 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220330 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 14 IP - 2 DP - 2022 Feb TI - Comparison of SYNTAX and Gensini Scores in the Decision of Surgery or Percutaneous Revascularization in Patients With Multivessel Coronary Artery Disease. PG - e22482 LID - 10.7759/cureus.22482 [doi] LID - e22482 AB - INTRODUCTION: Many scoring systems have been developed to determine the extent of coronary artery disease (CAD) in patients with multi-vessel disease. The most widely used of these are Synergy between percutaneous coronary intervention with Taxus and cardiac surgery (SYNTAX) and Gensini scoring. Gensini scoring system can successfully show coronary plaque burden. In our study, we aimed to test the predictive power of SYNTAX and Gensini scores for surgical or percutaneous intervention decisions made by the cardiac team in patients with three-vessel disease. METHODS: A total of 476 patients without ST-elevation myocardial infarction with the three-vessel disease were included in the study. SYNTAX and Gensini scores of the patients were calculated from their coronary angiographies. Receiver operating characteristic curve (ROC-curve) analysis was performed using both scores. RESULTS: Both the SYNTAX score and Gensini score were able to predict heart team decisions (AUC: 0.759, 0.680; p<0.001). Diabetes and smoking were more common in patients who were decided to have surgery (p<0.001). CONCLUSION: In the light of our study results, the decisions to be made with the SYNTAX score will be closer to the decisions of the heart team than the Gensini score. CI - Copyright (c) 2022, Boyraz et al. FAU - Boyraz, Bedrettin AU - Boyraz B AD - Cardiology, Private Doruk Yildirim Hospital, Bursa, TUR. FAU - Peker, Tezcan AU - Peker T AD - Cardiology, Private Doruk Yildirim Hospital, Bursa, TUR. LA - eng PT - Journal Article DEP - 20220222 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC8942066 OTO - NOTNLM OT - coronary artery by-pass grafting OT - gensini score OT - multivessel coronary artery disease (mvcad) OT - percutaneous coronary intervention OT - revascularization decision OT - syntax score COIS- The authors have declared that no competing interests exist. EDAT- 2022/03/30 06:00 MHDA- 2022/03/30 06:01 PMCR- 2022/02/22 CRDT- 2022/03/29 05:13 PHST- 2022/02/22 00:00 [accepted] PHST- 2022/03/29 05:13 [entrez] PHST- 2022/03/30 06:00 [pubmed] PHST- 2022/03/30 06:01 [medline] PHST- 2022/02/22 00:00 [pmc-release] AID - 10.7759/cureus.22482 [doi] PST - epublish SO - Cureus. 2022 Feb 22;14(2):e22482. doi: 10.7759/cureus.22482. eCollection 2022 Feb. PMID- 35345271 OWN - NLM STAT- MEDLINE DCOM- 20220418 LR - 20220418 IS - 2153-8174 (Electronic) IS - 1530-6550 (Linking) VI - 23 IP - 3 DP - 2022 Mar 16 TI - Endovascular therapeutic hypothermia adjunctive to percutaneous coronary intervention in acute myocardial infarction: realistic simulation as a game changer. PG - 104 LID - 10.31083/j.rcm2303104 [doi] AB - BACKGROUND: Endovascular therapeutic hypothermia (ETH) reduces the damage by ischemia/reperfusion cell syndrome in cardiac arrest and has been studied as an adjuvant therapy to percutaneous coronary intervention (PCI) in ST-elevation myocardial infarction (STEMI). New available advanced technology allows cooling much faster, but there is paucity of resources for training to avoid delays in door-to-balloon time (DTB) due to ETH and subsequently coronary reperfusion, which would derail the procedure. The aim of the study was to describe the process for the development of a simulation, training & educational protocol for the multidisciplinary team to perform optimized ETH as an adjunctive therapy for STEMI. METHODS AND RESULTS: We developed an optimized simulation protocol using modern mannequins in different realistic scenarios for the treatment of patients undergoing ETH adjunctive to PCI for STEMIs starting from the emergency room, through the CathLab, and to the intensive care unit (ICU) using the Proteus(R) Endovascular System (Zoll Circulation Inc, San Jose, CA, USA). The primary endpoint was door-to-balloon (DTB) time. We successfully trained 361 multidisciplinary professionals in realistic simulation using modern mannequins and sham situations in divisions of the hospital where real patients would be treated. The focus of simulation and training was logistical optimization and educational debriefing with strategies to reduce waste of time in patient's transportation from different departments, and avoiding excessive rewarming during transfer. Afterwards, the EHT protocol was successfully validated in a trial randomizing 50 patients for 18 minutes cooling before coronary recanalization at the target temperature of 32 +/- 1.0 composite functionC or PCI-only. A total of 35 patients underwent ETH (85.7% [30/35] in 90 +/- 15 minutes), without delays in the mean door-to-balloon time for primary PCI when compared to 15 control group patients (92.1 minutes versus 87 minutes, respectively; p = 0.509). CONCLUSIONS: Realistic simulation, intensive training and educational debriefing for the multidisciplinary team propitiated feasible endovascular therapeutic hypothermia as an adjuvant therapy to primary PCI in STEMI. CLINICALTRIALS: gov: NCT02664194. CI - (c) 2022 The Author(s). Published by IMR Press. FAU - Dallan, Luis Augusto Palma AU - Dallan LAP AD - Department of Cardiology, InCor - Heart Institute, School of Medicine, University of Sao Paulo, 05403-900 Sao Paulo, Brazil. AD - Harrington Heart & Vascular Institute, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA. FAU - Dae, Michael AU - Dae M AD - Department of Radiology, University of California, San Francisco, CA 94143, USA. FAU - Giannetti, Natali Schiavo AU - Giannetti NS AD - Department of Cardiology, InCor - Heart Institute, School of Medicine, University of Sao Paulo, 05403-900 Sao Paulo, Brazil. FAU - Polastri, Tathiane Facholi AU - Polastri TF AD - Department of Cardiology, InCor - Heart Institute, School of Medicine, University of Sao Paulo, 05403-900 Sao Paulo, Brazil. FAU - Lima, Marian Keiko Frossard AU - Lima MKF AD - Department of Cardiology, InCor - Heart Institute, School of Medicine, University of Sao Paulo, 05403-900 Sao Paulo, Brazil. FAU - Rochitte, Carlos Eduardo AU - Rochitte CE AD - Department of Cardiology, InCor - Heart Institute, School of Medicine, University of Sao Paulo, 05403-900 Sao Paulo, Brazil. FAU - Hajjar, Ludhmila Abrahao AU - Hajjar LA AD - Department of Cardiology, InCor - Heart Institute, School of Medicine, University of Sao Paulo, 05403-900 Sao Paulo, Brazil. FAU - San Martin, Claudia Yanet Bernoche AU - San Martin CYB AD - Department of Cardiology, InCor - Heart Institute, School of Medicine, University of Sao Paulo, 05403-900 Sao Paulo, Brazil. FAU - Lima, Felipe Gallego AU - Lima FG AD - Department of Cardiology, InCor - Heart Institute, School of Medicine, University of Sao Paulo, 05403-900 Sao Paulo, Brazil. FAU - Nicolau, Jose Carlos AU - Nicolau JC AD - Department of Cardiology, InCor - Heart Institute, School of Medicine, University of Sao Paulo, 05403-900 Sao Paulo, Brazil. FAU - de Oliveira, Mucio Tavares Jr AU - de Oliveira MT Jr AD - Department of Cardiology, InCor - Heart Institute, School of Medicine, University of Sao Paulo, 05403-900 Sao Paulo, Brazil. FAU - Dallan, Luis Alberto Oliveira AU - Dallan LAO AD - Department of Cardiology, InCor - Heart Institute, School of Medicine, University of Sao Paulo, 05403-900 Sao Paulo, Brazil. FAU - Ribeiro da Silva, Expedito Eustaquio AU - Ribeiro da Silva EE AD - Department of Cardiology, InCor - Heart Institute, School of Medicine, University of Sao Paulo, 05403-900 Sao Paulo, Brazil. FAU - Kalil Filho, Roberto AU - Kalil Filho R AD - Department of Cardiology, InCor - Heart Institute, School of Medicine, University of Sao Paulo, 05403-900 Sao Paulo, Brazil. FAU - Abizaid, Alexandre AU - Abizaid A AD - Department of Cardiology, InCor - Heart Institute, School of Medicine, University of Sao Paulo, 05403-900 Sao Paulo, Brazil. FAU - Lemos Neto, Pedro Alves AU - Lemos Neto PA AD - Department of Cardiology, InCor - Heart Institute, School of Medicine, University of Sao Paulo, 05403-900 Sao Paulo, Brazil. FAU - Timerman, Sergio AU - Timerman S AD - Department of Cardiology, InCor - Heart Institute, School of Medicine, University of Sao Paulo, 05403-900 Sao Paulo, Brazil. LA - eng SI - ClinicalTrials.gov/NCT02664194 PT - Journal Article PL - Singapore TA - Rev Cardiovasc Med JT - Reviews in cardiovascular medicine JID - 100960007 SB - IM MH - Humans MH - *Hypothermia, Induced/adverse effects MH - *Myocardial Infarction/diagnosis/therapy MH - *Percutaneous Coronary Intervention/adverse effects/methods MH - *ST Elevation Myocardial Infarction/diagnosis/therapy MH - Time Factors MH - Treatment Outcome OTO - NOTNLM OT - Acute coronary syndrome (ACS) OT - Coronary disease OT - Educational debriefing OT - Percutaneous coronary intervention (PCI) OT - ST elevation myocardial infarction (STEMI) OT - Simulation OT - Therapeutic hypothermia OT - Training COIS- Michael Dae is a consultant for ZOLL Circulation Inc (San Jose, CA, USA). None of the other authors have conflicts of interest related to this article. EDAT- 2022/03/30 06:00 MHDA- 2022/04/19 06:00 CRDT- 2022/03/29 01:40 PHST- 2021/11/27 00:00 [received] PHST- 2021/12/29 00:00 [revised] PHST- 2022/01/10 00:00 [accepted] PHST- 2022/03/29 01:40 [entrez] PHST- 2022/03/30 06:00 [pubmed] PHST- 2022/04/19 06:00 [medline] AID - S1530-6550(22)00428-8 [pii] AID - 10.31083/j.rcm2303104 [doi] PST - ppublish SO - Rev Cardiovasc Med. 2022 Mar 16;23(3):104. doi: 10.31083/j.rcm2303104. PMID- 35345255 OWN - NLM STAT- MEDLINE DCOM- 20220418 LR - 20220418 IS - 2153-8174 (Electronic) IS - 1530-6550 (Linking) VI - 23 IP - 3 DP - 2022 Mar 4 TI - Learning from Controversy and Revisiting the Randomized Trials of Secondary Mitral Regurgitation. PG - 88 LID - 10.31083/j.rcm2303088 [doi] AB - Until recently, conventional mitral valve surgery has been the treatment of choice even in secondary mitral regurgitation. Recent evidence, however, advocates the use of transcatheter edge-to-edge mitral valve repair (TEER) of the mitral valve. This has been reflected by the change in guidelines of the American College of Cardiology/American Heart Association. We reviewed the literature to shed light on the risks and benefits of all interventions, surgical, transcatheter and guideline-directed medical therapy. Secondary mitral regurgitation occurs due to an imbalance between closing forces and tethering forces. Given the pathology extends beyond the valve alone, treatment should be directed at restoring the geometrical shape of the left ventricle alongside the valve. Myocardial revascularization plays a pivotal role in preventing recurrence. The role of papillary muscle approximation in addition to restrictive mitral annuloplasty should be considered in a select group of patients. We also reviewed the current literature on TEERs from the COAPT and Mitra-FR trials while highlighting the concept of proportionate/disproportionate MR which may help identify which patients benefit from mitral valve restoration. Treatment of this condition will require robust randomized trials alongside the use of state-of-the-art imaging technologies available with the full complement of the multidisciplinary team to ensure the best outcomes for each patient. CI - (c) 2022 The Author(s). Published by IMR Press. FAU - Fiore, Antonio AU - Fiore A AD - Department of Cardiac Surgery, University Hospitals Henri Mondor, Assistance Publique-Hopitaux de Paris, 94000 Creteil, France. AD - Sapienza University of Rome, 00185 Rome, Italy. FAU - Avtaar Singh, Sanjeet Singh AU - Avtaar Singh SS AD - Department of Cardiothoracic Surgery, Golden Jubilee National Hospital, Clydebank G81 4DY Glasgow, UK. FAU - Nappi, Francesco AU - Nappi F AD - Department of Cardiac Surgery, Centre Cardiologique du Nord, 93200 Saint-Denis, France. LA - eng PT - Journal Article PT - Review PL - Singapore TA - Rev Cardiovasc Med JT - Reviews in cardiovascular medicine JID - 100960007 SB - IM MH - *Heart Valve Prosthesis Implantation/adverse effects MH - Humans MH - Mitral Valve/diagnostic imaging/surgery MH - *Mitral Valve Annuloplasty/adverse effects MH - *Mitral Valve Insufficiency/diagnostic imaging/surgery MH - Randomized Controlled Trials as Topic MH - Treatment Outcome OTO - NOTNLM OT - mitral valve repair OT - mitral valve replacement OT - secondary mitral regurgitation OT - subannular repair OT - transcatheter edge to edge repair COIS- The authors declare no conflict of interest. Francesco Nappi is serving as one of the Guest editors of this journal. We declare that Francesco Nappi had no involvement in the peer review of this article and has no access to information regarding its peer review. Full responsibility for the editorial process for this article was delegated to Francesco Onorati and Antonio Mangieri. EDAT- 2022/03/30 06:00 MHDA- 2022/04/19 06:00 CRDT- 2022/03/29 01:40 PHST- 2021/11/10 00:00 [received] PHST- 2022/01/25 00:00 [revised] PHST- 2022/02/10 00:00 [accepted] PHST- 2022/03/29 01:40 [entrez] PHST- 2022/03/30 06:00 [pubmed] PHST- 2022/04/19 06:00 [medline] AID - S1530-6550(22)00397-0 [pii] AID - 10.31083/j.rcm2303088 [doi] PST - ppublish SO - Rev Cardiovasc Med. 2022 Mar 4;23(3):88. doi: 10.31083/j.rcm2303088. PMID- 35344187 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220716 IS - 2193-8261 (Print) IS - 2193-6544 (Electronic) IS - 2193-6544 (Linking) VI - 11 IP - 2 DP - 2022 Jun TI - Coronary Artery Disease and Aspirin Intolerance: Background and Insights on Current Management. PG - 175-183 LID - 10.1007/s40119-022-00255-9 [doi] AB - Aspirin is one of the most widely used medications across the global healthcare system and is the foundation in treating ischemic heart disease, as well as secondary prevention for ischemic and valvular heart disease. Challenges arise in treating patients with cardiovascular disease who have concomitant aspirin intolerance. Through an extensive review of the literature, we provide a comprehensive background on the pharmacology of aspirin, the mechanisms behind aspirin intolerance, the importance of aspirin in cardiovascular disease, and the management of aspirin intolerance in both acute coronary syndrome and stable coronary artery disease. Our review includes a multidisciplinary approach from the internist, allergist/immunologist, and cardiologist when evaluating this important patient population. CI - (c) 2022. The Author(s). FAU - Thakker, Ravi A AU - Thakker RA AUID- ORCID: 0000-0001-7214-3439 AD - Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX, 77555, USA. ravi.a.thakker@gmail.com. FAU - Salazar, Leonardo AU - Salazar L AD - Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX, 77555, USA. FAU - Jazar, Deaa Abu AU - Jazar DA AD - Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX, 77555, USA. FAU - Bhakta, Pooja AU - Bhakta P AD - Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX, 77555, USA. FAU - Baker, Bryan AU - Baker B AD - Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX, 77555, USA. FAU - Patel, Chandani AU - Patel C AD - Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX, 77555, USA. FAU - Elbadawi, Ayman AU - Elbadawi A AD - Division of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, TX, USA. FAU - Agarwal, Mayank AU - Agarwal M AD - Division of Cardiology, University of Texas Medical Branch, Galveston, TX, USA. FAU - Albaeni, Aiham AU - Albaeni A AD - Division of Cardiology, University of Texas Medical Branch, Galveston, TX, USA. FAU - Saleh, Mohammed AU - Saleh M AD - Division of Cardiology, University of Texas Medical Branch, Galveston, TX, USA. FAU - Esclovan, Jonathan AU - Esclovan J AD - Division of Cardiology, University of Texas Medical Branch, Galveston, TX, USA. FAU - El Haddad, Danielle AU - El Haddad D AD - Division of Cardiology, University of Texas Medical Branch, Galveston, TX, USA. FAU - Alwash, Hashim AU - Alwash H AD - Division of Cardiology, University of Texas Medical Branch, Galveston, TX, USA. FAU - Kalra, Ankur AU - Kalra A AD - Division of Cardiovascular Medicine, Indiana University School of Medicine, Indianapolis, IN, USA. FAU - Goel, Sachin S AU - Goel SS AD - Department of Cardiology, Houston Methodist DeBakey Heart and Vascular Center, Houston, TX, USA. FAU - Widmer, Robert Jay AU - Widmer RJ AD - Division of Cardiology, Scott and White Heart Memorial Hospital, Baylor Scott and White Health, Temple, TX, USA. FAU - Chatila, Khaled AU - Chatila K AD - Division of Cardiology, University of Texas Medical Branch, Galveston, TX, USA. FAU - Khalife, Wissam AU - Khalife W AD - Division of Cardiology, University of Texas Medical Branch, Galveston, TX, USA. FAU - Motiwala, Afaq AU - Motiwala A AD - Division of Cardiology, University of Texas Medical Branch, Galveston, TX, USA. FAU - McCracken, Jennifer AU - McCracken J AD - Division of Allergy and Immunology, University of Texas Medical Branch, Galveston, TX, USA. FAU - Jneid, Hani AU - Jneid H AD - Division of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, TX, USA. FAU - Gilani, Syed AU - Gilani S AD - Division of Cardiology, University of Texas Medical Branch, Galveston, TX, USA. LA - eng PT - Journal Article PT - Review DEP - 20220328 PL - England TA - Cardiol Ther JT - Cardiology and therapy JID - 101634495 PMC - PMC9135937 OTO - NOTNLM OT - Acute coronary syndrome OT - Aspirin intolerance OT - Coronary artery disease EDAT- 2022/03/29 06:00 MHDA- 2022/03/29 06:01 PMCR- 2022/03/28 CRDT- 2022/03/28 12:17 PHST- 2022/01/05 00:00 [received] PHST- 2022/03/29 06:00 [pubmed] PHST- 2022/03/29 06:01 [medline] PHST- 2022/03/28 12:17 [entrez] PHST- 2022/03/28 00:00 [pmc-release] AID - 10.1007/s40119-022-00255-9 [pii] AID - 255 [pii] AID - 10.1007/s40119-022-00255-9 [doi] PST - ppublish SO - Cardiol Ther. 2022 Jun;11(2):175-183. doi: 10.1007/s40119-022-00255-9. Epub 2022 Mar 28. PMID- 35340045 OWN - NLM STAT- MEDLINE DCOM- 20220719 LR - 20221015 IS - 1099-1751 (Electronic) IS - 0749-6753 (Print) IS - 0749-6753 (Linking) VI - 37 IP - 4 DP - 2022 Jul TI - The teamwork structure, process, and context of a paediatric cardiac surgery team in Mongolia: A mixed-methods approach. PG - 2224-2239 LID - 10.1002/hpm.3463 [doi] AB - INTRODUCTION: Effective teamwork in paediatric cardiac surgery is known to improve team performance and surgical outcomes. However, teamwork in low- and middle-income countries (LMICs), including Mongolia, is understudied. We examined multiple dimensions of teamwork to inform a team-based training programme to strengthen paediatric cardiac surgical care in Mongolia. METHODS: We used a mixed-methods approach, combining social network analysis and in-depth interviews with medical staff, to explore the structure, process, quality, and context of teamwork at a single medical centre. We conceptualised the team's structure based on communication frequency among the members (n = 24) and explored the process, quality, and context of teamwork via in-depth interviews with select medical staff (n = 9). RESULTS: The team structure was highly dense and decentralised, but the intensive care unit nurses showed high betweenness-centrality. In the quality and process domain of teamwork, we did not find a regular joint decision-making process, leading to the absence of common goals among the team members. Although role assignment among the medical staff was explicit, those strictly defined roles hindered active communication about patient information and responsibility-sharing. Most interviewees did not agree with the organisational policies that limited discussions among team members; therefore, medical staff continued to share training and work experiences with each other, leading to strong and trustworthy relationships. CONCLUSION: The findings of this study underscore the importance of well-structured and goal-oriented communication between medical staff, as well as the management of the quality of collaboration within a team to increase teamwork effectiveness in paediatric cardiac surgery teams in LMICs. CI - (c) 2022 The Authors. The International Journal of Health Planning and Management published by John Wiley & Sons Ltd. FAU - Han, Seungheon AU - Han S AUID- ORCID: 0000-0001-9789-7034 AD - Korea Institute of Public Administration, Seoul, South Korea. AD - Program in Global Surgery and Implementation Science, JW LEE Center for Global Medicine, Seoul National University College of Medicine, Seoul, South Korea. FAU - Choi, Sugy AU - Choi S AUID- ORCID: 0000-0002-5549-2861 AD - Program in Global Surgery and Implementation Science, JW LEE Center for Global Medicine, Seoul National University College of Medicine, Seoul, South Korea. AD - Department of Population Health, New York University Grossman School of Medicine, New York, New York, USA. FAU - Park, Jayoung AU - Park J AUID- ORCID: 0000-0003-2612-5509 AD - Program in Global Surgery and Implementation Science, JW LEE Center for Global Medicine, Seoul National University College of Medicine, Seoul, South Korea. FAU - Kweon, Seoah AU - Kweon S AD - Program in Global Surgery and Implementation Science, JW LEE Center for Global Medicine, Seoul National University College of Medicine, Seoul, South Korea. FAU - Oh, Se Jin AU - Oh SJ AUID- ORCID: 0000-0002-1516-5313 AD - Department of Thoracic and Cardiovascular Surgery, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Korea. FAU - Shakya, Holly B AU - Shakya HB AUID- ORCID: 0000-0002-5320-9575 AD - Division of Global Public Health, School of Medicine, University of California San Diego, La Jolla, California, USA. FAU - Heo, Jongho AU - Heo J AUID- ORCID: 0000-0002-6405-3860 AD - Program in Global Surgery and Implementation Science, JW LEE Center for Global Medicine, Seoul National University College of Medicine, Seoul, South Korea. AD - National Assembly Futures Institute, Seoul, South Korea. FAU - Kim, Woong-Han AU - Kim WH AUID- ORCID: 0000-0003-2837-7929 AD - Program in Global Surgery and Implementation Science, JW LEE Center for Global Medicine, Seoul National University College of Medicine, Seoul, South Korea. AD - Department of Thoracic and Cardiovascular Surgery, Seoul National University College of Medicine, Seoul, South Korea. AD - Department of Thoracic and Cardiovascular Surgery, Seoul National University Children's Hospital, Seoul, South Korea. LA - eng GR - JW LEE Center for Global Medicine/ GR - Seoul Metropolitan Government Seoul National University Boramae Medical Center/ PT - Journal Article DEP - 20220326 PL - England TA - Int J Health Plann Manage JT - The International journal of health planning and management JID - 8605825 MH - Child MH - *Communication MH - Humans MH - Intensive Care Units MH - Mongolia MH - *Patient Care Team PMC - PMC9545841 OTO - NOTNLM OT - ICU nurses OT - LMICs OT - cardiovascular disease OT - child health OT - social network analysis OT - team-based training COIS- All authors have no conflicts of interest to declare. EDAT- 2022/03/28 06:00 MHDA- 2022/07/20 06:00 PMCR- 2022/10/07 CRDT- 2022/03/27 20:28 PHST- 2022/02/17 00:00 [revised] PHST- 2022/01/13 00:00 [received] PHST- 2022/03/08 00:00 [accepted] PHST- 2022/03/28 06:00 [pubmed] PHST- 2022/07/20 06:00 [medline] PHST- 2022/03/27 20:28 [entrez] PHST- 2022/10/07 00:00 [pmc-release] AID - HPM3463 [pii] AID - 10.1002/hpm.3463 [doi] PST - ppublish SO - Int J Health Plann Manage. 2022 Jul;37(4):2224-2239. doi: 10.1002/hpm.3463. Epub 2022 Mar 26. PMID- 35339610 OWN - NLM STAT- MEDLINE DCOM- 20220614 LR - 20250728 IS - 1873-6513 (Electronic) IS - 0885-3924 (Print) IS - 0885-3924 (Linking) VI - 64 IP - 1 DP - 2022 Jul TI - Intervention Codesign in the Pediatric Cardiac Intensive Care Unit to Improve Family Meetings. PG - 8-16 LID - S0885-3924(22)00475-4 [pii] LID - 10.1016/j.jpainsymman.2022.03.010 [doi] AB - CONTEXT: Family meetings are encouraged in the pediatric cardiac intensive care unit (CICU) with the expectation of supporting parental shared decision-making (SDM). However, they often fall short of this goal. Additionally, interprofessional team and family meetings are dominated by input from physicians, under-utilizing the skillset of the full clinical team. OBJECTIVES: 1) To determine feasibility of a codesign process to optimize the preparation of the interprofessional team and parents for conducting SDM-oriented family meetings in the CICU, and 2) to describe the resulting elements of the intervention including new support documents for the team and family to prepare for the meeting, team member roles in the meeting, and optimization of communication skills. METHODS: Experience-based codesign was used with CICU clinicians and parents of children hospitalized in the CICU to develop an intervention at a single institution. Sessions were audio recorded and transcribed and analyzed using modified grounded theory. Participants were surveyed about their engagement in the codesign process to assess feasibility. RESULTS: Fifteen professionals and six parents enrolled in the codesign and endorsed engagement in the process and importance of the intervention elements. Participants identified the benefit of complementary parent and team preparation for family meetings noting five distinct types of meetings that occurred frequently. Documents, processes, and skills training were developed to improve interprofessional teamwork regarding shared decision making and support of parents in family meetings. CONCLUSION: A codesign of an intervention with clinicians and parents in the CICU is a feasible and resulted in an intervention with broad support among clinicians in the CICU. CI - Copyright (c) 2022 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved. FAU - Walter, Jennifer K AU - Walter JK AD - Pediatric Advanced Care Team (J.K.W., C.F.), Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA; Children's Hospital of Philadelphia Research Institute (J.K.W., D.H., W.A.D., A.L., C.F.), Philadelphia, Pennsylvania, USA. Electronic address: Walterj1@chop.edu. FAU - Hill, Douglas AU - Hill D AD - Children's Hospital of Philadelphia Research Institute (J.K.W., D.H., W.A.D., A.L., C.F.), Philadelphia, Pennsylvania, USA. FAU - Drust, William A AU - Drust WA AD - Children's Hospital of Philadelphia Research Institute (J.K.W., D.H., W.A.D., A.L., C.F.), Philadelphia, Pennsylvania, USA. FAU - Lisanti, Amy AU - Lisanti A AD - Children's Hospital of Philadelphia Research Institute (J.K.W., D.H., W.A.D., A.L., C.F.), Philadelphia, Pennsylvania, USA; Department of Family and Community Health (A.L.), University of Pennsylvania School of Nursing, Philadelphia, Pennsylvania, USA. FAU - DeWitt, Aaron AU - DeWitt A AD - Division of Cardiac Critical Care Medicine (A.D., A.S.), Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. FAU - Seelhorst, Amanda AU - Seelhorst A AD - Division of Cardiac Critical Care Medicine (A.D., A.S.), Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. FAU - Hasiuk, Ma Luisa AU - Hasiuk ML AD - Department of Patient and Family Services (M.L.H.), Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. FAU - Arnold, Robert AU - Arnold R AD - Section of Palliative Care (R.A.), University of Pittsburgh School of Medicine, Palliative and Supportive Institute UMPC Health System, Pittsburgh, Pennsylvania, USA. FAU - Feudtner, Chris AU - Feudtner C AD - Pediatric Advanced Care Team (J.K.W., C.F.), Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA; Children's Hospital of Philadelphia Research Institute (J.K.W., D.H., W.A.D., A.L., C.F.), Philadelphia, Pennsylvania, USA. LA - eng GR - K23 HL141700/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20220323 PL - United States TA - J Pain Symptom Manage JT - Journal of pain and symptom management JID - 8605836 SB - IM MH - Child MH - Humans MH - *Intensive Care Units, Pediatric MH - Parents MH - *Physicians PMC - PMC9189043 MID - NIHMS1791843 OTO - NOTNLM OT - Codesign OT - cardiac intensive care unit OT - clinician-family communication OT - family meeting OT - interprofessional team OT - pediatrics EDAT- 2022/03/28 06:00 MHDA- 2022/06/15 06:00 PMCR- 2023/07/01 CRDT- 2022/03/27 20:20 PHST- 2022/02/26 00:00 [received] PHST- 2022/03/10 00:00 [revised] PHST- 2022/03/11 00:00 [accepted] PHST- 2022/03/28 06:00 [pubmed] PHST- 2022/06/15 06:00 [medline] PHST- 2022/03/27 20:20 [entrez] PHST- 2023/07/01 00:00 [pmc-release] AID - S0885-3924(22)00475-4 [pii] AID - 10.1016/j.jpainsymman.2022.03.010 [doi] PST - ppublish SO - J Pain Symptom Manage. 2022 Jul;64(1):8-16. doi: 10.1016/j.jpainsymman.2022.03.010. Epub 2022 Mar 23. PMID- 35334382 OWN - NLM STAT- MEDLINE DCOM- 20220525 LR - 20220530 IS - 1095-8673 (Electronic) IS - 0022-4804 (Linking) VI - 276 DP - 2022 Aug TI - Use of In-Situ Simulation Based Clinical Systems Test of Thoracic Robotic Surgery Emergencies. PG - 37-47 LID - S0022-4804(22)00111-1 [pii] LID - 10.1016/j.jss.2022.02.042 [doi] AB - INTRODUCTION: With the advancement of robotic surgery, some thoracic surgeons have been slow to adopt to this new operative approach, in part because they are un-scrubbed and away from the patient while operating. Aiming to allay surgeon concerns of intra-operative emergencies, an insitu simulation-based clinical system's test (SbCST) can be completed to test the current clinical system, and to practice low-frequency, high-stakes clinical scenarios with the entire operating room (OR) team. METHODS: Six different OR teams completed an insitu SbCST of an intra-operative pulmonary artery injury during a robot-assisted thoracic surgery at a single tertiary care center. The OR team consisted of an attending thoracic surgeon, surgery resident, anesthesia attending, anesthesia resident, circulating nurse, and a scrub technician. This test was conducted with an entire OR team along with study observers and simulation center staff. Outcomes included the identified latent safety threats (LSTs) and possible solutions for each LST, culminating in a complete failure mode and effects analysis (FMEA). A Risk Priority Number (RPN) was determined for each LST identified. Pre- and post-simulation surveys using Likert scales were also collected. RESULTS: The six FMEAs identified 28 potential LSTs in four categories. Of these 28 LSTs, nine were considered high priority based on their Risk Priority Number (RPN) with seven of the nine being repeated multiple times. Pre- and post-simulation survey responses were similar, with the majority of participants (94%) agreeing that high fidelity simulation of intra-operative emergencies is helpful and provides an opportunity to train for high-stakes, low-frequency events. After completing the SbCST, more participants felt confident that they knew their role during an intra-operative emergency than their pre-simulation survey responses. All participants agreed that simulation is an important part of continuing education and is helpful for learning skills that are infrequently used. Following the SbCST, more participants agreed that they knew how to safely undock the da Vinci robot during an emergency. CONCLUSIONS: SbCSTs provide an opportunity to test the current clinical system with a low-frequency, high-stakes event and allow medical personnels to practice their skills and teamwork. By completing multiple SbCSTs, we were able to identify multiple LSTs within different OR teams, allowing for a broader review of the current clinical systems in place. The use of these SbCSTs in conjunction with debriefing sessions and FMEA completion allows for the most significant potential improvement of the current system. This study shows that SbCST with FMEA completion can be used to test current systems and create better systems for patient safety. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Bludevich, Bryce M AU - Bludevich BM AD - Division of Thoracic Surgery, UMASS T.H. Chan School of Medicine, Worcester, Massachusetts. FAU - Buettner, Hannah AU - Buettner H AD - Division of Thoracic Surgery, UMASS T.H. Chan School of Medicine, Worcester, Massachusetts. FAU - Hazeltine, Max AU - Hazeltine M AD - Division of Thoracic Surgery, UMASS T.H. Chan School of Medicine, Worcester, Massachusetts. FAU - Zayaruzny, Maksim AU - Zayaruzny M AD - Department of Anesthesia, UMASS T.H. Chan School of Medicine, Worcester, Massachusetts. FAU - Yarzebski, Jorge AU - Yarzebski J AD - Department of Simulation, UMASS T.H. Chan School of Medicine, Worcester, Massachusetts. FAU - Weaver, Anne AU - Weaver A AD - Department of Simulation, UMASS T.H. Chan School of Medicine, Worcester, Massachusetts. FAU - Emmerick, Isabel AU - Emmerick I AD - Division of Thoracic Surgery, UMASS T.H. Chan School of Medicine, Worcester, Massachusetts. FAU - Maxfield, Mark W AU - Maxfield MW AD - Division of Thoracic Surgery, UMASS T.H. Chan School of Medicine, Worcester, Massachusetts. FAU - Kadiyala, Mamatha AU - Kadiyala M AD - Department of Anesthesia, UMASS T.H. Chan School of Medicine, Worcester, Massachusetts. FAU - Uy, Karl AU - Uy K AD - Division of Thoracic Surgery, UMASS T.H. Chan School of Medicine, Worcester, Massachusetts. FAU - Lou, Feiran AU - Lou F AD - Division of Thoracic Surgery, UMASS T.H. Chan School of Medicine, Worcester, Massachusetts. Electronic address: Feiran.lou@umassmemorial.org. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220322 PL - United States TA - J Surg Res JT - The Journal of surgical research JID - 0376340 SB - IM MH - Clinical Competence MH - Emergencies MH - Humans MH - Patient Care Team MH - *Robotic Surgical Procedures MH - *Robotics MH - *Thoracic Surgery OTO - NOTNLM OT - Intra-operative emergencies OT - Robotic surgery OT - Simulation training OT - Systems test OT - Thoracic surgery EDAT- 2022/03/26 06:00 MHDA- 2022/05/26 06:00 CRDT- 2022/03/25 20:11 PHST- 2021/12/30 00:00 [received] PHST- 2022/02/09 00:00 [revised] PHST- 2022/02/17 00:00 [accepted] PHST- 2022/03/26 06:00 [pubmed] PHST- 2022/05/26 06:00 [medline] PHST- 2022/03/25 20:11 [entrez] AID - S0022-4804(22)00111-1 [pii] AID - 10.1016/j.jss.2022.02.042 [doi] PST - ppublish SO - J Surg Res. 2022 Aug;276:37-47. doi: 10.1016/j.jss.2022.02.042. Epub 2022 Mar 22. PMID- 35333946 OWN - NLM STAT- MEDLINE DCOM- 20220923 LR - 20261029 IS - 1432-1971 (Electronic) IS - 0172-0643 (Linking) VI - 43 IP - 7 DP - 2022 Oct TI - Evaluation of an Outpatient and Telehealth Initiative to Reduce Tube Dependency in Infants with Complex Congenital Heart Disease. PG - 1429-1437 LID - 10.1007/s00246-022-02864-6 [doi] AB - Infants with congenital heart disease (CHD) often require supplemental nutrition via tube feeding, even after corrective surgical repair. The need for tube feeding can persist months after discharge home, and outpatient weaning from the tube can be a slow and difficult process. Lack of consensus exists in the literature as to the best approach to this challenge. We describe a single institution's initiative to decrease tube dependency after discharge through an intensive, telehealth-centric program for children with CHD. Of 16 children aged 1-26 months, 94% were able to be successfully tube weaned at home, with median time to tube-free of 12 days. No significant weight loss was noted during or after the wean process. Longer tube wean time was associated with older age at onset and comorbid genetic syndrome. Our telehealth-based intensive tube weaning program was successful but required a multidisciplinary team, targeted pre-participation patient evaluation, and frequent communication. CI - (c) 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Horsley, Megan AU - Horsley M AUID- ORCID: 0000-0003-0722-9230 AD - Division of Nutrition Therapy, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH, 45229, USA. Megan.horsley@cchmc.org. FAU - Hill, Garick D AU - Hill GD AD - Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. FAU - Kaskie, Sarah AU - Kaskie S AD - Division of Speech-Language Pathology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. FAU - Schnautz, Maureen AU - Schnautz M AD - Division of Speech-Language Pathology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. FAU - Brown, James AU - Brown J AD - Department of James M Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. FAU - Marcuccio, Elisa AU - Marcuccio E AD - Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. LA - eng PT - Journal Article DEP - 20220325 PL - United States TA - Pediatr Cardiol JT - Pediatric cardiology JID - 8003849 SB - IM MH - Child MH - Enteral Nutrition MH - *Heart Defects, Congenital/therapy MH - Humans MH - Infant MH - Outpatients MH - Patient Discharge MH - *Telemedicine OTO - NOTNLM OT - Congenital heart disease OT - Oral feeding OT - Telehealth OT - Tube dependency OT - Tube feed EDAT- 2022/03/26 06:00 MHDA- 2022/09/24 06:00 CRDT- 2022/03/25 17:25 PHST- 2021/12/31 00:00 [received] PHST- 2022/02/25 00:00 [accepted] PHST- 2022/03/26 06:00 [pubmed] PHST- 2022/09/24 06:00 [medline] PHST- 2022/03/25 17:25 [entrez] AID - 10.1007/s00246-022-02864-6 [pii] AID - 10.1007/s00246-022-02864-6 [doi] PST - ppublish SO - Pediatr Cardiol. 2022 Oct;43(7):1429-1437. doi: 10.1007/s00246-022-02864-6. Epub 2022 Mar 25. PMID- 35332760 OWN - NLM STAT- MEDLINE DCOM- 20220802 LR - 20250728 IS - 1827-1669 (Electronic) IS - 0026-4806 (Linking) VI - 113 IP - 4 DP - 2022 Aug TI - Role of new drug therapies and innovative procedures in older patients with heart failure: from trials to clinical practice. PG - 647-666 LID - 10.23736/S0026-4806.22.08082-X [doi] AB - During earliest years, new drug-therapies and novel interventional therapies have been tested to modify the detrimental effect of secondary valve diseases, adverse ventricular remodelling and persistent fluid overload in HF patients. However, the increased prevalence of older or very old patients with HF has made their widespread implementation more problematic due to complex comorbidity, frailty, or overt disability. This growing older population, often excluded by randomized trials, but with elevated risk of hospitalization, required a different clinical and management approach that allows clinicians to take full advantage in reducing mortality and morbidity from these new pharmacological and instrumental therapies. In this perspective, the role of multidisciplinary Heart Team is mandatory for better define a correct decision-making process and tailoring the best pharmacological therapy in each patient and to program a continuum care in a post-acute phase of treatment. In addition, the possibility to plan multicentre registries of several complex cases evaluated by Heart Team could become a very important source of real world data to further refine indications and contraindications of different highly technological therapeutic approach, today based often on randomized clinical trials that do not represent faithfully the current clinical practice population. FAU - Baldasseroni, Samuele AU - Baldasseroni S AD - Unit of Geriatric Intensive Care Medicine, Careggi University Hospital, University of Florence, Florence, Italy - pesine@libero.it. AD - Department of Clinical and Experimental Medicine, University of Florence, Florence, Italy - pesine@libero.it. AD - SICGE - Societa Italiana di Cardiologia Geriatrica, Florence, Italy - pesine@libero.it. FAU - Orso, Francesco AU - Orso F AD - Unit of Geriatric Intensive Care Medicine, Careggi University Hospital, University of Florence, Florence, Italy. AD - Department of Clinical and Experimental Medicine, University of Florence, Florence, Italy. FAU - Herbst, Andrea AU - Herbst A AD - Unit of Geriatric Intensive Care Medicine, Careggi University Hospital, University of Florence, Florence, Italy. AD - Department of Clinical and Experimental Medicine, University of Florence, Florence, Italy. FAU - Bo, Mario AU - Bo M AD - SICGE - Societa Italiana di Cardiologia Geriatrica, Florence, Italy. FAU - Boccanelli, Alessandro AU - Boccanelli A AD - SICGE - Societa Italiana di Cardiologia Geriatrica, Florence, Italy. FAU - Desideri, Giovanbattista AU - Desideri G AD - SICGE - Societa Italiana di Cardiologia Geriatrica, Florence, Italy. FAU - Rozzini, Renzo AU - Rozzini R AD - SICGE - Societa Italiana di Cardiologia Geriatrica, Florence, Italy. FAU - Terrosu, Pierfranco AU - Terrosu P AD - SICGE - Societa Italiana di Cardiologia Geriatrica, Florence, Italy. FAU - Alboni, Paolo AU - Alboni P AD - SICGE - Societa Italiana di Cardiologia Geriatrica, Florence, Italy. FAU - Marchionni, Niccolo AU - Marchionni N AD - Department of Clinical and Experimental Medicine, University of Florence, Florence, Italy. AD - SICGE - Societa Italiana di Cardiologia Geriatrica, Florence, Italy. AD - Division of Cardiology, Careggi University Hospital, University of Florence, Florence, Italy. FAU - Ungar, Andrea AU - Ungar A AD - Unit of Geriatric Intensive Care Medicine, Careggi University Hospital, University of Florence, Florence, Italy. AD - Department of Clinical and Experimental Medicine, University of Florence, Florence, Italy. AD - SICGE - Societa Italiana di Cardiologia Geriatrica, Florence, Italy. LA - eng PT - Journal Article DEP - 20220325 PL - Italy TA - Minerva Med JT - Minerva medica JID - 0400732 SB - IM MH - Aged MH - Comorbidity MH - *Heart Failure MH - Hospitalization MH - Humans MH - Registries EDAT- 2022/03/26 06:00 MHDA- 2022/08/03 06:00 CRDT- 2022/03/25 06:40 PHST- 2022/03/26 06:00 [pubmed] PHST- 2022/08/03 06:00 [medline] PHST- 2022/03/25 06:40 [entrez] AID - S0026-4806.22.08082-X [pii] AID - 10.23736/S0026-4806.22.08082-X [doi] PST - ppublish SO - Minerva Med. 2022 Aug;113(4):647-666. doi: 10.23736/S0026-4806.22.08082-X. Epub 2022 Mar 25. PMID- 35332751 OWN - NLM STAT- MEDLINE DCOM- 20230515 LR - 20230519 IS - 2724-5772 (Electronic) IS - 2724-5683 (Linking) VI - 71 IP - 3 DP - 2023 Jun TI - Transcatheter aortic valve implantation in patients with age 3000 screened with heart team involvement and >1500 receiving TAVI. Most common or relevant indications for TAVI reduced life expectancy (e.g. cardiogenic shock or severe left ventricular systolic dysfunction), chronic obstructive pulmonary disease, morbid obesity, active or recent extra-cardiac cancer, porcelain aorta, neurologic disability, cirrhosis, or prior surgical aortic valve replacement, as well as extreme cachexia, and Hutchinson-Gilford progeria. At least two contemporary high-risk features were present in most cases. Transapical access was used in 5 (12.8%) cases, and a sheathless approach in 15 (38.5%). A variety of devices were used, including both balloon- and self-expandable devices. Clinical outcomes were satisfactory, despite the high-risk profile, at both short- and mid-term, with no in-hospital death, and 5.1% (95% confidence interval 0-12.8%) mortality at a median follow-up of 15 months (minimum 1; maximum 85). Notably, no case of significant valve deterioration requiring reintervention occurred. CONCLUSIONS: In carefully selected patients with 70 years or less of age and prohibitive risk for surgery or reduced life expectancy, TAVI represents a safe option with a favorable mid-term survival and low rate of adverse events. FAU - Russo, Marco AU - Russo M AD - Department of Cardiac Surgery and Heart Transplantation, San Camillo Forlanini Hospital, Rome, Italy - mar.russo1987@gmail.com. FAU - Corcione, Nicola AU - Corcione N AD - Cardiovascular Interventional Unit, Pineta Grande Hospital, Castel Volturno, Caserta, Italy. FAU - Cammardella, Antonio G AU - Cammardella AG AD - Department of Cardiac Surgery and Heart Transplantation, San Camillo Forlanini Hospital, Rome, Italy. FAU - Ranocchi, Federico AU - Ranocchi F AD - Department of Cardiac Surgery and Heart Transplantation, San Camillo Forlanini Hospital, Rome, Italy. FAU - Lio, Antonio AU - Lio A AD - Department of Cardiac Surgery and Heart Transplantation, San Camillo Forlanini Hospital, Rome, Italy. FAU - Saitto, Guglielmo AU - Saitto G AD - Department of Cardiac Surgery and Heart Transplantation, San Camillo Forlanini Hospital, Rome, Italy. FAU - Nicolo, Francesca AU - Nicolo F AD - Department of Cardiac Surgery and Heart Transplantation, San Camillo Forlanini Hospital, Rome, Italy. FAU - Pergolini, Amedeo AU - Pergolini A AD - Department of Cardiac Surgery and Heart Transplantation, San Camillo Forlanini Hospital, Rome, Italy. FAU - Polizzi, Vincenzo AU - Polizzi V AD - Department of Cardiac Surgery and Heart Transplantation, San Camillo Forlanini Hospital, Rome, Italy. FAU - Ferraro, Paolo AU - Ferraro P AD - Unit of Hemodynamics, Santa Lucia Hospital, San Giuseppe Vesuviano, Naples, Italy. FAU - Morello, Alberto AU - Morello A AD - Cardiovascular Interventional Unit, Pineta Grande Hospital, Castel Volturno, Caserta, Italy. FAU - Cimmino, Michele AU - Cimmino M AD - Cardiovascular Interventional Unit, Pineta Grande Hospital, Castel Volturno, Caserta, Italy. FAU - Albanese, Michele AU - Albanese M AD - Unit of Hemodynamics, Santa Lucia Hospital, San Giuseppe Vesuviano, Naples, Italy. FAU - Nestola, Luisa AU - Nestola L AD - Cardiovascular Interventional Unit, Pineta Grande Hospital, Castel Volturno, Caserta, Italy. FAU - Biondi-Zoccai, Giuseppe AU - Biondi-Zoccai G AD - Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University, Latina, Italy. AD - Mediterranea Cardiocentro, Naples, Italy. FAU - Pepe, Martino AU - Pepe M AD - Section of Cardiovascular Diseases, Department of Emergency and Organ Transplantation (DETO), University of Bari Aldo Moro, Bari, Italy. FAU - Bardi, Luca AU - Bardi L AD - Cardiovascular Interventional Unit, Pineta Grande Hospital, Castel Volturno, Caserta, Italy. FAU - Giordano, Arturo AU - Giordano A AD - Cardiovascular Interventional Unit, Pineta Grande Hospital, Castel Volturno, Caserta, Italy. FAU - Musumeci, Francesco AU - Musumeci F AD - Department of Cardiac Surgery and Heart Transplantation, San Camillo Forlanini Hospital, Rome, Italy. LA - eng PT - Journal Article DEP - 20220325 PL - Italy TA - Minerva Cardiol Angiol JT - Minerva cardiology and angiology JID - 101776555 SB - IM CIN - Minerva Cardiol Angiol. 2023 Jun;71(3):321-323. doi: 10.23736/S2724-5683.22.06133-6. PMID: 36719672 MH - Humans MH - *Transcatheter Aortic Valve Replacement/adverse effects/methods MH - Retrospective Studies MH - *Aortic Valve Stenosis/surgery MH - Treatment Outcome MH - Aortic Valve/surgery EDAT- 2022/03/26 06:00 MHDA- 2023/05/15 06:42 CRDT- 2022/03/25 05:44 PHST- 2023/05/15 06:42 [medline] PHST- 2022/03/26 06:00 [pubmed] PHST- 2022/03/25 05:44 [entrez] AID - S2724-5683.22.06040-9 [pii] AID - 10.23736/S2724-5683.22.06040-9 [doi] PST - ppublish SO - Minerva Cardiol Angiol. 2023 Jun;71(3):324-332. doi: 10.23736/S2724-5683.22.06040-9. Epub 2022 Mar 25. PMID- 35332050 OWN - NLM STAT- MEDLINE DCOM- 20220412 LR - 20250103 IS - 2053-3624 (Print) IS - 2053-3624 (Electronic) IS - 2053-3624 (Linking) VI - 9 IP - 1 DP - 2022 Mar TI - Cardiac and obstetric outcomes in pregnant women with heart disease: appraisal of the 2018 mWHO classification. LID - 10.1136/openhrt-2021-001947 [doi] LID - e001947 AB - OBJECTIVE: To appraise the application of the 2018 European Society of Cardiology-adapted modified WHO (mWHO) classification to pregnant women with heart disease managed at our maternal-fetal medicine referral centre and to assess whether the lack of a multidisciplinary Pregnancy Heart team has influenced their outcomes. METHODS: A retrospective cohort study including all pregnancies with heart disease managed at our centre between June 2011 and December 2020. Cardiac conditions were categorised in five classes according to the mWHO classification. An additional class, named X, was created for conditions not included in this classification. Outcomes were compared among all classes and factors potentially associated to cardiac complications were assessed. RESULTS: We identified 162 women with 197 pregnancies, for a prevalence of 0.7%. Thirty-eight (19.3%) gestations were included in class X. Caesarean section was performed in 64.9% pregnancies in class X, a rate similar to that of class II, II-III, and III/IV, and mostly for obstetric indications; in turn, it was more commonly performed for cardiology reasons in class II-III and III/IV. Cardiac complications occurred in 10.7%, with class X and II pregnancies showing the highest number of events (n=30.8% and 34.6%, respectively). Multiple gestation and urgent caesarean section associated with a 5-fold and 6.5-fold increase in complication rates. CONCLUSIONS: Even in a maternal-fetal medicine referral centre, the lack of a multidisciplinary team approach to women with heart disease may negatively impact their outcomes. CI - (c) Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Ornaghi, Sara AU - Ornaghi S AUID- ORCID: 0000-0001-6898-7217 AD - School of Medicine and Surgery, University of Milan-Bicocca, Monza, Italy sara.ornaghi@unimib.it. AD - Department of Obstetrics, MBBM Foundation Onlus at San Gerardo Hospital, Monza, Italy. FAU - Bellante, Nicolo' AU - Bellante N AD - School of Medicine and Surgery, University of Milan-Bicocca, Monza, Italy. AD - Department of Obstetrics, MBBM Foundation Onlus at San Gerardo Hospital, Monza, Italy. FAU - Abbamondi, Alessandra AU - Abbamondi A AD - School of Medicine and Surgery, University of Milan-Bicocca, Monza, Italy. AD - Department of Obstetrics, MBBM Foundation Onlus at San Gerardo Hospital, Monza, Italy. FAU - Maini, Marzia AU - Maini M AD - School of Medicine and Surgery, University of Milan-Bicocca, Monza, Italy. AD - Department of Obstetrics, MBBM Foundation Onlus at San Gerardo Hospital, Monza, Italy. FAU - Cesana, Francesca AU - Cesana F AD - Department of Cardiology, San Gerardo Hospital, Monza, Italy. FAU - Trabucchi, Margherita AU - Trabucchi M AD - Department of Anesthesiology, San Gerardo Hospital, Monza, Italy. FAU - Corsi, Davide AU - Corsi D AD - Department of Cardiology, San Gerardo Hospital, Monza, Italy. FAU - Arosio, Viola AU - Arosio V AD - School of Medicine and Surgery, University of Milan-Bicocca, Monza, Italy. AD - Department of Obstetrics, MBBM Foundation Onlus at San Gerardo Hospital, Monza, Italy. FAU - Mariani, Silvana AU - Mariani S AD - Department of Obstetrics, MBBM Foundation Onlus at San Gerardo Hospital, Monza, Italy. FAU - Scian, Antonietta AU - Scian A AD - Department of Obstetrics, MBBM Foundation Onlus at San Gerardo Hospital, Monza, Italy. FAU - Colciago, Elisabetta AU - Colciago E AD - School of Medicine and Surgery, University of Milan-Bicocca, Monza, Italy. FAU - Lettino, Maddalena AU - Lettino M AD - Department of Cardiology, San Gerardo Hospital, Monza, Italy. FAU - Vergani, Patrizia AU - Vergani P AD - School of Medicine and Surgery, University of Milan-Bicocca, Monza, Italy. AD - Department of Obstetrics, MBBM Foundation Onlus at San Gerardo Hospital, Monza, Italy. LA - eng PT - Journal Article PL - England TA - Open Heart JT - Open heart JID - 101631219 SB - IM MH - Cesarean Section MH - Female MH - *Heart Diseases/diagnosis/epidemiology/therapy MH - Humans MH - Pregnancy MH - *Pregnancy Complications, Cardiovascular/diagnosis/epidemiology/therapy MH - Pregnancy Outcome/epidemiology MH - Pregnant People MH - Retrospective Studies PMC - PMC8948382 OTO - NOTNLM OT - heart failure OT - metabolic syndrome OT - pregnancy OT - stroke COIS- Competing interests: None declared. EDAT- 2022/03/26 06:00 MHDA- 2022/04/13 06:00 PMCR- 2022/03/24 CRDT- 2022/03/25 05:35 PHST- 2021/12/22 00:00 [received] PHST- 2022/03/07 00:00 [accepted] PHST- 2022/03/25 05:35 [entrez] PHST- 2022/03/26 06:00 [pubmed] PHST- 2022/04/13 06:00 [medline] PHST- 2022/03/24 00:00 [pmc-release] AID - openhrt-2021-001947 [pii] AID - 10.1136/openhrt-2021-001947 [doi] PST - ppublish SO - Open Heart. 2022 Mar;9(1):e001947. doi: 10.1136/openhrt-2021-001947. PMID- 35331450 OWN - NLM STAT- MEDLINE DCOM- 20220330 LR - 20230328 IS - 1876-7605 (Electronic) IS - 1936-8798 (Print) IS - 1936-8798 (Linking) VI - 15 IP - 6 DP - 2022 Mar 28 TI - Same-Day Discharge Post-Transcatheter Aortic Valve Replacement During the COVID-19 Pandemic: The Multicenter PROTECT TAVR Study. PG - 590-598 LID - S1936-8798(22)00025-5 [pii] LID - 10.1016/j.jcin.2021.12.046 [doi] AB - OBJECTIVES: The aim of this study was to determine the safety and efficacy of same-day discharge (SDD) after transcatheter aortic valve replacement (TAVR) during the COVID-19 pandemic. BACKGROUND: The COVID-19 pandemic has placed significant stress on health care systems worldwide. SDD in highly selected TAVR patients can facilitate the provision of essential cardiovascular care while managing competing COVID-19 resource demands. METHODS: Patient selection for SDD was at the discretion of the local multidisciplinary heart team, across 7 international sites. The primary outcome was a composite of cardiovascular death, stroke, myocardial infarction, all-cause readmission, major vascular complications, and new permanent pacemaker (PPM) implantation. RESULTS: From March 2020 to August 2021, 124 of 2,100 patients who underwent elective transfemoral TAVR were selected for SDD. The average age was 78.9 +/- 7.8 years, the median Society of Thoracic Surgeons score was 2.4 (IQR: 1.4-4.2), and 32.3% (n = 40) had preexisting PPMs. There were no major vascular complications, strokes, or deaths during the index admission. One patient (0.8%) required PPM implantation for complete heart block and was discharged the same day. No patient required a PPM between discharge home and 30-day follow-up. The composite of cardiovascular death, stroke, myocardial infarction, all-cause readmission, major vascular complications, and new PPM at 30 days occurred in 5.7% patients (n = 6 of 106). CONCLUSIONS: SDD post-TAVR is safe and feasible in selected patients at low risk for adverse clinical events postdischarge. This strategy may have a potential role in highly selected patients even when the COVID-19 pandemic abates. CI - Copyright (c) 2022 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. FAU - Barker, Madeleine AU - Barker M AD - Centre for Cardiovascular Innovation-Centre d'Innovation Cardiovasculaire, St. Paul's and Vancouver General Hospitals, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Sathananthan, Janarthanan AU - Sathananthan J AD - Centre for Cardiovascular Innovation-Centre d'Innovation Cardiovasculaire, St. Paul's and Vancouver General Hospitals, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Perdoncin, Emily AU - Perdoncin E AD - Division of Cardiology, Emory Structural Heart and Valve Center, Emory University Hospital Midtown, Atlanta, Georgia, USA. FAU - Devireddy, Chandan AU - Devireddy C AD - Division of Cardiology, Emory Structural Heart and Valve Center, Emory University Hospital Midtown, Atlanta, Georgia, USA. FAU - Keegan, Patricia AU - Keegan P AD - Division of Cardiology, Emory Structural Heart and Valve Center, Emory University Hospital Midtown, Atlanta, Georgia, USA. FAU - Grubb, Kendra AU - Grubb K AD - Division of Cardiology, Emory Structural Heart and Valve Center, Emory University Hospital Midtown, Atlanta, Georgia, USA. FAU - Pop, Andrei M AU - Pop AM AD - AMITA Alexian Brothers Medical Center, Elk Grove Village, Illinois, USA. FAU - Depta, Jeremiah P AU - Depta JP AD - Department of Cardiology, Sands Constellation Heart Institute, Rochester Regional Health, Rochester, New York, USA. FAU - Rai, Devesh AU - Rai D AD - Department of Internal Medicine, Rochester General Hospital, Rochester, New York, USA. FAU - Abtahian, Farhad AU - Abtahian F AD - Department of Cardiology, Sands Constellation Heart Institute, Rochester Regional Health, Rochester, New York, USA. FAU - Spence, Mark S AU - Spence MS AD - Department of Cardiology, Royal Victoria Hospital, Belfast Health & Social Care Trust, Belfast, United Kingdom. FAU - Mailey, Jonathan AU - Mailey J AD - Department of Cardiology, Royal Victoria Hospital, Belfast Health & Social Care Trust, Belfast, United Kingdom. FAU - Muir, Douglas F AU - Muir DF AD - Cardiothoracic Division, The James Cook University Hospital, Middlesbrough, United Kingdom. FAU - Russo, Mark J AU - Russo MJ AD - Division of Cardiac Surgery, Department of Surgery, Rutgers Roger Wood Johnson Medical School, New Brunswick, New Jersey, USA. FAU - Pineda-Salazar, Jennifer AU - Pineda-Salazar J AD - Division of Cardiac Surgery, Department of Surgery, Rutgers Roger Wood Johnson Medical School, New Brunswick, New Jersey, USA. FAU - Okoh, Alexis AU - Okoh A AD - Division of Cardiac Surgery, Department of Surgery, Rutgers Roger Wood Johnson Medical School, New Brunswick, New Jersey, USA. FAU - Smith, Meghan AU - Smith M AD - Division of Cardiac Surgery, Department of Surgery, Rutgers Roger Wood Johnson Medical School, New Brunswick, New Jersey, USA. FAU - Dahle, Thom G AU - Dahle TG AD - Department of Cardiology, CentraCare Heart and Vascular Center, St. Cloud, Minnesota, USA. FAU - Rana, Masud AU - Rana M AD - Centre for Cardiovascular Innovation-Centre d'Innovation Cardiovasculaire, St. Paul's and Vancouver General Hospitals, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Alfadhel, Mesfer AU - Alfadhel M AD - Centre for Cardiovascular Innovation-Centre d'Innovation Cardiovasculaire, St. Paul's and Vancouver General Hospitals, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Meier, David AU - Meier D AD - Centre for Cardiovascular Innovation-Centre d'Innovation Cardiovasculaire, St. Paul's and Vancouver General Hospitals, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Chatfield, Andrew AU - Chatfield A AD - Centre for Cardiovascular Innovation-Centre d'Innovation Cardiovasculaire, St. Paul's and Vancouver General Hospitals, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Akodad, Mariama AU - Akodad M AD - Centre for Cardiovascular Innovation-Centre d'Innovation Cardiovasculaire, St. Paul's and Vancouver General Hospitals, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Chuang, Anthony AU - Chuang A AD - Centre for Cardiovascular Innovation-Centre d'Innovation Cardiovasculaire, St. Paul's and Vancouver General Hospitals, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Samuel, Rohit AU - Samuel R AD - Centre for Cardiovascular Innovation-Centre d'Innovation Cardiovasculaire, St. Paul's and Vancouver General Hospitals, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Nestelberger, Thomas AU - Nestelberger T AD - Centre for Cardiovascular Innovation-Centre d'Innovation Cardiovasculaire, St. Paul's and Vancouver General Hospitals, University of British Columbia, Vancouver, British Columbia, Canada. FAU - McAlister, Cameron AU - McAlister C AD - Centre for Cardiovascular Innovation-Centre d'Innovation Cardiovasculaire, St. Paul's and Vancouver General Hospitals, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Lauck, Sandra AU - Lauck S AD - Centre for Cardiovascular Innovation-Centre d'Innovation Cardiovasculaire, St. Paul's and Vancouver General Hospitals, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Webb, John G AU - Webb JG AD - Centre for Cardiovascular Innovation-Centre d'Innovation Cardiovasculaire, St. Paul's and Vancouver General Hospitals, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Wood, David A AU - Wood DA AD - Centre for Cardiovascular Innovation-Centre d'Innovation Cardiovasculaire, St. Paul's and Vancouver General Hospitals, University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: david.wood@vch.ca. LA - eng PT - Journal Article PT - Multicenter Study PL - United States TA - JACC Cardiovasc Interv JT - JACC. Cardiovascular interventions JID - 101467004 SB - IM CIN - JACC Cardiovasc Interv. 2022 Mar 28;15(6):599-602. doi: 10.1016/j.jcin.2022.02.004. PMID: 35331451 MH - Aftercare MH - Aged MH - Aged, 80 and over MH - *Aortic Valve Stenosis/diagnostic imaging/etiology/surgery MH - *COVID-19 MH - Humans MH - Pandemics MH - Patient Discharge MH - *Transcatheter Aortic Valve Replacement/adverse effects MH - Treatment Outcome PMC - PMC8936029 OTO - NOTNLM OT - COVID-19 pandemic OT - same-day discharge OT - transcatheter aortic valve replacement COIS- Funding Support and Author Disclosures Dr Sathananthan is a consultant to Edwards Lifesciences and Medtronic; and has received speaker fees from Edwards Lifesciences and NVT. Dr Devireddy has received consulting fees from Edwards Lifesciences, Medtronic, ReCor Medical, and Shockwave Medical. Ms Keegan is a consultant for Edwards Lifesciences, Medtronic, and Abbott Vascular. Dr Grubb is a speaker, proctor, and principal investigator for Edwards Lifesciences and Medtronic; and receives grants and educational funding to her employer from Edwards Lifesciences and Medtronic. Dr Spence has received consulting fees and/or institutional research grants from Abbott, Boston Scientific, Edwards Lifesciences, and Medtronic. Dr Muir is a proctor for Edwards Lifesciences and Abbott Vascular; and has received departmental grants from Edwards Lifesciences and Abbott Vascular. Dr Russo is a speaker, proctor, and principal investigator for Edwards Lifesciences; and receives research funding to his employer from Edwards Lifesciences. Dr Pineda-Salazar receives research funding to her employer from Edwards Lifesciences. Ms Smith has received research funding to her employer from Edwards Lifesciences. Dr Dahle is a speaker, proctor, and principal investigator for Edwards Lifesciences and Medtronic. Dr Meier is supported by the Swiss National Science Foundation (grant P2LAP3_199561). Dr Akodad has received research funding from Medtronic, Biotronik, and Federation Francaise de Cardiologie. Dr Nestelberger has received research support from the Swiss National Science Foundation (P400PM_191037/1), the Swiss Heart Foundation (FF20079), the Prof Dr Max Cloetta Foundation, Margarete und Walter Lichtenstein-Stiftung (3MS1038), the University of Basel, and the University Hospital Basel; and has received speaker honoraria and consulting honoraria from Siemens, Beckman Coulter, Bayer, Ortho Clinical Diagnostics, and Orion. Dr Lauck is a consultant to Edwards Lifesciences. Dr Webb is a consultant to and receives unrestricted grant support from Medtronic, Edwards Lifesciences, and Abbott Vascular. Dr Wood has received consulting fees and/or institutional research grants from Abbott, Boston Scientific, Edwards Lifesciences, and Medtronic. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2022/03/26 06:00 MHDA- 2022/03/31 06:00 PMCR- 2022/03/21 CRDT- 2022/03/25 05:32 PHST- 2021/11/05 00:00 [received] PHST- 2021/12/16 00:00 [revised] PHST- 2021/12/21 00:00 [accepted] PHST- 2022/03/25 05:32 [entrez] PHST- 2022/03/26 06:00 [pubmed] PHST- 2022/03/31 06:00 [medline] PHST- 2022/03/21 00:00 [pmc-release] AID - S1936-8798(22)00025-5 [pii] AID - 10.1016/j.jcin.2021.12.046 [doi] PST - ppublish SO - JACC Cardiovasc Interv. 2022 Mar 28;15(6):590-598. doi: 10.1016/j.jcin.2021.12.046. PMID- 35330348 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240825 IS - 2075-4426 (Print) IS - 2075-4426 (Electronic) IS - 2075-4426 (Linking) VI - 12 IP - 3 DP - 2022 Feb 25 TI - Short- and Long-Term Outcomes of Left Main Coronary Artery Stenting in Patients Disqualified from Coronary Artery Bypass Graft Surgery. LID - 10.3390/jpm12030348 [doi] LID - 348 AB - The study aims to evaluate the short- and long-term outcomes of left main percutaneous coronary interventions (LM PCI) in patients disqualified from coronary artery bypass graft surgery (CABG). We included 459 patients (mean age: 68.4 +/- 9.4 years, 24.4% females), with at least 1-year follow-up; 396 patients in whom PCI was offered as an alternative to CABG (Group 1); and 63 patients who were disqualified from CABG by the Heart Team (Group 2). The SYNTAX score (29.1 +/- 9.5 vs. 23.2 +/- 9.7; p < 0.001) and Euroscore II value (2.72 +/- 2.01 vs. 2.15 +/- 2.16; p = 0.007) were significantly higher and ejection fraction was significantly lower (46% vs. 51.4%; p < 0.001) in Group 2. Patients in Group 2 more often required complex stenting techniques (33.3% vs. 16.2%; p = 0.001). The procedure success rates were very high and did not differ between groups (100% vs. 99.2%; p = 0.882). We observed no difference in periprocedural complication rates (12.7% vs. 7.8%; p = 0.198), but the long-term all-cause mortality rate was higher in Group 2 (26% vs. 21%; p = 0.031). LM PCI in patients disqualified from CABG is an effective and safe procedure with a low in-hospital complication rate. Long-term results are satisfactory. FAU - Skorupski, Wojciech Jan AU - Skorupski WJ AD - 1st Department of Cardiology, Poznan University of Medical Sciences, 61-848 Poznan, Poland. FAU - Kaluzna-Oleksy, Marta AU - Kaluzna-Oleksy M AUID- ORCID: 0000-0003-4048-6247 AD - 1st Department of Cardiology, Poznan University of Medical Sciences, 61-848 Poznan, Poland. FAU - Lesiak, Maciej AU - Lesiak M AUID- ORCID: 0000-0003-2630-5016 AD - 1st Department of Cardiology, Poznan University of Medical Sciences, 61-848 Poznan, Poland. FAU - Araszkiewicz, Aleksander AU - Araszkiewicz A AD - 1st Department of Cardiology, Poznan University of Medical Sciences, 61-848 Poznan, Poland. FAU - Skorupski, Wlodzimierz AU - Skorupski W AD - 1st Department of Cardiology, Poznan University of Medical Sciences, 61-848 Poznan, Poland. FAU - Grajek, Stefan AU - Grajek S AD - 1st Department of Cardiology, Poznan University of Medical Sciences, 61-848 Poznan, Poland. FAU - Mitkowski, Przemyslaw AU - Mitkowski P AD - 1st Department of Cardiology, Poznan University of Medical Sciences, 61-848 Poznan, Poland. FAU - Pyda, Malgorzata AU - Pyda M AD - 1st Department of Cardiology, Poznan University of Medical Sciences, 61-848 Poznan, Poland. FAU - Grygier, Marek AU - Grygier M AD - 1st Department of Cardiology, Poznan University of Medical Sciences, 61-848 Poznan, Poland. LA - eng PT - Journal Article DEP - 20220225 PL - Switzerland TA - J Pers Med JT - Journal of personalized medicine JID - 101602269 PMC - PMC8953089 OTO - NOTNLM OT - LM stenting OT - PCI OT - coronary artery disease OT - heart team OT - multivessel disease COIS- The authors declare no conflict of interest. EDAT- 2022/03/26 06:00 MHDA- 2022/03/26 06:01 PMCR- 2022/02/25 CRDT- 2022/03/25 01:12 PHST- 2022/01/24 00:00 [received] PHST- 2022/02/17 00:00 [revised] PHST- 2022/02/22 00:00 [accepted] PHST- 2022/03/25 01:12 [entrez] PHST- 2022/03/26 06:00 [pubmed] PHST- 2022/03/26 06:01 [medline] PHST- 2022/02/25 00:00 [pmc-release] AID - jpm12030348 [pii] AID - jpm-12-00348 [pii] AID - 10.3390/jpm12030348 [doi] PST - epublish SO - J Pers Med. 2022 Feb 25;12(3):348. doi: 10.3390/jpm12030348. PMID- 35330098 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220329 IS - 2075-1729 (Print) IS - 2075-1729 (Electronic) IS - 2075-1729 (Linking) VI - 12 IP - 3 DP - 2022 Feb 27 TI - Percutaneous Coronary Intervention versus Coronary Artery Bypass Grafting for Non-Protected Left Main Coronary Artery Disease: 1-Year Outcomes in a High Volume Single Center Study. LID - 10.3390/life12030347 [doi] LID - 347 AB - INTRODUCTION: There is clear evidence of a significant reduction in all major cardiovascular adverse events (MACE) by coronary artery bypass grafting (CABG) in left main coronary artery stenosis (LMCS), but revascularization by percutaneous coronary artery intervention (PCI) shows an increasingly important role as an alternative to CABG. Several recent trials aiming to test the difference in mortality between the two types of revascularization found conflicting data. The aim of this study is to determine whether PCI is non-inferior to CABG with respect to the occurrence of MACE at 1 year in patients with significant LMCS. MATERIAL AND METHODS: We prospectively enrolled 296 patients with chronic or acute coronary syndromes and significant LM stenosis. The angiography that recommended the revascularization procedure was used for the calculation of the Syntax II score, in order to classify the patients as low-, intermediate- or high-risk. Low- and high-risk patients were revascularized with either PCI or CABG, according to current guidelines, and were included in the subgroup S1. The second subgroup (S0) included intermediate-risk patients (Syntax II score 23-32), in whom the type of revascularization was chosen depending on the decision of the heart team or the patient preference. Patients were monitored according to the chosen mode of revascularization-PCI or CABG. LM revascularization was performed in all the patients. Clinical endpoints included cardiac death, myocardial infarction, need for revascularization and stroke. Patients were evaluated at 1 year after revascularization. Event rates were estimated using the Kaplan-Meier analysis in time to the first event. RESULTS: At 1-year follow-up, a primary endpoint occurred in 35/95 patients in the CABG group and 37/201 in the PCI group. There were no significant differences between the 2 treatment strategies in the 1-year components of the end-point. However, a tendency to higher occurrence of cardiac death (HR = 1.48 CI (0.55-3.9), p = 0.43), necessity of repeat revascularization (HR = 1.7, CI (0.81-3.6), p = 0.16) and stroke (HR = 1.52, CI (1.15-2.93), p = 0.58) were present after CABG. Contrariwise, although without statistical significance, MI was more frequent after PCI (HR = 2, CI (0.78-5.2), p = 0.14). The Kaplan-Meier estimates in subgroups demonstrated the same tendency to higher rates for cardiac death, repeat revascularization and stroke after CABG, and higher rates of MI after PCI. Although without statistical significance, patients with an intermediate-risk showed a slightly lower risk of MACE after PCI than CABG. With the exception of dyslipidemia and gender, other cardiovascular risk factors were in favor of CABG (CKD, obesity). CONCLUSION: In patients with LMCS, PCI with drug-eluting stents was non-inferior to CABG with respect to the composite of cardiac death, myocardial infarction, repeat revascularization and stroke at 1 year, even in patients with intermediate Syntax II risk score. FAU - Mot, Stefan Dan Cezar AU - Mot SDC AD - Cardiology Department, Heart Institute "N. Stancioiu", 400001 Cluj-Napoca, Romania. AD - 5th Department of Internal Medicine, Faculty of Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania. FAU - Serban, Adela Mihaela AU - Serban AM AD - Cardiology Department, Heart Institute "N. Stancioiu", 400001 Cluj-Napoca, Romania. AD - 5th Department of Internal Medicine, Faculty of Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania. FAU - Beyer, Ruxandra Stefana AU - Beyer RS AD - Cardiology Department, Heart Institute "N. Stancioiu", 400001 Cluj-Napoca, Romania. FAU - Cocoi, Mihai AU - Cocoi M AD - Cardiology Department, Heart Institute "N. Stancioiu", 400001 Cluj-Napoca, Romania. FAU - Iuga, Horia AU - Iuga H AD - Cardiology Department, Heart Institute "N. Stancioiu", 400001 Cluj-Napoca, Romania. FAU - Muresan, Ioana Danuta AU - Muresan ID AD - 5th Department of Internal Medicine, Faculty of Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania. AD - Department of Cardiology, Ares Hospital, 400015 Cluj-Napoca, Romania. FAU - Cozma, Simona AU - Cozma S AD - Department of Cardiology, Ares Hospital, 400015 Cluj-Napoca, Romania. FAU - Dadarlat-Pop, Alexandra AU - Dadarlat-Pop A AUID- ORCID: 0000-0003-3964-6995 AD - Cardiology Department, Heart Institute "N. Stancioiu", 400001 Cluj-Napoca, Romania. AD - 5th Department of Internal Medicine, Faculty of Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania. FAU - Tomoaia, Raluca AU - Tomoaia R AUID- ORCID: 0000-0002-1944-4088 AD - Cardiology Department, Heart Institute "N. Stancioiu", 400001 Cluj-Napoca, Romania. AD - 5th Department of Internal Medicine, Faculty of Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania. FAU - Pop, Dana AU - Pop D AD - 5th Department of Internal Medicine, Faculty of Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania. AD - Department of Cardiology, Clinical Rehabilitation Hospital, 400347 Cluj-Napoca, Romania. LA - eng PT - Journal Article DEP - 20220227 PL - Switzerland TA - Life (Basel) JT - Life (Basel, Switzerland) JID - 101580444 PMC - PMC8953531 OTO - NOTNLM OT - coronary artery bypass grafting OT - left main OT - mortality OT - percutaneous coronary intervention COIS- The authors declare no conflict of interest. EDAT- 2022/03/26 06:00 MHDA- 2022/03/26 06:01 PMCR- 2022/02/27 CRDT- 2022/03/25 01:12 PHST- 2022/01/27 00:00 [received] PHST- 2022/02/23 00:00 [revised] PHST- 2022/02/25 00:00 [accepted] PHST- 2022/03/25 01:12 [entrez] PHST- 2022/03/26 06:00 [pubmed] PHST- 2022/03/26 06:01 [medline] PHST- 2022/02/27 00:00 [pmc-release] AID - life12030347 [pii] AID - life-12-00347 [pii] AID - 10.3390/life12030347 [doi] PST - epublish SO - Life (Basel). 2022 Feb 27;12(3):347. doi: 10.3390/life12030347. PMID- 35329016 OWN - NLM STAT- MEDLINE DCOM- 20220419 LR - 20240825 IS - 1660-4601 (Electronic) IS - 1661-7827 (Print) IS - 1660-4601 (Linking) VI - 19 IP - 6 DP - 2022 Mar 11 TI - The Role of 3D Printing in Planning Complex Medical Procedures and Training of Medical Professionals-Cross-Sectional Multispecialty Review. LID - 10.3390/ijerph19063331 [doi] LID - 3331 AB - Medicine is a rapidly-evolving discipline, with progress picking up pace with each passing decade. This constant evolution results in the introduction of new tools and methods, which in turn occasionally leads to paradigm shifts across the affected medical fields. The following review attempts to showcase how 3D printing has begun to reshape and improve processes across various medical specialties and where it has the potential to make a significant impact. The current state-of-the-art, as well as real-life clinical applications of 3D printing, are reflected in the perspectives of specialists practicing in the selected disciplines, with a focus on pre-procedural planning, simulation (rehearsal) of non-routine procedures, and on medical education and training. A review of the latest multidisciplinary literature on the subject offers a general summary of the advances enabled by 3D printing. Numerous advantages and applications were found, such as gaining better insight into patient-specific anatomy, better pre-operative planning, mock simulated surgeries, simulation-based training and education, development of surgical guides and other tools, patient-specific implants, bioprinted organs or structures, and counseling of patients. It was evident that pre-procedural planning and rehearsing of unusual or difficult procedures and training of medical professionals in these procedures are extremely useful and transformative. FAU - Meyer-Szary, Jaroslaw AU - Meyer-Szary J AUID- ORCID: 0000-0001-8791-5497 AD - Department of Pediatric Cardiology and Congenital Heart Defects, Faculty of Medicine, Medical University of Gdansk, 80-210 Gdansk, Poland. FAU - Luis, Marlon Souza AU - Luis MS AUID- ORCID: 0000-0001-6789-2486 AD - Department of Pediatric Cardiology and Congenital Heart Defects, Faculty of Medicine, Medical University of Gdansk, 80-210 Gdansk, Poland. AD - First Doctoral School, Medical University of Gdansk, 80-211 Gdansk, Poland. FAU - Mikulski, Szymon AU - Mikulski S AD - Department of Head and Neck Surgery, Singapore General Hospital, Singapore 169608, Singapore. FAU - Patel, Agastya AU - Patel A AUID- ORCID: 0000-0002-0560-7552 AD - First Doctoral School, Medical University of Gdansk, 80-211 Gdansk, Poland. AD - Department of General, Endocrine and Transplant Surgery, Faculty of Medicine, Medical University of Gdansk, 80-214 Gdansk, Poland. FAU - Schulz, Finn AU - Schulz F AD - University Clinical Centre in Gdansk, 80-952 Gdansk, Poland. FAU - Tretiakow, Dmitry AU - Tretiakow D AUID- ORCID: 0000-0001-9251-4006 AD - Department of Otolaryngology, Faculty of Medicine, Medical University of Gdansk, 80-214 Gdansk, Poland. FAU - Fercho, Justyna AU - Fercho J AD - Neurosurgery Department, Faculty of Medicine, Medical University of Gdansk, 80-210 Gdansk, Poland. FAU - Jaguszewska, Kinga AU - Jaguszewska K AUID- ORCID: 0000-0002-0406-8016 AD - Department of Gynecology, Obstetrics and Neonatology, Division of Gynecology and Obstetrics, Faculty of Medicine, Medical University of Gdansk, 80-210 Gdansk, Poland. FAU - Frankiewicz, Mikolaj AU - Frankiewicz M AUID- ORCID: 0000-0001-6097-7508 AD - Department of Urology, Faculty of Medicine, Medical University of Gdansk, 80-210 Gdansk, Poland. FAU - Pawlowska, Ewa AU - Pawlowska E AUID- ORCID: 0000-0001-8807-2428 AD - Department of Oncology and Radiotherapy, Faculty of Medicine, Medical University of Gdansk, 80-210 Gdansk, Poland. FAU - Targonski, Radoslaw AU - Targonski R AD - 1st Department of Cardiology, Faculty of Medicine, Medical University of Gdansk, 80-210 Gdansk, Poland. FAU - Szarpak, Lukasz AU - Szarpak L AUID- ORCID: 0000-0002-0973-5455 AD - Institute of Outcomes Research, Maria Sklodowska-Curie Medical Academy, 03-411 Warsaw, Poland. AD - Research Unit, Maria Sklodowska-Curie Bialystok Oncology Center, 15-027 Bialystok, Poland. AD - Henry JN Taub Department of Emergency Medicine, Baylor College of Medicine, Houston, TX 77030, USA. FAU - Dadela, Katarzyna AU - Dadela K AD - Department of Pediatric Cardiology, University Children's Hospital, Faculty of Medicine, Jagiellonian University Medical College, 30-663 Krakow, Poland. FAU - Sabiniewicz, Robert AU - Sabiniewicz R AD - Department of Pediatric Cardiology and Congenital Heart Defects, Faculty of Medicine, Medical University of Gdansk, 80-210 Gdansk, Poland. FAU - Kwiatkowska, Joanna AU - Kwiatkowska J AD - Department of Pediatric Cardiology and Congenital Heart Defects, Faculty of Medicine, Medical University of Gdansk, 80-210 Gdansk, Poland. LA - eng PT - Journal Article PT - Review DEP - 20220311 PL - Switzerland TA - Int J Environ Res Public Health JT - International journal of environmental research and public health JID - 101238455 SB - IM MH - Cross-Sectional Studies MH - Humans MH - *Models, Anatomic MH - *Printing, Three-Dimensional MH - Prostheses and Implants PMC - PMC8953417 OTO - NOTNLM OT - 3D printing OT - additive manufacturing OT - cardiac surgery OT - cardiology OT - gynecology OT - head and neck surgery OT - mandible reconstruction OT - obstetrics OT - oncology OT - orthopedics OT - otolaryngology OT - outcomes OT - radiotherapy OT - simulation OT - surgery OT - three-dimensional printing OT - training OT - trauma OT - urology COIS- The authors declare no conflict of interest. EDAT- 2022/03/26 06:00 MHDA- 2022/04/20 06:00 PMCR- 2022/03/11 CRDT- 2022/03/25 01:08 PHST- 2022/01/18 00:00 [received] PHST- 2022/02/18 00:00 [revised] PHST- 2022/03/05 00:00 [accepted] PHST- 2022/03/25 01:08 [entrez] PHST- 2022/03/26 06:00 [pubmed] PHST- 2022/04/20 06:00 [medline] PHST- 2022/03/11 00:00 [pmc-release] AID - ijerph19063331 [pii] AID - ijerph-19-03331 [pii] AID - 10.3390/ijerph19063331 [doi] PST - epublish SO - Int J Environ Res Public Health. 2022 Mar 11;19(6):3331. doi: 10.3390/ijerph19063331. PMID- 35326958 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240825 IS - 2227-9032 (Print) IS - 2227-9032 (Electronic) IS - 2227-9032 (Linking) VI - 10 IP - 3 DP - 2022 Mar 4 TI - Cognitive Impairment in Convalescent COVID-19 Patients Undergoing Multidisciplinary Rehabilitation: The Association with the Clinical and Functional Status. LID - 10.3390/healthcare10030480 [doi] LID - 480 AB - BACKGROUND: Cognitive impairment has been reported in the aftermath of severe acute respiratory syndrome due to coronavirus 2 (SARS-CoV-2) infection. We investigated the possible association between cognitive impairment and the main clinical and functional status variables in a cohort of convalescent COVID-19 patients without premorbid diseases potentially affecting cognition. METHODS: We consecutively screened for inclusion of convalescent COVID-19 patients referring to a post-acute care facility for pulmonary rehabilitation. All the enrolled patients were assessed for cognitive functions. We also investigated features of psychological distress (anxiety, depression, symptoms of posttraumatic stress disorder and quality of life) and cardiac and pulmonary functional status. RESULTS: The 63 enrolled patients (mean age 59.82 +/- 10.78, male gender = 47) showed a high frequency of depressive symptoms (76.2%) and anxiety (55.5%), and a high prevalence of symptoms of posttraumatic stress disorder (PTSD, 44.4%). About half of the total sample showed reduced cognitive efficiency (RCE, 44.4%) in the domains of spatial and verbal long-term memory and executive functions. Patients with RCE more frequently showed alteration of blood pressure (BP) circadian rhythm (p = 0.01), higher levels of D-Dimer (p = 0.03), had experienced a severe illness (p = 0.02), had longer disease duration (p = 0.04), more clinically relevant symptoms of PTSD (p = 0.02), more frequent cognitive complaints (p = 0.002), higher anxiety scores (p = 0.01) and lower quality of life (p = 0.02) than patients with normal cognitive efficiency. CONCLUSIONS: Our findings indicated a possible association between the RCE after COVID-19 and some cardiological variables, including some indirect measures of a residual autonomic disorder, such as the presence of an altered BP circadian rhythm. Future research studies with large samples are needed to provide valid conclusions. FAU - Moretta, Pasquale AU - Moretta P AUID- ORCID: 0000-0003-2244-254X AD - Istituti Clinici Scientifici Maugeri IRCCS, Neurological Rehabilitation Unit of Telese Terme Institute, 82037 Telese Terme, Italy. FAU - Ambrosino, Pasquale AU - Ambrosino P AUID- ORCID: 0000-0002-9398-0428 AD - Istituti Clinici Scientifici Maugeri IRCCS, Cardiac Rehabilitation Unit of Telese Terme Institute, 82037 Telese Terme, Italy. FAU - Lanzillo, Anna AU - Lanzillo A AD - Istituti Clinici Scientifici Maugeri IRCCS, Neurological Rehabilitation Unit of Telese Terme Institute, 82037 Telese Terme, Italy. FAU - Marcuccio, Laura AU - Marcuccio L AD - Istituti Clinici Scientifici Maugeri IRCCS, Neurological Rehabilitation Unit of Telese Terme Institute, 82037 Telese Terme, Italy. FAU - Fuschillo, Salvatore AU - Fuschillo S AD - Istituti Clinici Scientifici Maugeri IRCCS, Pulmonary Rehabilitation Unit of Telese Terme Institute, 82037 Telese Terme, Italy. FAU - Papa, Antimo AU - Papa A AD - Istituti Clinici Scientifici Maugeri IRCCS, Cardiac Rehabilitation Unit of Telese Terme Institute, 82037 Telese Terme, Italy. FAU - Santangelo, Gabriella AU - Santangelo G AD - Department of Psychology, Universita della Campania Luigi Vanvitelli, 81100 Caserta, Italy. FAU - Trojano, Luigi AU - Trojano L AUID- ORCID: 0000-0002-0328-9642 AD - Department of Psychology, Universita della Campania Luigi Vanvitelli, 81100 Caserta, Italy. FAU - Maniscalco, Mauro AU - Maniscalco M AUID- ORCID: 0000-0001-6751-9921 AD - Istituti Clinici Scientifici Maugeri IRCCS, Pulmonary Rehabilitation Unit of Telese Terme Institute, 82037 Telese Terme, Italy. LA - eng PT - Journal Article DEP - 20220304 PL - Switzerland TA - Healthcare (Basel) JT - Healthcare (Basel, Switzerland) JID - 101666525 PMC - PMC8950669 OTO - NOTNLM OT - COVID-19 OT - cognitive impairment OT - disability OT - exercise OT - occupational medicine OT - outcome OT - rehabilitation COIS- The authors declare no conflict of interest. EDAT- 2022/03/26 06:00 MHDA- 2022/03/26 06:01 PMCR- 2022/03/04 CRDT- 2022/03/25 01:03 PHST- 2022/01/26 00:00 [received] PHST- 2022/03/01 00:00 [revised] PHST- 2022/03/01 00:00 [accepted] PHST- 2022/03/25 01:03 [entrez] PHST- 2022/03/26 06:00 [pubmed] PHST- 2022/03/26 06:01 [medline] PHST- 2022/03/04 00:00 [pmc-release] AID - healthcare10030480 [pii] AID - healthcare-10-00480 [pii] AID - 10.3390/healthcare10030480 [doi] PST - epublish SO - Healthcare (Basel). 2022 Mar 4;10(3):480. doi: 10.3390/healthcare10030480. PMID- 35321560 OWN - NLM STAT- MEDLINE DCOM- 20220428 LR - 20220613 IS - 1750-7448 (Electronic) IS - 1750-743X (Linking) VI - 14 IP - 7 DP - 2022 May TI - Immune checkpoint inhibitor-induced myocarditis, myositis, myasthenia gravis and transaminitis: a case series and review. PG - 511-520 LID - 10.2217/imt-2021-0225 [doi] AB - Immune checkpoint inhibitors have been incorporated into the treatment of various malignancies. An increasing body of literature is reporting rare but potentially fatal adverse events associated with these agents. In this case series, the authors report the clinical features and outcomes of seven patients who received immune checkpoint inhibitors for different solid organ malignancies and developed a tetrad of immune-related myocarditis, myositis, myasthenia gravis and transaminitis. Herein the authors review the literature and describe the current diagnostic and management approach for this overlapping syndrome. The authors' series highlights the importance of a high index of clinical suspicion, prompt comprehensive investigations, early multidisciplinary team involvement and initiation of immunosuppressive therapy when immune-related adverse events are suspected. FAU - Wai Siu, Derrick Ho AU - Wai Siu DH AUID- ORCID: 0000-0002-2219-2459 AD - Department of Medical Oncology, St George Hospital, Kogarah, New South Wales, 2217, Australia. AD - National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Camperdown, New South Wales, 2050, Australia. AD - Faculty of Medicine, The University of New South Wales, New South Wales, Australia. FAU - O'Neill, Robert Sean AU - O'Neill RS AUID- ORCID: 0000-0002-9576-2248 AD - Faculty of Medicine, The University of New South Wales, New South Wales, Australia. AD - Department of Medical Oncology, Sutherland Hospital, Caringbah, New South Wales, 2229, Australia. FAU - Harris, Carole A AU - Harris CA AUID- ORCID: 0000-0002-9562-8858 AD - Department of Medical Oncology, St George Hospital, Kogarah, New South Wales, 2217, Australia. AD - Faculty of Medicine, The University of New South Wales, New South Wales, Australia. AD - Department of Medical Oncology, Sutherland Hospital, Caringbah, New South Wales, 2229, Australia. FAU - Wang, Justine AU - Wang J AD - Faculty of Medicine, The University of New South Wales, New South Wales, Australia. AD - Department of Neurology, St George Hospital, Kogarah, New South Wales, 2217, Australia. AD - Institute of Neurological Sciences, Prince of Wales Hospital, Randwick, New South Wales, 2031, Australia. FAU - Ardolino, Luke AU - Ardolino L AUID- ORCID: 0000-0002-8998-7141 AD - Faculty of Medicine, The University of New South Wales, New South Wales, Australia. AD - Department of Medical Oncology, The Kinghorn Centre, St Vincent's Hospital, Darlinghurst, New South Wales, 2010, Australia. FAU - Downton, Teesha AU - Downton T AUID- ORCID: 0000-0002-3392-7465 AD - Department of Medical Oncology, The Wollongong Hospital, Wollongong, New South Wales, 2500, Australia. FAU - Tong, Matthew AU - Tong M AD - Department of Medical Oncology, Sutherland Hospital, Caringbah, New South Wales, 2229, Australia. FAU - Hong, Jun Hee AU - Hong JH AD - Department of Medical Oncology, St George Hospital, Kogarah, New South Wales, 2217, Australia. FAU - Chin, Venessa AU - Chin V AUID- ORCID: 0000-0002-4630-4451 AD - Department of Medical Oncology, The Kinghorn Centre, St Vincent's Hospital, Darlinghurst, New South Wales, 2010, Australia. AD - Single Cell and Computational Genomics Lab, The Garvan Institute of Medical Research, Darlinghurst, New South Wales, 2010, Australia. FAU - Clingan, Philip R AU - Clingan PR AD - Department of Medical Oncology, The Wollongong Hospital, Wollongong, New South Wales, 2500, Australia. AD - University of Wollongong, New South Wales, Australia. FAU - Aghmesheh, Morteza AU - Aghmesheh M AUID- ORCID: 0000-0003-1664-4743 AD - Department of Medical Oncology, The Wollongong Hospital, Wollongong, New South Wales, 2500, Australia. AD - University of Wollongong, New South Wales, Australia. FAU - Soudy, Hussein AU - Soudy H AUID- ORCID: 0000-0001-8236-9503 AD - Department of Medical Oncology, St George Hospital, Kogarah, New South Wales, 2217, Australia. AD - Faculty of Medicine, The University of New South Wales, New South Wales, Australia. AD - Department of Medical Oncology, Sutherland Hospital, Caringbah, New South Wales, 2229, Australia. LA - eng PT - Journal Article DEP - 20220324 PL - England TA - Immunotherapy JT - Immunotherapy JID - 101485158 RN - 0 (Immune Checkpoint Inhibitors) SB - IM MH - Humans MH - Immune Checkpoint Inhibitors/adverse effects MH - *Myasthenia Gravis/chemically induced MH - *Myocarditis/chemically induced/diagnosis/drug therapy MH - *Myositis/chemically induced/diagnosis MH - *Neoplasms/drug therapy OAB - Cancer immunotherapy is used in the treatment of different cancer types. Immunotherapy activates the immune system to detect and attack cancer cells, but side effects may arise from the immune system inadvertently attacking normal tissues and organs. The increased use of immunotherapy has led to an increase in the reporting of rare but potentially life-threatening treatment-related side effects. In this case series, the authors report the clinical features and outcomes of seven patients who developed inflammation of the heart, muscles, nerve and muscle junctions and liver following treatment with immunotherapy. The authors review the scientific literature and discuss the current understanding of and management approach to this rare syndrome. The authors' report highlights the importance of a high degree of clinical suspicion, prompt comprehensive testing to confirm diagnosis, early involvement of experts from different specialties and early initiation of treatment in the management of this unique syndrome. OABL- eng OTO - NOTNLM OT - immune checkpoint inhibitors OT - immune-related adverse events OT - immunotherapy OT - myasthenia OT - myocarditis OT - myositis OT - transaminitis EDAT- 2022/03/25 06:00 MHDA- 2022/04/29 06:00 CRDT- 2022/03/24 05:29 PHST- 2022/03/25 06:00 [pubmed] PHST- 2022/04/29 06:00 [medline] PHST- 2022/03/24 05:29 [entrez] AID - 10.2217/imt-2021-0225 [doi] PST - ppublish SO - Immunotherapy. 2022 May;14(7):511-520. doi: 10.2217/imt-2021-0225. Epub 2022 Mar 24. PMID- 35317392 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220324 IS - 1671-5411 (Print) IS - 1671-5411 (Linking) VI - 19 IP - 2 DP - 2022 Feb 28 TI - Mechanical circulatory support in cardiogenic shock and post-myocardial infarction mechanical complications. PG - 130-136 LID - 10.11909/j.issn.1671-5411.2022.02.004 [doi] AB - Despite advanced therapies, the mortality of patients with myocardial infarction (MI) complicated by cardiogenic shock (CS) remains around 50%. Mechanical complications of MI are rare nowadays but associated with high mortality in patients who present with CS. Different treatment strategies and mechanical circulatory support (MCS) devices have been increasingly used to improve the grim prognosis of refractory CS. This article discusses current evidence regarding the use of MCS in MI complicated by CS, ventricular septal rupture, free wall rupture and acute mitral regurgitation. Device selection should be tailored according to the cause and severity of CS. Early MCS initiation and multidisciplinary team cooperation is mandatory for good results. MCS associated bleeding remains a major complication and an obstacle to better outcomes. Ongoing prospective randomized trials will improve current knowledge regarding MCS indications, timing, and patient selection in the coming years. CI - Copyright and License information: Journal of Geriatric Cardiology 2022. FAU - Rob, Daniel AU - Rob D AD - 2nd Department of Medicine-Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic. FAU - Belohlavek, Jan AU - Belohlavek J AD - 2nd Department of Medicine-Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic. LA - eng PT - Journal Article PL - China TA - J Geriatr Cardiol JT - Journal of geriatric cardiology : JGC JID - 101237881 PMC - PMC8915426 EDAT- 2022/03/24 06:00 MHDA- 2022/03/24 06:01 PMCR- 2022/02/28 CRDT- 2022/03/23 05:13 PHST- 2022/03/23 05:13 [entrez] PHST- 2022/03/24 06:00 [pubmed] PHST- 2022/03/24 06:01 [medline] PHST- 2022/02/28 00:00 [pmc-release] AID - jgc-19-2-130 [pii] AID - 10.11909/j.issn.1671-5411.2022.02.004 [doi] PST - ppublish SO - J Geriatr Cardiol. 2022 Feb 28;19(2):130-136. doi: 10.11909/j.issn.1671-5411.2022.02.004. PMID- 35314335 OWN - NLM STAT- MEDLINE DCOM- 20220720 LR - 20220811 IS - 1916-7075 (Electronic) IS - 0828-282X (Linking) VI - 38 IP - 7 DP - 2022 Jul TI - Plastic Bronchitis and Protein-Losing Enteropathy in the Fontan Patient: Evolving Understanding and Emerging Therapies. PG - 988-1001 LID - S0828-282X(22)00200-8 [pii] LID - 10.1016/j.cjca.2022.03.011 [doi] AB - Plastic bronchitis (PB) and protein-losing enteropathy (PLE) are rare but potentially devastating complications of the Fontan circulation. PB occurs in approximately 4% of Fontan patients, typically presents within 2 to 3 years of Fontan completion with chronic cough, wheezing, fever, or acute asphyxiation, and is characterised by proteinaceous airway casts that are expectorated or found on bronchoscopy. PLE develops in 4% to 13% of patients, usually within 5 to 10 years post Fontan, and manifests with edema, ascites, hypoalbuminemia, lymphopenia, hypogammaglobulinemia, and elevated fecal alpha-1 antitrypsin 1. These disorders have similar pathophysiology involving disruption of the lymphatic system resulting from elevated central venous pressure combined with elevated lymphatic production and inflammation, resulting in lymphatic drainage into low-pressure circuits such as the airways (PB) and duodenum (PLE). Our understanding of these disorders has greatly improved over the past decade as a result of advances in imaging of the lymphatic system through magnetic resonance lymphangiography and early success with lymphatic interventions including lymphatic embolisation, thoracic duct embolisation, and percutaneous thoracic duct decompression. Both PB and PLE require a multidisciplinary approach that addresses and optimises residual hemodynamic lesions through catheter-based intervention, lowers central venous pressure through medical therapy, minimises symptoms, and targets abnormal lymphatic perfusion when symptoms persist. This review summarises the pathophysiology of these disorders and the current evidence base regarding management, proposes treatment algorithms, and identifies future research opportunities. Key considerations regarding the development of a lymphatic intervention program are also highlighted. CI - Copyright (c) 2022 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved. FAU - Mackie, Andrew S AU - Mackie AS AD - Division of Cardiology, Stollery Children's Hospital and University of Alberta, Edmonton, Alberta, Canada. Electronic address: andrew.mackie@ualberta.ca. FAU - Veldtman, Gruschen R AU - Veldtman GR AD - Scottish Adult Congenital Cardiac Service, Golden Jubilee Hospital and Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, Scotland. FAU - Thorup, Lene AU - Thorup L AD - Department of Cardiothoracic Surgery, Rigshospitalet, Copenhagen, Denmark. FAU - Hjortdal, Vibeke E AU - Hjortdal VE AD - Department of Cardiothoracic Surgery, Rigshospitalet, Copenhagen, Denmark. FAU - Dori, Yoav AU - Dori Y AD - Division of Cardiology, Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA. LA - eng PT - Journal Article PT - Review DEP - 20220318 PL - England TA - Can J Cardiol JT - The Canadian journal of cardiology JID - 8510280 RN - 0 (Plastics) SB - IM MH - *Bronchitis/diagnosis/etiology/therapy MH - *Fontan Procedure/adverse effects MH - *Heart Defects, Congenital/complications/surgery MH - Humans MH - Plastics MH - *Protein-Losing Enteropathies/diagnosis/etiology/therapy EDAT- 2022/03/23 06:00 MHDA- 2022/07/22 06:00 CRDT- 2022/03/22 05:34 PHST- 2021/12/15 00:00 [received] PHST- 2022/03/08 00:00 [revised] PHST- 2022/03/12 00:00 [accepted] PHST- 2022/03/23 06:00 [pubmed] PHST- 2022/07/22 06:00 [medline] PHST- 2022/03/22 05:34 [entrez] AID - S0828-282X(22)00200-8 [pii] AID - 10.1016/j.cjca.2022.03.011 [doi] PST - ppublish SO - Can J Cardiol. 2022 Jul;38(7):988-1001. doi: 10.1016/j.cjca.2022.03.011. Epub 2022 Mar 18. PMID- 35307751 OWN - NLM STAT- MEDLINE DCOM- 20220414 LR - 20261010 IS - 1432-1971 (Electronic) IS - 0172-0643 (Linking) VI - 43 IP - 4 DP - 2022 Apr TI - Management of Hypertrophic Cardiomyopathy in a Newborn with Dextro-Transposition of the Great Arteries. PG - 926-929 LID - 10.1007/s00246-022-02874-4 [doi] AB - Impaired maternal glucose metabolism during pregnancy can have significant effects on the cardiovascular system of the developing fetus. Early in pregnancy the teratogenic effects may lead to structural heart defects, while later in gestation a form of hypertrophic cardiomyopathy can develop due to overgrowth driven by fetal hyperinsulinism. We describe an infant with the uncommon combination of both dextro-transposition of the great arteries and hypertrophic cardiomyopathy. We emphasize the importance of a longitudinal multi-disciplinary approach, from fetal diagnosis to post-operative management, that allowed for an excellent outcome in this rare combination of severe cardiac malformations. CI - (c) 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Bigelow, Amee M AU - Bigelow AM AUID- ORCID: 0000-0003-1606-9144 AD - Department of Pediatrics, The Heart Center, Nationwide Children's Hospital, The Ohio State University, 700 Children's Drive, Columbus, OH, 43205, USA. amee.bigelow@nationwidechildrens.org. FAU - Ball, Molly K AU - Ball MK AD - Division of Neonatology, Nationwide Children's Hospital, The Ohio State University, Columbus, OH, USA. FAU - Galantowicz, Mark AU - Galantowicz M AD - Department of Cardiothoracic Surgery, The Heart Center, Nationwide Children's Hospital, The Ohio State University, Columbus, OH, USA. FAU - Fernandez, Richard P AU - Fernandez RP AD - Department of Pediatrics, The Heart Center, Nationwide Children's Hospital, The Ohio State University, 700 Children's Drive, Columbus, OH, 43205, USA. FAU - Gauntt, Jennifer AU - Gauntt J AD - Department of Pediatrics, The Heart Center, Nationwide Children's Hospital, The Ohio State University, 700 Children's Drive, Columbus, OH, 43205, USA. FAU - Texter, Karen M AU - Texter KM AD - Department of Pediatrics, The Heart Center, Nationwide Children's Hospital, The Ohio State University, 700 Children's Drive, Columbus, OH, 43205, USA. LA - eng PT - Journal Article DEP - 20220321 PL - United States TA - Pediatr Cardiol JT - Pediatric cardiology JID - 8003849 SB - IM MH - Arteries MH - *Cardiomyopathy, Hypertrophic MH - Female MH - Humans MH - Infant MH - Infant, Newborn MH - Pregnancy MH - Retrospective Studies MH - *Transposition of Great Vessels/diagnosis/surgery MH - Ultrasonography, Prenatal OTO - NOTNLM OT - Critical care management OT - Fetal diagnosis OT - Hypertrophic cardiomyopathy OT - Prenatal multidisciplinary approach OT - Transposition of the great arteries EDAT- 2022/03/22 06:00 MHDA- 2022/04/15 06:00 CRDT- 2022/03/21 05:45 PHST- 2022/02/22 00:00 [received] PHST- 2022/03/09 00:00 [accepted] PHST- 2022/03/22 06:00 [pubmed] PHST- 2022/04/15 06:00 [medline] PHST- 2022/03/21 05:45 [entrez] AID - 10.1007/s00246-022-02874-4 [pii] AID - 10.1007/s00246-022-02874-4 [doi] PST - ppublish SO - Pediatr Cardiol. 2022 Apr;43(4):926-929. doi: 10.1007/s00246-022-02874-4. Epub 2022 Mar 21. PMID- 35305892 OWN - NLM STAT- MEDLINE DCOM- 20220615 LR - 20220802 IS - 1532-8422 (Electronic) IS - 1053-0770 (Linking) VI - 36 IP - 8 Pt B DP - 2022 Aug TI - Echocardiography and Management for Cardiac Trauma. PG - 3265-3277 LID - S1053-0770(22)00120-3 [pii] LID - 10.1053/j.jvca.2022.02.010 [doi] AB - Trauma is the number one cause of death among Americans between the ages of 1 and 46, costing >$670 billion a year. Blunt and penetrating trauma can lead to cardiac and aortic injuries, with the incidence of death varying upon the location of the damage. Among those who reach the hospital alive, many may survive if the hemorrhage and cardiovascular injuries are diagnosed and treated adequately in a timely fashion. Although echocardiography often is underused in the setting of cardiac trauma, it offers significant diagnosis and treatment potential because it is accessible in most settings, safe, relatively noninvasive, and can provide rapid and accurate trauma assessment in the hands of trained providers. This review article aims to analyze the pathophysiology of cardiac injuries in patients with trauma and the role of echocardiography for the accurate diagnosis of cardiac injury in trauma. This review, additionally, will offer a patient-centered, team-based, early management plan with a treatment algorithm to help improve the quality of care among these patients with cardiac trauma. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Latif, Rana K AU - Latif RK AD - Department of Anesthesiology and Perioperative Medicine, University of Louisville, Louisville, KY; Paris Simulation Center, Office of Medical Education, University of Louisville School of Medicine, Louisville, KY; Outcomes Research Consortium, Cleveland, OH. Electronic address: rklati01@louisville.edu. FAU - Clifford, Sean P AU - Clifford SP AD - Department of Anesthesiology and Perioperative Medicine, University of Louisville, Louisville, KY. FAU - Ghafghazi, Shahab AU - Ghafghazi S AD - Department of Medicine, Cardiovascular Medicine; University of Louisville School of Medicine, Louisville, KY. FAU - Phipps, Zachary AU - Phipps Z AD - Department of Anesthesiology and Perioperative Medicine, University of Louisville, Louisville, KY. FAU - Chen, James J AU - Chen JJ AD - Department of Anesthesiology and Perioperative Medicine, University of Louisville, Louisville, KY. FAU - Sangroula, Daisy AU - Sangroula D AD - Department of Anesthesiology and Perioperative Medicine, University of Louisville, Louisville, KY. FAU - Khan, Areeba Z AU - Khan AZ AD - Department of Anesthesiology and Perioperative Medicine, University of Louisville, Louisville, KY. FAU - Saleem, Jawad AU - Saleem J AD - Department of Anesthesiology and Perioperative Medicine, University of Louisville, Louisville, KY. FAU - Farah, Ian AU - Farah I AD - Department of Anesthesiology and Perioperative Medicine, University of Louisville, Louisville, KY. FAU - Huang, Jiapeng AU - Huang J AD - Department of Anesthesiology and Perioperative Medicine, University of Louisville, Louisville, KY; Department of Cardiovascular & Thoracic Surgery, University of Louisville, Louisville, KY. FAU - Businger, Jerrad R AU - Businger JR AD - Department of Anesthesiology and Perioperative Medicine, University of Louisville, Louisville, KY. LA - eng PT - Journal Article PT - Review DEP - 20220212 PL - United States TA - J Cardiothorac Vasc Anesth JT - Journal of cardiothoracic and vascular anesthesia JID - 9110208 SB - IM MH - Adolescent MH - Adult MH - Child MH - Child, Preschool MH - Echocardiography MH - *Heart Injuries/diagnostic imaging/therapy MH - Humans MH - Infant MH - Middle Aged MH - *Wounds, Nonpenetrating/complications MH - *Wounds, Penetrating/complications/diagnosis MH - Young Adult OTO - NOTNLM OT - cardiac trauma OT - cardiac trauma management protocol OT - echocardiography EDAT- 2022/03/21 06:00 MHDA- 2022/06/16 06:00 CRDT- 2022/03/20 20:26 PHST- 2021/10/23 00:00 [received] PHST- 2022/01/19 00:00 [revised] PHST- 2022/02/08 00:00 [accepted] PHST- 2022/03/21 06:00 [pubmed] PHST- 2022/06/16 06:00 [medline] PHST- 2022/03/20 20:26 [entrez] AID - S1053-0770(22)00120-3 [pii] AID - 10.1053/j.jvca.2022.02.010 [doi] PST - ppublish SO - J Cardiothorac Vasc Anesth. 2022 Aug;36(8 Pt B):3265-3277. doi: 10.1053/j.jvca.2022.02.010. Epub 2022 Feb 12. PMID- 35303995 OWN - NLM STAT- MEDLINE DCOM- 20220816 LR - 20250728 IS - 1873-2623 (Electronic) IS - 0041-1345 (Linking) VI - 54 IP - 4 DP - 2022 May TI - Pregnancies After Orthotopic Heart Transplantation: A Single-Center Experience. PG - 1065-1069 LID - S0041-1345(22)00121-X [pii] LID - 10.1016/j.transproceed.2022.01.026 [doi] AB - BACKGROUND: Patients who underwent orthotopic heart transplantation have improved survival and quality of live. Some of them are women of childbearing age and have a wish to be pregnant. If the decision to have a child is made, the patient needs a multidisciplinary approach. MATERIAL AND METHODS: We analyzed the whole cohort of patients after orthotopic heart transplantation. From the whole group we extracted women of childbearing age between 16 and 45 years and at least 1 year after transplantation (85 patients). From this group, 8 patients gave birth to children. RESULTS: No cardiocirculatory problems were observed in the mothers during pregnancy and in follow-ups. Strong changes in immunosuppressive drug levels were observed during and directly after the pregnancies. Two children were born prematurely (at 31 and in 34 weeks of gestation). Two children developed cardiomyopathy (the same as in mother). CONCLUSION: The decision of childbearing should be made individually considering each patient's medical history and potential risks connected with the pregnancy. Pregnancy after heart transplantation is relatively safe for the mother. Risk of transmitting cardiomyopathies to the children, especially hypertrophic cardiomyopathy, is high. The patients should be aware of this fact and be carefully counseled preconceptionally. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Kuczaj, Agnieszka AU - Kuczaj A AD - Department of Cardiac, Vascular and Endovascular Surgery and Transplantology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Zabrze, Poland; Department of Cardiac Transplantation and Mechanical Circulatory Support, Silesian Center for Heart Diseases, Zabrze, Poland. Electronic address: agnieszka.kuczaj@gmail.com. FAU - Pawlak, Szymon AU - Pawlak S AD - Department of Cardiac, Vascular and Endovascular Surgery and Transplantology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Zabrze, Poland; Cardiac Surgery, Transplantology and Mechanical Circulatory Support in Children, Silesian Center for Heart Diseases, Zabrze, Poland. FAU - Sliwka, Joanna AU - Sliwka J AD - Cardiac Surgery, Transplantology and Mechanical Circulatory Support in Children, Silesian Center for Heart Diseases, Zabrze, Poland. FAU - Przybylowski, Piotr AU - Przybylowski P AD - Department of Cardiac, Vascular and Endovascular Surgery and Transplantology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Zabrze, Poland; Department of Cardiac Transplantation and Mechanical Circulatory Support, Silesian Center for Heart Diseases, Zabrze, Poland. LA - eng PT - Journal Article DEP - 20220316 PL - United States TA - Transplant Proc JT - Transplantation proceedings JID - 0243532 RN - 0 (Immunosuppressive Agents) SB - IM MH - Adolescent MH - Adult MH - Child MH - Female MH - *Heart Transplantation/adverse effects MH - Humans MH - Immunosuppressive Agents/adverse effects MH - Male MH - Middle Aged MH - Parturition MH - Pregnancy MH - Pregnancy Outcome MH - *Transplants MH - Young Adult EDAT- 2022/03/20 06:00 MHDA- 2022/08/17 06:00 CRDT- 2022/03/19 05:27 PHST- 2021/12/02 00:00 [received] PHST- 2022/01/07 00:00 [accepted] PHST- 2022/03/20 06:00 [pubmed] PHST- 2022/08/17 06:00 [medline] PHST- 2022/03/19 05:27 [entrez] AID - S0041-1345(22)00121-X [pii] AID - 10.1016/j.transproceed.2022.01.026 [doi] PST - ppublish SO - Transplant Proc. 2022 May;54(4):1065-1069. doi: 10.1016/j.transproceed.2022.01.026. Epub 2022 Mar 16. PMID- 35300594 OWN - NLM STAT- MEDLINE DCOM- 20220415 LR - 20220415 IS - 1471-2261 (Electronic) IS - 1471-2261 (Linking) VI - 22 IP - 1 DP - 2022 Mar 18 TI - The impact of implementing an endocarditis team in comparison to the classic heart team in a tertiary referral centre. PG - 114 LID - 10.1186/s12872-022-02558-0 [doi] LID - 114 AB - BACKGROUND: Infective endocarditis (IE) is a complex disease for which the European Society of Cardiology guideline recommends a dedicated multidisciplinary endocarditis team (ET) approach since 2015. It is currently unknown whether this ET approach is beneficial compared to a classic heart team approach including bedside consultation by an infectious disease specialist in Western Europe. METHODS: This retrospective single centre, observational cohort study was conducted at the Radboudumc, a tertiary referral centre in the Netherlands. Consecutive patients treated for IE were included from September 2017 to September 2018 before implementation of a dedicated ET and from May 2019 to May 2020 afterwards. RESULTS: In total, 90 IE patients (45 patients before and 45 patients after the implementation of the ET) were included. No significant differences were found in diagnostic workup, surgical treatment (surgery performed 69% vs. 71%, p = 0.82), time to surgery because of an urgent indication (median 4 vs. 6 days, p = 0.82), in-hospital complications (53% vs. 67%, p = 0.20), and 6-month mortality (11% vs. 13%, p = 0.75) between IE patients treated before and after the implementation of the ET. CONCLUSION: Formalization of the recommended multidisciplinary endocarditis team might not significantly improve the complication rate nor the short term outcome. CI - (c) 2022. The Author(s). FAU - van den Heuvel, F M A AU - van den Heuvel FMA AUID- ORCID: 0000-0001-9255-418X AD - Department of Cardiology, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6500 HB, Nijmegen, the Netherlands. frederik.vandenheuvel@radboudumc.nl. FAU - Bos, M AU - Bos M AD - Department of Cardiology, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6500 HB, Nijmegen, the Netherlands. FAU - Geuzebroek, G S C AU - Geuzebroek GSC AD - Department of Cardiothoracic Surgery, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Aarntzen, E H J G AU - Aarntzen EHJG AD - Department of Medical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Maat, I AU - Maat I AD - Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Dieker, H J AU - Dieker HJ AD - Department of Cardiology, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6500 HB, Nijmegen, the Netherlands. FAU - Verkroost, M AU - Verkroost M AD - Department of Cardiothoracic Surgery, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Rodwell, L AU - Rodwell L AD - Department of Health Evidence, Section Biostatistics, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Ten Oever, J AU - Ten Oever J AD - Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - van Crevel, R AU - van Crevel R AD - Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Habets, J AU - Habets J AD - Department of Medical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Kouijzer, I J E AU - Kouijzer IJE AD - Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Nijveldt, R AU - Nijveldt R AD - Department of Cardiology, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6500 HB, Nijmegen, the Netherlands. LA - eng PT - Journal Article PT - Observational Study DEP - 20220318 PL - England TA - BMC Cardiovasc Disord JT - BMC cardiovascular disorders JID - 100968539 SB - IM MH - Cohort Studies MH - *Endocarditis/diagnosis/surgery MH - *Endocarditis, Bacterial/diagnosis MH - Humans MH - Retrospective Studies MH - Tertiary Care Centers PMC - PMC8931961 OTO - NOTNLM OT - Cardiovascular imaging OT - Echocardiography OT - Endocarditis team OT - Heart team OT - Infective endocarditis COIS- All authors declare that they have no conflict of interest. EDAT- 2022/03/19 06:00 MHDA- 2022/04/16 06:00 PMCR- 2022/03/18 CRDT- 2022/03/18 05:34 PHST- 2021/12/02 00:00 [received] PHST- 2022/03/13 00:00 [accepted] PHST- 2022/03/18 05:34 [entrez] PHST- 2022/03/19 06:00 [pubmed] PHST- 2022/04/16 06:00 [medline] PHST- 2022/03/18 00:00 [pmc-release] AID - 10.1186/s12872-022-02558-0 [pii] AID - 2558 [pii] AID - 10.1186/s12872-022-02558-0 [doi] PST - epublish SO - BMC Cardiovasc Disord. 2022 Mar 18;22(1):114. doi: 10.1186/s12872-022-02558-0. PMID- 35300178 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220319 IS - 1178-2390 (Print) IS - 1178-2390 (Electronic) IS - 1178-2390 (Linking) VI - 15 DP - 2022 TI - Multidisciplinary Management of Fabry Disease: Current Perspectives. PG - 485-495 LID - 10.2147/JMDH.S290580 [doi] AB - Fabry disease (FD) is a rare, recessive X-linked, multisystemic lysosomal storage disorder (LSD) that results from a deficiency in the hydrolase alpha-galactosidase A (alpha-GalA) caused by a GLA gene variant. The progressive accumulation of the glycosphingolipid globotriaosylceramide (Gb3) in organs such as skin, kidney, brain, joints, vascular walls and eyes are responsible for the wide spectrum of clinical manifestations, often unspecific. In result, clinically relevant and life-threatening complications, such as malignant ventricular arrhythmia, sudden cardiac death, end stage kidney failure and stroke may occur. In this review, we will describe the clinical features and the current perspectives in the multidisciplinary management Of FD patients. CI - (c) 2022 Paim-Marques et al. FAU - Paim-Marques, Luciana AU - Paim-Marques L AD - Department of Pediatrics, University of Florida, Gainesville, FL, USA. FAU - de Oliveira, Rodrigo Joel AU - de Oliveira RJ AD - Department of Orthopedics, Rheumatology and Traumatology- School of Medical Sciences and University of Campinas (UNICAMP), Sao Paulo, Brazil. FAU - Appenzeller, Simone AU - Appenzeller S AUID- ORCID: 0000-0001-5075-4474 AD - Department of Orthopedics, Rheumatology and Traumatology- School of Medical Sciences and University of Campinas (UNICAMP), Sao Paulo, Brazil. LA - eng PT - Journal Article PT - Review DEP - 20220310 PL - New Zealand TA - J Multidiscip Healthc JT - Journal of multidisciplinary healthcare JID - 101512691 PMC - PMC8922235 OTO - NOTNLM OT - Fabry disease OT - alfa-galactosidase OT - multidisciplinary care COIS- All authors declare that they have no conflicts of interest related to the study. EDAT- 2022/03/19 06:00 MHDA- 2022/03/19 06:01 PMCR- 2022/03/10 CRDT- 2022/03/18 05:17 PHST- 2021/10/19 00:00 [received] PHST- 2022/02/03 00:00 [accepted] PHST- 2022/03/18 05:17 [entrez] PHST- 2022/03/19 06:00 [pubmed] PHST- 2022/03/19 06:01 [medline] PHST- 2022/03/10 00:00 [pmc-release] AID - 290580 [pii] AID - 10.2147/JMDH.S290580 [doi] PST - epublish SO - J Multidiscip Healthc. 2022 Mar 10;15:485-495. doi: 10.2147/JMDH.S290580. eCollection 2022. PMID- 38939078 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240629 IS - 2772-963X (Electronic) IS - 2772-963X (Linking) VI - 1 IP - 1 DP - 2022 Mar TI - The Heart Brain Team and Patient-Centered Management of Ischemic Stroke. PG - 100014 LID - 10.1016/j.jacadv.2022.100014 [doi] LID - 100014 AB - The multifaceted connections between the heart and the brain have been extensively studied at the anatomy, pathophysiology, and clinical levels. Studies have suggested a vital role for both cardiologists and neurologists in the management of various cardiovascular and neurological disorders. However, a true heart-brain team-based approach remained confined to large, specialized centers. In this paper, we review the various intersection areas of cardiology and neurology with regard to ischemic stroke. We focus our discussion on the challenges and opportunity for a heart-team approach to stroke in the context of atrial fibrillation, carotid disease, and patent foramen ovale, and in the setting of strokes complicating transcatheter endovascular interventions. CI - (c) 2022 The Authors. FAU - Alkhouli, Mohamad AU - Alkhouli M AD - Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA. FAU - Moussa, Issam AU - Moussa I AD - Carle Illinois College of Medicine, University of Illinois, Carle Heart and Vascular Institute, Champaign, Illinois, USA. FAU - Deshmukh, Abhishek AU - Deshmukh A AD - Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA. FAU - Ammash, Nasser M AU - Ammash NM AD - Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA. FAU - Klaas, James P AU - Klaas JP AD - Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA. FAU - Holmes, David R AU - Holmes DR AD - Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA. LA - eng PT - Journal Article PT - Review DEP - 20220316 PL - United States TA - JACC Adv JT - JACC. Advances JID - 9918419284106676 PMC - PMC11198076 OTO - NOTNLM OT - atrial fibrillation OT - heart-brain OT - mechanical thrombectomy OT - neuromodulation OT - patent foramen ovale OT - stroke EDAT- 2022/03/16 00:00 MHDA- 2022/03/16 00:01 PMCR- 2022/03/16 CRDT- 2024/06/28 04:54 PHST- 2022/01/10 00:00 [received] PHST- 2022/02/28 00:00 [revised] PHST- 2022/02/28 00:00 [accepted] PHST- 2022/03/16 00:01 [medline] PHST- 2022/03/16 00:00 [pubmed] PHST- 2024/06/28 04:54 [entrez] PHST- 2022/03/16 00:00 [pmc-release] AID - S2772-963X(22)00014-X [pii] AID - 100014 [pii] AID - 10.1016/j.jacadv.2022.100014 [doi] PST - epublish SO - JACC Adv. 2022 Mar 16;1(1):100014. doi: 10.1016/j.jacadv.2022.100014. eCollection 2022 Mar. PMID- 35288050 OWN - NLM STAT- MEDLINE DCOM- 20220503 LR - 20260120 IS - 2341-1929 (Electronic) IS - 2341-1929 (Linking) VI - 69 IP - 3 DP - 2022 Mar TI - Anaesthetic-surgical guide in the treatment of ascending aorta and surgery of the ascending aorta and aortic arch. Consensus document of the Spanish Society of Cardiovascular and Endovascular Surgery and the Sociedad of Anaesthesiology, Resuscitation and Pain Therapy. PG - 143-178 LID - S2341-1929(22)00044-0 [pii] LID - 10.1016/j.redare.2021.02.010 [doi] AB - Aortic pathology is always a challenge for the clinician, and must be diagnosed and treated by a multidisciplinary team due to the technical and technological complexity of the resources used. Ongoing efforts to implement a systematic, protocolized approach involving "Aortic teams" made up of cardiologists, cardiac surgeons, vascular surgeons, anaesthesiologists and radiologists, among others are now leading to improved outcomes. The aim of this consensus document drawn up by the Aortic working groups of the Spanish Society of Anaesthesiology, Resuscitation and Pain Therapy (SEDAR) and the Spanish Society of Thoracic and Cardiovascular Surgery (SECTCV) is to disseminate a set of working protocols. The latest consensus document of the European Association for Cardio-Thoracic Surgery (EACTS) and the European Society for Vascular Surgery (ESVS) define the concept of "AORTIC TEAM"(1). The aortic team should be closely involved from diagnosis to treatment and finally follow-up, and should be formed of cardiac and vascular surgeons working together with anaesthesiologists, cardiologists, radiologists and geneticists. Treatment of aortic pathologies should be centralised in large centres, because this is the only way to effectively understand the natural course of the disease, provide the entire range of treatment options under one umbrella and treat potential complications. A streamlined emergent care pathway (24/7 availability), adequate transportation and transfer capabilities, as well as rapid activation of the multidisciplinary team must be available. In light of the complexity and constant evolution of therapeutic options, we present this first version of the Anaesthesiology and surgical guidelines for surgery of the ascending aorta and aortic arch. Some questions will no doubt remain unanswered, and future versions will include new techniques that, though implemented in some centres, are still not widely recommended. CI - Copyright (c) 2021 Sociedad Espanola de Anestesiologia, Reanimacion y Terapeutica del Dolor. Publicado por Elsevier Espana, S.L.U. All rights reserved. FAU - Lopez Gomez, A AU - Lopez Gomez A AD - Servicio de Anestesiologia, Reanimacion y Terapeutica del dolor, Hospital Universitario y Politecnico La Fe, Valencia, Spain. Electronic address: amlogo20@hotmail.com. FAU - Rodriguez, R AU - Rodriguez R AD - Servicio de Cirugia Cardiaca, Hospital Universitario Vall d'Hebron, Barcelona, Spain. FAU - Zebdi, N AU - Zebdi N AD - Servicio de Anestesiologia, Reanimacion y Terapeutica del dolor, Hospital Universitario Vall d'Hebron, Barcelona, Spain. FAU - Rios Barrera, R AU - Rios Barrera R AD - Servicio de Cirugia Cardiaca, Hospital Universitario Vall d'Hebron, Barcelona, Spain. FAU - Forteza, A AU - Forteza A AD - Servicio de Cirugia Cardiaca, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain. FAU - Legarra Calderon, J J AU - Legarra Calderon JJ AD - Servicio de Cirugia Cardiaca, Hospital Alvaro Cunqueiro, Vigo, Spain. FAU - Garrido Martin, P AU - Garrido Martin P AD - Servicio de Cirugia Cardiaca, Hospital Universitario de Canarias, San Cristobal de La Laguna, Spain. FAU - Hernando, B AU - Hernando B AD - Servicio de Anestesiologia, Reanimacion y Terapeutica del dolor, Hospital Universitario Miguel Servet, Zaragoza, Spain. FAU - Sanjuan, A AU - Sanjuan A AD - Servicio de Anestesiologia, Reanimacion y Terapeutica del dolor, Hospital Universitario Miguel Servet, Zaragoza, Spain. FAU - Gonzalez Bardanca, S AU - Gonzalez Bardanca S AD - Servicio de Anestesiologia, Reanimacion y Terapeutica del dolor, Complejo Hospitalario Universitario de A Coruna, A Coruna, Spain. FAU - Varela Martinez, M A AU - Varela Martinez MA AD - Servicio de Anestesiologia, Reanimacion y Terapeutica del dolor, Hospital Alvaro Cunqueiro, Vigo, Spain. FAU - Fernandez, F E AU - Fernandez FE AD - Servicio de Anestesiologia, Reanimacion y Terapeutica del dolor, Hospital Universitario Central de Asturias, Oviedo, Spain. FAU - Llorens, R AU - Llorens R AD - Servicio de Cirugia Cardiaca, Hospital Hospiten Rambla, Tenerife, Spain. FAU - Valera Martinez, F J AU - Valera Martinez FJ AD - Servicio de Cirugia Cardiaca, Hospital Universitario y Politecnico La Fe, Valencia, Spain. FAU - Gomez Felices, A AU - Gomez Felices A AD - Servicio de Anestesiologia, Reanimacion y Terapeutica del dolor, Hospital Universitario Vall d'Hebron, Barcelona, Spain. FAU - Aranda Granados, P J AU - Aranda Granados PJ AD - Servicio de Cirugia Cardiaca, Hospital Universitario Carlos Haya, Malaga, Spain. FAU - Sadaba Sagredo, R AU - Sadaba Sagredo R AD - Servicio de Cirugia Cardiaca, Complejo Hospitalario de Navarra, Pamplona, Spain. FAU - Echevarria, J R AU - Echevarria JR AD - Servicio de Cirugia Cardiaca, Hospital Universitario de Valladolid, Valladolid, Spain. FAU - Vicente Guillen, R AU - Vicente Guillen R AD - Servicio de Anestesiologia, Reanimacion y Terapeutica del dolor, Hospital Universitario y Politecnico La Fe, Valencia, Spain. FAU - Silva Guisasola, J AU - Silva Guisasola J AD - Servicio de Cirugia Cardiaca, Hospital Universitario Central de Asturias, Oviedo, Spain. LA - eng PT - Consensus Statement PT - Journal Article DEP - 20220312 PL - Spain TA - Rev Esp Anestesiol Reanim (Engl Ed) JT - Revista espanola de anestesiologia y reanimacion JID - 101778594 RN - 0 (Anesthetics) SB - IM MH - *Anesthesiology MH - *Anesthetics MH - Aorta, Thoracic/surgery MH - Humans MH - Pain OTO - NOTNLM OT - Anesthesic and surgical treatment OT - Aneurisma de arco y aorta ascendente OT - Aortic acute syndrome OT - Ascending and aortic arch aneurysm OT - Guia practica OT - Manejo anestesico-quirurgico OT - Practice guideline OT - Sindrome aortico agudo EDAT- 2022/03/16 06:00 MHDA- 2022/05/04 06:00 CRDT- 2022/03/15 05:40 PHST- 2020/06/09 00:00 [received] PHST- 2021/02/09 00:00 [accepted] PHST- 2022/03/16 06:00 [pubmed] PHST- 2022/05/04 06:00 [medline] PHST- 2022/03/15 05:40 [entrez] AID - S2341-1929(22)00044-0 [pii] AID - 10.1016/j.redare.2021.02.010 [doi] PST - ppublish SO - Rev Esp Anestesiol Reanim (Engl Ed). 2022 Mar;69(3):143-178. doi: 10.1016/j.redare.2021.02.010. Epub 2022 Mar 12. PMID- 35287156 OWN - NLM STAT- MEDLINE DCOM- 20220427 LR - 20260127 IS - 1558-2035 (Electronic) IS - 1558-2027 (Linking) VI - 23 IP - 4 DP - 2022 Apr 1 TI - Recommendations in pre-procedural imaging assessment for transcatheter aortic valve implantation intervention: Italian Society of Cardiology (SIC)-Italian Society of Medical and Interventional Radiology (SIRM) position paper part 1 (Clinical Indication and Basic Technical Aspects, Heart Team, Role of Echocardiography). PG - 216-227 LID - 10.2459/JCM.0000000000001293 [doi] AB - Non-invasive cardiovascular imaging owns a pivotal role in the preoperative assessment of patients for transcatheter aortic valve implantation (TAVI), providing a wide range of crucial information to select the patients who will benefit the most and have the procedure done safely. Although advanced cardiac imaging with cardiac computed tomography is routinely used for a detailed anatomic assessment before TAVI, echocardiography remains the first imaging modality to assess aortic stenosis severity and to provide essential functional information. This document results from the collaboration between the Italian Society of Cardiology (SIC) and the Italian Society of Medical and Interventional Radiology (SIRM), aiming to produce an updated consensus statement about the pre-procedural imaging assessment in patient for TAVI. The writing committee is composed of radiologists and cardiologists, experts in the field of cardiac imaging and structural heart diseases. Part 1 of the document, after a brief overview of the clinical indication and basic technical aspects of TAVI, will focus on the role of echocardiography in TAVI pre-procedural planning. CI - Copyright (c) 2022 Italian Federation of Cardiology - I.F.C. All rights reserved. FAU - Pontone, Gianluca AU - Pontone G AD - Department of Cardiovascular Imaging, Centro Cardiologico Monzino IRCCS, Milan, Italy. FAU - Marano, Riccardo AU - Marano R AD - Department of Radiological and Hematological Sciences, Section of Radiology, Universita Cattolica del Sacro Cuore, Rome, Italy. AD - Department of Diagnostic Imaging, Oncological Radiotherapy and Hematology, Diagnostic Imaging Area, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy. FAU - Agricola, Eustachio AU - Agricola E AD - Cardiovascular Imaging Unit, Cardio-Thoracic-Vascular Department, IRCCS San Raffaele Scientific Institute, Milan, Italy. AD - School of Medicine, Vita-Salute San Raffaele University, Milan, Italy. FAU - Alushi, Brunilda AU - Alushi B AD - Department of General and Interventional Cardiology, Helios Clinics Erfurt, Department of Cardiology, Campus Benjamin Franklin, Charite Universitatsmedizin Berlin, Germany. AD - German Centre for Cardiovascular Research (DZHK), Berlin site, Berlin, Germany. FAU - Bartorelli, Antonio AU - Bartorelli A AD - Department of Cardiovascular Imaging, Centro Cardiologico Monzino IRCCS, Milan, Italy. FAU - Cameli, Matteo AU - Cameli M AD - Department of Medical Biotechnologies, Division of Cardiology, University of Siena, Siena, Italy. FAU - Carrabba, Nazario AU - Carrabba N AD - Cardiothoracovascular Department, Careggi Hospital, Florence, Italy. FAU - Esposito, Antonio AU - Esposito A AD - School of Medicine, Vita-Salute San Raffaele University, Milan, Italy. AD - Clinical and Experimental Radiology Unit, Experimental Imaging Center, IRCCS San Raffaele Scientific Institute, Milan, Italy. FAU - Faletti, Riccardo AU - Faletti R AD - University of Turin, Department of Surgical Sciences, Radiology Unit, Turin, Italy. FAU - Francone, Marco AU - Francone M AD - Department Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy. AD - IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. FAU - Galea, Nicola AU - Galea N AD - Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy. FAU - Golino, Paolo AU - Golino P AD - Division of Cardiology, Luigi Vanvitelli University (M.C.-B., P.G.), Monaldi Hospital, Naples, Italy. FAU - Guglielmo, Marco AU - Guglielmo M AD - Department of Cardiovascular Imaging, Centro Cardiologico Monzino IRCCS, Milan, Italy. FAU - Palmisano, Anna AU - Palmisano A AD - School of Medicine, Vita-Salute San Raffaele University, Milan, Italy. AD - Clinical and Experimental Radiology Unit, Experimental Imaging Center, IRCCS San Raffaele Scientific Institute, Milan, Italy. FAU - Petronio, Sonia AU - Petronio S AD - Cardiac Catheterization Laboratory, Cardiothoracic and Vascular Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy. FAU - Petulla, Maria AU - Petulla M AD - Department of Radiology, Azienda Ospedaliero-Universitaria Mater Domini, Magna Graecia University Catanzaro, Catanzaro, Italy. FAU - Pradella, Silvia AU - Pradella S AD - Department of Emergency Radiology, University Hospital Careggi, Florence, Italy. FAU - Ribichini, Flavio AU - Ribichini F AD - Division of Cardiology, Department of Medicine, School of Medicine, University of Verona, Verona, Italy. FAU - Romeo, Francesco AU - Romeo F AD - Complex Operative Unit of Cardiology, Policlinico Tor Vergata, Rome, Italy. AD - Department of System Medicine, University of Rome Tor Vergata, Rome, Italy. FAU - Russo, Vincenzo AU - Russo V AD - Radiologia Cardiovascolare Diagnostica ed Interventistica, U.O. Radiologia Cardio-Toracica, Polo Cardio-Toraco-Vascolare, Policlinico S.Orsola-Malpighi, Bologna, Italy. FAU - Scandura, Salvatore AU - Scandura S AD - Cardiac-Thoracic-Vascular and Transplant Department, Azienda Ospedaliero-Universitaria 'Policlinico-Vittorio Emanuele', Catania, Italy. FAU - Schicchi, Nicolo AU - Schicchi N AD - Department of Radiology, Ospedali Riuniti, Ancona, Italy. FAU - Spaccarotella, Carmen AU - Spaccarotella C AD - Division of Cardiology, Department of Advanced Biomedical Science, Federico II University, Naples, Italy. FAU - Tomai, Fabrizio AU - Tomai F AD - Department of Cardiovascular Sciences, European Hospital, Rome, Italy. FAU - Centonze, Maurizio AU - Centonze M AD - Department of Radiology, Apss of Trento, Trento, Italy. FAU - Indolfi, Ciro AU - Indolfi C AD - Division of Cardiology, Department of surgical and Medical Sciences, Magna Graecia University, Catanzaro, Italy. AD - Mediterranea Cardiocentro, Naples, Italy. LA - eng PT - Consensus Statement PT - Journal Article PL - United States TA - J Cardiovasc Med (Hagerstown) JT - Journal of cardiovascular medicine (Hagerstown, Md.) JID - 101259752 SB - IM MH - Aortic Valve/diagnostic imaging/surgery MH - *Aortic Valve Stenosis/diagnostic imaging/surgery MH - *Cardiology MH - Echocardiography MH - *Heart Valve Prosthesis Implantation/methods MH - Humans MH - Radiology, Interventional MH - *Transcatheter Aortic Valve Replacement/adverse effects/methods EDAT- 2022/03/15 06:00 MHDA- 2022/04/28 06:00 CRDT- 2022/03/14 20:15 PHST- 2022/03/14 20:15 [entrez] PHST- 2022/03/15 06:00 [pubmed] PHST- 2022/04/28 06:00 [medline] AID - 01244665-202204000-00002 [pii] AID - 10.2459/JCM.0000000000001293 [doi] PST - ppublish SO - J Cardiovasc Med (Hagerstown). 2022 Apr 1;23(4):216-227. doi: 10.2459/JCM.0000000000001293. PMID- 35285803 OWN - NLM STAT- MEDLINE DCOM- 20220425 LR - 20230423 IS - 1969-6213 (Electronic) IS - 1774-024X (Print) IS - 1774-024X (Linking) VI - 17 IP - 18 DP - 2022 Apr 22 TI - Bioabsorbable polymer drug-eluting stents with 4-month dual antiplatelet therapy versus durable polymer drug-eluting stents with 12-month dual antiplatelet therapy in patients with left main coronary artery disease: the IDEAL-LM randomised trial. PG - 1467-1476 LID - EIJ-D-21-00514 [pii] LID - 10.4244/EIJ-D-21-00514 [doi] AB - BACKGROUND: Improvements in drug-eluting stent design have led to a reduced frequency of repeat revascularisation and new biodegradable polymer coatings may allow a shorter duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI). AIMS: The Improved Drug-Eluting stent for All-comers Left Main (IDEAL-LM) study aims to investigate long-term clinical outcomes after implantation of a biodegradable polymer platinum-chromium everolimus-eluting stent (BP-PtCr-EES) followed by 4 months DAPT compared to a durable polymer cobalt-chromium everolimus-eluting stent (DP-CoCr-EES) followed by 12 months DAPT in patients undergoing PCI of unprotected left main coronary artery (LMCA) disease. METHODS: This is a multicentre randomised clinical trial study in patients with an indication for coronary artery revascularisation who have been accepted for PCI for LMCA disease after Heart Team consultation. Patients were randomly assigned in a 1:1 ratio to receive either the BP-PtCr-EES or the DP-CoCr-EES. The primary endpoint was a non-inferiority comparison of the rate of major adverse cardiovascular events (MACE), defined as all-cause death, myocardial infarction, or ischaemia-driven target vessel revascularisation at 2 years. RESULTS: Between December 2014 and October 2016, 818 patients (410 BP-PtCr-EES and 408 DP-CoCr-EES) were enrolled at 29 centres in Europe. At 2 years, the primary endpoint of MACE occurred in 59 patients (14.6%) in the BP-PtCr-EES group and 45 patients (11.4%) in the DP-CoCr-EES group; 1-sided upper 95% confidence interval (CI) 7.18%; p=0.04 for non-inferiority; p=0.17 for superiority. The secondary endpoint event of BARC 3 or 5 bleeding occurred in 11 patients (2.7%) in the BP-PtCr-EES group and 2 patients (0.5%) in the DP-CoCr-EES group (p=0.02). CONCLUSIONS: In patients undergoing PCI of LMCA disease, after two years of follow-up, the use of a BP-PtCr-EES with 4 months of DAPT was non-inferior to a DP-CoCr-EES with 12 months of DAPT with respect to the composite endpoint of all-cause death, myocardial infarction or ischaemia-driven target vessel revascularisation. FAU - van Geuns, Robert-Jan AU - van Geuns RJ AD - Department of Cardiology, Radboud University Medical Center, Nijmegen, the Netherlands. AD - Department of Cardiology, Thorax Center, Erasmus Medical Center, Rotterdam, the Netherlands. FAU - Chun-Chin, Chang AU - Chun-Chin C AD - Department of Cardiology, Thorax Center, Erasmus Medical Center, Rotterdam, the Netherlands. AD - Division of Cardiology, Department of Internal Medicine, Taipei Veterans General Hospital, Taipei, Taiwan. FAU - McEntegart, Margaret B AU - McEntegart MB AD - Golden Jubilee National Hospital, Glasgow, United Kingdom. FAU - Merkulov, Evgeny AU - Merkulov E AD - Russian Cardiology Research Center, Moscow, Russian Federation. FAU - Kretov, Evgeny AU - Kretov E AD - E.N. Meshalkin National Medical Research Center, Novosibirsk, Russian Federation. FAU - Lesiak, Maciej AU - Lesiak M AD - 1st Department of Cardiology, Poznan University of Medical Sciences, Poznan, Poland. FAU - O'Kane, Peter AU - O'Kane P AD - Department of Cardiology, Royal Bournemouth Hospital, Bournemouth, United Kingdom. FAU - Hanratty, Colm G AU - Hanratty CG AD - Belfast Health and Social Care Trust, Belfast, United Kingdom. FAU - Bressollette, Erwan AU - Bressollette E AD - Hopital Prive du Confluent, Nantes, France. FAU - Silvestri, Marc AU - Silvestri M AD - Clinique Axium, Aix-en-Provence, France. FAU - Wlodarczak, Adrian AU - Wlodarczak A AD - Department of Cardiology, Miedziowe Centrum Zdrowia S.A., Lubin, Poland. FAU - Barragan, Paul AU - Barragan P AD - Department of Cardiology, Polyclinique les Fleurs, Ollioules, France. FAU - Anderson, Richard AU - Anderson R AD - University Hospital of Wales, Cardiff, United Kingdom. FAU - Protopopov, Aleksey AU - Protopopov A AD - Krasnoyarsk Regional Vascular Centre, Krasnoyarsk, Russia. FAU - Peace, Aaron AU - Peace A AD - Altnagelvin Hospital, Londonderry, United Kingdom. FAU - Menown, Ian AU - Menown I AD - Craigavon Area Hospital, Craigavon, United Kingdom. FAU - Rocchiccioli, Paul AU - Rocchiccioli P AD - Golden Jubilee National Hospital, Glasgow, United Kingdom. FAU - Onuma, Yoshinobu AU - Onuma Y AD - Department of Cardiology, Thorax Center, Erasmus Medical Center, Rotterdam, the Netherlands. AD - Cardialysis, Rotterdam, the Netherlands. FAU - Oldroyd, Keith G AU - Oldroyd KG AD - Golden Jubilee National Hospital, Glasgow, United Kingdom. LA - eng PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial PL - France TA - EuroIntervention JT - EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology JID - 101251040 RN - 0 (Platelet Aggregation Inhibitors) RN - 0 (Polymers) RN - 0R0008Q3JB (Chromium) RN - 49DFR088MY (Platinum) RN - 9HW64Q8G6G (Everolimus) SB - IM MH - Absorbable Implants MH - Chromium MH - *Coronary Artery Disease/complications/surgery MH - *Drug-Eluting Stents/adverse effects MH - Everolimus/therapeutic use MH - Humans MH - *Myocardial Infarction/therapy MH - *Percutaneous Coronary Intervention/methods MH - Platelet Aggregation Inhibitors/therapeutic use MH - Platinum MH - Polymers MH - Treatment Outcome PMC - PMC9900447 COIS- R. van Geuns reports receiving grants and personal fees from Boston Scientific, during the conduct of the study; grants and personal fees from Abbott Vascular, AstraZeneca, and Amgen; and personal fees from Sanofi, outside the submitted work. M. Lesiak has received speaker's honoraria from Abbott Vascular, and Boston Scientific. Y. Onuma was an advisory board member of Abbott Vascular. M.B. McEntegart has a proctoring agreement with Boston Scientific and Vascular Perspectives. K.G. Oldroyd reports receiving grant support and lecture fees from AstraZeneca and lecture fees from Biosensors, Abbott Vascular, and GE. The other authors have no conflicts of interest to declare. EDAT- 2022/03/15 06:00 MHDA- 2022/04/26 06:00 PMCR- 2023/04/22 CRDT- 2022/03/14 12:13 PHST- 2022/03/15 06:00 [pubmed] PHST- 2022/04/26 06:00 [medline] PHST- 2022/03/14 12:13 [entrez] PHST- 2023/04/22 00:00 [pmc-release] AID - EIJ-D-21-00514 [pii] AID - 10.4244/EIJ-D-21-00514 [doi] PST - ppublish SO - EuroIntervention. 2022 Apr 22;17(18):1467-1476. doi: 10.4244/EIJ-D-21-00514. PMID- 35285514 OWN - NLM STAT- MEDLINE DCOM- 20240305 LR - 20260501 IS - 1898-018X (Electronic) IS - 1897-5593 (Print) IS - 1898-018X (Linking) VI - 31 IP - 1 DP - 2024 TI - Long-term outcomes and quality of life following implementation of dedicated mitral valve Heart Team decisions for patients with severe mitral valve regurgitation in tertiary cardiovascular care center. PG - 62-71 LID - 10.5603/CJ.a2022.0011 [doi] AB - BACKGROUND: This study was purposed to investigate which treatment strategy was associated with the most favourable prognosis for patients with severe mitral regurgitation (MR) following Heart Team (HT)-decisions implementation. METHODS: In this retrospective study, long-term outcomes of patients with severe MR qualified after HT discussion to: optimal medical treatment (OMT) alone, OMT and MitraClip (MC) procedure or OMT and mitral valve replacement (MVR) were evaluated. The primary endpoint was defined as cardiovascular (CV) death and the secondary endpoints included all-cause mortality, myocardial infarctions (MI), strokes, hospitalizations for heart failure exacerbation and CV events during a mean (standard deviation [SD]) follow-up of 29 (15) months. RESULTS: From 2016 to 2019, 176 HT meetings were held and a total of 157 participants (mean age [SD] = 71.0 [9.2], 63.7% male) with severe MR and completely implemented HT decisions (OMT, MC or MVR for 53, 58 and 46 patients, respectively) were included into final analysis. Comparing OMT, MC and MVR groups statistically significant differences between the implemented procedures and occurrence of primary and secondary endpoints with the most frequent in OMT-group were observed (p < 0.05). However, for interventional strategy MC was non-inferior to MVR for all endpoints (p > 0.05). General health status assessed at the end of follow-up were significantly the lowest for MVR, then for MC and the highest for OMT-group (p < 0.01). CONCLUSIONS: In the present study it was demonstrated that after careful HT evaluation of patients with severe MR at high risk of surgery, percutaneous strategy (MC) can be considered as equivalent to surgical treatment (MVR) with non-inferior outcomes. FAU - Jonik, Szymon AU - Jonik S AUID- ORCID: 0000-0002-9230-5455 AD - 1st Department of Cardiology, Medical University of Warsaw, Poland. FAU - Marchel, Michal AU - Marchel M AD - 1st Department of Cardiology, Medical University of Warsaw, Poland. FAU - Pedzich-Placha, Ewa AU - Pedzich-Placha E AD - 1st Department of Cardiology, Medical University of Warsaw, Poland. FAU - Pietrasik, Arkadiusz AU - Pietrasik A AD - 1st Department of Cardiology, Medical University of Warsaw, Poland. FAU - Rdzanek, Adam AU - Rdzanek A AD - 1st Department of Cardiology, Medical University of Warsaw, Poland. FAU - Huczek, Zenon AU - Huczek Z AD - 1st Department of Cardiology, Medical University of Warsaw, Poland. FAU - Kochman, Janusz AU - Kochman J AD - 1st Department of Cardiology, Medical University of Warsaw, Poland. FAU - Budnik, Monika AU - Budnik M AD - 1st Department of Cardiology, Medical University of Warsaw, Poland. FAU - Piatkowski, Radoslaw AU - Piatkowski R AD - 1st Department of Cardiology, Medical University of Warsaw, Poland. FAU - Scislo, Piotr AU - Scislo P AD - 1st Department of Cardiology, Medical University of Warsaw, Poland. FAU - Kochanowski, Janusz AU - Kochanowski J AD - 1st Department of Cardiology, Medical University of Warsaw, Poland. FAU - Czub, Pawel AU - Czub P AD - Department of Cardiac Surgery, Medical University of Warsaw, Poland. FAU - Wilimski, Radoslaw AU - Wilimski R AD - Department of Cardiac Surgery, Medical University of Warsaw, Poland. FAU - Hendzel, Piotr AU - Hendzel P AD - Department of Cardiac Surgery, Medical University of Warsaw, Poland. FAU - Grabowski, Marcin AU - Grabowski M AD - 1st Department of Cardiology, Medical University of Warsaw, Poland. FAU - Filipiak, Krzysztof J AU - Filipiak KJ AD - 1st Department of Cardiology, Medical University of Warsaw, Poland. FAU - Opolski, Grzegorz AU - Opolski G AD - 1st Department of Cardiology, Medical University of Warsaw, Poland. FAU - Mazurek, Tomasz AU - Mazurek T AUID- ORCID: 0000-0002-3693-8741 AD - 1st Department of Cardiology, Medical University of Warsaw, Poland. tomaszmazurek.wum@gmail.com. LA - eng PT - Journal Article DEP - 20220314 PL - Poland TA - Cardiol J JT - Cardiology journal JID - 101392712 SB - IM MH - Humans MH - Male MH - Female MH - *Mitral Valve Insufficiency/diagnosis/surgery MH - Mitral Valve/diagnostic imaging/surgery MH - Retrospective Studies MH - Quality of Life MH - *Heart Valve Prosthesis Implantation/adverse effects MH - Treatment Outcome PMC - PMC10919556 OTO - NOTNLM OT - Heart Team OT - MitraClip OT - heart failure OT - mitral regurgitation OT - mitral valve replacement COIS- Conflict of interest: None declared EDAT- 2022/03/15 06:00 MHDA- 2024/03/05 06:46 PMCR- 2024/02/29 CRDT- 2022/03/14 08:42 PHST- 2021/07/31 00:00 [received] PHST- 2021/11/21 00:00 [accepted] PHST- 2021/10/26 00:00 [revised] PHST- 2024/03/05 06:46 [medline] PHST- 2022/03/15 06:00 [pubmed] PHST- 2022/03/14 08:42 [entrez] PHST- 2024/02/29 00:00 [pmc-release] AID - VM/OJS/J/85100 [pii] AID - cardj-31-1-62 [pii] AID - 10.5603/CJ.a2022.0011 [doi] PST - ppublish SO - Cardiol J. 2024;31(1):62-71. doi: 10.5603/CJ.a2022.0011. Epub 2022 Mar 14. PMID- 35282346 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220315 IS - 2297-055X (Print) IS - 2297-055X (Electronic) IS - 2297-055X (Linking) VI - 9 DP - 2022 TI - Pediatric Cardiac Service Development in Croatia. PG - 793166 LID - 10.3389/fcvm.2022.793166 [doi] LID - 793166 AB - This article describes the establishment of a pediatric cardiac service program in a limited resource country. According to national epidemiological studies about 330 children with congenital heart disease (CHD) are born every year in Croatia. As a part of the former Yugoslavia, there was not an organized strategy for the pediatric cardiac service. After Croatian independence in 1991, even during the war, a need for such service led to the first step in the development of organized care for patients with CHD, a humanitarian mission provided by a non-governmental organization (NGO), from the United States. In the ten-year period (1993-2003), 601 children were operated on during this program. After the end of this program, the Croatian team was not able to cover the whole spectrum of pediatric cardiac care independently. About 60% of the children were sent abroad, and only about 40% of the operations were performed in Croatia. Over the time, the surgical team improved and after a specialized congenital heart surgeon joined, the number and quality of the program in the country raised, and the number of referrals to foreign centers gradually declined. In the meantime, a cardiological interventional program also improved. Today majority of standard congenital heart surgery procedures can be performed in Croatia. Last year our congenital heart team operated on 180 patients with low mortality and the interventional team (pediatric and adult) performed 66 procedures. In the article, we present positive shifts achieved during time as well as weaknesses and reasons for problems in establishing a high-quality CHD center. CI - Copyright (c) 2022 Malcic and Anic. FAU - Malcic, Ivan AU - Malcic I AD - Department of Paediatric Cardiology, University Hospital Centre Zagreb, Zagreb, Croatia. FAU - Anic, Darko AU - Anic D AD - Department of Cardiac Surgery, University Hospital Centre Zagreb, Zagreb, Croatia. LA - eng PT - Journal Article PT - Systematic Review DEP - 20220224 PL - Switzerland TA - Front Cardiovasc Med JT - Frontiers in cardiovascular medicine JID - 101653388 PMC - PMC8907509 OTO - NOTNLM OT - cardiovascular outcome assessment OT - congenital heart disease OT - humanitarian pediatric cardiac assistance OT - mortality OT - pediatric cardiology and surgery COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/03/15 06:00 MHDA- 2022/03/15 06:01 PMCR- 2022/01/01 CRDT- 2022/03/14 05:33 PHST- 2021/10/11 00:00 [received] PHST- 2022/01/26 00:00 [accepted] PHST- 2022/03/14 05:33 [entrez] PHST- 2022/03/15 06:00 [pubmed] PHST- 2022/03/15 06:01 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.3389/fcvm.2022.793166 [doi] PST - epublish SO - Front Cardiovasc Med. 2022 Feb 24;9:793166. doi: 10.3389/fcvm.2022.793166. eCollection 2022. PMID- 35281693 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240827 IS - 2542-4548 (Electronic) IS - 2542-4548 (Linking) VI - 6 IP - 3 DP - 2022 Jun TI - Multidisciplinary Approach for Lung Transplantation due to COVID-19. PG - 200-208 LID - 10.1016/j.mayocpiqo.2022.02.003 [doi] AB - Coronavirus disease 2019 (COVID-19), a novel etiology of end-stage lung disease, has resulted in major disruptions to the process of health care delivery worldwide. These disruptions have led to team-based innovations globally, resulting in a broad range of new processes in cardiopulmonary perioperative management. A key intersection of multidisciplinary teamwork and COVID-19 is found in lung transplantation, in which diverse teams collaborate throughout the perioperative period to achieve optimal outcomes. In this article, we describe the multidisciplinary approach taken by Mayo clinic in Florida to manage patients with COVID-19 presenting for lung transplantation. CI - (c) 2022 The Authors. FAU - Martin, Archer Kilbourne AU - Martin AK AD - Division of Cardiovascular and Thoracic Anesthesiology, Mayo Clinic in Florida, Jacksonville, FL. FAU - Shah, Sadia Z AU - Shah SZ AD - Department of Transplantation, Mayo Clinic in Florida, Jacksonville, FL. FAU - Guru, Pramod K AU - Guru PK AD - Department of Critical Care, Mayo Clinic in Florida, Jacksonville, FL. FAU - Chaudhary, Sanjay AU - Chaudhary S AD - Department of Critical Care, Mayo Clinic in Florida, Jacksonville, FL. FAU - Franco, Pablo Moreno AU - Franco PM AD - Department of Critical Care, Mayo Clinic in Florida, Jacksonville, FL. FAU - Makey, Ian AU - Makey I AD - Department of Cardiothoracic Surgery, Mayo Clinic in Florida, Jacksonville, FL. FAU - Fritz, Ashley Virginia AU - Fritz AV AD - Division of Cardiovascular and Thoracic Anesthesiology, Mayo Clinic in Florida, Jacksonville, FL. FAU - Pham, Si M AU - Pham SM AD - Department of Cardiothoracic Surgery, Mayo Clinic in Florida, Jacksonville, FL. FAU - Thomas, Mathew AU - Thomas M AD - Department of Cardiothoracic Surgery, Mayo Clinic in Florida, Jacksonville, FL. LA - eng PT - Journal Article PT - Review DEP - 20220309 PL - Netherlands TA - Mayo Clin Proc Innov Qual Outcomes JT - Mayo Clinic proceedings. Innovations, quality & outcomes JID - 101728275 PMC - PMC8904149 OTO - NOTNLM OT - ARDS, acute respiratory distress syndrome OT - CAD, coronary artery disease OT - COVID-19, coronavirus disease 2019 OT - ECMO, extracorporeal membrane oxygenation OT - ESLD, end-stage lung disease OT - ICU, intensive care unit OT - MCF, Mayo clinic in Florida OT - MDT, multidisciplinary team OT - OR, operating room OT - PCR, polymerase chain reaction OT - POD, postoperative day OT - PPE, personal protective equipment OT - SARS-CoV-2, severe acute respiratory syndrome coronavirus 2 OT - VA, veno-arterial OT - VV, veno-venous EDAT- 2022/03/15 06:00 MHDA- 2022/03/15 06:01 PMCR- 2022/03/09 CRDT- 2022/03/14 05:25 PHST- 2022/03/15 06:00 [pubmed] PHST- 2022/03/15 06:01 [medline] PHST- 2022/03/14 05:25 [entrez] PHST- 2022/03/09 00:00 [pmc-release] AID - S2542-4548(22)00011-X [pii] AID - 10.1016/j.mayocpiqo.2022.02.003 [doi] PST - ppublish SO - Mayo Clin Proc Innov Qual Outcomes. 2022 Jun;6(3):200-208. doi: 10.1016/j.mayocpiqo.2022.02.003. Epub 2022 Mar 9. PMID- 35277303 OWN - NLM STAT- MEDLINE DCOM- 20230502 LR - 20230502 IS - 1036-7314 (Print) IS - 1036-7314 (Linking) VI - 36 IP - 3 DP - 2023 May TI - Delivery, barriers, and enablers to patient participation in inpatient cardiac rehabilitation following cardiac surgery: An integrative review. PG - 420-430 LID - S1036-7314(22)00008-X [pii] LID - 10.1016/j.aucc.2022.01.007 [doi] AB - BACKGROUND: Cardiovascular disease is the leading cause of death worldwide. Cardiac surgery is the main treatment followed by inpatient cardiac rehabilitation (ICR) to prepare patients for recovery. AIM: The aim of this study was to describe the delivery, barriers, and enablers to patient participation in ICR programs after cardiac surgery. METHODS: This integrative review was guided by Whittemore and Knafl's methodology. This process included database searches, data evaluation, data integration, and presentation of results. Searched databases included Medline, CINAHL Complete, PsycINFO, Cochrane Library, and Web of Science. Publications dates included 2000 to 2021. Studies included Phase 1/inpatient phase cardiac rehabilitation following cardiac surgery. The Mixed Method Appraisal Tool (2018) was used to assess the quality of the included studies. Inductive content analysis was used to analyse the textual data. RESULTS: Using the inclusion and the exclusion criteria, 607 articles were screened. Five articles were included in this review, and they were appraised. Categories comprised of the following: i) ICR programs using a multidisciplinary approach beginning in the early postoperative stage; ii) ICR programs including multicomponents that were delivered through an individualised approach; and iii) enablers and barriers to patient participation to ICR. The enablers included religious faith and family support, whereas inconsistent pathways of cardiac rehabilitation referrals and detachment from patients' experiences and needs were barriers to participation in ICR. CONCLUSIONS: In some instances, ICR programs were delivered using individualised approaches, but this is an area that needs improvement. A multidisciplinary team including nurses should be involved in the ICR phase after cardiac surgery to provide holistic care and enhance patients' preparedness to participate in subsequent phases of rehabilitation. Only five relevant articles addressing the delivery of inpatient cardiac rehabilitation were identified in this specific topic area. CI - Copyright (c) 2022 Australian College of Critical Care Nurses Ltd. Published by Elsevier Ltd. All rights reserved. FAU - Nasrawi, Dima AU - Nasrawi D AD - School of Nursing and Midwifery, Griffith University, Logan Campus Meadowbrook QLD, Australia; School of Health and Human Sciences, Southern Cross University, Gold Coast Airport, Terminal Dr, Bilinga QLD 4225, Australia. Electronic address: dima.nasrawi@scu.edu.au. FAU - Latimer, Sharon AU - Latimer S AD - School of Nursing and Midwifery, Griffith University, Logan Campus Meadowbrook QLD, Australia; Nursing and Midwifery Education and Research Unit, Gold Coast Hospital and Health Service, Southport, QLD, Australia; NHMRC Centre of Research Excellence in Wiser Wounds, Menzies Health Institute QLD, School of Nursing and Midwifery, Griffith University, Southport QLD 4222, Australia. Electronic address: s.latimer@griffith.edu.au. FAU - Massey, Debbie AU - Massey D AD - School of Health and Human Sciences, Southern Cross University, Gold Coast Airport, Terminal Dr, Bilinga QLD 4225, Australia. Electronic address: deb.massey@scu.edu.au. FAU - Gillespie, Brigid M AU - Gillespie BM AD - Nursing and Midwifery Education and Research Unit, Gold Coast Hospital and Health Service, Southport, QLD, Australia; NHMRC Centre of Research Excellence in Wiser Wounds, Menzies Health Institute QLD, School of Nursing and Midwifery, Griffith University, Southport QLD 4222, Australia. Electronic address: b.gillespie@griffith.edu.au. LA - eng PT - Journal Article PT - Review DEP - 20220308 PL - Australia TA - Aust Crit Care JT - Australian critical care : official journal of the Confederation of Australian Critical Care Nurses JID - 9207852 MH - Humans MH - *Cardiac Rehabilitation MH - Patient Participation MH - Inpatients MH - *Cardiac Surgical Procedures OTO - NOTNLM OT - Cardiac rehabilitation OT - Cardiac surgical procedures OT - Inpatients OT - Patient education EDAT- 2022/03/13 06:00 MHDA- 2023/05/02 06:41 CRDT- 2022/03/12 05:23 PHST- 2021/08/14 00:00 [received] PHST- 2022/01/18 00:00 [revised] PHST- 2022/01/19 00:00 [accepted] PHST- 2023/05/02 06:41 [medline] PHST- 2022/03/13 06:00 [pubmed] PHST- 2022/03/12 05:23 [entrez] AID - S1036-7314(22)00008-X [pii] AID - 10.1016/j.aucc.2022.01.007 [doi] PST - ppublish SO - Aust Crit Care. 2023 May;36(3):420-430. doi: 10.1016/j.aucc.2022.01.007. Epub 2022 Mar 8. PMID- 35276540 OWN - NLM STAT- MEDLINE DCOM- 20220418 LR - 20220418 IS - 1872-6283 (Electronic) IS - 0379-0738 (Linking) VI - 334 DP - 2022 May TI - Benefits and outcomes of a new multidisciplinary approach for the management and financing of sudden unexplained death cases in a forensic setting in Switzerland. PG - 111240 LID - S0379-0738(22)00070-6 [pii] LID - 10.1016/j.forsciint.2022.111240 [doi] AB - Sudden cardiac death (SCD) is an important public health issue. In young persons aged between 1 and 40 years, most SCDs are caused by potentially inherited cardiac diseases, often not detectable during conventional medico-legal investigations and therefore termed as sudden unexplained deaths (SUD). In this study, we describe the implementation, feasibility and importance of a standardized procedure to investigate SUD cases within the forensic framework at the Zurich Institute of Forensic Medicine in Switzerland. This new approach involves a multidisciplinary collaboration including forensic autopsy, second pathology expert opinion, post-mortem molecular genetic testing, cardiac counselling of relatives, and a tentative financing. This procedure is in line with the published Swiss and European recommendations on the management of SCDs. During a two-year pilot project, 39 sudden and unexpected death cases were collected, whereof 10 deceased remained without any identifiable cause of death after medico-legal investigation and second expert evaluation. Molecular autopsy, including 393 genes involved in cardio-vascular and metabolic diseases, identified eight pathogenic or likely pathogenic genetic variants in five out of the 10 deceased (50%). Cardio-genetic follow-up investigations in the families of the 10 deceased revealed phenotype-positive relatives in four families and required specific therapies, including an implantable cardioverter defibrillator (ICD) for primary prevention. Multidisciplinary collaboration is crucial for an optimal management of sudden unexplained death cases, to identify additional relatives at risk, and to prevent other tragic deaths within a family. CI - Copyright (c) 2022 The Author(s). Published by Elsevier B.V. All rights reserved. FAU - Neubauer, Jacqueline AU - Neubauer J AD - Zurich Institute of Forensic Medicine, University of Zurich, Zurich, Switzerland. FAU - Kissel, Christine K AU - Kissel CK AD - Department of Cardiology, University Heart Center, University Hospital Zurich, Zurich, Switzerland. FAU - Bolliger, Stephan A AU - Bolliger SA AD - Zurich Institute of Forensic Medicine, University of Zurich, Zurich, Switzerland. FAU - Barbon, Daniela AU - Barbon D AD - Zurich Institute of Forensic Medicine, University of Zurich, Zurich, Switzerland. FAU - Thali, Michael J AU - Thali MJ AD - Zurich Institute of Forensic Medicine, University of Zurich, Zurich, Switzerland. FAU - Kloiber, Daniel AU - Kloiber D AD - Canton Zurich, Department of Justice, Bureau of Prosecution, Zurich, Switzerland. FAU - Bode, Peter K AU - Bode PK AD - Institute of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland. FAU - Kovacs, Boldizsar AU - Kovacs B AD - Department of Cardiology, University Heart Center, University Hospital Zurich, Zurich, Switzerland. FAU - Graf, Urs AU - Graf U AD - Institute of Medical Molecular Genetics, University of Zurich, Schlieren, Switzerland. FAU - Maspoli, Alessandro AU - Maspoli A AD - Institute of Medical Molecular Genetics, University of Zurich, Schlieren, Switzerland. FAU - Berger, Wolfgang AU - Berger W AD - Institute of Medical Molecular Genetics, University of Zurich, Schlieren, Switzerland; Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland; Neuroscience Center Zurich, University and ETH Zurich, Zurich, Switzerland. FAU - Saguner, Ardan M AU - Saguner AM AD - Department of Cardiology, University Heart Center, University Hospital Zurich, Zurich, Switzerland. FAU - Haas, Cordula AU - Haas C AD - Zurich Institute of Forensic Medicine, University of Zurich, Zurich, Switzerland. Electronic address: cordula.haas@irm.uzh.ch. LA - eng PT - Journal Article DEP - 20220225 PL - Ireland TA - Forensic Sci Int JT - Forensic science international JID - 7902034 SB - IM MH - Autopsy/methods MH - *Death, Sudden, Cardiac/etiology/pathology/prevention & control MH - *Genetic Testing/methods MH - Humans MH - Phenotype MH - Pilot Projects MH - Switzerland OTO - NOTNLM OT - Cardiac counselling OT - Cardiac diseases OT - Forensics OT - Postmortem molecular autopsy OT - Sudden cardiac death OT - Sudden unexplained death COIS- Declaration of Competing Interest Ardan M. Saguner received educational grants through his institution from Abbott, Bayer Healthcare, Biosense Webster, Biotronik, Boston Scientific, BMS/Pfizer, and Medtronic; and speaker fees from Bayer Healthcare, BMS/Pfizer and Daiichii Sankyo. The other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2022/03/12 06:00 MHDA- 2022/04/19 06:00 CRDT- 2022/03/11 20:15 PHST- 2021/12/23 00:00 [received] PHST- 2022/02/01 00:00 [revised] PHST- 2022/02/22 00:00 [accepted] PHST- 2022/03/12 06:00 [pubmed] PHST- 2022/04/19 06:00 [medline] PHST- 2022/03/11 20:15 [entrez] AID - S0379-0738(22)00070-6 [pii] AID - 10.1016/j.forsciint.2022.111240 [doi] PST - ppublish SO - Forensic Sci Int. 2022 May;334:111240. doi: 10.1016/j.forsciint.2022.111240. Epub 2022 Feb 25. PMID- 35274508 OWN - NLM STAT- MEDLINE DCOM- 20220428 LR - 20220428 IS - 1751-1887 (Electronic) IS - 1751-1879 (Linking) VI - ahead-of-print IP - ahead-of-print DP - 2022 Mar 14 TI - Review DebrIeF: a collaborative distributed leadership approach to "hot debrief" after cardiac arrest in the emergency department - a quality improvement project. LID - 10.1108/LHS-06-2021-0050 [doi] AB - PURPOSE: The purpose of this paper is to re-conceptualise the hot debrief process after cardiac arrest as a collaborative and distributed process across the multi-disciplinary team. There are multiple benefits to hot debriefs but there are also barriers to its implementation. Facilitating the hot debrief discussion usually falls within the remit of the physician; however, the American Heart Association suggests "a facilitator, typically a health-care professional, leads a discussion focused on identifying ways to improve performance". Empowering nurses through a distributed leadership approach supports the wider health-care team involvement and facilitation of the hot debrief process, while reducing the cognitive burden of the lead physician. DESIGN/METHODOLOGY/APPROACH: A mixed-method approach was taken to evaluate the experiences of staff in the Emergency Department (ED) to identify their experiences of hot debrief after cardiac arrest. There had been some staff dissatisfaction with the process with reports of negative experiences of unresolved issues after cardiac arrest. An audit identified zero hot debriefs occurring in 2019. A quality Improvement project (Model for Healthcare Improvement) used four plan do study act cycles from March 2020 to September 2021, using two questionnaires and semi-structured interviews to engage the team in the design and implementation of a hot debrief tool, using a distributed leadership approach. FINDINGS: The first survey (n = 78) provided a consensus to develop a hot debrief in the ED (84% in the ED; 85% in intensive care unit (ICU); and 92% from Acute Medicine). Three months after implementation of the hot debrief tool, 5 out of 12 cardiac arrests had a hot debrief, an increase of 42% in hot debriefs from a baseline of 0%. The hot debrief started to become embedded in the ED; however, six months on, there were still inconsistencies with implementation and barriers remained. Findings from the second survey (n = 58) suggest that doctors may not be convinced of the benefits of the hot debrief process, particularly its benefits to improve team performance and nurses appear more invested in hot debriefs when compared to doctors. RESEARCH LIMITATIONS/IMPLICATIONS: There are existing hot debrief tools; for example, STOP 5 and Take STOCK; however, creating a specific tool with QI methods, tailored to the specific ED context, is likely to produce higher levels of multi-disciplinary team engagement and result in distributed roles and responsibilities. Change is accepted when people are involved in the decisions that affect them and when they have the opportunity to influence that change. This approach is more likely to be achieved through distributed leadership rather than from more traditional top-down hierarchical leadership approaches. ORIGINALITY/VALUE: To the best of the authors' knowledge, this study is the first of its kind to integrate Royal College Quality Improvement requirements with a collaborative and distributed medical leadership approach, to steer a change project in the implementation of a hot debrief in the ED. EDs need to create a continuous quality improvement culture to support this integration of leadership and QI methods combined, to drive and sustain successful change in distributed leadership to support the implementation of clinical protocols across the multi-disciplinary team in the ED. CI - (c) Emerald Publishing Limited. FAU - James, Shobha AU - James S AD - Department of Emergency Medicine, Doncaster and Bassetlaw Hospitals NHS Foundation Trust, Doncaster, UK. FAU - Subedi, Prakash AU - Subedi P AD - Emergency Department, Doncaster Royal Infirmary, Doncaster, UK and QiMET International, Sheffield, UK. FAU - Indrasena, Buddhike Sri Harsha AU - Indrasena BSH AD - Institute for Quality Improvement, World Academy of Medical Leadership, Sheffield, UK and Department of General Surgery, Provincial General Hospital, Badulla, Sri Lanka. FAU - Aylott, Jill AU - Aylott J AD - Institute for Quality Improvement, World Academy of Medical Leadership, Sheffield, UK and QiMET International, Sheffield, UK. LA - eng PT - Journal Article PL - England TA - Leadersh Health Serv (Bradf Engl) JT - Leadership in health services (Bradford, England) JID - 101464443 MH - Emergency Service, Hospital MH - *Heart Arrest/therapy MH - Humans MH - *Leadership MH - Patient Care Team MH - Quality Improvement OTO - NOTNLM OT - Cardiac arrest OT - Collaborative leadership OT - Distributed leadership OT - Doctors OT - Hospitals OT - Hot debrief OT - Quality improvement OT - Systems development EDAT- 2022/03/12 06:00 MHDA- 2022/04/29 06:00 CRDT- 2022/03/11 05:45 PHST- 2022/03/11 05:45 [entrez] PHST- 2022/03/12 06:00 [pubmed] PHST- 2022/04/29 06:00 [medline] AID - 10.1108/LHS-06-2021-0050 [doi] PST - ppublish SO - Leadersh Health Serv (Bradf Engl). 2022 Mar 14;ahead-of-print(ahead-of-print). doi: 10.1108/LHS-06-2021-0050. PMID- 35271509 OWN - NLM STAT- MEDLINE DCOM- 20220527 LR - 20220607 IS - 1531-7080 (Electronic) IS - 0268-4705 (Linking) VI - 37 IP - 3 DP - 2022 May 1 TI - Team-based strategies to prevent heart failure. PG - 294-301 LID - 10.1097/HCO.0000000000000959 [doi] AB - PURPOSE OF REVIEW: The burden of heart failure (HF) in the United States and worldwide is projected to rise. Prevention of HF can curb the burden of this chronic syndrome, but current approaches are limited. This review discusses team-based strategies aimed to prevent HF. RECENT FINDINGS: Individuals at high risk for developing HF can be identified using HF risk scores, biomarkers, and cardiac imaging. Electronic medical records (EMR) can integrate clinical data to estimate HF risk and identify individuals who may benefit most from preventive therapies. Team-based interventions can lead to enhanced adherence to medications, optimization of medical management, and control of risk factors. Multifaceted interventions involve EMR-based strategies, pharmacist- and nurse-led initiatives, involvement of community personnel, polypills, and digital solutions. SUMMARY: Team-based strategies aimed to prevent HF incorporate a broad group of personnel and tools. Despite implementation challenges, existing resources can be efficiently utilized to facilitate team-based approaches to potentially reduce the burden of HF. CI - Copyright (c) 2022 Wolters Kluwer Health, Inc. All rights reserved. FAU - Taha, Mohamad B AU - Taha MB AD - Division of Cardiovascular Prevention and Wellness, Department of Cardiology, Houston Methodist DeBakey Heart & Vascular Center. FAU - Patel, Kershaw V AU - Patel KV AD - Division of Cardiovascular Prevention and Wellness, Department of Cardiology, Houston Methodist DeBakey Heart & Vascular Center. FAU - Nasir, Khurram AU - Nasir K AD - Division of Cardiovascular Prevention and Wellness, Department of Cardiology, Houston Methodist DeBakey Heart & Vascular Center. AD - Center for Outcomes Research, Houston Methodist, Houston, Texas, USA. LA - eng PT - Journal Article PT - Review DEP - 20220309 PL - United States TA - Curr Opin Cardiol JT - Current opinion in cardiology JID - 8608087 RN - 0 (Biomarkers) SB - IM MH - Biomarkers MH - Cardiac Imaging Techniques MH - *Heart Failure/prevention & control MH - Humans MH - Pharmacists MH - Risk Factors MH - United States EDAT- 2022/03/11 06:00 MHDA- 2022/05/28 06:00 CRDT- 2022/03/10 17:14 PHST- 2022/03/11 06:00 [pubmed] PHST- 2022/05/28 06:00 [medline] PHST- 2022/03/10 17:14 [entrez] AID - 00001573-202205000-00013 [pii] AID - 10.1097/HCO.0000000000000959 [doi] PST - ppublish SO - Curr Opin Cardiol. 2022 May 1;37(3):294-301. doi: 10.1097/HCO.0000000000000959. Epub 2022 Mar 9. PMID- 35270971 OWN - NLM STAT- MEDLINE DCOM- 20221223 LR - 20230308 IS - 1424-8220 (Electronic) IS - 1424-8220 (Linking) VI - 22 IP - 5 DP - 2022 Feb 25 TI - Use of CIED Generated Heart Failure Risk Score (HFRS) Alerts in an Integrated, Multi-Disciplinary Approach to HF Management-A Prospective Cohort Study. LID - 10.3390/s22051825 [doi] LID - 1825 AB - Aim: To evaluate use of CIED-generated Heart Failure Risk Score (HFRS) alerts in an integrated, multi-disciplinary approach to HF management. Methods: We undertook a prospective, single centre outcome study of patients implanted with an HFRS-enabled Medtronic CIED, generating a "high risk" alert between November 2018 and November 2020. All patients generating a "high risk" HFRS alert were managed within an integrated HF pathway. Alerts were shared with local HF teams, prompting patient contact and appropriate intervention. Outcome data on health care utilisation (HCU) and mortality were collected. A validated questionnaire was completed by the HF teams to obtain feedback. Results: 367 "High risk" alerts were noted in 188 patients. The mean patient age was 70 and 49% had a Charlson Comorbidity Score of >6. Mean number of alerts per patients was 1.95 and 44 (23%) of patients had >3 "high risk" alerts in the follow up period. Overall, 75 (39%) patients were hospitalised in the 4-6-week period of the alert; 53 (28%) were unplanned of which 24 (13%) were for decompensated HF. A total of 33 (18%) patients died in the study period. Having three or more alerts significantly increased the risk of hospitalisation for heart failure (HR 2.5, CI 1.1-5.6 p = 0.03). The feedback on the pathway was positive. Conclusions: Patients with "high risk" alerts are co-morbid and have significant HCU. An integrated approach can facilitate timely risk stratification and intervention. Intervention in these patients is not limited to HF alone and provides the opportunity for holistic management of this complex cohort. FAU - Garner, Daniel AU - Garner D AD - Liverpool Heart and Chest Hospital, Thomas Drive, Liverpool L14 3PE, UK. FAU - Lunt, Lindsay AU - Lunt L AD - Liverpool Heart and Chest Hospital, Thomas Drive, Liverpool L14 3PE, UK. FAU - Leung, Wing AU - Leung W AD - Liverpool Heart and Chest Hospital, Thomas Drive, Liverpool L14 3PE, UK. FAU - Llewellyn, Jennifer AU - Llewellyn J AD - Liverpool Heart and Chest Hospital, Thomas Drive, Liverpool L14 3PE, UK. FAU - Kahn, Matthew AU - Kahn M AUID- ORCID: 0000-0002-6259-5180 AD - Liverpool Heart and Chest Hospital, Thomas Drive, Liverpool L14 3PE, UK. FAU - Wright, David Jay AU - Wright DJ AUID- ORCID: 0000-0002-5783-6648 AD - Liverpool Heart and Chest Hospital, Thomas Drive, Liverpool L14 3PE, UK. FAU - Rao, Archana AU - Rao A AUID- ORCID: 0000-0002-3893-3944 AD - Liverpool Heart and Chest Hospital, Thomas Drive, Liverpool L14 3PE, UK. LA - eng PT - Journal Article DEP - 20220225 PL - Switzerland TA - Sensors (Basel) JT - Sensors (Basel, Switzerland) JID - 101204366 SB - IM MH - Humans MH - Cohort Studies MH - *Heart Failure/therapy MH - Prospective Studies MH - Risk Factors PMC - PMC8914972 OTO - NOTNLM OT - device diagnostics OT - heart failure risk OT - integrated care OT - outcomes COIS- Garner, Lunt, Leung and Llewellyn have no conflict of interest to declare. Wright has received fees from Medtronic and Boston Scientific for educational activities, grants and consultancy work. Rao and Kahn have received honoraria from Medtronic for training and educational activity. EDAT- 2022/03/11 06:00 MHDA- 2022/03/15 06:00 PMCR- 2022/02/25 CRDT- 2022/03/10 15:42 PHST- 2022/01/28 00:00 [received] PHST- 2022/02/22 00:00 [revised] PHST- 2022/02/23 00:00 [accepted] PHST- 2022/03/10 15:42 [entrez] PHST- 2022/03/11 06:00 [pubmed] PHST- 2022/03/15 06:00 [medline] PHST- 2022/02/25 00:00 [pmc-release] AID - s22051825 [pii] AID - sensors-22-01825 [pii] AID - 10.3390/s22051825 [doi] PST - epublish SO - Sensors (Basel). 2022 Feb 25;22(5):1825. doi: 10.3390/s22051825. PMID- 35263428 OWN - NLM STAT- MEDLINE DCOM- 20220517 LR - 20220610 IS - 1935-5548 (Electronic) IS - 0149-5992 (Linking) VI - 45 IP - 5 DP - 2022 May 1 TI - Association Between Team-Based Continuity of Care and Risk of Cardiovascular Diseases Among Patients With Diabetes: A Retrospective Cohort Study. PG - 1162-1169 LID - 10.2337/dc21-1217 [doi] AB - OBJECTIVE: Cardiovascular diseases (CVD) are a long-term sequela of diabetes. Better individual-based continuity of care has been reported to reduce the risk of chronic complications among patients with diabetes. Maintaining a one-to-one patient-physician relationship is often challenging, especially in public health care settings. This study aimed to evaluate the relationship between higher team-based continuity of care, defined as consultations provided by the same physician team, and CVD risks in patients with diabetes from public primary care clinics. RESEARCH DESIGN AND METHODS: This was a retrospective cohort study in Hong Kong of 312,068 patients with type 2 diabetes and without any history of CVD at baseline (defined as the earliest attendance at a doctor's consultation in a public-sector clinic between 2008 and 2018). Team-based continuity of care was measured using the usual provider continuity index (UPCI), calculated by the proportion of consultations provided by the most visited physician team in the 2 years before baseline. Patients were divided into quartiles based on their UPCI, and the characteristics of the quartiles were balanced using propensity score fine stratification weights. Multivariable Cox regression was applied to assess the effect of team-based continuity of care on CVD incidence. Patient demographics, smoking status, physiological measurements, number of attendances, comorbidities, and medications were adjusted for in the propensity weightings and regression analyses. RESULTS: After an average follow-up of 6.5 years, the total number of new CVD events was 52,428. Compared with patients in the 1st quartile, patients in the 2nd, 3rd, and 4th quartiles of the UCPI had a CVD hazard ratio (95% CI) of 0.95 (0.92-0.97), 0.92 (0.89-0.94), and 0.87 (0.84-0.89), respectively, indicating that higher continuity of care was associated with lower CVD risks. The subtypes of CVD, including coronary heart disease and stroke, also showed a similar pattern. Subgroup analyses suggested that patients <65 years of age had greater benefits from higher team-based continuity of care. CONCLUSIONS: Team-based continuity of care was associated with lower CVD risk among individuals with type 2 diabetes, especially those who were younger. This suggests a potential flexible alternative implementation of continuity of care in public clinics. CI - (c) 2022 by the American Diabetes Association. FAU - Chan, Kam Suen AU - Chan KS AD - Department of Family Medicine and Primary Care, The University of Hong Kong, Hong Kong Special Administrative Region, China. FAU - Wan, Eric Yuk Fai AU - Wan EYF AUID- ORCID: 0000-0002-6275-1147 AD - Department of Family Medicine and Primary Care, The University of Hong Kong, Hong Kong Special Administrative Region, China. AD - Department of Pharmacology and Pharmacy, The University of Hong Kong, Hong Kong Special Administrative Region, China. AD - Laboratory of Data Discovery for Health (D24H), Hong Kong Special Administrative Region, China. FAU - Chin, Weng Yee AU - Chin WY AD - Department of Family Medicine and Primary Care, The University of Hong Kong, Hong Kong Special Administrative Region, China. FAU - Yu, Esther Yee Tak AU - Yu EYT AD - Department of Family Medicine and Primary Care, The University of Hong Kong, Hong Kong Special Administrative Region, China. FAU - Mak, Ivy Lynn AU - Mak IL AD - Department of Family Medicine and Primary Care, The University of Hong Kong, Hong Kong Special Administrative Region, China. FAU - Cheng, Will Ho Gi AU - Cheng WHG AD - Department of Family Medicine and Primary Care, The University of Hong Kong, Hong Kong Special Administrative Region, China. FAU - Ho, Margaret Kay AU - Ho MK AD - Department of Family Medicine and Primary Care, The University of Hong Kong, Hong Kong Special Administrative Region, China. FAU - Lam, Cindy Lo Kuen AU - Lam CLK AD - Department of Family Medicine and Primary Care, The University of Hong Kong, Hong Kong Special Administrative Region, China. LA - eng SI - figshare/10.2337/figshare.19165346 PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Diabetes Care JT - Diabetes care JID - 7805975 SB - IM MH - *Cardiovascular Diseases/complications/epidemiology/therapy MH - Continuity of Patient Care MH - *Diabetes Mellitus, Type 2/complications/epidemiology/therapy MH - Humans MH - Incidence MH - Retrospective Studies MH - Risk Factors EDAT- 2022/03/10 06:00 MHDA- 2022/05/18 06:00 CRDT- 2022/03/09 17:12 PHST- 2021/06/10 00:00 [received] PHST- 2022/02/05 00:00 [accepted] PHST- 2022/03/10 06:00 [pubmed] PHST- 2022/05/18 06:00 [medline] PHST- 2022/03/09 17:12 [entrez] AID - 144698 [pii] AID - 10.2337/dc21-1217 [doi] PST - ppublish SO - Diabetes Care. 2022 May 1;45(5):1162-1169. doi: 10.2337/dc21-1217. PMID- 35253018 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220812 VI - 2021 DP - 2021 May TI - Towards an AI Coach to Infer Team Mental Model Alignment in Healthcare. PG - 39-44 LID - 10.1109/cogsima51574.2021.9475925 [doi] AB - Shared mental models are critical to team success; however, in practice, team members may have misaligned models due to a variety of factors. In safety-critical domains (e.g., aviation, healthcare), lack of shared mental models can lead to preventable errors and harm. Towards the goal of mitigating such preventable errors, here, we present a Bayesian approach to infer misalignment in team members' mental models during complex healthcare task execution. As an exemplary application, we demonstrate our approach using two simulated team-based scenarios, derived from actual teamwork in cardiac surgery. In these simulated experiments, our approach inferred model misalignment with over 75% recall, thereby providing a building block for enabling computer-assisted interventions to augment human cognition in the operating room and improve teamwork. FAU - Seo, Sangwon AU - Seo S AD - Department of Computer Science, Rice University, Houston, TX, USA. FAU - Kennedy-Metz, Lauren R AU - Kennedy-Metz LR AD - Harvard Medical School and U.S. Dept. of Veterans Affairs, Boston, MA, USA. FAU - Zenati, Marco A AU - Zenati MA AD - Harvard Medical School and U.S. Dept. of Veterans Affairs, Boston, MA, USA. FAU - Shah, Julie A AU - Shah JA AD - Massachusetts Institute of Technology, Cambridge, MA, USA. FAU - Dias, Roger D AU - Dias RD AD - Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. FAU - Unhelkar, Vaibhav V AU - Unhelkar VV AD - Department of Computer Science, Rice University, Houston, TX, USA. LA - eng GR - R01 HL126896/HL/NHLBI NIH HHS/United States PT - Journal Article DEP - 20210709 PL - United States TA - IEEE Conf Cogn Comput Asp Situat Manag JT - IEEE Conference on Cognitive and Computational Aspects of Situation Management (CogSIMA) JID - 9918451688906676 PMC - PMC8893011 MID - NIHMS1781319 OTO - NOTNLM OT - Bayesian inference OT - artificial intelligence OT - cardiac surgery OT - patient safety OT - surgical data science OT - teamwork EDAT- 2022/03/08 06:00 MHDA- 2022/03/08 06:01 PMCR- 2022/03/03 CRDT- 2022/03/07 06:11 PHST- 2022/03/07 06:11 [entrez] PHST- 2022/03/08 06:00 [pubmed] PHST- 2022/03/08 06:01 [medline] PHST- 2022/03/03 00:00 [pmc-release] AID - 10.1109/cogsima51574.2021.9475925 [doi] PST - ppublish SO - IEEE Conf Cogn Comput Asp Situat Manag. 2021 May;2021:39-44. doi: 10.1109/cogsima51574.2021.9475925. Epub 2021 Jul 9. PMID- 35252467 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220502 IS - 2328-8957 (Print) IS - 2328-8957 (Electronic) IS - 2328-8957 (Linking) VI - 9 IP - 3 DP - 2022 Mar TI - Creation of a Multidisciplinary Drug Use Endocarditis Treatment (DUET) Team: Initial Patient Characteristics, Outcomes, and Future Directions. PG - ofac047 LID - 10.1093/ofid/ofac047 [doi] LID - ofac047 AB - BACKGROUND: Consensus guidelines recommend multidisciplinary models to manage infective endocarditis, yet often do not address the unique challenges of treating people with drug use-associated infective endocarditis (DUA-IE). Our center is among the first to convene a Drug Use Endocarditis Treatment (DUET) team composed of specialists from Infectious Disease, Cardiothoracic Surgery, Cardiology, and Addiction Medicine. METHODS: The objective of this study was to describe the demographics, infectious characteristics, and clinical outcomes of the first cohort of patients cared for by the DUET team. This was a retrospective chart review of patients referred to the DUET team between August 2018 and May 2020 with DUA-IE. RESULTS: Fifty-seven patients were presented to the DUET team between August 2018 and May 2020. The cohort was young, with a median age of 35, and injected primarily opioids (82.5% heroin/fentanyl), cocaine (52.6%), and methamphetamine (15.8%). Overall, 14 individuals (24.6%) received cardiac surgery, and the remainder (75.4%) were managed with antimicrobial therapy alone. Nearly 65% of individuals were discharged on medication for opioid use disorder, though less than half (36.8%) were discharged with naloxone and only 1 patient was initiated on HIV pre-exposure prophylaxis. Overall, the cohort had a high rate of readmission (42.1%) within 90 days of discharge. CONCLUSIONS: Multidisciplinary care models such as the DUET team can help integrate nuanced decision-making from numerous subspecialties. They can also increase the uptake of addiction medicine and harm reduction tools, but further efforts are needed to integrate harm reduction strategies and improve follow-up in future iterations of the DUET team model. CI - (c) The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. FAU - Vyas, Darshali A AU - Vyas DA AD - Massachusetts General Hospital, Boston, Massachusetts, USA. AD - Harvard Medical School, Boston, Massachusetts, USA. AD - Division of General Medicine, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA. FAU - Marinacci, Lucas AU - Marinacci L AD - Harvard Medical School, Boston, Massachusetts, USA. AD - Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA. FAU - Bearnot, Benjamin AU - Bearnot B AD - Massachusetts General Hospital, Boston, Massachusetts, USA. AD - Harvard Medical School, Boston, Massachusetts, USA. AD - Division of General Medicine, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA. FAU - Wakeman, Sarah E AU - Wakeman SE AD - Massachusetts General Hospital, Boston, Massachusetts, USA. AD - Harvard Medical School, Boston, Massachusetts, USA. AD - Division of General Medicine, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA. FAU - Sundt, Thoralf M AU - Sundt TM AD - Massachusetts General Hospital, Boston, Massachusetts, USA. AD - Harvard Medical School, Boston, Massachusetts, USA. AD - Division of Cardiac Surgery, Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts, USA. AD - Corrigan Minehan Heart Center, Massachusetts General Hospital, Boston, Massachusetts, USA. FAU - Jassar, Arminder S AU - Jassar AS AD - Massachusetts General Hospital, Boston, Massachusetts, USA. AD - Harvard Medical School, Boston, Massachusetts, USA. AD - Division of Cardiac Surgery, Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts, USA. AD - Corrigan Minehan Heart Center, Massachusetts General Hospital, Boston, Massachusetts, USA. FAU - Triant, Virginia A AU - Triant VA AD - Massachusetts General Hospital, Boston, Massachusetts, USA. AD - Harvard Medical School, Boston, Massachusetts, USA. AD - Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA. AD - Division of General Medicine, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA. FAU - Nelson, Sandra B AU - Nelson SB AD - Massachusetts General Hospital, Boston, Massachusetts, USA. AD - Harvard Medical School, Boston, Massachusetts, USA. AD - Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA. FAU - Dudzinski, David M AU - Dudzinski DM AD - Massachusetts General Hospital, Boston, Massachusetts, USA. AD - Harvard Medical School, Boston, Massachusetts, USA. AD - Corrigan Minehan Heart Center, Massachusetts General Hospital, Boston, Massachusetts, USA. AD - Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA. FAU - Paras, Molly L AU - Paras ML AD - Massachusetts General Hospital, Boston, Massachusetts, USA. AD - Harvard Medical School, Boston, Massachusetts, USA. AD - Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA. LA - eng GR - R01 AG062393/AG/NIA NIH HHS/United States GR - R01 HL132786/HL/NHLBI NIH HHS/United States PT - Journal Article DEP - 20220302 PL - United States TA - Open Forum Infect Dis JT - Open forum infectious diseases JID - 101637045 PMC - PMC8890495 OTO - NOTNLM OT - drug use OT - endocarditis OT - multidisciplinary team OT - substance use EDAT- 2022/03/08 06:00 MHDA- 2022/03/08 06:01 PMCR- 2022/03/02 CRDT- 2022/03/07 06:08 PHST- 2021/11/01 00:00 [received] PHST- 2022/01/30 00:00 [accepted] PHST- 2022/03/07 06:08 [entrez] PHST- 2022/03/08 06:00 [pubmed] PHST- 2022/03/08 06:01 [medline] PHST- 2022/03/02 00:00 [pmc-release] AID - ofac047 [pii] AID - 10.1093/ofid/ofac047 [doi] PST - epublish SO - Open Forum Infect Dis. 2022 Mar 2;9(3):ofac047. doi: 10.1093/ofid/ofac047. eCollection 2022 Mar. PMID- 35251673 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220502 IS - 2054-3581 (Print) IS - 2054-3581 (Electronic) IS - 2054-3581 (Linking) VI - 9 DP - 2022 TI - A Unique Multi- and Interdisciplinary Cardiology-Renal-Endocrine Clinic: A Description and Assessment of Outcomes. PG - 20543581221081207 LID - 10.1177/20543581221081207 [doi] LID - 20543581221081207 AB - BACKGROUND: Patients with diabetes and co-existing chronic kidney disease and/or cardiovascular disease have complex medical needs with multiple indications for different guideline-directed medical therapies and require high health care resource utilization. The Cardiac and Renal Endocrine Clinic (C.a.R.E. Clinic) is a multi- and interdisciplinary clinic offering a unique care model to this population to overcome barriers to optimal care. OBJECTIVE: To describe the patient characteristics and clinical data of consecutive patients seen in the C.a.R.E. Clinic between 2014 and 2020, with a focus on the feasibility, strengths, and challenges of this outpatient care model. DESIGN: Single-center retrospective cohort study. SETTING: The C.a.R.E. Clinic is a multi- and interdisciplinary clinic at Toronto General Hospital in Toronto, Canada. PATIENTS: We reviewed the charts of all 118 patients who had been referred to the C.a.R.E. Clinic with type 2 diabetes mellitus, co-existing renal disease, and/or cardiovascular disease. MEASUREMENTS: Demographic data, medication data, clinic blood pressure measurements, and laboratory data were assessed at the first and last available clinic visit. METHODS: Data were extracted via manual chart review of paper and electronic medical records. RESULTS: First and last attended clinic visit data were available for descriptive analysis in 74 patients. There was a significant improvement in low-density lipoprotein (LDL) cholesterol (1.9 mmol/L vs 1.5 mmol/L, P < .01), hemoglobin A1C (7.5% vs 7.1%, P = .02), and the proportion of patients with blood pressure at target (52.7% vs 36.5%, P = .04), but not body mass index (29.7 kg/m(2) vs 29.6 kg/m(2), P = .15) between the last and first available clinic visits. There was higher uptake in evidence-based medication use including statins (93.2% vs 81.1%, P = .01), SGLT-2i (35.1% vs 4.1%, P < .01), and GLP-1 receptor agonists (13.5% vs 4.1%, P = .02), while RAAS inhibitor use was already high at baseline (81.8% vs 78.4%, P = .56). There remains a significant opportunity for therapy with sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists. LIMITATIONS: This is a retrospective chart review lacking a control group, therefore clinical improvements cannot be causally attributed to the clinic alone. New evidence and changes to guideline-recommended therapies also contributed to practice changes during this time period. CONCLUSIONS: A multi- and interdisciplinary clinic is a feasible and potentially effective way to improve evidence-based and patient-centered care for patients with diabetes, kidney, and cardiovascular disease. CI - (c) The Author(s) 2022. FAU - Dubrofsky, Lisa AU - Dubrofsky L AUID- ORCID: 0000-0002-6995-2064 AD - Division of Nephrology, Department of Medicine, Toronto General Hospital, University Health Network, University of Toronto, ON, Canada. FAU - Lee, Jason F AU - Lee JF AD - Division of Nephrology, Department of Medicine, Toronto General Hospital, University Health Network, University of Toronto, ON, Canada. FAU - Hajimirzarahimshirazi, Parisa AU - Hajimirzarahimshirazi P AD - Division of Cardiology, Department of Medicine, Women's College Hospital, University of Toronto, ON, Canada. FAU - Liu, Hongyan AU - Liu H AD - Division of Nephrology, Department of Medicine, Toronto General Hospital, University Health Network, University of Toronto, ON, Canada. FAU - Weisman, Alanna AU - Weisman A AD - Division of Endocrinology & Metabolism, Department of Medicine, University of Toronto, ON, Canada. FAU - Lawler, Patrick R AU - Lawler PR AD - Ted Rogers Centre for Heart Research, University of Toronto, ON, Canada. AD - Peter Munk Cardiac Centre, University Health Network, University of Toronto, ON, Canada. AD - University of Toronto, ON, Canada. FAU - Farkouh, Michael E AU - Farkouh ME AD - Peter Munk Cardiac Centre, University Health Network, University of Toronto, ON, Canada. FAU - Udell, Jacob A AU - Udell JA AD - Division of Cardiology, Department of Medicine, Women's College Hospital, University of Toronto, ON, Canada. AD - Women's College Research Institute and Cardiovascular Division, Department of Medicine, Women's College Hospital, University of Toronto, ON, Canada. AD - Institute for Clinical Evaluative Sciences, Toronto, ON, Canada. FAU - Cherney, David Z AU - Cherney DZ AUID- ORCID: 0000-0003-4164-0429 AD - Division of Nephrology, Department of Medicine, Toronto General Hospital, University Health Network, University of Toronto, ON, Canada. LA - eng PT - Journal Article DEP - 20220228 PL - England TA - Can J Kidney Health Dis JT - Canadian journal of kidney health and disease JID - 101640242 PMC - PMC8891862 OTO - NOTNLM OT - cardiovascular disease OT - chronic kidney disease OT - diabetes OT - interdisciplinary OT - multidisciplinary COIS- Declaration of Conflicting Interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: D.Z.C. has received honoraria from Boehringer Ingelheim-Lilly, Merck, AstraZeneca, Sanofi, Mitsubishi-Tanabe, Abbvie, Janssen, Bayer, Prometic, BMS, Maze, CSL-Behring, and Novo-Nordisk and has received operational funding for clinical trials from Boehringer Ingelheim-Lilly, Merck, Janssen, Sanofi, AstraZeneca, and Novo-Nordisk. J.A.U. has received speaker/consulting honoraria from Amgen, Boehringer Ingelheim, Janssen, Merck, Novartis, and Sanofi and has received grant support to his institutions from AstraZeneca, Bayer, Boehringer Ingelheim, Janssen, Novartis, and Sanofi. M.F. has received research grant support from Amgen, Novartis, and Novo-Nordisk. The other authors report no disclosures. EDAT- 2022/03/08 06:00 MHDA- 2022/03/08 06:01 PMCR- 2022/02/28 CRDT- 2022/03/07 06:05 PHST- 2021/11/01 00:00 [received] PHST- 2022/01/11 00:00 [accepted] PHST- 2022/03/07 06:05 [entrez] PHST- 2022/03/08 06:00 [pubmed] PHST- 2022/03/08 06:01 [medline] PHST- 2022/02/28 00:00 [pmc-release] AID - 10.1177_20543581221081207 [pii] AID - 10.1177/20543581221081207 [doi] PST - epublish SO - Can J Kidney Health Dis. 2022 Feb 28;9:20543581221081207. doi: 10.1177/20543581221081207. eCollection 2022. PMID- 35246453 OWN - NLM STAT- MEDLINE DCOM- 20221121 LR - 20221212 IS - 1468-2044 (Electronic) IS - 0003-9888 (Print) IS - 0003-9888 (Linking) VI - 107 IP - 12 DP - 2022 Dec TI - Noonan syndrome: improving recognition and diagnosis. PG - 1073-1078 LID - 10.1136/archdischild-2021-322858 [doi] AB - Noonan syndrome (NS) is a mostly dominantly inherited disorder affecting 1:1000 to 1:2500 live births. The phenotype varies in severity and can involve multiple organ systems over a patient's lifetime. Diagnosis is based on a combination of features, including typical facial features, short stature, skeletal abnormalities, presence of cardiac defects, mild developmental delay, cryptorchidism, lymphatic dysplasia and a family history of NS. The phenotype varies from oligosymptomatic adults without significant medical issues to severely affected neonates with life-threatening heart disease. Early, accurate diagnosis is important for individualised management and to optimise developmental and long-term outcomes, but mildly affected patients often go undiagnosed for both healthcare provider (HCP)-related and patient-related reasons. Lack of awareness of NS among HCPs means that some do not recognise the condition, particularly in mildly affected patients and families. Some families do not want to receive a diagnosis that medicalises a condition that may account for family traits (eg, distinctive facial features and short stature), particularly when a child's physical and cognitive development may be satisfactory. As for any condition with lifelong effects on multiple organ systems, a multidisciplinary approach provides the best care. It is proposed that increasing awareness of NS among non-specialist HCPs and other professionals could help direct a parent/carer to seek specialist advice and increase the number of NS diagnoses, with the potential to optimise lifelong patient outcomes. Non-specialists do not need to become experts in either diagnosis or treatment; however, early recognition of NS and referral to an appropriate specialist is important. CI - (c) Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Zenker, Martin AU - Zenker M AUID- ORCID: 0000-0003-1618-9269 AD - Institute of Human Genetics, University Hospital Magdeburg, Magdeburg, Germany martin.zenker@med.ovgu.de. FAU - Edouard, Thomas AU - Edouard T AD - Endocrine, Bone Diseases and Genetics Unit, Toulouse University Hospital, Toulouse, France. FAU - Blair, Joanne C AU - Blair JC AUID- ORCID: 0000-0003-3128-5574 AD - Department of Paediatric Endocrinology, Alder Hey Children's NHS Foundation Trust, Liverpool, UK. FAU - Cappa, Marco AU - Cappa M AD - Department of Endocrinology, Bambino Gesu Children's Hospital-Tor Vergata University, Rome, Italy. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20220304 PL - England TA - Arch Dis Child JT - Archives of disease in childhood JID - 0372434 SB - IM MH - Male MH - Humans MH - *Noonan Syndrome/diagnosis/genetics/therapy MH - Phenotype MH - *Heart Diseases PMC - PMC9685729 OTO - NOTNLM OT - endocrinology OT - genetics OT - syndrome COIS- Competing interests: The concept for this paper came about during discussions at an advisory board meeting organised and supported by Novo Nordisk Health Care, for which all attendees (JCB, MC, TE, MZ) received an honorarium. MZ has nothing further to disclose. TE passed his honorarium to the INSERM unit UMR 1043. He received research funding from Pfizer. JCB is a member of the Publication Steering Committee of a research study funded by Novo Nordisk Health Care and has received payment for this. She has received consultancy fees, honoraria and support to attend scientific meetings, also from Novo Nordisk Health Care. MC has had consultancy agreements with COR2ED, Merck Serono, Novo Nordisk Health Care, BlubirdBio and Ipsen. He has received honoraria for lectures from Novo Nordisk Health Care, Eli Lilly and Ipsen. EDAT- 2022/03/06 06:00 MHDA- 2022/11/22 06:00 PMCR- 2022/11/24 CRDT- 2022/03/05 05:28 PHST- 2021/07/14 00:00 [received] PHST- 2022/02/11 00:00 [accepted] PHST- 2022/03/06 06:00 [pubmed] PHST- 2022/11/22 06:00 [medline] PHST- 2022/03/05 05:28 [entrez] PHST- 2022/11/24 00:00 [pmc-release] AID - archdischild-2021-322858 [pii] AID - 10.1136/archdischild-2021-322858 [doi] PST - ppublish SO - Arch Dis Child. 2022 Dec;107(12):1073-1078. doi: 10.1136/archdischild-2021-322858. Epub 2022 Mar 4. PMID- 35246403 OWN - NLM STAT- MEDLINE DCOM- 20220712 LR - 20220712 IS - 1876-861X (Electronic) IS - 1876-861X (Linking) VI - 16 IP - 4 DP - 2022 Jul-Aug TI - Diagnostic concordance and discordance between angiography-based quantitative flow ratio and fractional flow reserve derived from computed tomography in complex coronary artery disease. PG - 336-342 LID - S1934-5925(22)00031-4 [pii] LID - 10.1016/j.jcct.2022.02.004 [doi] AB - BACKGROUND: Both quantitative flow ratio (QFR) and fractional flow reserve derived from computed tomography (FFR(CT)) have shown significant correlations with invasive wire-based fractional flow reserve. However, the correlation between QFR and FFR(CT) is not fully investigated in patients with complex coronary artery disease (CAD). The aim of this study is to investigate the correlation and agreement between QFR and FFR(CT) in patients with de novo three-vessel disease and/or left main CAD. METHODS: This is a post-hoc sub-analysis of the international, multicenter, and randomized SYNTAX III REVOLUTION trial, in which both invasive coronary angiography and coronary computed tomography angiography were prospectively obtained prior to the heart team discussion. QFR was performed in an independent core laboratory and compared with FFR(CT) analyzed by HeartFlow. The correlation and agreement between QFR and FFR(CT) were assessed per vessel. Furthermore, independent factors of diagnostic discordance between QFR and FFR(CT) were evaluated. RESULTS: Out of 223 patients, 40 patients were excluded from this analysis due to the unavailability of FFR(CT) and/or QFR, and a total of 469 vessels (183 patients) were analyzed. There was a strong correlation between QFR and FFR(CT) (R ​= ​0.759; p ​< ​0.001), and the Bland-Altman analysis demonstrated a mean difference of -0.005 and a standard deviation of 0.116. An independent predictor of diagnostic concordance between QFR and FFR(CT) was the lesion location in right coronary artery (RCA) (odds ratio 0.395; 95% confidence interval 0.174-0.894; P ​= ​0.026). CONCLUSION: In patients with complex CAD, QFR and FFR(CT) were strongly correlated. The location of the lesion in RCA was associated with the highest diagnostic concordance between QFR and FFR(CT). CI - Copyright (c) 2022 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Kawashima, Hideyuki AU - Kawashima H AD - Discipline of Cardiology, Saolta Group, Galway University Hospital, Health Service Executive and CORRIB Core Lab, National University of Ireland Galway (NUIG), Galway, Ireland; Department of Cardiology, Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands; Division of Cardiology, Department of Internal Medicine, Teikyo University Hospital, Tokyo, Japan. FAU - Kogame, Norihiro AU - Kogame N AD - Department of Cardiology, Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands. FAU - Ono, Masafumi AU - Ono M AD - Discipline of Cardiology, Saolta Group, Galway University Hospital, Health Service Executive and CORRIB Core Lab, National University of Ireland Galway (NUIG), Galway, Ireland; Department of Cardiology, Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands. FAU - Hara, Hironori AU - Hara H AD - Discipline of Cardiology, Saolta Group, Galway University Hospital, Health Service Executive and CORRIB Core Lab, National University of Ireland Galway (NUIG), Galway, Ireland; Department of Cardiology, Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands. FAU - Takahashi, Kuniaki AU - Takahashi K AD - Department of Cardiology, Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands. FAU - Reiber, Johan H C AU - Reiber JHC AD - Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands. FAU - Thomsen, Brian AU - Thomsen B AD - GE Healthcare, Milwaukee, WI, USA. FAU - de Winter, Robbert J AU - de Winter RJ AD - Department of Cardiology, Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands. FAU - Tanaka, Kaoru AU - Tanaka K AD - Universitair Ziekenhuis Brussel, VUB, Brussels, Belgium. FAU - La Meir, Mark AU - La Meir M AD - Universitair Ziekenhuis Brussel, VUB, Brussels, Belgium. FAU - de Mey, Johan AU - de Mey J AD - Universitair Ziekenhuis Brussel, VUB, Brussels, Belgium. FAU - Schneider, Ulrich AU - Schneider U AD - Jena University Hospital, Friedrich-Schiller-University of Jena, Jena, Germany. FAU - Doenst, Torsten AU - Doenst T AD - Jena University Hospital, Friedrich-Schiller-University of Jena, Jena, Germany. FAU - Teichgraber, Ulf AU - Teichgraber U AD - Jena University Hospital, Friedrich-Schiller-University of Jena, Jena, Germany. FAU - Wijns, William AU - Wijns W AD - Discipline of Cardiology, Saolta Group, Galway University Hospital, Health Service Executive and CORRIB Core Lab, National University of Ireland Galway (NUIG), Galway, Ireland; CURAM, The SFI Research Centre for Medical Devices, Galway, Ireland. FAU - Mushtaq, Saima AU - Mushtaq S AD - Centro Cardiologico Monzino, IRCCS, Milan, Italy. FAU - Pompilio, Giulio AU - Pompilio G AD - Centro Cardiologico Monzino, IRCCS, Milan, Italy; Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy. FAU - Bartorelli, Antonio L AU - Bartorelli AL AD - Centro Cardiologico Monzino, IRCCS, Milan, Italy; Department of Biomedical and Clinical Sciences "Luigi Sacco", University of Milan, Milan, Italy. FAU - Andreini, Daniele AU - Andreini D AD - Centro Cardiologico Monzino, IRCCS, Milan, Italy; Department of Clinical Sciences and Community Health, Cardiovascular Section, University of Milan, Milan, Italy. FAU - Serruys, Patrick W AU - Serruys PW AD - Discipline of Cardiology, Saolta Group, Galway University Hospital, Health Service Executive and CORRIB Core Lab, National University of Ireland Galway (NUIG), Galway, Ireland; CURAM, The SFI Research Centre for Medical Devices, Galway, Ireland; NHLI, Imperial College London, London, United Kingdom. Electronic address: patrick.w.j.c.serruys@gmail.com. FAU - Onuma, Yoshinobu AU - Onuma Y AD - Discipline of Cardiology, Saolta Group, Galway University Hospital, Health Service Executive and CORRIB Core Lab, National University of Ireland Galway (NUIG), Galway, Ireland; CURAM, The SFI Research Centre for Medical Devices, Galway, Ireland. LA - eng PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial DEP - 20220219 PL - United States TA - J Cardiovasc Comput Tomogr JT - Journal of cardiovascular computed tomography JID - 101308347 SB - IM CIN - J Cardiovasc Comput Tomogr. 2022 Jul-Aug;16(4):343-344. doi: 10.1016/j.jcct.2022.02.007. PMID: 35256296 MH - Computed Tomography Angiography MH - Coronary Angiography/methods MH - *Coronary Artery Disease/diagnostic imaging MH - *Coronary Stenosis/diagnosis MH - Coronary Vessels/diagnostic imaging MH - *Fractional Flow Reserve, Myocardial MH - Humans MH - Predictive Value of Tests MH - Severity of Illness Index OTO - NOTNLM OT - Coronary artery disease OT - Fractional flow reserve derived from computed tomography angiography OT - Multivessel disease OT - Quantitative flow ratio OT - SYNTAX score COIS- Declaration of competing interest Dr. Hara reports a grant for studying overseas from Japanese Circulation Society and a grant from Fukuda Foundation for Medical Technology, outside the submitted work. Brian Thomsen is an employee of GE Healthcare. Dr. Teichgraber reports grants from GE Healthcare, from null, outside the submitted work. Dr. Wijns reports grants and personal fees from MicroPort, outside the submitted work, and co-founder of Argonauts, an innovation facilitator. Dr. Serruys reports personal fees from SMT, Philips/Volcano, Xeltis, Novartis, and Merillife. All other authors have no conflict of interest to declare. EDAT- 2022/03/06 06:00 MHDA- 2022/07/14 06:00 CRDT- 2022/03/05 05:28 PHST- 2021/06/26 00:00 [received] PHST- 2022/01/28 00:00 [revised] PHST- 2022/02/09 00:00 [accepted] PHST- 2022/03/06 06:00 [pubmed] PHST- 2022/07/14 06:00 [medline] PHST- 2022/03/05 05:28 [entrez] AID - S1934-5925(22)00031-4 [pii] AID - 10.1016/j.jcct.2022.02.004 [doi] PST - ppublish SO - J Cardiovasc Comput Tomogr. 2022 Jul-Aug;16(4):336-342. doi: 10.1016/j.jcct.2022.02.004. Epub 2022 Feb 19. PMID- 35238818 OWN - NLM STAT- MEDLINE DCOM- 20220525 LR - 20230912 IS - 1535-2811 (Electronic) IS - 1535-2811 (Linking) VI - 21 IP - 2 DP - 2022 Jun 1 TI - Comparison of Pulmonary Emboli Management Between Pulmonary Emboli Response Team and the Conventional Method: The First Study From Iran. PG - 61-66 LID - 10.1097/HPC.0000000000000279 [doi] AB - BACKGROUND: We aimed to evaluate the effectiveness of the Pulmonary Embolism Response Team (PERT) for intermediate-high risk and high-risk pulmonary embolism (PE) patients. METHODS: This single-blind clinical trial was performed in 2019-2021, evaluating patients with intermediate-high risk and high risk of PE. Patients in the intervention group were managed by the PERT team, and treatment plans were implemented as soon as possible. Patients in the other group received conventional PE treatments based on the hospital protocols. We compared the primary outcome of short-term mortality between the 2 groups and secondary outcomes, including right ventricle indices, hospital length-of-stay, time to decision, 30-day and in-hospital bleeding. RESULTS: Data of 74 patients were analyzed. We found no significant differences between the 2 groups regarding short-term mortality (P = 0.642), bleeding, and other complications. However, the length-of-stay and time to decision were significantly lower in patients treated by the PERT team (P < 0.001 for both). Further evaluations revealed that patients in the intervention group had a more significant reduction in the right ventricle size and systolic pulmonary pressure compared with the control group (P = 0.015, P = 0.039, respectively). In addition, tricuspid annular plane systolic excursion and fractional area change increased more in the intervention group (P = 0.023, P = 0.016, respectively). CONCLUSIONS: The PERT team led to significantly less time to make decisions, and it was able to select patients for advanced treatments more appropriately. Due to these facts, patients treated by PERT had significantly lower hospitalization duration and better right ventricle indices compared to controls. CI - Copyright (c) 2022 Wolters Kluwer Health, Inc. All rights reserved. FAU - Mansouri, Mohammad Hadi AU - Mansouri MH AD - From the Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran. FAU - Esmaeili, Farid AU - Esmaeili F AD - From the Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran. FAU - Khosravi, Alireza AU - Khosravi A AD - From the Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran. FAU - Mansouri, Pejman AU - Mansouri P AD - Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran. FAU - Mirmohammadsadeghi, Mohsen AU - Mirmohammadsadeghi M AD - From the Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran. FAU - Dehghan, Hooman AU - Dehghan H AD - From the Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran. FAU - Jameie, Mana AU - Jameie M AD - Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran. FAU - Amirpour, Afshin AU - Amirpour A AD - From the Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran. FAU - Zavar, Reihaneh AU - Zavar R AD - From the Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran. LA - eng PT - Clinical Trial PT - Journal Article DEP - 20220302 PL - United States TA - Crit Pathw Cardiol JT - Critical pathways in cardiology JID - 101165286 SB - IM MH - Hemorrhage MH - Humans MH - Iran/epidemiology MH - *Patient Care Team MH - *Pulmonary Embolism/therapy MH - Single-Blind Method EDAT- 2022/03/04 06:00 MHDA- 2022/05/26 06:00 CRDT- 2022/03/03 12:17 PHST- 2022/03/04 06:00 [pubmed] PHST- 2022/05/26 06:00 [medline] PHST- 2022/03/03 12:17 [entrez] AID - 00132577-202206000-00001 [pii] AID - 10.1097/HPC.0000000000000279 [doi] PST - ppublish SO - Crit Pathw Cardiol. 2022 Jun 1;21(2):61-66. doi: 10.1097/HPC.0000000000000279. Epub 2022 Mar 2. PMID- 35238709 OWN - NLM STAT- MEDLINE DCOM- 20220425 LR - 20220425 IS - 2150-136X (Electronic) IS - 2150-1351 (Linking) VI - 13 IP - 2 DP - 2022 Mar TI - Impact of a Multidisciplinary Research Team Approach to Prevent Avoidable Mistakes for Neonatal CPB Population. PG - 220-230 LID - 10.1177/21501351211064182 [doi] AB - Significant progress has been made in neonatal cardiopulmonary bypass (CPB) over the years. At Penn State Health Children's Hospital, we have established a multidisciplinary research team that brings clinicians, engineers, scientists, research nurses, neuromonitoring technicians, perfusionists, and students from various departments to help reduce adverse outcomes following CPB in neonates. With the help of this team, we evaluate each CPB component in simulated conditions identical to those used in clinical practice. The objective of this review is to demonstrate the results of these translational projects and present critical mistakes to avoid for neonatal CPB patients. FAU - Patel, Krishna AU - Patel K AUID- ORCID: 0000-0002-5466-7711 AD - 12310Penn State Health Children's Hospital, Hershey, PA, USA. FAU - Undar, Akif AU - Undar A AD - 12310Penn State Health Children's Hospital, Hershey, PA, USA. LA - eng PT - Journal Article PT - Review PL - United States TA - World J Pediatr Congenit Heart Surg JT - World journal for pediatric & congenital heart surgery JID - 101518415 SB - IM MH - *Cardiopulmonary Bypass/adverse effects MH - Child MH - Humans MH - Infant, Newborn MH - *Interdisciplinary Research OTO - NOTNLM OT - CPB OT - congenital heart surgery OT - multidisciplinary research team OT - neonates OT - translational research EDAT- 2022/03/04 06:00 MHDA- 2022/04/26 06:00 CRDT- 2022/03/03 12:16 PHST- 2022/03/03 12:16 [entrez] PHST- 2022/03/04 06:00 [pubmed] PHST- 2022/04/26 06:00 [medline] AID - 10.1177/21501351211064182 [doi] PST - ppublish SO - World J Pediatr Congenit Heart Surg. 2022 Mar;13(2):220-230. doi: 10.1177/21501351211064182. PMID- 35238062 OWN - NLM STAT- MEDLINE DCOM- 20220419 LR - 20220511 IS - 1097-0223 (Electronic) IS - 0197-3851 (Linking) VI - 42 IP - 4 DP - 2022 Apr TI - Prenatal diagnosis of congenital ventricular aneurysm and diverticulum: Prenatal features and perinatal management. PG - 428-434 LID - 10.1002/pd.6122 [doi] AB - Congenital ventricular diverticulum (VD) and aneurysm are rare cardiac developmental anomalies and their pathophysiology is still unclear. They present as an anomaly of the four chambers view, cardiomegaly, arrhythmia, pericardial effusion, or hydrops. They are usually isolated anomalies. Differential diagnosis between diverticulum and aneurysm is challenging during the prenatal period. Management policy is not uniform either conservative or repeated pericardial puncture. OBJECTIVE: We wanted to describe prenatal features and post-natal outcomes of fetal cardiac out pouching. METHODS: We retrospectively report 6 cases of VD and aneurysm prenatally managed in our fetal medicine unit between 2010 and 2020. All cases were evaluated from the first or second trimester of pregnancy until postnatal follow-up (3 months to 3 years). RESULTS: All six cases underwent a monthly ultrasound follow-up with spontaneous regression of pericardial effusion, and normal hemodynamics at birth No pericardial puncture was done and postnatal outcome was favorable in all cases. CONCLUSION: Based on our experience and on cases previously published, prenatal counseling should be prudent regarding the final diagnosis. Referral and monthly prenatal ultrasound follow-up, birth in a tertiary center after multidisciplinary evaluation and cardiological evaluation at birth still seem mandatory. CI - (c) 2022 John Wiley & Sons Ltd. FAU - Morin, Cecile AU - Morin C AUID- ORCID: 0000-0002-8557-3937 AD - Fetal Medicine Unit, Hopital Universitaire Robert Debre, APHP, Paris, France. FAU - Ponzio, Alice AU - Ponzio A AD - Fetal Medicine Unit, Hopital Universitaire Robert Debre, APHP, Paris, France. FAU - Guirgis, Maurice AU - Guirgis M AD - Pediatric Cardiology Unit, Hopital Universitaire Robert Debre, APHP, Paris, France. FAU - Benzouid, Cherine AU - Benzouid C AD - Pediatric Cardiology Unit, Hopital Universitaire Robert Debre, APHP, Paris, France. FAU - Beyler, Constance AU - Beyler C AD - Pediatric Cardiology Unit, Hopital Universitaire Robert Debre, APHP, Paris, France. FAU - Rosenblatt, Jonathan AU - Rosenblatt J AUID- ORCID: 0000-0001-8877-0381 AD - Fetal Medicine Unit, Hopital Universitaire Robert Debre, APHP, Paris, France. LA - eng PT - Journal Article DEP - 20220308 PL - England TA - Prenat Diagn JT - Prenatal diagnosis JID - 8106540 SB - IM MH - *Aneurysm MH - *Diverticulum/diagnostic imaging MH - Female MH - *Heart Defects, Congenital/diagnostic imaging MH - Humans MH - Infant, Newborn MH - *Pericardial Effusion MH - Pregnancy MH - Prenatal Diagnosis MH - Retrospective Studies MH - Ultrasonography, Prenatal EDAT- 2022/03/04 06:00 MHDA- 2022/04/20 06:00 CRDT- 2022/03/03 05:39 PHST- 2022/02/05 00:00 [revised] PHST- 2021/12/13 00:00 [received] PHST- 2022/02/14 00:00 [accepted] PHST- 2022/03/04 06:00 [pubmed] PHST- 2022/04/20 06:00 [medline] PHST- 2022/03/03 05:39 [entrez] AID - 10.1002/pd.6122 [doi] PST - ppublish SO - Prenat Diagn. 2022 Apr;42(4):428-434. doi: 10.1002/pd.6122. Epub 2022 Mar 8. PMID- 35237434 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220502 IS - 2049-9361 (Print) IS - 2049-937X (Electronic) IS - 2049-9361 (Linking) VI - 9 DP - 2022 Jan-Dec TI - Management of infective endocarditis in pregnancy by a multidisciplinary team: a case series. PG - 20499361221080644 LID - 10.1177/20499361221080644 [doi] LID - 20499361221080644 AB - INTRODUCTION: The incidence of infective endocarditis (IE) in pregnancy is rare and has been increasing during the opioid epidemic. IE in pregnancy is associated with high rates of maternal and fetal morbidity and mortality. Multidisciplinary endocarditis teams for management of IE have been shown to reduce in-hospital and 1-year mortality. We present a single-center experience managing IE in pregnancy utilizing a multidisciplinary endocarditis team. METHODS: Patients diagnosed with IE while pregnant or within 30 days post-partum were identified. All patients discussed at the institution's weekly multidisciplinary endocarditis meeting were included. Demographic and clinical data and outcome-related variables were retrospectively reviewed and recorded. RESULTS: Between 1 October 2020 and 1 June 2021 6 pregnant or 30-day post-partum patients with IE were identified. All patients had co-morbid injection drug use; Staphylococcus aureus was the etiologic pathogen in all patients. All patients had embolic complications and 5 required ICU admission and mechanical ventilatory support. Four patients underwent valve replacement. There were no patient-directed discharges. All patients survived to hospital discharge and 90-days after diagnosis. Four pregnancies resulted in delivery at an average gestational age of 32.4 weeks with 3 requiring NICU admissions and prolonged lengths of stay. All patients were seen by addiction medicine and 5 were started on medication-assisted treatment for opioid use disorder. DISCUSSION: In a small retrospective cases series, coordination of care by a multidisciplinary endocarditis team led to a high-rate of surgical intervention with no patient-directed discharges and no in-hospital or 90-day mortality. CONCLUSION: Multidisciplinary endocarditis teams are a low-risk intervention that may improve outcomes in pregnant patients with IE. CI - (c) The Author(s), 2022. FAU - Shapero, Kayle S AU - Shapero KS AD - Heart and Vascular Institute, Department of Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. FAU - Nauriyal, Varidhi AU - Nauriyal V AD - Division of Infectious Diseases, Department of Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. FAU - Megli, Christina AU - Megli C AD - Department of Obstetrics and Gynecology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. FAU - Berlacher, Kathryn AU - Berlacher K AD - Heart and Vascular Institute, Department of Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. FAU - El-Dalati, Sami AU - El-Dalati S AUID- ORCID: 0000-0003-2603-2951 AD - Division of Infectious Diseases, Department of Internal Medicine, University of Kentucky Medical Center, 3101 Beaumont Centre Circle, Lexington, KY 40513, USA. LA - eng PT - Journal Article DEP - 20220224 PL - England TA - Ther Adv Infect Dis JT - Therapeutic advances in infectious disease JID - 101606715 PMC - PMC8883368 OTO - NOTNLM OT - endocarditis OT - injection drug use OT - multidisciplinary team OT - pregnancy COIS- Conflict of interest statement: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2022/03/04 06:00 MHDA- 2022/03/04 06:01 PMCR- 2022/02/24 CRDT- 2022/03/03 05:35 PHST- 2021/10/12 00:00 [received] PHST- 2022/01/29 00:00 [accepted] PHST- 2022/03/03 05:35 [entrez] PHST- 2022/03/04 06:00 [pubmed] PHST- 2022/03/04 06:01 [medline] PHST- 2022/02/24 00:00 [pmc-release] AID - 10.1177_20499361221080644 [pii] AID - 10.1177/20499361221080644 [doi] PST - epublish SO - Ther Adv Infect Dis. 2022 Feb 24;9:20499361221080644. doi: 10.1177/20499361221080644. eCollection 2022 Jan-Dec. PMID- 35236185 OWN - NLM STAT- MEDLINE DCOM- 20230403 LR - 20230403 IS - 1477-111X (Electronic) IS - 0267-6591 (Linking) VI - 38 IP - 3 DP - 2023 Apr TI - Venovenous extracorporeal membrane oxygenation experience in a community level I trauma center. PG - 484-490 LID - 10.1177/02676591211059743 [doi] AB - BACKGROUND: There is limited literature of venovenous extracorporeal membrane oxygenation use in a community, non-university, setting in the trauma population. METHODS: We reviewed our cases over 2 years from March 2018 to March 2020. This study was conducted in a community hospital with a General Surgery residency with no direct affiliation to a medical school. Primary outcome reviewed was survival to discharge. Secondary outcomes included duration of extracorporeal membranous oxygenation (ECMO) support, blood transfusion requirement, complications, and disposition. RESULTS: Five patients were cannulated during this time period. All patients survived to discharge. Mean time on ECMO was 153.4 h or 6.4 days (range 60-216 h). All patients required a transfusion while cannulated, with a mean of 10 units PRBC transfused (range 3-24). One patient required CPR, one required cessation of heparin drip for bleeding, and one had clinical signs of a stroke. Three patients were discharged to long-term acute care facilities and the other two to acute rehab. CONCLUSIONS: Community level I trauma centers are capable of handling trauma patients requiring ECMO. It does require a multi-disciplinary team of surgical intensivists and cardiothoracic surgeons along with the support of nursing, respiratory therapists, and perfusionists. The outcomes in this limited series show that ECMO can be a tool utilized in the community setting. FAU - Neubauer, Steven AU - Neubauer S AD - Department of General Surgery, 22987Mercy St. Elizabeth Hospital, Youngstown, OH, USA. FAU - DelloStritto, Daniel J AU - DelloStritto DJ AUID- ORCID: 0000-0001-8495-5231 AD - Department of General Surgery, 22987Mercy St. Elizabeth Hospital, Youngstown, OH, USA. FAU - Capal, Nicholas AU - Capal N AD - Department of General Surgery, 22987Mercy St. Elizabeth Hospital, Youngstown, OH, USA. FAU - Hotrum, Andrew AU - Hotrum A AD - Department of General Surgery, 22987Mercy St. Elizabeth Hospital, Youngstown, OH, USA. FAU - Henn, Lucas AU - Henn L AD - Department of Cardiothoracic Surgery, 22987Mercy St. Elizabeth Hospital, Youngstown, OH, USA. FAU - Marchand, Tiffany AU - Marchand T AD - Department of Trauma Surgery, 22987Mercy St. Elizabeth Hospital, Youngstown, OH, USA. LA - eng PT - Journal Article DEP - 20220302 PL - England TA - Perfusion JT - Perfusion JID - 8700166 RN - 9005-49-6 (Heparin) SB - IM MH - Humans MH - *Extracorporeal Membrane Oxygenation/adverse effects MH - Hemorrhage/etiology MH - Heparin MH - Retrospective Studies MH - Trauma Centers OTO - NOTNLM OT - adult OT - community medicine OT - extracorporeal membrane oxygenation OT - respiratory distress syndrome OT - survival EDAT- 2022/03/04 06:00 MHDA- 2023/03/21 06:00 CRDT- 2022/03/03 05:30 PHST- 2022/03/04 06:00 [pubmed] PHST- 2023/03/21 06:00 [medline] PHST- 2022/03/03 05:30 [entrez] AID - 10.1177/02676591211059743 [doi] PST - ppublish SO - Perfusion. 2023 Apr;38(3):484-490. doi: 10.1177/02676591211059743. Epub 2022 Mar 2. PMID- 35235693 OWN - NLM STAT- MEDLINE DCOM- 20220407 LR - 20220407 IS - 1522-726X (Electronic) IS - 1522-1946 (Linking) VI - 99 IP - 3 DP - 2022 Feb TI - Characteristics and outcomes of elderly patients undergoing carotid stenting: Experience of a high-volume interventional cardiology center. PG - 853-859 LID - 10.1002/ccd.30002 [doi] AB - BACKGROUND: Carotid artery stenting (CAS) is an attractive option in order to treat carotid artery stenosis. However, its safety in elderly patients is questioned. Aim of this single-center retrospective study was to assess data of elderly patients undergoing CAS, and to compare them with those of the younger (< 75 years). METHODS: We collected data of 580 consecutive patients undergoing CAS between December 2007 and June 2020 and compared clinical and procedural characteristics as well as in-hospital major adverse events (MACCE) and long-term mortality between patients < 75 years and patients >/= 75 years old. RESULTS: There were 272 patients (46.9%) with age >/= 75 years and 308 patients (53.1%) with age < 75 years. The median follow-up was 48 months (range 2-144). There was no significant difference about in-hospital MACCE between the two groups (4.7% in the older vs. 3.5% in the younger group, p = 0.9), but a higher rate of cerebral hemorrhage occurred in the older group (1.8% vs. = 0.3%, p = 0.07), even if not significant. Long-term mortality was significantly higher in the older group (27.9 vs. 20.1%, p = 0.027). Multivariate predictors of 12-months mortality were neurologic symptoms within 6 months (OR: 4.83; 95% CI: 2.04-11.42; p /= 75 years (OR: 2.78; 95% CI: 1.14-6.76; p = 0.024). CONCLUSIONS: In elderly patients, CAS can be carried out efficaciously with acceptable procedural risks, if performed by expert operators and after a correct selection by a multidisciplinary team. CI - (c) 2021 Wiley Periodicals LLC. FAU - Varbella, Ferdinando AU - Varbella F AD - Interventional Cardiology Unit, Infermi Hospital, Rivoli, Italy. AD - San Luigi Gonzaga Hospital, Orbassano, Italy. AD - Department of Cardiology, Infermi Hospital, Rivoli, Italy. FAU - Cerrato, Enrico AU - Cerrato E AUID- ORCID: 0000-0002-1260-7534 AD - Interventional Cardiology Unit, Infermi Hospital, Rivoli, Italy. AD - San Luigi Gonzaga Hospital, Orbassano, Italy. AD - Department of Cardiology, San Luigi Gonzaga Hospital, Orbassano, Italy. FAU - Rolfo, Cristina AU - Rolfo C AD - Interventional Cardiology Unit, Infermi Hospital, Rivoli, Italy. AD - San Luigi Gonzaga Hospital, Orbassano, Italy. AD - Department of Cardiology, Infermi Hospital, Rivoli, Italy. FAU - Quadri, Giorgio AU - Quadri G AUID- ORCID: 0000-0003-4164-2758 AD - Interventional Cardiology Unit, Infermi Hospital, Rivoli, Italy. AD - San Luigi Gonzaga Hospital, Orbassano, Italy. AD - Department of Cardiology, Infermi Hospital, Rivoli, Italy. FAU - Franze, Alfonso AU - Franze A AD - Interventional Cardiology Unit, Infermi Hospital, Rivoli, Italy. AD - San Luigi Gonzaga Hospital, Orbassano, Italy. AD - Department of Cardiology, Infermi Hospital, Rivoli, Italy. FAU - Ferrari, Fabio AU - Ferrari F AD - Interventional Cardiology Unit, Infermi Hospital, Rivoli, Italy. AD - San Luigi Gonzaga Hospital, Orbassano, Italy. AD - Department of Cardiology, San Luigi Gonzaga Hospital, Orbassano, Italy. FAU - Mariani, Fabio AU - Mariani F AD - Interventional Cardiology Unit, Infermi Hospital, Rivoli, Italy. AD - San Luigi Gonzaga Hospital, Orbassano, Italy. AD - Department of Cardiology, San Luigi Gonzaga Hospital, Orbassano, Italy. FAU - Giacobbe, Federico AU - Giacobbe F AD - Department of Cardiology, San Luigi Gonzaga Hospital, Orbassano, Italy. FAU - Lo Savio, Luca AU - Lo Savio L AD - Department of Cardiology, Infermi Hospital, Rivoli, Italy. FAU - Giay Pron, Paolo AU - Giay Pron P AD - Department of Cardiology, Infermi Hospital, Rivoli, Italy. FAU - Amaru, Salvatore AU - Amaru S AD - Department of Neurology, Infermi Hospital, Rivoli, Italy. FAU - Tomassini, Francesco AU - Tomassini F AUID- ORCID: 0000-0002-0445-5489 AD - Interventional Cardiology Unit, Infermi Hospital, Rivoli, Italy. AD - San Luigi Gonzaga Hospital, Orbassano, Italy. AD - Department of Cardiology, Infermi Hospital, Rivoli, Italy. LA - eng PT - Journal Article DEP - 20211114 PL - United States TA - Catheter Cardiovasc Interv JT - Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions JID - 100884139 SB - IM CIN - Catheter Cardiovasc Interv. 2022 Feb;99(3):860. doi: 10.1002/ccd.30122. PMID: 35235688 MH - Aged MH - *Cardiology MH - *Carotid Stenosis/diagnostic imaging/etiology/therapy MH - *Endarterectomy, Carotid/adverse effects MH - Humans MH - Retrospective Studies MH - Risk Assessment MH - Risk Factors MH - Stents MH - *Stroke/etiology MH - Time Factors MH - Treatment Outcome OTO - NOTNLM OT - carotid revascularization OT - cerebrovascular diseases OT - peripheral artery disease EDAT- 2022/03/03 06:00 MHDA- 2022/04/08 06:00 CRDT- 2022/03/02 17:11 PHST- 2021/09/28 00:00 [revised] PHST- 2021/01/31 00:00 [received] PHST- 2021/10/17 00:00 [accepted] PHST- 2022/03/02 17:11 [entrez] PHST- 2022/03/03 06:00 [pubmed] PHST- 2022/04/08 06:00 [medline] AID - 10.1002/ccd.30002 [doi] PST - ppublish SO - Catheter Cardiovasc Interv. 2022 Feb;99(3):853-859. doi: 10.1002/ccd.30002. Epub 2021 Nov 14. PMID- 35235532 OWN - NLM STAT- MEDLINE DCOM- 20220509 LR - 20240717 IS - 1557-2501 (Electronic) IS - 1042-3931 (Linking) VI - 34 IP - 3 DP - 2022 Mar TI - Post-Endomyocardial Biopsy Fistula Between Left Anterior Descending Artery and Right Ventricle. PG - E251-E252 AB - The image in this vignette helps to illustrate a rare, albeit reported, complication of endomyocardial biopsy. The case was discussed by the heart team. Fistula occlusion with microcoils was considered; however, the patient was asymptomatic and presented no reduction of left ventricular ejection fraction, and the documented ischemia was minor. Therefore, the patient received conservative treatment. FAU - Kanhouche, Gabriel AU - Kanhouche G FAU - de Sa Marchi, Mauricio Felippi AU - de Sa Marchi MF FAU - Marchiori, Gilberto Guilherme Ajjar AU - Marchiori GGA FAU - Freire, Antonio Fernando D AU - Freire AFD FAU - Cunha Abizaid, Alexandre A AU - Cunha Abizaid AA AD - Heart Institute of Sao Paulo (InCor), University of Sao Paulo - Brazil, Av. Dr. En as de Carvalho Aguiar, 44 05403-900, Sao Paulo, SP, Brazil. aabizaid@uol.com.br. LA - eng PT - Journal Article PL - United States TA - J Invasive Cardiol JT - The Journal of invasive cardiology JID - 8917477 SB - IM MH - Arteries MH - Biopsy/adverse effects MH - *Coronary Disease MH - *Fistula/complications/etiology MH - *Heart Transplantation/adverse effects MH - Heart Ventricles/diagnostic imaging MH - Humans MH - Stroke Volume MH - Ventricular Function, Left OTO - NOTNLM OT - coronary fistula OT - endomyocardial biopsy EDAT- 2022/03/03 06:00 MHDA- 2022/05/10 06:00 CRDT- 2022/03/02 17:10 PHST- 2022/03/02 17:10 [entrez] PHST- 2022/03/03 06:00 [pubmed] PHST- 2022/05/10 06:00 [medline] AID - 10.25270/jic/21.00362 [doi] PST - ppublish SO - J Invasive Cardiol. 2022 Mar;34(3):E251-E252. doi: 10.25270/jic/21.00362. PMID- 35221078 OWN - NLM STAT- MEDLINE DCOM- 20220302 LR - 20240911 IS - 1877-9190 (Electronic) IS - 1877-9182 (Print) IS - 1877-9182 (Linking) VI - 14 IP - 1 DP - 2022 Mar TI - Prevalence, Outcomes, and Management of Ventricular Arrhythmias in COVID-19 Patients. PG - 11-20 LID - S1877-9182(21)00099-X [pii] LID - 10.1016/j.ccep.2021.10.002 [doi] AB - We review the current data on epidemiology, the clinical significance, the pathophysiologic mechanisms, and the treatment of VAs in the setting of COVID-19. VAs prevail in 0.15% to 8% of hospitalized patients, but only sustained and rapid tachyarrhythmias are purportedly associated with a significant increase in mortality. Multiple factors can elicit VAs, which are ultimately deemed to be a marker of severe systemic disease rather than a distinct cardiac condition. Even though the electrophysiologist plays a determinant role in the secondary prevention of VAs, a multidisciplinary approach is indispensable for primary prophylaxis and acute management. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - Tarantino, Nicola AU - Tarantino N AD - Montefiore Medical Center, 111 E 210th street, Bronx, NY 10467, USA. FAU - Della Rocca, Domenico G AU - Della Rocca DG AD - Texas Cardiac Arrhythmia Institute at St. David's Medical Center, 3000 N I-35, Suite 720, Austin, TX 78705, USA. FAU - Zou, Fengwei AU - Zou F AD - Montefiore Medical Center, 111 E 210th street, Bronx, NY 10467, USA. FAU - Lin, Aung AU - Lin A AD - Montefiore Medical Center, 111 E 210th street, Bronx, NY 10467, USA. FAU - Natale, Andrea AU - Natale A AD - Texas Cardiac Arrhythmia Institute at St. David's Medical Center, 3000 N I-35, Suite 720, Austin, TX 78705, USA; Scripps Interventional Car, 9834 Genesee Ave, La Jolla, CA 92037, USA; Health Education Campus, 9501 Euclid Ave, Cleveland, OH 44106, USA. FAU - Di Biase, Luigi AU - Di Biase L AD - Montefiore Medical Center, 111 E 210th street, Bronx, NY 10467, USA; Texas Cardiac Arrhythmia Institute at St. David's Medical Center, 3000 N I-35, Suite 720, Austin, TX 78705, USA. Electronic address: dibbia@gmail.com. LA - eng PT - Journal Article PT - Review DEP - 20211029 PL - United States TA - Card Electrophysiol Clin JT - Cardiac electrophysiology clinics JID - 101549998 SB - IM MH - Arrhythmias, Cardiac/epidemiology/therapy MH - *COVID-19/epidemiology MH - Humans MH - Prevalence MH - SARS-CoV-2 MH - Tachycardia PMC - PMC8554003 OTO - NOTNLM OT - Arrhythmias OT - COVID-19 OT - Complications OT - Management OT - Outcomes OT - SARS-CoV-2 OT - Ventricular tachycardia COIS- Disclosure Dr A. Natale has received speaker honoraria from Boston Scientific, Biosense Webster, St. Jude Medical, Biotronik, and Medtronic; and is a consultant for Biosense Webster, St. Jude Medical, and Janssen. Dr L. Di Biase is a consultant for Biosense Webster, RMG, Stereotaxis, Boston Scientific, and Abbott. Dr L. Di Biase received speaker honoraria/travel from Medtronic, Atricure, and Biotronik. All other authors have reported that they have no relationships relevant to the contents of this article to disclose. EDAT- 2022/03/01 06:00 MHDA- 2022/03/03 06:00 PMCR- 2021/10/29 CRDT- 2022/02/28 05:29 PHST- 2022/02/28 05:29 [entrez] PHST- 2022/03/01 06:00 [pubmed] PHST- 2022/03/03 06:00 [medline] PHST- 2021/10/29 00:00 [pmc-release] AID - S1877-9182(21)00099-X [pii] AID - 10.1016/j.ccep.2021.10.002 [doi] PST - ppublish SO - Card Electrophysiol Clin. 2022 Mar;14(1):11-20. doi: 10.1016/j.ccep.2021.10.002. Epub 2021 Oct 29. PMID- 35219517 OWN - NLM STAT- MEDLINE DCOM- 20230814 LR - 20231031 IS - 1097-685X (Electronic) IS - 0022-5223 (Linking) VI - 166 IP - 3 DP - 2023 Sep TI - Primary cardiac sarcomas: Treatment strategies. PG - 828-838.e2 LID - S0022-5223(22)00100-3 [pii] LID - 10.1016/j.jtcvs.2021.10.070 [doi] AB - OBJECTIVE: Our multidisciplinary cardiac tumor team now has an experience of operating on 122 cases of primary cardiac sarcoma over a 23-year period. The purpose of this study is to present our short- and long-term outcomes for cardiac sarcoma. METHODS: We performed a retrospective review of a prospectively collected Institutional Review Board-approved cardiac tumor database for cardiac sarcoma. Patient characteristics, surgical factors, and patient outcomes were analyzed. Perioperative data were collected from direct patient communication and all available medical records. The primary end point was all-cause mortality at 1, 3, and 5 years from the time of our surgery and 1, 3, and 5 years from the initial diagnosis. The secondary end point was all-cause mortality between the first and second halves of the study. RESULTS: From October 1998 to April 2021, we operated on 122 patients with a primary cardiac sarcoma. The mean age was 45.3 years old, and 52.5% were male. Tumors were most frequently found in the left atrium (40.2%) and right atrium (32.0%). The most common type of tumor histologically was an angiosarcoma (38.5%), followed by high-grade sarcoma (14.8%). Survival from initial diagnosis at 1, 3, and 5 years was 88.4%, 43.15%, and 27.8%, respectively. Survival from surgery at our institution at 1 and 3 years was 57.1% and 24.5%, respectively. When comparing outcomes from different time periods, we found no significant difference in survival between the previous era (1998-2011) and the current era (2011-2021). CONCLUSIONS: Management of these complex patients can show reasonable outcomes in centers with a multidisciplinary cardiac tumor team. Mortality has not improved with time and is likely related to the systemic nature of this disease. CI - Copyright (c) 2022 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved. FAU - Chan, Edward Y AU - Chan EY AD - Division of Thoracic Surgery, Department of Surgery, Houston Methodist Hospital, Houston, Tex. FAU - Ali, Areeba AU - Ali A AD - Department of Structural Heart and Interventional Cardiology, Houston Methodist Research Institute, Houston Methodist Hospital, Houston, Tex. FAU - Zubair, M Mujeeb AU - Zubair MM AD - Department of Cardiovascular Surgery, Houston Methodist Hospital, Houston, Tex. FAU - Nguyen, Duc T AU - Nguyen DT AD - Department of Pathology and Genomic Medicine, Houston Methodist Research Institute, Houston Methodist Hospital, Houston, Tex. FAU - Ibarra-Cortez, Sergio H AU - Ibarra-Cortez SH AD - Department of Structural Heart and Interventional Cardiology, Houston Methodist Research Institute, Houston Methodist Hospital, Houston, Tex. FAU - Graviss, Edward A AU - Graviss EA AD - Department of Pathology and Genomic Medicine, Houston Methodist Research Institute, Houston Methodist Hospital, Houston, Tex. FAU - Shapira, Oz M AU - Shapira OM AD - Department of Cardiothoracic Surgery, Hebrew University, Hadassa Medical Center, Jerusalem, Israel. FAU - Ravi, Vinod AU - Ravi V AD - Department of Sarcoma Medical Oncology, MD Anderson Cancer Center, Houston, Tex. FAU - MacGillivray, Thomas E AU - MacGillivray TE AD - Department of Cardiovascular Surgery, Houston Methodist Hospital, Houston, Tex. FAU - Reardon, Michael J AU - Reardon MJ AD - Department of Cardiovascular Surgery, Houston Methodist Hospital, Houston, Tex. Electronic address: mreardon@houstonmethodist.org. LA - eng PT - Journal Article DEP - 20220201 PL - United States TA - J Thorac Cardiovasc Surg JT - The Journal of thoracic and cardiovascular surgery JID - 0376343 SB - IM CIN - J Thorac Cardiovasc Surg. 2023 Sep;166(3):839-840. doi: 10.1016/j.jtcvs.2021.10.046. PMID: 34785073 CIN - J Thorac Cardiovasc Surg. 2023 Sep;166(3):840-841. doi: 10.1016/j.jtcvs.2021.11.010. PMID: 34862054 MH - Humans MH - Male MH - Middle Aged MH - Female MH - *Sarcoma/surgery MH - *Hemangiosarcoma MH - *Heart Neoplasms/surgery MH - Retrospective Studies MH - Time Factors OTO - NOTNLM OT - autotransplant OT - sarcoma OT - tumor EDAT- 2022/02/28 06:00 MHDA- 2023/08/14 06:43 CRDT- 2022/02/27 20:27 PHST- 2021/06/14 00:00 [received] PHST- 2021/09/28 00:00 [revised] PHST- 2021/10/13 00:00 [accepted] PHST- 2023/08/14 06:43 [medline] PHST- 2022/02/28 06:00 [pubmed] PHST- 2022/02/27 20:27 [entrez] AID - S0022-5223(22)00100-3 [pii] AID - 10.1016/j.jtcvs.2021.10.070 [doi] PST - ppublish SO - J Thorac Cardiovasc Surg. 2023 Sep;166(3):828-838.e2. doi: 10.1016/j.jtcvs.2021.10.070. Epub 2022 Feb 1. PMID- 35218243 OWN - NLM STAT- MEDLINE DCOM- 20220404 LR - 20220519 IS - 1540-8191 (Electronic) IS - 0886-0440 (Print) IS - 0886-0440 (Linking) VI - 37 IP - 5 DP - 2022 May TI - Outcomes of surgical treatment for active infective endocarditis under COVID-19 pandemic. PG - 1161-1167 LID - 10.1111/jocs.16280 [doi] AB - BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic has been and will continue to be a challenge to the healthcare system worldwide. In this context, we aimed to discuss the impact of the COVID-19 pandemic on the diagnosis, timing, and prognosis of surgical treatment for active infective endocarditis (IE) during the pandemic and share our coping strategy. METHODS: A total of 39 patients were admitted for active IE in the year 2020. The number of the same period last year was 50. Medical information of these two groups was extracted from our surgical database. Data were compared between the two groups and differences with or without statistical significance were discussed. RESULTS: In the pandemic year, we admitted fewer transferred patients (64.1% vs. 80%, p = .094). Timespan for diagnosis were prolonged (60 vs. 34.5 days, p = .081). More patients were admitted in emergency (41% vs. 20%, p = .030) More patients had heart failure (74.4% vs. 40%, p = .001), sepsis (69.2% vs. 42.0%, p = .018), or cardiogenic shock (25.6% vs. 8.0%, p = .038). Overall surgical risk (EuroSCORE II) was higher (4.15% vs. 3.24%, p = .019) and more commando surgery was performed (7.7% vs. 2.0%, p = .441). However, we did not see more postoperative complications, and early mortality was not worse either (0 vs. 4%, p = .502). CONCLUSIONS: The negative impact of the COVID-19 pandemic on the clinical practice of surgical treatment for active IE was multifaceted. However, with the preservation of the effectiveness of multidisciplinary IE surgical team, the early outcomes were comparable with those in the normal years. CI - (c) 2022 Wiley Periodicals LLC. FAU - Liu, XinPei AU - Liu X AD - Department of Cardiac Surgery, Peking Union Medical College Hospital, Dongcheng District, Beijing, China. FAU - Miao, Qi AU - Miao Q AUID- ORCID: 0000-0003-3370-9692 AD - Peking Union Medical College Hospital, Dongcheng District, Beijing, China. FAU - Liu, XingRong AU - Liu X AD - Department of Cardiac Surgery, Peking Union Medical College Hospital, Dongcheng District, Beijing, China. FAU - Zhang, ChaoJi AU - Zhang C AD - Department of Cardiac Surgery, Peking Union Medical College Hospital, Dongcheng District, Beijing, China. FAU - Ma, GuoTao AU - Ma G AD - Department of Cardiac Surgery, Peking Union Medical College Hospital, Dongcheng District, Beijing, China. FAU - Liu, JianZhou AU - Liu J AD - Department of Cardiac Surgery, Peking Union Medical College Hospital, Dongcheng District, Beijing, China. LA - eng GR - 2017-I2M-1-003/CAMS Innovation Fund for Medical Science (CIFMS)/ PT - Journal Article DEP - 20220225 PL - United States TA - J Card Surg JT - Journal of cardiac surgery JID - 8908809 SB - IM MH - *COVID-19 MH - *Endocarditis/surgery MH - *Endocarditis, Bacterial/surgery MH - Humans MH - Pandemics MH - Postoperative Complications/epidemiology MH - Retrospective Studies MH - Treatment Outcome PMC - PMC9115300 OTO - NOTNLM OT - COVID-19 OT - aortic valve OT - commando surgery OT - infective endocarditis OT - mitral valve COIS- The authors declare that there are no conflict of interests. EDAT- 2022/02/27 06:00 MHDA- 2022/04/05 06:00 PMCR- 2022/02/25 CRDT- 2022/02/26 08:35 PHST- 2021/08/13 00:00 [revised] PHST- 2021/02/25 00:00 [received] PHST- 2022/01/02 00:00 [accepted] PHST- 2022/02/27 06:00 [pubmed] PHST- 2022/04/05 06:00 [medline] PHST- 2022/02/26 08:35 [entrez] PHST- 2022/02/25 00:00 [pmc-release] AID - JOCS16280 [pii] AID - 10.1111/jocs.16280 [doi] PST - ppublish SO - J Card Surg. 2022 May;37(5):1161-1167. doi: 10.1111/jocs.16280. Epub 2022 Feb 25. PMID- 35216880 OWN - NLM STAT- MEDLINE DCOM- 20220427 LR - 20220427 IS - 1873-2364 (Electronic) IS - 0960-8966 (Linking) VI - 32 IP - 3 DP - 2022 Mar TI - Clinical profile and multidisciplinary needs of patients with neuromuscular disorders transitioning from paediatric to adult care. PG - 206-212 LID - S0960-8966(21)00735-5 [pii] LID - 10.1016/j.nmd.2021.12.002 [doi] AB - Transition in paediatric health care refers to the planned process of shifting to an adult model of care and is highly individualised, patient focussed and requires a coordinated effort from different health care professionals. Through this retrospective study, we describe the spectrum of neuromuscular diseases evaluated through a paediatric to adult neuromuscular transition program in a tertiary academic centre in Canada, and also the speciality supports needed for these patients. 126 patients were transitioned during the study period. The most common clinical diagnosis was muscle disease (44.4%), followed by neuropathy (27.8%), neuromuscular junction disorders (15.9%) and motor neuron disease (MND) (10.3%). The majority of cases were inherited neuromuscular disorders (66.6%); 58.3% had a genetically confirmed diagnosis. Cardiac and respiratory abnormalities were encountered in 8.7% and 27.7% and transitioning was required for 39.8% and 35.7% respectively. Scoliosis was seen in 30.2% of patients; 9.5% underwent spine surgery. Patients with MND had maximum requirements for self-care (46.2% of MND) and a mobility device for ambulation was required in 69.2% of MND. We observed a wide range of systemic issues requiring the services of endocrinology, gastroenterology, speech and language pathology and psychiatry. A multidisciplinary clinical care model may provide optimal care for patients transitioning from paediatric to adult care health systems. CI - Copyright (c) 2021 Elsevier B.V. All rights reserved. FAU - Menon, Deepak AU - Menon D AD - University Health Network, Division of Neurology, Toronto General Hospital, University Health Network, Division of Neurology, Toronto, Ontario, Canada. FAU - Gonorazky, Hernan D AU - Gonorazky HD AD - Hospital for Sick Children, Division of Neurology, Toronto, Ontario, Canada. FAU - Dowling, James J AU - Dowling JJ AD - Hospital for Sick Children, Division of Neurology, Toronto, Ontario, Canada. FAU - McAdam, Laura AU - McAdam L AD - Holland Bloorview Kids Rehabilitation Hospital, Toronto, Ontario, Canada. FAU - Ansari, Tasjeel AU - Ansari T AD - Women's College Hospital, University Health Network, Division of Neurology, Toronto, Ontario, Canada. FAU - Vajsar, Jiri AU - Vajsar J AD - Hospital for Sick Children, Division of Neurology, Toronto, Ontario, Canada. FAU - Yoon, Grace AU - Yoon G AD - Hospital for Sick Children, Division of Neurology, Toronto, Ontario, Canada. FAU - Bril, Vera AU - Bril V AD - University Health Network, Division of Neurology, Toronto General Hospital, University Health Network, Division of Neurology, Toronto, Ontario, Canada. FAU - Katzberg, Hans AU - Katzberg H AD - University Health Network, Division of Neurology, Toronto General Hospital, University Health Network, Division of Neurology, Toronto, Ontario, Canada. Electronic address: hans.katzberg@utoronto.ca. LA - eng PT - Journal Article DEP - 20211211 PL - England TA - Neuromuscul Disord JT - Neuromuscular disorders : NMD JID - 9111470 SB - IM MH - Adult MH - Child MH - Humans MH - *Motor Neuron Disease MH - *Neuromuscular Diseases/therapy MH - Retrospective Studies MH - *Scoliosis/therapy MH - *Transition to Adult Care OTO - NOTNLM OT - Muscle disease Multidisciplinary care OT - Neuromuscular diseases OT - Paediatric> OT - Transition in health care EDAT- 2022/02/27 06:00 MHDA- 2022/04/28 06:00 CRDT- 2022/02/26 05:32 PHST- 2020/11/17 00:00 [received] PHST- 2021/09/19 00:00 [revised] PHST- 2021/12/08 00:00 [accepted] PHST- 2022/02/27 06:00 [pubmed] PHST- 2022/04/28 06:00 [medline] PHST- 2022/02/26 05:32 [entrez] AID - S0960-8966(21)00735-5 [pii] AID - 10.1016/j.nmd.2021.12.002 [doi] PST - ppublish SO - Neuromuscul Disord. 2022 Mar;32(3):206-212. doi: 10.1016/j.nmd.2021.12.002. Epub 2021 Dec 11. PMID- 35192138 OWN - NLM STAT- MEDLINE DCOM- 20220429 LR - 20261010 IS - 1534-6277 (Electronic) IS - 1534-6277 (Linking) VI - 23 IP - 2 DP - 2022 Feb TI - Cardiotoxicity of Systemic Melanoma Treatments. PG - 240-253 LID - 10.1007/s11864-021-00924-2 [doi] AB - Melanoma is the least common but most dangerous skin cancer, accounting for 75% of all deaths from a primary cutaneous malignancy, with incidence rates rising significantly over the last decade. Traditional treatments for melanoma including interferon and cytotoxic chemotherapy had marginal efficacy. With the advent of targeted and immunotherapies, the prognosis for patients with advanced melanoma has significantly improved including those with metastatic disease to the heart. BRAF and MEK inhibitors as well as immune checkpoint inhibitors have become front line therapy for eligible patients with metastatic melanoma and have led to long-term durable response and in some cases can be curative. Despite these oncologic advances, various treatment-limiting side effects can occur. In particular, cardiovascular toxicities can contribute to overall morbidity and mortality in these patients. Toxicities range from asymptomatic QT prolongation and mild LV dysfunction to fulminant myocarditis and potentially life-threatening arrhythmias. A multidisciplinary approach to the care of these patients which includes cardio-oncology evaluation is necessary to develop both risk mitigation and treatment strategies to ensure patients continue receiving necessary and effective melanoma treatments while minimizing long-term adverse cardiovascular effects. CI - (c) 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Mukunda, Neha AU - Mukunda N AD - Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA. FAU - Vallabhaneni, Srilakshmi AU - Vallabhaneni S AD - Cardio-Oncology Center of Excellence, Division of Cardiovascular Medicine, Perelman School of Medicine at the University of Pennsylvania, 3400 Civic Center Blvd, Philadelphia, PA, 19104, USA. FAU - Lefebvre, Benedicte AU - Lefebvre B AD - Cardio-Oncology Center of Excellence, Division of Cardiovascular Medicine, Perelman School of Medicine at the University of Pennsylvania, 3400 Civic Center Blvd, Philadelphia, PA, 19104, USA. FAU - Fradley, Michael G AU - Fradley MG AUID- ORCID: 0000-0001-8352-8975 AD - Cardio-Oncology Center of Excellence, Division of Cardiovascular Medicine, Perelman School of Medicine at the University of Pennsylvania, 3400 Civic Center Blvd, Philadelphia, PA, 19104, USA. Michael.fradley@pennmedicine.upenn.edu. LA - eng PT - Journal Article PT - Review DEP - 20220222 PL - United States TA - Curr Treat Options Oncol JT - Current treatment options in oncology JID - 100900946 RN - 0 (Immune Checkpoint Inhibitors) RN - EC 2.7.11.1 (Proto-Oncogene Proteins B-raf) SB - IM EIN - Curr Treat Options Oncol. 2022 Aug;23(8):1151. doi: 10.1007/s11864-022-00992-y. PMID: 35767134 MH - Cardiotoxicity/etiology MH - Humans MH - Immune Checkpoint Inhibitors MH - Immunotherapy/adverse effects MH - *Melanoma/drug therapy/etiology MH - Proto-Oncogene Proteins B-raf MH - *Skin Neoplasms/drug therapy/etiology OTO - NOTNLM OT - BRAF OT - Cardio-oncology OT - Cardiotoxicity OT - Immunotherapy OT - MEK OT - Melanoma EDAT- 2022/02/23 06:00 MHDA- 2022/04/30 06:00 CRDT- 2022/02/22 12:15 PHST- 2021/08/16 00:00 [accepted] PHST- 2022/02/23 06:00 [pubmed] PHST- 2022/04/30 06:00 [medline] PHST- 2022/02/22 12:15 [entrez] AID - 10.1007/s11864-021-00924-2 [pii] AID - 10.1007/s11864-021-00924-2 [doi] PST - ppublish SO - Curr Treat Options Oncol. 2022 Feb;23(2):240-253. doi: 10.1007/s11864-021-00924-2. Epub 2022 Feb 22. PMID- 35191104 OWN - NLM STAT- MEDLINE DCOM- 20220404 LR - 20220405 IS - 1540-8191 (Electronic) IS - 0886-0440 (Linking) VI - 37 IP - 5 DP - 2022 May TI - Primary malignant cardiac tumors: Sex-related therapy and multidisciplinary approach as a new challenge for the future. PG - 1287-1289 LID - 10.1111/jocs.16358 [doi] AB - Primary malignant cardiac tumors represent (PMCTs) a very rare disease with an incidence of 0.009%(1) (up to 10% of primary cardiac neoplasms) and are related to a very poor prognosis. The study by Mohamed Rahouma tries to give us information on sex differences in PMCTs, their incidence, behavior, and outcomes. Females were significantly older and had a lower stage of cancer. Males are known to have a more aggressive course and present at an earlier age. Sarcoma is the most common type of PMCTs in both males and females. There was no gender disparity in late mortality and patients who underwent surgery had a better prognosis than those who did not undergo surgery. Significant predictors of late mortality were found to be patients' high comorbidity index, angiosarcoma histology, and Stage III/IV. A challenge for cardiac surgeons is to improve survival in patients with cardiac malignancies, involving a multidisciplinary approach with oncologists, cardiologists, and radiologists. To pave the way for a significant improvement in survival in the future, more advanced sex-specific medical therapies for cancer such as novel chemotherapy agents, targeted immune therapies, genetic engineering need to be standardized to PMCTs and combined with radiological therapies such as gamma-knife and very advanced surgery to effectively treat even very aggressive forms of malignant tumors, with a significant impact on the patient's quality of life and survival. CI - (c) 2022 Wiley Periodicals LLC. FAU - Di Bari, Nicola AU - Di Bari N AUID- ORCID: 0000-0003-3606-2118 AD - Division of Cardiac Surgery, Department of Emergency and Organ Transplant, Policlinico Hospital, University of Bari, Bari, Italy. FAU - D'Errico Ramirez, Antonio AU - D'Errico Ramirez A AD - Division of Cardiac Surgery, Department of Emergency and Organ Transplant, Policlinico Hospital, University of Bari, Bari, Italy. FAU - Nasso, Giuseppe AU - Nasso G AUID- ORCID: 0000-0002-3519-770X AD - Department of Cardiovascular Surgery, GVM Care and Research, Anthea Hospital, Bari, Italy. LA - eng PT - Journal Article DEP - 20220221 PL - United States TA - J Card Surg JT - Journal of cardiac surgery JID - 8908809 SB - IM MH - Female MH - *Heart Neoplasms/surgery MH - *Hemangiosarcoma MH - Humans MH - Incidence MH - Male MH - Prognosis MH - Quality of Life OTO - NOTNLM OT - primary malignant cardiac tumors (PMCTs) EDAT- 2022/02/23 06:00 MHDA- 2022/04/05 06:00 CRDT- 2022/02/22 06:10 PHST- 2022/02/12 00:00 [received] PHST- 2022/02/14 00:00 [accepted] PHST- 2022/02/23 06:00 [pubmed] PHST- 2022/04/05 06:00 [medline] PHST- 2022/02/22 06:10 [entrez] AID - 10.1111/jocs.16358 [doi] PST - ppublish SO - J Card Surg. 2022 May;37(5):1287-1289. doi: 10.1111/jocs.16358. Epub 2022 Feb 21. PMID- 35190828 OWN - NLM STAT- MEDLINE DCOM- 20220707 LR - 20220902 IS - 1873-734X (Electronic) IS - 1010-7940 (Linking) VI - 62 IP - 1 DP - 2022 Jun 15 TI - Surgery for infective endocarditis following low-intermediate risk transcatheter aortic valve replacement-a multicentre experience. LID - ezac075 [pii] LID - 10.1093/ejcts/ezac075 [doi] AB - OBJECTIVES: With the expansion of transcatheter aortic valve replacement (TAVR) into intermediate and low risk, the number of TAVR procedures is bound to rise and along with it the number of cases of infective endocarditis following TAVR (TIE). The aim of this study was to review a multicentre experience of patients undergoing surgical intervention for TIE and to analyse the underlying indications and operative results. METHODS: We retrospectively identified and analysed 69 patients who underwent cardiac surgery due to TIE at 9 cardiac surgical departments across Germany. The primary outcome was operative mortality, 6-month and 1-year survival. RESULTS: Median age was 78 years (72-81) and 48(69.6%) were male. The median time to surgical aortic valve replacement was 14 months (5-24) after TAVR, with 32 patients (46.4%) being diagnosed with early TIE. Cardiac reoperations were performed in 17% of patients and 33% underwent concomitant mitral valve surgery. The main causative organisms were: Enterococcus faecalis (31.9%), coagulase-negative Staphylococcus spp. (26.1%), Methicillin-sensitive Staphylococcus aureus (15.9%) and viridians group streptococci (14.5%). Extracorporeal life support was required in 2 patients (2.9%) for a median duration of 3 days. Postoperative adverse cerebrovascular events were observed in 13 patients (18.9%). Postoperatively, 9 patients (13.0%) required a pacemaker and 33 patients (47.8%) needed temporary renal replacement therapy. Survival to discharge was 88.4% and survival at 6 months and 1 year was found to be 68% and 53%, respectively. CONCLUSIONS: Our results suggest that TIE can be treated according to the guidelines for prosthetic valve endocarditis, namely with early surgery. Surgery for TIE is associated with acceptable morbidity and mortality rates. Surgery should be discussed liberally as a treatment option in patients with TIE by the 'endocarditis team' in referral centres. CI - (c) The Author(s) 2022. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved. FAU - Saha, Shekhar AU - Saha S AUID- ORCID: 0000-0002-9903-3237 AD - Department of Cardiac Surgery, LMU University Hospital, Munich, Germany. AD - German Centre for Cardiovascular Research (DZHK), partner site Munich Heart Alliance, Munich, Germany. FAU - Joskowiak, Dominik AU - Joskowiak D AD - Department of Cardiac Surgery, LMU University Hospital, Munich, Germany. AD - German Centre for Cardiovascular Research (DZHK), partner site Munich Heart Alliance, Munich, Germany. FAU - Marin-Cuartas, Mateo AU - Marin-Cuartas M AUID- ORCID: 0000-0003-1000-4710 AD - University Department of Cardiac Surgery, Leipzig Heart Center, Leipzig, Germany. FAU - Diab, Mahmoud AU - Diab M AUID- ORCID: 0000-0003-1529-6046 AD - Department of Cardiothoracic Surgery, Jena University Hospital, Friedrich Schiller University Jena, Jena, Germany. FAU - Schwaiger, Benedikt M AU - Schwaiger BM AD - Department of Cardiac Surgery, Munich Municipal Hospital Bogenhausen, Technical University of Munich, Munich, Germany. FAU - Sandoval-Boburg, Rodrigo AU - Sandoval-Boburg R AD - Department of Thoracic and Cardiovascular Surgery, Eberhard Karls University of Tubingen, Tubingen, Germany. FAU - Popov, Aron-Frederik AU - Popov AF AUID- ORCID: 0000-0003-4226-3004 AD - Department of Thoracic and Cardiovascular Surgery, Eberhard Karls University of Tubingen, Tubingen, Germany. FAU - Weber, Carolyn AU - Weber C AD - Department of Cardiothoracic Surgery, Heart Center of the University of Cologne, Cologne, Germany. FAU - Varghese, Sam AU - Varghese S AD - Department of Cardiothoracic Surgery, Otto-von-Guericke University, Magdeburg, Germany. FAU - Martens, Andreas AU - Martens A AUID- ORCID: 0000-0002-7953-2645 AD - Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany. FAU - Cebotari, Serghei AU - Cebotari S AD - Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany. FAU - Scherner, Maximilian AU - Scherner M AD - Department of Cardiothoracic Surgery, Otto-von-Guericke University, Magdeburg, Germany. FAU - Eichinger, Walter AU - Eichinger W AD - Department of Cardiac Surgery, Munich Municipal Hospital Bogenhausen, Technical University of Munich, Munich, Germany. FAU - Holzhey, David AU - Holzhey D AD - University Department of Cardiac Surgery, Leipzig Heart Center, Leipzig, Germany. FAU - Dohle, Daniel-Sebastian AU - Dohle DS AD - Department of Cardiovascular Surgery, University Hospital Mainz, Mainz, Germany. FAU - Wahlers, Thorsten AU - Wahlers T AUID- ORCID: 0000-0002-8437-4119 AD - Department of Cardiothoracic Surgery, Heart Center of the University of Cologne, Cologne, Germany. FAU - Doenst, Torsten AU - Doenst T AD - Department of Cardiothoracic Surgery, Jena University Hospital, Friedrich Schiller University Jena, Jena, Germany. FAU - Misfeld, Martin AU - Misfeld M AD - University Department of Cardiac Surgery, Leipzig Heart Center, Leipzig, Germany. AD - Department of Cardiothoracic Surgery, Royal Prince Alfred Hospital, Sydney, NSW, Australia. AD - Institute of Academic Surgery, RPAH, Sydney, NSW, Australia. AD - The Baird Institute of Applied Heart and Lung Surgical Research, Sydney, Australia. AD - Sydney Medical School, University of Sydney, Sydney, NSW, Australia. FAU - Mehilli, Julinda AU - Mehilli J AUID- ORCID: 0000-0002-8750-5567 AD - Department of Cardiology, LMU University Hospital and German Centre for Cardiovascular Research (DZHK), partner site Munich Heart Alliance, Munich, Germany. AD - Department of Cardiology, Medizinische Klinik I, Landshut-Achdorf Hospital, Landshut, Germany. FAU - Massberg, Steffen AU - Massberg S AUID- ORCID: 0000-0001-7387-3986 AD - Department of Cardiology, LMU University Hospital and German Centre for Cardiovascular Research (DZHK), partner site Munich Heart Alliance, Munich, Germany. FAU - Hagl, Christian AU - Hagl C AD - Department of Cardiac Surgery, LMU University Hospital, Munich, Germany. AD - German Centre for Cardiovascular Research (DZHK), partner site Munich Heart Alliance, Munich, Germany. LA - eng PT - Journal Article PT - Multicenter Study PL - Germany TA - Eur J Cardiothorac Surg JT - European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery JID - 8804069 SB - IM CIN - Eur J Cardiothorac Surg. 2022 Jun 15;62(1):ezac150. doi: 10.1093/ejcts/ezac150. PMID: 35253867 MH - Aged MH - Aortic Valve/surgery MH - *Aortic Valve Stenosis/surgery MH - *Endocarditis/surgery MH - *Endocarditis, Bacterial/epidemiology/etiology/surgery MH - Female MH - *Heart Valve Prosthesis/adverse effects MH - Humans MH - Male MH - Retrospective Studies MH - Risk Factors MH - *Transcatheter Aortic Valve Replacement/adverse effects MH - Treatment Outcome OTO - NOTNLM OT - Infective endocarditis OT - transcather aortic valve replacement EDAT- 2022/02/23 06:00 MHDA- 2022/07/08 06:00 CRDT- 2022/02/22 06:08 PHST- 2021/08/04 00:00 [received] PHST- 2022/01/04 00:00 [revised] PHST- 2022/01/27 00:00 [accepted] PHST- 2022/02/23 06:00 [pubmed] PHST- 2022/07/08 06:00 [medline] PHST- 2022/02/22 06:08 [entrez] AID - 6534098 [pii] AID - 10.1093/ejcts/ezac075 [doi] PST - ppublish SO - Eur J Cardiothorac Surg. 2022 Jun 15;62(1):ezac075. doi: 10.1093/ejcts/ezac075. PMID- 35190114 OWN - NLM STAT- MEDLINE DCOM- 20220321 LR - 20220321 IS - 1548-5609 (Electronic) IS - 1548-5595 (Linking) VI - 28 IP - 5 DP - 2021 Sep TI - Onco-hypertension: An Emerging Specialty. PG - 477-489.e1 LID - S1548-5595(21)00100-2 [pii] LID - 10.1053/j.ackd.2021.09.011 [doi] AB - Cancer is one of the leading causes of death worldwide. With the introduction of newer chemotherapeutic agents, targeted therapies, and immunotherapy, the prognosis and survival of patients with cancer has remarkably improved. As a result, patients are living longer and experiencing long-term cardiovascular complications. Hypertension is an important risk factor for cardiovascular diseases. Patients with malignancy have multiple etiologies of hypertension development, worsening, or association. This is because of the complex interplay between cancer type, chemotherapeutic agent, patient age, antihypertensive agent, and preexisting comorbidities in the etiology and pathogenesis of hypertension. Management of hypertension in patients with cancer requires accurate blood pressure measurement and considering factors such as adjuvant therapy and cancer-related pain. There are no set guidelines for management of hypertension in this unique cohort, and the therapy should be individualized based on the treatment guidelines for the general population. Onco-hypertension is an emerging subspeciality and entails a multidisciplinary approach between oncology, primary care physicians, nephrology, and cardiology. CI - Copyright (c) 2021 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved. FAU - Gudsoorkar, Prakash AU - Gudsoorkar P AD - Division of Nephrology, Kidney C.A.R.E. Program, University of Cincinnati, Cincinnati, OH. FAU - Ruf, Rebecca AU - Ruf R AD - Division of Nephrology, The Polyclinic, Seattle, WA. FAU - Adnani, Harsha AU - Adnani H AD - Anne Arundel Medical Center, Luminis Health System, Annapolis, MD. FAU - Safdar, Komal AU - Safdar K AD - Department of Medicine, Duke University Health System, Durham, NC. FAU - Sparks, Matthew A AU - Sparks MA AD - Division of Nephrology, Department of Medicine, Duke University School of Medicine, Durham, NC; Renal Section, Durham VA Health Care System, Durham, NC. Electronic address: matthew.sparks@duke.edu. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review PL - United States TA - Adv Chronic Kidney Dis JT - Advances in chronic kidney disease JID - 101209214 RN - 0 (Antihypertensive Agents) RN - 0 (Antineoplastic Agents) SB - IM MH - Antihypertensive Agents/therapeutic use MH - *Antineoplastic Agents/adverse effects MH - *Cardiology MH - Humans MH - *Hypertension/complications/therapy MH - Medical Oncology MH - *Neoplasms/drug therapy OTO - NOTNLM OT - Cancer OT - Hypertension OT - Onconephrology OT - VEGF EDAT- 2022/02/23 06:00 MHDA- 2022/03/22 06:00 CRDT- 2022/02/22 05:44 PHST- 2021/05/17 00:00 [received] PHST- 2021/09/20 00:00 [revised] PHST- 2021/09/20 00:00 [accepted] PHST- 2022/02/22 05:44 [entrez] PHST- 2022/02/23 06:00 [pubmed] PHST- 2022/03/22 06:00 [medline] AID - S1548-5595(21)00100-2 [pii] AID - 10.1053/j.ackd.2021.09.011 [doi] PST - ppublish SO - Adv Chronic Kidney Dis. 2021 Sep;28(5):477-489.e1. doi: 10.1053/j.ackd.2021.09.011. PMID- 35182119 OWN - NLM STAT- MEDLINE DCOM- 20220222 LR - 20220222 IS - 0043-5147 (Print) IS - 0043-5147 (Linking) VI - 75 IP - 1 pt 2 DP - 2022 TI - CARDIOPULMONARY BYPASS IN PREGNANCY. A SINGLE-CENTER EXPERIENCE. PG - 181-186 AB - OBJECTIVE: The aim: Presentation of a single-center experience of cardiac surgery with cardiopulmonary bypass (CPB) in pregnant women with critical cardiac pathology. The possibility of minimally invasive technique in this group of patients were presented. PATIENTS AND METHODS: Materials and methods: The present study included 19 cases of multidisciplinary care with CPB surgery in pregnant women in single center from December 2013 to December 2020. 8 patients underwent J-form median mini-sternotomy. Maternal and neonatal outcomes depending on the type of surgery (urgent or elective) were reviewed. RESULTS: Results: There were no negative maternal consequences; there were 4 perinatal losses (21%): three after urgent and one after elective interventions. All other pregnancies (n=15) finished successfully with the birth of healthy newborns. We compared some values in two groups (urgent and elective) of patients who underwent CPB surgery during pregnancy. Despite the variability in some parameters the difference between the groups was not significant. Follow-up was from 5 to 72 months (39.7+/-16.9) without negative consequences. CONCLUSION: Conclusions: Multidisciplinary team management is an effective strategy for pregnant women with cardiac pathology. Elective cardiac surgery in expert centers during pregnancy is a safe and effective option. Urgent CPB cardiac surgery during pregnancy increases the risk for the fetus. J-form median mini-sternotomy is a good option during pregnancy in high-experienced centers. FAU - Siromakha, Sergii O AU - Siromakha SO AD - AMOSOV NATIONAL INSTITUTE OF CARDIOVASCULAR SURGERY NATIONAL ACADEMY OF MEDICAL SCIENCES OF UKRAINE, KYIV, UKRAINE. FAU - Davydova, Yuliia V AU - Davydova YV AD - INSTITUTE OF PEDIATRICS OBSTETRIC AND GYNECOLOGY NAMED BY LUKIANOVA NAMS UKRAINE, KYIV, UKRAINE. FAU - Kravchenko, Vitalii I AU - Kravchenko VI AD - AMOSOV NATIONAL INSTITUTE OF CARDIOVASCULAR SURGERY NATIONAL ACADEMY OF MEDICAL SCIENCES OF UKRAINE, KYIV, UKRAINE. FAU - Lazoryshynets, Vasyl V AU - Lazoryshynets VV AD - AMOSOV NATIONAL INSTITUTE OF CARDIOVASCULAR SURGERY NATIONAL ACADEMY OF MEDICAL SCIENCES OF UKRAINE, KYIV, UKRAINE. LA - eng PT - Journal Article PL - Poland TA - Wiad Lek JT - Wiadomosci lekarskie (Warsaw, Poland : 1960) JID - 9705467 SB - IM MH - *Cardiac Surgical Procedures/methods MH - *Cardiopulmonary Bypass/methods MH - Female MH - Humans MH - Infant, Newborn MH - Pregnancy MH - Retrospective Studies MH - Treatment Outcome OTO - NOTNLM OT - J-form median mini-sternotomy OT - cardiopulmonary bypass OT - pregnancy OT - pregnancy heart team EDAT- 2022/02/20 06:00 MHDA- 2022/02/23 06:00 CRDT- 2022/02/19 12:06 PHST- 2022/02/19 12:06 [entrez] PHST- 2022/02/20 06:00 [pubmed] PHST- 2022/02/23 06:00 [medline] PST - ppublish SO - Wiad Lek. 2022;75(1 pt 2):181-186. PMID- 35181885 OWN - NLM STAT- MEDLINE DCOM- 20220519 LR - 20260127 IS - 1749-6632 (Electronic) IS - 0077-8923 (Linking) VI - 1511 IP - 1 DP - 2022 May TI - Guidelines and standards for the study of death and recalled experiences of death--a multidisciplinary consensus statement and proposed future directions. PG - 5-21 LID - 10.1111/nyas.14740 [doi] AB - An inadvertent consequence of advances in stem cell research, neuroscience, and resuscitation science has been to enable scientific insights regarding what happens to the human brain in relation to death. The scientific exploration of death is in large part possible due to the recognition that brain cells are more resilient to the effects of anoxia than assumed. Hence, brain cells become irreversibly damaged and "die" over hours to days postmortem. Resuscitation science has enabled life to be restored to millions of people after their hearts had stopped. These survivors have described a unique set of recollections in relation to death that appear universal. We review the literature, with a focus on death, the recalled experiences in relation to cardiac arrest, post-intensive care syndrome, and related phenomena that provide insights into potential mechanisms, ethical implications, and methodologic considerations for systematic investigation. We also identify issues and controversies related to the study of consciousness and the recalled experience of cardiac arrest and death in subjects who have been in a coma, with a view to standardize and facilitate future research. CI - (c) 2022 New York Academy of Sciences. FAU - Parnia, Sam AU - Parnia S AD - Critical Care and Resuscitation Research, Division of Pulmonary and Critical Care Medicine, Department of Medicine, New York University Grossman School of Medicine, New York, New York. FAU - Post, Stephen G AU - Post SG AD - Department of Family, Population and Preventive Medicine, Stony Brook Medical Center, State University of New York at Stony Brook, New York, New York. FAU - Lee, Matthew T AU - Lee MT AD - Institute for Quantitative Social Science, Harvard University, Cambridge, Massachusetts. FAU - Lyubomirsky, Sonja AU - Lyubomirsky S AD - Department of Psychology, University of California, Riverside, California. FAU - Aufderheide, Tom P AU - Aufderheide TP AD - Department of Emergency Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin. FAU - Deakin, Charles D AU - Deakin CD AD - Department of Anesthetics, University Hospital Southampton, Southampton, UK. FAU - Greyson, Bruce AU - Greyson B AD - Department of Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville, Virginia. FAU - Long, Jeffrey AU - Long J AD - Mary Bird Perkins Terrebonne General Medical Cancer Center, Houma, Louisiana. FAU - Gonzales, Anelly M AU - Gonzales AM AD - Critical Care and Resuscitation Research, Division of Pulmonary and Critical Care Medicine, Department of Medicine, New York University Grossman School of Medicine, New York, New York. FAU - Huppert, Elise L AU - Huppert EL AD - Critical Care and Resuscitation Research, Division of Pulmonary and Critical Care Medicine, Department of Medicine, New York University Grossman School of Medicine, New York, New York. FAU - Dickinson, Analise AU - Dickinson A AD - Critical Care and Resuscitation Research, Division of Pulmonary and Critical Care Medicine, Department of Medicine, New York University Grossman School of Medicine, New York, New York. FAU - Mayer, Stephan AU - Mayer S AD - Departments of Neurology and Neurosurgery, New York Medical College, Valhalla, New York. FAU - Locicero, Briana AU - Locicero B AD - Department of Family, Population and Preventive Medicine, Stony Brook Medical Center, State University of New York at Stony Brook, New York, New York. FAU - Levin, Jeff AU - Levin J AD - Institute for Studies of Religion, Baylor University, Waco, Texas. FAU - Bossis, Anthony AU - Bossis A AD - Department of Psychiatry, New York University Grossman School of Medicine, New York, New York. FAU - Worthington, Everett AU - Worthington E AD - Department of Psychology, Virginia Commonwealth University, Richmond, Virginia. FAU - Fenwick, Peter AU - Fenwick P AD - Department of Neurophysiology, Sleep and Epilepsy, Institute of Psychiatry, King's College, London, UK. FAU - Shirazi, Tara Keshavarz AU - Shirazi TK AUID- ORCID: 0000-0001-5682-6774 AD - Critical Care and Resuscitation Research, Division of Pulmonary and Critical Care Medicine, Department of Medicine, New York University Grossman School of Medicine, New York, New York. LA - eng PT - Consensus Statement PT - Journal Article PT - Review DEP - 20220218 PL - United States TA - Ann N Y Acad Sci JT - Annals of the New York Academy of Sciences JID - 7506858 SB - IM CIN - Ann N Y Acad Sci. 2022 Sep;1515(1):5-9. doi: 10.1111/nyas.14846. PMID: 35729792 CIN - Ann N Y Acad Sci. 2022 Nov;1517(1):11-14. doi: 10.1111/nyas.14888. PMID: 36017883 MH - Brain MH - *Cardiopulmonary Resuscitation MH - Consciousness MH - *Heart Arrest/therapy MH - Humans MH - Mental Recall OTO - NOTNLM OT - cardiac arrest OT - cardiopulmonary resuscitation-induced consciousness (CPRIC) OT - death OT - death by brain death criteria OT - external visual awareness (EVA) OT - near-death experiences (NDEs) OT - out-of-body experiences (OBEs) OT - post-intensive care syndrome (PICS) OT - recalled experience of death (RED) coma OT - resuscitation EDAT- 2022/02/20 06:00 MHDA- 2022/05/20 06:00 CRDT- 2022/02/19 05:31 PHST- 2021/05/19 00:00 [received] PHST- 2022/02/20 06:00 [pubmed] PHST- 2022/05/20 06:00 [medline] PHST- 2022/02/19 05:31 [entrez] AID - 10.1111/nyas.14740 [doi] PST - ppublish SO - Ann N Y Acad Sci. 2022 May;1511(1):5-21. doi: 10.1111/nyas.14740. Epub 2022 Feb 18. PMID- 35179107 OWN - NLM STAT- MEDLINE DCOM- 20221115 LR - 20221115 IS - 1467-1107 (Electronic) IS - 1047-9511 (Linking) VI - 32 IP - 11 DP - 2022 Nov TI - An atypical cause of chest pain. PG - 1839-1841 LID - 10.1017/S1047951122000476 [doi] AB - Congenital coronary artery anomalies are of major significance in clinical cardiology and cardiac surgery due to their association with myocardial ischaemia and sudden death. Having a multidisciplinary approach in managing complex congenital conditions and including patients in the management decisions is essential for good doctor-patient relationship. Here within, we describe a complex coronary artery fistula leading to myocardial steal. FAU - Erdogan, Emrah AU - Erdogan E AD - Van Yuzuncu Yil University, Department of Cardiology, Van, Turkey. FAU - Kilic, Yakup AU - Kilic Y AUID- ORCID: 0000-0003-1319-9517 AD - Barnet General Hospital, Royal Free London, Barnet, UK. LA - eng PT - Journal Article DEP - 20220218 PL - England TA - Cardiol Young JT - Cardiology in the young JID - 9200019 SB - IM MH - Humans MH - *Coronary Vessel Anomalies/complications/diagnosis/surgery MH - Physician-Patient Relations MH - Chest Pain/etiology/complications MH - *Myocardial Ischemia MH - *Coronary Artery Disease/complications MH - Coronary Angiography OTO - NOTNLM OT - Congenital coronary artery fistula OT - congenital heart disease EDAT- 2022/02/19 06:00 MHDA- 2022/11/16 06:00 CRDT- 2022/02/18 08:40 PHST- 2022/02/19 06:00 [pubmed] PHST- 2022/11/16 06:00 [medline] PHST- 2022/02/18 08:40 [entrez] AID - S1047951122000476 [pii] AID - 10.1017/S1047951122000476 [doi] PST - ppublish SO - Cardiol Young. 2022 Nov;32(11):1839-1841. doi: 10.1017/S1047951122000476. Epub 2022 Feb 18. PMID- 35172919 OWN - NLM STAT- MEDLINE DCOM- 20221104 LR - 20230412 IS - 1001-9294 (Print) IS - 1001-9294 (Linking) VI - 37 IP - 3 DP - 2022 Sep 30 TI - Patient Blood Management: Single Center Evidence and Practice at Fuwai Hospital. PG - 246-260 LID - 10.24920/004035 [doi] AB - Blood loss and blood transfusion requirement are important quality control indicators of cardiovascular surgery and cardiovascular anesthesia. Patient blood management (PBM) is an evidence-based, multidisciplinary approach to optimizing the care of patients who may need transfusion, which encompasses anemia management, hemodilution, cell salvage, hemostatic treatment, and other approaches to reducing bleeding and minimizing blood transfusion. PBM in cardiovascular surgery is a "team sport" that involves cardiac and vascular surgeons, anesthesiologists, perfusionist, intensivists, and other health care providers. The current work provides an overview of evidence and practice of PBM at Fuwai Hospital. Implementation of PBM should also take local resource availability and cost-effectiveness of different devices, drugs, technologies, and techniques into consideration. FAU - Yao, Yun-Tai AU - Yao YT AD - Department of Anesthesiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China. FAU - Yuan, Xin AU - Yuan X AD - Department of Adult Cardiac Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China. FAU - He, Li-Xian AU - He LX AD - Department of Anesthesiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China. FAU - Yu, Yi-Ping AU - Yu YP AD - Department of Anesthesiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China. FAU - Du, Yu AU - Du Y AD - Department of Surgical Intensive Care Unit, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China. FAU - Liu, Gang AU - Liu G AD - Department of Cardiopulmonary Bypass, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China. FAU - Tian, Li-Juan AU - Tian LJ AD - Department of Anesthesiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China. FAU - Ma, Zu-Xuan AU - Ma ZX AD - Department of Transfusion, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China. FAU - Zhang, Yong-Bao AU - Zhang YB AD - Department of Vascular Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China. FAU - Ma, Jie AU - Ma J AD - Department of Pharmacy Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China. LA - eng PT - Journal Article PL - Netherlands TA - Chin Med Sci J JT - Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih JID - 9112559 SB - IM MH - Humans MH - *Blood Transfusion/methods MH - *Anemia/therapy MH - Hemorrhage MH - Hospitals MH - Blood Loss, Surgical OTO - NOTNLM OT - anesthesia OT - bleeding OT - blood management OT - blood transfusion OT - cardiovascular surgery EDAT- 2022/02/18 06:00 MHDA- 2022/11/05 06:00 CRDT- 2022/02/17 05:29 PHST- 2022/02/18 06:00 [pubmed] PHST- 2022/11/05 06:00 [medline] PHST- 2022/02/17 05:29 [entrez] AID - 4035 [pii] AID - 10.24920/004035 [doi] PST - ppublish SO - Chin Med Sci J. 2022 Sep 30;37(3):246-260. doi: 10.24920/004035. PMID- 35168753 OWN - NLM STAT- MEDLINE DCOM- 20220412 LR - 20220623 IS - 1879-1913 (Electronic) IS - 0002-9149 (Linking) VI - 169 DP - 2022 Apr 15 TI - Does a Heart Team Improve Clinical Outcomes? PG - 120-126 LID - S0002-9149(22)00024-8 [pii] LID - 10.1016/j.amjcard.2022.01.006 [doi] AB - Consultation by a Heart Team (HT) is a class I recommendation by the American College of Cardiology, American Heart Association, and the European Society of Cardiology for the management of patients with complex cardiac disease. Despite the class I recommendation, there is a paucity of data to support the role of an HT with only level C quality of evidence. This study was performed to follow patients who were referred for HT consultation and long-term outcomes in relation to whether the recommendation of the HT was followed or not. We performed a prospective analysis of our cohort of patients who underwent consultation by the HT. A total of 342 cases have been followed. Patient characteristics, referring physicians' favored treatment, and key outcomes were followed. A total of 336 patients were reviewed; 70.4% were male patients with a median age of 66.3 years and an average EuroSCORE II score of 7.2%. A total of 79.9% of the discussions resulted in a unanimous decision. The recommendations made by the HT differed from those documented by the referring physician in 54% of cases. In conclusion, recommendations made by the HT were followed in 269 cases (83.8%). There was a significant reduction in cardiac death (6.3% vs 15.3%, p = 0.042), composite cardiac outcome (23.4% vs 51.9%, p 50% of affected individuals); ectopia lentis (seen in approximately 60% of affected individuals); and an increased risk for retinal detachment, glaucoma, and early cataracts. Skeletal system manifestations include bone overgrowth and joint laxity; disproportionately long extremities for the size of the trunk (dolichostenomelia); overgrowth of the ribs that can push the sternum in (pectus excavatum) or out (pectus carinatum); and scoliosis that ranges from mild to severe and progressive. The major morbidity and early mortality in Marfan syndrome relate to the cardiovascular system and include dilatation of the aorta at the level of the sinuses of Valsalva (predisposing to aortic tear and rupture), mitral valve prolapse with or without regurgitation, tricuspid valve prolapse, and enlargement of the proximal pulmonary artery. Severe and prolonged regurgitation of the mitral and/or aortic valve can predispose to left ventricular dysfunction and occasionally heart failure. With proper management, the life expectancy of someone with Marfan syndrome approximates that of the general population. DIAGNOSIS/TESTING: The diagnosis of Marfan syndrome is established in a proband (by definition a person without a known family history of Marfan syndrome) who has an FBN1 pathogenic variant known to be associated with Marfan syndrome and EITHER of the following: Aortic root enlargement (z score >/=2.0). Ectopia lentis. MANAGEMENT: Treatment of manifestations: Comprehensive management by a multidisciplinary team including a clinical geneticist, cardiologist, ophthalmologist, orthopedist, and cardiothoracic surgeon is strongly recommended. Treatment typically includes spectacle correction for refractive errors and, sometimes, surgical removal of a dislocated lens with artificial lens implantation (preferably after growth is complete). Glaucoma, cataracts, and retinal detachment are treated in the standard fashion per an ophthalmologist. Scoliosis may require bracing or surgical stabilization; repair of pectus deformity is largely cosmetic. Functional deficits or pain associated with protusio acetabulae may respond to physical therapy, analgesics, or anti-inflammatory medications. Orthotics and arch supports can lessen leg fatigue, joint pain, and muscle cramps associated with pes planus. Dental crowding may be addressed through orthodontia and a palatal expander may be considered in some cases. Surgical repair of the aorta is indicated either when the maximal measurement of the aortic root approaches 5.0 cm in adults or older children, when the rate of increase of the aortic root diameter approaches 0.5-1.0 cm per year, or if there is progressive and severe aortic regurgitation. For younger children, aortic root surgery should be considered once: (1) the rate of increase of the aortic root diameter approaches 0.5-1.0 cm per year, or (2) there is progressive and severe aortic regurgitation. Severe and progressive mitral valve regurgitation with attendant ventricular dysfunction requires immediate attention of a cardiologist or cardiothoracic surgeon and is the leading indication for cardiovascular surgery in children with Marfan syndrome. Afterload-reducing agents can improve cardiovascular function when congestive heart failure is present. Standard treatment for hernias and pneumothorax is recommended. There are no known effective therapies for symptomatic dural ectasia. Prevention of primary manifestations: Medications that reduce hemodynamic stress on the aortic wall, such as beta-blockers or angiotensin receptor blockers (ARBs), are routinely prescribed. This therapy should be managed by a cardiologist or clinical geneticist familiar with its use. Therapy is generally initiated at the time of diagnosis with Marfan syndrome at any age or upon appreciation of progressive aortic root dilatation even in the absence of a definitive diagnosis. Surveillance: Measurement of length/height/weight at each visit. Ophthalmologic examination annually or as clinically indicated. Clinical assessment for chest wall deformities and scoliosis at each visit until skeletal maturity, although severe scoliosis may require ongoing surveillance in adulthood. At least annual dental evaluation, including orthodontia, as indicated. Echocardiography annually when aortic dimensions are small and the rate of aortic dilatation is slow; more frequent than annual examinations are indicated when the aortic root diameter exceeds approximately 4.5 cm in adults, rates of aortic dilatation exceed approximately 0.3 cm per year, or significant aortic regurgitation is present. Intermittent surveillance of the entire aorta with CT or MRA scans beginning in young adulthood or at least annually in anyone with a history of aortic root replacement or dissection. Agents/circumstances to avoid: Contact sports, competitive sports, and isometric exercise; activities that cause joint injury or pain; agents that stimulate the cardiovascular system, including decongestants and excessive caffeine; agents that cause vasoconstriction, including triptans; LASIK correction of refractive errors; breathing against resistance or positive pressure ventilation in those with a documented predisposition for pneumothorax; fluoroquinolone antibiotics, which may exacerbate the predisposition for aneurysm and dissection; classes of antihypertensive agents (e.g., calcium channel blockers, ACE inhibitors) where there is an absence of direct evidence for their efficacy or safety in individuals with Marfan syndrome. Evaluation of relatives at risk: It is recommended that the genetic status of at-risk relatives of any age be clarified so that affected individuals can undergo routine surveillance for early detection of medically significant complications, particularly potentially life-threatening cardiac manifestations. Genetic status of at-risk relatives can be established EITHER: By molecular genetic testing if the FBN1 pathogenic variant in the family is known; OR. In those with a rigorously defined family history of Marfan syndrome, by the presence of ONE OR MORE of the following: Ectopia lentis. A systemic score >/=7. Aortic root dilatation (z score >/=2.0 for individuals age >/=20 years or z score >/=3.0 for those age <20 years). Pregnancy management: An individual with Marfan syndrome should consider pregnancy only after appropriate counseling from a clinical geneticist or cardiologist familiar with this condition, a genetic counselor, and a high-risk obstetrician because of the risk of more rapid dilation of the aorta or aortic dissection during pregnancy, delivery, or in the immediate postpartum period. Cardiovascular imaging with echocardiography should be performed every two to three months during pregnancy to monitor aortic root size and growth. Monitoring should continue in the immediate postpartum period because of the increased risk for aortic dissection. Individuals with Marfan syndrome who anticipate pregnancy or become pregnant should continue use of beta-blockers; however, some other classes of medications such as ARBs should be discontinued because of the increased risk for fetal loss, oligohydramnios, and abnormal development, often related to second- and third-trimester exposure. GENETIC COUNSELING: Marfan syndrome is inherited in an autosomal dominant manner. Approximately 75% of individuals with Marfan syndrome have an affected parent; approximately 25% have a de novo FBN1 pathogenic variant. Each child of an individual with Marfan syndrome has a 50% chance of inheriting the pathogenic variant and the disorder. Once the FBN1 pathogenic variant has been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic testing are possible. CI - Copyright (c) 1993-2026, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved. FED - Adam, Margaret P ED - Adam MP FED - Bick, Sarah ED - Bick S FED - Mirzaa, Ghayda M ED - Mirzaa GM FED - Wallace, Stephanie E ED - Wallace SE FED - Amemiya, Anne ED - Amemiya A FAU - Dietz, Harry AU - Dietz H AD - Victor A McKusick Professor, Departments of Genetic Medicine, Pediatrics, Medicine, and Molecular Biology & Genetics;, Investigator, Howard Hughes Medical Institute;, Johns Hopkins University School of Medicine, Baltimore, Maryland LA - eng PT - Review PT - Book Chapter PL - Seattle (WA) OTO - NLM OT - Fibrillin-1 OT - FBN1 OT - FBN1-Related Marfan Syndrome EDAT- 2022/02/17 00:00 CRDT- 2022/02/17 00:00 AID - NBK1335 [bookaccession] PMID- 35167666 OWN - NLM STAT- MEDLINE DCOM- 20220809 LR - 20250728 IS - 2047-4881 (Electronic) IS - 2047-4873 (Linking) VI - 29 IP - 10 DP - 2022 Aug 5 TI - Cardiovascular disease in the elderly: proceedings of the European Society of Cardiology-Cardiovascular Round Table. PG - 1412-1424 LID - 10.1093/eurjpc/zwac033 [doi] AB - The growing elderly population worldwide represents a major challenge for caregivers, healthcare providers, and society. Older patients have a higher prevalence of cardiovascular (CV) disease, high rates of CV risk factors, and multiple age-related comorbidities. Although prevention and management strategies have been shown to be effective in older people, they continue to be under-used, and under-studied. In addition to hard endpoints, frailty, cognitive impairments, and patients' re-assessment of important outcomes (e.g. quality of life vs. longevity) are important aspects for older patients and emphasize the need to include a substantial proportion of older patients in CV clinical trials. To complement the often skewed age distribution in clinical trials, greater emphasis should be placed on real-world studies to assess longer-term outcomes, especially safety and quality of life outcomes. In the complex environment of the older patient, a multidisciplinary care team approach with the involvement of the individual patient in the decision-making process can help optimize prevention and management strategies. This article aims to demonstrate the growing burden of ageing in real life and illustrates the need to continue primary prevention to address CV risk factors. It summarizes factors to consider when choosing pharmacological and interventional treatments for the elderly and the need to consider quality of life and patient priorities when making decisions. CI - Published on behalf of the European Society of Cardiology. All rights reserved. (c) The European Society of Cardiology 2022. For permissions, please email: journals.permissions@oup.com. FAU - Lettino, Maddalena AU - Lettino M AUID- ORCID: 0000-0003-0146-9196 AD - Cardiovascular Department, San Gerardo Hospital of Monza, Via G. B. Pergolesi, 33, 20900 Monza MB, Italy. FAU - Mascherbauer, Julia AU - Mascherbauer J AUID- ORCID: 0000-0001-7478-1450 AD - Department of Internal Medicine, Karl Landsteiner University of Health Sciences, University Hospital St. Polten, Krems, Austria. FAU - Nordaby, Matias AU - Nordaby M AUID- ORCID: 0000-0003-1760-1550 AD - Heart Failure, Boehringer-Ingelheim, Ingelheim am Rhein, Germany. FAU - Ziegler, Andre AU - Ziegler A AD - Cardiovascular Diseases, Roche Diagnostics, Rotkreuz, Switzerland. FAU - Collet, Jean Philippe AU - Collet JP AD - ACTION Group, www.action-groupe.org, Sorbonne Universite, INSERM UMRS1166, Hopital Pitie-Salpetriere (AP-HP), Institut de Cardiologie, Paris, France. FAU - Derumeaux, Genevieve AU - Derumeaux G AD - Physiology Department, Henri Mondor Hospital (APHP), FHU SENEC, Creteil, France. AD - Mondor Biomedical Research Institute (IMRB), UPEC, Creteil, France. FAU - Hohnloser, Stefan H AU - Hohnloser SH AD - Department of Electrophysiology, J.W. Goethe University, Frankfurt, Germany. AD - Center of Thrombosis and Hemostasis, University of Mainz, Mainz, Germany. FAU - Leclercq, Christophe AU - Leclercq C AD - Department of Cardiology, CHU Rennes and Inserm, LTSI, University of Rennes, Rennes, France. FAU - O'Neill, Deirdre E AU - O'Neill DE AD - Department of Cardiology, University of Alberta Hospital, Edmonton, Alberta, Canada. AD - Mazankowski Heart Institute, Edmonton, Alberta, Canada. FAU - Visseren, Frank AU - Visseren F AD - Department of Vascular Medicine, University Medical Center, Utrecht, The Netherlands. FAU - Weidinger, Franz AU - Weidinger F AUID- ORCID: 0000-0003-0829-9097 AD - 2nd Medical Dept. with Cardiology and Intensive Care Medicine, Hospital Rudolfstiftung, Vienna, Austria. FAU - Richard-Lordereau, Isabelle AU - Richard-Lordereau I AD - General Medicine Europe, Amgen Europe, Rotkreutz ZG, Switzerland. LA - eng PT - Journal Article PL - England TA - Eur J Prev Cardiol JT - European journal of preventive cardiology JID - 101564430 SB - IM MH - Aged MH - Aging MH - *Cardiology MH - *Cardiovascular Diseases/diagnosis/epidemiology/prevention & control MH - Comorbidity MH - Humans MH - Quality of Life OTO - NOTNLM OT - Anticoagulant OT - Antiplatelet OT - Coronary revascularization OT - Older people OT - Primary prevention OT - Risk assessment COIS- Conflict of interest: M.L.: honoraria from Bristol-Meyers Squibb, Pfizer, Sanofi, Boehringer Ingelheim, Daiichi Sankyo, and Edwards Lifescience; advisory board participation for Boehringer Ingelheim and Edwards Lifescience; and a leadership role (President) with a multi-hospital Institutional Review Board. M.N.: employment with Boehringer Ingelheim International J.-P.C.: Grants or contracts from Bristol-Myers Squibb, Medtronic, and Pfizer; and honoraria from Abbott, AstraZeneca, Boston Scientific, and Sanofi. G.D.: institutional grants to INSERM (RHU CARMMA) from Agence Nationale pour la Recherche (ANR). S.H.H.: consulting fees from Bristol-Meyers Squibb, Pfizer, Boehringer Ingelheim, Bayer, and Daiichi Sankyo; and honoraria from Bristol-Meyers Squibb, Pfizer, Boehringer Ingelheim, Bayer, and Daiichi Sankyo. D.E.O.: honoraria from Servier Canada. F.V.: research funding from Amgen. I.R.-L.: employment with and stock options from Amgen. And all other authors have no conflict of interest to declare. EDAT- 2022/02/16 06:00 MHDA- 2022/08/10 06:00 CRDT- 2022/02/15 17:14 PHST- 2021/12/24 00:00 [received] PHST- 2022/01/24 00:00 [revised] PHST- 2022/02/10 00:00 [accepted] PHST- 2022/02/16 06:00 [pubmed] PHST- 2022/08/10 06:00 [medline] PHST- 2022/02/15 17:14 [entrez] AID - 6529006 [pii] AID - 10.1093/eurjpc/zwac033 [doi] PST - ppublish SO - Eur J Prev Cardiol. 2022 Aug 5;29(10):1412-1424. doi: 10.1093/eurjpc/zwac033. PMID- 35157989 OWN - NLM STAT- MEDLINE DCOM- 20220512 LR - 20220711 IS - 1916-7075 (Electronic) IS - 0828-282X (Linking) VI - 38 IP - 5 DP - 2022 May TI - Diagnostic and Therapeutic Challenges of Vasculitis. PG - 623-633 LID - S0828-282X(22)00125-8 [pii] LID - 10.1016/j.cjca.2022.02.007 [doi] AB - Systemic vasculitis can be a challenge to differentiate from other forms of vasculopathy. Because treatment for systemic vasculitis is disparate from that for other forms of vasculopathy, clinicians should strive for high diagnostic certainty. This review article aims to highlight the clinical, radiographic, and histologic clues to distinguish systemic vasculitis from mimics. Vasculitis should be considered in patients with preexisting conditions including autoimmune connective tissue diseases, multisystem manifestations, unexplained ischemic events, unusual radiographic findings, or signs of systemic inflammation. A multidisciplinary approach can be used among rheumatologists, vascular cardiologists, radiologists, and vascular interventionalists to raise diagnostic certainty in cases with large- and/or medium-vessel involvement. Recognition of cardiac manifestations, including myocarditis seen in forms of small-vessel vasculitis (eg, eosinophilic granulomatosis with polyangiitis) or coronary arteritis seen in forms of medium-vessel vasculitis (eg, polyarteritis nodosa and Kawasaki disease) is important owing to the associated mortality. Clinical phenotype, radiographic features, laboratory tests, and histology can help to differentiate vasculitis from noninflammatory vasculopathies and define the etiology of the vasculitis to help guide appropriate treatment. Various modalities of imaging can give clues to aid in diagnosis of vasculitis and can be considered in the context of physician preference and patient comorbidity. While conventional angiography can give important details regarding luminal anatomy and pressure gradients in medium- and large-vessel vasculitis, noninvasive imaging modalities such as computed tomographic angiography, magnetic resonance angiography, color Doppler ultrasound, and positron emission tomography/computed tomography are commonly used for both diagnosis and follow-up. Treatment for systemic vasculitis should be coordinated with an experienced rheumatologist. CI - Copyright (c) 2022 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved. FAU - Hansen, Megan E AU - Hansen ME AD - Vanderbilt University Medical Center, Nashville, Tennessee, USA. FAU - Springer, Jason AU - Springer J AD - Vanderbilt University Medical Center, Nashville, Tennessee, USA. FAU - Byram, Kevin AU - Byram K AD - Vanderbilt University Medical Center, Nashville, Tennessee, USA. Electronic address: kevin.byram@vumc.org. LA - eng PT - Journal Article PT - Review DEP - 20220211 PL - England TA - Can J Cardiol JT - The Canadian journal of cardiology JID - 8510280 SB - IM MH - *Churg-Strauss Syndrome MH - *Granulomatosis with Polyangiitis MH - Humans MH - Magnetic Resonance Angiography MH - *Mucocutaneous Lymph Node Syndrome MH - *Polyarteritis Nodosa EDAT- 2022/02/15 06:00 MHDA- 2022/05/14 06:00 CRDT- 2022/02/14 20:11 PHST- 2021/10/25 00:00 [received] PHST- 2022/02/05 00:00 [revised] PHST- 2022/02/07 00:00 [accepted] PHST- 2022/02/15 06:00 [pubmed] PHST- 2022/05/14 06:00 [medline] PHST- 2022/02/14 20:11 [entrez] AID - S0828-282X(22)00125-8 [pii] AID - 10.1016/j.cjca.2022.02.007 [doi] PST - ppublish SO - Can J Cardiol. 2022 May;38(5):623-633. doi: 10.1016/j.cjca.2022.02.007. Epub 2022 Feb 11. PMID- 35156887 OWN - NLM STAT- MEDLINE DCOM- 20220216 LR - 20220216 IS - 1938-2359 (Electronic) IS - 0090-4481 (Linking) VI - 51 IP - 2 DP - 2022 Feb TI - Primary Ciliary Dyskinesia: A Rare and Often Underdiagnosed Disease. PG - e82-e85 LID - 10.3928/19382359-20220119-01 [doi] AB - Primary ciliary dyskinesia (PCD) is a rare autosomal recessive disease with clinical features of ear, sinus, and pulmonary infections that overlap with common respiratory illnesses of childhood. It is a progressive disorder that has significant influence on quality of life, lung function, and survival. Given the considerable overlap of symptoms between common illnesses and PCD, a high index of suspicion by primary care providers is needed to consider the diagnosis. There is not a single "gold standard" diagnostic test for PCD and multiple diagnostic methods coupled with specialized expertise is often needed to make the diagnosis. Patients with PCD also have comorbidities requiring a multidisciplinary approach for optimal clinical management. It is important for primary care physicians to recognize the PCD clinical phenotype and have a diagnostic framework for these patients. [Pediatr Ann. 2022;51(2):e82-e85.]. FAU - Shah, Avani AU - Shah A FAU - Laguna, Theresa A AU - Laguna TA LA - eng PT - Journal Article DEP - 20220201 PL - United States TA - Pediatr Ann JT - Pediatric annals JID - 0356657 SB - IM MH - Humans MH - *Kartagener Syndrome/diagnosis/therapy MH - Phenotype MH - *Quality of Life EDAT- 2022/02/15 06:00 MHDA- 2022/02/17 06:00 CRDT- 2022/02/14 12:14 PHST- 2022/02/14 12:14 [entrez] PHST- 2022/02/15 06:00 [pubmed] PHST- 2022/02/17 06:00 [medline] AID - 10.3928/19382359-20220119-01 [doi] PST - ppublish SO - Pediatr Ann. 2022 Feb;51(2):e82-e85. doi: 10.3928/19382359-20220119-01. Epub 2022 Feb 1. PMID- 35156262 OWN - NLM STAT- MEDLINE DCOM- 20220426 LR - 20220512 IS - 1460-9592 (Electronic) IS - 1155-5645 (Linking) VI - 32 IP - 5 DP - 2022 May TI - Initial results from an enhanced recovery program for pediatric cardiac surgical patients. PG - 647-653 LID - 10.1111/pan.14418 [doi] AB - BACKGROUND: Over recent years, a number of enhanced recovery programs have appeared in first, adult colorectal surgery, and subsequently many other adult surgical specialties. Increasing interest in this approach to perioperative management in children culminated in the recent development of the first enhanced recovery pathway for pediatric intestinal surgery, endorsed by Enhanced Recovery after Surgery Society (ERAS(R)). In parallel, there has been increasing interest in the refinement of perioperative management of selected pediatric cardiac surgical patients, invariably referred to as "fast track" management. Initiatives have largely focused on duration of postoperative ventilation rather than on a much wider range of perioperative interventions to optimize recovery and ensure timely discharge after surgery. In our institution, a "Level 1" pediatric cardiac surgical center, we assembled a multidisciplinary team to design a comprehensive enhanced recovery pathway, based on ERAS(R) methodology, for selected cardiac surgical patients. After a lengthy period of planning, staff education, and preparation, we implemented the pathway at the end of November 2019. METHODS: We conducted a prospective audit of the perioperative management and outcomes of the first 88 patients managed according to this enhanced recovery pathway over a 25-month period in our institution. RESULTS: The mean age of the patients was 5.8 years (range 0.5-17.9), and the mean weight was 22.4 kg (range 6.6-57.2). Sixty-eight of the 88 patients were cardiopulmonary bypass cases. A total of 54% of patients received all four defined intraoperative anesthetic interventions (intravenous paracetamol, non-steroidal anti-inflammatory drug, antiemetic if aged more than 4 years, and use of a local anesthetic technique). A total of 89% of patients met the target extubation time of 6 h after administration of protamine. Median postoperative intensive care unit length of stay was 23.5 h (range 15.2-89.5). When compared to a historic control group, this represented a 22% reduction in median intensive care unit stay, although the total hospital length of stay remained unchanged. A total of 83% of patients met the target hospital discharge target of the fifth postoperative day. CONCLUSIONS: These preliminary results suggest that enhanced recovery pathway implementation for selected pediatric cardiac surgical patients is feasible, with acceptable outcomes. They suggest areas for further development and the potential for wider implementation. CI - (c) 2022 John Wiley & Sons Ltd. FAU - Murphy, Tim AU - Murphy T AUID- ORCID: 0000-0002-2744-0976 AD - Pediatric Cardiac Anesthesia, Bristol Royal Hospital for Children, Bristol, UK. FAU - Sale, Steven M AU - Sale SM AD - Pediatric Cardiac Anesthesia, Bristol Royal Hospital for Children, Bristol, UK. FAU - Gonzalez Barlatay, Francisco AU - Gonzalez Barlatay F AD - Pediatric Cardiology, Bristol Royal Hospital for Children, Bristol, UK. FAU - Armstrong, Catherine AU - Armstrong C AD - Pediatric Cardiology, Bristol Royal Hospital for Children, Bristol, UK. FAU - Parry, Andrew AU - Parry A AD - Congenital Cardiac Surgery, Bristol Royal Hospital for Children, Bristol, UK. FAU - Houghton, Ella AU - Houghton E AD - Bristol Royal Hospital for Children, Bristol, UK. FAU - Jerrom, Tom AU - Jerrom T AD - Pediatric Intensive Care, Bristol Royal Hospital for Children, Bristol, UK. FAU - Schadenberg, Alvin AU - Schadenberg A AD - Pediatric Intensive Care, Bristol Royal Hospital for Children, Bristol, UK. LA - eng PT - Journal Article DEP - 20220301 PL - France TA - Paediatr Anaesth JT - Paediatric anaesthesia JID - 9206575 SB - IM MH - Adolescent MH - Adult MH - *Cardiac Surgical Procedures MH - Child MH - Child, Preschool MH - *Digestive System Surgical Procedures MH - Humans MH - Infant MH - Intensive Care Units MH - Length of Stay MH - Patient Discharge MH - Postoperative Complications EDAT- 2022/02/15 06:00 MHDA- 2022/04/27 06:00 CRDT- 2022/02/14 05:39 PHST- 2022/01/07 00:00 [revised] PHST- 2021/07/05 00:00 [received] PHST- 2022/02/04 00:00 [accepted] PHST- 2022/02/15 06:00 [pubmed] PHST- 2022/04/27 06:00 [medline] PHST- 2022/02/14 05:39 [entrez] AID - 10.1111/pan.14418 [doi] PST - ppublish SO - Paediatr Anaesth. 2022 May;32(5):647-653. doi: 10.1111/pan.14418. Epub 2022 Mar 1. PMID- 35156032 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220501 IS - 2632-1823 (Electronic) IS - 2632-1823 (Linking) VI - 4 IP - 1 DP - 2022 Mar TI - Partial oral antibiotic treatment of endocarditis in patients who inject drugs: a case series. PG - dlac008 LID - 10.1093/jacamr/dlac008 [doi] LID - dlac008 AB - BACKGROUND: Recent literature has demonstrated that partial oral antibiotic treatment of infectious endocarditis is non-inferior to IV therapy in select patients. Despite the rising incidence of injection drug use-related endocarditis, partial oral therapy has not been well studied in persons who inject drugs. OBJECTIVES: To evaluate the rate of relapsed infection and 90 day mortality in patients with infectious endocarditis treated with partial oral antibiotic therapy. METHODS: Consecutive patients with infectious endocarditis treated with partial oral antibiotic therapy were identified by study investigators and reviewed by independent clinicians. The decision to use partial oral antibiotic therapy was made by the institution's multidisciplinary endocarditis team. RESULTS: In 11 cases of infective endocarditis treated with partial oral antibiotic therapy, 9 of which were complicated by injection drug use, there were no relapsed infections with the primary organism. Five patients underwent surgical valve replacement, and the median duration of oral antibiotic therapy was 23 days. All patients survived to in-hospital discharge and 90 days post-discharge. Ten patients followed up with an infectious diseases provider after discharge. CONCLUSIONS: These data add to existing literature demonstrating non-inferior outcomes with partial oral antibiotic treatment when compared with IV antibiotic treatment alone in patients with endocarditis, including persons who inject drugs. CI - (c) The Author(s) 2022. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. FAU - Miller, Kaylie AU - Miller K AD - University of Pittsburgh Medical Center, Department of Internal Medicine, 3601 Fifth Avenue Pittsburgh, PA 15213, USA. FAU - Evans, Emily AU - Evans E AD - University of Pittsburgh Medical Center, Department of Internal Medicine, 3601 Fifth Avenue Pittsburgh, PA 15213, USA. FAU - Sheridan, Kathleen R AU - Sheridan KR AD - University of Pittsburgh Medical Center, Division of Infectious Diseases, Department of Internal Medicine, 3601 Fifth Avenue Pittsburgh, PA 15213, USA. FAU - Nauriyal, Varidhi AU - Nauriyal V AD - University of Pittsburgh Medical Center, Division of Infectious Diseases, Department of Internal Medicine, 3601 Fifth Avenue Pittsburgh, PA 15213, USA. FAU - Viehman, J Alexander AU - Viehman JA AD - University of Pittsburgh Medical Center, Division of Infectious Diseases, Department of Internal Medicine, 3601 Fifth Avenue Pittsburgh, PA 15213, USA. FAU - Rivosecchi, Ryan AU - Rivosecchi R AD - University of Pittsburgh Medical Center, Department of Pharmacy, 3501 Terrace Street Pittsburgh, PA 15213, USA. FAU - Stoner, Bobbi Jo AU - Stoner BJ AD - University of Kentucky Medical Center, Division of Infectious Diseases, Department of Internal Medicine, 740 S. Limestone Street Lexington, KY 40536, USA. FAU - El-Dalati, Sami AU - El-Dalati S AUID- ORCID: 0000-0003-2603-2951 AD - University of Kentucky Medical Center, Division of Infectious Diseases, Department of Internal Medicine, 740 S. Limestone Street Lexington, KY 40536, USA. LA - eng PT - Journal Article DEP - 20220208 PL - England TA - JAC Antimicrob Resist JT - JAC-antimicrobial resistance JID - 101765283 PMC - PMC8827559 EDAT- 2022/02/15 06:00 MHDA- 2022/02/15 06:01 PMCR- 2022/02/08 CRDT- 2022/02/14 05:37 PHST- 2021/10/20 00:00 [received] PHST- 2022/01/10 00:00 [accepted] PHST- 2022/02/14 05:37 [entrez] PHST- 2022/02/15 06:00 [pubmed] PHST- 2022/02/15 06:01 [medline] PHST- 2022/02/08 00:00 [pmc-release] AID - dlac008 [pii] AID - 10.1093/jacamr/dlac008 [doi] PST - epublish SO - JAC Antimicrob Resist. 2022 Feb 8;4(1):dlac008. doi: 10.1093/jacamr/dlac008. eCollection 2022 Mar. PMID- 35152494 OWN - NLM STAT- MEDLINE DCOM- 20220404 LR - 20250530 IS - 1540-8191 (Electronic) IS - 0886-0440 (Linking) VI - 37 IP - 5 DP - 2022 May TI - Octogenarians needing reoperative aortic valve surgery-Does one size fit all? PG - 1272-1274 LID - 10.1111/jocs.16343 [doi] AB - Early and midterm outcomes, rather than long-term outcomes, are perhaps more relevant in octogenarians undergoing transcatheter aortic valve replacement (TAVR) or redo-surgical aortic valve replacement. Considering that early and midterm outcomes are similar with both the interventions, TAVR appears to be an attractive option in these patients. However, decision-making should consider other factors like presence of porcelain aorta, or severe primary mitral regurgitation among others that may influence the strategy to be adopted. The philosophy of shared decision making, and heart team consultation is, therefore, ever most relevant in these high-risk and vulnerable groups of patients. The recommendations rather than being universal must be individualized based on the type of previous surgery carried out, need for isolated AVR or concomitant surgery, co-morbid conditions, available expertise, and patient choice. CI - (c) 2022 Wiley Periodicals LLC. FAU - Narayan, Pradeep AU - Narayan P AUID- ORCID: 0000-0002-3843-1338 AD - Department of Cardiac Surgery, Rabindranath Tagore International Institute of Cardiac Sciences, Narayana Health, Kolkata, India. FAU - Dimagli, Arnaldo AU - Dimagli A AUID- ORCID: 0000-0003-0055-8656 AD - Department of Cardiac Surgery, Bristol Heart Institute, Bristol University, Bristol, UK. FAU - Angelini, Gianni D AU - Angelini GD AUID- ORCID: 0000-0002-1753-3730 AD - Department of Cardiac Surgery, Bristol Heart Institute, Bristol University, Bristol, UK. LA - eng GR - CH/1992027/7163/BHF_/British Heart Foundation/United Kingdom PT - Journal Article DEP - 20220213 PL - United States TA - J Card Surg JT - Journal of cardiac surgery JID - 8908809 SB - IM MH - Aged, 80 and over MH - Aortic Valve/surgery MH - *Aortic Valve Stenosis/etiology/surgery MH - *Heart Valve Prosthesis MH - *Heart Valve Prosthesis Implantation/adverse effects MH - Humans MH - Octogenarians MH - Risk Factors MH - *Transcatheter Aortic Valve Replacement/adverse effects MH - Treatment Outcome OTO - NOTNLM OT - SAVR OT - ViV-TAVR OT - reoperative surgery EDAT- 2022/02/14 06:00 MHDA- 2022/04/05 06:00 CRDT- 2022/02/13 20:38 PHST- 2022/02/03 00:00 [received] PHST- 2022/02/04 00:00 [accepted] PHST- 2022/02/14 06:00 [pubmed] PHST- 2022/04/05 06:00 [medline] PHST- 2022/02/13 20:38 [entrez] AID - 10.1111/jocs.16343 [doi] PST - ppublish SO - J Card Surg. 2022 May;37(5):1272-1274. doi: 10.1111/jocs.16343. Epub 2022 Feb 13. PMID- 35151776 OWN - NLM STAT- MEDLINE DCOM- 20220405 LR - 20220525 IS - 1873-1570 (Electronic) IS - 0300-9572 (Linking) VI - 173 DP - 2022 Apr TI - Effect of implementing decision support to activate a rapid response system by automated screening of verified vital sign data: A retrospective database study. PG - 23-30 LID - S0300-9572(22)00039-9 [pii] LID - 10.1016/j.resuscitation.2022.02.004 [doi] AB - AIM: Activating a rapid response system (RRS) at general wards requires memorizing trigger criteria, identifying deterioration, and timely notification of abnormalities. We aimed to assess the effect of decision support (DS)-linked RRS activation on management and outcomes. METHODS: We retrospectively analyzed general ward RRS activation cases from 2013 to 2017 and the incidence of cardiopulmonary resuscitations (CPR) from 2013 to 2020. A DS-alerting mechanism was added to the conventional RRS activation process in 2017, with an alert window appearing whenever the system automatically detected any verified abnormal vital sign entry, alerting the nurse to take further action. Logistic and linear regression analyses were used to compare outcomes. RESULTS: We analyzed 27,747 activations and 64,592 DS alerts. RRS activations increased from 3.5 to 30.3 per 1,000 patient-days (P < 0.001) after DS implementation. The first DS activations occurred earlier than conventional ones (-2.9 days, 95% confidence interval = -3.6 to -2.1 days). After adjustment with inverse probability of treatment weighting, main (conventional vs DS-linked activations after implementation) and sensitivity analyses showed that DS activation cases had a lower risk of CPR and in-hospital mortality. Cases with more DS alerts before RRS activation had a higher risk of CPR (P trend = 0.017) and in-hospital mortality (P trend < 0.001). The incidence of CPR at the general ward decreased. CONCLUSION: Implementing a DS mechanism with an automated screening of verified abnormal vital signs linked to RRS activations at general wards was associated with improved practice and timeliness of hospital-wide RRS activations and reduced in-hospital resuscitations and mortality. CI - Copyright (c) 2022 Elsevier B.V. All rights reserved. FAU - Jerng, Jih-Shuin AU - Jerng JS AD - Center for Quality Management, National Taiwan University Hospital, No. 7 Zhongshan South Road, Taipei 10002, Taiwan; Department of Internal Medicine, National Taiwan University Hospital, No. 7 Zhongshan South Road, Taipei 10002, Taiwan. FAU - Chen, Li-Chin AU - Chen LC AD - Center for Quality Management, National Taiwan University Hospital, No. 7 Zhongshan South Road, Taipei 10002, Taiwan. FAU - Chen, Shey-Ying AU - Chen SY AD - Center for Quality Management, National Taiwan University Hospital, No. 7 Zhongshan South Road, Taipei 10002, Taiwan; Department of Emergency Medicine, National Taiwan University Hospital, No. 7 Zhongshan South Road, Taipei 10002, Taiwan. Electronic address: erdrcsy@ntu.edu.tw. FAU - Kuo, Lu-Cheng AU - Kuo LC AD - Department of Internal Medicine, National Taiwan University Hospital, No. 7 Zhongshan South Road, Taipei 10002, Taiwan. FAU - Tsan, Chin-Yuan AU - Tsan CY AD - Department of Nursing, National Taiwan University Hospital, No. 7 Zhongshan South Road, Taipei 10002, Taiwan. FAU - Hsieh, Pei-Yin AU - Hsieh PY AD - Department of Nursing, National Taiwan University Hospital, No. 7 Zhongshan South Road, Taipei 10002, Taiwan. FAU - Chen, Chien-Min AU - Chen CM AD - Department of Information Technology, National Taiwan University Hospital, No. 7 Zhongshan South Road, Taipei 10002, Taiwan. FAU - Chuang, Pao-Yu AU - Chuang PY AD - Center for Quality Management, National Taiwan University Hospital, No. 7 Zhongshan South Road, Taipei 10002, Taiwan; Department of Nursing, National Taiwan University Hospital, No. 7 Zhongshan South Road, Taipei 10002, Taiwan. FAU - Huang, Hsiao-Fang AU - Huang HF AD - Center for Quality Management, National Taiwan University Hospital, No. 7 Zhongshan South Road, Taipei 10002, Taiwan. FAU - Huang, Szu-Fen AU - Huang SF AD - Department of Nursing, National Taiwan University Hospital, No. 7 Zhongshan South Road, Taipei 10002, Taiwan. LA - eng PT - Journal Article DEP - 20220210 PL - Ireland TA - Resuscitation JT - Resuscitation JID - 0332173 SB - IM MH - Hospital Mortality MH - *Hospital Rapid Response Team MH - Humans MH - Patients' Rooms MH - Retrospective Studies MH - Vital Signs OTO - NOTNLM OT - Cardiac arrest OT - Decision support OT - Patient monitoring OT - Rapid response system OT - Resuscitation COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2022/02/14 06:00 MHDA- 2022/04/06 06:00 CRDT- 2022/02/13 20:28 PHST- 2021/11/17 00:00 [received] PHST- 2022/01/23 00:00 [revised] PHST- 2022/02/04 00:00 [accepted] PHST- 2022/02/14 06:00 [pubmed] PHST- 2022/04/06 06:00 [medline] PHST- 2022/02/13 20:28 [entrez] AID - S0300-9572(22)00039-9 [pii] AID - 10.1016/j.resuscitation.2022.02.004 [doi] PST - ppublish SO - Resuscitation. 2022 Apr;173:23-30. doi: 10.1016/j.resuscitation.2022.02.004. Epub 2022 Feb 10. PMID- 37969243 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260312 IS - 2772-8129 (Electronic) IS - 2772-8129 (Linking) VI - 1 IP - 2 DP - 2022 Apr TI - Sudden Cardiac Arrest in the Paediatric Population. PG - 45-59 LID - 10.1016/j.cjcpc.2022.02.001 [doi] AB - Sudden cardiac arrest in the young is a rare event with a range of potential causes including cardiomyopathies, ion channelopathies, and autonomic nervous system dysfunction. Investigations into the cause involve a multidisciplinary team, including cardiologists, geneticists, and psychologists. In addition to a detailed medical history, family history and circumstances surrounding the event are important in determining the cause. Clinical investigations including an electrocardiogram are fundamental in diagnosis and should be interpreted cautiously because some children may have atypical presentations and an evolving phenotype. The potential for misdiagnosis exists that could lead to incorrect long-term management strategies. If an inherited condition is suspected, genetic testing of the patient and cascade screening of family members is recommended with genetic counselling and psychological support. Medical management is left to the treating physician acknowledging that a clear diagnosis cannot be made in approximately half of cases. Secondary prevention implantable defibrillators are widely deployed but can be associated with complications in young patients. A plan for safe return to activity is recommended along with a proper transition of care into adulthood. Broad screening of the general population for arrhythmia syndromes is not recommended; preventative measures include screening paediatric patients for risk factors by their primary care physician. Several milestone events or activities that take place in youth could be used as opportunities to promote safety. Further work into risk stratification of this paediatric population through patient registries and greater awareness of cardiopulmonary resuscitation and automated external defibrillator use in saving lives is warranted. CI - (c) 2022 The Author(s). FAU - Franciosi, Sonia AU - Franciosi S AD - BC Children's Hospital Heart Centre, Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Abrams, Dominic J AU - Abrams DJ AD - Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts, USA. FAU - Ingles, Jodie AU - Ingles J AD - Centre for Population Genomics, Garvan Institute of Medical Research, and UNSW Sydney, Sydney, New South Wales, Australia. AD - Centre for Population Genomics, Murdoch Children's Research Institute, Melbourne, Victoria, Australia. FAU - Sanatani, Shubhayan AU - Sanatani S AD - BC Children's Hospital Heart Centre, Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada. LA - eng PT - Journal Article PT - Review DEP - 20220210 PL - United States TA - CJC Pediatr Congenit Heart Dis JT - CJC pediatric and congenital heart disease JID - 9918697364606676 EIN - CJC Pediatr Congenit Heart Dis. 2023 May 05;2(3):162-165. doi: 10.1016/j.cjcpc.2023.05.002. PMID: 37969358 PMC - PMC10642157 EDAT- 2022/02/10 00:00 MHDA- 2022/02/10 00:01 PMCR- 2022/02/10 CRDT- 2023/11/16 04:19 PHST- 2021/11/18 00:00 [received] PHST- 2022/02/03 00:00 [accepted] PHST- 2022/02/10 00:01 [medline] PHST- 2022/02/10 00:00 [pubmed] PHST- 2023/11/16 04:19 [entrez] PHST- 2022/02/10 00:00 [pmc-release] AID - S2772-8129(22)00016-1 [pii] AID - 10.1016/j.cjcpc.2022.02.001 [doi] PST - epublish SO - CJC Pediatr Congenit Heart Dis. 2022 Feb 10;1(2):45-59. doi: 10.1016/j.cjcpc.2022.02.001. eCollection 2022 Apr. PMID- 35132722 OWN - NLM STAT- MEDLINE DCOM- 20220823 LR - 20251112 IS - 1540-8167 (Electronic) IS - 1045-3873 (Linking) VI - 33 IP - 8 DP - 2022 Aug TI - The Convergent procedure for AF: A surgeon's perspective. PG - 1919-1926 LID - 10.1111/jce.15404 [doi] AB - The Converge IDE Trial demonstrated improved patient outcomes in a challenging persistent and long-standing persistent atrial fibrillation population using a heart team hybrid approach with epicardial and endocardial staged ablations. Surgeons encounter unique circumstances with the surgical epicardial stage of the Convergent procedure which includes unfamiliarity with left atrial posterior anatomy, endoscopic/thoracoscopic visualization, minimally invasive left atrial appendage management, and expanded indications for the procedure. Overcoming these unique challenges is key to the adoption of the Convergent procedure as a critical off-pump approach that should be part of the surgical armamentarium in the treatment of atrial fibrillation. CI - (c) 2022 Wiley Periodicals LLC. FAU - Kiankhooy, Armin AU - Kiankhooy A AUID- ORCID: 0000-0001-7610-9406 AD - Department of Cardiothoracic & Vascular Surgery, Adventist Health - St. Helena, St. Helena, California, USA. FAU - McMenamy, Maureen E AU - McMenamy ME AD - Division of Adult Cardiothoracic Surgery, UCSF Medical Center at Parnassus, San Francisco, California, USA. LA - eng PT - Journal Article PT - Review DEP - 20220217 PL - United States TA - J Cardiovasc Electrophysiol JT - Journal of cardiovascular electrophysiology JID - 9010756 SB - IM MH - *Atrial Fibrillation/surgery MH - Humans MH - *Surgeons/psychology OTO - NOTNLM OT - Converge IDE Trial OT - Convergent procedure OT - heart team OT - hybrid maze EDAT- 2022/02/09 06:00 MHDA- 2022/08/24 06:00 CRDT- 2022/02/08 05:53 PHST- 2022/01/10 00:00 [revised] PHST- 2021/12/29 00:00 [received] PHST- 2022/01/20 00:00 [accepted] PHST- 2022/02/09 06:00 [pubmed] PHST- 2022/08/24 06:00 [medline] PHST- 2022/02/08 05:53 [entrez] AID - 10.1111/jce.15404 [doi] PST - ppublish SO - J Cardiovasc Electrophysiol. 2022 Aug;33(8):1919-1926. doi: 10.1111/jce.15404. Epub 2022 Feb 17. PMID- 35130773 OWN - NLM STAT- MEDLINE DCOM- 20220907 LR - 20250728 IS - 1940-5596 (Electronic) IS - 1089-2532 (Linking) VI - 26 IP - 3 DP - 2022 Sep TI - Role of Value-Added Care by Cardiothoracic Anesthesiology and Impact on Outcomes After Cardiac Surgery. PG - 173-178 LID - 10.1177/10892532211048953 [doi] AB - The medical community is increasingly aware of the need for high-quality and high-value patient care. Anesthesiologists in particular have long demonstrated leadership in the field of quality and safety. Cardiothoracic anesthesiologists can improve the quality of care delivered to cardiac patients both with anesthesia-specific practices and in a team-based approach with other perioperative care providers. Collecting large volumes of multicentered data to study, measure, and improve anesthesia care is one of the many commitments of cardiothoracic anesthesiologists to this cause. This article reviews this and other aspects of the work of cardiothoracic anesthesiologists to improve value-added care to cardiac patients. FAU - Ariyo, Promise AU - Ariyo P AUID- ORCID: 0000-0002-7518-3492 AD - 1500Johns Hopkins University School of Medicine, Baltimore, MD, USA. FAU - Abernathy, James H 3rd AU - Abernathy JH 3rd AD - 1500Johns Hopkins University School of Medicine, Baltimore, MD, USA. FAU - Hensley, Nadia B AU - Hensley NB AD - 1500Johns Hopkins University School of Medicine, Baltimore, MD, USA. LA - eng PT - Journal Article PT - Review DEP - 20220208 PL - United States TA - Semin Cardiothorac Vasc Anesth JT - Seminars in cardiothoracic and vascular anesthesia JID - 9807630 SB - IM MH - *Anesthesia MH - Anesthesiologists MH - *Anesthesiology MH - *Cardiac Surgical Procedures MH - Humans MH - Perioperative Care OTO - NOTNLM OT - cardiac surgery OT - cardiothoracic anesthesiology OT - outcomes OT - quality care OT - value-added care EDAT- 2022/02/09 06:00 MHDA- 2022/09/08 06:00 CRDT- 2022/02/08 05:37 PHST- 2022/02/09 06:00 [pubmed] PHST- 2022/09/08 06:00 [medline] PHST- 2022/02/08 05:37 [entrez] AID - 10.1177/10892532211048953 [doi] PST - ppublish SO - Semin Cardiothorac Vasc Anesth. 2022 Sep;26(3):173-178. doi: 10.1177/10892532211048953. Epub 2022 Feb 8. PMID- 35130320 OWN - NLM STAT- MEDLINE DCOM- 20220303 LR - 20220303 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 17 IP - 2 DP - 2022 TI - Healthcare providers experiences with shared medical appointments for heart failure. PG - e0263498 LID - 10.1371/journal.pone.0263498 [doi] LID - e0263498 AB - Shared medical appointments (SMAs) offer a means for providing knowledge and skills needed for chronic disease management to patients. However, SMAs require a time and attention investment from health care providers, who must understand the goals and potential benefits of SMAs from the perspective of patients and providers. To better understand how to gain provider engagement and inform future SMA implementation, qualitative inquiry of provider experience based on a knowledge-attitude-practice model was explored. Semi-structured interviews were conducted with 24 health care providers leading SMAs for heart failure at three Veterans Administration Medical Centers. Rapid matrix analysis process techniques including team-based qualitative inquiry followed by stakeholder validation was employed. The interview guide followed a knowledge-attitude-practice model with a priori domains of knowledge of SMA structure and content (understanding of how SMAs were structured), SMA attitude/beliefs (general expectations about SMA use), attitudes regarding how leading SMAs affected patients, and providers. Data regarding the patient referral process (organizational processes for referring patients to SMAs) and suggested improvements were collected to further inform the development of SMA implementation best practices. Providers from all three sites reported similar knowledge, attitude and beliefs of SMAs. In general, providers reported that the multi-disciplinary structure of SMAs was an effective strategy towards improving clinical outcomes for patients. Emergent themes regarding experiences with SMAs included improved self-efficacy gained from real-time collaboration with providers from multiple disciplines, perceived decrease in patient re-hospitalizations, and promotion of self-management skills for patients with HF. Most providers reported that the SMA-setting facilitated patient learning by providing opportunities for the sharing of experiences and knowledge. This was associated with the perception of increased comradery and support among patients. Future research is needed to test suggested improvements and to develop best practices for training additional sites to implement HF SMA. FAU - Marshall, Vanessa AU - Marshall V AD - Research, VA Northeast Ohio Healthcare System, Cleveland, Ohio, United States of America. AD - University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States of America. AD - Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio, United States of America. FAU - Jewett-Tennant, Jeri AU - Jewett-Tennant J AD - Health System Education/Opioid Data 2 Action, The Center for Health Affairs, Cleveland, Ohio, United States of America. FAU - Shell-Boyd, Jeneen AU - Shell-Boyd J AD - Research, VA Northeast Ohio Healthcare System, Cleveland, Ohio, United States of America. FAU - Stevenson, Lauren AU - Stevenson L AD - Research, VA Northeast Ohio Healthcare System, Cleveland, Ohio, United States of America. FAU - Hearns, Rene AU - Hearns R AD - Research, VA Northeast Ohio Healthcare System, Cleveland, Ohio, United States of America. FAU - Gee, Julie AU - Gee J AD - Research, VA Northeast Ohio Healthcare System, Cleveland, Ohio, United States of America. FAU - Schaub, Kimberley AU - Schaub K AD - Research, VA Northeast Ohio Healthcare System, Cleveland, Ohio, United States of America. FAU - LaForest, Sharon AU - LaForest S AUID- ORCID: 0000-0003-4076-186X AD - Research, VA Northeast Ohio Healthcare System, Cleveland, Ohio, United States of America. FAU - Taveira, Tracey H AU - Taveira TH AD - Medicine, Providence VA Medical Center, Providence, Rhode Island, United States of America. AD - College of Pharmacy, University of Rhode Island, Kingston, Rhode Island, United States of America. AD - The Warren Alpert School of Medicine, Brown University, Providence, Rhode Island, United States of American. FAU - Cohen, Lisa AU - Cohen L AD - Medicine, Providence VA Medical Center, Providence, Rhode Island, United States of America. AD - College of Pharmacy, University of Rhode Island, Kingston, Rhode Island, United States of America. FAU - Parent, Melanie AU - Parent M AD - Medicine, Providence VA Medical Center, Providence, Rhode Island, United States of America. FAU - Dev, Sandesh AU - Dev S AD - Medicine, Southern Arizona VA Health Care System, Tucson, Arizona, United States of America. FAU - Barrette, Amy AU - Barrette A AD - Medicine, Providence VA Medical Center, Providence, Rhode Island, United States of America. FAU - Oliver, Karen AU - Oliver K AD - Medicine, Providence VA Medical Center, Providence, Rhode Island, United States of America. FAU - Wu, Wen-Chih AU - Wu WC AD - Medicine, Providence VA Medical Center, Providence, Rhode Island, United States of America. AD - College of Pharmacy, University of Rhode Island, Kingston, Rhode Island, United States of America. AD - The Warren Alpert School of Medicine, Brown University, Providence, Rhode Island, United States of American. AD - Medicine, Southern Arizona VA Health Care System, Tucson, Arizona, United States of America. FAU - Ball, Sherry L AU - Ball SL AUID- ORCID: 0000-0002-2362-9499 AD - Research, VA Northeast Ohio Healthcare System, Cleveland, Ohio, United States of America. LA - eng PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial PT - Research Support, U.S. Gov't, Non-P.H.S. DEP - 20220207 PL - United States TA - PLoS One JT - PloS one JID - 101285081 SB - IM MH - Adult MH - Appointments and Schedules MH - Attitude of Health Personnel MH - Female MH - Group Processes MH - *Health Personnel/organization & administration/psychology MH - Heart Failure/*therapy MH - Humans MH - Interviews as Topic MH - Job Satisfaction MH - Male MH - Middle Aged MH - Perception MH - Primary Health Care/methods/organization & administration MH - Qualitative Research MH - *Shared Medical Appointments MH - Surveys and Questionnaires MH - United States MH - Young Adult PMC - PMC8820643 COIS- The authors have declared that no competing interests exist. EDAT- 2022/02/08 06:00 MHDA- 2022/03/04 06:00 PMCR- 2022/02/07 CRDT- 2022/02/07 17:13 PHST- 2021/02/11 00:00 [received] PHST- 2022/01/20 00:00 [accepted] PHST- 2022/02/07 17:13 [entrez] PHST- 2022/02/08 06:00 [pubmed] PHST- 2022/03/04 06:00 [medline] PHST- 2022/02/07 00:00 [pmc-release] AID - PONE-D-21-04750 [pii] AID - 10.1371/journal.pone.0263498 [doi] PST - epublish SO - PLoS One. 2022 Feb 7;17(2):e0263498. doi: 10.1371/journal.pone.0263498. eCollection 2022. PMID- 35126870 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220208 IS - 1949-8462 (Print) IS - 1949-8462 (Electronic) VI - 14 IP - 1 DP - 2022 Jan 26 TI - Role of genetic testing in cardiomyopathies: Alpha primer for cardiologists. PG - 29-39 LID - 10.4330/wjc.v14.i1.29 [doi] AB - Recent advances in cardiovascular genetics have transformed genetic testing into a valuable part of management of families with inherited cardiomyopathies. As novel mutations have been identified, understanding when to consider genetic testing has emerged as an important consideration in the management of these cases. Specific genetic testing has a paramount importance in the risk stratification of family members, in the prognosis of probands at higher risk of a serious phenotype expression, and finally in the identification of new mutations, all of which are discussed in this review. The indications for each type of cardiomyopathy are described, along with the limitations of genetic testing. Finally, the importance of public sharing of variants in large data sets is emphasized. The ultimate aim of this review is to present key messages about the genetic testing process in order to minimize potential harms and provide suggestions to specialized clinicians who act as a part of a multidisciplinary team in order to offer the best care to families with inherited cardiomyopathies. CI - (c)The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. FAU - Vogiatzi, Georgia AU - Vogiatzi G AD - The Third Department of Cardiology, Sotiria Hospital, Athens 11527, Greece. gvogiatz@yahoo.gr. FAU - Lazaros, George AU - Lazaros G AD - The First Department of Cardiology, Hippokration Hospital, Athens 11526, Greece. FAU - Oikonomou, Evangelos AU - Oikonomou E AD - The First Department of Cardiology, Hippokration Hospital, Medical School of National and Kapodistrian University of Athens, Athens 11527, Greece. FAU - Lazarou, Emilia AU - Lazarou E AD - The First Department of Cardiology, Hippokration Hospital, Athens 11526, Greece. FAU - Vavuranakis, Emmanouil AU - Vavuranakis E AD - The Third Department of Cardiology, Sotiria Hospital, Athens 11527, Greece. FAU - Tousoulis, Dimitris AU - Tousoulis D AD - The First Department of Cardiology, Hippokration Hospital, Athens 11526, Greece. LA - eng PT - Journal Article PT - Review PL - United States TA - World J Cardiol JT - World journal of cardiology JID - 101537090 PMC - PMC8788175 OTO - NOTNLM OT - Cardiomyopathy OT - Genetic counselling OT - Genetic testing OT - Hereditary OT - Variant COIS- Conflict-of-interest statement: The authors declare that there are no conflicts of interest. EDAT- 2022/02/08 06:00 MHDA- 2022/02/08 06:01 PMCR- 2022/01/26 CRDT- 2022/02/07 05:31 PHST- 2021/05/31 00:00 [received] PHST- 2021/07/18 00:00 [revised] PHST- 2022/01/11 00:00 [accepted] PHST- 2022/02/07 05:31 [entrez] PHST- 2022/02/08 06:00 [pubmed] PHST- 2022/02/08 06:01 [medline] PHST- 2022/01/26 00:00 [pmc-release] AID - 10.4330/wjc.v14.i1.29 [doi] PST - ppublish SO - World J Cardiol. 2022 Jan 26;14(1):29-39. doi: 10.4330/wjc.v14.i1.29. PMID- 35123903 OWN - NLM STAT- MEDLINE DCOM- 20220725 LR - 20250728 IS - 1934-8150 (Electronic) IS - 1551-7411 (Linking) VI - 18 IP - 9 DP - 2022 Sep TI - Implementation of Medication Reconciliation conducted by hospital pharmacists: A case study guided by the Consolidated Framework for Implementation Research. PG - 3631-3637 LID - S1551-7411(22)00032-8 [pii] LID - 10.1016/j.sapharm.2022.01.010 [doi] AB - BACKGROUND: Medication reconciliation (MR) implementation in hospital care transitions has proved to be a challenge for health professionals and managers. It points to the need to conduct Implementation Research with a view to understanding the tasks of the real world and knowing how they impact this process. Guided by the Consolidated Framework for Implementation Research (CFIR), this study aims to analyze the factors that influenced the MR implementation process conducted by pharmacists at a hospital setting. METHODS: A qualitative case study was carried out in the cardiology and gastroenterology units of a teaching hospital in Brazil, involving participant observation and semi-structured interviews with physicians, pharmacists, nurses, nutritionists and a social worker. The CFIR was used to guide data collection and thematic analysis. The constructs were classified according to their influence and strength. RESULTS: Sixteen health professionals involved directly or indirectly with MR implementation participated in the study. Based on the analysis of the participants' quotes and of the field diary, 18 constructs of the CFIR were identified as influencing MR implementation. The constructs that most strongly influenced MR implementation concerned "Inner Setting", "Characteristics of Individuals" and "Characteristics of Intervention". The participating professionals showed little knowledge of MR and had different points of view on its scope, weakly relating MR to patient safety. The tools used to conduct MR were adapted according to the hospital's needs, thus facilitating its implementation. However, MR proved to be complex and require clinical knowledge and aligned teamwork to identify and resolve undocumented medication discrepancies, being as well intertwined with culture and organizational communication. CONCLUSIONS: The results point to implementation failures and highlight that MR is a complex intervention, requiring specific knowledge from the multidisciplinary team and alignment with other existing workflows. The barriers and facilitators identified may serve to design and test implementation improvement strategies. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Fernandes, Brigida Dias AU - Fernandes BD AD - Faculty of Pharmacy, Federal University of Minas Gerais, Avenida Presidente Antonio Carlos, 6627, Pampulha, Belo Horizonte, Minas Gerais, 31270901, Brazil. Electronic address: brifernandes@gmail.com. FAU - Foppa, Aline Aparecida AU - Foppa AA AD - Faculty of Pharmacy, Federal University of Minas Gerais, Avenida Presidente Antonio Carlos, 6627, Pampulha, Belo Horizonte, Minas Gerais, 31270901, Brazil. FAU - Ayres, Lorena Rocha AU - Ayres LR AD - Department of Pharmaceutical Sciences, Federal University of Espirito Santo, Avenida Marechal Campos, 1468, Maruipe, Vitoria, Espirito Santo, 29043-900, Brazil. FAU - Chemello, Clarice AU - Chemello C AD - Faculty of Pharmacy, Federal University of Minas Gerais, Avenida Presidente Antonio Carlos, 6627, Pampulha, Belo Horizonte, Minas Gerais, 31270901, Brazil. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220201 PL - United States TA - Res Social Adm Pharm JT - Research in social & administrative pharmacy : RSAP JID - 101231974 SB - IM MH - Health Personnel MH - Hospitals MH - Humans MH - *Medication Reconciliation MH - *Pharmacists MH - Qualitative Research OTO - NOTNLM OT - Implementation science OT - Medication reconciliation OT - Patient safety OT - Pharmaceutical services EDAT- 2022/02/07 06:00 MHDA- 2022/07/26 06:00 CRDT- 2022/02/06 20:30 PHST- 2021/03/30 00:00 [received] PHST- 2022/01/28 00:00 [revised] PHST- 2022/01/30 00:00 [accepted] PHST- 2022/02/07 06:00 [pubmed] PHST- 2022/07/26 06:00 [medline] PHST- 2022/02/06 20:30 [entrez] AID - S1551-7411(22)00032-8 [pii] AID - 10.1016/j.sapharm.2022.01.010 [doi] PST - ppublish SO - Res Social Adm Pharm. 2022 Sep;18(9):3631-3637. doi: 10.1016/j.sapharm.2022.01.010. Epub 2022 Feb 1. PMID- 35120846 OWN - NLM STAT- MEDLINE DCOM- 20220719 LR - 20220811 IS - 1878-0938 (Electronic) IS - 1878-0938 (Linking) VI - 41 DP - 2022 Aug TI - The Outcomes of Percutaneous RevascularizaTIon for Management of SUrgically Ineligible Patients With Multivessel or Left Main Coronary Artery Disease (OPTIMUM) Registry: Rationale and Design. PG - 83-91 LID - S1553-8389(22)00008-2 [pii] LID - 10.1016/j.carrev.2022.01.008 [doi] AB - BACKGROUND: Guidelines endorse coronary artery bypass as the preferred revascularization strategy for patients with left main and/or multivessel coronary artery disease (CAD). However, many patients are deemed excessively high risk for surgery after Heart Team evaluation. No prospective studies have examined contemporary treatment patterns, rationale for surgical decision-making, completeness of revascularization with percutaneous coronary intervention (PCI), and outcomes in this high-risk population with advanced CAD. METHODS: We designed the Outcomes of Percutaneous RevascularizaTIon for Management of SUrgically Ineligible Patients with Multivessel or Left Main Coronary Artery Disease (OPTIMUM) registry, a prospective, multicenter study of patients with "surgical anatomy" determined to be at prohibitive risk for bypass surgery. The primary outcome is comparison of observed to predicted 30-day mortality, with secondary outcomes of patient-reported health status and the association between completeness of revascularization and clinical outcomes. Patient characteristics driving surgical risk determinations will be reported, and peri-operative risk will be assessed using validated scoring methods. Angiograms will be assessed by an independent core laboratory, and clinical events will be adjudicated. RESULTS: Clinical outcomes assessments will include 30-day and 1-year cardiovascular events, health status at 1, 6 and 12-months, and 5-year mortality. CONCLUSIONS: OPTIMUM is the first prospective, multicenter study to examine treatment strategies and outcomes among multivessel CAD patients deemed ineligible for surgical revascularization after Heart Team assessment. This registry will provide unique insights into the clinical decision-making, revascularization practices, safety, effectiveness, and health status outcomes in this high-risk population. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Salisbury, Adam C AU - Salisbury AC AD - Saint Luke's Mid America Heart Institute, Kansas City, MO, United States of America; University of Missouri-Kansas City, Kansas City, MO, United States of America. Electronic address: asalisbury@saint-lukes.org. FAU - Kirtane, Ajay J AU - Kirtane AJ AD - Columbia University and New York Presbyterian Hospital, New York, NY, United States of America. FAU - Ali, Ziad A AU - Ali ZA AD - Columbia University and New York Presbyterian Hospital, New York, NY, United States of America. FAU - Grantham, J Aaron AU - Grantham JA AD - Saint Luke's Mid America Heart Institute, Kansas City, MO, United States of America; University of Missouri-Kansas City, Kansas City, MO, United States of America. FAU - Lombardi, William L AU - Lombardi WL AD - University of Washington, Seattle, WA, United States of America. FAU - Yeh, Robert W AU - Yeh RW AD - Beth Israel Deaconess Medical Center, Boston, United States of America. FAU - Genereux, Philippe AU - Genereux P AD - Morristown Medical Center, Morristown, NJ, United States of America. FAU - Allen, Keith B AU - Allen KB AD - Saint Luke's Mid America Heart Institute, Kansas City, MO, United States of America; University of Missouri-Kansas City, Kansas City, MO, United States of America. FAU - Brown, W Morris AU - Brown WM AD - Piedmont Heart Institute, Atlanta, GA, United States of America. FAU - Nugent, Karen AU - Nugent K AD - Saint Luke's Mid America Heart Institute, Kansas City, MO, United States of America. FAU - Gosch, Kensey L AU - Gosch KL AD - Saint Luke's Mid America Heart Institute, Kansas City, MO, United States of America. FAU - Karmpaliotis, Dimitri AU - Karmpaliotis D AD - Columbia University and New York Presbyterian Hospital, New York, NY, United States of America. FAU - Spertus, John A AU - Spertus JA AD - Saint Luke's Mid America Heart Institute, Kansas City, MO, United States of America; University of Missouri-Kansas City, Kansas City, MO, United States of America. FAU - Kandzari, David E AU - Kandzari DE AD - Piedmont Heart Institute, Atlanta, GA, United States of America. CN - OPTIMUM Study Investigators LA - eng PT - Journal Article PT - Multicenter Study DEP - 20220131 PL - United States TA - Cardiovasc Revasc Med JT - Cardiovascular revascularization medicine : including molecular interventions JID - 101238551 SB - IM MH - Coronary Artery Bypass/adverse effects MH - *Coronary Artery Disease/diagnostic imaging/surgery MH - Humans MH - *Percutaneous Coronary Intervention/adverse effects MH - Registries MH - Risk Factors MH - Treatment Outcome OTO - NOTNLM OT - Cardiovascular surgery OT - Coronary artery disease OT - Quality of life OT - Revascularization COIS- Declaration of competing interest Dr. Salisbury reports consulting and advisory board fees from Medtronic and institutional grant support from Boston Scientific. Dr. Grantham reports speaking fees, honoraria and travel expense reimbursement from Asahi, Boston Scientific, Abbott and Corindus. Consulting fees and advisory board fees for Corindus and Boston Scientific. Institutional research grants Boston Scientific and Asahi. Dr. Kirtane reports Institutional funding to Columbia University and/or Cardiovascular Research Foundation from Medtronic, Boston Scientific, Abbott Vascular, Abiomed, CSI, Siemens, Philips, ReCor Medical, Neurotronic. In addition to research grants, institutional funding includes fees paid to Columbia University and/or Cardiovascular Research Foundation for consulting and/or speaking engagements in which Dr. Kirtane controlled the content. Personal: Consulting from IMDS; Travel Expenses/Meals from Medtronic, Boston Scientific, Abbott Vascular, Abiomed, CSI, Siemens, Philips, ReCor Medical, Chiesi, OpSens, Zoll, and Regeneron. Dr. Kandzari reports institutional research/grant support from Abbott Vascular, Biotronik, Boston Scientific, Cardiovascular Systems, Inc., Medtronic, Orbus Neich and Teleflex, and personal consulting honoraria from Biotronik, Cardiovascular Systems, Inc., and Medtronic. All remaining authors report no conflicts of interest. Dr. Ali reports institutional research/grant support from Abbott Vascular, Boston Scientific, Philips Volcano, Cardiovascular Systems, Inc., Medtronic, Acist Medical, Opsens, and personal consulting honoraria from Amgen, Astra Zeneca and Boston Scientific, and equity in Shockwave Medical. All remaining authors report no conflicts of interest. EDAT- 2022/02/06 06:00 MHDA- 2022/07/20 06:00 CRDT- 2022/02/05 05:36 PHST- 2021/11/19 00:00 [received] PHST- 2022/01/07 00:00 [revised] PHST- 2022/01/07 00:00 [accepted] PHST- 2022/02/06 06:00 [pubmed] PHST- 2022/07/20 06:00 [medline] PHST- 2022/02/05 05:36 [entrez] AID - S1553-8389(22)00008-2 [pii] AID - 10.1016/j.carrev.2022.01.008 [doi] PST - ppublish SO - Cardiovasc Revasc Med. 2022 Aug;41:83-91. doi: 10.1016/j.carrev.2022.01.008. Epub 2022 Jan 31. PMID- 35120196 OWN - NLM STAT- MEDLINE DCOM- 20220504 LR - 20220504 IS - 1528-1175 (Electronic) IS - 0003-3022 (Linking) VI - 136 IP - 4 DP - 2022 Apr 1 TI - Anesthesia Considerations in Infective Endocarditis. PG - 633-656 LID - 10.1097/ALN.0000000000004130 [doi] AB - The management of infective endocarditis is complex and inherently requires multidisciplinary cooperation. About half of all patients diagnosed with infective endocarditis will meet the criteria to undergo cardiac surgery, which regularly takes place in urgent or emergency settings. The pathophysiology and clinical presentation of infective endocarditis make it a unique disorder within cardiac surgery that warrants a thorough understanding of specific characteristics in the perioperative period. This includes, among others, echocardiography, coagulation, bleeding management, or treatment of organ dysfunction. In this narrative review article, the authors summarize the current knowledge on infective endocarditis relevant for the clinical anesthesiologist in perioperative management of respective patients. Furthermore, the authors advocate for the anesthesiologist to become a structural member of the endocarditis team. CI - Copyright (c) 2022, the American Society of Anesthesiologists. All Rights Reserved. FAU - Hermanns, Henning AU - Hermanns H AD - From the Department of Anesthesiology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands. FAU - Eberl, Susanne AU - Eberl S AUID- ORCID: 0000-0002-6609-5888 AD - From the Department of Anesthesiology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands. FAU - Terwindt, Lotte E AU - Terwindt LE AD - From the Department of Anesthesiology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands. FAU - Mastenbroek, Thierry C B AU - Mastenbroek TCB AD - From the Department of Anesthesiology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands. FAU - Bauer, Wolfgang O AU - Bauer WO AD - From the Department of Anesthesiology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands. FAU - van der Vaart, Thomas W AU - van der Vaart TW AD - the Department of Internal Medicine, Division of Infectious Diseases, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands. FAU - Preckel, Benedikt AU - Preckel B AD - From the Department of Anesthesiology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands. LA - eng PT - Journal Article PT - Review PL - United States TA - Anesthesiology JT - Anesthesiology JID - 1300217 SB - IM MH - *Anesthesia MH - *Cardiac Surgical Procedures MH - Echocardiography MH - *Endocarditis/diagnostic imaging/surgery MH - *Endocarditis, Bacterial MH - Humans EDAT- 2022/02/05 06:00 MHDA- 2022/05/06 06:00 CRDT- 2022/02/04 17:12 PHST- 2022/02/05 06:00 [pubmed] PHST- 2022/05/06 06:00 [medline] PHST- 2022/02/04 17:12 [entrez] AID - 118378 [pii] AID - 10.1097/ALN.0000000000004130 [doi] PST - ppublish SO - Anesthesiology. 2022 Apr 1;136(4):633-656. doi: 10.1097/ALN.0000000000004130. PMID- 35118579 OWN - NLM STAT- MEDLINE DCOM- 20230623 LR - 20230722 IS - 1932-2267 (Electronic) IS - 1932-2259 (Print) IS - 1932-2259 (Linking) VI - 17 IP - 4 DP - 2023 Aug TI - Future steps in cardio-oncology-a national multidisciplinary survey among healthcare professionals in the Netherlands. PG - 1131-1138 LID - 10.1007/s11764-022-01163-6 [doi] AB - BACKGROUND: The awareness of cancer therapy-related adverse cardiac effects is fueled by recent literature on cardiotoxicity incidence and detection strategies. Although this influences the sense of urgency, in current practice, cardiotoxicity monitoring and treatment is not structurally performed. With this study, we aimed to evaluate current perspectives on cardio-oncology and to assess needs, ultimately to determine an agenda for improvements in current practice. MATERIAL AND METHODS: A national multidisciplinary 36-question survey was conducted. The survey was developed by a multidisciplinary team, theoretically based on an implementation checklist and distributed by email, through cardiology and oncology societies as well as social media. RESULTS: One hundred ninety professionals completed the survey, of which 66 were cardiologists, 66 radiation oncologists, and 58 medical oncologists and hematologists. Many professionals were unaware of their specialisms' cardio-oncology guidelines: 62.1% of cardiologists and 29.3% of the hematologists and medical oncologists respectively. Many cardiologists (N = 46; 69.7%), radiation oncologists (N = 45; 68.2%), and hematologists and medical oncologists (N = 38; 65.5%) expressed that they did not have sufficient knowledge to treat cardio-oncology patients and would either refer a patient or aspire to gain more knowledge on the topic. CONCLUSION: The field of cardio-oncology is advancing rapidly, with progress in stratification and detection strategies leading to the development of new guidelines and consensus statements. However, the application of these guidelines in current practice appears to be lagging. Professionals express a need for additional training and a practical guideline including risk stratification, monitoring, and treatment strategies. Multidisciplinary discussion and consensus on cardio-oncology care is vital to improve implementation of cardio-oncology guidelines, ultimately to improve cardiac care for oncology patients. CI - (c) 2022. The Author(s). FAU - Koop, Yvonne AU - Koop Y AUID- ORCID: 0000-0001-6150-0859 AD - Department of Cardiology, Radboud University Medical Center, Nijmegen, The Netherlands. Yvonne.Koop@radboudumc.nl. FAU - Teske, Arco J AU - Teske AJ AD - Department of Cardiology, University Medical Center Utrecht, University of Utrecht, Utrecht, The Netherlands. FAU - Wanders, Iris AU - Wanders I AD - Department of Cardiology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Meijer, Hanneke AU - Meijer H AD - Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Kaanders, J H A M Hans AU - Kaanders JHAMH AD - Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Manintveld, Olivier C AU - Manintveld OC AD - Department of Cardiology, Erasmus University Medical Center, Rotterdam, The Netherlands. FAU - Hassing, H Carlijne AU - Hassing HC AD - Department of Cardiology, Erasmus University Medical Center, Rotterdam, The Netherlands. FAU - Vermeulen, Hester AU - Vermeulen H AD - Scientific Institute for Quality of Healthcare, Radboud University Medical Center, Nijmegen, The Netherlands. AD - Faculty of Health and Social Studies, Research Department of Emergency and Critical Care, HAN University of Applied Sciences, Nijmegen, The Netherlands. FAU - Maas, Angela H E M AU - Maas AHEM AD - Department of Cardiology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - van Spronsen, Dick-Johan AU - van Spronsen DJ AD - Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Atsma, Femke AU - Atsma F AD - Scientific Institute for Quality of Healthcare, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - El Messaoudi, Saloua AU - El Messaoudi S AD - Department of Cardiology, Radboud University Medical Center, Nijmegen, The Netherlands. LA - eng PT - Journal Article DEP - 20220204 PL - United States TA - J Cancer Surviv JT - Journal of cancer survivorship : research and practice JID - 101307557 SB - IM MH - Humans MH - Cardiotoxicity/etiology/diagnosis MH - Netherlands MH - *Cancer Survivors MH - *Neoplasms/epidemiology MH - Delivery of Health Care PMC - PMC10285002 OTO - NOTNLM OT - Cancer therapy-related cardiac dysfunction OT - Cardio-oncology OT - Guideline implementation OT - Healthcare professionals OT - Quality of care OT - Survey COIS- The authors declare no competing interests. EDAT- 2022/02/05 06:00 MHDA- 2023/06/23 06:42 PMCR- 2022/02/04 CRDT- 2022/02/04 05:55 PHST- 2021/12/13 00:00 [received] PHST- 2021/12/31 00:00 [accepted] PHST- 2023/06/23 06:42 [medline] PHST- 2022/02/05 06:00 [pubmed] PHST- 2022/02/04 05:55 [entrez] PHST- 2022/02/04 00:00 [pmc-release] AID - 10.1007/s11764-022-01163-6 [pii] AID - 1163 [pii] AID - 10.1007/s11764-022-01163-6 [doi] PST - ppublish SO - J Cancer Surviv. 2023 Aug;17(4):1131-1138. doi: 10.1007/s11764-022-01163-6. Epub 2022 Feb 4. PMID- 35108502 OWN - NLM STAT- MEDLINE DCOM- 20230828 LR - 20240923 IS - 1552-6259 (Electronic) IS - 0003-4975 (Print) IS - 0003-4975 (Linking) VI - 116 IP - 3 DP - 2023 Sep TI - Surgeons' Perspectives on Valve Surgery in People With Drug Use-Associated Infective Endocarditis. PG - 492-498 LID - S0003-4975(22)00126-6 [pii] LID - 10.1016/j.athoracsur.2021.12.068 [doi] AB - BACKGROUND: Hospitalizations for drug-use associated infective endocarditis (DUA-IE) have led to increasing surgical consultation for valve replacement. Cardiothoracic surgeons' perspectives about the process of decision making around operation for people with DUA-IE are largely unknown. METHODS: This multisite semiqualitative study sought to gather the perspectives of cardiothoracic surgeons on initial and repeat valve surgery for people with DUA-IE through purposeful sampling of surgeons at 7 hospitals: University of Alabama, Tufts Medical Center, Boston Medical Center, Massachusetts General Hospital, University of North Carolina-Chapel Hill, Vanderbilt University Medical Center, and Rhode Island Hospital-Brown University. RESULTS: Nineteen cardiothoracic surgeons (53% acceptance) were interviewed. Perceptions of the drivers of addiction varied as well as approaches to repeat valve operations. There were mixed views on multidisciplinary meetings, although many surgeons expressed an interest in more efficient meetings and more intensive postoperative and posthospitalization multidisciplinary care. CONCLUSIONS: Cardiothoracic surgeons are emotionally and professionally impacted by making decisions about whether to perform valve operation for people with DUA-IE. The use of efficient, agenda-based multidisciplinary care teams is an actionable solution to improve cross-disciplinary partnerships and outcomes for people with DUA-IE. CI - Copyright (c) 2023 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved. FAU - Wurcel, Alysse G AU - Wurcel AG AD - Tufts Medical Center, Boston, Massachusetts. Electronic address: awurcel@tuftsmedicalcenter.org. FAU - Zubiago, Julia AU - Zubiago J AD - Tufts Medical Center, Boston, Massachusetts. FAU - Reyes, Jessica AU - Reyes J AD - Tufts Medical Center, Boston, Massachusetts. FAU - Smyth, Emma AU - Smyth E AD - Tufts Medical Center, Boston, Massachusetts. FAU - Balsara, Keki R AU - Balsara KR AD - Vanderbilt University Medical Center, Nashville, Tennessee. FAU - Avila, Danielle AU - Avila D AD - University of Alabama at Birmingham, Birmingham, Alabama. FAU - Barocas, Joshua A AU - Barocas JA AD - Divisions of Internal Medicine and Infectious Diseases, University of Colorado, Denver, Colorado. FAU - Beckwith, Curt G AU - Beckwith CG AD - Division of Infectious Diseases, Alpert Medical School of Brown University/The Miriam Hospital, Providence, Rhode Island. FAU - Bui, Jenny AU - Bui J AD - Department of Surgery, Henry Ford Health System, Detroit, Michigan. FAU - Chastain, Cody A AU - Chastain CA AD - Vanderbilt University Medical Center, Nashville, Tennessee. FAU - Eaton, Ellen F AU - Eaton EF AD - University of Alabama at Birmingham, Birmingham, Alabama. FAU - Kimmel, Simeon AU - Kimmel S AD - Section of General Internal Medicine/Infectious Diseases, Boston Medical Center, Boston, Massachusetts. FAU - Paras, Molly L AU - Paras ML AD - Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts. FAU - Schranz, Asher J AU - Schranz AJ AD - University of North Carolina School of Medicine, Chapel Hill, North Carolina. FAU - Vyas, Darshali A AU - Vyas DA AD - Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts. FAU - Rapoport, Alison AU - Rapoport A AD - Cambridge Health Alliance, Cambridge, Massachusetts. LA - eng GR - K01 DA051684/DA/NIDA NIH HHS/United States GR - R01 MH124633/MH/NIMH NIH HHS/United States GR - L30 DA044651/DA/NIDA NIH HHS/United States GR - K23 DA054363/DA/NIDA NIH HHS/United States GR - P20 GM125507/GM/NIGMS NIH HHS/United States GR - KL2 TR002545/TR/NCATS NIH HHS/United States GR - DP2 DA051864/DA/NIDA NIH HHS/United States GR - K08 HS026008/HS/AHRQ HHS/United States GR - K23 DA049946/DA/NIDA NIH HHS/United States GR - R25 DA037190/DA/NIDA NIH HHS/United States GR - T32 AI070114/AI/NIAID NIH HHS/United States GR - P30 AI042853/AI/NIAID NIH HHS/United States PT - Journal Article DEP - 20220131 PL - Netherlands TA - Ann Thorac Surg JT - The Annals of thoracic surgery JID - 15030100R SB - IM MH - Humans MH - *Endocarditis, Bacterial/surgery/complications MH - *Endocarditis/surgery/complications MH - *Substance-Related Disorders/complications MH - *Heart Valve Prosthesis Implantation MH - *Surgeons PMC - PMC9339044 MID - NIHMS1778210 EDAT- 2022/02/03 06:00 MHDA- 2023/08/28 06:42 PMCR- 2024/09/01 CRDT- 2022/02/02 20:06 PHST- 2021/04/22 00:00 [received] PHST- 2021/11/01 00:00 [revised] PHST- 2021/12/09 00:00 [accepted] PHST- 2023/08/28 06:42 [medline] PHST- 2022/02/03 06:00 [pubmed] PHST- 2022/02/02 20:06 [entrez] PHST- 2024/09/01 00:00 [pmc-release] AID - S0003-4975(22)00126-6 [pii] AID - 10.1016/j.athoracsur.2021.12.068 [doi] PST - ppublish SO - Ann Thorac Surg. 2023 Sep;116(3):492-498. doi: 10.1016/j.athoracsur.2021.12.068. Epub 2022 Jan 31. PMID- 35108126 OWN - NLM STAT- MEDLINE DCOM- 20240313 LR - 20240822 IS - 1758-1109 (Electronic) IS - 1357-633X (Print) IS - 1357-633X (Linking) VI - 30 IP - 3 DP - 2024 Apr TI - Changes in telemedicine use and ambulatory visit volumes at a multispecialty cardiovascular center during the COVID-19 pandemic. PG - 543-548 LID - 10.1177/1357633X211073428 [doi] LID - 1357633X211073428 AB - Early in the COVID-19 pandemic, cardiology clinics rapidly implemented telemedicine to maintain access to care. Little is known about subsequent trends in telemedicine use and visit volumes across cardiology subspecialties. We conducted a retrospective cohort study including all patients with ambulatory visits at a multispecialty cardiovascular center in Northern California from March 2019 to February 2020 (pre-COVID) and March 2020 to February 2021 (COVID). Telemedicine use increased from 3.5% of visits (1200/33,976) during the pre-COVID period to 63.0% (21,251/33,706) during the COVID period. Visit volumes were below pre-COVID levels from March to May 2020 but exceeded pre-COVID levels after June 2020, including when local COVID-19 cases peaked. Telemedicine use was above 75% of visits in all cardiology subspecialties in April 2020 and stabilized at rates ranging from over 95% in electrophysiology to under 25% in heart transplant and vascular medicine. From June 2020 to February 2021, subspecialties delivering a greater percentage of visits through telemedicine experienced larger increases in new patient visits (r = 0.81, p = 0.029). Telemedicine can be used to deliver a significant proportion of outpatient cardiovascular care though utilization varies across subspecialties. Higher rates of telemedicine adoption may increase access to care in cardiology clinics. FAU - Kalwani, Neil M AU - Kalwani NM AUID- ORCID: 0000-0003-0075-6206 AD - Division of Cardiovascular Medicine and the Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA. RINGGOLD: 10624 AD - Department of Health Policy, Stanford University School of Medicine, Stanford, CA, USA. RINGGOLD: 10624 FAU - Osmanlliu, Esli AU - Osmanlliu E AUID- ORCID: 0000-0001-5590-8866 AD - Research Institute of the McGill University Health Centre, McGill University, Montreal, Canada. RINGGOLD: 507266 FAU - Parameswaran, Vijaya AU - Parameswaran V AD - Division of Cardiovascular Medicine and the Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA. RINGGOLD: 10624 FAU - Qureshi, Lubna AU - Qureshi L AD - Digital Health Care Integration, Stanford Health Care, Stanford, CA, USA. RINGGOLD: 474436 FAU - Dash, Rajesh AU - Dash R AD - Division of Cardiovascular Medicine and the Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA. RINGGOLD: 10624 FAU - Heidenreich, Paul A AU - Heidenreich PA AD - Division of Cardiovascular Medicine and the Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA. RINGGOLD: 10624 AD - VA Palo Alto Health Care System, Palo Alto, CA, USA. RINGGOLD: 19977 FAU - Scheinker, David AU - Scheinker D AD - Department of Management Science and Engineering, Stanford University, Stanford, CA, USA. RINGGOLD: 6429 AD - Clinical Excellence Research Center, Stanford University School of Medicine, Stanford, CA, USA. RINGGOLD: 10624 AD - Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA. RINGGOLD: 10624 FAU - Rodriguez, Fatima AU - Rodriguez F AUID- ORCID: 0000-0002-5226-0723 AD - Division of Cardiovascular Medicine and the Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA. RINGGOLD: 10624 LA - eng GR - K01 HL144607/HL/NHLBI NIH HHS/United States GR - T32 HS026128/HS/AHRQ HHS/United States PT - Journal Article DEP - 20220202 PL - England TA - J Telemed Telecare JT - Journal of telemedicine and telecare JID - 9506702 SB - IM MH - Humans MH - *COVID-19/epidemiology MH - Pandemics MH - Retrospective Studies MH - *Cardiology MH - *Telemedicine PMC - PMC8814611 OTO - NOTNLM OT - COVID-19 OT - Telecardiology OT - cardiovascular disease OT - telehealth OT - telemedicine COIS- Declaration of conflicting interestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: FR reports consulting fees from Novartis, Janssen, NovoNordisk, and HealthPals outside the submitted work. RD reports research funding from Bayer AG and consulting fees from HealthPals outside the submitted work. EDAT- 2022/02/03 06:00 MHDA- 2024/03/13 06:46 PMCR- 2022/02/02 CRDT- 2022/02/02 17:14 PHST- 2024/03/13 06:46 [medline] PHST- 2022/02/03 06:00 [pubmed] PHST- 2022/02/02 17:14 [entrez] PHST- 2022/02/02 00:00 [pmc-release] AID - 10.1177_1357633X211073428 [pii] AID - 10.1177/1357633X211073428 [doi] PST - ppublish SO - J Telemed Telecare. 2024 Apr;30(3):543-548. doi: 10.1177/1357633X211073428. Epub 2022 Feb 2. PMID- 35106316 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260531 IS - 2328-8957 (Print) IS - 2328-8957 (Electronic) IS - 2328-8957 (Linking) VI - 9 IP - 2 DP - 2022 Feb TI - Patients With Serious Injection Drug Use-Related Infections who Experience Patient-Directed Discharges on Oral Antibiotics Have High Rates of Antibiotic Adherence but Require Multidisciplinary Outpatient Support for Retention in Care. PG - ofab633 LID - 10.1093/ofid/ofab633 [doi] LID - ofab633 AB - BACKGROUND: Persons who inject drugs (PWID) are frequently admitted for serious injection-related infections (SIRIs). Outcomes and adherence to oral antibiotics for PWID with patient-directed discharge (PDD) remain understudied. METHODS: We conducted a prospective multicenter bundled quality improvement project of PWID with SIRI at 3 hospitals in Missouri. All PWID with SIRI were offered multidisciplinary care while inpatient, including the option of addiction medicine consultation and medications for opioid use disorder (MOUD). All patients were offered oral antibiotics in the event of a PDD either at discharge or immediately after discharge through an infectious diseases telemedicine clinic. Additional support services included health coaches, a therapist, a case manager, free clinic follow-up, and medications in an outpatient bridge program. Patient demographics, comorbidities, 90-day readmissions, and substance use disorder clinic follow-up were compared between PWID with PDD on oral antibiotics and those who completed intravenous (IV) antibiotics using an as-treated approach. RESULTS: Of 166 PWID with SIRI, 61 completed IV antibiotics inpatient (37%), while 105 had a PDD on oral antibiotics (63%). There was no significant difference in 90-day readmission rates between groups (P = .819). For PWID with a PDD on oral antibiotics, 7.6% had documented nonadherence to antibiotics, 67% had documented adherence, and 23% were lost to follow-up. Factors protective against readmission included antibiotic and MOUD adherence, engagement with support team, and clinic follow-up. CONCLUSIONS: PWID with SIRI who experience a PDD should be provided with oral antibiotics. Multidisciplinary outpatient support services are needed for PWID with PDD on oral antibiotics. CI - (c) The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. FAU - Lewis, Sophia AU - Lewis S AD - Division of Infectious Diseases, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA. FAU - Liang, Stephen Y AU - Liang SY AD - Division of Infectious Diseases, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA. AD - Department of Emergency Medicine, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA. FAU - Schwarz, Evan S AU - Schwarz ES AD - Department of Emergency Medicine, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA. AD - Division of Medical Toxicology, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA. FAU - Liss, David B AU - Liss DB AD - Department of Emergency Medicine, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA. AD - Division of Medical Toxicology, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA. FAU - Winograd, Rachel P AU - Winograd RP AD - Missouri Institute of Mental Health, University of Missouri-St. Louis, Missouri, USA. FAU - Nolan, Nathanial S AU - Nolan NS AD - Division of Infectious Diseases, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA. FAU - Durkin, Michael J AU - Durkin MJ AUID- ORCID: 0000-0003-4652-7089 AD - Division of Infectious Diseases, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA. FAU - Marks, Laura R AU - Marks LR AUID- ORCID: 0000-0002-5317-443X AD - Division of Infectious Diseases, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA. LA - eng GR - K23 DE029514/DE/NIDCR NIH HHS/United States GR - KL2 TR002346/TR/NCATS NIH HHS/United States GR - T32 AI007172/AI/NIAID NIH HHS/United States PT - Journal Article DEP - 20220106 PL - United States TA - Open Forum Infect Dis JT - Open forum infectious diseases JID - 101637045 PMC - PMC8801224 OTO - NOTNLM OT - Staphylococcus aureus OT - endocarditis OT - opioid use disorder OT - osteomyelitis OT - substance abuse EDAT- 2022/02/03 06:00 MHDA- 2022/02/03 06:01 PMCR- 2022/01/06 CRDT- 2022/02/02 05:35 PHST- 2021/09/29 00:00 [received] PHST- 2021/12/08 00:00 [accepted] PHST- 2022/02/02 05:35 [entrez] PHST- 2022/02/03 06:00 [pubmed] PHST- 2022/02/03 06:01 [medline] PHST- 2022/01/06 00:00 [pmc-release] AID - ofab633 [pii] AID - 10.1093/ofid/ofab633 [doi] PST - epublish SO - Open Forum Infect Dis. 2022 Jan 6;9(2):ofab633. doi: 10.1093/ofid/ofab633. eCollection 2022 Feb. PMID- 35096714 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220201 IS - 2296-2360 (Print) IS - 2296-2360 (Electronic) IS - 2296-2360 (Linking) VI - 9 DP - 2021 TI - Establishing Surgical Care Sustainability in Sub-Saharan Africa for Global Child Health: Insights From Pediatric Cardiac Surgical Capacity-Building Programs in Ethiopia and Cote d'Ivoire. PG - 806019 LID - 10.3389/fped.2021.806019 [doi] LID - 806019 AB - The global surgery research team of the JW LEE Center for Global Medicine, Seoul National University College of Medicine, introduced team-based health workforce training programs for pediatric cardiac surgery in Ethiopia and Cote d'Ivoire. A team-based collaborative capacity-building model was implemented in both countries, and details of the program design and delivery were documented. The research team shared their experiences and identified achievements, lessons, and challenges for cardiac surgical interventions in Sub-Saharan Africa. Future directions were put forward to advance and strengthen the low-and middle-income countries "Safe Surgery." CI - Copyright (c) 2022 Park, Heo and Kim. FAU - Park, Jayoung AU - Park J AD - Program in Global Surgery and Implementation Science, JW LEE Center for Global Medicine, Seoul National University College of Medicine, Seoul, South Korea. AD - Department of Human Systems Medicine, Seoul National University College of Medicine, Seoul, South Korea. FAU - Heo, Jongho AU - Heo J AD - Program in Global Surgery and Implementation Science, JW LEE Center for Global Medicine, Seoul National University College of Medicine, Seoul, South Korea. AD - National Assembly Futures Institute, Seoul, South Korea. FAU - Kim, Woong-Han AU - Kim WH AD - Program in Global Surgery and Implementation Science, JW LEE Center for Global Medicine, Seoul National University College of Medicine, Seoul, South Korea. AD - Department of Thoracic and Cardiovascular Surgery, Seoul National University Children's Hospital, Seoul National University College of Medicine, Seoul, South Korea. LA - eng PT - Journal Article DEP - 20220114 PL - Switzerland TA - Front Pediatr JT - Frontiers in pediatrics JID - 101615492 PMC - PMC8795907 OTO - NOTNLM OT - Sub-Saharan Africa OT - capacity-building OT - congenital heart disease OT - global surgery OT - team-based COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/02/01 06:00 MHDA- 2022/02/01 06:01 PMCR- 2022/01/14 CRDT- 2022/01/31 05:59 PHST- 2021/10/31 00:00 [received] PHST- 2021/12/17 00:00 [accepted] PHST- 2022/01/31 05:59 [entrez] PHST- 2022/02/01 06:00 [pubmed] PHST- 2022/02/01 06:01 [medline] PHST- 2022/01/14 00:00 [pmc-release] AID - 10.3389/fped.2021.806019 [doi] PST - epublish SO - Front Pediatr. 2022 Jan 14;9:806019. doi: 10.3389/fped.2021.806019. eCollection 2021. PMID- 35096385 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240405 IS - 2048-0040 (Print) IS - 2048-0040 (Electronic) IS - 2048-0040 (Linking) VI - 11 DP - 2022 Jan-Dec TI - From guideline to daily practice: Implementation of ESC-guidelines considering multidisciplinary and non-pharmacological care in heart failure in three ESC member states, a case study. PG - 20480040221074598 LID - 10.1177/20480040221074598 [doi] LID - 20480040221074598 AB - INTRODUCTION: To alleviate the burden of Heart Failure (HF), the European Society of cardiology developed guidelines (ESC-guidelines) to optimise HF-diagnosis and treatment. These guidelines state that optimal HF-care is organised in a multidisciplinary programme in which pharmacological and non-pharmacological treatment is offered. Research has proven that multidisciplinary programmes and effective self-care behaviour significantly reduce HF-mortality and (re)hospitalisation, yet little is known about implementation of these ESC-guidelines. Therefore, the INTERACT study investigated current HF-care processes and guideline adherence in three North-West European regions: Maastricht (the Netherlands), Aachen (Germany) and Noorder-Kempen (Belgium). METHODS: A case-study approach was adopted to study local implementation of ESC-guidelines considering non-pharmacological- and multidisciplinary care. National guidelines and local protocols were collected and studied to investigate the level of agreement with and implementation of ESC-guidelines. A matrix was developed to analyse the content of national and local guidelines and protocols in terms of non-pharmacological and multidisciplinary care. RESULTS: All national organisations promote ESC guidelines, and some developed additional national guidelines. In region A, B and C patients receive multidisciplinary care in hospital based HF-outpatient clinics. Moreover, region B and C patients benefit from either structural (region B) or project based (region C) integrated care, in which specialist- and primary care work together to provide seamless care for HF-patients. However, in region A this seamless integrated care remains to be implemented. CONCLUSION: Although ESC-guidelines recommend clearly considering Multidisciplinary- and non-pharmacological care implementation may differ between regions. CI - (c) The Author(s) 2022. FAU - Baldewijns, Karolien AU - Baldewijns K AUID- ORCID: 0000-0001-7842-5736 AD - Mobilab&Care, Thomas More University of Applied Sciences, Geel, Belgium. FAU - Boyne, Josiane AU - Boyne J AD - Cardiology Department, Maastricht University Medical Centre, Maastricht, Netherlands. RINGGOLD: 199236 FAU - de Maesschalck, Lieven AU - de Maesschalck L AD - Mobilab&Care, Thomas More University of Applied Sciences, Geel, Belgium. FAU - Deville, Aleidis AU - Deville A AD - Social Work Department, Thomas More University of Applied Sciences, Geel, Belgium. FAU - Brandenburg, Vincent AU - Brandenburg V AD - Uniklinik RWTH Aachen and Rhein-Maas Klinikum, Wuerselen, Germany. FAU - Brunner-La-Rocca, Hans-Peter AU - Brunner-La-Rocca HP AD - Cardiology Department, Maastricht University Medical Centre, Maastricht, Netherlands. RINGGOLD: 199236 LA - eng PT - Journal Article DEP - 20220124 PL - England TA - JRSM Cardiovasc Dis JT - JRSM cardiovascular disease JID - 101598607 PMC - PMC8793368 OTO - NOTNLM OT - Guidelines OT - disease management OT - heart failure OT - non-pharmacological care COIS- Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2022/02/01 06:00 MHDA- 2022/02/01 06:01 PMCR- 2022/01/24 CRDT- 2022/01/31 05:58 PHST- 2021/11/23 00:00 [received] PHST- 2021/12/08 00:00 [revised] PHST- 2021/12/28 00:00 [accepted] PHST- 2022/01/31 05:58 [entrez] PHST- 2022/02/01 06:00 [pubmed] PHST- 2022/02/01 06:01 [medline] PHST- 2022/01/24 00:00 [pmc-release] AID - 10.1177_20480040221074598 [pii] AID - 10.1177/20480040221074598 [doi] PST - epublish SO - JRSM Cardiovasc Dis. 2022 Jan 24;11:20480040221074598. doi: 10.1177/20480040221074598. eCollection 2022 Jan-Dec. PMID- 35095073 OWN - NLM STAT- MEDLINE DCOM- 20220204 LR - 20220204 IS - 1349-3299 (Electronic) IS - 1349-2365 (Linking) VI - 63 IP - 1 DP - 2022 TI - Short-Term Outcomes After Transcatheter Aortic Valve Replacement in Predominant Aortic Regurgitation with Left Ventricular Dysfunction. PG - 30-35 LID - 10.1536/ihj.21-360 [doi] AB - Patients with aortic stenosis and low left ventricular ejection fraction (LVEF) would benefit from transcatheter aortic valve replacement. However, the safety and efficacy of transcatheter aortic valve replacement in patients with aortic regurgitation and left ventricular dysfunction remains unknown.We defined LVEF < 50% as left ventricular dysfunction. A total of 27 symptomatic patients with aortic regurgitation and ejection fraction < 50% underwent transcatheter aortic valve replacement using the J-Valve system (JieCheng Medical Technology Co, Ltd, Suzhou, China) in Zhongshan Hospital, Fudan University, from May 2014 to June 2019. Procedural and postoperative clinical outcomes were analyzed according to Valve Academic Research Consortium-2 (VARC-2) criteria.All patients (eight females; 70.6 +/- 7.1 years) were considered to be at least intermediate surgical risk and/or severe comorbidity precluding for surgical aortic valve replacement (logistic European System for Cardiac Operative Risk Evaluation, 16.8 +/- 9.5%, range 4.6% to 37.9%) by a multidisciplinary heart team. Transapical implantations were successful in 26 (96.3%) patients. All-cause mortality was 3.7% in the latest follow-up (25-590 days, median 369 days). Significant improvements in LVEF, left ventricular end-diastolic, and systolic dimensions were observed after procedure (from 40.3 +/- 6.7% to 50.8 +/- 10.5%, P < 0.001; from 65.1 +/- 8.9 mm to 56.0 +/- 9.6 mm, P = 0.002; from 52.2 +/- 9.8 mm to 35.9 +/- 13.4 mm, P < 0.001, respectively). No patient had aortic stenosis and paravalvular leak more than moderate and heart function improvement was obtained in the majority of patients at 1-year follow-up.Transcatheter aortic valve replacement using the J-Valve system is a reasonable alternative for patients with aortic regurgitation and left ventricular dysfunction regarding promising short-term outcomes. FAU - Lu, Yuntao AU - Lu Y AD - Department of Cardiac Surgery, Zhongshan Hospital, Fudan University. AD - Shanghai Engineering Research Center of Heart Valve. FAU - Yang, Ye AU - Yang Y AD - Department of Cardiac Surgery, Zhongshan Hospital, Fudan University. AD - Shanghai Engineering Research Center of Heart Valve. FAU - Liu, Huan AU - Liu H AD - Department of Cardiac Surgery, Zhongshan Hospital, Fudan University. AD - Shanghai Engineering Research Center of Heart Valve. FAU - Wang, Wenshuo AU - Wang W AD - Department of Cardiac Surgery, Zhongshan Hospital, Fudan University. AD - Shanghai Engineering Research Center of Heart Valve. FAU - Chen, Jinmiao AU - Chen J AD - Department of Cardiac Surgery, Zhongshan Hospital, Fudan University. AD - Shanghai Engineering Research Center of Heart Valve. FAU - Liu, Shun AU - Liu S AD - Department of Cardiac Surgery, Zhongshan Hospital, Fudan University. AD - Shanghai Engineering Research Center of Heart Valve. FAU - Dong, Lili AU - Dong L AD - Department of Echocardiography, Zhongshan Hospital, Fudan University. FAU - Huang, Liqi AU - Huang L AD - Department of Cardiac Surgery, Zhongshan Hospital, Fudan University. AD - Shanghai Engineering Research Center of Heart Valve. FAU - Zhu, Liming AU - Zhu L AD - Department of Cardiac Surgery, Zhongshan Hospital, Fudan University. AD - Shanghai Engineering Research Center of Heart Valve. FAU - Wang, Chenghao AU - Wang C AD - Department of Nursing, Zhongshan Hospital Fudan University. FAU - Wang, Chunsheng AU - Wang C AD - Department of Cardiac Surgery, Zhongshan Hospital, Fudan University. AD - Shanghai Engineering Research Center of Heart Valve. FAU - Wei, Lai AU - Wei L AD - Department of Cardiac Surgery, Zhongshan Hospital, Fudan University. AD - Shanghai Engineering Research Center of Heart Valve. AD - Department of Cardiac Surgery, Shanghai Public Health Clinical Center. LA - eng PT - Journal Article PL - Japan TA - Int Heart J JT - International heart journal JID - 101244240 SB - IM MH - Aged MH - Aortic Valve Insufficiency/*complications/*surgery MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Middle Aged MH - Retrospective Studies MH - Stroke Volume MH - Time Factors MH - *Transcatheter Aortic Valve Replacement MH - Treatment Outcome MH - Ventricular Dysfunction, Left/*complications OTO - NOTNLM OT - Aortic insufficiency OT - LV function OT - Self-expanding valve EDAT- 2022/02/01 06:00 MHDA- 2022/02/05 06:00 CRDT- 2022/01/31 05:54 PHST- 2022/01/31 05:54 [entrez] PHST- 2022/02/01 06:00 [pubmed] PHST- 2022/02/05 06:00 [medline] AID - 10.1536/ihj.21-360 [doi] PST - ppublish SO - Int Heart J. 2022;63(1):30-35. doi: 10.1536/ihj.21-360. PMID- 35093159 OWN - NLM STAT- MEDLINE DCOM- 20220311 LR - 20260531 IS - 1750-1172 (Electronic) IS - 1750-1172 (Linking) VI - 17 IP - 1 DP - 2022 Jan 29 TI - Development of a standard of care for patients with valosin-containing protein associated multisystem proteinopathy. PG - 23 LID - 10.1186/s13023-022-02172-5 [doi] LID - 23 AB - Valosin-containing protein (VCP) associated multisystem proteinopathy (MSP) is a rare inherited disorder that may result in multisystem involvement of varying phenotypes including inclusion body myopathy, Paget's disease of bone (PDB), frontotemporal dementia (FTD), parkinsonism, and amyotrophic lateral sclerosis (ALS), among others. An international multidisciplinary consortium of 40+ experts in neuromuscular disease, dementia, movement disorders, psychology, cardiology, pulmonology, physical therapy, occupational therapy, speech and language pathology, nutrition, genetics, integrative medicine, and endocrinology were convened by the patient advocacy organization, Cure VCP Disease, in December 2020 to develop a standard of care for this heterogeneous and under-diagnosed disease. To achieve this goal, working groups collaborated to generate expert consensus recommendations in 10 key areas: genetic diagnosis, myopathy, FTD, PDB, ALS, Charcot Marie Tooth disease (CMT), parkinsonism, cardiomyopathy, pulmonology, supportive therapies, nutrition and supplements, and mental health. In April 2021, facilitated discussion of each working group's conclusions with consensus building techniques enabled final agreement on the proposed standard of care for VCP patients. Timely referral to a specialty neuromuscular center is recommended to aid in efficient diagnosis of VCP MSP via single-gene testing in the case of a known familial VCP variant, or multi-gene panel sequencing in undifferentiated cases. Additionally, regular and ongoing multidisciplinary team follow up is essential for proactive screening and management of secondary complications. The goal of our consortium is to raise awareness of VCP MSP, expedite the time to accurate diagnosis, define gaps and inequities in patient care, initiate appropriate pharmacotherapies and supportive therapies for optimal management, and elevate the recommended best practices guidelines for multidisciplinary care internationally. CI - (c) 2022. The Author(s). FAU - Korb, Manisha AU - Korb M AUID- ORCID: 0000-0002-4626-4007 AD - Department of Neurology, University of California - Irvine School of Medicine, Orange, CA, USA. mkak@uci.edu. FAU - Peck, Allison AU - Peck A AD - Cure VCP Disease, Americus, GA, USA. FAU - Alfano, Lindsay N AU - Alfano LN AD - The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA. FAU - Berger, Kenneth I AU - Berger KI AD - Department of Medicine (Pulmonary), NYU Grossman School of Medicine, New York, NY, USA. FAU - James, Meredith K AU - James MK AD - The John Walton Muscular Dystrophy Research Centre, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK. FAU - Ghoshal, Nupur AU - Ghoshal N AD - Department of Neurology and Psychiatry, Washington University in St. Louis, St. Louis, MO, USA. FAU - Healzer, Elise AU - Healzer E AD - Thriving Hope Consulting, Vinton, IA, USA. FAU - Henchcliffe, Claire AU - Henchcliffe C AD - Department of Neurology, University of California - Irvine School of Medicine, Orange, CA, USA. FAU - Khan, Shaida AU - Khan S AD - Department of Neurology & Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, TX, USA. FAU - Mammen, Pradeep P A AU - Mammen PPA AD - Department of Medicine (Cardiology), University of Texas Southwestern Medical Center, Dallas, TX, USA. FAU - Patel, Sujata AU - Patel S AD - Wellness with Sujata, Wadsworth, OH, USA. FAU - Pfeffer, Gerald AU - Pfeffer G AD - Hotchkiss Brain Institute, University of Calgary Cumming School of Medicine, Calgary, AB, Canada. FAU - Ralston, Stuart H AU - Ralston SH AD - Institute of Genetics and Cancer at the University of Edinburgh, Edinburgh, SCT, UK. FAU - Roy, Bhaskar AU - Roy B AD - Department of Neurology, Yale School of Medicine, New Haven, CT, USA. FAU - Seeley, William W AU - Seeley WW AD - Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA. FAU - Swenson, Andrea AU - Swenson A AD - Department of Neurology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA. FAU - Mozaffar, Tahseen AU - Mozaffar T AD - Department of Neurology, University of California - Irvine School of Medicine, Orange, CA, USA. AD - Department of Pathology & Laboratory Medicine, University of California - Irvine School of Medicine, Orange, CA, USA. FAU - Weihl, Conrad AU - Weihl C AD - Department of Neurology, Washington University in St. Louis, St. Louis, MO, USA. AD - The Hope Center, Washington University in St. Louis, St. Louis, MO, USA. FAU - Kimonis, Virginia AU - Kimonis V AD - Department of Pediatrics, University of California - Irvine School of Medicine, Orange, CA, USA. AD - Department of Pathology & Laboratory Medicine, University of California - Irvine School of Medicine, Orange, CA, USA. CN - VCP Standards of Care Working Group LA - eng GR - P50HD087351/NH/NIH HHS/United States GR - ALCHALABI-DOBSON/APR14/829-791/MNDA_/Motor Neurone Disease Association/United Kingdom GR - MR/L501529/1/MRC_/Medical Research Council/United Kingdom GR - UL1 TR001863/TR/NCATS NIH HHS/United States GR - G0600974/MRC_/Medical Research Council/United Kingdom GR - ALCHALABI-TALBOT/APR14/926-794/MNDA_/Motor Neurone Disease Association/United Kingdom GR - UL1 TR001414/TR/NCATS NIH HHS/United States GR - R01AR074457/NH/NIH HHS/United States GR - MR/R024804/1/MRC_/Medical Research Council/United Kingdom GR - P50 HD087351/HD/NICHD NIH HHS/United States GR - K24 AR073317/AR/NIAMS NIH HHS/United States GR - R01 AG031867/AG/NIA NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20220129 PL - England TA - Orphanet J Rare Dis JT - Orphanet journal of rare diseases JID - 101266602 RN - 0 (Cell Cycle Proteins) RN - EC 3.6.4.6 (Valosin Containing Protein) SB - IM MH - *Amyotrophic Lateral Sclerosis/genetics MH - Cell Cycle Proteins/genetics MH - Humans MH - Mutation MH - *Myositis, Inclusion Body MH - *Osteitis Deformans/genetics MH - Standard of Care MH - Valosin Containing Protein/genetics PMC - PMC8800193 COIS- MK has served on advisory boards for Biogen, Argenx, and CSL Behring, and on the speaker's bureau for Biogen. AP does not have any competing interests to disclose. LA reports grant support from Cure VCP Disease; provides consultancy services for training and quality control through ATOM International for the following companies: Amicus Therapeutics Pty Ltd, Catabasis, Genethon, Italfarmaco, NS Pharma, Pfizer, PTC Therapeutics; reports royalties and other support through Nationwide Children's Hospital from Sarepta Therapeutics; royalties for licensed technologies; other support through Nationwide Children's Hospital from Novartis Gene Therapies; advisory board for Biogen. KB has consulted for and/or served as a member of advisory boards for Sanofi-Genzyme, Inventiva Pharma, Amicus Therapeutics, Valerion Therapeutics, and Spark Therapeutics. MJ provides consultancy services for the following companies: ATOM International (covers consultancy services provided to Amicus Therapeutics Pty Ltd, Ascendis Pharma, Biomarin, Catabasis, Faraday, FibroGen, Genethon, Italfarmaco, NS Pharma, Pfizer, PTC Therapeutics, QED Therapeutics Ltd, Reveragen, Sarepta Therapeutics, outside the submitted work. MKJ has received payment for participation on Advisory Boards for F. Hoffman La Roche AG, PTC Therapeutics and fee support for PhD studies from the Jain Foundation, outside the submitted work. NG has participated or is currently participating in clinical trials of anti-dementia drugs sponsored by the following companies: Bristol Myers Squibb, Eli Lilly/Avid Radiopharmaceuticals, Janssen Immunotherapy, Novartis, Pfizer, Wyeth, SNIFF (The Study of Nasal Insulin to Fight Forgetfulness) study, and A4 (The Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease) trial. She receives research support from NIH, Tau Consortium, and the Association for Frontotemporal Degeneration. EH does not have any competing interests to disclose. CH has served on advisory boards for Axent Biosciences Inc, Acorda Therapeutics, Amneal Pharmaceuticals, Mitsubishi Tanabe Pharma, and US WorldMeds, and as a consultant for Zywie Bio. SK has served on advisory boards for Alexion Pharmaceuticals, Inc, UCB Pharmaceuticals, Inc, Immunovant, Inc, and Argenx. PM declares the following competing interests: American Heart Association (member of the AHA Career Development Research Grant Committee), California Institute of Regenerative Medicine (member of the Grants Working Group), CareDx Inc. (Site PI for the SHORE Registry), Catabasis Inc. (research grant), Dyne Therapeutics (consultant and member of the DMD Scientific Advisory Board), National Institute of Health (research grants and ad hoc grant reviewer for the NIH SMEP and MOSS Study Sections), Novartis Gene Therapies (member of the Data Monitoring and Safety Committee), and PhaseBio Inc. (research grant and member of the Scientific Advisory Board). SP owns a wellness company for supplements called Wellness with Sujata. GP does not have any competing interests to disclose. SR does not have any competing interests to disclose. BR has served as a consultant for Alexion Pharmaceuticals. WS does not have any competing interests to disclose. AS receives research support from Amylyx Pharmaceuticals, Alexion Pharmaceuticals, ALS Association, Mass General Hospital, NIH/NINDS, and Cytokinetics Inc, and serves on an IDMC for Alexion. TM has served in an advisory capacity for Abbvie, Alexion, Amicus, Argenx, Audentes, Maze Therapeutics, Modis, Momenta, Ra Pharmaceuticals, Sanofi-Genzyme, Sarepta, Spark Therapeutics, UCB, and Ultragenyx. He serves on the speaker's bureau for Sanofi-Genzyme. Dr. Mozaffar serves on the medical advisory board for the Myositis Association, Neuromuscular Disease Foundation, Myasthenia Gravis Foundation of California and Myasthenia Gravis Foundation of America. Dr. Mozaffar receives research funding from the Myositis Association, the Muscular Dystrophy Association, the National Institutes for Health and from the following sponsors: Alexion, Amicus, Argenx, Audentes, Bristol-Myers-Squib, Cartesian Therapeutics, Grifols, Momenta, Ra Pharmaceuticals, Sanofi-Genzyme, Spark Therapeutics, UCB, and Valerion. He serves on the data safety monitoring board for Acceleron, Avexis, Sarepta, and the NIH. CW has served on advisory boards for Acceleron, Sarepta, Abata, and Orphazyme, and as a consultant for Sarepta. VK does not have any competing interests to disclose. FIR - Fanganiello, Roberto IR - Fanganiello R FIR - Lee, Grace IR - Lee G FIR - Mahoney, Ryan Patrick IR - Mahoney RP FIR - Diaz-Manera, Jordi IR - Diaz-Manera J FIR - Evangelista, Teresinha IR - Evangelista T FIR - Freimer, Miriam IR - Freimer M FIR - Lloyd, Thomas E IR - Lloyd TE FIR - Keung, Benison IR - Keung B FIR - Kushlaf, Hani IR - Kushlaf H FIR - Milone, Margherita IR - Milone M FIR - Needham, Merrilee IR - Needham M FIR - Palmio, Johanna IR - Palmio J FIR - Stojkovic, Tanya IR - Stojkovic T FIR - Villar-Quiles, Rocio-Nur IR - Villar-Quiles RN FIR - Wang, Leo H IR - Wang LH FIR - Wicklund, Matthew P IR - Wicklund MP FIR - Singer, Frederick R IR - Singer FR FIR - Jones, Mallory IR - Jones M FIR - Miller, Bruce L IR - Miller BL FIR - Ahmad Sajjadi, S IR - Ahmad Sajjadi S FIR - Obenaus, Andre IR - Obenaus A FIR - Geschwind, Michael D IR - Geschwind MD FIR - Al-Chalabi, Ammar IR - Al-Chalabi A FIR - Wymer, James IR - Wymer J FIR - Chen, Nita IR - Chen N FIR - Kompoliti, Katie IR - Kompoliti K FIR - Wang, Stephani C IR - Wang SC FIR - Boissoneault, Catherine A IR - Boissoneault CA FIR - Cruz-Coble, Betsaida IR - Cruz-Coble B FIR - Garand, Kendrea L IR - Garand KL FIR - Rinholen, Anna J IR - Rinholen AJ FIR - Tabor-Gray, Lauren IR - Tabor-Gray L FIR - Rosenfeld, Jeffrey IR - Rosenfeld J FIR - Guo, Ming IR - Guo M FIR - Peck, Nathan IR - Peck N EDAT- 2022/01/31 06:00 MHDA- 2022/03/12 06:00 PMCR- 2022/01/29 CRDT- 2022/01/30 20:27 PHST- 2021/10/08 00:00 [received] PHST- 2022/01/16 00:00 [accepted] PHST- 2022/01/30 20:27 [entrez] PHST- 2022/01/31 06:00 [pubmed] PHST- 2022/03/12 06:00 [medline] PHST- 2022/01/29 00:00 [pmc-release] AID - 10.1186/s13023-022-02172-5 [pii] AID - 2172 [pii] AID - 10.1186/s13023-022-02172-5 [doi] PST - epublish SO - Orphanet J Rare Dis. 2022 Jan 29;17(1):23. doi: 10.1186/s13023-022-02172-5. PMID- 39130133 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240813 IS - 2772-9303 (Electronic) IS - 2772-9303 (Linking) VI - 1 IP - 1 DP - 2022 Jan-Feb TI - Zero-Contrast Conscious Sedation Transcatheter Aortic Valve Replacement-Keeping It Safe and Simple. PG - 100005 LID - 10.1016/j.jscai.2021.100005 [doi] LID - 100005 AB - 1.Contrast-free transfemoral transcatheter aortic valve replacement was performed in a case series of 4 patients using a novel technique guided by transthoracic echocardiography under conscious sedation.2.Outcomes including mortality, incidence of cerebrovascular accident, or heart block were comparable with those of the traditional approach while minimizing the risk of renal injury.3.This approach gives the heart team a technically feasible, safe, and effective option to minimize the risk of renal injury, the need for transesophageal echocardiogram, and higher levels of sedation. CI - (c) 2021 The Authors. FAU - Shrestha, Bishesh AU - Shrestha B AD - Department of Cardiology, Bassett Medical Center, Cooperstown, New York. FAU - Thyagaturu, Harshith AU - Thyagaturu H AD - Department of Cardiology, Bassett Medical Center, Cooperstown, New York. FAU - Kelley, John AU - Kelley J AD - Department of Cardiothoracic Surgery, Bassett Medical Center, Cooperstown, New York. FAU - Hong, Mun K AU - Hong MK AD - Department of Cardiology, Bassett Medical Center, Cooperstown, New York. FAU - Menzies, Dhananjai J AU - Menzies DJ AD - Department of Cardiology, Bassett Medical Center, Cooperstown, New York. LA - eng PT - Journal Article DEP - 20220130 PL - United States TA - J Soc Cardiovasc Angiogr Interv JT - Journal of the Society for Cardiovascular Angiography & Interventions JID - 9918419271306676 PMC - PMC11308228 OTO - NOTNLM OT - Contrast free OT - Transcatheter aortic valve replacement OT - Transthoracic echocardiography EDAT- 2022/01/30 00:00 MHDA- 2022/01/30 00:01 PMCR- 2022/01/30 CRDT- 2024/08/12 05:58 PHST- 2021/10/08 00:00 [received] PHST- 2021/11/26 00:00 [revised] PHST- 2021/11/27 00:00 [accepted] PHST- 2022/01/30 00:01 [medline] PHST- 2022/01/30 00:00 [pubmed] PHST- 2024/08/12 05:58 [entrez] PHST- 2022/01/30 00:00 [pmc-release] AID - S2772-9303(21)00005-3 [pii] AID - 100005 [pii] AID - 10.1016/j.jscai.2021.100005 [doi] PST - epublish SO - J Soc Cardiovasc Angiogr Interv. 2022 Jan 30;1(1):100005. doi: 10.1016/j.jscai.2021.100005. eCollection 2022 Jan-Feb. PMID- 35092871 OWN - NLM STAT- MEDLINE DCOM- 20220309 LR - 20220309 IS - 1873-491X (Electronic) IS - 0020-7489 (Linking) VI - 127 DP - 2022 Mar TI - Effects of nurse-led multidisciplinary team management on cardiovascular hospitalization and quality of life in patients with atrial fibrillation: Randomized controlled trial. PG - 104159 LID - S0020-7489(21)00304-7 [pii] LID - 10.1016/j.ijnurstu.2021.104159 [doi] AB - BACKGROUND: Atrial fibrillation is globally the most common sustained cardiac arrhythmia which increases patient morbidity and mortality, dramatically influencing well-being. Despite substantial efforts, an optimal clinical pathway for chronic atrial fibrillation management has yet to be developed. In recent practice, a multidisciplinary team management has been recommended for patients with atrial fibrillation. However, experiments exploring nurse-led multidisciplinary team management in chronic atrial fibrillation management relative to standard clinical management are still sparse and limited. OBJECTIVE: To evaluate the effects of a nurse-led multidisciplinary team approach on cardiovascular hospitalization and death, and quality of life in patients with atrial fibrillation. DESIGN: Randomized controlled trial. SETTING: The Cardiology Department of a tertiary referral hospital in Beijing, China. PARTICIPANTS: Eligible patients diagnosed with atrial fibrillation who consented. METHODS: Subjects were randomly assigned into one of two Cardiology Units upon admission. Patients in the control group (n = 119) received usual care and those in the intervention group (n = 116) underwent a nurse-led multidisciplinary team approach. Follow-up lasted for 12 months. The primary endpoint was a composite of cardiovascular hospitalization and cardiovascular death. The secondary endpoint was the differences in the quality of life between the groups observed at 6 months and 12 months of follow-up, compared to the baseline data, as determined using a Chinese version of the Medical Outcome Study Short-Form 36 General Health Survey. RESULTS: Patients under intervention showed a fewer cardiovascular hospitalization (17 vs. 35, p = 0.006) than those receiving usual care. Discernible differences were also observed in rates of cardiovascular hospitalization between the two groups (hazard ratio: 2.115, 95% confidential interval: 1.228-3.643, log-rank = 6.746, p = 0.009). Quality of life was improved in both groups, but more so in the intervention group (scores, 588.0 +/- 106.0 vs. 519.1 +/- 120.7 at 6 months and 674.4 +/- 53.4 vs. 584.1 +/- 105.9 at 12 months; both p < 0.001). Repeated measures analysis of variance indicated that group-by-time and between-subjects effects in respect of patients' quality of life (F = 9.310, p < 0.01; F = 29.042, p < 0.01, respectively). No relationships were found with cardiovascular death. CONCLUSIONS: Nurse-led multidisciplinary team management reduces cardiovascular hospitalization and improves quality of life in patients with atrial fibrillation, suggesting that this innovative management approach should be implemented in clinical practice. REGISTRATION NUMBER: Chinese Clinical Trial Registry (ChiCTR1800018851). CI - Copyright (c) 2021. Published by Elsevier Ltd. FAU - Yan, Hui AU - Yan H AD - College of Nursing, Capital Medical University, No. 10 You-an-men Wai Xi-tou-tiao, Feng-tai District, Beijing 100069, China. FAU - Du, Yi-Xiu AU - Du YX AD - College of Nursing, Capital Medical University, No. 10 You-an-men Wai Xi-tou-tiao, Feng-tai District, Beijing 100069, China; Department of Comprehensive Cardiovascular, Henan Key Laboratory for Nursing, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, No. 7, Weiwu Road, Jinshui District, Zhengzhou, Henan, 450003, China. FAU - Wu, Fang-Qin AU - Wu FQ AD - College of Nursing, Capital Medical University, No. 10 You-an-men Wai Xi-tou-tiao, Feng-tai District, Beijing 100069, China. Electronic address: wufangqin@ccmu.edu.cn. FAU - Lu, Xiao-Ying AU - Lu XY AD - Department of Cardiology Center, Beijing Chaoyang Hospital, Capital Medical University, No. 8, South Road of Worker's Stadium, Chaoyang District, Beijing, 100020, China. Electronic address: luxiaoying0408@163.com. FAU - Chen, Ru-Ming AU - Chen RM AD - Department of Cardiology Center, Beijing Chaoyang Hospital, Capital Medical University, No. 8, South Road of Worker's Stadium, Chaoyang District, Beijing, 100020, China. Electronic address: jiwangwang75@sina.com. FAU - Zhang, Yu AU - Zhang Y AD - Department of Cardiology Center, Beijing Chaoyang Hospital, Capital Medical University, No. 8, South Road of Worker's Stadium, Chaoyang District, Beijing, 100020, China. Electronic address: 2319293739@qq.com. LA - eng PT - Journal Article PT - Randomized Controlled Trial DEP - 20211217 PL - England TA - Int J Nurs Stud JT - International journal of nursing studies JID - 0400675 SB - IM MH - *Atrial Fibrillation/complications/diagnosis/therapy MH - Hospitalization MH - Humans MH - Nurse's Role MH - Patient Care Team MH - *Quality of Life OTO - NOTNLM OT - Atrial fibrillation OT - Hospitalization OT - Interdisciplinary OT - Mortality OT - Nursing care OT - Quality of life OT - Randomized controlled trial COIS- Declaration of Competing Interest None. EDAT- 2022/01/30 06:00 MHDA- 2022/03/11 06:00 CRDT- 2022/01/29 20:05 PHST- 2021/05/04 00:00 [received] PHST- 2021/12/09 00:00 [revised] PHST- 2021/12/10 00:00 [accepted] PHST- 2022/01/30 06:00 [pubmed] PHST- 2022/03/11 06:00 [medline] PHST- 2022/01/29 20:05 [entrez] AID - S0020-7489(21)00304-7 [pii] AID - 10.1016/j.ijnurstu.2021.104159 [doi] PST - ppublish SO - Int J Nurs Stud. 2022 Mar;127:104159. doi: 10.1016/j.ijnurstu.2021.104159. Epub 2021 Dec 17. PMID- 35091851 OWN - NLM STAT- MEDLINE DCOM- 20220406 LR - 20220810 IS - 1437-1596 (Electronic) IS - 0937-9827 (Print) IS - 0937-9827 (Linking) VI - 136 IP - 2 DP - 2022 Mar TI - Variant interpretation in molecular autopsy: a useful dilemma. PG - 475-482 LID - 10.1007/s00414-021-02764-z [doi] AB - Sudden cardiac death (SCD) in adolescents and young adults may be the first manifestation of an inherited arrhythmic syndrome. Thus identification of a genetic origin in sudden death cases deemed inconclusive after a comprehensive autopsy and may help to reduce the risk of lethal episodes in the remaining family. Using next-generation sequencing (NGS), a large number of variants of unknown significance (VUS) are detected. In the majority of cases, there is insufficient evidence of pathogenicity, representing a huge dilemma in current genetic investigations. Misinterpretation of such variants may lead to inaccurate genetic diagnoses and/or the adoption of unnecessary and/or inappropriate therapeutic approaches. In our study, we applied current (ACMG) recommendations for variant classification in post-mortem genetic screening of a cohort of 56 SCD victims. We identified a total 53 rare protein-altering variants (MAF < 0.2%) classified as VUS or worse. Twelve percent of the cases exhibited a clinically actionable variant (pathogenic, likely pathogenic or VUS - potentially pathogenic) that would warrant cascade genetic screening in relatives. Most of the variants detected by means of the post-mortem genetic investigations were VUS. Thus, genetic testing by itself might be fairly meaningless without supporting background data. This data reinforces the need for an experienced multidisciplinary team for obtaining reliable and accountable interpretations of variant significance for elucidating potential causes for SCDs in the young. This enables the early identification of relatives at risk or excludes family members as genetic carriers. Also, development of adequate forensic guidelines to enable appropriate interpretation of rare genetic variants is fundamental. CI - (c) 2021. The Author(s). FAU - Scheiper-Welling, Stefanie AU - Scheiper-Welling S AD - Institute of Legal Medicine, Goethe University, University Hospital Frankfurt, Frankfurt, Germany. FAU - Tabunscik, Monika AU - Tabunscik M AD - Institute of Legal Medicine, Goethe University, University Hospital Frankfurt, Frankfurt, Germany. FAU - Gross, Theresa E AU - Gross TE AD - Institute of Legal Medicine, Faculty of Medicine and University Clinic, University of Cologne, Cologne, Germany. FAU - Jenewein, Tina AU - Jenewein T AD - Institute of Legal Medicine, Goethe University, University Hospital Frankfurt, Frankfurt, Germany. FAU - Beckmann, Britt M AU - Beckmann BM AD - Institute of Legal Medicine, Goethe University, University Hospital Frankfurt, Frankfurt, Germany. FAU - Niess, Constanze AU - Niess C AD - Institute of Legal Medicine, Goethe University, University Hospital Frankfurt, Frankfurt, Germany. FAU - Gradhand, Elise AU - Gradhand E AD - Institute of Pathology, Goethe University, University Hospital Frankfurt, Kennedyallee 104, 60596, Frankfurt, Germany. FAU - Wunder, Cora AU - Wunder C AD - Institute of Legal Medicine, Goethe University, University Hospital Frankfurt, Frankfurt, Germany. FAU - Schneider, Peter M AU - Schneider PM AD - Institute of Legal Medicine, Faculty of Medicine and University Clinic, University of Cologne, Cologne, Germany. FAU - Rothschild, Markus A AU - Rothschild MA AD - Institute of Legal Medicine, Faculty of Medicine and University Clinic, University of Cologne, Cologne, Germany. FAU - Verhoff, Marcel A AU - Verhoff MA AD - Institute of Legal Medicine, Goethe University, University Hospital Frankfurt, Frankfurt, Germany. FAU - Kauferstein, Silke AU - Kauferstein S AUID- ORCID: 0000-0003-0066-8679 AD - Institute of Legal Medicine, Goethe University, University Hospital Frankfurt, Frankfurt, Germany. kauferstein@em.uni-frankfurt.de. LA - eng PT - Journal Article DEP - 20220129 PL - Germany TA - Int J Legal Med JT - International journal of legal medicine JID - 9101456 SB - IM MH - Adolescent MH - Autopsy MH - Cohort Studies MH - *Death, Sudden, Cardiac/etiology MH - *Genetic Testing MH - High-Throughput Nucleotide Sequencing MH - Humans MH - Young Adult PMC - PMC8847204 OTO - NOTNLM OT - Inherited arrhythmic syndrome OT - Molecular autopsy OT - Post-mortem genetic screening OT - Sudden cardiac death OT - Sudden death OT - VUS COIS- The authors declare no competing interests. EDAT- 2022/01/30 06:00 MHDA- 2022/04/07 06:00 PMCR- 2022/01/29 CRDT- 2022/01/29 05:46 PHST- 2021/09/08 00:00 [received] PHST- 2021/12/15 00:00 [accepted] PHST- 2022/01/30 06:00 [pubmed] PHST- 2022/04/07 06:00 [medline] PHST- 2022/01/29 05:46 [entrez] PHST- 2022/01/29 00:00 [pmc-release] AID - 10.1007/s00414-021-02764-z [pii] AID - 2764 [pii] AID - 10.1007/s00414-021-02764-z [doi] PST - ppublish SO - Int J Legal Med. 2022 Mar;136(2):475-482. doi: 10.1007/s00414-021-02764-z. Epub 2022 Jan 29. PMID- 35090810 OWN - NLM STAT- MEDLINE DCOM- 20220405 LR - 20220616 IS - 1557-3117 (Electronic) IS - 1053-2498 (Linking) VI - 41 IP - 4 DP - 2022 Apr TI - Axillary transvalvular microaxial pump as extended bridge to transcatheter aortic valve replacement in cardiogenic shock with severe aortic stenosis. PG - 434-437 LID - S1053-2498(22)00003-1 [pii] LID - 10.1016/j.healun.2021.12.010 [doi] AB - Cardiogenic shock in the setting of severe aortic stenosis is associated with poor outcomes. We describe 5 patients with cardiogenic shock and severe aortic stenosis who received an axillary microaxial pump (Impella) as an extended bridge to transcatheter aortic valve replacement. The median (range) age was 65 (61-87) years old, 80% were male, and 80% presented with stage D or E cardiogenic shock. In most cases, balloon aortic valvuloplasty was performed prior to pump insertion. Stabilization by Impella allowed for heart team evaluation and additional interventions, including percutaneous coronary intervention, MitraClip, and cardioversion. After a median (range) of 7 (5-14) days of Impella support, semi-elective transcatheter aortic valve replacement was successfully performed. All patients survived to discharge. Four patients (80%) were alive beyond 1 year. In these high-risk patients, prolonged support with a microaxial pump allowed for stabilization, ancillary interventions, and multi-disciplinary heart team evaluation prior to transcatheter aortic valve replacement. CI - Copyright (c) 2022 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved. FAU - Abraham, Jacob AU - Abraham J AD - Center for Cardiovascular Analytics, Research and Data Science (CARDS), Providence Heart Institute, Providence Research Network, Portland, Oregon. Electronic address: Jacob.Abraham@providence.org. FAU - Wang, Lian AU - Wang L AD - Center for Cardiovascular Analytics, Research and Data Science (CARDS), Providence Heart Institute, Providence Research Network, Portland, Oregon. FAU - Kumar, Vishesh AU - Kumar V AD - Center for Cardiovascular Analytics, Research and Data Science (CARDS), Providence Heart Institute, Providence Research Network, Portland, Oregon. FAU - Kirker, Eric B AU - Kirker EB AD - Center for Cardiovascular Analytics, Research and Data Science (CARDS), Providence Heart Institute, Providence Research Network, Portland, Oregon. FAU - Spinelli, Kateri J AU - Spinelli KJ AD - Center for Cardiovascular Analytics, Research and Data Science (CARDS), Providence Heart Institute, Providence Research Network, Portland, Oregon. LA - eng PT - Journal Article DEP - 20220108 PL - United States TA - J Heart Lung Transplant JT - The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation JID - 9102703 SB - IM MH - Aged MH - Aged, 80 and over MH - Aortic Valve/surgery MH - *Aortic Valve Stenosis/complications/surgery MH - *Heart-Assist Devices MH - Humans MH - Male MH - Shock, Cardiogenic/etiology/surgery MH - *Transcatheter Aortic Valve Replacement/adverse effects MH - Treatment Outcome OTO - NOTNLM OT - aortic stenosis OT - cardiogenic shock OT - congestive heart failure OT - mechanical circulatory support OT - transcatheter aortic valve replacement COIS- Disclosure statement None of the authors has a financial relationship with a commercial entity that has an interest in the subject of the presented manuscript or other conflicts of interest to disclose. JA: consultant, Abiomed. VK: structural/interventional fellowship sponsored by a grant from Edwards Lifesciences. LW, EBK, KJS: none. EDAT- 2022/01/30 06:00 MHDA- 2022/04/06 06:00 CRDT- 2022/01/29 05:34 PHST- 2021/09/14 00:00 [received] PHST- 2021/12/07 00:00 [revised] PHST- 2021/12/31 00:00 [accepted] PHST- 2022/01/30 06:00 [pubmed] PHST- 2022/04/06 06:00 [medline] PHST- 2022/01/29 05:34 [entrez] AID - S1053-2498(22)00003-1 [pii] AID - 10.1016/j.healun.2021.12.010 [doi] PST - ppublish SO - J Heart Lung Transplant. 2022 Apr;41(4):434-437. doi: 10.1016/j.healun.2021.12.010. Epub 2022 Jan 8. PMID- 35087932 OWN - NLM STAT- MEDLINE DCOM- 20220202 LR - 20220202 IS - 2374-8265 (Electronic) IS - 2374-8265 (Linking) VI - 18 DP - 2022 TI - Airborne Isolation Cardiac Arrest: A Simulation Program for Interdisciplinary Code Blue Team Training. PG - 11213 LID - 10.15766/mep_2374-8265.11213 [doi] LID - 11213 AB - INTRODUCTION: In-hospital cardiac arrest in patients with COVID-19 presents significant challenges to health care teams. Airborne precautions can delay patient care, place providers at high risk of virus exposure, and exacerbate an already stressful environment. Within the constraints of an ongoing pandemic, an efficient educational program is required to prepare health care teams for airborne isolation code blue. METHODS: This simulation was conducted in a room on the target unit using a CPR manikin to represent the patient. A "talk-through walk-through" scripted simulation directed learners (internal medicine residents, unit nurses, and other code blue responders) through a resuscitation using an airborne isolation code blue protocol. Key scripted events prompted role identification, communication, and item transfer. Learners self-assessed their airborne isolation code blue knowledge and skills and their confidence in providing quality care while maintaining safety using a pre-/posttraining 5-point Likert-scale survey. RESULTS: We trained 100 participants over a 5-month period, with 65 participants surveyed (43 respondents; 16 residents, 22 nurses). Following training, participants had a statistically significant (p < .001) increase in percentage selecting agree/strongly agree for all statements related to knowledge and skills specific to airborne isolation code blue protocol, as well as confidence in providing care while keeping themselves and their colleagues safe. DISCUSSION: Our simulation program allowed a small number of educators to feasibly train a large number of learners, let learners practice required skills, and improved learners' self-assessed knowledge, skills, and confidence regarding quality and safety of care. CI - (c) 2022 Collis et al. FAU - Collis, Alexandra C AU - Collis AC AUID- ORCID: 0000-0002-6352-0092 AD - Clinical Instructor, Division of General Internal Medicine, University of Washington Medical Center. FAU - Wescott, Andrew P AU - Wescott AP AD - Second-Year Internal Medicine Resident, University of Washington Medical Center. FAU - Greco, Sheryl AU - Greco S AD - Critical Care/Cardiac Clinical Nurse Specialist, University of Washington Medical Center. FAU - Solvang, Nicole AU - Solvang N AD - Resource Team Assistant Nurse Manager for Critical Care, STAT RNs and Vascular Access, University of Washington Medical Center. FAU - Lee, Joshua AU - Lee J AD - Fellow, Pulmonary and Critical Care, University of Washington Medical Center. FAU - Morris, Amy E AU - Morris AE AD - Associate Professor, Division of Pulmonary, Critical Care, and Sleep Medicine, University of Washington Medical Center. LA - eng PT - Journal Article DEP - 20220114 PL - United States TA - MedEdPORTAL JT - MedEdPORTAL : the journal of teaching and learning resources JID - 101714390 SB - IM MH - *COVID-19 MH - *Cardiopulmonary Resuscitation MH - Clinical Competence MH - *Heart Arrest/therapy MH - *Hospital Rapid Response Team MH - Humans MH - SARS-CoV-2 PMC - PMC8758800 OTO - NOTNLM OT - COVID-19 OT - Critical Care Medicine OT - Hospital Medicine OT - Interdisciplinary Medicine OT - Resuscitation OT - Simulation EDAT- 2022/01/29 06:00 MHDA- 2022/02/03 06:00 PMCR- 2022/01/14 CRDT- 2022/01/28 05:55 PHST- 2021/09/14 00:00 [received] PHST- 2021/10/13 00:00 [accepted] PHST- 2022/01/28 05:55 [entrez] PHST- 2022/01/29 06:00 [pubmed] PHST- 2022/02/03 06:00 [medline] PHST- 2022/01/14 00:00 [pmc-release] AID - 11213 [pii] AID - 10.15766/mep_2374-8265.11213 [doi] PST - epublish SO - MedEdPORTAL. 2022 Jan 14;18:11213. doi: 10.15766/mep_2374-8265.11213. eCollection 2022. PMID- 35087651 OWN - NLM STAT- MEDLINE DCOM- 20220503 LR - 20230206 IS - 2040-2309 (Electronic) IS - 2040-2295 (Print) IS - 2040-2295 (Linking) VI - 2022 DP - 2022 TI - Investigation on the Effect of Graded Emergency Nursing Group under the Assistance of Multidisciplinary First Aid Knowledge Internet-Based Approach on the First Aid of Acute Myocardial Infarction. PG - 8469930 LID - 10.1155/2022/8469930 [doi] LID - 8469930 AB - OBJECTIVE: To analyze the effect of a graded emergency nursing group under the assistance of multidisciplinary first aid knowledge Internet-based approach on the first aid of acute myocardial infarction (AMI). METHODS: The clinical data of 90 AMI patients treated in our hospital from March 2019 to March 2020 were selected for the retrospective analysis, and the patients were divided into the observation group and the routine group according to the first aid order, with 45 cases each. The patients in the routine group received the conventional first aid measures, and the graded emergency nursing group mode with the help of multidisciplinary first aid knowledge Internet-based approach was adopted for those in the observation group so as to compare the prognosis, nursing satisfaction scores, etc., between the two groups. RESULTS: Compared with the routine group, patients in the observation group obtained significantly lower various fast reaction indicators and quality of life score (P < 0.001), higher nursing satisfaction score (P < 0.001), lower total complication rate (P < 0.05), higher successful rescue rate (P < 0.05), and lower AMI recurrence rate and PCI reuse rate (P < 0.05). CONCLUSION: Rescue measures by the graded emergency nursing group with the help of multidisciplinary first aid knowledge Internet-based approach are a reliable method for improving AMI patients, and such strategy greatly promotes patients' quality of life and reduces the PCI reuse rate. Further research will be conducive to establishing a better solution for AMI patients. CI - Copyright (c) 2022 Lili Song et al. FAU - Song, Lili AU - Song L AUID- ORCID: 0000-0002-2438-4948 AD - Department of Emergency, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, No.1 Da HuaRoad, DongDan, Beijing 100730, China. FAU - Lu, Han AU - Lu H AD - Department of Emergency, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, No.1 Da HuaRoad, DongDan, Beijing 100730, China. FAU - Ru, Hong AU - Ru H AD - Department of Emergency, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, No.1 Da HuaRoad, DongDan, Beijing 100730, China. FAU - Zhao, Xue AU - Zhao X AD - Department of Emergency, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, No.1 Da HuaRoad, DongDan, Beijing 100730, China. LA - eng PT - Journal Article PT - Retracted Publication DEP - 20220118 PL - England TA - J Healthc Eng JT - Journal of healthcare engineering JID - 101528166 SB - IM RIN - J Healthc Eng. 2023 Jan 26;2023:9803083. doi: 10.1155/2023/9803083. PMID: 36741872 MH - *Emergency Nursing MH - First Aid MH - Humans MH - Internet MH - *Myocardial Infarction/therapy MH - *Percutaneous Coronary Intervention MH - Quality of Life MH - Retrospective Studies PMC - PMC8789469 COIS- The authors declare no conflicts of interest. EDAT- 2022/01/29 06:00 MHDA- 2022/05/04 06:00 PMCR- 2022/01/18 CRDT- 2022/01/28 05:54 PHST- 2021/11/29 00:00 [received] PHST- 2021/12/16 00:00 [revised] PHST- 2021/12/27 00:00 [accepted] PHST- 2022/01/28 05:54 [entrez] PHST- 2022/01/29 06:00 [pubmed] PHST- 2022/05/04 06:00 [medline] PHST- 2022/01/18 00:00 [pmc-release] AID - 10.1155/2022/8469930 [doi] PST - epublish SO - J Healthc Eng. 2022 Jan 18;2022:8469930. doi: 10.1155/2022/8469930. eCollection 2022. PMID- 35086889 OWN - NLM STAT- MEDLINE DCOM- 20221017 LR - 20221102 IS - 1468-201X (Electronic) IS - 1355-6037 (Print) IS - 1355-6037 (Linking) VI - 108 IP - 21 DP - 2022 Oct 13 TI - Supraventricular arrhythmia in pregnancy. PG - 1674-1681 LID - 10.1136/heartjnl-2021-320451 [doi] AB - The physiological changes during pregnancy predispose a woman for the development of new-onset or recurrent arrhythmia. Supraventricular arrhythmia is the most common form of arrhythmia during pregnancy and, although often benign in nature, can be concerning. We describe three complex cases of supraventricular arrhythmia during pregnancy and review the currently available literature on the subject. In pregnancies complicated by arrhythmia, a plan for follow-up and both maternal and fetal monitoring during pregnancy, delivery and post partum should be made in a multidisciplinary team. Diagnostic modalities should be used as in non-pregnant women if there is an indication. All antiarrhythmic drugs cross the placenta, but when necessary, medical treatment should be used with consideration to the fetus and the mother's altered pharmacodynamics and kinetics. Electrical cardioversion is safe during pregnancy, and electrophysiological study and catheter ablation can be performed in selected patients, preferably with zero-fluoroscopy technique. Sometimes, delivering the fetus (if viable) is the best therapeutic option. In this review, we provide a framework for the workup and clinical management of supraventricular arrhythmias in pregnant women, including cardiac, obstetric and neonatal perspectives. CI - (c) Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Ramlakhan, Karishma P AU - Ramlakhan KP AUID- ORCID: 0000-0002-6741-2603 AD - Department of Cardiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. AD - Department of Obstetrics and Fetal Medicine, Erasmus MC - Sophia Children's Hospital, University Medical Center Rotterdam, Rotterdam, The Netherlands. FAU - Kauling, Robert M AU - Kauling RM AD - Department of Cardiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. FAU - Schenkelaars, Nicole AU - Schenkelaars N AD - Department of Obstetrics and Fetal Medicine, Erasmus MC - Sophia Children's Hospital, University Medical Center Rotterdam, Rotterdam, The Netherlands. FAU - Segers, Dolf AU - Segers D AD - Department of Cardiology, Amphia Hospital, Breda, The Netherlands. FAU - Yap, Sing-Chien AU - Yap SC AD - Department of Cardiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. FAU - Post, Martijn C AU - Post MC AD - Department of Cardiology, Sint Antonius Hospital, Nieuwegein, The Netherlands. AD - Department of Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands. FAU - Cornette, Jerome AU - Cornette J AD - Department of Obstetrics and Fetal Medicine, Erasmus MC - Sophia Children's Hospital, University Medical Center Rotterdam, Rotterdam, The Netherlands. FAU - Roos-Hesselink, Jolien W AU - Roos-Hesselink JW AUID- ORCID: 0000-0002-6770-3830 AD - Department of Cardiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands j.roos@erasmusmc.nl. LA - eng PT - Journal Article PT - Review DEP - 20221013 PL - England TA - Heart JT - Heart (British Cardiac Society) JID - 9602087 RN - 0 (Anti-Arrhythmia Agents) SB - IM MH - Anti-Arrhythmia Agents/therapeutic use MH - Arrhythmias, Cardiac/diagnosis/etiology/therapy MH - *Catheter Ablation/methods MH - Electric Countershock MH - Female MH - Humans MH - Infant, Newborn MH - Pregnancy MH - *Tachycardia, Supraventricular/diagnosis/therapy PMC - PMC9606519 OTO - NOTNLM OT - arrhythmias OT - atrial fibrillation OT - atrial flutter OT - cardiac OT - pregnancy OT - supraventricular OT - tachycardia COIS- Competing interests: None declared. EDAT- 2022/01/29 06:00 MHDA- 2022/10/18 06:00 PMCR- 2022/10/27 CRDT- 2022/01/28 05:51 PHST- 2021/10/14 00:00 [received] PHST- 2021/12/30 00:00 [accepted] PHST- 2022/01/29 06:00 [pubmed] PHST- 2022/10/18 06:00 [medline] PHST- 2022/01/28 05:51 [entrez] PHST- 2022/10/27 00:00 [pmc-release] AID - heartjnl-2021-320451 [pii] AID - 10.1136/heartjnl-2021-320451 [doi] PST - epublish SO - Heart. 2022 Oct 13;108(21):1674-1681. doi: 10.1136/heartjnl-2021-320451. PMID- 35081388 OWN - NLM STAT- MEDLINE DCOM- 20220512 LR - 20220707 IS - 1555-7162 (Electronic) IS - 0002-9343 (Linking) VI - 135 Suppl 1 DP - 2022 Apr TI - Future Developments in Light Chain Amyloidosis Management. PG - S53-S57 LID - S0002-9343(22)00027-4 [pii] LID - 10.1016/j.amjmed.2022.01.007 [doi] AB - Light chain (AL) amyloidosis is challenging to diagnose, and it should be considered a cardiac emergency. There have been a great deal of advances in the treatment of AL amyloidosis from initial descriptions of melphalan therapy until the recent approval of the first AL amyloidosis specific drug (daratumumab). Comprehension of the pathophysiology and biology of AL amyloidosis is crucial to understanding the major therapeutic targets in which light chain stability remains as a major key target of therapy. Organ dysfunction is a result not only from disruption of organ architecture but also direct cellular toxicity. Novel antiplasma cell agents for AL like isatuximab (anti CD-38 monoclonal antibody), belantamab (anti-BCMA monoclonal antibody), and elotuzumab (anti-SLAMF7 monoclonal antibody) are currently under investigation. Both diagnostic and therapeutic advances make the future of AL management bright while acknowledging the complexity of this patient population and focusing on a multidisciplinary approach. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Rodriguez, Mario AU - Rodriguez M AD - Cardio-Oncology Center of Excellence, Cardiovascular Division, Washington University School of Medicine, St. Louis, Mo. Electronic address: mario.r@wustl.edu. FAU - Lenihan, Daniel AU - Lenihan D AD - Cardio-Oncology Center of Excellence, Cardiovascular Division, Washington University School of Medicine, St. Louis, Mo. FAU - Merlini, Giampaolo AU - Merlini G AD - Amyloidosis Research and Treatment Center, Foundation IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy. LA - eng PT - Journal Article DEP - 20220123 PL - United States TA - Am J Med JT - The American journal of medicine JID - 0267200 RN - 0 (Antibodies, Monoclonal) RN - 0 (Antineoplastic Agents) SB - IM MH - *Amyloidosis/diagnosis/drug therapy MH - Antibodies, Monoclonal/therapeutic use MH - *Antineoplastic Agents/therapeutic use MH - Humans MH - *Immunoglobulin Light-chain Amyloidosis/diagnosis/drug therapy OTO - NOTNLM OT - Amyloidosis OT - Cardiomyopathy OT - Myeloma EDAT- 2022/01/27 06:00 MHDA- 2022/05/14 06:00 CRDT- 2022/01/26 20:06 PHST- 2021/12/01 00:00 [received] PHST- 2022/01/14 00:00 [accepted] PHST- 2022/01/27 06:00 [pubmed] PHST- 2022/05/14 06:00 [medline] PHST- 2022/01/26 20:06 [entrez] AID - S0002-9343(22)00027-4 [pii] AID - 10.1016/j.amjmed.2022.01.007 [doi] PST - ppublish SO - Am J Med. 2022 Apr;135 Suppl 1:S53-S57. doi: 10.1016/j.amjmed.2022.01.007. Epub 2022 Jan 23. PMID- 35080704 OWN - NLM STAT- MEDLINE DCOM- 20220428 LR - 20261010 IS - 1534-3170 (Electronic) IS - 1523-3782 (Linking) VI - 24 IP - 3 DP - 2022 Mar TI - Anesthetic Management in Adults with Congenital Heart Disease. PG - 235-246 LID - 10.1007/s11886-022-01639-y [doi] AB - PURPOSE OF REVIEW: Adults with congenital heart disease (ACHD) are a complex and growing population that presents numerous challenges for anesthetic management. This review summarizes special considerations for anesthetic management in ACHD. RECENT FINDINGS: The adult patient with congenital heart disease may require anesthetic care for multiple surgeries and interventions throughout their lifetime. The cardiac and extracardiac manifestations of ACHD have important perioperative implications that affect anesthetic management. Recent American Heart Association/American College of Cardiology and European Society of Cardiology guidelines endorse a multidisciplinary, team-based approach to care. The cardiac anesthesiologist, endorsed as part of this multidisciplinary team, must have a thorough understanding of congenital heart disease pathophysiology and common extra-cardiac manifestations of ACHD. Safe anesthetic management in adult congenital heart disease should incorporate a multi-disciplinary approach to patient care. Anesthesiologists and centers with special expertise in ACHD care should be utilized or consulted whenever possible. CI - (c) 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Andrews, Jon S AU - Andrews JS AUID- ORCID: 0000-0002-0051-2482 AD - Division of Pediatric Anesthesiology, DUMC, Duke University Hospital, Box 3094, Durham, NC, 27710, USA. jon.andrews@duke.edu. FAU - Hashmi, Nazish K AU - Hashmi NK AD - Division of Cardiothoracic Anesthesiology and Critical Care Medicine, Duke University Hospital, Durham, NC, USA. LA - eng PT - Journal Article PT - Review DEP - 20220126 PL - United States TA - Curr Cardiol Rep JT - Current cardiology reports JID - 100888969 RN - 0 (Anesthetics) SB - IM MH - Adult MH - American Heart Association MH - *Anesthetics/therapeutic use MH - *Cardiology MH - *Heart Defects, Congenital/complications/surgery MH - Humans OTO - NOTNLM OT - ACHD OT - Cardiac anesthesia OT - Congenital heart disease OT - Extra-cardiac manifestations of ACHD EDAT- 2022/01/27 06:00 MHDA- 2022/04/29 06:00 CRDT- 2022/01/26 12:12 PHST- 2021/11/26 00:00 [accepted] PHST- 2022/01/27 06:00 [pubmed] PHST- 2022/04/29 06:00 [medline] PHST- 2022/01/26 12:12 [entrez] AID - 10.1007/s11886-022-01639-y [pii] AID - 10.1007/s11886-022-01639-y [doi] PST - ppublish SO - Curr Cardiol Rep. 2022 Mar;24(3):235-246. doi: 10.1007/s11886-022-01639-y. Epub 2022 Jan 26. PMID- 35076082 OWN - NLM STAT- MEDLINE DCOM- 20220307 LR - 20241219 IS - 1897-4279 (Electronic) IS - 0022-9032 (Linking) VI - 80 IP - 2 DP - 2022 TI - An expert opinion of the Heart Failure Association of the Polish Cardiac Society on the 2021 European Society of Cardiology guidelines for the diagnosis and treatment of acute and chronic heart failure: Heart failure guidelines from a national perspective. PG - 239-246 LID - 10.33963/KP.a2022.0021 [doi] AB - The Polish expert opinion of the Heart Failure Association of the Polish Cardiac Society on the 2021 European Society of Cardiology (ESC) guidelines for the diagnosis and treatment of heart failure points to differences in many aspects related to heart failure in Poland compared with other European countries. These differences include population issues, epidemiology, diagnostic and treatment options, or the organization of healthcare. This expert opinion also includes a review of new results of clinical trials completed after the publication of the ESC guidelines. FAU - Lelonek, Malgorzata AU - Lelonek M AD - Department of Noninvasive Cardiology, Medical University of Lodz, Lodz, Poland. malgorzata.lelonek@umed.lodz.pl. FAU - Grabowski, Marcin AU - Grabowski M AD - 1st Department of Cardiology, Medical University of Warsaw, Warszawa, Poland. FAU - Kasprzak, Jaroslaw D AU - Kasprzak JD AD - 1st Department of Cardiology, Medical University of Lodz, Bieganski Hospital, Lodz, Poland. FAU - Leszek, Przemyslaw AU - Leszek P AD - Department of Heart Failure and Transplantology, National Institute of Cardiology, Warszawa, Poland. FAU - Nessler, Jadwiga AU - Nessler J AD - Department of Coronary Disease and Heart Failure, John Paul II Hospital, Krakow, Poland. AD - Department of Coronary Disease and Heart Failure, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland. FAU - Pawlak, Agnieszka AU - Pawlak A AD - Department of Invasive Cardiology, Central Clinical Hospital of the Ministry of Interior and Administration, Warszawa, Poland. AD - Mossakowski Medical Research Center, Polish Academy of Sciences, Warszawa, Poland. FAU - Rozentryt, Piotr AU - Rozentryt P AD - Department of Toxicology and Health Protection, Faculty of Health Sciences in Bytom, Medical University of Silesia in Katowice, Bytom, Poland. AD - 3rd Department of Cardiology, SMDZ in Zabrze, Medical University of Silesia, Katowice, Silesian Centre for Heart Disease, Zabrze, Poland. FAU - Straburzynska-Migaj, Ewa AU - Straburzynska-Migaj E AD - 1st Department of Cardiology, University of Medical Sciences in Poznan, Heliodor Swiecicki University Hospital, Poznan, Poland. FAU - Rubis, Pawel AU - Rubis P AD - Department of Cardiac and Vascular Diseases, Institute of Cardiology, Jagiellonian University Collegium Medicum, Krakow, Poland. AD - John Paul II Hospital, Krakow, Poland. LA - eng PT - Journal Article PT - Review DEP - 20220125 PL - Poland TA - Kardiol Pol JT - Kardiologia polska JID - 0376352 SB - IM MH - *Cardiology MH - Chronic Disease MH - *Heart Failure/diagnosis/epidemiology/therapy MH - Humans MH - Poland OTO - NOTNLM OT - diagnosis and therapy OT - guidelines OT - heart failure OT - multidisciplinary approach EDAT- 2022/01/26 06:00 MHDA- 2022/03/08 06:00 CRDT- 2022/01/25 08:55 PHST- 2022/01/25 00:00 [received] PHST- 2022/01/25 00:00 [accepted] PHST- 2022/01/26 06:00 [pubmed] PHST- 2022/03/08 06:00 [medline] PHST- 2022/01/25 08:55 [entrez] AID - VM/OJS/J/88135 [pii] AID - 10.33963/KP.a2022.0021 [doi] PST - ppublish SO - Kardiol Pol. 2022;80(2):239-246. doi: 10.33963/KP.a2022.0021. Epub 2022 Jan 25. PMID- 35073178 OWN - NLM STAT- MEDLINE DCOM- 20220222 LR - 20220222 IS - 1524-4539 (Electronic) IS - 0009-7322 (Linking) VI - 145 IP - 4 DP - 2022 Jan 25 TI - The Clinical Impact of Device Lead-Associated Tricuspid Regurgitation: Need for a Multidisciplinary Approach. PG - 239-241 LID - 10.1161/CIRCULATIONAHA.121.055019 [doi] FAU - Vij, Aviral AU - Vij A AD - Division of Cardiology, Cook County Health, Chicago, IL (A.V.). AD - Division of Cardiology, Rush Medical College, Chicago, IL (A.V., C.J.K.). FAU - Kavinsky, Clifford J AU - Kavinsky CJ AD - Division of Cardiology, Rush Medical College, Chicago, IL (A.V., C.J.K.). LA - eng PT - Journal Article DEP - 20220124 PL - United States TA - Circulation JT - Circulation JID - 0147763 SB - IM MH - Female MH - Humans MH - Male MH - Tricuspid Valve Insufficiency/*physiopathology OTO - NOTNLM OT - defibrillators OT - implantable OT - pacemaker, artificial OT - tricuspid valve insufficiency OT - ventricular dysfunction, right EDAT- 2022/01/25 06:00 MHDA- 2022/02/23 06:00 CRDT- 2022/01/24 17:14 PHST- 2022/01/24 17:14 [entrez] PHST- 2022/01/25 06:00 [pubmed] PHST- 2022/02/23 06:00 [medline] AID - 10.1161/CIRCULATIONAHA.121.055019 [doi] PST - ppublish SO - Circulation. 2022 Jan 25;145(4):239-241. doi: 10.1161/CIRCULATIONAHA.121.055019. Epub 2022 Jan 24. PMID- 35072393 OWN - NLM STAT- MEDLINE DCOM- 20220331 LR - 20220401 IS - 1424-3997 (Electronic) IS - 0036-7672 (Linking) VI - 152 DP - 2022 Jan 3 TI - Sarcoidosis - a multisystem disease. PG - w30049 LID - Swiss Med Wkly. 2022;152:w30049 [pii] LID - 10.4414/smw.2022.w30049 [doi] AB - Sarcoidosis is a systemic inflammatory disease, characterised by granuloma formation upon an unknown trigger in genetically predisposed individuals. The inflammation is characterised by an activation of both the innate immune system, with macrophages differentiating into epitheloid cells and dendritic cells, and the adaptive immune system, particularly T helper (Th) 1 and Th17 cells. Since all organs can be affected to varying extents, clinical presentation is often diverse. Most commonly, the lungs, lymph nodes, skin and eyes are involved, whereas cardiac, renal and neurological manifestations are less common but associated with higher morbidity. Depending on the clinical symptoms, a detailed evaluation including thorough clinical examination, imaging and laboratory tests should explore all possible organ involvements. In some patients, fatigue manifests as a para-sarcoidosis symptom impacting quality of life, even if sarcoidosis is in remission. Some acute syndromic presentations, such as Lofgren's syndrome, have a good prognosis and are commonly self-limiting. If possible, a topical treatment, for example for cutaneous sarcoidosis or bronchial involvement, should be applied. Treatment of severe cases with persisting disease activity necessitates long-term immunosuppressive drugs, with glucocorticoids as the first-line option. Steroid-sparing and second-line drugs include methotrexate, azathioprine, mycophenolate mofetil and immunomodulators such hydroxychloroquine, with the latter being first-line therapy in cutaneous sarcoidosis. Tumour necrosis factor-alpha inhibitors (particularly adalimumab and infliximab) are used as third-line agents but are administered earlier in cases of persistent disease activity, severe organ-involvement or intolerance to conventional drugs. Treatment decisions should be based on a multidisciplinary approach, depending on organ involvement and treatment tolerability. Para-sarcoidosis manifestations, particularly fatigue, should also be carefully addressed, where the patient could also be enrolled in multidimensional rehabilitation programmes. With various organ involvement and different phenotypes, larger studies including real-world data from registries are necessary to evaluate different sarcoidosis endotypes and preferential treatment pathways. FAU - Franzen, Daniel P AU - Franzen DP AD - Department of Pulmonology, University Hospital Zurich, Switzerland. FAU - Brutsche, Martin AU - Brutsche M AD - Lung Centre, Cantonal Hospital St Gallen, Switzerland. FAU - Nilsson, Jakob AU - Nilsson J AD - Department of Immunology, University Hospital Zurich, Switzerland. FAU - Boni, Christian AU - Boni C AD - Department of Ophthalmology, University Hospital Zurich, University of Zurich, Switzerland. FAU - Daccord, Cecile AU - Daccord C AD - Department of Respiratory Medicine, Lausanne University Hospital and University of Lausanne, Switzerland. FAU - Distler, Oliver AU - Distler O AD - Department of Rheumatology, University Hospital Zurich, Switzerland. FAU - Elsener, Dieter AU - Elsener D AD - Department of Physiotherapy and Occupational Therapy, University Hospital Zurich, Switzerland. FAU - Funke-Chambour, Manuela AU - Funke-Chambour M AD - Department of Pulmonary Medicine, Inselspital, Bern University Hospital, University of Bern, Switzerland. FAU - Gruner, Christiane AU - Gruner C AD - Department of Cardiology, University Heart Centre, University Hospital Zurich, Switzerland. FAU - Hayward-Konnecke, Helen AU - Hayward-Konnecke H AD - Neuroimmunology and MS Research, Department of Neurology, University Hospital Zurich, Switzerland. FAU - Hostettler, Katrin E AU - Hostettler KE AD - Clinics of Respiratory Medicine, University Hospital Basel, University of Basel, Switzerland. FAU - Kundig, Thomas AU - Kundig T AD - Department of Dermatology, University Hospital Zurich, Switzerland. FAU - Ribi, Camillo AU - Ribi C AD - Service Immunologie et Allergie, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. FAU - Seebach, Jorg D AU - Seebach JD AD - Division of Allergy and Immunology, University Hospitals Geneva, Switzerland. FAU - Seeger, Harald AU - Seeger H AD - Division of Nephrology, University Hospital Zurich, Switzerland. FAU - Vrugt, Bart AU - Vrugt B AD - Institute of Pathology, Cantonal Hospital Munsterlingen, Switzerland. FAU - Kolios, Antonios G A AU - Kolios AGA AD - Department of Dermatology, University Hospital Zurich, Switzerland. AD - Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. LA - eng PT - Journal Article DEP - 20220114 PL - Switzerland TA - Swiss Med Wkly JT - Swiss medical weekly JID - 100970884 RN - 0 (Immunosuppressive Agents) RN - MRK240IY2L (Azathioprine) SB - IM MH - Azathioprine/therapeutic use MH - Humans MH - Immunosuppressive Agents/therapeutic use MH - Quality of Life MH - *Sarcoidosis/diagnosis/drug therapy MH - *Sarcoidosis, Pulmonary/drug therapy EDAT- 2022/01/25 06:00 MHDA- 2022/04/01 06:00 CRDT- 2022/01/24 09:40 PHST- 2022/01/24 09:40 [entrez] PHST- 2022/01/25 06:00 [pubmed] PHST- 2022/04/01 06:00 [medline] AID - Swiss Med Wkly. 2022;152:w30049 [pii] AID - 10.4414/smw.2022.w30049 [doi] PST - epublish SO - Swiss Med Wkly. 2022 Jan 14;152:w30049. doi: 10.4414/smw.2022.w30049. eCollection 2022 Jan 3. PMID- 35071961 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220430 IS - 2472-0054 (Electronic) IS - 2472-0054 (Linking) VI - 7 IP - 1 DP - 2022 Jan-Feb TI - Shifting the Paradigm: A Quality Improvement Approach to Proactive Cardiac Arrest Reduction in the Pediatric Cardiac Intensive Care Unit. PG - e525 LID - 10.1097/pq9.0000000000000525 [doi] LID - e525 AB - INTRODUCTION: Children with cardiac conditions are at higher risk of in-hospital pediatric cardiopulmonary arrest (CA), resulting in significant morbidity and mortality. Despite the elevated risk, proactive cardiac arrest prevention programs in the cardiac intensive care unit (CICU) remain underdeveloped. Our team developed a multidisciplinary program centered on developing a quality improvement (QI) bundle for patients at high risk of CA. METHODS: This project occurred in a 26-bed pediatric CICU of a tertiary care children's hospital. Statistical process control methodology tracked changes in CA rates over time. The global aim was to reduce CICU mortality; the smart aim was to reduce the CA rate by 50% over 12 months. Interprofessional development and implementation of a QI bundle included visual cues to identify high-risk patients, risk mitigation strategies, a new rounding paradigm, and defined escalation algorithms. Additionally, weekly event and long-term data reviews, arrest debriefs, and weekly unit-wide dissemination of key findings supported a culture change. RESULTS: After bundle implementation, CA rates decreased by 68% compared to baseline and 45% from the historical baseline. Major complications decreased from 17.1% to 12.6% (P < 0.001) and mortality decreased from 5.7% to 5.0% (P = 0.048). These results were sustained for 30 months. CONCLUSIONS: Cardiac arrest is a modifiable, rather than inevitable, metric in the CICU. Reduction is achievable through the interprofessional implementation of bundled interventions targeting proactive CA prevention. Once incorporated into widespread efforts to engage multidisciplinary CICU stakeholders, these patient-focused interventions resulted in sustained improvement. CI - Copyright (c) 2022 the Author(s). Published by Wolters Kluwer Health, Inc. FAU - Riley, Christine M AU - Riley CM AD - Children's National Hospital, Division of Cardiac Critical Care Medicine, Washington, D.C. AD - Division of Nursing, Children's National Hospital, Cardiac Intensive Care Unit, Washington, D.C. AD - Cardiac Acute and Critical Care, UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pa. AD - Division of Pediatric Critical Care, Barbara Bush Children's Hospital at Maine Medical Center, Portland, Maine. AD - Business Process Consultant, University of Maryland-College Park, College Park, Md. AD - Division of Quality and Patient Safety, Children's National Hospital, Washington, D.C. AD - Division of Safety and Performance Improvement, Children's National Hospital, Washington, D.C. AD - Heart Center, Children's National Hospital, Washington, D.C. AD - Division of Anesthesia Critical Care Medicine, Johns Hopkins Children's Center. FAU - Diddle, J Wesley AU - Diddle JW AD - Children's National Hospital, Division of Cardiac Critical Care Medicine, Washington, D.C. AD - Division of Nursing, Children's National Hospital, Cardiac Intensive Care Unit, Washington, D.C. AD - Cardiac Acute and Critical Care, UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pa. AD - Division of Pediatric Critical Care, Barbara Bush Children's Hospital at Maine Medical Center, Portland, Maine. AD - Business Process Consultant, University of Maryland-College Park, College Park, Md. AD - Division of Quality and Patient Safety, Children's National Hospital, Washington, D.C. AD - Division of Safety and Performance Improvement, Children's National Hospital, Washington, D.C. AD - Heart Center, Children's National Hospital, Washington, D.C. AD - Division of Anesthesia Critical Care Medicine, Johns Hopkins Children's Center. FAU - Harlow, Ashleigh AU - Harlow A AD - Division of Nursing, Children's National Hospital, Cardiac Intensive Care Unit, Washington, D.C. FAU - Klem, Kara AU - Klem K AD - Cardiac Acute and Critical Care, UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pa. FAU - Patregnani, Jason AU - Patregnani J AD - Division of Pediatric Critical Care, Barbara Bush Children's Hospital at Maine Medical Center, Portland, Maine. FAU - Hochberg, Evan AU - Hochberg E AD - Business Process Consultant, University of Maryland-College Park, College Park, Md. FAU - Cheng, Jenhao Jacob AU - Cheng JJ AD - Division of Quality and Patient Safety, Children's National Hospital, Washington, D.C. FAU - Bhattarai, Sopnil AU - Bhattarai S AD - Division of Safety and Performance Improvement, Children's National Hospital, Washington, D.C. FAU - Hom, Lisa AU - Hom L AD - Heart Center, Children's National Hospital, Washington, D.C. FAU - Fortkiewicz, Justine M AU - Fortkiewicz JM AD - Division of Nursing, Children's National Hospital, Cardiac Intensive Care Unit, Washington, D.C. FAU - Klugman, Darren AU - Klugman D AD - Division of Anesthesia Critical Care Medicine, Johns Hopkins Children's Center. LA - eng PT - Journal Article DEP - 20220121 PL - United States TA - Pediatr Qual Saf JT - Pediatric quality & safety JID - 101702480 PMC - PMC8782114 EDAT- 2022/01/25 06:00 MHDA- 2022/01/25 06:01 PMCR- 2022/01/21 CRDT- 2022/01/24 08:57 PHST- 2021/06/07 00:00 [received] PHST- 2021/10/18 00:00 [accepted] PHST- 2022/01/24 08:57 [entrez] PHST- 2022/01/25 06:00 [pubmed] PHST- 2022/01/25 06:01 [medline] PHST- 2022/01/21 00:00 [pmc-release] AID - 10.1097/pq9.0000000000000525 [doi] PST - epublish SO - Pediatr Qual Saf. 2022 Jan 21;7(1):e525. doi: 10.1097/pq9.0000000000000525. eCollection 2022 Jan-Feb. PMID- 35067910 OWN - NLM STAT- MEDLINE DCOM- 20220530 LR - 20220727 IS - 1720-8319 (Electronic) IS - 1594-0667 (Print) IS - 1594-0667 (Linking) VI - 34 IP - 5 DP - 2022 May TI - Application of integrated management bundle incorporating with multidisciplinary measures improved in-hospital outcomes and early survival in geriatric hip fracture patients with perioperative heart failure: a retrospective cohort study. PG - 1149-1158 LID - 10.1007/s40520-021-02038-z [doi] AB - BACKGROUND: In elderly, hip fracture is often complicated by perioperative heart failure, related to worse prognosis. We aimed to analyze the effects of integrated management bundle incorporating with multidisciplinary measures on in-hospital outcomes and early survival in elderly hip fracture patients with perioperative heart failure. METHODS: In this retrospective cohort study, a total of 421 hip fracture patients aged 65 and over who developed perioperative heart failure were included. According to different perioperative management modes applied, patients were retrospectively divided into multidisciplinary management group (Group A), including 277 patients, and integrated management bundle group (Group B), including 144 patients. The B-type natriuretic peptide (BNP) and C-reactive protein (CRP) levels, complications, length of stay, and hospitalization costs were observed and compared between two groups. Overall survival was compared by Kaplan-Meier methods. Cox regression analysis was used to identify prognostic factors associated with overall survival. RESULTS: A total of 421 patients were enrolled for analysis, including 277 in Group A and 144 in Group B. BNP and CRP levels were significantly decreased compared with admission (P < 0.05). Furthermore, BNP and CRP in Group B decreased much more than those in Group A (P < 0.05). The reductions were observed in length of stay, hospitalization costs and incidence of pulmonary infection, hypoproteinemia, and acute cerebral infarction in Group B (all P < 0.05). The Kaplan-Meier plots showed significantly superior overall survival in Group B. Integrated management bundle was independent favorable prognostic factors. CONCLUSIONS: The integrated management bundle incorporating with multidisciplinary measures significantly improved the therapeutic effect of perioperative heart failure, reduced inflammatory response, and yielded better hospital outcomes. It brought better survival benefits for geriatric hip fracture patients with perioperative heart failure. The results of this study can play an important role in clinical work and provide a valuable theoretical basis for selection of management model in elderly hip fracture patients with perioperative heart failure. CI - (c) 2021. The Author(s). FAU - Fu, Mingming AU - Fu M AD - Department of Geriatric Orthopedics, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050051, People's Republic of China. FAU - Zhang, Yaqian AU - Zhang Y AD - Department of Geriatric Orthopedics, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050051, People's Republic of China. FAU - Guo, Junfei AU - Guo J AD - Department of Orthopaedic Surgery, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050051, People's Republic of China. FAU - Zhao, Yuqi AU - Zhao Y AD - Department of Geriatric Orthopedics, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050051, People's Republic of China. FAU - Hou, Zhiyong AU - Hou Z AD - Department of Orthopaedic Surgery, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050051, People's Republic of China. AD - NHC Key Laboratory of Intelligent Orthopeadic Equipment (The Third Hospital of Hebei Medical University), Hebei, People's Republic of China. FAU - Wang, Zhiqian AU - Wang Z AD - Department of Geriatric Orthopedics, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050051, People's Republic of China. w18533112890@163.com. FAU - Zhang, Yingze AU - Zhang Y AD - Department of Orthopaedic Surgery, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050051, People's Republic of China. dryzzhang@126.com. AD - NHC Key Laboratory of Intelligent Orthopeadic Equipment (The Third Hospital of Hebei Medical University), Hebei, People's Republic of China. dryzzhang@126.com. AD - Chinese Academy of Engineering, Beijing, 100088, People's Republic of China. dryzzhang@126.com. LA - eng GR - H2019206046/Natural Science Foundation of Hebei Province/ PT - Journal Article DEP - 20220124 PL - Germany TA - Aging Clin Exp Res JT - Aging clinical and experimental research JID - 101132995 SB - IM MH - Aged MH - *Heart Failure/complications/therapy MH - *Hip Fractures/complications/surgery MH - Hospitalization MH - Hospitals MH - Humans MH - Length of Stay MH - Retrospective Studies PMC - PMC9135836 OTO - NOTNLM OT - Complications OT - Geriatric OT - Hip fracture OT - Management bundle OT - Perioperative heart failure OT - Survival COIS- The authors declare that there is no conflict of interest regarding the publication of this paper. EDAT- 2022/01/25 06:00 MHDA- 2022/05/31 06:00 PMCR- 2022/01/24 CRDT- 2022/01/24 05:50 PHST- 2021/09/14 00:00 [received] PHST- 2021/11/18 00:00 [accepted] PHST- 2022/01/25 06:00 [pubmed] PHST- 2022/05/31 06:00 [medline] PHST- 2022/01/24 05:50 [entrez] PHST- 2022/01/24 00:00 [pmc-release] AID - 10.1007/s40520-021-02038-z [pii] AID - 2038 [pii] AID - 10.1007/s40520-021-02038-z [doi] PST - ppublish SO - Aging Clin Exp Res. 2022 May;34(5):1149-1158. doi: 10.1007/s40520-021-02038-z. Epub 2022 Jan 24. PMID- 35067620 OWN - NLM STAT- MEDLINE DCOM- 20220930 LR - 20230928 IS - 1549-8425 (Electronic) IS - 1549-8417 (Linking) VI - 18 IP - 7 DP - 2022 Oct 1 TI - Discrepancies Between Clinical and Autopsy Diagnoses in Rapid Response Team-Assisted Patients: What Are We Missing? PG - 653-658 LID - 10.1097/PTS.0000000000000962 [doi] AB - OBJECTIVES: The rapid response team (RRT) assists hospitalized patients with sudden clinical deterioration. There is scarce evidence of diagnostic accuracy in this scenario, but it is possible that a considerable rate of misdiagnosis exists. Autopsy remains a valuable tool for assessing such question. This study aimed to compare clinical (premortem) and autopsy (postmortem) diagnoses in patients assisted by the RRT and describe major discrepancies. METHODS: We reviewed 104 clinical data and autopsies from patients assisted by the RRT during a cardiac arrest event in a tertiary care hospital in Brazil. Clinical and autopsy diagnostic discrepancies were classified using the Goldman criteria. Other clinical and pathological data were described, and the group with major diagnostic discrepancies was further analyzed. RESULTS: We found 39 (37.5%) patients with major diagnostic discrepancies. Most frequent immediate causes of death in this group determined by autopsy were sepsis (36%), pulmonary embolism (23%) and hemorrhagic shock (21%). Pulmonary embolism was the cause of death significantly more frequent in the major discrepancy group than in the minor discrepancy group (23% versus 3%, P = 0.002). We individually described all major diagnostic discrepancies. CONCLUSIONS: We found a high rate (37.5%) of major misdiagnosis in autopsies from patients assisted by the RRT in a tertiary teaching hospital. Pulmonary embolism was the most inaccurate fatal diagnosis detected by autopsy. CI - Copyright (c) 2022 Wolters Kluwer Health, Inc. All rights reserved. FAU - Giugni, Fernando Rabioglio AU - Giugni FR FAU - Salvadori, Fernanda Aburesi AU - Salvadori FA AD - Time de Resposta Rapida, Diretoria Clinica, Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo. FAU - Smeili, Luciana Andrea Avena AU - Smeili LAA AD - Time de Resposta Rapida, Diretoria Clinica, Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo. FAU - Marcilio, Izabel AU - Marcilio I AD - Nucleo de Vigilancia Epidemiologica do Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo. FAU - Perondi, Beatriz AU - Perondi B AD - Time de Resposta Rapida, Diretoria Clinica, Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo. FAU - Mauad, Thais AU - Mauad T AD - Departamento de Patologia, Faculdade de Medicina da Universidade de Sao Paulo. FAU - de Paiva, Edison Ferreira AU - de Paiva EF AD - Departamento de Clinica Medica, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, SP, Brazil. FAU - Duarte-Neto, Amaro Nunes AU - Duarte-Neto AN LA - eng PT - Journal Article PT - Review DEP - 20220124 PL - United States TA - J Patient Saf JT - Journal of patient safety JID - 101233393 SB - IM MH - Autopsy MH - Cause of Death MH - Diagnostic Errors MH - *Hospital Rapid Response Team MH - Humans MH - *Pulmonary Embolism MH - Retrospective Studies COIS- The authors disclose no conflict of interest. EDAT- 2022/01/25 06:00 MHDA- 2022/10/01 06:00 CRDT- 2022/01/24 05:48 PHST- 2022/01/25 06:00 [pubmed] PHST- 2022/10/01 06:00 [medline] PHST- 2022/01/24 05:48 [entrez] AID - 01209203-202210000-00001 [pii] AID - 10.1097/PTS.0000000000000962 [doi] PST - ppublish SO - J Patient Saf. 2022 Oct 1;18(7):653-658. doi: 10.1097/PTS.0000000000000962. Epub 2022 Jan 24. PMID- 35056446 OWN - NLM STAT- MEDLINE DCOM- 20220124 LR - 20220128 IS - 1648-9144 (Electronic) IS - 1010-660X (Print) IS - 1010-660X (Linking) VI - 58 IP - 1 DP - 2022 Jan 17 TI - Inter-Specialty Controversies on the Treatment of Cardiovascular Diseases during Pregnancy: A Questionnaire Study. LID - 10.3390/medicina58010138 [doi] LID - 138 AB - Background and Objectives: Management of cardiovascular disease (CVD) during pregnancy is challenging and usually requires eminence-based decisions due to limited strong-evidence data in this field. The purpose of our study was to compare the attitudes of anaesthesiologists, cardiologists, and gynaecologists towards the diagnosis and treatment of potentially life-threatening CVDs during pregnancy. Materials and Methods: A cross-sectional, questionnaire-based study was performed among 111 doctors (55 anaesthesiologists, 36 cardiologists, 20 gynaecologists). Personal opinions on the recommendations (n = 19) regarding rare, potentially life-threatening CVDs during pregnancy were recorded using a five-item Likert scale. Results: Opinions regarding eight statements (42%) varied substantially between specialties (p < 0.05). The most distinctive differences between physicians concerned the following recommendations: "thrombolysis should only be used in pulmonary embolism with cardiogenic shock" (agree: 52.7% of anaesthesiologists, 80.4% of cardiologists, 25.0% of gynaecologists; p < 0.001); "women with the antiphospholipid syndrome should restart treatment with vitamin K antagonists from the second trimester of pregnancy" (agree: 12.7% of anaesthesiologists, 69.4% of cardiologists, 20.0% of gynaecologists; p < 0.001); "women with symptomatic pulmonary hypertension should have a Swan-Ganz catheter inserted for labour" (agree: 20.0% of anaesthesiologists, 11.1% of cardiologists, 55.0% of gynaecologists; p = 0.001). Conclusions: Physicians' opinions regarding diagnostics and treatment of CVDs in pregnancy remain controversial. A multidisciplinary approach is recommended to ensure the safety and effectiveness of management in these unique medical conditions. FAU - Dziadosz, Dominika AU - Dziadosz D AD - Upper Silesian Medical Centre, Students' Scientific Society of the First Department of Cardiology, School of Medicine in Katowice, Medical University of Silesia, 40-055 Katowice, Poland. FAU - Dudzic, Katarzyna AU - Dudzic K AUID- ORCID: 0000-0002-7764-1362 AD - Students' Scientific Society, Department of Anesthesiology and Intensive Care, School of Medicine in Katowice, Medical University of Silesia, 40-752 Katowice, Poland. FAU - Morawska, Irmina AU - Morawska I AUID- ORCID: 0000-0003-2014-6771 AD - Upper Silesian Medical Centre, Students' Scientific Society of the First Department of Cardiology, School of Medicine in Katowice, Medical University of Silesia, 40-055 Katowice, Poland. FAU - Topolska, Dominika AU - Topolska D AD - Students' Scientific Society, Department of Anesthesiology and Intensive Care, School of Medicine in Katowice, Medical University of Silesia, 40-752 Katowice, Poland. FAU - Urban, Katarzyna AU - Urban K AD - Students' Scientific Society, Department of Anesthesiology and Intensive Care, School of Medicine in Katowice, Medical University of Silesia, 40-752 Katowice, Poland. FAU - Mizia-Stec, Katarzyna AU - Mizia-Stec K AUID- ORCID: 0000-0001-6907-2799 AD - First Department of Cardiology, School of Medicine in Katowice, Medical University of Silesia, 40-055 Katowice, Poland. FAU - Krzych, Lukasz J AU - Krzych LJ AUID- ORCID: 0000-0002-5252-8398 AD - Department of Anaesthesiology and Intensive Care, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-752 Katowice, Poland. LA - eng PT - Journal Article DEP - 20220117 PL - Switzerland TA - Medicina (Kaunas) JT - Medicina (Kaunas, Lithuania) JID - 9425208 SB - IM MH - *Cardiologists MH - *Cardiovascular Diseases MH - Cross-Sectional Studies MH - Female MH - Humans MH - *Physicians MH - Pregnancy MH - Surveys and Questionnaires PMC - PMC8780357 OTO - NOTNLM OT - cardiovascular disease OT - heart failure OT - pregnancy OT - pulmonary embolism OT - pulmonary hypertension COIS- The authors declare no conflict of interest. EDAT- 2022/01/22 06:00 MHDA- 2022/01/27 06:00 PMCR- 2022/01/17 CRDT- 2022/01/21 01:14 PHST- 2021/11/24 00:00 [received] PHST- 2022/01/09 00:00 [revised] PHST- 2022/01/12 00:00 [accepted] PHST- 2022/01/21 01:14 [entrez] PHST- 2022/01/22 06:00 [pubmed] PHST- 2022/01/27 06:00 [medline] PHST- 2022/01/17 00:00 [pmc-release] AID - medicina58010138 [pii] AID - medicina-58-00138 [pii] AID - 10.3390/medicina58010138 [doi] PST - epublish SO - Medicina (Kaunas). 2022 Jan 17;58(1):138. doi: 10.3390/medicina58010138. PMID- 35054184 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220128 IS - 2075-4418 (Print) IS - 2075-4418 (Electronic) IS - 2075-4418 (Linking) VI - 12 IP - 1 DP - 2021 Dec 23 TI - Fractional Flow Reserve in the Diagnosis of Ischemic Heart Disease in a Patient with Coronary Artery Ectasia. LID - 10.3390/diagnostics12010017 [doi] LID - 17 AB - Coronary artery ectasias (CAE) are diffuse dilatations of coronary artery segments with a diameter 1.5 times greater than the largest adjacent normal segment of the vessel. They are found in 0.3-5.0% of coronary angiography. Risk factors for CAE include atherosclerosis, previous percutaneous coronary interventions, arterial inflammation and connective tissue diseases. The diagnosis of CEA in a patient is a considerable diagnostic and therapeutic problem due to the unfavorable prognosis and the lack of guidelines. We present a case of a 69-year-old male patient with a history of retrosternal pain admitted to the clinic for the diagnosis of coronary artery disease. In coronary angiography, numerous ectases of the main coronary arteries and atherosclerotic lesions causing border stenosis of the left anterior descending (LAD), diagonal (2D) and marginal branch (OM). The heart team decided to assess the significance of the changes with the fractional flow reserve (FFR). The FFR was performed and haemodynamically insignificant stenoses of the ectatically dilated coronary arteries were found. The patient was qualified for conservative treatment. FAU - Zalewska-Adamiec, Malgorzata AU - Zalewska-Adamiec M AUID- ORCID: 0000-0002-2466-4093 AD - Department of Invasive Cardiology, Medical University of Bialystok, 15276 Bialystok, Poland. FAU - Kuzma, Lukasz AU - Kuzma L AUID- ORCID: 0000-0002-4156-5695 AD - Department of Invasive Cardiology, Medical University of Bialystok, 15276 Bialystok, Poland. FAU - Bachorzewska-Gajewska, Hanna AU - Bachorzewska-Gajewska H AD - Department of Invasive Cardiology, Medical University of Bialystok, 15276 Bialystok, Poland. AD - Department of Clinical Medicine, Medical University of Bialystok, 24A Sklodowskiej-Curie St., 15276 Bialystok, Poland. FAU - Dobrzycki, Slawomir AU - Dobrzycki S AD - Department of Invasive Cardiology, Medical University of Bialystok, 15276 Bialystok, Poland. LA - eng PT - Journal Article DEP - 20211223 PL - Switzerland TA - Diagnostics (Basel) JT - Diagnostics (Basel, Switzerland) JID - 101658402 PMC - PMC8774518 OTO - NOTNLM OT - coronarography OT - coronary artery aneurysm OT - coronary artery disease OT - coronary artery ectasia OT - fractional flow reserve COIS- The authors declare no conflict of interest. EDAT- 2022/01/22 06:00 MHDA- 2022/01/22 06:01 PMCR- 2021/12/23 CRDT- 2022/01/21 01:07 PHST- 2021/11/25 00:00 [received] PHST- 2021/12/13 00:00 [revised] PHST- 2021/12/16 00:00 [accepted] PHST- 2022/01/21 01:07 [entrez] PHST- 2022/01/22 06:00 [pubmed] PHST- 2022/01/22 06:01 [medline] PHST- 2021/12/23 00:00 [pmc-release] AID - diagnostics12010017 [pii] AID - diagnostics-12-00017 [pii] AID - 10.3390/diagnostics12010017 [doi] PST - epublish SO - Diagnostics (Basel). 2021 Dec 23;12(1):17. doi: 10.3390/diagnostics12010017. PMID- 35046639 OWN - NLM STAT- MEDLINE DCOM- 20220324 LR - 20220324 IS - 1177-8881 (Electronic) IS - 1177-8881 (Linking) VI - 16 DP - 2022 TI - Clinical Utility of Elosulfase Alfa in the Treatment of Morquio A Syndrome. PG - 143-154 LID - 10.2147/DDDT.S219433 [doi] AB - Mucopolysaccharidosis type IVA (MPS IVA or Morquio A) is an autosomal recessive disorder and is one of the lysosomal storage diseases. Patients with MPS IVA have a striking skeletal phenotype but normal intellect. The phenotypic continuum of MPS IVA ranges from severe and rapid progress to mild and slow progress. The diagnosis of MPS IVA is usually suspected based on abnormal bone findings and dysplasia on physical examination and radiographic investigation in the preschool years. In the past, only supportive care was available. Due to the early and severe skeletal abnormalities, the orthopedic specialist was usually the main care provider. However, patients need aggressive monitoring and management of their systemic disease. Therefore, they need an interdisciplinary team for their care, comprising medical geneticists, cardiologists, pulmonary specialists, gastroenterologists, otolaryngologists, audiologists, and ophthalmologists. After the US Food and Drug Administration approved elosulfase alfa in 2014, patients older than 5 years could benefit from this treatment. Clinical trials showed clinically meaningful improvements with once-a-week intravenous dosing (2.0 mg/kg per week), significantly improving the 6min walk test, the 3min stair climb test, and respiratory function when compared with placebo. Elosulfase alfa is well-tolerated, and there is a good response indicated by decreasing urine glycosaminoglycans. CI - (c) 2022 Lee et al. FAU - Lee, Chung-Lin AU - Lee CL AD - Department of Pediatrics, MacKay Memorial Hospital, Taipei, Taiwan. AD - Institute of Clinical Medicine, National Yang-Ming Chiao-Tung University, Taipei, Taiwan. AD - Department of Medicine, MacKay Medical College, New Taipei City, Taiwan. AD - MacKay Junior College of Medicine, Nursing and Management, Taipei, Taiwan. AD - Department of Rare Disease Center, MacKay Memorial Hospital, Taipei, Taiwan. FAU - Chuang, Chih-Kuang AU - Chuang CK AD - Division of Genetics and Metabolism, Department of Medical Research, MacKay Memorial Hospital, Taipei, Taiwan. AD - College of Medicine, Fu-Jen Catholic University, Taipei, Taiwan. FAU - Chiu, Huei-Ching AU - Chiu HC AD - Department of Pediatrics, MacKay Memorial Hospital, Taipei, Taiwan. FAU - Tu, Ru-Yi AU - Tu RY AD - Division of Genetics and Metabolism, Department of Medical Research, MacKay Memorial Hospital, Taipei, Taiwan. FAU - Lo, Yun-Ting AU - Lo YT AD - Department of Rare Disease Center, MacKay Memorial Hospital, Taipei, Taiwan. FAU - Chang, Ya-Hui AU - Chang YH AD - Department of Pediatrics, MacKay Memorial Hospital, Taipei, Taiwan. AD - Department of Rare Disease Center, MacKay Memorial Hospital, Taipei, Taiwan. FAU - Lin, Shuan-Pei AU - Lin SP AD - Department of Pediatrics, MacKay Memorial Hospital, Taipei, Taiwan. AD - Department of Medicine, MacKay Medical College, New Taipei City, Taiwan. AD - Department of Rare Disease Center, MacKay Memorial Hospital, Taipei, Taiwan. AD - Division of Genetics and Metabolism, Department of Medical Research, MacKay Memorial Hospital, Taipei, Taiwan. AD - Department of Infant and Child Care, National Taipei University of Nursing and Health Sciences, Taipei, Taiwan. FAU - Lin, Hsiang-Yu AU - Lin HY AUID- ORCID: 0000-0002-9619-0990 AD - Department of Pediatrics, MacKay Memorial Hospital, Taipei, Taiwan. AD - Department of Medicine, MacKay Medical College, New Taipei City, Taiwan. AD - MacKay Junior College of Medicine, Nursing and Management, Taipei, Taiwan. AD - Department of Rare Disease Center, MacKay Memorial Hospital, Taipei, Taiwan. AD - Division of Genetics and Metabolism, Department of Medical Research, MacKay Memorial Hospital, Taipei, Taiwan. AD - Department of Medical Research, China Medical University Hospital, China Medical University, Taichung, Taiwan. LA - eng PT - Journal Article PT - Review DEP - 20220110 PL - New Zealand TA - Drug Des Devel Ther JT - Drug design, development and therapy JID - 101475745 RN - EC 3.1.6.- (Chondroitinsulfatases) RN - EC 3.1.6.4 (GALNS protein, human) SB - IM MH - Chondroitinsulfatases/*therapeutic use MH - Enzyme Replacement Therapy MH - Humans MH - Mucopolysaccharidosis IV/*drug therapy MH - Phenotype PMC - PMC8759989 OTO - NOTNLM OT - GALNS OT - MPS IVA OT - Morquio A OT - elosulfasealfa OT - enzyme replacement therapy OT - lysosomal storage disorder OT - mucopolysaccharidosis COIS- The authors declare that they have no conflicts of interest. EDAT- 2022/01/21 06:00 MHDA- 2022/03/25 06:00 PMCR- 2022/01/10 CRDT- 2022/01/20 05:58 PHST- 2021/09/27 00:00 [received] PHST- 2021/12/07 00:00 [accepted] PHST- 2022/01/20 05:58 [entrez] PHST- 2022/01/21 06:00 [pubmed] PHST- 2022/03/25 06:00 [medline] PHST- 2022/01/10 00:00 [pmc-release] AID - 219433 [pii] AID - 10.2147/DDDT.S219433 [doi] PST - epublish SO - Drug Des Devel Ther. 2022 Jan 10;16:143-154. doi: 10.2147/DDDT.S219433. eCollection 2022. PMID- 35044353 OWN - NLM STAT- MEDLINE DCOM- 20220318 LR - 20230929 IS - 1538-8662 (Electronic) IS - 0361-1817 (Linking) VI - 47 IP - 2 DP - 2022 Feb 1 TI - Update on cardiogenic shock: The evolving landscape of a multidisciplinary and collaborative approach. PG - 40-46 LID - 10.1097/01.NPR.0000798232.07739.31 [doi] AB - The American Heart Association scientific statement on cardiogenic shock and the National Cardiogenic Shock Initiative have provided the impetus to advance knowledge and development of national guidelines for cardiogenic shock. We evaluate the current state of knowledge surrounding cardiogenic shock and limitations to the development of national guidelines. CI - Copyright (c) 2022 Wolters Kluwer Health, Inc. All rights reserved. FAU - Miller, Stephen L AU - Miller SL FAU - Foster, Malcolm T AU - Foster MT LA - eng PT - Journal Article PL - United States TA - Nurse Pract JT - The Nurse practitioner JID - 7603663 SB - IM MH - *American Heart Association MH - Humans MH - *Shock, Cardiogenic/therapy MH - United States EDAT- 2022/01/20 06:00 MHDA- 2022/03/19 06:00 CRDT- 2022/01/19 12:20 PHST- 2022/01/19 12:20 [entrez] PHST- 2022/01/20 06:00 [pubmed] PHST- 2022/03/19 06:00 [medline] AID - 00006205-202202000-00009 [pii] AID - 10.1097/01.NPR.0000798232.07739.31 [doi] PST - ppublish SO - Nurse Pract. 2022 Feb 1;47(2):40-46. doi: 10.1097/01.NPR.0000798232.07739.31. PMID- 35041736 OWN - NLM STAT- MEDLINE DCOM- 20220519 LR - 20220713 IS - 1559-0488 (Electronic) IS - 1559-047X (Linking) VI - 43 IP - 3 DP - 2022 May 17 TI - Management of Hydrocarbon Burns: Considering Mental Health and Biochemical Abnormalities. PG - 552-566 LID - 10.1093/jbcr/irac007 [doi] AB - Volatile substance misuse, particularly the inhalation of hydrocarbons, is a growing issue globally. Consequences of volatile substance misuse, both acute and chronic cause cardiovascular, respiratory, renal, metabolic, and central nervous system damage. Whilst the effects of hydrocarbon abuse have been reported, the combination of intoxication with hydrocarbon and burns sustained has not yet been presented. A retrospective case series of patients who presented in the last 5 years to the Royal Adelaide Hospital with hydrocarbon-related burns in the context of illicit use was undertaken. Our aims are to present to the wider scientific community the high morbidity and mortality of hydrocarbon burn injuries and why this tertiary Burns Unit feel it most appropriate to medically stabilize these patients prior to definitive surgery for their burn. All patients that presented with acute hydrocarbon intoxication and sustained concomitant burns had significant psychiatric disorder and substance abuse history and three of five had either not eaten in several days resulting in acute malnourishment, refeeding syndrome or had evidence of chronic malnourishment with deranged electrolytes and hypoalbuminemia. Their definitive burns surgery was delayed where appropriate in order to facilitate medical stabilization as they were too high risk of cardiac membrane instability, electrolyte derangement, and/or respiratory compromise to undergo safe general anesthetic and burns debridement. We propose a multidisciplinary team approach, utilizing not only our Burns Unit care model of physiotherapists, psychologists, social work, and burns trained nurses and surgeons but also Intensive Care, Toxicology, Addiction medicine and General Medical physicians in the management of these patients. CI - (c) The Author(s) 2022. Published by Oxford University Press on behalf of the American Burn Association. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. FAU - Rudduck, Emma-Leigh AU - Rudduck EL AD - Burns Unit, Royal Adelaide Hospital, South Australia, Australia. FAU - Concannon, Elizabeth AU - Concannon E AUID- ORCID: 0000-0002-1624-4371 AD - Burns Unit, Royal Adelaide Hospital, South Australia, Australia. FAU - Coghlan, Patrick AU - Coghlan P AD - Burns Unit, Royal Adelaide Hospital, South Australia, Australia. FAU - Govindan, Thiru AU - Govindan T AD - Department of Emergency Medicine, Royal Adelaide Hospital, South Australia, Australia. AD - Clinical Toxicology Service, Royal Adelaide Hospital, South Australia, Australia. FAU - Kurmis, Rochelle AU - Kurmis R AD - Burns Unit, Royal Adelaide Hospital, South Australia, Australia. FAU - Solanki, Nicholas AU - Solanki N AD - Burns Unit, Royal Adelaide Hospital, South Australia, Australia. LA - eng PT - Journal Article PL - England TA - J Burn Care Res JT - Journal of burn care & research : official publication of the American Burn Association JID - 101262774 RN - 0 (Hydrocarbons) SB - IM MH - Acute Disease MH - *Burns/complications MH - Humans MH - Hydrocarbons MH - *Malnutrition/complications MH - Mental Health MH - Retrospective Studies MH - *Substance-Related Disorders/complications EDAT- 2022/01/19 06:00 MHDA- 2022/05/20 06:00 CRDT- 2022/01/18 17:25 PHST- 2022/01/19 06:00 [pubmed] PHST- 2022/05/20 06:00 [medline] PHST- 2022/01/18 17:25 [entrez] AID - 6511006 [pii] AID - 10.1093/jbcr/irac007 [doi] PST - ppublish SO - J Burn Care Res. 2022 May 17;43(3):552-566. doi: 10.1093/jbcr/irac007. PMID- 35038280 OWN - NLM STAT- MEDLINE DCOM- 20230517 LR - 20260304 IS - 1531-1937 (Electronic) IS - 0897-1900 (Linking) VI - 36 IP - 3 DP - 2023 Jun TI - Key Points for Pharmacists From the ACC Expert Consensus Decision Pathway for Patients Hospitalized With Heart Failure. PG - 662-667 LID - 10.1177/08971900211064709 [doi] AB - Heart failure (HF) is a complex condition, and its clinical course often includes periods of decompensation that represent a deterioration in clinical status. During these periods, patients may experience worsening HF symptoms requiring hospitalization. Heart failure that necessitates hospitalization increases the risk of mortality and rehospitalization. In order to help facilitate appropriate care of patients hospitalized with HF, the American College Cardiology (ACC) published an expert consensus decision pathway (ECDP) that focuses on a multidisciplinary approach. The ECDP is divided into multiple nodes and pharmacists play integral roles in each one. There are many opportunities for pharmacists to optimize medical therapy, reinforce adherence, and provide medication and disease state education throughout hospitalization. This review article will highlight inpatient medication management of HF for hospital pharmacists. FAU - Tellor, Katie B AU - Tellor KB AUID- ORCID: 0000-0003-0980-9888 AD - Pfizer, Inc., St. Louis, MO, USA. FAU - Armbruster, Anastasia L AU - Armbruster AL AUID- ORCID: 0000-0002-1516-4118 AD - St. Louis College of Pharmacy at University of Health Sciences and Pharmacy, St. Louis, MO, USA. LA - eng PT - Consensus Statement PT - Journal Article PT - Review DEP - 20220117 PL - United States TA - J Pharm Pract JT - Journal of pharmacy practice JID - 8900945 SB - IM MH - Humans MH - United States MH - Pharmacists MH - *Heart Failure/diagnosis/drug therapy MH - Hospitalization MH - *Cardiology OTO - NOTNLM OT - and pharmacist OT - heart failure OT - hospitalization EDAT- 2022/01/18 06:00 MHDA- 2023/05/17 06:42 CRDT- 2022/01/17 17:06 PHST- 2023/05/17 06:42 [medline] PHST- 2022/01/18 06:00 [pubmed] PHST- 2022/01/17 17:06 [entrez] AID - 10.1177/08971900211064709 [doi] PST - ppublish SO - J Pharm Pract. 2023 Jun;36(3):662-667. doi: 10.1177/08971900211064709. Epub 2022 Jan 17. PMID- 35026012 OWN - NLM STAT- MEDLINE DCOM- 20220330 LR - 20250530 IS - 2058-1742 (Electronic) IS - 2058-1742 (Linking) VI - 8 IP - 2 DP - 2022 Mar 2 TI - Aortic regurgitation management: a systematic review of clinical practice guidelines and recommendations. PG - 113-126 LID - 10.1093/ehjqcco/qcac001 [doi] AB - Guidelines for the diagnosis and management of aortic regurgitation (AR) contain recommendations that do not always match. We systematically reviewed clinical practice guidelines and summarized similarities and differences in the recommendations as well as gaps in evidence on the management of AR. We searched MEDLINE and Embase (1 January 2011 to 1 September 2021), Google Scholar, and websites of relevant organizations for contemporary guidelines that were rigorously developed as assessed by the Appraisal of Guidelines for Research and Evaluation II tool. Three guidelines met our inclusion criteria. There was consensus on the definition of severe AR and use of echocardiography and of multimodality imaging for diagnosis, with emphasis on comprehensive assessment by the heart valve team to assess suitability and choice of intervention. Surgery is indicated in all symptomatic patients and aortic valve replacement is the cornerstone of treatment. There is consistency in the frequency of follow-up of patients, and safety of non-cardiac surgery in patients without indications for surgery. Discrepancies exist in recommendations for 3D imaging and the use of global longitudinal strain and biomarkers. Cut-offs for left ventricular ejection fraction and size for recommending surgery in severe asymptomatic AR also vary. There are no specific AR cut-offs for high-risk surgery and the role of percutaneous intervention is yet undefined. Recommendations on the treatment of mixed valvular disease are sparse and lack robust prospective data. CI - (c) The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology. FAU - Galusko, Victor AU - Galusko V AUID- ORCID: 0000-0001-5871-0900 AD - Department of Cardiology, King's College Hospital, London SE5 9RS, UK. FAU - Thornton, George AU - Thornton G AD - Barts Heart Centre, Barts Health NHS Trust, West Smithfield, London EC1A 7BE, UK. AD - Institute of Cardiovascular Science, University College London, London WC1E 6DD, UK. FAU - Jozsa, Csilla AU - Jozsa C AUID- ORCID: 0000-0003-3921-763X AD - Barts Heart Centre, Barts Health NHS Trust, West Smithfield, London EC1A 7BE, UK. AD - Department of Cardiology, Newham University Hospital, Barts Health NHS Trust, Glen Road, London E13 8SL, UK. FAU - Sekar, Baskar AU - Sekar B AD - Department of Cardiology, Gloucestershire Hospitals NHS Foundation Trust, Gloucester GL1 3NN, UK. FAU - Aktuerk, Dincer AU - Aktuerk D AD - Barts Heart Centre, Barts Health NHS Trust, West Smithfield, London EC1A 7BE, UK. FAU - Treibel, Thomas A AU - Treibel TA AUID- ORCID: 0000-0003-1560-7414 AD - Barts Heart Centre, Barts Health NHS Trust, West Smithfield, London EC1A 7BE, UK. AD - Institute of Cardiovascular Science, University College London, London WC1E 6DD, UK. FAU - Petersen, Steffen E AU - Petersen SE AD - Barts Heart Centre, Barts Health NHS Trust, West Smithfield, London EC1A 7BE, UK. AD - NIHR Barts Biomedical Research Centre, William Harvey Research Institute, Queen Mary University of London, London EC1A 7BE, UK. FAU - Ionescu, Adrian AU - Ionescu A AD - Morriston Hospital, UK Cardiac Regional Centre, Swansea Bay Health Board, Swansea SA6 6NL, UK. FAU - Ricci, Fabrizio AU - Ricci F AD - Department of Neuroscience, Imaging and Clinical Sciences, 'G.d'Annunzio' University of Chieti-Pescara, 66100 Chieti, Italy. AD - Department of Clinical Sciences, Lund University, Jan Waldenstroms gata 35, -205 02, Malmo, Sweden. AD - Casa di Cura Villa Serena, 65013 Citta Sant'Angelo, Pescara, Italy. FAU - Khanji, Mohammed Y AU - Khanji MY AUID- ORCID: 0000-0002-5903-4454 AD - Barts Heart Centre, Barts Health NHS Trust, West Smithfield, London EC1A 7BE, UK. AD - Department of Cardiology, Newham University Hospital, Barts Health NHS Trust, Glen Road, London E13 8SL, UK. AD - NIHR Barts Biomedical Research Centre, William Harvey Research Institute, Queen Mary University of London, London EC1A 7BE, UK. LA - eng GR - FS/19/35/34374/BHF_/British Heart Foundation/United Kingdom GR - FS/CRTF/21/24128/BHF_/British Heart Foundation/United Kingdom PT - Journal Article PT - Systematic Review PL - England TA - Eur Heart J Qual Care Clin Outcomes JT - European heart journal. Quality of care & clinical outcomes JID - 101677796 SB - IM MH - Aortic Valve/surgery MH - *Aortic Valve Insufficiency/diagnosis/surgery MH - Humans MH - Prospective Studies MH - Stroke Volume MH - Ventricular Function, Left OTO - NOTNLM OT - Aortic regurgitation OT - Aortic valve OT - Guidelines OT - Systematic review OT - Valvular heart disease EDAT- 2022/01/14 06:00 MHDA- 2022/03/31 06:00 CRDT- 2022/01/13 17:34 PHST- 2021/12/23 00:00 [received] PHST- 2022/01/05 00:00 [accepted] PHST- 2022/01/14 06:00 [pubmed] PHST- 2022/03/31 06:00 [medline] PHST- 2022/01/13 17:34 [entrez] AID - 6506448 [pii] AID - 10.1093/ehjqcco/qcac001 [doi] PST - ppublish SO - Eur Heart J Qual Care Clin Outcomes. 2022 Mar 2;8(2):113-126. doi: 10.1093/ehjqcco/qcac001. PMID- 35025978 OWN - NLM STAT- MEDLINE DCOM- 20220218 LR - 20220218 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 17 IP - 1 DP - 2022 TI - Trends of in-hospital cardiac arrests in a single tertiary hospital with a mature rapid response system. PG - e0262541 LID - 10.1371/journal.pone.0262541 [doi] LID - e0262541 AB - BACKGROUND: Most studies on rapid response system (RRS) have simply focused on its role and effectiveness in reducing in-hospital cardiac arrests (IHCAs) or hospital mortality, regardless of the predictability of IHCA. This study aimed to identify the characteristics of IHCAs including predictability of the IHCAs as our RRS matures for 10 years, to determine the best measure for RRS evaluation. METHODS: Data on all consecutive adult patients who experienced IHCA and received cardiopulmonary resuscitation in general wards between January 2010 and December 2019 were reviewed. IHCAs were classified into three groups: preventable IHCA (P-IHCA), non-preventable IHCA (NP-IHCA), and inevitable IHCA (I-IHCA). The annual changes of three groups of IHCAs were analyzed with Poisson regression models. RESULTS: Of a total of 800 IHCA patients, 149 (18.6%) had P-IHCA, 465 (58.1%) had NP-IHCA, and 186 (23.2%) had I-IHCA. The number of the RRS activations increased significantly from 1,164 in 2010 to 1,560 in 2019 (P = 0.009), and in-hospital mortality rate was significantly decreased from 9.20/1,000 patients in 2010 to 7.23/1000 patients in 2019 (P = 0.009). The trend for the overall IHCA rate was stable, from 0.77/1,000 patients in 2010 to 1.06/1,000 patients in 2019 (P = 0.929). However, while the incidence of NP-IHCA (P = 0.927) and I-IHCA (P = 0.421) was relatively unchanged over time, the incidence of P-IHCA decreased from 0.19/1,000 patients in 2010 to 0.12/1,000 patients in 2019 (P = 0.025). CONCLUSIONS: The incidence of P-IHCA could be a quality metric to measure the clinical outcomes of RRS implementation and maturation than overall IHCAs. FAU - Jung, Hohyung AU - Jung H AUID- ORCID: 0000-0002-5536-5483 AD - Department of Critical Care Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Ko, Ryoung-Eun AU - Ko RE AD - Department of Critical Care Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Ko, Myeong Gyun AU - Ko MG AD - Intensive Care Unit Nursing Department, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Jeon, Kyeongman AU - Jeon K AUID- ORCID: 0000-0002-4822-1772 AD - Department of Critical Care Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. AD - Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220113 PL - United States TA - PLoS One JT - PloS one JID - 101285081 SB - IM MH - Aged MH - Cardiopulmonary Resuscitation/adverse effects MH - Female MH - Heart Arrest/epidemiology/*mortality MH - Hospital Mortality/*trends MH - Hospital Rapid Response Team/*statistics & numerical data/trends MH - Hospitalization MH - Humans MH - Incidence MH - Male MH - Middle Aged MH - Tertiary Care Centers/trends PMC - PMC8757966 COIS- The authors have declared that no competing interests exist. EDAT- 2022/01/14 06:00 MHDA- 2022/02/19 06:00 PMCR- 2022/01/13 CRDT- 2022/01/13 17:31 PHST- 2021/09/28 00:00 [received] PHST- 2021/12/28 00:00 [accepted] PHST- 2022/01/13 17:31 [entrez] PHST- 2022/01/14 06:00 [pubmed] PHST- 2022/02/19 06:00 [medline] PHST- 2022/01/13 00:00 [pmc-release] AID - PONE-D-21-31238 [pii] AID - 10.1371/journal.pone.0262541 [doi] PST - epublish SO - PLoS One. 2022 Jan 13;17(1):e0262541. doi: 10.1371/journal.pone.0262541. eCollection 2022. PMID- 35023588 OWN - NLM STAT- MEDLINE DCOM- 20220303 LR - 20220303 IS - 1540-8191 (Electronic) IS - 0886-0440 (Linking) VI - 37 IP - 4 DP - 2022 Apr TI - Valve endocarditis, to repair or not to repair, is that really the question? PG - 1016-1018 LID - 10.1111/jocs.16232 [doi] AB - The meta-analysis by He et al. has the worth to cover, as much as possible, a gap of scientific evidence were conducting a randomized trial appears very complex for ethical and logistical reasons. The authors concluded that mitral valve repair (MVP) provides better-pooled results, both early and late, with respect to mitral valve replacement. However, the superiority of MVP is driven by some single large cohort studies where surgeons had wide experience in the field of MVP for infective endocarditis. This finding is also confirmed by other studies. But if mitral repair produces such a better short- and long-term survival than replacement, why are there no clear indications from consensus and guidelines pushing surgeons toward the pursuit of a reconstructive procedure at almost any cost? We wonder to repair or not to repair, is that really the question? The AATS consensus suggests repairing "whenever possible" but without providing more specific indications. If the two primary goals of surgery are total removal of infected tissues and reconstruction of cardiac morphology, including repair or replacement of the affected valve(s), probably MVP should be performed in case of less extensive tissue detriment by the infection. In more wide valve involvement, MVP may be the choice but only in very expert hands and in Centers with a very large volumes of valve repairing. This decision cannot, therefore, be the result of the choice of an individual but must derive from a careful multidisciplinary discussion to be held in an EndoTeam. CI - (c) 2022 Wiley Periodicals LLC. FAU - Di Mauro, Michele AU - Di Mauro M AUID- ORCID: 0000-0003-2611-5626 AD - Cardio-Thoracic Surgery Unit, Heart and Vascular Centre, Maastricht University Medical Centre (MUMC), Maastricht, The Netherlands. FAU - Bonalumi, Giorgia AU - Bonalumi G AD - Department of Cardiac Surgery, Centro Cardiologico Monzino, Milan, Italy. FAU - Calafiore, Antonio M AU - Calafiore AM AUID- ORCID: 0000-0002-1844-8861 AD - Division of Cardiac Surgery A, Henry Dunant Hospital, Athens, Greece. FAU - Lorusso, Roberto AU - Lorusso R AUID- ORCID: 0000-0002-1777-2045 AD - Cardio-Thoracic Surgery Unit, Heart and Vascular Centre, Maastricht University Medical Centre (MUMC), Maastricht, The Netherlands. LA - eng PT - Journal Article PT - Meta-Analysis DEP - 20220113 PL - United States TA - J Card Surg JT - Journal of cardiac surgery JID - 8908809 SB - IM MH - *Endocarditis/surgery MH - *Endocarditis, Bacterial/surgery MH - *Heart Valve Prosthesis Implantation/methods MH - Humans MH - Mitral Valve/surgery MH - Treatment Outcome OTO - NOTNLM OT - infective endocarditis OT - mitral valve repair OT - mitral valve replacement EDAT- 2022/01/14 06:00 MHDA- 2022/03/04 06:00 CRDT- 2022/01/13 08:51 PHST- 2021/12/30 00:00 [received] PHST- 2021/12/31 00:00 [accepted] PHST- 2022/01/14 06:00 [pubmed] PHST- 2022/03/04 06:00 [medline] PHST- 2022/01/13 08:51 [entrez] AID - 10.1111/jocs.16232 [doi] PST - ppublish SO - J Card Surg. 2022 Apr;37(4):1016-1018. doi: 10.1111/jocs.16232. Epub 2022 Jan 13. PMID- 35022197 OWN - NLM STAT- MEDLINE DCOM- 20220418 LR - 20220822 IS - 1554-6179 (Electronic) IS - 1539-4182 (Print) IS - 1539-4182 (Linking) VI - 20 IP - 1 DP - 2022 Mar TI - Determinants of Atrial Fibrillation Development among Patients undergoing Ibrutinib Therapy. PG - 16-22 LID - 10.3121/cmr.2021.1693 [doi] AB - Objective: Within the last decade, the use of ibrutinib, a first-generation, non-selective, irreversible Burton's tyrosine kinase inhibitor for the treatment of hematological malignancies has proven highly effective in improving patient outcomes.Background: Ibrutinib has been associated with an increase in atrial fibrillation (AF). The predisposing factors are thought to be pre-existing cardiovascular risk factors, but these have not been directly evaluated.Methods: We conducted a nested case-control study, recruiting consecutive ibrutinib treated subjects to evaluate cardiovascular risk factors associated with the development of AF in patients diagnosed with hematological B-cell malignancies.Results: Of the 189 patients treated with ibrutinib and without AF at baseline, 54 (29%) developed AF. Cardiovascular risk factors associated with AF development were, older age, prior hypertension (HTN), history of heart failure (HF) and congenital heart disease. A patient with HF at baseline had a 1, 2, 6, and 12 month cumulative hazard of AF of 40%, 48%, 64%, and 71%, respectively. Patients with prior HTN without HF at baseline had a 1, 2, 6, and 12 month cumulative hazard of AF of 5%, 10%, 23%, and 31%, respectively while on ibrutinib therapy.Conclusions: The relationship between ibrutinib, cardiovascular comorbidities, and AF is through pre-existing cardiovascular disease. An individualized, multidisciplinary approach involving cardiologists should be considered when initiating ibrutinib, particularly when there is a history of HTN, HF or congenital heart disease. In such patients, there should be close cardiovascular monitoring and prompt intervention when AF develops to improve patient outcomes. CI - (c) 2022 Marshfield Clinic Health System. FAU - Onitilo, Adedayo A AU - Onitilo AA AD - Marshfield Clinic Health System, Oncology Research, Marshfield, Wisconsin, USA Onitilo.adedayo@marshfieldclinic.org. FAU - Piwuna, Tinuade O AU - Piwuna TO AD - Marshfield Clinic Health System, Oncology Research, Marshfield, Wisconsin, USA. FAU - Islam, Nazmul AU - Islam N AD - Department of Public Health, College of Health Sciences, QU Health, Qatar University, Doha, Qatar. FAU - Furuya-Kanamori, Luis AU - Furuya-Kanamori L AD - Research School of Population Health, College of Health and Medicine, The Australian National University, ACT, Canberra, Australia. FAU - Kumar, Sanjay AU - Kumar S AD - Department of Cardiology-Electrophysiology, Marshfield Clinic Health System, Wisconsin. USA. FAU - Doi, Suhail A R AU - Doi SAR AD - Department of Population Medicine, College of Medicine, QU Health, Qatar University, Doha, Qatar. LA - eng PT - Journal Article DEP - 20220112 PL - United States TA - Clin Med Res JT - Clinical medicine & research JID - 101175887 RN - 0 (Piperidines) RN - 1X70OSD4VX (ibrutinib) RN - JAC85A2161 (Adenine) SB - IM MH - Adenine/analogs & derivatives MH - *Atrial Fibrillation/chemically induced/diagnosis MH - Case-Control Studies MH - *Heart Failure/complications MH - Humans MH - Piperidines MH - Risk Factors PMC - PMC9390851 OTO - NOTNLM OT - Atrial fibrillation OT - B-cell malignancies OT - Bruton's tyrosine kinase OT - Hematological malignancies OT - Ibrutinib OT - Risk factors EDAT- 2022/01/14 06:00 MHDA- 2022/04/19 06:00 PMCR- 2022/03/01 CRDT- 2022/01/13 05:54 PHST- 2021/05/11 00:00 [received] PHST- 2021/10/08 00:00 [accepted] PHST- 2022/01/14 06:00 [pubmed] PHST- 2022/04/19 06:00 [medline] PHST- 2022/01/13 05:54 [entrez] PHST- 2022/03/01 00:00 [pmc-release] AID - cmr.2021.1693 [pii] AID - 10.3121/cmr.2021.1693 [doi] PST - ppublish SO - Clin Med Res. 2022 Mar;20(1):16-22. doi: 10.3121/cmr.2021.1693. Epub 2022 Jan 12. PMID- 35017196 OWN - NLM STAT- MEDLINE DCOM- 20220914 LR - 20250728 IS - 1468-201X (Electronic) IS - 1355-6037 (Linking) VI - 108 IP - 19 DP - 2022 Sep 12 TI - Care of the patient after valve intervention. PG - 1516-1523 LID - 10.1136/heartjnl-2021-319767 [doi] AB - This review aims to outline the current evidence base and guidance for care of patients post-valve intervention. Careful follow-up, optimisation of medical therapy, antithrombotics, reduction of cardiovascular risk factors and patient education can help improve patient outcomes and quality of life. Those with mechanical valves should receive lifelong anticoagulation with a vitamin K antagonist but in certain circumstances may benefit from additional antiplatelet therapy. Patients with surgical bioprosthetic valves, valve repairs and transcatheter aortic valve implantation also benefit from antithrombotic therapy. Additionally, guideline-directed medical therapy for coexistent heart failure should be optimised. Cardiovascular risk factors such as hyperlipidaemia, hypertension and diabetes should be treated in the same way as those without valve intervention. Patients should also be encouraged to exercise regularly, eat healthily and maintain a healthy weight. Currently, there is not enough evidence to support routine cardiac rehabilitation in individuals post-valve surgery or intervention but this may be considered on a case-by-case basis. Women of childbearing age should be counselled regarding future pregnancy and the optimal management of their valve disease in this context. Patients should be educated regarding meticulous oral health, be encouraged to see their dentist regularly and antibiotics should be considered for high-risk dental procedures. Evidence shows that patients post-valve intervention or surgery are best treated in a dedicated valve clinic where they can undergo clinical review and surveillance echocardiography, be provided with heart valve education and have access to the multidisciplinary valve team if needed. CI - (c) Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Millar, Lynne Martina AU - Millar LM AUID- ORCID: 0000-0002-6800-5938 AD - Barts Heart Centre, St Bartholomew's Hospital, London, UK. FAU - Lloyd, Guy AU - Lloyd G AD - Barts Heart Centre, St Bartholomew's Hospital, London, UK. AD - William Harvey Research Institute, Queen Mary University of London, London, UK. FAU - Bhattacharyya, Sanjeev AU - Bhattacharyya S AUID- ORCID: 0000-0002-0234-5366 AD - Barts Heart Centre, St Bartholomew's Hospital, London, UK Sanjeev.Bhattacharyya@nhs.net. AD - William Harvey Research Institute, Queen Mary University of London, London, UK. LA - eng PT - Journal Article PT - Review DEP - 20220912 PL - England TA - Heart JT - Heart (British Cardiac Society) JID - 9602087 SB - IM MH - Aortic Valve/surgery MH - *Bioprosthesis/adverse effects MH - Female MH - *Heart Valve Diseases/drug therapy/surgery MH - *Heart Valve Prosthesis/adverse effects MH - *Heart Valve Prosthesis Implantation/adverse effects/methods MH - Humans MH - Pregnancy MH - Quality of Life MH - *Transcatheter Aortic Valve Replacement/adverse effects MH - Treatment Outcome OTO - NOTNLM OT - echocardiography OT - heart valve diseases COIS- Competing interests: None declared. EDAT- 2022/01/13 06:00 MHDA- 2022/09/15 06:00 CRDT- 2022/01/12 06:11 PHST- 2021/09/29 00:00 [received] PHST- 2021/12/16 00:00 [accepted] PHST- 2022/01/13 06:00 [pubmed] PHST- 2022/09/15 06:00 [medline] PHST- 2022/01/12 06:11 [entrez] AID - heartjnl-2021-319767 [pii] AID - 10.1136/heartjnl-2021-319767 [doi] PST - epublish SO - Heart. 2022 Sep 12;108(19):1516-1523. doi: 10.1136/heartjnl-2021-319767. PMID- 35016808 OWN - NLM STAT- MEDLINE DCOM- 20220802 LR - 20250728 IS - 1876-4738 (Electronic) IS - 0914-5087 (Linking) VI - 80 IP - 3 DP - 2022 Sep TI - Lifetime management for aortic stenosis: Planning for future therapies. PG - 185-189 LID - S0914-5087(21)00365-8 [pii] LID - 10.1016/j.jjcc.2021.12.010 [doi] AB - A shift to lifetime management has gained more focus with the approval of low-risk transcatheter aortic valve replacement (TAVR). This paper is therefore focused on the different approaches for lifetime management. Herein we discuss the procedural safety, durability, performance, and future options for each lifetime management strategy. In younger patients that elect to undergo surgical aortic valve replacement (SAVR), options for bioprosthetic failure are TAV-in-SAV or redo SAVR. Among patients that undergo TAVR, options for valve failure include TAVR explant with SAVR or TAV-in-TAV. Additionally, there are patients who may require a third valvular intervention. The initial therapy may limit re-intervention options down the road. This review discusses how options for future therapies affect the decision of SAVR vs TAVR in younger patients. CI - Copyright (c) 2021 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved. FAU - Basman, Craig AU - Basman C AD - Department of Cardiology and Cardiothoracic Surgery, Lenox Hill Hospital/Northwell Health, 130 East 77th Street, 4th floor, New York, NY, USA; Department of Cardiology, Northern Westchester Hospital/Northwell Health, Mount Kisco, NY, USA. Electronic address: cbasman@northwell.edu. FAU - Pirelli, Luigi AU - Pirelli L AD - Department of Cardiology and Cardiothoracic Surgery, Lenox Hill Hospital/Northwell Health, 130 East 77th Street, 4th floor, New York, NY, USA. FAU - Singh, Varinder P AU - Singh VP AD - Department of Cardiology and Cardiothoracic Surgery, Lenox Hill Hospital/Northwell Health, 130 East 77th Street, 4th floor, New York, NY, USA; Department of Cardiology, Northern Westchester Hospital/Northwell Health, Mount Kisco, NY, USA. FAU - Reimers, Carl D AU - Reimers CD AD - Department of Cardiology, Northern Westchester Hospital/Northwell Health, Mount Kisco, NY, USA. FAU - Hemli, Jonathan AU - Hemli J AD - Department of Cardiology and Cardiothoracic Surgery, Lenox Hill Hospital/Northwell Health, 130 East 77th Street, 4th floor, New York, NY, USA. FAU - Brinster, Derek R AU - Brinster DR AD - Department of Cardiology and Cardiothoracic Surgery, Lenox Hill Hospital/Northwell Health, 130 East 77th Street, 4th floor, New York, NY, USA. FAU - Patel, Nirav C AU - Patel NC AD - Department of Cardiology and Cardiothoracic Surgery, Lenox Hill Hospital/Northwell Health, 130 East 77th Street, 4th floor, New York, NY, USA. FAU - Scheinerman, S Jacob AU - Scheinerman SJ AD - Department of Cardiology and Cardiothoracic Surgery, Lenox Hill Hospital/Northwell Health, 130 East 77th Street, 4th floor, New York, NY, USA. FAU - Kliger, Chad A AU - Kliger CA AD - Department of Cardiology and Cardiothoracic Surgery, Lenox Hill Hospital/Northwell Health, 130 East 77th Street, 4th floor, New York, NY, USA. LA - eng PT - Journal Article PT - Review DEP - 20220110 PL - Netherlands TA - J Cardiol JT - Journal of cardiology JID - 8804703 SB - IM MH - Aortic Valve/surgery MH - *Aortic Valve Stenosis/etiology MH - *Heart Valve Prosthesis MH - *Heart Valve Prosthesis Implantation/adverse effects MH - Humans MH - Risk Factors MH - *Transcatheter Aortic Valve Replacement/adverse effects MH - Treatment Outcome OTO - NOTNLM OT - Heart team OT - Lifetime management OT - Multidetector computed tomography OT - Surgical aortic valve replacement OT - Transcatheter aortic valve replacement OT - Valve-in-valve EDAT- 2022/01/13 06:00 MHDA- 2022/08/03 06:00 CRDT- 2022/01/12 05:47 PHST- 2021/10/22 00:00 [received] PHST- 2021/11/26 00:00 [revised] PHST- 2021/12/03 00:00 [accepted] PHST- 2022/01/13 06:00 [pubmed] PHST- 2022/08/03 06:00 [medline] PHST- 2022/01/12 05:47 [entrez] AID - S0914-5087(21)00365-8 [pii] AID - 10.1016/j.jjcc.2021.12.010 [doi] PST - ppublish SO - J Cardiol. 2022 Sep;80(3):185-189. doi: 10.1016/j.jjcc.2021.12.010. Epub 2022 Jan 10. PMID- 35012417 OWN - NLM STAT- MEDLINE DCOM- 20220331 LR - 20220401 IS - 2154-8331 (Print) IS - 2154-8331 (Linking) VI - 49 IP - sup1 DP - 2021 Oct TI - Pediatric rapid response system innovations. PG - 399-404 LID - 10.1080/21548331.2022.2028468 [doi] AB - Rapid Response Systems (RRSs) are an organizational approach to support the timely recognition and treatment of decompensating patients and are used in many pediatric hospitals. These systems are comprised of afferent and efferent Limbs, as well as oversight arms. When incorporated into an RRS, standardized care algorithms can be helpful in identifying deteriorating patients and improving behaviors of the multidisciplinary team. The aim of this paper is to provide an overview of pediatric RRS and provide an example in which standardized care algorithms developed for the efferent limb of a pediatric RRS were associated with improvement in early escalation of care.PLAIN LANGUAGE SUMMARYThe Rapid Response System (RRS) is used in hospitals to recognize and care for hospitalized patients that are decompensating outside of an Intensive Care Unit. RRSs are made up of two main response components. The afferent limb focuses on the recognition and calls for help; the efferent limb focuses on correcting the deteriorating patient's physiology. Much energy has been put into afferent limb development to identify worsening patients before they progress to full cardiac or respiratory arrest. Standardization of efferent limb care algorithms can assist in developing and maintaining a shared mental model of care to improve communication and function of the multidisciplinary team. FAU - Troy, Lindsey AU - Troy L AD - Division of Pediatric Critical Care, Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, Utah, USA. FAU - Burch, Mary AU - Burch M AD - Department of Nursing Excellence, Intermountain Healthcare Primary Children's Hospital, Salt Lake City, Utah, USA. FAU - Sawicki, Jonathan G AU - Sawicki JG AD - Division of Pediatric Hospital Medicine, Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, Utah, USA. FAU - Henricksen, Jared W AU - Henricksen JW AUID- ORCID: 0000-0002-1326-8503 AD - Division of Pediatric Critical Care, Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, Utah, USA. LA - eng PT - Journal Article PT - Review DEP - 20220120 PL - England TA - Hosp Pract (1995) JT - Hospital practice (1995) JID - 101268948 SB - IM MH - Child MH - *Hospital Rapid Response Team MH - Hospitals, Pediatric MH - Humans MH - Intensive Care Units OTO - NOTNLM OT - Pediatric rapid response OT - care algorithm OT - complete clinician OT - patient safety OT - psychological distress OT - psychological safety OT - standardization of care OT - stress capacity OT - training EDAT- 2022/01/12 06:00 MHDA- 2022/04/01 06:00 CRDT- 2022/01/11 05:46 PHST- 2022/01/12 06:00 [pubmed] PHST- 2022/04/01 06:00 [medline] PHST- 2022/01/11 05:46 [entrez] AID - 10.1080/21548331.2022.2028468 [doi] PST - ppublish SO - Hosp Pract (1995). 2021 Oct;49(sup1):399-404. doi: 10.1080/21548331.2022.2028468. Epub 2022 Jan 20. PMID- 35012329 OWN - NLM STAT- MEDLINE DCOM- 20220308 LR - 20230302 IS - 1524-4628 (Electronic) IS - 0039-2499 (Print) IS - 0039-2499 (Linking) VI - 53 IP - 3 DP - 2022 Mar TI - From the Heart to the Brain: Building Bridges to a Better Future. PG - 1037-1042 LID - 10.1161/STROKEAHA.121.036763 [doi] AB - This Presidential Address was delivered at the International Stroke Conference in March 2021, during the coronavirus pandemic. Dr Elkind, the President of the American Heart Association (AHA) at the time, is a vascular neurologist with a research focus on stroke epidemiology. This address interweaves personal reflections on a career in clinical neurology, stroke research, and public health with a discussion of the role of the AHA in improving cardiovascular health at multiple levels. Throughout its history, the AHA has had leaders representing many different areas of cardiovascular science and medicine, including stroke. More recently, its focus has expanded from a traditional emphasis on cardiovascular events illness and events, like heart disease and stroke, to an appreciation of the role of the vascular system in brain health, healthy aging, cognitive decline, and dementia. During the pandemic, as the bidirectional effects of the coronavirus on cardiovascular disease has been elucidated, the benefits of a broad and multidisciplinary approach to cardiovascular disease and public health have become more apparent than ever. In addition, with growing awareness of the disproportionate effects of the pandemic on communities of color in the United States and globally, the AHA has redoubled its focus on addressing the social determinants of health, including structural racism. Central to these efforts is the construction of bridges between the generation of scientific knowledge and action for the public good. Our success will depend on the combination of basic, translational, clinical and population research with programs of public and professional education, advocacy, and social action. FAU - Elkind, Mitchell S V AU - Elkind MSV AUID- ORCID: 0000-0003-2562-1156 AD - Department of Neurology, Vagelos College of Physicians and Surgeons and Department of Epidemiology, Mailman School of Public Health, Columbia University, New York. LA - eng GR - R01 NS029993/NS/NINDS NIH HHS/United States GR - R01 NS048134/NS/NINDS NIH HHS/United States GR - R37 NS029993/NS/NINDS NIH HHS/United States GR - R56 NS029993/NS/NINDS NIH HHS/United States PT - Journal Article DEP - 20220111 PL - United States TA - Stroke JT - Stroke JID - 0235266 SB - IM MH - American Heart Association MH - *Brain MH - Cardiovascular Diseases MH - Heart Diseases/*epidemiology/*therapy MH - Humans MH - Stroke/*epidemiology/*therapy MH - United States/epidemiology PMC - PMC8885844 MID - NIHMS1766784 OTO - NOTNLM OT - brain OT - cerebrovascular disease OT - dementia OT - epidemiology OT - heart OT - pandemic EDAT- 2022/01/12 06:00 MHDA- 2022/03/09 06:00 PMCR- 2023/03/01 CRDT- 2022/01/11 05:43 PHST- 2022/01/12 06:00 [pubmed] PHST- 2022/03/09 06:00 [medline] PHST- 2022/01/11 05:43 [entrez] PHST- 2023/03/01 00:00 [pmc-release] AID - 10.1161/STROKEAHA.121.036763 [doi] PST - ppublish SO - Stroke. 2022 Mar;53(3):1037-1042. doi: 10.1161/STROKEAHA.121.036763. Epub 2022 Jan 11. PMID- 35008222 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220114 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 14 IP - 1 DP - 2021 Dec 23 TI - Late Cardiological Sequelae and Long-Term Monitoring in Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors: A Systematic Review by the Fondazione Italiana Linfomi. LID - 10.3390/cancers14010061 [doi] LID - 61 AB - Cardiotoxicity represents the most frequent cause with higher morbidity and mortality among long-term sequelae affecting classical Hodgkin lymphoma (cHL) and diffuse large B-cell lymphoma (DLBCL) patients. The multidisciplinary team of Fondazione Italiana Linfomi (FIL) researchers, with the methodological guide of Istituto di Ricerche Farmacologiche "Mario Negri", conducted a systematic review of the literature (PubMed, EMBASE, Cochrane database) according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, in order to analyze the following aspects of cHL and DLBCL survivorship: (i) incidence of cardiovascular disease (CVD); (ii) risk of long-term CVD with the use of less cardiotoxic therapies (reduced-field radiotherapy and liposomal doxorubicin); and (iii) preferable cardiovascular monitoring for left ventricular (LV) dysfunction, coronary heart disease (CHD) and valvular disease (VHD). After the screening of 659 abstracts and related 113 full-text papers, 23 publications were eligible for data extraction and included in the final sample. There was an increased risk for CVD in cHL survivors of 3.6 for myocardial infarction and 4.9 for congestive heart failure (CHF) in comparison to the general population; the risk increased over the years of follow-up. In addition, DLBCL patients presented a 29% increased risk for CHF. New radiotherapy techniques suggested reduced risk of late CVD, but only dosimetric studies were available. The optimal monitoring of LV function by 2D-STE echocardiography should be structured according to individual CV risk, mainly considering as risk factors a cumulative doxorubicine dose >250 mg per square meter (m(2)) and mediastinal radiotherapy >30 Gy, age at treatment <25 years and age at evaluation >60 years, evaluating LV ejection fraction, global longitudinal strain, and global circumferential strain. The evaluation for asymptomatic CHD should be offered starting from the 10th year after mediastinal RT, considering ECG, stress echo, or coronary artery calcium (CAC) score. Given the suggested increased risks of cardiovascular outcomes in lymphoma survivors compared to the general population, tailored screening and prevention programs may be warranted to offset the future burden of disease. FAU - Oliva, Stefano AU - Oliva S AUID- ORCID: 0000-0002-3200-2372 AD - Cardioncology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", 70124 Bari, Italy. FAU - Puzzovivo, Agata AU - Puzzovivo A AUID- ORCID: 0000-0001-5960-1925 AD - Cardioncology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", 70124 Bari, Italy. FAU - Gerardi, Chiara AU - Gerardi C AD - Istituto di Ricerche Farmacologiche "Mario Negri" IRCCS, 20156 Milan, Italy. FAU - Allocati, Eleonora AU - Allocati E AD - Istituto di Ricerche Farmacologiche "Mario Negri" IRCCS, 20156 Milan, Italy. FAU - De Sanctis, Vitaliana AU - De Sanctis V AD - Department of Medicine and Surgery and Translational Medicine, "Sapienza" University of Rome, Radiotherapy Oncology, St. Andrea Hospital, 00189 Rome, Italy. FAU - Minoia, Carla AU - Minoia C AD - Hematology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", 70124 Bari, Italy. FAU - Skrypets, Tetiana AU - Skrypets T AUID- ORCID: 0000-0002-2276-869X AD - Hematology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", 70124 Bari, Italy. FAU - Guarini, Attilio AU - Guarini A AD - Hematology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", 70124 Bari, Italy. FAU - Gini, Guido AU - Gini G AUID- ORCID: 0000-0002-1368-6342 AD - Clinic of Hematology, AOU Ospedali Riuniti Ancona-Universita Politecnica delle Marche, 60126 Ancona, Italy. LA - eng GR - R.C. 2021 funds, to the IRCCS Istituto Tumori "Giovanni Paolo II", Bari-Italy (del. 153/21)/Ministry of Health, Italian Government/ PT - Journal Article PT - Review DEP - 20211223 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC8750391 OTO - NOTNLM OT - cardiotoxicity OT - cardiovascular OT - classical Hodgkin lymphoma OT - diffuse large B-cell lymphoma OT - echocardiography OT - incidence OT - monitoring OT - risk factors OT - survivors OT - systematic review COIS- The authors declare no conflict of interest. EDAT- 2022/01/12 06:00 MHDA- 2022/01/12 06:01 PMCR- 2021/12/23 CRDT- 2022/01/11 01:01 PHST- 2021/09/16 00:00 [received] PHST- 2021/11/25 00:00 [revised] PHST- 2021/12/20 00:00 [accepted] PHST- 2022/01/11 01:01 [entrez] PHST- 2022/01/12 06:00 [pubmed] PHST- 2022/01/12 06:01 [medline] PHST- 2021/12/23 00:00 [pmc-release] AID - cancers14010061 [pii] AID - cancers-14-00061 [pii] AID - 10.3390/cancers14010061 [doi] PST - epublish SO - Cancers (Basel). 2021 Dec 23;14(1):61. doi: 10.3390/cancers14010061. PMID- 34992191 OWN - NLM STAT- MEDLINE DCOM- 20220719 LR - 20260705 IS - 1531-2291 (Electronic) IS - 0890-5339 (Linking) VI - 36 IP - 8 DP - 2022 Aug 1 TI - Evaluation of a Novel Multidisciplinary Preoperative Workup Strategy for Geriatric Hip Fractures. PG - 413-419 LID - 10.1097/BOT.0000000000002342 [doi] AB - OBJECTIVE: To determine the financial and clinical impact of a standardized, multidisciplinary team for surgical clearance and optimization in geriatric hip fracture patients. DESIGN: Retrospective case series. SETTING: Level-1 trauma center. PATIENTS: One hundred twenty-four geriatric patients (age >65 years old) in the preprotocol group (cohort 1; January 2017-December 2018) and 98 geriatric patients in the postprotocol group (cohort 2; October 2019-January 2021) with operative hip fractures. INTERVENTION: Implementation of a multidisciplinary team protocol consisting of Anesthesiology, Internal Medicine and Orthopedic Surgery departments for the assessment of medical readiness and optimization for surgical intervention in geriatric hip fractures. MAIN OUTCOME MEASURES: Rate of cardiology consultation, need for cardiac workup (echocardiography stress testing, heath catheterization), time to medical readiness (TTMR), time to surgery, case-cancellation rate, length of stay (LOS), and total hospitalization charges. RESULTS: Following implementation of the new protocol, there were significant ( P < 0.001) decreases in TTMR (19 vs. 11 hours), LOS (149 vs. 120 hours), case cancellation rate, and total hospital charges ($84,000 vs. $62,000). There were no significant differences with respect to in-hospital complications or readmission rates/mortality rates at 1 year. CONCLUSIONS: Following implementation of a protocolized, multidisciplinary approach to optimizing geriatric fracture patients, we were able to demonstrate a reduction in unnecessary preoperative testing, TTMR for surgery, case cancellation rate, LOS, and total hospitalization charge-without a concomitant increase in complications or mortality. This study highlights that standardization of the perioperative care for geriatric hip fracture patients can provide effective patient care while also lowering financial and logistical burden in care for these injuries. LEVEL OF EVIDENCE: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence. CI - Copyright (c) 2021 Wolters Kluwer Health, Inc. All rights reserved. FAU - Steffensmeier, Andrew AU - Steffensmeier A AD - Departments of Orthopaedic Surgery. FAU - Hoge, Connor AU - Hoge C AD - Departments of Orthopaedic Surgery. FAU - Shah, Nihar AU - Shah N AD - Departments of Orthopaedic Surgery. FAU - Matar, Robert AU - Matar R AD - Departments of Orthopaedic Surgery. FAU - Rice, Morgan AU - Rice M AD - Departments of Orthopaedic Surgery. FAU - Grawe, Erin AU - Grawe E AD - Anesthesiology, and. FAU - Held, Justin AU - Held J AD - Internal Medicine, University of Cincinnati Medical Center, Cincinnati, OH. FAU - Budde, Bradley AU - Budde B AD - Anesthesiology, and. FAU - Laughlin, Richard AU - Laughlin R AD - Departments of Orthopaedic Surgery. FAU - Sagi, H Claude AU - Sagi HC AD - Departments of Orthopaedic Surgery. LA - eng PT - Journal Article PL - United States TA - J Orthop Trauma JT - Journal of orthopaedic trauma JID - 8807705 SB - IM MH - Aged MH - *Hip Fractures/complications/diagnosis/surgery MH - Hospitalization MH - Humans MH - Length of Stay MH - Retrospective Studies MH - Trauma Centers COIS- The authors report no conflict of interest. EDAT- 2022/01/08 06:00 MHDA- 2022/07/20 06:00 CRDT- 2022/01/07 06:14 PHST- 2021/12/28 00:00 [accepted] PHST- 2022/01/08 06:00 [pubmed] PHST- 2022/07/20 06:00 [medline] PHST- 2022/01/07 06:14 [entrez] AID - 00005131-202208000-00009 [pii] AID - 10.1097/BOT.0000000000002342 [doi] PST - ppublish SO - J Orthop Trauma. 2022 Aug 1;36(8):413-419. doi: 10.1097/BOT.0000000000002342. PMID- 34991097 OWN - NLM STAT- MEDLINE DCOM- 20220701 LR - 20230818 IS - 1555-824X (Electronic) IS - 1062-8606 (Linking) VI - 37 IP - 4 DP - 2022 Jul-Aug 01 TI - A Resident-driven Quality Improvement Project to Increase Primary Care Follow-up after Congestive Heart Failure Exacerbation: Use of a Quality and Safety Award. PG - 314-320 LID - 10.1097/JMQ.0000000000000037 [doi] AB - OBJECTIVES: Congestive heart failure (CHF) is the most common cause of 30-day inpatient readmission. Studies have found that early follow-up with primary care physicians (PCP) within 7 days of discharge may improve 30-day readmission rates; however, many have used a multidisciplinary discharge coordination team, which is not a resource at all centers. Here, the authors present a resident-driven quality improvement initiative using a monthly quality and safety award to increase early PCP follow-up for veterans discharged following admissions due to a CHF exacerbation. Primary outcomes were percentage of PCP follow-up within 7 days and median time to PCP follow-up. Secondary outcomes included percentage of patients attending a PCP visit within 7 days, 30-day readmission, and 30-day mortality. METHODS: This prepost quasi-experimental cohort study evaluated 3 concurrent quality improvement interventions to increase PCP follow-up after CHF exacerbation. Process maps and Ishikawa diagrams examined the discharge process. Interventions included a standardized discharge scheduling order, monthly education on the process, and monthly aggregated performance feedback for each medical resident. A patient safety and quality award was given to the team with the highest rate of PCP appointments scheduled within 7 days. Patient characteristics and outcomes were gathered for a 6-month historic period and 6-month intervention period. Test of proportions and Wilcoxon Rank-Sum test were used to compare groups. RESULTS: A total of 294 patients were discharged (161 in historic group and 133 in intervention group). Appointments scheduled within 7 days of discharge increased from 43% to 79% ( P < 0.001). Median time to PCP follow-up decreased from 8 to 6 days ( P < 0.001). Patients who completed (showed up to) a PCP appointment within 7 days increased from 16% to 41% ( P < 0.001). There was no impact on 30-day readmission or mortality; however, the number of study subjects was too small to rule out an effect. CONCLUSIONS: A standardized discharge scheduling order, more robust resident education, and a monthly patient safety and quality award resulted in a significant increase in the rate of primary care follow-up within 7 days of CHF exacerbation. CI - Copyright (c) 2022 the American College of Medical Quality. FAU - Monday, Lea M AU - Monday LM AD - Division of Infectious Diseases, Department of Internal Medicine, Henry Ford Hospital, Detroit, MI. AD - Wayne State University School of Medicine, Detroit, MI. FAU - Sebastian, Joseph AU - Sebastian J AD - Division of General Internal Medicine, Department of Internal Medicine, Detroit Medical Center, Detroit, MI. FAU - Nguyen, Paul AU - Nguyen P AD - Wayne State University School of Medicine, Detroit, MI. FAU - Yazdanpanah, Omid AU - Yazdanpanah O AD - Division of General Internal Medicine, Department of Internal Medicine, Detroit Medical Center, Detroit, MI. FAU - Solokowski, Caleb AU - Solokowski C AD - Wayne State University School of Medicine, Detroit, MI. FAU - Chi, Jane AU - Chi J AD - Division of General Internal Medicine, Department of Internal Medicine, Detroit Medical Center, Detroit, MI. AD - Division of General Internal Medicine, Department of Internal Medicine, John D. Dingell Veterans Affairs Medical Center, Detroit, MI. FAU - Bazzy, Kareem AU - Bazzy K AD - Wayne State University School of Medicine, Detroit, MI. AD - Division of General Internal Medicine, Department of Internal Medicine, Detroit Medical Center, Detroit, MI. AD - Division of General Internal Medicine, Department of Internal Medicine, John D. Dingell Veterans Affairs Medical Center, Detroit, MI. LA - eng PT - Journal Article DEP - 20220104 PL - Netherlands TA - Am J Med Qual JT - American journal of medical quality : the official journal of the American College of Medical Quality JID - 9300756 SB - IM MH - *Awards and Prizes MH - Cohort Studies MH - Follow-Up Studies MH - *Heart Failure/therapy MH - Humans MH - Patient Discharge MH - Patient Readmission MH - Quality Improvement EDAT- 2022/01/07 06:00 MHDA- 2022/07/02 06:00 CRDT- 2022/01/06 20:30 PHST- 2022/01/07 06:00 [pubmed] PHST- 2022/07/02 06:00 [medline] PHST- 2022/01/06 20:30 [entrez] AID - 00008488-202207000-00005 [pii] AID - 10.1097/JMQ.0000000000000037 [doi] PST - ppublish SO - Am J Med Qual. 2022 Jul-Aug 01;37(4):314-320. doi: 10.1097/JMQ.0000000000000037. Epub 2022 Jan 4. PMID- 34990703 OWN - NLM STAT- MEDLINE DCOM- 20220412 LR - 20220716 IS - 2213-3763 (Electronic) IS - 0019-4832 (Print) IS - 0019-4832 (Linking) VI - 74 IP - 2 DP - 2022 Mar-Apr TI - Percutaneous coronary intervention in unprotected left main coronary artery stenosis: Mid-term outcomes of a single-center observational study. PG - 96-104 LID - S0019-4832(21)00465-X [pii] LID - 10.1016/j.ihj.2021.12.014 [doi] AB - BACKGROUND: Percutaneous coronary intervention (PCI) is an appropriate alternative to coronary artery bypass grafting (CABG) for revascularization of unprotected left main coronary artery (ULMCA) disease in patients with low-to-intermediate anatomic complexity or when the patient refuses CABG even after adequate counselling by heart team. We assessed the safety, in-hospital and mid-term outcomes of ULMCA stenting with drug-eluting stents (DES) in Indian patients. METHODS: Our study was a retrospective analysis of patients who had undergone ULMCA PCI at a tertiary center, between March 2011 and February 2020. Clinical characteristics, procedural data, and follow-up data were analyzed. The primary outcome was a composite of major adverse cardiovascular and cerebrovascular events (MACCE) during the hospital stay and at follow-up. The median follow-up was 2.8 years (interquartile range: 1.5-4.1 years). RESULTS: 661 patients (mean age, 63.5 +/- 10.9 years) had undergone ULMCA PCI. The mean SYNTAX score was 27.9 +/- 10.4 and the mean LVEF was 58.0 +/- 11.1%. 3-vessel disease and distal lesions were noted in 54% and 70.6% patients, respectively. The incidence of in-hospital MACCE was 1.8% and the MACCE during follow-up was 11.5% (including 48 [8.4%] cardiac deaths). The overall survival rates after one, three, five, and nine years were 94%, 88%, 84%, and 82%, respectively. The multivariate analysis revealed that age >65 years and high SYNTAX scores were independent predictors of mid to long-term mortality. CONCLUSION: ULMCA PCI with DES is safe and has acceptable in-hospital and mid-term outcomes among patients with low-to-intermediate SYNTAX score. CI - Copyright (c) 2022 Cardiological Society of India. Published by Elsevier, a division of RELX India, Pvt. Ltd. All rights reserved. FAU - Kumar N, Prathap AU - Kumar N P AD - Chief Interventional Cardiologist, Department of Cardiology, Meditrina Hospital, Kollam, Kerala, India. Electronic address: prathapndr@gmail.com. FAU - Roy, Stalin AU - Roy S AD - Interventional Cardiologist, Department of Cardiology, Meditrina Hospital, Kollam, Kerala, India. FAU - Rajendran, Manu AU - Rajendran M AD - Interventional Cardiologist, Department of Cardiology, Meditrina Hospital, Kollam, Kerala, India. FAU - Shafeeq, Ali AU - Shafeeq A AD - Interventional Cardiologist, Department of Cardiology, Meditrina Hospital, Kollam, Kerala, India. LA - eng PT - Journal Article PT - Observational Study DEP - 20220103 PL - India TA - Indian Heart J JT - Indian heart journal JID - 0374675 SB - IM MH - Aged MH - *Coronary Artery Disease/diagnosis/etiology/surgery MH - *Coronary Stenosis/diagnosis/etiology/surgery MH - Humans MH - Middle Aged MH - *Percutaneous Coronary Intervention/adverse effects MH - Retrospective Studies MH - Treatment Outcome PMC - PMC9039677 OTO - NOTNLM OT - Left main coronary artery disease OT - Percutaneous coronary intervention OT - SYNTAX score COIS- Declaration of competing interest The authors report no relationships that could be construed as a conflict of interest. EDAT- 2022/01/07 06:00 MHDA- 2022/04/13 06:00 PMCR- 2022/03/01 CRDT- 2022/01/06 20:13 PHST- 2021/12/07 00:00 [received] PHST- 2021/12/28 00:00 [revised] PHST- 2021/12/30 00:00 [accepted] PHST- 2022/01/07 06:00 [pubmed] PHST- 2022/04/13 06:00 [medline] PHST- 2022/01/06 20:13 [entrez] PHST- 2022/03/01 00:00 [pmc-release] AID - S0019-4832(21)00465-X [pii] AID - 10.1016/j.ihj.2021.12.014 [doi] PST - ppublish SO - Indian Heart J. 2022 Mar-Apr;74(2):96-104. doi: 10.1016/j.ihj.2021.12.014. Epub 2022 Jan 3. PMID- 34988537 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240904 IS - 2666-5204 (Electronic) IS - 2666-5204 (Linking) VI - 9 DP - 2022 Mar TI - Revisiting EEG as part of the multidisciplinary approach to post-cardiac arrest care and prognostication: A review. PG - 100189 LID - 10.1016/j.resplu.2021.100189 [doi] LID - 100189 AB - Since the 1960s, EEG has been used to assess the neurologic function of patients in the hours and days after cardiac arrest. Accurate and reliable prognostication after cardiac arrest is vital for tailoring aggressive patient care for those with a high likelihood of recovery and setting appropriate goals of care for those who have a high likelihood of a poor outcome. Attempts to define EEG's role in this process has evolved over the years. In this review, we provide important historical context about EEG's use, it's perceived unreliability in the post-cardiac arrest patient in the past and provide a detailed analysis of how this role has changed recently. A review of the 71 most recent and highest quality studies demonstrates that the introduction of a uniform classification and a timed approach to EEG analysis have positioned EEG as a complementary tool in the multimodal approach for prognostication. The review was created and intended for medical staff in the intensive care units and emphasizes EEG patterns and timing which portend both favorable and poor prognoses. Also, the review addresses the overall quality of the existing studies and discusses future directions to address the knowledge gaps in this field. CI - (c) 2021 The Authors. FAU - Bronder, Jay AU - Bronder J AD - Epilepsy Fellow, Department of Neurology, Johns Hopkins Hospital, 600 N. Wolfe St / Meyer 2-147, Baltimore, MD 21287-7247, USA. FAU - Cho, Sung-Min AU - Cho SM AD - Neuroscience Critical Care Division, Departments of Neurology, Neurosurgery, and Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, 600 N. Wolfe St, Baltimore, MD 21287, USA. FAU - Geocadin, Romergryko G AU - Geocadin RG AD - Professor of Neurology, Anesthesiology-Critical Care, Neurosurgery, and Joint Appointment in Medicine, The Johns Hopkins University School of Medicine, 600 N. Wolfe Street, Phipps 455, Baltimore, MD 21287, USA. FAU - Ritzl, Eva Katharina AU - Ritzl EK AD - Department of Neurology and Anesthesia and Critical Care Medicine, Johns Hopkins Hospital, 1800 Orleans Street, Suite 3329, Baltimore, MD 21287, USA. LA - eng GR - K23 HL157610/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Review DEP - 20211216 PL - Netherlands TA - Resusc Plus JT - Resuscitation plus JID - 101774410 PMC - PMC8693464 OTO - NOTNLM OT - EEG OT - Electroencephalography OT - Post cardiac arrest OT - Prognosis OT - Review COIS- The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2022/01/07 06:00 MHDA- 2022/01/07 06:01 PMCR- 2021/12/16 CRDT- 2022/01/06 06:05 PHST- 2021/10/20 00:00 [received] PHST- 2021/11/24 00:00 [revised] PHST- 2021/11/26 00:00 [accepted] PHST- 2022/01/06 06:05 [entrez] PHST- 2022/01/07 06:00 [pubmed] PHST- 2022/01/07 06:01 [medline] PHST- 2021/12/16 00:00 [pmc-release] AID - S2666-5204(21)00114-4 [pii] AID - 100189 [pii] AID - 10.1016/j.resplu.2021.100189 [doi] PST - epublish SO - Resusc Plus. 2021 Dec 16;9:100189. doi: 10.1016/j.resplu.2021.100189. eCollection 2022 Mar. PMID- 34988125 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240820 IS - 2297-055X (Print) IS - 2297-055X (Electronic) IS - 2297-055X (Linking) VI - 8 DP - 2021 TI - Multimodality Imaging in the Diagnosis of Prosthetic Valve Endocarditis: A Brief Review. PG - 750573 LID - 10.3389/fcvm.2021.750573 [doi] LID - 750573 AB - Infective endocarditis is a common and treatable condition that carries a high mortality rate. Currently the workup of infective endocarditis relies on the integration of clinical, microbiological and echocardiographic data through the use of the modified Duke criteria (MDC). However, in cases of prosthetic valve endocarditis (PVE) echocardiography can be normal or non-diagnostic in a high proportion of cases leading to decreased sensitivity for the MDC. Evolving multimodality imaging techniques including leukocyte scintigraphy (white blood cell imaging), (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET), multidetector computed tomographic angiography (MDCTA), and cardiac magnetic resonance imaging (CMRI) may each augment the standard workup of PVE and increase diagnostic accuracy. While further studies are necessary to clarify the ideal role for each of these imaging techniques, nevertheless, these modalities hold promise in determining the diagnosis, prognosis, and care of PVE. We start by presenting a clinical vignette, then evidence supporting various modality strategies, balanced by limitations, and review of formal guidelines, when available. The article ends with the authors' summary of future directions and case conclusion. CI - Copyright (c) 2021 Eder, Upadhyaya, Park, Ringer, Malinis, Young, Sugeng and Hur. FAU - Eder, Maxwell D AU - Eder MD AD - Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT, United States. FAU - Upadhyaya, Krishna AU - Upadhyaya K AD - Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT, United States. AD - Ascension Medical Group, Section of Cardiovascular Medicine, Milwaukee, WI, United States. FAU - Park, Jakob AU - Park J AD - Department of Internal Medicine, Yale New Haven Hospital, New Haven, CT, United States. FAU - Ringer, Matthew AU - Ringer M AD - Section of Infectious Diseases, Yale University School of Medicine, New Haven, CT, United States. FAU - Malinis, Maricar AU - Malinis M AD - Section of Infectious Diseases, Yale University School of Medicine, New Haven, CT, United States. FAU - Young, Bryan D AU - Young BD AD - Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT, United States. FAU - Sugeng, Lissa AU - Sugeng L AD - Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT, United States. FAU - Hur, David J AU - Hur DJ AD - Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT, United States. LA - eng PT - Journal Article PT - Review DEP - 20211220 PL - Switzerland TA - Front Cardiovasc Med JT - Frontiers in cardiovascular medicine JID - 101653388 PMC - PMC8720921 OTO - NOTNLM OT - endocarditis (infectious) OT - endocarditis team OT - imaging OT - multimodality OT - prosthetic OT - valve COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/01/07 06:00 MHDA- 2022/01/07 06:01 PMCR- 2021/01/01 CRDT- 2022/01/06 06:00 PHST- 2021/07/30 00:00 [received] PHST- 2021/11/29 00:00 [accepted] PHST- 2022/01/06 06:00 [entrez] PHST- 2022/01/07 06:00 [pubmed] PHST- 2022/01/07 06:01 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - 10.3389/fcvm.2021.750573 [doi] PST - epublish SO - Front Cardiovasc Med. 2021 Dec 20;8:750573. doi: 10.3389/fcvm.2021.750573. eCollection 2021. PMID- 34987041 OWN - NLM STAT- MEDLINE DCOM- 20220315 LR - 20220315 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 12 IP - 1 DP - 2022 Jan 5 TI - Implementing an enhanced recovery after thoracic surgery programme in the Netherlands: a qualitative study investigating facilitators and barriers for implementation. PG - e051513 LID - 10.1136/bmjopen-2021-051513 [doi] LID - e051513 AB - OBJECTIVES: This study aims to elucidate determinants for succesful implementation of the Enhanced Recovery After Thoracic Surgery (ERATS) protocol for perioperative care for surgical lung cancer patients in the Netherlands. SETTING: Lung cancer operations are performed in both academic and regional hospitals, either by cardiothoracic or general thoracic surgeons. Limiting the impact of these operations by optimising and standardising perioperative care with the ERATS protocol is thought to enable reduction in length of stay, complications and costs. PARTICIPANTS: A broad spectrum of stakeholders in perioperative care for patients with lung resection participated in this study, ranging from patient representatives, healthcare professionals to an insurance company representative. INTERVENTIONS: Semistructured interviews (N=14) were conducted with the stakeholders (N=18). The interviews were conducted one on one by telephone and two times, face to face, in small groups. Verbatim transcriptions of these interviews were coded for the purpose of thematic analysis. OUTCOME MEASURES: Determinants for successful implementation of the ERATS protocol in the Netherlands. RESULTS: Several determinants correspond with previous publications: having a multidisciplinary team, leadership from a senior clinician and support from an ERAS-coordinator as facilitators; lack of feedback on performance and absence of management support as barriers. Our study underscores the potential detrimental effect of inconsistent communication, the lack of support in the transition from hospital to home and the barrier posed by lack of accessible audit data. CONCLUSIONS: Based on a structured problem analysis among a wide selection of stakeholders, this study provides a solid basis for choosing adequate implementation strategies to introduce the ERATS protocol in the Netherlands. Emphasis on consistent and sufficient communication, support in the transition from hospital to home and adequate audit and feedback data, in addition to established implementation strategies for ERAS-type programmes, will enable a tailored approach to implementation of ERATS in the Dutch context. CI - (c) Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Meyenfeldt, Erik M von AU - Meyenfeldt EMV AUID- ORCID: 0000-0002-7839-2206 AD - Department of Thoracic Surgery, Albert Schweitzer Hospital, Dordrecht, Netherlands e.m.von.meyenfeldt@asz.nl. AD - Vrije Universiteit Amsterdam, Department of Public and Occupational Health, Amsterdam Public Health Institute, Amsterdam University Medical Centres, Amsterdam, Noord-Holland, Netherlands. FAU - van Nassau, Femke AU - van Nassau F AD - Vrije Universiteit Amsterdam, Department of Public and Occupational Health, Amsterdam Public Health Institute, Amsterdam University Medical Centres, Amsterdam, Noord-Holland, Netherlands. FAU - de Betue, Carlijn T I AU - de Betue CTI AD - Department of Thoracic Surgery, Albert Schweitzer Hospital, Dordrecht, Netherlands. FAU - Barberio, L AU - Barberio L AD - Patient Advocacy Group, Longkanker Nederland, Utrecht, Netherlands. FAU - Schreurs, Wilhelmina H AU - Schreurs WH AD - Department of Thoracic Surgery, Noordwest Ziekenhuisgroep, Alkmaar, Noord-Holland, Netherlands. FAU - Marres, Geertruid M H AU - Marres GMH AD - Department of Thoracic Surgery, Albert Schweitzer Hospital, Dordrecht, Netherlands. FAU - Bonjer, H Jaap AU - Bonjer HJ AD - Department of Surgery, Amsterdam UMC-Locatie VUMC, Amsterdam, Noord-Holland, Netherlands. FAU - Anema, Johannes AU - Anema J AD - Vrije Universiteit Amsterdam, Department of Public and Occupational Health, Amsterdam Public Health Institute, Amsterdam University Medical Centres, Amsterdam, Noord-Holland, Netherlands. LA - eng PT - Journal Article DEP - 20220105 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 SB - IM MH - Health Personnel MH - Humans MH - Netherlands MH - Qualitative Research MH - *Thoracic Surgery MH - *Thoracic Surgical Procedures PMC - PMC8734011 OTO - NOTNLM OT - medical education & training OT - organisational development OT - protocols & guidelines OT - qualitative research OT - respiratory tract tumours OT - thoracic surgery COIS- Competing interests: ERvM reports grants from Johnson&Johnson, outside the submitted work. LB, in her capacity as director of Longkanker Nederland, reports subsidies from KWF kankerbestrijding and PGO subsidie, grants from Abbvie, grants from AMGEN, grants from Astra Zeneca, grants from Boehringer Ingelheim, grants from BM-S, grants from Janssen-Cilag, grants from MSD, grants from Novartis, grants from Pfizer, grants from Roche, grants from Takeda; all outside the submitted work. JA reports grants from Various, grants from Pfizer & ZonMw, personal grant from Dutch Social Security Agency, personal fees from Various and personal fees from Evalua LtD and Ikherstel LtD, outside the submitted work; and he was an invited co-opted member of the guideline development group for the Dutch Occupational Medicine guideline for low back pain and the Dutch national Insurance Medicine protocol for Lumbosacral syndrome. He is appointed in 2016 as president of the Work disability Prevention and Integration committee of the International Commission on Occupational Health (ICOH). EDAT- 2022/01/07 06:00 MHDA- 2022/03/16 06:00 PMCR- 2022/01/05 CRDT- 2022/01/06 05:42 PHST- 2022/01/06 05:42 [entrez] PHST- 2022/01/07 06:00 [pubmed] PHST- 2022/03/16 06:00 [medline] PHST- 2022/01/05 00:00 [pmc-release] AID - bmjopen-2021-051513 [pii] AID - 10.1136/bmjopen-2021-051513 [doi] PST - epublish SO - BMJ Open. 2022 Jan 5;12(1):e051513. doi: 10.1136/bmjopen-2021-051513. PMID- 34979145 OWN - NLM STAT- MEDLINE DCOM- 20220314 LR - 20230916 IS - 1874-1754 (Electronic) IS - 0167-5273 (Linking) VI - 351 DP - 2022 Mar 15 TI - SGLT-2 inhibitors for treatment of heart failure in patients with and without type 2 diabetes: A practical approach for routine clinical practice. PG - 66-70 LID - S0167-5273(21)02054-4 [pii] LID - 10.1016/j.ijcard.2021.12.050 [doi] AB - Sodium-glucose cotransporter-2 inhibitors (SGLT-2i), initially studied and approved for the treatment of diabetes, are now becoming a promising class of agents to treat heart failure (HF) and chronic kidney disease (CKD), even in patients without diabetes. While the potential benefits in several diseases (usually treated by different medical specialties) is amplifying the interest in these drugs, their use in frail patients with multiple pathologies and on polypharmacy can be complex, requiring a composite multidisciplinary approach. Following a brief overview of the evidence supporting the benefits of SGLT-2i in patients with HF or CKD, we herein provide guidance for prescribing SGLT-2i in daily practice using a multidisciplinary approach. A shared treatment algorithm is presented for initiating an SGLT-2i in patients already being treated for diabetes and HF. Tools to prevent hypoglycemia, blood pressure drop, genital infections, euglycemic diabetic ketoacidosis and eGFR dip are also provided. It is hoped that this practical, multidisciplinary guidance for initiating SGLT-2i in patients with HF and/or CKD, whatever therapy they are currently on, can help to offer SGLT-2i to the largest population of patients possible to provide the most therapeutic benefit. CI - Copyright (c) 2021. Published by Elsevier B.V. FAU - Giaccari, Andrea AU - Giaccari A AD - Center for Endocrine and Metabolic Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS and Universita Cattolica del Sacro Cuore, Rome, Italy. FAU - Pontremoli, Roberto AU - Pontremoli R AD - University of Genoa and IRCCS Ospedale Policlinico San Martino, Genoa, Italy. Electronic address: roberto.pontremoli@unige.it. FAU - Perrone Filardi, Pasquale AU - Perrone Filardi P AD - Department of Advanced Biomedical Sciences, Federico II University of Naples, Italy, Mediterranea Cardiocentro, Naples, Italy. LA - eng PT - Journal Article PT - Review DEP - 20220101 PL - Netherlands TA - Int J Cardiol JT - International journal of cardiology JID - 8200291 RN - 0 (Hypoglycemic Agents) RN - 0 (Sodium-Glucose Transporter 2 Inhibitors) SB - IM CIN - Int J Cardiol. 2022 Apr 1;352:102-103. doi: 10.1016/j.ijcard.2022.01.067. PMID: 35134445 CIN - Int J Cardiol. 2023 Nov 1;390:131255. doi: 10.1016/j.ijcard.2023.131255. PMID: 37562752 MH - *Diabetes Mellitus, Type 2/complications/diagnosis/drug therapy MH - *Heart Failure/diagnosis/drug therapy/epidemiology MH - Humans MH - Hypoglycemic Agents/therapeutic use MH - *Renal Insufficiency, Chronic/complications/diagnosis/drug therapy MH - Risk Factors MH - *Sodium-Glucose Transporter 2 Inhibitors/therapeutic use OTO - NOTNLM OT - Heart failure OT - Management OT - Multidisciplinary OT - SGLT-2 inhibitors OT - Type 2 diabetes EDAT- 2022/01/04 06:00 MHDA- 2022/03/15 06:00 CRDT- 2022/01/03 20:12 PHST- 2021/09/29 00:00 [received] PHST- 2021/12/23 00:00 [revised] PHST- 2021/12/28 00:00 [accepted] PHST- 2022/01/04 06:00 [pubmed] PHST- 2022/03/15 06:00 [medline] PHST- 2022/01/03 20:12 [entrez] AID - S0167-5273(21)02054-4 [pii] AID - 10.1016/j.ijcard.2021.12.050 [doi] PST - ppublish SO - Int J Cardiol. 2022 Mar 15;351:66-70. doi: 10.1016/j.ijcard.2021.12.050. Epub 2022 Jan 1. PMID- 34974163 OWN - NLM STAT- MEDLINE DCOM- 20230508 LR - 20230523 IS - 1873-2615 (Electronic) IS - 1050-1738 (Linking) VI - 33 IP - 4 DP - 2023 May TI - Transcatheter interventions for valvular heart diseases in liver cirrhosis patients. PG - 242-249 LID - S1050-1738(21)00164-X [pii] LID - 10.1016/j.tcm.2021.12.014 [doi] AB - There is an increasing prevalence of patients who have both liver cirrhosis (LC) and severe valvular heart disease. This combination typically poses prohibitive risk for liver transplantation. LC related malnourishment, hypoalbuminemia and hyperdynamic circulation places patients with severe LC at higher rates for significant bleeding and/or thrombosis, as well as infectious and renal complications, after either surgical or transcatheter valvular interventions. Although there remains scarce comparative evidence, the preponderance of data suggest that percutaneous strategies are preferred over surgical ones. A multidisciplinary team is ideal for identifying those patients with LC who would benefit from transcatheter valvular heart interventions. CI - Copyright (c) 2021. Published by Elsevier Inc. FAU - Ahmed, Taha AU - Ahmed T AD - Department of Internal Medicine, University of Kentucky, Lexington, KY, USA. FAU - Misumida, Naoki AU - Misumida N AD - Department of Cardiovascular Medicine, Gill Heart and Vascular Institute, University of Kentucky, Lexington, KY, USA. FAU - Grigorian, Alla AU - Grigorian A AD - Department of Hepatology, University of Kentucky, Lexington, KY, USA. FAU - Tarantini, Giuseppe AU - Tarantini G AD - Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua Medical School, Padua, Italy. FAU - Messerli, Adrian W AU - Messerli AW AD - Department of Cardiovascular Medicine, Gill Heart and Vascular Institute, University of Kentucky, Lexington, KY, USA. Electronic address: adrian.messerli@uky.edu. LA - eng PT - Journal Article PT - Review DEP - 20211230 PL - United States TA - Trends Cardiovasc Med JT - Trends in cardiovascular medicine JID - 9108337 SB - IM CIN - Trends Cardiovasc Med. 2023 May;33(4):250-251. doi: 10.1016/j.tcm.2022.03.004. PMID: 35292352 MH - Humans MH - *Heart Valve Prosthesis Implantation/adverse effects MH - *Aortic Valve Stenosis/surgery MH - Treatment Outcome MH - Liver Cirrhosis/complications/diagnosis/therapy MH - *Heart Valve Diseases/diagnosis/surgery MH - *Transcatheter Aortic Valve Replacement MH - Aortic Valve/surgery MH - Risk Factors OTO - NOTNLM OT - Balloon aortic valvuloplasty OT - SAVR OT - TAVR OT - Transcatheter interventions OT - Transcatheter mitral valve repair OT - Transcatheter tricuspid valve repair OT - aortic stenosis OT - liver cirrhosis OT - surgical aortic valve replacement OT - transcatheter aortic valve replacement EDAT- 2022/01/03 06:00 MHDA- 2023/05/08 10:17 CRDT- 2022/01/02 20:24 PHST- 2021/10/29 00:00 [received] PHST- 2021/12/27 00:00 [revised] PHST- 2021/12/27 00:00 [accepted] PHST- 2023/05/08 10:17 [medline] PHST- 2022/01/03 06:00 [pubmed] PHST- 2022/01/02 20:24 [entrez] AID - S1050-1738(21)00164-X [pii] AID - 10.1016/j.tcm.2021.12.014 [doi] PST - ppublish SO - Trends Cardiovasc Med. 2023 May;33(4):242-249. doi: 10.1016/j.tcm.2021.12.014. Epub 2021 Dec 30. PMID- 34967780 OWN - NLM STAT- MEDLINE DCOM- 20220908 LR - 20250728 IS - 1538-943X (Electronic) IS - 1058-2916 (Linking) VI - 68 IP - 9 DP - 2022 Sep 1 TI - Management of Heparin-Induced Thrombocytopenia Using Plasmapharesis in Patients Undergoing HeartMate 3 Left Ventricular Assist Device. PG - e152-e155 LID - 10.1097/MAT.0000000000001631 [doi] AB - Heparin-induced thrombocytopenia (HIT) type-2 is a rare, but life-threatening complication that presents a unique challenge in patients undergoing cardiac surgery. Patients that require cardiac surgery with HIT present a dilemma between intraoperative anticoagulation, perioperative bleeding risk, and perioperative thrombotic events. We describe a case series of four patients who developed HIT in their hospital course before HeartMate 3 (HM3) left ventricular assist device implantation. Following a multidisciplinary approach, all patients did well intraoperatively with an approach of preoperative plasmapheresis, intraoperative unfractionated heparin (UFH), and postoperative conversion to bivalirudin with a bridge to warfarin. However, two patients had postoperative bleeding complications on bivalirudin. This case series details the therapeutic challenges encountered for HM3 implantation in patients with HIT and offers a therapeutic alternative to intraoperative bivalirudin in the effort to decrease perioperative complications in this challenging patient population. CI - Copyright (c) ASAIO 2021. FAU - Naqvi, Syed Yaseen AU - Naqvi SY AD - From the Department of Advanced Heart Failure and Transplantation, Division of Cardiology, University of Rochester Medical Center. FAU - Jawaid, Anas AU - Jawaid A FAU - Dao, Benjamin AU - Dao B FAU - Falvey, Jennifer AU - Falvey J AUID- ORCID: 0000-0002-7601-886 FAU - Vidula, Himabindu AU - Vidula H FAU - Gosev, Igor AU - Gosev I FAU - Thomas, Sabu AU - Thomas S LA - eng PT - Journal Article DEP - 20211228 PL - United States TA - ASAIO J JT - ASAIO journal (American Society for Artificial Internal Organs : 1992) JID - 9204109 RN - 0 (Anticoagulants) RN - 0 (Hirudins) RN - 0 (Peptide Fragments) RN - 0 (Recombinant Proteins) RN - 9005-49-6 (Heparin) SB - IM MH - Anticoagulants/therapeutic use MH - Blood Coagulation MH - *Heart-Assist Devices/adverse effects MH - Heparin/therapeutic use MH - Hirudins/adverse effects MH - Humans MH - Peptide Fragments/therapeutic use MH - Recombinant Proteins/therapeutic use MH - *Thrombocytopenia/chemically induced/therapy COIS- Disclosure: The authors have no conflicts of interest to report. EDAT- 2021/12/31 06:00 MHDA- 2022/09/09 06:00 CRDT- 2021/12/30 12:44 PHST- 2021/12/31 06:00 [pubmed] PHST- 2022/09/09 06:00 [medline] PHST- 2021/12/30 12:44 [entrez] AID - 00002480-202209000-00020 [pii] AID - 10.1097/MAT.0000000000001631 [doi] PST - ppublish SO - ASAIO J. 2022 Sep 1;68(9):e152-e155. doi: 10.1097/MAT.0000000000001631. Epub 2021 Dec 28. PMID- 34964577 OWN - NLM STAT- MEDLINE DCOM- 20220530 LR - 20220530 IS - 2532-5264 (Electronic) IS - 1122-0643 (Linking) VI - 92 IP - 3 DP - 2021 Dec 29 TI - A complex unit for a complex disease: the HCM-Family Unit. LID - 10.4081/monaldi.2021.2147 [doi] AB - Hypertrophic cardiomyopathy (HCM) is a group of heterogeneous disorders that are most commonly passed on in a heritable manner. It is a relatively rare disease around the globe, but due to increased rates of consanguinity within the Kingdom of Saudi Arabia, we speculate a high incidence of undiagnosed cases. The aim of this paper is to elucidate a systematic approach in dealing with HCM patients and since HCM has variable presentation, we have summarized differentials for diagnosis and how different subtypes and genes can have an impact on the clinical picture, management and prognosis. Moreover, we propose a referral multi-disciplinary team HCM-Family Unit in Saudi Arabia and an integrated role in a network between King Faisal Hospital and Inherited and Rare Cardiovascular Disease Unit-Monaldi Hospital, Italy (among the 24 excellence centers of the European Reference Network (ERN) GUARD-Heart). Graphical Abstract. FAU - Vriz, Olga AU - Vriz O AD - Department of Cardiology, King Faisal Specialist Hospital and Research Center, Riyadh. olgavriz@yahoo.com. FAU - AlSergani, Hani AU - AlSergani H AD - Department of Cardiology, King Faisal Specialist Hospital and Research Center, Riyadh. olgavriz@yahoo.com. FAU - Elshaer, Ahmed Nahid AU - Elshaer AN AD - AlFaisal University, School of Medicine, Riyadh. olgavriz@yahoo.com. FAU - Shaik, Abdullah AU - Shaik A AD - AlFaisal University, School of Medicine, Riyadh. olgavriz@yahoo.com. FAU - Mushtaq, Ali Hassan AU - Mushtaq AH AD - AlFaisal University, School of Medicine, Riyadh. olgavriz@yahoo.com. FAU - Lioncino, Michele AU - Lioncino M AD - Inherited and Rare Cardiovascular Disease Unit, Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", AORN dei Colli, Monaldi Hospital, Naples. olgavriz@yahoo.com. FAU - Alamro, Bandar AU - Alamro B AD - Department of Cardiology, King Faisal Specialist Hospital and Research Center, Riyadh. olgavriz@yahoo.com. FAU - Monda, Emanuele AU - Monda E AD - Inherited and Rare Cardiovascular Disease Unit, Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", AORN dei Colli, Monaldi Hospital, Naples. olgavriz@yahoo.com. FAU - Caiazza, Martina AU - Caiazza M AD - Inherited and Rare Cardiovascular Disease Unit, Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", AORN dei Colli, Monaldi Hospital, Naples. olgavriz@yahoo.com. FAU - Mauro, Ciro AU - Mauro C AD - Department of Cardiology, Cardarelli Hospital, Naples. olgavriz@yahoo.com. FAU - Bossone, Eduardo AU - Bossone E AD - Department of Cardiology, Cardarelli Hospital, Naples. olgavriz@yahoo.com. FAU - Al-Hassnan, Zuhair N AU - Al-Hassnan ZN AD - Cardiovascular Genetics Program and Department of Medical Genetics, King Faisal Specialist Hospital and Research Centre, Riyadh. olgavriz@yahoo.com. FAU - Albert-Brotons, Dimpna AU - Albert-Brotons D AD - Department of Cardiology, King Faisal Specialist Hospital and Research Center, Riyadh. olgavriz@yahoo.com. FAU - Limongelli, Giuseppe AU - Limongelli G AD - Inherited and Rare Cardiovascular Disease Unit, Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", AORN dei Colli, Monaldi Hospital, Naples. giuseppe.limongelli@unicampania.it. LA - eng PT - Journal Article DEP - 20211229 PL - Italy TA - Monaldi Arch Chest Dis JT - Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace JID - 9307314 SB - IM MH - *Cardiomyopathy, Hypertrophic/diagnosis/epidemiology/genetics MH - Humans MH - Italy/epidemiology MH - Prognosis EDAT- 2021/12/30 06:00 MHDA- 2022/05/31 06:00 CRDT- 2021/12/29 09:39 PHST- 2021/11/14 00:00 [received] PHST- 2021/11/30 00:00 [accepted] PHST- 2021/12/30 06:00 [pubmed] PHST- 2022/05/31 06:00 [medline] PHST- 2021/12/29 09:39 [entrez] AID - 10.4081/monaldi.2021.2147 [doi] PST - epublish SO - Monaldi Arch Chest Dis. 2021 Dec 29;92(3). doi: 10.4081/monaldi.2021.2147. PMID- 34964456 OWN - NLM STAT- MEDLINE DCOM- 20220307 LR - 20220307 IS - 1755-3245 (Electronic) IS - 0008-6363 (Linking) VI - 118 IP - 1 DP - 2022 Jan 7 TI - The 2021 ESC/EACTS guidelines for the management of valvular heart disease: a new template for Heart Teams and their patients. PG - e11-e13 LID - 10.1093/cvr/cvab362 [doi] FAU - Prendergast, Bernard AU - Prendergast B AUID- ORCID: 0000-0002-6031-2124 AD - Department of Cardiology, St Thomas' Hospital, Westminster Bridge Road, London SE1 7EH, UK. AD - Cleveland Clinic London, Grosvenor Place, London. FAU - Vahanian, Alec AU - Vahanian A AUID- ORCID: 0000-0001-9413-4891 AD - Universite de Paris, Paris, France. LA - eng PT - Journal Article PL - England TA - Cardiovasc Res JT - Cardiovascular research JID - 0077427 SB - IM MH - Cardiology/*standards MH - Clinical Decision-Making MH - Consensus MH - Europe MH - Heart Valve Diseases/diagnostic imaging/physiopathology/*surgery MH - Heart Valve Prosthesis Implantation/adverse effects/*standards MH - Heart Valves/diagnostic imaging/physiopathology/*surgery MH - Humans MH - Patient Care Team/*standards MH - Practice Guidelines as Topic/*standards MH - Risk Assessment MH - Risk Factors MH - Societies, Medical/*standards MH - Thoracic Surgery/*standards MH - Transcatheter Aortic Valve Replacement/adverse effects/*standards MH - Treatment Outcome OTO - NOTNLM OT - Guidelines OT - Mitral OT - SAVR OT - TAVI OT - Valvular heart disease EDAT- 2021/12/30 06:00 MHDA- 2022/03/08 06:00 CRDT- 2021/12/29 08:42 PHST- 2021/12/30 06:00 [pubmed] PHST- 2022/03/08 06:00 [medline] PHST- 2021/12/29 08:42 [entrez] AID - 6486881 [pii] AID - 10.1093/cvr/cvab362 [doi] PST - ppublish SO - Cardiovasc Res. 2022 Jan 7;118(1):e11-e13. doi: 10.1093/cvr/cvab362. PMID- 34963372 OWN - NLM STAT- MEDLINE DCOM- 20230508 LR - 20230508 IS - 1552-6127 (Electronic) IS - 1090-1981 (Linking) VI - 50 IP - 3 DP - 2023 Jun TI - Assessment of Chronic Disease Management Strategies Among Health Care Practices in Medically Underserved South Carolina Counties. PG - 406-415 LID - 10.1177/10901981211057538 [doi] AB - Diabetes and heart disease are among the leading causes of death and disability in the United States, and these conditions are especially prevalent in the South. South Carolina's persistent racial and socioeconomic disparities in chronic disease outcomes are well-documented, yet little is known about how health care practices in medically underserved areas are addressing these challenges. Data were collected through a cross-sectional survey as part of two complementary 5-year cooperative agreements between the Centers for Disease Control and Prevention and the Division of Diabetes and Heart Disease Management (the Division) at the South Carolina Department of Health and Environmental Control. The Division fielded a survey to (a) assist in determining which Rural Health Clinics (RHCs) and Federally Qualified Health Centers (FQHCs) were best poised to implement specific strategies as part of these cooperative agreements and (b) provide data to establish the baseline for performance measures. FQHCs and RHCs in the top 25% of counties with the highest diabetes and heart disease burden were surveyed about eight domains: staffing/services, electronic health records, team-based care policies, lifestyle change programs, medication therapy management, telehealth, quality improvement collaboratives, and patient demographics. Data representing 71 practices revealed contrasts between RHCs and FQHCs and opportunities for improvement. For example, while most practices reported they were not implementing evidence-based lifestyle change programs (e.g., the National Diabetes Prevention Program), most RHCs and FQHCs expressed interest in starting such programs. Findings are being used to guide efforts to improve diabetes and heart disease prevention and management in South Carolina. FAU - Mandelbaum, Jennifer AU - Mandelbaum J AUID- ORCID: 0000-0001-8797-3718 AD - South Carolina Department of Health and Environmental Control, Columbia, USA. AD - University of South Carolina, Columbia, USA. FAU - Myers, Kristian G AU - Myers KG AD - South Carolina Department of Health and Environmental Control, Columbia, USA. FAU - Brightharp, Courtney L AU - Brightharp CL AD - South Carolina Department of Health and Environmental Control, Columbia, USA. FAU - Hicks, Shauna P AU - Hicks SP AD - South Carolina Department of Health and Environmental Control, Columbia, USA. LA - eng GR - CC/CDC HHS/United States PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. DEP - 20211228 PL - United States TA - Health Educ Behav JT - Health education & behavior : the official publication of the Society for Public Health Education JID - 9704962 SB - IM MH - Humans MH - United States MH - South Carolina MH - Medically Underserved Area MH - Cross-Sectional Studies MH - Chronic Disease MH - *Heart Diseases MH - *Diabetes Mellitus/prevention & control MH - Disease Management OTO - NOTNLM OT - cardiovascular disease OT - evaluation OT - general terms OT - health administration OT - place OT - rural health EDAT- 2021/12/30 06:00 MHDA- 2023/05/08 10:17 CRDT- 2021/12/29 05:21 PHST- 2023/05/08 10:17 [medline] PHST- 2021/12/30 06:00 [pubmed] PHST- 2021/12/29 05:21 [entrez] AID - 10.1177/10901981211057538 [doi] PST - ppublish SO - Health Educ Behav. 2023 Jun;50(3):406-415. doi: 10.1177/10901981211057538. Epub 2021 Dec 28. PMID- 34962466 OWN - NLM STAT- MEDLINE DCOM- 20220203 LR - 20220203 IS - 1522-6662 (Electronic) IS - 1098-3511 (Linking) VI - 24 IP - 6 DP - 2021 Dec 14 TI - Surgical Treatment of Primary Cardiac Paragangliomas: A Single-Center Experience. PG - E1023-E1026 LID - 10.1532/hsf.4255 [doi] AB - BACKGROUND: Cardiac paragangliomas are rare neuroendocrine tumors that will cause significant morbidity if left undiagnosed. Because of the paucity of cohort data, their rapid diagnosis and appropriate management still pose unique challenges to cardiac surgeons. We aimed to investigate the clinical features and surgical management of primary cardiac paragangliomas in our single center. METHODS: From May 2014 to October 2020, patients diagnosed with primary cardiac paragangliomas retrospectively were reviewed. Demographic data, clinical presentation, preoperative imaging methods, surgical resection, perioperative management, histological analysis, and outcomes were recorded. Postoperative follow up also was reviewed. RESULTS: With multiple imaging methods, including echocardiography, computed tomography, positron-emission tomographic-computed tomography, and biochemical tests, there were five cases of primary cardiac paraganglioma verified by postoperative immunohistochemical staining, two of which were hormonally active. There were no metastatic cardiac paragangliomas, according to positron-emission tomographic-computed tomography, and all patients accepted surgical treatment. Preoperative adrenoceptor blockade was given to hormonally active patients, accordingly. Complete resection of the tumor was accomplished under cardiopulmonary bypass in each case. Tumor distribution included two masses on the roof of the left atrium, two masses in the right atrioventricular groove, and one between the ascending aorta and main pulmonary artery. Immunohistochemical staining for chromogranin, neuron-specific enolase, synaptophysin, and S-100 were positive, which were typical of cardiac paraganglioma. There were no operative deaths. All the patients had an uneventful recovery except one patient who underwent low cardiac output syndrome. During follow up (mean 4.2 years, range 0.6-7.0 years), all patients were well with New York Heart Association class I or II. Only one patient developed thyroid carcinoma three years after surgery but with no paraganglioma recurrence during periodic computed tomography, and this patient recovered well after thyroidectomy. CONCLUSION: Although cardiac paragangliomas are rare and may present surgical challenges for clinicians, surgical resection remains the choice of treatment with favorable outcomes through a multidisciplinary heart team. Moreover, lifelong surveillance still is recommended to detect possible recurrence or associated nonchromaffin tumors in time. FAU - Zheng, Jianjie AU - Zheng J AD - Department of Cardiovascular Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. 1369504368@qq.com. FAU - Li, Jianpeng AU - Li J AD - Department of Cardiovascular Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. 9175751@qq.com. FAU - Li, Jing AU - Li J AD - Department of Cardiovascular Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. xuexi86@126.com. FAU - Zhong, Liang AU - Zhong L AD - Department of Cardiovascular Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. 297123358@qq.com. FAU - Xu, Suochun AU - Xu S AD - Department of Cardiovascular Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. zhplove@xjtufh.edu.cn. FAU - Zhou, Heping AU - Zhou H AD - Department of Cardiovascular Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. 572552885@qq.com. LA - eng PT - Journal Article DEP - 20211214 PL - United States TA - Heart Surg Forum JT - The heart surgery forum JID - 100891112 RN - 0 (Biomarkers, Tumor) SB - IM MH - Adult MH - Biomarkers, Tumor/analysis MH - Female MH - Follow-Up Studies MH - Heart Neoplasms/diagnostic imaging/*surgery MH - Humans MH - Immunohistochemistry MH - Male MH - Middle Aged MH - Paraganglioma, Extra-Adrenal/diagnostic imaging/*surgery MH - Perioperative Care MH - Retrospective Studies MH - Treatment Outcome EDAT- 2021/12/29 06:00 MHDA- 2022/02/04 06:00 CRDT- 2021/12/28 12:11 PHST- 2021/08/23 00:00 [received] PHST- 2021/09/14 00:00 [accepted] PHST- 2021/12/28 12:11 [entrez] PHST- 2021/12/29 06:00 [pubmed] PHST- 2022/02/04 06:00 [medline] AID - 10.1532/hsf.4255 [doi] PST - epublish SO - Heart Surg Forum. 2021 Dec 14;24(6):E1023-E1026. doi: 10.1532/hsf.4255. PMID- 34961335 OWN - NLM STAT- MEDLINE DCOM- 20220228 LR - 20260306 IS - 1941-3084 (Electronic) IS - 1941-3149 (Print) IS - 1941-3084 (Linking) VI - 15 IP - 1 DP - 2022 Jan TI - Stimulant Drugs of Abuse and Cardiac Arrhythmias. PG - e010273 LID - 10.1161/CIRCEP.121.010273 [doi] AB - Nonmedical use of prescription and nonprescription drugs is a worldwide epidemic, rapidly growing in magnitude with deaths because of overdose and chronic use. A vast majority of these drugs are stimulants that have various effects on the cardiovascular system including the cardiac rhythm. Drugs, like cocaine and methamphetamine, have measured effects on the conduction system and through several direct and indirect pathways, utilizing multiple second messenger systems, change the structural and electrical substrate of the heart, thereby promoting cardiac dysrhythmias. Substituted amphetamines and cocaine affect the expression and activation kinetics of multiple ion channels and calcium signaling proteins resulting in EKG changes, and atrial and ventricular brady and tachyarrhythmias. Preexisting conditions cause substrate changes in the heart, which decrease the threshold for such drug-induced cardiac arrhythmias. The treatment of cardiac arrhythmias in patients who take drugs of abuse may be specialized and will require an understanding of the unique underlying mechanisms and necessitates a multidisciplinary approach. The use of primary or secondary prevention defibrillators in drug abusers with chronic systolic heart failure is both sensitive and controversial. This review provides a broad overview of cardiac arrhythmias associated with stimulant substance abuse and their management. FAU - Dominic, Paari AU - Dominic P AUID- ORCID: 0000-0002-7843-375X AD - Center of Excellence for Cardiovascular Diseases & Sciences (P.D., H.A., S.B., C.G.K.), Louisiana State University Health Sciences Center, Shreveport. AD - Department of Medicine (P.D., J.A., H.A.), Louisiana State University Health Sciences Center, Shreveport. FAU - Ahmad, Javaria AU - Ahmad J AD - Department of Medicine (P.D., J.A., H.A.), Louisiana State University Health Sciences Center, Shreveport. FAU - Awwab, Hajra AU - Awwab H AD - Center of Excellence for Cardiovascular Diseases & Sciences (P.D., H.A., S.B., C.G.K.), Louisiana State University Health Sciences Center, Shreveport. AD - Department of Medicine (P.D., J.A., H.A.), Louisiana State University Health Sciences Center, Shreveport. FAU - Bhuiyan, Md Shenuarin AU - Bhuiyan MS AUID- ORCID: 0000-0003-0073-3071 AD - Center of Excellence for Cardiovascular Diseases & Sciences (P.D., H.A., S.B., C.G.K.), Louisiana State University Health Sciences Center, Shreveport. AD - Department of Pathology and Translational Pathobiology (M.S.B., C.G.K.), Louisiana State University Health Sciences Center, Shreveport. AD - Department of Molecular and Cellular Physiology (M.S.B., C.G.K.), Louisiana State University Health Sciences Center, Shreveport. FAU - Kevil, Christopher G AU - Kevil CG AUID- ORCID: 0000-0003-0863-7260 AD - Center of Excellence for Cardiovascular Diseases & Sciences (P.D., H.A., S.B., C.G.K.), Louisiana State University Health Sciences Center, Shreveport. AD - Department of Pathology and Translational Pathobiology (M.S.B., C.G.K.), Louisiana State University Health Sciences Center, Shreveport. AD - Department of Molecular and Cellular Physiology (M.S.B., C.G.K.), Louisiana State University Health Sciences Center, Shreveport. AD - Department of Cellular Biology and Anatomy (C.G.K.), Louisiana State University Health Sciences Center, Shreveport. FAU - Goeders, Nicholas E AU - Goeders NE AD - Department of Pharmacology, Toxicology and Neuroscience (N.E.G., K.S.M.), Louisiana State University Health Sciences Center, Shreveport. FAU - Murnane, Kevin S AU - Murnane KS AD - Department of Pharmacology, Toxicology and Neuroscience (N.E.G., K.S.M.), Louisiana State University Health Sciences Center, Shreveport. AD - Department of Psychiatry (K.S.M., J.C.P.), Louisiana State University Health Sciences Center, Shreveport. FAU - Patterson, James C AU - Patterson JC AD - Department of Psychiatry (K.S.M., J.C.P.), Louisiana State University Health Sciences Center, Shreveport. FAU - Sandau, Kristin E AU - Sandau KE AUID- ORCID: 0000-0002-3755-1151 AD - Department of Nursing, Bethel University, St Paul, MN (K.E.S.). FAU - Gopinathannair, Rakesh AU - Gopinathannair R AUID- ORCID: 0000-0003-4611-3687 AD - The Kansas City Heart Rhythm Institute (KCHRI) & Research Foundation, Overland Park Regional Medical Center (R.G.). FAU - Olshansky, Brian AU - Olshansky B AUID- ORCID: 0000-0002-6044-045X AD - University of Iowa Carver College of Medicine, Iowa City (B.O.). LA - eng GR - P20 GM121307/GM/NIGMS NIH HHS/United States GR - R01 HL145753/HL/NHLBI NIH HHS/United States GR - R01 HL149264/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Review DEP - 20211228 PL - United States TA - Circ Arrhythm Electrophysiol JT - Circulation. Arrhythmia and electrophysiology JID - 101474365 RN - 0 (Amphetamines) RN - 0 (Central Nervous System Stimulants) RN - I5Y540LHVR (Cocaine) SB - IM MH - Amphetamine-Related Disorders/*complications MH - Amphetamines/*adverse effects MH - Arrhythmias, Cardiac/*chemically induced/physiopathology/therapy MH - Calcium Signaling/drug effects MH - Cardiotoxicity MH - Central Nervous System Stimulants/*adverse effects MH - Cocaine/*adverse effects MH - Cocaine-Related Disorders/*complications MH - Heart Conduction System/*drug effects/physiopathology MH - Heart Rate/*drug effects MH - Humans MH - Prognosis MH - Risk Assessment MH - Risk Factors PMC - PMC8766923 MID - NIHMS1764760 OTO - NOTNLM OT - amphetamines OT - arrhythmias OT - cocaine OT - ecstasy OT - methamphetamine COIS- Disclosures: All authors in this study declare no conflicts of interest. EDAT- 2021/12/29 06:00 MHDA- 2022/03/01 06:00 PMCR- 2023/01/01 CRDT- 2021/12/28 05:31 PHST- 2021/12/29 06:00 [pubmed] PHST- 2022/03/01 06:00 [medline] PHST- 2021/12/28 05:31 [entrez] PHST- 2023/01/01 00:00 [pmc-release] AID - 10.1161/CIRCEP.121.010273 [doi] PST - ppublish SO - Circ Arrhythm Electrophysiol. 2022 Jan;15(1):e010273. doi: 10.1161/CIRCEP.121.010273. Epub 2021 Dec 28. PMID- 34957877 OWN - NLM STAT- MEDLINE DCOM- 20221205 LR - 20230111 IS - 2515-7949 (Electronic) IS - 1750-4589 (Linking) VI - 32 IP - 12 DP - 2022 Dec TI - The current state of the surgical care team in the United Kingdom: Shall we 'do a time out'? PG - 368-378 LID - 10.1177/17504589211059328 [doi] AB - The reduction of junior doctors' working hours over the last two decades paved the way to non-medical practitioners providing care traditionally discharged by surgeons and other medics. These registered practitioners play a vital role in the care of patients in surgery and work within multi-disciplinary teams comprising surgical care practitioners, advanced clinical practitioners in surgery, and physician associates, with significant experience in nursing or allied health care professional practice. Health Education England and the Royal Colleges of Surgeons have invested considerably in developing the relevant educational frameworks to support and quality assure the training of non-medical practitioners. Notwithstanding, to ascertain whether advanced and extended practice have been developed appropriately, a wide critical stance is needed. This article aims to begin to analyse the status quo of the extended surgical team and of the associated pitfalls and challenges, making conservative comparisons between the roles with the international scene. The objective is to help students, trainees and all involved in surgical care to adopt an informed and critical viewpoint about the extended surgical team in the United Kingdom, in the hope that this can lead to improvement and forward planning in workforce design for the benefit of patients and their communities. FAU - Krishnamoorthy, Bhuvaneswari AU - Krishnamoorthy B AD - University Manchester, Manchester, UK. FAU - Britton, Carolina Relvas AU - Britton CR AUID- ORCID: 0000-0002-4280-3894 AD - Cambridge University Hospitals Cambridge, UK. LA - eng PT - Journal Article DEP - 20211227 PL - England TA - J Perioper Pract JT - Journal of perioperative practice JID - 101271023 MH - Humans MH - *Medical Staff, Hospital MH - United Kingdom MH - *Patient Care Team MH - England OTO - NOTNLM OT - Cardiothoracic surgery OT - Clinical education and training OT - Continuing professional development OT - Historical aspects of perioperative care and surgery OT - Interprofessional education or practice OT - Operating theatre OT - Professional identity OT - Surgical care practitioner OT - Surgical first assistant EDAT- 2021/12/28 06:00 MHDA- 2022/12/06 06:00 CRDT- 2021/12/27 08:40 PHST- 2021/12/28 06:00 [pubmed] PHST- 2022/12/06 06:00 [medline] PHST- 2021/12/27 08:40 [entrez] AID - 10.1177/17504589211059328 [doi] PST - ppublish SO - J Perioper Pract. 2022 Dec;32(12):368-378. doi: 10.1177/17504589211059328. Epub 2021 Dec 27. PMID- 34953737 OWN - NLM STAT- MEDLINE DCOM- 20220719 LR - 20220811 IS - 1878-0938 (Electronic) IS - 1878-0938 (Linking) VI - 41 DP - 2022 Aug TI - Can Transcatheter Aortic Valve Implantation (TAVI) Be Performed at Institutions Without On-Site Cardiac Surgery Departments? PG - 159-165 LID - S1553-8389(21)00807-1 [pii] LID - 10.1016/j.carrev.2021.12.009 [doi] AB - Transcatheter aortic valve implantation [TAVI] represents a paradigm shift in therapeutic options for patients with severe aortic stenosis [AS]. In less than 20 years, TAVI has rapidly disseminated to include a significant proportion of AS patients. The number of AS patients needing TAVI is expected to further increase. Since there is a limited number of centers performing TAVI, wait times are expected to increase. This might have a critical impact of AS patient life as mortality rate of AS patients awaiting TAVI, is substantial, ranging from 2 to 10%. With time, as more patients were treated, improved experience, better imaging and devices, this technology became safer with more reliable results. Today most TAVI complications are related to vascular access [4-6%] and there is less need for emergency thoracic bail out [0.2-0.5%]. In this review, we summarize the prognosis while waiting, the outcomes of patients undergoing TAVI at institutions without on-site cardiac surgery departments and the data describing rates and outcomes of TAVI patients requiring treatment of intra-procedural life-threatening complications. Similar to coronary interventions in the past, TAVI should be considered also in centers without on-site cardiac surgery departments under certain conditions such as, experienced operators, heart team discussion, well established imaging modalities, skilled and qualified support personal, and adequate pre- and post-care facility. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - Kobo, Ofer AU - Kobo O AD - Hillel Yaffe Medical Center, Technion - Israel Institute of Technology, Haifa, Israel. FAU - Saada, Majdi AU - Saada M AD - Hillel Yaffe Medical Center, Technion - Israel Institute of Technology, Haifa, Israel. FAU - Roguin, Ariel AU - Roguin A AD - Hillel Yaffe Medical Center, Technion - Israel Institute of Technology, Haifa, Israel. Electronic address: aroguin@technion.ac.il. LA - eng PT - Journal Article PT - Review DEP - 20211216 PL - United States TA - Cardiovasc Revasc Med JT - Cardiovascular revascularization medicine : including molecular interventions JID - 101238551 SB - IM MH - Aortic Valve/diagnostic imaging/surgery MH - *Aortic Valve Stenosis/diagnostic imaging/etiology/surgery MH - Fluoroscopy MH - *Heart Valve Prosthesis MH - *Heart Valve Prosthesis Implantation MH - Humans MH - Prognosis MH - *Transcatheter Aortic Valve Replacement/adverse effects/methods MH - Treatment Outcome OTO - NOTNLM OT - Aortic stenosis OT - Health economics OT - Interventional cardiology OT - Safety OT - Surgery OT - Valve treatment EDAT- 2021/12/27 06:00 MHDA- 2022/07/20 06:00 CRDT- 2021/12/26 20:29 PHST- 2021/10/09 00:00 [received] PHST- 2021/11/20 00:00 [revised] PHST- 2021/12/09 00:00 [accepted] PHST- 2021/12/27 06:00 [pubmed] PHST- 2022/07/20 06:00 [medline] PHST- 2021/12/26 20:29 [entrez] AID - S1553-8389(21)00807-1 [pii] AID - 10.1016/j.carrev.2021.12.009 [doi] PST - ppublish SO - Cardiovasc Revasc Med. 2022 Aug;41:159-165. doi: 10.1016/j.carrev.2021.12.009. Epub 2021 Dec 16. PMID- 34952860 OWN - NLM STAT- MEDLINE DCOM- 20220729 LR - 20250728 IS - 1468-201X (Electronic) IS - 1355-6037 (Linking) VI - 108 IP - 16 DP - 2022 Jul 27 TI - Aortic stenosis in chronic kidney disease: challenges in diagnosis and treatment. PG - 1260-1266 LID - 10.1136/heartjnl-2021-319604 [doi] AB - Chronic kidney disease (CKD) is becoming increasingly common and is associated with development and rapid progression of aortic stenosis (AS). Patients with AS and CKD have higher mortality rates than those with AS of similar severity and normal kidney function. The diagnosis of severe AS in patients with CKD is often challenging due to alterations in haemodynamics and heart structure, and integration of data from multiple imaging modalities may be required. When indicated, the definitive treatment for severe AS is aortic valve replacement. Patients with CKD are candidates for bioprosthetic valve replacement (surgical or transcatheter aortic valve implantation) or mechanical valve replacement. However, for patients with CKD, lifetime management is complex, as patients with CKD have a higher competing risk of bioprosthetic structural valve deterioration, bleeding in the setting of systemic anticoagulation and mortality related to CKD itself. The involvement of a heart-kidney multidisciplinary team in the care of patients with CKD and severe AS is ideal to navigate the complexities of diagnosis and management decisions. CI - (c) Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Gupta, Jessica I AU - Gupta JI AD - Internal Medicine, Division of Cardiology, Ann Arbor VA Medical Center, Ann Arbor, Michigan, USA jparsh@med.umich.edu. AD - Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, Michigan, USA. FAU - Gualano, Sarah K AU - Gualano SK AD - Internal Medicine, Division of Cardiology, Ann Arbor VA Medical Center, Ann Arbor, Michigan, USA. AD - Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, Michigan, USA. FAU - Bhave, Nicole AU - Bhave N AUID- ORCID: 0000-0002-6241-5303 AD - Internal Medicine, Division of Cardiology, Ann Arbor VA Medical Center, Ann Arbor, Michigan, USA. AD - Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, Michigan, USA. LA - eng PT - Journal Article PT - Review DEP - 20220727 PL - England TA - Heart JT - Heart (British Cardiac Society) JID - 9602087 SB - IM MH - Aortic Valve/surgery MH - *Aortic Valve Stenosis/complications/diagnosis/surgery MH - *Heart Valve Prosthesis MH - *Heart Valve Prosthesis Implantation MH - Humans MH - *Renal Insufficiency, Chronic/complications/diagnosis/therapy MH - Risk Factors MH - *Transcatheter Aortic Valve Replacement/methods MH - Treatment Outcome OTO - NOTNLM OT - aortic valve stenosis OT - cardiac imaging techniques OT - computed tomography angiography OT - echocardiography OT - heart valve prosthesis COIS- Competing interests: None declared. EDAT- 2021/12/26 06:00 MHDA- 2022/07/30 06:00 CRDT- 2021/12/25 05:25 PHST- 2021/10/15 00:00 [received] PHST- 2021/11/22 00:00 [accepted] PHST- 2021/12/26 06:00 [pubmed] PHST- 2022/07/30 06:00 [medline] PHST- 2021/12/25 05:25 [entrez] AID - heartjnl-2021-319604 [pii] AID - 10.1136/heartjnl-2021-319604 [doi] PST - epublish SO - Heart. 2022 Jul 27;108(16):1260-1266. doi: 10.1136/heartjnl-2021-319604. PMID- 34950478 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20211225 IS - 2049-9361 (Print) IS - 2049-937X (Electronic) IS - 2049-9361 (Linking) VI - 8 DP - 2021 Jan-Dec TI - A step-by-step guide to implementing a multidisciplinary endocarditis team. PG - 20499361211065596 LID - 10.1177/20499361211065596 [doi] LID - 20499361211065596 AB - Over the last several years multiple studies, primarily from European centers have demonstrated the clinical and outcomes benefits of multidisciplinary endocarditis teams. Despite this literature, adoption of this approach to patient care has been slower in the United States. While there is literature outlining the optimal composition of an endocarditis team, there is little information to guide providers as they attempt to transform practice from a fragmented, disjointed process to an efficient, collaborative care model. In this review, the authors will outline the steps they took to create and implement a successful multidisciplinary endocarditis team at the University of Michigan. In conjunction with existing data, this piece can be used as a resource for clinicians seeking to improve the care of patients with endocarditis at their institutions. CI - (c) The Author(s), 2021. FAU - El-Dalati, Sami AU - El-Dalati S AUID- ORCID: 0000-0003-2603-2951 AD - Division of Infectious Diseases, Department of Internal Medicine, University of Kentucky, 740 South Limestone Street, Lexington, KY 40536, USA. FAU - Cronin, Daniel AU - Cronin D AD - Division of Hospital Medicine, Department of Internal Medicine, Michigan Medicine - University of Michigan, Ann Arbor, MI, USA. FAU - Riddell, James 4th AU - Riddell J 4th AD - Division of Infectious Diseases, Department of Internal Medicine, Michigan Medicine - University of Michigan, Ann Arbor, MI, USA. FAU - Shea, Michael AU - Shea M AD - Division of Cardiology, Department of Internal Medicine, Michigan Medicine - University of Michigan, Ann Arbor, MI, USA. FAU - Weinberg, Richard L AU - Weinberg RL AD - Division of Cardiology, Department of Internal Medicine, Northwestern University, Chicago, IL, USA. FAU - Stoneman, Emily AU - Stoneman E AD - Division of Infectious Diseases, Department of Internal Medicine, Michigan Medicine - University of Michigan, Ann Arbor, MI, USA. FAU - Patel, Twisha AU - Patel T AD - College of Pharmacy, Michigan Medicine - University of Michigan, Ann Arbor, MI, USA. FAU - Ressler, Kirra AU - Ressler K AD - Department of Cardiac Surgery, Michigan Medicine - University of Michigan, Ann Arbor, MI, USA. FAU - Deeb, George Michael AU - Deeb GM AD - Department of Cardiac Surgery, Michigan Medicine - University of Michigan, Ann Arbor, MI, USA. LA - eng PT - Journal Article PT - Review DEP - 20211216 PL - England TA - Ther Adv Infect Dis JT - Therapeutic advances in infectious disease JID - 101606715 PMC - PMC8689603 OTO - NOTNLM OT - endocarditis OT - multidisciplinary care OT - quality improvement OT - valve surgery COIS- Conflict of interest statement: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2021/12/25 06:00 MHDA- 2021/12/25 06:01 PMCR- 2021/12/16 CRDT- 2021/12/24 05:50 PHST- 2021/10/04 00:00 [received] PHST- 2021/11/20 00:00 [accepted] PHST- 2021/12/24 05:50 [entrez] PHST- 2021/12/25 06:00 [pubmed] PHST- 2021/12/25 06:01 [medline] PHST- 2021/12/16 00:00 [pmc-release] AID - 10.1177_20499361211065596 [pii] AID - 10.1177/20499361211065596 [doi] PST - epublish SO - Ther Adv Infect Dis. 2021 Dec 16;8:20499361211065596. doi: 10.1177/20499361211065596. eCollection 2021 Jan-Dec. PMID- 34950245 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240819 IS - 1758-3764 (Electronic) IS - 1758-3756 (Print) IS - 1758-3756 (Linking) VI - 16 DP - 2021 Feb TI - Coronary Artery Disease in Patients with Aortic Stenosis and Transcatheter Aortic Valve Implantation: Implications for Management. PG - e49 LID - 10.15420/ecr.2021.27 [doi] LID - e49 AB - Aortic valve stenosis (AS) is the most common valvular heart disease among elderly patients. Since the pathophysiology of degenerative AS shares common pathways with atherosclerotic disease, the severity of AS in the elderly population is often concurrent to the presence of coronary artery disease (CAD). Although surgical aortic valve replacement has been the standard treatment for severe AS, the high operative morbidity and mortality in complex and fragile patients was the trigger to develop less invasive techniques. Transcatheter aortic valve implantation (TAVI) has been posed as the standard of care for elderly patients with severe AS with various risk profiles, which has meant that the concomitant management of CAD has become a crucial issue in such patients. Given the lack of randomised controlled trials evaluating the management of CAD in TAVI patients, most of the recommendations are based on retrospective cohort studies so that the Heart Team approach - together with an assessment of multiple parameters including symptoms and clinical characteristics, invasive and non-invasive ischaemic burden and anatomy - are crucial for the proper management of these patients. This article provides a review of current knowledge about assessment and therapeutic approaches for CAD and severe AS in patients undergoing TAVI. CI - Copyright (c) 2021, Radcliffe Cardiology. FAU - de Azevedo Filho, Antonio Fb AU - de Azevedo Filho AF AD - Department of Valvular Heart Disease, Heart Institute (InCor), University of Sao Paulo Sao Paulo, Brazil. FAU - Accorsi, Tarso Ad AU - Accorsi TA AD - Department of Valvular Heart Disease, Heart Institute (InCor), University of Sao Paulo Sao Paulo, Brazil. AD - Samaritano Paulista Hospital Sao Paulo, Brazil. FAU - Ribeiro, Henrique B AU - Ribeiro HB AD - Samaritano Paulista Hospital Sao Paulo, Brazil. AD - Interventional Cardiology Department, Heart Institute (InCor), University of Sao Paulo Sao Paulo, Brazil. LA - eng PT - Journal Article PT - Review DEP - 20211207 PL - England TA - Eur Cardiol JT - European cardiology JID - 101574780 PMC - PMC8674631 OTO - NOTNLM OT - Coronary artery disease OT - percutaneous coronary intervention OT - transcatheter aortic valve implantation COIS- Disclosure: The authors have no conflicts of interest to declare. EDAT- 2021/12/25 06:00 MHDA- 2021/12/25 06:01 PMCR- 2021/12/07 CRDT- 2021/12/24 05:48 PHST- 2021/06/11 00:00 [received] PHST- 2021/08/16 00:00 [accepted] PHST- 2021/12/24 05:48 [entrez] PHST- 2021/12/25 06:00 [pubmed] PHST- 2021/12/25 06:01 [medline] PHST- 2021/12/07 00:00 [pmc-release] AID - 10.15420/ecr.2021.27 [doi] PST - epublish SO - Eur Cardiol. 2021 Dec 7;16:e49. doi: 10.15420/ecr.2021.27. eCollection 2021 Feb. PMID- 34950244 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20211225 IS - 1758-3764 (Electronic) IS - 1758-3756 (Print) IS - 1758-3756 (Linking) VI - 16 DP - 2021 Feb TI - Coronary Artery Disease in Chronic Kidney Disease: Need for a Heart-Kidney Team-Based Approach. PG - e48 LID - 10.15420/ecr.2021.30 [doi] LID - e48 AB - Chronic kidney disease and coronary artery disease are co-prevalent conditions with unique epidemiological and pathophysiological features, that culminate in high rates of major adverse cardiovascular outcomes, including all-cause mortality. This review outlines a summary of the literature, and nuances pertaining to non-invasive risk assessment of this population, medical management options for coronary heart disease and coronary revascularisation. A collaborative heart-kidney team-based approach is imperative for critical management decisions for this patient population, especially coronary revascularisation; this review outlines specific periprocedural considerations pertaining to coronary revascularisation, and provides a proposed algorithm for approaching revascularisation choices in patients with end-stage kidney disease based on available literature. CI - Copyright (c) 2021, Radcliffe Cardiology. FAU - Shroff, Gautam R AU - Shroff GR AD - Division of Cardiology, Department of Medicine, Hennepin Healthcare & University of Minnesota Medical School Minneapolis, MN, US. FAU - Carlson, Michelle D AU - Carlson MD AD - Division of Cardiology, Department of Medicine, Hennepin Healthcare & University of Minnesota Medical School Minneapolis, MN, US. FAU - Mathew, Roy O AU - Mathew RO AD - Division of Nephrology, Department of Medicine, Columbia VA Health Care System Columbia, SC, US. LA - eng PT - Journal Article PT - Review DEP - 20211207 PL - England TA - Eur Cardiol JT - European cardiology JID - 101574780 PMC - PMC8674634 OTO - NOTNLM OT - Chronic kidney disease OT - coronary artery bypass surgery OT - coronary artery disease OT - dialysis OT - end-stage kidney disease OT - non-invasive imaging OT - percutaneous coronary intervention COIS- Disclosure: The authors have no conflicts of interest to declare. EDAT- 2021/12/25 06:00 MHDA- 2021/12/25 06:01 PMCR- 2021/12/07 CRDT- 2021/12/24 05:48 PHST- 2021/06/26 00:00 [received] PHST- 2021/10/19 00:00 [accepted] PHST- 2021/12/24 05:48 [entrez] PHST- 2021/12/25 06:00 [pubmed] PHST- 2021/12/25 06:01 [medline] PHST- 2021/12/07 00:00 [pmc-release] AID - 10.15420/ecr.2021.30 [doi] PST - epublish SO - Eur Cardiol. 2021 Dec 7;16:e48. doi: 10.15420/ecr.2021.30. eCollection 2021 Feb. PMID- 34945173 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20211229 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 10 IP - 24 DP - 2021 Dec 15 TI - Pre-Procedural Right Ventricular Longitudinal Strain and Post-Procedural Tricuspid Regurgitation Predict Mortality in Patients Undergoing Transcatheter Aortic Valve Implantation (TAVI). LID - 10.3390/jcm10245877 [doi] LID - 5877 AB - BACKGROUND: Right ventricular (RV) dysfunction has been linked to worse outcomes in patients undergoing TAVI. Assessment of RV function is challenging due to its complex morphology. RV longitudinal strain (LS) assessed by speckle-tracking echocardiography (STE) is a novel measure that may overcome most of the limitations of conventional echocardiographic parameters of RV function. The aim of current study was to assess the prognostic value of RV LS in patients undergoing TAVI and to assess echocardiographic predictors of long-term mortality. METHODS AND RESULTS: A retrospective analysis of all consecutive patients who underwent TAVI at our hospital between 1 January 2015 and 1 June 2016. Indication for TAVI was approved by a local heart-team. Echocardiographic data at baseline and after TAVI were re-analyzed and RV LS was measured in all patients with adequate image quality. A total of 229 patients were included in our study (mean age 83.8 +/- 5 years, 62% women, mean EuroSCORE II 5.7 +/- 5%). All-cause mortality occurred in 17.3% over a mean follow-up of 929 +/- 373 days. In multivariate analysis, only baseline average RV free-wall LS (HR 1.05, 95% CI (1.01 to 1.10), p = 0.049) and more than mild tricuspid valve regurgitation (TR) after TAVI (HR 4.39, 95% CI (2.22 to 8.70), p < 0.001) independently increased the risk of all-cause mortality at long- term follow-up (2.5 years), while conventional echocardiographic parameters of RV function did not predict mortality. CONCLUSION: Pre-procedural RV LS and post-procedural tricuspid regurgitation significantly predicted long-term all-cause mortality in patients undergoing TAVI while conventional echocardiographic parameters of RV function failed in predicting long-term outcome. RV longitudinal strain by STE should be considered in the routine echocardiographic assessments of patients with severe AS. FAU - Omran, Hazem AU - Omran H AUID- ORCID: 0000-0001-7342-3686 AD - Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW, Ruhr-Universitat Bochum, 32545 Bad Oeynhausen, Germany. FAU - Polimeni, Alberto AU - Polimeni A AUID- ORCID: 0000-0002-9166-3031 AD - Division of Cardiology, Department of Surgical and Medical Sciences, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy. FAU - Brandt, Verena AU - Brandt V AD - Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW, Ruhr-Universitat Bochum, 32545 Bad Oeynhausen, Germany. FAU - Rudolph, Volker AU - Rudolph V AD - Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW, Ruhr-Universitat Bochum, 32545 Bad Oeynhausen, Germany. FAU - Rudolph, Tanja K AU - Rudolph TK AD - Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW, Ruhr-Universitat Bochum, 32545 Bad Oeynhausen, Germany. FAU - Bleiziffer, Sabine AU - Bleiziffer S AD - Clinic for Thoracic and Cardiovascular Surgery, Herz- und Diabeteszentrum NRW, Ruhr-Universitat Bochum, 32545 Bad Oeynhausen, Germany. FAU - Friedrichs, Kai P AU - Friedrichs KP AD - Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW, Ruhr-Universitat Bochum, 32545 Bad Oeynhausen, Germany. FAU - Faber, Lothar AU - Faber L AD - Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW, Ruhr-Universitat Bochum, 32545 Bad Oeynhausen, Germany. FAU - Dimitriadis, Zisis AU - Dimitriadis Z AD - Department of Cardiology, University Hospital Frankfurt, 60590 Frankfurt, Germany. LA - eng PT - Journal Article DEP - 20211215 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC8707506 OTO - NOTNLM OT - RV function OT - TAVI OT - aortic stenosis OT - speckle-tracking echocardiography OT - tricuspid regurgitation COIS- The authors declare no conflict of interest. EDAT- 2021/12/25 06:00 MHDA- 2021/12/25 06:01 PMCR- 2021/12/15 CRDT- 2021/12/24 01:07 PHST- 2021/11/25 00:00 [received] PHST- 2021/12/10 00:00 [revised] PHST- 2021/12/11 00:00 [accepted] PHST- 2021/12/24 01:07 [entrez] PHST- 2021/12/25 06:00 [pubmed] PHST- 2021/12/25 06:01 [medline] PHST- 2021/12/15 00:00 [pmc-release] AID - jcm10245877 [pii] AID - jcm-10-05877 [pii] AID - 10.3390/jcm10245877 [doi] PST - epublish SO - J Clin Med. 2021 Dec 15;10(24):5877. doi: 10.3390/jcm10245877. PMID- 34943396 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20211228 IS - 2227-9067 (Print) IS - 2227-9067 (Electronic) IS - 2227-9067 (Linking) VI - 8 IP - 12 DP - 2021 Dec 18 TI - Pediatric Cardio-Oncology Medicine: A New Approach in Cardiovascular Care. LID - 10.3390/children8121200 [doi] LID - 1200 AB - Survival for pediatric patients diagnosed with cancer has improved significantly. This achievement has been made possible due to new treatment modalities and the incorporation of a systematic multidisciplinary approach for supportive care. Understanding the distinctive cardiovascular characteristics of children undergoing cancer therapies has set the underpinnings to provide comprehensive care before, during, and after the management of cancer. Nonetheless, we acknowledge the challenge to understand the rapid expansion of oncology disciplines. The limited guidelines in pediatric cardio-oncology have motivated us to develop risk-stratification systems to institute surveillance and therapeutic support for this patient population. Here, we describe a collaborative approach to provide wide-ranging cardiovascular care to children and young adults with oncology diseases. Promoting collaboration in pediatric cardio-oncology medicine will ultimately provide excellent quality of care for future generations of patients. FAU - Martinez, Hugo R AU - Martinez HR AUID- ORCID: 0000-0002-3655-7930 AD - Division of Pediatric Cardiology, The Heart Institute at Le Bonheur Children's Hospital, University of Tennessee Health Science Center, Memphis, TN 38163, USA. FAU - Beasley, Gary S AU - Beasley GS AUID- ORCID: 0000-0001-6137-6114 AD - Division of Pediatric Cardiology, The Heart Institute at Le Bonheur Children's Hospital, University of Tennessee Health Science Center, Memphis, TN 38163, USA. FAU - Goldberg, Jason F AU - Goldberg JF AD - Division of Pediatric Cardiology, The Heart Institute at Le Bonheur Children's Hospital, University of Tennessee Health Science Center, Memphis, TN 38163, USA. FAU - Absi, Mohammed AU - Absi M AD - Division of Pediatric Cardiology, The Heart Institute at Le Bonheur Children's Hospital, University of Tennessee Health Science Center, Memphis, TN 38163, USA. FAU - Ryan, Kaitlin A AU - Ryan KA AD - Division of Pediatric Cardiology, The Heart Institute at Le Bonheur Children's Hospital, University of Tennessee Health Science Center, Memphis, TN 38163, USA. FAU - Guerrier, Karine AU - Guerrier K AD - Division of Pediatric Cardiology, The Heart Institute at Le Bonheur Children's Hospital, University of Tennessee Health Science Center, Memphis, TN 38163, USA. FAU - Joshi, Vijaya M AU - Joshi VM AD - Division of Pediatric Cardiology, The Heart Institute at Le Bonheur Children's Hospital, University of Tennessee Health Science Center, Memphis, TN 38163, USA. FAU - Johnson, Jason N AU - Johnson JN AUID- ORCID: 0000-0003-0712-1123 AD - Division of Pediatric Cardiology, The Heart Institute at Le Bonheur Children's Hospital, University of Tennessee Health Science Center, Memphis, TN 38163, USA. FAU - Morin, Cara E AU - Morin CE AUID- ORCID: 0000-0003-1953-4486 AD - Department of Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, TN 38105, USA. FAU - Hurley, Caitlin AU - Hurley C AD - Division of Critical Care Medicine, St. Jude Children's Research Hospital, Memphis, TN 38105, USA. AD - Department of Bone Marrow Transplantation & Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN 38105, USA. FAU - Morrison, Ronald Ray AU - Morrison RR AD - Division of Critical Care Medicine, St. Jude Children's Research Hospital, Memphis, TN 38105, USA. FAU - Rai, Parul AU - Rai P AD - Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA. FAU - Hankins, Jane S AU - Hankins JS AUID- ORCID: 0000-0003-4439-7321 AD - Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA. FAU - Bishop, Michael W AU - Bishop MW AD - Division of Solid Tumor, St. Jude Children's Research Hospital, Memphis, TN 38105, USA. FAU - Triplett, Brandon M AU - Triplett BM AD - Department of Bone Marrow Transplantation & Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN 38105, USA. FAU - Ehrhardt, Matthew J AU - Ehrhardt MJ AD - Division of Cancer Survivorship, Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA. AD - Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN 38105, USA. FAU - Pui, Ching-Hon AU - Pui CH AD - Division of Leukemia/Lymphoma, St. Jude Children's Research Hospital, Memphis, TN 38105, USA. FAU - Inaba, Hiroto AU - Inaba H AD - Division of Leukemia/Lymphoma, St. Jude Children's Research Hospital, Memphis, TN 38105, USA. FAU - Towbin, Jeffrey A AU - Towbin JA AD - Division of Pediatric Cardiology, The Heart Institute at Le Bonheur Children's Hospital, University of Tennessee Health Science Center, Memphis, TN 38163, USA. LA - eng GR - CA21765/National Cancer Institute (Cancer Center Support CORE Grant)/ GR - R079700270/St. Jude Pediatric Research Recruitment Support Fund/ PT - Journal Article PT - Review DEP - 20211218 PL - Switzerland TA - Children (Basel) JT - Children (Basel, Switzerland) JID - 101648936 PMC - PMC8699848 OTO - NOTNLM OT - cardiovascular healthcare OT - early detection OT - individualization of therapies OT - oncology therapies OT - pediatric cardiology-oncology OT - predictive healthcare models COIS- The authors declare no conflict of interest. EDAT- 2021/12/25 06:00 MHDA- 2021/12/25 06:01 PMCR- 2021/12/18 CRDT- 2021/12/24 01:02 PHST- 2021/10/22 00:00 [received] PHST- 2021/12/08 00:00 [revised] PHST- 2021/12/10 00:00 [accepted] PHST- 2021/12/24 01:02 [entrez] PHST- 2021/12/25 06:00 [pubmed] PHST- 2021/12/25 06:01 [medline] PHST- 2021/12/18 00:00 [pmc-release] AID - children8121200 [pii] AID - children-08-01200 [pii] AID - 10.3390/children8121200 [doi] PST - epublish SO - Children (Basel). 2021 Dec 18;8(12):1200. doi: 10.3390/children8121200. PMID- 34937705 OWN - NLM STAT- MEDLINE DCOM- 20211224 LR - 20221115 IS - 1600-0617 (Electronic) IS - 0905-9180 (Print) IS - 0905-9180 (Linking) VI - 30 IP - 162 DP - 2021 Dec 31 TI - Perioperative approach to precapillary pulmonary hypertension in non-cardiac non-obstetric surgery. LID - 10.1183/16000617.0166-2021 [doi] LID - 210166 AB - Pulmonary hypertension (PH) confers a significant challenge in perioperative care. It is associated with substantial morbidity and mortality. A considerable amount of information about management of patients with PH has emerged over the past decade. However, there is still a paucity of information to guide perioperative evaluation and management of these patients. Yet, a satisfactory outcome is feasible by focusing on elaborate disease-adapted anaesthetic management of this complex disease with a multidisciplinary approach. The cornerstone of the peri-anaesthetic management of patients with PH is preservation of right ventricular (RV) function with attention on maintaining RV preload, contractility and limiting increase in RV afterload at each stage of the patient's perioperative care. Pre-anaesthetic evaluation, choice of anaesthetic agents, proper fluid management, appropriate ventilation, correction of hypoxia, hypercarbia, acid-base balance and pain control are paramount in this regard. Essentially, the perioperative management of PH patients is intricate and multifaceted. Unfortunately, a comprehensive evidence-based guideline is lacking to navigate us through this complex process. We conducted a literature review on patients with PH with a focus on the perioperative evaluation and suggest management algorithms for these patients during non-cardiac, non-obstetric surgery. CI - Copyright (c)The authors 2021. FAU - Bandyopadhyay, Debabrata AU - Bandyopadhyay D AUID- ORCID: 0000-0002-5323-9061 AD - Center for Advanced Lung Disease and Lung Transplant, University of South Florida - Tampa General Hospital, Tampa, FL, USA. FAU - Lai, Christopher AU - Lai C AUID- ORCID: 0000-0001-5088-3364 AD - Faculte de Medecine, Universite Paris-Saclay, Le Kremlin Bicetre, France. AD - Assistance Publique Hopitaux de Paris, Service de medecine intensive - reanimation, Hopital Bicetre, DMU CORREVE, FHU SEPSIS, Groupe de recherche clinique CARMAS, Le Kremlin-Bicetre, France. AD - Inserm UMR_S 999, Hopital Marie Lannelongue, Le Plessis Robinson, France. FAU - Pulido, Juan N AU - Pulido JN AD - Dept of Anesthesiology and Critical Care Medicine, Swedish Medical Center, Seattle, WA, USA and US Anesthesia Partners - Washington, Seattle, WA, USA. FAU - Restrepo-Jaramillo, Ricardo AU - Restrepo-Jaramillo R AD - Center for Advanced Lung Disease and Lung Transplant, University of South Florida - Tampa General Hospital, Tampa, FL, USA. FAU - Tonelli, Adriano R AU - Tonelli AR AD - Dept of Pulmonary, Allergy and Critical Care Medicine, Respiratory Institute, Cleveland Clinic, Cleveland, OH, USA. AD - Pathobiology Division, Lerner Research Institute, Cleveland Clinic, OH, USA. FAU - Humbert, Marc AU - Humbert M AUID- ORCID: 0000-0003-0703-2892 AD - Assistance Publique Hopitaux de Paris, Service de medecine intensive - reanimation, Hopital Bicetre, DMU CORREVE, FHU SEPSIS, Groupe de recherche clinique CARMAS, Le Kremlin-Bicetre, France marc.humbert@aphp.fr. AD - Inserm UMR_S 999, Hopital Marie Lannelongue, Le Plessis Robinson, France. AD - Assistance Publique Hopitaux de Paris, Service de Pneumologie et Soins Intensifs Respiratoires, Centre de Reference de l'Hypertension Pulmonaire, Hopital Bicetre, Le Kremlin-Bicetre, France. LA - eng PT - Journal Article PT - Review DEP - 20211222 PL - England TA - Eur Respir Rev JT - European respiratory review : an official journal of the European Respiratory Society JID - 9111391 SB - IM CIN - Eur Respir Rev. 2021 Dec 22;30(162):210258. doi: 10.1183/16000617.0258-2021. PMID: 34937707 MH - Humans MH - *Hypertension, Pulmonary/diagnosis/therapy MH - Hypoxia MH - Perioperative Care MH - *Ventricular Dysfunction, Right MH - Ventricular Function, Right PMC - PMC9489200 COIS- Conflict of interest: D. Bandyopadhyay received fees for a speaker bureau, advisory committee and research grants from Boehringer Ingelheim; and fees for a speaker bureau, advisory committee and research grants from United Therapeutics corporation. Conflict of interest: C. Lai has nothing to disclose. Conflict of interest: J.N. Pulido has nothing to disclose. Conflict of interest: R. Restrepo-Jaramillo received fees for a speaker bureau, advisory committee and research grants from Bayer; fees for a speaker bureau, advisory committee and research grants from Janssen Actelion; and fees for a speaker bureau, advisory committee and research grants from United Therapeutics corporation. Conflict of interest: A.R. Tonelli has nothing to disclose. Conflict of interest: M. Humbert reports grants, personal fees and non-financial support from GlaxoSmithKline; personal fees from AstraZeneca, Novartis, Roche, Sanofi, Merck and Teva; and grants and personal fees from Acceleron, Actelion and Bayer, outside the submitted work. EDAT- 2021/12/24 06:00 MHDA- 2021/12/25 06:00 PMCR- 2021/12/22 CRDT- 2021/12/23 05:33 PHST- 2021/07/11 00:00 [received] PHST- 2021/08/12 00:00 [accepted] PHST- 2021/12/23 05:33 [entrez] PHST- 2021/12/24 06:00 [pubmed] PHST- 2021/12/25 06:00 [medline] PHST- 2021/12/22 00:00 [pmc-release] AID - 30/162/210166 [pii] AID - ERR-0166-2021 [pii] AID - 10.1183/16000617.0166-2021 [doi] PST - epublish SO - Eur Respir Rev. 2021 Dec 22;30(162):210166. doi: 10.1183/16000617.0166-2021. Print 2021 Dec 31. PMID- 34937660 OWN - NLM STAT- MEDLINE DCOM- 20230814 LR - 20230814 IS - 1097-685X (Electronic) IS - 0022-5223 (Linking) VI - 166 IP - 3 DP - 2023 Sep TI - Atrial fibrillation in severe aortic stenosis: Prognostic value and results of aortic valve replacement. PG - 771-779 LID - S0022-5223(21)01680-9 [pii] LID - 10.1016/j.jtcvs.2021.11.055 [doi] AB - OBJECTIVES: Although atrial fibrillation (AF) is common, its impact on long-term mortality has not been reliably determined in patients with aortic stenosis (AS). We aimed to assess whether AF is associated with survival in patients with severe AS and to determine the impact of AF on the results of aortic valve replacement (AVR). METHODS: The study included 1838 consecutive patients with severe AS (77 +/- 11 years, male 47%). Upon AS diagnosis, patients were screened for AF using a 12-lead electrocardiogram. The treatment strategy (conservative management or AVR) was selected by the heart team in accordance with current guidelines. The effect of AVR on survival was analyzed as a time-dependent covariate using the entire follow-up period. RESULTS: AF, diagnosed in 593 (32%) patients was associated with poor survival at 5 years (55 +/- 2% vs 74 +/- 1% for patients in sinus rhythm, P < .001), even after adjustment for established outcome predictors (hazard ratio [HR], 1.56; 95% confidence interval [CI], 1.33-1.84; P < .001). In patients with AF, AVR was associated with lower mortality (HR, 0.16; 95% CI, 0.12-0.22; P < .001) even in those with no or minimal symptoms (HR, 0.12; 95% CI, 0.08-0.20; P < .001). However, among patients who underwent AVR, those in AF had an excess mortality (HR, 1.59; 95% CI, 1.22-2.08; P < .001). CONCLUSIONS: In severe AS, AF is a strong predictor of mortality even in asymptomatic or minimally symptomatic patients. After AVR, AF remains associated with poorer survival than sinus rhythm. In patients in AF, AVR is associated with lower mortality compared with conservative treatment. Further studies are needed to confirm the benefits of AVR in asymptomatic patients in AF with severe AS. CI - Copyright (c) 2021 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved. FAU - Kubala, Maciej AU - Kubala M AD - Department of Cardiology, Amiens University Hospital, Amiens, France; UR UPJV 7517, Jules Verne University of Picardie, Amiens, France. FAU - Bohbot, Yohann AU - Bohbot Y AD - Department of Cardiology, Amiens University Hospital, Amiens, France; UR UPJV 7517, Jules Verne University of Picardie, Amiens, France. FAU - Rusinaru, Dan AU - Rusinaru D AD - Department of Cardiology, Amiens University Hospital, Amiens, France; UR UPJV 7517, Jules Verne University of Picardie, Amiens, France. FAU - Marechaux, Sylvestre AU - Marechaux S AD - UR UPJV 7517, Jules Verne University of Picardie, Amiens, France; Groupement des Hopitaux de l'Institut Catholique de Lille/Faculte Libre de Medecine, Universite Lille Nord de France, Lille, France. FAU - Diouf, Momar AU - Diouf M AD - Department of Clinical Research, Amiens University Hospital, Amiens, France. FAU - Tribouilloy, Christophe AU - Tribouilloy C AD - Department of Cardiology, Amiens University Hospital, Amiens, France; UR UPJV 7517, Jules Verne University of Picardie, Amiens, France. Electronic address: tribouilloy.christophe@chu-amiens.fr. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20211129 PL - United States TA - J Thorac Cardiovasc Surg JT - The Journal of thoracic and cardiovascular surgery JID - 0376343 SB - IM CIN - J Thorac Cardiovasc Surg. 2023 Sep;166(3):780-781. doi: 10.1016/j.jtcvs.2021.12.017. PMID: 34952702 MH - Humans MH - Male MH - Aortic Valve/diagnostic imaging/surgery MH - *Atrial Fibrillation/complications/diagnosis MH - Prognosis MH - *Heart Valve Prosthesis Implantation/methods MH - *Aortic Valve Stenosis/complications/surgery/diagnosis MH - Treatment Outcome MH - Risk Factors OTO - NOTNLM OT - aortic stenosis OT - aortic valve replacement OT - atrial fibrillation OT - prognosis EDAT- 2021/12/24 06:00 MHDA- 2023/08/14 06:42 CRDT- 2021/12/23 05:30 PHST- 2021/05/18 00:00 [received] PHST- 2021/11/05 00:00 [revised] PHST- 2021/11/15 00:00 [accepted] PHST- 2023/08/14 06:42 [medline] PHST- 2021/12/24 06:00 [pubmed] PHST- 2021/12/23 05:30 [entrez] AID - S0022-5223(21)01680-9 [pii] AID - 10.1016/j.jtcvs.2021.11.055 [doi] PST - ppublish SO - J Thorac Cardiovasc Surg. 2023 Sep;166(3):771-779. doi: 10.1016/j.jtcvs.2021.11.055. Epub 2021 Nov 29. PMID- 34937657 OWN - NLM STAT- MEDLINE DCOM- 20220415 LR - 20220415 IS - 1879-1913 (Electronic) IS - 0002-9149 (Linking) VI - 166 DP - 2022 Mar 1 TI - In-Hospital Characteristics and 30-Day Readmissions for Acute Myocardial Infarction and Major Bleeding in Patients With Active Cancer. PG - 25-37 LID - S0002-9149(21)01138-3 [pii] LID - 10.1016/j.amjcard.2021.11.015 [doi] AB - There are limited data on readmission with ischemic and major bleeding events in patients with acute myocardial infarction (AMI) with active cancer. The purpose of our study was to evaluate in-hospital characteristics and 30-day readmission rates for recurrent AMI and major bleeding by cancer type in patients with AMI and active cancer. From 2016 through 2018, patients in the Nationwide Readmission Database admitted with AMI and underlying active colon, lung, breast, prostate, and hematological cancers were included. Thirty-day readmission for recurrent AMI and major bleeding were reported. Of 1,524,677 index hospitalizations for AMI, 35,790 patients (2.2%) had cancer (0.9% hematological; 0.5% lung; 0.4% prostate; 0.2% breast; and 0.1% colon). Compared with patients without cancer, patients with cancer were about 6 to 10 years older and had a higher proportion of atrial fibrillation, valvular heart disease, previous stroke, and a greater co-morbidity burden. Of all cancer types, only active breast cancer (adjusted odds ratios 1.82, 95% CI 1.11 to 2.98) was found to be significantly associated with elevated odds of readmission for major bleeding; no such association was observed for recurrent AMI. In conclusion, AMI in patients with breast cancer is associated with significantly greater odds of readmission for major bleeding within 30 days after discharge. Management of patients with concomitant AMI and cancer is challenging but should be based on a multidisciplinary approach and estimation of an individual patient's risk of major coronary thrombotic and bleeding events. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - Lahan, Shubham AU - Lahan S AD - Department of Cardiology, Houston Methodist Hospital, Houston, TX, United States. FAU - Bharadwaj, Aditya AU - Bharadwaj A AD - Division of Cardiology, Department of Medicine, Loma Linda University Health, Loma Linda, California. FAU - Cheng, Richard AU - Cheng R AD - Division of Cardiology, University of Washington, Seattle. FAU - Parwani, Purvi AU - Parwani P AD - Division of Cardiology, Department of Medicine, Loma Linda University Health, Loma Linda, California. FAU - Miller, Robert AU - Miller R AD - Department of Cardiac Sciences, University of Calgary, Calgary, Alberta, Canada. FAU - Cheung, Winson AU - Cheung W AD - Tom Baker Cancer Center, University of Calgary, Calgary, Alberta, Canada. FAU - Bianco, Christopher AU - Bianco C AD - Department of Cardiology, West Virginia University School of Medicine, West Virginia. FAU - Kheiri, Babikir AU - Kheiri B AD - Knight Cardiovascular Institute, Oregon Health and Science University, Portland, Oregon. FAU - Osman, Mohammed AU - Osman M AD - Knight Cardiovascular Institute, Oregon Health and Science University, Portland, Oregon. FAU - Mohamed, Mohamed AU - Mohamed M AD - Keele Cardiovascular Research Group, Keele University, Stoke-on-Trent, United Kingdom; Department of Cardiology, Royal Stoke University Hospital, Stoke-on-Trent, United Kingdom. FAU - Mamas, Mamas AU - Mamas M AD - Keele Cardiovascular Research Group, Keele University, Stoke-on-Trent, United Kingdom; Department of Cardiology, Royal Stoke University Hospital, Stoke-on-Trent, United Kingdom. Electronic address: mamasmamas1@yahoo.co.uk. LA - eng PT - Journal Article DEP - 20211220 PL - United States TA - Am J Cardiol JT - The American journal of cardiology JID - 0207277 SB - IM MH - *Breast Neoplasms/complications/epidemiology MH - Hemorrhage/complications/epidemiology MH - Hospitals MH - Humans MH - Male MH - *Myocardial Infarction/complications/epidemiology/therapy MH - Patient Readmission COIS- Disclosures The authors have no conflicts of interest to declare. EDAT- 2021/12/24 06:00 MHDA- 2022/04/16 06:00 CRDT- 2021/12/23 05:30 PHST- 2021/09/20 00:00 [received] PHST- 2021/11/14 00:00 [revised] PHST- 2021/11/16 00:00 [accepted] PHST- 2021/12/24 06:00 [pubmed] PHST- 2022/04/16 06:00 [medline] PHST- 2021/12/23 05:30 [entrez] AID - S0002-9149(21)01138-3 [pii] AID - 10.1016/j.amjcard.2021.11.015 [doi] PST - ppublish SO - Am J Cardiol. 2022 Mar 1;166:25-37. doi: 10.1016/j.amjcard.2021.11.015. Epub 2021 Dec 20. PMID- 34932825 OWN - NLM STAT- MEDLINE DCOM- 20220415 LR - 20220415 IS - 1440-1584 (Electronic) IS - 1038-5282 (Linking) VI - 30 IP - 2 DP - 2022 Apr TI - Importance of cardiac rehabilitation in rural and remote areas of Australia. PG - 149-163 LID - 10.1111/ajr.12818 [doi] AB - OBJECTIVE: To assess implementation of in-patient cardiac rehabilitation (Phase-1-cardiac rehabilitation), impact on people in rural and remote areas of Australia and potential methods for addressing identified weaknesses. DESIGN: Exploratory case study methodology using qualitative and quantitative methods. Qualitative data collection via semi-structured interviews, using thematic analysis, augmented by quantitative data collection via a medical record audit. SETTING: Four regional hospitals (2 Queensland Health and 2 private) providing tertiary health care. PARTICIPANTS: (a) Hospital in-patients with heart disease >/=18 years. (b) Staff responsible for their care. OUTCOME MEASURES: Implementation of Phase-1-cardiac rehabilitation in tertiary hosptials in North Queensland and the impact on in-patients discharge planning and post discharge care. Recommentations and implications for practice are proposed to address deficits. RESULTS: Phase-1-cardiac rehabilitation implementation rates, in-patient understanding and multidisciplinary team involvement were low. The highest rates of Phase-1-cardiac rehabilitation were for in-patients with a length of stay three days or more in cardiac units with cardiac educators. Rates were lower in cardiac units with no cardiac educators, and lowest for in-patients in all areas of all hospitals with length of stay of two days or less days. Low Phase-1-cardiac rehabilitation implementation rates resulted in poor in-patient understanding about their disease, treatment and post-discharge care. Further, medical discharge summaries rarely mentioned cardiac rehabilitation/secondary prevention or risk factor management resulting in a lack of information for health care providers on cardiac rehabilitation and holistic health care. CONCLUSION: Implementation of Phase-1-cardiac rehabilitation in regional hospitals in this study fell short of recommended best practice, resulting in patients' poor preparation for discharge, and insufficient information on holistic care for health care providers in rural and remote areas. These factors potentially impact on holistic care for people returning home following treatment for heart disease. CI - (c) 2021 National Rural Health Alliance Ltd. FAU - Field, Patricia AU - Field P AUID- ORCID: 0000-0001-8143-6081 AD - College of Public Health, Medicine and Veterinary Sciences, James Cook University, Townsville, QLD, Australia. FAU - Franklin, Richard C AU - Franklin RC AD - College of Public Health, Medicine and Veterinary Sciences, James Cook University, Townsville, QLD, Australia. FAU - Barker, Ruth AU - Barker R AUID- ORCID: 0000-0002-2546-2581 AD - College of Healthcare Sciences, James Cook University, Cairns, QLD, Australia. FAU - Ring, Ian AU - Ring I AD - Division of Tropical Health & Medicine, James Cook University, Townsville, QLD, Australia. FAU - Leggat, Peter AU - Leggat P AD - College of Public Health, Medicine and Veterinary Sciences, James Cook University, Townsville, QLD, Australia. AD - Faculty of Health Sciences, Flinders University, Adelaide, QLD, Australia. FAU - Canuto, Karla AU - Canuto K AD - College of Public Health, Medicine and Veterinary Sciences, James Cook University, Townsville, QLD, Australia. AD - South Australian Health and Medical Research Institute, Wardliparingga Aboriginal Health Equity, Adelaide, SA, Australia. LA - eng GR - JCU-QLD- 837551 - 2019/Far North Queensland Hospital Foundation/ PT - Journal Article DEP - 20211221 PL - Australia TA - Aust J Rural Health JT - The Australian journal of rural health JID - 9305903 MH - Aftercare MH - Australia MH - *Cardiac Rehabilitation MH - *Heart Diseases MH - Humans MH - Patient Discharge MH - *Rural Health Services OTO - NOTNLM OT - cardiac rehabilitation OT - health systems OT - rural and remote OT - secondary prevention EDAT- 2021/12/22 06:00 MHDA- 2022/04/16 06:00 CRDT- 2021/12/21 17:28 PHST- 2021/06/15 00:00 [revised] PHST- 2020/12/01 00:00 [received] PHST- 2021/09/22 00:00 [accepted] PHST- 2021/12/22 06:00 [pubmed] PHST- 2022/04/16 06:00 [medline] PHST- 2021/12/21 17:28 [entrez] AID - 10.1111/ajr.12818 [doi] PST - ppublish SO - Aust J Rural Health. 2022 Apr;30(2):149-163. doi: 10.1111/ajr.12818. Epub 2021 Dec 21. PMID- 34930958 OWN - NLM STAT- MEDLINE DCOM- 20220223 LR - 20220223 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 11 IP - 1 DP - 2021 Dec 20 TI - Surgical treatment of valve endocarditis in high-risk patients and predictors of long-term outcomes. PG - 24223 LID - 10.1038/s41598-021-03602-3 [doi] LID - 24223 AB - Infective endocarditis represents a surgical challenge associated with perioperative mortality. The aim of this study is to evaluate the predictors of operative mortality and long-term outcomes in high-risk patients. We retrospectively analyzed 123 patients operated on for infective endocarditis from January 2011 to December 2020. Logistic regression model was used to identify prognostic factors of in-hospital mortality. Long term follow-up was made to asses late prognosis. Preoperative renal failure, an elevation EuroSCORE II and prior aortic valve re-replacement were found to be preoperative risk factors significantly associated with mortality. In-hospital mortality was 27% in patients who had previously undergone aortic valve replacement (n = 4 out of 15 operated, p = 0.01). Patients who were operated on during the active phase of infective endocarditis showed a higher mortality rate than those operated on after the acute phase (16% vs. 0%; p = 0.02). The type of prosthesis used (biological or mechanical) was not associated with mortality, whereas cross-clamp time significantly correlated with mortality (mean cross-clamp time 135 +/- 65 min in dead patients vs. 76 +/- 32 min in surviving patients; p = 0.0005). Mean follow up was 57.94 +/- 30.9 months. Twelve patients died (11.65%). Among the twelve mortalities, five were adjudicated to cardiac causes and seven were non-cardiac (two cancers, one traumatic accident, one cerebral hemorrhage, two bronchopneumonia, one peritonitis). Overall survival probability (freedom from death, all causes) at 3, 5, 7 and 8 years was 98.9% (95% CI 97-100%), 96% (95% CI 92-100%), 85.9% (95% CI 76-97%), and 74% (95% CI 60-91%) respectively. Our study demonstrates that an early surgical approach may represent a valuable treatment option for high-risk patients with infective endocarditis, also in case of prosthetic valve endocarditis. Although several risk factors are associated with higher mortality, no patient subset is inoperable. These findings can be helpful to inform decision-making in heart team discussion. CI - (c) 2021. The Author(s). FAU - Nasso, Giuseppe AU - Nasso G AD - Department of Cardiac Surgery, Anthea Hospital, GVM Care and Research, Via Camillo Rosalba, 35/38, Bari, Italy. FAU - Santarpino, Giuseppe AU - Santarpino G AD - Department of Cardiac Surgery, Anthea Hospital, GVM Care and Research, Via Camillo Rosalba, 35/38, Bari, Italy. AD - Department of Cardiac Surgery, Paracelsus Medical University, Nuremberg, Germany. AD - Department of Clinical and Experimental Medicine, Magna Graecia University, Catanzaro, Italy. FAU - Moscarelli, Marco AU - Moscarelli M AD - Department of Cardiac Surgery, Anthea Hospital, GVM Care and Research, Via Camillo Rosalba, 35/38, Bari, Italy. FAU - Condello, Ignazio AU - Condello I AD - Department of Cardiac Surgery, Anthea Hospital, GVM Care and Research, Via Camillo Rosalba, 35/38, Bari, Italy. ignicondello@hotmail.it. FAU - Dell'Aquila, Angelo Maria AU - Dell'Aquila AM AD - Department of Cardiac Surgery, University of Munster, Munster, Germany. FAU - Peivandi, Armin Darius AU - Peivandi AD AD - Department of Cardiac Surgery, University of Munster, Munster, Germany. FAU - Gaudino, Mario AU - Gaudino M AD - Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, NY, USA. FAU - Fiore, Flavio AU - Fiore F AD - Department of Cardiac Surgery, Anthea Hospital, GVM Care and Research, Via Camillo Rosalba, 35/38, Bari, Italy. FAU - Mastroroberto, Pasquale AU - Mastroroberto P AD - Department of Clinical and Experimental Medicine, Magna Graecia University, Catanzaro, Italy. FAU - Di Bari, Nicola AU - Di Bari N AD - Department of Cardiac Surgery, Anthea Hospital, GVM Care and Research, Via Camillo Rosalba, 35/38, Bari, Italy. FAU - Speziale, Giuseppe AU - Speziale G AD - Department of Cardiac Surgery, Anthea Hospital, GVM Care and Research, Via Camillo Rosalba, 35/38, Bari, Italy. LA - eng PT - Journal Article DEP - 20211220 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 SB - IM MH - Aged MH - Aortic Valve/*surgery MH - Echocardiography, Transesophageal MH - Endocarditis/*mortality/*surgery MH - Female MH - Follow-Up Studies MH - *Heart Valve Prosthesis MH - Humans MH - Male MH - Middle Aged MH - Mitral Valve/surgery MH - Prognosis MH - Prosthesis-Related Infections/*mortality/*surgery MH - Retrospective Studies MH - Risk MH - Risk Factors MH - Treatment Outcome PMC - PMC8688441 COIS- The authors declare no competing interests. EDAT- 2021/12/22 06:00 MHDA- 2022/02/24 06:00 PMCR- 2021/12/20 CRDT- 2021/12/21 06:21 PHST- 2021/05/11 00:00 [received] PHST- 2021/12/07 00:00 [accepted] PHST- 2021/12/21 06:21 [entrez] PHST- 2021/12/22 06:00 [pubmed] PHST- 2022/02/24 06:00 [medline] PHST- 2021/12/20 00:00 [pmc-release] AID - 10.1038/s41598-021-03602-3 [pii] AID - 3602 [pii] AID - 10.1038/s41598-021-03602-3 [doi] PST - epublish SO - Sci Rep. 2021 Dec 20;11(1):24223. doi: 10.1038/s41598-021-03602-3. PMID- 34928457 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220107 IS - 2191-219X (Print) IS - 2191-219X (Electronic) IS - 2191-219X (Linking) VI - 11 IP - 1 DP - 2021 Dec 20 TI - The usefulness of repeated CMR and FDG PET/CT in the diagnosis of patients with initial possible cardiac sarcoidosis. PG - 129 LID - 10.1186/s13550-021-00870-y [doi] LID - 129 AB - BACKGROUND: Cardiac sarcoidosis (CS) diagnosis is usually based on advanced imaging techniques and multidisciplinary evaluation. Diagnosis is classified as definite, probable, possible or unlikely. If diagnostic confidence remains uncertain, cardiac imaging can be repeated. The objective is to evaluate the usefulness of repeated cardiac magnetic resonance imaging (CMR) and fluorodeoxyglucose positron emission tomography (FDG PET/CT) for CS diagnosis in patients with an initial "possible" CS diagnosis. METHODS: We performed a retrospective cohort study in 35 patients diagnosed with possible CS by our multidisciplinary team (MDT), who received repeated CMR and FDG PET/CT within 12 months after diagnosis. Imaging modalities were scored on abnormalities suggestive for CS and classified as CMR+/PET+, CMR+/PET-, CMR-/PET+ and CMR-/PET-. Primary endpoint was final MDT diagnosis of CS. RESULTS: After re-evaluation, nine patients (25.7%) were reclassified as probable CS and 16 patients (45.7%) as unlikely CS. Two patients started immunosuppressive treatment after re-evaluation. At baseline, eleven patients (31.4%) showed late gadolinium enhancement (LGE) on CMR (CMR+) and 26 (74.3%) patients showed myocardial FDG-uptake (PET+). At re-evaluation, nine patients (25.7%) showed LGE (CMR+), while 16 patients (45.7%) showed myocardial FDG-uptake (PET+). When considering both imaging modalities together, 82.6% of patients with CMR-/PET+ at baseline were reclassified as possible or unlikely CS, while 36.4% of patients with CMR+ at baseline were reclassified as probable CS. Three patients with initial CMR-/PET+ showed LGE at re-evaluation. CONCLUSION: Repeated CMR and FDG PET/CT may be useful in establishing or rejecting CS diagnosis, when initial diagnosis is uncertain. However, clinical relevance has to be further determined. CI - (c) 2021. The Author(s). FAU - Mathijssen, H AU - Mathijssen H AD - Department of Cardiology, St. Antonius Hospital Nieuwegein, Koekoekslaan 1, 3435CM, Nieuwegein, Utrecht, The Netherlands. h.mathijssen@antoniusziekenhuis.nl. FAU - Tjoeng, T W H AU - Tjoeng TWH AD - Department of Cardiology, St. Antonius Hospital Nieuwegein, Koekoekslaan 1, 3435CM, Nieuwegein, Utrecht, The Netherlands. FAU - Keijsers, R G M AU - Keijsers RGM AD - Department of Nuclear Medicine, St. Antonius Hospital Nieuwegein, Nieuwegein, Utrecht, The Netherlands. FAU - Bakker, A L M AU - Bakker ALM AD - Department of Cardiology, St. Antonius Hospital Nieuwegein, Koekoekslaan 1, 3435CM, Nieuwegein, Utrecht, The Netherlands. FAU - Akdim, F AU - Akdim F AD - Department of Cardiology, St. Antonius Hospital Nieuwegein, Koekoekslaan 1, 3435CM, Nieuwegein, Utrecht, The Netherlands. FAU - van Es, H W AU - van Es HW AD - Department of Radiology, St. Antonius Hospital Nieuwegein, Nieuwegein, Utrecht, The Netherlands. FAU - van Beek, F T AU - van Beek FT AD - Department of Pulmonology, St. Antonius Hospital Nieuwegein, Nieuwegein, Utrecht, The Netherlands. FAU - Veltkamp, M V AU - Veltkamp MV AD - Department of Pulmonology, St. Antonius Hospital Nieuwegein, Nieuwegein, Utrecht, The Netherlands. AD - Department of Pulmonology, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands. FAU - Grutters, J C AU - Grutters JC AD - Department of Pulmonology, St. Antonius Hospital Nieuwegein, Nieuwegein, Utrecht, The Netherlands. AD - Department of Pulmonology, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands. FAU - Post, M C AU - Post MC AD - Department of Cardiology, St. Antonius Hospital Nieuwegein, Koekoekslaan 1, 3435CM, Nieuwegein, Utrecht, The Netherlands. AD - Department of Cardiology, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands. LA - eng PT - Journal Article DEP - 20211220 PL - Germany TA - EJNMMI Res JT - EJNMMI research JID - 101560946 PMC - PMC8688603 OTO - NOTNLM OT - Cardiac magnetic resonance imaging OT - Cardiac sarcoidosis OT - Diagnosis OT - Positron emission tomography COIS- The authors declare that they have no competing interests. EDAT- 2021/12/21 06:00 MHDA- 2021/12/21 06:01 PMCR- 2021/12/20 CRDT- 2021/12/20 12:27 PHST- 2021/08/26 00:00 [received] PHST- 2021/11/30 00:00 [accepted] PHST- 2021/12/20 12:27 [entrez] PHST- 2021/12/21 06:00 [pubmed] PHST- 2021/12/21 06:01 [medline] PHST- 2021/12/20 00:00 [pmc-release] AID - 10.1186/s13550-021-00870-y [pii] AID - 870 [pii] AID - 10.1186/s13550-021-00870-y [doi] PST - epublish SO - EJNMMI Res. 2021 Dec 20;11(1):129. doi: 10.1186/s13550-021-00870-y. PMID- 34924236 OWN - NLM STAT- MEDLINE DCOM- 20220609 LR - 20220614 IS - 1876-4738 (Electronic) IS - 0914-5087 (Linking) VI - 80 IP - 2 DP - 2022 Aug TI - Interventional heart failure therapy: A new concept fighting against heart failure. PG - 101-109 LID - S0914-5087(21)00339-7 [pii] LID - 10.1016/j.jjcc.2021.11.018 [doi] AB - Heart failure is a progressive disease that is associated with repeated exacerbations and hospitalizations. The rapid increase in the number of heart failure patients is a global health problem known as the 'heart failure pandemic'. To control the pandemic, multifaceted approaches are essential, ranging from prevention of onset to long-term disease management. Especially in patients with moderate to severe heart failure (stages C and D), surgical and catheter-based interventions are prerequisites for saving lives, preserving cardiac function, improving quality of life (QOL), and prognosis. In addition, various new medical technologies for these interventions have been clinically applied and have been shown to be effective against symptoms and improve the QOL and prognosis of patients with heart failure. Furthermore, the concept of interventional heart failure (IHF) therapy, which considers heart recovery and prevention of worsening of heart failure via multidisciplinary treatment using surgical, catheter interventions, and mechanical circulatory support devices, has been proposed worldwide. This review discusses the importance of IHF therapy in heart failure management, recent changes in interventional technologies and strategies for patients with heart failure, and worldwide education attempts for IHF specialists. CI - Copyright (c) 2021. Published by Elsevier Ltd. FAU - Saku, Keita AU - Saku K AD - Department of Cardiovascular Dynamics, National Cerebral and Cardiovascular Center Research Institute, Suita, Japan. Electronic address: saku.keita@ncvc.go.jp. FAU - Yokota, Shohei AU - Yokota S AD - Department of Cardiovascular Dynamics, National Cerebral and Cardiovascular Center Research Institute, Suita, Japan. FAU - Nishikawa, Takuya AU - Nishikawa T AD - Department of Cardiovascular Dynamics, National Cerebral and Cardiovascular Center Research Institute, Suita, Japan. FAU - Kinugawa, Koichiro AU - Kinugawa K AD - Second Department of Internal Medicine, Toyama University, Japan. LA - eng PT - Journal Article PT - Review DEP - 20211216 PL - Netherlands TA - J Cardiol JT - Journal of cardiology JID - 8804703 SB - IM MH - *Heart Failure/prevention & control MH - *Heart-Assist Devices MH - Hospitalization MH - Humans MH - Prognosis MH - Quality of Life OTO - NOTNLM OT - Education OT - Heart failure OT - Heart team OT - Intervention OT - Mechanical circulatory support OT - Medical device OT - Multidisciplinary approach EDAT- 2021/12/21 06:00 MHDA- 2022/06/10 06:00 CRDT- 2021/12/20 05:42 PHST- 2021/11/08 00:00 [received] PHST- 2021/11/24 00:00 [accepted] PHST- 2021/12/21 06:00 [pubmed] PHST- 2022/06/10 06:00 [medline] PHST- 2021/12/20 05:42 [entrez] AID - S0914-5087(21)00339-7 [pii] AID - 10.1016/j.jjcc.2021.11.018 [doi] PST - ppublish SO - J Cardiol. 2022 Aug;80(2):101-109. doi: 10.1016/j.jjcc.2021.11.018. Epub 2021 Dec 16. PMID- 34922811 OWN - NLM STAT- MEDLINE DCOM- 20220314 LR - 20240910 IS - 1873-460X (Electronic) IS - 1056-8727 (Print) IS - 1056-8727 (Linking) VI - 36 IP - 2 DP - 2022 Feb TI - DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. PG - 108101 LID - S1056-8727(21)00325-1 [pii] LID - 10.1016/j.jdiacomp.2021.108101 [doi] AB - Type 2 diabetes (T2D), chronic kidney disease (CKD), atherosclerotic cardiovascular disease (ASCVD), and heart failure (HF)-along with their associated risk factors-have overlapping etiologies, and two or more of these conditions frequently occur in the same patient. Many recent cardiovascular outcome trials (CVOTs) have demonstrated the benefits of agents originally developed to control T2D, ASCVD, or CKD risk factors, and these agents have transcended their primary indications to confer benefits across a range of conditions. This evolution in CVOT evidence calls for practice recommendations that are not constrained by a single discipline to help clinicians manage patients with complex conditions involving diabetes, cardiorenal, and/or metabolic (DCRM) diseases. The ultimate goal for these recommendations is to be comprehensive yet succinct and easy to follow by the nonexpert-whether a specialist or a primary care clinician. To meet this need, we formed a volunteer task force comprising leading cardiologists, nephrologists, endocrinologists, and primary care physicians to develop the DCRM Practice Recommendations, a multispecialty consensus on the comprehensive management of the patient with complicated metabolic disease. The task force recommendations are based on strong evidence and incorporate practical guidance that is clinically relevant and simple to implement, with the aim of improving outcomes in patients with DCRM. The recommendations are presented as 18 separate graphics covering lifestyle therapy, patient self-management education, technology for DCRM management, prediabetes, cognitive dysfunction, vaccinations, clinical tests, lipids, hypertension, anticoagulation and antiplatelet therapy, antihyperglycemic therapy, hypoglycemia, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), ASCVD, HF, CKD, and comorbid HF and CKD, as well as a graphical summary of medications used for DCRM. CI - Copyright (c) 2021. Published by Elsevier Inc. FAU - Handelsman, Yehuda AU - Handelsman Y AD - Metabolic Institute of America, Tarzana, CA, USA. Electronic address: yhandelsman@gmail.com. FAU - Anderson, John E AU - Anderson JE AD - The Frist Clinic, Nashville, TN, USA. FAU - Bakris, George L AU - Bakris GL AD - University of Chicago Medicine, Chicago, IL, USA. FAU - Ballantyne, Christie M AU - Ballantyne CM AD - Baylor College of Medicine, Houston, TX, USA. FAU - Beckman, Joshua A AU - Beckman JA AD - Vanderbilt University Medical Center, Nashville, TN, USA. FAU - Bhatt, Deepak L AU - Bhatt DL AD - Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. FAU - Bloomgarden, Zachary T AU - Bloomgarden ZT AD - Mount Sinai School of Medicine, New York, NY, USA. FAU - Bozkurt, Biykem AU - Bozkurt B AD - Baylor College of Medicine, Houston, TX, USA. FAU - Budoff, Matthew J AU - Budoff MJ AD - David Geffen School of Medicine, UCLA, Los Angeles, CA, USA. FAU - Butler, Javed AU - Butler J AD - University of Mississippi Medical Center, Jackson, MS, USA. FAU - Dagogo-Jack, Samuel AU - Dagogo-Jack S AD - University of Tennessee Health Science Center, Memphis, TN, USA. FAU - de Boer, Ian H AU - de Boer IH AD - University of Washington, Seattle, WA, USA. FAU - DeFronzo, Ralph A AU - DeFronzo RA AD - University of Texas Health Science Center, San Antonio, TX, USA. FAU - Eckel, Robert H AU - Eckel RH AD - University of Colorado Anschutz Medical Campus, Denver, CO, USA. FAU - Einhorn, Daniel AU - Einhorn D AD - Scripps Whittier Institute for Diabetes, San Diego, CA, USA. FAU - Fonseca, Vivian A AU - Fonseca VA AD - Tulane University Health Sciences Center, New Orleans, LA, USA. FAU - Green, Jennifer B AU - Green JB AD - Duke University Medical Center, Durham, NC, USA. FAU - Grunberger, George AU - Grunberger G AD - Grunberger Diabetes Institute, Bloomfield Hills, MI, USA, Wayne State University School of Medicine, Detroit, MI, USA, Oakland University William Beaumont School of Medicine, Rochester, MI, USA, Charles University, Prague, Czech Republic. FAU - Guerin, Chris AU - Guerin C AD - University of California San Diego School of Medicine, San Diego, CA, USA. FAU - Inzucchi, Silvio E AU - Inzucchi SE AD - Yale School of Medicine, New Haven, CT, USA. FAU - Jellinger, Paul S AU - Jellinger PS AD - The Center for Diabetes & Endocrine Care, University of Miami Miller School of Medicine, Hollywood, FL, USA. FAU - Kosiborod, Mikhail N AU - Kosiborod MN AD - Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City, Kansas City, MO, USA. FAU - Kushner, Pamela AU - Kushner P AD - University of California at Irvine, Irvine, CA, USA. FAU - Lepor, Norman AU - Lepor N AD - David Geffen School of Medicine, UCLA, Los Angeles, CA, USA. FAU - Mende, Christian W AU - Mende CW AD - University of California San Diego School of Medicine, San Diego, CA, USA. FAU - Michos, Erin D AU - Michos ED AD - Johns Hopkins University School of Medicine, Baltimore, MD, USA. FAU - Plutzky, Jorge AU - Plutzky J AD - Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. FAU - Taub, Pam R AU - Taub PR AD - University of California San Diego School of Medicine, San Diego, CA, USA. FAU - Umpierrez, Guillermo E AU - Umpierrez GE AD - Emory University, Atlanta, GA, USA. FAU - Vaduganathan, Muthiah AU - Vaduganathan M AD - Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. FAU - Weir, Matthew R AU - Weir MR AD - University of Maryland School of Medicine, Baltimore, MD, USA. LA - eng GR - R01 DK107239/DK/NIDDK NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20211207 PL - United States TA - J Diabetes Complications JT - Journal of diabetes and its complications JID - 9204583 RN - 0 (Hypoglycemic Agents) SB - IM MH - *Cardiovascular Diseases/complications/epidemiology/prevention & control MH - *Cardiovascular System MH - *Diabetes Mellitus, Type 2/complications/epidemiology/therapy MH - Humans MH - Hypoglycemic Agents/therapeutic use MH - *Renal Insufficiency, Chronic/complications/epidemiology/therapy PMC - PMC9803322 MID - NIHMS1853694 OTO - NOTNLM OT - Atherosclerotic cardiovascular disease OT - Chronic kidney disease OT - Clinical practice OT - Consensus recommendations OT - Heart failure OT - Type 2 diabetes COIS- Declaration of competing interest None of the Task Force members received monetary renumeration for their contributions to the creation or writing of this consensus document. See the Supplementary Appendix for full declarations of competing interests for each author. EDAT- 2021/12/20 06:00 MHDA- 2022/03/15 06:00 PMCR- 2022/12/30 CRDT- 2021/12/19 20:39 PHST- 2021/11/27 00:00 [received] PHST- 2021/11/27 00:00 [accepted] PHST- 2021/12/20 06:00 [pubmed] PHST- 2022/03/15 06:00 [medline] PHST- 2021/12/19 20:39 [entrez] PHST- 2022/12/30 00:00 [pmc-release] AID - S1056-8727(21)00325-1 [pii] AID - 10.1016/j.jdiacomp.2021.108101 [doi] PST - ppublish SO - J Diabetes Complications. 2022 Feb;36(2):108101. doi: 10.1016/j.jdiacomp.2021.108101. Epub 2021 Dec 7. PMID- 34917749 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240404 IS - 2352-9067 (Print) IS - 2352-9067 (Electronic) IS - 2352-9067 (Linking) VI - 37 DP - 2021 Dec TI - Hybrid coronary revascularization versus percutaneous coronary intervention: A systematic review and meta-analysis. PG - 100916 LID - 10.1016/j.ijcha.2021.100916 [doi] LID - 100916 AB - BACKGROUND: Hybrid coronary revascularization (HCR) is an emerging approach for multivessel coronary artery disease (MVD) which combines the excellent long-term outcomes of surgery with the early recovery and reduced short-term complications of percutaneous coronary intervention (PCI). Here, we evaluated the effectiveness of HCR compared to PCI in patients with MVD. METHODS: A systematic database search in PubMed/MEDLINE, Embase, Scopus, and CENTRAL/CCTR was conducted by June 2021. Random-effects meta-analysis was performed, comparing major adverse cardiac and cerebrovascular events (MACCE) at 30 days and at latest follow-up between patients undergoing HCR versus PCI. RESULTS: A total of 27,041 patients (HCR: 939 patients, PCI: 26,102 patients) were included from seven studies published between 2013 and 2021. At latest follow-up, HCR was associated with lower rates of myocardial infarction (OR 0.40, 95% CI 0.20-0.80, p = 0.010) and target vessel revascularization (OR 0.49, 95% CI 0.37-0.64, p < 0.001), while the difference for MACCE did not reach statistical significance (OR 0.46, 95% CI 0.20-1.05, p = 0.061). No differences were observed in terms of 30-day outcomes, nor rates of mortality or stroke at latest follow-up. CONCLUSIONS: HCR might be a valid alternative to multivessel PCI, demonstrating a lower incidence of MI and TVR. Center experience, well-coordinated heart team discussions, and good patient selection likely remain essential to ensure optimal outcomes. Future comparative studies are required to define the optimal target population. CI - (c) 2021 Published by Elsevier B.V. FAU - Van den Eynde, Jef AU - Van den Eynde J AD - Department of Cardiovascular Diseases, University Hospitals Leuven & Department of Cardiovascular Sciences, KU Leuven, Leuven, Belgium. AD - Helen B. Taussig Heart Center, The Johns Hopkins Hospital and School of Medicine, Baltimore, USA. FAU - Sa, Michel Pompeu AU - Sa MP AD - Department of Cardiothoracic Surgery, Lankenau Heart Institute, Main Line Health Wynnewood, PA, USA. AD - Department of Cardiac Surgery Research, Lankenau Institute for Medical Research, Wynnewood, PA, USA. FAU - De Groote, Senne AU - De Groote S AD - Department of Cardiovascular Diseases, University Hospitals Leuven & Department of Cardiovascular Sciences, KU Leuven, Leuven, Belgium. FAU - Amabile, Andrea AU - Amabile A AD - Division of Cardiac Surgery, Department of Surgery, Yale School of Medicine, New Haven, CT, USA. FAU - Sicouri, Serge AU - Sicouri S AD - Department of Cardiac Surgery Research, Lankenau Institute for Medical Research, Wynnewood, PA, USA. FAU - Ramlawi, Basel AU - Ramlawi B AD - Department of Cardiothoracic Surgery, Lankenau Heart Institute, Main Line Health Wynnewood, PA, USA. AD - Department of Cardiac Surgery Research, Lankenau Institute for Medical Research, Wynnewood, PA, USA. FAU - Torregrossa, Gianluca AU - Torregrossa G AD - Department of Cardiothoracic Surgery, Lankenau Heart Institute, Main Line Health Wynnewood, PA, USA. FAU - Oosterlinck, Wouter AU - Oosterlinck W AD - Department of Cardiovascular Diseases, University Hospitals Leuven & Department of Cardiovascular Sciences, KU Leuven, Leuven, Belgium. LA - eng PT - Journal Article PT - Review DEP - 20211201 PL - Ireland TA - Int J Cardiol Heart Vasc JT - International journal of cardiology. Heart & vasculature JID - 101649525 PMC - PMC8645443 OTO - NOTNLM OT - CABG, coronary artery bypass grafting OT - CI, confidence interval OT - Clinical outcomes OT - HCR, hybrid coronary revascularization OT - Hybrid coronary revascularization OT - LAD, left anterior descending coronary artery OT - LITA, left internal thoracic artery OT - MACCE, major adverse cardiac and cerebrovascular events OT - MD, mean difference OT - MI, myocardial infarction OT - MVD, multivessel coronary artery disease OT - Meta-analysis OT - OR, odds ratio OT - PCI, percutaneous coronary intervention OT - PRISMA, Preferred Reporting Items for Systematic reviews Meta-Analyses OT - Percutaneous coronary Intervention OT - TVR, target vessel revascularization COIS- The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.The authors declare that they have no competing interests. EDAT- 2021/12/18 06:00 MHDA- 2021/12/18 06:01 PMCR- 2021/12/01 CRDT- 2021/12/17 07:01 PHST- 2021/11/05 00:00 [received] PHST- 2021/11/07 00:00 [accepted] PHST- 2021/12/17 07:01 [entrez] PHST- 2021/12/18 06:00 [pubmed] PHST- 2021/12/18 06:01 [medline] PHST- 2021/12/01 00:00 [pmc-release] AID - S2352-9067(21)00204-9 [pii] AID - 100916 [pii] AID - 10.1016/j.ijcha.2021.100916 [doi] PST - epublish SO - Int J Cardiol Heart Vasc. 2021 Dec 1;37:100916. doi: 10.1016/j.ijcha.2021.100916. eCollection 2021 Dec. PMID- 34916818 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20211217 IS - 1178-7031 (Print) IS - 1178-7031 (Electronic) IS - 1178-7031 (Linking) VI - 14 DP - 2021 TI - Erratum: Comprehensive Mechanism, Novel Markers and Multidisciplinary Treatment of Severe Acute Pancreatitis-Associated Cardiac Injury - A Narrative Review [Corrigendum]. PG - 6669-6670 LID - 10.2147/JIR.S352173 [doi] AB - [This corrects the article DOI: 10.2147/JIR.S310990.]. CI - (c) 2021 Luo et al. LA - eng PT - Published Erratum DEP - 20211208 PL - New Zealand TA - J Inflamm Res JT - Journal of inflammation research JID - 101512684 EFR - J Inflamm Res. 2021 Jul 12;14:3145-3169. doi: 10.2147/JIR.S310990. PMID: 34285540 PMC - PMC8669752 EDAT- 2021/12/18 06:00 MHDA- 2021/12/18 06:01 PMCR- 2021/12/08 CRDT- 2021/12/17 06:50 PHST- 2021/12/02 00:00 [received] PHST- 2021/12/02 00:00 [accepted] PHST- 2021/12/17 06:50 [entrez] PHST- 2021/12/18 06:00 [pubmed] PHST- 2021/12/18 06:01 [medline] PHST- 2021/12/08 00:00 [pmc-release] AID - 352173 [pii] AID - 10.2147/JIR.S352173 [doi] PST - epublish SO - J Inflamm Res. 2021 Dec 8;14:6669-6670. doi: 10.2147/JIR.S352173. eCollection 2021. PMID- 34916163 OWN - NLM STAT- MEDLINE DCOM- 20220201 LR - 20220430 IS - 1467-2995 (Electronic) IS - 1467-2987 (Linking) VI - 49 IP - 1 DP - 2022 Jan TI - The perioperative management of small animals with previously implanted pacemakers undergoing anaesthesia. PG - 7-17 LID - S1467-2987(21)00302-0 [pii] LID - 10.1016/j.vaa.2021.05.007 [doi] AB - OBJECTIVE: There is little information in the veterinary literature about the perioperative management of small animal patients with previously implanted pacemakers undergoing elective or emergency non-cardiac procedures. The purpose of this article is to review the current literature with regard to human patients, with previously implanted pacemakers, undergoing general anaesthesia. Using this and the current information on pacemakers and anaesthesia in dogs and cats, we provide recommendations for small animal patients in this situation. DATABASES USED: Google Scholar, PubMed and CAB Abstracts using and interlinking and narrowing the search terms: "dog", "cat", "small animals", "anaesthesia", "pacemaker", "perioperative", "transvenous pacing", "temporary pacing". Scientific reports and human and small animal studies from the reference lists of the retrieved papers were reviewed. In addition, related human and veterinary cardiology and anaesthesia textbooks were also included to create a narrative review of the subject. CONCLUSIONS: The best perioperative care for these animals comes from a multidisciplinary approach involving the anaesthetist, cardiologist, surgeon and intensive care unit team. When such an approach is not feasible, the anaesthetist should be familiar with pacemaker technology and how to avoid perioperative complications such as electromagnetic interference, lead damage and reprogramming of the device. The preanaesthetic assessment should be thorough. Information regarding the indication for pacemaker placement, complications during the procedure, location, type and programming of the pacemaker should be readily available. The anaesthetic management of these veterinary patients aims to preserve cardiovascular function while avoiding hypotension, and backup pacing should be available during the perioperative period. Further prospective studies are needed to describe the best perioperative care in small animals with a previously implanted pacemaker. CI - Copyright (c) 2021 Association of Veterinary Anaesthetists and American College of Veterinary Anesthesia and Analgesia. Published by Elsevier Ltd. All rights reserved. FAU - de Carellan Mateo, Alejandra Garcia AU - de Carellan Mateo AG AD - Anaesthesia and Analgesia Service, Teaching Veterinary Hospital, Department of Animal Medicine and Surgery, School of Veterinary Science, Catholic University of Valencia, Valencia, Spain. Electronic address: alejandra.gcm@ucv.es. FAU - Casamian-Sorrosal, Domingo AU - Casamian-Sorrosal D AD - Cardiology and Interventional Cardiology Service, Teaching Veterinary Hospital, Department of Animal Medicine and Surgery, School of Veterinary Science, Catholic University of Valencia, Valencia, Spain. LA - eng PT - Journal Article PT - Review DEP - 20211122 PL - United States TA - Vet Anaesth Analg JT - Veterinary anaesthesia and analgesia JID - 100956422 SB - IM MH - Anesthesia, General/veterinary MH - *Anesthesiology MH - Animals MH - *Cat Diseases MH - Cats MH - *Dog Diseases MH - Dogs MH - Humans MH - *Pacemaker, Artificial/veterinary OTO - NOTNLM OT - anaesthesia OT - electromagnetic interference OT - pacemaker OT - perioperative OT - small animal EDAT- 2021/12/18 06:00 MHDA- 2022/02/02 06:00 CRDT- 2021/12/17 05:51 PHST- 2020/07/28 00:00 [received] PHST- 2020/11/26 00:00 [revised] PHST- 2021/05/25 00:00 [accepted] PHST- 2021/12/18 06:00 [pubmed] PHST- 2022/02/02 06:00 [medline] PHST- 2021/12/17 05:51 [entrez] AID - S1467-2987(21)00302-0 [pii] AID - 10.1016/j.vaa.2021.05.007 [doi] PST - ppublish SO - Vet Anaesth Analg. 2022 Jan;49(1):7-17. doi: 10.1016/j.vaa.2021.05.007. Epub 2021 Nov 22. PMID- 34916158 OWN - NLM STAT- MEDLINE DCOM- 20230111 LR - 20230111 IS - 1878-0938 (Electronic) IS - 1878-0938 (Linking) VI - 39 DP - 2022 Jun TI - Endovascular Stent Repair of Aortic Coarctation in a Developing Country: A Single-Center Experience. PG - 66-72 LID - S1553-8389(21)00688-6 [pii] LID - 10.1016/j.carrev.2021.10.010 [doi] AB - BACKGROUND/PURPOSE: CoA remains one of the most common congenital heart diseases and is associated with significant morbidity and mortality and if untreated. We aim to evaluate the safety, feasibility, and outcomes of endovascular stenting of Coarctation of the aorta (CoA) in a developing country with limited resources and compare it to available benchmarks. MATERIALS/METHODS: A retrospectively review of all patients who underwent endovascular stent repair of aortic coarctation at our tertiary center since 2009 was done. RESULTS: 18 patients were identified, sixteen had native CoA, while two had recurrent CoA. mean age at the time of procedure was 21.2 +/- 9.8 years (range 10-45 years), and 12(66%) patients were males. The mean follow-up duration was 4 +/- 2.8 years. Post stenting, the average ascending-to-descending aorta systolic gradient decreased by 42.9 +/- 20.4 mmHg (p < 0.001). After the intervention, 13(72.2%) patients achieved normal BP while 5(27.8%) had residual hypertension. Fourteen patients received bare-metal stents, and four had covered stents. Attempted stent implantation was successful in all patients. Our procedural success rate was 94%. On follow-up, no dissections or aneurysmal changes were detected, four patients underwent re-expansion of the stent, one patient with suboptimal stenting result required surgery 6 months after stenting, and two patients had minor post-operative complications. CONCLUSIONS: Endovascular stenting for de-novo or recurrent CoA in children and adults at a tertiary center in a developing country is feasible and safe with outcomes comparable to developed countries. A multidisciplinary team approach is paramount in achieving good results and low complication rates in limited-resource settings. CI - Copyright (c) 2021. Published by Elsevier Inc. FAU - Homsi, Mouafak AU - Homsi M AD - American University of Beirut Medical Center, Department of Vascular Surgery, Lebanon. FAU - El Khoury, Maya AU - El Khoury M AD - American University of Beirut Medical Center, Department of Pediatrics and Adolescent Medicine, Children Heart Center, Lebanon. FAU - Hmedeh, Caroline AU - Hmedeh C AD - American University of Beirut Medical Center, Department of Vascular Surgery, Lebanon. FAU - Arabi, Mariam AU - Arabi M AD - American University of Beirut Medical Center, Department of Pediatrics and Adolescent Medicine, Children Heart Center, Lebanon. FAU - El Rassi, Issam AU - El Rassi I AD - American University of Beirut Medical Center, Department of surgery, Children Heart Center, Lebanon. FAU - Bulbul, Ziad AU - Bulbul Z AD - American University of Beirut Medical Center, Department of Pediatrics and Adolescent Medicine, Children Heart Center, Lebanon. FAU - Sawaya, Fadi AU - Sawaya F AD - American University of Beirut Medical Center, Department of Medicine, Lebanon. FAU - Bitar, Fadi AU - Bitar F AD - American University of Beirut Medical Center, Department of Pediatrics and Adolescent Medicine, Children Heart Center, Lebanon. FAU - Haddad, Fady AU - Haddad F AD - American University of Beirut Medical Center, Department of Vascular Surgery, Lebanon. Electronic address: fh16@aub.edu.lb. LA - eng PT - Journal Article DEP - 20211026 PL - United States TA - Cardiovasc Revasc Med JT - Cardiovascular revascularization medicine : including molecular interventions JID - 101238551 SB - IM MH - Adolescent MH - Adult MH - Child MH - Female MH - Humans MH - Male MH - Middle Aged MH - Young Adult MH - *Aortic Coarctation/diagnostic imaging/surgery MH - Developing Countries MH - Retrospective Studies MH - Stents MH - Treatment Outcome OTO - NOTNLM OT - Coarctation of aorta OT - Congenital heart disease OT - Developing countries OT - Endovascular stenting COIS- Declaration of competing interest None. EDAT- 2021/12/18 06:00 MHDA- 2022/05/25 06:00 CRDT- 2021/12/17 05:51 PHST- 2021/06/15 00:00 [received] PHST- 2021/10/10 00:00 [revised] PHST- 2021/10/21 00:00 [accepted] PHST- 2021/12/18 06:00 [pubmed] PHST- 2022/05/25 06:00 [medline] PHST- 2021/12/17 05:51 [entrez] AID - S1553-8389(21)00688-6 [pii] AID - 10.1016/j.carrev.2021.10.010 [doi] PST - ppublish SO - Cardiovasc Revasc Med. 2022 Jun;39:66-72. doi: 10.1016/j.carrev.2021.10.010. Epub 2021 Oct 26. PMID- 39629147 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241205 IS - 2146-4618 (Print) IS - 2146-4626 (Electronic) IS - 2146-4626 (Linking) VI - 13 IP - 3 DP - 2024 Sep TI - Pediatric Inflammatory Multisystem Syndrome Temporally Associated with SARS-CoV-2-Case Series of a Pediatric Intensive Care Unit in Portugal. PG - 230-234 LID - 10.1055/s-0041-1740587 [doi] AB - Pediatric inflammatory multisystem syndrome temporally associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; PIMS-TS) is a novel condition with persistent fever, inflammation, and single or multiorgan dysfunction. We aimed to describe the characteristics of children more severely affected and our clinical approach. We retrospectively collected clinical, treatment, and early outcomes data during a 3-month period in a pediatric intensive care unit (PICU) of a tertiary university hospital in Portugal. Twelve children who fulfilled the Royal College of Pediatrics and Child Health case definition were hospitalized, seven needed PICU admission. Median age was 13 years and three were overweight, with no other comorbidity. All had positive immunoglobulin G antibodies for SARS-CoV-2. All presented with prolonged fever, asthenia, hypotension, and shock. Other prominent symptoms were abdominal complaints and rash. All patients had leukocytosis, neutrophilia, and marked elevation of inflammatory markers. Cardiac involvement was observed in all patients with elevated levels of troponin and B-type natriuretic peptide along with left ventricular hypokinesis. Depressed left ventricular function was observed in four patients. All patients received broad-spectrum antibiotics, intravenous immunoglobulin, methylprednisolone, low-dose aspirin, and vasoactive medications. Four patients received prophylactic enoxaparin. All patients needed supplementary oxygen; however, high-flow oxygen therapy and noninvasive ventilatory support with positive end-expiratory pressure were required in three and two patients, respectively. Five patients required invasive mechanical ventilation. The mean duration of PICU stay was 7.1 days. The median Pediatric Risk of Mortality-III score was 9 and no mortality was observed. PIMS-TS demands a prompt and multidisciplinary approach. Risk factors, best clinical pathway, and long-term complications are still unknown. CI - Thieme. All rights reserved. FAU - Miranda, Joao AU - Miranda J AUID- ORCID: 0000-0003-4896-2201 AD - Department of Pediatrics, Pediatric Intensive Care Unit, Centro Hospitalar Universitario Sao Joao, Porto, Portugal. FAU - Grilo, Marta AU - Grilo M AD - Department of Pediatrics, Pediatric Intensive Care Unit, Centro Hospitalar Universitario Sao Joao, Porto, Portugal. FAU - Baptista, Carolina AU - Baptista C AD - Department of Pediatrics, Pediatric Intensive Care Unit, Centro Hospitalar Universitario Sao Joao, Porto, Portugal. FAU - Melo, Ana Reis E AU - Melo ARE AD - Department of Pediatrics, Immunodeficiency and Infectious Diseases Unit, Centro Hospitalar Universitario Sao Joao, Porto, Portugal. FAU - Tavares, Margarida AU - Tavares M AUID- ORCID: 0000-0002-9544-0484 AD - Department of Pediatrics, Immunodeficiency and Infectious Diseases Unit, Centro Hospitalar Universitario Sao Joao, Porto, Portugal. FAU - Ribeiro, Augusto AU - Ribeiro A AD - Department of Pediatrics, Pediatric Intensive Care Unit, Centro Hospitalar Universitario Sao Joao, Porto, Portugal. LA - eng PT - Journal Article DEP - 20211217 PL - Germany TA - J Pediatr Intensive Care JT - Journal of pediatric intensive care JID - 101592756 PMC - PMC11379517 OTO - NOTNLM OT - COVID-19 OT - PIMS-TS OT - SARS-CoV-2 OT - care OT - shock COIS- Conflict of Interest None declared. EDAT- 2021/12/17 00:00 MHDA- 2021/12/17 00:01 PMCR- 2022/12/17 CRDT- 2024/12/04 04:46 PHST- 2021/07/15 00:00 [received] PHST- 2021/11/10 00:00 [accepted] PHST- 2021/12/17 00:01 [medline] PHST- 2021/12/17 00:00 [pubmed] PHST- 2024/12/04 04:46 [entrez] PHST- 2022/12/17 00:00 [pmc-release] AID - JPIC-D-21-00082 [pii] AID - 10.1055/s-0041-1740587 [doi] PST - epublish SO - J Pediatr Intensive Care. 2021 Dec 17;13(3):230-234. doi: 10.1055/s-0041-1740587. eCollection 2024 Sep. PMID- 34908923 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20211216 IS - 1671-5411 (Print) IS - 1671-5411 (Linking) VI - 18 IP - 11 DP - 2021 Nov 28 TI - Blood lead level in Chinese adults with and without coronary artery disease. PG - 857-866 LID - 10.11909/j.issn.1671-5411.2021.11.004 [doi] AB - BACKGROUND: The Trial to Assess Chelation Therapy study found that edetate disodium (disodium ethylenediaminetetraacetic acid) chelation therapy significantly reduced the incidence of cardiac events in stable post-myocardial infarction patients, and a body of epidemiological data has shown that accumulation of biologically active metals, such as lead and cadmium, is an important risk factor for cardiovascular disease. However, limited studies have focused on the relationship between angiographically diagnosed coronary artery disease (CAD) and lead exposure. This study compared blood lead level (BLL) in Chinese patients with and without CAD. METHODS: In this prospective, observational study, 450 consecutive patients admitted to Beijing Anzhen Hospital with suspected CAD from November 1, 2018, to January 30, 2019, were enrolled. All patients underwent coronary angiography, and an experienced heart team calculated the SYNTAX scores (SXscore) for all available coronary angiograms. BLLs were determined with atomic absorption spectrophotometry and compared between patients with angiographically diagnosed CAD and those without CAD. RESULTS: In total, 343 (76%) patients had CAD, of whom 42% had low (0-22), 22% had intermediate (23-32), and 36% had high (>/= 33) SXscore. BLLs were 36.8 +/- 16.95 mug/L in patients with CAD and 31.2 +/- 15.75 mug/L in those without CAD (P = 0.003). When BLLs were categorized into three groups (low, middle, high), CAD prevalence increased with increasing BLLs (P < 0.05). In the multivariate regression model, BLLs were associated with CAD (odds ratio (OR): 1.023, 95% confidence interval (CI): 1.008-1.039; P = 0.0017). OR in the high versus low BLL group was 2.36 (95% CI: 1.29-4.42,P = 0.003). Furthermore, BLLs were independently associated with intermediate and high SXscore (adjusted OR: 1.050, 95% CI: 1.036-1.066; P < 0.0001). CONCLUSION: BLLs were significantly associated with angiographically diagnosed CAD. Furthermore, BLLs showed excellent predictive value for SXscore, especially for complex coronary artery lesions. CI - Copyright and License information: Journal of Geriatric Cardiology 2021. FAU - Li, Shi-Hong AU - Li SH AD - Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China. FAU - Zhang, Hong-Ju AU - Zhang HJ AD - Department of Echocardiography, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China. FAU - Li, Xiao-Dong AU - Li XD AD - Department of Cardiology, Shougang Changzhi Steel Hospital, Changzhi, China. FAU - Cui, Jian AU - Cui J AD - Department of Cardiology, Shougang Changzhi Steel Hospital, Changzhi, China. FAU - Cheng, Yu-Tong AU - Cheng YT AD - Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China. FAU - Wang, Qian AU - Wang Q AD - Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China. FAU - Wang, Su AU - Wang S AD - Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China. FAU - Krittanawong, Chayakrit AU - Krittanawong C AD - Department of Cardiology, Baylor College of Medicine, Houston, USA. FAU - El-Am, Edward A AU - El-Am EA AD - Department of Medicine, Indiana University School of Medicine, Indianapolis, USA. FAU - Bou Chaaya, Rody G AU - Bou Chaaya RG AD - Department of Medicine, Indiana University School of Medicine, Indianapolis, USA. FAU - Wu, Xiang-Yu AU - Wu XY AD - Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China. FAU - Gu, Wei AU - Gu W AD - Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China. FAU - Liu, Hong-Hong AU - Liu HH AD - Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China. FAU - Yan, Xian-Liang AU - Yan XL AD - Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China. FAU - Li, Zhi-Zhong AU - Li ZZ AD - Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China. FAU - Yang, Shi-Wei AU - Yang SW AD - Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China. FAU - Sun, Tao AU - Sun T AD - Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China. LA - eng PT - Journal Article PL - China TA - J Geriatr Cardiol JT - Journal of geriatric cardiology : JGC JID - 101237881 PMC - PMC8648547 EDAT- 2021/12/16 06:00 MHDA- 2021/12/16 06:01 PMCR- 2021/11/28 CRDT- 2021/12/15 12:26 PHST- 2021/12/15 12:26 [entrez] PHST- 2021/12/16 06:00 [pubmed] PHST- 2021/12/16 06:01 [medline] PHST- 2021/11/28 00:00 [pmc-release] AID - jgc-18-11-857 [pii] AID - 10.11909/j.issn.1671-5411.2021.11.004 [doi] PST - ppublish SO - J Geriatr Cardiol. 2021 Nov 28;18(11):857-866. doi: 10.11909/j.issn.1671-5411.2021.11.004. PMID- 34907530 OWN - NLM STAT- MEDLINE DCOM- 20220311 LR - 20260109 IS - 1399-6576 (Electronic) IS - 0001-5172 (Linking) VI - 66 IP - 3 DP - 2022 Mar TI - Rapid response teams-how and who? A protocol for a randomised clinical trial evaluating the composition of the efferent limb of the rapid response system. PG - 401-407 LID - 10.1111/aas.14017 [doi] AB - BACKGROUND: Many patients experiencing deterioration have documented deviation of vital signs prior to the deterioration event. Increasing focus on these patients led to the rapid response systems and their configuration with afferent and efferent limbs. The two most prevalent team constellations in the efferent limb are the medical emergency team (MET), usually led by a doctor, and the critical care outreach team (CCOT), usually led by a nurse. The two constellations have not previously been examined in a comparative clinical trial. METHODS: This is a single centre non-inferiority randomised controlled trial of MET vs CCOT. All patients will be randomised at the time of the call. The intervention group will be the critical care outreach team. The primary outcome is mortality at 30 days and the occurrence of serious adverse events. All patients will be followed for 90 days. We aim to detect or reject a change of 7% in mortality whilst accepting a type I error of 5 and type II error of 20, using a sample size of maximum of 2000 individual patients. DISCUSSION: There is evidence supporting a benefit for the patient when using rapid response systems; however, earlier randomised studies are marked by cross-contamination and selection bias. Previous studies have primarily examined the effect of RRS on hospital cardiac arrests (IHCA) and mortality. Our study will be examining the effect on intensive care unit admissions as well as the ICHA and mortality. CONCLUSION: This study may highlight potential benefits of specific configurations of rapid response systems and their impact on safety outcomes. CI - (c) 2021 The Acta Anaesthesiologica Scandinavica Foundation. Published by John Wiley & Sons Ltd. FAU - Fons-Sonderskov, Morten B AU - Fons-Sonderskov MB AUID- ORCID: 0000-0002-7139-8146 AD - Department of Anesthesia and Intensive Care, Copenhagen University Hospital - North Zealand, Hillerod, Denmark. FAU - Subbe, Chris AU - Subbe C AD - School of Medical Sciences, Bangor University, Bangor, Wales, England. FAU - Kodal, Anne Marie AU - Kodal AM AD - Department of Anesthesia and Intensive Care, Copenhagen University Hospital - North Zealand, Hillerod, Denmark. FAU - Bunkenborg, Gitte AU - Bunkenborg G AD - Holbaek Hospital, University of Southern Denmark, Holbaek, Denmark. FAU - Bestle, Morten H AU - Bestle MH AD - Department of Anesthesia and Intensive Care, Copenhagen University Hospital - North Zealand, Hillerod, Denmark. AD - Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. LA - eng GR - Nordsjaellands Hospital/ PT - Clinical Trial Protocol PT - Journal Article DEP - 20211227 PL - England TA - Acta Anaesthesiol Scand JT - Acta anaesthesiologica Scandinavica JID - 0370270 SB - IM MH - Critical Care/methods MH - *Heart Arrest MH - *Hospital Rapid Response Team MH - Humans MH - Intensive Care Units MH - Randomized Controlled Trials as Topic MH - Vital Signs MH - Equivalence Trials as Topic OTO - NOTNLM OT - critical care outreach OT - medical emergency team OT - patient safety OT - rapid response systems OT - rapid response teams EDAT- 2021/12/16 06:00 MHDA- 2022/03/12 06:00 CRDT- 2021/12/15 07:34 PHST- 2021/11/24 00:00 [received] PHST- 2021/12/07 00:00 [accepted] PHST- 2021/12/16 06:00 [pubmed] PHST- 2022/03/12 06:00 [medline] PHST- 2021/12/15 07:34 [entrez] AID - 10.1111/aas.14017 [doi] PST - ppublish SO - Acta Anaesthesiol Scand. 2022 Mar;66(3):401-407. doi: 10.1111/aas.14017. Epub 2021 Dec 27. PMID- 34902393 OWN - NLM STAT- MEDLINE DCOM- 20220926 LR - 20220926 IS - 1535-6280 (Electronic) IS - 0146-2806 (Linking) VI - 47 IP - 11 DP - 2022 Nov TI - The Transcatheter Tricuspid Valve-in-Valve Technique in Degenerated Bioprostheses Without Fluoroscopic Radiopaque Landmarks. PG - 101081 LID - S0146-2806(21)00289-9 [pii] LID - 10.1016/j.cpcardiol.2021.101081 [doi] AB - Nonetheless, in principle, bioprosthetic heart valves are often preferred to mechanical valves in that not only do they obviate the need for high-level systemic anticoagulation and the attendant bleeding risks, but also higher rates of prosthetic valve thrombosis have been reported observed in the tricuspid position. The transcatheter tricuspid valve-in-valve (TVIV) procedure has expanded the horizons of cardiac surgery by allowing the implantation of stent-valves within degenerated bioprostheses in older adults and even young patients as the reported rate of the mortality of redo surgery in antecedent studies is at least 37%. Fluoroscopic guidance can assist the operator in implanting a bioprosthetic valve by radiopaque findings in the ideal position and depth; nonetheless, the complete radiolucency of some bioprosthetic valves represents a significant hurdle. In this state-of-the-art manuscript, we decided to deeply explain the appropriate heart-team approach in this scenario. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - Firouzi, Ata AU - Firouzi A AD - Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran. FAU - Khalilipur, Ehsan AU - Khalilipur E AD - Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran. FAU - Abdi, Seifollah AU - Abdi S AD - Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran. FAU - Alemzadeh-Ansari, Mohammad Javad AU - Alemzadeh-Ansari MJ AD - Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran. FAU - Alizadehasl, Azin AU - Alizadehasl A AD - Rajaie Cardiovascular Medical and Research Center, Cardio-Oncology Department and Research Center, Iran University of Medical Sciences, Tehran, Iran. FAU - Khajali, Zahra AU - Khajali Z AD - Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran. FAU - Hosseini, Zahra AU - Hosseini Z AD - Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran. Electronic address: Hosseini.zahra64@gmail.com. LA - eng PT - Journal Article PT - Review DEP - 20211211 PL - Netherlands TA - Curr Probl Cardiol JT - Current problems in cardiology JID - 7701802 RN - 0 (Anticoagulants) SB - IM MH - Aged MH - Anticoagulants MH - Aortic Valve/surgery MH - *Bioprosthesis/adverse effects MH - *Heart Valve Prosthesis/adverse effects MH - *Heart Valve Prosthesis Implantation/adverse effects/methods MH - Humans MH - Prosthesis Design MH - Prosthesis Failure MH - Treatment Outcome MH - Tricuspid Valve/diagnostic imaging/surgery EDAT- 2021/12/14 06:00 MHDA- 2022/09/28 06:00 CRDT- 2021/12/13 20:14 PHST- 2021/11/26 00:00 [received] PHST- 2021/12/05 00:00 [accepted] PHST- 2021/12/14 06:00 [pubmed] PHST- 2022/09/28 06:00 [medline] PHST- 2021/12/13 20:14 [entrez] AID - S0146-2806(21)00289-9 [pii] AID - 10.1016/j.cpcardiol.2021.101081 [doi] PST - ppublish SO - Curr Probl Cardiol. 2022 Nov;47(11):101081. doi: 10.1016/j.cpcardiol.2021.101081. Epub 2021 Dec 11. PMID- 34899392 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240829 IS - 1664-042X (Print) IS - 1664-042X (Electronic) IS - 1664-042X (Linking) VI - 12 DP - 2021 TI - Impact of and Reasons for Not Performing Exercise Training After an Acute Coronary Syndrome in the Setting of an Interdisciplinary Cardiac Rehabilitation Program: Results From a Risk-Op- Acute Coronary Syndrome Ambispective Registry. PG - 768199 LID - 10.3389/fphys.2021.768199 [doi] LID - 768199 AB - Background and Aims: Exercise training (ET) is a critical component of cardiac rehabilitation (CR), but it remains underused. The aim of this study was to compare clinical outcomes between patients who completed ET (A-T), those who accepted ET but did not complete it (A-NT), and those who did not accept to undergo it (R-NT), and to analyze reasons for rejecting or not completing ET. Methods and Results: A unicenter ambispective observational registry study of 497 patients with acute coronary syndrome (ACS) was carried out in Barcelona, Spain, from 2016 to 2019. The primary endpoint was a composite of all-cause mortality, hospitalization for ACS, or need for revascularization during follow-up. Multivariable analysis was carried out to identify variables independently associated with the primary outcome. Initially, 70% of patients accepted participating in the ET, but only 50.5% completed it. The A-T group were younger and had fewer comorbidities. Baseline characteristics in A-NT and R-NT groups were very similar. The main reason for not undergoing or completing ET was rejection (reason unknown) or work/schedule incompatibility. The median follow-up period was 31 months. Both the composite primary endpoint and mortality were significantly lower in the A-T group compared to the A-NT and R-NT (primary endpoint: 3.6% vs. 23.2% vs. 20.4%, p < 0.001, respectively; mortality: 0.8% vs. 9.1% vs. 8.2%, p < 0.001; respectively). During multivariable analysis, the only variables that remained statistically significant with the composite endpoint were ET completion, previous ACS, and anemia. Conclusion: Completion of ET after ACS was associated with improved prognosis. Only half of the patients completed the ET program, with the leading reasons for not completing it being refusal (reason unknown) and work/schedule incompatibility. These results highlight the need to focus on the needs of patients in order to guarantee that structural barriers to ET no longer exist. CI - Copyright (c) 2021 Cabrera-Aguilera, Ivern, Badosa, Marco, Salas-Medina, Mojon, Vicente, Llagostera, Farre and Ruiz-Bustillo. FAU - Cabrera-Aguilera, Ignacio AU - Cabrera-Aguilera I AD - Facultat de Medicina i Ciencies de la Salut, Unitat de Biofisica i Bioenginyeria, Universitat de Barcelona, Barcelona, Spain. AD - Heart Diseases Biomedical Research Group, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain. AD - Department of Human Movement Sciences, Faculty of Health Sciences, School of Kinesiology, Universidad de Talca, Talca, Chile. FAU - Ivern, Consolacio AU - Ivern C AD - Heart Diseases Biomedical Research Group, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain. AD - Cardiac Rehabilitation Unit, Department of Cardiology, Hospital del Mar, Barcelona, Spain. FAU - Badosa, Neus AU - Badosa N AD - Heart Diseases Biomedical Research Group, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain. AD - Cardiac Rehabilitation Unit, Department of Cardiology, Hospital del Mar, Barcelona, Spain. FAU - Marco, Ester AU - Marco E AD - Cardiac Rehabilitation Unit, Physical Medicine and Rehabilitation Department, Parc de Salut Mar (Hospital del Mar - Hospital de l'Esperanca), Barcelona, Spain. AD - Rehabilitation Research Group, Hospital del Mar Medical Research Institute, Barcelona, Spain. AD - Department of Medicine, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Salas-Medina, Luis AU - Salas-Medina L AD - Cardiac Rehabilitation Unit, Physical Medicine and Rehabilitation Department, Parc de Salut Mar (Hospital del Mar - Hospital de l'Esperanca), Barcelona, Spain. FAU - Mojon, Diana AU - Mojon D AD - Cardiac Rehabilitation Unit, Department of Cardiology, Hospital del Mar, Barcelona, Spain. FAU - Vicente, Miren AU - Vicente M AD - Cardiac Rehabilitation Unit, Department of Cardiology, Hospital del Mar, Barcelona, Spain. FAU - Llagostera, Marc AU - Llagostera M AD - Cardiac Rehabilitation Unit, Department of Cardiology, Hospital del Mar, Barcelona, Spain. FAU - Farre, Nuria AU - Farre N AD - Heart Diseases Biomedical Research Group, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain. AD - Cardiac Rehabilitation Unit, Department of Cardiology, Hospital del Mar, Barcelona, Spain. AD - Department of Medicine, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Ruiz-Bustillo, Sonia AU - Ruiz-Bustillo S AD - Heart Diseases Biomedical Research Group, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain. AD - Cardiac Rehabilitation Unit, Department of Cardiology, Hospital del Mar, Barcelona, Spain. AD - Department of Medicine, Universitat Pompeu Fabra, Barcelona, Spain. LA - eng PT - Journal Article DEP - 20211124 PL - Switzerland TA - Front Physiol JT - Frontiers in physiology JID - 101549006 PMC - PMC8654103 OTO - NOTNLM OT - acute coronary syndrome OT - cardiac rehabilitation OT - event-free survival OT - exercise training OT - ischemic heart disease OT - rehabilitation adherence COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/12/14 06:00 MHDA- 2021/12/14 06:01 PMCR- 2021/11/24 CRDT- 2021/12/13 17:54 PHST- 2021/08/31 00:00 [received] PHST- 2021/10/31 00:00 [accepted] PHST- 2021/12/13 17:54 [entrez] PHST- 2021/12/14 06:00 [pubmed] PHST- 2021/12/14 06:01 [medline] PHST- 2021/11/24 00:00 [pmc-release] AID - 10.3389/fphys.2021.768199 [doi] PST - epublish SO - Front Physiol. 2021 Nov 24;12:768199. doi: 10.3389/fphys.2021.768199. eCollection 2021. PMID- 34895951 OWN - NLM STAT- MEDLINE DCOM- 20220214 LR - 20220415 IS - 1558-3597 (Electronic) IS - 0735-1097 (Linking) VI - 79 IP - 2 DP - 2022 Jan 18 TI - 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. PG - 197-215 LID - S0735-1097(21)06157-X [pii] LID - 10.1016/j.jacc.2021.09.005 [doi] AB - AIM: The executive summary of the American College of Cardiology/American Heart Association/Society for Cardiovascular Angiography and Interventions coronary artery revascularization guideline provides the top 10 items readers should know about the guideline. In the full guideline, the recommendations replace the 2011 coronary artery bypass graft surgery guideline and the 2011 and 2015 percutaneous coronary intervention guidelines. This summary offers a patient-centric approach to guide clinicians in the treatment of patients with significant coronary artery disease undergoing coronary revascularization, as well as the supporting documentation to encourage their use. METHODS: A comprehensive literature search was conducted from May 2019 to September 2019, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from PubMed, EMBASE, the Cochrane Collaboration, CINHL Complete, and other relevant databases. Additional relevant studies, published through May 2021, were also considered. STRUCTURE: Recommendations from the earlier percutaneous coronary intervention and coronary artery bypass graft surgery guidelines have been updated with new evidence to guide clinicians in caring for patients undergoing coronary revascularization. This summary includes recommendations, tables, and figures from the full guideline that relate to the top 10 take-home messages. The reader is referred to the full guideline for graphical flow charts, supportive text, and tables with additional details about the rationale for and implementation of each recommendation, and the evidence tables detailing the data considered in the development of this guideline. CI - Copyright (c) 2022 The American College of Cardiology Foundation and the American Heart Association, Inc. Published by Elsevier Inc. All rights reserved. CN - Writing Committee Members FAU - Lawton, Jennifer S AU - Lawton JS FAU - Tamis-Holland, Jacqueline E AU - Tamis-Holland JE FAU - Bangalore, Sripal AU - Bangalore S FAU - Bates, Eric R AU - Bates ER FAU - Beckie, Theresa M AU - Beckie TM FAU - Bischoff, James M AU - Bischoff JM FAU - Bittl, John A AU - Bittl JA FAU - Cohen, Mauricio G AU - Cohen MG FAU - DiMaio, J Michael AU - DiMaio JM FAU - Don, Creighton W AU - Don CW FAU - Fremes, Stephen E AU - Fremes SE FAU - Gaudino, Mario F AU - Gaudino MF FAU - Goldberger, Zachary D AU - Goldberger ZD FAU - Grant, Michael C AU - Grant MC FAU - Jaswal, Jang B AU - Jaswal JB FAU - Kurlansky, Paul A AU - Kurlansky PA FAU - Mehran, Roxana AU - Mehran R FAU - Metkus, Thomas S Jr AU - Metkus TS Jr FAU - Nnacheta, Lorraine C AU - Nnacheta LC FAU - Rao, Sunil V AU - Rao SV FAU - Sellke, Frank W AU - Sellke FW FAU - Sharma, Garima AU - Sharma G FAU - Yong, Celina M AU - Yong CM FAU - Zwischenberger, Brittany A AU - Zwischenberger BA LA - eng PT - Journal Article PT - Practice Guideline DEP - 20211209 PL - United States TA - J Am Coll Cardiol JT - Journal of the American College of Cardiology JID - 8301365 SB - IM EIN - J Am Coll Cardiol. 2022 Apr 19;79(15):1547. doi: 10.1016/j.jacc.2022.03.329. PMID: 35422253 MH - Algorithms MH - American Heart Association MH - Coronary Artery Disease/*therapy MH - Decision Making, Shared MH - Diabetes Mellitus MH - Dual Anti-Platelet Therapy MH - Humans MH - Myocardial Revascularization/methods/*standards MH - Patient Care Team MH - Risk Assessment MH - United States OTO - NOTNLM OT - ACC/AHA Clinical Practice Guidelines OT - angiogram OT - angiography OT - angioplasty OT - arterial graft OT - cardiac surgery OT - coronary artery bypass graft (CABG) surgery OT - coronary atherosclerosis OT - internal mammary artery graft OT - internal thoracic artery graft OT - left ventricular dysfunction OT - multivessel PCI OT - myocardial infarction OT - myocardial revascularization OT - non-ST-segment-elevated myocardial infarction OT - percutaneous coronary intervention (PCI) OT - percutaneous transluminal coronary angioplasty OT - post-bypass OT - saphenous vein graft OT - stent(s) OT - vein graft lesions EDAT- 2021/12/14 06:00 MHDA- 2022/02/15 06:00 CRDT- 2021/12/13 12:07 PHST- 2021/12/14 06:00 [pubmed] PHST- 2022/02/15 06:00 [medline] PHST- 2021/12/13 12:07 [entrez] AID - S0735-1097(21)06157-X [pii] AID - 10.1016/j.jacc.2021.09.005 [doi] PST - ppublish SO - J Am Coll Cardiol. 2022 Jan 18;79(2):197-215. doi: 10.1016/j.jacc.2021.09.005. Epub 2021 Dec 9. PMID- 34895759 OWN - NLM STAT- MEDLINE DCOM- 20220411 LR - 20220411 IS - 1958-5578 (Electronic) IS - 0040-5957 (Linking) VI - 77 IP - 2 DP - 2022 Mar-Apr TI - From cardio-oncology to cardio-onco-pharmacology: Towards a multidisciplinary approach in the understanding and management of cardiotoxicity. PG - 197-206 LID - S0040-5957(21)00244-4 [pii] LID - 10.1016/j.therap.2021.09.008 [doi] AB - Cardio-oncology is an emerging field that transformed the medical management of patients with cancer. It encompasses the prevention and treatment of cardiovascular toxicities related to cancer treatments, aiming to reduce cardiac adverse events among cancer survivors. Cardiovascular toxicities related to cancer treatments are described through data collected during phase I to phase III therapeutic trials, and post-marketing surveillance (phase IV). Pharmacovigilance analyses, based on datamining from these extensive databases, allowed to understanding and identifying new adverse drug reactions, some recently made available, such as immunotherapy or inhibitor of Bruton tyrosine kinase (IBTK). CI - Copyright (c) 2021 Societe francaise de pharmacologie et de therapeutique. Published by Elsevier Masson SAS. All rights reserved. FAU - Ederhy, Stephane AU - Ederhy S AD - Department of Cardiology, AP-HP, Saint Antoine Hospital, UNICO Cardio-oncology program, GRC n(o) 27, 184, rue du faubourg saint Antoine, 75012 Paris, France. Electronic address: stephane.ederhy@aphp.fr. FAU - Devos, Perrine AU - Devos P AD - Department of Cardiology, AP-HP, Pitie-Salpetriere Hospital, UNICO Cardio-oncology program, 75012 Paris, France. FAU - Cohen, Ariel AU - Cohen A AD - Department of Cardiology, AP-HP, Saint Antoine Hospital, UNICO Cardio-oncology program, GRC n(o) 27, 184, rue du faubourg saint Antoine, 75012 Paris, France. FAU - Pinna, Bruno AU - Pinna B AD - INSERM, CIC-1901, Sorbonne Universite, AP-HP, Pitie-Salpetriere Hospital, Department of Pharmacology, UNICO Cardio-oncology program, 75013 Paris, France. FAU - Bretagne, Marie AU - Bretagne M AD - INSERM, CIC-1901, Sorbonne Universite, AP-HP, Pitie-Salpetriere Hospital, Department of Pharmacology, UNICO Cardio-oncology program, 75013 Paris, France. FAU - Nguyen, Lee S AU - Nguyen LS AD - Research & Innovation of CMC Ambroise Pare, 92200 Neuilly-sur-Seine, France. FAU - Salem, Joe-Elie AU - Salem JE AD - INSERM, CIC-1901, Sorbonne Universite, AP-HP, Pitie-Salpetriere Hospital, Department of Pharmacology, UNICO Cardio-oncology program, 75013 Paris, France; Research & Innovation of CMC Ambroise Pare, 92200 Neuilly-sur-Seine, France. LA - eng PT - Journal Article DEP - 20211125 PL - France TA - Therapie JT - Therapie JID - 0420544 RN - 0 (Antineoplastic Agents) SB - IM MH - *Antineoplastic Agents MH - Cardiotoxicity/drug therapy/etiology/prevention & control MH - *Cardiovascular Diseases/chemically induced/drug therapy/prevention & control MH - Humans MH - Medical Oncology MH - *Neoplasms/chemically induced OTO - NOTNLM OT - Anthracyclines OT - Cancer OT - Cardiotoxicity OT - Immunotherapy OT - Molecular Targeted agents EDAT- 2021/12/14 06:00 MHDA- 2022/04/12 06:00 CRDT- 2021/12/13 12:00 PHST- 2021/08/24 00:00 [received] PHST- 2021/09/22 00:00 [accepted] PHST- 2021/12/14 06:00 [pubmed] PHST- 2022/04/12 06:00 [medline] PHST- 2021/12/13 12:00 [entrez] AID - S0040-5957(21)00244-4 [pii] AID - 10.1016/j.therap.2021.09.008 [doi] PST - ppublish SO - Therapie. 2022 Mar-Apr;77(2):197-206. doi: 10.1016/j.therap.2021.09.008. Epub 2021 Nov 25. PMID- 34889766 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220111 IS - 1929-0748 (Print) IS - 1929-0748 (Electronic) IS - 1929-0748 (Linking) VI - 10 IP - 12 DP - 2021 Dec 10 TI - The Communicating Narrative Concerns Entered by Registered Nurses (CONCERN) Clinical Decision Support Early Warning System: Protocol for a Cluster Randomized Pragmatic Clinical Trial. PG - e30238 LID - 10.2196/30238 [doi] LID - e30238 AB - BACKGROUND: Every year, hundreds of thousands of inpatients die from cardiac arrest and sepsis, which could be avoided if those patients' risk for deterioration were detected and timely interventions were initiated. Thus, a system is needed to convert real-time, raw patient data into consumable information that clinicians can utilize to identify patients at risk of deterioration and thus prevent mortality and improve patient health outcomes. The overarching goal of the COmmunicating Narrative Concerns Entered by Registered Nurses (CONCERN) study is to implement and evaluate an early warning score system that provides clinical decision support (CDS) in electronic health record systems. With a combination of machine learning and natural language processing, the CONCERN CDS utilizes nursing documentation patterns as indicators of nurses' increased surveillance to predict when patients are at the risk of clinical deterioration. OBJECTIVE: The objective of this cluster randomized pragmatic clinical trial is to evaluate the effectiveness and usability of the CONCERN CDS system at 2 different study sites. The specific aim is to decrease hospitalized patients' negative health outcomes (in-hospital mortality, length of stay, cardiac arrest, unanticipated intensive care unit transfers, and 30-day hospital readmission rates). METHODS: A multiple time-series intervention consisting of 3 phases will be performed through a 1-year period during the cluster randomized pragmatic clinical trial. Phase 1 evaluates the adoption of our algorithm through pilot and trial testing, phase 2 activates optimized versions of the CONCERN CDS based on experience from phase 1, and phase 3 will be a silent release mode where no CDS is viewable to the end user. The intervention deals with a series of processes from system release to evaluation. The system release includes CONCERN CDS implementation and user training. Then, a mixed methods approach will be used with end users to assess the system and clinician perspectives. RESULTS: Data collection and analysis are expected to conclude by August 2022. Based on our previous work on CONCERN, we expect the system to have a positive impact on the mortality rate and length of stay. CONCLUSIONS: The CONCERN CDS will increase team-based situational awareness and shared understanding of patients predicted to be at risk for clinical deterioration in need of intervention to prevent mortality and associated harm. TRIAL REGISTRATION: ClinicalTrials.gov NCT03911687; https://clinicaltrials.gov/ct2/show/NCT03911687. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/30238. CI - (c)Sarah Collins Rossetti, Patricia C Dykes, Christopher Knaplund, Min-Jeoung Kang, Kumiko Schnock, Jose Pedro Garcia Jr, Li-Heng Fu, Frank Chang, Tien Thai, Matthew Fred, Tom Z Korach, Li Zhou, Jeffrey G Klann, David Albers, Jessica Schwartz, Graham Lowenthal, Haomiao Jia, Fang Liu, Kenrick Cato. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 10.12.2021. FAU - Rossetti, Sarah Collins AU - Rossetti SC AUID- ORCID: 0000-0003-2632-8867 AD - Department of Biomedical Informatics, Columbia University, New York, NY, United States. AD - School of Nursing, Columbia University Medical Center, New York, NY, United States. FAU - Dykes, Patricia C AU - Dykes PC AUID- ORCID: 0000-0003-4597-0732 AD - Brigham and Women's Hospital, Boston, MA, United States. AD - Harvard Medical School, Boston, MA, United States. FAU - Knaplund, Christopher AU - Knaplund C AUID- ORCID: 0000-0002-9441-0021 AD - Department of Biomedical Informatics, Columbia University, New York, NY, United States. FAU - Kang, Min-Jeoung AU - Kang MJ AUID- ORCID: 0000-0001-9130-3741 AD - Brigham and Women's Hospital, Boston, MA, United States. AD - Harvard Medical School, Boston, MA, United States. FAU - Schnock, Kumiko AU - Schnock K AUID- ORCID: 0000-0002-1107-6399 AD - Brigham and Women's Hospital, Boston, MA, United States. AD - Harvard Medical School, Boston, MA, United States. FAU - Garcia, Jose Pedro Jr AU - Garcia JP Jr AUID- ORCID: 0000-0001-5089-547X AD - Brigham and Women's Hospital, Boston, MA, United States. FAU - Fu, Li-Heng AU - Fu LH AUID- ORCID: 0000-0001-5662-8321 AD - Department of Biomedical Informatics, Columbia University, New York, NY, United States. FAU - Chang, Frank AU - Chang F AUID- ORCID: 0000-0003-1774-9926 AD - Brigham and Women's Hospital, Boston, MA, United States. FAU - Thai, Tien AU - Thai T AUID- ORCID: 0000-0002-9746-4658 AD - Brigham and Women's Hospital, Boston, MA, United States. FAU - Fred, Matthew AU - Fred M AUID- ORCID: 0000-0002-7749-1907 AD - Working Diagnosis, Haddonfield, NJ, United States. FAU - Korach, Tom Z AU - Korach TZ AUID- ORCID: 0000-0002-6533-7961 AD - Brigham and Women's Hospital, Boston, MA, United States. AD - Harvard Medical School, Boston, MA, United States. FAU - Zhou, Li AU - Zhou L AUID- ORCID: 0000-0003-3874-4833 AD - Brigham and Women's Hospital, Boston, MA, United States. AD - Harvard Medical School, Boston, MA, United States. FAU - Klann, Jeffrey G AU - Klann JG AUID- ORCID: 0000-0003-2043-1601 AD - Harvard Medical School, Boston, MA, United States. FAU - Albers, David AU - Albers D AUID- ORCID: 0000-0002-5369-526X AD - Department of Biomedical Informatics, Columbia University, New York, NY, United States. AD - Anschutz Medical Campus, University of Colorado, Aurora, CO, United States. FAU - Schwartz, Jessica AU - Schwartz J AUID- ORCID: 0000-0002-1457-5724 AD - School of Nursing, Columbia University Medical Center, New York, NY, United States. FAU - Lowenthal, Graham AU - Lowenthal G AUID- ORCID: 0000-0002-5480-0711 AD - Brigham and Women's Hospital, Boston, MA, United States. FAU - Jia, Haomiao AU - Jia H AUID- ORCID: 0000-0002-1391-8190 AD - School of Nursing, Columbia University Medical Center, New York, NY, United States. FAU - Liu, Fang AU - Liu F AUID- ORCID: 0000-0003-2922-4414 AD - Department of Biomedical Informatics, Columbia University, New York, NY, United States. FAU - Cato, Kenrick AU - Cato K AUID- ORCID: 0000-0002-0704-3826 AD - School of Nursing, Columbia University Medical Center, New York, NY, United States. LA - eng SI - ClinicalTrials.gov/NCT03911687 GR - R01 NR016941/NR/NINR NIH HHS/United States PT - Journal Article DEP - 20211210 PL - Canada TA - JMIR Res Protoc JT - JMIR research protocols JID - 101599504 PMC - PMC8709914 OTO - NOTNLM OT - clinical decision support system OT - clinical trial OT - deterioration OT - early warning system OT - natural language processing OT - nursing documentation OT - prediction COIS- Conflicts of Interest: None declared. EDAT- 2021/12/11 06:00 MHDA- 2021/12/11 06:01 PMCR- 2021/12/10 CRDT- 2021/12/10 12:17 PHST- 2021/05/12 00:00 [received] PHST- 2021/09/16 00:00 [accepted] PHST- 2021/09/01 00:00 [revised] PHST- 2021/12/10 12:17 [entrez] PHST- 2021/12/11 06:00 [pubmed] PHST- 2021/12/11 06:01 [medline] PHST- 2021/12/10 00:00 [pmc-release] AID - v10i12e30238 [pii] AID - 10.2196/30238 [doi] PST - epublish SO - JMIR Res Protoc. 2021 Dec 10;10(12):e30238. doi: 10.2196/30238. PMID- 34880080 OWN - NLM STAT- MEDLINE DCOM- 20220725 LR - 20251112 IS - 1469-0756 (Electronic) IS - 0032-5473 (Linking) VI - 98 IP - 1162 DP - 2022 Aug TI - Emerging spectrum of post-COVID-19 syndrome. PG - 633-643 LID - 10.1136/postgradmedj-2020-139585 [doi] AB - 'Post-COVID-19 syndrome' refers to symptoms in the convalescent phase following initial COVID-19 infection. This term encompasses a wide array of presentation involving lungs, heart and the neuromuscular system. Pulmonary manifestations include post-COVID-19 fibrosis, which is akin to post acute respiratory distress syndrome fibrosis and may reflect the permanent damage to the lungs following an initial bout of infection. Cardiovascular system is often involved, and the presentation can be in terms of acute coronary syndrome, myocarditis and heart failure. Clinical manifestations are often varied and non-specific, which entails a detailed workup and a multidisciplinary approach. Post-COVID-19 syndrome adds to the overall disease morbidity and leads to a prolonged hospital stay, greater healthcare utilisation and loss of productivity marring the country's dwindling economy. Thus, it is imperative that post-COVID-19 syndrome be prevented and identified early followed by a prompt treatment. CI - (c) Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Kunal, Shekhar AU - Kunal S AUID- ORCID: 0000-0002-0319-9241 AD - Department of Cardiology, SMS Medical College and Hospital, Jaipur, Rajasthan, India shekhar.kunal09@gmail.com. FAU - Madan, Manu AU - Madan M AD - Department of Pulmonary, Critical Care and Sleep Medicine, All India Institute of Medical Sciences, New Delhi, Delhi, India. FAU - Tarke, Chandrakant AU - Tarke C AD - Department of Pulmonology, Apollo Hospital, Hyderabad, Telangana, India. FAU - Gautam, Dinesh Kumar AU - Gautam DK AD - Department of Cardiology, SMS Medical College and Hospital, Jaipur, Rajasthan, India. FAU - Kinkar, Jiwan Shriram AU - Kinkar JS AD - Department of Neurology, SMS Medical College and Hospital, Jaipur, Rajasthan, India. FAU - Gupta, Kashish AU - Gupta K AD - Department of Medicine, SG Diabetes Centre, Delhi, India. FAU - Agarwal, Ritu AU - Agarwal R AD - Department of Radiodiagnosis, SMS Medical College and Hospital, Jaipur, Rajasthan, India. FAU - Mittal, Shruti AU - Mittal S AD - Department of Radiodiagnosis, Maulana Azad Medical College, New Delhi, India. FAU - Sharma, Shashi Mohan AU - Sharma SM AD - Department of Cardiology, SMS Medical College and Hospital, Jaipur, Rajasthan, India. LA - eng PT - Journal Article PT - Review DEP - 20211208 PL - England TA - Postgrad Med J JT - Postgraduate medical journal JID - 0234135 SB - IM MH - *Acute Coronary Syndrome MH - *COVID-19/complications MH - Fibrosis MH - Humans MH - *Myocarditis/diagnosis/therapy MH - SARS-CoV-2 OTO - NOTNLM OT - COVID-19 OT - myocardial infarction OT - respiratory infections OT - thromboembolism COIS- Competing interests: None declared. EDAT- 2021/12/10 06:00 MHDA- 2022/07/26 06:00 CRDT- 2021/12/09 05:49 PHST- 2020/12/12 00:00 [received] PHST- 2021/11/13 00:00 [accepted] PHST- 2021/12/10 06:00 [pubmed] PHST- 2022/07/26 06:00 [medline] PHST- 2021/12/09 05:49 [entrez] AID - postgradmedj-2020-139585 [pii] AID - 10.1136/postgradmedj-2020-139585 [doi] PST - ppublish SO - Postgrad Med J. 2022 Aug;98(1162):633-643. doi: 10.1136/postgradmedj-2020-139585. Epub 2021 Dec 8. PMID- 34879128 OWN - NLM STAT- MEDLINE DCOM- 20211210 LR - 20211214 IS - 1559-7776 (Electronic) IS - 1559-7768 (Linking) VI - 32 IP - 4 DP - 2021 Dec 15 TI - The Fountain of Youth Will Not Last Forever: End of Life in Patients Receiving Mechanical Circulatory Support. PG - 452-460 LID - 10.4037/aacnacc2021501 [doi] AB - Health care providers face a unique set of decision-making, assessment, and equipment challenges at the end of life of patients supported with a left ventricular assist device. The aim for this article is to assist the multidisciplinary team in caring for patients with a left ventricular assist device in all phases of end-of-life care. This review includes common causes of death for patients with a left ventricular assist device, assessment at end of life, physiological and palliative care considerations, withdrawal of left ventricular assist device support, and equipment considerations. CI - (c)2021 American Association of Critical-Care Nurses. FAU - Johnson, Mary H AU - Johnson MH AD - Mary H. Johnson is VAD Educator, The Christ Hospital, 2123 Auburn Avenue, Suite 115, Cincinnati, OH (mary.johnson@thechristhospital.com). FAU - Bass, Colleen AU - Bass C AD - Colleen Bass is Palliative Care Nurse Practitioner, The Christ Hospital, Cincinnati, Ohio. FAU - Schroeder, Sarah E AU - Schroeder SE AD - Sarah E. Schroeder is VAD Nurse Practitioner and Program Manager, Bryan Heart, Lincoln, Nebraska. LA - eng PT - Journal Article PT - Review PL - United States TA - AACN Adv Crit Care JT - AACN advanced critical care JID - 101269322 MH - Adolescent MH - Death MH - *Heart Failure/therapy MH - *Heart-Assist Devices MH - Humans MH - Palliative Care MH - *Terminal Care OTO - NOTNLM OT - LVAD OT - end of life OT - hospice OT - palliative care OT - ventricular assist device EDAT- 2021/12/09 06:00 MHDA- 2021/12/15 06:00 CRDT- 2021/12/08 17:23 PHST- 2021/12/08 17:23 [entrez] PHST- 2021/12/09 06:00 [pubmed] PHST- 2021/12/15 06:00 [medline] AID - 31627 [pii] AID - 10.4037/aacnacc2021501 [doi] PST - ppublish SO - AACN Adv Crit Care. 2021 Dec 15;32(4):452-460. doi: 10.4037/aacnacc2021501. PMID- 34879126 OWN - NLM STAT- MEDLINE DCOM- 20211210 LR - 20211214 IS - 1559-7776 (Electronic) IS - 1559-7768 (Linking) VI - 32 IP - 4 DP - 2021 Dec 15 TI - Psychological Journey of a Patient With a Ventricular Assist Device: A VAD Coordinator's Perspective. PG - 443-451 LID - 10.4037/aacnacc2021744 [doi] AB - BACKGROUND: A thorough psychosocial assessment is needed during the evaluation of candidacy for ventricular assist device placement to identify potential barriers that would limit success with the device. Ventricular assist device coordinators are generally involved in the psychosocial assessment of the patient, allowing them to provide a more holistic approach to ventricular assist device candidacy during discussions at multidisciplinary meetings. There is a gap in the literature describing the psychological journey of patients after ventricular assist device implantation and the challenges ventricular assist device coordinators face when caring for this complex population. OBJECTIVE: The psychological journey of 3 patients with a ventricular assist device was explored to determine if common themes exist and to describe the experiences faced by the ventricular assist device coordinators with each patient. METHODS: Three patient case scenarios are described, as are the interactions with the patients' ventricular assist device coordinator team members. RESULTS: All 3 case scenarios demonstrate similarities of younger ages, the need of family and social support, and ventricular assist device coordinators who went beyond the call of duty to assist in the successful heart transplantation for 2 cases and the successful decommission of the ventricular assist device in another case. CONCLUSION: The psychosocial needs of patients with a ventricular assist device and ventricular assist device coordinators require ongoing assessment because of the many physical and emotional challenges that arise during the time a patient has an implanted ventricular assist device. CI - (c)2021 American Association of Critical-Care Nurses. FAU - Meehan, Karen AU - Meehan K AD - Karen Meehan is Advanced Practice Nurse, MCS Coordinator, Department of Cardiac Surgery, University of Chicago Medical Center, 5841 S. Maryland Avenue, Suite E500, MC5040, Chicago, IL 60637 (Karen.meehan@uchospitals.edu). FAU - Schroeder, Sarah E AU - Schroeder SE AD - Sarah E. Schroeder is MCS Nurse Practitioner and Program Manager, Division of MCS Therapy, Bryant Heart, Lincoln, Nebraska. FAU - Creighton, Shana AU - Creighton S AD - Shana Creighton is Advanced Practice Nurse, MCS Coordinator, Department of Cardiac Surgery, University of Chicago Medical Center, Chicago, Illinois. FAU - Labuhn, Colleen AU - Labuhn C AD - Colleen Labuhn is Executive Director of the Heart and Vascular Institute, Assistant Director of Advanced Practice Services, and Advanced Practice Nurse, MCS Coordinator, Department of Cardiac Surgery, University of Chicago Medical Center, Chicago, Illinois. LA - eng PT - Journal Article PL - United States TA - AACN Adv Crit Care JT - AACN advanced critical care JID - 101269322 MH - *Heart Failure/therapy MH - *Heart-Assist Devices MH - Humans OTO - NOTNLM OT - VAD coordinator OT - psychological journey OT - ventricular assist device EDAT- 2021/12/09 06:00 MHDA- 2021/12/15 06:00 CRDT- 2021/12/08 17:23 PHST- 2021/12/08 17:23 [entrez] PHST- 2021/12/09 06:00 [pubmed] PHST- 2021/12/15 06:00 [medline] AID - 31625 [pii] AID - 10.4037/aacnacc2021744 [doi] PST - ppublish SO - AACN Adv Crit Care. 2021 Dec 15;32(4):443-451. doi: 10.4037/aacnacc2021744. PMID- 34878987 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220111 IS - 2291-9694 (Print) IS - 2291-9694 (Electronic) IS - 2291-9694 (Linking) VI - 9 IP - 12 DP - 2021 Dec 7 TI - A Smartphone App (AnSim) With Various Types and Forms of Messages Using the Transtheoretical Model for Cardiac Rehabilitation in Patients With Coronary Artery Disease: Development and Usability Study. PG - e23285 LID - 10.2196/23285 [doi] LID - e23285 AB - BACKGROUND: Despite strong evidence of clinical benefit, cardiac rehabilitation (CR) programs are currently underutilized and smartphone-based CR strategies are thought to address this unmet need. However, data regarding the detailed process of development are scarce. OBJECTIVE: This study focused on the development of a smartphone-based, patient-specific, messaging app for patients who have undergone percutaneous coronary intervention (PCI). METHODS: The AnSim app was developed in collaboration with a multidisciplinary team that included cardiologists, psychiatrists, nurses, pharmacists, nutritionists, and rehabilitation doctors and therapists. First, a focus group interview was conducted, and the narratives of the patients were analyzed to identify their needs and preferences. Based on the results, health care experts and clinicians drafted messages into 5 categories: (1) general information regarding cardiovascular health and medications, (2) nutrition, (3) physical activity, (4) destressing, and (5) smoking cessation. In each category, 90 messages were developed according to 3 simplified steps of the transtheoretical model of behavioral change: (1) precontemplation, (2) contemplation and preparation, and (3) action and maintenance. After an internal review and feedback from potential users, a bank of 450 messages was developed. RESULTS: The focus interview was conducted with 8 patients with PCI within 1 year, and 450 messages, including various forms of multimedia, were developed based on the transtheoretical model of behavioral change in each category. Positive feedback was obtained from the potential users (n=458). The mean Likert scale score was 3.95 (SD 0.39) and 3.91 (SD 0.39) for readability and usefulness, respectively, and several messages were refined based on the feedback. Finally, the patient-specific message delivery system was developed according to the baseline characteristics and stages of behavioral change in each participant. CONCLUSIONS: We developed an app (AnSim), which includes a bank of 450 patient-specific messages, that provides various medical information and CR programs regarding coronary heart disease. The detailed process of multidisciplinary collaboration over the course of the study provides a scientific basis for various medical professionals planning smartphone-based clinical research. CI - (c)Jah Yeon Choi, Ji Bak Kim, Sunki Lee, Seo-Joon Lee, Seung Eon Shin, Se Hyun Park, Eun Jin Park, Woohyeun Kim, Jin Oh Na, Cheol Ung Choi, Seung-Woon Rha, Chang Gyu Park, Hong Seog Seo, Jeonghoon Ahn, Hyun-Ghang Jeong, Eung Ju Kim. Originally published in JMIR Medical Informatics (https://medinform.jmir.org), 07.12.2021. FAU - Choi, Jah Yeon AU - Choi JY AUID- ORCID: 0000-0002-6793-4137 AD - Cardiovascular Center, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea. FAU - Kim, Ji Bak AU - Kim JB AUID- ORCID: 0000-0001-6357-3592 AD - Cardiovascular Center, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea. FAU - Lee, Sunki AU - Lee S AUID- ORCID: 0000-0002-5247-7981 AD - Division of Cardiology, Department of Internal Medicine, Hallym University Dongtan Sacred Heart Hospital, Dongtan, Republic of Korea. FAU - Lee, Seo-Joon AU - Lee SJ AUID- ORCID: 0000-0001-5710-6971 AD - Department of Medical Informatics, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. FAU - Shin, Seung Eon AU - Shin SE AUID- ORCID: 0000-0002-9211-9142 AD - Cardiovascular Center, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea. FAU - Park, Se Hyun AU - Park SH AUID- ORCID: 0000-0002-5630-1449 AD - Sports Medical Center, Seoul, Republic of Korea. FAU - Park, Eun Jin AU - Park EJ AUID- ORCID: 0000-0001-6777-3508 AD - Cardiovascular Center, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea. FAU - Kim, Woohyeun AU - Kim W AUID- ORCID: 0000-0002-6939-5958 AD - Cardiovascular Center, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea. FAU - Na, Jin Oh AU - Na JO AUID- ORCID: 0000-0002-5096-4428 AD - Cardiovascular Center, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea. FAU - Choi, Cheol Ung AU - Choi CU AUID- ORCID: 0000-0003-2815-9358 AD - Cardiovascular Center, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea. FAU - Rha, Seung-Woon AU - Rha SW AUID- ORCID: 0000-0001-9456-9852 AD - Cardiovascular Center, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea. FAU - Park, Chang Gyu AU - Park CG AUID- ORCID: 0000-0001-9654-9257 AD - Cardiovascular Center, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea. FAU - Seo, Hong Seog AU - Seo HS AUID- ORCID: 0000-0002-3228-7988 AD - Cardiovascular Center, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea. FAU - Ahn, Jeonghoon AU - Ahn J AUID- ORCID: 0000-0002-0177-0192 AD - Department of Health Convergence, Ewha Womans University, Seoul, Republic of Korea. FAU - Jeong, Hyun-Ghang AU - Jeong HG AUID- ORCID: 0000-0002-0318-5069 AD - Department of Psychiatry, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea. FAU - Kim, Eung Ju AU - Kim EJ AUID- ORCID: 0000-0003-2322-6267 AD - Sports Medical Center, Seoul, Republic of Korea. LA - eng PT - Journal Article DEP - 20211207 PL - Canada TA - JMIR Med Inform JT - JMIR medical informatics JID - 101645109 PMC - PMC8693185 OTO - NOTNLM OT - cardiac rehabilitation OT - coronary heart disease OT - smartphone app COIS- Conflicts of Interest: None declared. EDAT- 2021/12/09 06:00 MHDA- 2021/12/09 06:01 PMCR- 2021/12/07 CRDT- 2021/12/08 17:16 PHST- 2020/08/08 00:00 [received] PHST- 2021/10/10 00:00 [accepted] PHST- 2021/03/27 00:00 [revised] PHST- 2021/12/08 17:16 [entrez] PHST- 2021/12/09 06:00 [pubmed] PHST- 2021/12/09 06:01 [medline] PHST- 2021/12/07 00:00 [pmc-release] AID - v9i12e23285 [pii] AID - 10.2196/23285 [doi] PST - epublish SO - JMIR Med Inform. 2021 Dec 7;9(12):e23285. doi: 10.2196/23285. PMID- 34878118 OWN - NLM STAT- MEDLINE DCOM- 20220818 LR - 20250728 IS - 2058-1742 (Electronic) IS - 2058-1742 (Linking) VI - 8 IP - 5 DP - 2022 Aug 17 TI - Mitral regurgitation management: a systematic review of clinical practice guidelines and recommendations. PG - 481-495 LID - 10.1093/ehjqcco/qcab082 [doi] AB - Multiple guidelines exist for the diagnosis and management of mitral regurgitation (MR), the second most common valvular heart disease in high-income countries, with recommendations that do not always match. We systematically reviewed guidelines on diagnosis and management of MR, highlighting similarities and differences to guide clinical decision-making. We searched national and international guidelines in MEDLINE and EMBASE (1 June 2010 to 1 September 2021), the Guidelines International Network, National Guideline Clearinghouse, National Library for Health Guidelines Finder, Canadian Medical Association Clinical Practice Guidelines Infobase, and websites of relevant organizations. Two reviewers independently screened the abstracts and identified articles of interest. Guidelines that were rigorously developed (as assessed with the Appraisal of Guidelines for Research and Evaluation II instrument) were retained for analysis. Five guidelines were retained. There was consensus on a multidisciplinary approach from the heart team and for the definition and grading of severe primary MR. There was general agreement on the thresholds for intervention in symptomatic and asymptomatic primary MR; however, discrepancies were present. There was agreement on optimization of medical therapy in severe secondary MR and intervention in patients symptomatic despite optimal medical therapy, but no consensus on the choice of intervention (surgical repair/replacement vs. transcatheter approach). Cut-offs for high-risk intervention in MR, risk stratification of progressive MR, and guidance on mixed valvular disease were sparse. CI - (c) The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology. FAU - Galusko, Victor AU - Galusko V AUID- ORCID: 0000-0001-5871-0900 AD - Department of Cardiology, King's College Hospital, London SE5 9RS, UK. FAU - Sekar, Baskar AU - Sekar B AD - Department of Cardiology, Gloucestershire Hospitals NHS Foundation Trust, Gloucester GL1 3NN, UK. FAU - Ricci, Fabrizio AU - Ricci F AUID- ORCID: 0000-0002-1401-6623 AD - Department of Neuroscience, Imaging and Clinical Sciences, Institute of Advanced Biomedical Technologies, G.d'Annunzio University, 66100 Chieti, Italy. AD - Department of Clinical Sciences, Lund University, Jan Waldenstroms gata 35-205, Malmo 22100, Sweden. AD - Department of Cardiology, Casa di Cura Villa Serena, 65013 Citta Sant'Angelo, Pescara, Italy. FAU - Wong, Kit AU - Wong K AD - Department of Cardiology, Barts Heart Centre, Barts Health NHS Trust, West Smithfield, London EC1A 7BE, UK. FAU - Bhattacharyya, Sanjeev AU - Bhattacharyya S AUID- ORCID: 0000-0002-0234-5366 AD - Department of Cardiology, Barts Heart Centre, Barts Health NHS Trust, West Smithfield, London EC1A 7BE, UK. AD - NIHR Barts Biomedical Research Centre, William Harvey Research Institute, Queen Mary University of London, London EC1A 7BE, UK. FAU - Mullen, Michael AU - Mullen M AD - Department of Cardiology, Barts Heart Centre, Barts Health NHS Trust, West Smithfield, London EC1A 7BE, UK. FAU - Gallina, Sabina AU - Gallina S AD - Department of Neuroscience, Imaging and Clinical Sciences, Institute of Advanced Biomedical Technologies, G.d'Annunzio University, 66100 Chieti, Italy. FAU - Ionescu, Adrian AU - Ionescu A AD - Department of Cardiology, Morriston Cardiac Regional Centre, Swansea Bay Health Board, Swansea SA6 6NL, UK. FAU - Khanji, Mohammed Yunus AU - Khanji MY AUID- ORCID: 0000-0002-5903-4454 AD - Department of Cardiology, Barts Heart Centre, Barts Health NHS Trust, West Smithfield, London EC1A 7BE, UK. AD - NIHR Barts Biomedical Research Centre, William Harvey Research Institute, Queen Mary University of London, London EC1A 7BE, UK. AD - Department of Cardiology, Newham University Hospital, Barts Health NHS Trust, Glen Road, London E13 8SL, UK. LA - eng PT - Journal Article PT - Systematic Review PL - England TA - Eur Heart J Qual Care Clin Outcomes JT - European heart journal. Quality of care & clinical outcomes JID - 101677796 SB - IM MH - Canada MH - Clinical Decision-Making MH - Consensus MH - *Heart Valve Diseases MH - Humans MH - *Mitral Valve Insufficiency/diagnosis/surgery OTO - NOTNLM OT - Guidelines OT - Mitral regurgitation OT - Mitral valve OT - Systematic review OT - Valvular heart disease EDAT- 2021/12/09 06:00 MHDA- 2022/08/19 06:00 CRDT- 2021/12/08 09:21 PHST- 2021/11/01 00:00 [received] PHST- 2021/11/08 00:00 [accepted] PHST- 2021/12/09 06:00 [pubmed] PHST- 2022/08/19 06:00 [medline] PHST- 2021/12/08 09:21 [entrez] AID - 6456346 [pii] AID - 10.1093/ehjqcco/qcab082 [doi] PST - ppublish SO - Eur Heart J Qual Care Clin Outcomes. 2022 Aug 17;8(5):481-495. doi: 10.1093/ehjqcco/qcab082. PMID- 34873012 OWN - NLM STAT- MEDLINE DCOM- 20220307 LR - 20240929 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 11 IP - 12 DP - 2021 Dec 6 TI - Transcatheter aortic valve implantation versus surgical aortic valve replacement in patients with severe aortic stenosis: a systematic review and meta-analysis. PG - e054222 LID - 10.1136/bmjopen-2021-054222 [doi] LID - e054222 AB - OBJECTIVES: Patients undergoing surgery for severe aortic stenosis (SAS) can be treated with either transcatheter aortic valve implantation (TAVI) or surgical aortic valve replacement (SAVR). The choice of procedure depends on several factors, including the clinical judgement of the heart team and patient preferences, which are captured by actively informing and involving patients in a process of shared decision making (SDM). We synthesised the most up-to-date and accessible evidence on the benefits and risks that may be associated with TAVI versus SAVR to support SDM in this highly personalised decision-making process. DESIGN: Systematic review and meta-analysis. DATA SOURCES: MEDLINE (Ovid), Embase (Ovid) and the Cochrane Central Register of Controlled Trials (CENTRAL; Wiley) were searched from January 2000 to August 2020 with no language restrictions. Reference lists of included studies were searched to identify additional studies. ELIGIBILITY CRITERIA: Randomised controlled trials (RCTs) that compared TAVI versus SAVR in patients with SAS and reported on all-cause or cardiovascular mortality, length of stay in intensive care unit or hospital, valve durability, rehospitalisation/reintervention, stroke (any stroke or major/disabling stroke), myocardial infarction, major vascular complications, major bleeding, permanent pacemaker (PPM) implantation, new-onset or worsening atrial fibrillation (NOW-AF), endocarditis, acute kidney injury (AKI), recovery time or pain were included. DATA EXTRACTION AND SYNTHESIS: Two independent reviewers were involved in data extraction and risk of bias (ROB) assessment using the Cochrane tool (one reviewer extracted/assessed the data, and the second reviewer checked it). Dichotomous data were pooled using the Mantel-Haenszel method with random-effects to generate a risk ratio (RR) with 95% CI. Continuous data were pooled using the inverse-variance method with random-effects and expressed as a mean difference (MD) with 95% CI. Heterogeneity was assessed using the I(2) statistic. RESULTS: 8969 records were retrieved and nine RCTs (61 records) were ultimately included (n=8818 participants). Two RCTs recruited high-risk patients, two RCTs recruited intermediate-risk patients, two RCTs recruited low-risk patients, one RCT recruited high-risk (>/=70 years) or any-risk (>/=80 years) patients; and two RCTs recruited all-risk or 'operable' patients. While there was no overall change in the risk of dying from any cause (30 day: RR 0.89, 95% CI 0.65 to 1.22; /=18 years of age who completed a visit in the University of Michigan Post Intensive Cardiac Care Outpatient Long-Term Outreach (PICCOLO) Clinic from July 2018 to May 2020. RESULTS: One hundred and six CICU survivors were referred. Of these 12 chose to follow-up with long term care providers. A total of 70 of the remaining 94 (74%) completed a visit. The median age was 65 (54-72) years, 71.4% were male, and 85.7% were Caucasian. The median number of pharmacist interventions at each visit was 4 (3-5), all patients had at least 1 intervention. Interventions included medication dose adjustment (n = 46); GDMT optimization (n = 42); medication change (n = 18); medication addition (n = 23) and cessation (n = 21); lab monitoring (n = 97); refill assistance (n = 16); pillbox provision (n = 8); and medication cost assistance (n = 8). CONCLUSIONS: Pharmacist led interventions in a post CICU clinic resulted in medication changes to optimize therapy, increased laboratory monitoring, medication cost savings for patients, and interventions to facilitate GDMT adherence. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - Adie, Sarah K AU - Adie SK AD - Department of Clinical Pharmacy, University of Michigan, Ann Arbor, MI, United States. Electronic address: adies@med.umcih.edu. FAU - Thompson, Amy N AU - Thompson AN AD - Department of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, MI, United States. FAU - Konerman, Matthew C AU - Konerman MC AD - Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, United States. FAU - Shea, Michael J AU - Shea MJ AD - Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, United States. FAU - Thomas, Michael P AU - Thomas MP AD - Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, United States. FAU - Thompson, Andrea D AU - Thompson AD AD - Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, United States. LA - eng PT - Journal Article DEP - 20211203 PL - United States TA - Heart Lung JT - Heart & lung : the journal of critical care JID - 0330057 SB - IM MH - Aged MH - Critical Care MH - Female MH - Guideline Adherence MH - Humans MH - *Intensive Care Units MH - Male MH - *Pharmacists MH - Retrospective Studies OTO - NOTNLM OT - Cardiac intensive care OT - Guideline-directed medical therapy OT - Multidisciplinary OT - Pharmacist OT - Post-ICU EDAT- 2021/12/07 06:00 MHDA- 2022/05/03 06:00 CRDT- 2021/12/06 20:26 PHST- 2021/08/31 00:00 [received] PHST- 2021/11/19 00:00 [revised] PHST- 2021/11/23 00:00 [accepted] PHST- 2021/12/07 06:00 [pubmed] PHST- 2022/05/03 06:00 [medline] PHST- 2021/12/06 20:26 [entrez] AID - S0147-9563(21)00288-0 [pii] AID - 10.1016/j.hrtlng.2021.11.010 [doi] PST - ppublish SO - Heart Lung. 2022 Mar-Apr;52:48-51. doi: 10.1016/j.hrtlng.2021.11.010. Epub 2021 Dec 3. PMID- 34871480 OWN - NLM STAT- MEDLINE DCOM- 20220421 LR - 20240825 IS - 2005-6648 (Electronic) IS - 1226-3303 (Print) IS - 1226-3303 (Linking) VI - 37 IP - 2 DP - 2022 Mar TI - Clinical outcome in patients with end-stage heart failure who underwent continuous-flow left ventricular assist devices in a single center. PG - 340-349 LID - 10.3904/kjim.2021.088 [doi] AB - BACKGROUND/AIMS: The continuous flow left ventricular assist device (cf-LVAD) has improved the survival of chronic end-stage heart failure (HF) patients. Here we describe our clinical experience of the initial 50 LVAD patients from a single center. METHODS: A total of 50 patients underwent LVAD implantation as bridge to transplantation (BTT; n = 28, 56%), bridge to candidacy (BTC; n = 2, 4%), or as destination therapy (DT; n = 20, 40%) from 2012 to 2019. Pre-implant characteristics and clinical outcomes were compared between BTT/BTC and DT. RESULTS: The median age of patients was 67 years (range, 59 to 73). Men were more likely to receive LVAD (76% vs. 24%) than women. DT patients were older, had smaller body surface area, and worse laboratory profiles than BTT/BTC patients. There was no in-hospital mortality. During an average of 14 months (range, 8 to 23), the all-cause mortality was 22%. The first-year survival was 86 and 90% in BTT/BTC and DT groups, respectively. Hemorrhagic stroke was the most common cause (27%) of death. In the BTT/BTC group, 22 patients successfully underwent heart transplantation during median duration of 10 months (range, 7 to 14). The most common post-LVAD complication during the first year of LVAD implantation was major bleeding (44%). A significant proportion (76%) of patients experienced rehospitalization with gastrointestinal bleeding as the most common cause. CONCLUSION: We describe short-term clinical outcome of LVAD patients from a single center for the first time in Korea. With the newer generation LVAD and a dedicated team approach, improved clinical outcomes of LVAD for end-stage HF are expected. FAU - Park, Yoonjee AU - Park Y AD - Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Kim, Darae AU - Kim D AD - Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Yang, Jeong Hoon AU - Yang JH AD - Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. AD - Department of Critical Care Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Cho, Yang Hyun AU - Cho YH AD - Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Choi, Jin-Oh AU - Choi JO AD - Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Jeon, Eun-Seok AU - Jeon ES AD - Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. LA - eng GR - Ministry of Science and ICT/ GR - Ministry of Trade, Industry and Energy/ GR - Ministry of Health and Welfare/ GR - Ministry of Food and Drug Safety/ GR - 1711138313/Korea Medical Device Development Fund/ GR - KMDF_PR_20200901_0159/Korea Medical Device Development Fund/ PT - Journal Article DEP - 20211207 PL - Korea (South) TA - Korean J Intern Med JT - The Korean journal of internal medicine JID - 8712418 SB - IM MH - Aged MH - Female MH - *Heart Failure/diagnosis/therapy MH - *Heart Transplantation MH - *Heart-Assist Devices MH - Humans MH - Male MH - Middle Aged MH - Republic of Korea MH - Retrospective Studies MH - Treatment Outcome PMC - PMC8925944 OTO - NOTNLM OT - Heart failure OT - Left ventricular assist device OT - Ventricular assist device COIS- No potential conflict of interest relevant to this article was reported. EDAT- 2021/12/07 06:00 MHDA- 2022/04/22 06:00 PMCR- 2022/03/01 CRDT- 2021/12/06 18:34 PHST- 2021/02/15 00:00 [received] PHST- 2021/03/19 00:00 [accepted] PHST- 2021/12/07 06:00 [pubmed] PHST- 2022/04/22 06:00 [medline] PHST- 2021/12/06 18:34 [entrez] PHST- 2022/03/01 00:00 [pmc-release] AID - kjim.2021.088 [pii] AID - kjim-2021-088 [pii] AID - 10.3904/kjim.2021.088 [doi] PST - ppublish SO - Korean J Intern Med. 2022 Mar;37(2):340-349. doi: 10.3904/kjim.2021.088. Epub 2021 Dec 7. PMID- 34869628 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20211207 IS - 2297-055X (Print) IS - 2297-055X (Electronic) IS - 2297-055X (Linking) VI - 8 DP - 2021 TI - Interventional Treatment of Access Site Complications During Transfemoral TAVI: A Single Center Experience. PG - 725079 LID - 10.3389/fcvm.2021.725079 [doi] LID - 725079 AB - Introduction: Transcatheter aortic valve implantation (TAVI) has rapidly developed over the last decade and is nowadays the treatment of choice in the elderly patients irrespective of surgical risk. The outcome of these patients is mainly determined not only by the interventional procedure itself, but also by its complications. Material and Methods: We analyzed the outcome and procedural events of transfemoral TAVI procedures performed per year at our institution. The mean age of these patients is 79.2 years and 49% are female. All the patients underwent duplex ultrasonography of the iliac arteries and inguinal vessels before the procedure and CT of the aorta and iliac arteries. Results: Transfemoral access route is associated with a number of challenges and complications, especially in the patients suffering from peripheral artery disease (PAD). The rate of vascular complications at our center was 2.76% (19/689). Typical vascular complications (VC) include bleeding and pseudoaneurysms at the puncture site, acute or subacute occlusion of the access vessel, and dissection or perforation of the iliac vessels. In addition, there is the need for primary PTA of the access pathway in the presence of additional PAD of the common femoral artery (CFA) and iliac vessels. Balloon angioplasty, implantation of covered and uncovered stents, lithoplasty, and ultrasound-guided thrombin injection are available to treat the described issues. Conclusion: Interventional therapy of access vessels can preoperatively enable the transfemoral approach and successfully treat post-operative VC in most of the cases. Training the heart team to address these issues is a key focus, and an interventional vascular specialist should be part of this team. CI - Copyright (c) 2021 Thieme, Moebius-Winkler, Franz, Baez, Schulze, Butter, Edlinger and Kretzschmar. FAU - Thieme, Marcus AU - Thieme M AD - Clinic for Internal Medicine I, University Hospital Jena, Jena, Germany. AD - REGIOMED Vascular Center, Sonneberg, Germany. FAU - Moebius-Winkler, Sven AU - Moebius-Winkler S AD - Clinic for Internal Medicine I, University Hospital Jena, Jena, Germany. FAU - Franz, Marcus AU - Franz M AD - Clinic for Internal Medicine I, University Hospital Jena, Jena, Germany. FAU - Baez, Laura AU - Baez L AD - Clinic for Internal Medicine I, University Hospital Jena, Jena, Germany. FAU - Schulze, Christian P AU - Schulze CP AD - Clinic for Internal Medicine I, University Hospital Jena, Jena, Germany. FAU - Butter, Christian AU - Butter C AD - Department of Cardiology, Heart Center Brandenburg, Immanuel Klinikum Bernau, Bernau, Germany. AD - Brandenburg Medical School Theodor Fontane, Neuruppin, Germany. FAU - Edlinger, Christoph AU - Edlinger C AD - Department of Cardiology, Heart Center Brandenburg, Immanuel Klinikum Bernau, Bernau, Germany. AD - Brandenburg Medical School Theodor Fontane, Neuruppin, Germany. FAU - Kretzschmar, Daniel AU - Kretzschmar D AD - Clinic for Internal Medicine I, University Hospital Jena, Jena, Germany. LA - eng PT - Journal Article DEP - 20211115 PL - Switzerland TA - Front Cardiovasc Med JT - Frontiers in cardiovascular medicine JID - 101653388 PMC - PMC8634400 OTO - NOTNLM OT - PAD-peripheral arterial disease OT - TAVI-transcatheter aortic valve implantation OT - access site bleeding OT - access site complication (ASC) OT - dissection OT - interventional treatment OT - lithoplasty OT - pseudoaneurysms COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/12/07 06:00 MHDA- 2021/12/07 06:01 PMCR- 2021/01/01 CRDT- 2021/12/06 09:22 PHST- 2021/06/14 00:00 [received] PHST- 2021/10/08 00:00 [accepted] PHST- 2021/12/06 09:22 [entrez] PHST- 2021/12/07 06:00 [pubmed] PHST- 2021/12/07 06:01 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - 10.3389/fcvm.2021.725079 [doi] PST - epublish SO - Front Cardiovasc Med. 2021 Nov 15;8:725079. doi: 10.3389/fcvm.2021.725079. eCollection 2021. PMID- 34864261 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231108 IS - 2210-2612 (Print) IS - 2210-2612 (Electronic) IS - 2210-2612 (Linking) VI - 89 DP - 2021 Dec TI - Unclear retroperitoneal tumors, an interdisciplinary challenge - A case report and review of the literature. PG - 106634 LID - S2210-2612(21)01136-6 [pii] LID - 10.1016/j.ijscr.2021.106634 [doi] LID - 106634 AB - INTRODUCTION AND IMPORTANCE: Unclear retroperitoneal tumors impose major challenges for clinicians. Tumors can originate primarily from retroperitoneal tissue or secondarily invade into the retroperitoneum. While benign lesions also occur, malignant tumors are far more common. Clinical presentation depends on replacement or invasion of other organs and is therefore highly variable. The heterogeneous tumor composition makes a definitive preoperative diagnosis difficult. Surgical resection is the gold standard for treatment but often proves challenging due to frequent involvement of large retroperitoneal vessels. CASE PRESENTATION: We present the case of a 70-year old woman diagnosed with a large, unclear retroperitoneal tumor. Initial clinical symptoms were increasing dyspnea and dysphagia in our clinic. Gastroenterologic and cardiologic workup was unremarkable. Computed Tomography (CT) revealed a large retroperitoneal mass in the right upper abdomen with severe displacement of the inferior vena cava and renal veins. The patient was scheduled for primary tumor resection. The procedure was challenging due to the vessel involvement and large blood pressure alterations during tumor mobilization. The post-op pathologic workup then revealed the rare finding of a completely resected paraganglioma. The post-surgical course was uneventful. One year after diagnosis, the patient is relapse-free. CLINICAL DISCUSSION: Among retroperitoneal tumors, paragangliomas and pheochromocytomas are rare tumor entities. Asymptomatic, sporadic disease is hard to identify preoperatively and can cause unexpected complications in the OR. An experienced team is crucial in achieving best short- and long-term outcomes. CONCLUSION: This case impressively shows the challenges of retroperitoneal tumors and the importance of interdisciplinary work in these cases. CI - Copyright (c) 2021 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Traub, Benno AU - Traub B AD - Department of General and visceral surgery, University Hospital of Ulm, Albert-Einstein Allee 23, 89081 Ulm, Germany. Electronic address: Benno.traub@uniklinik-ulm.de. FAU - Haggenmuller, Benedikt AU - Haggenmuller B AD - Department of Radiology, University Hospital of Ulm, Albert-Einstein Allee 23, 89081 Ulm, Germany. FAU - Baumann, Lisa AU - Baumann L AD - Department of Pathology, University Hospital of Ulm, Albert-Einstein Allee 23, 89081 Ulm, Germany. FAU - Lemke, Johannes AU - Lemke J AD - Department of General and visceral surgery, University Hospital of Ulm, Albert-Einstein Allee 23, 89081 Ulm, Germany. FAU - Henne-Bruns, Doris AU - Henne-Bruns D AD - Department of General and visceral surgery, University Hospital of Ulm, Albert-Einstein Allee 23, 89081 Ulm, Germany. FAU - Wittau, Mathias AU - Wittau M AD - Department of General and visceral surgery, University Hospital of Ulm, Albert-Einstein Allee 23, 89081 Ulm, Germany. LA - eng PT - Journal Article DEP - 20211125 PL - United States TA - Int J Surg Case Rep JT - International journal of surgery case reports JID - 101529872 PMC - PMC8645916 OTO - NOTNLM OT - Case report OT - PPGL OT - Paraganglioma OT - Pheochromocytoma OT - Retroperitoneal tumor OT - Surgery COIS- The authors declare no conflicts of interest. EDAT- 2021/12/06 06:00 MHDA- 2021/12/06 06:01 PMCR- 2021/11/25 CRDT- 2021/12/05 21:08 PHST- 2021/10/14 00:00 [received] PHST- 2021/11/21 00:00 [revised] PHST- 2021/11/21 00:00 [accepted] PHST- 2021/12/06 06:00 [pubmed] PHST- 2021/12/06 06:01 [medline] PHST- 2021/12/05 21:08 [entrez] PHST- 2021/11/25 00:00 [pmc-release] AID - S2210-2612(21)01136-6 [pii] AID - 106634 [pii] AID - 10.1016/j.ijscr.2021.106634 [doi] PST - ppublish SO - Int J Surg Case Rep. 2021 Dec;89:106634. doi: 10.1016/j.ijscr.2021.106634. Epub 2021 Nov 25. PMID- 34862134 OWN - NLM STAT- MEDLINE DCOM- 20220328 LR - 20220328 IS - 1096-7206 (Electronic) IS - 1096-7192 (Linking) VI - 134 IP - 4 DP - 2021 Dec TI - Pediatric single large-scale mtDNA deletion syndromes: The power of patient reported outcomes. PG - 301-308 LID - S1096-7192(21)00822-2 [pii] LID - 10.1016/j.ymgme.2021.11.004 [doi] AB - There is a limited understanding of system-level clinical outcomes and interventions associated with single large-scale mitochondrial DNA deletion syndromes (SLSMDS). Additionally, no research exists that describes patient reported outcomes (PROs) of children with SLSMDS. A global and observational registry was established to understand the multi-systemic course of SLSMDS and track clinical outcomes. The development and design of the registry is described. Demographic characteristics, history and diagnoses, and system level prevalence of problems and interventions are reported for 42 children. System level problems and interventions include information on the following body systems: audiology, cardiac, endocrine, gastrointestinal (including pancreatic and hepatobiliary system), hematological, metabolic, neurological (including autonomic, mobility, & learning), ophthalmic, psychiatric, renal, and respiratory. Results emphasize the need of patient registries and suggest that the diagnostic odyssey and burden of disease for children with SLSMDS is significant. System-level findings may help families and clinical providers with diagnosis, prognostication, and treatment. A multidisciplinary team of clinical experts with a central coordinating specialist for children with SLSMDS is recommended. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - Reynolds, Elizabeth AU - Reynolds E AD - The Champ Foundation, 4711 Hope Valley Road 4F PMB 1171, Durham, NC 27707, United States of America. Electronic address: elizabeth.reynolds@thechampfoundation.org. FAU - Byrne, Matthew AU - Byrne M AD - University of Cincinnati College of Medicine, 3230 Eden Ave, Cincinnati, OH 45267, United States of America. FAU - Ganetzky, Rebecca AU - Ganetzky R AD - Department of Pediatrics, The Perelman School of Medicine, University of Pennsylvania, 3400 Civic Center Blvd, Philadelphia, PA 19104, United States of America; Mitochondrial Medicine Frontier Program, Division of Human Genetics, Children's Hospital of Philadelphia, 3401 Civic Center Blvd, Philadelphia, PA 19104, United States of America. Electronic address: GanetzkyR@chop.edu. FAU - Parikh, Sumit AU - Parikh S AD - Mitochondrial Medicine Center, Neurosciences Institute, 9500 Euclid Avenue Cleveland, OH 44195, United States of America. Electronic address: parikhs@ccf.org. LA - eng PT - Journal Article DEP - 20211114 PL - United States TA - Mol Genet Metab JT - Molecular genetics and metabolism JID - 9805456 RN - VLCAD deficiency SB - IM MH - Adolescent MH - Child MH - Child, Preschool MH - Congenital Bone Marrow Failure Syndromes/*complications/diagnosis/therapy MH - Female MH - Humans MH - Infant MH - Infant, Newborn MH - Kearns-Sayre Syndrome/*complications/diagnosis/therapy MH - Lipid Metabolism, Inborn Errors/*complications/diagnosis/therapy MH - Male MH - Mitochondrial Diseases/*complications/diagnosis/therapy MH - Muscular Diseases/*complications/diagnosis/therapy MH - *Patient Reported Outcome Measures OTO - NOTNLM OT - Kearns-Sayre syndrome OT - Pearson syndrome OT - Rare disease registry OT - Single large-scale mitochondrial deletion syndromes OT - mtDNA COIS- Declaration of Competing Interest The Champ Foundation is the financial sponsor of the Champ Foundation Registry. The Champ Foundation is a non-profit organization dedicated to supporting research to find treatment and a cure for SLSMDS. The Champ Foundation was founded in 2015 by Jeff and Elizabeth Reynolds. Elizabeth Reynolds is a co-author of this paper. Dr. Matthew Byrne sits on the Science Advisory Board to The Champ Foundation. Dr. Rebecca Ganetzky declares that she receives consulting fees from Minovia Therapeutics, served an advisory role in the development of the CFR and sits on the Scientific Advisory Board to The Champ Foundation. Dr. Sumit Parikh sits on the Science Advisory Board to The Champ Foundation and is the principal investigator on the Champ Foundation Registry. EDAT- 2021/12/05 06:00 MHDA- 2022/03/29 06:00 CRDT- 2021/12/04 05:34 PHST- 2021/07/19 00:00 [received] PHST- 2021/11/08 00:00 [revised] PHST- 2021/11/09 00:00 [accepted] PHST- 2021/12/05 06:00 [pubmed] PHST- 2022/03/29 06:00 [medline] PHST- 2021/12/04 05:34 [entrez] AID - S1096-7192(21)00822-2 [pii] AID - 10.1016/j.ymgme.2021.11.004 [doi] PST - ppublish SO - Mol Genet Metab. 2021 Dec;134(4):301-308. doi: 10.1016/j.ymgme.2021.11.004. Epub 2021 Nov 14. PMID- 34861044 OWN - NLM STAT- MEDLINE DCOM- 20220307 LR - 20241219 IS - 1897-4279 (Electronic) IS - 0022-9032 (Linking) VI - 79 IP - 12 DP - 2021 TI - Mechanical circulatory support. An expert opinion of the Association of Intensive Cardiac Care and the Association of Cardiovascular Interventions of the Polish Cardiac Society. PG - 1399-1410 LID - 10.33963/KP.a2021.0169 [doi] AB - Mechanical circulatory support (MCS) methods are used in patients with both acute and chronic heart failure, who have exhausted other options for pharmacological or surgical treatments. The purpose of their use is to support, partially or completely, the failed ventricles and ensure adequate organ perfusion, which allows patients to restore full cardiovascular capacity, prolonging their life and effectively improving its quality. The three most popular devices include an intra-aortic balloon pump (IABP), percutaneous assist devices (including Impella, TandemHeart), and venoarterial extracorporeal membrane oxygenation (VA-ECMO). A multidisciplinary approach with the special participation of the Heart Team is required to determine the proper MCS strategy, the choice of the supporting method, and the time of its use. The studies published so far do not allow us to determine which MCS method is the safest and the most effective. Thus, the site experience and accessibility of the method seem to matter most today. MCS finds particular application in patients with acute coronary syndromes complicated by refractory cardiogenic shock, as well as in patients with acute heart failure of the high potential for reversibility. It can also serve as a backup for percutaneous coronary interventions of high risk (complex and high-risk indicated percutaneous coronary intervention [PCI], complex and high-risk indicated PCI [CHIP]). The use of appropriate supportive drugs, precise hemodynamic and echocardiographic monitoring, as well as optimal non-invasive or mechanical ventilation, are extremely important in the management of a patient with MCS. The most serious complications of MCS include bleeding, thromboembolic events, as well as infections, and hemolysis. FAU - Tycinska, Agnieszka AU - Tycinska A AD - Department of Cardiology, Medical University of Bialystok, Bialystok, Poland. agnieszka.tycinska@gmail.com. FAU - Grygier, Marek AU - Grygier M AD - 1st Department of Cardiology, Poznan University of Medical Sciences, Poznan, Poland. FAU - Biegus, Jan AU - Biegus J AD - Institute of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland. FAU - Czarnik, Tomasz AU - Czarnik T AD - Department of Anesthesiology and Intensive Care, Institute of Medical Sciences, University of Opole, Opole, Poland. FAU - Dabrowski, Maciej AU - Dabrowski M AD - Department of Interventional Cardiology and Angiology, National Institute of Cardiology, Warszawa, Poland. FAU - Depukat, Rafal AU - Depukat R AD - Department of Anesthesiology and Intensive Care, University Hospital, Krakow, Poland. FAU - Gierlotka, Marek AU - Gierlotka M AD - Department of Cardiology, Institute of Medical Sciences, University of Opole, Opole, Poland. FAU - Gil, Monika AU - Gil M AD - Department of Cardiology, Medical University of Bialystok, Bialystok, Poland. FAU - Hawranek, Michal AU - Hawranek M AD - 3rd Department of Cardiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland. FAU - Hirnle, Tomasz AU - Hirnle T AD - Department of Cardiac Surgery, Medical University of Bialystok, Bialystok, Poland. FAU - Jemielity, Marek AU - Jemielity M AD - Department of Cardiac Surgery and Transplantology, Poznan University of Medical Sciences, Poznan, Poland. FAU - Kapelak, Boguslaw AU - Kapelak B AD - John Paul II Hospital, Krakow, Poland. AD - Department of Cardiovascular Surgery and Transplantology, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland. FAU - Kralisz, Pawel AU - Kralisz P AD - Department of Invasive Cardiology, Medical University of Bialystok, Bialystok, Poland. FAU - Kuliczkowski, Wiktor AU - Kuliczkowski W AD - Institute of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland. FAU - Kusmierczyk, Mariusz AU - Kusmierczyk M AD - National Institute of Cardiology, Warszawa, Poland. FAU - Ligowski, Marcin AU - Ligowski M AD - Department of Cardiac Surgery and Transplantology, Poznan University of Medical Sciences, Poznan, Poland. FAU - Lopatowska, Paulina AU - Lopatowska P AD - Department of Cardiology, Medical University of Bialystok, Bialystok, Poland. FAU - Puslecki, Mateusz AU - Puslecki M AD - Department of Cardiac Surgery and Transplantology, Poznan University of Medical Sciences, Poznan, Poland. AD - Department of Medical Rescue, Poznan University of Medical Sciences, Poznan, Poland. FAU - Swiatkowski, Andrzej AU - Swiatkowski A AD - Intensive Cardiac Care Unit, 1st Department of Cardiology and Angiology, Silesian Center of Heart Diseases, Zabrze, Poland. FAU - Trzeciak, Przemyslaw AU - Trzeciak P AD - 3rd Department of Cardiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland. FAU - Zawislak, Barbara AU - Zawislak B AD - Intensive Cardiac Care Unit, University Hospital, Krakow, Poland. FAU - Zembala, Michal AU - Zembala M AD - Department of Cardiac Surgery, Heart and Lung Transplantation and Mechanical Circulatory Support, Silesian Center For Heart Diseases, Zabrze, Poland. AD - Pomeranian Medical University, Szczecin, Poland. FAU - Zymlinski, Robert AU - Zymlinski R AD - Institute of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland. LA - eng PT - Journal Article DEP - 20211203 PL - Poland TA - Kardiol Pol JT - Kardiologia polska JID - 0376352 SB - IM MH - *Heart-Assist Devices/adverse effects MH - Humans MH - Intra-Aortic Balloon Pumping/adverse effects/methods MH - *Percutaneous Coronary Intervention/adverse effects MH - Poland MH - Shock, Cardiogenic/therapy OTO - NOTNLM OT - hemodynamic and echocardiographic monitoring OT - indications and complications OT - mechanical circulatory support-type and extension OT - multidisciplinary approach OT - ventilation and pharmacotherapy EDAT- 2021/12/04 06:00 MHDA- 2022/03/08 06:00 CRDT- 2021/12/03 17:33 PHST- 2021/12/03 00:00 [received] PHST- 2021/12/03 00:00 [accepted] PHST- 2021/12/04 06:00 [pubmed] PHST- 2022/03/08 06:00 [medline] PHST- 2021/12/03 17:33 [entrez] AID - VM/OJS/J/87250 [pii] AID - 10.33963/KP.a2021.0169 [doi] PST - ppublish SO - Kardiol Pol. 2021;79(12):1399-1410. doi: 10.33963/KP.a2021.0169. Epub 2021 Dec 3. PMID- 34857720 OWN - NLM STAT- MEDLINE DCOM- 20220429 LR - 20220429 IS - 1531-7080 (Electronic) IS - 0268-4705 (Linking) VI - 37 IP - 1 DP - 2022 Jan 1 TI - The systemic right ventricle in adult congenital heart disease: why is it still such a challenge and is there any hope on the horizon? PG - 123-129 LID - 10.1097/HCO.0000000000000933 [doi] AB - PURPOSE OF REVIEW: Adult congenital heart disease patients with systemic right ventricle comprise a distinctly clinically challenging group of patients with increased morbidity and mortality. This article aims to review the different subgroups, most common complications and different treatment strategies. RECENT FINDINGS: Most commons long-term complications include heart failure and arrhythmias. Heart failure medical therapy treatments include several new agents, which show promise in systemic right ventricle patients. In addition, interventional therapies to mitigate atrioventricular valve regurgitation, baffle/conduit stenosis are discussed. Furthermore, several electrophysiological approaches to manage tachyarrhythmias as well as bradycardias are discussed. There is ongoing excitement on the new medical as well as interventional therapies that could provide benefit in additional to standard goal-directed medical therapy. SUMMARY: There is an array of medications as well as interventions aimed to treat patients with systemic right ventricle with limited benefits. A multidisciplinary approach with a prudent combination of such therapies to maximize benefit is imperative. This article reviews the data supporting such therapies. CI - Copyright (c) 2021 Wolters Kluwer Health, Inc. All rights reserved. FAU - Lluri, Gentian AU - Lluri G AD - Ahmanson/UCLA Adult Congenital Heart Disease Center, University of California Los Angeles, Los Angeles, California, USA. FAU - Aboulhosn, Jamil AU - Aboulhosn J LA - eng PT - Journal Article PT - Review PL - United States TA - Curr Opin Cardiol JT - Current opinion in cardiology JID - 8608087 SB - IM MH - Adult MH - Arrhythmias, Cardiac MH - *Heart Defects, Congenital/complications/therapy MH - *Heart Failure/etiology/therapy MH - Heart Ventricles MH - Humans EDAT- 2021/12/04 06:00 MHDA- 2022/04/30 06:00 CRDT- 2021/12/03 06:13 PHST- 2021/12/03 06:13 [entrez] PHST- 2021/12/04 06:00 [pubmed] PHST- 2022/04/30 06:00 [medline] AID - 00001573-202201000-00019 [pii] AID - 10.1097/HCO.0000000000000933 [doi] PST - ppublish SO - Curr Opin Cardiol. 2022 Jan 1;37(1):123-129. doi: 10.1097/HCO.0000000000000933. PMID- 34857431 OWN - NLM STAT- MEDLINE DCOM- 20220816 LR - 20250728 IS - 1876-4738 (Electronic) IS - 0914-5087 (Linking) VI - 80 IP - 4 DP - 2022 Oct TI - Comprehensive cardiac rehabilitation program for peripheral arterial diseases. PG - 303-305 LID - S0914-5087(21)00322-1 [pii] LID - 10.1016/j.jjcc.2021.11.011 [doi] AB - Peripheral arterial disease (PAD) is a phenotype of atherosclerotic disease often associated with cerebrovascular or coronary artery disease. The incidence of cardiovascular events in patients with PAD is 5.4% per year, which is higher than that of cerebrovascular or coronary artery disease. The most useful screening method for PAD is the ankle brachial pressure index (ABI). The ABI should be measured in (1) all patients with lower limb symptoms such as claudication, (2) all patients aged 65 years and over, and (3) those aged 50 to 65 years who have risk factors such as smoking and diabetes mellitus. PAD is diagnosed if the ABI is <0.9. A comprehensive cardiac rehabilitation program includes complete smoking cessation, blood pressure control with antihypertensive medications and salt reduction for hypertension, glycemic control for diabetes mellitus, and appropriate medications such as antiplatelet agents and statins. A multidisciplinary team approach is effective in comprehensive cardiac rehabilitation for patients with PAD, even those with critical limb ischemia (CLI). Exercise therapy is a crucial and essential treatment for PAD, except in CLI. Exercise therapy is contraindicated in patients with acute arterial occlusion and CLI with infection. PAD is often associated with other atherosclerotic diseases; the patient should be monitored for ischemic heart disease during the initial exercise stress test using the Gardner treadmill protocol. Supervised exercise therapy is highly recommended (Class I, Level of Evidence A). Alternatively, a home-based exercise program is feasible (Class IIa, Level of Evidence A). The exercise type (treadmill, track walking, ergometer), frequency (3 to 5 days per week), intensity (speed and incline), and duration (30 minutes) are determined based on the exercise stress test results for each patient. Exercise should be continued at least 3 times a week for at least 12 weeks. Cilostazol is highly recommended (Class I, Level of Evidence A). CI - Copyright (c) 2021. Published by Elsevier Ltd. FAU - Yasu, Takanori AU - Yasu T AD - Department of Cardiovascular Medicine & Nephrology, Dokkyo Medical University. Electronic address: tyasu@dokkyomed.ac.jp. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20211129 PL - Netherlands TA - J Cardiol JT - Journal of cardiology JID - 8804703 SB - IM MH - Ankle Brachial Index/adverse effects MH - *Cardiac Rehabilitation MH - *Coronary Artery Disease/complications MH - Humans MH - Intermittent Claudication/etiology/therapy MH - *Peripheral Arterial Disease/complications MH - Walking OTO - NOTNLM OT - Ankle brachial pressure index OT - Exercise OT - Multidisciplinary team approach OT - Treadmill test EDAT- 2021/12/04 06:00 MHDA- 2022/08/17 06:00 CRDT- 2021/12/03 05:54 PHST- 2021/11/08 00:00 [received] PHST- 2021/11/16 00:00 [accepted] PHST- 2021/12/04 06:00 [pubmed] PHST- 2022/08/17 06:00 [medline] PHST- 2021/12/03 05:54 [entrez] AID - S0914-5087(21)00322-1 [pii] AID - 10.1016/j.jjcc.2021.11.011 [doi] PST - ppublish SO - J Cardiol. 2022 Oct;80(4):303-305. doi: 10.1016/j.jjcc.2021.11.011. Epub 2021 Nov 29. PMID- 34856953 OWN - NLM STAT- MEDLINE DCOM- 20211206 LR - 20211214 IS - 1472-684X (Electronic) IS - 1472-684X (Linking) VI - 20 IP - 1 DP - 2021 Dec 2 TI - Prevalence and characteristics of patients with heart failure needing palliative care. PG - 184 LID - 10.1186/s12904-021-00850-y [doi] LID - 184 AB - BACKGROUND: Few hospitals and heart failure (HF) clinics offer concurrent palliative care (PC) together with life-prolonging therapies. To know the prevalence of patients in HF clinics needing PC and useful tools to recognize them are the first steps to extending PC in those settings. However, it is still unknown whether tools commonly used to identify patients with HF needing PC can correctly distinguish them. Two systematic reviews found that the NECesidades PALiativas (NECPAL) tool was one of the two most commonly used tools to asses PC needs in HF patients. Therefore, we assessed 1) the prevalence of PC needs in HF clinics according to the NECPAL tool, and 2) the characteristics of the patients identified as having PC; mainly, their quality of life (QoL), symptom burden, and psychosocial problems. METHODS: This cross-sectional study was conducted at two HF clinics in Colombia. We assessed the prevalence of PC in the overall sample and in subgroups according to clinical and demographic variables. We assessed QoL, symptom burden, and psychosocial problems using the 12-Item Short-Form Health Survey (SF-12), the Kansas City Cardiomyopathy Questionnaire (KCCQ) and the Edmonton Symptom Assessment System (ESAS). We compared the results of these tools between patients identified as having PC needs (+NECPAL) and patients identified as not having PC needs (-NECPAL). RESULTS: Among the 178 patients, 78 (44%) had PC needs. The prevalence of PC needs was twice as nigh in patients NYHA III/IV as in patients NYHA I/II and almost twice as high in patients older than 70 years as in patients younger than 70 years. Compared to -NECPAL patients, +NECPAL patients had worse QoL, more severe shortness of breath, tiredness, drowsiness, and pain, and more psychosocial problems. CONCLUSION: The prevalence of PC needs in outpatient HF clinics is high and is even higher in older patients and in patients at more advanced NYHA stages. Compared to patients identified as not having PC needs, patients identified as having PC needs have worse QoL, more severe symptoms, and greater psychosocial problems. Including a PC provider in the multidisciplinary team of HF clinics may help to assess and cover these needs. CI - (c) 2021. The Author(s). FAU - Arenas Ochoa, Luisa Fernanda AU - Arenas Ochoa LF AD - Pain and Palliative Care Group, School of Health Sciences, Universidad Pontificia Bolivariana, Medellin, Colombia. AD - Department of Palliative Care, Clinica Cardio VID, Medellin, Colombia. FAU - Gonzalez-Jaramillo, Valentina AU - Gonzalez-Jaramillo V AD - Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland. valentina.gonzalez@ispm.unibe.ch. AD - Graduate School for Health Sciences, University of Bern, Bern, Switzerland. valentina.gonzalez@ispm.unibe.ch. FAU - Saldarriaga, Clara AU - Saldarriaga C AD - Department of Cardiology, Clinica Cardio VID, Medellin, Colombia. AD - Cardiology Department, Universidad de Antioquia, Medellin, Colombia. FAU - Lemos, Mariantonia AU - Lemos M AD - Department of Psychology, School of Humanities, Universidad EAFIT, Medellin, Colombia. FAU - Krikorian, Alicia AU - Krikorian A AD - Pain and Palliative Care Group, School of Health Sciences, Universidad Pontificia Bolivariana, Medellin, Colombia. FAU - Vargas, John Jairo AU - Vargas JJ AD - Pain and Palliative Care Group, School of Health Sciences, Universidad Pontificia Bolivariana, Medellin, Colombia. AD - Institute of Cancerology, Clinica Las Americas, Medellin, Colombia. FAU - Gomez-Batiste, Xavier AU - Gomez-Batiste X AD - Chair Qualy Palliative Care, Faculty Medicine, University of Vic/Central of Catalonia, Barcelona, Spain. FAU - Gonzalez-Jaramillo, Nathalia AU - Gonzalez-Jaramillo N AD - Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland. AD - Graduate School for Health Sciences, University of Bern, Bern, Switzerland. FAU - Eychmuller, Steffen AU - Eychmuller S AD - University Center for Palliative Care, Inselspital University Hospital Bern, University of Bern, Bern, Switzerland. LA - eng PT - Journal Article DEP - 20211202 PL - England TA - BMC Palliat Care JT - BMC palliative care JID - 101088685 SB - IM MH - Aged MH - Cross-Sectional Studies MH - *Heart Failure/epidemiology/therapy MH - Humans MH - Palliative Care MH - Prevalence MH - *Quality of Life PMC - PMC8638101 OTO - NOTNLM OT - Health services needs and demands OT - Heart failure OT - Needs assessment OT - Palliative care OT - Patient-centered care OT - Prognosis COIS- The authors have no conflicts of interest to declare that are relevant to the content of this article. EDAT- 2021/12/04 06:00 MHDA- 2021/12/15 06:00 PMCR- 2021/12/02 CRDT- 2021/12/03 05:39 PHST- 2021/07/12 00:00 [received] PHST- 2021/09/16 00:00 [accepted] PHST- 2021/12/03 05:39 [entrez] PHST- 2021/12/04 06:00 [pubmed] PHST- 2021/12/15 06:00 [medline] PHST- 2021/12/02 00:00 [pmc-release] AID - 10.1186/s12904-021-00850-y [pii] AID - 850 [pii] AID - 10.1186/s12904-021-00850-y [doi] PST - epublish SO - BMC Palliat Care. 2021 Dec 2;20(1):184. doi: 10.1186/s12904-021-00850-y. PMID- 34855015 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231108 IS - 2524-8987 (Electronic) IS - 2524-8987 (Linking) VI - 13 IP - 1 DP - 2021 Dec 2 TI - Point-of-care ultrasound in cardiorespiratory arrest (POCUS-CA): narrative review article. PG - 46 LID - 10.1186/s13089-021-00248-0 [doi] LID - 46 AB - The POCUS-CA (Point-of-care ultrasound in cardiac arrest) is a diagnostic tool in the Intensive Care Unit and Emergency Department setting. The literature indicates that in the patient in a cardiorespiratory arrest it can provide information of the etiology of the arrest in patients with non-defibrillable rhythms, assess the quality of compressions during cardiopulmonary resuscitation (CPR), and define prognosis of survival according to specific findings and, thus, assist the clinician in decision-making during resuscitation. This narrative review of the literature aims to expose the usefulness of ultrasound in the setting of cardiorespiratory arrest as a tool that allows making a rapid diagnosis and making decisions about reversible causes of this entity. More studies are needed to support the evidence to make ultrasound part of the resuscitation algorithms. Teamwork during cardiopulmonary resuscitation and the inclusion of ultrasound in a multidisciplinary approach is important to achieve a favorable clinical outcome. CI - (c) 2021. The Author(s). FAU - Avila-Reyes, Diana AU - Avila-Reyes D AUID- ORCID: 0000-0001-7140-5046 AD - Department of Critical Care Medicine, Universidad Tecnologica de Pereira, Grupo de Investigacion Medicina Critica Y Cuidados Intensivos (GIMCCI), Pereira, Colombia. diana.avila@utp.edu.co. FAU - Acevedo-Cardona, Andres O AU - Acevedo-Cardona AO AD - Department of Critical Care Medicine, Universidad Tecnologica de Pereira,, Pereira, Colombia. AD - Master en Ecocardiografia en Cuidados Intensivos, Sociedad Espanola de Imagen Cardiaca/Universidad Francisco de Vitoria, Espana, Pereira, Spain. FAU - Gomez-Gonzalez, Jose F AU - Gomez-Gonzalez JF AD - Department of Critical Care Medicine, Universidad Tecnologica de Pereira, Pereira, Colombia. AD - Grupo Investigacion de Medicina Critica Y Cuidados Intensivos (GIMCCI), Pereira, Colombia. FAU - Echeverry-Piedrahita, David R AU - Echeverry-Piedrahita DR AD - Department of Critical Care Medicine, Universidad Tecnologica de Pereira, Pereira, Colombia. FAU - Aguirre-Florez, Mateo AU - Aguirre-Florez M AD - Department of Medicine, Universidad Tecnologica de Pereira, Pereira, Colombia. FAU - Giraldo-Diaconeasa, Adrian AU - Giraldo-Diaconeasa A AD - Department of Medicine, Universidad Tecnologica de Pereira, Pereira, Colombia. LA - eng PT - Journal Article PT - Review DEP - 20211202 PL - Italy TA - Ultrasound J JT - The ultrasound journal JID - 101742146 PMC - PMC8639882 OTO - NOTNLM OT - Cardiac arrest OT - Cardiopulmonary resuscitation OT - Critical Care OT - Echocardiography OT - POCUS-point-of-care ultrasound OT - Ultrasound COIS- No conflicts of interest for all authors. EDAT- 2021/12/03 06:00 MHDA- 2021/12/03 06:01 PMCR- 2021/12/02 CRDT- 2021/12/02 12:25 PHST- 2021/06/16 00:00 [received] PHST- 2021/11/12 00:00 [accepted] PHST- 2021/12/02 12:25 [entrez] PHST- 2021/12/03 06:00 [pubmed] PHST- 2021/12/03 06:01 [medline] PHST- 2021/12/02 00:00 [pmc-release] AID - 10.1186/s13089-021-00248-0 [pii] AID - 248 [pii] AID - 10.1186/s13089-021-00248-0 [doi] PST - epublish SO - Ultrasound J. 2021 Dec 2;13(1):46. doi: 10.1186/s13089-021-00248-0. PMID- 34853571 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220720 IS - 1061-1711 (Print) IS - 1615-5939 (Electronic) IS - 1061-1711 (Linking) VI - 30 IP - 4 DP - 2021 Dec TI - Cancer-Associated Atherothrombosis: The Challenge. PG - 249-256 LID - 10.1055/s-0041-1729920 [doi] AB - The association between venous thrombosis and malignancy, having typical features of a paraneoplastic syndrome, has been established for a century. Currently, it is recognized that arterial thromboembolism (ATE) may also behave as a paraneoplastic syndrome. Recent matched cohort studies, systematic reviews, and observational studies concur in showing an increased incidence of acute coronary events, ischemic stroke, accelerated peripheral arterial disease, and in-stent thrombosis during the 6-month period before cancer diagnosis, peaking for 30 days immediately before cancer diagnosis. Cancer patients with ATE are at higher risk of in-hospital and long-term mortality as compared with noncancer patients. In the present review, we focus on the epidemiology, clinical variants and presentation, morbidity, mortality, primary and secondary prevention, and treatment of cancer-associated ATE. The awareness that cancer can be a risk factor for ATE and that cancer therapy can initiate cardiovascular complications make it mandatory to identify high-risk patients, modify preexistent cardiovascular risk factors, and adopt effective antithrombotic prophylaxis. For ATE prophylaxis, modifiable patient-related risk factors and oncology treatment-related factors are levers for intervention. Statins and platelet antiaggregants have been studied, but their efficacy for prevention of cancer-associated ATE remains to be demonstrated. Results of revascularization procedures for cancer-associated ATE are worse than for ATE in noncancer patients. It is important that a multidisciplinary approach is adopted for making informed decisions, by involving the vascular surgeon, interventional radiologist, oncologist, and palliative medicine, as well as the patients and their family. CI - International College of Angiology. This article is published by Thieme. FAU - Naschitz, Jochanan E AU - Naschitz JE AD - The Ruth and Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel. AD - Comprehensive Geriatric Ward, Bait Balev Nesher, Nesher, Israel. LA - eng PT - Journal Article PT - Review DEP - 20210719 PL - United States TA - Int J Angiol JT - The International journal of angiology : official publication of the International College of Angiology, Inc JID - 9504821 PMC - PMC8608482 OTO - NOTNLM OT - cancer OT - coronary artery disease OT - paraneoplastic OT - peripheral arterial disease OT - stroke OT - thrombosis COIS- Conflict of Interest None declared. EDAT- 2021/12/03 06:00 MHDA- 2021/12/03 06:01 PMCR- 2022/07/19 CRDT- 2021/12/02 06:35 PHST- 2021/12/02 06:35 [entrez] PHST- 2021/12/03 06:00 [pubmed] PHST- 2021/12/03 06:01 [medline] PHST- 2022/07/19 00:00 [pmc-release] AID - 210007 [pii] AID - 10.1055/s-0041-1729920 [doi] PST - epublish SO - Int J Angiol. 2021 Jul 19;30(4):249-256. doi: 10.1055/s-0041-1729920. eCollection 2021 Dec. PMID- 34852145 OWN - NLM STAT- MEDLINE DCOM- 20211208 LR - 20240404 IS - 1980-5322 (Electronic) IS - 1807-5932 (Print) IS - 1807-5932 (Linking) VI - 76 DP - 2021 TI - Persistent symptoms and decreased health-related quality of life after symptomatic pediatric COVID-19: A prospective study in a Latin American tertiary hospital. PG - e3511 LID - 10.6061/clinics/2021/e3511 [doi] LID - e3511 AB - OBJECTIVES: To prospectively evaluate demographic, anthropometric and health-related quality of life (HRQoL) in pediatric patients with laboratory-confirmed coronavirus disease 2019 (COVID-19). METHODS: This was a longitudinal observational study of surviving pediatric post-COVID-19 patients (n=53) and pediatric subjects without laboratory-confirmed COVID-19 included as controls (n=52) was performed. RESULTS: The median duration between COVID-19 diagnosis (n=53) and follow-up was 4.4 months (0.8-10.7). Twenty-three of 53 (43%) patients reported at least one persistent symptom at the longitudinal follow-up visit and 12/53 (23%) had long COVID-19, with at least one symptom lasting for >12 weeks. The most frequently reported symptoms at the longitudinal follow-up visit were headache (19%), severe recurrent headache (9%), tiredness (9%), dyspnea (8%), and concentration difficulty (4%). At the longitudinal follow-up visit, the frequencies of anemia (11% versus 0%, p=0.030), lymphopenia (42% versus 18%, p=0.020), C-reactive protein level of >30 mg/L (35% versus 0%, p=0.0001), and D-dimer level of >1000 ng/mL (43% versus 6%, p=0.0004) significantly reduced compared with baseline values. Chest X-ray abnormalities (11% versus 2%, p=0.178) and cardiac alterations on echocardiogram (33% versus 22%, p=0.462) were similar at both visits. Comparison of characteristic data between patients with COVID-19 at the longitudinal follow-up visit and controls showed similar age (p=0.962), proportion of male sex (p=0.907), ethnicity (p=0.566), family minimum monthly wage (p=0.664), body mass index (p=0.601), and pediatric pre-existing chronic conditions (p=1.000). The Pediatric Quality of Live Inventory 4.0 scores, median physical score (69 [0-100] versus 81 [34-100], p=0.012), and school score (60 [15-100] versus 70 [15-95], p=0.028) were significantly lower in pediatric patients with COVID-19 at the longitudinal follow-up visit than in controls. CONCLUSIONS: Pediatric patients with COVID-19 showed a longitudinal impact on HRQoL parameters, particularly in physical/school domains, reinforcing the need for a prospective multidisciplinary approach for these patients. These data highlight the importance of closer monitoring of children and adolescents by the clinical team after COVID-19. FAU - Fink, Thais T AU - Fink TT AUID- ORCID: 0000-0001-7580-8088 AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR. FAU - Marques, Heloisa H S AU - Marques HHS AUID- ORCID: 0000-0002-0940-7793 AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR. FAU - Gualano, Bruno AU - Gualano B AUID- ORCID: 0000-0001-7100-8681 AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR. FAU - Lindoso, Livia AU - Lindoso L AUID- ORCID: 0000-0003-3452-8789 AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR. FAU - Bain, Vera AU - Bain V AUID- ORCID: 0000-0002-5290-6897 AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR. FAU - Astley, Camilla AU - Astley C AUID- ORCID: 0000-0003-4033-2432 AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR. FAU - Martins, Fernanda AU - Martins F AUID- ORCID: 0000-0001-5233-1926 AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR. FAU - Matheus, Denise AU - Matheus D AUID- ORCID: 0000-0003-3312-9268 AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR. FAU - Matsuo, Olivia M AU - Matsuo OM AUID- ORCID: 0000-0002-7971-1168 AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR. FAU - Suguita, Priscila AU - Suguita P AUID- ORCID: 0000-0002-6212-5058 AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR. FAU - Trindade, Vitor AU - Trindade V AUID- ORCID: 0000-0002-1766-4028 AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR. FAU - Paula, Camila S Y AU - Paula CSY AUID- ORCID: 0000-0002-7056-582X AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR. FAU - Farhat, Sylvia C L AU - Farhat SCL AUID- ORCID: 0000-0003-4036-5226 AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR. FAU - Palmeira, Patricia AU - Palmeira P AUID- ORCID: 0000-0002-6268-8141 AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR. FAU - Leal, Gabriela N AU - Leal GN AUID- ORCID: 0000-0002-6600-2311 AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR. FAU - Suzuki, Lisa AU - Suzuki L AUID- ORCID: 0000-0001-6045-0191 AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR. FAU - Odone Filho, Vicente AU - Odone Filho V AUID- ORCID: 0000-0003-4221-0551 AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR. FAU - Carneiro-Sampaio, Magda AU - Carneiro-Sampaio M AUID- ORCID: 0000-0002-1924-4043 AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR. FAU - Duarte, Alberto Jose S AU - Duarte AJS AUID- ORCID: 0000-0002-0673-0413 AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR. FAU - Antonangelo, Leila AU - Antonangelo L AUID- ORCID: 0000-0002-8634-5100 AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR. FAU - Batisttella, Linamara R AU - Batisttella LR AUID- ORCID: 0000-0001-5275-0733 AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR. FAU - Polanczyk, Guilherme V AU - Polanczyk GV AUID- ORCID: 0000-0003-2311-3289 AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR. FAU - Pereira, Rosa Maria R AU - Pereira RMR AUID- ORCID: 0000-0002-3723-5028 AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR. FAU - Carvalho, Carlos Roberto R AU - Carvalho CRR AUID- ORCID: 0000-0002-1618-8509 AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR. FAU - Buchpiguel, Carlos A AU - Buchpiguel CA AUID- ORCID: 0000-0003-0956-2790 AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR. FAU - Xavier, Ana Claudia L AU - Xavier ACL AUID- ORCID: 0000-0001-6782-693X AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR. FAU - Seelaender, Marilia AU - Seelaender M AUID- ORCID: 0000-0002-9999-8020 AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR. FAU - Silva, Clovis Artur AU - Silva CA AUID- ORCID: 0000-0001-9250-6508 AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR. FAU - Pereira, Maria Fernanda B AU - Pereira MFB AUID- ORCID: 0000-0001-8844-8245 AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR. CN - HC-FMUSP Pediatric Post-COVID-19 Study Group FAU - Sallum, Adriana M E AU - Sallum AME AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, BR. FAU - Brentani, Alexandra V M AU - Brentani AVM AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, BR. FAU - Neto, Alvaro Jose S AU - Neto AJS AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, BR. FAU - Ihara, Amanda AU - Ihara A AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, BR. FAU - Santos, Andrea R AU - Santos AR AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, BR. FAU - Canton, Ana Pinheiro M AU - Canton APM AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, BR. FAU - Watanabe, Andreia AU - Watanabe A AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, BR. FAU - Santos, Angelica C Dos AU - Santos ACD AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, BR. FAU - Pastorino, Antonio C AU - Pastorino AC AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, BR. FAU - Franco, Bernadette D G M AU - Franco BDGM AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, BR. FAU - Caruzo, Bruna AU - Caruzo B AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, BR. FAU - Ceneviva, Carina AU - Ceneviva C AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, BR. FAU - Martins, Carolina C M F AU - Martins CCMF AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, BR. FAU - Prado, Danilo AU - Prado D AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, BR. FAU - Abellan, Deipara M AU - Abellan DM AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, BR. FAU - Benatti, Fabiana B AU - Benatti FB AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, BR. FAU - Smaria, Fabiana AU - Smaria F AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, BR. FAU - Goncalves, Fernanda T AU - Goncalves FT AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, BR. FAU - Penteado, Fernando D AU - Penteado FD AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, BR. FAU - Castro, Gabriela S F de AU - Castro GSF AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, BR. FAU - Goncalves, Guilherme S AU - Goncalves GS AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, BR. FAU - Roschel, Hamilton AU - Roschel H AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, BR. FAU - Disi, Ilana R AU - Disi IR AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, BR. FAU - Marques, Isabela G AU - Marques IG AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, BR. FAU - Castro, Inar A AU - Castro IA AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, BR. FAU - Buscatti, Izabel M AU - Buscatti IM AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, BR. FAU - Faiad, Jaline Z AU - Faiad JZ AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, BR. FAU - Fiamoncini, Jarlei AU - Fiamoncini J AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, BR. FAU - Rodrigues, Joaquim C AU - Rodrigues JC AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, BR. FAU - Carneiro, Jorge D A AU - Carneiro JDA AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, BR. FAU - Paz, Jose A AU - Paz JA AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, BR. FAU - Ferreira, Juliana C AU - Ferreira JC AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, BR. FAU - Ferreira, Juliana C O AU - Ferreira JCO AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, BR. FAU - Silva, Katia R AU - Silva KR AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, BR. FAU - Bastos, Karina L M AU - Bastos KLM AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, BR. FAU - Kozu, Katia AU - Kozu K AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, BR. FAU - Cristofani, Lilian M AU - Cristofani LM AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, BR. FAU - Souza, Lucas V B AU - Souza LVB AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, BR. FAU - Campos, Lucia M A AU - Campos LMA AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, BR. FAU - Silva Filho, Luiz Vicente R F AU - Silva Filho LVRF AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, BR. FAU - Sapienza, Marcelo T AU - Sapienza MT AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, BR. FAU - Lima, Marcos S AU - Lima MS AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, BR. FAU - Garanito, Marlene P AU - Garanito MP AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, BR. FAU - Santos, Marcia F A AU - Santos MFA AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, BR. FAU - Dorna, Mayra B AU - Dorna MB AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, BR. FAU - Aikawa, Nadia E AU - Aikawa NE AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, BR. FAU - Litvinov, Nadia AU - Litvinov N AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, BR. FAU - Sakita, Neusa K AU - Sakita NK AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, BR. FAU - Gaiolla, Paula V V AU - Gaiolla PVV AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, BR. FAU - Pasqualucci, Paula AU - Pasqualucci P AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, BR. FAU - Toma, Ricardo K AU - Toma RK AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, BR. FAU - Correa-Silva, Simone AU - Correa-Silva S AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, BR. FAU - Sieczkowska, Sofia M AU - Sieczkowska SM AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, BR. FAU - Imamura, Marta AU - Imamura M AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, BR. FAU - Forsait, Silvana AU - Forsait S AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, BR. FAU - Santos, Vera A AU - Santos VA AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, BR. FAU - Zheng, Yingying AU - Zheng Y AD - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SP, BR. LA - eng PT - Journal Article PT - Observational Study DEP - 20211126 PL - United States TA - Clinics (Sao Paulo) JT - Clinics (Sao Paulo, Brazil) JID - 101244734 SB - IM EIN - Clinics (Sao Paulo). 2022 Mar 3;77:100024. doi: 10.1016/j.clinsp.2022.100024. PMID: 35421764 MH - Adolescent MH - *COVID-19/complications MH - COVID-19 Testing MH - Child MH - Humans MH - Latin America MH - Male MH - Prospective Studies MH - Quality of Life MH - SARS-CoV-2 MH - Tertiary Care Centers MH - Post-Acute COVID-19 Syndrome PMC - PMC8595593 COIS- No potential conflict of interest was reported. EDAT- 2021/12/02 06:00 MHDA- 2021/12/15 06:00 PMCR- 2021/11/17 CRDT- 2021/12/01 17:24 PHST- 2021/09/20 00:00 [received] PHST- 2021/10/25 00:00 [accepted] PHST- 2021/12/01 17:24 [entrez] PHST- 2021/12/02 06:00 [pubmed] PHST- 2021/12/15 06:00 [medline] PHST- 2021/11/17 00:00 [pmc-release] AID - S1807-5932(22)00258-7 [pii] AID - cln_76p1 [pii] AID - 10.6061/clinics/2021/e3511 [doi] PST - epublish SO - Clinics (Sao Paulo). 2021 Nov 26;76:e3511. doi: 10.6061/clinics/2021/e3511. eCollection 2021. PMID- 34848159 OWN - NLM STAT- MEDLINE DCOM- 20220404 LR - 20220405 IS - 1938-131X (Electronic) IS - 1553-7250 (Linking) VI - 48 IP - 1 DP - 2022 Jan TI - Harnessing the Potential of Primary Care Pharmacists to Improve Heart Failure Management. PG - 25-32 LID - S1553-7250(21)00269-5 [pii] LID - 10.1016/j.jcjq.2021.10.004 [doi] AB - BACKGROUND: Improved utilization of guideline-directed medical therapy (GDMT) in the management of heart failure with reduced ejection fraction (HFrEF) can reduce mortality, reduce heart failure hospitalizations, and improve quality of life. Despite well-established clinical guidelines, these therapies remain significantly underprescribed. The goal of this intervention was to increase prescribing of angiotensin-converting enzyme inhibitor (ACEI)/angiotensin II receptor blocker (ARB), angiotensin receptor neprilysin inhibitor (ARNI), and beta-blockers at >/= 50% target doses. METHODS: The study team identified key drivers to adequate dosing of GDMT: (1) frequent and reliable follow-up visits for titration opportunities, (2) identification of actionable patients for therapy initiation and titration, and (3) reduction in prescribing practice variability. The interventions were implemented at an outpatient clinical site and consisted of three main components: (1) establishing a pharmacist-led heart failure medication titration clinic, (2) creation of a standardized titration protocol, and (3) utilization of a patient dashboard to identify eligible patients. RESULTS: For patients seen in the titration clinic, in 14 months, the mean dose per patient increased from 31.3% to 70.5% of target dose for ACEI/ARB/ARNI, and from 45.8% to 85.4% for beta-blockers. At this clinical site, the percentage of HFrEF patients receiving > 50% of targeted dose increased from 39.7% to 46.7% for ACEI/ARB/ARNI, and from 39.5% to 42.9% for beta-blockers. For ACEI/ARB/ARNI, use of target doses was 5.9% higher (95% confidence interval [CI] = 3.6%-8.3%, p < 0.0001) for the intervention site, 0.2% higher (95% CI = -2.2%-2.5%, p = 0.89) during the intervention period, and 10.4% higher (95% CI = 6.9%-13.9%, p < 0.0001) for the interaction (intervention site during the intervention time period). For beta-blockers, use of target doses was 1.0% higher (95% CI = -0.6%-2.6%, p = 0.20) for the intervention site, 0.8% lower (95% CI = -2.4%-0.8%, p = 0.29) for the intervention period, and 5.8% higher (95% CI = 3.5%-8.1%, p < 0.0001) for the interaction (intervention site during the intervention time period). CONCLUSION: Through this project's interventions, the prescribing of ACEI/ARB/ARNI and beta-blocker therapy at >/= 50% target doses for patients with HFrEF was increased. This study demonstrates the value of a multifaceted, team-based approach that integrates population-level interventions such as clinical dashboard management with a pharmacist-led heart failure medication titration clinic. CI - Copyright (c) 2021 The Joint Commission. Published by Elsevier Inc. All rights reserved. FAU - Slade, Justin AU - Slade J FAU - Lee, Michelle AU - Lee M FAU - Park, Jun AU - Park J FAU - Liu, Alexander AU - Liu A FAU - Heidenreich, Paul AU - Heidenreich P FAU - Allaudeen, Nazima AU - Allaudeen N LA - eng PT - Journal Article DEP - 20211029 PL - Netherlands TA - Jt Comm J Qual Patient Saf JT - Joint Commission journal on quality and patient safety JID - 101238023 RN - 0 (Angiotensin Receptor Antagonists) RN - 0 (Angiotensin-Converting Enzyme Inhibitors) SB - IM CIN - Jt Comm J Qual Patient Saf. 2022 Jan;48(1):3-4. doi: 10.1016/j.jcjq.2021.11.002. PMID: 34840128 MH - Angiotensin Receptor Antagonists/therapeutic use MH - Angiotensin-Converting Enzyme Inhibitors/therapeutic use MH - *Heart Failure/drug therapy MH - Humans MH - Pharmacists MH - Primary Health Care MH - Quality of Life MH - Stroke Volume COIS- Conflicts of Interest All authors report no conflicts of interest. EDAT- 2021/12/02 06:00 MHDA- 2022/04/05 06:00 CRDT- 2021/12/01 05:59 PHST- 2021/02/16 00:00 [received] PHST- 2021/10/18 00:00 [revised] PHST- 2021/10/19 00:00 [accepted] PHST- 2021/12/02 06:00 [pubmed] PHST- 2022/04/05 06:00 [medline] PHST- 2021/12/01 05:59 [entrez] AID - S1553-7250(21)00269-5 [pii] AID - 10.1016/j.jcjq.2021.10.004 [doi] PST - ppublish SO - Jt Comm J Qual Patient Saf. 2022 Jan;48(1):25-32. doi: 10.1016/j.jcjq.2021.10.004. Epub 2021 Oct 29. PMID- 34845825 OWN - NLM STAT- MEDLINE DCOM- 20220418 LR - 20220418 IS - 1552-4833 (Electronic) IS - 1552-4825 (Linking) VI - 188 IP - 3 DP - 2022 Mar TI - 22q11.2 duplications: Expanding the clinical presentation. PG - 779-787 LID - 10.1002/ajmg.a.62577 [doi] AB - 22q11.2 duplication syndrome has a frequency of ~1/700 in the intellectual disability population. Despite this frequency, there is limited information on the variable clinical presentation. Although the phenotype and incidence of congenital anomalies are well described for 22q11.2 deletion syndrome, they are not as well understood for individuals with 22q11.2 duplication syndrome. This study is a single-center, retrospective review of patients diagnosed with 22q11.2 duplication syndrome designed to categorize the variable phenotype seen in these individuals. The data suggest that the incidence of congenital anomalies may be higher than previously reported for this syndrome. Affected individuals are at increased risk for a variety of problems including gastrointestinal complications, endocrine dysfunction, ophthalmologic abnormalities, palatal anomalies, congenital heart disease, musculoskeletal differences, and neurologic abnormalities. Individuals with 22q11.2 duplication syndrome would benefit from care coordinated by a multidisciplinary team and managed according to the 22q11.2 deletion syndrome guidelines. CI - (c) 2021 Wiley Periodicals LLC. FAU - Bartik, Lauren E AU - Bartik LE AUID- ORCID: 0000-0001-6581-6252 AD - Division of Clinical Genetics, Children's Mercy Hospital, Kansas City, Missouri, USA. AD - University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, USA. FAU - Hughes, Susan S AU - Hughes SS AD - Division of Clinical Genetics, Children's Mercy Hospital, Kansas City, Missouri, USA. AD - University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, USA. FAU - Tracy, Meghan AU - Tracy M AD - Division of Plastic Surgery, Children's Mercy Hospital, Kansas City, Missouri, USA. FAU - Feldt, M Max AU - Feldt MM AUID- ORCID: 0000-0003-4884-5515 AD - Division of Pediatric Endocrinology, Children's Mercy Hospital, Kansas City, Missouri, USA. FAU - Zhang, Lei AU - Zhang L AD - University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, USA. AD - Department of Pathology and Laboratory Medicine, Children's Mercy Hospital, Kansas City, Missouri, USA. FAU - Arganbright, Jill AU - Arganbright J AD - University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, USA. AD - Division of Pediatric Otolaryngology, Children's Mercy Hospital, Kansas City, Missouri, USA. FAU - Kaye, Alison AU - Kaye A AUID- ORCID: 0000-0002-4826-1133 AD - University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, USA. AD - Division of Plastic Surgery, Children's Mercy Hospital, Kansas City, Missouri, USA. LA - eng PT - Journal Article DEP - 20211129 PL - United States TA - Am J Med Genet A JT - American journal of medical genetics. Part A JID - 101235741 RN - Chromosome 22q11.2 Microduplication Syndrome SB - IM MH - *Abnormalities, Multiple/diagnosis/genetics MH - Chromosome Deletion MH - Chromosome Duplication/genetics MH - Chromosomes, Human, Pair 22/genetics MH - *DiGeorge Syndrome/diagnosis/genetics MH - *Heart Defects, Congenital/genetics MH - Humans MH - Phenotype OTO - NOTNLM OT - TBX1 OT - chromosome 22q11.2 OT - chromosome microarray OT - microduplication OT - multidisciplinary care OT - multiple anomaly syndrome EDAT- 2021/12/01 06:00 MHDA- 2022/04/19 06:00 CRDT- 2021/11/30 07:10 PHST- 2021/09/06 00:00 [revised] PHST- 2021/06/23 00:00 [received] PHST- 2021/11/02 00:00 [accepted] PHST- 2021/12/01 06:00 [pubmed] PHST- 2022/04/19 06:00 [medline] PHST- 2021/11/30 07:10 [entrez] AID - 10.1002/ajmg.a.62577 [doi] PST - ppublish SO - Am J Med Genet A. 2022 Mar;188(3):779-787. doi: 10.1002/ajmg.a.62577. Epub 2021 Nov 29. PMID- 34845464 OWN - NLM STAT- MEDLINE DCOM- 20211209 LR - 20211214 IS - 2208-7958 (Electronic) VI - 50 IP - 12 DP - 2021 Dec TI - Infantile haemangiomas: Identifying high-risk lesions in primary care. PG - 887-892 LID - 10.31128/AJGP-01-21-5815 [doi] AB - BACKGROUND: Infantile haemangiomas (IHs) are benign vascular tumours that affect up to 10% of infants and arise in the first few weeks-to-months of life. Some are associated with an increased risk of complications and poor cosmetic outcomes. General practitioners (GPs) are ideally placed to identify high-risk IHs and coordinate their management. OBJECTIVE: The aim of this article is to outline strategies to identify high-risk IHs and when to involve a multidisciplinary team. DISCUSSION: IHs that involve the lower face or neck can be associated with airway obstruction. Having five or more IHs is associated with hepatic haemangiomas, high-output cardiac failure and hypothyroidism. IHs that involve the eyes or mouth can cause functional impairments such as amblyopia and feeding difficulties, respectively. Large segmental IHs maybe associated with syndromic presentations including PHACE syndrome when on the lower face, PELVIS syndrome when on the perineum and LUMBAR syndrome when on the lower back. FAU - Joseph, Joseph AU - Joseph J AD - BPharm (Hons), MD, DH, General Practice Registrar, Westmead Hospital, Westmead, NSW. FAU - Wain, Thevaki AU - Wain T AD - MBBS, BMedSci, MPH, FACD, Dermatologist, Westmead Hospital, Westmead, NSW. LA - eng PT - Journal Article PL - Australia TA - Aust J Gen Pract JT - Australian journal of general practice JID - 101718099 SB - IM MH - *Heart Failure MH - *Hemangioma/complications/diagnosis MH - Humans MH - Infant MH - Primary Health Care MH - Syndrome EDAT- 2021/12/01 06:00 MHDA- 2021/12/15 06:00 CRDT- 2021/11/30 06:51 PHST- 2021/11/30 06:51 [entrez] PHST- 2021/12/01 06:00 [pubmed] PHST- 2021/12/15 06:00 [medline] AID - 10.31128/AJGP-01-21-5815 [doi] PST - ppublish SO - Aust J Gen Pract. 2021 Dec;50(12):887-892. doi: 10.31128/AJGP-01-21-5815. PMID- 34843965 OWN - NLM STAT- MEDLINE DCOM- 20220502 LR - 20220502 IS - 1556-3871 (Electronic) IS - 1547-5271 (Linking) VI - 19 IP - 3 DP - 2022 Mar TI - Long-term monitoring of arrhythmias with cardiovascular implantable electronic devices in patients with cardiac sarcoidosis. PG - 352-360 LID - S1547-5271(21)02415-2 [pii] LID - 10.1016/j.hrthm.2021.11.025 [doi] AB - BACKGROUND: Risk stratification for sudden cardiac death (SCD) in cardiac sarcoidosis (CS) is challenging in patients without overt cardiac symptoms. OBJECTIVE: The purpose of this study was to determine the incidence of ventricular arrhythmias (VAs) and mortality after long-term monitoring with a cardiovascular implantable electronic device (CIED) in CS patients identified after systematic screening of patients with extracardiac sarcoidosis (ECS). METHODS: A retrospective study was performed in 547 predominantly Caucasian patients with ECS screened for cardiac involvement. If CS was diagnosed, risk stratification (high vs low risk) for SCD was performed by a multidisciplinary team. The primary endpoint was defined as sustained VA, appropriate implantable cardioverter-defibrillator (ICD) therapy, or cardiac death. RESULTS: In total, 105 patients were included (mean follow-up 33 +/- 16 months). An ICD was implanted in 17 high-risk patients (16.2%), whereas 80 low-risk patients (76.1%) received an implantable loop recorder (ILR). Eight low-risk patients (7.6%) did not receive a device. The primary endpoint occurred in 4.8% (n = 5), with an overall annualized event rate of 1.7%. The annualized event rate was 9.8% in high-risk patients and 0.4% in low-risk patients. Nine low-risk patients received an ICD during follow-up, in 7 patients as a result of the ILR recordings. None of these patients required ICD therapy. CONCLUSION: In CS patients without overt cardiac symptoms at initial presentation the annualized overall event rate was 1.7%; 10% in high-risk patients, but only 0.4% in low-risk patients. In low-risk patients long-term arrhythmia monitoring with an ILR enabled early detection of clinically important arrhythmias without showing impact on prognosis. CI - Copyright (c) 2021 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved. FAU - Bakker, Annelies AU - Bakker A AD - Department of Cardiology, St. Antonius Hospital Nieuwegein/Utrecht, Nieuwegein, The Netherlands; Department of Cardiology, Amphia Hospital Breda, Breda, The Netherlands. Electronic address: abakker3@amphia.nl. FAU - Mathijssen, Harold AU - Mathijssen H AD - Department of Cardiology, St. Antonius Hospital Nieuwegein/Utrecht, Nieuwegein, The Netherlands. FAU - Dorland, Galina AU - Dorland G AD - Department of Cardiology, St. Antonius Hospital Nieuwegein/Utrecht, Nieuwegein, The Netherlands. FAU - Balt, Jippe C AU - Balt JC AD - Department of Cardiology, St. Antonius Hospital Nieuwegein/Utrecht, Nieuwegein, The Netherlands. FAU - van Dijk, Vincent F AU - van Dijk VF AD - Department of Cardiology, St. Antonius Hospital Nieuwegein/Utrecht, Nieuwegein, The Netherlands. FAU - Veltkamp, Marcel AU - Veltkamp M AD - Department of Pulmonology, St. Antonius Hospital Nieuwegein/Utrecht, Nieuwegein, The Netherlands; Department of Pulmonology, University Medical Center Utrecht, Utrecht, The Netherlands. FAU - Akdim, Fatima AU - Akdim F AD - Department of Cardiology, St. Antonius Hospital Nieuwegein/Utrecht, Nieuwegein, The Netherlands. FAU - Grutters, Jan C AU - Grutters JC AD - Department of Pulmonology, St. Antonius Hospital Nieuwegein/Utrecht, Nieuwegein, The Netherlands; Department of Pulmonology, University Medical Center Utrecht, Utrecht, The Netherlands. FAU - Post, Martijn C AU - Post MC AD - Department of Cardiology, St. Antonius Hospital Nieuwegein/Utrecht, Nieuwegein, The Netherlands; Department of Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands. LA - eng PT - Journal Article DEP - 20211126 PL - United States TA - Heart Rhythm JT - Heart rhythm JID - 101200317 SB - IM CIN - Heart Rhythm. 2022 Mar;19(3):361-362. doi: 10.1016/j.hrthm.2021.12.015. PMID: 34923160 MH - Arrhythmias, Cardiac/diagnosis/epidemiology/etiology MH - Death, Sudden, Cardiac/epidemiology/etiology/prevention & control MH - *Defibrillators, Implantable/adverse effects MH - Electronics MH - Humans MH - *Myocarditis/complications MH - Retrospective Studies MH - *Sarcoidosis/complications/diagnosis/epidemiology OTO - NOTNLM OT - Cardiac sarcoidosis OT - Cardiovascular implantable electronic device OT - Implantable cardioverter-defibrillator OT - Implantable loop recorder OT - Risk stratification OT - Sudden cardiac death OT - Ventricular arrhythmia EDAT- 2021/11/30 06:00 MHDA- 2022/05/03 06:00 CRDT- 2021/11/29 20:15 PHST- 2021/02/26 00:00 [received] PHST- 2021/11/06 00:00 [revised] PHST- 2021/11/18 00:00 [accepted] PHST- 2021/11/30 06:00 [pubmed] PHST- 2022/05/03 06:00 [medline] PHST- 2021/11/29 20:15 [entrez] AID - S1547-5271(21)02415-2 [pii] AID - 10.1016/j.hrthm.2021.11.025 [doi] PST - ppublish SO - Heart Rhythm. 2022 Mar;19(3):352-360. doi: 10.1016/j.hrthm.2021.11.025. Epub 2021 Nov 26. PMID- 34840415 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240829 IS - 2174-2030 (Electronic) IS - 0870-2551 (Print) IS - 0870-2551 (Linking) VI - 41 IP - 3 DP - 2022 Mar TI - Digital home-based multidisciplinary cardiac rehabilitation: How to counteract physical inactivity during the COVID-19 pandemic. PG - 209-218 LID - S0870-2551(21)00463-7 [pii] LID - 10.1016/j.repc.2021.05.013 [doi] AB - INTRODUCTION AND OBJECTIVES: Center-based cardiac rehabilitation (CR) programs have been forced to close due to COVID-19. Alternative delivery models to maintain access to CR programs and to avoid physical inactivity should be considered. The aim of this study was to assess physical activity (PA) levels after completing a home-based digital CR program. METHODS: A total of 116 cardiovascular disease (CVD) patients (62.6+/-8.9 years, 95 male) who had been attending a face-to-face CR program were recruited and assessed (baseline and at three months) on the following parameters: PA, sedentary behavior, adherence, cardiovascular and non-cardiovascular symptoms, feelings toward the pandemic, dietary habits, risk factor control, safety and adverse events. The intervention consisted of a multidisciplinary digital CR program, including regular patient assessment, and exercise, educational and psychological group sessions. RESULTS: Ninety-eight CVD patients successfully completed all the online assessments (15.5% drop-out rate). A favorable main effect of time was an increase in moderate to vigorous PA and a decrease in sedentary time at three months. Almost half of the participants completed at least one online exercise training session per week and attended at least one of the online educational sessions. No major adverse events were reported and only one minor event occurred. CONCLUSION: During the pandemic, levels of moderate to vigorous PA improved after three months of home-based CR in CVD patients with previous experience in a face-to-face CR model. Diversified CR programs with a greater variety of content tailored to individual preferences are needed to meet the motivational and clinical requirements of CVD patients. CI - (c) 2021 Sociedade Portuguesa de Cardiologia. Published by Elsevier Espana, S.L.U. FAU - Pinto, Rita AU - Pinto R AD - Servico de Cardiologia, Departamento Coracao e Vasos, Centro Hospitalar Universitario Lisboa Norte, CAML, CCUL, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal. Electronic address: mrpinto@medicina.ulisboa.pt. FAU - Pires, Madalena Lemos AU - Pires ML AD - Servico de Cardiologia, Departamento Coracao e Vasos, Centro Hospitalar Universitario Lisboa Norte, CAML, CCUL, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal. FAU - Borges, Mariana AU - Borges M AD - Servico de Cardiologia, Departamento Coracao e Vasos, Centro Hospitalar Universitario Lisboa Norte, CAML, CCUL, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal. FAU - Pinto, Mariana Linan AU - Pinto ML AD - Laboratorio de Nutricao, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal. FAU - Sousa Guerreiro, Catarina AU - Sousa Guerreiro C AD - Laboratorio de Nutricao, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal; Instituto de Saude Ambiental, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal. FAU - Miguel, Sandra AU - Miguel S AD - Servico de Medicina Fisica e Reabilitacao, Centro Hospitalar Universitario Lisboa Norte, EPE, Lisboa, Portugal. FAU - Santos, Olga AU - Santos O AD - Servico de Medicina Fisica e Reabilitacao, Centro Hospitalar Universitario Lisboa Norte, EPE, Lisboa, Portugal. FAU - Ricardo, Ines AU - Ricardo I AD - Servico de Cardiologia, Departamento Coracao e Vasos, Centro Hospitalar Universitario Lisboa Norte, CAML, CCUL, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal. FAU - Cunha, Nelson AU - Cunha N AD - Servico de Cardiologia, Departamento Coracao e Vasos, Centro Hospitalar Universitario Lisboa Norte, CAML, CCUL, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal. FAU - Alves da Silva, Pedro AU - Alves da Silva P AD - Servico de Cardiologia, Departamento Coracao e Vasos, Centro Hospitalar Universitario Lisboa Norte, CAML, CCUL, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal. FAU - Correia, Ana Luisa AU - Correia AL AD - Servico de Cardiologia, Departamento Coracao e Vasos, Centro Hospitalar Universitario Lisboa Norte, CAML, CCUL, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal. FAU - Fiuza, Silvia AU - Fiuza S AD - Servico de Cardiologia, Departamento Coracao e Vasos, Centro Hospitalar Universitario Lisboa Norte, CAML, CCUL, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal. FAU - Caldeira, Edite AU - Caldeira E AD - Servico de Cardiologia, Departamento Coracao e Vasos, Centro Hospitalar Universitario Lisboa Norte, CAML, CCUL, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal. FAU - Salazar, Fatima AU - Salazar F AD - Servico de Cardiologia, Departamento Coracao e Vasos, Centro Hospitalar Universitario Lisboa Norte, CAML, CCUL, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal. FAU - Rodrigues, Carla AU - Rodrigues C AD - Servico de Cardiologia, Departamento Coracao e Vasos, Centro Hospitalar Universitario Lisboa Norte, CAML, CCUL, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal. FAU - Cordeiro Ferreira, Mariana AU - Cordeiro Ferreira M AD - Servico de Psiquiatria e Saude Mental, Unidade de Psicologia, Centro Hospitalar Universitario Lisboa Norte, EPE, Lisboa, Portugal. FAU - Afonso, Gisela AU - Afonso G AD - Servico de Medicina Fisica e Reabilitacao, Centro Hospitalar Universitario Lisboa Norte, EPE, Lisboa, Portugal. FAU - Araujo, Graca AU - Araujo G AD - Servico de Medicina Fisica e Reabilitacao, Centro Hospitalar Universitario Lisboa Norte, EPE, Lisboa, Portugal. FAU - Martins, Joana AU - Martins J AD - Servico de Medicina Fisica e Reabilitacao, Centro Hospitalar Universitario Lisboa Norte, EPE, Lisboa, Portugal. FAU - Ramalhinho, Marta AU - Ramalhinho M AD - Servico de Medicina Fisica e Reabilitacao, Centro Hospitalar Universitario Lisboa Norte, EPE, Lisboa, Portugal. FAU - Sousa, Paula AU - Sousa P AD - Servico de Cardiologia, Departamento Coracao e Vasos, Centro Hospitalar Universitario Lisboa Norte, CAML, CCUL, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal. FAU - Pires, Susana AU - Pires S AD - Servico de Cardiologia, Departamento Coracao e Vasos, Centro Hospitalar Universitario Lisboa Norte, CAML, CCUL, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal. FAU - Jordao, Alda AU - Jordao A AD - Servico de Medicina III, Centro Hospitalar Universitario Lisboa Norte, EPE, Lisboa, Portugal. FAU - Pinto, Fausto J AU - Pinto FJ AD - Servico de Cardiologia, Departamento Coracao e Vasos, Centro Hospitalar Universitario Lisboa Norte, CAML, CCUL, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal. FAU - Abreu, Ana AU - Abreu A AD - Servico de Cardiologia, Departamento Coracao e Vasos, Centro Hospitalar Universitario Lisboa Norte, CAML, CCUL, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal. LA - eng PT - Journal Article DEP - 20211120 PL - Portugal TA - Rev Port Cardiol JT - Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology JID - 8710716 PMC - PMC8604709 OTO - NOTNLM OT - COVID-19 OT - Cardiovascular disease OT - Home-based cardiac rehabilitation OT - Secondary prevention OT - Telemedicine EDAT- 2021/11/30 06:00 MHDA- 2021/11/30 06:01 PMCR- 2021/11/20 CRDT- 2021/11/29 06:22 PHST- 2020/12/15 00:00 [received] PHST- 2021/05/29 00:00 [accepted] PHST- 2021/11/30 06:00 [pubmed] PHST- 2021/11/30 06:01 [medline] PHST- 2021/11/29 06:22 [entrez] PHST- 2021/11/20 00:00 [pmc-release] AID - S0870-2551(21)00463-7 [pii] AID - 10.1016/j.repc.2021.05.013 [doi] PST - ppublish SO - Rev Port Cardiol. 2022 Mar;41(3):209-218. doi: 10.1016/j.repc.2021.05.013. Epub 2021 Nov 20. PMID- 34840216 OWN - NLM STAT- MEDLINE DCOM- 20220701 LR - 20220701 IS - 1347-3409 (Electronic) IS - 1345-4676 (Linking) VI - 89 IP - 3 DP - 2022 Jun 28 TI - Role of a Fetal Ultrasound Clinic in Promoting Multidisciplinary and Inter-Facility Perinatal Care. PG - 337-341 LID - 10.1272/jnms.JNMS.2022_89-309 [doi] AB - BACKGROUND: With the increasing rate of high-risk pregnancies, there is an increased need for early evaluation of at-risk fetuses. Fetal ultrasound imaging has become a pivotal part of this evaluation. METHODS: To evaluate the role played by a fetal ultrasound clinic in promoting comprehensive perinatal care of patients with high-risk pregnancies, we retrospectively analyzed the indications and findings of fetal scans and the outcomes of the examined fetuses collected over the past 7 years (2014-2020) by our institute, which is reorganized as a perinatal medical center. RESULTS: During the study period, we conducted 345 fetal scans in high-risk pregnancy cases. Of these, 158 cases (46%) were referrals from other institutes. Eighty-nine neonates were admitted to our neonatal intensive care unit (NICU) after being evaluated, of which 10 neonates underwent surgery during their NICU stays. Thirty-nine pregnant women were referred to other tertiary care hospitals mainly due to fetal diagnoses with complex cardiac anomalies. Fourteen cases resulted in intrauterine fetal death or artificial abortion. CONCLUSIONS: Fetal ultrasound clinics have established their role in facilitating sophisticated regional perinatal care via multidisciplinary and inter-facility cooperation for high-risk pregnancy cases. In addition, providing psychological support and counseling for pregnant women whose fetuses are diagnosed with severe congenital anomalies should not be neglected. FAU - Shima, Yoshio AU - Shima Y AD - Department of Neonatal Medicine, Nippon Medical School Musashikosugi Hospital. FAU - Fukami, Takehiko AU - Fukami T AD - Department of Obstetrics and Gynecology, Nippon Medical School Musashikosugi Hospital. FAU - Takahashi, Tsubasa AU - Takahashi T AD - Department of Pediatric Surgery, Nippon Medical School Musashikosugi Hospital. FAU - Sasaki, Takashi AU - Sasaki T AD - Department of Cardiovascular Surgery, Nippon Medical School. FAU - Migita, Makoto AU - Migita M AD - Department of Pediatrics, Nippon Medical School Musashikosugi Hospital. LA - eng PT - Journal Article DEP - 20211126 PL - Japan TA - J Nippon Med Sch JT - Journal of Nippon Medical School = Nippon Ika Daigaku zasshi JID - 100935589 SB - IM MH - Child MH - Female MH - Fetus/diagnostic imaging MH - Humans MH - Infant, Newborn MH - *Perinatal Care MH - Pregnancy MH - Prenatal Diagnosis MH - Retrospective Studies MH - *Ultrasonography, Prenatal OTO - NOTNLM OT - fetal ultrasound OT - multidisciplinary perinatal care OT - prenatal diagnosis EDAT- 2021/11/30 06:00 MHDA- 2022/07/02 06:00 CRDT- 2021/11/29 06:18 PHST- 2021/11/30 06:00 [pubmed] PHST- 2022/07/02 06:00 [medline] PHST- 2021/11/29 06:18 [entrez] AID - 10.1272/jnms.JNMS.2022_89-309 [doi] PST - ppublish SO - J Nippon Med Sch. 2022 Jun 28;89(3):337-341. doi: 10.1272/jnms.JNMS.2022_89-309. Epub 2021 Nov 26. PMID- 39720503 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250104 IS - 1758-3896 (Electronic) IS - 1758-3896 (Print) IS - 1758-3896 (Linking) VI - 15 DP - 2021 TI - Shockwave and Non-transfemoral Transcatheter Aortic Valve Replacement. PG - e25 LID - 10.15420/usc.2021.16 [doi] LID - e25 AB - Transcatheter aortic valve replacement (TAVR) has become a widely adopted treatment modality for severe aortic stenosis. Transfemoral access is the approach of choice; however, approximately 25% of patients undergoing TAVR also have concomitant peripheral arterial disease. The recent advent of intravascular lithotripsy has enabled preservation of transfemoral access in some patients; although, a proportion still require alternative, non-femoral access. Alternative access sites can be broadly categorized into transthoracic and peripheral, facilitated by surgical or percutaneous techniques. In this review, the technical details and clinical outcomes of various TAVR accesses are discussed. Initially, transthoracic approaches were most common, but recently, the trend has been toward alternative peripheral access due to superior outcomes. Although there are no randomized data to support all the alternative access sites, the experiences reported provide available options for a large portion of patients to be candidates for TAVR. The intervention site should be selected by a multidisciplinary heart team based on patient anatomical factors and institutional expertise. CI - Copyright (c) The Author(s), 2021. Published by Radcliffe Group Ltd. FAU - Payabyab, Eden C AU - Payabyab EC AD - Department of Cardiothoracic Surgery, Weill Cornell Medicine New York City, NY. FAU - Elbaum, Lindsay S AU - Elbaum LS AD - Division of Cardiology, Department of Medicine, Weill Cornell Medical College, NewYork-Presbyterian Hospital New York City, NY. FAU - Sharma, Navneet AU - Sharma N AD - Division of Cardiology, Department of Medicine, Weill Cornell Medical College, NewYork-Presbyterian Hospital New York City, NY. FAU - George, Isaac AU - George I AD - NewYork-Presbyterian Hospital, Columbia University Medical Center New York City, NY. FAU - Mick, Stephanie L AU - Mick SL AD - Department of Cardiothoracic Surgery, Weill Cornell Medicine New York City, NY. LA - eng PT - Journal Article PT - Review DEP - 20211129 PL - England TA - US Cardiol JT - US cardiology JID - 101574791 PMC - PMC11664780 OTO - NOTNLM OT - Shockwave OT - Transcatheter aortic valve replacement OT - alternative access OT - transaxillary OT - transcarotid OT - transcaval OT - transthoracic COIS- Disclosure: The authors have no conflicts of interest to declare. EDAT- 2021/11/29 00:00 MHDA- 2021/11/29 00:01 PMCR- 2021/11/29 CRDT- 2024/12/25 04:25 PHST- 2021/05/12 00:00 [received] PHST- 2021/09/22 00:00 [accepted] PHST- 2021/11/29 00:01 [medline] PHST- 2021/11/29 00:00 [pubmed] PHST- 2024/12/25 04:25 [entrez] PHST- 2021/11/29 00:00 [pmc-release] AID - 10.15420/usc.2021.16 [doi] PST - epublish SO - US Cardiol. 2021 Nov 29;15:e25. doi: 10.15420/usc.2021.16. eCollection 2021. PMID- 34839103 OWN - NLM STAT- MEDLINE DCOM- 20220324 LR - 20220324 IS - 2059-7029 (Electronic) IS - 2059-7029 (Linking) VI - 6 IP - 6 DP - 2021 Dec TI - How we identify and treat neuromuscular toxicity induced by immune checkpoint inhibitors. PG - 100317 LID - S2059-7029(21)00279-9 [pii] LID - 10.1016/j.esmoop.2021.100317 [doi] LID - 100317 AB - Immune-related neuromuscular adverse events are rare, but potentially life-threatening side-effects of immune checkpoint inhibitors (ICIs). They usually arise within the first 3 months after initiation of ICIs. Subacute symptom onset with more rapid progression than in idiopathic autoimmune neuromuscular diseases is typical. Prompt clinical diagnosis and treatment is essential for a favourable outcome. The importance of careful medical history and a well-established clinical diagnosis is emphasised rather than antibody detection or radiologic visualisation. Muscle weakness as a leading symptom can give rise to the suspicion of either neuropathy or myositis-myasthenia complex and differentiation may be complicated by their overlap. It is of utmost importance to recognise immune-related myositis and monitor for myocardial as well as bulbar involvement that may rapidly lead to cardiac or respiratory failure, persisting disability or even a fatal outcome. Symptoms typically improve with ICI discontinuation and early administration of glucocorticoids (prednisolone 1-2 mg/kg/day) in patients markedly affected. Severe and persisting symptoms including myocardial or bulbar affection can require therapy escalation to steroid-sparing agents. In patients with mild symptoms, not influencing functional abilities, careful clinical monitoring while staying on ICI therapy may be sufficient. Re-challenging with ICIs may be considered in selected cases, based on the initial severity of immune-related adverse events (irAEs) and clinical disease course. Depending on the individual irAE characteristics, the decision should be preferably discussed in an interdisciplinary irAE expert team with an experienced neurologist, rheumatologist and/or cardiologist and take the patient's preferences into account. The yet unmet need of systematic data on treatment, follow-up results and options of re-challenge of ICI treatment in neuromuscular toxicity has to be particularly considered in the shared decision-making process. CI - Copyright (c) 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved. FAU - Jordan, B AU - Jordan B AD - Department of Neurology, University of Heidelberg, Heidelberg, Germany; Department of Neurology, University of Halle-Wittenberg, Halle-Saale, Germany. FAU - Benesova, K AU - Benesova K AD - Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, Heidelberg, Germany. FAU - Hassel, J C AU - Hassel JC AD - Department of Dermatology, University of Heidelberg, Heidelberg, Germany. FAU - Wick, W AU - Wick W AD - Department of Neurology, University of Heidelberg, Heidelberg, Germany; Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany. FAU - Jordan, K AU - Jordan K AD - Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, Heidelberg, Germany; Department of Hematology, Oncology and Palliative Medicine, Ernst von Bergmann Hospital, Potsdam, Germany. Electronic address: karin.jordan@med.uni-heidelberg.de. LA - eng PT - Journal Article PT - Review DEP - 20211125 PL - England TA - ESMO Open JT - ESMO open JID - 101690685 RN - 0 (Immune Checkpoint Inhibitors) SB - IM MH - Humans MH - *Immune Checkpoint Inhibitors/adverse effects MH - *Myositis/chemically induced/diagnosis/drug therapy MH - Treatment Outcome PMC - PMC8637479 OTO - NOTNLM OT - immune checkpoint inhibitors OT - myasthenia gravis OT - myositis OT - neuromuscular toxicity OT - neuropathy COIS- Disclosure BJ: advisory board and/or honoraria for presentations for Alexion Pharmaceuticals, Temmler (Hormosan Pharma), Novartis, Biomarin, Merz Pharmaceuticals, Ipsen Pharma and Allergan. KB: Consultancy and/or speaker fees and/or travel reimbursements: Abbvie, Bristol Myers Squibb (BMS), Janssen, Merck Sharp & Dohme (MSD), Mundipharma, Novartis, Pfizer, Roche, UCB. Scientific support: AbbVie, United States, Novartis, Switzerland. JH: advisory board and/or honoraria for presentations Almirall, BMS, Immunocore, MSD, Novartis Pharma, Pierre Fabre Pharmaceuticals, Inc., Roche Germany, Sanofi-Aventis, Sun Pharmaceutical Industries Inc. WW has declared no conflicts of interest. KJ: advisory board and/or honoraria for MSD, Merck, Amgen, Hexal, Riemser, Helsinn, Kreussler, Voluntis, Pfizer, Pomme-med, PharmaMar, art tempi and Onko Solutions. EDAT- 2021/11/29 06:00 MHDA- 2022/03/25 06:00 PMCR- 2021/11/25 CRDT- 2021/11/28 21:01 PHST- 2021/10/10 00:00 [received] PHST- 2021/10/25 00:00 [revised] PHST- 2021/10/27 00:00 [accepted] PHST- 2021/11/29 06:00 [pubmed] PHST- 2022/03/25 06:00 [medline] PHST- 2021/11/28 21:01 [entrez] PHST- 2021/11/25 00:00 [pmc-release] AID - S2059-7029(21)00279-9 [pii] AID - 100317 [pii] AID - 10.1016/j.esmoop.2021.100317 [doi] PST - ppublish SO - ESMO Open. 2021 Dec;6(6):100317. doi: 10.1016/j.esmoop.2021.100317. Epub 2021 Nov 25. PMID- 34836605 OWN - NLM STAT- MEDLINE DCOM- 20220221 LR - 20220221 IS - 1557-3117 (Electronic) IS - 1053-2498 (Linking) VI - 40 IP - 12 DP - 2021 Dec TI - Swallowing and laryngeal complications in lung and heart transplantation: Etiologies and diagnosis. PG - 1483-1494 LID - S1053-2498(21)02460-8 [pii] LID - 10.1016/j.healun.2021.08.006 [doi] AB - Despite continued surgical advancements in the field of cardiothoracic transplantation, post-operative complications remain a burden for the patient and the multidisciplinary team. Lesser-known complications including swallowing disorders (dysphagia), and voice disorders (dysphonia), are now being reported. Such disorders are known to be associated with increased morbidity and mortality in other medical populations, however their etiology amongst the heart and lung transplant populations has received little attention in the literature. This paper explores the potential mechanisms of oropharyngeal dysphagia and dysphonia following transplantation and discusses optimal modalities of diagnostic evaluation and management. A greater understanding of the implications of swallowing and laryngeal dysfunction in the heart and lung transplant populations is important to expedite early diagnosis and management in order to optimize patient outcomes, minimize allograft injury and improve quality of life. CI - Copyright (c) 2021 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Black, Rebecca J AU - Black RJ AD - Speech Pathology Department, St Vincent's Hospital, Darlinghurst, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Australia. Electronic address: Rebecca.Black@svha.org.au. FAU - Novakovic, Daniel AU - Novakovic D AD - Faculty of Medicine and Health, The University of Sydney, Australia. FAU - Plit, Marshall AU - Plit M AD - St Vincent's Hospital, Darlinghurst, NSW, Australia. FAU - Miles, Anna AU - Miles A AD - University of Auckland, New Zealand. FAU - MacDonald, Peter AU - MacDonald P AD - Faculty of Medicine and Health, The University of Sydney, Australia. FAU - Madill, Catherine AU - Madill C AD - Faculty of Medicine and Health, The University of Sydney, Australia. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20210826 PL - United States TA - J Heart Lung Transplant JT - The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation JID - 9102703 SB - IM EIN - J Heart Lung Transplant. 2022 Feb;41(2):268. doi: 10.1016/j.healun.2021.12.001. PMID: 35086667 MH - Deglutition Disorders/*diagnosis/*etiology/therapy MH - Heart Transplantation/*adverse effects MH - Humans MH - Laryngeal Diseases/*diagnosis/*etiology/therapy MH - Lung Transplantation/*adverse effects MH - Postoperative Complications/diagnosis/etiology/therapy OTO - NOTNLM OT - dysphagia OT - dysphonia OT - laryngeal OT - swallowing OT - voice COIS- Disclosure statement The authors have no conflict of interest to declare. This work was conducted at St Vincent's hospital, Sydney and was partially funded from the trust funds of the department of thoracic medicine. The production of the manuscript was supported by the Dr Liang voice programme at the University of Sydney. EDAT- 2021/11/28 06:00 MHDA- 2022/02/22 06:00 CRDT- 2021/11/27 05:23 PHST- 2021/04/22 00:00 [received] PHST- 2021/07/29 00:00 [revised] PHST- 2021/08/19 00:00 [accepted] PHST- 2021/11/27 05:23 [entrez] PHST- 2021/11/28 06:00 [pubmed] PHST- 2022/02/22 06:00 [medline] AID - S1053-2498(21)02460-8 [pii] AID - 10.1016/j.healun.2021.08.006 [doi] PST - ppublish SO - J Heart Lung Transplant. 2021 Dec;40(12):1483-1494. doi: 10.1016/j.healun.2021.08.006. Epub 2021 Aug 26. PMID- 34834414 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20211130 IS - 2075-4426 (Print) IS - 2075-4426 (Electronic) IS - 2075-4426 (Linking) VI - 11 IP - 11 DP - 2021 Oct 22 TI - A Sneak-Peek into the Physician's Brain: A Retrospective Machine Learning-Driven Investigation of Decision-Making in TAVR versus SAVR for Young High-Risk Patients with Severe Symptomatic Aortic Stenosis. LID - 10.3390/jpm11111062 [doi] LID - 1062 AB - Transcatheter aortic valve replacement (TAVR) has rapidly become a viable alternative to the conventional isolated surgical aortic valve replacement (iSAVR) for treating severe symptomatic aortic stenosis. However, data on younger patients is scarce and a gap exists between data-based recommendations and the clinical use of TAVR. In our study, we utilized a machine learning (ML) driven approach to model the complex decision-making process of Heart Teams when treating young patients with severe symptomatic aortic stenosis with either TAVR or iSAVR and to identify the relevant considerations. Out of the considered factors, the variables most prominently featured in our ML model were congestive heart failure, established risk assessment scores, previous cardiac surgeries, a reduced left ventricular ejection fraction and peripheral vascular disease. Our study demonstrates a viable application of ML-based approaches for studying and understanding complex clinical decision-making processes. FAU - Hasimbegovic, Ena AU - Hasimbegovic E AD - Division of Cardiac Surgery, Department of Surgery, Medical University of Vienna, 1090 Vienna, Austria. AD - Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria. FAU - Papp, Laszlo AU - Papp L AUID- ORCID: 0000-0002-9049-9989 AD - Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, 1090 Vienna, Austria. FAU - Grahovac, Marko AU - Grahovac M AD - Division of Nuclear Medicine, Medical University of Vienna, 1090 Vienna, Austria. FAU - Krajnc, Denis AU - Krajnc D AUID- ORCID: 0000-0003-1786-4297 AD - Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, 1090 Vienna, Austria. FAU - Poschner, Thomas AU - Poschner T AUID- ORCID: 0000-0003-0374-8375 AD - Division of Cardiac Surgery, Department of Surgery, Medical University of Vienna, 1090 Vienna, Austria. FAU - Hasan, Waseem AU - Hasan W AD - Faculty of Medicine, Imperial College London, London SW7 2AZ, UK. FAU - Andreas, Martin AU - Andreas M AD - Division of Cardiac Surgery, Department of Surgery, Medical University of Vienna, 1090 Vienna, Austria. FAU - Gross, Christoph AU - Gross C AUID- ORCID: 0000-0003-1583-5783 AD - Division of Cardiac Surgery, Department of Surgery, Medical University of Vienna, 1090 Vienna, Austria. AD - Vienna North Hospital-Floridsdorf Clinic and the Karl Landsteiner Institute for Cardiovascular and Critical Care Research, 1090 Vienna, Austria. FAU - Strouhal, Andreas AU - Strouhal A AD - Department of Cardiovascular Surgery, Hospital Hietzing and the Karl Landsteiner Institute for Cardiovascular and Critical Care Research, 1090 Vienna, Austria. FAU - Delle-Karth, Georg AU - Delle-Karth G AD - Department of Cardiovascular Surgery, Hospital Hietzing and the Karl Landsteiner Institute for Cardiovascular and Critical Care Research, 1090 Vienna, Austria. FAU - Grabenwoger, Martin AU - Grabenwoger M AD - Faculty of Medicine, Sigmund Freud University, 1090 Vienna, Austria. AD - Imed19-Internal Medicine Doebling, 1090 Vienna, Austria. FAU - Adlbrecht, Christopher AU - Adlbrecht C AD - Department of Cardiovascular Surgery, Hospital Hietzing and the Karl Landsteiner Institute for Cardiovascular and Critical Care Research, 1090 Vienna, Austria. AD - Imed19-Internal Medicine Doebling, 1090 Vienna, Austria. FAU - Mach, Markus AU - Mach M AUID- ORCID: 0000-0002-3184-4914 AD - Division of Cardiac Surgery, Department of Surgery, Medical University of Vienna, 1090 Vienna, Austria. AD - Department of Cardiovascular Surgery, Hospital Hietzing and the Karl Landsteiner Institute for Cardiovascular and Critical Care Research, 1090 Vienna, Austria. LA - eng PT - Journal Article DEP - 20211022 PL - Switzerland TA - J Pers Med JT - Journal of personalized medicine JID - 101602269 PMC - PMC8622882 OTO - NOTNLM OT - TAVI OT - TAVR OT - aortic stenosis OT - heart team OT - iSAVR OT - machine learning COIS- Markus Mach has received a research grant from Edwards Lifesciences, JenaValve and Symetis. Andreas is a proctor, speaker and consultant for Edwards Lifesciences, Abbott, Medtronic and received institutional grants from Edwards Lifesciences, Abbott, Medtronic and LSI. All other authors have reported that they have no relationships relevant to the content. EDAT- 2021/11/28 06:00 MHDA- 2021/11/28 06:01 PMCR- 2021/10/22 CRDT- 2021/11/27 01:24 PHST- 2021/09/13 00:00 [received] PHST- 2021/10/10 00:00 [revised] PHST- 2021/10/16 00:00 [accepted] PHST- 2021/11/27 01:24 [entrez] PHST- 2021/11/28 06:00 [pubmed] PHST- 2021/11/28 06:01 [medline] PHST- 2021/10/22 00:00 [pmc-release] AID - jpm11111062 [pii] AID - jpm-11-01062 [pii] AID - 10.3390/jpm11111062 [doi] PST - epublish SO - J Pers Med. 2021 Oct 22;11(11):1062. doi: 10.3390/jpm11111062. PMID- 34833412 OWN - NLM STAT- MEDLINE DCOM- 20211130 LR - 20211130 IS - 1648-9144 (Electronic) IS - 1010-660X (Print) IS - 1010-660X (Linking) VI - 57 IP - 11 DP - 2021 Nov 2 TI - Clinical Sign-Based Rapid Response Team Call Criteria for Identifying Patients Requiring Intensive Care Management in Japan. LID - 10.3390/medicina57111194 [doi] LID - 1194 AB - Background and Objectives: For effective function of the rapid response system (RRS), prompt identification of patients at a high risk of cardiac arrest and RRS activation without hesitation are important. This study aimed to identify clinical factors that increase the risk of intensive care unit (ICU) transfer and cardiac arrest to identify patients who are likely to develop serious conditions requiring ICU management and appropriate RRS activation in Japan. Materials and Methods: We performed a single-center, case control study among patients requiring a rapid response team (RRT) call from 2017 to 2020. We extracted the demographic data, vital parameters, blood oxygen saturation (SpO(2)) and the fraction of inspired oxygen (FiO(2)) from the medical records at the time of RRT call. The patients were divided into two groups to identify clinical signs that correlated with the progression of clinical deterioration. Patient characteristics in the two groups were compared using statistical tests based on the distribution. Receiver operating characteristic (ROC) curve analysis was used to identify the appropriate cut-off values of vital parameters or FiO(2) that showed a significant difference between-group. Multivariate logistic regression analysis was used to identify patient factors that were predictive of RRS necessity. Results: We analyzed the data of 65 patients who met our hospital's RRT call criteria. Among the clinical signs in RRT call criteria, respiratory rate (RR) (p < 0.01) and the needed FiO(2) were significantly increased (p < 0.01) in patients with severe disease course. ROC curve analysis revealed RR and needed FiO(2) cut-off values of 25.5 breaths/min and 30%. The odds ratio for the progression of clinical deterioration was 40.5 times higher with the combination of RR >/= 26 breaths/min and needed FiO(2) >/= 30%. Conclusions: The combined use of RR >/= 26 breaths/min and needed FiO(2) >/= 30% might be valid for identifying patients requiring intensive care management. FAU - Okawa, Reiko AU - Okawa R AD - Emergency and Critical Care Center, Nagaoka Red Cross Hospital, Nagaoka 940-2085, Japan. FAU - Yokono, Tomoe AU - Yokono T AUID- ORCID: 0000-0002-6565-756X AD - Department of Nursing, Niigata University Graduate School of Health Sciences, Niigata 951-8518, Japan. FAU - Koyama, Yu AU - Koyama Y AUID- ORCID: 0000-0001-9743-6473 AD - Department of Nursing, Niigata University Graduate School of Health Sciences, Niigata 951-8518, Japan. FAU - Uchiyama, Mieko AU - Uchiyama M AD - Department of Nursing, Niigata University Graduate School of Health Sciences, Niigata 951-8518, Japan. FAU - Oono, Naoko AU - Oono N AD - Niigata College of Medical Technolgy, Niigata 950-2076, Japan. LA - eng PT - Journal Article DEP - 20211102 PL - Switzerland TA - Medicina (Kaunas) JT - Medicina (Kaunas, Lithuania) JID - 9425208 SB - IM MH - Case-Control Studies MH - Critical Care MH - *Hospital Rapid Response Team MH - Humans MH - Intensive Care Units MH - Japan/epidemiology MH - Retrospective Studies PMC - PMC8619995 OTO - NOTNLM OT - inspired oxygen OT - rapid response system OT - rapid response team OT - respiratory rates COIS- The authors declare no conflict of interest. EDAT- 2021/11/28 06:00 MHDA- 2021/12/01 06:00 PMCR- 2021/11/02 CRDT- 2021/11/27 01:21 PHST- 2021/08/20 00:00 [received] PHST- 2021/10/30 00:00 [revised] PHST- 2021/11/01 00:00 [accepted] PHST- 2021/11/27 01:21 [entrez] PHST- 2021/11/28 06:00 [pubmed] PHST- 2021/12/01 06:00 [medline] PHST- 2021/11/02 00:00 [pmc-release] AID - medicina57111194 [pii] AID - medicina-57-01194 [pii] AID - 10.3390/medicina57111194 [doi] PST - epublish SO - Medicina (Kaunas). 2021 Nov 2;57(11):1194. doi: 10.3390/medicina57111194. PMID- 34830690 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240818 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 10 IP - 22 DP - 2021 Nov 19 TI - Heart Team for Optimal Management of Patients with Severe Aortic Stenosis-Long-Term Outcomes and Quality of Life from Tertiary Cardiovascular Care Center. LID - 10.3390/jcm10225408 [doi] LID - 5408 AB - BACKGROUND: This retrospective study was proposed to investigate outcomes of patients with severe aortic stenosis (AS) after implementation of various treatment strategies following dedicated Heart Team (HT) decisions. METHODS: Primary and secondary endpoints and quality of life during a median follow-up of 866 days of patients with severe AS qualified after HT discussion to: optimal medical treatment (OMT) alone, OMT and transcather aortic valve replacement (TAVR) or OMT and surgical aortic valve replacement (SAVR) were evaluated. As the primary endpoint composite of all-cause mortality, non-fatal disabling strokes and non-fatal rehospitalizations for AS were considered, while other clinical outcomes were determined as secondary endpoints. RESULTS: From 2016 to 2019, 176 HT meetings were held, and a total of 482 participants with severe AS and completely implemented HT decisions (OMT, TAVR and SAVR for 79, 318 and 85, respectively) were included in the final analysis. SAVR and TAVR were found to be superior to OMT for primary and all secondary endpoints (p < 0.05). Comparing interventional strategies only, TAVR was associated with reduced risk of acute kidney injury, new onset of atrial fibrillation and major bleeding, while the superiority of SAVR for major vascular complications and need for permanent pacemaker implantation was observed (p < 0.05). The quality of life assessed at the end of follow-up was significantly better for patients who underwent TAVR or SAVR than in OMT-group (p < 0.05). CONCLUSIONS: We demonstrated that after careful implementation of HT decisions interventional strategies compared to OMT only provide superior outcomes and quality of life for patients with AS. FAU - Jonik, Szymon AU - Jonik S AD - 1st Department of Cardiology, Medical University of Warsaw, Banacha 1a Str., 01-267 Warsaw, Poland. FAU - Marchel, Michal AU - Marchel M AD - 1st Department of Cardiology, Medical University of Warsaw, Banacha 1a Str., 01-267 Warsaw, Poland. FAU - Pedzich-Placha, Ewa AU - Pedzich-Placha E AUID- ORCID: 0000-0001-8965-0736 AD - 1st Department of Cardiology, Medical University of Warsaw, Banacha 1a Str., 01-267 Warsaw, Poland. FAU - Huczek, Zenon AU - Huczek Z AD - 1st Department of Cardiology, Medical University of Warsaw, Banacha 1a Str., 01-267 Warsaw, Poland. FAU - Kochman, Janusz AU - Kochman J AD - 1st Department of Cardiology, Medical University of Warsaw, Banacha 1a Str., 01-267 Warsaw, Poland. FAU - Scislo, Piotr AU - Scislo P AD - 1st Department of Cardiology, Medical University of Warsaw, Banacha 1a Str., 01-267 Warsaw, Poland. FAU - Czub, Pawel AU - Czub P AD - Department of Cardiac Surgery, Medical University of Warsaw, Banacha 1a Str., 01-267 Warsaw, Poland. FAU - Wilimski, Radoslaw AU - Wilimski R AD - Department of Cardiac Surgery, Medical University of Warsaw, Banacha 1a Str., 01-267 Warsaw, Poland. FAU - Hendzel, Piotr AU - Hendzel P AD - Department of Cardiac Surgery, Medical University of Warsaw, Banacha 1a Str., 01-267 Warsaw, Poland. FAU - Opolski, Grzegorz AU - Opolski G AD - 1st Department of Cardiology, Medical University of Warsaw, Banacha 1a Str., 01-267 Warsaw, Poland. FAU - Grabowski, Marcin AU - Grabowski M AD - 1st Department of Cardiology, Medical University of Warsaw, Banacha 1a Str., 01-267 Warsaw, Poland. FAU - Mazurek, Tomasz AU - Mazurek T AD - 1st Department of Cardiology, Medical University of Warsaw, Banacha 1a Str., 01-267 Warsaw, Poland. LA - eng PT - Journal Article DEP - 20211119 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC8623928 OTO - NOTNLM OT - aortic stenosis OT - heart failure OT - heart team OT - optimal medical therapy OT - surgical aortic valve replacement OT - transcatheter aortic valve replacement COIS- The authors declare no conflict of interest. EDAT- 2021/11/28 06:00 MHDA- 2021/11/28 06:01 PMCR- 2021/11/19 CRDT- 2021/11/27 01:12 PHST- 2021/10/26 00:00 [received] PHST- 2021/11/16 00:00 [revised] PHST- 2021/11/18 00:00 [accepted] PHST- 2021/11/27 01:12 [entrez] PHST- 2021/11/28 06:00 [pubmed] PHST- 2021/11/28 06:01 [medline] PHST- 2021/11/19 00:00 [pmc-release] AID - jcm10225408 [pii] AID - jcm-10-05408 [pii] AID - 10.3390/jcm10225408 [doi] PST - epublish SO - J Clin Med. 2021 Nov 19;10(22):5408. doi: 10.3390/jcm10225408. PMID- 34827702 OWN - NLM STAT- MEDLINE DCOM- 20240724 LR - 20240724 IS - 2218-273X (Electronic) IS - 2218-273X (Linking) VI - 11 IP - 11 DP - 2021 Nov 16 TI - Three-Dimensional Virtual and Printed Prototypes in Complex Congenital and Pediatric Cardiac Surgery-A Multidisciplinary Team-Learning Experience. LID - 10.3390/biom11111703 [doi] LID - 1703 AB - Three-dimensional (3D) virtual modeling and printing advances individualized medicine and surgery. In congenital cardiac surgery, 3D virtual models and printed prototypes offer advantages of better understanding of complex anatomy, hands-on preoperative surgical planning and emulation, and improved communication within the multidisciplinary team and to patients. We report our single center team-learning experience about the realization and validation of possible clinical benefits of 3D-printed models in surgical planning of complex congenital cardiac surgery. CT-angiography raw data were segmented into 3D-virtual models of the heart-great vessels. Prototypes were 3D-printed as rigid "blood-volume" and flexible "hollow". The accuracy of the models was evaluated intraoperatively. Production steps were realized in the framework of a clinical/research partnership. We produced 3D prototypes of the heart-great vessels for 15 case scenarios (nine males, median age: 11 months) undergoing complex intracardiac repairs. Parity between 3D models and intraoperative structures was within 1 mm range. Models refined diagnostics in 13/15, provided new anatomic information in 9/15. As a team-learning experience, all complex staged redo-operations (13/15; Aristotle-score mean: 10.64 +/- 1.95) were rehearsed on the 3D models preoperatively. 3D-printed prototypes significantly contributed to an improved/alternative operative plan on the surgical approach, modification of intracardiac repair in 13/15. No operative morbidity/mortality occurred. Our clinical/research partnership provided coverage for the extra time/labor and material/machinery not financed by insurance. 3D-printed models provided a team-learning experience and contributed to the safety of complex congenital cardiac surgeries. A clinical/research partnership may open avenues for bioprinting of patient-specific implants. FAU - Kiraly, Laszlo AU - Kiraly L AUID- ORCID: 0000-0002-3193-9753 AD - Division of Pediatric Cardiac Surgery, Cardiac Sciences, Sheikh Khalifa Medical City, Abu Dhabi P.O. Box 51900, United Arab Emirates. AD - Department of Public Health, Semmelweis University, H-1085 Budapest, Hungary. AD - Department of Cardiac, Thoracic and Vascular Surgery, National University Hospital System, 1E Kent Ridge Road, NUHS Tower Block, Level 9, Singapore 119228, Singapore. AD - Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge Road, NUHS Tower Block, Level 8, Singapore 119228, Singapore. FAU - Shah, Nishant C AU - Shah NC AD - Division of Pediatric Cardiology, Cardiac Sciences, Sheikh Khalifa Medical City, Abu Dhabi P.O. Box 51900, United Arab Emirates. FAU - Abdullah, Osama AU - Abdullah O AD - Core Technology Platform Operations, New York University Abu Dhabi, Abu Dhabi P.O. Box 129188, United Arab Emirates. FAU - Al-Ketan, Oraib AU - Al-Ketan O AUID- ORCID: 0000-0003-2736-3779 AD - Core Technology Platform Operations, New York University Abu Dhabi, Abu Dhabi P.O. Box 129188, United Arab Emirates. FAU - Rowshan, Reza AU - Rowshan R AUID- ORCID: 0000-0002-3206-0986 AD - Core Technology Platform Operations, New York University Abu Dhabi, Abu Dhabi P.O. Box 129188, United Arab Emirates. LA - eng PT - Journal Article DEP - 20211116 PL - Switzerland TA - Biomolecules JT - Biomolecules JID - 101596414 MH - Humans MH - *Printing, Three-Dimensional MH - Male MH - Female MH - Infant MH - *Cardiac Surgical Procedures/methods/education MH - *Heart Defects, Congenital/surgery/diagnostic imaging MH - Patient Care Team MH - Models, Anatomic MH - Child MH - Child, Preschool MH - Imaging, Three-Dimensional PMC - PMC8615737 OTO - NOTNLM OT - congenital heart disease OT - congenital heart surgery OT - hands-on surgical training OT - surgical simulation OT - surgical training OT - three-dimensional printing COIS- The authors declare no conflict of interest. The Hamdan bin Rashid Al Maktoum Foundation for Distinguished Academic Performance, Dubai, UAE, had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. EDAT- 2021/11/28 06:00 MHDA- 2022/01/13 06:00 PMCR- 2021/11/16 CRDT- 2021/11/27 01:03 PHST- 2021/10/15 00:00 [received] PHST- 2021/11/05 00:00 [revised] PHST- 2021/11/06 00:00 [accepted] PHST- 2021/11/27 01:03 [entrez] PHST- 2021/11/28 06:00 [pubmed] PHST- 2022/01/13 06:00 [medline] PHST- 2021/11/16 00:00 [pmc-release] AID - biom11111703 [pii] AID - biomolecules-11-01703 [pii] AID - 10.3390/biom11111703 [doi] PST - epublish SO - Biomolecules. 2021 Nov 16;11(11):1703. doi: 10.3390/biom11111703. PMID- 34827576 OWN - NLM STAT- MEDLINE DCOM- 20240725 LR - 20240725 IS - 2218-273X (Electronic) IS - 2218-273X (Linking) VI - 11 IP - 11 DP - 2021 Oct 25 TI - Myocardial and Arrhythmic Spectrum of Neuromuscular Disorders in Children. LID - 10.3390/biom11111578 [doi] LID - 1578 AB - Neuromuscular disorders (NMDs) are highly heterogenous from both an etiological and clinical point of view. Their signs and symptoms are often multisystemic, with frequent cardiac involvement. In fact, childhood onset forms can predispose a person to various progressive cardiac abnormalities including cardiomyopathies (CMPs), valvulopathies, atrioventricular conduction defects (AVCD), supraventricular tachycardia (SVT) and ventricular arrhythmias (VA). In this review, we selected and described five specific NMDs: Friedreich's Ataxia (FRDA), congenital and childhood forms of Myotonic Dystrophy type 1 (DM1), Kearns Sayre Syndrome (KSS), Ryanodine receptor type 1-related myopathies (RYR1-RM) and Laminopathies. These changes are widely investigated in adults but less researched in children. We focused on these specific topics due their relative frequency and their potential unexpected cardiac manifestations in children. Moreover these conditions present different inheritance patterns and mechanisms of action. We decided not to discuss Duchenne and Becker muscular dystrophies due to extensive work regarding the cardiac aspects in children. For each described NMD, we focused on the possible cardiac manifestations such as different types of CMPs (dilated-DCM, hypertrophic-HCM, restrictive-RCM or left ventricular non compaction-LVNC), structural heart abnormalities (including valvulopathies), and progressive heart rhythm changes (AVCD, SVT, VA). We describe the current management strategies for these conditions. We underline the importance, especially for children, of a serial multidisciplinary personalized approach and the need for periodic surveillance by a dedicated heart team. This is largely due to the fact that in children, the diagnosis of certain NMDs might be overlooked and the cardiac aspect can provide signs of their presence even prior to overt neurological diagnosis. FAU - Baban, Anwar AU - Baban A AD - The European Reference Network for Rare, Low Prevalence and Complex Diseases of the Heart-ERN GUARD-Heart, Department of Pediatric Cardiology and Cardiac Surgery, Heart and Lung Transplantation, Bambino Gesu Children Hospital and Research Institute, IRCCS, 00165 Rome, Italy. FAU - Lodato, Valentina AU - Lodato V AD - The European Reference Network for Rare, Low Prevalence and Complex Diseases of the Heart-ERN GUARD-Heart, Department of Pediatric Cardiology and Cardiac Surgery, Heart and Lung Transplantation, Bambino Gesu Children Hospital and Research Institute, IRCCS, 00165 Rome, Italy. FAU - Parlapiano, Giovanni AU - Parlapiano G AUID- ORCID: 0000-0002-2275-9670 AD - Laboratory of Medical Genetics, Translational Cytogenomics Research Unit, Bambino Gesu Children Hospital and Research Institute, IRCCS, 00165 Rome, Italy. FAU - di Mambro, Corrado AU - di Mambro C AD - The European Reference Network for Rare, Low Prevalence and Complex Diseases of the Heart-ERN GUARD-Heart, Department of Pediatric Cardiology and Cardiac Surgery, Heart and Lung Transplantation, Bambino Gesu Children Hospital and Research Institute, IRCCS, 00165 Rome, Italy. FAU - Adorisio, Rachele AU - Adorisio R AUID- ORCID: 0000-0002-9577-2155 AD - The European Reference Network for Rare, Low Prevalence and Complex Diseases of the Heart-ERN GUARD-Heart, Department of Pediatric Cardiology and Cardiac Surgery, Heart and Lung Transplantation, Bambino Gesu Children Hospital and Research Institute, IRCCS, 00165 Rome, Italy. FAU - Bertini, Enrico Silvio AU - Bertini ES AD - The European Reference Network for Neuromuscular Disorders (ERN NMD), Unit of Neuromuscular and Neurodegenerative Disorders, Bambino Gesu Children Hospital and Research Institute, IRCCS, 00146 Rome, Italy. FAU - Dionisi-Vici, Carlo AU - Dionisi-Vici C AD - Division of Metabolism, Bambino Gesu Children Hospital and Research Institute, IRCCS, 00165 Rome, Italy. FAU - Drago, Fabrizio AU - Drago F AD - The European Reference Network for Rare, Low Prevalence and Complex Diseases of the Heart-ERN GUARD-Heart, Department of Pediatric Cardiology and Cardiac Surgery, Heart and Lung Transplantation, Bambino Gesu Children Hospital and Research Institute, IRCCS, 00165 Rome, Italy. FAU - Martinelli, Diego AU - Martinelli D AD - Division of Metabolism, Bambino Gesu Children Hospital and Research Institute, IRCCS, 00165 Rome, Italy. LA - eng PT - Journal Article PT - Review DEP - 20211025 PL - Switzerland TA - Biomolecules JT - Biomolecules JID - 101596414 MH - Humans MH - Child MH - *Arrhythmias, Cardiac/genetics MH - *Neuromuscular Diseases/genetics MH - Cardiomyopathies/genetics MH - Myotonic Dystrophy/genetics MH - Friedreich Ataxia/genetics/diagnosis/complications MH - Kearns-Sayre Syndrome/genetics/diagnosis/complications PMC - PMC8615674 OTO - NOTNLM OT - age related penetrance OT - anticipation OT - cardiac involvement OT - heterogeneity OT - neuromuscular disorders OT - rarity COIS- The authors declare no conflict of interest. EDAT- 2021/11/28 06:00 MHDA- 2022/01/13 06:00 PMCR- 2021/10/25 CRDT- 2021/11/27 01:03 PHST- 2021/08/26 00:00 [received] PHST- 2021/10/02 00:00 [revised] PHST- 2021/10/14 00:00 [accepted] PHST- 2021/11/27 01:03 [entrez] PHST- 2021/11/28 06:00 [pubmed] PHST- 2022/01/13 06:00 [medline] PHST- 2021/10/25 00:00 [pmc-release] AID - biom11111578 [pii] AID - biomolecules-11-01578 [pii] AID - 10.3390/biom11111578 [doi] PST - epublish SO - Biomolecules. 2021 Oct 25;11(11):1578. doi: 10.3390/biom11111578. PMID- 34825999 OWN - NLM STAT- MEDLINE DCOM- 20211210 LR - 20220218 IS - 1534-6307 (Electronic) IS - 1523-3774 (Print) IS - 1523-3774 (Linking) VI - 23 IP - 11 DP - 2021 Nov 26 TI - The Musculoskeletal Manifestations of Marfan Syndrome: Diagnosis, Impact, and Management. PG - 81 LID - 10.1007/s11926-021-01045-3 [doi] LID - 81 AB - PURPOSE OF REVIEW: Marfan syndrome (MFS) is an autosomal dominant heritable disorder of fibrillin-1 (FBN1) with predominantly ocular, cardiovascular, and musculoskeletal manifestations that has a population prevalence of approximately 1 in 5-10,000 (Chiu et al. Mayo Clin Proc. 89(1):34-42, 146, Dietz 3, Loeys et al. J Med Genet. 47(7):476-85, 4). RECENT FINDINGS: The vascular complications of MFS still pose the greatest threat, but effective management options, such as regular cardiac monitoring and elective surgical intervention, have reduced the risk of life-threatening cardiovascular events, such as aortic dissection. Although cardiovascular morbidity and mortality remains high, these improvements in cardiovascular management have extended the life expectancy of those with MFS by perhaps 30-50 years from an estimated mean of 32 years in 1972 (Dietz 3, Gott et al. Eur J Cardio-thoracic Surg. 10(3):149-58, 147, Murdoch et al. N Engl J Med. 286(15):804-8, 148). The musculoskeletal manifestations of MFS, which to date have received less attention, can also have a significant impact on the quality of life and are likely to become more important as the age of the Marfan syndrome population increases (Hasan et al. Int J Clin Pract. 61(8):1308-1320, 127). In addition, musculoskeletal manifestations are often critically important in the diagnosis of MFS. Here, we review the main clinically relevant and diagnostically useful musculoskeletal features of MFS, which together contribute to the "systemic features score" (referred to hereafter as systemic score), part of the revised Ghent nosology for MFS. We discuss current treatment strategies and highlight the need for a multidisciplinary approach to diagnosis and management. Finally, we review new pharmacological approaches that may be disease modifying and could help to improve the outcome for individuals with this syndrome. CI - (c) 2021. The Author(s). FAU - Pollock, Lily AU - Pollock L AD - Kennedy Institute of Rheumatology, NDORMS, University of Oxford, Oxford, UK. FAU - Ridout, Ashley AU - Ridout A AD - Department of Rheumatology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. FAU - Teh, James AU - Teh J AD - Department of Radiology, Oxford University Hospitals NHS Foundation Trust, Oxford, England, UK. FAU - Nnadi, Colin AU - Nnadi C AD - Department of Surgery, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. FAU - Stavroulias, Dionisios AU - Stavroulias D AD - Department of Surgery, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. FAU - Pitcher, Alex AU - Pitcher A AD - Department of Cardiology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. FAU - Blair, Edward AU - Blair E AD - Department of Clinical Genetics, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. FAU - Wordsworth, Paul AU - Wordsworth P AD - Department of Rheumatology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. FAU - Vincent, Tonia L AU - Vincent TL AD - Kennedy Institute of Rheumatology, NDORMS, University of Oxford, Oxford, UK. tonia.vincent@kennedy.ox.ac.uk. AD - Department of Rheumatology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. tonia.vincent@kennedy.ox.ac.uk. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20211126 PL - United States TA - Curr Rheumatol Rep JT - Current rheumatology reports JID - 100888970 SB - IM MH - *Cardiovascular Diseases MH - Humans MH - *Marfan Syndrome/diagnosis/therapy MH - Quality of Life PMC - PMC8626407 OTO - NOTNLM OT - Arachnodactyly OT - Dural ectasia OT - Marfan syndrome OT - Pectus deformity OT - Scoliosis COIS- The authors declare no competing interests. EDAT- 2021/11/27 06:00 MHDA- 2021/12/15 06:00 PMCR- 2021/11/26 CRDT- 2021/11/26 12:16 PHST- 2021/09/20 00:00 [accepted] PHST- 2021/11/26 12:16 [entrez] PHST- 2021/11/27 06:00 [pubmed] PHST- 2021/12/15 06:00 [medline] PHST- 2021/11/26 00:00 [pmc-release] AID - 10.1007/s11926-021-01045-3 [pii] AID - 1045 [pii] AID - 10.1007/s11926-021-01045-3 [doi] PST - epublish SO - Curr Rheumatol Rep. 2021 Nov 26;23(11):81. doi: 10.1007/s11926-021-01045-3. PMID- 34823657 OWN - NLM STAT- MEDLINE DCOM- 20220104 LR - 20220104 IS - 1558-3597 (Electronic) IS - 0735-1097 (Linking) VI - 78 IP - 22 DP - 2021 Nov 30 TI - Life Expectancy After Surgical Aortic Valve Replacement. PG - 2147-2157 LID - S0735-1097(21)07175-8 [pii] LID - 10.1016/j.jacc.2021.09.861 [doi] AB - BACKGROUND: Surgical risk, age, perceived life expectancy, and valve durability influence the choice between surgical aortic valve replacement (SAVR) and transcatheter aortic valve implantation. The contemporaneous life expectancy after SAVR, in relation to surgical risk and age, is unknown. OBJECTIVES: The purpose of this study was to determine median survival time in relation to surgical risk and chronological age in SAVR patients. METHODS: Patients >/=60 years with aortic stenosis who underwent isolated SAVR with a bioprosthesis (n = 8,353) were risk-stratified before surgery into low, intermediate, or high surgical risk using the logistic EuroSCORE (2001-2011) or EuroSCORE II (2012-2017) and divided into age groups. Median survival time and cumulative 5-year mortality were estimated with Kaplan-Meier curves. Cox regression analysis was used to further determine the importance of age. RESULTS: There were 7,123 (85.1%) low-risk patients, 942 (11.3%) intermediate-risk patients, and 288 (3.5%) high-risk patients. Median survival time was 10.9 years (95% confidence interval: 10.6-11.2 years) in low-risk, 7.3 years (7.0-7.9 years) in intermediate-risk, and 5.8 years (5.4-6.5 years) in high-risk patients. The 5-year cumulative mortality was 16.5% (15.5%-17.4%), 30.7% (27.5%-33.7%), and 43.0% (36.8%-48.7%), respectively. In low-risk patients, median survival time ranged from 16.2 years in patients aged 60 to 64 years to 6.1 years in patients aged >/=85 years. Age was associated with 5-year mortality only in low-risk patients (interaction P < 0.001). CONCLUSIONS: Eighty-five percent of SAVR patients receiving bioprostheses have low surgical risk. Estimated survival is substantial following SAVR, especially in younger, low-risk patients, which should be considered in Heart Team discussions. CI - Copyright (c) 2021 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Martinsson, Andreas AU - Martinsson A AD - Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden; Department of Molecular and Clinical Medicine, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden. Electronic address: andreas.s.martinsson@vgregion.se. FAU - Nielsen, Susanne J AU - Nielsen SJ AD - Department of Molecular and Clinical Medicine, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden; Department of Cardiothoracic Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden. FAU - Milojevic, Milan AU - Milojevic M AD - Department of Cardiovascular Research, Dedinje Cardiovascular Institute, Belgrade, Serbia; Department of Cardiothoracic Surgery, Erasmus University Medical Centre, Rotterdam, the Netherlands. FAU - Redfors, Bjorn AU - Redfors B AD - Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden; Department of Molecular and Clinical Medicine, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden. FAU - Omerovic, Elmir AU - Omerovic E AD - Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden; Department of Molecular and Clinical Medicine, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden. FAU - Tonnessen, Theis AU - Tonnessen T AD - Department of Cardiothoracic Surgery, Oslo University Hospital, Oslo, Norway; University of Oslo, Oslo, Norway. FAU - Gudbjartsson, Tomas AU - Gudbjartsson T AD - Department of Cardiothoracic Surgery, Landspitali University Hospital, Reykjavik, Iceland; Faculty of Medicine, University of Iceland, Reykjavik, Iceland. FAU - Dellgren, Goran AU - Dellgren G AD - Department of Molecular and Clinical Medicine, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden; Department of Cardiothoracic Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden. FAU - Jeppsson, Anders AU - Jeppsson A AD - Department of Molecular and Clinical Medicine, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden; Department of Cardiothoracic Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden. LA - eng PT - Journal Article PT - Multicenter Study PT - Observational Study PT - Research Support, Non-U.S. Gov't PL - United States TA - J Am Coll Cardiol JT - Journal of the American College of Cardiology JID - 8301365 SB - IM CIN - J Am Coll Cardiol. 2021 Nov 30;78(22):2158-2160. doi: 10.1016/j.jacc.2021.09.860. PMID: 34823658 MH - Aged MH - Aged, 80 and over MH - Aortic Valve/*surgery MH - Aortic Valve Stenosis/mortality/*surgery MH - Heart Valve Prosthesis Implantation/*methods MH - Humans MH - Life Expectancy/*trends MH - Middle Aged MH - Postoperative Period MH - Severity of Illness Index MH - Survival Rate/trends MH - Sweden/epidemiology MH - Treatment Outcome OTO - NOTNLM OT - aortic stenosis OT - aortic valve replacement OT - epidemiology OT - valvular heart disease COIS- Funding Support and Author Disclosures This work was supported by grants from The Swedish Heart-Lung Foundation (20180560 to Dr Jeppsson and 201604 to Dr Nielsen), The Swedish state under the agreement between the Swedish government and the county councils concerning economic support of research and education of doctors (ALF agreement) (ALFGBG-725131 to Dr Jeppsson), and Vastra Gotaland Region (VGFOUREG-847811 and VGFOUREG-665591 to Dr Jeppsson), and Family Nils Winberg's Foundation. The supporting bodies had no influence on the analysis and interpretation of data, on the writing of the report, or on the decision to submit the paper for publication. Dr Omerovic has received an institutional research grant from AstraZeneca; has received consultancy fees from Bayer and Novartis; and has received speaker honorarium from Merck, Sharp & Dohme, all outside the present work. Dr Dellgren has received an institutional grant for the SweVAD study from Abbott; and has received an institutional grant for the ScanCLAD study from Astellas. Dr Dellgren has received speaker's fees from XVIVO, all outside the present work. Dr Milojevic has received speaker's fees from LivaNova outside the present work. Dr Jeppsson has received fees for consultancy or lectures from Werfen, Boehringer Ingelheim, Portola, Baxter, and LFB Biomedicaments, all unrelated to the present work. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2021/11/27 06:00 MHDA- 2022/01/05 06:00 CRDT- 2021/11/26 05:42 PHST- 2021/05/18 00:00 [received] PHST- 2021/08/12 00:00 [revised] PHST- 2021/09/06 00:00 [accepted] PHST- 2021/11/26 05:42 [entrez] PHST- 2021/11/27 06:00 [pubmed] PHST- 2022/01/05 06:00 [medline] AID - S0735-1097(21)07175-8 [pii] AID - 10.1016/j.jacc.2021.09.861 [doi] PST - ppublish SO - J Am Coll Cardiol. 2021 Nov 30;78(22):2147-2157. doi: 10.1016/j.jacc.2021.09.861. PMID- 34822807 OWN - NLM STAT- MEDLINE DCOM- 20220413 LR - 20220531 IS - 1873-1740 (Electronic) IS - 0033-0620 (Linking) VI - 69 DP - 2021 Nov-Dec TI - Current interventional therapies in acute pulmonary embolism. PG - 54-61 LID - S0033-0620(21)00128-6 [pii] LID - 10.1016/j.pcad.2021.11.009 [doi] AB - Pulmonary embolism (PE) is the third leading cause of cardiovascular mortality. The management of PE is currently evolving given the development of new technologies and team-based approaches. This document will focus on risk stratification of PEs, review of the current interventional therapies, the role of clinical endpoints to assess the effectiveness of different interventional therapies, and the role for mechanical circulatory support in the complex management of this disease. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - Jamil, Alisha AU - Jamil A AD - Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, United States of America. FAU - Johnston-Cox, Hillary AU - Johnston-Cox H AD - Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, United States of America; Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, United States of America. FAU - Pugliese, Steven AU - Pugliese S AD - Division of Pulmonary and Critical Care Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, United States of America. FAU - Nathan, Ashwin S AU - Nathan AS AD - Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, United States of America; Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, United States of America; Center for Cardiovascular Outcomes, Quality, and Evaluative Research, United States of America. FAU - Fiorilli, Paul AU - Fiorilli P AD - Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, United States of America; Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, United States of America; Center for Cardiovascular Outcomes, Quality, and Evaluative Research, United States of America. FAU - Khandhar, Sameer AU - Khandhar S AD - Division of Cardiovascular Medicine, Penn Presbyterian Medical Center, Philadelphia, PA 19104, United States of America. FAU - Weinberg, Mitchell D AU - Weinberg MD AD - Zucker School of Medicine at Hofstra/Northwell, Staten Island University Hospital, Staten Island, NY 10305, United States of America. FAU - Giri, Jay AU - Giri J AD - Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, United States of America; Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, United States of America; Center for Cardiovascular Outcomes, Quality, and Evaluative Research, United States of America. FAU - Kobayashi, Taisei AU - Kobayashi T AD - Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, United States of America; Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, United States of America; Center for Cardiovascular Outcomes, Quality, and Evaluative Research, United States of America. Electronic address: Taisei.Kobayashi@pennmedicine.upenn.edu. LA - eng PT - Journal Article PT - Review DEP - 20211122 PL - United States TA - Prog Cardiovasc Dis JT - Progress in cardiovascular diseases JID - 0376442 SB - IM MH - Acute Disease MH - Humans MH - *Pulmonary Embolism/therapy MH - Risk Factors OTO - NOTNLM OT - Acute pulmonary embolism OT - Cardiogenic shock OT - Catheter directed embolectomy OT - Catheter directed thrombolysis OT - Pulmonary embolism response team EDAT- 2021/11/26 06:00 MHDA- 2022/04/14 06:00 CRDT- 2021/11/25 20:10 PHST- 2021/11/14 00:00 [received] PHST- 2021/11/14 00:00 [accepted] PHST- 2021/11/26 06:00 [pubmed] PHST- 2022/04/14 06:00 [medline] PHST- 2021/11/25 20:10 [entrez] AID - S0033-0620(21)00128-6 [pii] AID - 10.1016/j.pcad.2021.11.009 [doi] PST - ppublish SO - Prog Cardiovasc Dis. 2021 Nov-Dec;69:54-61. doi: 10.1016/j.pcad.2021.11.009. Epub 2021 Nov 22. PMID- 34822197 OWN - NLM STAT- MEDLINE DCOM- 20220106 LR - 20220106 IS - 1540-8191 (Electronic) IS - 0886-0440 (Linking) VI - 37 IP - 2 DP - 2022 Feb TI - Mitral valve paravalvular leaks: Comprehensive review of literature. PG - 418-430 LID - 10.1111/jocs.16145 [doi] AB - BACKGROUND: Mitral paravalvular leaks (mPVL) are a recognized complication for patients with mitral valve prostheses. Although clinically insignificant for many patients, it may pose life-threatening haemolysis and regurgitation-induced heart failure, and so clinicians should have a high index of suspicion in the presence of new symptoms. AIMS: This review discusses the pathogenesis, clinical features, diagnosis, imaging and treatment of mPVLs. METHODS: A comprehensive literature search was performed using PubMed, EMBASE, Cochrane database, Google Scholar and Ovid. Search terms used included "mitral valve paravalvular leak," "transthoracic echocardiography," "2D transoesophageal echocardiography," "3D transoesophageal echocardiography," "cardiac computed tomography," (CT) "cardiac magnetic resonance imaging," "intracardiac echocardiography," "cinefluoroscopy," "fluoroscopy," and "percutaneous closure." RESULTS: All patients with mPVLs should undergo regular full evaluation, including patient history, physical examination, laboratory work-up, imaging, and referral, if necessary. Echocardiography is fundamental to the diagnosis, and is augmented with cardiac magnetic resonance imaging, cardiac computerized tomography and fluoroscopy for further characterization and procedural planning amongst the structural heart team. CONCLUSION: The prevalence of mPVL is expected to increase proportionally to the growing number of surgical and transcatheter valve replacements conducted in the ageing population. Multimodal imaging is instrumental in guiding diagnostic and therapeutic strategies when managing mPVLs. Advances in imaging and capabilities of transcather devices will prompt growing uptake of percutaneous treatment over conventional, higher-risk surgery for mPVL management. CI - (c) 2021 Wiley Periodicals LLC. FAU - Janmohamed, Imran Karim AU - Janmohamed IK AUID- ORCID: 0000-0003-0755-7242 AD - Faculty of Medicine and Health, University of Leeds School of Medicine, Leeds, UK. FAU - Mishra, Vaibhav AU - Mishra V AUID- ORCID: 0000-0003-3958-7032 AD - St. George's University of London Medical School, Tooting, London, UK. FAU - Geragotellis, Alexander AU - Geragotellis A AUID- ORCID: 0000-0001-7191-7885 AD - Faculty of Health Sciences, Observatory, University of Cape Town School of Medicine, Cape Town, South Africa. FAU - Sherif, Mohamed AU - Sherif M AUID- ORCID: 0000-0001-5544-3528 AD - Department of Cardiothoracic, Northern General Hospital, Sheffield, UK. FAU - Harky, Amer AU - Harky A AUID- ORCID: 0000-0001-5507-5841 AD - Department of Cardiac Surgery, Liverpool Heart and Chest Hospital, Liverpool, UK. LA - eng PT - Journal Article PT - Review DEP - 20211125 PL - United States TA - J Card Surg JT - Journal of cardiac surgery JID - 8908809 SB - IM MH - Cardiac Catheterization MH - Echocardiography, Transesophageal MH - *Heart Valve Prosthesis/adverse effects MH - *Heart Valve Prosthesis Implantation/adverse effects MH - Humans MH - Mitral Valve/diagnostic imaging/surgery MH - *Mitral Valve Insufficiency/diagnostic imaging/etiology MH - Prosthesis Failure OTO - NOTNLM OT - echocardiography OT - mitral valve OT - paravalvular leak OT - transcatheter closure EDAT- 2021/11/26 06:00 MHDA- 2022/01/07 06:00 CRDT- 2021/11/25 12:26 PHST- 2021/10/13 00:00 [revised] PHST- 2021/09/06 00:00 [received] PHST- 2021/10/29 00:00 [accepted] PHST- 2021/11/26 06:00 [pubmed] PHST- 2022/01/07 06:00 [medline] PHST- 2021/11/25 12:26 [entrez] AID - 10.1111/jocs.16145 [doi] PST - ppublish SO - J Card Surg. 2022 Feb;37(2):418-430. doi: 10.1111/jocs.16145. Epub 2021 Nov 25. PMID- 34822043 OWN - NLM STAT- MEDLINE DCOM- 20220825 LR - 20261029 IS - 1572-8595 (Electronic) IS - 1383-875X (Linking) VI - 64 IP - 2 DP - 2022 Aug TI - Percutaneous left atrial appendage closure in patients with primary hemostasis disorders and atrial fibrillation. PG - 497-509 LID - 10.1007/s10840-021-01073-0 [doi] AB - BACKGROUND OR PURPOSE: We report our single-center experience with percutaneous left atrial appendage closure (LAAC) in patients with non-valvular atrial fibrillation (NVAF) and primary hemostasis disorders (HD). METHODS: Consecutive patients with primary HD who underwent a percutaneous LAAC were included. Baseline characteristics, procedural data, and clinical outcomes were prospectively collected and compared with the overall LAAC cohort without HD. RESULTS: Since 2013, among 229 LAAC, 17 patients (7%) had a primary HD: thrombocytopenia (n = 5), myelodysplastic syndrome (n = 6), von Willebrand syndrome (n = 4), type A hemophilia (n = 1), and dysfibrinogenemia (n = 1). The HD population's age ranged from 61 to 87 years, and the median CHA(2)DS(2)VASc was 5. Periprocedural plasmatic management was required in 47% of patients. The immediate LAAC implantation success rate was 100%. Patients received a direct oral anticoagulant (DOA) (n = 9), dual antiplatelet (n = 6), aspirin (n = 1), or no therapy (n = 1) during the first six postoperative weeks, followed with single antiplatelet (n = 16) or no therapy (n = 1) during lifelong. After 20 months, the technical success rate and procedural success rate were 100% and 94%. Zero device-/procedure-related complication and only one life-threatening bleeding occurred. Compared to patients without HD (n = 212), a baseline history of bleeding was less frequent (53% vs 91%, p < 0.001), and more patients received a perioperative blood transfusion (47% vs 4%, p < 0.001) in the HD group. The efficacy and safety outcomes did not differ between HD and non-HD cohorts. CONCLUSIONS: Percutaneous LAAC in primary HD carriers appeared as safe and as effective as in overall LAAC population for stroke and bleeding prevention at midterm follow-up. Percutaneous left atrial appendage closure in patients with atrial fibrillation and primary hemostasis disorders. The percutaneous LAAC in primary hemostasis disorders and AF carriers requires a multidisciplinary approach. Cardiologist, anesthesiologist, and hematologist discussion is a cornerstone to assess anticoagulant contraindication, LAAC feasibility, periprocedural management, and follow-up (high). This multidisciplinary care is illustrated by the case of a 61-year-old male with hemophilia type A and recurrent hemarthrosis. Pre-LAAC assessment confirmed procedural indication and cactus LAA anatomy (left). After plasmatic management with factor VIII infusion, a WATCHMAN no. 21 was successfully implanted (middle). During follow-up, without antithrombotic regime, no ischemic or hemorrhagic complication occurred (right). LAA, left atrial appendage; LAAC, left atrial appendage closure; TEE, transesophageal echocardiography. Percutaneous LAAC in primary HD carriers appeared as safe and as effective as in overall LAAC population for stroke and bleeding prevention at midterm follow-up. CI - (c) 2021. Springer Science+Business Media, LLC, part of Springer Nature. FAU - Dognin, Nicolas AU - Dognin N AUID- ORCID: 0000-0002-9993-1846 AD - Service de Cardiologie, Institut Universitaire de Cardiologie Et de Pneumologie de Quebec, 2725 Chemin de Sainte-Foy, Quebec City, Quebec, G1V 4G5, Canada. nicolas-philippe.dognin.1@ulaval.ca. FAU - Salaun, Erwan AU - Salaun E AD - Service de Cardiologie, Institut Universitaire de Cardiologie Et de Pneumologie de Quebec, 2725 Chemin de Sainte-Foy, Quebec City, Quebec, G1V 4G5, Canada. FAU - Champagne, Catherine AU - Champagne C AD - Service de Cardiologie, Institut Universitaire de Cardiologie Et de Pneumologie de Quebec, 2725 Chemin de Sainte-Foy, Quebec City, Quebec, G1V 4G5, Canada. FAU - Domain, Guillaume AU - Domain G AD - Service de Cardiologie, Institut Universitaire de Cardiologie Et de Pneumologie de Quebec, 2725 Chemin de Sainte-Foy, Quebec City, Quebec, G1V 4G5, Canada. FAU - O'Hara, Gilles AU - O'Hara G AD - Service de Cardiologie, Institut Universitaire de Cardiologie Et de Pneumologie de Quebec, 2725 Chemin de Sainte-Foy, Quebec City, Quebec, G1V 4G5, Canada. FAU - Philippon, Francois AU - Philippon F AD - Service de Cardiologie, Institut Universitaire de Cardiologie Et de Pneumologie de Quebec, 2725 Chemin de Sainte-Foy, Quebec City, Quebec, G1V 4G5, Canada. FAU - Paradis, Jean-Michel AU - Paradis JM AD - Service de Cardiologie, Institut Universitaire de Cardiologie Et de Pneumologie de Quebec, 2725 Chemin de Sainte-Foy, Quebec City, Quebec, G1V 4G5, Canada. FAU - Faroux, Laurent AU - Faroux L AD - Service de Cardiologie, Institut Universitaire de Cardiologie Et de Pneumologie de Quebec, 2725 Chemin de Sainte-Foy, Quebec City, Quebec, G1V 4G5, Canada. FAU - Beaudoin, Jonathan AU - Beaudoin J AD - Service de Cardiologie, Institut Universitaire de Cardiologie Et de Pneumologie de Quebec, 2725 Chemin de Sainte-Foy, Quebec City, Quebec, G1V 4G5, Canada. FAU - O'Connor, Kim AU - O'Connor K AD - Service de Cardiologie, Institut Universitaire de Cardiologie Et de Pneumologie de Quebec, 2725 Chemin de Sainte-Foy, Quebec City, Quebec, G1V 4G5, Canada. FAU - Bernier, Mathieu AU - Bernier M AD - Service de Cardiologie, Institut Universitaire de Cardiologie Et de Pneumologie de Quebec, 2725 Chemin de Sainte-Foy, Quebec City, Quebec, G1V 4G5, Canada. FAU - Rodes-Cabau, Josep AU - Rodes-Cabau J AD - Service de Cardiologie, Institut Universitaire de Cardiologie Et de Pneumologie de Quebec, 2725 Chemin de Sainte-Foy, Quebec City, Quebec, G1V 4G5, Canada. FAU - Champagne, Jean AU - Champagne J AD - Service de Cardiologie, Institut Universitaire de Cardiologie Et de Pneumologie de Quebec, 2725 Chemin de Sainte-Foy, Quebec City, Quebec, G1V 4G5, Canada. LA - eng PT - Journal Article DEP - 20211125 PL - Netherlands TA - J Interv Card Electrophysiol JT - Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing JID - 9708966 RN - 0 (Anticoagulants) SB - IM MH - Aged MH - Aged, 80 and over MH - Anticoagulants/therapeutic use MH - *Atrial Appendage/diagnostic imaging/surgery MH - *Atrial Fibrillation/complications/surgery MH - *Hemophilia A/complications MH - Hemorrhage MH - Hemostasis MH - Humans MH - Male MH - Middle Aged MH - *Stroke/epidemiology/etiology/prevention & control MH - Treatment Outcome OTO - NOTNLM OT - Atrial fibrillation OT - Hemostasis disorders OT - Left atrial appendage closure OT - Myelodysplastic syndrome OT - Stroke OT - Thrombocytopenia EDAT- 2021/11/26 06:00 MHDA- 2022/08/26 06:00 CRDT- 2021/11/25 12:20 PHST- 2021/05/05 00:00 [received] PHST- 2021/10/04 00:00 [accepted] PHST- 2021/11/26 06:00 [pubmed] PHST- 2022/08/26 06:00 [medline] PHST- 2021/11/25 12:20 [entrez] AID - 10.1007/s10840-021-01073-0 [pii] AID - 10.1007/s10840-021-01073-0 [doi] PST - ppublish SO - J Interv Card Electrophysiol. 2022 Aug;64(2):497-509. doi: 10.1007/s10840-021-01073-0. Epub 2021 Nov 25. PMID- 34822042 OWN - NLM STAT- MEDLINE DCOM- 20220629 LR - 20261028 IS - 1572-8595 (Electronic) IS - 1383-875X (Linking) VI - 64 IP - 1 DP - 2022 Jun TI - Left atrial appendage occlusion in haemophilia patients with atrial fibrillation. PG - 95-102 LID - 10.1007/s10840-021-01090-z [doi] AB - PURPOSE: Advanced targeted therapy has resulted in increasing life expectancy and incidence of age-related cardiovascular diseases like atrial fibrillation in patients with haemophilia. Oral anticoagulation constitutes a significant dilemma in this patient category as the risks of stroke and bleeding are difficult to balance. We sought to demonstrate the feasibility of left atrial appendage occlusion (LAAO) in patients with haemophilia and atrial fibrillation. METHODS: All patients with haemophilia treated with LAAO at Aarhus University Hospital, Denmark, were identified from a local prospective database comprising all consecutive LAAO procedures from 2010 up to November 2020. Based on review of the medical records, a retrospective descriptive analysis was performed. RESULTS: Seven patients with haemophilia A and atrial fibrillation underwent LAAO after multidisciplinary conference. Peri-procedural coagulation management was guided by factor VIII activity and treated with repeated bolus administrations of recombinant factor VIII targeting an activity of 100%. The implantation was successful in all patients with only minor bleeding complications post-procedurally. Based on these experiences, a suggested regime has been formulated. CONCLUSIONS: LAAO is feasible in haemophilia patients with concurrent atrial fibrillation. However, special care including intravenous substitution with coagulation factors must be given in the periprocedural management. CI - (c) 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Kramer, Anders Dahl AU - Kramer AD AUID- ORCID: 0000-0002-5546-8693 AD - Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark. anha@clin.au.dk. FAU - Korsholm, Kasper AU - Korsholm K AD - Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark. FAU - Kristensen, Andreas AU - Kristensen A AD - Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark. AD - Department of Cardiology, University Hospital of North Norway, Tromso, Norway. FAU - Poulsen, Lone Hvitfeldt AU - Poulsen LH AD - Department of Haematology, Haemophilia Centre West, Aarhus University Hospital, Aarhus, Denmark. FAU - Nielsen-Kudsk, Jens Erik AU - Nielsen-Kudsk JE AD - Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark. LA - eng PT - Journal Article DEP - 20211125 PL - Netherlands TA - J Interv Card Electrophysiol JT - Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing JID - 9708966 RN - 9001-27-8 (Factor VIII) SB - IM MH - *Atrial Appendage/surgery MH - *Atrial Fibrillation/complications/surgery MH - Factor VIII MH - *Hemophilia A/complications/drug therapy MH - Humans MH - Retrospective Studies MH - *Septal Occluder Device MH - *Stroke/etiology/prevention & control MH - Treatment Outcome OTO - NOTNLM OT - Atrial fibrillation OT - Factor replacement therapy OT - Haemophilia OT - Left atrial appendage occlusion EDAT- 2021/11/26 06:00 MHDA- 2022/06/30 06:00 CRDT- 2021/11/25 12:20 PHST- 2021/08/06 00:00 [received] PHST- 2021/11/04 00:00 [accepted] PHST- 2021/11/26 06:00 [pubmed] PHST- 2022/06/30 06:00 [medline] PHST- 2021/11/25 12:20 [entrez] AID - 10.1007/s10840-021-01090-z [pii] AID - 10.1007/s10840-021-01090-z [doi] PST - ppublish SO - J Interv Card Electrophysiol. 2022 Jun;64(1):95-102. doi: 10.1007/s10840-021-01090-z. Epub 2021 Nov 25. PMID- 34820282 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240509 IS - 2214-4269 (Print) IS - 2214-4269 (Electronic) IS - 2214-4269 (Linking) VI - 29 DP - 2021 Dec TI - A retrospective longitudinal study and comprehensive review of adult patients with glycogen storage disease type III. PG - 100821 LID - 10.1016/j.ymgmr.2021.100821 [doi] LID - 100821 AB - INTRODUCTION: A deficiency of glycogen debrancher enzyme in patients with glycogen storage disease type III (GSD III) manifests with hepatic, cardiac, and muscle involvement in the most common subtype (type a), or with only hepatic involvement in patients with GSD IIIb. OBJECTIVE AND METHODS: To describe longitudinal biochemical, radiological, muscle strength and ambulation, liver histopathological findings, and clinical outcomes in adults (>/=18 years) with glycogen storage disease type III, by a retrospective review of medical records. RESULTS: Twenty-one adults with GSD IIIa (14 F & 7 M) and four with GSD IIIb (1 F & 3 M) were included in this natural history study. At the most recent visit, the median (range) age and follow-up time were 36 (19-68) and 16 years (0-41), respectively. For the entire cohort: 40% had documented hypoglycemic episodes in adulthood; hepatomegaly and cirrhosis were the most common radiological findings; and 28% developed decompensated liver disease and portal hypertension, the latter being more prevalent in older patients. In the GSD IIIa group, muscle weakness was a major feature, noted in 89% of the GSD IIIa cohort, a third of whom depended on a wheelchair or an assistive walking device. Older individuals tended to show more severe muscle weakness and mobility limitations, compared with younger adults. Asymptomatic left ventricular hypertrophy (LVH) was the most common cardiac manifestation, present in 43%. Symptomatic cardiomyopathy and reduced ejection fraction was evident in 10%. Finally, a urinary biomarker of glycogen storage (Glc(4)) was significantly associated with AST, ALT and CK. CONCLUSION: GSD III is a multisystem disorder in which a multidisciplinary approach with regular clinical, biochemical, radiological and functional (physical therapy assessment) follow-up is required. Despite dietary modification, hepatic and myopathic disease progression is evident in adults, with muscle weakness as the major cause of morbidity. Consequently, definitive therapies that address the underlying cause of the disease to correct both liver and muscle are needed. CI - (c) 2021 The Authors. Published by Elsevier Inc. FAU - Hijazi, Ghada AU - Hijazi G AD - Division of Medical Genetics, Department of Pediatrics, Duke University Medical Center, Durham, NC, USA. FAU - Paschall, Anna AU - Paschall A AD - Division of Medical Genetics, Department of Pediatrics, Duke University Medical Center, Durham, NC, USA. FAU - Young, Sarah P AU - Young SP AD - Division of Medical Genetics, Department of Pediatrics, Duke University Medical Center, Durham, NC, USA. FAU - Smith, Brian AU - Smith B AD - Division of Neonatal-Perinatal Medicine, Department of Pediatrics, Duke University Medical Center, Durham, NC, USA. FAU - Case, Laura E AU - Case LE AD - Doctor of Physical Therapy Division, Department of Orthopedic Surgery, Duke University School of Medicine, Durham, NC, USA. FAU - Boggs, Tracy AU - Boggs T AD - Duke University Health System, Department of Physical Therapy and Occupational Therapy, USA. FAU - Amarasekara, Sathya AU - Amarasekara S AD - Duke University School of Nursing, Durham, NC, USA. FAU - Austin, Stephanie L AU - Austin SL AD - Division of Medical Genetics, Department of Pediatrics, Duke University Medical Center, Durham, NC, USA. FAU - Pendyal, Surekha AU - Pendyal S AD - Division of Medical Genetics, Department of Pediatrics, Duke University Medical Center, Durham, NC, USA. FAU - El-Gharbawy, Areeg AU - El-Gharbawy A AD - Division of Medical Genetics, Department of Pediatrics, Duke University Medical Center, Durham, NC, USA. FAU - Deak, Kristen L AU - Deak KL AD - Department of Pathology, Duke University, Durham, NC, USA. FAU - Muir, Andrew J AU - Muir AJ AD - Division of Gastroenterology, Duke University School of Medicine, Durham, NC, USA. FAU - Kishnani, Priya S AU - Kishnani PS AD - Division of Medical Genetics, Department of Pediatrics, Duke University Medical Center, Durham, NC, USA. LA - eng GR - TL1 TR002555/TR/NCATS NIH HHS/United States PT - Journal Article DEP - 20211111 PL - United States TA - Mol Genet Metab Rep JT - Molecular genetics and metabolism reports JID - 101624422 PMC - PMC8600151 OTO - NOTNLM OT - AFP, Alpha-fetoprotein OT - ALT, Alanine aminotransferase OT - AST, Aspartate aminotransferase OT - BG, Blood glucose OT - BMI, Body mass index OT - CEA, Carcinoembryonic antigen OT - CPK, Creatine phosphokinase OT - CT scan, Computerized tomography scan OT - Cardiomyopathy OT - Cirrhosis OT - DM, Diabetes mellitus OT - GDE, Glycogen debrancher enzyme OT - GGT, Gamma glutamyl transferase OT - GSD, Glycogen storage disease OT - Glc4, Glucose tetrasaccharide OT - Glycogen storage disease type III (GSD III) OT - HDL, High density lipoprotein OT - Hypoglycemia OT - LDL, Low density lipoproteins OT - LT, liver transplantation. OT - Left ventricular hypertrophy (LVH) OT - MRI, Magnetic resonance imaging OT - TGs, Triglycerides OT - US, Ultrasound OT - and myopathy EDAT- 2021/11/26 06:00 MHDA- 2021/11/26 06:01 PMCR- 2021/11/11 CRDT- 2021/11/25 06:38 PHST- 2021/10/19 00:00 [received] PHST- 2021/11/09 00:00 [accepted] PHST- 2021/11/25 06:38 [entrez] PHST- 2021/11/26 06:00 [pubmed] PHST- 2021/11/26 06:01 [medline] PHST- 2021/11/11 00:00 [pmc-release] AID - S2214-4269(21)00116-6 [pii] AID - 100821 [pii] AID - 10.1016/j.ymgmr.2021.100821 [doi] PST - epublish SO - Mol Genet Metab Rep. 2021 Nov 11;29:100821. doi: 10.1016/j.ymgmr.2021.100821. eCollection 2021 Dec. PMID- 34819960 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240818 IS - 1734-9338 (Print) IS - 1897-4295 (Electronic) IS - 1734-9338 (Linking) VI - 17 IP - 3 DP - 2021 Sep TI - Interdisciplinary management of acute ischaemic stroke - current evidence on training requirements for endovascular stroke treatment. Position Paper from the ESC Council on Stroke and the European Association for Percutaneous Cardiovascular Interventions with the support of the European Board of Neurointervention: A step forward. PG - 245-250 LID - 10.5114/aic.2021.109832 [doi] AB - Stroke, a vascular disease of the brain, is the #1 cause of disability and a major cause of death worldwide. Stroke has a major negative impact on the life of stroke-affected individuals, their families and the society. A significant proportion of stroke victims indicate that would have preferred death over their after-stroke quality of life. Mechanical thrombectomy (MT), opening the occluded artery using mechanical aspiration or a thrombus-entrapment device, is a guideline-mandated (class I, level of evidence A) treatment modality in patients with large vessel occlusion stroke. MT clinical benefit magnitude indicates that a universal access to this treatment strategy should be the standard of care. Today there is a substantial geographic variation in MT deliverability, with large-scale disparities in MT implementation. In many countries effective access to MT remains severely limited. In addition, many of the MT-treated patients are treated too late for a good functional outcome because of logistic delays that include transportations to remotely located, scarce, comprehensive stroke centres. Position Paper from the European Society of Cardiology Council on Stroke and European Association for Percutaneous Cardiovascular Interventions on interdisciplinary management of acute ischaemic stroke, developed with the support of the European Board of Neurointervention fills an important gap in systematically enabling interventional cardiologists to support stroke intervention in the geographic areas of unmet needs in particular. We review strengths and weaknesses of the document, and suggest directions for the next steps that are swiftly needed to deliver MT to stroke patients more effectively. CI - Copyright: (c) 2021 Termedia Sp. z o. o. FAU - Musialek, Piotr AU - Musialek P AD - Department of Cardiac and Vascular Diseases, Jagiellonian University, John Paul II Hospital, Krakow, Poland. FAU - Nizankowski, Rafal AU - Nizankowski R AD - Accreditation Council, National Centre for Health Quality Assessment, Krakow, Poland. FAU - Hopkins, L Nelson AU - Hopkins LN AD - Departments of Neurosurgery and Radiology, School of Medicine and Biomedical Sciences, State University of New York, Buffalo, New York, United States; Jacobs Institute, Gates Vascular Institute, Kaleida Health, Buffalo, New York, United States. FAU - Micari, Antonio AU - Micari A AD - Department of Cardiology, University of Messina Department of Biomedical and Dental Sciences and Morphological and Functional Imaging, A.O.U. Policlinic "G. Martino", Messina, Italy. FAU - Alvarez, Carlos Alejandro AU - Alvarez CA AD - Hospital Italiano Regional Del Sur, Hospital Privado Del Sur and Hospital Regional Espanol, Bahia Blanca, Argentina. FAU - Nikas, Dimitrios N AU - Nikas DN AD - Cardiology Department, Ioannina University Hospital, Ioannina, Greece. FAU - Ruzsa, Zoltan AU - Ruzsa Z AD - Invasive Cardiology Department, Bacs-Kiskun County Hospital, Teaching Hospital of the Szent-Gyorgyi Albert Medical University, Kecskemet, Hungary. FAU - Kuhn, Anna Luisa AU - Kuhn AL AD - Division of Neurointerventional Radiology, Department of Radiology, University of Masachusetts Medical Center, Worcester, MA, USA. FAU - Petrov, Ivo AU - Petrov I AD - Acibadem City Clinic Cardiovascular Center, Sofia, Bulgaria. FAU - Politi, Maria AU - Politi M AD - Department of Diagnostic and Interventional Neuroradiology, Hospital Bremen-Mitte, Germany. FAU - Pillai, Sanjay AU - Pillai S AD - NHS Tayside Interventional Radiology, Dundee, Scotland, United Kingdom. FAU - Papanagiotou, Panagiotis AU - Papanagiotou P AD - Department of Diagnostic and Interventional Neuroradiology, Hospital Bremen-Mitte, Germany. AD - Areteion University Hospital, National and Kapodistrian University of Athens, Athens, Greece. FAU - Mathias, Klaus AU - Mathias K AD - Department of Radiology, University of Munster, Munster, Germany. FAU - Sievert, Horst AU - Sievert H AD - CardioVascular Center Frankfurt, Germany. AD - University of California San Francisco UCSF, San Francisco, California, USA. FAU - Grunwald, Iris Q AU - Grunwald IQ AD - Chair of Neuroradiology, Department of Radiology, University of Dundee, Ninewells Hospital, Dundee, Scotland, United Kingdom. LA - eng PT - Journal Article PT - Review DEP - 20211020 PL - Poland TA - Postepy Kardiol Interwencyjnej JT - Postepy w kardiologii interwencyjnej = Advances in interventional cardiology JID - 101272671 PMC - PMC8596728 OTO - NOTNLM OT - acute ischaemic stroke OT - cardiology cathlab-based treatment OT - cerebral resuscitation OT - mechanical thrombectomy OT - multispecialty team OT - unmet needs COIS- PM is the Polish Cardiac Society Board Representative for Stroke and Vascular Interventions. Other authors declare no conflicts of interest in relation to this paper. EDAT- 2021/11/26 06:00 MHDA- 2021/11/26 06:01 PMCR- 2021/09/01 CRDT- 2021/11/25 06:34 PHST- 2021/09/30 00:00 [received] PHST- 2021/09/30 00:00 [accepted] PHST- 2021/11/25 06:34 [entrez] PHST- 2021/11/26 06:00 [pubmed] PHST- 2021/11/26 06:01 [medline] PHST- 2021/09/01 00:00 [pmc-release] AID - 45398 [pii] AID - 10.5114/aic.2021.109832 [doi] PST - ppublish SO - Postepy Kardiol Interwencyjnej. 2021 Sep;17(3):245-250. doi: 10.5114/aic.2021.109832. Epub 2021 Oct 20. PMID- 34815334 OWN - NLM STAT- MEDLINE DCOM- 20220715 LR - 20221113 IS - 1468-201X (Electronic) IS - 1355-6037 (Linking) VI - 108 IP - 15 DP - 2022 Jul 13 TI - Non-cardiac surgery in patients with valvular heart disease. PG - 1171-1178 LID - 10.1136/heartjnl-2021-319160 [doi] AB - In patients with significant valvular heart disease (VHD) undergoing non-cardiac surgery (NCS), perioperative adverse cardiac events are a relevant issue. Although postoperative outcomes can be adversely affected by valve-related haemodynamic instability, recommended perioperative risk scores prioritise the risk of the surgical procedure and the presence of cardiovascular risk factors, neglecting the presence or extent of VHD. Perioperative management and anaesthetic approach should focus on the underlying type and severity of VHD, the compensatory mechanisms deployed by left ventricle and right ventricle and the type and risk of NCS. Due to the lack of randomised trials investigating different therapeutic approaches of valvular intervention prior to NCS, recommendations mainly rely on consensus opinion and inference based on large observational registries. As a general rule, valvular intervention is recommended prior to NCS in symptomatic patients or in those who meet standard criteria for cardiac intervention. In the absence of such conditions, it is reasonable to perform NCS with tailored anaesthetic management and close invasive perioperative haemodynamic monitoring. However, patient-specific management strategies should be discussed with the heart team preoperatively. Symptomatic patients with severe VHD or those undergoing high-risk NCS should ideally be treated at a high-volume medical centre that is equipped to manage haemodynamically complex patients during the perioperative period. CI - (c) Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Sorrentino, Regina AU - Sorrentino R AD - Department of Advanced Biomedical Science, Federico II University Hospital, Napoli, Italy. AD - Centro Cardiologico Gentile, Napoli, Campania, Italy. FAU - Santoro, Ciro AU - Santoro C AD - Department of Advanced Biomedical Science, Federico II University Hospital, Napoli, Italy. FAU - Bardi, Luca AU - Bardi L AD - Department of Advanced Biomedical Science, Federico II University Hospital, Napoli, Italy. FAU - Rigolin, Vera AU - Rigolin V AUID- ORCID: 0000-0001-6872-7861 AD - Medicine/Cardiology, Northwestern University, Chicago, Illinois, USA. FAU - Gentile, Federico AU - Gentile F AUID- ORCID: 0000-0002-0065-9281 AD - Centro Cardiologico Gentile, Napoli, Campania, Italy fdrcgentile@gmail.com. LA - eng PT - Journal Article PT - Review DEP - 20220713 PL - England TA - Heart JT - Heart (British Cardiac Society) JID - 9602087 SB - IM MH - *Cardiac Surgical Procedures MH - *Heart Valve Diseases/complications/drug therapy/surgery MH - *Heart Valve Prosthesis Implantation MH - Humans MH - Risk Factors OTO - NOTNLM OT - cardiac imaging techniques OT - heart valve diseases OT - heart valve prosthesis implantation OT - transcatheter aortic valve replacement COIS- Competing interests: None declared. EDAT- 2021/11/25 06:00 MHDA- 2022/07/16 06:00 CRDT- 2021/11/24 05:48 PHST- 2021/08/13 00:00 [received] PHST- 2021/11/02 00:00 [accepted] PHST- 2021/11/25 06:00 [pubmed] PHST- 2022/07/16 06:00 [medline] PHST- 2021/11/24 05:48 [entrez] AID - heartjnl-2021-319160 [pii] AID - 10.1136/heartjnl-2021-319160 [doi] PST - epublish SO - Heart. 2022 Jul 13;108(15):1171-1178. doi: 10.1136/heartjnl-2021-319160. PMID- 34814198 OWN - NLM STAT- MEDLINE DCOM- 20211129 LR - 20220428 IS - 1438-9010 (Electronic) IS - 1438-9010 (Linking) VI - 193 IP - 12 DP - 2021 Dec TI - Transcatheter Aortic Valve Implantation: The Evolving Role of the Radiologist in 2021. PG - 1411-1425 LID - 10.1055/a-1645-1873 [doi] AB - BACKGROUND: Transcatheter aortic valve implantation (TAVI) has gained worldwide acceptance and implementation as an alternative therapeutic option in patients with severe aortic valve stenosis unable to safely undergo surgical aortic valve replacement. This transformative technique places the radiologist in a key position in the pre-procedural assessment of potential candidates for this technique, delivering key anatomical information necessary for patient eligibility and procedural safety. Recent trials also provide encouraging results to potentially extend the indication to patients with safer risk profiles. METHOD: The review is based on a PubMed literature search using the search terms "transcatheter heart valve", "TAVI", "TAVR", "CT", "imaging", "MR" over a period from 2010-2020, combined with personal comments based on the author's experience. RESULTS AND CONCLUSION: CT plays a prominent role in the pre-procedural workup, delivering as a true 3D imaging modality optimal visualization of the complex anatomy of the aortic root with simultaneous evaluation of the patency of the different access routes. As such, the contribution of CT is key for the determination of patient eligibility and procedural safety. This input is supplementary to the contributions of other imaging modalities and forms an important element in the discussions of the Heart Valve Team. Knowledge of the procedure and its characteristics is necessary in order to provide a comprehensive and complete report. While the role of CT in the pre-procedural evaluation is well established, the contribution of CT and MR and the clinical significance of their findings in the routine follow-up after the intervention are less clear and currently the subject of intense investigation. Important issues remain, including the occurrence and significance of subclinical leaflet thrombosis, prosthetic heart valve endocarditis, and long-term structural valve degeneration. KEY POINTS: . CT plays a crucial role in evaluating transcatheter heart valve candidates. . Evaluation must include the dimensions of the aortic root and access paths. . The exact post-procedural role of CT and MRI has not yet been determined.. CITATION FORMAT: . Salgado R, El Addouli H, Budde RP. Transcatheter Aortic Valve Implantation: The Evolving Role of the Radiologist in 2021. Fortschr Rontgenstr 2021; 193: 1411 - 1425. CI - Thieme. All rights reserved. FAU - Salgado, Rodrigo AU - Salgado R AUID- ORCID: 0000-0003-4060-1612 AD - Radiology, UZA, Edegem, Belgium. AD - Radiology, Holy Heart Hospital Lier, Belgium. FAU - El Addouli, Haroun AU - El Addouli H AD - Radiology, UZA, Edegem, Belgium. FAU - Budde, Ricardo P J AU - Budde RPJ AUID- ORCID: 0000-0003-3792-615X AD - Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, Netherlands. LA - eng PT - Journal Article TT - Transkatheter-Aortenklappenimplantation: Die neue Rolle des Radiologen im Jahr 2021. DEP - 20211123 PL - Germany TA - Rofo JT - RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin JID - 7507497 SB - IM MH - Aortic Valve/diagnostic imaging/surgery MH - *Aortic Valve Stenosis/diagnostic imaging/surgery MH - *Heart Valve Prosthesis Implantation MH - Humans MH - Radiologists MH - *Transcatheter Aortic Valve Replacement MH - Treatment Outcome COIS- The authors declare that they have no conflict of interest. EDAT- 2021/11/24 06:00 MHDA- 2021/11/30 06:00 CRDT- 2021/11/23 20:29 PHST- 2021/11/23 20:29 [entrez] PHST- 2021/11/24 06:00 [pubmed] PHST- 2021/11/30 06:00 [medline] AID - 10.1055/a-1645-1873 [doi] PST - ppublish SO - Rofo. 2021 Dec;193(12):1411-1425. doi: 10.1055/a-1645-1873. Epub 2021 Nov 23. PMID- 34811718 OWN - NLM STAT- MEDLINE DCOM- 20220408 LR - 20260127 IS - 1898-018X (Electronic) IS - 1897-5593 (Print) IS - 1898-018X (Linking) VI - 29 IP - 1 DP - 2022 TI - Management of dyslipidemia in Poland: Interdisciplinary Expert Position Statement endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy. The Fourth Declaration of Sopot. PG - 1-26 LID - 10.5603/CJ.a2021.0147 [doi] FAU - Szymanski, Filip M AU - Szymanski FM AD - Department of Civilization Diseases, Faculty of Medicine, Collegium Medicum, Cardinal Stefan Wyszynski University in Warsaw, Poland. filip.szymanski@ptchc.pl. FAU - Mickiewicz, Agnieszka AU - Mickiewicz A AD - 1st Department of Cardiology, Medical University of Gdansk, Poland. FAU - Dzida, Grzegorz AU - Dzida G AD - Chair and Department of Internal Diseases, Medical University of Lublin, Poland. FAU - Gorczyca-Glowacka, Iwona AU - Gorczyca-Glowacka I AD - 1st Department of Cardiology and Electrotherapy, Swietokrzyskie Cardiology Center, Faculty of Medical and Health Sciences, The University of Jan Kochanowski, Kielce, Poland. FAU - Kozlowski, Dariusz AU - Kozlowski D AD - Department of Cardiology and Electrotherapy, Medical University of Gdansk, Poland. FAU - Widecka, Krystyna AU - Widecka K AD - Department of Hypertension and Internal Medicine, Pomeranian Medical University, Szczecin, Poland. FAU - Krasinski, Zbigniew AU - Krasinski Z AD - Department of Vascular and Endovascular Surgery, Angiology and Phlebology, Institute of Surgery, Poznan University of Medical Sciences, Poznan, Poland. FAU - Kobayashi, Adam AU - Kobayashi A AD - Department of Pharmacology and Clinical Pharmacology, Faculty of Medicine, Collegium Medicum, Cardinal Stefan Wyszynski University in Warsaw, Poland. AD - Department of Neurology with Stoke Unit, St. John Paul II Mazovian Provincial Hospital in Siedlce, Poland. FAU - Hering, Dagmara AU - Hering D AD - Department of Hypertension and Diabetology, Medical University of Gdansk, Poland. FAU - Mizia-Stec, Katarzyna AU - Mizia-Stec K AD - 1st Department of Cardiology, Medical University of Silesia, Katowice, Poland. FAU - Kasprzak, Jaroslaw D AU - Kasprzak JD AD - 1st Department of Cardiology, Medical University of Lodz, Poland. FAU - Zubilewicz, Tomasz AU - Zubilewicz T AD - Department of Vascular Surgery and Angiology, Medical University of Lublin, Poland. FAU - Narkiewicz, Krzysztof AU - Narkiewicz K AD - Department of Hypertension and Diabetology, Medical University of Gdansk, Poland. FAU - Kozinski, Marek AU - Kozinski M AD - Department of Cardiology and Internal Diseases, Institute of Maritime and Tropical Medicine, Gdynia, Poland. FAU - Platek, Anna E AU - Platek AE AD - Department of Biophysics, Physiology and Pathophysiology, Medical University of Warsaw, Poland. FAU - Rys-Czaporowska, Anna AU - Rys-Czaporowska A AD - 1st Department of Cardiology, Medical University of Warsaw, Poland. FAU - Chelstowska, Beata AU - Chelstowska B AD - Department of Biochemistry and Laboratory Diagnostics, Faculty of Medicine, Collegium Medicum, Cardinal Stefan Wyszynski University in Warsaw, Poland. FAU - Grajek, Stefan AU - Grajek S AD - 1st Department of Cardiology, Poznan University of Medical Sciences, Poznan, Poland. FAU - Welnicki, Marcin AU - Welnicki M AD - 3rd Department of Cardiology and Internal Diseases, Medical University of Warsaw, Poland. FAU - Mamcarz, Artur AU - Mamcarz A AD - 3rd Department of Cardiology and Internal Diseases, Medical University of Warsaw, Poland. FAU - Barylski, Marcin AU - Barylski M AD - Department of Internal Medicine and Cardiac Rehabilitation, Medical University of Lodz, Poland. FAU - Wozakowska-Kaplon, Beata AU - Wozakowska-Kaplon B AD - 1st Department of Cardiology and Electrotherapy, Swietokrzyskie Cardiology Center, Faculty of Medical and Health Sciences, The University of Jan Kochanowski, Kielce, Poland. FAU - Jaguszewski, Milosz J AU - Jaguszewski MJ AD - 1st Department of Cardiology, Medical University of Gdansk, Poland. FAU - Gruchala, Marcin AU - Gruchala M AD - 1st Department of Cardiology, Medical University of Gdansk, Poland. FAU - Filipiak, Krzysztof J AU - Filipiak KJ AD - Institute of Clinical Sciences, Maria Sklodowska-Curie Medical Academy, Warsaw, Poland. LA - eng PT - Consensus Statement PT - Journal Article DEP - 20211123 PL - Poland TA - Cardiol J JT - Cardiology journal JID - 101392712 SB - IM MH - *Cardiology MH - *Dyslipidemias/diagnosis/drug therapy MH - Heart MH - Humans MH - Poland MH - Societies, Medical PMC - PMC8890423 COIS- Conflict of interest: Filip M. Szymanski - Participation in satellite sessions/workshops: Bausch Health, Sanofi, Adamed, Krka, Sandoz Polska, Zentiva, Viatris (Mylan), USP Zdrowie sp. z o.o.; Agnieszka Mickiewicz - Honorarium payments for lectures, participation in satellite sessions and consulting groups: Krka, Sanofi, Amgen, Novartis, Zentiva, Egis, Servier; Grzegorz Dzida - Participation in satellite sessions/workshops: Krka, Polpharma, Viatris (Mylan); Iwona Gorczyca-Glowacka - None declared; Dariusz Kozlowski - None declared; Krystyna Widecka - None declared; Zbigniew Krasinski - None declared; Adam Kobayashi - None declared; Dagmara Hering - None declared; Katarzyna Mizia-Stec - None declared; Jaroslaw D. Kasprzak - Honorarium payments for lectures, participation in satellite sessions and consulting groups: Amgen, Sanofi, Polpharma, Servier, Pfizer, Aflofarm, AstraZeneca, Novartis; Tomasz Zubilewicz - None declared; Krzysztof Narkiewicz - Participation in satellite sessions/workshops: Egis, Krka, Servier; Marek Kozinski - None declared; Anna E. Platek - None declared; Anna Rys-Czaporowska - None declared; Beata Chelstowska - None declared; Stefan Grajek - None declared; Marcin Welnicki - Honorarium payments for lectures, training sessions, educational resources for the pharmaceutical companies: Egis, AstraZeneca, Novartis, Novo Nordisk, Apotex, Aurotivas, Polpharma, Bayer, Berlin-Chemie Menarini, Boehringer Ingelheim, Krka, Pfizer, Sanofi-Aventis, Servier, Teva, Valeant; Artur Mamcarz - Participation in satellite sessions and consulting groups of the following Polish and European drugs manufacturers: Adamed, Amgen, AstraZeneca, Bausch Health, Bayer, Berlin-Chemie Menarini, Boehringer Ingelheim, Egis, Krka, Merck, Mylan, Sandoz, Sanofi-Aventis, Servier, Zentiva; Marcin Barylski - None declared; Beata Wozakowska-Kaplon - Honorarium payments for lectures, participation in satellite sessions and consulting groups, clinical research sponsored by the following drugs manufacturers: Adamed, Alfasigma, Amgen, AstraZeneca, Bausch Health, Bayer, Berlin-Chemie Menarini, Boehringer Ingelheim, Egis, Krka, Novartis, Pfizer, Sanofi-Aventis, Servier; Milosz J. Jaguszewski - None declared; Marcin Gruchala - None declared; Krzysztof J. Filipiak - Participation in satellite sessions, Polish and European consulting groups, clinical-research and research grants sponsored by the following manufacturers of drugs and diagnostic tests: Adamed, Alfasigma, Amgen, AstraZeneca, Bausch Health, Bayer, Berlin-Chemie Menarini, Boehringer Ingelheim, Egis, Krka, Merck, Mylan, Sandoz, Sanofi, Servier, Zentiva. EDAT- 2021/11/24 06:00 MHDA- 2022/04/09 06:00 PMCR- 2022/02/23 CRDT- 2021/11/23 06:42 PHST- 2021/10/26 00:00 [received] PHST- 2021/10/26 00:00 [accepted] PHST- 2021/11/24 06:00 [pubmed] PHST- 2022/04/09 06:00 [medline] PHST- 2021/11/23 06:42 [entrez] PHST- 2022/02/23 00:00 [pmc-release] AID - VM/OJS/J/86591 [pii] AID - cardj-29-1-1 [pii] AID - 10.5603/CJ.a2021.0147 [doi] PST - ppublish SO - Cardiol J. 2022;29(1):1-26. doi: 10.5603/CJ.a2021.0147. Epub 2021 Nov 23. PMID- 34809961 OWN - NLM STAT- MEDLINE DCOM- 20220315 LR - 20220527 IS - 1531-5037 (Electronic) IS - 0022-3468 (Linking) VI - 57 IP - 4 DP - 2022 Apr TI - Intrathoracic prosthesis in children in preventing post pneumonectomy syndrome: Its role in congenital single lung and post pneumonectomy situations. PG - 581-585 LID - S0022-3468(21)00719-3 [pii] LID - 10.1016/j.jpedsurg.2021.10.010 [doi] AB - BACKGROUND: Postpneumopnectomy syndrome (PPS) is an extreme rotation and malposition of mediastinum causing dynamic and symptomatic central airway compression, arisingafter pneumonectomy or more uncommonly, in congenital single lung physiology. Affected patients present with severe respiratory compromise. Intrathoracic prosthesis placement is an evolving technique in children that mitigate the effects of thoracic dead space. RESEARCH QUESTION: Assessment of clinical recovery and functional benefit in children undergoing placement of intrathoracic prosthesis following pneumonectomy or in congenital single lung situations. STUDY DESIGN AND METHODS: Retrospective chart review of patients at Great Ormond Street Hospital from 2010 to 2020 was performed of all patients who underwent intrathoracic tissue expander placement. We summarize the outcomes of twenty four children, including those with both congenital and postpneumonectomy PPS etiology. RESULTS: 24 Children who underwent placement of intrathoracic prosthesis for PPS in the study period with median age of 3.5 months and weight of 5 kg. Single lung etiology was congenital in 15 children (6 agenesis, 9 hypoplasia), and postpneumonectomy in 9 children. In seven patients, there was associated long segment tracheal stenosis. Pre operative ECMO was required in 2 patients, and pre operative ventilation was required in 12 patients all of whom had congenital single lung. Intrathoracic prosthesis placement was concurrent with intracardiac repair in 5 patients. There were no operative deaths, but one early postoperative death related to septicaemia. Median follow up was 75 months with 10 patients on continued respiratory support and 3 on nocturnal support with good quality of life. Two children needed reoperations for replacement of prosthesis. CONCLUSION: The use of tissue expanders is within the armamentarium of most plastic surgeons' practice. We also therefore advocate for a collaborative team approach involving Plastic and Cardiothoracic Surgery for surgical treatment of these patients. This multidisciplinary strategy has improved management of this rare and debilitating condition of PPS, thereby offering significant improvements in general progress of these sick children having single lung physiology. Evidence is still lacking on functional outcomes in these children and further work is necessary to prove that this is indeed achievable. CI - Copyright (c) 2021. Published by Elsevier Inc. FAU - Quong, Whitney L AU - Quong WL AD - Plastic and reconstructive surgery, Great Ormond Street Hospital, London, United Kingdom. FAU - Bulstrode, Neil AU - Bulstrode N AD - Plastic and reconstructive surgery, Great Ormond Street Hospital, London, United Kingdom. FAU - Beeman, Arun AU - Beeman A AD - Departments of Cardiothoracic Surgery, Consultant Cardiothoracic Surgeon, Great Ormond Street Hospital, Great Ormond Street, London WC1N 3JH, United Kingdom. FAU - Ramaswamy, Madhavan AU - Ramaswamy M AD - Departments of Cardiothoracic Surgery, Consultant Cardiothoracic Surgeon, Great Ormond Street Hospital, Great Ormond Street, London WC1N 3JH, United Kingdom. FAU - Sivakumar, Brannavan AU - Sivakumar B AD - Plastic and reconstructive surgery, Great Ormond Street Hospital, London, United Kingdom. FAU - Wallis, Colin AU - Wallis C AD - Paediatric Pulmonology, Great Ormond Street Hospital, London, United Kingdom. FAU - Elliott, Martin J AU - Elliott MJ AD - Departments of Cardiothoracic Surgery, Consultant Cardiothoracic Surgeon, Great Ormond Street Hospital, Great Ormond Street, London WC1N 3JH, United Kingdom. FAU - Muthialu, Nagarajan AU - Muthialu N AD - Departments of Cardiothoracic Surgery, Consultant Cardiothoracic Surgeon, Great Ormond Street Hospital, Great Ormond Street, London WC1N 3JH, United Kingdom. Electronic address: nagarajan.muthialu@gosh.nhs.uk. LA - eng PT - Journal Article DEP - 20211022 PL - United States TA - J Pediatr Surg JT - Journal of pediatric surgery JID - 0052631 SB - IM CIN - J Pediatr Surg. 2022 Apr;57(4):586. doi: 10.1016/j.jpedsurg.2021.10.015. PMID: 34736772 MH - Child MH - Humans MH - Infant MH - Lung/surgery MH - *Pneumonectomy/adverse effects/methods MH - *Quality of Life MH - Retrospective Studies MH - Tissue Expansion Devices OTO - NOTNLM OT - Intrathoracic prosthesis OT - Mediastinum OT - Post pneumonectomy syndrome COIS- Declaration of Competing Interest The authors have no conflicts of interest to declare. EDAT- 2021/11/24 06:00 MHDA- 2022/03/16 06:00 CRDT- 2021/11/23 05:45 PHST- 2021/03/24 00:00 [received] PHST- 2021/09/07 00:00 [revised] PHST- 2021/10/06 00:00 [accepted] PHST- 2021/11/24 06:00 [pubmed] PHST- 2022/03/16 06:00 [medline] PHST- 2021/11/23 05:45 [entrez] AID - S0022-3468(21)00719-3 [pii] AID - 10.1016/j.jpedsurg.2021.10.010 [doi] PST - ppublish SO - J Pediatr Surg. 2022 Apr;57(4):581-585. doi: 10.1016/j.jpedsurg.2021.10.010. Epub 2021 Oct 22. PMID- 34808707 OWN - NLM STAT- MEDLINE DCOM- 20231205 LR - 20250501 IS - 2737-5935 (Electronic) IS - 0037-5675 (Print) IS - 0037-5675 (Linking) VI - 64 IP - 12 DP - 2023 Dec TI - Approach to clinically significant vascular anomalies in children. PG - 714-720 LID - 10.11622/smedj.2021209 [doi] AB - Vascular anomalies consist of tumours or malformations made up of abnormal growth or collections of blood vessels that can result in functional or cosmetic problems. While many vascular anomalies are present at birth, some do not appear until later in life, making diagnosis more challenging. Although many vascular anomalies are benign, some are associated with serious complications and may involve multiple organ systems. This article highlights the important features of clinically significant vascular anomalies to help physicians promptly identify and refer these cases to a specialised multidisciplinary team for evaluation and management. The discussion includes the various presenting complaints of vascular anomalies in children, namely, rapidly growing birthmarks, painful lesions, seizures/neurological manifestations, bleeding diathesis, cardiac/airway abnormalities and part of an overgrowth syndrome. FAU - Tanugroho, Raymond Reinaldo AU - Tanugroho RR AD - Department of Paediatrics, KK Women's and Children's Hospital, Singapore. FAU - Wee, Lynette Wei Yi AU - Wee LWY AD - Dermatology Service, KK Women's and Children's Hospital, Singapore. FAU - Koh, Mark Jean Aan AU - Koh MJA AD - Dermatology Service, KK Women's and Children's Hospital, Singapore. FAU - Chong, Jin Ho AU - Chong JH AD - Raffles Children's Centre, Raffles Hospital, Singapore. LA - eng PT - Journal Article PT - Review PL - India TA - Singapore Med J JT - Singapore medical journal JID - 0404516 SB - IM MH - Infant, Newborn MH - Child MH - Humans MH - *Vascular Malformations/diagnosis/therapy/pathology MH - *Vascular Diseases MH - Syndrome PMC - PMC10775298 OTO - NOTNLM OT - Birthmarks OT - overgrowth syndrome OT - vascular anomalies OT - vascular malformations OT - vascular tumours COIS- None EDAT- 2021/11/23 06:00 MHDA- 2023/12/05 12:42 PMCR- 2021/11/19 CRDT- 2021/11/22 20:50 PHST- 2023/12/05 12:42 [medline] PHST- 2021/11/23 06:00 [pubmed] PHST- 2021/11/22 20:50 [entrez] PHST- 2021/11/19 00:00 [pmc-release] AID - 390379 [pii] AID - SMJ-64-714 [pii] AID - 10.11622/smedj.2021209 [doi] PST - ppublish SO - Singapore Med J. 2023 Dec;64(12):714-720. doi: 10.11622/smedj.2021209. PMID- 34808700 OWN - NLM STAT- MEDLINE DCOM- 20211206 LR - 20260905 IS - 1469-493X (Electronic) IS - 1361-6137 (Linking) VI - 11 IP - 11 DP - 2021 Nov 22 TI - Early warning systems and rapid response systems for the prevention of patient deterioration on acute adult hospital wards. PG - CD005529 LID - 10.1002/14651858.CD005529.pub3 [doi] LID - CD005529 AB - BACKGROUND: Early warning systems (EWS) and rapid response systems (RRS) have been implemented internationally in acute hospitals to facilitate early recognition, referral and response to patient deterioration as a solution to address suboptimal ward-based care. EWS and RRS facilitate healthcare decision-making using checklists and provide structure to organisational practices through governance and clinical audit. However, it is unclear whether these systems improve patient outcomes. This is the first update of a previously published (2007) Cochrane Review. OBJECTIVES: To determine the effect of EWS and RRS implementation on adults who deteriorate on acute hospital wards compared to people receiving hospital care without EWS and RRS in place. SEARCH METHODS: We searched CENTRAL, MEDLINE, Embase and two trial registers on 28 March 2019. We subsequently ran a MEDLINE update on 15 May 2020 that identified no further studies. We checked references of included studies, conducted citation searching, and contacted experts and critical care organisations. SELECTION CRITERIA: We included randomised trials, non-randomised studies, controlled before-after (CBA) studies, and interrupted time series (ITS) designs measuring our outcomes of interest following implementation of EWS and RRS in acute hospital wards compared to ward settings without EWS and RRS. DATA COLLECTION AND ANALYSIS: Two review authors independently checked studies for inclusion, extracted data and assessed methodological quality using standard Cochrane and Effective Practice and Organisation of Care (EPOC) Group methods. Where possible, we standardised data to rates per 1000 admissions; and calculated risk differences and 95% confidence intervals (CI) using the Newcombe and Altman method. We reanalysed three CBA studies as ITS designs using segmented regression analysis with Newey-West autocorrelation adjusted standard errors with lag of order 1. We assessed the certainty of evidence using the GRADE approach. MAIN RESULTS: We included four randomised trials (455,226 participants) and seven non-randomised studies (210,905 participants reported in three studies). All 11 studies implemented an intervention comprising an EWS and RRS conducted in high- or middle-income countries. Participants were admitted to 282 acute hospitals. We were unable to perform meta-analyses due to clinical and methodological heterogeneity across studies. Randomised trials were assessed as high risk of bias due to lack of blinding participants and personnel across all studies. Risk of bias for non-randomised studies was critical (three studies) due to high risk of confounding and unclear risk of bias due to no reporting of deviation from protocol or serious (four studies) but not critical due to use of statistical methods to control for some but not all baseline confounders. Where possible we presented original study data which reported the adjusted relative effect given these were appropriately adjusted for design and participant characteristics. We compared outcomes of randomised and non-randomised studies reported them separately to determine which studies contributed to the overall certainty of evidence. We reported findings from key comparisons. Hospital mortality Randomised trials provided low-certainty evidence that an EWS and RRS intervention may result in little or no difference in hospital mortality (4 studies, 455,226 participants; results not pooled). The evidence on hospital mortality from three non-randomised studies was of very low certainty (210,905 participants). Composite outcome (unexpected cardiac arrests, unplanned ICU admissions and death) One randomised study showed that an EWS and RRS intervention probably results in no difference in this composite outcome (adjusted odds ratio (aOR) 0.98, 95% CI 0.83 to 1.16; 364,094 participants; moderate-certainty evidence). One non-randomised study suggests that implementation of an EWS and RRS intervention may slightly reduce this composite outcome (aOR 0.85, 95% CI 0.72 to 0.99; 57,858 participants; low-certainty evidence). Unplanned ICU admissions Randomised trials provided low-certainty evidence that an EWS and RRS intervention may result in little or no difference in unplanned ICU admissions (3 studies, 452,434 participants; results not pooled). The evidence from one non-randomised study is of very low certainty (aOR 0.88, 95% CI 0.75 to 1.02; 57,858 participants). ICU readmissions No studies reported this outcome. Length of hospital stay Randomised trials provided low-certainty evidence that an EWS and RRS intervention may have little or no effect on hospital length of stay (2 studies, 21,417 participants; results not pooled). Adverse events (unexpected cardiac or respiratory arrest) Randomised trials provided low-certainty evidence that an EWS and RRS intervention may result in little or no difference in adverse events (3 studies, 452,434 participants; results not pooled). The evidence on adverse events from three non-randomised studies (210,905 participants) is very uncertain. AUTHORS' CONCLUSIONS: Given the low-to-very low certainty evidence for all outcomes from non-randomised studies, we have drawn our conclusions from the randomised evidence. This evidence provides low-certainty evidence that EWS and RRS may lead to little or no difference in hospital mortality, unplanned ICU admissions, length of hospital stay or adverse events; and moderate-certainty evidence of little to no difference on composite outcome. The evidence from this review update highlights the diversity in outcome selection and poor methodological quality of most studies investigating EWS and RRS. As a result, no strong recommendations can be made regarding the effectiveness of EWS and RRS based on the evidence currently available. There is a need for development of a patient-informed core outcome set comprising clear and consistent definitions and recommendations for measurement as well as EWS and RRS interventions conforming to a standard to facilitate meaningful comparison and future meta-analyses. CI - Copyright (c) 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. FAU - McGaughey, Jennifer AU - McGaughey J AD - School of Nursing and Midwifery, Queen's University Belfast, Belfast, UK. FAU - Fergusson, Dean A AU - Fergusson DA AD - Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Canada. FAU - Van Bogaert, Peter AU - Van Bogaert P AD - Nursing and Midwifery Sciences, Centre for Research and Innovation in Care, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium. FAU - Rose, Louise AU - Rose L AD - Florence Nightingale Faculty of Nursing, Midwifery and Palliative Care, King's College London, London, UK. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20211122 PL - England TA - Cochrane Database Syst Rev JT - The Cochrane database of systematic reviews JID - 100909747 SB - IM UOF - Cochrane Database Syst Rev. 2007 Jul 18;(3):CD005529. doi: 10.1002/14651858.CD005529.pub2. PMID: 17636805 MH - Adult MH - Humans MH - Critical Care MH - Hospital Mortality MH - Hospitalization MH - *Hospitals MH - Length of Stay MH - *Hospital Rapid Response Team MH - *Clinical Deterioration PMC - PMC8608437 COIS- JM: none. PVB: none. DF: none. LR: none. EDAT- 2021/11/23 06:00 MHDA- 2021/12/15 06:00 PMCR- 2022/11/22 CRDT- 2021/11/22 20:32 PHST- 2021/11/22 20:32 [entrez] PHST- 2021/11/23 06:00 [pubmed] PHST- 2021/12/15 06:00 [medline] PHST- 2022/11/22 00:00 [pmc-release] AID - CD005529.pub3 [pii] AID - 10.1002/14651858.CD005529.pub3 [doi] PST - epublish SO - Cochrane Database Syst Rev. 2021 Nov 22;11(11):CD005529. doi: 10.1002/14651858.CD005529.pub3. PMID- 34801449 OWN - NLM STAT- MEDLINE DCOM- 20220427 LR - 20220427 IS - 1876-7591 (Electronic) IS - 1876-7591 (Linking) VI - 15 IP - 3 DP - 2022 Mar TI - Combined cCTA and TAVR Planning for Ruling Out Significant CAD: Added Value of ML-Based CT-FFR. PG - 476-486 LID - S1936-878X(21)00697-5 [pii] LID - 10.1016/j.jcmg.2021.09.013 [doi] AB - OBJECTIVES: The purpose of this study was to analyze the ability of machine-learning (ML)-based computed tomography (CT)-derived fractional flow reserve (CT-FFR) to further improve the diagnostic performance of coronary CT angiography (cCTA) for ruling out significant coronary artery disease (CAD) during pre-transcatheter aortic valve replacement (TAVR) evaluation in patients with a high pre-test probability for CAD. BACKGROUND: CAD is a frequent comorbidity in patients undergoing TAVR. Current guidelines recommend its assessment before TAVR. If significant CAD can be excluded on cCTA, invasive coronary angiography (ICA) may be avoided. Although cCTA is a very sensitive test, it is limited by relatively low specificity and positive predictive value, particularly in high-risk patients. METHODS: Overall, 460 patients (age 79.6 +/- 7.4 years) undergoing pre-TAVR CT were included and examined with an electrocardiogram-gated CT scan of the heart and high-pitch scan of the vascular access route. Images were evaluated for significant CAD. Patients routinely underwent ICA (388/460), which was omitted at the discretion of the local Heart Team if CAD could be effectively ruled out on cCTA (72/460). CT examinations in which CAD could not be ruled out (CAD(+)) (n = 272) underwent additional ML-based CT-FFR. RESULTS: ML-based CT-FFR was successfully performed in 79.4% (216/272) of all CAD(+) patients and correctly reclassified 17 patients as CAD negative. CT-FFR was not feasible in 20.6% because of reduced image quality (37/56) or anatomic variants (19/56). Sensitivity, specificity, positive predictive value, and negative predictive value were 94.9%, 52.0%, 52.2%, and 94.9%, respectively. The additional evaluation with ML-based CT-FFR increased accuracy by Delta+3.4% (CAD(+): Delta+6.0%) and raised the total number of examinations negative for CAD to 43.9% (202/460). CONCLUSIONS: ML-based CT-FFR may further improve the diagnostic performance of cCTA by correctly reclassifying a considerable proportion of patients with morphological signs of obstructive CAD on cCTA during pre-TAVR evaluation. Thereby, CT-FFR has the potential to further reduce the need for ICA in this challenging elderly group of patients before TAVR. CI - Copyright (c) 2022 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Gohmann, Robin F AU - Gohmann RF AD - Department of Diagnostic and Interventional Radiology, Heart Center Leipzig, Leipzig, Germany; Medical Faculty, University of Leipzig, Leipzig, Germany. Electronic address: robin.gohmann@gmx.de. FAU - Pawelka, Konrad AU - Pawelka K AD - Department of Diagnostic and Interventional Radiology, Heart Center Leipzig, Leipzig, Germany; Medical Faculty, University of Leipzig, Leipzig, Germany. FAU - Seitz, Patrick AU - Seitz P AD - Department of Diagnostic and Interventional Radiology, Heart Center Leipzig, Leipzig, Germany. FAU - Majunke, Nicolas AU - Majunke N AD - Department of Cardiology, Heart Center Leipzig at University of Leipzig, Leipzig, Germany. FAU - Heiser, Linda AU - Heiser L AD - Department of Diagnostic and Interventional Radiology, Heart Center Leipzig, Leipzig, Germany. FAU - Renatus, Katharina AU - Renatus K AD - Department of Diagnostic and Interventional Radiology, Heart Center Leipzig, Leipzig, Germany; Medical Faculty, University of Leipzig, Leipzig, Germany. FAU - Desch, Steffen AU - Desch S AD - Department of Cardiology, Heart Center Leipzig at University of Leipzig, Leipzig, Germany. FAU - Lauten, Philipp AU - Lauten P AD - Department of Cardiology, Heart Center Leipzig at University of Leipzig, Leipzig, Germany. FAU - Holzhey, David AU - Holzhey D AD - Department of Cardiac Surgery, Heart Center Leipzig at University of Leipzig, Leipzig, Germany. FAU - Noack, Thilo AU - Noack T AD - Department of Cardiac Surgery, Heart Center Leipzig at University of Leipzig, Leipzig, Germany. FAU - Wilde, Johannes AU - Wilde J AD - Department of Cardiology, Heart Center Leipzig at University of Leipzig, Leipzig, Germany. FAU - Kiefer, Philipp AU - Kiefer P AD - Department of Cardiac Surgery, Heart Center Leipzig at University of Leipzig, Leipzig, Germany. FAU - Krieghoff, Christian AU - Krieghoff C AD - Department of Diagnostic and Interventional Radiology, Heart Center Leipzig, Leipzig, Germany. FAU - Lucke, Christian AU - Lucke C AD - Department of Diagnostic and Interventional Radiology, Heart Center Leipzig, Leipzig, Germany. FAU - Gottschling, Sebastian AU - Gottschling S AD - Department of Diagnostic and Interventional Radiology, Heart Center Leipzig, Leipzig, Germany. FAU - Ebel, Sebastian AU - Ebel S AD - Department of Diagnostic and Interventional Radiology, Heart Center Leipzig, Leipzig, Germany; Medical Faculty, University of Leipzig, Leipzig, Germany. FAU - Borger, Michael A AU - Borger MA AD - Department of Cardiac Surgery, Heart Center Leipzig at University of Leipzig, Leipzig, Germany; Leipzig Heart Institute, Leipzig, Germany. FAU - Thiele, Holger AU - Thiele H AD - Department of Cardiology, Heart Center Leipzig at University of Leipzig, Leipzig, Germany; Leipzig Heart Institute, Leipzig, Germany. FAU - Panknin, Christoph AU - Panknin C AD - Siemens Healthcare GmbH, Erlangen, Germany. FAU - Horn, Matthias AU - Horn M AD - Institute for Medical Informatics, Statistics and Epidemiology (IMISE), University of Leipzig, Leipzig, Germany. FAU - Abdel-Wahab, Mohamed AU - Abdel-Wahab M AD - Department of Cardiology, Heart Center Leipzig at University of Leipzig, Leipzig, Germany. FAU - Gutberlet, Matthias AU - Gutberlet M AD - Department of Diagnostic and Interventional Radiology, Heart Center Leipzig, Leipzig, Germany; Medical Faculty, University of Leipzig, Leipzig, Germany; Leipzig Heart Institute, Leipzig, Germany. LA - eng PT - Journal Article DEP - 20211117 PL - United States TA - JACC Cardiovasc Imaging JT - JACC. Cardiovascular imaging JID - 101467978 SB - IM CIN - JACC Cardiovasc Imaging. 2022 Mar;15(3):487-488. doi: 10.1016/j.jcmg.2021.10.002. PMID: 34801451 MH - Aged MH - Aged, 80 and over MH - Computed Tomography Angiography/methods MH - Coronary Angiography/methods MH - *Coronary Artery Disease/diagnostic imaging/therapy MH - *Coronary Stenosis MH - *Fractional Flow Reserve, Myocardial MH - Humans MH - Machine Learning MH - Predictive Value of Tests MH - Tomography, X-Ray Computed MH - *Transcatheter Aortic Valve Replacement/adverse effects OTO - NOTNLM OT - aortic stenosis OT - computed tomography coronary angiography OT - coronary angiography OT - coronary artery disease OT - diagnostic accuracy OT - machine learning OT - transcatheter aortic valve implantation COIS- Funding Support and Author Disclosures Mr Panknin is an employee of Siemens Healthcare. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2021/11/22 06:00 MHDA- 2022/04/28 06:00 CRDT- 2021/11/21 20:37 PHST- 2021/03/26 00:00 [received] PHST- 2021/09/07 00:00 [revised] PHST- 2021/09/10 00:00 [accepted] PHST- 2021/11/22 06:00 [pubmed] PHST- 2022/04/28 06:00 [medline] PHST- 2021/11/21 20:37 [entrez] AID - S1936-878X(21)00697-5 [pii] AID - 10.1016/j.jcmg.2021.09.013 [doi] PST - ppublish SO - JACC Cardiovasc Imaging. 2022 Mar;15(3):476-486. doi: 10.1016/j.jcmg.2021.09.013. Epub 2021 Nov 17. PMID- 34798427 OWN - NLM STAT- MEDLINE DCOM- 20220406 LR - 20220406 IS - 1095-8673 (Electronic) IS - 0022-4804 (Linking) VI - 270 DP - 2022 Feb TI - Revascularization Strategies for Multivessel Coronary Artery Disease in the Elderly Population. PG - 444-454 LID - S0022-4804(21)00676-4 [pii] LID - 10.1016/j.jss.2021.10.013 [doi] AB - BACKGROUND: Prospective trials comparing coronary artery bypass grafting (CABG) with percutaneous coronary intervention (PCI) for the treatment of multivessel coronary disease (MVCAD) have included mostly younger patients. We compared treatment strategies in the elderly population. MATERIALS AND METHODS: We performed a propensity-score-matched comparison of patients >/=75 y who underwent isolated CABG or PCI for MVCAD between 2011 and 2018, excluding those with prior cardiac surgery and/or significant left main disease. The primary outcome was 5-year Kaplan Meier survival, and secondary outcomes included readmissions and major adverse cardiovascular and cerebrovascular events (MACCE). RESULTS: Propensity-matching yielded 536 patients (266 PCI and 266 CABG). Rates of complete revascularization of all stenotic lesions were higher in the CABG arm (86.8% versus 21.8%; P < 0.001). Thirty-d mortality was similar between cohorts, though PCI recipients had shorter hospital stay and greater likelihood of discharge to home. Unadjusted one- (89.1% versus 88.4%) and 5-year (73.8% versus 60.1%) survival were both higher in patients who underwent CABG (P = 0.0332). Patients undergoing CABG had reduced, but nonsignificant cumulative incidence of all-cause hospital readmission and MACCE at 5 y. Subgroup analysis of patients 80 y or older revealed similar late survival benefit with CABG when compared to PCI. Among patients undergoing CABG, there did not appear to be any 5-year benefits from multi-arterial grafting. CONCLUSIONS: Despite longer hospitalization and higher rate of nonhome discharge, CABG was associated with improved late survival over PCI in the elderly population. Cardiac surgeons should be included in the multidisciplinary evaluation of older patients with MVCAD. CI - Copyright (c) 2021. Published by Elsevier Inc. FAU - Hess, Nicholas R AU - Hess NR AD - Division of Cardiac Surgery, Department of Cardiothoracic Surgery, University of Pittsburgh School of Medicine. FAU - Kilic, Arman AU - Kilic A AD - Division of Cardiothoracic Surgery, Department of Surgery, Medical University of South Carolina, South Carolina. FAU - Wang, Yisi AU - Wang Y AD - Division of Cardiac Surgery, Department of Cardiothoracic Surgery, University of Pittsburgh School of Medicine; University of Pittsburgh Medical Center Heart and Vascular Institute, Pittsburgh, Pennsylvania. FAU - Yoon, Pyongsoo D AU - Yoon PD AD - Division of Cardiac Surgery, Department of Cardiothoracic Surgery, University of Pittsburgh School of Medicine; University of Pittsburgh Medical Center Heart and Vascular Institute, Pittsburgh, Pennsylvania. FAU - Navid, Forozan AU - Navid F AD - Division of Cardiac Surgery, Department of Cardiothoracic Surgery, University of Pittsburgh School of Medicine; University of Pittsburgh Medical Center Heart and Vascular Institute, Pittsburgh, Pennsylvania. FAU - Sultan, Ibrahim AU - Sultan I AD - Division of Cardiac Surgery, Department of Cardiothoracic Surgery, University of Pittsburgh School of Medicine; University of Pittsburgh Medical Center Heart and Vascular Institute, Pittsburgh, Pennsylvania. FAU - Chu, Danny AU - Chu D AD - Division of Cardiac Surgery, Department of Cardiothoracic Surgery, University of Pittsburgh School of Medicine; University of Pittsburgh Medical Center Heart and Vascular Institute, Pittsburgh, Pennsylvania. Electronic address: chud@upmc.edu. LA - eng PT - Journal Article DEP - 20211116 PL - United States TA - J Surg Res JT - The Journal of surgical research JID - 0376340 SB - IM MH - Aged MH - Coronary Artery Bypass/adverse effects MH - *Coronary Artery Disease/surgery MH - Humans MH - *Percutaneous Coronary Intervention/adverse effects MH - Prospective Studies MH - Treatment Outcome OTO - NOTNLM OT - Coronary artery bypass graft OT - Coronary artery disease OT - Coronary stents OT - Elderly OT - Percutaneous coronary intervention OT - Survival EDAT- 2021/11/20 06:00 MHDA- 2022/04/07 06:00 CRDT- 2021/11/19 20:25 PHST- 2021/03/07 00:00 [received] PHST- 2021/09/23 00:00 [revised] PHST- 2021/10/10 00:00 [accepted] PHST- 2021/11/20 06:00 [pubmed] PHST- 2022/04/07 06:00 [medline] PHST- 2021/11/19 20:25 [entrez] AID - S0022-4804(21)00676-4 [pii] AID - 10.1016/j.jss.2021.10.013 [doi] PST - ppublish SO - J Surg Res. 2022 Feb;270:444-454. doi: 10.1016/j.jss.2021.10.013. Epub 2021 Nov 16. PMID- 34796878 OWN - NLM STAT- MEDLINE DCOM- 20211122 LR - 20240908 IS - 1969-6213 (Electronic) IS - 1774-024X (Print) IS - 1774-024X (Linking) VI - 17 IP - 10 DP - 2021 Nov 19 TI - Transcatheter treatment for tricuspid valve disease. PG - 791-808 LID - EIJ-D-21-00695 [pii] LID - 10.4244/EIJ-D-21-00695 [doi] AB - Approximately 4% of subjects aged 75 years or more have clinically relevant tricuspid regurgitation (TR). Primary TR results from anatomical abnormality of the tricuspid valve apparatus and is observed in only 8-10% of the patients with tricuspid valve disease. Secondary TR is more common and arises as a result of annular dilation caused by right ventricular enlargement and dysfunction as a consequence of pulmonary hypertension, often caused by left-sided heart disease or atrial fibrillation. Irrespective of its aetiology, TR leads to volume overload and increased wall stress, both of which negatively contribute to detrimental remodelling and worsening TR. This vicious circle translates into impaired survival and increased heart failure symptoms in patients with and without reduced left ventricular ejection fraction. Interventions to correct TR are underutilised in daily clinical practice owing to increased surgical risk and late patient presentation. The recently introduced transcatheter tricuspid valve interventions aim to address this unmet need. Dedicated expertise and an interdisciplinary Heart Team evaluation are essential to integrate these new techniques successfully and select patients. The present article proposes a standardised approach to evaluate patients with TR who may be candidates for transcatheter interventions. In addition, a state-of-the-art review of the available transcatheter therapies, the main criteria for patient and device selection, and information concerning the remaining uncertainties are provided. FAU - Praz, Fabien AU - Praz F AD - Bern University Hospital, University of Bern, Bern, Switzerland. FAU - Muraru, Denisa AU - Muraru D FAU - Kreidel, Felix AU - Kreidel F FAU - Lurz, Philipp AU - Lurz P FAU - Hahn, Rebecca T AU - Hahn RT FAU - Delgado, Victoria AU - Delgado V FAU - Senni, Michele AU - Senni M FAU - von Bardeleben, Ralph Stephan AU - von Bardeleben RS FAU - Nickenig, Georg AU - Nickenig G FAU - Hausleiter, Jorg AU - Hausleiter J FAU - Mangieri, Antonio AU - Mangieri A FAU - Zamorano, Jose L AU - Zamorano JL FAU - Prendergast, Bernard D AU - Prendergast BD FAU - Maisano, Francesco AU - Maisano F LA - eng PT - Journal Article PL - France TA - EuroIntervention JT - EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology JID - 101251040 SB - IM MH - *Heart Valve Diseases MH - *Heart Valve Prosthesis Implantation/adverse effects MH - Humans MH - Stroke Volume MH - Treatment Outcome MH - Tricuspid Valve/diagnostic imaging/surgery MH - *Tricuspid Valve Insufficiency/diagnostic imaging/surgery MH - Ventricular Function, Left PMC - PMC9724890 COIS- F. Praz has received travel expenses from Abbott Vascular, Edwards Lifesciences, and Polares Medical. D. Muraru is part of the speaker's bureau for GE Healthcare and received research equipment support from GE Vingmed. F. Kreidel has received speaker's honoraria from Abbott Vascular. P. Lurtz has served as a consultant for Abbott Structural Heart, Edwards Lifesciences, and Medtronic. R. Hahn has received speaker fees from Boston Scientific, Baylis Medical, Edwards Lifescience and Medtronic, consulting fees for Abbott Structural, Edwards Lifesciences, Gore&Associates, Medtronic, Navigate, and Philips Healthcare, non-financial support from 3mensio, has equity with Navigate, and is the Chief Scientific Officer for the Echocardiography Core Laboratory at the Cardiovascular Research Foundation for multiple industry-sponsored trials, for which she receives no direct industry compensation. V. Delgado has received speaker fees from Abbott Vascular, Edwards Lifesciences, GE Healthcare, Novartis, MSD and Medtronic. M. Senni has received personal fees from Novartis during the conduct of the study and personal fees from Bayer, Abbott, Merck, AstraZeneca, Vifor Pharma and Boehringer outside the submitted work. R.S. von Bardeleben is a consultant for Abbott Vascular. G. Nickenig has received research funding from the Deutsche Forschungsgemeinschaft, the German Federal Ministry of Education and Research, the EU, Abbott, Edwards Lifesciences, Medtronic, and St. Jude Medical, and has received honoraria for lectures or advisory boards from Abbott, Edwards Lifesciences, Medtronic, and St. Jude Medical. J. Hausleiter has received speaker honoraria from Abbott Vascular and Edwards Lifesciences. A. Mangieri has received an institutional grant from Boston Scientific and is part of the advisory board of Boston -Scientific. J. Zamorano has received speaker honoraria from -Daichii Sankyo and Pfizer. B. Prendergast has received unrestricted educational and research grants from Edwards -Lifesciences and speaker/consultancy fees from Edwards Lifesciences, Abbott, and Anteris. F. Maisano reports grant and/or research institutional support from Abbott, Medtronic, Edwards Lifesciences, Biotronik, Boston Scientific Corporation, NVT, and Terumo, consulting fees, honoraria (personal and institutional) from Abbott, Medtronic, Edwards Lifesciences, Xeltis, Cardiovalve, Occlufit, Simulands, has royalty income/IP rights from Edwards Lifesciences, and is a shareholder (including share options) of Cardiogard, Magenta, SwissVortex, Transseptalsolutions, Occlufit, 4Tech, and Perifect. M. Adamo has no conflicts of interest to declare. M. Andreas reports receiving grants and fees from Edwards Lifesciences, Abbott, and Medtronic. L. Badano reports receiving consulting fees from Edwards Lifesciences, Esaote, and Jansen, and speaker fees from GE Healthcare, Esaote, and Philips. S. Baldus reports receiving a research grant Abbott, and speaker fees from Abbott and Edwards. M. Barreiro reports receiving speaker fees Abbott Vascular, Philips Healthcare and Boston Scientific. J. Bax reports receiving speaker fees Edwards Lifesciences and Abbott. M. Borger reports that his hospital receives consulting fees and/or speakers' honoraria on his behalf from Edwards Lifesciences, Medtronic, Abbott and CryoLife. J. Cavalcante reports receiving consulting fees Edwards Lifesciences, Abbott Structural, Medtronic, Inc., Boston Scientific, and VDYNE. L. Conradi reports receiving consulting and speaker fees from Edwards -Lifesciences, Boston Scientific, Medtronic, and Abbott. P. Denti reports receiving a consulting fee from InnovHeart, and speaker fees from Abbott and Edwards. E. Donal reports receiving speaker fees from Abbott Vascular, Philips Healthcare and Boston -Scientific. G. Dreyfus reports being a consultant from Edwards -Lifesciences. N. Dumonteil reports receiving consulting and speaker fees from Abbott Vascular, Ancora Heart, Boston Scientific, Edwards -Lifesciences, and Medtronic. A. Duncan reports lectures/presentations for Abbott Vascular, Edwards Lifesciences, and -Boston Scientific. R. Estevez-Loureiro reports receiving speaker fees Abbott Vascular, Edwards Lifesciences, and Boston Scientific. N. Fam has no conflicts of interest to declare. L. Fiocca has no conflicts of interest to declare. X. Freixa reports receiving consulting and speaker fees from Abbott Vascular. K. Friedrichs reports receiving grants from Edwards Lifesciences. M. Gavazzoni reports receiving personal fees from Abbott Vascular. J. Grapsa has no conflicts of interest to declare. C. Grasso reports receiving fees from Abbott Medical, Boston Scientific, and Edwards -Lifesciences. A. Guidotti has no conflicts of interest to declare. E. Ho reports receiving support for attending meetings from Abbott, Edwards Lifesciences, and Medtronic. N. Karam reports receiving consulting fees from Abbott, Edwards Lifesciences, and Medtronic, and speaker fees from Edwards Lifesciences. R. Lange reports receiving consulting fees and royalties from Medtronic. A. Latib reports receiving consulting fees from Edwards -Lifesciences, Abbott, Medtronic, and Boston Scientific. S. Lim reports receiving grants from Abbott Vascular and Edwards -Lifesciences. C. Lotan has no conflicts of interest to declare. M. Metra reports receiving consulting fees from Amgen, -AstraZeneca, Servier, Vifor Pharma, and WindTree Therapeutics, and speaker fees from Abbott Vascular, and Edwards Therapeutics. T. Modine is a consultant for Boston Scientific, Medtronic, Edwards, MicroPort, GE, and Abbott, and has received a research support grant from Edwards. H. Mollmann reports receiving consulting and speaker fees from Abbott Vascular, Boston Scientific and Edwards Lifesciences. L. Ortega-Paz has no conflicts of interest to declare. N. Piazza reports receiving consulting fees from Medtronic, Peijia Medical, and Highlife. W. Rottbauer reports receiving funding for this ms from Edwards Lifesciences, and consulting fees from Edwards Lifesciences and Abbott. V. Rudolph reports receiving grants from Edwards Lifesciences and Abbott Vascular. M. Sarano has no conflicts of interest to declare. M. Sitges reports receiving grants from Abbott, Medtronic, and Edward Lifesciences, and consulting and speaker fees from Abbott, Medtronic, and Edwards Lifesciences. O. Soliman has no conflicts of interest to declare. L. Sondergaard reports receiving consulting and speaker fees from Abbott, Boston Scientific, Medtronic, and SMT. M. Swaans reports receiving consulting fees from -BioVentrix, Inc., and speakers fees from Abbott Vascular, Edwards -Lifesciences, and Philips Healthcare. G. Tang reports receiving consulting and speaker fees from Abbott Structural Heart and Medtronic. M. Taramasso repors receiving consultant fees from Abbott, Edwards Lifesciences, Shenqi Medical, Boston Scientific, 4tech, CoreMedic, Simulands, MTEx, and Occlufit, and speaker fees from Abbott, and Edwards Lifesciences. D. Tchetche reports receiving consulting fees Abbott, Boston, Edwards, and Medtronic. H. Thiele has no conflicts of interest to declare. Y. Topilsky reports receiving consulting fees from Edwards, and MitralTech, and speaker fees from Edwards, and Abbott. H. Treede has received research support from Abbott Vascular, Boston -Scientific, Edwards Lifesciences, JenaValve Technology, Medtronic, Tricares and -Abiomed. A. Vahanian reports consultancy for -CardioValve, and receiving consulting fees from Abbott Vascular, Edwards -Lifescience, and Medtronic. N. van Mieghem has received grants and personal fees from Abbott Vascular, Medtronic, Boston -Scientific, and PulseCath BV. K. Vitanova reports receiving speakers honoraria from Medtronic. S. Windecker reports receiving research and educational grants to the institution from Abbott, Amgen, BMS, Bayer, Boston Scientific, Biotronik, Cardinal Health, CSL Behring, Daiichi Sankyo, Edwards -Lifesciences, Johnson&Johnson, Medtronic, Querbet, Polares, Sanofi, Terumo, and Sinomed. N. Wunderlich reports receiving consulting fees from Edwards Lifesciences, Holitstick Medical and Cardiac Implants, and speaker fees from Cardiac Dimension, GE, Philipps, Gore, Abbott, Edwards Lifesciences, Occlutech, and Alnylam. M. Zuber has received fees from Edwards Lifesciences, and Abbott. EDAT- 2021/11/20 06:00 MHDA- 2021/11/23 06:00 PMCR- 2022/11/19 CRDT- 2021/11/19 08:44 PHST- 2021/11/19 08:44 [entrez] PHST- 2021/11/20 06:00 [pubmed] PHST- 2021/11/23 06:00 [medline] PHST- 2022/11/19 00:00 [pmc-release] AID - EIJ-D-21-00695 [pii] AID - 10.4244/EIJ-D-21-00695 [doi] PST - ppublish SO - EuroIntervention. 2021 Nov 19;17(10):791-808. doi: 10.4244/EIJ-D-21-00695. PMID- 34795950 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220816 IS - 2072-1439 (Print) IS - 2077-6624 (Electronic) IS - 2072-1439 (Linking) VI - 13 IP - 10 DP - 2021 Oct TI - Peri-operative approach to esophagectomy: a narrative review from the anesthesiological standpoint. PG - 6037-6051 LID - 10.21037/jtd-21-940 [doi] AB - OBJECTIVE: This review summarizes the peri-operative anesthesiological approaches to esophagectomy considering the best up-to-date, evidence-based medicine, discussed from the anesthesiologist's standpoint. BACKGROUND: Esophagectomy is the only curative therapy for esophageal cancer. Despite the many advancements made in the surgical treatment of this tumour, esophagectomy still carries a morbidity rate reaching 60%. Patients undergoing esophagectomy should be referred to high volume centres where they can receive a multidisciplinary approach to treatment, associated with better outcomes. The anesthesiologist is the key figure who should guide the peri-operative phase, from diagnosis through to post-surgery rehabilitation. We performed an updated narrative review devoted to the study of anesthesia management for esophagectomy in cancer patients. METHODS: We searched MEDLINE, Scopus and Google Scholar databases from inception to May 2021. We used the following terms: "esophagectomy", "esophagectomy AND pre-operative evaluation", "esophagectomy AND protective lung ventilation", "esophagectomy AND hemodynamic monitoring" and "esophagectomy AND analgesia". We considered only articles with abstract written in English and available to the reader. We excluded single case-reports. CONCLUSIONS: Pre-operative anesthesiological evaluation is mandatory in order to stratify and optimize any medical condition. During surgery, protective ventilation and judicious fluid management are the cornerstones of intraoperative "protective anesthesia". Post-operative care should be provided by an intensive care unit or high-dependency unit depending on the patient's condition, the type of surgery endured and the availability of local resources. The provision of adequate post-operative analgesia favours early mobilization and rapid recovery. Anesthesiologist has an important role during the peri-operative care for esophagectomy. However, there are still some topics that need to be further studied to improve the outcome of these patients. CI - 2021 Journal of Thoracic Disease. All rights reserved. FAU - Deana, Cristian AU - Deana C AD - Department of Anesthesia and Intensive Care, ASUFC-Academic Hospital of Udine, Udine, Italy. FAU - Vetrugno, Luigi AU - Vetrugno L AD - Department of Anesthesia and Intensive Care, ASUFC-Academic Hospital of Udine, Udine, Italy. AD - Department of Medical Area, University of Udine, Udine, Italy. FAU - Bignami, Elena AU - Bignami E AD - Anesthesiology, Critical Care and Pain Medicine Division, Department of Medicine and Surgery, University of Parma, Parma, Italy. FAU - Bassi, Flavio AU - Bassi F AD - Department of Anesthesia and Intensive Care, ASUFC-Academic Hospital of Udine, Udine, Italy. LA - eng PT - Journal Article PT - Review PL - China TA - J Thorac Dis JT - Journal of thoracic disease JID - 101533916 PMC - PMC8575828 OTO - NOTNLM OT - Esophagectomy OT - hemodynamic monitoring OT - perioperative cardiac risk assessment OT - perioperative fluid management OT - protective lung ventilation COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://dx.doi.org/10.21037/jtd-21-940). The authors have no conflicts of interest to declare. EDAT- 2021/11/20 06:00 MHDA- 2021/11/20 06:01 PMCR- 2021/10/01 CRDT- 2021/11/19 06:56 PHST- 2021/06/07 00:00 [received] PHST- 2021/08/19 00:00 [accepted] PHST- 2021/11/19 06:56 [entrez] PHST- 2021/11/20 06:00 [pubmed] PHST- 2021/11/20 06:01 [medline] PHST- 2021/10/01 00:00 [pmc-release] AID - jtd-13-10-6037 [pii] AID - 10.21037/jtd-21-940 [doi] PST - ppublish SO - J Thorac Dis. 2021 Oct;13(10):6037-6051. doi: 10.21037/jtd-21-940. PMID- 34795930 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220428 IS - 2072-1439 (Print) IS - 2077-6624 (Electronic) IS - 2072-1439 (Linking) VI - 13 IP - 10 DP - 2021 Oct TI - A single center experience with minimally invasive approaches in congenital cardiac surgery. PG - 5818-5825 LID - 10.21037/jtd-21-836 [doi] AB - BACKGROUND: Cardiac surgery is a technically demanding field with an appreciable learning curve that extends beyond formal training. Minimally invasive congenital cardiac surgery has one of the steepest learning curves. Early complications often discourage surgeons, particularly those at lower volume centers, from pursuing innovative approaches. Over the past three years, we have utilized a number of minimally invasive approaches including pulmonary valve replacement, anomalous aortic origin coronary artery repair, atrial septal defect repair, epicardial lead placement, and partial anomalous pulmonary venous return. Herein we report on our experience performing minimally invasive congenital cardiac surgery, lessons learned, and how our approach has evolved. METHODS: We performed a single institution, retrospective review, wherein continuous variables were reported as median (interquartile range). RESULTS: Between September 2017 and May 2020, minimally invasive approaches were attempted on 49 patients with a median age of 19 years (14-47 years) for nine distinct congenital cardiac diagnoses. Seven patients (14%) required conversion to larger incisions, including four patients or 36% of those undergoing anomalous aortic origin of a coronary artery repair. Patients who were converted had a higher body mass index 33.1 (31.7-37.8) than those who were not (24.2, 20.8-29.3) (P=0.009). CONCLUSIONS: Minimally invasive approaches for congenital cardiac conditions require a team approach. Patients with a body mass index greater than 30 should be counseled on the higher rate of conversion. We no longer perform minimally invasive anomalous aortic origin of a coronary artery repair given the high rate of conversions and complications. Surgeons attempting this procedure should do so cautiously. CI - 2021 Journal of Thoracic Disease. All rights reserved. FAU - Nellis, Joseph R AU - Nellis JR AD - Department of Surgery, Duke University, Durham, NC, USA. AD - Duke Congenital Heart Surgery Research & Training Laboratory, Durham, NC, USA. FAU - Daneshmand, Mani A AU - Daneshmand MA AD - Department of Surgery, Duke University, Durham, NC, USA. AD - Division of Thoracic and Cardiovascular Surgery, Duke University, Durham, NC, USA. FAU - Gaca, Jeffrey G AU - Gaca JG AD - Department of Surgery, Duke University, Durham, NC, USA. AD - Division of Thoracic and Cardiovascular Surgery, Duke University, Durham, NC, USA. FAU - Andersen, Nicholas D AU - Andersen ND AD - Department of Surgery, Duke University, Durham, NC, USA. AD - Duke Congenital Heart Surgery Research & Training Laboratory, Durham, NC, USA. AD - Division of Thoracic and Cardiovascular Surgery, Duke University, Durham, NC, USA. AD - Pediatric & Congenital Heart Center, Duke Children's Hospital, Durham, NC, USA. FAU - Haney, John C AU - Haney JC AD - Department of Surgery, Duke University, Durham, NC, USA. AD - Division of Thoracic and Cardiovascular Surgery, Duke University, Durham, NC, USA. FAU - Turek, Joseph W AU - Turek JW AD - Department of Surgery, Duke University, Durham, NC, USA. AD - Duke Congenital Heart Surgery Research & Training Laboratory, Durham, NC, USA. AD - Division of Thoracic and Cardiovascular Surgery, Duke University, Durham, NC, USA. AD - Pediatric & Congenital Heart Center, Duke Children's Hospital, Durham, NC, USA. LA - eng PT - Journal Article PL - China TA - J Thorac Dis JT - Journal of thoracic disease JID - 101533916 CIN - J Thorac Dis. 2021 Nov;13(11):6209-6213. doi: 10.21037/jtd-21-1498. PMID: 34992800 PMC - PMC8575860 OTO - NOTNLM OT - Congenital cardiac OT - anomalous aortic origin of a coronary artery OT - learning curve OT - minimally invasive OT - pulmonary valve replacement COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://dx.doi.org/10.21037/jtd-21-836). Dr. JWT serves as an unpaid editorial board member of Journal of Thoracic Disease. The other authors have no conflicts of interest to declare. EDAT- 2021/11/20 06:00 MHDA- 2021/11/20 06:01 PMCR- 2021/10/01 CRDT- 2021/11/19 06:56 PHST- 2021/05/15 00:00 [received] PHST- 2021/07/14 00:00 [accepted] PHST- 2021/11/19 06:56 [entrez] PHST- 2021/11/20 06:00 [pubmed] PHST- 2021/11/20 06:01 [medline] PHST- 2021/10/01 00:00 [pmc-release] AID - jtd-13-10-5818 [pii] AID - 10.21037/jtd-21-836 [doi] PST - ppublish SO - J Thorac Dis. 2021 Oct;13(10):5818-5825. doi: 10.21037/jtd-21-836. PMID- 34795366 OWN - NLM STAT- MEDLINE DCOM- 20220225 LR - 20220225 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 11 IP - 1 DP - 2021 Nov 18 TI - Comparison of two strategies for managing in-hospital cardiac arrest. PG - 22522 LID - 10.1038/s41598-021-02027-2 [doi] LID - 22522 AB - In-hospital cardiac arrest (IHCA) is associated with poor outcomes. There are currently no standards for cardiac arrest teams in terms of member composition and task allocation. Here we aimed to compare two different cardiac arrest team concepts to cover IHCA management in terms of survival and neurological outcomes. This prospective study enrolled 412 patients with IHCA from general medical wards. From May 2014 to April 2016, 228 patients were directly transferred to the intensive care unit (ICU) for ongoing resuscitation. In the ICU, resuscitation was extended to advanced cardiac life support (ACLS) (Load-and-Go [LaG] group). By May 2016, a dedicated cardiac arrest team provided by the ICU provided ACLS in the ward. After return of spontaneous circulation (ROSC), the patients (n = 184) were transferred to the ICU (Stay-and-Treat [SaT] group). Overall, baseline characteristics, aetiologies, and characteristics of cardiac arrest were similar between groups. The time to endotracheal intubation was longer in the LaG group than in the SaT group (6 [5, 8] min versus 4 [2, 5] min, p = 0.001). In the LaG group, 96% of the patients were transferred to the ICU regardless of ROSC achievement. In the SaT group, 83% of patients were transferred to the ICU (p = 0.001). Survival to discharge did not differ between the LaG (33%) and the SaT (35%) groups (p = 0.758). Ultimately, 22% of patients in the LaG group versus 21% in the SaT group were discharged with good neurological outcomes (p = 0.857). In conclusion, we demonstrated that the cardiac arrest team concepts for the management of IHCA did not differ in terms of survival and neurological outcomes. However, a dedicated (intensive care) cardiac arrest team could take some load off the ICU. CI - (c) 2021. The Author(s). FAU - Haschemi, Jafer AU - Haschemi J AD - Department of Cardiology, Pulmonology and Vascular Medicine, Medical Faculty of the Heinrich Heine University, Moorenstr. 5, 40225, Duesseldorf, Germany. FAU - Erkens, Ralf AU - Erkens R AD - Department of Cardiology, Pulmonology and Vascular Medicine, Medical Faculty of the Heinrich Heine University, Moorenstr. 5, 40225, Duesseldorf, Germany. FAU - Orzech, Robert AU - Orzech R AD - Department of Cardiology, Pulmonology and Vascular Medicine, Medical Faculty of the Heinrich Heine University, Moorenstr. 5, 40225, Duesseldorf, Germany. FAU - Haurand, Jean Marc AU - Haurand JM AD - Department of Cardiology, Pulmonology and Vascular Medicine, Medical Faculty of the Heinrich Heine University, Moorenstr. 5, 40225, Duesseldorf, Germany. FAU - Jung, Christian AU - Jung C AD - Department of Cardiology, Pulmonology and Vascular Medicine, Medical Faculty of the Heinrich Heine University, Moorenstr. 5, 40225, Duesseldorf, Germany. FAU - Kelm, Malte AU - Kelm M AD - Department of Cardiology, Pulmonology and Vascular Medicine, Medical Faculty of the Heinrich Heine University, Moorenstr. 5, 40225, Duesseldorf, Germany. AD - Cardiovascular Research Institute, Medical Faculty of the Heinrich-Heine University, Dusseldorf, Germany. FAU - Westenfeld, Ralf AU - Westenfeld R AD - Department of Cardiology, Pulmonology and Vascular Medicine, Medical Faculty of the Heinrich Heine University, Moorenstr. 5, 40225, Duesseldorf, Germany. FAU - Horn, Patrick AU - Horn P AD - Department of Cardiology, Pulmonology and Vascular Medicine, Medical Faculty of the Heinrich Heine University, Moorenstr. 5, 40225, Duesseldorf, Germany. patrick.horn@med.uni-duesseldorf.de. LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20211118 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 SB - IM MH - Advanced Cardiac Life Support/methods MH - Aged MH - Aged, 80 and over MH - Cardiology/methods/organization & administration/*standards MH - Cardiopulmonary Resuscitation MH - Critical Care/methods/organization & administration MH - Female MH - Heart Arrest/*mortality/*therapy MH - Hospital Mortality MH - Hospitalization MH - Hospitals MH - Humans MH - Intensive Care Units MH - Male MH - Middle Aged MH - Patient Care Team MH - Prospective Studies MH - Treatment Outcome PMC - PMC8602649 COIS- The authors declare no competing interests. EDAT- 2021/11/20 06:00 MHDA- 2022/02/26 06:00 PMCR- 2021/11/18 CRDT- 2021/11/19 06:41 PHST- 2021/06/29 00:00 [received] PHST- 2021/11/08 00:00 [accepted] PHST- 2021/11/19 06:41 [entrez] PHST- 2021/11/20 06:00 [pubmed] PHST- 2022/02/26 06:00 [medline] PHST- 2021/11/18 00:00 [pmc-release] AID - 10.1038/s41598-021-02027-2 [pii] AID - 2027 [pii] AID - 10.1038/s41598-021-02027-2 [doi] PST - epublish SO - Sci Rep. 2021 Nov 18;11(1):22522. doi: 10.1038/s41598-021-02027-2. PMID- 34794873 OWN - NLM STAT- MEDLINE DCOM- 20220221 LR - 20250623 IS - 1444-2892 (Electronic) IS - 1443-9506 (Linking) VI - 31 IP - 3 DP - 2022 Mar TI - Polycythaemia Vera and Coronary Artery Bypass Graft Surgery: A Systematic Review of the Literature. PG - 304-312 LID - S1443-9506(21)01308-1 [pii] LID - 10.1016/j.hlc.2021.10.012 [doi] AB - OBJECTIVES: Polycythaemia vera (PV) is a condition that may potentially put patients undergoing cardiac surgery at an increased risk of bleeding and thrombosis; however, there is currently a paucity of literature regarding the management of these patients. We aim to examine the literature in this systematic review to indicate the interventions that may be considered to minimise complications. METHODS: We conducted a literature search using keywords and MeSH terms to identify articles discussing PV and cardiac surgery. The studies were identified and qualitatively analysed using the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) protocol. RESULTS: In total, 10 case reports representing 11 patients were identified for this systematic review and were included in qualitative analysis. 63.6% of patients had preoperative intermittent phlebotomy, and the majority of patients received postoperative therapy that involved one antiplatelet agent and one anticoagulant. Generous perioperative fluid management, phlebotomy, preservation of core body temperature, early extubation, monitoring of myocardial ischaemia, infarction and vascular events, intense chest physiotherapy and patient mobilisation are important to consider to reduce the risk of complications arising from surgery. CONCLUSION: These considerations should be systematically discussed in a multidisciplinary team, where the acute surgical need can be balanced appropriately against the risk of haemorrhage and thrombosis. CI - Copyright (c) 2021 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights reserved. FAU - Janmohamed, Imran Karim AU - Janmohamed IK AD - University of Leeds, Faculty of Health and Medicine, Leeds, UK. FAU - Sondh, Rajan Singh AU - Sondh RS AD - St George's Hospital Medical School, University of London, London, UK. FAU - Ahmed, Hasan AU - Ahmed H AD - Imperial College London, Department of Medicine, London, UK. FAU - Afzal, Muhammad Bilal AU - Afzal MB AD - Imperial College London, Department of Medicine, London, UK. FAU - Tyson, Nathan AU - Tyson N AD - Nottingham University Hospitals, Department of Cardiac Surgery, UK. FAU - Harky, Amer AU - Harky A AD - Department of Cardiothoracic Surgery, Liverpool Heart and Chest Hospital, UK. Electronic address: amer.harky@lhch.nhs.uk. LA - eng PT - Journal Article PT - Systematic Review DEP - 20211115 PL - Australia TA - Heart Lung Circ JT - Heart, lung & circulation JID - 100963739 RN - 0 (Anticoagulants) RN - 0 (Platelet Aggregation Inhibitors) SB - IM MH - Anticoagulants/adverse effects MH - Coronary Artery Bypass/adverse effects MH - Humans MH - Platelet Aggregation Inhibitors MH - *Polycythemia Vera/chemically induced/complications/therapy MH - *Thrombosis/etiology OTO - NOTNLM OT - Cardiac surgery OT - Coronary artery bypass grafting OT - Haematology OT - Myeloproliferative disorder OT - Polycythaemia vera OT - Thrombosis EDAT- 2021/11/20 06:00 MHDA- 2022/02/22 06:00 CRDT- 2021/11/19 05:47 PHST- 2021/07/17 00:00 [received] PHST- 2021/09/15 00:00 [revised] PHST- 2021/10/14 00:00 [accepted] PHST- 2021/11/20 06:00 [pubmed] PHST- 2022/02/22 06:00 [medline] PHST- 2021/11/19 05:47 [entrez] AID - S1443-9506(21)01308-1 [pii] AID - 10.1016/j.hlc.2021.10.012 [doi] PST - ppublish SO - Heart Lung Circ. 2022 Mar;31(3):304-312. doi: 10.1016/j.hlc.2021.10.012. Epub 2021 Nov 15. PMID- 34794388 OWN - NLM STAT- MEDLINE DCOM- 20211206 LR - 20220304 IS - 1471-2296 (Electronic) IS - 1471-2296 (Linking) VI - 22 IP - 1 DP - 2021 Nov 18 TI - Low-touch, team-based care for co-morbidity management in cancer patients: the ONE TEAM randomized controlled trial. PG - 234 LID - 10.1186/s12875-021-01569-8 [doi] LID - 234 AB - BACKGROUND: As treatments for cancer have improved, more people are surviving cancer. However, compared to people without a history of cancer, cancer survivors are more likely to die of cardiovascular disease (CVD). Increased risk for CVD-related mortality among cancer survivors is partially due to lack of medication adherence and problems that exist in care coordination between cancer specialists, primary care physicians, and cardiologists. METHODS/DESIGN: The Onco-primary care networking to support TEAM-based care (ONE TEAM) study is an 18-month cluster-randomized controlled trial with clustering at the primary care clinic level. ONE TEAM compares the provision of the iGuide intervention to patients and primary care providers versus an education-only control. For phase 1, at the patient level, the intervention includes video vignettes and a live webinar; provider-level interventions include electronic health records-based communication and case-based webinars. Participants will be enrolled from across North Carolina one of their first visits with a cancer specialist (e.g., surgeon, radiation or medical oncologist). We use a sequential multiple assignment randomized trial (SMART) design. Outcomes (measured at the patient level) will include Healthcare Effectiveness Data and Information Set (HEDIS) quality measures of management of three CVD comorbidities using laboratory testing (glycated hemoglobin [A1c], lipid profile) and blood pressure measurements; (2) medication adherence assessed pharmacy refill data using Proportion of Days Covered (PDC); and (3) patient-provider communication (Patient-Centered Communication in Cancer Care, PCC-Ca-36). Primary care clinics in the intervention arm will be considered non-responders if 90% or more of their participating patients do not meet the modified HEDIS quality metrics at the 6-month measurement, assessed once the first enrollee from each practice reaches the 12-month mark. Non-responders will be re-randomized to either continue to receive the iGuide 1 intervention, or to receive the iGuide 2 intervention, which includes tailored videos for participants and specialist consults with primary care providers. DISCUSSION: As the population of cancer survivors grows, ONE TEAM will contribute to closing the CVD outcomes gap among cancer survivors by optimizing and integrating cancer care and primary care teams. ONE TEAM is designed so that it will be possible for others to emulate and implement at scale. TRIAL REGISTRATION: This study (NCT04258813) was registered in clinicaltrals.gov on February 6, 2020. CI - (c) 2021. The Author(s). FAU - Zullig, Leah L AU - Zullig LL AUID- ORCID: 0000-0002-6638-409X AD - Department of Population Health Sciences, Duke University School Of Medicine, 215 Morris St, Durham, NC, 27701, USA. leah.zullig@duke.edu. AD - Department of Population Health Sciences, Duke University School of Medicine, 411 West Chapel Hill Street, Suite 600, Durham, NC, 27701, USA. leah.zullig@duke.edu. FAU - Shahsahebi, Mohammad AU - Shahsahebi M AD - Duke University Family Medicine and Community Health, 2424 Erwin Rd, Ste 601, DUMC, Box 2714, Durham, NC, 27705, USA. AD - Center for Onco-Primary Care, Duke Cancer Institute, 2424 Erwin Road, Hock Plaza, Ste 601, Durham, NC, 27705, USA. FAU - Neely, Benjamin AU - Neely B AD - Duke Cancer Institute, Duke University, 2424 Erwin Rd, Durham, NC, 27701, USA. FAU - Hyslop, Terry AU - Hyslop T AD - Department of Biostatistics, Duke University, 2424 Erwin Road, 9064 Hock Plaza, Durham, NC, 27705, USA. FAU - Avecilla, Renee A V AU - Avecilla RAV AD - Center for Onco-Primary Care, Duke Cancer Institute, 2424 Erwin Road, Hock Plaza, Ste 601, Durham, NC, 27705, USA. FAU - Griffin, Brittany M AU - Griffin BM AD - Center for Onco-Primary Care, Duke Cancer Institute, 2424 Erwin Road, Hock Plaza, Ste 601, Durham, NC, 27705, USA. FAU - Clayton-Stiglbauer, Kacey AU - Clayton-Stiglbauer K AD - Center for Onco-Primary Care, Duke Cancer Institute, 2424 Erwin Road, Hock Plaza, Ste 601, Durham, NC, 27705, USA. FAU - Coles, Theresa AU - Coles T AD - Department of Population Health Sciences, Duke University School Of Medicine, 215 Morris St, Durham, NC, 27701, USA. FAU - Owen, Lynda AU - Owen L AD - Duke Cancer Network, 20 Duke Medicine Circle, Durham, NC, 27710, USA. FAU - Reeve, Bryce B AU - Reeve BB AD - Department of Population Health Sciences, Duke University School Of Medicine, 215 Morris St, Durham, NC, 27701, USA. FAU - Shah, Kevin AU - Shah K AD - Duke Institute for Health Innovation, Duke University Health System, 200 Morris St, Durham, NC, 27701, USA. FAU - Shelby, Rebecca A AU - Shelby RA AD - Duke Psychiatry and Behavioral Sciences, Duke University School of Medicine, 2200 W. Main St, Ste 340, Durham, NC, 27705, USA. FAU - Sutton, Linda AU - Sutton L AD - Duke Cancer Network, 20 Duke Medicine Circle, Durham, NC, 27710, USA. FAU - Dinan, Michaela A AU - Dinan MA AD - Department of Chronic Disease Epidemiology, Yale School of Public Health, 60 College Street, New Haven, CT, 06510, USA. FAU - Zafar, S Yousuf AU - Zafar SY AD - Duke University School of Medicine, 2200 W. Main St, Ste 340, Durham, NC, 27705, USA. FAU - Shah, Nishant P AU - Shah NP AD - Duke Heart Center, Duke University School of Medicine, 2200 W. Main St, Ste 340, Durham, NC, 27705, USA. FAU - Dent, Susan AU - Dent S AD - Duke Cancer Institute, Duke University, 2200 W. Main St, Ste 340, Durham, NC, 27705, USA. FAU - Oeffinger, Kevin C AU - Oeffinger KC AD - Duke Cancer Institute, Duke University School of Medicine, 2200 W. Main St, Ste 340, Durham, NC, 27705, USA. LA - eng SI - ClinicalTrials.gov/NCT04258813 GR - R01 CA249568/CA/NCI NIH HHS/United States GR - P30CA014236/CA/NCI NIH HHS/United States GR - 1R01CA249568-01/CA/NCI NIH HHS/United States PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, N.I.H., Extramural DEP - 20211118 PL - England TA - BMC Fam Pract JT - BMC family practice JID - 100967792 SB - IM MH - *Cancer Survivors MH - Health Personnel MH - Humans MH - Medication Adherence MH - Morbidity MH - *Neoplasms/therapy MH - Touch PMC - PMC8600877 OTO - NOTNLM OT - Cancer survivorship OT - health services research OT - onco-primary care OT - oncology OT - primary care COIS- The authors report no financial or non-financial interests related to the current work. Unrelated to the current work, Dr. Zullig reports research funding from Proteus Digital Health and the PhRMA Foundation, as well as consulting from Novartis and Pfizer. Dr. Zafar reports employment and stock from Shattuck Labs (to his spouse), serving on advisory boards for Vivor, LLC (uncompensated) and Cancer Support Community (uncompensated), serving on the Board of Directors ffor Family Reach (uncompensated), and being a board member for WCG IRB. Dr. Zafar also reports research funding from AstraZeneca and consulting for RTI, McKesson, Quintiles, and Change Healthcare. Dr. Dent reports research funding from Novartis. EDAT- 2021/11/20 06:00 MHDA- 2021/12/15 06:00 PMCR- 2021/11/18 CRDT- 2021/11/19 05:32 PHST- 2021/09/29 00:00 [received] PHST- 2021/10/19 00:00 [accepted] PHST- 2021/11/19 05:32 [entrez] PHST- 2021/11/20 06:00 [pubmed] PHST- 2021/12/15 06:00 [medline] PHST- 2021/11/18 00:00 [pmc-release] AID - 10.1186/s12875-021-01569-8 [pii] AID - 1569 [pii] AID - 10.1186/s12875-021-01569-8 [doi] PST - epublish SO - BMC Fam Pract. 2021 Nov 18;22(1):234. doi: 10.1186/s12875-021-01569-8. PMID- 34793745 OWN - NLM STAT- MEDLINE DCOM- 20220117 LR - 20250516 IS - 1474-547X (Electronic) IS - 0140-6736 (Linking) VI - 398 IP - 10318 DP - 2021 Dec 18 TI - Percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting in left main coronary artery disease: an individual patient data meta-analysis. PG - 2247-2257 LID - S0140-6736(21)02334-5 [pii] LID - 10.1016/S0140-6736(21)02334-5 [doi] AB - BACKGROUND: The optimal revascularisation strategy for patients with left main coronary artery disease is uncertain. We therefore aimed to evaluate long-term outcomes for patients treated with percutaneous coronary intervention (PCI) with drug-eluting stents versus coronary artery bypass grafting (CABG). METHODS: In this individual patient data meta-analysis, we searched MEDLINE, Embase, and the Cochrane database using the search terms "left main", "percutaneous coronary intervention" or "stent", and "coronary artery bypass graft*" to identify randomised controlled trials (RCTs) published in English between database inception and Aug 31, 2021, comparing PCI with drug-eluting stents with CABG in patients with left main coronary artery disease that had at least 5 years of patient follow-up for all-cause mortality. Two authors (MSS and BAB) identified studies meeting the criteria. The primary endpoint was 5-year all-cause mortality. Secondary endpoints were cardiovascular death, spontaneous myocardial infarction, procedural myocardial infarction, stroke, and repeat revascularisation. We used a one-stage approach; event rates were calculated by use of the Kaplan-Meier method and treatment group comparisons were made by use of a Cox frailty model, with trial as a random effect. In Bayesian analyses, the probabilities of absolute risk differences in the primary endpoint between PCI and CABG being more than 0.0%, and at least 1.0%, 2.5%, or 5.0%, were calculated. FINDINGS: Our literature search yielded 1599 results, of which four RCTs-SYNTAX, PRECOMBAT, NOBLE, and EXCEL-meeting our inclusion criteria were included in our meta-analysis. 4394 patients, with a median SYNTAX score of 25.0 (IQR 18.0-31.0), were randomly assigned to PCI (n=2197) or CABG (n=2197). The Kaplan-Meier estimate of 5-year all-cause death was 11.2% (95% CI 9.9-12.6) with PCI and 10.2% (9.0-11.6) with CABG (hazard ratio 1.10, 95% CI 0.91-1.32; p=0.33), resulting in a non-statistically significant absolute risk difference of 0.9% (95% CI -0.9 to 2.8). In Bayesian analyses, there was an 85.7% probability that death at 5 years was greater with PCI than with CABG; this difference was more likely than not less than 1.0% (<0.2% per year). The numerical difference in mortality was comprised more of non-cardiovascular than cardiovascular death. Spontaneous myocardial infarction (6.2%, 95% CI 5.2-7.3 vs 2.6%, 2.0-3.4; hazard ratio [HR] 2.35, 95% CI 1.71-3.23; p<0.0001) and repeat revascularisation (18.3%, 16.7-20.0 vs 10.7%, 9.4-12.1; HR 1.78, 1.51-2.10; p<0.0001) were more common with PCI than with CABG. Differences in procedural myocardial infarction between strategies depended on the definition used. Overall, there was no difference in the risk of stroke between PCI (2.7%, 2.0-3.5) and CABG (3.1%, 2.4-3.9; HR 0.84, 0.59-1.21; p=0.36), but the risk was lower with PCI in the first year after randomisation (HR 0.37, 0.19-0.69). INTERPRETATION: Among patients with left main coronary artery disease and, largely, low or intermediate coronary anatomical complexity, there was no statistically significant difference in 5-year all-cause death between PCI and CABG, although a Bayesian approach suggested a difference probably exists (more likely than not <0.2% per year) favouring CABG. There were trade-offs in terms of the risk of myocardial infarction, stroke, and revascularisation. A heart team approach to communicate expected outcome differences might be useful to assist patients in reaching a treatment decision. FUNDING: No external funding. CI - Copyright (c) 2021 Elsevier Ltd. All rights reserved. FAU - Sabatine, Marc S AU - Sabatine MS AD - Thrombolysis in Myocardial Infarction Study Group, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. Electronic address: msabatine@bwh.harvard.edu. FAU - Bergmark, Brian A AU - Bergmark BA AD - Thrombolysis in Myocardial Infarction Study Group, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. FAU - Murphy, Sabina A AU - Murphy SA AD - Thrombolysis in Myocardial Infarction Study Group, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. FAU - O'Gara, Patrick T AU - O'Gara PT AD - Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. FAU - Smith, Peter K AU - Smith PK AD - Department of Surgery (Cardiothoracic), Duke University School of Medicine, Duke Clinical Research Institute, Durham, NC, USA. FAU - Serruys, Patrick W AU - Serruys PW AD - Department of Cardiology, National University of Ireland Galway, Galway, Ireland; National Heart and Lung Institute, Imperial College London, London, UK. FAU - Kappetein, A Pieter AU - Kappetein AP AD - Department of Cardiothoracic Surgery, Erasmus University Medical Centre, Rotterdam, Netherlands; Medtronic, Maastricht, Netherlands. FAU - Park, Seung-Jung AU - Park SJ AD - Department of Cardiology, Asan Medical Center, Seoul, South Korea. FAU - Park, Duk-Woo AU - Park DW AD - Department of Cardiology, Asan Medical Center, Seoul, South Korea. FAU - Christiansen, Evald H AU - Christiansen EH AD - Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark. FAU - Holm, Niels R AU - Holm NR AD - Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark. FAU - Nielsen, Per H AU - Nielsen PH AD - Department of Cardiothoracic and Vascular Surgery, Aarhus University Hospital, Aarhus, Denmark. FAU - Stone, Gregg W AU - Stone GW AD - The Zena and Michael A Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Cardiovascular Research Foundation, New York, NY, USA. FAU - Sabik, Joseph F AU - Sabik JF AD - Department of Surgery, University Hospitals Cleveland Medical Center, Cleveland, OH, USA. FAU - Braunwald, Eugene AU - Braunwald E AD - Thrombolysis in Myocardial Infarction Study Group, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. LA - eng PT - Comparative Study PT - Journal Article PT - Meta-Analysis PT - Review DEP - 20211115 PL - England TA - Lancet JT - Lancet (London, England) JID - 2985213R SB - IM CIN - Lancet. 2021 Dec 18;398(10318):2208-2209. doi: 10.1016/S0140-6736(21)02491-0. PMID: 34793742 EIN - Lancet. 2022 Apr 23;399(10335):1606. doi: 10.1016/S0140-6736(22)00701-2. PMID: 35461554 EIN - Lancet. 2022 Oct 15;400(10360):1304. doi: 10.1016/S0140-6736(22)01944-4. PMID: 36244381 MH - Coronary Artery Bypass/*methods MH - Coronary Artery Disease/*mortality/*surgery MH - *Drug-Eluting Stents MH - Humans MH - Percutaneous Coronary Intervention/*methods MH - Randomized Controlled Trials as Topic COIS- Declaration of interests MSS, BAB, SAM, and EB are members of the Thrombolysis in Myocardial Infarction Study Group, which has received grant support through Brigham and Women's Hospital (Boston, MA, USA) from Abbott, Amgen, Anthos Therapeutics, AstraZeneca, Bayer HealthCare Pharmaceuticals, Daiichi-Sankyo, Eisai, Intarcia, Ionis, MedImmune, Merck, Novartis, Pfizer, Quark Pharmaceuticals, Regeneron Pharmaceuticals, Roche, Siemens Healthcare Diagnostics, The Medicines Company, and Zora Biosciences. MSS declares research grant support through Brigham and Women's Hospital from Abbott, Amgen, Anthos Therapeutics, AstraZeneca, Bayer, Daiichi-Sankyo, Eisai, Intarcia, Ionis, The Medicines Company, MedImmune, Merck, Novartis, Pfizer, and Quark Pharmaceuticals, and has consulted for Althera, Amgen, Anthos Therapeutics, AstraZeneca, Bristol Myers Squibb, CVS Caremark, DalCor, Dr Reddy's Laboratories, Fibrogen, IFM Therapeutics, Intarcia, MedImmune, Merck, Moderna, Novo Nordisk, and Silence Therapeutics. BAB declares research grants through Brigham and Women's Hospital from Pfizer, Ionis, Quark, AstraZeneca/MedImmune, and Amgen, and consulting or personal fees from Philips, Abbott Vascular, CSI, Abiomed, Servier, Janssen, Quark, and Daiichi Sankyo. PWS declares consultancy or personal fees from SMT, Novartis, Philips, Xeltis, and Merillife. APK is an employee of Medtronic. S-JP declares grants from Abbott Vascular, Daiichi-Sankyo, ChongKunDang Pharm, Daewoong Pharm, and Edwards, and personal fees from Abbott Vascular and Edwards, all outside the submitted work. D-WP declares grants from Daiichi-Sankyo, ChongKunDang Pharm, Daewoong Pharm, and Abbott Vascular, and personal fees from Edwards, Abbott Vascular, and Medtronic, all outside the submitted work. EHC declares institutional research grants from Abbott, Biosensors, and Boston Scientific, and speaker fees from Abbott. NRH declares institutional research grants from Abbott, Biosensors, Bbraun, Boston Scientific, and Reva Medical, and speaker fees from Abbott, Reva Medical, and Terumo. GWS declares speaker honoraria from Cook and Infraredx; consultancy for Valfix, TherOx, Robocath, HeartFlow, Ablative Solutions, Vectorious, Miracor, Neovasc, Abiomed, Ancora, Elucid Bio, Occlutech, CorFlow, Apollo Therapeutics, Impulse Dynamics, Reva, Vascular Dynamics, Shockwave, V-Wave, Cardiomech, and Gore; equity or options from Ancora, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, Valfix, and MedFocus family of funds; that Columbia University (New York, NY, USA) received payments from Abbott for research activities related and not related to EXCEL and royalties for sale of the MitraClip; and that Mount Sinai Hospital (New York, NY, USA) receives research funding from Abbott. JFS was the North American Surgical Principal Investigator in the EXCEL trial. EB declares research grants through Brigham and Women's Hospital from AstraZeneca, Daiichi-Sankyo, Merck, and Novartis, and consultancies with Amgen, Boehringer-Ingelheim/Lilly, Bristol Myers Squibb (MyoKardia), Cardurion, NovoNordisk, and Verve. All author authors declare no competing interests. EDAT- 2021/11/19 06:00 MHDA- 2022/01/18 06:00 CRDT- 2021/11/18 20:11 PHST- 2021/09/23 00:00 [received] PHST- 2021/10/11 00:00 [revised] PHST- 2021/10/14 00:00 [accepted] PHST- 2021/11/19 06:00 [pubmed] PHST- 2022/01/18 06:00 [medline] PHST- 2021/11/18 20:11 [entrez] AID - S0140-6736(21)02334-5 [pii] AID - 10.1016/S0140-6736(21)02334-5 [doi] PST - ppublish SO - Lancet. 2021 Dec 18;398(10318):2247-2257. doi: 10.1016/S0140-6736(21)02334-5. Epub 2021 Nov 15. PMID- 34791132 OWN - NLM STAT- MEDLINE DCOM- 20220331 LR - 20250530 IS - 1522-9645 (Electronic) IS - 0195-668X (Print) IS - 0195-668X (Linking) VI - 43 IP - 2 DP - 2022 Jan 13 TI - Myocardial viability testing: all STICHed up, or about to be REVIVED? PG - 118-126 LID - 10.1093/eurheartj/ehab729 [doi] AB - Patients with ischaemic left ventricular dysfunction frequently undergo myocardial viability testing. The historical model presumes that those who have extensive areas of dysfunctional-yet-viable myocardium derive particular benefit from revascularization, whilst those without extensive viability do not. These suppositions rely on the theory of hibernation and are based on data of low quality: taking a dogmatic approach may therefore lead to patients being refused appropriate, prognostically important treatment. Recent data from a sub-study of the randomized STICH trial challenges these historical concepts, as the volume of viable myocardium failed to predict the effectiveness of coronary artery bypass grafting. Should the Heart Team now abandon viability testing, or are new paradigms needed in the way we interpret viability? This state-of-the-art review critically examines the evidence base for viability testing, focusing in particular on the presumed interactions between viability, functional recovery, revascularization and prognosis which underly the traditional model. We consider whether viability should relate solely to dysfunctional myocardium or be considered more broadly and explore wider uses of viability testingoutside of revascularization decision-making. Finally, we look forward to ongoing and future randomized trials, which will shape evidence-based clinical practice in the future. CI - (c) The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology. FAU - Ryan, Matthew AU - Ryan M AUID- ORCID: 0000-0001-8256-195X AD - School of Cardiovascular Medicine and Sciences, King's College London, Westminster Bridge Road, London SE1 7EH, UK. FAU - Morgan, Holly AU - Morgan H AUID- ORCID: 0000-0002-6636-6174 AD - School of Cardiovascular Medicine and Sciences, King's College London, Westminster Bridge Road, London SE1 7EH, UK. FAU - Chiribiri, Amedeo AU - Chiribiri A AD - School of Biomedical Engineering and Imaging Sciences, King's College London, Westminster Bridge Road, London SE1 7EH, UK. FAU - Nagel, Eike AU - Nagel E AUID- ORCID: 0000-0002-6044-950X AD - Institute for Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging, University Hospital Frankfurt, Frankfurt am Main, Germany. FAU - Cleland, John AU - Cleland J AUID- ORCID: 0000-0002-1471-7016 AD - Robertson Centre for Biostatistics, University of Glasgow, University Avenue, Glasgow G12 8QQ, UK. FAU - Perera, Divaka AU - Perera D AUID- ORCID: 0000-0001-6362-1291 AD - School of Cardiovascular Medicine and Sciences, King's College London, Westminster Bridge Road, London SE1 7EH, UK. LA - eng GR - FS/CRTF/21/24190/BHF_/British Heart Foundation/United Kingdom GR - RE16349/BHF_/British Heart Foundation/United Kingdom GR - FS 18/16/33396/BHF_/British Heart Foundation/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Eur Heart J JT - European heart journal JID - 8006263 SB - IM MH - Coronary Artery Bypass MH - Humans MH - *Myocardial Ischemia MH - Myocardial Revascularization MH - Myocardium MH - Prognosis MH - *Ventricular Dysfunction, Left PMC - PMC8757581 OTO - NOTNLM OT - Ischaemic cardiomyopathy OT - Ischaemic left ventricular dysfunction OT - Myocardial hibernation OT - Myocardial viability EDAT- 2021/11/19 06:00 MHDA- 2022/04/01 06:00 PMCR- 2021/11/13 CRDT- 2021/11/18 07:18 PHST- 2021/07/14 00:00 [received] PHST- 2021/09/14 00:00 [revised] PHST- 2021/09/30 00:00 [accepted] PHST- 2021/11/19 06:00 [pubmed] PHST- 2022/04/01 06:00 [medline] PHST- 2021/11/18 07:18 [entrez] PHST- 2021/11/13 00:00 [pmc-release] AID - 6427439 [pii] AID - ehab729 [pii] AID - 10.1093/eurheartj/ehab729 [doi] PST - ppublish SO - Eur Heart J. 2022 Jan 13;43(2):118-126. doi: 10.1093/eurheartj/ehab729. PMID- 34787873 OWN - NLM STAT- MEDLINE DCOM- 20220325 LR - 20220927 IS - 2284-0729 (Electronic) IS - 1128-3602 (Linking) VI - 25 IP - 21 DP - 2021 Nov TI - Prehabilitation and heart failure: perspective in primary outcomes, a randomized controlled trial. PG - 6684-6690 LID - 27113 [pii] LID - 10.26355/eurrev_202111_27113 [doi] AB - OBJECTIVE: Prehabilitation, intended as a multidisciplinary approach where physical training is combined with educational and counselling training, in cardiology could optimizing care, and has been shown to be able to reduce morbidity and mortality in several diseases. The present study aims to assess the effectiveness of a prehabilitation program in elderly patients (over 65) with chronic heart failure and to evaluate functional and quality indices of life. PATIENTS AND METHODS: This is randomized, single blind controlled trial. Fourteen older adult patients diagnosed with chronic heart failure were enrolled. Patients were randomly assigned into the study or the control group. Patients in the study group underwent physical training organized into 10 twice-weekly meetings, nutritional and lifestyle counseling. RESULTS: In the Study Group, the quality of life improved significantly (EQoL-5D), and between the two groups there is a statistically significant difference in the motor dimension of SF-36. CONCLUSIONS: Because of our preliminary results, prehabilitation program should be included among the management strategies of in elderly patients with chronic heart failure to better manage their disease and to improve their Quality of Life. FAU - Giovannini, S AU - Giovannini S AD - Department of Geriatrics and Orthopaedics, Universita Cattolica del Sacro Cuore, Rome, Italy. silvia.giovannini@unicatt.it. FAU - Coraci, D AU - Coraci D FAU - Di Caro, F AU - Di Caro F FAU - Castelli, L AU - Castelli L FAU - Loreti, C AU - Loreti C FAU - Chicco, A AU - Chicco A FAU - Fiori, M AU - Fiori M FAU - Bellieni, A AU - Bellieni A FAU - Gerardino, L AU - Gerardino L FAU - Nigito, C AU - Nigito C FAU - Laudisio, A AU - Laudisio A FAU - Brau, F AU - Brau F FAU - D'Angelo, E AU - D'Angelo E FAU - Caliandro, P AU - Caliandro P FAU - Biscotti, L AU - Biscotti L FAU - Padua, L AU - Padua L FAU - Zuccala, G AU - Zuccala G FAU - Bernabei, R AU - Bernabei R LA - eng PT - Journal Article PT - Randomized Controlled Trial PL - United States TA - Eur Rev Med Pharmacol Sci JT - European review for medical and pharmacological sciences JID - 9717360 SB - IM CIN - Eur Rev Med Pharmacol Sci. 2022 Jul;26(14):4948. doi: 10.26355/eurrev_202207_29278. PMID: 35916788 MH - Aged MH - Aged, 80 and over MH - Chronic Disease MH - Exercise Therapy MH - Female MH - Heart Failure/physiopathology/*therapy MH - Humans MH - Life Style MH - Male MH - Nutrition Assessment MH - Nutrition Therapy MH - Patient Education as Topic MH - Quality of Life MH - Single-Blind Method MH - Stroke Volume MH - Treatment Outcome EDAT- 2021/11/18 06:00 MHDA- 2022/03/26 06:00 CRDT- 2021/11/17 12:34 PHST- 2021/11/17 12:34 [entrez] PHST- 2021/11/18 06:00 [pubmed] PHST- 2022/03/26 06:00 [medline] AID - 27113 [pii] AID - 10.26355/eurrev_202111_27113 [doi] PST - ppublish SO - Eur Rev Med Pharmacol Sci. 2021 Nov;25(21):6684-6690. doi: 10.26355/eurrev_202111_27113. PMID- 34783997 OWN - NLM STAT- MEDLINE DCOM- 20211209 LR - 20261012 IS - 1546-9549 (Electronic) IS - 1546-9530 (Linking) VI - 18 IP - 6 DP - 2021 Dec TI - Management of Maternal Complex Congenital Heart Disease During Pregnancy. PG - 353-361 LID - 10.1007/s11897-021-00534-x [doi] AB - PURPOSE OF THE REVIEW: The purpose of this review is to discuss the risk stratification and management of pregnancy in women with complex congenital heart disease. RECENT FINDINGS: Classifying congenital heart defects (CHD) including both anatomy and physiology is important for maternal risk stratification. Although most women with CHD can tolerate the physiological challenge of pregnancy, some may experience serious risks both to their health and that of their foetus. The WHO maternal risk classification model remains the best-validated risk measure. Ideally, women with CHD should have pre-conception assessment with a CHD cardiologist. General principles of management, such as need for expert centre delivery, a multidisciplinary team, epidural and mode of delivery are based on WHO risk in combination with expert assessment of status. CHD is increasingly prevalent in women of child-bearing age. Assessment by an adult CHD cardiologist, ideally pre-conception, is key in assessing and minimising risk to mother and foetus. CI - (c) 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Kearney, Katherine AU - Kearney K AUID- ORCID: 0000-0003-1052-2542 AD - Cardiology Department, St Vincent's Hospital, Sydney, Australia. AD - St Vincent's Clinical School, University of New South Wales, Sydney, Australia. AD - Victor Chang Cardiac Research Institute, Sydney, Australia. FAU - Zentner, Dominica AU - Zentner D AD - Department of Cardiology, Royal Melbourne Hospital, Melbourne, Australia. AD - Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia. FAU - Cordina, Rachael AU - Cordina R AD - Department of Cardiology, Royal Prince Alfred Hospital, Camperdown, Australia. rachael.cordina@sydney.edu.au. AD - Sydney Medical School, University of Sydney, Sydney, Australia. rachael.cordina@sydney.edu.au. AD - Heart Research Institute, Sydney, Australia. rachael.cordina@sydney.edu.au. LA - eng PT - Journal Article PT - Review DEP - 20211116 PL - United States TA - Curr Heart Fail Rep JT - Current heart failure reports JID - 101196487 SB - IM MH - Adult MH - Female MH - *Heart Defects, Congenital/epidemiology/therapy MH - *Heart Failure MH - Humans MH - Pregnancy MH - *Pregnancy Complications, Cardiovascular/epidemiology/therapy MH - Risk Factors OTO - NOTNLM OT - Congenital heart disease OT - Fontan OT - Pregnancy OT - Pulmonary hypertension OT - Risk stratification EDAT- 2021/11/17 06:00 MHDA- 2021/12/15 06:00 CRDT- 2021/11/16 12:30 PHST- 2021/08/29 00:00 [accepted] PHST- 2021/11/17 06:00 [pubmed] PHST- 2021/12/15 06:00 [medline] PHST- 2021/11/16 12:30 [entrez] AID - 10.1007/s11897-021-00534-x [pii] AID - 10.1007/s11897-021-00534-x [doi] PST - ppublish SO - Curr Heart Fail Rep. 2021 Dec;18(6):353-361. doi: 10.1007/s11897-021-00534-x. Epub 2021 Nov 16. PMID- 34774748 OWN - NLM STAT- MEDLINE DCOM- 20220621 LR - 20250728 IS - 1532-8414 (Electronic) IS - 1071-9164 (Linking) VI - 28 IP - 6 DP - 2022 Jun TI - Emerging Implantable-Device Technology for Patients at the Intersection of Electrophysiology and Heart Failure Interdisciplinary Care. PG - 991-1015 LID - S1071-9164(21)00465-6 [pii] LID - 10.1016/j.cardfail.2021.11.006 [doi] AB - Cardiac implantable electronic devices, including implantable cardioverter-defibrillators and therapy, are part of guideline-indicated treatment for a subset of patients with heart failure with reduced ejection fraction. Current technological advancements in cardiac implantable electronic devices have allowed the detection of specific physiological parameters that are used to forecast clinical decompensation through algorithmic, multiparameter remote monitoring. Other recent emerging technologies, including cardiac contractility modulation and baroreflex activation therapy, may provide symptomatic or physiological benefits in patients without indications for cardiac resynchronization. Our goal in this state-of-the-art review is to describe the new commercially available technologies, their purported mechanisms of action, and the evidence surrounding their clinical roles, limitations and future directions. Finally, we underline the need for standardized workflow and close interdisciplinary management of this population to ensure the delivery of high-quality care. CI - Copyright (c) 2021 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Mastoris, Ioannis AU - Mastoris I AD - Department of Cardiovascular Medicine, University of Kansas School of Medicine, Kansas City, Kansas. FAU - Spall, Harriette G C Van AU - Spall HGCV AD - Department of Medicine, Department of Health Research Methods, Evidence, and Impact, Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada. FAU - Sheldon, Seth H AU - Sheldon SH AD - Department of Cardiovascular Medicine, University of Kansas School of Medicine, Kansas City, Kansas. FAU - Pimentel, Rhea C AU - Pimentel RC AD - Department of Cardiovascular Medicine, University of Kansas School of Medicine, Kansas City, Kansas. FAU - Steinkamp, Leslie AU - Steinkamp L AD - Department of Cardiovascular Medicine, University of Kansas School of Medicine, Kansas City, Kansas. FAU - Shah, Zubair AU - Shah Z AD - Department of Cardiovascular Medicine, University of Kansas School of Medicine, Kansas City, Kansas. FAU - Al-Khatib, Sana M AU - Al-Khatib SM AD - Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina. FAU - Singh, Jagmeet P AU - Singh JP AD - Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. FAU - Sauer, Andrew J AU - Sauer AJ AD - Department of Cardiovascular Medicine, University of Kansas School of Medicine, Kansas City, Kansas. Electronic address: asauer@kumc.edu. LA - eng GR - CIHR/Canada PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20211110 PL - United States TA - J Card Fail JT - Journal of cardiac failure JID - 9442138 SB - IM MH - *Cardiac Resynchronization Therapy MH - Cardiac Resynchronization Therapy Devices MH - *Defibrillators, Implantable MH - Electrophysiology MH - *Heart Failure/therapy MH - Humans MH - Technology OTO - NOTNLM OT - Remote monitoring OT - cardiac implantable electronic devices EDAT- 2021/11/15 06:00 MHDA- 2022/06/22 06:00 CRDT- 2021/11/14 20:47 PHST- 2021/08/01 00:00 [received] PHST- 2021/11/01 00:00 [revised] PHST- 2021/11/05 00:00 [accepted] PHST- 2021/11/15 06:00 [pubmed] PHST- 2022/06/22 06:00 [medline] PHST- 2021/11/14 20:47 [entrez] AID - S1071-9164(21)00465-6 [pii] AID - 10.1016/j.cardfail.2021.11.006 [doi] PST - ppublish SO - J Card Fail. 2022 Jun;28(6):991-1015. doi: 10.1016/j.cardfail.2021.11.006. Epub 2021 Nov 10. PMID- 34770166 OWN - NLM STAT- MEDLINE DCOM- 20211119 LR - 20240404 IS - 1660-4601 (Electronic) IS - 1661-7827 (Print) IS - 1660-4601 (Linking) VI - 18 IP - 21 DP - 2021 Nov 6 TI - Lean Six Sigma Redesign of a Process for Healthcare Mandatory Education in Basic Life Support-A Pilot Study. LID - 10.3390/ijerph182111653 [doi] LID - 11653 AB - Healthcare staff are required to undertake mandatory training programs to ensure they maintain key clinical competencies. This study was conducted in a private hospital in Ireland, where the processes for accessing mandatory training were found to be highly complex and non-user friendly, resulting in missed training opportunities, specific training license expiration, and underutilized training slots which resulted in lost time for both the trainers and trainees. A pilot study was undertaken to review the process for accessing mandatory training with a focus on the mandatory training program of Basic Life Support (BLS). This was chosen due to its importance in patient resuscitation and its requirement in the hospital achieving Joint Commission International (JCI) accreditation. A pre- and post-team-based intervention design was used with Lean Six Sigma (LSS) methodology employed to redesign the process of booking, scheduling, and delivery of BLS training leading to staff individual BLS certification for a period of two years. The redesign of the BLS training program resulted in a new blended delivery method, and the initiation of a pilot project led to a 50% increase in the volume of BLS classes and a time saving of 154 h 30 min for staff and 48 h 14 min for BLS instructors. The success of the BLS process access pilot has functioned as a platform for the redesign of other mandatory education programs and will be of interest to hospitals with mandatory training requirements that are already facing healthcare challenges and demands on staff time. FAU - Dempsey, Anne AU - Dempsey A AD - Beacon Hospital, Sandyford, D18 AK68 Dublin, Ireland. FAU - Robinson, Ciara AU - Robinson C AD - Beacon Hospital, Sandyford, D18 AK68 Dublin, Ireland. FAU - Moffatt, Niamh AU - Moffatt N AD - Beacon Hospital, Sandyford, D18 AK68 Dublin, Ireland. FAU - Hennessy, Therese AU - Hennessy T AD - Beacon Hospital, Sandyford, D18 AK68 Dublin, Ireland. FAU - Bradshaw, Annmarie AU - Bradshaw A AD - Beacon Hospital, Sandyford, D18 AK68 Dublin, Ireland. FAU - Teeling, Sean Paul AU - Teeling SP AUID- ORCID: 0000-0002-4102-7280 AD - UCD Centre for Interdisciplinary Research, Education & Innovation in Health Systems, School of Nursing, Midwifery & Health Systems, University College Dublin, D04 V1W8 Dublin, Ireland. AD - Centre for Person-Centred Practice Research Division of Nursing, School of Health Sciences, Queen Margaret University Drive, Queen Margaret University, Musselburgh EH21 6UU, UK. FAU - Ward, Marie AU - Ward M AUID- ORCID: 0000-0002-6638-8461 AD - Centre for Innovative Human Systems, School of Psychology, Trinity College, The University of Dublin, D02 PN40 Dublin, Ireland. FAU - McNamara, Martin AU - McNamara M AUID- ORCID: 0000-0001-7257-9654 AD - UCD Centre for Interdisciplinary Research, Education & Innovation in Health Systems, School of Nursing, Midwifery & Health Systems, University College Dublin, D04 V1W8 Dublin, Ireland. LA - eng PT - Journal Article DEP - 20211106 PL - Switzerland TA - Int J Environ Res Public Health JT - International journal of environmental research and public health JID - 101238455 SB - IM MH - *Cardiopulmonary Resuscitation MH - Clinical Competence MH - Delivery of Health Care MH - Humans MH - Pilot Projects MH - *Total Quality Management PMC - PMC8583709 OTO - NOTNLM OT - American Heart Association OT - Basic Life Support OT - blended learning in healthcare OT - cardiac pulmonary resuscitation OT - education OT - lean six sigma OT - mandatory education OT - process improvement OT - training OT - virtual learning environment COIS- The authors declare no conflict of interest. EDAT- 2021/11/14 06:00 MHDA- 2021/11/20 06:00 PMCR- 2021/11/06 CRDT- 2021/11/13 01:09 PHST- 2021/09/28 00:00 [received] PHST- 2021/11/03 00:00 [revised] PHST- 2021/11/04 00:00 [accepted] PHST- 2021/11/13 01:09 [entrez] PHST- 2021/11/14 06:00 [pubmed] PHST- 2021/11/20 06:00 [medline] PHST- 2021/11/06 00:00 [pmc-release] AID - ijerph182111653 [pii] AID - ijerph-18-11653 [pii] AID - 10.3390/ijerph182111653 [doi] PST - epublish SO - Int J Environ Res Public Health. 2021 Nov 6;18(21):11653. doi: 10.3390/ijerph182111653. PMID- 34768660 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240818 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 10 IP - 21 DP - 2021 Oct 31 TI - Updates on the Latest Surgical Approach of the Aortic Stenosis. LID - 10.3390/jcm10215140 [doi] LID - 5140 AB - Over the last twenty years, we marked significant progresses in the field of tissue engineering and the development of new aortic valve structural and delivery systems. These continuous iterations on the field, have completely changed the surgical indications and approaches for AVR. Nowadays, therapeutic decisions are endorsed by international guidelines; however, new technical advances need a new integrated approach. The clinical scenarios issued from the interaction between the Guidelines and the newest approaches and technologies are regularly on debate by the Heart Team. We will present some of our most encountered situations and the pattern of our therapeutic decisions. To easily navigate through Guidelines and clinical scenarios, we reported in this review a simplified and easy to use Clinical decision-making algorithm that may be a valuable tool in our daily practice. FAU - Geicu, Lucian AU - Geicu L AD - Department of Cardiac Surgery, Montreal Heart Institute, Montreal University, Montreal, QC H1T 1C8, Canada. FAU - Busuttil, Olivier AU - Busuttil O AD - Unite Medico-Chirurgicale, Hopital Haut Leveque, CHU de Bordeaux, CEDEX, 33604 Pessac, France. FAU - D'Ostrevy, Nicolas AU - D'Ostrevy N AD - Cardiac Surgery Department, CHU de Clermont Ferrand, 63003 Clermont Ferrand, France. FAU - Pernot, Mathieu AU - Pernot M AD - Unite Medico-Chirurgicale, Hopital Haut Leveque, CHU de Bordeaux, CEDEX, 33604 Pessac, France. FAU - Benali, Walid AU - Benali W AD - Department of Cardiac Surgery, Montreal Heart Institute, Montreal University, Montreal, QC H1T 1C8, Canada. FAU - Labrousse, Louis AU - Labrousse L AD - Unite Medico-Chirurgicale, Hopital Haut Leveque, CHU de Bordeaux, CEDEX, 33604 Pessac, France. FAU - Modine, Thomas AU - Modine T AD - Unite Medico-Chirurgicale, Hopital Haut Leveque, CHU de Bordeaux, CEDEX, 33604 Pessac, France. LA - eng PT - Journal Article DEP - 20211031 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC8584939 OTO - NOTNLM OT - AVR OT - Ross procedure OT - TAVI OT - V-in-V OT - aortic root enlargement OT - decision making algorithm OT - mini-invasive surgery OT - new valve technologies COIS- The authors declare no conflict of interest. EDAT- 2021/11/14 06:00 MHDA- 2021/11/14 06:01 PMCR- 2021/10/31 CRDT- 2021/11/13 01:02 PHST- 2021/10/18 00:00 [received] PHST- 2021/10/26 00:00 [revised] PHST- 2021/10/29 00:00 [accepted] PHST- 2021/11/13 01:02 [entrez] PHST- 2021/11/14 06:00 [pubmed] PHST- 2021/11/14 06:01 [medline] PHST- 2021/10/31 00:00 [pmc-release] AID - jcm10215140 [pii] AID - jcm-10-05140 [pii] AID - 10.3390/jcm10215140 [doi] PST - epublish SO - J Clin Med. 2021 Oct 31;10(21):5140. doi: 10.3390/jcm10215140. PMID- 34768640 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240818 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 10 IP - 21 DP - 2021 Oct 31 TI - Diagnostic Work-Up of the Aortic Patient: An Integrated Approach toward the Best Therapeutic Option. LID - 10.3390/jcm10215120 [doi] LID - 5120 AB - Aortic stenosis (AS) is the most common valvular heart disease. In the last decade, transcatheter aortic valve implantation (TAVI) has become the standard of care for symptomatic patients at high surgical risk. Recently, indications to TAVI have also been extended to the low surgical risk and intermediate surgical risk populations. Consequently, in this setting, some aspects acquire greater relevance: surgical risk evaluation, clinical assessment, multimodality imaging of the valve, and management of coronary artery disease. Moreover, future issues such as coronary artery re-access and valve-in-valve interventions should be considered in the valve selection process. This review aims to summarize the principal aspects of a multidimensional (multidisciplinary) and comprehensive preprocedural work-up. The Heart Team is at the center of the decision-making process of the management of aortic valve disease and bears responsibility for offering each patient a tailored approach based on an individual evaluation of technical aspects together with the risks and benefits of each modality. Considering the progressive expansion in TAVI indication and technological progress, the role of a work-up and multidisciplinary Heart Team will be even more relevant. FAU - Pighi, Michele AU - Pighi M AUID- ORCID: 0000-0003-3703-3837 AD - Division of Cardiology, Department of Medicine, McGill University Health Center, Montreal, QC H4A 3J1, Canada. AD - Division of Cardiology, Department of Medicine, University of Verona, 37126 Verona, Italy. FAU - Giovannini, Davide AU - Giovannini D AUID- ORCID: 0000-0002-2227-0525 AD - Division of Cardiology, Department of Medicine, University of Verona, 37126 Verona, Italy. FAU - Scarsini, Roberto AU - Scarsini R AUID- ORCID: 0000-0002-5916-8882 AD - Division of Cardiology, Department of Medicine, University of Verona, 37126 Verona, Italy. FAU - Piazza, Nicolo AU - Piazza N AUID- ORCID: 0000-0003-2809-3408 AD - Division of Cardiology, Department of Medicine, McGill University Health Center, Montreal, QC H4A 3J1, Canada. LA - eng PT - Journal Article PT - Review DEP - 20211031 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC8584438 OTO - NOTNLM OT - TAVI OT - aortic stenosis OT - work-up COIS- The authors declare no conflict of interest. EDAT- 2021/11/14 06:00 MHDA- 2021/11/14 06:01 PMCR- 2021/10/31 CRDT- 2021/11/13 01:02 PHST- 2021/09/29 00:00 [received] PHST- 2021/10/22 00:00 [revised] PHST- 2021/10/29 00:00 [accepted] PHST- 2021/11/13 01:02 [entrez] PHST- 2021/11/14 06:00 [pubmed] PHST- 2021/11/14 06:01 [medline] PHST- 2021/10/31 00:00 [pmc-release] AID - jcm10215120 [pii] AID - jcm-10-05120 [pii] AID - 10.3390/jcm10215120 [doi] PST - epublish SO - J Clin Med. 2021 Oct 31;10(21):5120. doi: 10.3390/jcm10215120. PMID- 34765982 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20211126 IS - 2639-8028 (Electronic) IS - 2639-8028 (Linking) VI - 3 IP - 11 DP - 2021 Nov TI - The Effect of Chaplain Patient Navigators and Multidisciplinary Family Meetings on Patient Outcomes in the ICU: The Critical Care Collaboration and Communication Project. PG - e0574 LID - 10.1097/CCE.0000000000000574 [doi] LID - e0574 AB - OBJECTIVES: To assess the effectiveness of a chaplain patient navigator in improving outcomes and reducing costs in the ICU setting. DESIGN: A randomized controlled trial at a large, urban, academic community hospital in Baltimore, Maryland. SETTING/PATIENTS: All patients admitted to the Johns Hopkins Bayview Medical Center Cardiac and Medical ICUs between March 2015 and December 2015. INTERVENTIONS: Patients in the intervention group were assigned a chaplain patient navigator to facilitate communication, offer support, and setup multidisciplinary family meetings. MEASUREMENTS AND MAIN RESULTS: The primary outcomes were hospital and ICU length of stay. Secondary outcomes included total and ICU charges, 60- and 90-day readmission rates, and the number of palliative care consults. For all outcomes, patients were included in the intention-to-treat analyses only if they remained in the ICU greater than 24 hours. In total, 1,174 were randomly assigned to "usual care" (n = 573) or to the intervention (n = 601). In the intervention group, 44.8% (269/601) had meetings within 24 hours of admission and, of those patients, 32.8% (88/268) took part in the larger multidisciplinary family meeting 2-3 days later. The intervention group had longer mean adjusted hospital length of stay (7.78 vs 8.63 d; p /=65 years (59%) and male (54%). Hypertension (59%), dyslipidemia (36%), and diabetes (20%) were the most common preexisting cardiovascular diseases. Brain imaging, carotid imaging, and cardiac testing were performed in 20.3%, 7.1%, and 23.8% of the patients, respectively; at least 1 test from each of these 3 categories was performed in 4.1% of the patients. Half of the patients were hospitalized. Factors that increased the chances of hospitalization included the following (P < 0.05): age of <45 years; female sex; a history of smoking; presenting to a metropolitan hospital and having giant cell arteritis, carotid artery disease, atrial fibrillation, cardiac valve disease, obesity, dyslipidemia, hypertension, diabetes, and chronic ischemic heart disease. CONCLUSIONS: Most patients who presented to an ED with an RAO did not receive emergency brain imaging, carotid imaging, or basic cardiac testing. A multidisciplinary approach is needed to raise awareness that RAOs should be treated as a precursor of stroke or a stroke equivalent. CI - Copyright (c) 2021 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved. FAU - Yousuf, Salman J AU - Yousuf SJ AD - Department of Ophthalmology, Howard University College of Medicine, Washington, DC. Electronic address: salman.yousuf@howard.edu. FAU - Guiseppi, Rodney AU - Guiseppi R AD - Department of Ophthalmology, Howard University College of Medicine, Washington, DC. FAU - Katz, David M AU - Katz DM AD - Department of Ophthalmology, Howard University College of Medicine, Washington, DC. FAU - Nnorom, Siobhan O AU - Nnorom SO AD - The Clive O. Callender, M.D., Howard-Harvard Health Sciences Outcomes Research Center, Department of Surgery, Howard University College of Medicine, Washington, DC. FAU - Akinyemi, Oluwasegun A AU - Akinyemi OA AD - The Clive O. Callender, M.D., Howard-Harvard Health Sciences Outcomes Research Center, Department of Surgery, Howard University College of Medicine, Washington, DC. LA - eng PT - Journal Article DEP - 20211103 PL - United States TA - Ophthalmol Retina JT - Ophthalmology. Retina JID - 101695048 SB - IM MH - Cross-Sectional Studies MH - Emergency Service, Hospital MH - Female MH - Humans MH - *Hypertension MH - Male MH - *Retinal Artery Occlusion/diagnosis MH - Retrospective Studies MH - Risk Factors MH - *Stroke MH - United States OTO - NOTNLM OT - emergency departments OT - retinal artery occlusions OT - strokes EDAT- 2021/11/08 06:00 MHDA- 2022/04/12 06:00 CRDT- 2021/11/07 20:37 PHST- 2021/09/22 00:00 [received] PHST- 2021/10/13 00:00 [revised] PHST- 2021/10/28 00:00 [accepted] PHST- 2021/11/08 06:00 [pubmed] PHST- 2022/04/12 06:00 [medline] PHST- 2021/11/07 20:37 [entrez] AID - S2468-6530(21)00349-3 [pii] AID - 10.1016/j.oret.2021.10.011 [doi] PST - ppublish SO - Ophthalmol Retina. 2022 Apr;6(4):318-324. doi: 10.1016/j.oret.2021.10.011. Epub 2021 Nov 3. PMID- 34735967 OWN - NLM STAT- MEDLINE DCOM- 20211229 LR - 20221207 IS - 1532-8171 (Electronic) IS - 0735-6757 (Linking) VI - 51 DP - 2022 Jan TI - Management of acute aortic syndromes from initial presentation to definitive treatment. PG - 108-113 LID - S0735-6757(21)00851-2 [pii] LID - 10.1016/j.ajem.2021.10.016 [doi] AB - BACKGROUND: Acute aortic syndromes comprise a spectrum of diseases including aortic dissection, intramural hematoma, and penetrating atherosclerotic ulcers. Early diagnosis, rapid intervention, and multidisciplinary team care are vital to efficiently manage time-sensitive aortic emergencies, mobilize appropriate resources, and optimize clinical outcomes. OBJECTIVE: This comprehensive review outlines the multidisciplinary team approach from initial presentation to definitive interventional treatment and post-operative care. DISCUSSION: Acute aortic syndromes can be life-threatening and require prompt diagnosis and aggressive initiation of blood pressure and pain control to prevent subsequent complications. Early time to diagnosis and intervention are associated with improved outcomes. CONCLUSIONS: A multidisciplinary team can help promptly diagnose and manage aortic syndromes. CI - Copyright (c) 2021. Published by Elsevier Inc. FAU - Mehta, Christopher K AU - Mehta CK AD - Division of Cardiac Surgery, Bluhm Cardiovascular Institute, Northwestern Medicine, Chicago, IL, United States of America. Electronic address: Christopher.mehta@nm.org. FAU - Son, Andre Y AU - Son AY AD - Division of Cardiac Surgery, Bluhm Cardiovascular Institute, Northwestern Medicine, Chicago, IL, United States of America. FAU - Chia, Matthew C AU - Chia MC AD - Division of Vascular Surgery, Bluhm Cardiovascular Institute, Northwestern Medicine, Chicago, IL, United States of America. FAU - Budd, Ashley N AU - Budd AN AD - Department of Anesthesiology, Northwestern Medicine, Chicago, IL, United States of America. FAU - Allen, Bradley D AU - Allen BD AD - Department of Radiology, Northwestern Medicine, Chicago, IL, United States of America. FAU - Vassallo, Patricia AU - Vassallo P AD - Division of Cardiology, Bluhm Cardiovascular Institute, Northwestern Medicine, Chicago, IL, United States of America. FAU - Hoel, Andrew W AU - Hoel AW AD - Division of Vascular Surgery, Bluhm Cardiovascular Institute, Northwestern Medicine, Chicago, IL, United States of America. FAU - Brady, William J AU - Brady WJ AD - Departments of Emergency Medicine and Internal Medicine, University of Virginia, Charlottesville, VA, United States of America. FAU - Nable, Jose V AU - Nable JV AD - Department of Emergency Medicine, MedStar Georgetown University Hospital, Washington D.C., United States of America. LA - eng PT - Journal Article PT - Review DEP - 20211021 PL - United States TA - Am J Emerg Med JT - The American journal of emergency medicine JID - 8309942 SB - IM MH - Acute Disease MH - Aortic Dissection/*diagnosis/therapy MH - Aortic Diseases/*diagnosis/therapy MH - Blood Pressure MH - Hematoma/*diagnosis/therapy MH - Humans MH - Pain Management MH - Patient Care Team MH - Syndrome MH - Thoracic Surgery MH - Ulcer/*diagnosis/therapy MH - Vascular Surgical Procedures OTO - NOTNLM OT - Aortic dissection OT - Aortic syndromes OT - Cardiac surgery OT - Vascular surgery COIS- Declaration of Competing Interest All authors report no disclosures. EDAT- 2021/11/05 06:00 MHDA- 2021/12/30 06:00 CRDT- 2021/11/04 20:13 PHST- 2021/06/22 00:00 [received] PHST- 2021/10/07 00:00 [revised] PHST- 2021/10/11 00:00 [accepted] PHST- 2021/11/05 06:00 [pubmed] PHST- 2021/12/30 06:00 [medline] PHST- 2021/11/04 20:13 [entrez] AID - S0735-6757(21)00851-2 [pii] AID - 10.1016/j.ajem.2021.10.016 [doi] PST - ppublish SO - Am J Emerg Med. 2022 Jan;51:108-113. doi: 10.1016/j.ajem.2021.10.016. Epub 2021 Oct 21. PMID- 34729509 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20211105 IS - 2666-0849 (Electronic) IS - 2666-0849 (Linking) VI - 3 IP - 14 DP - 2021 Oct 20 TI - Left Main Coronary Artery to Superior Vena Cava Fistula Unmasked by Endarteritis. PG - 1599-1601 LID - 10.1016/j.jaccas.2021.06.025 [doi] AB - Coronary artery fistulas are rare vascular malformations that can present with a broad range of symptoms. We present a case of a left main coronary artery to superior vena cava fistula that was discovered during a work-up for sepsis. A multidisciplinary approach is crucial for successful management of these vascular malformations. (Level of Difficulty: Beginner.). CI - (c) 2021 The Authors. FAU - Bakhshi, Hooman AU - Bakhshi H AD - Inova Heart and Vascular Institute, Falls Church, Virginia, USA. FAU - Guo, Abra AU - Guo A AD - Department of Internal Medicine, Medstar Georgetown University Hospital, Washington, DC, USA. FAU - Tehrani, Behnam AU - Tehrani B AD - Inova Heart and Vascular Institute, Falls Church, Virginia, USA. FAU - Thompson, James AU - Thompson J AD - Johns Hopkins All Children's Hospital, St. Petersburg, Florida, USA. FAU - Batchelor, Wayne AU - Batchelor W AD - Inova Heart and Vascular Institute, Falls Church, Virginia, USA. LA - eng PT - Journal Article DEP - 20211020 PL - Netherlands TA - JACC Case Rep JT - JACC. Case reports JID - 101757292 PMC - PMC8543127 OTO - NOTNLM OT - AVF, arteriovenous fistula OT - CT, computed tomography OT - LMCA, left main coronary artery OT - SVC, superior vena cava OT - arteriovenous fistula OT - coronary fistula OT - endarteritis OT - percutaneous closure OT - septic emboli COIS- Dr Tehrani is a consultant and speaker for Medtronic. Dr Thompson is a proctor for Abbott. Dr Batchelor is a consultant and speaker for Abbott; and is a consultant for Boston Scientific, V-Wave. Idorsia. and Philips. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2021/11/04 06:00 MHDA- 2021/11/04 06:01 PMCR- 2021/10/20 CRDT- 2021/11/03 07:01 PHST- 2021/06/02 00:00 [received] PHST- 2021/06/15 00:00 [accepted] PHST- 2021/11/03 07:01 [entrez] PHST- 2021/11/04 06:00 [pubmed] PHST- 2021/11/04 06:01 [medline] PHST- 2021/10/20 00:00 [pmc-release] AID - S2666-0849(21)00623-9 [pii] AID - 10.1016/j.jaccas.2021.06.025 [doi] PST - epublish SO - JACC Case Rep. 2021 Oct 20;3(14):1599-1601. doi: 10.1016/j.jaccas.2021.06.025. eCollection 2021 Oct 20. PMID- 34725139 OWN - NLM STAT- MEDLINE DCOM- 20220322 LR - 20250103 IS - 1526-9906 (Electronic) IS - 1526-9906 (Linking) VI - 22 IP - 11 DP - 2021 Nov TI - Cardiovascular Disease in Pregnancy. PG - e747-e759 LID - 10.1542/neo.22-11-e747 [doi] AB - Cardiovascular disease remains a major contributor to rising maternal morbidity and mortality. Both the pregnant woman and fetus are exposed to many potential complications as a result of the physiologic changes of pregnancy. These changes can exacerbate existing cardiac disease, as well as lead to the development of de novo issues during gestation, delivery, and the postnatal period. For women with preexisting cardiac disease, including congenital malformations, valvular disease, coronary artery disease, and aortopathies, it is crucial that they receive multidisciplinary evaluation, counseling, and optimization before conception, as well as close monitoring and medication management during pregnancy. Close monitoring is also essential for patients who develop cardiovascular complications such as preeclampsia, cardiomyopathy, congestive heart failure, coronary events, and arrhythmias during pregnancy. In addition, concerning disparities in maternal morbidity and mortality exist across many dimensions, in part because of the lack of uniformity of care in different treatment settings. Establishment of multidisciplinary cardio-obstetric teams including representatives from cardiology, anesthesia, obstetrics, maternal-fetal medicine, and specialized nursing has proven instrumental to delivering evidence-based and equitable care to high-risk patients. Multidisciplinary teams should work to guide these patients through the preconception, antepartum, delivery, and postpartum phases to ensure appropriate care for weeks to years after pregnancy. CI - Copyright (c) 2021 by the American Academy of Pediatrics. FAU - Mcilvaine, Susan AU - Mcilvaine S AD - Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA. AD - Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA. FAU - Feinberg, Loryn AU - Feinberg L AD - Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA. FAU - Spiel, Melissa AU - Spiel M AD - Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA. AD - Department of Obstetrics, Gynecology, and Reproductive Biology, Harvard Medical School, Boston, MA. LA - eng PT - Journal Article PT - Review PL - United States TA - Neoreviews JT - NeoReviews JID - 101085360 SB - IM MH - *Cardiovascular Diseases/diagnosis/therapy MH - Female MH - *Heart Diseases MH - Humans MH - *Obstetrics MH - Pregnancy MH - *Pregnancy Complications, Cardiovascular/diagnosis/therapy MH - Pregnant People EDAT- 2021/11/03 06:00 MHDA- 2022/03/23 06:00 CRDT- 2021/11/02 05:37 PHST- 2021/11/02 05:37 [entrez] PHST- 2021/11/03 06:00 [pubmed] PHST- 2022/03/23 06:00 [medline] AID - 22/11/e747 [pii] AID - 10.1542/neo.22-11-e747 [doi] PST - ppublish SO - Neoreviews. 2021 Nov;22(11):e747-e759. doi: 10.1542/neo.22-11-e747. PMID- 39720506 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250104 IS - 1758-3896 (Electronic) IS - 1758-3896 (Print) IS - 1758-3896 (Linking) VI - 15 DP - 2021 TI - Current Landscape of Temporary Percutaneous Mechanical Circulatory Support Technology. PG - e21 LID - 10.15420/usc.2021.15 [doi] LID - e21 AB - Mechanical circulatory support devices provide hemodynamic support to patients who present with cardiogenic shock. These devices work using different mechanisms to provide univentricular or biventricular support. There is a growing body of evidence supporting use of these devices as a goal for cardiac recovery or as a bridge to definitive therapy, but definitive, well-powered studies are still needed. Mechanical circulatory support devices are increasingly used using shock team and protocols, which can help clinicians in decision making, balancing operator and institutional experience and expertise. The aim of this article is to review commercially available mechanical circulatory support devices, their profiles and mechanisms of action, and the evidence available regarding their use. CI - Copyright (c) The Author(s), 2021. Published by Radcliffe Group Ltd. FAU - Upadhyay, Rani AU - Upadhyay R AD - Section of Interventional Cardiology, Stanford Health Care Oakland, CA. FAU - Alrayes, Hussayn AU - Alrayes H AD - Division of Cardiology, Henry Ford Hospital Detroit, MI. FAU - Arno, Scott AU - Arno S AD - Division of Cardiology, Henry Ford Hospital Detroit, MI. FAU - Kaushik, Milan AU - Kaushik M AD - Wayne State University Detroit, MI. FAU - Basir, Mir B AU - Basir MB AD - Division of Cardiology, Henry Ford Hospital Detroit, MI. LA - eng PT - Journal Article PT - Review DEP - 20211102 PL - England TA - US Cardiol JT - US cardiology JID - 101574791 PMC - PMC11664789 OTO - NOTNLM OT - Cardiogenic shock OT - MI OT - devices OT - heart failure OT - mechanical circulatory support COIS- Disclosure: MBB is a consultant for Abbott Vascular, Abiomed, Cardiovascular Systems, Chiesi, Procyrion, and Zoll. All other authors have no conflicts of interest to declare. EDAT- 2021/11/02 00:00 MHDA- 2021/11/02 00:01 PMCR- 2021/11/02 CRDT- 2024/12/25 04:25 PHST- 2021/04/05 00:00 [received] PHST- 2021/07/06 00:00 [accepted] PHST- 2021/11/02 00:01 [medline] PHST- 2021/11/02 00:00 [pubmed] PHST- 2024/12/25 04:25 [entrez] PHST- 2021/11/02 00:00 [pmc-release] AID - 10.15420/usc.2021.15 [doi] PST - epublish SO - US Cardiol. 2021 Nov 2;15:e21. doi: 10.15420/usc.2021.15. eCollection 2021. PMID- 34722676 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20211102 IS - 2297-055X (Print) IS - 2297-055X (Electronic) IS - 2297-055X (Linking) VI - 8 DP - 2021 TI - When Aortic Stenosis Is Not Alone: Epidemiology, Pathophysiology, Diagnosis and Management in Mixed and Combined Valvular Disease. PG - 744497 LID - 10.3389/fcvm.2021.744497 [doi] LID - 744497 AB - Aortic stenosis (AS) may present frequently combined with other valvular diseases or mixed with aortic regurgitation, with peculiar physio-pathological and clinical implications. The hemodynamic interactions between AS in mixed or combined valve disease depend on the specific combination of valve lesions and may result in diagnostic pitfalls at echocardiography; other imaging modalities may be helpful. Indeed, diagnosis is challenging because several echocardiographic methods commonly used to assess stenosis or regurgitation have been validated only in patients with the single-valve disease. Moreover, in the developed world, patients with multiple valve diseases tend to be older and more fragile over time; also, when more than one valvular lesion needs to address the surgical risk rises together with the long-term risk of morbidity and mortality associated with multiple valve prostheses, and the likelihood and risk of reoperation. Therefore, when AS presents mixed or combined valve disease, the heart valve team must integrate various parameters into the diagnosis and management strategy, including suitability for single or multiple transcatheter valve procedures. This review aims to summarize the most critical pathophysiological mechanisms underlying AS when associated with mitral regurgitation, mitral stenosis, aortic regurgitation, and tricuspid regurgitation. We will focus on echocardiography, clinical implications, and the most important treatment strategies. CI - Copyright (c) 2021 Mantovani, Fanti, Tafciu, Fezzi, Setti, Rossi, Ribichini and Benfari. FAU - Mantovani, Francesca AU - Mantovani F AD - Cardiology, Azienda USL- IRCCS di Reggio Emilia, Reggio Emilia, Italy. FAU - Fanti, Diego AU - Fanti D AD - University of Verona, Section of Cardiology, Verona, Italy. FAU - Tafciu, Elvin AU - Tafciu E AD - University of Verona, Section of Cardiology, Verona, Italy. FAU - Fezzi, Simone AU - Fezzi S AD - University of Verona, Section of Cardiology, Verona, Italy. FAU - Setti, Martina AU - Setti M AD - University of Verona, Section of Cardiology, Verona, Italy. FAU - Rossi, Andrea AU - Rossi A AD - University of Verona, Section of Cardiology, Verona, Italy. FAU - Ribichini, Flavio AU - Ribichini F AD - University of Verona, Section of Cardiology, Verona, Italy. FAU - Benfari, Giovanni AU - Benfari G AD - University of Verona, Section of Cardiology, Verona, Italy. LA - eng PT - Journal Article PT - Review DEP - 20211015 PL - Switzerland TA - Front Cardiovasc Med JT - Frontiers in cardiovascular medicine JID - 101653388 PMC - PMC8554031 OTO - NOTNLM OT - aortic regurgitation OT - aortic stenosis OT - combined valve disease OT - echocardiography OT - mitral regurgitation OT - mitral stenosis OT - mixed valve disease OT - tricuspid regurgitation COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/11/02 06:00 MHDA- 2021/11/02 06:01 PMCR- 2021/01/01 CRDT- 2021/11/01 09:26 PHST- 2021/07/20 00:00 [received] PHST- 2021/09/13 00:00 [accepted] PHST- 2021/11/01 09:26 [entrez] PHST- 2021/11/02 06:00 [pubmed] PHST- 2021/11/02 06:01 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - 10.3389/fcvm.2021.744497 [doi] PST - epublish SO - Front Cardiovasc Med. 2021 Oct 15;8:744497. doi: 10.3389/fcvm.2021.744497. eCollection 2021. PMID- 34718909 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20211105 IS - 2198-7793 (Print) IS - 2198-7793 (Electronic) IS - 2198-7793 (Linking) VI - 7 IP - 1 DP - 2021 Oct 30 TI - Severe liver injury with traumatic cardiac arrest successfully treated by damage control surgery and transcatheter arterial embolization in the hybrid operating room: a case report. PG - 234 LID - 10.1186/s40792-021-01317-1 [doi] LID - 234 AB - BACKGROUND: The damage control approach is known to reduce the mortality rate in severely injured patients and has now become a common practice. Transcatheter arterial embolization (TAE) has been shown to be useful with combining with damage control laparotomy in identifying and controlling active arterial hemorrhage. Hybrid operating room (OR) allows both damaged control surgery and TAE in the same location in minimal time. We report a case of a patient with three cardiac arrests who was saved by early intervention using damage control surgery (DCS) with interventional radiology (IVR) in the hybrid OR. CASE PRESENTATION: A 46-year-old woman was injured in a collision with a tree while snowboarding. She was eventually transported to hybrid operating room in our hospital with the diagnosis of significant liver laceration and hemorrhagic shock. Damage control surgery was performed with perihepatic packing (PHP) and TAE was conducted to stop active bleeding from right hepatic artery. She experienced 3 times of cardiopulmonary arrest, which was successfully resuscitated on each occasion. Although she had total of 3 times of laparotomy but tolerated well. She was discharged on day 82 of hospitalization and showed no neurological sequelae. CONCLUSION: Saving the life of a patient with severe trauma requires a multidisciplinary approach with cooperation and early information sharing among trauma team members. Sharing treatment strategy with the trauma team and early intervention using DCS with IVR in the hybrid operating room could save the patient's life. CI - (c) 2021. The Author(s). FAU - Hagiwara, Masahiro AU - Hagiwara M AUID- ORCID: 0000-0002-2589-3955 AD - Division of Hepato-Biliary-Pancreatic and Transplant Surgery, Department of Surgery, Asahikawa Medical University, 2-1, Midorigaoka-Higashi, Asahikawa, Hokkaido, Japan. mahagi@asahikawa-med.ac.jp. FAU - Iwata, Yoshihiro AU - Iwata Y AD - Division of Hepato-Biliary-Pancreatic and Transplant Surgery, Department of Surgery, Asahikawa Medical University, 2-1, Midorigaoka-Higashi, Asahikawa, Hokkaido, Japan. FAU - Takahashi, Hiroyuki AU - Takahashi H AD - Division of Hepato-Biliary-Pancreatic and Transplant Surgery, Department of Surgery, Asahikawa Medical University, 2-1, Midorigaoka-Higashi, Asahikawa, Hokkaido, Japan. FAU - Imai, Koji AU - Imai K AD - Division of Hepato-Biliary-Pancreatic and Transplant Surgery, Department of Surgery, Asahikawa Medical University, 2-1, Midorigaoka-Higashi, Asahikawa, Hokkaido, Japan. FAU - Yokoo, Hideki AU - Yokoo H AD - Division of Hepato-Biliary-Pancreatic and Transplant Surgery, Department of Surgery, Asahikawa Medical University, 2-1, Midorigaoka-Higashi, Asahikawa, Hokkaido, Japan. FAU - Ishitoya, Shunta AU - Ishitoya S AD - Department of Radiology, Asahikawa Medical University, Asahikawa, Japan. FAU - Ogata, Miki AU - Ogata M AD - Department of Radiology, Asahikawa Medical University, Asahikawa, Japan. FAU - Matsuno, Naoto AU - Matsuno N AD - Division of Hepato-Biliary-Pancreatic and Transplant Surgery, Department of Surgery, Asahikawa Medical University, 2-1, Midorigaoka-Higashi, Asahikawa, Hokkaido, Japan. FAU - Sumi, Yasuo AU - Sumi Y AD - Division of Gastrointestinal Surgery, Department of Surgery, Asahikawa Medical University, Asahikawa, Japan. FAU - Furukawa, Hiroyuki AU - Furukawa H AD - Division of Hepato-Biliary-Pancreatic and Transplant Surgery, Department of Surgery, Asahikawa Medical University, 2-1, Midorigaoka-Higashi, Asahikawa, Hokkaido, Japan. LA - eng PT - Journal Article DEP - 20211030 PL - Japan TA - Surg Case Rep JT - Surgical case reports JID - 101662125 PMC - PMC8556852 OTO - NOTNLM OT - Blunt hepatic injury OT - Damage control surgery OT - Hybrid operating room OT - Interventional radiology OT - Traumatic cardiac arrest COIS- The authors disclose no conflicts. EDAT- 2021/11/01 06:00 MHDA- 2021/11/01 06:01 PMCR- 2021/10/30 CRDT- 2021/10/31 21:22 PHST- 2021/01/19 00:00 [received] PHST- 2021/10/19 00:00 [accepted] PHST- 2021/10/31 21:22 [entrez] PHST- 2021/11/01 06:00 [pubmed] PHST- 2021/11/01 06:01 [medline] PHST- 2021/10/30 00:00 [pmc-release] AID - 10.1186/s40792-021-01317-1 [pii] AID - 1317 [pii] AID - 10.1186/s40792-021-01317-1 [doi] PST - epublish SO - Surg Case Rep. 2021 Oct 30;7(1):234. doi: 10.1186/s40792-021-01317-1. PMID- 34714208 OWN - NLM STAT- MEDLINE DCOM- 20211224 LR - 20211224 IS - 1651-1999 (Electronic) IS - 0803-7051 (Linking) VI - 30 IP - 6 DP - 2021 Dec TI - Hypertension telemonitoring and home-based physical training programs. PG - 428-438 LID - 10.1080/08037051.2021.1996221 [doi] AB - PURPOSE: Hypertensive patients with access to telemedicine can receive telemonitoring of blood pressure and cardiovascular risk factors such as sedentary lifestyle, diet, and remote supervision of treatment compliance. Faced with this challenge, electronic devices for telemonitoring of BP have gained space. They have shown to be effective in the follow-up of hypertensive patients and assist in the adherence and control of associated risk factors such as physical inactivity and obesity. MATERIALS AND METHODS: Narrative Review. RESULTS: The use of advanced smartwatches, smartphone apps, and online software for monitoring physical activity is increasingly common. Electronic equipment is briefly presented here as a support for better addressing some cardiovascular variables. Using various automated feedback services with a follow-up multidisciplinary clinical team is the ideal strategy. CONCLUSION: Mobile health can improve risk factors and health status, particularly for hypertensive patients, improving access to cardiac rehabilitation and reducing the cost. FAU - Ruberti, Olivia Moraes AU - Ruberti OM AUID- ORCID: 0000-0002-9164-6768 AD - Laboratory of Cardiovascular Investigation & Exercise, School of Physical Education, University of Campinas (UNICAMP), Campinas, Brazil. FAU - Yugar-Toledo, Juan Carlos AU - Yugar-Toledo JC AD - Department of Medicine, Rio Preto Faculty of Medicine (FAMERP), Sao Jose do Rio Preto, Brazil. FAU - Moreno, Heitor AU - Moreno H AD - Laboratory of Cardiovascular Pharmacology & Hypertension, School of Medical Sciences, University of Campinas (UNICAMP), Campinas, Brazil. FAU - Rodrigues, Bruno AU - Rodrigues B AUID- ORCID: 0000-0003-4246-4703 AD - Laboratory of Cardiovascular Investigation & Exercise, School of Physical Education, University of Campinas (UNICAMP), Campinas, Brazil. AD - Laboratory of Cardiovascular Pharmacology & Hypertension, School of Medical Sciences, University of Campinas (UNICAMP), Campinas, Brazil. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20211029 PL - England TA - Blood Press JT - Blood pressure JID - 9301454 SB - IM MH - Blood Pressure MH - Humans MH - *Hypertension/therapy MH - *Mobile Applications MH - Patient Compliance MH - *Telemedicine OTO - NOTNLM OT - Hypertension OT - cardiovascular diseases OT - home-based physical training OT - physical training OT - telemonitoring EDAT- 2021/10/30 06:00 MHDA- 2021/12/25 06:00 CRDT- 2021/10/29 12:19 PHST- 2021/10/30 06:00 [pubmed] PHST- 2021/12/25 06:00 [medline] PHST- 2021/10/29 12:19 [entrez] AID - 10.1080/08037051.2021.1996221 [doi] PST - ppublish SO - Blood Press. 2021 Dec;30(6):428-438. doi: 10.1080/08037051.2021.1996221. Epub 2021 Oct 29. PMID- 34713454 OWN - NLM STAT- MEDLINE DCOM- 20220207 LR - 20220207 IS - 1573-2665 (Electronic) IS - 0141-8955 (Linking) VI - 45 IP - 1 DP - 2022 Jan TI - Current and future treatment approaches for Barth syndrome. PG - 17-28 LID - 10.1002/jimd.12453 [doi] AB - Barth Syndrome is an X-linked disorder of mitochondrial cardiolipin metabolism caused by pathogenic variants in TAFAZZIN with pleiotropic effects including cardiomyopathy, neutropenia, growth delay, and skeletal myopathy. Management requires a multidisciplinary approach to the organ-specific manifestations including specialists from cardiology, hematology, nutrition, physical therapy, genetics, and metabolism. Currently, treatment is centered on management of specific clinical features, and is not targeted toward remediating the underlying biochemical defect. However, two clinical trials have been recently undertaken which target the mitochondrial pathology of this disease: a study to examine the effects of elamipretide, a cardiolipin targeted agent, and a study to examine the effects of bezafibrate, a peroxisome proliferator-activated receptor (PPAR) agonist. Treatments to directly target the defective TAFAZZIN pathway are under development, including enzyme and gene therapies. CI - (c) 2021 SSIEM. FAU - Thompson, Reid AU - Thompson R AD - Department of Pediatric Cardiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. FAU - Jefferies, John AU - Jefferies J AD - The Cardiovascular Institute, The University of Tennessee Health Science Center, Memphis, Tennessee, USA. FAU - Wang, Suya AU - Wang S AD - Department of Cardiology, Boston Children's Hospital, Boston, Massachusetts, USA. FAU - Pu, William T AU - Pu WT AD - Department of Cardiology, Boston Children's Hospital, Boston, Massachusetts, USA. AD - Harvard Stem Cell Institute, Cambridge, Massachusetts, USA. FAU - Takemoto, Clifford AU - Takemoto C AD - Division of Clinical Hematology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA. FAU - Hornby, Brittany AU - Hornby B AD - Department of Physical Therapy, Kennedy Krieger Institute, Baltimore, Maryland, USA. FAU - Heyman, Andrea AU - Heyman A AD - Department of Nutrition, Kennedy Krieger Institute, Baltimore, Maryland, USA. FAU - Chin, Michael T AU - Chin MT AD - Molecular Cardiology Research Institute, Tufts Medical Center, Boston, Massachusetts, USA. FAU - Vernon, Hilary J AU - Vernon HJ AUID- ORCID: 0000-0001-9940-9866 AD - Department of Genetics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. AD - Department of Neurogenetics, Kennedy Krieger Institute, Baltimore, Maryland, USA. LA - eng PT - Journal Article PT - Review DEP - 20211110 PL - United States TA - J Inherit Metab Dis JT - Journal of inherited metabolic disease JID - 7910918 RN - 0 (Cardiolipins) RN - 0 (Oligopeptides) RN - 0 (Peroxisome Proliferator-Activated Receptors) RN - 0 (arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide) RN - EC 2.3.- (Acyltransferases) RN - EC 2.3.1.- (TAFAZZIN protein, human) RN - Y9449Q51XH (Bezafibrate) SB - IM MH - Acyltransferases/genetics MH - Animals MH - Barth Syndrome/genetics/metabolism/*therapy MH - Bezafibrate/*therapeutic use MH - Cardiolipins/metabolism MH - Cardiomyopathies/metabolism/therapy MH - Clinical Trials as Topic MH - Enzyme Therapy MH - Genetic Therapy MH - Humans MH - Mice MH - Muscular Diseases/metabolism/therapy MH - Neutropenia/metabolism/therapy MH - Oligopeptides/*therapeutic use MH - Peroxisome Proliferator-Activated Receptors/agonists OTO - NOTNLM OT - Barth syndrome OT - TAFAZZIN OT - cardiolipin OT - cardiomyopathy EDAT- 2021/10/30 06:00 MHDA- 2022/02/08 06:00 CRDT- 2021/10/29 06:42 PHST- 2021/10/18 00:00 [revised] PHST- 2021/07/21 00:00 [received] PHST- 2021/10/26 00:00 [accepted] PHST- 2021/10/30 06:00 [pubmed] PHST- 2022/02/08 06:00 [medline] PHST- 2021/10/29 06:42 [entrez] AID - 10.1002/jimd.12453 [doi] PST - ppublish SO - J Inherit Metab Dis. 2022 Jan;45(1):17-28. doi: 10.1002/jimd.12453. Epub 2021 Nov 10. PMID- 34711339 OWN - NLM STAT- MEDLINE DCOM- 20211227 LR - 20221104 IS - 1558-3597 (Electronic) IS - 0735-1097 (Print) IS - 0735-1097 (Linking) VI - 78 IP - 18 DP - 2021 Nov 2 TI - Adverse Cardiovascular and Pulmonary Events Associated With Chimeric Antigen Receptor T-Cell Therapy. PG - 1800-1813 LID - S0735-1097(21)06092-7 [pii] LID - 10.1016/j.jacc.2021.08.044 [doi] AB - BACKGROUND: Pivotal trials of chimeric antigen receptor T-cell (CAR-T) have identified common toxicities but may have been underpowered to detect cardiovascular and pulmonary adverse events (CPAEs). OBJECTIVES: This study sought to investigate CPAEs associated with commercial CD19-directed CAR-T therapy. METHODS: In this retrospective, pharmacovigilance study, the authors used the Food and Drug Administration adverse event reporting system to identify CPAEs associated with axicabtagene-ciloleucel and tisagenlecleucel. The authors evaluated disproportionate reporting by the reporting odds ratio (ROR) and the lower bound of the information component 95% credibility interval (IC(025) >0 is deemed significant). Significant associations were further adjusted to age and sex (adj.ROR). RESULTS: The authors identified CAR-T reports of 2,657 patients, including 546 CPAEs (20.5%). CPAEs overlapped with cytokine release syndrome in 68.3% (373 of 546) of the reports. Compared with the full database, CAR-T was associated with overreporting of tachyarrhythmias (n = 74 [2.8%], adj.ROR = 2.78 [95% CI: 2.21-3.51]), cardiomyopathy (n = 69 [2.6%], adj.ROR = 3.51 [2.42-5.09]), pleural disorders (n = 46 [1.7%], adj.ROR = 3.91 [2.92-5.23]), and pericardial diseases (n = 11 [0.4%], adj.ROR = 2.26 [1.25-4.09], all IC(025) >0). Venous thromboembolic events (VTEs) were associated only with axicabtagene-ciloleucel therapy (n = 28 [1.6%], adj.ROR = 1.80 [1.24-2.62], IC(025) >0). Atrial fibrillation (n = 55) was the leading tachyarrhythmia, followed by ventricular arrhythmias (n = 14). Tachyarrhythmias and VTEs were reported more often following axicabtagene-ciloleucel than tisagenlecleucel in an age- and sex-adjusted model (adj.ROR = 1.82 [1.04-3.18] and adj.ROR = 2.86 [1.18-6.93], respectively). Finally, the fatality rate of CPAEs was 30.9%. CONCLUSIONS: In this largest post-marketing study to date, the authors identified an association between CAR-T and various CPAEs, including tachyarrhythmias, cardiomyopathy, pericardial and pleural disorders, and VTEs. These findings should be considered in the multidisciplinary assessment for and monitoring of CAR-T therapy recipients. CI - Copyright (c) 2021 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. FAU - Goldman, Adam AU - Goldman A AD - Leviev Heart Center, Chaim Sheba Medical Center, Ramat Gan, Israel; School of Medicine, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel. FAU - Maor, Elad AU - Maor E AD - Leviev Heart Center, Chaim Sheba Medical Center, Ramat Gan, Israel; School of Medicine, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel. FAU - Bomze, David AU - Bomze D AD - School of Medicine, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel. FAU - Liu, Jennifer E AU - Liu JE AD - Cardiology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA; Department of Medicine, Weill Cornell Medical College, New York, New York, USA. FAU - Herrmann, Joerg AU - Herrmann J AD - Department of Cardiovascular Disease, Mayo Clinic, Rochester, Minnesota, USA. FAU - Fein, Joshua AU - Fein J AD - Department of Internal Medicine, UCONN Health, Farmington, Connecticut, USA. FAU - Steingart, Richard M AU - Steingart RM AD - Cardiology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA; Department of Medicine, Weill Cornell Medical College, New York, New York, USA. FAU - Mahmood, Syed S AU - Mahmood SS AD - Cardiology Division, New York-Presbyterian Hospital, Weill Cornell Medical Center, New York, New York, USA. FAU - Schaffer, Wendy L AU - Schaffer WL AD - Cardiology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA; Department of Medicine, Weill Cornell Medical College, New York, New York, USA. FAU - Perales, Miguel-Angel AU - Perales MA AD - Department of Medicine, Weill Cornell Medical College, New York, New York, USA; Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA. FAU - Shouval, Roni AU - Shouval R AD - Department of Medicine, Weill Cornell Medical College, New York, New York, USA; Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Electronic address: shouvalr@mskcc.org. LA - eng GR - P30 CA008748/CA/NCI NIH HHS/United States GR - R01 CA233610/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PL - United States TA - J Am Coll Cardiol JT - Journal of the American College of Cardiology JID - 8301365 RN - 0 (Antineoplastic Agents, Immunological) RN - 0 (Biological Products) RN - 0 (CD19-specific chimeric antigen receptor) RN - 0 (Receptors, Antigen, T-Cell) RN - Q6C9WHR03O (tisagenlecleucel) RN - U2I8T43Y7R (axicabtagene ciloleucel) SB - IM CIN - J Am Coll Cardiol. 2021 Nov 2;78(18):1814-1816. doi: 10.1016/j.jacc.2021.09.008. PMID: 34711340 MH - Adverse Drug Reaction Reporting Systems/statistics & numerical data MH - Antineoplastic Agents, Immunological/administration & dosage/adverse effects MH - *Biological Products/administration & dosage/adverse effects MH - *Cardiotoxicity/diagnosis/etiology/prevention & control MH - *Cardiovascular Diseases/chemically induced/classification/diagnosis/prevention & control MH - Drug Monitoring/methods MH - Humans MH - *Immunotherapy, Adoptive/adverse effects/methods/statistics & numerical data MH - *Lung Diseases/chemically induced/classification/diagnosis/prevention & control MH - Needs Assessment MH - Pharmacovigilance MH - Receptors, Antigen, T-Cell/*administration & dosage MH - United States MH - United States Food and Drug Administration/statistics & numerical data PMC - PMC8562317 MID - NIHMS1745412 OTO - NOTNLM OT - cardiac arrhythmias OT - cardio-oncology OT - cardiovascular adverse events OT - chimeric antigen receptor T cell OT - pharmacovigilance OT - venous thromboembolism COIS- Funding Support and Author Disclosures This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748. This study was supported in part by NIH/NCI grant RO1-CA 233610 (Dr Herrmann). Dr Perales has received personal fees from Abbvie, Bellicum, Bristol Myers Squibb, Celgene, Cidara Theraputics, Incyte, Kite/Gilead, Medigene, Miltenyi, MolMed, Nektar Therapeutics, NexImmune, Novartis, Omeros, Merck, Servier, and Tekeda; has served on data safety and monitoring boards for Cidara Therapeutics, Medigene, and Servier; and has received clinical trial support from Incyte, Kite/Gilead, and Miltenyi. Data presented in this study do not represent the opinion of the United States Food and Drug Administration (FDA). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2021/10/30 06:00 MHDA- 2021/12/28 06:00 PMCR- 2022/11/02 CRDT- 2021/10/29 05:38 PHST- 2021/05/26 00:00 [received] PHST- 2021/08/16 00:00 [revised] PHST- 2021/08/17 00:00 [accepted] PHST- 2021/10/29 05:38 [entrez] PHST- 2021/10/30 06:00 [pubmed] PHST- 2021/12/28 06:00 [medline] PHST- 2022/11/02 00:00 [pmc-release] AID - S0735-1097(21)06092-7 [pii] AID - 10.1016/j.jacc.2021.08.044 [doi] PST - ppublish SO - J Am Coll Cardiol. 2021 Nov 2;78(18):1800-1813. doi: 10.1016/j.jacc.2021.08.044. PMID- 34710590 OWN - NLM STAT- MEDLINE DCOM- 20220331 LR - 20260404 IS - 1559-2030 (Electronic) IS - 1551-7144 (Linking) VI - 111 DP - 2021 Dec TI - Design and baseline results of a coaching intervention for implementation of trans-radial access in percutaneous coronary intervention. PG - 106606 LID - S1551-7144(21)00342-6 [pii] LID - 10.1016/j.cct.2021.106606 [doi] AB - Trans-radial artery access (TRA) for cardiac catheterization and percutaneous coronary intervention has many advantages over trans-femoral artery access (TFA), but implementation has been slow. The steep learning curve, logistical issues, and radiation exposure have been documented as barriers to implementation. Although many cardiac catheterization laboratories have overcome these barriers, we lack evidence on effective implementation strategies. Our objective is to test a team-based coaching intervention that targets the learning curve and other barriers to increase use of TRA. We use a stepped-wedge cluster-randomized trial to test a coaching intervention in Department of Veterans Affairs cardiac catheterization laboratories. The coaching intervention comprises team-based didactic instruction with live observation at a TRA-proficient lab, followed by a visit from a cardiologist and catheterization laboratory nurse coaching team. Interview and survey data are collected from participants to test and adapt an implementation science framework known as the Promoting Action on Research Implementation in Health Services (PARIHS) framework. This study is designed to test the effectiveness of the coaching intervention on TRA implementation, inform changes to the coaching intervention itself, and test and adapt the PARIHS framework in practice. While the benefits of TRA, including increased clinical efficiency, patient comfort, and reduced patient complications, are well understood, the underlying drivers of TRA adoption and sustained practice are not. Findings from this trial can inform future research to facilitate change in the cardiac catheterization laboratory. CI - Published by Elsevier Inc. FAU - Beaver, Kristine AU - Beaver K AD - Department of Veterans Affairs Puget Sound Health Care System, 1660 South Columbian Way S-152, Seattle, WA 98018, United States of America. Electronic address: Kristine.Beaver@va.gov. FAU - Naranjo, Diana AU - Naranjo D AD - Department of Veterans Affairs Puget Sound Health Care System, 1660 South Columbian Way S-152, Seattle, WA 98018, United States of America. FAU - Doll, Jacob AU - Doll J AD - Department of Veterans Affairs Puget Sound Health Care System, 1660 South Columbian Way S-152, Seattle, WA 98018, United States of America. FAU - Maynard, Charles AU - Maynard C AD - Department of Veterans Affairs Puget Sound Health Care System, 1660 South Columbian Way S-152, Seattle, WA 98018, United States of America. FAU - Taylor, Leslie AU - Taylor L AD - Department of Veterans Affairs Puget Sound Health Care System, 1660 South Columbian Way S-152, Seattle, WA 98018, United States of America. FAU - Plomondon, Mary AU - Plomondon M AD - Department of Veterans Affairs Eastern Colorado Health Care System, 1055 Clermont St, Denver, CO 80220, United States of America; Clinical Assessment Reporting and Tracking Program, Department of Veterans Affairs Office of Quality and Patient Safety, 810 Vermont Avenue NW, Washington, DC 20420, United States of America. FAU - Waldo, Stephen AU - Waldo S AD - Department of Veterans Affairs Eastern Colorado Health Care System, 1055 Clermont St, Denver, CO 80220, United States of America; Clinical Assessment Reporting and Tracking Program, Department of Veterans Affairs Office of Quality and Patient Safety, 810 Vermont Avenue NW, Washington, DC 20420, United States of America. FAU - Helfrich, Christian D AU - Helfrich CD AD - Department of Veterans Affairs Puget Sound Health Care System, 1660 South Columbian Way S-152, Seattle, WA 98018, United States of America. FAU - Rao, Sunil V AU - Rao SV AD - Department of Veterans Affairs Durham Health Care System, 508 Fulton Street Durham, NC 27705, United States of America. LA - eng GR - I01 HX002043/HX/HSRD VA/United States PT - Clinical Trial Protocol PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20211025 PL - United States TA - Contemp Clin Trials JT - Contemporary clinical trials JID - 101242342 SB - IM MH - Coronary Angiography/methods MH - Femoral Artery MH - Humans MH - *Mentoring MH - *Percutaneous Coronary Intervention/methods MH - Radial Artery MH - Treatment Outcome MH - Randomized Controlled Trials as Topic OTO - NOTNLM OT - Coaching OT - Innovation implementation OT - Stepped-wedge cluster-randomized trial OT - Trans-radial access EDAT- 2021/10/29 06:00 MHDA- 2022/04/01 06:00 CRDT- 2021/10/28 20:16 PHST- 2021/07/02 00:00 [received] PHST- 2021/10/18 00:00 [revised] PHST- 2021/10/21 00:00 [accepted] PHST- 2021/10/29 06:00 [pubmed] PHST- 2022/04/01 06:00 [medline] PHST- 2021/10/28 20:16 [entrez] AID - S1551-7144(21)00342-6 [pii] AID - 10.1016/j.cct.2021.106606 [doi] PST - ppublish SO - Contemp Clin Trials. 2021 Dec;111:106606. doi: 10.1016/j.cct.2021.106606. Epub 2021 Oct 25. PMID- 34710094 OWN - NLM STAT- MEDLINE DCOM- 20211124 LR - 20211124 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 16 IP - 10 DP - 2021 TI - The Second Heart Program-A multidisciplinary team supporting people who inject drugs with infective endocarditis: Protocol of a feasibility study. PG - e0256839 LID - 10.1371/journal.pone.0256839 [doi] LID - e0256839 AB - INTRODUCTION: Infective endocarditis (IE) is a severe and highly prevalent infection among people who inject drugs (PWID). While short-term (30-day) outcomes are similar between PWID and non-PWID, the long-term outcomes among PWID after IE are poor, with 1-year mortality rates in excess of 25%. Novel clinical interventions are needed to address the unique needs of PWID with IE, including increasing access to substance use treatment and addressing structural barriers and social determinants of health. METHODS AND ANALYSIS: PWID with IE will be connected to a multidisciplinary team that will transition with them from hospital to the community. The six components of the Second Heart Team are: (1) peer support worker with lived experience, (2) systems navigator, (3) addiction medicine physician, (4) primary care physician, (5) infectious diseases specialist, (6) cardiovascular surgeon. A convergent mixed-methods study design will be used to test the feasibility of this intervention. We will concurrently collect quantitative and qualitative data and 'mix' at the interpretation stage of the study to answer our research questions. ETHICS AND DISSEMINATION: This study has been approved by the Hamilton Integrated Research Ethics Board (Project No. 7012). Results will be presented at national and international conferences and submitted for publication in a scientific journal. CLINICAL TRAIL REGISTRARION: Trial registration number: ISRCTN14968657 https://www.isrctn.com/ISRCTN14968657. FAU - Lennox, Robin AU - Lennox R AUID- ORCID: 0000-0001-8490-1997 AD - Department of Family Medicine, McMaster University, Hamilton, Ontario, Canada. FAU - Lamarche, Larkin AU - Lamarche L AD - Department of Family Medicine, McMaster University, Hamilton, Ontario, Canada. FAU - Martin, Leslie AU - Martin L AUID- ORCID: 0000-0001-9655-1373 AD - Department of Medicine, McMaster University, Hamilton, Ontario, Canada. FAU - O'Shea, Tim AU - O'Shea T AD - Division of Infectious Diseases, Department of Medicine, McMaster University, Hamilton, Ontario, Canada. FAU - Belley-Cote, Emilie AU - Belley-Cote E AD - Division of Cardiology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada. AD - Population Health Research Institute, Hamilton, Canada, Hamilton, Ontario, Canada. FAU - Cvetkovic, Anna AU - Cvetkovic A AD - Division of Infectious Diseases, Department of Medicine, McMaster University, Hamilton, Ontario, Canada. FAU - Virag, Olivia AU - Virag O AD - Department of Family Medicine, McMaster University, Hamilton, Ontario, Canada. FAU - Whitlock, Richard AU - Whitlock R AD - Population Health Research Institute, Hamilton, Canada, Hamilton, Ontario, Canada. AD - Division of Cardiac Surgery, Department of Surgery, McMaster University, Hamilton, Ontario, Canada. LA - eng SI - ISRCTN/ISRCTN14968657 PT - Clinical Trial Protocol PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20211028 PL - United States TA - PLoS One JT - PloS one JID - 101285081 SB - IM MH - Clinical Trials as Topic MH - Disease Management MH - Endocarditis/*complications/therapy MH - Feasibility Studies MH - Humans MH - Patient Care Team MH - Patient Selection MH - Substance Abuse, Intravenous/*complications/therapy PMC - PMC8553071 COIS- The authors have declared that no competing interests exist. EDAT- 2021/10/29 06:00 MHDA- 2021/11/25 06:00 PMCR- 2021/10/28 CRDT- 2021/10/28 17:21 PHST- 2021/07/22 00:00 [received] PHST- 2021/08/12 00:00 [accepted] PHST- 2021/10/28 17:21 [entrez] PHST- 2021/10/29 06:00 [pubmed] PHST- 2021/11/25 06:00 [medline] PHST- 2021/10/28 00:00 [pmc-release] AID - PONE-D-21-20169 [pii] AID - 10.1371/journal.pone.0256839 [doi] PST - epublish SO - PLoS One. 2021 Oct 28;16(10):e0256839. doi: 10.1371/journal.pone.0256839. eCollection 2021. PMID- 34702596 OWN - NLM STAT- MEDLINE DCOM- 20220316 LR - 20220316 IS - 1532-8449 (Electronic) IS - 0882-5963 (Linking) VI - 63 DP - 2022 Mar-Apr TI - Modification of a children's hospital pediatric early warning score (EWS): An evaluation of inter-rater reliability, nurses' critical thinking and perceptions of the tool. PG - 90-95 LID - S0882-5963(21)00291-8 [pii] LID - 10.1016/j.pedn.2021.09.023 [doi] AB - Pediatric early warning scores (EWS) have been utilized to assist the identification of children at risk for clinically decompensating, experiencing a cardiac or respiratory arrest, or requiring a transfer to a higher level of care. Although their use is widespread, little consistency exists between tools and research evaluating the effectiveness of these tools is lacking. This quasi-experimental project evaluated twenty-five medical-surgical staff nurses' use and perceptions as well as the inter-rater reliability of a newly modified pediatric EWS tool at a free standing, academic Midwestern pediatric hospital. The tool was modified utilizing existing literature and an interdisciplinary team's expertise. Five fictionalized patients, presented in case studies, were developed and nurses were asked to score these patients using the newly modified tool with rationale. Inter-rater reliability was assessed utilizing Fleiss' Kappa and qualitative questionnaire data was analyzed for emerging themes. Overall, Fleiss' Kappa showed that there was moderate agreement between the nurses' judgments and scoring, with scores primarily differing due to the difficulty level of each case study. Nurses' responses to a questionnaire indicated differing levels of comfort identifying and managing children that present with mid-range total scores as opposed to those who scored in the lower or higher ranges. This project's findings highlight nurses' concerns that an objective tool may not accurately describe a subjective assessment. The results of this project indicated that use of this tool, with some modifications to address nursing concerns, may help to identify clinically decompensating pediatric patients being treated on medical-surgical units. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - Schleisman, Adrienne S AU - Schleisman AS AD - Creighton University, Children's Hospital & Medical Center, Omaha, NE 68124, United States of America. Electronic address: adrienneschleisman@gmail.com. FAU - Potthoff, Meghan AU - Potthoff M AD - Creighton University, 2500 California Plaza, Omaha, NE 68178, United States of America. Electronic address: meghanpotthoff@creighton.edu. FAU - Schjodt, Katharine AU - Schjodt K AD - Children's Hospital & Medical Center, 8200 Dodge Street, Omaha, NE 68114, United States of America. Electronic address: kschjodt@ChildrensOmaha.org. LA - eng PT - Journal Article DEP - 20211024 PL - United States TA - J Pediatr Nurs JT - Journal of pediatric nursing JID - 8607529 SB - IM MH - Child MH - *Early Warning Score MH - Hospitals, Pediatric MH - Humans MH - *Nurses MH - Reproducibility of Results MH - Thinking OTO - NOTNLM OT - Children's hospital early warning system (CHEWS) OT - Inter-rater reliability OT - Pediatric early warning score (EWS) EDAT- 2021/10/28 06:00 MHDA- 2022/03/17 06:00 CRDT- 2021/10/27 05:51 PHST- 2021/04/26 00:00 [received] PHST- 2021/08/02 00:00 [revised] PHST- 2021/09/22 00:00 [accepted] PHST- 2021/10/28 06:00 [pubmed] PHST- 2022/03/17 06:00 [medline] PHST- 2021/10/27 05:51 [entrez] AID - S0882-5963(21)00291-8 [pii] AID - 10.1016/j.pedn.2021.09.023 [doi] PST - ppublish SO - J Pediatr Nurs. 2022 Mar-Apr;63:90-95. doi: 10.1016/j.pedn.2021.09.023. Epub 2021 Oct 24. PMID- 34700325 OWN - NLM STAT- MEDLINE DCOM- 20220425 LR - 20230818 IS - 1945-1474 (Electronic) IS - 1062-2551 (Print) IS - 1062-2551 (Linking) VI - 44 IP - 2 DP - 2022 Mar-Apr 01 TI - Reducing Cardiovascular Risk for Patients With Diabetes: An Evidence-Based, Population Health Management Program. PG - 103-112 LID - 10.1097/JHQ.0000000000000332 [doi] AB - Those with diabetes are at an increased risk of cardiovascular disease (CVD). Safety net clinics serve populations that bear a significant burden of disease and disparities and are a key setting in which to focus on reducing CVD. An integrated health system provided funding and technical assistance (TA) to safety net organizations (community health centers and public hospitals) in Northern California to decrease the risk of cardiovascular events for patients with diabetes. This was a program called Preventing Heart Attacks and Strokes Everyday (PHASE), which combined an evidence-based medication protocol with population health management and team-based care strategies. The TA supported organizations by sharing best practices, providing quality improvement coaching, and facilitating peer learning. A mixed-methods evaluation found that organizations involved in PHASE improved rates of blood pressure control and cardioprotective medication prescriptions for patients with diabetes. They made progress on these measures through strategies such as leveraging team-based care, providing education on evidence-based protocols, and using data to drive improvements. The evaluation concluded that financially supporting and providing focused TA to safety net organizations can help them build capacity and leverage their strengths to improve outcomes and potentially decrease the risk of heart attacks and strokes in communities. CI - Copyright (c) 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the National Association for Healthcare Quality. FAU - Levitz, Carly AU - Levitz C FAU - Jones, Maggie AU - Jones M FAU - Nudelman, Jean AU - Nudelman J FAU - Cox, Michael AU - Cox M FAU - Camacho, Diana AU - Camacho D FAU - Wielunski, Alexis AU - Wielunski A FAU - Rothman, Michael AU - Rothman M FAU - Tomlin, Juliane AU - Tomlin J FAU - Jaffe, Marc AU - Jaffe M LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - J Healthc Qual JT - Journal for healthcare quality : official publication of the National Association for Healthcare Quality JID - 9202994 MH - *Cardiovascular Diseases/prevention & control MH - *Diabetes Mellitus/prevention & control MH - Heart Disease Risk Factors MH - Humans MH - *Myocardial Infarction/prevention & control MH - *Population Health Management MH - Risk Factors MH - *Stroke/prevention & control PMC - PMC8887839 COIS- The authors declare no conflicts of interest. EDAT- 2021/10/27 06:00 MHDA- 2022/04/26 06:00 PMCR- 2022/03/01 CRDT- 2021/10/26 20:32 PHST- 2021/10/27 06:00 [pubmed] PHST- 2022/04/26 06:00 [medline] PHST- 2021/10/26 20:32 [entrez] PHST- 2022/03/01 00:00 [pmc-release] AID - 01445442-202204000-00006 [pii] AID - JHQ-D-21-00130 [pii] AID - 10.1097/JHQ.0000000000000332 [doi] PST - ppublish SO - J Healthc Qual. 2022 Mar-Apr 01;44(2):103-112. doi: 10.1097/JHQ.0000000000000332. PMID- 34699685 OWN - NLM STAT- MEDLINE DCOM- 20230501 LR - 20230607 IS - 1478-5153 (Electronic) IS - 1362-1017 (Linking) VI - 28 IP - 3 DP - 2023 May TI - Simulation-based assessment of care for an infant with cardiogenic shock in the emergency department. PG - 353-361 LID - 10.1111/nicc.12716 [doi] AB - BACKGROUND: Congenital heart disease (CHD) is the leading cause of infant deaths associated with birth defects. Neonates with undiagnosed CHD often present to general emergency departments (GEDs) for initial resuscitation that are less prepared than paediatric centres, resulting in disparities in the quality of care. Neonates with undiagnosed CHD represent a challenge; thus, it is necessary for GEDs to be prepared for this population. AIM: To evaluate the process of resuscitative care provided to a neonate in cardiogenic shock due to CHD in the GEDs in a simulated setting and to describe the impact of teams and GED variables on the process of care. METHODS: This is a prospective simulation-based assessment of the process of care provided to a neonate with coarctation of the aorta in cardiogenic shock. Simulation sessions were conducted at participating GEDs utilizing each GED's interdisciplinary team and resources. The primary outcome was adherence to best practice, as measured by a 15-item overall composite adherence score (CAS). In addition, we stratified the overall CAS into CHD-critical items and the general resuscitation items CAS. The secondary outcome was the impact of the team's and GED's characteristics on the scores. RESULTS: This study enrolled 32 teams from 12 GEDs. Among 161 participants, 103 (63.97%) were registered nurses, 33 (20.50%) were physicians, 17 (10.56%) were respiratory therapists, and 8 (4.97%) were other medical professionals. The overall median CAS was 84, with the CHD-critical items having a median CAS of 34.5. The most underperformed tasks are checking pulses on the upper and lower extremities (44%), obtaining blood pressure in the upper and lower extremities (25%), and administering prostaglandin E1 (22%). CONCLUSIONS: Using in situ simulation in a set of GEDs, we revealed gaps in the resuscitation care of neonates with CHD in cardiogenic shock. RELEVANCE TO CLINICAL PRACTICE: These findings highlight the importance of targeted improvement programs for high-stakes illnesses in GED. CI - (c) 2021 British Association of Critical Care Nurses. FAU - Alsaedi, Hani AU - Alsaedi H AUID- ORCID: 0000-0003-0936-687X AD - Division of Pediatric Critical Care Medicine, Department of Pediatrics, Indiana University School of Medicine and Riley Hospital for Children at Indiana University Health, Indianapolis, Indiana, USA. FAU - Berrens, Zachary J AU - Berrens ZJ AD - Division of Pediatric Critical Care Medicine, Department of Pediatrics, Indiana University School of Medicine and Riley Hospital for Children at Indiana University Health, Indianapolis, Indiana, USA. FAU - Lutfi, Riad AU - Lutfi R AD - Division of Pediatric Critical Care Medicine, Department of Pediatrics, Indiana University School of Medicine and Riley Hospital for Children at Indiana University Health, Indianapolis, Indiana, USA. FAU - Weinstein, Elizabeth AU - Weinstein E AD - Department of Emergency Medicine, Indiana University School of Medicine and Riley Hospital for Children at Indiana University Health, Indianapolis, Indiana, USA. FAU - Montgomery, Erin E AU - Montgomery EE AD - LifeLine Critical Care Transport, Indiana University Health, Indianapolis, Indiana, USA. FAU - Pearson, Kellie J AU - Pearson KJ AD - LifeLine Critical Care Transport, Indiana University Health, Indianapolis, Indiana, USA. FAU - Kirby, Michelle L AU - Kirby ML AD - LifeLine Critical Care Transport, Indiana University Health, Indianapolis, Indiana, USA. FAU - Abu-Sultaneh, Samer AU - Abu-Sultaneh S AUID- ORCID: 0000-0002-2659-2070 AD - Division of Pediatric Critical Care Medicine, Department of Pediatrics, Indiana University School of Medicine and Riley Hospital for Children at Indiana University Health, Indianapolis, Indiana, USA. FAU - Abulebda, Kamal AU - Abulebda K AD - Division of Pediatric Critical Care Medicine, Department of Pediatrics, Indiana University School of Medicine and Riley Hospital for Children at Indiana University Health, Indianapolis, Indiana, USA. FAU - Thammasitboon, Satid AU - Thammasitboon S AD - Associate Professor of Pediatrics, Critical Care Medicine Section, Director, Center for Research, Innovation and Scholarship in Medical Education (CRIS), Chair, Resident Scholarship Program Executive Committee, Texas Children's Hospital Baylor College of Medicine, Houston, Texas, USA. LA - eng GR - Indiana University Health values grant/ GR - Indiana University School of Medicine Department of Pediatrics/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20211026 PL - England TA - Nurs Crit Care JT - Nursing in critical care JID - 9808649 MH - Infant, Newborn MH - Child MH - Humans MH - Infant MH - *Shock, Cardiogenic/therapy MH - *Emergency Service, Hospital MH - Resuscitation OTO - NOTNLM OT - cardiac education OT - emergency care OT - heart disease OT - nursing education OT - paediatrics EDAT- 2021/10/27 06:00 MHDA- 2023/05/01 06:42 CRDT- 2021/10/26 17:33 PHST- 2021/08/17 00:00 [revised] PHST- 2020/10/13 00:00 [received] PHST- 2021/09/02 00:00 [accepted] PHST- 2023/05/01 06:42 [medline] PHST- 2021/10/27 06:00 [pubmed] PHST- 2021/10/26 17:33 [entrez] AID - 10.1111/nicc.12716 [doi] PST - ppublish SO - Nurs Crit Care. 2023 May;28(3):353-361. doi: 10.1111/nicc.12716. Epub 2021 Oct 26. PMID- 34699395 OWN - NLM STAT- MEDLINE DCOM- 20220315 LR - 20230928 IS - 1533-4112 (Electronic) IS - 1095-0680 (Linking) VI - 38 IP - 1 DP - 2022 Mar 1 TI - The Cardiovascular Side Effects of Electroconvulsive Therapy and Their Management. PG - 2-9 LID - 10.1097/YCT.0000000000000802 [doi] AB - Electroconvulsive therapy (ECT) remains stigmatized in the broader medical community because of misunderstandings about treatment procedures, mortality rates, and cardiovascular complications. Electroconvulsive therapy causes periprocedural hemodynamic variability because of the surges in parasympathetic and sympathetic nervous systems after the administration of the electrical charge. Patients experience an increase in cardiac workload, which is potentially dangerous for patients with preexisting heart disease. Several findings suggest that cardiac complications occur most frequently in patients with underlying cardiovascular disease. We describe the cardiovascular complications that may result from ECT treatment and offer insight on how to mitigate these concerns if they occur. PubMed was queried using terms "electroconvulsive therapy" and "cardiovascular adverse effects." A table is provided with the common cardiovascular side effects of ECT and the most recent evidence-based treatment strategies to manage them. Generally, ECT is a safe procedure in which complications are minor and manageable. Most major complications caused by ECT are related to the cardiovascular system; however, with an appropriate pre-ECT evaluation and a comprehensive multidisciplinary team approach, the cardiovascular complications can be well managed and minimized. Providing proper cardiac clearance can prevent cardiac complications and provide timely care to treatment-resistant populations who are at risk for excessive morbidity and suicide. CI - Copyright (c) 2021 Wolters Kluwer Health, Inc. All rights reserved. FAU - Hermida, Adriana P AU - Hermida AP AD - From the Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA. FAU - Mohsin, Mamoona AU - Mohsin M AD - Department of Psychiatry and Behavioral Medicine, Charleston Area Medical Center/West Virginia University, Charleston, West Virginia. FAU - Marques Pinheiro, Ana P AU - Marques Pinheiro AP AD - From the Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA. FAU - McCord, Elizabeth AU - McCord E AD - From the Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA. FAU - Lisko, John C AU - Lisko JC AD - Division of Cardiology, Department of Internal Medicine, Emory University School of Medicine, Atlanta, GA. FAU - Head, Lyndsay W AU - Head LW AD - Department of Anesthesiology, Emory University School of Medicine, Atlanta, GA. LA - eng PT - Journal Article PL - United States TA - J ECT JT - The journal of ECT JID - 9808943 SB - IM MH - *Cardiovascular Diseases/etiology MH - *Cardiovascular System MH - *Electroconvulsive Therapy/adverse effects MH - Hemodynamics MH - Humans COIS- The authors have no conflicts of interest or financial disclosures to report. EDAT- 2021/10/27 06:00 MHDA- 2022/03/16 06:00 CRDT- 2021/10/26 17:23 PHST- 2021/10/27 06:00 [pubmed] PHST- 2022/03/16 06:00 [medline] PHST- 2021/10/26 17:23 [entrez] AID - 00124509-202203000-00002 [pii] AID - 10.1097/YCT.0000000000000802 [doi] PST - ppublish SO - J ECT. 2022 Mar 1;38(1):2-9. doi: 10.1097/YCT.0000000000000802. PMID- 34699079 OWN - NLM STAT- MEDLINE DCOM- 20220222 LR - 20220222 IS - 1540-8159 (Electronic) IS - 0147-8389 (Linking) VI - 45 IP - 1 DP - 2022 Jan TI - The valuable interaction among cardiac surgeon and electrophysiologist for transvenous rotational mechanical lead extraction. PG - 92-102 LID - 10.1111/pace.14396 [doi] AB - BACKGROUND: Recent studies have shown that Evolution RL bidirectional rotational mechanical sheath (Cook Medical, USA) is an effective and safe technique for transvenous lead extraction (TLE). We reported our experience with the bidirectional rotational mechanical tools using a multidisciplinary approach highlighting the value of a joint cardiac surgeon and electrophysiologist collaboration. METHODS: The study population comprised 84 patients (77% male; mean age 65 +/- 18 years) undergoing TLE. After a multidisciplinary evaluation, a combined procedure was considered. RESULTS: The main indication for TLE was infection in 54 cases (64%). Overall, 152 leads were extracted with a mean implant duration of 94 +/- 63 months (range 12-421). Complete procedural success rate, clinical success rate, and lead removal with clinical success rate were 91.6% (77/84), 97.6% (82/84), and 98.6% (150/152), respectively. Eighteen combined procedures were performed in 12 patients (14%), such as "hybrid approach" (n = 2) or TLE concomitant to: 1) transcatheter aspiration procedure for large vegetation (n = 8); 2) left ventricular assistance device implantation as bridge to cardiac transplantation (n = 1); 3) permanent pacing with epicardial leads (n = 6); 4) tricuspid valve replacement (n = 1). One major complication (1.2%) and 11 (13%) minor complications were encountered. No injury to the superior vena cava occurred and no procedure-related deaths were reported. During a mean time follow-up of 21 +/- 18 months, 17 patients (20%) died. They were more often diabetics (p = .02), and they underwent TLE more often for infection (p = .004). CONCLUSIONS: Our results support the finding that excellent outcomes can be achieved in performing TLE of chronically implanted leads by using the Evolution RL bidirectional rotational mechanical sheath and a multidisciplinary team approach involving both electrophysiologist and cardiac surgeon as first line operators. CI - (c) 2021 Wiley Periodicals LLC. FAU - Migliore, Federico AU - Migliore F AUID- ORCID: 0000-0001-8574-9421 AD - Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy. FAU - Tarzia, Vincenzo AU - Tarzia V AD - Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy. FAU - Dall'Aglio, Pietro Bernardo AU - Dall'Aglio PB AD - Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy. FAU - Falzone, Pasquale Valerio AU - Falzone PV AD - Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy. FAU - De Lazzari, Manuel AU - De Lazzari M AD - Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy. FAU - Bottio, Tomaso AU - Bottio T AD - Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy. FAU - D'Onofrio, Augusto AU - D'Onofrio A AD - Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy. FAU - Padalino, Massimo AU - Padalino M AD - Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy. FAU - Vida, Vladimiro AU - Vida V AD - Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy. FAU - Rosso, Jacopo AU - Rosso J AD - Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy. FAU - Leoni, Loira AU - Leoni L AD - Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy. FAU - Pittarello, Demetrio AU - Pittarello D AD - Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy. FAU - Bertaglia, Emanuele AU - Bertaglia E AUID- ORCID: 0000-0002-3878-2904 AD - Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy. FAU - Iliceto, Sabino AU - Iliceto S AD - Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy. FAU - Gerosa, Gino AU - Gerosa G AD - Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy. LA - eng PT - Journal Article DEP - 20211209 PL - United States TA - Pacing Clin Electrophysiol JT - Pacing and clinical electrophysiology : PACE JID - 7803944 SB - IM MH - Aged MH - Cardiac Electrophysiology MH - *Cardiologists MH - Defibrillators, Implantable MH - Device Removal/*methods MH - *Electrodes, Implanted MH - Female MH - Humans MH - *Interprofessional Relations MH - Male MH - Pacemaker, Artificial MH - Prosthesis-Related Infections/*therapy MH - *Surgeons OTO - NOTNLM OT - cardiac surgeon OT - electrophysiologist OT - mechanical lead extraction OT - multidisciplinary team OT - transvenous lead extraction EDAT- 2021/10/27 06:00 MHDA- 2022/02/23 06:00 CRDT- 2021/10/26 12:39 PHST- 2021/09/23 00:00 [revised] PHST- 2021/07/17 00:00 [received] PHST- 2021/10/24 00:00 [accepted] PHST- 2021/10/27 06:00 [pubmed] PHST- 2022/02/23 06:00 [medline] PHST- 2021/10/26 12:39 [entrez] AID - 10.1111/pace.14396 [doi] PST - ppublish SO - Pacing Clin Electrophysiol. 2022 Jan;45(1):92-102. doi: 10.1111/pace.14396. Epub 2021 Dec 9. PMID- 34698666 OWN - NLM STAT- MEDLINE DCOM- 20220429 LR - 20220429 IS - 1531-7080 (Electronic) IS - 0268-4705 (Linking) VI - 37 IP - 1 DP - 2022 Jan 1 TI - When is enough, enough? Exploring ethical and team considerations in paediatric cardiac care dilemmas. PG - 109-114 LID - 10.1097/HCO.0000000000000926 [doi] AB - PURPOSE OF REVIEW: Therapies for paediatric congenital and acquired heart disease continue to evolve and the appropriateness of pursuing life sustaining interventions at margins of standard therapy is ethically challenging. RECENT FINDINGS: With ongoing emphasis on shared decision making, recent literature explored physician and parental perspectives on communication with families and offering interventions for complex congenital heart disease and advanced heart failure. The inclusion of parental values and views in this process is now widely accepted. Identified outstanding challenges include difficulty with prognostication from the outset, adjusting long-term goals of care to changes in clinical parameters, need for consistency in communication including regular review meetings with family or surrogate decision-makers. Bioethics consultation and multidisciplinary team reviews may be helpful supports. Palliative care involvement in this population improves quality of life and alleviates parental distress but this collaboration is not optimized. SUMMARY: Decision to offer, forgo, or discontinue life-sustaining therapies for children with heart disease has nuanced and context-specific considerations, and must integrate burdens of interventions with patient and family values. Thus, decision making remains complex and demands thoughtful review of not only risks and benefits, but views and values, clearly communicated to team and family. CI - Copyright (c) 2021 Wolters Kluwer Health, Inc. All rights reserved. FAU - Lynch, Aine AU - Lynch A AD - Division of Cardiology, The Hospital for Sick Children. AD - Department of Pediatrics, University of Toronto. FAU - Kirsch, Roxanne AU - Kirsch R AD - Department of Pediatrics, University of Toronto. AD - Department of Critical Care Medicine. AD - Department of Bioethics, The Hospital for Sick Children, Toronto, Ontario, Canada. LA - eng PT - Journal Article PT - Review PL - United States TA - Curr Opin Cardiol JT - Current opinion in cardiology JID - 8608087 SB - IM MH - Child MH - Communication MH - Decision Making MH - *Heart Failure MH - Humans MH - Palliative Care MH - *Quality of Life EDAT- 2021/10/27 06:00 MHDA- 2022/04/30 06:00 CRDT- 2021/10/26 12:22 PHST- 2021/10/27 06:00 [pubmed] PHST- 2022/04/30 06:00 [medline] PHST- 2021/10/26 12:22 [entrez] AID - 00001573-202201000-00017 [pii] AID - 10.1097/HCO.0000000000000926 [doi] PST - ppublish SO - Curr Opin Cardiol. 2022 Jan 1;37(1):109-114. doi: 10.1097/HCO.0000000000000926. PMID- 34697831 OWN - NLM STAT- MEDLINE DCOM- 20211203 LR - 20211214 IS - 1540-8191 (Electronic) IS - 0886-0440 (Linking) VI - 37 IP - 1 DP - 2022 Jan TI - Lifetime management of aortic valve disease: Aligning surgical and transcatheter armamentarium to set the tone for the present and the future. PG - 205-213 LID - 10.1111/jocs.16110 [doi] AB - Transcatheter aortic valve replacement (TAVR) has already received the green light for high-, intermediate- and low-risk profiles and is an alternative for all patients regardless of age. It is clear that there has been a push towards the use of TAVR in younger and younger patients (<65 years), which has never been formally tested in randomized controlled trials but seems inevitable as TAVR technology makes steady progress. Lifetime management as a concept will set the tone in the field of the structural heart. Some subjects in this scenario arise, including the importance of optimized prosthetic hemodynamics for lifetime care; surgical procedures in the aortic root; management of structural valve degeneration with valve-in-valve procedures (TAVR-in-surgical aortic valve replacement [SAVR] and TAVR-in-TAVR) and redo SAVR; commissural alignment and cusp overlap for TAVR; the rise in the number of surgical procedures for TAVR explantation; and the renewed interest in the Ross procedure. This article reviews all these issues which will become commonplace during heart team meetings and preoperative conversations with patients in the coming years. CI - (c) 2021 Wiley Periodicals LLC. FAU - Sa, Michel Pompeu AU - Sa MP AUID- ORCID: 0000-0001-5356-2996 AD - Department of Cardiac Surgery Research, Lankenau Institute for Medical Research, Main Line Health, Wynnewood, Pennsylvania, USA. AD - Department of Cardiothoracic Surgery, Lankenau Heart Institute, Main Line Health, Wynnewood, Pennsylvania, USA. FAU - Ramlawi, Basel AU - Ramlawi B AD - Department of Cardiac Surgery Research, Lankenau Institute for Medical Research, Main Line Health, Wynnewood, Pennsylvania, USA. AD - Department of Cardiothoracic Surgery, Lankenau Heart Institute, Main Line Health, Wynnewood, Pennsylvania, USA. FAU - Sicouri, Serge AU - Sicouri S AUID- ORCID: 0000-0002-1822-768X AD - Department of Cardiothoracic Surgery, Lankenau Heart Institute, Main Line Health, Wynnewood, Pennsylvania, USA. FAU - Torregrossa, Gianluca AU - Torregrossa G AD - Department of Cardiothoracic Surgery, Lankenau Heart Institute, Main Line Health, Wynnewood, Pennsylvania, USA. FAU - Al Abri, Qasim AU - Al Abri Q AD - Department of Cardiothoracic Surgery, DeBakey Heart and Vascular Center, Houston Methodist Hospital, Houston, Texas, USA. FAU - Kempfert, Jorg AU - Kempfert J AD - Department of Cardiothoracic and Vascular Surgery, German Heart Center Berlin, Berlin, Germany. AD - German Center for Cardiovascular Research (DZHK), Partner Site Berlin, Berlin, Germany. FAU - Kofler, Markus AU - Kofler M AD - Department of Cardiothoracic and Vascular Surgery, German Heart Center Berlin, Berlin, Germany. AD - German Center for Cardiovascular Research (DZHK), Partner Site Berlin, Berlin, Germany. FAU - Falk, Volkmar AU - Falk V AD - Department of Cardiothoracic and Vascular Surgery, German Heart Center Berlin, Berlin, Germany. AD - German Center for Cardiovascular Research (DZHK), Partner Site Berlin, Berlin, Germany. AD - Berlin Institute of Health, Berlin, Germany. AD - Department of Cardiovascular Surgery, Charite-Universitatsmedizin Berlin, Berlin, Germany. AD - Department of Health Sciences and Technology, Institute of Translational Medicine, Swiss Federal Institute of Technology, Translational Cardiovascular Technologies, Zurich, Switzerland. FAU - Unbehaun, Axel AU - Unbehaun A AD - Department of Cardiothoracic and Vascular Surgery, German Heart Center Berlin, Berlin, Germany. AD - German Center for Cardiovascular Research (DZHK), Partner Site Berlin, Berlin, Germany. FAU - Van Praet, Karel M AU - Van Praet KM AD - Department of Cardiothoracic and Vascular Surgery, German Heart Center Berlin, Berlin, Germany. AD - German Center for Cardiovascular Research (DZHK), Partner Site Berlin, Berlin, Germany. LA - eng PT - Journal Article PT - Review DEP - 20211025 PL - United States TA - J Card Surg JT - Journal of cardiac surgery JID - 8908809 SB - IM MH - *Aortic Valve Disease MH - *Aortic Valve Stenosis/surgery MH - *Heart Valve Prosthesis Implantation MH - Humans MH - Risk Factors MH - Treatment Outcome OTO - NOTNLM OT - aortic valve OT - aortic valve stenosis OT - cardiac surgical procedure OT - cardiovascular surgical procedures OT - heart valve prosthesis implantation OT - transcatheter aortic valve implantation OT - transcatheter aortic valve replacement EDAT- 2021/10/27 06:00 MHDA- 2021/12/15 06:00 CRDT- 2021/10/26 06:37 PHST- 2021/10/05 00:00 [received] PHST- 2021/10/13 00:00 [accepted] PHST- 2021/10/27 06:00 [pubmed] PHST- 2021/12/15 06:00 [medline] PHST- 2021/10/26 06:37 [entrez] AID - 10.1111/jocs.16110 [doi] PST - ppublish SO - J Card Surg. 2022 Jan;37(1):205-213. doi: 10.1111/jocs.16110. Epub 2021 Oct 25. PMID- 34696849 OWN - NLM STAT- MEDLINE DCOM- 20211125 LR - 20211125 IS - 1558-5069 (Electronic) VI - 31 IP - 4 DP - 2021 Nov TI - Guiding Principles on the Importance of Thoracic Surgical Education on Establishing Integrated Thoracic Surgery Program, Interdisciplinary Thoracic Oncology Conferences, and an Interdisciplinary Approach to Management of Thoracic Malignancies. PG - 367-377 LID - S1547-4127(21)00065-7 [pii] LID - 10.1016/j.thorsurg.2021.07.007 [doi] AB - The objective of these notes is to stress the principles underlying the management of primary lung cancers and other types of malignancies in the thorax-diffuse malignant mesothelioma, invasive mediastinal tumors, chest wall sarcoma, and tracheal neoplasms-and from these considerations to outline a routine scheme for management, which can be followed easily by all staff. It is hoped that by adherence to this routine, adequate and efficient management of all cases will be obtained, both in the very important matter of preoperative preparation, as well in the postoperative management. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - Shamji, Farid M AU - Shamji FM AD - University of Ottawa, General Campus, Ottawa Hospital, 501 Smyth Road, Ottawa, Ontario K1H 8L6, Canada. Electronic address: faridmashamji@gmail.com. FAU - Sekhon, Harman Jatinder S AU - Sekhon HJS AD - Department of Pathology and Laboratory Medicine, The Ottawa Hospital, CCW, Room 4240, Box 117, 501 Smyth Road, Ottawa, Ontario K1H8L6, Canada. FAU - MacRae, Robert Malcolm AU - MacRae RM AD - Division of Radiation Oncology & Radiation Medicine Program, The Ottawa Hospital, The University of Ottawa, Box 903, 501 Smyth Road, Ottawa, Ontario K1H 8L6, Canada. FAU - Maziak, Donna E AU - Maziak DE AD - University of Ottawa, Surgical Oncology Division of Thoracic Surgery, Ottawa Hospital - General Division, 501 Smyth Road 6NW-6364, Ottawa, Ontario K1H 8L6, Canada. LA - eng PT - Journal Article PT - Review PL - United States TA - Thorac Surg Clin JT - Thoracic surgery clinics JID - 101198195 SB - IM MH - Humans MH - *Lung Neoplasms/surgery MH - *Sarcoma MH - *Thoracic Neoplasms/surgery MH - *Thoracic Surgery MH - *Thoracic Surgical Procedures MH - *Thoracic Wall OTO - NOTNLM OT - Fast tracking OT - Integrated thoracic surgery program OT - Requirements for thoracic surgical education OT - Surgical intuition EDAT- 2021/10/27 06:00 MHDA- 2021/11/26 06:00 CRDT- 2021/10/26 05:37 PHST- 2021/10/26 05:37 [entrez] PHST- 2021/10/27 06:00 [pubmed] PHST- 2021/11/26 06:00 [medline] AID - S1547-4127(21)00065-7 [pii] AID - 10.1016/j.thorsurg.2021.07.007 [doi] PST - ppublish SO - Thorac Surg Clin. 2021 Nov;31(4):367-377. doi: 10.1016/j.thorsurg.2021.07.007. PMID- 34688669 OWN - NLM STAT- MEDLINE DCOM- 20220719 LR - 20220729 IS - 1873-1740 (Electronic) IS - 0033-0620 (Linking) VI - 72 DP - 2022 May-Jun TI - Transcatheter valve-in-valve implantation in degenerated surgical aortic and mitral bioprosthesis: Current state and future perspectives. PG - 54-65 LID - S0033-0620(21)00108-0 [pii] LID - 10.1016/j.pcad.2021.10.001 [doi] AB - The use of bioprosthetic valves for treating patients with severe valve disease has increased over the last 2 decades, and, as a consequence, a growing number of patients with failing surgical bioprosthesis is expected in the near future. In this setting, valve-in-valve (ViV) transcatheter aortic/mitral valve replacement (TAVR and TMVR) has emerged as an alternative to redo surgery. Despite the increasing experience in ViV procedures, the development of these techniques faces several specific challenges, mainly related to the unique anatomical and physiological characteristics of ViV-TAVR/TMVR. Subsequently, various approaches have been proposed to overcome ViV-related complications and pitfalls. A growing body of evidence is currently available concerning early- and long-term clinical outcomes of patients undergoing ViV-TAVR/TMVR. These data should be comprehensively evaluated by the Heart Team in the decision-making process involving patients with failing surgical bioprostheses. In this review, we aimed to delineate the technical challenges and risks associated with ViV-TAVR and ViV-TMVR, provide an updated overview of the main clinical results, and summarize the future perspectives of this evolving field. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - Alperi, Alberto AU - Alperi A AD - Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada. FAU - Garcia, Santiago AU - Garcia S AD - Minneapolis Heart Institute, Minneapolis, MN, United States of America. FAU - Rodes-Cabau, Josep AU - Rodes-Cabau J AD - Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada; Hospital Clinic Barcelona, Barcelona, Spain. Electronic address: josep.rodes@criucpq.ulaval.ca. LA - eng PT - Journal Article PT - Review DEP - 20211021 PL - United States TA - Prog Cardiovasc Dis JT - Progress in cardiovascular diseases JID - 0376442 SB - IM MH - Aortic Valve/diagnostic imaging/surgery MH - *Aortic Valve Stenosis/surgery MH - *Bioprosthesis/adverse effects MH - *Heart Valve Prosthesis MH - *Heart Valve Prosthesis Implantation/adverse effects/methods MH - Humans MH - Prosthesis Design MH - Prosthesis Failure MH - Treatment Outcome OTO - NOTNLM OT - Degenerated surgical bioprosthesis OT - Transcatheter aortic valve implantation OT - Transcatheter mitral valve implantation OT - Valve in valve EDAT- 2021/10/25 06:00 MHDA- 2022/07/20 06:00 CRDT- 2021/10/24 20:33 PHST- 2021/10/16 00:00 [received] PHST- 2021/10/16 00:00 [accepted] PHST- 2021/10/25 06:00 [pubmed] PHST- 2022/07/20 06:00 [medline] PHST- 2021/10/24 20:33 [entrez] AID - S0033-0620(21)00108-0 [pii] AID - 10.1016/j.pcad.2021.10.001 [doi] PST - ppublish SO - Prog Cardiovasc Dis. 2022 May-Jun;72:54-65. doi: 10.1016/j.pcad.2021.10.001. Epub 2021 Oct 21. PMID- 34686568 OWN - NLM STAT- MEDLINE DCOM- 20220614 LR - 20220722 IS - 1468-201X (Electronic) IS - 1355-6037 (Linking) VI - 108 IP - 13 DP - 2022 Jun 10 TI - Percutaneous management of paravalvular leaks. PG - 1005-1011 LID - 10.1136/heartjnl-2021-319159 [doi] AB - Paravalvular leak (PVL) is a challenging complication of valve replacement surgery that can cause heart failure and haemolysis. Surgical repair is the traditional treatment for severe, symptomatic PVL, but many patients with PVL fall into high-risk categories for redo surgery. Percutaneous techniques for closure of PVL have been increasingly refined over the last decade with availability of approved purpose-specific devices for closure. Percutaneous closure requires a heart team approach, with attention paid to appropriate preprocedural and periprocedural imaging to ensure a successful closure with minimal residual leak or complication. There are limited studies addressing the selection of a percutaneous approach to PVL. No randomised trials comparing surgical and percutaneous repair have been conducted. Large national registries from the UK and Ireland and from Spain have demonstrated that high rates of technical success can be achieved, with mortality comparable with surgical repair. Six retrospective studies comparing surgical and percutaneous approaches have been published. These broadly show comparable technical success between the interventions, with reduced short-term mortality among patients treated percutaneously. Long-term outcomes were similar between both treatment options. Percutaneous repair is an attractive treatment option in many patients due to its reduced invasiveness and quicker recovery period. However, more prospective studies are needed to validate its place in the armamentarium of the heart team. CI - (c) Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Giblett, Joel P AU - Giblett JP AD - Liverpool Centre for Cardiovascular Science, Liverpool Heart and Chest Hospital NHS Foundation Trust, Liverpool, UK. FAU - Williams, Lynne K AU - Williams LK AD - Department of Cardiology, Royal Papworth Hospital NHS Foundation Trust, Cambridge, UK. FAU - Moorjani, Narain AU - Moorjani N AD - Department of Cardiothoracic Surgery, Royal Papworth Hospital NHS Foundation Trust, Cambridge, UK. FAU - Calvert, Patrick A AU - Calvert PA AUID- ORCID: 0000-0001-8020-5433 AD - Department of Cardiology, Royal Papworth Hospital NHS Foundation Trust, Cambridge, UK paddy@doctors.org.uk. AD - Division of Cardiovascular Medicine, University of Cambridge, Cambridge, UK. LA - eng PT - Journal Article PT - Review DEP - 20220610 PL - England TA - Heart JT - Heart (British Cardiac Society) JID - 9602087 SB - IM MH - Cardiac Catheterization/adverse effects MH - *Heart Failure/etiology MH - *Heart Valve Prosthesis/adverse effects MH - *Heart Valve Prosthesis Implantation/methods MH - Humans MH - Prosthesis Failure MH - Retrospective Studies MH - Treatment Outcome OTO - NOTNLM OT - endovascular procedures OT - heart valve diseases OT - heart valve prosthesis OT - heart valve prosthesis implantation COIS- Competing interests: None declared. EDAT- 2021/10/24 06:00 MHDA- 2022/06/15 06:00 CRDT- 2021/10/23 05:39 PHST- 2021/06/29 00:00 [received] PHST- 2021/09/09 00:00 [accepted] PHST- 2021/10/24 06:00 [pubmed] PHST- 2022/06/15 06:00 [medline] PHST- 2021/10/23 05:39 [entrez] AID - heartjnl-2021-319159 [pii] AID - 10.1136/heartjnl-2021-319159 [doi] PST - epublish SO - Heart. 2022 Jun 10;108(13):1005-1011. doi: 10.1136/heartjnl-2021-319159. PMID- 34686413 OWN - NLM STAT- MEDLINE DCOM- 20220117 LR - 20220117 IS - 1444-2892 (Electronic) IS - 1443-9506 (Linking) VI - 31 IP - 2 DP - 2022 Feb TI - Cardiac Surgery in Patients With Blood Disorders. PG - 167-176 LID - S1443-9506(21)01254-3 [pii] LID - 10.1016/j.hlc.2021.09.013 [doi] AB - Blood disorders that can contribute to abnormal bleeding can have a detrimental effect during cardiac surgery. Patients who are known to have such pathologies should be investigated thoroughly and cautious measures would need to be taken when cardiac surgery is needed in this cohort. The majority of current literature for cardiac surgery in patients with von Willebrand Disease and haemophilia are case reports. Nevertheless, evidence shows that optimising factor levels pre, intra and postoperatively offers outcomes similar to that of patients without these disorders. Preoperative screening followed by appropriate iron therapy reduces mortality for patients with anaemia. In this group, haemoglobin levels can be improved postoperatively through iron supplementation. The management strategy of cardiac surgery for people with blood disorders requires a multidisciplinary approach that is highly individualised for each patient. It is essential to adequately adjust preoperative, perioperative and postoperative care to the patient's blood disorder in order to achieve outcomes similar to that of patients without blood disorders. CI - Copyright (c) 2021 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights reserved. FAU - Nair, Devika AU - Nair D AD - College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK. FAU - Sreejith, Nayanika AU - Sreejith N AD - Medical Sciences Division, University of Oxford, Oxford, UK. FAU - Bhambra, Amman AU - Bhambra A AD - College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK. FAU - Bruce, Jonathan AU - Bruce J AD - College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK. FAU - Mellor, Sophie AU - Mellor S AD - Sandwell & West Birmingham NHS Trust, Sandwell General Hospital, West Bromwich, UK. FAU - Brown, Louise J AU - Brown LJ AD - North Cumbria Integrated Care NHS Foundation Trust, Cumberland Infirmary, Carlisle, UK. FAU - Harky, Amer AU - Harky A AD - Department of Cardiothoracic Surgery, Liverpool Heart and Chest, Liverpool, UK; Department of Cardiac Surgery, Alder Hey Children Hospital, Liverpool, UK. Electronic address: amer.harky@lhch.nhs.uk. LA - eng PT - Journal Article PT - Review DEP - 20211020 PL - Australia TA - Heart Lung Circ JT - Heart, lung & circulation JID - 100963739 RN - E1UOL152H7 (Iron) SB - IM MH - *Anemia/diagnosis/epidemiology/etiology MH - *Cardiac Surgical Procedures/adverse effects MH - Humans MH - Iron OTO - NOTNLM OT - Anaemia OT - Cardiac surgery OT - Haemophilia A OT - Haemophilia B OT - von Willebrand Disease EDAT- 2021/10/24 06:00 MHDA- 2022/01/18 06:00 CRDT- 2021/10/23 05:34 PHST- 2021/06/27 00:00 [received] PHST- 2021/08/18 00:00 [revised] PHST- 2021/09/07 00:00 [accepted] PHST- 2021/10/24 06:00 [pubmed] PHST- 2022/01/18 06:00 [medline] PHST- 2021/10/23 05:34 [entrez] AID - S1443-9506(21)01254-3 [pii] AID - 10.1016/j.hlc.2021.09.013 [doi] PST - ppublish SO - Heart Lung Circ. 2022 Feb;31(2):167-176. doi: 10.1016/j.hlc.2021.09.013. Epub 2021 Oct 20. PMID- 34682856 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20211026 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 10 IP - 20 DP - 2021 Oct 15 TI - Impact of an In-Hospital Endocarditis Team and a State-Wide Endocarditis Network on Perioperative Outcomes. LID - 10.3390/jcm10204734 [doi] LID - 4734 AB - BACKGROUND: Infective endocarditis (IE) requires multidisciplinary management. We established an endocarditis team within our hospital in 2011 and a state-wide endocarditis network with referring hospitals in 2015. We aimed to investigate their impact on perioperative outcomes. METHODS: We retrospectively analyzed data from patients operated on for IE in our center between 01/2007 and 03/2018. To investigate the impact of the endocarditis network on referral latency and pre-operative complications we divided patients into two eras: before (n = 409) and after (n = 221) 01/2015. To investigate the impact of the endocarditis team on post-operative outcomes we conducted multivariate binary logistic regression analyses for the whole population. Kaplan-Meier estimates of 5-year survival were reported. RESULTS: In the second era, after establishing the endocarditis network, the median time from symptoms to referral was halved (7 days (interquartile range: 2-19) vs. 15 days (interquartile range: 6-35)), and pre-operative endocarditis-related complications were reduced, i.e., stroke (14% vs. 27%, p < 0.001), heart failure (45% vs. 69%, p < 0.001), cardiac abscesses (24% vs. 34%, p = 0.018), and acute requirement of hemodialysis (8% vs. 14%, p = 0.026). In both eras, a lack of recommendations from the endocarditis team was an independent predictor for in-hospital mortality (adjusted odds ratio: 2.12, 95% CI: 1.27-3.53, p = 0.004) and post-operative stroke (adjusted odds ratio: 2.23, 95% CI: 1.12-4.39, p = 0.02), and was associated with worse 5-year survival (59% vs. 40%, log-rank < 0.001). CONCLUSION: The establishment of an endocarditis network led to the earlier referral of patients with fewer pre-operative endocarditis-related complications. Adhering to endocarditis team recommendations was an independent predictor for lower post-operative stroke and in-hospital mortality, and was associated with better 5-year survival. FAU - Diab, Mahmoud AU - Diab M AD - Department of Cardiothoracic Surgery, Jena University Hospital-Friedrich Schiller University of Jena, 07743 Jena, Germany. AD - Center for Sepsis Care and Control (CSCC), Jena University Hospital-Friedrich Schiller University of Jena, 07743 Jena, Germany. FAU - Franz, Marcus AU - Franz M AUID- ORCID: 0000-0001-6543-4684 AD - Department of Internal Medicine I, Jena University Hospital-Friedrich Schiller University of Jena, 07743 Jena, Germany. FAU - Hagel, Stefan AU - Hagel S AD - Center for Sepsis Care and Control (CSCC), Jena University Hospital-Friedrich Schiller University of Jena, 07743 Jena, Germany. AD - Institute for Infectious Diseases and Infection Control, Jena University Hospital-Friedrich Schiller University of Jena, 07743 Jena, Germany. FAU - Guenther, Albrecht AU - Guenther A AD - Department of Neurology, Jena University Hospital-Friedrich Schiller University of Jena, 07743 Jena, Germany. FAU - Struve, Antonio AU - Struve A AUID- ORCID: 0000-0002-5915-2557 AD - Department of Cardiothoracic Surgery, Jena University Hospital-Friedrich Schiller University of Jena, 07743 Jena, Germany. FAU - Musleh, Rita AU - Musleh R AD - Department of Neurology, Jena University Hospital-Friedrich Schiller University of Jena, 07743 Jena, Germany. FAU - Penzel, Anika AU - Penzel A AD - Institute of Medical Microbiology, Jena University Hospital-Friedrich Schiller University of Jena, 07743 Jena, Germany. FAU - Sponholz, Christoph AU - Sponholz C AD - Department of Anaesthesiology and Critical Care Medicine, Jena University Hospital-Friedrich Schiller University of Jena, 07743 Jena, Germany. FAU - Lehmann, Thomas AU - Lehmann T AD - Center of Clinical Studies, Jena University Hospital-Friedrich Schiller University of Jena, 07743 Jena, Germany. FAU - Kuehn, Henning AU - Kuehn H AD - Thuringia Clinics Georgius Agricola Saalfeld, Clinic for Internal Medicine III, 07318 Saalfeld, Germany. FAU - Ibrahim, Karim AU - Ibrahim K AD - Chemnitz Clinic, Internal Medicine I, 09113 Chemnitz, Germany. FAU - Jahnecke, Marcus AU - Jahnecke M AD - St. Georg Clinic Eisenach, Clinic for Internal Medicine I, 99817 Eisenach, Germany. FAU - Sigusch, Holger AU - Sigusch H AD - Heinrich-Braun-Clinic Zwickau, Clinic for Internal Medicine I, 08060 Zwickau, Germany. FAU - Ebelt, Henning AU - Ebelt H AD - Catholic Hospital St. Johann Nepomuk Erfurt, Clinic for Internal Medicine II, 99097 Erfurt, Germany. FAU - Faerber, Gloria AU - Faerber G AD - Department of Cardiothoracic Surgery, Jena University Hospital-Friedrich Schiller University of Jena, 07743 Jena, Germany. FAU - Witte, Otto W AU - Witte OW AUID- ORCID: 0000-0003-2101-4105 AD - Department of Neurology, Jena University Hospital-Friedrich Schiller University of Jena, 07743 Jena, Germany. FAU - Loeffler, Bettina AU - Loeffler B AD - Center for Sepsis Care and Control (CSCC), Jena University Hospital-Friedrich Schiller University of Jena, 07743 Jena, Germany. AD - Institute of Medical Microbiology, Jena University Hospital-Friedrich Schiller University of Jena, 07743 Jena, Germany. FAU - Bauer, Michael AU - Bauer M AD - Center for Sepsis Care and Control (CSCC), Jena University Hospital-Friedrich Schiller University of Jena, 07743 Jena, Germany. AD - Department of Anaesthesiology and Critical Care Medicine, Jena University Hospital-Friedrich Schiller University of Jena, 07743 Jena, Germany. FAU - Pletz, Mathias W AU - Pletz MW AUID- ORCID: 0000-0001-8157-2753 AD - Center for Sepsis Care and Control (CSCC), Jena University Hospital-Friedrich Schiller University of Jena, 07743 Jena, Germany. AD - Institute for Infectious Diseases and Infection Control, Jena University Hospital-Friedrich Schiller University of Jena, 07743 Jena, Germany. FAU - Schulze, P Christian AU - Schulze PC AD - Department of Internal Medicine I, Jena University Hospital-Friedrich Schiller University of Jena, 07743 Jena, Germany. FAU - Doenst, Torsten AU - Doenst T AD - Department of Cardiothoracic Surgery, Jena University Hospital-Friedrich Schiller University of Jena, 07743 Jena, Germany. LA - eng PT - Journal Article DEP - 20211015 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC8541635 OTO - NOTNLM OT - endocarditis network OT - endocarditis team OT - infective endocarditis COIS- The authors declare no conflict of interest. EDAT- 2021/10/24 06:00 MHDA- 2021/10/24 06:01 PMCR- 2021/10/15 CRDT- 2021/10/23 01:13 PHST- 2021/09/20 00:00 [received] PHST- 2021/10/06 00:00 [revised] PHST- 2021/10/06 00:00 [accepted] PHST- 2021/10/23 01:13 [entrez] PHST- 2021/10/24 06:00 [pubmed] PHST- 2021/10/24 06:01 [medline] PHST- 2021/10/15 00:00 [pmc-release] AID - jcm10204734 [pii] AID - jcm-10-04734 [pii] AID - 10.3390/jcm10204734 [doi] PST - epublish SO - J Clin Med. 2021 Oct 15;10(20):4734. doi: 10.3390/jcm10204734. PMID- 34673502 OWN - NLM STAT- MEDLINE DCOM- 20220322 LR - 20230319 IS - 1969-6213 (Electronic) IS - 1774-024X (Print) IS - 1774-024X (Linking) VI - 17 IP - 16 DP - 2022 Mar 18 TI - Clinical outcomes of transcatheter aortic valve implantation in patients younger than 70 years rejected for surgery: the AMTRAC registry. PG - 1289-1297 LID - EIJ-D-21-00613 [pii] LID - 10.4244/EIJ-D-21-00613 [doi] AB - BACKGROUND: The mean age of transcatheter aortic valve implantation (TAVI) patients is steadily decreasing. AIMS: The aim of the study was to describe the characteristics, the indications for and the outcomes of TAVI in patients <70 years old. METHODS: All patients undergoing TAVI (n=8,626) from the 18 participating centres between January 2007 and June 2020 were stratified by age (70). For patients <70, the indications for TAVI were extracted from Heart Team discussions and the baseline characteristics and mortality were compared between the two groups. RESULTS: Overall, 640 (7.4%) patients were <70 (9.1% during 2018-2020, p<0.001); the mean age was 65.0+/-2.3 years. The younger patients were more often male, with bicuspid valves or needing valve-in-valve procedures. They had a higher prevalence of lung disease and diabetes. In 80.7% of cases, the Heart Team estimated an increased surgical risk and TAVI was selected, reflected by an STS score >4% in 20.4%. Five-year mortality was similar (29.4 vs 29.8%, HR 0.95, p=0.432) in the <70 and >70 groups. In the <70 group, mortality was higher for those referred for TAVI due to an increased surgical risk compared to those referred for other reasons (31.6 vs 24.5%, HR 1.23, p=0.021). Mortality was similar regardless of the STS stratum in patients judged by the Heart Team to be at increased surgical risk (32.6 vs 30.4%, HR 0.98, p=0.715). CONCLUSIONS: Use of TAVI in patients <70 is becoming more frequent. The main reason for choosing TAVI is due to an increased surgical risk not adequately represented by the STS score. The outcomes for these patients are similar to those for older TAVI patients. Dedicated trials of TAVI/SAVR in younger patients are needed to guide decisions concerning expansion of TAVI indications. ((ClinicalTrials.gov: NCT04031274). FAU - Witberg, Guy AU - Witberg G AD - Division of Cardiology, Rabin Medical Centre, Petah-Tikva, Israel. AD - The Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. FAU - Landes, Uri AU - Landes U AD - Division of Cardiology, Rabin Medical Centre, Petah-Tikva, Israel. AD - The Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. FAU - Codner, Pablo AU - Codner P AD - Division of Cardiology, Rabin Medical Centre, Petah-Tikva, Israel. AD - The Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. FAU - Barbanti, Marco AU - Barbanti M AD - Division of Cardiology, University of Catania, Catania, Italy. FAU - Valvo, Roberto AU - Valvo R AD - Division of Cardiology, University of Catania, Catania, Italy. FAU - De Backer, Ole AU - De Backer O AD - The Heart Center, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. FAU - Ooms, Joris F AU - Ooms JF AD - Department of Cardiology, Thoraxcenter, Erasmus University Medical Center, Rotterdam, the Netherlands. FAU - McInerney, Angela AU - McInerney A AD - Cardiovascular Institute, Hospital Clinico San Carlos, IdISSC, Madrid, Spain. FAU - Masiero, Giulia AU - Masiero G AD - Department of Cardiac, Thoracic and Vascular Sciences, University of Padua Medical School, Padua, Italy. FAU - Werner, Paul AU - Werner P AD - Division of Cardiac Surgery, Medical University of Vienna, Vienna, Austria. FAU - Armario, Xavier AU - Armario X AD - Department of Cardiology, University Hospital Galway, National University of Ireland, Galway, Ireland. FAU - Fiorina, Claudia AU - Fiorina C AD - Cardiovascular Department, Spedali Civili, Brescia, Italy. FAU - Arzamendi, Dabit AU - Arzamendi D AD - Hospital de Sant Creu i Sant Pau Barcelona, Barcelona, Spain. FAU - Santos-Martinez, Sandra AU - Santos-Martinez S AD - CIBERCV, Hospital Clinico Universitario de Valladolid, Valladolid, Spain. FAU - Baz, Jose A AU - Baz JA AD - Servicio de Cardiologia, Hospital Alvaro Cunqueiro, Vigo, Pontevedra, Spain. FAU - Steblovnik, Klemen AU - Steblovnik K AD - Department of Cardiology, University Medical Centre, Ljubljana, Slovenia. FAU - Mauri, Victor AU - Mauri V AD - Department of Cardiology, Heart Centre, Faculty of Medicine, University of Cologne, Cologne, Germany. FAU - Adam, Matti AU - Adam M AD - Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. FAU - Merdler, Ilan AU - Merdler I AD - Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. FAU - Hein, Manuel AU - Hein M AD - Department of Cardiology and Angiology II, University Heart Center Freiburg-Bad Krozingen, Bad Krozingen, Germany. FAU - Ruile, Philipp AU - Ruile P AD - Department of Cardiology and Angiology II, University Heart Center Freiburg-Bad Krozingen, Bad Krozingen, Germany. FAU - Russo, Marco AU - Russo M AD - San Camillo Forlanini Hospital, Rome, Italy. FAU - Musumeci, Francesco AU - Musumeci F AD - San Camillo Forlanini Hospital, Rome, Italy. FAU - Sedaghat, Alexander AU - Sedaghat A AD - Herzzentrum Bonn Universitatsklinikum Bonn, Bonn, Germany. FAU - Sugiura, Atsushi AU - Sugiura A AD - Herzzentrum Bonn Universitatsklinikum Bonn, Bonn, Germany. FAU - Grasso, Carmelo AU - Grasso C AD - Division of Cardiology, University of Catania, Catania, Italy. FAU - Branca, Luca AU - Branca L AD - Cardiovascular Department, Spedali Civili, Brescia, Italy. FAU - Estevez-Loureiro, Rodrigo AU - Estevez-Loureiro R AD - Servicio de Cardiologia, Hospital Alvaro Cunqueiro, Vigo, Pontevedra, Spain. FAU - Amat-Santos, Ignacio J AU - Amat-Santos IJ AD - CIBERCV, Hospital Clinico Universitario de Valladolid, Valladolid, Spain. FAU - Mylotte, Darren AU - Mylotte D AD - Department of Cardiology, University Hospital Galway, National University of Ireland, Galway, Ireland. FAU - Andreas, Martin AU - Andreas M AD - Division of Cardiac Surgery, Medical University of Vienna, Vienna, Austria. FAU - Bunc, Matjaz AU - Bunc M AD - Department of Cardiology, University Medical Centre, Ljubljana, Slovenia. FAU - Tarantini, Giuseppe AU - Tarantini G AD - Department of Cardiac, Thoracic and Vascular Sciences, University of Padua Medical School, Padua, Italy. FAU - Nombela-Franco, Luis AU - Nombela-Franco L AD - Cardiovascular Institute, Hospital Clinico San Carlos, IdISSC, Madrid, Spain. FAU - Sondergaard, Lars AU - Sondergaard L AD - The Heart Center, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. FAU - Van Mieghem, Nicolas M AU - Van Mieghem NM AD - Department of Cardiology, Thoraxcenter, Erasmus University Medical Center, Rotterdam, the Netherlands. FAU - Finkelstein, Ariel AU - Finkelstein A AD - The Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. AD - Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. FAU - Kornowski, Ran AU - Kornowski R AD - Division of Cardiology, Rabin Medical Centre, Petah-Tikva, Israel. AD - The Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. LA - eng SI - ClinicalTrials.gov/NCT04031274 PT - Clinical Trial PT - Journal Article PL - France TA - EuroIntervention JT - EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology JID - 101251040 SB - IM MH - Aged MH - Aortic Valve/surgery MH - *Aortic Valve Stenosis/surgery MH - *Heart Valve Prosthesis Implantation/methods MH - Humans MH - Male MH - Middle Aged MH - Registries MH - Risk Factors MH - *Transcatheter Aortic Valve Replacement/adverse effects MH - Treatment Outcome PMC - PMC9743236 COIS- N.M. Van Miegham received research grant support from Abbott, Boston Scientific, Edwards Lifescience, Medtronic, PulseCath BV and Daiichi Sankyo, advisory fees from Abbott, Boston Scientific, Ancora, Medtronic, PulseCath BV and Daiichi Sankyo. M. Barbanti received consultant fees from Edwards Lifesciences. C. Grasso is a proctor for Abbott Vascular. O. De Backer received research grants and consultant fees from Abbott and Boston Scientific. M. Andreas is a proctor/consultant for Abbott, Medtronic and Edwards Lifesciences, received institutional grant support from Edwards, Abbott, Medtronic and LSI. R. Estevez-Loureiro is a consultant for Abbott Vascular and Boston Scientific. L. Nombela-Franco received consultant fees from Edwards Lifesciences and is a proctor for Abbott. L. Sondergaard received consultant fees and institutional research grants from Abbott, Boston Scientific, Edwards Lifesciences and Medtronic. I. J. Amat-Santos is a proctor for Boston Scientific. M. Bunc is a proctor for Edwards, Medtronic, Abbott, and Meril and is on an advisory board for Medtronic. M. Adam received consultant fees from Medtronic, Edwards Lifescience and Boston Scientific. The other authors have no conflicts of interests to declare. EDAT- 2021/10/22 06:00 MHDA- 2022/03/23 06:00 PMCR- 2023/03/18 CRDT- 2021/10/21 21:07 PHST- 2021/10/22 06:00 [pubmed] PHST- 2022/03/23 06:00 [medline] PHST- 2021/10/21 21:07 [entrez] PHST- 2023/03/18 00:00 [pmc-release] AID - EIJ-D-21-00613 [pii] AID - 10.4244/EIJ-D-21-00613 [doi] PST - ppublish SO - EuroIntervention. 2022 Mar 18;17(16):1289-1297. doi: 10.4244/EIJ-D-21-00613. PMID- 34670594 OWN - NLM STAT- MEDLINE DCOM- 20211022 LR - 20211026 IS - 1749-8090 (Electronic) IS - 1749-8090 (Linking) VI - 16 IP - 1 DP - 2021 Oct 20 TI - Antimicrobial stewardship measures in cardiac surgery and its impact on surgical site infections. PG - 309 LID - 10.1186/s13019-021-01693-7 [doi] LID - 309 AB - OBJECTIVE: The goal of this study was to monitor the compliance and impact on a protocol change of surgical antimicrobial prophylaxis in cardiac surgery favouring cefazolin instead cefuroxime, initiated by the hospital's antimicrobial stewardship team. METHODS: This quality improvement study was performed in a tertiary care hospital in collaboration with the department of cardiothoracic surgery and the hospitals antimicrobial stewardship team following a revision of the standard for surgical antimicrobial prophylaxis including 1029 patients who underwent cardiac surgery. 582 patients receiving cefuroxime and 447 patients receiving cefazolin respectively were compared without altering any other preventative perioperative measures including its postoperative duration of less than 24 h. Adherence and surgical site infections were compiled and analysed. RESULTS: A complete adherence was achieved. Overall surgical site infections occurred in 37 (3.6%) of the cases, 20 (3.4%) in cefuroxime patients and 17 (3.8%) in cefazolin patients (p value = 0.754). No statistically significant differences could be found in any of the primary endpoints, but there was a trend towards less deep sternal wound infections in the cefazolin group. CONCLUSIONS: The study supports the role of antimicrobial stewardship in cardiac surgery and mirrors the success of a multidisciplinary team aiming to minimize adverse events by optimizing antibiotic use. CI - (c) 2021. The Author(s). FAU - Surat, Guzin AU - Surat G AD - Unit for Infection Control and Antimicrobial Stewardship, University Hospital of Wurzburg, Wurzburg, Germany. surat_g@ukw.de. FAU - Bernsen, Dominik AU - Bernsen D AD - Julius-Maximilians-University Wurzburg, Wurzburg, Germany. FAU - Schimmer, Christoph AU - Schimmer C AD - Department of Cardiothoracic and Thoracic Vascular Surgery, University Hospital of Wurzburg, Wurzburg, Germany. LA - eng PT - Journal Article DEP - 20211020 PL - England TA - J Cardiothorac Surg JT - Journal of cardiothoracic surgery JID - 101265113 RN - IHS69L0Y4T (Cefazolin) SB - IM MH - Antibiotic Prophylaxis MH - *Antimicrobial Stewardship MH - *Cardiac Surgical Procedures/adverse effects MH - Cefazolin MH - Humans MH - Surgical Wound Infection/epidemiology/prevention & control PMC - PMC8527641 OTO - NOTNLM OT - Antimicrobial stewardship OT - Cardiac surgery OT - Surgical antimicrobial prophylaxis OT - Surgical site infections COIS- The authors declare that they have no competing interests. EDAT- 2021/10/22 06:00 MHDA- 2021/10/27 06:00 PMCR- 2021/10/20 CRDT- 2021/10/21 05:34 PHST- 2021/01/07 00:00 [received] PHST- 2021/10/11 00:00 [accepted] PHST- 2021/10/21 05:34 [entrez] PHST- 2021/10/22 06:00 [pubmed] PHST- 2021/10/27 06:00 [medline] PHST- 2021/10/20 00:00 [pmc-release] AID - 10.1186/s13019-021-01693-7 [pii] AID - 1693 [pii] AID - 10.1186/s13019-021-01693-7 [doi] PST - epublish SO - J Cardiothorac Surg. 2021 Oct 20;16(1):309. doi: 10.1186/s13019-021-01693-7. PMID- 39720489 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250104 IS - 1758-3896 (Electronic) IS - 1758-3896 (Print) IS - 1758-3896 (Linking) VI - 15 DP - 2021 TI - Cardiogenic Shock: Protocols, Teams, Centers, and Networks. PG - e18 LID - 10.15420/usc.2021.10 [doi] LID - e18 AB - The mortality of cardiogenic shock (CS) remains unacceptably high. Delays in the recognition of CS and access to disease-modifying or hemodynamically stabilizing interventions likely contribute to poor outcomes. In parallel to successful initiatives in other disease states, such as acute ST-elevation MI and major trauma, institutions are increasingly advocating the use of a multidisciplinary 'shock team' approach to CS management. A volume-outcome relationship exists in CS, as with many other acute cardiovascular conditions, and the emergence of 'shock hubs' as experienced facilities with an interest in improving CS outcomes through a hub-and-spoke 'shock network' approach provides another opportunity to deliver improved CS care as widely and equitably as possible. This narrative review outlines improvements from a networked approach to care, discusses a team-based and protocolized approach to CS management, reviews the available evidence and discusses the potential benefits, challenges, and opportunities of such systems of care. CI - Copyright (c) The Author(s), 2021. Published by Radcliffe Group Ltd. FAU - Warren, Alex F AU - Warren AF AD - South-East Scotland School of Anaesthesia Edinburgh, UK. AD - Anaesthesia, Critical Care and Pain, University of Edinburgh Edinburgh, UK. FAU - Rosner, Carolyn AU - Rosner C AD - Inova Heart and Vascular Institute Falls Church, VA. FAU - Gattani, Raghav AU - Gattani R AD - Inova Heart and Vascular Institute Falls Church, VA. FAU - Truesdell, Alex G AU - Truesdell AG AD - Inova Heart and Vascular Institute Falls Church, VA. AD - Virginia Heart Falls Church, VA. FAU - Proudfoot, Alastair G AU - Proudfoot AG AD - Department of Perioperative Medicine, Barts Heart Centre London, UK. AD - Clinic for Anaesthesiology and Intensive Care, Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt Universitat zu Berlin Berlin, Germany. AD - Department of Anaesthesiology and Intensive Care, German Heart Centre Berlin Berlin, Germany. AD - Queen Mary University of London London, UK. LA - eng PT - Journal Article PT - Review DEP - 20211020 PL - England TA - US Cardiol JT - US cardiology JID - 101574791 PMC - PMC11664751 OTO - NOTNLM OT - Cardiogenic shock OT - acute MI OT - percutaneous coronary intervention OT - shock networks OT - shock teams COIS- Disclosure: AGT is a consultant for Abiomed and serves on the speakers bureau for Abiomed. AGP declares an unrestricted educational grant from Abbott Vascular. AGT is a Guest Editor for US Cardiology Review; this did not influence peer review. All other authors have no conflicts of interest to declare. EDAT- 2021/10/20 00:00 MHDA- 2021/10/20 00:01 PMCR- 2021/10/20 CRDT- 2024/12/25 04:25 PHST- 2021/03/22 00:00 [received] PHST- 2021/06/14 00:00 [accepted] PHST- 2021/10/20 00:01 [medline] PHST- 2021/10/20 00:00 [pubmed] PHST- 2024/12/25 04:25 [entrez] PHST- 2021/10/20 00:00 [pmc-release] AID - 10.15420/usc.2021.10 [doi] PST - epublish SO - US Cardiol. 2021 Oct 20;15:e18. doi: 10.15420/usc.2021.10. eCollection 2021. PMID- 34661634 OWN - NLM STAT- MEDLINE DCOM- 20220414 LR - 20221014 IS - 1941-7225 (Electronic) IS - 0895-7061 (Print) IS - 0895-7061 (Linking) VI - 35 IP - 3 DP - 2022 Mar 8 TI - Cost-Effectiveness of Recommendations From the Surgeon General's Call-to-Action to Control Hypertension. PG - 225-231 LID - 10.1093/ajh/hpab162 [doi] AB - In response to high prevalence of hypertension and suboptimal rates of blood pressure (BP) control in the United States, the Surgeon General released a Call-to-Action to Control Hypertension (Call-to-Action) in the fall of 2020 to address the negative consequences of uncontrolled BP. In addition to morbidity and mortality associated with hypertension, hypertension has an annual cost to the US healthcare system of $71 billion. The Call-to-Action makes recommendations for improving BP control, and the purpose of this review was to summarize the literature on the cost-effectiveness of these strategies. We identified a number of studies that demonstrate the cost saving or cost-effectiveness of recommendations in the Call-to-Action including strategies to promote access to and availability of physical activity opportunities and healthy food options within communities, advance the use of standardized treatment approaches and guideline-recommended care, to promote the use of healthcare teams to manage hypertension, and to empower and equip patients to use self-measured BP monitoring and medication adherence strategies. While the current review identified numerous cost-effective methods to achieve the Surgeon General's recommendations for improving BP control, future work should determine the cost-effectiveness of the 2017 American College of Cardiology and American Heart Association Hypertension guidelines, interventions to lower therapeutic inertia, and optimal team-based care strategies, among other areas of research. Economic evaluation studies should also be prioritized to generate more comprehensive data on how to provide efficient and high value care to improve BP control. CI - (c) American Journal of Hypertension, Ltd 2021. All rights reserved. For Permissions, please email: journals.permissions@oup.com. FAU - Tajeu, Gabriel S AU - Tajeu GS AUID- ORCID: 0000-0002-9982-5250 AD - Department of Health Services Administration and Policy, Temple University, Philadelphia, Pennsylvania, USA. FAU - Tsipas, Stavros AU - Tsipas S AD - American Medical Association, Chicago, Illinois, USA. FAU - Rakotz, Michael AU - Rakotz M AD - American Medical Association, Chicago, Illinois, USA. FAU - Wozniak, Gregory AU - Wozniak G AD - American Medical Association, Chicago, Illinois, USA. LA - eng GR - K01 HL151974/HL/NHLBI NIH HHS/United States GR - R01 DK108628/DK/NIDDK NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Review PL - United States TA - Am J Hypertens JT - American journal of hypertension JID - 8803676 SB - IM MH - American Heart Association MH - Blood Pressure MH - Blood Pressure Determination MH - Cost-Benefit Analysis MH - Humans MH - *Hypertension/diagnosis/drug therapy/epidemiology MH - United States/epidemiology PMC - PMC8903883 OTO - NOTNLM OT - Call-to-Action OT - Surgeon General OT - blood pressure OT - blood pressure control OT - cost-effectiveness OT - hypertension EDAT- 2021/10/19 06:00 MHDA- 2022/04/15 06:00 PMCR- 2022/10/13 CRDT- 2021/10/18 12:29 PHST- 2021/09/02 00:00 [received] PHST- 2021/10/08 00:00 [revised] PHST- 2021/10/19 06:00 [pubmed] PHST- 2022/04/15 06:00 [medline] PHST- 2021/10/18 12:29 [entrez] PHST- 2022/10/13 00:00 [pmc-release] AID - 6400065 [pii] AID - hpab162 [pii] AID - 10.1093/ajh/hpab162 [doi] PST - ppublish SO - Am J Hypertens. 2022 Mar 8;35(3):225-231. doi: 10.1093/ajh/hpab162. PMID- 34656770 OWN - NLM STAT- MEDLINE DCOM- 20220324 LR - 20220324 IS - 2665-9867 (Electronic) IS - 1701-2163 (Linking) VI - 44 IP - 2 DP - 2022 Feb TI - Obstetric Emergencies Requiring Rapid Response Team Activation: A Retrospective Cohort Study in a High-Risk Tertiary Care Centre. PG - 167-174.e5 LID - S1701-2163(21)00754-4 [pii] LID - 10.1016/j.jogc.2021.09.016 [doi] AB - OBJECTIVE: The purpose of this study was to better understand obstetric codes requiring rapid response team activation by examining their incidence, indications, team response, and patient outcomes. METHODS: This was a retrospective study in peripartum women who required activation of the following codes during hospitalization between January 2014 and May 2018: "Code 77 (C77)" (obstetric emergency), "Code Blue (CB)" (cardiopulmonary compromise) or "Code Omega (CO)" (massive transfusion). Hospital database and health records were searched to identify and review cases. Data on code characteristics, resuscitative measures, and maternal and neonatal outcomes were collected. RESULTS: A total of 147 codes were identified during the study period (C77, 110; CO, 25; CB 12), with an overall incidence of 1 per 203 deliveries (C77, 1:271 deliveries, CO, 1:1194 deliveries; CB, 1:2488 deliveries). Common indications for C77 were cord prolapse (33%) and fetal bradycardia (32%), and for CO and CB, postpartum hemorrhage (84%) and cardiac arrest (42%), respectively. Most codes (67%) occurred after hours. The median decision-to-delivery interval was 8 (interquartile range 5-15) minutes after C77. Emergency cesarean delivery was performed for 57% of obstetric emergencies, and general anesthesia was administered in 63% of cesarean deliveries. Maternal and neonatal mortality rates were 0.68% and 7%, respectively. Major maternal morbidity was seen in 33% of cases. Debrief was documented for 4% of codes. CONCLUSION: Rapid response team activation was required more commonly in C77 than in CO or CB. Their response time and decision-to-delivery intervals were rapid. Mortality was low; however, one-third of parturients had major morbidities. We suggest closer patient monitoring, immediate availability of resources, and appropriate documentation and debriefing. CI - Copyright (c) 2021 The Society of Obstetricians and Gynaecologists of Canada/La Societe des obstetriciens et gynecologues du Canada. Published by Elsevier Inc. All rights reserved. FAU - Taras, Jillian AU - Taras J AD - Department of Anesthesiology and Pain Medicine, University of Toronto, Toronto, ON. FAU - Raghavan, Gita AU - Raghavan G AD - Department of Anesthesiology and Pain Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON. FAU - Downey, Kristi AU - Downey K AD - Department of Anesthesiology and Pain Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON. FAU - Balki, Mrinalini AU - Balki M AD - Department of Anesthesiology and Pain Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON; Department of Obstetrics & Gynaecology, Mount Sinai Hospital, University of Toronto, Toronto, ON; Department of Physiology, Mount Sinai Hospital, University of Toronto, Toronto, ON; Lunenfeld-Tanenbaum Research Institute, Toronto, ON. Electronic address: mrinalini.balki@uhn.ca. LA - eng PT - Journal Article DEP - 20211014 PL - Netherlands TA - J Obstet Gynaecol Can JT - Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC JID - 101126664 SB - IM MH - Cesarean Section MH - Delivery, Obstetric MH - Emergencies MH - Female MH - *Hospital Rapid Response Team MH - Humans MH - Infant, Newborn MH - Pregnancy MH - Retrospective Studies MH - Tertiary Care Centers OTO - NOTNLM OT - blood transfusion OT - cardiopulmonary resuscitation OT - emergency OT - hospital rapid response team EDAT- 2021/10/18 06:00 MHDA- 2022/03/25 06:00 CRDT- 2021/10/17 20:40 PHST- 2021/03/03 00:00 [received] PHST- 2021/09/14 00:00 [revised] PHST- 2021/09/15 00:00 [accepted] PHST- 2021/10/18 06:00 [pubmed] PHST- 2022/03/25 06:00 [medline] PHST- 2021/10/17 20:40 [entrez] AID - S1701-2163(21)00754-4 [pii] AID - 10.1016/j.jogc.2021.09.016 [doi] PST - ppublish SO - J Obstet Gynaecol Can. 2022 Feb;44(2):167-174.e5. doi: 10.1016/j.jogc.2021.09.016. Epub 2021 Oct 14. PMID- 34649806 OWN - NLM STAT- MEDLINE DCOM- 20220510 LR - 20220519 IS - 1532-8422 (Electronic) IS - 1053-0770 (Linking) VI - 36 IP - 6 DP - 2022 Jun TI - How We Would Treat Our Own Pulmonary Hypertension if We Needed to Undergo Cardiac Surgery. PG - 1540-1548 LID - S1053-0770(21)00843-0 [pii] LID - 10.1053/j.jvca.2021.09.030 [doi] AB - Pulmonary hypertension (PH) is a disease that has many etiologies and is particularly prevalent in patients presenting for cardiac surgery, with which it is linked to poor outcomes. This manuscript is intended to provide a comprehensive review of the impact of PH on the perioperative management of patients who are undergoing cardiac surgery. The diagnosis of PH often involves a combination of noninvasive and invasive testing, whereas preoperative optimization frequently necessitates the use of specific medications that affect anesthetic management of these patients. The authors postulate that a thoughtful, multidisciplinary approach is required to deliver excellent perioperative care. Furthermore, they use an index case to illustrate the implications of managing a patient with pulmonary hypertension who presents for cardiac surgery with cardiopulmonary bypass. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - Diaz-Rodriguez, Natalia AU - Diaz-Rodriguez N AD - Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University, Baltimore, MD. FAU - Nyhan, Sinead M AU - Nyhan SM AD - Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University, Baltimore, MD. FAU - Kolb, Todd M AU - Kolb TM AD - Division of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, MD. FAU - Steppan, Jochen AU - Steppan J AD - Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University, Baltimore, MD. Electronic address: J.Steppan@jhmi.edu. LA - eng PT - Journal Article PT - Review DEP - 20210924 PL - United States TA - J Cardiothorac Vasc Anesth JT - Journal of cardiothoracic and vascular anesthesia JID - 9110208 RN - 0 (Anesthetics) SB - IM CIN - J Cardiothorac Vasc Anesth. 2022 Jun;36(6):1549-1551. doi: 10.1053/j.jvca.2022.01.018. PMID: 35181235 MH - *Anesthetics MH - *Cardiac Surgical Procedures/adverse effects MH - Humans MH - *Hypertension, Pulmonary/diagnosis/surgery MH - Perioperative Care OTO - NOTNLM OT - anesthesia OT - cardiac surgery OT - cardiopulmonary bypass OT - perioperative management OT - pulmonary arterial hypertension OT - pulmonary hypertension EDAT- 2021/10/16 06:00 MHDA- 2022/05/11 06:00 CRDT- 2021/10/15 05:38 PHST- 2021/06/18 00:00 [received] PHST- 2021/09/13 00:00 [revised] PHST- 2021/09/19 00:00 [accepted] PHST- 2021/10/16 06:00 [pubmed] PHST- 2022/05/11 06:00 [medline] PHST- 2021/10/15 05:38 [entrez] AID - S1053-0770(21)00843-0 [pii] AID - 10.1053/j.jvca.2021.09.030 [doi] PST - ppublish SO - J Cardiothorac Vasc Anesth. 2022 Jun;36(6):1540-1548. doi: 10.1053/j.jvca.2021.09.030. Epub 2021 Sep 24. PMID- 34647430 OWN - NLM STAT- MEDLINE DCOM- 20220321 LR - 20220321 IS - 2055-5822 (Electronic) IS - 2055-5822 (Linking) VI - 8 IP - 6 DP - 2021 Dec TI - Judgement of the multidisciplinary team is an important predictor of mortality after cardiac resynchronization therapy. PG - 5275-5281 LID - 10.1002/ehf2.13611 [doi] AB - AIMS: Cardiac resynchronization therapy (CRT) in appropriately selected patients with heart failure improves symptoms and survival. It is necessary to correctly identify patients who will benefit most from this therapy. We aimed to assess the predictive power of the multidisciplinary team's clinical judgement in the short-term death after CRT implantation. METHODS AND RESULTS: Patients with heart failure and referred for the first CRT implant were prospectively included. Prior to implantation, all patients underwent a systematic assessment with a team composed of social work, nurse, psychologist, nutritionist, and clinical cardiologist. Based on this assessment, patients could be contraindicated to CRT or referred to the procedure as favourable or unfavourable. All patients should complete 12 months of follow-up; 172 patients were referred for CRT, 21 (12.2%) were contraindicated after the multidisciplinary team evaluation, 71 (47%) referred to CRT as non-favourable implants, and 80 (53%) as favourable implants. All-cause mortality occurred in only 2 (2.5%) patients in the favourable group and in 30 (42.3%) in the non-favourable group, P < 0.001 (log rank). Among the 20 variables used as possible predictors of worse prognosis by the multidisciplinary team, four were independently associated with mortality in the follow-up after the multivariate analysis: 1 year MAGGIC score between 40% and 49%, relative risk (RR) 5.0, 95% confidence interval (CI) 1.3-18.6, P = 0.016; poor pharmacological adherence, RR 4.9, 95% CI 1.6-15.6, P = 0.007; glomerular filtration rate <35 mL/min/1.73 m(2) , RR 3.0, 95% CI 1.1-8.5, P = 0.041; and right ventricular dysfunction, RR 2.6, 95% CI 1.2-5.7, P = 0.018. CONCLUSIONS: The clinical judgement before the CRT implantation performed by a multidisciplinary team through the analysis of clinical and psychosocial variables is a strong predictor of short-term mortality. CI - (c) 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. FAU - Passos, Luiz Carlos Santana AU - Passos LCS AUID- ORCID: 0000-0001-7608-1482 AD - Hospital Ana Nery, R. Saldanha Marinho, s/n-Caixa D'agua, Salvador, Bahia, CEP 40301-155, Brazil. FAU - Viana, Taina Teixeira AU - Viana TT AUID- ORCID: 0000-0003-1194-8246 AD - Hospital Ana Nery, R. Saldanha Marinho, s/n-Caixa D'agua, Salvador, Bahia, CEP 40301-155, Brazil. FAU - Carvalho, William AU - Carvalho W AD - Hospital Ana Nery, R. Saldanha Marinho, s/n-Caixa D'agua, Salvador, Bahia, CEP 40301-155, Brazil. FAU - Grimaldi, Aline AU - Grimaldi A AD - Hospital Ana Nery, R. Saldanha Marinho, s/n-Caixa D'agua, Salvador, Bahia, CEP 40301-155, Brazil. FAU - Roriz, Pollianna AU - Roriz P AD - Hospital Ana Nery, R. Saldanha Marinho, s/n-Caixa D'agua, Salvador, Bahia, CEP 40301-155, Brazil. FAU - Figueiredo, Clara AU - Figueiredo C AUID- ORCID: 0000-0002-7722-9087 AD - Hospital Ana Nery, R. Saldanha Marinho, s/n-Caixa D'agua, Salvador, Bahia, CEP 40301-155, Brazil. FAU - Nascimento, Thais AU - Nascimento T AD - Hospital Ana Nery, R. Saldanha Marinho, s/n-Caixa D'agua, Salvador, Bahia, CEP 40301-155, Brazil. FAU - Vieira de Melo, Rodrigo Morel AU - Vieira de Melo RM AD - Hospital Ana Nery, R. Saldanha Marinho, s/n-Caixa D'agua, Salvador, Bahia, CEP 40301-155, Brazil. LA - eng PT - Journal Article DEP - 20211014 PL - England TA - ESC Heart Fail JT - ESC heart failure JID - 101669191 SB - IM MH - *Cardiac Resynchronization Therapy/methods MH - Glomerular Filtration Rate MH - *Heart Failure MH - Humans MH - Patient Care Team MH - Prognosis PMC - PMC8712906 OTO - NOTNLM OT - Cardiac resynchronization therapy OT - Device team OT - Heart failure OT - Multidisciplinary care COIS- None declared. EDAT- 2021/10/15 06:00 MHDA- 2022/03/22 06:00 PMCR- 2021/10/14 CRDT- 2021/10/14 06:59 PHST- 2021/08/23 00:00 [revised] PHST- 2021/04/28 00:00 [received] PHST- 2021/08/30 00:00 [accepted] PHST- 2021/10/15 06:00 [pubmed] PHST- 2022/03/22 06:00 [medline] PHST- 2021/10/14 06:59 [entrez] PHST- 2021/10/14 00:00 [pmc-release] AID - EHF213611 [pii] AID - 10.1002/ehf2.13611 [doi] PST - ppublish SO - ESC Heart Fail. 2021 Dec;8(6):5275-5281. doi: 10.1002/ehf2.13611. Epub 2021 Oct 14. PMID- 34647059 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220427 IS - 2666-2507 (Electronic) IS - 2666-2507 (Linking) VI - 9 DP - 2021 Oct TI - Early outcomes of transatrial mitral valve replacement in severe mitral annular calcification. PG - 49-56 LID - 10.1016/j.xjtc.2021.06.015 [doi] AB - OBJECTIVE: Mitral valve replacement (MVR) in the setting of severe mitral annular calcification is a technically challenging operation with increased morbidity and mortality. Transseptal/apical transcatheter MVR (TMVR) in mitral annular calcification has emerged as an option for these cases, although may not be feasible due to anatomical reasons. Transatrial TMVR is a potential treatment option for this subgroup of patients. METHODS: Patients who underwent transatrial TMVR between June 2018 and November 2020 at a single institution were included. Patients were selected by a structural heart team based on their surgical risk, pattern of mitral annular calcification, risk of valve migration, left ventricular outflow obstruction, and paravalvular leak. RESULTS: A total of 11 patients underwent transatrial TMVR. Mean patient age was 74.2 years and mean Society of Thoracic Surgeons predicted risk of mortality score was 9.1%. All patients had the presence of both mitral stenosis and regurgitation-dominant etiology-was mitral stenosis in 81.2%, and mitral regurgitation in 18.8%. Among patients, 54.5% had a concomitant cardiac procedure. There was no in-hospital or 30-day mortality. Technical success defined by the Mitral Valve Academic Research Consortium was achieved in 90.9% of patients. Postoperative paravalvular leak was mild or less in all patients. CONCLUSIONS: In this series, transatrial TMVR was shown to be a safe and effective treatment option for patients who are high risk for surgical MVR and should be in surgeons' armamentarium in the treatment of this high-risk patient population. Dissemination of safe technique will be critical in the successful conduct of this surgery. CI - (c) 2021 The Author(s). FAU - Kawano, Yuji AU - Kawano Y AD - Division of Cardiac Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass. AD - Division of Cardiac Surgery, Emory University School of Medicine, Atlanta, Ga. FAU - Newell, Paige AU - Newell P AD - Division of Cardiac Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass. FAU - Harloff, Morgan AU - Harloff M AD - Division of Cardiac Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass. FAU - Hirji, Sameer AU - Hirji S AD - Division of Cardiac Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass. FAU - Percy, Edward AU - Percy E AD - Division of Cardiac Surgery, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Shah, Pinak AU - Shah P AD - Division of Cardiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass. FAU - Kaneko, Tsuyoshi AU - Kaneko T AD - Division of Cardiac Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass. LA - eng PT - Journal Article DEP - 20210617 PL - United States TA - JTCVS Tech JT - JTCVS techniques JID - 101768546 PMC - PMC8501192 OTO - NOTNLM OT - CT, computed tomography OT - EOA, effective orifice area OT - LVOT, left ventricular outflow tract OT - MAC, mitral annular calcification OT - MVR, mitral valve replacement OT - PVL, paravalvular leak OT - TAVR, transcatheter aortic valve replacement OT - THV, transcatheter heart valve OT - TMVR, transcatheter mitral valve replacement OT - mitral annular calcification OT - mitral valve replacement OT - transatrial OT - transcatheter EDAT- 2021/10/15 06:00 MHDA- 2021/10/15 06:01 PMCR- 2021/06/17 CRDT- 2021/10/14 06:43 PHST- 2021/01/18 00:00 [received] PHST- 2021/06/07 00:00 [accepted] PHST- 2021/10/14 06:43 [entrez] PHST- 2021/10/15 06:00 [pubmed] PHST- 2021/10/15 06:01 [medline] PHST- 2021/06/17 00:00 [pmc-release] AID - S2666-2507(21)00411-9 [pii] AID - 10.1016/j.xjtc.2021.06.015 [doi] PST - epublish SO - JTCVS Tech. 2021 Jun 17;9:49-56. doi: 10.1016/j.xjtc.2021.06.015. eCollection 2021 Oct. PMID- 34643260 OWN - NLM STAT- MEDLINE DCOM- 20220307 LR - 20220307 IS - 1897-4279 (Electronic) IS - 0022-9032 (Linking) VI - 79 IP - 12 DP - 2021 TI - Pulmonary embolism response team: A multidisciplinary approach to pulmonary embolism treatment. Polish PERT Initiative Report. PG - 1311-1319 LID - 10.33963/KP.a2021.0130 [doi] AB - BACKGROUND: A pulmonary embolism response team (PERT) is a multidisciplinary team established to improve clinical care for patients with pulmonary embolism (PE). However, data regarding detailed institutional experience and clinical outcomes from such teams are sparse. AIMS: We aim to assess the frequency of activations, patients' characteristics, PE severity, applied treatments, and outcomes of PE patients treated by Polish PERTs. METHODS: The survey registry was conducted between June 2018 and July 2020. All consecutive PERT activations of four institutionalized PERTs in Poland were analyzed. Patients' characteristics, therapies applied, and in-hospital outcomes were evaluated. RESULTS: There were 680 unique PERT activations. Most activations originated from Emergency Departments (44.9%), and the remaining originated from internal medicine/cardiology units (31.1%), surgery/orthopedics (9.1 %), oncology (6.3%), intensive care units (6.0%), and others (2.5%). The origin of activation varied significantly among institutions (P <0.01). Most PERT cases were patients with intermediate-high risk PE (42.9%), whereas high-risk PE occurred in 10% of patients. Anticoagulation alone was delivered to 80.3% of patients, and 23.3% of patients received at least one advanced therapy: catheter-directed therapies (11.3%), systemic thrombolysis (5.3%), surgical embolectomy (2.4%), vena cava filter placement (3.7%), and extracorporeal membrane oxygenation (0.6%). In-hospital mortality in the whole study group was 5.1%, with significant differences between institutions (P = 0.01). CONCLUSIONS: The frequency of PE severity, type of delivered catheter-directed treatment, and in-hospital mortality vary between institutions without significant discrepancies in PERT activations. This variation between expert centers highlights the local differences in PERTs' organizational and operational forms. FAU - Araszkiewicz, Aleksander AU - Araszkiewicz A AD - 1st Department of Cardiology, Poznan University of Medical Sciences, Poznan, Poland. FAU - Kurzyna, Marcin AU - Kurzyna M AD - Department of Pulmonary Circulation, Thromboembolic Diseases and Cardiology European Health Center in Otwock, Medical Center for Postgraduate Education, Otwock, Poland. FAU - Kopec, Grzegorz AU - Kopec G AD - Department of Cardiac and Vascular Diseases, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland. AD - John Paul II Hospital, Krakow, Poland. FAU - Slawek-Szmyt, Sylwia AU - Slawek-Szmyt S AD - 1st Department of Cardiology, Poznan University of Medical Sciences, Poznan, Poland. sylwia.slawek@skpp.edu.pl. FAU - Wrona, Katarzyna AU - Wrona K AD - Department of Pulmonary Circulation, Thromboembolic Diseases and Cardiology European Health Center in Otwock, Medical Center for Postgraduate Education, Otwock, Poland. FAU - Stepniewski, Jakub AU - Stepniewski J AD - Department of Cardiac and Vascular Diseases, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland. AD - John Paul II Hospital, Krakow, Poland. FAU - Jankiewicz, Stanislaw AU - Jankiewicz S AD - 1st Department of Cardiology, Poznan University of Medical Sciences, Poznan, Poland. FAU - Pietrasik, Arkadiusz AU - Pietrasik A AD - Department and Faculty of Cardiology, Medical University of Warsaw, Warszawa, Poland. FAU - Machowski, Michal AU - Machowski M AD - Department of Internal Medicine and Cardiology, Medical University of Warsaw, Warszawa, Poland. FAU - Darocha, Szymon AU - Darocha S AD - Department of Pulmonary Circulation, Thromboembolic Diseases and Cardiology European Health Center in Otwock, Medical Center for Postgraduate Education, Otwock, Poland. FAU - Mularek-Kubzdela, Tatiana AU - Mularek-Kubzdela T AD - 1st Department of Cardiology, Poznan University of Medical Sciences, Poznan, Poland. FAU - Torbicki, Adam AU - Torbicki A AD - Department of Pulmonary Circulation, Thromboembolic Diseases and Cardiology European Health Center in Otwock, Medical Center for Postgraduate Education, Otwock, Poland. FAU - Pruszczyk, Piotr AU - Pruszczyk P AD - Department of Internal Medicine and Cardiology, Medical University of Warsaw, Warszawa, Poland. FAU - Roik, Marek AU - Roik M AD - Department of Internal Medicine and Cardiology, Medical University of Warsaw, Warszawa, Poland. LA - eng PT - Journal Article DEP - 20211013 PL - Poland TA - Kardiol Pol JT - Kardiologia polska JID - 0376352 SB - IM MH - Embolectomy MH - Hospital Mortality MH - Humans MH - *Patient Care Team MH - Poland MH - *Pulmonary Embolism/therapy MH - Thrombolytic Therapy OTO - NOTNLM OT - anticoagulation OT - catheter-directed therapy OT - pulmonary embolism OT - pulmonary embolism response team EDAT- 2021/10/14 06:00 MHDA- 2022/03/08 06:00 CRDT- 2021/10/13 08:46 PHST- 2021/10/08 00:00 [received] PHST- 2021/10/08 00:00 [accepted] PHST- 2021/10/14 06:00 [pubmed] PHST- 2022/03/08 06:00 [medline] PHST- 2021/10/13 08:46 [entrez] AID - VM/OJS/J/86311 [pii] AID - 10.33963/KP.a2021.0130 [doi] PST - ppublish SO - Kardiol Pol. 2021;79(12):1311-1319. doi: 10.33963/KP.a2021.0130. Epub 2021 Oct 13. PMID- 34638275 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20211016 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 13 IP - 19 DP - 2021 Sep 24 TI - Pertuzumab and Trastuzumab Combination with Concomitant Locoregional Radiotherapy for the Treatment of Breast Cancers with HER2 Receptor Overexpression. LID - 10.3390/cancers13194790 [doi] LID - 4790 AB - BACKGROUND: The combination of pertuzumab and trastuzumab dual HER2 blockade with concomitant curative dose locoregional breast radiotherapy in patients with metastatic breast cancer is an important part of treatment strategy. METHODS: This was a retrospective study conducted at the Institut Curie on all patients treated concomitantly with pertuzumab/trastuzumab and locoregional breast radiotherapy. Toxicity was evaluated according to the NCICTCAEv4.0. Overall survival, progression-free survival and locoregional recurrence-free survival were evaluated in metastatic patients who were initially well controlled by chemotherapy, for whom local treatment was decided by the multidisciplinary team. RESULTS: Fifty-five patients treated between October 2013 and December 2019 were included, with a median follow-up of 4.1 years. The median age was 53 years (range: 28-81). All patients received curative dose radiotherapy (RT) concomitantly with pertuzumab and trastuzumab (Pertu/Trastu). The median radiation dose was 50 Gy. Safety evaluation did not reveal any significant adverse effects, with 3 cases of grade 3 radiodermatitis (5.4%), but no significant gastrointestinal or cardiac toxicity. The mean difference in LVEF before any chemotherapy and after radiotherapy was -2.43% (p < 0.01). CONCLUSIONS: This study demonstrates that the combination of locoregional breast RT with dual HER2 blockade by Pertu/Trastu was very well tolerated, suggesting that RT can be safely administered to patients with HER2-positive breast cancer. FAU - Aboudaram, Amelie AU - Aboudaram A AUID- ORCID: 0000-0001-8011-4208 AD - Department of Radiation Oncology, Institut Curie, 75005 Paris, France. FAU - Loap, Pierre AU - Loap P AD - Department of Radiation Oncology, Institut Curie, 75005 Paris, France. FAU - Loirat, Delphine AU - Loirat D AD - Department of Medical Oncology, Institut Curie, 75005 Paris, France. FAU - Dhia, Syrine Ben AU - Dhia SB AD - Department of Radiation Oncology, Institut Curie, 75005 Paris, France. FAU - Cao, Kim AU - Cao K AUID- ORCID: 0000-0003-2475-1821 AD - Department of Radiation Oncology, Institut Curie, 75005 Paris, France. FAU - Fourquet, Alain AU - Fourquet A AD - Department of Radiation Oncology, Institut Curie, 75005 Paris, France. FAU - Kirova, Youlia AU - Kirova Y AD - Department of Radiation Oncology, Institut Curie, 75005 Paris, France. LA - eng PT - Journal Article DEP - 20210924 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC8507738 OTO - NOTNLM OT - breast cancer OT - concurrent pertuzumab-trastuzumab-radiotherapy COIS- The authors declare no conflict of interest. EDAT- 2021/10/14 06:00 MHDA- 2021/10/14 06:01 PMCR- 2021/09/24 CRDT- 2021/10/13 01:01 PHST- 2021/08/21 00:00 [received] PHST- 2021/09/22 00:00 [revised] PHST- 2021/09/23 00:00 [accepted] PHST- 2021/10/13 01:01 [entrez] PHST- 2021/10/14 06:00 [pubmed] PHST- 2021/10/14 06:01 [medline] PHST- 2021/09/24 00:00 [pmc-release] AID - cancers13194790 [pii] AID - cancers-13-04790 [pii] AID - 10.3390/cancers13194790 [doi] PST - epublish SO - Cancers (Basel). 2021 Sep 24;13(19):4790. doi: 10.3390/cancers13194790. PMID- 34634101 OWN - NLM STAT- MEDLINE DCOM- 20221028 LR - 20221108 IS - 2058-1742 (Electronic) IS - 2058-1742 (Linking) VI - 8 IP - 7 DP - 2022 Oct 26 TI - Optimal Heart Team Protocol to Improve Revascularization Decisions in Patients with Complex Coronary Artery Disease: A Sequential Mixed Method Study. PG - 739-749 LID - 10.1093/ehjqcco/qcab074 [doi] AB - AIMS: Current guidelines recommend a heart team in the decision-making for patients with complex coronary artery disease (CAD). However, the decision-making stability of these teams has not been evaluated and the optimum protocol is unknown. We assessed inter-team agreement for revascularization decision-making and influencing factors to inform the development of a heart team protocol. METHODS AND RESULTS: This sequential, explanatory mixed methods study included (i) a cross-sectional quantitative study to assess inter-team agreement on treatment strategy for retrospectively enrolled complex CAD patients and (ii) a qualitative study that used semi-structured interviews with heart team members to identify factors influencing decision-making discrepancy. We randomly selected 101 complex CAD patients. Sixteen specialists were randomly assigned to four heart teams to make decisions for these patients. The primary outcome kappa of inter-team decision-making agreement was moderate (kappa 0.58). Factors influencing decision-making were generated through inductive thematic analysis and were summarized by 3 themes (specialist quality, team composition, and meeting process) and 10 subthemes. Recommendations of heart team implementation were generated based on qualitative and quantitative data at five levels: specialist selection, specialist training, team composition, team training, and meeting process. A detailed protocol on the integration of guidelines, previous experience, and recommendations was generated to establish and deploy a qualified heart team. CONCLUSION: Agreement between heart teams for revascularization decision-making in complex CAD patients was moderate. Potential factors associated with decision discrepancies were summarized and recommendations were generated. A detailed heart team protocol was designed and should be validated in future. CI - (c) The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology. FAU - Ma, Hanping AU - Ma H AD - National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China. FAU - Lin, Shen AU - Lin S AD - National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China. AD - Department of Cardiovascular Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China. FAU - Li, Xi AU - Li X AUID- ORCID: 0000-0003-2249-688X AD - National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China. FAU - Dou, Kefei AU - Dou K AD - National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China. AD - Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China. FAU - Yang, Weixian AU - Yang W AD - National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China. AD - Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China. FAU - Feng, Wei AU - Feng W AUID- ORCID: 0000-0003-1157-8302 AD - National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China. AD - Department of Cardiovascular Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China. FAU - Liu, Sheng AU - Liu S AD - National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China. AD - Department of Cardiovascular Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China. FAU - Wu, Yuan AU - Wu Y AD - National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China. AD - Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China. FAU - Peng, Boshizhang AU - Peng B AD - National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China. FAU - Zheng, Zhe AU - Zheng Z AUID- ORCID: 0000-0002-9162-6492 AD - National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China. AD - Department of Cardiovascular Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China. AD - National Health Commission Key Laboratory of Cardiovascular Regenerative Medicine, Fuwai Central-China Hospital, Central-China Branch of National Center for Cardiovascular Diseases, Zhengzhou, People's Republic of China. LA - eng PT - Clinical Trial Protocol PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Eur Heart J Qual Care Clin Outcomes JT - European heart journal. Quality of care & clinical outcomes JID - 101677796 SB - IM MH - Humans MH - *Coronary Artery Disease/surgery MH - Coronary Artery Bypass/methods MH - *Percutaneous Coronary Intervention/methods MH - Retrospective Studies MH - Cross-Sectional Studies MH - Patient Care Team MH - Randomized Controlled Trials as Topic OTO - NOTNLM OT - Complex coronary artery disease OT - Decision-making agreement OT - Heart team OT - Mixed methods study EDAT- 2021/10/12 06:00 MHDA- 2022/10/29 06:00 CRDT- 2021/10/11 17:20 PHST- 2021/06/25 00:00 [received] PHST- 2021/09/30 00:00 [revised] PHST- 2021/10/08 00:00 [accepted] PHST- 2021/10/12 06:00 [pubmed] PHST- 2022/10/29 06:00 [medline] PHST- 2021/10/11 17:20 [entrez] AID - 6388353 [pii] AID - 10.1093/ehjqcco/qcab074 [doi] PST - ppublish SO - Eur Heart J Qual Care Clin Outcomes. 2022 Oct 26;8(7):739-749. doi: 10.1093/ehjqcco/qcab074. PMID- 34628561 OWN - NLM STAT- MEDLINE DCOM- 20220421 LR - 20261010 IS - 1970-9366 (Electronic) IS - 1828-0447 (Linking) VI - 17 IP - 3 DP - 2022 Apr TI - The clinical features and treatment of eosinophilic granulomatosis with polyangiitis (EGPA) in Turkey: one or two distinct diseases? PG - 743-751 LID - 10.1007/s11739-021-02863-0 [doi] AB - Eosinophilic granulomatosis with polyangiitis (EGPA) is defined the disease as having two subgroups, ANCA (+) and ANCA (-). We aimed to compare EGPA subgroups in terms of clinical features, outcomes, and treatments. A multidisciplinary team was established under our vasculitis centre since October 2014. Totally 50 EGPA patients were enrolled. Clinical features, treatments, and outcomes (FFS, VDI, relapse) were reviewed. For relapse-free survival analysis, time to first relapse was compared according to ANCA phenotype by Kaplan-Meier survival analysis and log-rank test. 17 (34%) patients were in ANCA (+), 33 (66%) patients were in ANCA (-) group. ANCA (-) patients were significantly younger at the diagnosis time (37.9 +/- 14.3 vs 53.8 +/- 16.3; p = 0.001) and had more nasal polyposis (45.5% vs 11.8%; p = 0.017). ANCA (+) patients had higher BVAS (17[13] vs 9[4]; p = 0.002), renal involvement and peripheral neuropathy were more common in this group, while cardiac involvement was seen only in ANCA (-) group (n = 3). Biological agents (mepolizumab or rituximab) were prescribed to nine patients in ANCA (-) and two patients in ANCA (+) group. The median duration of follow-up was 47 (IQR 69.9) months. ~ 40% of patients had at least one relapse, but relapse-free survival rate was similar between the groups. However, the predictor of first relapse was elevated Ig E level [OR (95% CI): 6.5 (1.09-38.63) p = 0.04]. Consequently, both clinical features, disease activity, and treatments appear to be significantly different between EGPA subgroups. The relapse risk was similar although clinical features and treatment strategies were different. Also, elevated Ig E levels may be a precursor for the relapse. CI - (c) 2021. Societa Italiana di Medicina Interna (SIMI). FAU - Duran, Emine AU - Duran E AD - Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey. AD - Hacettepe University Vasculitis Research Centre, Ankara, Turkey. FAU - Bostan, Ozge Can AU - Bostan OC AD - Division of Allergy and Clinical Immunology, Department of Chest Diseases, Faculty of Medicine, Hacettepe University, Ankara, Turkey. FAU - Bilgin, Emre AU - Bilgin E AD - Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey. AD - Hacettepe University Vasculitis Research Centre, Ankara, Turkey. FAU - Kaya, Saltuk Bugra AU - Kaya SB AD - Division of Allergy and Clinical Immunology, Department of Chest Diseases, Faculty of Medicine, Hacettepe University, Ankara, Turkey. FAU - Bolek, Ertugrul Cagri AU - Bolek EC AD - Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey. AD - Hacettepe University Vasculitis Research Centre, Ankara, Turkey. FAU - Ozer, Serdar AU - Ozer S AD - Department of Otolaryngology, Faculty of Medicine, Hacettepe University, Ankara, Turkey. FAU - Damadoglu, Ebru AU - Damadoglu E AD - Division of Allergy and Clinical Immunology, Department of Chest Diseases, Faculty of Medicine, Hacettepe University, Ankara, Turkey. FAU - Bilgen, Sule Apras AU - Bilgen SA AD - Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey. AD - Hacettepe University Vasculitis Research Centre, Ankara, Turkey. FAU - Karakaya, Gul AU - Karakaya G AD - Division of Allergy and Clinical Immunology, Department of Chest Diseases, Faculty of Medicine, Hacettepe University, Ankara, Turkey. FAU - Karadag, Omer AU - Karadag O AUID- ORCID: 0000-0002-3443-3117 AD - Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey. omerkaradag@ymail.com. AD - Hacettepe University Vasculitis Research Centre, Ankara, Turkey. omerkaradag@ymail.com. LA - eng PT - Journal Article DEP - 20211010 PL - Italy TA - Intern Emerg Med JT - Internal and emergency medicine JID - 101263418 RN - 0 (Antibodies, Antineutrophil Cytoplasmic) SB - IM MH - Antibodies, Antineutrophil Cytoplasmic MH - *Churg-Strauss Syndrome/diagnosis/drug therapy MH - *Granulomatosis with Polyangiitis/diagnosis/drug therapy MH - Humans MH - Recurrence MH - Turkey/epidemiology OTO - NOTNLM OT - ANCA subgroups OT - Biologic agents OT - Eosinophilic granulomatosis with polyangiitis OT - Mepolizumab OT - Relapse OT - Rituximab EDAT- 2021/10/11 06:00 MHDA- 2022/04/22 06:00 CRDT- 2021/10/10 21:17 PHST- 2021/06/21 00:00 [received] PHST- 2021/09/27 00:00 [accepted] PHST- 2021/10/11 06:00 [pubmed] PHST- 2022/04/22 06:00 [medline] PHST- 2021/10/10 21:17 [entrez] AID - 10.1007/s11739-021-02863-0 [pii] AID - 10.1007/s11739-021-02863-0 [doi] PST - ppublish SO - Intern Emerg Med. 2022 Apr;17(3):743-751. doi: 10.1007/s11739-021-02863-0. Epub 2021 Oct 10. PMID- 34627726 OWN - NLM STAT- MEDLINE DCOM- 20211220 LR - 20211220 IS - 2253-8089 (Electronic) IS - 2253-8089 (Linking) VI - 40 IP - 6 DP - 2021 Nov-Dec TI - (18)F-FDG PET/CT in cardiovascular infection and inflammation. PG - 397-408 LID - S2253-8089(21)00142-7 [pii] LID - 10.1016/j.remnie.2021.09.008 [doi] AB - The diagnosis of cardiovascular infection and inflammation by [(18)F]FDG PET/CT in Nuclear Cardiology is of growing interest, because with respect to echocardiography this technique has improved the certainty in the diagnosis of infective endocarditis in patients with prosthetic valves, the increasing number of patients with implantable cardiac devices because of the progressive ageing of the population, as well as in patients with suspected large vessel vasculitis. All are serious clinical situations which require correct diagnosis and appropriate treatment as soon as possible, because they can cause severe complications, high mortality and also increased health care costs. We review the use of [(18)F]FDG PET/CT in cardiovascular infection and inflammation, including the clinical point of view and the contribution of other image modalities. We focus on the appropriate methodology for this exploration, patient preparation, image acquisition and correct interpretation and the quantification possibilities, defining the specific characteristics of the diagnosis in patients with prosthetic valves, implantable cardiac devices and large vessel vasculitis in the initial diagnosis as well as during follow-up to assess treatment response. We analyze the possible causes of false positive and false negative results and emphasize the special value of a multidisciplinary team for optimal management of these patients. CI - Copyright (c) 2021. Published by Elsevier Espana, S.L.U. FAU - Casans-Tormo, I AU - Casans-Tormo I AD - Servicio de Medicina Nuclear, Hospital Clinico Universitario de Valencia, Universidad de Valencia, Valencia, Spain. Electronic address: casans_ire@gva.es. FAU - Alcala-Lopez, J E AU - Alcala-Lopez JE AD - Servicio de Cardiologia, Hospital Universitario Virgen de las Nieves, Granada, Spain. FAU - Espinet-Coll, C AU - Espinet-Coll C AD - Servicio de Medicina Nuclear, Hospital Universitario Vall d'Hebron, Barcelona, Spain. FAU - Pubul-Nunez, V AU - Pubul-Nunez V AD - Servicio de Medicina Nuclear, Hospital Clinico Universitario de Santiago de Compostela, Santiago de Compostela, La Coruna, Spain. FAU - Martinez-Rodriguez, I AU - Martinez-Rodriguez I AD - Servicio de Medicina Nuclear, Hospital Universitario Marques de Valdecilla, Grupo de Imagen Molecular (IDIVAL), Universidad de Cantabria, Santander, Cantabria, Spain. LA - eng PT - Journal Article DEP - 20211006 PL - Spain TA - Rev Esp Med Nucl Imagen Mol (Engl Ed) JT - Revista espanola de medicina nuclear e imagen molecular JID - 101770941 RN - 0 (Radiopharmaceuticals) RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18) SB - IM MH - Brain/diagnostic imaging MH - Cardiovascular Infections/*diagnostic imaging MH - Defibrillators, Implantable/adverse effects MH - Echocardiography MH - Endocarditis/diagnostic imaging MH - *Fluorodeoxyglucose F18 MH - Giant Cell Arteritis/diagnostic imaging MH - Heart/diagnostic imaging MH - Heart Valve Prosthesis/adverse effects MH - Heart-Assist Devices/adverse effects MH - Humans MH - Magnetic Resonance Imaging MH - Pacemaker, Artificial/adverse effects MH - Positron Emission Tomography Computed Tomography/*methods MH - Prognosis MH - Prostheses and Implants MH - Prosthesis-Related Infections/*diagnostic imaging MH - *Radiopharmaceuticals MH - Takayasu Arteritis/diagnostic imaging MH - Tomography, X-Ray Computed MH - Vasculitis/*diagnostic imaging OTO - NOTNLM OT - (18)F-FDG OT - Cardiologia nuclear OT - Dispositivo intracardiaco OT - Endocarditis infecciosa OT - Implantable cardiac device OT - Infective endocarditis OT - Large vessel vasculitis OT - Nuclear cardiology OT - PET/CT OT - PET/TC OT - Prosthetic valves OT - Protesis valvular OT - Vasculitis de grandes vasos EDAT- 2021/10/11 06:00 MHDA- 2021/12/21 06:00 CRDT- 2021/10/10 20:45 PHST- 2021/08/31 00:00 [received] PHST- 2021/09/22 00:00 [accepted] PHST- 2021/10/11 06:00 [pubmed] PHST- 2021/12/21 06:00 [medline] PHST- 2021/10/10 20:45 [entrez] AID - S2253-8089(21)00142-7 [pii] AID - 10.1016/j.remnie.2021.09.008 [doi] PST - ppublish SO - Rev Esp Med Nucl Imagen Mol (Engl Ed). 2021 Nov-Dec;40(6):397-408. doi: 10.1016/j.remnie.2021.09.008. Epub 2021 Oct 6. PMID- 34625983 OWN - NLM STAT- MEDLINE DCOM- 20220426 LR - 20220426 IS - 1365-2125 (Electronic) IS - 0306-5251 (Linking) VI - 88 IP - 4 DP - 2022 Feb TI - Physicians' and pharmacists' views and experiences regarding use of direct oral anticoagulants in clinical practice. PG - 1856-1865 LID - 10.1111/bcp.15106 [doi] AB - AIM: Direct oral anticoagulants (DOACs) are increasingly used compared to vitamin K antagonists (VKAs). Guidelines advocate a structured multidisciplinary approach in the management of patients treated with DOACs. The aim of this study was to assess the views and experiences of physicians and pharmacists regarding DOAC use in clinical practice. METHODS: An online questionnaire was sent to both primary (general practitioners [GPs], community pharmacists) and secondary healthcare professionals (cardiologists, residents in internal medicine and hospital pharmacists) between March and July 2020. The questionnaire covered four topics: (i) current practice, (ii) prescribing behaviour (only for physicians), (iii) self-perceived knowledge about DOACs and (iv) views and opinions about DOACs versus VKAs. RESULTS: In total, 110 physicians and 111 pharmacists completed the survey. Healthcare professionals in secondary care had more experience with DOACs and felt more confident with higher self-perceived knowledge about DOACs compared to their colleagues in primary care. Healthcare professionals' self-perceived knowledge was more or less complementary, for example physicians felt less confident in managing drug-drug interactions (DDIs) where pharmacists reported being more confident in this topic. Physicians reported uncertainties on the potential impact of risk factors - such as older age, lower body weight and DDIs - on appropriate DOAC dosing. CONCLUSION: Complementarity in physicians' and pharmacists' self-perceived knowledge levels of DOACs may facilitate and necessitate future multidisciplinary collaboration initiatives for the management and follow-up of DOAC patients. CI - (c) 2021 British Pharmacological Society. FAU - Capiau, Andreas AU - Capiau A AUID- ORCID: 0000-0003-2458-5237 AD - Pharmaceutical Care Unit, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium. FAU - Mehuys, Els AU - Mehuys E AD - Pharmaceutical Care Unit, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium. FAU - Dhondt, Eline AU - Dhondt E AD - Pharmaceutical Care Unit, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium. FAU - De Backer, Tine AU - De Backer T AD - Department of Cardiology, Heart Centre, Ghent University Hospital, Ghent, Belgium. AD - Department of Internal Medicine and Paediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium. FAU - Boussery, Koen AU - Boussery K AD - Pharmaceutical Care Unit, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium. LA - eng PT - Journal Article DEP - 20211030 PL - England TA - Br J Clin Pharmacol JT - British journal of clinical pharmacology JID - 7503323 RN - 0 (Anticoagulants) SB - IM MH - Administration, Oral MH - Anticoagulants/adverse effects MH - *General Practitioners MH - Humans MH - *Pharmacists MH - Practice Patterns, Physicians' OTO - NOTNLM OT - drug information OT - drug utilization OT - prescribing OT - quality use of medicines EDAT- 2021/10/10 06:00 MHDA- 2022/04/27 06:00 CRDT- 2021/10/09 06:31 PHST- 2021/09/16 00:00 [revised] PHST- 2021/04/25 00:00 [received] PHST- 2021/09/27 00:00 [accepted] PHST- 2021/10/10 06:00 [pubmed] PHST- 2022/04/27 06:00 [medline] PHST- 2021/10/09 06:31 [entrez] AID - 10.1111/bcp.15106 [doi] PST - ppublish SO - Br J Clin Pharmacol. 2022 Feb;88(4):1856-1865. doi: 10.1111/bcp.15106. Epub 2021 Oct 30. PMID- 34620393 OWN - NLM STAT- MEDLINE DCOM- 20211101 LR - 20211101 IS - 1876-7605 (Electronic) IS - 1936-8798 (Linking) VI - 14 IP - 19 DP - 2021 Oct 11 TI - Outcomes After Transcatheter Aortic Valve Replacement in Bicuspid Versus Tricuspid Anatomy: A Systematic Review and Meta-Analysis. PG - 2144-2155 LID - S1936-8798(21)01445-X [pii] LID - 10.1016/j.jcin.2021.07.052 [doi] AB - OBJECTIVES: The aim of this study was to compare the feasibility, safety, and clinical outcomes of transcatheter aortic valve replacement (TAVR) in bicuspid aortic valve (BAV) versus tricuspid aortic valve (TAV) stenosis. BACKGROUND: At present, limited observational data exist supporting TAVR in the context of bicuspid anatomy. METHODS: Primary endpoints were 1-year survival and device success. Secondary endpoints included moderate to severe paravalvular leak (PVL) and a composite endpoint of periprocedural complications; incidence rates of individual procedural endpoints were also explored individually. RESULTS: In the main analysis, 17 studies and 181,433 patients undergoing TAVR were included, of whom 6,669 (0.27%) had BAV. A secondary analysis of 7,071 matched subjects with similar baseline characteristics was also performed. Device success and 1-year survival rates were similar between subjects with BAV and those with TAV (97% vs 94% [P = 0.55] and 91.3% vs 90.8% [P = 0.22], respectively). In patients with BAV, a trend toward a higher risk for periprocedural complications was observed in our main analysis (risk ratio [RR]: 1.12; 95% CI: 0.99-1.27; P = 0.07) but not in the matched population secondary analysis (RR: 1.00; 95% CI: 0.81-1.24; P = 0.99). The risk for moderate to severe PVL was higher in subjects with BAV (RR: 1.42; 95% CI: 1.29-1.58; P < 0.0001) as well as the incidence of cerebral ischemic events (2.4% vs 1.6%; P = 0.015) and of annular rupture (0.3% vs 0.02%; P = 0.014) in matched subjects. CONCLUSIONS: TAVR is a feasible option among selected patients with BAV anatomy, but the higher rates of moderate to severe PVL, annular rupture, and cerebral ischemic events observed in the BAV group warrant caution and further evidence. CI - Copyright (c) 2021 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. FAU - Montalto, Claudio AU - Montalto C AD - Department of Molecular Medicine, University of Pavia, Pavia, Italy; Oxford Heart Center, Oxford University Hospital NHS Trust, Oxford, United Kingdom. FAU - Sticchi, Alessandro AU - Sticchi A AD - Centro per la Lotta Contro l'Infarto Foundation, Rome, Italy; Unicamillus, Saint Camillus International University of Health Sciences, Rome, Italy. FAU - Crimi, Gabriele AU - Crimi G AD - Cardio-Thoraco-Vascular Department, IRCCS Ospedale Policlinico San Martino, Genova, Italy. FAU - Laricchia, Alessandra AU - Laricchia A AD - GVM Care and Research, Maria Cecilia Hospital, Cotignola, Italy. FAU - Khokhar, Arif A AU - Khokhar AA AD - GVM Care and Research, Maria Cecilia Hospital, Cotignola, Italy. FAU - Giannini, Francesco AU - Giannini F AD - GVM Care and Research, Maria Cecilia Hospital, Cotignola, Italy. FAU - Reimers, Bernhard AU - Reimers B AD - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; Cardio Center, Humanitas Research Hospital IRCCS, Rozzano, Milan, Italy. FAU - Colombo, Antonio AU - Colombo A AD - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; Cardio Center, Humanitas Research Hospital IRCCS, Rozzano, Milan, Italy. FAU - Latib, Azeem AU - Latib A AD - Montefiore Medical Center, New York, New York, USA. FAU - Waksman, Ron AU - Waksman R AD - Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia, USA. FAU - Mangieri, Antonio AU - Mangieri A AD - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; Cardio Center, Humanitas Research Hospital IRCCS, Rozzano, Milan, Italy. Electronic address: antonio.mangieri@gmail.com. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review PL - United States TA - JACC Cardiovasc Interv JT - JACC. Cardiovascular interventions JID - 101467004 SB - IM CIN - JACC Cardiovasc Interv. 2021 Oct 11;14(19):2156-2157. doi: 10.1016/j.jcin.2021.08.052. PMID: 34620394 MH - Aortic Valve/diagnostic imaging/surgery MH - *Aortic Valve Stenosis/diagnostic imaging/surgery MH - Humans MH - *Transcatheter Aortic Valve Replacement/adverse effects MH - Treatment Outcome MH - *Tricuspid Valve Stenosis/surgery OTO - NOTNLM OT - TAVR OT - aortic stenosis OT - bicuspid aortic valve OT - heart team OT - transcatheter aortic valve replacement COIS- Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2021/10/09 06:00 MHDA- 2021/11/03 06:00 CRDT- 2021/10/08 05:48 PHST- 2021/05/18 00:00 [received] PHST- 2021/07/22 00:00 [revised] PHST- 2021/07/27 00:00 [accepted] PHST- 2021/10/08 05:48 [entrez] PHST- 2021/10/09 06:00 [pubmed] PHST- 2021/11/03 06:00 [medline] AID - S1936-8798(21)01445-X [pii] AID - 10.1016/j.jcin.2021.07.052 [doi] PST - ppublish SO - JACC Cardiovasc Interv. 2021 Oct 11;14(19):2144-2155. doi: 10.1016/j.jcin.2021.07.052. PMID- 34620388 OWN - NLM STAT- MEDLINE DCOM- 20211101 LR - 20250530 IS - 1876-7605 (Electronic) IS - 1936-8798 (Linking) VI - 14 IP - 19 DP - 2021 Oct 11 TI - Coronary Revascularization in Patients Undergoing Aortic Valve Replacement for Severe Aortic Stenosis. PG - 2083-2096 LID - S1936-8798(21)01555-7 [pii] LID - 10.1016/j.jcin.2021.07.058 [doi] AB - Aortic stenosis (AS) and coronary artery disease (CAD) frequently coexist, with up to two thirds of patients with AS having significant CAD. Given the challenges when both disease states are present, these patients require a tailored approach diagnostically and therapeutically. In this review the authors address the impact of AS and aortic valve replacement (AVR) on coronary hemodynamic status and discuss the assessment of CAD and the role of revascularization in patients with concomitant AS and CAD. Remodeling in AS increases the susceptibility of myocardial ischemia, which can be compounded by concomitant CAD. AVR can improve coronary hemodynamic status and reduce ischemia. Assessment of the significance of coexisting CAD can be done using noninvasive and invasive metrics. Revascularization in patients undergoing AVR can benefit certain patients in whom CAD is either prognostically or symptomatically important. Identifying this cohort of patients is challenging and as yet incomplete. Patients with dual pathology present a diagnostic and therapeutic challenge; both AS and CAD affect coronary hemodynamic status, they provoke similar symptoms, and their respective treatments can have an impact on both diseases. Decisions regarding coronary revascularization should be based on understanding this complex relationship, using appropriate coronary assessment and consensus within a multidisciplinary team. CI - Copyright (c) 2021 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. FAU - Patel, Kush P AU - Patel KP AD - Institute of Cardiovascular Science, University College London, London, United Kingdom; Barts Heart Centre, St. Bartholomew's Hospital, London, United Kingdom. FAU - Michail, Michael AU - Michail M AD - Institute of Cardiovascular Science, University College London, London, United Kingdom; Sussex Cardiac Centre, Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom. FAU - Treibel, Thomas A AU - Treibel TA AD - Institute of Cardiovascular Science, University College London, London, United Kingdom; Barts Heart Centre, St. Bartholomew's Hospital, London, United Kingdom. FAU - Rathod, Krishnaraj AU - Rathod K AD - Barts Heart Centre, St. Bartholomew's Hospital, London, United Kingdom. FAU - Jones, Daniel A AU - Jones DA AD - Barts Heart Centre, St. Bartholomew's Hospital, London, United Kingdom; Centre for Cardiovascular Medicine and Devices, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom. FAU - Ozkor, Mick AU - Ozkor M AD - Barts Heart Centre, St. Bartholomew's Hospital, London, United Kingdom. FAU - Kennon, Simon AU - Kennon S AD - Barts Heart Centre, St. Bartholomew's Hospital, London, United Kingdom. FAU - Forrest, John K AU - Forrest JK AD - Yale University School of Medicine, New Haven, Connecticut, USA. FAU - Mathur, Anthony AU - Mathur A AD - Barts Heart Centre, St. Bartholomew's Hospital, London, United Kingdom; Centre for Cardiovascular Medicine and Devices, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom. FAU - Mullen, Michael J AU - Mullen MJ AD - Institute of Cardiovascular Science, University College London, London, United Kingdom; Barts Heart Centre, St. Bartholomew's Hospital, London, United Kingdom. FAU - Lansky, Alexandra AU - Lansky A AD - Centre for Cardiovascular Medicine and Devices, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom; Yale University School of Medicine, New Haven, Connecticut, USA. FAU - Baumbach, Andreas AU - Baumbach A AD - Barts Heart Centre, St. Bartholomew's Hospital, London, United Kingdom; Centre for Cardiovascular Medicine and Devices, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom; Yale University School of Medicine, New Haven, Connecticut, USA. Electronic address: a.baumbach@qmul.ac.uk. LA - eng GR - FS/19/35/34374/BHF_/British Heart Foundation/United Kingdom GR - FS/19/48/34523/BHF_/British Heart Foundation/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review PL - United States TA - JACC Cardiovasc Interv JT - JACC. Cardiovascular interventions JID - 101467004 SB - IM MH - Aortic Valve/diagnostic imaging/surgery MH - *Aortic Valve Stenosis/diagnostic imaging/surgery MH - *Coronary Artery Disease/complications/diagnostic imaging/surgery MH - *Heart Valve Prosthesis MH - Humans MH - Risk Factors MH - *Transcatheter Aortic Valve Replacement MH - Treatment Outcome OTO - NOTNLM OT - aortic stenosis OT - chronic coronary syndromes OT - coronary artery disease OT - coronary hemodynamic status OT - revascularization COIS- Funding Support and Author Disclosures Dr Patel is supported by a clinical research training fellowship from the British Heart Foundation (FS/19/48/34523) and an unrestricted research grant from Edwards Lifesciences. Dr Treibel is directly and indirectly supported by the University College London Hospital and Barts National Institute for Health Research Biomedical Research Units. Dr Mullen has received grants and personal fees from Edwards Lifesciences; and has received personal fees from Abbott Vascular. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2021/10/09 06:00 MHDA- 2021/11/03 06:00 CRDT- 2021/10/08 05:48 PHST- 2021/02/25 00:00 [received] PHST- 2021/06/25 00:00 [revised] PHST- 2021/07/27 00:00 [accepted] PHST- 2021/10/08 05:48 [entrez] PHST- 2021/10/09 06:00 [pubmed] PHST- 2021/11/03 06:00 [medline] AID - S1936-8798(21)01555-7 [pii] AID - 10.1016/j.jcin.2021.07.058 [doi] PST - ppublish SO - JACC Cardiovasc Interv. 2021 Oct 11;14(19):2083-2096. doi: 10.1016/j.jcin.2021.07.058. PMID- 34619802 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20211022 IS - 2325-4637 (Print) IS - 2325-4637 (Electronic) IS - 2325-4637 (Linking) VI - 9 IP - 2 DP - 2021 Apr TI - Transcatheter Aortic Valve Replacement in Pure Native Aortic Valve Regurgitation: Challenging Pathology Awaiting Specialized Devices. PG - 56-59 LID - 10.1055/s-0041-1725122 [doi] AB - Patients with aortic incompetence frequently present with anatomical and pathological challenges such as elliptical dilated annulus, dilated aortic root, dilated ascending aorta, and with no calcification in the aortic cusps or annulus. Patients are commonly in graver clinical condition as a result of a long silent clinical course before overt congestive heart failure. All of the above make transcatheter therapies for native aortic valve regurgitation more challenging with poorer outcomes, escalating the risk of insufficient anchoring, prosthesis migration, and residual paravalvular leak compared with current transcatheter aortic valve replacement (TAVR) outcomes for aortic stenosis. There is a need for specialized TAVR devices to address this complex pathology. Surgical aortic valve replacement is the current treatment option and the gold standard for patients with aortic incompetence (AR). Currently, the specific off-label indication for TAVR in pure native AR could be a feasible and reasonable option, as a compassionate treatment is limited to inoperable patients and agreed on by the heart team. CI - The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/). FAU - El-Gamel, Adam AU - El-Gamel A AUID- ORCID: 0000-0003-3414-8436 AD - Cardiothoracic Unit, Waikato Hospital, Hamilton, New Zealand. AD - Department of Surgery, The University of Auckland, Auckland, New Zealand. AD - Medical Reseach Department, Waikato University, New Zealand. LA - eng PT - Journal Article DEP - 20211007 PL - Germany TA - Aorta (Stamford) JT - Aorta (Stamford, Conn.) JID - 101655549 PMC - PMC8526145 COIS- The authors declare no conflict of interest related to this article. EDAT- 2021/10/08 06:00 MHDA- 2021/10/08 06:01 PMCR- 2021/10/01 CRDT- 2021/10/07 20:38 PHST- 2021/10/08 06:00 [pubmed] PHST- 2021/10/08 06:01 [medline] PHST- 2021/10/07 20:38 [entrez] PHST- 2021/10/01 00:00 [pmc-release] AID - 200012 [pii] AID - 10.1055/s-0041-1725122 [doi] PST - ppublish SO - Aorta (Stamford). 2021 Apr;9(2):56-59. doi: 10.1055/s-0041-1725122. Epub 2021 Oct 7. PMID- 34617425 OWN - NLM STAT- MEDLINE DCOM- 20211011 LR - 20211027 IS - 1678-9741 (Electronic) IS - 0102-7638 (Print) IS - 0102-7638 (Linking) VI - 36 IP - 4 DP - 2021 Aug 6 TI - Applicability of the Disruptions in Surgery Index in the Cardiovascular Management Scenarios - A Marker for Developing Functionally Efficient Teams. PG - 445-452 LID - 10.21470/1678-9741-2020-0685 [doi] AB - INTRODUCTION: To support the development of practices and guidelines that might help to reduce adverse events related to human factors, we aimed to study the response and perception by members of a cardiovascular surgery team of various error-driven or adverse features that might arise in the operating room (OR). METHODS: A previously validated Disruptions in Surgery Index (DiSI) questionnaire was completed by individuals working together in a cardiovascular surgical unit. Results were submitted to reliability analysis by calculating the Cronbach's alpha coefficient. Non-parametric Kruskal-Wallis test and Dunn's post-test were performed to estimate differences in perceptions of adverse events or outcomes between the groups (surgeons, nurses, anesthesiologists, and technicians). P<0.05 was considered statistically significant. RESULTS: Cronbach's alpha reliability coefficients showed consistency within the recommended range for all disruption types assessed in DiSI: an individual's skill (0.85), OR environment (0.88), communication (0.81), situational awareness (0.92), patient-related disruption (0.89), team cohesion (0.83), and organizational disruption (0.83). Nurses (27.4%) demonstrated significantly higher perception of disruptions than surgeons (25.4%), anesthetists (23.3%), and technicians (23.0%) (P=0.005). Study participants were more observant of their colleagues' disruptive behaviors than their own (P=0.0001). CONCLUSION: Our results revealed that there is a tendency among participants to hold a positive self-perception position. DiSI appears to be a reliable and useful tool to assess surgical disruptions in cardiovascular OR teams, identifying negative features that might imperil teamwork and safety in the OR. And human factors training interventions are available to develop team skills and improve safety and efficiency in the cardiovascular OR. FAU - Nina, Vinicius AU - Nina V AUID- ORCID: 0000-0003-3852-0602 AD - Department of Medicine I, Universidade Federal do Maranhao, Sao Luis, Maranhao, Brazil. FAU - Mendes, Augusto Goncalves AU - Mendes AG AD - Health Service & Population Research, King's College London, London, London, United Kingdom of Great Britain and Northern Ireland. FAU - Sevdalis, Nick AU - Sevdalis N AD - CardioStart International, Tampa, Florida, United States of America. FAU - Marath, Aubyn AU - Marath A AD - Department of Cardiovascular Surgery, Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Sao Paulo, Brazil. FAU - Mejia, Omar Vilca AU - Mejia OV AD - Hospital do Cancer Tarquinio Lopes Filho, Sao Luis, Maranhao, Brazil. FAU - Brandao, Carlos Manuel A AU - Brandao CMA AD - Department of Cardiac Surgery, Instituto do Coracao, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Sao Paulo, Brazil. FAU - Monteiro, Rosangela AU - Monteiro R AD - Department of Cardiovascular Surgery, Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Sao Paulo, Brazil. FAU - Mendes, Vinicius Giuliano AU - Mendes VG AD - Hospital do Cancer Tarquinio Lopes Filho, Sao Luis, Maranhao, Brazil. FAU - Jatene, Fabio B AU - Jatene FB AD - Universidade de Sao Paulo Faculdade de Medicina Instituto do Coracao Sao Paulo Sao Paulo Brazil Department of Cardiac Surgery, Instituto do Coracao, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Sao Paulo, Brazil. LA - eng PT - Journal Article DEP - 20210806 PL - Brazil TA - Braz J Cardiovasc Surg JT - Brazilian journal of cardiovascular surgery JID - 101677045 SB - IM MH - Communication MH - Humans MH - Operating Rooms MH - *Patient Care Team MH - Reproducibility of Results MH - *Surgeons PMC - PMC8522325 OTO - NOTNLM OT - Cardiovascular Surgery OT - Communication OT - Patient Safety OT - Perception OT - Problem Behavior OT - Self-Concept OT - Surgeons COIS- Conflict of interest: NS is the director of the London Safety and Training Solutions Ltd, which offers training in patient safety, implementation solutions and human factors to healthcare organizations and the pharmaceutical industry. The other authors have no conflicts of interest to declare. EDAT- 2021/10/08 06:00 MHDA- 2021/10/12 06:00 PMCR- 2021/07/01 CRDT- 2021/10/07 07:31 PHST- 2021/10/08 06:00 [pubmed] PHST- 2021/10/12 06:00 [medline] PHST- 2021/10/07 07:31 [entrez] PHST- 2021/07/01 00:00 [pmc-release] AID - 10.21470/1678-9741-2020-0685 [doi] PST - epublish SO - Braz J Cardiovasc Surg. 2021 Aug 6;36(4):445-452. doi: 10.21470/1678-9741-2020-0685. PMID- 34616782 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20211008 IS - 2297-055X (Print) IS - 2297-055X (Electronic) IS - 2297-055X (Linking) VI - 8 DP - 2021 TI - Systems of Care in Cardiogenic Shock. PG - 712594 LID - 10.3389/fcvm.2021.712594 [doi] LID - 712594 AB - Outcomes for cardiogenic shock (CS) patients remain relatively poor despite significant advancements in primary percutaneous coronary interventions (PCI) and temporary circulatory support (TCS) technologies. Mortality from CS shows great disparities that seem to reflect large variations in access to care and physician practice patterns. Recent reports of different models to standardize care in CS have shown considerable potential at improving outcomes. The creation of regional, integrated, 3-tiered systems, would facilitate standardized interventions and equitable access to care. Multidisciplinary CS teams at Level I centers would direct care in a hub-and-spoke model through jointly developed protocols and real-time shared decision making. Levels II and III centers would provide early access to life-saving therapies and safe transfer to designated hub centers. In regions with large geographical distances, the implementation of telemedicine-cardiac intensive care unit (CICU) care can be an important resource for the creation of effective systems of care. CI - Copyright (c) 2021 Alvarez Villela, Clark, William, Sims and Jorde. FAU - Alvarez Villela, Miguel AU - Alvarez Villela M AD - Division of Cardiology, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY, United States. AD - Division of Cardiology, Jacobi Medical Center, Albert Einstein College of Medicine, New York, NY, United States. FAU - Clark, Rachel AU - Clark R AD - Division of Cardiology, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY, United States. FAU - William, Preethi AU - William P AD - Division of Cardiology, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY, United States. AD - Division of Cardiology, Banner University Medical Center, Tucson, University of Arizona, Tucson, AZ, United States. FAU - Sims, Daniel B AU - Sims DB AD - Division of Cardiology, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY, United States. FAU - Jorde, Ulrich P AU - Jorde UP AD - Division of Cardiology, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY, United States. LA - eng PT - Journal Article PT - Review DEP - 20210916 PL - Switzerland TA - Front Cardiovasc Med JT - Frontiers in cardiovascular medicine JID - 101653388 PMC - PMC8489379 OTO - NOTNLM OT - AHF-CS OT - AMI-CS OT - cardiogenic shock OT - hub and spoke OT - shock team OT - systems of care COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/10/08 06:00 MHDA- 2021/10/08 06:01 PMCR- 2021/01/01 CRDT- 2021/10/07 07:00 PHST- 2021/05/20 00:00 [received] PHST- 2021/08/26 00:00 [accepted] PHST- 2021/10/07 07:00 [entrez] PHST- 2021/10/08 06:00 [pubmed] PHST- 2021/10/08 06:01 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - 10.3389/fcvm.2021.712594 [doi] PST - epublish SO - Front Cardiovasc Med. 2021 Sep 16;8:712594. doi: 10.3389/fcvm.2021.712594. eCollection 2021. PMID- 34611882 OWN - NLM STAT- MEDLINE DCOM- 20211115 LR - 20211115 IS - 1897-4279 (Electronic) IS - 0022-9032 (Linking) VI - 79 IP - 10 DP - 2021 TI - Heart Failure Heart Team - time to act... now. PG - 1163-1164 LID - 10.33963/KP.a2021.0123 [doi] FAU - Zembala, Michal AU - Zembala M AD - Silesian Center for Heart Diseases, Zabrze, Poland. FAU - Hryniewiecki, Tomasz AU - Hryniewiecki T AD - Cardinal Stefan Wyszynski National Institute of Cardiology, Warsaw, Poland. FAU - Wita, Krystian AU - Wita K AD - Leszek Giec Upper-Silesian Medical Centre of the Silesian Medical University in Katowice, Poland. FAU - Kalarus, Zbigniew AU - Kalarus Z AD - Silesian Center for Heart Diseases, Zabrze, Poland. FAU - Gasior, Mariusz AU - Gasior M AD - Silesian Center for Heart Diseases, Zabrze, Poland. FAU - Zembala, Marian AU - Zembala M AD - Silesian Center for Heart Diseases, Zabrze, Poland. m.zembala@sccs.pl. LA - eng PT - Journal Article DEP - 20211006 PL - Poland TA - Kardiol Pol JT - Kardiologia polska JID - 0376352 SB - IM MH - *Heart Failure/diagnosis/therapy MH - Humans MH - Patient Care Team EDAT- 2021/10/07 06:00 MHDA- 2021/11/16 06:00 CRDT- 2021/10/06 07:04 PHST- 2021/10/06 00:00 [received] PHST- 2021/10/06 00:00 [accepted] PHST- 2021/10/07 06:00 [pubmed] PHST- 2021/11/16 06:00 [medline] PHST- 2021/10/06 07:04 [entrez] AID - VM/OJS/J/86281 [pii] AID - 10.33963/KP.a2021.0123 [doi] PST - ppublish SO - Kardiol Pol. 2021;79(10):1163-1164. doi: 10.33963/KP.a2021.0123. Epub 2021 Oct 6. PMID- 34607763 OWN - NLM STAT- MEDLINE DCOM- 20220615 LR - 20260127 IS - 1532-8422 (Electronic) IS - 1053-0770 (Linking) VI - 36 IP - 8 Pt B DP - 2022 Aug TI - Functional Mitral Regurgitation in Heart Failure: Analysis of the ESC Multidisciplinary Heart-Team Position Statement and Review of Current Guidelines. PG - 3357-3364 LID - S1053-0770(21)00797-7 [pii] LID - 10.1053/j.jvca.2021.09.004 [doi] FAU - Cormican, Daniel S AU - Cormican DS AD - Department of Anesthesiology, Divisions of Cardiothoracic Anesthesiology and Critical Care Medicine, Allegheny Health Network, Pittsburgh, PA. FAU - Drennen, Zachary AU - Drennen Z AD - Department of Anesthesiology, Allegheny Health Network, Pittsburgh, PA. FAU - Sonny, Abraham AU - Sonny A AD - Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Boston, MA. FAU - Crowley, Jerome C AU - Crowley JC AD - Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Boston, MA. FAU - Gil, Ivan J Nunez AU - Gil IJN AD - Interventional Cardiology, Cardiovascular Institute, Hospital Clinico San Carlos, Madrid, Spain. FAU - Ramakrishna, Harish AU - Ramakrishna H AD - Division of Cardiovascular and Thoracic Anesthesiology, Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN. Electronic address: Ramakrishna.harish@mayo.edu. LA - eng PT - Consensus Statement PT - Journal Article PT - Review DEP - 20210910 PL - United States TA - J Cardiothorac Vasc Anesth JT - Journal of cardiothoracic and vascular anesthesia JID - 9110208 SB - IM MH - Heart MH - *Heart Failure/diagnosis/therapy MH - *Heart Valve Prosthesis Implantation MH - Humans MH - *Mitral Valve Insufficiency/diagnosis/surgery OTO - NOTNLM OT - guideline-directed therapy OT - ischemic heart disease OT - secondary mitral regugitation OT - valvular heart disease COIS- Conflict of Interest None. EDAT- 2021/10/06 06:00 MHDA- 2022/06/16 06:00 CRDT- 2021/10/05 05:44 PHST- 2021/09/01 00:00 [received] PHST- 2021/09/03 00:00 [accepted] PHST- 2021/10/06 06:00 [pubmed] PHST- 2022/06/16 06:00 [medline] PHST- 2021/10/05 05:44 [entrez] AID - S1053-0770(21)00797-7 [pii] AID - 10.1053/j.jvca.2021.09.004 [doi] PST - ppublish SO - J Cardiothorac Vasc Anesth. 2022 Aug;36(8 Pt B):3357-3364. doi: 10.1053/j.jvca.2021.09.004. Epub 2021 Sep 10. PMID- 34605364 OWN - NLM STAT- MEDLINE DCOM- 20211028 LR - 20220427 IS - 1607-8454 (Electronic) IS - 1024-5332 (Linking) VI - 26 IP - 1 DP - 2021 Dec TI - Management of ibrutinib treatment in patients with B-cell malignancies: clinical practice in Portugal and multidisciplinary recommendations. PG - 785-798 LID - 10.1080/16078454.2021.1980690 [doi] AB - OBJECTIVES: Ibrutinib, a potent inhibitor of the Bruton tyrosine kinase, has revolutionized the treatment of many B-cell malignancies. Ibrutinib has an established favorable toxicity profile with up to 8 years of experience in clinical trials; however, despite ibrutinib's favorable toxicity profile, dose reductions and treatment discontinuations are becoming more evident in clinical practice, particularly in the setting of specific clinical contexts and patient characteristics. This manuscript is set to provide practical recommendations on the management of patients treated with this agent in daily practice. METHODS: A group of multidisciplinary experts from Portugal met to discuss and highlight practical recommendations, supported on both literature and clinical insights, for the management of the treatment with ibrutinib. RESULTS/DISCUSSION: Handling of both toxicities and drug-drug interactions during ibrutinib treatment poses several challenges to healthcare providers and can benefit from a multidisciplinary approach. The involvement of specialties, such as cardiology, infectiology and pharmacology, can bring an added value to patient care, not only in anticipating/managing safety issues and dose adjustments but also in enhancing adherence to treatment, ultimately improving the risk/benefit balance. CONCLUSION: By involving a multidisciplinary group of experts, this work provides a set of key recommendations to optimize care and outcomes for ibrutinib-treated patients. Despite not being a fully comprehensive review on the topic, it is intended as a framework to hematologists and other healthcare professionals who manage these patients in their daily clinical practice. FAU - Carda, Jose Pedro AU - Carda JP AUID- ORCID: 0000-0002-8198-9812 AD - Servico de Hematologia Clinica, Faculdade de Medicina da Universidade de Coimbra, Centro Hospitalar e Universitario de Coimbra, Coimbra Institute for Clinical and Biomedical Research (iCBR), Coimbra, Portugal. FAU - Santos, Lurdes AU - Santos L AUID- ORCID: 0000-0002-0622-6823 AD - Centro Hospitalar Universitario de Sao Joao, Faculdade de Medicina, Universidade do Porto, Porto, Portugal. AD - Nephrology and Infectious Diseases R&D, I3S - Instituto de Investigacao e Inovacao em Saude, Universidade do Porto, Porto, Portugal. FAU - Mariz, Jose Mario AU - Mariz JM AUID- ORCID: 0000-0003-0240-4749 AD - Onco-Haematology Clinic, Instituto Portugues de Oncologia do Porto, EPE/IPOFG - CRO, Porto, Portugal. FAU - Monteiro, Pedro AU - Monteiro P AUID- ORCID: 0000-0002-6631-207X AD - Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal. FAU - Goncalves, Humberto Miguel AU - Goncalves HM AD - Servico Farmaceutico, Instituto Portugues de Oncologia de Lisboa, Francisco Gentil, Lisboa, Portugal. FAU - Raposo, Joao AU - Raposo J AD - Centro Hospitalar Universitario Lisboa Norte, EPE, Lisboa, Portugal. FAU - Gomes da Silva, Maria AU - Gomes da Silva M AUID- ORCID: 0000-0002-6993-2450 AD - Instituto Portugues de Oncologia de Lisboa, Francisco Gentil, EPE, Lisbon, Portugal. LA - eng PT - Journal Article PL - England TA - Hematology JT - Hematology (Amsterdam, Netherlands) JID - 9708388 RN - 0 (Piperidines) RN - 0 (Protein Kinase Inhibitors) RN - 1X70OSD4VX (ibrutinib) RN - EC 2.7.10.2 (Agammaglobulinaemia Tyrosine Kinase) RN - EC 2.7.10.2 (BTK protein, human) RN - JAC85A2161 (Adenine) SB - IM MH - Adenine/adverse effects/*analogs & derivatives/therapeutic use MH - Agammaglobulinaemia Tyrosine Kinase/antagonists & inhibitors MH - Disease Management MH - Humans MH - Leukemia, B-Cell/*drug therapy/epidemiology MH - Patient Care MH - Piperidines/adverse effects/*therapeutic use MH - Portugal/epidemiology MH - Protein Kinase Inhibitors/adverse effects/*therapeutic use OTO - NOTNLM OT - B-cell malignancies OT - Bruton tyrosine kinase inhibitor OT - ibrutinib OT - recommendations EDAT- 2021/10/05 06:00 MHDA- 2021/10/29 06:00 CRDT- 2021/10/04 08:44 PHST- 2021/10/04 08:44 [entrez] PHST- 2021/10/05 06:00 [pubmed] PHST- 2021/10/29 06:00 [medline] AID - 10.1080/16078454.2021.1980690 [doi] PST - ppublish SO - Hematology. 2021 Dec;26(1):785-798. doi: 10.1080/16078454.2021.1980690. PMID- 34604797 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260726 IS - 2666-0873 (Electronic) IS - 2666-0873 (Linking) VI - 3 IP - 3 DP - 2021 Sep TI - Cardiovascular Manifestations From Therapeutic Radiation: A Multidisciplinary Expert Consensus Statement From the International Cardio-Oncology Society. PG - 360-380 LID - 10.1016/j.jaccao.2021.06.003 [doi] AB - Radiation therapy is a cornerstone of cancer therapy, with >50% of patients undergoing therapeutic radiation. As a result of widespread use and improved survival, there is increasing focus on the potential long-term effects of ionizing radiation, especially cardiovascular toxicity. Radiation therapy can lead to atherosclerosis of the vasculature as well as valvular, myocardial, and pericardial dysfunction. We present a consensus statement from the International Cardio-Oncology Society based on general principles of radiotherapy delivery and cardiovascular risk assessment and risk mitigation in this population. Anatomical-based recommendations for cardiovascular management and follow-up are provided, and a priority is given to the early detection of atherosclerotic vascular disease on imaging to help guide preventive therapy. Unique management considerations in radiation-induced cardiovascular disease are also discussed. Recommendations are based on the most current literature and represent a unanimous consensus by the multidisciplinary expert panel. CI - (c) 2021 The Authors. FAU - Mitchell, Joshua D AU - Mitchell JD AD - Cardio-Oncology Center of Excellence, Washington University in St. Louis, St. Louis, Missouri, USA. FAU - Cehic, Daniel A AU - Cehic DA AD - GenesisCare, Australia. FAU - Morgia, Marita AU - Morgia M AD - Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, New South Wales, Australia. FAU - Bergom, Carmen AU - Bergom C AD - Cardio-Oncology Center of Excellence, Washington University in St. Louis, St. Louis, Missouri, USA. AD - Department of Radiation Oncology, Washington University in St. Louis, St. Louis, Missouri, USA. FAU - Toohey, Joanne AU - Toohey J AD - Department of Radiation Oncology, GenesisCare, St. Vincent's Hospital, Sydney, New South Wales, Australia. FAU - Guerrero, Patricia A AU - Guerrero PA AD - AdventHealth Orlando Cardiovascular Institute, Orlando, Florida, USA. FAU - Ferencik, Maros AU - Ferencik M AD - Knight Cardiovascular Institute, Oregon Health & Science University, Portland, Oregon, USA. FAU - Kikuchi, Robin AU - Kikuchi R AD - Division of Medical Oncology, Duke Cancer Institute, Duke University, Durham, North Carolina, USA. FAU - Carver, Joseph R AU - Carver JR AD - Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA. FAU - Zaha, Vlad G AU - Zaha VG AD - Cardiology Division, Department of Internal Medicine, Harold C. Simmons Comprehensive Cancer Center, Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA. AD - Parkland Health and Hospital System, Dallas, Texas, USA. FAU - Alvarez-Cardona, Jose A AU - Alvarez-Cardona JA AD - Cardio-Oncology Center of Excellence, Washington University in St. Louis, St. Louis, Missouri, USA. FAU - Szmit, Sebastian AU - Szmit S AD - Department of Pulmonary Circulation, Thromboembolic Diseases and Cardiology, Centre of Postgraduate Medical Education, European Health Centre, Otwock, Poland. FAU - Daniele, Andres J AU - Daniele AJ AD - Roffo Institute, Buenos Aires, Argentina. FAU - Lopez-Mattei, Juan AU - Lopez-Mattei J AD - Departments of Cardiology and Thoracic Imaging, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. FAU - Zhang, Lili AU - Zhang L AD - Cardio-Oncology Program, Division of Cardiology, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA. FAU - Herrmann, Jorg AU - Herrmann J AD - Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA. FAU - Nohria, Anju AU - Nohria A AD - Cardio-Oncology Program, Dana Farber Cancer Institute/Brigham and Women's Hospital, Boston, Massachusetts, USA. FAU - Lenihan, Daniel J AU - Lenihan DJ AD - Cardio-Oncology Center of Excellence, Washington University in St. Louis, St. Louis, Missouri, USA. FAU - Dent, Susan F AU - Dent SF AD - Division of Medical Oncology, Duke Cancer Institute, Duke University, Durham, North Carolina, USA. LA - eng GR - R01 HL147884/HL/NHLBI NIH HHS/United States GR - UL1 TR002345/TR/NCATS NIH HHS/United States PT - Journal Article PT - Review DEP - 20210921 PL - United States TA - JACC CardioOncol JT - JACC. CardioOncology JID - 101761697 PMC - PMC8463721 OTO - NOTNLM OT - CABG, coronary artery bypass graft OT - CAC, coronary artery calcium OT - CAD, coronary artery disease OT - CI, confidence interval OT - CT, computed tomography OT - CTCA, computed tomography coronary angiography OT - CV, cardiovascular OT - DIBH, deep inspiratory breath hold OT - HF, heart failure OT - HL, Hodgkin lymphoma OT - HNC, head and neck cancer OT - HR, hazard ratio OT - LIMA, left internal mammary artery OT - MRI, magnetic resonance imaging OT - NT-proBNP, N-terminal pro-B-type natriuretic peptide OT - OR, odds ratio OT - PAD, peripheral arterial disease OT - RT, radiation therapy OT - SAVR, surgical aortic valve replacement OT - SVC, superior vena cava OT - TAVR, transcatheter aortic valve replacement OT - TTE, transthoracic echocardiogram OT - aHR, adjusted hazard ratio OT - cancer OT - cardiovascular disease OT - imaging OT - prevention OT - radiation therapy OT - screening COIS- Research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number UL1TR002345 as well as by the National Institutes of Health grant R01 HL147884. Dr Mitchell has received research funding from Pfizer, Longer Life Foundation, and Children's Discovery Institute; and is a consultant for Pfizer (modest). Dr Bergrom has received research support from the Susan G. Komen Foundation and Innovation Pathways. Dr Ferencik has received research support from the National Institutes of Health and the American Heart Association; and is a consultant for Biograph, Inc (unrelated to current work). Dr Szmit has received personal fees from Amgen, Angelini, AstraZeneca, Bayer, Berlin-Chemie, Bristol Myers Squibb, Clinigen, Janssen-Cilag, Pfizer, Polpharma, Roche, and TEVA. Dr Zaha has received support from the Cancer Prevention Research Institute of Texas (RP180404). Dr Herrmann was supported by the National Cancer Institute of the National Institutes of Health (CA233610), the Miami Heart Foundation, and the Mayo Clinic. Dr Nohria has received research funding from Amgen, Inc; and is a consultant for Takeda Oncology and AstraZeneca. Dr Lenihan has received research funding from Myocardial Solutions; and is a consultant for Lilly, Prothena, AstraZeneca, Roche, Clementia, and Eidos (all consultancy renumeration is modest). Dr Dent has received research funding from Novartis; and is a consultant for Novartis and Eli Lilly. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2021/10/05 06:00 MHDA- 2021/10/05 06:01 PMCR- 2021/09/21 CRDT- 2021/10/04 06:16 PHST- 2021/01/14 00:00 [received] PHST- 2021/06/09 00:00 [revised] PHST- 2021/06/14 00:00 [accepted] PHST- 2021/10/04 06:16 [entrez] PHST- 2021/10/05 06:00 [pubmed] PHST- 2021/10/05 06:01 [medline] PHST- 2021/09/21 00:00 [pmc-release] AID - S2666-0873(21)00149-6 [pii] AID - 10.1016/j.jaccao.2021.06.003 [doi] PST - epublish SO - JACC CardioOncol. 2021 Sep 21;3(3):360-380. doi: 10.1016/j.jaccao.2021.06.003. eCollection 2021 Sep. PMID- 34604746 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220716 IS - 2632-1823 (Electronic) IS - 2632-1823 (Linking) VI - 3 IP - 3 DP - 2021 Sep TI - Oxacillin plus ertapenem combination therapy leads to rapid blood culture clearance and positive outcomes among patients with persistent MSSA bacteraemia: a case series. PG - dlab148 LID - 10.1093/jacamr/dlab148 [doi] LID - dlab148 AB - BACKGROUND: Bloodstream infections caused by MSSA are associated with significant morbidity and mortality. Traditional treatment of MSSA bacteraemia includes an IV antistaphylococcal beta-lactam and surgical source control when indicated. OBJECTIVES: To evaluate the time to blood culture clearance as well as in-hospital and 90 day mortality in patients with persistent MSSA bacteraemia treated with combination antistaphylococcal penicillin plus carbapenem therapy. METHODS: Consecutive patients with persistent MSSA bacteraemia treated with combination therapy were identified by study investigators and reviewed by independent clinicians. The decision to initiate combination therapy was made by the consulting clinician or by the institution's multidisciplinary endocarditis team. RESULTS: Among 10 patients with a median of 5 days of persistent MSSA bacteraemia, treatment with an antistaphylococcal penicillin plus carbapenem led to sterilization of blood cultures in all patients. Blood culture clearance occurred in a median of 1 day and patients received a median of 6 days of combination treatment. Four of seven patients who underwent source control of their primary site of infection cleared their bacteraemia on combination therapy prior to the surgical intervention. All patients survived to hospital discharge and 90 days post-discharge. CONCLUSIONS: These data extend prior findings and provide further evidence that suggests the potential benefits of combination therapy among patients with persistent MSSA bacteraemia. CI - (c) The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. FAU - El-Dalati, Sami AU - El-Dalati S AUID- ORCID: 0000-0003-2603-2951 AD - Division of Infectious Diseases, Department of Internal Medicine, University of Pittsburgh Medical Center, 3601 Fifth Avenue, Pittsburgh, PA 15213, USA. FAU - Sridaran, Sanjay AU - Sridaran S AD - Department of Internal Medicine, University of Pittsburgh Medical Center, 200 Lothrop Street, Pittsburgh, PA 15213, USA. FAU - Uricchio, Marissa AU - Uricchio M AD - Department of Pharmacy, University of Pittsburgh Medical Center, 3501 Terrace Street, Pittsburgh, PA 15213, USA. FAU - Kline, Ellen G AU - Kline EG AD - Division of Infectious Diseases, Department of Internal Medicine, University of Pittsburgh Medical Center, 3601 Fifth Avenue, Pittsburgh, PA 15213, USA. FAU - Shields, Ryan AU - Shields R AD - Division of Infectious Diseases, Department of Internal Medicine, University of Pittsburgh Medical Center, 3601 Fifth Avenue, Pittsburgh, PA 15213, USA. LA - eng GR - R03 AI144636/AI/NIAID NIH HHS/United States GR - R21 AI151363/AI/NIAID NIH HHS/United States PT - Journal Article DEP - 20210929 PL - England TA - JAC Antimicrob Resist JT - JAC-antimicrobial resistance JID - 101765283 PMC - PMC8480914 EDAT- 2021/10/05 06:00 MHDA- 2021/10/05 06:01 PMCR- 2021/09/29 CRDT- 2021/10/04 06:15 PHST- 2021/07/12 00:00 [received] PHST- 2021/09/02 00:00 [accepted] PHST- 2021/10/04 06:15 [entrez] PHST- 2021/10/05 06:00 [pubmed] PHST- 2021/10/05 06:01 [medline] PHST- 2021/09/29 00:00 [pmc-release] AID - dlab148 [pii] AID - 10.1093/jacamr/dlab148 [doi] PST - epublish SO - JAC Antimicrob Resist. 2021 Sep 29;3(3):dlab148. doi: 10.1093/jacamr/dlab148. eCollection 2021 Sep. PMID- 34602268 OWN - NLM STAT- MEDLINE DCOM- 20211028 LR - 20211028 IS - 1557-9808 (Electronic) IS - 1557-9808 (Linking) VI - 24 IP - 2 DP - 2021 Jun TI - Hybrid Surgical and Endovascular Management of Ascending and Arch Dissection. PG - 100755 LID - S1089-2516(21)00036-6 [pii] LID - 10.1016/j.tvir.2021.100755 [doi] AB - Historically, a variety of non-dissection proximal aortic pathologies with suitable anatomy have been treated with thoracic endovascular aortic repair (TEVAR) with high technical success rates. However, TEVAR use for acute type A aortic dissection has been extremely limited due to the unique challenging anatomic and clinical features and the lack of specifically-designed endoprostheses. These features include: proximity of the aortic valve, coronary arteries, and supra-aortic vessels, related aortic insufficiency, diffusely dilated aorta diameter, entry tear extension into the aortic root and/or aortic arch, the dissection involvement of supra-aortic vessels, high degrees of ascending aortic curvature and notable length discrepancies between the greater and lesser curvatures, and tissue fragility at prosthesis-tissue transition zones. Additionally, the presence of patent coronary artery bypass grafting conduits on the ascending aorta is another factor precluding endovascular options and hybrid surgical and endovascular approaches may be considered. In contrast, early feasibility clinical trials of investigational devices specifically designed to treat type A aortic dissections have been currently underway. In our opinion, the location and extent of intimal tears are quite variable and only a minority of patients with type A aortic dissection are deemed suitable candidates for ascending TEVAR. On the contrary, combined application of aortic arch endograft, as demonstrated in the present report, likely increases TEVAR candidacy as well as procedural success rates. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - Fukuhara, Shinichi AU - Fukuhara S AD - Department of Cardiac Surgery, University of Michigan, Ann Arbor, MI. Electronic address: fukuhara@med.umich.edu. FAU - Yang, Bo AU - Yang B AD - Department of Cardiac Surgery, University of Michigan, Ann Arbor, MI. FAU - Williams, David AU - Williams D AD - Department of Radiology, University of Michigan, Ann Arbor, MI. FAU - Khaja, Minhaj S AU - Khaja MS AD - Department of Radiology, University of Michigan, Ann Arbor, MI. FAU - Patel, Himanshu AU - Patel H AD - Department of Cardiac Surgery, University of Michigan, Ann Arbor, MI. LA - eng PT - Journal Article DEP - 20210726 PL - United States TA - Tech Vasc Interv Radiol JT - Techniques in vascular and interventional radiology JID - 9806675 SB - IM MH - *Aortic Aneurysm, Thoracic/diagnostic imaging/surgery MH - Blood Vessel Prosthesis MH - *Blood Vessel Prosthesis Implantation/adverse effects MH - Dissection MH - *Endovascular Procedures/adverse effects MH - Humans MH - Retrospective Studies MH - Stents MH - Treatment Outcome OTO - NOTNLM OT - Type A aortic dissection OT - hybrid ascending and aortic arch repair OT - multidisciplinary team approach OT - thoracic endovascular aortic repair OT - type B aortic dissection EDAT- 2021/10/05 06:00 MHDA- 2021/10/29 06:00 CRDT- 2021/10/04 05:35 PHST- 2021/10/04 05:35 [entrez] PHST- 2021/10/05 06:00 [pubmed] PHST- 2021/10/29 06:00 [medline] AID - S1089-2516(21)00036-6 [pii] AID - 10.1016/j.tvir.2021.100755 [doi] PST - ppublish SO - Tech Vasc Interv Radiol. 2021 Jun;24(2):100755. doi: 10.1016/j.tvir.2021.100755. Epub 2021 Jul 26. PMID- 34602081 OWN - NLM STAT- MEDLINE DCOM- 20211006 LR - 20240403 IS - 1750-1172 (Electronic) IS - 1750-1172 (Linking) VI - 16 IP - 1 DP - 2021 Oct 3 TI - Expert opinion on monitoring symptomatic hereditary transthyretin-mediated amyloidosis and assessment of disease progression. PG - 411 LID - 10.1186/s13023-021-01960-9 [doi] LID - 411 AB - BACKGROUND: Hereditary transthyretin-mediated amyloidosis, also known as ATTRv amyloidosis (v for variant), is a rare, autosomal dominant, fatal disease, in which systemic amyloid progressively impairs multiple organs, leading to disability and death. The recent approval of disease-modifying therapies offers the hope of stabilization or eventual reversal of disease progression, and yet highlights a lack of disease-management guidance. A multidisciplinary panel of expert clinicians from France and the US came to consensus on monitoring the disease and identifying progression through a clinical opinion questionnaire, a roundtable meeting, and multiple rounds of feedback. MONITORING DISEASE AND PROGRESSION: A multidisciplinary team should monitor ATTRv amyloidosis disease course by assessing potential target organs at baseline and during follow-up for signs and symptoms of somatic and autonomic neuropathy, cardiac dysfunction and restrictive cardiomyopathy, and other manifestations. Variability in penetrance, symptoms, and course of ATTRv amyloidosis requires that all patients, regardless of variant status, undergo regular and standardized assessment in all these categories. Progression in ATTRv amyloidosis may be indicated by: worsening of several existing quantifiable symptoms or signs; the appearance of a new symptom; or the worsening of a single symptom that results in a meaningful functional impairment. CONCLUSIONS: We suggest that a multisystem approach to monitoring the signs and symptoms of ATTRv amyloidosis best captures the course of the disease. We hope this work will help form the basis of further, consensus-based guidance for the treatment of ATTRv amyloidosis. CI - (c) 2021. The Author(s). FAU - Adams, David AU - Adams D AD - Universite Paris-Saclay, U1195, INSERM, Le Kremlin Bicetre, France. AD - Neurology Department, AP-HP, CHU Bicetre, Le Kremlin Bicetre, France. FAU - Algalarrondo, Vincent AU - Algalarrondo V AD - Cardiology Department, CHU Bichat-Claude-Bernard, 46 rue Henri Huchard, 75018, Paris, France. FAU - Polydefkis, Michael AU - Polydefkis M AD - Department of Neurology, Johns Hopkins Hospital, 855 North Wolfe Street, Baltimore, MD, 21205, USA. FAU - Sarswat, Nitasha AU - Sarswat N AD - Department of Medicine, University of Chicago, 5841 S Maryland Ave, Chicago, IL, 60637, USA. FAU - Slama, Michel S AU - Slama MS AD - Cardiology Department, CHU Bichat-Claude-Bernard, 46 rue Henri Huchard, 75018, Paris, France. FAU - Nativi-Nicolau, Jose AU - Nativi-Nicolau J AUID- ORCID: 0000-0002-5481-2122 AD - Department of Internal Medicine, University of Utah, 30 N 1900 E, Salt Lake City, UT, 84132, USA. nativinicolau.jose@mayo.edu. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20211003 PL - England TA - Orphanet J Rare Dis JT - Orphanet journal of rare diseases JID - 101266602 RN - 0 (Prealbumin) SB - IM MH - *Amyloid Neuropathies, Familial/diagnosis/genetics MH - Consensus MH - Disease Progression MH - Humans MH - *Prealbumin PMC - PMC8489116 OTO - NOTNLM OT - ATTRv amyloidosis OT - Amyloid cardiomyopathies OT - Amyloid neuropathies OT - Diagnostic techniques and procedures OT - Disease progression OT - Familial OT - Transthyretin OT - hATTR amyloidosis COIS- DA acknowledges consultancy fees and institutional grants from Alnylam Pharmaceuticals and Pfizer Inc., and symposium honoraria from Pfizer Inc. outside the submitted work. VA reports consultancy fees from Pfizer Inc. and consultancy fees and institutional grants from Alnylam Pharmaceuticals outside the submitted work. JN-N's institution received funding for clinical trials for Pfizer Inc., Akcea Therapeutics, and Eidos, and educational grants from Pfizer Inc., and received consulting income from Pfizer Inc., Eidos, Akcea Therapeutics, and Alnylam Pharmaceuticals outside the submitted work. MP reports consultancy and principal investigator fees from Alnylam Pharmaceuticals in relation to this work and from Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Pfizer Inc. outside the submitted work. NS reports funding for clinical trials for Pfizer, Akcea/Ionis, Alnylam, and Eidos, and consulting income from Pfizer, Akcea, and Alnylam. MSS acknowledges personal consultancy fees and symposium honoraria from Alnylam Pharmaceuticals and Pfizer Inc. outside the submitted work. The authors were not paid for their work developing the manuscript. The sponsor initially contacted the authors to ascertain their interest in writing the manuscript but had no role in the design, execution, interpretation, or writing of the study. EDAT- 2021/10/05 06:00 MHDA- 2021/10/07 06:00 PMCR- 2021/10/03 CRDT- 2021/10/04 05:30 PHST- 2021/03/19 00:00 [received] PHST- 2021/07/18 00:00 [accepted] PHST- 2021/10/04 05:30 [entrez] PHST- 2021/10/05 06:00 [pubmed] PHST- 2021/10/07 06:00 [medline] PHST- 2021/10/03 00:00 [pmc-release] AID - 10.1186/s13023-021-01960-9 [pii] AID - 1960 [pii] AID - 10.1186/s13023-021-01960-9 [doi] PST - epublish SO - Orphanet J Rare Dis. 2021 Oct 3;16(1):411. doi: 10.1186/s13023-021-01960-9. PMID- 34600866 OWN - NLM STAT- MEDLINE DCOM- 20211130 LR - 20220531 IS - 1875-2128 (Electronic) IS - 1875-2128 (Linking) VI - 114 IP - 10 DP - 2021 Oct TI - Current treatment of symptomatic aortic stenosis in elderly patients: Do risk scores really matter after 80 years of age? PG - 624-633 LID - S1875-2136(21)00135-2 [pii] LID - 10.1016/j.acvd.2021.06.011 [doi] AB - BACKGROUND: According to the guidelines, surgical aortic valve replacement (SAVR) is recommended in patients at low surgical risk (EuroSCORE II<4%), whereas for other patients, the decision between transcatheter aortic valve implantation (TAVI) and surgery should be made by the Heart Team, with TAVI being favoured in elderly patients. AIM: The RAC prospective multicentre survey assessed the respective contributions of age and surgical risk scores in therapeutic decision making in elderly patients with severe symptomatic aortic stenosis. METHODS: In September and October 2016, 1049 consecutive patients aged >/= 75 years were included in 32 centres with on-site TAVI and surgical facilities. The primary endpoint was the decision between medical management, TAVI or SAVR. RESULTS: Mean age was 84+/-5 years and 53% of patients were female. The surgical risk was classified as high (EuroSCORE II>8%) in 18% of patients, intermediate (EuroSCORE II 4-8%) in 34% and low (EuroSCORE II/= 80 years were referred for TAVI, despite a low estimated surgical risk. CONCLUSIONS: The impact of risk scores depends strongly on age, and decreases considerably after 80 years, most patients being referred for TAVI, independent of their estimated surgical risk. Despite medical advancements, 10% of patients were still denied any intervention. CI - Copyright (c) 2021 Elsevier Masson SAS. All rights reserved. FAU - Bouleti, Claire AU - Bouleti C AD - CIC Inserm 1402, Cardiology Department, Poitiers University Hospital, Poitiers University, 2, rue de la Miletrie, 86000 Poitiers, France. Electronic address: claire.bouleti@gmail.com. FAU - Michel, Morgane AU - Michel M AD - ECEVE UMR 1123, Inserm, Hopital Robert-Debre, URC Eco, Hotel-Dieu, AP-HP, 75019 Paris, France. FAU - Jobbe Duval, Antoine AU - Jobbe Duval A AD - Nantes University Hospital, 44903 Nantes, France. FAU - Hemery, Thibaut AU - Hemery T AD - Rouen University Hospital, 76000 Rouen, France. FAU - Nicol, Pierre-Philippe AU - Nicol PP AD - Brest University Hospital, 29200 Brest, France. FAU - Didier, Romain AU - Didier R AD - Brest University Hospital, 29200 Brest, France. FAU - Zeyons, Floriane AU - Zeyons F AD - Strasbourg University Hospital, 67200 Strasbourg, France. FAU - Zouaghi, Oualid AU - Zouaghi O AD - Clinique du Tonkin, 69100 Villeurbanne, France. FAU - Tchetche, Didier AU - Tchetche D AD - Clinique Pasteur, 31076 Toulouse, France. FAU - Delon, Clemence AU - Delon C AD - Toulouse University Hospital, 31059 Toulouse, France. FAU - Delomez, Maxence AU - Delomez M AD - Polyclinique du Bois, 59000 Lille, France. FAU - Dibie, Alain AU - Dibie A AD - Institut Mutualiste Montsouris, 75014 Paris, France. FAU - Attias, David AU - Attias D AD - Centre Cardiologique du Nord, 93200 Saint-Denis, France. FAU - Le Breton, Herve AU - Le Breton H AD - Pontchaillou University Hospital, 35000 Rennes, France. FAU - Cormier, Bertrand AU - Cormier B AD - Institut Cardiovasculaire Paris Sud, 91300 Massy, France. FAU - Obadia, Jean-Francois AU - Obadia JF AD - Hopital Cardiothoracique Louis-Pradel, 69500 Bron, France. FAU - Tribouilloy, Christophe AU - Tribouilloy C AD - Amiens University Hospital, 80054 Amiens, France. FAU - Lansac, Emmanuel AU - Lansac E AD - Institut Mutualiste Montsouris, 75014 Paris, France. FAU - Chevreul, Karine AU - Chevreul K AD - ECEVE UMR 1123, Inserm, Hopital Robert-Debre, URC Eco, Hotel-Dieu, AP-HP, 75019 Paris, France. FAU - Naccache, Nicole AU - Naccache N AD - Commission des Registres, French Society of Cardiology, Paris, France. FAU - Eltchaninoff, Helene AU - Eltchaninoff H AD - Rouen University Hospital, 76000 Rouen, France. FAU - Gilard, Martine AU - Gilard M AD - Brest University Hospital, 29200 Brest, France. FAU - Iung, Bernard AU - Iung B AD - Bichat Hospital, DHU Fire, Universite de Paris, AP-HP, 75018 Paris, France. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20210929 PL - Netherlands TA - Arch Cardiovasc Dis JT - Archives of cardiovascular diseases JID - 101465655 SB - IM MH - Aged MH - Aged, 80 and over MH - *Aortic Valve Stenosis/diagnostic imaging/surgery MH - Female MH - *Heart Valve Prosthesis Implantation/adverse effects MH - Humans MH - Male MH - Prospective Studies MH - Risk Assessment MH - Risk Factors MH - Severity of Illness Index OTO - NOTNLM OT - Aortic stenosis OT - Remplacement valvulaire aortique chirurgical OT - Remplacement valvulaire aortique percutane OT - Risk assessment OT - Risque operatoire OT - Retrecissement aortique OT - Surgical aortic valve replacement OT - Transcatheter aortic valve implantation EDAT- 2021/10/04 06:00 MHDA- 2021/12/01 06:00 CRDT- 2021/10/03 20:37 PHST- 2021/03/08 00:00 [received] PHST- 2021/04/28 00:00 [revised] PHST- 2021/06/10 00:00 [accepted] PHST- 2021/10/04 06:00 [pubmed] PHST- 2021/12/01 06:00 [medline] PHST- 2021/10/03 20:37 [entrez] AID - S1875-2136(21)00135-2 [pii] AID - 10.1016/j.acvd.2021.06.011 [doi] PST - ppublish SO - Arch Cardiovasc Dis. 2021 Oct;114(10):624-633. doi: 10.1016/j.acvd.2021.06.011. Epub 2021 Sep 29. PMID- 34600085 OWN - NLM STAT- MEDLINE DCOM- 20211230 LR - 20211230 IS - 1916-7075 (Electronic) IS - 0828-282X (Linking) VI - 37 IP - 12 DP - 2021 Dec TI - Cardiomyopathy and Pregnancy: Considerations for Women With Severely Reduced Left Ventricular Dysfunction. PG - 2067-2075 LID - S0828-282X(21)00744-3 [pii] LID - 10.1016/j.cjca.2021.09.023 [doi] AB - Women with dilated cardiomyopathy or left ventricular (LV) dysfunction (LV ejection fraction [LVEF] < 40%) from other etiology are at increased risk of maternal and fetal mortality and morbidity. They should undergo preconception evaluation, risk assessment, and treatment modification including discontinuation and replacement of contraindicated medications. A close follow-up and treatment by a multidisciplinary team is recommended at all stages: preconception, gestation, delivery, and postpartum. An early gestational and delivery plan has to be prepared to face complications and to achieve a successful delivery and outcome. Long-term postpartum cardiac follow-up is recommended anticipating potential adverse effects of pregnancy. The recommended mode of delivery for most patients is vaginal. The indications for cesarian section are mainly obstetric, unless the patient is in severely decompensated heart failure or urgent delivery if the patient is receiving warfarin therapy. Cardiac events during pregnancy or in the first months postpartum occur in 32%-60% of patients. Prepregnancy signs of heart failure, atrial fibrillation, and New York Heart Association functional classification (NYHA FC) > II were associated with a poor cardiac outcome. Predictors of deterioration during pregnancy that are considered very high risk and should be advised to avoid pregnancy are: patients with NYHA FC III/IV unless improved under treatment and LVEF < 20%. Predictors for high risk of adverse outcome include: LVEF < 30%, NYHA FC II, ventricular tachyarrhythmias (including patients with implantable cardioverter defibrillator or cardiac resynchronization therapy defibrillator),atrial fibrillation with rapid ventricular rate, severe mitral regurgitation, significant right ventricular failure, and hypotension. Overall, despite a high rate of complications, most women with LV dysfunction can undergo a successful pregnancy. CI - Copyright (c) 2021 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved. FAU - Shotan, Avraham AU - Shotan A AD - Heart Institute, Laniado Medical Center, Netanya, Adelson School of Medicine, Ariel University, Israel. Electronic address: avraham@shotana.com. FAU - Roos-Hesselink, Jolien AU - Roos-Hesselink J AD - Department of Cardiology, Erasmus Medical Center, Rotterdam, The Netherlands. FAU - Baris, Lucia AU - Baris L AD - Department of Cardiology, Erasmus Medical Center, Rotterdam, The Netherlands. FAU - Goland, Sorel AU - Goland S AD - Heart Institute, Kaplan Medical Center, Rehovot, Hebrew University, Jerusalem, Israel. FAU - Yekel, Yael AU - Yekel Y AD - Obstetrics and Gynecology Department, Laniado Medical Center, Netanya, Adelson School of Medicine, Ariel University Israel. FAU - Elkayam, Uri AU - Elkayam U AD - Department of Medicine, Division of Cardiovascular Medicine and Department of Obstetrics and Gynecology, University of Southern California, Keck School of Medicine, Los Angeles, California, USA. LA - eng PT - Journal Article PT - Review DEP - 20210929 PL - England TA - Can J Cardiol JT - The Canadian journal of cardiology JID - 8510280 SB - IM MH - Cardiomyopathies/complications/*diagnosis/epidemiology MH - Diagnostic Imaging/*methods MH - Female MH - Global Health MH - Humans MH - Incidence MH - Patient Acuity MH - Pregnancy MH - Pregnancy Complications, Cardiovascular/*diagnosis/epidemiology MH - Ventricular Dysfunction, Left/*diagnosis/epidemiology/etiology EDAT- 2021/10/03 06:00 MHDA- 2021/12/31 06:00 CRDT- 2021/10/02 20:11 PHST- 2021/04/27 00:00 [received] PHST- 2021/08/26 00:00 [revised] PHST- 2021/09/16 00:00 [accepted] PHST- 2021/10/03 06:00 [pubmed] PHST- 2021/12/31 06:00 [medline] PHST- 2021/10/02 20:11 [entrez] AID - S0828-282X(21)00744-3 [pii] AID - 10.1016/j.cjca.2021.09.023 [doi] PST - ppublish SO - Can J Cardiol. 2021 Dec;37(12):2067-2075. doi: 10.1016/j.cjca.2021.09.023. Epub 2021 Sep 29. PMID- 34599387 OWN - NLM STAT- MEDLINE DCOM- 20211022 LR - 20220218 IS - 1534-3170 (Electronic) IS - 1523-3782 (Print) IS - 1523-3782 (Linking) VI - 23 IP - 11 DP - 2021 Oct 1 TI - Septal Ablation Versus Surgical Myomectomy for Hypertrophic Obstructive Cardiomyopathy. PG - 165 LID - 10.1007/s11886-021-01600-5 [doi] LID - 165 AB - PURPOSE OF REVIEW: Patients with hypertrophic cardiomyopathy (HCM) who have left ventricular outflow tract obstruction (LVOTO) often experience severe symptoms and functional limitation. Relief of LVOTO can be achieved by two invasive interventions, i.e., surgery myectomy and alcohol septal ablation (ASA), leading in experienced hands to a dramatic improvement in clinical status. Despite extensive research, however, the choice of the best option in individual patients remains challenging and poses numerous clinical dilemmas. RECENT FINDINGS: Invasive strategies have been recently incorporated in recommendations for the diagnosis and treatment of HCM on both sides of the Atlantic. These guidelines are based on a bulk of well-designed but retrospective studies as well as on expert opinions. Evidence now exists that adequate evaluation and management of HCM requires a multidisciplinary team capable of choosing the best available options. Management of LVOTO still varies largely based on local expertise and patient preference. Following the trend that has emerged for other cardiac diseases amenable to invasive interventions, the concept of a "HCM heart team" is coming of age. CI - (c) 2021. The Author(s). FAU - Pelliccia, F AU - Pelliccia F AUID- ORCID: 0000-0003-1260-1308 AD - Department of Cardiovascular Sciences, University Sapienza, Via del Policlinico 155, 00161, Rome, Italy. f.pelliccia@mclink.it. FAU - Seggewiss, H AU - Seggewiss H AD - Comprehensive Heart Failure Center (CHFC), Deutsches Zentrum Fur Herzinsuffizienz (DZHI), Universitatsklinikum Wurzburg, Wurzburg, Germany. FAU - Cecchi, F AU - Cecchi F AD - Department of Cardiovascular, Neural and Metabolic Sciences, IRCCS Istituto Auxologico Italiano, San Luca Hospital, Milan, Italy. FAU - Calabro, P AU - Calabro P AD - Department of Translational Medical Sciences, University of Campania 'Luigi Vanvitelli', Naples, Italy. FAU - Limongelli, G AU - Limongelli G AD - Department of Translational Medical Sciences, University of Campania 'Luigi Vanvitelli', Naples, Italy. AD - Institute of Cardiovascular Sciences, University College of London, St. Bartholomew's Hospital, London, UK. FAU - Alfieri, O AU - Alfieri O AD - Department of Cardiovascular and Thoracic Surgery, San Raffaele University Hospital, Milan, Italy. FAU - Ferrazzi, P AU - Ferrazzi P AD - Hypertrophic Cardiomyopathy Center, Policlinico Di Monza, Monza, Italy. FAU - Yacoub, M H AU - Yacoub MH AD - Heart Science Centre, National Heart and Lung Institute, Imperial College London, London, UK. FAU - Olivotto, I AU - Olivotto I AD - Cardiomyopathy Unit, Careggi University Hospital, Florence, Italy. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20211001 PL - United States TA - Curr Cardiol Rep JT - Current cardiology reports JID - 100888969 SB - IM MH - *Cardiac Surgical Procedures MH - *Cardiomyopathy, Hypertrophic/surgery MH - *Catheter Ablation MH - Female MH - Humans MH - Retrospective Studies MH - *Uterine Myomectomy PMC - PMC8486700 OTO - NOTNLM OT - Alcohol septal ablation OT - Gradient OT - Hypertrophic cardiomyopathy OT - Left ventricular outflow tract OT - Myectomy OT - Obstruction COIS- No author has any conflict of interest to disclose. EDAT- 2021/10/03 06:00 MHDA- 2021/10/24 06:00 PMCR- 2021/10/01 CRDT- 2021/10/02 06:20 PHST- 2021/07/13 00:00 [accepted] PHST- 2021/10/02 06:20 [entrez] PHST- 2021/10/03 06:00 [pubmed] PHST- 2021/10/24 06:00 [medline] PHST- 2021/10/01 00:00 [pmc-release] AID - 10.1007/s11886-021-01600-5 [pii] AID - 1600 [pii] AID - 10.1007/s11886-021-01600-5 [doi] PST - epublish SO - Curr Cardiol Rep. 2021 Oct 1;23(11):165. doi: 10.1007/s11886-021-01600-5. PMID- 34598909 OWN - NLM STAT- MEDLINE DCOM- 20220407 LR - 20220407 IS - 2152-2669 (Electronic) IS - 2152-2669 (Linking) VI - 22 IP - 2 DP - 2022 Feb TI - The Impact of Atrial Fibrillation on hospitalization Outcomes for Patients With Chronic Lymphocytic Leukemia Using the National Inpatient Sample Database. PG - 98-104 LID - S2152-2650(21)00364-5 [pii] LID - 10.1016/j.clml.2021.08.006 [doi] AB - BACKGROUND: The incidence of atrial fibrillation (AF) in patients with chronic lymphocytic leukemia (CLL) has been on the rise. However, the excess burden added by AF to the morbidity and mortality of CLL patients especially in the hospitalized setting is undetermined. METHODS: The National Inpatient Sample (NIS) database was accessed to gather data of hospitalized CLL patients with AF from 2009 to 2018. Propensity-score matching (PSM) and logistic regression model were performed to control for baseline patient factors to match 7265 CLL patient admissions with AF and 7265 CLL patient admissions without AF. The primary outcome was all-cause mortality (ACM), while the secondary outcomes included acute coronary syndrome (ACS), acute myocardial infarction (AMI), and the need for percutaneous coronary intervention (PCI), acute heart failure (AHF), acute hypoxic respiratory failure (AHRF), cardiac arrest (CA), cardiogenic shock (CS), stroke, and the total cost of hospitalization. RESULTS: CLL patients with AF had a higher rate of ACM (6.06% vs 4.47%; odds ratio [OR] 1.39, 95% confidence interval [CI] 1.19-1.61; P =< .001). All other secondary outcomes including ACS, AMI, PCI, AHRF, CA, CS, and stroke were observed at a significantly higher rate in the AF group as well. The median total hospital cost was also higher in the AF group ($9097 vs. $7646; P value < .0001) CONCLUSION: CLL patients with AF are at a significantly increased risk of all-cause mortality, cardiac-related mortality, and stroke. For this population, a multidisciplinary approach should be orchestrated for better management and outcomes. CI - Copyright (c) 2021. Published by Elsevier Inc. FAU - Ammad Ud Din, Mohammad AU - Ammad Ud Din M AD - Department of Internal Medicine, Rochester General Hospital, Rochester, NY. Electronic address: ammadahr@gmail.com. FAU - Thakkar, Samarthkumar AU - Thakkar S AD - Department of Internal Medicine, Rochester General Hospital, Rochester, NY. FAU - Patel, Harsh AU - Patel H AD - Department of Internal Medicine, Louis A. Weiss Memorial Hospital, Chicago, IL. FAU - Saeed, Hassan AU - Saeed H AD - Department of Internal Medicine, Rochester General Hospital, Rochester, NY. FAU - Hussain, Syed Ather AU - Hussain SA AD - Department of Internal Medicine, Rochester General Hospital, Rochester, NY. FAU - Liaqat, Hania AU - Liaqat H AD - Department of Internal Medicine, Rochester General Hospital, Rochester, NY. FAU - Zafar, Aneeqa AU - Zafar A AD - Department of Hospitalist Medicine, El Camino Health Mountain View Campus, Mountain View, CA. FAU - Dani, Sourbha S AU - Dani SS AD - Department of Cardiology, Lahey Hospital & Medical Center, MA. FAU - Ganatra, Sarju AU - Ganatra S AD - Department of Cardiology, Lahey Hospital & Medical Center, MA. FAU - Anwer, Faiz AU - Anwer F AD - Taussig Cancer Center, Cleveland Clinic, Cleveland, OH. LA - eng PT - Journal Article DEP - 20210828 PL - United States TA - Clin Lymphoma Myeloma Leuk JT - Clinical lymphoma, myeloma & leukemia JID - 101525386 SB - IM MH - *Atrial Fibrillation/complications/epidemiology MH - Hospital Mortality MH - Hospitalization MH - Humans MH - Inpatients MH - *Leukemia, Lymphocytic, Chronic, B-Cell/complications/epidemiology MH - *Percutaneous Coronary Intervention/adverse effects MH - Risk Factors OTO - NOTNLM OT - Arrhythmias OT - Bruton tyrosine kinase inhibitors OT - Cardio-oncology OT - Ibrutinib OT - Targeted therapy EDAT- 2021/10/03 06:00 MHDA- 2022/04/08 06:00 CRDT- 2021/10/02 05:32 PHST- 2021/07/18 00:00 [received] PHST- 2021/08/15 00:00 [revised] PHST- 2021/08/23 00:00 [accepted] PHST- 2021/10/03 06:00 [pubmed] PHST- 2022/04/08 06:00 [medline] PHST- 2021/10/02 05:32 [entrez] AID - S2152-2650(21)00364-5 [pii] AID - 10.1016/j.clml.2021.08.006 [doi] PST - ppublish SO - Clin Lymphoma Myeloma Leuk. 2022 Feb;22(2):98-104. doi: 10.1016/j.clml.2021.08.006. Epub 2021 Aug 28. PMID- 34598001 OWN - NLM STAT- MEDLINE DCOM- 20211123 LR - 20211123 IS - 1873-4499 (Electronic) IS - 0899-7071 (Linking) VI - 81 DP - 2022 Jan TI - AngioVac aspiration of right atrial cardiac pacemaker lead-associated thrombus with concurrent PE under fluoroscopic and transesophageal echocardiographic guidance: a multidisciplinary collaboration for improved patient outcome. PG - 33-36 LID - S0899-7071(21)00351-X [pii] LID - 10.1016/j.clinimag.2021.08.017 [doi] AB - In the U.S., pulmonary embolism (PE) is a common cause of cardiovascular death. Right heart thrombus (RHT) occurs in approximately 4% of patients with PE, and when concurrent is associated with increased 30-day PE-related and all-cause mortality. The consensus on optimal management of acute massive or high-risk PE is unclear, and even less so for concurrent RHT. In this report, we review a successful multidisciplinary coordination of vacuum-assisted thrombectomy (VAT) of a complex pacemaker lead-associated RHT in a patient with concurrent acute PE and significant comorbidities, using the AngioVac system (Vortex Medical, Norwell, MA). VAT is a reasonable treatment option that should be considered particularly for patients who are poor surgical or thrombolytic candidates. Procedural success and patient outcomes can be further optimized through multidisciplinary collaboration such as with the Pulmonary Embolism Response Team (PERT) model. CI - Copyright (c) 2021 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Yu, Tiffany AU - Yu T AD - Department of Radiological Sciences, University of California at Los Angeles, 757 Westwood Plaza, Los Angeles, CA 90095, United States of America. Electronic address: ttyu@mednet.ucla.edu. FAU - Yang, Eric H AU - Yang EH AD - UCLA Cardio-Oncology Program, Division of Cardiology, Department of Medicine, University of California at Los Angeles, 757 Westwood Plaza, Los Angeles, CA 90095, United States of America. Electronic address: ehyang@mednet.ucla.edu. FAU - Ranade, Mona AU - Ranade M AD - Department of Radiological Sciences, University of California at Los Angeles, 757 Westwood Plaza, Los Angeles, CA 90095, United States of America. Electronic address: mranade@mednet.ucla.edu. LA - eng PT - Journal Article PT - Review DEP - 20210830 PL - United States TA - Clin Imaging JT - Clinical imaging JID - 8911831 SB - IM MH - Echocardiography, Transesophageal MH - Humans MH - *Pacemaker, Artificial/adverse effects MH - *Pulmonary Embolism MH - Thrombectomy MH - *Thrombosis/diagnostic imaging/etiology/therapy MH - Treatment Outcome OTO - NOTNLM OT - AngioVac OT - Cardiac device lead-associated thrombus OT - Right heart thrombus OT - Thrombectomy EDAT- 2021/10/02 06:00 MHDA- 2021/11/24 06:00 CRDT- 2021/10/01 20:28 PHST- 2021/06/22 00:00 [received] PHST- 2021/07/21 00:00 [revised] PHST- 2021/08/09 00:00 [accepted] PHST- 2021/10/02 06:00 [pubmed] PHST- 2021/11/24 06:00 [medline] PHST- 2021/10/01 20:28 [entrez] AID - S0899-7071(21)00351-X [pii] AID - 10.1016/j.clinimag.2021.08.017 [doi] PST - ppublish SO - Clin Imaging. 2022 Jan;81:33-36. doi: 10.1016/j.clinimag.2021.08.017. Epub 2021 Aug 30. PMID- 34595885 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20211113 IS - 1738-5520 (Print) IS - 1738-5555 (Electronic) IS - 1738-5520 (Linking) VI - 51 IP - 11 DP - 2021 Nov TI - Association between a Multidisciplinary Team Approach and Clinical Outcomes in Patients Undergoing Extracorporeal Cardiopulmonary Resuscitation in the Emergency Department. PG - 908-918 LID - 10.4070/kcj.2021.0167 [doi] AB - BACKGROUND AND OBJECTIVES: Despite recent improvements in advanced life support, the overall survival rate after cardiac arrest remains low. We aimed to examine the association of a multidisciplinary team approach with clinical outcomes in patients undergoing extracorporeal cardiopulmonary resuscitation (ECPR) in the emergency department (ED). METHODS: This retrospective, single-center, observational study included 125 patients who underwent ECPR in the ED between May 2004-December 2018. In January 2014, our institution implemented a multidisciplinary extracorporeal membrane oxygenation (ECMO) team. Eligible patients were classified into pre-ECMO-team (n=65) and post-ECMO-team (n=60) groups. The primary outcome was in-hospital mortality. RESULTS: In-hospital mortality (72.3% vs. 58.3%, p=0.102) and poor neurological outcomes (78.5% vs. 68.3%, p=0.283) did not differ significantly between the pre- and post-ECMO-team groups. However, among the 60 patients who experienced in-hospital cardiac arrest, in-hospital mortality (75.8% vs. 40.7%, p=0.006) and poor neurological outcomes (78.8% vs. 48.1%, p=0.015) significantly decreased after the multidisciplinary team formation. Multivariable logistic regression analysis showed that the multidisciplinary team approach (adjusted odds ratio, 0.20; 95% confidence interval, 0.07-0.61; p=0.005) was an independent prognostic factor for in-hospital mortality in in-hospital cardiac arrest patients. CONCLUSIONS: A multidisciplinary team approach was associated with improved clinical outcomes in in-hospital cardiac arrest patients undergoing ECPR in the ED. These findings may help in improving the selection criteria for ECPR in the ED. Further studies to overcome the study limitations may help improving the outcomes of out-of-hospital cardiac arrest patients. CI - Copyright (c) 2021. The Korean Society of Cardiology. FAU - Lee, Ji Han AU - Lee JH AUID- ORCID: 0000-0003-1972-6170 AD - Department of Emergency Medicine, Chungbuk National University Hospital, Cheongju, Korea. FAU - Ko, Ryoung Eun AU - Ko RE AUID- ORCID: 0000-0003-4945-5623 AD - Department of Critical Care Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Park, Taek Kyu AU - Park TK AUID- ORCID: 0000-0003-1440-3583 AD - Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Cho, Yang Hyun AU - Cho YH AUID- ORCID: 0000-0003-1685-3641 AD - Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Suh, Gee Young AU - Suh GY AUID- ORCID: 0000-0001-5473-1712 AD - Department of Critical Care Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Yang, Jeong Hoon AU - Yang JH AUID- ORCID: 0000-0001-8138-1367 AD - Department of Critical Care Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. AD - Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. jhysmc@gmail.com. LA - eng PT - Journal Article DEP - 20210827 PL - Korea (South) TA - Korean Circ J JT - Korean circulation journal JID - 101247141 PMC - PMC8558569 OTO - NOTNLM OT - Cardiac arrest OT - Emergency medicine OT - Extracorporeal life support OT - Resuscitation COIS- The authors have no financial conflicts of interest. EDAT- 2021/10/02 06:00 MHDA- 2021/10/02 06:01 PMCR- 2021/11/01 CRDT- 2021/10/01 07:57 PHST- 2021/05/12 00:00 [received] PHST- 2021/07/19 00:00 [revised] PHST- 2021/08/18 00:00 [accepted] PHST- 2021/10/02 06:00 [pubmed] PHST- 2021/10/02 06:01 [medline] PHST- 2021/10/01 07:57 [entrez] PHST- 2021/11/01 00:00 [pmc-release] AID - 51.e112 [pii] AID - 10.4070/kcj.2021.0167 [doi] PST - ppublish SO - Korean Circ J. 2021 Nov;51(11):908-918. doi: 10.4070/kcj.2021.0167. Epub 2021 Aug 27. PMID- 34595498 OWN - NLM STAT- MEDLINE DCOM- 20211125 LR - 20211125 IS - 1940-8250 (Electronic) IS - 0279-5442 (Linking) VI - 41 IP - 5 DP - 2021 Oct 1 TI - Promoting Early Mobility in Patients After Transcatheter Aortic Valve Replacement: An Evidence-Based Protocol. PG - e9-e16 LID - 10.4037/ccn2021925 [doi] AB - BACKGROUND: Aortic stenosis is prevalent among older adults and is commonly treated with transcatheter aortic valve replacement. Both high- and low-risk patients benefit from early mobility and discharge after this procedure; however, hospital protocols to improve patient mobility and shorten hospital stays have not been systematically implemented. OBJECTIVE: To develop and evaluate a post-transcatheter aortic valve replacement protocol to standardize care and efficiently advance patients from the operating room to discharge. METHODS: A prospective pre-post design was used to evaluate the effect of the new standardized protocol on length of stay, timing of mobility, time spent in intensive care, and quality of life in patients undergoing transcatheter aortic valve replacement between April 2019 and March 2020. INTERVENTIONS: Interventions included team-based education and integration of an evidence-based order set into the electronic health record. Education was provided to both patients and staff. RESULTS: At 6 months after implementation of the intervention, statistically significant improvements were observed in mean overall (5.26 vs 2.45 days; P = .001) and postprocedure (3.05 vs 2.16 days; P = .004) length of stay. No significant difference was found in performance on the 5-meter walk test. Quality of life improved in both groups from baseline to 30-day follow-up (P = .01). CONCLUSION: Implementation of the post-transcatheter aortic valve replacement protocol was associated with significant improvement in overall and postprocedure length of stay and improved quality of life. Additional work is needed to examine strategies to ensure safe next-day discharge. CI - (c)2021 American Association of Critical-Care Nurses. FAU - Hart, Lindsey AU - Hart L AD - Lindsey Hart is an adult-gerontology nurse practitioner in the Structural Heart Program within the Heart and Vascular Institute, Maimonides Medical Center, Brooklyn, New York. FAU - Frankel, Robert AU - Frankel R AD - Robert Frankel is vice chairman of the Department of Cardiology and director of interventional cardiology, Maimonides Medical Center. FAU - Crooke, Gregory AU - Crooke G AD - Gregory Crooke is a cardiothoracic surgeon, Maimonides Medical Center. FAU - Noto, Stefanie AU - Noto S AD - Stefanie Noto is a nurse clinician, Maimonides Medical Center. FAU - Moors, Mary Alice AU - Moors MA AD - Mary Alice Moors is the lead nurse practitioner for the cardiothoracic intensive care unit and cardiothoracic step-down unit, Maimonides Medical Center. FAU - Granger, Bradi B AU - Granger BB AD - Bradi Granger is a professor at the Duke University School of Nursing and Director of the Duke Heart Center Nursing Research Program, Durham, North Carolina. LA - eng PT - Journal Article PL - United States TA - Crit Care Nurse JT - Critical care nurse JID - 8207799 MH - Aged MH - *Aortic Valve Stenosis/surgery MH - Humans MH - Length of Stay MH - Prospective Studies MH - Quality of Life MH - Risk Factors MH - Time Factors MH - *Transcatheter Aortic Valve Replacement MH - Treatment Outcome EDAT- 2021/10/02 06:00 MHDA- 2021/11/26 06:00 CRDT- 2021/10/01 07:40 PHST- 2021/10/01 07:40 [entrez] PHST- 2021/10/02 06:00 [pubmed] PHST- 2021/11/26 06:00 [medline] AID - 31587 [pii] AID - 10.4037/ccn2021925 [doi] PST - ppublish SO - Crit Care Nurse. 2021 Oct 1;41(5):e9-e16. doi: 10.4037/ccn2021925. PMID- 34593117 OWN - NLM STAT- MEDLINE DCOM- 20211025 LR - 20211025 IS - 2211-7466 (Electronic) IS - 2211-7458 (Linking) VI - 10 IP - 4 DP - 2021 Oct TI - Revascularization in the Transcatheter Aortic Valve Replacement Population. PG - 553-563 LID - S2211-7458(21)00054-7 [pii] LID - 10.1016/j.iccl.2021.06.003 [doi] AB - Transcatheter aortic valve replacement (TAVR) is a standard treatment option for patients with severe aortic stenosis. Management of concomitant coronary artery disease (CAD) in these patients remains controversial with no randomized clinical trials to guide decision making in this cohort. The role of CAD in TAVR has been difficult to evaluate given the current heterogeneity in defining CAD, and the used methods to assess CAD. Subsequently, the role of coronary revascularization remains individualized and assessed on a case-by-case basis by the heart team. In this article, the authors discuss the rationale and prognostic role of CAD in patients undergoing TAVR. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - Alkhalil, Mohammad AU - Alkhalil M AD - Department of Cardiothoracic Services, Freeman Hospital, Newcastle-upon-Tyne NE7 7DN, UK; Vascular Biology, Newcastle University, Newcastle-upon-Tyne NE7 7DN, UK. FAU - Jabri, Ahmad AU - Jabri A AD - Case Western Reserve University/MetroHealth Medical Center, Cleveland, OH 44109, USA. FAU - Puri, Rishi AU - Puri R AD - Department of Cardiovascular Medicine, Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland, OH 44195, USA. FAU - Kalra, Ankur AU - Kalra A AD - Department of Cardiovascular Medicine, Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland, OH 44195, USA; Section of Cardiovascular Research, Heart, Vascular, and Thoracic Department, Cleveland Clinic Akron General, Akron, OH, USA; Department of Cardiovascular Medicine, Heart, Vascular, and Thoracic Institute, Cleveland Clinic, 224 West Exchange Street, Suite 225, Akron, OH 44302, USA. Electronic address: kalramd.ankur@gmail.com. LA - eng PT - Journal Article PT - Review PL - Netherlands TA - Interv Cardiol Clin JT - Interventional cardiology clinics JID - 101615153 SB - IM MH - *Aortic Valve Stenosis/surgery MH - Humans MH - Risk Factors MH - Time Factors MH - *Transcatheter Aortic Valve Replacement MH - Treatment Outcome OTO - NOTNLM OT - Aortic stenosis OT - Coronary artery disease OT - Percutaneous coronary intervention OT - Transcatheter aortic valve replacement COIS- Disclosure None. EDAT- 2021/10/02 06:00 MHDA- 2021/10/26 06:00 CRDT- 2021/10/01 05:48 PHST- 2021/10/01 05:48 [entrez] PHST- 2021/10/02 06:00 [pubmed] PHST- 2021/10/26 06:00 [medline] AID - S2211-7458(21)00054-7 [pii] AID - 10.1016/j.iccl.2021.06.003 [doi] PST - ppublish SO - Interv Cardiol Clin. 2021 Oct;10(4):553-563. doi: 10.1016/j.iccl.2021.06.003. PMID- 34592735 OWN - NLM STAT- MEDLINE DCOM- 20220603 LR - 20220603 IS - 1421-9921 (Electronic) IS - 0014-312X (Linking) VI - 63 IP - 2 DP - 2022 TI - Screening, Management, and Acceptance of Patients with Aorto-Iliac Vascular Disease for Kidney Transplantation: A Survey among 161 Transplant Surgeons. PG - 77-84 LID - 10.1159/000519208 [doi] AB - INTRODUCTION: Aorto-iliac vascular disease (AVD) is frequently found during the workup for kidney transplantation. However, recommendations on screening and management are lacking. We aimed to assess differences in screening, management, and acceptance of these patients for transplantation by performing a survey among transplant surgeons. Second, we aimed to identify center- and surgeon-related factors associated with decline or acceptance of kidney transplant candidates with AVD. METHODS: A survey was sent to transplant surgeons and urologists. The survey contained general questions (part I) and 2 patient-based cases (part II) with Trans-Atlantic Inter-Society Consensus (TASC) D and B AVD supported with videos of their CT scans. RESULTS: One hundred ninety-one (20.3%) participants responded; 171 were currently involved in kidney transplantation: 161 (94.2%) completed part I and 145 (84.8%) part II. Screening for AVD was often (38.5%) restricted to high-risk patients. The majority of respondents (67.7%) rated "technical problems" as the most important concern in case of AVD, followed by "increased mortality risk because of cardiovascular comorbidity" (29.8%). Pretransplant vascular interventions to facilitate transplantation were infrequently performed (71.4% mentioned <10 per year). Ninety (64.3%) respondents answered that an open vascular procedure should preferably be performed prior to kidney transplantation while 42 (30.0%) respondents preferred a simultaneous open vascular procedure. The decline rate was higher in the TASC D case compared to the TASC B case (26.9% and 9.7%, respectively). Respondents from centers with expertise in pretransplant vascular interventions were more likely to accept both patients with TASC D and B for transplantation. CONCLUSION: There is no uniformity in the screening, management, and acceptance of patients with AVD for transplantation. If a center declines a patient with AVD because of technical concerns, the patient should be referred for a second opinion to a tertiary center with expertise in pretransplant vascular interventions. Multidisciplinary meetings including a vascular surgeon and a cardiologist could help optimize these patients for transplantation. CI - (c) 2021 The Author(s) Published by S. Karger AG, Basel. FAU - Rijkse, Elsaline AU - Rijkse E AD - Division of HPB and Transplant Surgery, Department of Surgery, Erasmus MC Transplant Institute, Rotterdam, The Netherlands. FAU - Kimenai, Hendrikus J A N AU - Kimenai HJAN AD - Division of HPB and Transplant Surgery, Department of Surgery, Erasmus MC Transplant Institute, Rotterdam, The Netherlands. FAU - Dor, Frank J M F AU - Dor FJMF AD - Imperial College Transplant Centre, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom. AD - Department of Surgery and Cancer, Imperial College, London, United Kingdom. FAU - IJzermans, Jan N M AU - IJzermans JNM AD - Division of HPB and Transplant Surgery, Department of Surgery, Erasmus MC Transplant Institute, Rotterdam, The Netherlands. FAU - Minnee, Robert C AU - Minnee RC AD - Division of HPB and Transplant Surgery, Department of Surgery, Erasmus MC Transplant Institute, Rotterdam, The Netherlands. LA - eng PT - Journal Article DEP - 20210930 PL - Switzerland TA - Eur Surg Res JT - European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes JID - 0174752 SB - IM MH - Humans MH - Iliac Artery/surgery MH - *Kidney Transplantation MH - Risk Factors MH - *Surgeons MH - Surveys and Questionnaires MH - *Vascular Diseases/diagnosis/etiology/surgery OTO - NOTNLM OT - Atherosclerosis OT - Kidney transplantation OT - Recipient management EDAT- 2021/10/01 06:00 MHDA- 2022/06/07 06:00 CRDT- 2021/09/30 20:32 PHST- 2021/05/05 00:00 [received] PHST- 2021/08/10 00:00 [accepted] PHST- 2021/10/01 06:00 [pubmed] PHST- 2022/06/07 06:00 [medline] PHST- 2021/09/30 20:32 [entrez] AID - 000519208 [pii] AID - 10.1159/000519208 [doi] PST - ppublish SO - Eur Surg Res. 2022;63(2):77-84. doi: 10.1159/000519208. Epub 2021 Sep 30. PMID- 34589247 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220427 IS - 1301-5680 (Print) IS - 2149-8156 (Electronic) IS - 1301-5680 (Linking) VI - 29 IP - 3 DP - 2021 Jul TI - Surgical results of chronic thromboembolic pulmonary endarterectomy in our recently developed program. PG - 295-303 LID - 10.5606/tgkdc.dergisi.2021.21234 [doi] AB - BACKGROUND: In this case series, we aimed to present our diagnostic workup, surgical management, and results of the patients who underwent pulmonary endarterectomy. METHODS: In this case series, a total of 26 patients (8 males, 18 females; median age: 58 years; range, 34 to 67 years) who were evaluated by a multidisciplinary team and were diagnosed with chronic thromboembolic pulmonary hypertension who underwent pulmonary endarterectomy in our clinic between November 2015 and December 2019 were included. Pulmonary endarterectomy procedure was performed in all cases under cardiopulmonary bypass and total circulatory arrest. The results of the procedures were analyzed retrospectively. RESULTS: Perioperative complications were observed in seven patients (26.9%) and in-hospital mortality rate caused by perioperative complications was 15.38%. At one-year of postoperative follow-up, the mean systolic pulmonary artery pressure decreased from 78+/-22 mmHg to 41+/-20 mmHg, pulmonary vascular resistance decreased from 698+/-10 dyn.s.cm-5 to 235+/-10 dyn.s.cm-5, 6-min walk distance increased from 345+/-10 m to 460+/-10 m and, arterial oxygen saturation increased from 85+/-3.5% to 95+/-4%. New York Heart Association functional class improvement from Class III-IV to Class I-II was observed in most patients, and one-year mortality rate was 19.23%. CONCLUSION: We suggest that patients diagnosed chronic thromboembolic pulmonary hypertension should be referred to cardiac surgery centers for pulmonary thromboendarterectomy, early before irreversible arteriopathy occurs. CI - Copyright (c) 2021, Turkish Society of Cardiovascular Surgery. FAU - Orhan, Gokcen AU - Orhan G AUID- ORCID: 0000-0003-4809-6139 AD - Department of Cardiovascular Surgery, Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital, Istanbul, Turkey. FAU - Kuplay, Huseyin AU - Kuplay H AUID- ORCID: 0000-0002-1710-109X AD - Department of Cardiovascular Surgery, Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital, Istanbul, Turkey. FAU - Selcuk, Nehir AU - Selcuk N AD - Department of Cardiovascular Surgery, Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital, Istanbul, Turkey. FAU - Sert, Sena AU - Sert S AUID- ORCID: 0000-0003-0364-7654 AD - Department of Cardiology, Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital, Istanbul, Turkey. FAU - Yildirimturk, Ozlem AU - Yildirimturk O AUID- ORCID: 0000-0001-9841-4524 AD - Department of Cardiology, Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital, Istanbul, Turkey. LA - eng PT - Journal Article DEP - 20210726 PL - Turkey TA - Turk Gogus Kalp Damar Cerrahisi Derg JT - Turk gogus kalp damar cerrahisi dergisi JID - 100887967 PMC - PMC8462111 OTO - NOTNLM OT - Chronic thromboembolic pulmonary hypertension OT - pulmonary embolism OT - pulmonary thromboendarterectomy COIS- Conflict of Interest: The authors declared no conflicts of interest with respect to the authorship and/or publication of this article. EDAT- 2021/10/01 06:00 MHDA- 2021/10/01 06:01 PMCR- 2021/07/26 CRDT- 2021/09/30 07:14 PHST- 2020/12/21 00:00 [received] PHST- 2021/05/30 00:00 [accepted] PHST- 2021/09/30 07:14 [entrez] PHST- 2021/10/01 06:00 [pubmed] PHST- 2021/10/01 06:01 [medline] PHST- 2021/07/26 00:00 [pmc-release] AID - 10.5606/tgkdc.dergisi.2021.21234 [doi] PST - epublish SO - Turk Gogus Kalp Damar Cerrahisi Derg. 2021 Jul 26;29(3):295-303. doi: 10.5606/tgkdc.dergisi.2021.21234. eCollection 2021 Jul. PMID- 34584882 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220910 IS - 2224-4344 (Print) IS - 2224-4344 (Electronic) IS - 2224-4336 (Linking) VI - 10 IP - 8 DP - 2021 Aug TI - A narrative review of modern approach and outcomes evaluation in congenital heart defects. PG - 2114-2122 LID - 10.21037/tp-21-163 [doi] AB - OBJECTIVE: The purpose of this review is to highlight critical advances and innovative approaches to the most challenging clinical situations in congenital heart surgery, to establish a new perspective from which to evaluate current clinical practice patterns and contemporary United States program ranking systems. BACKGROUND: The past decades have witnessed substantial advances in the treatment of congenital heart defects. New strategies are deeply rooted in calculated risk-taking innovations. Pioneer surgeons developed, improved and refined critical operative skills and techniques to optimize cardiovascular physiology, decrease operative mortality and improve clinical outcomes. METHODS: Unfortunately, in the modern surgical era, supportive environments to allow surgeons to make similar gains and innovative contributions remain scarce. In the current practice, overall procedure volume is prioritized to safeguard quality metrics, including hospital survival and length of stay, surgical complications, and neurocognitive outcomes. As a result, exceptional surgical results have become translated and defined by public ranking systems such as the US News and World Report Best Children's Hospital National Ranking (USNWR) and the Congenital Heart Surgery Database of the Society for Thoracic Surgeons (CHSD-STS), primary based upon early post-operative mortality. This reality places surgeons in a vulnerable position where pressure to achieve a high clinical ranking contrasts with a surgeon definition of "acceptable" surgical risk. Currently, the most frequently used risk stratification tools do not factor in important differences in strategies, such as staged palliation versus complete repair, or bi-ventricular versus uni-ventricular physiology. This favors hospitals pursuing multistage surgical approaches, even if the result is worse long-term morbidity, mortality and increased resource utilization. This economy of ranking-based decision-making causes surgeons either avoid operating altogether or accept less advantageous multi-staged treatment strategies for patients with elevated expected mortality. Such an environment also might present much farther-reaching negative impacts on the growth and development of junior surgeons and trainees, as well as on the pursuit of new surgical innovations to aid future generations of patients. CONCLUSIONS: Risk aversive surgical behavior is creating an environment not favorable for the children born with truly complex congenital heart defects. KEYWORDS: Biventricular conversion; congenital heart surgery; multidisciplinary approach; risk-stratification; surgical outcomes. CI - 2021 Translational Pediatrics. All rights reserved. FAU - Corno, Antonio F AU - Corno AF AD - Pediatric and Congenital Cardiac Surgery, Houston Children's Heart Institute, Memorial Hermann Children's Hospital, University of Texas Health, McGovern Medical School, Houston, Texas, USA. FAU - LaPar, Damien J AU - LaPar DJ AD - Pediatric and Congenital Cardiac Surgery, Houston Children's Heart Institute, Memorial Hermann Children's Hospital, University of Texas Health, McGovern Medical School, Houston, Texas, USA. FAU - Li, Wen AU - Li W AD - Division of Clinical and Translational Sciences, Department of Internal Medicine, University of Texas Health, McGovern Medical School, Houston, Texas, USA. FAU - Salazar, Jorge D AU - Salazar JD AD - Pediatric and Congenital Cardiac Surgery, Houston Children's Heart Institute, Memorial Hermann Children's Hospital, University of Texas Health, McGovern Medical School, Houston, Texas, USA. LA - eng PT - Journal Article PT - Review PL - China TA - Transl Pediatr JT - Translational pediatrics JID - 101649179 PMC - PMC8429879 COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://dx.doi.org/10.21037/tp-21-163). AFC serves as an unpaid editorial board member of Translational Pediatrics from Apr 2020 to Mar 2022. The other authors have no conflicts of interest to declare. EDAT- 2021/09/30 06:00 MHDA- 2021/09/30 06:01 PMCR- 2021/08/01 CRDT- 2021/09/29 06:57 PHST- 2021/04/13 00:00 [received] PHST- 2021/07/23 00:00 [accepted] PHST- 2021/09/29 06:57 [entrez] PHST- 2021/09/30 06:00 [pubmed] PHST- 2021/09/30 06:01 [medline] PHST- 2021/08/01 00:00 [pmc-release] AID - tp-10-08-2114 [pii] AID - 10.21037/tp-21-163 [doi] PST - ppublish SO - Transl Pediatr. 2021 Aug;10(8):2114-2122. doi: 10.21037/tp-21-163. PMID- 34584599 OWN - NLM STAT- MEDLINE DCOM- 20211004 LR - 20231107 IS - 1937-8688 (Electronic) VI - 39 DP - 2021 TI - Cardiac manifestations of the coronavirus disease-19: a review of pathogenesis, clinical manifestations, diagnosis, and treatment. PG - 173 LID - 10.11604/pamj.2021.39.173.27802 [doi] LID - 173 AB - The coronavirus disease-19 (COVID-19), first appearing in Wuhan, China, and later declared as a pandemic, has caused serious morbidity and mortality worldwide. Severe cases usually present with acute respiratory distress syndrome (ARDS), pneumonia, acute kidney injury (AKI), liver damage, or septic shock. However, with recent advances in severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) research, the virus s effect on cardiac tissues has become evident. Reportedly, an increased number of COVID-19 patients manifested serious cardiac complications such as heart failure, increased troponin, and N-terminal pro-B-type natriuretic peptide levels (NT-proBNP), cardiomyopathies, and myocarditis. These cardiac complications initially present as chest tightness, chest pain, and heart palpitations. Diagnostic investigations such as telemetry, electrocardiogram (ECG), cardiac biomarkers (troponin, NT-proBNP), and inflammatory markers (D-dimer, fibrinogen, PT, PTT), must be performed according to the patient s condition. The best available options for treatment are the provision of supportive care, anti-viral therapy, hemodynamic monitoring, IL-6 blockers, statins, thrombolytic, and anti-hypertensive drugs. Cardiovascular disease (CVD) healthcare workers should be well-informed about the evolving research regarding COVID-19 and approach as a multi-disciplinary team to devise effective strategies for challenging situations to reduce cardiac complications. CI - Copyright: Momina Khalid et al. FAU - Khalid, Momina AU - Khalid M AD - Department of Internal Medicine, Jinnah Sindh Medical University, Karachi, Pakistan. FAU - Awan, Sana AU - Awan S AD - Department of Internal Medicine, Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan. FAU - Jatoi, Nadia Nazir AU - Jatoi NN AD - Department of Internal Medicine, Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan. FAU - Jatoi, Hafsa Nazir AU - Jatoi HN AD - Department of Internal Medicine, Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan. FAU - Yasmin, Farah AU - Yasmin F AD - Department of Internal Medicine, Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan. FAU - Ochani, Rohan Kumar AU - Ochani RK AD - Department of Internal Medicine, Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan. FAU - Batra, Simran AU - Batra S AD - Department of Internal Medicine, Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan. FAU - Malik, Farheen AU - Malik F AD - Department of Internal Medicine, Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan. FAU - Ahmed, Jawad AU - Ahmed J AD - Department of Internal Medicine, Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan. FAU - Chawla, Sanchit AU - Chawla S AD - Department of Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, 44111, United States of America. FAU - Mustafa, Ahmad AU - Mustafa A AD - Department of Internal Medicine, Staten Island University Hospital, New York, United States of America. FAU - Lak, Hassan Mehmood AU - Lak HM AD - Department of Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, 44111, United States of America. FAU - Surani, Salim AU - Surani S AD - Department of Internal Medicine, Corpus Christi Medical Center, Corpus Christi, United States of America. AD - Department of Internal Medicine, University of North Texas, Dallas, United States of America. LA - eng PT - Journal Article PT - Review DEP - 20210706 PL - Uganda TA - Pan Afr Med J JT - The Pan African medical journal JID - 101517926 RN - 0 (Biomarkers) SB - IM MH - Biomarkers/metabolism MH - COVID-19/*complications/diagnosis MH - COVID-19 Testing MH - Heart Diseases/diagnosis/physiopathology/*virology MH - Humans MH - Patient Care Team/organization & administration MH - SARS-CoV-2/*isolation & purification PMC - PMC8449581 OTO - NOTNLM OT - COVID-19 OT - IL-6 blockers OT - SARS-CoV-2 OT - cardiovascular disease OT - electrocardiogram OT - myocarditis OT - thrombolytic OT - troponin COIS- The authors declared no competing interests. EDAT- 2021/09/30 06:00 MHDA- 2021/10/05 06:00 PMCR- 2021/07/06 CRDT- 2021/09/29 06:54 PHST- 2021/01/11 00:00 [received] PHST- 2021/05/30 00:00 [accepted] PHST- 2021/09/29 06:54 [entrez] PHST- 2021/09/30 06:00 [pubmed] PHST- 2021/10/05 06:00 [medline] PHST- 2021/07/06 00:00 [pmc-release] AID - PAMJ-39-173 [pii] AID - 10.11604/pamj.2021.39.173.27802 [doi] PST - epublish SO - Pan Afr Med J. 2021 Jul 6;39:173. doi: 10.11604/pamj.2021.39.173.27802. eCollection 2021. PMID- 34584197 OWN - NLM STAT- MEDLINE DCOM- 20220429 LR - 20261010 IS - 1476-5543 (Electronic) IS - 0743-8346 (Linking) VI - 42 IP - 1 DP - 2022 Jan TI - Standardizing premedication for non-emergent neonatal tracheal intubations improves compliance and patient outcomes. PG - 132-138 LID - 10.1038/s41372-021-01215-2 [doi] AB - OBJECTIVE: We sought to standardize and improve compliance with evidence-based premedication for non-emergent neonatal intubations in two academic-affiliated Neonatal Intensive Care Units. STUDY DESIGN: A multidisciplinary team created guidelines and electronic medical record order sets for intubation. Compliance with recommended premedication, number of intubation attempts, and frequency of bradycardia and desaturation were assessed. RESULTS: 387 intubation procedures were reviewed. Provision of recommended premedication increased by 36% and 75% at the level III and IV units, respectively. Decreased frequency of bradycardia during intubation (p = 0.0003) occurred in the level III unit. A reduction in number of intubation attempts (p 0.050). Multiple early red flag events preceded CA diagnose several years in ATTR: Left ventricular hypertrophy (LVH, 60%, 4.9 +/- 4.3 y), heart failure (54%, 2.5 +/- 3.5 y), atrial fibrillation (47%, 5.9 +/- 6.7 y), bilateral carpal tunnel syndrome (43%, 9.5 +/- 5.7 y) and spinal stenosis (40%, 7.4 +/- 6.5 y). LVH >/= 12 mm was absent in 11% ATTR (n = 13/114) and 5% AL (n = 1/21) patients. Hypertension was common in both ATTR (n = 70/114, 62%) and AL (n = 10/21, 48%). 56% (n = 78/139) of CA presented with heart failure. Cumulative 1 and 5-year mortality of 10%/66%, 40%/52% and 75%/75% for ATTR, AL, and AA, respectively, remains high. CONCLUSIONS: Although CA diagnostic uptake and referral improve, specialist-specific disease and diagnostic red flag ignorance result in non-timely diagnosis and unfavourable outcome. FAU - Debonnaire, Philippe AU - Debonnaire P AD - Departments of Cardiology, Bruges Amyloidosis Centre, Sint-Jan Hospital Bruges, Bruges, Belgium. FAU - Claeys, Mathias AU - Claeys M AD - Departments of Cardiology, Bruges Amyloidosis Centre, Sint-Jan Hospital Bruges, Bruges, Belgium. AD - Department of Cardiology, University Hospital Leuven, Belgium. FAU - De Smet, Maarten AU - De Smet M AD - Departments of Cardiology, Bruges Amyloidosis Centre, Sint-Jan Hospital Bruges, Bruges, Belgium. AD - Department of Cardiology, University Hospital Ghent, Belgium. FAU - Trenson, Sander AU - Trenson S AD - Departments of Cardiology, Bruges Amyloidosis Centre, Sint-Jan Hospital Bruges, Bruges, Belgium. FAU - Lycke, Michelle AU - Lycke M AD - Departments of Cardiology, Bruges Amyloidosis Centre, Sint-Jan Hospital Bruges, Bruges, Belgium. FAU - Demeester, Catherine AU - Demeester C AD - Departments of Cardiology, Bruges Amyloidosis Centre, Sint-Jan Hospital Bruges, Bruges, Belgium. FAU - Van Droogenbroeck, Jan AU - Van Droogenbroeck J AD - Department of Haematology, Bruges Amyloidosis Centre, Sint-Jan Hospital Bruges, Bruges, Belgium. FAU - De Vriese, An S AU - De Vriese AS AD - Department of Nephrology, Bruges Amyloidosis Centre, Sint-Jan Hospital Bruges, Bruges, Belgium. FAU - Verhoeven, Kristof AU - Verhoeven K AD - Department of Neurology, Bruges Amyloidosis Centre, Sint-Jan Hospital Bruges, Bruges, Belgium. FAU - Vantomme, Nikolaas AU - Vantomme N AD - Department of Neurosurgery, Bruges Amyloidosis Centre, Sint-Jan Hospital Bruges, Bruges, Belgium. FAU - Van Meirhaeghe, Jan AU - Van Meirhaeghe J AD - Department of Orthopaedic surgery, Bruges Amyloidosis Centre, Sint-Jan Hospital Bruges, Bruges, Belgium. FAU - Willandt, Barbara AU - Willandt B AD - Department of Gastroenterology, Bruges Amyloidosis Centre, Sint-Jan Hospital Bruges, Bruges, Belgium. FAU - Lambert, Margareta AU - Lambert M AD - Department of Geriatry, Bruges Amyloidosis Centre, Sint-Jan Hospital Bruges, Bruges, Belgium. FAU - de Paepe, Pascale AU - de Paepe P AD - Departments of Pathology, Bruges Amyloidosis Centre, Sint-Jan Hospital Bruges, Bruges, Belgium. FAU - Delanote, Joost AU - Delanote J AD - Departments of Radiology, Bruges Amyloidosis Centre, Sint-Jan Hospital Bruges, Bruges, Belgium. FAU - De Geeter, Frank AU - De Geeter F AD - Departments of Nuclear Medicine, Bruges Amyloidosis Centre, Sint-Jan Hospital Bruges, Bruges, Belgium. FAU - Tavernier, Rene AU - Tavernier R AD - Departments of Cardiology, Bruges Amyloidosis Centre, Sint-Jan Hospital Bruges, Bruges, Belgium. LA - eng PT - Journal Article DEP - 20210927 PL - England TA - Acta Cardiol JT - Acta cardiologica JID - 0370570 SB - IM MH - Humans MH - *Amyloid Neuropathies, Familial/diagnosis/epidemiology/complications MH - *Atrial Fibrillation/complications MH - *Heart Failure/complications MH - Referral and Consultation MH - *Cardiomyopathies/diagnosis/complications OTO - NOTNLM OT - ATTR amyloidosis OT - cardiac amyloidosis OT - outcome OT - red flags OT - transthyretin EDAT- 2021/09/28 06:00 MHDA- 2023/01/13 06:00 CRDT- 2021/09/27 05:28 PHST- 2021/09/28 06:00 [pubmed] PHST- 2023/01/13 06:00 [medline] PHST- 2021/09/27 05:28 [entrez] AID - 10.1080/00015385.2021.1976450 [doi] PST - ppublish SO - Acta Cardiol. 2022 Nov;77(9):791-804. doi: 10.1080/00015385.2021.1976450. Epub 2021 Sep 27. PMID- 34559431 OWN - NLM STAT- MEDLINE DCOM- 20220221 LR - 20220221 IS - 1540-8167 (Electronic) IS - 1045-3873 (Linking) VI - 32 IP - 12 DP - 2021 Dec TI - The surgical technique of the convergent procedure. PG - 3221-3227 LID - 10.1111/jce.15252 [doi] AB - The convergent procedure is a newly developed hybrid ablation procedure that involves extensive epicardial ablation of the posterior left atrial wall followed by endocardial mapping and addition of pulmonary vein isolation. It is a team-based approach that provides a promising option for patients with persistent and permanent atrial fibrillation. In this manuscript, we present a detailed description of the surgical component of this procedure and include potential pitfalls based on our experience in performing it. CI - (c) 2021 Wiley Periodicals LLC. FAU - Yammine, Maroun AU - Yammine M AUID- ORCID: 0000-0002-0189-7644 AD - Department of Cardiovascular Surgery, Mount Sinai Hospital, New York City, New York, USA. FAU - Puskas, John AU - Puskas J AD - Department of Cardiovascular Surgery, Mount Sinai Morningside Hospital, New York City, New York, USA. FAU - El Moheb, Mohamad AU - El Moheb M AUID- ORCID: 0000-0002-1897-2145 AD - Department of Surgery, Emory University Hospital, Atlanta, Georgia, USA. FAU - Lattouf, Omar AU - Lattouf O AD - Department of Cardiovascular Surgery, Mount Sinai Morningside Hospital, New York City, New York, USA. AD - Department of Surgery, Emory University Hospital, Atlanta, Georgia, USA. LA - eng PT - Journal Article DEP - 20211004 PL - United States TA - J Cardiovasc Electrophysiol JT - Journal of cardiovascular electrophysiology JID - 9010756 SB - IM MH - *Atrial Fibrillation/diagnosis/surgery MH - *Catheter Ablation/methods MH - Endocardium MH - Humans MH - *Pulmonary Veins/diagnostic imaging/surgery MH - Treatment Outcome OTO - NOTNLM OT - atrial fibrillation OT - convergent procedure OT - endocardial ablation OT - epicardial ablation OT - minimally invasive EDAT- 2021/09/25 06:00 MHDA- 2022/02/22 06:00 CRDT- 2021/09/24 12:31 PHST- 2021/09/02 00:00 [revised] PHST- 2021/01/01 00:00 [received] PHST- 2021/09/08 00:00 [accepted] PHST- 2021/09/25 06:00 [pubmed] PHST- 2022/02/22 06:00 [medline] PHST- 2021/09/24 12:31 [entrez] AID - 10.1111/jce.15252 [doi] PST - ppublish SO - J Cardiovasc Electrophysiol. 2021 Dec;32(12):3221-3227. doi: 10.1111/jce.15252. Epub 2021 Oct 4. PMID- 34556415 OWN - NLM STAT- MEDLINE DCOM- 20220110 LR - 20220110 IS - 1878-1594 (Electronic) IS - 1521-690X (Linking) VI - 35 IP - 6 DP - 2021 Dec TI - Hormone therapy and cardiovascular disease: Benefits and harms. PG - 101576 LID - S1521-690X(21)00093-2 [pii] LID - 10.1016/j.beem.2021.101576 [doi] AB - Menopause transition marks an important phase in life when cardiovascular risk in women gradually takes an adverse turn. Although menopausal hormone therapy has gained a negative appreciation over the last decades, its value in the treatment of disabling vasomotor symptoms is still undisputed. Cardiovascular risk assessment has become a matter of precision medicine, which is helpful for safe menopausal hormone therapy prescription. With a multidisciplinary approach the current available hormone regimens can be even given to women at intermediate cardiovascular risk, when risk factors such as hypertension and dyslipidemia are adequately monitored and treated. CI - Copyright (c) 2021 The Author. Published by Elsevier Ltd.. All rights reserved. FAU - Maas, Angela H E M AU - Maas AHEM AD - Chair Women's Cardiovascular Health Program, Department of Cardiology, Radboud University Medical Center, Nijmegen, the Netherlands. Electronic address: angela.maas@radboudumc.nl. LA - eng PT - Journal Article PT - Review DEP - 20210910 PL - Netherlands TA - Best Pract Res Clin Endocrinol Metab JT - Best practice & research. Clinical endocrinology & metabolism JID - 101120682 RN - 0 (Hormones) SB - IM MH - *Cardiovascular Diseases/chemically induced/epidemiology MH - Estrogen Replacement Therapy/adverse effects MH - Female MH - Hormone Replacement Therapy/adverse effects MH - Hormones MH - Humans MH - Menopause MH - Risk Factors OTO - NOTNLM OT - atherosclerosis OT - cardiovascular risk OT - coronary artery calcium score OT - menopausal hormone therapy EDAT- 2021/09/25 06:00 MHDA- 2022/01/11 06:00 CRDT- 2021/09/24 05:50 PHST- 2021/09/25 06:00 [pubmed] PHST- 2022/01/11 06:00 [medline] PHST- 2021/09/24 05:50 [entrez] AID - S1521-690X(21)00093-2 [pii] AID - 10.1016/j.beem.2021.101576 [doi] PST - ppublish SO - Best Pract Res Clin Endocrinol Metab. 2021 Dec;35(6):101576. doi: 10.1016/j.beem.2021.101576. Epub 2021 Sep 10. PMID- 34556316 OWN - NLM STAT- MEDLINE DCOM- 20211220 LR - 20211220 IS - 1558-3597 (Electronic) IS - 0735-1097 (Linking) VI - 78 IP - 13 DP - 2021 Sep 28 TI - Management and Outcomes of Cardiogenic Shock in Cardiac ICUs With Versus Without Shock Teams. PG - 1309-1317 LID - S0735-1097(21)05782-X [pii] LID - 10.1016/j.jacc.2021.07.044 [doi] AB - BACKGROUND: Single-center studies suggest that implementation of multidisciplinary cardiogenic shock (CS) teams is associated with improved CS survival. OBJECTIVES: The aim was to characterize practice patterns and outcomes in the management of CS across multiple centers with versus without shock teams. METHODS: The Critical Care Cardiology Trials Network is a multicenter network of cardiac intensive care units (CICUs) in North America. All consecutive medical admissions to each CICU (n = 24) were captured during annual 2-month collection periods (2017-2019; n = 6,872). Shock management and CICU mortality among centers with versus without shock teams were compared using inverse probability weighting. RESULTS: Ten of the 24 centers had shock teams. Among 1,242 CS admissions, 44% were at shock team centers. The groups were well-balanced with respect to demographics, shock etiology, Sequential Organ Failure Assessment score, biochemical markers of end organ dysfunction, and invasive hemodynamics. Centers with shock teams used more pulmonary artery catheters (60% vs 49%; adjusted odds ratio [OR]: 1.86; 95% CI: 1.47-2.35; P < 0.001), less overall mechanical circulatory support (MCS) (35% vs 43%; adjusted OR: 0.74; 95% CI: 0.59-0.95; P = 0.016), and more advanced types of MCS (53% vs 43% of all MCS; adjusted OR: 1.73; 95% CI: 1.19-2.51; P = 0.005) rather than intra-aortic balloon pumps. The presence of a shock team was independently associated with lower CICU mortality (23% vs 29%; adjusted OR: 0.72; 95% CI: 0.55-0.94; P = 0.016). CONCLUSIONS: In this multicenter observational study, centers with shock teams were more likely to obtain invasive hemodynamics, use advanced types of MCS, and have lower risk-adjusted mortality. A standardized multidisciplinary shock team approach may improve outcomes in CS. CI - Copyright (c) 2021 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. FAU - Papolos, Alexander I AU - Papolos AI AD - Departments of Cardiology and Critical Care, MedStar Washington Hospital Center, Washington, DC, USA. Electronic address: Alexander.Papolos@Medstar.net. FAU - Kenigsberg, Benjamin B AU - Kenigsberg BB AD - Departments of Cardiology and Critical Care, MedStar Washington Hospital Center, Washington, DC, USA. FAU - Berg, David D AU - Berg DD AD - TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA. FAU - Alviar, Carlos L AU - Alviar CL AD - The Leon H. Charney Division of Cardiology, New York University School of Medicine, New York, New York, USA. FAU - Bohula, Erin AU - Bohula E AD - TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA. FAU - Burke, James A AU - Burke JA AD - Lehigh Valley Heart Institute, Allentown, Pennsylvania, USA. FAU - Carnicelli, Anthony P AU - Carnicelli AP AD - Department of Medicine, Duke University Hospital, Durham, North Carolina, USA. FAU - Chaudhry, Sunit-Preet AU - Chaudhry SP AD - Department of Medicine, St Vincent Heart Center, Indianapolis, Indiana, USA. FAU - Drakos, Stavros AU - Drakos S AD - Division of Cardiovascular Medicine, Department of Medicine, University of Utah, Salt Lake City, Utah, USA. FAU - Gerber, Daniel A AU - Gerber DA AD - Department of Medicine, Stanford University School of Medicine, Stanford, California, USA. FAU - Guo, Jianping AU - Guo J AD - TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA. FAU - Horowitz, James M AU - Horowitz JM AD - The Leon H. Charney Division of Cardiology, New York University School of Medicine, New York, New York, USA. FAU - Katz, Jason N AU - Katz JN AD - Department of Medicine, Duke University Hospital, Durham, North Carolina, USA. FAU - Keeley, Ellen C AU - Keeley EC AD - Department of Medicine University of Florida Gainesville, Gainesville, Florida, USA. FAU - Metkus, Thomas S AU - Metkus TS AD - Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. FAU - Nativi-Nicolau, Jose AU - Nativi-Nicolau J AD - Division of Cardiovascular Medicine, Department of Medicine, University of Utah, Salt Lake City, Utah, USA. FAU - Snell, Jeffrey R AU - Snell JR AD - Department of Internal Medicine, Division of Cardiology, Rush University Medical Center, Chicago, Illinois, USA. FAU - Sinha, Shashank S AU - Sinha SS AD - Inova Heart and Vascular Institute, Inova Fairfax Medical Center, Falls Church, Virginia, USA. FAU - Tymchak, Wayne J AU - Tymchak WJ AD - Department of Critical Care Medicine and Division of Cardiology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada. FAU - Van Diepen, Sean AU - Van Diepen S AD - Department of Critical Care Medicine and Division of Cardiology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada. FAU - Morrow, David A AU - Morrow DA AD - TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA. FAU - Barnett, Christopher F AU - Barnett CF AD - Departments of Cardiology and Critical Care, MedStar Washington Hospital Center, Washington, DC, USA. CN - Critical Care Cardiology Trials Network Investigators LA - eng PT - Comparative Study PT - Journal Article PT - Multicenter Study PL - United States TA - J Am Coll Cardiol JT - Journal of the American College of Cardiology JID - 8301365 SB - IM CIN - J Am Coll Cardiol. 2021 Sep 28;78(13):1318-1320. doi: 10.1016/j.jacc.2021.07.041. PMID: 34556317 MH - Aged MH - Coronary Care Units/*statistics & numerical data MH - Female MH - Hospital Rapid Response Team/*statistics & numerical data MH - Humans MH - Male MH - Middle Aged MH - North America/epidemiology MH - *Registries MH - Shock, Cardiogenic/*mortality/therapy OTO - NOTNLM OT - cardiac intensive care unit OT - cardiogenic shock OT - mechanical circulatory support OT - pulmonary artery catheter OT - shock team COIS- Funding Support and Author Disclosures Dr Drakos has served as a consultant to Abbott. Dr Sinha has served as a consultant to the Abiomed Critical Care Advisory Board. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2021/09/25 06:00 MHDA- 2021/12/21 06:00 CRDT- 2021/09/24 05:47 PHST- 2021/06/23 00:00 [received] PHST- 2021/07/19 00:00 [accepted] PHST- 2021/09/24 05:47 [entrez] PHST- 2021/09/25 06:00 [pubmed] PHST- 2021/12/21 06:00 [medline] AID - S0735-1097(21)05782-X [pii] AID - 10.1016/j.jacc.2021.07.044 [doi] PST - ppublish SO - J Am Coll Cardiol. 2021 Sep 28;78(13):1309-1317. doi: 10.1016/j.jacc.2021.07.044. PMID- 34542953 OWN - NLM STAT- MEDLINE DCOM- 20220802 LR - 20250728 IS - 1827-1669 (Electronic) IS - 0026-4806 (Linking) VI - 113 IP - 4 DP - 2022 Aug TI - Severe aortic stenosis and transcatheter aortic valve replacement in elderly patients: utility vs. futility. PG - 640-646 LID - 10.23736/S0026-4806.21.07777-6 [doi] AB - Recently, transcatheter aortic valve replacement (TAVR) has emerged as established standard treatment for symptomatic severe aortic stenosis, providing an effective, less-invasive alternative to open cardiac surgery for inoperable or high-risk older patients. In order to assess the anticipated benefit of aortic replacement, considerable interest now lies in better identifying factors likely to predict outcome. In the elderly population frailty and medical comorbidities have been shown to significantly predict mortality, functional recovery and quality of life after transcatheter aortic valve replacement. Scientific literature focused on the three items will be discussed. High likelihood of futility is described in patients with severe chronic lung, kidney, liver disease and/or frailty. The addition of frailty components to conventional risk prediction has been shown to result in improved discrimination for death and disability following the procedure and identifies those individuals least likely to derive benefit. Several dedicated risk score have been proposed to provide new insights into predicted "futile" outcome. However, assessment of frailty according to a limited number of variables is not sufficient, while a multi-dimensional geriatric assessment significantly improves risk prediction. A multidisciplinary heart team that includes geriatricians can allow the customization of therapeutic interventions in elderly patients to optimise care and avoid futility. FAU - Terrosu, Pierfranco AU - Terrosu P AD - SICGe - Societa Italiana di Cardiologia Geriatrica, Florence, Italy - pterrosu@hotmail.com. FAU - Boccanelli, Alessandro AU - Boccanelli A AD - SICGe - Societa Italiana di Cardiologia Geriatrica, Florence, Italy. FAU - Sabino, Giuseppe AU - Sabino G AD - Unit of Cardiology, SS. Annunziata University Hospital, Sassari, Italy. FAU - Alboni, Paolo AU - Alboni P AD - SICGe - Societa Italiana di Cardiologia Geriatrica, Florence, Italy. FAU - Baldasseroni, Samuele AU - Baldasseroni S AD - SICGe - Societa Italiana di Cardiologia Geriatrica, Florence, Italy. FAU - Bo, Mario AU - Bo M AD - SICGe - Societa Italiana di Cardiologia Geriatrica, Florence, Italy. FAU - Desideri, Giovambattista AU - Desideri G AD - SICGe - Societa Italiana di Cardiologia Geriatrica, Florence, Italy. FAU - Marchionni, Niccolo AU - Marchionni N AD - SICGe - Societa Italiana di Cardiologia Geriatrica, Florence, Italy. FAU - Palazzo, Giuseppe AU - Palazzo G AD - SICGe - Societa Italiana di Cardiologia Geriatrica, Florence, Italy. FAU - Rozzini, Renzo AU - Rozzini R AD - SICGe - Societa Italiana di Cardiologia Geriatrica, Florence, Italy. FAU - Ungar, Andrea AU - Ungar A AD - SICGe - Societa Italiana di Cardiologia Geriatrica, Florence, Italy. FAU - Vetta, Francesco AU - Vetta F AD - SICGe - Societa Italiana di Cardiologia Geriatrica, Florence, Italy. FAU - Zito, Giovanni AU - Zito G AD - SICGe - Societa Italiana di Cardiologia Geriatrica, Florence, Italy. LA - eng PT - Journal Article DEP - 20210920 PL - Italy TA - Minerva Med JT - Minerva medica JID - 0400732 SB - IM MH - Aged MH - Aortic Valve/surgery MH - *Aortic Valve Stenosis MH - Frail Elderly MH - *Frailty/etiology/surgery MH - Humans MH - Medical Futility MH - Quality of Life MH - Risk Assessment MH - Risk Factors MH - Severity of Illness Index MH - *Transcatheter Aortic Valve Replacement/adverse effects MH - Treatment Outcome EDAT- 2021/09/21 06:00 MHDA- 2022/08/03 06:00 CRDT- 2021/09/20 12:40 PHST- 2021/09/21 06:00 [pubmed] PHST- 2022/08/03 06:00 [medline] PHST- 2021/09/20 12:40 [entrez] AID - S0026-4806.21.07777-6 [pii] AID - 10.23736/S0026-4806.21.07777-6 [doi] PST - ppublish SO - Minerva Med. 2022 Aug;113(4):640-646. doi: 10.23736/S0026-4806.21.07777-6. Epub 2021 Sep 20. PMID- 34542615 OWN - NLM STAT- MEDLINE DCOM- 20220113 LR - 20220113 IS - 2574-3805 (Electronic) IS - 2574-3805 (Linking) VI - 4 IP - 9 DP - 2021 Sep 1 TI - Interventions to Reduce Hospital Length of Stay in High-risk Populations: A Systematic Review. PG - e2125846 LID - 10.1001/jamanetworkopen.2021.25846 [doi] LID - e2125846 AB - IMPORTANCE: Many strategies to reduce hospital length of stay (LOS) have been implemented, but few studies have evaluated hospital-led interventions focused on high-risk populations. The Agency for Healthcare Research and Quality (AHRQ) Learning Health System panel commissioned this study to further evaluate system-level interventions for LOS reduction. OBJECTIVE: To identify and synthesize evidence regarding potential systems-level strategies to reduce LOS for patients at high risk for prolonged LOS. EVIDENCE REVIEW: Multiple databases, including MEDLINE and Embase, were searched for English-language systematic reviews from January 1, 2010, through September 30, 2020, with updated searches through January 19, 2021. The scope of the protocol was determined with input from AHRQ Key Informants. Systematic reviews were included if they reported on hospital-led interventions intended to decrease LOS for high-risk populations, defined as those with high-risk medical conditions or socioeconomically vulnerable populations (eg, patients with high levels of socioeconomic risk, who are medically uninsured or underinsured, with limited English proficiency, or who are hospitalized at a safety-net, tertiary, or quaternary care institution). Exclusion criteria included interventions that were conducted outside of the hospital setting, including community health programs. Data extraction was conducted independently, with extraction of strength of evidence (SOE) ratings provided by systematic reviews; if unavailable, SOE was assessed using the AHRQ Evidence-Based Practice Center methods guide. FINDINGS: Our searches yielded 4432 potential studies. We included 19 systematic reviews reported in 20 articles. The reviews described 8 strategies for reducing LOS in high-risk populations: discharge planning, geriatric assessment, medication management, clinical pathways, interdisciplinary or multidisciplinary care, case management, hospitalist services, and telehealth. Interventions were most frequently designed for older patients, often those who were frail (9 studies), or patients with heart failure. There were notable evidence gaps, as there were no systematic reviews studying interventions for patients with socioeconomic risk. For patients with medically complex conditions, discharge planning, medication management, and interdisciplinary care teams were associated with inconsistent outcomes (LOS, readmissions, mortality) across populations. For patients with heart failure, clinical pathways and case management were associated with reduced length of stay (clinical pathways: mean difference reduction, 1.89 [95% CI, 1.33 to 2.44] days; case management: mean difference reduction, 1.28 [95% CI, 0.52 to 2.04] days). CONCLUSIONS AND RELEVANCE: This systematic review found inconsistent results across all high-risk populations on the effectiveness associated with interventions, such as discharge planning, that are often widely used by health systems. This systematic review highlights important evidence gaps, such as the lack of existing systematic reviews focused on patients with socioeconomic risk factors, and the need for further research. FAU - Siddique, Shazia Mehmood AU - Siddique SM AD - Division of Gastroenterology, University of Pennsylvania, Philadelphia. AD - Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia. AD - Center for Evidence-Based Practice, University of Pennsylvania Health System, Philadelphia. FAU - Tipton, Kelley AU - Tipton K AD - ECRI Evidence-based Practice Center, Center for Clinical Evidence and Guidelines, Plymouth Meeting, Pennsylvania. FAU - Leas, Brian AU - Leas B AD - Center for Evidence-Based Practice, University of Pennsylvania Health System, Philadelphia. FAU - Greysen, S Ryan AU - Greysen SR AD - Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia. AD - Center for Evidence-Based Practice, University of Pennsylvania Health System, Philadelphia. AD - Division of General Internal Medicine, University of Pennsylvania, Philadelphia. FAU - Mull, Nikhil K AU - Mull NK AD - Center for Evidence-Based Practice, University of Pennsylvania Health System, Philadelphia. AD - Division of General Internal Medicine, University of Pennsylvania, Philadelphia. FAU - Lane-Fall, Meghan AU - Lane-Fall M AD - Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia. AD - Center for Evidence-Based Practice, University of Pennsylvania Health System, Philadelphia. AD - Department of Anesthesiology and Critical Care, University of Pennsylvania, Philadelphia. FAU - McShea, Kristina AU - McShea K AD - ECRI Evidence-based Practice Center, Center for Clinical Evidence and Guidelines, Plymouth Meeting, Pennsylvania. FAU - Tsou, Amy Y AU - Tsou AY AD - ECRI Evidence-based Practice Center, Center for Clinical Evidence and Guidelines, Plymouth Meeting, Pennsylvania. AD - Division of Neurology, Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania. LA - eng PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20210901 PL - United States TA - JAMA Netw Open JT - JAMA network open JID - 101729235 SB - IM MH - Age Factors MH - Aged MH - Case Management MH - Critical Pathways MH - Geriatric Assessment MH - Heart Failure/therapy MH - Hospitalists MH - Humans MH - *Length of Stay MH - Patient Care Team MH - *Patient Discharge MH - Risk Assessment/*methods MH - Socioeconomic Factors MH - Telemedicine MH - United States MH - Vulnerable Populations PMC - PMC8453321 COIS- Conflict of Interest Disclosures: Dr Leas reported receiving grants from the Agency for Healthcare Research and Quality (AHRQ) outside the submitted work. No other disclosures were reported. EDAT- 2021/09/21 06:00 MHDA- 2022/01/14 06:00 PMCR- 2021/09/20 CRDT- 2021/09/20 12:26 PHST- 2021/09/20 12:26 [entrez] PHST- 2021/09/21 06:00 [pubmed] PHST- 2022/01/14 06:00 [medline] PHST- 2021/09/20 00:00 [pmc-release] AID - 2784338 [pii] AID - zoi210761 [pii] AID - 10.1001/jamanetworkopen.2021.25846 [doi] PST - epublish SO - JAMA Netw Open. 2021 Sep 1;4(9):e2125846. doi: 10.1001/jamanetworkopen.2021.25846. PMID- 34542612 OWN - NLM STAT- MEDLINE DCOM- 20220307 LR - 20231105 IS - 1569-9285 (Electronic) IS - 1569-9293 (Print) IS - 1569-9285 (Linking) VI - 34 IP - 2 DP - 2022 Jan 18 TI - Impact of coronary calcification assessed by coronary CT angiography on treatment decision in patients with three-vessel CAD: insights from SYNTAX III trial. PG - 176-184 LID - 10.1093/icvts/ivab249 [doi] AB - OBJECTIVES: The aim of this study was to determine Syntax scores based on coronary computed tomography angiography (CCTA) and invasive coronary angiography (ICA) and to assess whether heavy coronary calcification significantly limits the CCTA evaluation and the impact of severe calcification on heart team's treatment decision and procedural planning in patients with three-vessel coronary artery disease (CAD) with or without left main disease. METHODS: SYNTAX III was a multicentre, international study that included patients with three-vessel CAD with or without left main disease. The heart teams were randomized to either assess coronary arteries with coronary CCTA or ICA. We stratified the patients based on the presence of at least 1 lesion with heavy calcification defined as arc of calcium >180 degrees within the lesion using CCTA. Agreement on the anatomical SYNTAX score and treatment decision was compared between patients with and without heavy calcifications. RESULTS: Overall, 222 patients with available CCTA and ICA were included in this trial subanalysis (104 with heavy calcification, 118 without heavy calcification). The mean difference in the anatomical SYNTAX score (CCTA derived-ICA derived) was lower in patients without heavy calcifications [mean (-1.96 SD; +1.96 SD) = 1.5 (-19.3; 22.4) vs 5.9 (-17.5; +29.3), P = 0.004]. The agreement on treatment decision did not differ between patients with (Cohen's kappa 0.79) or without coronary calcifications (Cohen's kappa 0.84). The agreement on the treatment planning did not differ between patients with (concordance 80.3%) or without coronary calcifications (concordance 82.8%). CONCLUSIONS: An overall good correlation between CCTA- and ICA-derived Syntax score was found. The presence of heavy coronary calcification moderately influenced the agreement between CCTA and ICA on the anatomical SYNTAX score. However, agreement on the treatment decision and planning was high and irrespective of the presence of calcified lesions. CI - (c) The Author(s) 2021. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. FAU - Andreini, Daniele AU - Andreini D AD - Department of Cardiovascular Imaging, Centro Cardiologico Monzino, IRCCS, Milan, Italy. AD - Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy. FAU - Takahashi, Kuniaki AU - Takahashi K AUID- ORCID: 0000-0001-5748-7700 AD - Department of Cardiology, Amsterdam University Medical Center, Amsterdam, Netherlands. FAU - Mushtaq, Saima AU - Mushtaq S AD - Department of Cardiovascular Imaging, Centro Cardiologico Monzino, IRCCS, Milan, Italy. FAU - Conte, Edoardo AU - Conte E AUID- ORCID: 0000-0003-1443-5788 AD - Department of Cardiovascular Imaging, Centro Cardiologico Monzino, IRCCS, Milan, Italy. FAU - Modolo, Rodrigo AU - Modolo R AUID- ORCID: 0000-0002-0047-7859 AD - Department of Cardiology, Amsterdam University Medical Center, Amsterdam, Netherlands. AD - Cardiology Division, Department of Internal Medicine, Hospital de Clinicas, University of Campinas, Campinas, Sao Paulo, Brazil. FAU - Sonck, Jeroen AU - Sonck J AD - Cardiovascular Center Aalst, OLV Hospital, Aalst, Belgium. FAU - De Mey, Johan AU - De Mey J AD - Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussel, Belgium. FAU - Ravagnani, Paolo AU - Ravagnani P AUID- ORCID: 0000-0003-2368-337X AD - Department of Cardiovascular Imaging, Centro Cardiologico Monzino, IRCCS, Milan, Italy. FAU - Schoors, Danny AU - Schoors D AD - University of Zurich, Zurich, Switzerland. FAU - Maisano, Francesco AU - Maisano F AD - University of Zurich, Zurich, Switzerland. FAU - Kaufmann, Philipp AU - Kaufmann P AD - University of Zurich, Zurich, Switzerland. FAU - Lindeboom, Wietze AU - Lindeboom W AD - Cardialysis BV, Rotterdam, Netherlands. FAU - Morel, Marie-Angele AU - Morel MA AD - Cardialysis BV, Rotterdam, Netherlands. FAU - Doenst, Torsten AU - Doenst T AD - Jena University Hospital, Friedrich-Schiller-University of Jena, Jena, Germany. FAU - Teichgraber, Ulf AU - Teichgraber U AD - Jena University Hospital, Friedrich-Schiller-University of Jena, Jena, Germany. FAU - Pontone, Gianluca AU - Pontone G AUID- ORCID: 0000-0002-1339-6679 AD - Department of Cardiovascular Imaging, Centro Cardiologico Monzino, IRCCS, Milan, Italy. FAU - Pompilio, Giulio AU - Pompilio G AD - Department of Cardiovascular Imaging, Centro Cardiologico Monzino, IRCCS, Milan, Italy. AD - Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy. FAU - Bartorelli, Antonio AU - Bartorelli A AD - Department of Cardiovascular Imaging, Centro Cardiologico Monzino, IRCCS, Milan, Italy. AD - Department of Biomedical and Clinical Sciences "Luigi Sacco", University of Milan, Milan, Italy. FAU - Onuma, Yoshinobu AU - Onuma Y AD - Thoraxcenter, Erasmus MC, Rotterdam, Netherlands. FAU - Serruys, Patrick W AU - Serruys PW AD - Department of Cardiology, Royal Brompton and Harefield Hospitals, Imperial College London, London, UK. CN - Syntax III Revolution Investigators LA - eng PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't PL - England TA - Interact Cardiovasc Thorac Surg JT - Interactive cardiovascular and thoracic surgery JID - 101158399 SB - IM MH - Computed Tomography Angiography/methods MH - Coronary Angiography/methods MH - *Coronary Artery Disease/diagnostic imaging/etiology/therapy MH - *Coronary Stenosis/etiology MH - Humans MH - Predictive Value of Tests MH - Tomography, X-Ray Computed/methods PMC - PMC8766208 OTO - NOTNLM OT - Coronary calcification OT - Coronary computed tomography angiography OT - Heart team EDAT- 2021/09/21 06:00 MHDA- 2022/03/08 06:00 PMCR- 2021/09/20 CRDT- 2021/09/20 12:26 PHST- 2021/04/21 00:00 [received] PHST- 2021/07/13 00:00 [revised] PHST- 2021/08/13 00:00 [accepted] PHST- 2021/09/21 06:00 [pubmed] PHST- 2022/03/08 06:00 [medline] PHST- 2021/09/20 12:26 [entrez] PHST- 2021/09/20 00:00 [pmc-release] AID - 6372723 [pii] AID - ivab249 [pii] AID - 10.1093/icvts/ivab249 [doi] PST - ppublish SO - Interact Cardiovasc Thorac Surg. 2022 Jan 18;34(2):176-184. doi: 10.1093/icvts/ivab249. PMID- 34540917 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220419 IS - 2297-055X (Print) IS - 2297-055X (Electronic) IS - 2297-055X (Linking) VI - 8 DP - 2021 TI - Severe Cardiac Toxicity Induced by Cancer Therapies Requiring Intensive Care Unit Admission. PG - 713694 LID - 10.3389/fcvm.2021.713694 [doi] LID - 713694 AB - A steadying increase of cancer survivors has been observed as a consequence of more effective therapies. However, chemotherapy regimens are often associated with significant toxicity, and cardiac damage emerges as a prominent clinical issue. Many mechanisms sustain chemotherapy-induced cardiac toxicity: direct myocyte damage, arrhythmia induction, coronary vasospasm, and accelerated atherosclerosis. Anthracyclines are the most studied cardiotoxic drugs and represent a clinical model for cardiac damage induced by chemotherapy. In patients suffering from advanced heart failure (HF) because of chemotherapy-related cardiomyopathy, when refractory to optimal medical therapy, mechanical circulatory support or heart transplantation represents an effective treatment. Here, the main mechanisms of cardiac toxicity induced by cancer therapies are analyzed, with a focus on patients requiring intensive care unit (ICU) admission during the course of the disease because of acute cardiac toxicity, takotsubo syndrome, and acute-on-chronic HF in patients suffering from chemotherapy-induced cardiomyopathy. In a subset of patients, cardiac toxicity can be acute and life-threatening, leading to overt cardiogenic shock. The management of critically ill cancer patients poses a unique challenge and requires a multidisciplinary approach. Moreover, no etiologic therapy is available, and only supportive measures can be implemented. CI - Copyright (c) 2021 Montisci, Palmieri, Liu, Vietri, Cirri, Donatelli and Napoli. FAU - Montisci, Andrea AU - Montisci A AD - Division of Cardiothoracic Intensive Care, Azienda Socio-Sanitaria Territoriale (ASST) Spedali Civili, Brescia, Italy. FAU - Palmieri, Vittorio AU - Palmieri V AD - Department of Cardiac Surgery and Transplantation, Ospedali dei Colli Monaldi-Cotugno-CTO, Naples, Italy. FAU - Liu, Jennifer E AU - Liu JE AD - Department of Medicine/Cardiology Service, Memorial Sloan Kettering Cancer Center, New York, NY, United States. FAU - Vietri, Maria T AU - Vietri MT AD - Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy. FAU - Cirri, Silvia AU - Cirri S AD - Department of Anesthesia and Intensive Care, Istituto Clinico Sant'Ambrogio, Milan, Italy. FAU - Donatelli, Francesco AU - Donatelli F AD - Department of Cardiac Surgery, University of Milan, Milan, Italy. FAU - Napoli, Claudio AU - Napoli C AD - Clinical Department of Internal Medicine and Specialistics, University Department of Advanced Clinical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy. AD - Istituto di Ricovero e Cura a Carattere Scientifico - Synlab Diagnostica Nucleare (IRCCS SDN), Naples, Italy. LA - eng GR - P30 CA008748/CA/NCI NIH HHS/United States PT - Journal Article PT - Review DEP - 20210903 PL - Switzerland TA - Front Cardiovasc Med JT - Frontiers in cardiovascular medicine JID - 101653388 PMC - PMC8446380 OTO - NOTNLM OT - anthracycline OT - cancer OT - chemotherapy OT - chemotherapy toxicity OT - heart failure OT - heart transplant OT - mechanical circulatory support COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/09/21 06:00 MHDA- 2021/09/21 06:01 PMCR- 2021/01/01 CRDT- 2021/09/20 06:14 PHST- 2021/05/23 00:00 [received] PHST- 2021/07/27 00:00 [accepted] PHST- 2021/09/20 06:14 [entrez] PHST- 2021/09/21 06:00 [pubmed] PHST- 2021/09/21 06:01 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - 10.3389/fcvm.2021.713694 [doi] PST - epublish SO - Front Cardiovasc Med. 2021 Sep 3;8:713694. doi: 10.3389/fcvm.2021.713694. eCollection 2021. PMID- 34538632 OWN - NLM STAT- MEDLINE DCOM- 20220221 LR - 20220221 IS - 1876-7591 (Electronic) IS - 1876-7591 (Linking) VI - 15 IP - 2 DP - 2022 Feb TI - Diagnostic Value of (18)F-Fluorodeoxyglucose Positron Emission Tomography Computed Tomography in Prosthetic Pulmonary Valve Infective Endocarditis. PG - 299-308 LID - S1936-878X(21)00569-6 [pii] LID - 10.1016/j.jcmg.2021.07.015 [doi] AB - OBJECTIVES: The aim of this study was to assess the diagnostic performances of (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography (PET)/computed tomography (CT) in congenital heart disease (CHD) patients with pulmonary prosthetic valve or conduit endocarditis (PPVE) suspicion. BACKGROUND: PPVE is a major issue in the growing CHD population. Diagnosis is challenging, and usual imaging tools are not always efficient or validated in this specific population. Particularly, the diagnostic yield of (18)F-FDG PET/CT remains poorly studied in PPVE. METHODS: A retrospective multicenter study was conducted in 8 French tertiary centers. Children and adult CHD patients who underwent (18)F-FDG PET/CT in the setting of PPVE suspicion between January 2010 and May 2020 were included. The cases were initially classified as definite, possible, or rejected PPVE regarding the modified Duke criteria and finally by the Endocarditis Team consensus. The result of (18)F-FDG PET/CT had been compared with final diagnosis consensus used as gold-standard in our study. RESULTS: A total of 66 cases of PPVE suspicion involving 59 patients (median age 23 years, 73% men) were included. Sensitivity, specificity, positive predictive value, and negative predictive value of (18)F-FDG PET/CT in PPVE suspicion were respectively: 79.1% (95% CI: 68.4%-91.4%), 72.7% (95% CI: 60.4%-85.0%), 91.9% (95% CI: 79.6%-100.0%), and 47.1% (95% CI: 34.8%-59.4%). (18)F-FDG PET/CT findings would help to correctly reclassify 57% (4 of 7) of possible PPVE to definite PPVE. CONCLUSIONS: Using (18)F-FDG PET/CT improves the diagnostic accuracy of the Duke criteria in CHD patients with suspected PPVE. Its high positive predictive value could be helpful in routine to shorten diagnosis and treatment delays and improve clinical outcomes. CI - Copyright (c) 2022 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Venet, Maelys AU - Venet M AD - Bordeaux University Hospital (CHU), Department of Pediatric and Adult Congenital Cardiology, Pessac, France; IHU Liryc, Electrophysiology and Heart Modeling Institute, Fondation Bordeaux Universite, Pessac-Bordeaux, France; INSERM, Centre de recherche Cardio-Thoracique de Bordeaux, U1045, Bordeaux, France. Electronic address: maelys.venet@yahoo.fr. FAU - Jalal, Zakaria AU - Jalal Z AD - Bordeaux University Hospital (CHU), Department of Pediatric and Adult Congenital Cardiology, Pessac, France; IHU Liryc, Electrophysiology and Heart Modeling Institute, Fondation Bordeaux Universite, Pessac-Bordeaux, France; INSERM, Centre de recherche Cardio-Thoracique de Bordeaux, U1045, Bordeaux, France. FAU - Ly, Reaksmei AU - Ly R AD - Congenital Heart Diseases Unit, Hopital Europeen Georges-Pompidou, Paris, France. FAU - Malekzadeh-Milani, Sophie AU - Malekzadeh-Milani S AD - Congenital Heart Diseases Unit, Hopital Europeen Georges-Pompidou, Paris, France. FAU - Hascoet, Sebastien AU - Hascoet S AD - Paris-Sud Faculty of Medicine, Marie-Lannelongue Hospital, Paris, Saclay, Le Plessis-Robinson, France. FAU - Fournier, Emmanuelle AU - Fournier E AD - Paris-Sud Faculty of Medicine, Marie-Lannelongue Hospital, Paris, Saclay, Le Plessis-Robinson, France. FAU - Ovaert, Caroline AU - Ovaert C AD - Pediatric and Congenital Cardiology Department, La Timone University Hospital, Marseille, France. FAU - Casalta, Anne Claire AU - Casalta AC AD - Pediatric and Congenital Cardiology Department, La Timone University Hospital, Marseille, France. FAU - Karsenty, Clement AU - Karsenty C AD - Pediatric Cardiology Unit, Children's Hospital, CHU Toulouse, France. FAU - Baruteau, Alban Elouen AU - Baruteau AE AD - L'institut du thorax, Congenital and Pediatric Cardiology Unit, CHU de Nantes, Nantes, France; Department of Pediatric Cardiology and Pediatric Cardiac Surgery, Children's Hospital, CHU Nantes, Nantes, France, (j)Pediatric-Cardiology, Amiens-Picardie University Hospital, Amiens, France. FAU - Le Gloan, Laurianne AU - Le Gloan L AD - L'institut du thorax, Congenital and Pediatric Cardiology Unit, CHU de Nantes, Nantes, France; Department of Pediatric Cardiology and Pediatric Cardiac Surgery, Children's Hospital, CHU Nantes, Nantes, France, (j)Pediatric-Cardiology, Amiens-Picardie University Hospital, Amiens, France. FAU - Selegny, Maelle AU - Selegny M AD - Department of Pediatric Cardiology and Pediatric Cardiac Surgery, Children's Hospital, CHU Nantes, Nantes, France, (j)Pediatric-Cardiology, Amiens-Picardie University Hospital, Amiens, France. FAU - Douchin, Stephanie AU - Douchin S AD - Pediatric Cardiology, CHU Grenoble, Grenoble, France. FAU - Bouvaist, Helene AU - Bouvaist H AD - Cardiology Department, CHU Grenoble, Grenoble, France. FAU - Belaroussi, Yaniss AU - Belaroussi Y AD - INSERM, Bordeaux Population Health Research Center, ISPED, University of Bordeaux, Bordeaux, France, (n)INSERM CIC1401, Clinical and Epidemiological Research Unit, Institut Bergonie, Bordeaux, France; Cardiology Department, CHU Grenoble, Grenoble, France; Department of Thoracic Surgery, Haut-Leveque Hospital, Bordeaux University, Bordeaux, France. FAU - Camou, Fabrice AU - Camou F AD - Medical Intensive Care Unit, Hopital Saint Andre, CHU de Bordeaux, Bordeaux, France. FAU - Tlili, Ghoufrane AU - Tlili G AD - Nuclear Medicine Department, Hopital cardiologique du Haut Leveque, CHU de Bordeaux, Pessac, France. FAU - Thambo, Jean-Benoit AU - Thambo JB AD - Bordeaux University Hospital (CHU), Department of Pediatric and Adult Congenital Cardiology, Pessac, France; IHU Liryc, Electrophysiology and Heart Modeling Institute, Fondation Bordeaux Universite, Pessac-Bordeaux, France; INSERM, Centre de recherche Cardio-Thoracique de Bordeaux, U1045, Bordeaux, France. LA - eng PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't DEP - 20210915 PL - United States TA - JACC Cardiovasc Imaging JT - JACC. Cardiovascular imaging JID - 101467978 RN - 0 (Radiopharmaceuticals) RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18) SB - IM CIN - JACC Cardiovasc Imaging. 2022 Feb;15(2):309-311. doi: 10.1016/j.jcmg.2021.09.002. PMID: 34656474 MH - Adult MH - Child MH - *Endocarditis/diagnostic imaging MH - Female MH - Fluorodeoxyglucose F18 MH - *Heart Valve Prosthesis MH - Humans MH - Male MH - Positron Emission Tomography Computed Tomography/methods MH - Predictive Value of Tests MH - *Pulmonary Valve/diagnostic imaging/surgery MH - Radiopharmaceuticals MH - Retrospective Studies MH - Young Adult OTO - NOTNLM OT - (18)F-FDG PET/CT OT - congenital heart disease OT - infective endocarditis OT - pulmonary valve COIS- Funding Support and Author Disclosures Drs Venet, Jalal, and Thambo were supported by the French Government as part of the "Investments of the future" program managed by the National Research Agency (grant reference ANR-10-IAHU-04). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2021/09/21 06:00 MHDA- 2022/02/22 06:00 CRDT- 2021/09/20 05:43 PHST- 2021/03/29 00:00 [received] PHST- 2021/06/23 00:00 [revised] PHST- 2021/07/06 00:00 [accepted] PHST- 2021/09/21 06:00 [pubmed] PHST- 2022/02/22 06:00 [medline] PHST- 2021/09/20 05:43 [entrez] AID - S1936-878X(21)00569-6 [pii] AID - 10.1016/j.jcmg.2021.07.015 [doi] PST - ppublish SO - JACC Cardiovasc Imaging. 2022 Feb;15(2):299-308. doi: 10.1016/j.jcmg.2021.07.015. Epub 2021 Sep 15. PMID- 34535456 OWN - NLM STAT- MEDLINE DCOM- 20211101 LR - 20211101 IS - 2399-6641 (Electronic) IS - 2399-6641 (Linking) VI - 10 IP - 3 DP - 2021 Sep TI - Multidisciplinary, early mobility approach to enhance functional independence in patients admitted to a cardiothoracic intensive care unit: a quality improvement programme. LID - 10.1136/bmjoq-2020-001256 [doi] LID - e001256 AB - Early mobilisation following cardiac surgery is vital for improved patient outcomes, as it has a positive effect on a patient's physical and psychological recovery following surgery. We observed that patients admitted to the cardiothoracic intensive care unit (CTICU) following cardiac surgery had only bed exercises and were confined to bed until the chest tubes were removed, which may have delayed patients achieving functional independence. Therefore, the CTICU team implemented a quality improvement (QI) project aimed at the early mobilisation of patients after cardiac surgery.A retrospective analysis was undertaken to define the current mobilisation practices in the CTICU. The multidisciplinary team identified various practice gaps and tested several changes that led to the implementation of a successful early mobility programme. The tests were carried out and reported using rapid cycle changes. A model for improvement methodology was used to run the project. The outcomes of the project were analysed using standard 'run chart rules' to detect changes in outcomes over time and Welch's t-test to assess the significance of these outcomes.This project was implemented in 2015. Patient compliance with early activity and mobilisation gradually reached 95% in 2016 and was sustained over the next 3 years. After the programme was implemented, the mean hours required for initiating out-of-bed-mobilisation was reduced from 22.77 hours to 11.74 hours. Similarly, functional independence measures and intensive care unit mobility scores also showed a statistically significant (p<0.005) improvement in patient transfers out of the CTICU.Implementing an early mobility programme for post-cardiac surgery patients is both safe and feasible. This QI project allowed for early activity and mobilisation, a substantial reduction in the number of hours required for initiating out-of-bed mobilisation following cardiac surgery, and facilitated the achievement of early ambulation and functional milestones in our patients. CI - (c) Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Jacob, Prasobh AU - Jacob P AD - Cardiac Rehabilitation Department, Heart Hospital, Hamad Medical Corporation, Doha, Qatar. FAU - Gupta, Poonam AU - Gupta P AUID- ORCID: 0000-0001-8737-8804 AD - Performance Improvement Department, Heart Hospital, Hamad Medical Corporation, Doha, Qatar dubai.poonam@gmail.com. FAU - Shiju, Shiny AU - Shiju S AD - Nursing Department, Heart Hospital, Hamad Medical Corporation, Doha, Qatar. FAU - Omar, Amr Salah AU - Omar AS AD - Senior Consultant, Cardiac Anesthesia Department, Heart Hospital, Hamad Medical Corporaton, Doha, Qatar. FAU - Ansari, Syed AU - Ansari S AD - Cardiac Rehabilitation Department, Heart Hospital, Hamad Medical Corporation, Doha, Qatar. FAU - Mathew, Gigi AU - Mathew G AD - Cardiac Rehabilitation Department, Heart Hospital, Hamad Medical Corporation, Doha, Qatar. FAU - Varghese, Miki AU - Varghese M AUID- ORCID: 0000-0003-1337-3685 AD - Nursing Department, Heart Hospital, Hamad Medical Corporation, Doha, Qatar. FAU - Pulimoottil, Jinsograce AU - Pulimoottil J AD - Nursing Department, Heart Hospital, Hamad Medical Corporation, Doha, Qatar. FAU - Varkey, Sumi AU - Varkey S AD - Nursing Department, Heart Hospital, Hamad Medical Corporation, Doha, Qatar. FAU - Mahinay, Menandro AU - Mahinay M AD - Cardiac Rehabilitation Department, Heart Hospital, Hamad Medical Corporation, Doha, Qatar. FAU - Jesus, Darlene AU - Jesus D AD - Data Informatics Department, Heart Hospital, Hamad Medical Corporation, Doha, Qatar. FAU - Surendran, Praveen AU - Surendran P AD - Cardiac Rehabilitation Department, Heart Hospital, Hamad Medical Corporation, Doha, Qatar. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - BMJ Open Qual JT - BMJ open quality JID - 101710381 SB - IM MH - Early Ambulation MH - *Functional Status MH - Humans MH - Intensive Care Units MH - *Quality Improvement MH - Retrospective Studies PMC - PMC8451290 OTO - NOTNLM OT - PDSA OT - control charts/run charts OT - evidence-based practice OT - quality improvement COIS- Competing interests: None declared. EDAT- 2021/09/19 06:00 MHDA- 2021/11/03 06:00 PMCR- 2021/09/17 CRDT- 2021/09/18 05:39 PHST- 2020/10/28 00:00 [received] PHST- 2021/08/29 00:00 [accepted] PHST- 2021/09/18 05:39 [entrez] PHST- 2021/09/19 06:00 [pubmed] PHST- 2021/11/03 06:00 [medline] PHST- 2021/09/17 00:00 [pmc-release] AID - bmjoq-2020-001256 [pii] AID - 10.1136/bmjoq-2020-001256 [doi] PST - ppublish SO - BMJ Open Qual. 2021 Sep;10(3):e001256. doi: 10.1136/bmjoq-2020-001256. PMID- 34535426 OWN - NLM STAT- MEDLINE DCOM- 20211125 LR - 20260115 IS - 2341-1929 (Electronic) IS - 2341-1929 (Linking) VI - 68 IP - 8 DP - 2021 Oct TI - SEDAR/SECCE ECMO management consensus document. PG - 443-471 LID - S2341-1929(21)00122-0 [pii] LID - 10.1016/j.redare.2020.12.002 [doi] AB - ECMO is an extracorporeal cardiorespiratory support system whose use has been increased in the last decade. Respiratory failure, postcardiotomy shock, and lung or heart primary graft failure may require the use of cardiorespiratory mechanical assistance. In this scenario perioperative medical and surgical management is crucial. Despite the evolution of technology in the area of extracorporeal support, morbidity and mortality of these patients continues to be high, and therefore the indication as well as the ECMO removal should be established within a multidisciplinary team with expertise in the area. This consensus document aims to unify medical knowledge and provides recommendations based on both the recent bibliography and the main national ECMO implantation centres experience with the goal of improving comprehensive patient care. CI - Copyright (c) 2021 Sociedad Espanola de Anestesiologia, Reanimacion y Terapeutica del Dolor. Publicado por Elsevier Espana, S.L.U. All rights reserved. FAU - Zarragoikoetxea, I AU - Zarragoikoetxea I AD - Servicio de Anestesiologia y Reanimacion, Hospital Universitari i Politecnic La Fe, Valencia, Spain. Electronic address: iratxezarra@gmail.com. FAU - Pajares, A AU - Pajares A AD - Servicio de Anestesiologia y Reanimacion, Hospital Universitari i Politecnic La Fe, Valencia, Spain. FAU - Moreno, I AU - Moreno I AD - Servicio de Anestesiologia y Reanimacion, Hospital Universitari i Politecnic La Fe, Valencia, Spain. FAU - Porta, J AU - Porta J AD - Servicio de Anestesiologia y Reanimacion, Hospital Universitari i Politecnic La Fe, Valencia, Spain. FAU - Koller, T AU - Koller T AD - Servicio de Anestesiologia y Reanimacion, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. FAU - Cegarra, V AU - Cegarra V AD - Servicio de Anestesiologia y Reanimacion, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. FAU - Gonzalez, A I AU - Gonzalez AI AD - Servicio de Anestesiologia y Reanimacion, Hospital Puerta de Hierro, Madrid, Spain. FAU - Eiras, M AU - Eiras M AD - Servicio de Anestesiologia y Reanimacion, Hospital Clinico Universitario de Santiago, La Coruna, Spain. FAU - Sandoval, E AU - Sandoval E AD - Servicio de Cirugia Cardiovascular, Hospital Clinic de Barcelona, Barcelona, Spain. FAU - Aurelio Sarralde, J AU - Aurelio Sarralde J AD - Servicio de Cirugia Cardiovascular, Hospital Universitario Marques de Valdecilla, Santander, Spain. FAU - Quintana-Villamandos, B AU - Quintana-Villamandos B AD - Servicio de Anestesiologia y Reanimacion, Hospital General Universitario Gregorio Maranon, Madrid, Spain. FAU - Vicente Guillen, R AU - Vicente Guillen R AD - Servicio de Anestesiologia y Reanimacion, Hospital Universitari i Politecnic La Fe, Valencia, Spain. LA - eng PT - Consensus Statement PT - Journal Article DEP - 20210914 PL - Spain TA - Rev Esp Anestesiol Reanim (Engl Ed) JT - Revista espanola de anestesiologia y reanimacion JID - 101778594 SB - IM MH - *Extracorporeal Membrane Oxygenation/adverse effects MH - *Heart Diseases MH - Humans MH - *Respiratory Insufficiency/therapy MH - *Shock OTO - NOTNLM OT - Cardiogenic shock OT - Complicaciones OT - Complications OT - ECMO OT - Insuficiencia respiratoria OT - Perioperative OT - Perioperatorio OT - Respiratory failure OT - Shock cardiogenico OT - Transplantation OT - Trasplante EDAT- 2021/09/19 06:00 MHDA- 2021/11/26 06:00 CRDT- 2021/09/18 05:38 PHST- 2020/04/04 00:00 [received] PHST- 2020/12/14 00:00 [accepted] PHST- 2021/09/19 06:00 [pubmed] PHST- 2021/11/26 06:00 [medline] PHST- 2021/09/18 05:38 [entrez] AID - S2341-1929(21)00122-0 [pii] AID - 10.1016/j.redare.2020.12.002 [doi] PST - ppublish SO - Rev Esp Anestesiol Reanim (Engl Ed). 2021 Oct;68(8):443-471. doi: 10.1016/j.redare.2020.12.002. Epub 2021 Sep 14. PMID- 34534690 OWN - NLM STAT- MEDLINE DCOM- 20220406 LR - 20220406 IS - 1778-7254 (Electronic) IS - 1297-319X (Linking) VI - 89 IP - 1 DP - 2022 Jan TI - Joint involvement in Noonan syndrome. A retrospective paediatric descriptive study. PG - 105270 LID - S1297-319X(21)00143-3 [pii] LID - 10.1016/j.jbspin.2021.105270 [doi] AB - OBJECTIVES: Noonan syndrome is a rare genetic disorder characterized mainly by congenital heart disease, occasional intellectual disability, and varied orthopaedic, rheumatological and haematologic anomalies. Despite potentially serious functional consequences, joint involvement has been rarely studied in the literature. Our objective was to perform a retrospective study evaluating the prevalence and characteristics of joint involvement in Noonan syndrome. METHODS: We recorded articular symptoms, including their type and frequency, in patients with Noonan syndrome followed up in French hospitals. Patients were included if the diagnosis was confirmed before the age of 20 based on the van der Burgt criteria or genetic analysis. Data are presented as frequencies or medians (ranges), and patient groups were compared using chi-square or Fisher tests. RESULTS: Seventy-one patients were included from 4 centres. The average age was 12.5 years (range: 2-36). Musculoskeletal pain was found in 18 patients (25%) and joint stiffness in 10 (14%) located in the wrists, elbows, ankles, knees and hips, which was usually bilateral. Only one destructive form was described (multiple villonodular synovitis and a giant cell lesion of the jaw). There were no cases of systemic lupus erythaematosus (SLE) or other autoimmune arthritis. Raynaud's phenomenon was observed in 3 patients. Only 50% of joint complaints led to additional exploration. SOS1 mutations (P<0.05) and treatment with growth hormone (GH) (P<0.05) were the only factors significantly related to musculoskeletal pain. Patients treated with GH did not have more SOS1 mutations. Patients experiencing pain were not more likely to experience stiffness, joint hypermobility, or coagulation abnormalities. CONCLUSION: Joint manifestations were frequent in Noonan syndrome, predominant in large joints, and rarely explored. Multiple villonodular synovitis is characteristic but rare. Auto-immune disorders were not described in this cohort. A more multidisciplinary approach could be recommended for the early detection of possibly disabling rheumatologic manifestations. CI - Copyright (c) 2021. Published by Elsevier Masson SAS. FAU - Le Quellec, Aurore AU - Le Quellec A AD - Rheumatology department, Center of Autoimmune Rare Diseases (CERAINO), CHU Cavale Blanche, Brest, France. FAU - Edouard, Thomas AU - Edouard T AD - Endocrinology, bone diseases and genetics unit, hopital des Enfants, CHU de Toulouse, France. FAU - Audebert-Bellanger, Severine AU - Audebert-Bellanger S AD - Pediatric and genetic department, CHU Morvan, Brest, France. FAU - Pouzet, Antoine AU - Pouzet A AD - Pediatric and genetic department, CHU Morvan, Brest, France. FAU - Bourdet, Karine AU - Bourdet K AD - Pediatric department, CHU Morvan, Brest, France. FAU - Colson, Cindy AU - Colson C AD - Genetic department, CHU de Caen, France. FAU - Oriot, Charlotte AU - Oriot C AD - Pediatric and genetic department, CHU de Nantes, France. FAU - Poignant, Sylvaine AU - Poignant S AD - Pediatric and genetic department, CHU de Nantes, France. FAU - Saraux, Alain AU - Saraux A AD - Rheumatology department, Center of Autoimmune Rare Diseases (CERAINO), CHU Cavale Blanche, Brest, France; Endocrinology, bone diseases and genetics unit, hopital des Enfants, CHU de Toulouse, France; Pediatric and genetic department, CHU Morvan, Brest, France; Pediatric department, CHU Morvan, Brest, France; Genetic department, CHU de Caen, France; Pediatric and genetic department, CHU de Nantes, France; UMR1227, Inserm, universite de Bretagne Occidentale, Brest, France. FAU - Devauchelle-Pensec, Valerie AU - Devauchelle-Pensec V AD - Rheumatology department, Center of Autoimmune Rare Diseases (CERAINO), CHU Cavale Blanche, Brest, France; Endocrinology, bone diseases and genetics unit, hopital des Enfants, CHU de Toulouse, France; Pediatric and genetic department, CHU Morvan, Brest, France; Pediatric department, CHU Morvan, Brest, France; Genetic department, CHU de Caen, France; Pediatric and genetic department, CHU de Nantes, France; UMR1227, Inserm, universite de Bretagne Occidentale, Brest, France. Electronic address: valerie.devauchelle-pensec@chu-brest.fr. LA - eng PT - Journal Article DEP - 20210914 PL - France TA - Joint Bone Spine JT - Joint bone spine JID - 100938016 SB - IM MH - Child MH - Humans MH - *Lupus Erythematosus, Systemic MH - *Noonan Syndrome/diagnosis/epidemiology/genetics MH - Retrospective Studies MH - *Synovitis MH - *Synovitis, Pigmented Villonodular/pathology OTO - NOTNLM OT - Central giant cell granuloma OT - Joint involvement OT - Noonan Syndrome OT - Pigmented villonodular synovitis OT - RASopathy EDAT- 2021/09/18 06:00 MHDA- 2022/04/07 06:00 CRDT- 2021/09/17 20:14 PHST- 2021/01/20 00:00 [received] PHST- 2021/08/26 00:00 [accepted] PHST- 2021/09/18 06:00 [pubmed] PHST- 2022/04/07 06:00 [medline] PHST- 2021/09/17 20:14 [entrez] AID - S1297-319X(21)00143-3 [pii] AID - 10.1016/j.jbspin.2021.105270 [doi] PST - ppublish SO - Joint Bone Spine. 2022 Jan;89(1):105270. doi: 10.1016/j.jbspin.2021.105270. Epub 2021 Sep 14. PMID- 34534620 OWN - NLM STAT- MEDLINE DCOM- 20211230 LR - 20211230 IS - 1916-7075 (Electronic) IS - 0828-282X (Linking) VI - 37 IP - 12 DP - 2021 Dec TI - A Detailed Review of Critical Care Considerations for the Pregnant Cardiac Patient. PG - 1979-2000 LID - S0828-282X(21)00665-6 [pii] LID - 10.1016/j.cjca.2021.08.020 [doi] AB - Maternal cardiovascular disease is a leading cause of maternal death worldwide and recently, maternal mortality has increased secondary to cardiovascular causes. Maternal admissions to critical care encompass 1%-2% of all critical care admissions, and although not common, the management of the critically ill pregnant patient is complex. Caring for the critically ill pregnant cardiac patient requires integration of pregnancy-associated physiologic changes, understanding pathophysiologic disease states unique to pregnancy, and a multidisciplinary approach to timing around delivery as well as antenatal and postpartum care. Herein we describe cardiorespiratory changes that occur during pregnancy and the differential diagnosis for cardiorespiratory failure in pregnancy. Cardiorespiratory diseases that are either associated or exacerbated by pregnancy are highlighted with emphasis on perturbations secondary to pregnancy and appropriate management strategies. Finally, we describe general management of the pregnant cardiac patient admitted to critical care. CI - Copyright (c) 2021 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved. FAU - Kidson, Kristen M AU - Kidson KM AD - Department of Anesthesiology and Perioperative Care, Vancouver General Hospital, Vancouver, British Columbia, Canada; Department of Critical Care Medicine, Vancouver General Hospital, Vancouver, British Columbia, Canada. FAU - Lapinsky, Stephen AU - Lapinsky S AD - Mount Sinai Hospital and the Interdepartmental Division of Critical Care, University of Toronto, Toronto, Ontario, Canada. FAU - Grewal, Jasmine AU - Grewal J AD - Division of Cardiology, University of British Columbia, Pacific Adult Congenital Heart Disease Program, St Paul's Hospital, Vancouver, British Columbia, Canada. Electronic address: jasmine.grewal@vch.ca. LA - eng PT - Journal Article PT - Review DEP - 20210915 PL - England TA - Can J Cardiol JT - The Canadian journal of cardiology JID - 8510280 SB - IM MH - Critical Care/*methods MH - Critical Illness/mortality/*therapy MH - Female MH - Global Health MH - Humans MH - *Intensive Care Units MH - Maternal Mortality/trends MH - Morbidity/trends MH - Pregnancy MH - Pregnancy Complications/epidemiology/*therapy MH - Pregnancy Complications, Cardiovascular/epidemiology/*therapy EDAT- 2021/09/18 06:00 MHDA- 2021/12/31 06:00 CRDT- 2021/09/17 20:13 PHST- 2021/05/17 00:00 [received] PHST- 2021/08/31 00:00 [revised] PHST- 2021/08/31 00:00 [accepted] PHST- 2021/09/18 06:00 [pubmed] PHST- 2021/12/31 06:00 [medline] PHST- 2021/09/17 20:13 [entrez] AID - S0828-282X(21)00665-6 [pii] AID - 10.1016/j.cjca.2021.08.020 [doi] PST - ppublish SO - Can J Cardiol. 2021 Dec;37(12):1979-2000. doi: 10.1016/j.cjca.2021.08.020. Epub 2021 Sep 15. PMID- 34531661 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240403 IS - 1178-2390 (Print) IS - 1178-2390 (Electronic) IS - 1178-2390 (Linking) VI - 14 DP - 2021 TI - Takotsubo Syndrome: Optimizing Care with a Multidisciplinary Approach. PG - 2487-2499 LID - 10.2147/JMDH.S283667 [doi] AB - Symptoms of takotsubo syndrome (TTS) include acute and transient regional systolic dysfunction of the left ventricle, as well as a variety of wall-motion abnormalities. The clinical features of TTS, including initial symptoms, cardiac biomarkers, and electrocardiogram (ECG) changes, are similar to those of acute coronary syndrome, with the exception that TTS patients typically have no obstructive coronary artery disease. TTS primarily affects elderly women, and emotional or physical stress is a common cause of the disease. Exaggerated sympathetic stimulation associated with dysfunction of the limbic system has also been reported to be related to TTS occurrence. Cancer also induces emotional and physical stress. Therefore, optimization of TTS care should involve cardiac, neurological, psychiatric, and oncological approaches. The first step in optimizing TTS care is to diagnose it by cardiac means. Multimodality imaging, including ECG, echocardiogram, angiography, ventriculography, and cardiac magnetic resonance imaging, is indispensable for diagnosis, therapy management, and the evaluation of prognosis in the acute and chronic phases of TTS. The current cardiac approach during the acute phase is primarily supportive, with the goal of preventing life-threatening complications. As central nervous system diseases frequently trigger TTS, a neurological approach is also required. Appropriate psychiatric medication may reduce the risk of TTS recurrence, as not only psychiatric disorders themselves but also psychiatric medications can be the trigger for TTS. Several conditions are associated with TTS, including the novel coronavirus disease 2019. We present current knowledge of TTS in this review and describe how to optimize TTS care through a multidisciplinary approach. CI - (c) 2021 Kinno and Ono. FAU - Kinno, Ryuta AU - Kinno R AUID- ORCID: 0000-0002-1905-2869 AD - Division of Neurology, Department of Internal Medicine, Showa University Northern Yokohama Hospital, Yokohama City, Kanagawa, 224-8503, Japan. FAU - Ono, Kenjiro AU - Ono K AUID- ORCID: 0000-0001-8454-6155 AD - Division of Neurology, Department of Medicine, Showa University School of Medicine, Tokyo, 142-8555, Japan. LA - eng PT - Journal Article PT - Review DEP - 20210910 PL - New Zealand TA - J Multidiscip Healthc JT - Journal of multidisciplinary healthcare JID - 101512691 PMC - PMC8439972 OTO - NOTNLM OT - cardiac approach OT - exaggerated sympathetic stimulation OT - limbic system OT - neurological approach OT - oncological approach OT - psychiatric approach COIS- The authors report no conflicts of interest in this work. EDAT- 2021/09/18 06:00 MHDA- 2021/09/18 06:01 PMCR- 2021/09/10 CRDT- 2021/09/17 07:10 PHST- 2021/07/08 00:00 [received] PHST- 2021/08/23 00:00 [accepted] PHST- 2021/09/17 07:10 [entrez] PHST- 2021/09/18 06:00 [pubmed] PHST- 2021/09/18 06:01 [medline] PHST- 2021/09/10 00:00 [pmc-release] AID - 283667 [pii] AID - 10.2147/JMDH.S283667 [doi] PST - epublish SO - J Multidiscip Healthc. 2021 Sep 10;14:2487-2499. doi: 10.2147/JMDH.S283667. eCollection 2021. PMID- 34530109 OWN - NLM STAT- MEDLINE DCOM- 20211230 LR - 20211230 IS - 1916-7075 (Electronic) IS - 0828-282X (Linking) VI - 37 IP - 12 DP - 2021 Dec TI - Coronary Events in the Pregnant Patient: Who Is at Risk and How Best to Manage? PG - 2026-2034 LID - S0828-282X(21)00727-3 [pii] LID - 10.1016/j.cjca.2021.09.009 [doi] AB - Coronary events in pregnancy are a rare but growing cause of maternal morbidity and mortality. Pregnancy presents unique challenges across a broad spectrum of disciplines and requires a multidisciplinary approach to optimise maternal and fetal outcomes. The early involvement of the "cardio-obstetrics" team in prepregnancy counselling, the antenatal period, delivery, and postpartum is vital to ensuring better outcomes for patients at high risk of coronary pathology. The overall risk for coronary events complicating pregnancy is increasing owing to a number of factors, including advancing maternal age and increases in traditional cardiac risk factors contributing to higher rates of maternal morbidity and mortality. The majority of pregnant women experiencing a coronary event do not have previous coronary disease, and the pathologic mechanisms involved are predominantly nonatherosclerotic. Diagnosis and management should follow standard guideline-based practices for acute coronary syndrome (ACS), including the use of diagnostic coronary angiography to guide percutaneous intervention when needed. Management of ACS should not be delayed to facilitate delivery, which can proceed following stent implantation and dual antiplatelet therapy. The timing and mode of delivery should be based on assessment of maternal and fetal status, but vaginal delivery is preferred when possible. This review aims to provide an overview of the major etiologies, risk factors, diagnoses, and management strategies for patients at risk of or presenting with coronary events in pregnancy. CI - Copyright (c) 2021 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved. FAU - Samuel, Rohit AU - Samuel R AD - Division of Cardiology, Vancouver General Hospital, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Alfadhel, Mesfer AU - Alfadhel M AD - Division of Cardiology, Vancouver General Hospital, University of British Columbia, Vancouver, British Columbia, Canada. FAU - McAlister, Cameron AU - McAlister C AD - Division of Cardiology, Vancouver General Hospital, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Nestelberger, Thomas AU - Nestelberger T AD - Division of Cardiology, Vancouver General Hospital, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Saw, Jacqueline AU - Saw J AD - Division of Cardiology, Vancouver General Hospital, University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: jsaw@mail.ubc.ca. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20210914 PL - England TA - Can J Cardiol JT - The Canadian journal of cardiology JID - 8510280 SB - IM MH - Acute Coronary Syndrome/*epidemiology/therapy MH - *Disease Management MH - Female MH - Global Health MH - Humans MH - Morbidity MH - Pregnancy MH - Pregnancy Complications, Cardiovascular/*epidemiology/therapy MH - *Pregnancy Outcome MH - Risk Factors EDAT- 2021/09/17 06:00 MHDA- 2021/12/31 06:00 CRDT- 2021/09/16 20:14 PHST- 2021/05/15 00:00 [received] PHST- 2021/08/23 00:00 [revised] PHST- 2021/09/10 00:00 [accepted] PHST- 2021/09/17 06:00 [pubmed] PHST- 2021/12/31 06:00 [medline] PHST- 2021/09/16 20:14 [entrez] AID - S0828-282X(21)00727-3 [pii] AID - 10.1016/j.cjca.2021.09.009 [doi] PST - ppublish SO - Can J Cardiol. 2021 Dec;37(12):2026-2034. doi: 10.1016/j.cjca.2021.09.009. Epub 2021 Sep 14. PMID- 34529168 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20211002 IS - 2090-911X (Electronic) IS - 1110-2608 (Print) IS - 1110-2608 (Linking) VI - 73 IP - 1 DP - 2021 Sep 16 TI - Giant descending aortic pseudo-aneurysm in an adult man with uncorrected aortic coarctation. PG - 80 LID - 10.1186/s43044-021-00206-0 [doi] LID - 80 AB - BACKGROUND: Aortic coarctation (CoAo) accounts for 6 to 8% of all congenital heart diseases and occurs two to five times more often in males. The uncorrected aortic coarctation is complicated by hypertension, ascending and descending aortic aneurysms, endarteritis, and heart failure. The aortic pseudo-aneurysm (APD) usually occurs in patients with endarteritis. We report an adult man with bicuspid aortic valve, perimembranous ventricular septal defect, and uncorrected aortic coarctation complicated by descending aortic pseudo-aneurysm without aortic endarteritis. CASE PRESENTATION: A 40-year-old man was referred to our division for hemoptysis and severe aortic coarctation. Echocardiography confirmed the aortic coarctation diagnosis and showed a large aortic pseudo-aneurysm at the coarctation site with intra-cavity mural thrombus. Subsequently, the patient underwent contrast-enhanced computed tomography angiography, and diagnosis of coarctation and APD was confirmed. Due to various malformations and considering that the patient had become unstable due to hemoptysis, it was discussed in the heart team, and it was decided that the patient would undergo staged surgery. CONCLUSIONS: The aortic pseudo-aneurysm is a rare complication in patients with untreated coarctation that requires prompt surgery, and this complication should be considered in patients with untreated aortic coarctation who present with hemoptysis. CI - (c) 2021. The Author(s). FAU - Jabbary, Zahra AU - Jabbary Z AUID- ORCID: 0000-0002-2877-9250 AD - Cardiovascular Research Center, Shahid Madani Heart Center, Tabriz University of Medical Sciences, Tabriz, Iran. Dr.z.Jabbary@gmail.com. FAU - Toufan, Mehrnoush AU - Toufan M AD - Cardiovascular Research Center, Shahid Madani Heart Center, Tabriz University of Medical Sciences, Tabriz, Iran. LA - eng PT - Journal Article DEP - 20210916 PL - Germany TA - Egypt Heart J JT - The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology JID - 9106952 PMC - PMC8446111 OTO - NOTNLM OT - Aortic coarctation OT - Aortic pseudo-aneurysm OT - Echocardiography COIS- The authors declare that they have no competing interests. EDAT- 2021/09/17 06:00 MHDA- 2021/09/17 06:01 PMCR- 2021/09/16 CRDT- 2021/09/16 12:28 PHST- 2021/06/29 00:00 [received] PHST- 2021/09/06 00:00 [accepted] PHST- 2021/09/16 12:28 [entrez] PHST- 2021/09/17 06:00 [pubmed] PHST- 2021/09/17 06:01 [medline] PHST- 2021/09/16 00:00 [pmc-release] AID - 10.1186/s43044-021-00206-0 [pii] AID - 206 [pii] AID - 10.1186/s43044-021-00206-0 [doi] PST - epublish SO - Egypt Heart J. 2021 Sep 16;73(1):80. doi: 10.1186/s43044-021-00206-0. PMID- 34528686 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220105 IS - 1522-9645 (Electronic) IS - 0195-668X (Linking) VI - 43 IP - 1 DP - 2021 Dec 28 TI - Living the heart team live on stage in Serbia cardiac surgeons and cardiologists met at the second BELgrade Valve International Symposium. PG - 6-8 LID - 10.1093/eurheartj/ehab527 [doi] FAU - Banovic, Marko AU - Banovic M AUID- ORCID: 0000-0002-0017-6140 AD - Belgrade Medical School, Dr Subotica Starijeg 8, Belgrade, Serbia. AD - Cardiology Dpt, University Clinical Centre of Serbia, Pasterova 2, Belgrade, Serbia. FAU - Putnik, Svetozar AU - Putnik S AD - Belgrade Medical School, Dr Subotica Starijeg 8, Belgrade, Serbia. AD - Cardiac-surgery Dpt, University Clinical Centre of Serbia, Pasterova 2, Belgrade, Serbia. FAU - Binder, Ronald AU - Binder R AUID- ORCID: 0000-0001-9985-3748 AD - Dpt of Cardiology and Intensive Care, Klinikum Wels-Grieskirchen, Grieskirchnerstrasse 42, Wels 4600, Austria. LA - eng PT - Journal Article PL - England TA - Eur Heart J JT - European heart journal JID - 8006263 SB - IM EDAT- 2021/09/17 06:00 MHDA- 2021/09/17 06:01 CRDT- 2021/09/16 08:59 PHST- 2021/09/17 06:00 [pubmed] PHST- 2021/09/17 06:01 [medline] PHST- 2021/09/16 08:59 [entrez] AID - 6370992 [pii] AID - 10.1093/eurheartj/ehab527 [doi] PST - ppublish SO - Eur Heart J. 2021 Dec 28;43(1):6-8. doi: 10.1093/eurheartj/ehab527. PMID- 34527621 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220426 IS - 2284-2594 (Electronic) IS - 2284-2594 (Linking) VI - 8 IP - 8 DP - 2021 TI - A Life-Threatening Presentation of Primary Small Cell Colorectal Non-Hodgkin Lymphoma as Cardiac Tamponade and Its Challenging Management. PG - 002753 LID - 10.12890/2021_002753 [doi] LID - 002753 AB - Colorectal non-Hodgkin lymphoma (NHL) is quite aggressive and rare, only constituting less than 1% of all cases of colorectal cancer. The pericardium is an extremely rare first site of metastasis. Cardiac tamponade can be a life-threatening initial presentation. We report a 55-year-old female who presented with severe shortness of breath, intermittent abdominal pain and altered bowel habits. She had low blood pressure with congested neck veins. Her echocardiogram showed pericardial and cardiac infiltration with tumour mass; a large pericardial effusion with signs of cardiac tamponade. There was no safe window for percutaneous drainage, and the patient was not physically fit for surgical drainage. A multidisciplinary approach was used to diagnose and manage the case involving a cardiologist, gastroenterologist, pathologist, radiologist and oncologist. CT scans of the whole body showed a large rectosigmoid mass infiltrating the uterus and adnexa. Flexible sigmoidoscopy showed a large bleeding mass at the rectosigmoid junction. The biopsy confirmed small cell NHL. Three cycles of chemotherapy were urgently commenced over a period of 5 weeks (1 cycle of CVP; 2 cycles of CHOP). The patient showed significant symptomatic improvement. A 5-week follow-up echocardiogram showed significant shrinkage of the pericardial tumour and only a small rim of pericardial effusion. The effusion did not recollect in her follow-up echocardiograms. A year later, she was referred to the palliative care team due to the further spreading of her lymphoma. In conclusion, colorectal small cell NHL may initially present as cardiac tamponade. Urgent initiation of chemotherapy can be a treatment option whenever a drainage procedure is unsafe. LEARNING POINTS: Colorectal small cell NHL is a quite rare malignancy that may present initially with pericardial metastasis.Cardiac tamponade secondary to colorectal NHL is a life-threatening presentation. It can be managed by timely chemotherapy alone whenever the usual drainage procedures are not safe.A multidisciplinary approach is a cornerstone in the management of unstable lymphoma patients. It helps the rapid diagnosis and initiation of appropriate chemotherapy. CI - (c) EFIM 2021. FAU - Elkammash, Amr AU - Elkammash A AD - Department of General Internal Medicine, University Hospitals Dorset, The Royal Bournemouth Hospital, Bournemouth, UK. FAU - Abdel-Hay, Mohamed Ayman AU - Abdel-Hay MA AD - Department of Cardiology, Alexandria University Hospitals, Alexandria, Egypt. FAU - Kanaan, Saleh AU - Kanaan S AD - Department of General Internal Medicine, University Hospitals Dorset, The Royal Bournemouth Hospital, Bournemouth, UK. FAU - Alsinan, Mustafa AU - Alsinan M AD - Department of General Internal Medicine, University Hospitals Dorset, The Royal Bournemouth Hospital, Bournemouth, UK. FAU - Taha, Yosra AU - Taha Y AD - Department of General Internal Medicine, University Hospitals Dorset, The Royal Bournemouth Hospital, Bournemouth, UK. FAU - Fadul, Mohammed AU - Fadul M AD - Department of General Internal Medicine, University Hospitals Dorset, The Royal Bournemouth Hospital, Bournemouth, UK. FAU - Degheidy, Nourhan AU - Degheidy N AD - Medical Research Institute, Alexandria, Egypt. LA - eng PT - Journal Article DEP - 20210806 PL - Italy TA - Eur J Case Rep Intern Med JT - European journal of case reports in internal medicine JID - 101648453 PMC - PMC8436839 OTO - NOTNLM OT - Tamponade OT - chemotherapy OT - colon OT - drainage OT - lymphoma COIS- Conflicts of Interests: The authors declare there are no competing interests. EDAT- 2021/09/17 06:00 MHDA- 2021/09/17 06:01 PMCR- 2021/08/06 CRDT- 2021/09/16 07:17 PHST- 2021/07/06 00:00 [received] PHST- 2021/07/12 00:00 [accepted] PHST- 2021/09/16 07:17 [entrez] PHST- 2021/09/17 06:00 [pubmed] PHST- 2021/09/17 06:01 [medline] PHST- 2021/08/06 00:00 [pmc-release] AID - 2753-1-24007-1-10-20210730 [pii] AID - 10.12890/2021_002753 [doi] PST - epublish SO - Eur J Case Rep Intern Med. 2021 Aug 6;8(8):002753. doi: 10.12890/2021_002753. eCollection 2021. PMID- 34527357 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220816 IS - 2072-1439 (Print) IS - 2077-6624 (Electronic) IS - 2072-1439 (Linking) VI - 13 IP - 8 DP - 2021 Aug TI - The intersection of bronchoscopy and extracorporeal membrane oxygenation. PG - 5176-5182 LID - 10.21037/jtd-2019-ipicu-08 [doi] AB - Central airway obstruction (CAO), which results from malignant, benign or iatrogenic etiologies, causes significant morbidity and mortality and can be seen in both the pediatric and adult patient population. Patients frequently present to the hospital with dyspnea, stridor, and respiratory distress, indicating impending respiratory failure. Heliox is used to help alleviate symptoms while procedural planning takes place. A multidisciplinary approach to airway management is often needed. Interventional pulmonologists treat CAO with rigid of flexible bronchoscopy in order to deliver therapeutic interventions under general anesthesia. In severe CAO where there is concern for total loss of the airway creating a life-threatening situation for the patient during procedural intervention, short term extracorporeal membrane oxygenation or ECMO has been successfully reported in the literature to provide ventilation and oxygenation support throughout the procedure. Venoarterial ECMO can be used to augment cardiac output in cases of central tumors with cardiac involvement. ECMO can also be used for the removal of tracheal stents when there is a concern that ventilation will be interrupted for a prolonged period of time. ECMO has also been reported as a salvage measure for patients with life threatening hemoptysis until more definitive interventions can be performed. Short term ECMO cannulation can be used with limited associated morbidity and a heparin-free approach can be pursued when there is a concern for bleeding. We will briefly review the anesthetic considerations in CAO as well as review cases of CAO where ECMO was employed to safely alleviate the airway compromise. CI - 2021 Journal of Thoracic Disease. All rights reserved. FAU - Lin, Julie AU - Lin J AD - Department of Pulmonary of Critical Care Medicine, University of Chicago Medical Center, Chicago, IL, USA. FAU - Frye, Laura AU - Frye L AD - Division of Allergy, Pulmonary, and Critical Care Medicine, University of Wisconsin, Madison, WI, USA. LA - eng GR - T32 HL007605/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Review PL - China TA - J Thorac Dis JT - Journal of thoracic disease JID - 101533916 PMC - PMC8411169 OTO - NOTNLM OT - Central airway obstruction (CAO) OT - extracorporeal membrane oxygenation (ECMO) OT - hemoptysis COIS- Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at: http://dx.doi.org/10.21037/jtd-2019-ipicu-08). The series "Interventional Pulmonology in the Intensive Care Unit Environment" was commissioned by the editorial office without any funding or sponsorship. Dr. Lin reports grants from the T32 HL007605 from the NIH/NHLBI during the conduct of the study. The other author has no conflicts of interest to declare. EDAT- 2021/09/17 06:00 MHDA- 2021/09/17 06:01 PMCR- 2021/08/01 CRDT- 2021/09/16 07:09 PHST- 2020/01/25 00:00 [received] PHST- 2020/04/29 00:00 [accepted] PHST- 2021/09/16 07:09 [entrez] PHST- 2021/09/17 06:00 [pubmed] PHST- 2021/09/17 06:01 [medline] PHST- 2021/08/01 00:00 [pmc-release] AID - jtd-13-08-5176 [pii] AID - 10.21037/jtd-2019-ipicu-08 [doi] PST - ppublish SO - J Thorac Dis. 2021 Aug;13(8):5176-5182. doi: 10.21037/jtd-2019-ipicu-08. PMID- 34518075 OWN - NLM STAT- MEDLINE DCOM- 20220301 LR - 20220301 IS - 1876-4738 (Electronic) IS - 0914-5087 (Linking) VI - 79 IP - 1 DP - 2022 Jan TI - Sutureless versus transcatheter aortic valve replacement: A multicenter analysis of "real-world" data. PG - 121-126 LID - S0914-5087(21)00225-2 [pii] LID - 10.1016/j.jjcc.2021.08.022 [doi] AB - BACKGROUND: Recent data suggested that transcatheter aortic valve replacement (TAVR) may be indicated also for low-risk patients. However, robust evidence is still lacking, particularly regarding valve performance at follow-up that confers a limitation to its use in young patients. Moreover, a literature gap exists in terms of 'real-world' data analysis. The aim of this study is to compare the cost-effectiveness of sutureless aortic valve replacement (SuAVR) versus transfemoral TAVR. METHODS: Prospectively collected data were retrieved from a centralized database of nine cardiac surgery centers between 2010 and 2018. Follow-up was completed in June 2019. A propensity score matching (PSM) analysis was performed. RESULTS: Patients in the TAVR group (n=1002) were older and with more comorbidities than SuAVR patients (n=443). The PSM analysis generated 172 pairs. No differences were recorded between groups in 30-day mortality [SuAVR vs TAVR: n=7 (4%) vs n=5 (2.9%); p=0.7] and need for pacemaker implant [n=10 (5.8%) vs n=20 (11.6%); p=0.1], but costs were lower in the SuAVR group (20486.6+/-4188euro vs 24181.5+/-3632euro; p<0.01). Mean follow-up was 1304+/-660 days. SuAVR patients had a significantly higher probability of survival than TAVR patients (no. of fatal events: 22 vs 74; p<0.014). Median follow-up was 2231 days and 2394 days in the SuAVR and TAVR group, respectively. CONCLUSION: The treatment of aortic valve stenosis with surgical sutureless or transcatheter prostheses is safe and effective. By comparing the two approaches, patients who can undergo surgery after heart team evaluation show longer lasting results and a more favorable cost ratio. CI - Copyright (c) 2021. Published by Elsevier Ltd. FAU - Santarpino, Giuseppe AU - Santarpino G AD - Citta di Lecce Hospital, Department of Cardiac Surgery, GVM Care & Research, Lecce, Italy; Department of Cardiac Surgery, Paracelsus Medical University Nuremberg, Nuremberg, Germany; Cardiac Surgery Unit, Department of Experimental and Clinical Medicine, University "Magna Graecia", Catanzaro (CZ), Italy. FAU - Lorusso, Roberto AU - Lorusso R AD - Cardio-Thoracic Surgery Department, Heart & Vascular Centre, Maastricht University Medical Hospital, Maastricht, the Netherlands. FAU - Moscarelli, Marco AU - Moscarelli M AD - Anthea Hospital, Department of Cardiac Surgery, GVM Care & Research, Bari (BA), Italy. FAU - Mikus, Elisa AU - Mikus E AD - Maria Cecilia Hospital, Department of Cardiac Surgery, GVM Care & Research, Cotignola (RA), Italy. FAU - Wisniewski, Konrad AU - Wisniewski K AD - Department of Cardiothoracic Surgery, University Hospital Munster, Munster, Germany. Electronic address: kk.wisniewski@gmail.com. FAU - Dell'Aquila, Angelo Maria AU - Dell'Aquila AM AD - Department of Cardiothoracic Surgery, University Hospital Munster, Munster, Germany. FAU - Margari, Vito AU - Margari V AD - Santa Maria Hospital, Department of Cardiac Surgery, GVM Care & Research, Bari (BA), Italy. FAU - Carrozzo, Alessandro AU - Carrozzo A AD - ICLAS, Department of Cardiac Surgery, GVM Care & Research, Rapallo (GE), Italy. FAU - Barbato, Luciano AU - Barbato L AD - Maria Pia Hospital, Department of Cardiac Surgery, GVM Care & Research, Turin, Italy. FAU - Fiorani, Vinicio AU - Fiorani V AD - Salus Hospital, Department of Cardiac Surgery, GVM Care & Research, Reggio Emilia, Italy. FAU - Lamarra, Mauro AU - Lamarra M AD - Villa Torri, Department of Cardiac Surgery, GVM Care & Research, Bologna, Italy. FAU - Fattouch, Khalil AU - Fattouch K AD - Maria Eleonora Hospital, Department of Cardiac Surgery, GVM Care & Research, Palermo, Italy. FAU - Squeri, Angelo AU - Squeri A AD - Maria Cecilia Hospital, Department of Cardiology, GVM Care & Research, Cotignola (RA), Italy. FAU - Giannini, Francesco AU - Giannini F AD - Maria Cecilia Hospital, Department of Cardiology, GVM Care & Research, Cotignola (RA), Italy. FAU - Marchese, Alfredo AU - Marchese A AD - Santa Maria Hospital, Department of Cardiology, GVM Care & Research, Bari, Italy. FAU - Farahani, Kia AU - Farahani K AD - Citta di Lecce Hospital, Department of Cardiology, GVM Care & Research, Lecce, Italy. FAU - Gregorini, Renato AU - Gregorini R AD - Citta di Lecce Hospital, Department of Cardiac Surgery, GVM Care & Research, Lecce, Italy. FAU - Comoglio, Chiara AU - Comoglio C AD - Maria Pia Hospital, Department of Cardiac Surgery, GVM Care & Research, Turin, Italy. FAU - Martinelli, Luigi AU - Martinelli L AD - ICLAS, Department of Cardiac Surgery, GVM Care & Research, Rapallo (GE), Italy. FAU - Calvi, Simone AU - Calvi S AD - Maria Cecilia Hospital, Department of Cardiac Surgery, GVM Care & Research, Cotignola (RA), Italy. FAU - Avolio, Maria AU - Avolio M AD - Clinical Data Management, GVM Care & Research, Rome, Italy. FAU - Paparella, Domenico AU - Paparella D AD - Santa Maria Hospital, Department of Cardiac Surgery, GVM Care & Research, Bari (BA), Italy; Department of Emergency and Organ Transplant, Aldo Moro University of Bari, Bari, Italy. FAU - Albertini, Alberto AU - Albertini A AD - Maria Cecilia Hospital, Department of Cardiac Surgery, GVM Care & Research, Cotignola (RA), Italy. FAU - Speziale, Giuseppe AU - Speziale G AD - Anthea Hospital, Department of Cardiac Surgery, GVM Care & Research, Bari (BA), Italy. LA - eng PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't DEP - 20210910 PL - Netherlands TA - J Cardiol JT - Journal of cardiology JID - 8804703 SB - IM MH - Aortic Valve/surgery MH - *Aortic Valve Stenosis MH - *Heart Valve Prosthesis Implantation/methods MH - Humans MH - Risk Factors MH - *Transcatheter Aortic Valve Replacement/adverse effects MH - Treatment Outcome OTO - NOTNLM OT - Aortic valve replacement OT - Aortic valve stenosis OT - Transcatheter aortic valve replacement EDAT- 2021/09/15 06:00 MHDA- 2022/03/03 06:00 CRDT- 2021/09/14 05:50 PHST- 2021/04/09 00:00 [received] PHST- 2021/08/08 00:00 [revised] PHST- 2021/08/13 00:00 [accepted] PHST- 2021/09/15 06:00 [pubmed] PHST- 2022/03/03 06:00 [medline] PHST- 2021/09/14 05:50 [entrez] AID - S0914-5087(21)00225-2 [pii] AID - 10.1016/j.jjcc.2021.08.022 [doi] PST - ppublish SO - J Cardiol. 2022 Jan;79(1):121-126. doi: 10.1016/j.jjcc.2021.08.022. Epub 2021 Sep 10. PMID- 34513752 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210914 IS - 2296-2360 (Print) IS - 2296-2360 (Electronic) IS - 2296-2360 (Linking) VI - 9 DP - 2021 TI - A Multidisciplinary Approach in Prenatal Diagnosis of TSC With Cardiac Rhabdomyoma as the Initial Symptom. PG - 628238 LID - 10.3389/fped.2021.628238 [doi] LID - 628238 AB - The long-term prognosis of a fetus with cardiac rhabdomyoma (CR) depends on the correlation with tuberous sclerosis complex (TSC). In recent years, the numerous variations of uncertain significance (VUS) of TSC genes produced by high-throughput sequencing have made counseling challenging, studies until now have tended to side-step the tricky topics. Here, we integrated detailed parental phenotype, echocardiography, neuro MRI, and genetic information to conduct a comprehensive evaluation of 61 CR fetuses. As a result, multiple CRs and cerebral lesions appeared in 90 and 80%, respectively of fetuses with pathogenic (P)/likely pathogenic (LP) TSC1/TSC2 variations. Overall, 85.7% of the live-born infants with P/LP presented with TSC-associated signs. While, 85.7% of VUS without nervous findings had good prognoses. Genetic evidence and cerebral MRI findings are the most sensitive index to assess long-term prognosis, which complement and confirm each other for a TSC diagnosis. In total, 68.9% of fetuses with CR could benefit from this multidisciplinary approach, which turned out to be potentially clinically actionable with precise clinical/genetic diagnosis or had a foreseeable outcome. Our practice provides a practical and feasible solution for perinatal management and prognostic guidance for fetuses with CR. CI - Copyright (c) 2021 Qi, Ding, Huang, Zeng, Yu, Liu, Zhang and Yin. FAU - Qi, Yiming AU - Qi Y AD - Prenatal Diagnosis Centre, Guangdong Women and Children Hospital, Guangzhou, China. AD - Maternal and Children Metabolic-Genetic Key Laboratory, Guangdong Women and Children Hospital, Guangzhou, China. FAU - Ding, Hongke AU - Ding H AD - Prenatal Diagnosis Centre, Guangdong Women and Children Hospital, Guangzhou, China. AD - Maternal and Children Metabolic-Genetic Key Laboratory, Guangdong Women and Children Hospital, Guangzhou, China. FAU - Huang, Yanlin AU - Huang Y AD - Prenatal Diagnosis Centre, Guangdong Women and Children Hospital, Guangzhou, China. AD - Maternal and Children Metabolic-Genetic Key Laboratory, Guangdong Women and Children Hospital, Guangzhou, China. FAU - Zeng, Yukun AU - Zeng Y AD - Maternal and Children Metabolic-Genetic Key Laboratory, Guangdong Women and Children Hospital, Guangzhou, China. FAU - Yu, Lihua AU - Yu L AD - Maternal and Children Metabolic-Genetic Key Laboratory, Guangdong Women and Children Hospital, Guangzhou, China. FAU - Liu, Ling AU - Liu L AD - Maternal and Children Metabolic-Genetic Key Laboratory, Guangdong Women and Children Hospital, Guangzhou, China. FAU - Zhang, Yan AU - Zhang Y AD - Maternal and Children Metabolic-Genetic Key Laboratory, Guangdong Women and Children Hospital, Guangzhou, China. FAU - Yin, Aihua AU - Yin A AD - Prenatal Diagnosis Centre, Guangdong Women and Children Hospital, Guangzhou, China. AD - Maternal and Children Metabolic-Genetic Key Laboratory, Guangdong Women and Children Hospital, Guangzhou, China. LA - eng PT - Journal Article DEP - 20210827 PL - Switzerland TA - Front Pediatr JT - Frontiers in pediatrics JID - 101615492 PMC - PMC8429840 OTO - NOTNLM OT - cardiac rhabdomyoma OT - fetal tumor OT - prenatal diagnoses OT - targeted exome capture sequencing OT - tuberous sclerosis (TSC) COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/09/14 06:00 MHDA- 2021/09/14 06:01 PMCR- 2021/08/27 CRDT- 2021/09/13 06:55 PHST- 2021/02/12 00:00 [received] PHST- 2021/06/21 00:00 [accepted] PHST- 2021/09/13 06:55 [entrez] PHST- 2021/09/14 06:00 [pubmed] PHST- 2021/09/14 06:01 [medline] PHST- 2021/08/27 00:00 [pmc-release] AID - 10.3389/fped.2021.628238 [doi] PST - epublish SO - Front Pediatr. 2021 Aug 27;9:628238. doi: 10.3389/fped.2021.628238. eCollection 2021. PMID- 34510310 OWN - NLM STAT- MEDLINE DCOM- 20220405 LR - 20220531 IS - 1437-2320 (Electronic) IS - 0344-5607 (Print) IS - 0344-5607 (Linking) VI - 45 IP - 2 DP - 2022 Apr TI - Spontaneous spondylodiscitis and endocarditis: interdisciplinary experience from a tertiary institutional case series and proposal of a treatment algorithm. PG - 1335-1342 LID - 10.1007/s10143-021-01640-z [doi] AB - Previously, the simultaneous presence of endocarditis (IE) has been reported in 3-30% of spondylodiscitis cases. The specific implications on therapy and outcome of a simultaneous presence of both diseases are not yet fully evaluated. Therefore, the aim of this study was to investigate the influence of a simultaneously present endocarditis on the course of therapy and outcome of spondylodiscitis. A prospective database analysis of 328 patients diagnosed with spontaneous spondylodiscitis (S) using statistical analysis with propensity score matching was conducted. Thirty-six patients (11.0%) were diagnosed with concurrent endocarditis (SIE) by means of transoesophageal echocardiography. In our cohort, the average age was 65.82 +/- 4.12 years and 64.9% of patients were male. The incidence of prior cardiac or renal disease was significantly higher in the SIE group (coronary heart disease SIE n = 13/36 vs. S n = 57/292, p < 0.05 and chronic heart failure n = 11/36 vs. S n = 41/292, p < 0.05, chronic renal failure SIE n = 14/36 vs. S n = 55/292, p < 0.05). Complex interdisciplinary coordination and diagnostics lead to a significant delay in surgical intervention (S = 4.5 +/- 4.5 days vs. SIE = 8.9 +/- 9.5 days, p < 0.05). Mortality did not show statistically significant differences: S (13.4%) and SIE (19.1%). Time to diagnosis and treatment is a key to efficient treatment and patient safety. In order to counteract delayed therapy, we developed a novel therapy algorithm based on the analysis of treatment processes of the SIE group. We propose a clear therapy pathway to avoid frequently observed pitfalls and delays in diagnosis to improve patient care and outcome. CI - (c) 2021. The Author(s). FAU - Viezens, Lennart AU - Viezens L AUID- ORCID: 0000-0001-9353-667X AD - Division of Spine Surgery, Department of Trauma and Orthopedic Surgery, University Medical Center Hamburg-Eppendorf, Martinistr. 52, Hamburg, Germany. l.viezens@uke.de. FAU - Dreimann, Marc AU - Dreimann M AD - Division of Spine Surgery, Department of Trauma and Orthopedic Surgery, University Medical Center Hamburg-Eppendorf, Martinistr. 52, Hamburg, Germany. FAU - Strahl, Andre AU - Strahl A AD - Division of Orthopedics, Department of Trauma and Orthopedic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Heuer, Annika AU - Heuer A AD - Division of Spine Surgery, Department of Trauma and Orthopedic Surgery, University Medical Center Hamburg-Eppendorf, Martinistr. 52, Hamburg, Germany. FAU - Koepke, Leon-Gordian AU - Koepke LG AD - Division of Spine Surgery, Department of Trauma and Orthopedic Surgery, University Medical Center Hamburg-Eppendorf, Martinistr. 52, Hamburg, Germany. FAU - Bay, Benjamin AU - Bay B AD - Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Waldeyer, Christoph AU - Waldeyer C AD - Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Stangenberg, Martin AU - Stangenberg M AD - Division of Spine Surgery, Department of Trauma and Orthopedic Surgery, University Medical Center Hamburg-Eppendorf, Martinistr. 52, Hamburg, Germany. LA - eng PT - Journal Article DEP - 20210911 PL - Germany TA - Neurosurg Rev JT - Neurosurgical review JID - 7908181 SB - IM MH - Aged MH - Algorithms MH - *Discitis/diagnosis/surgery MH - *Endocarditis/diagnosis/surgery MH - *Endocarditis, Bacterial/diagnosis/epidemiology MH - Humans MH - Incidence MH - Male MH - Middle Aged PMC - PMC8976816 OTO - NOTNLM OT - Endocarditis OT - Spinal infection OT - Spondylodiscitis OT - Treatment algorithm COIS- M.D. reports being a consultant to Stryker, Medtronic, and Spineart. The other authors declare no competing interests. EDAT- 2021/09/13 06:00 MHDA- 2022/04/06 06:00 PMCR- 2021/09/11 CRDT- 2021/09/12 21:11 PHST- 2021/05/11 00:00 [received] PHST- 2021/09/02 00:00 [accepted] PHST- 2021/08/01 00:00 [revised] PHST- 2021/09/13 06:00 [pubmed] PHST- 2022/04/06 06:00 [medline] PHST- 2021/09/12 21:11 [entrez] PHST- 2021/09/11 00:00 [pmc-release] AID - 10.1007/s10143-021-01640-z [pii] AID - 1640 [pii] AID - 10.1007/s10143-021-01640-z [doi] PST - ppublish SO - Neurosurg Rev. 2022 Apr;45(2):1335-1342. doi: 10.1007/s10143-021-01640-z. Epub 2021 Sep 11. PMID- 34510088 OWN - NLM STAT- MEDLINE DCOM- 20220816 LR - 20250728 IS - 1935-3227 (Electronic) IS - 1932-0620 (Linking) VI - 16 IP - 4 DP - 2022 Jul-Aug 01 TI - The Need for Multidisciplinary Hospital Teams for Injection Drug Use-related Infective Endocarditis. PG - 375-378 LID - 10.1097/ADM.0000000000000916 [doi] AB - Injection drug use-related infective endocarditis (IDU-IE) is a complex disease with increasing incidence. Although universally recognized that IDU-IE requires antibiotics and often requires cardiac surgery, most patients do not receive addiction treatment which substantially increases their risk of recurrent IDU-IE from drug use recurrence. Accordingly, a multidisciplinary approach integrating addiction treatment may benefit patients with IDU-IE. We describe the format and structure of a team called the Multidisciplinary Endocarditis Evaluation Team (MEET) whose purpose is to optimize, formalize, and standardize the care of patients with IDUIE. Given the complexity of IDU-IE, MEET is comprised of addiction medicine, anesthesia, cardiology, cardiac surgery, infectious disease, case management, nursing, and social work. MEET strived to be acceptable to patients and families to support their preferences and values. MEET focused treatment of IDU-IE on the patient's medical and surgical needs with attention to the patients' underlying substance use disorder as an essential component. CI - Copyright (c) 2021 American Society of Addiction Medicine. FAU - Weimer, Melissa B AU - Weimer MB AD - From the Department of Medicine, Yale School of Medicine, New Haven, CT (MBW, CGF, NS, MG, SCH), Department of Surgery, Yale School of Medicine, New Haven, CT (AG, PV). FAU - Falker, Caroline G AU - Falker CG FAU - Seval, Nikhil AU - Seval N FAU - Golden, Marjorie AU - Golden M FAU - Hull, Sarah C AU - Hull SC FAU - Geirsson, Arnar AU - Geirsson A FAU - Vallabhajosyula, Prashanth AU - Vallabhajosyula P LA - eng PT - Journal Article DEP - 20210910 PL - Netherlands TA - J Addict Med JT - Journal of addiction medicine JID - 101306759 SB - IM MH - *Endocarditis/etiology/therapy MH - Hospitals MH - Humans MH - *Substance Abuse, Intravenous/complications/epidemiology MH - *Substance-Related Disorders/complications EDAT- 2021/09/13 06:00 MHDA- 2022/08/17 06:00 CRDT- 2021/09/12 21:03 PHST- 2021/09/13 06:00 [pubmed] PHST- 2022/08/17 06:00 [medline] PHST- 2021/09/12 21:03 [entrez] AID - 01271255-900000000-98991 [pii] AID - 10.1097/ADM.0000000000000916 [doi] PST - ppublish SO - J Addict Med. 2022 Jul-Aug 01;16(4):375-378. doi: 10.1097/ADM.0000000000000916. Epub 2021 Sep 10. PMID- 34506704 OWN - NLM STAT- MEDLINE DCOM- 20211028 LR - 20250130 IS - 2463-0225 (Electronic) IS - 0034-7434 (Print) IS - 0034-7434 (Linking) VI - 72 IP - 2 DP - 2021 Jun 30 TI - Structure and roles of rapid response teams for adult care in high complexity hospitals: Scoping review. PG - 171-192 LID - 10.18597/rcog.3671 [doi] AB - OBJECTIVE: A significant proportion of hospitalized patients experience severe clinical deterioration that may result in adverse events, unexpected cardiac arrest, or death. Rapid response teams (RRTs) have been created to reduce the frequency and prevent the consequences of these events. The objective of this scoping review is to describe the structure, role and results of the implementation of RRTs in the hospital context, with a focus on gynecological surgery and obstetric care. MATERIALS AND METHODS: A search was conducted in the Medline via Pubmed, Embase via OVID, LILACS, Cochrane Library and Open Gray medical databases. The search included descriptive and analytical observational studies, experimental studies and qualitative studies that included RRTs in high complexity healthcare institutions or teaching hospitals. Two researchers selected the studies and extracted data pertaining to the structure, roles and team activation criteria, response times or tools to assess their performance. No date or publication status restrictions were applied. Studies in English, Spanish and Portuguese were included. A narrative synthesis of the findings is made. RESULTS: Overall, 15,833 titles were retrieved, of which 15 studies met the inclusion criteria. Only one study mentions the use of RRTs in obstetric services. RRTs have a multidisciplinary structure and they must be available at least 12 hours a day. The roles of RRTs include identification of patients who are deteriorating, especially outside the intensive care setting, and of patients with underlying conditions or triggering events that increase the risk of cardiac arrest. In addition, they implement rapid multifaceted interventions that include pharmacological treatments, cardiopulmonary procedures, and they develop communication and training activities. Tools for team activation and care process assessment are available. CONCLUSION: The structure and roles of RRTs are clearly described, making it possible to assemble them in high complexity hospitals. Further research is required to explore risks and benefits of using RRTs to mitigate harm in patients with adverse events and to compare effectiveness and safety between code activation and RRT strategies in obstetrics services. FAU - Rincon-Lopez, Juliana Vanessa AU - Rincon-Lopez JV AD - Facultad de Medicina, Universidad Nacional de Colombia, Bogota (Colombia). julianav.rincon@gmail.com. FAU - Larrotta-Castillo, Diego AU - Larrotta-Castillo D AD - Facultad de Medicina, Universidad Nacional de Colombia, Bogota (Colombia). dalarrottac@unal.edu.co. FAU - Estrada-Orozco, Kelly AU - Estrada-Orozco K AD - Facultad de Medicina, Universidad Nacional de Colombia, Bogota (Colombia). kpestradao@unal.edu.co. FAU - Gaitan-Duarte, Hernando AU - Gaitan-Duarte H AD - Facultad de Medicina, Universidad Nacional de Colombia, Bogota (Colombia). hggaitand@unal.edu.co. LA - eng LA - spa PT - Journal Article PT - Scoping Review TT - Estructura y funcion de los equipos de respuesta rapida para la atencion de adultos en contextos hospitalarios de alta complejidad: Revision sistematica de alcance. DEP - 20210630 PL - Colombia TA - Rev Colomb Obstet Ginecol JT - Revista colombiana de obstetricia y ginecologia JID - 0404263 SB - IM MH - Adult MH - *Clinical Deterioration MH - Female MH - *Heart Arrest/therapy MH - *Hospital Rapid Response Team MH - Hospitals MH - Humans MH - Pregnancy MH - Qualitative Research PMC - PMC8425358 OAB - INTRODUCTION AND OBJECTIVE: A significant proportion of hospitalized patients experience severe clinical deterioration that may result in adverse events, unexpected cardiac arrest, or death. Rapid response teams (RRTs) have been created to reduce the frequency and prevent the consequences of these events. The objective of this scoping review is to describe the structure, role and results of the implementation of RRTs in the hospital context, with a focus on gynecological surgery and obstetric care. MATERIALS AND METHODS: A search was conducted in the Medline via Pubmed, Embase via OVID, LILACS, Cochrane Library and Open Gray medical databases. The search included descriptive and analytical observational studies, experimental studies and qualitative studies that included RRTs in high complexity healthcare institutions or teaching hospitals. Two researchers selected the studies and extracted data pertaining to the structure, roles and team activation criteria, response times or tools to assess their performance. No date or publication status restrictions were applied. Studies in English, Spanish and Portuguese were included. A narrative synthesis of the findings is made. RESULTS: Overall, 15,833 titles were retrieved, of which 15 studies met the inclusion criteria. Only one study mentions the use of RRTs in obstetric services. RRTs have a multidisciplinary structure and they must be available at least 12 hours a day. The roles of RRTs include identification of patients who are deteriorating, especially outside the intensive care setting, and of patients with underlying conditions or triggering events that increase the risk of cardiac arrest. In addition, they implement rapid multifaceted interventions that include pharmacological treatments, cardiopulmonary procedures, and they develop communication and training activities. Tools for team activation and care process assessment are available. CONCLUSION: The structure and roles of RRTs are clearly described, making it possible to assemble them in high complexity hospitals. Further research is required to explore risks and benefits of using RRTs to mitigate harm in patients with adverse events and to compare effectiveness and safety between code activation and RRT strategies in obstetrics services. OABL- eng OTO - NOTNLM OT - hospital rapid response team OT - risk management OT - patient safety OT - early warning score OT - clinical deterioration COIS- Conflicto de intereses: ninguno de los autores declara conflicto de intereses. Todos los autores declaran su independencia de los financiadores del estudio. EDAT- 2021/09/11 06:00 MHDA- 2021/10/29 06:00 PMCR- 2021/06/30 CRDT- 2021/09/10 17:28 PHST- 2021/03/21 00:00 [received] PHST- 2021/07/09 00:00 [accepted] PHST- 2021/09/10 17:28 [entrez] PHST- 2021/09/11 06:00 [pubmed] PHST- 2021/10/29 06:00 [medline] PHST- 2021/06/30 00:00 [pmc-release] AID - 10.18597/rcog.3671 [doi] PST - epublish SO - Rev Colomb Obstet Ginecol. 2021 Jun 30;72(2):171-192. doi: 10.18597/rcog.3671. PMID- 34506074 OWN - NLM STAT- MEDLINE DCOM- 20220105 LR - 20220105 IS - 1522-726X (Electronic) IS - 1522-1946 (Linking) VI - 98 IP - 7 DP - 2021 Dec 1 TI - Surgical versus transcatheter aortic valve replacement in low-risk patients: A long-term propensity score-matched analysis. PG - E1033-E1043 LID - 10.1002/ccd.29948 [doi] AB - BACKGROUND: Recent studies suggest the use of transcatheter aortic valve implantation (TAVI) as an alternative to surgical aortic valve replacement (SAVR) in lower risk populations, but real-world data are scarce. METHODS: Single-center retrospective study of patients undergoing SAVR (between June 2009 and July 2016, n = 682 patients) or TAVI (between June 2009 and July 2017, n = 400 patients). Low surgical risk was defined as EuroSCORE II (ES II) < 4% for single noncoronary artery bypass graft procedure. TAVI patients were propensity score-matched in a 1:1 ratio with SAVR patients, paired by age, New York Heart Association class, diabetes mellitus, chronic obstructive pulmonary disease, atrial fibrillation, creatinine clearance, and left ventricular ejection fraction < 50%. RESULTS: A total of 158 patients (79 SAVR and 79 TAVI) were matched (mean age 79 +/- 6 years, 79 men). TAVI patients had a higher incidence of permanent pacemaker implantation (0% vs. 19%, p < 0.001) and more than mild paravalvular leak (4% vs. 18%, p = 0.009), but comparable rates of stroke, major or life-threatening bleeding, emergent cardiac surgery, new-onset atrial fibrillation, and need for renal replacement therapy. Hospital length-of-stay and 30-day mortality were similar. At a median follow-up of 4.5 years (IQR 3.0-6.9), treatment strategy did not influence all-cause mortality (HR 1.19, 95% CI 0.77-1.83, log rank p = 0.43) nor rehospitalization (crude subdistribution HR 1.56, 95% CI 0.71-3.41, p = 0.26). ES II remained the only independent predictor of long-term all-cause mortality (adjusted HR 1.40, 95% CI 1.04-1.90, p = 0.029). CONCLUSION: In this low surgical risk severe aortic stenosis population, we observed similar rates of 30-day and long-term all-cause mortality, despite higher rates of permanent pacemaker implantation and more than mild paravalvular leak in TAVI patients. The results of this small study suggest that both procedures are safe and effective in the short-term, while the Heart Team remains essential to assess both options on the long-term. CI - (c) 2021 Wiley Periodicals LLC. FAU - Brizido, Catarina AU - Brizido C AUID- ORCID: 0000-0001-5614-5880 AD - Department of Cardiology, Hospital Santa Cruz, Centro Hospitalar Lisboa Ocidental, Carnaxide, Portugal. FAU - Madeira, Marcio AU - Madeira M AD - Department of Cardiothoracic Surgery, Hospital Santa Cruz, Centro Hospitalar Lisboa Ocidental, Carnaxide, Portugal. FAU - Brito, Joao AU - Brito J AD - Department of Cardiology, Hospital Santa Cruz, Centro Hospitalar Lisboa Ocidental, Carnaxide, Portugal. FAU - Madeira, Sergio AU - Madeira S AD - Department of Cardiology, Hospital Santa Cruz, Centro Hospitalar Lisboa Ocidental, Carnaxide, Portugal. FAU - Campante Teles, Rui AU - Campante Teles R AUID- ORCID: 0000-0002-7952-6878 AD - Department of Cardiology, Hospital Santa Cruz, Centro Hospitalar Lisboa Ocidental, Carnaxide, Portugal. AD - CEDOC, Chronic Diseases Research Center, NOVA Medical School, Lisbon, Portugal. FAU - Raposo, Luis AU - Raposo L AD - Department of Cardiology, Hospital Santa Cruz, Centro Hospitalar Lisboa Ocidental, Carnaxide, Portugal. AD - CEDOC, Chronic Diseases Research Center, NOVA Medical School, Lisbon, Portugal. FAU - Mesquita Gabriel, Henrique AU - Mesquita Gabriel H AD - Department of Cardiology, Hospital Santa Cruz, Centro Hospitalar Lisboa Ocidental, Carnaxide, Portugal. FAU - Nolasco, Tiago AU - Nolasco T AD - Department of Cardiothoracic Surgery, Hospital Santa Cruz, Centro Hospitalar Lisboa Ocidental, Carnaxide, Portugal. FAU - de Araujo Goncalves, Pedro AU - de Araujo Goncalves P AD - Department of Cardiology, Hospital Santa Cruz, Centro Hospitalar Lisboa Ocidental, Carnaxide, Portugal. AD - CEDOC, Chronic Diseases Research Center, NOVA Medical School, Lisbon, Portugal. FAU - Sousa-Uva, Miguel AU - Sousa-Uva M AD - Department of Cardiothoracic Surgery, Hospital Santa Cruz, Centro Hospitalar Lisboa Ocidental, Carnaxide, Portugal. FAU - Abecasis, Miguel AU - Abecasis M AD - Department of Cardiothoracic Surgery, Hospital Santa Cruz, Centro Hospitalar Lisboa Ocidental, Carnaxide, Portugal. FAU - de Sousa Almeida, Manuel AU - de Sousa Almeida M AD - Department of Cardiology, Hospital Santa Cruz, Centro Hospitalar Lisboa Ocidental, Carnaxide, Portugal. AD - CEDOC, Chronic Diseases Research Center, NOVA Medical School, Lisbon, Portugal. FAU - Neves, Jose Pedro AU - Neves JP AD - Department of Cardiothoracic Surgery, Hospital Santa Cruz, Centro Hospitalar Lisboa Ocidental, Carnaxide, Portugal. FAU - Mendes, Miguel AU - Mendes M AD - Department of Cardiology, Hospital Santa Cruz, Centro Hospitalar Lisboa Ocidental, Carnaxide, Portugal. LA - eng PT - Journal Article DEP - 20210910 PL - United States TA - Catheter Cardiovasc Interv JT - Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions JID - 100884139 SB - IM MH - Aged MH - Aged, 80 and over MH - Aortic Valve/diagnostic imaging/surgery MH - *Aortic Valve Stenosis/diagnostic imaging/surgery MH - *Heart Valve Prosthesis Implantation MH - Humans MH - Male MH - Propensity Score MH - Retrospective Studies MH - Risk Factors MH - Stroke Volume MH - *Transcatheter Aortic Valve Replacement/adverse effects MH - Treatment Outcome MH - Ventricular Function, Left OTO - NOTNLM OT - aortic valve disease OT - percutaneous intervention OT - surgery OT - transcatheter valve implantation OT - valvular EDAT- 2021/09/11 06:00 MHDA- 2022/01/06 06:00 CRDT- 2021/09/10 12:21 PHST- 2021/04/18 00:00 [received] PHST- 2021/08/30 00:00 [accepted] PHST- 2021/09/11 06:00 [pubmed] PHST- 2022/01/06 06:00 [medline] PHST- 2021/09/10 12:21 [entrez] AID - 10.1002/ccd.29948 [doi] PST - ppublish SO - Catheter Cardiovasc Interv. 2021 Dec 1;98(7):E1033-E1043. doi: 10.1002/ccd.29948. Epub 2021 Sep 10. PMID- 34503343 OWN - NLM STAT- MEDLINE DCOM- 20211229 LR - 20260305 IS - 1524-4539 (Electronic) IS - 0009-7322 (Linking) VI - 144 IP - 15 DP - 2021 Oct 12 TI - Guidance for Timely and Appropriate Referral of Patients With Advanced Heart Failure: A Scientific Statement From the American Heart Association. PG - e238-e250 LID - 10.1161/CIR.0000000000001016 [doi] AB - Among the estimated 6.2 million Americans living with heart failure (HF), approximately 5%/y may progress to advanced, or stage D, disease. Advanced HF has a high morbidity and mortality, such that early recognition of this condition is important to optimize care. Delayed referral or lack of referral in patients who are likely to derive benefit from an advanced HF evaluation can have important adverse consequences for patients and their families. A 2-step process can be used by practitioners when considering referral of a patient with advanced HF for consideration of advanced therapies, focused on recognizing the clinical clues associated with stage D HF and assessing potential benefits of referral to an advanced HF center. Although patients are often referred to an advanced HF center to undergo evaluation for advanced therapies such as heart transplantation or implantation of a left ventricular assist device, there are other reasons to refer, including access to the infrastructure and multidisciplinary team of the advanced HF center that offers a broad range of expertise. The intent of this statement is to provide a framework for practitioners and health systems to help identify and refer patients with HF who are most likely to derive benefit from referral to an advanced HF center. FAU - Morris, Alanna A AU - Morris AA AUID- ORCID: 0000-0002-8033-3707 FAU - Khazanie, Prateeti AU - Khazanie P FAU - Drazner, Mark H AU - Drazner MH FAU - Albert, Nancy M AU - Albert NM FAU - Breathett, Khadijah AU - Breathett K FAU - Cooper, Lauren B AU - Cooper LB FAU - Eisen, Howard J AU - Eisen HJ FAU - O'Gara, Patrick AU - O'Gara P FAU - Russell, Stuart D AU - Russell SD CN - American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; and Council on Hypertension LA - eng GR - K23 HL145122/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Review DEP - 20210910 PL - United States TA - Circulation JT - Circulation JID - 0147763 SB - IM CIN - J Cardiothorac Vasc Anesth. 2022 May;36(5):1228-1230. doi: 10.1053/j.jvca.2021.12.010. PMID: 35063348 MH - American Heart Association MH - Guidelines as Topic MH - Heart Failure/*epidemiology MH - Humans MH - Referral and Consultation MH - Time Factors MH - United States OTO - NOTNLM OT - AHA Scientific Statements OT - advance care planning OT - heart failure OT - heart transplantation OT - heart-assist devices OT - inotropes OT - referral and consultation EDAT- 2021/09/11 06:00 MHDA- 2021/12/30 06:00 CRDT- 2021/09/10 05:28 PHST- 2021/09/11 06:00 [pubmed] PHST- 2021/12/30 06:00 [medline] PHST- 2021/09/10 05:28 [entrez] AID - 10.1161/CIR.0000000000001016 [doi] PST - ppublish SO - Circulation. 2021 Oct 12;144(15):e238-e250. doi: 10.1161/CIR.0000000000001016. Epub 2021 Sep 10. PMID- 34501793 OWN - NLM STAT- MEDLINE DCOM- 20210914 LR - 20240403 IS - 1660-4601 (Electronic) IS - 1661-7827 (Print) IS - 1660-4601 (Linking) VI - 18 IP - 17 DP - 2021 Aug 31 TI - The Impact of COVID-19 Outbreak on Syncope Units Activities in Italy: A Report from the Italian Multidisciplinary Working Group on Syncope (GIMSI). LID - 10.3390/ijerph18179194 [doi] LID - 9194 AB - The aim of our study was to evaluate the impact of the COVID-19 outbreak on Syncope Units (SUs) Activities in Italy. Methods: Data about types of SU activities and admissions were obtained from 10 SUs throughout Italy, certified by the Italian Multidisciplinary Working Group on Syncope (GIMSI), from 10 March 2020 to 31 December 2020 and compared with the same time frame in 2019. Results: A remarkable reduction in overall non-invasive diagnostic tests (-67%; p < 0.001) and cardiac invasive procedure. Elective cardiac pacing procedures disclosed a significant decrease (-62.7%; p < 0.001); conversely, the decrease of urgent procedures was not significant (-50%; p = 0.08). There was a significantly increased rate of patients who underwent both telemedicine follow-up visits (+225%, p < 0.001) and cardiac implantable electronic devices (CIEDs) remote monitoring follow-up visits (+100%; p < 0.001). Conclusion: The COVID-19 outbreak was associated with a remarkable decrease in all clinical activities of Syncope Units in Italy, including both non-invasive tests and cardiac invasive procedures; conversely, a significant increase in telehealth activities was shown. FAU - Russo, Vincenzo AU - Russo V AUID- ORCID: 0000-0002-9227-0360 AD - Cardiology and Syncope Unit, Department of Medical Translational Sciences, University of Campania "Luigi Vanvitelli"-Monaldi Hospital, 80131 Naples, Italy. FAU - Boggian, Giulio AU - Boggian G AUID- ORCID: 0000-0002-9990-6499 AD - Internal Medicine and Syncope Unit, Bentivoglio Hospital, Health Authority Bologna, 40053 Bologna, Italy. FAU - Bolognesi, Maria Giulia AU - Bolognesi MG AD - Cardiology and Syncope Unit, Guglielmo da Saliceto Hospital, 29121 Piacenza, Italy. FAU - Carretta, Domenico Maria AU - Carretta DM AD - Cardiology and Syncope Unit, Giovanni XXIII Hospital, 70126 Bari, Italy. FAU - Cencetti, Simone AU - Cencetti S AD - Internal Medicine and Syncope Unit, Piero Palagi Hospital, Health Authority Toscana Centro, 50122 Firenze, Italy. FAU - De Laura, Domenica AU - De Laura D AD - Cardiology and Syncope Unit, San Paolo Hospital, 70123 Bari, Italy. FAU - Hrovatin, Enzo AU - Hrovatin E AD - Cardiology and Syncope Unit, Monfalcone Hospital, Health Authority Giuliano Isontina (GO), 34074 Monfalcone, Italy. FAU - Pastori, Paolo AU - Pastori P AD - Cardiology and Syncope Unit, Fidenza Hospital, Health Authority Parma, 43036 Fidenza, Italy. FAU - Tomaselli, Caterina AU - Tomaselli C AD - Cardiology and Syncope Unit, Annunziata Hospital, 87100 Cosenza, Italy. FAU - Parente, Erika AU - Parente E AD - Cardiology and Syncope Unit, Department of Medical Translational Sciences, University of Campania "Luigi Vanvitelli"-Monaldi Hospital, 80131 Naples, Italy. FAU - Rafanelli, Martina AU - Rafanelli M AD - Geriatrics and Intensive Care Unit, Hypertension Centre-Syncope Unit University of Florence and Careggi Hospital, 50134 Florence, Italy. FAU - Ungar, Andrea AU - Ungar A AD - Geriatrics and Intensive Care Unit, Hypertension Centre-Syncope Unit University of Florence and Careggi Hospital, 50134 Florence, Italy. FAU - On Behalf Of Covid-Gimsi Study Group AU - On Behalf Of Covid-Gimsi Study Group LA - eng PT - Journal Article DEP - 20210831 PL - Switzerland TA - Int J Environ Res Public Health JT - International journal of environmental research and public health JID - 101238455 SB - IM MH - *COVID-19 MH - Disease Outbreaks MH - Humans MH - Italy/epidemiology MH - SARS-CoV-2 MH - Syncope/epidemiology PMC - PMC8431220 OTO - NOTNLM OT - COVID-19 OT - cardiac invasive procedure OT - clinical activities OT - lockdown OT - outbreak OT - syncope OT - syncope unit COIS- The authors declare no conflict of interest. EDAT- 2021/09/11 06:00 MHDA- 2021/09/15 06:00 PMCR- 2021/08/31 CRDT- 2021/09/10 01:05 PHST- 2021/07/16 00:00 [received] PHST- 2021/08/26 00:00 [revised] PHST- 2021/08/28 00:00 [accepted] PHST- 2021/09/10 01:05 [entrez] PHST- 2021/09/11 06:00 [pubmed] PHST- 2021/09/15 06:00 [medline] PHST- 2021/08/31 00:00 [pmc-release] AID - ijerph18179194 [pii] AID - ijerph-18-09194 [pii] AID - 10.3390/ijerph18179194 [doi] PST - epublish SO - Int J Environ Res Public Health. 2021 Aug 31;18(17):9194. doi: 10.3390/ijerph18179194. PMID- 34501278 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210913 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 10 IP - 17 DP - 2021 Aug 26 TI - Importance of In-Hospital Prospective Registry and Infectious Endocarditis Heart Team to Monitor and Improve Quality of Care in Patients with Infectious Endocarditis. LID - 10.3390/jcm10173832 [doi] LID - 3832 AB - AIM: To investigate the value of prospective in-hospital registry data and the impact of an infectious endocarditis heart team approach (IEHT) on improvement in quality of care and monitor outcomes in hospitalized patients with IE. METHODS: Between December 2014 and the end of 2019, 160 patients were hospitalized in one centre with the definite diagnosis of infectious endocarditis (IE) and entered in a prospective registry. From 2017, an IEHT was introduced. Propensity score matching was used to assess the impact of an IEHT approach on clinical outcomes. RESULTS: Median age was 72.5 y (62.75-80.00), diabetes was present in 33.1%, chronic kidney disease in 27.5%, COPD in 17.5%, and a history of ischaemic heart disease in 30.6%. Prosthetic valve IE was observed in 43.8% and device-related IE in 16.9% of patients. Staphylococcus (37.5%) was the most frequent pathogen followed by streptococcus (24.4%) and enterococcus (23.1%). Overall, 30-day and 1-year mortality were 19.4% and 37.5%, respectively. The introduction of prospective data collection and IE heart team was associated with a trend towards reduction of adjusted 1-year mortality (26.5% IEHT vs. 41.2% controls, p = 0.0699). An IEHT clinical decision-making approach was independently associated with a shorter length of stay (p = 0.04). CONCLUSIONS: Use of a prospective registry of IE coupled with a heart team approach was associated with more efficient patient management and a trend towards lower mortality. Prospective data collection and dedicated IEHT have the potential to improve patient care and clinical outcomes. FAU - Van Camp, Guy AU - Van Camp G AUID- ORCID: 0000-0002-9815-8337 AD - Cardiovascular Center, OLV Aalst, Moorselbaan 164, 9300 Aalst, Belgium. FAU - Beles, Monika AU - Beles M AD - Cardiovascular Center, OLV Aalst, Moorselbaan 164, 9300 Aalst, Belgium. FAU - Penicka, Martin AU - Penicka M AD - Cardiovascular Center, OLV Aalst, Moorselbaan 164, 9300 Aalst, Belgium. FAU - Schelfaut, Dan AU - Schelfaut D AD - Cardiovascular Center, OLV Aalst, Moorselbaan 164, 9300 Aalst, Belgium. FAU - Wouters, Stijn AU - Wouters S AD - Cardiovascular Center, OLV Aalst, Moorselbaan 164, 9300 Aalst, Belgium. FAU - De Raedt, Herbert AU - De Raedt H AD - Cardiovascular Center, OLV Aalst, Moorselbaan 164, 9300 Aalst, Belgium. FAU - Wyffels, Eric AU - Wyffels E AD - Cardiovascular Center, OLV Aalst, Moorselbaan 164, 9300 Aalst, Belgium. FAU - Spapen, Jerrold AU - Spapen J AD - Cardiovascular Center, OLV Aalst, Moorselbaan 164, 9300 Aalst, Belgium. FAU - Nasser, Riwa AU - Nasser R AD - Cardiovascular Center, OLV Aalst, Moorselbaan 164, 9300 Aalst, Belgium. FAU - Balogh, Zsuzsanna AU - Balogh Z AD - Gottsegen Gyorgy National Institute of Cardilogy, Haller u. 29, 1096 Budapest, Hungary. FAU - Albano, Marzia AU - Albano M AD - Cardiology Unit, S. Maria Nuova Hospital, Via Amendola 2, 42122 Reggio Emilia, Italy. FAU - De Beenhouwer, Hans AU - De Beenhouwer H AD - Department of Microbiology, OLV Aalst, Moorselbaan 164, 9300 Aalst, Belgium. FAU - Van Vaerenbergh, Kristien AU - Van Vaerenbergh K AD - Department of Microbiology, OLV Aalst, Moorselbaan 164, 9300 Aalst, Belgium. FAU - Van Praet, Frank AU - Van Praet F AD - Cardiovascular and Thoracic Surgery, OLV Aalst, Moorselbaan 164, 9300 Aalst, Belgium. FAU - Degrieck, Ivan AU - Degrieck I AD - Cardiovascular and Thoracic Surgery, OLV Aalst, Moorselbaan 164, 9300 Aalst, Belgium. FAU - Stockman, Bernard AU - Stockman B AD - Cardiovascular and Thoracic Surgery, OLV Aalst, Moorselbaan 164, 9300 Aalst, Belgium. FAU - Casselman, Filip AU - Casselman F AD - Cardiovascular and Thoracic Surgery, OLV Aalst, Moorselbaan 164, 9300 Aalst, Belgium. FAU - Collet, Carlos AU - Collet C AD - Cardiovascular Center, OLV Aalst, Moorselbaan 164, 9300 Aalst, Belgium. LA - eng PT - Journal Article DEP - 20210826 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC8432016 OTO - NOTNLM OT - infectious endocarditis OT - outcome OT - quality of care COIS- The authors declare no conflict of interest. EDAT- 2021/09/11 06:00 MHDA- 2021/09/11 06:01 PMCR- 2021/08/26 CRDT- 2021/09/10 01:03 PHST- 2021/07/04 00:00 [received] PHST- 2021/08/09 00:00 [revised] PHST- 2021/08/23 00:00 [accepted] PHST- 2021/09/10 01:03 [entrez] PHST- 2021/09/11 06:00 [pubmed] PHST- 2021/09/11 06:01 [medline] PHST- 2021/08/26 00:00 [pmc-release] AID - jcm10173832 [pii] AID - jcm-10-03832 [pii] AID - 10.3390/jcm10173832 [doi] PST - epublish SO - J Clin Med. 2021 Aug 26;10(17):3832. doi: 10.3390/jcm10173832. PMID- 34479246 OWN - NLM STAT- MEDLINE DCOM- 20210910 LR - 20210910 IS - 2452-6053 (Electronic) IS - 2452-6045 (Linking) VI - 92 IP - 3 DP - 2021 Jun TI - Pediatric Multisystemic Inflammatory Syndrome Temporarily associated with COVID-19: Clinical characteristics and management in a Pediatric Critical Care Unit. PG - 395-405 LID - S2452-60532021005000504 [pii] LID - 10.32641/andespediatr.v92i3.3333 [doi] AB - INTRODUCTION: In April 2020, the pediatric multisystem inflammatory syndrome temporarily associated with COVID-19 (MIS-C) was described for the first time. MIS-C could have a severe course and may require critical care support. OBJECTIVE: To describe the clinical, laboratory, and management characteristics of hospitalized children who meet MIS-C criteria with severe presentation in a pediatric critical pa tient unit. PATIENTS AND METHOD: Descriptive prospective study of children with severe MIS-C mana ged by treatment phases with immunoglobulin and methylprednisolone, according to their clinical response. Epidemiological, clinical, laboratory and imaging data were obtained. Phenotypes were classified into Kawasaki and not Kawasaki, comparing their findings. RESULTS: 20 patients were analy zed, the median age was 6 years, 60% were female, and 40% presented comorbidity. SARS-CoV-2 was detected in 90% of the patients. They presented fever as the first symptom, followed by brief and early gastrointestinal symptoms (70%). 75% presented the Kawasaki phenotype. They evolved with lymphopenia, hypoalbuminemia, coagulation alterations, and elevated systemic and cardiac in flammatory parameters. 80% of the cases presented echocardiographic alterations and 90% shock that required critical care support. All the patients had a short and favorable evolution. All patients responded to the established therapy, but 40% required a second phase of treatment. There were no differences when comparing phenotypes. No deaths were reported. CONCLUSION: MIS-C is a new childhood disease whose presentation could be life-threatening. It requires early suspicion, immuno modulatory management, critical care support, and a multidisciplinary approach to obtain the best results and optimize its prognosis. FAU - Yagnam R, Felipe AU - Yagnam R F AD - Hospital de ninos Dr. Exequiel Gonzalez Cortes, Santiago, Chile. FAU - Izquierdo C, Giannina AU - Izquierdo C G AD - Departamento de Pediatria y cirugia Infantil campus Sur, Facultad de Medicina, Universidad de Chile, Santiago, Chile. FAU - Villena M, Rodolfo AU - Villena M R AD - Departamento de Pediatria y cirugia Infantil campus Sur, Facultad de Medicina, Universidad de Chile, Santiago, Chile. FAU - Gonzalez M, Claudio AU - Gonzalez M C AD - Hospital de ninos Dr. Exequiel Gonzalez Cortes, Santiago, Chile. FAU - Drago-T, Michele AU - Drago-T M AD - Hospital de ninos Dr. Exequiel Gonzalez Cortes, Santiago, Chile. LA - eng LA - spa PT - Journal Article TT - Sindrome Inflamatorio Multisistemico Pediatrico asociado a COVID-19: Caracteristicas clinicas y manejo en una Unidad de Paciente Critico Pediatrico. PL - Chile TA - Andes Pediatr JT - Andes pediatrica : revista Chilena de pediatria JID - 101778868 RN - 0 (Adrenal Cortex Hormones) RN - 0 (Anti-Bacterial Agents) RN - 0 (Anticoagulants) RN - 0 (Heparin, Low-Molecular-Weight) RN - 0 (Immunoglobulins, Intravenous) RN - 0 (Immunologic Factors) RN - pediatric multisystem inflammatory disease, COVID-19 related SB - IM MH - Adrenal Cortex Hormones/therapeutic use MH - Anti-Bacterial Agents/therapeutic use MH - Anticoagulants/therapeutic use MH - Blood Coagulation Disorders/etiology MH - *COVID-19/complications/diagnosis/therapy MH - Child MH - Critical Care MH - Female MH - Heparin, Low-Molecular-Weight/therapeutic use MH - Humans MH - Hypoalbuminemia/etiology MH - Immunoglobulins, Intravenous/administration & dosage MH - Immunologic Factors/administration & dosage MH - Intensive Care Units, Pediatric MH - Lymphopenia/etiology MH - Male MH - Mucocutaneous Lymph Node Syndrome/diagnosis MH - Prospective Studies MH - *SARS-CoV-2/isolation & purification MH - Shock/etiology/therapy MH - Symptom Assessment MH - *Systemic Inflammatory Response Syndrome/complications/diagnosis/therapy EDAT- 2021/09/04 06:00 MHDA- 2021/09/11 06:00 CRDT- 2021/09/03 20:30 PHST- 2020/09/21 00:00 [received] PHST- 2021/03/16 00:00 [accepted] PHST- 2021/09/03 20:30 [entrez] PHST- 2021/09/04 06:00 [pubmed] PHST- 2021/09/11 06:00 [medline] AID - S2452-60532021005000504 [pii] AID - 10.32641/andespediatr.v92i3.3333 [doi] PST - ppublish SO - Andes Pediatr. 2021 Jun;92(3):395-405. doi: 10.32641/andespediatr.v92i3.3333. PMID- 34477068 OWN - NLM STAT- MEDLINE DCOM- 20210909 LR - 20210909 IS - 1847-6538 (Electronic) IS - 1330-027X (Linking) VI - 291 IP - 1 DP - 2021 Apr TI - A Reminder of Skin Cancer During the COVID-19 Pandemic. PG - 58 AB - The year 2020 has been marked by the coronavirus disease 2019 (COVID-19) pandemic, caused by an RNA virus called SARS-COV2 (severe acute respiratory syndrome coronavirus). The fight against this epidemic has become the center of our daily clinical practice as well as of our private lives, in which avoiding infection has become one of our most important goals. Even though COVID-19 is a potentially lethal disease, especially for the elderly and people with chronic diseases, it did not cause all the other life-threatening diseases to vanish. On the contrary, many scheduled medical activities and procedures, especially preventive and non-urgent internal and surgical activities, had to be postponed due to COVID-19 crisis. This interruption in the health care system can negatively affect the diagnosis and management of our patients with other health issues, namely malignant skin tumors, of which melanoma is the most aggressive. In this letter, we as dermatovenereologists from the Croatian Referral Centre of The Ministry of Health for Melanoma needed to express our concern regarding the increasing number of patients with delayed diagnosis of skin cancer, with special emphasis on melanoma detection and treatment. In the last few months, a large number of our newly-diagnosed patients with melanoma, as well as those with non-melanoma skin cancers, reported that they had noticed a suspicious skin lesion a few months ago but decided not to seek help from dermatologist due to the worrisome epidemiologic situation. In the current environment, clinical skin examination may be viewed as less important and thus postponed, but neglecting melanoma throughout the virus outbreak may lead to increased rates of morbidity, mortality, and consequently a greater financial burden for the health system (1). There are several reasons for such a relaxed attitude towards skin health in our patients. Unlike cardiac, pulmonary, or digestive difficulties, which patients consider life-threatening and for which they seek emergency care despite the coronavirus pandemic, skin tumors do not cause great subjective or significantly noticeable objective symptoms. Moreover, all of the skin tumors and especially melanoma , mostly present as small changes of just a few millimeters in diameter in the early stage at which they are prognostically most favorable. For the average person with no medical education, such small lesions usually do not cause any concern as they have no awareness of the fact that small and inconspicuous skin lesions may be dangerous and potentially even lethal. According to the recommendations concerning patient management during COVID-19 pandemic, oncological examinations should still be performed regularly (2). In spite of that, the cancelation of appointments, especially by patients who are being monitored for high-risk lesions, is inevitable when COVID-19 is disrupting everyone's lives. With the pandemic evolving and no clear solutions in sight, now is the time to emphasize the importance of self-examination and teledermatology in early melanoma diagnosis. Even though diagnosing and managing pigmented skin lesions usually requires face-to-face examinations and dermoscopy as a crucial tool in early melanoma detection, in these times, and especially for people with a higher risk of SARS-COV2 infection, remote communication could prevent delays resulting in worse prognosis and could also eliminate the risk of infecting healthcare workers. Moreover, teledermatology can also be initiated by doctors asking patients to monitor lesions between clinical visits (3). However, we should not rely solely on this technology but should instead assess every patient individually and insist on a face-to-face examination for those at greater risk, with the aim that, if necessary, surgery be performed in timely manner. The collaboration between general practitioners and dermatologists represents an important aspect of achieving the most rational and effective health care in terms of performing triage of patients who can be assessed by teledermatology as well as referring to hospital centers those who need face-to-face examination and further treatment. During the first breakout of the epidemic in March 2020, the multidisciplinary team for melanoma from the Croatian National Referral Melanoma Centre provided recommendations for the management of patients with melanoma during COVID epidemic, designed according to the guidelines of the National Comprehensive Cancer Network (NCCN) (4) and considering the specifics of health care and clinical practice in the Republic of Croatia. Due to epidemic circumstances, preventive actions such as Euromelanoma and many other campaigns that included massive preventive skin examinations of the population and which were conducted for years by Croatian dermatologists throughout the country, could not be organized this year. This is particularly worrisome because on average about 800 patients are diagnosed with melanoma annually in Croatia, of which 60 during public health preventive actions. Despite these circumstances, we were able to maintain public awareness of the importance of early skin cancer recognition by sending the message through different media such as newspapers, television, and social media (Facebook and Instagram). We find that now more than ever it is essential to remind and teach the population about the importance of regular monthly skin self-examinations and recognition of atypical lesions. Clearly, a thorough dermatological examination includes full skin examination from head to toe. Herein we would also like to remind our readers that most skin cancers develop in the head and neck area, which is the most UV-exposed part of the body. Therefore, despite the epidemic conditions, the removal of patients' masks and thorough inspection of the face is mandatory. We find it most practical and efficient to perform the body and scalp examination first, followed by the face examination after the patient gets dressed. Prior to removal of the mask, we ask the patient not to talk during close examination. Even though this could make dermoscopic examination harder to perform, we strongly suggest wearing a protective shield and mask during close examination whenever possible. Between patients, the examining room should be disinfected and ventilated. As doctors, we live in uncertain times when we are heavily burdened by the currently unstoppable COVID epidemic, always awaiting new instructions from the state administration every day and wondering whether perhaps tomorrow we dermatologists will be assigned solely to the service of patients with COVID-19. In the end, we would like to once again remind you that despite the ravaging COVID pandemic and all the epidemiological measures that come with it, other diseases still exist. It is expected of us to draw attention to the still growing incidence of skin cancers and the serious consequences that can occur as a result of a delayed diagnosis. FAU - Situm, Mirna AU - Situm M FAU - Filipovic, Nika AU - Filipovic N AD - Nika Filipovic, MD. University Hospital Centre Sestre Milosrdnice. Vinogradska cesta 29, Zagreb, Croatia; nikafilipovic07@gmail.com. FAU - Buljan, Marija AU - Buljan M LA - eng PT - Journal Article PL - Croatia TA - Acta Dermatovenerol Croat JT - Acta dermatovenerologica Croatica : ADC JID - 9433781 SB - IM MH - COVID-19/*epidemiology MH - Croatia/epidemiology MH - *Delayed Diagnosis MH - Health Services Accessibility MH - Humans MH - Melanoma/*diagnosis/*therapy MH - Pandemics MH - Patient Acceptance of Health Care MH - SARS-CoV-2 MH - Skin Neoplasms/*diagnosis/*therapy MH - *Time-to-Treatment EDAT- 2021/09/04 06:00 MHDA- 2021/09/10 06:00 CRDT- 2021/09/03 08:41 PHST- 2021/09/03 08:41 [entrez] PHST- 2021/09/04 06:00 [pubmed] PHST- 2021/09/10 06:00 [medline] PST - ppublish SO - Acta Dermatovenerol Croat. 2021 Apr;291(1):58. PMID- 34475919 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220426 IS - 1682-024X (Print) IS - 1681-715X (Electronic) IS - 1681-715X (Linking) VI - 37 IP - 5 DP - 2021 Sep-Oct TI - Demographic profile and clinical picture of patients presented with Paraphenylene Diamine (PPD)/ Kala Pathar poisoning at a District Teaching Hospital. PG - 1397-1401 LID - 10.12669/pjms.37.5.4251 [doi] AB - OBJECTIVES: To document demographic profile, clinical features and management of patients presented with PPD/Kala Pathar poisoning at District Teaching Hospital Sahiwal, Pakistan. METHODS: This cross-sectional study utilized data for cases of PPD poisoning presented at study place from 1(st) July 2019 to 30(th) June 2020. Relevant information was recorded on a proforma. RESULTS: A total of 111 cases were included in study. Mean age was 23.01 +/- 7.24 years. Majority of cases were observed in females (82%) and majority presented from rural areas (87.4%). Cervico-facial edema (78.4%) and respiratory distress (66.7%) were the most common findings. Evidence of some level of organ damage was recorded in following manner: kidneys (44.1%), musculoskeletal (50.5%) and cardiac (45.9%). Tracheostomy was carried out in 47.7% cases and dialysis in 11.7% cases. All cases ingested PPD in raw form. Mortality rate was 50.5%. CONCLUSION: PPD poisoning is associated with high rate of morbidity and mortality. Effective clinical management requires multidisciplinary approach. Measures to restrict access to this means of suicide are urgently needed. We need to set up a surveillance system for cases of attempted suicide. CI - Copyright: (c) Pakistan Journal of Medical Sciences. FAU - Akbar, Sheraz AU - Akbar S AD - Dr. Sheraz Akbar (MBBS), Demonstrator Community Medicine Department, Sahiwal Medical College (SLMC), Sahiwal, Punjab-Pakistan. FAU - Siddiqui, Zahid Kamal AU - Siddiqui ZK AD - Dr. Zahid Kamal Siddiqui (MBBS, FRCS, FCPS), Professor of Ophthalmology and Principal, Sahiwal Medical College (SLMC), Sahiwal, Punjab-Pakistan. FAU - Diwan, Rana Aamir AU - Diwan RA AD - Dr. Rana Aamir Diwan (MBBS, MPH), Professor and Head of Community Medicine Department, Sahiwal Medical College (SLMC), Sahiwal, Punjab-Pakistan. FAU - Rehm, Muhammad Hassam AU - Rehm MH AD - Dr. Muhammad Hassam Rehm (MBBS, MHM), Assistant Professor Community Medicine Department, Sahiwal Medical College (SLMC), Sahiwal, Punjab-Pakistan. LA - eng PT - Journal Article PL - Pakistan TA - Pak J Med Sci JT - Pakistan journal of medical sciences JID - 100913117 PMC - PMC8377935 OTO - NOTNLM OT - Cervico-facial edema OT - Paraphenylene Diamine (PPD) OT - Suicide OT - Tracheostomy OT - deliberate self-harm OT - kala Pathar COIS- Conflict of Interest: None. EDAT- 2021/09/04 06:00 MHDA- 2021/09/04 06:01 PMCR- 2021/09/01 CRDT- 2021/09/03 06:49 PHST- 2021/02/05 00:00 [received] PHST- 2021/05/06 00:00 [accepted] PHST- 2021/09/03 06:49 [entrez] PHST- 2021/09/04 06:00 [pubmed] PHST- 2021/09/04 06:01 [medline] PHST- 2021/09/01 00:00 [pmc-release] AID - PJMS-37-1397 [pii] AID - 10.12669/pjms.37.5.4251 [doi] PST - ppublish SO - Pak J Med Sci. 2021 Sep-Oct;37(5):1397-1401. doi: 10.12669/pjms.37.5.4251. PMID- 34475150 OWN - NLM STAT- MEDLINE DCOM- 20210915 LR - 20210923 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 11 IP - 9 DP - 2021 Sep 2 TI - Barriers and facilitators to interdisciplinary communication during consultations: a qualitative study. PG - e046111 LID - 10.1136/bmjopen-2020-046111 [doi] LID - e046111 AB - OBJECTIVE: Communication failures between clinicians lead to poor patient outcomes. Critically injured patients have multiple injured organ systems and require complex multidisciplinary care from a wide range of healthcare professionals and communication failures are abundantly common. This study sought to determine barriers and facilitators to interdisciplinary communication between the consulting trauma, intensive care unit (ICU) team and specialty consultants for critically injured patients at an urban, safety-net, level 1 trauma centre. DESIGN: An observational qualitative study of barriers and facilitators to interdisciplinary communication. SETTING: We conducted observations of daily rounds in two trauma surgical ICUs and recorded the most frequently consulted teams. PARTICIPANTS: Key informant interviews after presenting clinical vignettes as discussion prompts were conducted with a broad range of clinicians from the ICUs and physicians and nurse practitioners from the consultant teams who were identified during the observations. Interviews were recorded and transcribed verbatim. Data of these 10 interviews were combined with primary transcript data from prior study (25 interviews) and analysed together because of the same setting with same themes. Independent coding of the transcripts, with iterative reconciliation, was performed by two coders. OUTCOMES MEASURES: Facilitators and barriers of interdisciplinary communication were identified. RESULTS: A total of 35 interview transcripts were analysed. Cardiology and interventional radiology were the most frequently consulted teams. Consulting and consultant clinicians reported that perceived accessibility from the team seeking a consultation and the consultant team impacted interdisciplinary communication. Accessibility had a physical dimension as well as a psychological dimension. Accessibility was demonstrated by responsiveness between clinicians of different disciplines and in turn facilitated interdisciplinary communication. Social norms, cognitive biases, hierarchy and relationships were reported as both facilitators and barriers to accessibility, and therefore, interdisciplinary communication. CONCLUSION: Accessibility impacted interdisciplinary communication between the consulting and the consultant team. ARTICLE SUMMARY: Elucidates barriers and facilitators to interdisciplinary communication between consulting and consultant teams. CI - (c) Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Liu, Pingyang AU - Liu P AD - Department of Surgery, University of California San Francisco, San Francisco, California, USA. FAU - Lyndon, Audrey AU - Lyndon A AUID- ORCID: 0000-0003-2215-4273 AD - Rory Meyers College of Nursing, New York University, New York City, New York, USA. FAU - Holl, Jane L AU - Holl JL AD - Department of Neurology, University of Chicago, Chicago, Illinois, USA. FAU - Johnson, Julie AU - Johnson J AD - Center of Health Services and Outcomes Research, Institute for Public Health and Medicine, Chicago, Illinois, USA. AD - Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. FAU - Bilimoria, Karl Y AU - Bilimoria KY AD - Center of Health Services and Outcomes Research, Institute for Public Health and Medicine, Chicago, Illinois, USA. AD - Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. FAU - Stey, Anne M AU - Stey AM AUID- ORCID: 0000-0002-8334-0304 AD - Center of Health Services and Outcomes Research, Institute for Public Health and Medicine, Chicago, Illinois, USA as013j@gmail.com. AD - Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. LA - eng PT - Journal Article PT - Observational Study DEP - 20210902 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 SB - IM MH - Communication MH - Communication Barriers MH - Health Personnel MH - Humans MH - Intensive Care Units MH - *Interdisciplinary Communication MH - Qualitative Research MH - *Referral and Consultation PMC - PMC8413943 OTO - NOTNLM OT - adult intensive & critical care OT - organisational development OT - qualitative research OT - trauma management COIS- Competing interests: None declared. EDAT- 2021/09/04 06:00 MHDA- 2021/09/16 06:00 PMCR- 2021/09/02 CRDT- 2021/09/03 05:58 PHST- 2021/09/03 05:58 [entrez] PHST- 2021/09/04 06:00 [pubmed] PHST- 2021/09/16 06:00 [medline] PHST- 2021/09/02 00:00 [pmc-release] AID - bmjopen-2020-046111 [pii] AID - 10.1136/bmjopen-2020-046111 [doi] PST - epublish SO - BMJ Open. 2021 Sep 2;11(9):e046111. doi: 10.1136/bmjopen-2020-046111. PMID- 36409795 STAT- Publisher PB - Canadian Agency for Drugs and Technologies in Health CTI - CADTH Health Technology Review DP - 2021 Sep BTI - Heart Function Clinics for Patients With Heart Failure AB - A 2018 report from the Canadian Chronic Disease Surveillance System estimated about 669,600 (3.6%) Canadian adults aged 40 years and older were living with heart failure (HF). The direct health care cost for HF in Canada was estimated to be CA$2.8 billion per year by a 2016 Heart and Stroke Foundation report. Despite recent developments in evidence-based care for HF, the overall hospital readmission and all-cause mortality rates among people living with HF remain relatively high. Many strategies have been developed for the transition care for patients with HF after being discharged from the hospital, with an intent to improve outcomes and to reduce mortality and rehospitalization. Models of care that appear to be more effective among treatment strategies in reducing mortality and rehospitalization include nurse-led titration of drugs, programs promoting self-care, outpatient cardiologist care, and multidisciplinary clinics. A multidisciplinary team of health care professionals includes, at a minimum, a cardiologist and a nurse specialist, with other specialists including a dietician, pharmacist, psychologist, physiotherapist, and/or social worker. Recent evidence has shown that many multidisciplinary disease management programs including HF clinics were associated with reductions in mortality and readmission rates. However, the clinical benefit of the multidisciplinary HF clinics remains uncertain and whether the benefit is balanced against the cost for implementing this intervention is unknown. The aim of this report is to summarize the evidence regarding the clinical effectiveness and cost-effectiveness of multidisciplinary HF clinics in adults with HF. The terms "heart function clinic" and "heart failure clinic" are synonymous and, as all the included studies for this report used "heart failure clinic," the latter term is used throughout this report. CI - Copyright (c) 2021 Canadian Agency for Drugs and Technologies in Health. FAU - Tran, Khai AU - Tran K FAU - Butcher, Robyn AU - Butcher R LA - eng PT - Review PT - Book PL - Ottawa (ON) EDAT- 2021/09/01 00:00 CRDT- 2021/09/01 00:00 AID - NBK586485 [bookaccession] PMID- 34459226 OWN - NLM STAT- MEDLINE DCOM- 20220104 LR - 20220115 IS - 2047-9980 (Electronic) IS - 2047-9980 (Linking) VI - 10 IP - 17 DP - 2021 Sep 7 TI - Redo Surgical Mitral Valve Replacement Versus Transcatheter Mitral Valve in Valve From the National Inpatient Sample. PG - e020948 LID - 10.1161/JAHA.121.020948 [doi] LID - e020948 AB - Background Redo mitral valve surgery is required in up to one-third of patients and is associated with significant mortality and morbidity. Valve-in-valve transcatheter mitral valve replacement (ViV TMVR) is less invasive and could be considered in those at prohibitive surgical risk. Studies on comparative outcomes of ViV TMVR and redo surgical mitral valve replacement (SMVR) remain limited. Our study aimed to investigate the real-world outcomes of the above procedures using the National Inpatient Sample database. Methods and Results We analyzed National Inpatient Sample data using the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) from September 2015 to December 2018. A total of 495 and 2250 patients underwent redo ViV TMVR and SMVR, respectively. The patients who underwent ViV TMVR were older (77 versus 68 years, P<0.01). Adjusted mortality was higher in the redo SMVR group compared with the ViV TMVR group (7.6% versus <2.8%, P<0.01). Perioperative complications were higher among patients undergoing redo SMVR including blood transfusions (38% versus 7.6%, P<0.01) and acute kidney injury (36.7% versus 13.9%, P<0.01). Cost of care was higher (USD$57 172 versus USD$52 579, P<0.01), length of stay was longer (10 versus 3 days, P<0.01), and discharge to home was lower (20.3% versus 64.6%, P<0.01) in the SMVR group compared with the ViV TMVR group. Conclusions ViV TMVR is associated with lower mortality, periprocedural morbidity, and resource use compared with patients undergoing redo SMVR. ViV TMVR may be a viable option for some patients with mitral prosthesis dysfunction. Studies evaluating long-term outcomes and durability of ViV TMVR are needed. A patient-centered approach by the heart team, local institutional expertise, and careful preprocedure planning can help decision-making about the choice of intervention for the individual patient. FAU - Zia Khan, Muhammad AU - Zia Khan M AUID- ORCID: 0000-0001-8473-8069 AD - Division of Cardiovascular Medicine West Virginia University Heart & Vascular Institute Morgantown WV. FAU - Zahid, Salman AU - Zahid S AUID- ORCID: 0000-0003-2754-9397 AD - Department of Medicine Rochester General Hospital Rochester NY. FAU - Khan, Muhammad U AU - Khan MU AD - Division of Cardiovascular Medicine West Virginia University Heart & Vascular Institute Morgantown WV. FAU - Kichloo, Asim AU - Kichloo A AUID- ORCID: 0000-0003-4788-8572 AD - St. Mary's of Saginaw Hospital Saginaw MI. FAU - Jamal, Shakeel AU - Jamal S AD - St. Mary's of Saginaw Hospital Saginaw MI. FAU - Mannan Khan Minhas, Abdul AU - Mannan Khan Minhas A AD - Forrest General Hospital Hattiesburg MS. FAU - Ullah, Waqas AU - Ullah W AUID- ORCID: 0000-0002-4850-0309 AD - Abington Jefferson Health PA. FAU - Sattar, Yasar AU - Sattar Y AUID- ORCID: 0000-0002-1304-5748 AD - Division of Cardiovascular Medicine West Virginia University Heart & Vascular Institute Morgantown WV. FAU - Balla, Sudarshan AU - Balla S AUID- ORCID: 0000-0002-7872-3757 AD - Division of Cardiovascular Medicine West Virginia University Heart & Vascular Institute Morgantown WV. LA - eng PT - Journal Article DEP - 20210828 PL - England TA - J Am Heart Assoc JT - Journal of the American Heart Association JID - 101580524 SB - IM MH - *Cardiac Catheterization MH - *Heart Valve Prosthesis Implantation/adverse effects MH - Humans MH - Inpatients MH - *Mitral Valve/surgery MH - *Reoperation MH - Treatment Outcome PMC - PMC8649266 OTO - NOTNLM OT - redo mitral valve surgery OT - redo valve replacement OT - transcatheter mitral valve in valve COIS- None. EDAT- 2021/08/31 06:00 MHDA- 2022/01/05 06:00 PMCR- 2021/09/07 CRDT- 2021/08/30 08:39 PHST- 2021/08/31 06:00 [pubmed] PHST- 2022/01/05 06:00 [medline] PHST- 2021/08/30 08:39 [entrez] PHST- 2021/09/07 00:00 [pmc-release] AID - JAH36679 [pii] AID - 10.1161/JAHA.121.020948 [doi] PST - ppublish SO - J Am Heart Assoc. 2021 Sep 7;10(17):e020948. doi: 10.1161/JAHA.121.020948. Epub 2021 Aug 28. PMID- 34458879 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220426 IS - 2666-5204 (Electronic) IS - 2666-5204 (Linking) VI - 7 DP - 2021 Sep TI - The use of a cognitive aid app supports guideline-conforming cardiopulmonary resuscitations: A randomized study in a high-fidelity simulation. PG - 100152 LID - 10.1016/j.resplu.2021.100152 [doi] LID - 100152 AB - AIM: Cardiac arrests require fast, well-timed, and well-coordinated interventions delivered by several staff members. We evaluated a cognitive aid that works as an attentional aid to support specifically the timing and coordination of these interventions. We report the results of an experimental, simulation-based evaluation of the tablet-based cognitive aid in performing guideline-conforming cardiopulmonary resuscitation. METHODS: In a parallel group design, emergency teams (one qualified emergency physician as team leader and one qualified nurse) were randomly assigned to the cognitive aid application (CA App) group or the no application (No App) group and then participated in a simulated scenario of a cardiac arrest. The primary outcome was a cardiopulmonary resuscitation performance score ranging from zero to two for each team based on the videotaped scenarios in relation to twelve performance variables derived from the European Resuscitation Guidelines. As a secondary outcome, we measured the participants' subjective workload. RESULTS: A total of 67 teams participated. The CA App group (n = 32 teams) showed significantly better cardiopulmonary resuscitation performance than the No App group (n = 31 teams; mean difference = 0.23, 95 %CI = 0.08 to 0.38, p = 0.002, d = 0.83). The CA App group team leaders indicated significantly less mental and physical demand and less effort to achieve their performance compared to the No App group team leaders. CONCLUSIONS: Among well-trained in-hospital emergency teams, the cognitive aid could improve cardiopulmonary resuscitation coordination performance and decrease mental workload. CI - (c) 2021 The Author(s). FAU - Grundgeiger, T AU - Grundgeiger T AD - Institute Human-Computer-Media, Julius-Maximilians-Universitat Wurzburg, Oswald-Kulpe-Weg 82, 97074 Wurzburg, Germany. FAU - Hahn, F AU - Hahn F AD - Department of Anaesthesiology, Intensive Care, Emergency and Pain Medicine, University Hospital of Wurzburg, Oberdurrbacher Strasse 6, 97080 Wurzburg, Germany. FAU - Wurmb, T AU - Wurmb T AD - Department of Anaesthesiology, Intensive Care, Emergency and Pain Medicine, University Hospital of Wurzburg, Oberdurrbacher Strasse 6, 97080 Wurzburg, Germany. FAU - Meybohm, P AU - Meybohm P AD - Department of Anaesthesiology, Intensive Care, Emergency and Pain Medicine, University Hospital of Wurzburg, Oberdurrbacher Strasse 6, 97080 Wurzburg, Germany. FAU - Happel, O AU - Happel O AD - Department of Anaesthesiology, Intensive Care, Emergency and Pain Medicine, University Hospital of Wurzburg, Oberdurrbacher Strasse 6, 97080 Wurzburg, Germany. LA - eng PT - Journal Article DEP - 20210817 PL - Netherlands TA - Resusc Plus JT - Resuscitation plus JID - 101774410 PMC - PMC8379507 OTO - NOTNLM OT - Cardiopulmonary resuscitation OT - Checklists OT - Crisis management OT - Information technology OT - Medical emergency team OT - Simulation COIS- The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2021/08/31 06:00 MHDA- 2021/08/31 06:01 PMCR- 2021/08/17 CRDT- 2021/08/30 06:10 PHST- 2021/04/07 00:00 [received] PHST- 2021/06/24 00:00 [revised] PHST- 2021/07/06 00:00 [accepted] PHST- 2021/08/30 06:10 [entrez] PHST- 2021/08/31 06:00 [pubmed] PHST- 2021/08/31 06:01 [medline] PHST- 2021/08/17 00:00 [pmc-release] AID - S2666-5204(21)00077-1 [pii] AID - 100152 [pii] AID - 10.1016/j.resplu.2021.100152 [doi] PST - epublish SO - Resusc Plus. 2021 Aug 17;7:100152. doi: 10.1016/j.resplu.2021.100152. eCollection 2021 Sep. PMID- 34453829 OWN - NLM STAT- MEDLINE DCOM- 20211124 LR - 20260120 IS - 2048-8734 (Electronic) IS - 2048-8726 (Linking) VI - 10 IP - 8 DP - 2021 Oct 27 TI - Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Consensus Document of the Acute CardioVascular Care (ACVC) association and the ESC council of Cardio-Oncology-Part 1: acute coronary syndromes and acute pericardial diseases. PG - 947-959 LID - 10.1093/ehjacc/zuab056 [doi] AB - Advances in treatment, common cardiovascular (CV) risk factors and the ageing of the population have led to an increasing number of cancer patients presenting with acute CV diseases. These events may be related to the cancer itself or the cancer treatment. Acute cardiac care specialists must be aware of these acute CV complications and be able to manage them. This may require an individualized and multidisciplinary approach. We summarize the most common acute CV complications of cytotoxic, targeted, and immune-based therapies. This is followed by a proposal for a multidisciplinary approach where acute cardiologists work close together with the treating oncologists, haematologists, and radiation specialists, especially in situations where immediate therapeutic decisions are needed. In this first part, we further focus on the management of acute coronary syndromes and acute pericardial diseases in patients with cancer. CI - Published on behalf of the European Society of Cardiology. All rights reserved. (c) The Author(s) 2021. For permissions, please email: journals.permissions@oup.com. FAU - Gevaert, Sofie A AU - Gevaert SA AUID- ORCID: 0000-0002-8721-3003 AD - Department of Cardiology, Ghent University Hospital, C Heymanslaan 10, 9000 Gent, Belgium. FAU - Halvorsen, Sigrun AU - Halvorsen S AD - Department of Cardiology, Oslo University Hospital Ulleval and University of Oslo, Kirkeveien 166, 0450 Oslo, Norway. FAU - Sinnaeve, Peter R AU - Sinnaeve PR AD - Department of Cardiology, University Hospital Leuven, Herestraat 49, 3000 Leuven, Belgium. FAU - Sambola, Antonia AU - Sambola A AD - Department of Cardiology, University Hospital Vall d'Hebron, Universitat Autonoma, CIBER-CV, Passeig de la Vall d'Hebron 119, 08035 Barcelona, Spain. FAU - Gulati, Geeta AU - Gulati G AD - Department of Cardiology, Oslo University Hospital Ulleval and University of Oslo, Kirkeveien 166, 0450 Oslo, Norway. FAU - Lancellotti, Patrizio AU - Lancellotti P AUID- ORCID: 0000-0002-0804-8194 AD - University of Liege Hospital, GIGA Cardiovascular Science and Department of Cardiology, CHU Sart Tilman, Avenue del'Hopital 1, 4000 Liege, Belgium. FAU - Van Der Meer, Peter AU - Van Der Meer P AD - Department of Cardiology, University of Groningen University Medical Center Groningen and University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands. FAU - Lyon, Alexander R AU - Lyon AR AD - Cardio-Oncology Clinic at Royal Brompton Hospital and Imperial College, Sydney street, SW3 6NP London, UK. FAU - Farmakis, Dimitrios AU - Farmakis D AD - University of Cyprus Medical School, Agio Nikolaou street 93, 2408 Nicosia, Cyprus. FAU - Lee, Geraldine AU - Lee G AD - Florence Nightingale Faculty of Nursing, Midwifery and Palliative Care, King's College, Strand, WC2R 2LS London, UK. FAU - Boriani, Giuseppe AU - Boriani G AUID- ORCID: 0000-0002-9820-4815 AD - Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia and Policlinico Di Modena, Via Giuseppe Campi 287, 41125 Modena, Italy. FAU - Wechalekar, Ashutosh AU - Wechalekar A AD - Department of Haematology, University College London/University College London Hospitals, Huntley street 72, WC1E 6DD London, UK. FAU - Okines, Alicia AU - Okines A AD - Department of Medicine, The Royal Marsden NHS Foundation Trust, Fulham road 203, SW3 6JJ London, UK. FAU - Asteggiano, Riccardo AU - Asteggiano R AUID- ORCID: 0000-0002-2273-7228 AD - Insubria University, Via Ravasi 2, 21100 Varese, Italy. AD - LARC (Laboratorio Analisi e Ricerca Clinica), Via Mombarcaro 80, 10136 Turin, Italy. LA - eng PT - Consensus Statement PT - Journal Article PL - England TA - Eur Heart J Acute Cardiovasc Care JT - European heart journal. Acute cardiovascular care JID - 101591369 SB - IM MH - *Acute Coronary Syndrome/therapy MH - *Cardiovascular Diseases/epidemiology/etiology/therapy MH - Humans MH - *Neoplasms/complications/therapy MH - Pericardium OTO - NOTNLM OT - Acute coronary syndromes OT - Cancer therapy OT - Cardio-oncology OT - Pericardial effusion OT - Pericarditis OT - Tamponade EDAT- 2021/08/29 06:00 MHDA- 2021/11/25 06:00 CRDT- 2021/08/28 17:04 PHST- 2021/05/17 00:00 [received] PHST- 2021/06/22 00:00 [revised] PHST- 2021/06/30 00:00 [accepted] PHST- 2021/08/29 06:00 [pubmed] PHST- 2021/11/25 06:00 [medline] PHST- 2021/08/28 17:04 [entrez] AID - 6359200 [pii] AID - 10.1093/ehjacc/zuab056 [doi] PST - ppublish SO - Eur Heart J Acute Cardiovasc Care. 2021 Oct 27;10(8):947-959. doi: 10.1093/ehjacc/zuab056. PMID- 34450470 OWN - NLM STAT- MEDLINE DCOM- 20211208 LR - 20211214 IS - 1532-8449 (Electronic) IS - 0882-5963 (Linking) VI - 61 DP - 2021 Nov-Dec TI - Emergency Planning as Part of Healthcare Transition Preparation for Patients with Duchenne Muscular Dystrophy. PG - 298-304 LID - S0882-5963(21)00236-0 [pii] LID - 10.1016/j.pedn.2021.08.003 [doi] AB - BACKGROUND: Emergency care planning is an important component of healthcare transition, particularly for patients with medical complexity. Duchenne muscular dystrophy (DMD) is a complex, progressive pediatric-onset disease affecting multiple organ systems including impairment of cardiac and pulmonary function, high risk for fractures, fat embolism, adrenal crisis and malignant hyperthermia. Appropriate interdisciplinary emergency management is critical for survival for these patients. The purpose of this quality improvement project was to develop a process to reliably share an individualized emergency care plan (ECP) with patients and their families as part of a larger plan to develop an integrated transition program. METHODS: An interdisciplinary team of nurses and clinicians used the principles of quality improvement to develop a reliable process to assure patients with DMD received an individualized, multidisciplinary ECP at routine interdisciplinary clinic visits. Additionally, the project used surveys to assess patient and family satisfaction with the letter and whether it improved their knowledge of emergency care. RESULTS: Sixty-two patients were seen during the study timeframe. All received an ECP. Sixty-two surveys were sent and twenty-three surveys were returned. Of those that responded, the majority stated the ECP increased their knowledge of emergency care. CONCLUSION: ECPs can be developed and disseminated to patients with DMD and their caregivers. This tool can potentially promote timely and appropriate emergency care for these patients with unique and complex medical needs. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - Chouteau, Wendy A AU - Chouteau WA AD - Neurology, Cincinnati Children's Hospital, OH, United States of America. Electronic address: WChouteau@icloud.com. FAU - Burrows, Carolyn AU - Burrows C AD - Pulmonary Medicine, Cincinnati Children's Hospital, OH, United States of America. Electronic address: Carolyn.Burrows@cchmc.org. FAU - Wittekind, Samuel G AU - Wittekind SG AD - Cardiology, Cincinnati Children's Hospital, OH, United States of America. Electronic address: Samuel.Wittekind@cchmc.org. FAU - Rutter, Meilan M AU - Rutter MM AD - Endocrinology, Cincinnati Children's Hospital, OH, United States of America. Electronic address: Meilan.Rutter@cchmc.org. FAU - Bange, Jean E AU - Bange JE AD - Neurology, Cincinnati Children's Hospital, OH, United States of America. Electronic address: Jean.Bange@cchmc.org. FAU - Sabla, Gregg E AU - Sabla GE AD - Pulmonary Medicine, Cincinnati Children's Hospital, OH, United States of America. Electronic address: Gregg.Sabla@cchmc.org. FAU - Rybalsky, Irina AU - Rybalsky I AD - Neurology, Cincinnati Children's Hospital, OH, United States of America. Electronic address: Irina.Rybalsky@cchmc.org. FAU - Tian, Cuixia AU - Tian C AD - Neurology, Cincinnati Children's Hospital, OH, United States of America. Electronic address: Cuixia.Tian@cchmc.org. LA - eng PT - Journal Article DEP - 20210825 PL - United States TA - J Pediatr Nurs JT - Journal of pediatric nursing JID - 8607529 SB - IM MH - Caregivers MH - Child MH - *Emergency Medical Services MH - Humans MH - *Muscular Dystrophy, Duchenne/therapy MH - Surveys and Questionnaires MH - *Transition to Adult Care OTO - NOTNLM OT - Duchenne muscular dystrophy OT - Emergency care plan OT - Health care transition OT - Quality improvement COIS- Declaration of competing interest All authors have no potential conflicts of interest. EDAT- 2021/08/28 06:00 MHDA- 2021/12/15 06:00 CRDT- 2021/08/27 20:24 PHST- 2020/12/11 00:00 [received] PHST- 2021/08/04 00:00 [revised] PHST- 2021/08/04 00:00 [accepted] PHST- 2021/08/28 06:00 [pubmed] PHST- 2021/12/15 06:00 [medline] PHST- 2021/08/27 20:24 [entrez] AID - S0882-5963(21)00236-0 [pii] AID - 10.1016/j.pedn.2021.08.003 [doi] PST - ppublish SO - J Pediatr Nurs. 2021 Nov-Dec;61:298-304. doi: 10.1016/j.pedn.2021.08.003. Epub 2021 Aug 25. PMID- 34449851 OWN - NLM STAT- MEDLINE DCOM- 20210903 LR - 20220426 IS - 1533-9866 (Electronic) IS - 0029-7828 (Linking) VI - 76 IP - 8 DP - 2021 Aug TI - Peripartum Cardiomyopathy. PG - 485-492 LID - 10.1097/OGX.0000000000000903 [doi] AB - IMPORTANCE: Peripartum cardiomyopathy is a rare form of heart failure due to left ventricular systolic dysfunction that affects women late in pregnancy and the postpartum period. A diagnosis of exclusion, peripartum cardiomyopathy can be difficult to diagnose in the context of the normal physiologic changes of pregnancy and requires a high index of suspicion. EVIDENCE ACQUISITION: Original research articles, review articles, and guidelines on peripartum cardiomyopathy were reviewed. RESULTS: The etiology of peripartum cardiomyopathy remains poorly defined, but theories include genetic predisposition, as well as myocardial inflammation and angiogenic dysregulation. Risk factors for this condition include hypertensive disorders of pregnancy, Black race, and maternal age older than 30 years. Patients with peripartum cardiomyopathy are at increased risk of acute clinical decompensation, cardiac arrhythmias, thromboembolic complications, and death. Primary treatment modalities include initiation of a medication regimen aimed at the optimization of preload and reduction of afterload. Maternal clinical status is the primary determinant for timing of delivery. CONCLUSIONS: Prompt diagnosis and medical management by an interdisciplinary care team are vital for improving outcomes in patients with peripartum cardiomyopathy. FAU - Farrell, Amanda S AU - Farrell AS AD - Medical Student. FAU - Kuller, Jeffrey A AU - Kuller JA AD - Professor, Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology. FAU - Goldstein, Sarah A AU - Goldstein SA AD - Adult Congenital Heart Disease Fellow, Division of Cardiology, Department of Medicine. FAU - Dotters-Katz, Sarah K AU - Dotters-Katz SK AD - Assistant Professor, Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Duke University School of Medicine, Durham, NC. LA - eng PT - Journal Article PT - Review PL - United States TA - Obstet Gynecol Surv JT - Obstetrical & gynecological survey JID - 0401007 SB - IM MH - Cardiomyopathies/*diagnosis/epidemiology/etiology/*pathology MH - *Disease Management MH - Female MH - Humans MH - *Peripartum Period MH - Pregnancy MH - Pregnancy Complications, Cardiovascular/*diagnosis/epidemiology/etiology/*pathology MH - Prognosis MH - Risk Factors EDAT- 2021/08/28 06:00 MHDA- 2021/09/04 06:00 CRDT- 2021/08/27 17:39 PHST- 2021/08/27 17:39 [entrez] PHST- 2021/08/28 06:00 [pubmed] PHST- 2021/09/04 06:00 [medline] AID - 10.1097/OGX.0000000000000903 [doi] PST - ppublish SO - Obstet Gynecol Surv. 2021 Aug;76(8):485-492. doi: 10.1097/OGX.0000000000000903. PMID- 34432875 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220307 IS - 2332-4260 (Electronic) IS - 2332-4252 (Linking) VI - 21 IP - 6 DP - 2021 Nov 15 TI - Intraoperative Simulation: Team Training for Resuscitation While Using Intraoperative Computed Tomography: 2-Dimensional Operative Video. PG - E546-E547 LID - 10.1093/ons/opab304 [doi] AB - Spine surgeons increasingly use intraoperative computed tomography (iCT) to facilitate surgery. iCT has several advantages, including the ability to decrease radiation exposure, improve surgical accuracy, and decrease operative time.1-3 However, the large footprint of the equipment can impede fast patient access in the event of an emergency resuscitation. This challenge is compounded when the patient is prone with rigid head fixation. To achieve fast, high-quality resuscitation, a large team must overcome numerous challenges. Cohesive team functioning under these circumstances requires planning, practice, and refinement.4 As a result of our simulation sessions, we have made several changes to the setup of our iCT cases. The following equipment is now routinely used: extralong tubing between the anesthesia circuit and patient, portable vital monitor, additional intravenous access is obtained, and extension tubing is used with all lines. We have created educational diagrams to streamline 2 challenging processes: optimal bed placement (for supination) and removal of equipment from the operating room (OR) to accommodate an influx of emergency personnel and equipment. Since the implementation of this protocol, 1 prone posterior cervical patient had intraoperative cardiac arrest. The protocol was followed. Return of spontaneous circulation was achieved within 5 min. The patient was discharged from the hospital with no neurological sequelae. During debriefing, stakeholders uniformly credited the simulated practice with this positive outcome. Emergency planning is a multifaceted process that continually evolves. With a steady flux of personnel and equipment, ongoing practice is essential to ensure readiness. Here, we share the key elements of our twice-yearly simulation. This simulation was performed on a training mannequin. This study did not involve human subjects. Any depictions of care rendered to nonidentifiable patients were standard (nonexperimental). CI - (c) Congress of Neurological Surgeons 2021. FAU - Goldberg, Jacob L AU - Goldberg JL AUID- ORCID: 0000-0003-0827-9387 AD - Department of Neurosurgery, Weill Cornell Medicine, New York, New York, USA. FAU - Bustillo, Maria AU - Bustillo M AD - Department of Anesthesiology, Weill Cornell Medicine, New York, New York, USA. FAU - Usenko, Jaroslav K AU - Usenko JK AD - Department of Anesthesiology, Weill Cornell Medicine, New York, New York, USA. FAU - Kuo, Philip AU - Kuo P AD - Department of Anesthesiology, Weill Cornell Medicine, New York, New York, USA. FAU - Kirnaz, Sertac AU - Kirnaz S AUID- ORCID: 0000-0002-4104-3985 AD - Department of Neurosurgery, Weill Cornell Medicine, New York, New York, USA. FAU - Carnevale, Joseph A AU - Carnevale JA AUID- ORCID: 0000-0002-9477-9996 AD - Department of Neurosurgery, Weill Cornell Medicine, New York, New York, USA. FAU - Schwarz, Justin T AU - Schwarz JT AD - Department of Neurosurgery, Weill Cornell Medicine, New York, New York, USA. FAU - McGrath, Lynn AU - McGrath L AD - Department of Neurosurgery, Weill Cornell Medicine, New York, New York, USA. FAU - Sommer, Fabian AU - Sommer F AD - Department of Neurosurgery, Weill Cornell Medicine, New York, New York, USA. FAU - Medary, Branden AU - Medary B AD - Department of Neurosurgery, Weill Cornell Medicine, New York, New York, USA. FAU - Hartl, Roger AU - Hartl R AD - Department of Neurosurgery, Weill Cornell Medicine, New York, New York, USA. LA - eng PT - Journal Article PL - United States TA - Oper Neurosurg JT - Operative neurosurgery (Hagerstown, Md.) JID - 101635417 SB - IM OTO - NOTNLM OT - Interdisciplinary team training OT - Intraoperative CT OT - Resuscitation OT - Workflow EDAT- 2021/08/26 06:00 MHDA- 2021/08/26 06:01 CRDT- 2021/08/25 17:27 PHST- 2021/04/20 00:00 [received] PHST- 2021/07/04 00:00 [accepted] PHST- 2021/08/26 06:00 [pubmed] PHST- 2021/08/26 06:01 [medline] PHST- 2021/08/25 17:27 [entrez] AID - 6357786 [pii] AID - 10.1093/ons/opab304 [doi] PST - ppublish SO - Oper Neurosurg. 2021 Nov 15;21(6):E546-E547. doi: 10.1093/ons/opab304. PMID- 34422930 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230920 IS - 2297-055X (Print) IS - 2297-055X (Electronic) IS - 2297-055X (Linking) VI - 8 DP - 2021 TI - Antithrombotic Treatment After Surgical and Transcatheter Heart Valve Repair and Replacement. PG - 702780 LID - 10.3389/fcvm.2021.702780 [doi] LID - 702780 AB - New antithrombotic drugs have been developed, new valve types have been designed and minimally invasive transcatheter techniques have emerged, making the choice of antithrombotic therapy after surgical or transcatheter heart valve repair and replacement increasingly complex. Moreover, due to a lack of large randomized controlled trials many recommendations for antithrombotic therapy are based on expert opinion, reflected by divergent recommendations in current guidelines. Therefore, decision-making in clinical practice regarding antithrombotic therapy for prosthetic heart valves is difficult, potentially resulting in sub-optimal patient treatment. This article compares the 2017 ESC/EACTS and 2020 ACC/AHA guidelines on the management of valvular heart disease and summarizes the available evidence. Finally, we established a convenient consensus on antithrombotic therapy after valve interventions based on over 800 annual cases of surgical and transcatheter heart valve repair and replacement and a multidisciplinary team discussion between the department of cardiovascular diseases and cardiac surgery of the University Hospitals Leuven, Belgium. CI - Copyright (c) 2021 Verstraete, Herregods, Verbrugghe, Lamberigts, Vanassche, Meyns, Oosterlinck, Rega, Adriaenssens, Van Hoof, Keuleers, Vandenbriele, Sinnaeve, Janssens, Dubois, Meuris and Verhamme. FAU - Verstraete, Andreas AU - Verstraete A AD - Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium. FAU - Herregods, Marie Christine AU - Herregods MC AD - Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium. FAU - Verbrugghe, Peter AU - Verbrugghe P AD - Department of Cardiac Surgery, University Hospitals Leuven, Leuven, Belgium. FAU - Lamberigts, Marie AU - Lamberigts M AD - Department of Cardiac Surgery, University Hospitals Leuven, Leuven, Belgium. FAU - Vanassche, Thomas AU - Vanassche T AD - Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium. FAU - Meyns, Bart AU - Meyns B AD - Department of Cardiac Surgery, University Hospitals Leuven, Leuven, Belgium. FAU - Oosterlinck, Wouter AU - Oosterlinck W AD - Department of Cardiac Surgery, University Hospitals Leuven, Leuven, Belgium. FAU - Rega, Filip AU - Rega F AD - Department of Cardiac Surgery, University Hospitals Leuven, Leuven, Belgium. FAU - Adriaenssens, Tom AU - Adriaenssens T AD - Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium. FAU - Van Hoof, Lucas AU - Van Hoof L AD - Department of Cardiac Surgery, University Hospitals Leuven, Leuven, Belgium. FAU - Keuleers, Siegmund AU - Keuleers S AD - Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium. FAU - Vandenbriele, Christophe AU - Vandenbriele C AD - Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium. FAU - Sinnaeve, Peter AU - Sinnaeve P AD - Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium. FAU - Janssens, Stefan AU - Janssens S AD - Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium. FAU - Dubois, Christophe AU - Dubois C AD - Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium. FAU - Meuris, Bart AU - Meuris B AD - Department of Cardiac Surgery, University Hospitals Leuven, Leuven, Belgium. FAU - Verhamme, Peter AU - Verhamme P AD - Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium. LA - eng PT - Journal Article PT - Systematic Review DEP - 20210805 PL - Switzerland TA - Front Cardiovasc Med JT - Frontiers in cardiovascular medicine JID - 101653388 PMC - PMC8375148 OTO - NOTNLM OT - anTithrombotic treatment OT - surgical valve repair OT - surgical valve replacement OT - transcatheter aortic valve implantation OT - transcatheter valve repair OT - transcatheter valve replacement OT - valve intervention OT - valvular heart disease COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/08/24 06:00 MHDA- 2021/08/24 06:01 PMCR- 2021/01/01 CRDT- 2021/08/23 06:37 PHST- 2021/04/29 00:00 [received] PHST- 2021/07/05 00:00 [accepted] PHST- 2021/08/23 06:37 [entrez] PHST- 2021/08/24 06:00 [pubmed] PHST- 2021/08/24 06:01 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - 10.3389/fcvm.2021.702780 [doi] PST - epublish SO - Front Cardiovasc Med. 2021 Aug 5;8:702780. doi: 10.3389/fcvm.2021.702780. eCollection 2021. PMID- 34417288 OWN - NLM STAT- MEDLINE DCOM- 20211018 LR - 20211018 IS - 1098-4275 (Electronic) IS - 0031-4005 (Linking) VI - 148 IP - 3 DP - 2021 Sep TI - Improving Discharge Efficiency and Charge Containment on a Pediatric Acute Care Cardiology Unit. LID - e2020004663 [pii] LID - 10.1542/peds.2020-004663 [doi] AB - BACKGROUND: Hospital discharge delays can negatively affect patient flow and hospital charges. Our primary aim was to increase the percentage of acute care cardiology patients discharged within 2 hours of meeting standardized medically ready (MedR) discharge criteria. Secondary aims were to reduce length of stay (LOS) and lower hospital charges. METHODS: A multidisciplinary team used quality improvement methods to implement and study MedR discharge criteria in our hospital electronic health record. The criteria were ordered on admission and modified on daily rounds. Bedside nurses documented the time when all MedR discharge criteria were met. A statistical process control chart measured interventions over time. Discharge before noon and 30-day readmissions were also tracked. Average LOS was examined, comparing the first 6 months of the intervention period to the last 6 months. Inpatient charges were reviewed for patients with >2 hours MedR discharge delay. RESULTS: The mean percentage of patients discharged within 2 hours of meeting MedR discharge criteria increased from 20% to 78% over 22 months, with more patients discharged before noon (19%-32%). Median LOS decreased from 11 days (interquartile range: 6-21) to 10 days (interquartile range: 5-19) (P = .047), whereas 30-day readmission remained stable at 16.3%. A total of 265 delayed MedR discharges beyond 2 hours occurred. The sum of inpatient charges from care provided after meeting MedR criteria was $332 038 (average $1253 per delayed discharge). CONCLUSIONS: Discharge timeliness in pediatric acute care cardiology patients can be improved by standardizing medical discharge criteria, which may shorten LOS and decrease medical charges. CI - Copyright (c) 2021 by the American Academy of Pediatrics. FAU - Madsen, Nicolas L AU - Madsen NL AD - Heart Institute nicolas.madsen@cchmc.org. AD - Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, Ohio. FAU - Porter, Andrew AU - Porter A AD - Division of Pediatric Cardiology, Department of Pediatrics, School of Medicine, Emory University, Atlanta, Georgia. FAU - Cable, Rhonda AU - Cable R AD - Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, Ohio. FAU - Hanke, Samuel P AU - Hanke SP AD - Heart Institute. AD - Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, Ohio. AD - James M Anderson Center for Health Systems Excellence. FAU - Hoerst, Amanda AU - Hoerst A AD - Heart Institute. FAU - Neogi, Smriti AU - Neogi S AD - James M Anderson Center for Health Systems Excellence. FAU - Brower, Laura H AU - Brower LH AD - Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, Ohio. AD - Division of Hospital Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. FAU - White, Christine M AU - White CM AD - Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, Ohio. AD - James M Anderson Center for Health Systems Excellence. AD - Division of Hospital Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. FAU - Statile, Angela M AU - Statile AM AD - Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, Ohio. AD - James M Anderson Center for Health Systems Excellence. AD - Division of Hospital Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. LA - eng PT - Journal Article PL - United States TA - Pediatrics JT - Pediatrics JID - 0376422 SB - IM MH - Benchmarking MH - *Cardiology Service, Hospital MH - *Hospital Units MH - Hospitals, Pediatric MH - Humans MH - Length of Stay/statistics & numerical data MH - Ohio MH - Patient Care Team MH - *Patient Discharge MH - Patient Readmission/statistics & numerical data MH - *Pediatrics MH - Quality Improvement/*organization & administration COIS- POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential conflicts of interest to disclose. EDAT- 2021/08/22 06:00 MHDA- 2021/10/21 06:00 CRDT- 2021/08/21 05:35 PHST- 2021/03/04 00:00 [accepted] PHST- 2021/08/22 06:00 [pubmed] PHST- 2021/10/21 06:00 [medline] PHST- 2021/08/21 05:35 [entrez] AID - peds.2020-004663 [pii] AID - 10.1542/peds.2020-004663 [doi] PST - ppublish SO - Pediatrics. 2021 Sep;148(3):e2020004663. doi: 10.1542/peds.2020-004663. PMID- 34417049 OWN - NLM STAT- MEDLINE DCOM- 20230411 LR - 20230419 IS - 1097-685X (Electronic) IS - 0022-5223 (Linking) VI - 165 IP - 5 DP - 2023 May TI - Prevention of postoperative delirium after cardiovascular surgery: A team-based approach. PG - 1873-1881.e2 LID - S0022-5223(21)01126-0 [pii] LID - 10.1016/j.jtcvs.2021.07.027 [doi] AB - OBJECTIVE: We investigated the efficacy of the Delirium Team Approach program for delirium prevention after cardiovascular surgery. METHODS: We retrospectively investigated 256 patients who underwent cardiac or thoracic vascular surgery between May 2017 and May 2020. We compared the outcomes before and after implementation of the Delirium Team Approach program in December 2018. The program included the following components: (a) educational sessions for the medical team regarding delirium and its management, (b) review of preprinted physician orders for insomnia and agitation, and (c) routine screening for delirium. We investigated the early outcomes and effects of the Delirium Team Approach program on postoperative delirium. RESULTS: The incidence of postoperative delirium significantly decreased from 53.3% to 37.0% after implementation of the Delirium Team Approach program (P = .008). Although no intergroup differences were observed in the rates of stroke and reexploration for bleeding, the length of intensive care unit stay and the overall length of postoperative hospital stay were shorter in the postintervention group. Hospital costs, excluding surgery, and the cost during intensive care unit stay were lower in the postintervention group. Multivariable analysis showed that the Delirium Team Approach program was associated with a reduction in postoperative delirium (odds ratio, 0.38; 95% confidence interval, 0.21-0.67; P = .001). Other predictors of delirium included age, dementia, chronic kidney disease, and intubation time. After risk adjustment using propensity score matching, the rate of postoperative delirium was lower in the postintervention group. CONCLUSIONS: Implementation of the Delirium Team Approach program was associated with a lower incidence of postoperative delirium in patients who underwent cardiovascular surgery. CI - Copyright (c) 2021 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved. FAU - Enomoto, Kiichi AU - Enomoto K AD - Department of Pharmacy, Nerima Hikarigaoka Hospital, Tokyo, Japan. FAU - Kosaka, Shintaro AU - Kosaka S AD - Department of Internal Medicine, Nerima Hikarigaoka Hospital, Tokyo, Japan. FAU - Kimura, Toru AU - Kimura T AD - Department of Rehabilitation, Nerima Hikarigaoka Hospital, Tokyo, Japan. FAU - Matsubara, Mikako AU - Matsubara M AD - Department of Rehabilitation, Nerima Hikarigaoka Hospital, Tokyo, Japan. FAU - Kitada, Yuichiro AU - Kitada Y AD - Department of Cardiovascular Surgery, Nerima Hikarigaoka Hospital, Tokyo, Japan. FAU - Mieno, Makiko AU - Mieno M AD - Department of Medical Informatics, Center for Information, Jichi Medical University, Tochigi, Japan. FAU - Okamura, Homare AU - Okamura H AD - Department of Cardiovascular Surgery, Nerima Hikarigaoka Hospital, Tokyo, Japan. Electronic address: homareo@jadecom.jp. LA - eng PT - Journal Article DEP - 20210724 PL - United States TA - J Thorac Cardiovasc Surg JT - The Journal of thoracic and cardiovascular surgery JID - 0376343 SB - IM CIN - J Thorac Cardiovasc Surg. 2023 May;165(5):1883-1884. doi: 10.1016/j.jtcvs.2021.08.002. PMID: 34417047 CIN - J Thorac Cardiovasc Surg. 2023 May;165(5):1882-1883. doi: 10.1016/j.jtcvs.2021.08.003. PMID: 34454732 MH - Humans MH - *Emergence Delirium MH - Retrospective Studies MH - Educational Status MH - Heart MH - Hospital Costs OTO - NOTNLM OT - Delirium Team Approach program OT - benzodiazepine OT - cardiovascular surgery OT - postoperative delirium EDAT- 2021/08/22 06:00 MHDA- 2023/04/11 06:42 CRDT- 2021/08/21 05:28 PHST- 2021/02/01 00:00 [received] PHST- 2021/06/29 00:00 [revised] PHST- 2021/07/15 00:00 [accepted] PHST- 2023/04/11 06:42 [medline] PHST- 2021/08/22 06:00 [pubmed] PHST- 2021/08/21 05:28 [entrez] AID - S0022-5223(21)01126-0 [pii] AID - 10.1016/j.jtcvs.2021.07.027 [doi] PST - ppublish SO - J Thorac Cardiovasc Surg. 2023 May;165(5):1873-1881.e2. doi: 10.1016/j.jtcvs.2021.07.027. Epub 2021 Jul 24. PMID- 34410528 OWN - NLM STAT- MEDLINE DCOM- 20210825 LR - 20261012 IS - 1534-3170 (Electronic) IS - 1523-3782 (Linking) VI - 23 IP - 10 DP - 2021 Aug 19 TI - Pregnancy-Associated Myocardial Infarction: A Review of Current Practices and Guidelines. PG - 142 LID - 10.1007/s11886-021-01579-z [doi] AB - PURPOSE OF REVIEW: Pregnancy-associated myocardial infarction is a principal cause of cardiovascular disease with a steadily rising incidence of 4.98 AMI events/100,000 deliveries over the last four decades in the USA. It is also linked with significant maternal and fetal morbidity and mortality, with maternal case fatality rate ranging from 5.1 to 37%. The management of acute myocardial infarction can be challenging in pregnant patients since treatment modalities and medication use are limited by their safety during pregnancy. RECENT FINDINGS: Limited guidelines exist regarding the management of pregnancy-associated myocardial infarction. Routinely used medications in myocardial infarction including angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), and statin therapy are contraindicated during pregnancy. Aspirin use is considered safe in pregnant women, but dual antiplatelet therapy and therapeutic anticoagulation can be associated with increased risk of maternal and fetal complications, and should only be used after a comprehensive benefit-to-risk assessment. The standard approach to revascularization requires additional caution in pregnant women. Percutaneous coronary intervention is generally considered safe but can be associated with high failure rates and poor outcomes depending on the etiology. Fibrinolytic therapy may have significant sequelae in pregnant patients, and hemodynamic management during surgery is complex and adds risk during pregnancy. Understanding the risks and benefits of the different treatment modalities available and their utility depending on the underlying etiology, encompassed with a multidisciplinary team approach, is vital to improve outcomes and minimize maternal and fetal complications. CI - (c) 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Alameh, Anas AU - Alameh A AUID- ORCID: 0000-0002-3121-7435 AD - Department of Internal Medicine, Cleveland Clinic Akron General, Akron, OH, USA. FAU - Jabri, Ahmad AU - Jabri A AD - Heart and Vascular Center, Case Western Reserve University/MetroHealth Medical Center, Cleveland, OH, USA. FAU - Aleyadeh, Wesam AU - Aleyadeh W AD - Toronto General Hospital, University Health Network, Toronto, Ontario, Canada. FAU - Nasser, Farhan AU - Nasser F AD - Heart and Vascular Center, Case Western Reserve University/MetroHealth Medical Center, Cleveland, OH, USA. FAU - Al Abdouh, Ahmad AU - Al Abdouh A AD - Department of Internal Medicine, Saint Agnes Hospital, Baltimore, MD, USA. FAU - Kondapaneni, Meera AU - Kondapaneni M AD - Heart and Vascular Center, Case Western Reserve University/MetroHealth Medical Center, Cleveland, OH, USA. FAU - Gulati, Martha AU - Gulati M AD - Division of Cardiology, University of Arizona College of Medicine, Phoenix, AZ, USA. FAU - Mattina, Deirdre AU - Mattina D AD - Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA. FAU - Singh, Katherine AU - Singh K AD - Department of Obstetrics and Gynecology, Cleveland Clinic, Cleveland, OH, USA. FAU - Hargrave, Jennifer AU - Hargrave J AD - Department of Cardiothoracic Anesthesiology, Cleveland Clinic, Cleveland, OH, USA. FAU - Roselli, Eric E AU - Roselli EE AD - Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH, USA. FAU - Khot, Umesh N AU - Khot UN AD - Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA. FAU - Cho, Leslie AU - Cho L AD - Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA. FAU - Kalra, Ankur AU - Kalra A AD - Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA. kalraa@ccf.org. AD - Section of Cardiovascular Research, Heart, Vascular and Thoracic Department, Cleveland Clinic Akron General, Akron, OH, USA. kalraa@ccf.org. LA - eng PT - Journal Article PT - Review DEP - 20210819 PL - United States TA - Curr Cardiol Rep JT - Current cardiology reports JID - 100888969 RN - 0 (Angiotensin Receptor Antagonists) RN - 0 (Angiotensin-Converting Enzyme Inhibitors) SB - IM MH - Angiotensin Receptor Antagonists MH - Angiotensin-Converting Enzyme Inhibitors/therapeutic use MH - Female MH - Humans MH - Incidence MH - *Myocardial Infarction/therapy MH - *Percutaneous Coronary Intervention MH - Pregnancy OTO - NOTNLM OT - Cardio-obstetrics OT - Dissection OT - Myocardial infarction OT - Pregnancy OT - Revascularization EDAT- 2021/08/20 06:00 MHDA- 2021/08/26 06:00 CRDT- 2021/08/19 12:29 PHST- 2021/06/10 00:00 [accepted] PHST- 2021/08/19 12:29 [entrez] PHST- 2021/08/20 06:00 [pubmed] PHST- 2021/08/26 06:00 [medline] AID - 10.1007/s11886-021-01579-z [pii] AID - 10.1007/s11886-021-01579-z [doi] PST - epublish SO - Curr Cardiol Rep. 2021 Aug 19;23(10):142. doi: 10.1007/s11886-021-01579-z. PMID- 34410511 OWN - NLM STAT- MEDLINE DCOM- 20210825 LR - 20261010 IS - 1534-3170 (Electronic) IS - 1523-3782 (Linking) VI - 23 IP - 10 DP - 2021 Aug 19 TI - Diagnosis and Management of Failed Surgical Tricuspid Valve Annuloplasty. PG - 137 LID - 10.1007/s11886-021-01569-1 [doi] AB - PURPOSE OF THE REVIEW: Annular-based strategies for treating tricuspid valve (TV) regurgitation do not always have satisfactory long-term outcomes. Management of failed TV annuloplasty can be challenging and requires a dedicated heart team approach. This review explores the treatment options available for failed TV annuloplasty. RECENT FINDINGS: Recent developments and novel percutaneous treatment options have emerged as promising alternatives for patients with failed TV annuloplasty. Leaflet-based interventions, valve-in-valve procedures, transcatheter tricuspid valves and new-generation trans-caval valves are all feasible options, which can assure good results whilst minimizing risks for the patient. Failure of tricuspid annuloplasty is not uncommon amongst patients treated with either a tricuspid ring or suture-based device. The complex anatomy, physiology and clinical risk profile should be carefully evaluated on an individual patient-by-patient basis in order to select the most appropriate clinical and percutaneous treatment strategy. Different transcatheter tricuspid valve repair or replacement techniques may provide an attractive alternative treatment option for managing this challenging patient cohort. CI - (c) 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Mangieri, Antonio AU - Mangieri A AD - Invasive Cardiology Unit, Humanitas Clinical and Research Center, IRCCS, Alessandro Manzoni, 56, 20089, Rozzano, Milan, Italy. AD - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy. FAU - Laricchia, Alessandra AU - Laricchia A AD - Cardiology Unit, ASST Melegnano-Martesana, Milan, Italy. FAU - Cereda, Alberto AU - Cereda A AD - Cardiovascular Department, ASST Santi Paolo e Carlo, Milan, Italy. FAU - Khokhar, Arif A AU - Khokhar AA AD - GVM Care & Research, Maria Cecilia Hospital, Cotignola, Italy. FAU - Regazzoli, Damiano AU - Regazzoli D AD - Invasive Cardiology Unit, Humanitas Clinical and Research Center, IRCCS, Alessandro Manzoni, 56, 20089, Rozzano, Milan, Italy. AD - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy. FAU - Giannini, Francesco AU - Giannini F AD - GVM Care & Research, Maria Cecilia Hospital, Cotignola, Italy. FAU - Reimers, Bernhard AU - Reimers B AD - Invasive Cardiology Unit, Humanitas Clinical and Research Center, IRCCS, Alessandro Manzoni, 56, 20089, Rozzano, Milan, Italy. AD - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy. FAU - Colombo, Antonio AU - Colombo A AD - Invasive Cardiology Unit, Humanitas Clinical and Research Center, IRCCS, Alessandro Manzoni, 56, 20089, Rozzano, Milan, Italy. ac84344@gmail.com. AD - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy. ac84344@gmail.com. LA - eng PT - Journal Article PT - Review DEP - 20210819 PL - United States TA - Curr Cardiol Rep JT - Current cardiology reports JID - 100888969 SB - IM MH - Aortic Valve MH - *Heart Valve Prosthesis MH - *Heart Valve Prosthesis Implantation MH - Humans MH - Mitral Valve/surgery MH - Recurrence MH - Treatment Outcome MH - Tricuspid Valve/diagnostic imaging/surgery MH - *Tricuspid Valve Insufficiency/diagnostic imaging/surgery OTO - NOTNLM OT - Surgery OT - Transcatheter tricuspid valve repair OT - Transcatheter tricuspid valve replacement OT - Tricuspid annulus OT - Tricuspid regurgitation OT - Tricuspid valve EDAT- 2021/08/20 06:00 MHDA- 2021/08/26 06:00 CRDT- 2021/08/19 12:28 PHST- 2021/05/03 00:00 [accepted] PHST- 2021/08/19 12:28 [entrez] PHST- 2021/08/20 06:00 [pubmed] PHST- 2021/08/26 06:00 [medline] AID - 10.1007/s11886-021-01569-1 [pii] AID - 10.1007/s11886-021-01569-1 [doi] PST - epublish SO - Curr Cardiol Rep. 2021 Aug 19;23(10):137. doi: 10.1007/s11886-021-01569-1. PMID- 34407898 OWN - NLM STAT- MEDLINE DCOM- 20220616 LR - 20220616 IS - 1467-1107 (Electronic) IS - 1047-9511 (Linking) VI - 32 IP - 6 DP - 2022 Jun TI - Paediatric cardiac rapid response systems: a survey of multicentre practices. PG - 944-951 LID - 10.1017/S1047951121003322 [doi] AB - INTRODUCTION: While the efficacy and guidelines for implementation of rapid response systems are well established, limited information exists about rapid response paradigms for paediatric cardiac patients despite their unique pathophysiology. METHODS: With endorsement from the Paediatric Cardiac Intensive Care Society, we designed and implemented a web-based survey of paediatric cardiac and multidisciplinary ICU medical directors in the United States of America and Canada to better understand paediatric cardiac rapid response practices. RESULTS: Sixty-five (52%) of 125 centres responded. Seventy-one per cent of centres had approximately 300 non-ICU beds and 71% had dedicated cardiac ICUs. To respond to cardiac patients, dedicated cardiac rapid response teams were utilised in 29% of all centres (39% and 5% in centres with and without dedicated cardiac ICUs, respectively) [p = 0.006]. Early warning scores were utilised in 62% of centres. Only 31% reported that rapid response teams received specialised training. Transfers to ICU were higher for cardiac (73%) compared to generalised rapid response events (54%). The monitoring and reassessment of patients not transferred to ICU after the rapid response was variable. Cardiac and respiratory arrests outside the ICU were infrequent. Only 29% of centres formally appraise critical deterioration events (need for ventilation and/or inotropes post-rapid response) and 34% perform post-event debriefs. CONCLUSION: Paediatric cardiac rapid response practices are variable and dedicated paediatric cardiac rapid response systems are infrequent in the United States of America and Canada. Opportunity exists to delineate best practices for paediatric cardiac rapid response and standardise practices for activation, training, patient monitoring post-rapid response events, and outcomes evaluation. FAU - Bavare, Aarti C AU - Bavare AC AUID- ORCID: 0000-0002-3282-443X AD - Department of Paediatrics, Critical Care Medicine, Baylor College of Medicine, Houston, TX, USA. FAU - Afonso, Natasha S AU - Afonso NS AD - Department of Paediatrics, Critical Care Medicine, Baylor College of Medicine, Houston, TX, USA. FAU - Sembera, Kerry A AU - Sembera KA AD - Cardiac Critical Care, Texas Children's Hospital, Houston, TX, USA. FAU - Buckley, Jason R AU - Buckley JR AD - Department of Paediatrics, Medical University of South Carolina College of Medicine, MUSC Children's Hospital, Charleston, SC, USA. FAU - Raymond, Tia T AU - Raymond TT AUID- ORCID: 0000-0001-9454-8410 AD - Department of Paediatrics, Cardiac Critical Care, Medical City Children's Hospital, Dallas, TX, USA. FAU - McKeta, Angela AU - McKeta A AUID- ORCID: 0000-0003-1026-0829 AD - Department of Paediatrics, Medical University of South Carolina College of Medicine, MUSC Children's Hospital, Charleston, SC, USA. FAU - Costello, John M AU - Costello JM AD - Department of Paediatrics, Medical University of South Carolina College of Medicine, MUSC Children's Hospital, Charleston, SC, USA. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20210819 PL - England TA - Cardiol Young JT - Cardiology in the young JID - 9200019 SB - IM MH - Child MH - *Heart Arrest MH - *Hospital Rapid Response Team MH - Humans MH - Intensive Care Units MH - Monitoring, Physiologic MH - Surveys and Questionnaires MH - United States OTO - NOTNLM OT - Rapid response teams OT - cardiac arrest OT - cardiac critical care OT - clinical outcomes OT - paediatric EDAT- 2021/08/20 06:00 MHDA- 2022/06/18 06:00 CRDT- 2021/08/19 05:41 PHST- 2021/08/20 06:00 [pubmed] PHST- 2022/06/18 06:00 [medline] PHST- 2021/08/19 05:41 [entrez] AID - S1047951121003322 [pii] AID - 10.1017/S1047951121003322 [doi] PST - ppublish SO - Cardiol Young. 2022 Jun;32(6):944-951. doi: 10.1017/S1047951121003322. Epub 2021 Aug 19. PMID- 34404328 OWN - NLM STAT- MEDLINE DCOM- 20220516 LR - 20220516 IS - 1364-6893 (Electronic) IS - 0144-3615 (Linking) VI - 42 IP - 4 DP - 2022 May TI - Ebstein's anomaly during pregnancy: experience from a tertiary care centre - a case series and review of literature. PG - 594-596 LID - 10.1080/01443615.2021.1932777 [doi] AB - Pregnancy complicated with uncorrected Ebstein's anomaly is uncommon and may pose a serious threat to maternal and foetal life in the clinical setting of altered hemodynamics of pregnancy. Data of eight pregnancies in four women with Ebstein's anomaly who delivered in a tertiary care institute was analysed. Among the four women, one had associated atrial septal defect, one had pulmonary hypertension and three had right bundle branch block. There were two miscarriages and six successful pregnancies resulting in live births. Three of the pregnancies were delivered by caesarean section. There was one pregnancy complicated by severe preeclampsia, no preterm births or maternal cardiac complications. There was one neonate with congenital ostium secundum atrial septal defect. All patients were managed by a multidisciplinary team involving Obstetrician, Cardiologist, Anaesthesiologist and Neonatologist.IMPACT STATEMENTWhat is already known on this subject? Ebstein's anomaly is a rare congenital anomaly with apical displacement of the septal tricuspid leaflet in association with leaflet dysplasia. It may cause varied presentation in pregnancy depending on the severity of the lesion.What do the results of this study add? Ebstein's anomaly may become symptomatic for the first-time during pregnancy. Patients with NYHA class II symptoms and no cyanosis generally tolerate pregnancy well. Miscarriages and intrauterine growth restriction may occur in the presence of this condition. Vaginal delivery is advised and caesarean is done only for obstetric indications.What are the implications of these findings for clinical practise and/or future research? The management of pregnancy with uncorrected Ebstein's anomaly is highly challenging especially in a low resource setting and requires tertiary centre care. Multidisciplinary team involvement can help to improve the outcomes in such pregnancies. FAU - Suriya, J Yavana AU - Suriya JY AUID- ORCID: 0000-0002-3295-3119 AD - Department of Obstetrics and Gynaecology, Jawaharlal Institute of Post Graduate Medical Education and Research (JIPMER), Puducherry, India. FAU - Raj, Ashwini AU - Raj A AUID- ORCID: 0000-0002-3216-6414 AD - Department of Obstetrics and Gynaecology, Jawaharlal Institute of Post Graduate Medical Education and Research (JIPMER), Puducherry, India. FAU - Pillai, Ajith Ananthakrishna AU - Pillai AA AUID- ORCID: 0000-0002-6860-5765 AD - Department of Cardiology, JIPMER, Puducherry, India. FAU - Satheesh, Santhosh AU - Satheesh S AUID- ORCID: 0000-0001-7762-2164 AD - Department of Cardiology, JIPMER, Puducherry, India. FAU - Plakkal, Nishad AU - Plakkal N AUID- ORCID: 0000-0002-9711-018X AD - Department of Neonatology, JIPMER, Puducherry, India. FAU - Kundra, Pankaj AU - Kundra P AUID- ORCID: 0000-0002-5670-7932 AD - Anaesthesiology and Critical Care, JIPMER, Puducherry, India. FAU - Keepanasseril, Anish AU - Keepanasseril A AUID- ORCID: 0000-0002-4881-0382 AD - Department of Obstetrics and Gynaecology, Jawaharlal Institute of Post Graduate Medical Education and Research (JIPMER), Puducherry, India. LA - eng PT - Journal Article PT - Review DEP - 20210818 PL - England TA - J Obstet Gynaecol JT - Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology JID - 8309140 SB - IM MH - *Abortion, Spontaneous/epidemiology/etiology MH - Cesarean Section/adverse effects MH - Cyanosis/complications MH - *Ebstein Anomaly/complications/diagnosis MH - Female MH - Humans MH - Infant, Newborn MH - Pregnancy MH - Tertiary Care Centers OTO - NOTNLM OT - Ebstein's anomaly in pregnancy OT - atrial septal defect OT - cardiac anomaly OT - congenital heart disease in pregnancy OT - septal leaflet displacement EDAT- 2021/08/19 06:00 MHDA- 2022/05/17 06:00 CRDT- 2021/08/18 05:32 PHST- 2021/08/19 06:00 [pubmed] PHST- 2022/05/17 06:00 [medline] PHST- 2021/08/18 05:32 [entrez] AID - 10.1080/01443615.2021.1932777 [doi] PST - ppublish SO - J Obstet Gynaecol. 2022 May;42(4):594-596. doi: 10.1080/01443615.2021.1932777. Epub 2021 Aug 18. PMID- 34401696 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220425 IS - 2589-790X (Electronic) IS - 2589-790X (Linking) VI - 3 IP - 7 DP - 2021 Jul TI - Injection Drug Use Endocarditis: An Inner-City Hospital Experience. PG - 896-903 LID - 10.1016/j.cjco.2021.02.015 [doi] AB - BACKGROUND: There has been a rise in the incidence of injection drug use and associated infective endocarditis. METHODS: The clinical outcomes of 39 patients admitted with injection drug use-associated infective endocarditis were collected with a mean follow-up of 14 months. The outcomes were compared for patients treated medically with those undergoing surgical intervention. Re sults: The mean age was 39 +/- 11 years; 54% were female. Thirty-two patients (82%) had native and 7 (18%) prosthetic infective endocarditis. The tricuspid valve was affected in 17 patients (43%), the mitral in 10 (26%), the aortic in 4 (10%), and multiple valves in 8 (20%). Sixteen (41%) patients underwent surgery, and 23 (59%) were treated with medical therapy. The indications for surgery included heart failure, systemic emboli, recurrent infection, and vegetation size >/=10 mm. Patients undergoing surgery had a higher rate of paravalvular abscess (25% vs 0%, P = 0.02), valve perforation (37% vs 11%, P = 0.04), and mitral valve involvement (44% vs 13%, P = 0.06), whereas medically treated patients had higher tricuspid valve involvement (61% vs 19%, P = 0.02). During follow-up, 26% of medical and 31% of surgical cohort patients died (P = 0.7). Mortality was highest (54%) among those who continued medical management despite an indication for surgery. Univariate predictors of mortality were age (odds ratio [OR] 1.09, 95% confidence interval [CI]: 1.01-1.17; P = 0.02), heart failure (OR 6.9; 95% CI: 1.24-37.49; P = 0.02), septicemia (OR 4.40; 95% CI:0.99-19.54; P = 0.05), and shock (OR 10.8; 95% CI: 1.68-69.92; P = 0.01). CONCLUSIONS: Despite contemporary therapy, patients with injection drug use-associated infective endocarditis remain at high risk of complications and poor clinical outcomes. These findings highlight the need for developing new care pathways and a team approach for effective management. CI - (c) 2021 The Authors. FAU - Syed, Ishba M AU - Syed IM AD - Division of Cardiology, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada. FAU - Yanagawa, Bobby AU - Yanagawa B AD - Division of Cardiac Surgery, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada. FAU - Jeyaganth, Suganthiny AU - Jeyaganth S AD - Division of Cardiology, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada. FAU - Verma, Subodh AU - Verma S AD - Division of Cardiac Surgery, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada. FAU - Cheema, Asim N AU - Cheema AN AD - Division of Cardiology, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada. LA - eng PT - Journal Article DEP - 20210309 PL - United States TA - CJC Open JT - CJC open JID - 101763635 PMC - PMC8347875 EDAT- 2021/08/18 06:00 MHDA- 2021/08/18 06:01 PMCR- 2021/03/09 CRDT- 2021/08/17 07:34 PHST- 2021/02/01 00:00 [received] PHST- 2021/02/25 00:00 [accepted] PHST- 2021/08/17 07:34 [entrez] PHST- 2021/08/18 06:00 [pubmed] PHST- 2021/08/18 06:01 [medline] PHST- 2021/03/09 00:00 [pmc-release] AID - S2589-790X(21)00070-6 [pii] AID - 10.1016/j.cjco.2021.02.015 [doi] PST - epublish SO - CJC Open. 2021 Mar 9;3(7):896-903. doi: 10.1016/j.cjco.2021.02.015. eCollection 2021 Jul. PMID- 34401195 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231107 IS - 2055-2238 (Electronic) IS - 2055-2238 (Linking) VI - 7 IP - 4 DP - 2021 Aug TI - The Families Improving Health Together (FIT) Program: Initial evaluation of retention and research in a multispecialty clinic for children with obesity. PG - 357-367 LID - 10.1002/osp4.498 [doi] AB - BACKGROUND: Obesity affects approximately 17% of US children, with parallel increases in multiple comorbidities, especially among African-, Asian-, Hispanic-, and Native-Americans. Barriers to patient retention in pediatric obesity programs include lack of centralized care, and frequent subspecialty MD visits which conflict with patient school attendance and parental work attendance as well as with support service utilization. Lack of integration of multispecialty clinical care with interdisciplinary research is a major barrier to fuller exploration of the treatment, prevention, and understanding of obesity in childhood. OBJECTIVE: To test the hypothesis, a novel multispecialty/interdisciplinary clinical and research infrastructure with strong emphasis on a primary obesity care physician for children with early-onset (<9 years) obesity (Families Improving health Together [FIT]) could promote lower patient attrition (primary goal) and foster productive research in pediatric obesity (secondary goal). RESULTS: Data support the hypotheses. Over 15 months, FIT reported a >90% participant retention (p < 0.001 vs. expected rate based on other studies of similar programs). Though 90% of children had at least one adiposity-related comorbidity and 70% had at least two, there was no need for additional subspecialist visits with cardiologists, endocrinologists, gastroenterologists, or molecular geneticists. Three abstracts were presented at national meetings, and two manuscripts were published all with junior faculty as primary authors. CONCLUSION: This pilot study suggests that an integrated multispecialty/interdisciplinary approach to children with obesity improves patient retention and can be integrated successfully with research. CI - (c) 2021 The Authors. Obesity Science & Practice published by World Obesity and The Obesity Society and John Wiley & Sons Ltd. FAU - Rosenbaum, Michael AU - Rosenbaum M AUID- ORCID: 0000-0003-2835-9202 AD - Berrie Diabetes Research Pavilion Columbia University Medical College New York USA. FAU - Garofano, Robert AU - Garofano R AD - Berrie Diabetes Research Pavilion Columbia University Medical College New York USA. FAU - Liimatta, Kalle AU - Liimatta K AD - Berrie Diabetes Research Pavilion Columbia University Medical College New York USA. FAU - McArthur, Kerry AU - McArthur K AD - Berrie Diabetes Research Pavilion Columbia University Medical College New York USA. FAU - Paul, Erin AU - Paul E AD - Berrie Diabetes Research Pavilion Columbia University Medical College New York USA. FAU - Starc, Thomas AU - Starc T AD - Berrie Diabetes Research Pavilion Columbia University Medical College New York USA. FAU - Sopher, Aviva B AU - Sopher AB AD - Berrie Diabetes Research Pavilion Columbia University Medical College New York USA. FAU - Thaker, Vidhu AU - Thaker V AD - Berrie Diabetes Research Pavilion Columbia University Medical College New York USA. FAU - Baidal, Jennifer Woo AU - Baidal JW AD - Berrie Diabetes Research Pavilion Columbia University Medical College New York USA. LA - eng GR - K23 DK110539/DK/NIDDK NIH HHS/United States GR - UL1 TR000040/TR/NCATS NIH HHS/United States PT - Journal Article DEP - 20210323 PL - United States TA - Obes Sci Pract JT - Obesity science & practice JID - 101675151 PMC - PMC8346376 OTO - NOTNLM OT - child OT - interdisciplinary research OT - multispecialty treatment OT - obesity COIS- The authors declared no conflict of interest. The views expressed in this paper are those of the authors, and do not necessarily represent the positions of the NIH, the DHHS, or the Federal Government. EDAT- 2021/08/18 06:00 MHDA- 2021/08/18 06:01 PMCR- 2021/03/23 CRDT- 2021/08/17 07:30 PHST- 2020/09/07 00:00 [received] PHST- 2021/02/18 00:00 [revised] PHST- 2021/02/19 00:00 [accepted] PHST- 2021/08/17 07:30 [entrez] PHST- 2021/08/18 06:00 [pubmed] PHST- 2021/08/18 06:01 [medline] PHST- 2021/03/23 00:00 [pmc-release] AID - OSP4498 [pii] AID - 10.1002/osp4.498 [doi] PST - epublish SO - Obes Sci Pract. 2021 Mar 23;7(4):357-367. doi: 10.1002/osp4.498. eCollection 2021 Aug. PMID- 34400923 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220425 IS - 1734-9338 (Print) IS - 1897-4295 (Electronic) IS - 1734-9338 (Linking) VI - 17 IP - 2 DP - 2021 Jun TI - Contrast-free percutaneous pulmonary valve replacement: a safe approach for valve-in-valve procedures. PG - 200-209 LID - 10.5114/aic.2021.107500 [doi] AB - INTRODUCTION: Percutaneous pulmonary valve replacement (PPVI) continues to gather pace in pediatric and adult congenital practice. This is fueled by an expanding repertoire of devices, techniques and equipment to suit the heterogenous anatomical landscape of patients with lesions of the right ventricular outflow tract (RVOT). Contrast-induced nephropathy is a real risk for teenagers and adults with congenital heart disease (CHD). AIM: To present a series of patients who underwent PPVI without formal RVOT angiography and propose case selection criteria for patients who may safely benefit from this approach. MATERIAL AND METHODS: We retrospectively collected PPVI data from the preceding 2 years at our institution identifying patients who had been listed as suitable for consideration for contrast-free PPVI from our multidisciplinary team (MDT) meeting based on predefined criteria. Demographic, clinical, imaging and hemodynamic data were collected. Data were analyzed using SPSS. RESULTS: Twenty-one patients were identified. All patients had a technically successful implantation with improvements seen in invasive and echocardiographic hemodynamic measurements. 90% of patients had a bio-prosthetic valve (BPV) in situ prior to PPVI. One patient had a complication which may have been recognized earlier with post-intervention RVOT contrast injection. CONCLUSIONS: Zero-contrast PPVI is technically feasible and the suitability criteria for those who might benefit are potentially straightforward. The advent of fusion and 3D imaging in cardiac catheterization laboratories is likely to expand our capacity to perform more procedures with less contrast. Patients with bio-prosthetic valves in the pulmonary position may benefit from contrast-free percutaneous pulmonary valve implantation. CI - Copyright: (c) 2021 Termedia Sp. z o. o. FAU - O'Callaghan, Barry AU - O'Callaghan B AD - The Heart Institute, Children's Hospital Colorado, Aurora, USA. FAU - Zablah, Jenny AU - Zablah J AD - The Heart Institute, Children's Hospital Colorado, Aurora, USA. FAU - Leahy, Ryan AU - Leahy R AD - The Heart Institute, Children's Hospital Colorado, Aurora, USA. FAU - Shorofsky, Michael AU - Shorofsky M AD - The Heart Institute, Children's Hospital Colorado, Aurora, USA. FAU - Kay, Joseph AU - Kay J AD - The Heart Institute, Children's Hospital Colorado, Aurora, USA. FAU - Morgan, Gareth AU - Morgan G AD - The Heart Institute, Children's Hospital Colorado, Aurora, USA. LA - eng PT - Journal Article DEP - 20210709 PL - Poland TA - Postepy Kardiol Interwencyjnej JT - Postepy w kardiologii interwencyjnej = Advances in interventional cardiology JID - 101272671 PMC - PMC8356834 OTO - NOTNLM OT - adult congenital heart disease OT - congenital heart disease OT - pediatric cardiac catheterization OT - percutaneous pulmonary valve implantation OT - tetralogy of Fallot COIS- Dr Morgan is a proctor for Edwards Lifesciences Corporation. The remaining declare no conflict of interest. EDAT- 2021/08/18 06:00 MHDA- 2021/08/18 06:01 PMCR- 2021/06/01 CRDT- 2021/08/17 07:28 PHST- 2020/10/06 00:00 [received] PHST- 2021/03/04 00:00 [accepted] PHST- 2021/08/17 07:28 [entrez] PHST- 2021/08/18 06:00 [pubmed] PHST- 2021/08/18 06:01 [medline] PHST- 2021/06/01 00:00 [pmc-release] AID - 44594 [pii] AID - 10.5114/aic.2021.107500 [doi] PST - ppublish SO - Postepy Kardiol Interwencyjnej. 2021 Jun;17(2):200-209. doi: 10.5114/aic.2021.107500. Epub 2021 Jul 9. PMID- 34397894 OWN - NLM STAT- MEDLINE DCOM- 20210831 LR - 20210901 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 100 IP - 32 DP - 2021 Aug 13 TI - Role of a rapid response system and code status discussion as determinants of prognosis for critical inpatients: An observational study in a Japanese urban hospital. PG - e26856 LID - 10.1097/MD.0000000000026856 [doi] LID - e26856 AB - Rapid response systems (RRS) have been introduced worldwide to reduce unpredicted in-hospital cardiac arrest (IHCA) and in-hospital mortality. The role of advance care planning (ACP) in the management of critical patients has not yet been fully determined in Japan.We retrospectively assessed the characteristics of all inpatients with unpredicted IHCA in our hospital between 2016 and 2018. Yearly changes in the number of RRS activations and the incidence of unpredicted IHCA with or without code status discussion were evaluated from 2014 to 2018. Hospital standardized mortality ratios were assessed from the data reported in the annual reports by the National Hospital Organization.A total of 81 patients (age: 70.9 +/- 13.3 years) suffered an unpredicted IHCA and had multiple background diseases, including heart disease (75.3%), chronic kidney disease (25.9%), and postoperative status (cardiovascular surgery, 18.5%). Most of the patients manifested non-shockable rhythms (69.1%); survival to hospital discharge rate was markedly lower than that with shockable rhythms (26.8% vs 72.0%, P < .001). The hospital standardized mortality ratios was maintained nearly constant at approximately 50.0% for 3 consecutive years. The number of cases of RRS activation markedly increased from 75 in 2014 to 274 patients in 2018; conversely, the number of unpredicted IHCA cases was reduced from 40 in 2014 to 18 in 2018 (P < .001). Considering the data obtained in 2014 and 2015 as references, the RRS led to a reduction in the relative risk of unpredicted IHCA from 2016 to 2018 (ie, 0.618, 95% confidence interval 0.453-0.843). The reduction in unpredicted IHCA was attributed partly to the increased number of patients who had discussed the code status, and a significant correlation was observed between these parameters (R2 = 0.992, P < .001). The reduction in the number of patients with end-stage disease, including congestive heart failure and chronic renal failure, paralleled the incidence of unpredicted IHCA.Both RRS and ACP reduced the incidence of unpredicted IHCA; RRS prevents progression to unpredicted IHCA, whereas ACP decreases the number of patients with no code status discussion and thus potentially reducing the patient subgroup progressing to an unpredicted IHCA. CI - Copyright (c) 2021 the Author(s). Published by Wolters Kluwer Health, Inc. FAU - Higashino, Makoto AU - Higashino M AD - Department of Nephrology, Endocrinology and Diabetes, Tokyo Bay Urayasu Ichikawa Medical Center, Chiba, Japan. AD - Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Ehime, Japan. FAU - Hiraoka, Eiji AU - Hiraoka E AD - Department of General Medicine, Tokyo Bay Urayasu Ichikawa Medical Center, Chiba, Japan. FAU - Kudo, Yoshiko AU - Kudo Y AD - Intensive Care Unit, Tokyo Bay Urayasu Ichikawa Medical Center, Chiba, Japan. FAU - Hoshina, Yuiko AU - Hoshina Y AD - Strategic Planning and Analysis Division, Tokyo Bay Urayasu Ichikawa Medical Center, Chiba, Japan. FAU - Kitamura, Koichi AU - Kitamura K AD - Department of Nephrology, Endocrinology and Diabetes, Tokyo Bay Urayasu Ichikawa Medical Center, Chiba, Japan. FAU - Sakai, Masahiro AU - Sakai M AD - Department of Nephrology, Endocrinology and Diabetes, Tokyo Bay Urayasu Ichikawa Medical Center, Chiba, Japan. FAU - Ito, Shinsuke AU - Ito S AD - Department of Nephrology, Endocrinology and Diabetes, Tokyo Bay Urayasu Ichikawa Medical Center, Chiba, Japan. FAU - Fujimoto, Yoshihisa AU - Fujimoto Y AD - Department of Emergency and Critical Care Medicine, Division of Critical Care, Tokyo Bay Urayasu Ichikawa Medical Center, Chiba, Japan. FAU - Hiasa, Yoichi AU - Hiasa Y AD - Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Ehime, Japan. FAU - Hayashi, Koichi AU - Hayashi K AD - Department of Emergency and Critical Care Medicine, St. Marianna University School of Medicine, Kanagawa, Japan. FAU - Fujitani, Shigeki AU - Fujitani S AD - Department of Emergency and Critical Care Medicine, St. Marianna University School of Medicine, Kanagawa, Japan. FAU - Suzuki, Toshihiko AU - Suzuki T AUID- ORCID: 0000-0002-4545-9769 AD - Department of Nephrology, Endocrinology and Diabetes, Tokyo Bay Urayasu Ichikawa Medical Center, Chiba, Japan. LA - eng PT - Journal Article PT - Observational Study PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R SB - IM MH - Advance Care Planning/organization & administration MH - Aged MH - *Cardiopulmonary Resuscitation/methods/standards MH - *Critical Illness/mortality/therapy MH - Female MH - *Heart Arrest/diagnosis/etiology/mortality MH - Hospital Mortality MH - *Hospital Rapid Response Team/organization & administration/standards MH - *Hospitals, Urban/organization & administration/standards MH - Humans MH - Incidence MH - Japan/epidemiology MH - Male MH - Needs Assessment MH - Prognosis MH - Risk Assessment PMC - PMC8360430 COIS- The authors have no conflicts of interest to disclose. EDAT- 2021/08/17 06:00 MHDA- 2021/09/01 06:00 PMCR- 2021/08/13 CRDT- 2021/08/16 12:51 PHST- 2021/04/06 00:00 [received] PHST- 2021/07/20 00:00 [accepted] PHST- 2021/08/16 12:51 [entrez] PHST- 2021/08/17 06:00 [pubmed] PHST- 2021/09/01 06:00 [medline] PHST- 2021/08/13 00:00 [pmc-release] AID - 00005792-202108130-00028 [pii] AID - MD-D-21-02683 [pii] AID - 10.1097/MD.0000000000026856 [doi] PST - ppublish SO - Medicine (Baltimore). 2021 Aug 13;100(32):e26856. doi: 10.1097/MD.0000000000026856. PMID- 34397466 OWN - NLM STAT- MEDLINE DCOM- 20210921 LR - 20210921 IS - 1531-7080 (Electronic) IS - 0268-4705 (Linking) VI - 36 IP - 5 DP - 2021 Sep 1 TI - Coronary artery disease in patients with cancer: challenges and opportunities for improvement. PG - 597-608 LID - 10.1097/HCO.0000000000000878 [doi] AB - PURPOSE OF REVIEW: Coronary artery disease (CAD) is a common comorbidity in patients with cancer. We review shared risk factors between the two diseases and cancer treatments that increase the risk of CAD. We also discuss outcomes and management considerations of patients with cancer who develop CAD. RECENT FINDINGS: Several traditional and novel risk factors promote the development of both CAD and cancer. Several cancer treatments further increase the risk of CAD. The presence of cancer is associated with a higher burden of comorbidities and thrombocytopenia, which predisposes patients to higher bleeding risks. Patients with cancer who develop acute coronary syndromes are less likely to receive timely revascularization or appropriate medical therapy, despite evidence showing that receipt of these interventions is associated with substantial benefit. Accordingly, a cancer diagnosis is associated with worse outcomes in patients with CAD. The risk-benefit balance of revascularization is becoming more favorable due to the improving prognosis of many cancers and safer revascularization strategies, including shorter requirements for dual antiplatelet therapy after revascularization. SUMMARY: Several factors increase the complexity of managing CAD in patients with cancer. A multidisciplinary approach is recommended to guide treatment decisions in this high-risk and growing patient group. CI - Copyright (c) 2021 Wolters Kluwer Health, Inc. All rights reserved. FAU - Carrillo-Estrada, Montserrat AU - Carrillo-Estrada M AD - Ted Rogers Program in Cardiotoxicity Prevention, Peter Munk Cardiac Center, University Health Network. FAU - Bobrowski, David AU - Bobrowski D AD - Department of Medicine and Division of Cardiology, Women's College Hospital. FAU - Carrasco, Rodrigo AU - Carrasco R AD - Ted Rogers Program in Cardiotoxicity Prevention, Peter Munk Cardiac Center, University Health Network. FAU - Nadler, Michelle B AU - Nadler MB AD - Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre. FAU - Kalra, Sanjog AU - Kalra S AD - Division of Cardiology, Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada. FAU - Thavendiranathan, Paaladinesh AU - Thavendiranathan P AD - Ted Rogers Program in Cardiotoxicity Prevention, Peter Munk Cardiac Center, University Health Network. FAU - Abdel-Qadir, Husam AU - Abdel-Qadir H AD - Ted Rogers Program in Cardiotoxicity Prevention, Peter Munk Cardiac Center, University Health Network. AD - Department of Medicine and Division of Cardiology, Women's College Hospital. LA - eng PT - Journal Article PT - Review PL - United States TA - Curr Opin Cardiol JT - Current opinion in cardiology JID - 8608087 SB - IM MH - *Acute Coronary Syndrome/epidemiology/therapy MH - *Coronary Artery Disease/epidemiology/therapy MH - Hemorrhage MH - Humans MH - Myocardial Revascularization MH - *Neoplasms/complications/epidemiology/therapy MH - Risk Assessment MH - Risk Factors MH - Treatment Outcome EDAT- 2021/08/17 06:00 MHDA- 2021/09/22 06:00 CRDT- 2021/08/16 12:44 PHST- 2021/08/16 12:44 [entrez] PHST- 2021/08/17 06:00 [pubmed] PHST- 2021/09/22 06:00 [medline] AID - 00001573-202109000-00014 [pii] AID - 10.1097/HCO.0000000000000878 [doi] PST - ppublish SO - Curr Opin Cardiol. 2021 Sep 1;36(5):597-608. doi: 10.1097/HCO.0000000000000878. PMID- 34397464 OWN - NLM STAT- MEDLINE DCOM- 20210921 LR - 20230206 IS - 1531-7080 (Electronic) IS - 0268-4705 (Linking) VI - 36 IP - 5 DP - 2021 Sep 1 TI - Impact of social determinants of health on cardiovascular disease prevention. PG - 572-579 LID - 10.1097/HCO.0000000000000893 [doi] AB - PURPOSE OF REVIEW: Social determinants of health (SDOH) describe conditions in one's environment that have an impact on health, quality-of-life, outcomes, and risks. These include income, education, employment, culture, language, healthcare access, social support, race, ethnicity, structural racism, discrimination, social support, neighborhood characteristics, and others. SDOH manifest as persistent inequalities in cardiovascular risk factors and disease, and, therefore, contribute to cardiovascular disease (CVD)-related morbidity and mortality. This article reviews how SDOH affect CVD risk and the role they play in CVD prevention. RECENT FINDINGS: The 2019 American College of Cardiology/American Heart Association (AHA) guideline on the primary prevention of CVD recommends that clinicians evaluate SDOH on an individual basis to inform treatment decisions for CVD prevention efforts. Recent evidence shows that low socioeconomic status, adverse childhood experiences, less social support, reduced health literacy, and limited healthcare access are associated with higher CVD risk and poorer health outcomes. A 2020 AHA statement emphasized the role of structural racism as a fundamental driver of health disparities. The AHA 2030 Impact Goals state a desire to achieve health equity by identifying and removing barriers to healthcare access and quality. SUMMARY: SDOH affect CVD prevention efforts. The SDOH that affect cardiovascular risk factors, diseases, and outcomes are complex and intersect. Addressing them can be challenging and will require a multilevel and multidisciplinary approach, involving public health measures, changes in health systems, team-based care, and dismantling of structural racism. More studies are needed to investigate the effect of interventions that improve SDOH and prevent CVD or lower CVD risk. CI - Copyright (c) 2021 Wolters Kluwer Health, Inc. All rights reserved. FAU - Mannoh, Ivy AU - Mannoh I AD - School of Medicine. FAU - Hussien, Merna AU - Hussien M AD - Department of Medicine. FAU - Commodore-Mensah, Yvonne AU - Commodore-Mensah Y AD - School of Nursing. FAU - Michos, Erin D AU - Michos ED AD - Division of Cardiology, Johns Hopkins University, Baltimore, Maryland, USA. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review PL - United States TA - Curr Opin Cardiol JT - Current opinion in cardiology JID - 8608087 SB - IM MH - *Cardiovascular Diseases/epidemiology/prevention & control MH - Ethnicity MH - Health Services Accessibility MH - Humans MH - *Social Determinants of Health MH - Social Support MH - United States EDAT- 2021/08/17 06:00 MHDA- 2021/09/22 06:00 CRDT- 2021/08/16 12:44 PHST- 2021/08/16 12:44 [entrez] PHST- 2021/08/17 06:00 [pubmed] PHST- 2021/09/22 06:00 [medline] AID - 00001573-202109000-00011 [pii] AID - 10.1097/HCO.0000000000000893 [doi] PST - ppublish SO - Curr Opin Cardiol. 2021 Sep 1;36(5):572-579. doi: 10.1097/HCO.0000000000000893. PMID- 34396339 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240403 IS - 2666-0873 (Electronic) IS - 2666-0873 (Linking) VI - 3 IP - 2 DP - 2021 Jun TI - Left Ventricular Assist Devices in Patients With Active Malignancies. PG - 305-315 LID - 10.1016/j.jaccao.2021.04.008 [doi] AB - BACKGROUND: There are limited data to guide oncology and cardiology decision-making in patients with a left ventricular assist device (LVAD) and concurrent active malignancy. OBJECTIVES: The goal of this study was to describe cancer treatment approaches, complications, and survival among patients with active cancer on LVAD support in 2 tertiary heart failure and oncology programs. METHODS: In this retrospective cohort study, LVAD databases were reviewed to identify patients with a cancer diagnosis at the time of or after LVAD implantation. We created a 3:1 matched cohort based on age, sex, etiology of cardiomyopathy, LVAD implant strategy, and INTERMACS profile stratified by site. Kaplan-Meier analysis and Cox proportional hazards models were used to compare survival between patients with cancer and non-cancer comparators. RESULTS: Among 1,123 patients who underwent LVAD implantation between 2005 and 2019, 22 patients with LVADs with active cancer and 66 matched non-cancer comparators were identified. Median age was 62 years (range 41 to 73 years); 50% of patients with cancer were African-American, and 27% were women. Prostate cancer, followed by renal cell cancer and hematologic malignancies were the most common diagnoses. There was no significant difference in unadjusted Kaplan-Meier median survival estimates from the time of LVAD placement between patients with cancer (3.53 years; 95% confidence interval [CI]: 1.41 to 5.33) and non-cancer comparators (3.03 years; 95% CI: 1.83 to 5.26; log-rank P = 0.99). In Cox proportional hazard models, cancer diagnosis as a time-varying variable was associated with a statistically significant increase in death (hazard ratio: 2.05; 95% CI: 1.03 to 4.12; P = 0.04). Patients with cancer had less gastrointestinal bleeding compared with matched non-cancer comparators (P = 0.016). Other complications were not significantly different. CONCLUSIONS: Our study provides initial feasibility and safety data and set a framework for multidisciplinary team management of patients with cancer and LVADs. CI - (c) 2021 The Authors. FAU - Schlam, Ilana AU - Schlam I AD - MedStar Washington Cancer Institute, Washington, DC, USA. AD - Department of Hematology-Oncology, MedStar Washington Hospital Center, Washington, DC, USA. FAU - Lee, Andy Y AU - Lee AY AD - Department of Cardiology, University of Washington Medical Center, Department of Cardiology, Seattle, Washington, USA. FAU - Li, Song AU - Li S AD - Department of Cardiology, University of Washington Medical Center, Department of Cardiology, Seattle, Washington, USA. FAU - Sheikh, Farooq H AU - Sheikh FH AD - MedStar Heart and Vascular Institute, Washington, DC, USA. AD - Department of Cardiology, MedStar Washington Hospital Center, Washington, DC, USA. AD - Georgetown University, Washington, DC, USA. FAU - Zaghlol, Raja AU - Zaghlol R AD - Internal Medicine Department, MedStar Washington Hospital Center, Washington, DC, USA. FAU - Basyal, Binaya AU - Basyal B AD - MedStar Heart and Vascular Institute, Washington, DC, USA. AD - Department of Cardiology, MedStar Washington Hospital Center, Washington, DC, USA. AD - Georgetown University, Washington, DC, USA. FAU - Gallagher, Christopher AU - Gallagher C AD - MedStar Washington Cancer Institute, Washington, DC, USA. AD - Department of Hematology-Oncology, MedStar Washington Hospital Center, Washington, DC, USA. FAU - Molina, Ezequiel AU - Molina E AD - MedStar Heart and Vascular Institute, Washington, DC, USA. AD - Department of Cardiology, MedStar Washington Hospital Center, Washington, DC, USA. AD - Georgetown University, Washington, DC, USA. FAU - Mahr, Claudius AU - Mahr C AD - Department of Cardiology, University of Washington Medical Center, Department of Cardiology, Seattle, Washington, USA. FAU - Cheng, Richard K AU - Cheng RK AD - Department of Cardiology, University of Washington Medical Center, Department of Cardiology, Seattle, Washington, USA. FAU - Barac, Ana AU - Barac A AD - MedStar Heart and Vascular Institute, Washington, DC, USA. AD - Department of Cardiology, MedStar Washington Hospital Center, Washington, DC, USA. AD - Georgetown University, Washington, DC, USA. LA - eng PT - Journal Article DEP - 20210615 PL - United States TA - JACC CardioOncol JT - JACC. CardioOncology JID - 101761697 PMC - PMC8352017 OTO - NOTNLM OT - CI, confidence interval OT - CMP, cardiomyopathy OT - CTCAE, common terminology criteria for adverse events OT - CVD, cardiovascular disease OT - DT, destination therapy OT - GI, gastrointestinal OT - HF, heart failure OT - LVAD, left ventricular assist device OT - advanced heart failure OT - cancer OT - cancer therapies OT - left ventricular assist device COIS- Dr Gallagher has been a member of the advisory board for Daiichi Sankyo and Seattle Genetics. Dr Sheikh has been an investigator, has received travel support, has received institutional research; and has received speaker's fees from Abbott; and has received travel support from Medtronic. Dr Mahr has been an investigator and consultant for Abbott, Medtronic, Abiomed, and Syncardia. Dr Barac has received honoraria from Takeda. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2021/08/17 06:00 MHDA- 2021/08/17 06:01 PMCR- 2021/06/15 CRDT- 2021/08/16 06:10 PHST- 2020/09/14 00:00 [received] PHST- 2021/04/07 00:00 [revised] PHST- 2021/04/13 00:00 [accepted] PHST- 2021/08/16 06:10 [entrez] PHST- 2021/08/17 06:00 [pubmed] PHST- 2021/08/17 06:01 [medline] PHST- 2021/06/15 00:00 [pmc-release] AID - S2666-0873(21)00090-9 [pii] AID - 10.1016/j.jaccao.2021.04.008 [doi] PST - epublish SO - JACC CardioOncol. 2021 Jun 15;3(2):305-315. doi: 10.1016/j.jaccao.2021.04.008. eCollection 2021 Jun. PMID- 34396262 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240403 IS - 2666-0873 (Electronic) IS - 2666-0873 (Linking) VI - 2 IP - 3 DP - 2020 Sep TI - Multimodality Treatment for Advanced Cervical Cancer With Isolated Metastasis to Interventricular Septum of the Heart. PG - 519-522 LID - 10.1016/j.jaccao.2020.06.008 [doi] FAU - Shapira-Daniels, Ayelet AU - Shapira-Daniels A AD - Department of Cardiothoracic Surgery, Hadassah Hebrew University Medical Center, Jerusalem, Israel. FAU - Katz, Daniela AU - Katz D AD - Department of Oncology, Shamir Medical Center, Beer Yaacov, Israel. FAU - Aviel, Gal AU - Aviel G AD - Department of Cardiothoracic Surgery, Hadassah Hebrew University Medical Center, Jerusalem, Israel. FAU - Meirovitz, Amichay AU - Meirovitz A AD - Department of Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel. FAU - Gilon, Dan AU - Gilon D AD - Department of Cardiology, Hadassah Hebrew University Medical Center, Jerusalem, Israel. AD - Department of Cardiology, Shamir Medical Center, Beer Yaacov, Israel. FAU - Shapira, Oz M AU - Shapira OM AD - Department of Cardiothoracic Surgery, Hadassah Hebrew University Medical Center, Jerusalem, Israel. LA - eng PT - Journal Article PT - Review DEP - 20200915 PL - United States TA - JACC CardioOncol JT - JACC. CardioOncology JID - 101761697 PMC - PMC8352254 OTO - NOTNLM OT - 18F-FDG-PET, 18F-fluorodeoxyglucose positron emission tomography OT - CMR, cardiac magnetic resonance imaging OT - CT, computed tomography OT - IVS, interventricular septum OT - LVEF, left ventricular ejection fraction OT - SCC, squamous cell carcinoma OT - SUV, standard-uptake value OT - cardiac mass OT - cervical cancer OT - heart metastasis OT - multidisciplinary team OT - multimodality treatment EDAT- 2021/08/17 06:00 MHDA- 2021/08/17 06:01 PMCR- 2020/09/15 CRDT- 2021/08/16 06:10 PHST- 2020/04/29 00:00 [received] PHST- 2020/06/08 00:00 [revised] PHST- 2020/06/10 00:00 [accepted] PHST- 2021/08/16 06:10 [entrez] PHST- 2021/08/17 06:00 [pubmed] PHST- 2021/08/17 06:01 [medline] PHST- 2020/09/15 00:00 [pmc-release] AID - S2666-0873(20)30158-7 [pii] AID - 10.1016/j.jaccao.2020.06.008 [doi] PST - epublish SO - JACC CardioOncol. 2020 Sep 15;2(3):519-522. doi: 10.1016/j.jaccao.2020.06.008. eCollection 2020 Sep. PMID- 34396119 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220425 IS - 2632-1823 (Electronic) IS - 2632-1823 (Linking) VI - 3 IP - 3 DP - 2021 Sep TI - Use of dalbavancin in infective endocarditis: a case series. PG - dlab099 LID - 10.1093/jacamr/dlab099 [doi] LID - dlab099 AB - BACKGROUND: Infective endocarditis, typically caused by Gram-positive organisms such as viridans group streptococci and Staphylococcus aureus, is associated with high mortality and morbidity and requires aggressive, prolonged antimicrobial treatment and sometimes surgery. Dalbavancin, a lipoglycopeptide active against Gram-positive pathogens, has a long half-life, which allows IV treatment as one dose or two doses with a prolonged interval, offering personalized treatment for complex psychosocial situations or facilitating early discharge. In the absence of randomized controlled trials in infective endocarditis, current evidence derives from real-world case series involving off-licence use. The Austrian Society for Infectious Disease and Tropical Medicine includes dalbavancin as an option for infective endocarditis. OBJECTIVES: This retrospective case series reports use of dalbavancin in a small cohort of patients with infective endocarditis treated at Lancashire Cardiac Centre, Blackpool Teaching Hospitals Foundation Trust, UK. RESULTS: The pharmacy database included 11 patients in whom dalbavancin was used to address either complex psychosocial circumstances or the need for early discharge. The endocarditis multidisciplinary team selected dalbavancin from available treatment options. Structures affected by infective endocarditis included aortic, mitral and tricuspid valves; aortic composite grafts; implantable cardioverter defibrillator leads; and prosthetic aortic valves. Eight patients underwent surgery; three were managed conservatively with antibiotics. Dalbavancin was curative in all but one patient, whose signs and symptoms of infection improved. No patients developed adverse reactions. CONCLUSIONS: Dalbavancin is an alternative treatment option at hospital discharge when conventional antibiotics may not be suitable due to complex psychosocial issues or early discharge is required. CI - (c) The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. FAU - Guleri, Achyut AU - Guleri A AD - Lancashire Cardiac Centre, Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool, UK. FAU - More, Ranjit AU - More R AD - Lancashire Cardiac Centre, Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool, UK. FAU - Sharma, Rashmi AU - Sharma R AD - Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool, UK. FAU - Wong, Michelle AU - Wong M AD - Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool, UK. FAU - Abdelrahman, Amr AU - Abdelrahman A AD - Lancashire Cardiac Centre, Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool, UK. LA - eng PT - Journal Article DEP - 20210812 PL - England TA - JAC Antimicrob Resist JT - JAC-antimicrobial resistance JID - 101765283 PMC - PMC8360293 EDAT- 2021/08/17 06:00 MHDA- 2021/08/17 06:01 PMCR- 2021/08/12 CRDT- 2021/08/16 06:09 PHST- 2021/02/02 00:00 [received] PHST- 2021/06/17 00:00 [accepted] PHST- 2021/08/16 06:09 [entrez] PHST- 2021/08/17 06:00 [pubmed] PHST- 2021/08/17 06:01 [medline] PHST- 2021/08/12 00:00 [pmc-release] AID - dlab099 [pii] AID - 10.1093/jacamr/dlab099 [doi] PST - epublish SO - JAC Antimicrob Resist. 2021 Aug 12;3(3):dlab099. doi: 10.1093/jacamr/dlab099. eCollection 2021 Sep. PMID- 34390242 OWN - NLM STAT- MEDLINE DCOM- 20220908 LR - 20221108 IS - 2058-1742 (Electronic) IS - 2058-1742 (Linking) VI - 8 IP - 6 DP - 2022 Sep 5 TI - Quality indicators in the management of elderly Chinese patients with atrial fibrillation: a report from the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry. PG - 651-658 LID - 10.1093/ehjqcco/qcab057 [doi] AB - AIMS: To evaluate the quality measures and clinical performance indicators among elderly Chinese patients with atrial fibrillation (AF). The management of patients with AF requires a holistic, multidisciplinary approach. Quality indicators have been proposed to assess the quality of care in 'real-world' clinical practice when managing patients with AF. METHODS AND RESULTS: The Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry is a prospective, observational, large-scale multicentre registry conducted between October 2014 and December 2018 in China. Data were collected at the enrolment and during the follow-up visits by the local investigators. In the ChiOTEAF registry, 14 primary and 8 secondary indicators from six domains of care were assessed. Six thousand four hundred twenty patients who completed the 1-year follow-up were included in the analysis. Median age was 76 years, and the majority of patients was male (60.8%). Overall, 3246 patients (54.8%) were not treated with oral anticoagulants (OACs) appropriate to their risk of stroke; specifically, among those at highest risk of stroke, OACs were prescribed in only 43.3% patients (1258/2905). Among patients with permanent AF, 32 (3.6%) were prescribed antiarrhythmic drugs, and among those with paroxysmal AF, catheter ablation was performed in 20.7%. Patients were overburdened with multi-morbidities, including hypertension, diabetes mellitus, obesity, and sleep apnoea. During 1-year follow-up, 435 deaths (6.8%) and 89 thromboembolic events (1.4%) occurred. Patient-reported outcomes showed that 55% of patients had indicators of reduced quality of life. CONCLUSION: Assessment of quality indicators revealed the gaps in AF care among Chinese patients, highlighting the need for a more integrated or holistic approach to AF management. CI - (c) The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology. FAU - Guo, Yutao AU - Guo Y AUID- ORCID: 0000-0002-7626-7751 AD - Department of Pulmonary Vessel and Thrombotic Disease, Sixth Medical Centre, Chinese PLA General Hospital, Beijing 100142, China. AD - Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK. FAU - Kotalczyk, Agnieszka AU - Kotalczyk A AUID- ORCID: 0000-0002-6762-3187 AD - Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK. AD - Department of Cardiology, Congenital Heart Diseases and Electrotherapy, Medical University of Silesia, Silesian Centre for Heart Diseases, Zabrze, Poland. FAU - Imberti, Jacopo F AU - Imberti JF AD - Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK. AD - Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy. FAU - Wang, Yutang AU - Wang Y AD - Department of Cardiology, Second Medical Centre, Chinese PLA General Hospital, Beijing 100853, China. FAU - Lip, Gregory Y H AU - Lip GYH AD - Department of Pulmonary Vessel and Thrombotic Disease, Sixth Medical Centre, Chinese PLA General Hospital, Beijing 100142, China. AD - Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK. AD - Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. CN - ChiOTEAF Registry Investigators LA - eng PT - Journal Article PT - Multicenter Study PT - Observational Study PT - Research Support, Non-U.S. Gov't PL - England TA - Eur Heart J Qual Care Clin Outcomes JT - European heart journal. Quality of care & clinical outcomes JID - 101677796 RN - 0 (Anticoagulants) SB - IM MH - Aged MH - Anticoagulants MH - *Atrial Fibrillation/complications/drug therapy MH - Female MH - Humans MH - Male MH - Prospective Studies MH - Quality Indicators, Health Care MH - Quality of Life MH - Registries MH - *Stroke/prevention & control MH - *Venous Thromboembolism/drug therapy OTO - NOTNLM OT - Atrial fibrillation OT - Integrated care OT - Quality indicators EDAT- 2021/08/15 06:00 MHDA- 2022/09/09 06:00 CRDT- 2021/08/14 08:34 PHST- 2021/05/17 00:00 [received] PHST- 2021/08/03 00:00 [revised] PHST- 2021/08/09 00:00 [accepted] PHST- 2021/08/15 06:00 [pubmed] PHST- 2022/09/09 06:00 [medline] PHST- 2021/08/14 08:34 [entrez] AID - 6352336 [pii] AID - 10.1093/ehjqcco/qcab057 [doi] PST - ppublish SO - Eur Heart J Qual Care Clin Outcomes. 2022 Sep 5;8(6):651-658. doi: 10.1093/ehjqcco/qcab057. PMID- 34388239 OWN - NLM STAT- MEDLINE DCOM- 20210906 LR - 20220805 IS - 1526-6702 (Electronic) IS - 0730-2347 (Print) IS - 0730-2347 (Linking) VI - 48 IP - 3 DP - 2021 Jul 1 TI - Sustained Use of the Impella 5.0 Heart Pump Enables Bridge to Clinical Decisions in 34 Patients. LID - 10.14503/THIJ-20-7260 [doi] LID - e207260 AB - We studied whether sustained hemodynamic support (>7 d) with the Impella 5.0 heart pump can be used as a bridge to clinical decisions in patients who present with cardiogenic shock, and whether such support can improve their outcomes. We retrospectively reviewed cases of patients who had Impella 5.0 support at our hospital from August 2017 through May 2019. Thirty-four patients (23 with cardiogenic shock and 11 with severely decompensated heart failure) underwent sustained support for a mean duration of 11.7 +/- 9.3 days (range, /=60, body mass index >/=30 kg/m(2), estimated glomerular filtration rate <60 mL/min per 1.73 m(2), dyslipidemia, and diabetes mellitus), radiation to the left breast, and anthracycline dose per 100 mg/m(2) were included in the risk prediction model. The time-dependent C-indices at 3 and 7 years after BC diagnosis were 0.876 and 0.842, respectively, in the validation cohort. Conclusions A prediction score model, including BC treatment-related risk factors and conventional risk factors, was developed and validated to predict major adverse cardiovascular events in patients with BC. The CHEMO-RADIAT (congestive heart failure, hypertension, elderly, myocardial infarction/peripheral artery occlusive disease, obesity, renal failure, abnormal lipid profile, diabetes mellitus, irradiation of the left breast, anthracycline dose, and transient ischemic attack/stroke) score may provide overall cardiovascular risk stratification in survivors of BC and can assist physicians in multidisciplinary decision-making regarding the BC treatment. FAU - Kim, Do Young AU - Kim DY AD - Division of Cardiology Dongtan Sacred Heart HospitalHallym University College of Medicine Hwaseong Republic of Korea. FAU - Park, Myung-Soo AU - Park MS AD - Division of Cardiology Dongtan Sacred Heart HospitalHallym University College of Medicine Hwaseong Republic of Korea. FAU - Youn, Jong-Chan AU - Youn JC AD - Division of Cardiology Dongtan Sacred Heart HospitalHallym University College of Medicine Hwaseong Republic of Korea. AD - Division of Cardiology Department of Internal Medicine Seoul St. Mary's HospitalCatholic Research Institute for Intractable Cardiovascular DiseaseCollege of MedicineThe Catholic University of Korea Seoul Republic of Korea. FAU - Lee, Sunki AU - Lee S AD - Division of Cardiology Dongtan Sacred Heart HospitalHallym University College of Medicine Hwaseong Republic of Korea. FAU - Choi, Jae Hyuk AU - Choi JH AD - Division of Cardiology Dongtan Sacred Heart HospitalHallym University College of Medicine Hwaseong Republic of Korea. FAU - Jung, Mi-Hyang AU - Jung MH AD - Division of Cardiology Dongtan Sacred Heart HospitalHallym University College of Medicine Hwaseong Republic of Korea. FAU - Kim, Lee Su AU - Kim LS AD - Division of Breast and Endocrine Surgery Hallym University Sacred Heart HospitalHallym University College of Medicine Anyang Republic of Korea. FAU - Kim, Sung Hea AU - Kim SH AD - Division of Cardiology Department of Internal Medicine Konkuk University HospitalSchool of MedicineKonkuk University Seoul Republic of Korea. FAU - Han, Seongwoo AU - Han S AD - Division of Cardiology Dongtan Sacred Heart HospitalHallym University College of Medicine Hwaseong Republic of Korea. FAU - Ryu, Kyu-Hyung AU - Ryu KH AD - Division of Cardiology Dongtan Sacred Heart HospitalHallym University College of Medicine Hwaseong Republic of Korea. LA - eng PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't PT - Validation Study DEP - 20210807 PL - England TA - J Am Heart Assoc JT - Journal of the American Heart Association JID - 101580524 RN - 0 (Antineoplastic Agents) SB - IM MH - Adult MH - Antineoplastic Agents/administration & dosage/*adverse effects MH - Breast Neoplasms/diagnosis/mortality/*therapy MH - Cardiotoxicity MH - Cardiovascular Diseases/diagnosis/*etiology/mortality MH - Clinical Decision-Making MH - *Decision Support Techniques MH - Female MH - Humans MH - Middle Aged MH - Predictive Value of Tests MH - Radiation Injuries/diagnosis/*etiology/mortality MH - Radiotherapy/adverse effects MH - Reproducibility of Results MH - Republic of Korea MH - Retrospective Studies MH - Risk Assessment MH - Risk Factors MH - Time Factors MH - Treatment Outcome PMC - PMC8475066 OTO - NOTNLM OT - breast cancer OT - major adverse cardiovascular events OT - multicenter cohort OT - prediction model OT - risk stratification COIS- None. EDAT- 2021/08/10 06:00 MHDA- 2021/11/03 06:00 PMCR- 2021/08/17 CRDT- 2021/08/09 08:42 PHST- 2021/08/10 06:00 [pubmed] PHST- 2021/11/03 06:00 [medline] PHST- 2021/08/09 08:42 [entrez] PHST- 2021/08/17 00:00 [pmc-release] AID - JAH36622 [pii] AID - 10.1161/JAHA.121.021931 [doi] PST - ppublish SO - J Am Heart Assoc. 2021 Aug 17;10(16):e021931. doi: 10.1161/JAHA.121.021931. Epub 2021 Aug 7. PMID- 34367691 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220425 IS - 2090-8016 (Print) IS - 2090-0597 (Electronic) IS - 2090-0597 (Linking) VI - 2021 DP - 2021 TI - Restricted Use of Echocardiography in Suspected Endocarditis during COVID-19 Lockdown: A Multidisciplinary Team Approach. PG - 5565200 LID - 10.1155/2021/5565200 [doi] LID - 5565200 AB - BACKGROUND: Infective endocarditis (IE) is challenging to manage in the COVID-19 lockdown period, in part given its reliance on echocardiography for diagnosis and management and the associated virus transmission risks to patients and healthcare workers. This study assesses utilisation of the endocarditis team (ET) in limiting routine echocardiography, especially transoesophageal echocardiography (TOE), in patients with suspected IE, and explores the effect on clinical outcomes. METHODS: All patients discussed at the ET meeting at Imperial College Healthcare NHS Trust during the first lockdown in the UK (23 March to 8 July 2020) were prospectively included and analysed in this observational study. RESULTS: In total, 38 patients were referred for ET review (71% male, median age 54 [interquartile range 48, 65.5] years). At the time of ET discussion, 21% had no echo imaging, 16% had point-of-care ultrasound only, and 63% had formal TTE. In total, only 16% underwent TOE. The ability of echocardiography, in those where it was performed, to affect IE diagnosis according to the Modified Duke Criteria was significant (p=0.0099); however, sensitivity was not affected. All-cause mortality was 17% at 30 days and 25% at 12 months from ET discussion in those with confirmed IE. CONCLUSION: Limiting echocardiography in patients with a low pretest probability (not probable or definite IE according to the Modified Duke Criteria) did not affect the diagnostic ability of the Modified Duke Criteria to rule out IE in this small study. Moreover, restricting nonessential echocardiography, and importantly TOE, in patients with suspected IE through use of the ET did not impact all-cause mortality. CI - Copyright (c) 2021 Adam Hartley et al. FAU - Hartley, Adam AU - Hartley A AUID- ORCID: 0000-0003-1431-2200 AD - National Heart and Lung Institute, Imperial College London, London, UK. AD - Imperial College Healthcare NHS Trust, London, UK. FAU - El-Sayed, Ahmed AU - El-Sayed A AD - Imperial College Healthcare NHS Trust, London, UK. FAU - Abbara, Aula AU - Abbara A AD - Imperial College Healthcare NHS Trust, London, UK. FAU - Henderson, Jamie AU - Henderson J AD - Imperial College Healthcare NHS Trust, London, UK. FAU - Ghazy, Anan AU - Ghazy A AD - Imperial College Healthcare NHS Trust, London, UK. FAU - Davies, Frances AU - Davies F AD - Imperial College Healthcare NHS Trust, London, UK. AD - NIHR Health Protection Research Unit in HCAI and AMR, Imperial College London, London, UK. FAU - Price, James R AU - Price JR AD - Imperial College Healthcare NHS Trust, London, UK. AD - NIHR Health Protection Research Unit in HCAI and AMR, Imperial College London, London, UK. FAU - Punjabi, Prakash P AU - Punjabi PP AD - National Heart and Lung Institute, Imperial College London, London, UK. AD - Imperial College Healthcare NHS Trust, London, UK. FAU - Anderson, Jon AU - Anderson J AD - Imperial College Healthcare NHS Trust, London, UK. FAU - Casula, Roberto AU - Casula R AD - Imperial College Healthcare NHS Trust, London, UK. FAU - Naderi, Hafiz AU - Naderi H AD - Imperial College Healthcare NHS Trust, London, UK. FAU - Asaria, Perviz AU - Asaria P AD - Imperial College Healthcare NHS Trust, London, UK. FAU - Sutaria, Nilesh AU - Sutaria N AD - Imperial College Healthcare NHS Trust, London, UK. FAU - Malik, Iqbal S AU - Malik IS AD - Imperial College Healthcare NHS Trust, London, UK. FAU - Pabari, Punam A AU - Pabari PA AD - Imperial College Healthcare NHS Trust, London, UK. FAU - Rana, Bushra S AU - Rana BS AUID- ORCID: 0000-0002-7327-0728 AD - National Heart and Lung Institute, Imperial College London, London, UK. AD - Imperial College Healthcare NHS Trust, London, UK. LA - eng GR - WT_/Wellcome Trust/United Kingdom PT - Journal Article DEP - 20210730 PL - United States TA - Cardiol Res Pract JT - Cardiology research and practice JID - 101516542 PMC - PMC8342166 COIS- The authors declare no conflicts of interest. EDAT- 2021/08/10 06:00 MHDA- 2021/08/10 06:01 PMCR- 2021/07/30 CRDT- 2021/08/09 06:36 PHST- 2021/02/15 00:00 [received] PHST- 2021/06/24 00:00 [revised] PHST- 2021/07/24 00:00 [accepted] PHST- 2021/08/09 06:36 [entrez] PHST- 2021/08/10 06:00 [pubmed] PHST- 2021/08/10 06:01 [medline] PHST- 2021/07/30 00:00 [pmc-release] AID - 10.1155/2021/5565200 [doi] PST - epublish SO - Cardiol Res Pract. 2021 Jul 30;2021:5565200. doi: 10.1155/2021/5565200. eCollection 2021. PMID- 34351783 OWN - NLM STAT- MEDLINE DCOM- 20211101 LR - 20260127 IS - 2047-9980 (Electronic) IS - 2047-9980 (Linking) VI - 10 IP - 16 DP - 2021 Aug 17 TI - Research Priorities in the Secondary Prevention of Atrial Fibrillation: A National Heart, Lung, and Blood Institute Virtual Workshop Report. PG - e021566 LID - 10.1161/JAHA.121.021566 [doi] LID - e021566 AB - There has been sustained focus on the secondary prevention of coronary heart disease and heart failure; yet, apart from stroke prevention, the evidence base for the secondary prevention of atrial fibrillation (AF) recurrence, AF progression, and AF-related complications is modest. Although there are multiple observational studies, there are few large, robust, randomized trials providing definitive effective approaches for the secondary prevention of AF. Given the increasing incidence and prevalence of AF nationally and internationally, the AF field needs transformative research and a commitment to evidenced-based secondary prevention strategies. We report on a National Heart, Lung, and Blood Institute virtual workshop directed at identifying knowledge gaps and research opportunities in the secondary prevention of AF. Once AF has been detected, lifestyle changes and novel models of care delivery may contribute to the prevention of AF recurrence, AF progression, and AF-related complications. Although benefits seen in small subgroups, cohort studies, and selected randomized trials are impressive, the widespread effectiveness of AF secondary prevention strategies remains unknown, calling for development of scalable interventions suitable for diverse populations and for identification of subpopulations who may particularly benefit from intensive management. We identified critical research questions for 6 topics relevant to the secondary prevention of AF: (1) weight loss; (2) alcohol intake, smoking cessation, and diet; (3) cardiac rehabilitation; (4) approaches to sleep disorders; (5) integrated, team-based care; and (6) nonanticoagulant pharmacotherapy. Our goal is to stimulate innovative research that will accelerate the generation of the evidence to effectively pursue the secondary prevention of AF. FAU - Benjamin, Emelia J AU - Benjamin EJ AD - Cardiovascular Medicine Department of Medicine Boston University School of Medicine Boston MA. AD - Department of Epidemiology Boston University School of Public Health Boston MA. FAU - Al-Khatib, Sana M AU - Al-Khatib SM AD - Division of Cardiology and Duke Clinical Research Institute Duke University Medical Center Durham NC. FAU - Desvigne-Nickens, Patrice AU - Desvigne-Nickens P AD - Division of Cardiovascular Sciences National Heart, Lung, and Blood InstituteNational Institutes of Health Bethesda MD. FAU - Alonso, Alvaro AU - Alonso A AD - Department of Epidemiology Rollins School of Public Health Emory University Atlanta GA. FAU - Djousse, Luc AU - Djousse L AD - Division of Aging Department of Medicine Brigham and Women's Hospital and Harvard Medical School Boston MA. FAU - Forman, Daniel E AU - Forman DE AD - Divisions of Geriatrics and Cardiology University of Pittsburgh Medical CenterAging InstituteUniversity of PittsburghVA Pittsburgh Healthcare System Pittsburgh PA. FAU - Gillis, Anne M AU - Gillis AM AD - Libin Cardiovascular Institute of AlbertaUniversity of Calgary Alberta Canada. FAU - Hendriks, Jeroen M L AU - Hendriks JML AD - Centre for Heart Rhythm Disorders University of Adelaide, and Royal Adelaide Hospital Adelaide Australia. AD - Caring Futures Institute College of Nursing and Health Sciences Flinders University Adelaide Australia. FAU - Hills, Mellanie True AU - Hills MT AD - StopAfib.org American Foundation for Women's Health Decatur TX. FAU - Kirchhof, Paulus AU - Kirchhof P AD - Department of Cardiology University Heart and Vascular Center UKE Hamburg Hamburg Germany. AD - Institute of Cardiovascular Science University of Birmingham United Kingdom. AD - German Center for Cardiovascular Research, Partner Site Hamburg/Kiel/Lubeck Berlin Germany. AD - AFNET Munster Germany. FAU - Link, Mark S AU - Link MS AD - Division of Cardiology Department of Medicine UT Southwestern Medical Center Dallas TX. FAU - Marcus, Gregory M AU - Marcus GM AD - Division of Cardiology University of California, San Francisco San Francisco CA. FAU - Mehra, Reena AU - Mehra R AD - Sleep Disorders Center Neurologic Institute Respiratory Institute Heart and Vascular Institute, and Molecular Cardiology Department of the Lerner Research Institute Cleveland Clinic Cleveland OH. FAU - Murray, Katherine T AU - Murray KT AD - Vanderbilt University School of Medicine Nashville TN. FAU - Parkash, Ratika AU - Parkash R AD - Division of Cardiology QEII Health Sciences Center/Dalhousie University Halifax Nova Scotia Canada. FAU - Pina, Ileana L AU - Pina IL AD - Wayne State University Detroit MI. AD - Central Michigan University Mt Pleasant MI. AD - FDAOPEQCenter for Devices and Radiological Health Silver Spring MD. FAU - Redline, Susan AU - Redline S AD - Department of Medicine Brigham and Women's Hospital Boston MA. FAU - Rienstra, Michiel AU - Rienstra M AD - Department of Cardiology University of GroningenUniversity Medical Center Groningen Groningen the Netherlands. FAU - Sanders, Prashanthan AU - Sanders P AD - Centre for Heart Rhythm Disorders University of Adelaide, and Royal Adelaide Hospital Adelaide Australia. FAU - Somers, Virend K AU - Somers VK AD - Department of Cardiovascular Medicine Mayo Clinic Rochester MN. FAU - Van Wagoner, David R AU - Van Wagoner DR AD - Cleveland Clinic Lerner College of Medicine Cleveland OH. FAU - Wang, Paul J AU - Wang PJ AD - Stanford University School of Medicine Palo Alto CA. FAU - Cooper, Lawton S AU - Cooper LS AD - Division of Cardiovascular Sciences National Heart, Lung, and Blood InstituteNational Institutes of Health Bethesda MD. FAU - Go, Alan S AU - Go AS AD - Division of Research Kaiser Permanente Northern California Oakland CA. AD - Department of Health System Science Kaiser Permanente Bernard J. Tyson School of Medicine Pasadena CA. AD - Departments of Epidemiology, Biostatistics and Medicine University of California, San Francisco San Francisco CA. AD - Departments of Medicine Health Research and Policy Stanford University Stanford CA. LA - eng GR - FS/13/43/30324/BHF_/British Heart Foundation/United Kingdom GR - AA/18/2/34218/BHF_/British Heart Foundation/United Kingdom GR - R01 AG066010/AG/NIA NIH HHS/United States GR - 75N91020C00039/CA/NCI NIH HHS/United States GR - U01 AR071130/AR/NIAMS NIH HHS/United States GR - R01 HL131687/HL/NHLBI NIH HHS/United States GR - U54 HL120163/HL/NHLBI NIH HHS/United States GR - PG/20/22/35093/BHF_/British Heart Foundation/United Kingdom GR - K24 HL148521/HL/NHLBI NIH HHS/United States GR - R01 HL111314/HL/NHLBI NIH HHS/United States GR - R01 AA022222/AA/NIAAA NIH HHS/United States GR - R01 HL092577/HL/NHLBI NIH HHS/United States GR - R01 HL141434/HL/NHLBI NIH HHS/United States GR - U2C EB021881/EB/NIBIB NIH HHS/United States GR - 75N92019C00011/HL/NHLBI NIH HHS/United States GR - R01 DK107972/DK/NIDDK NIH HHS/United States GR - R01 HL128914/HL/NHLBI NIH HHS/United States GR - 16EIA26410001/AHA/American Heart Association-American Stroke Association/United States GR - R01 AG060499/AG/NIA NIH HHS/United States GR - R21 AG058445/AG/NIA NIH HHS/United States GR - R01 HL142834/HL/NHLBI NIH HHS/United States GR - R01 HL137338/HL/NHLBI NIH HHS/United States GR - P30 AG024827/AG/NIA NIH HHS/United States GR - R35 HL135818/HL/NHLBI NIH HHS/United States GR - R01 DK103612/DK/NIDDK NIH HHS/United States GR - R01 AG066914/AG/NIA NIH HHS/United States GR - R01 AG053325/AG/NIA NIH HHS/United States GR - R01 HL153874/HL/NHLBI NIH HHS/United States GR - R01 AG058883/AG/NIA NIH HHS/United States GR - PG/17/30/32961/BHF_/British Heart Foundation/United Kingdom PT - Conference Proceedings PT - News PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, Non-P.H.S. DEP - 20210805 PL - England TA - J Am Heart Assoc JT - Journal of the American Heart Association JID - 101580524 RN - 0 (Anti-Arrhythmia Agents) SB - IM MH - Animals MH - Anti-Arrhythmia Agents/therapeutic use MH - Atrial Fibrillation/diagnosis/epidemiology/*prevention & control MH - *Biomedical Research MH - Body Composition MH - Cardiac Rehabilitation MH - Comorbidity MH - Disease Progression MH - Health Priorities MH - Health Services Needs and Demand MH - Healthy Lifestyle MH - Humans MH - *National Heart, Lung, and Blood Institute (U.S.) MH - Needs Assessment MH - Recurrence MH - *Research Design MH - Risk Assessment MH - Risk Factors MH - *Secondary Prevention MH - Treatment Outcome MH - United States MH - Weight Loss PMC - PMC8475065 OTO - NOTNLM OT - atrial fibrillation OT - cardiac rehabilitation OT - prevention OT - research OT - risk factors OT - sleep COIS- Dr Benjamin was an uncompensated member for MyHeartLab Steering Committee, a PI-initiated study from Samsung to University of California, San Francisco. Principal Investigator, Jeffrey Olgin, MD, in 2020. Dr Al-Khatib receives consulting fees from Milestone Pharmaceuticals, research, speaking, and consulting fees from Medtronic, research and speaking fees from Abbott, and research fees from Boston Scientific. Dr Alonso is a member of the Scientific Advisory Board of Corify Care SL. Dr Djousse in an uncompensated member of the International Scientific Forum on Alcohol Research. He received an investigator-initiated research grant from the American Egg Board in the past (2016-2018). Professor Hendriks reports that the University of Adelaide has received on his behalf lecture and/or consulting fees from Medtronic and Pfizer/BMS. Dr Kirchhof receives research support for basic, translational, and clinical research projects from European Union, British Heart Foundation, Leducq Foundation, Medical Research Council (United Kingdom), and German Centre for Cardiovascular Research, from several drug and device companies active in atrial fibrillation, and has received honoraria from several such companies in the past, but not in the past 3 years. Dr Kirchhof is listed as inventor on 2 patents held by University of Birmingham (Atrial Fibrillation Therapy WO 2015140571 and Markers for Atrial Fibrillation WO 2016012783). Dr Marcus receives research funding from Baylis Medical, Medtronic, Jawbone, and Eight Sleep; consulting as member of steering committee for Johnson & Johnson; and consultant for InCarda and equity in InCarda as a cofounder. Dr Murray has a pending patent application, Metabolic Technologies Inc. Dr Parkash receives research funding from Medtronic, Abbott, Novartis, and Pfizer. Dr Pina is on the Advisory Board of Relypsa. Dr Redline received consulting fee for participating in advisory meetings held by Respicardia and Eisai Inc, and consulting fees from Jazz Pharmaceuticals and Apnimed Inc. Dr Sanders reports having served on the advisory board of Medtronic, Abbott, Boston Scientific, Pacemate, and CathRx. The University of Adelaide reports receiving on behalf of Dr Sanders lecture and/or consulting fees from Medtronic, Abbott, Boston Scientific, and Bayer. The University of Adelaide reports receiving on behalf of Dr Sanders research funding from Medtronic, Abbott, Boston Scientific, and Microport. Dr Somers is a consultant for Baker Tilly; Jazz Pharmaceuticals; Sleep Number; and Respicardia. Dr Go has received a research grant through his institution from iRhythm Technologies. Dr Go is also a member of the Operations Committee and Steering Committee for A Study to Determine if Identification of Undiagnosed Atrial Fibrillation in People at Least 70 Years of Age Reduces the Risk of Stroke (GUARD-AF) Study (NCT04126486) sponsored by Bristol Meyers Squibb and Pfizer. The remaining authors have no disclosures to report. EDAT- 2021/08/06 06:00 MHDA- 2021/11/03 06:00 PMCR- 2021/08/17 CRDT- 2021/08/05 17:12 PHST- 2021/08/06 06:00 [pubmed] PHST- 2021/11/03 06:00 [medline] PHST- 2021/08/05 17:12 [entrez] PHST- 2021/08/17 00:00 [pmc-release] AID - JAH36378 [pii] AID - 10.1161/JAHA.121.021566 [doi] PST - ppublish SO - J Am Heart Assoc. 2021 Aug 17;10(16):e021566. doi: 10.1161/JAHA.121.021566. Epub 2021 Aug 5. PMID- 34350424 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220812 VI - 2020 DP - 2020 Aug TI - Autonomic Activity and Surgical Flow Disruptions in Healthcare Providers during Cardiac Surgery. LID - 10.1109/cogsima49017.2020.9216076 [doi] AB - Cardiac surgery represents a complex sociotechnical environment relying on a combination of technical and non-technical team-based expertise. Surgical flow disruptions (SFDs) may be influenced by a variety of sources, including social, environmental, and emotional factors affecting healthcare providers (HCPs). Many of these factors can be readily observed, except for emotional factors (i.e. distress), which represents an underappreciated yet critical source of SFDs. The aim of this study was to demonstrate the sensitivity of autonomic activity metrics to detect an SFD during cardiac surgery. We integrated heart rate variability (HRV) analysis with observation-based annotations to allow data triangulation. Following a critical medication administration error by the anesthesiologist in-training, data sources were consulted to identify events precipitating this near-miss event. Using pyphysio, an open-source physiological signal processing package, we analyzed the attending anesthesiologists' HRV, specifically the low frequency (LF) power, high frequency (HF) power, LF/HF ratio, standard deviation of normal-to-normal (SDNN), and root mean square of the successive differences (RMSSD) as indicators of ANS activity. A heightened SNS response in the attending anesthesiologists' physiological arousal was observed as elevations in LF power and LF/HF ratio, as well as depressions in HF power, SDNN, and RMSSD prior to the near-miss event. The attending anesthesiologist subjectively confirmed a state of high distress induced by task-irrelevant environmental factors during this time. Qualitative analysis of audio/video recordings objectively revealed that the autonomic nervous system (ANS) activation detected was temporally associated with an argument over operating room management. This study confirms that it is possible to recognize detrimental psychophysiological influences in cardiac surgery procedures via advanced HRV analysis. To our knowledge, ours is the first such case demonstrating ANS activity coinciding with strong self-reported emotion during live surgery using HRV. Despite extensive experience in the cardiac OR, transient but intense emotional changes may have the potential to disrupt attention processes in even the most experienced HCP. A primary implication of this work is the possibility to detect real-time ANS activity, which could enable personalized interventions to proactively mitigate downstream adverse events. Additional studies on our large database of surgical cases are underway and new studies are actively being planned to confirm this preliminary observation. FAU - Kennedy-Metz, Lauren R AU - Kennedy-Metz LR AD - Medical Robotics and Computer-Assisted Surgery Lab Harvard Medical School and U.S. Dept. of Veterans Affairs Boston, MA, USA. FAU - Bizzego, Andrea AU - Bizzego A AD - Department of Psychology and Cognitive Science University of Trento Trento, Italy. FAU - Esposito, Gianluca AU - Esposito G AD - Department of Psychology and Cognitive Science, University of Trento Trento, Italy School of Social Sciences, Lee Kong Chian School of Medicine Nanyang Technological University, Singapore. FAU - Dias, Roger D AU - Dias RD AD - Human Factors & Cognitive Engineering lab, STRATUS Center for Medical Simulation Brigham and Women's Hospital Boston, MA, USA. FAU - Zenati, Marco A AU - Zenati MA AD - Medical Robotics and Computer-Assisted Surgery Lab Harvard Medical School and U.S. Dept. of Veterans Affairs Boston, MA, USA. FAU - Furlanello, Cesare AU - Furlanello C AD - HK3 Lab & Bruno Kessler Foundation Trento, Italy. LA - eng GR - R01 HL126896/HL/NHLBI NIH HHS/United States PT - Journal Article DEP - 20201007 PL - United States TA - IEEE Conf Cogn Comput Asp Situat Manag JT - IEEE Conference on Cognitive and Computational Aspects of Situation Management (CogSIMA) JID - 9918451688906676 PMC - PMC8329755 MID - NIHMS1658725 OTO - NOTNLM OT - cardiac surgery OT - cognitive engineering OT - emotion recognition OT - heart rate variability OT - neuroergonomics EDAT- 2021/08/06 06:00 MHDA- 2021/08/06 06:01 PMCR- 2021/08/03 CRDT- 2021/08/05 06:33 PHST- 2021/08/05 06:33 [entrez] PHST- 2021/08/06 06:00 [pubmed] PHST- 2021/08/06 06:01 [medline] PHST- 2021/08/03 00:00 [pmc-release] AID - 10.1109/cogsima49017.2020.9216076 [doi] PST - ppublish SO - IEEE Conf Cogn Comput Asp Situat Manag. 2020 Aug;2020:10.1109/cogsima49017.2020.9216076. doi: 10.1109/cogsima49017.2020.9216076. Epub 2020 Oct 7. PMID- 34350262 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210806 IS - 2305-5839 (Print) IS - 2305-5847 (Electronic) IS - 2305-5839 (Linking) VI - 9 IP - 11 DP - 2021 Jun TI - A narrative review of hybrid ablation for persistent and longstanding persistent atrial fibrillation. PG - 947 LID - 10.21037/atm-21-196 [doi] LID - 947 AB - Atrial fibrillation is the most common sustained arrhythmia and is characterized by rapid and irregular atrial activation with loss of atrial contraction. There has been a significant evolution of treatments over the past 30 years. Initially, cardiac surgeons developed approaches via sternotomy with superior efficacy, however early iterations of the procedure were associated with prolonged recovery time and frequent need for pacemaker placement. The current surgical approach to the maze procedure via sternotomy yields excellent efficacy and is a Class 1 recommendation for patients with atrial fibrillation undergoing a concomitant procedure. Several years following the initial development of the surgical maze procedure, cardiac electrophysiologists developed less invasive, however less efficacious catheter ablation options by percutaneous approach. Both the surgical and transcatheter approaches have their advantages and disadvantages with varying risks of complications and efficacy. Through the combination of expertise of cardiac surgeons paired with the electrophysiology team, a hybrid ablation procedure has been developed offering an increased efficacy with a less-invasive approach than the current gold standard treatment of Cox-maze IV procedure. This review will discuss the hybrid ablation procedure, review recent associated clinical trials, and discuss advantages and challenges associated with this multidisciplinary approach for management of patients with AF. CI - 2021 Annals of Translational Medicine. All rights reserved. FAU - Khoynezhad, Ali AU - Khoynezhad A AD - MemorialCare Heart and Vascular Institute, Long Beach, CA, USA. FAU - Warrier, Nikhil AU - Warrier N AD - MemorialCare Heart and Vascular Institute, Long Beach, CA, USA. FAU - Worthington, Tiffany AU - Worthington T AD - MemorialCare Heart and Vascular Institute, Long Beach, CA, USA. FAU - Shandling, Adrian AU - Shandling A AD - MemorialCare Heart and Vascular Institute, Long Beach, CA, USA. LA - eng PT - Journal Article PT - Review PL - China TA - Ann Transl Med JT - Annals of translational medicine JID - 101617978 PMC - PMC8263859 OTO - NOTNLM OT - Atrial fibrillation OT - cardiac surgical procedures OT - electrophysiology COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at: http://dx.doi.org/10.21037/atm-21-196). AK serves as an unpaid editorial board member of Annals of Translational Medicine from May 2019 to Apr 2021. The authors have no other conflicts of interest to declare. EDAT- 2021/08/06 06:00 MHDA- 2021/08/06 06:01 PMCR- 2021/06/01 CRDT- 2021/08/05 06:31 PHST- 2021/01/14 00:00 [received] PHST- 2021/04/26 00:00 [accepted] PHST- 2021/08/05 06:31 [entrez] PHST- 2021/08/06 06:00 [pubmed] PHST- 2021/08/06 06:01 [medline] PHST- 2021/06/01 00:00 [pmc-release] AID - atm-09-11-947 [pii] AID - 10.21037/atm-21-196 [doi] PST - ppublish SO - Ann Transl Med. 2021 Jun;9(11):947. doi: 10.21037/atm-21-196. PMID- 34348946 OWN - NLM STAT- MEDLINE DCOM- 20210809 LR - 20210821 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 11 IP - 8 DP - 2021 Aug 4 TI - Institutional infrastructural preconditions and current perioperative anaesthesia practice in patients undergoing transfemoral transcatheter aortic valve implantation: a cross-sectional study in German heart centres. PG - e045330 LID - 10.1136/bmjopen-2020-045330 [doi] LID - e045330 AB - OBJECTIVES: Transfemoral transcatheter aortic valve implantation (TF-TAVI) is an established therapy for patients with symptomatic aortic stenosis, which requires periprocedural anaesthesia care. In 2015, the German Federal Joint Committee released a directive on minimally invasive heart valve interventions which defines institutional infrastructural requirements in German heart centres. But still generally accepted expert consensus recommendations or national or international guidelines regarding periprocedural anaesthesia management for TF-TAVI are lacking. This nationwide cross-sectional study had two major objectives: first to assess the concordance with existing national regulations regarding infrastructural requirements and second to evaluate the status quo of periprocedural anaesthesia management for patients undergoing TF-TAVI in German heart centres. DESIGN: Multicentre cross-sectional online study to evaluate the periprocedural anaesthesia management. SETTING: In this nationwide cross-sectional study, electronic questionnaires were sent out to anaesthesia departments at TF-TAVI-performing centres in Germany in March 2019. PARTICIPANTS: 78 anaesthesia departments of German heart centres. RESULTS: 54 (69.2%) centres returned the questionnaire of which 94.4% stated to hold regular Heart Team meetings, 75.9% to have ready-to-use heart-lung machines available on-site, 77.8% to have cardiac surgeons and 66.7% to have perfusionists routinely attending throughout TF-TAVI procedures. Regarding periprocedural anaesthesia management, 41 (75.9%) of the participating centres reported to predominantly use 'monitored anaesthesia care' and 13 (24.1%) to favour general anaesthesia. 49 (90.7%) centres stated to use institutional standard operating procedures for anaesthesia. Five-lead ECG, central venous lines, capnometry and intraprocedural echocardiography were reported to be routine measures in 85.2%, 83.3%, 77.8% and 51.9% of the surveyed heart centres. CONCLUSIONS: The concordance with national regulations, anaesthesia management and in-house standards for TF-TAVI vary broadly among German heart centres. According to the opinion of the authors, international expert consensus recommendations and/or guidelines would be helpful to standardise peri interventional anaesthesia care. CI - (c) Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Loser, Benjamin AU - Loser B AUID- ORCID: 0000-0001-8442-7797 AD - Department of Anaesthesiology, Center of Anaesthesiology and Intensive Care Medicine, University Medicine Rostock, Rostock, Germany benjamin.loeser@med.uni-rostock.de. FAU - Haas, Annika AU - Haas A AD - Department of Anaesthesiology, Center of Anaesthesiology and Intensive Care Medicine, University Medicine Rostock, Rostock, Germany. FAU - Zitzmann, Amelie AU - Zitzmann A AD - Department of Anaesthesiology, Center of Anaesthesiology and Intensive Care Medicine, University Medicine Rostock, Rostock, Germany. FAU - Dankert, Andre AU - Dankert A AD - Department of Anaesthesiology, Center of Anaesthesiology and Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Treskatsch, Sascha AU - Treskatsch S AD - Department of Anaesthesiology and Operative Intensive Care Medicine, Charite - Universitatsmedizin Berlin, Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Charite Campus Benjamin Franklin, Berlin, Germany. FAU - Reuter, Daniel A AU - Reuter DA AD - Department of Anaesthesiology, Center of Anaesthesiology and Intensive Care Medicine, University Medicine Rostock, Rostock, Germany. FAU - Haas, Sebastian AU - Haas S AD - Department of Anaesthesiology, Center of Anaesthesiology and Intensive Care Medicine, University Medicine Rostock, Rostock, Germany. FAU - Glass, Anne AU - Glass A AD - Institute for Biostatistics and Informatics in Medicine and Ageing Research, University Medicine Rostock, Rostock, Germany. FAU - Petzoldt, Martin AU - Petzoldt M AUID- ORCID: 0000-0001-5295-2925 AD - Department of Anaesthesiology, Center of Anaesthesiology and Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. LA - eng PT - Journal Article DEP - 20210804 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 SB - IM MH - Anesthesia, General MH - Aortic Valve/surgery MH - *Aortic Valve Stenosis/surgery MH - Cross-Sectional Studies MH - *Heart Valve Prosthesis Implantation MH - Humans MH - *Transcatheter Aortic Valve Replacement MH - Treatment Outcome PMC - PMC8340292 OTO - NOTNLM OT - adult anaesthesia OT - adult intensive & critical care OT - anaesthesia in cardiology COIS- Competing interests: ST reports grants and personal fees from ORION Pharma, personal fees and non-financial support from Edwards, personal fees from Amomed Pharma, outside the submitted work. BL, AH, AZ, AD, DAR, SH, AG and MP declare no conflict of interest. EDAT- 2021/08/06 06:00 MHDA- 2021/08/10 06:00 PMCR- 2021/08/04 CRDT- 2021/08/05 05:42 PHST- 2021/08/05 05:42 [entrez] PHST- 2021/08/06 06:00 [pubmed] PHST- 2021/08/10 06:00 [medline] PHST- 2021/08/04 00:00 [pmc-release] AID - bmjopen-2020-045330 [pii] AID - 10.1136/bmjopen-2020-045330 [doi] PST - epublish SO - BMJ Open. 2021 Aug 4;11(8):e045330. doi: 10.1136/bmjopen-2020-045330. PMID- 34345945 OWN - NLM STAT- MEDLINE DCOM- 20211028 LR - 20240823 IS - 1534-6242 (Electronic) IS - 1523-3804 (Print) IS - 1523-3804 (Linking) VI - 23 IP - 10 DP - 2021 Aug 4 TI - Managing Ischemic Heart Disease in Women: Role of a Women's Heart Center. PG - 56 LID - 10.1007/s11883-021-00956-x [doi] LID - 56 AB - PURPOSE OF REVIEW: Heart centers for women (HCW) were developed due to the rising cardiovascular morbidity and mortality in women in the United States in the early 1990s. Our review encompasses the epidemiology, risk factors, diagnostic strategies, treatments, and the role of HCW in managing women with ischemic heart disease (IHD). RECENT FINDINGS: HCW use a multidisciplinary team to manage women with IHD. Due to the paucity of randomized controlled trials investigating various manifestations of IHD, some treatments are not evidence-based such as those for coronary microvascular dysfunction and spontaneous coronary artery dissection. Sex-specific risk factors have been identified and multimodality cardiac imaging is improving in diagnosing IHD in women. Treatments are being studied to help improve symptoms and outcomes in women with IHD. There has been progress in the care of women with IHD. HCW can be instrumental in treating women with IHD, doing research, and being a source of research study participants. CI - (c) 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Khandelwal, Abha AU - Khandelwal A AD - Division of Cardiology, Women's Heart Health, Stanford University, Palo Alto, CA, USA. FAU - Bakir, May AU - Bakir M AD - Division of Cardiology, Women's Heart Health Center, Loyola University, Chicago, IL, USA. FAU - Bezaire, Meghan AU - Bezaire M AD - Rush Heart Center for Women, Division of Cardiology, Rush University Medical Center, Chicago, IL, USA. FAU - Costello, Briana AU - Costello B AD - Center for Women's Heart & Vascular Health, Texas Heart Institute, and Baylor St. Luke's Medical Center Hospital, Houston, TX, USA. FAU - Gomez, Joanne Michelle D AU - Gomez JMD AD - Barbra Streisand Women's Heart Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA. FAU - Hoover, Valerie AU - Hoover V AD - Department of Psychology, Stanford University, Palo Alto, CA, USA. FAU - Nazir, Noreen T AU - Nazir NT AD - Division of Cardiology, Department of Medicine, University of Illinois, Chicago, Chicago, USA. FAU - Nichols, Katherine AU - Nichols K AD - Division of Cardiology, Massachusetts General Hospital, Harvard University, Boston, MA, USA. FAU - Reisenberg, Amy AU - Reisenberg A AD - Stanford Healthcare, Stanford University, Palo Alto, CA, USA. FAU - Rao, Anupama AU - Rao A AD - Division of Cardiology, Rush University Medical Center, Chicago, IL, USA. FAU - Sanghani, Rupa AU - Sanghani R AD - Rush Heart Center for Women, Division of Cardiology, Rush University Medical Center, Chicago, IL, USA. FAU - Tracy, Melissa AU - Tracy M AD - Rush Heart Center for Women, Division of Cardiology, Rush University Medical Center, Chicago, IL, USA. FAU - Volgman, Annabelle Santos AU - Volgman AS AUID- ORCID: 0000-0002-9918-0878 AD - Rush Heart Center for Women, Division of Cardiology, Rush University Medical Center, Chicago, IL, USA. Annabelle_Volgman@rush.edu. AD - , Chicago, USA. Annabelle_Volgman@rush.edu. LA - eng GR - R01 NR018443/NR/NINR NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20210804 PL - United States TA - Curr Atheroscler Rep JT - Current atherosclerosis reports JID - 100897685 SB - IM MH - Female MH - Humans MH - Male MH - *Myocardial Ischemia/diagnosis/epidemiology/therapy MH - Risk Factors MH - Sex Factors MH - United States PMC - PMC8331213 OTO - NOTNLM OT - Ischemia with non-obstructive coronary arteries (INOCA) OT - Multidisciplinary healthcare delivery OT - Myocardial infarction with non-obstructive coronary arteries (MINOCA) OT - Non-obstructive coronary artery disease OT - Sex differences in cardiovascular disease COIS- No authors have any conflict of interest in writing this paper. The authors have no financial or proprietary interests in any material discussed in this article. Bakir-consultant Amgen. Khandelwal-Research Funding Novartis CTQJ. Volgman-Research funding: NIH IND Number 119127; NIH NINR R01NR018443; Novartis CTQJ230A12001; Stock ownership: Apple, Inc.; MSD/Bayer Virtual Global Advisory Board Member, Bristol Myers Squibb Foundation Diverse Clinical Investigator Career Development Program (DCICDP) National Advisory Committee (NAC). EDAT- 2021/08/05 06:00 MHDA- 2021/10/29 06:00 PMCR- 2021/08/03 CRDT- 2021/08/04 07:15 PHST- 2021/06/08 00:00 [accepted] PHST- 2021/08/04 07:15 [entrez] PHST- 2021/08/05 06:00 [pubmed] PHST- 2021/10/29 06:00 [medline] PHST- 2021/08/03 00:00 [pmc-release] AID - 10.1007/s11883-021-00956-x [pii] AID - 956 [pii] AID - 10.1007/s11883-021-00956-x [doi] PST - epublish SO - Curr Atheroscler Rep. 2021 Aug 4;23(10):56. doi: 10.1007/s11883-021-00956-x. PMID- 34345629 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231107 IS - 2312-0541 (Print) IS - 2312-0541 (Electronic) IS - 2312-0541 (Linking) VI - 7 IP - 3 DP - 2021 Jul TI - Descriptive analysis of long COVID sequelae identified in a multidisciplinary clinic serving hospitalised and non-hospitalised patients. LID - 00205-2021 [pii] LID - 10.1183/23120541.00205-2021 [doi] AB - BACKGROUND: There are emerging data of long-term effects of coronavirus disease 2019 (COVID-19) comprising a diversity of symptoms. The aim of this study was to systematically describe and measure pulmonary and extra-pulmonary post-COVID-19 complications in relation to acute COVID-19 severity. METHODS: Patients attending a standard of care 3 months post-hospitalisation follow-up visit and those referred by their general practitioner because of persistent post-COVID-19 symptoms were included. Patients underwent symptomatic, quality of life, pulmonary (lung function and high-resolution computed tomography (HRCT)), cardiac (high-resolution ECG), physical (1-min sit and stand test (1-MSTST), handgrip strength, cardiopulmonary exercise testing (CPET)) and cognitive evaluations. RESULTS: All 34 hospitalised and 22 out of 23 non-hospitalised patients had >/=1 complaint or abnormal finding at follow-up. Overall, 67% of patients were symptomatic (Medical Research Council (MRC) >/=2 or COPD assessment test (CAT) >/=10), with no difference between hospitalised versus non-hospitalised patients. Pulmonary function (forced expiratory volume in 1 s (FEV(1)) or diffusing capacity of the lung for carbon monoxide (D (LCO))) <80% of predicted) was impaired in 68% of patients. D (LCO) was significantly lower in those hospitalised compared to non-hospitalised (70.1+/-18.0 versus 80.2+/-11.2% predicted, p=0.02). Overall, 53% had an abnormal HRCT (predominantly ground-glass opacities) with higher composite computed tomography (CT) scores in hospitalised versus non-hospitalised patients (2.3 (0.1-4.8) and 0.0 (0.0-0.3), p<0.001). 1-MSTST was below the 25th percentile in almost half of patients, but no signs of cardiac dysfunction were found. Cognitive impairments were present in 59-66% of hospitalised and 31-44% of non-hospitalised patients (p=0.08). CONCLUSION: Three months after COVID-19 infection, patients were still symptomatic and demonstrated objective respiratory, functional, radiological and cognitive abnormalities, which were more prominent in hospitalised patients. Our study underlines the importance of multidimensional management strategies in these patients. CI - Copyright (c)The authors 2021. FAU - Johnsen, Stine AU - Johnsen S AUID- ORCID: 0000-0001-7823-3697 AD - Dept of Respiratory Medicine, Copenhagen University Hospital at Bispebjerg, Copenhagen, Denmark. AD - These authors contributed equally. FAU - Sattler, Stefan M AU - Sattler SM AD - Dept of Respiratory Medicine, Copenhagen University Hospital at Bispebjerg, Copenhagen, Denmark. AD - Biomedical Institute, Copenhagen University, Copenhagen, Denmark. AD - These authors contributed equally. FAU - Miskowiak, Kamilla Woznica AU - Miskowiak KW AD - Neurocognition and Emotion in Affective Disorders, Copenhagen, Denmark. FAU - Kunalan, Keerthana AU - Kunalan K AD - Dept of Respiratory Medicine, Copenhagen University Hospital at Bispebjerg, Copenhagen, Denmark. FAU - Victor, Alan AU - Victor A AD - Dept of Respiratory Medicine, Copenhagen University Hospital at Bispebjerg, Copenhagen, Denmark. FAU - Pedersen, Lars AU - Pedersen L AUID- ORCID: 0000-0002-5950-652X AD - Dept of Respiratory Medicine, Copenhagen University Hospital at Bispebjerg, Copenhagen, Denmark. FAU - Andreassen, Helle Frost AU - Andreassen HF AD - Dept of Respiratory Medicine, Copenhagen University Hospital at Bispebjerg, Copenhagen, Denmark. FAU - Jorgensen, Barbara Jolanta AU - Jorgensen BJ AD - Dept of Radiology, Copenhagen University Hospital at Bispebjerg, Copenhagen, Denmark. FAU - Heeboll, Hanne AU - Heeboll H AD - Dept of Radiology, Copenhagen University Hospital at Bispebjerg, Copenhagen, Denmark. FAU - Andersen, Michael Brun AU - Andersen MB AD - Dept of Radiology, Copenhagen University Hospital at Herlev/Gentofte, Copenhagen, Denmark. FAU - Marner, Lisbeth AU - Marner L AD - Dept of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital at Bispebjerg and Frederiksberg, Copenhagen, Denmark. FAU - Haedersdal, Carsten AU - Haedersdal C AD - Dept of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital at Bispebjerg and Frederiksberg, Copenhagen, Denmark. FAU - Hansen, Henrik AU - Hansen H AD - Respiratory Research Unit, Dept of Respiratory Medicine, Copenhagen University Hospital at Bispebjerg, Copenhagen, Denmark. AD - Respiratory Research Unit, Dept of Respiratory Medicine, Copenhagen University Hospital at Hvidovre, Copenhagen, Denmark. FAU - Ditlev, Sisse Bolm AU - Ditlev SB AD - Respiratory Research Unit, Dept of Respiratory Medicine, Copenhagen University Hospital at Bispebjerg, Copenhagen, Denmark. AD - Copenhagen Center for Translational Research, Copenhagen University Hospital at Bispebjerg, Copenhagen, Denmark. FAU - Porsbjerg, Celeste AU - Porsbjerg C AD - Dept of Respiratory Medicine, Copenhagen University Hospital at Bispebjerg, Copenhagen, Denmark. AD - Respiratory Research Unit, Dept of Respiratory Medicine, Copenhagen University Hospital at Bispebjerg, Copenhagen, Denmark. FAU - Lapperre, Therese S AU - Lapperre TS AUID- ORCID: 0000-0002-5176-0101 AD - Dept of Respiratory Medicine, Copenhagen University Hospital at Bispebjerg, Copenhagen, Denmark. AD - Dept of Pulmonology, University Hospital Antwerp, Antwerp, Belgium. AD - Laboratory of Experimental Medicine and Paediatrics, University of Antwerp, Antwerp, Belgium. LA - eng PT - Journal Article DEP - 20210802 PL - England TA - ERJ Open Res JT - ERJ open research JID - 101671641 PMC - PMC8091683 COIS- Conflict of interest: S. Johnsen has nothing to disclose. Conflict of interest: S.M. Sattler has nothing to disclose. Conflict of interest: K.W. Miskowiak reports personal feels from Lundbeck outside the submitted work. Conflict of interest: K. Kunalan has nothing to disclose. Conflict of interest: A. Victor has nothing to disclose. Conflict of interest: L. Pedersen has nothing to disclose. Conflict of interest: H.F. Andreassen has nothing to disclose. Conflict of interest: B.J. Jorgensen has nothing to disclose. Conflict of interest: H. Heeboll has nothing to disclose. Conflict of interest: M.B. Andersen has nothing to disclose. Conflict of interest: L. Marner has nothing to disclose. Conflict of interest: C. Haedersdal has nothing to disclose. Conflict of interest: H. Hansen has nothing to disclose. Conflict of interest: S. Ditlev has nothing to disclose. Conflict of interest: C. Porsbjerg has nothing to disclose. Conflict of interest: T.S. Lapperre has nothing to disclose. EDAT- 2021/08/05 06:00 MHDA- 2021/08/05 06:01 PMCR- 2021/08/02 CRDT- 2021/08/04 07:09 PHST- 2021/03/20 00:00 [received] PHST- 2021/04/20 00:00 [accepted] PHST- 2021/08/04 07:09 [entrez] PHST- 2021/08/05 06:00 [pubmed] PHST- 2021/08/05 06:01 [medline] PHST- 2021/08/02 00:00 [pmc-release] AID - 00205-2021 [pii] AID - 10.1183/23120541.00205-2021 [doi] PST - epublish SO - ERJ Open Res. 2021 Aug 2;7(3):00205-2021. doi: 10.1183/23120541.00205-2021. eCollection 2021 Jul. PMID- 34333616 OWN - NLM STAT- MEDLINE DCOM- 20211125 LR - 20211125 IS - 1940-8250 (Electronic) IS - 0279-5442 (Linking) VI - 41 IP - 4 DP - 2021 Aug 1 TI - Mobilization of Patients Receiving Extracorporeal Membrane Oxygenation Before Lung Transplant. PG - 39-45 LID - 10.4037/ccn2021689 [doi] AB - BACKGROUND: Extracorporeal membrane oxygenation is increasingly used to provide cardiopulmonary support to patients awaiting lung transplant. Although studies have shown that these patients benefit from early mobilization, the care team often has concerns about related complications, particularly for patients requiring femoral cannulation. OBJECTIVE: To assess the safety of mobilizing patients receiving extracorporeal membrane oxygenation before lung transplant using a standardized mobility protocol. METHODS: A retrospective review was performed of the electronic health records of patients receiving extracorporeal membrane oxygenation before or immediately after lung transplant who were mobilized according to a standardized protocol from April through October 2018. The setting was an 18-bed cardiothoracic intensive care unit in a Magnet-designated teaching hospital. Patients were helped to ambulate by an interdisciplinary team, with careful assessment for any related complications. RESULTS: During the study period, 37 patients received extracorporeal membrane oxygenation, and 9 were mobilized. Two hundred forty-two therapy sessions were conducted involving 47 700 feet of ambulation. Patients experienced the following complications: chugging (1 patient), decrease in flow rate (2 patients), bleeding at the cannula site (2 patients), neck hyperextension (1 patient), fear/anxiety (1 patient), and shortness of breath (2 patients). Bleeding and neck hyperextension led to discontinuation of therapy until the problems were resolved. No changes were made to the protocol. CONCLUSIONS: Patients receiving extracorporeal membrane oxygenation before lung transplant, including those with femoral cannulation, can be mobilized safely with the use of an interprofessional ambulation protocol. Further evaluation is indicated, including research on clinical outcomes. CI - (c)2021 American Association of Critical-Care Nurses. FAU - Patrick, Kelly AU - Patrick K AD - Kelly Patrick is a nurse and a cardiothoracic intensive care unit nurse educator, Tampa General Hospital, Tampa, Florida. FAU - Adams, Anthony AU - Adams A AD - Anthony Adams is a nurse manager in the cardiothoracic intensive care unit, Anderson Hospital, Cincinnati, Ohio. LA - eng PT - Journal Article PL - United States TA - Crit Care Nurse JT - Critical care nurse JID - 8207799 MH - Early Ambulation MH - *Extracorporeal Membrane Oxygenation MH - Humans MH - Intensive Care Units MH - *Lung Transplantation/adverse effects MH - Retrospective Studies EDAT- 2021/08/02 06:00 MHDA- 2021/11/26 06:00 CRDT- 2021/08/01 21:10 PHST- 2021/08/01 21:10 [entrez] PHST- 2021/08/02 06:00 [pubmed] PHST- 2021/11/26 06:00 [medline] AID - 31508 [pii] AID - 10.4037/ccn2021689 [doi] PST - ppublish SO - Crit Care Nurse. 2021 Aug 1;41(4):39-45. doi: 10.4037/ccn2021689. PMID- 34333613 OWN - NLM STAT- MEDLINE DCOM- 20211125 LR - 20261012 IS - 1940-8250 (Electronic) IS - 0279-5442 (Linking) VI - 41 IP - 4 DP - 2021 Aug 1 TI - Triggers and Interventions of Patients Who Require Medical Emergency Team Reviews: A Cross-Sectional Analysis of Single Versus Multiple Reviews. PG - e1-e10 LID - 10.4037/ccn2021407 [doi] AB - BACKGROUND: Medical emergency teams constitute part of the escalation protocol of early warning systems in many hospitals. The literature indicates that medical emergency teams may reduce hospital mortality and cardiac arrest. A greater understanding of pathways of patients who experience multiple medical emergency team reviews will inform clinical decision-making. OBJECTIVES: To explore differences between patients who require a single medical emergency team review and those who require multiple reviews, and to identify any differences between patients who were reviewed only once during admission and patients who required multiple reviews. METHODS: Data for this retrospective cross-sectional review, including demographic data, call triggers, outcomes, and interventions, were routinely collected from January 2013 through December 2015. The study adhered to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) collaborative's cross-sectional studies checklist (version 4). RESULTS: Of 54 787 admitted patients, 1274 (2%) required a call to a medical emergency team; of those, 260 patients (20%) needed multiple calls. Patients requiring multiple calls demonstrated higher mortality (odds ratio, 1.49 [95% CI, 1.12-1.98]). A logistic regression model identified surgical patients and those receiving antibiotics and respiratory interventions at the first medical emergency team review as being more likely to require multiple reviews. Patients transferred to a higher level of care after the first review were less likely to require another review. CONCLUSIONS: Patients requiring multiple medical emergency team reviews have higher mortality. Surgical patients have a higher risk of requiring multiple reviews. Hospitals need to include more details on surgical patients when auditing medical emergency team activation. CI - (c)2021 American Association of Critical-Care Nurses. FAU - Byrne, Gobnait AU - Byrne G AD - Gobnait Byrne is Director, Trinity Centre for Practice and Health-care Innovation, and an assistant professor, School of Nursing and Midwifery, Trinity College Dublin, Dublin, Ireland. FAU - Ennis, Shauna AU - Ennis S AD - Shauna Ennis is Head of Learning and Development, Tallaght University Hospital, Dublin, Ireland. FAU - Barnes, Anne Marie AU - Barnes AM AD - Anne Marie Barnes is the Emergency Response System Coordinator, Tallaght University Hospital. FAU - Morrison, Patricia AU - Morrison P AD - Patricia Morrison is the Assistant Director of Nursing and Lead Assistant Director of Nursing for the Perioperative Directorate, Tallaght University Hospital. FAU - Connors, Siobhan AU - Connors S AD - Siobhan Connors is a critical care outreach nurse, Tallaght University Hospital. FAU - Quirke, Mary B AU - Quirke MB AD - Mary B. Quirke is a research fellow, Trinity Centre for Practice and Healthcare Innovation, School of Nursing and Midwifery, Trinity College Dublin. LA - eng PT - Journal Article PT - Observational Study PL - United States TA - Crit Care Nurse JT - Critical care nurse JID - 8207799 MH - Humans MH - Cross-Sectional Studies MH - Hospital Mortality MH - *Hospital Rapid Response Team MH - Hospitalization MH - Retrospective Studies EDAT- 2021/08/02 06:00 MHDA- 2021/11/26 06:00 CRDT- 2021/08/01 21:10 PHST- 2021/08/01 21:10 [entrez] PHST- 2021/08/02 06:00 [pubmed] PHST- 2021/11/26 06:00 [medline] AID - 31505 [pii] AID - 10.4037/ccn2021407 [doi] PST - ppublish SO - Crit Care Nurse. 2021 Aug 1;41(4):e1-e10. doi: 10.4037/ccn2021407. PMID- 34331844 OWN - NLM STAT- MEDLINE DCOM- 20220202 LR - 20221015 IS - 1522-726X (Electronic) IS - 1522-1946 (Print) IS - 1522-1946 (Linking) VI - 99 IP - 1 DP - 2022 Jan 1 TI - Final 3-year clinical outcomes following transcatheter aortic valve implantation with a supra-annular self-expanding repositionable valve in a real-world setting: Results from the multicenter FORWARD study. PG - 171-178 LID - 10.1002/ccd.29889 [doi] AB - OBJECTIVES: The Evolut R FORWARD study confirmed safety and effectivenesss of the Evolut R THV in routine clinical practice out to 1 year. Herein, we report the final 3-year clinical follow up of the FORWARD study. BACKGROUND: Transcatheter aortic valve replacement (TAVR) is a proven alternative to surgery in elderly patients with symptomatic severe aortic stenosis. Long-term clinical outcome data with the Evolut R platform are scarce. METHODS: FORWARD is a prospective multicenter observational study that evaluated the Evolut R system in routine clinical practice at 53 centres. Eligible patients had symptomatic native aortic valve stenosis or failed surgical aortic bioprosthesis and elevated operative risk per Heart-Team assessment. TAVR was attempted in 1039 patients. RESULTS: Mean age was 81.8 +/- 6.2 years, 64.9% were women, STS score was 5.5 +/- 4.5% and 34.2% were frail. Rates of all-cause mortality and disabling stroke were 24.8% and 4.8% at 3 years. Early need for a new pacemaker implantation after TAVR (all-cause mortality: with new PPI; 21.0% vs. without; 22.8%, p = 0.55) and the presence of > trace paravalvular regurgitation (all-cause mortality: no or trace; 22.0% vs. >/= mild; 25.5%, p = 0.29) did not affect survival. Between 1 and 3 years incidence rates of valve related intervention, endocarditis and clinically relevant valve thrombosis were low. CONCLUSIONS: The Evolut R valve maintained a favorable safety profile through 3 years in routine clinical practice. Rates of transcatheter heart valve-related adverse events were low. CI - (c) 2021 The Authors. Catheterization and Cardiovascular Interventions published by Wiley Periodicals LLC. FAU - Van Mieghem, Nicolas M AU - Van Mieghem NM AUID- ORCID: 0000-0002-2732-1205 AD - Department of Cardiology, Erasmus Medical Centre, Rotterdam, The Netherlands. FAU - Windecker, Stephan AU - Windecker S AD - Department of Cardiology, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland. FAU - Manoharan, Ganesh AU - Manoharan G AD - Regional Cardiology Department, Royal Victoria Hospital, Belfast, UK. FAU - Bosmans, Johan AU - Bosmans J AD - Department of Cardiology, University Hospital Antwerp, Antwerp, Belgium. FAU - Bleiziffer, Sabine AU - Bleiziffer S AD - Department of Cardiovascular Surgery, German Heart Center, Munich, Germany. FAU - Modine, Thomas AU - Modine T AUID- ORCID: 0000-0003-4169-3766 AD - Department of Cardiovascular Surgery, Universite de Lille, Lille, France. FAU - Linke, Axel AU - Linke A AD - Department of Internal Medicine/Cardiology, Heart Centre University of Leipzig, Leipzig, Germany. FAU - Scholtz, Werner AU - Scholtz W AD - Department of Interventional Cardiology, Heart and Diabetes Centre NRW Bad Oeynhausen, Bad Oeynhausen, Germany. FAU - Tchetche, Didier AU - Tchetche D AD - Department of Cardiology, Clinique Pasteur Toulouse, Toulouse, France. FAU - Finkelstein, Ariel AU - Finkelstein A AD - Department of Cardiology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. FAU - Ito, Saki AU - Ito S AD - Department of Internal Medicine, Cardiovascular diseases, Mayo Clinic, Rochester, Minnesota, USA. FAU - Eisenberg, Ruth AU - Eisenberg R AD - Statistical Services Medtronic, Minneapolis, Minnesota, USA. FAU - Grube, Eberhard AU - Grube E AD - Department of Medicine, University of Bonn, Bonn, Germany. LA - eng GR - Medtronic funded the FORWARD study/ PT - Journal Article PT - Multicenter Study PT - Observational Study PT - Research Support, Non-U.S. Gov't DEP - 20210731 PL - United States TA - Catheter Cardiovasc Interv JT - Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions JID - 100884139 SB - IM CIN - Catheter Cardiovasc Interv. 2022 Jan 1;99(1):179-180. doi: 10.1002/ccd.30033. PMID: 34994505 MH - Aged MH - Aged, 80 and over MH - Aortic Valve/diagnostic imaging/surgery MH - *Aortic Valve Stenosis/diagnostic imaging/surgery MH - Female MH - *Heart Valve Prosthesis MH - Humans MH - Prospective Studies MH - Prosthesis Design MH - Risk Factors MH - Time Factors MH - *Transcatheter Aortic Valve Replacement/adverse effects MH - Treatment Outcome PMC - PMC9541125 OTO - NOTNLM OT - safety outcomes OT - self-expanding OT - supra-annular OT - transcatheter aortic valve implantation OT - transcatheter aortic valve replacement. COIS- Prof. Van Mieghem has received institutional research grants from Abbott Vascular, Boston Scientific, Medtronic, Edwards Lifesciences, PulseCath BV, Abiomed and Daiichi Sankyo; Prof. Windecker reports research and educational grants to the institution from Abbott, Amgen, BMS, Bayer, Boston Scientific, Biotronik, Cardinal Health, CardioValve, CSL Behring, Daiichi Sankyo, Edwards Lifesciences, Johnson&Johnson, Medtronic, Querbet, Polares, Sanofi, Terumo, Sinomed. Prof. Windecker serves as unpaid advisory board member and/or unpaid member of the steering/executive group of trials funded by Abbott, Abiomed, Amgen, Astra Zeneca, BMS, Boston Scientific, Biotronik, Cardiovalve, Edwards Lifesciences, MedAlliance, Medtronic, Novartis, Polares, Sinomed, V-Wave and Xeltis, but has not received personal payments by pharmaceutical companies or device manufacturers. He is also member of the steering/excecutive committee group of several investigated-initiated trials that receive funding by industry without impact on his personal remuneration. Stephan Windecker is an unpaid member of the Pfizer Research Award selection committee in Switzerland; Dr. Manoharan has served as a proctor for Boston Scientific, Medtronic and St. Jude Medical; Prof. Bosmans serves as a proctor for Medtronic; Prof. Bleiziffer has served as a consultant and proctor for Medtronic, a proctor for JenaValve, a proctor for Boston Scientific, and has received travel expenses from Medtronic; Dr. Modine serves as a proctor for Medtronic; Prof. Linke has received speaker honoraria or served as a consultant for the following companies: Medtronic, St. Jude Medical, Claret Medical Inc., Boston Scientific, Edwards Lifesciences, Symetis, and Bard, and holds stock options from Claret Medical Inc. In addition, he received grant support from Medtronic and Claret Medical Inc.; Dr. Scholtz has received honoraria and travel expense reimbursements from Medtronic; Dr. Tchetche has received honoraria or consultation fees from Abbott, Boston Scientific, Edwards Lifesciences and Medtronic; Dr. Finkelstein serves as a proctor and consultant for Edwards Lifesciences and Medtronic; Dr. Ito has nothing to disclose; Ms. Eisenberg is an employee and shareholder of Medtronic, plc; Prof. Grube serves on an advisory board for Medtronic, Boston Scientific and High Life, and has an equity interest in CardioValve, Valve Medical, Shockwave, Millipede, Pie-Cardia, Pipeline, Ancora and Laminar. EDAT- 2021/08/01 06:00 MHDA- 2022/02/03 06:00 PMCR- 2022/10/07 CRDT- 2021/07/31 17:07 PHST- 2021/06/21 00:00 [revised] PHST- 2021/05/17 00:00 [received] PHST- 2021/07/12 00:00 [accepted] PHST- 2021/08/01 06:00 [pubmed] PHST- 2022/02/03 06:00 [medline] PHST- 2021/07/31 17:07 [entrez] PHST- 2022/10/07 00:00 [pmc-release] AID - CCD29889 [pii] AID - 10.1002/ccd.29889 [doi] PST - ppublish SO - Catheter Cardiovasc Interv. 2022 Jan 1;99(1):171-178. doi: 10.1002/ccd.29889. Epub 2021 Jul 31. PMID- 34324263 OWN - NLM STAT- MEDLINE DCOM- 20220331 LR - 20220401 IS - 1463-1326 (Electronic) IS - 1462-8902 (Linking) VI - 24 Suppl 2 DP - 2022 Feb TI - Non-alcoholic fatty liver disease-related risk of cardiovascular disease and other cardiac complications. PG - 28-43 LID - 10.1111/dom.14484 [doi] AB - BACKGROUND/AIM: Non-alcoholic fatty liver disease (NAFLD) affects approximately 25% of the global adult population. The aim of this narrative review is to describe the associations between NAFLD and cardiovascular disease (CVD), arrhythmias, cardiac conduction defects, myocardial remodelling and heart failure. We also discuss the potential mechanisms that mediate or attenuate the strength of these associations, and briefly summarize the effect of treatments that both ameliorate NAFLD and decrease risk of CVD. METHODS: Searches of PubMed were performed by the two authors using the terms listed in Appendix. We limited the timeframe to the last decade due to the vast amount of research in the field (up to April 2021) for meta-analyses, reviews and original papers. Only articles published in English were considered. RESULTS: NAFLD is associated with an increased risk of fatal/non-fatal CVD events and other cardiac and arrhythmic complications (left ventricular hypertrophy, aortic-valve sclerosis and certain arrhythmias), independently of common CVD risk factors. There are probably several underlying mechanisms, including hepatic/systemic insulin resistance, atherogenic dyslipidaemia, hypertension and pro-atherogenic, pro-coagulant and pro-inflammatory mediators released from the steatotic/inflamed liver that may be involved. Some genetic polymorphisms, such as PNPLA3 (rs738409 C>G) and TM6SF2 (rs58542926 C>T), may worsen the liver disease, but also attenuate the strength of the association between NAFLD and CVD, possibly via their effects on lipoprotein metabolism. Of the currently tested drugs for treating NAFLD that also benefit the vasculature, pioglitazone and GLP-1 receptor agonists are the most promising. CONCLUSIONS: The complex interplay between the liver and cardiometabolic risk factors contributes to CVD, arrhythmias and cardiac disease in NAFLD. There is an urgent need for a multidisciplinary approach to manage both liver disease and cardiometabolic risk, and to test the cardiovascular and cardiac effects of new drugs for NAFLD. CI - (c) 2021 John Wiley & Sons Ltd. FAU - Byrne, Christopher D AU - Byrne CD AUID- ORCID: 0000-0001-6322-7753 AD - Nutrition and Metabolism, Faculty of Medicine, University of Southampton, Southampton, UK. AD - Southampton National Institute for Health Research Biomedical Research Centre, University Hospital Southampton, Southampton General Hospital, Southampton, UK. FAU - Targher, Giovanni AU - Targher G AUID- ORCID: 0000-0002-4325-3900 AD - Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20210813 PL - England TA - Diabetes Obes Metab JT - Diabetes, obesity & metabolism JID - 100883645 SB - IM MH - Adult MH - *Cardiovascular Diseases/complications/etiology MH - *Dyslipidemias/complications MH - *Heart Diseases/complications MH - Humans MH - Liver MH - *Non-alcoholic Fatty Liver Disease/epidemiology MH - Risk Factors OTO - NOTNLM OT - CVD OT - NAFLD OT - arrhythmias OT - cardiovascular disease OT - conduction defects OT - heart failure OT - nonalcoholic fatty liver disease EDAT- 2021/07/30 06:00 MHDA- 2022/04/01 06:00 CRDT- 2021/07/29 12:42 PHST- 2021/06/15 00:00 [revised] PHST- 2021/05/18 00:00 [received] PHST- 2021/06/27 00:00 [accepted] PHST- 2021/07/30 06:00 [pubmed] PHST- 2022/04/01 06:00 [medline] PHST- 2021/07/29 12:42 [entrez] AID - 10.1111/dom.14484 [doi] PST - ppublish SO - Diabetes Obes Metab. 2022 Feb;24 Suppl 2:28-43. doi: 10.1111/dom.14484. Epub 2021 Aug 13. PMID- 34321032 OWN - NLM STAT- MEDLINE DCOM- 20211007 LR - 20211007 IS - 1749-8090 (Electronic) IS - 1749-8090 (Linking) VI - 16 IP - 1 DP - 2021 Jul 28 TI - A multidisciplinary team nursing model in the treatment of patients undergoing transapical mitral valve clamping: a prospective study. PG - 203 LID - 10.1186/s13019-021-01588-7 [doi] LID - 203 AB - BACKGROUND: As a new surgical method for older adults with cardiac insufficiency, transapical mitral valve clamp surgery requires the cooperation of practitioners across multiple disciplines to ensure appropriate treatment and nursing care. This study aimed to explore the utility of a multidisciplinary team nursing model in the clinical treatment and nursing care of patients undergoing transapical mitral valve clamping. METHODS: Our sample of ten patients included four men (40%) and six women (60%), with a mean age of 71.4 +/- 5.2 years. The multidisciplinary team comprised nurses that specialized in severe illness, cardiac health, rehabilitation, psychology, nutrition, and pain. The team engaged in comprehensive discussions regarding problems specific to the patients undergoing transapical mitral valve surgery, allowing them to formulate individualized nursing measures and implement precise policies. RESULTS: No serious postoperative complications occurred in any of the ten patients included in this study, and a significant improvement was noted in the cardiac status of all the patients. Color ultrasound findings at discharge indicated that the degree of reflux of all the patients was 10% oversize and a >30-mm seal in healthy aorta compared with those experiencing these complications (11 of 23 vs 0 of 13; P = .0031). Conversely, 11 of 36 patients (31%) with adequately oversized and sealed stents developed fewer endoleaks compared with those without (0 of 11 vs 10 of 14; P < .0004). Patients with endoleak or sac expansion had smaller mean distal stent oversize and shorter mean sealing length compared with those without endoleak or sac expansion (2.3 +/- 3.9% vs 18 +/- 2.9% [P = .0023] and 1 +/- 0.7 mm vs 34 +/- 6 mm [P = .0005], respectively). CONCLUSIONS: We recommend >10% distal stent oversize and >30-mm sealing length to minimize endoleak and reintervention. Increasing multidisciplinary collaboration with endovascular surgeons will improve distal stent planning. CI - (c) 2020 The Authors. FAU - Kandola, Sandhir AU - Kandola S AD - Liverpool Vascular and Endovascular Service, Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom. FAU - Abdulsalam, Ahmed AU - Abdulsalam A AD - Department of Cardiothoracic Surgery, Liverpool Heart and Chest Hospital, Liverpool, United Kingdom. FAU - Field, Mark AU - Field M AD - Department of Cardiothoracic Surgery, Liverpool Heart and Chest Hospital, Liverpool, United Kingdom. FAU - Fisher, Robert K AU - Fisher RK AD - Liverpool Vascular and Endovascular Service, Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom. LA - eng PT - Journal Article DEP - 20200620 PL - United States TA - JTCVS Tech JT - JTCVS techniques JID - 101768546 PMC - PMC8302997 OTO - NOTNLM OT - CTA, computed tomography angiography OT - DTA, descending thoracic aorta OT - EACTS, European Association for Cardiothoracic Surgery OT - FET, frozen elephant trunk OT - MDT, multidisciplinary team OT - TEVAR, thoracic endovascular aneurysm repair OT - computed tomography angiography OT - descending thoracic aorta OT - frozen elephant trunk OT - multidisciplinary team OT - thoracic endovascular aneurysm repair EDAT- 2021/07/29 06:00 MHDA- 2021/07/29 06:01 PMCR- 2020/06/20 CRDT- 2021/07/28 06:40 PHST- 2020/05/26 00:00 [received] PHST- 2020/05/26 00:00 [revised] PHST- 2020/06/12 00:00 [accepted] PHST- 2021/07/28 06:40 [entrez] PHST- 2021/07/29 06:00 [pubmed] PHST- 2021/07/29 06:01 [medline] PHST- 2020/06/20 00:00 [pmc-release] AID - S2666-2507(20)30293-5 [pii] AID - 10.1016/j.xjtc.2020.06.015 [doi] PST - epublish SO - JTCVS Tech. 2020 Jun 20;3:13-20. doi: 10.1016/j.xjtc.2020.06.015. eCollection 2020 Sep. PMID- 34308687 OWN - NLM STAT- MEDLINE DCOM- 20211022 LR - 20240612 IS - 2047-9980 (Electronic) IS - 2047-9980 (Linking) VI - 10 IP - 15 DP - 2021 Aug 3 TI - Perceptions of Bereaved Caregivers and Clinicians About End-of-Life Care for Patients With Destination Therapy Left Ventricular Assist Devices. PG - e020949 LID - 10.1161/JAHA.121.020949 [doi] LID - e020949 AB - Background Patients with left ventricular assist devices (LVADs) implanted as destination therapy may receive suboptimal preparation for and care at the end of life, but there is limited understanding of the reasons for these shortcomings. Exploring perceptions of individuals (caregivers and clinicians) who are closely involved in the end-of-life experience with patients with destination therapy LVADs can help identify key opportunities for improving care. Methods and Results We conducted semistructured qualitative interviews with 7 bereaved caregivers of patients with destination therapy LVADs and 10 interdisciplinary LVAD clinicians. Interviews explored perceptions of preparing for end of life, communicating about end of life, and providing and receiving end-of-life care, and were analyzed using a 2-step team-based inductive approach to coding and analysis. Six themes pertaining to end-of-life experiences were derived: (1) timing end-of-life discussions in the setting of unpredictable illness trajectories, (2) prioritizing end-of-life preparation and decision-making, (3) communicating uncertainty while providing support and hope, (4) lack of consensus on responsibility for end-of-life discussions, (5) perception of the LVAD team as invincible, and (6) divergent perceptions of LVAD withdrawal. Conclusions This study revealed 6 unique aspects of end-of-life care for patients with destination therapy LVADs as reported by clinicians and caregivers. Themes coalesced around communication, team-based care, and challenges unique to patients with LVADs at end of life. Programmatic changes may address some aspects, including training clinicians in LVAD-specific communication skills. Other aspects, such as standardizing the role of the palliative care team and developing practical interventions that enable timely advance care planning during LVAD care, will require multifaceted interventions. FAU - Chuzi, Sarah AU - Chuzi S AD - Division of Cardiology Department of Medicine Feinberg School of Medicine Northwestern University Chicago IL. FAU - Ogunseitan, Adeboye AU - Ogunseitan A AD - Division of Hospital Medicine (Palliative Care) Department of Medicine Feinberg School of Medicine Northwestern University Chicago IL. FAU - Cameron, Kenzie A AU - Cameron KA AD - Division of General Internal Medicine and Geriatrics Department of Medicine Feinberg School of Medicine Northwestern University Chicago IL. FAU - Grady, Kathleen AU - Grady K AD - Division of Cardiology Department of Medicine Feinberg School of Medicine Northwestern University Chicago IL. AD - Division of Cardiac Surgery Department of Surgery Feinberg School of Medicine Northwestern University Chicago IL. FAU - Schulze, Lauren AU - Schulze L AD - Division of Cardiac Surgery Department of Surgery Feinberg School of Medicine Northwestern University Chicago IL. FAU - Wilcox, Jane E AU - Wilcox JE AD - Division of Cardiology Department of Medicine Feinberg School of Medicine Northwestern University Chicago IL. LA - eng GR - UL1 TR001422/TR/NCATS NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210726 PL - England TA - J Am Heart Assoc JT - Journal of the American Heart Association JID - 101580524 SB - IM MH - Advance Care Planning/organization & administration MH - Attitude of Health Personnel MH - Caregivers/*psychology MH - Female MH - Health Services Needs and Demand MH - *Heart Failure/epidemiology/psychology/therapy MH - *Heart-Assist Devices/ethics/psychology MH - Hospice Care/ethics/psychology/standards MH - Humans MH - Male MH - Middle Aged MH - Palliative Care/methods/standards MH - Patient Care Team/standards MH - Qualitative Research MH - Quality Improvement MH - *Quality of Life MH - *Social Perception MH - *Terminal Care/ethics/psychology/standards MH - United States MH - Withholding Treatment/ethics PMC - PMC8475670 OTO - NOTNLM OT - end-of-life care OT - palliative care OT - ventricular assist device COIS- Dr Cameron has current funding from the American Heart Association and National Institutes of Health (NIH) (National Cancer Institute, National Institute on Aging [NIA], National Institute of Diabetes and Digestive and Kidney Diseases, and National Center for Advancing Translational Sciences). Dr Wilcox has received consulting/speaking honoraria from Medtronic, serves as a scientific consultant/advisory board member for Cytokinetics, and has current funding from the NIH. Dr Grady has received consulting fees from Amgen, speaker fees from the American Heart Association, and has current funding from the NIH (NIA and National Heart, Lung, and Blood Institute). The remaining authors have no disclosures to report. EDAT- 2021/07/27 06:00 MHDA- 2022/03/25 06:00 PMCR- 2021/08/03 CRDT- 2021/07/26 08:46 PHST- 2021/07/27 06:00 [pubmed] PHST- 2022/03/25 06:00 [medline] PHST- 2021/07/26 08:46 [entrez] PHST- 2021/08/03 00:00 [pmc-release] AID - JAH36516 [pii] AID - 10.1161/JAHA.121.020949 [doi] PST - ppublish SO - J Am Heart Assoc. 2021 Aug 3;10(15):e020949. doi: 10.1161/JAHA.121.020949. Epub 2021 Jul 26. PMID- 34307254 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210727 IS - 2296-2360 (Print) IS - 2296-2360 (Electronic) IS - 2296-2360 (Linking) VI - 9 DP - 2021 TI - Hypertension in Children and Adolescents: A Position Statement From a Panel of Multidisciplinary Experts Coordinated by the French Society of Hypertension. PG - 680803 LID - 10.3389/fped.2021.680803 [doi] LID - 680803 AB - Hypertension is much less common in children than in adults. The group of experts decided to perform a review of the literature to draw up a position statement that could be used in everyday practice. The group rated recommendations using the GRADE approach. All children over the age of 3 years should have their blood pressure measured annually. Due to the lack of data on cardiovascular morbidity and mortality associated with blood pressure values, the definition of hypertension in children is a statistical value based on the normal distribution of blood pressure in the paediatric population, and children and adolescents are considered as having hypertension when their blood pressure is greater than or equal to the 95th percentile. Nevertheless, it is recommended to use normative blood pressure tables developed according to age, height and gender, to define hypertension. Measuring blood pressure in children can be technically challenging and several measurement methods are listed here. Regardless of the age of the child, it is recommended to carefully check for a secondary cause of hypertension as in 2/3 of cases it has a renal or cardiac origin. The care pathway and principles of the therapeutic strategy are described here. CI - Copyright (c) 2021 Bouhanick, Sosner, Brochard, Mounier-Vehier, Plu-Bureau, Hascoet, Ranchin, Pietrement, Martinerie, Boivin, Fauvel and Bacchetta. FAU - Bouhanick, Beatrice AU - Bouhanick B AD - Service d'Hypertension Arterielle et Therapeutique, CHU Rangueil, CERPOP, Universite de Toulouse, Inserm, UPS, Toulouse, France. FAU - Sosner, Philippe AU - Sosner P AD - Centre Medico-Sportif MON STADE, Paris, France. AD - Hopital Hotel-Dieu, APHP, Centre de Diagnostic et de Therapeutique, Paris, France. AD - Laboratoire MOVE (EA 6314), Universite de Poitiers, Faculte des Sciences du Sport, Poitiers, France. FAU - Brochard, Karine AU - Brochard K AD - Service de Nephrologie Medecine Interne Pediatrique, Hopital des Enfants, CHU Toulouse, Toulouse, France. FAU - Mounier-Vehier, Claire AU - Mounier-Vehier C AD - Institut Coeur-Poumon, Medecine Vasculaire et HTA, CHU, Universite Lille, EA 2694 - Sante Publique: Epidemiologie et Qualite des Soins Lille, Lille, France. FAU - Plu-Bureau, Genevieve AU - Plu-Bureau G AD - Unite de Gynecologie Medicale, AP-HP, Hopital Port-Royal, Universite de Paris, Paris, France. FAU - Hascoet, Sebastien AU - Hascoet S AD - Pole des Cardiopathies Congenitales du Nouveau-Ne a L'adulte - Centre Constitutif Cardiopathies Congenitales Complexes M3C, Groupe Hospitalier Paris Saint-Joseph, Hopital Marie-Lannelongue, Inserm U999, Universite Paris-Saclay, Le Plessis-Robinson, France. FAU - Ranchin, Bruno AU - Ranchin B AD - Centre de Reference des Maladies Renales Rares, Service de Nephrologie Rhumatologie et Dermatologie Pediatriques, Filieres Maladies Rares ORKID et ERK-Net, Hospices Civils de Lyon, Hopital Femme Mere Enfant, Bron, France. AD - Faculte de Medecine Lyon Est, Universite Lyon 1, Lyon, France. FAU - Pietrement, Christine AU - Pietrement C AD - Unite de Nephrologie Pediatrique, CHU Reims, Reims, France. FAU - Martinerie, Laetitia AU - Martinerie L AD - Centre de Reference des Maladies Rares de la Croissance et du Developpement, Universite de Paris, Endocrinologie et Diabetologie Pediatrique, AP-HP, Hopital Robert-Debre, Paris, France. FAU - Boivin, Jean Marc AU - Boivin JM AD - Departement de Medecine Generale, Universite de Lorraine, Inserm CIC-P Pierre Drouin Vandoeuvre-Les-Nancy, Vandoeuvre-les-Nancy, France. FAU - Fauvel, Jean Pierre AU - Fauvel JP AD - Service de Nephrologie Hospices Civils, Hopital Edouard Herriot, Lyon, France. AD - UMR CNRS 5558, Universite Claude Bernard Lyon 1, Villeurbanne, France. FAU - Bacchetta, Justine AU - Bacchetta J AD - Centre de Reference des Maladies Renales Rares, Service de Nephrologie Rhumatologie et Dermatologie Pediatriques, Filieres Maladies Rares ORKID et ERK-Net, Hospices Civils de Lyon, Hopital Femme Mere Enfant, Bron, France. AD - Faculte de Medecine Lyon Est, Universite Lyon 1, Lyon, France. LA - eng PT - Journal Article PT - Systematic Review DEP - 20210707 PL - Switzerland TA - Front Pediatr JT - Frontiers in pediatrics JID - 101615492 PMC - PMC8292722 OTO - NOTNLM OT - French position statement OT - adolescents OT - children OT - high blood pressure OT - hypertension COIS- JMB was employed by the company Inserm CIC-P Pierre Drouin, France. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/07/27 06:00 MHDA- 2021/07/27 06:01 PMCR- 2021/07/07 CRDT- 2021/07/26 06:38 PHST- 2021/03/15 00:00 [received] PHST- 2021/06/09 00:00 [accepted] PHST- 2021/07/26 06:38 [entrez] PHST- 2021/07/27 06:00 [pubmed] PHST- 2021/07/27 06:01 [medline] PHST- 2021/07/07 00:00 [pmc-release] AID - 10.3389/fped.2021.680803 [doi] PST - epublish SO - Front Pediatr. 2021 Jul 7;9:680803. doi: 10.3389/fped.2021.680803. eCollection 2021. PMID- 34304388 OWN - NLM STAT- MEDLINE DCOM- 20220217 LR - 20261012 IS - 1720-8386 (Electronic) IS - 0391-4097 (Linking) VI - 44 IP - 12 DP - 2021 Dec TI - Protocol for presurgical and anesthetic management of pheochromocytomas and sympathetic paragangliomas: a multidisciplinary approach. PG - 2545-2555 LID - 10.1007/s40618-021-01649-7 [doi] AB - OBJECTIVE: To offer a practical guide for the presurgical and anesthetic management of pheochromocytomas and sympathetic paragangliomas (PGLs). METHODS: This protocol was based on a comprehensive review of the literature and on our own multidisciplinary team's experience from managing pheochromocytoma and sympathetic PGLs at a referral center. RESULTS: Patients with pheochromocytomas and sympathetic paragangliomas (PGLs) may develop potentially life-threatening complications, especially during surgical procedures. A complete biochemical, radiological, genetic, and cardiological assessment is recommended in the preoperative stage as it provides an evaluation of the risk of surgical complications and malignancy, allowing individualization of the presurgical treatment. Treatment with alpha-blockade and proper volume expansion in the preoperative stage significantly reduces the perioperative morbidity. During surgery, the anesthesiologist should look for a deep anesthetic level that inhibits the cardiovascular effects of catecholamines to minimize the risk of intraoperative complications. CONCLUSIONS: An optimal presurgical evaluation of pheochromocytomas/ sympathetic PGL requires a multidisciplinary approach, including a complete hormonal, radiological, cardiac, genetic, and functioning evaluation in most cases. A proper preoperative evaluation in combination with strict blood pressure and heart rate control, and blood volume status optimization, will significantly reduce the risk of intraoperative and perioperative complications. In those patients who unfortunately develop intraoperative complications, the role of the anesthesiologist is essential since the selection of the appropriate management has a direct impact on morbimortality reduction. CI - (c) 2021. Italian Society of Endocrinology (SIE). FAU - Araujo-Castro, M AU - Araujo-Castro M AUID- ORCID: 0000-0002-0519-0072 AD - Neuroendocrinology Division, Department of Endocrinology and Nutrition, IRYCIS, Hospital Universitario Ramon y Cajal, Colmenar Viejo street, S/N, 28034, Madrid, Spain. marta.araujo@salud.madrid.org. FAU - Pascual-Corrales, E AU - Pascual-Corrales E AD - Neuroendocrinology Division, Department of Endocrinology and Nutrition, IRYCIS, Hospital Universitario Ramon y Cajal, Colmenar Viejo street, S/N, 28034, Madrid, Spain. FAU - Nattero Chavez, L AU - Nattero Chavez L AD - Neuroendocrinology Division, Department of Endocrinology and Nutrition, IRYCIS, Hospital Universitario Ramon y Cajal, Colmenar Viejo street, S/N, 28034, Madrid, Spain. FAU - Martinez Lorca, A AU - Martinez Lorca A AD - Department of Nuclear Medicine, Hospital Universitario Ramon y Cajal, Madrid, Spain. FAU - Alonso-Gordoa, T AU - Alonso-Gordoa T AD - Department of Medical Oncology, IRYCIS, Hospital Universitario Ramon y Cajal, Madrid, Spain. FAU - Molina-Cerrillo, J AU - Molina-Cerrillo J AD - Department of Medical Oncology, IRYCIS, Hospital Universitario Ramon y Cajal, Madrid, Spain. FAU - Lorca Alvaro, J AU - Lorca Alvaro J AD - Department of Urology, Hospital Universitario Ramon y Cajal, Madrid, Spain. FAU - Minguez Ojeda, C AU - Minguez Ojeda C AD - Department of Urology, Hospital Universitario Ramon y Cajal, Madrid, Spain. FAU - Redondo Lopez, S AU - Redondo Lopez S AD - Department of Vascular Surgery, Hospital Universitario Ramon y Cajal, Madrid, Spain. FAU - Barbera Durban, R AU - Barbera Durban R AD - Department of Otorhinolaryngology, Hospital Universitario Ramon y Cajal, Madrid, Spain. FAU - Polo Lopez, R AU - Polo Lopez R AD - Department of Otorhinolaryngology, Hospital Universitario Ramon y Cajal, Madrid, Spain. FAU - Moreno Mata, N AU - Moreno Mata N AD - Department of Thoracic Surgery, Hospital Universitario Ramon y Cajal, Madrid, Spain. FAU - Caballero Silva, U AU - Caballero Silva U AD - Department of Thoracic Surgery, Hospital Universitario Ramon y Cajal, Madrid, Spain. FAU - Pian, H AU - Pian H AD - Department of Pathology, Hospital Universitario Ramon y Cajal, Madrid, Spain. FAU - Ruz-Caracuel, I AU - Ruz-Caracuel I AD - Department of Pathology, Hospital Universitario Ramon y Cajal, Madrid, Spain. FAU - Sanjuanbenito Dehesa, A AU - Sanjuanbenito Dehesa A AD - Department of General and Digestive Surgery, Hospital Universitario Ramon y Cajal, Madrid, Spain. FAU - Gomez Dos Santos, V AU - Gomez Dos Santos V AD - Department of Urology, Hospital Universitario Ramon y Cajal, Madrid, Spain. FAU - Serrano Romero, A B AU - Serrano Romero AB AD - Department of Anesthesia, Hospital Universitario Ramon y Cajal, Madrid, Spain. LA - eng PT - Journal Article PT - Review DEP - 20210725 PL - Italy TA - J Endocrinol Invest JT - Journal of endocrinological investigation JID - 7806594 SB - IM MH - Adrenal Gland Neoplasms/pathology/*surgery MH - Humans MH - Intraoperative Complications/*prevention & control MH - Paraganglioma/pathology/*surgery MH - Patient Care Planning/standards MH - Pheochromocytoma/pathology/*surgery MH - Practice Guidelines as Topic MH - Preoperative Care/*methods MH - Risk Adjustment OTO - NOTNLM OT - Anesthetic treatment OT - Paragangliomas OT - Pheochromocytoma OT - Presurgical management OT - alpha-blockade EDAT- 2021/07/26 06:00 MHDA- 2022/02/19 06:00 CRDT- 2021/07/25 20:56 PHST- 2021/03/31 00:00 [received] PHST- 2021/07/21 00:00 [accepted] PHST- 2021/07/26 06:00 [pubmed] PHST- 2022/02/19 06:00 [medline] PHST- 2021/07/25 20:56 [entrez] AID - 10.1007/s40618-021-01649-7 [pii] AID - 10.1007/s40618-021-01649-7 [doi] PST - ppublish SO - J Endocrinol Invest. 2021 Dec;44(12):2545-2555. doi: 10.1007/s40618-021-01649-7. Epub 2021 Jul 25. PMID- 34295711 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210724 IS - 2223-3652 (Print) IS - 2223-3660 (Electronic) IS - 2223-3652 (Linking) VI - 11 IP - 3 DP - 2021 Jun TI - State-of-the-art narrative review: multimodality imaging in electrophysiology and cardiac device therapies. PG - 881-895 LID - 10.21037/cdt-20-724 [doi] AB - Cardiac electrophysiology procedures have evolved to provide improvement in morbidity and mortality for many patients. Cardiac resynchronization therapy (CRT), implantable cardioverter/defibrillator (ICD) placement and lead extraction procedures are proven procedures, associated with significant reductions in patient morbidity and mortality as well as improved quality of life. The applications and optimization of these therapies are an evolving field. The optimal use and outcomes of cardiac electrophysiology procedures require a multidisciplinary approach to patient selection, device selection, and procedural planning. Cardiac imaging using echocardiography plays a key role in selection of patients for CRT therapy, for guidance of left ventricular (LV) lead placement, and for optimization of atrioventricular pacing delays in patients with CRT. Cardiac computed tomography (CT) is an important tool in assessment of lead perforation, as well as assessing risk of lead extraction and procedural planning. Cardiac magnetic resonance imaging (MRI) is an important adjunct to transthoracic echocardiography for patient selection and risk stratification for defibrillator therapy for multiple disease states including ischemic cardiomyopathy, hypertrophic cardiomyopathy, cardiac sarcoidosis, and arrhythmogenic right ventricular cardiomyopathy (ARVC). Cardiac positron emission tomography (PET) is a useful adjunct to the diagnosis of device infections as well as inflammatory conditions including cardiac sarcoidosis. Our review attempts to summarize the contemporary roles of multimodality imaging in CRT therapy, ICD therapy and lead extraction therapy. CI - 2021 Cardiovascular Diagnosis and Therapy. All rights reserved. FAU - Laczay, Balint AU - Laczay B AD - Heart, Vascular & Thoracic Institute, Cleveland Clinic Foundation, Cleveland, OH, USA. FAU - Patel, Divyang AU - Patel D AD - Heart, Vascular & Thoracic Institute, Cleveland Clinic Foundation, Cleveland, OH, USA. FAU - Grimm, Richard AU - Grimm R AD - Heart, Vascular & Thoracic Institute, Cleveland Clinic Foundation, Cleveland, OH, USA. FAU - Xu, Bo AU - Xu B AD - Heart, Vascular & Thoracic Institute, Cleveland Clinic Foundation, Cleveland, OH, USA. LA - eng PT - Journal Article PT - Review PL - China TA - Cardiovasc Diagn Ther JT - Cardiovascular diagnosis and therapy JID - 101601613 PMC - PMC8261739 OTO - NOTNLM OT - Echocardiography OT - cardiac magnetic resonance imaging (cardiac MRI) OT - cardiac resynchronization therapy (CRT) OT - implantable cardioverter/defibrillator (ICD) OT - lead extraction OT - positron emission tomography/computed tomography (PET/CT) OT - resynchronization COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/cdt-20-724). The series "Heart Valve Disease" was commissioned by the editorial office without any funding or sponsorship. BX served as the unpaid Guest Editor of the series. The authors have no other conflicts of interest to declare. EDAT- 2021/07/24 06:00 MHDA- 2021/07/24 06:01 PMCR- 2021/06/01 CRDT- 2021/07/23 06:50 PHST- 2020/08/18 00:00 [received] PHST- 2020/11/30 00:00 [accepted] PHST- 2021/07/23 06:50 [entrez] PHST- 2021/07/24 06:00 [pubmed] PHST- 2021/07/24 06:01 [medline] PHST- 2021/06/01 00:00 [pmc-release] AID - cdt-11-03-881 [pii] AID - 10.21037/cdt-20-724 [doi] PST - ppublish SO - Cardiovasc Diagn Ther. 2021 Jun;11(3):881-895. doi: 10.21037/cdt-20-724. PMID- 34292505 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20211111 IS - 2193-8261 (Print) IS - 2193-6544 (Electronic) IS - 2193-6544 (Linking) VI - 10 IP - 2 DP - 2021 Dec TI - Correction to: Preoperative, Multidisciplinary Clinical Optimization of Patients with Severely Depressed Left Ventricular Ejection Fraction Who Are Undergoing Coronary Artery Bypass Grafting. PG - 609-610 LID - 10.1007/s40119-021-00235-5 [doi] FAU - Shehata, Islam Mohammad AU - Shehata IM AD - Department of Anesthesiology, Faculty of Medicine, Ain Shams University, Cairo, Egypt. FAU - Odell, Tiffany D AU - Odell TD AD - Department of Neurosurgery, Desert Regional Medical Center, Palm Springs, CA, USA. FAU - Elhassan, Amir AU - Elhassan A AD - Department of Anesthesiology, Desert Regional Medical Center, Palm Springs, CA, USA. FAU - Spektor, Maxim AU - Spektor M AD - Department of Surgery, Desert Regional Medical Center, Palm Springs, CA, USA. FAU - Urits, Ivan AU - Urits I AD - Department of Anesthesiology, Critical Care, and Pain Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA, USA. AD - Department of Anesthesiology, LSU Health Shreveport, Shreveport, LA, USA. FAU - Viswanath, Omar AU - Viswanath O AD - Department of Anesthesiology, LSU Health Shreveport, Shreveport, LA, USA. AD - Department of Anesthesiology, University of Arizona College of Medicine, Phoenix, Phoenix, AZ, USA. AD - Department of Anesthesiology, Creighton University School of Medicine, Omaha, NE, USA. AD - Valley Anesthesiology and Pain Consultants, Envision Physician Services, Phoenix, AZ, USA. FAU - Jeha, George M AU - Jeha GM AD - Louisiana State University Health Sciences Center, New Orleans, LA, USA. FAU - Cornett, Elyse M AU - Cornett EM AD - Department of Anesthesiology, LSU Health Shreveport, Shreveport, LA, USA. FAU - Kaye, Alan D AU - Kaye AD AUID- ORCID: 0000-0003-2464-0187 AD - Department of Anesthesiology, LSU Health Shreveport, Shreveport, LA, USA. akaye@lsuhsc.edu. LA - eng PT - Published Erratum PL - England TA - Cardiol Ther JT - Cardiology and therapy JID - 101634495 EFR - Cardiol Ther. 2021 Jun;10(1):57-66. doi: 10.1007/s40119-020-00207-1. PMID: 33367988 PMC - PMC8555017 EDAT- 2021/07/23 06:00 MHDA- 2021/07/23 06:01 PMCR- 2021/07/22 CRDT- 2021/07/22 12:33 PHST- 2021/07/23 06:00 [pubmed] PHST- 2021/07/23 06:01 [medline] PHST- 2021/07/22 12:33 [entrez] PHST- 2021/07/22 00:00 [pmc-release] AID - 10.1007/s40119-021-00235-5 [pii] AID - 235 [pii] AID - 10.1007/s40119-021-00235-5 [doi] PST - ppublish SO - Cardiol Ther. 2021 Dec;10(2):609-610. doi: 10.1007/s40119-021-00235-5. PMID- 34290617 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210723 IS - 1664-042X (Print) IS - 1664-042X (Electronic) IS - 1664-042X (Linking) VI - 12 DP - 2021 TI - Cardiovascular Issues in Tyrosine Kinase Inhibitors Treatments for Chronic Myeloid Leukemia: A Review. PG - 675811 LID - 10.3389/fphys.2021.675811 [doi] LID - 675811 AB - Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm driven by a fusion gene, encoding for the chimeric protein BCR-ABL, with constitutive tyrosine kinase activity. The use of tyrosine kinase inhibitors (TKIs) has drastically improved survival, but there are significant concerns about cardiovascular toxicity. Cardiovascular risk can be lowered with appropriate baseline evaluation, accurate choice of TKI therapy, improvement of modifiable cardiovascular risk factors through lifestyle modifications, and prescription of drugs for primary or secondary prevention. Which examinations are necessary, and when do they have to be scheduled? How often should a TKI-treated patient undergo which cardiology test or exam? Is there an accurate way to estimate the risk that each TKI may determine a cardiovascular adverse event in a CML patient? In a few words, how can we optimize the cardiovascular risk management in CML patients before and during TKI treatment? The aim of this review is to describe cardiac and vascular toxicity of TKIs used for CML treatment according to the most recent literature and to identify unmet clinical needs in cardiovascular risk management and complications in these patients. Regarding the TKI-induced cardiovascular toxicity, the full mechanism is still unclear, but it is accepted that different factors may play different roles: endothelial damage and atherosclerosis, metabolic impairment, hypertensive effect, glomerular impairment, and mast-cell disruption. Preventive strategies are aimed at minimizing cardiovascular risk when CML is diagnosed. Cardio-oncology units in specialized hematology centers may afford a personalized and multidisciplinary approach to the patient, optimizing the balance between treatment of the neoplasm and management of cardiovascular risk. CI - Copyright (c) 2021 Santoro, Mancuso, Accurso, Di Lisi, Novo and Siragusa. FAU - Santoro, Marco AU - Santoro M AD - Department of Surgical, Oncological and Stomatological Disciplines, University of Palermo, Palermo, Italy. AD - Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, PROMISE, University of Palermo, Palermo, Italy. FAU - Mancuso, Salvatrice AU - Mancuso S AD - Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, PROMISE, University of Palermo, Palermo, Italy. AD - Hematology Unit, University Hospital "Paolo Giaccone", Palermo, Italy. FAU - Accurso, Vincenzo AU - Accurso V AD - Hematology Unit, University Hospital "Paolo Giaccone", Palermo, Italy. FAU - Di Lisi, Daniela AU - Di Lisi D AD - Department of Cardiology, University Hospital Policlinico "Paolo Giaccone", Palermo, Italy. FAU - Novo, Giuseppina AU - Novo G AD - Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, PROMISE, University of Palermo, Palermo, Italy. AD - Department of Cardiology, University Hospital Policlinico "Paolo Giaccone", Palermo, Italy. FAU - Siragusa, Sergio AU - Siragusa S AD - Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, PROMISE, University of Palermo, Palermo, Italy. LA - eng PT - Journal Article PT - Review DEP - 20210705 PL - Switzerland TA - Front Physiol JT - Frontiers in physiology JID - 101549006 PMC - PMC8287514 OTO - NOTNLM OT - cardio-oncology OT - cardiovascular events OT - cardiovascular risk OT - chronic myelocytic leukemia OT - tyrosine kinase inhibitions therapy COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/07/23 06:00 MHDA- 2021/07/23 06:01 PMCR- 2021/07/05 CRDT- 2021/07/22 06:31 PHST- 2021/03/04 00:00 [received] PHST- 2021/05/17 00:00 [accepted] PHST- 2021/07/22 06:31 [entrez] PHST- 2021/07/23 06:00 [pubmed] PHST- 2021/07/23 06:01 [medline] PHST- 2021/07/05 00:00 [pmc-release] AID - 10.3389/fphys.2021.675811 [doi] PST - epublish SO - Front Physiol. 2021 Jul 5;12:675811. doi: 10.3389/fphys.2021.675811. eCollection 2021. PMID- 34285540 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20211217 IS - 1178-7031 (Print) IS - 1178-7031 (Electronic) IS - 1178-7031 (Linking) VI - 14 DP - 2021 TI - Comprehensive Mechanism, Novel Markers and Multidisciplinary Treatment of Severe Acute Pancreatitis-Associated Cardiac Injury - A Narrative Review. PG - 3145-3169 LID - 10.2147/JIR.S310990 [doi] AB - Acute pancreatitis (AP) is one of the common acute abdominal inflammatory diseases in clinic with acute onset and rapid progress. About 20% of the patients will eventually develop into severe acute pancreatitis (SAP) characterized by a large number of inflammatory cells infiltration, gland flocculus flaky necrosis and hemorrhage, finally inducing systemic inflammatory response syndrome (SIRS) and multiple organ dysfunction syndrome (MODS). Pancreatic enzyme activation, intestinal endotoxemia (IETM), cytokine activation, microcirculation disturbance, autonomic nerve dysfunction and autophagy dysregulation all play an essential role in the occurrence and progression of SAP. Organ dysfunction is the main cause of early death in SAP. Acute kidney injury (AKI) and acute lung injury (ALI) are common, while cardiac injury (CI) is not, but the case fatality risk is high. Many basic studies have observed obvious ultrastructure change of heart in SAP, including myocardial edema, cardiac hypertrophy, myocardial interstitial collagen deposition. Moreover, in clinical practice, patients with SAP often presented various abnormal electrocardiogram (ECG) and cardiac function. Cases complicated with acute myocardial infarction and pericardial tamponade have also been reported and even result in stress cardiomyopathy. Due to the molecular mechanisms underlying SAP-associated cardiac injury (SACI) remain poorly understood, and there is no complete, unified treatment and sovereign remedy at present, this article reviews reports referring to the pathogenesis, potential markers and treatment methods of SACI in recent years, in order to improve the understanding of cardiac injury in severe pancreatitis. CI - (c) 2021 Luo et al. FAU - Luo, YaLan AU - Luo Y AUID- ORCID: 0000-0002-9619-5468 AD - Institute (College) of Integrative Medicine, Dalian Medical University, Dalian, Liaoning, People's Republic of China. AD - Department of General Surgery, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, People's Republic of China. AD - Laboratory of Integrative Medicine, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, People's Republic of China. FAU - Li, ZhaoXia AU - Li Z AD - Department of General Surgery, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, People's Republic of China. FAU - Ge, Peng AU - Ge P AD - Institute (College) of Integrative Medicine, Dalian Medical University, Dalian, Liaoning, People's Republic of China. AD - Department of General Surgery, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, People's Republic of China. AD - Laboratory of Integrative Medicine, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, People's Republic of China. FAU - Guo, HaoYa AU - Guo H AD - Institute (College) of Integrative Medicine, Dalian Medical University, Dalian, Liaoning, People's Republic of China. AD - Department of General Surgery, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, People's Republic of China. AD - Laboratory of Integrative Medicine, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, People's Republic of China. FAU - Li, Lei AU - Li L AD - Department of Vascular Surgery, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, People's Republic of China. FAU - Zhang, GuiXin AU - Zhang G AD - Department of General Surgery, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, People's Republic of China. FAU - Xu, CaiMing AU - Xu C AD - Department of General Surgery, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, People's Republic of China. FAU - Chen, HaiLong AU - Chen H AD - Department of General Surgery, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, People's Republic of China. LA - eng PT - Journal Article PT - Review DEP - 20210712 PL - New Zealand TA - J Inflamm Res JT - Journal of inflammation research JID - 101512684 EIN - J Inflamm Res. 2021 Dec 08;14:6669-6670. doi: 10.2147/JIR.S352173. PMID: 34916818 PMC - PMC8286248 OTO - NOTNLM OT - biomarkers OT - cardiac dysfunction OT - cardiac injury OT - inflammatory mediators OT - severe acute pancreatitis OT - treatment COIS- Yalan Luo, Zhaoxia Li and Peng Ge are co-first authors. The authors declare that there are no conflicts of interest. EDAT- 2021/07/22 06:00 MHDA- 2021/07/22 06:01 PMCR- 2021/07/12 CRDT- 2021/07/21 06:31 PHST- 2021/03/23 00:00 [received] PHST- 2021/06/15 00:00 [accepted] PHST- 2021/07/21 06:31 [entrez] PHST- 2021/07/22 06:00 [pubmed] PHST- 2021/07/22 06:01 [medline] PHST- 2021/07/12 00:00 [pmc-release] AID - 310990 [pii] AID - 10.2147/JIR.S310990 [doi] PST - epublish SO - J Inflamm Res. 2021 Jul 12;14:3145-3169. doi: 10.2147/JIR.S310990. eCollection 2021. PMID- 34279602 OWN - NLM STAT- MEDLINE DCOM- 20211021 LR - 20260120 IS - 1522-9645 (Electronic) IS - 0195-668X (Linking) VI - 42 IP - 39 DP - 2021 Oct 14 TI - Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombosis, and the ESC working group on cardiovascular pharmacotherapy. PG - 4013-4024 LID - 10.1093/eurheartj/ehab390 [doi] AB - The aim of this collaborative document is to provide an update for clinicians on best antithrombotic strategies in patients with aortic and/or peripheral arterial diseases. Antithrombotic therapy is a pillar of optimal medical treatment for these patients at very high cardiovascular risk. While the number of trials on antithrombotic therapies in patients with aortic or peripheral arterial diseases is substantially smaller than for those with coronary artery disease, recent evidence deserves to be incorporated into clinical practice. In the absence of specific indications for chronic oral anticoagulation due to concomitant cardiovascular disease, a single antiplatelet agent is the basis for long-term antithrombotic treatment in patients with aortic or peripheral arterial diseases. Its association with another antiplatelet agent or low-dose anticoagulants will be discussed, based on patient's ischaemic and bleeding risk as well therapeutic paths (e.g. endovascular therapy). This consensus document aims to provide a guidance for antithrombotic therapy according to arterial disease localizations and clinical presentation. However, it cannot substitute multidisciplinary team discussions, which are particularly important in patients with uncertain ischaemic/bleeding balance. Importantly, since this balance evolves over time in an individual patient, a regular reassessment of the antithrombotic therapy is of paramount importance. CI - Published on behalf of the European Society of Cardiology. All rights reserved. (c) The Author(s) 2021. For permissions, please email: journals.permissions@oup.com. FAU - Aboyans, Victor AU - Aboyans V AD - Department of Cardiology, Dupuytren University Hospital, and INSERM 1094 & IRD, University of Limoges, 2, Martin Luther King ave, 87042, Limoges, France. FAU - Bauersachs, Rupert AU - Bauersachs R AUID- ORCID: 0000-0001-6192-1741 AD - Department of Vascular Medicine, Klinikum Darmstadt GmbH, Darmstadt Germany, and Center for Thrombosis and Hemostasis, University of Mainz, Mainz, Germany. FAU - Mazzolai, Lucia AU - Mazzolai L AUID- ORCID: 0000-0002-2022-6440 AD - Division of Angiology, Heart and Vessel Department, Lausanne University Hospital (CHUV), Lausanne, Switzerland. FAU - Brodmann, Marianne AU - Brodmann M AD - Division of Angiology, Medical University Graz, Austria. FAU - Palomares, Jose F Rodriguez AU - Palomares JFR AUID- ORCID: 0000-0002-7229-9780 AD - Department of Cardiology, Vall d'Hebron Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autonoma de Barcelona, Centro de Investigacion Biomedica en RedCV, CIBER CV, Barcelona, Spain. FAU - Debus, Sebastian AU - Debus S AD - Department of Vascular Medicine, University Heart Centre Hamburg, University Medical Centre HamburgEppendorf, Hamburg, Germany. FAU - Collet, Jean-Philippe AU - Collet JP AUID- ORCID: 0000-0003-3750-5347 AD - Sorbonne Universite, ACTION Study Group (www.actioncoeur.org), INSERM UMRS 1166, Institut de Cardiologie, Hopital PitieSalpetriere (APHP), Paris, France. FAU - Drexel, Heinz AU - Drexel H AUID- ORCID: 0000-0002-4677-9756 AD - Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Landeskrankenhaus Feldkirch, Austria. FAU - Espinola-Klein, Christine AU - Espinola-Klein C AD - Section Angiology, Department of Cardiology, Cardiology I, University Medical Center Mainz, Mainz, Germany. FAU - Lewis, Basil S AU - Lewis BS AUID- ORCID: 0000-0001-5604-6399 AD - Lady Davis Carmel Medical Center and the Ruth and Bruce Rappaport School of Medicine, TechnionIsrael Institute of Technology, Haifa, Israel. FAU - Roffi, Marco AU - Roffi M AUID- ORCID: 0000-0002-3051-0170 AD - Division of Cardiology, University Hospitals, Geneva, Switzerland. FAU - Sibbing, Dirk AU - Sibbing D AUID- ORCID: 0000-0002-0698-2696 AD - Ludwig Maximilians Universitat Munchen and Privatklinik Lauterbacher Muhle am Ostersee, Munich, Germany. FAU - Sillesen, Henrik AU - Sillesen H AUID- ORCID: 0000-0002-3302-6288 AD - Department of Vascular Surgery, Rigshospitalet, University of Copenhagen, Denmark. AD - Department of Clinical Medicine, University of Copenhagen, Denmark. FAU - Stabile, Eugenio AU - Stabile E AD - Division of Cardiology, Department of Advanced Biomedical Sciences, University of Naples 'Federico II', Naples, Italy. FAU - Schlager, Oliver AU - Schlager O AD - Division of Angiology, 2nd Department of Medicine, Medical University of Vienna, Austria. FAU - De Carlo, Marco AU - De Carlo M AUID- ORCID: 0000-0002-5763-9804 AD - Cardiothoracic and Vascular Department, Azienda OspedalieroUniversitaria Pisana, Pisa, Italy. LA - eng PT - Consensus Statement PT - Journal Article PL - England TA - Eur Heart J JT - European heart journal JID - 8006263 RN - 0 (Anticoagulants) RN - 0 (Fibrinolytic Agents) RN - 0 (Platelet Aggregation Inhibitors) SB - IM CIN - Eur J Vasc Endovasc Surg. 2022 Jun;63(6):851. doi: 10.1016/j.ejvs.2022.03.010. PMID: 35443913 MH - Anticoagulants/therapeutic use MH - Aorta MH - Fibrinolytic Agents/therapeutic use MH - Humans MH - *Peripheral Arterial Disease/drug therapy MH - Platelet Aggregation Inhibitors/adverse effects MH - *Thrombosis/drug therapy/prevention & control OTO - NOTNLM OT - Anticoagulant OT - Antiplatelet drug OT - Antithrombotic therapy OT - Aorta OT - Carotid artery OT - Lower-extremity artery disease OT - Mesenteric artery OT - Peripheral arterial disease OT - Renal artery OT - Subclavian artery OT - Thrombosis OT - Vertebral artery EDAT- 2021/07/20 06:00 MHDA- 2022/08/10 06:00 CRDT- 2021/07/19 12:57 PHST- 2021/02/27 00:00 [received] PHST- 2021/04/27 00:00 [revised] PHST- 2021/06/03 00:00 [accepted] PHST- 2021/07/20 06:00 [pubmed] PHST- 2022/08/10 06:00 [medline] PHST- 2021/07/19 12:57 [entrez] AID - 6323985 [pii] AID - 10.1093/eurheartj/ehab390 [doi] PST - ppublish SO - Eur Heart J. 2021 Oct 14;42(39):4013-4024. doi: 10.1093/eurheartj/ehab390. PMID- 34274511 OWN - NLM STAT- MEDLINE DCOM- 20220727 LR - 20260127 IS - 1542-7714 (Electronic) IS - 1542-3565 (Print) IS - 1542-3565 (Linking) VI - 20 IP - 8 DP - 2022 Aug TI - North American Practice-Based Recommendations for Transjugular Intrahepatic Portosystemic Shunts in Portal Hypertension. PG - 1636-1662.e36 LID - S1542-3565(21)00749-7 [pii] LID - 10.1016/j.cgh.2021.07.018 [doi] AB - Complications of portal hypertension, including ascites, gastrointestinal bleeding, hepatic hydrothorax, and hepatic encephalopathy, are associated with significant morbidity and mortality. Despite few high-quality randomized controlled trials to guide therapeutic decisions, transjugular intrahepatic portosystemic shunt (TIPS) creation has emerged as a crucial therapeutic option to treat complications of portal hypertension. In North America, the decision to perform TIPS involves gastroenterologists, hepatologists, and interventional radiologists, but TIPS creation is performed by interventional radiologists. This is in contrast to other parts of the world where TIPS creation is performed primarily by hepatologists. Thus, the successful use of TIPS in North America is dependent on a multidisciplinary approach and technical expertise, so as to optimize outcomes. Recently, new procedural techniques, TIPS stent technology, and indications for TIPS have emerged. As a result, practices and outcomes vary greatly across institutions and significant knowledge gaps exist. In this consensus statement, the Advancing Liver Therapeutic Approaches group critically reviews the application of TIPS in the management of portal hypertension. Advancing Liver Therapeutic Approaches convened a multidisciplinary group of North American experts from hepatology, interventional radiology, transplant surgery, nephrology, cardiology, pulmonology, and hematology to critically review existing literature and develop practice-based recommendations for the use of TIPS in patients with any cause of portal hypertension in terms of candidate selection, procedural best practices and, post-TIPS management; and to develop areas of consensus for TIPS indications and the prevention of complications. Finally, future research directions are identified related to TIPS for the management of portal hypertension. CI - Copyright (c) 2022 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Boike, Justin R AU - Boike JR AD - Division of Gastroenterology and Hepatology, Department of Medicine, Chicago, Illinois. FAU - Thornburg, Bartley G AU - Thornburg BG AD - Division of Vascular and Interventional Radiology, Department of Radiology, Chicago, Illinois. FAU - Asrani, Sumeet K AU - Asrani SK AD - Division of Gastroenterology, Department of Medicine, Baylor University Medical Center, Dallas, Texas. FAU - Fallon, Michael B AU - Fallon MB AD - Division of Gastroenterology and Hepatology, Department of Medicine, Banner-University Medical Center Phoenix, Phoenix, Arizona. FAU - Fortune, Brett E AU - Fortune BE AD - Division of Gastroenterology and Hepatology, Department of Medicine, Weill Cornell Medical College, New York, New York. FAU - Izzy, Manhal J AU - Izzy MJ AD - Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. FAU - Verna, Elizabeth C AU - Verna EC AD - Division of Digestive and Liver Diseases, New York, New York. FAU - Abraldes, Juan G AU - Abraldes JG AD - Division of Gastroenterology, Liver Unit, University of Alberta, Edmonton, Alberta, Canada. FAU - Allegretti, Andrew S AU - Allegretti AS AD - Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. FAU - Bajaj, Jasmohan S AU - Bajaj JS AD - Division of Gastroenterology, Hepatology, and Nutrition, Department of Internal Medicine, Virginia Commonwealth University, Central Virginia Veterans Healthcare System, Richmond, Virginia. FAU - Biggins, Scott W AU - Biggins SW AD - Division of Gastroenterology and Hepatology, Department of Medicine, University of Washington Medical Center, Seattle, Washington. FAU - Darcy, Michael D AU - Darcy MD AD - Division of Interventional Radiology, Department of Radiology, Washington University School of Medicine, St. Louis, Missouri. FAU - Farr, Maryjane A AU - Farr MA AD - Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York. FAU - Farsad, Khashayar AU - Farsad K AD - Dotter Department of Interventional Radiology, Portland, Oregon. FAU - Garcia-Tsao, Guadalupe AU - Garcia-Tsao G AD - Department of Digestive Diseases, Veterans Administration-Connecticut Healthcare System, New Haven, Connecticut. FAU - Hall, Shelley A AU - Hall SA AD - Division of Cardiology, Department of Internal Medicine, Dallas, Texas. FAU - Jadlowiec, Caroline C AU - Jadlowiec CC AD - Division of Transplant Surgery, Department of Surgery, Mayo Clinic, Phoenix, Arizona. FAU - Krowka, Michael J AU - Krowka MJ AD - Division of Gastroenterology and Hepatology, Department of Pulmonary and Critical Care Medicine, Rochester, Minnesota. FAU - Laberge, Jeanne AU - Laberge J AD - Division of Interventional Radiology, Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California. FAU - Lee, Edward W AU - Lee EW AD - Division of Interventional Radiology, Department of Radiology, University of California-Los Angeles David Geffen School of Medicine, Los Angeles, California. FAU - Mulligan, David C AU - Mulligan DC AD - Division of Transplantation, Department of Surgery, Yale University School of Medicine, New Haven, Connecticut. FAU - Nadim, Mitra K AU - Nadim MK AD - Division of Nephrology and Hypertension, Department of Medicine, University of Southern California, Los Angeles, California. FAU - Northup, Patrick G AU - Northup PG AD - Division of Gastroenterology and Hepatology, Department of Medicine, University of Virginia, Charlottesville, Virginia. FAU - Salem, Riad AU - Salem R AD - Division of Vascular and Interventional Radiology, Department of Radiology, Chicago, Illinois. FAU - Shatzel, Joseph J AU - Shatzel JJ AD - Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon. FAU - Shaw, Cathryn J AU - Shaw CJ AD - Division of Interventional Radiology, Department of Radiology, Dallas, Texas. FAU - Simonetto, Douglas A AU - Simonetto DA AD - Division of Gastroenterology and Hepatology, Department of Physiology, Mayo Clinic, Rochester, Minnesota. FAU - Susman, Jonathan AU - Susman J AD - Division of Interventional Radiology, Department of Radiology, Columbia University Irving Medical Center, New York, New York. FAU - Kolli, K Pallav AU - Kolli KP AD - Division of Interventional Radiology, Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California. FAU - VanWagner, Lisa B AU - VanWagner LB AD - Division of Gastroenterology and Hepatology, Department of Medicine, Chicago, Illinois; Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois. Electronic address: lvw@northwestern.edu. CN - Advancing Liver Therapeutic Approaches (ALTA) Consortium LA - eng GR - UL1 TR001863/TR/NCATS NIH HHS/United States GR - K23 HL136891/HL/NHLBI NIH HHS/United States GR - P30 DK132710/DK/NIDDK NIH HHS/United States GR - UL1 TR001422/TR/NCATS NIH HHS/United States GR - R01 HL151367/HL/NHLBI NIH HHS/United States PT - Consensus Statement PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20210715 PL - United States TA - Clin Gastroenterol Hepatol JT - Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association JID - 101160775 SB - IM CIN - Clin Gastroenterol Hepatol. 2023 Jun;21(6):1673-1674. doi: 10.1016/j.cgh.2022.08.006. PMID: 35985638 MH - Ascites/etiology MH - *Esophageal and Gastric Varices/complications MH - Gastrointestinal Hemorrhage/complications/surgery MH - Humans MH - *Hypertension, Portal/complications/surgery MH - *Portasystemic Shunt, Transjugular Intrahepatic/adverse effects MH - Treatment Outcome PMC - PMC8760361 MID - NIHMS1724703 OTO - NOTNLM OT - Ascites OT - Cirrhosis OT - Complications OT - Consensus Statement OT - End-Stage Liver Disease OT - Guidance Document OT - TIPS Procedure OT - Variceal Bleeding EDAT- 2021/07/19 06:00 MHDA- 2022/07/28 06:00 PMCR- 2022/08/01 CRDT- 2021/07/18 20:37 PHST- 2021/04/30 00:00 [received] PHST- 2021/07/01 00:00 [revised] PHST- 2021/07/13 00:00 [accepted] PHST- 2021/07/19 06:00 [pubmed] PHST- 2022/07/28 06:00 [medline] PHST- 2021/07/18 20:37 [entrez] PHST- 2022/08/01 00:00 [pmc-release] AID - S1542-3565(21)00749-7 [pii] AID - 10.1016/j.cgh.2021.07.018 [doi] PST - ppublish SO - Clin Gastroenterol Hepatol. 2022 Aug;20(8):1636-1662.e36. doi: 10.1016/j.cgh.2021.07.018. Epub 2021 Jul 15. PMID- 34274113 OWN - NLM STAT- MEDLINE DCOM- 20220203 LR - 20220203 IS - 1768-3181 (Electronic) IS - 0003-3928 (Linking) VI - 71 IP - 1 DP - 2022 Feb TI - Diagnosis and management of heart failure from hospital admission to discharge: A practical expert guidance. PG - 41-52 LID - S0003-3928(21)00068-8 [pii] LID - 10.1016/j.ancard.2021.05.004 [doi] AB - Heart failure (HF) has high event rates, mortality, and is challenging to manage in clinical practice. Clinical management is complicated by complex therapeutic strategies in a population with a high prevalence of comorbidity and general frailty. In the last four years, an abundance of research has become available to support multidisciplinary management of heart failure from within the hospital through to discharge and primary care as well as supporting diagnosis and comorbidity management. Within the hospital setting, recent evidence supports sacubitril-valsartan combination in frail, deteriorating or de novo patients with LVEF/=1 stenosis of >/=25% underwent FFR(CT) analysis. The Heart Team reviewed clinical data and CTCA findings, blinded to FFR(CT) values, and documented hypothetical consensus management. FFR(CT) results were then unblinded and hypothetical consensus management re-recorded. Diagnostic waiting times for management pathways were estimated. A per-patient cost analysis for diagnostic certainty regarding coronary artery disease (CAD) management was performed using 2014-2020 NHS tariffs for pre- and post-FFR(CT) pathways. RESULTS: Two hundred and fifty-one CTCAs were performed during the study period. Fifty-seven percent (145/251) had no CAD or stenosis <25%. One study was non-diagnostic. Of the remaining 42% (105/251), two were ineligible for FFR(CT) and there was a 5% (5/103) failure rate. FFR(CT) led to a change in hypothetical management in 65% (64/98; p<0.001) patients with a functional imaging test cancelled in 17% (17/98) and a diagnostic angiogram cancelled in 47% (46/98). FFR(CT)-guided management had a reduced mean time to definitive investigation compared with CTCA alone (28 +/- 4 versus 44 +/- 4 days; p=0.004). Using the proposed 2020/21 tariff, CTCA + FFR(CT) for stenosis >/=50% resulted in a diagnostic pathway pound44.97 more expensive per patient than usual care without FFR(CT). CONCLUSIONS: In the real-world NHS setting, FFR(CT)-guided management has the potential to rationalise patient management, accelerate diagnostic pathways, and depending on the stenosis severity modelled, may be cost-effective. CI - Crown Copyright (c) 2021. Published by Elsevier Ltd. All rights reserved. FAU - Graby, J AU - Graby J AD - Department of Cardiology, Royal United Hospitals Bath NHS Foundation Trust, Combe Park, Bath, BA1 3NG, UK; Department for Health, University of Bath, Claverton Down, Bath, BA2 7AY UK. FAU - Metters, R AU - Metters R AD - Department of Cardiology, Royal United Hospitals Bath NHS Foundation Trust, Combe Park, Bath, BA1 3NG, UK. FAU - Kandan, S R AU - Kandan SR AD - Department of Cardiology, Royal United Hospitals Bath NHS Foundation Trust, Combe Park, Bath, BA1 3NG, UK. FAU - McKenzie, D AU - McKenzie D AD - Department of Cardiology, Royal United Hospitals Bath NHS Foundation Trust, Combe Park, Bath, BA1 3NG, UK. FAU - Lowe, R AU - Lowe R AD - Department of Cardiology, Royal United Hospitals Bath NHS Foundation Trust, Combe Park, Bath, BA1 3NG, UK. FAU - Carson, K AU - Carson K AD - Department of Cardiology, Royal United Hospitals Bath NHS Foundation Trust, Combe Park, Bath, BA1 3NG, UK. FAU - Hudson, B J AU - Hudson BJ AD - Department of Radiology, Royal United Hospitals Bath NHS Foundation Trust, Combe Park, Bath, BA1 3NG, UK. FAU - Rodrigues, J C L AU - Rodrigues JCL AD - Department of Radiology, Royal United Hospitals Bath NHS Foundation Trust, Combe Park, Bath, BA1 3NG, UK; Department for Health, University of Bath, Claverton Down, Bath, BA2 7AY UK. Electronic address: j.rodrigues1@nhs.net. LA - eng PT - Journal Article DEP - 20210711 PL - England TA - Clin Radiol JT - Clinical radiology JID - 1306016 SB - IM MH - Computed Tomography Angiography/*economics/*methods MH - Coronary Angiography/*economics/*methods MH - Coronary Stenosis/*diagnostic imaging/economics/physiopathology MH - Costs and Cost Analysis/*methods/statistics & numerical data MH - Female MH - Fractional Flow Reserve, Myocardial/*physiology MH - Humans MH - Male MH - Middle Aged MH - Predictive Value of Tests MH - Retrospective Studies MH - Severity of Illness Index MH - State Medicine MH - United Kingdom EDAT- 2021/07/16 06:00 MHDA- 2021/12/15 06:00 CRDT- 2021/07/15 05:36 PHST- 2021/01/06 00:00 [received] PHST- 2021/06/15 00:00 [accepted] PHST- 2021/07/16 06:00 [pubmed] PHST- 2021/12/15 06:00 [medline] PHST- 2021/07/15 05:36 [entrez] AID - S0009-9260(21)00334-2 [pii] AID - 10.1016/j.crad.2021.06.009 [doi] PST - ppublish SO - Clin Radiol. 2021 Nov;76(11):862.e19-862.e28. doi: 10.1016/j.crad.2021.06.009. Epub 2021 Jul 11. PMID- 34261085 OWN - NLM STAT- MEDLINE DCOM- 20211015 LR - 20211015 IS - 1531-6971 (Electronic) IS - 1070-5287 (Linking) VI - 27 IP - 5 DP - 2021 Sep 1 TI - Update on sarcoidosis guidelines. PG - 484-489 LID - 10.1097/MCP.0000000000000807 [doi] AB - PURPOSE OF REVIEW: The current review summarizes recent guidance in the diagnosis and management of sarcoidosis. Until recently, the main guidelines were the 1999 International Statement on Sarcoidosis. However, in 2020 two new guidelines were published by the American and British Thoracic Societies. They have a number of key updates and this review aims to summarize these. RECENT FINDINGS: The key findings from 2020 revolve around several themes. First, the need for a histological diagnosis should be supported by a multidisciplinary team approach. When a histological biopsy is needed of the lungs, thought is given to the approach taken for this and to whether an endobronchial ultrasound, endoscopic ultrasound or transbronchial biopsy is needed. Second, information regarding supporting tests including blood biomarkers, lung function and imaging. Third, a section specific to cardiac sarcoidosis. Finally, a summary of guidance for treating sarcoidosis including the need to treat fatigue. SUMMARY: The recent guidance suggests that a histological biopsy is only needed in cases of diagnostic uncertainty or in patients with typical long standing features on imaging. The guidelines also provide a clear pathway on the type of lung biopsy needed depending on the extent of mediastinal or parenchymal involvement. Support is given to steroid regimens and indication for second-line immunosuppression. CI - Copyright (c) 2021 Wolters Kluwer Health, Inc. All rights reserved. FAU - Millward, Kate AU - Millward K AD - Respiratory Sleep and Support Centre, Royal Papworth Hospital. FAU - Fiddler, Christine A AU - Fiddler CA AD - Cambridge Interstitial Lung Disease Service, Royal Papworth Hospital NHS Foundation Trust, Cambridge Biomedical Campus. FAU - Thillai, Muhunthan AU - Thillai M AD - Cambridge Interstitial Lung Disease Service, Royal Papworth Hospital NHS Foundation Trust, Cambridge Biomedical Campus. AD - Department of Medicine, University of Cambridge, Cambridge, UK. LA - eng PT - Journal Article PT - Review PL - United States TA - Curr Opin Pulm Med JT - Current opinion in pulmonary medicine JID - 9503765 SB - IM MH - Biopsy MH - Bronchoscopy MH - Endosonography MH - Humans MH - *Sarcoidosis/diagnosis/drug therapy MH - *Sarcoidosis, Pulmonary/diagnosis/drug therapy EDAT- 2021/07/15 06:00 MHDA- 2021/10/16 06:00 CRDT- 2021/07/14 20:12 PHST- 2021/07/15 06:00 [pubmed] PHST- 2021/10/16 06:00 [medline] PHST- 2021/07/14 20:12 [entrez] AID - 00063198-202109000-00028 [pii] AID - 10.1097/MCP.0000000000000807 [doi] PST - ppublish SO - Curr Opin Pulm Med. 2021 Sep 1;27(5):484-489. doi: 10.1097/MCP.0000000000000807. PMID- 34258571 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240505 IS - 2589-5370 (Electronic) IS - 2589-5370 (Linking) VI - 37 DP - 2021 Jul TI - Extrapulmonary sarcoidosis with a focus on cardiac, nervous system, and ocular involvement. PG - 100966 LID - 10.1016/j.eclinm.2021.100966 [doi] LID - 100966 AB - Sarcoidosis is a poorly understood granulomatous disease that involves the lungs and/or intrathoracic lymph nodes in more than 90% of cases. Although pulmonary sarcoidosis is the leading cause of mortality in this disease, this review focuses on three sites of extrapulmonary involvement (heart, nervous system, and eyes), since involvement of any of these sites can be catastrophic, leading to death, debilitation, or blindness. Patients with cardiac, ocular and neurosarcoidosis necessitate a multidisciplinary approach with careful and long-term follow-up. Prompt diagnosis with imaging and/or biopsy and treatment is required to avoid irreversible damage. Corticosteroids are the mainstay of therapy and are often associated with rapid and durable remissions. Immunosuppressive or biologic agents are reserved for patients failing or experiencing side effects from steroids. Managing sarcoidosis requires vigilance, judgement, and awareness of the vagaries of this fascinating disease. CI - (c) 2021 Published by Elsevier Ltd. FAU - Belperio, John A AU - Belperio JA AD - The Division of Pulmonary and Critical Care Medicine, Holt and Jo Hickman Endowed Chair of Advanced Lung Disease and Lung Transplantation, Clinical Immunology, and Allergy, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave, Room 37-131 CHS, Los Angeles, CA 90095, United States. FAU - Shaikh, Faisal AU - Shaikh F AD - The Division of Pulmonary and Critical Care Medicine, Holt and Jo Hickman Endowed Chair of Advanced Lung Disease and Lung Transplantation, Clinical Immunology, and Allergy, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave, Room 37-131 CHS, Los Angeles, CA 90095, United States. FAU - Abtin, Fereidoun AU - Abtin F AD - Department of Radiology, Thoracic and Interventional Section, David Geffen School of Medicine at UCLA, United States. FAU - Fishbein, Michael C AU - Fishbein MC AD - Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, United States. FAU - Saggar, Rajan AU - Saggar R AD - The Division of Pulmonary and Critical Care Medicine, Holt and Jo Hickman Endowed Chair of Advanced Lung Disease and Lung Transplantation, Clinical Immunology, and Allergy, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave, Room 37-131 CHS, Los Angeles, CA 90095, United States. FAU - Tsui, Edmund AU - Tsui E AD - Department of Ophthalmology, David Geffen School of Medicine at UCLA, United States. FAU - Lynch, Joseph P 3rd AU - Lynch JP 3rd AD - The Division of Pulmonary and Critical Care Medicine, Holt and Jo Hickman Endowed Chair of Advanced Lung Disease and Lung Transplantation, Clinical Immunology, and Allergy, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave, Room 37-131 CHS, Los Angeles, CA 90095, United States. LA - eng GR - P01 HL108793/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Review DEP - 20210627 PL - England TA - EClinicalMedicine JT - EClinicalMedicine JID - 101733727 PMC - PMC8254127 OTO - NOTNLM OT - Cardiac sarcoidosis OT - Granulomatous OT - Immunosuppression OT - Neurosarcoidosis OT - Sarcoidosis OT - Uveitis COIS- In the compiling and writing of this manuscript, there are no conflicts from the any of the represented authors. Dr. Tsui reports and Research support from Kowa Company Ltd. EDAT- 2021/07/15 06:00 MHDA- 2021/07/15 06:01 PMCR- 2021/06/27 CRDT- 2021/07/14 07:12 PHST- 2020/07/10 00:00 [received] PHST- 2021/05/26 00:00 [revised] PHST- 2021/05/26 00:00 [accepted] PHST- 2021/07/14 07:12 [entrez] PHST- 2021/07/15 06:00 [pubmed] PHST- 2021/07/15 06:01 [medline] PHST- 2021/06/27 00:00 [pmc-release] AID - S2589-5370(21)00246-7 [pii] AID - 100966 [pii] AID - 10.1016/j.eclinm.2021.100966 [doi] PST - epublish SO - EClinicalMedicine. 2021 Jun 27;37:100966. doi: 10.1016/j.eclinm.2021.100966. eCollection 2021 Jul. PMID- 34258260 OWN - NLM STAT- MEDLINE DCOM- 20210922 LR - 20220424 IS - 2314-6141 (Electronic) IS - 2314-6133 (Print) VI - 2021 DP - 2021 TI - Exploring the Operative Strategy for Secondary Mitral Regurgitation: A Systematic Review. PG - 3466813 LID - 10.1155/2021/3466813 [doi] LID - 3466813 AB - BACKGROUND: Mitral valve disease surgery is an evolving field with multiple possible interventions. There is an increasing body of evidence regarding the optimal strategy in secondary mitral regurgitation where the pathology lies within the ventricle. We conducted a systematic review to identify the benefits and limitations of each surgical option. METHODS: A systematic review of the literature was performed to identify pertinent randomized controlled trials (RCTs), propensity-matched observational series, and meta-analyses which were considered initially and followed by unmatched observational series using the MEDLINE, Ovid EMBASE, and Cochrane Library. RESULTS: We identified 6 different strategies for treating secondary mitral valve regurgitation: mitral valve replacement, restrictive mitral annuloplasty, surgical revascularization (with and without mitral annuloplasty), subvalvular procedures (papillary muscle approximation, papillary muscle relocation, ring and string procedure), and procedures directly targeting the mitral valve (edge-to-edge repair and anterior leaflet enlargement) alongside transcatheter heart valve therapy. We also highlighted the role of left ventricular assist devices in the management of this condition. The benefits and limitations of each intervention are highlighted. CONCLUSION: There is currently no unanimous and shared strategy for the optimal treatment of patients with secondary IMR. The management of patients with secondary mitral regurgitation must be entrusted to a multidisciplinary Heart Team to ensure ideal intervention and patient matching for the best outcomes. CI - Copyright (c) 2021 Francesco Nappi et al. FAU - Nappi, Francesco AU - Nappi F AUID- ORCID: 0000-0002-9705-5360 AD - Department of Cardiac Surgery, Centre Cardiologique du Nord de Saint-Denis, Paris, France. FAU - Singh, Sanjeet Singh Avtaar AU - Singh SSA AUID- ORCID: 0000-0003-4320-0734 AD - Department of Cardiothoracic Surgery, Golden Jubilee National Hospital, Glasgow, UK. FAU - Bellomo, Francesca AU - Bellomo F AD - Department of Clinical and Experimental Medicine, University of Messina, Italy. FAU - Nappi, Pierluigi AU - Nappi P AD - Department of Clinical and Experimental Medicine, University of Messina, Italy. FAU - Chello, Camilla AU - Chello C AD - Regenerative Medicine, Universita Campus Bio-Medico di Roma, 00128 Rome, Italy. FAU - Iervolino, Adelaide AU - Iervolino A AUID- ORCID: 0000-0002-3208-4689 AD - Department of Cardiovascular Sciences, Fondazione Policlinico Universitario A. Gemelli IRCSS, Italy. FAU - Chello, Massimo AU - Chello M AD - Cardiovascular Surgery, Universita Campus Bio-Medico di Roma, 00128 Rome, Italy. LA - eng PT - Journal Article PT - Systematic Review DEP - 20210622 PL - United States TA - Biomed Res Int JT - BioMed research international JID - 101600173 SB - IM MH - Apoptosis MH - Fibrosis MH - Heart Valve Prosthesis Implantation MH - Humans MH - Mitral Valve Annuloplasty MH - Mitral Valve Insufficiency/*surgery MH - Papillary Muscles/pathology MH - ROC Curve MH - Treatment Outcome MH - *Vascular Surgical Procedures PMC - PMC8245239 COIS- All authors declare no conflicts of interest. EDAT- 2021/07/15 06:00 MHDA- 2021/09/23 06:00 PMCR- 2021/06/22 CRDT- 2021/07/14 07:09 PHST- 2021/05/25 00:00 [received] PHST- 2021/06/05 00:00 [revised] PHST- 2021/06/16 00:00 [accepted] PHST- 2021/07/14 07:09 [entrez] PHST- 2021/07/15 06:00 [pubmed] PHST- 2021/09/23 06:00 [medline] PHST- 2021/06/22 00:00 [pmc-release] AID - 10.1155/2021/3466813 [doi] PST - epublish SO - Biomed Res Int. 2021 Jun 22;2021:3466813. doi: 10.1155/2021/3466813. eCollection 2021. PMID- 34257484 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210715 IS - 1011-6842 (Print) IS - 1011-6842 (Linking) VI - 37 IP - 4 DP - 2021 Jul TI - 2021 TSOC Expert Consensus on the Clinical Features, Diagnosis, and Clinical Management of Cardiac Manifestations of Fabry Disease. PG - 337-354 LID - 10.6515/ACS.202107_37(4).20210601A [doi] AB - Fabry disease (FD) is an X-linked, rare inherited lysosomal storage disease caused by alpha-galactosidase A gene variants resulting in deficient or undetectable alpha-galactosidase A enzyme activity. Progressive accumulation of pathogenic globotriaosylceramide and its deacylated form globotriaosylsphingosine in multiple cell types and organs is proposed as main pathophysiology of FD, with elicited pro-inflammatory cascade as alternative key pathological process. The clinical manifestations may present with either early onset and multisystemic involvement (cutaneous, neurological, nephrological and the cardiovascular system) with a progressive disease nature in classic phenotype, or present with a later-onset course with predominant cardiac involvement (non-classical or cardiac variant; e.g. IVS4+919G>A in Taiwan) from missense variants. In either form, cardiac involvement is featured by progressive cardiac hypertrophy, myocardial fibrosis, various arrhythmias, and heart failure known as Fabry cardiomyopathy with potential risk of sudden cardiac death. Several plasma biomarkers and advances in imaging modalities along with novel parameters, cardiac magnetic resonance (CMR: native T1/T2 mapping) for myocardial tissue characterization or echocardiographic deformations, have shown promising performance in differentiating from other etiologies of cardiomyopathy and are presumed to be helpful in assessing the extent of cardiac involvement of FD and in guiding or monitoring subsequent treatment. Early recognition from extra-cardiac red flag signs either in classic form or red flags from cardiac manifestations in cardiac variants, and awareness from multispecialty team work remains the cornerstone for timely managements and beneficial responses from therapeutic interventions (e.g. oral chaperone therapy or enzyme replacement therapy) prior to irreversible organ damage. We aim to summarize contemporary knowledge based on literature review and the gap or future perspectives in clinical practice of FD-related cardiomyopathy in an attempt to form a current expert consensus in Taiwan. FAU - Hung, Chung-Lieh AU - Hung CL AD - Division of Cardiology, Departments of Internal Medicine, MacKay Memorial Hospital, Taipei. AD - Institute of Biomedical Sciences, Mackay Medical College. FAU - Wu, Yen-Wen AU - Wu YW AD - Division of Cardiology, Cardiovascular Medical Center, Far Eastern Memorial Hospital, New Taipei City. AD - School of Medicine, National Yang Ming Chiao Tung University, Taipei. FAU - Lin, Chih-Chan AU - Lin CC AD - Division of Cardiology, Department of Internal Medicine, National Cheng Kung University Hospital. AD - Department of Internal Medicine, College of Medicine, National Cheng Kung University, Tainan. FAU - Lai, Chih-Hung AU - Lai CH AD - Cardiovascular Center, Taichung Veterans General Hospital, Taichung. FAU - Jyh-Ming Juang, Jimmy AU - Jyh-Ming Juang J AD - Division of Cardiology, Department of Internal Medicine and Cardiovascular Center, National Taiwan University Hospital. AD - College of Medicine, National Taiwan University. FAU - Chao, Ting-Hsing AU - Chao TH AD - Division of Cardiology, Department of Internal Medicine, National Cheng Kung University Hospital. AD - Department of Internal Medicine, College of Medicine, National Cheng Kung University, Tainan. FAU - Kuo, Ling AU - Kuo L AD - Division of Cardiology, Taipei Veterans General Hospital, Taipei. FAU - Sung, Kuo-Tzu AU - Sung KT AD - Division of Cardiology, Departments of Internal Medicine, MacKay Memorial Hospital, Taipei. FAU - Wang, Chao-Yung AU - Wang CY AD - Division of Cardiology, Chang Gung Memorial Hospital, Linkou Medical Center. AD - School of Medicine, College of Medicine, Chang Gung University, Taoyuan. AD - Institute of Cellular and System Medicine, National Health Research Institutes, Zhunan. FAU - Wang, Chun-Li AU - Wang CL AD - Division of Cardiology, Chang Gung Memorial Hospital, Linkou Medical Center. AD - School of Medicine, College of Medicine, Chang Gung University, Taoyuan. FAU - Chu, Chun-Yuan AU - Chu CY AD - Division of Cardiology, Kaohsiung Medical University Hospital, Kaohsiung. FAU - Yu, Wen-Chung AU - Yu WC AD - School of Medicine, National Yang Ming Chiao Tung University, Taipei. AD - Division of Cardiology, Taipei Veterans General Hospital, Taipei. FAU - Hou, Charles Jia-Yin AU - Hou CJ AD - Division of Cardiology, Departments of Internal Medicine, MacKay Memorial Hospital, Taipei. AD - Department of Medicine, Mackay Medical College, New Taipei City, Taiwan. LA - eng PT - Journal Article PT - Review PL - China (Republic : 1949- ) TA - Acta Cardiol Sin JT - Acta Cardiologica Sinica JID - 101687085 PMC - PMC8261701 OTO - NOTNLM OT - Cardiac magnetic resonance (CMR) OT - Cardiac variant OT - Chaperone OT - Enzyme replacement therapy (ERT) OT - Fabry disease (FD) OT - Globotriaosylceramide (Gb3) OT - Globotriaosylsphingosine (Lyso-Gb3) OT - IVS4+919G>A OT - alpha-galactosidase A (GLA) gene EDAT- 2021/07/15 06:00 MHDA- 2021/07/15 06:01 PMCR- 2021/07/01 CRDT- 2021/07/14 07:01 PHST- 2021/05/16 00:00 [received] PHST- 2021/06/01 00:00 [accepted] PHST- 2021/07/14 07:01 [entrez] PHST- 2021/07/15 06:00 [pubmed] PHST- 2021/07/15 06:01 [medline] PHST- 2021/07/01 00:00 [pmc-release] AID - 10.6515/ACS.202107_37(4).20210601A [doi] PST - ppublish SO - Acta Cardiol Sin. 2021 Jul;37(4):337-354. doi: 10.6515/ACS.202107_37(4).20210601A. PMID- 34254137 OWN - NLM STAT- MEDLINE DCOM- 20220304 LR - 20220304 IS - 1873-734X (Electronic) IS - 1010-7940 (Linking) VI - 60 IP - 6 DP - 2021 Dec 1 TI - A heart-team hybrid approach for atrial fibrillation: a single-centre long-term clinical outcome cohort study. PG - 1343-1350 LID - 10.1093/ejcts/ezab197 [doi] AB - OBJECTIVES: The Cox-maze IV is the gold standard for surgical ablation of atrial fibrillation (AF). A heart-team hybrid approach using selected epicardial thoracoscopic surgical ablations and completion endocardial ablations to replicate the Cox-maze IV lesion set has gained popularity and early results have been promising. We herein report our single-centre long-term clinical outcomes using the heart-team hybrid approach with 455 patients. METHODS: From 1 March 2013 to 1 July 2019, we prospectively collected data on all patients referred to our heart team for rhythm-control strategy for AF. Baseline characteristics, procedural complications and long-term freedom from AF (FFAF) both on and off anti-arrhythmic drug therapy were analysed. Ambulatory monitoring (>7 days) was obtained at 3 months and annually thereafter. RESULTS: Four hundred and fifty-five patients completed the hybrid approach. Four hundred and forty-five (97.8%) patients had non-paroxysmal AF (long-standing persistent AF n = 249, 54.7%; persistent AF n = 196, 43.1%; paroxysmal AF n = 10, 2.2%). Average duration of AF was 5.9 +/- 6.1 years. Average left atrial diameter was 4.8 +/- 0.8 cm. FFAF at 3, 12, 24 and 36 months was 92%, 87%, 81% and 72%, respectively. FFAF without the use of anti-arrhythmic medications was 75%, 81%, 76% and 66%. Any surgical complications occurred in 28 (6.1%) patients. CONCLUSIONS: A heart-team hybrid strategy for the treatment of AF is safe and effective. In a predominantly non-paroxysmal population with AF, at the 3-year follow-up, FFAF in patients on and off anti-arrhythmic drugs approaches that of patients who had the Cox-maze IV. CI - (c) The Author(s) 2021. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved. FAU - Dunnington, Gansevoort H AU - Dunnington GH AD - Department of Cardiothoracic Surgery, Adventist Health-Saint Helena, Saint Helena, CA, USA. FAU - Pierce, Carrie L AU - Pierce CL AD - Department of Cardiothoracic Surgery, Adventist Health-Saint Helena, Saint Helena, CA, USA. FAU - Eisenberg, Susan AU - Eisenberg S AD - Department of Cardiothoracic Surgery, Adventist Health-Saint Helena, Saint Helena, CA, USA. FAU - Bing, Liem L AU - Bing LL AD - Department of Cardiothoracic Surgery, Adventist Health-Saint Helena, Saint Helena, CA, USA. AD - Department of Electrophysiology, El Camino Health, Mountain View, CA, USA. AD - Department of Electrophysiology, Veterans Affairs Health Care, University of California San rancisco, San Francisco, CA, USA. FAU - Chang-Sing, Peter AU - Chang-Sing P AD - Department of Cardiothoracic Surgery, Adventist Health-Saint Helena, Saint Helena, CA, USA. AD - Department of Electrophysiology, St. Joseph Health, Santa Rosa Memorial Hospital, Santa Rosa, CA, USA. FAU - Kaiser, Daniel W AU - Kaiser DW AUID- ORCID: 0000-0003-0778-3055 AD - Department of Cardiothoracic Surgery, Adventist Health-Saint Helena, Saint Helena, CA, USA. AD - Department of Electrophysiology, El Camino Health, Mountain View, CA, USA. AD - Department of Electrophysiology, Ascension Saint Thomas Heart, Nashville, TN, USA. FAU - Burk, Shelby AU - Burk S AD - Department of Cardiothoracic Surgery, Adventist Health-Saint Helena, Saint Helena, CA, USA. FAU - Moulton, Linda C AU - Moulton LC AD - Critical Care ED/CCE Consulting, Calistoga, CA, USA. FAU - Kiankhooy, Armin AU - Kiankhooy A AUID- ORCID: 0000-0001-7610-9406 AD - Department of Cardiothoracic Surgery, Adventist Health-Saint Helena, Saint Helena, CA, USA. LA - eng PT - Journal Article PL - Germany TA - Eur J Cardiothorac Surg JT - European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery JID - 8804069 SB - IM CIN - Eur J Cardiothorac Surg. 2021 Dec 1;60(6):1351-1352. doi: 10.1093/ejcts/ezab291. PMID: 34329415 MH - *Atrial Fibrillation/etiology MH - *Catheter Ablation/adverse effects/methods MH - Cohort Studies MH - Humans MH - Recurrence MH - Time Factors MH - Treatment Outcome OTO - NOTNLM OT - Arrhythmia surgery OT - Atrial fibrillation OT - Hybrid ablation OT - Maze surgery EDAT- 2021/07/14 06:00 MHDA- 2022/03/05 06:00 CRDT- 2021/07/13 06:34 PHST- 2020/09/17 00:00 [received] PHST- 2021/01/22 00:00 [revised] PHST- 2021/03/25 00:00 [accepted] PHST- 2021/07/14 06:00 [pubmed] PHST- 2022/03/05 06:00 [medline] PHST- 2021/07/13 06:34 [entrez] AID - 6319843 [pii] AID - 10.1093/ejcts/ezab197 [doi] PST - ppublish SO - Eur J Cardiothorac Surg. 2021 Dec 1;60(6):1343-1350. doi: 10.1093/ejcts/ezab197. PMID- 34252060 OWN - NLM STAT- MEDLINE DCOM- 20220209 LR - 20230825 IS - 2163-0763 (Electronic) IS - 2163-0755 (Linking) VI - 92 IP - 1 DP - 2022 Jan 1 TI - A surgical needs assessment for airway rapid responses: A retrospective observational study. PG - 126-134 LID - 10.1097/TA.0000000000003348 [doi] AB - BACKGROUND: Airway rapid response (ARR) teams can be compiled of anesthesiologists, intensivists, otolaryngologists, general and thoracic surgeons, respiratory therapists, and nurses. The optimal composition of an ARR team is unknown but considered to be resource intensive. We sought to determine the type of technical procedures performed during an ARR activation to inform team composition. METHODS: A large urban quaternary academic medical center retrospective review (2016-2019) of adult ARR patients was performed. Analysis included ARR demographics, patient characteristics, characteristics of preexisting tracheostomies, incidence of concomitant conditions, and procedures completed during an ARR event. RESULTS: A total of 345 ARR patients with a median age of 60 years (interquartile range, 47-69 years) and a median time to ARR conclusion of 28 minutes (interquartile range, 14-47 minutes) were included. About 41.7% of the ARR had a preexisting tracheostomy. Overall, there were 130 procedures completed that can be performed by a general surgeon in addition to the 122 difficult intubations. These procedures included recannulation of a tracheostomy, operative intervention, new emergent tracheostomy or cricothyroidotomy, thoracostomy tube placement, initiation of extracorporeal membrane oxygenation, and pericardiocentesis. CONCLUSION: Highly technical procedures are common during an ARR, including procedures related to tracheostomies. Surgeons possess a comprehensive skill set that is unique and comprehensive with respect to airway emergencies. This distinctive skill set creates an important role within the ARR team to perform these urgent technical procedures. LEVEL OF EVIDENCE: Epidemiologic/prognostic, level III. CI - Copyright (c) 2021 Wolters Kluwer Health, Inc. All rights reserved. FAU - Hynes, Allyson M AU - Hynes AM AD - From the Division of Traumatology, Surgical Critical Care and Emergency Surgery (A.M.H., D.R.S., B.C.B., M.J.S., N.D.M.), Nursing Rapid Response Team (L.D.L.), Department of Anesthesiology and Critical Care (J.H.A.), and Department of Otorhinolaryngology: Head and Neck Surgery (C.H.R.), Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. FAU - Lambe, Leah D AU - Lambe LD FAU - Scantling, Dane R AU - Scantling DR FAU - Bormann, Bradford C AU - Bormann BC FAU - Atkins, Joshua H AU - Atkins JH FAU - Rassekh, Christopher H AU - Rassekh CH FAU - Seamon, Mark J AU - Seamon MJ FAU - Martin, Niels D AU - Martin ND LA - eng PT - Journal Article PT - Observational Study PL - United States TA - J Trauma Acute Care Surg JT - The journal of trauma and acute care surgery JID - 101570622 SB - IM MH - Academic Medical Centers/statistics & numerical data MH - *Airway Management/methods/standards MH - Clinical Competence/*standards MH - Comprehensive Health Care/methods/statistics & numerical data MH - Critical Care/*methods MH - Emergencies/epidemiology MH - Extracorporeal Membrane Oxygenation/statistics & numerical data MH - Female MH - *Hospital Rapid Response Team/organization & administration/standards MH - Humans MH - Male MH - Middle Aged MH - Needs Assessment MH - Patient Care Team/organization & administration MH - Pericardiocentesis/statistics & numerical data MH - Time-to-Treatment MH - *Tracheostomy/adverse effects/methods/statistics & numerical data MH - United States/epidemiology EDAT- 2021/07/13 06:00 MHDA- 2022/02/10 06:00 CRDT- 2021/07/12 17:22 PHST- 2021/07/13 06:00 [pubmed] PHST- 2022/02/10 06:00 [medline] PHST- 2021/07/12 17:22 [entrez] AID - 01586154-202201000-00022 [pii] AID - 10.1097/TA.0000000000003348 [doi] PST - ppublish SO - J Trauma Acute Care Surg. 2022 Jan 1;92(1):126-134. doi: 10.1097/TA.0000000000003348. PMID- 34251127 OWN - NLM STAT- MEDLINE DCOM- 20210722 LR - 20221207 IS - 3135-8225 (Electronic) IS - 1565-1088 (Linking) VI - 23 IP - 7 DP - 2021 Jul TI - Anesthesia in Parturients Presenting with Marfan Syndrome. PG - 437-440 AB - BACKGROUND: Pregnant women with Marfan syndrome (MS) have a high risk of aortic dissection around delivery and their optimal management requires a multi-disciplinary approach, including proper cardio-obstetric care and adequate pain management during labor, which may be difficult due to the high prevalence of dural ectasia (DE) in these patients. OBJECTIVES: To evaluate the multidisciplinary management of MS patients during labor. METHODS: Nineteen pregnant women (31 pregnancies) with MS were followed by a multi-disciplinary team (cardiologist, obstetrician, anesthesiologist) prior to delivery. RESULTS: Two patients had kyphoscoliosis; none had previous spine surgery nor complaints compatible with DE. In eight pregnancies (7 patients), aortic root diameter (ARd) before pregnancy was 40 to 46 mm. In this high-risk group, one patient underwent elective termination, two underwent an urgent cesarean section (CS) under general anesthesia, and five had elective CS; two under general anesthesia (GA), and three under spinal anesthesia. In 23 pregnancies (12 patients), ARd was < 40 mm. In this non-high-risk group three pregnancies (1 patient) were electively terminated. Of the remaining 20 deliveries (11 patients), 14 were vaginal deliveries, 9 with epidural analgesia and 5 without. Six patients had a CS; four under GA and two2 under spinal anesthesia. There were no epidural placement failures and no failed responses. There were 2 cases of aortic dissection, unrelated to the anesthetic management. CONCLUSIONS: The optimal anesthetic strategy during labor in MS patients should be decided by a multi-disciplinary team. Anesthetic complications due to DE were not encountered during neuraxial block. FAU - Weinstein, Jacob AU - Weinstein J AD - Department of Anesthesiology, Sheba Medical Center, Tel Hashomer, Israel. AD - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. FAU - Shinfeld, Amichai AU - Shinfeld A AD - Department of Cardiac Surgery, Sheba Medical Center, Tel Hashomer, Israel. AD - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. FAU - Simchen, Michal AU - Simchen M AD - Department of Obstetrics and Gynecology, Sheba Medical Center, Tel Hashomer, Israel. AD - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. FAU - Cahan, Tal AU - Cahan T AD - Department of Obstetrics and Gynecology, Sheba Medical Center, Tel Hashomer, Israel. AD - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. FAU - Frogel, Jonathan AU - Frogel J AD - Department of Anesthesiology, Sheba Medical Center, Tel Hashomer, Israel. AD - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. FAU - Arad, Michael AU - Arad M AD - Leviev Heart Center, Sheba Medical Center, Tel Hashomer, Israel. AD - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. FAU - Berkenstadt, Haim AU - Berkenstadt H AD - Department of Anesthesiology, Sheba Medical Center, Tel Hashomer, Israel. AD - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. FAU - Kuperstein, Rafael AU - Kuperstein R AD - Leviev Heart Center, Sheba Medical Center, Tel Hashomer, Israel. AD - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. LA - eng PT - Journal Article PL - Israel TA - Isr Med Assoc J JT - The Israel Medical Association journal : IMAJ JID - 100930740 SB - IM MH - Adult MH - *Anesthesia, Obstetrical/adverse effects/methods/statistics & numerical data MH - *Aortic Dissection/diagnosis/prevention & control MH - *Aortic Diseases/complications/diagnosis/etiology MH - *Delivery, Obstetric/adverse effects/methods/statistics & numerical data MH - Female MH - Humans MH - Interdisciplinary Communication MH - Israel/epidemiology MH - *Marfan Syndrome/complications/epidemiology/physiopathology MH - Monitoring, Physiologic/methods MH - *Obstetric Labor Complications/diagnosis/etiology/prevention & control MH - Outcome and Process Assessment, Health Care MH - Pregnancy MH - *Pregnancy Complications/diagnosis/physiopathology/therapy MH - Pregnancy Outcome/epidemiology MH - Pregnancy, High-Risk EDAT- 2021/07/13 06:00 MHDA- 2021/07/23 06:00 CRDT- 2021/07/12 09:09 PHST- 2021/07/12 09:09 [entrez] PHST- 2021/07/13 06:00 [pubmed] PHST- 2021/07/23 06:00 [medline] PST - ppublish SO - Isr Med Assoc J. 2021 Jul;23(7):437-440. PMID- 34243155 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240814 IS - 1933-0715 (Electronic) IS - 1933-0707 (Linking) VI - 28 IP - 3 DP - 2021 Sep 1 TI - Acute neurological injury in pediatric patients with single-ventricle congenital heart disease. PG - 335-343 LID - 10.3171/2021.2.PEDS2142 [doi] AB - OBJECTIVE: Single-ventricle congenital heart disease (CHD) in pediatric patients with Glenn and Fontan physiology represents a unique physiology requiring the surgical diversion of the systemic venous return from the superior vena cava (Glenn) and then the inferior vena cava (Fontan) directly to the pulmonary arteries. Because many of these patients are on chronic anticoagulation therapy and may have right-to-left shunts, arrhythmias, or lymphatic disorders that predispose them to bleeding and/or clotting, they are at risk of experiencing neurological injury requiring intubation and positive pressure ventilation, which can significantly hamper pulmonary blood flow and cardiac output. The aim of this study was to describe the complex neurological and cardiopulmonary interactions of these pediatric patients after acute central nervous system (CNS) injury. METHODS: The authors retrospectively analyzed the records of pediatric patients who had been admitted to a quaternary children's hospital with CHD palliated to bidirectional Glenn (BDG) or Fontan circulation and acute CNS injury and who had undergone intubation and mechanical ventilation. Patients who had been admitted from 2005 to 2019 were included in the study. Clinical characteristics, surgical outcomes, cardiovascular and pulmonary data, and intracranial pressure data were collected and analyzed. RESULTS: Nine pediatric single-ventricle patients met the study inclusion criteria. All had undergone the BDG procedure, and the majority (78%) were status post Fontan palliation. The mean age was 7.4 years (range 1.3-17.3 years). At the time of acute CNS injury, which included traumatic brain injury, intracranial hemorrhage, and cerebral infarct, the median time interval from the most recent cardiac surgical procedure was 3 years (range 2 weeks-11 years). Maintaining normocarbia to mild hypercarbia for most patients during intubation periods did not cause neurological deterioration, and hemodynamic profiles were more favorable as compared to periods of hypocarbia. Hypocarbia was associated with unfavorable hemodynamics but was necessary to decrease intracranial hypertension. Most patients were managed using low mean airway pressure (MAWP) in order to minimize the impact on preload and cardiac output. CONCLUSIONS: The authors highlight the complex neurological and cardiopulmonary interactions with respect to partial pressure of arterial CO2 (PaCO2) and MAWP when pediatric CHD patients with single-ventricle physiology require mechanical ventilation. The study data demonstrated that tight control of PaCO2 and minimizing MAWP with the goal of early extubation may be beneficial in this population. A multidisciplinary team of pediatric critical care intensivists, cardiac intensivists and anesthesiologists, and pediatric neurosurgeons and neurologists are recommended to ensure the best possible outcomes. FAU - Lang, Shih-Shan AU - Lang SS AD - 1Division of Neurosurgery, Children's Hospital of Philadelphia, Department of Neurosurgery, University of Pennsylvania, Perelman School of Medicine, Philadelphia. AD - 2Center for Data Driven Discovery in Biomedicine, Children's Hospital of Philadelphia, Philadelphia. FAU - Valeri, Amber AU - Valeri A AD - 3Department of Neurosurgery, Philadelphia College of Osteopathic Medicine, Philadelphia. FAU - Storm, Phillip B AU - Storm PB AD - 1Division of Neurosurgery, Children's Hospital of Philadelphia, Department of Neurosurgery, University of Pennsylvania, Perelman School of Medicine, Philadelphia. AD - 2Center for Data Driven Discovery in Biomedicine, Children's Hospital of Philadelphia, Philadelphia. FAU - Heuer, Gregory G AU - Heuer GG AD - 1Division of Neurosurgery, Children's Hospital of Philadelphia, Department of Neurosurgery, University of Pennsylvania, Perelman School of Medicine, Philadelphia. AD - 2Center for Data Driven Discovery in Biomedicine, Children's Hospital of Philadelphia, Philadelphia. FAU - Tucker, Alexander M AU - Tucker AM AD - 1Division of Neurosurgery, Children's Hospital of Philadelphia, Department of Neurosurgery, University of Pennsylvania, Perelman School of Medicine, Philadelphia. AD - 2Center for Data Driven Discovery in Biomedicine, Children's Hospital of Philadelphia, Philadelphia. FAU - Kennedy, Benjamin C AU - Kennedy BC AD - 1Division of Neurosurgery, Children's Hospital of Philadelphia, Department of Neurosurgery, University of Pennsylvania, Perelman School of Medicine, Philadelphia. AD - 2Center for Data Driven Discovery in Biomedicine, Children's Hospital of Philadelphia, Philadelphia. FAU - Kozyak, Benjamin W AU - Kozyak BW AD - 4Department of Anesthesiology and Critical Care Medicine, Children's Hospital of Philadelphia, University of Pennsylvania, Perelman School of Medicine, Philadelphia. AD - 5Division of Cardiac Critical Care Medicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; and. FAU - Sinha, Anjuli AU - Sinha A AD - 4Department of Anesthesiology and Critical Care Medicine, Children's Hospital of Philadelphia, University of Pennsylvania, Perelman School of Medicine, Philadelphia. AD - 6Division of Pediatric Cardiology, Lucile Packard Stanford Children's Hospital, Palo Alto, California. FAU - Kilbaugh, Todd J AU - Kilbaugh TJ AD - 4Department of Anesthesiology and Critical Care Medicine, Children's Hospital of Philadelphia, University of Pennsylvania, Perelman School of Medicine, Philadelphia. FAU - Huh, Jimmy W AU - Huh JW AD - 4Department of Anesthesiology and Critical Care Medicine, Children's Hospital of Philadelphia, University of Pennsylvania, Perelman School of Medicine, Philadelphia. LA - eng PT - Journal Article DEP - 20210709 PL - United States TA - J Neurosurg Pediatr JT - Journal of neurosurgery. Pediatrics JID - 101463759 SB - IM OTO - NOTNLM OT - Fontan physiology OT - Glenn physiology OT - carbon dioxide OT - cerebral ischemia OT - congenital heart disease OT - intracranial hemorrhage OT - intracranial hypertension OT - mean airway pressure OT - pediatric OT - trauma OT - traumatic brain injury OT - vascular disorders EDAT- 2021/07/10 06:00 MHDA- 2021/07/10 06:01 CRDT- 2021/07/09 20:35 PHST- 2021/01/20 00:00 [received] PHST- 2021/02/22 00:00 [accepted] PHST- 2021/07/10 06:01 [medline] PHST- 2021/07/10 06:00 [pubmed] PHST- 2021/07/09 20:35 [entrez] AID - 10.3171/2021.2.PEDS2142 [doi] PST - epublish SO - J Neurosurg Pediatr. 2021 Jul 9;28(3):335-343. doi: 10.3171/2021.2.PEDS2142. Print 2021 Sep 1. PMID- 34239633 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210710 IS - 1881-641X (Print) IS - 1881-6428 (Electronic) IS - 1881-641X (Linking) VI - 14 IP - 2 DP - 2021 Jun 25 TI - Deep Vein Thrombosis (DVT) Prophylactic Team Activity to Support DVT Prevention Protocol for the Purpose of the Prophylaxis of Pulmonary Thromboembolism (PTE) and Operation. PG - 99-107 LID - 10.3400/avd.oa.21-00017 [doi] AB - Objective: In 2017, the Medical Accident Investigation and Support center in Japan released an analysis of acute pulmonary thromboembolism (PTE) related mortality. This recommendation called for maintaining a "team in charge of PTE's risk assessment, prevention, diagnosis and treatment" and preventing PTE through team activities. Therefore, we recommended establishing a deep vein thrombosis (DVT) prevention team. Before this recommendation, a multidisciplinary DVT prevention team was established in our hospital, with excellent outcomes. In the current study, we report the results of the DVT prevention team. Methods: Our multidisciplinary team consisted of several departments: Cardiovascular Surgery, ward nurses, medical safety managers, and clerks. The following themes were launched: 1) preparation of DVT prevention protocol; 2) preparation of DVT preventive manual; 3) regular round for evaluating DVT preventive measures; 4) staff education. The protocol's strong point was that nurses evaluated patients over 16-year-old with Wells' score for DVT on admission. We retrospectively investigated the diagnosis rate of DVT and PTE for 9 months before and after protocol operation. Results: The diagnosis rate of DVT was significantly improved after protocol implementation (before: 0.06% vs. after: 0.56%, p=0.0017). However, no significant difference was observed in the diagnosis rate of PTE before and after the protocol execution (before: 0.03% vs. after: 0.07%, p=0.98). Conclusion: Our DVT prophylactic protocol improved the diagnostic rate of DVT resulting in a decrease of PTE in our hospital. (This is a translation of Jpn J Phlebol 2019; 30(3): 285-293.). CI - (c) 2021 The Editorial Committee of Annals of Vascular Diseases. FAU - Tamura, Shozo AU - Tamura S AD - Department of Medical Safety room, Ako Central Hospital, Ako, Hyogo, Japan. FAU - Yamamoto, Mai AU - Yamamoto M AD - Department of Nursing, Ako Central Hospital, Ako, Hyogo, Japan. FAU - Kitagawa, Atsushi AU - Kitagawa A AD - Department of Cardiovascular Surgery, Ako Central Hospital, Ako, Hyogo, Japan. FAU - Nagao, Toshihiko AU - Nagao T AD - Department of Cardiovascular Surgery, Ako Central Hospital, Ako, Hyogo, Japan. LA - eng PT - Journal Article PL - Japan TA - Ann Vasc Dis JT - Annals of vascular diseases JID - 101471467 PMC - PMC8241545 OTO - NOTNLM OT - Wells' score for DVT OT - deep vein thrombosis OT - prophylactic team OT - protocol OT - pulmonary thromboembolism COIS- Disclosure StatementAll authors report no potential conflicts. EDAT- 2021/07/10 06:00 MHDA- 2021/07/10 06:01 PMCR- 2021/06/25 CRDT- 2021/07/09 06:57 PHST- 2021/01/28 00:00 [received] PHST- 2021/02/15 00:00 [accepted] PHST- 2021/07/09 06:57 [entrez] PHST- 2021/07/10 06:00 [pubmed] PHST- 2021/07/10 06:01 [medline] PHST- 2021/06/25 00:00 [pmc-release] AID - 10.3400/avd.oa.21-00017 [doi] PST - ppublish SO - Ann Vasc Dis. 2021 Jun 25;14(2):99-107. doi: 10.3400/avd.oa.21-00017. PMID- 34238793 OWN - NLM STAT- MEDLINE DCOM- 20211108 LR - 20230912 IS - 1535-2811 (Electronic) IS - 1535-2811 (Linking) VI - 20 IP - 3 DP - 2021 Sep 1 TI - Promoting Cardiac Rehabilitation in Acute Coronary Syndrome Patients: Quality Initiative Based on Education, Automated Referral, and Multidisciplinary Rounds. PG - 115-118 LID - 10.1097/HPC.0000000000000263 [doi] AB - Cardiac rehabilitation is a class 1 recommendation for acute coronary syndrome (ACS) patients according to the American College of Cardiology/American Heart Association. However, only 1 in 5 ACS patients are referred for cardiac rehabilitation nationally, and even fewer at our institution. We sought to improve the number of referrals to cardiac rehabilitation for post-ACS patients admitted to our inpatient cardiology service, and ultimately their participation in the program. We designed a quality improvement initiative that included education of patients and house staff, automated referral order, and participation of cardiac rehabilitation staff members on multidisciplinary rounds. We compared the number of patients who received a referral to cardiac rehabilitation, had the first appointment scheduled before hospital discharge, and attended the program before and after our intervention. Six months after initiation of the project, the proportion of ACS patients referred to cardiac rehabilitation before hospital discharge increased from 10% to 43% (P < 0.001). The mean number of patients with a cardiac rehabilitation appointment scheduled before discharge was 2 before and 5 after the intervention (P < 0.001), and the mean number of patients who attended their scheduled appointment was 1 before and 3 after the intervention (P = 0.001). Run charts demonstrated that the number of referrals and the number of scheduled appointments remained above the median following the intervention. In conclusion, an initiative that included education, automated referrals, and direct one-on-one contact with cardiac rehabilitation staff before discharge increased the number of cardiac rehabilitation referrals, and appointments scheduled and attended in post-ACS patients. CI - Copyright (c) 2021 Wolters Kluwer Health, Inc. All rights reserved. FAU - Matthia, Eldon L AU - Matthia EL AD - From the Department of Medicine. FAU - Mohadjer, Ashley AU - Mohadjer A AD - Division of Cardiovascular Medicine, University of Florida, Gainesville, FL. FAU - Randall, Morgan H AU - Randall MH AD - Division of Cardiovascular Medicine, University of Florida, Gainesville, FL. FAU - Canha, Catarina AU - Canha C AD - Division of Cardiovascular Medicine, University of Florida, Gainesville, FL. FAU - Warren, Elizabeth AU - Warren E AD - Division of Cardiovascular Medicine, University of Florida, Gainesville, FL. FAU - Ashraf, Hassan M AU - Ashraf HM AD - From the Department of Medicine. FAU - Plasschaert, Jeffrey M AU - Plasschaert JM AD - Division of Cardiovascular Medicine, University of Florida, Gainesville, FL. FAU - Winchester, David E AU - Winchester DE AD - Division of Cardiovascular Medicine, University of Florida, Gainesville, FL. FAU - Keeley, Ellen C AU - Keeley EC AD - Division of Cardiovascular Medicine, University of Florida, Gainesville, FL. LA - eng PT - Journal Article PL - United States TA - Crit Pathw Cardiol JT - Critical pathways in cardiology JID - 101165286 SB - IM MH - *Acute Coronary Syndrome MH - *Cardiac Rehabilitation MH - Humans MH - Patient Discharge MH - Quality Improvement MH - Referral and Consultation EDAT- 2021/07/10 06:00 MHDA- 2021/11/09 06:00 CRDT- 2021/07/09 06:11 PHST- 2021/07/10 06:00 [pubmed] PHST- 2021/11/09 06:00 [medline] PHST- 2021/07/09 06:11 [entrez] AID - 00132577-202109000-00001 [pii] AID - 10.1097/HPC.0000000000000263 [doi] PST - ppublish SO - Crit Pathw Cardiol. 2021 Sep 1;20(3):115-118. doi: 10.1097/HPC.0000000000000263. PMID- 34236825 OWN - NLM STAT- MEDLINE DCOM- 20211215 LR - 20220531 IS - 1678-9741 (Electronic) IS - 0102-7638 (Print) IS - 0102-7638 (Linking) VI - 36 IP - 3 DP - 2021 Dec 9 TI - Teams, Rapid Recovery Protocols and Technology to Resume Cardiac Surgery in the COVID-19 Era. PG - 822-824 LID - 10.21470/1678-9741-2021-0035 [doi] AB - The coronavirus disease 2019 (COVID-19) pandemic brings numerous challenges to the health ecosystem, including the safe resumption of elective cardiac surgery. In the pre-pandemic period, rapid recovery protocols demonstrated, through strategies focused on the multidisciplinary approach, reduction of hospital length of stay, infection rates and, consequently, costs. Even with several studies proving the benefits of these protocols, their acceptance and implementation have been slow. It is believed that the resumption of surgeries in the current context requires the use of rapid recovery protocols combined with the use of a mobile application promoting greater engagement between patients, caregivers and care teams. FAU - Lima, Mariana Kabakura do Amaral AU - Lima MKDA AD - Instituto do Coracao do Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo (INCOR), Sao Paulo, Brazil. FAU - Borgomoni, Gabrielle Barbosa AU - Borgomoni GB AD - Instituto do Coracao do Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo (INCOR), Sao Paulo, Brazil. AD - Hospital Samaritano Paulista, Sao Paulo, Brazil. FAU - Mejia, Omar Asdrubal Vilca AU - Mejia OAV AUID- ORCID: 0000-0002-1635-4984 AD - Instituto do Coracao do Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo (INCOR), Sao Paulo, Brazil. AD - Hospital Samaritano Paulista, Sao Paulo, Brazil. LA - eng PT - Journal Article DEP - 20211209 PL - Brazil TA - Braz J Cardiovasc Surg JT - Brazilian journal of cardiovascular surgery JID - 101677045 SB - IM MH - *COVID-19 MH - *Cardiac Surgical Procedures MH - Elective Surgical Procedures MH - Enhanced Recovery After Surgery MH - Humans MH - Mobile Applications MH - Patient Care Team MH - *Technology PMC - PMC8641763 OTO - NOTNLM OT - Cardiovascular Surgical Procedures OT - Coronavirus Infections OT - Patient Safety OT - Quality Improvement OT - Technology COIS- No conflict of interest. EDAT- 2021/07/09 06:00 MHDA- 2021/12/16 06:00 PMCR- 2021/11/01 CRDT- 2021/07/08 15:21 PHST- 2021/07/09 06:00 [pubmed] PHST- 2021/12/16 06:00 [medline] PHST- 2021/07/08 15:21 [entrez] PHST- 2021/11/01 00:00 [pmc-release] AID - 10.21470/1678-9741-2021-0035 [doi] PST - epublish SO - Braz J Cardiovasc Surg. 2021 Dec 9;36(3):822-824. doi: 10.21470/1678-9741-2021-0035. PMID- 34234917 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220424 IS - 2000-9666 (Print) IS - 2000-9666 (Electronic) IS - 2000-9666 (Linking) VI - 11 IP - 3 DP - 2021 TI - AL type cardiac amyloidosis: a devastating fatal disease. PG - 407-412 LID - 10.1080/20009666.2021.1915547 [doi] AB - INTRODUCTION: Cardiac amyloidosis is a rare entity with a grave prognosis. Due to the low index of suspicion secondary to non-specific symptoms, it is often diagnosed at an advanced stage with multi-organ involvement. METHODS: We report a case of systemic AL amyloidosis with predominant cardiac and renal involvement associated with multiple myeloma. CASE SUMMARY: A 60-year-old male presented with progressive anasarca, orthopnea and weight gain over 8 months. On clinical examination, 3+ pitting edema was found in bilateral extremities and scrotum. Serum N-type proBNP and troponin T were elevated, and EKG showed diffuse low voltage QRS, right axis deviation, and 1(st) degree AV block. Echocardiography revealed granular myocardium, biventricular hypertrophy, bi-atrial dilation and apical sparing pattern on global longitudinal strain which was suggestive of cardiac amyloidosis. Light chain assessment showed elevated kappa and lambda chains with kappa to lambda ratio of 16.2. Endomyocardial biopsy revealed AL type cardiac amyloidosis, and bone marrow biopsy confirmed the diagnosis of multiple myeloma. He received six cycles of bortezomib, cyclophosphamide, and dexamethasone but continued to deteriorate. He experienced an episode of cardiac arrest following which he had a return of spontaneous circulation but due to poor prognosis, the family opted for pursuing comfort measures only. CONCLUSIONS: Cardiac involvement in AL type amyloidosis imparts significant morbidity and mortality. The management of cardiac amyloidosis entails a multidisciplinary approach with an emphasis on cardiology and oncology. Despite the novel diagnostic modalities and treatment regimens, the outcome for AL-type cardiac amyloidosis remains poor. CI - (c) 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group on behalf of Greater Baltimore Medical Center. FAU - Nasrullah, Adeel AU - Nasrullah A AD - Department of Medicine, Allegheny Health Network, Pittsburgh, USA. FAU - Javed, Anam AU - Javed A AD - Department of Medicine, Allegheny Health Network, Pittsburgh, USA. FAU - Jayakrishnan, Thejus T AU - Jayakrishnan TT AD - Department of Medicine, Allegheny Health Network, Pittsburgh, USA. FAU - Brumbaugh, Aaron AU - Brumbaugh A AD - Department of Radiology, Allegheny Health Network, Pittsburgh, USA. FAU - Sandhu, Ariel AU - Sandhu A AD - Department of Pathology, Allegheny Health Network, Pittsburgh, USA. FAU - Hardman, Brent AU - Hardman B AD - Department of Medicine, Allegheny Health Network, Pittsburgh, USA. LA - eng PT - Journal Article DEP - 20210510 PL - United States TA - J Community Hosp Intern Med Perspect JT - Journal of community hospital internal medicine perspectives JID - 101601396 PMC - PMC8118408 OTO - NOTNLM OT - Al type amyloidosis OT - Cardiac Failure OT - Multiple Myeloma OT - Renal Failure COIS- No potential conflict of interest was reported by the author(s). EDAT- 2021/07/09 06:00 MHDA- 2021/07/09 06:01 PMCR- 2021/05/10 CRDT- 2021/07/08 06:41 PHST- 2021/07/08 06:41 [entrez] PHST- 2021/07/09 06:00 [pubmed] PHST- 2021/07/09 06:01 [medline] PHST- 2021/05/10 00:00 [pmc-release] AID - 1915547 [pii] AID - 10.1080/20009666.2021.1915547 [doi] PST - epublish SO - J Community Hosp Intern Med Perspect. 2021 May 10;11(3):407-412. doi: 10.1080/20009666.2021.1915547. eCollection 2021. PMID- 34228177 OWN - NLM STAT- MEDLINE DCOM- 20210906 LR - 20261010 IS - 1435-1544 (Electronic) IS - 0938-7412 (Linking) VI - 32 IP - 3 DP - 2021 Sep TI - Ablation therapy of postural orthostatic tachycardia syndrome, inappropriate sinus tachycardia and primary electrical diseases: new insights in invasive treatment options in severely symptomatic patients. PG - 323-329 LID - 10.1007/s00399-021-00778-z [doi] AB - Achieving the goal management of some arrhythmic syndromes can be challenging; medical treatment for inappropriate sinus tachycardia (IST) and postural orthostatic tachycardia syndrome (POTS) may be ineffective, necessitating multidisciplinary team treatment. Implantable defibrillator devices (ICDs), along with anti-arrhythmic drugs (AADs), remain the first-line treatment for primary electrical diseases that pose a risk of sudden cardiac death (SCD). Ablation of the arrhythmogenic substrate is not always suggested in patients with these pathologies, but it may be a valuable support for reducing arrhythmic burden, improving quality of life, and treating pathologies that are resistant to pharmacological treatment; however, this option is not often considered due to the potential risks associated with an invasive approach. Minimally invasive hybrid ablation in these syndromes, such as a hybrid thoracoscopic approach and the use of non-invasive mapping systems, reduces post-surgery complications and ensures the best possible outcome for the patient. CI - (c) 2021. Springer Medizin Verlag GmbH, ein Teil von Springer Nature. FAU - Monaco, Cinzia AU - Monaco C AD - Heart Rhythm Management Centre, Postgraduate Course in Cardiac Electrophysiology and Pacing, Vrije Universiteit Brussel, Universitair Ziekenhuis, Laarbeeklaan 101, 1090, Brussels, Belgium. FAU - Sorgente, Antonio AU - Sorgente A AD - Heart Rhythm Management Centre, Postgraduate Course in Cardiac Electrophysiology and Pacing, Vrije Universiteit Brussel, Universitair Ziekenhuis, Laarbeeklaan 101, 1090, Brussels, Belgium. FAU - Ramak, Robbert AU - Ramak R AD - Heart Rhythm Management Centre, Postgraduate Course in Cardiac Electrophysiology and Pacing, Vrije Universiteit Brussel, Universitair Ziekenhuis, Laarbeeklaan 101, 1090, Brussels, Belgium. FAU - Chierchia, Gian Battista AU - Chierchia GB AD - Heart Rhythm Management Centre, Postgraduate Course in Cardiac Electrophysiology and Pacing, Vrije Universiteit Brussel, Universitair Ziekenhuis, Laarbeeklaan 101, 1090, Brussels, Belgium. FAU - La Meir, Mark AU - La Meir M AD - Cardiac Surgery Department, Vrije Universiteit Brussel, Universitair Ziekenhuis Brussel, Brussels, Belgium. FAU - de Asmundis, Carlo AU - de Asmundis C AD - Heart Rhythm Management Centre, Postgraduate Course in Cardiac Electrophysiology and Pacing, Vrije Universiteit Brussel, Universitair Ziekenhuis, Laarbeeklaan 101, 1090, Brussels, Belgium. carlo.deasmundis@uzbrussel.be. LA - eng PT - Journal Article PT - Review TT - Ablationstherapie bei posturalem orthostatischen Tachykardiesyndrom, inadaquater Sinustachykardie und primaren elektromagnetischen Erkrankungen: neue Erkenntnisse zu invasiven Behandlungsmoglichkeiten bei schwer symptomatischen Patienten. DEP - 20210706 PL - Germany TA - Herzschrittmacherther Elektrophysiol JT - Herzschrittmachertherapie & Elektrophysiologie JID - 9425873 SB - IM EIN - Herzschrittmacherther Elektrophysiol. 2021 Sep;32(3):421. doi: 10.1007/s00399-021-00799-8. PMID: 34383178 MH - *Catheter Ablation MH - Death, Sudden, Cardiac MH - *Defibrillators, Implantable MH - Humans MH - *Postural Orthostatic Tachycardia Syndrome/diagnosis/therapy MH - Quality of Life MH - Tachycardia, Sinus/surgery/therapy OTO - NOTNLM OT - Arrhythmogenic substrate ablation OT - Electrocardiographic mapping OT - IST OT - POTS OT - Thoracoscopic hybrid ablation EDAT- 2021/07/07 06:00 MHDA- 2021/09/07 06:00 CRDT- 2021/07/06 13:19 PHST- 2021/04/20 00:00 [received] PHST- 2021/06/01 00:00 [accepted] PHST- 2021/07/07 06:00 [pubmed] PHST- 2021/09/07 06:00 [medline] PHST- 2021/07/06 13:19 [entrez] AID - 10.1007/s00399-021-00778-z [pii] AID - 10.1007/s00399-021-00778-z [doi] PST - ppublish SO - Herzschrittmacherther Elektrophysiol. 2021 Sep;32(3):323-329. doi: 10.1007/s00399-021-00778-z. Epub 2021 Jul 6. PMID- 34224723 OWN - NLM STAT- MEDLINE DCOM- 20220525 LR - 20220610 IS - 1552-6259 (Electronic) IS - 0003-4975 (Linking) VI - 113 IP - 6 DP - 2022 Jun TI - Routine Collection of Patient-Reported Outcomes in Thoracic Surgery: A Quality Improvement Study. PG - 1845-1852 LID - S0003-4975(21)01097-3 [pii] LID - 10.1016/j.athoracsur.2021.05.091 [doi] AB - BACKGROUND: Patient-reported outcomes are critical for delivering high-quality surgical care, yet they are seldom collected in routine clinical practice. The objective of this quality improvement study was to improve routine patient-reported outcomes collection in a thoracic surgery clinic. METHODS: Thoracic surgery patients at a single academic institution were prospectively monitored from April 2019 to March 2020. The National Institutes of Health-validated Patient-Reported Outcomes Measurement Information System (PROMIS) was used. Using a Model for Improvement design and through multidisciplinary participant observation, we performed multiple plan-do-study-act cycles, an iterative, 4-stage model for rapidly testing interventions, to improve routine collection reliability. RESULTS: During the study period, 2315 patient visits occurred. The baseline PROMIS assessment collection rate was 53%. After convening a multidisciplinary stakeholder team, the key drivers for PROMIS collection were having engaged staff, engaged patients, adequate technological capacity, and adequate time for survey completion, including when to complete the survey during the patient visits. Regular meetings between stakeholders were initiated to promote these key drivers. Several plan-do-study-act cycles were then used to test different interventions, resulting in several positive system shifts, as demonstrated on a statistical process control chart. Adherence to survey collection reached 91% of office visits by approximately 7 months, a 72% relative improvement, which was sustained. CONCLUSIONS: Routine collection of patient-reported outcomes, such as PROMIS, are critical for improving thoracic surgical care. Our study shows that reliably collecting these data is possible in a clinical setting with minimal additional hospital resources. CI - Copyright (c) 2022 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved. FAU - Heiden, Brendan T AU - Heiden BT AD - Division of Cardiothoracic Surgery, Washington University in St. Louis School of Medicine, St Louis, Missouri. FAU - Subramanian, Melanie P AU - Subramanian MP AD - Division of Cardiothoracic Surgery, Washington University in St. Louis School of Medicine, St Louis, Missouri. FAU - Nava, Ruben G AU - Nava RG AD - Division of Cardiothoracic Surgery, Washington University in St. Louis School of Medicine, St Louis, Missouri. FAU - Patterson, Alexander G AU - Patterson AG AD - Division of Cardiothoracic Surgery, Washington University in St. Louis School of Medicine, St Louis, Missouri. FAU - Meyers, Bryan F AU - Meyers BF AD - Division of Cardiothoracic Surgery, Washington University in St. Louis School of Medicine, St Louis, Missouri. FAU - Puri, Varun AU - Puri V AD - Division of Cardiothoracic Surgery, Washington University in St. Louis School of Medicine, St Louis, Missouri. FAU - Oncken, Christian AU - Oncken C AD - Division of Cardiothoracic Surgery, Washington University in St. Louis School of Medicine, St Louis, Missouri. FAU - Keith, Angela AU - Keith A AD - Division of Cardiothoracic Surgery, Washington University in St. Louis School of Medicine, St Louis, Missouri. FAU - Guthrie, Tracey J AU - Guthrie TJ AD - Division of Cardiothoracic Surgery, Washington University in St. Louis School of Medicine, St Louis, Missouri. FAU - Epstein, Deirdre J AU - Epstein DJ AD - Division of Cardiothoracic Surgery, Washington University in St. Louis School of Medicine, St Louis, Missouri. FAU - Lenk, Mary Anne AU - Lenk MA AD - James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital, Cincinnati, Ohio. FAU - Kozower, Benjamin D AU - Kozower BD AD - Division of Cardiothoracic Surgery, Washington University in St. Louis School of Medicine, St Louis, Missouri. Electronic address: kozower@wustl.edu. LA - eng PT - Journal Article DEP - 20210702 PL - Netherlands TA - Ann Thorac Surg JT - The Annals of thoracic surgery JID - 15030100R SB - IM MH - Humans MH - Patient Reported Outcome Measures MH - *Quality Improvement MH - Reproducibility of Results MH - Surveys and Questionnaires MH - *Thoracic Surgery EDAT- 2021/07/06 06:00 MHDA- 2022/05/26 06:00 CRDT- 2021/07/05 20:11 PHST- 2021/01/16 00:00 [received] PHST- 2021/05/03 00:00 [revised] PHST- 2021/05/31 00:00 [accepted] PHST- 2021/07/06 06:00 [pubmed] PHST- 2022/05/26 06:00 [medline] PHST- 2021/07/05 20:11 [entrez] AID - S0003-4975(21)01097-3 [pii] AID - 10.1016/j.athoracsur.2021.05.091 [doi] PST - ppublish SO - Ann Thorac Surg. 2022 Jun;113(6):1845-1852. doi: 10.1016/j.athoracsur.2021.05.091. Epub 2021 Jul 2. PMID- 34223393 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220424 IS - 2666-5204 (Electronic) IS - 2666-5204 (Linking) VI - 7 DP - 2021 Sep TI - Can hospital adult code-teams and individual members perform high-quality CPR? A multicenter simulation-based study incorporating an educational intervention with CPR feedback. PG - 100126 LID - 10.1016/j.resplu.2021.100126 [doi] LID - 100126 AB - AIMS: A multicenter simulation-based research study to assess the ability of interprofessional code-teams and individual members to perform high-quality CPR (HQ-CPR) at baseline and following an educational intervention with a CPR feedback device. METHODS: Five centers recruited ten interprofessional teams of AHA-certified adult code-team members with a goal of 200 participants. Baseline testing of chest compression (CC) quality was measured for all individuals. Teams participated in a baseline simulated cardiac arrest (SCA) where CC quality, chest compression fraction (CCF), and peri-shock pauses were recorded. Teams participated in a standardized HQ-CPR and abbreviated TeamSTEPPS(R) didactic, then engaged in deliberate practice with a CPR feedback device. Individuals were assessed to determine if they could achieve >/=80% combined rate and depth within 2020 AHA guidelines. Teams completed a second SCA and CPR metrics were recorded. Feedback was disabled for assessments except at one site where real-time CPR feedback was the institutional standard. Linear regression models were used to test for site effect and paired t-tests to evaluate significant score changes. Logistic univariate regression models were used to explore characteristics associated with the individual achieving competency. RESULTS: Data from 184 individuals and 45 teams were analyzed. Baseline HQ-CPR mean score across all sites was 18.5% for individuals and 13.8% for teams. Post-intervention HQ-CPR mean score was 59.8% for individuals and 37.0% for teams. There was a statistically significant improvement in HQ-CPR mean scores of 41.3% (36.1, 46.5) for individuals and 23.2% (17.1, 29.3) for teams (p < 0.0001). CCF increased at 3 out of 5 sites and there was a mean 5-s reduction in peri-shock pauses (p < 0.0001). Characteristics with a statistically significant association were height (p = 0.01) and number of times performed CPR (p = 0.01). CONCLUSION: Code-teams and individuals struggle to perform HQ-CPR but show improvement after deliberate practice with feedback as part of an educational intervention. Only one site that incorporated real-time CPR feedback devices routinely achieved >/=80% HQ-CPR. CI - (c) 2021 The Authors. FAU - Rideout, Jesse M AU - Rideout JM AD - Department of Emergency Medicine, Tufts Medical Center, United States. FAU - Ozawa, Edwin T AU - Ozawa ET AD - Department of Anesthesiology, Lahey Hospital & Medical Center, United States. FAU - Bourgeois, Darlene J AU - Bourgeois DJ AD - Center for Professional Development & Simulation, Lahey Hospital & Medical Center, United States. FAU - Chipman, Micheline AU - Chipman M AD - Hannaford Center for Safety, Innovation & Simulation, Maine Medical Center, United States. FAU - Overly, Frank L AU - Overly FL AD - Brown Emergency Medicine and Pediatrics, Hasbro Children's Hospital, United States. LA - eng PT - Journal Article DEP - 20210612 PL - Netherlands TA - Resusc Plus JT - Resuscitation plus JID - 101774410 PMC - PMC8244252 OTO - NOTNLM OT - Basic life support OT - CPR feedback device OT - Deliberate practice OT - High-quality CPR OT - In-hospital cardiac arrest OT - Inter-professional team training OT - Simulation EDAT- 2021/07/06 06:00 MHDA- 2021/07/06 06:01 PMCR- 2021/06/12 CRDT- 2021/07/05 10:24 PHST- 2021/01/29 00:00 [received] PHST- 2021/04/03 00:00 [revised] PHST- 2021/04/12 00:00 [accepted] PHST- 2021/07/05 10:24 [entrez] PHST- 2021/07/06 06:00 [pubmed] PHST- 2021/07/06 06:01 [medline] PHST- 2021/06/12 00:00 [pmc-release] AID - S2666-5204(21)00051-5 [pii] AID - 100126 [pii] AID - 10.1016/j.resplu.2021.100126 [doi] PST - epublish SO - Resusc Plus. 2021 Jun 12;7:100126. doi: 10.1016/j.resplu.2021.100126. eCollection 2021 Sep. PMID- 34223314 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250130 IS - 2666-5204 (Electronic) IS - 2666-5204 (Linking) VI - 4 DP - 2020 Dec TI - Cardiac arrest: An interdisciplinary scoping review of the literature from 2019. PG - 100037 LID - 10.1016/j.resplu.2020.100037 [doi] LID - 100037 AB - OBJECTIVES: The Interdisciplinary Cardiac Arrest Research Review (ICARE) group was formed in 2018 to conduct a systematic annual search of peer-reviewed literature relevant to cardiac arrest. Now in its second year, the goals of the review are to illustrate best practices in research and help reduce compartmentalization of knowledge by disseminating clinically relevant advances in the field of cardiac arrest across disciplines. METHODS: An electronic search of PubMed using keywords related to cardiac arrest was conducted. Title and abstracts retrieved by these searches were screened for relevance, classified by article type (original research or review), and sorted into 7 categories. Screened manuscripts underwent standardized scoring of overall methodological quality and impact on the categorized fields of study by reviewer teams lead by a subject-matter expert editor. Articles scoring higher than 99 percentiles by category-type were selected for full critique. Systematic differences between editors' and reviewers' scores were assessed using Wilcoxon signed-rank test. RESULTS: A total of 3348 articles were identified on initial search; of these, 1364 were scored after screening for relevance and deduplication, and forty-five underwent full critique. Epidemiology & Public Health represented 24% of fully reviewed articles with Prehospital Resuscitation, Technology & Care, and In-Hospital Resuscitation & Post-Arrest Care Categories both representing 20% of fully reviewed articles. There were no significant differences between editor and reviewer scoring. CONCLUSIONS: The sheer number of articles screened is a testament to the need for an accessible source calling attention to high-quality and impactful research and serving as a high-yield reference for clinicians and scientists seeking to follow the ever-growing body of cardiac arrest-related literature. This will promote further development of the unique and interdisciplinary field of cardiac arrest medicine. CI - (c) 2020 The Author(s). FAU - Murphy, Travis W AU - Murphy TW AD - Division of Critical Care Medicine, Department of Emergency Medicine, University of Florida, Gainesville, FL, USA. AD - Department of Emergency Medicine, University of Florida, Gainesville, FL, USA. FAU - Cohen, Scott A AU - Cohen SA AD - Department of Emergency Medicine, University of Florida, Gainesville, FL, USA. FAU - Avery, K Leslie AU - Avery KL AD - Division of Pediatric Critical Care, Department of Pediatrics, University of Florida, Gainesville, FL, USA. FAU - Balakrishnan, Meenakshi P AU - Balakrishnan MP AD - Department of Emergency Medicine, University of Florida, Gainesville, FL, USA. FAU - Balu, Ramani AU - Balu R AD - Division of Neurocritical Care, Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA. FAU - Chowdhury, Muhammad Abdul Baker AU - Chowdhury MAB AD - Department of Emergency Medicine, University of Florida, Gainesville, FL, USA. FAU - Crabb, David B AU - Crabb DB AD - Department of Emergency Medicine, University of Florida, Gainesville, FL, USA. FAU - Huesgen, Karl W AU - Huesgen KW AD - Department of Emergency Medicine, University of Florida, Gainesville, FL, USA. FAU - Hwang, Charles W AU - Hwang CW AD - Department of Emergency Medicine, University of Florida, Gainesville, FL, USA. FAU - Maciel, Carolina B AU - Maciel CB AD - Division of Neurocritical Care, Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA. AD - Department of Neurology, Yale University, New Haven, CT, USA. AD - Division of Neurocritical Care, Department of Neurology, University of Florida, Gainesville, FL, USA. FAU - Gul, Sarah S AU - Gul SS AD - Department of Surgery, Yale University, New Haven, CT, USA. FAU - Han, Francis AU - Han F AD - Department of Emergency Medicine, University of Florida, Gainesville, FL, USA. FAU - Becker, Torben K AU - Becker TK AD - Division of Critical Care Medicine, Department of Emergency Medicine, University of Florida, Gainesville, FL, USA. AD - Department of Emergency Medicine, University of Florida, Gainesville, FL, USA. CN - Interdisciplinary Cardiac Arrest Research Review (ICARE) group LA - eng GR - UL1 TR001863/TR/NCATS NIH HHS/United States PT - Journal Article PT - Scoping Review DEP - 20201104 PL - Netherlands TA - Resusc Plus JT - Resuscitation plus JID - 101774410 PMC - PMC8244427 OTO - NOTNLM OT - Cardiopulmonary resuscitation OT - Emergency medical services OT - Epidemiology OT - Heart arrest OT - Out-of-hospital cardiac arrest OT - Sudden cardiac death EDAT- 2021/07/06 06:00 MHDA- 2021/07/06 06:01 PMCR- 2020/11/04 CRDT- 2021/07/05 10:24 PHST- 2020/08/05 00:00 [received] PHST- 2020/09/29 00:00 [revised] PHST- 2020/10/04 00:00 [accepted] PHST- 2021/07/05 10:24 [entrez] PHST- 2021/07/06 06:00 [pubmed] PHST- 2021/07/06 06:01 [medline] PHST- 2020/11/04 00:00 [pmc-release] AID - S2666-5204(20)30037-0 [pii] AID - 100037 [pii] AID - 10.1016/j.resplu.2020.100037 [doi] PST - epublish SO - Resusc Plus. 2020 Nov 4;4:100037. doi: 10.1016/j.resplu.2020.100037. eCollection 2020 Dec. PMID- 34215967 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240402 IS - 2090-911X (Electronic) IS - 1110-2608 (Print) IS - 1110-2608 (Linking) VI - 73 IP - 1 DP - 2021 Jul 2 TI - Thymic carcinoma with extrinsic occlusion of the left anterior descending artery: a distinctive case of myocardial infarction in a young woman. PG - 60 LID - 10.1186/s43044-021-00178-1 [doi] LID - 60 AB - BACKGROUND: Thymic epithelial tumour (TET) is the most common tumour affecting the anterior mediastinum in adults. The cardiac extension is often limited to the pericardium, and intracardiac extension is rare. We present a unique case of encasement and displacement of the left anterior descending coronary artery by the large mediastinal tumour leading to myocardial ischemia. CASE PRESENTATION: Our patient is a 28-year-old lady with stage 4 TET. She presented with acute chest pain associated with 12-lead ECG changes and a significant rise in serial troponin I. Multimodality cardiac imaging revealed encasement and displacement of the left anterior descending coronary artery by the large mediastinal tumour. CT-FFR demonstrates evidence of ischemia which would account for her acute presentation. Following detailed MDT discussions between cardiologists, oncologists and cardiothoracic surgeons, the decision was made to treat this lady with palliative chemotherapy. Given the extent of the tumour invasion and failure of the initial therapy, her prognosis and the outcome were poor. CONCLUSIONS: TET could cause atrial compression, myocardial infiltration, and invasion of the pulmonary and caval veins; however, to the best of our knowledge, this is the first case reported of coronary artery displacement and encasement by TET. FAU - Ayuna, Ahmed AU - Ayuna A AUID- ORCID: 0000-0002-2059-8447 AD - Salford Royal NHS Foundation Trust, Manchester, UK. drahmedayuna@gmail.com. FAU - Ahmad, Saad AU - Ahmad S AD - Salford Royal NHS Foundation Trust, Manchester, UK. FAU - Alam, Sjirjel AU - Alam S AD - Manchester Universities Foundation Trust, Manchester, UK. FAU - Abidin, Nik AU - Abidin N AD - Salford Royal NHS Foundation Trust, Manchester, UK. LA - eng PT - Journal Article DEP - 20210702 PL - Germany TA - Egypt Heart J JT - The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology JID - 9106952 PMC - PMC8253867 OTO - NOTNLM OT - CT-FFR OT - Coronary artery displacement OT - Myocardial ischemia OT - TET OT - Thymic carcinoma OT - Thymoma COIS- The authors declare that they have no competing interests. EDAT- 2021/07/04 06:00 MHDA- 2021/07/04 06:01 PMCR- 2021/07/02 CRDT- 2021/07/03 06:14 PHST- 2021/03/15 00:00 [received] PHST- 2021/06/05 00:00 [accepted] PHST- 2021/07/03 06:14 [entrez] PHST- 2021/07/04 06:00 [pubmed] PHST- 2021/07/04 06:01 [medline] PHST- 2021/07/02 00:00 [pmc-release] AID - 10.1186/s43044-021-00178-1 [pii] AID - 178 [pii] AID - 10.1186/s43044-021-00178-1 [doi] PST - epublish SO - Egypt Heart J. 2021 Jul 2;73(1):60. doi: 10.1186/s43044-021-00178-1. PMID- 34212863 OWN - NLM STAT- MEDLINE DCOM- 20220201 LR - 20230222 IS - 1969-6213 (Electronic) IS - 1774-024X (Print) IS - 1774-024X (Linking) VI - 17 IP - 13 DP - 2022 Jan 28 TI - Geographical variations in left main coronary artery revascularisation: a prespecified analysis of the EXCEL trial. PG - 1081-1090 LID - EIJ-D-21-00338 [pii] LID - 10.4244/EIJ-D-21-00338 [doi] AB - BACKGROUND: The EXCEL trial reported similar five-year rates of the primary composite outcome of death, myocardial infarction (MI), or stroke after percutaneous coronary intervention (PCI) compared with coronary artery bypass grafting (CABG) for treatment of obstructive left main coronary artery disease (LMCAD). AIMS: We sought to determine whether these outcomes remained consistent regardless of geography of enrolment. METHODS: We performed a prespecified subgroup analysis based on regional enrolment. RESULTS: Among 1,905 patients randomised to PCI (n=948) or CABG (n=957), 1,075 (56.4%) were recruited at 52 European Union (EU) centres, and 752 (39.5%) were recruited at 67 North American (NA) centres. EU versus NA patients varied according to numerous baseline demographics, anatomy, pharmacotherapy and procedural characteristics. Nonetheless, the relative rates of the primary endpoint after PCI versus CABG were consistent across EU versus NA centres at 30 days and 5 years. However, NA participants had substantially higher late rates of ischaemia-driven revascularisation (IDR) after PCI, driven predominantly by the need for greater target vessel and lesion revascularisation. This culminated in a significant difference in the relative risk of the secondary composite outcome of death, MI, stroke, or IDR at 5 years (p(interaction)=0.02). CONCLUSIONS: In the EXCEL trial, the relative risks for the 30-day and five-year primary composite outcome of death, MI or stroke after PCI versus CABG were consistent irrespective of geography. However, five-year rates of IDR after PCI were significantly higher in NA centres, a finding the Heart Team and patients should consider when making treatment decisions. ClinicalTrials.gov identifier: NCT01205776. FAU - Myat, Aung AU - Myat A AD - Sussex Cardiac Centre, Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom. AD - Division of Clinical and Experimental Medicine, Brighton and Sussex Medical School, Brighton, United Kingdom. FAU - Hildick-Smith, David AU - Hildick-Smith D AD - Sussex Cardiac Centre, Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom. FAU - de Belder, Adam J AU - de Belder AJ AD - Sussex Cardiac Centre, Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom. FAU - Trivedi, Uday AU - Trivedi U AD - Sussex Cardiac Centre, Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom. FAU - Crowley, Aaron AU - Crowley A AD - Clinical Trials Centre, Cardiovascular Research Foundation, New York, NY, USA. FAU - Morice, Marie-Claude AU - Morice MC AD - Hopital Prive Jacques Cartier, Ramsay Generale de Sante, Massy, France. FAU - Kandzari, David E AU - Kandzari DE AD - Piedmont Heart Institute, Atlanta, GA, USA. FAU - Lembo, Nicholas J AU - Lembo NJ AD - Clinical Trials Centre, Cardiovascular Research Foundation, New York, NY, USA. AD - NewYork-Presbyterian Hospital/Columbia University Medical Center, New York, NY, USA. FAU - Brown, W Morris III AU - Brown WM III AD - Piedmont Heart Institute, Atlanta, GA, USA. FAU - Serruys, Patrick W AU - Serruys PW AD - Department of Cardiology, National University of Ireland Galway (NUIG), Galway, Ireland. AD - Department of Cardiology, Imperial College London, London, United Kingdom. FAU - Kappetein, Arie Pieter AU - Kappetein AP AD - Thoraxcentre, Erasmus Medical Centre, Rotterdam, the Netherlands. FAU - Sabik, Joseph F III AU - Sabik JF III AD - Department of Surgery, UH Cleveland Medical Center, Cleveland, OH, USA. FAU - Stone, Gregg AU - Stone G AD - Clinical Trials Centre, Cardiovascular Research Foundation, New York, NY, USA. AD - The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. LA - eng SI - ClinicalTrials.gov/NCT01205776 PT - Journal Article PT - Randomized Controlled Trial PL - France TA - EuroIntervention JT - EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology JID - 101251040 SB - IM MH - Coronary Artery Bypass MH - *Coronary Artery Disease/epidemiology/surgery MH - Coronary Vessels MH - Geography MH - Humans MH - *Percutaneous Coronary Intervention/adverse effects MH - Treatment Outcome PMC - PMC9724945 COIS- A. de Belder reports grant support from Abbott Vascular and Medtronic, and consultancy/honoraria from Boston Scientific Corporation. D.E. Kandzari reports institutional research/grant support from Abbott Vascular, Biotronik, Boston Scientific, Cardiovascular Systems, Medtronic, and Teleflex, personal consulting honoraria from Cardiovascular Systems, and Medtronic. N.J. Lembo reports being on the advisory board of Abbott Vascular, and on the speakers bureau of Abbott Vascular, Boston Scientific, Medtronic, and Abiomed. P.W. Serruys reports being a consultant for Biosensors, Sinomed, SMT, Balton sp, Philips/Volcano, Xeltis, HeartFlow, Novartis, and Meril Life, and being a DSMB member for PROSPECT ABSORB. A.P. Kappetein reports being an employee of Medtronic. J.F. Sabik III reports being a consultant for Medtronic, being on the advisory board of Medtronic Cardiac Surgery, and being Abbott North America Surgical PI for the EXCEL trial (no payments). G.W. Stone reports speaker or other honoraria from Terumo, Infraredx, and Cook, being a consultant to Valfix, TherOx, Robocath, HeartFlow, Ablative Solutions, Vectorious, Miracor, Neovasc, Abiomed, Ancora, Elucid Bio, Occlutech, CorFlow, Reva, MAIA Pharmaceuticals, Vascular Dynamics, Shockwave, V-Wave, Cardiomech, and Gore, and equity/options from Ancora, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, Valfix, and MedFocus family of funds. In addition, Mount Sinai Hospital receives grants from Abbott for research, and the Cardiovascular Research Foundation receives payments to the institution from Abbott for biostatistics, clinical events committee and core laboratory work on the clinical trials and for support to attend meetings. The other authors have no conflicts of interest to declare. EDAT- 2021/07/03 06:00 MHDA- 2022/02/02 06:00 PMCR- 2023/01/28 CRDT- 2021/07/02 09:02 PHST- 2021/07/03 06:00 [pubmed] PHST- 2022/02/02 06:00 [medline] PHST- 2021/07/02 09:02 [entrez] PHST- 2023/01/28 00:00 [pmc-release] AID - EIJ-D-21-00338 [pii] AID - 10.4244/EIJ-D-21-00338 [doi] PST - ppublish SO - EuroIntervention. 2022 Jan 28;17(13):1081-1090. doi: 10.4244/EIJ-D-21-00338. PMID- 34210749 OWN - NLM STAT- MEDLINE DCOM- 20220429 LR - 20220429 IS - 1468-201X (Electronic) IS - 1355-6037 (Linking) VI - 108 IP - 6 DP - 2022 Mar TI - Implications of cancer prior to and after heart transplantation. PG - 414-421 LID - 10.1136/heartjnl-2020-318139 [doi] AB - Cancer and cardiovascular disease share many risk factors. Due to improved survival of patients with cancer, the cohort of cancer survivors with heart failure referred for heart transplantation (HT) is growing. Specific considerations include time interval between cancer treatment and HT, risk for recurrence and risk for de novo malignancy (dnM). dnM is an important cause of post-HT morbidity and mortality, with nearly a third diagnosed with malignancy by 10 years post-HT. Compared with the age-matched general population, HT recipients have an approximately 2.5-fold to 4-fold increased risk of developing cancer. HT recipients with prior malignancy show variable cancer recurrence rates, depending on years in remission before HT: 5% recurrence if >5 years in remission, 26% recurrence if 1-5 years in remission and 63% recurrence if <1 year in remission. A myriad of mechanisms influence oncogenesis following HT, including reduced host immunosurveillance from chronic immunosuppression, influence of oncogenic viruses, and the cumulative intensity and duration of immunosuppression. Conversely, protective factors include acyclovir prophylaxis, use of proliferation signal inhibitors (PSI) and female gender. Management involves reducing immunosuppression, incorporating a PSI for immunosuppression and heightened surveillance for allograft rejection. Cancer treatment, including immunotherapy, may be cardiotoxic and lead to graft failure or rejection. Additionally, there exists a competing risk to reduce immunosuppression to improve cancer outcomes, which may increase risk for rejection. A multidisciplinary cardio-oncology team approach is recommended to optimise care and should include an oncologist, transplant cardiologist, transplant pharmacist, palliative care, transplant coordinator and cardio-oncologist. CI - (c) Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Mudigonda, Parvathi AU - Mudigonda P AD - Department of Medicine, Division of Cardiology, University of Washington, Seattle, Washington, USA. FAU - Berardi, Cecilia AU - Berardi C AD - Department of Medicine, Division of Cardiology, University of Washington, Seattle, Washington, USA. FAU - Chetram, Vishaka AU - Chetram V AD - Department of Medicine, MedStar Washington Hospital Center, Georgetown University, Washington, DC, USA. FAU - Barac, Ana AU - Barac A AD - Department of Cardiology, MedStar Heart and Vascular Institute, Georgetown University, Washington, DC, USA. FAU - Cheng, Richard AU - Cheng R AUID- ORCID: 0000-0001-5994-5998 AD - Department of Medicine, Division of Cardiology, University of Washington, Seattle, Washington, USA rkcheng@uw.edu. LA - eng PT - Journal Article PT - Review DEP - 20210701 PL - England TA - Heart JT - Heart (British Cardiac Society) JID - 9602087 SB - IM MH - Female MH - Graft Rejection/prevention & control MH - *Heart Failure/etiology MH - *Heart Transplantation/adverse effects MH - Humans MH - Immunosuppression Therapy MH - *Neoplasms/epidemiology/etiology/therapy MH - Risk Factors OTO - NOTNLM OT - heart failure OT - heart transplantation COIS- Competing interests: None declared. EDAT- 2021/07/03 06:00 MHDA- 2022/04/30 06:00 CRDT- 2021/07/02 05:51 PHST- 2021/03/27 00:00 [received] PHST- 2021/06/02 00:00 [accepted] PHST- 2021/07/03 06:00 [pubmed] PHST- 2022/04/30 06:00 [medline] PHST- 2021/07/02 05:51 [entrez] AID - heartjnl-2020-318139 [pii] AID - 10.1136/heartjnl-2020-318139 [doi] PST - ppublish SO - Heart. 2022 Mar;108(6):414-421. doi: 10.1136/heartjnl-2020-318139. Epub 2021 Jul 1. PMID- 34210615 OWN - NLM STAT- MEDLINE DCOM- 20220117 LR - 20220117 IS - 1444-2892 (Electronic) IS - 1443-9506 (Linking) VI - 31 IP - 2 DP - 2022 Feb TI - Presentation, Treatment and Long-Term Outcomes of a Multidisciplinary Acute Atrial Fibrillation Pathway: A 12-Month Follow-Up Study. PG - 216-223 LID - S1443-9506(21)00582-5 [pii] LID - 10.1016/j.hlc.2021.05.102 [doi] AB - AIM: Atrial fibrillation/flutter (AF/AFL) is associated with high rates of emergency department (ED) visits and acute hospitalisation. A recently established multidisciplinary acute AF treatment pathway seeks to avoid hospital admissions by early discharge of haemodynamically stable, low risk patients from the ED with next-working-day return to a ward-based AF clinic for further assessment. We conducted a preliminary analysis of the clinical outcomes of this pathway. METHODS: We retrospectively reviewed clinical records of all patients assessed at the AF clinic at Christchurch Hospital, New Zealand, over a 12-month period. Data related to presentation, patient characteristics, treatment, and 12-month outcomes were analysed. RESULTS: A total of 143 patients (median age 65, interquartile range: 57-74 years, 59% male, 87% European) were assessed. Of these, 87 (60.8%) presented with their first episode of AF/AFL. Spontaneous cardioversion occurred in 41% at ED discharge, and this increased to 73% at AF clinic review. Electrical cardioversion was subsequently performed in 16 patients (11.2%), and 16 (11.2%) ultimately required hospital admission (eight to facilitate electrical cardioversion). At a median of 1 day, 83.9% were discharged from the AF clinic in sinus rhythm. During 12-month follow-up, there were 25 AF-related hospitalisations (20 patients, 14%) and one patient underwent electrical cardioversion; additionally, one patient had had a stroke and eight had bleeding complications giving a combined outcome rate of 6.3%. CONCLUSION: Utilising a rate-control strategy with ED discharge and early return to a dedicated AF clinic can safely prevent the majority of hospitalisations, avert unnecessary procedures, and facilitate longitudinal care. CI - Copyright (c) 2021 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights reserved. FAU - Al-Busaidi, Ibrahim S AU - Al-Busaidi IS AD - Department of Medicine, University of Otago, Christchurch, New Zealand; Department of Cardiology, Christchurch Hospital, Christchurch, New Zealand. Electronic address: ibrahim.al-busaidi@otago.ac.nz. FAU - Clare, Geoffrey C AU - Clare GC AD - Department of Medicine, University of Otago, Christchurch, New Zealand; Department of Cardiology, Christchurch Hospital, Christchurch, New Zealand. FAU - Joyce, Laura R AU - Joyce LR AD - Department of Surgery, University of Otago, Christchurch, New Zealand; Department of Emergency Medicine, Christchurch Hospital, Christchurch, New Zealand. FAU - Pearson, Scott AU - Pearson S AD - Department of Emergency Medicine, Christchurch Hospital, Christchurch, New Zealand. FAU - Lainchbury, John AU - Lainchbury J AD - Department of Medicine, University of Otago, Christchurch, New Zealand; Department of Cardiology, Christchurch Hospital, Christchurch, New Zealand. FAU - Than, Martin AU - Than M AD - Department of Emergency Medicine, Christchurch Hospital, Christchurch, New Zealand. FAU - Troughton, Richard W AU - Troughton RW AD - Department of Medicine, University of Otago, Christchurch, New Zealand; Department of Cardiology, Christchurch Hospital, Christchurch, New Zealand. LA - eng PT - Journal Article DEP - 20210629 PL - Australia TA - Heart Lung Circ JT - Heart, lung & circulation JID - 100963739 SB - IM MH - Aged MH - *Atrial Fibrillation/diagnosis/epidemiology/therapy MH - *Atrial Flutter MH - Electric Countershock MH - Emergency Service, Hospital MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Retrospective Studies MH - Treatment Outcome OTO - NOTNLM OT - Atrial fibrillation OT - Atrial flutter OT - Cardioversion OT - Emergency department OT - New Zealand OT - Oral anticoagulation OT - Risk stratification EDAT- 2021/07/03 06:00 MHDA- 2022/01/18 06:00 CRDT- 2021/07/02 05:48 PHST- 2021/02/11 00:00 [received] PHST- 2021/04/01 00:00 [revised] PHST- 2021/05/16 00:00 [accepted] PHST- 2021/07/03 06:00 [pubmed] PHST- 2022/01/18 06:00 [medline] PHST- 2021/07/02 05:48 [entrez] AID - S1443-9506(21)00582-5 [pii] AID - 10.1016/j.hlc.2021.05.102 [doi] PST - ppublish SO - Heart Lung Circ. 2022 Feb;31(2):216-223. doi: 10.1016/j.hlc.2021.05.102. Epub 2021 Jun 29. PMID- 34204032 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240402 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 10 IP - 11 DP - 2021 Jun 6 TI - A Multidisciplinary Approach to Evaluate the Presence of Hepatic and Cardiac Abnormalities in Patients with Post-Acute COVID-19 Syndrome-A Pilot Study. LID - 10.3390/jcm10112507 [doi] LID - 2507 AB - (1) Background: Patients suffering from the novel coronavirus 2019 (COVID-19) disease could experience several extra-pulmonary involvements, including cardiovascular complications and liver injury. This study aims to evaluate the presence of cardiac and liver alterations in patients with post-acute COVID-19 syndrome using transthoracic echocardiography (TTE) and liver elastography (LE). (2) Methods: A total of 97 subjects recovering from COVID-19, attending the hospital's specialized outpatient clinic for persisting symptoms at 3 to 11 weeks after the acute illness, were included in this study. They all had a basal COVID-19 assessment, and subsequently, a clinical evaluation, laboratory tests, TTE, and LE. (3) Results: considering the presence of pulmonary injury during COVID-19, patients were divided into two groups. Although none of them had altered systolic function, we evidenced pulmonary hypertension, diastolic dysfunction, increased liver stiffness, viscosity, and steatosis in around one-third of the patients, with significantly higher values in subjects with pulmonary injury compared to those without. (4) Conclusion: persisting symptoms characterizing the post-acute COVID-19 syndrome could be explained by residual cardiac and hepatic lesions, which were worse in more severe COVID-19 forms. These patients may be at risk of developing liver fibrosis and cardiac alterations and should be investigated in the first 12 weeks after the onset of the infection. FAU - Bende, Felix AU - Bende F AUID- ORCID: 0000-0003-3820-7325 AD - Department of Gastroenterology and Hepatology, University of Medicine and Pharmacy "Victor Babes" Timisoara, 300041 Timisoara, Romania. AD - Center of Advanced Research in Gastroenterology and Hepatology, Faculty of Medicine, University of Medicine and Pharmacy "Victor Babes" Timisoara, 300041 Timisoara, Romania. AD - County Emergency Hospital "Pius Brinzeu", L. Rebreanu, Nr. 156, 300723 Timisoara, Romania. FAU - Tudoran, Cristina AU - Tudoran C AUID- ORCID: 0000-0002-7351-741X AD - County Emergency Hospital "Pius Brinzeu", L. Rebreanu, Nr. 156, 300723 Timisoara, Romania. AD - Center of Molecular Research in Nephrology and Vascular Disease, Faculty of Medicine, University of Medicine and Pharmacy "Victor Babes" Timisoara, E. Murgu Square, Nr. 2, 300041 Timisoara, Romania. AD - Department VII, Internal Medicine II, Discipline of Cardiology, University of Medicine and Pharmacy "Victor Babes" Timisoara, E. Murgu Square, Nr. 2, 300041 Timisoara, Romania. FAU - Sporea, Ioan AU - Sporea I AD - Department of Gastroenterology and Hepatology, University of Medicine and Pharmacy "Victor Babes" Timisoara, 300041 Timisoara, Romania. AD - Center of Advanced Research in Gastroenterology and Hepatology, Faculty of Medicine, University of Medicine and Pharmacy "Victor Babes" Timisoara, 300041 Timisoara, Romania. AD - County Emergency Hospital "Pius Brinzeu", L. Rebreanu, Nr. 156, 300723 Timisoara, Romania. FAU - Fofiu, Renata AU - Fofiu R AD - Department of Gastroenterology and Hepatology, University of Medicine and Pharmacy "Victor Babes" Timisoara, 300041 Timisoara, Romania. AD - Center of Advanced Research in Gastroenterology and Hepatology, Faculty of Medicine, University of Medicine and Pharmacy "Victor Babes" Timisoara, 300041 Timisoara, Romania. FAU - Baldea, Victor AU - Baldea V AD - Department of Gastroenterology and Hepatology, University of Medicine and Pharmacy "Victor Babes" Timisoara, 300041 Timisoara, Romania. AD - Center of Advanced Research in Gastroenterology and Hepatology, Faculty of Medicine, University of Medicine and Pharmacy "Victor Babes" Timisoara, 300041 Timisoara, Romania. FAU - Cotrau, Radu AU - Cotrau R AD - Department of Gastroenterology and Hepatology, University of Medicine and Pharmacy "Victor Babes" Timisoara, 300041 Timisoara, Romania. AD - Center of Advanced Research in Gastroenterology and Hepatology, Faculty of Medicine, University of Medicine and Pharmacy "Victor Babes" Timisoara, 300041 Timisoara, Romania. FAU - Popescu, Alina AU - Popescu A AD - Department of Gastroenterology and Hepatology, University of Medicine and Pharmacy "Victor Babes" Timisoara, 300041 Timisoara, Romania. AD - Center of Advanced Research in Gastroenterology and Hepatology, Faculty of Medicine, University of Medicine and Pharmacy "Victor Babes" Timisoara, 300041 Timisoara, Romania. AD - County Emergency Hospital "Pius Brinzeu", L. Rebreanu, Nr. 156, 300723 Timisoara, Romania. FAU - Sirli, Roxana AU - Sirli R AUID- ORCID: 0000-0002-0179-1014 AD - Department of Gastroenterology and Hepatology, University of Medicine and Pharmacy "Victor Babes" Timisoara, 300041 Timisoara, Romania. AD - Center of Advanced Research in Gastroenterology and Hepatology, Faculty of Medicine, University of Medicine and Pharmacy "Victor Babes" Timisoara, 300041 Timisoara, Romania. AD - County Emergency Hospital "Pius Brinzeu", L. Rebreanu, Nr. 156, 300723 Timisoara, Romania. FAU - Ungureanu, Bogdan Silviu AU - Ungureanu BS AD - Research Center of Gastroenterology and Hepatology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania. FAU - Tudoran, Mariana AU - Tudoran M AD - County Emergency Hospital "Pius Brinzeu", L. Rebreanu, Nr. 156, 300723 Timisoara, Romania. AD - Center of Molecular Research in Nephrology and Vascular Disease, Faculty of Medicine, University of Medicine and Pharmacy "Victor Babes" Timisoara, E. Murgu Square, Nr. 2, 300041 Timisoara, Romania. AD - Department VII, Internal Medicine II, Discipline of Cardiology, University of Medicine and Pharmacy "Victor Babes" Timisoara, E. Murgu Square, Nr. 2, 300041 Timisoara, Romania. LA - eng PT - Journal Article DEP - 20210606 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC8201250 OTO - NOTNLM OT - COVID-19 OT - cardiovascular alterations OT - cytokine storm OT - inflammation OT - liver elastography OT - liver injury OT - transthoracic echocardiography COIS- The authors declare no conflict of interest. EDAT- 2021/07/03 06:00 MHDA- 2021/07/03 06:01 PMCR- 2021/06/06 CRDT- 2021/07/02 01:19 PHST- 2021/05/18 00:00 [received] PHST- 2021/06/02 00:00 [revised] PHST- 2021/06/04 00:00 [accepted] PHST- 2021/07/02 01:19 [entrez] PHST- 2021/07/03 06:00 [pubmed] PHST- 2021/07/03 06:01 [medline] PHST- 2021/06/06 00:00 [pmc-release] AID - jcm10112507 [pii] AID - jcm-10-02507 [pii] AID - 10.3390/jcm10112507 [doi] PST - epublish SO - J Clin Med. 2021 Jun 6;10(11):2507. doi: 10.3390/jcm10112507. PMID- 34201876 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210726 IS - 2227-9067 (Print) IS - 2227-9067 (Electronic) IS - 2227-9067 (Linking) VI - 8 IP - 7 DP - 2021 Jun 23 TI - Development of a Multidisciplinary Aerodigestive Program: An Institutional Experience. LID - 10.3390/children8070535 [doi] LID - 535 AB - We share our experience on the implementation of a multidisciplinary aerodigestive program comprising an aerodigestive team (ADT) so as to evaluate its feasibility. We performed a retrospective chart review of the patients discussed at the monthly ADT meetings and analyzed the data. A total of 98 children were referred to the ADT during the study period. The number of cases increased steadily from 3.5 cases per month in 2019 to 8.5 cases per month in 2020. The median age of patients was 34.5 months, and 55% were male. Among the chronic comorbidities, neurologic disease was the most common (85%), followed by respiratory (36%) and cardiac (13%) disorders. The common reasons for consultation were suspected aspiration (56%), respiratory difficulty (44%), drooling/stertor (30%), regurgitation/vomiting (18%), and feeding/swallowing difficulty (17%). Following discussions, 58 patients received active interventions, including fundoplication, gastrostomy, laryngomicrosurgery, tracheostomy, and primary dilatation of the airway. According to the questionnaire of the caregiver, the majority agreed that the main symptoms and quality of life of patients had improved (88%), reducing the burden on caregivers (77%). Aerodigestive programs may provide comprehensive and multidisciplinary management for children with complex airway and digestive tract disorders. FAU - Kim, Seung AU - Kim S AUID- ORCID: 0000-0003-4373-9828 AD - Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Yonsei University College of Medicine, Severance Children's Hospital, Seoul 03722, Korea. FAU - Park, Mireu AU - Park M AD - Department of Pediatrics, Severance Hospital, Institute of Allergy, Institute for Immunology and Immunological Diseases, Severance Biomedical Science Institute, Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul 03722, Korea. FAU - Kim, Eunyoung AU - Kim E AD - Department of Nursing, Severance Children Hospital, Yonsei University Health System, Seoul 03722, Korea. FAU - Kim, Ga Eun AU - Kim GE AD - Department of Pediatrics, Severance Hospital, Institute of Allergy, Institute for Immunology and Immunological Diseases, Severance Biomedical Science Institute, Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul 03722, Korea. FAU - Jung, Jae Hwa AU - Jung JH AD - Department of Pediatrics, Severance Hospital, Institute of Allergy, Institute for Immunology and Immunological Diseases, Severance Biomedical Science Institute, Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul 03722, Korea. FAU - Kim, Soo Yeon AU - Kim SY AD - Department of Pediatrics, Severance Hospital, Institute of Allergy, Institute for Immunology and Immunological Diseases, Severance Biomedical Science Institute, Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul 03722, Korea. FAU - Kim, Min Jung AU - Kim MJ AUID- ORCID: 0000-0002-5634-9709 AD - Department of Pediatrics, Severance Hospital, Institute of Allergy, Institute for Immunology and Immunological Diseases, Severance Biomedical Science Institute, Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul 03722, Korea. FAU - Kim, Da Hee AU - Kim DH AD - Department of Otorhinolaryngology, Yonsei University College of Medicine, Seoul 03722, Korea. FAU - Park, Sowon AU - Park S AD - Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Yonsei University College of Medicine, Severance Children's Hospital, Seoul 03722, Korea. FAU - Koh, Hong AU - Koh H AD - Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Yonsei University College of Medicine, Severance Children's Hospital, Seoul 03722, Korea. FAU - Ho, In Geol AU - Ho IG AUID- ORCID: 0000-0003-4195-871X AD - Department of Pediatric Surgery, Severance Children's Hospital, Yonsei University College of Medicine, Seoul 03722, Korea. FAU - Kim, Seung Ki AU - Kim SK AUID- ORCID: 0000-0002-8823-6258 AD - Department of Rehabilitation Medicine, Yongin Severance Hospital, Research Institute of Rehabilitation Medicine, Yonsei University College of Medicine, Seoul 03722, Korea. FAU - Hwang, Sangwon AU - Hwang S AD - Department and Research Institute of Rehabilitation Medicine, Yonsei University College of Medicine, Seoul 03722, Korea. FAU - Shin, Kyeong Hun AU - Shin KH AD - Department of Nutrition Care, Severance Hospital, Yonsei University Health System, Seoul 03722, Korea. FAU - Lee, Hosun AU - Lee H AD - Department of Nutrition Care, Severance Hospital, Yonsei University Health System, Seoul 03722, Korea. FAU - Lee, Bobae AU - Lee B AD - Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Yonsei University College of Medicine, Severance Children's Hospital, Seoul 03722, Korea. FAU - Lee, Hyeyeon AU - Lee H AD - Department of Pediatric Occupational Therapy, Severance Rehabilitation Hospital, Yonsei University Health System, Seoul 03722, Korea. FAU - Park, Minhwa AU - Park M AD - Department of Pediatric Occupational Therapy, Severance Rehabilitation Hospital, Yonsei University Health System, Seoul 03722, Korea. FAU - Sohn, Myung Hyun AU - Sohn MH AD - Department of Pediatrics, Severance Hospital, Institute of Allergy, Institute for Immunology and Immunological Diseases, Severance Biomedical Science Institute, Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul 03722, Korea. FAU - Rha, Dong-Wook AU - Rha DW AUID- ORCID: 0000-0002-7153-4937 AD - Department and Research Institute of Rehabilitation Medicine, Yonsei University College of Medicine, Seoul 03722, Korea. FAU - Kim, Kyung Won AU - Kim KW AUID- ORCID: 0000-0003-4529-6135 AD - Department of Pediatrics, Severance Hospital, Institute of Allergy, Institute for Immunology and Immunological Diseases, Severance Biomedical Science Institute, Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul 03722, Korea. LA - eng GR - C-2020-0014/Severance Hospital Research fund for Clinical excellence (SHRC)/ PT - Journal Article DEP - 20210623 PL - Switzerland TA - Children (Basel) JT - Children (Basel, Switzerland) JID - 101648936 PMC - PMC8307318 OTO - NOTNLM OT - aerodigestive team OT - children OT - feeding OT - multidisciplinary care OT - pediatric OT - respiratory difficulty OT - swallowing COIS- The authors declare no conflict of interest. EDAT- 2021/07/03 06:00 MHDA- 2021/07/03 06:01 PMCR- 2021/06/23 CRDT- 2021/07/02 01:12 PHST- 2021/06/07 00:00 [received] PHST- 2021/06/19 00:00 [revised] PHST- 2021/06/21 00:00 [accepted] PHST- 2021/07/02 01:12 [entrez] PHST- 2021/07/03 06:00 [pubmed] PHST- 2021/07/03 06:01 [medline] PHST- 2021/06/23 00:00 [pmc-release] AID - children8070535 [pii] AID - children-08-00535 [pii] AID - 10.3390/children8070535 [doi] PST - epublish SO - Children (Basel). 2021 Jun 23;8(7):535. doi: 10.3390/children8070535. PMID- 36165108 OWN - NLM STAT- MEDLINE DCOM- 20220928 LR - 20260127 IS - 2013-2514 (Electronic) IS - 2013-2514 (Linking) VI - 41 IP - 4 DP - 2021 Jul-Aug TI - Developing the subspecialty of cardio-nephrology: The time has come. A position paper from the coordinating committee from the Working Group for Cardiorenal Medicine of the Spanish Society of Nephrology. PG - 391-402 LID - S2013-2514(21)00098-5 [pii] LID - 10.1016/j.nefroe.2021.02.010 [doi] AB - Patients with the dual burden of chronic kidney disease (CKD) and cardiovascular disease (CVD) experience unacceptably high rates of morbidity and mortality, which also entail unfavorable effects on healthcare systems. Currently, concerted efforts to identify, prevent and treat CVD in CKD patients are lacking at the institutional level, with emphasis still being placed on individual specialty views on this topic. The authors of this position paper endorse the need for a dedicated interdisciplinary team of subspecialists in cardio-nephrology that manages appropriate clinical interventions across the inpatient and outpatient settings. There is a critical need for training programs, guidelines and best clinical practice models, and research funding from nephrology, cardiology and other professional societies, to support the development of the subspecialty of cardio-nephrology. This position paper from the coordinating committee from the Working Group for Cardiorenal Medicine of the Spanish Society of Nephrology (S.E.N.) is intended to be the starting point to develop the subspecialty of cardio-nephrology within the S.E.N.. The implementation of the subspecialty in day-to-day nephrological practice will help to diagnose, treat, and prevent CVD in CKD patients in a precise, clinically effective, and health cost-favorable manner. CI - Copyright (c) 2021 Sociedad Espanola de Nefrologia. Published by Elsevier Espana, S.L.U. All rights reserved. FAU - Diez, Javier AU - Diez J AD - Departments of Nephrology and Cardiology, University of Navarra Clinic, Pamplona, Spain; Program of Cardiovascular Diseases, Center of Applied Medical Research, University of Navarra, Pamplona, Spain. Electronic address: jadimar@unav.es. FAU - Navarro-Gonzalez, Juan F AU - Navarro-Gonzalez JF AD - Division of Nephrology and Research Unit, University Hospital Nuestra Senora de Candelaria, and Universitary Institute of Biomedical Technologies, University of La Laguna, Santa Cruz de Tenerife, Spain; Red de Investigacion Renal (REDINREN), Madrid, Spain. FAU - Ortiz, Alberto AU - Ortiz A AD - Red de Investigacion Renal (REDINREN), Madrid, Spain; Division of Nephrology IIS-Fundacion Jimenez Diaz, University Autonoma of Madrid, Madrid, Spain. FAU - Santamaria, Rafael AU - Santamaria R AD - Red de Investigacion Renal (REDINREN), Madrid, Spain; Division of Nephrology, University Hospital Reina Sofia, Cordoba, Spain; Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Spain. FAU - de Sequera, Patricia AU - de Sequera P AD - Nephrology Department, Hospital Universitario Infanta Leonor, University Complutense of Madrid, Madrid, Spain. LA - eng PT - Consensus Statement PT - Journal Article PT - Review PL - Spain TA - Nefrologia (Engl Ed) JT - Nefrologia JID - 101778581 SB - IM MH - *Cardiovascular Diseases/prevention & control MH - Humans MH - *Nephrology/education MH - *Renal Insufficiency, Chronic/complications/diagnosis/therapy OTO - NOTNLM OT - Cardio-nefrologia OT - Cardio-nephrology OT - Cardiorenal medicine OT - Cardiovascular disease OT - Chronic kidney disease OT - Enfermedad cardiovascular OT - Enfermedad renal cronica OT - Medicina cardiorenal EDAT- 2021/07/01 00:00 MHDA- 2022/09/28 06:00 CRDT- 2022/09/27 05:59 PHST- 2021/02/02 00:00 [received] PHST- 2021/02/21 00:00 [accepted] PHST- 2022/09/27 05:59 [entrez] PHST- 2021/07/01 00:00 [pubmed] PHST- 2022/09/28 06:00 [medline] AID - S2013-2514(21)00098-5 [pii] AID - 10.1016/j.nefroe.2021.02.010 [doi] PST - ppublish SO - Nefrologia (Engl Ed). 2021 Jul-Aug;41(4):391-402. doi: 10.1016/j.nefroe.2021.02.010. PMID- 34192188 OWN - NLM STAT- MEDLINE DCOM- 20220214 LR - 20250623 IS - 2399-9772 (Electronic) IS - 2399-9772 (Linking) VI - 5 IP - 1 DP - 2021 TI - Paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): a narrative review and the viewpoint of the Latin American Society of Pediatric Intensive Care (SLACIP) Sepsis Committee. PG - e000894 LID - 10.1136/bmjpo-2020-000894 [doi] LID - e000894 AB - BACKGROUND: In this review, we discuss some important aspects of paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS), a new syndrome that is temporally related to previous exposure to SARS-CoV-2 infection. This virus has a broad spectrum of presentation that may overlap with Kawasaki disease in terms of presenting symptoms and laboratory and cardiac findings. Our objective was to review and summarise published evidence regarding the most important aspects of PIMS-TS, with special emphasis on the treatment strategies suggested for middle-income and low-income countries. METHODS: A systematic review of the literature was performed in the principal medical databases including PubMed, Embase (OVID) and Google Scholar between December 2019 and August 2020. RESULTS: A total of 69 articles were identified in the described databases. Altogether, 13 articles met the inclusion criteria and were eligible. The most frequently described symptoms of PIMS-TS include fever (82%), shock (67%) and gastrointestinal (87%), skin (71%) and cardiac disorders (75%). In most series, it has been observed between 4 and 6 weeks after the pandemic appears in the general population. Multisystem inflammatory syndrome in children is presented as a great systemic inflammatory response syndrome, which sometimes presents as shock requiring fluid resuscitation and vasoactive drug support (26%). Several treatment strategies have been used, including immunoglobulin, steroids, aspirin, anakinra and anticoagulation among others. These general and specific interventions should be guided by an interdisciplinary and multidisciplinary team, especially in settings with limited resources. CONCLUSIONS: PIMS-TS COVID-19 is a new type of presentation of SARS-CoV-2 infection, with an exaggerated inflammatory response and frequent-but not exclusive-digestive and myocardial involvement. It is important to describe the clinical course and outcomes in countries with limited resources as well as establish the role of biomarkers for early diagnosis, effective therapeutic strategies and outpatient follow-up schemes. CI - (c) Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Fernandez-Sarmiento, Jaime AU - Fernandez-Sarmiento J AUID- ORCID: 0000-0003-2874-2949 AD - Department of Critical Care Medicine and Pediatrics Fundacion Cardioinfantil - Instituto de Cardiologia, Universidad de la Sabana, CES Graduate School, Sepsis Committee Latin American Society of Pediatric Intensive Care (SLACIP), Bogota, Colombia. FAU - De Souza, Daniela AU - De Souza D AD - Pediatric Intensive Care Unit and Department of Pediatrics, Hospital Universitario da Universidad de Sao Paulo and Hospital Sirio Libanes, Sepsis Committee Latin American Society of Pediatric Intensive Care (SLACIP), Sao Paulo, Brazil. FAU - Jabornisky, Roberto AU - Jabornisky R AD - Department of Pediatrics Facultad de Medicina Universidad Nacional del Nordeste, Sepsis Committee Latin American Society of Pediatric Intensive Care (SLACIP), Corrientes, Argentina. FAU - Gonzalez, Gustavo Ariel AU - Gonzalez GA AD - Pediatric Intensive Care Unit. Hospital Churruca - Visca Medical Complex, Ricardo Gutierrez Children's Hospital, Sepsis Committee. Latin American Society of Pediatric Intensive Care (SLACIP), Buenos Aires, Argentina. FAU - Arias Lopez, Maria Del Pilar AU - Arias Lopez MDP AD - Pediatric Intensive Care Unit Ricardo Gutierrez Children's Hospital, Sepsis Committee Latin American Society of Pediatric Intensive Care (SLACIP), Buenos Aires, Argentina. FAU - Palacio, Gladys AU - Palacio G AD - Pediatric Intensive Care Unit Ricardo Gutierrez Children's Hospital, Sepsis Committee. Latin American Society of Pediatric Intensive Care (SLACIP), Buenos Aires, Argentina. LA - eng PT - Journal Article PT - Systematic Review DEP - 20210204 PL - England TA - BMJ Paediatr Open JT - BMJ paediatrics open JID - 101715309 RN - pediatric multisystem inflammatory disease, COVID-19 related MH - *COVID-19/complications MH - Child MH - Critical Care MH - Humans MH - Latin America MH - SARS-CoV-2 MH - *Sepsis MH - Systemic Inflammatory Response Syndrome PMC - PMC7868133 OTO - NOTNLM OT - mortality OT - pathology OT - syndrome OT - therapeutics OT - virology COIS- Competing interests: None declared. EDAT- 2021/07/01 06:00 MHDA- 2021/07/01 06:01 PMCR- 2021/02/07 CRDT- 2021/06/30 17:32 PHST- 2020/10/16 00:00 [received] PHST- 2020/12/29 00:00 [revised] PHST- 2021/01/07 00:00 [accepted] PHST- 2021/06/30 17:32 [entrez] PHST- 2021/07/01 06:00 [pubmed] PHST- 2021/07/01 06:01 [medline] PHST- 2021/02/07 00:00 [pmc-release] AID - bmjpo-2020-000894 [pii] AID - 10.1136/bmjpo-2020-000894 [doi] PST - epublish SO - BMJ Paediatr Open. 2021 Feb 4;5(1):e000894. doi: 10.1136/bmjpo-2020-000894. eCollection 2021. PMID- 34192017 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210702 IS - 2055-642X (Print) IS - 2055-642X (Electronic) IS - 2055-642X (Linking) VI - 7 IP - 2 DP - 2021 Apr TI - Remote multidisciplinary heart team meetings in immersive virtual reality: a first experience during the COVID-19 pandemic. PG - 311-315 LID - 10.1136/bmjinnov-2021-000662 [doi] FAU - Sadeghi, Amir H AU - Sadeghi AH AUID- ORCID: 0000-0002-6118-2341 AD - Department of Cardiothoracic Surgery, Erasmus Medical Center, Rotterdam, The Netherlands. FAU - Wahadat, Ali R AU - Wahadat AR AD - Department of Cardiology, Erasmus Medical Center, Rotterdam, The Netherlands. AD - Department of Cardiology, Haga Hospital, Den Haag, The Netherlands. FAU - Dereci, Adem AU - Dereci A AD - Department of Cardiology, Erasmus Medical Center, Rotterdam, The Netherlands. FAU - Budde, Ricardo P J AU - Budde RPJ AD - Department of Cardiology, Erasmus Medical Center, Rotterdam, The Netherlands. AD - Department of Radiology and Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands. FAU - Tanis, Wilco AU - Tanis W AD - Department of Cardiology, Haga Hospital, Den Haag, The Netherlands. FAU - Roos-Hesselink, Jolien W AU - Roos-Hesselink JW AD - Department of Cardiology, Erasmus Medical Center, Rotterdam, The Netherlands. FAU - Takkenberg, Hanneke AU - Takkenberg H AD - Department of Cardiothoracic Surgery, Erasmus Medical Center, Rotterdam, The Netherlands. FAU - Taverne, Yannick J H J AU - Taverne YJHJ AD - Department of Cardiothoracic Surgery, Erasmus Medical Center, Rotterdam, The Netherlands. FAU - Mahtab, Edris A F AU - Mahtab EAF AD - Department of Cardiothoracic Surgery, Erasmus Medical Center, Rotterdam, The Netherlands. FAU - Bogers, Ad J J C AU - Bogers AJJC AD - Department of Cardiothoracic Surgery, Erasmus Medical Center, Rotterdam, The Netherlands. LA - eng PT - Journal Article DEP - 20210305 PL - England TA - BMJ Innov JT - BMJ innovations JID - 101659377 PMC - PMC7938471 OTO - NOTNLM OT - COVID-19 OT - cardiology OT - cardiovascular diseases OT - health COIS- Competing interests: None declared. EDAT- 2021/07/01 06:00 MHDA- 2021/07/01 06:01 PMCR- 2021/03/08 CRDT- 2021/06/30 17:30 PHST- 2021/01/05 00:00 [received] PHST- 2021/02/08 00:00 [revised] PHST- 2021/02/17 00:00 [accepted] PHST- 2021/06/30 17:30 [entrez] PHST- 2021/07/01 06:00 [pubmed] PHST- 2021/07/01 06:01 [medline] PHST- 2021/03/08 00:00 [pmc-release] AID - bmjinnov-2021-000662 [pii] AID - 10.1136/bmjinnov-2021-000662 [doi] PST - ppublish SO - BMJ Innov. 2021 Apr;7(2):311-315. doi: 10.1136/bmjinnov-2021-000662. Epub 2021 Mar 5. PMID- 34186538 OWN - NLM STAT- MEDLINE DCOM- 20210906 LR - 20250103 IS - 1661-7819 (Electronic) IS - 1661-7800 (Linking) VI - 118 IP - 4 DP - 2021 TI - Intrauterine Growth Retardation in Pregnant Women with Long QT Syndrome Treated with Beta-Receptor Blockers. PG - 406-415 LID - 10.1159/000516845 [doi] AB - Pregnant women with inherited long QT syndrome (iLQTS) are at an increased risk for preterm delivery and intrauterine growth retardation (IUGR) due to their underlying disease. Additionally, they are at a risk of arrhythmogenic events, particularly during the postpartum period because of physiological changes and increased emotional/physical stress. beta-receptor blockers can effectively prevent life-threatening Torsades de Pointes ventricular tachycardia and they are the treatment of choice in iLQTS. Use of beta-receptor blockers in pregnancy is recommended, although IUGR is commonly reported for prenatally exposed infants. IUGR, particularly in preterm infants, can result in adverse neonatal outcomes. This review was performed to support clinicians in their selection of beta-receptor blocker treatment for their pregnant iLQTS women by (i) summarizing the available literature addressing the impact of different beta-receptor blockers on IUGR and (ii) reporting additional aspects which might influence the beta-receptor blocker selection. In general, experts recommend to use nonselective beta-receptor blockers, such as nadolol and propranolol, for iLQTS management as these drugs seem to be superior in effectiveness. However, beta-1-selective receptor blockers, such as bisoprolol or metoprolol, seem to affect less likely uterine contraction, peripheral vasodilation, and are associated with lower IUGR rates and fetal hypoglycemia. They are therefore recommended, except atenolol, as first-line therapy for pregnant women. Additionally, maternal factors such as iLQTS genotype, other underlying comorbidities (e.g., diabetes mellitus type 1, asthma bronchiale), and uteroplacental dysfunction or fetal factors have to be taken into account. Therefore, each woman with iLQTS who wants to become pregnant should be well-advised for a personalized beta-receptor blocker therapy according to the individual risk-benefit evaluation by a multidisciplinary team of cardiologists, gynecologists, pediatric cardiologists, neonatologists, and clinical pharmacologists. During pregnancy, a close monitoring of IUGR and, after birth, monitoring of bradycardia, hypoglycemia, and respiratory depression in the neonate is mandatory. This review summarizes available data on beta-receptor blocker-related risk for IUGR in prenatally exposed infants and illustrates which factors might influence beta-receptor blocker selection with the aim to support clinicians in their pharmacological management of their pregnant iLQTS patients. CI - (c) 2021 The Author(s). Published by S. Karger AG, Basel. FAU - Welzel, Tatjana AU - Welzel T AD - Pediatric Pharmacology and Pharmacometrics, University Children's Hospital of Basel, (UKBB), University of Basel, Basel, Switzerland. FAU - Donner, Birgit AU - Donner B AD - Pediatric Cardiology, University Children's Hospital of Basel (UKBB), University of Basel, Basel, Switzerland. FAU - van den Anker, Johannes N AU - van den Anker JN AD - Pediatric Pharmacology and Pharmacometrics, University Children's Hospital of Basel, (UKBB), University of Basel, Basel, Switzerland. AD - Division of Clinical Pharmacology, Children's National Hospital, Washington, District of Columbia, USA. LA - eng PT - Journal Article PT - Review DEP - 20210629 PL - Switzerland TA - Neonatology JT - Neonatology JID - 101286577 RN - 0 (Adrenergic beta-Antagonists) SB - IM MH - Adrenergic beta-Antagonists/adverse effects MH - Child MH - Female MH - *Fetal Growth Retardation/drug therapy MH - Humans MH - Infant MH - Infant, Newborn MH - Infant, Premature MH - *Long QT Syndrome MH - Pregnancy MH - Pregnant People OTO - NOTNLM OT - Long QT syndrome OT - Pregnancy OT - Side effects OT - Small for gestational age OT - beta-receptor blockers EDAT- 2021/06/30 06:00 MHDA- 2021/09/07 06:00 CRDT- 2021/06/29 20:28 PHST- 2021/02/15 00:00 [received] PHST- 2021/04/22 00:00 [accepted] PHST- 2021/06/30 06:00 [pubmed] PHST- 2021/09/07 06:00 [medline] PHST- 2021/06/29 20:28 [entrez] AID - 000516845 [pii] AID - 10.1159/000516845 [doi] PST - ppublish SO - Neonatology. 2021;118(4):406-415. doi: 10.1159/000516845. Epub 2021 Jun 29. PMID- 34182537 OWN - NLM STAT- MEDLINE DCOM- 20211025 LR - 20240918 IS - 1557-2501 (Electronic) IS - 1042-3931 (Linking) VI - 33 IP - 8 DP - 2021 Aug TI - Transcatheter Mitral Valve Repair Using MitraClip in Patients With Renal Transplantation. PG - E628-E631 LID - JIC20210628-1 [pii] AB - OBJECTIVES: To evaluate the renal function in patients with renal transplantation 1 month after treatment of their severe symptomatic mitral regurgitation using transcatheter mitral valve repair (TMVRep) using MitraClip (Abbott Cardiovascular). METHODS: We enrolled 22 patients with previous history of end-stage renal disease and kidney transplant with severe symptomatic mitral regurgitation (MR) in this study. Each patient was evaluated by the structural heart team and underwent transesophageal echocardiographic evaluation for MR etiology, severity, and location of the MR jet, as well as to rule out left atrial appendage clot formation. Serum creatinine and estimated glomerular filtration rate using the Modification of Diet in Renal Disease formula were measured at baseline and at 1-month follow-up. RESULTS: Fourteen patients (64%) were male and mean age of the study group was 50.4 +/- 11.0 years. Mean ejection fraction was 29.0 +/- 5.6%. The majority (86%) of the MRs treated were classified as functional MR. Follow-up creatinine values were significantly lower after treatment of their symptomatic MR with TMVRep compared with baseline creatinine values (baseline, 3.2 +/- 0.49 mg/dL; follow-up, 1.99 +/- 0.31 mg/dL; P<.05). CONCLUSIONS: TMVRep in patients with renal transplantation was associated with lower serum creatinine values at 1-month follow-up and represents an alternative to surgery in this high-risk group of patients. Further studies are needed to confirm our findings and to find the best treatment option for these patients. FAU - Kilic, Ismail Dogu AU - Kilic ID FAU - Ates, Ismail AU - Ates I FAU - Marmagkiolis, Konstantinos AU - Marmagkiolis K FAU - Iliescu, Cezar AU - Iliescu C FAU - Yavuz, Asuman AU - Yavuz A FAU - Demirbas, Alper AU - Demirbas A FAU - Cilingiroglu, Mehmet AU - Cilingiroglu M AD - UC Irvine, 11800 Carmel Creek Road, San Diego, CA 92130 USA. cilingiroglumehmet@gmail.com. LA - eng PT - Journal Article DEP - 20210628 PL - United States TA - J Invasive Cardiol JT - The Journal of invasive cardiology JID - 8917477 SB - IM MH - Adult MH - Cardiac Catheterization MH - *Heart Valve Prosthesis Implantation MH - Humans MH - *Kidney Transplantation MH - Male MH - Middle Aged MH - Mitral Valve/diagnostic imaging/surgery MH - *Mitral Valve Insufficiency/diagnosis/surgery MH - Treatment Outcome OTO - NOTNLM OT - renal function OT - renal transplantation OT - transcatheter mitral valve repair EDAT- 2021/06/29 06:00 MHDA- 2021/10/26 06:00 CRDT- 2021/06/28 20:31 PHST- 2021/06/29 06:00 [pubmed] PHST- 2021/10/26 06:00 [medline] PHST- 2021/06/28 20:31 [entrez] AID - JIC20210628-1 [pii] AID - 10.25270/jic/20.00584 [doi] PST - ppublish SO - J Invasive Cardiol. 2021 Aug;33(8):E628-E631. doi: 10.25270/jic/20.00584. Epub 2021 Jun 28. PMID- 34171598 OWN - NLM STAT- MEDLINE DCOM- 20210817 LR - 20210817 IS - 1873-4499 (Electronic) IS - 0899-7071 (Linking) VI - 78 DP - 2021 Oct TI - Implementing a standardized and symptom-oriented flowchart "Kielsflow" for advanced cardiac imaging in a 24/7 interdisciplinary emergency department using spectral CT. PG - 256-261 LID - S0899-7071(21)00229-1 [pii] LID - 10.1016/j.clinimag.2021.05.021 [doi] AB - This work focuses on implementing a standardized and symptom-oriented flowchart for advanced cardiac imaging in a 24/7 emergency setting using a dual-layer spectral detector CT system. This flowchart was designed to optimize patient management and standardize imaging workflow. It includes acquisition parameters and contrast agent protocols for the most relevant clinical questions regarding cardiac CT imaging in the interdisciplinary emergency department. The automated reconstruction of symptom-oriented spectral images represents an additional strength here. This implementation is designed to be time-efficient and user-friendly and improves diagnostic quality, independent of the qualification level of clinical and technical personnel. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - Langguth, Patrick AU - Langguth P AD - Department for Radiology and Neuroradiology, University Hospital Schleswig-Holstein, Campus Kiel, Germany. Electronic address: Patrick.Langguth@uksh.de. FAU - Austein, Friederike AU - Austein F AD - Department for Diagnostic and Interventional Neuroradiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Campbell, Graeme M AU - Campbell GM AD - Philips GmbH Healthcare Division, Hamburg, Germany. FAU - Eden, Matthias AU - Eden M AD - Department for Internal Medicine III, Molecular Cardiology and Angiology, University Hospital Schleswig-Holstein, Campus Kiel, Germany. FAU - Schunk, Domagoj AU - Schunk D AD - Department for Interdisciplinary Emergency, University Hospital Schleswig-Holstein, Campus Kiel, Germany. FAU - Jansen, Olav AU - Jansen O AD - Department for Radiology and Neuroradiology, University Hospital Schleswig-Holstein, Campus Kiel, Germany. FAU - Both, Marcus AU - Both M AD - Department for Radiology and Neuroradiology, University Hospital Schleswig-Holstein, Campus Kiel, Germany. FAU - Salehi Ravesh, Mona AU - Salehi Ravesh M AD - Department for Radiology and Neuroradiology, University Hospital Schleswig-Holstein, Campus Kiel, Germany. LA - eng PT - Journal Article DEP - 20210531 PL - United States TA - Clin Imaging JT - Clinical imaging JID - 8911831 RN - 0 (Contrast Media) SB - IM MH - *Contrast Media MH - Emergency Service, Hospital MH - Humans MH - Software Design MH - *Tomography, X-Ray Computed OTO - NOTNLM OT - Cardiac imaging OT - Computed tomography OT - Dual-layer spectral detector computed tomography OT - Emergency department OT - Patient management OT - Workflow EDAT- 2021/06/26 06:00 MHDA- 2021/08/18 06:00 CRDT- 2021/06/25 20:21 PHST- 2020/07/28 00:00 [received] PHST- 2021/04/27 00:00 [revised] PHST- 2021/05/21 00:00 [accepted] PHST- 2021/06/26 06:00 [pubmed] PHST- 2021/08/18 06:00 [medline] PHST- 2021/06/25 20:21 [entrez] AID - S0899-7071(21)00229-1 [pii] AID - 10.1016/j.clinimag.2021.05.021 [doi] PST - ppublish SO - Clin Imaging. 2021 Oct;78:256-261. doi: 10.1016/j.clinimag.2021.05.021. Epub 2021 May 31. PMID- 34168722 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240402 IS - 1948-9358 (Print) IS - 1948-9358 (Electronic) IS - 1948-9358 (Linking) VI - 12 IP - 6 DP - 2021 Jun 15 TI - Role of novel biomarkers in diabetic cardiomyopathy. PG - 685-705 LID - 10.4239/wjd.v12.i6.685 [doi] AB - Diabetic cardiomyopathy (DCM) is commonly defined as cardiomyopathy in patients with diabetes mellitus in the absence of coronary artery disease and hypertension. As DCM is now recognized as a cause of substantial morbidity and mortality among patients with diabetes mellitus and clinical diagnosis is still inappropriate, various expert groups struggled to identify a suitable biomarker that will help in the recognition and management of DCM, with little success so far. Hence, we thought it important to address the role of biomarkers that have shown potential in either human or animal studies and which could eventually result in mitigating the poor outcomes of DCM. Among the array of biomarkers we thoroughly analyzed, long noncoding ribonucleic acids, soluble form of suppression of tumorigenicity 2 and galectin-3 seem to be most beneficial for DCM detection, as their plasma/serum levels accurately correlate with the early stages of DCM. The combination of relatively inexpensive and accurate speckle tracking echocardiography with some of the highlighted biomarkers may be a promising screening method for newly diagnosed diabetes mellitus type 2 patients. The purpose of the screening test would be to direct affected patients to more specific confirmation tests. This perspective is in concordance with current guidelines that accentuate the importance of an interdisciplinary team-based approach. CI - (c)The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. FAU - Kumric, Marko AU - Kumric M AD - Department of Pathophysiology, University of Split School of Medicine, Split 21000, Croatia. FAU - Ticinovic Kurir, Tina AU - Ticinovic Kurir T AD - Department of Pathophysiology, University of Split School of Medicine, Split 21000, Croatia. FAU - Borovac, Josip A AU - Borovac JA AD - Department of Pathophysiology, University of Split School of Medicine, Split 21000, Croatia. FAU - Bozic, Josko AU - Bozic J AD - Department of Pathophysiology, University of Split School of Medicine, Split 21000, Croatia. josko.bozic@mefst.hr. LA - eng PT - Journal Article PT - Review PL - United States TA - World J Diabetes JT - World journal of diabetes JID - 101547524 PMC - PMC8192249 OTO - NOTNLM OT - Biomarkers OT - Cardiomyopathy OT - Diabetes mellitus OT - Diabetic cardiomyopathy OT - Heart failure COIS- Conflict-of-interest statement: We report no conflicts of interest. EDAT- 2021/06/26 06:00 MHDA- 2021/06/26 06:01 PMCR- 2021/06/15 CRDT- 2021/06/25 06:51 PHST- 2020/12/28 00:00 [received] PHST- 2021/01/22 00:00 [revised] PHST- 2021/03/18 00:00 [accepted] PHST- 2021/06/25 06:51 [entrez] PHST- 2021/06/26 06:00 [pubmed] PHST- 2021/06/26 06:01 [medline] PHST- 2021/06/15 00:00 [pmc-release] AID - 10.4239/wjd.v12.i6.685 [doi] PST - ppublish SO - World J Diabetes. 2021 Jun 15;12(6):685-705. doi: 10.4239/wjd.v12.i6.685. PMID- 34156404 OWN - NLM STAT- MEDLINE DCOM- 20210712 LR - 20220424 IS - 1538-3598 (Electronic) IS - 0098-7484 (Linking) VI - 325 IP - 24 DP - 2021 Jun 22 TI - Transcatheter Treatment of Valvular Heart Disease: A Review. PG - 2480-2494 LID - 10.1001/jama.2021.2133 [doi] AB - IMPORTANCE: More than 40 million people are living with either mitral or aortic valve disease worldwide, and more than 180 000 heart valve replacement surgeries are performed each year in the US. Transcatheter valve repair has emerged as an important therapeutic option for patients who are candidates for heart valve replacement. OBSERVATIONS: All transcatheter valve therapies involve a multidisciplinary team of interventional cardiologists, cardiothoracic surgeons, radiologists, echocardiographers, nurses, and social workers, termed the heart team, to determine the optimal approach for managing each patient. Transcatheter aortic valve implantation (TAVI) is an aortic valve replacement procedure that is performed percutaneously and is currently approved for patients with severe, symptomatic aortic stenosis in all surgical risk categories. The TAVI procedure can be performed using a balloon-expandable or self-expanding valve. In a low-risk cohort of patients (PARTNER [Placement of Aortic Transcatheter Valves] 3 trial), the rates of death from any cause, stroke, or rehospitalization were 8.5% for patients receiving TAVI and 15.1% for patients undergoing surgical aortic valve replacement. Decision-making regarding therapy choice should be based on individual anatomy (including the number of leaflets, annular size, and peripheral arterial anatomy), comorbidities (including concomitant coronary artery disease and aortopathies), and patient preference guide. A mitral transcatheter edge-to-edge repair device is approved by the US Food and Drug Administration for high-risk patients with degenerative and functional mitral regurgitation that has excellent safety and efficacy in these populations. In the COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation) trial, the annualized rate of all hospitalizations for heart failure was 35.8% among patients who underwent transcatheter edge-to-edge repair and received medical therapy compared with 67.9% among patients in the medical therapy alone group. Transcatheter tricuspid valve repair and replacement trials are ongoing and show promise for the treatment of patients with tricuspid regurgitation, which previously had limited therapeutic options. Multimodality imaging, which includes transthoracic echocardiography, transesophageal echocardiography, computed tomography, and intracardiac echocardiography, is important for preprocedural planning, device selection, and optimal outcomes. CONCLUSIONS AND RELEVANCE: Approximately 78 000 TAVI procedures and 10 000 transcatheter mitral valve repairs take place yearly in the US to treat patients with severe, symptomatic aortic stenosis and mitral regurgitation, respectively. Transcatheter valve therapies have expanded therapeutic options for patients, including for those who previously had no viable surgical options. FAU - Davidson, Laura J AU - Davidson LJ AD - Bluhm Cardiovascular Institute and Departments of Medicine and Cardiology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. FAU - Davidson, Charles J AU - Davidson CJ AD - Bluhm Cardiovascular Institute and Departments of Medicine and Cardiology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. LA - eng PT - Journal Article PT - Review PL - United States TA - JAMA JT - JAMA JID - 7501160 SB - IM CIN - JAMA. 2021 Nov 2;326(17):1747. doi: 10.1001/jama.2021.14066. PMID: 34726714 MH - Aortic Valve/*surgery MH - Cardiac Surgical Procedures/*methods MH - Humans MH - Mitral Valve/*surgery MH - Mitral Valve Insufficiency/*surgery MH - Risk Factors MH - *Transcatheter Aortic Valve Replacement/methods MH - Tricuspid Valve/surgery MH - Tricuspid Valve Insufficiency/surgery EDAT- 2021/06/23 06:00 MHDA- 2021/07/13 06:00 CRDT- 2021/06/22 12:15 PHST- 2021/06/22 12:15 [entrez] PHST- 2021/06/23 06:00 [pubmed] PHST- 2021/07/13 06:00 [medline] AID - 2781245 [pii] AID - 10.1001/jama.2021.2133 [doi] PST - ppublish SO - JAMA. 2021 Jun 22;325(24):2480-2494. doi: 10.1001/jama.2021.2133. PMID- 34155897 OWN - NLM STAT- MEDLINE DCOM- 20211029 LR - 20211029 IS - 2047-9980 (Electronic) IS - 2047-9980 (Linking) VI - 10 IP - 13 DP - 2021 Jul 6 TI - Temporal Trends and Drivers of Heart Team Utilization in Transcatheter Aortic Valve Replacement: A Population-Based Study in Ontario, Canada. PG - e020741 LID - 10.1161/JAHA.120.020741 [doi] LID - e020741 AB - Background The multidisciplinary Heart Team (HT) is recommended for management decisions for transcatheter aortic valve replacement (TAVR) candidates, and during TAVR procedures. Empiric evidence to support these recommendations is limited. We aimed to explore temporal trends, drivers, and outcomes associated with HT utilization. Methods and Results TAVR candidates were identified in Ontario, Canada, from April 1, 2012 to March 31, 2019. The HT was defined as having a billing code for both a cardiologist and cardiac surgeon during the referral period. The procedural team was defined as a billing code during the TAVR procedure. Hierarchical logistical models were used to determine the drivers of HT. Median odds ratios were calculated to quantify the degree of variation among hospitals. Of 10 412 patients referred for TAVR consideration, 5489 (52.7%) patients underwent a HT during the referral period, with substantial range between hospitals (median odds ratio of 1.78). Utilization of a HT for TAVR referrals declined from 69.9% to 41.1% over the years of the study. Patient characteristics such as older age, frailty and dementia, and hospital characteristics including TAVR program size, were found associated with lower HT utilization. In TAVR procedures, the procedural team included both cardiologists and cardiac surgeons in 94.9% of cases, with minimal variation over time or between hospitals. Conclusions There has been substantial decline in HT utilization for TAVR candidates over time. In addition, maturity of TAVR programs was associated with lower HT utilization. FAU - Marcus, Gil AU - Marcus G AD - Schulich Heart Program Division of Cardiology Sunnybrook Health Sciences Centre University of Toronto Ontario Canada. FAU - Qiu, Feng AU - Qiu F AD - ICES Toronto Ontario Canada. FAU - Manoragavan, Ragavie AU - Manoragavan R AD - Schulich Heart Program Division of Cardiology Sunnybrook Health Sciences Centre University of Toronto Ontario Canada. FAU - Ko, Dennis T AU - Ko DT AD - Schulich Heart Program Division of Cardiology Sunnybrook Health Sciences Centre University of Toronto Ontario Canada. AD - ICES Toronto Ontario Canada. AD - Institute for Health Policy Management and Evaluation University of Toronto Ontario Canada. FAU - Elbaz-Greener, Gabby AU - Elbaz-Greener G AD - Department of Cardiology Hadassah Medical Center Jerusalem Israel. AD - Faculty of Medicine Hebrew University of Jerusalem Israel. FAU - Chung, Jennifer C Y AU - Chung JCY AD - Division of Cardiovascular Surgery Department of Surgery Peter Munk Cardiac Centre University Health NetworkUniversity of Toronto Ontario Canada. FAU - Sud, Maneesh AU - Sud M AD - Schulich Heart Program Division of Cardiology Sunnybrook Health Sciences Centre University of Toronto Ontario Canada. AD - ICES Toronto Ontario Canada. AD - Institute for Health Policy Management and Evaluation University of Toronto Ontario Canada. FAU - Farkouh, Michael E AU - Farkouh ME AD - Peter Munk Cardiac Centre and Heart and Stroke Richard Lewar Centre University of Toronto Canada. FAU - Madan, Mina AU - Madan M AD - Schulich Heart Program Division of Cardiology Sunnybrook Health Sciences Centre University of Toronto Ontario Canada. FAU - Fremes, Stephen E AU - Fremes SE AD - Schulich Heart Program Division of Cardiac Surgery Sunnybrook Health Sciences Centre University of Toronto Ontario Canada. FAU - Wijeysundera, Harindra C AU - Wijeysundera HC AD - Schulich Heart Program Division of Cardiology Sunnybrook Health Sciences Centre University of Toronto Ontario Canada. AD - ICES Toronto Ontario Canada. AD - Institute for Health Policy Management and Evaluation University of Toronto Ontario Canada. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210622 PL - England TA - J Am Heart Assoc JT - Journal of the American Heart Association JID - 101580524 SB - IM MH - Aged MH - Aged, 80 and over MH - Aortic Valve Stenosis/diagnostic imaging/physiopathology/*surgery MH - Cardiologists/*trends MH - Female MH - Humans MH - Male MH - Ontario MH - Patient Care Team/*trends MH - Practice Patterns, Physicians'/*trends MH - Program Evaluation MH - Referral and Consultation/trends MH - Retrospective Studies MH - Risk Assessment MH - Risk Factors MH - Surgeons/*trends MH - Time Factors MH - Transcatheter Aortic Valve Replacement/adverse effects/*trends MH - Treatment Outcome PMC - PMC8403321 OTO - NOTNLM OT - Heart Team OT - aortic stenosis OT - transcatheter aortic valve replacement COIS- None. EDAT- 2021/06/23 06:00 MHDA- 2021/10/30 06:00 PMCR- 2021/07/06 CRDT- 2021/06/22 08:40 PHST- 2021/06/23 06:00 [pubmed] PHST- 2021/10/30 06:00 [medline] PHST- 2021/06/22 08:40 [entrez] PHST- 2021/07/06 00:00 [pmc-release] AID - JAH36345 [pii] AID - 10.1161/JAHA.120.020741 [doi] PST - ppublish SO - J Am Heart Assoc. 2021 Jul 6;10(13):e020741. doi: 10.1161/JAHA.120.020741. Epub 2021 Jun 22. PMID- 34154001 OWN - NLM STAT- MEDLINE DCOM- 20220117 LR - 20220117 IS - 1098-9064 (Electronic) IS - 0094-6176 (Linking) VI - 47 IP - 8 DP - 2021 Nov TI - Cardiovascular Oncology: The Need for a Multidisciplinary Approach. PG - 907-913 LID - 10.1055/s-0041-1726297 [doi] AB - Improved cancer survivorship has led to an increase in cardiovascular (CV) complications in the oncologic population, mainly associated with therapeutic regimens. Hence, cardio-oncology has grown toward unifying the cancer care process in which the best prevention, early detection, treatment, and CV surveillance are offered to patients. This multidisciplinary approach allows us to optimize and agree upon clinical decisions to enhance clinical outcomes. Atrial fibrillation is one of the hot topics in the field because it is still challenging in cancer patients. The optimal antithrombotic therapy remains unclear. Nevertheless, evidence supports that specific recommendations are needed due to a hemorrhagic/thrombotic disbalance present within this subgroup of patients and a low rate of anticoagulation treatments compared with the general population. Further, cardiotoxicity management is currently transforming. Increasingly, early detection of subclinical alterations is raising awareness. When medical therapy is initiated early, fewer patients progress to ventricular dysfunction and the rate of patients completing cancer therapy gradually increases. New approaches are demonstrating better outcomes and these strategies will expectedly be established in clinical practice. Cardio-oncology enables us to find the best balance between cancer treatment and CV health protection. Nowadays, more and more physicians are being instructed in this discipline, which gradually exhibits a greater presence in conferences and scientific journals. However, given the need for physicians thoroughly trained in cardio-oncology, this subspecialty must be promoted further. CI - Thieme. All rights reserved. FAU - Ortega Perez, Rodrigo AU - Ortega Perez R AD - Department of Cardiology, University Hospital Ramon y Cajal, Madrid, Spain. FAU - Pardo Sanz, Ana AU - Pardo Sanz A AD - Department of Cardiology, University Hospital Ramon y Cajal, Madrid, Spain. FAU - Garcia Gutierrez, Valentin AU - Garcia Gutierrez V AD - Department of hematology, University Hospital Ramony Cajal, Madrid, Spain. FAU - Zamorano Gomez, Jose Luis AU - Zamorano Gomez JL AD - Department of Cardiology, University Hospital Ramon y Cajal, Madrid, Spain. LA - eng PT - Journal Article DEP - 20210621 PL - United States TA - Semin Thromb Hemost JT - Seminars in thrombosis and hemostasis JID - 0431155 SB - IM MH - Cardiotoxicity MH - *Cardiovascular System MH - Humans MH - Medical Oncology MH - *Neoplasms/drug therapy COIS- None declared. EDAT- 2021/06/22 06:00 MHDA- 2022/01/18 06:00 CRDT- 2021/06/21 20:36 PHST- 2021/06/22 06:00 [pubmed] PHST- 2022/01/18 06:00 [medline] PHST- 2021/06/21 20:36 [entrez] AID - 10.1055/s-0041-1726297 [doi] PST - ppublish SO - Semin Thromb Hemost. 2021 Nov;47(8):907-913. doi: 10.1055/s-0041-1726297. Epub 2021 Jun 21. PMID- 34149680 OWN - NLM STAT- MEDLINE DCOM- 20210823 LR - 20210823 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 12 DP - 2021 TI - Correlation Between Skin and Affected Organs in 52 Sclerodermic Patients Followed in a Diseases Management Team: Development of a Risk Prediction Model of Organ-Specific Complications. PG - 588753 LID - 10.3389/fimmu.2021.588753 [doi] LID - 588753 AB - OBJECTIVE: To identify the existence of a correlation among the various organs affected, focusing primarily on immuno-dermatological aspects, and to create a risk prediction model of organ-specific complications. MATERIAL AND METHODS: Fifty-two patients with stable scleroderma, followed between 2015 and 2019, were investigated through an extensive multidisciplinary evaluation in the last year. RESULTS: Patients with lung involvement presented a worse degree of skin fibrosis than patients without it (p <0.001). No relationship was observed for the heart, kidney, and esophagus. Patients with pulmonary involvement had a lower pressure of the low esophagus sphincter and a higher Warrick score than patients without it (p <0.05). Age was significantly higher in patients with kidney involvement. Diffuse scleroderma patients had a worse pulmonary impairment than limited scleroderma patients (p <0.05). The manometric "sclerodermic" pattern was observed to be the most frequent (55.6%, p <0.05) in dcSSc patients while the sclerodermic and normal pattern were equally represented (41.2 and 32.4% respectively, p <0.05) in lcSSc patients. When compared to the negative serological groups, anti-Scl-70 positive patients presented a worse lung involvement while anti-centromere patients presented a better lung outcome (p <0.05). PM-Scl 100/75 positive patients presented mostly a pulmonary fibrotic pattern (p <0.05) and, also, heart complications were more likely associated with anti PM-Scl 100/75 positivity (p <0.05). The risk prediction model for organ-specific complications had an accuracy of 84.4% (95%CI 78, 89) in complication-site prediction, AUC of 0.871, 86% of sensitivity, and 83% of specificity, Cohen's Kappa (k) of 0.68. CONCLUSIONS: Out of all the organs studied, the skin is the one that correlates with the lung. Patients with a diffuse form of disease presented more frequently the anti Scl-70 antibody and had a worse lung and esophageal involvement (scleroderma pattern) than the negative group. Conversely, patients with limited disease presented all positive for the anti-centromere antibody with a better lung involvement than the negative group, without any difference among the esophageal manometric pattern. Anti PM-Scl 100/75 antibody patients were associated with pulmonary fibrosis and presented cardiac involvement. The model created has demonstrated excellent values of sensitivity, specificity, and accuracy, but further studies are needed for validation. CI - Copyright (c) 2021 Cozzani, Muracchioli, Murdaca, Beccalli, Caprioli, Zentilin, Ameri, Grosso, Russo, Carmisciano and Parodi. FAU - Cozzani, Emanuele AU - Cozzani E AD - Dermatologic Unit, University of Genoa, DiSSal, Ospedale-Policlinico San Martino, IRCCS, Genova, Italy. FAU - Muracchioli, Andrea AU - Muracchioli A AD - Dermatologic Unit, University of Genoa, DiSSal, Ospedale-Policlinico San Martino, IRCCS, Genova, Italy. FAU - Murdaca, Giuseppe AU - Murdaca G AD - Departments of Internal Medicine, Scleroderma Unit, Clinical Immunology Unit, University of Genova, Ospedale-Policlinico San Martino, IRCCS, Genova, Italy. FAU - Beccalli, Mirko AU - Beccalli M AD - Departments of Internal Medicine, Scleroderma Unit, Clinical Immunology Unit, University of Genova, Ospedale-Policlinico San Martino, IRCCS, Genova, Italy. FAU - Caprioli, Simone AU - Caprioli S AD - Department of Healt Sciences DiSSal, University of Genova, Ospedale-Policlinico San Martino, IRCCS, Genova, Italy. FAU - Zentilin, Patrizia AU - Zentilin P AD - Division of Gastroenterology, Department of Internal Medicine, University of Genova, Ospedale-Policlinico San Martino, IRCCS, Genova, Italy. FAU - Ameri, Pietro AU - Ameri P AD - Cardiovascular Disease Unit, IRCCS, Ospedale-Policlinico San Martino; Department of Internal Medicine, University of Genova, Genova, Italy. FAU - Grosso, Marco AU - Grosso M AD - Interventional Pneumology Unit, Ospedale-Policlinico San Martino, IRCCS, Genova, Italy. FAU - Russo, Rodolfo AU - Russo R AD - Nephrology, Dialysis, and Transplantation, Ospedale-Policlinico San Martino, IRCCS, Genova, Italy. FAU - Carmisciano, Luca AU - Carmisciano L AD - Department of Healt Sciences DiSSal, University of Genova, Ospedale-Policlinico San Martino, IRCCS, Genova, Italy. FAU - Parodi, Aurora AU - Parodi A AD - Dermatologic Unit, University of Genoa, DiSSal, Ospedale-Policlinico San Martino, IRCCS, Genova, Italy. LA - eng PT - Journal Article DEP - 20210602 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 SB - IM MH - Age Factors MH - Aged MH - Female MH - Humans MH - Logistic Models MH - Lung/*pathology MH - Lung Diseases/*diagnosis/epidemiology/pathology MH - Male MH - Middle Aged MH - Organ Specificity MH - Prognosis MH - Risk MH - Scleroderma, Systemic/*diagnosis/epidemiology/pathology MH - Sensitivity and Specificity MH - Skin/*pathology PMC - PMC8207468 OTO - NOTNLM OT - mRSS (Rodnan Score) OT - organ complications OT - predictive model OT - scleroderma OT - systemic sclerosis COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/06/22 06:00 MHDA- 2021/08/24 06:00 PMCR- 2021/01/01 CRDT- 2021/06/21 05:52 PHST- 2020/07/29 00:00 [received] PHST- 2021/05/10 00:00 [accepted] PHST- 2021/06/21 05:52 [entrez] PHST- 2021/06/22 06:00 [pubmed] PHST- 2021/08/24 06:00 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - 10.3389/fimmu.2021.588753 [doi] PST - epublish SO - Front Immunol. 2021 Jun 2;12:588753. doi: 10.3389/fimmu.2021.588753. eCollection 2021. PMID- 34145474 OWN - NLM STAT- MEDLINE DCOM- 20220315 LR - 20220315 IS - 1432-0711 (Electronic) IS - 0932-0067 (Linking) VI - 305 IP - 2 DP - 2022 Feb TI - Prenatal sonographic and cytogenetic/molecular findings of 22q11.2 microdeletion syndrome in 48 confirmed cases in a single tertiary center. PG - 323-342 LID - 10.1007/s00404-021-06125-4 [doi] AB - PURPOSE: We aimed to present the fetal ultrasound, cytogenetic/molecular testing and postmortem or postnatal clinical findings of cases with 22q11.2DS diagnosed prenatally. MATERIALS AND METHODS: A retrospective medical record review of 48 prenatal cases diagnosed with 22q11.2DS were evaluated in our institution. Detailed ultrasound examination was performed on all fetuses. Postmortem and postnatal examinations were evaluated. The microdeletions were detected by karyotyping or microarray, then confirmed by FISH. Descriptive statistical analysis was performed. RESULTS: Demographic data of 48 prenatal cases including 46 singletons and 1 dichorionic diamniotic twin pregnancy were evaluated. The most common extracardiac anomaly was skeletal system anomalies (25%), in which PEV was the most frequent one (20.8%). Polyhydramnios rate was detected as 31%, in 6.6% as an isolated finding. Microdeletion has been detected by karyotyping in 13 cases (13/47, 27.7%) (including 2 unbalanced translocations), by FISH in 28 cases (28/48, 58.3%), by microarray/a-CGH testing in 7 cases. Microarray analysis showed that in one case with unbalanced translocation had two consecutive deletions; one was proximal and other one distal to critical region and not encompassing TBX1 gene but CRKL and LZTR1 genes. CONCLUSION: The current study demonstrates the whole spectrum of atypical phenotypic and genotypic variations of 22q11.2DS in the largest prenatal case series reported to date. Therefore, differential diagnosis should be considered not solely in CHD, but also in the presence of isolated clubfeet and polyhydramnios. Establishing the diagnosis in the prenatal period may allow a postnatal multidisciplinary approach, as well as affect the actual prevalence of the disease. CI - (c) 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Sarac Sivrikoz, Tugba AU - Sarac Sivrikoz T AUID- ORCID: 0000-0001-5482-9429 AD - Division of Perinatology, Department of Obstetrics and Gynecology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. tugbasrc@gmail.com. FAU - Basaran, Seher AU - Basaran S AD - Department of Medical Genetics, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. AD - PREMED, Center for Genetic Diagnosis and Research, Mecidiyekoy, Istanbul, Turkey. FAU - Has, Recep AU - Has R AD - Division of Perinatology, Department of Obstetrics and Gynecology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. FAU - Karaman, Birsen AU - Karaman B AD - Department of Medical Genetics, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. AD - Department of Pediatric Basic Science, Child Health Institute, Istanbul University, Istanbul, Turkey. FAU - Kalelioglu, Ibrahim Halil AU - Kalelioglu IH AD - Division of Perinatology, Department of Obstetrics and Gynecology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. FAU - Kirgiz, Melike AU - Kirgiz M AD - PREMED, Center for Genetic Diagnosis and Research, Mecidiyekoy, Istanbul, Turkey. FAU - Altunoglu, Umut AU - Altunoglu U AD - Department of Medical Genetics, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. FAU - Yuksel, Atil AU - Yuksel A AD - Division of Perinatology, Department of Obstetrics and Gynecology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. LA - eng PT - Journal Article DEP - 20210618 PL - Germany TA - Arch Gynecol Obstet JT - Archives of gynecology and obstetrics JID - 8710213 RN - 0 (LZTR1 protein, human) RN - 0 (Transcription Factors) SB - IM MH - *DiGeorge Syndrome/diagnostic imaging/genetics MH - Female MH - Humans MH - Karyotyping MH - *Polyhydramnios MH - Pregnancy MH - Prenatal Diagnosis MH - Retrospective Studies MH - Transcription Factors MH - Ultrasonography, Prenatal OTO - NOTNLM OT - 22q11.2 microdeletion syndrome OT - Array-based comparative genomic hybridization analysis OT - DiGeorge syndrome OT - Prenatal diagnosis EDAT- 2021/06/20 06:00 MHDA- 2022/03/16 06:00 CRDT- 2021/06/19 06:20 PHST- 2021/02/03 00:00 [received] PHST- 2021/06/12 00:00 [accepted] PHST- 2021/06/20 06:00 [pubmed] PHST- 2022/03/16 06:00 [medline] PHST- 2021/06/19 06:20 [entrez] AID - 10.1007/s00404-021-06125-4 [pii] AID - 10.1007/s00404-021-06125-4 [doi] PST - ppublish SO - Arch Gynecol Obstet. 2022 Feb;305(2):323-342. doi: 10.1007/s00404-021-06125-4. Epub 2021 Jun 18. PMID- 34136565 OWN - NLM STAT- MEDLINE DCOM- 20211018 LR - 20211018 IS - 2314-6141 (Electronic) IS - 2314-6133 (Print) VI - 2021 DP - 2021 TI - Percutaneous versus Surgical Intervention for Severe Aortic Valve Stenosis: A Systematic Review. PG - 3973924 LID - 10.1155/2021/3973924 [doi] LID - 3973924 AB - Aortic stenosis is a disease that is increasing in prevalence and manifests as decreased cardiac output, which if left untreated can result in heart failure and ultimately death. It is primarily a disease of the elderly who often have multiple comorbidities. The advent of transcatheter aortic valve therapies has changed the way we treat these conditions. However, long-term results of these therapies remain uncertain. Recently, there has been an increasing number of studies examining the role of both surgical aortic valve replacement and transcatheter aortic valve replacement. We therefore performed a systematic review using Ovid MEDLINE, Ovid Embase, and the Cochrane Library. Two investigators searched papers published between January 1, 2007, and to date using the following terms: "aortic valve stenosis," "aortic valve operation," and "transcatheter aortic valve therapy." Both strategies in aortic stenosis treatment highlighted specific indications alongside the pitfalls such as structural valve degeneration and valve thrombosis which have a bearing on clinical outcomes. We propose some recommendations to help clinicians in the decision-making process as technological improvements make both surgical and transcatheter therapies viable options for patients with aortic stenosis. Finally, we assess the role of finite element analysis in patient selection for aortic valve replacement. THVT and AVR-S are both useful tools in the armamentarium against aortic stenosis. The decision between the two treatment strategies should be best guided by a strong robust evidence base, ideally with a long-term follow-up. This is best performed by the heart team with the patient as the center of the discussion. CI - Copyright (c) 2021 Adelaide Iervolino et al. FAU - Iervolino, Adelaide AU - Iervolino A AUID- ORCID: 0000-0002-3208-4689 AD - Department of Cardiovascular Sciences, Fondazione Policlinico Universitario A. Gemelli IRCSS, Italy. FAU - Singh, Sanjeet Singh Avtaar AU - Singh SSA AUID- ORCID: 0000-0003-4320-0734 AD - Department of Cardiothoracic Surgery, Golden Jubilee National Hospital, Glasgow, UK. FAU - Nappi, Pierluigi AU - Nappi P AD - Department of Clinical and Experimental Medicine, University of Messina, Italy. FAU - Bellomo, Francesca AU - Bellomo F AD - Department of Clinical and Experimental Medicine, University of Messina, Italy. FAU - Nappi, Francesco AU - Nappi F AUID- ORCID: 0000-0002-9705-5360 AD - Department of Cardiac Surgery, Centre Cardiologique du Nord de Saint-Denis, Paris, France. LA - eng PT - Comparative Study PT - Journal Article PT - Systematic Review DEP - 20210526 PL - United States TA - Biomed Res Int JT - BioMed research international JID - 101600173 RN - 0 (Fibrinolytic Agents) SB - IM MH - Aged MH - Aortic Valve/surgery MH - Aortic Valve Stenosis/*surgery/*therapy MH - Comorbidity MH - Decision Making MH - Fibrinolytic Agents/therapeutic use MH - Heart Valve Prosthesis MH - Humans MH - Percutaneous Coronary Intervention/*methods MH - Risk Factors MH - Thrombosis/etiology MH - Transcatheter Aortic Valve Replacement/methods PMC - PMC8175165 COIS- The authors declare that they have no conflicts of interest. EDAT- 2021/06/18 06:00 MHDA- 2021/10/21 06:00 PMCR- 2021/05/26 CRDT- 2021/06/17 06:48 PHST- 2021/04/08 00:00 [received] PHST- 2021/05/04 00:00 [revised] PHST- 2021/05/14 00:00 [accepted] PHST- 2021/06/17 06:48 [entrez] PHST- 2021/06/18 06:00 [pubmed] PHST- 2021/10/21 06:00 [medline] PHST- 2021/05/26 00:00 [pmc-release] AID - 10.1155/2021/3973924 [doi] PST - epublish SO - Biomed Res Int. 2021 May 26;2021:3973924. doi: 10.1155/2021/3973924. eCollection 2021. PMID- 34135577 OWN - NLM STAT- MEDLINE DCOM- 20210628 LR - 20220424 IS - 1178-1998 (Electronic) IS - 1176-9092 (Print) IS - 1176-9092 (Linking) VI - 16 DP - 2021 TI - Potentially Inappropriate Medication and Associated Factors Among Older Patients with Chronic Coronary Syndrome at Hospital Discharge in Beijing, China. PG - 1047-1056 LID - 10.2147/CIA.S305006 [doi] AB - PURPOSE: Medication therapy is crucial in the management of chronic coronary syndrome (CCS). The use of potentially inappropriate medications (PIMs) contributes to poor outcomes in older patients, making it a major public health concern. However, few studies are available on PIMs use in older Chinese CCS patients. To investigate the frequency of prescribed PIMs at discharge and explore risk factors in older adults with CCS. PATIENTS AND METHODS: The cross-sectional study was conducted in a tertiary hospital in China over three months, from 1st October to 31st December, 2019. CCS patients aged over 60 years who were discharged alive were recruited. Information on demographics and medications at discharge was collected. Clinical data including diagnoses, frailty status, New York Heart Association (NYHA) class and age-adjusted Charlson Comorbidity Index (ACCI) were evaluated in each patient. PIMs were identified using the 2019 Beers criteria. Binary logistic regression was performed to recognize variables related to PIMs. RESULTS: A total of 447 eligible patients with 2947 medications were included. The prevalence of PIMs use was 38%. Medications to be avoided, to be used with caution, and with drug-drug interactions were 38.4%, 48.9% and 12.7% of the PIMs, respectively. Medications with drug-disease/syndrome interactions and those adjusted for kidney function were not identified. The common PIMs were diuretics (37.1%), benzodiazepines and benzodiazepine receptor agonist hypnotics (15.2%), glimepiride (13.1%), and co-prescription of potassium-sparing diuretics and renin-angiotensin system (RAS) inhibitors (9.7%). Individuals with frailty syndrome, polypharmacy, multiple comorbidities, atrial fibrillation, psychiatric disorders and greater NYHA class severity were more likely to receive PIMs. CONCLUSION: Prescription of PIMs was a common burden in older adults. A CCS multidisciplinary team is needed to control PIMs, especially in vulnerable older patients. CI - (c) 2021 Zhao et al. FAU - Zhao, Mei AU - Zhao M AUID- ORCID: 0000-0001-5092-7793 AD - Department of Pharmacy, Peking University People's Hospital, Beijing, People's Republic of China. FAU - Song, Jun-Xian AU - Song JX AD - Department of Cardiology, Peking University People's Hospital, Beijing, People's Republic of China. FAU - Zheng, Fang-Fang AU - Zheng FF AD - Department of Cardiology, Peking University People's Hospital, Beijing, People's Republic of China. FAU - Huang, Lin AU - Huang L AD - Department of Pharmacy, Peking University People's Hospital, Beijing, People's Republic of China. FAU - Feng, Yu-Fei AU - Feng YF AD - Department of Pharmacy, Peking University People's Hospital, Beijing, People's Republic of China. LA - eng PT - Journal Article DEP - 20210609 PL - New Zealand TA - Clin Interv Aging JT - Clinical interventions in aging JID - 101273480 RN - 0 (Antihypertensive Agents) SB - IM MH - Aged MH - Aged, 80 and over MH - Antihypertensive Agents/*adverse effects/therapeutic use MH - Beijing MH - Cardiovascular Diseases/*drug therapy/epidemiology MH - Cross-Sectional Studies MH - Frail Elderly/*statistics & numerical data MH - Humans MH - Inappropriate Prescribing/*adverse effects/statistics & numerical data MH - Logistic Models MH - Male MH - Patient Discharge/statistics & numerical data MH - Polypharmacy MH - Potentially Inappropriate Medication List/*statistics & numerical data MH - Prevalence MH - Risk Factors MH - Tertiary Care Centers PMC - PMC8200161 OTO - NOTNLM OT - Beers criteria OT - chronic coronary syndrome OT - discharge OT - older adults OT - potentially inappropriate medication COIS- The authors declare no conflicts of interest in this work. EDAT- 2021/06/18 06:00 MHDA- 2021/06/29 06:00 PMCR- 2021/06/09 CRDT- 2021/06/17 06:37 PHST- 2021/02/05 00:00 [received] PHST- 2021/05/23 00:00 [accepted] PHST- 2021/06/17 06:37 [entrez] PHST- 2021/06/18 06:00 [pubmed] PHST- 2021/06/29 06:00 [medline] PHST- 2021/06/09 00:00 [pmc-release] AID - 305006 [pii] AID - 10.2147/CIA.S305006 [doi] PST - epublish SO - Clin Interv Aging. 2021 Jun 9;16:1047-1056. doi: 10.2147/CIA.S305006. eCollection 2021. PMID- 34131956 OWN - NLM STAT- MEDLINE DCOM- 20210812 LR - 20210812 IS - 1540-8191 (Electronic) IS - 0886-0440 (Linking) VI - 36 IP - 9 DP - 2021 Sep TI - Multi-disciplinary frameworks for the treatment of primary cardiac sarcoma. PG - 3456-3457 LID - 10.1111/jocs.15742 [doi] FAU - Stevens, Randy M AU - Stevens RM AUID- ORCID: 0000-0001-8454-6956 AD - Division of Pediatric Cardiac Surgery, Pediatric Cardiac Surgery, St. Christopher's Hospital for Children, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA. FAU - Silverman, Ayaka AU - Silverman A AD - Department of Pathology, St. Christopher's Hospital for Children, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA. FAU - Pascasio, Judy AU - Pascasio J AD - Department of Pathology, St. Christopher's Hospital for Children, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA. FAU - Sun, Jie AU - Sun J AD - Division of Pediatric Cardiology, Pediatric Cardiology, St. Christopher's Hospital for Children, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA. FAU - Throckmorton, Amy AU - Throckmorton A AUID- ORCID: 0000-0002-3773-8928 AD - BioCirc Research Laboratory, School of Biomedical Engineering, Science and Health Systems, Drexel University, Philadelphia, Pennsylvania, USA. FAU - Mulinari, Leonardo AU - Mulinari L AUID- ORCID: 0000-0001-7138-9912 AD - Pediatric and Congenital Cardiac Surgery, DeWitt Daughtry Family Department of Surgery, Congenital Heart Center, Holtz Children's Hospital, University of Miami Leonard Miller School of Medicine, Miami, Florida, USA. FAU - Cusimano, Robert James AU - Cusimano RJ AD - Division of Cardiac Surgery, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada. LA - eng PT - Journal Article DEP - 20210615 PL - United States TA - J Card Surg JT - Journal of cardiac surgery JID - 8908809 SB - IM MH - *Heart Neoplasms/diagnostic imaging/surgery MH - *Hemangiosarcoma MH - Humans MH - *Sarcoma OTO - NOTNLM OT - fetal survival OT - pregnancy OT - primary cardiac angiosarcoma OT - right atrial tumor EDAT- 2021/06/17 06:00 MHDA- 2021/08/13 06:00 CRDT- 2021/06/16 07:04 PHST- 2021/06/07 00:00 [received] PHST- 2021/06/08 00:00 [accepted] PHST- 2021/06/17 06:00 [pubmed] PHST- 2021/08/13 06:00 [medline] PHST- 2021/06/16 07:04 [entrez] AID - 10.1111/jocs.15742 [doi] PST - ppublish SO - J Card Surg. 2021 Sep;36(9):3456-3457. doi: 10.1111/jocs.15742. Epub 2021 Jun 15. PMID- 34131793 OWN - NLM STAT- MEDLINE DCOM- 20210927 LR - 20260304 IS - 1618-727X (Electronic) IS - 0897-1889 (Print) IS - 0897-1889 (Linking) VI - 34 IP - 3 DP - 2021 Jun TI - Multispecialty Enterprise Imaging Workgroup Consensus on Interactive Multimedia Reporting Current State and Road to the Future: HIMSS-SIIM Collaborative White Paper. PG - 495-522 LID - 10.1007/s10278-021-00450-5 [doi] AB - Diagnostic and evidential static image, video clip, and sound multimedia are captured during routine clinical care in cardiology, dermatology, ophthalmology, pathology, physiatry, radiation oncology, radiology, endoscopic procedural specialties, and other medical disciplines. Providers typically describe the multimedia findings in contemporaneous electronic health record clinical notes or associate a textual interpretative report. Visual communication aids commonly used to connect, synthesize, and supplement multimedia and descriptive text outside medicine remain technically challenging to integrate into patient care. Such beneficial interactive elements may include hyperlinks between text, multimedia elements, alphanumeric and geometric annotations, tables, graphs, timelines, diagrams, anatomic maps, and hyperlinks to external educational references that patients or provider consumers may find valuable. This HIMSS-SIIM Enterprise Imaging Community workgroup white paper outlines the current and desired clinical future state of interactive multimedia reporting (IMR). The workgroup adopted a consensus definition of IMR as "interactive medical documentation that combines clinical images, videos, sound, imaging metadata, and/or image annotations with text, typographic emphases, tables, graphs, event timelines, anatomic maps, hyperlinks, and/or educational resources to optimize communication between medical professionals, and between medical professionals and their patients." This white paper also serves as a precursor for future efforts toward solving technical issues impeding routine interactive multimedia report creation and ingestion into electronic health records. CI - (c) 2021. The Author(s). FAU - Roth, Christopher J AU - Roth CJ AUID- ORCID: 0000-0002-9634-7126 AD - Department of Radiology, Duke University, Durham, NC, USA. christopher.roth@duke.edu. FAU - Clunie, David A AU - Clunie DA AD - PixelMed Publishing, LLC, Bangor, PA, USA. FAU - Vining, David J AU - Vining DJ AD - Department of Abdominal Imaging, MD Anderson Cancer Center, Houston, TX, USA. FAU - Berkowitz, Seth J AU - Berkowitz SJ AD - Department of Radiology, Beth Israel Deaconess Medical Center, Boston, MA, USA. FAU - Berlin, Alejandro AU - Berlin A AD - Radiation Medicine Program, Princess Margaret Cancer Centre - University Health Network, Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada. FAU - Bissonnette, Jean-Pierre AU - Bissonnette JP AD - Departments of Radiation Oncology and Medical Biophysics, University of Toronto, Toronto, ON, Canada. FAU - Clark, Shawn D AU - Clark SD AD - University of Miami Hospitals and Clinics, Miami, FL, USA. FAU - Cornish, Toby C AU - Cornish TC AD - Department of Pathology, University of Colorado School of Medicine, Aurora, CO, USA. FAU - Eid, Monief AU - Eid M AD - eHealth & Digital Transformation Agency, Ministry of Health, Riyadh, Saudi Arabia. FAU - Gaskin, Cree M AU - Gaskin CM AD - Department of Radiology and Medical Imaging, University of Virginia, Charlottesville, VA, USA. FAU - Goel, Alexander K AU - Goel AK AD - PuraJuniper, Toronto, ON, Canada. FAU - Jacobs, Genevieve C AU - Jacobs GC AD - Norton Healthcare, Louisville, KY, USA. FAU - Kwan, David AU - Kwan D AD - Health Technology and Information Management, Ontario Health (Cancer Care Ontario), Toronto, ON, Canada. FAU - Luviano, Damien M AU - Luviano DM AD - Department of Surgery, Virginia Tech Carilion School of Medicine, Roanoke, VA, USA. FAU - McBee, Morgan P AU - McBee MP AD - Department of Radiology and Radiological Science, Medical University of South Carolina, Charleston, SC, USA. FAU - Miller, Kelly AU - Miller K AD - Memorial Health System, Springfield, IL, USA. FAU - Hafiz, Abdul Moiz AU - Hafiz AM AD - Division of Cardiology, Southern Illinois University School of Medicine, Springfield, IL, USA. FAU - Obcemea, Ceferino AU - Obcemea C AD - Radiation Research Program, National Cancer Institute, Bethesda, MD, USA. FAU - Parwani, Anil V AU - Parwani AV AD - Department of Pathology, The Ohio State University, Columbus, OH, USA. FAU - Rotemberg, Veronica AU - Rotemberg V AD - Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Silver, Elliot L AU - Silver EL AD - Argentix Informatics, Vancouver, BC, Canada. FAU - Storm, Erik S AU - Storm ES AD - Department of Radiology and Medical Education, Salem VA Medical Center, Salem, VA, USA. FAU - Tcheng, James E AU - Tcheng JE AD - Department of Medicine, Division of Cardiology, Duke University, Durham, NC, USA. FAU - Thullner, Karen S AU - Thullner KS AD - PenRad Technologies, Inc, Buffalo, MN, USA. FAU - Folio, Les R AU - Folio LR AD - Lead CT Radiologist, NIH Clinical Center, Bethesda, MD, USA. LA - eng GR - P30 CA008748/CA/NCI NIH HHS/United States PT - Consensus Statement PT - Journal Article PT - Review DEP - 20210615 PL - United States TA - J Digit Imaging JT - Journal of digital imaging JID - 9100529 SB - IM MH - Diagnostic Imaging MH - Humans MH - Multimedia MH - *Radiology MH - *Radiology Information Systems PMC - PMC8329131 OTO - NOTNLM OT - Enterprise imaging OT - HIT standards OT - Interoperability OT - Multimedia OT - Reporting COIS- Seth Berkowitz: a. Grants, Philips Healthcare. b. Personal fees, Change Healthcare. David Clunie: a. Consultant, Philips Algotec. b. Consultant, Essex Leidos CBIIT NCI. c. Consultant, Brigham and Women's Hospital NCI Imaging Data Commons (IDC). d. Consultant, University of Leeds Northern Pathology Imaging Co-operative (NPIC). e. Advisory Board, maiData. Toby Cornish: a. Personal fees, Leica Biosystems. b. Patent, "Method and System to Digitize Pathology Slides in a Stepwise Fashion for Review." US Patent 9,214,019. Les Folio: a. Patent (no royalties), "Radiographic marker that displays upright angle on portable x-rays." US Patent 9,541,822 B2. b. Patent (no royalties), "Multigrayscale Universal CT Window." US Patent 8,406,493 B2. c. Research agreement, Philips Healthcare. d. Author royalties, Springer. e. Funding statement, Supported in part by the NIH Clinical Center Intramural Research Program. Cree Gaskin: a. Research Grant, Philips Healthcare. b. Paid speaker, Philips Healthcare. c. Author Royalties, Oxford University Press. Alex Goel: a. Consultant, College of American Pathologists. Morgan McBee: a. Consultant, Digital identity management startup ValidIDe. Elliot Silver: a. Founder, Argentix Informatics Inc. b. Consultant, Zebra Medical. c. Consultant, MEDO.ai. David Vining: a. Founder and CEO, VisionSR, Inc. b. Royalties, Bracco Diagnostics, Inc. c. Patents, "Image reporting method and system." US Patents 6,819,785 and 6,785,410. d. Patent, "Method and system for producing interactive, three-dimensional renderings of selected body organs having hollow lumens to enable simulated movement through the lumen." US Patent 5,782,762. All remaining authors, including corresponding author Christopher Roth: The authors declare that they have no conflict of interest. EDAT- 2021/06/17 06:00 MHDA- 2021/09/28 06:00 PMCR- 2021/06/15 CRDT- 2021/06/16 06:55 PHST- 2021/01/27 00:00 [received] PHST- 2021/03/19 00:00 [accepted] PHST- 2021/03/05 00:00 [revised] PHST- 2021/06/17 06:00 [pubmed] PHST- 2021/09/28 06:00 [medline] PHST- 2021/06/16 06:55 [entrez] PHST- 2021/06/15 00:00 [pmc-release] AID - 10.1007/s10278-021-00450-5 [pii] AID - 450 [pii] AID - 10.1007/s10278-021-00450-5 [doi] PST - ppublish SO - J Digit Imaging. 2021 Jun;34(3):495-522. doi: 10.1007/s10278-021-00450-5. Epub 2021 Jun 15. PMID- 34127541 OWN - NLM STAT- MEDLINE DCOM- 20211207 LR - 20211214 IS - 1468-201X (Electronic) IS - 1355-6037 (Linking) VI - 107 IP - 18 DP - 2021 Sep TI - Clinical practice guideline for transcatheter versus surgical valve replacement in patients with severe aortic stenosis in Latin America. PG - 1450-1457 LID - 10.1136/heartjnl-2021-319489 [doi] AB - In elderly (75 years or older) patients living in Latin America with severe symptomatic aortic stenosis candidates for transfemoral approach, the panel suggests the use of transcatheter aortic valve implant (TAVI) over surgical aortic valve replacement (SAVR). This is a conditional recommendation, based on moderate certainty in the evidence (⨁⨁⨁Omicron).This recommendation does not apply to patients in which there is a standard of care, like TAVI for patients at very high risk for cardiac surgery or inoperable patients, or SAVR for non-elderly patients (eg, under 65 years old) at low risk for cardiac surgery. The suggested age threshold of 75 years old is based on judgement of limited available literature and should be used as a guide rather than a determinant threshold.The conditional nature of this recommendation means that the majority of patients in this situation would want a transfemoral TAVI over SAVR, but some may prefer SAVR. For clinicians, this means that they must be familiar with the evidence supporting this recommendation and help each patient to arrive at a management decision integrating a multidisciplinary team discussion (Heart Team), patient's values and preferences through shared decision-making, and available resources. Policymakers will require substantial debate and the involvement of various stakeholders to implement this recommendation. CI - (c) Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Lamelas, Pablo AU - Lamelas P AUID- ORCID: 0000-0003-2008-3870 AD - Interventional Cardiology, Instituto Cardiovascular de Buenos Aires, Buenos Aires, Argentina plamelas@icba.com.ar. AD - Department of Health Research Methods Evidence and Impact, McMaster University, Hamilton, Ontario, Canada. FAU - Ragusa, Martin Alberto AU - Ragusa MA AD - Internal Medicine, Hospital Aleman, Buenos Aires, Argentina. AD - Internal Medicine, Hospital General de Agudos Juan A Fernandez, Buenos Aires, Argentina. FAU - Bagur, Rodrigo AU - Bagur R AUID- ORCID: 0000-0003-1888-9429 AD - Medicine, London Health Sciences Centre, Western University, London, Ontario, Canada. FAU - Jaffer, Iqbal AU - Jaffer I AD - Cardiac Surgery, McMaster University, Hamilton, Ontario, Canada. FAU - Ribeiro, Henrique AU - Ribeiro H AD - Medical sciences, University of Sao Paulo, Sao Paulo, Brazil. FAU - Baranchuk, Adrian AU - Baranchuk A AD - Medicine, Queen's University, Kingston, Ontario, Canada. FAU - Wyss, Fernando AU - Wyss F AUID- ORCID: 0000-0003-1700-4692 AD - Cardiology, Guatemala Cardiovascular Services and Technology, Guatemala, Guatemala. FAU - Sosa Liprandi, Alvaro AU - Sosa Liprandi A AD - Cardiology, Sanatorio Guemes, Buenos Aires, Argentina. FAU - Olivares, Gabriel AU - Olivares G AD - Surgery, Clinica Universidad de los Andes, Las Condes, Chile. FAU - Arrais, Magaly AU - Arrais M AD - Cardiac Surgery, Dante Pazzanese Institute, Sao Paulo, Brazil. FAU - Rendon, Juan Camilo AU - Rendon JC AD - Surgery, Clinica CardioVid, Medellin, Colombia. FAU - Catrip, Jorge AU - Catrip J AD - Surgery, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico, Mexico. FAU - Agatiello, Carla AU - Agatiello C AD - Interventional Cardiology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. FAU - Cura, Fernando AU - Cura F AD - Interventional Cardiology, Instituto Cardiovascular de Buenos Aires, Buenos Aires, Argentina. FAU - Marchena, Alfaro AU - Marchena A AD - Cardiology, Clinica Hospital San Fernando, Panama City, Panama. FAU - Sandoli de Brito, Fabio Jr AU - Sandoli de Brito F Jr AD - Interventional Cardiology, Hospital Israelita Albert Einstein, Sao Paulo, Brazil. FAU - Mangione, Jose A AU - Mangione JA AD - Interventional Cardiology, Beneficencia Portuguesa de Sao Paulo, Sao Paulo, Brazil. FAU - Damonte, Anibal AU - Damonte A AD - Interventional Cardiology, Instituto Cardiovascular de Rosario, Rosario, Argentina. FAU - Santaera, Omar AU - Santaera O AD - Cardiology, Clinica Privada Provincial de Merlo, Buenos Aires, Argentina. FAU - Hidalgo, Pedro AU - Hidalgo P AD - Interventional Cardiology, Policlinica Amado, Maracaibo, Venezuela. FAU - Nieuwlaat, Robby AU - Nieuwlaat R AD - Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada. FAU - Izcovich, Ariel AU - Izcovich A AD - Internal Medicine, Hospital Aleman, Buenos Aires, Argentina. CN - Endorsed by the Sociedad Latino Americana de Cardiologia Intervencionista (SOLACI) and the Sociedad Interamericana de Cardiologia (SIAC) LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20210614 PL - England TA - Heart JT - Heart (British Cardiac Society) JID - 9602087 SB - IM MH - Aortic Valve Stenosis/diagnosis/*surgery MH - Heart Valve Prosthesis Implantation/standards MH - Humans MH - Latin America MH - *Practice Guidelines as Topic MH - Severity of Illness Index MH - Transcatheter Aortic Valve Replacement/*standards OTO - NOTNLM OT - aortic valve stenosis OT - heart valve prosthesis implantation OT - transcatheter aortic valve replacement COIS- Competing interests: FSB: proctoring fees from Edwards LifeSciences, Medtronic and Boston Scientific. CA, MA, FC: proctoring fees from Edwards LifeSciences and Boston Scientific. Participants without voting rights: PL: proctoring fees from Edwards LifeSciences, Medtronic, Boston Scientific (significant); consulting fees Boston Scientific (not significant). HR: proctoring fees from Edwards LifeSciences, Boston Scientific and Medtronic, and research grants from Edwards LifeSciences, Boston Scientific and Medtronic. Clinical external reviewers: MT: Nothing to declare. OM: Consulting honoraria from Medtronic, Boston Scientific and Philips. CR: Nothing to declare. EDAT- 2021/06/16 06:00 MHDA- 2021/12/15 06:00 CRDT- 2021/06/15 06:10 PHST- 2021/04/06 00:00 [received] PHST- 2021/05/17 00:00 [accepted] PHST- 2021/06/16 06:00 [pubmed] PHST- 2021/12/15 06:00 [medline] PHST- 2021/06/15 06:10 [entrez] AID - heartjnl-2021-319489 [pii] AID - 10.1136/heartjnl-2021-319489 [doi] PST - ppublish SO - Heart. 2021 Sep;107(18):1450-1457. doi: 10.1136/heartjnl-2021-319489. Epub 2021 Jun 14. PMID- 34127530 OWN - NLM STAT- MEDLINE DCOM- 20211129 LR - 20250530 IS - 2053-3624 (Print) IS - 2053-3624 (Electronic) IS - 2053-3624 (Linking) VI - 8 IP - 1 DP - 2021 Jun TI - Coagulation derangement and risk factors for valve thrombosis following transcatheter aortic valve implantation. LID - 10.1136/openhrt-2020-001496 [doi] LID - e001496 AB - AIMS: Durability of transcatheter aortic valve implantation (TAVI) is key to its expansion. We sought to identify incidence of valve thrombosis and predictors of valve thrombosis in our single centre with associated coagulation testing pre-TAVI and post-TAVI. METHODS AND RESULTS: This single-centre observational study comprised patients undergoing transfemoral TAVI discussed in the Heart Team meeting . Patients were followed up with echocardiography at 120 days to identify incidence of elevated transvalvular gradient and multivariable analysis was performed to identify factors associated with an increased odds of developing valve thrombosis. In addition, 11 patients underwent baseline, day 1 and day 120 post-TAVI coagulation testing. Between August 2017 and August 2019, 437 consecutive patients underwent transfemoral TAVI. Of these patients, 207/437 (47.4%) had 3-month follow-up echo data available and were analysed. Of these patients, 26/207 (12.6%) had elevated transvalvular gradients. These patients tended to be younger (80+/-14 vs 83+/-6 years; p=0.047) with a lower ejection fraction (49+/-13 vs 54%+/-11%; p=0.021), with a greater proportion of the population experiencing atrial fibrillation (14/21, 54% vs 68/181, 38%; p=0.067). Following multivariable analysis, there remained a trend towards higher eccentricity index associated with elevated gradients. Baseline (pre-TAVI) elevation of thrombin antithrombin levels (56+/-63; reference range 1.0-4.1 ng/L) and PF 1+2 (791+/-632; reference range 69-229 ng/mL) normalised at 120 days post-TAVI CONCLUSION: This study demonstrated that in the cohort of patients undergoing transfemoral TAVI in our centre: younger age, poor ejection fraction, atrial fibrillation and increased baseline eccentricity of the aortic valve annulus were present to a greater extent in patients exhibiting elevated transvalvular gradients at 3-month follow-up. Further work is required to delineate the extent of coagulation derangement and confirm predictors of thrombosis. CI - (c) Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ. FAU - Patterson, Tiffany AU - Patterson T AUID- ORCID: 0000-0001-7619-9122 AD - Cardiovascular Division, School of Life Science and Medicine, King's College London, London, UK tiffany.patterson@kcl.ac.uk. FAU - Hurrell, Harriet AU - Hurrell H AD - Cardiovascular Division, School of Life Science and Medicine, King's College London, London, UK. FAU - Lee, Jack AU - Lee J AD - Division of Biomedical Engineering and Imaging Sciences, King's College London, London, UK. FAU - Esposito, Giulia AU - Esposito G AD - Cardiovascular Division, School of Life Science and Medicine, King's College London, London, UK. FAU - Dutta, Utkarsh AU - Dutta U AD - Cardiovascular Division, School of Life Science and Medicine, King's College London, London, UK. FAU - Grapsa, Julia AU - Grapsa J AD - Cardiovascular Department, Guy's and St Thomas' NHS Foundation Trust, London, UK. FAU - Aroney, Nicholas AU - Aroney N AD - Cardiovascular Department, Guy's and St Thomas' NHS Foundation Trust, London, UK. FAU - Ahmed-Jushuf, Fiyyaz AU - Ahmed-Jushuf F AD - Cardiovascular Department, Guy's and St Thomas' NHS Foundation Trust, London, UK. FAU - Allen, Christopher AU - Allen C AD - Cardiovascular Division, School of Life Science and Medicine, King's College London, London, UK. FAU - Rajani, Ronak AU - Rajani R AD - Cardiovascular Department, Guy's and St Thomas' NHS Foundation Trust, London, UK. FAU - Preston, Rebecca AU - Preston R AD - Department of Radiology and Cardiac CT, Guy's and St Thomas' NHS Foundation Trust, London, UK. FAU - Young, Christopher AU - Young C AD - Cardiovascular Department, Guy's and St Thomas' NHS Foundation Trust, London, UK. FAU - Lucchese, Gianluca AU - Lucchese G AD - Cardiovascular Department, Guy's and St Thomas' NHS Foundation Trust, London, UK. FAU - Parmar, Kiran AU - Parmar K AD - Department of Haematology and Thrombosis, Guy's and St Thomas' NHS Foundation Trust, London, UK. FAU - Hunt, Beverley AU - Hunt B AD - Department of Haematology and Thrombosis, Guy's and St Thomas' NHS Foundation Trust, London, UK. FAU - Prendergast, Bernard D AU - Prendergast BD AD - Cardiovascular Department, Guy's and St Thomas' NHS Foundation Trust, London, UK. FAU - Redwood, Simon R AU - Redwood SR AD - Cardiovascular Division, School of Life Science and Medicine, King's College London, London, UK. LA - eng GR - FS/14/11/30526/BHF_/British Heart Foundation/United Kingdom PT - Journal Article PT - Observational Study PT - Research Support, Non-U.S. Gov't PL - England TA - Open Heart JT - Open heart JID - 101631219 RN - 0 (Biomarkers) SB - IM MH - Aged, 80 and over MH - Aortic Valve/diagnostic imaging/surgery MH - Aortic Valve Stenosis/blood/diagnosis/*surgery MH - Biomarkers/blood MH - Blood Coagulation/*physiology MH - Blood Coagulation Disorders/*blood/complications/epidemiology MH - Echocardiography MH - Female MH - Follow-Up Studies MH - Heart Diseases/*blood/epidemiology/etiology MH - Heart Valve Prosthesis/*adverse effects MH - Humans MH - Incidence MH - Male MH - Prospective Studies MH - Prosthesis Design MH - Risk Assessment/*methods MH - Risk Factors MH - Thrombosis/*blood/epidemiology/etiology MH - Transcatheter Aortic Valve Replacement/adverse effects MH - Treatment Outcome MH - United Kingdom/epidemiology PMC - PMC8204180 OTO - NOTNLM OT - aortic valve stenosis OT - heart valve diseases OT - transcatheter aortic valve replacement COIS- Competing interests: None declared. EDAT- 2021/06/16 06:00 MHDA- 2021/11/30 06:00 PMCR- 2021/06/14 CRDT- 2021/06/15 06:10 PHST- 2020/11/02 00:00 [received] PHST- 2021/03/01 00:00 [revised] PHST- 2021/04/12 00:00 [accepted] PHST- 2021/06/15 06:10 [entrez] PHST- 2021/06/16 06:00 [pubmed] PHST- 2021/11/30 06:00 [medline] PHST- 2021/06/14 00:00 [pmc-release] AID - openhrt-2020-001496 [pii] AID - 10.1136/openhrt-2020-001496 [doi] PST - ppublish SO - Open Heart. 2021 Jun;8(1):e001496. doi: 10.1136/openhrt-2020-001496. PMID- 34127277 OWN - NLM STAT- MEDLINE DCOM- 20210823 LR - 20250228 IS - 1097-685X (Electronic) IS - 0022-5223 (Linking) VI - 162 IP - 3 DP - 2021 Sep TI - Is this an adventure? PG - 907-916 LID - S0022-5223(21)00812-6 [pii] LID - 10.1016/j.jtcvs.2021.05.026 [doi] FAU - Moon, Marc R AU - Moon MR AD - Division of Cardiothoracic Surgery, Washington University School of Medicine, St Louis, Mo. Electronic address: moonm@wustl.edu. LA - eng PT - Address DEP - 20210523 PL - United States TA - J Thorac Cardiovasc Surg JT - The Journal of thoracic and cardiovascular surgery JID - 0376343 SB - IM MH - Anger MH - Attitude of Health Personnel MH - Cooperative Behavior MH - *Education, Medical, Graduate MH - Health Knowledge, Attitudes, Practice MH - Humans MH - *Internship and Residency MH - Leadership MH - Mentors MH - Patient Care Team MH - Societies, Medical MH - Surgeons/*education/psychology MH - Thoracic Surgery/*education MH - Thoracic Surgical Procedures/*education EDAT- 2021/06/16 06:00 MHDA- 2021/08/24 06:00 CRDT- 2021/06/15 06:02 PHST- 2021/05/08 00:00 [received] PHST- 2021/05/08 00:00 [revised] PHST- 2021/05/11 00:00 [accepted] PHST- 2021/06/16 06:00 [pubmed] PHST- 2021/08/24 06:00 [medline] PHST- 2021/06/15 06:02 [entrez] AID - S0022-5223(21)00812-6 [pii] AID - 10.1016/j.jtcvs.2021.05.026 [doi] PST - ppublish SO - J Thorac Cardiovasc Surg. 2021 Sep;162(3):907-916. doi: 10.1016/j.jtcvs.2021.05.026. Epub 2021 May 23. PMID- 34124512 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240402 IS - 2472-5390 (Electronic) IS - 2472-5390 (Linking) VI - 5 IP - 3 DP - 2021 Jul TI - Development of a Rigorously Designed Procedural Checklist for Assessment of Emergency Medicine Resident Performance of Temporary Transvenous Cardiac Pacing. PG - e10566 LID - 10.1002/aet2.10566 [doi] LID - e10566 AB - OBJECTIVES: Temporary transvenous cardiac pacing (TVP) is a potentially lifesaving intervention included in the list of essential core procedures for emergency medicine (EM) training; however, opportunities to perform TVP during residency cannot be guaranteed. EM graduates report feeling subjectively underprepared for this procedure, but objective performance data are lacking. Checklist-based simulated assessment is an increasing focus of competency-based medical education, particularly for invasive procedures like TVP. The objectives of this paper were as follows: first, to enlist a multidisciplinary team of experts to create an assessment tool for TVP using best practices in checklist development; second, to determine the reliability of checklist scoring; and third, to assess EM residents' baseline ability to perform TVP using a dedicated task trainer. METHODS: This study was conducted at a single 4-year EM residency. A panel of emergency physicians and cardiologists designed a TVP checklist using a modified Delphi approach. After consensus was achieved on a final checklist, EM residents were assessed using a dedicated TVP task trainer. Inter-rater reliability was determined using Cohen's kappa coefficient. Resident performance was determined by number of correctly performed checklist items. RESULTS: The expert panel achieved consensus on a 30-item checklist after three rounds of revisions. The Cohen's kappa coefficient for the overall checklist score was 0.87, with individual checklist items ranging from 0.63 to 1.00. In total, 58 residents were assessed with a mean score of 13.5 of 30 checklist items. Scores increased with each year of training. CONCLUSIONS: This study details the rigorous development of a TVP checklist designed by a multidisciplinary team of experts. Checklist scores demonstrated strong inter-rater reliability. The overall poor performance of this cohort suggests the current approach to TVP training does not provide sufficient preparation for EM residents. Competency-based techniques, such as simulation-based mastery learning, should be explored. CI - (c) 2020 by the Society for Academic Emergency Medicine. FAU - Klein, Matthew R AU - Klein MR AUID- ORCID: 0000-0001-7888-6372 AD - Department of Emergency Medicine Northwestern University Feinberg School of Medicine Chicago IL USA. FAU - Schmitz, Zachary P AU - Schmitz ZP AD - Department of Emergency Medicine Northwestern University Feinberg School of Medicine Chicago IL USA. FAU - Adler, Mark D AU - Adler MD AUID- ORCID: 0000-0003-1857-8639 AD - the Department of Pediatrics Northwestern University Feinberg School of Medicine Chicago IL USA. AD - and the Department of Medical Education Northwestern University Feinberg School of Medicine Chicago IL USA. FAU - Salzman, David H AU - Salzman DH AD - Department of Emergency Medicine Northwestern University Feinberg School of Medicine Chicago IL USA. AD - and the Department of Medical Education Northwestern University Feinberg School of Medicine Chicago IL USA. LA - eng PT - Journal Article DEP - 20210106 PL - United States TA - AEM Educ Train JT - AEM education and training JID - 101722142 PMC - PMC8171784 EDAT- 2021/06/15 06:00 MHDA- 2021/06/15 06:01 PMCR- 2022/01/06 CRDT- 2021/06/14 09:55 PHST- 2020/08/25 00:00 [received] PHST- 2020/11/17 00:00 [revised] PHST- 2020/11/24 00:00 [accepted] PHST- 2021/06/14 09:55 [entrez] PHST- 2021/06/15 06:00 [pubmed] PHST- 2021/06/15 06:01 [medline] PHST- 2022/01/06 00:00 [pmc-release] AID - AET210566 [pii] AID - 10.1002/aet2.10566 [doi] PST - epublish SO - AEM Educ Train. 2021 Jan 6;5(3):e10566. doi: 10.1002/aet2.10566. eCollection 2021 Jul. PMID- 34115019 OWN - NLM STAT- MEDLINE DCOM- 20210624 LR - 20240811 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 100 IP - 23 DP - 2021 Jun 11 TI - Prevalence of rapid response systems in small hospitals: A questionnaire survey. PG - e26261 LID - 10.1097/MD.0000000000026261 [doi] LID - e26261 AB - The rapid response system (RRS) was introduced for early stage intervention in patients with deteriorating clinical conditions. Responses to unexpected in-hospital patient emergencies varied among hospitals. This study was conducted to understand the prevalence of RRS in smaller hospitals and to identify the need for improvements in the responses to in-hospital emergencies.A questionnaire survey of 971 acute-care hospitals in western Japan was conducted from May to June 2019 on types of in-hospital emergency response for patients in cardiac arrest (e.g., medical emergency teams [METs]), before obvious deterioration (e.g., rapid response teams [RRTs]), and areas for improvement.We received 149 responses, including those from 56 smaller hospitals (/= 33. Spearman's correlation and receiver operator characteristic analysis were conducted to investigate the role of the GRACE score as a predictor of the SYNTAX score. There was a significantly positive correlation between the SYNTAX and the GRACE scores (r = 0.32, p < 0.001). The GRACE score predicted severe CAD (SYNTAX >/= 33) moderately well (the area under the curve was 0.595 (0.522-0.667)). A GRACE score of 126 was documented as the optimal cut-off for the prediction of a SYNTAX score >/= 33 (sensitivity = 53.5% and specificity = 66%). Therefore, our study reports a significantly positive correlation between the GRACE and the SYNTAX score in patients with ACS. Notably, NSTEMI patients with a high-risk coronary anatomy have higher calculated GRACE scores. A multidisciplinary approach by a heart team could possibly alter the therapeutic approach and management in patients presenting with ACS and a high calculated GRACE score. FAU - Sofidis, Georgios AU - Sofidis G AD - First Department of Cardiology, AHEPA University Hospital, Aristotle University of Thessaloniki, St. Kiriakidi 1, 54636 Thessaloniki, Greece. FAU - Otountzidis, Nikolaos AU - Otountzidis N AUID- ORCID: 0000-0003-1721-6468 AD - First Department of Cardiology, AHEPA University Hospital, Aristotle University of Thessaloniki, St. Kiriakidi 1, 54636 Thessaloniki, Greece. FAU - Stalikas, Nikolaos AU - Stalikas N AUID- ORCID: 0000-0002-0190-5392 AD - First Department of Cardiology, AHEPA University Hospital, Aristotle University of Thessaloniki, St. Kiriakidi 1, 54636 Thessaloniki, Greece. FAU - Karagiannidis, Efstratios AU - Karagiannidis E AUID- ORCID: 0000-0001-8328-5942 AD - First Department of Cardiology, AHEPA University Hospital, Aristotle University of Thessaloniki, St. Kiriakidi 1, 54636 Thessaloniki, Greece. FAU - Papazoglou, Andreas S AU - Papazoglou AS AUID- ORCID: 0000-0003-4981-8121 AD - First Department of Cardiology, AHEPA University Hospital, Aristotle University of Thessaloniki, St. Kiriakidi 1, 54636 Thessaloniki, Greece. FAU - Moysidis, Dimitrios V AU - Moysidis DV AUID- ORCID: 0000-0001-9083-0267 AD - First Department of Cardiology, AHEPA University Hospital, Aristotle University of Thessaloniki, St. Kiriakidi 1, 54636 Thessaloniki, Greece. FAU - Panteris, Eleftherios AU - Panteris E AD - Laboratory of Forensic Medicine and Toxicology, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece. AD - Biomic_AUTh, Center for Interdisciplinary Research and Innovation (CIRI-AUTH), Balkan Center, B1.4, 10th km Thessaloniki-Thermi Rd, P.O. Box 8318, 57001 Thessaloniki, Greece. FAU - Deda, Olga AU - Deda O AUID- ORCID: 0000-0003-3642-7367 AD - Laboratory of Forensic Medicine and Toxicology, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece. AD - Biomic_AUTh, Center for Interdisciplinary Research and Innovation (CIRI-AUTH), Balkan Center, B1.4, 10th km Thessaloniki-Thermi Rd, P.O. Box 8318, 57001 Thessaloniki, Greece. FAU - Kartas, Anastasios AU - Kartas A AUID- ORCID: 0000-0002-1170-9133 AD - First Department of Cardiology, AHEPA University Hospital, Aristotle University of Thessaloniki, St. Kiriakidi 1, 54636 Thessaloniki, Greece. FAU - Zegkos, Thomas AU - Zegkos T AD - First Department of Cardiology, AHEPA University Hospital, Aristotle University of Thessaloniki, St. Kiriakidi 1, 54636 Thessaloniki, Greece. FAU - Daskalaki, Paraskevi AU - Daskalaki P AUID- ORCID: 0000-0001-5532-2646 AD - First Department of Cardiology, AHEPA University Hospital, Aristotle University of Thessaloniki, St. Kiriakidi 1, 54636 Thessaloniki, Greece. FAU - Theodoridou, Niki AU - Theodoridou N AUID- ORCID: 0000-0003-3194-594X AD - First Department of Cardiology, AHEPA University Hospital, Aristotle University of Thessaloniki, St. Kiriakidi 1, 54636 Thessaloniki, Greece. FAU - Stefanopoulos, Leandros AU - Stefanopoulos L AD - Lab of Computing, Medical Informatics and Biomedical Imaging Technologies, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece. FAU - Karvounis, Haralambos AU - Karvounis H AD - First Department of Cardiology, AHEPA University Hospital, Aristotle University of Thessaloniki, St. Kiriakidi 1, 54636 Thessaloniki, Greece. FAU - Gika, Helen AU - Gika H AUID- ORCID: 0000-0002-1893-937X AD - Laboratory of Forensic Medicine and Toxicology, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece. AD - Biomic_AUTh, Center for Interdisciplinary Research and Innovation (CIRI-AUTH), Balkan Center, B1.4, 10th km Thessaloniki-Thermi Rd, P.O. Box 8318, 57001 Thessaloniki, Greece. FAU - Theodoridis, Georgios AU - Theodoridis G AUID- ORCID: 0000-0002-2015-108X AD - Biomic_AUTh, Center for Interdisciplinary Research and Innovation (CIRI-AUTH), Balkan Center, B1.4, 10th km Thessaloniki-Thermi Rd, P.O. Box 8318, 57001 Thessaloniki, Greece. AD - Laboratory of Analytical Chemistry, Department of Chemistry, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece. FAU - Sianos, Georgios AU - Sianos G AUID- ORCID: 0000-0002-3042-0757 AD - First Department of Cardiology, AHEPA University Hospital, Aristotle University of Thessaloniki, St. Kiriakidi 1, 54636 Thessaloniki, Greece. LA - eng GR - T1EDK-04005/European Social Fund/ GR - T1EDK-04005/Greek National Funds/ PT - Journal Article DEP - 20210520 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC8160761 OTO - NOTNLM OT - GRACE score OT - SYNTAX score OT - acute coronary syndrome OT - coronary angiography COIS- The authors declare no conflict of interest. EDAT- 2021/06/03 06:00 MHDA- 2021/06/03 06:01 PMCR- 2021/05/20 CRDT- 2021/06/02 01:12 PHST- 2021/04/25 00:00 [received] PHST- 2021/05/11 00:00 [revised] PHST- 2021/05/17 00:00 [accepted] PHST- 2021/06/02 01:12 [entrez] PHST- 2021/06/03 06:00 [pubmed] PHST- 2021/06/03 06:01 [medline] PHST- 2021/05/20 00:00 [pmc-release] AID - jcm10102210 [pii] AID - jcm-10-02210 [pii] AID - 10.3390/jcm10102210 [doi] PST - epublish SO - J Clin Med. 2021 May 20;10(10):2210. doi: 10.3390/jcm10102210. PMID- 34064850 OWN - NLM STAT- MEDLINE DCOM- 20210603 LR - 20210615 IS - 1648-9144 (Electronic) IS - 1010-660X (Print) IS - 1010-660X (Linking) VI - 57 IP - 5 DP - 2021 May 11 TI - Unraveling the Etiology of Pediatric Vertigo and Dizziness: A Tertiary Pediatric Center Experience. LID - 10.3390/medicina57050475 [doi] LID - 475 AB - Background and Objectives: Numerous authors have reported that the commonest type of vertigo in children is migraine-associated vertigo (vestibular migraine and benign paroxysmal vertigo of childhood-BPV). We aimed to provide the possible etiological background of vertigo and dizziness in Slovenian children. Materials and Methods: A retrospective case series of pediatric vertigo and dizziness children referred to the tertiary pediatric otorhinolaryngology center from 2015 to 2020. Children received a complete audiological and vestibular workup and were referred to pediatric specialists depending on the clinical presentation. Results: Of 257 children (42% male, 58% female) aged 1-17 years (M = 10.9, SD = 4.3 years) in 19.1% vertigo and dizziness were classified as central, in 12.4% as a peripheral vestibular, in 10.9% as a hemodynamic, in 5.8% as a psychological and none as visual by pediatric neurologists, otorhinolaryngologists, cardiologists, psychologists or ophthalmologists, respectively. 40.8% (20) children with central vertigo had BPV (7.8% of all children) and 8.2% (4) migrainous vertigo. In 43.6% (112 children), the etiology remained unclassified. Conclusions: After a thorough multidisciplinary workup, the etiology of vertigo and dizziness was unraveled in the majority of children referred to our tertiary otorhinolaryngology center. The most common cause was central; however, in a considerable number, the etiology remained unclassified. The latter could be attributed to the self-limiting nature of vertigo spells. Hence, a child presenting with dizziness and vertigo requires a multidisciplinary approach, in which referral to a neurologist is, in most cases, essential. FAU - Bozanic Urbancic, Nina AU - Bozanic Urbancic N AD - Department of Otorhinolaryngology and Cervicofacial Surgery, University Medical Centre Ljubljana, Zaloska Cesta 2, SI-1000 Ljubljana, Slovenia. AD - Faculty of Medicine, University of Ljubljana, Vrazov Trg 2, SI-1000 Ljubljana, Slovenia. FAU - Vozel, Domen AU - Vozel D AUID- ORCID: 0000-0002-9992-5892 AD - Department of Otorhinolaryngology and Cervicofacial Surgery, University Medical Centre Ljubljana, Zaloska Cesta 2, SI-1000 Ljubljana, Slovenia. AD - Faculty of Medicine, University of Ljubljana, Vrazov Trg 2, SI-1000 Ljubljana, Slovenia. FAU - Urbancic, Jure AU - Urbancic J AD - Department of Otorhinolaryngology and Cervicofacial Surgery, University Medical Centre Ljubljana, Zaloska Cesta 2, SI-1000 Ljubljana, Slovenia. AD - Faculty of Medicine, University of Ljubljana, Vrazov Trg 2, SI-1000 Ljubljana, Slovenia. FAU - Battelino, Saba AU - Battelino S AUID- ORCID: 0000-0003-1478-0573 AD - Department of Otorhinolaryngology and Cervicofacial Surgery, University Medical Centre Ljubljana, Zaloska Cesta 2, SI-1000 Ljubljana, Slovenia. AD - Faculty of Medicine, University of Ljubljana, Vrazov Trg 2, SI-1000 Ljubljana, Slovenia. LA - eng GR - 20200036/University Medical Centre Ljubljana, Slovenia/ GR - P3-0374/Slovenian Research Agency/ PT - Journal Article DEP - 20210511 PL - Switzerland TA - Medicina (Kaunas) JT - Medicina (Kaunas, Lithuania) JID - 9425208 SB - IM MH - Child MH - *Dizziness/epidemiology/etiology MH - Family MH - Female MH - Humans MH - Male MH - *Migraine Disorders/complications/diagnosis/epidemiology MH - Retrospective Studies MH - Vertigo/diagnosis/epidemiology/etiology PMC - PMC8151727 OTO - NOTNLM OT - Lyme neuroborreliosis OT - adolescent OT - child OT - dizziness OT - headache OT - interdisciplinary communication OT - medulloblastoma OT - migraine disorders OT - somatoform disorders OT - vertigo COIS- The authors declare no conflict of interest. The sponsors had no role in the design, execution, interpretation, or writing of the study. EDAT- 2021/06/03 06:00 MHDA- 2021/06/04 06:00 PMCR- 2021/05/11 CRDT- 2021/06/02 01:11 PHST- 2021/03/30 00:00 [received] PHST- 2021/05/07 00:00 [revised] PHST- 2021/05/10 00:00 [accepted] PHST- 2021/06/02 01:11 [entrez] PHST- 2021/06/03 06:00 [pubmed] PHST- 2021/06/04 06:00 [medline] PHST- 2021/05/11 00:00 [pmc-release] AID - medicina57050475 [pii] AID - medicina-57-00475 [pii] AID - 10.3390/medicina57050475 [doi] PST - epublish SO - Medicina (Kaunas). 2021 May 11;57(5):475. doi: 10.3390/medicina57050475. PMID- 34064463 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210605 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 10 IP - 9 DP - 2021 May 4 TI - The Spectrum of COVID-19-Associated Myocarditis: A Patient-Tailored Multidisciplinary Approach. LID - 10.3390/jcm10091974 [doi] LID - 1974 AB - BACKGROUND: Myocarditis lacks systematic characterization in COVID-19 patients. METHODS: We enrolled consecutive patients with newly diagnosed myocarditis in the context of COVID-19 infection. Diagnostic and treatment strategies were driven by a dedicated multidisciplinary disease unit for myocarditis. Multimodal outcomes were assessed during prospective follow-up. RESULTS: Seven consecutive patients (57% males, age 51 +/- 9 y) with acute COVID-19 infection received a de novo diagnosis of myocarditis. Endomyocardial biopsy was of choice in hemodynamically unstable patients (n = 4, mean left ventricular ejection fraction (LVEF) 25 +/- 9%), whereas cardiac magnetic resonance constituted the first exam in stable patients (n = 3, mean LVEF 48 +/- 10%). Polymerase chain reaction (PCR) analysis revealed an intra-myocardial SARS-CoV-2 genome in one of the six cases undergoing biopsy: in the remaining patients, myocarditis was either due to other viruses (n = 2) or virus-negative (n = 3). Hemodynamic support was needed for four unstable patients (57%), whereas a cardiac device implant was chosen in two of four cases showing ventricular arrhythmias. Medical treatment included immunosuppression (43%) and biological therapy (29%). By the 6-month median follow-up, no patient died or experienced malignant arrhythmias. However, two cases (29%) were screened for heart transplantation. CONCLUSIONS: Myocarditis associated with acute COVID-19 infection is a spectrum of clinical manifestations and underlying etiologies. A multidisciplinary approach is the cornerstone for tailored management. FAU - Peretto, Giovanni AU - Peretto G AD - Department of Cardiac Electrophysiology and Arrhythmology, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy. AD - Myocarditis Disease Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy. AD - School of Medicine, San Raffaele Vita-Salute University, 20132 Milan, Italy. FAU - Villatore, Andrea AU - Villatore A AUID- ORCID: 0000-0002-2858-1404 AD - School of Medicine, San Raffaele Vita-Salute University, 20132 Milan, Italy. FAU - Rizzo, Stefania AU - Rizzo S AD - Department of Cardiac Thoracic Vascular Sciences and Public Health, Cardiovascular Pathology, Padua University, 35128 Padua, Italy. FAU - Esposito, Antonio AU - Esposito A AD - Myocarditis Disease Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy. AD - School of Medicine, San Raffaele Vita-Salute University, 20132 Milan, Italy. AD - Experimental Imaging Center, Radiology Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy. FAU - De Luca, Giacomo AU - De Luca G AD - Myocarditis Disease Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy. AD - Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy. FAU - Palmisano, Anna AU - Palmisano A AD - Myocarditis Disease Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy. AD - Experimental Imaging Center, Radiology Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy. FAU - Vignale, Davide AU - Vignale D AD - Myocarditis Disease Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy. AD - Experimental Imaging Center, Radiology Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy. FAU - Cappelletti, Alberto Maria AU - Cappelletti AM AD - Department of Clinical Cardiology and Intensive Care Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy. FAU - Tresoldi, Moreno AU - Tresoldi M AD - Unit of General Medicine and Advanced Care, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy. AD - COVID-19 Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy. FAU - Campochiaro, Corrado AU - Campochiaro C AUID- ORCID: 0000-0001-6806-3794 AD - Myocarditis Disease Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy. AD - Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy. FAU - Sartorelli, Silvia AU - Sartorelli S AD - Myocarditis Disease Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy. AD - Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy. FAU - Ripa, Marco AU - Ripa M AUID- ORCID: 0000-0002-6380-0377 AD - COVID-19 Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy. AD - Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy. FAU - De Gaspari, Monica AU - De Gaspari M AUID- ORCID: 0000-0001-9528-4883 AD - Department of Cardiac Thoracic Vascular Sciences and Public Health, Cardiovascular Pathology, Padua University, 35128 Padua, Italy. FAU - Busnardo, Elena AU - Busnardo E AD - Myocarditis Disease Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy. AD - Department of Nuclear Medicine, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy. FAU - Ferro, Paola AU - Ferro P AD - Department of Nuclear Medicine, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy. FAU - Calabro, Maria Grazia AU - Calabro MG AD - Cardiac Surgery Intensive Care Unit, Division of Anesthesiology, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy. FAU - Fominskiy, Evgeny AU - Fominskiy E AUID- ORCID: 0000-0002-3198-4458 AD - Cardiac Surgery Intensive Care Unit, Division of Anesthesiology, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy. FAU - Monaco, Fabrizio AU - Monaco F AUID- ORCID: 0000-0001-5186-1976 AD - Cardiac Surgery Intensive Care Unit, Division of Anesthesiology, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy. FAU - Cavalli, Giulio AU - Cavalli G AD - Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy. FAU - Gianolli, Luigi AU - Gianolli L AD - Department of Nuclear Medicine, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy. FAU - De Cobelli, Francesco AU - De Cobelli F AUID- ORCID: 0000-0003-4014-3711 AD - School of Medicine, San Raffaele Vita-Salute University, 20132 Milan, Italy. AD - Experimental Imaging Center, Radiology Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy. FAU - Margonato, Alberto AU - Margonato A AD - Department of Clinical Cardiology and Intensive Care Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy. FAU - Dagna, Lorenzo AU - Dagna L AD - School of Medicine, San Raffaele Vita-Salute University, 20132 Milan, Italy. AD - Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy. FAU - Scandroglio, Mara AU - Scandroglio M AD - Cardiac Surgery Intensive Care Unit, Division of Anesthesiology, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy. FAU - Camici, Paolo Guido AU - Camici PG AD - School of Medicine, San Raffaele Vita-Salute University, 20132 Milan, Italy. FAU - Mazzone, Patrizio AU - Mazzone P AD - Department of Cardiac Electrophysiology and Arrhythmology, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy. FAU - Della Bella, Paolo AU - Della Bella P AD - Department of Cardiac Electrophysiology and Arrhythmology, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy. FAU - Basso, Cristina AU - Basso C AUID- ORCID: 0000-0002-0195-9753 AD - Department of Cardiac Thoracic Vascular Sciences and Public Health, Cardiovascular Pathology, Padua University, 35128 Padua, Italy. FAU - Sala, Simone AU - Sala S AUID- ORCID: 0000-0003-3303-8892 AD - Department of Cardiac Electrophysiology and Arrhythmology, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy. AD - Myocarditis Disease Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy. LA - eng PT - Journal Article DEP - 20210504 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC8124580 OTO - NOTNLM OT - COVID-19 OT - SARS-CoV-2 OT - cardiac magnetic resonance OT - endomyocardial biopsy OT - immunosuppression OT - inflammation OT - multidisciplinary OT - myocarditis OT - ventricular arrhythmias COIS- The authors declare no conflict of interest. EDAT- 2021/06/03 06:00 MHDA- 2021/06/03 06:01 PMCR- 2021/05/04 CRDT- 2021/06/02 01:09 PHST- 2021/03/17 00:00 [received] PHST- 2021/04/08 00:00 [revised] PHST- 2021/04/22 00:00 [accepted] PHST- 2021/06/02 01:09 [entrez] PHST- 2021/06/03 06:00 [pubmed] PHST- 2021/06/03 06:01 [medline] PHST- 2021/05/04 00:00 [pmc-release] AID - jcm10091974 [pii] AID - jcm-10-01974 [pii] AID - 10.3390/jcm10091974 [doi] PST - epublish SO - J Clin Med. 2021 May 4;10(9):1974. doi: 10.3390/jcm10091974. PMID- 34061804 OWN - NLM STAT- MEDLINE DCOM- 20211209 LR - 20230714 IS - 1940-5480 (Electronic) IS - 1067-151X (Linking) VI - 29 IP - 24 DP - 2021 Dec 15 TI - Preventing Acute Kidney Injury and Hypotension After Elective Total Joint Arthroplasty Is Possible: An Update to an Established Multidisciplinary Protocol. PG - e1303-e1312 LID - 10.5435/JAAOS-D-20-01352 [doi] AB - INTRODUCTION: Based on preoperative and perioperative risk factors that have been found to correlate with the development of acute kidney injury (AKI), our institution developed a protocol aimed at managing and improving outcomes in all elective THA and TKA patients. This article highlights the continued success and growth of our protocol aimed at decreasing AKI and hypotension in elective total joint arthroplasty patients. METHOD: A multidisciplinary team comprising orthopaedic surgeons, nephrologists, anesthesiologists, cardiologists, and internal medicine hospitalists created a comprehensive protocol aimed at decreasing complications after elective joint arthroplasty and improving clinical outcomes across multiple hospitals. Patient demographics, hospital length of stay, readmission rates, mortality, and postoperative AKI and hypotension incidences were recorded and compared between preprotocol phase I (initial protocol implementation) and phase II (protocol expansion across 10 hospitals) patient cohorts. RESULTS: Overall, 3,222 patients over 56 months and 10 hospitals were included. Our phase II AKI rate (0.6%) was significantly lower than our preprotocol rate (6.2%, P < 0.01) and statistically similar to our phase I rate (1.2%, P = 0.61). Our hypotension rate in phase II (6.8%) was significantly lower than our preprotocol rate (12.7%, P < 0.01) but statistically similar to our phase I rate (5.9%, P = 0.40). Furthermore, a significant decrease was observed in hospital length of stay (P < 0.01) over time, but no difference was observed in readmission (P = 0.59) and mortality rates (P = 1.00) over time. DISCUSSION: This protocol-driven interventional study provides a detailed and successful multidisciplinary method to manage and decrease rates of AKI and hypotension in a large patient cohort across multiple hospital centers. CI - Copyright (c) 2021 by the American Academy of Orthopaedic Surgeons. FAU - Malige, Ajith AU - Malige A AUID- ORCID: 0000-0002-3984-4804 AD - From the St. Luke's University Health Network, Bethlehem, PA. FAU - Carmona, Aldo AU - Carmona A FAU - Roscher, Christopher AU - Roscher C FAU - Herman, Daniel AU - Herman D FAU - Filipkowski, Amy AU - Filipkowski A FAU - Rowbotham, Jaclyn AU - Rowbotham J FAU - Sgro, Jessica AU - Sgro J FAU - Gould, William AU - Gould W FAU - DeLong, William AU - DeLong W FAU - Gayner, Robert AU - Gayner R LA - eng PT - Journal Article PL - United States TA - J Am Acad Orthop Surg JT - The Journal of the American Academy of Orthopaedic Surgeons JID - 9417468 SB - IM MH - *Acute Kidney Injury/epidemiology/etiology/prevention & control MH - *Arthroplasty, Replacement, Hip/adverse effects MH - *Arthroplasty, Replacement, Knee/adverse effects MH - Humans MH - *Hypotension/epidemiology/etiology/prevention & control MH - Length of Stay MH - Postoperative Complications/epidemiology/etiology/prevention & control MH - Retrospective Studies MH - Risk Factors EDAT- 2021/06/02 06:00 MHDA- 2021/12/15 06:00 CRDT- 2021/06/01 17:20 PHST- 2020/12/14 00:00 [received] PHST- 2021/03/26 00:00 [accepted] PHST- 2021/06/02 06:00 [pubmed] PHST- 2021/12/15 06:00 [medline] PHST- 2021/06/01 17:20 [entrez] AID - 00124635-202112150-00009 [pii] AID - 10.5435/JAAOS-D-20-01352 [doi] PST - ppublish SO - J Am Acad Orthop Surg. 2021 Dec 15;29(24):e1303-e1312. doi: 10.5435/JAAOS-D-20-01352. PMID- 34058163 OWN - NLM STAT- MEDLINE DCOM- 20211022 LR - 20211022 IS - 1097-6744 (Electronic) IS - 0002-8703 (Linking) VI - 240 DP - 2021 Oct TI - Cardiac rehabilitation availability and characteristics in Latin America and the Caribbean: A Global Comparison. PG - 16-27 LID - S0002-8703(21)00139-3 [pii] LID - 10.1016/j.ahj.2021.05.010 [doi] AB - BACKGROUND: This study aimed to establish availability and characteristics of cardiac rehabilitation (CR) in Latin America and the Caribbean (LAC), where cardiovascular disease is highly prevalent. METHODS: In this cross-sectional sub-analysis focusing on the 35 LAC countries, local cardiovascular societies identified CR programs globally. An online survey was administered to identified programs, assessing capacity and characteristics. CR need was computed relative to ischemic heart disease (IHD) incidence from the Global Burden of Disease study. RESULTS: >/=1 CR program was identified in 24 LAC countries (68.5% availability; median = 3 programs/country). Data were collected in 20/24 countries (83.3%); 139/255 programs responded (54.5%), and compared to responses from 1082 programs in 111 countries. LAC density was 1 CR spot per 24 IHD patients/year (vs 18 globally). Greatest need was observed in Brazil, Dominican Republic and Mexico (all with >150,000 spots needed/year). In 62.8% (vs 37.2% globally P < .001) of CR programs, patients pay out-of-pocket for some or all of CR. CR teams were comprised of a mean of 5.0 +/- 2.3 staff (vs 6.0 +/- 2.8 globally; P < .001); Social workers, dietitians, kinesiologists, and nurses were significantly less common on CR teams than globally. Median number of core components offered was 8 (vs 9 globally; P < .001). Median dose of CR was 36 sessions (vs 24 globally; P < .001). Only 27 (20.9%) programs offered alternative CR models (vs 31.1% globally; P < .01). CONCLUSION: In LAC countries, there is very limited CR capacity in relation to need. CR dose is high, but comprehensiveness low, which could be rectified with a more multidisciplinary team. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - Chacin-Suarez, Audry AU - Chacin-Suarez A AD - Mayo Clinic, Rochester, MN. FAU - Grace, Sherry L AU - Grace SL AD - York University & University Health Network (KITE & Peter Munk Cardiac Centre), University of Toronto, Canada. FAU - Anchique-Santos, Claudia AU - Anchique-Santos C AD - Mediagnostica Duitama, Boyaca, Colombia. FAU - Supervia, Marta AU - Supervia M AD - Mayo Clinic, Rochester, MN; Gregorio Maranon General University Hospital, Gregorio Maranon Health Research Institute, Madrid, Spain. FAU - Turk-Adawi, Karam AU - Turk-Adawi K AD - Qatar University, Doha, Qatar. FAU - Britto, Raquel R AU - Britto RR AD - Federal University of Minas Gerais, Belo Horizonte, Brazil. FAU - Scantlebury, Dawn C AU - Scantlebury DC AD - University of the West Indies at Cave Hill, St. Michael, Barbados. FAU - Araya-Ramirez, Felipe AU - Araya-Ramirez F AD - Center of Cardiovascular Rehabilitation, National University, Costa Rica. FAU - Gonzalez, Graciela AU - Gonzalez G AD - National Cardiovascular Prevention Program, Asuncion, Paraguay. FAU - Benaim, Briseida AU - Benaim B AD - Asociacion Cardiovascular Centro-occidental (ASCARDIO), Barquisimeto, Venezuela. FAU - Fernandez, Rosalia AU - Fernandez R AD - Instituto Nacional Cardiovascular (INCOR), Lima, Peru. FAU - Hol, Jacqueline AU - Hol J AD - Rafana Medical Exercise Center, Willemstad, Curacao. FAU - Burdiat, Gerard AU - Burdiat G AD - Spanish Association Hospital, Montevideo, Uruguay. FAU - Salmon, Richard AU - Salmon R AD - PHYSIS Prevencion Cardiovascular, Guayaquil, Ecuador. FAU - Lomeli, Hermes AU - Lomeli H AD - Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico. FAU - Mamataz, Taslima AU - Mamataz T AD - York University & University Health Network (KITE & Peter Munk Cardiac Centre), University of Toronto, Canada. FAU - Medina-Inojosa, Jose R AU - Medina-Inojosa JR AD - Mayo Clinic, Rochester, MN. FAU - Lopez-Jimenez, Francisco AU - Lopez-Jimenez F AD - Mayo Clinic, Rochester, MN. Electronic address: lopez@mayo.edu. LA - eng PT - Journal Article DEP - 20210528 PL - United States TA - Am Heart J JT - American heart journal JID - 0370465 SB - IM MH - Cardiac Rehabilitation/economics/*statistics & numerical data MH - Caribbean Region/epidemiology MH - Cost of Illness MH - Cross-Sectional Studies MH - Health Expenditures MH - Health Services Accessibility/*statistics & numerical data MH - Humans MH - Incidence MH - Insurance Coverage MH - Latin America/epidemiology MH - Myocardial Ischemia/economics/epidemiology/*rehabilitation MH - Patient Care Team EDAT- 2021/06/01 06:00 MHDA- 2023/02/25 06:00 CRDT- 2021/05/31 20:10 PHST- 2021/01/07 00:00 [received] PHST- 2021/05/20 00:00 [accepted] PHST- 2021/06/01 06:00 [pubmed] PHST- 2023/02/25 06:00 [medline] PHST- 2021/05/31 20:10 [entrez] AID - S0002-8703(21)00139-3 [pii] AID - 10.1016/j.ahj.2021.05.010 [doi] PST - ppublish SO - Am Heart J. 2021 Oct;240:16-27. doi: 10.1016/j.ahj.2021.05.010. Epub 2021 May 28. PMID- 34058117 OWN - NLM STAT- MEDLINE DCOM- 20210607 LR - 20230713 IS - 1478-7083 (Electronic) IS - 0035-8843 (Print) IS - 0035-8843 (Linking) VI - 103 IP - 6 DP - 2021 Jun TI - Establishing minimally invasive cardiac surgery in a low-volume mitral surgery centre. PG - 444-451 LID - 10.1308/rcsann.2020.7092 [doi] AB - INTRODUCTION: Despite early enthusiasm, minimally invasive cardiac surgery has had a low uptake compared with novel techniques in interventional cardiology. Steep learning curves from high-volume centres have deterred smaller units from engaging, even though low-volume centres undertake a large proportion of surgical interventions worldwide. We sought to identify the safety and experience of learning minimally invasive cardiac surgery after undertaking a structured fellowship at Blackpool Victoria Hospital, a low-volume centre. MATERIALS AND METHODS: A retrospective analysis of outcomes for all consecutive minimally invasive cardiac surgery procedures performed via a right mini-thoracotomy at our institution between 2007 and 2017 was undertaken. Clinical outcomes included death, conversion to sternotomy, stroke, renal failure and other organ support. Cardiopulmonary bypass, aortic cross-clamp times and learning cumulative sum sequential probability method curves were also assessed to determine how safely the procedure was adopted. RESULTS: A total of 316 patients were operated on for mitral, tricuspid, atrial fibrillation, septal defects or other conditions. The mean logistic European System for Cardiac Operative Risk Evaluation score was 7.0 (+/- 8.5). Conversion to sternotomy occurred in 12 patients (3.8%) and in-hospital mortality was 7 (2.2%). None of the converted patients died. The learning curves showed an accelerated process of adoption, similar to reference figures from a high-volume German centre. DISCUSSION: It is possible for low-volume cardiac surgical centres to undertake minimally invasive surgical programmes with good outcomes and short learning curves. Despite technical complexities, with a team approach, the learning curve can be navigated safely. FAU - Kirmani, B H AU - Kirmani BH AD - Blackpool Victoria Hospital, Blackpool, UK. FAU - Knowles, A AU - Knowles A AD - Blackpool Victoria Hospital, Blackpool, UK. FAU - Saravanan, P AU - Saravanan P AD - Blackpool Victoria Hospital, Blackpool, UK. FAU - Zacharias, J AU - Zacharias J AD - Blackpool Victoria Hospital, Blackpool, UK. LA - eng PT - Journal Article PL - England TA - Ann R Coll Surg Engl JT - Annals of the Royal College of Surgeons of England JID - 7506860 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Atrial Fibrillation/surgery MH - Cardiac Surgical Procedures/*statistics & numerical data MH - Cardiopulmonary Bypass MH - Female MH - Heart Diseases/*surgery MH - Heart Septal Defects/surgery MH - Heart Valve Diseases/surgery MH - Hospital Mortality MH - Hospitals, Low-Volume/organization & administration/*statistics & numerical data MH - Humans MH - Learning Curve MH - Male MH - Middle Aged MH - Minimally Invasive Surgical Procedures/statistics & numerical data MH - Operative Time MH - Retrospective Studies MH - Sternotomy MH - Thoracotomy/methods MH - Young Adult PMC - PMC10335028 OTO - NOTNLM OT - Learning curve OT - Minimally invasive surgical procedures OT - Mitral valve EDAT- 2021/06/01 06:00 MHDA- 2021/06/08 06:00 PMCR- 2022/06/01 CRDT- 2021/05/31 20:09 PHST- 2021/05/31 20:09 [entrez] PHST- 2021/06/01 06:00 [pubmed] PHST- 2021/06/08 06:00 [medline] PHST- 2022/06/01 00:00 [pmc-release] AID - rcsann.2020.7092 [pii] AID - 10.1308/rcsann.2020.7092 [doi] PST - ppublish SO - Ann R Coll Surg Engl. 2021 Jun;103(6):444-451. doi: 10.1308/rcsann.2020.7092. PMID- 34052027 OWN - NLM STAT- MEDLINE DCOM- 20211125 LR - 20211125 IS - 1532-7361 (Electronic) IS - 0039-6060 (Linking) VI - 170 IP - 3 DP - 2021 Sep TI - Bariatric surgery in patients with advanced heart failure: A proposed multi-disciplinary pathway for surgical care in medically complex patients. PG - 659-663 LID - S0039-6060(21)00408-6 [pii] LID - 10.1016/j.surg.2021.04.036 [doi] AB - BACKGROUND: The objective of this study was to develop a multi-disciplinary care pathway to minimize perioperative complications in patients with advanced heart failure undergoing bariatric surgery. Patients with severe obesity and heart failure carry increased perioperative surgical risk compared to patients with no heart failure due to the severity of their cardiac disease state and associated comorbidities. Our bariatric program routinely excluded patients with advanced heart failure from undergoing bariatric surgery due to the high reported perioperative risk. However, knowing the potential beneficial impact of bariatric surgery for advanced heart failure, our program hoped that the thoughtful development of a perioperative pathway before inclusion of patients with advanced heart failure in the bariatric surgery program could minimize the morbidity of these high-risk patients in comparison to prior publications in the literature. METHODS: Two multi-disciplinary care pathways were developed, including advanced heart failure, anticoagulation specialists, and transplant cardiologists, to optimize bariatric care for severely obese patients with advanced heart failure with or without mechanical circulatory support and implementation was evaluated for short-term 30-day complications and 6 month cardiac and weight-loss outcomes. RESULTS: Two multi-disciplinary care pathways were developed and implemented on 5 patients with heart failure with reduced ejection fraction (pathway 1) and 3 patients requiring mechanical circulatory support (pathway 2). There were no in-hospital complications or mortality following either pathway, and there was only 1 emergency room visit and 1 re-admission. The average length of stay for patients with heart failure with reduced ejection fraction without mechanical circulatory support was 2.4 days and for heart failure with reduced ejection fraction with mechanical circulatory support was 4.3 days. Three patients met body mass index criteria for transplant listing at 6 months. Ejection fraction increased an average of 9% at 6 months postoperatively for patients with heart failure with reduced ejection fraction not requiring mechanical circulatory support. CONCLUSION: With multi-disciplinary care pathway development designed to maximize safety by intensely supporting preoperative cardiac optimization and medication titration postoperatively, bariatric surgery can be performed in patients with advanced heart failure with or without mechanical circulatory support, allowing patients the opportunity for weight loss as a bridge to transplant or potentially meaningful cardiac recovery. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - Kindel, Tammy L AU - Kindel TL AD - Division of Minimally Invasive Gastrointestinal Surgery, Department of Surgery, Medical College of Wisconsin, Milwaukee, WI. Electronic address: tkindel@mcw.edu. FAU - Higgins, Rana M AU - Higgins RM AD - Division of Minimally Invasive Gastrointestinal Surgery, Department of Surgery, Medical College of Wisconsin, Milwaukee, WI. FAU - Lak, Kate AU - Lak K AD - Division of Minimally Invasive Gastrointestinal Surgery, Department of Surgery, Medical College of Wisconsin, Milwaukee, WI. FAU - Gould, Jon AU - Gould J AD - Division of Minimally Invasive Gastrointestinal Surgery, Department of Surgery, Medical College of Wisconsin, Milwaukee, WI. FAU - Baumann Kreuziger, Lisa AU - Baumann Kreuziger L AD - Division of Hematology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI. FAU - Mohammed, Asim AU - Mohammed A AD - Division of Cardiovascular Medicine, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI. FAU - Gaglianello, Nunzio AU - Gaglianello N AD - Division of Cardiovascular Medicine, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI. FAU - Ishizawar, David AU - Ishizawar D AD - Division of Cardiovascular Medicine, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI. LA - eng PT - Journal Article DEP - 20210527 PL - United States TA - Surgery JT - Surgery JID - 0417347 SB - IM MH - Adult MH - Bariatric Surgery/*methods MH - *Body Mass Index MH - Comorbidity MH - Delivery of Health Care/*organization & administration MH - Female MH - Heart Failure/*epidemiology MH - Humans MH - Incidence MH - *Interdisciplinary Communication MH - Male MH - Middle Aged MH - Obesity, Morbid/epidemiology/*surgery MH - Postoperative Complications/epidemiology/*prevention & control MH - Retrospective Studies MH - Wisconsin/epidemiology MH - Young Adult EDAT- 2021/05/31 06:00 MHDA- 2021/11/26 06:00 CRDT- 2021/05/30 20:34 PHST- 2020/12/16 00:00 [received] PHST- 2021/03/22 00:00 [revised] PHST- 2021/04/27 00:00 [accepted] PHST- 2021/05/31 06:00 [pubmed] PHST- 2021/11/26 06:00 [medline] PHST- 2021/05/30 20:34 [entrez] AID - S0039-6060(21)00408-6 [pii] AID - 10.1016/j.surg.2021.04.036 [doi] PST - ppublish SO - Surgery. 2021 Sep;170(3):659-663. doi: 10.1016/j.surg.2021.04.036. Epub 2021 May 27. PMID- 34050365 OWN - NLM STAT- MEDLINE DCOM- 20220509 LR - 20220607 IS - 1930-613X (Electronic) IS - 0026-4075 (Linking) VI - 187 IP - 5-6 DP - 2022 May 3 TI - Simulation-Based Training Program to Improve Cardiopulmonary Resuscitation and Teamwork Skills for the Urgent Care Clinic Staff. PG - e764-e769 LID - 10.1093/milmed/usab198 [doi] AB - INTRODUCTION: Lack of high-quality cardiopulmonary resuscitation (CPR) and effective team communication during cardiovascular emergencies could lead to poor patient outcomes and adverse events. Studies have shown that CPR psychomotor skills declined 3 months and plateaued up to 6 months after the completion of CPR training. The Urgent Care Clinic (UCC) interprofessional staff did not receive consistent training on CPR and teamwork skills beyond what was received from the biannual American Red Cross (ARC) Basic Life Support (BLS) training and semiannual Resuscitative Care Function mock cardiac arrest. Most participants took their last CPR training for more than 6 months (n = 12, 67%), between 3 and 6 months (n = 2, 11%), and within the last 3 months before the pre-intervention period (n = 4, 22%). The purpose of the project was to form an interprofessional team to lead the development and implementation of a theory- and evidence-based simulation-based training program to improve CPR and teamwork skills while enhancing patient safety and emergency medical readiness in the hospital and UCC. MATERIALS AND METHODS: The quality improvement project utilized an interprofessional in situ simulation-based training to improve participants' CPR and teamwork skills. The UCC physicians, nurses, and medical technicians completed a CPR and teamwork simulation-based training with a high-fidelity mannequin, pre-simulation preparation, briefing, and debriefing. The project collected pre-intervention and post-intervention data for CPR competence and teamwork perceptions. A paired t-test was used to assess differences in participant CPR skills and Team Strategies to Enhance Performance and Patient Safety Teamwork Perceptions Questionnaire responses before and after the simulation-based training intervention. The 59th Medical Wing and the University of South Alabama Institutional Review Boards approved the quality improvement project. RESULTS: A total of 18 participants completed the ARC BLS and Team Strategies to Enhance Performance and Patient Safety simulation-based training. Most participants were medical technicians (n = 8, 44%), followed by physicians (n = 5, 28%) and (n = 5, 28%) nurses. There was a statistical significance in participants' ARC BLS scores, with a pre-simulation mean score of 45.42 and a post-simulation mean score of 89.21 (P = .000, 95% CI = 36.89-50.68). For Team Strategies to Enhance Performance and Patient Safety teamwork perceptions, there was a statistically significant increase in the participants' teamwork perception levels, with a pre-simulation mean score of 4.61 and a post-simulation mean score of 4.86 (P = .000, 95% CI = 0.20-0.31). CONCLUSIONS: Our results demonstrated that the participants' ARC BLS scores and UCC's team perceptions have increased after in situ simulation-based training. We did not assess the ideal time for re-training. We recommend a 3- to 6-month post-training assessment to determine the optimal time for a CPR and teamwork refresher training. A high-fidelity simulation-based program with trained facilitators that assess the healthcare providers' CPR and teamwork skills could enhance the delivery of high-quality CPR and execution of effective teamwork skills in their workplace. CI - Published by Oxford University Press on behalf of the Association of Military Surgeons of the United States 2021. This work is written by (a) US Government employee(s) and is in the public domain in the US. FAU - Laco, Rupert Biacora AU - Laco RB AUID- ORCID: 0000-0002-9227-4636 AD - Emergency Services Flight, 374th Medical Group, Yokota Air Base, APO, AP 96328, Japan. FAU - Stuart, Wilma Powell AU - Stuart WP AD - Adult Health Nursing, University of South Alabama College of Nursing, Mobile, AL 36688-0002, USA. LA - eng PT - Journal Article PL - England TA - Mil Med JT - Military medicine JID - 2984771R SB - IM MH - Ambulatory Care Facilities MH - *Cardiopulmonary Resuscitation MH - Clinical Competence MH - Humans MH - Manikins MH - Patient Care Team MH - *Simulation Training EDAT- 2021/05/30 06:00 MHDA- 2022/05/10 06:00 CRDT- 2021/05/29 06:16 PHST- 2020/09/18 00:00 [received] PHST- 2021/02/10 00:00 [revised] PHST- 2021/05/10 00:00 [accepted] PHST- 2021/05/30 06:00 [pubmed] PHST- 2022/05/10 06:00 [medline] PHST- 2021/05/29 06:16 [entrez] AID - 6288045 [pii] AID - 10.1093/milmed/usab198 [doi] PST - ppublish SO - Mil Med. 2022 May 3;187(5-6):e764-e769. doi: 10.1093/milmed/usab198. PMID- 34049435 OWN - NLM STAT- MEDLINE DCOM- 20211025 LR - 20211025 IS - 1445-6354 (Electronic) IS - 1445-6354 (Linking) VI - 21 IP - 2 DP - 2021 May TI - Role of portable ultrasound during a short-term medical service trip to rural Guatemala: a collaborative mission of trainees and physicians. PG - 6056 LID - 10.22605/RRH6056 [doi] AB - INTRODUCTION: Access to health care in developing countries is scarce. One solution to this problem has been for doctors from the USA to provide single-visit care through short-term medical service trips. There is interest in using ultrasound imaging as a portable diagnostic tool; however, data describing its usefulness are scarce. Therefore, the goal of this study was to determine the usefulness of portable ultrasound imaging during a medical service trip to rural Guatemala. METHODS: A multidisciplinary team of physicians examined patients at a mobile clinic in Antigua, Guatemala. Patients with clinical indications for ultrasound had their suspected diagnoses recorded before ultrasound testing. After imaging, updated diagnoses were recorded and compared with the pre-test suspected diagnoses to determine how often ultrasound results changed the medical management of the patients and to assess the most common indications for ultrasound imaging. RESULTS: During the trip, 205 patients were seen. Of these, 24 (12%) were given ultrasound exams. The results of 13 (54%) exams altered their medical management, and the remaining 11 (46%) exams confirmed the pre-test suspected diagnoses. The most common indications for ultrasound testing were suspected cardiac (11 patients, 46%) and gastrointestinal (8 patients, 33%) diseases. CONCLUSION: Portable ultrasound imaging improved the medical team's ability to diagnose disease and clinically manage patients in a rural medical service trip. Ultrasound imaging may provide a low-cost solution to the growing demand for care in developing countries. FAU - Elsayes, Ahmed K AU - Elsayes AK AD - Department of Biology, The University of Texas at Austin, Austin, TX 78712, USA elsayes.ahmed99@yahoo.com. FAU - Rohren, Scott A AU - Rohren SA AD - School of Medicine, Baylor College of Medicine, Houston, TX 77030, USA scott.rohren@bcm.edu. FAU - Islam, Nadim B AU - Islam NB AD - Department of Emergency Medicine, Houston Methodist, Houston, TX 77030, USA nislam@houstonmethodist.org. FAU - Blair, Katherine J AU - Blair KJ AD - Department of Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA kathblair89@gmail.com. FAU - Silvestre, Alicia V AU - Silvestre AV AD - Department of Radiology, TecniScan De Guatemala, Guatemala City, Guatemala alicesilvestregt@gmail.com. FAU - Segura, Daniela C AU - Segura DC AD - Department of Diagnostic Radiology, Clínica Universitaria, Bogotá, Columbia dc.seguragu@unisanitas.edu.co. FAU - Dubinsky, Theodore J AU - Dubinsky TJ AD - Department of Radiology, University of Washington, Seattle, WA 98195, USA tdub@uw.edu. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210529 PL - Australia TA - Rural Remote Health JT - Rural and remote health JID - 101174860 SB - IM MH - Delivery of Health Care MH - Guatemala MH - Humans MH - *Physicians MH - *Rural Population MH - Ultrasonography OTO - NOTNLM OT - Guatemala OT - South America OT - primary health care OT - radiology OT - evidence-based care EDAT- 2021/05/30 06:00 MHDA- 2021/10/26 06:00 CRDT- 2021/05/29 05:22 PHST- 2021/05/29 05:22 [entrez] PHST- 2021/05/30 06:00 [pubmed] PHST- 2021/10/26 06:00 [medline] AID - 6056 [pii] AID - 10.22605/RRH6056 [doi] PST - ppublish SO - Rural Remote Health. 2021 May;21(2):6056. doi: 10.22605/RRH6056. Epub 2021 May 29. PMID- 34048302 OWN - NLM STAT- MEDLINE DCOM- 20210818 LR - 20210818 IS - 1938-2472 (Electronic) IS - 0022-0124 (Linking) VI - 52 IP - 6 DP - 2021 Jun TI - Incorporating Rapid Cycle Deliberate Practice Cardiac Arrest Simulation Program Into Nursing Staff Continuing Professional Development. PG - 274-279 LID - 10.3928/00220124-20210514-06 [doi] AB - BACKGROUND: The Rapid Cycle Deliberate Practice (RCDP) is an innovative team-based simulation method that has been shown to be effective particularly in cardiac arrest education. Via a partnership between an educational institution and a hospital, the RCDP cardiac arrest simulation program was developed to improve nurses' cardiac arrest response preparation. METHOD: A pre- and posttest educational intervention study design was used. Participants included staff nurses (n = 89) who underwent a 2-hour RCDP simulation. The adapted version of the Simulation Effectiveness Tool-Modified and a five-question pre- and posttest knowledge survey were used to assess the effectiveness of the intervention. RESULTS: The simulation program increased participants' knowledge of cardiac arrest response (p < .05) and improved their confidence in communication (p = .036) and assessment skills (p = .029). CONCLUSION: The RCDP cardiac arrest simulation is an effective strategy for increasing nurses' confidence and knowledge in cardiopulmonary resuscitation delivery. [J Contin Educ Nurs. 2021;52(6):274-279.]. FAU - Ozkara San, Eda AU - Ozkara San E FAU - Maneval, Rhonda AU - Maneval R FAU - Myers, Patricia AU - Myers P LA - eng PT - Journal Article DEP - 20210601 PL - United States TA - J Contin Educ Nurs JT - Journal of continuing education in nursing JID - 0262321 MH - *Cardiopulmonary Resuscitation MH - Clinical Competence MH - Education, Nursing, Continuing MH - *Heart Arrest MH - Humans MH - *Nursing Staff, Hospital EDAT- 2021/05/29 06:00 MHDA- 2021/08/19 06:00 CRDT- 2021/05/28 17:14 PHST- 2021/05/28 17:14 [entrez] PHST- 2021/05/29 06:00 [pubmed] PHST- 2021/08/19 06:00 [medline] AID - 10.3928/00220124-20210514-06 [doi] PST - ppublish SO - J Contin Educ Nurs. 2021 Jun;52(6):274-279. doi: 10.3928/00220124-20210514-06. Epub 2021 Jun 1. PMID- 34047656 OWN - NLM STAT- MEDLINE DCOM- 20220117 LR - 20220531 IS - 1744-2818 (Electronic) IS - 1350-6129 (Linking) VI - 28 IP - 3 DP - 2021 Sep TI - Neurological involvement in Ile68Leu (p.Ile88Leu) ATTR amyloidosis: not only a cardiogenic mutation. PG - 173-181 LID - 10.1080/13506129.2021.1917357 [doi] AB - BACKGROUND: Ile68Leu transthyretin-related amyloidosis (ATTR) is known as a mainly or exclusively cardiogenic variant. We hypothesized that an accurate specialized neurological evaluation could reveal a consistent frequency of mixed phenotypes. METHODS: Forty-six consecutive subjects with transthyretin (TTR) Ile68Leu (p.Ile88Leu) mutation (29 patients and 17 unaffected carriers) underwent an in-depth cardiac and neurologic evaluation at a single center. RESULTS: All 29 patients showed cardiac involvement. In 20 (69%) cases, it was associated with neurological abnormalities (i.e. a mixed phenotype): 10 (35% of the total) had signs and symptoms of neuropathy, 5 (17%) had abnormalities at the neurologic specialist examination but without symptoms, and 5 (17%) had abnormal nerve conduction study only. None of the asymptomatic carriers showed neurological abnormalities or cardiac involvement. The Neuropathy Impairment Score was > 5 in seven patients at baseline, and became >5 in six more patients during follow-up. The probability of experiencing a major adverse cardiac event (MACE) during follow-up was higher in the mixed than cardiologic phenotype (p = 0.026). Age and phenotype were independent prognostic predictors of MACE. CONCLUSION: At least two-thirds of patients with Ile68Leu ATTR and amyloidotic cardiomyopathy show an associated - definite or probable - neurologic impairment of variable degree if accurately evaluated in a neurologic setting. This proportion can rise during follow-up. The mixed phenotype carries a worse prognosis compared to the exclusively cardiologic one. These observations show that more patients could be eligible for treatment with gene silencers than currently indicated and highlight the need for an in-depth and continuous multidisciplinary evaluation of Ile68Leu ATTR patients. FAU - Pastorelli, Francesca AU - Pastorelli F AD - UOC Neurologia, IRCCS Scienze Neurologiche, Bellaria Hospital, Bologna, Italy. FAU - Fabbri, Gioele AU - Fabbri G AD - Cardiologic Center, University of Ferrara, Azienda Ospedaliero-Universitaria di Ferrara, Cona, Italy. FAU - Rapezzi, Claudio AU - Rapezzi C AD - Cardiologic Center, University of Ferrara, Azienda Ospedaliero-Universitaria di Ferrara, Cona, Italy. AD - Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy. FAU - Serenelli, Matteo AU - Serenelli M AD - Cardiologic Center, University of Ferrara, Azienda Ospedaliero-Universitaria di Ferrara, Cona, Italy. FAU - Plasmati, Rosaria AU - Plasmati R AD - UOC Neurologia, IRCCS Scienze Neurologiche, Bellaria Hospital, Bologna, Italy. FAU - Vacchiano, Veria AU - Vacchiano V AD - UOC Neurologia, IRCCS Scienze Neurologiche, Bellaria Hospital, Bologna, Italy. FAU - Ferlini, Alessandra AU - Ferlini A AD - Unit of Medical Genetics, Department of Diagnostic and Experimental Medicine, University of Ferrara, Italy. FAU - Manfrini, Marco AU - Manfrini M AD - Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy. FAU - Salvi, Fabrizio AU - Salvi F AD - UOC Neurologia, IRCCS Scienze Neurologiche, Bellaria Hospital, Bologna, Italy. AD - Centro 'il Bene', IRCCS Scienze Neurologiche, Bellaria Hospital, Bologna, Italy. LA - eng PT - Journal Article DEP - 20210528 PL - England TA - Amyloid JT - Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis JID - 9433802 RN - 0 (Prealbumin) RN - 0 (TTR protein, human) SB - IM MH - *Amyloid Neuropathies, Familial/genetics MH - *Cardiomyopathies MH - Humans MH - Mutation MH - Phenotype MH - Prealbumin/genetics OTO - NOTNLM OT - Amyloidosis OT - Ile88Leu OT - cardiomyopathy OT - polyneuropathy OT - transthyretin EDAT- 2021/05/29 06:00 MHDA- 2022/01/18 06:00 CRDT- 2021/05/28 12:11 PHST- 2021/05/29 06:00 [pubmed] PHST- 2022/01/18 06:00 [medline] PHST- 2021/05/28 12:11 [entrez] AID - 10.1080/13506129.2021.1917357 [doi] PST - ppublish SO - Amyloid. 2021 Sep;28(3):173-181. doi: 10.1080/13506129.2021.1917357. Epub 2021 May 28. PMID- 34039677 OWN - NLM STAT- MEDLINE DCOM- 20210809 LR - 20210809 IS - 1708-8267 (Electronic) IS - 1081-5589 (Linking) VI - 69 IP - 6 DP - 2021 Aug TI - Impact and role of pulmonary embolism response teams in venous thromboembolism associated with COVID-19. PG - 1153-1155 LID - 10.1136/jim-2021-001856 [doi] AB - Venous thromboembolism associated with COVID-19, particularly acute pulmonary embolism, may represent a challenging and complex clinical scenario. The benefits of having a multidisciplinary pulmonary embolism response team (PERT) can be important during such a pandemic. The aim of PERT in the care of such patients is to provide fast, appropriate, multidisciplinary, team-based approach, with the common goal to tailor the best therapeutic decision making, prioritizing always optimal patient care, especially given lack of evidence-based clinical practice guidelines in the setting of COVID-19, which potentially confers a significant prothrombotic state. Herein, we would like to briefly emphasize the importance and potential critical role of PERT in the care of patients in which these two devastating illnesses are present together. CI - (c) American Federation for Medical Research 2021. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Porres-Aguilar, Mateo AU - Porres-Aguilar M AUID- ORCID: 0000-0002-2180-3000 AD - Internal Medicine and Hospital Medicine, Texas Tech University Health Sciences Center El Paso Paul L Foster School of Medicine, El Paso, Texas, USA mporres1980@gmail.com. FAU - Tapson, Victor F AU - Tapson VF AD - Division of Pulmonary and Critical Care Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA. FAU - Rivera-Lebron, Belinda N AU - Rivera-Lebron BN AUID- ORCID: 0000-0002-7842-671X AD - Division of Pulmonary and Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA. FAU - Rali, Parth M AU - Rali PM AD - Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine, Temple University Health System Inc, Philadelphia, Pennsylvania, USA. FAU - Jimenez, David AU - Jimenez D AUID- ORCID: 0000-0002-4571-7721 AD - Respiratory Division, Ramon y Cajal University Hospital, Madrid, Spain. AD - Department of Medicine, Faculty of Medicine and Health Sciences, University of Alcala de Henares, Madrid, Spain. FAU - Porres-Munoz, Mateo AU - Porres-Munoz M AD - Department of Internal Medicine and Geriatrics, Sociedad de Beneficencia Espanola AC, Tampico, Mexico. FAU - Barraza, Sarah AU - Barraza S AD - Division of Cardiology, Del Sol Medical Center, El Paso, Texas, USA. FAU - Munoz, Oscar C AU - Munoz OC AD - Division of Cardiology, Del Sol Medical Center, El Paso, Texas, USA. FAU - Mukherjee, Debabrata AU - Mukherjee D AUID- ORCID: 0000-0002-5131-3694 AD - Division of Cardiovascular Diseases, Texas Tech University Health Sciences Center El Paso, El Paso, Texas, USA. LA - eng PT - Journal Article PT - Review DEP - 20210526 PL - England TA - J Investig Med JT - Journal of investigative medicine : the official publication of the American Federation for Clinical Research JID - 9501229 RN - 0 (Anticoagulants) SB - IM MH - Acute Disease MH - Anticoagulants/therapeutic use MH - COVID-19/complications/*therapy MH - Cardiology/organization & administration MH - Decision Making MH - Evidence-Based Medicine MH - Humans MH - Interdisciplinary Communication MH - Practice Guidelines as Topic MH - Pulmonary Embolism/complications/*therapy MH - Pulmonary Medicine/organization & administration MH - Quality of Life MH - SARS-CoV-2 MH - Thromboembolism/complications/*therapy MH - Thrombolytic Therapy MH - Treatment Outcome MH - Venous Thromboembolism/complications/*therapy OTO - NOTNLM OT - COVID-19 OT - pulmonary embolism OT - thromboembolism OT - thrombosis OT - vascular diseases COIS- Competing interests: None declared. EDAT- 2021/05/28 06:00 MHDA- 2021/08/10 06:00 CRDT- 2021/05/27 05:51 PHST- 2021/05/03 00:00 [accepted] PHST- 2021/05/28 06:00 [pubmed] PHST- 2021/08/10 06:00 [medline] PHST- 2021/05/27 05:51 [entrez] AID - jim-2021-001856 [pii] AID - 10.1136/jim-2021-001856 [doi] PST - ppublish SO - J Investig Med. 2021 Aug;69(6):1153-1155. doi: 10.1136/jim-2021-001856. Epub 2021 May 26. PMID- 34039617 OWN - NLM STAT- MEDLINE DCOM- 20210929 LR - 20210929 IS - 2399-6641 (Electronic) IS - 2399-6641 (Linking) VI - 10 IP - 2 DP - 2021 May TI - Value improvement at the point of care: engaging and empowering front-line teams with a new quality improvement methodology. LID - 10.1136/bmjoq-2020-001233 [doi] LID - e001233 AB - BACKGROUND: Healthcare organisations require systems to consistently meet the needs of their patients while providing excellent quality of care. The value improvement (VI) approach was developed by the Institute for healthcare improvement and successfully piloted at Raigmore Hospital, Scotland. It showed positive results in improving outcomes and reducing costs. Our multidisciplinary team from a tertiary care cardiac hospital in Doha, Qatar wanted to see if we could improve value in a clinically and geographically distinct context. We sought to understand the effectiveness of this approach as an integrative management philosophy that aims for continuous improvement in the quality of services by increasing efficiency and reducing waste. METHODS: This study evaluates the outcomes achieved from applying the VI methodology. The method is rooted in a framework that emphasises standardisation, continuous process improvement and rightsizing capacity to demand. The main tools include a data box score, a visual management board and weekly communication huddles. RESULTS: As a result of the VI methodology, our team achieved improvements across performance, staff capacity and cost domains. Compared with the 4-8 weeks baseline data collection period, these improvements included an increase in discharges before 13:00 hour by 61%, a reduction in the number of blood samples per patient per day by 20%, an increase in nursing time spent in direct patient care by 18%, and an increase in staff satisfaction to 40%. CONCLUSIONS: We found that the VI approach offered a systematic method for continuously improving the quality of care by focusing attention each week on safety, efficiency and patient experience. The team improved numerous processes and outcomes resulting in a positive impact on patients and families and increased the engagement of staff in continuous improvement. In this way, we improved our capacity to undertake and complete quality projects. CI - (c) Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Gupta, Poonam AU - Gupta P AUID- ORCID: 0000-0002-9654-244X AD - Performance Improvement, Heart Hospital, Hamad Medical Corporation, Doha, Qatar dubai.poonam@gmail.com. FAU - Chacko, Gracy AU - Chacko G AD - Nursing Department, Heart Hospital, Hamad Medical Corporation, Doha, Qatar. FAU - Mavin, Paul AU - Mavin P AD - Executive Director, Heart hospital, Hamad Medical Corporation, Doha, Qatar. FAU - McDonald, Ian AU - McDonald I AD - Nursing Department, Heart Hospital, Hamad Medical Corporation, Doha, Qatar. FAU - El Hassan, Mawahib AU - El Hassan M AD - Consultant Cardiology, Heart Hospital, Hamad Medical Corporation, Doha, Qatar. FAU - Omari, Emad AU - Omari E AD - Nursing Department, Heart Hospital, Hamad Medical Corporation, Doha, Qatar. FAU - Ali, Azhar AU - Ali A AD - Institute for Healthcare Improvement, Cambridge, Massachusetts, USA. FAU - Siddiqui, Raana AU - Siddiqui R AD - Hamad Healthcare Quality Institute, Hamad Medical Corporation, Doha, Qatar. FAU - Khan, Needa AU - Khan N AD - Hamad Healthcare Quality Institute, Hamad Medical Corporation, Doha, Qatar. FAU - McKenzie, Lisa AU - McKenzie L AD - Institute for Healthcare Improvement, Cambridge, Massachusetts, USA. FAU - Bolender, Tricia AU - Bolender T AD - Institute for Healthcare Improvement, Cambridge, Massachusetts, USA. FAU - Andrews, William AU - Andrews W AD - Performance Improvement, Heart Hospital, Hamad Medical Corporation, Doha, Qatar. LA - eng PT - Journal Article PL - England TA - BMJ Open Qual JT - BMJ open quality JID - 101710381 SB - IM MH - Delivery of Health Care MH - Hospitals MH - Humans MH - *Point-of-Care Systems MH - Power, Psychological MH - *Quality Improvement PMC - PMC8160168 OTO - NOTNLM OT - communication OT - evidence-based practice OT - quality improvement OT - teamwork COIS- Competing interests: None declared. EDAT- 2021/05/28 06:00 MHDA- 2021/09/30 06:00 PMCR- 2021/05/26 CRDT- 2021/05/27 05:50 PHST- 2020/10/13 00:00 [received] PHST- 2021/05/07 00:00 [accepted] PHST- 2021/05/27 05:50 [entrez] PHST- 2021/05/28 06:00 [pubmed] PHST- 2021/09/30 06:00 [medline] PHST- 2021/05/26 00:00 [pmc-release] AID - bmjoq-2020-001233 [pii] AID - 10.1136/bmjoq-2020-001233 [doi] PST - ppublish SO - BMJ Open Qual. 2021 May;10(2):e001233. doi: 10.1136/bmjoq-2020-001233. PMID- 34033863 OWN - NLM STAT- MEDLINE DCOM- 20210628 LR - 20210628 IS - 1873-1570 (Electronic) IS - 0300-9572 (Linking) VI - 164 DP - 2021 Jul TI - Barriers and facilitators for in-hospital resuscitation: A prospective clinical study. PG - 70-78 LID - S0300-9572(21)00188-X [pii] LID - 10.1016/j.resuscitation.2021.05.007 [doi] AB - INTRODUCTION: Guideline deviations with impact on patient outcomes frequently occur during in-hospital cardiopulmonary resuscitation (CPR). However, barriers and facilitators for preventing these guideline deviations are understudied. We aimed to characterize challenges occurring during IHCA and identify barriers and facilitators perceived by actual team members immediately following IHCA events. METHODS: This was a prospective multicenter clinical study. Following each resuscitation attempt in 6 hospitals over a 4-year period, we immediately sent web-based structured questionnaires to all responding team members, reporting their perceived resuscitation quality, teamwork, and communication and what they perceived as barriers or facilitators. Comments were analyzed using qualitative inductive thematic analysis methodology. RESULTS: We identified 924 resuscitation attempts and 3,698 survey responses were collected including 2,095 qualitative comments (response rate: 65%). Most frequent challenges were overcrowding (27%) and poor ergonomics/choreography of people in the room (17%). Narrative comments aligned into 24 unique barrier and facilitator themes in 4 domains: 6 related to treatment (most prevalent: CPR, rhythm check, equipment), 7 for teamwork (most prevalent: role allocation, crowd control, collaboration with ward staff), 6 for leadership (most prevalent: visible and distinct leader, multiple leaders, leader experience), and 5 for communication (most prevalent: closed loops, atmosphere in room, speaking loud/clear). CONCLUSION: Using novel, immediate after-event survey methodology of individual cardiac arrest team members, we characterized challenges and identified 24 themes within 4 domains that were barriers and facilitators for in-hospital resuscitation teams. We believe this level of detail is necessary to contextualize guidelines and training to facilitate high-quality resuscitation. CI - Copyright (c) 2021 Elsevier B.V. All rights reserved. FAU - Lauridsen, Kasper G AU - Lauridsen KG AD - Research Center for Emergency Medicine, Aarhus University Hospital, Denmark; Department of Medicine, Randers Regional Hospital, Denmark; Department of Anesthesiology and Critical Care Medicine, Children's Hospital of Philadelphia, United States. Electronic address: kglerup@clin.au.dk. FAU - Krogh, Kristian AU - Krogh K AD - Research Center for Emergency Medicine, Aarhus University Hospital, Denmark; Department of Anesthesiology and Critical Care Medicine, Aarhus University Hospital, Denmark. FAU - Muller, Sune D AU - Muller SD AD - Department of Management, Aarhus University, Denmark. FAU - Schmidt, Anders S AU - Schmidt AS AD - Research Center for Emergency Medicine, Aarhus University Hospital, Denmark; Department of Medicine, Randers Regional Hospital, Denmark. FAU - Nadkarni, Vinay M AU - Nadkarni VM AD - Department of Anesthesiology and Critical Care Medicine, Children's Hospital of Philadelphia, United States. FAU - Berg, Robert A AU - Berg RA AD - Department of Anesthesiology and Critical Care Medicine, Children's Hospital of Philadelphia, United States. FAU - Bach, Leif AU - Bach L AD - Department of Anesthesiology and Critical Care Medicine, Randers Regional Hospital, Denmark. FAU - Dodt, Karen K AU - Dodt KK AD - Department of Medicine, Regional Hospital of Horsens, Denmark. FAU - Maack, Thea Celander AU - Maack TC AD - Department of Medicine, Regional Hospital of Horsens, Denmark. FAU - Moller, Dorthe S AU - Moller DS AD - Department of Cardiology, Viborg Regional Hospital, Denmark. FAU - Qvortrup, Mette AU - Qvortrup M AD - Department of Cardiology, Viborg Regional Hospital, Denmark. FAU - Nielsen, Rasmus P AU - Nielsen RP AD - Department of Anesthesiology and Critical Care Medicine, Regional Hospital West Jutland, Denmark. FAU - Hojbjerg, Rikke AU - Hojbjerg R AD - Emergency Department, Aarhus University Hospital, Denmark. FAU - Kirkegaard, Hans AU - Kirkegaard H AD - Research Center for Emergency Medicine, Aarhus University Hospital, Denmark. FAU - Lofgren, Bo AU - Lofgren B AD - Research Center for Emergency Medicine, Aarhus University Hospital, Denmark; Department of Medicine, Randers Regional Hospital, Denmark. LA - eng PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't DEP - 20210524 PL - Ireland TA - Resuscitation JT - Resuscitation JID - 0332173 SB - IM MH - *Cardiopulmonary Resuscitation MH - *Heart Arrest/therapy MH - Hospitals MH - Humans MH - Patient Care Team MH - Prospective Studies OTO - NOTNLM OT - Cardiac arrest teams OT - Communication OT - Errors OT - In-hospital cardiac arrest OT - Leadership OT - Quality improvement EDAT- 2021/05/26 06:00 MHDA- 2021/06/29 06:00 CRDT- 2021/05/25 20:11 PHST- 2021/01/31 00:00 [received] PHST- 2021/04/26 00:00 [revised] PHST- 2021/05/10 00:00 [accepted] PHST- 2021/05/26 06:00 [pubmed] PHST- 2021/06/29 06:00 [medline] PHST- 2021/05/25 20:11 [entrez] AID - S0300-9572(21)00188-X [pii] AID - 10.1016/j.resuscitation.2021.05.007 [doi] PST - ppublish SO - Resuscitation. 2021 Jul;164:70-78. doi: 10.1016/j.resuscitation.2021.05.007. Epub 2021 May 24. PMID- 34031866 OWN - NLM STAT- MEDLINE DCOM- 20210917 LR - 20210917 IS - 1898-018X (Electronic) IS - 1897-5593 (Print) IS - 1898-018X (Linking) VI - 28 IP - 4 DP - 2021 TI - Long-term antibiotic therapy in patients with surgery-indicated not undergoing surgery infective endocarditis. PG - 566-578 LID - 10.5603/CJ.a2021.0054 [doi] AB - BACKGROUND: To date, there is little information regarding management of patients with infective endocarditis (IE) that did not undergo an indicated surgery. Therefore, we aimed to evaluate prognosis of these patients treated with a long-term antibiotic treatment strategy, including oral long term suppressive antibiotic treatment in five referral centres with a multidisciplinary endocarditis team. METHODS: This retrospective, multicenter study retrieved individual patient-level data from five referral centres in Spain. Among a total of 1797, 32 consecutive patients with IE were examined (median age 72 years; 78% males) who had not undergone an indicated surgery, but received long-term antibiotic treatment (LTAT) and were followed by a multidisciplinary endocarditis team, between 2011 and 2019. Primary outcomes were infection relapse and mortality during follow-up. RESULTS: Among 32 patients, 21 had IE associated with prostheses. Of the latter, 8 had an ascending aorta prosthetic graft. In 24 patients, a switch to long-term oral suppressive antibiotic treatment (LOSAT) was considered. The median duration of LOSAT was 277 days. Four patients experienced a relapse during follow-up. One patient died within 60 days, and 12 patients died between 60 days and 3 years. However, only 4 deaths were related to IE. CONCLUSIONS: The present study results suggest that a LTAT strategy, including LOSAT, might be considered for patients with IE that cannot undergo an indicated surgery. After hospitalization, they should be followed by a multidisciplinary endocarditis team. FAU - Vallejo Camazon, Nuria AU - Vallejo Camazon N AUID- ORCID: 0000-0001-6644-6767 AD - Heart Institute, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain. nvallejo73@hotmail.com. AD - Department of Medicine, CIBERCV, Autonomous University of Barcelona, Barcelona, Spain. nvallejo73@hotmail.com. FAU - Mateu, Lourdes AU - Mateu L AD - Unitat Malalties Infeccioses, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain. FAU - Cediel, German AU - Cediel G AD - Heart Institute, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain. FAU - Escola-Verge, Laura AU - Escola-Verge L AD - Servei de Malalties Infeccioses, Hospital Universitari Vall d'Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Fernandez-Hidalgo, Nuria AU - Fernandez-Hidalgo N AD - Servei de Malalties Infeccioses, Hospital Universitari Vall d'Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Gurgui Ferrer, Mercedes AU - Gurgui Ferrer M AD - Unitat de Malalties Infeccioses, Hospital Santa Creu i Sant Pau,Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Perez Rodriguez, Maria Teresa AU - Perez Rodriguez MT AD - Unidad de Enfermedades Infecciosas, Servicio de Medicina Interna, Complexo Hospitalario de Vigo, Vigo, Spain. FAU - Cuervo, Guillermo AU - Cuervo G AD - Department of Infectious Diseases, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain. FAU - Nunez Aragon, Raquel AU - Nunez Aragon R AD - Internal Medicine Department, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain. FAU - Llibre, Cinta AU - Llibre C AD - Heart Institute, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain. FAU - Sopena, Nieves AU - Sopena N AD - Unitat Malalties Infeccioses, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain. FAU - Quesada, Maria Dolores AU - Quesada MD AD - Microbiology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain. FAU - Berastegui, Elisabeth AU - Berastegui E AD - Heart Institute, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain. FAU - Teis, Albert AU - Teis A AD - Heart Institute, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain. FAU - Lopez Ayerbe, Jorge AU - Lopez Ayerbe J AD - Heart Institute, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain. FAU - Junca, Gladys AU - Junca G AD - Heart Institute, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain. FAU - Gual, Francisco AU - Gual F AD - Heart Institute, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain. FAU - Ferrer Sistach, Elena AU - Ferrer Sistach E AD - Heart Institute, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain. FAU - Vivero, Ainhoa AU - Vivero A AD - Internal Medicine Department, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain. FAU - Reynaga, Esteban AU - Reynaga E AD - Unitat Malalties Infeccioses, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain. FAU - Hernandez Perez, Maria AU - Hernandez Perez M AD - Neurology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain. FAU - Munoz Guijosa, Christian AU - Munoz Guijosa C AD - Heart Institute, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain. FAU - Pedro-Botet, Lluisa AU - Pedro-Botet L AD - Department of Medicine, CIBERCV, Autonomous University of Barcelona, Barcelona, Spain. AD - Unitat Malalties Infeccioses, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain. FAU - Bayes-Genis, Antoni AU - Bayes-Genis A AD - Heart Institute, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain. AD - Department of Medicine, CIBERCV, Autonomous University of Barcelona, Barcelona, Spain. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20210525 PL - Poland TA - Cardiol J JT - Cardiology journal JID - 101392712 RN - 0 (Anti-Bacterial Agents) SB - IM MH - Aged MH - Anti-Bacterial Agents/therapeutic use MH - *Endocarditis/diagnosis/drug therapy/surgery MH - *Endocarditis, Bacterial/diagnosis/drug therapy/surgery MH - Female MH - Humans MH - Male MH - Prognosis MH - Retrospective Studies PMC - PMC8276997 OTO - NOTNLM OT - infective endocarditis OT - suppressive antibiotic treatment OT - surgery COIS- Conflict of interest: None declared EDAT- 2021/05/26 06:00 MHDA- 2021/09/18 06:00 PMCR- 2021/07/06 CRDT- 2021/05/25 06:50 PHST- 2021/02/15 00:00 [received] PHST- 2021/04/23 00:00 [accepted] PHST- 2021/05/21 00:00 [revised] PHST- 2021/05/26 06:00 [pubmed] PHST- 2021/09/18 06:00 [medline] PHST- 2021/05/25 06:50 [entrez] PHST- 2021/07/06 00:00 [pmc-release] AID - VM/OJS/J/74991 [pii] AID - cardj-28-4-566 [pii] AID - 10.5603/CJ.a2021.0054 [doi] PST - ppublish SO - Cardiol J. 2021;28(4):566-578. doi: 10.5603/CJ.a2021.0054. Epub 2021 May 25. PMID- 34031158 OWN - NLM STAT- MEDLINE DCOM- 20211207 LR - 20211214 IS - 1468-201X (Electronic) IS - 1355-6037 (Linking) VI - 107 IP - 16 DP - 2021 Aug TI - Weathering the perfect storm: management of heart failure in patients with substance use disorders. PG - 1353-1354 LID - 10.1136/heartjnl-2021-319103 [doi] FAU - DesJardin, Jacqueline AU - DesJardin J AD - Cardiology, University of California San Francisco, San Francisco, California, USA. FAU - Leyde, Sarah AU - Leyde S AD - Division of General Internal Medicine, Harborview Medical Center, University of Washington, Seattle, Washington, USA. FAU - Davis, Jonathan AU - Davis J AUID- ORCID: 0000-0003-2822-6776 AD - Cardiology, University of California San Francisco, San Francisco, California, USA jonathan.davis@ucsf.edu. AD - Cardiology, Zuckerberg San Francisco General Hospital, San Francisco, CA, USA. LA - eng PT - Journal Article DEP - 20210524 PL - England TA - Heart JT - Heart (British Cardiac Society) JID - 9602087 SB - IM MH - Health Services Misuse/*prevention & control MH - Health Services Needs and Demand MH - Heart Disease Risk Factors MH - *Heart Failure/mortality/psychology/therapy MH - Humans MH - Interdisciplinary Communication MH - Patient-Centered Care/*organization & administration MH - Psychology MH - Risk Adjustment MH - Socioeconomic Factors MH - *Stereotyping MH - *Substance-Related Disorders/epidemiology/physiopathology MH - United States COIS- Competing interests: None declared. EDAT- 2021/05/26 06:00 MHDA- 2021/12/15 06:00 CRDT- 2021/05/25 06:05 PHST- 2021/05/26 06:00 [pubmed] PHST- 2021/12/15 06:00 [medline] PHST- 2021/05/25 06:05 [entrez] AID - heartjnl-2021-319103 [pii] AID - 10.1136/heartjnl-2021-319103 [doi] PST - ppublish SO - Heart. 2021 Aug;107(16):1353-1354. doi: 10.1136/heartjnl-2021-319103. Epub 2021 May 24. PMID- 34031021 OWN - NLM STAT- MEDLINE DCOM- 20211122 LR - 20230222 IS - 1969-6213 (Electronic) IS - 1774-024X (Print) IS - 1774-024X (Linking) VI - 17 IP - 10 DP - 2021 Nov 19 TI - Thirty-day outcomes of the Cardioband tricuspid system for patients with symptomatic functional tricuspid regurgitation: The TriBAND study. PG - 809-817 LID - EIJ-D-21-00300 [pii] LID - 10.4244/EIJ-D-21-00300 [doi] AB - BACKGROUND: Severe tricuspid regurgitation (TR) has limited treatment options and is associated with high morbidity and mortality. AIMS: We evaluated the safety and effectiveness of the Cardioband tricuspid valve reconstruction system from the ongoing European single-arm, multicentre, prospective TriBAND post-market clinical follow-up study. METHODS: Eligible patients had chronic symptomatic functional TR despite diuretic therapy and were deemed candidates for transcatheter tricuspid repair by the local Heart Team. RESULTS: Sixty-one patients had >/=severe functional TR. At baseline, 85% of patients were in NYHA Class III-IV, 94% had >/=severe TR (core laboratory-assessed) with 6.8% EuroSCORE II and 53% LVEF. Device success was 96.7%. At discharge, 59% (p<0.001) of patients achieved /=severe functional TR. Results showed significant reductions in annular diameter and TR severity, accompanied by early evidence of right heart remodelling and improvements in functional status and quality of life. FAU - Nickenig, Georg AU - Nickenig G AD - University Hospital Bonn, Bonn, Germany. FAU - Friedrichs, Kai P AU - Friedrichs KP FAU - Baldus, Stephan AU - Baldus S FAU - Arnold, Martin AU - Arnold M FAU - Seidler, Tim AU - Seidler T FAU - Hakmi, Samer AU - Hakmi S FAU - Linke, Axel AU - Linke A FAU - Schafer, Ulrich AU - Schafer U FAU - Dreger, Henryk AU - Dreger H FAU - Reinthaler, Markus AU - Reinthaler M FAU - von Bardeleben, Ralph Stephan AU - von Bardeleben RS FAU - Mollmann, Helge AU - Mollmann H FAU - Weber, Marcel AU - Weber M FAU - Roder, Fabian AU - Roder F FAU - Korber, Maria Isabel AU - Korber MI FAU - Landendinger, Melanie AU - Landendinger M FAU - Wolf, Frieder AU - Wolf F FAU - Alessandrini, Hannes AU - Alessandrini H FAU - Sveric, Krunoslav AU - Sveric K FAU - Schewel, Dimitry AU - Schewel D FAU - Romero-Dorta, Elena AU - Romero-Dorta E FAU - Kasner, Mario AU - Kasner M FAU - Dahou, Abdellaziz AU - Dahou A FAU - Hahn, Rebecca T AU - Hahn RT FAU - Windecker, Stephan AU - Windecker S LA - eng PT - Journal Article PL - France TA - EuroIntervention JT - EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology JID - 101251040 SB - IM MH - Cardiac Catheterization MH - Follow-Up Studies MH - *Heart Valve Prosthesis Implantation/adverse effects MH - Humans MH - Prospective Studies MH - Quality of Life MH - Severity of Illness Index MH - Time Factors MH - Treatment Outcome MH - *Tricuspid Valve Insufficiency/diagnostic imaging/surgery PMC - PMC9724867 COIS- G. Nickenig, S. Baldus, M. Arnold, U. Schafer, R.S. von Bardeleben, M. Weber and R.T. Hahn have received speakers' honoraria or travel/grant support from Edwards Lifesciences. G. Nickenig has received research funding from the Deutsche Forschungsgemeinschaft (DFG), the Federal Ministry of Education and Research (BMBF), the European Union, Abbott, AGA Medical, AstraZeneca, Bayer, Berlin Chemie, BioSensus, Biotronik, Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Edwards Lifesciences, Medtronic, Novartis, Pfizer, Sanofi, and St. Jude Medical, honoraria for lectures or advisory boards from Abbott, AGA Medical, AstraZeneca, Bayer, Berlin, Cardiovalve, Berlin Chemie, BioSensus, Biotronik, Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Medtronic, Novartis, Pfizer, Sanofi, and St. Jude Medical, and has participated in clinical trials for Abbott, AGA Medical, AstraZeneca, Bayer, Berlin Chemie, BioSensus, Biotronik, Bristol-Myers Squibb, Boehringer Ingelheim, Cardiovalve, Daiichi Sankyo, Edwards Lifesciences, Medtronic, Novartis, Pfizer, Sanofi and St. Jude Medical. M. Arnold has received lecture fees and honoraria for advisory board activities from Abbott. S. Windecker has received research and educational grants to the institution from Abbott, Amgen, BMS, Bayer, Boston Scientific, Biotronik, Cardinal Health, Cardiovalve, CSL Behring, Daiichi Sankyo, Edwards Lifesciences, Johnson & Johnson, Medtronic, Querbet, Polares, Sanofi, Terumo, and Sinomed, and has served as unpaid advisory board member and/or unpaid member of the steering/executive group of trials funded by Abbott, Abiomed, Amgen, AstraZeneca, BMS, Boston Scientific, Biotronik, Cardiovalve, Edwards Lifesciences, MedAlliance, Medtronic, Novartis, Polares, Sinomed, V-Wave and Xeltis, but has not received personal payments by pharmaceutical companies or device manufacturers. He is also a member of the steering/executive committee group of several investigator-initiated trials that receive funding by industry without impact on his personal remuneration, and is an unpaid member of the Pfizer Research Award selection committee in Switzerland. R.T. Hahn has received speaker honoraria from Abbott Vascular, Edwards Lifesciences and Philips Healthcare, reports consulting for Abbott Structural, Edwards Lifesciences, Medtronic, Navigate, and Philips Healthcare, and is the Chief Scientific Officer for the Echocardiography Core Laboratory at the Cardiovascular Research Foundation for multiple industry-sponsored trials, for which she received no direct industry compensation. The other authors have no conflicts of interest to declare. EDAT- 2021/05/26 06:00 MHDA- 2021/11/23 06:00 PMCR- 2022/11/19 CRDT- 2021/05/25 06:03 PHST- 2021/05/26 06:00 [pubmed] PHST- 2021/11/23 06:00 [medline] PHST- 2021/05/25 06:03 [entrez] PHST- 2022/11/19 00:00 [pmc-release] AID - EIJ-D-21-00300 [pii] AID - 10.4244/EIJ-D-21-00300 [doi] PST - ppublish SO - EuroIntervention. 2021 Nov 19;17(10):809-817. doi: 10.4244/EIJ-D-21-00300. PMID- 34030760 OWN - NLM STAT- MEDLINE DCOM- 20220118 LR - 20250530 IS - 1467-1107 (Electronic) IS - 1047-9511 (Linking) VI - 32 IP - 1 DP - 2022 Jan TI - Pre-conceptual counselling in cardiology patients: still work to do and still missed opportunities. A comparison between 2015 and 2019 in women with cardiac disease attending combined obstetric cardiology clinics. Should the European Guidelines change anything? PG - 64-70 LID - 10.1017/S1047951121001530 [doi] AB - Women with underlying cardiac conditions have an increased risk of adverse pregnancy outcomes. Counselling reproductive age women with heart disease is important to assist them in deciding whether to pursue pregnancy, to ensure their best cardiovascular status prior to pregnancy, and that they understand the risks of pregnancy for them and baby. This also provides an opportunity to explore management strategies to reduce risks. For this growing cohort of women, there is a great need for pre-conceptual counselling.This retrospective comparative audit assessed new referrals and pre-conceptual counselling of women attending a joint obstetric-cardiology clinic at a tertiary maternity centre in a 12-month period of 2015-2016 compared with 2018-2019. This reflected the timing of the introduction of a multidisciplinary meeting prior to clinics and assessed the impact on referrals with the introduction of the European Society of Cardiology guidelines.Data were reviewed from 56 and 67 patients in respective audit periods. Patient's risk was stratified using modified World Health Organization classification.Less than 50% of women with pre-existing cardiac conditions had received pre-conceptual counselling, although half of them had risks clearly documented. The majority of patients had a recent electrocardiograph and echocardiogram performed prior to counselling, and there was a modest improvement in the number of appropriate functional tests performed between time points. One-third of patients in both cohorts were taking cardiac medications during pregnancy.There was a significant increase in the number of pregnant women with cardiac disease and in complexity according to modified World Health Organization risk classification. While there have been improvements, it is clear that further work to improve availability and documentation of pre-pregnancy counselling is needed. FAU - Kasargod Prabhakar, Chethan R AU - Kasargod Prabhakar CR AUID- ORCID: 0000-0001-8050-2833 AD - Queen Elizabeth Hospital, Birmingham, UK. FAU - Pamment, Daisy AU - Pamment D AD - University of Birmingham Medical School, Birmingham, UK. FAU - Thompson, Peter J AU - Thompson PJ AD - Birmingham Women's Hospital, Birmingham, UK. FAU - Chong, Hsu AU - Chong H AD - The Rosie Maternity Hospital, Cambridge, UK. FAU - Thorne, Sara A AU - Thorne SA AD - Toronto General Hospital, Toronto, ON, Canada. FAU - Fox, Caroline AU - Fox C AD - Birmingham Women's Hospital, Birmingham, UK. FAU - Morris, Katie AU - Morris K AD - Birmingham Women's, Birmingham, UK. FAU - Hudsmith, Lucy H AU - Hudsmith LH AD - Queen Elizabeth Hospital, Birmingham, UK. LA - eng GR - G0700526/MRC_/Medical Research Council/United Kingdom PT - Journal Article DEP - 20210525 PL - England TA - Cardiol Young JT - Cardiology in the young JID - 9200019 SB - IM MH - *Cardiology MH - Counseling MH - Female MH - *Heart Diseases/complications/epidemiology/prevention & control MH - Humans MH - Pregnancy MH - Pregnancy Outcome MH - Retrospective Studies OTO - NOTNLM OT - Cardiac diseases in pregnancy OT - Maternal Cardiology OT - Pre-conception Counselling EDAT- 2021/05/26 06:00 MHDA- 2022/01/19 06:00 CRDT- 2021/05/25 05:53 PHST- 2021/05/26 06:00 [pubmed] PHST- 2022/01/19 06:00 [medline] PHST- 2021/05/25 05:53 [entrez] AID - S1047951121001530 [pii] AID - 10.1017/S1047951121001530 [doi] PST - ppublish SO - Cardiol Young. 2022 Jan;32(1):64-70. doi: 10.1017/S1047951121001530. Epub 2021 May 25. PMID- 34029524 OWN - NLM STAT- MEDLINE DCOM- 20210909 LR - 20210909 IS - 1555-7162 (Electronic) IS - 0002-9343 (Linking) VI - 134 IP - 9 DP - 2021 Sep TI - A Comprehensive Cardiovascular-Renal-Metabolic Risk Reduction Approach to Patients with Type 2 Diabetes Mellitus. PG - 1076-1084 LID - S0002-9343(21)00317-X [pii] LID - 10.1016/j.amjmed.2021.04.024 [doi] AB - Despite decades of research into risk-reduction strategies, cardiovascular disease and renal disease remain leading causes of morbidity and mortality among patients with type 2 diabetes mellitus. Given the tight clustering of cardiovascular and renal disease with the metabolic abnormalities of type 2 diabetes mellitus, we can think of these conditions together as cardiovascular-renal-metabolic disease states. A holistic view of cardiovascular-renal-metabolic disease states is critical to provide integrated patient-centered care to individuals with these disease states. Here, we explore the cardiovascular and renal risks associated with type 2 diabetes mellitus and highlight the importance of reducing cardiovascular-renal-metabolic disease risk in a comprehensive manner. We advocate a cross-disciplinary, team-based model to manage cardiovascular-renal-metabolic disease risk among patients with type 2 diabetes mellitus. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - Pagidipati, Neha J AU - Pagidipati NJ AD - Duke Clinical Research Institute, Durham NC. FAU - Deedwania, Prakash AU - Deedwania P AD - School of Medicine, University of California, San Francisco, Fresno. Electronic address: deed@ucsf.edu. LA - eng PT - Journal Article PT - Review DEP - 20210523 PL - United States TA - Am J Med JT - The American journal of medicine JID - 0267200 SB - IM MH - Cardiometabolic Risk Factors MH - Diabetes Mellitus, Type 2/complications/metabolism/therapy MH - *Diabetic Angiopathies/metabolism/prevention & control MH - *Diabetic Cardiomyopathies/metabolism/prevention & control MH - *Diabetic Nephropathies/metabolism/prevention & control MH - Humans MH - Models, Organizational MH - *Patient-Centered Care/methods/organization & administration MH - Risk Assessment OTO - NOTNLM OT - Cardiovascular OT - Diabetes mellitus OT - Patient-centered OT - Prevention OT - Risk reduction EDAT- 2021/05/25 06:00 MHDA- 2021/09/10 06:00 CRDT- 2021/05/24 20:21 PHST- 2021/04/15 00:00 [received] PHST- 2021/04/27 00:00 [revised] PHST- 2021/04/27 00:00 [accepted] PHST- 2021/05/25 06:00 [pubmed] PHST- 2021/09/10 06:00 [medline] PHST- 2021/05/24 20:21 [entrez] AID - S0002-9343(21)00317-X [pii] AID - 10.1016/j.amjmed.2021.04.024 [doi] PST - ppublish SO - Am J Med. 2021 Sep;134(9):1076-1084. doi: 10.1016/j.amjmed.2021.04.024. Epub 2021 May 23. PMID- 34024540 OWN - NLM STAT- MEDLINE DCOM- 20210924 LR - 20210924 IS - 2405-4577 (Electronic) IS - 2405-4577 (Linking) VI - 43 DP - 2021 Jun TI - Factors influencing adequate protein and energy delivery among critically ill children with heart disease in pediatric intensive care unit. PG - 353-359 LID - S2405-4577(21)00127-3 [pii] LID - 10.1016/j.clnesp.2021.03.024 [doi] AB - BACKGROUND & AIMS: Inadequate nutrition delivery in critically ill children has shown associated with poor clinical outcomes. Therefore, identifying barriers to deliver adequate nutrition is vital. The aim of this study was to identify factors influencing adequate protein and energy delivery among critically ill children with heart disease in pediatric intensive care unit (PICU). METHODS: This single-centre prospective study, involved children aged from birth to 3 years old, admitted to PICU longer than 72 hours. They received either enteral nutrition (EN) or combination of EN and partial parenteral nutrition (PPN). Clinical and nutrition delivery characteristics were recorded from admission until transferred out of PICU. Multiple regression analysis at significant level p < 0.05 were used to identify independent risk factors for lower protein and energy intake. RESULTS: One hundred and thirty-nine patients were included in this study with median age 6.5 (1.8-20.6) months and median PICU length of stay of 6 (4-7) days. The median energy and protein adequacy were 83.2% and 46.7%, respectively. In multivariable analysis, children who underwent surgery (AOR 0.97; 95% CI 0.27-0.75; p = 0.041), with fluid restriction (AOR 0.97; 95% CI 0.25-0.73; p = 0.041), longer length of PICU stay (AOR 0.35; 95% CI 0.18-0.64; p = 0.001) and longer feeding interruptions (AOR 3.57; 95% CI 1.39-9.15; p = 0.008) were more likely to have lower energy intake. Children at risk of malnutrition (weight-for-age Z score of < -2 SD) (AOR 2.54; 95% CI 1.12 to 5.77; p = 0.026) and longer duration of mechanical ventilation (AOR 0.73; 95% CI 0.53 to 0.98; p = 0.041) were more likely to have lower protein intake. CONCLUSION: This study highlighted the factors influencing adequate protein and energy delivery in critically ill children with heart disease in PICU. Strategies to improve the nutrition delivery in this group of patients should be outlined and implemented by the dietitians along with multidisciplinary team. CI - Copyright (c) 2021 European Society for Clinical Nutrition and Metabolism. Published by Elsevier Ltd. All rights reserved. FAU - Sundar, Vatana V AU - Sundar VV AD - Dietetics and Food Services, National Heart Institute, 145, Jalan Tun Razak, 50400 Kuala Lumpur, Malaysia. Electronic address: vatana14@gmail.com. FAU - Sehu Allavudin, Siti Farhath AU - Sehu Allavudin SF AD - Dietetics and Food Services, National Heart Institute, 145, Jalan Tun Razak, 50400 Kuala Lumpur, Malaysia. Electronic address: farhath@ijn.com.my. FAU - Easaw, Mary Easaw P M AU - Easaw MEPM AD - Dietetics and Food Services, National Heart Institute, 145, Jalan Tun Razak, 50400 Kuala Lumpur, Malaysia. Electronic address: maryroshini16@gmail.com. LA - eng PT - Journal Article DEP - 20210425 PL - England TA - Clin Nutr ESPEN JT - Clinical nutrition ESPEN JID - 101654592 SB - IM MH - Child MH - *Critical Illness MH - Enteral Nutrition MH - *Heart Diseases MH - Humans MH - Intensive Care Units, Pediatric MH - Prospective Studies OTO - NOTNLM OT - Critically ill children OT - Energy intake OT - Heart disease OT - Nutrition OT - Paediatric intensive care unit OT - Protein intake COIS- Declaration of competing interest None. EDAT- 2021/05/25 06:00 MHDA- 2021/09/25 06:00 CRDT- 2021/05/24 06:15 PHST- 2019/10/08 00:00 [received] PHST- 2021/02/27 00:00 [revised] PHST- 2021/03/24 00:00 [accepted] PHST- 2021/05/24 06:15 [entrez] PHST- 2021/05/25 06:00 [pubmed] PHST- 2021/09/25 06:00 [medline] AID - S2405-4577(21)00127-3 [pii] AID - 10.1016/j.clnesp.2021.03.024 [doi] PST - ppublish SO - Clin Nutr ESPEN. 2021 Jun;43:353-359. doi: 10.1016/j.clnesp.2021.03.024. Epub 2021 Apr 25. PMID- 34020928 OWN - NLM STAT- MEDLINE DCOM- 20211029 LR - 20220707 IS - 1876-7605 (Electronic) IS - 1936-8798 (Linking) VI - 14 IP - 14 DP - 2021 Jul 26 TI - 2-Year Outcomes for Transcatheter Repair in Patients With Mitral Regurgitation From the CLASP Study. PG - 1538-1548 LID - S1936-8798(21)00675-0 [pii] LID - 10.1016/j.jcin.2021.04.001 [doi] AB - OBJECTIVES: This study reports 2-year outcomes from the multicenter, prospective, single-arm CLASP study with functional mitral regurgitation (FMR) and degenerative MR (DMR) analysis. BACKGROUND: Transcatheter repair is a favorable option to treat MR. Long-term prognostic impact of the PASCAL transcatheter valve repair system in patients with clinically significant MR remains to be established. METHODS: Patients had clinically significant MR >/=3+ as evaluated by the echocardiographic core laboratory and were deemed candidates for transcatheter repair by the heart team. Assessments were performed by clinical events committee to 1 year (site-reported thereafter) and core laboratory to 2 years. RESULTS: A total of 124 patients (69% FMR, 31% DMR) were enrolled with a mean age of 75 years, 56% were male, 60% were New York Heart Association functional class III to IVa, and 100% had MR >/=3+. At 2 years, Kaplan-Meier estimates showed 80% survival (72% FMR, 94% DMR) and 84% freedom from heart failure (HF) hospitalization (78% FMR, 97% DMR), with 85% reduction in annualized HF hospitalization rate (81% FMR, 98% DMR). MR 30 days post-ICH. Among patients considered unable to take OAC, left atrial appendage occlusion procedure was the therapy of choice in 73.3% respondents. When deciding on ATT, respondents considered patient's CHA2DS2-VASc score, ICH type, demographics, risk factors, and patient adherence. The main reason for not restarting or commencing ATT was concern about recurrent ICH (80.8%). National or international clinical guidelines would be advantageous to support decision-making (84.3%). Other helpful resources reported were multidisciplinary team involvement (46.9%) and patient education (82%). In summary, most survey respondents would prescribe OAC therapy for patients with AF who have sustained an ICH on OAC and would restart OAC >30 days post-ICH. The risk of recurrent ICH was the main reason for not prescribing any ATT post-ICH. CI - Published on behalf of the European Society of Cardiology. All rights reserved. (c) The Author(s) 2021. For permissions, please email: journals.permissions@oup.com. FAU - Ivany, Elena AU - Ivany E AD - Liverpool Centre for Cardiovascular Science, University of Liverpool, 6 West Derby Street, Liverpool L7 8TX, UK. FAU - Lane, Deirdre A AU - Lane DA AUID- ORCID: 0000-0002-5604-9378 AD - Liverpool Centre for Cardiovascular Science, University of Liverpool, 6 West Derby Street, Liverpool L7 8TX, UK. AD - Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. FAU - Dan, Gheorghe-Andrei AU - Dan GA AD - 'Internal Medicine, Carol Davila' University of Medicine, Colentina University Hospital, Bucharest, Romania. FAU - Doehner, Wolfram AU - Doehner W AUID- ORCID: 0000-0001-7598-708X AD - Berlin Institute of Health Center for Regenerative Therapies, Berlin, Germany. AD - Department of Cardiology (Virchow Klinikum), Charite - Universitatsmedizin Berlin, Berlin, Germany. AD - German Centre for Cardiovascular Research (DZHK), Partner Site Berlin, Berlin, Germany. AD - Center for Stroke Research Berlin, Charite - Universitatsmedizin Berlin, Berlin, Germany. FAU - Farkowski, Michal M AU - Farkowski MM AD - II Department of Heart Arrhythmia, National Institute of Cardiology, Warsaw, Poland. FAU - Iliodromitis, Konstantinos AU - Iliodromitis K AD - Clinic for Cardiology and Electrophysiology, Evangelisches Krankenhaus Hagen-Haspe, Hagen, Germany. FAU - Lenarczyk, Radoslaw AU - Lenarczyk R AD - Department of Cardiology, Congenital Heart Defects and Electrotherapy, Medical University of Silesia, Silesian Center of Heart Disease, Zabrze, Poland. FAU - Potpara, Tatjana S AU - Potpara TS AD - Serbia School of Medicine, University of Belgrade, Belgrade, Serbia. AD - Department for Intensive Care in Cardiac Arrhythmias, Cardiology Clinic, Clinical Centre of Serbia, Belgrade, Serbia. LA - eng PT - Journal Article PL - England TA - Europace JT - Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology JID - 100883649 RN - 0 (Anticoagulants) RN - 0 (Fibrinolytic Agents) SB - IM MH - Administration, Oral MH - Anticoagulants/adverse effects MH - *Atrial Fibrillation/complications/diagnosis/drug therapy MH - Cerebral Hemorrhage/chemically induced/diagnosis/epidemiology MH - Fibrinolytic Agents/adverse effects MH - Humans MH - *Stroke/diagnosis/epidemiology/etiology MH - Surveys and Questionnaires OTO - NOTNLM OT - Anticoagulation OT - Atrial fibrillation OT - EHRA survey OT - Intracerebral haemorrhage OT - Non-vitamin K antagonist oral anticoagulants OT - Vitamin K antagonist EDAT- 2021/05/22 06:00 MHDA- 2021/08/10 06:00 CRDT- 2021/05/21 20:33 PHST- 2020/11/30 00:00 [received] PHST- 2020/12/30 00:00 [accepted] PHST- 2021/05/21 20:33 [entrez] PHST- 2021/05/22 06:00 [pubmed] PHST- 2021/08/10 06:00 [medline] AID - 6124844 [pii] AID - 10.1093/europace/euaa423 [doi] PST - ppublish SO - Europace. 2021 May 21;23(5):806-814. doi: 10.1093/europace/euaa423. PMID- 34009907 OWN - NLM STAT- MEDLINE DCOM- 20220203 LR - 20230824 IS - 1559-713X (Electronic) IS - 1559-2332 (Linking) VI - 17 IP - 1 DP - 2022 Feb 1 TI - Rapid Cycle Deliberate Practice Improves Retention of Pediatric Resuscitation Skills Compared With Postsimulation Debriefing. PG - e20-e27 LID - 10.1097/SIH.0000000000000568 [doi] AB - INTRODUCTION: Rapid cycle deliberate practice (RCDP) for teaching team-based resuscitation is associated with similar improvements in immediate performance as compared with postsimulation debriefing (PSD). Limited studies compare skill retention between these 2 modalities. Our objective was to compare retention of team leader performance in residents trained with RCDP versus PSD. METHODS: This was a cluster-randomized trial comparing RCDP and PSD from January 2018 to April 2019. Pediatric and emergency medicine residents participated in simulation-based pediatric resuscitation education, and teams were randomized to undergo either RCDP or PSD. Each participant's team leader performance was assessed 1 to 12 months after training via a simulated cardiac arrest. The primary outcome was time to defibrillation. Secondary outcomes included overall team leader performance and time to chest compressions. RESULTS: Thirty-two residents (90.6% pediatrics, 9.4% emergency medicine) met inclusion criteria (16 RCDP, 16 PSD). Of the 32 residents, 40% returned in 1 to 3 months, 25% 3 to 6 months, 16% 6 to 9 months, and 19% 10 to 12 months. Participants in RCDP had more than 5 times the odds of achieving defibrillation versus those in the PSD group (odds ratio = 5.57, 95% confidence interval = 1.13-27.52, P = 0.04). The RCDP group had a higher mean Resident Team Leader Evaluation score (0.54 +/- 0.19) than the PSD group (0.34 +/- 0.16, P < 0.001). CONCLUSIONS: This study shows significant differences in subsequent performance in the team leader trained with RCDP and suggests that RCDP may improve retention of pediatric resuscitation skills compared with PSD. Future studies should focus on best applications for RCDP with attention to knowledge and skill decay. CI - Copyright (c) 2021 Society for Simulation in Healthcare. FAU - Won, Sharon K AU - Won SK AD - From the Section of Emergency Medicine, Department of Pediatrics, Texas Children's Hospital, Baylor College of Medicine, Houston, TX. FAU - Doughty, Cara B AU - Doughty CB FAU - Young, Ann L AU - Young AL FAU - Welch-Horan, T Bram AU - Welch-Horan TB FAU - Rus, Marideth C AU - Rus MC FAU - Camp, Elizabeth A AU - Camp EA FAU - Lemke, Daniel S AU - Lemke DS LA - eng PT - Journal Article PT - Randomized Controlled Trial PL - United States TA - Simul Healthc JT - Simulation in healthcare : journal of the Society for Simulation in Healthcare JID - 101264408 SB - IM MH - Child MH - Clinical Competence MH - *Heart Arrest/therapy MH - Humans MH - *Internship and Residency MH - *Pediatrics MH - Resuscitation COIS- The authors declare no conflict of interest. EDAT- 2021/05/20 06:00 MHDA- 2022/02/04 06:00 CRDT- 2021/05/19 16:24 PHST- 2021/05/20 06:00 [pubmed] PHST- 2022/02/04 06:00 [medline] PHST- 2021/05/19 16:24 [entrez] AID - 01266021-202202000-00015 [pii] AID - 10.1097/SIH.0000000000000568 [doi] PST - ppublish SO - Simul Healthc. 2022 Feb 1;17(1):e20-e27. doi: 10.1097/SIH.0000000000000568. PMID- 34004077 OWN - NLM STAT- MEDLINE DCOM- 20211020 LR - 20211020 IS - 1522-726X (Electronic) IS - 1522-1946 (Linking) VI - 98 IP - 4 DP - 2021 Oct TI - Early outcomes from the CLASP IID trial roll-in cohort for prohibitive risk patients with degenerative mitral regurgitation. PG - E637-E646 LID - 10.1002/ccd.29749 [doi] AB - OBJECTIVES: We report the 30-day outcomes from the roll-in cohort of the CLASP IID trial, representing the first procedures performed by each site. BACKGROUND: The currently enrolling CLASP IID/IIF pivotal trial is a multicenter, prospective, randomized trial assessing the safety and effectiveness of the PASCAL transcatheter valve repair system in patients with clinically significant MR. The trial allows for up to three roll-in patients per site. METHODS: Eligibility criteria were: DMR >/=3+, prohibitive surgical risk, and deemed suitable for transcatheter repair by the local heart team. Trial oversight included a central screening committee and echocardiographic core laboratory. The primary safety endpoint was a 30-day composite MAE: cardiovascular mortality, stroke, myocardial infarction (MI), new need for renal replacement therapy, severe bleeding, and non-elective mitral valve re-intervention, adjudicated by an independent clinical events committee. Thirty-day echocardiographic, functional, and quality of life outcomes were assessed. RESULTS: A total of 45 roll-in patients with mean age of 83 years and 69% in NYHA class III/IV were treated. Successful implantation was achieved in 100%. The 30-day composite MAE rate was 8.9% including one cardiovascular death (2.2%) due to severe bleeding from a hemorrhagic stroke, one MI, and no need for re-intervention. MR/=3+ at prohibitive surgical risk. CI - (c) 2021 Wiley Periodicals LLC. FAU - Lim, D Scott AU - Lim DS AUID- ORCID: 0000-0001-6951-6660 AD - Department of Medicine, Division of Cardiovascular Medicine, University of Virginia Health System, Charlottesville, Virginia, USA. FAU - Smith, Robert L AU - Smith RL AD - Department of Surgery, Division of Cardiovascular Surgery, Baylor Scott and White The Heart Hospital Plano, Plano, Texas, USA. FAU - Zahr, Firas AU - Zahr F AUID- ORCID: 0000-0001-8448-8880 AD - Department of Medicine, Division of Cardiovascular Medicine, Oregon Health & Science University, Portland, Oregon, USA. FAU - Dhoble, Abhijeet AU - Dhoble A AUID- ORCID: 0000-0001-8244-274X AD - Department of Medicine, Division of Cardiovascular Medicine, The University of Texas Health Science Center at Houston, Houston, Texas, USA. FAU - Laham, Roger AU - Laham R AD - Department of Medicine, Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA. FAU - Lazkani, Mohamad AU - Lazkani M AD - Department of Medicine, Division of Cardiovascular Medicine, UCHealth Medical Center of the Rockies, Loveland, Colorado, USA. FAU - Kodali, Susheel AU - Kodali S AD - Department of Medicine, Division of Cardiovascular Medicine, Columbia University Medical Center, New York, New York, USA. FAU - Kliger, Chad AU - Kliger C AD - Department of Medicine, Division of Cardiovascular Medicine, Northwell-Lenox Hill, New York, New York, USA. FAU - Hermiller, James AU - Hermiller J AD - Department of Medicine, Division of Cardiovascular Medicine, St. Vincent Heart Center of Indiana, Indianapolis, Indiana, USA. FAU - Vora, Amit AU - Vora A AD - Department of Medicine, Division of Cardiovascular Medicine, UPMC Pinnacle Health Harrisburg, Harrisburg, Pennsylvania, USA. FAU - Sarembock, Ian J AU - Sarembock IJ AD - Department of Medicine, Division of Cardiovascular Medicine, The Christ Hospital and Lindner Clinical Research Center, Cincinnati, Ohio, USA. FAU - Gray, William AU - Gray W AD - Department of Medicine, Division of Cardiovascular Medicine, Lankenau Heart Institute, Wynnewood, Pennsylvania, USA. FAU - Kapadia, Samir AU - Kapadia S AUID- ORCID: 0000-0002-0026-3391 AD - Department of Medicine, Division of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA. FAU - Greenbaum, Adam AU - Greenbaum A AD - Department of Medicine, Division of Cardiovascular Medicine, Emory University, Atlanta, Georgia, USA. FAU - Rassi, Andrew AU - Rassi A AD - Department of Medicine, Division of Cardiovascular Medicine, Kaiser Permanente San Francisco Medical Center, San Francisco, California, USA. FAU - Lee, David AU - Lee D AD - Department of Medicine, Division of Cardiovascular Medicine, Stanford University Medical Center, Palo Alto, California, USA. FAU - Chhatriwalla, Adnan AU - Chhatriwalla A AD - Department of Medicine, Division of Cardiovascular Medicine, Saint Luke's Hospital of Kansas City, Kansas City, Missouri, USA. FAU - Shah, Pinak AU - Shah P AUID- ORCID: 0000-0002-1642-7557 AD - Department of Medicine, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA. FAU - Rodes-Cabau, Josep AU - Rodes-Cabau J AD - Department of Medicine, Division of Cardiovascular Medicine, Laval Hospital, Quebec City, Quebec, Canada. FAU - Ibrahim, Homam AU - Ibrahim H AD - Department of Medicine, Division of Cardiovascular Medicine, New York University Langone Medical Center, New York, New York, USA. FAU - Satler, Lowell AU - Satler L AUID- ORCID: 0000-0001-6446-2683 AD - Department of Medicine, Division of Cardiovascular Medicine, MedStar Washington Hospital Center, Washington, District of Columbia, USA. FAU - Herrmann, Howard C AU - Herrmann HC AUID- ORCID: 0000-0003-3322-9568 AD - Department of Medicine, Division of Cardiovascular Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. FAU - Mahoney, Paul AU - Mahoney P AD - Department of Medicine, Division of Cardiovascular Medicine, Sentara Norfolk General Hospital, Norfolk, Virginia, USA. FAU - Davidson, Charles AU - Davidson C AD - Department of Medicine, Division of Cardiovascular Medicine, Northwestern University, Chicago, Illinois, USA. FAU - Petrossian, George AU - Petrossian G AD - Department of Medicine, Division of Cardiovascular Medicine, St. Francis Hospital, The Heart Center, Roslyn, New York, USA. FAU - Guerrero, Mayra AU - Guerrero M AD - Department of Medicine, Division of Cardiovascular Medicine, Mayo Clinic Rochester, Rochester, Minnesota, USA. FAU - Koulogiannis, Konstantinos AU - Koulogiannis K AD - Department of Medicine, Division of Cardiovascular Medicine, Atlantic Health System Morristown Medical Center, Morristown, New Jersey, USA. FAU - Marcoff, Leo AU - Marcoff L AD - Department of Medicine, Division of Cardiovascular Medicine, Atlantic Health System Morristown Medical Center, Morristown, New Jersey, USA. FAU - Gillam, Linda AU - Gillam L AD - Department of Medicine, Division of Cardiovascular Medicine, Atlantic Health System Morristown Medical Center, Morristown, New Jersey, USA. CN - CLASP IID Pivotal Trial Investigators LA - eng GR - Edwards Lifesciences/ PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20210518 PL - United States TA - Catheter Cardiovasc Interv JT - Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions JID - 100884139 SB - IM MH - Aged, 80 and over MH - *Heart Valve Prosthesis Implantation/adverse effects MH - Humans MH - *Mitral Valve Insufficiency/diagnostic imaging/surgery MH - Prospective Studies MH - Quality of Life MH - Treatment Outcome OTO - NOTNLM OT - PASCAL OT - degenerative OT - mitral regurgitation OT - mitral repair OT - transcatheter EDAT- 2021/05/19 06:00 MHDA- 2021/10/21 06:00 CRDT- 2021/05/18 17:27 PHST- 2021/03/16 00:00 [received] PHST- 2021/04/21 00:00 [accepted] PHST- 2021/05/19 06:00 [pubmed] PHST- 2021/10/21 06:00 [medline] PHST- 2021/05/18 17:27 [entrez] AID - 10.1002/ccd.29749 [doi] PST - ppublish SO - Catheter Cardiovasc Interv. 2021 Oct;98(4):E637-E646. doi: 10.1002/ccd.29749. Epub 2021 May 18. PMID- 34003666 OWN - NLM STAT- MEDLINE DCOM- 20211015 LR - 20211015 IS - 1941-7632 (Electronic) IS - 1941-7640 (Linking) VI - 14 IP - 5 DP - 2021 May TI - Valve-in-Surgical-Valve With SAPIEN 3 for Transcatheter Aortic Valve Replacement Based on Society of Thoracic Surgeons Predicted Risk of Mortality. PG - e010288 LID - 10.1161/CIRCINTERVENTIONS.120.010288 [doi] AB - BACKGROUND: The use of valve-in-valve-transcatheter aortic valve replacement (VIV-TAVR) in degenerated aortic bioprosthesis has been increasing, but the Food and Drug Administration approval is limited to high-risk patients. We analyzed the real-world experience of SAPIEN 3 VIV-TAVR, especially in lower-risk patients, based on the Society of Thoracic Surgeons (STS) score. METHODS: All transfemoral VIV-TAVR with the SAPIEN 3 and Ultra valves between June 2015 and January 2020 were identified using the STS/American College of Cardiology Transcatheter Valve Therapies Registry. Patients were grouped based on STS score (low score: <4%, intermediate score: 4%8%). Propensity-matched (1:3) analysis was conducted to compare to patients undergoing native TAVR. RESULTS: Of 145 917 SAPIEN 3 TAVR patients, 4460 (3%) underwent transfemoral VIV-TAVR with available baseline STS data in 4276 patients. Average age was 73.9+/-11.2, 66.4% were male, and the mean STS score was 6.9+/-6.0%. Overall 30-day mortality was 2.4% (observed to expected ratio, 0.33), and 1-year mortality was 10.8%. 30-day mortality and observed to expected ratio were 0.9% and 0.32 in low-score, 2.2% and 0.38 in the intermediate-score, and 4.3% and 0.31 in the high-score group. Based on propensity-matched analysis, 30-day mortality was similar and 1-year mortality was lower in VIV compared to native TAVR among all risk groups. When the groups were analyzed based on the Heart Team risk stratification using high-risk and non-high risk, the findings remained consistent. CONCLUSIONS: In this real-world study, VIV-TAVR had excellent 30-day and 1-year outcomes, especially in lower-risk patients. These findings may suggest the feasibility and expansion of VIV-TAVR in lower-risk patients. However, long-term follow-up continues to be crucial. FAU - Kaneko, Tsuyoshi AU - Kaneko T AD - Division of Cardiac Surgery (T.K.), Brigham and Women's Hospital, Boston, MA. FAU - Makkar, Raj R AU - Makkar RR AD - Department of Cardiology, Cedars Sinai Medical Center, Los Angeles, CA (R.R.M.). FAU - Krishnaswami, Amar AU - Krishnaswami A AD - Division of Cardiology, Cleveland Clinic, OH (A.K.). FAU - Hermiller, James AU - Hermiller J AD - The Heart Center of Indiana, Indianapolis (J.H., S.K.). FAU - Greenbaum, Adam AU - Greenbaum A AD - Division of Cardiology, Emory University Medical Center, Atlanta, GA (A.G., V.B.). FAU - Babaliaros, Vasilis AU - Babaliaros V AD - Division of Cardiology, Emory University Medical Center, Atlanta, GA (A.G., V.B.). FAU - Shah, Pinak B AU - Shah PB AD - Division of Cardiology (P.B.S.), Brigham and Women's Hospital, Boston, MA. FAU - Bailey, Stephen H AU - Bailey SH AD - Division of Cardiac Surgery, Allegheny General Hospital, Pittsburgh, PA (S.H.B.). FAU - Bapat, Vinnie AU - Bapat V AD - Division of Cardiac Surgery, Minneapolis Heart Institute, MN (V.B.). FAU - Kapadia, Samir AU - Kapadia S AD - The Heart Center of Indiana, Indianapolis (J.H., S.K.). FAU - Abbas, Amr E AU - Abbas AE AD - Division of Cardiac Surgery, Minneapolis Heart Institute, MN (V.B.). LA - eng PT - Journal Article DEP - 20210518 PL - United States TA - Circ Cardiovasc Interv JT - Circulation. Cardiovascular interventions JID - 101499602 SB - IM CIN - Circ Cardiovasc Interv. 2021 May;14(5):e010883. doi: 10.1161/CIRCINTERVENTIONS.121.010883. PMID: 34003668 EIN - Circ Cardiovasc Interv. 2021 Jul;14(7):e000083. doi: 10.1161/HCV.0000000000000083. PMID: 34283630 MH - Aged MH - Aortic Valve/diagnostic imaging/surgery MH - *Aortic Valve Stenosis/diagnostic imaging/surgery MH - *Heart Valve Prosthesis MH - *Heart Valve Prosthesis Implantation/adverse effects MH - Humans MH - Male MH - Registries MH - Risk Factors MH - *Surgeons MH - *Transcatheter Aortic Valve Replacement/adverse effects MH - Treatment Outcome OTO - NOTNLM OT - bioprosthetic OT - mortality OT - registry OT - risk OT - transcatheter aortic valve replacement EDAT- 2021/05/19 06:00 MHDA- 2021/10/16 06:00 CRDT- 2021/05/18 17:10 PHST- 2021/05/18 17:10 [entrez] PHST- 2021/05/19 06:00 [pubmed] PHST- 2021/10/16 06:00 [medline] AID - 10.1161/CIRCINTERVENTIONS.120.010288 [doi] PST - ppublish SO - Circ Cardiovasc Interv. 2021 May;14(5):e010288. doi: 10.1161/CIRCINTERVENTIONS.120.010288. Epub 2021 May 18. PMID- 34003433 OWN - NLM STAT- MEDLINE DCOM- 20220203 LR - 20240812 IS - 1573-2592 (Electronic) IS - 0271-9142 (Print) IS - 0271-9142 (Linking) VI - 41 IP - 5 DP - 2021 Jul TI - Care of Children with DiGeorge Before and After Cultured Thymus Tissue Implantation. PG - 896-905 LID - 10.1007/s10875-021-01044-0 [doi] AB - BACKGROUND: Children with complete DiGeorge anomaly (cDGA) have congenital athymia plus a myriad of other challenging clinical conditions. The term cDGA encompasses children with congenital athymia secondary to 22q11.2DS, CHARGE syndrome (coloboma, heart defects, choanal atresia, growth or mental retardation, genital abnormalities, and ear abnormalities and/or deafness), and other genetic abnormalities. Some children have no known genetic defects. Since 1993, more than 100 children with congenital athymia have been treated with cultured thymus tissue implantation (CTTI). Naive T cells develop approximately 6 to 12 months after CTTI. Most of the children had significant comorbidities such as heart disease, hypoparathyroidism, and infections requiring complex clinical care post cultured thymus tissue implantation (CTTI). OBJECTIVE: The purpose of this guidance is to assist multidisciplinary teams in caring for children with cDGA both before and after CTTI. METHODS: Thirty-one specialists, in addition to the authors, were asked to share their experience in caring for children with cDGA at Duke University Health System, before and after CTTI. These specialists included physicians, nurses, dentists, therapists, and dieticians. RESULTS: The goal of a multidisciplinary approach is to have children in the best possible condition for receiving CTTI and provide optimal care post CTTI through development of naive T cells and beyond. The CTT (cultured thymus tissue) must be protected from high doses of steroids which can damage CTT. Organs must be protected from adverse effects of immunosuppression. CONCLUSION: Creating a multidisciplinary team and a detailed plan of care for children with cDGA is important for optimal outcomes. FAU - Gupton, Stephanie E AU - Gupton SE AUID- ORCID: 0000-0002-4222-4622 AD - Department of Pediatrics, Division of Allergy and Immunology, Duke University Medical Center, Durham, NC, USA. stephanie.gupton@duke.edu. FAU - McCarthy, Elizabeth A AU - McCarthy EA AD - Department of Pediatrics, Division of Allergy and Immunology, Duke University Medical Center, Durham, NC, USA. FAU - Markert, M Louise AU - Markert ML AD - Department of Pediatrics, Division of Allergy and Immunology, Duke University Medical Center, Durham, NC, USA. AD - Department of Immunology, Duke University Medical Center, Durham, NC, USA. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210518 PL - Netherlands TA - J Clin Immunol JT - Journal of clinical immunology JID - 8102137 RN - 0 (Anti-Infective Agents) SB - IM MH - Anti-Infective Agents/therapeutic use MH - Bacterial Infections/prevention & control MH - Child MH - DiGeorge Syndrome/diagnosis/genetics/immunology/*therapy MH - Humans MH - Immunization MH - Mycoses/prevention & control MH - Practice Guidelines as Topic MH - Thymus Gland/*transplantation MH - Tissue Culture Techniques PMC - PMC8249267 OTO - NOTNLM OT - 22q11.2 deletion syndrome OT - CHARGE syndrome OT - Complete DiGeorge anomaly OT - Congenital athymia OT - Cultured thymus tissue implantation COIS- Cultured thymus tissue implantation (CTTI) is an investigational product implanted into patients under an Investigational New Drug (IND) application with the Food and Drug Administration (FDA). Dr. Markert is the "sponsor" of the investigations. Dr. Markert developed the technology for CTTI. Duke has licensed the technology to Enzyvant Therapeutics GmbH. Dr. Markert and Duke have received royalties from Enzyvant. Portions of Dr. Markert's and her research team's salaries are being paid by funding from Enzyvant. If the technology is commercially successful in the future, Dr. Markert and Duke may benefit financially. The salary and other items needed to create CTTI are paid at cost by insurance. There is no conflict of interest to disclose by Gupton and McCarthy. EDAT- 2021/05/19 06:00 MHDA- 2022/02/04 06:00 PMCR- 2021/05/18 CRDT- 2021/05/18 12:23 PHST- 2021/02/10 00:00 [received] PHST- 2021/04/14 00:00 [accepted] PHST- 2021/05/19 06:00 [pubmed] PHST- 2022/02/04 06:00 [medline] PHST- 2021/05/18 12:23 [entrez] PHST- 2021/05/18 00:00 [pmc-release] AID - 10.1007/s10875-021-01044-0 [pii] AID - 1044 [pii] AID - 10.1007/s10875-021-01044-0 [doi] PST - ppublish SO - J Clin Immunol. 2021 Jul;41(5):896-905. doi: 10.1007/s10875-021-01044-0. Epub 2021 May 18. PMID- 34000896 OWN - NLM STAT- MEDLINE DCOM- 20221129 LR - 20221129 IS - 1531-1937 (Electronic) IS - 0897-1900 (Linking) VI - 35 IP - 6 DP - 2022 Dec TI - Under the Microscope: A Look Into the Role of Critical Care Pharmacists During the COVID-19 Pandemic. PG - 1007-1011 LID - 10.1177/08971900211013991 [doi] AB - Among disciplines, the COVID-19 pandemic has reinforced the importance of critical care pharmacists in assuming responsibility for managing medication therapy in direct patient care settings. Historically, pharmacists have been relied upon for prospective evaluation of drug therapy for appropriate indications, dosage, drug interactions, and drug allergies; monitoring patients' pharmacotherapeutic regimens for effectiveness and adverse effects; providing drug information to providers; and educating health professionals regarding drug therapies. Specific to COVID-19, pharmacists have been an integral member of the multidisciplinary rounding team, assisting with drug shortages and strategies for drug conservation; participating in emergencies, such as advanced cardiac life support (ACLS) and rapid sequence intubations; and creating as well as integrating evidence-based guidelines and pathways during the pandemic into clinical practice. The purpose of this article is to demonstrate the various roles of critical care pharmacists among the healthcare team in caring for critically ill COVID-19 patients. FAU - Gurnani, Payal K AU - Gurnani PK AUID- ORCID: 0000-0002-8929-2139 AD - Department of Pharmacy, 2468Rush University Medical Center, Chicago, IL, USA. AD - Department of Internal Medicine, Rush Medical College, Chicago, IL, USA. FAU - Peksa, Gary D AU - Peksa GD AD - Department of Pharmacy, 2468Rush University Medical Center, Chicago, IL, USA. AD - Department of Emergency Medicine, 2468Rush University Medical Center, Chicago, IL, USA. FAU - Panos, Nicholas G AU - Panos NG AUID- ORCID: 0000-0002-9868-699X AD - Department of Pharmacy, 2468Rush University Medical Center, Chicago, IL, USA. FAU - DeMott, Joshua M AU - DeMott JM AUID- ORCID: 0000-0002-2151-4049 AD - Department of Pharmacy, 2468Rush University Medical Center, Chicago, IL, USA. AD - Department of Emergency Medicine, 2468Rush University Medical Center, Chicago, IL, USA. LA - eng PT - Journal Article PT - Review DEP - 20210518 PL - United States TA - J Pharm Pract JT - Journal of pharmacy practice JID - 8900945 SB - IM MH - Humans MH - *Pharmacists MH - *COVID-19 MH - Pandemics MH - Critical Care MH - Patient Care Team MH - Professional Role OTO - NOTNLM OT - critical care OT - emergency medicine EDAT- 2021/05/19 06:00 MHDA- 2022/11/30 06:00 CRDT- 2021/05/18 05:39 PHST- 2021/05/19 06:00 [pubmed] PHST- 2022/11/30 06:00 [medline] PHST- 2021/05/18 05:39 [entrez] AID - 10.1177/08971900211013991 [doi] PST - ppublish SO - J Pharm Pract. 2022 Dec;35(6):1007-1011. doi: 10.1177/08971900211013991. Epub 2021 May 18. PMID- 33996847 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210518 IS - 2296-858X (Print) IS - 2296-858X (Electronic) IS - 2296-858X (Linking) VI - 8 DP - 2021 TI - Treatment of Behcet's Disease: An Algorithmic Multidisciplinary Approach. PG - 624795 LID - 10.3389/fmed.2021.624795 [doi] LID - 624795 AB - Behcet's disease (BD) is a chronic, relapsing inflammatory, multisystem disease of unknown etiology. The disease has a wide clinical spectrum of mucocutaneous lesions and ocular, vascular, articular, neurologic, gastrointestinal and cardiac involvement. Although the number of effective drugs used in the disease's treatment has increased in recent years, BD is still associated with severe morbidity because of mainly mucocutaneous, articular and ocular symptoms and an increased mortality because of large vessel, neurological, gastrointestinal and cardiac involvement. Many factors are associated with a more serious course, such as male gender and a younger age of onset. While the severity of the disease is more pronounced in the first years of the disease, it decreases in most patients after the age of forties. The primary goal of treatment should be the prevention of irreversible organ damage. Therefore, early diagnosis and appropriate treatment and close follow-up are mandatory to reduce the morbidity and mortality of the disease. Treatment varies depending on the organ involved and the severity of the involvement. For all these reasons, the treatment should be personalized and arranged with a multidisciplinary approach according to the organs involved. Treatment is mainly based on suppression of the inflammatory attacks of the disease using local and systemic immunomodulatory and immunosuppressive drugs. In this review, based on the mainly controlled studies and personal experience in clinical practice and basic research in this field, we propose a stepwise, symptom-based, algorithmic approach for the management of BD with a holistic perspective. CI - Copyright (c) 2021 Alpsoy, Leccese, Emmi and Ohno. FAU - Alpsoy, Erkan AU - Alpsoy E AD - Department of Dermatology and Venereology, School of Medicine, Akdeniz University, Antalya, Turkey. FAU - Leccese, Pietro AU - Leccese P AD - Rheumatology Department of Lucania, Rheumatology Institute of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza and Matera, Italy. FAU - Emmi, Giacomo AU - Emmi G AD - Department of Experimental and Clinical Medicine, University of Firenze, Firenze, Italy. FAU - Ohno, Shigeaki AU - Ohno S AD - Ophthalmology Center, Aishin Memorial Hospital, Sapporo, Japan. AD - Department of Ophthalmology, Faculty of Medicine, Graduate School of Medicine, Hokkaido University, Sapporo, Japan. LA - eng PT - Journal Article PT - Review DEP - 20210428 PL - Switzerland TA - Front Med (Lausanne) JT - Frontiers in medicine JID - 101648047 PMC - PMC8115406 OTO - NOTNLM OT - Behcet's disease OT - algorithms OT - morbidity OT - mortality OT - therapeutics COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/05/18 06:00 MHDA- 2021/05/18 06:01 PMCR- 2021/04/28 CRDT- 2021/05/17 06:17 PHST- 2020/11/02 00:00 [received] PHST- 2021/03/01 00:00 [accepted] PHST- 2021/05/17 06:17 [entrez] PHST- 2021/05/18 06:00 [pubmed] PHST- 2021/05/18 06:01 [medline] PHST- 2021/04/28 00:00 [pmc-release] AID - 10.3389/fmed.2021.624795 [doi] PST - epublish SO - Front Med (Lausanne). 2021 Apr 28;8:624795. doi: 10.3389/fmed.2021.624795. eCollection 2021. PMID- 33994035 OWN - NLM STAT- MEDLINE DCOM- 20211108 LR - 20211108 IS - 1535-6280 (Electronic) IS - 0146-2806 (Linking) VI - 46 IP - 12 DP - 2021 Dec TI - Current Trends in TAVI Access. PG - 100844 LID - S0146-2806(21)00059-1 [pii] LID - 10.1016/j.cpcardiol.2021.100844 [doi] AB - The optimal approach for Transcatheter aortic valve implantation (TAVI) is the transfemoral access but alternative TAVI approaches offer the possibility of valve replacement in patients who are not eligible to the transfemoral route. This review paper intends to compare the current available alternative approaches for TAVI in terms of their safety and efficacy, based on the current literature. The transapical, transaortic, transsubclavian, transcarotid, transcaval and suprasternal approaches have been analyzed. The choice of the alternative approach dependents on local Heart Team expertise, patient specific characteristics, access specific characteristics and the need or not for general anesthesia. More studies are needed to investigate the impact of each individual approach on long-term outcomes. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - Mitsis, Andreas AU - Mitsis A AD - Cardiology Department, Nicosia General Hospital, 2029, Nicosia, Cyprus. Electronic address: andymits7@gmail.com. FAU - Eftychiou, Christos AU - Eftychiou C AD - Cardiology Department, Nicosia General Hospital, 2029, Nicosia, Cyprus. FAU - Eteokleous, Nicolaos AU - Eteokleous N AD - Cardiology Department, Nicosia General Hospital, 2029, Nicosia, Cyprus. FAU - Papadopoulos, Kyriakos AU - Papadopoulos K AD - Cardiology Department, Nicosia General Hospital, 2029, Nicosia, Cyprus. FAU - Zittis, Ioannis AU - Zittis I AD - Cardiology Department, Nicosia General Hospital, 2029, Nicosia, Cyprus. FAU - Avraamides, Panayiotis AU - Avraamides P AD - Cardiology Department, Nicosia General Hospital, 2029, Nicosia, Cyprus. LA - eng PT - Journal Article PT - Review DEP - 20210319 PL - Netherlands TA - Curr Probl Cardiol JT - Current problems in cardiology JID - 7701802 SB - IM MH - Aortic Valve/surgery MH - *Aortic Valve Stenosis/surgery MH - Humans MH - *Transcatheter Aortic Valve Replacement/adverse effects MH - Treatment Outcome EDAT- 2021/05/18 06:00 MHDA- 2021/11/09 06:00 CRDT- 2021/05/17 05:40 PHST- 2021/03/03 00:00 [received] PHST- 2021/03/08 00:00 [accepted] PHST- 2021/05/18 06:00 [pubmed] PHST- 2021/11/09 06:00 [medline] PHST- 2021/05/17 05:40 [entrez] AID - S0146-2806(21)00059-1 [pii] AID - 10.1016/j.cpcardiol.2021.100844 [doi] PST - ppublish SO - Curr Probl Cardiol. 2021 Dec;46(12):100844. doi: 10.1016/j.cpcardiol.2021.100844. Epub 2021 Mar 19. PMID- 33992736 OWN - NLM STAT- MEDLINE DCOM- 20211227 LR - 20211227 IS - 1916-7075 (Electronic) IS - 0828-282X (Print) IS - 0828-282X (Linking) VI - 37 IP - 10 DP - 2021 Oct TI - Catastrophic Cardiac Events During Transcatheter Aortic Valve Replacement. PG - 1522-1529 LID - S0828-282X(21)00246-4 [pii] LID - 10.1016/j.cjca.2021.05.002 [doi] AB - BACKGROUND: Perioperative complications of transcatheter aortic valve replacement (TAVR) are decreasing but can be catastrophic when they occur. Systematic reports of the nature of these events are lacking in the contemporary era. Our study aimed to report the incidence, outcomes, and perioperative management of catastrophic cardiac events in patients undergoing TAVR and to propose a working strategy to address these complications. METHODS: This is a retrospective cohort study of patients who developed catastrophic cardiac events during or immediately after TAVR between 2015 and 2019 at a single academic centre. RESULTS: Of 2102 patients who underwent TAVR, 51 (2.5%) developed catastrophic cardiac events. The causes included cardiac perforation and tamponade (n = 19, 37.3%), acute left- ventricular failure (n = 10, 19.6%), coronary artery obstruction (n = 10, 19.6%), aortic-root disruption (n = 7, 13.7%), and device embolization (n = 5, 9.8%). Twenty-four patients (47.0%) with catastrophic cardiac events required stabilization by either intra-aortic balloon counter-pulsation or extracorporeal membrane oxygenation. The in-hospital mortality rate increased by 11.7-fold for patients with catastrophic cardiac events compared with those without (25.5% vs 2.0%, P < 0.001). Patients who developed aortic root disruption had the highest mortality rate (42.8%) compared with the others. The incidence of catastrophic cardiac events remained stable over a 5-year period, but the associated mortality decreased from 38.5% in 2015 to 9.1% in 2019. CONCLUSIONS: Catastrophic cardiac events during TAVR are rare, but they account for a dramatic increase in perioperative mortality. Early recognition and development of a standardized perioperative team approach can help manage patients experiencing these complications. CI - Copyright (c) 2021 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved. FAU - Liang, Yafen AU - Liang Y AD - Department of Anesthesiology, The University of Texas at Houston, McGovern Medical School/Memorial Hermann Heart and Vascular Institute, Houston, Texas, USA. Electronic address: yafen.liang@uth.tmc.edu. FAU - Dhoble, Abhijeet AU - Dhoble A AD - Department of Cardiology, The University of Texas at Houston, McGovern Medical School/Memorial Hermann Heart and Vascular Institute, Houston, Texas, USA. FAU - Pakanati, Adarsh AU - Pakanati A AD - Department of Anesthesiology, The University of Texas at Houston, McGovern Medical School/Memorial Hermann Heart and Vascular Institute, Houston, Texas, USA. FAU - Zhao, Yelin AU - Zhao Y AD - Department of Cardiology, The University of Texas at Houston, McGovern Medical School/Memorial Hermann Heart and Vascular Institute, Houston, Texas, USA. FAU - Kork, Felix AU - Kork F AD - Department of Anesthesiology, Medical Faculty, RWTH Aachen University, Aachen, Germany. FAU - Ruan, Wei AU - Ruan W AD - Department of Anesthesiology, The University of Texas at Houston, McGovern Medical School/Memorial Hermann Heart and Vascular Institute, Houston, Texas, USA. FAU - Markham, Travis AU - Markham T AD - Department of Anesthesiology, The University of Texas at Houston, McGovern Medical School/Memorial Hermann Heart and Vascular Institute, Houston, Texas, USA. FAU - Smalling, Richard AU - Smalling R AD - Department of Cardiology, The University of Texas at Houston, McGovern Medical School/Memorial Hermann Heart and Vascular Institute, Houston, Texas, USA. FAU - Balan, Prakash AU - Balan P AD - Department of Cardiology, The University of Texas at Houston, McGovern Medical School/Memorial Hermann Heart and Vascular Institute, Houston, Texas, USA. FAU - Estrera, Anthony AU - Estrera A AD - Department of Cardiac Surgery, The University of Texas Health Science Center at Houston, McGovern Medical School/Memorial Hermann Heart and Vascular Institute, Houston, Texas, USA. FAU - Nguyen, Tom C AU - Nguyen TC AD - Department of Cardiac Surgery, The University of Texas Health Science Center at Houston, McGovern Medical School/Memorial Hermann Heart and Vascular Institute, Houston, Texas, USA. FAU - Gregoric, Igor AU - Gregoric I AD - Department of Advanced Cardiopulmonary Therapies and Transplantation, The University of Texas at Houston, McGovern Medical School/Memorial Hermann Heart and Vascular Institute, Houston, Texas, USA. FAU - Kar, Biswajit AU - Kar B AD - Department of Advanced Cardiopulmonary Therapies and Transplantation, The University of Texas at Houston, McGovern Medical School/Memorial Hermann Heart and Vascular Institute, Houston, Texas, USA. FAU - Eltzschig, Holger AU - Eltzschig H AD - Department of Anesthesiology, The University of Texas at Houston, McGovern Medical School/Memorial Hermann Heart and Vascular Institute, Houston, Texas, USA. LA - eng GR - R01 DK109574/DK/NIDDK NIH HHS/United States GR - R01 DK122796/DK/NIDDK NIH HHS/United States GR - R01 HL133900/HL/NHLBI NIH HHS/United States GR - R01 HL154720/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Observational Study PT - Research Support, Non-U.S. Gov't DEP - 20210514 PL - England TA - Can J Cardiol JT - The Canadian journal of cardiology JID - 8510280 SB - IM CIN - Can J Cardiol. 2021 Oct;37(10):1500-1501. doi: 10.1016/j.cjca.2021.04.011. PMID: 33961982 MH - Aged MH - Aortic Valve/*surgery MH - Aortic Valve Stenosis/*surgery MH - Female MH - Follow-Up Studies MH - Heart Failure/epidemiology/*etiology MH - Hospital Mortality/trends MH - Humans MH - Incidence MH - Male MH - Postoperative Complications/epidemiology/*etiology MH - Retrospective Studies MH - Risk Assessment/*methods MH - Risk Factors MH - Survival Rate/trends MH - Texas/epidemiology MH - Transcatheter Aortic Valve Replacement/*adverse effects PMC - PMC8590698 MID - NIHMS1744747 EDAT- 2021/05/17 06:00 MHDA- 2021/12/28 06:00 PMCR- 2021/11/25 CRDT- 2021/05/16 20:38 PHST- 2020/11/20 00:00 [received] PHST- 2021/05/03 00:00 [revised] PHST- 2021/05/05 00:00 [accepted] PHST- 2021/05/17 06:00 [pubmed] PHST- 2021/12/28 06:00 [medline] PHST- 2021/05/16 20:38 [entrez] PHST- 2021/11/25 00:00 [pmc-release] AID - S0828-282X(21)00246-4 [pii] AID - 10.1016/j.cjca.2021.05.002 [doi] PST - ppublish SO - Can J Cardiol. 2021 Oct;37(10):1522-1529. doi: 10.1016/j.cjca.2021.05.002. Epub 2021 May 14. PMID- 33992314 OWN - NLM STAT- MEDLINE DCOM- 20211028 LR - 20211028 IS - 1532-9453 (Electronic) IS - 1055-8586 (Linking) VI - 30 IP - 2 DP - 2021 Apr TI - Cardiac critical care of the post-operative congenital heart disease patient. PG - 151037 LID - S1055-8586(21)00025-1 [pii] LID - 10.1016/j.sempedsurg.2021.151037 [doi] AB - Cardiac critical care has become an increasingly complex subspecialty, involving multiple subspecialists to support patients with congenital heart disease. This requires understanding of their physiology and the impact of medical interventions. The purpose of this article is to provide a concise review of the current strategies utilized by cardiac intensivists to optimize outcomes for this vulnerable patient population, with the goal of broadening the knowledge of other members of the multi-disciplinary team. CI - Copyright (c) 2021. Published by Elsevier Inc. FAU - Miller-Smith, Laura AU - Miller-Smith L AD - Division of Cardiac Critical Care Medicine, Children's Mercy Kansas City, 2401 Gillham Road, Kansas City, MO 64108, United States. FAU - Flint, Jennifer L AU - Flint JL AD - Division of Cardiac Critical Care Medicine, Children's Mercy Kansas City, 2401 Gillham Road, Kansas City, MO 64108, United States. FAU - Allen, Geoffrey L AU - Allen GL AD - Division of Cardiac Critical Care Medicine, Children's Mercy Kansas City, 2401 Gillham Road, Kansas City, MO 64108, United States. Electronic address: glallen@cmh.edu. LA - eng PT - Journal Article DEP - 20210321 PL - United States TA - Semin Pediatr Surg JT - Seminars in pediatric surgery JID - 9216162 SB - IM MH - Critical Care MH - *Heart Defects, Congenital/surgery MH - Humans EDAT- 2021/05/17 06:00 MHDA- 2021/10/29 06:00 CRDT- 2021/05/16 20:27 PHST- 2021/05/16 20:27 [entrez] PHST- 2021/05/17 06:00 [pubmed] PHST- 2021/10/29 06:00 [medline] AID - S1055-8586(21)00025-1 [pii] AID - 10.1016/j.sempedsurg.2021.151037 [doi] PST - ppublish SO - Semin Pediatr Surg. 2021 Apr;30(2):151037. doi: 10.1016/j.sempedsurg.2021.151037. Epub 2021 Mar 21. PMID- 33990102 OWN - NLM STAT- MEDLINE DCOM- 20220128 LR - 20220629 IS - 1473-6551 (Electronic) IS - 1350-7540 (Linking) VI - 34 IP - 5 DP - 2021 Oct 1 TI - New developments in myotonic dystrophies from a multisystemic perspective. PG - 738-747 LID - 10.1097/WCO.0000000000000964 [doi] AB - PURPOSE OF REVIEW: The multisystemic involvement of myotonic dystrophies (DMs) intricates disease monitoring, patients' care and trial design. This update of the multifaceted comorbidities observed in DMs aims to assist neurologists in the complex management of patients and to encourage further studies for still under-investigated aspects of the disease. RECENT FINDINGS: We reviewed the most recent studies covering pathogenesis and clinical aspects of extra-muscular involvement in DM1 and DM2. The largest body of evidence regards the cardiac and respiratory features, for which experts' recommendations have been produced. Gastrointestinal symptoms emerge as one of the most prevalent complaints in DMs. The alteration of insulin signaling pathways, involved in gastrointestinal manifestations, carcinogenesis, muscle function, cognitive and endocrinological aspects, gain further relevance in the light of recent evidence of metformin efficacy in DM1. Still, too few studies are performed on large DM2 cohorts, so that current recommendations mainly rely on data gathered in DM1 that cannot be fully translated to DM2. SUMMARY: Extra-muscular manifestations greatly contribute to the overall disease burden. A multidisciplinary approach is the key for the management of patients. Consensus-based recommendations for DM1 and DM2 allow high standards of care but further evidence are needed to implement these recommendations. CI - Copyright (c) 2021 Wolters Kluwer Health, Inc. All rights reserved. FAU - Montagnese, Federica AU - Montagnese F AD - Friedrich-Baur-Institute, Department of Neurology, Ludwig-Maximilians-University, Munich, Germany. FAU - Schoser, Benedikt AU - Schoser B LA - eng PT - Journal Article PT - Review PL - England TA - Curr Opin Neurol JT - Current opinion in neurology JID - 9319162 SB - IM MH - Comorbidity MH - *Gastrointestinal Diseases MH - Humans MH - *Myotonic Dystrophy/diagnosis/epidemiology/therapy EDAT- 2021/05/15 06:00 MHDA- 2022/01/29 06:00 CRDT- 2021/05/14 20:27 PHST- 2021/05/15 06:00 [pubmed] PHST- 2022/01/29 06:00 [medline] PHST- 2021/05/14 20:27 [entrez] AID - 00019052-202110000-00018 [pii] AID - 10.1097/WCO.0000000000000964 [doi] PST - ppublish SO - Curr Opin Neurol. 2021 Oct 1;34(5):738-747. doi: 10.1097/WCO.0000000000000964. PMID- 33984484 OWN - NLM STAT- MEDLINE DCOM- 20220603 LR - 20250929 IS - 1532-9488 (Electronic) IS - 1043-0679 (Print) IS - 1043-0679 (Linking) VI - 34 IP - 2 DP - 2022 Summer TI - Quality of Life Worsens After Surgical Repair of Acute Type A Aortic Dissection. PG - 399-407 LID - S1043-0679(21)00188-X [pii] LID - 10.1053/j.semtcvs.2021.03.040 [doi] AB - This study aimed to determine how acute type A aortic dissection (ATAAD) impacts patients' quality of life. The 36-Item Short Form Survey (SF-36) was used to measure quality of life. The eight SF-36 scales were aggregated into a two-factor summary: physical and mental component summary scales (PCS and MCS). One hundred fourteen patients were included in the ATAAD group and 81 patients in the aortic valve replacement (AVR) group. All patients underwent surgery between June 2007 and December 2018. Surveys were completed after the operation. The mean scaled score of the ATAAD group decreased significantly in all eight domains of the SF-36 survey after aortic dissection repair except mental health. Also, the postsurgery PCS score was significantly lower than the presurgery score (39 vs 49; P < 0.0001). Multivariable regression confirmed the negative impact of ATAAD on postsurgery PCS score and higher presurgery PCS score had a significant positive impact. The postsurgery MCS score did not change significantly (49 vs 50; P = 0.32), but higher preoperative MCS score had a significant positive impact on the postsurgery MCS score. Age, sex, connective tissue disorders, and stroke did not contribute significantly to the postsurgery PCS and MCS scores. The AVR group had significantly increased postsurgery PCS and MCS scores compared to the presurgery scores (47 vs 41; P < 0.0001) and (53 vs 51; P = 0.02) respectively. Patients reported significantly decreased physical health after recovery from acute type A aortic dissection repair. A multidisciplinary approach is needed to improve patients' quality of life. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - St Pierre, Emma C AU - St Pierre EC AD - Department of Cardiac Surgery, Michigan Medicine, Ann Arbor, Michigan. FAU - Orelaru, Felix AU - Orelaru F AD - Department of General Surgery, St. Joseph Mercy, Ann Arbor, Michigan. FAU - Naeem, Aroma AU - Naeem A AD - Department of Cardiac Surgery, Michigan Medicine, Ann Arbor, Michigan. FAU - Farhat, Linda AU - Farhat L AD - Department of Cardiac Surgery, Michigan Medicine, Ann Arbor, Michigan. FAU - Wu, Xiaoting AU - Wu X AD - Department of Cardiac Surgery, Michigan Medicine, Ann Arbor, Michigan. FAU - Yang, Bo AU - Yang B AD - Department of Cardiac Surgery, Michigan Medicine, Ann Arbor, Michigan. Electronic address: boya@med.umich.edu. LA - eng GR - K08 HL130614/HL/NHLBI NIH HHS/United States GR - R01 HL141891/HL/NHLBI NIH HHS/United States GR - R01 HL151776/HL/NHLBI NIH HHS/United States PT - Journal Article DEP - 20210511 PL - United States TA - Semin Thorac Cardiovasc Surg JT - Seminars in thoracic and cardiovascular surgery JID - 8917640 SB - IM CIN - Semin Thorac Cardiovasc Surg. 2022 Summer;34(2):408-409. doi: 10.1053/j.semtcvs.2021.04.019. PMID: 34004295 MH - *Aortic Dissection/diagnostic imaging/surgery MH - Aortic Valve/diagnostic imaging/surgery MH - Humans MH - *Quality of Life MH - Surveys and Questionnaires MH - Treatment Outcome PMC - PMC8581075 MID - NIHMS1702563 OTO - NOTNLM OT - Aortic valve replacement OT - Mental health OT - Quality of life OT - SF-36 OT - Type A aortic dissection COIS- Conflict of Interest: None related to this study. EDAT- 2021/05/14 06:00 MHDA- 2022/06/07 06:00 PMCR- 2023/07/01 CRDT- 2021/05/13 20:13 PHST- 2021/02/19 00:00 [received] PHST- 2021/03/04 00:00 [accepted] PHST- 2021/05/14 06:00 [pubmed] PHST- 2022/06/07 06:00 [medline] PHST- 2021/05/13 20:13 [entrez] PHST- 2023/07/01 00:00 [pmc-release] AID - S1043-0679(21)00188-X [pii] AID - 10.1053/j.semtcvs.2021.03.040 [doi] PST - ppublish SO - Semin Thorac Cardiovasc Surg. 2022 Summer;34(2):399-407. doi: 10.1053/j.semtcvs.2021.03.040. Epub 2021 May 11. PMID- 33980041 OWN - NLM STAT- MEDLINE DCOM- 20211228 LR - 20211228 IS - 1524-4539 (Electronic) IS - 0009-7322 (Linking) VI - 143 IP - 25 DP - 2021 Jun 22 TI - Evaluation and Management of Aortic Stenosis in Chronic Kidney Disease: A Scientific Statement From the American Heart Association. PG - e1088-e1114 LID - 10.1161/CIR.0000000000000979 [doi] AB - Aortic stenosis with concomitant chronic kidney disease (CKD) represents a clinical challenge. Aortic stenosis is more prevalent and progresses more rapidly and unpredictably in CKD, and the presence of CKD is associated with worse short-term and long-term outcomes after aortic valve replacement. Because patients with advanced CKD and end-stage kidney disease have been excluded from randomized trials, clinicians need to make complex management decisions in this population that are based on retrospective and observational evidence. This statement summarizes the epidemiological and pathophysiological characteristics of aortic stenosis in the context of CKD, evaluates the nuances and prognostic information provided by noninvasive cardiovascular imaging with echocardiography and advanced imaging techniques, and outlines the special risks in this population. Furthermore, this statement provides a critical review of the existing literature pertaining to clinical outcomes of surgical versus transcatheter aortic valve replacement in this high-risk population to help guide clinical decision making in the choice of aortic valve replacement and specific prosthesis. Finally, this statement provides an approach to the perioperative management of these patients, with special attention to a multidisciplinary heart-kidney collaborative team-based approach. FAU - Shroff, Gautam R AU - Shroff GR FAU - Bangalore, Sripal AU - Bangalore S FAU - Bhave, Nicole M AU - Bhave NM FAU - Chang, Tara I AU - Chang TI FAU - Garcia, Santiago AU - Garcia S FAU - Mathew, Roy O AU - Mathew RO FAU - Rangaswami, Janani AU - Rangaswami J FAU - Ternacle, Julien AU - Ternacle J FAU - Thourani, Vinod H AU - Thourani VH FAU - Pibarot, Philippe AU - Pibarot P CN - American Heart Association Council on the Kidney in Cardiovascular Disease and Stroke Council LA - eng PT - Journal Article PT - Review DEP - 20210513 PL - United States TA - Circulation JT - Circulation JID - 0147763 SB - IM MH - *American Heart Association MH - Aortic Valve Stenosis/*diagnostic imaging/epidemiology/*therapy MH - Comorbidity MH - *Disease Management MH - Echocardiography/standards MH - Humans MH - Renal Insufficiency, Chronic/*diagnostic imaging/epidemiology/*therapy MH - Risk Assessment/methods MH - United States/epidemiology OTO - NOTNLM OT - AHA Scientific Statements OT - aortic valve disease OT - aortic valve stenosis OT - chronic OT - dialysis OT - heart valve prosthesis OT - heart valve prosthesis implantation OT - renal insufficiency OT - transcatheter aortic valve replacement EDAT- 2021/05/14 06:00 MHDA- 2021/12/29 06:00 CRDT- 2021/05/13 05:25 PHST- 2021/05/14 06:00 [pubmed] PHST- 2021/12/29 06:00 [medline] PHST- 2021/05/13 05:25 [entrez] AID - 10.1161/CIR.0000000000000979 [doi] PST - ppublish SO - Circulation. 2021 Jun 22;143(25):e1088-e1114. doi: 10.1161/CIR.0000000000000979. Epub 2021 May 13. PMID- 33970800 OWN - NLM STAT- MEDLINE DCOM- 20211025 LR - 20220423 IS - 1839-3535 (Electronic) IS - 1037-6178 (Linking) VI - 57 IP - 1-2 DP - 2021 Feb-Apr TI - Attitudes and practices towards palliative care in chronic heart failure: a survey of cardiovascular nurses and physicians. PG - 113-127 LID - 10.1080/10376178.2021.1928522 [doi] AB - BACKGROUND: Heart failure is a chronic condition with various implications for individuals and families. Although the importance of implementing palliative care is recommended in best practice guidelines, implementation strategies are less clear. AIMS: This study sought to; (1) determine Australian and New Zealand cardiovascular nurses and physicians' end of life care attitudes and specialist palliative care referral in heart failure and; (2) determine self-reported delivery of supportive care and attitudes towards service names. METHODS: An electronic survey was emailed to members of four peak bodies and professional networks. Participants were also recruited through social media. Paper-based versions of the survey were completed by attendees of the 66th Cardiac Society of Australia and New Zealand Annual Scientific Meeting, August 2018. FINDINGS: There were 113 completed responses included in the analyses. Participants were nurses (n = 75), physicians (n = 32) and allied health professionals (n = 4). Most (67%) reported they were comfortable with providing end of life care; however, fewer respondents agreed they received support for their dying patients and one-third experienced a sense of failure when heart failure progressed. Most (84-100%) participants agreed they would refer a heart failure patient later in the illness trajectory. There was a more favourable attitude towards the service name 'supportive care' than to 'palliative care'. CONCLUSION: Comfort with end of life discussions is encouraging as it may lead to a greater likelihood of planning future care and identifying palliative care needs. Peer support and supervision may be useful for addressing feelings of failure. The use of needs-based assessment tools, adopting the service name 'supportive care' and further research focusing on primary palliative team-based approach is required to improve palliative care access. IMPACT STATEMENT: Cardiovascular nurses and physicians are comfortable providing end of life care, but referrals to palliative care in the later stages of heart failure persists. FAU - Singh, Gursharan K AU - Singh GK AUID- ORCID: 0000-0003-1945-7556 AD - School of Nursing & Midwifery, Western Sydney University, Locked Bag 1797, Penrith, NSW 2751, Australia. FAU - Ferguson, Caleb AU - Ferguson C AUID- ORCID: 0000-0002-2417-2216 AD - School of Nursing & Midwifery, Western Sydney University, Locked Bag 1797, Penrith, NSW 2751, Australia. AD - Western Sydney Local Health District, Blacktown Hospital, Blacktown, NSW 2148, Australia. FAU - Davidson, Patricia M AU - Davidson PM AD - School of Nursing, Johns Hopkins University, Baltimore, MD, USA. AD - Faculty of Health, University of Technology Sydney, Sydney, Australia. FAU - Newton, Phillip J AU - Newton PJ AD - School of Nursing & Midwifery, Western Sydney University, Locked Bag 1797, Penrith, NSW 2751, Australia. LA - eng PT - Journal Article DEP - 20210528 PL - United States TA - Contemp Nurse JT - Contemporary nurse JID - 9211867 MH - Attitude of Health Personnel MH - Australia MH - *Heart Failure/therapy MH - Humans MH - *Nurse Clinicians MH - Palliative Care MH - *Physicians MH - Surveys and Questionnaires MH - *Terminal Care OTO - NOTNLM OT - health personnel OT - heart failure OT - palliative care OT - surveys and questionnaires OT - terminal care EDAT- 2021/05/11 06:00 MHDA- 2021/10/26 06:00 CRDT- 2021/05/10 17:55 PHST- 2021/05/11 06:00 [pubmed] PHST- 2021/10/26 06:00 [medline] PHST- 2021/05/10 17:55 [entrez] AID - 10.1080/10376178.2021.1928522 [doi] PST - ppublish SO - Contemp Nurse. 2021 Feb-Apr;57(1-2):113-127. doi: 10.1080/10376178.2021.1928522. Epub 2021 May 28. PMID- 33970732 OWN - NLM STAT- MEDLINE DCOM- 20210929 LR - 20221207 IS - 1744-764X (Electronic) IS - 1474-0338 (Linking) VI - 20 IP - 10 DP - 2021 Oct TI - Trends and concerns of potentially inappropriate medication use in patients with cardiovascular diseases. PG - 1191-1206 LID - 10.1080/14740338.2021.1928632 [doi] AB - Introduction: The use of potentially inappropriate medications (PIM) is an alarming social risk factor in cardiovascular patients. PIM administration may result in iatrogenic disorders and adverse consequences may be attenuated by limiting PIM intake.Areas covered: The goal of this review article is to discuss the trends, risks, and concerns regarding PIM administration with focus on cardiovascular patients. To find data, we searched literature using electronic databases (Pubmed/Medline 1966-2021 and Web of Science 1975-2021). The data search terms were cardiovascular diseases, potentially inappropriate medication, potentially harmful drug-drug combination, potentially harmful drug-disease combination, drug interaction, deprescribing, and electronic health record.Expert opinion: Drugs for heart diseases are the most commonly prescribed medications in older individuals. Despite the availability of explicit and implicit PIM criteria, the incidence of PIM use in cardiovascular patients remains high ranging from 7 to 85% in different patient categories. Physician-induced disorders often occur when PIM is administered and adverse effects may be reduced by limiting PIM intake. Main strategies promising for addressing PIM use include deprescribing, implementation of systematic electronic records, pharmacist medication review, and collaboration among cardiologists, internists, geriatricians, clinical pharmacologists, pharmacists, and other healthcare professionals as basis of multidisciplinary assessment teams. FAU - Anfinogenova, Nina D AU - Anfinogenova ND AUID- ORCID: 0000-0003-1106-0730 AD - Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Russian Federation. FAU - Trubacheva, Irina A AU - Trubacheva IA AD - Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Russian Federation. FAU - Popov, Sergey V AU - Popov SV AD - Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Russian Federation. FAU - Efimova, Elena V AU - Efimova EV AD - Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Russian Federation. FAU - Ussov, Wladimir Y AU - Ussov WY AD - Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Russian Federation. LA - eng PT - Journal Article PT - Review DEP - 20210517 PL - England TA - Expert Opin Drug Saf JT - Expert opinion on drug safety JID - 101163027 RN - 0 (Antiviral Agents) RN - 0 (Cardiovascular Agents) SB - IM MH - Antiviral Agents/adverse effects MH - Cardiovascular Agents/adverse effects/*therapeutic use MH - Cardiovascular Diseases/*drug therapy MH - Drug Interactions MH - Humans MH - Inappropriate Prescribing/adverse effects/*trends MH - Polypharmacy MH - Potentially Inappropriate Medication List/*trends MH - Risk Assessment MH - Risk Factors MH - COVID-19 Drug Treatment OTO - NOTNLM OT - COVID-19 OT - Cardiovascular diseases OT - polypharmacy OT - potential drug-drug interaction OT - potentially inappropriate medication OT - risk factor EDAT- 2021/05/11 06:00 MHDA- 2021/09/30 06:00 CRDT- 2021/05/10 17:28 PHST- 2021/05/11 06:00 [pubmed] PHST- 2021/09/30 06:00 [medline] PHST- 2021/05/10 17:28 [entrez] AID - 10.1080/14740338.2021.1928632 [doi] PST - ppublish SO - Expert Opin Drug Saf. 2021 Oct;20(10):1191-1206. doi: 10.1080/14740338.2021.1928632. Epub 2021 May 17. PMID- 33970332 OWN - NLM STAT- MEDLINE DCOM- 20210602 LR - 20261010 IS - 1435-1544 (Electronic) IS - 0938-7412 (Linking) VI - 32 IP - 2 DP - 2021 Jun TI - Pregnancy in patients with implantable cardiac defibrillators. PG - 214-220 LID - 10.1007/s00399-021-00750-x [doi] AB - The number of patients of reproductive age with inherited and congenital heart disease receiving implantable cardiac defibrillators (ICD) is steadily increasing. Safely and effectively coordinating pregnancy in this high-risk cohort is important to optimise maternal-foetal outcomes. As members of the multidisciplinary team caring for pregnant patients with indications for ICD, cardiologists and electrophysiologists should be aware of the considerations and nuances involved in managing these patients. This article reviews the pathophysiology of arrhythmias, ICD implantation considerations, novel minimal fluoroscopy techniques and subcutaneous ICD. In addition, antenatal and device management during pregnancy and delivery are discussed. FAU - Wong, Geoffrey R AU - Wong GR AD - Department of Electrophysiology, St Bartholomews Hospital NHS Trust & Institute of Cardiovascular Science UCL, London, UK. FAU - Ang, Megan AU - Ang M AD - Department of Obstetric Imaging, Mercy Hospital for Women, Melbourne, Australia. FAU - Jayarajan, Jasveer AU - Jayarajan J AD - Department of Obstetric Imaging, Mercy Hospital for Women, Melbourne, Australia. FAU - Walker, Fiona AU - Walker F AD - Department of Grown-Up Congenital Heart Disease, St Bartholomews Hospital, London, UK. FAU - Lambiase, Pier D AU - Lambiase PD AD - Department of Electrophysiology, St Bartholomews Hospital NHS Trust & Institute of Cardiovascular Science UCL, London, UK. pier.lambiase@nhs.net. LA - eng PT - Journal Article PT - Review TT - Schwangerschaft bei Patientinnen mit implantierbaren Defibrillatoren. DEP - 20210510 PL - Germany TA - Herzschrittmacherther Elektrophysiol JT - Herzschrittmachertherapie & Elektrophysiologie JID - 9425873 SB - IM MH - Arrhythmias, Cardiac MH - Death, Sudden, Cardiac/prevention & control MH - *Defibrillators, Implantable MH - Female MH - *Heart Defects, Congenital MH - Humans MH - Pregnancy OTO - NOTNLM OT - Antenatal care OT - Cardiomyopathy OT - ICD implantation OT - Inherited arrhythmia syndrome OT - Obstetric care EDAT- 2021/05/11 06:00 MHDA- 2021/06/03 06:00 CRDT- 2021/05/10 12:30 PHST- 2021/01/14 00:00 [received] PHST- 2021/03/15 00:00 [accepted] PHST- 2021/05/11 06:00 [pubmed] PHST- 2021/06/03 06:00 [medline] PHST- 2021/05/10 12:30 [entrez] AID - 10.1007/s00399-021-00750-x [pii] AID - 10.1007/s00399-021-00750-x [doi] PST - ppublish SO - Herzschrittmacherther Elektrophysiol. 2021 Jun;32(2):214-220. doi: 10.1007/s00399-021-00750-x. Epub 2021 May 10. PMID- 33968632 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210513 IS - 2223-3652 (Print) IS - 2223-3660 (Electronic) IS - 2223-3652 (Linking) VI - 11 IP - 2 DP - 2021 Apr TI - Narrative review of: risk stratification and implantable cardioverter-defibrillator therapy in adults with congenital heart disease. PG - 538-549 LID - 10.21037/cdt-20-633 [doi] AB - Fortunately, the population of adults with congenital heart disease (ACHD) is growing due to improved operation techniques. Life expectancy is continuously rising, nevertheless, sudden cardiac death is one of the leading causes of mortality in ACHD late after initial diagnosis. Risk stratification in ACHD remains challenging as large study results are missing, congenital defects and operation methods differ considerably between individual patients and results from acquired heart diseases are often not conferrable. The purpose of this narrative review is to objectively summarize the current knowledge on arrhythmogenic risk of ACHD and to give an overview on implantable cardioverter-defibrillator (ICD) therapy in this collective. Remarkable progress has been made in electrophysiological understanding of critical areas of slow conduction especially in patients with Tetralogy of Fallot (ToF). In patients with transposition of the great arteries after atrial baffling (Mustard/Senning procedure) atrial arrhythmias play a crucial role in sudden cardiac death. ICD therapy in ACHD may pose special technical challenges due to limited access for intracardiac leads. The introduction of the totally subcutaneous ICD improved therapeutic options for ACHD especially when contraindications for transvenous leads are present. Risk stratification in ACHD has to be seen as a team approach, requires thorough understanding of congenital heart defects and the operation techniques and needs unconventional technical approaches in some cases. CI - 2021 Cardiovascular Diagnosis and Therapy. All rights reserved. FAU - Kobe, Julia AU - Kobe J AD - Department of Cardiology II - Electrophysiology, University Hospital Muenster, Muenster, Germany. FAU - Willy, Kevin AU - Willy K AD - Department of Cardiology II - Electrophysiology, University Hospital Muenster, Muenster, Germany. FAU - Eckardt, Lars AU - Eckardt L AD - Department of Cardiology II - Electrophysiology, University Hospital Muenster, Muenster, Germany. FAU - Baumgartner, Helmut AU - Baumgartner H AD - Department of Cardiology III, Adult Congenital and Valvular Heart Disease, University Hospital Muenster, Muenster, Germany. FAU - Wasmer, Kristina AU - Wasmer K AD - Department of Cardiology II - Electrophysiology, University Hospital Muenster, Muenster, Germany. LA - eng PT - Journal Article PT - Review PL - China TA - Cardiovasc Diagn Ther JT - Cardiovascular diagnosis and therapy JID - 101601613 PMC - PMC8102248 OTO - NOTNLM OT - Adults with congenital heart diseases (ACHD) OT - ventricular arrhythmia, risk stratification, implantable-cardioverter-defibrillator COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/cdt-20-633). The series "Current Management Aspects in Adult Congenital Heart Disease (ACHD): Part III" was commissioned by the editorial office without any funding or sponsorship. Dr. HB reports other from Edwards Lifesciences, other from Actelion, outside the submitted work. The authors have no other conflicts of interest to declare. EDAT- 2021/05/11 06:00 MHDA- 2021/05/11 06:01 PMCR- 2021/04/01 CRDT- 2021/05/10 06:27 PHST- 2021/05/10 06:27 [entrez] PHST- 2021/05/11 06:00 [pubmed] PHST- 2021/05/11 06:01 [medline] PHST- 2021/04/01 00:00 [pmc-release] AID - cdt-11-02-538 [pii] AID - 10.21037/cdt-20-633 [doi] PST - ppublish SO - Cardiovasc Diagn Ther. 2021 Apr;11(2):538-549. doi: 10.21037/cdt-20-633. PMID- 33966677 OWN - NLM STAT- MEDLINE DCOM- 20220210 LR - 20220210 IS - 1467-1107 (Electronic) IS - 1047-9511 (Linking) VI - 32 IP - 2 DP - 2022 Feb TI - Identifying gaps in parental support for families of children with hypoplastic left heart syndrome. PG - 215-222 LID - 10.1017/S1047951121001736 [doi] AB - PURPOSE: The purpose of this study is to identify gaps in support for parents of children with Hypoplastic Left Heart Syndrome. DESIGN AND METHODS: Using a mixed-methods approach, the researchers first studied the parental and care team experience through interviews of Hypoplastic Left Heart Syndrome mothers and members of the inter-professional care team and then conducted an international survey of 690 Hypoplastic Left Heart Syndrome primary caregivers to validate the qualitative findings. RESULTS: Parental and care team interviews revealed three main gaps in parental support, including lack of open communication, unrealistic parental expectations, and unclear inter-professional team roles. Survey results found that parents whose children were diagnosed with Hypoplastic Left Heart Syndrome after birth indicated significant dissatisfaction with the care team's open communication and welcoming of feedback (p = 0.008). As parents progress through the stages of surgical intervention, they also indicate significant dissatisfaction with the care team's anticipation of parental emotional needs and provision of coping resources (p = 0.003). CONCLUSIONS: Parental support interventions should focus on providing resources to help parents cope, helping the care team model open communication, and welcoming feedback on the parental experience. PRACTICE IMPLICATIONS: Interventions should be piloted with parents who are in the later stages of the surgical intervention timeline or whose children were diagnosed after birth as they are the populations who perceived the least support within this study. FAU - Landry, Meghan AU - Landry M AD - Nursing Department, St. Catherine University, St. Paul, MN, USA. FAU - Katers, Meghan AU - Katers M AD - Nursing Department, St. Catherine University, St. Paul, MN, USA. FAU - Olson, Erica AU - Olson E AD - Nursing Department, St. Catherine University, St. Paul, MN, USA. FAU - Cern, Lynn AU - Cern L AD - Wanek Program for Hypoplastic Left Heart Syndrome, Mayo Clinic, Rochester, MN, USA. FAU - Nelson, Timothy J AU - Nelson TJ AD - Center for Regenerative Medicine, Mayo Clinic, Rochester, MN, USA. AD - Division of General Internal Medicine, Mayo Clinic, Rochester, MN, USA. AD - Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA. AD - Division of Pediatric Cardiology, Mayo Clinic, Rochester, MN, USA. AD - Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA. FAU - Campbell, Katherine A AU - Campbell KA AUID- ORCID: 0000-0002-4571-3149 AD - Department of Interprofessional Education, St. Catherine University, St. Paul, MN, USA. AD - Women's Health Integrative Research Center, St. Catherine University, St. Paul, MN, USA. LA - eng PT - Journal Article DEP - 20210510 PL - England TA - Cardiol Young JT - Cardiology in the young JID - 9200019 SB - IM MH - Adaptation, Psychological MH - Child MH - Female MH - Humans MH - *Hypoplastic Left Heart Syndrome/surgery MH - Mothers MH - Parents MH - Surveys and Questionnaires OTO - NOTNLM OT - Hypoplastic left heart syndrome (HLHS) OT - congenital heart disease (CHD) OT - family-centred care OT - inter-professional care team OT - parental support EDAT- 2021/05/11 06:00 MHDA- 2022/02/11 06:00 CRDT- 2021/05/10 06:01 PHST- 2021/05/11 06:00 [pubmed] PHST- 2022/02/11 06:00 [medline] PHST- 2021/05/10 06:01 [entrez] AID - S1047951121001736 [pii] AID - 10.1017/S1047951121001736 [doi] PST - ppublish SO - Cardiol Young. 2022 Feb;32(2):215-222. doi: 10.1017/S1047951121001736. Epub 2021 May 10. PMID- 33966333 OWN - NLM STAT- MEDLINE DCOM- 20210819 LR - 20210819 IS - 1478-3231 (Electronic) IS - 1478-3223 (Linking) VI - 41 IP - 9 DP - 2021 Sep TI - Evaluation of cardiovascular events in patients with hepatocellular carcinoma treated with sorafenib in the clinical practice. The CARDIO-SOR study. PG - 2200-2211 LID - 10.1111/liv.14941 [doi] AB - BACKGROUND AND AIMS: The effectiveness of systemic treatment in advanced hepatocellular carcinoma (HCC) depends on the selection of patients, management of cirrhosis complications and expertise to treat adverse events. The aims of the study are to assess the frequency and management of cardiovascular events in HCC patients treated with sorafenib (SOR) and to create a scale to predict the onset of major adverse cardiovascular events (MACE). METHOD: Observational retrospective study with consecutive HCC patients treated with SOR between 2007 and 2019 in a western centre. In order to classify cardiovascular risk pre-SOR, we designed the CARDIOSOR scale with age, hypertension, diabetes, dyslipidaemia and peripheral vascular disease. Other adverse events, dosing and outcome data were collected during a homogeneous protocolled follow-up. RESULTS: Two hundred ninety-nine patients were included (219 BCLC-C). The median overall survival was 11.1 months (IQR 5.6-20.5), and duration of treatment was 7.4 months (IQR 3.3-14.7). Seventeen patients (6%) stopped SOR due to cardiovascular event. Thirty-three patients suffered MACE (7 heart failure, 11 acute coronary syndrome, 12 cerebrovascular accident and 8 peripheral vascular ischemia); 99 had a minor cardiovascular event, mainly hypertension (n = 81). Age was the only independent factor associated to MACE (HR 1.07; 95% CI 1.03-1.12; P = .002). The CARDIOSOR scale allows to identify the group of patients with higher risk of MACE (sHR 3.4; 95% CI 1.4-6.7; P = .04). CONCLUSION: The incidence of cardiovascular events in HCC patients treated with SOR is higher than expected. Multidisciplinary approach and clinical tools like CARDIOSOR scale could be helpful to manage these patients. CI - (c) 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. FAU - Carballo-Folgoso, Lorena AU - Carballo-Folgoso L AUID- ORCID: 0000-0002-3473-5027 AD - Liver Unit, Division of Gastroenterology and Hepatology, Hospital Universitario Central de Asturias, Oviedo, Spain. FAU - Alvarez-Velasco, Rut AU - Alvarez-Velasco R AUID- ORCID: 0000-0002-2837-7374 AD - Department of Cardiology, Hospital Universitario Central de Asturias, Oviedo, Spain. FAU - Lorca, Rebeca AU - Lorca R AD - Department of Cardiology, Hospital Universitario Central de Asturias, Oviedo, Spain. AD - ISPA, Oviedo, Spain. FAU - Castano-Garcia, Andres AU - Castano-Garcia A AD - Liver Unit, Division of Gastroenterology and Hepatology, Hospital Universitario Central de Asturias, Oviedo, Spain. FAU - Cuevas, Javier AU - Cuevas J AUID- ORCID: 0000-0003-0388-844X AD - Department of Cardiology, Hospital Universitario Central de Asturias, Oviedo, Spain. FAU - Gonzalez-Dieguez, Maria Luisa AU - Gonzalez-Dieguez ML AD - Liver Unit, Division of Gastroenterology and Hepatology, Hospital Universitario Central de Asturias, Oviedo, Spain. FAU - Martin, Maria AU - Martin M AD - Department of Cardiology, Hospital Universitario Central de Asturias, Oviedo, Spain. FAU - Alvarez-Navascues, Carmen AU - Alvarez-Navascues C AD - Liver Unit, Division of Gastroenterology and Hepatology, Hospital Universitario Central de Asturias, Oviedo, Spain. FAU - Cadahia, Valle AU - Cadahia V AD - Liver Unit, Division of Gastroenterology and Hepatology, Hospital Universitario Central de Asturias, Oviedo, Spain. FAU - Moris, Cesar AU - Moris C AUID- ORCID: 0000-0002-2871-190X AD - Department of Cardiology, Hospital Universitario Central de Asturias, Oviedo, Spain. AD - ISPA, Oviedo, Spain. AD - Department of Medicine, Universidad de Oviedo, Oviedo, Spain. FAU - Rodriguez, Manuel AU - Rodriguez M AD - Liver Unit, Division of Gastroenterology and Hepatology, Hospital Universitario Central de Asturias, Oviedo, Spain. AD - ISPA, Oviedo, Spain. AD - Department of Medicine, Universidad de Oviedo, Oviedo, Spain. FAU - Varela, Maria AU - Varela M AUID- ORCID: 0000-0003-4288-2593 AD - Liver Unit, Division of Gastroenterology and Hepatology, Hospital Universitario Central de Asturias, Oviedo, Spain. AD - ISPA, Oviedo, Spain. AD - Department of Medicine, Universidad de Oviedo, Oviedo, Spain. AD - IUOPA, Oviedo, Spain. LA - eng PT - Journal Article DEP - 20210526 PL - United States TA - Liver Int JT - Liver international : official journal of the International Association for the Study of the Liver JID - 101160857 RN - 0 (Antineoplastic Agents) RN - 0 (Phenylurea Compounds) RN - 25X51I8RD4 (Niacinamide) RN - 9ZOQ3TZI87 (Sorafenib) SB - IM MH - *Antineoplastic Agents/adverse effects MH - *Carcinoma, Hepatocellular/drug therapy MH - *Cardiovascular Diseases/chemically induced/epidemiology MH - Humans MH - *Liver Neoplasms/drug therapy MH - Niacinamide/adverse effects MH - Phenylurea Compounds/adverse effects MH - Retrospective Studies MH - Sorafenib/therapeutic use MH - Treatment Outcome OTO - NOTNLM OT - hepatocellular carcinoma OT - hypertension heart disease risk factors OT - sorafenib OT - survival EDAT- 2021/05/10 06:00 MHDA- 2021/08/20 06:00 CRDT- 2021/05/09 21:08 PHST- 2021/03/31 00:00 [revised] PHST- 2020/12/08 00:00 [received] PHST- 2021/05/04 00:00 [accepted] PHST- 2021/05/10 06:00 [pubmed] PHST- 2021/08/20 06:00 [medline] PHST- 2021/05/09 21:08 [entrez] AID - 10.1111/liv.14941 [doi] PST - ppublish SO - Liver Int. 2021 Sep;41(9):2200-2211. doi: 10.1111/liv.14941. Epub 2021 May 26. PMID- 33966127 OWN - NLM STAT- MEDLINE DCOM- 20220112 LR - 20261010 IS - 1861-0692 (Electronic) IS - 1861-0684 (Linking) VI - 110 IP - 9 DP - 2021 Sep TI - New challenges in cardiac intensive care units. PG - 1369-1379 LID - 10.1007/s00392-021-01869-0 [doi] AB - Critical care cardiology is a steadily and rapidly developing sub-specialization within cardiovascular medicine, since the first emergence of a coronary care unit in the early 1960s. Today, modern cardiac intensive care units (CICU) serve a complex patient population with a high burden of cardiovascular and non-cardiovascular critical illnesses. Treatment of these patients requires a multidisciplinary approach, with a combination of highly specialized knowledge and skills in cardiovascular diseases, as well as emergency, critical-care and internal medicine. The CICU has always posed special challenges to both experienced intensivists as well as fellows-in-training (FIT) and is certainly one of the most demanding training phases. In recent years, these challenges have grown significantly owing to technological innovations, with new and steadily rising numbers of complex interventional procedures and new options for temporary circulatory support for critically ill patients, such as venoarterial extracorporeal membrane oxygenation (VA-ECMO). Herein, we focus on the successful CICU management of these special patient cohorts, which must become an integral part of critical-care training. CI - (c) 2021. Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Lusebrink, Enzo AU - Lusebrink E AUID- ORCID: 0000-0002-3214-5672 AD - Cardiac Intensive Care Unit, Medizinische Klinik und Poliklinik I, Klinikum der Universitat Munchen, Marchioninistrasse 15, 81377, Munich, Germany. AD - DZHK (German Center for Cardiovascular Research), Partner Site Munich Heart Alliance, Medizinische Klinik und Poliklinik I, Klinikum der Universitat Munchen, Munich, Germany. FAU - Kellnar, Antonia AU - Kellnar A AD - Cardiac Intensive Care Unit, Medizinische Klinik und Poliklinik I, Klinikum der Universitat Munchen, Marchioninistrasse 15, 81377, Munich, Germany. AD - DZHK (German Center for Cardiovascular Research), Partner Site Munich Heart Alliance, Medizinische Klinik und Poliklinik I, Klinikum der Universitat Munchen, Munich, Germany. FAU - Scherer, Clemens AU - Scherer C AD - Cardiac Intensive Care Unit, Medizinische Klinik und Poliklinik I, Klinikum der Universitat Munchen, Marchioninistrasse 15, 81377, Munich, Germany. AD - DZHK (German Center for Cardiovascular Research), Partner Site Munich Heart Alliance, Medizinische Klinik und Poliklinik I, Klinikum der Universitat Munchen, Munich, Germany. FAU - Krieg, Kathrin AU - Krieg K AD - Cardiac Intensive Care Unit, Medizinische Klinik und Poliklinik I, Klinikum der Universitat Munchen, Marchioninistrasse 15, 81377, Munich, Germany. AD - DZHK (German Center for Cardiovascular Research), Partner Site Munich Heart Alliance, Medizinische Klinik und Poliklinik I, Klinikum der Universitat Munchen, Munich, Germany. FAU - Orban, Mathias AU - Orban M AD - Cardiac Intensive Care Unit, Medizinische Klinik und Poliklinik I, Klinikum der Universitat Munchen, Marchioninistrasse 15, 81377, Munich, Germany. AD - DZHK (German Center for Cardiovascular Research), Partner Site Munich Heart Alliance, Medizinische Klinik und Poliklinik I, Klinikum der Universitat Munchen, Munich, Germany. FAU - Petzold, Tobias AU - Petzold T AD - Cardiac Intensive Care Unit, Medizinische Klinik und Poliklinik I, Klinikum der Universitat Munchen, Marchioninistrasse 15, 81377, Munich, Germany. AD - DZHK (German Center for Cardiovascular Research), Partner Site Munich Heart Alliance, Medizinische Klinik und Poliklinik I, Klinikum der Universitat Munchen, Munich, Germany. FAU - Peterss, Sven AU - Peterss S AD - Herzchirurgische Klinik und Poliklinik, Klinikum der Universitat Munchen, Munich, Germany. FAU - Kaab, Stefan AU - Kaab S AD - Cardiac Intensive Care Unit, Medizinische Klinik und Poliklinik I, Klinikum der Universitat Munchen, Marchioninistrasse 15, 81377, Munich, Germany. AD - DZHK (German Center for Cardiovascular Research), Partner Site Munich Heart Alliance, Medizinische Klinik und Poliklinik I, Klinikum der Universitat Munchen, Munich, Germany. FAU - Brunner, Stefan AU - Brunner S AD - Cardiac Intensive Care Unit, Medizinische Klinik und Poliklinik I, Klinikum der Universitat Munchen, Marchioninistrasse 15, 81377, Munich, Germany. AD - DZHK (German Center for Cardiovascular Research), Partner Site Munich Heart Alliance, Medizinische Klinik und Poliklinik I, Klinikum der Universitat Munchen, Munich, Germany. FAU - Braun, Daniel AU - Braun D AD - Cardiac Intensive Care Unit, Medizinische Klinik und Poliklinik I, Klinikum der Universitat Munchen, Marchioninistrasse 15, 81377, Munich, Germany. AD - DZHK (German Center for Cardiovascular Research), Partner Site Munich Heart Alliance, Medizinische Klinik und Poliklinik I, Klinikum der Universitat Munchen, Munich, Germany. FAU - Hagl, Christian AU - Hagl C AD - Herzchirurgische Klinik und Poliklinik, Klinikum der Universitat Munchen, Munich, Germany. FAU - Hausleiter, Jorg AU - Hausleiter J AD - Cardiac Intensive Care Unit, Medizinische Klinik und Poliklinik I, Klinikum der Universitat Munchen, Marchioninistrasse 15, 81377, Munich, Germany. AD - DZHK (German Center for Cardiovascular Research), Partner Site Munich Heart Alliance, Medizinische Klinik und Poliklinik I, Klinikum der Universitat Munchen, Munich, Germany. FAU - Massberg, Steffen AU - Massberg S AD - Cardiac Intensive Care Unit, Medizinische Klinik und Poliklinik I, Klinikum der Universitat Munchen, Marchioninistrasse 15, 81377, Munich, Germany. AD - DZHK (German Center for Cardiovascular Research), Partner Site Munich Heart Alliance, Medizinische Klinik und Poliklinik I, Klinikum der Universitat Munchen, Munich, Germany. FAU - Orban, Martin AU - Orban M AD - Cardiac Intensive Care Unit, Medizinische Klinik und Poliklinik I, Klinikum der Universitat Munchen, Marchioninistrasse 15, 81377, Munich, Germany. MartinOrban@gmail.com. AD - DZHK (German Center for Cardiovascular Research), Partner Site Munich Heart Alliance, Medizinische Klinik und Poliklinik I, Klinikum der Universitat Munchen, Munich, Germany. MartinOrban@gmail.com. LA - eng PT - Journal Article DEP - 20210509 PL - Germany TA - Clin Res Cardiol JT - Clinical research in cardiology : official journal of the German Cardiac Society JID - 101264123 SB - IM MH - Cardiology/*trends MH - Cardiovascular Diseases/therapy MH - Clinical Competence MH - Coronary Care Units/*organization & administration/trends MH - Critical Care/*methods/trends MH - Critical Illness/therapy MH - Extracorporeal Membrane Oxygenation/methods MH - Humans OTO - NOTNLM OT - Cardiac intensive care units OT - Interventional cardiology OT - Interventional procedures OT - Venoarterial extracorporeal membrane oxygenation EDAT- 2021/05/10 06:00 MHDA- 2022/01/13 06:00 CRDT- 2021/05/09 21:01 PHST- 2021/01/07 00:00 [received] PHST- 2021/05/04 00:00 [accepted] PHST- 2021/05/10 06:00 [pubmed] PHST- 2022/01/13 06:00 [medline] PHST- 2021/05/09 21:01 [entrez] AID - 10.1007/s00392-021-01869-0 [pii] AID - 10.1007/s00392-021-01869-0 [doi] PST - ppublish SO - Clin Res Cardiol. 2021 Sep;110(9):1369-1379. doi: 10.1007/s00392-021-01869-0. Epub 2021 May 9. PMID- 33964404 OWN - NLM STAT- MEDLINE DCOM- 20220613 LR - 20220714 IS - 1873-2615 (Electronic) IS - 1050-1738 (Linking) VI - 32 IP - 5 DP - 2022 Jul TI - A new era of genetic testing in congenital heart disease: A review. PG - 311-319 LID - S1050-1738(21)00055-4 [pii] LID - 10.1016/j.tcm.2021.04.011 [doi] AB - Genetic and genomic testing in pediatric CHD is becoming increasingly routine, and can have important psychosocial, clinical and reproductive implications. In this paper we highlight important challenges and considerations when providing genetics consults and testing in pediatric CHD and illustrate the role of a dedicated CHD genetics clinic. Key lessons include that a) a genetic diagnosis can have clinical utility that justifies testing early in life, b) adequate genetic counselling is crucial to ensure families are supported, understand the range of possible results, and are prepared for new or unexpected health information, and c) further integration of the clinical genetics and cardiology workflows will be required to effectively manage the burgeoning information arising from genetic testing. Our experience demonstrates that a dedicated CHD genetics clinic is a valuable addition to a multidisciplinary team providing care to children with CHD. CI - Copyright (c) 2021. Published by Elsevier Inc. FAU - Morrish, Ansley M AU - Morrish AM AD - Heart Centre for Children, The Children's Hospital at Westmead, Sydney, Australia; Department of Clinical Genetics, The Children's Hospital at Westmead, Sydney, Australia. FAU - Smith, Janine AU - Smith J AD - Department of Clinical Genetics, The Children's Hospital at Westmead, Sydney, Australia; Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia. FAU - Enriquez, Annabelle AU - Enriquez A AD - Department of Clinical Genetics, The Children's Hospital at Westmead, Sydney, Australia; Victor Chang Cardiac Research Institute, Darlinghurst, Sydney, Australia; Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; St Vincent's Clinical School Faculty of Medicine, UNSW Sydney, Sydney, Australia; Department of Clinical Genetics, Nepean Hospital, Sydney, Australia. FAU - Sholler, Gary F AU - Sholler GF AD - Heart Centre for Children, The Children's Hospital at Westmead, Sydney, Australia; Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia. FAU - Mervis, Jonathan AU - Mervis J AD - Heart Centre for Children, The Children's Hospital at Westmead, Sydney, Australia. FAU - Dunwoodie, Sally L AU - Dunwoodie SL AD - Victor Chang Cardiac Research Institute, Darlinghurst, Sydney, Australia; St Vincent's Clinical School Faculty of Medicine, UNSW Sydney, Sydney, Australia. FAU - Kirk, Edwin P AU - Kirk EP AD - Centre for Clinical Genetics, Sydney Children's Hospital, Sydney, Australia; School of Women's and Children's Health, Faculty of Medicine, UNSW, Sydney, Australia; Randwick Genomics Laboratory, NSW Health Pathology, Sydney, Australia. FAU - Winlaw, David S AU - Winlaw DS AD - Heart Centre for Children, The Children's Hospital at Westmead, Sydney, Australia; Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Cincinati Children's Hospital Medical Centre, Cincinnati, OH, United States. FAU - Blue, Gillian M AU - Blue GM AD - Heart Centre for Children, The Children's Hospital at Westmead, Sydney, Australia; Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia. Electronic address: gillian.blue@health.nsw.gov.au. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20210505 PL - United States TA - Trends Cardiovasc Med JT - Trends in cardiovascular medicine JID - 9108337 SB - IM CIN - Trends Cardiovasc Med. 2022 Jul;32(5):320-321. doi: 10.1016/j.tcm.2021.05.001. PMID: 34062259 MH - Child MH - Genetic Counseling MH - *Genetic Testing MH - *Heart Defects, Congenital/diagnosis/genetics/therapy MH - Humans MH - Referral and Consultation OTO - NOTNLM OT - Congenital heart disease OT - Genetic counselling OT - Genetic testing OT - Genomics EDAT- 2021/05/09 06:00 MHDA- 2022/06/14 06:00 CRDT- 2021/05/08 20:11 PHST- 2021/03/03 00:00 [received] PHST- 2021/04/07 00:00 [revised] PHST- 2021/04/29 00:00 [accepted] PHST- 2021/05/09 06:00 [pubmed] PHST- 2022/06/14 06:00 [medline] PHST- 2021/05/08 20:11 [entrez] AID - S1050-1738(21)00055-4 [pii] AID - 10.1016/j.tcm.2021.04.011 [doi] PST - ppublish SO - Trends Cardiovasc Med. 2022 Jul;32(5):311-319. doi: 10.1016/j.tcm.2021.04.011. Epub 2021 May 5. PMID- 33957142 OWN - NLM STAT- MEDLINE DCOM- 20210706 LR - 20210706 IS - 1872-8227 (Electronic) IS - 0168-8227 (Linking) VI - 176 DP - 2021 Jun TI - Interdisciplinary assessment and diagnostic algorithm: The role of the cardiologist. PG - 108851 LID - S0168-8227(21)00210-2 [pii] LID - 10.1016/j.diabres.2021.108851 [doi] AB - Patients with diabetes have an increased risk of developing heart failure and those with heart failure are at higher risk of developing diabetes. In patients with diabetes antidiabetic medications and the metabolic alterations of diabetes increase the risk of developing heart failure. In diabetic patients with heart failure and in those with an increased likelihood of developing the disease a stepwise approach based on the use of natriuretic peptides and echocardiography to rule out the presence of heart failure should be used. Once the diagnosis of heart failure is established it will be important to define the phenotype according to the left ventricular function and, where appropriate, use additional tests to identify possible additional underlying causes of heart failure like coronary artery disease. A multidisciplinary heart failure management programs is recommended in all patients with diabetes mellitus and heart failure to enable appropriate investigations, accurate diagnosis, and appropriate agreed evidence-based therapy and care plan. The implementation of a multidisciplinary heart failure management program requires a multidisciplinary team that will have to follow the patients throughout the whole heart failure trajectory and that should consider a holistic approach to the diabetic patient with heart failure rather than focussing merely on either heart failure or diabetes. CI - Crown Copyright (c) 2021. Published by Elsevier B.V. All rights reserved. FAU - Rosano, Giuseppe M C AU - Rosano GMC AD - St George's Hospital Medical School, London, United Kingdom; IRCCS San Raffaele Roma, Italy; St Heliers and Epsom Hospital, United Kingdom. Electronic address: grosano@sgul.ac.uk. FAU - Vitale, Cristiana AU - Vitale C AD - St George's Hospital Medical School, London, United Kingdom; IRCCS San Raffaele Roma, Italy; St Heliers and Epsom Hospital, United Kingdom. FAU - Maltese, Giuseppe AU - Maltese G AD - St George's Hospital Medical School, London, United Kingdom; IRCCS San Raffaele Roma, Italy; St Heliers and Epsom Hospital, United Kingdom. LA - eng PT - Journal Article PT - Review DEP - 20210504 PL - Ireland TA - Diabetes Res Clin Pract JT - Diabetes research and clinical practice JID - 8508335 RN - 0 (Hypoglycemic Agents) SB - IM MH - *Algorithms MH - *Cardiologists MH - Diabetic Angiopathies/*diagnosis/drug therapy/physiopathology MH - Diagnostic Techniques, Cardiovascular MH - Diagnostic Techniques, Endocrine MH - Heart Failure/*diagnosis/drug therapy/etiology/physiopathology MH - Humans MH - Hypoglycemic Agents/therapeutic use MH - Patient Care Team MH - *Physician's Role MH - Prognosis MH - Ventricular Function, Left/physiology OTO - NOTNLM OT - Diabetes mellitus OT - Diagnosis OT - Echocardiography OT - Heart failure OT - Prognosis COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2021/05/07 06:00 MHDA- 2021/07/07 06:00 CRDT- 2021/05/06 20:30 PHST- 2021/04/28 00:00 [received] PHST- 2021/04/28 00:00 [accepted] PHST- 2021/05/07 06:00 [pubmed] PHST- 2021/07/07 06:00 [medline] PHST- 2021/05/06 20:30 [entrez] AID - S0168-8227(21)00210-2 [pii] AID - 10.1016/j.diabres.2021.108851 [doi] PST - ppublish SO - Diabetes Res Clin Pract. 2021 Jun;176:108851. doi: 10.1016/j.diabres.2021.108851. Epub 2021 May 4. PMID- 33957141 OWN - NLM STAT- MEDLINE DCOM- 20210706 LR - 20210706 IS - 1872-8227 (Electronic) IS - 0168-8227 (Linking) VI - 176 DP - 2021 Jun TI - Interdisciplinary assessment and diagnostic algorithm: The role of the diabetologist. PG - 108850 LID - S0168-8227(21)00209-6 [pii] LID - 10.1016/j.diabres.2021.108850 [doi] AB - In recent years, many studies have revealed the importance of heart failure (HF) development in type 2 diabetes (T2D), which increases the morbidity and mortality during the course of diabetes. In this context, it became important to emphasize the role of both cardiologists and diabetologists in the early diagnosis and further adequate treatment of HF in T2D. While HF appears in two major forms, with reduced or preserved ejection fraction (EF), namely HFrEF and HFpEF, it became important to define the optimal approach to the diagnostics. Regarding HFrEF, the role of cardiological methods remained dominant, while the complexity of early diagnosis requires nowadays more active participation of diabetologists. The absence of abundant symptoms and echocardiographic findings imposed the need for the use of risk markers based on metabolic variables and low-grade inflammation parameters. Following that unmet need, numerous studies have defined the possible relationship between metabolic variables in diabetes and the risk for HF. Moreover, attempts have been made to integrate biochemical and clinical parameters into risk score engines and some of them gave promising results. However, the follow-up studies in T2D subjects are needed to determine the clinical relevance of these new approaches. CI - Copyright (c) 2021. Published by Elsevier B.V. FAU - Lalic, Nebojsa M AU - Lalic NM AD - Faculty of Medicine, University of Belgrade, Clinic for Endocrinology, Diabetes and Metabolic Diseases, University Clinical Center of Serbia, Dr Subotica str. no 13, 11000 Belgrade, Serbia. Electronic address: lalic.nm@gmail.com. LA - eng PT - Journal Article PT - Review DEP - 20210504 PL - Ireland TA - Diabetes Res Clin Pract JT - Diabetes research and clinical practice JID - 8508335 SB - IM MH - *Algorithms MH - Diabetes Mellitus, Type 2/complications/diagnosis/therapy MH - Diabetic Angiopathies/*diagnosis/therapy MH - Diagnostic Techniques, Cardiovascular MH - Diagnostic Techniques, Endocrine MH - *Endocrinologists MH - Follow-Up Studies MH - Heart Failure/*diagnosis/therapy MH - Humans MH - Patient Care Team MH - *Physician's Role MH - Prognosis OTO - NOTNLM OT - Biomarkers OT - Heart failure OT - Risk calculators OT - Type 2 diabetes COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2021/05/07 06:00 MHDA- 2021/07/07 06:00 CRDT- 2021/05/06 20:30 PHST- 2021/04/04 00:00 [received] PHST- 2021/04/29 00:00 [revised] PHST- 2021/04/29 00:00 [accepted] PHST- 2021/05/07 06:00 [pubmed] PHST- 2021/07/07 06:00 [medline] PHST- 2021/05/06 20:30 [entrez] AID - S0168-8227(21)00209-6 [pii] AID - 10.1016/j.diabres.2021.108850 [doi] PST - ppublish SO - Diabetes Res Clin Pract. 2021 Jun;176:108850. doi: 10.1016/j.diabres.2021.108850. Epub 2021 May 4. PMID- 33957103 OWN - NLM STAT- MEDLINE DCOM- 20210826 LR - 20260127 IS - 1097-6744 (Electronic) IS - 0002-8703 (Linking) VI - 238 DP - 2021 Aug TI - Comparative effectiveness of team-based care with a clinical decision support system versus team-based care alone on cardiovascular risk reduction among patients with diabetes: Rationale and design of the D4C trial. PG - 45-58 LID - S0002-8703(21)00111-3 [pii] LID - 10.1016/j.ahj.2021.04.009 [doi] AB - BACKGROUND: Diabetes has become a major public health challenge worldwide, especially in low- and middle-income countries (LMICs). Uncontrolled hyperglycemia, hypertension, and dyslipidemia major risk factors for all-cause mortality and cardiovascular disease (CVD) are common in patients with diabetes in China. We propose to compare the effectiveness of team-based care plus a clinical decision support system (CDSS) with team-based care alone on glycemic, blood pressure (BP), and lipid control, and clinical CVD reduction among patients with type-2 diabetes and at high risk for CVD. METHODS: The Diabetes Complication Control in Community Clinics (D4C) study is a cluster-randomized trial conducted among 38 community health centers in Xiamen City, China. Nineteen clinics have been randomly assigned to team-based care plus CDSS and 19 to team-based care alone. Team-based care includes primary care providers, health coaches, and diabetes specialists working collaboratively with patients to achieve shared treatment goals for CVD risk factor reduction. The CDSS integrates guideline-based treatment algorithms for glycemic, BP, and lipid control, along with a patient's medical history and insurance policy, to recommend treatment and follow-up plans. In phase 1, the co-primary outcomes are mean reduction in glycated hemoglobin (HbA1c), systolic BP (SBP), and low-density lipoprotein (LDL)-cholesterol over 18 months, and the proportion of patients with controlled HbA1c, SBP, and LDL-cholesterol at 18 months' between the 2 comparison groups. In phase 2, the primary outcome is the difference in major CVD incidence (non-fatal stroke, non-fatal myocardial infarction, hospitalized heart failure, and CVD mortality) between the 2 comparison groups. Mean reduction in HbA1c, SBP, and LDL-cholesterol levels will be simultaneously modeled for a single overall treatment effect. CONCLUSION: The D4C trial will generate evidence on whether a CDSS will further reduce the CVD burden among patients with diabetes beyond team-based care at community clinics. If proven effective, this implementation strategy could be scaled up within primary care settings in China and other LMICs to reduce CVD incidence and mortality among patients with diabetes. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - Shi, Xiulin AU - Shi X AD - Department of Endocrinology and Diabetes, Xiamen Diabetes Institute, and Xiamen Clinical Medical Center for Endocrine and Metabolic Diseases, the First Affiliated Hospital of Xiamen University, Xiamen, China; Fujian Province Key Laboratory of Diabetes Translational Medicine, Xiamen, China. FAU - He, Jiang AU - He J AD - Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA; Tulane University Translational Science Institute, New Orleans, LA. Electronic address: jhe@tulane.edu. FAU - Lin, Mingzhu AU - Lin M AD - Department of Endocrinology and Diabetes, Xiamen Diabetes Institute, and Xiamen Clinical Medical Center for Endocrine and Metabolic Diseases, the First Affiliated Hospital of Xiamen University, Xiamen, China; Fujian Province Key Laboratory of Diabetes Translational Medicine, Xiamen, China. FAU - Liu, Changqin AU - Liu C AD - Department of Endocrinology and Diabetes, Xiamen Diabetes Institute, and Xiamen Clinical Medical Center for Endocrine and Metabolic Diseases, the First Affiliated Hospital of Xiamen University, Xiamen, China; Fujian Province Key Laboratory of Diabetes Translational Medicine, Xiamen, China. FAU - Yan, Bing AU - Yan B AD - Department of Endocrinology and Diabetes, Xiamen Diabetes Institute, and Xiamen Clinical Medical Center for Endocrine and Metabolic Diseases, the First Affiliated Hospital of Xiamen University, Xiamen, China; Fujian Province Key Laboratory of Diabetes Translational Medicine, Xiamen, China. FAU - Song, Haiqu AU - Song H AD - Department of Endocrinology and Diabetes, Xiamen Diabetes Institute, and Xiamen Clinical Medical Center for Endocrine and Metabolic Diseases, the First Affiliated Hospital of Xiamen University, Xiamen, China; Fujian Province Key Laboratory of Diabetes Translational Medicine, Xiamen, China. FAU - Wang, Caihong AU - Wang C AD - Department of Endocrinology and Diabetes, Xiamen Diabetes Institute, and Xiamen Clinical Medical Center for Endocrine and Metabolic Diseases, the First Affiliated Hospital of Xiamen University, Xiamen, China; Fujian Province Key Laboratory of Diabetes Translational Medicine, Xiamen, China. FAU - Xiao, Fangsen AU - Xiao F AD - Department of Endocrinology and Diabetes, Xiamen Diabetes Institute, and Xiamen Clinical Medical Center for Endocrine and Metabolic Diseases, the First Affiliated Hospital of Xiamen University, Xiamen, China; Fujian Province Key Laboratory of Diabetes Translational Medicine, Xiamen, China. FAU - Huang, Peiying AU - Huang P AD - Department of Endocrinology and Diabetes, Xiamen Diabetes Institute, and Xiamen Clinical Medical Center for Endocrine and Metabolic Diseases, the First Affiliated Hospital of Xiamen University, Xiamen, China; Fujian Province Key Laboratory of Diabetes Translational Medicine, Xiamen, China. FAU - Wang, Liying AU - Wang L AD - Department of Endocrinology and Diabetes, Xiamen Diabetes Institute, and Xiamen Clinical Medical Center for Endocrine and Metabolic Diseases, the First Affiliated Hospital of Xiamen University, Xiamen, China; Fujian Province Key Laboratory of Diabetes Translational Medicine, Xiamen, China. FAU - Li, Zhibin AU - Li Z AD - Epidemiology Research Unit, the First Affiliated Hospital of Xiamen University, Xiamen, China. FAU - Huang, Yinxiang AU - Huang Y AD - Department of Endocrinology and Diabetes, Xiamen Diabetes Institute, and Xiamen Clinical Medical Center for Endocrine and Metabolic Diseases, the First Affiliated Hospital of Xiamen University, Xiamen, China; Fujian Province Key Laboratory of Diabetes Translational Medicine, Xiamen, China. FAU - Zhang, Mulin AU - Zhang M AD - Department of Endocrinology and Diabetes, Xiamen Diabetes Institute, and Xiamen Clinical Medical Center for Endocrine and Metabolic Diseases, the First Affiliated Hospital of Xiamen University, Xiamen, China; Fujian Province Key Laboratory of Diabetes Translational Medicine, Xiamen, China. FAU - Chen, Chung-Shiuan AU - Chen CS AD - Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA; Tulane University Translational Science Institute, New Orleans, LA. FAU - Obst, Katherine AU - Obst K AD - Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA; Tulane University Translational Science Institute, New Orleans, LA. FAU - Li, Weihua AU - Li W AD - Department of Cardiology, the First Affiliated Hospital of Xiamen University, Xiamen, China. FAU - Yang, Shuyu AU - Yang S AD - Department of Endocrinology and Diabetes, Xiamen Diabetes Institute, and Xiamen Clinical Medical Center for Endocrine and Metabolic Diseases, the First Affiliated Hospital of Xiamen University, Xiamen, China; Fujian Province Key Laboratory of Diabetes Translational Medicine, Xiamen, China. FAU - Yao, Guanhua AU - Yao G AD - Xiamen Municipal Health Commission, Xiamen, China. FAU - Li, Xuejun AU - Li X AD - Department of Endocrinology and Diabetes, Xiamen Diabetes Institute, and Xiamen Clinical Medical Center for Endocrine and Metabolic Diseases, the First Affiliated Hospital of Xiamen University, Xiamen, China; Fujian Province Key Laboratory of Diabetes Translational Medicine, Xiamen, China.. Electronic address: xmlixuejun@163.com. LA - eng PT - Clinical Trial Protocol PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210504 PL - United States TA - Am Heart J JT - American heart journal JID - 0370465 RN - 0 (Cholesterol, LDL) RN - 0 (Glycated Hemoglobin) SB - IM MH - Blood Pressure MH - Cardiovascular Diseases/epidemiology/mortality/*prevention & control MH - China MH - Cholesterol, LDL/blood MH - *Decision Support Systems, Clinical MH - Diabetes Mellitus, Type 2/blood/*complications MH - Female MH - Glycated Hemoglobin MH - *Heart Disease Risk Factors MH - Heart Failure/prevention & control MH - Humans MH - Incidence MH - Male MH - Middle Aged MH - Myocardial Infarction/prevention & control MH - Patient Care Team/*organization & administration MH - *Risk Reduction Behavior MH - Stroke/prevention & control MH - Multicenter Studies as Topic MH - Randomized Controlled Trials as Topic EDAT- 2021/05/07 06:00 MHDA- 2021/08/27 06:00 CRDT- 2021/05/06 20:29 PHST- 2020/11/28 00:00 [received] PHST- 2021/04/25 00:00 [accepted] PHST- 2021/05/07 06:00 [pubmed] PHST- 2021/08/27 06:00 [medline] PHST- 2021/05/06 20:29 [entrez] AID - S0002-8703(21)00111-3 [pii] AID - 10.1016/j.ahj.2021.04.009 [doi] PST - ppublish SO - Am Heart J. 2021 Aug;238:45-58. doi: 10.1016/j.ahj.2021.04.009. Epub 2021 May 4. PMID- 33956313 OWN - NLM STAT- MEDLINE DCOM- 20211108 LR - 20261012 IS - 1546-9549 (Electronic) IS - 1546-9530 (Linking) VI - 18 IP - 4 DP - 2021 Aug TI - The Surgeon's Role in Cardiogenic Shock. PG - 240-251 LID - 10.1007/s11897-021-00514-1 [doi] AB - PURPOSE OF REVIEW: Cardiogenic shock represents a very challenging patient population due to the undifferentiated pathologies presenting as cardiogenic shock, difficult decision-making, prognostication, and ever-expanding support options. The role of cardiac surgeons on this team is evolving. RECENT FINDINGS: The implementation of a shock team is associated with improved outcomes in patients with cardiogenic shock. Early deployment of mechanical circulatory support devices may allow an opportunity to rescue these patients. Cardiothoracic surgeons are a critical component of the shock team who can deploy timely mechanical support and surgical intervention in selected patients for optimal outcomes. CI - (c) 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Sperry, Alexandra E AU - Sperry AE AD - Division of Cardiovascular Surgery, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA. FAU - Williams, Matthew AU - Williams M AD - Division of Cardiovascular Surgery, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA. FAU - Atluri, Pavan AU - Atluri P AD - Division of Cardiovascular Surgery, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA. FAU - Szeto, Wilson Y AU - Szeto WY AD - Division of Cardiovascular Surgery, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA. FAU - Cevasco, Marisa AU - Cevasco M AD - Division of Cardiovascular Surgery, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA. FAU - Bermudez, Christian A AU - Bermudez CA AD - Division of Cardiovascular Surgery, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA. FAU - Acker, Michael A AU - Acker MA AD - Division of Cardiovascular Surgery, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA. FAU - Ibrahim, Michael AU - Ibrahim M AD - Division of Cardiovascular Surgery, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA. Michael.ibrahim@uphs.upenn.edu. LA - eng PT - Journal Article PT - Review DEP - 20210506 PL - United States TA - Curr Heart Fail Rep JT - Current heart failure reports JID - 101196487 SB - IM MH - *Heart Failure MH - *Heart-Assist Devices MH - Humans MH - Shock, Cardiogenic/therapy MH - *Surgeons OTO - NOTNLM OT - Cardiogenic shock OT - Cardiothoracic surgeon OT - Mechanical circulatory support OT - Shock team EDAT- 2021/05/07 06:00 MHDA- 2021/11/09 06:00 CRDT- 2021/05/06 13:11 PHST- 2021/04/07 00:00 [accepted] PHST- 2021/05/07 06:00 [pubmed] PHST- 2021/11/09 06:00 [medline] PHST- 2021/05/06 13:11 [entrez] AID - 10.1007/s11897-021-00514-1 [pii] AID - 10.1007/s11897-021-00514-1 [doi] PST - ppublish SO - Curr Heart Fail Rep. 2021 Aug;18(4):240-251. doi: 10.1007/s11897-021-00514-1. Epub 2021 May 6. PMID- 33954707 OWN - NLM STAT- Publisher LR - 20240222 IS - 1940-8250 (Electronic) IS - 0279-5442 (Linking) DP - 2021 May 6 TI - Situational Awareness Huddles in a Pediatric Cardiac Intensive Care Unit During the COVID-19 Pandemic. PG - e1-e8 LID - 10.4037/ccn2021975 [doi] AB - BACKGROUND: The COVID-19 pandemic has created challenges for provider teams working in intensive care units, including rapidly changing patient care regulations, staffing considerations, and preservation of personal protective equipment. The need for enhanced respiratory precautions for infected patients and patients under investigation has necessitated a new process for interventions and resuscitation. LOCAL PROBLEM: Along with changing regulations and equipment, significant staff anxiety surrounded caring for infected patients and preparing for emergency situations. METHODS: A huddle process was implemented in the pediatric cardiac intensive care unit for acutely ill patients who required enhanced respiratory precautions and were at risk of imminent decompensation, or who required a bedside procedure. During a huddle, the multidisciplinary team used process maps displayed in patient rooms; the huddle process created a situational awareness of events among these teams. INTERVENTION: After implementation of huddles, a survey was distributed to cardiac intensive care unit staff in order to understand their satisfaction with the huddle process. RESULTS: A total of 36 staff responded to the survey. They thought the huddles helped them to prepare for resuscitation scenarios, helped limit the number of personnel responding to an emergency, and reduced their anxiety surrounding caring for these patients. Staff suggested generalizing this huddle process to all patients at acute risk for decompensation in the cardiac intensive care unit. CONCLUSIONS: A novel huddle process created situational awareness among staff caring for patients requiring enhanced respiratory isolation because of COVID-19. Multidisciplinary huddles allowed staff from various disciplines to apply a process map for interventions and resuscitations among critically ill children with heart disease. CI - (c)2021 American Association of Critical-Care Nurses. FAU - Christensen, Kristen AU - Christensen K AD - Kristen Christensen is a staff nurse and a clinical nurse leader in the cardiac intensive care unit, Children's Healthcare of Atlanta, Atlanta, Georgia. FAU - Colman, Nora AU - Colman N AD - Nora Colman is an attending physician in the pediatric intensive care unit, Children's Healthcare of Atlanta, and an assistant professor of pediatrics, Emory University School of Medicine, Atlanta, Georgia. FAU - Van Voorhis, Kay AU - Van Voorhis K AD - Kay Van Voorhis is a staff nurse and an assistant nurse manager in the cardiac intensive care unit, Children's Healthcare of Atlanta. FAU - Daniels, Katherine AU - Daniels K AD - Katherine Daniels is a staff nurse and an assistant nurse manager in the pediatric intensive care unit, Children's Healthcare of Atlanta. FAU - Culpepper, Haley AU - Culpepper H AD - Haley Culpepper is a staff nurse and nurse educator in the pediatric intensive care unit, Children's Healthcare of Atlanta. FAU - Hebbar, Kiran AU - Hebbar K AD - Kiran Hebbar is an attending physician in the pediatric intensive care unit and Director of the Simulation Center, Children's Healthcare of Atlanta, and a professor of pediatrics, Emory University School of Medicine. FAU - Wolf, Michael AU - Wolf M AD - Michael Wolf is an attending physician in the cardiac and pediatric intensive care units and the Associate Medical Director of the cardiac intensive care unit, Children's Healthcare of Atlanta, and an associate professor of pediatrics, Emory University School of Medicine. LA - eng PT - Journal Article DEP - 20210506 PL - United States TA - Crit Care Nurse JT - Critical care nurse JID - 8207799 EDAT- 2021/05/07 06:00 MHDA- 2021/05/07 06:00 CRDT- 2021/05/06 07:13 PHST- 2021/05/06 07:13 [entrez] PHST- 2021/05/07 06:00 [pubmed] PHST- 2021/05/07 06:00 [medline] AID - 31446 [pii] AID - 10.4037/ccn2021975 [doi] PST - aheadofprint SO - Crit Care Nurse. 2021 May 6:e1-e8. doi: 10.4037/ccn2021975. PMID- 33950116 OWN - NLM STAT- MEDLINE DCOM- 20210621 LR - 20220422 IS - 1984-0446 (Electronic) IS - 0034-7167 (Linking) VI - 74 IP - 2 DP - 2021 TI - Nursing care for patient in post operatory heart surgery in the Intensive Care Unit. PG - e20200163 LID - S0034-71672021000200158 [pii] LID - 10.1590/0034-7167-2020-0163 [doi] AB - OBJECTIVE: To investigate the critical nodes related to nursing care for patients in the postoperative period of cardiac surgery. METHODS: Exploratory study with a qualitative approach. Data collected through semi-structured interviews with 27 members of the nursing team working in the Intensive Care Unit. Material submitted to thematic analysis. RESULTS: Three categories emerged: Flaws in the professional qualification for patient care in the postoperative period of cardiac surgery; Team challenges concerning specific patient care in the postoperative period of cardiac surgery; and (dis) organization of work in the Intensive Care Unit and its impact on nursing care for patients in the postoperative period of cardiac surgery. FINAL CONSIDERATIONS: Given the identification of the critical nodes, the professionals presented suggestions to overcome daily difficulties: investments in strategies for Permanent Education in Health; creation of tools to guide patient assistance in the postoperative of cardiac surgery; and provision of adequate human resources. FAU - Reisdorfer, Ariele Priebe AU - Reisdorfer AP AUID- ORCID: 0000-0002-0172-8197 AD - Universidade Federal de Santa Maria. Santa Maria, Rio Grande do Sul, Brazil. FAU - Leal, Sandra Maria Cezar AU - Leal SMC AUID- ORCID: 0000-0003-4611-0988 AD - Universidade do Vale do Rio dos Sinos. Porto Alegre, Rio Grande do Sul, Brazil. FAU - Mancia, Joel Rolim AU - Mancia JR AUID- ORCID: 0000-0001-9817-2537 AD - Universidade do Vale do Rio dos Sinos. Porto Alegre, Rio Grande do Sul, Brazil. LA - eng LA - por PT - Journal Article DEP - 20210503 PL - Brazil TA - Rev Bras Enferm JT - Revista brasileira de enfermagem JID - 7910105 EIN - Rev Bras Enferm. 2021 Jul 23;74(3):e2021n3e08. doi: 10.1590/0034-7167.20217403e08. PMID: 34320099 MH - *Cardiac Surgical Procedures MH - Humans MH - Intensive Care Units MH - *Nursing Care MH - Nursing, Team MH - Qualitative Research EDAT- 2021/05/06 06:00 MHDA- 2021/06/22 06:00 CRDT- 2021/05/05 12:28 PHST- 2020/03/13 00:00 [received] PHST- 2020/11/01 00:00 [accepted] PHST- 2021/05/05 12:28 [entrez] PHST- 2021/05/06 06:00 [pubmed] PHST- 2021/06/22 06:00 [medline] AID - S0034-71672021000200158 [pii] AID - 10.1590/0034-7167-2020-0163 [doi] PST - epublish SO - Rev Bras Enferm. 2021 May 3;74(2):e20200163. doi: 10.1590/0034-7167-2020-0163. eCollection 2021. PMID- 33949154 OWN - NLM STAT- MEDLINE DCOM- 20220119 LR - 20220119 IS - 2324-9269 (Electronic) IS - 2324-9269 (Linking) VI - 9 IP - 5 DP - 2021 May TI - Association between subjective well-being and perception of medical care system among patients with Marfan syndrome: A cross-sectional study. PG - e1661 LID - 10.1002/mgg3.1661 [doi] LID - e1661 AB - BACKGROUND: This study investigated the association between subjective well-being and perception for collaboration among clinical departments of adult Marfan syndrome (MFS) patients. METHODS: We performed a self-administered questionnaire survey to ask about current medical treatment and support systems and subjective well-being for 114 patients with MFS aged 18-64 years. It was hypothesized that patients' perception of collaboration between clinical departments would raise their subjective well-being. Mean value differences were predicted by a multiple regression analysis model, with supportive medical staff, age, sex, aorta dissection, family history, marriage status, and educational background adjusted. RESULTS: Patients' perception of collaboration between clinical departments and being married raised SWLS scores (mean difference for patients' perception of collaboration versus not = 3.41, 95% CI = 0.28, 6.53, p = .03; for married versus single = 5.22, 95% CI = 1.75, 8.69, p = .003). CONCLUSION: Our results have suggested that it is necessary to maintain and enhance the medical treatment system with the patients for improving the subjective well-being of MFS patients. In addition, the result indicated the need for intervention to the patients themselves and also their family so that it allows patients to receive physical and emotional support from people close to them. CI - (c) 2021 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals LLC. FAU - Shimizu, Tomoko AU - Shimizu T AUID- ORCID: 0000-0003-1181-1362 AD - Division of Health Sciences, Osaka University Graduate School of Medicine, Suita, Osaka, Japan. FAU - Shimizu, Yasuko AU - Shimizu Y AUID- ORCID: 0000-0002-7398-4587 AD - Division of Health Sciences, Osaka University Graduate School of Medicine, Suita, Osaka, Japan. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210505 PL - United States TA - Mol Genet Genomic Med JT - Molecular genetics & genomic medicine JID - 101603758 SB - IM MH - Adolescent MH - Adult MH - Aged MH - *Attitude MH - *Diagnostic Self Evaluation MH - Female MH - Hospital Departments/standards MH - Humans MH - Intersectoral Collaboration MH - Male MH - Marfan Syndrome/epidemiology/*psychology/therapy MH - Marital Status MH - Middle Aged MH - Patient Care Team/*standards MH - Patient Satisfaction MH - Surveys and Questionnaires PMC - PMC8172200 OTO - NOTNLM OT - Marfan syndrome OT - comprehensive health care OT - intersectoral collaboration OT - marital status OT - subjective well-being COIS- All authors have no conflict of interest. EDAT- 2021/05/06 06:00 MHDA- 2022/01/20 06:00 PMCR- 2021/05/05 CRDT- 2021/05/05 06:55 PHST- 2020/07/21 00:00 [revised] PHST- 2020/04/21 00:00 [received] PHST- 2021/03/01 00:00 [accepted] PHST- 2021/05/06 06:00 [pubmed] PHST- 2022/01/20 06:00 [medline] PHST- 2021/05/05 06:55 [entrez] PHST- 2021/05/05 00:00 [pmc-release] AID - MGG31661 [pii] AID - 10.1002/mgg3.1661 [doi] PST - ppublish SO - Mol Genet Genomic Med. 2021 May;9(5):e1661. doi: 10.1002/mgg3.1661. Epub 2021 May 5. PMID- 33949050 OWN - NLM STAT- MEDLINE DCOM- 20210705 LR - 20250103 IS - 1447-0756 (Electronic) IS - 1341-8076 (Linking) VI - 47 IP - 7 DP - 2021 Jul TI - Cardiovascular disease among pregnant women after anticancer therapy. PG - 2278-2290 LID - 10.1111/jog.14812 [doi] AB - Recent advances in cancer therapies have enabled many women diagnosed with malignancies during childhood and adolescence to survive longer and therefore to reach an age where they wish to conceive. When providing cancer treatment such as anticancer drugs and radiotherapy, attention is often paid to preserving future fertility, but little is known about maternal pregnancy risks, and in particular cardiovascular complications. Recent studies have shown that cardiovascular diseases such as cardiomyopathy, heart failure, and arrhythmias often occur during and soon after anticancer therapy. This has led to the emergence of the specialized field of "onco-cardiology" or "cardio-oncology," in which oncologists and cardiologists collaborate, as well as the publication of multiple clinical practice guidelines. The interdisciplinary onco-cardiology team plays an important role in further improving the prognosis of cancer survivors. The current recommendation for women after anticancer therapy who wish to conceive is to undergo cardiovascular screening, regardless of whether there is a history of cardiovascular complications or not, in order to provide preconception counseling. Pregnancies in cancer-survivors, who experience cardiovascular complications, should be managed perinatally by a multidisciplinary team including obstetricians and cardiologists. Absence of cardiovascular disease on screening does not preclude the possibility that new cardiac dysfunction may occur during the perinatal period, especially in women with a history of high-dose anthracycline drug administration and/or radiation therapy. In such high-risk cases, follow-up of cardiac function throughout the perinatal period is required. CI - (c) 2021 Japan Society of Obstetrics and Gynecology. FAU - Aoki-Kamiya, Chizuko AU - Aoki-Kamiya C AD - Department of Obstetrics and Gynecology, National Cerebral and Cardiovascular Center, Osaka, Japan. FAU - Shioyama, Wataru AU - Shioyama W AD - Department of Cardiovascular Medicine, Shiga University of Medical Science, Otsu, Japan. FAU - Nakagawa, Yoshihisa AU - Nakagawa Y AD - Department of Cardiovascular Medicine, Shiga University of Medical Science, Otsu, Japan. FAU - Yoshimatsu, Jun AU - Yoshimatsu J AD - Department of Obstetrics and Gynecology, National Cerebral and Cardiovascular Center, Osaka, Japan. LA - eng PT - Journal Article PT - Review DEP - 20210504 PL - Australia TA - J Obstet Gynaecol Res JT - The journal of obstetrics and gynaecology research JID - 9612761 SB - IM MH - Adolescent MH - *Cardiology MH - *Cardiovascular Diseases MH - Female MH - Humans MH - Medical Oncology MH - *Neoplasms MH - Pregnancy MH - Pregnant People OTO - NOTNLM OT - cancer OT - cardiovascular disease OT - pregnancy EDAT- 2021/05/06 06:00 MHDA- 2021/07/06 06:00 CRDT- 2021/05/05 06:47 PHST- 2021/04/08 00:00 [received] PHST- 2021/04/22 00:00 [accepted] PHST- 2021/05/06 06:00 [pubmed] PHST- 2021/07/06 06:00 [medline] PHST- 2021/05/05 06:47 [entrez] AID - 10.1111/jog.14812 [doi] PST - ppublish SO - J Obstet Gynaecol Res. 2021 Jul;47(7):2278-2290. doi: 10.1111/jog.14812. Epub 2021 May 4. PMID- 33941604 OWN - NLM STAT- MEDLINE DCOM- 20211125 LR - 20211125 IS - 1939-2869 (Electronic) IS - 0891-1150 (Linking) VI - 88 IP - 5 DP - 2021 May 3 TI - CABG: When, why, and how? PG - 295-303 LID - 10.3949/ccjm.88a.20115 [doi] AB - Coronary revascularization has matured as a field since coronary artery bypass grafting (CABG) was first developed over 50 years ago, with diagnostic and treatment methods having advanced dramatically. CABG remains the standard of care for obstructive coronary artery disease, particularly for patients with multivessel disease or diabetes. It is now recognized that not all CABG is created equal-operative strategy, including conduit choice for bypass grafts and target coronary selection, affects survival. A multidisciplinary approach including surgeons with a special interest in CABG is recommended to optimize treatment selection and outcomes. CI - Copyright (c) 2021 The Cleveland Clinic Foundation. All Rights Reserved. FAU - Dimeling, George AU - Dimeling G AD - Department of Thoracic and Cardiovascular Surgery, Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland, OH. FAU - Bakaeen, Laurice AU - Bakaeen L AD - Department of Pharmacy, Marymount Hospital, Cleveland Clinic Health System, Cleveland, OH. FAU - Khatri, Jaikirshan AU - Khatri J AD - Department of Cardiovascular Medicine, Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland, OH; Clinical Assistant Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH. FAU - Bakaeen, Faisal G AU - Bakaeen FG AD - Director, Coronary Revascularization Center, Sheikh Hamdan bin Rashid Al Maktoum Distinguished Chair, Department of Thoracic and Cardiovascular Surgery, Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland, OH; Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH bakaeef@ccf.org. LA - eng PT - Journal Article PT - Review DEP - 20210503 PL - United States TA - Cleve Clin J Med JT - Cleveland Clinic journal of medicine JID - 8703441 SB - IM MH - *Coronary Artery Bypass MH - *Coronary Artery Disease/surgery MH - Humans MH - Treatment Outcome EDAT- 2021/05/05 06:00 MHDA- 2021/11/26 06:00 CRDT- 2021/05/04 06:25 PHST- 2021/05/04 06:25 [entrez] PHST- 2021/05/05 06:00 [pubmed] PHST- 2021/11/26 06:00 [medline] AID - 88/5/295 [pii] AID - 10.3949/ccjm.88a.20115 [doi] PST - epublish SO - Cleve Clin J Med. 2021 May 3;88(5):295-303. doi: 10.3949/ccjm.88a.20115. PMID- 33940193 OWN - NLM STAT- MEDLINE DCOM- 20211123 LR - 20211123 IS - 1916-7075 (Electronic) IS - 0828-282X (Linking) VI - 37 IP - 7 DP - 2021 Jul TI - Real-World Health-Economic Considerations Around Aortic-Valve Replacement in a Publicly Funded Health System. PG - 992-1003 LID - S0828-282X(20)31116-8 [pii] LID - 10.1016/j.cjca.2020.11.015 [doi] AB - Herein, we describe the unique interplay among biomedical ethics, principles of distributive justice, and economic theory to highlight the role of health technology assessments to compare therapeutic options for aortic valve replacement. From the perspective of the Canadian health care system, transcatheter aortic-valve implantation is associated with higher costs but also higher incremental health benefits compared with surgical aortic-valve replacement. At current willingness to pay thresholds, transcatheter aortic-valve replacement is likely cost effective across the spectrum of risk, from inoperable patients to those at low surgical risk. However, we highlight the nuances within each subgroup of surgical risk that merit careful consideration by the heart team. Moreover, incorporation of patients and their preferences in decision-making is key. In particular, in young, low-risk patients, there remains uncertainty regarding the optimal treatment, with unique concerns around valve durability, selection of valve prosthesis, and consideration for special procedures such as the Ross procedure. Nonetheless, current research suggests that, universally, patients prefer a less invasive approach compared with a more invasive approach. Finally, we highlight that there remain critical issues around timeliness of access to care and unacceptable geographic inequities across Canada. Further research into alternative funding mechanisms and integrated cross-sector care pathways is necessary to address these issues. CI - Copyright (c) 2020 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved. FAU - Tam, Derrick Y AU - Tam DY AD - Division of Cardiac Surgery, Department of Surgery, Schulich Heart Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada. FAU - Miranda, Rafael Neves AU - Miranda RN AD - Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; Division of Cardiology, Department of Medicine, Schulich Heart Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; ICES, Toronto, Ontario, Canada. FAU - Elbatarny, Malak AU - Elbatarny M AD - Division of Cardiac Surgery, Department of Surgery, Schulich Heart Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada. FAU - Wijeysundera, Harindra C AU - Wijeysundera HC AD - Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; Division of Cardiology, Department of Medicine, Schulich Heart Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; ICES, Toronto, Ontario, Canada. Electronic address: harindra.wijeysundera@sunnybrook.ca. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20210501 PL - England TA - Can J Cardiol JT - The Canadian journal of cardiology JID - 8510280 SB - IM MH - Aortic Valve/*surgery MH - *Aortic Valve Stenosis/epidemiology/surgery MH - Canada MH - Decision Making, Shared MH - *Heart Valve Prosthesis MH - *Heart Valve Prosthesis Implantation/adverse effects/economics/methods MH - Humans MH - Outcome Assessment, Health Care MH - *Postoperative Complications/epidemiology/prevention & control MH - Public Health Systems Research MH - Risk Adjustment/methods MH - *Transcatheter Aortic Valve Replacement/adverse effects/economics/methods EDAT- 2021/05/04 06:00 MHDA- 2021/11/24 06:00 CRDT- 2021/05/03 20:14 PHST- 2020/09/27 00:00 [received] PHST- 2020/11/25 00:00 [revised] PHST- 2020/11/27 00:00 [accepted] PHST- 2021/05/04 06:00 [pubmed] PHST- 2021/11/24 06:00 [medline] PHST- 2021/05/03 20:14 [entrez] AID - S0828-282X(20)31116-8 [pii] AID - 10.1016/j.cjca.2020.11.015 [doi] PST - ppublish SO - Can J Cardiol. 2021 Jul;37(7):992-1003. doi: 10.1016/j.cjca.2020.11.015. Epub 2021 May 1. PMID- 33932992 OWN - NLM STAT- MEDLINE DCOM- 20211221 LR - 20241127 IS - 1471-2261 (Electronic) IS - 1471-2261 (Linking) VI - 21 IP - 1 DP - 2021 May 1 TI - An Aboriginal and Torres Strait Islander Cardiac Rehabilitation program delivered in a non-Indigenous health service (Yeddung Gauar): a mixed methods feasibility study. PG - 222 LID - 10.1186/s12872-021-02016-3 [doi] LID - 222 AB - BACKGROUND: There is limited evidence of Aboriginal and Torres Strait Islander people attending cardiac rehabilitation (CR) programs despite high levels of heart disease. One key enabler for CR attendance is a culturally safe program. This study evaluates improving access for Aboriginal and Torres Strait Islander women to attend a CR program in a non-Indigenous health service, alongside improving health workforce cultural safety. METHODS: An 18-week mixed-methods feasibility study was conducted, with weekly flexible CR sessions delivered by a multidisciplinary team and an Aboriginal and/or Torres Strait Islander Health Worker (AHW) at a university health centre. Aboriginal and Torres Strait Islander women who were at risk of, or had experienced, a cardiac event were recruited. Data was collected from participants at baseline, and at every sixth-session attended, including measures of disease risk, quality-of-life, exercise capacity and anxiety and depression. Cultural awareness training was provided for health professionals before the program commenced. Assessment of health professionals' cultural awareness pre- and post-program was evaluated using a questionnaire (n = 18). Qualitative data from participants (n = 3), the AHW, health professionals (n = 4) and referrers (n = 4) was collected at the end of the program using yarning methodology and analysed thematically using Charmaz's constant comparative approach. RESULTS: Eight referrals were received for the CR program and four Aboriginal women attended the program, aged from 24 to 68 years. Adherence to the weekly sessions ranged from 65 to 100%. At the program's conclusion, there was a significant change in health professionals' perception of social policies implemented to 'improve' Aboriginal people, and self-reported changes in health professionals' behaviours and skills. Themes were identified for recruitment, participants, health professionals and program delivery, with cultural safety enveloping all areas. Trust was a major theme for recruitment and adherence of participants. The AHW was a key enabler of cultural authenticity, and the flexibility of the program contributed greatly to participant perceptions of cultural safety. Barriers for attendance were not unique to this population. CONCLUSION: The flexible CR program in a non-Indigenous service provided a culturally safe environment for Aboriginal women but referrals were low. Importantly, the combination of cultural awareness training and participation in the program delivery improved health professionals' confidence in working with Aboriginal people. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry (ANZCTR) 12618000581268, http://www.ANZCTR.org.au/ACTRN12618000581268.aspx , registered 16 April 2018. FAU - Freene, Nicole AU - Freene N AUID- ORCID: 0000-0002-2047-7012 AD - Physiotherapy, Faculty of Health, University of Canberra, Bruce, ACT, 2617, Australia. Nicole.Freene@canberra.edu.au. AD - Health Research Institute, University of Canberra, Bruce, ACT, Australia. Nicole.Freene@canberra.edu.au. FAU - Brown, Roslyn AU - Brown R AD - Ngunnawal Centre, Office of Aboriginal and Torres Strait Islander Leadership and Strategy, University of Canberra, Bruce, ACT, Australia. FAU - Collis, Paul AU - Collis P AD - Faculty of Arts and Design, University of Canberra, Bruce, ACT, Australia. FAU - Bourke, Chris AU - Bourke C AD - Australian Healthcare and Hospitals Association, Deakin, ACT, Australia. FAU - Silk, Katharine AU - Silk K AD - Australian Healthcare and Hospitals Association, Deakin, ACT, Australia. FAU - Jackson, Alicia AU - Jackson A AD - Physiotherapy, Faculty of Health, University of Canberra, Bruce, ACT, 2617, Australia. FAU - Davey, Rachel AU - Davey R AD - Health Research Institute, University of Canberra, Bruce, ACT, Australia. FAU - Northam, Holly L AU - Northam HL AD - Nursing, Midwifery and Public Health, Faculty of Health, University of Canberra, Bruce, ACT, Australia. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210501 PL - England TA - BMC Cardiovasc Disord JT - BMC cardiovascular disorders JID - 100968539 SB - IM MH - Adult MH - Aged MH - Attitude of Health Personnel/ethnology MH - Australia MH - *Cardiac Rehabilitation MH - Cultural Characteristics MH - *Culturally Competent Care MH - Feasibility Studies MH - Female MH - Functional Status MH - Health Knowledge, Attitudes, Practice/ethnology MH - Heart Diseases/diagnosis/ethnology/*rehabilitation MH - Humans MH - *Inservice Training MH - Mental Health/ethnology MH - Middle Aged MH - Patient Acceptance of Health Care/ethnology MH - *Patient Care Team MH - Quality of Life MH - Time Factors MH - Treatment Outcome MH - *Women's Health Services MH - Young Adult PMC - PMC8088627 OTO - NOTNLM OT - Cardiovascular disease OT - Coronary heart disease OT - Cultural safety OT - Health workforce OT - Indigenous health OT - Prevention COIS- All authors declare that they have no competing interests. EDAT- 2021/05/03 06:00 MHDA- 2021/12/22 06:00 PMCR- 2021/05/01 CRDT- 2021/05/02 20:24 PHST- 2020/08/15 00:00 [received] PHST- 2021/04/15 00:00 [accepted] PHST- 2021/05/02 20:24 [entrez] PHST- 2021/05/03 06:00 [pubmed] PHST- 2021/12/22 06:00 [medline] PHST- 2021/05/01 00:00 [pmc-release] AID - 10.1186/s12872-021-02016-3 [pii] AID - 2016 [pii] AID - 10.1186/s12872-021-02016-3 [doi] PST - epublish SO - BMC Cardiovasc Disord. 2021 May 1;21(1):222. doi: 10.1186/s12872-021-02016-3. PMID- 33932630 OWN - NLM STAT- MEDLINE DCOM- 20210910 LR - 20210910 IS - 2589-9333 (Electronic) IS - 2589-9333 (Linking) VI - 3 IP - 4 DP - 2021 Jul TI - Impact of type of maternal cardiovascular disease on pregnancy outcomes among women managed in a multidisciplinary cardio-obstetrics program. PG - 100377 LID - S2589-9333(21)00072-0 [pii] LID - 10.1016/j.ajogmf.2021.100377 [doi] AB - BACKGROUND: Maternal cardiovascular disease complicates up to 4% of pregnancies in the United States. Knowledge regarding the impact of the cardiovascular disease category is limited. OBJECTIVE: The purpose of this study was to compare the maternal and neonatal outcomes among women with different types of cardiovascular diseases managed in a multidisciplinary program. STUDY DESIGN: This was a retrospective cohort study of patients with documented structural or functional cardiovascular disease who received care in a multidisciplinary program with maternal-fetal medicine and cardiology specialists at a single institution between March 2010 and November 2019. Women were categorized as having congenital heart disease, acquired heart disease, arrhythmias and channelopathies, or aortopathies. Women were excluded from the pregnancy outcome analysis if they never became pregnant or delivered at a different institution. The outcomes were analyzed according to the disease category using univariate techniques. RESULTS: A total of 232 women with 253 pregnancies met the inclusion criteria for pregnancy outcome analysis. Of these, 77 (30.4%) had congenital heart disease, 63 (24.9%) had acquired heart disease, 94 (37.2%) had arrhythmias or channelopathies, and 19 (7.5%) had aortopathies. Obesity and hypertension were more common among women with acquired heart disease, and women with acquired heart disease and arrhythmias had higher Cardiac Disease in Pregnancy II scores. Most of the pregnancies had good maternal and neonatal outcomes. Preeclampsia occurred more commonly in women with acquired heart disease (27% among those with acquired heart disease vs 10.4% among those with congenital heart disease, 13.8% among those with arrhythmias or channelopathies, and 0% among those with aortopathies; P=.009). Indicated preterm birth was highest among women with acquired heart disease (15.9%). Significant postpartum arrhythmias occurred in 2.4% of women. Preconception counseling was underutilized. CONCLUSION: Most women with preexisting cardiovascular disease experienced good pregnancy and neonatal outcomes when managed in a specialized, multidisciplinary program. Women with acquired heart disease were at highest risk for pregnancy complications such as preeclampsia and preterm birth. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - Quinones, Joanne N AU - Quinones JN AD - Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Lehigh Valley Health Network, Allentown, PA (Drs Quinones and Rochon); Scholarly Excellence, Leadership Experiences, Collaborative Training (SELECT) Program, Morsani College of Medicine, University of South Florida, Tampa, FL (Drs Quinones, Walheim and Rochon); Department of Medicine, Division of Cardiology, Lehigh Valley Heart Institute, Lehigh Valley Health Network, Allentown, PA (Drs Mann and Ahnert). Electronic address: joanne_n.quinones@lvhn.org. FAU - Walheim, Lauren AU - Walheim L AD - Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Lehigh Valley Health Network, Allentown, PA (Drs Quinones and Rochon); Scholarly Excellence, Leadership Experiences, Collaborative Training (SELECT) Program, Morsani College of Medicine, University of South Florida, Tampa, FL (Drs Quinones, Walheim and Rochon); Department of Medicine, Division of Cardiology, Lehigh Valley Heart Institute, Lehigh Valley Health Network, Allentown, PA (Drs Mann and Ahnert). FAU - Mann, Kailyn AU - Mann K AD - Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Lehigh Valley Health Network, Allentown, PA (Drs Quinones and Rochon); Scholarly Excellence, Leadership Experiences, Collaborative Training (SELECT) Program, Morsani College of Medicine, University of South Florida, Tampa, FL (Drs Quinones, Walheim and Rochon); Department of Medicine, Division of Cardiology, Lehigh Valley Heart Institute, Lehigh Valley Health Network, Allentown, PA (Drs Mann and Ahnert). FAU - Rochon, Meredith AU - Rochon M AD - Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Lehigh Valley Health Network, Allentown, PA (Drs Quinones and Rochon); Scholarly Excellence, Leadership Experiences, Collaborative Training (SELECT) Program, Morsani College of Medicine, University of South Florida, Tampa, FL (Drs Quinones, Walheim and Rochon); Department of Medicine, Division of Cardiology, Lehigh Valley Heart Institute, Lehigh Valley Health Network, Allentown, PA (Drs Mann and Ahnert). FAU - Ahnert, Amy M AU - Ahnert AM AD - Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Lehigh Valley Health Network, Allentown, PA (Drs Quinones and Rochon); Scholarly Excellence, Leadership Experiences, Collaborative Training (SELECT) Program, Morsani College of Medicine, University of South Florida, Tampa, FL (Drs Quinones, Walheim and Rochon); Department of Medicine, Division of Cardiology, Lehigh Valley Heart Institute, Lehigh Valley Health Network, Allentown, PA (Drs Mann and Ahnert). LA - eng PT - Journal Article DEP - 20210428 PL - United States TA - Am J Obstet Gynecol MFM JT - American journal of obstetrics & gynecology MFM JID - 101746609 SB - IM MH - *Cardiovascular Diseases/epidemiology MH - Female MH - *Heart Defects, Congenital/complications MH - Humans MH - Infant, Newborn MH - *Obstetrics MH - Pregnancy MH - Pregnancy Outcome/epidemiology MH - *Premature Birth/epidemiology MH - Retrospective Studies MH - United States OTO - NOTNLM OT - cardio-obstetrics program OT - cardiovascular disease OT - high-risk pregnancy OT - multidisciplinary care OT - preeclampsia EDAT- 2021/05/02 06:00 MHDA- 2021/09/11 06:00 CRDT- 2021/05/01 20:12 PHST- 2021/02/09 00:00 [received] PHST- 2021/04/06 00:00 [revised] PHST- 2021/04/12 00:00 [accepted] PHST- 2021/05/02 06:00 [pubmed] PHST- 2021/09/11 06:00 [medline] PHST- 2021/05/01 20:12 [entrez] AID - S2589-9333(21)00072-0 [pii] AID - 10.1016/j.ajogmf.2021.100377 [doi] PST - ppublish SO - Am J Obstet Gynecol MFM. 2021 Jul;3(4):100377. doi: 10.1016/j.ajogmf.2021.100377. Epub 2021 Apr 28. PMID- 33927612 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210502 IS - 1663-9812 (Print) IS - 1663-9812 (Electronic) IS - 1663-9812 (Linking) VI - 12 DP - 2021 TI - Medication-Related Hospital Readmissions Within 30 Days of Discharge: Prevalence, Preventability, Type of Medication Errors and Risk Factors. PG - 567424 LID - 10.3389/fphar.2021.567424 [doi] LID - 567424 AB - Background: Hospital readmission rates are increasingly used as a measure of healthcare quality. Medicines are the most common therapeutic intervention but estimating the contribution of adverse drug events as a cause of readmissions is difficult. Objectives: To assess the prevalence and preventability of medication-related readmissions within 30 days after hospital discharge and to describe the risk factors, type of medication errors and types of medication involved in these preventable readmissions. Design: A cross-sectional observational study. Setting: The study took place across the cardiology, gastroenterology, internal medicine, neurology, psychiatry, pulmonology and general surgery departments in the OLVG teaching hospital, Netherlands. Participants: Patients with an unplanned readmission within 30 days after discharge from an earlier hospitalization (index hospitalization: IH) were reviewed. Measurements: The prevalence and preventability of medication-related readmissions were assessed by residents in multidisciplinary meetings. A senior internist and hospital pharmacist reassessed the prevalence and preventability of identified cases. Generalized estimating equation with logistic regression was performed to identify risk factors of potentially preventable medication-related readmissions. Results: Of 1,111 included readmissions, 181 (16%) were medication-related, of which 72 (40%) were potentially preventable. The number of medication changes at IH (Adjusted odds ratio [OR(adj)]: 1.14; 95% CI: 1.05-1.24) and having >/=3 hospitalizations 6 months before IH (ORadj: 2.11; 95% CI: 1.12-3.98) were risk factors of a preventable medication-related readmission. Of these preventable readmissions, 35% were due to prescribing errors, 35% by non-adherence and 30% by transition errors. Medications most frequently involved were diuretics and antidiabetics. Conclusion: This study shows that 16% of readmissions are medication-related, of which 40% are potentially preventable. If the results are confirmed in larger multicentre studies, this may indicate that more attention should be paid to medication-related harm in order to lower the overall readmission rates. CI - Copyright (c) 2021 Uitvlugt, Janssen, Siegert, Kneepkens, van den Bemt, van den Bemt and Karapinar-Carkit. FAU - Uitvlugt, Elien B AU - Uitvlugt EB AD - Onze Lieve Vrouwe Gasthuis OLVG, Department of Hospital Pharmacy, Amsterdam, Netherlands. FAU - Janssen, Marjo J A AU - Janssen MJA AD - Onze Lieve Vrouwe Gasthuis OLVG, Department of Hospital Pharmacy, Amsterdam, Netherlands. FAU - Siegert, Carl E H AU - Siegert CEH AD - Onze Lieve Vrouwe Gasthuis OLVG, Department of Internal Medicine, Amsterdam, Netherlands. FAU - Kneepkens, Eva L AU - Kneepkens EL AD - Onze Lieve Vrouwe Gasthuis OLVG, Department of Hospital Pharmacy, Amsterdam, Netherlands. FAU - van den Bemt, Bart J F AU - van den Bemt BJF AD - Department of Pharmacy, Sint Maartenskliniek, Nijmegen, Netherlands. AD - Department of Pharmacy, Radboud University Medical Centre, Nijmegen, Netherlands. FAU - van den Bemt, Patricia M L A AU - van den Bemt PMLA AD - Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Groningen, Netherlands. FAU - Karapinar-Carkit, Fatma AU - Karapinar-Carkit F AD - Onze Lieve Vrouwe Gasthuis OLVG, Department of Hospital Pharmacy, Amsterdam, Netherlands. LA - eng PT - Journal Article DEP - 20210413 PL - Switzerland TA - Front Pharmacol JT - Frontiers in pharmacology JID - 101548923 PMC - PMC8077030 OTO - NOTNLM OT - ADEs OT - medication related problem OT - quality of care OT - readmission OT - transitions in care COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/05/01 06:00 MHDA- 2021/05/01 06:01 PMCR- 2021/04/13 CRDT- 2021/04/30 06:51 PHST- 2020/05/29 00:00 [received] PHST- 2021/02/11 00:00 [accepted] PHST- 2021/04/30 06:51 [entrez] PHST- 2021/05/01 06:00 [pubmed] PHST- 2021/05/01 06:01 [medline] PHST- 2021/04/13 00:00 [pmc-release] AID - 567424 [pii] AID - 10.3389/fphar.2021.567424 [doi] PST - epublish SO - Front Pharmacol. 2021 Apr 13;12:567424. doi: 10.3389/fphar.2021.567424. eCollection 2021. PMID- 33926670 OWN - NLM STAT- MEDLINE DCOM- 20210701 LR - 20210701 IS - 1558-5069 (Electronic) VI - 31 IP - 2 DP - 2021 May TI - Value of a Multidisciplinary Team Approach to Treatment of Emphysema. PG - 171-175 LID - S1547-4127(21)00008-6 [pii] LID - 10.1016/j.thorsurg.2021.02.004 [doi] AB - Lung volume reduction surgery can significantly improve quality of life for properly selected patients who are symptomatic despite maximal medical management for emphysema. This requires a well-constructed multidisciplinary team (including transplant) to evaluate and treat these patients. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - Wightman, Sean C AU - Wightman SC AD - Division of Thoracic Surgery, Keck School of Medicine, The University of Southern California, Los Angeles, CA, USA. FAU - McKenna, Robert J Jr AU - McKenna RJ Jr AD - Department of Surgery, John Wayne Cancer Institute, Los Angeles, CA, USA; Thoracic Surgery, Stanford University. Electronic address: Robert.mckenna@providence.org. LA - eng PT - Journal Article PT - Review PL - United States TA - Thorac Surg Clin JT - Thoracic surgery clinics JID - 101198195 SB - IM MH - Anesthesiology MH - Emphysema/*surgery MH - Humans MH - Interdisciplinary Communication MH - Lung/physiology/surgery MH - *Patient Care Team MH - Patient Selection MH - Pneumonectomy/*methods MH - Pulmonary Emphysema/*surgery MH - Pulmonary Medicine/methods/*organization & administration MH - Quality of Life MH - Radiology MH - Thoracic Surgery/*organization & administration MH - Treatment Outcome OTO - NOTNLM OT - LVRS OT - Lung volume reduction surgery OT - National emphysema treatment trial (NETT) COIS- Disclosure None. EDAT- 2021/05/01 06:00 MHDA- 2021/07/02 06:00 CRDT- 2021/04/30 05:50 PHST- 2021/04/30 05:50 [entrez] PHST- 2021/05/01 06:00 [pubmed] PHST- 2021/07/02 06:00 [medline] AID - S1547-4127(21)00008-6 [pii] AID - 10.1016/j.thorsurg.2021.02.004 [doi] PST - ppublish SO - Thorac Surg Clin. 2021 May;31(2):171-175. doi: 10.1016/j.thorsurg.2021.02.004. PMID- 33926336 OWN - NLM STAT- MEDLINE DCOM- 20211028 LR - 20211028 IS - 1745-5065 (Electronic) IS - 1745-5057 (Print) IS - 1745-5057 (Linking) VI - 17 DP - 2021 Jan-Dec TI - Report from a large and comprehensive single-center Women's Health Cardiology Clinic. PG - 17455065211013767 LID - 10.1177/17455065211013767 [doi] LID - 17455065211013767 AB - OBJECTIVE: This article describes the women population and work at a unique Women's Health Cardiology Clinic in order to raise cardiovascular disease awareness with an emphasis on women-specific risk factors, and thus to improve women's clinical outcomes. This expectantly will aid in opening similar centers allowing more women to get superior care. METHODS: Electronic medical records of women referred to the Women's Health Cardiology Clinic were analyzed. The statistical analysis is descriptive in nature. Women's Health Cardiology Clinic personnel work as a multidisciplinary team, and patients receive specialized diagnostic tests and treatments. Referrals are by physicians according to traditional and women's specific risk factors for cardiovascular disease. RESULTS: 985 women visited the Women's Health Cardiology Clinic, accumulating 2062 visits. Median age was 57.5 years. The majority of the women were menopausal (575 women, 58%), 62 pregnant with complications and 25 oncology patients. At least, 30% of women had diabetes/hypertension/or dyslipidemia. 72 women had a history of either cerebrovascular event or acute coronary syndrome, and 139 women had evidence of atherosclerosis. Overall, 388 women underwent endothelial function test, 40% of these women had a score indicating endothelial dysfunction. 277 women underwent a psychological intervention. CONCLUSION: Described here are the experiences from a multidisciplinary Women's Health Cardiology Clinic using a gender-specific cardiovascular care approach for women geared toward improved health and wellbeing. It is of utmost importance that this report will raise women-specific cardiovascular disease risk factors awareness in order to promote women's cardiovascular and overall health. FAU - Schuchalter Ludmir, Shlomit AU - Schuchalter Ludmir S AUID- ORCID: 0000-0003-3852-0506 AD - Department of Internal Medicine "A," Assuta Ashdod, Ashdod, Israel. FAU - Bental, Tamir AU - Bental T AD - Department of Cardiology, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel. AD - Sackler Faculty of Medicine, Tel-Aviv, Israel. FAU - Itzhaki Ben Zadok, Osnat AU - Itzhaki Ben Zadok O AD - Department of Cardiology, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel. AD - Sackler Faculty of Medicine, Tel-Aviv, Israel. FAU - Eisen, Alon AU - Eisen A AD - Department of Cardiology, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel. AD - Sackler Faculty of Medicine, Tel-Aviv, Israel. FAU - Shochat, Tzippy AU - Shochat T AD - Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel. FAU - Heruti, Irit AU - Heruti I AD - Department of Psychology, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel. FAU - Kornowski, Ran AU - Kornowski R AD - Department of Cardiology, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel. AD - Sackler Faculty of Medicine, Tel-Aviv, Israel. FAU - Porter, Avital AU - Porter A AD - Department of Cardiology, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel. AD - Sackler Faculty of Medicine, Tel-Aviv, Israel. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Womens Health (Lond) JT - Women's health (London, England) JID - 101271249 SB - IM MH - *Cardiology MH - *Cardiovascular Diseases/epidemiology MH - Female MH - Humans MH - *Hypertension MH - Middle Aged MH - Pregnancy MH - Risk Factors MH - Women's Health PMC - PMC8111522 OTO - NOTNLM OT - cardiovascular disease OT - women-specific risk factors OT - women's health COIS- Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2021/05/01 06:00 MHDA- 2021/10/29 06:00 PMCR- 2021/04/29 CRDT- 2021/04/30 05:36 PHST- 2021/04/30 05:36 [entrez] PHST- 2021/05/01 06:00 [pubmed] PHST- 2021/10/29 06:00 [medline] PHST- 2021/04/29 00:00 [pmc-release] AID - 10.1177_17455065211013767 [pii] AID - 10.1177/17455065211013767 [doi] PST - ppublish SO - Womens Health (Lond). 2021 Jan-Dec;17:17455065211013767. doi: 10.1177/17455065211013767. PMID- 33926210 OWN - NLM STAT- MEDLINE DCOM- 20211015 LR - 20240610 IS - 1941-7705 (Electronic) IS - 1941-7713 (Print) IS - 1941-7713 (Linking) VI - 14 IP - 5 DP - 2021 May TI - Provider Care Team Segregation and Operative Mortality Following Coronary Artery Bypass Grafting. PG - e007778 LID - 10.1161/CIRCOUTCOMES.120.007778 [doi] AB - BACKGROUND: Studies have shown that Black patients die more frequently following coronary artery bypass grafting than their White counterparts for reasons not fully explained by disease severity or comorbidity. To examine whether provider care team segregation within hospitals contributes to this inequity, we analyzed national Medicare data. METHODS: Using national Medicare data, we identified beneficiaries who underwent coronary artery bypass grafting at hospitals where this procedure was performed on at least 10 Black and 10 White patients between 2008 and 2014 (n=12 646). After determining the providers who participated in their perioperative care, we examined the extent to which Black and White patients were cared for by unique networks of provider care teams within the same hospital. We then evaluated whether a lack of overlap in composition of the provider care teams treating Black versus White patients (ie, high segregation) was associated with higher 90-day operative mortality among Black patients. RESULTS: The median level of provider care team segregation was high (0.89) but varied across hospitals (interquartile range, 0.85-0.90). On multivariable analysis, after controlling for patient-, hospital-, and community-level differences, mortality rates for White patients were comparable at hospitals with high and low levels of provider care segregation (5.4% [95% CI, 4.7%-6.1%] versus 5.8% [95% CI, 4.7%-7.0%], respectively; P=0.601), while Black patients treated at high-segregation hospitals had significantly higher mortality than those treated at low-segregation hospitals (8.3% [95% CI, 5.4%-12.4%] versus 3.3% [95% CI, 2.0%-5.4%], respectively; P=0.017). The difference in mortality rates for Black and White patients treated at low-segregation hospitals was nonsignificant (-2.5%; P=0.098). CONCLUSIONS: Black patients who undergo coronary artery bypass grafting at a hospital with a higher level of provider care team segregation die more frequently after surgery than Black patients treated at a hospital with a lower level. FAU - Hollingsworth, John M AU - Hollingsworth JM AD - Department of Urology (J.M.H., P.L.Y.), University of Michigan Medical School, Ann Arbor. FAU - Yu, Xianshi AU - Yu X AD - Michigan Integrated Center for Health Analytics and Medical Prediction, University of Michigan, Ann Arbor (X.Y., H.Y., J.Z., A.K.W., B.K.N.). AD - Department of Statistics, University of Michigan College of Literature, Science, and Arts, Ann Arbor (X.Y., H.Y., J.Z.). FAU - Yan, Phyllis L AU - Yan PL AD - Department of Urology (J.M.H., P.L.Y.), University of Michigan Medical School, Ann Arbor. FAU - Yoo, Hyesun AU - Yoo H AD - Michigan Integrated Center for Health Analytics and Medical Prediction, University of Michigan, Ann Arbor (X.Y., H.Y., J.Z., A.K.W., B.K.N.). AD - Department of Statistics, University of Michigan College of Literature, Science, and Arts, Ann Arbor (X.Y., H.Y., J.Z.). FAU - Telem, Dana A AU - Telem DA AD - Department of Surgery (D.A.T.), University of Michigan Medical School, Ann Arbor. FAU - Yankah, Ekow N AU - Yankah EN AD - Cardozo Law School, New York, NY (E.N.Y.). FAU - Zhu, Ji AU - Zhu J AD - Michigan Integrated Center for Health Analytics and Medical Prediction, University of Michigan, Ann Arbor (X.Y., H.Y., J.Z., A.K.W., B.K.N.). AD - Department of Statistics, University of Michigan College of Literature, Science, and Arts, Ann Arbor (X.Y., H.Y., J.Z.). FAU - Waljee, Akbar K AU - Waljee AK AD - Division of Gastroenterology and Hepatology (A.K.W.), University of Michigan Medical School, Ann Arbor. AD - Department of Internal Medicine (A.K.W., B.K.N.), University of Michigan Medical School, Ann Arbor. AD - Michigan Integrated Center for Health Analytics and Medical Prediction, University of Michigan, Ann Arbor (X.Y., H.Y., J.Z., A.K.W., B.K.N.). AD - VA Center for Clinical Management Research, VA Ann Arbor Health Care System, MI (A.K.W., B.K.N.). FAU - Nallamothu, Brahmajee K AU - Nallamothu BK AD - and Division of Cardiology (B.K.N.), University of Michigan Medical School, Ann Arbor. AD - Department of Internal Medicine (A.K.W., B.K.N.), University of Michigan Medical School, Ann Arbor. AD - Michigan Integrated Center for Health Analytics and Medical Prediction, University of Michigan, Ann Arbor (X.Y., H.Y., J.Z., A.K.W., B.K.N.). AD - VA Center for Clinical Management Research, VA Ann Arbor Health Care System, MI (A.K.W., B.K.N.). LA - eng GR - R01 DK121709/DK/NIDDK NIH HHS/United States GR - R01 HS024728/HS/AHRQ HHS/United States GR - R01 HS024525/HS/AHRQ HHS/United States GR - R01 HS026908/HS/AHRQ HHS/United States GR - R01 AG068074/AG/NIA NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, U.S. Gov't, P.H.S. PT - Retracted Publication DEP - 20210430 PL - United States TA - Circ Cardiovasc Qual Outcomes JT - Circulation. Cardiovascular quality and outcomes JID - 101489148 SB - IM RIN - Circ Cardiovasc Qual Outcomes. 2023 Nov;16(11):e000125. doi: 10.1161/HCQ.0000000000000125. PMID: 37988442 MH - Black or African American MH - Aged MH - *Coronary Artery Bypass/adverse effects MH - Hospital Mortality MH - Humans MH - *Medicare MH - Patient Care Team MH - United States/epidemiology PMC - PMC8137653 MID - NIHMS1689686 OTO - NOTNLM OT - Medicare OT - comorbidity OT - coronary artery disease OT - hospitals OT - mortality COIS- Disclosure Statement There are no relevant disclosures or conflicts of interest for the authors. EDAT- 2021/05/01 06:00 MHDA- 2021/10/16 06:00 PMCR- 2022/05/01 CRDT- 2021/04/30 05:31 PHST- 2021/05/01 06:00 [pubmed] PHST- 2021/10/16 06:00 [medline] PHST- 2021/04/30 05:31 [entrez] PHST- 2022/05/01 00:00 [pmc-release] AID - 10.1161/CIRCOUTCOMES.120.007778 [doi] PST - ppublish SO - Circ Cardiovasc Qual Outcomes. 2021 May;14(5):e007778. doi: 10.1161/CIRCOUTCOMES.120.007778. Epub 2021 Apr 30. PMID- 33919643 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210518 IS - 2075-4418 (Print) IS - 2075-4418 (Electronic) IS - 2075-4418 (Linking) VI - 11 IP - 4 DP - 2021 Apr 18 TI - Advantages of 18F-FDG PET/CT Imaging over Modified Duke Criteria and Clinical Presumption in Patients with Challenging Suspicion of Infective Endocarditis. LID - 10.3390/diagnostics11040720 [doi] LID - 720 AB - According to European Society of Cardiology guidelines (ESC2015) for infective endocarditis (IE) management, modified Duke criteria (mDC) are implemented with a degree of clinical suspicion degree, leading to grades such as "possible" or "rejected" IE despite a persisting high level of clinical suspicion. Herein, we evaluate the (18)F-FDG PET/CT diagnostic and therapeutic impact in IE suspicion, with emphasis on possible/rejected IE with a high clinical suspicion. Excluding cases of definite IE diagnosis, 53 patients who underwent (18)F-FDG PET/CT for IE suspicion were selected and afterwards classified according to both mDC (possible IE/Duke 1, rejected IE/Duke 0) and clinical suspicion degree (high and low IE suspicion). The final status regarding IE diagnosis (gold standard) was based on the multidisciplinary decision of the Endocarditis Team, including the 'imaging specialist'. PET/CT images of the cardiac area were qualitatively interpreted and the intensity of each focus of extra-physiologic (18)F-FDG uptake was evaluated by a maximum standardized uptake value (SUVmax) measurement. Extra-cardiac (18)F-FDG PET/CT pathological findings were considered to be a possible embolic event, a possible source of IE, or even a concomitant infection. Based on the Endocarditis Team consensus, final diagnosis of IE was retained in 19 (36%) patients and excluded in 34 (64%). With a sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and global accuracy of 79%, 100%, 100%, 89%, and 92%, respectively, PET/CT performed significantly better than mDC (p = 0.003), clinical suspicion degree (p = 0.001), and a combination of both (p = 0.001) for IE diagnosis. In 41 patients with possible/rejected IE but high clinical suspicion, sensitivity, specificity, PPV, NPV, and global accuracies were 78%, 100%, 100%, 85%, and 90%, respectively. Moreover, PET/CT contributed to patient management in 24 out of 53 (45%) cases. (18)F-FDG PET/CT represents a valuable diagnostic tool that could be proposed for challenging IE cases with significant differences between mDC and clinical suspicion degree. (18)F-FDG PET/CT allows a binary diagnosis (definite or rejected IE) by removing uncertain diagnostic situations, thus improving patient therapeutic management. FAU - Pretet, Valentin AU - Pretet V AD - Nuclear Medicine and Molecular Imaging, ICANS, University Hospitals of Strasbourg, rue Albert Calmette, 67093 Strasbourg, France. FAU - Blondet, Cyrille AU - Blondet C AD - Nuclear Medicine and Molecular Imaging, ICANS, University Hospitals of Strasbourg, rue Albert Calmette, 67093 Strasbourg, France. AD - Faculty of Medicine, FMTS, University of Strasbourg, 67000 Strasbourg, France. FAU - Ruch, Yvon AU - Ruch Y AUID- ORCID: 0000-0002-4713-9478 AD - Faculty of Medicine, FMTS, University of Strasbourg, 67000 Strasbourg, France. AD - Infectious Diseases, University Hospitals of Strasbourg, 67000 Strasbourg, France. FAU - Martinez, Matias AU - Martinez M AD - Nuclear Medicine and Molecular Imaging, ICANS, University Hospitals of Strasbourg, rue Albert Calmette, 67093 Strasbourg, France. AD - Nuclear Medicine and Molecular Imaging, Oulton Institute, 5000 Cordoba, Argentina. AD - Nuclear Medicine, Hospital Privado Universitario, 5000 Cordoba, Argentina. FAU - El Ghannudi, Soraya AU - El Ghannudi S AUID- ORCID: 0000-0002-3706-8039 AD - Nuclear Medicine and Molecular Imaging, ICANS, University Hospitals of Strasbourg, rue Albert Calmette, 67093 Strasbourg, France. AD - Radiology, University Hospitals of Strasbourg, 67000 Strasbourg, France. FAU - Morel, Olivier AU - Morel O AD - Cardiology, University Hospitals of Strasbourg, 67000 Strasbourg, France. FAU - Hansmann, Yves AU - Hansmann Y AUID- ORCID: 0000-0001-8903-0027 AD - Faculty of Medicine, FMTS, University of Strasbourg, 67000 Strasbourg, France. AD - Infectious Diseases, University Hospitals of Strasbourg, 67000 Strasbourg, France. FAU - Schindler, Thomas H AU - Schindler TH AD - Mallinckrodt Institute of Radiology, Division of Nuclear Medicine, Washington University, St Louis, MO 63110, USA. FAU - Imperiale, Alessio AU - Imperiale A AD - Nuclear Medicine and Molecular Imaging, ICANS, University Hospitals of Strasbourg, rue Albert Calmette, 67093 Strasbourg, France. AD - Faculty of Medicine, FMTS, University of Strasbourg, 67000 Strasbourg, France. AD - Molecular Imaging-DRHIM, IPHC, UMR 7178, CNRS, 67037 Strasbourg, France. LA - eng PT - Journal Article DEP - 20210418 PL - Switzerland TA - Diagnostics (Basel) JT - Diagnostics (Basel, Switzerland) JID - 101658402 PMC - PMC8073326 OTO - NOTNLM OT - 18F-FDG PET/CT OT - infective endocarditis OT - modified Duke criteria COIS- The authors declare no conflict of interest. EDAT- 2021/05/01 06:00 MHDA- 2021/05/01 06:01 PMCR- 2021/04/18 CRDT- 2021/04/30 01:13 PHST- 2021/03/29 00:00 [received] PHST- 2021/04/12 00:00 [revised] PHST- 2021/04/16 00:00 [accepted] PHST- 2021/04/30 01:13 [entrez] PHST- 2021/05/01 06:00 [pubmed] PHST- 2021/05/01 06:01 [medline] PHST- 2021/04/18 00:00 [pmc-release] AID - diagnostics11040720 [pii] AID - diagnostics-11-00720 [pii] AID - 10.3390/diagnostics11040720 [doi] PST - epublish SO - Diagnostics (Basel). 2021 Apr 18;11(4):720. doi: 10.3390/diagnostics11040720. PMID- 33919045 OWN - NLM STAT- MEDLINE DCOM- 20210514 LR - 20210526 IS - 1648-9144 (Electronic) IS - 1010-660X (Print) IS - 1010-660X (Linking) VI - 57 IP - 5 DP - 2021 Apr 21 TI - Interventions after Arterial Switch: A Single Low Case-Volume Center Experience. LID - 10.3390/medicina57050401 [doi] LID - 401 AB - Background and Objectives: With the growing population of arterial switch operation survivors, the rate of late complications associated with the operation is growing as well. The aim of this publication is to share our experience and encourage collaboration between congenital cardiac surgeons and interventional cardiologists in treating late complications after arterial switch operation. Materials and Methods: A retrospective analysis of Vilnius University Santaros Clinics Cardiothoracic Surgery Centre arterial switch operation survivors who underwent additional treatment for late neo-pulmonary artery stenosis and aortic arch obstruction between 1989 and 2019 was conducted. Results: Out of 95 arterial switch operation survivors 14 (15%) underwent 36 reinterventions. The majority were treated for neo-pulmonary stenosis. The median time from arterial switch operation to the first reintervention was 1.4 years (interquartile range, 2 months to 2.4 years). 1, 3, 5, and 10 years intervention-free survival in patients treated for neo-pulmonary stenosis and aortic arch obstruction was 98, 94, 94, and 93% vs. 95, 94, 94, and 93%, respectively. There were no complications associated with redo surgical procedures, while eight patients who underwent catheter-based interventional treatment had treatment-related complications, including one death. Conclusions: Both neo-pulmonary stenosis and aortic arch obstruction (new aortic coarctations or aortic recoarctations) tend to develop in the first decade after an arterial switch operation. Surgical and catheter-based interventional treatment with good results is possible even in a small volume center. Close collaboration of the congenital heart team (congenital cardiac surgeons and interventional cardiologists) in choosing the best treatment option for an individual patient helps to minimize the risk of potential complications. FAU - Jonas, Karolis AU - Jonas K AD - Center of Cardiothoracic Surgery, Clinic of Cardiovascular Diseases, Institute of Clinical Medicine, Vilnius University Faculty of Medicine, Santariskiu St. 2, LT-08661 Vilnius, Lithuania. FAU - Jakutis, Virginijus AU - Jakutis V AD - Clinic of Anesthesiology and Intensive Care, Institute of Clinical Medicine, Vilnius University Faculty of Medicine, Santariskiu St. 2, LT-08661 Vilnius, Lithuania. FAU - Sudikiene, Rita AU - Sudikiene R AD - Center of Cardiothoracic Surgery, Clinic of Cardiovascular Diseases, Institute of Clinical Medicine, Vilnius University Faculty of Medicine, Santariskiu St. 2, LT-08661 Vilnius, Lithuania. FAU - Lebetkevicius, Virgilijus AU - Lebetkevicius V AD - Center of Cardiothoracic Surgery, Clinic of Cardiovascular Diseases, Institute of Clinical Medicine, Vilnius University Faculty of Medicine, Santariskiu St. 2, LT-08661 Vilnius, Lithuania. FAU - Tarutis, Virgilijus AU - Tarutis V AD - Center of Cardiothoracic Surgery, Clinic of Cardiovascular Diseases, Institute of Clinical Medicine, Vilnius University Faculty of Medicine, Santariskiu St. 2, LT-08661 Vilnius, Lithuania. LA - eng PT - Journal Article DEP - 20210421 PL - Switzerland TA - Medicina (Kaunas) JT - Medicina (Kaunas, Lithuania) JID - 9425208 SB - IM MH - Aorta MH - *Arterial Switch Operation/adverse effects MH - Follow-Up Studies MH - Humans MH - Infant MH - Postoperative Complications/epidemiology MH - Reoperation MH - Retrospective Studies MH - *Transposition of Great Vessels/surgery MH - Treatment Outcome PMC - PMC8142980 OTO - NOTNLM OT - aortic arch obstruction after arterial switch operation OT - catheter-based treatment after arterial switch operation OT - late complications after arterial switch operation OT - pulmonary stenosis after arterial switch operation COIS- The authors declare no conflict of interest. EDAT- 2021/05/01 06:00 MHDA- 2021/05/15 06:00 PMCR- 2021/04/21 CRDT- 2021/04/30 01:11 PHST- 2021/03/05 00:00 [received] PHST- 2021/04/06 00:00 [revised] PHST- 2021/04/19 00:00 [accepted] PHST- 2021/04/30 01:11 [entrez] PHST- 2021/05/01 06:00 [pubmed] PHST- 2021/05/15 06:00 [medline] PHST- 2021/04/21 00:00 [pmc-release] AID - medicina57050401 [pii] AID - medicina-57-00401 [pii] AID - 10.3390/medicina57050401 [doi] PST - epublish SO - Medicina (Kaunas). 2021 Apr 21;57(5):401. doi: 10.3390/medicina57050401. PMID- 33914438 OWN - NLM STAT- MEDLINE DCOM- 20210505 LR - 20210505 IS - 1533-4406 (Electronic) IS - 0028-4793 (Linking) VI - 384 IP - 17 DP - 2021 Apr 29 TI - Zoom Family Meeting. PG - 1586-1587 LID - 10.1056/NEJMp2035869 [doi] FAU - Lee, Thomas H AU - Lee TH AD - From Brigham and Women's Hospital and Press Ganey - both in Boston. LA - eng PT - Journal Article DEP - 20210424 PL - United States TA - N Engl J Med JT - The New England journal of medicine JID - 0255562 SB - IM MH - Female MH - Heart Failure/complications MH - Humans MH - Male MH - *Patient Care Team MH - *Professional-Family Relations MH - Renal Insufficiency/etiology MH - *Telemedicine EDAT- 2021/04/30 06:00 MHDA- 2021/05/06 06:00 CRDT- 2021/04/29 12:46 PHST- 2021/04/29 12:46 [entrez] PHST- 2021/04/30 06:00 [pubmed] PHST- 2021/05/06 06:00 [medline] AID - 10.1056/NEJMp2035869 [doi] PST - ppublish SO - N Engl J Med. 2021 Apr 29;384(17):1586-1587. doi: 10.1056/NEJMp2035869. Epub 2021 Apr 24. PMID- 33911022 OWN - NLM STAT- MEDLINE DCOM- 20211122 LR - 20211122 IS - 2053-3624 (Print) IS - 2053-3624 (Electronic) IS - 2053-3624 (Linking) VI - 8 IP - 1 DP - 2021 Apr TI - Transcatheter mitral valve repair: an overview of current and future devices. LID - 10.1136/openhrt-2020-001564 [doi] LID - e001564 AB - The field of transcatheter mitral valve repair (TMVr) for mitral regurgitation (MR) is rapidly evolving. Besides the well-established transcatheter mitral edge-to-edge repair approach, there is also growing evidence for therapeutic strategies targeting the mitral annulus and mitral valve chordae. A patient-tailored approach, careful patient selection and an experienced interventional team is crucial in order to optimise procedural and clinical outcomes. With further data from ongoing clinical trials to be expected, consensus in the Heart Team is needed to address these complexities and determine the most appropriate TMVr therapy, either single or combined, for patients with severe MR. CI - (c) Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - De Backer, Ole AU - De Backer O AUID- ORCID: 0000-0002-9674-0278 AD - Cardiology, Rigshospitalet, Kobenhavn, Denmark ole.debacker@gmail.com. FAU - Wong, Ivan AU - Wong I AD - Cardiology, Rigshospitalet, Kobenhavn, Denmark. FAU - Taramasso, Maurizio AU - Taramasso M AD - Department of Cardiothoracic Surgery, University Hospital Zurich, Zurich, Switzerland. FAU - Maisano, Francesco AU - Maisano F AD - Valve Center, Ospedale San Raffaele, Milan, Italy. FAU - Franzen, Olaf AU - Franzen O AD - Hirslanden Klinik im Park, Zurich, Switzerland. FAU - Sondergaard, Lars AU - Sondergaard L AD - Cardiology, Rigshospitalet, Kobenhavn, Denmark. LA - eng PT - Comparative Study PT - Journal Article PT - Review PL - England TA - Open Heart JT - Open heart JID - 101631219 SB - IM EIN - Open Heart. 2021 Jun;8(1):e001564corr1. doi: 10.1136/openhrt-2020-001564corr1. PMID: 34083393 MH - Cardiac Catheterization/*adverse effects MH - Cardiac Surgical Procedures/*instrumentation/trends MH - Cardiac Valve Annuloplasty/methods MH - Chordae Tendineae/pathology/surgery MH - Heart Valve Prosthesis Implantation/*adverse effects MH - Humans MH - Mitral Valve/pathology/*surgery MH - Mitral Valve Insufficiency/*surgery MH - Patient Selection MH - Treatment Outcome PMC - PMC8094333 OTO - NOTNLM OT - endovascular procedures OT - heart valve prosthesis implantation OT - mitral valve insufficiency COIS- Competing interests: ODB received institutional research grants and consulting fees from Abbott and Boston Scientific. MT is a consultant for Abbott Vascular, Boston Scientific and 4tech; received personal fees from Edwards Lifesciences, Mitraltech, CoreMedic and Swissvortex; and is a shareholder of 4Tech. FM obtained grant and/or research institutional support from Abbott, Medtronic, Edwards Lifesciences, Biotronik, Boston Scientific Corporation, NVT, Terumo, Consulting fees, Honoraria personal and institutional from Abbott, Medtronic, Edwards Lifesciences, Xeltis, Cardiovalve, Occlufit, Simulands, Occlufit; has Royalty Income/IP Rights Edwards Lifesciences; and is shareholder (including share options) of Cardiogard, Magenta, SwissVortex, Transseptal solutions, Occlufit, 4Tech, Perifect. LS received institutional research grants and consulting fees from Abbott, Boston Scientific, Medtronic and Edwards Lifesciences. All other coauthors have no conflict of interest to disclose concerning this manuscript. EDAT- 2021/04/30 06:00 MHDA- 2021/11/23 06:00 PMCR- 2021/04/28 CRDT- 2021/04/29 05:48 PHST- 2020/12/31 00:00 [received] PHST- 2021/02/19 00:00 [revised] PHST- 2021/04/12 00:00 [accepted] PHST- 2021/04/29 05:48 [entrez] PHST- 2021/04/30 06:00 [pubmed] PHST- 2021/11/23 06:00 [medline] PHST- 2021/04/28 00:00 [pmc-release] AID - openhrt-2020-001564 [pii] AID - 10.1136/openhrt-2020-001564 [doi] PST - ppublish SO - Open Heart. 2021 Apr;8(1):e001564. doi: 10.1136/openhrt-2020-001564. PMID- 33909349 OWN - NLM STAT- MEDLINE DCOM- 20211019 LR - 20260304 IS - 1522-726X (Electronic) IS - 1522-1946 (Linking) VI - 98 IP - 2 DP - 2021 Aug 1 TI - SCAI expert consensus update on best practices in the cardiac catheterization laboratory: This statement was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), and the Heart Rhythm Society (HRS) in April 2021. PG - 255-276 LID - 10.1002/ccd.29744 [doi] AB - The current document commissioned by the Society for Cardiovascular Angiography and Interventions (SCAI) and endorsed by the American College of Cardiology, the American Heart Association, and Heart Rhythm Society represents a comprehensive update to the 2012 and 2016 consensus documents on patient-centered best practices in the cardiac catheterization laboratory. Comprising updates to staffing and credentialing, as well as evidence-based updates to the pre-, intra-, and post-procedural logistics, clinical standards and patient flow, the document also includes an expanded section on CCL governance, administration, and approach to quality metrics. This update also acknowledges the collaboration with various specialties, including discussion of the heart team approach to management, and working with electrophysiology colleagues in particular. It is hoped that this document will be utilized by hospitals, health systems, as well as regulatory bodies involved in assuring and maintaining quality, safety, efficiency, and cost-effectiveness of patient throughput in this high volume area. CI - (c) 2021 Wiley Periodicals LLC. FAU - Naidu, Srihari S AU - Naidu SS AD - Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, New York, USA. FAU - Abbott, J Dawn AU - Abbott JD AUID- ORCID: 0000-0002-2560-0155 AD - Cardiovascular Institute of Lifespan, Division of Cardiology, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA. FAU - Bagai, Jayant AU - Bagai J AD - Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA. FAU - Blankenship, James AU - Blankenship J AUID- ORCID: 0000-0003-4966-533X AD - Cardiology Division, The University of New Mexico, Albuquerque, New Mexico, USA. FAU - Garcia, Santiago AU - Garcia S AUID- ORCID: 0000-0003-3715-8082 AD - Minneapolis Heart Institute, Minneapolis, Minnesota, USA. FAU - Iqbal, Sohah N AU - Iqbal SN AD - Mass General Brigham Salem Hospital, Salem, Massachusetts, USA. FAU - Kaul, Prashant AU - Kaul P AD - Piedmont Heart Institute, Atlanta, Georgia, USA. FAU - Khuddus, Matheen A AU - Khuddus MA AD - The Cardiac and Vascular Institute and North Florida Regional Medical Center, Gainesville, Florida, USA. FAU - Kirkwood, Lorrena AU - Kirkwood L AD - Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, New York, USA. FAU - Manoukian, Steven V AU - Manoukian SV AD - HCA Healthcare, Nashville, Tennessee, USA. FAU - Patel, Manesh R AU - Patel MR AD - Duke University Medical Center and Duke Clinical Research Institute, Durham, North Carolina, USA. FAU - Skelding, Kimberly AU - Skelding K AD - Confluence Health, Wenatchee, Washington, USA. FAU - Slotwiner, David AU - Slotwiner D AD - Division of Cardiology, New York Presbyterian, Weill Cornell Medicine Population Health Sciences, Queens, New York, USA. FAU - Swaminathan, Rajesh V AU - Swaminathan RV AD - Duke University Medical Center and Duke Clinical Research Institute, Durham, North Carolina, USA. FAU - Welt, Frederick G AU - Welt FG AUID- ORCID: 0000-0003-1802-0491 AD - Division of Cardiovascular Medicine, University of Utah Health, Salt Lake City, Utah, USA. FAU - Kolansky, Daniel M AU - Kolansky DM AD - Division of Cardiovascular Medicine, Perelman School of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA. LA - eng PT - Consensus Statement PT - Journal Article DEP - 20210519 PL - United States TA - Catheter Cardiovasc Interv JT - Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions JID - 100884139 SB - IM MH - *American Heart Association MH - Angiography MH - Cardiac Catheterization MH - *Cardiology MH - Humans MH - Laboratories MH - Treatment Outcome MH - United States OTO - NOTNLM OT - appropriate use OT - econonics/cost-effectiveness OT - electrophysiology OT - evidence-based medicine OT - health care outcomes OT - health care policy EDAT- 2021/04/29 06:00 MHDA- 2021/10/21 06:00 CRDT- 2021/04/28 12:33 PHST- 2021/04/23 00:00 [received] PHST- 2021/04/23 00:00 [accepted] PHST- 2021/04/29 06:00 [pubmed] PHST- 2021/10/21 06:00 [medline] PHST- 2021/04/28 12:33 [entrez] AID - 10.1002/ccd.29744 [doi] PST - ppublish SO - Catheter Cardiovasc Interv. 2021 Aug 1;98(2):255-276. doi: 10.1002/ccd.29744. Epub 2021 May 19. PMID- 33907969 OWN - NLM STAT- MEDLINE DCOM- 20210625 LR - 20261010 IS - 1708-0428 (Electronic) IS - 0960-8923 (Linking) VI - 31 IP - 7 DP - 2021 Jul TI - Development of the "OS-SEV90 Score" to Predict Severe Postoperative Complications at 90 Days Following Bariatric Surgery. PG - 3053-3064 LID - 10.1007/s11695-021-05367-0 [doi] AB - BACKGROUND: Bariatric surgery may be associated with severe postoperative complications (SPC). Factors associated with the risk of SPC have not been fully investigated. OBJECTIVES: This study aimed to identify preoperative risk factors of SPC within 90 days and to develop a risk prediction model based on these factors. METHODS: We conducted a retrospective single-center cohort study based on a prospectively maintained database of obese patients undergoing laparoscopic bariatric surgery from October 2005 to May 2019. All SPC occurring up to the 90th postoperative day were recorded according to the Dindo-Clavien classification. Associations between potential risk factors and SPC were analyzed using a logistic regression model, and the risk prediction ("OS-SEV90 score") was computed. Based on the OS-SEV90 score, the patients were grouped into 3 categories of risk: low, intermediate, and high. RESULTS: Among 1963 consecutive patients, no patient died and 82 (4.2%) experienced SPC within 90 days. History of gastric or esophageal surgery (adjusted odds ratio (aOR) 3.040, 95% confidence interval; CI 1.78-5.20, p< 0.0001), past of thromboembolic event aOR 2.26, 95%; CI 1.12-4.55, p = 0.0225), and surgery performed by a junior surgeon (aOR 1.99, 95%; CI 1.26-3.13, p = 0.003) were all independently associated with risk for SPC, adjusting for ASA physical status system (ASA) score >/= 3, severe OSA, psychiatric disease, asthma, a history of abdominal surgery, alcohol, cardiac disease, and dyslipidemia. "the OS-SEV90 score" based on these factors was constructed to classify patients into 3 risk groups: low (/=5). According to "the OS-SEV90 score," SPC increased significantly from 2.9% in the low-risk group, 7.7% in the intermediate-risk group, and 23.3% in the high-risk group. CONCLUSIONS: A predictive model of SPC within 90 days "the OS-SEV90 score" has been developed using 9 baseline risk factors. The use of the OS-SEV90 score may help the multidisciplinary team to identify the specific risk of each patient and inform them about and optimize the comorbidities before the surgery. Further studies are warranted to validate this score in a new independent cohort before using it in clinical practice. FAU - Meunier, Hugo AU - Meunier H AD - Department of Digestive Surgery, University Hospital of Caen, Avenue de la cote de Nacre, 14033, Caen cedex, France. FAU - Menahem, Benjamin AU - Menahem B AUID- ORCID: 0000-0001-8452-5346 AD - Department of Digestive Surgery, University Hospital of Caen, Avenue de la cote de Nacre, 14033, Caen cedex, France. menahem-b@chu-caen.fr. AD - UMR INSERM 1086 "Cancers et preventions", Centre Francois Baclesse, 3 avenue du General Harris, 14045, Caen cedex, France. menahem-b@chu-caen.fr. AD - UFR de Medecine, 2 avenue des Rochambelles, CS 60001, 14033, Caen cedex, France. menahem-b@chu-caen.fr. FAU - Le Roux, Yannick AU - Le Roux Y AD - Department of Digestive Surgery, University Hospital of Caen, Avenue de la cote de Nacre, 14033, Caen cedex, France. FAU - Bion, Adrien Lee AU - Bion AL AD - Department of Digestive Surgery, University Hospital of Caen, Avenue de la cote de Nacre, 14033, Caen cedex, France. FAU - Marion, Yoann AU - Marion Y AD - Department of Digestive Surgery, University Hospital of Caen, Avenue de la cote de Nacre, 14033, Caen cedex, France. FAU - Vallois, Antoine AU - Vallois A AD - Department of Digestive Surgery, University Hospital of Caen, Avenue de la cote de Nacre, 14033, Caen cedex, France. FAU - Contival, Nicolas AU - Contival N AD - Department of Digestive Surgery, University Hospital of Caen, Avenue de la cote de Nacre, 14033, Caen cedex, France. FAU - Gautier, Thomas AU - Gautier T AD - Department of Digestive Surgery, University Hospital of Caen, Avenue de la cote de Nacre, 14033, Caen cedex, France. FAU - Lubrano, Jean AU - Lubrano J AD - Department of Digestive Surgery, University Hospital of Caen, Avenue de la cote de Nacre, 14033, Caen cedex, France. AD - UFR de Medecine, 2 avenue des Rochambelles, CS 60001, 14033, Caen cedex, France. FAU - Briant, Anais AU - Briant A AD - Department of Biostatistics, University Hospital of Caen, Caen, France. FAU - Parienti, Jean-Jacques AU - Parienti JJ AD - UFR de Medecine, 2 avenue des Rochambelles, CS 60001, 14033, Caen cedex, France. AD - Department of Biostatistics, University Hospital of Caen, Caen, France. FAU - Alves, Arnaud AU - Alves A AD - Department of Digestive Surgery, University Hospital of Caen, Avenue de la cote de Nacre, 14033, Caen cedex, France. AD - UMR INSERM 1086 "Cancers et preventions", Centre Francois Baclesse, 3 avenue du General Harris, 14045, Caen cedex, France. AD - UFR de Medecine, 2 avenue des Rochambelles, CS 60001, 14033, Caen cedex, France. LA - eng PT - Journal Article DEP - 20210428 PL - United States TA - Obes Surg JT - Obesity surgery JID - 9106714 SB - IM MH - *Bariatric Surgery/adverse effects MH - Cohort Studies MH - Gastrectomy MH - *Gastric Bypass MH - Humans MH - *Laparoscopy MH - *Obesity, Morbid/surgery MH - Postoperative Complications/epidemiology/etiology MH - Retrospective Studies OTO - NOTNLM OT - Gastric bypass OT - Morbi-mortality OT - Postoperative score OT - Predictive model OT - Severe postoperative complication OT - Sleeve gastrectomy OT - aparoscopic bariatric surgery EDAT- 2021/04/29 06:00 MHDA- 2021/06/29 06:00 CRDT- 2021/04/28 06:30 PHST- 2020/10/14 00:00 [received] PHST- 2021/03/22 00:00 [accepted] PHST- 2021/03/15 00:00 [revised] PHST- 2021/04/29 06:00 [pubmed] PHST- 2021/06/29 06:00 [medline] PHST- 2021/04/28 06:30 [entrez] AID - 10.1007/s11695-021-05367-0 [pii] AID - 10.1007/s11695-021-05367-0 [doi] PST - ppublish SO - Obes Surg. 2021 Jul;31(7):3053-3064. doi: 10.1007/s11695-021-05367-0. Epub 2021 Apr 28. PMID- 33907552 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210429 IS - 1671-5411 (Print) IS - 1671-5411 (Linking) VI - 18 IP - 3 DP - 2021 Mar 28 TI - Heart failure in the elderly. PG - 219-232 LID - 10.11909/j.issn.1671-5411.2021.03.009 [doi] AB - Heart failure (HF) is a clinical syndrome caused by structural and/or functional cardiac abnormalities, resulting in a reduced cardiac output and/or elevated intracardiac filling pressures at rest or during stress. HF is a major public health problem with high prevalence and incidence, involving both high morbidity and mortality, but also high economic costs. The incidence of HF progressively increases with age, reaching around 20% among people over 75 years old. Indeed, HF represents the leading cause of hospitalization in patients older than 65 years in Western countries. Hence, some authors even consider HF a geriatric syndrome, entailing worse prognosis and high residual disability, and often associating some complex comorbidities, common in older population, that may further complicate the course of the disease. On the other hand, however, clinical course and prognosis may be often difficult to predict. In this article, main pathophysiological issues related to the aging heart are addressed, together with key aspects related to both diagnosis and prognosis in elderly patients with HF. Besides, main geriatric conditions, common in the elderly population, are reviewed, highlighting the importance of a comprehensive and multidisciplinary approach. CI - Copyright and License information: Journal of Geriatric Cardiology 2021. FAU - Diez-Villanueva, Pablo AU - Diez-Villanueva P AD - Cardiology Department, Hospital Universitario La Princesa, Universidad Autonoma de Madrid, CIBER-CV, Madrid, Spain. FAU - Jimenez-Mendez, Cesar AU - Jimenez-Mendez C AD - Cardiology Department, Hospital Universitario La Princesa, Universidad Autonoma de Madrid, CIBER-CV, Madrid, Spain. FAU - Alfonso, Fernando AU - Alfonso F AD - Cardiology Department, Hospital Universitario La Princesa, Universidad Autonoma de Madrid, CIBER-CV, Madrid, Spain. LA - eng PT - Journal Article PL - China TA - J Geriatr Cardiol JT - Journal of geriatric cardiology : JGC JID - 101237881 PMC - PMC8047189 EDAT- 2021/04/29 06:00 MHDA- 2021/04/29 06:01 PMCR- 2021/03/28 CRDT- 2021/04/28 06:20 PHST- 2021/04/28 06:20 [entrez] PHST- 2021/04/29 06:00 [pubmed] PHST- 2021/04/29 06:01 [medline] PHST- 2021/03/28 00:00 [pmc-release] AID - jgc-18-3-219 [pii] AID - 10.11909/j.issn.1671-5411.2021.03.009 [doi] PST - ppublish SO - J Geriatr Cardiol. 2021 Mar 28;18(3):219-232. doi: 10.11909/j.issn.1671-5411.2021.03.009. PMID- 33903717 OWN - NLM STAT- MEDLINE DCOM- 20210510 LR - 20240809 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 11 IP - 1 DP - 2021 Apr 26 TI - Safe and effective protocol for discharge 3 days after cardiac surgery. PG - 8979 LID - 10.1038/s41598-021-88582-0 [doi] LID - 8979 AB - The Enhanced Recovery After Surgery (ERAS) protocol affected traditional cardiac surgery processes and COVID-19 is expected to accelerate its scalability. The aim of this study was to assess the impact of an ERAS-based protocol on the length of hospital stay after cardiac surgery. From January 2019 to June 2020, 664 patients underwent consecutive cardiac surgery at a Latin American center. Here, 46 patients were prepared for a rapid recovery through a multidisciplinary institutional protocol based on the ERAS concept, the "TotalCor protocol". After the propensity score matching, 46 patients from the entire population were adjusted for 12 variables. Patients operated on the TotalCor protocol had reduced intensive care unit time (P < 0.025), postoperative stay (P 70% adherences. In conclusion, the TotalCor protocol was safe and effective for a 3-day discharge after cardiac surgery. Postoperative atrial fibrillation and renal failure were predictors of postoperative stay > 5 days. FAU - Mejia, Omar Asdrubal Vilca AU - Mejia OAV AD - Hospital Samaritano Paulista, Sao Paulo, Sao Paulo, Brazil. omar.mejia@incor.usp.br. AD - Department of Cardiovascular Surgery, Instituto do Coracao do Hospital das Clinicas da Faculdade de Medicina do Estado de Sao Paulo (InCor), Sao Paulo, Sao Paulo, Brazil. omar.mejia@incor.usp.br. FAU - Borgomoni, Gabrielle Barbosa AU - Borgomoni GB AD - Hospital Samaritano Paulista, Sao Paulo, Sao Paulo, Brazil. AD - Department of Cardiovascular Surgery, Instituto do Coracao do Hospital das Clinicas da Faculdade de Medicina do Estado de Sao Paulo (InCor), Sao Paulo, Sao Paulo, Brazil. FAU - Lasta, Nilza AU - Lasta N AD - Hospital Samaritano Paulista, Sao Paulo, Sao Paulo, Brazil. FAU - Okada, Mariana Yumi AU - Okada MY AD - Hospital Samaritano Paulista, Sao Paulo, Sao Paulo, Brazil. FAU - Gomes, Mariana Silva Biason AU - Gomes MSB AD - Hospital Samaritano Paulista, Sao Paulo, Sao Paulo, Brazil. FAU - Foz, Mary Lee Norris Nelsen AU - Foz MLNN AD - Hospital Samaritano Paulista, Sao Paulo, Sao Paulo, Brazil. FAU - Bischoff, Helga Priscila Giugno AU - Bischoff HPG AD - Hospital Samaritano Paulista, Sao Paulo, Sao Paulo, Brazil. FAU - Saruhashi, Tatiana AU - Saruhashi T AD - Hospital Samaritano Paulista, Sao Paulo, Sao Paulo, Brazil. FAU - Melro, Livia Maria Garcia AU - Melro LMG AD - Hospital Samaritano Paulista, Sao Paulo, Sao Paulo, Brazil. FAU - Sampaio, Marcio Campos AU - Sampaio MC AD - Hospital Samaritano Paulista, Sao Paulo, Sao Paulo, Brazil. FAU - de Barros E Silva, Pedro Gabriel Melo AU - de Barros E Silva PGM AD - Hospital Samaritano Paulista, Sao Paulo, Sao Paulo, Brazil. FAU - Garcia, Jose Carlos Teixeira AU - Garcia JCT AD - Hospital Samaritano Paulista, Sao Paulo, Sao Paulo, Brazil. FAU - Furlan, Valter AU - Furlan V AD - Hospital Samaritano Paulista, Sao Paulo, Sao Paulo, Brazil. LA - eng PT - Journal Article DEP - 20210426 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 SB - IM MH - Cardiac Surgical Procedures/adverse effects MH - *Enhanced Recovery After Surgery MH - Guideline Adherence MH - Humans MH - *Length of Stay MH - Patient Care Team MH - *Patient Discharge MH - *Patient Safety MH - Postoperative Complications MH - Propensity Score PMC - PMC8076282 COIS- The authors declare no competing interests. EDAT- 2021/04/28 06:00 MHDA- 2021/05/11 06:00 PMCR- 2021/04/26 CRDT- 2021/04/27 06:46 PHST- 2020/10/29 00:00 [received] PHST- 2021/04/12 00:00 [accepted] PHST- 2021/04/27 06:46 [entrez] PHST- 2021/04/28 06:00 [pubmed] PHST- 2021/05/11 06:00 [medline] PHST- 2021/04/26 00:00 [pmc-release] AID - 10.1038/s41598-021-88582-0 [pii] AID - 88582 [pii] AID - 10.1038/s41598-021-88582-0 [doi] PST - epublish SO - Sci Rep. 2021 Apr 26;11(1):8979. doi: 10.1038/s41598-021-88582-0. PMID- 33900945 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210429 IS - 2211-4599 (Print) IS - 2211-4599 (Electronic) IS - 2211-4599 (Linking) VI - 14 IP - s4 DP - 2021 Feb TI - A Rare Entity in the Lumbar Epidural Region: T-Cell Lymphoblastic Lymphoma. PG - S52-S56 LID - 10.14444/7165 [doi] AB - BACKGROUND: T-cell lymphoblastic lymphoma is a rare disease and an aggressive neoplasm of precursor lymphoblasts. We present a case of lumbar epidural T-cell lymphoblastic lymphoma which appeared with clinical features of epidural spinal cord compression. METHODS: A 38-year-old male patient presented with weakness in the lower extremities and newly developed urinary incontinence. His medical history included precursor T-cell acute lymphoblastic leukemia and treatment with allogeneic bone-marrow transplantation 5 years previously. Spinal magnetic resonance imaging (MRI) revealed an epidural mass lesion at L2-L4 levels and there was no sign of leukemia or lymphoma in clinical, laboratory, and radiological examinations. Surgery was planned for obtaining diagnostic material. Decompressive laminectomy and subtotal excision of the tumor were performed. RESULTS: At surgery, the tumor consisted of yellow-colored and hypovascular soft tissue fragments. It was encircling the spinal cord and spreading through the left L3 foramen. The patient underwent adjuvant chemoradiotherapy after the histopathological evaluation. At 2-month follow-up, the patient was able to walk without assistance, but the urinary incontinence was the same. At 5-month follow-up, the disease progressed, and the patient passed away because of infective endocarditis. CONCLUSION: Spinal lymphomas may display its characteristic "wrap-around" fashion in the MRI. In this report, we shared the microsurgical appearance of this fashion. As the lymphomas are chemoradiosensitive tumors, the treatment should be managed with a multidisciplinary approach. CI - This manuscript is generously published free of charge by ISASS, the International Society for the Advancement of Spine Surgery. Copyright (c) 2020 ISASS. FAU - Erdem, Munibe Busra AU - Erdem MB AD - Department of Neurosurgery, Gazi University Faculty of Medicine, Ankara, Turkey. FAU - Kale, Aydemir AU - Kale A AD - Department of Neurosurgery, Gazi University Faculty of Medicine, Ankara, Turkey. FAU - Yaman, Mesut Emre AU - Yaman ME AD - Department of Neurosurgery, Gazi University Faculty of Medicine, Ankara, Turkey. FAU - Emmez, Hakan AU - Emmez H AD - Department of Neurosurgery, Gazi University Faculty of Medicine, Ankara, Turkey. LA - eng PT - Journal Article DEP - 20210118 PL - Netherlands TA - Int J Spine Surg JT - International journal of spine surgery JID - 101579005 PMC - PMC7888206 OTO - NOTNLM OT - epidural space OT - precursor T-cell lymphoblastic leukemia-lymphoma OT - recurrence OT - spinal cord compression OT - tumor COIS- Disclosures and COI: We did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The authors report no conflicts of interest. EDAT- 2021/04/27 06:00 MHDA- 2021/04/27 06:01 PMCR- 2021/02/11 CRDT- 2021/04/26 17:16 PHST- 2021/04/26 17:16 [entrez] PHST- 2021/04/27 06:00 [pubmed] PHST- 2021/04/27 06:01 [medline] PHST- 2021/02/11 00:00 [pmc-release] AID - 7165 [pii] AID - IJSSURGERY-D-19-00085 [pii] AID - 10.14444/7165 [doi] PST - ppublish SO - Int J Spine Surg. 2021 Feb;14(s4):S52-S56. doi: 10.14444/7165. Epub 2021 Jan 18. PMID- 33896274 OWN - NLM STAT- MEDLINE DCOM- 20220325 LR - 20230202 IS - 1553-3514 (Electronic) IS - 1553-3506 (Print) IS - 1553-3506 (Linking) VI - 29 IP - 1 DP - 2022 Feb TI - Impact of Advanced Practice Provider Integration into Multispecialty Group Practices on Outcomes Following Major Surgery. PG - 111-117 LID - 10.1177/15533506211013150 [doi] AB - Background. While advanced practice providers (APPs) are increasingly integrated into care delivery models, little is known about their impact in surgical settings. Given that many patients undergo surgery in multispecialty group practice settings, we examined the impact of APP integration into such practices on outcomes after major surgery. Methods. We used a 20% sample of national Medicare claims to identify 190 101 patients who underwent 1 of 4 major surgeries (coronary artery bypass graft [CABG], colectomy, major joint replacement, and cystectomy) at multispecialty group practices from 2010 through 2016. The level of APP integration was measured as the ratio of APPs to physicians within each practice. Rates of mortality, major complications, and readmission within 30 days of discharge after the index surgery were compared between patients treated in practices with low, medium, and high levels of APP integration using multivariable regression analysis. Results. Relative to patients treated in practices with low APP integration, those treated in practices with medium or high APP integration had significantly lower rates of mortality (2.4% [low integration] vs 1.9% [medium integration] vs 2.0% [high integration]; P < .01), major complications (34.1% [low] vs 31.2% [medium] vs 30.2% [high]; P < .01), and readmission (11.7% [low] vs 10.6% [medium] vs 10.1% [high]; P < .01). This relationship was consistent for virtually all outcomes when considering each surgery type individually. Conclusions. Integration of APPs into multispecialty group practices was associated with improved postoperative outcomes after major surgery. Future research should identify the mechanisms by which APPs improve outcomes to inform optimal utilization. FAU - Lai, Lillian Y AU - Lai LY AUID- ORCID: 0000-0002-0831-2979 AD - Department of Urology, 21614University of Michigan, Ann Arbor, MI, USA. FAU - Kaufman, Samuel R AU - Kaufman SR AD - Department of Urology, 21614University of Michigan, Ann Arbor, MI, USA. FAU - Modi, Parth K AU - Modi PK AD - Department of Urology, University of Chicago, Chicago, IL, USA. FAU - Ellimoottil, Chad AU - Ellimoottil C AD - Department of Urology, 21614University of Michigan, Ann Arbor, MI, USA. FAU - Oerline, Mary AU - Oerline M AD - Department of Urology, 21614University of Michigan, Ann Arbor, MI, USA. FAU - Caram, Megan E V AU - Caram MEV AD - Departments of Medicine, 21614University of Michigan, Ann Arbor, MI, USA. AD - Veterans Affairs Health Services Research & Development, Center for Clinical Management and Research, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, MI, USA. FAU - Hollenbeck, Brent K AU - Hollenbeck BK AD - Department of Urology, 21614University of Michigan, Ann Arbor, MI, USA. FAU - Shahinian, Vahakn B AU - Shahinian VB AD - Department of Urology, 21614University of Michigan, Ann Arbor, MI, USA. AD - Departments of Medicine, 21614University of Michigan, Ann Arbor, MI, USA. LA - eng GR - R01 AG048071/AG/NIA NIH HHS/United States GR - T32 CA180984/CA/NCI NIH HHS/United States PT - Journal Article DEP - 20210424 PL - United States TA - Surg Innov JT - Surgical innovation JID - 101233809 SB - IM MH - Aged MH - Colectomy MH - Coronary Artery Bypass/adverse effects MH - *Group Practice MH - Humans MH - Medicare MH - *Physicians MH - United States PMC - PMC8542060 MID - NIHMS1691905 OTO - NOTNLM OT - colorectal surgery OT - general surgery OT - surgical oncology OT - the business of surgery OT - urology COIS- Declaration of Conflicting Interests The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2021/04/27 06:00 MHDA- 2022/03/26 06:00 PMCR- 2023/02/01 CRDT- 2021/04/26 05:22 PHST- 2021/04/27 06:00 [pubmed] PHST- 2022/03/26 06:00 [medline] PHST- 2021/04/26 05:22 [entrez] PHST- 2023/02/01 00:00 [pmc-release] AID - 10.1177/15533506211013150 [doi] PST - ppublish SO - Surg Innov. 2022 Feb;29(1):111-117. doi: 10.1177/15533506211013150. Epub 2021 Apr 24. PMID- 33894931 OWN - NLM STAT- MEDLINE DCOM- 20211025 LR - 20211025 IS - 1558-2264 (Electronic) IS - 0733-8651 (Linking) VI - 39 IP - 2 DP - 2021 May TI - Advances in Mitral Valve Repair for Degenerative Mitral Regurgitation: Philosophy, Technical Details, and Long-Term Results. PG - 175-184 LID - S0733-8651(21)00001-1 [pii] LID - 10.1016/j.ccl.2021.01.001 [doi] AB - Degenerative mitral valve disease represents the most common cause of mitral regurgitation in industrialized countries. When left untreated, patients with severe degenerative mitral regurgitation show a poor clinical outcome. Conversely, a timely and appropriate correction provides a restored life expectancy and a good quality of life. Therefore, in this scenario, surgical mitral valve repair represents the gold standard of treatment. This review aims to analyze the indications, timing, and contemporary surgical techniques of mitral valve repair for degenerative mitral regurgitation. Moreover, the value of heart team approach and centers of excellence for mitral valve repair are also deeply discussed. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - Del Forno, Benedetto AU - Del Forno B AD - Department of Cardiac Surgery, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, Milan 20132, Italy. Electronic address: delforno.benedetto@hsr.it. FAU - Ascione, Guido AU - Ascione G AD - Department of Cardiac Surgery, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, Milan 20132, Italy. FAU - De Bonis, Michele AU - De Bonis M AD - Department of Cardiac Surgery, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, Milan 20132, Italy. LA - eng PT - Journal Article PT - Review DEP - 20210324 PL - Netherlands TA - Cardiol Clin JT - Cardiology clinics JID - 8300331 SB - IM MH - *Cardiac Surgical Procedures MH - *Heart Valve Prosthesis Implantation MH - Humans MH - Mitral Valve/diagnostic imaging/surgery MH - *Mitral Valve Insufficiency/surgery MH - Quality of Life MH - Treatment Outcome OTO - NOTNLM OT - Barlow disease OT - Centers of excellence OT - Degenerative mitral valve disease OT - Fibroelastic deficiency OT - Heart team OT - Mitral regurgitation OT - Mitral valve repair OT - Myxomatous degeneration COIS- Competing interests The authors declare no competing interests. EDAT- 2021/04/26 06:00 MHDA- 2021/10/26 06:00 CRDT- 2021/04/25 20:22 PHST- 2021/04/25 20:22 [entrez] PHST- 2021/04/26 06:00 [pubmed] PHST- 2021/10/26 06:00 [medline] AID - S0733-8651(21)00001-1 [pii] AID - 10.1016/j.ccl.2021.01.001 [doi] PST - ppublish SO - Cardiol Clin. 2021 May;39(2):175-184. doi: 10.1016/j.ccl.2021.01.001. Epub 2021 Mar 24. PMID- 33890132 OWN - NLM STAT- MEDLINE DCOM- 20210729 LR - 20261010 IS - 1432-1971 (Electronic) IS - 0172-0643 (Linking) VI - 42 IP - 6 DP - 2021 Aug TI - Causes of Death in Infants and Children with Congenital Heart Disease. PG - 1308-1315 LID - 10.1007/s00246-021-02612-2 [doi] AB - With improved surgical outcomes, infants and children with congenital heart disease (CHD) may die from other causes of death (COD) other than CHD. We sought to describe the COD in youth with CHD in North Carolina (NC). Patients from birth to 20 years of age with a healthcare encounter between 2008 and 2013 in NC were identified by ICD-9 code. Patients who could be linked to a NC death certificate between 2008 and 2016 were included. Patients were divided by CHD subtypes (severe, shunt, valve, other). COD was compared between groups. Records of 35,542 patients < 20 years old were evaluated. There were 15,277 infants with an annual mortality rate of 3.5 deaths per 100 live births. The most frequent COD in infants (age < 1 year) were CHD (31.7%), lung disease (16.1%), and infection (11.4%). In 20,265 children (age 1 to < 20 years), there was annual mortality rate of 9.7 deaths per 1000 at risk. The most frequent COD in children were CHD (34.2%), neurologic disease (10.2%), and infection (9.5%). In the severe subtype, CHD was the most common COD. In infants with shunt-type CHD disease, lung disease (19.5%) was the most common COD. The mortality rate in infants was three times higher when compared to children. CHD is the most common underlying COD, but in those with shunt-type lesions, extra-cardiac COD is more common. A multidisciplinary approach in CHD patients, where development of best practice models regarding comorbid conditions such as lung disease and neurologic disease could improve outcomes in this patient population. CI - (c) 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Williams, Jason L AU - Williams JL AUID- ORCID: 0000-0003-4165-6463 AD - Department of Pediatrics, Division of Pediatric Cardiology, Duke University Medical Center, Box 3090, Durham, NC, 27710, USA. FAU - Torok, Rachel D AU - Torok RD AUID- ORCID: 0000-0002-8406-2107 AD - Department of Pediatrics, Division of Pediatric Cardiology, Duke University Medical Center, Box 3090, Durham, NC, 27710, USA. FAU - D'Ottavio, Alfred AU - D'Ottavio A AD - Duke Clinical Research Institute, Duke University Medical Center, Box 3090, Durham, NC, 27710, USA. FAU - Spears, Tracy AU - Spears T AUID- ORCID: 0000-0002-7169-5853 AD - Duke Clinical Research Institute, Duke University Medical Center, Box 3090, Durham, NC, 27710, USA. FAU - Chiswell, Karen AU - Chiswell K AUID- ORCID: 0000-0002-0279-9093 AD - Duke Clinical Research Institute, Duke University Medical Center, Box 3090, Durham, NC, 27710, USA. FAU - Forestieri, Nina E AU - Forestieri NE AD - North Carolina Division of Public Health, Birth Defects Monitoring Program, State Center for Health Statistics, Raleigh, NC, USA. FAU - Sang, Charlie J AU - Sang CJ AD - Department of Pediatrics, Division of Pediatric Cardiology, Vidant Medical Center, Greenville, NC, USA. FAU - Paolillo, Joseph A AU - Paolillo JA AUID- ORCID: 0000-0003-0726-1337 AD - Sanger Heart and Vascular Institute, Atrium Health, Charlotte, NC, USA. FAU - Walsh, Michael J AU - Walsh MJ AD - Department of Pediatrics, Division of Pediatric Cardiology, Wake Forest Baptist Health, Winston-Salem, NC, USA. FAU - Hoffman, Timothy M AU - Hoffman TM AUID- ORCID: 0000-0001-7715-8197 AD - Department of Pediatrics, Division of Pediatric Cardiology, University of North Carolina Medical Center, Chapel Hill, NC, USA. FAU - Kemper, Alex R AU - Kemper AR AUID- ORCID: 0000-0001-5491-3997 AD - Department of Pediatrics, Division of Primary Care Pediatrics, Nationwide Children's Hospital, Columbus, OH, USA. FAU - Li, Jennifer S AU - Li JS AUID- ORCID: 0000-0002-3254-1712 AD - Department of Pediatrics, Division of Pediatric Cardiology, Duke University Medical Center, Box 3090, Durham, NC, 27710, USA. jennifer.li@duke.edu. AD - Duke Clinical Research Institute, Duke University Medical Center, Box 3090, Durham, NC, 27710, USA. jennifer.li@duke.edu. LA - eng GR - NU50DD004933-03-00/CC/CDC HHS/United States GR - NU50DD004933-03-00/CC/CDC HHS/United States PT - Journal Article DEP - 20210422 PL - United States TA - Pediatr Cardiol JT - Pediatric cardiology JID - 8003849 SB - IM MH - Adolescent MH - Cause of Death/*trends MH - Child MH - Child, Preschool MH - Female MH - Heart Defects, Congenital/*mortality MH - Humans MH - Infant MH - Infant, Newborn MH - Male MH - North Carolina/epidemiology MH - Young Adult OTO - NOTNLM OT - Anomalies OT - Congenital heart disease OT - Death EDAT- 2021/04/24 06:00 MHDA- 2021/07/30 06:00 CRDT- 2021/04/23 06:39 PHST- 2021/01/13 00:00 [received] PHST- 2021/04/07 00:00 [accepted] PHST- 2021/04/24 06:00 [pubmed] PHST- 2021/07/30 06:00 [medline] PHST- 2021/04/23 06:39 [entrez] AID - 10.1007/s00246-021-02612-2 [pii] AID - 10.1007/s00246-021-02612-2 [doi] PST - ppublish SO - Pediatr Cardiol. 2021 Aug;42(6):1308-1315. doi: 10.1007/s00246-021-02612-2. Epub 2021 Apr 22. PMID- 33889762 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220422 IS - 2405-8440 (Print) IS - 2405-8440 (Electronic) IS - 2405-8440 (Linking) VI - 7 IP - 4 DP - 2021 Apr TI - Endovascular therapies for pulmonary embolism. PG - e06574 LID - 10.1016/j.heliyon.2021.e06574 [doi] LID - e06574 AB - PURPOSE: The aim of this article is to define the place of new endovascular methods for the management of pulmonary embolisms (PE), on the basis of a multidisciplinary consensus. METHOD AND RESULTS: Briefly, from the recent literature, for high-risk PE presenting with shock or cardiac arrest, systemic thrombolysis or embolectomy is recommended, while for lowrisk PE, anticoagulation alone is proposed. Normo-tense patients with PE but with biological or imaging signs of right heart dysfunction constitute a group known as "at intermediate risk" for which the therapeutic strategy remains controversial. In fact, some patients may require more aggressive treatment in addition to the anticoagulant treatment, because approximately 10% will decompensate hemodynamically with a high risk of mortality. Systemic thrombolysis may be an option, but with hemorrhagic risks, particularly intra cranial. Various hybrid pharmacomechanical approaches are proposed to maintain the benefits of thrombolysis while reducing its risks, but the overall clinical experience of these different techniques remains limited. Patients with high intermediate and high risk pulmonary embolism should be managed by a multidisciplinary team combining the skills of cardiologists, resuscitators, pneumologists, interventional radiologists and cardiac surgeons. Such a team can determine which intervention - thrombolysis alone or assisted, percutaneous mechanical fragmentation of the thrombus or surgical embolectomy - is best suited to a particular patient. CONCLUSIONS: This consensus document define the place of endovascular thrombectomy based on an appropriate risk stratification of PE. CI - (c) 2021 The Author(s). FAU - Rousseau, Herve AU - Rousseau H AD - Service d'imagerie CHU Toulouse, Rangueil, France. FAU - Del Giudice, Costantino AU - Del Giudice C AD - Service de Radiologie interventionnelle HEGP Paris, France. FAU - Sanchez, Olivier AU - Sanchez O AD - Service de Pneumologie et soins intensifs HEGP Paris, France. FAU - Ferrari, Emile AU - Ferrari E AD - Service de Cardiologie CHU Nice, France. FAU - Sapoval, Marc AU - Sapoval M AD - Service de Radiologie interventionnelle HEGP Paris, France. FAU - Marek, Pierre AU - Marek P AD - Service d'imagerie CHU Toulouse, Rangueil, France. FAU - Delmas, Clement AU - Delmas C AD - Service de Cardiologie CHU Toulouse, Rangueil, France. FAU - Zadro, Charline AU - Zadro C AD - Service d'imagerie CHU Toulouse, Rangueil, France. FAU - Revel-Mouroz, Paul AU - Revel-Mouroz P AD - Service d'imagerie CHU Toulouse, Rangueil, France. LA - eng PT - Journal Article PT - Review DEP - 20210401 PL - England TA - Heliyon JT - Heliyon JID - 101672560 PMC - PMC8047492 OTO - NOTNLM OT - Embolectomy OT - Pharmacomechanical thrombectomy OT - Pulmonary embolism OT - Thrombectomy OT - Thrombolytic therapy COIS- The authors declare no conflict of interest. EDAT- 2021/04/24 06:00 MHDA- 2021/04/24 06:01 PMCR- 2021/04/01 CRDT- 2021/04/23 06:31 PHST- 2020/09/30 00:00 [received] PHST- 2020/11/18 00:00 [revised] PHST- 2021/03/17 00:00 [accepted] PHST- 2021/04/23 06:31 [entrez] PHST- 2021/04/24 06:00 [pubmed] PHST- 2021/04/24 06:01 [medline] PHST- 2021/04/01 00:00 [pmc-release] AID - S2405-8440(21)00677-0 [pii] AID - e06574 [pii] AID - 10.1016/j.heliyon.2021.e06574 [doi] PST - epublish SO - Heliyon. 2021 Apr 1;7(4):e06574. doi: 10.1016/j.heliyon.2021.e06574. eCollection 2021 Apr. PMID- 33886858 OWN - NLM STAT- MEDLINE DCOM- 20211125 LR - 20220422 IS - 1982-4335 (Electronic) IS - 0103-507X (Print) IS - 0103-507X (Linking) VI - 33 IP - 1 DP - 2021 Jan-Mar TI - Changes in cardiac arrest profiles after the implementation of a Rapid Response Team. PG - 96-101 LID - S0103-507X2021000100096 [pii] LID - 10.5935/0103-507X.20210010 [doi] AB - OBJECTIVE: To evaluate changes in the characteristics of in-hospital cardiac arrest after the implementation of a Rapid Response Team. METHODS: This was a prospective observational study of in-hospital cardiac arrest that occurred from January 2013 to December 2017. The exclusion criterion was in-hospital cardiac arrest in the intensive care unit, emergency room or operating room. The Rapid Response Team was implemented in July 2014 in the study hospital. Patients were classified into two groups: a Pre-Rapid Response Team (in-hospital cardiac arrest before Rapid Response Team implementation) and a Post-Rapid Response Team (in-hospital cardiac arrest after Rapid Response Team implementation). Patients were followed until hospital discharge or death. RESULTS: We had a total of 308 cardiac arrests (64.6 +/- 15.2 years, 60.3% men, 13.9% with initial shockable rhythm). There was a decrease from 4.2 to 2.5 in-hospital cardiac arrest/1000 admissions after implementation of the Rapid Response Team, and we had approximately 124 calls/1000 admissions. Pre-Rapid Response Team cardiac arrest was associated with more hypoxia (29.4 versus 14.3%; p = 0.006) and an altered respiratory rate (14.7 versus 4.2%; p = 0.004) compared with post-Rapid Response Team cardiac arrest. Cardiac arrest due to hypoxia was more common before Rapid Response Team implementation (61.2 versus 38.1%, p < 0.001). In multivariate analysis, return of spontaneous circulation was associated with shockable rhythm (OR 2.97; IC95% 1.04 - 8.43) and witnessed cardiac arrest (OR 2.52; IC95% 1.39 - 4.59) but not with Rapid Response Team implementation (OR 1.40; IC95% 0.70 - 2.81) or premonitory signs (OR 0.71; IC95% 0.39 - 1.28). In multivariate analysis, in-hospital mortality was associated with non-shockable rhythm (OR 5.34; IC95% 2.28 - 12.53) and age (OR 1.03; IC95% 1.01 - 1.05) but not with Rapid Response Team implementation (OR 0.89; IC95% 0.40 - 2.02). CONCLUSION: Even though Rapid Response Team implementation is associated with a reduction in in-hospital cardiac arrest, it was not associated with the mortality of in-hospital cardiac arrest victims. A significant decrease in cardiac arrests due to respiratory causes was noted after Rapid Response Team implementation. FAU - Viana, Marina Vercoza AU - Viana MV AUID- ORCID: 0000-0001-9564-4885 AD - Unidade de Terapia Intensiva, Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul - Porto Alegre (RS), Brasil. AD - Grupo de Trabalho em Ressuscitacao Cardiopulmonar, Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul - Porto Alegre (RS), Brasil. FAU - Nunes, Diego Silva Leite AU - Nunes DSL AD - Unidade de Terapia Intensiva, Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul - Porto Alegre (RS), Brasil. FAU - Teixeira, Cassiano AU - Teixeira C AUID- ORCID: 0000-0002-7651-3799 AD - Unidade de Terapia Intensiva, Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul - Porto Alegre (RS), Brasil. FAU - Vieira, Silvia Regina Rios AU - Vieira SRR AD - Unidade de Terapia Intensiva, Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul - Porto Alegre (RS), Brasil. AD - Grupo de Trabalho em Ressuscitacao Cardiopulmonar, Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul - Porto Alegre (RS), Brasil. FAU - Torres, Grazziela AU - Torres G AD - Unidade de Terapia Intensiva, Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul - Porto Alegre (RS), Brasil. AD - Grupo de Trabalho em Ressuscitacao Cardiopulmonar, Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul - Porto Alegre (RS), Brasil. FAU - Brauner, Janete Salles AU - Brauner JS AD - Unidade de Terapia Intensiva, Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul - Porto Alegre (RS), Brasil. AD - Grupo de Trabalho em Ressuscitacao Cardiopulmonar, Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul - Porto Alegre (RS), Brasil. FAU - Muller, Helena AU - Muller H AD - Grupo de Trabalho em Ressuscitacao Cardiopulmonar, Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul - Porto Alegre (RS), Brasil. FAU - Butelli, Thais Crivellaro Dutra AU - Butelli TCD AD - Unidade de Terapia Intensiva, Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul - Porto Alegre (RS), Brasil. FAU - Boniatti, Marcio Manozzo AU - Boniatti MM AD - Unidade de Terapia Intensiva, Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul - Porto Alegre (RS), Brasil. LA - por LA - eng PT - Journal Article PT - Observational Study TT - Modificacoes no perfil de paradas cardiacas apos implantacao de um Time de Resposta Rapida. PL - Brazil TA - Rev Bras Ter Intensiva JT - Revista Brasileira de terapia intensiva JID - 9506692 SB - IM MH - *Cardiopulmonary Resuscitation MH - Emergency Service, Hospital MH - Female MH - *Heart Arrest/epidemiology/therapy MH - Hospital Mortality MH - *Hospital Rapid Response Team MH - Humans MH - Intensive Care Units MH - Male PMC - PMC8075345 COIS- Conflicts of interest: None. EDAT- 2021/04/23 06:00 MHDA- 2021/11/26 06:00 PMCR- 2021/01/01 CRDT- 2021/04/22 17:35 PHST- 2020/02/04 00:00 [received] PHST- 2020/05/28 00:00 [accepted] PHST- 2021/04/22 17:35 [entrez] PHST- 2021/04/23 06:00 [pubmed] PHST- 2021/11/26 06:00 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - S0103-507X2021000100096 [pii] AID - 10.5935/0103-507X.20210010 [doi] PST - ppublish SO - Rev Bras Ter Intensiva. 2021 Jan-Mar;33(1):96-101. doi: 10.5935/0103-507X.20210010. PMID- 33886582 OWN - NLM STAT- MEDLINE DCOM- 20210916 LR - 20231111 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 16 IP - 4 DP - 2021 TI - Strategies to prevent hospital readmission and death in patients with chronic heart failure, chronic obstructive pulmonary disease, and chronic kidney disease: A systematic review and meta-analysis. PG - e0249542 LID - 10.1371/journal.pone.0249542 [doi] LID - e0249542 AB - BACKGROUND: Readmission following hospital discharge is common and is a major financial burden on healthcare systems. OBJECTIVES: Our objectives were to 1) identify studies describing post-discharge interventions and their efficacy with respect to reducing risk of mortality and rate of hospital readmission; and 2) identify intervention characteristics associated with efficacy. METHODS: A systematic review of the literature was performed. We searched MEDLINE, PubMed, Cochrane, EMBASE and CINAHL. Our selection criteria included randomized controlled trials comparing post-discharge interventions with usual care on rates of hospital readmission and mortality in high-risk chronic disease patient populations. We used random effects meta-analyses to estimate pooled risk ratios for all-cause and cause-specific mortality as well as all-cause and cause-specific hospitalization. RESULTS: We included 31 randomized controlled trials encompassing 9654 patients (24 studies in CHF, 4 in COPD, 1 in both CHF and COPD, 1 in CKD and 1 in an undifferentiated population). Meta-analysis showed post-discharge interventions reduced cause-specific (RR = 0.71, 95% CI = 0.63-0.80) and all cause (RR = 0.90, 95% CI = 0.81-0.99) hospitalization, all-cause (RR = 0.73, 95% CI = 0.65-0.83) and cause-specific mortality (RR = 0.68, 95% CI = 0.54-0.84) in CHF studies, and all-cause hospitalization (RR = 0.52, 95% CI = 0.32-0.83) in COPD studies. The inclusion of a cardiac nurse in the multidisciplinary team was associated with greater efficacy in reducing all-cause mortality among patients discharged after heart failure admission (HR = 0.64, 95% CI = 0.54-0.75 vs. HR = 0.87, 95% CI = 0.73-1.03). CONCLUSIONS: Post-discharge interventions reduced all-cause mortality, cause-specific mortality, and cause-specific hospitalization in CHF patients and all-cause hospitalization in COPD patients. The presence of a cardiac nurse was associated with greater efficacy in included studies. Additional research is needed on the impact of post-discharge intervention strategies in COPD and CKD patients. FAU - Bamforth, Ryan J AU - Bamforth RJ AUID- ORCID: 0000-0002-8316-2325 AD - Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada. AD - Seven Oaks Hospital Chronic Disease Innovation Centre, Winnipeg, Manitoba, Canada. FAU - Chhibba, Ruchi AU - Chhibba R AD - Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada. AD - Seven Oaks Hospital Chronic Disease Innovation Centre, Winnipeg, Manitoba, Canada. FAU - Ferguson, Thomas W AU - Ferguson TW AD - Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada. AD - Seven Oaks Hospital Chronic Disease Innovation Centre, Winnipeg, Manitoba, Canada. FAU - Sabourin, Jenna AU - Sabourin J AD - Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada. AD - Seven Oaks Hospital Chronic Disease Innovation Centre, Winnipeg, Manitoba, Canada. FAU - Pieroni, Domenic AU - Pieroni D AUID- ORCID: 0000-0002-2975-0898 AD - Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada. AD - Seven Oaks Hospital Chronic Disease Innovation Centre, Winnipeg, Manitoba, Canada. FAU - Askin, Nicole AU - Askin N AD - Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada. FAU - Tangri, Navdeep AU - Tangri N AD - Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada. AD - Seven Oaks Hospital Chronic Disease Innovation Centre, Winnipeg, Manitoba, Canada. FAU - Komenda, Paul AU - Komenda P AD - Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada. AD - Seven Oaks Hospital Chronic Disease Innovation Centre, Winnipeg, Manitoba, Canada. FAU - Rigatto, Claudio AU - Rigatto C AD - Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada. AD - Seven Oaks Hospital Chronic Disease Innovation Centre, Winnipeg, Manitoba, Canada. LA - eng PT - Journal Article PT - Meta-Analysis PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20210422 PL - United States TA - PLoS One JT - PloS one JID - 101285081 SB - IM MH - Cause of Death MH - Heart Failure/*mortality MH - Humans MH - Patient Discharge MH - Patient Readmission/*economics/statistics & numerical data MH - Patient-Centered Care/economics/*methods MH - Pulmonary Disease, Chronic Obstructive/*mortality MH - Quality of Life MH - Randomized Controlled Trials as Topic MH - Renal Insufficiency, Chronic/*mortality PMC - PMC8062060 COIS- The authors have declared that no competing interests exist. EDAT- 2021/04/23 06:00 MHDA- 2021/09/18 06:00 PMCR- 2021/04/22 CRDT- 2021/04/22 17:28 PHST- 2020/08/19 00:00 [received] PHST- 2021/03/21 00:00 [accepted] PHST- 2021/04/22 17:28 [entrez] PHST- 2021/04/23 06:00 [pubmed] PHST- 2021/09/18 06:00 [medline] PHST- 2021/04/22 00:00 [pmc-release] AID - PONE-D-20-21147 [pii] AID - 10.1371/journal.pone.0249542 [doi] PST - epublish SO - PLoS One. 2021 Apr 22;16(4):e0249542. doi: 10.1371/journal.pone.0249542. eCollection 2021. PMID- 33881608 OWN - NLM STAT- MEDLINE DCOM- 20210602 LR - 20261010 IS - 1435-1544 (Electronic) IS - 0938-7412 (Linking) VI - 32 IP - 2 DP - 2021 Jun TI - Pregnancy in catecholaminergic polymorphic ventricular tachycardia: therapeutic optimization and multidisciplinary care are key to success. PG - 199-206 LID - 10.1007/s00399-021-00755-6 [doi] AB - Women of child-bearing age comprise a large proportion of the patients followed by inherited arrhythmia clinics. Despite being a rare and dangerous diagnosis, cardiac and obstetric care providers should know that catecholaminergic polymorphic ventricular tachycardia (CPVT) is not a contraindication to pregnancy. In fact, pregnancy was not associated with an increased risk of CPVT-associated arrhythmias in a recent large cohort study, and most guideline-based anti-arrhythmic drug treatments are life-saving and carry a low risk of teratogenesis. In principle, the potential for CPVT destabilization may be more likely to occur after anti-arrhythmic drugs are decreased or stopped during pregnancy, when an implantable cardioverter defibrillator (ICD) shock exacerbates catecholamine release, or if adrenaline surges are triggered by labor and delivery. Therefore, all pregnant women should be followed by a cardio-obstetrics team with extensive knowledge of CPVT diagnosis, as well as arrhythmia risk stratification fand management. This multidisciplinary care should begin preconception and involve counseling on preimplantation genetic testing, choosing safe and effective anti-arrhythmic drugs, stopping contraindicated medications, optimal programming of ICDs, and planning for the brief hyper-adrenergic period of labor and delivery. The latest data on pregnancy in CPVT is reviewed here and the optimal care for this rare and complex patient population outlined. FAU - Roston, Thomas M AU - Roston TM AD - Centre for Cardiovascular Innovation, Division of Cardiology, Department of Medicine, The University of British Columbia, Vancouver, Canada. FAU - Grewal, Jasmine AU - Grewal J AD - Centre for Cardiovascular Innovation, Division of Cardiology, Department of Medicine, The University of British Columbia, Vancouver, Canada. FAU - Krahn, Andrew D AU - Krahn AD AD - Centre for Cardiovascular Innovation, Division of Cardiology, Department of Medicine, The University of British Columbia, Vancouver, Canada. akrahn@mail.ubc.ca. AD - , 211-1033 Davie Street, V6E 1M7, Vancouver, BC, Canada. akrahn@mail.ubc.ca. LA - eng PT - Journal Article PT - Review TT - Schwangerschaft bei katecholaminerger polymorpher ventrikularer Tachykardie: Therapieoptimierung und multidisziplinare Betreuung sind der Schlussel zum Erfolg. DEP - 20210421 PL - Germany TA - Herzschrittmacherther Elektrophysiol JT - Herzschrittmachertherapie & Elektrophysiologie JID - 9425873 RN - 0 (Ryanodine Receptor Calcium Release Channel) SB - IM MH - Child MH - Cohort Studies MH - *Death, Sudden, Cardiac MH - Electrocardiography MH - Female MH - Humans MH - Pregnancy MH - Ryanodine Receptor Calcium Release Channel MH - *Tachycardia, Ventricular/diagnosis/therapy MH - Polymorphic Catecholaminergic Ventricular Tachycardia OTO - NOTNLM OT - CPVT OT - Inherited arrhythmia OT - Maternal/fetal risk OT - Ryanodine receptor OT - Sudden cardiac arrest EDAT- 2021/04/22 06:00 MHDA- 2021/06/03 06:00 CRDT- 2021/04/21 12:20 PHST- 2021/01/07 00:00 [received] PHST- 2021/03/18 00:00 [accepted] PHST- 2021/04/22 06:00 [pubmed] PHST- 2021/06/03 06:00 [medline] PHST- 2021/04/21 12:20 [entrez] AID - 10.1007/s00399-021-00755-6 [pii] AID - 10.1007/s00399-021-00755-6 [doi] PST - ppublish SO - Herzschrittmacherther Elektrophysiol. 2021 Jun;32(2):199-206. doi: 10.1007/s00399-021-00755-6. Epub 2021 Apr 21. PMID- 33880854 OWN - NLM STAT- MEDLINE DCOM- 20220407 LR - 20220511 IS - 1478-5153 (Electronic) IS - 1362-1017 (Linking) VI - 27 IP - 2 DP - 2022 Mar TI - Impact of a sleep promotion protocol on off-pump coronary artery bypass graft patients. PG - 214-222 LID - 10.1111/nicc.12637 [doi] AB - BACKGROUND: Sleep abnormalities frequently occur in intensive care unit (ICU) patients, and the consequences of sleep abnormalities in patients who undergo off-pump coronary artery bypass graft (OPCABG) surgery are particularly significant. Although many interventions have been reported to improve sleep, few sleep promotion protocols have been designed specifically for patients in cardiac ICUs. AIMS AND OBJECTIVES: This study aimed to explore the effects of an evidence-based sleep promotion protocol on patients who underwent OPCABG in a cardiac ICU. DESIGN: A quasi-experimental study was conducted in a comprehensive hospital in Shandong province of China. METHODS: Overall, 67 participants were recruited (37 in the control group and 30 in the intervention group). An evidence-based sleep promotion protocol was developed by a 10-member interprofessional collaborative team and then applied. Sound levels, light intensity, and the number of nocturnal interventions were compared between groups. The Chinese version of the Richards-Campbell Sleep Questionnaire (RCSQ) was used to compare intergroup sleep status on two consecutive postoperative nights. RESULTS: No significant differences were found for demographics or disease severity between the groups. In the intervention group, sound levels and light intensity were significantly lower at various times, and nocturnal interventions were significantly less frequent over the two consecutive nights. RCSQ scores were significantly higher in the intervention group for both nights. CONCLUSIONS: The sleep promotion protocol reduced sound levels, night-time light intensity, the number of nocturnal interventions, and improved sleep among OPCABG patients in a cardiac ICU. RELEVANCE TO CLINICAL PRACTICE: Evidence-based practice can help to promote good quality of care, improve patient outcomes, and advance nursing in clinical settings. CI - (c) 2021 British Association of Critical Care Nurses. FAU - Chen, Lin AU - Chen L AUID- ORCID: 0000-0003-2529-8563 AD - CCU, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China. FAU - Zheng, Jing AU - Zheng J AD - Cardiac Intensive Care Unit, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China. FAU - Lv, Shanshan AU - Lv S AD - Cardiac Intensive Care Unit, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China. FAU - Li, Baobao AU - Li B AD - Cardiac Intensive Care Unit, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China. FAU - Yang, Lijuan AU - Yang L AUID- ORCID: 0000-0001-6889-5638 AD - Nursing Department, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China. LA - eng GR - 2017WS464/Medical and Health Development Program Foundation of Shandong Province/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210420 PL - England TA - Nurs Crit Care JT - Nursing in critical care JID - 9808649 MH - *Coronary Artery Bypass, Off-Pump/adverse effects MH - Critical Care MH - Humans MH - Intensive Care Units MH - Sleep MH - Surveys and Questionnaires OTO - NOTNLM OT - cardiology OT - evidence-based health care OT - intensive care unit OT - sleep EDAT- 2021/04/22 06:00 MHDA- 2022/04/08 06:00 CRDT- 2021/04/21 07:03 PHST- 2021/04/08 00:00 [revised] PHST- 2020/10/29 00:00 [received] PHST- 2021/04/10 00:00 [accepted] PHST- 2021/04/22 06:00 [pubmed] PHST- 2022/04/08 06:00 [medline] PHST- 2021/04/21 07:03 [entrez] AID - 10.1111/nicc.12637 [doi] PST - ppublish SO - Nurs Crit Care. 2022 Mar;27(2):214-222. doi: 10.1111/nicc.12637. Epub 2021 Apr 20. PMID- 33871034 OWN - NLM STAT- MEDLINE DCOM- 20210517 LR - 20220209 IS - 1651-2081 (Electronic) IS - 1650-1977 (Print) IS - 1650-1977 (Linking) VI - 53 IP - 4 DP - 2021 Apr 28 TI - A Nationwide pilot project to develop rehabilitation services for patients with cardiovascular diseases. PG - jrm00186 LID - 10.2340/16501977-2833 [doi] LID - 2790 AB - OBJECTIVE: To measure progress towards introducing a 3-phase rehabilitation programme, based on the multidisciplinary approach, for patients with cardiovascular diseases. METHODS: Seventeen hospital and outpatient medical centres from 13 regions of the Pilot Project. Baseline questionnaires assessed the involvement of multidisciplinary teams, staffing, and the equipment in healthcare facilities. These questionnaires covered 3 rehabilitation phases: inpatient rehabilitation in the intensive care units and departments of myocardial infarction/cardiac surgery; early in-hospital rehabilitation; and outpatient rehabilitation. RESULTS: The pilot project was initiated in 2013. At the 5-year follow-up, phase I was established across all 17 sites, phase II at 13 sites, and phase III at 9 sites. By 2017, multidisciplinary teams were deployed to manage patients at all sites. Early rehabilitation in regional vascular centres, reduced patients' stay from 13.7 (2.1) days in 2013 to 7.6 (1.1) days in 2017. CONCLUSION: Despite successful implementation of the 3-phase rehabilitation programme based on the multidisciplinary approach, further improvement is required, with the main focus shifted to patients routing between healthcare facilities. Particular attention should be paid to the standards for providing phase III cardiac rehabilitation, in order to ensure continuity of cardiac rehabilitation. The next step should include assessment of the effectiveness of the implemented cardiac rehabilitation programme and its translation to other regions of the country. FAU - Bubnova, Marina AU - Bubnova M AD - Department for Rehabilitation and Secondary Prevention, Federal State Budgetary Institution National Medical Research Centre for Preventive Medicine of the Ministry of Healthcare of the Russian Federation, Moscow, Russian Federation. FAU - Aronov, David AU - Aronov D FAU - Barbarash, Olga AU - Barbarash O FAU - Lyamina, Nadezhda AU - Lyamina N FAU - Pomeshkina, Svetlana AU - Pomeshkina S FAU - Chumakova, Galina AU - Chumakova G CN - the Pilot Project Research Group LA - eng PT - Journal Article DEP - 20210428 PL - Sweden TA - J Rehabil Med JT - Journal of rehabilitation medicine JID - 101088169 SB - IM MH - Cardiac Rehabilitation/*methods MH - Female MH - Humans MH - Male MH - Pilot Projects MH - Rehabilitation Centers/*standards MH - Surveys and Questionnaires PMC - PMC8814881 OTO - NOTNLM OT - cardiac rehabilitation OT - cardiovascular disease OT - myocardial infarction COIS- The authors have no conflicts of interest to declare. EDAT- 2021/04/20 06:00 MHDA- 2021/05/18 06:00 PMCR- 2021/04/19 CRDT- 2021/04/19 08:52 PHST- 2021/04/20 06:00 [pubmed] PHST- 2021/05/18 06:00 [medline] PHST- 2021/04/19 08:52 [entrez] PHST- 2021/04/19 00:00 [pmc-release] AID - JRM-53-4-2790 [pii] AID - 10.2340/16501977-2833 [doi] PST - epublish SO - J Rehabil Med. 2021 Apr 28;53(4):jrm00186. doi: 10.2340/16501977-2833. PMID- 33870440 OWN - NLM STAT- MEDLINE DCOM- 20210624 LR - 20261012 IS - 1432-1971 (Electronic) IS - 0172-0643 (Linking) VI - 42 IP - 5 DP - 2021 Jun TI - Status of Multidisciplinary Collaboration in Neonatal Cardiac Care in the United States. PG - 1088-1101 LID - 10.1007/s00246-021-02586-1 [doi] AB - While outcomes for neonates with congenital heart disease have improved, it is apparent that substantial variability exists among centers with regard to the multidisciplinary approach to care for this medically fragile patient population. We endeavored to understand the landscape of neonatal cardiac care in the United States. A survey was distributed to physicians who provide neonatal cardiac care in the United States regarding (1) collaborative efforts in care of neonates with congenital heart disease (CHD); (2) access to neonatal cardiac training; and (3) barriers to the implementation of protocols for neonatal cardiac care. Responses were collected from 10/2018 to 6/2019. We received responses from 172 of 608 physicians (28% response rate) from 89 centers. When compared to responses received from physicians at low-volume centers (< 300 annual bypass cases), those at high-volume centers reported more involvement from the neurodevelopmental teams (58% vs. 29%; P = 0.012) and a standardized transition to outpatient care (68% vs. 52%; P = 0.038). While a majority of cardiothoracic surgery and anesthesiology respondents reported multidisciplinary involvement, less than half of cardiology and neonatology supported this statement. The most commonly reported obstacles to multidisciplinary engagement were culture (61.6%) and logistics (47.1%). Having a standardized neonatal cardiac curriculum for neonatal fellows was positively associated with the perception that multidisciplinary collaboration was "always" in place (53% vs. 40%; P = 0.09). There is considerable variation among centers in regard to personnel involved in neonatal cardiac care, related education, and perceived multidisciplinary collaboration among team members. The survey findings suggest the need to establish concrete standards for neonatal cardiac surgical programs, with ongoing quality improvement processes. FAU - Levy, Victor Y AU - Levy VY AUID- ORCID: 0000-0001-5703-2909 AD - Department of Pediatrics, Texas Tech University Health Sciences Center, Lubbock, TX, USA. victor.levy@ttuhsc.edu. AD - Department of Pediatrics, Texas Tech University Health Science Center School of Medicine, 701 West 5th Street, Odessa, TX, 79763, USA. victor.levy@ttuhsc.edu. FAU - Bhombal, Shazia AU - Bhombal S AD - Department of Pediatrics, Stanford University, Palo Alto, CA, USA. FAU - Villafane, Juan AU - Villafane J AD - Department of Pediatrics, University of Cincinnati, Cincinnati Children's Hospital, Cincinnati, OH, USA. FAU - McBride, Mary E AU - McBride ME AD - Department of Pediatrics, Northwestern University, Feinberg School of Medicine, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA. FAU - Chung, Sukyung AU - Chung S AD - Department of Medicine, Stanford University, Palo Alto, CA, USA. FAU - Figueroa, Mayte AU - Figueroa M AD - Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, USA. FAU - Hopper, Andrew AU - Hopper A AD - Department of Pediatrics, Loma Linda University School of Medicine, Loma Linda, CA, USA. FAU - Johnson, Jonathan N AU - Johnson JN AD - Department of Pediatrics, Division of Pediatric Cardiology, Mayo Clinic Children's Center Rochester, Rochester, MN, USA. FAU - Costello, John M AU - Costello JM AD - Department of Pediatrics, Shawn Jenkins Children's Hospital, Medical University of South Carolina, Charleston, SC, USA. CN - Neonatal Cardiac Care Collaborative(NeoC3) LA - eng PT - Journal Article PT - Multicenter Study DEP - 20210418 PL - United States TA - Pediatr Cardiol JT - Pediatric cardiology JID - 8003849 SB - IM MH - Cardiac Surgical Procedures/standards MH - Cardiology/education/*methods MH - Cooperative Behavior MH - Curriculum MH - Heart Defects, Congenital/*surgery MH - Humans MH - Infant, Newborn MH - Intensive Care Units, Neonatal/*organization & administration MH - Neonatology/education/*methods MH - Quality Improvement MH - Surveys and Questionnaires MH - United States OTO - NOTNLM OT - Cardiac OT - Collaboration OT - Neonatal cardiac care OT - Survey EDAT- 2021/04/20 06:00 MHDA- 2021/06/25 06:00 CRDT- 2021/04/19 06:46 PHST- 2020/11/01 00:00 [received] PHST- 2021/03/18 00:00 [accepted] PHST- 2021/04/20 06:00 [pubmed] PHST- 2021/06/25 06:00 [medline] PHST- 2021/04/19 06:46 [entrez] AID - 10.1007/s00246-021-02586-1 [pii] AID - 10.1007/s00246-021-02586-1 [doi] PST - ppublish SO - Pediatr Cardiol. 2021 Jun;42(5):1088-1101. doi: 10.1007/s00246-021-02586-1. Epub 2021 Apr 18. PMID- 36713609 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230202 IS - 2634-3916 (Electronic) IS - 2634-3916 (Linking) VI - 2 IP - 3 DP - 2021 Sep TI - Personalized teleprehabilitation in elective cardiac surgery: a study protocol of the Digital Cardiac Counselling randomized controlled trial. PG - 477-486 LID - 10.1093/ehjdh/ztab041 [doi] AB - AIMS: Previous research has shown the possibility to use the pre-operative period to improve a patient's tolerance for surgery. However, there is limited experience with prehabilitation in cardiac surgery. The aim of this study is to evaluate the effect of a comprehensive personalized teleprehabilitation programme on major adverse cardiac events (MACE) in patients scheduled for elective cardiac surgery. Secondary outcomes are post-operative complications, cardiovascular risk factors, quality of life, and cost-effectiveness. METHODS AND RESULTS: In this single-centre randomized controlled trial, patients are eligible for inclusion when they are >/=18 years of age and cardiac surgery is scheduled at least 8 weeks from informed consent. Participants will be randomized to the teleprehabilitation group or the control group. After a digital baseline screening for perioperative risk factors, patients in the intervention arm can pre-operatively be referred to one or more of the prehabilitation modules (functional exercise training, inspiratory muscle training, psychological support, nutritional support, and/or smoking cessation). The programme is targeted at a duration of at least 6 weeks. It is executed by a multidisciplinary team using (video)calls and supported by a custom-made digital platform. During the pre-operative period, the platform is also used to inform patients about their upcoming surgery and for telemonitoring. CONCLUSION: Reducing perioperative risk factors might result in a reduction of MACE, post-operative complications, length of stay, and cardiovascular risk factors, as well as improved quality of life. Cost-effectiveness will be evaluated. CI - (c) The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology. FAU - Scheenstra, Bart AU - Scheenstra B AUID- ORCID: 0000-0001-5778-2574 AD - Department of Cardiothoracic Surgery, Heart and Vascular Centre, Maastricht University Medical Centre, P. Debyelaan 25, 6229 HX Maastricht, The Netherlands. AD - Department of Cardiothoracic Surgery, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands. FAU - Mohansingh, Chanu AU - Mohansingh C AD - Department of Cardiothoracic Surgery, Heart and Vascular Centre, Maastricht University Medical Centre, P. Debyelaan 25, 6229 HX Maastricht, The Netherlands. FAU - Bongers, Bart C AU - Bongers BC AD - Department of Epidemiology, Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands. AD - Department of Nutrition and Human Movement Sciences, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands. FAU - Dahmen, Sandra AU - Dahmen S AD - Department of Cardiothoracic Surgery, Heart and Vascular Centre, Maastricht University Medical Centre, P. Debyelaan 25, 6229 HX Maastricht, The Netherlands. FAU - Wouters, Yvonne I M S AU - Wouters YIMS AD - Department of Physiotherapy, Maastricht University Medical Centre, Maastricht, The Netherlands. FAU - Lenssen, Ton F AU - Lenssen TF AD - Department of Physiotherapy, Maastricht University Medical Centre, Maastricht, The Netherlands. FAU - Geerlings, Phil AU - Geerlings P AD - Department of Dietetics, Maastricht University Medical Centre, Maastricht, The Netherlands. FAU - Knols, Henriette F M AU - Knols HFM AD - Department of Psychiatry and Psychology, Maastricht University Medical Centre, Maastricht, The Netherlands. FAU - van Kuijk, Sander M J AU - van Kuijk SMJ AD - Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre, Maastricht, The Netherlands. FAU - Kimman, Merel L AU - Kimman ML AD - Department of Epidemiology, Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands. AD - Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre, Maastricht, The Netherlands. FAU - Nieman, Maxime AU - Nieman M AD - Department of Pulmonology, Maastricht University Medical Centre, Maastricht, The Netherlands. FAU - Maessen, Jos G AU - Maessen JG AD - Department of Cardiothoracic Surgery, Heart and Vascular Centre, Maastricht University Medical Centre, P. Debyelaan 25, 6229 HX Maastricht, The Netherlands. AD - Department of Cardiothoracic Surgery, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands. FAU - Van't Hof, Arnoud W J AU - Van't Hof AWJ AD - Department of Cardiothoracic Surgery, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands. AD - Department of Cardiology, Heart and Vascular Centre, Maastricht University Medical Centre, Maastricht, The Netherlands. AD - Department of Cardiology, Zuyderland Medical Centre, Heerlen, The Netherlands. FAU - Peyman, Sardari Nia AU - Peyman SN AD - Department of Cardiothoracic Surgery, Heart and Vascular Centre, Maastricht University Medical Centre, P. Debyelaan 25, 6229 HX Maastricht, The Netherlands. AD - Department of Cardiothoracic Surgery, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands. LA - eng PT - Journal Article DEP - 20210419 PL - England TA - Eur Heart J Digit Health JT - European heart journal. Digital health JID - 101778323 EIN - Eur Heart J Digit Health. 2021 Nov 11;3(1):114. doi: 10.1093/ehjdh/ztab094. PMID: 36716116 PMC - PMC9708005 OTO - NOTNLM OT - Cardiac events OT - Physical fitness OT - Pre-operative assessment OT - Prehabilitation OT - Telehealth OT - Teleprehabilitation EDAT- 2021/04/19 00:00 MHDA- 2021/04/19 00:01 PMCR- 2021/04/19 CRDT- 2023/01/30 04:16 PHST- 2021/01/28 00:00 [received] PHST- 2021/03/27 00:00 [revised] PHST- 2021/04/15 00:00 [accepted] PHST- 2023/01/30 04:16 [entrez] PHST- 2021/04/19 00:00 [pubmed] PHST- 2021/04/19 00:01 [medline] PHST- 2021/04/19 00:00 [pmc-release] AID - ztab041 [pii] AID - 10.1093/ehjdh/ztab041 [doi] PST - epublish SO - Eur Heart J Digit Health. 2021 Apr 19;2(3):477-486. doi: 10.1093/ehjdh/ztab041. eCollection 2021 Sep. PMID- 33861982 OWN - NLM STAT- MEDLINE DCOM- 20210813 LR - 20210813 IS - 2352-4650 (Electronic) IS - 2352-4642 (Linking) VI - 5 IP - 7 DP - 2021 Jul TI - Juvenile haemochromatosis. PG - 524-530 LID - S2352-4642(20)30392-8 [pii] LID - 10.1016/S2352-4642(20)30392-8 [doi] AB - Juvenile haemochromatosis is a severe inherited iron-loading disorder that can present in children and adolescents. Typical manifestations include heart failure, endocrine failure (including diabetes and hypogonadism), cirrhosis, and arthropathy. Compared with HFE haemochromatosis, juvenile haemochromatosis affects female and male individuals similarly, presents at a younger age, and causes multiple organ dysfunction; the principle of iron loading into tissues from the gut is shared by both forms, but the process is far more rapid in juvenile haemochromatosis. Juvenile haemochromatosis is initially recognised by extreme increases of serum ferritin and transferrin saturation, which is supported by an MRI showing iron deposition in the heart and liver. MRI software techniques allow quantification of iron in these organs, and can therefore be used to monitor progress. Juvenile haemochromatosis is autosomal recessive and is generally associated with mutations in HJV (type 2A) or HAMP (type 2B). Mutations in TFR2 cause an intermediate severity phenotype (type 3), but this phenotype can cross over into the juvenile haemochromatosis spectrum so it might need to be additionally considered during diagnosis. Treatment needs to be administered without delay, in the form of aggressive iron chelation, and a multidisciplinary approach is essential. Because iron is removed, organ function is restored, which could obviate the need for cardiac or liver transplantation. Substantial restoration of health can ensue, but patients require life-long monitoring. Family screening is an important component of the management of juvenile haemochromatosis. Genetic advances which underpin the haemochromatosis types also clarify the role of iron metabolism in health and disease, particularly the role of hepcidin in regulating iron homoeostasis. Therefore, juvenile haemochromatosis is an important condition to understand; it can present insidiously in children and adolescents, and awareness of the diagnosis is needed to inform early recognition and treatment. CI - Copyright (c) 2021 Elsevier Ltd. All rights reserved. FAU - Griffiths, William J H AU - Griffiths WJH AD - Liver Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. Electronic address: bill.griffiths@addenbrookes.nhs.uk. FAU - Besser, Martin AU - Besser M AD - Department of Haematology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. FAU - Bowden, David J AU - Bowden DJ AD - Department of Radiology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. FAU - Kelly, Deirdre A AU - Kelly DA AD - Liver Unit, Birmingham Women's and Children's NHS Trust and University of Birmingham, Birmingham, UK. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20210415 PL - England TA - Lancet Child Adolesc Health JT - The Lancet. Child & adolescent health JID - 101712925 RN - Hemochromatosis, type 2 SB - IM MH - Adolescent MH - Child MH - Female MH - Hemochromatosis/*congenital/diagnosis/therapy MH - Humans MH - Male COIS- Declaration of interests MB has received fees from Amgen, Werfen, Pharmacosmos, Stago, Agios, and Novartis, as well as grant support from Mitsubishi Pharma. The other authors declared no competing interests. EDAT- 2021/04/17 06:00 MHDA- 2021/08/14 06:00 CRDT- 2021/04/16 20:09 PHST- 2020/08/11 00:00 [received] PHST- 2020/11/25 00:00 [revised] PHST- 2020/12/09 00:00 [accepted] PHST- 2021/04/17 06:00 [pubmed] PHST- 2021/08/14 06:00 [medline] PHST- 2021/04/16 20:09 [entrez] AID - S2352-4642(20)30392-8 [pii] AID - 10.1016/S2352-4642(20)30392-8 [doi] PST - ppublish SO - Lancet Child Adolesc Health. 2021 Jul;5(7):524-530. doi: 10.1016/S2352-4642(20)30392-8. Epub 2021 Apr 15. PMID- 33858622 OWN - NLM STAT- MEDLINE DCOM- 20211013 LR - 20211013 IS - 1558-3597 (Electronic) IS - 0735-1097 (Linking) VI - 77 IP - 15 DP - 2021 Apr 20 TI - Long-Term Outcomes of Patients With Late Presentation of ST-Segment Elevation Myocardial Infarction. PG - 1859-1870 LID - S0735-1097(21)00495-2 [pii] LID - 10.1016/j.jacc.2021.02.041 [doi] AB - BACKGROUND: Real-world data on baseline characteristics, clinical practice, and outcomes of late presentation (12 to 48 h of symptom onset) in patients with ST-segment elevation myocardial infarction (STEMI) are limited. OBJECTIVES: This study aimed to investigate real-world features of STEMI late presenters in the contemporary percutaneous coronary intervention (PCI) era. METHODS: Of 13,707 patients from the Korea Acute Myocardial Infarction Registry-National Institutes of Health database, 5,826 consecutive patients diagnosed with STEMI within 48 h of symptom onset during 2011 to 2015 were categorized as late (12 to 48 h; n = 624) or early (<12 h; n = 5,202) presenters. Coprimary outcomes were 180-day and 3-year all-cause mortality. RESULTS: Late presenters had remarkably worse clinical outcomes than early presenters (180-day mortality: 10.7% vs. 6.8%; 3-year mortality: 16.2% vs. 10.6%; both log-rank p < 0.001), whereas presentation at >/=12 h of symptom onset was not independently associated with increased mortality after STEMI. The use of invasive interventional procedures abruptly decreased from the first (<12 h) to the second (12 to 24 h) 12-h interval of symptom-to-door time ("no primary PCI strategy" increased from 4.9% to 12.4%, and "no PCI" from 2.3% to 6.6%; both p < 0.001). Mortality rates abruptly increased from the first to the second 12-h interval of symptom-to-door time (from 6.8% to 11.2% for 180-day mortality; from 10.6% to 17.3% for 3-year mortality; all p < 0.05). CONCLUSIONS: Data from a nationwide prospective Korean registry reveal that inverse steep differences in the use of invasive interventional procedures and mortality rates were found between early and late presenters after STEMI. A multidisciplinary approach is required in identifying late presenters of STEMI who can benefit from invasive interventional procedures until further studied. CI - Copyright (c) 2021 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. FAU - Cho, Kyung Hoon AU - Cho KH AD - Department of Cardiology, Chonnam National University Hospital, Gwangju, Republic of Korea. FAU - Han, Xiongyi AU - Han X AD - Department of Cardiology, Chonnam National University Hospital, Gwangju, Republic of Korea. FAU - Ahn, Joon Ho AU - Ahn JH AD - Department of Cardiology, Chonnam National University Hospital, Gwangju, Republic of Korea. FAU - Hyun, Dae Young AU - Hyun DY AD - Department of Cardiology, Chonnam National University Hospital, Gwangju, Republic of Korea. FAU - Kim, Min Chul AU - Kim MC AD - Department of Cardiology, Chonnam National University Hospital, Gwangju, Republic of Korea; Department of Cardiology, Chonnam National University Medical School, Gwangju, Republic of Korea. FAU - Sim, Doo Sun AU - Sim DS AD - Department of Cardiology, Chonnam National University Hospital, Gwangju, Republic of Korea; Department of Cardiology, Chonnam National University Medical School, Gwangju, Republic of Korea. FAU - Hong, Young Joon AU - Hong YJ AD - Department of Cardiology, Chonnam National University Hospital, Gwangju, Republic of Korea; Department of Cardiology, Chonnam National University Medical School, Gwangju, Republic of Korea. FAU - Kim, Ju Han AU - Kim JH AD - Department of Cardiology, Chonnam National University Hospital, Gwangju, Republic of Korea; Department of Cardiology, Chonnam National University Medical School, Gwangju, Republic of Korea. FAU - Ahn, Youngkeun AU - Ahn Y AD - Department of Cardiology, Chonnam National University Hospital, Gwangju, Republic of Korea; Department of Cardiology, Chonnam National University Medical School, Gwangju, Republic of Korea. FAU - Hwang, Jin Yong AU - Hwang JY AD - Department of Cardiology, Gyeongsang National University, School of Medicine, Jinju, Republic of Korea. FAU - Oh, Seok Kyu AU - Oh SK AD - Department of Cardiology, Wonkwang University Hospital, Iksan, Republic of Korea. FAU - Cha, Kwang Soo AU - Cha KS AD - Department of Cardiology, Pusan National University Hospital, Busan, Republic of Korea. FAU - Choi, Cheol Ung AU - Choi CU AD - Department of Cardiology, Korea University Guro Hospital, Seoul, Republic of Korea. FAU - Hwang, Kyung-Kuk AU - Hwang KK AD - Department of Cardiology, Chungbuk National University Hospital, Cheongju, Republic of Korea. FAU - Gwon, Hyeon Cheol AU - Gwon HC AD - Department of Cardiology, Seoul Samsung Medical Center, Seoul, Republic of Korea. FAU - Jeong, Myung Ho AU - Jeong MH AD - Department of Cardiology, Chonnam National University Hospital, Gwangju, Republic of Korea; Department of Cardiology, Chonnam National University Medical School, Gwangju, Republic of Korea. Electronic address: myungho@chollian.net. CN - KAMIR-NIH Investigators LA - eng PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't PL - United States TA - J Am Coll Cardiol JT - Journal of the American College of Cardiology JID - 8301365 SB - IM CIN - J Am Coll Cardiol. 2021 Apr 20;77(15):1871-1874. doi: 10.1016/j.jacc.2021.03.003. PMID: 33858623 MH - Aged MH - Delayed Diagnosis MH - Female MH - Humans MH - Male MH - Middle Aged MH - Percutaneous Coronary Intervention MH - Registries MH - Republic of Korea MH - ST Elevation Myocardial Infarction/*diagnosis/mortality/*therapy MH - Time Factors MH - Time-to-Treatment MH - Treatment Outcome OTO - NOTNLM OT - Republic of Korea OT - ST-segment elevation myocardial infarction OT - percutaneous coronary intervention OT - registries COIS- Funding Support and Author Disclosures This work was funded by the Research of Korea Centers for Disease Control and Prevention (2016-ER6304-02) and supported by the Chonnam National University Hospital Biomedical Research Institute (BCRI-20075). The authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2021/04/17 06:00 MHDA- 2021/10/14 06:00 CRDT- 2021/04/16 05:45 PHST- 2020/11/23 00:00 [received] PHST- 2021/01/26 00:00 [revised] PHST- 2021/02/18 00:00 [accepted] PHST- 2021/04/16 05:45 [entrez] PHST- 2021/04/17 06:00 [pubmed] PHST- 2021/10/14 06:00 [medline] AID - S0735-1097(21)00495-2 [pii] AID - 10.1016/j.jacc.2021.02.041 [doi] PST - ppublish SO - J Am Coll Cardiol. 2021 Apr 20;77(15):1859-1870. doi: 10.1016/j.jacc.2021.02.041. PMID- 33851397 OWN - NLM STAT- MEDLINE DCOM- 20211210 LR - 20211214 IS - 1098-9021 (Electronic) IS - 0271-8235 (Linking) VI - 41 IP - 4 DP - 2021 Aug TI - Cerebrovascular Complication and Valve Surgery in Infective Endocarditis. PG - 437-446 LID - 10.1055/s-0041-1726327 [doi] AB - Infective endocarditis (IE) with neurologic complications is common in patients with active IE. The most common and feared neurological complication of left-sided IE is cerebrovascular, from septic emboli causing ischemic stroke, intracranial hemorrhage (ICH), or an infectious intracranial aneurysm with or without rupture. In patients with cerebrovascular complications, valve replacement surgery is often delayed for concern of further neurological worsening. However, in circumstances when an indication for valve surgery to treat IE is present, the benefits of early surgical treatment may outweigh the potential neurologic deterioration. Furthermore, valve surgery has been associated with lower in-hospital mortality than medical therapy with intravenous antibiotics alone. Early valve surgery can be performed within 7 days of transient ischemic attack or asymptomatic stroke when medically indicated. Timing of valve surgery for IE after symptomatic medium or large symptomatic ischemic stroke or ICH remains challenging, and current data in the literature are conflicting about the risks and benefits. A delay of 2 to 4 weeks from the time of the cerebrovascular event is often recommended, balancing the risks and benefits of surgery. The range of timing of valve surgery varies depending on the clinical scenario, and is best determined by a multidisciplinary decision between cardiothoracic surgeons, cardiologists, infectious disease experts, and vascular neurologists in an experienced referral center. CI - Thieme. All rights reserved. FAU - Rice, Cory J AU - Rice CJ AD - Erlanger Medical Center, University of Tennessee-Chattanooga College of Medicine, Chattanooga, Tennessee. FAU - Kovi, Shivakrishna AU - Kovi S AD - Department of Neurology, Cerebrovascular Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio. FAU - Wisco, Dolora R AU - Wisco DR AUID- ORCID: 0000-0003-4265-5868 AD - Department of Neurology, Cerebrovascular Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio. LA - eng PT - Journal Article DEP - 20210413 PL - United States TA - Semin Neurol JT - Seminars in neurology JID - 8111343 SB - IM MH - *Endocarditis/complications/surgery MH - *Endocarditis, Bacterial/complications/surgery MH - Humans MH - *Stroke/etiology COIS- None declared. EDAT- 2021/04/15 06:00 MHDA- 2021/12/15 06:00 CRDT- 2021/04/14 06:45 PHST- 2021/04/15 06:00 [pubmed] PHST- 2021/12/15 06:00 [medline] PHST- 2021/04/14 06:45 [entrez] AID - 10.1055/s-0041-1726327 [doi] PST - ppublish SO - Semin Neurol. 2021 Aug;41(4):437-446. doi: 10.1055/s-0041-1726327. Epub 2021 Apr 13. PMID- 33851392 OWN - NLM STAT- MEDLINE DCOM- 20211210 LR - 20211214 IS - 1098-9021 (Electronic) IS - 0271-8235 (Linking) VI - 41 IP - 4 DP - 2021 Aug TI - Brain Injury in Extracorporeal Membrane Oxygenation: A Multidisciplinary Approach. PG - 422-436 LID - 10.1055/s-0041-1726284 [doi] AB - Extracorporeal membrane oxygenation (ECMO) represents an established technique to provide temporary cardiac and/or pulmonary support. ECMO, in veno-venous, veno-arterial or in extracorporeal carbon dioxide removal modality, is associated with a high rate of brain injuries. These complications have been reported in 7 to 15% of adults and 20% of neonates, and are associated with poor survival. Thromboembolic events, loss of cerebral autoregulation, alteration of the blood-brain barrier, and hemorrhage related to anticoagulation represent the main causes of severe brain injury during ECMO. The most frequent forms of acute neurological injuries in ECMO patients are intracranial hemorrhage (2-21%), ischemic stroke (2-10%), seizures (2-6%), and hypoxic-ischemic brain injury; brain death may also occur in this population. Other frequent complications are infarction (1-8%) and cerebral edema (2-10%), as well as neuropsychological and psychiatric sequelae, including posttraumatic stress disorder. CI - Thieme. All rights reserved. FAU - Chiarini, Giovanni AU - Chiarini G AD - Department of Cardiothoracic Surgery, Heart and Vascular Centre, Maastricht University Medical Centre (MUMC), Maastricht, The Netherlands. AD - Division of Anesthesiology, Intensive Care and Emergency Medicine, Spedali Civili University, Affiliated Hospital of Brescia, Brescia, Italy. FAU - Cho, Sung-Min AU - Cho SM AD - Departments of Neurology, Anesthesiology, and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland. FAU - Whitman, Glenn AU - Whitman G AD - Division of Cardiac Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland. FAU - Rasulo, Frank AU - Rasulo F AD - Division of Anesthesiology, Intensive Care and Emergency Medicine, Spedali Civili University, Affiliated Hospital of Brescia, Brescia, Italy. FAU - Lorusso, Roberto AU - Lorusso R AD - Department of Cardiothoracic Surgery, Heart and Vascular Centre, Maastricht University Medical Centre (MUMC), Maastricht, The Netherlands. AD - Cardiovascular Research Institute Maastricht (CARIM), Maastricht, The Netherlands. LA - eng PT - Journal Article DEP - 20210413 PL - United States TA - Semin Neurol JT - Seminars in neurology JID - 8111343 SB - IM MH - Adult MH - Brain Death MH - *Brain Injuries/etiology/therapy MH - *Extracorporeal Membrane Oxygenation/adverse effects MH - Humans MH - Infant, Newborn MH - Seizures MH - *Stroke COIS- None declared. EDAT- 2021/04/15 06:00 MHDA- 2021/12/15 06:00 CRDT- 2021/04/14 06:45 PHST- 2021/04/15 06:00 [pubmed] PHST- 2021/12/15 06:00 [medline] PHST- 2021/04/14 06:45 [entrez] AID - 10.1055/s-0041-1726284 [doi] PST - ppublish SO - Semin Neurol. 2021 Aug;41(4):422-436. doi: 10.1055/s-0041-1726284. Epub 2021 Apr 13. PMID- 33841982 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210413 IS - 2072-1439 (Print) IS - 2077-6624 (Electronic) IS - 2072-1439 (Linking) VI - 13 IP - 3 DP - 2021 Mar TI - Minimally invasive mitral valve surgery. PG - 1960-1970 LID - 10.21037/jtd-20-2114 [doi] AB - There is considerable interest and demand in the application of minimally invasive techniques in cardiac surgery driven by multiple factors including patient cosmesis and satisfaction, reduction of surgical trauma and the development of specialized instrumentation that allows these procedures to be performed safely. Minimally invasive mitral valve surgery (MIMVS) has been conducted for more than 25 years and has been shown to offer multiple benefits including better cosmetic results, enhanced post-operative recovery, improved patient satisfaction and most importantly, equivalent clinical outcomes with regards to quality and safety when compared to the standard sternotomy approach. MIMVS may be particularly beneficial in certain subgroups of patients, for example patients undergoing redo mitral valve surgery. In this article, we discuss patient selection criteria for MIMVS, the merits and drawbacks of MIMVS relative to conventional sternotomy approaches, and detail procedural aspects including anaesthetic management, intraoperative technique, and important considerations in myocardial protection and cardiopulmonary bypass (CPB). When considering developing a MIMVS programme, as for any new technique, a team approach to the introduction of the programme is essential. Although it is clear that patient selection is important, particularly early in a surgical programme, with experience complex repairs can be performed through a minimally invasive approach with excellent outcomes. CI - 2021 Journal of Thoracic Disease. All rights reserved. FAU - Abu-Omar, Yasir AU - Abu-Omar Y AD - University Hospitals Cleveland Medical Center, Cleveland, OH, USA. FAU - Fazmin, Ibrahim T AU - Fazmin IT AD - Department of Cardiothoracic Surgery, Royal Papworth Hospital, Cambridge, UK. FAU - Ali, Jason M AU - Ali JM AD - Department of Cardiothoracic Surgery, Royal Papworth Hospital, Cambridge, UK. FAU - Pelletier, Marc P AU - Pelletier MP AD - University Hospitals Cleveland Medical Center, Cleveland, OH, USA. LA - eng PT - Journal Article PT - Review PL - China TA - J Thorac Dis JT - Journal of thoracic disease JID - 101533916 PMC - PMC8024816 OTO - NOTNLM OT - Mini-thoracotomy OT - mini-mitral surgery OT - minimally invasive surgery COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/jtd-20-2114). The series "Minimally Invasive Cardiac Surgery" was commissioned by the editorial office without any funding or sponsorship. Jason Ali and Yasir Abu-Omar served as the unpaid Guest Editors of the series. Jason Ali serves as an unpaid editorial board member of Journal of Thoracic Disease from Oct 2019 to Sep 2021. The authors have no other conflicts of interest to declare. EDAT- 2021/04/13 06:00 MHDA- 2021/04/13 06:01 PMCR- 2021/03/01 CRDT- 2021/04/12 06:21 PHST- 2021/04/12 06:21 [entrez] PHST- 2021/04/13 06:00 [pubmed] PHST- 2021/04/13 06:01 [medline] PHST- 2021/03/01 00:00 [pmc-release] AID - jtd-13-03-1960 [pii] AID - 10.21037/jtd-20-2114 [doi] PST - ppublish SO - J Thorac Dis. 2021 Mar;13(3):1960-1970. doi: 10.21037/jtd-20-2114. PMID- 33841977 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210916 IS - 2072-1439 (Print) IS - 2077-6624 (Electronic) IS - 2072-1439 (Linking) VI - 13 IP - 3 DP - 2021 Mar TI - Anesthesia for minimally invasive cardiac surgery. PG - 1886-1898 LID - 10.21037/jtd-20-1804 [doi] AB - Due to its potential benefits and increased patient satisfaction minimal invasive cardiac surgery (MICS) is rapidly gaining in popularity. These procedures are not without challenges and require careful planning, pre-operative patient assessment and excellent intraoperative communication. Assessment of patient suitability for MICS by a multi-disciplinary team during pre-operative workup is desirable. MICS requires additional skills that many might not consider to be part of the standard cardiac anesthetic toolkit. Anesthetists involved in MICS need not only be highly skilled in performing transesophageal echocardiography (TEE) but need to be proficient in multimodal analgesia, including locoregional or neuroaxial techniques. MICS procedures tend to cause more postoperative pain than standard median sternotomies do, and patients need analgesic management more in keeping with thoracic operations. Ultrasound guided peripheral regional anesthesia techniques like serratus anterior block can offer an advantage over neuroaxial techniques in patients on anti-platelet therapy or anticoagulation with low molecular weight or unfractionated heparin The article reviews the salient points pertaining to pre-operative assessment and suitability, intraoperative process and postoperative management of minimally invasive cardiac procedures in the operating theatre as well as the catheterization lab. Special emphasis is given to anesthetic management and analgesia techniques. CI - 2021 Journal of Thoracic Disease. All rights reserved. FAU - White, Alexander AU - White A AD - Senior Fellow in Anaesthetics and Intensive Care, The Royal Papworth Hospital NHS Foundation Trust, Cambridge, UK. FAU - Patvardhan, Chinmay AU - Patvardhan C AD - Consultant in Anaesthetics and Intensive Care, The Royal Papworth Hospital NHS Foundation Trust, Cambridge, UK. FAU - Falter, Florian AU - Falter F AD - Consultant in Anaesthetics and Intensive Care, The Royal Papworth Hospital NHS Foundation Trust, Cambridge, UK. LA - eng PT - Journal Article PT - Review PL - China TA - J Thorac Dis JT - Journal of thoracic disease JID - 101533916 CIN - J Thorac Dis. 2021 Aug;13(8):5111-5112. doi: 10.21037/jtd-21-910. PMID: 34527348 PMC - PMC8024802 OTO - NOTNLM OT - Minimal invasive cardiac surgery (MICS) OT - anesthesia OT - regional anesthesia OT - transesophageal echocardiography (TEE) COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/jtd-20-1804). The series "Minimally Invasive Cardiac Surgery" was commissioned by the editorial office without any funding or sponsorship. The authors have no other conflicts of interest to declare. EDAT- 2021/04/13 06:00 MHDA- 2021/04/13 06:01 PMCR- 2021/03/01 CRDT- 2021/04/12 06:21 PHST- 2021/04/12 06:21 [entrez] PHST- 2021/04/13 06:00 [pubmed] PHST- 2021/04/13 06:01 [medline] PHST- 2021/03/01 00:00 [pmc-release] AID - jtd-13-03-1886 [pii] AID - 10.21037/jtd-20-1804 [doi] PST - ppublish SO - J Thorac Dis. 2021 Mar;13(3):1886-1898. doi: 10.21037/jtd-20-1804. PMID- 33840473 OWN - NLM STAT- MEDLINE DCOM- 20231026 LR - 20231112 IS - 1097-685X (Electronic) IS - 0022-5223 (Linking) VI - 165 IP - 3 DP - 2023 Mar TI - Clinical impact of the heart team on the outcomes of surgical aortic valve replacement among octogenarians. PG - 1010-1019.e5 LID - S0022-5223(21)00451-7 [pii] LID - 10.1016/j.jtcvs.2021.03.030 [doi] AB - OBJECTIVES: The effectiveness of a multidisciplinary heart team in the management of patients with severe symptomatic aortic stenosis is unknown. This study evaluated the impact of a heart team on the outcomes of surgical aortic valve replacement in octogenarians. METHODS: Between May 2007 and January 2016, 528 patients aged 80 years or more were referred to our institutional heart team for a transcatheter aortic valve replacement. Among these, 101 were redirected to surgical aortic valve replacement (heart team group). These patients were compared with a surgical aortic valve replacement cohort (n = 506) without prior heart team screening (non-heart team group), taken from the same time period. Propensity score matching with bootstrap analysis was performed; 76 heart team patients were matched to 76 non-heart team patients. Early and late outcomes including survival and readmission for cardiovascular causes were compared. RESULTS: Matched subgroups were largely comparable; congestive heart failure and echocardiographic pulmonary hypertension were more prevalent in the heart team group. In-hospital mortality was significantly lower in the matched heart team group (0% vs 6.0%, bootstrap mean difference 6.0%, 95% confidence interval, 2.2-9.8). The risk of stroke, low cardiac output state, reexploration for bleeding, pneumonia, and prolonged ventilation was also significantly lower in the heart team group. There was no significant between-group difference regarding late survival (hazard ratio, 0.86, 95% confidence interval, 0.55-1.33, P = .49) or readmission for cardiovascular reasons (hazard ratio, 0.70, 95% confidence interval, 0.41-1.20, P = .19). CONCLUSIONS: Preoperative multidisciplinary assessment of octogenarians by a heart team was associated with lower in-hospital mortality and adverse events after surgical aortic valve replacement. CI - Copyright (c) 2021 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved. FAU - Porterie, Jean AU - Porterie J AD - Department of Cardiac Surgery, Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada. FAU - Kalavrouziotis, Dimitri AU - Kalavrouziotis D AD - Department of Cardiac Surgery, Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada. FAU - Dumont, Eric AU - Dumont E AD - Department of Cardiac Surgery, Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada. FAU - Paradis, Jean-Michel AU - Paradis JM AD - Department of Cardiology, Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada. FAU - De Larochelliere, Robert AU - De Larochelliere R AD - Department of Cardiology, Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada. FAU - Rodes-Cabau, Josep AU - Rodes-Cabau J AD - Department of Cardiology, Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada. FAU - Mohammadi, Siamak AU - Mohammadi S AD - Department of Cardiac Surgery, Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada. Electronic address: siamak.mohammadi@fmed.ulaval.ca. LA - eng PT - Journal Article DEP - 20210311 PL - United States TA - J Thorac Cardiovasc Surg JT - The Journal of thoracic and cardiovascular surgery JID - 0376343 SB - IM CIN - J Thorac Cardiovasc Surg. 2023 Mar;165(3):1020-1021. doi: 10.1016/j.jtcvs.2021.03.029. PMID: 33814171 MH - Aged, 80 and over MH - Humans MH - Aortic Valve/diagnostic imaging/surgery MH - Octogenarians MH - *Aortic Valve Stenosis/diagnostic imaging/surgery MH - *Heart Valve Prosthesis Implantation/adverse effects MH - Treatment Outcome MH - *Transcatheter Aortic Valve Replacement/adverse effects MH - Risk Factors OTO - NOTNLM OT - aortic valve replacement OT - heart team OT - octogenarians OT - surgery EDAT- 2021/04/13 06:00 MHDA- 2023/10/26 06:42 CRDT- 2021/04/12 05:33 PHST- 2020/07/06 00:00 [received] PHST- 2021/02/17 00:00 [revised] PHST- 2021/03/02 00:00 [accepted] PHST- 2023/10/26 06:42 [medline] PHST- 2021/04/13 06:00 [pubmed] PHST- 2021/04/12 05:33 [entrez] AID - S0022-5223(21)00451-7 [pii] AID - 10.1016/j.jtcvs.2021.03.030 [doi] PST - ppublish SO - J Thorac Cardiovasc Surg. 2023 Mar;165(3):1010-1019.e5. doi: 10.1016/j.jtcvs.2021.03.030. Epub 2021 Mar 11. PMID- 33838482 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210601 IS - 2210-2612 (Print) IS - 2210-2612 (Electronic) IS - 2210-2612 (Linking) VI - 82 DP - 2021 May TI - Necrotising fasciitis of the posterior neck crossing the midline: A case report. PG - 105851 LID - S2210-2612(21)00353-9 [pii] LID - 10.1016/j.ijscr.2021.105851 [doi] LID - 105851 AB - INTRODUCTION AND IMPORTANCE: Craniofacial necrotising fasciitis is a complex condition, with high mortality given its propensity to descend via the deep neck spaces into the chest and mediastinum. Management requires optimal antimicrobial therapy with associated aggressive surgical debridement. PRESENTATION OF CASE: A 64-year-old man presented to ENT with a posterior neck swelling. Despite incision and drainage of the swelling following a trial of antimicrobial therapy, it increased in size, with areas of overlying necrosis demonstrated. Based on radiological and clinical findings, a diagnosis of necrotising fasciitis was made. He was taken to theatre for debridement. Intra-operatively, carotid sheath suppuration was noted, after tissue retraction resulted in copious bleeding from the anterior wound bed, requiring vigorous resuscitation and clamping of underlying structures to achieve haemostasis. Senior ENT and vascular surgery involvement was quickly sought to achieve haemostasis, however bleeding from the wound bed was difficult to control. This was due to the significant watershed area at the posterior neck which would not have been amenable to selective vessel ligation. After multiple cardiac arrests, a team decision was taken to discontinue resuscitation. CLINICAL DISCUSSION: Operating in this area of anatomical complexity required input from a number of different specialty teams. Although input from infectious diseases, microbiology, plastic surgery and tissue viability was commendable, there was room for optimising this further. Early patient referral to a tertiary centre where on-site input was available from maxillofacial surgery and plastic surgery would have been beneficial; a set-up commonly seen in regional trauma networks. CONCLUSION: This case demonstrates the intricacies surrounding a rare occurrence of necrotising fasciitis of the neck crossing the midline. Multi-disciplinary team involvement is imperative and should be encouraged at an early stage. CI - Copyright (c) 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved. FAU - Ross, Talisa AU - Ross T AD - Northwick Park Hospital, London Northwest University Healthcare NHS Trust, Watford Road, Harrow, HA1 3UJ, United Kingdom; Imperial College London, South Kensington, London, SW7 2BU, United Kingdom. Electronic address: talisa.ross@nhs.net. FAU - Acharya, Vikas AU - Acharya V AD - Northwick Park Hospital, London Northwest University Healthcare NHS Trust, Watford Road, Harrow, HA1 3UJ, United Kingdom. Electronic address: Vikas.acharya@nhs.net. FAU - Patel, Arran AU - Patel A AD - Northwick Park Hospital, London Northwest University Healthcare NHS Trust, Watford Road, Harrow, HA1 3UJ, United Kingdom. Electronic address: Arran.patel@nhs.net. FAU - Tatla, Taran AU - Tatla T AD - Northwick Park Hospital, London Northwest University Healthcare NHS Trust, Watford Road, Harrow, HA1 3UJ, United Kingdom. Electronic address: Ttatla@nhs.net. LA - eng PT - Journal Article DEP - 20210401 PL - United States TA - Int J Surg Case Rep JT - International journal of surgery case reports JID - 101529872 PMC - PMC8056421 OTO - NOTNLM OT - Case report OT - Infection OT - Necrotising fasciitis OT - Posterior neck EDAT- 2021/04/11 06:00 MHDA- 2021/04/11 06:01 PMCR- 2021/04/01 CRDT- 2021/04/10 20:14 PHST- 2021/03/11 00:00 [received] PHST- 2021/03/26 00:00 [revised] PHST- 2021/03/28 00:00 [accepted] PHST- 2021/04/11 06:00 [pubmed] PHST- 2021/04/11 06:01 [medline] PHST- 2021/04/10 20:14 [entrez] PHST- 2021/04/01 00:00 [pmc-release] AID - S2210-2612(21)00353-9 [pii] AID - 105851 [pii] AID - 10.1016/j.ijscr.2021.105851 [doi] PST - ppublish SO - Int J Surg Case Rep. 2021 May;82:105851. doi: 10.1016/j.ijscr.2021.105851. Epub 2021 Apr 1. PMID- 33837764 OWN - NLM STAT- MEDLINE DCOM- 20210806 LR - 20210806 IS - 1468-2834 (Electronic) IS - 0002-0729 (Linking) VI - 50 IP - 4 DP - 2021 Jun 28 TI - New horizons in cardiogeriatrics: geriatricians and heart failure care-the custard in the tart, not the icing on the cake. PG - 1064-1068 LID - 10.1093/ageing/afab057 [doi] AB - Heart failure (HF) can be considered a disease of older people. It is a leading cause of hospitalisation and is associated with high rates of morbidity and mortality in the over-65s. In 2012, an editorial in this journal detailed the latest HF research and guidelines, calling for greater integration of geriatricians in HF care. This current article reflects upon what has been achieved in this field in recent years, highlighting some future challenges and promising areas. It is written from the perspective of one such integrated team and explores the new role of cardiogeriatrician, working in a multidisciplinary team to deliver and improve care to increasingly complex, older, frail patients with multiple comorbidities who present with primary cardiology problems, especially decompensated HF. Geriatric liaison has improved the care of frail patients in orthopaedics, cancer services, stroke, acute medicine and numerous community settings. We propose that this vital role should now be extended to cardiology teams in general and to HF in particular. CI - (c) The Author(s) 2021. Published by Oxford University Press on behalf of the British Geriatrics Society. All rights reserved. For permissions, please email: journals.permissions@oup.com. FAU - Levy, Shuli AU - Levy S AD - Department of Cardiology, Imperial College Healthcare NHS Trust, London, UK. AD - Department of Medicine for the Elderly, Imperial College Healthcare NHS Trust, London, UK. FAU - Cole, Graham AU - Cole G AD - Department of Cardiology, Imperial College Healthcare NHS Trust, London, UK. FAU - Pabari, Punam AU - Pabari P AD - Department of Cardiology, Imperial College Healthcare NHS Trust, London, UK. FAU - Dani, Melanie AU - Dani M AD - Department of Medicine for the Elderly, Imperial College Healthcare NHS Trust, London, UK. FAU - Barton, Carys AU - Barton C AD - Department of Cardiology, Imperial College Healthcare NHS Trust, London, UK. FAU - Mayet, Jamil AU - Mayet J AD - Department of Cardiology, Imperial College Healthcare NHS Trust, London, UK. FAU - McDonagh, Theresa AU - McDonagh T AD - Department of Cardiology, Kings College Hospital NHS Foundation Trust, London, UK. FAU - Baxter, John AU - Baxter J AD - Department of Medicine for the Elderly, Sunderland Royal Hospital, Sunderland, UK. FAU - Plymen, Carla AU - Plymen C AD - Department of Cardiology, Imperial College Healthcare NHS Trust, London, UK. LA - eng PT - Journal Article PL - England TA - Age Ageing JT - Age and ageing JID - 0375655 SB - IM MH - Aged MH - *Cardiology MH - Comorbidity MH - Geriatricians MH - *Heart Failure/diagnosis/epidemiology/therapy MH - Hospitalization MH - Humans OTO - NOTNLM OT - cardiogeriatrics OT - frail OT - heart failure OT - multimorbid OT - older people EDAT- 2021/04/11 06:00 MHDA- 2021/08/07 06:00 CRDT- 2021/04/10 12:06 PHST- 2020/07/13 00:00 [received] PHST- 2021/04/11 06:00 [pubmed] PHST- 2021/08/07 06:00 [medline] PHST- 2021/04/10 12:06 [entrez] AID - 6218822 [pii] AID - 10.1093/ageing/afab057 [doi] PST - ppublish SO - Age Ageing. 2021 Jun 28;50(4):1064-1068. doi: 10.1093/ageing/afab057. PMID- 33833010 OWN - NLM STAT- MEDLINE DCOM- 20210910 LR - 20210910 IS - 1558-7118 (Electronic) IS - 1557-2625 (Linking) VI - 34 IP - 2 DP - 2021 Mar-Apr TI - Management of Acute Pulmonary Embolism With a Pulmonary Embolism Response Team. PG - 402-408 LID - 10.3122/jabfm.2021.02.200308 [doi] AB - Despite recent advances in the assessment, risk stratification, and treatment of acute pulmonary embolism (PE), it remains a leading cause of cardiovascular morbidity and mortality in the United States each year. Patient presentation and prognosis are heterogeneous, and a variety of diagnostic and therapeutic instruments have arisen to assist in providing patients with the appropriate level of care and aggressiveness of approach. Fortunately, a growing number of institutions now have pulmonary embolism response teams (PERT) that urgently assist with risk assessment and management of patients with massive and sub-massive PE. In service of providers at the point of contact with acute PE, this review aims to summarize the data pertinent to rapid risk assessment and the interpretation of diagnostics used to that end. The role of PERT and the indications for systemic fibrinolysis and invasive therapies are also discussed. CI - (c) Copyright 2021 by the American Board of Family Medicine. FAU - Cuomo, Jason R AU - Cuomo JR AD - From the Division of Cardiology, Yale University, New Haven, CT (JC); Division of Cardiology, Medical College of Georgia at the Augusta University Medical Center (VA); and the Department of Family Medicine, Medical College of Georgia at the Augusta University Medical Center, Augusta (TW). FAU - Arora, Vishal AU - Arora V AD - From the Division of Cardiology, Yale University, New Haven, CT (JC); Division of Cardiology, Medical College of Georgia at the Augusta University Medical Center (VA); and the Department of Family Medicine, Medical College of Georgia at the Augusta University Medical Center, Augusta (TW). FAU - Wilkins, Thad AU - Wilkins T AD - From the Division of Cardiology, Yale University, New Haven, CT (JC); Division of Cardiology, Medical College of Georgia at the Augusta University Medical Center (VA); and the Department of Family Medicine, Medical College of Georgia at the Augusta University Medical Center, Augusta (TW). jwilkins@augusta.edu. LA - eng PT - Journal Article PT - Review PL - United States TA - J Am Board Fam Med JT - Journal of the American Board of Family Medicine : JABFM JID - 101256526 SB - IM MH - Humans MH - *Patient Care Team MH - Prognosis MH - *Pulmonary Embolism/diagnosis/therapy MH - Risk Assessment MH - Thrombolytic Therapy OTO - NOTNLM OT - Cardiology OT - Clinical Decision-Making OT - Echocardiography OT - Fibrinolysis OT - Patient Care Team OT - Pulmonary Embolism OT - Pulmonary Medicine OT - Radiology OT - Risk Assessment OT - Thrombolytic Therapy OT - Venous Thromboembolism COIS- Conflict of interest: The authors report are no conflicts of interest. EDAT- 2021/04/10 06:00 MHDA- 2021/09/11 06:00 CRDT- 2021/04/09 05:49 PHST- 2020/06/23 00:00 [received] PHST- 2020/09/13 00:00 [revised] PHST- 2020/09/14 00:00 [accepted] PHST- 2021/04/09 05:49 [entrez] PHST- 2021/04/10 06:00 [pubmed] PHST- 2021/09/11 06:00 [medline] AID - 34/2/402 [pii] AID - 10.3122/jabfm.2021.02.200308 [doi] PST - ppublish SO - J Am Board Fam Med. 2021 Mar-Apr;34(2):402-408. doi: 10.3122/jabfm.2021.02.200308. PMID- 33832605 OWN - NLM STAT- MEDLINE DCOM- 20211012 LR - 20260928 IS - 1558-3597 (Electronic) IS - 0735-1097 (Print) IS - 0735-1097 (Linking) VI - 77 IP - 14 DP - 2021 Apr 13 TI - Management of Women With Congenital or Inherited Cardiovascular Disease From Pre-Conception Through Pregnancy and Postpartum: JACC Focus Seminar 2/5. PG - 1778-1798 LID - S0735-1097(21)00400-9 [pii] LID - 10.1016/j.jacc.2021.02.026 [doi] AB - Maternal morbidity and mortality continue to rise in the United States, with cardiovascular disease as the leading cause of maternal deaths. Congenital heart disease is now the most common cardiovascular condition encountered during pregnancy, and its prevalence will continue to grow. In tandem with these trends, maternal cardiovascular health is becoming increasingly complex. The identification of women at highest risk for cardiovascular complications is essential, and a team-based approach is recommended to optimize maternal and fetal outcomes. This document, the second of a 5-part series, will provide practical guidance from pre-conception through postpartum for cardiovascular conditions that are predominantly congenital or heritable in nature, including aortopathies, congenital heart disease, pulmonary hypertension, and valvular heart disease. CI - Copyright (c) 2021 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. FAU - Lindley, Kathryn J AU - Lindley KJ AD - Cardiovascular Division, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA. Electronic address: Kathryn.lindley@wustl.edu. FAU - Bairey Merz, C Noel AU - Bairey Merz CN AD - Barbra Streisand Women's Heart Center, Cedars-Sinai Smidt Heart Institute, Los Angeles, California, USA. FAU - Asgar, Anita W AU - Asgar AW AD - Division of Cardiology, Institut de Cardiologie de Montreal, Universite de Montreal, Montreal, Quebec, Canada. FAU - Bello, Natalie A AU - Bello NA AD - Department of Medicine, Division of Cardiology, Columbia University Irving Medical Center, New York, New York, USA. FAU - Chandra, Sonal AU - Chandra S AD - Division of Cardiology, Rush University Medical Center, Chicago, Illinois, USA. FAU - Davis, Melinda B AU - Davis MB AD - Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA. FAU - Gomberg-Maitland, Mardi AU - Gomberg-Maitland M AD - George Washington University School of Medicine and Health Sciences, Washington, DC, USA. FAU - Gulati, Martha AU - Gulati M AD - Department of Medicine (Cardiology), University of Arizona-Phoenix, Phoenix, Arizona, USA. FAU - Hollier, Lisa M AU - Hollier LM AD - Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, Texas, USA. FAU - Krieger, Eric V AU - Krieger EV AD - Seattle Adult Congenital Heart Service, University of Washington School of Medicine, Seattle, Washington, USA. FAU - Park, Ki AU - Park K AD - Cardiovascular Medicine, University of Florida College of Medicine, Gainesville, Florida, USA. FAU - Silversides, Candice AU - Silversides C AD - Division of Cardiology, University of Toronto Pregnancy and Heart Disease Program, Mount Sinai Hospital and University Health Network, University of Toronto, Toronto, Ontario, Canada. FAU - Wolfe, Natasha K AU - Wolfe NK AD - Cardiovascular Division, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA. FAU - Pepine, Carl J AU - Pepine CJ AD - Cardiovascular Medicine, University of Florida College of Medicine, Gainesville, Florida, USA. CN - American College of Cardiology Cardiovascular Disease in Women Committee and the Cardio-Obstetrics Work Group LA - eng GR - K23 HL136853/HL/NHLBI NIH HHS/United States GR - R01 HL153382/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Review PL - United States TA - J Am Coll Cardiol JT - Journal of the American College of Cardiology JID - 8301365 SB - IM MH - *Cardiovascular Diseases/classification/congenital/physiopathology/therapy MH - Female MH - Humans MH - Peripartum Period MH - Practice Guidelines as Topic MH - Pregnancy MH - *Pregnancy Complications, Cardiovascular/classification/physiopathology/therapy MH - Pregnancy, High-Risk MH - Risk Adjustment/*methods PMC - PMC8061781 MID - NIHMS1674090 OTO - NOTNLM OT - aortopathy OT - cardio-obstetrics OT - congenital OT - pregnancy OT - pulmonary hypertension COIS- Funding Support and Author Disclosures Dr. Bairey Merz has served as a consultant for Abbott and Sanofi; and has served on the Board of Directors for iRhythm. Dr. Bello is supported by the National Institutes of Health/National Heart, Lung, and Blood Institute (K23 HL136853-03, R01 HL153382-01). Dr. Gomberg-Maitland has received research grant support to GWU-MFA from Acceleron, Bayer, Complexa, and United Therapeutics; and has served as a consultant for Actelion, Altavant, Acceleron, Bayer, Gilead, Insemed, Reata, and United Therapeutics. Dr. Park has served as a consultant for Abbott. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2021/04/10 06:00 MHDA- 2021/10/13 06:00 PMCR- 2022/04/13 CRDT- 2021/04/09 05:37 PHST- 2020/11/25 00:00 [received] PHST- 2021/01/19 00:00 [revised] PHST- 2021/02/12 00:00 [accepted] PHST- 2021/04/09 05:37 [entrez] PHST- 2021/04/10 06:00 [pubmed] PHST- 2021/10/13 06:00 [medline] PHST- 2022/04/13 00:00 [pmc-release] AID - S0735-1097(21)00400-9 [pii] AID - 10.1016/j.jacc.2021.02.026 [doi] PST - ppublish SO - J Am Coll Cardiol. 2021 Apr 13;77(14):1778-1798. doi: 10.1016/j.jacc.2021.02.026. PMID- 33832604 OWN - NLM STAT- MEDLINE DCOM- 20211012 LR - 20220414 IS - 1558-3597 (Electronic) IS - 0735-1097 (Print) IS - 0735-1097 (Linking) VI - 77 IP - 14 DP - 2021 Apr 13 TI - Team-Based Care of Women With Cardiovascular Disease From Pre-Conception Through Pregnancy and Postpartum: JACC Focus Seminar 1/5. PG - 1763-1777 LID - S0735-1097(21)00412-5 [pii] LID - 10.1016/j.jacc.2021.02.033 [doi] AB - The specialty of cardio-obstetrics has emerged in response to the rising rates of maternal morbidity and mortality related to cardiovascular disease (CVD) during pregnancy. Women of childbearing age with or at risk for CVD should receive appropriate counseling regarding maternal and fetal risks of pregnancy, medical optimization, and contraception advice. A multidisciplinary cardio-obstetrics team should ensure appropriate monitoring during pregnancy, plan for labor and delivery, and ensure close follow-up during the postpartum period when CVD complications remain common. The hemodynamic changes throughout pregnancy and during labor and delivery should be considered with respect to the individual cardiac disease of the patient. The fourth trimester refers to the 12 weeks after delivery and is a key time to address contraception, mental health, cardiovascular risk factors, and identify any potential postpartum complications. Women with adverse pregnancy outcomes are at increased risk of long-term CVD and should receive appropriate education and longitudinal follow-up. CI - Copyright (c) 2021 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. FAU - Davis, Melinda B AU - Davis MB AD - Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA. Electronic address: davismb@med.umich.edu. FAU - Arendt, Katherine AU - Arendt K AD - Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota, USA. FAU - Bello, Natalie A AU - Bello NA AD - Department of Medicine, Division of Cardiology, Columbia University Irving Medical Center, New York, New York, USA. FAU - Brown, Haywood AU - Brown H AD - Department of Obstetrics and Gynecology, University of South Florida, Tampa, Florida, USA. FAU - Briller, Joan AU - Briller J AD - Division of Cardiology, Department of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA. FAU - Epps, Kelly AU - Epps K AD - Division of Cardiology, Inova Heart and Vascular Institute, Fairfax, Virginia, USA. FAU - Hollier, Lisa AU - Hollier L AD - Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, Texas, USA. FAU - Langen, Elizabeth AU - Langen E AD - Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, Michigan, USA. FAU - Park, Ki AU - Park K AD - Division of Cardiovascular Medicine, University of Florida College of Medicine, Gainesville, Florida, USA. FAU - Walsh, Mary Norine AU - Walsh MN AD - Division of Cardiology, St. Vincent Heart Center, Indianapolis, Indiana, USA. FAU - Williams, Dominique AU - Williams D AD - Cardiovascular Division, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA. FAU - Wood, Malissa AU - Wood M AD - Division of Cardiology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA. FAU - Silversides, Candice K AU - Silversides CK AD - Division of Cardiology, Pregnancy and Heart Disease Program, Mount Sinai Hospital and University Health Network, University of Toronto, Toronto, Ontario, Canada. FAU - Lindley, Kathryn J AU - Lindley KJ AD - Cardiovascular Division, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA. CN - American College of Cardiology Cardiovascular Disease in Women Committee and the Cardio-Obstetrics Work Group LA - eng GR - K23 HL136853/HL/NHLBI NIH HHS/United States GR - R01 HL153382/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Review PL - United States TA - J Am Coll Cardiol JT - Journal of the American College of Cardiology JID - 8301365 SB - IM MH - *Cardiovascular Diseases/classification/physiopathology/therapy MH - Female MH - Heart Disease Risk Factors MH - Humans MH - Patient Care Team/*organization & administration MH - Peripartum Period MH - Pregnancy MH - *Pregnancy Complications, Cardiovascular/classification/physiopathology/therapy MH - Risk Adjustment/*methods PMC - PMC8238394 MID - NIHMS1683490 OTO - NOTNLM OT - cardio-obstetrics OT - cardiovascular disease OT - pregnancy OT - team care OT - women COIS- Funding Support and Author Disclosures Supported by National Institutes of Health/National Heart, Lung, and Blood Institute grants K23 HL136853-03 and R01 HL153382-01 (Dr. Bello). Dr. Brown is a coauthor of UpToDate. Dr. Park has served as a consultant for Abbott Diagnostics. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. EDAT- 2021/04/10 06:00 MHDA- 2021/10/13 06:00 PMCR- 2022/04/13 CRDT- 2021/04/09 05:37 PHST- 2020/11/30 00:00 [received] PHST- 2021/01/19 00:00 [revised] PHST- 2021/02/08 00:00 [accepted] PHST- 2021/04/09 05:37 [entrez] PHST- 2021/04/10 06:00 [pubmed] PHST- 2021/10/13 06:00 [medline] PHST- 2022/04/13 00:00 [pmc-release] AID - S0735-1097(21)00412-5 [pii] AID - 10.1016/j.jacc.2021.02.033 [doi] PST - ppublish SO - J Am Coll Cardiol. 2021 Apr 13;77(14):1763-1777. doi: 10.1016/j.jacc.2021.02.033. PMID- 33831398 OWN - NLM STAT- MEDLINE DCOM- 20210719 LR - 20210719 IS - 1873-1740 (Electronic) IS - 0033-0620 (Linking) VI - 65 DP - 2021 Mar-Apr TI - Abdominal aortic aneurysms. PG - 34-43 LID - S0033-0620(21)00037-2 [pii] LID - 10.1016/j.pcad.2021.03.009 [doi] AB - Abdominal aortic aneurysms (AAA) are prevalent among older adults and can cause significant morbidity and mortality if not addressed in a timely fashion. Their etiology remains the topic of continued investigation. Known causes include trauma, infection, and inflammatory disorders. Risk factors include cigarette smoking, advanced age, dyslipidemia, hypertension, and coronary artery disease. The pathophysiology of the disease is related to an initial arterial insult causing a cascade of inflammation and extracellular matrix protein breakdown by proteinases leading to arterial wall weakening. When identified early, aneurysms must be monitored for size, growth rate, and other factors which could increase the risk of rupture. Factors predisposing to rupture include size, active smoking, rate of growth, aberrant biomechanical properties of the aneurysmal sac, and female sex. Medical management includes the control of risk factors that may prevent growth, stabilize the aneurysm, and prevent rupture. Surgical management prevents rupture of high risk aneurysms, most commonly predicted by size. Less frequently, surgical management is required when the aneurysm has ruptured. Surgery involves a multidisciplinary approach to evaluate the patient's risk profile and to develop an operative plan involving either an endovascular or an open surgical repair. The patient must be carefully monitored post-operatively for complications and, in the case of endovascular repairs, for endoleaks. AAA management has evolved rapidly in recent years. Technical and technological advances have transformed the diagnosis and treatment of this disease. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - Anagnostakos, John AU - Anagnostakos J AD - Center for Vascular Research, University of Maryland, United States of America. FAU - Lal, Brajesh K AU - Lal BK AD - Center for Vascular Research, University of Maryland, United States of America; University of Maryland, United States of America; Endovascular Surgery, University of Maryland Medical Center, United States of America; Baltimore VA Medical Center, United States of America. Electronic address: blal@som.umaryland.edu. LA - eng PT - Journal Article PT - Review DEP - 20210405 PL - United States TA - Prog Cardiovasc Dis JT - Progress in cardiovascular diseases JID - 0376442 SB - IM MH - Aortic Aneurysm, Abdominal/diagnostic imaging/mortality/physiopathology/*surgery MH - Aortic Rupture/diagnostic imaging/mortality/physiopathology/*surgery MH - Blood Vessel Prosthesis MH - *Blood Vessel Prosthesis Implantation/adverse effects/instrumentation/mortality MH - *Endovascular Procedures/adverse effects/instrumentation/mortality MH - Humans MH - Postoperative Complications/etiology MH - Risk Assessment MH - Risk Factors MH - Treatment Outcome OTO - NOTNLM OT - Abdominal aorta OT - Abdominal aortic aneurysm OT - Vascular disease EDAT- 2021/04/09 06:00 MHDA- 2021/07/20 06:00 CRDT- 2021/04/08 20:16 PHST- 2021/03/29 00:00 [received] PHST- 2021/03/29 00:00 [accepted] PHST- 2021/04/09 06:00 [pubmed] PHST- 2021/07/20 06:00 [medline] PHST- 2021/04/08 20:16 [entrez] AID - S0033-0620(21)00037-2 [pii] AID - 10.1016/j.pcad.2021.03.009 [doi] PST - ppublish SO - Prog Cardiovasc Dis. 2021 Mar-Apr;65:34-43. doi: 10.1016/j.pcad.2021.03.009. Epub 2021 Apr 5. PMID- 33828165 OWN - NLM STAT- MEDLINE DCOM- 20211029 LR - 20211029 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 11 IP - 1 DP - 2021 Apr 7 TI - Real-time coronary artery stenosis detection based on modern neural networks. PG - 7582 LID - 10.1038/s41598-021-87174-2 [doi] LID - 7582 AB - Invasive coronary angiography remains the gold standard for diagnosing coronary artery disease, which may be complicated by both, patient-specific anatomy and image quality. Deep learning techniques aimed at detecting coronary artery stenoses may facilitate the diagnosis. However, previous studies have failed to achieve superior accuracy and performance for real-time labeling. Our study is aimed at confirming the feasibility of real-time coronary artery stenosis detection using deep learning methods. To reach this goal we trained and tested eight promising detectors based on different neural network architectures (MobileNet, ResNet-50, ResNet-101, Inception ResNet, NASNet) using clinical angiography data of 100 patients. Three neural networks have demonstrated superior results. The network based on Faster-RCNN Inception ResNet V2 is the most accurate and it achieved the mean Average Precision of 0.95, F1-score 0.96 and the slowest prediction rate of 3 fps on the validation subset. The relatively lightweight SSD MobileNet V2 network proved itself as the fastest one with a low mAP of 0.83, F1-score of 0.80 and a mean prediction rate of 38 fps. The model based on RFCN ResNet-101 V2 has demonstrated an optimal accuracy-to-speed ratio. Its mAP makes up 0.94, F1-score 0.96 while the prediction speed is 10 fps. The resultant performance-accuracy balance of the modern neural networks has confirmed the feasibility of real-time coronary artery stenosis detection supporting the decision-making process of the Heart Team interpreting coronary angiography findings. FAU - Danilov, Viacheslav V AU - Danilov VV AD - Tomsk Polytechnic University, Tomsk, Russia. viacheslav.v.danilov@gmail.com. AD - University of Leeds, Leeds, UK. viacheslav.v.danilov@gmail.com. FAU - Klyshnikov, Kirill Yu AU - Klyshnikov KY AD - Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russia. FAU - Gerget, Olga M AU - Gerget OM AD - Tomsk Polytechnic University, Tomsk, Russia. FAU - Kutikhin, Anton G AU - Kutikhin AG AD - Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russia. FAU - Ganyukov, Vladimir I AU - Ganyukov VI AD - Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russia. FAU - Frangi, Alejandro F AU - Frangi AF AD - University of Leeds, Leeds, UK. FAU - Ovcharenko, Evgeny A AU - Ovcharenko EA AD - Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russia. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210407 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 SB - IM MH - Aged MH - Algorithms MH - Computer Systems MH - Coronary Angiography/*statistics & numerical data MH - Coronary Stenosis/*diagnosis/*diagnostic imaging MH - *Deep Learning MH - Feasibility Studies MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neural Networks, Computer MH - Radiographic Image Interpretation, Computer-Assisted/*methods/statistics & numerical data PMC - PMC8027436 COIS- The authors declare no competing interests. EDAT- 2021/04/09 06:00 MHDA- 2021/10/30 06:00 PMCR- 2021/04/07 CRDT- 2021/04/08 06:08 PHST- 2020/12/17 00:00 [received] PHST- 2021/03/24 00:00 [accepted] PHST- 2021/04/08 06:08 [entrez] PHST- 2021/04/09 06:00 [pubmed] PHST- 2021/10/30 06:00 [medline] PHST- 2021/04/07 00:00 [pmc-release] AID - 10.1038/s41598-021-87174-2 [pii] AID - 87174 [pii] AID - 10.1038/s41598-021-87174-2 [doi] PST - epublish SO - Sci Rep. 2021 Apr 7;11(1):7582. doi: 10.1038/s41598-021-87174-2. PMID- 33826652 OWN - NLM STAT- MEDLINE DCOM- 20210917 LR - 20240808 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 16 IP - 4 DP - 2021 TI - Outcomes in asymptomatic, severe aortic stenosis. PG - e0249610 LID - 10.1371/journal.pone.0249610 [doi] LID - e0249610 AB - BACKGROUND AND AIM OF THE STUDY: Patients with asymptomatic, severe aortic stenosis are presumed to have a benign prognosis. In this retrospective cohort study, we examined the natural history of contemporary patients advised against aortic valve replacement due to a perceived lack of symptoms. MATERIALS AND METHODS: We reviewed the medical records of every patient given the ICD-10-code for aortic stenosis (I35.0) at Oslo University Hospital, Rikshospitalet, between Dec 1st, 2002 and Dec 31st, 2016. Patients who were evaluated by the heart team due to severe aortic stenosis were categorized by treatment strategy. We recorded baseline data, adverse events and survival for the patients characterized as asymptomatic and for 100 age and gender matched patients scheduled for aortic valve replacement. RESULTS: Of 2341 patients who were evaluated for aortic valve replacement due to severe aortic stenosis, 114 patients received conservative treatment due to a lack of symptoms. Asymptomatic patients had higher mortality than patients who had aortic valve replacement, log-rank p<0.001 (mean follow-up time: 4.0 (SD: 2.5) years). Survival at 1, 2 and 3 years for the asymptomatic patients was 88%, 75% and 63%, compared with 92%, 83% and 78% in the matched patients scheduled for aortic valve replacement. 28 (25%) of the asymptomatic patients had aortic valve replacement during follow-up. Age, previous history of coronary artery disease and N-terminal pro B-type natriuretic peptide (NT-proBNP) were predictors of mortality and coronary artery disease and NT-proBNP were predictors of 3-year morbidity in asymptomatic patients. CONCLUSIONS: In this retrospective study, asymptomatic patients with severe aortic stenosis who were advised against surgery had significantly higher mortality than patients who had aortic valve replacement. FAU - Kvaslerud, Anette Borger AU - Kvaslerud AB AUID- ORCID: 0000-0001-9923-2685 AD - Faculty of Medicine, University of Oslo, Oslo, Norway. AD - Department of Cardiology, Oslo University Hospital, Rikshospitalet, Norway. AD - KG Jebsen Cardiac Research Center and Center for Heart Failure Research, Oslo University Hospital, Ulleval, Norway. FAU - Santic, Kenan AU - Santic K AD - Faculty of Medicine, University of Oslo, Oslo, Norway. FAU - Hussain, Amjad Iqbal AU - Hussain AI AD - Department of Cardiology, Oslo University Hospital, Rikshospitalet, Norway. AD - KG Jebsen Cardiac Research Center and Center for Heart Failure Research, Oslo University Hospital, Ulleval, Norway. FAU - Auensen, Andreas AU - Auensen A AD - Faculty of Medicine, University of Oslo, Oslo, Norway. AD - Department of Cardiology, Oslo University Hospital, Rikshospitalet, Norway. AD - KG Jebsen Cardiac Research Center and Center for Heart Failure Research, Oslo University Hospital, Ulleval, Norway. FAU - Fiane, Arnt AU - Fiane A AD - Faculty of Medicine, University of Oslo, Oslo, Norway. AD - Department of Cardiothoracic Surgery, Oslo University Hospital, Rikshospitalet, Norway. FAU - Skulstad, Helge AU - Skulstad H AD - Faculty of Medicine, University of Oslo, Oslo, Norway. AD - Department of Cardiology, Oslo University Hospital, Rikshospitalet, Norway. FAU - Aaberge, Lars AU - Aaberge L AD - Department of Cardiology, Oslo University Hospital, Rikshospitalet, Norway. FAU - Gullestad, Lars AU - Gullestad L AD - Faculty of Medicine, University of Oslo, Oslo, Norway. AD - Department of Cardiology, Oslo University Hospital, Rikshospitalet, Norway. AD - KG Jebsen Cardiac Research Center and Center for Heart Failure Research, Oslo University Hospital, Ulleval, Norway. FAU - Broch, Kaspar AU - Broch K AD - Department of Cardiology, Oslo University Hospital, Rikshospitalet, Norway. AD - KG Jebsen Cardiac Research Center and Center for Heart Failure Research, Oslo University Hospital, Ulleval, Norway. LA - eng PT - Journal Article DEP - 20210407 PL - United States TA - PLoS One JT - PloS one JID - 101285081 SB - IM MH - Aged MH - Aged, 80 and over MH - Aortic Valve Stenosis/*mortality/pathology/therapy MH - Asymptomatic Diseases/*mortality/therapy MH - Case-Control Studies MH - Female MH - Heart Valve Prosthesis Implantation/*mortality MH - Humans MH - Male MH - Prognosis MH - Retrospective Studies MH - *Severity of Illness Index MH - Survival Rate PMC - PMC8026050 COIS- The authors have declared that no competing interests exist. EDAT- 2021/04/08 06:00 MHDA- 2021/09/18 06:00 PMCR- 2021/04/07 CRDT- 2021/04/07 17:29 PHST- 2020/12/02 00:00 [received] PHST- 2021/03/19 00:00 [accepted] PHST- 2021/04/07 17:29 [entrez] PHST- 2021/04/08 06:00 [pubmed] PHST- 2021/09/18 06:00 [medline] PHST- 2021/04/07 00:00 [pmc-release] AID - PONE-D-20-37902 [pii] AID - 10.1371/journal.pone.0249610 [doi] PST - epublish SO - PLoS One. 2021 Apr 7;16(4):e0249610. doi: 10.1371/journal.pone.0249610. eCollection 2021. PMID- 33823973 OWN - NLM STAT- MEDLINE DCOM- 20210615 LR - 20210615 IS - 1938-4114 (Electronic) IS - 1937-1888 (Linking) VI - 82 IP - 2 DP - 2021 Mar TI - Hospital- and Patient-Level Characteristics Associated With Unplanned Readmissions and In-Patient Mortality in Men and Women With Alcoholic Cardiomyopathy. PG - 257-268 AB - OBJECTIVE: The aims of the study were to (a) determine rates of early, late, and overall 30-day all-cause readmission for women and men with the diagnosis of alcoholic cardiomyopathy (ACM), (b) examine hospital- and patient-level characteristics associated with the risk of readmission and how these factors differed by sex, and (c) examine the association between sex and in-patient mortality during readmission. METHOD: We conducted a multi-year cross-sectional analysis of adult (>/=18 years) inpatient hospitalizations in the United States. Descriptive statistics including frequencies and percentages were used to describe the study population, stratified by sex. We then used Poisson regression with robust error variance estimation to estimate risk ratios (RRs) and 95% confidence intervals (CIs) that represented the associations between sex and likelihood of 30-day all-cause readmission and inpatient mortality. RESULTS: Among more than 116 million hospitalizations, there were 53,207 ACM-related hospitalizations (45,573 men and 7,634 women). Thirty-day all-cause readmission rates following an ACM-related index hospitalization were similar between men (20.3%) and women (20.5%). For men and women, cancer, hepatitis, chronic renal failure, cirrhosis, asthma, and anemia were associated with a higher risk of readmission. Although crude in-hospital mortality rates were higher among women (6.6%) than men (4.3%), there were no sex differences in mortality after adjusting for confounders (RR = 1.26, 95% CI [0.88, 1.81]). CONCLUSIONS: Although men are more likely to be hospitalized for ACM, readmission risk is high (approximately 20%) and is similar in men and women following hospitalization for ACM. Hospital care transition programs that include a multidisciplinary approach are needed to help prevent these readmissions and associated morbidity and mortality. FAU - Mogos, Mulubrhan F AU - Mogos MF AD - Center for Research Development and Scholarship, Vanderbilt University School of Nursing, Nashville, Tennessee. FAU - Salemi, Jason L AU - Salemi JL AD - Department of Family and Community Medicine, Baylor College of Medicine, Houston, Texas. AD - College of Public Health, University of South Florida, Tampa, Florida. AD - Department of Obstetrics and Gynecology, Morsani College of Medicine, University of South Florida, Tampa, Florida. FAU - Modak, Sanjukta AU - Modak S AD - Department of Family and Community Medicine, Baylor College of Medicine, Houston, Texas. FAU - Zoorob, Roger J AU - Zoorob RJ AD - Department of Family and Community Medicine, Baylor College of Medicine, Houston, Texas. FAU - Piano, Mariann R AU - Piano MR AD - Center for Research Development and Scholarship, Vanderbilt University School of Nursing, Nashville, Tennessee. LA - eng PT - Journal Article PL - United States TA - J Stud Alcohol Drugs JT - Journal of studies on alcohol and drugs JID - 101295847 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Cardiomyopathy, Alcoholic/*epidemiology MH - Cross-Sectional Studies MH - Female MH - *Hospital Mortality MH - Hospitalization/*statistics & numerical data MH - Hospitals MH - Humans MH - Male MH - Middle Aged MH - Patient Readmission/*statistics & numerical data MH - Risk Factors MH - United States MH - Young Adult EDAT- 2021/04/08 06:00 MHDA- 2021/06/16 06:00 CRDT- 2021/04/07 05:44 PHST- 2021/04/07 05:44 [entrez] PHST- 2021/04/08 06:00 [pubmed] PHST- 2021/06/16 06:00 [medline] PST - ppublish SO - J Stud Alcohol Drugs. 2021 Mar;82(2):257-268. PMID- 33822894 OWN - NLM STAT- MEDLINE DCOM- 20220103 LR - 20220103 IS - 1755-3245 (Electronic) IS - 0008-6363 (Linking) VI - 117 IP - 5 DP - 2021 Apr 23 TI - The neurology of hypertension: merging academic specialties to connect heart and brain pathophysiology. PG - e70-e72 LID - 10.1093/cvr/cvab089 [doi] FAU - Lembo, Giuseppe AU - Lembo G AD - Department of Molecular Medicine, "Sapienza" University of Rome, Viale Regina Elena, 00161 Rome, Italy. AD - Department of Angiocardioneurology and Translational Medicine, Via dell'Elettronica, IRCCS Neuromed, 86077 Pozzilli, IS, Italy. FAU - Perrotta, Marialuisa AU - Perrotta M AD - Department of Molecular Medicine, "Sapienza" University of Rome, Viale Regina Elena, 00161 Rome, Italy. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Cardiovasc Res JT - Cardiovascular research JID - 0077427 SB - IM MH - Animals MH - *Blood Pressure MH - Brain/metabolism/*physiopathology MH - *Cardiology MH - Cardiovascular System/*innervation MH - Humans MH - Hypertension/diagnosis/metabolism/*physiopathology MH - Interdisciplinary Communication MH - Neuroimmunomodulation MH - *Neurosciences MH - Signal Transduction OTO - NOTNLM OT - Autonomic nervous system OT - Brain OT - Dementia OT - Hypertension OT - Immunity EDAT- 2021/04/07 06:00 MHDA- 2022/01/04 06:00 CRDT- 2021/04/06 17:24 PHST- 2021/04/07 06:00 [pubmed] PHST- 2022/01/04 06:00 [medline] PHST- 2021/04/06 17:24 [entrez] AID - 6210680 [pii] AID - 10.1093/cvr/cvab089 [doi] PST - ppublish SO - Cardiovasc Res. 2021 Apr 23;117(5):e70-e72. doi: 10.1093/cvr/cvab089. PMID- 33811130 OWN - NLM STAT- MEDLINE DCOM- 20211207 LR - 20211214 IS - 1468-201X (Electronic) IS - 1355-6037 (Linking) VI - 107 IP - 23 DP - 2021 Dec TI - Axial flow ventricular assist devices in cardiogenic shock complicating acute myocardial infarction. PG - 1856-1861 LID - 10.1136/heartjnl-2020-318226 [doi] AB - Cardiogenic shock (CS) remains the leading cause of death in patients hospitalised with acute myocardial infarction with mortality as high as 40%-50% prior to hospital discharge. The failure of inotropic therapy to maintain adequate perfusion and to prevent irreversible end-organ failure has led to attempts to improve outcomes by mechanical circulatory support (MCS) devices. Axial flow ventricular assist devices, namely Impella, are an attractive therapeutic option due to their positive haemodynamic benefits and ease of use. Despite clear beneficial haemodynamic effects, which should significantly impact on the pathophysiology of CS, there are currently no clear data to support their use in the reduction of clinical end points such as cardiac death. This review summarises and critically evaluates the current scientific evidence for the use of axial flow ventricular assist devices and highlights gaps in our understanding. Given such gaps, a consensus multidisciplinary approach, predicated on emphasising timely diagnosis and appropriate use of MCS, is vital to ensure that the right patient is paired with the right device at the right time. CI - (c) Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. FAU - McGovern, Laurna AU - McGovern L AUID- ORCID: 0000-0002-7674-5442 AD - Cardiology, Saint James's Hospital, Dublin, Ireland lkmcgovern2@gmail.com. FAU - Cosgrave, John AU - Cosgrave J AD - Cardiology, Saint James's Hospital, Dublin, Ireland. LA - eng PT - Journal Article PT - Review DEP - 20210402 PL - England TA - Heart JT - Heart (British Cardiac Society) JID - 9602087 SB - IM MH - *Heart-Assist Devices MH - Humans MH - Myocardial Infarction/*complications MH - Shock, Cardiogenic/etiology/*therapy OTO - NOTNLM OT - Advanced heart failure therapies (LV assist devices total artificial heart) OT - acute myocardial infarction OT - percutaneous coronary intervention COIS- Competing interests: None declared. EDAT- 2021/04/04 06:00 MHDA- 2021/12/15 06:00 CRDT- 2021/04/03 05:35 PHST- 2020/09/06 00:00 [received] PHST- 2021/02/12 00:00 [revised] PHST- 2021/02/17 00:00 [accepted] PHST- 2021/04/04 06:00 [pubmed] PHST- 2021/12/15 06:00 [medline] PHST- 2021/04/03 05:35 [entrez] AID - heartjnl-2020-318226 [pii] AID - 10.1136/heartjnl-2020-318226 [doi] PST - ppublish SO - Heart. 2021 Dec;107(23):1856-1861. doi: 10.1136/heartjnl-2020-318226. Epub 2021 Apr 2.